PMID- 32580960
OWN - NLM
STAT- MEDLINE
DCOM- 20210819
LR  - 20210819
IS  - 1554-6179 (Electronic)
IS  - 1539-4182 (Print)
IS  - 1539-4182 (Linking)
VI  - 18
IP  - 2-3
DP  - 2020 Aug
TI  - Aspirin in Primary Prevention of Cardiovascular Events.
PG  - 89-94
LID - 10.3121/cmr.2020.1548 [doi]
AB  - Aspirin has demonstrated a clear benefit in secondary prevention of coronary 
      syndrome, while aspirin's effect in primary prevention is unclear. This report 
      will explore the role of aspirin as primary prevention for various vascular 
      events. It strives to provide a clear guide for clinicians on whether or not to 
      prescribe aspirin for their patients for primary prevention. Current guidelines 
      and recent trials failed to show clear benefit against primary prevention, with 
      risks outweighing benefits in moderate to high risk patients. A thoughtful 
      discussion between patients and their doctors should be conducted before 
      beginning aspirin use. More studies are needed to gain a better understanding of 
      aspirin use in primary prevention.
CI  - © 2020 Marshfield Clinic.
FAU - Soodi, Deepa
AU  - Soodi D
AD  - Department of Internal Medicine, Marshfield Clinic Health System, Marshfield, WI.
FAU - VanWormer, Jeffrey J
AU  - VanWormer JJ
AD  - Clinical Epidemiology & Population Health, Marshfield Clinic Research Institute, 
      Marshfield, WI.
FAU - Rezkalla, Shereif H
AU  - Rezkalla SH
AD  - Department of Cardiology, Marshfield Clinic Health System, Marshfield, WI 
      rezkalla.shereif@marshfieldclinic.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200624
PL  - United States
TA  - Clin Med Res
JT  - Clinical medicine & research
JID - 101175887
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Clin Med Res. 2021 Mar;19(1):1. PMID: 33547166
CIN - Clin Med Res. 2021 Mar;19(1):1-2. PMID: 33547168
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases
MH  - Humans
MH  - *Primary Prevention
MH  - Risk Factors
PMC - PMC7428211
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular events
OT  - Prevention
EDAT- 2020/06/26 06:00
MHDA- 2021/08/20 06:00
CRDT- 2020/06/26 06:00
PHST- 2019/12/23 00:00 [received]
PHST- 2020/06/02 00:00 [revised]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/08/20 06:00 [medline]
PHST- 2020/06/26 06:00 [entrez]
AID - cmr.2020.1548 [pii]
AID - 0180089 [pii]
AID - 10.3121/cmr.2020.1548 [doi]
PST - ppublish
SO  - Clin Med Res. 2020 Aug;18(2-3):89-94. doi: 10.3121/cmr.2020.1548. Epub 2020 Jun 
      24.

PMID- 29129461
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20180727
IS  - 1768-3122 (Electronic)
IS  - 0248-8663 (Linking)
VI  - 38
IP  - 12
DP  - 2017 Dec
TI  - [Aspirin: Indications and use during pregnancy].
PG  - 825-832
LID - S0248-8663(17)31111-6 [pii]
LID - 10.1016/j.revmed.2017.10.419 [doi]
AB  - Aspirin (acetylsalicylic acid) has been used ever since the Antiquity for its 
      painkilling and anti-inflammatory effects. Its antiplatelet properties have then 
      extended its indications to the field of coronaropathy and vascular cerebral 
      disease, and finally to vascular placental disease. Aspirin has been widely 
      prescribed since the 1980's to prevent pre-eclampsia, intra-uterine growth 
      retardation and fetal death of vascular origin. It has also been proposed to 
      prevent unexplained recurrent miscarriages. Its use during pregnancy is 
      considered as safe, provided the daily doses do not exceed 100mg. Aspirin has 
      been proven efficient to prevent pre-eclampsia and fetal growth restriction in 
      high-risk patients. The benefits of prescribing aspirin have been demonstrated 
      neither for vascular placental disease prevention in low risk patients, nor in 
      cases of unexplained recurrent miscarriages.
CI  - Copyright © 2017 Société Nationale Française de Médecine Interne (SNFMI). 
      Published by Elsevier SAS. All rights reserved.
FAU - Belhomme, N
AU  - Belhomme N
AD  - Service de médecine interne, hôpital Sud, université Rennes 1, CHU, 16, boulevard 
      de Bulgarie, 35200 Rennes, France. Electronic address: 
      nicolas.belhomme@chu-rennes.fr.
FAU - Doudnikoff, C
AU  - Doudnikoff C
AD  - Service d'ophtalmologie, université Rennes 1, CHU Pontchaillou, 35033 Rennes, 
      France.
FAU - Polard, E
AU  - Polard E
AD  - Service de pharmacologie, pharmacovigilance, centre d'information sur le 
      médicament, CHU Pontchaillou, 35033 Rennes, France; Équipe de pharmacologie 
      (CETAD-PEPI), CHU Pontchaillou, 35033 Rennes, France.
FAU - Henriot, B
AU  - Henriot B
AD  - Service de médecine interne, hôpital Sud, université Rennes 1, CHU, 16, boulevard 
      de Bulgarie, 35200 Rennes, France.
FAU - Isly, H
AU  - Isly H
AD  - Service de gynécologie et obstétrique, hôpital Sud, CHU, 35200 Rennes, France.
FAU - Jego, P
AU  - Jego P
AD  - Service de médecine interne, hôpital Sud, université Rennes 1, CHU, 16, boulevard 
      de Bulgarie, 35200 Rennes, France; UMR Inserm U1085, institut de recherche sur la 
      santé, l'environnement et le travail (IRSET), université de Rennes 1, 35000 
      Rennes, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Aspirine : indications et utilisation durant la grossesse.
DEP - 20171110
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fetal Death/*prevention & control
MH  - Fetal Growth Retardation/*prevention & control
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy, High-Risk/drug effects
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirine
OT  - Cyclo-oxygénase
OT  - Cyclooxygenase
OT  - Grossesse
OT  - Insuffisance placentaire
OT  - Placental insufficiency
OT  - Pre-eclampsia
OT  - Pregnancy
OT  - Pré-éclampsie
EDAT- 2017/11/14 06:00
MHDA- 2018/07/28 06:00
CRDT- 2017/11/14 06:00
PHST- 2017/04/25 00:00 [received]
PHST- 2017/09/13 00:00 [revised]
PHST- 2017/10/12 00:00 [accepted]
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2017/11/14 06:00 [entrez]
AID - S0248-8663(17)31111-6 [pii]
AID - 10.1016/j.revmed.2017.10.419 [doi]
PST - ppublish
SO  - Rev Med Interne. 2017 Dec;38(12):825-832. doi: 10.1016/j.revmed.2017.10.419. Epub 
      2017 Nov 10.

PMID- 31669590
OWN - NLM
STAT- MEDLINE
DCOM- 20200602
LR  - 20200602
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 866
DP  - 2020 Jan 5
TI  - Aspirin and its pleiotropic application.
PG  - 172762
LID - S0014-2999(19)30714-9 [pii]
LID - 10.1016/j.ejphar.2019.172762 [doi]
AB  - Aspirin (acetylsalicylic acid), the oldest synthetic drug, was originally used as 
      an anti-inflammatory medication. Being an irreversible inhibitor of COX 
      (prostaglandin-endoperoxide synthase) enzymes that produce precursors for 
      prostaglandins and thromboxanes, it has gradually found several other 
      applications. Sometimes these applications are unrelated to its original purpose 
      for example its use as an anticoagulant. Applications such as these have opened 
      opportunities for new treatments. In this case, it has been tested in patients 
      with cardiovascular disease to reduce the risk of myocardial infarct. Its 
      function as an anticoagulant has also been explored in the prophylaxis and 
      treatment of pre-eclampsia, where due to its anti-inflammatory properties, 
      aspirin intake may be used to reduce the risk of colorectal cancer. It is 
      important to always consider both the risks and benefits of aspirin's 
      application. This is especially important for proposed use in the prevention and 
      treatment of neurologic ailments like Alzheimer's disease, or in the prophylaxis 
      of myocardial infarct. In such cases, the decision if aspirin should be applied, 
      and at what dose may be guided by specific molecular markers. In this revived 
      paper, the pleiotropic application of aspirin is summarized.
CI  - Copyright © 2019 Elsevier B.V. All rights reserved.
FAU - Hybiak, Jolanta
AU  - Hybiak J
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland. 
      Electronic address: jhybiak@pum.edu.pl.
FAU - Broniarek, Izabela
AU  - Broniarek I
AD  - Department of Gene Expression, Institute of Molecular Biology and Biotechnology, 
      Adam Mickiewicz University Poznan, Poland.
FAU - Kiryczyński, Gerard
AU  - Kiryczyński G
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
FAU - Los, Laura D
AU  - Los LD
AD  - Faculty of Science, University of Manitoba, Winnipeg, Canada.
FAU - Rosik, Jakub
AU  - Rosik J
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
FAU - Machaj, Filip
AU  - Machaj F
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
FAU - Sławiński, Hubert
AU  - Sławiński H
AD  - Wellcome Centre for Human Genetics, University of Oxford, United Kingdom.
FAU - Jankowska, Kornelia
AU  - Jankowska K
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
FAU - Urasińska, Elżbieta
AU  - Urasińska E
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191026
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Mental Disorders/drug therapy
MH  - Neoplasms/drug therapy/prevention & control
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - Anticoagulant
OT  - Aspirin
OT  - Cancer
OT  - Cardiovascular
OT  - Cyclooxygenase
OT  - Pre-eclampsia
EDAT- 2019/11/02 06:00
MHDA- 2020/06/03 06:00
CRDT- 2019/11/01 06:00
PHST- 2019/08/11 00:00 [received]
PHST- 2019/10/21 00:00 [revised]
PHST- 2019/10/25 00:00 [accepted]
PHST- 2019/11/02 06:00 [pubmed]
PHST- 2020/06/03 06:00 [medline]
PHST- 2019/11/01 06:00 [entrez]
AID - S0014-2999(19)30714-9 [pii]
AID - 10.1016/j.ejphar.2019.172762 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2020 Jan 5;866:172762. doi: 10.1016/j.ejphar.2019.172762. Epub 
      2019 Oct 26.

PMID- 31280821
OWN - NLM
STAT- MEDLINE
DCOM- 20200113
LR  - 20200301
IS  - 2213-3763 (Electronic)
IS  - 0019-4832 (Print)
IS  - 0019-4832 (Linking)
VI  - 71
IP  - 2
DP  - 2019 Mar-Apr
TI  - Aspirin for primary prevention: Is this the end of the road?
PG  - 113-117
LID - S0019-4832(18)31268-9 [pii]
LID - 10.1016/j.ihj.2019.04.001 [doi]
AB  - Aspirin is one of the oldest and most commonly used cardiovascular drugs. Despite 
      there being high-quality evidence supporting the use of aspirin for patients with 
      known cardiovascular disease, a definitive consensus regarding its use for 
      patients at risk for cardiovascular disease (and without established 
      cardiovascular disease) has never been reached. Many randomized control trials 
      have produced conflicting results, and consequently, society guidelines have 
      issued differring recommendations. Three major trials were published in 2018, 
      which supplement the existing data on aspirin's role in primary prevention and 
      provide further guidance on this contentious issue. This article reviews the 
      history of aspirin through the last two decades, with special emphasis on these 
      new trials.
CI  - Copyright © 2019 Cardiological Society of India. Published by Elsevier B.V. All 
      rights reserved.
FAU - Singal, Aayush Kumar
AU  - Singal AK
AD  - Department of Cardiology, Cardiothoracic Sciences Centre, All India Institute of 
      Medical Sciences (AIIMS), New Delhi, India. Electronic address: 
      doc.aayush@gmail.com.
FAU - Karthikeyan, Ganesan
AU  - Karthikeyan G
AD  - Department of Cardiology, Cardiothoracic Sciences Centre, All India Institute of 
      Medical Sciences (AIIMS), New Delhi, India. Electronic address: 
      karthik2010@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190502
PL  - India
TA  - Indian Heart J
JT  - Indian heart journal
JID - 0374675
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Primary Prevention/*methods
PMC - PMC6620426
OTO - NOTNLM
OT  - Aspirin
OT  - MI-bleed trade-off
OT  - Primary prevention
EDAT- 2019/07/10 06:00
MHDA- 2020/01/14 06:00
CRDT- 2019/07/09 06:00
PHST- 2018/12/20 00:00 [received]
PHST- 2019/03/28 00:00 [revised]
PHST- 2019/04/15 00:00 [accepted]
PHST- 2019/07/09 06:00 [entrez]
PHST- 2019/07/10 06:00 [pubmed]
PHST- 2020/01/14 06:00 [medline]
AID - S0019-4832(18)31268-9 [pii]
AID - 10.1016/j.ihj.2019.04.001 [doi]
PST - ppublish
SO  - Indian Heart J. 2019 Mar-Apr;71(2):113-117. doi: 10.1016/j.ihj.2019.04.001. Epub 
      2019 May 2.

PMID- 26868177
OWN - NLM
STAT- MEDLINE
DCOM- 20160706
LR  - 20220330
IS  - 1474-1768 (Electronic)
IS  - 1474-175X (Print)
IS  - 1474-175X (Linking)
VI  - 16
IP  - 3
DP  - 2016 Mar
TI  - Aspirin and colorectal cancer: the promise of precision chemoprevention.
PG  - 173-86
LID - 10.1038/nrc.2016.4 [doi]
AB  - Aspirin (acetylsalicylic acid) has become one of the most commonly used drugs, 
      given its role as an analgesic, antipyretic and agent for cardiovascular 
      prophylaxis. Several decades of research have provided considerable evidence 
      demonstrating its potential for the prevention of cancer, particularly colorectal 
      cancer. Broader clinical recommendations for aspirin-based chemoprevention 
      strategies have recently been established; however, given the known hazards of 
      long-term aspirin use, larger-scale adoption of an aspirin chemoprevention 
      strategy is likely to require improved identification of individuals for whom the 
      protective benefits outweigh the harms. Such a precision medicine approach may 
      emerge through further clarification of aspirin's mechanism of action.
FAU - Drew, David A
AU  - Drew DA
AD  - Massachusetts General Hospital and Harvard Medical School, Clinical and 
      Translational Epidemiology Unit, 55 Fruit Street, Bartlett Ext. 9, Boston, 
      Massachusetts 02114, USA.
FAU - Cao, Yin
AU  - Cao Y
AD  - Massachusetts General Hospital and Harvard Medical School, Clinical and 
      Translational Epidemiology Unit, and Harvard T.H. Chan School of Public Health, 
      Department of Nutrition, 55 Fruit Street, Bartlett Ext. 9, Boston, Massachusetts 
      02114, USA.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Massachusetts General Hospital and Harvard Medical School, Clinical and 
      Translational Epidemiology Unit, Division of Gastroenterology, GRJ-825C, Boston, 
      Massachusetts 02114, USA.
LA  - eng
GR  - K24 DK098311/DK/NIDDK NIH HHS/United States
GR  - L30 CA209764/CA/NCI NIH HHS/United States
GR  - P30 DK043351/DK/NIDDK NIH HHS/United States
GR  - R01 CA137178/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20160212
PL  - England
TA  - Nat Rev Cancer
JT  - Nature reviews. Cancer
JID - 101124168
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Chemoprevention
MH  - Colorectal Neoplasms/etiology/pathology/*prevention & control
MH  - Humans
MH  - Precision Medicine
PMC - PMC6741347
MID - NIHMS1046413
EDAT- 2016/02/13 06:00
MHDA- 2016/07/07 06:00
CRDT- 2016/02/13 06:00
PHST- 2016/02/13 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2016/07/07 06:00 [medline]
AID - nrc.2016.4 [pii]
AID - 10.1038/nrc.2016.4 [doi]
PST - ppublish
SO  - Nat Rev Cancer. 2016 Mar;16(3):173-86. doi: 10.1038/nrc.2016.4. Epub 2016 Feb 12.

PMID- 34824680
OWN - NLM
STAT- MEDLINE
DCOM- 20211129
LR  - 20211129
IS  - 1947-6108 (Electronic)
IS  - 1947-6094 (Print)
IS  - 1947-6108 (Linking)
VI  - 17
IP  - 4
DP  - 2021
TI  - Aspirin in the Modern Era of Cardiovascular Disease Prevention.
PG  - 36-47
LID - 10.14797/mdcvj.293 [doi]
AB  - Aspirin's antithrombotic effects have a long-established place in the prevention 
      of cardiovascular disease (CVD), and its traditional use as a core therapy for 
      secondary prevention of CVD is well recognized. However, with the advent of newer 
      antiplatelet agents and an increasing understanding of aspirin's bleeding risks, 
      its role across the full spectrum of modern CVD prevention has become less 
      certain. As a consequence, recent trials have begun investigating aspirin-free 
      strategies in secondary prevention. For example, a contemporary metanalysis of 
      trials that assessed P2Y(12) inhibitor monotherapy versus prolonged (≥ 12 months) 
      dual antiplatelet therapy (which includes aspirin) after percutaneous coronary 
      intervention reported a lower risk of major bleeding and no increase in stent 
      thrombosis, all-cause mortality, myocardial infarction (MI), or stroke in the 
      P2Y(12) monotherapy group. In contrast to secondary prevention, aspirin's role in 
      primary prevention has always been more controversial. While historical trials 
      reported a reduction in MI and stroke, more contemporary trials have suggested 
      diminishing benefit for aspirin in this setting, with no reduction in hard 
      outcomes, and some primary prevention trials have even indicated a potential for 
      harm. In this review, we discuss how changing population demographics, enhanced 
      control of lipids and blood pressure, changes in the definition of outcomes like 
      MI, evolution of aspirin formulations, and updated clinical practice guidelines 
      have all impacted the use of aspirin for primary and secondary CVD prevention.
CI  - Copyright: © 2021 The Author(s).
FAU - Murphy, Ella
AU  - Murphy E
AD  - National University of Ireland, Galway, Ireland.
FAU - Curneen, James M G
AU  - Curneen JMG
AUID- ORCID: 0000-0002-6414-9803
AD  - National University of Ireland, Galway, Ireland.
FAU - McEvoy, John W
AU  - McEvoy JW
AUID- ORCID: 0000-0001-6530-5479
AD  - National University of Ireland, Galway, Ireland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210924
PL  - United States
TA  - Methodist Debakey Cardiovasc J
JT  - Methodist DeBakey cardiovascular journal
JID - 101508600
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/epidemiology/prevention & control
MH  - Humans
MH  - *Myocardial Infarction
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Purinergic P2Y Receptor Antagonists
PMC - PMC8588762
OTO - NOTNLM
OT  - antiplatelet
OT  - aspirin
OT  - cardiovascular disease
OT  - preventive cardiology
COIS- The authors have completed and submitted the Methodist DeBakey Cardiovascular 
      Journal Conflict of Interest statement and none were reported.
EDAT- 2021/11/27 06:00
MHDA- 2021/11/30 06:00
CRDT- 2021/11/26 06:54
PHST- 2021/02/27 00:00 [received]
PHST- 2021/04/18 00:00 [accepted]
PHST- 2021/11/26 06:54 [entrez]
PHST- 2021/11/27 06:00 [pubmed]
PHST- 2021/11/30 06:00 [medline]
AID - 10.14797/mdcvj.293 [doi]
PST - epublish
SO  - Methodist Debakey Cardiovasc J. 2021 Sep 24;17(4):36-47. doi: 10.14797/mdcvj.293. 
      eCollection 2021.

PMID- 33035431
OWN - NLM
STAT- MEDLINE
DCOM- 20211029
LR  - 20220128
IS  - 1545-326X (Electronic)
IS  - 0066-4219 (Print)
IS  - 0066-4219 (Linking)
VI  - 72
DP  - 2021 Jan 27
TI  - Aspirin in the Prevention of Colorectal Neoplasia.
PG  - 415-430
LID - 10.1146/annurev-med-060319-120913 [doi]
AB  - High-quality evidence indicates that regular use of aspirin is effective in 
      reducing the risk for precancerous colorectal neoplasia and colorectal cancer 
      (CRC). This has led to US and international guidelines recommending aspirin for 
      the primary prevention of CRC in specific populations. In this review, we 
      summarize key questions that require addressing prior to broader adoption of 
      aspirin-based chemoprevention, review recent evidence related to the benefits and 
      harms of aspirin use among specific populations, and offer a rationale for 
      precision prevention approaches. We specifically consider the mechanistic 
      implications of evidence showing differences in aspirin's effects according to 
      age, the potential role of modifiable mechanistic biomarkers for personalizing 
      prevention, and emerging evidence that the gut microbiota may offer novel 
      aspirin-associated preventive targets to reduce high-risk neoplasia.
FAU - Drew, David A
AU  - Drew DA
AD  - Clinical and Translational Epidemiology Unit and Division of Gastroenterology, 
      Department of Medicine, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts 02114, USA; email: dadrew@mgh.harvard.edu, 
      achan@mgh.harvard.edu.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Clinical and Translational Epidemiology Unit and Division of Gastroenterology, 
      Department of Medicine, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts 02114, USA; email: dadrew@mgh.harvard.edu, 
      achan@mgh.harvard.edu.
AD  - Department of Immunology and Infectious Disease, Harvard T.H. Chan School of 
      Public Health, Boston, Massachusetts 02114, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
LA  - eng
GR  - K01 DK120742/DK/NIDDK NIH HHS/United States
GR  - L30 CA209764/CA/NCI NIH HHS/United States
GR  - R01 CA137178/CA/NCI NIH HHS/United States
GR  - R35 CA253185/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201009
PL  - United States
TA  - Annu Rev Med
JT  - Annual review of medicine
JID - 2985151R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Chemoprevention/methods
MH  - Colorectal Neoplasms/*prevention & control
MH  - Humans
MH  - Precision Medicine/methods
PMC - PMC7880546
MID - NIHMS1662466
OTO - NOTNLM
OT  - chemoprevention
OT  - colorectal cancer
OT  - nonsteroidal anti-inflammatory drugs
OT  - personalized medicine
OT  - precision chemoprevention
EDAT- 2020/10/10 06:00
MHDA- 2021/10/30 06:00
CRDT- 2020/10/09 20:08
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/10/30 06:00 [medline]
PHST- 2020/10/09 20:08 [entrez]
AID - 10.1146/annurev-med-060319-120913 [doi]
PST - ppublish
SO  - Annu Rev Med. 2021 Jan 27;72:415-430. doi: 10.1146/annurev-med-060319-120913. 
      Epub 2020 Oct 9.

PMID- 33893087
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20220127
IS  - 1538-7445 (Electronic)
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 81
IP  - 14
DP  - 2021 Jul 15
TI  - Aspirin in Hepatocellular Carcinoma.
PG  - 3751-3761
LID - 10.1158/0008-5472.CAN-21-0758 [doi]
AB  - Preclinical and clinical studies provide evidence for aspirin as a preventative 
      agent for cancer. Compelling direct evidence supports a chemopreventive effect of 
      aspirin in individuals at high risk of developing colorectal cancer due to Lynch 
      syndrome, while indirect evidence indicates that aspirin may reduce the risk of 
      and mortality from sporadic colorectal cancer. There is weaker evidence for a 
      protective effect of aspirin against all cancers taken as a group. Nevertheless, 
      the results of recent retrospective cohort studies consistently indicate a 
      beneficial effect of aspirin as a chemopreventive or adjuvant chemotherapeutic 
      agent in hepatocellular carcinoma (HCC). Epidemiologic studies conducted in the 
      general population or in selected populations at higher risk for HCC reveal that 
      regular aspirin use is associated with reduced HCC incidence. In addition, 
      aspirin may act as an adjuvant to other therapies in reducing HCC recurrence. 
      According to studies in animal models, the cancer-preventative effect of aspirin 
      may be related to its antiplatelet and anti-inflammatory activities. Prospective 
      studies are warranted to determine whether aspirin should be recommended to 
      diverse populations of patients at risk for HCC.
CI  - ©2021 American Association for Cancer Research.
FAU - Ricciotti, Emanuela
AU  - Ricciotti E
AUID- ORCID: 0000-0002-6971-3215
AD  - Department of Systems Pharmacology and Translational Therapeutics, Perelman 
      School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
AD  - Institute for Translational Medicine and Therapeutics, Perelman School of 
      Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - Wangensteen, Kirk J
AU  - Wangensteen KJ
AUID- ORCID: 0000-0001-6042-6490
AD  - Institute for Translational Medicine and Therapeutics, Perelman School of 
      Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
AD  - Department of Medicine, Division of Gastroenterology and Hepatology, Perelman 
      School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - FitzGerald, Garret A
AU  - FitzGerald GA
AD  - Department of Systems Pharmacology and Translational Therapeutics, Perelman 
      School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 
      garret@upenn.edu.
AD  - Institute for Translational Medicine and Therapeutics, Perelman School of 
      Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
LA  - eng
GR  - R01 HL141912/HL/NHLBI NIH HHS/United States
GR  - R03 DK123543/DK/NIDDK NIH HHS/United States
GR  - UL1 TR001878/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210423
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Carcinoma, Hepatocellular/*prevention & control
MH  - Humans
MH  - Liver Neoplasms/*prevention & control
MH  - Retrospective Studies
PMC - PMC8286305
MID - NIHMS1698652
EDAT- 2021/04/25 06:00
MHDA- 2022/01/28 06:00
CRDT- 2021/04/24 05:39
PHST- 2021/03/10 00:00 [received]
PHST- 2021/04/20 00:00 [revised]
PHST- 2021/04/20 00:00 [accepted]
PHST- 2021/04/25 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
PHST- 2021/04/24 05:39 [entrez]
AID - 0008-5472.CAN-21-0758 [pii]
AID - 10.1158/0008-5472.CAN-21-0758 [doi]
PST - ppublish
SO  - Cancer Res. 2021 Jul 15;81(14):3751-3761. doi: 10.1158/0008-5472.CAN-21-0758. 
      Epub 2021 Apr 23.

PMID- 28590311
OWN - NLM
STAT- MEDLINE
DCOM- 20180322
LR  - 20180322
IS  - 1473-6322 (Electronic)
IS  - 1473-6322 (Linking)
VI  - 17
IP  - 4
DP  - 2017 Aug
TI  - Aspirin challenge and desensitization: how, when and why.
PG  - 247-254
LID - 10.1097/ACI.0000000000000374 [doi]
AB  - PURPOSE OF REVIEW: To investigate the current approach to aspirin challenge (drug 
      provocation) and/or desensitization in patients with histories of 
      hypersensitivity reactions to it, particularly in those with cardiovascular 
      diseases. RECENT FINDINGS: The literature indicates that patients with coronary 
      artery disease (CAD), including those with an acute coronary syndrome, may safely 
      undergo low-dose aspirin challenge and/or desensitization. Recently, flowcharts 
      regarding challenge/desensitization procedures with aspirin in patients with CAD 
      and histories of aspirin hypersensitivity reactions have become available. 
      Aspirin desensitization and continuous aspirin therapy constitute an effective 
      option in patients with nonsteroidal anti-inflammatory drug-exacerbated 
      respiratory diseases (NERD) who have suboptimally controlled asthma or 
      rhinosinusitis, or require multiple revision polypectomies. SUMMARY: The use of 
      aspirin has proven to reduce morbidity and mortality associated with CAD. There 
      is a general consensus on aspirin's effectiveness in secondary prevention of CAD. 
      Therefore, aspirin desensitization is necessary in patients with CAD and 
      histories of hypersensitivity reactions to it. The effectiveness of aspirin 
      desensitization and continuous therapy in patients with NERD has been shown in 
      numerous studies. However, shared selection criteria of candidates for aspirin 
      challenge/desensitization procedures, and simple and homogeneous protocols are 
      necessary. Moreover, preventive safety measures are still needed in order to 
      reduce the potential risks of these procedures.
FAU - Cortellini, Gabriele
AU  - Cortellini G
AD  - aInternal Medicine and Rheumatology Department, Azienda Sanitaria Romagna, Rimini 
      Hospital, Rimini bAllergy Unit, Fondazione Policlinico Gemelli - Presidio 
      Columbus cAllergy Unit, Presidio Columbus, Rome dIRCCS Oasi Maria S.S., Troina, 
      Italy.
FAU - Caruso, Cristiano
AU  - Caruso C
FAU - Romano, Antonino
AU  - Romano A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Allergy Clin Immunol
JT  - Current opinion in allergy and clinical immunology
JID - 100936359
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Asthma, Aspirin-Induced/*therapy
MH  - Coronary Artery Disease/*drug therapy
MH  - Desensitization, Immunologic/*methods
MH  - Humans
MH  - *Rhinitis, Allergic/chemically induced/therapy
EDAT- 2017/06/08 06:00
MHDA- 2018/03/23 06:00
CRDT- 2017/06/08 06:00
PHST- 2017/06/08 06:00 [pubmed]
PHST- 2018/03/23 06:00 [medline]
PHST- 2017/06/08 06:00 [entrez]
AID - 10.1097/ACI.0000000000000374 [doi]
PST - ppublish
SO  - Curr Opin Allergy Clin Immunol. 2017 Aug;17(4):247-254. doi: 
      10.1097/ACI.0000000000000374.

PMID- 36099932
OWN - NLM
STAT- MEDLINE
DCOM- 20220915
LR  - 20230425
IS  - 2046-2441 (Electronic)
IS  - 2046-2441 (Linking)
VI  - 12
IP  - 9
DP  - 2022 Sep
TI  - Aspirin and cancer: biological mechanisms and clinical outcomes.
PG  - 220124
LID - 10.1098/rsob.220124 [doi]
LID - 220124
AB  - Evidence on aspirin and cancer comes from two main sources: (1) the effect of 
      aspirin upon biological mechanisms in cancer, and (2) clinical studies of 
      patients with cancer, some of whom take aspirin. A series of systematic 
      literature searches identified published reports relevant to these two sources. 
      The effects of aspirin upon biological mechanisms involved in cancer initiation 
      and growth appear to generate reasonable expectations of effects upon the 
      progress and mortality of cancer. Clinical evidence on aspirin appears overall to 
      be favourable to the use of aspirin, but evidence from randomized trials is 
      limited, and inconsistent. The main body of evidence comes from meta-analyses of 
      observational studies of patients with a wide range of cancers, about 25% of whom 
      were taking aspirin. Heterogeneity is large but, overall, aspirin is associated 
      with increases in survival and reductions in metastatic spread and vascular 
      complications of different cancers. It is important that evaluations of aspirin 
      used as an adjunct cancer treatment are based upon all the available relevant 
      evidence, and there appears to be a marked harmony between the effects of aspirin 
      upon biological mechanisms and upon the clinical progress of cancer.
FAU - Elwood, Peter
AU  - Elwood P
AUID- ORCID: 0000-0003-4352-1570
AD  - Division of Population Medicine, University of Cardiff, Cardiff, Wales CF10 3AT, 
      UK.
FAU - Protty, Majd
AU  - Protty M
AD  - Department of Cardiology, Cardiff Lipidomic Group, University of Cardiff, 
      Cardiff, Wales, UK.
FAU - Morgan, Gareth
AU  - Morgan G
AD  - Public Health Wales, Cardiff, Wales, UK.
FAU - Pickering, Janet
AU  - Pickering J
AD  - Division of Population Medicine, University of Cardiff, Cardiff, Wales CF10 3AT, 
      UK.
FAU - Delon, Christine
AU  - Delon C
AD  - Independent Research, London, England, UK.
FAU - Watkins, John
AU  - Watkins J
AD  - Division of Population Medicine, University of Cardiff, Cardiff, Wales CF10 3AT, 
      UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220914
PL  - England
TA  - Open Biol
JT  - Open biology
JID - 101580419
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Cardiovascular Diseases/drug therapy
MH  - Humans
MH  - *Neoplasms/drug therapy
PMC - PMC9470249
OTO - NOTNLM
OT  - aspirin
OT  - bleeding
OT  - cancer
OT  - survival
OT  - thromboembolism
COIS- We declare we have no competing interests.
EDAT- 2022/09/14 06:00
MHDA- 2022/09/16 06:00
CRDT- 2022/09/13 19:03
PHST- 2022/09/13 19:03 [entrez]
PHST- 2022/09/14 06:00 [pubmed]
PHST- 2022/09/16 06:00 [medline]
AID - rsob220124 [pii]
AID - 10.1098/rsob.220124 [doi]
PST - ppublish
SO  - Open Biol. 2022 Sep;12(9):220124. doi: 10.1098/rsob.220124. Epub 2022 Sep 14.

PMID- 26739313
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181113
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 41
IP  - 3
DP  - 2016 Apr
TI  - Aspirin dosing frequency in the primary and secondary prevention of 
      cardiovascular events.
PG  - 493-504
LID - 10.1007/s11239-015-1307-2 [doi]
AB  - Aspirin has been a cornerstone of cardiovascular disease prevention since the 
      late 1980s. Despite the popularity of aspirin and its wide use, the proper dosing 
      and frequency of aspirin has yet to be determined. Early aspirin trials focused 
      on its utility in broad target populations, but this strategy did not magnify the 
      benefit of aspirin, and rather increased the complication rate. We have learned 
      from previous studies that laboratory and clinical response to aspirin therapy in 
      patients with different conditions and settings are diverse. This difference in 
      aspirin response necessitates a personalized, tailored aspirin therapy. We aim to 
      perform a comprehensive review of the current evidence surrounding aspirin 
      responsiveness in several distinct patient populations and the rationale of 
      different aspirin frequency and dosing strategies. Our conclusions call for 
      future studies to determine individualized aspirin strategies to maximize the 
      benefit and minimize the risk of aspirin.
FAU - Kim, Joonseok
AU  - Kim J
AD  - Division of Cardiovascular Health and Disease, Department of Medicine, University 
      of Cincinnati College of Medicine, Cincinnati, OH, 45257, USA.
FAU - Becker, Richard C
AU  - Becker RC
AD  - Division of Cardiovascular Health and Disease, Department of Medicine, University 
      of Cincinnati College of Medicine, Cincinnati, OH, 45257, USA. 
      richard.becker@uc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Trials as Topic
MH  - Humans
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirin dosing and frequency
OT  - Cardiovascular prevention
OT  - Coronary artery disease
OT  - Coronary heart disease prevention
EDAT- 2016/01/08 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/01/08 06:00
PHST- 2016/01/08 06:00 [entrez]
PHST- 2016/01/08 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1007/s11239-015-1307-2 [pii]
AID - 10.1007/s11239-015-1307-2 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2016 Apr;41(3):493-504. doi: 10.1007/s11239-015-1307-2.

PMID- 17523700
OWN - NLM
STAT- MEDLINE
DCOM- 20070720
LR  - 20181113
IS  - 1174-5878 (Print)
IS  - 1174-5878 (Linking)
VI  - 9
IP  - 3
DP  - 2007
TI  - Aspirin and Reye syndrome: a review of the evidence.
PG  - 195-204
AB  - Reye syndrome is an extremely rare but severe and often fatal disease. Death 
      occurs in about 30-40% of cases from brainstem dysfunction. The disease typically 
      is preceded by a viral infection with an intermediate disease-free interval of 
      3-5 days. The biochemical explanation for Reye-like symptoms is a generalized 
      disturbance in mitochondrial metabolism, eventually resulting in metabolic 
      failure in the liver and other tissues. The etiology of 'classical' Reye syndrome 
      is unknown. Hypothetically, the syndrome may result from an unusual response to 
      the preceding viral infection, which is determined by host genetic factors but 
      can be modified by a variety of exogenous agents. Thus, several infections and 
      diseases might present clinically with Reye-like symptoms. Exogenous agents 
      involve a number of toxins, drugs (including aspirin [acetylsalicylic acid]), and 
      other chemicals. The 'rise and fall' in the incidence of Reye syndrome is still 
      poorly understood and unexplained. With a few exceptions, there were probably no 
      new Reye-like diseases reported during the last 10 years that could not be 
      explained by an inherited disorder of metabolism or a misdiagnosis. This may 
      reflect scientific progress in the better understanding of cellular and molecular 
      dysfunctions as disease-determining factors. Alternatively, the immune response 
      to and the virulence of a virus might have changed by alteration of its genetic 
      code. The suggestion of a defined cause-effect relationship between aspirin 
      intake and Reye syndrome in children is not supported by sufficient facts. 
      Clearly, no drug treatment is without side effects. Thus, a balanced view of 
      whether treatment with a certain drug is justified in terms of the benefit/risk 
      ratio is always necessary. Aspirin is no exception.
FAU - Schrör, Karsten
AU  - Schrör K
AD  - Institut für Pharmakologie und Klinische Pharmakologie, 
      Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany. 
      kschroer@uni-duesseldorf.de
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Switzerland
TA  - Paediatr Drugs
JT  - Paediatric drugs
JID - 100883685
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Paediatr Drugs. 2007;9(3):205-6. PMID: 17523701
MH  - Aspirin/administration & dosage/*adverse effects/pharmacokinetics/pharmacology
MH  - Child
MH  - Energy Metabolism
MH  - Humans
MH  - Liver/drug effects/metabolism
MH  - *Reye Syndrome/chemically induced/epidemiology/etiology
RF  - 95
EDAT- 2007/05/26 09:00
MHDA- 2007/07/21 09:00
CRDT- 2007/05/26 09:00
PHST- 2007/05/26 09:00 [pubmed]
PHST- 2007/07/21 09:00 [medline]
PHST- 2007/05/26 09:00 [entrez]
AID - 938 [pii]
AID - 10.2165/00148581-200709030-00008 [doi]
PST - ppublish
SO  - Paediatr Drugs. 2007;9(3):195-204. doi: 10.2165/00148581-200709030-00008.

PMID- 33824205
OWN - NLM
STAT- MEDLINE
DCOM- 20211001
LR  - 20211001
IS  - 2150-7511 (Electronic)
VI  - 12
IP  - 2
DP  - 2021 Apr 6
TI  - Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium 
      nucleatum.
LID - 10.1128/mBio.00547-21 [doi]
LID - e00547-21
AB  - Aspirin is a chemopreventive agent for colorectal adenoma and cancer (CRC) that, 
      like many drugs inclusive of chemotherapeutics, has been investigated for its 
      effects on bacterial growth and virulence gene expression. Given the evolving 
      recognition of the roles for bacteria in CRC, in this work, we investigate the 
      effects of aspirin with a focus on one oncomicrobe-Fusobacterium nucleatum We 
      show that aspirin and its primary metabolite salicylic acid alter F. nucleatum 
      strain Fn7-1 growth in culture and that aspirin can effectively kill both 
      actively growing and stationary Fn7-1. We also demonstrate that, at levels that 
      do not inhibit growth, aspirin influences Fn7-1 gene expression. To assess 
      whether aspirin modulation of F. nucleatum may be relevant in vivo, we use the 
      Apc(Min/+) mouse intestinal tumor model in which Fn7-1 is orally inoculated daily 
      to reveal that aspirin-supplemented chow is sufficient to inhibit F. 
      nucleatum-potentiated colonic tumorigenesis. We expand our characterization of 
      aspirin sensitivity across other F. nucleatum strains, including those isolated 
      from human CRC tissues, as well as other CRC-associated microbes, enterotoxigenic 
      Bacteroides fragilis, and colibactin-producing Escherichia coli Finally, we 
      determine that individuals who use aspirin daily have lower fusobacterial 
      abundance in colon adenoma tissues, as determined by quantitative PCR performed 
      on adenoma DNA. Together, our data support that aspirin has direct antibiotic 
      activity against F. nucleatum strains and suggest that consideration of the 
      potential effects of aspirin on the microbiome holds promise in optimizing 
      risk-benefit assessments for use of aspirin in CRC prevention and 
      management.IMPORTANCE There is an increasing understanding of the clinical 
      correlations and potential mechanistic roles of specific members of the gut and 
      tumoral microbiota in colorectal cancer (CRC) initiation, progression, and 
      survival. However, we have yet to parlay this knowledge into better CRC outcomes 
      through microbially informed diagnostic, preventive, or therapeutic approaches. 
      Here, we demonstrate that aspirin, an established CRC chemopreventive, exhibits 
      specific effects on the CRC-associated Fusobacterium nucleatum in culture, an 
      animal model of intestinal tumorigenesis, and in human colonic adenoma tissues. 
      Our work proposes a potential role for aspirin in influencing CRC-associated 
      bacteria to prevent colorectal adenomas and cancer, beyond aspirin's canonical 
      anti-inflammatory role targeting host tissues. Future research, such as studies 
      investigating the effects of aspirin on fusobacterial load in patients, will help 
      further elucidate the prospect of using aspirin to modulate F. nucleatumin vivo 
      for improving CRC outcomes.
CI  - Copyright © 2021 Brennan et al.
FAU - Brennan, Caitlin A
AU  - Brennan CA
AD  - Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of 
      Public Health, Boston, Massachusetts, USA.
AD  - Harvard T. H. Chan Microbiome in Public Health Center, Boston, Massachusetts, 
      USA.
FAU - Nakatsu, Geicho
AU  - Nakatsu G
AD  - Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of 
      Public Health, Boston, Massachusetts, USA.
AD  - Harvard T. H. Chan Microbiome in Public Health Center, Boston, Massachusetts, 
      USA.
FAU - Gallini Comeau, Carey Ann
AU  - Gallini Comeau CA
AD  - Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of 
      Public Health, Boston, Massachusetts, USA.
FAU - Drew, David A
AU  - Drew DA
AD  - Clinical and Translational Epidemiology Unit, Department of Medicine, 
      Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, 
      USA.
AD  - Division of Gastroenterology, Department of Medicine, Massachusetts General 
      Hospital and Harvard Medical School, Boston, Massachusetts, USA.
FAU - Glickman, Jonathan N
AU  - Glickman JN
AD  - Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
FAU - Schoen, Robert E
AU  - Schoen RE
AD  - Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, 
      University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of 
      Public Health, Boston, Massachusetts, USA.
AD  - Harvard T. H. Chan Microbiome in Public Health Center, Boston, Massachusetts, 
      USA.
AD  - Clinical and Translational Epidemiology Unit, Department of Medicine, 
      Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, 
      USA.
AD  - Division of Gastroenterology, Department of Medicine, Massachusetts General 
      Hospital and Harvard Medical School, Boston, Massachusetts, USA.
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
FAU - Garrett, Wendy S
AU  - Garrett WS
AD  - Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of 
      Public Health, Boston, Massachusetts, USA wgarrett@hsph.harvard.edu.
AD  - Harvard T. H. Chan Microbiome in Public Health Center, Boston, Massachusetts, 
      USA.
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
AD  - Department and Division of Medical Oncology, Dana-Farber Cancer Institute and 
      Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Molecular Metabolism, Harvard T. H. Chan School of Public Health, 
      Boston, Massachusetts, USA.
LA  - eng
GR  - K01 DK120742/DK/NIDDK NIH HHS/United States
GR  - R01 CA202704/CA/NCI NIH HHS/United States
GR  - U01 CA152753/CA/NCI NIH HHS/United States
GR  - T32 CA207021/CA/NCI NIH HHS/United States
GR  - R01 CA154426/CA/NCI NIH HHS/United States
GR  - R35 CA253185/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210406
PL  - United States
TA  - mBio
JT  - mBio
JID - 101519231
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/*microbiology
MH  - Animals
MH  - Aspirin/*administration & dosage/*pharmacology
MH  - Bacteria/drug effects/pathogenicity
MH  - Carcinogenesis
MH  - Cell Transformation, Neoplastic
MH  - Colon/drug effects/microbiology
MH  - Colorectal Neoplasms/*microbiology/prevention & control
MH  - Female
MH  - Fusobacterium nucleatum/*drug effects/genetics/pathogenicity
MH  - Humans
MH  - Male
MH  - Mice
PMC - PMC8092249
OTO - NOTNLM
OT  - Fusobacterium nucleatum
OT  - aspirin
OT  - colon cancer
EDAT- 2021/04/08 06:00
MHDA- 2021/10/02 06:00
CRDT- 2021/04/07 05:59
PHST- 2021/04/07 05:59 [entrez]
PHST- 2021/04/08 06:00 [pubmed]
PHST- 2021/10/02 06:00 [medline]
AID - mBio.00547-21 [pii]
AID - mBio00547-21 [pii]
AID - 10.1128/mBio.00547-21 [doi]
PST - epublish
SO  - mBio. 2021 Apr 6;12(2):e00547-21. doi: 10.1128/mBio.00547-21.

PMID- 33050859
OWN - NLM
STAT- MEDLINE
DCOM- 20211126
LR  - 20211126
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Linking)
VI  - 22
IP  - 1
DP  - 2021
TI  - Progress on the Mechanism for Aspirin's Anti-tumor Effects.
PG  - 105-111
LID - 10.2174/1389450121999201013152931 [doi]
AB  - Since its discovery more than 100 years ago, aspirin has been widely used for its 
      antipyretic, analgesic, anti-inflammatory, and anti-rheumatic activities. In 
      addition to these applications, it is increasingly becoming clear that the drug 
      also has great potential in the field of cancer. Here, we briefly review the 
      current insights on aspirin's anti-tumor effects. These are multiple and vary 
      from inhibiting the major cellular mTOR pathways, acting as a calorie-restricted 
      mimetic by inhibition of energy production, suppressing platelet aggregation and 
      granule release, inhibiting the immune escape of tumor cells, to decreasing 
      inflammatory responses. We consider these five mechanisms of action the most 
      significant for aspirin's anti-tumor effects, whereby the anti-tumor effect may 
      ultimately stem from its inhibition of energy metabolism, platelet function, and 
      inflammatory response. As such, aspirin can play an important role to reduce the 
      occurrence, proliferation, and metastasis of various types of tumors. However, 
      most of the collected data are still based on epidemiological investigations. 
      More direct and effective evidence is needed, and the side effects of aspirin 
      intake need to be solved before this drug can be widely applied in cancer 
      treatment.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Zheng, Lin
AU  - Zheng L
AD  - Department of Clinical Laboratory, Shunde Hospital of Southern Medical University 
      (The First People's Hospital of Shunde), Foshan 528300, Guangdong, China.
FAU - Lv, Weibiao
AU  - Lv W
AD  - Department of Clinical Laboratory, Shunde Hospital of Southern Medical University 
      (The First People's Hospital of Shunde), Foshan 528300, Guangdong, China.
FAU - Zhou, Yuanqing
AU  - Zhou Y
AD  - Department of Clinical Laboratory, Shunde Hospital of Southern Medical University 
      (The First People's Hospital of Shunde), Foshan 528300, Guangdong, China.
FAU - Lin, Xu
AU  - Lin X
AD  - Medical Research Center, Shunde Hospital of Southern Medical University (The 
      First People's Hospital of Shunde Foshan), Foshan, Guangdong, China.
FAU - Yao, Jie
AU  - Yao J
AD  - Department of Clinical Laboratory, Shunde Hospital of Southern Medical University 
      (The First People's Hospital of Shunde), Foshan 528300, Guangdong, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacology
MH  - Humans
MH  - *Neoplasms/drug therapy
OTO - NOTNLM
OT  - Aspirin
OT  - acetyl salicylic acid
OT  - anti-tumor activity
OT  - cancer
OT  - cellular mTOR pathways
OT  - inflammatory
EDAT- 2020/10/15 06:00
MHDA- 2021/11/27 06:00
CRDT- 2020/10/14 08:54
PHST- 2020/04/15 00:00 [received]
PHST- 2020/08/04 00:00 [revised]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2021/11/27 06:00 [medline]
PHST- 2020/10/14 08:54 [entrez]
AID - CDT-EPUB-110639 [pii]
AID - 10.2174/1389450121999201013152931 [doi]
PST - ppublish
SO  - Curr Drug Targets. 2021;22(1):105-111. doi: 10.2174/1389450121999201013152931.

PMID- 30562044
OWN - NLM
STAT- MEDLINE
DCOM- 20190607
LR  - 20210804
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Print)
IS  - 0008-4212 (Linking)
VI  - 97
IP  - 3
DP  - 2019 Mar
TI  - The role of aspirin and inflammation on reproduction: the EAGeR trial (1).
PG  - 187-192
LID - 10.1139/cjpp-2018-0368 [doi]
AB  - Inflammation has been linked to several complications in pregnancy, including 
      pregnancy loss. Due to its anti-inflammatory properties, aspirin, a widely 
      available and inexpensive therapy, has potential to help mitigate the negative 
      effects of inflammation along the reproductive pathway. Therefore, the Effects of 
      Aspirin in Gestation and Reproduction (EAGeR) trial was designed to elucidate 
      whether preconception-initiated daily low-dose aspirin would increase the live 
      birth rate in women with 1-2 prior pregnancy losses and no infertility diagnosis 
      and attempting unassisted conception. Here, we present an overview of the 
      collected findings. Low-dose aspirin was associated with an increased live birth 
      rate among women with a single loss at <20 weeks gestation within the past year. 
      When stratified by tertile of C-reactive protein (CRP), a biomarker of 
      inflammation, treatment with aspirin restored a decrement in the live birth rate 
      in women in the highest CRP tertile (relative risk 1.35, 95% confidence interval 
      1.08-1.67), increasing to similar rates as women of the lower and mid-CRP 
      tertiles. The same effect modification by inflammation status was observed when 
      examining the effect of low-dose aspirin on offspring sex ratio. These results 
      suggest that inflammation plays an important role in reproduction, and that 
      chronic, low-grade inflammation may be amenable to aspirin treatment.
FAU - Levine, Lindsay D
AU  - Levine LD
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Holland, Tiffany L
AU  - Holland TL
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Kim, Keewan
AU  - Kim K
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Sjaarda, Lindsey A
AU  - Sjaarda LA
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Mumford, Sunni L
AU  - Mumford SL
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Schisterman, Enrique F
AU  - Schisterman EF
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD 20892, USA.
LA  - eng
GR  - Z01 HD008795/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20181218
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Reproduction/*physiology
PMC - PMC8330243
MID - NIHMS1728096
OTO - NOTNLM
OT  - C-reactive protein
OT  - aspirin
OT  - aspirine
OT  - fausse couche
OT  - grossesse
OT  - inflammation
OT  - live birth
OT  - miscarriage
OT  - naissance vivante
OT  - perte de grossesse
OT  - pregnancy
OT  - pregnancy loss
OT  - protéine C réactive
EDAT- 2018/12/19 06:00
MHDA- 2019/06/08 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2019/06/08 06:00 [medline]
PHST- 2018/12/19 06:00 [entrez]
AID - 10.1139/cjpp-2018-0368 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2019 Mar;97(3):187-192. doi: 10.1139/cjpp-2018-0368. 
      Epub 2018 Dec 18.

PMID- 28762014
OWN - NLM
STAT- MEDLINE
DCOM- 20180402
LR  - 20200502
IS  - 1573-7233 (Electronic)
IS  - 0167-7659 (Print)
IS  - 0167-7659 (Linking)
VI  - 36
IP  - 2
DP  - 2017 Jun
TI  - Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms 
      of chemoprevention.
PG  - 289-303
LID - 10.1007/s10555-017-9675-z [doi]
AB  - After more than a century, aspirin remains one of the most commonly used drugs in 
      western medicine. Although mainly used for its anti-thrombotic, anti-pyretic, and 
      analgesic properties, a multitude of clinical studies have provided convincing 
      evidence that regular, low-dose aspirin use dramatically lowers the risk of 
      cancer. These observations coincide with recent studies showing a functional 
      relationship between platelets and tumors, suggesting that aspirin's 
      chemopreventive properties may result, in part, from direct modulation of 
      platelet biology and biochemistry. Here, we present a review of the biochemistry 
      and pharmacology of aspirin with particular emphasis on its 
      cyclooxygenase-dependent and cyclooxygenase-independent effects in platelets. We 
      also correlate the results of proteomic-based studies of aspirin acetylation in 
      eukaryotic cells with recent developments in platelet proteomics to identify 
      non-cyclooxygenase targets of aspirin-mediated acetylation in platelets that may 
      play a role in its chemopreventive mechanism.
FAU - Ornelas, Argentina
AU  - Ornelas A
AD  - Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Zacharias-Millward, Niki
AU  - Zacharias-Millward N
AD  - Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Menter, David G
AU  - Menter DG
AD  - Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer 
      Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Davis, Jennifer S
AU  - Davis JS
AD  - Department of Epidemiology, Division of Cancer Prevention and Population 
      Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Lichtenberger, Lenard
AU  - Lichtenberger L
AD  - McGovern Medical School, Department of Integrative Biology and Pharmacology, The 
      University of Texas Health Science Center at Houston, Houston, TX, USA.
FAU - Hawke, David
AU  - Hawke D
AD  - Department of Systems Biology, Proteomics and Metabolomics Facility, The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Hawk, Ernest
AU  - Hawk E
AD  - Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and 
      Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Vilar, Eduardo
AU  - Vilar E
AD  - Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and 
      Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Bhattacharya, Pratip
AU  - Bhattacharya P
AD  - Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Millward, Steven
AU  - Millward S
AD  - Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA. 
      smillward@mdanderson.or.
LA  - eng
GR  - R25 CA057730/CA/NCI NIH HHS/United States
GR  - R21 CA181994/CA/NCI NIH HHS/United States
GR  - R01 CA172670/CA/NCI NIH HHS/United States
GR  - R01 CA184843/CA/NCI NIH HHS/United States
GR  - R01 CA187238/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Cancer Metastasis Rev
JT  - Cancer metastasis reviews
JID - 8605731
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticarcinogenic Agents/chemistry/pharmacology
MH  - Aspirin/*chemistry/*pharmacology
MH  - Blood Platelets/*drug effects/enzymology
MH  - Cyclooxygenase 1/*metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Cyclooxygenase Inhibitors/chemistry/pharmacology
MH  - Humans
MH  - Neoplasms/*blood/*prevention & control
PMC - PMC5557878
OTO - NOTNLM
OT  - Acetylome
OT  - Aspirin
OT  - Chemoprevention
OT  - Cyclooxygenase-1
OT  - Cyclooxygenase-2
OT  - Platelets
EDAT- 2017/08/02 06:00
MHDA- 2018/04/03 06:00
CRDT- 2017/08/02 06:00
PHST- 2017/08/02 06:00 [pubmed]
PHST- 2018/04/03 06:00 [medline]
PHST- 2017/08/02 06:00 [entrez]
AID - 10.1007/s10555-017-9675-z [pii]
AID - 9675 [pii]
AID - 10.1007/s10555-017-9675-z [doi]
PST - ppublish
SO  - Cancer Metastasis Rev. 2017 Jun;36(2):289-303. doi: 10.1007/s10555-017-9675-z.

PMID- 12243613
OWN - NLM
STAT- MEDLINE
DCOM- 20030425
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 36
IP  - 10
DP  - 2002 Oct
TI  - Aspirin resistance.
PG  - 1620-4
AB  - OBJECTIVE: To review the literature addressing the problem of aspirin resistance 
      in patients with vascular disease. DATA SOURCES: A MEDLINE search (1966-February 
      2002) was performed. Key search terms included aspirin, resistance, resistant, 
      failure, tolerance, and nonresponder. English-language studies were identified as 
      well as pertinent references from these articles. DATA SYNTHESIS: Aspirin 
      resistance has been reported in patients with cardiovascular, cerebrovascular, 
      and peripheral vascular disease. Because of differences in the definition of 
      resistance, variations in detection methods, and a lack of controlled trials, the 
      true significance of the problem remains unknown. Multiple mechanisms for 
      resistance have been proposed, including increased reactivity to platelet 
      aggregating factors, genetic polymorphism, and alternate pathways for thromboxane 
      synthesis. The studies to date have failed to demonstrate consistent 
      relationships between aspirin's platelet-inhibiting effects, the impact of dosage 
      escalation, and clinical outcomes. CONCLUSIONS: For many patients, aspirin is an 
      effective antithrombotic agent. However, patients taking aspirin may demonstrate 
      highly variable responses to in vitro tests for platelet aggregation and may 
      experience breakthrough thromboembolic events. Although this phenomenon has been 
      termed aspirin resistance, the lack of a uniform definition or agreement on 
      diagnostic criteria precludes definitive recommendations at this time. In 
      addition, strategies are needed to identify patients at risk for aspirin 
      resistance who might benefit from alternative or combined antiplatelet therapy.
FAU - Howard, Patricia A
AU  - Howard PA
AD  - Department of Pharmacy, University of Kansas Medical Center, 3901 Rainbow Blvd., 
      Kansas City, KS 66160-7231, USA. phoward@kumc.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/*therapeutic use
MH  - Vascular Diseases/*prevention & control
RF  - 25
EDAT- 2002/09/24 06:00
MHDA- 2003/04/26 05:00
CRDT- 2002/09/24 06:00
PHST- 2002/09/24 06:00 [pubmed]
PHST- 2003/04/26 05:00 [medline]
PHST- 2002/09/24 06:00 [entrez]
AID - 10.1345/aph.1C013 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2002 Oct;36(10):1620-4. doi: 10.1345/aph.1C013.

PMID- 33221264
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 141
DP  - 2021 Feb 15
TI  - Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current 
      Evidence.
PG  - 38-48
LID - S0002-9149(20)31240-6 [pii]
LID - 10.1016/j.amjcard.2020.11.014 [doi]
AB  - Aspirin has been the mainstay of both secondary and primary prevention of 
      cardiovascular disease for half a century. In 2018, 3 trials showed a modest 
      reduction in cardiovascular outcomes that appeared counterbalanced by the risk of 
      clinically significant bleeding. The latest ACC/AHA primary prevention guidelines 
      downgraded their recommendation for aspirin use in primary prevention to that of 
      physician preference. Despite the consistent and robust evidence previously 
      supporting the use of aspirin in cardiovascular disease prevention, little 
      discussion has been given to mechanisms or analytic explanations for this 
      revision of recommendations. In this review, we explore 3 possible mechanisms 
      that may have contributed to the alteration of our perception of aspirin's role 
      in primary prevention. These include changes in the population potentially using 
      aspirin in primary prevention, changes in cardiovascular disease and its 
      presentation, and changes in aspirin itself. Here we present a translational look 
      at knowledge gaps that should be addressed to better guide contemporary aspirin 
      use in primary prevention. In conclusion, based on these considerations, the 
      current recommendations might be improved by recalibration of the cardiovascular 
      risk threshold above which aspirin should be recommended for primary prevention, 
      including the incorporation of newer risk assessment modalities such as calcium 
      scoring. A second enhancement would be developing a bleeding risk calculator to 
      support clinicians' assessment of risk vs benefit. The use of enteric-coated 
      aspirin vs noncoated aspirin should also be reassessed.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Dasa, Osama
AU  - Dasa O
AD  - Department of Medicine and Epidemiology, College of Public Health and Health 
      Professions, College of Medicine, University of Florida, Gainesville, FL.
FAU - Pepine, Carl J
AU  - Pepine CJ
AD  - Division of Cardiovascular Medicine, Department of Medicine, University of 
      Florida, Gainesville, FL.
FAU - Pearson, Thomas A
AU  - Pearson TA
AD  - Department of Medicine and Epidemiology, College of Public Health and Health 
      Professions, College of Medicine, University of Florida, Gainesville, FL. 
      Electronic address: tapearson@ufl.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201119
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Coronary Artery Disease/diagnostic imaging
MH  - Evidence-Based Medicine
MH  - *Heart Disease Risk Factors
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Practice Guidelines as Topic
MH  - Primary Prevention/*methods
MH  - Risk Assessment
MH  - Vascular Calcification/diagnostic imaging
COIS- Declaration of Interests The authors declare that they have no known competing 
      financial interests or personal relationships that could have appeared to 
      influence the work reported in this paper.
EDAT- 2020/11/23 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/11/22 20:33
PHST- 2020/08/31 00:00 [received]
PHST- 2020/11/05 00:00 [revised]
PHST- 2020/11/06 00:00 [accepted]
PHST- 2020/11/23 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/11/22 20:33 [entrez]
AID - S0002-9149(20)31240-6 [pii]
AID - 10.1016/j.amjcard.2020.11.014 [doi]
PST - ppublish
SO  - Am J Cardiol. 2021 Feb 15;141:38-48. doi: 10.1016/j.amjcard.2020.11.014. Epub 
      2020 Nov 19.

PMID- 32159800
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 59
IP  - 8
DP  - 2020 Aug 1
TI  - What dose of aspirin should be used in the initial treatment of Kawasaki disease? 
      A meta-analysis.
PG  - 1826-1833
LID - 10.1093/rheumatology/keaa050 [doi]
AB  - OBJECTIVE: The use of IVIG plus high- or low-dose aspirin for the initial 
      treatment of Kawasaki disease remains controversial. The aim of this study was to 
      evaluate the efficacy of IVIG plus high-dose aspirin compared with IVIG plus 
      low-dose aspirin in the treatment of Kawasaki disease. METHODS: Studies related 
      to aspirin therapy for Kawasaki disease were selected by searching the databases 
      of Medline (PubMed), Embase and the Cochrane Library before March 2019. 
      Statistical analyses were performed by using a Review Manager Software package 
      and STATA v.15.1. RESULTS: Eight retrospective cohort studies, characterizing 
      12 176 patients, were analysed. Overall, no significant difference was found in 
      the incidence of coronary artery abnormalities between the high- and low-dose 
      aspirin groups [relative risk (RR) 1.15; 95% CI: 0.93, 1.43; P = 0.19; 
      random-effects model]. The patients treated with high-dose aspirin had slightly 
      faster resolution of fever [mean difference (MD) -0.30; 95% CI: -0.58, -0.02; P = 
      0.04; random-effects model]. but the rates of IVIG resistance (RR, 1.26; 95% CI: 
      0.55, 2.92; P = 0.59; random-effects model) and days in hospital (MD, 0.22; 95% 
      CI: -0.93, 1.37; P = 0.71; random-effects model) were similar between the two 
      groups. CONCLUSION: Low-dose aspirin plus IVIG might be as effective as high-dose 
      aspirin plus IVIG for the initial treatment of Kawasaki disease. Considering that 
      high-dose aspirin may cause more adverse reactions than low-dose aspirin, 
      low-dose aspirin plus IVIG should be recommended as the first-line therapy in the 
      initial treatment of Kawasaki disease.
CI  - © The Author(s) 2020. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology. All rights reserved. For permissions, please 
      email: journals.permissions@oup.com.
FAU - Jia, Xinyi
AU  - Jia X
AD  - Department of Gastroenterology, Children's Hospital, Zhejiang University School 
      of Medicine, National Clinical Research Center for Child Health, Hangzhou.
AD  - Department of Pediatrics, Jinhua Hospital, Zhejiang University and Jinhua 
      Municipal Central Hospital, Jinhua, Zhejiang, People's Republic of China.
FAU - Du, Xiao
AU  - Du X
AD  - Department of Gastroenterology, Children's Hospital, Zhejiang University School 
      of Medicine, National Clinical Research Center for Child Health, Hangzhou.
FAU - Bie, Shuxian
AU  - Bie S
AD  - Department of Gastroenterology, Children's Hospital, Zhejiang University School 
      of Medicine, National Clinical Research Center for Child Health, Hangzhou.
FAU - Li, Xiaobing
AU  - Li X
AD  - Department of Pediatrics, Jinhua Hospital, Zhejiang University and Jinhua 
      Municipal Central Hospital, Jinhua, Zhejiang, People's Republic of China.
FAU - Bao, Yunguang
AU  - Bao Y
AD  - Department of Pediatrics, Jinhua Hospital, Zhejiang University and Jinhua 
      Municipal Central Hospital, Jinhua, Zhejiang, People's Republic of China.
FAU - Jiang, Mizu
AU  - Jiang M
AD  - Department of Gastroenterology, Children's Hospital, Zhejiang University School 
      of Medicine, National Clinical Research Center for Child Health, Hangzhou.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Mucocutaneous Lymph Node Syndrome/*drug therapy
OTO - NOTNLM
OT  - Kawasaki disease
OT  - aspirin
OT  - coronary artery abnormalities
OT  - meta-analysis
EDAT- 2020/03/12 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/03/12 06:00
PHST- 2019/06/27 00:00 [received]
PHST- 2019/12/19 00:00 [revised]
PHST- 2020/03/12 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/03/12 06:00 [entrez]
AID - 5803118 [pii]
AID - 10.1093/rheumatology/keaa050 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2020 Aug 1;59(8):1826-1833. doi: 
      10.1093/rheumatology/keaa050.

PMID- 36202092
OWN - NLM
STAT- MEDLINE
DCOM- 20230124
LR  - 20230202
IS  - 1545-4304 (Electronic)
IS  - 0362-1642 (Linking)
VI  - 63
DP  - 2023 Jan 20
TI  - An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention.
PG  - 165-186
LID - 10.1146/annurev-pharmtox-052020-023107 [doi]
AB  - Chemoprevention refers to the use of natural or synthetic agents to reverse, 
      suppress, or prevent the progression or recurrence of cancer. A large body of 
      preclinical and clinical data suggest the ability of aspirin to prevent precursor 
      lesions and cancers, but much of the clinical data are inferential and based on 
      descriptive epidemiology, case control, and cohort studies or studies designed to 
      answer other questions (e.g., cardiovascular mortality). Multiple 
      pharmacological, clinical, and epidemiologic studies suggest that aspirin can 
      prevent certain cancers but may also cause other effects depending on the tissue 
      or disease and organ site in question. The best-known biological targets of 
      aspirin are cyclooxygenases, which drive a wide variety of functions, including 
      hemostasis, inflammation, and immune modulation. Newly recognized molecular and 
      cellular interactions suggest additional modifiable functional targets, and the 
      existence of consensus molecular cancer subtypes suggests that aspirin may have 
      differential effects based on tumor heterogeneity. This review focuses on new 
      pharmacological developments and innovations in biopharmacology that clarify the 
      potential role of aspirin in cancer chemoprevention.
FAU - Menter, David G
AU  - Menter DG
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas, USA.
FAU - Bresalier, Robert S
AU  - Bresalier RS
AD  - Department of Gastroenterology, Hepatology and Nutrition, The University of Texas 
      MD Anderson Cancer Center, Houston, Texas, USA; email: rbresali@mdanderson.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221006
PL  - United States
TA  - Annu Rev Pharmacol Toxicol
JT  - Annual review of pharmacology and toxicology
JID - 7607088
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
SB  - IM
MH  - Humans
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - *Neoplasms/drug therapy/prevention & control
MH  - Inflammation/drug therapy
MH  - Chemoprevention
OTO - NOTNLM
OT  - aspirin
OT  - chemoprevention
OT  - cyclooxygenase
OT  - prostacyclin
OT  - prostaglandin
OT  - thromboxane
EDAT- 2022/10/07 06:00
MHDA- 2023/01/25 06:00
CRDT- 2022/10/06 18:33
PHST- 2022/10/07 06:00 [pubmed]
PHST- 2023/01/25 06:00 [medline]
PHST- 2022/10/06 18:33 [entrez]
AID - 10.1146/annurev-pharmtox-052020-023107 [doi]
PST - ppublish
SO  - Annu Rev Pharmacol Toxicol. 2023 Jan 20;63:165-186. doi: 
      10.1146/annurev-pharmtox-052020-023107. Epub 2022 Oct 6.

PMID- 15033621
OWN - NLM
STAT- MEDLINE
DCOM- 20040520
LR  - 20131121
IS  - 1302-8723 (Print)
IS  - 1302-8723 (Linking)
VI  - 4
IP  - 1
DP  - 2004 Mar
TI  - [Aspirin resistance].
PG  - 59-62
AB  - Aspirin is an effective antithrombotic agent for many patients. However, patients 
      taking aspirin might exhibit variable responses to in vitro tests for platelet 
      aggregation and might experience breakthrough thromboembolic events. Although 
      this phenomenon has been called aspirin resistance, the lack of an uniform 
      definition or agreement on diagnostic criteria precludes definitive 
      recommendations at this time. Aspirin resistance has been defined in patients 
      with cardiovascular, cerebrovascular, and peripheral vascular disease. In this 
      article, mechanisms related with aspirin resistance and clinical background in 
      which resistance is defined, are reviewed.
FAU - Yilmaz, Mehmet Birhan
AU  - Yilmaz MB
AD  - Türkiye Yüksek Ihtisas Hastanesi, Kardiyoloji Kiniği, Ankara. 
      cardioceptor@ttnet.net.tr
FAU - Balbay, Yücel
AU  - Balbay Y
FAU - Korkmaz, Sule
AU  - Korkmaz S
LA  - tur
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspirin Direnci.
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - *Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Vascular Diseases/*prevention & control
RF  - 34
EDAT- 2004/03/23 05:00
MHDA- 2004/05/21 05:00
CRDT- 2004/03/23 05:00
PHST- 2004/03/23 05:00 [pubmed]
PHST- 2004/05/21 05:00 [medline]
PHST- 2004/03/23 05:00 [entrez]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2004 Mar;4(1):59-62.

PMID- 22172645
OWN - NLM
STAT- MEDLINE
DCOM- 20120529
LR  - 20131121
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 12
IP  - 1
DP  - 2012 Jan
TI  - Aspirin and immune system.
PG  - 10-20
LID - 10.1016/j.intimp.2011.11.021 [doi]
AB  - The time-tested gradual exploration of aspirin's diverse pharmacological 
      properties has made it the most reliable therapeutic agent worldwide. In addition 
      to its well-argued anti-inflammatory effects, many new and exciting data have 
      emerged regarding the role of aspirin in cells of the immune system and certain 
      immunopathological states. For instance, aspirin induces tolerogenic activity in 
      dendritic cells and determines the fate of naive T cells to regulatory 
      phenotypes, which suggests its immunoregulatory potential in relevance to immune 
      tolerance. It also displays some intriguing traits to modulate the innate and 
      adaptive immune responses. In this article, the immunomodulatory relation of 
      aspirin to different immune cells, such as neutrophils, macrophages, dendritic 
      cells (DCs), natural killer (NK) cells, and the T and B lymphocytes has been 
      highlighted. Moreover, the clinical prospects of aspirin in terms of 
      autoimmunity, allograft rejection and immune tolerance have also been outlined.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Hussain, Muzammal
AU  - Hussain M
AD  - Department of Pharmacology & Toxicology, University of Veterinary and Animal 
      Sciences, Lahore, Pakistan.
FAU - Javeed, Aqeel
AU  - Javeed A
FAU - Ashraf, Muhammad
AU  - Ashraf M
FAU - Zhao, Yong
AU  - Zhao Y
FAU - Mukhtar, Muhammad Mahmood
AU  - Mukhtar MM
FAU - Rehman, Muti Ur
AU  - Rehman MU
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20111213
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunologic Factors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Autoimmune Diseases/drug therapy/immunology
MH  - Dendritic Cells/drug effects/immunology
MH  - Graft Rejection/immunology/prevention & control
MH  - Humans
MH  - Immune Tolerance/drug effects
MH  - Immunologic Factors/*pharmacology/therapeutic use
MH  - Inflammation/drug therapy/immunology
MH  - Leukocytes/drug effects/immunology
MH  - Macrophages/drug effects/immunology
EDAT- 2011/12/17 06:00
MHDA- 2012/05/30 06:00
CRDT- 2011/12/17 06:00
PHST- 2011/10/29 00:00 [received]
PHST- 2011/11/26 00:00 [revised]
PHST- 2011/11/29 00:00 [accepted]
PHST- 2011/12/17 06:00 [entrez]
PHST- 2011/12/17 06:00 [pubmed]
PHST- 2012/05/30 06:00 [medline]
AID - S1567-5769(11)00461-9 [pii]
AID - 10.1016/j.intimp.2011.11.021 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2012 Jan;12(1):10-20. doi: 10.1016/j.intimp.2011.11.021. 
      Epub 2011 Dec 13.

PMID- 35323950
OWN - NLM
STAT- MEDLINE
DCOM- 20220401
LR  - 20220716
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 5
IP  - 3
DP  - 2022 Mar 1
TI  - Association of Early Aspirin Use With In-Hospital Mortality in Patients With 
      Moderate COVID-19.
PG  - e223890
LID - 10.1001/jamanetworkopen.2022.3890 [doi]
LID - e223890
AB  - IMPORTANCE: Prior observational studies suggest that aspirin use may be 
      associated with reduced mortality in high-risk hospitalized patients with 
      COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well 
      studied. OBJECTIVE: To assess whether early aspirin use is associated with lower 
      odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, 
      SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized 
      patients with moderate COVID-19, enrolled from January 1, 2020, through September 
      10, 2021, at 64 health systems in the United States participating in the National 
      Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: 
      Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: 
      The primary outcome was 28-day in-hospital mortality, and secondary outcomes were 
      pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were 
      calculated using marginal structural Cox and logistic regression models. Inverse 
      probability of treatment weighting was used to reduce bias from confounding and 
      balance characteristics between groups. RESULTS: Among the 2 446 650 
      COVID-19-positive patients who were screened, 189 287 were hospitalized and 
      112 269 met study inclusion. For the full cohort, Median age was 63 years (IQR, 
      47-74 years); 16.1% of patients were African American, 3.8% were Asian, 52.7% 
      were White, 5.0% were of other races and ethnicities, 22.4% were of unknown race 
      and ethnicity. In-hospital mortality occurred in 10.9% of patients. After inverse 
      probability treatment weighting, 28-day in-hospital mortality was significantly 
      lower in those who received aspirin (10.2% vs 11.8%; odds ratio [OR], 0.85; 95% 
      CI, 0.79-0.92; P < .001). The rate of pulmonary embolism, but not deep vein 
      thrombosis, was also significantly lower in patients who received aspirin (1.0% 
      vs 1.4%; OR, 0.71; 95% CI, 0.56-0.90; P = .004). Patients who received early 
      aspirin did not have higher rates of gastrointestinal hemorrhage (0.8% aspirin vs 
      0.7% no aspirin; OR, 1.04; 95% CI, 0.82-1.33; P = .72), cerebral hemorrhage (0.6% 
      aspirin vs 0.4% no aspirin; OR, 1.32; 95% CI, 0.92-1.88; P = .13), or blood 
      transfusion (2.7% aspirin vs 2.3% no aspirin; OR, 1.14; 95% CI, 0.99-1.32; 
      P = .06). The composite of hemorrhagic complications did not occur more often in 
      those receiving aspirin (3.7% aspirin vs 3.2% no aspirin; OR, 1.13; 95% CI, 
      1.00-1.28; P = .054). Subgroups who appeared to benefit the most included 
      patients older than 60 years (61-80 years: OR, 0.79; 95% CI, 0.72-0.87; P < .001; 
      >80 years: OR, 0.79; 95% CI, 0.69-0.91; P < .001) and patients with comorbidities 
      (1 comorbidity: 6.4% vs 9.2%; OR, 0.68; 95% CI, 0.55-0.83; P < .001; 2 
      comorbidities: 10.5% vs 12.8%; OR, 0.80; 95% CI, 0.69-0.93; P = .003; 3 
      comorbidities: 13.8% vs 17.0%, OR, 0.78; 95% CI, 0.68-0.89; P < .001; >3 
      comorbidities: 17.0% vs 21.6%; OR, 0.74; 95% CI, 0.66-0.84; P < .001). 
      CONCLUSIONS AND RELEVANCE: In this cohort study of US adults hospitalized with 
      moderate COVID-19, early aspirin use was associated with lower odds of 28-day 
      in-hospital mortality. A randomized clinical trial that includes diverse patients 
      with moderate COVID-19 is warranted to adequately evaluate aspirin's efficacy in 
      patients with high-risk conditions.
FAU - Chow, Jonathan H
AU  - Chow JH
AD  - Department of Anesthesiology and Critical Care Medicine, George Washington 
      University School of Medicine and Health Sciences, Washington, DC.
FAU - Rahnavard, Ali
AU  - Rahnavard A
AD  - George Washington University Computational Biology Institute, Department of 
      Biostatistics and Bioinformatics, Milken Institute School of Public Health, 
      Washington, DC.
FAU - Gomberg-Maitland, Mardi
AU  - Gomberg-Maitland M
AD  - Division of Cardiology, Department of Medicine, George Washington University 
      School of Medicine and Health Sciences, Washington, DC.
FAU - Chatterjee, Ranojoy
AU  - Chatterjee R
AD  - George Washington University Computational Biology Institute, Department of 
      Biostatistics and Bioinformatics, Milken Institute School of Public Health, 
      Washington, DC.
FAU - Patodi, Pranay
AU  - Patodi P
AD  - George Washington University Computational Biology Institute, Department of 
      Biostatistics and Bioinformatics, Milken Institute School of Public Health, 
      Washington, DC.
FAU - Yamane, David P
AU  - Yamane DP
AD  - Department of Anesthesiology and Critical Care Medicine, George Washington 
      University School of Medicine and Health Sciences, Washington, DC.
AD  - Department of Emergency Medicine, George Washington University School of Medicine 
      and Health Sciences, Washington, DC.
FAU - Levine, Andrea R
AU  - Levine AR
AD  - Division of Pulmonary and Critical Care, Department of Medicine, University of 
      Maryland School of Medicine, Baltimore.
FAU - Davison, Danielle
AU  - Davison D
AD  - Department of Anesthesiology and Critical Care Medicine, George Washington 
      University School of Medicine and Health Sciences, Washington, DC.
FAU - Hawkins, Katrina
AU  - Hawkins K
AD  - Department of Anesthesiology and Critical Care Medicine, George Washington 
      University School of Medicine and Health Sciences, Washington, DC.
FAU - Jackson, Amanda M
AU  - Jackson AM
AD  - Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Walter 
      Reed National Military Medical Center, Bethesda, Maryland.
FAU - Quintana, Megan T
AU  - Quintana MT
AD  - Department of Surgery, George Washington University School of Medicine and Health 
      Sciences, Washington, DC.
FAU - Lankford, Allison S
AU  - Lankford AS
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, 
      University of Maryland School of Medicine, Baltimore.
AD  - Division of Critical Care Medicine, Department of Surgery, R. Adams Cowley Shock 
      Trauma Center, Baltimore, Maryland.
FAU - Keneally, Ryan J
AU  - Keneally RJ
AD  - Department of Anesthesiology and Critical Care Medicine, George Washington 
      University School of Medicine and Health Sciences, Washington, DC.
FAU - Al-Mashat, Mustafa
AU  - Al-Mashat M
AD  - Department of Anesthesiology and Critical Care Medicine, George Washington 
      University School of Medicine and Health Sciences, Washington, DC.
FAU - Fisher, Daniel
AU  - Fisher D
AD  - Department of Anesthesiology and Critical Care Medicine, George Washington 
      University School of Medicine and Health Sciences, Washington, DC.
FAU - Williams, Jeffrey
AU  - Williams J
AD  - Department of Anesthesiology and Critical Care Medicine, George Washington 
      University School of Medicine and Health Sciences, Washington, DC.
FAU - Berger, Jeffrey S
AU  - Berger JS
AD  - Department of Anesthesiology and Critical Care Medicine, George Washington 
      University School of Medicine and Health Sciences, Washington, DC.
FAU - Mazzeffi, Michael A
AU  - Mazzeffi MA
AD  - Department of Anesthesiology and Critical Care Medicine, George Washington 
      University School of Medicine and Health Sciences, Washington, DC.
FAU - Crandall, Keith A
AU  - Crandall KA
AD  - George Washington University Computational Biology Institute, Department of 
      Biostatistics and Bioinformatics, Milken Institute School of Public Health, 
      Washington, DC.
CN  - N3C Consortium and ANCHOR Investigators
LA  - eng
GR  - K23 DK124654/DK/NIDDK NIH HHS/United States
GR  - UL1 TR001876/TR/NCATS NIH HHS/United States
GR  - U24 TR002306/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20220301
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Aspirin/therapeutic use
MH  - *COVID-19
MH  - Cohort Studies
MH  - Hospital Mortality
MH  - Hospitalization
MH  - Humans
MH  - Middle Aged
MH  - United States/epidemiology
PMC - PMC8948531
COIS- Conflict of Interest Disclosures: Dr Chow reported serving on the speaker’s 
      bureau for La Jolla Pharmaceutical Company outside the submitted work. Dr 
      Gomberg-Maitland reported receiving honoraria from Medscape and serving as a 
      consultant and member of the steering committees for Acceleron/Merck, Bayer, 
      Janssen, and United Therapeutics outside the submitted work. Dr Mazzeffi reported 
      receiving consulting fees from Hemosonics outside the submitted work. Dr Crandall 
      reported receiving grants from the National Institutes of Health (NIH) and the 
      National Science Foundation during the conduct of the study. No other disclosures 
      were reported.
FIR - Benjenk, Ivy
IR  - Benjenk I
FIR - Amor, Benjamin
IR  - Amor B
FIR - Austin, Christopher
IR  - Austin C
FIR - Bennett, Tellen
IR  - Bennett T
FIR - Bissell, Mark
IR  - Bissell M
FIR - Bozzette, Samuel
IR  - Bozzette S
FIR - Bradwell, Katie
IR  - Bradwell K
FIR - Bramante, Carolyn
IR  - Bramante C
FIR - Chae, Yooree
IR  - Chae Y
FIR - Chute, Christopher
IR  - Chute C
FIR - Clark, Marshall
IR  - Clark M
FIR - Cook, Conor
IR  - Cook C
FIR - Deacy, Mariam
IR  - Deacy M
FIR - Dest, Alexandra
IR  - Dest A
FIR - Dietz, Racquel
IR  - Dietz R
FIR - Dillon, Thomas
IR  - Dillon T
FIR - Eichmann, David
IR  - Eichmann D
FIR - Francis, Patricia
IR  - Francis P
FIR - Fuentes, Rafel
IR  - Fuentes R
FIR - Gabriel, Davera
IR  - Gabriel D
FIR - Garbarini, Nicole
IR  - Garbarini N
FIR - Gersing, Kenneth
IR  - Gersing K
FIR - Girvin, Andrew
IR  - Girvin A
FIR - Graves, Alexis
IR  - Graves A
FIR - Guinney, Justin
IR  - Guinney J
FIR - Haendel, Melissa
IR  - Haendel M
FIR - Harper, Jeremy
IR  - Harper J
FIR - Hernandez, Wenndy
IR  - Hernandez W
FIR - Hong, Stephanie
IR  - Hong S
FIR - Kibbe, Warren
IR  - Kibbe W
FIR - Koraishy, Farrukh
IR  - Koraishy F
FIR - Kostka, Kristin
IR  - Kostka K
FIR - Kurilla, Michael
IR  - Kurilla M
FIR - Lee, Adam
IR  - Lee A
FIR - Lehmann, Harold
IR  - Lehmann H
FIR - Liu, Hongfang
IR  - Liu H
FIR - Manna, Amin
IR  - Manna A
FIR - Mariona, Federico
IR  - Mariona F
FIR - McMurry, Julie
IR  - McMurry J
FIR - Michael, Sam
IR  - Michael S
FIR - Miller, Robert
IR  - Miller R
FIR - Moffitt, Richard
IR  - Moffitt R
FIR - Morris, Michele
IR  - Morris M
FIR - Neumann, Andrew
IR  - Neumann A
FIR - O'Neil, Shawn
IR  - O'Neil S
FIR - Palchuk, Matvey
IR  - Palchuk M
FIR - Payne, Philip
IR  - Payne P
FIR - Pfaff, Emily
IR  - Pfaff E
FIR - Qureshi, Nabeel
IR  - Qureshi N
FIR - Robinson, Peter
IR  - Robinson P
FIR - Rutter, Joni
IR  - Rutter J
FIR - Saltz, Joel
IR  - Saltz J
FIR - Saltz, Mary
IR  - Saltz M
FIR - Saha, Amit
IR  - Saha A
FIR - Sheikh, Usman
IR  - Sheikh U
FIR - Spratt, Heidi
IR  - Spratt H
FIR - Starren, Justin
IR  - Starren J
FIR - Suver, Christine
IR  - Suver C
FIR - Temple-O'Connor, Meredity
IR  - Temple-O'Connor M
FIR - Vedula, Satyanarayana
IR  - Vedula S
FIR - Volz, Andrea
IR  - Volz A
FIR - Walden, Anita
IR  - Walden A
FIR - Walters, Kellie
IR  - Walters K
FIR - Wilcox, Adam
IR  - Wilcox A
FIR - Williams, Andew
IR  - Williams A
FIR - Wu, Chunlei
IR  - Wu C
FIR - Zampino, Elizabeth
IR  - Zampino E
FIR - Zhang, Ziaohan
IR  - Zhang Z
FIR - Zhu, Richard
IR  - Zhu R
EDAT- 2022/03/25 06:00
MHDA- 2022/04/02 06:00
CRDT- 2022/03/24 12:16
PHST- 2022/03/24 12:16 [entrez]
PHST- 2022/03/25 06:00 [pubmed]
PHST- 2022/04/02 06:00 [medline]
AID - 2790439 [pii]
AID - zoi220142 [pii]
AID - 10.1001/jamanetworkopen.2022.3890 [doi]
PST - epublish
SO  - JAMA Netw Open. 2022 Mar 1;5(3):e223890. doi: 10.1001/jamanetworkopen.2022.3890.

PMID- 17192817
OWN - NLM
STAT- MEDLINE
DCOM- 20070424
LR  - 20180914
IS  - 1129-2369 (Print)
IS  - 1129-2377 (Electronic)
IS  - 1129-2369 (Linking)
VI  - 8
IP  - 1
DP  - 2007 Feb
TI  - Aspirin and tension-type headache.
PG  - 49-55
AB  - Acetylsalicylic acid (ASA, Aspirin) is among the most used drugs worldwide. At 
      present, Aspirin represents a quite versatile drug employed in the control of 
      pain symptomatologies and in situations such as prevention of both ischaemic 
      stroke and cardiovascular events. Aspirin causes inhibition of prostaglandin (PG) 
      synthesis by inactivation of the cyclooxygenase (COX) enzyme. ASA constitutes the 
      focus of new researches explaining more widely Aspirin's control of inflammation. 
      The induction of the endogenous epimers lipoxins (Aspirin-triggered 
      15-epi-lipoxins, ATLs) represents one of the most recent achievements. This 
      particular feature of Aspirin is not shared by other NSAIDs. ASA is well known as 
      a headache medication, figuring as a possible treatment choice in tension-type 
      headache but also in acute migraine attacks. Furthermore, a new Aspirin 
      formulation with a greater rapidity of action has been introduced. In conclusion, 
      little information exists on the subject and more studies are required.
FAU - Farinelli, Ivano
AU  - Farinelli I
AD  - Department of Clinical Sciences, Sapienza University of Rome, 2nd School of 
      Medicine, Sant'Andrea Hospital, Via di Grottarossa 1035, I-00189, Rome, Italy.
FAU - Martelletti, Paolo
AU  - Martelletti P
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20070102
PL  - England
TA  - J Headache Pain
JT  - The journal of headache and pain
JID - 100940562
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Tension-Type Headache/*drug therapy/epidemiology
PMC - PMC3476118
EDAT- 2006/12/29 09:00
MHDA- 2007/04/25 09:00
CRDT- 2006/12/29 09:00
PHST- 2006/09/27 00:00 [received]
PHST- 2006/12/19 00:00 [accepted]
PHST- 2006/12/29 09:00 [pubmed]
PHST- 2007/04/25 09:00 [medline]
PHST- 2006/12/29 09:00 [entrez]
AID - 357 [pii]
AID - 10.1007/s10194-006-0357-4 [doi]
PST - ppublish
SO  - J Headache Pain. 2007 Feb;8(1):49-55. doi: 10.1007/s10194-006-0357-4. Epub 2007 
      Jan 2.

PMID- 16610572
OWN - NLM
STAT- MEDLINE
DCOM- 20060425
LR  - 20181201
IS  - 0025-6196 (Print)
IS  - 0025-6196 (Linking)
VI  - 81
IP  - 4
DP  - 2006 Apr
TI  - Aspirin and clopidogrel resistance.
PG  - 518-26
AB  - Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular 
      (CV) events, recurrent CV events still occur in patients receiving antiplatelet 
      therapy. Many of these patients are resistant or only partially responsive to the 
      antiplatelet effects of aspirin and clopidogrel, as determined by standard 
      platelet assays. However, current clinical guidelines do not support routine 
      screening for aspirin or clopidogrel resistance, in part because determination of 
      the most appropriate screening test has not been established. This review 
      attempts to (1) describe the phenomena of clinical aspirin and clopidogrel 
      resistance (ie, treatment failure), (2) discuss the complexity of defining and 
      identifying aspirin and clopidogrel resistance, (3) identify factors that may be 
      responsible for aspirin and clopidogrel resistance, (4) outline several standard 
      platelet function assays and their limitations, and (5) describe potential new 
      antiplatelet therapies that may benefit aspirin- or clopidogrel-resistant 
      patients.
FAU - Michos, Erin D
AU  - Michos ED
AD  - Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
FAU - Ardehali, Reza
AU  - Ardehali R
FAU - Blumenthal, Roger S
AU  - Blumenthal RS
FAU - Lange, Richard A
AU  - Lange RA
FAU - Ardehali, Hossein
AU  - Ardehali H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Mayo Clin Proc. 2006 Jul;81(7):989; author reply 990. PMID: 16835978
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/blood/*prevention & control
MH  - Clopidogrel
MH  - Drug Resistance, Multiple/*physiology
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
RF  - 77
EDAT- 2006/04/14 09:00
MHDA- 2006/04/28 09:00
CRDT- 2006/04/14 09:00
PHST- 2006/04/14 09:00 [pubmed]
PHST- 2006/04/28 09:00 [medline]
PHST- 2006/04/14 09:00 [entrez]
AID - S0025-6196(11)61900-9 [pii]
AID - 10.4065/81.4.518 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2006 Apr;81(4):518-26. doi: 10.4065/81.4.518.

PMID- 31764014
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20210203
IS  - 1538-4683 (Electronic)
IS  - 1061-5377 (Linking)
VI  - 28
IP  - 2
DP  - 2020 Mar/Apr
TI  - Aspirin for the Primary Prevention of Cardiovascular Disease: A Review of the 
      Literature and Considerations for Clinical Practice.
PG  - 98-106
LID - 10.1097/CRD.0000000000000297 [doi]
AB  - Cardiovascular disease is the leading cause of death globally, and deaths due to 
      coronary heart disease or stroke account for over half of all cardiovascular 
      deaths in the United States. While many important advances have been made in the 
      treatment and secondary prevention of atherosclerotic cardiovascular disease 
      (ASCVD), morbidity and mortality remain high. Aspirin has been commonly used for 
      the primary and secondary prevention of ASCVD for decades and is an easily 
      accessible therapeutic option. While it is a cornerstone of secondary prevention, 
      its role in primary prevention is less clear and professional guidelines have 
      differed in their recommendations. As literature has substantially evolved over 
      the past 40 years, so too has our understanding of aspirin's role in the primary 
      prevention of ASCVD. This article reviews landmark clinical trials of aspirin in 
      primary prevention and highlights key changes in dosing strategies and 
      demographics.
FAU - Cicci, Jonathan D
AU  - Cicci JD
AD  - From the Department of Pharmacy, University of North Carolina Medical Center, 
      Chapel Hill, NC.
FAU - Iyer, Prashanth
AU  - Iyer P
AD  - From the Department of Pharmacy, University of North Carolina Medical Center, 
      Chapel Hill, NC.
FAU - Clarke, Megan M
AU  - Clarke MM
AD  - From the Department of Pharmacy, University of North Carolina Medical Center, 
      Chapel Hill, NC.
FAU - Mazzella, Anthony J
AU  - Mazzella AJ
AD  - Division of Cardiology, Department of Medicine, University of North Carolina 
      Hospitals, Chapel Hill, NC.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiol Rev
JT  - Cardiology in review
JID - 9304686
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Atherosclerosis
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus
MH  - Female
MH  - Humans
MH  - Male
MH  - *Primary Prevention
EDAT- 2019/11/26 06:00
MHDA- 2020/11/03 06:00
CRDT- 2019/11/26 06:00
PHST- 2019/11/26 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2019/11/26 06:00 [entrez]
AID - 00045415-202003000-00006 [pii]
AID - 10.1097/CRD.0000000000000297 [doi]
PST - ppublish
SO  - Cardiol Rev. 2020 Mar/Apr;28(2):98-106. doi: 10.1097/CRD.0000000000000297.

PMID- 22257089
OWN - NLM
STAT- MEDLINE
DCOM- 20120912
LR  - 20191112
VI  - 7
IP  - 1
DP  - 2012 Apr
TI  - Aspirin: from a historical perspective.
PG  - 71-6
AB  - Aspirin is one of the oldest medicines. Due to its wide range usage in different 
      fields of medicine, we aimed to present the history, effects and different uses 
      of aspirin in this review. Furthermore, recent patents of novel pharmaceutical 
      interventions in the field of acetylsalicylic acid, expanding treatment options 
      are presented. Literature search was performed in order to reach data and present 
      information about aspirin from a historical perspective. Since its first use as a 
      pain killer, aspirin has found a broad range of use in general medicine, 
      cardiovascular medicine, neurology, obstetrics and gynecology, dentistry, 
      gastroenterology, oncology with its different effects. Aspirin, a painkilling 
      gift of history to mankind, with a history dating back to BC and various healing 
      effects, promises to be of greater use in different fields of medicine with the 
      light of recent studies, inspiring more research and gaining more popularity.
FAU - Ugurlucan, Murat
AU  - Ugurlucan M
AD  - Anadolu Medical Center Hospital, Cardiovascular Surgery Clinic, Turkey. 
      muratugurlucan@yahoo.com
FAU - Caglar, Ilker M
AU  - Caglar IM
FAU - Caglar, Fatma N Turhan
AU  - Caglar FN
FAU - Ziyade, Sedat
AU  - Ziyade S
FAU - Karatepe, Oguzhan
AU  - Karatepe O
FAU - Yildiz, Yahya
AU  - Yildiz Y
FAU - Zencirci, Ertugrul
AU  - Zencirci E
FAU - Ugurlucan, Funda Gungor
AU  - Ugurlucan FG
FAU - Arslan, Ahmet H
AU  - Arslan AH
FAU - Korkmaz, Semra
AU  - Korkmaz S
FAU - Filizcan, Ugur
AU  - Filizcan U
FAU - Cicek, Sertac
AU  - Cicek S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Recent Pat Cardiovasc Drug Discov
JT  - Recent patents on cardiovascular drug discovery
JID - 101263805
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Humans
EDAT- 2012/01/20 06:00
MHDA- 2012/09/13 06:00
CRDT- 2012/01/20 06:00
PHST- 2011/07/21 00:00 [received]
PHST- 2012/01/01 00:00 [revised]
PHST- 2011/12/19 00:00 [accepted]
PHST- 2012/01/20 06:00 [entrez]
PHST- 2012/01/20 06:00 [pubmed]
PHST- 2012/09/13 06:00 [medline]
AID - PRC-EPUB-20120116-002 [pii]
AID - 10.2174/157489012799362377 [doi]
PST - ppublish
SO  - Recent Pat Cardiovasc Drug Discov. 2012 Apr;7(1):71-6. doi: 
      10.2174/157489012799362377.

PMID- 10763202
OWN - NLM
STAT- MEDLINE
DCOM- 20000427
LR  - 20190826
IS  - 0248-8663 (Print)
IS  - 0248-8663 (Linking)
VI  - 21 Suppl 1
DP  - 2000 Mar
TI  - [Aspirin and hemostasis].
PG  - 27s-34s
AB  - Aspirin is one hundred years old, though its use has clearly evolved during the 
      last 25 years. Identifying its action mechanism has allowed us to better 
      understand the antithrombotic impact. Prostaglandin H synthetase (PGHS) is a 
      bifunctional enzyme with cyclooxygenase and peroxydase activities. There are two 
      isoforms: constitutive PGHS-1 and inducible PGHS-2. Aspirin irreversive 
      acetylates the platelet cyclooxygenase involved in the formation of thromboxane 
      A2, a powerful proaggregating agent and vasoconstrictor. More than 95% of 
      inhibition of this synthesis takes place in two to three days using very weak 
      doses of aspirin, on the order of 30 to 50 mg per day. Under some circumstances, 
      this inhibition requires higher dosages. Certain clinical and biological 
      circumstances could lead to a resistance to aspirin, making a readjustment of 
      doses and sometimes complementary explorations necessary. The ISIS 2 study showed 
      in an apparently irrefutable way the entry of aspirin into the antithrombotics 
      arsenal, with a significant risk reduction of vascular death and recurrence of 
      infarctus. Numerous studies have confirmed this efficacy. Consensus studies are 
      based on information showing total coherence between the dose necessary to 
      acetylate the enzyme to inhibit thromboxane A2 platelet production and the 
      clinical antithrombotic effect. Aspirin seems to have a secure place, and it 
      begins the third millennium in relative peace with new extra-platelet 
      potentialities outside the framework of hemostasis and thrombosis.
FAU - Samama, M M
AU  - Samama MM
AD  - Service d'hématologie biologique, Hôtel-Dieu, Paris, France.
FAU - Elalamy, I
AU  - Elalamy I
LA  - fre
PT  - Comparative Study
PT  - Historical Article
PT  - Journal Article
PT  - Review
TT  - Aspirine et hémostase.
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/history/*pharmacology/therapeutic use
MH  - Aspirin/history/*pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/history/*pharmacology/therapeutic use
MH  - Fibrinolytic Agents/history/*pharmacology/therapeutic use
MH  - France
MH  - Germany
MH  - Hemostasis/*drug effects
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/drug therapy/prevention & control
MH  - Platelet Aggregation Inhibitors/history/*pharmacology/therapeutic use
MH  - Research
MH  - Russia (Pre-1917)
MH  - United Kingdom
MH  - United States
RF  - 43
EDAT- 2000/04/14 09:00
MHDA- 2000/04/29 09:00
CRDT- 2000/04/14 09:00
PHST- 2000/04/14 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/04/14 09:00 [entrez]
AID - S0248-8663(00)88722-6 [pii]
AID - 10.1016/s0248-8663(00)88722-6 [doi]
PST - ppublish
SO  - Rev Med Interne. 2000 Mar;21 Suppl 1:27s-34s. doi: 10.1016/s0248-8663(00)88722-6.

PMID- 18081940
OWN - NLM
STAT- MEDLINE
DCOM- 20080221
LR  - 20131121
IS  - 0029-7828 (Print)
IS  - 0029-7828 (Linking)
VI  - 63
IP  - 1
DP  - 2008 Jan
TI  - Aspirin and reproductive outcomes.
PG  - 49-57
AB  - In the late 1980s and early 1990s, researchers hypothesized that aspirin could be 
      used to prevent or delay the onset of preeclampsia. This hypothesis was tested in 
      numerous trials which showed limited, but positive results. Subsequently, aspirin 
      has been used in an attempt to improve pregnancy outcomes in women who have both 
      antiphospholipid antibodies and a history of recurrent loss, and has also been 
      used in an attempt to improve the success of in vitro fertilization. In theory, 
      aspirin has both positive and negative effects on reproduction. Aspirin, which 
      suppresses cyclooxygenase, has the potential to interfere with implantation, but 
      also has the potential to support the maintenance of pregnancy. Aspirin is 
      prescribed with increasing frequency to reduce the risk of maternal thrombosis 
      and reduce the risk of miscarriage and poor pregnancy outcome. Aspirin alone, 
      however, is not considered sufficient to prevent thrombosis and even in women 
      with the antiphospholipid syndrome, the question as to whether low-dose aspirin 
      improves pregnancy outcomes has not been answered affirmatively. Aspirin has 
      potential risks. Aspirin inhibits platelet function and can contribute to 
      maternal and fetal bleeding. Aspirin crosses the placenta. Although aspirin has 
      not been associated with other congenital anomalies, it has been associated with 
      an increased risk of vascular disruptions, particularly gastroschisis and 
      possibly premature closure of the ductus arteriosus. Nonetheless, large trials 
      demonstrate low-dose aspirin's relative safety and generally positive effects on 
      reproductive outcomes.
FAU - James, Andra H
AU  - James AH
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Duke University Medical Center, Durham, North Carolina 27710, USA. 
      andra.james@duke.edu
FAU - Brancazio, Leo R
AU  - Brancazio LR
FAU - Price, Thomas
AU  - Price T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Obstet Gynecol Surv
JT  - Obstetrical & gynecological survey
JID - 0401007
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced
MH  - Antibodies, Antiphospholipid/drug effects
MH  - Aspirin/*administration & dosage/adverse effects/pharmacokinetics
MH  - Cyclooxygenase Inhibitors/*administration & dosage/adverse 
      effects/pharmacokinetics
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fertilization in Vitro/drug effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Pre-Eclampsia/drug therapy
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Pregnancy Outcome
MH  - Thrombosis/prevention & control
RF  - 67
EDAT- 2007/12/18 09:00
MHDA- 2008/02/22 09:00
CRDT- 2007/12/18 09:00
PHST- 2007/12/18 09:00 [pubmed]
PHST- 2008/02/22 09:00 [medline]
PHST- 2007/12/18 09:00 [entrez]
AID - 0006254-200801000-00022 [pii]
AID - 10.1097/OGX.0b013e31815e8731 [doi]
PST - ppublish
SO  - Obstet Gynecol Surv. 2008 Jan;63(1):49-57. doi: 10.1097/OGX.0b013e31815e8731.

PMID- 2030640
OWN - NLM
STAT- MEDLINE
DCOM- 19910614
LR  - 20190606
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 70
IP  - 3
DP  - 1991 May
TI  - Aspirin in the prevention of thrombosis.
PG  - 161-78
AB  - More than a decade has passed since the introduction of the concept that 
      inhibition of platelet function may be helpful in preventing the initiation of 
      thrombus formation. Aspirin has been recognized as inhibiting normal platelet 
      function and the mechanism has been clearly delineated. Legions of patients have 
      been studied to answer the question of whether aspirin is efficacious in the 
      primary prevention of acute myocardial infarction. At the present time, however, 
      a solid, clear answer is not available and firm recommendations cannot be made. A 
      large number of studies evaluating aspirin and other antiplatelet agents in the 
      prevention or delay of recurrent myocardial infarction (secondary prevention) 
      have been completed and those studies reporting a favorable beneficial effect are 
      in the minority. In these secondary prevention studies reporting success, the 
      doses of aspirin employed were large enough to inhibit both the cyclo-oxygenase 
      system and thromboxane A2 production as well as the synthesis of prostacyclin. 
      Thus, in these studies if aspirin is effective in reducing adverse cardiovascular 
      events, its efficacy is being mediated by an unknown mechanism. If the reader of 
      the few studies that report positive results is convinced of the benefit of 
      aspirin, it must be emphasized that thoughtful, cautious patient selection based 
      upon the individual's cardiovascular risk profile must be exercised. Individual 
      variation may exist with respect to aspirin's beneficial effect. It must be 
      absolutely recognized that aspirin or any antiplatelet agent does not in any way 
      substitute for the removal or treatment of coexisting risk factors such as 
      tobacco, obesity, hypercholesterolemia, hyperlipidemia, hypertension, and 
      metabolic disease. In contrast to aspirin, control of the above risk factors has 
      been established as beneficial. Aspirin is not free of undesirable side-effects; 
      fatalities secondary to hemorrhage have been reported, and these must be known in 
      detail and understood by both physician and patient before this agent is 
      prescribed in the prophylactic treatment of cardiovascular disease.
FAU - Lekstrom, J A
AU  - Lekstrom JA
AD  - Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland.
FAU - Bell, W R
AU  - Bell WR
LA  - eng
GR  - HL 24898/HL/NHLBI NIH HHS/United States
GR  - HL 36260/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Cerebrovascular Disorders/prevention & control
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Thrombosis/*prevention & control
RF  - 78
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
AID - 10.1097/00005792-199105000-00001 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 1991 May;70(3):161-78. doi: 
      10.1097/00005792-199105000-00001.

PMID- 28881293
OWN - NLM
STAT- MEDLINE
DCOM- 20180619
LR  - 20180620
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 95
DP  - 2017 Nov
TI  - The anti-tumor effect of aspirin: What we know and what we expect.
PG  - 656-661
LID - S0753-3322(17)33251-1 [pii]
LID - 10.1016/j.biopha.2017.08.085 [doi]
AB  - Aspirin has been widely used as an antipyretic analgesic drug. More and more 
      evidences have shown that aspirin may be play some role on anti-tumor. In this 
      article, we reviewed the research history of aspirin in the treatment and 
      prevention of cancer. Many epidemiological and clinical studies have shown that 
      aspirin can reduce the risk of a variety of malignant tumors and reduce cancer 
      mortality. In addition, we discuss the specific mechanisms of aspirin in the 
      anti-tumor effects. It has been found that aspirin mainly depends on the COX 
      pathway and non-COX pathway to inhibit tumor cell growth and to curb tumor 
      development. In this article, clinical studies and anti-tumor mechanism studies 
      published in recent years are reviewed.
CI  - Copyright © 2017. Published by Elsevier Masson SAS.
FAU - Ma, Ji
AU  - Ma J
AD  - Department of Oncology, Chengdu General Hospital of PLA, Chengdu, Sichuan 610000, 
      PR China; Department of Breast Surgery, Lanzhou General Hospital of PLA, Lanzhou, 
      Gansu 730000, PR China.
FAU - Cai, Zhonglin
AU  - Cai Z
AD  - Department of Urology, Lanzhou General Hospital of PLA, Lanzhou, Gansu 730000, PR 
      China.
FAU - Wei, Hongliang
AU  - Wei H
AD  - Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth 
      Military Medical University, Xi'an, Shaanxi 710032, PR China.
FAU - Liu, Xinlan
AU  - Liu X
AD  - Departments of Oncology, General Hospital of Ningxia Medical University, 
      Yinchuan, Ningxia 750000, PR China.
FAU - Zhao, Qingli
AU  - Zhao Q
AD  - Department of Breast Surgery, Lanzhou General Hospital of PLA, Lanzhou, Gansu 
      730000, PR China.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Department of Oncology, Chengdu General Hospital of PLA, Chengdu, Sichuan 610000, 
      PR China. Electronic address: zhangtao269@126.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170904
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antineoplastic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Autophagy/drug effects
MH  - Humans
MH  - Neoplasms/*drug therapy/pathology
MH  - Oxidative Stress/drug effects
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer
OT  - Clinical research
OT  - Molecular mechanisms
EDAT- 2017/09/08 06:00
MHDA- 2018/06/21 06:00
CRDT- 2017/09/08 06:00
PHST- 2017/07/04 00:00 [received]
PHST- 2017/08/19 00:00 [revised]
PHST- 2017/08/23 00:00 [accepted]
PHST- 2017/09/08 06:00 [pubmed]
PHST- 2018/06/21 06:00 [medline]
PHST- 2017/09/08 06:00 [entrez]
AID - S0753-3322(17)33251-1 [pii]
AID - 10.1016/j.biopha.2017.08.085 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2017 Nov;95:656-661. doi: 10.1016/j.biopha.2017.08.085. Epub 
      2017 Sep 4.

PMID- 22084361
OWN - NLM
STAT- MEDLINE
DCOM- 20120608
LR  - 20211021
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 5
IP  - 2
DP  - 2012 Feb
TI  - Aspirin in the chemoprevention of colorectal neoplasia: an overview.
PG  - 164-78
LID - 10.1158/1940-6207.CAPR-11-0391 [doi]
AB  - Considerable evidence supports the effectiveness of aspirin for chemoprevention 
      of colorectal cancer (CRC) in addition to its well-established benefits in the 
      prevention of vascular disease. Epidemiologic studies have consistently observed 
      an inverse association between aspirin use and risk of CRC. A recent pooled 
      analysis of a long-term posttrial follow-up of nearly 14,000 patients from four 
      randomized, cardiovascular disease prevention trials showed that daily aspirin 
      treatment for about five years was associated with a 34% reduction in 20-year CRC 
      mortality. A separate metaanalysis of nearly 3,000 patients with a history of 
      colorectal adenoma or cancer in four randomized adenoma prevention trials showed 
      that aspirin reduced the occurrence of advanced adenomas by 28% and any adenoma 
      by 17%. Aspirin has also been shown to be beneficial in a clinical trial of 
      patients with Lynch syndrome, a hereditary CRC syndrome; in those treated with 
      aspirin for at least two years, there was a 50% or more reduction in the risk of 
      CRC commencing five years after randomization and after aspirin had been 
      discontinued. A few observational studies have shown an increase in survival 
      among patients with CRC who use aspirin. Taken together, these findings 
      strengthen the case for consideration of long-term aspirin use in CRC prevention. 
      Despite these compelling data, there is a lack of consensus about the balance of 
      risks and benefits associated with long-term aspirin use, particularly in 
      low-risk populations. The optimal dose to use for cancer prevention and the 
      precise mechanism underlying aspirin's anticancer effect require further 
      investigation.
CI  - ©2011 AACR.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical 
      School, 55 Fruit St, Boston, MA 02114, USA. achan@partners.org
FAU - Arber, Nadir
AU  - Arber N
FAU - Burn, John
AU  - Burn J
FAU - Chia, Whay Kuang
AU  - Chia WK
FAU - Elwood, Peter
AU  - Elwood P
FAU - Hull, Mark A
AU  - Hull MA
FAU - Logan, Richard F
AU  - Logan RF
FAU - Rothwell, Peter M
AU  - Rothwell PM
FAU - Schrör, Karsten
AU  - Schrör K
FAU - Baron, John A
AU  - Baron JA
LA  - eng
GR  - 09/100/25/DH_/Department of Health/United Kingdom
GR  - G116/146(60953)/MRC_/Medical Research Council/United Kingdom
GR  - EME/09/100/25/DH_/Department of Health/United Kingdom
GR  - R01 CA137178/CA/NCI NIH HHS/United States
GR  - G116/146/MRC_/Medical Research Council/United Kingdom
GR  - R01 CA059005/CA/NCI NIH HHS/United States
GR  - R01 CA137178-03/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20111114
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Colorectal Neoplasms/*prevention & control
MH  - Humans
PMC - PMC3273592
MID - NIHMS338653
EDAT- 2011/11/16 06:00
MHDA- 2012/06/09 06:00
CRDT- 2011/11/16 06:00
PHST- 2011/11/16 06:00 [entrez]
PHST- 2011/11/16 06:00 [pubmed]
PHST- 2012/06/09 06:00 [medline]
AID - 1940-6207.CAPR-11-0391 [pii]
AID - 10.1158/1940-6207.CAPR-11-0391 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2012 Feb;5(2):164-78. doi: 
      10.1158/1940-6207.CAPR-11-0391. Epub 2011 Nov 14.

PMID- 18175654
OWN - NLM
STAT- MEDLINE
DCOM- 20080208
LR  - 20131121
IS  - 0019-5499 (Print)
IS  - 0019-5499 (Linking)
VI  - 51
IP  - 2
DP  - 2007 Apr-Jun
TI  - Aspirin resistance.
PG  - 109-17
AB  - Aspirin reduces the odds of serious atherothrombotic vascular events and death in 
      a broad category of high risk patients by about one quarter. The term 'aspirin 
      resistance' has been used to describe not only an absence of the expected 
      pharmacologic effects of aspirin on platelets but also poor clinical outcomes, 
      such as recurrent vascular events, in patients treated with aspirin. Various 
      factors such as genetic, nonadherence, variable response to different doses, 
      co-morbid conditions and drug interactions are responsible for aspirin 
      resistance. Many methods, with their limitations, are available to measure the 
      effects on platelets. Despite treatment failures, aspirin remains the single most 
      cost-effective drug for the secondary prevention of atherothrombotic disease. To 
      optimize its clinical effectiveness, clinicians should be aware of the potential 
      causes of aspirin treatment failure, prescribe aspirin in appropriate doses, and 
      encourage patients to take aspirin, stop smoking, and avoid regular use of 
      NSAIDs.
FAU - Ashwin, K A
AU  - Ashwin KA
AD  - Department of Pharmacology, Kasturba Medical College, Manipal 576 104.
FAU - Bairy, K L
AU  - Bairy KL
FAU - Vidyasagar, Sudha
AU  - Vidyasagar S
FAU - Verma, Muralidhar
AU  - Verma M
FAU - Prashanth, C K
AU  - Prashanth CK
FAU - Sachidananda, A
AU  - Sachidananda A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Physiol Pharmacol
JT  - Indian journal of physiology and pharmacology
JID - 0374707
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Atherosclerosis/drug therapy
MH  - Blood Platelets/drug effects
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Risk Factors
RF  - 44
EDAT- 2008/01/08 09:00
MHDA- 2008/02/09 09:00
CRDT- 2008/01/08 09:00
PHST- 2008/01/08 09:00 [pubmed]
PHST- 2008/02/09 09:00 [medline]
PHST- 2008/01/08 09:00 [entrez]
PST - ppublish
SO  - Indian J Physiol Pharmacol. 2007 Apr-Jun;51(2):109-17.

PMID- 32556683
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210107
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Linking)
VI  - 22
IP  - 8
DP  - 2020 Jun 18
TI  - Is There Still a Role for Aspirin in Primary Prevention in Women in 2020?
PG  - 34
LID - 10.1007/s11883-020-00851-x [doi]
AB  - PURPOSE OF REVIEW: Aspirin's place in primary prevention for females has not been 
      well delineated and has been under increased scrutiny in light of recent 
      literature and guideline recommendations. The purpose of this review is to 
      discuss current literature reviewing aspirin use for primary prevention in women 
      and to discuss when use is appropriate. RECENT FINDINGS: The Women's Health Study 
      found no differences in major adverse cardiovascular events (MACE) in women 
      randomized to aspirin vs. placebo, though a significant reduction was observed in 
      women ≥ 65 years. More recent literature evaluated outcomes for primary 
      prevention use in patients at increased cardiovascular risk, patients with 
      diabetes, and patients who are elderly. These trials found either no benefit in 
      MACE outcomes or a slight benefit accompanied by an increased risk of bleeding. 
      Furthermore, no difference in outcomes were found in subgroup analyses comparing 
      females receiving aspirin vs. placebo or comparing events in males vs. females. 
      With improvements in risk factor reduction, such as blood pressure control, 
      statin use, diabetes management, and smoking cessation, the role of aspirin for 
      primary prevention in women is still uncertain. Aspirin use for primary 
      prevention in females has failed to show a clear benefit except in women 
      ≥ 65 years old, with a potential increase in bleeding events. An effort to better 
      study aspirin in female patients would allow for better identification of women 
      who would or would not benefit from therapy.
FAU - Sulaica, Elisabeth M
AU  - Sulaica EM
AUID- ORCID: 0000-0002-5655-5318
AD  - Department of Pharmacy Practice and Translational Research, University of Houston 
      College of Pharmacy, 4849 Calhoun Road Health 2, Room 3044, Houston, TX, 
      77204-5039, USA. emsulaic@central.uh.edu.
FAU - Asias-Dinh, Bernadette D
AU  - Asias-Dinh BD
AD  - Department of Pharmacy Practice and Translational Research, University of Houston 
      College of Pharmacy, 4849 Calhoun Road Health 2, Room 3044, Houston, TX, 
      77204-5039, USA.
FAU - Wanat, Matthew A
AU  - Wanat MA
AD  - Department of Pharmacy Practice and Translational Research, University of Houston 
      College of Pharmacy, 4849 Calhoun Road Health 2, Room 3044, Houston, TX, 
      77204-5039, USA.
FAU - Birtcher, Kim K
AU  - Birtcher KK
AD  - Department of Pharmacy Practice and Translational Research, University of Houston 
      College of Pharmacy, 4849 Calhoun Road Health 2, Room 3044, Houston, TX, 
      77204-5039, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200618
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - *Primary Prevention
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Female
OT  - Primary prevention
OT  - Women
EDAT- 2020/06/20 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
AID - 10.1007/s11883-020-00851-x [pii]
AID - 10.1007/s11883-020-00851-x [doi]
PST - epublish
SO  - Curr Atheroscler Rep. 2020 Jun 18;22(8):34. doi: 10.1007/s11883-020-00851-x.

PMID- 34166171
OWN - NLM
STAT- MEDLINE
DCOM- 20220329
LR  - 20220329
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 33
IP  - 3
DP  - 2022 Apr 3
TI  - Platelet Function Assays for the Diagnosis of Aspirin Resistance.
PG  - 329-338
LID - 10.1080/09537104.2021.1942816 [doi]
AB  - Aspirin, an antiplatelet drug, is commonly used at low doses for numerous 
      indications, including prophylaxis of cardiovascular, neurovascular, and venous 
      thromboembolic events. Due to review articles suggesting that aspirin resistance 
      may result in poorer outcomes, interest in assessing platelet function is 
      increasing. Despite this, platelet function tests are rarely used as part of 
      routine clinical practice and therefore, a basic understanding of these tests may 
      be lacking. Although aspirin resistance can be categorized as clinical or 
      laboratory resistance, determining laboratory resistance is the only way to 
      determine resistance before treatment failure occurs. Therefore, knowledge of 
      platelet assays to determine aspirin resistance is of importance. The following 
      review aims to provide a framework for clinicians to understand the main 
      principles of platelet function tests. This includes comparison of the most 
      frequently used platelet assays to diagnose aspirin resistance, including the 
      basic mechanism, methodology, reference ranges, inter-assay comparison, and their 
      respective clinical considerations when using.
FAU - Van Oosterom, Nameer
AU  - Van Oosterom N
AUID- ORCID: 0000-0001-9380-2739
AD  - School of Pharmacy, University of Queensland, Brisbane, Australia.
AD  - Pharmacy Department, Princess Alexandra Hospital, Brisbane, Australia.
FAU - Barras, Michael
AU  - Barras M
AD  - School of Pharmacy, University of Queensland, Brisbane, Australia.
AD  - Pharmacy Department, Princess Alexandra Hospital, Brisbane, Australia.
FAU - Cottrell, Neil
AU  - Cottrell N
AD  - School of Pharmacy, University of Queensland, Brisbane, Australia.
FAU - Bird, Robert
AU  - Bird R
AD  - Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210624
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Biological Assay/*methods
MH  - Drug Resistance/*drug effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests/*methods
OTO - NOTNLM
OT  - Aspirin
OT  - blood platelets
OT  - drug resistance
OT  - platelet function tests
OT  - venous thromboembolism
EDAT- 2021/06/25 06:00
MHDA- 2022/03/30 06:00
CRDT- 2021/06/24 17:18
PHST- 2021/06/25 06:00 [pubmed]
PHST- 2022/03/30 06:00 [medline]
PHST- 2021/06/24 17:18 [entrez]
AID - 10.1080/09537104.2021.1942816 [doi]
PST - ppublish
SO  - Platelets. 2022 Apr 3;33(3):329-338. doi: 10.1080/09537104.2021.1942816. Epub 
      2021 Jun 24.

PMID- 26201059
OWN - NLM
STAT- MEDLINE
DCOM- 20160921
LR  - 20151221
IS  - 1098-8823 (Print)
IS  - 1098-8823 (Linking)
VI  - 121
IP  - Pt A
DP  - 2015 Sep
TI  - Aspirin and lipid mediators in the cardiovascular system.
PG  - 17-23
LID - S1098-8823(15)30005-8 [pii]
LID - 10.1016/j.prostaglandins.2015.07.004 [doi]
AB  - Aspirin is an unique compound because it bears two active moieties within one and 
      the same molecule: a reactive acetyl group and the salicylate metabolite. 
      Salicylate has some effects similar to aspirin, however only at higher 
      concentrations, usually in the millimolar range, which are not obtained at 
      conventional antiplatelet aspirin doses of 100-300 mg/day. Pharmacological 
      actions of aspirin in the cardiovascular system at these doses are largely if not 
      entirely due to target structure acetylation. Several classes of lipid mediators 
      become affected: Best known is the cyclooxygenase-1 (COX-1) in platelets with 
      subsequent inhibition of thromboxane and, possibly, thrombin formation. By this 
      action, aspirin also inhibits paracrine thromboxane functions on other lipid 
      mediators, such as the platelet storage product sphingosine-1-phosphate (S1P), an 
      inflammatory mediator. Acetylation of COX-2 allows for generation of 15-(R)HETE 
      and subsequent formation of "aspirin-triggered lipoxin" (ATL) by interaction with 
      white cell lipoxygenases. In the cardiovascular system, aspirin also acetylates 
      eNOS with subsequent upregulation of NO formation and enhanced expression of the 
      antioxidans heme-oxygenase-1. This action is possibly also COX-2/ATL mediated. 
      Many more acetylation targets have been identified in live cells by quantitative 
      acid-cleavable activity-based protein profiling and might result in discovery of 
      even more aspirin targets in the near future.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Schrör, Karsten
AU  - Schrör K
AD  - Institut für Pharmakologie und Klinische Pharmakologie, 
      Heinrich-Heine-Universität Düsseldorf and *Institut für Pharmakologie, 
      Ernst-Moritz Arndt Universität, Greifswald, Germany. Electronic address: 
      schroer.frechen@uni-duesseldorf.de.
FAU - Rauch, Bernhard H
AU  - Rauch BH
AD  - Institut für Pharmakologie und Klinische Pharmakologie, 
      Heinrich-Heine-Universität Düsseldorf and *Institut für Pharmakologie, 
      Ernst-Moritz Arndt Universität, Greifswald, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150719
PL  - United States
TA  - Prostaglandins Other Lipid Mediat
JT  - Prostaglandins & other lipid mediators
JID - 9808648
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/pharmacokinetics/*pharmacology
MH  - Cardiovascular System/*drug effects/*metabolism
MH  - Humans
MH  - Lipid Metabolism/*drug effects
MH  - Molecular Targeted Therapy
OTO - NOTNLM
OT  - Aspirin
OT  - Cycloxygenases
OT  - Lipoxins
OT  - Nitric oxide
OT  - Prostaglandins
OT  - Sphingosine-1-phosphate
OT  - Thromboxane
EDAT- 2015/07/23 06:00
MHDA- 2016/09/23 06:00
CRDT- 2015/07/23 06:00
PHST- 2015/03/06 00:00 [received]
PHST- 2015/07/15 00:00 [revised]
PHST- 2015/07/15 00:00 [accepted]
PHST- 2015/07/23 06:00 [entrez]
PHST- 2015/07/23 06:00 [pubmed]
PHST- 2016/09/23 06:00 [medline]
AID - S1098-8823(15)30005-8 [pii]
AID - 10.1016/j.prostaglandins.2015.07.004 [doi]
PST - ppublish
SO  - Prostaglandins Other Lipid Mediat. 2015 Sep;121(Pt A):17-23. doi: 
      10.1016/j.prostaglandins.2015.07.004. Epub 2015 Jul 19.

PMID- 24709195
OWN - NLM
STAT- MEDLINE
DCOM- 20150406
LR  - 20190221
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 127
IP  - 7
DP  - 2014
TI  - Aspirin and esophageal squamous cell carcinoma: bedside to bench.
PG  - 1365-9
AB  - OBJECTIVE: To review the advances of studies on clinical results of aspirin's 
      chemopreventive effect against esophageal squamous cell carcinoma (ESCC) and 
      evidences for mechanisms of the antitumoural effects of aspirin in experimental 
      research. DATA SOURCES: A comprehensive search of the PubMed literatures without 
      restriction on the publication date was carried out using keywords such as 
      aspirin and esophageal cancer. STUDY SELECTION: Articles associated with aspirin 
      and esophageal cancer are analyzed. RESULTS: This review focuses on the current 
      evidence for use of aspirin as a chemopreventive agent in ESCC. Aspirin is the 
      most widely used among all nonsteroidal anti-inflammatory drugs (NSAIDs), which 
      is cheap and acceptable to patients. Several observational results provide the 
      further investigation of prevention and therapy of aspirin or similar drugs in 
      esophageal cancer. Data from case control studies, cohort studies and randomized 
      controlled trials (RCTs) also give some support of a beneficial role of aspirin 
      on ESCC. Experimental data suggest that aspirin may prevent carcinogenesis of 
      ESCC by favorably affecting proliferation, apoptosis, or other as yet 
      unidentified growth-regulating processes. But the mechanism by which aspirin 
      influence on esophageal squamous cell carcinoma needs further investigation. 
      CONCLUSION: A wealth of evidences ranging from clinical data to experimental 
      results are building to suggest that aspirin has significant effects in reducing 
      both the incidence and mortality of ESCC.
FAU - Li, Peng
AU  - Li P
AD  - Department of Digestive Diseases, Beijing Friendship Hospital, Capital Medical 
      University; Beijing Key Laboratory for Precancerous Lesion of Digestive Diseases; 
      Beijing Digestive Diseases Center, Beijing 100050, China.
FAU - Cheng, Rui
AU  - Cheng R
AD  - Department of Digestive Diseases, Beijing Friendship Hospital, Capital Medical 
      University; Beijing Key Laboratory for Precancerous Lesion of Digestive Diseases; 
      Beijing Digestive Diseases Center, Beijing 100050, China.
FAU - Zhang, Shutian
AU  - Zhang S
AD  - Department of Digestive Diseases, Beijing Friendship Hospital, Capital Medical 
      University; Beijing Key Laboratory for Precancerous Lesion of Digestive Diseases; 
      Beijing Digestive Diseases Center, Beijing 100050, China. Email: 
      zhangst@ccmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Carcinoma, Squamous Cell/*drug therapy/*prevention & control
MH  - Esophageal Neoplasms/*drug therapy/*prevention & control
MH  - Esophageal Squamous Cell Carcinoma
MH  - Humans
EDAT- 2014/04/09 06:00
MHDA- 2015/04/07 06:00
CRDT- 2014/04/09 06:00
PHST- 2014/04/09 06:00 [entrez]
PHST- 2014/04/09 06:00 [pubmed]
PHST- 2015/04/07 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2014;127(7):1365-9.

PMID- 22918730
OWN - NLM
STAT- MEDLINE
DCOM- 20130110
LR  - 20131121
IS  - 0171-2004 (Print)
IS  - 0171-2004 (Linking)
IP  - 210
DP  - 2012
TI  - Aspirin and Other COX-1 inhibitors.
PG  - 137-64
LID - 10.1007/978-3-642-29423-5_6 [doi]
AB  - Currently available antiplatelet drugs interfere with the process of platelet 
      activation and aggregation by selectively blocking key enzymes involved in the 
      synthesis of platelet agonists, or membrane receptors mediating activation 
      signals. Pharmacological interference with critical molecular pathways of 
      platelet activation and aggregation may reduce the risk of atherothrombotic 
      complications through mechanisms that are also responsible for an increased risk 
      of bleeding. Acetylsalicylic acid (aspirin) represents a prototypic antiplatelet 
      agent. The aim of this chapter is to integrate our current understanding of the 
      molecular mechanism of action of aspirin with the results of clinical trials and 
      epidemiological studies assessing its efficacy and safety. Moreover, the 
      antiplatelet properties of reversible inhibitors of the same drug target will 
      also be reviewed.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Largo F. 
      Vito, 1, 00168, Rome, Italy. carlo.patrono@rm.unicatt.it
FAU - Rocca, Bianca
AU  - Rocca B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Germany
TA  - Handb Exp Pharmacol
JT  - Handbook of experimental pharmacology
JID - 7902231
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*pharmacology/therapeutic use
MH  - Atherosclerosis/drug therapy
MH  - Atrial Fibrillation/drug therapy
MH  - Cyclooxygenase 1/*physiology
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Female
MH  - Humans
MH  - Placental Insufficiency/drug therapy
MH  - Pregnancy
MH  - Venous Thrombosis/drug therapy
EDAT- 2012/08/25 06:00
MHDA- 2013/01/11 06:00
CRDT- 2012/08/25 06:00
PHST- 2012/08/25 06:00 [entrez]
PHST- 2012/08/25 06:00 [pubmed]
PHST- 2013/01/11 06:00 [medline]
AID - 10.1007/978-3-642-29423-5_6 [doi]
PST - ppublish
SO  - Handb Exp Pharmacol. 2012;(210):137-64. doi: 10.1007/978-3-642-29423-5_6.

PMID- 19630812
OWN - NLM
STAT- MEDLINE
DCOM- 20091201
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 7 Suppl 1
DP  - 2009 Jul
TI  - Aspirin, 110 years later.
PG  - 258-61
LID - 10.1111/j.1538-7836.2009.03391.x [doi]
AB  - Although conceived at the end of the 19th century as a synthetic analgesic agent 
      with improved gastric tolerability vs. naturally occurring salicylates, 
      acetylsalicylic acid (marketed as aspirin in 1899) turned out to be an ideal 
      antiplatelet agent about 90 years later, following the understanding of its 
      mechanism of action, the development of a mechanism-based biomarker for 
      dose-finding studies, and the initiation of a series of appropriately sized, 
      randomized clinical trials to test its efficacy and safety at low doses given 
      once daily. At the turn of its 110th anniversary, aspirin continues to attract 
      heated debates on a number of issues including (i) the optimal dose to maximize 
      efficacy and minimize toxicity; (ii) the possibility that some patients may be 
      'resistant' to its antiplatelet effects; and (iii) the balance of benefits and 
      risks in primary vs. secondary prevention.
FAU - Patrono, C
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. 
      carlo.patrono@rm.unicatt.it
FAU - Rocca, B
AU  - Rocca B
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/history/*therapeutic use
MH  - Drug Resistance
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Platelet Aggregation Inhibitors
MH  - Risk Assessment
RF  - 17
EDAT- 2009/07/28 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/07/28 09:00
PHST- 2009/07/28 09:00 [entrez]
PHST- 2009/07/28 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S1538-7836(22)17411-8 [pii]
AID - 10.1111/j.1538-7836.2009.03391.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2009 Jul;7 Suppl 1:258-61. doi: 
      10.1111/j.1538-7836.2009.03391.x.

PMID- 33879541
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 2009-8774 (Electronic)
IS  - 2305-6983 (Print)
IS  - 2305-6983 (Linking)
VI  - 9
IP  - 2
DP  - 2021 Apr
TI  - Rationales and uncertainties for aspirin use in COVID-19: a narrative review.
LID - 10.1136/fmch-2020-000741 [doi]
LID - e000741
AB  - OBJECTIVES: To review the pathophysiology of COVID-19 disease, potential aspirin 
      targets on this pathogenesis and the potential role of aspirin in patients with 
      COVID-19. DESIGN: Narrative review. SETTING: The online databases PubMed, OVID 
      Medline and Cochrane Library were searched using relevant headlines from 1 
      January 2016 to 1 January 2021. International guidelines from relevant societies, 
      journals and forums were also assessed for relevance. PARTICIPANTS: Not 
      applicable. RESULTS: A review of the selected literature revealed that clinical 
      deterioration in COVID-19 is attributed to the interplay between endothelial 
      dysfunction, coagulopathy and dysregulated inflammation. Aspirin has 
      anti-inflammatory effects, antiplatelet aggregation, anticoagulant properties as 
      well as pleiotropic effects on endothelial function. During the COVID-19 
      pandemic, low-dose aspirin is used effectively in secondary prevention of 
      atherosclerotic cardiovascular disease, prevention of venous thromboembolism 
      after total hip or knee replacement, prevention of pre-eclampsia and 
      postdischarge treatment for multisystem inflammatory syndrome in children. 
      Prehospital low-dose aspirin therapy may reduce the risk of intensive care unit 
      admission and mechanical ventilation in hospitalised patients with COVID-19, 
      whereas aspirin association with mortality is still debatable. CONCLUSION: The 
      authors recommend a low-dose aspirin regimen for primary prevention of arterial 
      thromboembolism in patients aged 40-70 years who are at high atherosclerotic 
      cardiovascular disease risk, or an intermediate risk with a risk-enhancer and 
      have a low risk of bleeding. Aspirin's protective roles in COVID-19 associated 
      with acute lung injury, vascular thrombosis without previous cardiovascular 
      disease and mortality need further randomised controlled trials to establish 
      causal conclusions.
CI  - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sayed Ahmed, Hazem A
AU  - Sayed Ahmed HA
AUID- ORCID: 0000-0002-4922-8706
AD  - Department of Family Medicine, Suez Canal University Faculty of Medicine, 
      Ismailia, Egypt.
FAU - Merrell, Eric
AU  - Merrell E
AD  - Department of Medicine, State University of New York Upstate Medical University, 
      Syracuse, New York, USA.
FAU - Ismail, Mansoura
AU  - Ismail M
AD  - Department of Family Medicine, Suez Canal University Faculty of Medicine, 
      Ismailia, Egypt.
FAU - Joudeh, Anwar I
AU  - Joudeh AI
AUID- ORCID: 0000-0001-8323-1303
AD  - Department of Internal Medicine, The University of Jordan, Amman, Jordan 
      anwarjoudeh@gmail.com.
FAU - Riley, Jeffrey B
AU  - Riley JB
AD  - Department of Cardiovascular Perfusion, State University of New York Upstate 
      Medical University, Syracuse, New York, USA.
FAU - Shawkat, Ahmed
AU  - Shawkat A
AD  - Department of Critical Care, State University of New York Upstate Medical 
      University, Syracuse, New York, USA.
FAU - Habeb, Hanan
AU  - Habeb H
AD  - Egypt Ministry of Health and Population, Cairo, Egypt.
FAU - Darling, Edward
AU  - Darling E
AD  - Department of Cardiovascular Perfusion, State University of New York Upstate 
      Medical University, Syracuse, New York, USA.
FAU - Goweda, Reda A
AU  - Goweda RA
AD  - Department of Family Medicine, Suez Canal University Faculty of Medicine, 
      Ismailia, Egypt.
AD  - Department of Community Medicine, Umm Al-Qura University College of Medicine, 
      Makkah, Saudi Arabia.
FAU - Shehata, Mohamed H
AU  - Shehata MH
AD  - Department of Family and Community Medicine, Arabian Gulf University College of 
      Medicine and Medical Science, Manama, Bahrain.
FAU - Amin, Hossam
AU  - Amin H
AD  - Department of Critical Care, New York Medical College, Valhalla, New York, USA.
FAU - Nieman, Gary F
AU  - Nieman GF
AD  - Department of Surgery, State University of New York Upstate Medical University, 
      Syracuse, New York, USA.
FAU - Aiash, Hani
AU  - Aiash H
AD  - Department of Family Medicine, Suez Canal University Faculty of Medicine, 
      Ismailia, Egypt.
AD  - Department of Cardiovascular Perfusion, State University of New York Upstate 
      Medical University, Syracuse, New York, USA.
AD  - Department of Surgery, State University of New York Upstate Medical University, 
      Syracuse, New York, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Fam Med Community Health
JT  - Family medicine and community health
JID - 101700650
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/therapeutic use
MH  - *Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - *COVID-19/complications/physiopathology/therapy
MH  - Humans
MH  - Inflammation
MH  - Middle Aged
MH  - Practice Guidelines as Topic
MH  - *Thromboembolism/drug therapy/etiology/prevention & control
PMC - PMC8061559
OTO - NOTNLM
OT  - COVID-19
OT  - cardiovascular diseases
OT  - global health
OT  - infectious disease medicine
OT  - respiratory system
COIS- Competing interests: GFN reports grants from Drager Medial, outside the submitted 
      work.
EDAT- 2021/04/22 06:00
MHDA- 2021/04/29 06:00
CRDT- 2021/04/21 06:18
PHST- 2021/04/21 06:18 [entrez]
PHST- 2021/04/22 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
AID - fmch-2020-000741 [pii]
AID - 10.1136/fmch-2020-000741 [doi]
PST - ppublish
SO  - Fam Med Community Health. 2021 Apr;9(2):e000741. doi: 10.1136/fmch-2020-000741.

PMID- 22165084
OWN - NLM
STAT- MEDLINE
DCOM- 20120117
LR  - 20131121
IS  - 0024-3477 (Print)
IS  - 0024-3477 (Linking)
VI  - 133
IP  - 9-10
DP  - 2011 Sep-Oct
TI  - [Aspirin resistance].
PG  - 337-42
AB  - Although present in pharmacotherapy for more than 100 years, aspirin still 
      represents a cornerstone in the primary and secondary prevention of 
      cardiovascular patients. Despite undoubtful benefit, a certain proportion of 
      patients treated with aspirin develops adverse atherothrombotic events like stent 
      thrombosis, myocardial infarction, stroke and cardiovascular death. In recent 
      years, there is a growing scientific interest concerning the relationship of 
      suboptimal antiplatelet response to aspirin and cardiovascular prognosis that has 
      led to the concept of "aspirin resistance". Besides the absence of uniform 
      definition of aspirin resistance, an important issue in these studies are 
      numerous and poorly standardized laboratory methods that are used in its 
      detection. Despite an increasing number of reports that favour its clinical 
      significance, there are still no expert recommendations for routine assessment of 
      platelet aggregation as well as for modification of antiplatelet doses or 
      regimens in the case of established aspirin resistance.
FAU - Milicić, Davor
AU  - Milicić D
AD  - Klinika za bolesti srca i krvnih zila Medicinskog fakulteta Sveucilista u 
      Zagrebu, KBC Zagreb.
FAU - Skorić, Bosko
AU  - Skorić B
LA  - hrv
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspirinska rezistencija.
PL  - Croatia
TA  - Lijec Vjesn
JT  - Lijecnicki vjesnik
JID - 0074253
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
EDAT- 2011/12/15 06:00
MHDA- 2012/01/18 06:00
CRDT- 2011/12/15 06:00
PHST- 2011/12/15 06:00 [entrez]
PHST- 2011/12/15 06:00 [pubmed]
PHST- 2012/01/18 06:00 [medline]
PST - ppublish
SO  - Lijec Vjesn. 2011 Sep-Oct;133(9-10):337-42.

PMID- 9282411
OWN - NLM
STAT- MEDLINE
DCOM- 19970923
LR  - 20191102
IS  - 0012-6543 (Print)
IS  - 0012-6543 (Linking)
VI  - 35
IP  - 1
DP  - 1997 Jan
TI  - Which prophylactic aspirin?
PG  - 7-8
AB  - Low doses of aspirin are now a standard part of the management of patients with 
      thromboembolic disease. One risk of taking even low doses is bleeding from the 
      gut, and various aspirin formulations are marketed with claims that they reduce 
      this problem. In this article we review the formulations available and consider 
      their relative safety.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/chemistry/therapeutic use
MH  - Chemistry, Pharmaceutical
MH  - Delayed-Action Preparations
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/chemistry/therapeutic use
MH  - Thromboembolism/*prevention & control
RF  - 19
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1136/dtb.1997.3517 [doi]
PST - ppublish
SO  - Drug Ther Bull. 1997 Jan;35(1):7-8. doi: 10.1136/dtb.1997.3517.

PMID- 18657017
OWN - NLM
STAT- MEDLINE
DCOM- 20081202
LR  - 20131121
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 28
IP  - 8
DP  - 2008 Aug
TI  - Aspirin resistance: disparities and clinical implications.
PG  - 999-1018
LID - 10.1592/phco.28.8.999 [doi]
AB  - Abstract Aspirin is one of the most widely prescribed drugs for the prevention of 
      thrombosis in patients with vascular disease. Yet, aspirin is unable to prevent 
      thrombosis in all patients. The term "aspirin resistance" has been used to 
      broadly define the failure of aspirin to prevent a thrombotic event. Whether this 
      is directly related to aspirin itself through biochemical aspirin resistance or 
      treatment failure, or if it is because of aspirin's inability to overcome the 
      thrombogenic aspects of the disease process itself, has not been elucidated. This 
      can have dramatic clinical implications for a variety of vascular disease subsets 
      and is cause for concern, considering the high prevalence of aspirin use for both 
      primary and secondary prevention. Disparities exist in the rates of aspirin 
      resistance among certain patient populations, such as women, patients with 
      diabetes mellitus, and those with heart failure, and across clinical conditions, 
      such as cardiovascular and cerebrovascular disease. Clinical trial data from 
      studies observing resistance have revealed that regardless of study size, dose of 
      aspirin, control for drug interactions and adherence, or assay used to measure 
      platelet function, aspirin resistance is associated with an increased risk for 
      adverse events. Although the evidence is mounting, there has yet to be a 
      consensus on the appropriate clinical response to aspirin resistance.
FAU - Airee, Anita
AU  - Airee A
AD  - University of Tennessee College of Pharmacy, Knoxville Campus, 1924 Alcoa 
      Highway, Knoxville, TN 37920, USA. aairee@utmem.edu
FAU - Draper, Heather M
AU  - Draper HM
FAU - Finks, Shannon W
AU  - Finks SW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects/physiology
MH  - Coronary Artery Bypass
MH  - Diabetes Mellitus/blood
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Resistance
MH  - Female
MH  - Heart Failure/blood
MH  - Humans
MH  - Male
MH  - Medication Adherence
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Treatment Failure
RF  - 113
EDAT- 2008/07/29 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/07/29 09:00
PHST- 2008/07/29 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/07/29 09:00 [entrez]
AID - 10.1592/phco.28.8.999 [pii]
AID - 10.1592/phco.28.8.999 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2008 Aug;28(8):999-1018. doi: 10.1592/phco.28.8.999.

PMID- 31957518
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20210823
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 32
IP  - 1
DP  - 2021 Jan 2
TI  - Novel approaches to P2Y(12) inhibition and aspirin dosing.
PG  - 7-14
LID - 10.1080/09537104.2020.1714574 [doi]
AB  - Aspirin and P2Y(12) inhibitors remain commonly prescribed antiplatelet drugs in 
      the treatment of atherothrombotic conditions. Despite established benefits of 
      dual antiplatelet therapy (DAPT) in the setting of acute coronary syndromes, 
      there remains residual ischemic risk in this group and the problem of bleeding 
      complications is an ongoing issue. DAPT with aspirin and ticagrelor has now been 
      studied in other patient groups such as those with concurrent diabetes and stable 
      coronary artery disease, and those undergoing elective percutaneous coronary 
      intervention (PCI). Recent trials of ticagrelor monotherapy have suggested this 
      may have benefits over standard-of-care in some settings, such as PCI, but not in 
      others such as peripheral arterial disease or stroke. A novel subcutaneously 
      administered P2Y(12) inhibitor, selatogrel, has shown powerful, rapid and 
      consistent effect in a phase 2 study. Aspirin dosing remains an area of 
      investigation, particularly in the setting of DAPT. A novel regimen of 
      very-low-dose twice-daily aspirin has hypothetical advantages in pharmacodynamic 
      and pharmacokinetic effects, maintaining antiplatelet effect whilst reducing 
      potentially harmful peak-trough variation.
FAU - Parker, William A E
AU  - Parker WAE
AUID- ORCID: 0000-0002-7822-8852
AD  - Department of Infection, Immunity and Cardiovascular Disease, University of 
      Sheffield , Sheffield, UK.
AD  - South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS 
      Foundation Trust , Sheffield, UK.
FAU - Storey, Robert F
AU  - Storey RF
AD  - Department of Infection, Immunity and Cardiovascular Disease, University of 
      Sheffield , Sheffield, UK.
AD  - South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS 
      Foundation Trust , Sheffield, UK.
LA  - eng
GR  - FS/18/49/33752/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20200119
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Humans
MH  - Purinergic P2Y Receptor Antagonists/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - P2Y12 inhibitors
OT  - atherothrombosis
EDAT- 2020/01/21 06:00
MHDA- 2021/08/24 06:00
CRDT- 2020/01/21 06:00
PHST- 2020/01/21 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
PHST- 2020/01/21 06:00 [entrez]
AID - 10.1080/09537104.2020.1714574 [doi]
PST - ppublish
SO  - Platelets. 2021 Jan 2;32(1):7-14. doi: 10.1080/09537104.2020.1714574. Epub 2020 
      Jan 19.

PMID- 22591976
OWN - NLM
STAT- MEDLINE
DCOM- 20120628
LR  - 20131121
IS  - 0888-5109 (Print)
IS  - 0888-5109 (Linking)
VI  - 27
IP  - 5
DP  - 2012 May
TI  - Aspirin: a history, a love story.
PG  - 322-9
LID - 10.4140/TCP.n.2012.322 [doi]
AB  - Most pharmacists know that aspirin's origins lie with willow bark, but they may 
      be unaware of its role in the development of the pharmaceutical industry. 
      Evolving from salacin (the active ingredient in many plant remedies) to salicylic 
      acid (an analgesic in its own right) to the more effective, less toxic 
      acetylsalicylic acid, this pain reliever cornered the nonsteroidal 
      anti-inflammatory market for more than 70 years. It helped the dye industry 
      branch into pharmaceuticals, and is now used in multiple indications.
FAU - Wick, Jeannette Y
AU  - Wick JY
AD  - University of Connecticut School of Pharmacy, Storrs, CT, USA.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant 
      Pharmacists
JID - 9013983
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Benzyl Alcohols)
RN  - 0 (Glucosides)
RN  - 4649620TBZ (salicin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/*history
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*history/therapeutic use
MH  - Aspirin/adverse effects/*history/therapeutic use
MH  - Benzyl Alcohols/chemistry
MH  - Cardiovascular Diseases/prevention & control
MH  - Drug Hypersensitivity
MH  - Drug Resistance
MH  - Glucosides/chemistry
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Neoplasms/prevention & control
MH  - Salix/chemistry
MH  - Sex Characteristics
EDAT- 2012/05/18 06:00
MHDA- 2012/06/29 06:00
CRDT- 2012/05/18 06:00
PHST- 2012/05/18 06:00 [entrez]
PHST- 2012/05/18 06:00 [pubmed]
PHST- 2012/06/29 06:00 [medline]
AID - R207K522419211M0 [pii]
AID - 10.4140/TCP.n.2012.322 [doi]
PST - ppublish
SO  - Consult Pharm. 2012 May;27(5):322-9. doi: 10.4140/TCP.n.2012.322.

PMID- 9372101
OWN - NLM
STAT- MEDLINE
DCOM- 19971223
LR  - 20191102
IS  - 1065-6251 (Print)
IS  - 1065-6251 (Linking)
VI  - 3
IP  - 5
DP  - 1996 Sep
TI  - Aspirin therapy for cardiovascular disease.
PG  - 355-60
AB  - Aspirin is a widely used and effective antithrombotic agent. Recent studies 
      suggest that aspirin's anti-inflammatory effects are mediated via inhibition of 
      an inducible isoform of cyclooxygenase in inflammatory cells (COX-2) and through 
      blockade of the nuclear transcription factor, NF-kappa B. The optimal dose of 
      aspirin for most clinical situations is 75 to 325 mg/d, but debate continues as 
      to whether higher doses are needed to prevent cerebral ischemia. Aspirin is very 
      effective for inhibition of platelet-mediated thrombosis at sites of vascular 
      injury but does not reduce restenosis after coronary angioplasty or carotid 
      endarterectomy, nor does it prevent a first stroke. Combined therapy with 
      warfarin and aspirin has been shown to limit systemic embolic in high-risk 
      patients with artificial heart valves, but at the cost of increased bleeding. A 
      new aspirin derivative is currently being developed that appears to stimulate 
      platelet nitric oxide release, inhibit thrombin-induced platelet aggregation, and 
      lower gastric toxicity.
FAU - Goodnight, S H
AU  - Goodnight SH
AD  - Oregon Health Sciences University, Department of Pathology, Portland 97201-3098, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Hematol
JT  - Current opinion in hematology
JID - 9430802
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 49
EDAT- 1996/09/01 00:00
MHDA- 1997/12/31 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1997/12/31 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - 10.1097/00062752-199603050-00004 [doi]
PST - ppublish
SO  - Curr Opin Hematol. 1996 Sep;3(5):355-60. doi: 10.1097/00062752-199603050-00004.

PMID- 10472429
OWN - NLM
STAT- MEDLINE
DCOM- 19991021
LR  - 20141120
IS  - 0753-3322 (Print)
IS  - 0753-3322 (Linking)
VI  - 53
IP  - 7
DP  - 1999 Aug
TI  - Aspirin in the prevention of strokes.
PG  - 309-11
AB  - Aspirin leads to a moderate but significant reduction of stroke, myocardial 
      infarction (MI), and vascular deaths in patients with transient ischemic attack 
      (TIA) and ischemic stroke. Low doses are as effective as high doses but are 
      better tolerated in terms of gastro-intestinal side-effects. The recommended 
      daily aspirin dose is therefore between 50 and 325 mg. Bleeding complications are 
      not dose dependent and occur with the lowest doses.
FAU - Diener, H C
AU  - Diener HC
AD  - Department of Neurology, University Essen, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/mortality/*prevention & control
MH  - Clinical Trials as Topic
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Secondary Prevention
MH  - Time Factors
RF  - 31
EDAT- 1999/09/03 00:00
MHDA- 1999/09/03 00:01
CRDT- 1999/09/03 00:00
PHST- 1999/09/03 00:00 [pubmed]
PHST- 1999/09/03 00:01 [medline]
PHST- 1999/09/03 00:00 [entrez]
AID - S0753-3322(00)88501-7 [pii]
AID - 10.1016/S0753-3322(00)88501-7 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 1999 Aug;53(7):309-11. doi: 10.1016/S0753-3322(00)88501-7.

PMID- 15079767
OWN - NLM
STAT- MEDLINE
DCOM- 20040610
LR  - 20131121
IS  - 1078-5884 (Print)
IS  - 1078-5884 (Linking)
VI  - 27
IP  - 5
DP  - 2004 May
TI  - Aspirin resistance in cardiovascular disease: a review.
PG  - 456-65
AB  - BACKGROUND: Aspirin is effective at reducing the cardiovascular event rate in 
      defined patient groups. The introduction of antiplatelet therapies other than 
      aspirin and the concept of aspirin resistance have led to critical reappraisal of 
      current treatment. This review aims to clarify the evidence for aspirin 
      resistance in patients with atherosclerosis. METHODS: Medline search was 
      performed to identify publications concerned with antiplatelet effects of aspirin 
      and failure of aspirin therapy. Manual cross referencing was also performed. 
      RESULTS AND CONCLUSION: Wide variations in the rate of aspirin resistance 
      (5.5-75%) have been reported. The lack of consensus on an appropriate definition 
      and the number of different tests used to investigate aspirin resistance needs to 
      be addressed. There are few studies where the primary aim was to document aspirin 
      resistance or aspirin non-response. Further work should aim to investigate if 
      aspirin resistance is clinically important and, if it is, what treatments may be 
      beneficial to the at risk patient.
FAU - Wong, S
AU  - Wong S
AD  - Department of Vascular Surgery, The Royal North Shore Hospital, St Leonard's, 
      Sydney, NSW 2065, Australia.
FAU - Appleberg, M
AU  - Appleberg M
FAU - Ward, C M
AU  - Ward CM
FAU - Lewis, D R
AU  - Lewis DR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur J Vasc Endovasc Surg
JT  - European journal of vascular and endovascular surgery : the official journal of 
      the European Society for Vascular Surgery
JID - 9512728
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis/*prevention & control
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/therapeutic 
      use
RF  - 60
EDAT- 2004/04/14 05:00
MHDA- 2004/06/21 10:00
CRDT- 2004/04/14 05:00
PHST- 2004/04/14 05:00 [pubmed]
PHST- 2004/06/21 10:00 [medline]
PHST- 2004/04/14 05:00 [entrez]
AID - S107858840300604X [pii]
AID - 10.1016/j.ejvs.2003.12.025 [doi]
PST - ppublish
SO  - Eur J Vasc Endovasc Surg. 2004 May;27(5):456-65. doi: 10.1016/j.ejvs.2003.12.025.

PMID- 24558899
OWN - NLM
STAT- MEDLINE
DCOM- 20140331
LR  - 20140224
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 10
IP  - 412-413
DP  - 2014 Jan 15
TI  - [Aspirin: once or twice a day?].
PG  - 53-6
AB  - Aspirin is a cornerstone in the prevention of ischemic events and guidelines 
      usually recommend a once-daily dosing. This dosing is based at least in part on 
      the platelet renewal rate, which is of only 10-15% a day. A once-daily dosing is 
      now challenged by several studies demonstrating that when platelet turnover is 
      increased, such as in patients with diabetes or essential thrombocytemia, the 
      inhibition of platelet function provided by aspirin is no longer homogeneous 
      between dosing with a significant recovery of platelet function within a day that 
      is blunted by a twice-daily dosing. This review addresses the issue of aspirin 
      dosing in selected patients in the controversial era of personalized antiplatelet 
      therapy.
FAU - Fontana, Pierre
AU  - Fontana P
AD  - Service d'angiologie et d'hémostase, HUG, 1211 Genève 14. pierre.fontana@hcuge.ch
FAU - Casini, Alessandro
AU  - Casini A
AD  - Service d'hématologie, HUG, 1211 Genève 14.
FAU - Boehlen, Françoise
AU  - Boehlen F
AD  - Service d'angiologie et d'hémostase, HUG, 1211 Genève 14.
FAU - Reny, Jean-Luc
AU  - Reny JL
AD  - Service de médecine interne, et de réhabilitation, HUG, 1211 Genève 14.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Hémostase. Aspirine: une ou deux fois par jour?
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/metabolism
MH  - Blood Platelets/drug effects/physiology
MH  - Drug Administration Schedule
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Individuality
EDAT- 2014/02/25 06:00
MHDA- 2014/04/01 06:00
CRDT- 2014/02/25 06:00
PHST- 2014/02/25 06:00 [entrez]
PHST- 2014/02/25 06:00 [pubmed]
PHST- 2014/04/01 06:00 [medline]
PST - ppublish
SO  - Rev Med Suisse. 2014 Jan 15;10(412-413):53-6.

PMID- 17131625
OWN - NLM
STAT- MEDLINE
DCOM- 20061219
LR  - 20191110
IS  - 0065-2423 (Print)
IS  - 0065-2423 (Linking)
VI  - 42
DP  - 2006
TI  - Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical 
      utility.
PG  - 81-110
AB  - Ingestion of a daily aspirin in patients with coronary artery disease decreases 
      the rate of occlusive atherosclerotic events by about 25 percent. Some patients 
      whose platelets are minimally inhibited by aspirin are categorized as aspirin 
      resistant. Three reports document an increased risk for future vascular events in 
      aspirin resistant patients. Aspirin's platelet inhibitory effect is measured 
      using a variety of techniques. The demarcation between minimal and expected 
      aspirin inhibition of platelets is arbitrarily determined by each investigator 
      which leads to confusion in translating these reports to patient care. The focus 
      of this report is the relative merits of the different techniques and their 
      utility for defining patients with minimal aspirin induced platelet inhibition. 
      The clinically useful mechanisms underlying decreased aspirin induced platelet 
      inhibition include failure of a patient to take their daily aspirin, poor 
      compliance, and nonsteroidal anti-inflammatory drugs (NSAIDs) interference with 
      aspirin's ability to get to its binding site on the cyclooxygenase enzyme-1 
      (COX-1)]. Compliance is best assessed by comparing the results obtained with 
      arachidonic acid (AA) stimulated light aggregation at two time points. The first 
      time point is while the patient is supposedly taking their usual daily aspirin 
      and the second time point is 2 hours after the patient is observed to ingest 325 
      mg of aspirin. After observed ingestion of aspirin, those patients with minimal 
      aspirin inhibition of platelets are best detected using light aggregation 
      stimulated by a new platelet agonist platelet prostaglandin agonist (PPA). In 
      order for the results of a particular technique to be clinically meaningful it 
      must be shown that those patients with minimal aspirin inhibition of platelets 
      have an increased risk for a future vascular event that is independent from known 
      major cardiovascular risk factors.
FAU - Schwartz, Kenneth A
AU  - Schwartz KA
AD  - Department of Medicine, Michigan State University, Michigan, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Clin Chem
JT  - Advances in clinical chemistry
JID - 2985173R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/physiopathology
MH  - Cerebrovascular Disorders/physiopathology
MH  - *Drug Resistance
MH  - Humans
RF  - 69
EDAT- 2006/11/30 09:00
MHDA- 2006/12/21 09:00
CRDT- 2006/11/30 09:00
PHST- 2006/11/30 09:00 [pubmed]
PHST- 2006/12/21 09:00 [medline]
PHST- 2006/11/30 09:00 [entrez]
AID - 10.1016/s0065-2423(06)42003-5 [doi]
PST - ppublish
SO  - Adv Clin Chem. 2006;42:81-110. doi: 10.1016/s0065-2423(06)42003-5.

PMID- 2519899
OWN - NLM
STAT- MEDLINE
DCOM- 19920309
LR  - 20131121
IS  - 0921-8319 (Print)
IS  - 0921-8319 (Linking)
VI  - 1
IP  - 5
DP  - 1989 Sep-Oct
TI  - Aspirin, platelets and prevention of vascular disease.
PG  - 289-96
AB  - Aspirin inhibits thromboxane and prostaglandin formation in platelets and in 
      vascular cells. It prevents platelet aggregation by irreversible acetylation of 
      cyclooxygenase, a key enzyme in arachidonic acid metabolism. On the basis of its 
      antiplatelet effect, aspirin has been assessed during the past two decades in 
      patients with a history of myocardial infarction, stroke, transient ischemic 
      attack or unstable angina. A meta-analysis of randomized controlled trials of 
      long-term aspirin treatment for the secondary prevention of vascular disease 
      indicated that aspirin (300-1500 mg daily) significantly reduced fatal and 
      non-fatal vascular events. More recently aspirin (160 mg daily) produced a 
      significant reduction in hospital vascular mortality and in non-fatal events in 
      patients with suspected acute myocardial infarction. The combination of aspirin 
      and streptokinase was significantly better than either drug alone. On the other 
      hand, two primary prevention trials of aspirin in healthy doctors did not show 
      any modification of vascular mortality despite an overall reduction of non-fatal 
      myocardial infarction. Resolution of some problems related to the mechanism of 
      action of aspirin and to selection of trial populations will possibly increase 
      the benefit/risk ratio of aspirin treatment for the prevention of vascular 
      disease.
FAU - de Gaetano, G
AU  - de Gaetano G
AD  - Istituto di Richerche Farmacologiche Mario Negri, Santa Maria Imbaro, Italy.
FAU - Cerletti, C
AU  - Cerletti C
LA  - eng
PT  - Clinical Trial
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - J Lipid Mediat
JT  - Journal of lipid mediators
JID - 8913460
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/history/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - History, 20th Century
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Streptokinase/pharmacology
MH  - Vascular Diseases/*prevention & control
RF  - 33
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
PST - ppublish
SO  - J Lipid Mediat. 1989 Sep-Oct;1(5):289-96.

PMID- 2191940
OWN - NLM
STAT- MEDLINE
DCOM- 19900726
LR  - 20131121
IS  - 0098-6151 (Print)
IS  - 0098-6151 (Linking)
VI  - 90
IP  - 5
DP  - 1990 May
TI  - Aspirin and stroke prevention: how much?
PG  - 435-7
AB  - Media attention concerning aspirin and the prevention of heart attack has been 
      great, but there has been no similar attention to the subject of aspirin and 
      stroke prevention. Clinical information is available in the literature concerning 
      aspirin dosage and stroke prevention following transient ischemic attack (TIA). 
      However, confusion still exists regarding appropriate dosing as well as the 
      effectiveness of other antiplatelet agents. This review focuses on the mechanism 
      of action of aspirin and cites the rationale provided by clinical trials for a 
      recommendation of 1300 mg of aspirin per day as the sole orally administered 
      antiplatelet agent.
FAU - Toffol, G J
AU  - Toffol GJ
AD  - College of Osteopathic Medicine of the Pacific, Pomona, Calif.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Osteopath Assoc
JT  - The Journal of the American Osteopathic Association
JID - 7503065
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacology/therapeutic use
MH  - Cerebrovascular Disorders/*drug therapy/prevention & control
MH  - Humans
RF  - 15
EDAT- 1990/05/01 00:00
MHDA- 1990/05/01 00:01
CRDT- 1990/05/01 00:00
PHST- 1990/05/01 00:00 [pubmed]
PHST- 1990/05/01 00:01 [medline]
PHST- 1990/05/01 00:00 [entrez]
PST - ppublish
SO  - J Am Osteopath Assoc. 1990 May;90(5):435-7.

PMID- 33318029
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20221005
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 30
IP  - 3
DP  - 2021 Mar
TI  - A Combined Proteomics and Mendelian Randomization Approach to Investigate the 
      Effects of Aspirin-Targeted Proteins on Colorectal Cancer.
PG  - 564-575
LID - 10.1158/1055-9965.EPI-20-1176 [doi]
AB  - BACKGROUND: Evidence for aspirin's chemopreventative properties on colorectal 
      cancer (CRC) is substantial, but its mechanism of action is not well-understood. 
      We combined a proteomic approach with Mendelian randomization (MR) to identify 
      possible new aspirin targets that decrease CRC risk. METHODS: Human colorectal 
      adenoma cells (RG/C2) were treated with aspirin (24 hours) and a stable isotope 
      labeling with amino acids in cell culture (SILAC) based proteomics approach 
      identified altered protein expression. Protein quantitative trait loci (pQTLs) 
      from INTERVAL (N = 3,301) and expression QTLs (eQTLs) from the eQTLGen Consortium 
      (N = 31,684) were used as genetic proxies for protein and mRNA expression levels. 
      Two-sample MR of mRNA/protein expression on CRC risk was performed using 
      eQTL/pQTL data combined with CRC genetic summary data from the Colon Cancer 
      Family Registry (CCFR), Colorectal Transdisciplinary (CORECT), Genetics and 
      Epidemiology of Colorectal Cancer (GECCO) consortia and UK Biobank (55,168 cases 
      and 65,160 controls). RESULTS: Altered expression was detected for 125/5886 
      proteins. Of these, aspirin decreased MCM6, RRM2, and ARFIP2 expression, and MR 
      analysis showed that a standard deviation increase in mRNA/protein expression was 
      associated with increased CRC risk (OR: 1.08, 95% CI, 1.03-1.13; OR: 3.33, 95% 
      CI, 2.46-4.50; and OR: 1.15, 95% CI, 1.02-1.29, respectively). CONCLUSIONS: MCM6 
      and RRM2 are involved in DNA repair whereby reduced expression may lead to 
      increased DNA aberrations and ultimately cancer cell death, whereas ARFIP2 is 
      involved in actin cytoskeletal regulation, indicating a possible role in 
      aspirin's reduction of metastasis. IMPACT: Our approach has shown how laboratory 
      experiments and population-based approaches can combine to identify 
      aspirin-targeted proteins possibly affecting CRC risk.
CI  - ©2020 American Association for Cancer Research.
FAU - Nounu, Aayah
AU  - Nounu A
AUID- ORCID: 0000-0002-3579-1864
AD  - Medical Research Council (MRC) Integrative Epidemiology Unit, Bristol Medical 
      School, University of Bristol, Bristol, United Kingdom. an0435@bristol.ac.uk.
AD  - School of Cellular and Molecular Medicine, University of Bristol, Bristol, United 
      Kingdom.
FAU - Greenhough, Alexander
AU  - Greenhough A
AUID- ORCID: 0000-0002-8306-811X
AD  - School of Cellular and Molecular Medicine, University of Bristol, Bristol, United 
      Kingdom.
AD  - Centre for Research in Biosciences, The Faculty of Health and Applied Sciences, 
      The University of the West of England, Bristol, United Kingdom.
FAU - Heesom, Kate J
AU  - Heesom KJ
AUID- ORCID: 0000-0002-5418-5392
AD  - Proteomics Facility, Faculty of Life Sciences, University of Bristol, Bristol, 
      United Kingdom.
FAU - Richmond, Rebecca C
AU  - Richmond RC
AD  - Medical Research Council (MRC) Integrative Epidemiology Unit, Bristol Medical 
      School, University of Bristol, Bristol, United Kingdom.
FAU - Zheng, Jie
AU  - Zheng J
AD  - Medical Research Council (MRC) Integrative Epidemiology Unit, Bristol Medical 
      School, University of Bristol, Bristol, United Kingdom.
FAU - Weinstein, Stephanie J
AU  - Weinstein SJ
AUID- ORCID: 0000-0002-3834-1535
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, Bethesda, Maryland.
FAU - Albanes, Demetrius
AU  - Albanes D
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, Bethesda, Maryland.
FAU - Baron, John A
AU  - Baron JA
AUID- ORCID: 0000-0003-3461-1056
AD  - Department of Medicine, University of North Carolina School of Medicine, Chapel 
      Hill, North Carolina.
FAU - Hopper, John L
AU  - Hopper JL
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and 
      Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
AD  - Department of Epidemiology, School of Public Health and Institute of Health and 
      Environment, Seoul National University, Seoul, South Korea.
FAU - Figueiredo, Jane C
AU  - Figueiredo JC
AD  - Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, 
      Cedars-Sinai Medical Center, Los Angeles, California.
AD  - Department of Preventive Medicine, Keck School of Medicine, University of 
      Southern California, Los Angeles, California.
FAU - Newcomb, Polly A
AU  - Newcomb PA
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
AD  - School of Public Health, University of Washington, Seattle, Washington.
FAU - Lindor, Noralane M
AU  - Lindor NM
AD  - Department of Health Science Research, Mayo Clinic, Scottsdale, Arizona.
FAU - Casey, Graham
AU  - Casey G
AD  - Center for Public Health Genomics, University of Virginia, Charlottesville, 
      Virginia.
FAU - Platz, Elizabeth A
AU  - Platz EA
AUID- ORCID: 0000-0003-3676-8954
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, Maryland.
FAU - Le Marchand, Loïc
AU  - Le Marchand L
AD  - University of Hawaii Cancer Center, Honolulu, Hawaii.
FAU - Ulrich, Cornelia M
AU  - Ulrich CM
AD  - Huntsman Cancer Institute and Department of Population Health Sciences, 
      University of Utah, Salt Lake City, Utah.
FAU - Li, Christopher I
AU  - Li CI
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
FAU - van Duijnhoven, Fränzel J B
AU  - van Duijnhoven FJB
AUID- ORCID: 0000-0001-8367-2352
AD  - Division of Human Nutrition and Health, Wageningen University & Research, 
      Wageningen, the Netherlands.
FAU - Gsur, Andrea
AU  - Gsur A
AUID- ORCID: 0000-0002-9795-1528
AD  - Institute of Cancer Research, Department of Medicine I, Medical University 
      Vienna, Vienna, Austria.
FAU - Campbell, Peter T
AU  - Campbell PT
AD  - Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, 
      Georgia.
FAU - Moreno, Víctor
AU  - Moreno V
AUID- ORCID: 0000-0002-2818-5487
AD  - Oncology Data Analytics Program, Catalan Institute of Oncology-IDIBELL, 
      L'Hospitalet de Llobregat, Barcelona, Spain.
AD  - CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
AD  - Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, 
      Barcelona, Spain.
AD  - ONCOBEL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet 
      de Llobregat, Barcelona, Spain.
FAU - Vodicka, Pavel
AU  - Vodicka P
AD  - Department of Molecular Biology of Cancer, Institute of Experimental Medicine of 
      the Czech Academy of Sciences, Prague, Czech Republic.
AD  - Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles 
      University, Prague, Czech Republic.
AD  - Faculty of Medicine and Biomedical Center in Pilsen, Charles University, Pilsen, 
      Czech Republic.
FAU - Vodickova, Ludmila
AU  - Vodickova L
AD  - Department of Molecular Biology of Cancer, Institute of Experimental Medicine of 
      the Czech Academy of Sciences, Prague, Czech Republic.
AD  - Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles 
      University, Prague, Czech Republic.
AD  - Faculty of Medicine and Biomedical Center in Pilsen, Charles University, Pilsen, 
      Czech Republic.
FAU - Brenner, Hermann
AU  - Brenner H
AUID- ORCID: 0000-0002-6129-1572
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research 
      Center (DKFZ), Heidelberg, Germany.
AD  - Division of Preventive Oncology, German Cancer Research Center (DKFZ) and 
      National Center for Tumor Diseases (NCT), Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Chang-Claude, Jenny
AU  - Chang-Claude J
AUID- ORCID: 0000-0001-8919-1971
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
AD  - University Medical Centre Hamburg-Eppendorf, University Cancer Centre Hamburg 
      (UCCH), Hamburg, Germany.
FAU - Hoffmeister, Michael
AU  - Hoffmeister M
AUID- ORCID: 0000-0002-8307-3197
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research 
      Center (DKFZ), Heidelberg, Germany.
FAU - Sakoda, Lori C
AU  - Sakoda LC
AUID- ORCID: 0000-0002-0900-5735
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
AD  - Division of Research, Kaiser Permanente Northern California, Oakland, California.
FAU - Slattery, Martha L
AU  - Slattery ML
AUID- ORCID: 0000-0002-1655-6543
AD  - Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
FAU - Schoen, Robert E
AU  - Schoen RE
AUID- ORCID: 0000-0001-7153-2766
AD  - Department of Medicine and Epidemiology, University of Pittsburgh Medical Center, 
      Pittsburgh, Pennsylvania.
FAU - Gunter, Marc J
AU  - Gunter MJ
AD  - Nutrition and Metabolism Section, International Agency for Research on Cancer, 
      World Health Organization, Lyon, France.
FAU - Castellví-Bel, Sergi
AU  - Castellví-Bel S
AUID- ORCID: 0000-0003-1217-5097
AD  - Gastroenterology Department, Hospital Clínic, Institut d'Investigacions 
      Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en 
      Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, 
      Barcelona, Spain.
FAU - Kim, Hyeong Rok
AU  - Kim HR
AD  - Department of Surgery, Chonnam National University Hwasun Hospital and Medical 
      School, Hwasun, Korea.
FAU - Kweon, Sun-Seog
AU  - Kweon SS
AUID- ORCID: 0000-0003-2378-8550
AD  - Department of Preventive Medicine, Chonnam National University Medical School, 
      Gwangju, Korea.
AD  - Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts.
AD  - Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard 
      Medical School, Boston, Massachusetts.
AD  - Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and 
      Harvard Medical School, Boston, Massachusetts.
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard 
      University, Boston, Massachusetts.
AD  - Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of 
      Public Health, Harvard University, Boston, Massachusetts.
FAU - Li, Li
AU  - Li L
AD  - Department of Family Medicine, University of Virginia, Charlottesville, Virginia.
FAU - Zheng, Wei
AU  - Zheng W
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer 
      Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, 
      Nashville, Tennessee.
FAU - Bishop, D Timothy
AU  - Bishop DT
AUID- ORCID: 0000-0002-8752-8785
AD  - Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United 
      Kingdom.
FAU - Buchanan, Daniel D
AU  - Buchanan DD
AUID- ORCID: 0000-0003-2225-6675
AD  - Colorectal Oncogenomics Group, Department of Clinical Pathology, The University 
      of Melbourne, Parkville, Victoria, Australia.
AD  - University of Melbourne Centre for Cancer Research, Victorian Comprehensive 
      Cancer Centre, Parkville, Victoria, Australia.
AD  - Genetic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, 
      Parkville, Victoria, Australia.
FAU - Giles, Graham G
AU  - Giles GG
AUID- ORCID: 0000-0003-4946-9099
AD  - Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, 
      Australia.
AD  - Precision Medicine, School of Clinical Sciences at Monash Health, Monash 
      University, Clayton, Victoria, Australia.
FAU - Gruber, Stephen B
AU  - Gruber SB
AUID- ORCID: 0000-0001-8656-7822
AD  - Department of Preventive Medicine & USC Norris Comprehensive Cancer Center, Keck 
      School of Medicine, University of Southern California, Los Angeles, California.
FAU - Rennert, Gad
AU  - Rennert G
AD  - Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical 
      Center, Haifa, Israel.
AD  - Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of 
      Technology, Haifa, Israel.
AD  - Clalit National Cancer Control Center, Haifa, Israel.
FAU - Stadler, Zsofia K
AU  - Stadler ZK
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Harrison, Tabitha A
AU  - Harrison TA
AUID- ORCID: 0000-0002-4173-7530
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
FAU - Lin, Yi
AU  - Lin Y
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
FAU - Keku, Temitope O
AU  - Keku TO
AD  - Center for Gastrointestinal Biology and Disease, University of North Carolina, 
      Chapel Hill, North Carolina.
FAU - Woods, Michael O
AU  - Woods MO
AUID- ORCID: 0000-0001-8180-418X
AD  - Discipline of Genetics, Memorial University of Newfoundland, St. John's, Canada.
FAU - Schafmayer, Clemens
AU  - Schafmayer C
AD  - Department of General Surgery, University Hospital Rostock, Rostock, Germany.
FAU - Van Guelpen, Bethany
AU  - Van Guelpen B
AUID- ORCID: 0000-0002-9692-101X
AD  - Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden.
AD  - Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden.
FAU - Gallinger, Steven
AU  - Gallinger S
AD  - Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of 
      Toronto, Toronto, Ontario, Canada.
FAU - Hampel, Heather
AU  - Hampel H
AUID- ORCID: 0000-0001-7558-9794
AD  - Division of Human Genetics, Department of Internal Medicine, The Ohio State 
      University Comprehensive Cancer Center, Columbus, Ohio.
FAU - Berndt, Sonja I
AU  - Berndt SI
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, Bethesda, Maryland.
FAU - Pharoah, Paul D P
AU  - Pharoah PDP
AUID- ORCID: 0000-0001-8494-732X
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge, 
      United Kingdom.
FAU - Lindblom, Annika
AU  - Lindblom A
AD  - Department of Clinical Genetics, Karolinska University Hospital, Stockholm, 
      Sweden.
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Wolk, Alicja
AU  - Wolk A
AUID- ORCID: 0000-0001-7387-6845
AD  - Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
AD  - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
FAU - Wu, Anna H
AU  - Wu AH
AD  - University of Southern California, Preventative Medicine, Los Angeles, 
      California.
FAU - White, Emily
AU  - White E
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
AD  - Department of Epidemiology, University of Washington School of Public Health, 
      Seattle, Washington.
FAU - Peters, Ulrike
AU  - Peters U
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
AD  - Department of Epidemiology, University of Washington School of Public Health, 
      Seattle, Washington.
FAU - Drew, David A
AU  - Drew DA
AUID- ORCID: 0000-0002-8813-0816
AD  - Massachusetts General Hospital and Harvard Medical School, Clinical and 
      Translational Epidemiology Unit, Boston, Massachusetts.
FAU - Scherer, Dominique
AU  - Scherer D
AUID- ORCID: 0000-0003-4430-296X
AD  - Institute of Medical Biometry and Informatics, University of Heidelberg, 
      Heidelberg, Germany.
FAU - Bermejo, Justo Lorenzo
AU  - Bermejo JL
AD  - Institute of Medical Biometry and Informatics, University of Heidelberg, 
      Heidelberg, Germany.
FAU - Williams, Ann C
AU  - Williams AC
AD  - School of Cellular and Molecular Medicine, University of Bristol, Bristol, United 
      Kingdom.
FAU - Relton, Caroline L
AU  - Relton CL
AD  - Medical Research Council (MRC) Integrative Epidemiology Unit, Bristol Medical 
      School, University of Bristol, Bristol, United Kingdom.
LA  - eng
GR  - R01 CA067941/CA/NCI NIH HHS/United States
GR  - U01 HG004438/HG/NHGRI NIH HHS/United States
GR  - U01 HG004446/HG/NHGRI NIH HHS/United States
GR  - U10 CA037429/CA/NCI NIH HHS/United States
GR  - K05 CA154337/CA/NCI NIH HHS/United States
GR  - U01 CA164930/CA/NCI NIH HHS/United States
GR  - P30 CA076292/CA/NCI NIH HHS/United States
GR  - R01 CA042182/CA/NCI NIH HHS/United States
GR  - P50 CA127003/CA/NCI NIH HHS/United States
GR  - U01 CA067941/CA/NCI NIH HHS/United States
GR  - R01 CA059045/CA/NCI NIH HHS/United States
GR  - HHSN268201100001I/HL/NHLBI NIH HHS/United States
GR  - R01 CA197350/CA/NCI NIH HHS/United States
GR  - R01 CA076366/CA/NCI NIH HHS/United States
GR  - R35 CA197735/CA/NCI NIH HHS/United States
GR  - R01 CA072520/CA/NCI NIH HHS/United States
GR  - P01 CA087969/CA/NCI NIH HHS/United States
GR  - P30 CA015704/CA/NCI NIH HHS/United States
GR  - HHSN268201100004I/HL/NHLBI NIH HHS/United States
GR  - P30 CA006973/CA/NCI NIH HHS/United States
GR  - U24 CA074783/CA/NCI NIH HHS/United States
GR  - P01 CA055075/CA/NCI NIH HHS/United States
GR  - S10 OD028685/OD/NIH HHS/United States
GR  - R01 CA151993/CA/NCI NIH HHS/United States
GR  - HHSN268201100046C/HL/NHLBI NIH HHS/United States
GR  - P30 DK034987/DK/NIDDK NIH HHS/United States
GR  - R01 CA048998/CA/NCI NIH HHS/United States
GR  - U01 CA137088/CA/NCI NIH HHS/United States
GR  - 11975/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 CA189184/CA/NCI NIH HHS/United States
GR  - U01 CA167552/CA/NCI NIH HHS/United States
GR  - HHSN268201100003C/WH/WHI NIH HHS/United States
GR  - MC_UU_12013_2/MRC_/Medical Research Council/United Kingdom
GR  - Z01 CP010200/ImNIH/Intramural NIH HHS/United States
GR  - U24 CA074794/CA/NCI NIH HHS/United States
GR  - R01 CA066635/CA/NCI NIH HHS/United States
GR  - R21 CA191312/CA/NCI NIH HHS/United States
GR  - U01 CA206110/CA/NCI NIH HHS/United States
GR  - HHSN268201200008C/HL/NHLBI NIH HHS/United States
GR  - C18281/A19169/CRUK_/Cancer Research UK/United Kingdom
GR  - R01 CA137178/CA/NCI NIH HHS/United States
GR  - U01 CA074794/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - U01 CA167551/CA/NCI NIH HHS/United States
GR  - P30 CA014089/CA/NCI NIH HHS/United States
GR  - R01 CA081488/CA/NCI NIH HHS/United States
GR  - HHSN271201100004C/AG/NIA NIH HHS/United States
GR  - R01 CA201407/CA/NCI NIH HHS/United States
GR  - R01 CA063464/CA/NCI NIH HHS/United States
GR  - P01 CA033619/CA/NCI NIH HHS/United States
GR  - U01 CA086308/CA/NCI NIH HHS/United States
GR  - UM1 CA186107/CA/NCI NIH HHS/United States
GR  - HHSN268201100002C/WH/WHI NIH HHS/United States
GR  - R01 CA207371/CA/NCI NIH HHS/United States
GR  - R03 CA153323/CA/NCI NIH HHS/United States
GR  - T32 ES013678/ES/NIEHS NIH HHS/United States
GR  - R01 CA136726/CA/NCI NIH HHS/United States
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - UM1 CA167552/CA/NCI NIH HHS/United States
GR  - K05 CA152715/CA/NCI NIH HHS/United States
GR  - U01 CA122839/CA/NCI NIH HHS/United States
GR  - WT_/Wellcome Trust/United Kingdom
GR  - HHSN268201100003I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201100002I/HL/NHLBI NIH HHS/United States
GR  - U01 CA074783/CA/NCI NIH HHS/United States
GR  - U01 CA084968/CA/NCI NIH HHS/United States
GR  - KL2 TR000421/TR/NCATS NIH HHS/United States
GR  - MR/R017247/1/MRC_/Medical Research Council/United Kingdom
GR  - UM1 CA182883/CA/NCI NIH HHS/United States
GR  - K07 CA190673/CA/NCI NIH HHS/United States
GR  - HHSN268201200008I/HL/NHLBI NIH HHS/United States
GR  - 217487/Z/19/Z/WT_/Wellcome Trust/United Kingdom
GR  - U01 CA164973/CA/NCI NIH HHS/United States
GR  - R37 CA054281/CA/NCI NIH HHS/United States
GR  - HHSN268201100001C/WH/WHI NIH HHS/United States
GR  - HHSN268201100004C/WH/WHI NIH HHS/United States
GR  - R01 CA097325/CA/NCI NIH HHS/United States
GR  - HHSN268201700006C/HL/NHLBI NIH HHS/United States
GR  - U19 CA148107/CA/NCI NIH HHS/United States
GR  - U01 AG018033/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201214
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Humans
MH  - Mendelian Randomization Analysis/*methods
MH  - Proteomics/*methods
MH  - Risk Factors
PMC - PMC8086774
MID - NIHMS1676470
COIS- Conflict of interest Elizabeth A. Platz is the Editor-in-Chief of Cancer 
      Epidemiology, Biomarkers and Prevention.
EDAT- 2020/12/16 06:00
MHDA- 2022/02/03 06:00
CRDT- 2020/12/15 05:53
PHST- 2020/08/17 00:00 [received]
PHST- 2020/10/09 00:00 [revised]
PHST- 2020/12/09 00:00 [accepted]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
PHST- 2020/12/15 05:53 [entrez]
AID - 1055-9965.EPI-20-1176 [pii]
AID - 10.1158/1055-9965.EPI-20-1176 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):564-575. doi: 
      10.1158/1055-9965.EPI-20-1176. Epub 2020 Dec 14.

PMID- 3552588
OWN - NLM
STAT- MEDLINE
DCOM- 19870619
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 32 Suppl 4
DP  - 1986
TI  - Aspirin and related derivatives of salicylic acid.
PG  - 8-26
AB  - After almost 90 years of clinical use, aspirin remains one of the world's most 
      extensively used 'over-the-counter' drugs, and it is still recognised as the 
      standard analgesic/antipyretic/anti-inflammatory agent by which newer drugs are 
      assessed. However, its pre-eminent position as the analgesic of choice for mild 
      to moderate pain has been seriously challenged with the introduction of many 
      'new' non-steroidal non-narcotic analgesic drugs. Indeed, there is convincing 
      scientific evidence that many of the 'newer' non-steroidal drugs such as 
      diflunisal, ibuprofen, flurbiprofen etc. are significantly superior analgesics 
      and, in many cases, have a longer duration of action. In recent years the 
      salicylates, aspirin in particular, have been the focus of much attention 
      regarding their side effect profiles. At usual dosages for relief of pain and 
      during occasional use, aspirin is well tolerated by the vast majority of 
      patients. Adverse reactions, of which there is a wide spectrum, most frequently 
      accompany anti-inflammatory doses of aspirin, or may be the result of accidental 
      overdosing (particularly in children and the elderly)--probably a reflection of 
      the lay population's acceptability of aspirin's presumed safety. As with other 
      non-steroidal analgesic drugs, gastrointestinal complaints are the most commonly 
      reported side effects. The existence of many shared clinical, adverse and toxic 
      effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is 
      thought to be accounted for by a common mechanism--inhibition of the ubiquitous 
      cyclo-oxygenase enzyme. Thus, suppression of prostaglandin biosynthesis is widely 
      considered to explain the common properties of NSAIDS, although further research 
      is still necessary to clarify some inconsistencies and to complete our 
      understanding of the processes involved. Aspirin and salicylates have been 
      reported to have a wide range of drug interactions but only relatively few seem 
      to be clinically important. Many of the interactions are pharmacokinetic in 
      nature. Drugs considered to produce the most significant interactions with 
      salicylates include anticoagulants and thrombolytic agents, uricosuric agents, 
      corticosteroids, methotrexate and sulphonylurea hypoglycaemic agents.
FAU - Clissold, S P
AU  - Clissold SP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism/*pharmacology
MH  - Humans
MH  - Kinetics
MH  - Salicylates/metabolism/*pharmacology
RF  - 78
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.2165/00003495-198600324-00003 [doi]
PST - ppublish
SO  - Drugs. 1986;32 Suppl 4:8-26. doi: 10.2165/00003495-198600324-00003.

PMID- 2660918
OWN - NLM
STAT- MEDLINE
DCOM- 19890803
LR  - 20191022
IS  - 0753-3322 (Print)
IS  - 0753-3322 (Linking)
VI  - 43
IP  - 2
DP  - 1989
TI  - Aspirin and prevention of myocardial infarction.
PG  - 73-7
AB  - Determining the cardioprotective effects of aspirin (acetylsalicylic acid) 
      remains a focus for both basic science and clinical investigation. Although other 
      contributors are probably present, the favorable prostacyclin-to-thromboxane 
      ratio induced by low-dose aspirin appears beneficial for reducing cardiovascular 
      mortality associated with unstable angina and myocardial infarction. The precise 
      dosage, frequency and timing of aspirin's administration to reduce the incidence 
      of vaso-occlusive events remains to be determined. This article reviews aspirin's 
      mechanism of action and use for the prevention of myocardial infarction.
FAU - Hartney, T J
AU  - Hartney TJ
AD  - Department of Medicine, Medical College of Georgia, Augusta 30912-3104.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
RF  - 45
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 0753-3322(89)90133-9 [pii]
AID - 10.1016/0753-3322(89)90133-9 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 1989;43(2):73-7. doi: 10.1016/0753-3322(89)90133-9.

PMID- 37115694
OWN - NLM
STAT- MEDLINE
DCOM- 20230501
LR  - 20230520
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 133
IP  - 9
DP  - 2023 May 1
TI  - Aspirin and immunotherapy: a Faustian bargain?
LID - 10.1172/JCI169598 [doi]
LID - e169598
AB  - Fibrinogen-like protein 1 (FGL1) has been associated with improved survival in 
      hepatocellular carcinoma (HCC). However, recent evidence suggests that FGL1 may 
      bind to surface receptors on lymphocytes and induce immune senescence. In this 
      issue of the JCI, Lin and co-authors show that FGL1 may be acetylated by aspirin 
      and targeted for degradation, which is associated with increased antitumor 
      immunity and improved survival. Similar findings were obtained with inhibitors of 
      sirtuin 2 (SIRT2), a histone deacetylase. These findings expand our current 
      understanding of the role of FGL1 in cancer and provide an impetus for the 
      evaluation of alternative immunotherapy combinations in HCC.
FAU - Goethe, Eric A
AU  - Goethe EA
AD  - Baylor College of Medicine Department of Neurosurgery, Houston, Texas, USA.
FAU - Heimberger, Amy B
AU  - Heimberger AB
AD  - Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern 
      University, Chicago, Illinois, USA.
FAU - Rao, Ganesh
AU  - Rao G
AD  - Baylor College of Medicine Department of Neurosurgery, Houston, Texas, USA.
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20230501
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - R16CO5Y76E (Aspirin)
RN  - 9001-32-5 (Fibrinogen)
RN  - 0 (FGL1 protein, human)
SB  - IM
CON - J Clin Invest. 2023 May 1;133(9):. PMID: 37115693
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - *Liver Neoplasms/metabolism
MH  - Aspirin/pharmacology/therapeutic use
MH  - Fibrinogen
MH  - Immunotherapy
PMC - PMC10145917
COIS- Conflict of interest: The authors have declared that no conflict of interest 
      exists.
EDAT- 2023/04/28 18:42
MHDA- 2023/05/01 06:42
CRDT- 2023/04/28 12:43
PHST- 2023/05/01 06:42 [medline]
PHST- 2023/04/28 18:42 [pubmed]
PHST- 2023/04/28 12:43 [entrez]
AID - 169598 [pii]
AID - 10.1172/JCI169598 [doi]
PST - epublish
SO  - J Clin Invest. 2023 May 1;133(9):e169598. doi: 10.1172/JCI169598.

PMID- 29855050
OWN - NLM
STAT- MEDLINE
DCOM- 20190218
LR  - 20190219
IS  - 1098-1128 (Electronic)
IS  - 0198-6325 (Linking)
VI  - 39
IP  - 1
DP  - 2019 Jan
TI  - Complex roles of the old drug aspirin in cancer chemoprevention and therapy.
PG  - 114-145
LID - 10.1002/med.21514 [doi]
AB  - The nonsteroidal anti-inflammatory agent aspirin is widely used for preventing 
      and treating cardiovascular and cerebrovascular diseases. In addition, 
      epidemiologic evidences reveal that aspirin may prevent a variety of human 
      cancers, while data on the association between aspirin and some kinds of cancer 
      are conflicting. Preclinical studies and clinical trials also reveal the 
      therapeutic effect of aspirin on cancer. Although cyclooxygenase is a well-known 
      target of aspirin, recent studies uncover other targets of aspirin and its 
      metabolites, such as AMP-activated protein kinase, cyclin-dependent kinase, 
      heparanase, and histone. Accumulating evidence demonstrate that aspirin may act 
      in different cell types, such as epithelial cell, tumor cell, endothelial cell, 
      platelet, and immune cell. Therefore, aspirin acts on diverse hallmarks of 
      cancer, such as sustained tumor growth, metastasis, angiogenesis, inflammation, 
      and immune evasion. In this review, we focus on recent progress in the use of 
      aspirin for cancer chemoprevention and therapy, and integratively analyze the 
      mechanisms underlying the anticancer effects of aspirin and its metabolites. We 
      also discuss mechanisms of aspirin resistance and describe some derivatives of 
      aspirin, which aim to overcome the adverse effects of aspirin.
CI  - © 2018 Wiley Periodicals, Inc.
FAU - Hua, Hui
AU  - Hua H
AD  - Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy and Cancer 
      Center, West China Hospital, Sichuan University, Chengdu, China.
AD  - Collaborative Innovation Center of Biotherapy, Chengdu, China.
FAU - Zhang, Hongying
AU  - Zhang H
AD  - Collaborative Innovation Center of Biotherapy, Chengdu, China.
AD  - Laboratory of Oncogene, State Key Laboratory of Biotherapy and Cancer Center, 
      West China Hospital, Sichuan University, Chengdu, China.
FAU - Kong, Qingbin
AU  - Kong Q
AD  - Collaborative Innovation Center of Biotherapy, Chengdu, China.
AD  - Laboratory of Oncogene, State Key Laboratory of Biotherapy and Cancer Center, 
      West China Hospital, Sichuan University, Chengdu, China.
FAU - Wang, Jiao
AU  - Wang J
AD  - School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, China.
FAU - Jiang, Yangfu
AU  - Jiang Y
AUID- ORCID: 0000-0002-8696-2651
AD  - Collaborative Innovation Center of Biotherapy, Chengdu, China.
AD  - Laboratory of Oncogene, State Key Laboratory of Biotherapy and Cancer Center, 
      West China Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180601
PL  - United States
TA  - Med Res Rev
JT  - Medicinal research reviews
JID - 8103150
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Aspirin/adverse effects/chemistry/*therapeutic use
MH  - Biomarkers, Tumor/metabolism
MH  - *Chemoprevention
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Neoplasms/*drug therapy/epidemiology
OTO - NOTNLM
OT  - aspirin
OT  - cancer
OT  - cancer therapy
OT  - chemoprevention
OT  - cyclooxygenase
EDAT- 2018/06/02 06:00
MHDA- 2019/02/20 06:00
CRDT- 2018/06/02 06:00
PHST- 2018/02/23 00:00 [received]
PHST- 2018/05/04 00:00 [revised]
PHST- 2018/05/12 00:00 [accepted]
PHST- 2018/06/02 06:00 [pubmed]
PHST- 2019/02/20 06:00 [medline]
PHST- 2018/06/02 06:00 [entrez]
AID - 10.1002/med.21514 [doi]
PST - ppublish
SO  - Med Res Rev. 2019 Jan;39(1):114-145. doi: 10.1002/med.21514. Epub 2018 Jun 1.

PMID- 9143711
OWN - NLM
STAT- MEDLINE
DCOM- 19970627
LR  - 20131121
IS  - 0163-7525 (Print)
IS  - 0163-7525 (Linking)
VI  - 18
DP  - 1997
TI  - Aspirin in the treatment and prevention of cardiovascular disease.
PG  - 37-49
AB  - Aspirin irreversibly inhibits cyclooxygenase in platelets for their entire 
      lifespan, raising the possibility of clinical benefits by decreasing risks of 
      occlusive vascular events. In secondary prevention among patients with a wide 
      range of prior occlusive vascular events, including myocardial infarction (MI), 
      stroke, transient ischemic attacks (TIAs), as well as unstable and chronic stable 
      angina, aspirin therapy is associated with a reduction in risks of subsequent MI, 
      stroke, and vascular deaths. In acute MI, aspirin also confers clear benefits on 
      subsequent MI, stroke, and vascular deaths. In primary prevention, the available 
      randomized trial data, which to date are limited to men, indicate a clear 
      reduction in risk of a first MI; the current data are inconclusive concerning 
      aspirin's effect on stroke and total vascular mortality. A currently ongoing 
      trial among 40,000 apparently healthy women will provide reliable data concerning 
      the balance of benefits and risks of aspirin in primary prevention.
FAU - Hennekens, C H
AU  - Hennekens CH
AD  - Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Annu Rev Public Health
JT  - Annual review of public health
JID - 8006431
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/epidemiology
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Recurrence
MH  - Risk Factors
MH  - Survival Analysis
RF  - 30
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1146/annurev.publhealth.18.1.37 [doi]
PST - ppublish
SO  - Annu Rev Public Health. 1997;18:37-49. doi: 10.1146/annurev.publhealth.18.1.37.

PMID- 790585
OWN - NLM
STAT- MEDLINE
DCOM- 19761223
LR  - 20150205
IS  - 0582-8082 (Print)
VI  - 8
IP  - 3
DP  - 1975
TI  - Aspirin revisited.
PG  - 141-50
AB  - ASA is a safe drug to relieve pain, lessen fever, diminish the inflammatory 
      reaction and treat arthritis. This drug can be given to people in a very safe 
      soluble and buffered form which minimizes its major potential side effect: G.I. 
      bleeding. The G.I. bleeding seen with ASA is due to its local effect on the 
      gastric mucosa. The evidence that exists shows that ASA's effect upon the 
      platelet does not contribute to the gastric bleeding. It is unclear to what 
      extent those diseases mediated by thrombosis can be prevented by ASA and other 
      platelet-suppressive drugs. Thrombosis is not equivalent to hemostasis, but is a 
      distortion of the hemostatic process. Clinical trials are now underway but they 
      will probably be inconclusive. Presently, the literature is contradictory and, 
      therefore, the decision to use ASA as an anti-thrombotic durg remains with the 
      individual physician.
FAU - Rodvein, R
AU  - Rodvein R
FAU - Cooke, A R
AU  - Cooke AR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - Denmark
TA  - Ser Haematol
JT  - Series haematologica (1968)
JID - 101650673
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Clinical Trials as Topic
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Hemostasis
MH  - Humans
MH  - Thrombosis/blood/*drug therapy/prevention & control
RF  - 53
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
PST - ppublish
SO  - Ser Haematol. 1975;8(3):141-50.

PMID- 27064482
OWN - NLM
STAT- MEDLINE
DCOM- 20170427
LR  - 20220408
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 164
IP  - 12
DP  - 2016 Jun 21
TI  - Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence 
      Reviews for the U.S. Preventive Services Task Force.
PG  - 814-25
LID - 10.7326/M15-2117 [doi]
AB  - BACKGROUND: Cancer is the second leading cause of death in the United States. 
      PURPOSE: To conduct systematic reviews of aspirin and 1) total cancer mortality 
      and incidence in persons eligible for primary prevention of cardiovascular 
      disease (CVD) and 2) colorectal cancer (CRC) mortality and incidence in persons 
      at average CRC risk. DATA SOURCES: MEDLINE, PubMed, and the Cochrane Central 
      Register of Controlled Trials through January 2015 and relevant references from 
      other reviews. STUDY SELECTION: Trials comparing oral aspirin versus placebo or 
      no treatment in adults aged 40 years or older were included. Two investigators 
      independently reviewed abstracts and articles against inclusion and quality 
      criteria. DATA EXTRACTION: Data from 20 good- or fair-quality trials were 
      abstracted by one reviewer and checked by another. DATA SYNTHESIS: In CVD primary 
      prevention trials, cancer mortality (relative risk [RR], 0.96 [95% CI, 0.87 to 
      1.06]) (10 trials; n = 103 787) and incidence (RR, 0.98 [CI, 0.93 to 1.04]) (6 
      trials; n = 72 926) were similar in aspirin and control groups over 3.6 to 10.1 
      years. In CVD primary and secondary prevention trials, 20-year CRC mortality was 
      reduced among persons assigned to aspirin therapy (RR, 0.67 [CI, 0.52 to 0.86]) 
      (4 trials; n = 14 033). Aspirin appeared to reduce CRC incidence beginning 10 to 
      19 years after initiation (RR, 0.60 [CI, 0.47 to 0.76]) (3 trials; n = 47 464). 
      LIMITATIONS: Most data were from clinically and methodologically heterogeneous 
      CVD prevention trials. Outcome assessment and follow-up length varied across 
      studies. Data on non-CRC cancer types and subgroups were limited. CONCLUSION: In 
      CVD primary prevention populations, aspirin's effect on total cancer mortality 
      and incidence was not clearly established. Evidence from CVD primary and 
      secondary prevention studies suggested that aspirin therapy reduces CRC incidence 
      and perhaps mortality approximately 10 years after initiation. PRIMARY FUNDING 
      SOURCE: Agency for Healthcare Research and Quality.
FAU - Chubak, Jessica
AU  - Chubak J
FAU - Whitlock, Evelyn P
AU  - Whitlock EP
FAU - Williams, Selvi B
AU  - Williams SB
FAU - Kamineni, Aruna
AU  - Kamineni A
FAU - Burda, Brittany U
AU  - Burda BU
FAU - Buist, Diana S M
AU  - Buist DS
FAU - Anderson, Melissa L
AU  - Anderson ML
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160412
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2016 Aug 16;165(4):JC16. PMID: 27538177
MH  - Adult
MH  - Anticarcinogenic Agents/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Colorectal Neoplasms/epidemiology/mortality/prevention & control
MH  - Humans
MH  - Incidence
MH  - Neoplasms/epidemiology/mortality/*prevention & control
MH  - *Primary Prevention
MH  - United States/epidemiology
EDAT- 2016/04/12 06:00
MHDA- 2017/04/28 06:00
CRDT- 2016/04/12 06:00
PHST- 2016/04/12 06:00 [entrez]
PHST- 2016/04/12 06:00 [pubmed]
PHST- 2017/04/28 06:00 [medline]
AID - 2513177 [pii]
AID - 10.7326/M15-2117 [doi]
PST - ppublish
SO  - Ann Intern Med. 2016 Jun 21;164(12):814-25. doi: 10.7326/M15-2117. Epub 2016 Apr 
      12.

PMID- 16623655
OWN - NLM
STAT- MEDLINE
DCOM- 20060803
LR  - 20131121
IS  - 1744-8360 (Electronic)
IS  - 1473-7175 (Linking)
VI  - 6
IP  - 4
DP  - 2006 Apr
TI  - Aspirin in the treatment of acute migraine attacks.
PG  - 563-73
AB  - Acetylsalicylic acid (aspirin or ASA) has been used for many years as an 
      analgesic, antipyretic and anti-inflammatory drug. In recent years, evidence for 
      its effectiveness in migraine headache has been demonstrated in several clinical 
      trials. The effervescent highly buffered preparation of aspirin was shown to be 
      effective, safe and well tolerated compared with placebo or other treatment 
      options. The effervescent aspirin preparation is at least as effective as the 
      combination of aspirin plus metoclopramide, but has fewer side effects. This 
      review summarizes and analyzes clinical data of aspirin in the treatment of acute 
      migraine attacks with respect to the different galenic formulations.
FAU - Diener, Hans-Christoph
AU  - Diener HC
AD  - Department of Neurology, University Duisburg-Essen, Hufelandstrasse 55, 45122, 
      Essen, Germany. h.diener@uni-essen.de
FAU - Lampl, Christian
AU  - Lampl C
FAU - Reimnitz, Peter
AU  - Reimnitz P
FAU - Voelker, Michael
AU  - Voelker M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Neurother
JT  - Expert review of neurotherapeutics
JID - 101129944
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/blood/pharmacology/*therapeutic use
MH  - Humans
MH  - Migraine Disorders/blood/*drug therapy/epidemiology
MH  - Pain Measurement/drug effects
RF  - 45
EDAT- 2006/04/21 09:00
MHDA- 2006/08/04 09:00
CRDT- 2006/04/21 09:00
PHST- 2006/04/21 09:00 [pubmed]
PHST- 2006/08/04 09:00 [medline]
PHST- 2006/04/21 09:00 [entrez]
AID - 10.1586/14737175.6.4.563 [doi]
PST - ppublish
SO  - Expert Rev Neurother. 2006 Apr;6(4):563-73. doi: 10.1586/14737175.6.4.563.

PMID- 16919334
OWN - NLM
STAT- MEDLINE
DCOM- 20070126
LR  - 20131121
IS  - 0163-7258 (Print)
IS  - 0163-7258 (Linking)
VI  - 112
IP  - 3
DP  - 2006 Dec
TI  - Aspirin resistance: truth or dare.
PG  - 733-43
AB  - Acetylsalicylic acid, or aspirin (ASA), is widely used in patients with 
      cardiovascular disease to prevent acute ischemic events. However, platelet 
      response to ASA is not equal in all individuals, and a high variability in the 
      prevalence of ASA resistance is reported in the literature (0.4-83%). Actually, 
      ASA resistance is poorly understood; this stems from the fact that its definition 
      is unclear, its presence can be evaluated by a number of assays that are not 
      equivalent, and its prevalence may vary widely based on the population studied. 
      This article (1) exposes the difficulties in defining ASA resistance; (2) 
      discusses the mechanisms by which ASA resistance may occur; (3) presents the 
      characteristics that may put patients at greater risk of exhibiting ASA 
      resistance; and (4) discusses the clinical impact of ASA resistance in patients 
      requiring chronic therapy.
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
AD  - Faculty of Pharmacy, Université de Montréal, Montréal, Canada.
FAU - Pharand, Chantal
AU  - Pharand C
FAU - Palisaitis, Donald A
AU  - Palisaitis DA
FAU - Diodati, Jean G
AU  - Diodati JG
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060817
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
RF  - 89
EDAT- 2006/08/22 09:00
MHDA- 2007/01/27 09:00
CRDT- 2006/08/22 09:00
PHST- 2006/05/30 00:00 [received]
PHST- 2006/05/30 00:00 [accepted]
PHST- 2006/08/22 09:00 [pubmed]
PHST- 2007/01/27 09:00 [medline]
PHST- 2006/08/22 09:00 [entrez]
AID - S0163-7258(06)00111-2 [pii]
AID - 10.1016/j.pharmthera.2006.05.011 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2006 Dec;112(3):733-43. doi: 10.1016/j.pharmthera.2006.05.011. 
      Epub 2006 Aug 17.

PMID- 23425247
OWN - NLM
STAT- MEDLINE
DCOM- 20130903
LR  - 20131121
IS  - 1520-5126 (Electronic)
IS  - 0002-7863 (Linking)
VI  - 135
IP  - 9
DP  - 2013 Mar 6
TI  - Twisted aspirin crystals.
PG  - 3395-8
LID - 10.1021/ja400833r [doi]
AB  - Banded spherulites of aspirin have been crystallized from the melt in the 
      presence of salicylic acid either generated from aspirin decomposition or added 
      deliberately (2.6-35.9 mol %). Scanning electron microscopy, X-ray diffraction 
      analysis, and optical polarimetry show that the spherulites are composed of 
      helicoidal crystallites twisted along the <010> growth directions. Mueller matrix 
      imaging reveals radial oscillations in not only linear birefringence, but also 
      circular birefringence, whose origin is explained through slight (∼1.3°) but 
      systematic splaying of individual lamellae in the film. Strain associated with 
      the replacement of aspirin molecules by salicylic acid molecules in the crystal 
      structure is computed to be large enough to work as the driving force for the 
      twisting of crystallites.
FAU - Cui, Xiaoyan
AU  - Cui X
AD  - Department of Chemistry, New York University, 100 Washington Square East, Silver 
      Center, Room 1001, New York, New York 10003, United States.
FAU - Rohl, Andrew L
AU  - Rohl AL
FAU - Shtukenberg, Alexander
AU  - Shtukenberg A
FAU - Kahr, Bart
AU  - Kahr B
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130225
PL  - United States
TA  - J Am Chem Soc
JT  - Journal of the American Chemical Society
JID - 7503056
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Particle Size
MH  - Surface Properties
EDAT- 2013/02/22 06:00
MHDA- 2013/09/04 06:00
CRDT- 2013/02/22 06:00
PHST- 2013/02/22 06:00 [entrez]
PHST- 2013/02/22 06:00 [pubmed]
PHST- 2013/09/04 06:00 [medline]
AID - 10.1021/ja400833r [doi]
PST - ppublish
SO  - J Am Chem Soc. 2013 Mar 6;135(9):3395-8. doi: 10.1021/ja400833r. Epub 2013 Feb 
      25.

PMID- 17509593
OWN - NLM
STAT- MEDLINE
DCOM- 20071108
LR  - 20220310
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 88
IP  - 4
DP  - 2007 Oct
TI  - Aspirin in women undergoing in vitro fertilization treatment: a systematic review 
      and meta-analysis.
PG  - 822-31
AB  - OBJECTIVE: Many trials have evaluated the effects of aspirin in women undergoing 
      IVF or intracytoplasmic sperm injection (ICSI) treatment. These trials have 
      generally shown inconclusive or inconsistent findings. We conducted a systematic 
      review of trials of aspirin during IVF or ICSI treatment to generate more precise 
      estimates of effects and attempt to explore the reasons for the inconsistencies. 
      DESIGN: A systematic review and meta-analysis. SETTING: Assisted conception units 
      in different countries. PATIENT(S): Seven trials including 1,241 women undergoing 
      controlled ovarian hyperstimulation (COH), IVF, or ICSI and day 3 embryo 
      transfer. INTERVENTION(S): Low-dose aspirin supplementation versus placebo or no 
      supplementation. MAIN OUTCOME MEASURE(S): Clinical pregnancy and live birth. 
      RESULT(S): Searches were conducted in MEDLINE, EMBASE, Cochrane Library, ISI 
      Proceedings, and SCISEARCH, and all randomized controlled trials that evaluated 
      the effectiveness of aspirin compared to placebo or no treatment in women 
      undergoing IVF-ICSI treatment were included. Study selection, quality appraisal, 
      and data extractions were performed independently and in duplicate. Seven 
      relevant trials were identified. Meta-analysis of these studies did not show a 
      significant benefit of aspirin therapy in improving clinical pregnancy rate 
      (relative risk [RR] 1.11, 95% confidence interval [CI] 0.95, 1.31) or live birth 
      rate (RR 0.94, 95% CI 0.64, 1.39). There was no significant difference in 
      miscarriage rate (RR 1.06, 95% CI 0.53, 2.11) or ectopic pregnancy rate (RR 2.24, 
      95% CI 0.70, 7.24). An improvement was noted in uterine artery pulsatility index 
      (weighted mean difference: -0.78, 95% CI -0.87, -0.69) in women taking low-dose 
      aspirin. The evidence regarding other outcomes was either not significant or 
      contradictory. CONCLUSION(S): Currently available evidence does not support the 
      use of aspirin in IVF or ICSI treatment. However, the noted trend of improvement 
      in clinical pregnancy, and the lack of power even when the studies were pooled 
      highlight the need for a definitive trial.
FAU - Khairy, Mohammed
AU  - Khairy M
AD  - Assisted Conception Unit, Guys Hospital, London, United Kingdom.
FAU - Banerjee, Kaberi
AU  - Banerjee K
FAU - El-Toukhy, Tarek
AU  - El-Toukhy T
FAU - Coomarasamy, Arri
AU  - Coomarasamy A
FAU - Khalaf, Yakoub
AU  - Khalaf Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20070516
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Fertil Steril. 2008 Apr;89(4):1035-6. PMID: 18353319
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Fertilization in Vitro/*methods
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Sperm Injections, Intracytoplasmic/methods
RF  - 26
EDAT- 2007/05/19 09:00
MHDA- 2007/11/09 09:00
CRDT- 2007/05/19 09:00
PHST- 2006/08/17 00:00 [received]
PHST- 2006/12/09 00:00 [revised]
PHST- 2006/12/13 00:00 [accepted]
PHST- 2007/05/19 09:00 [pubmed]
PHST- 2007/11/09 09:00 [medline]
PHST- 2007/05/19 09:00 [entrez]
AID - S0015-0282(07)00071-4 [pii]
AID - 10.1016/j.fertnstert.2006.12.080 [doi]
PST - ppublish
SO  - Fertil Steril. 2007 Oct;88(4):822-31. doi: 10.1016/j.fertnstert.2006.12.080. Epub 
      2007 May 16.

PMID- 24114189
OWN - NLM
STAT- MEDLINE
DCOM- 20140505
LR  - 20211021
IS  - 1534-6269 (Electronic)
IS  - 1523-3790 (Linking)
VI  - 15
IP  - 6
DP  - 2013 Dec
TI  - Role of aspirin in cancer prevention.
PG  - 533-40
LID - 10.1007/s11912-013-0351-3 [doi]
AB  - Since its first synthesis in 1897, several medicinal roles and mechanisms of 
      action of aspirin have become apparent; the latest among these being its role in 
      cancer prevention and treatment. A large body of evidence supports aspirin's 
      effect in reducing cancer incidence and cancer mortality, but duration of use 
      needs to be at least 5 years. The beneficial effects are particularly large for 
      colorectal, oesophageal and gastric cancers, with apparently smaller reductions 
      for breast, prostate and lung cancer. The major harm is gastrointestinal 
      bleeding, but serious sequelae are minimal at ages <70 years. It is very likely 
      that use of prophylactic aspirin in the general population aged 50-70+ years will 
      result in net overall benefit. Outstanding issues are: whether standard dose 
      (~300 mg/day) can lead to greater net benefits than low dose (75-100 mg/day), the 
      optimum duration of use, and appropriate ages for use in average-risk 
      individuals.
FAU - Thorat, Mangesh A
AU  - Thorat MA
AD  - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen 
      Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK, 
      m.thorat@qmul.ac.uk.
FAU - Cuzick, Jack
AU  - Cuzick J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Oncol Rep
JT  - Current oncology reports
JID - 100888967
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Anticarcinogenic Agents/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Neoplasms/*prevention & control
MH  - Organ Specificity
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
EDAT- 2013/10/12 06:00
MHDA- 2014/05/06 06:00
CRDT- 2013/10/12 06:00
PHST- 2013/10/12 06:00 [entrez]
PHST- 2013/10/12 06:00 [pubmed]
PHST- 2014/05/06 06:00 [medline]
AID - 10.1007/s11912-013-0351-3 [doi]
PST - ppublish
SO  - Curr Oncol Rep. 2013 Dec;15(6):533-40. doi: 10.1007/s11912-013-0351-3.

PMID- 11496056
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190921
IS  - 1062-4821 (Print)
IS  - 1062-4821 (Linking)
VI  - 10
IP  - 5
DP  - 2001 Sep
TI  - Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in 
      hypertension or heart failure?
PG  - 625-31
AB  - There is a wealth of data that suggests an important interaction between aspirin 
      and angiotensin-converting enzyme inhibitors in patients with chronic stable 
      cardiovascular disease. The interaction is less obvious in the postinfarction 
      setting, possibly reflecting the fact that many patients stop their aspirin 
      therapy within a few months of such an event. An interaction is biologically 
      plausible, because there is considerable evidence that angiotensin-converting 
      enzyme inhibitors exert important effects through increasing the production of 
      vasodilator prostaglandins, whereas aspirin blocks their production through 
      inhibition of cyclooxygenase, even at low doses. There is some evidence that 
      low-dose aspirin may raise systolic and diastolic blood pressure. There is also 
      considerable evidence that aspirin may entirely neutralize the clinical benefits 
      of angiotensin-converting enzyme inhibitors in patients with heart failure. In 
      addition, aspirin may have an adverse effect on outcome in patients with heart 
      failure that is independent of any interaction with angiotensin-converting enzyme 
      inhibitors, possibly by blocking endogenous vasodilator prostaglandin production 
      and enhancing the vasoconstrictor potential of endothelin. The evidence is not 
      sufficient to justify advising long-term aspirin therapy for patients with 
      cardiovascular disease in general, and for those with heart failure in 
      particular. Thus, the lack of evidence of benefit with aspirin in patients with 
      heart failure and coronary disease, along with growing evidence that aspirin is 
      directly harmful in patients with heart failure and that aspirin may negate the 
      benefits of angiotensin-converting enzyme inhibitors suggest that, unless there 
      is an opportunity to randomize the patient into a study of antithrombotic 
      strategies, then aspirin should be withdrawn or possibly substituted with an 
      anticoagulant or an antiplatelet agent that does not block cyclooxygenase. In 
      contrast, there is fairly robust evidence for a benefit of both aspirin and 
      angiotensin-converting enzyme inhibitors during the first 5 weeks after a 
      myocardial infarction, with little evidence of an interaction. The combination of 
      aspirin and angiotensin-converting enzyme inhibitors is warranted during this 
      period, after which discontinuation or substitution of aspirin with another agent 
      should be considered.
FAU - Cleland, J G
AU  - Cleland JG
AD  - Department of Cardiology, Castle Hill Hospital, University of Hull, Kingston upon 
      Hull, UK. J.G.Cleland@medschool.hull.ac.uk
FAU - John, J
AU  - John J
FAU - Houghton, T
AU  - Houghton T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Nephrol Hypertens
JT  - Current opinion in nephrology and hypertension
JID - 9303753
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Randomized Controlled Trials as Topic
RF  - 71
EDAT- 2001/08/10 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/08/10 10:00
PHST- 2001/08/10 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/08/10 10:00 [entrez]
AID - 10.1097/00041552-200109000-00012 [doi]
PST - ppublish
SO  - Curr Opin Nephrol Hypertens. 2001 Sep;10(5):625-31. doi: 
      10.1097/00041552-200109000-00012.

PMID- 15658056
OWN - NLM
STAT- MEDLINE
DCOM- 20050310
LR  - 20181201
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 59
IP  - 12
DP  - 2004 Dec
TI  - [Aspirin: recent advances in cardiovascular prevention].
PG  - 695-703
AB  - More than a century after being launched onto the market, aspirin still remains a 
      fascinating drug, both for its demonstrated antalgic, antipyretic, 
      antiinflammatory and antithrombotic properties and, also, for newer, yet 
      conjectural, applications mentioned in recent publications. The role of aspirin, 
      as an irreversible COX-1 inhibitor and antiplatelet agent, is well elucidated and 
      established. Our purpose is to review the value of aspirin for primary and 
      secondary prevention of ischemic cardiovascular events. The clinician constantly 
      has to manage a trade off between the protective effects of aspirin and its 
      possible hemorrhagic, notably gastrointestinal, side-effects. The Task Force of 
      the ESC recommends the use of doses no higher than 75-100 mg/d. New antiplatelet 
      agents (thienopyridin derivatives), which have a totally different mode of 
      action, have been introduced and were compared with aspirin. Although clopidogrel 
      may be slightly superior to the latter, according to the European experts: "the 
      size of any additional benefit is statistically uncertain and the drug has not 
      been granted a claim, of superiority". Economical considerations reinforce this 
      view. Clopidogrel is undoubtedly a good alternative when aspirin is 
      contra-indicated, poorly tolerated, or not efficacious. Resistance to aspirin and 
      resistance to clopidogrel have been described. In some high-risk patients, the 
      combined use of aspirin and clopidogrel is deemed justified.
FAU - Kulbertus, H
AU  - Kulbertus H
AD  - ULg.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - L'aspirine: acquisitions récentes en prévention cardiovasculaire.
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/economics/*pharmacology
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/economics/*pharmacology
MH  - Primary Prevention
MH  - Ticlopidine/*analogs & derivatives/pharmacology
RF  - 49
EDAT- 2005/01/22 09:00
MHDA- 2005/03/11 09:00
CRDT- 2005/01/22 09:00
PHST- 2005/01/22 09:00 [pubmed]
PHST- 2005/03/11 09:00 [medline]
PHST- 2005/01/22 09:00 [entrez]
PST - ppublish
SO  - Rev Med Liege. 2004 Dec;59(12):695-703.

PMID- 30654618
OWN - NLM
STAT- MEDLINE
DCOM- 20200414
LR  - 20200414
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 53
IP  - 7
DP  - 2019 Jul
TI  - Recent Evidence Examining Efficacy and Safety of Aspirin for Primary 
      Cardiovascular Disease Prevention.
PG  - 738-745
LID - 10.1177/1060028018825140 [doi]
AB  - BACKGROUND: Data on aspirin for primary prevention of cardiovascular disease 
      (CVD) are conflicting and changing as new trials are published on the subject. 
      OBJECTIVE: To review recent data evaluating the efficacy and safety of aspirin 
      for primary prevention of CVD. DATA SOURCES: Articles evaluating aspirin for 
      primary prevention of CVD were gathered using a MEDLINE search with the keywords 
      aspirin review, aspirin peripheral artery disease, aspirin stroke, aspirin 
      coronary artery disease, aspirin diabetes, aspirin primary prophylaxis, and 
      aspirin elderly. Primary literature published from January 2008 through November 
      2018 was reviewed. Additional references were identified from a review of 
      citations. STUDY SELECTION AND DATA EXTRACTION: Randomized clinical trials that 
      reported on aspirin for primary CVD prevention were included. In all, 10 
      publications met the inclusion criteria. The authors individually compared and 
      contrasted the results from each publication. DATA SYNTHESIS: The evidence for 
      primary CVD prevention using aspirin varies widely. Previous analyses identified 
      a benefit to aspirin use in certain populations, and current guidelines reflect 
      this. However, new studies published in the past 10 years call the historically 
      identified benefit of aspirin into question and force us to reexamine which 
      patients, if any, are indicated for aspirin for primary prevention of CVD. 
      Relevance to Patient Care and Clinical Practice: This review provides a thorough 
      discussion on the evidence behind aspirin for primary prevention of CVD. 
      CONCLUSION: Based on current evidence, aspirin is not recommended for primary 
      prevention of CVD.
FAU - Carson, Erin
AU  - Carson E
AD  - 1 UIC College of Pharmacy, Rockford, IL, USA.
FAU - Hemenway, Alice N
AU  - Hemenway AN
AUID- ORCID: 0000-0002-2363-4431
AD  - 1 UIC College of Pharmacy, Rockford, IL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190117
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/blood/*prevention & control
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Primary Prevention/*methods
OTO - NOTNLM
OT  - antiplatelets
OT  - cardiology
OT  - cardiovascular drugs
OT  - coronary artery disease
OT  - preventive medicine
EDAT- 2019/01/19 06:00
MHDA- 2020/04/15 06:00
CRDT- 2019/01/19 06:00
PHST- 2019/01/19 06:00 [pubmed]
PHST- 2020/04/15 06:00 [medline]
PHST- 2019/01/19 06:00 [entrez]
AID - 10.1177/1060028018825140 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2019 Jul;53(7):738-745. doi: 10.1177/1060028018825140. Epub 
      2019 Jan 17.

PMID- 32134226
OWN - NLM
STAT- MEDLINE
DCOM- 20200310
LR  - 20200310
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 16
IP  - 684
DP  - 2020 Mar 4
TI  - [Aspirin for primary cardiovascular prevention : the end of an era ?].
PG  - 459-462
AB  - Low-dose aspirin in primary prevention of cardiovascular disease is still 
      debated. Recent clinical trials of aspirin vs placebo reported an unfavourable 
      risk-benefit ratio with an increase in major bleedings without reduction on the 
      occurrence of non-fatal cardiovascular events. These studies also highlight that 
      current cardiovascular risk calculators overestimate cardiovascular risk, which 
      is probably related to the improvement in the management of cardiovascular risk 
      factors over the last decades. In accordance with European cardiovascular 
      prevention recommendations, aspirin should not be prescribed for the primary 
      prevention of cardiovascular disease.
FAU - Ravach, Gaël
AU  - Ravach G
AD  - Département des policliniques, Centre universitaire de médecine générale et santé 
      publique, Unisanté, 1011 Lausanne.
FAU - Fournier, Stéphane
AU  - Fournier S
AD  - Service de cardiologie, Département cœur-vaisseaux, CHUV, 1011 Lausanne.
FAU - Mazzolai, Lucia
AU  - Mazzolai L
AD  - Service d'angiologie, Département cœur-vaisseaux, CHUV, 1011 Lausanne.
FAU - Nanchen, David
AU  - Nanchen D
AD  - Consultation de prévention cardiovasculaire-cholestérol et style de vie, 
      Département promotion de la santé et prévention, Centre universitaire de médecine 
      générale et santé publique, Unisanté, 1011 Lausanne.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Aspirine en prévention cardiovasculaire primaire : la fin d’une époque ?
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Primary Prevention/*methods/*trends
MH  - Risk Assessment
COIS- Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
EDAT- 2020/03/07 06:00
MHDA- 2020/03/11 06:00
CRDT- 2020/03/06 06:00
PHST- 2020/03/06 06:00 [entrez]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2020/03/11 06:00 [medline]
AID - RMS0684-007 [pii]
PST - ppublish
SO  - Rev Med Suisse. 2020 Mar 4;16(684):459-462.

PMID- 22380694
OWN - NLM
STAT- MEDLINE
DCOM- 20130524
LR  - 20131121
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Linking)
VI  - 44
IP  - 8
DP  - 2012 Dec
TI  - A contemporary viewpoint on 'aspirin resistance'.
PG  - 773-83
LID - 10.3109/07853890.2011.605388 [doi]
AB  - Aspirin is an irreversible inhibitor of platelet prostaglandin synthase activity, 
      and is the most widely prescribed drug for the secondary prevention of 
      cardiovascular disease. In recent years, clinical and laboratory evidence has 
      shown significant individual variability in the response to aspirin and its link 
      to clinical outcome. The term 'aspirin resistance' has been introduced to 
      describe situations when clinical or ex-vivo effects of aspirin are less than 
      expected. The accumulating evidence of increased risk of major adverse clinical 
      events (MACE) associated with 'aspirin resistance' in the settings of acute 
      coronary syndrome (ACS), stroke, and peripheral arterial disease has stimulated 
      the search for ways of overcoming aspirin resistance. Existence of the link 
      between high on-treatment platelet reactivity and atherothrombotic events 
      suggests the common mechanisms for atherosclerosis progression and thrombotic 
      complications with the platelets, being a key cellular interface between 
      coagulation and inflammation. This review article provides a contemporary view on 
      'aspirin resistance' and discusses its definition, clinical importance, and 
      possible mechanisms in light of recent data on the role of platelets in 
      atherothrombosis.
FAU - Kuzniatsova, Nadzeya
AU  - Kuzniatsova N
AD  - University of Birmingham Centre for Cardiovascular Sciences, City Hospital, 
      Birmingham B18 7QH, England, United Kingdom.
FAU - Shantsila, Eduard
AU  - Shantsila E
FAU - Blann, Andrew
AU  - Blann A
FAU - Lip, Gregory Y H
AU  - Lip GY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120301
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism/pharmacokinetics/*therapeutic use
MH  - Biological Availability
MH  - Blood Platelets/*physiology
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/metabolism/pharmacokinetics/*therapeutic use
EDAT- 2012/03/03 06:00
MHDA- 2013/05/28 06:00
CRDT- 2012/03/03 06:00
PHST- 2012/03/03 06:00 [entrez]
PHST- 2012/03/03 06:00 [pubmed]
PHST- 2013/05/28 06:00 [medline]
AID - 10.3109/07853890.2011.605388 [doi]
PST - ppublish
SO  - Ann Med. 2012 Dec;44(8):773-83. doi: 10.3109/07853890.2011.605388. Epub 2012 Mar 
      1.

PMID- 22873346
OWN - NLM
STAT- MEDLINE
DCOM- 20130213
LR  - 20151119
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 23
IP  - 7
DP  - 2012
TI  - Advances in monitoring of aspirin therapy.
PG  - 526-36
AB  - The efficacy of aspirin to prevent thrombotic events in cardiovascular patients 
      is well established, with >100 randomized trials having been conducted in 
      high-risk patients and demonstrating a reduction in vascular death of 
      approximately 15% and a further reduction in non-fatal vascular events of 
      approximately 30%. While the benefit of aspirin is undisputed, it is also known 
      that aspirin is associated with a dose-dependent increase in the risk of 
      bleeding. It follows that most treatment guidelines advocate the use of the 
      lowest aspirin dose effective in preventing thrombotic complications to minimize 
      the risk of major bleeding. From this, a need for monitoring of aspirin therapy 
      has emerged and prompted the development and investigation of numerous assays of 
      platelet function. The intention behind monitoring of aspirin's antithrombotic 
      effects is to maximize benefit and to personalize treatment based on individual 
      patient characteristics. This article reviews the recent literature on the 
      usefulness of platelet function testing in patients requiring aspirin; the 
      variability of platelet reactivity in patients taking aspirin and its clinical 
      impact; the potential mechanisms underlying suboptimal platelet inhibition by 
      aspirin and future directions in terms of management of aspirin therapy.
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
AD  - Centre for Cardiovascular Sciences, Institute of Biomedical Research, College of 
      Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 
      2TT, UK. m.lordkipanidze@bham.ac.uk
LA  - eng
GR  - British Heart Foundation/United Kingdom
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120808
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Platelets/drug effects/physiology
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Hemorrhage/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Platelet Function Tests/instrumentation/*methods
MH  - Precision Medicine
MH  - Risk
MH  - Thrombosis/metabolism/*prevention & control
EDAT- 2012/08/10 06:00
MHDA- 2013/02/14 06:00
CRDT- 2012/08/10 06:00
PHST- 2012/08/10 06:00 [entrez]
PHST- 2012/08/10 06:00 [pubmed]
PHST- 2013/02/14 06:00 [medline]
AID - 10.3109/09537104.2012.711865 [doi]
PST - ppublish
SO  - Platelets. 2012;23(7):526-36. doi: 10.3109/09537104.2012.711865. Epub 2012 Aug 8.

PMID- 16894401
OWN - NLM
STAT- MEDLINE
DCOM- 20061003
LR  - 20170427
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 42
IP  - 7
DP  - 2006 Jul
TI  - Aspirin for the primary prevention of cardiovascular events.
PG  - 467-79
AB  - There is significant evidence that low-dose aspirin is effective in preventing 
      the first myocardial infarction in men and ischemic stroke in women. There is 
      also an increased risk for major gastrointestinal tract hemorrhage and a 
      suggestive, but nonsignificant, increase in the risk for hemorrhagic stroke. If 
      there is a history of ulcer disease or upper-gastrointestinal tract bleeding, 
      Helicobacter pylori should be eradicated (if present) and a proton pump inhibitor 
      used with aspirin therapy. In conclusion, the benefits of low-dose aspirin 
      (75-162 mg/day) in the prevention of myocardial infarction in men and thrombotic 
      stroke in women generally outweigh the risks of serious bleeding in adults with a 
      coronary heart disease risk >1% per year or >1% in 10 years.
CI  - (c) 2006 Prous Science. All rights reserved.
FAU - Colwell, John A
AU  - Colwell JA
AD  - Medical University of South Carolina, Charleston, South Carolina 29425, USA. 
      colwelja@musc.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
RPI - Timely Top Med Cardiovasc Dis. 2006;10:E25. PMID: 17066145
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/therapeutic use
MH  - Practice Guidelines as Topic
RF  - 36
EDAT- 2006/08/09 09:00
MHDA- 2006/10/04 09:00
CRDT- 2006/08/09 09:00
PHST- 2006/08/09 09:00 [pubmed]
PHST- 2006/10/04 09:00 [medline]
PHST- 2006/08/09 09:00 [entrez]
AID - 1009900 [pii]
AID - 10.1358/dot.2006.42.7.1009900 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2006 Jul;42(7):467-79. doi: 10.1358/dot.2006.42.7.1009900.

PMID- 7805078
OWN - NLM
STAT- MEDLINE
DCOM- 19950131
LR  - 20131121
IS  - 0733-8651 (Print)
IS  - 0733-8651 (Linking)
VI  - 12
IP  - 3
DP  - 1994 Aug
TI  - Aspirin in the primary prevention of cardiovascular disease.
PG  - 443-50
AB  - The ability of aspirin to reduce cardiovascular disease risks has been tested in 
      randomized trials in a wide range of patient categories. There are clear benefits 
      of aspirin on nonfatal myocardial infarction, nonfatal stroke, and vascular death 
      among patients with prior manifestations of cardiovascular disease, such as 
      myocardial infarction, unstable angina, and stroke. Aspirin is also beneficial to 
      those in the acute phase of evolving myocardial infarction. In primary 
      prevention, there is a clear reduction in myocardial infarction in men. A 
      large-scale primary prevention trial in women is presently underway.
FAU - Hennekens, C H
AU  - Hennekens CH
AD  - Department of Medicine, Harvard Medical School, Boston, Massachusetts.
FAU - Buring, J E
AU  - Buring JE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cardiol Clin
JT  - Cardiology clinics
JID - 8300331
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Randomized Controlled Trials as Topic
RF  - 27
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
PST - ppublish
SO  - Cardiol Clin. 1994 Aug;12(3):443-50.

PMID- 31300475
OWN - NLM
STAT- MEDLINE
DCOM- 20200415
LR  - 20200801
IS  - 1538-7445 (Electronic)
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 79
IP  - 15
DP  - 2019 Aug 1
TI  - Are Platelets the Primary Target of Aspirin's Remarkable Anticancer Activity?
PG  - 3820-3823
LID - 10.1158/0008-5472.CAN-19-0762 [doi]
AB  - Aspirin, when administered at low doses, has emerged as a powerful anticancer 
      drug due to both chemopreventive activity against many forms of cancer and its 
      ability to block metastases when administered postdiagnosis. Platelets, which are 
      often elevated in circulation during the latter stages of cancer, are known to 
      promote epithelial-mesenchymal transition, cancer cell growth, survival in 
      circulation, and angiogenesis at sites of metastases. Low-dose aspirin has been 
      demonstrated to block this procarcinogenic action of platelets. In this article, 
      we present evidence that aspirin's unique ability to irreversibly inhibit 
      platelet cyclooxygenase-1 is a key mechanism by which aspirin exerts anticancer 
      activity.
CI  - ©2019 American Association for Cancer Research.
FAU - Lichtenberger, Lenard M
AU  - Lichtenberger LM
AD  - Department of Integrative Biology & Pharmacology, McGovern Medical School, The 
      University of Texas Health Science Center at Houston, Houston, Texas. 
      lenard.m.lichtenberger@uth.tmc.edu.
FAU - Vijayan, K Vinod
AU  - Vijayan KV
AD  - Department of Medicine, Baylor College of Medicine and Center for Translational 
      Research on Inflammatory Diseases, Michael E. DeBakey, Veterans Affairs Medical 
      Center, Houston, Texas.
LA  - eng
GR  - R21 CA182798/CA/NCI NIH HHS/United States
GR  - R42 CA171408/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20190712
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/pathology
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Humans
MH  - Neoplasms/*blood/*drug therapy/pathology
PMC - PMC6679799
MID - NIHMS1530491
COIS- Conflict of interest statement: Dr. Lichtenberger is a co-founder of and 
      shareholder in PLx Pharma Inc that is developing a phosphatidylcholine 
      -associated aspirin for cardiovascular indications.
EDAT- 2019/07/14 06:00
MHDA- 2020/04/16 06:00
CRDT- 2019/07/14 06:00
PHST- 2019/03/07 00:00 [received]
PHST- 2019/04/18 00:00 [revised]
PHST- 2019/05/22 00:00 [accepted]
PHST- 2019/07/14 06:00 [pubmed]
PHST- 2020/04/16 06:00 [medline]
PHST- 2019/07/14 06:00 [entrez]
AID - 0008-5472.CAN-19-0762 [pii]
AID - 10.1158/0008-5472.CAN-19-0762 [doi]
PST - ppublish
SO  - Cancer Res. 2019 Aug 1;79(15):3820-3823. doi: 10.1158/0008-5472.CAN-19-0762. Epub 
      2019 Jul 12.

PMID- 33260951
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 23
DP  - 2020 Nov 27
TI  - Mechanisms of Colorectal Cancer Prevention by Aspirin-A Literature Review and 
      Perspective on the Role of COX-Dependent and -Independent Pathways.
LID - 10.3390/ijms21239018 [doi]
LID - 9018
AB  - Aspirin, synthesized and marketed in 1897 by Bayer, is one of the most widely 
      used drugs in the world. It has a well-recognized role in decreasing 
      inflammation, pain and fever, and in the prevention of thrombotic cardiovascular 
      diseases. Its anti-inflammatory and cardio-protective actions have been well 
      studied and occur through inhibition of cyclooxygenases (COX). Interestingly, a 
      vast amount of epidemiological, preclinical and clinical studies have revealed 
      aspirin as a promising chemopreventive agent, particularly against colorectal 
      cancers (CRC); however, the primary mechanism by which it decreases the 
      occurrences of CRC has still not been established. Numerous mechanisms have been 
      proposed for aspirin's chemopreventive properties among which the inhibition of 
      COX enzymes has been widely discussed. Despite the wide attention COX-inhibition 
      has received as the most probable mechanism of cancer prevention by aspirin, it 
      is clear that aspirin targets many other proteins and pathways, suggesting that 
      these extra-COX targets may also be equally important in preventing CRC. In this 
      review, we discuss the COX-dependent and -independent pathways described in 
      literature for aspirin's anti-cancer effects and highlight the strengths and 
      limitations of the proposed mechanisms. Additionally, we emphasize the potential 
      role of the metabolites of aspirin and salicylic acid (generated in the gut 
      through microbial biotransformation) in contributing to aspirin's chemopreventive 
      actions. We suggest that the preferential chemopreventive effect of aspirin 
      against CRC may be related to direct exposure of aspirin/salicylic acid or its 
      metabolites to the colorectal tissues. Future investigations should shed light on 
      the role of aspirin, its metabolites and the role of the gut microbiota in cancer 
      prevention against CRC.
FAU - Sankaranarayanan, Ranjini
AU  - Sankaranarayanan R
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      College of Pharmacy and Allied Health Professions, South Dakota State University, 
      Brookings, SD 57007, USA.
FAU - Kumar, D Ramesh
AU  - Kumar DR
AD  - Department of Entomology, University of Kentucky, Lexington, KY 40506, USA.
FAU - Altinoz, Meric A
AU  - Altinoz MA
AD  - Department of Biochemistry, Acibadem M.A.A. University, Istanbul, Turkey.
FAU - Bhat, G Jayarama
AU  - Bhat GJ
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      College of Pharmacy and Allied Health Professions, South Dakota State University, 
      Brookings, SD 57007, USA.
LA  - eng
GR  - Pilot research grant/South Dakota State University/
PT  - Journal Article
PT  - Review
DEP - 20201127
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Chemoprevention
MH  - Colorectal Neoplasms/drug therapy/*enzymology/*prevention & control
MH  - Cyclooxygenase Inhibitors/pharmacology/therapeutic use
MH  - Gastrointestinal Microbiome/drug effects
MH  - Humans
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
PMC - PMC7729916
OTO - NOTNLM
OT  - 2,3-dihydroxybenzoic acid
OT  - 2,5-dihydroxybenzoic acid
OT  - aspirin
OT  - colorectal cancer
OT  - cyclin dependent kinases
OT  - cyclooxygenase
OT  - gentisic acid
OT  - gut microbiota
OT  - hydroxybenzoic acid
OT  - salicylic acid
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2020/12/03 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/12/02 01:03
PHST- 2020/11/05 00:00 [received]
PHST- 2020/11/25 00:00 [revised]
PHST- 2020/11/26 00:00 [accepted]
PHST- 2020/12/02 01:03 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - ijms21239018 [pii]
AID - ijms-21-09018 [pii]
AID - 10.3390/ijms21239018 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Nov 27;21(23):9018. doi: 10.3390/ijms21239018.

PMID- 29922878
OWN - NLM
STAT- MEDLINE
DCOM- 20190322
LR  - 20190322
IS  - 1976-3786 (Electronic)
IS  - 0253-6269 (Linking)
VI  - 41
IP  - 10
DP  - 2018 Oct
TI  - Aspirin-inspired acetyl-donating HDACs inhibitors.
PG  - 967-976
LID - 10.1007/s12272-018-1045-z [doi]
AB  - Aspirin is one of the oldest drugs for the treatment of inflammation, fever, and 
      pain. It is reported to covalently modify COX-2 enzyme by acetylating a serine 
      amino acid residue. By virtue of aspirin's acetylating potential, we for the 
      first time developed novel acetyl-donating HDAC inhibitors. In this study, we 
      report the design, synthesis, in silico docking study, and biological evaluation 
      of acetyl-donating HDAC inhibitors. The exposure of MDA-MB-231 cells with 
      compound 4c significantly promotes the acetylation of α-tubulin and histone H3, 
      which are substrates of HDAC6 and HDAC1, respectively. In silico docking 
      simulation also indicates that compound 4c tightly binds to the deep 
      substrate-binding pocket of HDAC6 by coordinating the active zinc ion in a 
      bidentate manner and forming hydrogen bond interactions with Ser531 and His573 
      amino acid residues. In particular, compound 4c (GI(50) = 147 μM) affords the 
      significant enhancement of anti-proliferative effect on MDA-MB-231 cells, 
      compared with its parent compound 2c (GI(50) > 1000 μM) and acetyl-donating group 
      deficient compound 6 (GI(50) = 554 μM). Overall, compound 4c presents a novel 
      strategy for developing acetyl-donating HDAC inhibitors.
FAU - Lim, Jiah
AU  - Lim J
AD  - College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea.
FAU - Song, Yoojin
AU  - Song Y
AD  - College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea.
FAU - Jang, Jung-Hee
AU  - Jang JH
AD  - Department of Pharmacology, School of Medicine, Keimyung University, Daegu, 
      42601, Republic of Korea.
FAU - Jeong, Chul-Ho
AU  - Jeong CH
AD  - College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea.
FAU - Lee, Sooyeun
AU  - Lee S
AD  - College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea.
FAU - Park, Byoungduck
AU  - Park B
AD  - College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea.
FAU - Seo, Young Ho
AU  - Seo YH
AUID- ORCID: 0000-0002-2268-8761
AD  - College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea. 
      seoyho@kmu.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20180620
PL  - Korea (South)
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry/metabolism
MH  - Aspirin/*chemistry/metabolism
MH  - Cell Line
MH  - Cell Proliferation/drug effects/physiology
MH  - Crystallography, X-Ray/methods
MH  - Histone Deacetylase Inhibitors/*chemistry/metabolism
MH  - Humans
MH  - Molecular Docking Simulation/*methods
MH  - Protein Structure, Tertiary
OTO - NOTNLM
OT  - Alzheimer’s disease
OT  - Aspirin
OT  - Cancers
OT  - Drug addiction
OT  - Histone deacetylases
EDAT- 2018/06/21 06:00
MHDA- 2019/03/23 06:00
CRDT- 2018/06/21 06:00
PHST- 2018/03/13 00:00 [received]
PHST- 2018/06/04 00:00 [accepted]
PHST- 2018/06/21 06:00 [pubmed]
PHST- 2019/03/23 06:00 [medline]
PHST- 2018/06/21 06:00 [entrez]
AID - 10.1007/s12272-018-1045-z [pii]
AID - 10.1007/s12272-018-1045-z [doi]
PST - ppublish
SO  - Arch Pharm Res. 2018 Oct;41(10):967-976. doi: 10.1007/s12272-018-1045-z. Epub 
      2018 Jun 20.

PMID- 34705291
OWN - NLM
STAT- MEDLINE
DCOM- 20220412
LR  - 20230502
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 88
IP  - 5
DP  - 2022 May
TI  - Aspirin effects on platelet gene expression are associated with a paradoxical, 
      increase in platelet function.
PG  - 2074-2083
LID - 10.1111/bcp.15127 [doi]
AB  - Aspirin has known effects beyond inhibiting platelet cyclooxygenase-1 (COX-1) 
      that have been incompletely characterized. Transcriptomics can comprehensively 
      characterize the on- and off-target effects of medications. We used a systems 
      pharmacogenomics approach of aspirin exposure in volunteers coupled with serial 
      platelet function and purified platelet mRNA sequencing to test the hypothesis 
      that aspirin's effects on the platelet transcriptome are associated with platelet 
      function. We prospectively recruited 74 adult volunteers for a randomized 
      crossover study of 81- vs. 325 mg/day, each for 4 weeks. Using mRNA sequencing of 
      purified platelets collected before and after each 4-week exposure, we identified 
      208 aspirin-responsive genes with no evidence for dosage effects. In independent 
      cohorts of healthy volunteers and patients with diabetes, we validated aspirin's 
      effects on five genes: EIF2S3, CHRNB1, EPAS1, SLC9A3R2 and HLA-DRA. Functional 
      characterization of the effects of aspirin on mRNA as well as platelet ribosomal 
      RNA demonstrated that aspirin may act as an inhibitor of protein synthesis. 
      Database searches for small molecules that mimicked the effects of aspirin on 
      platelet gene expression in vitro identified aspirin but no other molecules that 
      share aspirin's known mechanisms of action. The effects of aspirin on platelet 
      mRNA were correlated with higher levels of platelet function both at baseline and 
      after aspirin exposure-an effect that counteracts aspirin's known antiplatelet 
      effect. In summary, this work collectively demonstrates a dose-independent effect 
      of aspirin on the platelet transcriptome that counteracts the well-known 
      antiplatelet effects of aspirin.
CI  - © 2021 British Pharmacological Society.
FAU - Myers, Rachel A
AU  - Myers RA
AD  - Center for Applied Genomics & Precision Medicine, Duke University School of 
      Medicine, Durham, NC, United States.
FAU - Ortel, Thomas L
AU  - Ortel TL
AD  - Division of Hematology, Department of Medicine, Duke University Medical Center, 
      Durham, NC, United States.
FAU - Waldrop, Alexander
AU  - Waldrop A
AD  - Center for Genomics and Computational Biology, Duke University, Durham, NC, 
      United States.
FAU - Dave, Sandeep
AU  - Dave S
AD  - Center for Genomics and Computational Biology, Duke University, Durham, NC, 
      United States.
FAU - Ginsburg, Geoffrey S
AU  - Ginsburg GS
AD  - Center for Applied Genomics & Precision Medicine, Duke University School of 
      Medicine, Durham, NC, United States.
FAU - Voora, Deepak
AU  - Voora D
AUID- ORCID: 0000-0003-0015-5179
AD  - Center for Applied Genomics & Precision Medicine, Duke University School of 
      Medicine, Durham, NC, United States.
LA  - eng
GR  - R01 HL118049/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20211127
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Aspirin/adverse effects
MH  - *Blood Platelets
MH  - Cross-Over Studies
MH  - Gene Expression
MH  - Humans
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - RNA, Messenger/metabolism
PMC - PMC9007832
MID - NIHMS1751843
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular disease
OT  - platelet aggregometry
OT  - transcriptomics
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2021/10/28 06:00
MHDA- 2022/04/13 06:00
CRDT- 2021/10/27 12:40
PHST- 2021/10/10 00:00 [revised]
PHST- 2021/07/21 00:00 [received]
PHST- 2021/10/18 00:00 [accepted]
PHST- 2021/10/28 06:00 [pubmed]
PHST- 2022/04/13 06:00 [medline]
PHST- 2021/10/27 12:40 [entrez]
AID - 10.1111/bcp.15127 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2022 May;88(5):2074-2083. doi: 10.1111/bcp.15127. Epub 2021 
      Nov 27.

PMID- 36129381
OWN - NLM
STAT- MEDLINE
DCOM- 20230316
LR  - 20230316
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 161
IP  - 1
DP  - 2023 Apr
TI  - Prevention of pre-eclampsia with aspirin: A systematic review of guidelines and 
      evaluation of the quality of recommendation evidence.
PG  - 26-39
LID - 10.1002/ijgo.14471 [doi]
AB  - BACKGROUND: Evidence has shown significant benefits of aspirin for preventing 
      pre-eclampsia. OBJECTIVES: The objective of this study was to systematically 
      review recommendations from clinical practice guidelines and other recommendation 
      documents on aspirin for the prevention of pre-eclampsia. SEARCH STRATEGY: Ten 
      databases were searched for statements from December 1, 2013, to January 1, 2022. 
      SELECTION CRITERIA: Without language restrictions, the most recent version of 
      documents was considered. DATA COLLECTION AND ANALYSIS: Two authors independently 
      extracted recommendations. Guideline quality was assessed using a modified 
      AGREE-II instrument and the AGREE-REX tool. MAIN RESULTS: Out of 48 statements on 
      the prevention of pre-eclampsia, 46 had recommendations on use of aspirin. Of 
      them, 39 were supported by evidence from systematic reviews or randomized 
      controlled trials. Three statements reported aspirin's significant reductions in 
      preterm pre-eclampsia and one in perinatal death. Concerning quality, 41% of 
      statements were rated as high quality in all domains of the AGREE-II tool, 15% 
      were rated high quality in all domains of the AGREE-REX tool, and 11% were rated 
      high quality in all domains on both tools. CONCLUSIONS: While 96% of statements 
      advocated for use of aspirin, only 9% reported a significant reduction in preterm 
      pre-eclampsia or perinatal death. Based on the AGREE tools, future statements 
      could use methodological improvement.
CI  - © 2022 International Federation of Gynecology and Obstetrics.
FAU - Ninan, Kiran
AU  - Ninan K
AD  - Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, 
      Canada.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Ali, Rifaa
AU  - Ali R
AD  - Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Morfaw, Frederick
AU  - Morfaw F
AD  - Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - McDonald, Sarah D
AU  - McDonald SD
AUID- ORCID: 0000-0002-4461-2178
AD  - Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, 
      Canada.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Division of Maternal-Fetal Medicine, McMaster University, Hamilton, Ontario, 
      Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20221001
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Infant, Newborn
MH  - Humans
MH  - Aspirin/therapeutic use
MH  - *Pre-Eclampsia/prevention & control/drug therapy
MH  - *Perinatal Death
OTO - NOTNLM
OT  - aspirin
OT  - pre-eclampsia
OT  - pregnancy-induced hypertension
OT  - systematic review
EDAT- 2022/09/22 06:00
MHDA- 2023/03/17 06:00
CRDT- 2022/09/21 09:43
PHST- 2022/08/19 00:00 [revised]
PHST- 2022/06/03 00:00 [received]
PHST- 2022/08/30 00:00 [accepted]
PHST- 2022/09/22 06:00 [pubmed]
PHST- 2023/03/17 06:00 [medline]
PHST- 2022/09/21 09:43 [entrez]
AID - 10.1002/ijgo.14471 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2023 Apr;161(1):26-39. doi: 10.1002/ijgo.14471. Epub 2022 
      Oct 1.

PMID- 16972540
OWN - NLM
STAT- MEDLINE
DCOM- 20061109
LR  - 20131121
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 2
IP  - 76
DP  - 2006 Aug 23
TI  - [Aspirin therapy for cardiovascular prevention in the diabetic patient: what have 
      we learned from the evidence?].
PG  - 1904-8
AB  - Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an 
      especially elevated relative risk among women. Aspirin prescription is mandatory 
      in secondary prevention, even if the protection by aspirin appears less 
      efficacious in diabetic than in non-diabetic patients. In primary prevention, 
      available data are paradoxically rather scarce, but also suggest a less effective 
      prevention when diabetes is present. Aspirin remains the first antiplatelet agent 
      in the diabetic population in all international guidelines of cardiovascular 
      prevention although a higher daily dose may be proposed in this subgroup of 
      patients (160-300 mg rather than 75-100 mg).
FAU - Legrand, D A
AU  - Legrand DA
AD  - Université de Liège, Service de diabétologie, nutrition et maladies métaboliques, 
      CHU SartTilman, B-4000 Liège I.
FAU - Scheen, A J
AU  - Scheen AJ
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Prévention cardiovasculaire par l'aspirine chez le patient diabétique: que nous 
      apprend la médecine factuelle?
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - *Diabetes Complications
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 36
EDAT- 2006/09/16 09:00
MHDA- 2006/11/11 09:00
CRDT- 2006/09/16 09:00
PHST- 2006/09/16 09:00 [pubmed]
PHST- 2006/11/11 09:00 [medline]
PHST- 2006/09/16 09:00 [entrez]
PST - ppublish
SO  - Rev Med Suisse. 2006 Aug 23;2(76):1904-8.

PMID- 23469916
OWN - NLM
STAT- MEDLINE
DCOM- 20130826
LR  - 20131121
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 11
IP  - 3
DP  - 2013 Mar
TI  - Identifying determinants of variability to tailor aspirin therapy.
PG  - 365-79
LID - 10.1586/erc.12.144 [doi]
AB  - Once-daily, low-dose aspirin is a cornerstone in the prophylaxis and treatment of 
      cardiovascular diseases. Aspirin 'resistance' still lacks definition, a 
      standardized reference assay, underlying mechanisms, clinical impact or efficacy 
      of alternative antiplatelet drugs. Aspirin response in several studies has been 
      measured by different platelet function tests, not always reflecting aspirin 
      pharmacodynamics, thus generating significantly heterogeneous results. The EMA 
      indicated serum thromboxane B2 as the only valid surrogate assay to study 
      different aspirin formulations. Rather than resistance, recent studies focused on 
      sources of intra- and inter-individual variability in response to aspirin, based 
      on pharmacokinetic and/or pharmacodynamic mechanisms. Drug interactions, 
      diabetes, conditions of increased platelet output, obesity and aging can 
      potentially increase the variability of aspirin response. Preliminary studies 
      testing different aspirin regimens showed that twice-daily low doses were more 
      effective than once-daily higher aspirin doses on surrogate end points of 
      platelet inhibition. Large studies are needed to test new disease-tailored, 
      low-dose aspirin regimens.
FAU - Rocca, Bianca
AU  - Rocca B
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. 
      b.rocca@tiscali.it
FAU - Dragani, Alfredo
AU  - Dragani A
FAU - Pagliaccia, Francesca
AU  - Pagliaccia F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/*drug therapy/physiopathology/prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Platelet Function Tests
EDAT- 2013/03/09 06:00
MHDA- 2013/08/27 06:00
CRDT- 2013/03/09 06:00
PHST- 2013/03/09 06:00 [entrez]
PHST- 2013/03/09 06:00 [pubmed]
PHST- 2013/08/27 06:00 [medline]
AID - 10.1586/erc.12.144 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2013 Mar;11(3):365-79. doi: 10.1586/erc.12.144.

PMID- 10763200
OWN - NLM
STAT- MEDLINE
DCOM- 20000427
LR  - 20190826
IS  - 0248-8663 (Print)
IS  - 0248-8663 (Linking)
VI  - 21 Suppl 1
DP  - 2000 Mar
TI  - [Aspirin throughout the ages: a historical review].
PG  - 8s-17s
AB  - Even at the beginning of the next millennium, aspirin will still offer surprises. 
      Its relatively young pharmacological history compares with the early use of 
      salicylate-containing plants since antiquity. The Assyrians and the Egyptians 
      were aware of the analgesic effects of a decoction of myrtle or willow leaves for 
      joint pains. Hippocrates recommended chewing willow leaves for analgesia in 
      childbirth and the Reverend Edward Stones is acknowledged as the first person to 
      scientifically define the beneficial antipyretic effects of willow bark. At the 
      beginning of the 19th century salicin was extracted from willow bark and 
      purified. Although a French chemist, Charles Gerhardt, was the first to 
      synthesize aspirin in a crude form, the compound was ignored, and later studied 
      by Felix Hoffmann. He reportedly tested the rediscovered agent on himself and on 
      his father, who suffered from chronic arthritis--a legend was born and Bayer 
      Laboratories rose to the heights of the pharmacological world. First used for its 
      potent analgesic, antipyretic and anti-inflammatory properties, aspirin was 
      successfully used as an antithrombotic agent. Sir John Vane elucidated aspirin's 
      active mechanism as an inhibitor of prostaglandin synthetase and received the 
      Nobel Price in Medicine for this work in 1982. Two isoform of cyclooxygenase 
      (COX-1 and COX-2) have now been identified, each possessing similar activities, 
      but differing in characteristic tissue expression. The cox enzyme is now a target 
      of drug interventions against the inflammatory process. After two centuries of 
      evaluation, aspirin remains topical, and new therapeutic indications are 
      increasingly being studied.
FAU - Lévesque, H
AU  - Lévesque H
AD  - Département de médecine interne, centre hospitalier universitaire 
      Rouen-Boisguillaume, France.
FAU - Lafont, O
AU  - Lafont O
LA  - fre
PT  - English Abstract
PT  - Historical Article
PT  - Journal Article
PT  - Review
TT  - L'aspirine à travers les siècles: rappel historique.
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analgesia, Obstetrical/history
MH  - Anti-Inflammatory Agents, Non-Steroidal/*history
MH  - Aspirin/*history
MH  - Child
MH  - Cyclooxygenase Inhibitors/*history
MH  - England
MH  - Female
MH  - Fibrinolytic Agents/*history
MH  - France
MH  - Germany
MH  - History, 16th Century
MH  - History, 17th Century
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, Ancient
MH  - History, Medieval
MH  - Humans
MH  - Male
MH  - Peru
MH  - Platelet Aggregation Inhibitors/*history
MH  - Pregnancy
MH  - Russia (Pre-1917)
MH  - United States
RF  - 54
EDAT- 2000/04/14 09:00
MHDA- 2000/04/29 09:00
CRDT- 2000/04/14 09:00
PHST- 2000/04/14 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/04/14 09:00 [entrez]
AID - S0248-8663(00)88720-2 [pii]
AID - 10.1016/s0248-8663(00)88720-2 [doi]
PST - ppublish
SO  - Rev Med Interne. 2000 Mar;21 Suppl 1:8s-17s. doi: 10.1016/s0248-8663(00)88720-2.

PMID- 25501125
OWN - NLM
STAT- MEDLINE
DCOM- 20160301
LR  - 20181113
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 21
IP  - 7
DP  - 2015 Apr 1
TI  - Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to 
      cancer prevention and treatment.
PG  - 1543-8
LID - 10.1158/1078-0432.CCR-14-0877 [doi]
AB  - The anti-inflammatory properties of aspirin have resulted in its widespread use 
      as an analgesic, antipyretic, and cardioprotective agent. Beyond these 
      applications, multiple observational studies and randomized controlled trials 
      have demonstrated a chemopreventative role for aspirin, particularly in the 
      development of colorectal neoplasia. Given the critical importance of Wnt 
      dysregulation in colorectal carcinogenesis, the interplay between aspirin and 
      canonical Wnt signaling has become a focus of investigation. These studies have 
      illuminated our understanding of the anticancer mechanisms of aspirin, yielding 
      the identification of potential biomarkers for which aspirin's chemopreventative 
      efficacy can be safely optimized into routine clinical practice and providing 
      leads into the discovery of novel preventive and therapeutic targets. In this 
      review, we summarize key experimental and clinical studies of this interaction, 
      as well as highlighting future strategies to advance their clinical translation.
CI  - ©2014 American Association for Cancer Research.
FAU - Gala, Manish K
AU  - Gala MK
AD  - Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts. mgala@mgh.harvard.edu achan@mgh.harvard.edu.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts. Channing Division of Network Medicine, Department 
      of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, 
      Massachusetts. mgala@mgh.harvard.edu achan@mgh.harvard.edu.
LA  - eng
GR  - R01CA176272/CA/NCI NIH HHS/United States
GR  - K23DK103119/DK/NIDDK NIH HHS/United States
GR  - K23 DK103119/DK/NIDDK NIH HHS/United States
GR  - R01 CA137178/CA/NCI NIH HHS/United States
GR  - R01 CA176272/CA/NCI NIH HHS/United States
GR  - K24 DK098311/DK/NIDDK NIH HHS/United States
GR  - R01CA137178/CA/NCI NIH HHS/United States
GR  - P50CA127003/CA/NCI NIH HHS/United States
GR  - K24DK098311/DK/NIDDK NIH HHS/United States
GR  - P50 CA127003/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20141211
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Colorectal Neoplasms/*prevention & control
MH  - Humans
MH  - Molecular Targeted Therapy/*methods
MH  - Neoplasms/*prevention & control
MH  - Wnt Signaling Pathway/*drug effects
PMC - PMC4383688
MID - NIHMS647917
EDAT- 2014/12/17 06:00
MHDA- 2016/03/02 06:00
CRDT- 2014/12/16 06:00
PHST- 2014/09/28 00:00 [received]
PHST- 2014/10/01 00:00 [accepted]
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2016/03/02 06:00 [medline]
AID - 1078-0432.CCR-14-0877 [pii]
AID - 10.1158/1078-0432.CCR-14-0877 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2015 Apr 1;21(7):1543-8. doi: 10.1158/1078-0432.CCR-14-0877. 
      Epub 2014 Dec 11.

PMID- 36047408
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20221103
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Print)
IS  - 1079-5642 (Linking)
VI  - 42
IP  - 10
DP  - 2022 Oct
TI  - Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a 
      Platelet-Guided Approach.
PG  - 1207-1216
LID - 10.1161/ATVBAHA.122.318020 [doi]
AB  - Aspirin protects against atherothrombosis while increasing the risk of major 
      bleeding. Although it is widely used to prevent cardiovascular disease (CVD), its 
      benefit does not outweigh its risk for primary CVD prevention in large population 
      settings. The recent United States Preventive Services Task Force guidelines on 
      aspirin use to prevent CVD reflect this clinical tradeoff as well as the 
      persistent struggle to define a population that would benefit from prophylactic 
      aspirin therapy. Past clinical trials of primary CVD prevention with aspirin have 
      not included consideration of a biomarker relevant to aspirin's mechanism of 
      action, platelet inhibition. This approach is at odds with the paradigm used in 
      other key areas of pharmacological CVD prevention, including antihypertensive and 
      statin therapy, which combine cardiovascular risk assessment with the measurement 
      of mechanistic biomarkers (eg, blood pressure and LDL [low-density 
      lipoprotein]-cholesterol). Reliable methods for quantifying platelet activity, 
      including light transmission aggregometry and platelet transcriptomics, exist and 
      should be considered to identify individuals at elevated cardiovascular risk due 
      to a hyperreactive platelet phenotype. Therefore, we propose a new, 
      platelet-guided approach to the study of prophylactic aspirin therapy. We think 
      that this new approach will reveal a population with hyperreactive platelets who 
      will benefit most from primary CVD prevention with aspirin and usher in a new era 
      of precision-guided antiplatelet therapy.
FAU - Cofer, Lucas B
AU  - Cofer LB
AUID- ORCID: 0000-0001-6388-2088
AD  - NYU Grossman School of Medicine.
FAU - Barrett, Tessa J
AU  - Barrett TJ
AUID- ORCID: 0000-0003-0751-1578
AD  - NYU Grossman School of Medicine.
FAU - Berger, Jeffrey S
AU  - Berger JS
AUID- ORCID: 0000-0001-8216-4647
AD  - NYU Grossman School of Medicine.
LA  - eng
GR  - R35 HL144993/HL/NHLBI NIH HHS/United States
GR  - R01 HL114978/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20220901
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arterioscler Thromb Vasc Biol. 2022 Oct;42(10):1217-1219. PMID: 36047409
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/epidemiology
MH  - Cholesterol
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Lipoproteins, LDL
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Primary Prevention/methods
PMC - PMC9484763
OTO - NOTNLM
OT  - aspirin
OT  - blood pressure
OT  - cardiovascular disease
OT  - cholesterol
OT  - risk factors
EDAT- 2022/09/02 06:00
MHDA- 2022/09/24 06:00
CRDT- 2022/09/01 05:03
PHST- 2022/09/02 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/09/01 05:03 [entrez]
AID - 10.1161/ATVBAHA.122.318020 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2022 Oct;42(10):1207-1216. doi: 
      10.1161/ATVBAHA.122.318020. Epub 2022 Sep 1.

PMID- 25502483
OWN - NLM
STAT- MEDLINE
DCOM- 20160115
LR  - 20181202
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Print)
IS  - 1175-3277 (Linking)
VI  - 15
IP  - 2
DP  - 2015 Apr
TI  - A systematic review of aspirin in primary prevention: is it time for a new 
      approach?
PG  - 113-33
LID - 10.1007/s40256-014-0100-5 [doi]
AB  - BACKGROUND AND OBJECTIVES: While evidence in support of aspirin use in secondary 
      prevention is well documented, the role of aspirin in primary prevention remains 
      unclear. We conducted a systematic literature review to evaluate aspirin use in 
      cardiovascular disease (CVD) and cancer primary prevention, and consider whether 
      aspirin's role is set to become more clearly defined based on past and 
      prospective studies. DATA SOURCES: Utilizing PubMed, the reviewers identified 
      appropriate Medical Subject Headings (MeSH) terms to establish CVD-based studies, 
      cancer-based studies, and studies on adherence. STUDY ELIGIBILITY CRITERIA: Date 
      restrictions of May 31, 2008 to May 31, 2013 were applied to capture the most 
      robust meta-analyses and randomized controlled trials. Websites of relevant EU 
      and US scientific societies were used to identify the key guidelines for aspirin 
      use in primary prevention of CVD, and ClinicalTrials.gov was used to establish 
      future or ongoing trials. RESULTS: Evidence in support of aspirin prophylaxis is 
      conflicting, though some meta-analyses have underlined potential benefit in 
      reducing cardiovascular events. Despite this apparent benefit, bleeding risk with 
      aspirin is consistently higher versus control, and remains a concern. A reduction 
      of cancer incidence and mortality after a least 3 and 5 years treatment, 
      respectively, is also apparent with aspirin. CONCLUSION: Available data on 
      aspirin in primary prevention suggest a modest benefit for patients at high risk 
      of CVD, and a promising benefit for those at risk of cancer. Future studies 
      should help to elucidate whether the benefit of aspirin outweighs risk in 
      appropriate patient groups.
FAU - Brotons, Carlos
AU  - Brotons C
AD  - Research Unit, Sardenya Primary Health Care Center, Biomedical Research Institute 
      Sant Pau. Teaching Unit of Family Medicine ACEBA, Sardenya 466, 08025, Barcelona, 
      Spain, cbrotons@eapsardenya.cat.
FAU - Benamouzig, Robert
AU  - Benamouzig R
FAU - Filipiak, Krzysztof J
AU  - Filipiak KJ
FAU - Limmroth, Volker
AU  - Limmroth V
FAU - Borghi, Claudio
AU  - Borghi C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Primary Prevention/methods/*trends
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic/methods
MH  - Time Factors
PMC - PMC4383813
EDAT- 2014/12/17 06:00
MHDA- 2016/01/16 06:00
CRDT- 2014/12/16 06:00
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2016/01/16 06:00 [medline]
AID - 100 [pii]
AID - 10.1007/s40256-014-0100-5 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2015 Apr;15(2):113-33. doi: 10.1007/s40256-014-0100-5.

PMID- 18589844
OWN - NLM
STAT- MEDLINE
DCOM- 20080724
LR  - 20220716
IS  - 1529-7322 (Print)
IS  - 1529-7322 (Linking)
VI  - 8
IP  - 3
DP  - 2008 May
TI  - The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis.
PG  - 245-52
AB  - Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease 
      characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway 
      reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs). For 
      patients who have inadequately controlled rhinosinusitis and/or asthma despite 
      treatment with topical corticosteroids and leukotriene-modifying drugs, aspirin 
      desensitization is an important therapeutic option. This review examines the 
      evidence supporting the effectiveness of aspirin desensitization for the 
      treatment of chronic rhinosinusitis in patients with AERD. Practical aspects of 
      conducting safe aspirin desensitization procedures and optimizing therapeutic 
      benefits are also reviewed. When conducted in accordance with current guidelines, 
      aspirin desensitization is a safe procedure that allows patients with AERD who 
      have an indication for aspirin or other NSAIDs to safely ingest these 
      medications. There is now strong evidence that aspirin desensitization and daily 
      aspirin therapy is effective for treatment of the chronic inflammatory disease of 
      the upper airway and lower airways in AERD.
FAU - Williams, Adam N
AU  - Williams AN
AD  - Division of Allergy, Asthma, and Immunology, Scripps Clinic, 3811 Valley Centre 
      Drive, San Diego, CA 92130, USA. williams.adam@scrippshealth.org
FAU - Woessner, Katharine M
AU  - Woessner KM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Allergy Asthma Rep
JT  - Current allergy and asthma reports
JID - 101096440
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*adverse effects/analogs & 
      derivatives/*immunology/therapeutic use
MH  - Chronic Disease
MH  - *Desensitization, Immunologic
MH  - Humans
MH  - Lysine/analogs & derivatives/therapeutic use
MH  - Nasal Polyps/drug therapy
MH  - Patient Selection
MH  - Respiratory Hypersensitivity/*therapy
MH  - Rhinitis/*therapy
MH  - Sinusitis/*therapy
RF  - 41
EDAT- 2008/07/01 09:00
MHDA- 2008/07/25 09:00
CRDT- 2008/07/01 09:00
PHST- 2008/07/01 09:00 [pubmed]
PHST- 2008/07/25 09:00 [medline]
PHST- 2008/07/01 09:00 [entrez]
AID - 10.1007/s11882-008-0041-7 [doi]
PST - ppublish
SO  - Curr Allergy Asthma Rep. 2008 May;8(3):245-52. doi: 10.1007/s11882-008-0041-7.

PMID- 37286223
OWN - NLM
STAT- MEDLINE
DCOM- 20230609
LR  - 20230609
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 36
IP  - 1
DP  - 2023 Dec
TI  - The effect of aspirin on uterine arterial blood flow and endometrium in moderate 
      and severe intrauterine adhesion after transcervical resection of adhesion: a 
      systematic review and meta-analysis.
PG  - 2209818
LID - 10.1080/14767058.2023.2209818 [doi]
AB  - BACKGROUND: Transcervical resection of adhesion (TCRA) and postoperative adjuvant 
      estrogen and progestin are the main treatments for cavity adhesions, but the 
      recurrence rate after surgery is still high. It was showed that aspirin could 
      promote endometrial proliferation and repair after TCRA in patients with severe 
      cavity adhesions, but the effect on reproduction was uncertain. OBJECTIVE: To 
      assess the effect of aspirin on uterine arterial blood flow and endometrium in 
      moderate and severe intrauterine adhesion after transcervical resection of 
      adhesion. METHODS: The databases used included Cumulative Index to PubMed, 
      EMBASE, Chinese National Knowledge Infrastructure (CNKI), and Wanfang database. 
      Studies published before June 2022 were included. Each participant received an 
      aspirin-based intervention aimed at improving uterine status, which was compared 
      to a sham intervention. The primary outcome measure was a change in endometrium 
      thickness. Secondary outcomes included uterine artery resistance index, blood 
      flow index, and endometrial arterial resistance index. RESULT: A total of 19 
      studies (n = 1361 participants) that met the inclusion criteria were included in 
      this study. The aspirin-based intervention was strongly associated with better 
      clinical outcome at second-look endometrium thickness (MD 0.81, CI 0.46-1.16; 
      p < .00001) and blood flow Index (FI) (MD 4.1, CI 2.3-5.9; p < .00001). Besides, 
      the analysis of arterial pulsatility index (PI) showed a significantly reduced 
      after transcervical resection of adhesion (MD -0.9, CI -1.2 to 0.6; p < .00001); 
      whereas no significant difference was found in endometrial arterial resistance 
      index (RI) (95% CI, -0.30 to 0.01; p = .07). CONCLUSION: Our study proved the 
      effect of aspirin on uterine arterial blood flow and endometrium in moderate and 
      severe intrauterine adhesion after transcervical resection of adhesion. However, 
      the review requires evidence from additional randomized controlled trials and 
      high-quality research. More strictly designed research studies are needed to 
      assess the effectiveness of aspirin administration after transcervical resection 
      of adhesion.
FAU - Li, Li-Na
AU  - Li LN
AD  - Guangdong Hospital of Traditional Chinese Medical, Zhuhai, China.
FAU - Li, Xiao-Dan
AU  - Li XD
AD  - Guangdong Hospital of Traditional Chinese Medical, Zhuhai, China.
FAU - Du, Juan
AU  - Du J
AD  - Guangdong Hospital of Traditional Chinese Medical, Zhuhai, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Uterine Artery/surgery
MH  - *Uterine Diseases
MH  - Endometrium/surgery
MH  - Uterus/surgery
OTO - NOTNLM
OT  - Aspirin
OT  - intrauterine adhesion
OT  - meta-analysis
OT  - systematic review
OT  - transcervical resection of adhesion
EDAT- 2023/06/08 01:08
MHDA- 2023/06/09 06:42
CRDT- 2023/06/07 20:43
PHST- 2023/06/09 06:42 [medline]
PHST- 2023/06/08 01:08 [pubmed]
PHST- 2023/06/07 20:43 [entrez]
AID - 10.1080/14767058.2023.2209818 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2023 Dec;36(1):2209818. doi: 
      10.1080/14767058.2023.2209818.

PMID- 29036741
OWN - NLM
STAT- MEDLINE
DCOM- 20180912
LR  - 20191008
IS  - 1526-4564 (Electronic)
IS  - 1526-8004 (Print)
IS  - 1526-4564 (Linking)
VI  - 35
IP  - 4
DP  - 2017 Jul
TI  - The Effects of Aspirin in Gestation and Reproduction (EAGeR) Trial: A Story of 
      Discovery.
PG  - 344-352
LID - 10.1055/s-0037-1606384 [doi]
AB  - Human reproduction is an inefficient process. There are several drivers of 
      complications along the path to and during pregnancy, one of which is 
      inflammation. Treatments to mitigate the deleterious effects of aberrant 
      inflammation with something inexpensive and widely available like aspirin could 
      have dramatic global impact. The Effects of Aspirin in Gestation and Reproduction 
      (EAGeR) trial enrolled women aged 18 to 40 years with one to two prior pregnancy 
      losses and no diagnosis of infertility. Patients were randomized to either 
      low-dose aspirin or placebo. Here, we review the collective findings of the EAGeR 
      trial to date and discuss several important lessons learned from the unique data 
      resulting from this groundbreaking trial. Findings reported from this trial 
      provide significant advances in the understanding of aspirin’s potential 
      mechanisms in modulating reproductive processes and the role of inflammation in 
      these processes. This review describes the collective findings of the EAGeR trial 
      in the context of the existing literature regarding aspirin and inflammation in 
      reproduction to inform relevant next steps in fertility and obstetric research, 
      as well as potential implications for clinical care.
FAU - Connell, Matthew T
AU  - Connell MT
AD  - Division of Intramural Population Health Research, Eunice Kennedy Shriver 
      National Institute of Child Health and Human Development, National Institutes of 
      Health, Bethesda, Maryland.
AD  - Program of Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National 
      Institute of Child Health and Human Development, National Institutes of Health, 
      Bethesda, Maryland.
FAU - Sjaarda, Lindsey A
AU  - Sjaarda LA
AD  - Division of Intramural Population Health Research, Eunice Kennedy Shriver 
      National Institute of Child Health and Human Development, National Institutes of 
      Health, Bethesda, Maryland.
FAU - Radin, Rose G
AU  - Radin RG
AD  - Division of Intramural Population Health Research, Eunice Kennedy Shriver 
      National Institute of Child Health and Human Development, National Institutes of 
      Health, Bethesda, Maryland.
FAU - Kuhr, Daniel
AU  - Kuhr D
AD  - Division of Intramural Population Health Research, Eunice Kennedy Shriver 
      National Institute of Child Health and Human Development, National Institutes of 
      Health, Bethesda, Maryland.
FAU - Mumford, Sunni L
AU  - Mumford SL
AD  - Division of Intramural Population Health Research, Eunice Kennedy Shriver 
      National Institute of Child Health and Human Development, National Institutes of 
      Health, Bethesda, Maryland.
FAU - Plowden, Torie C
AU  - Plowden TC
AD  - Division of Intramural Population Health Research, Eunice Kennedy Shriver 
      National Institute of Child Health and Human Development, National Institutes of 
      Health, Bethesda, Maryland.
AD  - Program of Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National 
      Institute of Child Health and Human Development, National Institutes of Health, 
      Bethesda, Maryland.
FAU - Silver, Robert M
AU  - Silver RM
AD  - Department of Obstetrics and Gynecology, University of Utah and Intermountain 
      Healthcare, Salt Lake City, Utah.
FAU - Schisterman, Enrique F
AU  - Schisterman EF
AD  - Division of Intramural Population Health Research, Eunice Kennedy Shriver 
      National Institute of Child Health and Human Development, National Institutes of 
      Health, Bethesda, Maryland.
LA  - eng
GR  - Z01 HD008796-01/Intramural NIH HHS/United States
GR  - ZIA HD008795-11/Intramural NIH HHS/United States
GR  - ZIA HD008795-09/Intramural NIH HHS/United States
GR  - Z01 HD008795-01/Intramural NIH HHS/United States
GR  - ZIA HD008795-04/Intramural NIH HHS/United States
GR  - ZIA HD008795-03/Intramural NIH HHS/United States
GR  - ZIA HD008795-07/Intramural NIH HHS/United States
GR  - ZIA HD008795-12/Intramural NIH HHS/United States
GR  - ZIA HD008795-06/Intramural NIH HHS/United States
GR  - ZIA HD008795-08/Intramural NIH HHS/United States
GR  - ZIA HD008795-10/Intramural NIH HHS/United States
GR  - Z01 HD008795-02/Intramural NIH HHS/United States
GR  - ZIA HD008795-05/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20171016
PL  - United States
TA  - Semin Reprod Med
JT  - Seminars in reproductive medicine
JID - 100909394
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - C-Reactive Protein/drug effects
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*prevention & control
MH  - *Pregnancy Rate
MH  - Premature Birth/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Reproduction/*drug effects
MH  - Young Adult
PMC - PMC6234510
MID - NIHMS991788
COIS- Conflict of Interest: The authors have no conflict of interest to disclose.
EDAT- 2017/10/17 06:00
MHDA- 2018/09/13 06:00
CRDT- 2017/10/17 06:00
PHST- 2017/10/17 06:00 [entrez]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2018/09/13 06:00 [medline]
AID - 10.1055/s-0037-1606384 [doi]
PST - ppublish
SO  - Semin Reprod Med. 2017 Jul;35(4):344-352. doi: 10.1055/s-0037-1606384. Epub 2017 
      Oct 16.

PMID- 1485363
OWN - NLM
STAT- MEDLINE
DCOM- 19930218
LR  - 20190902
IS  - 0163-4356 (Print)
IS  - 0163-4356 (Linking)
VI  - 14
IP  - 6
DP  - 1992 Dec
TI  - Acute aspirin overdose: mechanisms of toxicity.
PG  - 441-51
AB  - The case history described herein illustrates many of the salient clinical and 
      laboratory features of acute salicylate overdose. Aspirin overdose remains a 
      commonly used means of attempting suicide in young adults. This case demonstrates 
      the role of the laboratory in the management of salicylate overdose. Medical 
      treatment of several critical concurrent metabolic responses was dependent on 
      frequent evaluations of serum electrolytes, blood and urine pH, blood PO2, blood 
      PCO2, and blood HCO3- concentrations. In addition, essential to her excellent 
      medical care was the ongoing close interaction between the clinical toxicology 
      laboratory and the clinical staff.
FAU - Krause, D S
AU  - Krause DS
AD  - Department of Pathology and Laboratory Medicine, Hospital of the University of 
      Pennsylvania, Philadelphia 19104.
FAU - Wolf, B A
AU  - Wolf BA
FAU - Shaw, L M
AU  - Shaw LM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ther Drug Monit
JT  - Therapeutic drug monitoring
JID - 7909660
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/pharmacokinetics/pharmacology/*poisoning
MH  - Drug Overdose/diagnosis/physiopathology/therapy
MH  - Female
MH  - Humans
MH  - Risk Factors
RF  - 57
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
AID - 10.1097/00007691-199212000-00001 [doi]
PST - ppublish
SO  - Ther Drug Monit. 1992 Dec;14(6):441-51. doi: 10.1097/00007691-199212000-00001.

PMID- 15978791
OWN - NLM
STAT- MEDLINE
DCOM- 20060120
LR  - 20131121
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 73
IP  - 3-4
DP  - 2005 Sep-Oct
TI  - The role of aspirin-triggered lipoxins in the mechanism of action of aspirin.
PG  - 203-10
AB  - Few drugs have treated so many diseases, provided us with so much understanding 
      of their pathogenesis, and tested our scientific creativity over the last 100 
      years as much as aspirin. Originally, the beneficial effects of aspirin were 
      shown to stem from its inhibition of cyclooxygenase (COX 2)-derived prostanoids, 
      fatty acid metabolites that modulate host defense and regulate the cardiovascular 
      system. However, the inhibition of COX 2 enzyme activity and prostaglandin 
      synthesis has never fully explained aspirin's repertoire of anti-inflammatory 
      effects, leaving many questions pertaining to its true mechanism of action 
      unanswered. Here, data from a series of comparatively recent experiments 
      exploring aspirin's unique ability to acetylate the active site of inducible COX 
      2 and generate a family of lipid mediators called the epi-Lipoxins will be 
      discussed in light of their ability to exert profound modulatory effects on the 
      innate and adaptive immune systems.
FAU - Gilroy, Derek W
AU  - Gilroy DW
AD  - Centre for Clinical Pharmacology and Therapeutics, BHF Laboratories, Division of 
      Medicine, University College London, 5 University Street, London WC1E 6JJ, UK. 
      d.gilroy@ucl.ac.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipoxins)
RN  - 0 (Prostaglandin Antagonists)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/metabolism/*pharmacology/therapeutic use
MH  - Aspirin/metabolism/*pharmacology/therapeutic use
MH  - Cyclooxygenase 2/metabolism
MH  - Humans
MH  - Inflammation/metabolism/*physiopathology
MH  - Lipoxins/*physiology
MH  - Nitric Oxide/biosynthesis
MH  - Nitric Oxide Synthase/metabolism
MH  - Prostaglandin Antagonists/*pharmacology
RF  - 43
EDAT- 2005/06/28 09:00
MHDA- 2006/01/21 09:00
CRDT- 2005/06/28 09:00
PHST- 2005/06/28 09:00 [pubmed]
PHST- 2006/01/21 09:00 [medline]
PHST- 2005/06/28 09:00 [entrez]
AID - S0952-3278(05)00085-2 [pii]
AID - 10.1016/j.plefa.2005.05.007 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):203-10. doi: 
      10.1016/j.plefa.2005.05.007.

PMID- 17979514
OWN - NLM
STAT- MEDLINE
DCOM- 20080425
LR  - 20131121
IS  - 1744-8042 (Electronic)
IS  - 1462-2416 (Linking)
VI  - 8
IP  - 10
DP  - 2007 Oct
TI  - Pharmacogenomics of platelet responsiveness to aspirin.
PG  - 1413-25
AB  - Aspirin is the most widely used drug in the world for cardiovascular protection. 
      Aspirin's ability to suppress platelet function varies widely among individuals 
      and lesser suppression of platelet function is associated with increased risk of 
      myocardial infarction, stroke and cardiovascular death. Platelet response to 
      aspirin is a complex phenotype involving multiple genes and molecular pathways. 
      Aspirin response phenotypes can be categorized as directly or indirectly related 
      to cyclooxygenase-1 (COX-1) activity, with phenotypic variation indirectly 
      related to COX-1 being much more prominent. Recent data indicate that variability 
      in platelet response to aspirin is genetically determined, but the specific gene 
      variants that contribute to phenotypic variation are not known. An understanding 
      of the relationship between genotype, aspirin response phenotype and clinical 
      outcome will help to bring about a personalized approach to antiplatelet therapy 
      that maximizes antithrombotic benefit whilst minimizing bleeding risk for 
      individual patients.
FAU - Faraday, Nauder
AU  - Faraday N
AD  - Johns Hopkins University School of Medicine, Department of 
      Anesthesiology/Critical Care Medicine, Division of Cardiac Surgical Intensive 
      Care, 298 Meyer Bldg, 600 N Wolfe St, Baltimore, MD 21287, USA. nfaraday@jhmi.edu
FAU - Becker, Diane M
AU  - Becker DM
FAU - Becker, Lewis C
AU  - Becker LC
LA  - eng
GR  - U01 HL72518/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Platelets/drug effects/*physiology
MH  - Coronary Disease/prevention & control
MH  - Cyclooxygenase 1/drug effects/metabolism
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Humans
MH  - Myocardial Infarction/genetics
MH  - *Pharmacogenetics
MH  - Platelet Activation/*drug effects
RF  - 93
EDAT- 2007/11/06 09:00
MHDA- 2008/04/26 09:00
CRDT- 2007/11/06 09:00
PHST- 2007/11/06 09:00 [pubmed]
PHST- 2008/04/26 09:00 [medline]
PHST- 2007/11/06 09:00 [entrez]
AID - 10.2217/14622416.8.10.1413 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2007 Oct;8(10):1413-25. doi: 10.2217/14622416.8.10.1413.

PMID- 12020174
OWN - NLM
STAT- MEDLINE
DCOM- 20020715
LR  - 20220321
IS  - 0114-5916 (Print)
IS  - 0114-5916 (Linking)
VI  - 25
IP  - 5
DP  - 2002
TI  - Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a 
      meta-analysis.
PG  - 373-8
AB  - BACKGROUND: Recently, studies have attempted to explore the interaction between 
      ACE inhibitors and aspirin (acetylsalicylic acid) when both drugs are used 
      concomitantly to reduce mortality in patients with coronary artery disease. 
      Results have been conflicting due, in part, to sub-optimal methods used to 
      explore this interaction. METHODS: We reviewed systematically all studies on 
      mortality in patients treated with ACE inhibitors and aspirin and conducted a 
      meta-analysis in order to explore the interaction between both drugs and resolve 
      discrepancies. To be included, each study had to provide data on mortality of 
      patients who received both drugs, either drug and no drug. These data were 
      necessary to calculate the synergy index (S) and its 95% confidence interval (CI) 
      that we used to quantify the effect due to interaction between ACE inhibitors and 
      aspirin. After testing for heterogeneity of effects, we pooled the S values from 
      the individual studies into one summary measure. Subsequently, we compared our 
      results with those obtained through the most common but incorrect method of 
      evaluating interaction. This method uses significance testing of the relative 
      risk of mortality when a 'product term' between ACE inhibitors and aspirin is 
      entered in a logistic regression model. RESULTS: Eight studies met the inclusion 
      criteria. The pooled synergy index S indicates slight but precise antagonism 
      between ACE inhibitors and aspirin (S = 0.91; 95% CI 0.80 to 1.03). In contrast, 
      the pooled 'product term' is not significant and would have lead to the 
      conclusion of absence of interaction (p = 0.15). CONCLUSION: There seems to be an 
      antagonistic interaction between ACE inhibitors and aspirin. Former discrepancies 
      were due to inadequate assessment of interaction. Results from the Studies on 
      Left Ventricular Dysfunction (SOLVD) and Heart Outcome Prevention Evaluation 
      (HOPE) trials that assessed the effect of combined administration of ACE 
      inhibitors and aspirin were not included in this meta-analysis because those 
      trials did not provide enough data to compute the S statistic. It is possible 
      that results from on-going trials such as Women's Atovarstatin Trial on 
      Cholesterol (WATCH) will shed more light on ACE inhibitor and aspirin interaction 
      in the future.
FAU - Takkouche, Bahi
AU  - Takkouche B
AD  - Department of Preventive Medicine, University of Santiago de Compostela, Santiago 
      de Compostela, Spain. mrbahi@usc.es
FAU - Etminan, Mahyar
AU  - Etminan M
FAU - Caamaño, Francisco
AU  - Caamaño F
FAU - Rochon, Paula A
AU  - Rochon PA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy/mortality
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Meta-Analysis as Topic
RF  - 26
EDAT- 2002/05/22 10:00
MHDA- 2002/07/16 10:01
CRDT- 2002/05/22 10:00
PHST- 2002/05/22 10:00 [pubmed]
PHST- 2002/07/16 10:01 [medline]
PHST- 2002/05/22 10:00 [entrez]
AID - 250505 [pii]
AID - 10.2165/00002018-200225050-00005 [doi]
PST - ppublish
SO  - Drug Saf. 2002;25(5):373-8. doi: 10.2165/00002018-200225050-00005.

PMID- 31939218
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20200810
IS  - 2192-6506 (Electronic)
IS  - 2192-6506 (Linking)
VI  - 84
IP  - 4
DP  - 2019 Apr
TI  - Insight into the Biological Activity of Organometallic Acetylsalicylic Acid 
      (Aspirin) Derivatives.
PG  - 403-415
LID - 10.1002/cplu.201900086 [doi]
AB  - Despite of its long history as a drug, aspirin (acetylsalicylic acid, ASA) still 
      fascinates investigators across the fields of chemistry, biology and medicine. In 
      this regard, the development of aspirin derivatives with new, beneficial, 
      biological properties still remains a challenge for chemists. This short review 
      focuses on the chemistry and the biological activity of organometallic (those 
      with metal-carbon bond) aspirin derivatives. Organometallic derivatization of 
      aspirin has a profound influence on its mode of action and biological activity 
      profile. In most organometallic ASA derivatives, the original ability for COX-1/2 
      acetylation persists, yet the acetylation sites are modified in comparison to 
      that triggered by ASA itself. This alternation results from a combination of the 
      electronic effect and the steric hindrance provided by the organometallic entity. 
      Secondly, the metal center itself has a strong influence on biological activity 
      through e. g., the ability for reactive oxygen species (ROS) generation in the 
      cells. All of these examples, which are uncommon for ASA molecular action 
      mechanisms, contribute to new pharmacological properties of organometallic ASA 
      derivatives. These properties comprise anticancer, antiparasitic, and 
      antibacterial activity.
CI  - © 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Kowalski, Konrad
AU  - Kowalski K
AUID- ORCID: 0000-0003-0600-3205
AD  - Faculty of Chemistry Department of Organic Chemistry, University of Łódź, Tamka 
      12, 91-403 Łódź, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Germany
TA  - Chempluschem
JT  - ChemPlusChem
JID - 101580948
RN  - 0 (Organometallic Compounds)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Chempluschem. 2019 Jul;84(7):821. PMID: 31943996
MH  - Aspirin/analogs & derivatives/chemistry/*metabolism
MH  - Molecular Structure
MH  - Organometallic Compounds/chemistry/*metabolism
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - anticancer activity
OT  - aspirin derivatives
OT  - bioorganometallics
OT  - metallodrugs
EDAT- 2020/01/16 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/01/16 06:00
PHST- 2019/02/04 00:00 [received]
PHST- 2019/03/27 00:00 [revised]
PHST- 2020/01/16 06:00 [entrez]
PHST- 2020/01/16 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - 10.1002/cplu.201900086 [doi]
PST - ppublish
SO  - Chempluschem. 2019 Apr;84(4):403-415. doi: 10.1002/cplu.201900086.

PMID- 24874482
OWN - NLM
STAT- MEDLINE
DCOM- 20141106
LR  - 20211021
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 111
IP  - 1
DP  - 2014 Jul 8
TI  - Molecular targets of aspirin and cancer prevention.
PG  - 61-7
LID - 10.1038/bjc.2014.271 [doi]
AB  - Salicylates from plant sources have been used for centuries by different cultures 
      to treat a variety of ailments such as inflammation, fever and pain. A chemical 
      derivative of salicylic acid, aspirin, was synthesised and mass produced by the 
      end of the 19th century and is one of the most widely used drugs in the world. 
      Its cardioprotective properties are well established; however, recent evidence 
      shows that it can also act as a chemopreventive agent. Its antithrombotic and 
      anti-inflammatory actions occur through the inhibition of cyclooxygenases. The 
      precise mechanisms leading to its anticancer effects are not clearly established, 
      although multiple mechanisms affecting enzyme activity, transcription factors, 
      cellular signalling and mitochondrial functions have been proposed. This review 
      presents a brief account of the major COX-dependent and independent pathways 
      described in connection with aspirin's anticancer effects. Aspirin's unique 
      ability to acetylate biomolecules besides COX has not been thoroughly 
      investigated nor have all the targets of its primary metabolite, salicylic acid 
      been identified. Recent reports on the ability of aspirin to acetylate multiple 
      cellular proteins warrant a comprehensive study to investigate the role of this 
      posttranslational modification in its anticancer effects. In this review, we also 
      raise the intriguing possibility that aspirin may interact and acetylate cellular 
      molecules such as RNA, and metabolites such as CoA, leading to a change in their 
      function. Research in this area will provide a greater understanding of the 
      mechanisms of action of this drug.
FAU - Alfonso, L
AU  - Alfonso L
AD  - DYouville College School of Pharmacy, Buffalo, NY, USA.
FAU - Ai, G
AU  - Ai G
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Brookings, SD, USA.
FAU - Spitale, R C
AU  - Spitale RC
AD  - Department of Pharmaceutical Sciences, University of California, Irvine, CA, USA.
FAU - Bhat, G J
AU  - Bhat GJ
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Brookings, SD, USA.
LA  - eng
GR  - R03 CA133061/CA/NCI NIH HHS/United States
GR  - 5R03CA133061-02/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140529
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Anticarcinogenic Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Neoplasms/drug therapy/*prevention & control
PMC - PMC4090734
EDAT- 2014/05/31 06:00
MHDA- 2014/11/07 06:00
CRDT- 2014/05/31 06:00
PHST- 2014/02/12 00:00 [received]
PHST- 2014/03/24 00:00 [revised]
PHST- 2014/04/08 00:00 [accepted]
PHST- 2014/05/31 06:00 [entrez]
PHST- 2014/05/31 06:00 [pubmed]
PHST- 2014/11/07 06:00 [medline]
AID - bjc2014271 [pii]
AID - 10.1038/bjc.2014.271 [doi]
PST - ppublish
SO  - Br J Cancer. 2014 Jul 8;111(1):61-7. doi: 10.1038/bjc.2014.271. Epub 2014 May 29.

PMID- 18069572
OWN - NLM
STAT- MEDLINE
DCOM- 20080206
LR  - 20150826
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 62
IP  - 10
DP  - 2007 Oct
TI  - [Aspirin resistance in diabetic patients: laboratory entity or clinical 
      reality?].
PG  - 610-5
AB  - Aspirin is considered the gold standard antiplatelet therapy for primary and 
      secondary prevention of cardiovascular (CV) disease. However, it appears less 
      protective in diabetic patients than in the general population. This difference 
      is attributed to a higher level of aspirin resistance observed in these subjects 
      when in vitro tests are performed. The frequency of this problem, its mechanistic 
      aspects and its clinical relevance remain largely unknown. Our analysis of the 
      literature confirms a higher proportion of platelets resistant to aspirin in 
      diabetic than in control individuals. This observation deserves further research 
      because it may be associated with an increased risk of CV events and worse 
      prognosis.
FAU - Legrand, D A
AU  - Legrand DA
AD  - Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de 
      Pharmacologie clinique, CHU Sart Tilman, Liège, Belgique.
FAU - Scheen, A J
AU  - Scheen AJ
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - La résistance à l'aspirine chez le patient diabétique: découverte de laboratoire 
      ou réalité clinique?
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Protective Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Chemoprevention
MH  - Diabetes Complications/*prevention & control
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Prognosis
MH  - Protective Agents/therapeutic use
RF  - 36
EDAT- 2007/12/12 09:00
MHDA- 2008/02/07 09:00
CRDT- 2007/12/12 09:00
PHST- 2007/12/12 09:00 [pubmed]
PHST- 2008/02/07 09:00 [medline]
PHST- 2007/12/12 09:00 [entrez]
PST - ppublish
SO  - Rev Med Liege. 2007 Oct;62(10):610-5.

PMID- 31905341
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20220111
IS  - 1552-5775 (Electronic)
IS  - 1552-5767 (Print)
IS  - 1552-5767 (Linking)
VI  - 24
DP  - 2020
TI  - Aspirin Use, Compliance, and Knowledge of Anticancer Effect in the Community.
LID - 10.7812/TPP/19.116 [doi]
LID - 19.116
AB  - INTRODUCTION: Millions of adults worldwide use low-dose aspirin for secondary 
      prevention of heart disease. Results of randomized trials indicate that regular 
      use of low-dose aspirin may reduce the risk of colorectal cancer by more than 
      20%, leading to speculation of its chemoprevention role for high-risk groups. 
      Little is known, however, about the use of aspirin in our community. OBJECTIVE: 
      To determine aspirin use and therapy compliance (never or rarely missing a dose) 
      and to assess whether patients in our community are aware of its anticancer 
      effect. METHODS: Observational study. Prospective data were collected during a 
      1-year period from patients in our general surgical clinic regarding aspirin use, 
      comorbidities, adverse effects, and awareness of anticancer effect. Statistical 
      analysis was performed. RESULTS: Among aspirin users (n = 137), the mean age was 
      65.8 years. Most (76.6%) received an 81-mg daily dose of aspirin. Compliance was 
      25.6% and was significantly associated with diabetes mellitus (p = 0.0028). Only 
      9.5% were aware of the medication's anticancer effect. Among nonusers (n = 383), 
      the mean age was 53.3 years, a significant difference vs that of aspirin users (p 
      < 0.001). Only 4.7% of nonusers knew of the anticancer effect. Nonusers were more 
      likely to be women (p = 0.0005), younger than age 40 years (p < 0.0001), and have 
      comorbidities or polypharmacy (p = 0.002). No significant difference was found 
      between groups in anticoagulants use, nonsteroidal anti-inflammatory drug use, 
      and smoking. CONCLUSION: Knowledge of aspirin's anticancer effect is low. More 
      research is required to understand why aspirin compliance is also low.
FAU - Ranger, Gurpreet Singh
AU  - Ranger GS
AD  - Department of Surgery, Upper River Valley Hospital, Waterville, New Brunswick, 
      Canada.
AD  - Mount Allison University, Faculty of Science, Sackville, New Brunswick, Canada.
FAU - McKinley-Brown, Cindy
AU  - McKinley-Brown C
AD  - Department of Surgery, Upper River Valley Hospital, Waterville, New Brunswick, 
      Canada.
FAU - Rogerson, Emma
AU  - Rogerson E
AD  - Mount Allison University, Faculty of Science, Sackville, New Brunswick, Canada.
FAU - Schimp-Manuel, Krystal
AU  - Schimp-Manuel K
AD  - Department of Surgery, Upper River Valley Hospital, Waterville, New Brunswick, 
      Canada.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20191218
PL  - United States
TA  - Perm J
JT  - The Permanente journal
JID - 9800474
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Colorectal Neoplasms/*prevention & control
MH  - Comorbidity
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Polypharmacy
MH  - Prospective Studies
MH  - Sex Factors
MH  - Young Adult
PMC - PMC6972634
COIS- Disclosure Statement The author(s) have no conflicts of interest to disclose.
EDAT- 2020/01/07 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/01/07 06:00
PHST- 2020/01/07 06:00 [entrez]
PHST- 2020/01/07 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
AID - 19.116 [pii]
AID - 10.7812/TPP/19.116 [doi]
PST - ppublish
SO  - Perm J. 2020;24:19.116. doi: 10.7812/TPP/19.116. Epub 2019 Dec 18.

PMID- 15071257
OWN - NLM
STAT- MEDLINE
DCOM- 20040826
LR  - 20131121
IS  - 1385-2264 (Print)
IS  - 1385-2264 (Linking)
VI  - 7
IP  - 4
DP  - 2003 Dec
TI  - Aspirin--anticoagulant combination in patients with non valvular atrial 
      fibrillation commentary on the FFAACS study results.
PG  - 372-3
AB  - The prevention of the thromboembolic complications of chronic atrial fibrillation 
      remains a therapeutic challenge because they cannot be completely suppressed by 
      vitamin K antagonists with a target international normalized ratio between 2 and 
      3. Evaluation of the combination at that international normalized ratio level 
      with antiplatelet therapy was the aim of the placebo-controlled double-blind 
      Fluindione Fibrillation Auriculaire, Aspirine et Contraste Spontané (FFAACS) 
      study with fluindione (as anticoagulant) and aspirin (100 mg) in patients with 
      chronic atrial fibrillation at high risk of thromboembolic complications. The 
      study was prematurely stopped because of insufficient recruitment rate resulting 
      in very low power. An increase of minor bleeding complications was observed in 
      the combination arm. Given these preliminary results, this combination cannot be 
      recommended in such patients. The question remains with respect to antithrombotic 
      therapy in patients with atrial fibrillation if the risk of severe bleeding 
      complications outweighs the benefit of avoiding ischemic stroke.
FAU - Lechat, Philippe P
AU  - Lechat PP
AD  - Pharmacology Department, Hôpital Pitié-Salpêtrière, Paris, France. 
      philippe.lechat@psl.ap-hop-paris.fr
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Card Electrophysiol Rev
JT  - Cardiac electrophysiology review
JID - 9708907
RN  - 0 (Anticoagulants)
RN  - 5M7Y6274ZE (Phenindione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Phenindione/*analogs & derivatives
MH  - Thromboembolism/etiology/*prevention & control
MH  - Thrombolytic Therapy
RF  - 9
EDAT- 2004/04/09 05:00
MHDA- 2004/08/27 05:00
CRDT- 2004/04/09 05:00
PHST- 2004/04/09 05:00 [pubmed]
PHST- 2004/08/27 05:00 [medline]
PHST- 2004/04/09 05:00 [entrez]
AID - 5257228 [pii]
AID - 10.1023/B:CEPR.0000023142.88884.d8 [doi]
PST - ppublish
SO  - Card Electrophysiol Rev. 2003 Dec;7(4):372-3. doi: 
      10.1023/B:CEPR.0000023142.88884.d8.

PMID- 17622365
OWN - NLM
STAT- MEDLINE
DCOM- 20070801
LR  - 20181227
IS  - 0730-2347 (Print)
IS  - 0730-2347 (Linking)
VI  - 34
IP  - 2
DP  - 2007
TI  - The discovery of aspirin's antithrombotic effects.
PG  - 179-86
AB  - Aspirin has long been established as a useful analgesic and antipyretic. Even in 
      ancient times, salicylate-containing plants such as the willow were commonly used 
      to relieve pain and fever. In the 20th century, scientists discovered many 
      details of aspirin's anti-inflammatory and analgesic properties, including its 
      molecular mechanism of action. In addition, the latter half of the century 
      brought reports that daily, low doses of aspirin could prevent myocardial 
      infarction and stroke. This finding was first reported by Lawrence Craven, a 
      suburban general practitioner in Glendale, California. Unfortunately, Craven's 
      work went largely unnoticed, and decades passed before his observations were 
      verified by clinical trial. We present Craven's story, which demonstrates the 
      value of a single physician's commitment to lifelong learning. In addition, we 
      summarize the work of the physicians and scientists who discovered the molecular 
      mechanisms by which aspirin exerts its antiplatelet effects. Collectively, these 
      discoveries exemplify the complementary roles of basic science and clinical 
      observation in advancing medicine.
FAU - Miner, Jonathan
AU  - Miner J
AD  - University of Oklahoma College of Medicine and Oklahoma Medical Research 
      Foundation, Oklahoma City, Oklahoma 73104, USA. jonathan-miner@ouhsc.edu
FAU - Hoffhines, Adam
AU  - Hoffhines A
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Tex Heart Inst J
JT  - Texas Heart Institute journal
JID - 8214622
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Tex Heart Inst J. 2007;34(3):392. PMID: 17948099
CIN - Tex Heart Inst J. 2007;34(3):392-3. PMID: 17948100
MH  - Animals
MH  - Aspirin/*history/therapeutic use
MH  - Awards and Prizes
MH  - California
MH  - Fibrinolytic Agents/*history/therapeutic use
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Myocardial Infarction/*history/prevention & control
MH  - Platelet Aggregation Inhibitors/*history/therapeutic use
MH  - Stroke/*history/prevention & control
PS  - Craven L
FPS - Craven, Lawrence
PMC - PMC1894700
EDAT- 2007/07/12 09:00
MHDA- 2007/08/02 09:00
CRDT- 2007/07/12 09:00
PHST- 2007/07/12 09:00 [pubmed]
PHST- 2007/08/02 09:00 [medline]
PHST- 2007/07/12 09:00 [entrez]
AID - 0010801-200706000-00010 [pii]
PST - ppublish
SO  - Tex Heart Inst J. 2007;34(2):179-86.

PMID- 36592127
OWN - NLM
STAT- MEDLINE
DCOM- 20230116
LR  - 20230223
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
VI  - 164
IP  - 3
DP  - 2023 Jan 9
TI  - Aspirin Suppresses Hepatic Glucagon Signaling Through Decreasing Production of 
      Thromboxane A2.
LID - bqac217 [pii]
LID - 10.1210/endocr/bqac217 [doi]
AB  - Excessive hepatic glucose production (HGP) is a major cause of fasting 
      hyperglycemia in diabetes, and antihyperglycemic therapy takes center stage. 
      Nonsteroidal anti-inflammatory drugs, such as acetylsalicylic acid (aspirin), 
      reduce hyperglycemia caused by unrestrained gluconeogenesis in diabetes, but its 
      mechanism is incompletely understood. Here, we reported that aspirin lowers 
      fasting blood glucose and hepatic gluconeogenesis, corresponds with lower 
      thromboxane A2 (TXA2) levels, and the hypoglycemic effect of aspirin could be 
      rescued by TP agonist treatment. On fasting and diabetes stress, the 
      cyclooxygenase (COX)/TXA2/thromboxane A2 receptor (TP) axis was increased in the 
      livers. TP deficiency suppressed starvation-induced hepatic glucose output, thus 
      inhibiting the progression of diabetes, whereas TP activation promoted 
      gluconeogenesis. Aspirin restrains glucagon signaling and gluconeogenic gene 
      expression (phosphoenolpyruvate carboxykinase [PCK1] and glucose-6-phosphatase 
      [G6Pase]) through the TXA2/TP axis. TP mediates hepatic gluconeogenesis by 
      activating PLC/IP3/IP3R signaling, which subsequently enhances CREB 
      phosphorylation via facilitating CRTC2 nuclear translocation. Thus, our findings 
      demonstrate that TXA2/TP plays a crucial role in aspirin's inhibition of hepatic 
      glucose metabolism, and TP may represent a therapeutic target for diabetes.
CI  - © The Author(s) 2023. Published by Oxford University Press on behalf of the 
      Endocrine Society. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Dai, Yufeng
AU  - Dai Y
AUID- ORCID: 0000-0002-6598-8203
AD  - State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 
      Jiangsu 214122, China.
AD  - School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, 
      China.
FAU - Xu, Ruijie
AU  - Xu R
AD  - State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 
      Jiangsu 214122, China.
AD  - School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, 
      China.
FAU - Wu, Guanglu
AU  - Wu G
AD  - State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 
      Jiangsu 214122, China.
AD  - School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, 
      China.
FAU - Yin, Zihao
AU  - Yin Z
AD  - State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 
      Jiangsu 214122, China.
AD  - School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, 
      China.
FAU - Zhang, Hao
AU  - Zhang H
AD  - State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 
      Jiangsu 214122, China.
AD  - School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, 
      China.
AD  - National Engineering Research Center for Functional Food, Jiangnan University, 
      Wuxi, Jiangsu 214122, China.
FAU - Li, Haitao
AU  - Li H
AUID- ORCID: 0000-0002-1493-8679
AD  - State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 
      Jiangsu 214122, China.
AD  - School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, 
      China.
FAU - Chen, Wei
AU  - Chen W
AD  - State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 
      Jiangsu 214122, China.
AD  - School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, 
      China.
AD  - National Engineering Research Center for Functional Food, Jiangnan University, 
      Wuxi, Jiangsu 214122, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
RN  - 9007-92-5 (Glucagon)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
RN  - IY9XDZ35W2 (Glucose)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
CIN - Endocrinology. 2023 Feb 21;:. PMID: 36809391
MH  - Humans
MH  - Glucagon/metabolism
MH  - Thromboxane A2/metabolism
MH  - Aspirin/pharmacology/metabolism
MH  - Liver/metabolism
MH  - Glucose/metabolism
MH  - Gluconeogenesis
MH  - *Diabetes Mellitus/metabolism
MH  - Hypoglycemic Agents
MH  - *Hyperglycemia/metabolism
OTO - NOTNLM
OT  - COX
OT  - CREB
OT  - TXA2/TP
OT  - aspirin
OT  - diabetes
OT  - hepatic gluconeogenesis
EDAT- 2023/01/03 06:00
MHDA- 2023/01/17 06:00
CRDT- 2023/01/02 09:43
PHST- 2022/11/08 00:00 [received]
PHST- 2023/01/03 06:00 [pubmed]
PHST- 2023/01/17 06:00 [medline]
PHST- 2023/01/02 09:43 [entrez]
AID - 6967064 [pii]
AID - 10.1210/endocr/bqac217 [doi]
PST - ppublish
SO  - Endocrinology. 2023 Jan 9;164(3):bqac217. doi: 10.1210/endocr/bqac217.

PMID- 30406348
OWN - NLM
STAT- MEDLINE
DCOM- 20190219
LR  - 20200225
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 47
IP  - 1
DP  - 2019 Jan
TI  - A narrative review of the cardiovascular risks associated with concomitant 
      aspirin and NSAID use.
PG  - 16-30
LID - 10.1007/s11239-018-1764-5 [doi]
AB  - The concomitant use of low-dose aspirin for cardioprotection and non-steroidal 
      anti-inflammatory agents for pain relief is prevalent, particularly in the 
      elderly for whom cardiovascular disease and pain are common co-morbidities. 
      Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) are known to 
      interfere with the antiplatelet effect of aspirin through competitive binding 
      with COX-1. While the clinical significance of this interference is still 
      unclear, this review sought to assess the body of literature which has evaluated 
      the potential attenuation of the anti-platelet effect of aspirin when dosed 
      concomitantly with an NSAID. This review supports that the pharmacodynamic 
      interaction between aspirin and non-selective NSAIDs occurs, but finds that the 
      interaction varies amongst agents, and is highly dependent on numerous factors 
      including: dose timing, dose of aspirin, and dose of the NSAID in question. 
      Recent findings suggest that patient factors, such as body weight may also be 
      indicators of aspirin's cardiovascular effectiveness. Ultimately, the clinical 
      decision making for concomitant NSAID and low-dose aspirin regimens remains at 
      the patient level.
FAU - Gurbel, Paul
AU  - Gurbel P
AD  - Inova Center for Thrombosis Research and Drug Development, Inova Heart and 
      Vascular Institute, 3300 Gallows Road, Falls Church, VA, 22042, USA. 
      paul.gurbel@inova.org.
FAU - Tantry, Udaya
AU  - Tantry U
AD  - Platelet and Thrombosis Research, LLC, Lutherville, MD, USA.
FAU - Weisman, Steven
AU  - Weisman S
AD  - Innovative Science Solutions, LLC, Morristown, NJ, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*etiology
MH  - Drug Interactions
MH  - Drug Therapy, Combination/*adverse effects
MH  - Humans
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Cyclooxygenase-1
OT  - Non-steroidal anti-inflammatory drugs
EDAT- 2018/11/09 06:00
MHDA- 2019/03/21 06:00
CRDT- 2018/11/09 06:00
PHST- 2018/11/09 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
PHST- 2018/11/09 06:00 [entrez]
AID - 10.1007/s11239-018-1764-5 [pii]
AID - 10.1007/s11239-018-1764-5 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2019 Jan;47(1):16-30. doi: 10.1007/s11239-018-1764-5.

PMID- 19679423
OWN - NLM
STAT- MEDLINE
DCOM- 20091221
LR  - 20131121
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Linking)
VI  - 50
IP  - 6
DP  - 2009 Dec
TI  - Current evidence and clinical implications of aspirin resistance.
PG  - 1500-10
LID - 10.1016/j.jvs.2009.06.023 [doi]
AB  - Atherothrombosis, characterized by atherosclerotic plaque rupture and subsequent 
      occlusive or subocclusive thrombus formation is the primary cause of acute 
      ischemic syndromes involving all vascular beds and accounts for more than 
      one-third of all deaths in the developed world. Platelet activation and 
      aggregation constitute the most critical component in the pathophysiology of 
      atherothrombotic disease. Aspirin is currently the most commonly used 
      antiplatelet agent and one of the most frequently prescribed drugs, with as many 
      as 30 million Americans on chronic aspirin regimens. Multiple well-designed 
      prospective randomized clinical trials have demonstrated aspirin's efficacy in 
      both primary and secondary prevention of a wide variety of entities that the 
      atherothrombotic disease spectrum encompasses, such as cerebrovascular, coronary 
      artery, and peripheral vascular disease. Despite its proven benefit, however, a 
      growing body of evidence suggests that up to 70% of aspirin-takers may still be 
      at risk for atherothrombotic complications due to resistance. Patients with 
      laboratory-confirmed aspirin resistance seem to have an almost fourfold increase 
      in their risk for acute thrombotic episodes, which underlines the magnitude of 
      the problem for the vascular specialist. In this article, we review the 
      physiology of platelet activation and the role of aspirin as an antiplatelet 
      agent; the various laboratory assays used in assessing aspirin effectiveness; and 
      current data on aspirin resistance and its clinical implications in patients with 
      cardiovascular disease. We also review the studies that explore this phenomenon 
      in patients with peripheral arterial disease and discuss the optimal management 
      options in aspirin-resistant individuals. Suggestions are advanced for the 
      direction of future trials evaluating aspirin resistance in patients with 
      vascular disease.
FAU - Kasotakis, George
AU  - Kasotakis G
AD  - Department Surgery, Creighton University Medical Center, Omaha, Neb, USA.
FAU - Pipinos, Iraklis I
AU  - Pipinos II
FAU - Lynch, Thomas G
AU  - Lynch TG
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20090812
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/history/*therapeutic use
MH  - Bleeding Time
MH  - Cardiovascular Diseases/blood/*drug therapy/surgery
MH  - *Drug Resistance
MH  - Evidence-Based Medicine
MH  - Fibrinolytic Agents/history/*therapeutic use
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, Ancient
MH  - Humans
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/history/*therapeutic use
MH  - Platelet Function Tests
MH  - Predictive Value of Tests
MH  - Vascular Surgical Procedures/adverse effects
RF  - 114
EDAT- 2009/08/15 09:00
MHDA- 2009/12/22 06:00
CRDT- 2009/08/15 09:00
PHST- 2009/03/20 00:00 [received]
PHST- 2009/06/11 00:00 [revised]
PHST- 2009/06/14 00:00 [accepted]
PHST- 2009/08/15 09:00 [entrez]
PHST- 2009/08/15 09:00 [pubmed]
PHST- 2009/12/22 06:00 [medline]
AID - S0741-5214(09)01334-2 [pii]
AID - 10.1016/j.jvs.2009.06.023 [doi]
PST - ppublish
SO  - J Vasc Surg. 2009 Dec;50(6):1500-10. doi: 10.1016/j.jvs.2009.06.023. Epub 2009 
      Aug 12.

PMID- 12106797
OWN - NLM
STAT- MEDLINE
DCOM- 20021213
LR  - 20220321
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 447
IP  - 1
DP  - 2002 Jun 28
TI  - Anti-inflammatory effects of aspirin and sodium salicylate.
PG  - 1-9
AB  - Aspirin (acetylsalicylic acid) is one of the most widely used drugs worldwide. It 
      acetylates cyclooxygenases thereby irreversibly blocking the conversion of 
      arachidonic acid to prostanoids. Biotransformation of aspirin yields salicylate, 
      a compound that possesses similar anti-inflammatory potency as aspirin but lacks 
      aspirin's inhibitory effect on the activity of isolated cyclooxygenase. This 
      article is aimed at providing an overview about the often conflicting results 
      concerning the mechanisms of action of aspirin and sodium salicylate. At present, 
      there is no common agreement about the extent to which salicylate contributes to 
      aspirin's anti-inflammatory properties, as well as there is still no final 
      conclusion reached about the mechanisms of action of sodium salicylate. Several 
      possible sites of action of salicylate have been suggested: It has been shown 
      that in intact cells-but not in purified enzyme preparations-, sodium salicylate 
      inhibits prostanoid biosynthesis. This effect seems to be prevented in the 
      presence of high concentrations of arachidonic acid, which has been shown to 
      interfere with inhibition by salicylate of cyclooxygenase-2-mediated prostanoid 
      formation in vitro. Other possible sites of action that are not directly related 
      to cyclooxygenase inhibition have been suggested based on observations made in 
      vitro using high concentrations of aspirin and sodium salicylate. These effects 
      target intracellular signaling mechanisms such as kinases, including the mitogen 
      activated protein-kinases (MAPK) cascade. With the exception of reported 
      salicylate-induced activation of p38 MAPK, observed effects are usually 
      inhibitory. This may be one reason for the observation that, downstream to 
      kinases, inhibitory effects of salicylates have been observed on several nuclear 
      transcription factors, such as nuclear transcription factor kappa B (NF-kB) or 
      activator protein 1 (AP-1). Several reports have also shown interference by 
      salicylates with the expression of cyclooxygenase-2, which, depending on 
      experimental models, can be observed as inhibitory but also stimulatory effects. 
      Antioxidant properties of salicylates, adenosine release induced by sodium 
      salicylate and aspirin-triggered lipoxin formation are additional mechanisms that 
      may contribute to anti-inflammatory properties of aspirin and/or sodium 
      salicylate. An additional focus of this review is the discussion of interactions 
      between aspirin, sodium salicylate and other non-steroidal anti-inflammatory 
      drugs (NSAIDs), which are of particular relevance in the gastro-intestinal and 
      cardiovascular systems.
FAU - Amann, Rainer
AU  - Amann R
AD  - Institute for Experimental and Clinical Pharmacology, University of Graz, 
      Univ.-Platz 4, A-8010, Graz, Austria. rainer.aann@uni-graz.at
FAU - Peskar, Bernhard A
AU  - Peskar BA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology
MH  - Antioxidants/pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Cardiovascular System/drug effects
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Digestive System/drug effects
MH  - Drug Interactions
MH  - Humans
MH  - Signal Transduction/drug effects
MH  - Sodium Salicylate/*pharmacology
RF  - 106
EDAT- 2002/07/11 10:00
MHDA- 2002/12/17 04:00
CRDT- 2002/07/11 10:00
PHST- 2002/07/11 10:00 [pubmed]
PHST- 2002/12/17 04:00 [medline]
PHST- 2002/07/11 10:00 [entrez]
AID - S0014299902018289 [pii]
AID - 10.1016/s0014-2999(02)01828-9 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2002 Jun 28;447(1):1-9. doi: 10.1016/s0014-2999(02)01828-9.

PMID- 35908144
OWN - NLM
STAT- MEDLINE
DCOM- 20221102
LR  - 20221128
IS  - 2629-3277 (Electronic)
IS  - 2629-3277 (Linking)
VI  - 18
IP  - 8
DP  - 2022 Dec
TI  - Aspirin-Mediated Reset of Preeclamptic Placental Stem Cell Transcriptome - 
      Implication for Stabilized Placental Function.
PG  - 3066-3082
LID - 10.1007/s12015-022-10419-8 [doi]
AB  - Preeclampsia (PE) is a pregnancy-specific disease, occurring in ~ 2-10% of all 
      pregnancies. PE is associated with increased maternal and perinatal morbidity and 
      mortality, hypertension, proteinuria, disrupted artery remodeling, placental 
      ischemia and reperfusion, and inflammation. The mechanism of PE pathogenesis 
      remains unresolved explaining limited treatment. Aspirin is used to reduce the 
      risk of developing PE. This study investigated aspirin's effect on PE-derived 
      placenta mesenchymal stem cells (P-MSCs). P-MSCs from chorionic membrane (CM), 
      chorionic villi, membranes from the maternal and amniotic regions, and umbilical 
      cord were similar in morphology, phenotype and multipotency. Since CM-derived 
      P-MSCs could undergo long-term passages, the experimental studies were conducted 
      with this source of P-MSCs. Aspirin (1 mM) induced significant functional and 
      transcriptomic changes in PE-derived P-MSCs, similar to healthy P-MSCs. These 
      include cell cycle quiescence, improved angiogenic pathways, and immune 
      suppressor potential. The latter indicated that aspirin could induce an indirect 
      program to mitigate PE-associated inflammation. As a mediator of activating the 
      DNA repair program, aspirin increased p53, and upregulated genes within the basic 
      excision repair pathway. The robust ability for P-MSCs to maintain its function 
      with high dose aspirin contrasted bone marrow (M) MSCs, which differentiated with 
      eventual senescence/aging with 100 fold less aspirin. This difference cautions 
      how data from other MSC sources are extrapolated to evaluate PE pathogenesis. 
      Dysfunction among P-MSCs in PE involves a network of multiple pathways that can 
      be restored to an almost healthy functional P-MSC. The findings could lead to 
      targeted treatment for PE.
CI  - © 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Romagano, Matthew P
AU  - Romagano MP
AD  - Department of Obstetrics, Gynecology and Reproductive Health, D-Maternal Fetal 
      Medicine, Rutgers New Jersey Medical School, Newark, NJ, 07103, USA.
FAU - Sherman, Lauren S
AU  - Sherman LS
AD  - Department of Medicine-Hematology/Oncology, Rutgers New Jersey Medical School, 
      Newark, NJ, USA.
AD  - Rutgers School of Graduate Studies at New Jersey Medical School, Newark, NJ, USA.
FAU - Shadpoor, Bobak
AU  - Shadpoor B
AD  - Department of Medicine-Hematology/Oncology, Rutgers New Jersey Medical School, 
      Newark, NJ, USA.
AD  - Rutgers School of Graduate Studies at New Jersey Medical School, Newark, NJ, USA.
FAU - El-Far, Markos
AU  - El-Far M
AD  - Rutgers School of Graduate Studies at New Jersey Medical School, Newark, NJ, USA.
FAU - Souayah, Sami
AU  - Souayah S
AD  - Department of Medicine-Hematology/Oncology, Rutgers New Jersey Medical School, 
      Newark, NJ, USA.
FAU - Pamarthi, Sri Harika
AU  - Pamarthi SH
AD  - Department of Medicine-Hematology/Oncology, Rutgers New Jersey Medical School, 
      Newark, NJ, USA.
FAU - Kra, Joshua
AU  - Kra J
AD  - Department of Medicine-Hematology/Oncology, Rutgers New Jersey Medical School, 
      Newark, NJ, USA.
AD  - Rutgers Cancer Institute of New Jersey, Newark, NJ, USA.
FAU - Hood-Nehra, Anupama
AU  - Hood-Nehra A
AD  - Department of Medicine-Hematology/Oncology, Rutgers New Jersey Medical School, 
      Newark, NJ, USA.
AD  - Rutgers Cancer Institute of New Jersey, Newark, NJ, USA.
FAU - Etchegaray, Jean-Pierre
AU  - Etchegaray JP
AD  - Department of Biology, Rutgers University, Newark, NJ, USA.
FAU - Williams, Shauna F
AU  - Williams SF
AD  - Department of Obstetrics, Gynecology and Reproductive Health, D-Maternal Fetal 
      Medicine, Rutgers New Jersey Medical School, Newark, NJ, 07103, USA. 
      williash@njms.rutgers.edu.
FAU - Rameshwar, Pranela
AU  - Rameshwar P
AUID- ORCID: 0000-0003-0434-9034
AD  - Department of Medicine-Hematology/Oncology, Rutgers New Jersey Medical School, 
      Newark, NJ, USA. rameshwa@njms.rutgers.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220731
PL  - United States
TA  - Stem Cell Rev Rep
JT  - Stem cell reviews and reports
JID - 101752767
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Female
MH  - Pregnancy
MH  - *Pre-Eclampsia/genetics/metabolism
MH  - Placenta
MH  - Transcriptome/genetics
MH  - *Mesenchymal Stem Cells
MH  - Aspirin/pharmacology/metabolism
MH  - Stem Cells
MH  - Inflammation/metabolism
OTO - NOTNLM
OT  - Angiogenesis
OT  - Aspirin
OT  - Basic excision repair
OT  - Bone marrow
OT  - Inflammation
OT  - Preclampsia
OT  - Stem cell
EDAT- 2022/07/31 06:00
MHDA- 2022/11/03 06:00
CRDT- 2022/07/30 23:40
PHST- 2022/06/23 00:00 [accepted]
PHST- 2022/07/31 06:00 [pubmed]
PHST- 2022/11/03 06:00 [medline]
PHST- 2022/07/30 23:40 [entrez]
AID - 10.1007/s12015-022-10419-8 [pii]
AID - 10.1007/s12015-022-10419-8 [doi]
PST - ppublish
SO  - Stem Cell Rev Rep. 2022 Dec;18(8):3066-3082. doi: 10.1007/s12015-022-10419-8. 
      Epub 2022 Jul 31.

PMID- 2282348
OWN - NLM
STAT- MEDLINE
DCOM- 19910315
LR  - 20191029
IS  - 0894-1939 (Print)
IS  - 0894-1939 (Linking)
VI  - 3
IP  - 1
DP  - 1990
TI  - The effect of prolonged aspirin therapy on experimental balloon-catheter arterial 
      wall injury.
PG  - 5-10
AB  - Indications for aspirin following percutaneous transluminal angioplasty are not 
      well defined. Although aspirin's early antithrombotic effect is believed to be 
      beneficial, the long-term influence of aspirin on myointimal proliferative 
      response following balloon-catheter angioplasty is still being investigated. This 
      study quantitates arterial wall thickening, including intimal hyperplasia, at 4 
      months following balloon-catheter aortic injury in New Zealand white rabbits (n = 
      12), comparing aspirin treatment (30 mg/kg) with controls. Aspirin was 
      administered daily for 1 month prior and 4 months following aortic injury. 
      Myointimal proliferation was noted in both groups. The mean area of the intima 
      and media as well as the maximum thickness of the intima were similar (p greater 
      than .05) in both the aspirin treatment and control groups. Cellular hyperplasia 
      was evaluated by media smooth muscle cell counts using an ocular reticle. There 
      was a trend toward higher cell counts with aspirin treatment, although there was 
      no significant difference between the two groups. Prolonged aspirin therapy did 
      not alter the degree of myointimal hyperplasia at 4 months postinjury in our 
      model.
FAU - Yeager, R A
AU  - Yeager RA
AD  - Surgical Service, Veterans Administration Medical Center Portland, OR 97207.
FAU - Trune, D R
AU  - Trune DR
FAU - Jacobson, S
AU  - Jacobson S
FAU - Connell, R S
AU  - Connell RS
FAU - Galey, W T
AU  - Galey WT
FAU - Shoemake, R G
AU  - Shoemake RG
FAU - Vetto, R M
AU  - Vetto RM
LA  - eng
GR  - S07 RR05412/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - J Invest Surg
JT  - Journal of investigative surgery : the official journal of the Academy of 
      Surgical Research
JID - 8809255
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta, Abdominal/*injuries/pathology/surgery
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Catheterization/*adverse effects
MH  - Hyperplasia
MH  - Male
MH  - Rabbits
RF  - 31
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.3109/08941939009140331 [doi]
PST - ppublish
SO  - J Invest Surg. 1990;3(1):5-10. doi: 10.3109/08941939009140331.

PMID- 17209500
OWN - NLM
STAT- MEDLINE
DCOM- 20070621
LR  - 20150826
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 61
IP  - 10
DP  - 2006 Oct
TI  - [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: 
      focus on gender difference and insulin resistance].
PG  - 682-90
AB  - Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the 
      primary and secondary prevention of cardiovascular diseases. However, the effects 
      appear to be different according to the studied population, with a reduction of 
      coronary events in men and, rather, a diminution of strokes in women. Diabetes 
      mellitus markedly increases the risk of cardiovascular diseases, with an 
      especially elevated relative risk among women. We present a detailed analysis of 
      the literature about the efficacy of aspirin in the primary prevention of 
      cardiovascular complications in the diabetic population. Limited available data 
      suggest a lower protection in the diabetic than in the non-diabetic population. A 
      greater aspirin resistance has been suggested in diabetic patents, which might 
      lead to the use of a higher daily dosage of aspirin in diabetic than in non 
      diabetic patients. Whatsoever, aspirin remains the first antiplatelet agent in 
      the diabetic population in all international guidelines of cardiovascular 
      prevention.
FAU - Legrand, D A
AU  - Legrand DA
AD  - Université de Liège, Belgique.
FAU - Scheen, A J
AU  - Scheen AJ
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - L'aspirine en prévention primaire des maladies cardio-vasculaires chez le patient 
      diabétique.
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*metabolism/*prevention & control
MH  - Diabetes Complications/*metabolism/*prevention & control
MH  - Female
MH  - Humans
MH  - *Insulin Resistance
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Sex Factors
RF  - 44
EDAT- 2007/01/11 09:00
MHDA- 2007/06/22 09:00
CRDT- 2007/01/11 09:00
PHST- 2007/01/11 09:00 [pubmed]
PHST- 2007/06/22 09:00 [medline]
PHST- 2007/01/11 09:00 [entrez]
PST - ppublish
SO  - Rev Med Liege. 2006 Oct;61(10):682-90.

PMID- 6344623
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 74
IP  - 6A
DP  - 1983 Jun 14
TI  - The biologic background to some therapeutic uses of aspirin.
PG  - 2-9
AB  - The therapeutic success of aspirin as an effective analgesic, antipyretic, and 
      anti-inflammatory drug had been universally established for many decades before 
      its mode of action was discovered in 1971. This mode of action is the prevention, 
      or diminution, of prostaglandin biosynthesis through the inhibition of the 
      enzyme, cyclo-oxygenase. Demonstrations of the major contributions of 
      prostaglandins to pain, fever, and other cardinal features of inflammation 
      provided rational explanations for the well-established therapeutic uses of 
      aspirin. It had been shown earlier that aspirin antagonized two mediators of 
      inflammation by an indirect process. While aspirin's mode of action was being 
      discovered, research on platelets in hemostasis and thrombosis was also being 
      done. It was shown that aspirin inhibited an exocytotic reaction (the release 
      reaction) of platelets. This reaction was regarded as essential for their 
      aggregation as thrombi in, most importantly, coronary and cerebral arteries. This 
      observation was the starting point of an enormous effort, still going on to 
      determine through both fundamental and clinical investigations, the therapeutic 
      potential of aspirin as an antithrombotic drug. Costly clinical trials have 
      provided evidence in favor of aspirin preventing thrombotic events affecting the 
      brain; its effectiveness against coronary thrombosis is not yet definitely 
      established. Possible explanations for this situation will be considered on the 
      basis of rapidly advancing biologic knowledge about the mechanism of thrombosis.
FAU - Born, G V
AU  - Born GV
FAU - Görög, P
AU  - Görög P
FAU - Begent, N A
AU  - Begent NA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arterial Occlusive Diseases/blood/drug therapy
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Carotid Artery Diseases/blood/drug therapy
MH  - Coronary Disease/blood/drug therapy
MH  - Humans
MH  - Inflammation/metabolism
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandins/biosynthesis
MH  - Thrombosis/blood/drug therapy
RF  - 45
EDAT- 1983/06/14 00:00
MHDA- 1983/06/14 00:01
CRDT- 1983/06/14 00:00
PHST- 1983/06/14 00:00 [pubmed]
PHST- 1983/06/14 00:01 [medline]
PHST- 1983/06/14 00:00 [entrez]
AID - 0002-9343(83)90522-3 [pii]
AID - 10.1016/0002-9343(83)90522-3 [doi]
PST - ppublish
SO  - Am J Med. 1983 Jun 14;74(6A):2-9. doi: 10.1016/0002-9343(83)90522-3.

PMID- 19110389
OWN - NLM
STAT- MEDLINE
DCOM- 20090424
LR  - 20181201
IS  - 0398-0499 (Print)
IS  - 0398-0499 (Linking)
VI  - 34
IP  - 1
DP  - 2009 Feb
TI  - [Variable platelet response to aspirin and new therapeutic targets].
PG  - 16-25
LID - 10.1016/j.jmv.2008.10.009 [doi]
AB  - Aspirin is the first-line oral antiplatelet drug to prevent thromboembolic 
      arterial occlusions. Aspirin irreversibly inhibits cyclooxygenase (COX) 1 
      involved in the platelet production of thromboxane (TX) A(2), an inducer of 
      vasoconstriction and a platelet activating agent. Recurrent vascular events 
      despite aspirin intake, combined with laboratory evidence of poor antiplatelet 
      effect, suggested what has been called "aspirin resistance". For clarity's sake a 
      real aspirin resistance would be the absence of COX1 inhibition due to intrinsic 
      platelet factors (which has never been reported). What has been described is 
      (expected) variability. COX1 inhibition can be insufficient to modify 
      TX-dependent platelet behaviour. Other agonists, the production of which does not 
      involve COX1, can stimulate TX-receptors. The antiplatelet effect of aspirin can 
      be insufficient for pharmacokinetic or pharmacodynamic reasons, the latter being 
      further classified as TX-dependent or not. If platelets are so reactive that 
      responses are more TX-independent than normally, then neither aspirin nor any 
      drugs acting on this pathway can do the job. These mechanisms should be better 
      understood and diagnosed, and this is the prerequisite for the development of 
      newer antiplatelet agents.
FAU - Richard, S
AU  - Richard S
AD  - Inserm U734 << nouvelles approches antithrombotiques >>, faculté de médecine, 
      université de Nancy, CHU de Nancy, Nancy, France. s.richard@chu-nancy.fr
FAU - Toussaint-Hacquard, M
AU  - Toussaint-Hacquard M
FAU - Lecompte, T
AU  - Lecompte T
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Variabilité de réponse plaquettaire à l'aspirine et nouvelles cibles 
      thérapeutiques.
DEP - 20081224
PL  - France
TA  - J Mal Vasc
JT  - Journal des maladies vasculaires
JID - 7707965
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*pharmacology
MH  - Blood Platelets/drug effects/*physiology
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacology
MH  - Ticlopidine/analogs & derivatives/pharmacology
RF  - 84
EDAT- 2008/12/27 09:00
MHDA- 2009/04/25 09:00
CRDT- 2008/12/27 09:00
PHST- 2008/10/20 00:00 [received]
PHST- 2008/10/30 00:00 [accepted]
PHST- 2008/12/27 09:00 [entrez]
PHST- 2008/12/27 09:00 [pubmed]
PHST- 2009/04/25 09:00 [medline]
AID - S0398-0499(08)00406-X [pii]
AID - 10.1016/j.jmv.2008.10.009 [doi]
PST - ppublish
SO  - J Mal Vasc. 2009 Feb;34(1):16-25. doi: 10.1016/j.jmv.2008.10.009. Epub 2008 Dec 
      24.

PMID- 27064261
OWN - NLM
STAT- MEDLINE
DCOM- 20170427
LR  - 20220408
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 164
IP  - 12
DP  - 2016 Jun 21
TI  - Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic 
      Review for the U.S. Preventive Services Task Force.
PG  - 826-35
LID - 10.7326/M15-2112 [doi]
AB  - BACKGROUND: The balance between potential aspirin-related risks and benefits is 
      critical in primary prevention. PURPOSE: To evaluate the risk for serious 
      bleeding with regular aspirin use in cardiovascular disease (CVD) primary 
      prevention. DATA SOURCES: PubMed, MEDLINE, Cochrane Central Register of 
      Controlled Trials (2010 through 6 January 2015), and relevant references from 
      other reviews. STUDY SELECTION: Randomized, controlled trials; cohort studies; 
      and meta-analyses comparing aspirin with placebo or no treatment to prevent CVD 
      or cancer in adults. DATA EXTRACTION: One investigator abstracted data, another 
      checked for accuracy, and 2 assessed study quality. DATA SYNTHESIS: In CVD 
      primary prevention studies, very-low-dose aspirin use (≤100 mg daily or every 
      other day) increased major gastrointestinal (GI) bleeding risk by 58% (odds ratio 
      [OR], 1.58 [95% CI, 1.29 to 1.95]) and hemorrhagic stroke risk by 27% (OR, 1.27 
      [CI, 0.96 to 1.68]). Projected excess bleeding events with aspirin depend on 
      baseline assumptions. Estimated excess major bleeding events were 1.39 (CI, 0.70 
      to 2.28) for GI bleeding and 0.32 (CI, -0.05 to 0.82) for hemorrhagic stroke per 
      1000 person-years of aspirin exposure using baseline bleeding rates from a 
      community-based observational sample. Such events could be greater among older 
      persons, men, and those with CVD risk factors that also increase bleeding risk. 
      LIMITATIONS: Power to detect effects on hemorrhagic stroke was limited. Harms 
      other than serious bleeding were not examined. CONCLUSION: Consideration of the 
      safety of primary prevention with aspirin requires an individualized assessment 
      of aspirin's effects on bleeding risks and expected benefits because absolute 
      bleeding risk may vary considerably by patient. PRIMARY FUNDING SOURCE: Agency 
      for Healthcare Research and Quality.
FAU - Whitlock, Evelyn P
AU  - Whitlock EP
FAU - Burda, Brittany U
AU  - Burda BU
FAU - Williams, Selvi B
AU  - Williams SB
FAU - Guirguis-Blake, Janelle M
AU  - Guirguis-Blake JM
FAU - Evans, Corinne V
AU  - Evans CV
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20160412
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2016 Aug 16;165(4):JC17. PMID: 27538178
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Fibrinolytic Agents/administration & dosage/*adverse effects
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - *Primary Prevention
MH  - Risk Factors
MH  - Stroke/*chemically induced
EDAT- 2016/04/12 06:00
MHDA- 2017/04/28 06:00
CRDT- 2016/04/12 06:00
PHST- 2016/04/12 06:00 [entrez]
PHST- 2016/04/12 06:00 [pubmed]
PHST- 2017/04/28 06:00 [medline]
AID - 2513175 [pii]
AID - 10.7326/M15-2112 [doi]
PST - ppublish
SO  - Ann Intern Med. 2016 Jun 21;164(12):826-35. doi: 10.7326/M15-2112. Epub 2016 Apr 
      12.

PMID- 15837265
OWN - NLM
STAT- MEDLINE
DCOM- 20050512
LR  - 20141120
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 45
IP  - 8
DP  - 2005 Apr 19
TI  - Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy 
      subjects.
PG  - 1295-301
AB  - OBJECTIVES: We investigated the occurrence of pharmacodynamic interaction between 
      low-dose aspirin and naproxen. BACKGROUND: The uncertainty of cardioprotection by 
      naproxen has encouraged its combination with aspirin in patients with arthritis 
      and cardiovascular disease. METHODS: The incubation of washed platelets with 
      naproxen for 5 min before the addition of aspirin reduced the irreversible 
      inhibition of thromboxane (TX)B(2) production by aspirin. The pharmacodynamic 
      interaction between the two drugs was then investigated in four healthy 
      volunteers who received aspirin (100 mg daily) for 6 days and then the 
      combination of aspirin and naproxen for further 6 days: aspirin 2 h before 
      naproxen (500 mg, twice-daily dosing). After 14 days of washout, naproxen was 
      given 2 h before aspirin for further 6 days. RESULTS: The inhibition of serum 
      TXB(2) production (index of platelet cyclooxygenase [COX]-1 activity) and 
      platelet aggregation ex vivo and urinary 11-dehydro-TXB(2) levels (index of 
      TXB(2) biosynthesis in vivo) by aspirin alone (99 +/- 0.2%, 95 +/- 0.6%, and 81 
      +/- 4%, respectively) was not significantly altered by the co-administration of 
      naproxen, given either 2 h after aspirin or in reverse order. In a second study, 
      the concurrent administration of a single dose of aspirin and naproxen did not 
      affect platelet TXB(2) production and aggregation at 1 h after dosing, when 
      aspirin alone causes maximal inhibitory effect. Moreover, the rapid recovery of 
      platelet COX-1 activity and function supports the occurrence of a pharmacodynamic 
      interaction between naproxen and aspirin. CONCLUSIONS: Naproxen interfered with 
      the inhibitory effect of aspirin on platelet COX-1 activity and function. This 
      pharmacodynamic interaction might undermine the sustained inhibition of platelet 
      COX-1 that is necessary for aspirin's cardioprotective effects.
FAU - Capone, Marta L
AU  - Capone ML
AD  - Department of Medicine and Center of Excellence on Aging, School of Medicine, G. 
      d'Annunzio University, Chieti, Italy.
FAU - Sciulli, Maria G
AU  - Sciulli MG
FAU - Tacconelli, Stefania
AU  - Tacconelli S
FAU - Grana, Marilena
AU  - Grana M
FAU - Ricciotti, Emanuela
AU  - Ricciotti E
FAU - Renda, Giulia
AU  - Renda G
FAU - Di Gregorio, Patrizia
AU  - Di Gregorio P
FAU - Merciaro, Gabriele
AU  - Merciaro G
FAU - Patrignani, Paola
AU  - Patrignani P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Membrane Proteins)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57Y76R9ATQ (Naproxen)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2005 Apr 19;45(8):1302-3. PMID: 15837266
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Arthritis/drug therapy
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Cardiovascular Diseases/drug therapy
MH  - Cyclooxygenase 1
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - In Vitro Techniques
MH  - Membrane Proteins
MH  - Naproxen/*pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandin-Endoperoxide Synthases
MH  - Thromboxane B2/antagonists & inhibitors
RF  - 30
EDAT- 2005/04/20 09:00
MHDA- 2005/05/13 09:00
CRDT- 2005/04/20 09:00
PHST- 2004/10/22 00:00 [received]
PHST- 2004/12/17 00:00 [revised]
PHST- 2005/01/04 00:00 [accepted]
PHST- 2005/04/20 09:00 [pubmed]
PHST- 2005/05/13 09:00 [medline]
PHST- 2005/04/20 09:00 [entrez]
AID - S0735-1097(05)00422-5 [pii]
AID - 10.1016/j.jacc.2005.01.045 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2005 Apr 19;45(8):1295-301. doi: 10.1016/j.jacc.2005.01.045.

PMID- 36847696
OWN - NLM
STAT- MEDLINE
DCOM- 20230301
LR  - 20230304
IS  - 1308-5263 (Electronic)
IS  - 1300-7777 (Print)
IS  - 1300-7777 (Linking)
VI  - 40
IP  - 1
DP  - 2023 Feb 28
TI  - Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover 
      Matter?
PG  - 37-42
LID - 10.4274/tjh.galenos.2023.2022.0452 [doi]
AB  - OBJECTIVE: Platelet aggregation tests and the analysis of thromboxane A2 
      metabolites [serum thromboxane B2 (TXB2) and urine 11-dehydro TXB2] are used to 
      evaluate the efficacy of aspirin. In myeloproliferative neoplasms (MPNs), the 
      immature platelet fraction (IPF) rises due to enhanced platelet turnover, and 
      this has been thought to reduce the efficacy of aspirin. This phenomenon is 
      overcome by the recommendation of aspirin intake in divided doses. We aimed to 
      evaluate aspirin efficacy in patients who were receiving aspirin treatment of 100 
      mg/day. MATERIALS AND METHODS: Thirty-eight MPN patients and 30 control patients 
      (non-MPN patients who received a single daily dose of aspirin at 100 mg for 
      nonhematological conditions) were enrolled. IPF, serum TXB2, and urine 11-dehydro 
      TXB2 levels were measured and aggregation tests with arachidonic acid and 
      adenosine diphosphate were performed by light transmission aggregometry (LTA). 
      RESULTS: Mean IPF and TXB2 levels were higher in the MPN group (p=0.008 and 
      p=0.003, respectively). IPF levels were lower in patients on cytoreductive 
      therapy in the MPN group (p=0.001), but these values were similar between 
      patients on hydroxyurea and the non-MPN group (p=0.72). TXB2 levels did not 
      differ according to hydroxyurea treatment status but were higher in the MPN group 
      compared to non-MPN patients (23.63 ng/mL and 19.78 ng/mL, respectively; p=0.04). 
      TXB2 values were higher in patients with essential thrombocythemia and a history 
      of thrombotic events (p=0.031). No difference was observed in LTA between the MPN 
      and non-MPN patient groups (p=0.513). CONCLUSION: Higher levels of IPF and TXB2 
      in the MPN patient group indicated platelets that could not be inhibited by 
      aspirin. It was observed that patients under cytoreductive therapy had lower IPF 
      values, but the expected decrease in TXB2 levels was not observed. These findings 
      suggest that a lack of response to aspirin may be due to additional intrinsic 
      factors rather than increased platelet turnover.
CI  - ©Copyright 2023 by Turkish Society of Hematology | Turkish Journal of Hematology, 
      Published by Galenos Publishing House.
FAU - Koçak Göktürk, Ilgın
AU  - Koçak Göktürk I
AUID- ORCID: 0000-0001-9193-7541
AD  - İstanbul Medeniyet University Faculty of Medicine, Department of Internal 
      Medicine, İstanbul, Türkiye
FAU - Erdoğan Özünal, Işıl
AU  - Erdoğan Özünal I
AUID- ORCID: 0000-0002-5289-7134
AD  - İstanbul Medeniyet University Faculty of Medicine, Department of Hematology, 
      İstanbul, Türkiye
FAU - Göktürk, Alican
AU  - Göktürk A
AUID- ORCID: 0000-0002-7487-0653
AD  - University of Health Sciences Türkiye, İstanbul Prof. Dr. Cemil Taşçıoğlu City 
      Hospital, Clinic of Family Medicine, İstanbul, Türkiye
FAU - Kaya, Ali Hakan
AU  - Kaya AH
AUID- ORCID: 0000-0003-0496-0984
AD  - Ümraniye Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye
FAU - Yılmaz, Güven
AU  - Yılmaz G
AUID- ORCID: 0000-0001-9972-2537
AD  - University of Health Sciences Türkiye, Kartal Dr. Lütfi Kırdar City Hospital, 
      Clinic of Hematology, İstanbul, Türkiye
FAU - Akay, Olga Meltem
AU  - Akay OM
AUID- ORCID: 0000-0002-6759-1939
AD  - Koç University Hospital, Department of Hematology, İstanbul, Türkiye
FAU - Öztürk, Erman
AU  - Öztürk E
AUID- ORCID: 0000-0002-1559-8047
AD  - İstanbul Medeniyet University Faculty of Medicine, Department of Hematology, 
      İstanbul, Türkiye
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Turk J Haematol
JT  - Turkish journal of haematology : official journal of Turkish Society of 
      Haematology
JID - 9606065
RN  - X6Q56QN5QC (Hydroxyurea)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Hydroxyurea
MH  - *Neoplasms
MH  - *Myeloproliferative Disorders/drug therapy
MH  - Blood Platelets
MH  - Aspirin/pharmacology/therapeutic use
PMC - PMC9979736
OTO - NOTNLM
OT  - Thromboxane B2
OT  - Platelet aggregation
OT  - Platelets
OT  - Arachidonic acid
OT  - Aspirin
COIS- Conflict of Interest: No conflict of interest was declared by the authors.
EDAT- 2023/02/28 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/02/27 10:33
PHST- 2023/02/27 10:33 [entrez]
PHST- 2023/02/28 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
AID - 58770 [pii]
AID - 10.4274/tjh.galenos.2023.2022.0452 [doi]
PST - ppublish
SO  - Turk J Haematol. 2023 Feb 28;40(1):37-42. doi: 
      10.4274/tjh.galenos.2023.2022.0452.

PMID- 10536687
OWN - NLM
STAT- MEDLINE
DCOM- 19991104
LR  - 20190513
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 43
IP  - 1
DP  - 1999 Jul
TI  - New look at myocardial infarction: toward a better aspirin.
PG  - 25-31
AB  - The evidence for the formation of NO and of its oxidation products, as well as of 
      prostacyclin and thromboxane by the infarcted heart muscle is reviewed. The 
      importance of inflammatory cells, primarily macrophages of cardiac origin is 
      documented. Because of its side effects on gastric mucosa and kidney by aspirin, 
      several modifications of aspirin are currently being developed. These are based 
      on eliminating their inflammatory effect by selective inhibition of COX-2, or by 
      attaching an NO-delivering side chain to the aspirin molecule (NO-aspirin), or by 
      combining two preparations, an NO donor with aspirin. NO-aspirins and the 
      combination of an NO-donor with aspirin promise to be beneficial in the early 
      stages of myocardial infarction. Unfortunately, the main beneficial effect of 
      aspirin, that of inhibition of thrombus formation, is also the cause for its most 
      dreaded complication, hemorrhagic stroke. None of the new aspirins is able to 
      prevent this complication.
FAU - Bing, R J
AU  - Bing RJ
AD  - Department of Experimental Cardiology, Huntington Medical Research Institutes, 
      Pasadena, CA, USA.
FAU - Yamamoto, T
AU  - Yamamoto T
FAU - Yamamoto, M
AU  - Yamamoto M
FAU - Kakar, R
AU  - Kakar R
FAU - Cohen, A
AU  - Cohen A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Drug Combinations)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cyclooxygenase Inhibitors/adverse effects/therapeutic use
MH  - Drug Combinations
MH  - Drug Design
MH  - Epoprostenol/metabolism
MH  - Humans
MH  - Macrophages/metabolism
MH  - Myocardial Infarction/immunology/*metabolism/prevention & control
MH  - Myocardium/immunology/*metabolism
MH  - Nitric Oxide/metabolism
MH  - Thromboxane A2/metabolism
RF  - 65
EDAT- 1999/10/28 00:00
MHDA- 1999/10/28 00:01
CRDT- 1999/10/28 00:00
PHST- 1999/10/28 00:00 [pubmed]
PHST- 1999/10/28 00:01 [medline]
PHST- 1999/10/28 00:00 [entrez]
AID - S0008-6363(99)00074-7 [pii]
AID - 10.1016/s0008-6363(99)00074-7 [doi]
PST - ppublish
SO  - Cardiovasc Res. 1999 Jul;43(1):25-31. doi: 10.1016/s0008-6363(99)00074-7.

PMID- 20144820
OWN - NLM
STAT- MEDLINE
DCOM- 20101129
LR  - 20131121
IS  - 1130-6343 (Print)
IS  - 1130-6343 (Linking)
VI  - 34
IP  - 1
DP  - 2010 Jan-Feb
TI  - [Resistance to aspirin: prevalence, mechanisms of action and association with 
      thromboembolic events. A narrative review].
PG  - 32-43
LID - 10.1016/j.farma.2009.08.002 [doi]
AB  - OBJECTIVES: The purpose of this study is to review the prevalence of aspirin 
      resistance in patients with a high risk of cardiovascular events, and secondly, 
      to investigate its epidemiology and mechanism of action, and the clinical 
      consequences it can provoke. MATERIAL AND METHODS: A search was run on PubMed, 
      EMBASE and Reviews Database for English or Spanish articles on aspirin resistance 
      published up to November 2008. Additional studies were obtained by searching the 
      reference lists in the selected articles for articles relevant to our secondary 
      objectives. RESULTS: Aspirin resistance is described as affecting 0 to 57% of the 
      population, and is related to a decreased protective effect against strokes and 
      cardiovascular events. Many modifiable and unmodifiable factors can affect the 
      efficacy of antiplatelet drugs. Possible strategies for overcoming this decreased 
      antiaggregant effect include increasing the aspirin dosage or dual therapy with 
      another antiplatelet agent. CONCLUSIONS: Lack of response to aspirin decreases 
      its protective effects. However, lack of a standard definition for aspirin 
      resistance, the absence of diagnostic reference methods to identify resistant 
      patients, and the different mechanisms of action involved in platelet aggregation 
      call the clinical importance of this fact into question. Additional well-designed 
      studies are needed to detect patients with real resistance in order to have more 
      effective prevention of cardiovascular morbidity and mortality.
CI  - Copyright (c) 2009 SEFH. Published by Elsevier Espana. All rights reserved.
FAU - Cañivano Petreñas, L
AU  - Cañivano Petreñas L
AD  - Servicio de Farmacia, Guy's & St. Thomas Hospital NHS Foundation Trust, Londres, 
      UK. leti-27@hotmail.com
FAU - García Yubero, C
AU  - García Yubero C
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Resistencia a la aspirina: prevalencia, mecanismos de acción y asociación con 
      eventos tromboembólicos. Revisión narrativa.
DEP - 20100125
PL  - Spain
TA  - Farm Hosp
JT  - Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad 
      Espanola de Farmacia Hospitalaria
JID - 9440679
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Prevalence
MH  - Thromboembolism/*etiology
EDAT- 2010/02/11 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/02/11 06:00
PHST- 2009/04/16 00:00 [received]
PHST- 2009/07/30 00:00 [revised]
PHST- 2009/08/07 00:00 [accepted]
PHST- 2010/02/11 06:00 [entrez]
PHST- 2010/02/11 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - S1130-6343(09)00007-5 [pii]
AID - 10.1016/j.farma.2009.08.002 [doi]
PST - ppublish
SO  - Farm Hosp. 2010 Jan-Feb;34(1):32-43. doi: 10.1016/j.farma.2009.08.002. Epub 2010 
      Jan 25.

PMID- 34904537
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20220816
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 33
IP  - 6
DP  - 2022 Aug 18
TI  - Platelet response to aspirin in UK and Irish pregnancy cohorts: a genome-wide 
      approach.
PG  - 911-917
LID - 10.1080/09537104.2021.2007872 [doi]
AB  - A multi-center prospective cross-sectional and genome-wide association study 
      (GWAS) recruited pregnant women taking low dose aspirin. Objectives were to (i) 
      develop pregnancy-specific 95% reference intervals for a range of laboratory 
      based platelet function tests (PFTs); (ii) select an optimal and acceptable PFT 
      that reflected aspirin's COX-1 inhibition in women with confirmed aspirin 
      adherence in pregnancy; and (iii) identify genomic variants that may influence 
      pregnant women's platelet response to aspirin.The study included two independent 
      cohorts of pregnant women. A range of PFTs and matched phenotyping with urinary 
      11-dehydrothromboxane B(2) (11DTXB2) and nuclear magnetic resonance (NMR) 
      spectroscopy detection of urinary salicyluric acid as a measure of aspirin 
      adherence were performed. Genome-wide data was acquired from the UK Biobank 
      Axiom® (Thermo Fisher Scientific). 11DTXB2 in combination with adherence testing 
      with NMR salicyluric acid was an accurate and acceptable testing strategy for 
      detecting biochemical aspirin responsiveness in pregnant women, with the 
      provision of relevant reference ranges. GWAS meta-analysis found no significant 
      single nucleotide polymorphisms in association with response to aspirin in 
      pregnancy. Further evaluation in relation to effective dosing of aspirin in 
      pregnancy and optimizing the benefits to specific subgroups should now be a 
      priority for future research.
FAU - Mone, Fionnuala
AU  - Mone F
AUID- ORCID: 0000-0002-0718-7547
AD  - Centre for Public Health, Queen's University Belfast, Belfast, UK.
FAU - Gupta, Juhi K
AU  - Gupta JK
AD  - Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
FAU - Phelan, Marie M
AU  - Phelan MM
AD  - NMR Centre for Structural Biology, Institute of Integrative Biology & Technology 
      Directorate, University of Liverpool, UK.
FAU - Meher, Shireen
AU  - Meher S
AD  - Fetal Medicine Centre, Birmingham Women's and Children's NHS Foundation Trust, 
      Birmingham, UK.
AD  - Centre for Women's Health Research, Institute of Translational Medicine, 
      University of Liverpool, Liverpool, UK.
FAU - Lian, Lu Yung
AU  - Lian LY
AD  - NMR Centre for Structural Biology, Institute of Integrative Biology & Technology 
      Directorate, University of Liverpool, UK.
FAU - Francis, Ben
AU  - Francis B
AD  - Department of Pharmacology& Therapeutics, University of Liverpool, Liverpool, UK.
FAU - Zhang, Eunice
AU  - Zhang E
AD  - Department of Pharmacology& Therapeutics, University of Liverpool, Liverpool, UK.
FAU - Mulcahy, Cecilia
AU  - Mulcahy C
AD  - UCD Perinatal Research Centre, School of Medicine, University College Dublin, 
      National Maternity Hospital, Dublin, Ireland.
FAU - Alfirevic, Ana
AU  - Alfirevic A
AD  - Department of Pharmacology& Therapeutics, University of Liverpool, Liverpool, UK.
FAU - Mcauliffe, Fionnuala M
AU  - Mcauliffe FM
AD  - UCD Perinatal Research Centre, School of Medicine, University College Dublin, 
      National Maternity Hospital, Dublin, Ireland.
FAU - Navaratnam, Kate
AU  - Navaratnam K
AD  - Centre for Women's Health Research, Institute of Translational Medicine, 
      University of Liverpool, Liverpool, UK.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20211214
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Cross-Sectional Studies
MH  - Female
MH  - Genome-Wide Association Study
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Pregnancy
MH  - Prospective Studies
MH  - Thromboxane B2
MH  - United Kingdom
OTO - NOTNLM
OT  - Aspirin
OT  - aspirin resistance
OT  - genome-wide association
OT  - platelet function
OT  - pregnancy
EDAT- 2021/12/15 06:00
MHDA- 2022/08/17 06:00
CRDT- 2021/12/14 09:29
PHST- 2021/12/15 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
PHST- 2021/12/14 09:29 [entrez]
AID - 10.1080/09537104.2021.2007872 [doi]
PST - ppublish
SO  - Platelets. 2022 Aug 18;33(6):911-917. doi: 10.1080/09537104.2021.2007872. Epub 
      2021 Dec 14.

PMID- 20883232
OWN - NLM
STAT- MEDLINE
DCOM- 20110315
LR  - 20211217
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Print)
IS  - 1524-6175 (Linking)
VI  - 12
IP  - 9
DP  - 2010 Sep
TI  - Aspirin resistance in hypertensive patients.
PG  - 714-20
LID - 10.1111/j.1751-7176.2010.00307.x [doi]
AB  - Aspirin resistance is associated with poor clinical prognosis. The authors 
      investigated aspirin resistance in 200 hypertensive patients (111 men, age: 
      68.3±11.4 years) by the Ultegra Rapid Platelet Function Assay-ASA (Accumetrics 
      Inc., San Diego, CA). Aspirin resistance was defined as an aspirin reaction unit 
      ≥550. Aspirin resistance was detected in 42 patients. Aspirin resistance was 
      present in 25.6% of the patients with poor blood pressure control, while in 17.8% 
      of the patients with controlled blood pressure (P=.182). Female gender and 
      creatinine levels were significantly higher (P=.028 and P=.030, respectively), 
      while platelet count was significantly lower (P=.007) in aspirin-resistant 
      patients. Multivariate analysis revealed that female gender (odds ratio [OR], 
      2.445; P=.045), creatinine levels (OR, 1.297; P=.015) and platelet count (OR, 
      0.993; P=.005) were independent predictors of aspirin resistance. The frequency 
      of aspirin resistance is not low in hypertensive patients. Female hypertensive 
      patients, especially, with higher creatinine levels and lower platelet count are 
      at higher risk for aspirin resistance.
CI  - © 2010 Wiley Periodicals, Inc.
FAU - Ozben, Beste
AU  - Ozben B
AD  - Department of Cardiology, Marmara University Faculty of Medicine, Istanbul, 
      Turkey. bestes@doctor.com
FAU - Tanrikulu, Azra M
AU  - Tanrikulu AM
FAU - Ozben, Tomris
AU  - Ozben T
FAU - Caymaz, Oguz
AU  - Caymaz O
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Treatment Outcome
PMC - PMC8672989
EDAT- 2010/10/05 06:00
MHDA- 2011/03/16 06:00
CRDT- 2010/10/02 06:00
PHST- 2010/10/02 06:00 [entrez]
PHST- 2010/10/05 06:00 [pubmed]
PHST- 2011/03/16 06:00 [medline]
AID - JCH307 [pii]
AID - 10.1111/j.1751-7176.2010.00307.x [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2010 Sep;12(9):714-20. doi: 
      10.1111/j.1751-7176.2010.00307.x.

PMID- 15182075
OWN - NLM
STAT- MEDLINE
DCOM- 20040722
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 97
IP  - 4
DP  - 2004 Apr
TI  - [Aspirin resistance 2003: a review of the literature].
PG  - 320-6
AB  - Despite the development of new molecules, aspirin remains a mainstay of the 
      antiplatelet therapy, indispensable for the secondary prevention of 
      cardiovascular events. The therapeutic used is based on the platelet aggregation 
      inhibition induced by aspirin. The concept of aspirin resistance corresponds to a 
      total or almost total absence of the platelet aggregation inhibition generally 
      observed in vitro under aspirin. The frequency of this resistance depends on the 
      platelet aggregation test used and the population studied. In a population with 
      stable coronary disease treated in the long term with 160 to 325 mg of aspirin 
      daily, 8 to 35% of patients are non-responders. Many hypothesis on the mechanisms 
      of the lack of antiplatelet effect of aspirin are under investigation. The 
      clinical implication of the in vitro antiplatelet effect resistance of aspirin 
      has recently been evidenced by a relative risk of cardiovascular events at two 
      years at 3. This would support an individual adaptation of the anti-platelet 
      therapy.
FAU - Christiaens, L
AU  - Christiaens L
AD  - Département médico-chirurgical de cardiologie, Pr Allal, CHU hôpital la Milétrie, 
      Poitiers. l.christiaens@chu-poitiers.fr
FAU - Macchi, L
AU  - Macchi L
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Actualités sur la résistance à l'aspirine en 2003.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
RF  - 50
EDAT- 2004/06/09 05:00
MHDA- 2004/07/23 05:00
CRDT- 2004/06/09 05:00
PHST- 2004/06/09 05:00 [pubmed]
PHST- 2004/07/23 05:00 [medline]
PHST- 2004/06/09 05:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 2004 Apr;97(4):320-6.

PMID- 30753849
OWN - NLM
STAT- MEDLINE
DCOM- 20190506
LR  - 20190506
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 149
DP  - 2019 Mar
TI  - Aspirin in people with diabetes: Time to clean up the prescription list?
PG  - 208-209
LID - S0168-8227(19)30043-9 [pii]
LID - 10.1016/j.diabres.2019.02.005 [doi]
AB  - The effect of aspirin in primary cardiovascular (CV) prevention in people with 
      diabetes is still a matter of debate. Recent results of ASCEND trial suggest that 
      the absolute benefit on CV events is largely counter-balanced by the bleeding 
      risk. However, one crucial question is whether aspirin should be maintained or 
      withdrawn from the prescription list of those who are already under this therapy 
      since a while ago. Indeed, large epidemiological data reported that the aspirin 
      discontinuation was associated to an increased risk of CV events. Moreover, 
      besides the CV outcome, potential positive impact of aspirin on cancer is still 
      under investigation. To conclude, there is no more systematic indication for 
      aspirin in people with diabetes free of CV disease, especially when diabetes and 
      all other CV risk factors are optimally controlled. For those already on aspirin, 
      data are not conclusive enough for a systematic approach and benefit/risk balance 
      must be discussed with patients to take a shared decision.
CI  - Copyright © 2019. Published by Elsevier B.V.
FAU - Vouillarmet, Julien
AU  - Vouillarmet J
AD  - Hospices Civils de Lyon, Diabetes Department, Centre Hospitalier Lyon-Sud, Pierre 
      Bénite, France. Electronic address: julien.vouillarmet@chu-lyon.fr.
FAU - Aboyans, Victor
AU  - Aboyans V
AD  - Department of Cardiology, Dupuytren University Hospital, Limoges, France.
LA  - eng
PT  - Journal Article
DEP - 20190210
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Diabetes Mellitus/*drug therapy/pathology
MH  - Humans
MH  - Primary Prevention
MH  - Risk Assessment
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular
OT  - Diabetes
EDAT- 2019/02/13 06:00
MHDA- 2019/05/07 06:00
CRDT- 2019/02/13 06:00
PHST- 2019/01/09 00:00 [received]
PHST- 2019/02/06 00:00 [accepted]
PHST- 2019/02/13 06:00 [pubmed]
PHST- 2019/05/07 06:00 [medline]
PHST- 2019/02/13 06:00 [entrez]
AID - S0168-8227(19)30043-9 [pii]
AID - 10.1016/j.diabres.2019.02.005 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2019 Mar;149:208-209. doi: 
      10.1016/j.diabres.2019.02.005. Epub 2019 Feb 10.

PMID- 21612354
OWN - NLM
STAT- MEDLINE
DCOM- 20111115
LR  - 20160701
IS  - 1745-5065 (Electronic)
IS  - 1745-5057 (Linking)
VI  - 7
IP  - 3
DP  - 2011 May
TI  - Gender differences in the primary prevention of stroke with aspirin.
PG  - 341-52; quiz 352-3
LID - 10.2217/whe.11.21 [doi]
AB  - Aspirin is used to prevent ischemic stroke and other types of cardiovascular 
      disease. Seven trials of aspirin focusing on the effectiveness of primary 
      prevention of stroke and other cardiovascular events have been performed, but 
      three of these did not include women. Data from these trials, and one 
      meta-analysis, suggest that aspirin prevents myocardial infarction in men and 
      stroke in women, although the findings in women were driven by the results of a 
      single large study, and a subsequent meta-analysis did not find a gender 
      difference. The reasons for the possible gender differences in aspirin's 
      effectiveness are not entirely clear.
FAU - Adelman, Eric E
AU  - Adelman EE
AD  - Department of Neurology, University of Michigan, Cardiovascular Center, Ann 
      Arbor, MI 48109, USA.
FAU - Lisabeth, Lynda
AU  - Lisabeth L
FAU - Brown, Devin L
AU  - Brown DL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Womens Health (Lond)
JT  - Women's health (London, England)
JID - 101271249
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Brain Ischemia/*prevention & control
MH  - Cardiovascular Diseases/prevention & control
MH  - Female
MH  - Fibrinolytic Agents/*pharmacology
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Practice Guidelines as Topic
MH  - Primary Prevention/methods
MH  - Randomized Controlled Trials as Topic
MH  - Sex Factors
MH  - Stroke/*epidemiology/*prevention & control
EDAT- 2011/05/27 06:00
MHDA- 2011/11/16 06:00
CRDT- 2011/05/27 06:00
PHST- 2011/05/27 06:00 [entrez]
PHST- 2011/05/27 06:00 [pubmed]
PHST- 2011/11/16 06:00 [medline]
AID - 10.2217/whe.11.21 [doi]
PST - ppublish
SO  - Womens Health (Lond). 2011 May;7(3):341-52; quiz 352-3. doi: 10.2217/whe.11.21.

PMID- 37207561
OWN - NLM
STAT- MEDLINE
DCOM- 20230606
LR  - 20230606
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 667
DP  - 2023 Jul 30
TI  - Aspirin loaded extracellular vesicles inhibit inflammation of macrophages via 
      switching metabolic phenotype in periodontitis.
PG  - 25-33
LID - S0006-291X(23)00579-X [pii]
LID - 10.1016/j.bbrc.2023.05.024 [doi]
AB  - OBJECTIVES: Changes of macrophage in the local immune microenvironment of 
      periodontitis cause alveolar bone resorption. This study aims to investigate the 
      effect of a new drug delivery method of aspirin on the immune microenvironment of 
      periodontitis to promote alveolar bone repair, and to explore mechanism of 
      aspirin's effect on macrophage. METHODS: We isolated extracellular vesicles (EVs) 
      from periodontal stem cells (PDLSCs) and loaded with aspirin by sonication, and 
      then evaluated the treatment efficacy of aspirin-loaded vesicles (EVs-ASP) in 
      periodontitis model in mice. In vitro, we explored the role of EVs-ASP in the 
      regulation of LPS-induced macrophages. The underlying mechanism by which EVs-ASP 
      regulates phenotypic remodeling of macrophages in periodontitis was further 
      investigated. RESULTS: EVs-ASP inhibited the inflammatory environment of 
      LPS-induced macrophage, and promoted anti-inflammatory macrophages formation both 
      in vivo and in vitro, and reduced bone loss in periodontitis models. Moreover, 
      EVs-ASP enhanced oxidative phosphorylation and suppressed glycolysis in 
      macrophages. CONCLUSIONS: Consequently, EVs-ASP improves the periodontal immune 
      microenvironment by enhancing oxidative phosphorylation (OXPHOS) in macrophages, 
      resulting in a certain degree of regeneration of alveolar bone height. Our study 
      provides a new potential strategy for bone repair in periodontitis therapy.
CI  - Copyright © 2023 Elsevier Inc. All rights reserved.
FAU - Shi, Yuanyuan
AU  - Shi Y
AD  - The College of Life Sciences and Medicine, Northwest University, Xi'an, China; 
      State Key Laboratory of Military Stomatology & National Clinical Research Center 
      for Oral Diseases & Shaanxi International Joint Research Center for Oral 
      Diseases, Center for Tissue Engineering, School of Stomatology, The Fourth 
      Military Medical University, Xi'an, China.
FAU - Zhang, Ruijie
AU  - Zhang R
AD  - State Key Laboratory of Military Stomatology & National Clinical Research Center 
      for Oral Diseases & Shaanxi International Joint Research Center for Oral 
      Diseases, Center for Tissue Engineering, School of Stomatology, The Fourth 
      Military Medical University, Xi'an, China; Department of Orthodontics, School of 
      Stomatology, The Fourth Military Medical University, Xi'an, China.
FAU - Da, Ningning
AU  - Da N
AD  - The College of Life Sciences and Medicine, Northwest University, Xi'an, China; 
      State Key Laboratory of Military Stomatology & National Clinical Research Center 
      for Oral Diseases & Shaanxi International Joint Research Center for Oral 
      Diseases, Center for Tissue Engineering, School of Stomatology, The Fourth 
      Military Medical University, Xi'an, China.
FAU - Wang, Yiming
AU  - Wang Y
AD  - State Key Laboratory of Military Stomatology & National Clinical Research Center 
      for Oral Diseases & Shaanxi International Joint Research Center for Oral 
      Diseases, Center for Tissue Engineering, School of Stomatology, The Fourth 
      Military Medical University, Xi'an, China; Department of Oral and Maxillofacial 
      surgery, School of Stomatology, The Fourth Military Medical University, Xi'an, 
      China.
FAU - Yang, Jianhua
AU  - Yang J
AD  - State Key Laboratory of Military Stomatology & National Clinical Research Center 
      for Oral Diseases & Shaanxi International Joint Research Center for Oral 
      Diseases, Center for Tissue Engineering, School of Stomatology, The Fourth 
      Military Medical University, Xi'an, China.
FAU - Li, Bei
AU  - Li B
AD  - State Key Laboratory of Military Stomatology & National Clinical Research Center 
      for Oral Diseases & Shaanxi International Joint Research Center for Oral 
      Diseases, Center for Tissue Engineering, School of Stomatology, The Fourth 
      Military Medical University, Xi'an, China. Electronic address: 
      libei2021@fmmu.edu.cn.
FAU - He, Xiaoning
AU  - He X
AD  - State Key Laboratory of Military Stomatology & National Clinical Research Center 
      for Oral Diseases & Shaanxi International Joint Research Center for Oral 
      Diseases, Center for Tissue Engineering, School of Stomatology, The Fourth 
      Military Medical University, Xi'an, China. Electronic address: 
      hxn_800222@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230512
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Lipopolysaccharides)
SB  - IM
MH  - Mice
MH  - Animals
MH  - Aspirin/pharmacology/metabolism
MH  - Lipopolysaccharides/pharmacology
MH  - Inflammation/drug therapy/metabolism
MH  - *Periodontitis/drug therapy/metabolism
MH  - Macrophages/metabolism
MH  - *Extracellular Vesicles/metabolism
MH  - Phenotype
OTO - NOTNLM
OT  - Aspirin
OT  - Drug loading
OT  - Extracellular vesicles
OT  - Macrophages
OT  - Metabolic reprograming
OT  - Periodontitis
COIS- Declaration of competing interest All authors have seen and approved the final 
      version. The authors have declared that no competing interest exists.
EDAT- 2023/05/20 09:42
MHDA- 2023/06/06 06:42
CRDT- 2023/05/19 18:08
PHST- 2023/04/10 00:00 [received]
PHST- 2023/04/26 00:00 [revised]
PHST- 2023/05/05 00:00 [accepted]
PHST- 2023/06/06 06:42 [medline]
PHST- 2023/05/20 09:42 [pubmed]
PHST- 2023/05/19 18:08 [entrez]
AID - S0006-291X(23)00579-X [pii]
AID - 10.1016/j.bbrc.2023.05.024 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2023 Jul 30;667:25-33. doi: 
      10.1016/j.bbrc.2023.05.024. Epub 2023 May 12.

PMID- 11837115
OWN - NLM
STAT- MEDLINE
DCOM- 20020717
LR  - 20131121
IS  - 0028-2200 (Print)
IS  - 0028-2200 (Linking)
VI  - 102
IP  - 8
DP  - 1995 Aug
TI  - [Aspirin, a risk factor for bleeding at dental procedures].
PG  - 293-5
AB  - Aspirin is widely used as an antithrombotic drug in the prevention of 
      cardiovascular events. It causes a usually mild bleeding tendency. When used 
      before dental or surgical procedures, aspirin increases the risk of bleeding, 
      contrary to the postoperative administration of aspirin, which has not been 
      associated with increased risk of bleeding. To estimate the risk of bleeding, a 
      history on bleeding tendency and information on the recent use of aspirin is 
      worthwhile. It is recommended to delay procedures for at least one week after the 
      last ingestion of aspirin, if possible. In case of urgent surgical procedures or 
      in patients who suffer from serious bleeding due to the use of aspirin, a single 
      preoperative transfusion of a suspension of platelets is usually sufficient to 
      antagonize the effects of aspirin. Tranexamic acid can be given alternatively. 
      The preferred policy depends on the type of the procedure to be performed, or the 
      nature of the bleeding.
FAU - van der Meer, J
AU  - van der Meer J
AD  - Afdeling Hematologie, Sectle Haemostase, Thrombose en Rheologie, Academisch 
      Ziekenhuis, postbus 30.001, 9700 RB Groningen.
LA  - dut
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspirine, een risicofactor bij bloedige tandheelkundige ingrepen.
PL  - Netherlands
TA  - Ned Tijdschr Tandheelkd
JT  - Nederlands tijdschrift voor tandheelkunde
JID - 0400771
RN  - 0 (Antifibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
MH  - Antifibrinolytic Agents/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Loss, Surgical/*prevention & control
MH  - Humans
MH  - Intraoperative Complications/prevention & control
MH  - Oral Hemorrhage/*chemically induced/prevention & control
MH  - Oral Surgical Procedures
MH  - Postoperative Complications/chemically induced/prevention & control
MH  - Risk Factors
MH  - Time Factors
RF  - 15
EDAT- 1995/08/01 00:00
MHDA- 2002/07/18 10:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 2002/07/18 10:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Tandheelkd. 1995 Aug;102(8):293-5.

PMID- 19236833
OWN - NLM
STAT- MEDLINE
DCOM- 20090508
LR  - 20131121
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 63
IP  - 6
DP  - 2008 Nov-Dec
TI  - [Aspirin in decompression sickness].
PG  - 419-23
LID - 10.2515/therapie/2008067 [doi]
AB  - OBJECTIVE: We have performed a survey on the use of aspirin in decompression 
      sickness (DCS) treatment in French hyperbaric centers'. We also conducted a 
      review of literature to determine if aspirin was beneficial to treat human 
      victims of DCS. METHODS: Prospective observational study investigating French 
      hyperbaric centers' prescription of aspirin to DCS' divers victims. The question 
      we asked by mail or phone to French hyperbaric centers was: Do you give some 
      aspirin to a diver with DCS if this treatment has not been given yet (on the site 
      of accident). RESULTS: A large majority of French hyperbaric centers (77.5%) 
      consider aspirin in DCS treatment. However this practice is not consensual. There 
      is no evidence from the literature to support the efficiency of aspirin in DCS. 
      CONCLUSIONS: Although aspirin is widely used for DCS treatment in France, more 
      research is needed to determine if aspirin is useful.
FAU - Bessereau, Jacques
AU  - Bessereau J
AD  - Pôle RUSH, Assistance Publique des Hôpitaux de Marseille, Marseille, France. 
      jacques.bessereau@ap-hm.fr
FAU - Coulange, Mathieu
AU  - Coulange M
FAU - Genotelle, Nicolas
AU  - Genotelle N
FAU - Barthélémy, Alain
AU  - Barthélémy A
FAU - Michelet, Pierre
AU  - Michelet P
FAU - Bruguerolle, Bernard
AU  - Bruguerolle B
FAU - Annane, Djillali
AU  - Annane D
FAU - Auffray, Jean-Pierre
AU  - Auffray JP
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Place de l'aspirine dans le traitement médicamenteux de l'accident de 
      désaturation.
DEP - 20090224
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Data Collection
MH  - Decompression Sickness/*drug therapy
MH  - Drug Utilization
MH  - France
MH  - Humans
MH  - Prospective Studies
EDAT- 2009/02/25 09:00
MHDA- 2009/05/09 09:00
CRDT- 2009/02/25 09:00
PHST- 2009/02/25 09:00 [entrez]
PHST- 2009/02/25 09:00 [pubmed]
PHST- 2009/05/09 09:00 [medline]
AID - th081737 [pii]
AID - 10.2515/therapie/2008067 [doi]
PST - ppublish
SO  - Therapie. 2008 Nov-Dec;63(6):419-23. doi: 10.2515/therapie/2008067. Epub 2009 Feb 
      24.

PMID- 15928593
OWN - NLM
STAT- MEDLINE
DCOM- 20060410
LR  - 20161021
IS  - 1732-2693 (Electronic)
IS  - 0032-5449 (Linking)
VI  - 59
DP  - 2005 Mar 23
TI  - [Aspirin--the prodigious panacea? Molecular mechanisms of the action of 
      acetylsalicylic acid in the organism].
PG  - 105-15
AB  - Aspirin (acetylsalicylic acid) is a commonly used non-steroidal anti-inflammatory 
      drug capable of acetylating proteins in the course of a simple, non-enzymatic 
      chemical reaction. Its main physiological effect is inhibiting prostanoid 
      synthesis. Cyclooxygenases, COX-1 and COX-2, are crucial in the metabolic pathway 
      leading to the generation of prostanoids. Both enzymes are major cellular targets 
      for aspirin. The physiological spectrum of the biological activity of the 
      prostanoids is very broad, and underlies the high clinical effectiveness of 
      aspirin as an anti-inflammatory, antipyretic, and analgesic drug. Apart from the 
      inhibition of prostanoid synthesis aspirin shows a variety of pharmacological 
      activities, including reduction of ATP storage pools, increased extracellular 
      adenosine, lowered inducible nitric oxide synthase activity, modulation of 
      mitogen-activated protein kinases, and the expression of a plethora of genes 
      induced under conditions of cell stress via the regulation of transcription 
      factor NFkappaB activity. Such multipotent action explains its wide use in 
      clinical practice. Regardless of the accumulated evidence on the molecular 
      mechanisms of aspirin's action, the rationale of the appropriate dosing and 
      monitoring of aspirin therapy and prophylaxis remains obscure. Hence, an 
      evaluation and reasonable weighing of the cost/benefit ratio of aspirin therapy 
      in various diseases seems appropriate.
FAU - Czyz, Małgorzata
AU  - Czyz M
AD  - Zakład Chemii Medycznej, Instytut Fizjologii i Biochemii, Uniwersytetu 
      Medycznego, Łódz.
FAU - Watała, Cezary
AU  - Watała C
LA  - pol
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspiryna--cudowne panaceum? Molekularne mechanizmy działania kwasu 
      acetylosalicylowego w organizmie.
PL  - Poland
TA  - Postepy Hig Med Dosw (Online)
JT  - Postepy higieny i medycyny doswiadczalnej (Online)
JID - 101206517
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/pharmacology
MH  - Analgesics, Non-Narcotic/pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Drug Resistance
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Neoplasms/prevention & control
MH  - Prostaglandin Antagonists/pharmacology
MH  - Prostaglandins/biosynthesis
MH  - Signal Transduction/drug effects
MH  - Thrombosis/drug therapy
RF  - 111
EDAT- 2005/06/02 09:00
MHDA- 2006/04/11 09:00
CRDT- 2005/06/02 09:00
PHST- 2004/12/10 00:00 [received]
PHST- 2005/02/15 00:00 [accepted]
PHST- 2005/06/02 09:00 [pubmed]
PHST- 2006/04/11 09:00 [medline]
PHST- 2005/06/02 09:00 [entrez]
AID - 7247 [pii]
PST - ppublish
SO  - Postepy Hig Med Dosw (Online). 2005 Mar 23;59:105-15.

PMID- 16597054
OWN - NLM
STAT- MEDLINE
DCOM- 20060504
LR  - 20131121
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 2
IP  - 56
DP  - 2006 Mar 8
TI  - [The role of aspirin in the primary prevention of cardiovascular disease].
PG  - 646-51
AB  - For persons without cardiovascular disease, the benefit of aspirin in primary 
      prevention has been controversial until the recent publication of several major 
      randomized controlled trials. Since then, several medical societies recommend 
      that clinicians discuss aspirin prevention with adults at high cardiovascular 
      risk. Patients with low cardiovascular risk are unlikely to benefit from aspirin, 
      as potential harms (hemorrhagic strokes, gastrointestinal bleedings) may outweigh 
      benefits. Aspirin should be recommended in primary prevention only in patients 
      with a 10-year cardiovascular risk > or = 10% or in diabetic patients aged > or = 
      40 years with a concomitant cardiovascular risk factor, after assessing 
      contraindications for aspirin and individual's preferences for the risks and 
      benefits associated with aspirin.
FAU - Rodondi, N
AU  - Rodondi N
AD  - Prévention cardiovasculaire Policlinique médicale universitaire et Institut 
      universitaire de médecine sociale et preventive Département de médecine et de 
      santé communautaire Université de Lausanne. Nicolas.Rodondi@hospvd.ch
FAU - Cornuz, J
AU  - Cornuz J
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Place de l'aspirine en prévention primaire des maladies cardiovasculaires.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Primary Prevention
RF  - 46
EDAT- 2006/04/07 09:00
MHDA- 2006/05/05 09:00
CRDT- 2006/04/07 09:00
PHST- 2006/04/07 09:00 [pubmed]
PHST- 2006/05/05 09:00 [medline]
PHST- 2006/04/07 09:00 [entrez]
PST - ppublish
SO  - Rev Med Suisse. 2006 Mar 8;2(56):646-51.

PMID- 32445718
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20210430
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 133
IP  - 9
DP  - 2020 Sep
TI  - Aspirin for Primary Atherosclerotic Cardiovascular Disease Prevention as Baseline 
      Risk Increases: A Meta-Regression Analysis.
PG  - 1056-1064
LID - S0002-9343(20)30432-0 [pii]
LID - 10.1016/j.amjmed.2020.04.028 [doi]
AB  - BACKGROUND: Aspirin has long had a role in the primary prevention of 
      atherosclerotic cardiovascular disease (ASCVD); however, recent randomized 
      controlled trials (RCTs) have challenged this practice. Despite this, aspirin is 
      still commonly recommended for high-risk primary prevention. We tested the 
      hypothesis that aspirin is more efficacious for the primary prevention of ASCVD 
      as the baseline risk increases. METHODS: RCTs that compared aspirin with control 
      for primary prevention and evaluated ASCVD (composite of myocardial infarction 
      and ischemic stroke) and major bleeding were included. Rate ratios (RR) and 95% 
      confidence intervals (CI) were calculated. A regression analysis was performed 
      using the ASCVD event rate in the control arm of each RCT as the moderator. 
      RESULTS: Twelve RCTs were identified with 963,829 patient-years of follow-up. 
      Aspirin was associated with a reduction in ASCVD (4.7 vs 5.3 events per 1000 
      patient-years; RR 0.86; 95% CI, 0.79-0.92). There was increased major bleeding 
      among aspirin users (2.5 vs 1.8 events per 1000 patient-years; RR 1.41; 95% CI, 
      1.29-1.54). Regression analysis found no relationship between the log RR of ASCVD 
      or major bleeding and rate of ASCVD in the control arm of each RCT. CONCLUSION: 
      Aspirin is associated with a reduction in ASCVD when used for primary prevention; 
      however, it is unlikely to be clinically significant given the increase in 
      bleeding. More importantly, aspirin's treatment effect does not increase as ASCVD 
      risk increases, as many hypothesize. There is no suggestion from these data that 
      use of aspirin for higher-risk primary prevention patients is beneficial.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Nudy, Matthew
AU  - Nudy M
AD  - Division of Cardiology, Penn State Heart and Vascular Institute, Hershey, PA. 
      Electronic address: mnudy@pennstatehealth.psu.edu.
FAU - Cooper, Jennifer
AU  - Cooper J
AD  - Department of Medicine, Penn State College of Medicine, Hershey, PA.
FAU - Ghahramani, Mehrdad
AU  - Ghahramani M
AD  - Division of Cardiology, Penn State Heart and Vascular Institute, Hershey, PA.
FAU - Ruzieh, Mohammed
AU  - Ruzieh M
AD  - Division of Cardiology, Penn State Heart and Vascular Institute, Hershey, PA.
FAU - Mandrola, John
AU  - Mandrola J
AD  - Department of Cardiology, Baptist Health Louisville, Louisville, KY.
FAU - Foy, Andrew J
AU  - Foy AJ
AD  - Division of Cardiology, Penn State Heart and Vascular Institute, Hershey, PA; 
      Department of Public Health Sciences, Penn State College of Medicine, Hershey, 
      PA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200520
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2020 Oct 20;173(8):JC39. PMID: 33075272
CIN - Am J Med. 2021 Apr;134(4):e299. PMID: 33888225
CIN - Am J Med. 2021 Apr;134(4):e300. PMID: 33888226
MH  - Aspirin/*therapeutic use
MH  - Atherosclerosis/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Regression Analysis
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Atherosclerotic cardiovascular disease
OT  - Ischemic stroke
OT  - Major bleeding
OT  - Myocardial infarction
OT  - Primary prevention
EDAT- 2020/05/24 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/05/24 06:00
PHST- 2019/11/11 00:00 [received]
PHST- 2020/04/02 00:00 [revised]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - S0002-9343(20)30432-0 [pii]
AID - 10.1016/j.amjmed.2020.04.028 [doi]
PST - ppublish
SO  - Am J Med. 2020 Sep;133(9):1056-1064. doi: 10.1016/j.amjmed.2020.04.028. Epub 2020 
      May 20.

PMID- 26653848
OWN - NLM
STAT- MEDLINE
DCOM- 20160718
LR  - 20181202
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 128
IP  - 2
DP  - 2016
TI  - Aspirin in the prevention of cardiovascular events in patients with diabetes.
PG  - 180-90
LID - 10.1080/00325481.2016.1131106 [doi]
AB  - Diabetes imparts a substantial increased risk for cardiovascular disease-related 
      mortality and morbidity. Because of this, current medical guidelines recommend 
      prophylactic treatment with once-daily, low-dose aspirin (acetylsalicylic acid) 
      for primary and secondary prevention of cardiovascular (CV) events in high-risk 
      patients. However, only modest reductions in CV events and mortality have been 
      observed with once-daily aspirin treatment in patients with diabetes, including 
      patients with a previous CV event, perhaps because of disparity between aspirin 
      pharmacokinetics and diabetes-related platelet abnormalities. Once-daily aspirin 
      irreversibly inactivates platelets for only a short duration (acetylsalicylic 
      acid half-life, approximately 15-20 minutes), after which time newly generated, 
      active platelets enter the circulation and weaken aspirin's effect. Platelets 
      from patients with diabetes are more reactive and are turned over more rapidly 
      than platelets from normal individuals; the short inhibitory window provided by 
      once-daily aspirin may therefore be insufficient to provide 24-h protection 
      against CV events. Alternative conventional aspirin regimens (e.g. higher daily 
      dose, twice-daily dosing, combination with clopidogrel) and newer formulations 
      (e.g. 24-h, extended-release) have been proposed to overcome the apparent limited 
      efficacy of conventional aspirin in patients with diabetes; however, tolerability 
      concerns and limited clinical efficacy data need to be taken into account when 
      considering the use of such regimens.
FAU - Bell, David S H
AU  - Bell DS
AD  - a Southside Endocrinology , Mountain Brook , AL , USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160112
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clopidogrel
MH  - *Diabetes Complications
MH  - Diabetes Mellitus
MH  - Drug Administration Schedule
MH  - Half-Life
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Ticlopidine/administration & dosage/analogs & derivatives
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - cardiovascular disease
OT  - diabetes complications
OT  - extended-release aspirin
OT  - high on-treatment platelet reactivity
EDAT- 2015/12/15 06:00
MHDA- 2016/07/19 06:00
CRDT- 2015/12/15 06:00
PHST- 2015/12/15 06:00 [entrez]
PHST- 2015/12/15 06:00 [pubmed]
PHST- 2016/07/19 06:00 [medline]
AID - 10.1080/00325481.2016.1131106 [doi]
PST - ppublish
SO  - Postgrad Med. 2016;128(2):180-90. doi: 10.1080/00325481.2016.1131106. Epub 2016 
      Jan 12.

PMID- 32635638
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 13
DP  - 2020 Jul 5
TI  - Aspirin Induces Mitochondrial Ca(2+) Remodeling in Tumor Cells via 
      ROS‒Depolarization‒Voltage-Gated Ca(2+) Entry.
LID - 10.3390/ijms21134771 [doi]
LID - 4771
AB  - Aspirin (acetylsalicylic acid) and its metabolite salicylate, have an 
      anti-melanoma effect by evoking mitochondrial dysfunction through poorly 
      understood mechanisms. Depolarization of the plasma membrane potential leads to 
      voltage-gated Ca(2+) entry (VGCE) and caspase-3 activation. In the present study, 
      we investigated the role of depolarization and VGCE in aspirin's anti-melanoma 
      effect. Aspirin and to a lesser extent, salicylate (≥2.5 mM) induced a rapid 
      (within seconds) depolarization, while they caused comparable levels of 
      depolarization with a lag of 2~4 h. Reactive oxygen species (ROS) generation also 
      occurred in the two-time points, and antioxidants abolished the early ROS 
      generation and depolarization. At the same concentrations, the two drugs induced 
      apoptotic and necrotic cell death in a caspase-independent manner, and 
      antioxidants and Ca(2+) channel blockers prevented cell death. Besides ROS 
      generation, reduced mitochondrial Ca(2+) (Ca(2+)(m)) and mitochondrial membrane 
      potential preceded cell death. Moreover, the cells expressed the Ca(v)1.2 isoform 
      of l-type Ca(2+) channel, and knockdown of Ca(v)1.2 abolished the decrease in 
      Ca(2+)(m). Our findings suggest that aspirin and salicylate induce Ca(2+)(m) 
      remodeling, mitochondrial dysfunction, and cell death via ROS-dependent 
      depolarization and VGCE activation.
FAU - Fujikawa, Itsuho
AU  - Fujikawa I
AUID- ORCID: 0000-0002-3026-3878
AD  - Department of Dermatology, Nihon University Hospital, Tokyo 101-830, Japan.
AD  - Plasma ChemiBio Laboratory, Nasushiobara, Tochigi 329-2813, Japan.
FAU - Ando, Takashi
AU  - Ando T
AD  - Department of Orthopedic Surgery, Yamanashi University School of Medicine, 
      Yamanashi 409-3898, Japan.
FAU - Suzuki-Karasaki, Manami
AU  - Suzuki-Karasaki M
AD  - Plasma ChemiBio Laboratory, Nasushiobara, Tochigi 329-2813, Japan.
FAU - Suzuki-Karasaki, Miki
AU  - Suzuki-Karasaki M
AD  - Plasma ChemiBio Laboratory, Nasushiobara, Tochigi 329-2813, Japan.
FAU - Ochiai, Toyoko
AU  - Ochiai T
AD  - Department of Dermatology, Nihon University Hospital, Tokyo 101-830, Japan.
AD  - Plasma ChemiBio Laboratory, Nasushiobara, Tochigi 329-2813, Japan.
FAU - Suzuki-Karasaki, Yoshihiro
AU  - Suzuki-Karasaki Y
AD  - Plasma ChemiBio Laboratory, Nasushiobara, Tochigi 329-2813, Japan.
LA  - eng
GR  - 15K09792/Japan Society for the Promotion of Science/
GR  - 18K09121/Japan Society for the Promotion of Science/
PT  - Journal Article
DEP - 20200705
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (CACNA1C protein, human)
RN  - 0 (Calcium Channels, L-Type)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Calcium/metabolism
MH  - Calcium Channels, L-Type/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Melanoma/*drug therapy
MH  - Mitochondria/*drug effects
PMC - PMC7370041
OTO - NOTNLM
OT  - apoptosis
OT  - aspirin
OT  - depolarization
OT  - l-type Ca2+ channel
OT  - melanoma
OT  - mitochondria
OT  - salicylate
OT  - voltage-gated Ca2+ entry
COIS- M.S.-K. (Manami Suzuki-Karasaki), M.S.-K. (Miki Suzuki-Karasaki), and Y.S.-K. are 
      employees of the non-profit Institute Plasma ChemiBio Laboratory. Other authors 
      have no conflicts of interest. The funders had no role in the design of the 
      study; in the collection, analyses, or interpretation of data; in the writing of 
      the manuscript, or in the decision to publish the results.
EDAT- 2020/07/09 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/06/27 00:00 [revised]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - ijms21134771 [pii]
AID - ijms-21-04771 [pii]
AID - 10.3390/ijms21134771 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Jul 5;21(13):4771. doi: 10.3390/ijms21134771.

PMID- 4121596
OWN - NLM
STAT- MEDLINE
DCOM- 19730621
LR  - 20150616
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 7810
DP  - 1973 May 5
TI  - Prostaglandins, aspirin, and analgesia.
PG  - 979
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesia
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Depression, Chemical
MH  - Humans
MH  - *Inflammation
MH  - Prostaglandins/*biosynthesis
OID - PIP: 001245
OID - POP: 00086787
OAB - The mechanism of action of aspirin and similar drugs and the role of 
      prostaglandins in the pathogenesis of inflammation are being actively studied. 
      That prostaglandins have a role in inflammation seems obvious from their recovery 
      in a number of exudates produced by experimental inflammatory stimuli. Therefore, 
      drugs such as aspirin, indomethacin, and phenylbutazone probably act to block 
      prostaglandin synthesis and relieve symptoms. Similarly, the antipyretic actions 
      of these antiinflammatory agents is explained by the finding that some 
      prostaglandins are potent pyrogens. It has also been suggested that inhibition of 
      prostaglandin synthesis accounts for the gastrointestinal toxicity of 
      antiinflammatory drugs and that aspirin might prevent abortion and interfere with 
      IUDs. Apparently, many actions of aspirin-like drugs are explained by a common 
      mechanism. Aspirin's analgesic action is being investigated; an intermediate to 
      prostaglandin release is the production of unstable cyclic peroxides; pain is now 
      hypothesized to result from these fatty acid hydroperoxides, since pain was not 
      caused by the parent fatty acids. Infusion of prostaglandins at high enough 
      concentrations also caused hyperalgesia. Hence, 2 types of pain have been found 
      capable of treatment by aspirin-like drugs--pain caused by synthesis of 
      inflammatory substances (which aspirin blocks), and pain caused by sensitization 
      of pain receptors.
OABL- eng
OTO - PIP
OT  - *Analgesia
OT  - Biology
OT  - Diseases
OT  - Endocrine System
OT  - *Pain
OT  - Physiology
OT  - *Prostaglandins--pharmacodynamics
OT  - Signs And Symptoms
OT  - Treatment
GN  - PIP: TJ: LANCET.
EDAT- 1973/05/05 00:00
MHDA- 1973/05/05 00:01
CRDT- 1973/05/05 00:00
PHST- 1973/05/05 00:00 [pubmed]
PHST- 1973/05/05 00:01 [medline]
PHST- 1973/05/05 00:00 [entrez]
AID - S0140-6736(73)91610-3 [pii]
PST - ppublish
SO  - Lancet. 1973 May 5;1(7810):979.

PMID- 17105376
OWN - NLM
STAT- MEDLINE
DCOM- 20070313
LR  - 20191110
IS  - 1744-7631 (Electronic)
IS  - 1472-8222 (Linking)
VI  - 10
IP  - 6
DP  - 2006 Dec
TI  - Therapeutic effects of nitric oxide-aspirin hybrid drugs.
PG  - 911-22
AB  - This review examines the therapeutic potential and mechanisms of action of drugs 
      known as nitric oxide (NO)-aspirins. Drugs of this class have an NO-releasing 
      moiety joined by ester linkage to the aspirin molecule. NO-aspirins have the 
      capability to release NO in addition to retaining the cyclooxygenase-inhibitory 
      action of aspirin. The protective nature of NO led to the development of 
      NO-aspirins in the hope that they might avoid the gastric side effects associated 
      with aspirin. However, it has become apparent that the drug-derived NO instills 
      potential for a wide range of added beneficial effects over the parent compound. 
      In this review, the authors focus on the analgesic, anti-inflammatory, 
      cardiovascular and chemopreventative actions of compounds of this emerging drug 
      class.
FAU - Turnbull, Catriona M
AU  - Turnbull CM
AD  - Queen's Medical Research Institute, University of Edinburgh, Centre for 
      Cardiovascular Science, Edinburgh, EH16 4TJ, UK. s9901288@sms.ed.ac.uk
FAU - Rossi, Adriano G
AU  - Rossi AG
FAU - Megson, Ian L
AU  - Megson IL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Ther Targets
JT  - Expert opinion on therapeutic targets
JID - 101127833
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/chemistry/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*therapeutic use
MH  - Antineoplastic Agents/chemistry/*therapeutic use
MH  - Aspirin/*chemistry/pharmacology/*therapeutic use
MH  - Humans
MH  - Nitric Oxide/*chemistry/pharmacology/*therapeutic use
RF  - 157
EDAT- 2006/11/16 09:00
MHDA- 2007/03/14 09:00
CRDT- 2006/11/16 09:00
PHST- 2006/11/16 09:00 [pubmed]
PHST- 2007/03/14 09:00 [medline]
PHST- 2006/11/16 09:00 [entrez]
AID - 10.1517/14728222.10.6.911 [doi]
PST - ppublish
SO  - Expert Opin Ther Targets. 2006 Dec;10(6):911-22. doi: 10.1517/14728222.10.6.911.

PMID- 26139061
OWN - NLM
STAT- MEDLINE
DCOM- 20150916
LR  - 20150703
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 66
IP  - 1
DP  - 2015 Jul 7
TI  - The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin.
PG  - 74-85
LID - S0735-1097(15)02282-2 [pii]
LID - 10.1016/j.jacc.2015.05.012 [doi]
AB  - Inactivation of platelet cyclooxygenase (COX)-1 by low-dose aspirin leads to 
      long-lasting suppression of thromboxane (TX) A2 production and TXA2-mediated 
      platelet activation and aggregation. This effect is necessary and sufficient to 
      explain aspirin's unique (among other COX-1 inhibitors) effectiveness in 
      preventing atherothrombosis, as well as its shared (with other antiplatelet 
      agents) bleeding liability. However, different mechanisms of action have been 
      suggested to explain other beneficial effects of aspirin, such as prevention of 
      venous thromboembolism, chemoprevention of colorectal (and other) cancers, and 
      reduced risk of dementia. These mechanisms include acetylation of other proteins 
      in blood coagulation, inhibition of COX-2 activity, and other COX-independent 
      mechanisms. The intent of this review is to develop the concept that the 
      multifaceted therapeutic effects of low-dose aspirin may reflect pleiotropic 
      consequences of platelet inhibition on pathophysiological tissue repair 
      processes. Furthermore, the clinical implications of this concept will be 
      discussed in terms of current clinical practice and future research.
CI  - Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. 
      Electronic address: carlo.patrono@rm.unicatt.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Chemoprevention
MH  - Colorectal Neoplasms/prevention & control
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Dementia, Vascular/prevention & control
MH  - Humans
MH  - Vascular Diseases/*prevention & control
MH  - Wound Healing/*drug effects
OTO - NOTNLM
OT  - atherothrombosis
OT  - colorectal cancer
OT  - platelet COX-1
OT  - venous thromboembolism
EDAT- 2015/07/04 06:00
MHDA- 2015/09/17 06:00
CRDT- 2015/07/04 06:00
PHST- 2015/02/27 00:00 [received]
PHST- 2015/04/21 00:00 [revised]
PHST- 2015/05/05 00:00 [accepted]
PHST- 2015/07/04 06:00 [entrez]
PHST- 2015/07/04 06:00 [pubmed]
PHST- 2015/09/17 06:00 [medline]
AID - S0735-1097(15)02282-2 [pii]
AID - 10.1016/j.jacc.2015.05.012 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2015 Jul 7;66(1):74-85. doi: 10.1016/j.jacc.2015.05.012.

PMID- 27729421
OWN - NLM
STAT- MEDLINE
DCOM- 20170427
LR  - 20220410
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 134
IP  - 20
DP  - 2016 Nov 15
TI  - Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes 
      Mellitus.
PG  - 1579-1594
AB  - Daily administration of low-dose aspirin has proved to be beneficial in 
      preventing recurrent cardiovascular events. However, the role of aspirin for 
      primary prevention in patients with no overt cardiovascular disease is more 
      controversial. In fact, in lower risk patients, the modest benefit in reducing 
      serious vascular events can be offset by the increased risk of bleeding, 
      including intracranial and gastrointestinal hemorrhage. Diabetes mellitus has 
      been associated with a substantially increased risk of both first and recurrent 
      atherothrombotic events, which makes aspirin therapy of potential value in these 
      subjects. Moving from general aspects of aspirin pharmacology and specific issues 
      in diabetes mellitus, this article reviews the literature on the topic of aspirin 
      for primary prevention in general, and in subjects with diabetes mellitus in 
      particular, to culminate with arguments pro and con and a practical risk-based 
      algorithm for aspirin initiation in daily practice.
CI  - © 2016 American Heart Association, Inc.
FAU - Capodanno, Davide
AU  - Capodanno D
AD  - From Ferrarotto Hospital, University of Catania, Catania, Italy (D.C.); and 
      University of Florida College of Medicine-Jacksonville (D.J.A.). 
      dcapodanno@gmail.com.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - From Ferrarotto Hospital, University of Catania, Catania, Italy (D.C.); and 
      University of Florida College of Medicine-Jacksonville (D.J.A.).
LA  - eng
PT  - Journal Article
DEP - 20161011
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacokinetics/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Diabetes Mellitus/*drug therapy
MH  - Humans
MH  - Risk Factors
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - aspirin
OT  - diabetes mellitus
OT  - primary prevention
EDAT- 2016/10/13 06:00
MHDA- 2017/04/28 06:00
CRDT- 2016/10/13 06:00
PHST- 2016/08/11 00:00 [received]
PHST- 2016/08/30 00:00 [accepted]
PHST- 2016/10/13 06:00 [pubmed]
PHST- 2017/04/28 06:00 [medline]
PHST- 2016/10/13 06:00 [entrez]
AID - CIRCULATIONAHA.116.023164 [pii]
AID - 10.1161/CIRCULATIONAHA.116.023164 [doi]
PST - ppublish
SO  - Circulation. 2016 Nov 15;134(20):1579-1594. doi: 
      10.1161/CIRCULATIONAHA.116.023164. Epub 2016 Oct 11.

PMID- 35768902
OWN - NLM
STAT- MEDLINE
DCOM- 20221010
LR  - 20230302
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 33
IP  - 8
DP  - 2022 Nov 17
TI  - Platelet inhibition by low-dose aspirin is not influenced by body mass or weight.
PG  - 1208-1213
LID - 10.1080/09537104.2022.2087868 [doi]
AB  - Aspirin's clinical efficacy may be influenced by body weight and mass. Although 
      inadequate platelet inhibition by aspirin is suggested as responsible, evidence 
      for this in non-diabetic patients is sparse. We investigated the influence of 
      body weight and mass on aspirin's inhibition of platelet aggregation in healthy 
      adults without diabetes. Cohort one (NYU, n = 84) had light transmission 
      aggregometry (LTA) of platelet-rich plasma to submaximal adenosine diphosphate 
      (ADP) and arachidonic acid (AA) before and following 1 week of daily 81 mg 
      non-enteric coated aspirin. Subjects in the validation cohort (Duke, n = 66) were 
      randomized to 81 mg or 325 mg non-enteric coated aspirin for 4 weeks, immediately 
      followed by 4 weeks of the other dose, with LTA to submaximal collagen, ADP, and 
      AA before and after each dosage period. Body mass index (BMI) range was 18.0-57.5 
      kg/m(2) and 25% were obese. Inhibition of platelet aggregation was similar 
      irrespective of BMI, body weight and aspirin dose. There was no correlation 
      between platelet aggregation before or after aspirin with BMI or body weight. Our 
      data demonstrate that aspirin produces potent inhibition of direct and indirect 
      COX1-mediated platelet aggregation in healthy adults without diabetes regardless 
      of body weight or mass - suggesting that other mechanisms explain lower 
      preventive efficacy of low-dose aspirin with increasing body weight/mass.
FAU - Heffron, Sean P
AU  - Heffron SP
AD  - Leon H Charney Division of Cardiology, Department of Medicine, NYU Grossman 
      School of Medicine, New York, NY, USA.
AD  - NYU Center for the Prevention of Cardiovascular Disease, NYU Langone Health, New 
      York, NY, USA.
FAU - Windheim, Joseph
AU  - Windheim J
AD  - Leon H Charney Division of Cardiology, Department of Medicine, NYU Grossman 
      School of Medicine, New York, NY, USA.
FAU - Barrett, Tessa J
AU  - Barrett TJ
AD  - Leon H Charney Division of Cardiology, Department of Medicine, NYU Grossman 
      School of Medicine, New York, NY, USA.
FAU - Voora, Deepak
AU  - Voora D
AD  - Department of Medicine, Duke Center for Applied Genomics & Precision Medicine, 
      Durham, NC, USA.
FAU - Berger, Jeffrey S
AU  - Berger JS
AD  - Leon H Charney Division of Cardiology, Department of Medicine, NYU Grossman 
      School of Medicine, New York, NY, USA.
AD  - NYU Center for the Prevention of Cardiovascular Disease, NYU Langone Health, New 
      York, NY, USA.
AD  - Division of Vascular Surgery, Department of Surgery, NYU Grossman School of 
      Medicine, New York, NY, USA.
LA  - eng
GR  - R01 HL114978/HL/NHLBI NIH HHS/United States
GR  - R01 HL157430/HL/NHLBI NIH HHS/United States
GR  - R35 HL144993/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220629
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Arachidonic Acid/pharmacology
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets
MH  - Body Weight
MH  - Collagen/pharmacology
MH  - Humans
MH  - Platelet Aggregation
MH  - *Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Platelet Function Tests
PMC - PMC9976777
MID - NIHMS1873267
OTO - NOTNLM
OT  - Aspirin
OT  - body weight
OT  - cyclooxygenase 1
OT  - obesity
OT  - platelet aggregation
COIS- Declaration of Interest: All authors report no conflict of interest.
EDAT- 2022/07/01 06:00
MHDA- 2022/10/12 06:00
PMCR- 2023/11/17
CRDT- 2022/06/30 00:32
PHST- 2023/11/17 00:00 [pmc-release]
PHST- 2022/07/01 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/06/30 00:32 [entrez]
AID - 10.1080/09537104.2022.2087868 [doi]
PST - ppublish
SO  - Platelets. 2022 Nov 17;33(8):1208-1213. doi: 10.1080/09537104.2022.2087868. Epub 
      2022 Jun 29.

PMID- 20632895
OWN - NLM
STAT- MEDLINE
DCOM- 20110609
LR  - 20131121
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 13
IP  - 3
DP  - 2010
TI  - A review of international pharmacoeconomic models assessing the use of aspirin in 
      primary prevention.
PG  - 418-27
LID - 10.3111/13696998.2010.499731 [doi]
AB  - PURPOSE: The aim of this narrative review was to summarise the cost analyses and 
      supporting trial data for aspirin prophylaxis in primary prevention. METHODS: A 
      PubMed search using the term 'aspirin and cost-effective and primary prevention' 
      was performed. Professional meetings (2009) were also searched for any relevant 
      abstracts contacting the terms 'aspirin' and 'cost effectiveness'. Where 
      possible, outcomes were discussed in terms of cost implications (expressed as 
      quality-adjusted life-year [QALY], disability-adjusted life-year or incremental 
      cost-effectiveness ratio) in relation to the annual risk of cardiovascular 
      disease. Aspirin was included in cost-effectiveness models that determined direct 
      cost savings. RESULTS: A total of 67 papers were identified using PubMed, and 17 
      cost-effectiveness studies, which assessed aspirin in primary prevention (largely 
      based on the key primary prevention studies), and two abstracts were included in 
      the review. These analyses showed that low-dose aspirin was cost effective in a 
      variety of scenarios. In the UK, Germany, Spain, Italy and Japan, the mean 
      10-year direct cost saving (including follow-up costs and aspirin costs) per 
      patient was €201, €281, €797, €427 and €889 with aspirin use in patients with an 
      annual coronary heart disease risk of 1.5%. Cost-effectiveness analyses were 
      affected by age, risk level for stroke and myocardial infarction (MI), risk of 
      bleeds and adherence to aspirin. Underutilisation is a major limiting factor, as 
      the appropriate use of aspirin in an eligible population (n=301,658) based on the 
      NHANES database would prevent 1273 MIs, 2184 angina episodes and 565 ischaemic 
      strokes in patients without previous events; this would result in a direct cost 
      saving of $79.6 million (€54.7 million; 2010 values), which includes aspirin 
      costs. CONCLUSIONS: Most analyses in primary prevention have shown that low-dose 
      aspirin is a cost-effective option, and is likely to meet the willingness of a 
      healthcare system to pay for any additional QALY gained in the majority of 
      healthcare systems.
FAU - Annemans, Lieven
AU  - Annemans L
AD  - Ghent University, Ghent, Belgium and Vrije Universiteit Brussel, Brussels, 
      Belgium.
FAU - Wittrup-Jensen, Kim
AU  - Wittrup-Jensen K
FAU - Bueno, Héctor
AU  - Bueno H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*economics/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*economics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Economics, Pharmaceutical
MH  - Female
MH  - Humans
MH  - Male
MH  - Models, Econometric
MH  - Primary Prevention/*economics/methods
EDAT- 2010/07/17 06:00
MHDA- 2011/06/10 06:00
CRDT- 2010/07/17 06:00
PHST- 2010/07/17 06:00 [entrez]
PHST- 2010/07/17 06:00 [pubmed]
PHST- 2011/06/10 06:00 [medline]
AID - 10.3111/13696998.2010.499731 [doi]
PST - ppublish
SO  - J Med Econ. 2010;13(3):418-27. doi: 10.3111/13696998.2010.499731.

PMID- 26574989
OWN - NLM
STAT- MEDLINE
DCOM- 20180216
LR  - 20181202
IS  - 1646-0758 (Electronic)
IS  - 0870-399X (Linking)
VI  - 28
IP  - 4
DP  - 2015 Jul-Aug
TI  - [The Role of Aspirin in Preeclampsia Prevention: State of the Art].
PG  - 517-24
AB  - INTRODUCTION: The role of acetyl salicylic acid (ASA or aspirin) in preeclampsia 
      prevention and in other complications has been subject to studies and 
      controversies for the last 30 years. The first research results concerning the 
      role of placenta in preeclampsia have been published by the end of seventies and 
      they showed an increase in the platelet activity and a prostaglandin synthesis 
      disturbance, as a consequence of a deficient placentation. In the last twenty 
      years of the XX century important studies were published on the 
      aspirinprophylactic role in preeclampsia risk reduction. MATERIAL AND METHODS: To 
      analyze published studies about Aspirin use for preeclampsia prevention and about 
      the more adequate dosage to be administered, Medline was used for searching the 
      most relevant prospective research papers on this subject in order to evaluate 
      current evidence about the use of aspirin in this context. Relevant citations 
      were extracted from Embase, PubMed and the Cochrane Central Register of 
      Controlled Trials. We divided the studies in two groups; one with aspirine 
      administration before 16 weeks and the other having a larger use, between the 
      first and the third trimester. RESULTS AND DISCUSSION: The first group of 
      studies, with a lesser number of cases but an earlier time of administration 
      until 16 weeks, concluded that a positive role of aspirine was possible in 
      reducing severity of preeclampsia; the second group with a larger number of cases 
      but less restricted conditions and timing of administration, had controversial 
      results, with reduced positive actions of the drug. Meta-analysis of these 
      published studies concluded that favorable results were associated to stricter 
      criteria and ideal timing for startingthe drug. CONCLUSION: As we do not have 
      other pharmacologic alternatives, low dosage of Aspirin between 80-150 mg a day 
      in the first trimester and until 16 weeks, at evening time, is a possible choice 
      in cases of risk, and is still contributing for an early preeclampsia risk 
      reduction.
FAU - Campos, Ana
AU  - Campos A
AD  - Departamento de Obstetrícia. Maternidade Alfredo da Costa. Centro Hospitalar 
      Lisboa Central. Lisboa. Portugal. Faculdade de Ciências Médicas. Universidade 
      Nova de Lisboa. Lisboa. Portugal.
LA  - por
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
TT  - O Papel da Aspirina na Prevenção da Pré-Eclâmpsia: Estado da Arte.
DEP - 20150831
PL  - Portugal
TA  - Acta Med Port
JT  - Acta medica portuguesa
JID - 7906803
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/drug therapy/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Prospective Studies
EDAT- 2015/11/18 06:00
MHDA- 2018/02/17 06:00
CRDT- 2015/11/18 06:00
PHST- 2014/11/18 00:00 [received]
PHST- 2015/06/22 00:00 [accepted]
PHST- 2015/11/18 06:00 [entrez]
PHST- 2015/11/18 06:00 [pubmed]
PHST- 2018/02/17 06:00 [medline]
PST - ppublish
SO  - Acta Med Port. 2015 Jul-Aug;28(4):517-24. Epub 2015 Aug 31.

PMID- 35366783
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20221207
IS  - 1875-6182 (Electronic)
IS  - 1871-5257 (Linking)
VI  - 20
IP  - 3
DP  - 2022
TI  - The Effect of Aspirin on the Prevention of Pro-thrombotic States in Hospitalized 
      COVID-19 Patients: Systematic Review.
PG  - 189-196
LID - 10.2174/1871525720666220401102728 [doi]
AB  - INTRODUCTION: Thromboembolic events are one of the important complications in 
      COVID-19 patients, especially in severe cases. Aspirin affects platelet function 
      by irreversibly inhibiting cyclooxygenase activity, reducing the risk of 
      thrombosis. The current systematic review aimed to evaluate aspirin's 
      effectiveness in preventing pro-thrombotic states in COVID-19 hospitalized 
      patients. METHODS: The systematic search was done in PubMed/Medline, EMBASE, and 
      Medrxiv until September 27, 2021. The following keywords were used: "COVID-19", 
      "SARS-CoV-2", "2019 Novel Coronavirus", "Aspirin," and "Acetylsalicylic Acid." 
      RESULTS: Twelve studies were included. In COVID-19 patients, aspirin can reduce 
      CRP, IL-6 levels, and platelet aggregation by inhibiting thromboxane A2. It can 
      also improve antiviral immunity by hindering the biosynthesis of prostaglandins 
      and lipoxin. Eight out of twelve articles indicated that aspirin provided a 
      beneficial effect on COVID-19. Most studies consider lowered mechanical 
      ventilation needs, ICU admission, illness severity, overt thrombosis, and 
      clinical outcomes in COVID-19 patients receiving aspirin. CONCLUSION: Aspirin as 
      an antiplatelet and anti-inflammatory agent may reduce the mortality rates in 
      hospitalized patients with severe COVID-19. Further observational studies are 
      necessary to determine the effect of aspirin on the prevention of pro-thrombotic 
      states in hospitalized COVID- 19 patients.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Abdi, Masoumeh
AU  - Abdi M
AD  - Student Research Committee, School of Medicine, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
FAU - Lamardi, Zahra Hoseini
AU  - Lamardi ZH
AD  - Student Research Committee, School of Medicine, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
FAU - Shirjan, Fatemeh
AU  - Shirjan F
AD  - Student Research Committee, School of Medicine, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
FAU - Mohammadi, Leila
AU  - Mohammadi L
AD  - Student Research Committee, School of Medicine, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
FAU - Abadi, Sahel Shafiee Dolat
AU  - Abadi SSD
AD  - Department of Microbiology, School of Medicine, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
FAU - Massoudi, Nilofar
AU  - Massoudi N
AD  - Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran.
FAU - Zangiabadian, Moein
AU  - Zangiabadian M
AD  - Student Research Committee, School of Medicine, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
FAU - Nasiri, Mohammad Javad
AU  - Nasiri MJ
AD  - Department of Microbiology, School of Medicine, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - Netherlands
TA  - Cardiovasc Hematol Agents Med Chem
JT  - Cardiovascular & hematological agents in medicinal chemistry
JID - 101266881
RN  - 0 (Antiviral Agents)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipoxins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prostaglandins)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Interleukin-6
MH  - *Lipoxins
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prostaglandin-Endoperoxide Synthases
MH  - Prostaglandins
MH  - SARS-CoV-2
MH  - *Thrombosis/drug therapy/prevention & control
MH  - Thromboxane A2
MH  - *COVID-19 Drug Treatment
OTO - NOTNLM
OT  - Aspirin
OT  - COVID-19
OT  - SARS-COV-2
OT  - acetylsalicylic acid
OT  - pro-thrombotic
OT  - thrombosis
EDAT- 2022/04/04 06:00
MHDA- 2022/09/24 06:00
CRDT- 2022/04/03 20:21
PHST- 2022/01/06 00:00 [received]
PHST- 2022/02/04 00:00 [revised]
PHST- 2022/02/18 00:00 [accepted]
PHST- 2022/04/04 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/04/03 20:21 [entrez]
AID - CHAMC-EPUB-122127 [pii]
AID - 10.2174/1871525720666220401102728 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Agents Med Chem. 2022;20(3):189-196. doi: 
      10.2174/1871525720666220401102728.

PMID- 15962098
OWN - NLM
STAT- MEDLINE
DCOM- 20051214
LR  - 20220311
IS  - 0074-0276 (Print)
IS  - 0074-0276 (Linking)
VI  - 100 Suppl 1
DP  - 2005 Mar
TI  - New insights into the anti-inflammatory actions of aspirin-induction of nitric 
      oxide through the generation of epi-lipoxins.
PG  - 49-54
AB  - Aspirin has always remained an enigmatic drug. Not only does it present with new 
      benefits for treating an ever-expanding list of apparently unrelated diseases at 
      an astounding rate but also because aspirin enhances our understanding of the 
      nature of these diseases process. Originally, the beneficial effects of aspirin 
      were shown to stem from its inhibition of cyclooxygenase-derived prostaglandins, 
      fatty acid metabolites that modulate host defense. However, in addition to 
      inhibiting cyclooxygenase activity aspirin can also inhibit pro-inflammatory 
      signaling pathways, gene expression and other factors distinct from eicosanoid 
      biosynthesis that drive inflammation as well as enhance the synthesis of 
      endogenous protective anti-inflammatory factors. Its true mechanism of action in 
      anti-inflammation remains unclear. Here the data from a series of recent 
      experiments proposing that one of aspirin's predominant roles in inflammation is 
      the induction of nitric oxide, which potently inhibits leukocyte/endothelium 
      interaction during acute inflammation, will be discussed. It will be argued that 
      this nitric oxide-inducing effects are exclusive to aspirin due to its unique 
      ability, among the family of traditional anti-inflammatory drugs, to acetylate 
      the active site of inducible cyclooxygenase and generate a family of lipid 
      mediators called the epi-lipoxins that are increasingly being shown to have 
      profound roles in a range of host defense responses.
FAU - Gilroy, Derek W
AU  - Gilroy DW
AD  - BHF Laboratories, Division of Medicine, Centre for Clinical Pharmacology and 
      Therapeutics, University College London, London WC1E 6JJ, UK. d.gilroy@ucl.ac.uk
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20050614
PL  - Brazil
TA  - Mem Inst Oswaldo Cruz
JT  - Memorias do Instituto Oswaldo Cruz
JID - 7502619
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Eicosanoids)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Lipoxins)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Eicosanoids/metabolism
MH  - Humans
MH  - Inflammation/*drug therapy/metabolism
MH  - Inflammation Mediators/*metabolism
MH  - Lipoxins/*biosynthesis
MH  - Nitric Oxide/*metabolism
RF  - 30
EDAT- 2005/06/18 09:00
MHDA- 2005/12/15 09:00
CRDT- 2005/06/18 09:00
PHST- 2005/06/18 09:00 [pubmed]
PHST- 2005/12/15 09:00 [medline]
PHST- 2005/06/18 09:00 [entrez]
AID - S0074-02762005000900009 [pii]
AID - 10.1590/s0074-02762005000900009 [doi]
PST - ppublish
SO  - Mem Inst Oswaldo Cruz. 2005 Mar;100 Suppl 1:49-54. doi: 
      10.1590/s0074-02762005000900009. Epub 2005 Jun 14.

PMID- 27789660
OWN - NLM
STAT- MEDLINE
DCOM- 20180209
LR  - 20180402
IS  - 1708-8267 (Electronic)
IS  - 1081-5589 (Linking)
VI  - 65
IP  - 2
DP  - 2017 Feb
TI  - Does aspirin use reduce the risk for cancer?
PG  - 391-392
LID - 10.1136/jim-2016-000275 [doi]
AB  - Recently, studies have reported that aspirin has chemopreventive properties. In 
      this study, we used the Taiwan NHI database, which covers a population of 23 
      million (99.99%) Taiwanese from 2001 to 2011. This was a case-control study which 
      identified 601,733 patients using ICD-9-CM codes who were diagnosed with cancer. 
      Each case with 4 eligible controls was matched for age, sex, and index date and 
      adjusted for confounding factors. The observed overall cancer risk (adjusted OR 
      (AOR), 0.95; 95% CI 0.94 to 0.96) reduced with aspirin use, specifically, 
      colorectal (AOR, 0.97; 95% CI 0.94 to 0.99) and digestive system (AOR, 0.96; 95% 
      CI 0.94 to 0.98) cancers. Findings from the Asian population would contribute to 
      the discussion on aspirin's safety profile.
CI  - Copyright © 2016 American Federation for Medical Research.
FAU - Iqbal, Usman
AU  - Iqbal U
AD  - Masters Program in Global Health and Development Department, College of Public 
      Health, Taipei Medical University, Taipei, Taiwan.
AD  - International Center for Health Information Technology, Taipei, Taiwan.
FAU - Yang, Hsuan-Chia
AU  - Yang HC
AD  - International Center for Health Information Technology, Taipei, Taiwan.
AD  - Institute of Biomedical Informatics, National Yang Ming University, Taipei, 
      Taiwan.
FAU - Jian, Wen-Shan
AU  - Jian WS
AD  - International Center for Health Information Technology, Taipei, Taiwan.
AD  - School of Health Care Administration, College of Management, Taipei Medical 
      University, Taipei, Taiwan.
FAU - Yen, Yun
AU  - Yen Y
AD  - College of Medical Science and Technology, Taipei Medical University, Taipei, 
      Taiwan.
AD  - City of Hope, Duarte, California, USA.
FAU - Li, Yu-Chuan Jack
AU  - Li YJ
AD  - International Center for Health Information Technology, Taipei, Taiwan.
AD  - College of Medical Science and Technology, Taipei Medical University, Taipei, 
      Taiwan.
AD  - Department of Dermatology, Wan Fang Hospital, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161027
PL  - England
TA  - J Investig Med
JT  - Journal of investigative medicine : the official publication of the American 
      Federation for Clinical Research
JID - 9501229
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoplasms/*epidemiology
MH  - Risk Factors
MH  - Taiwan/epidemiology
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer
OT  - Carcinogenesis
OT  - Drug-Related Side Effects and Adverse Reactions
OT  - Drugs, Investigational
EDAT- 2016/10/30 06:00
MHDA- 2018/02/10 06:00
CRDT- 2016/10/30 06:00
PHST- 2016/09/23 00:00 [accepted]
PHST- 2016/10/30 06:00 [pubmed]
PHST- 2018/02/10 06:00 [medline]
PHST- 2016/10/30 06:00 [entrez]
AID - jim-2016-000275 [pii]
AID - 10.1136/jim-2016-000275 [doi]
PST - ppublish
SO  - J Investig Med. 2017 Feb;65(2):391-392. doi: 10.1136/jim-2016-000275. Epub 2016 
      Oct 27.

PMID- 18677248
OWN - NLM
STAT- MEDLINE
DCOM- 20081028
LR  - 20141009
IS  - 1542-538X (Electronic)
IS  - 0744-6020 (Linking)
VI  - 27
IP  - 4
DP  - 2008 Jul-Aug
TI  - Venous thromboembolic prophylaxis: the use of aspirin.
PG  - 225-30; quiz 231-2
LID - 10.1097/01.NOR.0000330303.68232.47 [doi]
AB  - Venous thromboembolism (VTE) is a term used collectively for deep vein thrombosis 
      (DVT) and pulmonary embolism. Without prophylaxis, the incidence of documented 
      DVT in the orthopaedic surgery patient is reported in the range of 50%-60%. A 
      multimodal approach to DVT prophylaxis is the standard of care for all patients 
      undergoing total hip arthroplasty and total knee arthroplasty. At our local 
      hospital, low-risk patients are being sent home with aspirin as the medication 
      for VTE prophylaxis. This article will provide an overview of the pathophysiology 
      of VTE and the current prevention guidelines including the use of aspirin.
FAU - Snyder, Brenda K
AU  - Snyder BK
AD  - Labor and Delivery, St. Vincent Health Center, Erie, PA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Orthop Nurs
JT  - Orthopedic nursing
JID - 8409486
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Education, Continuing
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Venous Thromboembolism/physiopathology/*prevention & control
RF  - 17
EDAT- 2008/08/05 09:00
MHDA- 2008/10/29 09:00
CRDT- 2008/08/05 09:00
PHST- 2008/08/05 09:00 [pubmed]
PHST- 2008/10/29 09:00 [medline]
PHST- 2008/08/05 09:00 [entrez]
AID - 00006416-200807000-00006 [pii]
AID - 10.1097/01.NOR.0000330303.68232.47 [doi]
PST - ppublish
SO  - Orthop Nurs. 2008 Jul-Aug;27(4):225-30; quiz 231-2. doi: 
      10.1097/01.NOR.0000330303.68232.47.

PMID- 27315190
OWN - NLM
STAT- MEDLINE
DCOM- 20170509
LR  - 20221207
IS  - 1525-6065 (Electronic)
IS  - 1064-1955 (Linking)
VI  - 35
IP  - 3
DP  - 2016 Aug
TI  - Preventing preeclampsia and its fetal complications with low-dose aspirin in East 
      Asians and non-East Asians:A systematic review and meta-analysis.
PG  - 426-35
LID - 10.1080/10641955.2016.1178772 [doi]
AB  - BACKGROUND: Low-dose aspirin can reduce the incidence of preeclampsia and 
      intrauterine growth restriction (IUGR). However, the effects of ethnicity upon 
      low-dose aspirin's efficacy has not been analyzed. Here, we comparatively 
      evaluated the efficacy of low-dose aspirin in preventing preeclampsia and related 
      fetal complications in East Asian and non-East Asian pregnant women at risk for 
      preeclampsia. METHODS: Several databases were searched for randomized controlled 
      trials (RCTs) comparing low-dose aspirin with either placebo or no treatment in 
      pregnant women at risk for preeclampsia. Odds ratios (ORs) and associated 95% 
      confidence intervals (CIs) for preeclampsia and related fetal outcomes were 
      tabulated. RESULTS: Low-dose aspirin significantly reduced preeclampsia risk in 
      both East Asians (OR = 0.20, 95% CI: 0.11-0.35) and non-East Asians (OR = 0.84, 
      95% CI: 0.77-0.92). Low-dose aspirin significantly reduced IUGR risk in East 
      Asians (OR = 0.36, 95% CI: 0.20-0.67) but not in non-East Asians (OR = 0.85, 95% 
      CI: 0.41-1.77). Low-dose aspirin did not significantly reduce the risk of 
      cesarean section in either East Asians (OR = 0.67, 95% CI: 0.14-3.22) or non-East 
      Asians (OR = 1.01, 95% CI: 0.86-1.19). CONCLUSIONS: Low-dose aspirin is effective 
      in reducing preeclampsia risk in both East Asians and non-East Asians and has 
      differential effects in East Asians and non-East Asians with respect to IUGR.
FAU - Gan, Jie
AU  - Gan J
AD  - a Department of Obstetrics and Gynecology , The First Affiliated Hospital of 
      Chongqong Medical University , Yuzhong , Chongqing , P. R. China.
FAU - He, Huan
AU  - He H
AD  - a Department of Obstetrics and Gynecology , The First Affiliated Hospital of 
      Chongqong Medical University , Yuzhong , Chongqing , P. R. China.
FAU - Qi, Hongbo
AU  - Qi H
AD  - a Department of Obstetrics and Gynecology , The First Affiliated Hospital of 
      Chongqong Medical University , Yuzhong , Chongqing , P. R. China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160617
PL  - England
TA  - Hypertens Pregnancy
JT  - Hypertension in pregnancy
JID - 9421297
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Hypertens Pregnancy. 2017 Aug;36(3):282. PMID: 28635350
MH  - Asian People
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Fetal Growth Retardation/ethnology/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pre-Eclampsia/ethnology/*prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Asian
OT  - IUGR
OT  - aspirin
OT  - intrauterine growth restriction
OT  - preeclampsia
EDAT- 2016/06/18 06:00
MHDA- 2017/05/10 06:00
CRDT- 2016/06/18 06:00
PHST- 2016/06/18 06:00 [entrez]
PHST- 2016/06/18 06:00 [pubmed]
PHST- 2017/05/10 06:00 [medline]
AID - 10.1080/10641955.2016.1178772 [doi]
PST - ppublish
SO  - Hypertens Pregnancy. 2016 Aug;35(3):426-35. doi: 10.1080/10641955.2016.1178772. 
      Epub 2016 Jun 17.

PMID- 12515107
OWN - NLM
STAT- MEDLINE
DCOM- 20030212
LR  - 20191106
IS  - 0003-3928 (Print)
IS  - 0003-3928 (Linking)
VI  - 51
IP  - 5
DP  - 2002 Nov
TI  - [What is the place of aspirin in venous thrombosis prophylaxis?].
PG  - 296-302
AB  - Since Virchow triade, it is well established that venous thrombosis is a 
      multifactorial process involving various cellular and plasmatic protagonists. 
      Aspirin antihrombotic efficacy seems not only due to its antiplatelet effects and 
      thromboxane A2 synthesis inhibition. Anti-Platelet Trialists Collaboration 
      metaanalysis stressed in 1994 the interest of aspirin treatment leading to 40% 
      reduction of thrombosis relative risk. Regarding studies heterogeneity and 
      outcomes criteria variety, its use in such context remains a matter of debate. Is 
      the recent publication of PEP trial showing a significant decrease of pulmonary 
      embolism mortality (0.6 versus 0.3%, p = 0.03) able to reinforce aspirin use in 
      venous thrombosis prophylaxis? Were numerous and consecutive criticisms 
      justified? Is there still a potential indication for aspirin in this setting? The 
      experts of the last ACCP consensus conference recommended not to recommend 
      aspirin in venous thrombosis prophylaxis with the highest level of evidence 
      (grade A).
FAU - Elalamy, I
AU  - Elalamy I
AD  - Service d'hématologie biologique, Hôtel-Dieu, place du parvis-Notre-Dame, 75181 
      Paris, France. ismail.elalamy@htd.ap-hop-paris.fr
FAU - Hatmi, M
AU  - Hatmi M
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Quelle place pour l'aspirine en prophylaxie antithrombotique veineuse?
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Evidence-Based Medicine
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Pulmonary Embolism/*prevention & control
MH  - Venous Thrombosis/*prevention & control
RF  - 37
EDAT- 2003/01/08 04:00
MHDA- 2003/02/14 04:00
CRDT- 2003/01/08 04:00
PHST- 2003/01/08 04:00 [pubmed]
PHST- 2003/02/14 04:00 [medline]
PHST- 2003/01/08 04:00 [entrez]
AID - S0003-3928(02)00131-2 [pii]
AID - 10.1016/s0003-3928(02)00131-2 [doi]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 2002 Nov;51(5):296-302. doi: 
      10.1016/s0003-3928(02)00131-2.

PMID- 1859235
OWN - NLM
STAT- MEDLINE
DCOM- 19910829
LR  - 20131121
IS  - 0003-9764 (Print)
IS  - 0003-9764 (Linking)
VI  - 48
IP  - 5
DP  - 1991 May
TI  - [Pharmacokinetics of aspirin in African children with normal nutrition and 
      malnutrition].
PG  - 337-41
AB  - Pharmacokinetics of aspirin given orally at antipyretic dose (12 mg/kg) were 
      studied in 11 African children aged 4-48 months. In order to examine the 
      influence of nutritional status on aspirin kinetics, children were classified 
      according to Waterlow criteria. Blood samples were collected during the 8 hours 
      following the initial dose. Albumin, prealbumin and transferrin plasma levels 
      were measured and plasma salicylic acid (SA) concentrations determined by a 
      fluorometric method. Nutritional status seemed to have no prominent effect on 
      plasma concentrations of SA. The volume of distribution found in our study was 
      lower than those obtained in other studies. This could be explained by lower 
      plasma aspirin esterase activities in black children. There were large individual 
      variations in plasma salicylate concentrations. For example, even at antipyretic 
      doses, saturation phenomena appeared in two children.
FAU - Treluyer, J M
AU  - Treluyer JM
AD  - Service de Pédiatrie, Hôpital Ambroise-Paré, Boulogne.
FAU - Sultan, E
AU  - Sultan E
FAU - Alexandre, J A
AU  - Alexandre JA
FAU - Roux, A
AU  - Roux A
FAU - Flouvat, B
AU  - Flouvat B
FAU - Lagardère, B
AU  - Lagardère B
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Pharmacocinétique de l'aspirine chez l'enfant africain normonutri et malnutri.
PL  - France
TA  - Arch Fr Pediatr
JT  - Archives francaises de pediatrie
JID - 0372421
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacokinetics
MH  - Child, Preschool
MH  - Gabon
MH  - Humans
MH  - Infant
MH  - Nutrition Disorders/*metabolism
MH  - *Nutritional Status
RF  - 22
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
PST - ppublish
SO  - Arch Fr Pediatr. 1991 May;48(5):337-41.

PMID- 17435267
OWN - NLM
STAT- MEDLINE
DCOM- 20070511
LR  - 20191110
IS  - 0098-8243 (Print)
IS  - 0098-8243 (Linking)
VI  - 32
IP  - 3
DP  - 2006 Fall
TI  - New mechanism for an old drug: aspirin triggers anti-inflammatory lipid mediators 
      with gender implications.
PG  - 150-7
AB  - Aspirin increases anti-inflammatory aspirin-triggered lipoxin A4 levels in 
      healthy subjects in a gender-specific manner in a randomized clinical study. 
      Thus, formation of aspirin-triggered lipoxin A4 may provide a novel mechanism 
      underlying aspirin's clinical benefits, and shed light on gender-dependent 
      therapeutics of aspirin.
FAU - Chiang, Nan
AU  - Chiang N
AD  - The Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Serhan, Charles N
AU  - Serhan CN
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Compr Ther
JT  - Comprehensive therapy
JID - 7605837
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/*pharmacology
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Humans
MH  - Lipoxins/*biosynthesis
MH  - Neutrophils/metabolism
MH  - Randomized Controlled Trials as Topic
MH  - Sex Factors
MH  - Thromboxane B2/antagonists & inhibitors
RF  - 37
EDAT- 2007/04/17 09:00
MHDA- 2007/05/12 09:00
CRDT- 2007/04/17 09:00
PHST- 2006/04/28 00:00 [received]
PHST- 1999/11/30 00:00 [revised]
PHST- 2006/05/11 00:00 [accepted]
PHST- 2007/04/17 09:00 [pubmed]
PHST- 2007/05/12 09:00 [medline]
PHST- 2007/04/17 09:00 [entrez]
AID - COMP:32:3:150 [pii]
AID - 10.1007/s12019-006-0005-6 [doi]
PST - ppublish
SO  - Compr Ther. 2006 Fall;32(3):150-7. doi: 10.1007/s12019-006-0005-6.

PMID- 22494617
OWN - NLM
STAT- MEDLINE
DCOM- 20121011
LR  - 20131121
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 22
IP  - 9
DP  - 2012 May 1
TI  - Glucose-aspirin: Synthesis and in vitro anti-cancer activity studies.
PG  - 3168-71
LID - 10.1016/j.bmcl.2012.03.053 [doi]
AB  - Glucose-aspirin (GA) was synthesized by conjugating aspirin (ASA) to glucose. The 
      water solubility and biological activity of GA was studied in comparison to 
      aspirin. The human serum protease activity on the ester showed a slower 
      hydrolysis rate, compared to ASA. Glucose-aspirin was sevenfold more water 
      soluble than aspirin and it was about 8- to 9-fold more active in inhibiting cell 
      growth than aspirin in their anti-cancer cell culture activity on breast (SKBR3), 
      pancreatic (PANC-1), and prostate (PC3) cell lines, whereas the activity was 
      similar on a benign non-cancerous cell line (WI 38). In conclusion, GA is a 
      highly water soluble derivative of aspirin. Although the serum hydrolysis for GA 
      was slower, there was significant anti-cancer activity at the doses studied under 
      the experimental conditions.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Jacob, James N
AU  - Jacob JN
AD  - Organomed Corporation, 11 Grandview St., Unit 8, Coventry, RI 02816, USA. 
      info@organomed.com
FAU - Tazawa, Makio J
AU  - Tazawa MJ
LA  - eng
PT  - Journal Article
DEP - 20120323
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (3-O-(2'-acetoxy)benzoyl-2-glucopyranose)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Glucosides)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*chemical synthesis/pharmacology
MH  - Aspirin/*analogs & derivatives/*chemical synthesis/chemistry/therapeutic use
MH  - Cell Line, Tumor
MH  - Early Detection of Cancer
MH  - Glucose/*chemistry/therapeutic use
MH  - Glucosides/*chemical synthesis/chemistry/therapeutic use
MH  - Humans
MH  - Hydrolysis
MH  - Peptide Hydrolases/blood/metabolism
MH  - Solubility
EDAT- 2012/04/13 06:00
MHDA- 2012/10/12 06:00
CRDT- 2012/04/13 06:00
PHST- 2012/01/06 00:00 [received]
PHST- 2012/03/08 00:00 [revised]
PHST- 2012/03/13 00:00 [accepted]
PHST- 2012/04/13 06:00 [entrez]
PHST- 2012/04/13 06:00 [pubmed]
PHST- 2012/10/12 06:00 [medline]
AID - S0960-894X(12)00374-5 [pii]
AID - 10.1016/j.bmcl.2012.03.053 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2012 May 1;22(9):3168-71. doi: 10.1016/j.bmcl.2012.03.053. 
      Epub 2012 Mar 23.

PMID- 6107463
OWN - NLM
STAT- MEDLINE
DCOM- 19810116
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8198
DP  - 1980 Oct 11
TI  - Aspirin and fluid losses in diarrhoea.
PG  - 793-4
FAU - Nalin, D R
AU  - Nalin DR
LA  - eng
PT  - Letter
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Dehydration/*physiopathology
MH  - Diarrhea, Infantile/*drug therapy/physiopathology
MH  - Humans
MH  - Infant
OID - PIP: 801972
OID - POP: 00081240
OAB - Dr. Burke et al's aspirin therapy of diarrhea raises several issues, particularly 
      the methodological aspect. The difference in stool volume between the aspirin and 
      placebo groups is small (99 ml/day) but the difference between aspirin and 
      'untreated' groups is not statistically significant, suggesting that the placebo 
      might have aggravated diarrhea. The small difference between the stool volumes 
      might be due to the aspirin's small glucose-like effect which make the 
      aspirin-containing solution more absorbable than in the control group, rather 
      than to any antagonism of enterotoxin effects. A slight osmotic aggravation of 
      diarrhea may have been caused by the placebo and this could have led to the 
      erroneous conclusion that aspirin was reducing diarrhea by anti-enterotoxic 
      action. Other criticisms of Dr. Burke's study concern: 1) inconsistencies in the 
      use of weight gain as the covariate in the ANOVA analysis; 2) inadequate data on 
      degeee of admission dehydration, and 3) derivation of the distribution 20, 31, 
      31. The statement that aspirin could be a substitute in areas where intravenous 
      fluids are scarce is unjustified.
OABL- eng
OTO - PIP
OT  - Biology
OT  - *Diarrhea
OT  - Diseases
OT  - *Fluid Balance
OT  - Homeostasis
OT  - Oral Rehydration
OT  - Physiology
GN  - PIP: TJ: LANCET.
EDAT- 1980/10/11 00:00
MHDA- 1980/10/11 00:01
CRDT- 1980/10/11 00:00
PHST- 1980/10/11 00:00 [pubmed]
PHST- 1980/10/11 00:01 [medline]
PHST- 1980/10/11 00:00 [entrez]
AID - S0140-6736(80)90398-0 [pii]
AID - 10.1016/s0140-6736(80)90398-0 [doi]
PST - ppublish
SO  - Lancet. 1980 Oct 11;2(8198):793-4. doi: 10.1016/s0140-6736(80)90398-0.

PMID- 25743752
OWN - NLM
STAT- MEDLINE
DCOM- 20150831
LR  - 20171116
IS  - 1880-3989 (Electronic)
IS  - 0388-1350 (Linking)
VI  - 40
IP  - 1
DP  - 2015 Feb
TI  - Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling 
      pathway.
PG  - 127-36
LID - 10.2131/jts.40.127 [doi]
AB  - Aspirin has been reported to regulate lipid metabolism. However, the mechanism 
      underlying the regulation is not clear. We presently investigated aspirin's 
      promotion of AMP-activated protein kinase (AMPK) pathway activation in human 
      hepatoma HepG2 cells by examining AMPK expression, the promotion of AMPK 
      activation. Then we investigated the influence of aspirin-promoted AMPK signaling 
      on fatty acid oxidation in HepG2 cells. The results demonstrated that aspirin 
      treatment did not regulate the expression of AMPK and its downstream target, 
      Acetyl-Coenzyme A Carboxylase (ACC), but activated the AMPK signaling pathway by 
      promoting the phosphorylation of AMPK and ACC. And, interestingly, the promotion 
      by aspirin is dependent of cellular esterase, which catalyzes aspirin to 
      salicylate. Moreover, the activated AMPK signaling promoted the fatty acid 
      oxidation, by promoting expression of Carnitine palmitoyltransferase I (CPT1) and 
      Medium-Chain Acyl-CoA Dehydrogenase (MCAD) in both mRNA and protein levels. Thus, 
      we confirmed in this study that aspirin promoted lipid oxidation by upregulating 
      the AMPK signaling pathway.
FAU - He, Zhenxing
AU  - He Z
AD  - Department of Hepatopancreatobiliary Surgery, Nanchong Central Hospital, China.
FAU - Peng, Yong
AU  - Peng Y
FAU - Duan, Wentao
AU  - Duan W
FAU - Tian, Yunhong
AU  - Tian Y
FAU - Zhang, Jian
AU  - Zhang J
FAU - Hu, Tao
AU  - Hu T
FAU - Cai, Yu
AU  - Cai Y
FAU - Feng, Yuan
AU  - Feng Y
FAU - Li, Guangming
AU  - Li G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - J Toxicol Sci
JT  - The Journal of toxicological sciences
JID - 7805798
RN  - 0 (Fatty Acids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - EC 1.3.8.7 (Acyl-CoA Dehydrogenase)
RN  - EC 2.3.1.21 (Carnitine O-Palmitoyltransferase)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - EC 6.4.1.2 (Acetyl-CoA Carboxylase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - AMP-Activated Protein Kinases/*metabolism
MH  - Acetyl-CoA Carboxylase/metabolism
MH  - Acyl-CoA Dehydrogenase/metabolism
MH  - Aspirin/metabolism/*pharmacology
MH  - Carcinoma, Hepatocellular/*metabolism
MH  - Carnitine O-Palmitoyltransferase/metabolism
MH  - Fatty Acids/metabolism
MH  - Hep G2 Cells
MH  - Humans
MH  - Lipid Metabolism/*drug effects
MH  - Liver Neoplasms/*metabolism
MH  - Phosphorylation/drug effects
MH  - Platelet Aggregation Inhibitors/metabolism/*pharmacology
MH  - RNA, Messenger/metabolism
MH  - Signal Transduction/*drug effects/genetics
MH  - Up-Regulation/drug effects
EDAT- 2015/03/07 06:00
MHDA- 2015/09/01 06:00
CRDT- 2015/03/07 06:00
PHST- 2015/03/07 06:00 [entrez]
PHST- 2015/03/07 06:00 [pubmed]
PHST- 2015/09/01 06:00 [medline]
AID - 10.2131/jts.40.127 [doi]
PST - ppublish
SO  - J Toxicol Sci. 2015 Feb;40(1):127-36. doi: 10.2131/jts.40.127.

PMID- 27998883
OWN - NLM
STAT- MEDLINE
DCOM- 20171113
LR  - 20190420
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 10
IP  - 2
DP  - 2017 Feb
TI  - Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting 
      Platelet Cyclooxygenase-1.
PG  - 142-152
LID - 10.1158/1940-6207.CAPR-16-0241 [doi]
AB  - The mechanism by which aspirin consumption is linked to significant reductions in 
      the incidence of multiple forms of cancer and metastatic spread to distant 
      tissues, resulting in increased cancer patient survival is not well understood. 
      In this study, using colon cancer as an example, we provide both in vitro (cell 
      culture) and in vivo (chemically induced mouse model of colon cancer) evidence 
      that this profound antineoplastic action may be associated with aspirin's ability 
      to irreversibly inhibit COX-1-mediated platelet activation, thereby blocking 
      platelet-cancer cell interactions, which promote cancer cell number and invasive 
      potential. This process may be driven by platelet-induced epithelial-mesenchymal 
      transition (EMT), as assessed using confocal microscopy, based upon changes in 
      cell morphology, growth characteristics and fibronectin expression, and 
      biochemical/molecular analysis by measuring changes in the expression of the EMT 
      markers; vimentin, β-catenin, and SNAIL. We also provide evidence that a novel, 
      gastrointestinal-safe phosphatidylcholine (PC)-associated aspirin, PL2200 
      Aspirin, possesses the same or more pronounced actions versus unmodified aspirin 
      with regard to antiplatelet effects (in vitro: reducing platelet activation as 
      determined by measuring the release of thromboxane and VEGF in culture medium; in 
      vivo: inhibiting platelet number/activation and extravasation into tumor tissue) 
      and chemoprevention (in vitro: inhibiting colonic cell growth and invasive 
      activity; in vivo: inhibiting colonic dysplasia, inflammation, and tumor mass). 
      These results suggest that aspirin's chemopreventive effects may be due, in part, 
      to the drug blocking the proneoplastic action of platelets, and the potential use 
      of Aspirin-PC/PL2200 as an effective and safer chemopreventive agent for 
      colorectal cancer and possibly other cancers. Cancer Prev Res; 10(2); 142-52. 
      ©2016 AACR.
CI  - ©2016 American Association for Cancer Research.
FAU - Lichtenberger, Lenard M
AU  - Lichtenberger LM
AD  - Department of Integrative Biology & Pharmacology, The University of Texas Health 
      Science Center at Houston-McGovern Medical School, Houston, Texas. 
      lenard.m.lichtenberger@uth.tmc.edu.
FAU - Fang, Dexing
AU  - Fang D
AD  - Department of Integrative Biology & Pharmacology, The University of Texas Health 
      Science Center at Houston-McGovern Medical School, Houston, Texas.
FAU - Bick, Roger J
AU  - Bick RJ
AD  - Department of Pathology and Laboratory Medicine, The University of Texas Health 
      Science Center at Houston-McGovern Medical School, Houston, Texas.
FAU - Poindexter, Brian J
AU  - Poindexter BJ
AD  - Department of Pathology and Laboratory Medicine, The University of Texas Health 
      Science Center at Houston-McGovern Medical School, Houston, Texas.
FAU - Phan, Tri
AU  - Phan T
AD  - Department of Integrative Biology & Pharmacology, The University of Texas Health 
      Science Center at Houston-McGovern Medical School, Houston, Texas.
FAU - Bergeron, Angela L
AU  - Bergeron AL
AD  - Department of Medicine, Baylor College of Medicine and Center for Translational 
      Research on Inflammatory Diseases, Michael E. DeBakey Veterans Affairs Medical 
      Center, Houston, Texas.
FAU - Pradhan, Subhashree
AU  - Pradhan S
AD  - Department of Medicine, Baylor College of Medicine and Center for Translational 
      Research on Inflammatory Diseases, Michael E. DeBakey Veterans Affairs Medical 
      Center, Houston, Texas.
FAU - Dial, Elizabeth J
AU  - Dial EJ
AD  - Department of Integrative Biology & Pharmacology, The University of Texas Health 
      Science Center at Houston-McGovern Medical School, Houston, Texas.
FAU - Vijayan, K Vinod
AU  - Vijayan KV
AD  - Department of Medicine, Baylor College of Medicine and Center for Translational 
      Research on Inflammatory Diseases, Michael E. DeBakey Veterans Affairs Medical 
      Center, Houston, Texas.
LA  - eng
GR  - R01 HL081613/HL/NHLBI NIH HHS/United States
GR  - R21 CA182798/CA/NCI NIH HHS/United States
GR  - R41 CA171408/CA/NCI NIH HHS/United States
GR  - R42 CA171408/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20161220
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/enzymology
MH  - Cell Line, Tumor
MH  - Colonic Neoplasms/*pathology
MH  - Cyclooxygenase 1/*metabolism
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Epithelial-Mesenchymal Transition/drug effects
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Platelet Activation/*drug effects
PMC - PMC5292092
MID - NIHMS838620
COIS- of Potential Conflicts of Interest: L. Lichtenberger is a co-founder and 
      shareholder in PLx Pharma Inc which is developing PC-NSAIDs for commercial use.
EDAT- 2016/12/22 06:00
MHDA- 2017/11/14 06:00
CRDT- 2016/12/22 06:00
PHST- 2016/09/15 00:00 [received]
PHST- 2016/11/29 00:00 [revised]
PHST- 2016/11/30 00:00 [accepted]
PHST- 2016/12/22 06:00 [pubmed]
PHST- 2017/11/14 06:00 [medline]
PHST- 2016/12/22 06:00 [entrez]
AID - 1940-6207.CAPR-16-0241 [pii]
AID - 10.1158/1940-6207.CAPR-16-0241 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2017 Feb;10(2):142-152. doi: 
      10.1158/1940-6207.CAPR-16-0241. Epub 2016 Dec 20.

PMID- 28537433
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20181210
IS  - 1557-7716 (Electronic)
IS  - 1523-0864 (Print)
IS  - 1523-0864 (Linking)
VI  - 27
IP  - 17
DP  - 2017 Dec 10
TI  - Aspirin-Mediated Acetylation Protects Against Multiple Neurodegenerative 
      Pathologies by Impeding Protein Aggregation.
PG  - 1383-1396
LID - 10.1089/ars.2016.6978 [doi]
AB  - AIMS: Many progressive neurological disorders, including Alzheimer's disease 
      (AD), Huntington's disease, and Parkinson's disease (PD), are characterized by 
      accumulation of insoluble protein aggregates. In prospective trials, the 
      cyclooxygenase inhibitor aspirin (acetylsalicylic acid) reduced the risk of AD 
      and PD, as well as cardiovascular events and many late-onset cancers. Considering 
      the role played by protein hyperphosphorylation in aggregation and 
      neurodegenerative diseases, and aspirin's known ability to donate acetyl groups, 
      we asked whether aspirin might reduce both phosphorylation and aggregation by 
      acetylating protein targets. RESULTS: Aspirin was substantially more effective 
      than salicylate in reducing or delaying aggregation in human neuroblastoma cells 
      grown in vitro, and in Caenorhabditis elegans models of human neurodegenerative 
      diseases in vivo. Aspirin acetylates many proteins, while reducing 
      phosphorylation, suggesting that acetylation may oppose phosphorylation. 
      Surprisingly, acetylated proteins were largely excluded from compact aggregates. 
      Molecular-dynamic simulations indicate that acetylation of amyloid peptide 
      energetically disfavors its association into dimers and octamers, and oligomers 
      that do form are less compact and stable than those comprising unacetylated 
      peptides. INNOVATION: Hyperphosphorylation predisposes certain proteins to 
      aggregate (e.g., tau, α-synuclein, and transactive response DNA-binding protein 
      43 [TDP-43]), and it is a critical pathogenic marker in both cardiovascular and 
      neurodegenerative diseases. We present novel evidence that acetylated proteins 
      are underrepresented in protein aggregates, and that aggregation varies inversely 
      with acetylation propensity after diverse genetic and pharmacologic 
      interventions. CONCLUSIONS: These results are consistent with the hypothesis that 
      aspirin inhibits protein aggregation and the ensuing toxicity of aggregates 
      through its acetyl-donating activity. This mechanism may contribute to the 
      neuro-protective, cardio-protective, and life-prolonging effects of aspirin. 
      Antioxid. Redox Signal. 27, 1383-1396.
FAU - Ayyadevara, Srinivas
AU  - Ayyadevara S
AD  - 1 Central Arkansas Veterans Healthcare System, Research & Development Service , 
      Little Rock, Arkansas.
AD  - 2 Department of Geriatrics, Reynolds Institute on Aging, University of Arkansas 
      for Medical Sciences , Little Rock, Arkansas.
FAU - Balasubramaniam, Meenakshisundaram
AU  - Balasubramaniam M
AD  - 1 Central Arkansas Veterans Healthcare System, Research & Development Service , 
      Little Rock, Arkansas.
AD  - 2 Department of Geriatrics, Reynolds Institute on Aging, University of Arkansas 
      for Medical Sciences , Little Rock, Arkansas.
FAU - Kakraba, Samuel
AU  - Kakraba S
AD  - 3 Bioinformatics Program, University of Arkansas for Medical Sciences, and 
      University of Arkansas at Little Rock , Little Rock, Arkansas.
FAU - Alla, Ramani
AU  - Alla R
AD  - 1 Central Arkansas Veterans Healthcare System, Research & Development Service , 
      Little Rock, Arkansas.
AD  - 2 Department of Geriatrics, Reynolds Institute on Aging, University of Arkansas 
      for Medical Sciences , Little Rock, Arkansas.
FAU - Mehta, Jawahar L
AU  - Mehta JL
AD  - 1 Central Arkansas Veterans Healthcare System, Research & Development Service , 
      Little Rock, Arkansas.
AD  - 4 Divison of Cardiology, Department of Medicine, University of Arkansas for 
      Medical Sciences , Little Rock, Arkansas.
FAU - Shmookler Reis, Robert J
AU  - Shmookler Reis RJ
AD  - 1 Central Arkansas Veterans Healthcare System, Research & Development Service , 
      Little Rock, Arkansas.
AD  - 2 Department of Geriatrics, Reynolds Institute on Aging, University of Arkansas 
      for Medical Sciences , Little Rock, Arkansas.
AD  - 3 Bioinformatics Program, University of Arkansas for Medical Sciences, and 
      University of Arkansas at Little Rock , Little Rock, Arkansas.
LA  - eng
PT  - Journal Article
DEP - 20170628
PL  - United States
TA  - Antioxid Redox Signal
JT  - Antioxidants & redox signaling
JID - 100888899
RN  - 0 (Protein Aggregates)
RN  - 0 (Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Caenorhabditis elegans
MH  - Cell Line
MH  - Disease Models, Animal
MH  - Humans
MH  - Molecular Dynamics Simulation
MH  - Neurodegenerative Diseases/*drug therapy/metabolism
MH  - Phosphorylation/drug effects
MH  - Protein Aggregates/drug effects
MH  - Proteins/*chemistry/metabolism
PMC - PMC5661865
OTO - NOTNLM
OT  - (protein) acetylation
OT  - (protein) aggregation
OT  - (protein) phosphorylation
OT  - aspirin (acetylsalicylic acid)
OT  - inflammation
OT  - neurodegeneration
COIS- No competing financial interests exist.
EDAT- 2017/05/26 06:00
MHDA- 2018/03/10 06:00
CRDT- 2017/05/25 06:00
PHST- 2017/05/26 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
PHST- 2017/05/25 06:00 [entrez]
AID - 10.1089/ars.2016.6978 [pii]
AID - 10.1089/ars.2016.6978 [doi]
PST - ppublish
SO  - Antioxid Redox Signal. 2017 Dec 10;27(17):1383-1396. doi: 10.1089/ars.2016.6978. 
      Epub 2017 Jun 28.

PMID- 9538362
OWN - NLM
STAT- MEDLINE
DCOM- 19980430
LR  - 20131121
IS  - 0003-3928 (Print)
IS  - 0003-3928 (Linking)
VI  - 46
IP  - 8
DP  - 1997 Oct
TI  - [Aspirin in secondary cardiovascular prevention: from clinical studies to daily 
      practice].
PG  - 507-12
AB  - The clinical benefit of aspirin in coronary insufficiency has been validated in 
      the acute phase of myocardial infarction and in secondary prevention with a 
      reduction of the risk of recurrent infarction of the order of 30%. By interfering 
      with the process of thrombolysis, aspirin modifies the natural history of 
      coronary artery disease by decreasing the frequency and severity of pathological 
      events. Although a relative consensus has been reached concerning the dosages 
      (160 to 325 mg/day), the use of aspirin nevertheless remains very insufficient, 
      sometimes because of the risk of gastrointestinal intolerance related to the 
      gastrotoxicity of aspirin, hence the importance of pharmaceutical forms designed 
      to improve the gastrointestinal tolerance, such as calcium carbasalate (soluble 
      aspirin complex), which appears to be particularly well tolerated.
FAU - Garnier, L F
AU  - Garnier LF
AD  - Service de Cardiologie, Centre Hospitalier, Vendôme.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - L'aspirine en prévention secondaire cardio-vasculaire: des études cliniques à la 
      pratique quotidienne.
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Circadian Rhythm
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Myocardial Infarction/*drug therapy/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
RF  - 35
EDAT- 1998/04/16 00:00
MHDA- 1998/04/16 00:01
CRDT- 1998/04/16 00:00
PHST- 1998/04/16 00:00 [pubmed]
PHST- 1998/04/16 00:01 [medline]
PHST- 1998/04/16 00:00 [entrez]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 1997 Oct;46(8):507-12.

PMID- 2101031
OWN - NLM
STAT- MEDLINE
DCOM- 19910904
LR  - 20131121
IS  - 1220-0875 (Print)
IS  - 1220-0875 (Linking)
VI  - 34
IP  - 1
DP  - 1990 Jan-Mar
TI  - [Aspirin in the preventive treatment of cataract].
PG  - 43-6
AB  - In the patients with rheumatoid arthritis treated for a long time with aspirin, 
      the percent of cataract is very low. Three action ways of aspirin were formulated 
      in hindering the appearance of cataract: 1) acetylation of the lens proteins; 2) 
      decrease of glycemia and 3) decrease of triptophen amount in the blood plasma. 
      The lab experiments plead for these hypotheses. For preventing cataract, the 
      persons with high risk of cataract and with incipient signs of opacity are 
      recommended a daily and long treatment with 1/2 buffered and effervescent aspirin 
      tablet, or 1 tablet at two days, under careful ophthalmologic surveillance.
FAU - Mihail, S
AU  - Mihail S
AD  - Policlinica specială nr. 2, serviciul Oftalmologic Bucuresti.
LA  - rum
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspirina în tratamentul preventiv al cataractei.
PL  - Romania
TA  - Oftalmologia
JT  - Oftalmologia (Bucharest, Romania : 1990)
JID - 9111247
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Cataract/*prevention & control
MH  - Humans
MH  - Lens, Crystalline/drug effects
MH  - Middle Aged
RF  - 16
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - Oftalmologia. 1990 Jan-Mar;34(1):43-6.

PMID- 36918009
OWN - NLM
STAT- MEDLINE
DCOM- 20230320
LR  - 20230504
IS  - 1678-4227 (Electronic)
IS  - 0004-282X (Print)
IS  - 0004-282X (Linking)
VI  - 81
IP  - 1
DP  - 2023 Jan
TI  - Impact of pharmacogenetics on aspirin resistance: a systematic review.
PG  - 62-73
LID - 10.1055/s-0042-1758445 [doi]
AB  - BACKGROUND: Pharmacogenetics promises better control of diseases such as 
      cardiovascular disease (CVD). Acetylsalicylic acid, aspirin, prevents the 
      formation of an activating agent of platelet aggregation and vasoconstriction, 
      and it is used to prevent CVD. Nevertheless, patients may have treatment failure 
      due to genetic variants that modify the metabolism of the drug causing aspirin 
      resistance (AR). OBJECTIVES: To realize a systematic literature review to 
      determine the impact of genetic variants on AR. METHODS: Articles published in 
      the MEDLINE/PubMed, Cochrane, Scopus, LILACS, and SCIELO databases were 
      systematically screened. A total of 290 articles were identified and 269 articles 
      were excluded because they did not comply with the previously established 
      inclusion criteria. A total of 20 case-control studies and 1 cohort was included. 
      RESULTS: The genetic variants rs1126643 (ITGA2), rs3842787 (PTGS1), rs20417 
      (PTGS2), and rs5918 (ITGB3) were the most studied. As for relevance, of the 64 
      genetic variants evaluated by the articles, 14 had statistical significance 
      (p < 0.05; 95% confidence interval [CI]) in at least one article. Among them, the 
      following have had unanimous results: rs1371097 (P2RY1), rs1045642 (MDR1), 
      rs1051931 and rs7756935 (PLA2G7), rs2071746 (HO1), rs1131882 and rs4523 (TBXA2R), 
      rs434473 (ALOX12), rs9315042 (ALOX5AP), and rs662 (PON1), while these differ in 
      real interference in AR: rs5918 (ITGB3), rs2243093 (GP1BA), rs1330344 (PTGS1), 
      and rs20417 (PTGS2). As study limitations, we highlight the nonuniform 
      methodologies of the analyzed articles and population differences. CONCLUSION: It 
      is noteworthy that pharmacogenetics is an expanding area. Therefore, further 
      studies are needed to better understand the association between genetic variants 
      and AR.
CI  - Academia Brasileira de Neurologia. This is an open access article published by 
      Thieme under the terms of the Creative Commons 
      Attribution-NonDerivative-NonCommercial License, permitting copying and 
      reproduction so long as the original work is given appropriate credit. Contents 
      may not be used for commercial purposes, or adapted, remixed, transformed or 
      built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
FAU - Silva, Gustavo Figueiredo da
AU  - Silva GFD
AUID- ORCID: 0000-0003-2508-1989
AD  - Universidade da Região de Joinville, Departamento de Medicina, Joinville SC, 
      Brazil.
FAU - Lopes, Bruno Mattei
AU  - Lopes BM
AUID- ORCID: 0000-0001-7241-4323
AD  - Universidade da Região de Joinville, Departamento de Medicina, Joinville SC, 
      Brazil.
FAU - Moser, Vinicius
AU  - Moser V
AUID- ORCID: 0000-0003-1837-5532
AD  - Universidade da Região de Joinville, Departamento de Medicina, Joinville SC, 
      Brazil.
FAU - Ferreira, Leslie Ecker
AU  - Ferreira LE
AUID- ORCID: 0000-0003-0276-9043
AD  - Universidade da Região de Joinville, Departamento de Medicina, Joinville SC, 
      Brazil.
AD  - Universidade da Região de Joinville, Joinville Stroke Biobank, Joinville SC, 
      Brazil.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
TT  - Impacto da farmacogenética na resistência à aspirina: uma revisão sistemática.
DEP - 20230314
PL  - Germany
TA  - Arq Neuropsiquiatr
JT  - Arquivos de neuro-psiquiatria
JID - 0125444
RN  - R16CO5Y76E (Aspirin)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Cardiovascular Diseases
MH  - Cyclooxygenase 2
MH  - *Pharmacogenetics
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Drug Resistance
PMC - PMC10014202
COIS- The authors have no conflict of interests to declare.
EDAT- 2023/03/15 06:00
MHDA- 2023/03/17 06:00
CRDT- 2023/03/14 19:52
PHST- 2023/03/14 19:52 [entrez]
PHST- 2023/03/15 06:00 [pubmed]
PHST- 2023/03/17 06:00 [medline]
AID - ANP-2021.0400 [pii]
AID - 10.1055/s-0042-1758445 [doi]
PST - ppublish
SO  - Arq Neuropsiquiatr. 2023 Jan;81(1):62-73. doi: 10.1055/s-0042-1758445. Epub 2023 
      Mar 14.

PMID- 33967038
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211230
IS  - 1875-8622 (Electronic)
IS  - 1386-0291 (Print)
IS  - 1386-0291 (Linking)
VI  - 79
IP  - 2
DP  - 2021
TI  - Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment 
      of therapeutic platelet inhibition in patients with cardiac diseases.
PG  - 327-334
LID - 10.3233/CH-211171 [doi]
AB  - BACKGROUND: Assessment of platelet inhibition for aspirin therapy is important to 
      manage patients who are at potential risk of developing thrombotic and 
      hemorrhagic complications. OBJECTIVE: This study aimed to evaluate a new platelet 
      assay (Anysis-aspirin), compare it with VerifyNow-aspirin in patients with 
      cardiac diseases, and analyze the aspirin resistance rates between the two 
      devices. METHODS: Citrated blood samples were collected from patients with 
      cardiac diseases referred for the aspirin response test. In the Anysis assay, a 
      test result was provided with a blood flow migration distance (MD) until blood 
      flow stoppage, which was comparable to aspirin reaction units (ARUs) obtained 
      using VerifyNow. The measurements were simultaneously conducted using the two 
      devices and compared. RESULTS: The MD without and with aspirin use was 160±33 and 
      254±23 mm, respectively (p < 0.0001). Compared with VerifyNow (reference), the 
      sensitivity and specificity of Anysis-200 were 96.3 and 90.3%, respectively (area 
      under the curve, 0.968). Furthermore, the aspirin resistance rate in 
      aspirin-administered patients was 20.9%using VerifyNow and 16.5%for Anysis-200. 
      The Cohen's kappa coefficient between the two devices was 0.81, indicating an 
      almost perfect agreement between the two devices. CONCLUSIONS: Anysis-aspirin, a 
      novel aspirin assay for assessing platelet inhibition, showed excellent agreement 
      with VerifyNow-aspirin with high accuracy and precision. The Anysis-aspirin assay 
      would be used as a point-of-care test to assess aspirin non-responsiveness and 
      abnormal platelet reactivity.
FAU - Piao, Jinxiang
AU  - Piao J
AD  - Engineering Research Center for Biofluid Biopsy, Korea University, Seoul, Korea.
FAU - Yoo, Chaeyoung
AU  - Yoo C
AD  - Engineering Research Center for Biofluid Biopsy, Korea University, Seoul, Korea.
FAU - Kim, SeonYoung
AU  - Kim S
AD  - R&D Center, Rheomeditech. Inc., Seoul, Korea.
FAU - Whang, Youn-Wha
AU  - Whang YW
AD  - Division of Cardiology, Department of Internal Medicine, College of Medicine, 
      Korea University, Seoul, Korea.
FAU - Choi, Cheol Ung
AU  - Choi CU
AD  - Division of Cardiology, Department of Internal Medicine, College of Medicine, 
      Korea University, Seoul, Korea.
FAU - Shin, Sehyun
AU  - Shin S
AD  - Engineering Research Center for Biofluid Biopsy, Korea University, Seoul, Korea.
AD  - School of Mechanical Engineering, Korea University, Seoul, Korea.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets
MH  - *Heart Diseases
MH  - Humans
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Platelet Function Tests
PMC - PMC8673509
OTO - NOTNLM
OT  - Anysis-200 analyzer
OT  - Platelet function
OT  - VerifyNow
OT  - aspirin
COIS- The authors declare no conflicts of interest.
EDAT- 2021/05/11 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/05/10 06:10
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
PHST- 2021/05/10 06:10 [entrez]
AID - CH211171 [pii]
AID - 10.3233/CH-211171 [doi]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 2021;79(2):327-334. doi: 10.3233/CH-211171.

PMID- 15366673
OWN - NLM
STAT- MEDLINE
DCOM- 20050414
LR  - 20201208
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 28 Spec No 3
DP  - 2004 Apr
TI  - [Epidemiology of digestive complications associated with use of low-dose 
      aspirin].
PG  - C37-44
AB  - Low-dose aspirin (< 330 mg/d) is recommended for the prevention of myocardial 
      infarction or ischemic stroke. Six to 12% of the general population is exposed to 
      low-dose aspirin. The most frequently studied digestive complications are 
      bleeding peptic ulcers, whose risk is increased twofold by low-dose aspirin 
      treatment, and non-complicated peptic ulcers. History of bleeding or 
      non-complicated peptic ulcer, alcohol intake, concomitant treatment with NSAID or 
      calcic inhibitors are demonstrated risk factors of bleeding ulcer associated with 
      low-dose aspirin. The role of enteric coating, of low-dose aspirin dose, of delay 
      since low-dose aspirin treatment onset, and of Helicobacter pylori infection, 
      remains controversial. Antisecretory drugs (H2 inhibitors, proton pump 
      inhibitors), and nitroglycerin are associated with a decreased risk of bleeding 
      ulcer. The protective effect of COX-2 inhibitors on the risk of bleeding ulcer is 
      suppressed by concomitant treatment with low-dose aspirin. The risk of no- 
      complicated peptic ulcer was increased by low-dose aspirin intake by a factor 2.9 
      in one study. Low-dose aspirin dose, infection by Helicobacter pylori, NSAID 
      intake, and absence of enteric coating, are possible risk factors for 
      non-complicated peptic ulcer. No association was retrieved with alcohol intake 
      and peptic ulcer history.
FAU - Czernichow, Pierre
AU  - Czernichow P
AD  - Réseau de Recherche sur le Système de Soins, Université de Rouen, Département 
      d'Epidémiologie et de Santé Publique, CHU, Hôpitaux de Rouen. 
      pierre.czernichow@chu-rouen.fr
FAU - Merle, Véronique
AU  - Merle V
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Epidémiologie des complications digestives liées à l'aspirine à faible dose.
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Gastrointestinal Diseases/*chemically induced/*epidemiology/etiology
MH  - Helicobacter Infections/complications
MH  - Helicobacter pylori
MH  - Humans
MH  - Risk Factors
RF  - 42
EDAT- 2004/09/16 05:00
MHDA- 2005/04/15 09:00
CRDT- 2004/09/16 05:00
PHST- 2004/09/16 05:00 [pubmed]
PHST- 2005/04/15 09:00 [medline]
PHST- 2004/09/16 05:00 [entrez]
AID - s0399-8320(04)95277-3 [pii]
AID - 10.1016/s0399-8320(04)95277-3 [doi]
PST - ppublish
SO  - Gastroenterol Clin Biol. 2004 Apr;28 Spec No 3:C37-44. doi: 
      10.1016/s0399-8320(04)95277-3.

PMID- 16997401
OWN - NLM
STAT- MEDLINE
DCOM- 20070822
LR  - 20171116
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 118
IP  - 2
DP  - 2007 May 31
TI  - Nitric oxide-releasing aspirin: will it say NO to atherothrombosis?
PG  - 170-2
AB  - Aspirin is a powerful anti-platelet drug widely used in patients with coronary 
      atherosclerosis, but its side effects and especially its toxicity for 
      gastrointestinal tract limit its usefulness in specific groups of patients. A new 
      category of agents, nitric oxide-releasing aspirins (such as NCX-4016), seems to 
      provide an alternative solution. Although this drug is still at phase II clinical 
      trials, it has provided promising results until now. When administered in vivo, 
      it is separated into an aspirin moiety and an NO-donating complex, providing both 
      the antithrombotic effect of aspirin and the gastroprotective effect of NO. 
      Additionally, it increases NO bioavailability as a vascular level, and it may 
      have the antiatherogenic properties of endogenously produced NO. Finally, recent 
      evidence suggests that it may also improve functional aspects of vein grafts used 
      in CABG, with possible benefit on graft patency. However, the outcome of the 
      large ongoing trials is needed before any conclusion is made about the role of 
      NO-releasing aspirins in cardiovascular disease.
FAU - Antoniades, Charalambos
AU  - Antoniades C
FAU - Tousoulis, Dimitris
AU  - Tousoulis D
FAU - Stefanadis, Christodoulos
AU  - Stefanadis C
LA  - eng
PT  - Editorial
DEP - 20060925
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Fibrinolytic Agents)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Coronary Thrombosis/*drug therapy
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Treatment Outcome
EDAT- 2006/09/26 09:00
MHDA- 2007/08/23 09:00
CRDT- 2006/09/26 09:00
PHST- 2006/05/10 00:00 [received]
PHST- 2006/08/04 00:00 [accepted]
PHST- 2006/09/26 09:00 [pubmed]
PHST- 2007/08/23 09:00 [medline]
PHST- 2006/09/26 09:00 [entrez]
AID - S0167-5273(06)00779-0 [pii]
AID - 10.1016/j.ijcard.2006.08.002 [doi]
PST - ppublish
SO  - Int J Cardiol. 2007 May 31;118(2):170-2. doi: 10.1016/j.ijcard.2006.08.002. Epub 
      2006 Sep 25.

PMID- 33277869
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20210820
IS  - 2241-6293 (Electronic)
IS  - 1107-0625 (Linking)
VI  - 25
IP  - 5
DP  - 2020 Sep-Oct
TI  - Effects of aspirin on pancreatic cancer cells PANC-1 and its potential molecular 
      mechanism.
PG  - 2449-2455
AB  - PURPOSE: To explore the effects of aspirin on the proliferation and apoptosis of 
      human pancreatic cancer cells and its potential molecular mechanism. METHODS: 
      This study included patients with pancreatic cancer who were divided into 
      experimental group and control group. The cell proliferation ability was detected 
      via cell counting kit-8 (CCK-8) assay and colony forming ability via colony 
      formation assay. In addition, changes in proteins in the phosphatidyl 
      inositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin 
      (mTOR) pathway were assessed using Western blotting, and rescue experiment was 
      conducted to investigate whether aspirin can affect cell proliferation by 
      inhibiting the PI3K/Akt/mTOR signaling pathway. RESULTS: The results of CCK-8 
      assay showed that the proliferation rate of PANC-1 cells was decreased in a time- 
      and dose-dependent manner after they were treated with aspirin at different 
      concentrations. Colony formation assay confirmed that cell colony forming ability 
      was significantly reduced with the increase in aspirin treatment concentration 
      (p<0.05). Besides, the apoptosis rate and the number of cells in the experimental 
      group were higher and larger than those in the control group (p<0.05). According 
      to Western blotting results, the protein expressions of PI3K, phosphorylated 
      (p)-Akt and p-mTOR were decreased after aspirin treatment. Rescue experimental 
      results manifested that insulin-like growth factor 1 (IGF-1) supplementation 
      remarkably elevated the expressions of PI3K, p-Akt and p-mTOR compared with 
      phosphate-buffered saline (PBS) supplementation. It was found in CCK-8 assay that 
      IGF-1 supplementation markedly reversed the inhibition of aspirin on the 
      proliferation of PANC-1 cells in comparison with PBS supplementation. 
      CONCLUSIONS: Aspirin inhibits the proliferation and promotes the apoptosis of 
      pancreatic cancer cells by inactivating the PI3K/Akt/mTOR signaling pathway.
FAU - Lin, Shengping
AU  - Lin S
AD  - Department of Emergency, Sir Run Run Shaw Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - Pan, Yun
AU  - Pan Y
FAU - Xu, Chenglei
AU  - Xu C
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cell Proliferation
MH  - Humans
MH  - Pancreatic Neoplasms/*drug therapy
EDAT- 2020/12/06 06:00
MHDA- 2021/08/21 06:00
CRDT- 2020/12/05 05:35
PHST- 2020/12/05 05:35 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
PST - ppublish
SO  - J BUON. 2020 Sep-Oct;25(5):2449-2455.

PMID- 27500549
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20220408
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 120
DP  - 2016 Oct
TI  - Aspirin for primary prevention of cardiovascular disease in patients with 
      diabetes: A meta-analysis.
PG  - 31-9
LID - S0168-8227(16)30267-4 [pii]
LID - 10.1016/j.diabres.2016.07.012 [doi]
AB  - AIMS: Aspirin use for primary prevention of cardiovascular disease (CVD) is 
      controversial, especially in patients with diabetes. The objective of this 
      meta-analysis was to evaluate aspirin's safety and efficacy for primary 
      prevention of CVD [fatal or nonfatal myocardial infarction (MI), fatal or 
      nonfatal stroke, angina, transient ischemic attack (TIA), peripheral artery 
      disease (PAD) and revascularization] in patients with diabetes. METHODS: A 
      literature search was conducted using the terms cardiovascular disease, aspirin, 
      diabetes mellitus to identify trials of patients with diabetes who received 
      aspirin for primary prevention of CVD. Study sample size, and ischemic and 
      bleeding events were extracted and analyzed using RevMan 5.2.7. RESULTS: In 
      total, 6 studies (n=10,117) met criteria. Aspirin doses ranged from 100mg every 
      other day to 650mg daily. Follow-up ranged from 3.6 to 10.1years. In patients 
      with diabetes, there was no difference between aspirin and placebo with respect 
      to the risk of all cause mortality (OR 0.93, 95% CI 0.81-1.06), or individual 
      atherosclerotic events compared to placebo. There were no differences in bleeding 
      (OR 2.53, 95% CI 0.77-8.34), GI bleeding (OR 2.14, 95% CI 0.63-7.33) or 
      hemorrhagic stroke rates (OR 0.90, 0.34-2.33) between groups. CONCLUSIONS: It 
      remains unclear whether aspirin may reduce the occurrence of a first 
      atherosclerotic event or mortality in patients with diabetes. More research on 
      this use of aspirin in patients with diabetes is required to supplement currently 
      available research.
CI  - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Kokoska, Lianne A
AU  - Kokoska LA
AD  - United Physicians Inc., Bingham Farms, MI, United States. Electronic address: 
      lkokoska@updoctors.com.
FAU - Wilhelm, Sheila M
AU  - Wilhelm SM
AD  - Department of Pharmacy, Harper University Hospital, Detroit Medical Center, 
      Detroit, MI, United States; Department of Pharmacy Practice, Eugene Applebaum 
      College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, 
      United States. Electronic address: swilhelm@wayne.edu.
FAU - Garwood, Candice L
AU  - Garwood CL
AD  - Department of Pharmacy, Harper University Hospital, Detroit Medical Center, 
      Detroit, MI, United States; Department of Pharmacy Practice, Eugene Applebaum 
      College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, 
      United States. Electronic address: cgarwood@wayne.edu.
FAU - Berlie, Helen D
AU  - Berlie HD
AD  - Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health 
      Sciences, Wayne State University, Detroit, MI, United States; Health Centers of 
      Detroit Medical Group, Detroit, MI, United States. Electronic address: 
      hnberlie@wayne.edu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20160728
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Diabetes Complications/etiology/*prevention & control
MH  - Diabetes Mellitus/*physiopathology
MH  - Humans
MH  - Primary Prevention
OTO - NOTNLM
OT  - Aspirin
OT  - Atherosclerosis
OT  - Cardiovascular disease
OT  - Diabetes mellitus
OT  - Primary prevention
EDAT- 2016/08/09 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/08/09 06:00
PHST- 2016/01/27 00:00 [received]
PHST- 2016/05/23 00:00 [revised]
PHST- 2016/07/24 00:00 [accepted]
PHST- 2016/08/09 06:00 [entrez]
PHST- 2016/08/09 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S0168-8227(16)30267-4 [pii]
AID - 10.1016/j.diabres.2016.07.012 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2016 Oct;120:31-9. doi: 10.1016/j.diabres.2016.07.012. 
      Epub 2016 Jul 28.

PMID- 6318345
OWN - NLM
STAT- MEDLINE
DCOM- 19840220
LR  - 20131121
VI  - 59
IP  - 46
DP  - 1983 Dec 12
TI  - [Ketoprofen-aspirin interaction].
PG  - 3218-20
AB  - Eighteen patients with chronic inflammatory joint disease were treated for two 
      successive five day sequences, in a double blind crossover study, with 300 mg per 
      day ketoprofen given alone or combined with 1,500 mg aspirin. Bioavailability and 
      pharmacokinetics of total serum ketoprofen studied in eight patients did not 
      appear to be significantly modified by addition of aspirin. Measurements of 
      Ritchie's articular index and Lee's functional index demonstrated that ketoprofen 
      was clinically as effective when given alone as in association with aspirin. 
      Measurement of the sedimentation rate by the sigma ESR technique showed that 
      aspirin produced a marked reduction of the antiinflammatory biological activity 
      of ketoprofen which did not however reach statistical significance. This study of 
      interactions between ketoprofen and aspirin shows that it is useless and perhaps 
      harmful to combine the two medications.
FAU - Pawlotsky, Y
AU  - Pawlotsky Y
FAU - Louboutin, J Y
AU  - Louboutin JY
FAU - Chales, G
AU  - Chales G
FAU - Flouvat, B
AU  - Flouvat B
FAU - Roux, A
AU  - Roux A
LA  - fre
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Interactions kétoprofène-aspirine.
PL  - France
TA  - Sem Hop
JT  - La semaine des hopitaux : organe fonde par l'Association d'enseignement medical 
      des hopitaux de Paris
JID - 9410059
RN  - 0 (Phenylpropionates)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism/*pharmacology
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ketoprofen/metabolism/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Phenylpropionates/*pharmacology
EDAT- 1983/12/12 00:00
MHDA- 1983/12/12 00:01
CRDT- 1983/12/12 00:00
PHST- 1983/12/12 00:00 [pubmed]
PHST- 1983/12/12 00:01 [medline]
PHST- 1983/12/12 00:00 [entrez]
PST - ppublish
SO  - Sem Hop. 1983 Dec 12;59(46):3218-20.

PMID- 415531
OWN - NLM
STAT- MEDLINE
DCOM- 19780426
LR  - 20131121
IS  - 0379-0363 (Print)
IS  - 0379-0363 (Linking)
IP  - 1
DP  - 1977
TI  - Aspirin and ulcers.
PG  - 81-3
AB  - In eastern Australia, there is an epidemic of gastric ulcer which began 30 years 
      in young women who are now middle-aged, (b) This epidemic is associated with the 
      regular use of aspirin most often in the form of A.P.C. powders taken for 
      non-medical reasons, (c) Data from three separate studies in America confirms a 
      statistically significant association of regular aspirin use and chronic gastric 
      ulcer, and (d) An explanation is provided by the effect of aspirin in inhibiting 
      prostaglandin synthetase.
FAU - Duggan, J M
AU  - Duggan JM
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions Suppl
JT  - Agents and actions. Supplements
JID - 7801014
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/pharmacology/therapeutic use
MH  - Cyclooxygenase Inhibitors
MH  - Female
MH  - Humans
MH  - Male
MH  - Stomach Ulcer/*chemically induced
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Agents Actions Suppl. 1977;(1):81-3.

PMID- 22297838
OWN - NLM
STAT- MEDLINE
DCOM- 20130117
LR  - 20131121
IS  - 1099-0801 (Electronic)
IS  - 0269-3879 (Linking)
VI  - 26
IP  - 8
DP  - 2012 Aug
TI  - Review of HPLC methods and HPLC methods with mass spectrometric detection for 
      direct determination of aspirin with its metabolite(s) in various biological 
      matrices.
PG  - 906-41
LID - 10.1002/bmc.2694 [doi]
AB  - Aspirin, the most widely used drug in the world, has been known to mankind for 
      over a century. It is not only the pharmacologically active entity, but is also 
      biotransformed into a major metabolite, i.e. salicylic acid, which also exhibits 
      similar pharmacologic/pharmacodynamic properties. Hence it is necessary to 
      quantitate aspirin along with its metabolite(s) in various biological matrices 
      accurately and precisely to correlate with pharmacological/pharmacodynamic 
      activity. This paper provides a comprehensive overview of various bioanalytical 
      methods (HPLC and LC-MS/MS) that have been reported for direct quantitation of 
      aspirin along with its metabolite(s). The review also provides general 
      information on sample collection, sample processing, internal standard selection, 
      conditions for chromatographic separation, succinct validation data and 
      applicable conclusions for reported assays in a structured manner.
CI  - Copyright © 2012 John Wiley & Sons, Ltd.
FAU - Mullangi, Ramesh
AU  - Mullangi R
AD  - Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, 
      Yeshwanthpur, Bangalore, 560 022, India. mullangi_ramesh@jubilantinnovation.com
FAU - Sharma, Kuldeep
AU  - Sharma K
FAU - Srinivas, Nuggehally R
AU  - Srinivas NR
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120202
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analysis/metabolism
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Humans
MH  - Tandem Mass Spectrometry/*methods
EDAT- 2012/02/03 06:00
MHDA- 2013/01/18 06:00
CRDT- 2012/02/03 06:00
PHST- 2011/11/22 00:00 [received]
PHST- 2011/12/05 00:00 [accepted]
PHST- 2012/02/03 06:00 [entrez]
PHST- 2012/02/03 06:00 [pubmed]
PHST- 2013/01/18 06:00 [medline]
AID - 10.1002/bmc.2694 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2012 Aug;26(8):906-41. doi: 10.1002/bmc.2694. Epub 2012 Feb 2.

PMID- 28342880
OWN - NLM
STAT- MEDLINE
DCOM- 20180711
LR  - 20180711
IS  - 2468-7189 (Electronic)
IS  - 2468-7189 (Linking)
VI  - 45
IP  - 4
DP  - 2017 Apr
TI  - [For a targeted use of aspirin].
PG  - 224-230
LID - S2468-7189(17)30037-5 [pii]
LID - 10.1016/j.gofs.2017.02.001 [doi]
AB  - The use of low-dose aspirin in pregnancy should remain a highly targeted 
      indication since its long-term safety has not been established and should be 
      restricted to women at high risk of vascular complications. Indications for which 
      the benefit of aspirin has been shown are women with a history of preeclampsia 
      responsible for a premature birth before 34 weeks, those having at least two 
      history of preeclampsia, those with an antiphospholipid syndrome and those with 
      lupus associated with positive antiphospholipid antibodies or renal failure. In 
      all other cases, the level of evidence of the benefit of aspirin is insufficient 
      to recommend its routine prescription.
CI  - Copyright © 2017 Elsevier Masson SAS. All rights reserved.
FAU - Madar, H
AU  - Madar H
AD  - Service de gynécologie-obstétrique, CHU de Bordeaux, place Amélie-Raba-Léon, 
      33076 Bordeaux, France. Electronic address: hugo.madar@gmail.com.
FAU - Brun, S
AU  - Brun S
AD  - Service de gynécologie-obstétrique, CHU de Bordeaux, place Amélie-Raba-Léon, 
      33076 Bordeaux, France.
FAU - Coatleven, F
AU  - Coatleven F
AD  - Service de gynécologie-obstétrique, CHU de Bordeaux, place Amélie-Raba-Léon, 
      33076 Bordeaux, France.
FAU - Nithart, A
AU  - Nithart A
AD  - Service de gynécologie-obstétrique, CHU de Bordeaux, place Amélie-Raba-Léon, 
      33076 Bordeaux, France.
FAU - Lecoq, C
AU  - Lecoq C
AD  - Service de gynécologie-obstétrique, CHU de Bordeaux, place Amélie-Raba-Léon, 
      33076 Bordeaux, France.
FAU - Gleyze, M
AU  - Gleyze M
AD  - Service de gynécologie-obstétrique, CHU de Bordeaux, place Amélie-Raba-Léon, 
      33076 Bordeaux, France.
FAU - Merlot, B
AU  - Merlot B
AD  - Service de gynécologie-obstétrique, CHU de Bordeaux, place Amélie-Raba-Léon, 
      33076 Bordeaux, France.
FAU - Sentilhes, L
AU  - Sentilhes L
AD  - Service de gynécologie-obstétrique, CHU de Bordeaux, place Amélie-Raba-Léon, 
      33076 Bordeaux, France.
LA  - fre
PT  - Journal Article
TT  - Pour une prescription ciblée de l’aspirine.
DEP - 20170323
PL  - France
TA  - Gynecol Obstet Fertil Senol
JT  - Gynecologie, obstetrique, fertilite & senologie
JID - 101693805
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gynecol Obstet Fertil Senol. 2017 Jul - Aug;45(7-8):447-448. PMID: 28716489
CIN - Gynecol Obstet Fertil Senol. 2017 Jul - Aug;45(7-8):448-449. PMID: 28757107
MH  - Abnormalities, Drug-Induced/etiology
MH  - Antiphospholipid Syndrome/complications/drug therapy
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/drug therapy
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*drug therapy
MH  - Premature Birth/prevention & control
MH  - Risk Factors
OTO - NOTNLM
OT  - Antiphospholipid antibody syndrome
OT  - Aspirin
OT  - Aspirine
OT  - Intrauterine growth restriction
OT  - Lupus
OT  - Preeclampsia
OT  - Pré-éclampsie
OT  - Retard de croissance intra-utérin
OT  - Syndrome des antiphospholipides
EDAT- 2017/03/28 06:00
MHDA- 2018/07/12 06:00
CRDT- 2017/03/27 06:00
PHST- 2016/11/20 00:00 [received]
PHST- 2017/02/08 00:00 [accepted]
PHST- 2017/03/28 06:00 [pubmed]
PHST- 2018/07/12 06:00 [medline]
PHST- 2017/03/27 06:00 [entrez]
AID - S2468-7189(17)30037-5 [pii]
AID - 10.1016/j.gofs.2017.02.001 [doi]
PST - ppublish
SO  - Gynecol Obstet Fertil Senol. 2017 Apr;45(4):224-230. doi: 
      10.1016/j.gofs.2017.02.001. Epub 2017 Mar 23.

PMID- 36857596
OWN - NLM
STAT- MEDLINE
DCOM- 20230329
LR  - 20230530
IS  - 2515-5091 (Electronic)
IS  - 2515-5091 (Linking)
VI  - 7
IP  - 2
DP  - 2023 Mar 1
TI  - Association of metformin, aspirin, and cancer incidence with mortality risk in 
      adults with diabetes.
LID - 10.1093/jncics/pkad017 [doi]
LID - pkad017
AB  - BACKGROUND: Metformin and aspirin are commonly co-prescribed to people with 
      diabetes. Metformin may prevent cancer, but in older people (over 70 years), 
      aspirin has been found to increase cancer mortality. This study examined whether 
      metformin reduces cancer mortality and incidence in older people with diabetes; 
      it used randomization to 100 mg aspirin or placebo in the ASPirin in Reducing 
      Events in the Elderly (ASPREE) trial to quantify aspirin's impact on metformin 
      users. METHODS: Analysis included community-dwelling ASPREE participants (aged 
      ≥70 years, or ≥65 years for members of US minority populations) with diabetes. 
      Diabetes was defined as a fasting blood glucose level greater than 125 mg/dL, 
      self-report of diabetes, or antidiabetic medication use. Cox proportional hazards 
      regression models were used to analyze the association of metformin and a 
      metformin-aspirin interaction with cancer incidence and mortality, with 
      adjustment for confounders. RESULTS: Of 2045 participants with diabetes at 
      enrollment, 965 were concurrently using metformin. Metformin was associated with 
      a reduced cancer incidence risk (adjusted hazard ratio [HR] = 0.68, 95% 
      confidence interval [CI] = 0.51 to 0.90), but no conclusive benefit for cancer 
      mortality (adjusted HR = 0.72, 95% CI = 0.43 to 1.19). Metformin users randomized 
      to aspirin had greater risk of cancer mortality compared with placebo (HR = 2.53, 
      95% CI = 1.18 to 5.43), but no effect was seen for cancer incidence (HR = 1.11, 
      95% CI = 0.75 to 1.64). The possible effect modification of aspirin on cancer 
      mortality, however, was not statistically significant (interaction P = .11). 
      CONCLUSIONS: In community-dwelling older adults with diabetes, metformin use was 
      associated with reduced cancer incidence. Increased cancer mortality risk in 
      metformin users randomized to aspirin warrants further investigation. ASPREE 
      TRIAL REGISTRATION: ClinicalTrials.gov ID NCT01038583.
CI  - © The Author(s) 2023. Published by Oxford University Press.
FAU - Orchard, Suzanne G
AU  - Orchard SG
AUID- ORCID: 0000-0003-0211-3183
AD  - School of Public Health and Preventive Medicine, Monash University, 
      Melbourne,VIC, Australia.
FAU - Lockery, Jessica E
AU  - Lockery JE
AUID- ORCID: 0000-0001-6664-1239
AD  - School of Public Health and Preventive Medicine, Monash University, 
      Melbourne,VIC, Australia.
AD  - Translational Immunology and Nanotechnology Research Theme, School of Health and 
      Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
AD  - Department of Internal Medicine, Division of Cancer Prevention and Control, Ohio 
      State University, Columbus, OH, USA.
FAU - Broder, Jonathan C
AU  - Broder JC
AD  - School of Public Health and Preventive Medicine, Monash University, 
      Melbourne,VIC, Australia.
FAU - Ernst, Michael E
AU  - Ernst ME
AUID- ORCID: 0000-0003-0267-4888
AD  - Department of Pharmacy Practice and Science, College of Pharmacy and Department 
      of Family Medicine, Carver College of Medicine, The University of Iowa, Iowa 
      City, IA, USA.
FAU - Espinoza, Sara
AU  - Espinoza S
AD  - Division of Geriatrics, Gerontology and Palliative Medicine, Barshop Institute 
      for Longevity and Aging Studies, University of Texas Health Science Center, and 
      Geriatrics Research, Education and Clinical Center, South Texas Veterans Health 
      Care System, San Antonio, TX, USA.
FAU - Gibbs, Peter
AU  - Gibbs P
AD  - The Walter & Eliza Hall Institute of Medical Research, Royal Parade, Parkville, 
      Melbourne, VIC, Australia.
AD  - Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, 
      Australia.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - School of Public Health and Preventive Medicine, Monash University, 
      Melbourne,VIC, Australia.
FAU - Polekhina, Galina
AU  - Polekhina G
AUID- ORCID: 0000-0001-9535-9291
AD  - School of Public Health and Preventive Medicine, Monash University, 
      Melbourne,VIC, Australia.
FAU - Zoungas, Sophia
AU  - Zoungas S
AD  - School of Public Health and Preventive Medicine, Monash University, 
      Melbourne,VIC, Australia.
FAU - Loomans-Kropp, Holli A
AU  - Loomans-Kropp HA
AUID- ORCID: 0000-0002-9681-8725
AD  - Department of Internal Medicine, Division of Cancer Prevention and Control, Ohio 
      State University, Columbus, OH, USA.
AD  - Cancer Prevention Fellowship Program, Division of Cancer Prevention, National 
      Cancer Institute, Rockville, MD, USA.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - School of Public Health and Preventive Medicine, Monash University, 
      Melbourne,VIC, Australia.
CN  - ASPREE Investigator Group
LA  - eng
SI  - ClinicalTrials.gov/NCT01038583
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U19 AG062682/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - JNCI Cancer Spectr
JT  - JNCI cancer spectrum
JID - 101721827
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Humans
MH  - *Metformin/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Diabetes Mellitus, Type 2
MH  - Incidence
MH  - *Neoplasms/drug therapy/epidemiology/complications
PMC - PMC10042437
COIS- The authors declared no potential conflicts of interest concerning this article’s 
      research, authorship, and/or publication.
FIR - McNeil, John
IR  - McNeil J
FIR - Woods, Robyn
IR  - Woods R
FIR - Wolfe, Rory
IR  - Wolfe R
FIR - Murray, Anne
IR  - Murray A
FIR - Chan, Andrew
IR  - Chan A
FIR - Orchard, Suzanne
IR  - Orchard S
FIR - Lockery, Jessica
IR  - Lockery J
FIR - Nelson, Mark
IR  - Nelson M
FIR - Reid, Christorpher
IR  - Reid C
FIR - Shah, Raj
IR  - Shah R
FIR - Newmann, Anne
IR  - Newmann A
FIR - Storey, Elsdon
IR  - Storey E
FIR - Stocks, Nigel
IR  - Stocks N
FIR - Tonkin, Andrew
IR  - Tonkin A
FIR - Espinoza, Sara
IR  - Espinoza S
EDAT- 2023/03/02 06:00
MHDA- 2023/03/29 06:05
CRDT- 2023/03/01 15:33
PHST- 2022/12/11 00:00 [received]
PHST- 2023/02/06 00:00 [revised]
PHST- 2023/02/20 00:00 [accepted]
PHST- 2023/03/29 06:05 [medline]
PHST- 2023/03/02 06:00 [pubmed]
PHST- 2023/03/01 15:33 [entrez]
AID - 7066922 [pii]
AID - pkad017 [pii]
AID - 10.1093/jncics/pkad017 [doi]
PST - ppublish
SO  - JNCI Cancer Spectr. 2023 Mar 1;7(2):pkad017. doi: 10.1093/jncics/pkad017.

PMID- 12007083
OWN - NLM
STAT- MEDLINE
DCOM- 20020530
LR  - 20190922
IS  - 0033-0620 (Print)
IS  - 0033-0620 (Linking)
VI  - 44
IP  - 4
DP  - 2002 Jan-Feb
TI  - Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack 
      of evidence supporting the use of aspirin for cardiovascular disease.
PG  - 275-92
AB  - It is currently fashionable to prescribe aspirin, long-term to people with or at 
      high risk of vascular events due to atherosclerosis. There is a moderately 
      conclusive evidence for a short-term benefit after an acute vascular event. 
      However, there is remarkably little evidence that long-term aspirin is effective 
      for the prevention of vascular events and managing side effects may be expensive. 
      Reductions in nonfatal vascular events may reflect an ability of aspirin to alter 
      cosmetically the presentation of disease without exerting real benefit. 
      Cardiovascular medicine appears prone to fads and fashions that are poorly 
      substantiated by evidence. The current fashion for prescribing aspirin is 
      reminiscent of the now discredited practice of widespread prescription of class I 
      anti-arrhythmic drugs for ventricular ectopics. We should learn from experience.
CI  - Copyright 2002, Elsevier Science.
FAU - Cleland, John G F
AU  - Cleland JG
AD  - Department of Cardiology, Castle Hill Hospital, University of Hull, 
      Kingston-upon-Hull, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Prog Cardiovasc Dis
JT  - Progress in cardiovascular diseases
JID - 0376442
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
RF  - 125
EDAT- 2002/05/15 10:00
MHDA- 2002/05/31 10:01
CRDT- 2002/05/15 10:00
PHST- 2002/05/15 10:00 [pubmed]
PHST- 2002/05/31 10:01 [medline]
PHST- 2002/05/15 10:00 [entrez]
AID - S0033062002500049 [pii]
AID - 10.1053/pcad.2002.31597 [doi]
PST - ppublish
SO  - Prog Cardiovasc Dis. 2002 Jan-Feb;44(4):275-92. doi: 10.1053/pcad.2002.31597.

PMID- 9556499
OWN - NLM
STAT- MEDLINE
DCOM- 20050505
LR  - 20190831
IS  - 1093-9946 (Print)
IS  - 1093-4715 (Linking)
VI  - 3
DP  - 1998 Apr 27
TI  - Vascular smooth muscle, endothelial regulation and effects of aspirin in 
      hypertension.
PG  - e23-38
AB  - Dysfunction of vascular smooth muscle (VSM) is at the center of occlusive 
      disorders of the cardiovascular system such as hypertension, atherosclerosis, 
      coronary artery disease and hypoxia. In addition to circulating biogenic amines 
      and various neurotransmitters originating from the central nervous system and 
      endocrine system, various autocoids of arachidonic acid metabolism in the blood 
      as well as in the endothelium play an important regulatory role in the 
      maintenance of the tone and the contractile function of VSM. A monolayer of 
      endothelial cells lining the heart and large blood vessels is responsible for 
      producing and releasing both endocrine and paracrine substances such as 
      endothelins, nitric oxide, prostaglandins and prostacyclins. Aspirin, 
      (acetylsalicylic acid/ASA) an ancient remedy against fever and pain, is emerging 
      as an effective drug not only against occlusive disorders but also against 
      various cancers and the AIDs virus. During pregnancy induced hypertension (PIH) 
      and in occlusive disorders, aspirin provides relief through inhibition of 
      cyclooxygenase, an enzyme required for the metabolism of arachidonic acid to 
      produce prostaglandins and prostacyclins in platelets and in endothelial cells. 
      Because of its unique molecular constitution, synergistic ability and solubility 
      in the lipidic environment, various mechanisms of aspirin's actions are being 
      currently investigated. In this review, the effect of aspirin on the regulation 
      of VSM in the presence and absence of endothelium are discussed.
FAU - Rahmani, M A
AU  - Rahmani MA
AD  - Division of Science and Mathematics, Bethune-Cookman College, Daytona Beach, FL 
      32114, USA. rahman @cookman.edu
LA  - eng
GR  - GMO 8119/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
DEP - 19980427
PL  - United States
TA  - Front Biosci
JT  - Frontiers in bioscience : a journal and virtual library
JID - 9709506
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cyclooxygenase Inhibitors/*pharmacology/therapeutic use
MH  - Endothelium, Vascular/*physiopathology
MH  - Humans
MH  - Hypertension/*drug therapy/*physiopathology
MH  - Muscle, Smooth, Vascular/drug effects/*physiopathology
MH  - Rats
MH  - Vasoconstriction/drug effects
RF  - 171
EDAT- 1998/04/29 00:00
MHDA- 2005/05/06 09:00
CRDT- 1998/04/29 00:00
PHST- 1998/04/29 00:00 [pubmed]
PHST- 2005/05/06 09:00 [medline]
PHST- 1998/04/29 00:00 [entrez]
AID - 10.2741/a365 [doi]
PST - epublish
SO  - Front Biosci. 1998 Apr 27;3:e23-38. doi: 10.2741/a365.

PMID- 31335509
OWN - NLM
STAT- MEDLINE
DCOM- 20200623
LR  - 20200623
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
VI  - 37
IP  - 12
DP  - 2019 Dec
TI  - Aspirin enhances trophoblast invasion and represses soluble fms-like tyrosine 
      kinase 1 production: a putative mechanism for preventing preeclampsia.
PG  - 2461-2469
LID - 10.1097/HJH.0000000000002185 [doi]
AB  - OBJECTIVE: Recent studies suggested that prophylactic aspirin prior to 16 weeks 
      of gestation in high-risk patients may reduce the risk of developing 
      preeclampsia; however, the exact mechanism of aspirin's effect on the 
      pathophysiology of preeclampsia is not clear. This study was designed to 
      investigate the effect of aspirin on trophoblast cell function and its effect on 
      soluble fms-like tyrosine kinase 1 (sFlt-1) production to elucidate the 
      preventive mechanisms for preeclampsia. METHODS AND RESULTS: We used two human 
      trophoblastic cell lines (HTR-8/SVneo and JAR) and freshly isolated 
      cytotrophoblasts from normal and preeclamptic placenta at term to determine the 
      effect of aspirin on trophoblast cell function. Trophoblasts were pretreated with 
      aspirin, and then cell functions and sFlt-1 expression were assessed. Our results 
      showed that aspirin promoted trophoblast invasion not only in HTR-8/SVneo and JAR 
      cells, but also in isolated cytotrophoblasts. sFlt-1 production was repressed by 
      aspirin in a dose-dependent manner. By adding Flt-1 recombinant protein, the 
      trophoblast invasion ability was inhibited in HTR-8/SVneo cells, which was 
      reversed by Flt-1 small interfering ribonucleic acid knockdown. In addition, 
      metalloproteinase 2/9 expression and activity were activated by aspirin but 
      inhibited by sFlt-1. Aspirin also downregulated Akt phosphorylation, and 
      trophoblast invasiveness was facilitated under Akt inhibitor treatment. 
      CONCLUSION: Aspirin enhances cell invasiveness and inhibits sFlt-1 production in 
      trophoblasts. Moreover, sFlt-1 itself also inhibits trophoblast invasion. Our 
      novel findings suggest that the preeclampsia prevention effect of aspirin may be 
      exerted through these two mechanisms.
FAU - Su, Mei-Tsz
AU  - Su MT
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital.
FAU - Wang, Chia-Yih
AU  - Wang CY
AD  - Department of Cell Biology and Anatomy.
AD  - Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung 
      University, Tainan, Taiwan.
FAU - Tsai, Pei-Yin
AU  - Tsai PY
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital.
FAU - Chen, Ting-Yu
AU  - Chen TY
AD  - Department of Cell Biology and Anatomy.
AD  - Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung 
      University, Tainan, Taiwan.
FAU - Tsai, Hui-Ling
AU  - Tsai HL
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital.
FAU - Kuo, Pao-Lin
AU  - Kuo PL
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
RN  - EC 2.7.10.1 (FLT1 protein, human)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cell Line
MH  - Cells, Cultured
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*metabolism/prevention & control
MH  - Pregnancy
MH  - Trophoblasts/*drug effects
MH  - Vascular Endothelial Growth Factor Receptor-1/*metabolism
EDAT- 2019/07/25 06:00
MHDA- 2020/06/24 06:00
CRDT- 2019/07/24 06:00
PHST- 2019/07/25 06:00 [pubmed]
PHST- 2020/06/24 06:00 [medline]
PHST- 2019/07/24 06:00 [entrez]
AID - 10.1097/HJH.0000000000002185 [doi]
PST - ppublish
SO  - J Hypertens. 2019 Dec;37(12):2461-2469. doi: 10.1097/HJH.0000000000002185.

PMID- 24924486
OWN - NLM
STAT- MEDLINE
DCOM- 20150721
LR  - 20211021
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 7
IP  - 9
DP  - 2014 Sep
TI  - Aspirin and serum estrogens in postmenopausal women: a randomized controlled 
      clinical trial.
PG  - 906-12
LID - 10.1158/1940-6207.CAPR-14-0109 [doi]
AB  - Epidemiologic studies suggest a reduced risk of breast cancer among women who use 
      aspirin. A plausible mechanism is through aspirin's effect on estrogens, possibly 
      mediated through interference with estrogen synthesis via reduction in 
      inflammation, which is increased in adipose tissues, including breast. In a 
      randomized placebo-controlled trial, we evaluated the effects of six-month 
      administration of 325 mg/day aspirin on serum estrogens (estradiol, estrone, free 
      estradiol, and bioavailable estradiol) and sex hormone-binding globulin (SHBG) in 
      144 healthy postmenopausal women. Eligible participants, recruited 2005-2007, 
      were not taking nonsteroidal anti-inflammatory medication, including aspirin >2 
      times/week or menopausal hormone therapy, and had a Breast Imaging-Reporting and 
      Data System (BI-RADS) mammographic density classification of 2, 3, or 4. The 
      intervention effects (intent-to-treat) were evaluated by differences in the 
      geometric mean outcome changes at six months between aspirin and placebo groups 
      using generalized estimating equations (GEE). Participants were a mean 59.4 (SD, 
      5.4) years of age, with a mean body mass index (BMI) of 26.4 (SD, 5.4) kg/m(2). 
      Between baseline and six months, none of the serum estrogens or SHBG changed 
      substantially and there were no differences between groups. Stratifying by BMI 
      did not change results. In conclusion, a single daily administration of 325 mg of 
      aspirin for six months had no effect on serum estrogens or SHBG in postmenopausal 
      women. Larger doses or longer duration of aspirin administration may be needed to 
      affect circulating estrogens. Alternately, if aspirin influences breast cancer 
      risk in postmenopausal women, it may do so through direct breast tissue effects, 
      or through pathways other than estrogens.
CI  - ©2014 American Association for Cancer Research.
FAU - Duggan, Catherine
AU  - Duggan C
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington.
FAU - Wang, Ching-Yun
AU  - Wang CY
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington.
FAU - Xiao, Liren
AU  - Xiao L
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington.
FAU - McTiernan, Anne
AU  - McTiernan A
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington. Department of Epidemiology, School of Public Health and 
      Community Medicine, University of Washington, Seattle, Washington. 
      amctiern@fhcrc.org.
LA  - eng
GR  - P50 CA083636/CA/NCI NIH HHS/United States
GR  - U54 CA116847/CA/NCI NIH HHS/United States
GR  - P50 CA83636/CA/NCI NIH HHS/United States
GR  - U54CA116847/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140612
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Estrogens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Breast Neoplasms/prevention & control
MH  - Double-Blind Method
MH  - Estrogens/*blood
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Postmenopause
PMC - PMC4155012
MID - NIHMS605979
EDAT- 2014/06/14 06:00
MHDA- 2015/07/22 06:00
CRDT- 2014/06/14 06:00
PHST- 2014/06/14 06:00 [entrez]
PHST- 2014/06/14 06:00 [pubmed]
PHST- 2015/07/22 06:00 [medline]
AID - 1940-6207.CAPR-14-0109 [pii]
AID - 10.1158/1940-6207.CAPR-14-0109 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2014 Sep;7(9):906-12. doi: 
      10.1158/1940-6207.CAPR-14-0109. Epub 2014 Jun 12.

PMID- 7763529
OWN - NLM
STAT- MEDLINE
DCOM- 19930510
LR  - 20191031
IS  - 0268-2575 (Print)
IS  - 0268-2575 (Linking)
VI  - 56
IP  - 3
DP  - 1993
TI  - Technetium-aspirin molecule complexes.
PG  - 227-31
AB  - Technetium-aspirin and technetium-aspirin-like molecule complexes were prepared. 
      The structure of N-acetyl-anthranilic acid (NAA) has been decided through CNDO 
      calculations. The ionization potential and electron affinity of the NAA molecule 
      as well as the charge densities were calculated. Comparative studies of the 
      electronic absorption spectra of acetylthio-salicylic acid (ATS) and aspirin 
      (Asp) reveal the structure resemblance in which the acetyl carbonyl group is 
      perpendicular to the plane of the corresponding organic acid. The studies of the 
      electronic absorption spectra of NAA and anthranilic acid reveal the planarity of 
      the NAA molecule. The electronic absorption spectra of Tc(V)-Asp and Tc(V)-ATS 
      complexes have two characteristic absorption bands at 450 and 600 nm, but the 
      Tc(V)-NAA spectrum has one characteristic band at 450 nm. As a comparative study, 
      Mo-ATS complex was prepared and its electronic absorption spectrum is comparable 
      with the Tc-ATS complex spectrum.
FAU - el-Shahawy, A S
AU  - el-Shahawy AS
AD  - Chemistry Department, Faculty of Science, Assiut University, Egypt.
FAU - Mahfouz, R M
AU  - Mahfouz RM
FAU - Aly, A A
AU  - Aly AA
FAU - el-Zohry, M
AU  - el-Zohry M
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Chem Technol Biotechnol
JT  - Journal of chemical technology and biotechnology (Oxford, Oxfordshire : 1986)
JID - 8711102
RN  - 0 (ortho-Aminobenzoates)
RN  - 7440-26-8 (Technetium)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/analogs & derivatives/*chemistry
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Electrochemistry
MH  - Molecular Conformation
MH  - Spectrophotometry, Ultraviolet
MH  - Technetium/*chemistry
MH  - ortho-Aminobenzoates/chemistry
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1002/jctb.280560302 [doi]
PST - ppublish
SO  - J Chem Technol Biotechnol. 1993;56(3):227-31. doi: 10.1002/jctb.280560302.

PMID- 28390056
OWN - NLM
STAT- MEDLINE
DCOM- 20180720
LR  - 20180720
IS  - 1365-2885 (Electronic)
IS  - 0140-7783 (Linking)
VI  - 40
IP  - 6
DP  - 2017 Dec
TI  - Suspected aspirin resistance in individual healthy adult warmblood horses.
PG  - e16-e22
LID - 10.1111/jvp.12408 [doi]
AB  - The reasons for this prospective experimental study were to determine a dosing 
      scheme with loading and maintenance dose of aspirin inducing inhibition of 
      platelet function measured by whole blood impedance aggregometry. Ten horses 
      received aspirin orally in the morning with one loading dose of 4.7-5 mg/kg and 
      maintenance doses of 1-1.3 mg/kg daily the following 4 days. Aggregometries 
      (COLtest, ASPItest, ADPtest) and serum salicylic acid were measured. ASPItest 
      showed significant difference in inhibition at 24 and 48 hr (p < .05) and 96 hr 
      (p < .01). Significant change for ADPtest and COLtest couldn't be detected. Serum 
      salicylic acid concentrations were significantly (p < .01) increased at 6 and 
      12 hr. Despite this, three horses failed any inhibitory effect of platelet 
      function, suspecting an aspirin resistance. Regarding the other seven horses 
      platelet aggregation induced by ASPItest was reduced between 37% and 100% from 
      baseline at 6 and 12 hr and between 0 and 98% during the next 4 days. 
      Correlations of serum concentration of salicylic acid and aggregometries couldn't 
      be detected. It can be presumed that equine platelets are less susceptible to 
      aspirin what may compromise eventually the anticoagulatory effects and efficacy 
      in preventing and treating diseases with increased platelet activation as 
      endotoxaemia or laminitis.
CI  - © 2017 John Wiley & Sons Ltd.
FAU - Roscher, K A
AU  - Roscher KA
AUID- ORCID: 0000-0002-3810-8004
AD  - Equine Clinic, Internal Medicine, Department of Veterinary Clinical Science, 
      Justus Liebig University, Giessen, Germany.
FAU - Failing, K
AU  - Failing K
AD  - Unit for Biomathematics and Data Processing, Justus Liebig University, Giessen, 
      Germany.
FAU - Schenk, I
AU  - Schenk I
AD  - Institute of Biochemistry, German Sport University Cologne, Cologne, Germany.
FAU - Moritz, A
AU  - Moritz A
AD  - Clinical Pathophysiology and Veterinary Clinical Pathology, Department of 
      Veterinary Clinical Science, Justus Liebig University, Giessen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20170407
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Drug Administration Schedule/veterinary
MH  - Drug Resistance
MH  - Female
MH  - Horses/*blood
MH  - Male
MH  - Platelet Aggregation/drug effects
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - multiplate analyzer
OT  - multiple electrode aggregometry (MEA)
OT  - platelet
EDAT- 2017/04/09 06:00
MHDA- 2018/07/22 06:00
CRDT- 2017/04/09 06:00
PHST- 2016/07/22 00:00 [received]
PHST- 2017/03/09 00:00 [accepted]
PHST- 2017/04/09 06:00 [pubmed]
PHST- 2018/07/22 06:00 [medline]
PHST- 2017/04/09 06:00 [entrez]
AID - 10.1111/jvp.12408 [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 2017 Dec;40(6):e16-e22. doi: 10.1111/jvp.12408. Epub 2017 
      Apr 7.

PMID- 9589361
OWN - NLM
STAT- MEDLINE
DCOM- 19980624
LR  - 20131121
IS  - 0733-1959 (Print)
IS  - 0733-1959 (Linking)
VI  - 28-29
DP  - 1997
TI  - Colon cancer chemoprevention: clinical development of aspirin as a 
      chemopreventive agent.
PG  - 148-58
AB  - We have studied aspirin as a potential chemopreventive for colorectal cancer, 
      completing Phase I studies on aspirin pharmacology and potential biomarker assays 
      (prostaglandins, PGE2 and PGF2 alpha and cyclooxygenase modulation) in normal 
      human subjects. These studies have determined the optimal dose of aspirin for 
      future Phase IIa and IIb chemopreventive trials in high-risk cohorts of patients 
      for colon cancer. Aspirin's effects on rectal prostaglandins are prolonged, 
      detectable even after aspirin and its metabolite are removed from the plasma. 
      Aspirin-mediated inhibition of prostaglandin production in the human rectal 
      epithelium may be related to direct suppression of cyclooxygenase transcription 
      and not to enzyme inactivation by acetylation. A systematic method to monitor 
      adherence (self-report, telephone contact, pill count, and microelectronic 
      monitoring) has been established for future trials. Strategies to improve 
      recruitment of high-risk cohorts have been developed. Phase IIa non-randomized 
      studies with aspirin at 81 mg in high-risk cohorts (resected Duke's A colon 
      cancer, Duke's C colon cancer treated with adjuvant therapy and disease-free at 5 
      years, history of colon adenomas > 1 cm, two or more first-degree relatives with 
      colon cancer, and familial adenomatous polyposis and hereditary non-polyposis 
      colorectal cancer syndromes) are currently being conducted for surrogate 
      end-point biomarker (prostaglandins, cyclooxygenase, cellular mucins, and 
      proliferation) modulation.
FAU - Krishnan, K
AU  - Krishnan K
AD  - Department of Internal Medicine, James H. Quillen College of Medicine, Johnson 
      City, Tennessee, USA.
FAU - Ruffin, M T
AU  - Ruffin MT
FAU - Brenner, D E
AU  - Brenner DE
LA  - eng
GR  - CN-25429/CN/NCI NIH HHS/United States
GR  - MOI-RR00042/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - J Cell Biochem Suppl
JT  - Journal of cellular biochemistry. Supplement
JID - 8207539
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Colonic Neoplasms/*prevention & control
MH  - Humans
RF  - 63
EDAT- 1997/01/01 00:00
MHDA- 1998/05/20 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1998/05/20 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - J Cell Biochem Suppl. 1997;28-29:148-58.

PMID- 15366679
OWN - NLM
STAT- MEDLINE
DCOM- 20050414
LR  - 20201105
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 28 Spec No 3
DP  - 2004 Apr
TI  - [Prevention of gastroduodenal complications in patients taking low-dose aspirin].
PG  - C84-9
AB  - Use of low-dose aspirin is associated with an increased risk of gastroduodenal 
      ulcers and upper gastrointestinal bleeding. The risk is increased by the old age 
      and by cardiovascular and cerebrovascular diseases of the patients receiving 
      low-dose aspirin. Combination with nonsteroidal anti-inflammatory drugs, 
      corticosteroids or anticoagulant increases the risk of complications and should 
      be avoided. Proton-pump inhibitor and eradication of Helicobacter pylori are not 
      efficient in primary prevention of ulcer complications related to low-dose 
      aspirin use. Patients at high risk of gastroduodenal complications due to age, 
      morbidity or concomitant use of gastrotoxic therapy should be given prophylactic 
      treatment. Assessment of what constitutes the most effective therapy 
      (misoprostol, proton-pump inhibitor) should be defined in controlled trials. 
      Among patients with Helicobacter pylori infection and a history of upper 
      gastrointestinal bleeding who are taking low-dose aspirin, the eradication of 
      Helicobacter pylori is equivalent to treatment with proton-pump inhibitor in 
      preventing recurrent bleeding. Long term treatment with proton-pump inhibitor in 
      addition to the eradication of Helicobacter pylori should be considered in 
      patients who had ulcer complications related to the use of low-dose aspirin.
FAU - Chryssostalis, Ariane
AU  - Chryssostalis A
AD  - Service de Gastro-Entérologie, Hôpital Cochin-SVP, Université Paris V, 27, rue du 
      Fbg-Saint-Jacques, 75014 Paris.
FAU - Marck, Géraldine
AU  - Marck G
FAU - Sibilia, Jean
AU  - Sibilia J
FAU - Chaussade, Stanislas
AU  - Chaussade S
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Slratégie de prévention des complications gastro-duodénales chez les patients 
      traités par aspirine à faible dose.
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Interactions
MH  - Humans
MH  - Peptic Ulcer/*chemically induced/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk Factors
RF  - 40
EDAT- 2004/09/16 05:00
MHDA- 2005/04/15 09:00
CRDT- 2004/09/16 05:00
PHST- 2004/09/16 05:00 [pubmed]
PHST- 2005/04/15 09:00 [medline]
PHST- 2004/09/16 05:00 [entrez]
AID - s0399-8320(04)95283-9 [pii]
AID - 10.1016/s0399-8320(04)95283-9 [doi]
PST - ppublish
SO  - Gastroenterol Clin Biol. 2004 Apr;28 Spec No 3:C84-9. doi: 
      10.1016/s0399-8320(04)95283-9.

PMID- 9844080
OWN - NLM
STAT- MEDLINE
DCOM- 19990129
LR  - 20190515
IS  - 0884-8734 (Print)
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
VI  - 13
IP  - 12
DP  - 1998 Dec
TI  - Aspirin for primary prevention of cardiovascular events.
PG  - 824-35
AB  - OBJECTIVE: The use of aspirin for primary prevention of cardiovascular events in 
      the general population is controversial. The purpose of this study was to create 
      a versatile model to evaluate the effects of aspirin in the primary prevention of 
      cardiovascular events in patients with different risk profiles. DESIGN: A Markov 
      decision-analytic model evaluated the expected length and quality of life for the 
      cohort's next 10 years as measured by quality-adjusted survival for the options 
      of taking or not taking aspirin. SETTING: Hypothetical model of patients in a 
      primary care setting. PATIENTS: Several cohorts of patients with a range of risk 
      profiles typically seen in a primary care setting were considered. Risk factors 
      considered included gender, age, cholesterol levels, systolic blood pressure, 
      smoking status, diabetes, and presence of left ventricular hypertrophy. The 
      cohorts were followed for 10 years. Outcomes were myocardial infarction, stroke, 
      gastrointestinal bleed, ulcer, and death. MAIN RESULTS: For the cases considered, 
      the effects of aspirin varied according to the cohort's risk profile. By taking 
      aspirin, the lowest-risk cohort would be the most harmed with a loss of 1.8 
      quality-adjusted life days by taking aspirin; the highest risk cohort would 
      achieve the most benefit with a gain of 11.3 quality-adjusted life days. Results 
      without quality adjustment favored taking aspirin in all the cohorts, with a gain 
      of 0.73 to 8.04 days. The decision was extremely sensitive to variations in the 
      utility of taking aspirin and to aspirin's effects on cardiovascular mortality. 
      The model was robust to other probability and utility changes within reasonable 
      parameters. CONCLUSIONS: The decision of whether to take aspirin as primary 
      prevention for cardiovascular events depends on patient risk. It is a harmful 
      intervention for patients with no risk factors, and it is beneficial in moderate 
      and high-risk patients. The benefits of aspirin in this population are comparable 
      to those of other widely accepted preventive strategies. It is especially 
      dependent on the patient's risk profile, patient preferences for the adverse 
      effects of aspirin, and on the level of beneficial effects of aspirin on 
      cardiovascular-related mortality.
FAU - Augustovski, F A
AU  - Augustovski FA
AD  - Hospital Italiano de Buenos Aires, Unidad de Medicina Familiar y Preventiva, 
      Buenos Aires, Argentina.
FAU - Cantor, S B
AU  - Cantor SB
FAU - Thach, C T
AU  - Thach CT
FAU - Spann, S J
AU  - Spann SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - *Decision Support Techniques
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Quality of Life
MH  - Risk Assessment
PMC - PMC1497039
EDAT- 1998/12/09 00:00
MHDA- 1998/12/09 00:01
CRDT- 1998/12/09 00:00
PHST- 1998/12/09 00:00 [pubmed]
PHST- 1998/12/09 00:01 [medline]
PHST- 1998/12/09 00:00 [entrez]
AID - 10.1046/j.1525-1497.1998.00246.x [doi]
PST - ppublish
SO  - J Gen Intern Med. 1998 Dec;13(12):824-35. doi: 10.1046/j.1525-1497.1998.00246.x.

PMID- 17081097
OWN - NLM
STAT- MEDLINE
DCOM- 20061121
LR  - 20131121
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 4
IP  - 5
DP  - 2006 Sep
TI  - My health: whose responsibility? Low-dose aspirin and older people.
PG  - 755-64
AB  - The benefit of aspirin as a prophylactic after a thrombotic event was first 
      observed 30 years ago. Its use after coronary or cerebral thrombosis, and in 
      patients judged to be at increased risk of a thrombotic event, is now virtually 
      mandatory, unless there are signs of intolerance. The present policy in the UK 
      for cardiovascular protection by low-dose aspirin is dependent upon the 
      identification of people at high vascular risk. The policy has had only very 
      limited success, partly owing to the fact that only a relatively small proportion 
      of people with levels of vascular risk factors that would justify aspirin 
      prophylaxis are identified. In fact, it has been demonstrated that the 
      application of accepted guidelines for aspirin prophylaxis to risk factor data in 
      representative UK population samples gives a cost-effective evidence-base for a 
      reasonable extension of prophylaxis to all people aged over approximately 50 
      years. It is possible that reductions in both dementia and cancer incidence could 
      also follow the wider use of low-dose aspirin but further research on these 
      outcomes is urgently required. The evidence on possible benefits and harm from 
      low-dose aspirin should therefore be publicized widely, and everything possible 
      should be done to stimulate discussion involving the general public. In the end, 
      however, the preservation of health is one's own responsibility and, therefore, 
      people should generally be encouraged to evaluate the evidence on 
      health-promotion measures, including low-dose aspirin, and take responsibility 
      for their own health.
FAU - Elwood, Peter
AU  - Elwood P
AD  - Department of Epidemiology, Statistics and Public Health, College of Medicine, 
      Cardiff University, Heath Park, Cardiff, CF14 4XN, UK. pelwood@doctors.org.uk
FAU - Longley, Marcus
AU  - Longley M
FAU - Morgan, Gareth
AU  - Morgan G
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*administration & dosage/adverse effects/history/therapeutic use
MH  - Aspirin/*administration & dosage/adverse effects/history/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - *Health
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Neoplasms/prevention & control
MH  - *Self Care
MH  - Vascular Diseases/*prevention & control
RF  - 87
EDAT- 2006/11/04 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/11/04 09:00
PHST- 2006/11/04 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/11/04 09:00 [entrez]
AID - 10.1586/14779072.4.5.755 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2006 Sep;4(5):755-64. doi: 10.1586/14779072.4.5.755.

PMID- 480047
OWN - NLM
STAT- MEDLINE
DCOM- 19791129
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 95
IP  - 4
DP  - 1979 Oct
TI  - Aspirin dosage for infants and children.
PG  - 617-25
AB  - The labeled dosage schedule that has long been on pediatric aspirin preparations 
      is at variance with the recommendation in authoritative medical references, 
      studies demonstrating antipyretic effectiveness in children, and the prescribing 
      habits of pediatricians as revealed by a poll conducted by the authors. Aspirin 
      pharmacokinetics are influenced by a number of physiologic factors, as well as by 
      dosage, and complicate the problem of assuring safe and effective pediatric use. 
      Basic pharmacokinetic considerations indicate that the increase in size of 
      individual doses needed to assure therapeutic salicyate blood levels, thereby 
      removing the temptation of parents to administer the drug too often, is made 
      permissible (i.e., safe while effective) by expanding the interdose interval to 
      four hours instead of three. A revised pediatric aspirin disage schedule is 
      presented that better meets the practices of the pediatric community and the 
      needs of consumers.
FAU - Done, A K
AU  - Done AK
FAU - Yaffe, S J
AU  - Yaffe SJ
FAU - Clayton, J M
AU  - Clayton JM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/*administration & dosage/metabolism/pharmacology
MH  - Body Surface Area
MH  - Body Weight
MH  - Child
MH  - Child, Preschool
MH  - Drug Administration Schedule
MH  - Drug Labeling
MH  - Drug Prescriptions
MH  - Half-Life
MH  - Humans
MH  - Infant
MH  - Kinetics
MH  - Pediatrics
EDAT- 1979/10/01 00:00
MHDA- 1979/10/01 00:01
CRDT- 1979/10/01 00:00
PHST- 1979/10/01 00:00 [pubmed]
PHST- 1979/10/01 00:01 [medline]
PHST- 1979/10/01 00:00 [entrez]
AID - S0022-3476(79)80783-0 [pii]
AID - 10.1016/s0022-3476(79)80783-0 [doi]
PST - ppublish
SO  - J Pediatr. 1979 Oct;95(4):617-25. doi: 10.1016/s0022-3476(79)80783-0.

PMID- 25088031
OWN - NLM
STAT- MEDLINE
DCOM- 20150518
LR  - 20140908
IS  - 1096-1208 (Electronic)
IS  - 0882-4010 (Linking)
VI  - 74
DP  - 2014 Sep
TI  - Aspirin is an efficient inhibitor of quorum sensing, virulence and toxins in 
      Pseudomonas aeruginosa.
PG  - 25-32
LID - S0882-4010(14)00105-3 [pii]
LID - 10.1016/j.micpath.2014.07.008 [doi]
AB  - Quorum sensing (QS) plays a vital role in regulation of virulence factors and 
      toxins in Pseudomonas aeruginosa, which can cause serious human infections. 
      Therefore, the QS system in P. aeruginosa may be an important target for 
      pharmacological intervention. Activity of aspirin on the QS system was assessed 
      using a reporter strain assay and confirmed using RT-PCR to test expression of 
      virulence factors and toxins. In addition, molecular modeling techniques 
      including docking, flexible alignment and surface mapping were also applied to 
      further understand aspirin's potential QS inhibition activity. Aspirin (6 mg/ml) 
      showed significant reduction (p < 0.01) of quorum sensing signals in 
      P. aeruginosa, including expression of elastase, total proteases, and 
      pyocyanin (p < 0.01) without affecting bacterial viability. Aspirin also 
      significantly reduced organism motility and biofilm production (p < 0.01) and 
      decreased expression of lasI, lasR, rhlI, rhlR, pqsA and pqsR genes by 38, 72, 
      69, 72, 74 and 43% respectively. Moreover, the expression of Pseudomonas toxins 
      exoS and exoY was reduced by 47 and 55% respectively. The molecular modeling 
      analysis suggests the QS inhibitory action of aspirin occurs through interaction 
      of aspirin's aryl group and Tyr-88 of the LasR receptor, by strong π-π stacking 
      interactions, which associated with a conformational change of the 
      receptor-aspirin complex. The inhibitory effect of aspirin on virulence factors 
      was specific to P. aeruginosa as aspirin at sub-MIC did not affect the biofilm or 
      motility of Escherichia coli. To summarize, the collective data demonstrate that 
      low concentrations of aspirin inhibit quorum sensing of P. aeruginosa.
CI  - Copyright © 2014 Elsevier Ltd. All rights reserved.
FAU - El-Mowafy, Somaia A
AU  - El-Mowafy SA
AD  - Department of Microbiology, Faculty of Pharmacy, Mansoura University, Mansoura 
      35516, Egypt. Electronic address: dr_msm4e2013@hotmail.com.
FAU - Abd El Galil, Khaled H
AU  - Abd El Galil KH
AD  - Department of Microbiology, Faculty of Pharmacy, Mansoura University, Mansoura 
      35516, Egypt. Electronic address: kelgalil@hotmail.com.
FAU - El-Messery, Shahenda M
AU  - El-Messery SM
AD  - Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura 
      35516, Egypt. Electronic address: shahenda76@yahoo.com.
FAU - Shaaban, Mona I
AU  - Shaaban MI
AD  - Department of Microbiology, Faculty of Pharmacy, Mansoura University, Mansoura 
      35516, Egypt. Electronic address: mona_ibrahem@mans.edu.eg.
LA  - eng
PT  - Journal Article
DEP - 20140801
PL  - England
TA  - Microb Pathog
JT  - Microbial pathogenesis
JID - 8606191
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Bacterial Proteins)
RN  - 0 (Bacterial Toxins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Bacterial Proteins/biosynthesis
MH  - Bacterial Toxins/*antagonists & inhibitors
MH  - Escherichia coli/drug effects
MH  - Gene Expression Profiling
MH  - Humans
MH  - Locomotion/drug effects
MH  - Microbial Viability/drug effects
MH  - Pseudomonas aeruginosa/*drug effects/*physiology
MH  - Quorum Sensing/*drug effects
MH  - Virulence/drug effects
OTO - NOTNLM
OT  - Aspirin
OT  - Pseudomonas aeruginosa
OT  - Quorum sensing
OT  - Toxins
OT  - Virulence
EDAT- 2014/08/05 06:00
MHDA- 2015/05/20 06:00
CRDT- 2014/08/05 06:00
PHST- 2014/04/12 00:00 [received]
PHST- 2014/06/30 00:00 [revised]
PHST- 2014/07/22 00:00 [accepted]
PHST- 2014/08/05 06:00 [entrez]
PHST- 2014/08/05 06:00 [pubmed]
PHST- 2015/05/20 06:00 [medline]
AID - S0882-4010(14)00105-3 [pii]
AID - 10.1016/j.micpath.2014.07.008 [doi]
PST - ppublish
SO  - Microb Pathog. 2014 Sep;74:25-32. doi: 10.1016/j.micpath.2014.07.008. Epub 2014 
      Aug 1.

PMID- 12846439
OWN - NLM
STAT- MEDLINE
DCOM- 20031202
LR  - 20191107
IS  - 1590-8658 (Print)
IS  - 1590-8658 (Linking)
VI  - 35 Suppl 2
DP  - 2003 May
TI  - NO-aspirin: mechanism of action and gastrointestinal safety.
PG  - S9-19
AB  - Nitric oxide-releasing aspirins are new chemical entities obtained by adding a 
      nitric oxide-releasing moiety to aspirin. NCX-4016 is the prototype of this 
      family of molecules. NCX-4016 consists of the parent molecule (aspirin) linked to 
      a 'spacer' via an ester linkage, which is in turn connected to a nitric 
      oxide-releasing moiety. Both aspirin and nitric oxide moieties of NCX-4016 
      contribute to its effectiveness, the latter occurring via both cyclic guanosyl 
      monophosphate-dependent and -independent mechanisms. In vitro studies have shown 
      that NCX-4016 inhibits platelet aggregation induced by aspirin-sensitive 
      (arachidonic acid) and aspirin-insensitive (thrombin) agonist. In contrast to 
      aspirin, NCX-4016 exerts a multilevel regulation of inflammatory target, 
      including caspase-1 and NF-kappaB. This broad spectrum of activities translates 
      to an increased potency of this drug in modulating cardiovascular inflammation. 
      Human studies have shown, that while nitric oxide-aspirin maintains its 
      anti-thrombotic activity, it spares the gastrointestinal tract. Indeed, a 7-day 
      course of NCX-4016 results in 90% reduction of gastric damage caused by equimolar 
      doses of aspirin. Further studies are ongoing to define whether this superior 
      anti-inflammatory and anti-thrombotic profile translates in clinical benefits in 
      patients with cardiovascular diseases.
FAU - Fiorucci, S
AU  - Fiorucci S
AD  - Gastrointestinal and Liver Unit, Department of Internal Medicine, University of 
      Perugia, Perugia, Italy. fiorucci@unipg.it
FAU - Del Soldato, P
AU  - Del Soldato P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/analogs & derivatives/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Digestive System/blood supply/*drug effects
MH  - Humans
MH  - Nitric Oxide/administration & dosage/*pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Regional Blood Flow
EDAT- 2003/07/09 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/07/09 05:00
PHST- 2003/07/09 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/07/09 05:00 [entrez]
AID - S1590-8658(03)00047-1 [pii]
AID - 10.1016/s1590-8658(03)00047-1 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2003 May;35 Suppl 2:S9-19. doi: 10.1016/s1590-8658(03)00047-1.

PMID- 15087598
OWN - NLM
STAT- MEDLINE
DCOM- 20041214
LR  - 20181113
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 16
IP  - 3
DP  - 2003 Dec
TI  - Aspirin use post-acute coronary syndromes: intolerance, bleeding and 
      discontinuation.
PG  - 119-28
AB  - BACKGROUND: While aspirin's secondary prevention benefit is clear, prior reports 
      indicate that 19-83% of eligible patients may not use aspirin chronically. 
      METHODS: We investigated intolerance and bleeding while on aspirin and aspirin 
      discontinuation using 5337 post-acute coronary syndrome patients considered 
      appropriate for chronic antiplatelet therapy who were randomly assigned to 
      aspirin in SYMPHONY and 2nd SYMPHONY and followed for 94 (64,157) days. 
      Multivariable logistic regression models tested associations between baseline 
      characteristics and aspirin discontinuation and bleeding. RESULTS: Nearly 18% of 
      patients discontinued study aspirin; 48% subsequently used open-label aspirin and 
      5% other antiplatelet or anticoagulant therapy. Black race, recurrent ischemia, 
      hypertension, chronic obstructive pulmonary disease, lighter weight, shorter time 
      to treatment and use of non-steroidal anti-inflammatory agents, diuretics, and 
      digitalis were independently associated with early discontinuation. Early 
      discontinuation was less likely in Eastern Europe, Latin America and Asia. 
      Although major or minor bleeding was common (12.6%), only 1.0% of aspirin-treated 
      patients were reported to discontinue due to bleeding. Gastrointestinal (10.5%) 
      and puncture site (7.6%) were the most common bleeding locations. Bleeding risk 
      was associated with lower estimated creatinine clearance, shorter time to 
      treatment, smoking, Killip class >II, higher systolic blood pressure, and use of 
      aspirin or heparin prior to starting study aspirin. CONCLUSIONS: Despite early 
      initiation and close follow-up, more than 9% of aspirin-treated patients 
      discontinued therapy early and remained off treatment. Addressing the factors 
      associated with both bleeding and discontinuation during chronic therapy is 
      necessary to improve adherence to this inexpensive, life-saving therapy.
FAU - Newby, L Kristin
AU  - Newby LK
AD  - Duke Clinical Research Institute and the Duke Centers for Education & Research on 
      Therapeutics (CERTs), Durham, NC 27715-7969, USA. newby001@mc.duke.edu
FAU - Bhapkar, Manjushri V
AU  - Bhapkar MV
FAU - White, Harvey D
AU  - White HD
FAU - Moliterno, David J
AU  - Moliterno DJ
FAU - LaPointe, Nancy M Allen
AU  - LaPointe NM
FAU - Kandzari, David E
AU  - Kandzari DE
FAU - Verheugt, Freek W A
AU  - Verheugt FW
FAU - Kramer, Judith M
AU  - Kramer JM
FAU - Armstrong, Paul W
AU  - Armstrong PW
FAU - Califf, Robert M
AU  - Califf RM
CN  - SYMPHONY and 2nd SYMPHONY investigators
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Coronary Disease/complications/*drug therapy
MH  - Female
MH  - Hemorrhage/*chemically induced/etiology
MH  - Humans
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Patient Compliance
MH  - Risk Factors
EDAT- 2004/04/17 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/04/17 05:00
PHST- 2004/04/17 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/04/17 05:00 [entrez]
AID - 5268632 [pii]
AID - 10.1023/B:THRO.0000024050.78728.35 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2003 Dec;16(3):119-28. doi: 
      10.1023/B:THRO.0000024050.78728.35.

PMID- 25847199
OWN - NLM
STAT- MEDLINE
DCOM- 20160113
LR  - 20150407
IS  - 1776-2588 (Electronic)
IS  - 0761-8425 (Linking)
VI  - 32
IP  - 3
DP  - 2015 Mar
TI  - [Aspirin hypersensitivity: characteristics and diagnostic approach].
PG  - 221-8
LID - S0761-8425(14)00237-X [pii]
LID - 10.1016/j.rmr.2014.04.100 [doi]
AB  - INTRODUCTION: In routine medical practice, the diagnosis of aspirin 
      hypersensitivity (AH) remains difficult. No clinical feature or biomarker is 
      available to reliably confirm this diagnosis and oral provocation tests (OPT) are 
      rarely performed. AIM: To compare asthmatics with and without AH. METHOD: The 
      clinical characteristics of 21 asthmatics with and 24 without AH respectively 
      were determined. AH was defined by a positive OPT. A full blood count was done 
      before and 24 hours after the OPT. RESULTS: The medical history was associated 
      with a weak sensitivity (52%) and a good specificity (96%) for assessing the 
      diagnosis of AH. There was a higher prevalence of AH in women, and a higher 
      frequency of allergic rhinitis in AH, but no characteristic was useful to 
      facilitate the diagnosis of AH in asthmatic patients. Our results demonstrate 
      higher values of platelets in AH patients. Following OPT, in AH patients only, a 
      decrease in blood eosinophils and an increase in neutrophils was observed. 
      CONCLUSIONS: These results confirm that the diagnosis of AH is challenging, with 
      the history having only weak sensitivity. The observation that fluctuations in 
      eosinophils and neutrophils occur following OPT in AH patients only warrants 
      further investigations and suggests a rapid pro-inflammatory role for aspirin.
CI  - Copyright © 2014 SPLF. Published by Elsevier Masson SAS. All rights reserved.
FAU - Baudrand, H
AU  - Baudrand H
AD  - Service de pneumologie, centre hospitalier Lyon Sud, HCL, 69317 Lyon, France.
FAU - Zaouche, S
AU  - Zaouche S
AD  - Service d'ORL, centre hospitalier Lyon Sud, HCL, 69003 Lyon, France.
FAU - Dubost, R
AU  - Dubost R
AD  - Service de pneumologie, hôpital Louis-Pradel, HCL, 69500 Lyon, France.
FAU - Carsin, A
AU  - Carsin A
AD  - Service de pneumologie, centre hospitalier Lyon Sud, HCL, 69317 Lyon, France.
FAU - Chatte, G
AU  - Chatte G
AD  - Service de pneumologie, 69004 Caluire, France.
FAU - Freymond, N
AU  - Freymond N
AD  - Service de pneumologie, centre hospitalier Lyon Sud, HCL, 69317 Lyon, France.
FAU - Piperno, D
AU  - Piperno D
AD  - Service de pneumologie, 69006 Lyon, France.
FAU - Dubreuil, C
AU  - Dubreuil C
AD  - Service d'ORL, centre hospitalier Lyon Sud, HCL, 69003 Lyon, France.
FAU - Froehlich, P
AU  - Froehlich P
AD  - Service d'ORL, hôpital E.-Herriot, HCL, 69003 Lyon, France.
FAU - Pacheco, Y
AU  - Pacheco Y
AD  - Service de pneumologie, centre hospitalier Lyon Sud, HCL, 69317 Lyon, France.
FAU - Devouassoux, G
AU  - Devouassoux G
AD  - Service de pneumologie, hôpital de la Croix-Rousse, HCL, 103, 
      Grande-Rue-de-la-Croix-Rousse, 69317 Lyon cedex 04, France. Electronic address: 
      gilles.devouassoux@chu-lyon.fr.
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Intolérance à l'aspirine : caractéristiques et éléments diagnostiques.
DEP - 20140625
PL  - France
TA  - Rev Mal Respir
JT  - Revue des maladies respiratoires
JID - 8408032
RN  - 0 (Anti-Asthmatic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Asthmatic Agents/therapeutic use
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/diagnosis/drug therapy/epidemiology
MH  - Blood Cell Count
MH  - Blood Platelets/drug effects
MH  - Comorbidity
MH  - Diagnosis, Differential
MH  - Drug Hypersensitivity/*diagnosis/epidemiology
MH  - Eosinophils/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Medical History Taking
MH  - Middle Aged
MH  - Nasal Polyps/diagnosis/epidemiology
MH  - Neutrophils/drug effects
MH  - Prospective Studies
MH  - Respiratory Hypersensitivity/chemically induced
MH  - Rhinitis, Allergic, Perennial/diagnosis/epidemiology
MH  - Sensitivity and Specificity
MH  - Sex Distribution
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirine
OT  - Asthma
OT  - Asthme
OT  - Drug hypersensitivity
OT  - Inflammation
OT  - Intolérance médicamenteuse
OT  - Nasal polyposis
OT  - Polypose naso-sinusienne
EDAT- 2015/04/08 06:00
MHDA- 2016/01/14 06:00
CRDT- 2015/04/08 06:00
PHST- 2013/09/03 00:00 [received]
PHST- 2014/03/31 00:00 [accepted]
PHST- 2015/04/08 06:00 [entrez]
PHST- 2015/04/08 06:00 [pubmed]
PHST- 2016/01/14 06:00 [medline]
AID - S0761-8425(14)00237-X [pii]
AID - 10.1016/j.rmr.2014.04.100 [doi]
PST - ppublish
SO  - Rev Mal Respir. 2015 Mar;32(3):221-8. doi: 10.1016/j.rmr.2014.04.100. Epub 2014 
      Jun 25.

PMID- 26525539
OWN - NLM
STAT- MEDLINE
DCOM- 20170228
LR  - 20181113
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
VI  - 51
IP  - 7
DP  - 2016 Jul
TI  - Aspirin-induced gastrointestinal damage is associated with an inhibition of 
      epithelial cell autophagy.
PG  - 691-701
LID - 10.1007/s00535-015-1137-1 [doi]
AB  - BACKGROUND: Aspirin (ASA) causes gastrotoxicity by hampering the epithelial 
      defense against luminal contents through cyclooxygenase inhibition. Since cell 
      survival in tough conditions may depend on rescue mechanisms like autophagy, we 
      analyzed whether epithelial cells rely on this process to defend themselves from 
      aspirin's damaging action. METHODS: Rats received a single dose of ASA 
      (150 mg/kg, p.o.) with or without pretreatment with the autophagy inhibitor 
      3-methyladenine, and gastric injury and epithelial autophagy were evaluated 3 h 
      later. The effects of ASA on cell viability and autophagy were also evaluated in 
      gastric epithelial AGS cells. RESULTS: Basal autophagy in the gastric mucosa was 
      inhibited by ASA as demonstrated by increased levels of p62 and ubiquitinated 
      proteins and total LC3 and a reduced LC3-II/LC3-I ratio. Similarly, ASA increased 
      p62 and decreased LC3-II accumulation and the number of EmGFP/LC3B puncta in AGS 
      cells. ASA activated the PI3K/Akt-GSK3-mTOR pathway, which phosphorylates ULK1 to 
      prevent autophagy initiation, changes that were inhibited by the PI3K-inhibitor 
      wortmannin. Autophagy inhibition seems to enhance the vulnerability of gastric 
      epithelial cells as a combination of ASA with 3-methyladenine exacerbated rat 
      gastric damage and AGS cell apoptosis. CONCLUSIONS: Our data highlight the 
      importance of autophagy in the gastric mucosa as a protective mechanism when the 
      epithelium is injured. In the stomach, aspirin induces mucosal damage and reduces 
      autophagy, thus, eliminating a protective mechanism that epithelial cells could 
      use to escape death. We hypothesize that the combination of aspirin with drugs 
      that activate autophagy could protect against gastric damage.
FAU - Hernández, Carlos
AU  - Hernández C
AUID- ORCID: 0000-0001-8536-429X
AD  - Departamento de Farmacología and CIBER, Facultad de Medicina, Universidad de 
      Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain. 
      carlos.hernandez-saez@uv.es.
AD  - FISABIO, Hospital Dr. Peset, Av. Cataluña, 21, 46020, Valencia, Spain. 
      carlos.hernandez-saez@uv.es.
FAU - Barrachina, Maria Dolores
AU  - Barrachina MD
AD  - Departamento de Farmacología and CIBER, Facultad de Medicina, Universidad de 
      Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain.
FAU - Vallecillo-Hernández, Jorge
AU  - Vallecillo-Hernández J
AD  - Departamento de Farmacología and CIBER, Facultad de Medicina, Universidad de 
      Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain.
FAU - Álvarez, Ángeles
AU  - Álvarez Á
AD  - Departamento de Farmacología and CIBER, Facultad de Medicina, Universidad de 
      Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain.
AD  - Fundación General Universidad de Valencia, Calle Amadeo de Saboya, 4, 46010, 
      Valencia, Spain.
FAU - Ortiz-Masiá, Dolores
AU  - Ortiz-Masiá D
AD  - Departamento de Farmacología and CIBER, Facultad de Medicina, Universidad de 
      Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain.
FAU - Cosín-Roger, Jesús
AU  - Cosín-Roger J
AD  - Departamento de Farmacología and CIBER, Facultad de Medicina, Universidad de 
      Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain.
FAU - Esplugues, Juan Vicente
AU  - Esplugues JV
AD  - Departamento de Farmacología and CIBER, Facultad de Medicina, Universidad de 
      Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain.
AD  - FISABIO, Hospital Dr. Peset, Av. Cataluña, 21, 46020, Valencia, Spain.
FAU - Calatayud, Sara
AU  - Calatayud S
AD  - Departamento de Farmacología and CIBER, Facultad de Medicina, Universidad de 
      Valencia, Av. Blasco Ibáñez, 15, 46010, Valencia, Spain.
LA  - eng
PT  - Journal Article
DEP - 20151103
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*pharmacology
MH  - Autophagy/*drug effects
MH  - Cell Survival/drug effects
MH  - Cyclooxygenase Inhibitors/adverse effects/*pharmacology
MH  - Epithelial Cells/*drug effects
MH  - Female
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Male
MH  - Mice, Inbred BALB C
MH  - Rats
MH  - Rats, Sprague-Dawley
OTO - NOTNLM
OT  - Aspirin
OT  - Autophagy
OT  - Epithelial cells
OT  - Gastric damage
OT  - NSAID
EDAT- 2015/11/04 06:00
MHDA- 2017/03/01 06:00
CRDT- 2015/11/04 06:00
PHST- 2015/04/02 00:00 [received]
PHST- 2015/10/16 00:00 [accepted]
PHST- 2015/11/04 06:00 [entrez]
PHST- 2015/11/04 06:00 [pubmed]
PHST- 2017/03/01 06:00 [medline]
AID - 10.1007/s00535-015-1137-1 [pii]
AID - 10.1007/s00535-015-1137-1 [doi]
PST - ppublish
SO  - J Gastroenterol. 2016 Jul;51(7):691-701. doi: 10.1007/s00535-015-1137-1. Epub 
      2015 Nov 3.

PMID- 29540563
OWN - NLM
STAT- MEDLINE
DCOM- 20190522
LR  - 20190522
IS  - 1521-0103 (Electronic)
IS  - 0022-3565 (Linking)
VI  - 365
IP  - 2
DP  - 2018 May
TI  - Morphine Interaction with Aspirin: a Double-Blind, Crossover Trial in Healthy 
      Volunteers.
PG  - 430-436
LID - 10.1124/jpet.117.247213 [doi]
AB  - Aspirin is a cornerstone in the antiplatelet therapy for acute coronary 
      syndromes. Coadministration of morphine may potentially influence the intestinal 
      absorption, pharmacokinetics, and pharmacodynamics, as seen with P2Y(12) 
      inhibitors. In this trial, healthy volunteers were randomized to receive morphine 
      (5 mg, i.v. bolus injection) at one of seven different time points before, after, 
      or with aspirin (162 mg, p.o.) in a double-blind, placebo-controlled fashion. 
      After a 14-day washout, subjects received placebo instead of morphine. 
      Pharmacokinetics were determined by liquid chromatography, and aspirin's effects 
      were measured by platelet function tests (whole-blood platelet aggregation: 
      multiplate, platelet plug formation: PFA-100). Morphine increased the total 
      acetylsalicylic acid exposure by 20% compared with placebo when given 
      simultaneously with aspirin, whereas C(max) and t(max) were not altered. Morphine 
      had no significant effect on aspirin-induced platelet inhibition. In contrast to 
      coadministration with P2Y(12) inhibitors, morphine appears to have negligible 
      interaction with aspirin.
CI  - Copyright © 2018 by The Author(s).
FAU - Bartko, Johann
AU  - Bartko J
AD  - Department of Clinical Pharmacology, Medical University of Vienna (J.B., C.S., 
      M.S., P.W., B.J., E.-L.H.), and Ludwig Boltzmann Institute of Osteology, Hanusch 
      Hospital of WGKK, AUVA Trauma Centre Meidling (J.B.), Vienna, Austria; and 
      Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland (J.K.).
FAU - Schoergenhofer, Christian
AU  - Schoergenhofer C
AD  - Department of Clinical Pharmacology, Medical University of Vienna (J.B., C.S., 
      M.S., P.W., B.J., E.-L.H.), and Ludwig Boltzmann Institute of Osteology, Hanusch 
      Hospital of WGKK, AUVA Trauma Centre Meidling (J.B.), Vienna, Austria; and 
      Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland (J.K.).
FAU - Schwameis, Michael
AU  - Schwameis M
AD  - Department of Clinical Pharmacology, Medical University of Vienna (J.B., C.S., 
      M.S., P.W., B.J., E.-L.H.), and Ludwig Boltzmann Institute of Osteology, Hanusch 
      Hospital of WGKK, AUVA Trauma Centre Meidling (J.B.), Vienna, Austria; and 
      Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland (J.K.).
FAU - Wadowski, Patricia
AU  - Wadowski P
AD  - Department of Clinical Pharmacology, Medical University of Vienna (J.B., C.S., 
      M.S., P.W., B.J., E.-L.H.), and Ludwig Boltzmann Institute of Osteology, Hanusch 
      Hospital of WGKK, AUVA Trauma Centre Meidling (J.B.), Vienna, Austria; and 
      Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland (J.K.).
FAU - Kubica, Jacek
AU  - Kubica J
AD  - Department of Clinical Pharmacology, Medical University of Vienna (J.B., C.S., 
      M.S., P.W., B.J., E.-L.H.), and Ludwig Boltzmann Institute of Osteology, Hanusch 
      Hospital of WGKK, AUVA Trauma Centre Meidling (J.B.), Vienna, Austria; and 
      Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland (J.K.).
FAU - Jilma, Bernd
AU  - Jilma B
AD  - Department of Clinical Pharmacology, Medical University of Vienna (J.B., C.S., 
      M.S., P.W., B.J., E.-L.H.), and Ludwig Boltzmann Institute of Osteology, Hanusch 
      Hospital of WGKK, AUVA Trauma Centre Meidling (J.B.), Vienna, Austria; and 
      Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland (J.K.) 
      bernd.jilma@meduniwien.ac.at.
FAU - Hobl, Eva-Luise
AU  - Hobl EL
AD  - Department of Clinical Pharmacology, Medical University of Vienna (J.B., C.S., 
      M.S., P.W., B.J., E.-L.H.), and Ludwig Boltzmann Institute of Osteology, Hanusch 
      Hospital of WGKK, AUVA Trauma Centre Meidling (J.B.), Vienna, Austria; and 
      Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland (J.K.).
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180314
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 76I7G6D29C (Morphine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Female
MH  - *Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Morphine/*pharmacology
MH  - Tissue Distribution/drug effects
EDAT- 2018/03/16 06:00
MHDA- 2019/05/23 06:00
CRDT- 2018/03/16 06:00
PHST- 2017/12/14 00:00 [received]
PHST- 2018/02/23 00:00 [accepted]
PHST- 2018/03/16 06:00 [pubmed]
PHST- 2019/05/23 06:00 [medline]
PHST- 2018/03/16 06:00 [entrez]
AID - jpet.117.247213 [pii]
AID - 10.1124/jpet.117.247213 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2018 May;365(2):430-436. doi: 10.1124/jpet.117.247213. Epub 
      2018 Mar 14.

PMID- 2690562
OWN - NLM
STAT- MEDLINE
DCOM- 19900201
LR  - 20151119
IS  - 0001-6497 (Print)
IS  - 0001-6497 (Linking)
VI  - 43
IP  - 2
DP  - 1989
TI  - [Asthma relieved by aspirin].
PG  - 131-9
AB  - Some particular cases of bronchial asthma are improved by acetylsalicylic acid. 
      The clinical characteristics of these patients are very similar to those of 
      asthmatic ASA-sensitive cases: a cortico-dependent asthma occurring in later 
      life, in nonatopic patients with chronic rhinitis, sinusitis and/or nasal 
      polyposis. The patient notices that taking an occasional aspirin tablet for some 
      other problem reduces his respiratory symptoms. The bronchodilator effect of 
      aspirin and other Non Steroidal Anti-Inflammatory Drugs in such patients has been 
      clearly demonstrated, although all drugs don't have the same effectiveness. It is 
      important to diagnose these aspirin-relieved asthma cases, using an oral aspirin 
      test, because the treatment with aspirin allows us then to reduce the needed 
      corticosteroid dose. We hypothesize that a diversion of the arachidonic acid 
      metabolism towards cyclo-oxygenase products causes this syndrome.
FAU - Garin, P
AU  - Garin P
AD  - Département de Médecine Internè, Cliniques Universitaires Saint-Luc (UCL), 
      Bruxelles.
FAU - Frans, A
AU  - Frans A
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - L'asthme soulagé par l'aspirine.
PL  - Belgium
TA  - Acta Otorhinolaryngol Belg
JT  - Acta oto-rhino-laryngologica Belgica
JID - 0373057
RN  - 0 (Arachidonic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acids/physiology
MH  - Aspirin/metabolism/*therapeutic use
MH  - Asthma/*drug therapy/physiopathology
MH  - Bronchial Provocation Tests
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
RF  - 20
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Otorhinolaryngol Belg. 1989;43(2):131-9.

PMID- 518111
OWN - NLM
STAT- MEDLINE
DCOM- 19800228
LR  - 20190501
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Print)
IS  - 0003-9888 (Linking)
VI  - 54
IP  - 9
DP  - 1979 Sep
TI  - Rectal aspirin--absorption and antipyretic effect.
PG  - 713-5
AB  - Rectal acetylsalicylic acid was given to 14 children who had undergone open heart 
      surgery. The effect on their temperatures was similar whether 15--30 or 30--50 
      mg/kg was given. Either dose was more effective than no treatment. The greatest 
      fall in temperature occurred after 4 or 5 hours. Rectal aspirin in a triglyceride 
      base is effective in lowering postoperative temperature. It should also be of use 
      in treating other fevers. A dose of 20--25 mg/kg is suggested.
FAU - Connolly, K
AU  - Connolly K
FAU - Lam, L
AU  - Lam L
FAU - Ward, O C
AU  - Ward OC
LA  - eng
PT  - Journal Article
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
RN  - 0 (Suppositories)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*administration & dosage/metabolism/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Fever/*drug therapy
MH  - Humans
MH  - Intestinal Absorption
MH  - Postoperative Complications/*drug therapy
MH  - Rectum
MH  - Suppositories
PMC - PMC1545810
EDAT- 1979/09/01 00:00
MHDA- 1979/09/01 00:01
CRDT- 1979/09/01 00:00
PHST- 1979/09/01 00:00 [pubmed]
PHST- 1979/09/01 00:01 [medline]
PHST- 1979/09/01 00:00 [entrez]
AID - 10.1136/adc.54.9.713 [doi]
PST - ppublish
SO  - Arch Dis Child. 1979 Sep;54(9):713-5. doi: 10.1136/adc.54.9.713.

PMID- 18160360
OWN - NLM
STAT- MEDLINE
DCOM- 20080221
LR  - 20131121
IS  - 1308-0032 (Electronic)
IS  - 1302-8723 (Linking)
VI  - 7 Suppl 2
DP  - 2007 Dec
TI  - [Use of aspirin in diabetic patients].
PG  - 5-8
AB  - Major cardiovascular events cause about 80% of the total mortality in diabetic 
      patients. It has been shown that diabetic patients have hyperactive platelets. It 
      may be expected that aspirin, through its antiplatelet action, could change the 
      risk for vascular events in people with diabetes. However, some data suggest that 
      aspirin may be less effective than expected in preventing cardiovascular events 
      in patients with diabetes. In this paper, we review the aspirin use in diabetics 
      with respect to cardiovascular endpoints.
FAU - Türkoğlu, Sedat
AU  - Türkoğlu S
AD  - Gazi Universitesi Tip Fakültesi Kardiyoloji Anabilim Dali, Ankara, Türkiye.
FAU - Abaci, Adnan
AU  - Abaci A
LA  - tur
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Diyabetik hastalarda aspirin.
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/complications/*prevention & control
MH  - *Diabetes Mellitus
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
RF  - 38
EDAT- 2008/02/09 09:00
MHDA- 2008/02/22 09:00
CRDT- 2008/02/09 09:00
PHST- 2008/02/09 09:00 [pubmed]
PHST- 2008/02/22 09:00 [medline]
PHST- 2008/02/09 09:00 [entrez]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2007 Dec;7 Suppl 2:5-8.

PMID- 34154964
OWN - NLM
STAT- MEDLINE
DCOM- 20220523
LR  - 20220523
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 32
IP  - 6
DP  - 2022 May
TI  - The safety of continued low dose aspirin therapy during Complete Supine 
      Percutaneous Nephrolithotomy (csPCNL).
PG  - 458-464
LID - S1166-7087(21)00097-X [pii]
LID - 10.1016/j.purol.2021.04.005 [doi]
AB  - OBJECTIVE: Using anticoagulants and antiplatelet drugs in patients with 
      cardiovascular and medical comorbidities is prevalent. Because of hyper vascular 
      nature of kidney, physicians tend to stop using aspirin before percutaneous 
      nephrolithotomy (PCNL). We have shown the effects of remaining on low dose 
      aspirin in complete supine PCNL (csPCNL). MATERIAL AND METHODS: The records of 
      643 patients who underwent csPCNL between 2012 and 2018 were analyzed. Surgical 
      outcomes and complications of patients who were on aspirin therapy and continued 
      it daily (group A) were compared with those not taking aspirin (group B). 
      RESULTS: Of the 643 csPCNLs, 40 (6%) were performed in patients of group A and 
      the rest of 603 (94%) cases were in group B. The differences between the mean age 
      of groups were statistically significant (60.08±9.45, group A and 48.66±12.32, 
      group B) (P<0.001). Thirty-nine (97.5%) of patients in group A and 548 (90.9%) of 
      group B were stone free by the end of the study which was not statistically 
      significant (P=0.118). The mean operative time between groups A and B 
      (43.20±21.37 and 44.83±16.83, respectively) was not considered significant 
      (P=0.561). There was also no significant difference between 2 groups in any types 
      of complications. Multivariate analysis showed that, perioperative aspirin use 
      was not a significant predictor of transfusion, Hb drop, operative time and other 
      complications. CONCLUSIONS: Remaining on aspirin does not increase the risk of 
      bleeding, transfusionand other complications. Consequently, continuing aspirin 
      prioperatively in csPCNL appears safe. There is no fear for continuing aspirin in 
      csPCNL.
CI  - Copyright © 2021 Elsevier Masson SAS. All rights reserved.
FAU - Falahatkar, S
AU  - Falahatkar S
AD  - Urology Research Center, Razi Hospital, School of Medicine, Guilan University of 
      Medical Sciences, Rasht, Iran. Electronic address: falahatkar_s@yahoo.com.
FAU - Esmaeili, S
AU  - Esmaeili S
AD  - Urology Research Center, Razi Hospital, School of Medicine, Guilan University of 
      Medical Sciences, Rasht, Iran. Electronic address: samaneh_815@yahoo.com.
FAU - Rastjou Herfeh, N
AU  - Rastjou Herfeh N
AD  - Urology Research Center, Razi Hospital, School of Medicine, Guilan University of 
      Medical Sciences, Rasht, Iran. Electronic address: nadia.rastjou@gmail.com.
FAU - Kazemnezhad, E
AU  - Kazemnezhad E
AD  - Urology Research Center, Razi Hospital, School of Medicine, Guilan University of 
      Medical Sciences, Rasht, Iran. Electronic address: kazem_eh@yahoo.com.
FAU - Falahatkar, R
AU  - Falahatkar R
AD  - Urology Research Center, Razi Hospital, School of Medicine, Guilan University of 
      Medical Sciences, Rasht, Iran. Electronic address: rfalahatkar76@gmail.com.
FAU - Yeganeh, M
AU  - Yeganeh M
AD  - Urology Research Center, Razi Hospital, School of Medicine, Guilan University of 
      Medical Sciences, Rasht, Iran. Electronic address: urc1384@yahoo.com.
FAU - Jafari, A
AU  - Jafari A
AD  - Urology Research Center, Razi Hospital, School of Medicine, Guilan University of 
      Medical Sciences, Rasht, Iran. Electronic address: dr.alireza.jafari@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20210618
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la 
      Societe francaise d'urologie
JID - 9307844
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Humans
MH  - *Kidney Calculi/complications
MH  - *Nephrolithotomy, Percutaneous/adverse effects
MH  - *Nephrostomy, Percutaneous
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirine
OT  - Bleeding
OT  - Calcul rénal
OT  - CsPCNL
OT  - Décubitus
OT  - Kidney stone
OT  - NLPC en DDC
OT  - Néphrolithotomie percutanée
OT  - Percutaneous nephrolithotomy
OT  - Saignement
OT  - Supine
OT  - Transfusion
EDAT- 2021/06/23 06:00
MHDA- 2022/05/24 06:00
CRDT- 2021/06/22 05:51
PHST- 2020/07/04 00:00 [received]
PHST- 2021/02/24 00:00 [revised]
PHST- 2021/04/02 00:00 [accepted]
PHST- 2021/06/23 06:00 [pubmed]
PHST- 2022/05/24 06:00 [medline]
PHST- 2021/06/22 05:51 [entrez]
AID - S1166-7087(21)00097-X [pii]
AID - 10.1016/j.purol.2021.04.005 [doi]
PST - ppublish
SO  - Prog Urol. 2022 May;32(6):458-464. doi: 10.1016/j.purol.2021.04.005. Epub 2021 
      Jun 18.

PMID- 3826379
OWN - NLM
STAT- MEDLINE
DCOM- 19870416
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 252
IP  - 3 Pt 1
DP  - 1987 Mar
TI  - Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity?
PG  - G421-30
AB  - Intraluminally administered aspirin disrupts the gastric mucosal barrier in a 
      pH-dependent manner and may do so by compromising the hydrophobic or nonwettable 
      lining to the stomach. We examined the pH dependence and time-course of aspirin's 
      effects on barrier integrity by measuring the aspirin-induced changes in surface 
      wettability, potential difference (PD), and electrical resistance (R) of canine 
      gastric mucosa mounted in Ussing chambers. Luminal surface hydrophobicity, as 
      determined by contact angle (CA) measurements, and PD were reduced by acidic 
      aspirin solutions but were not reduced by acidic solutions without aspirin (pH 
      2.6) or by aspirin solutions that were neutral or only mildly acidic (pH greater 
      than 4.0). Significant reductions in CA were correlated well with the proportion 
      of aspirin in its lipid-soluble undissociated form (r = 0.93, P less than 0.001). 
      Acidified-aspirin solutions significantly reduced CA and PD after a 2.5-min 
      incubation period. Significant reductions in R occurred 25 min after exposure to 
      acidified aspirin. Morphological damage to the gastric epithelium was not 
      apparent after a 5-min exposure to acidified aspirin but was conspicuous 30 min 
      after aspirin treatment. Aspirin-induced reductions in CA were highly associated 
      with decreases in mucosal PD in both the pH and time-dependent studies (r = 0.93 
      and r = 0.99, respectively, P less than 0.001). These data support the hypothesis 
      that the undissociated form of aspirin compromises the protective nonwettable 
      lining of the stomach and in doing so, disrupts the gastric mucosal barrier.
FAU - Goddard, P J
AU  - Goddard PJ
FAU - Hills, B A
AU  - Hills BA
FAU - Lichtenberger, L M
AU  - Lichtenberger LM
LA  - eng
GR  - AM-00842/AM/NIADDK NIH HHS/United States
GR  - AM-33239/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Surface-Active Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dogs
MH  - Electrophysiology
MH  - Female
MH  - Gastric Mucosa/cytology/*drug effects/physiology
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Solubility
MH  - Surface Properties
MH  - Surface-Active Agents
MH  - Time Factors
OID - NASA: 87153926
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 10.1152/ajpgi.1987.252.3.G421 [doi]
PST - ppublish
SO  - Am J Physiol. 1987 Mar;252(3 Pt 1):G421-30. doi: 10.1152/ajpgi.1987.252.3.G421.

PMID- 16369302
OWN - NLM
STAT- MEDLINE
DCOM- 20060713
LR  - 20181203
IS  - 1531-0132 (Electronic)
IS  - 1531-0132 (Linking)
VI  - 7
IP  - 3
DP  - 2005 Jul 11
TI  - Aspirin resistance and its implications in clinical practice.
PG  - 76
AB  - Recent studies have suggested that some patients may not obtain the full benefits 
      of aspirin's antiplatelet effects. An international roundtable of experts was 
      held November 6, 2004, in New Orleans, Louisiana, to address the concept of 
      aspirin resistance and its clinical implications. Panelists discussed various 
      definitions and possible mechanisms of aspirin resistance, along with several 
      tests currently available to measure platelet function. They recommended that 
      until the clinical importance of these tests is known, physicians should continue 
      to prescribe low-dose aspirin therapy for individuals at high risk for 
      cardiovascular events and patients currently taking aspirin should continue to 
      comply with their prescribed therapy.
FAU - Eikelboom, John
AU  - Eikelboom J
AD  - McMaster University, Hamilton, Ontario, Canada. eikelbj@mcmaster.ca
FAU - Feldman, Mark
AU  - Feldman M
FAU - Mehta, Shamir R
AU  - Mehta SR
FAU - Michelson, Alan D
AU  - Michelson AD
FAU - Oates, John A
AU  - Oates JA
FAU - Topol, Eric
AU  - Topol E
LA  - eng
PT  - Congress
DEP - 20050711
PL  - United States
TA  - MedGenMed
JT  - MedGenMed : Medscape general medicine
JID - 100894134
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - *Drug Resistance
MH  - Humans
PMC - PMC1681651
EDAT- 2005/12/22 09:00
MHDA- 2006/07/14 09:00
CRDT- 2005/12/22 09:00
PHST- 2005/12/22 09:00 [pubmed]
PHST- 2006/07/14 09:00 [medline]
PHST- 2005/12/22 09:00 [entrez]
AID - 506101 [pii]
PST - epublish
SO  - MedGenMed. 2005 Jul 11;7(3):76.

PMID- 31552879
OWN - NLM
STAT- MEDLINE
DCOM- 20200525
LR  - 20200525
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 9
IP  - 3
DP  - 2019 Jul-Sep
TI  - Hydrogen sulphide-releasing aspirin enhances cell capabilities of anti-oxidative 
      lesions and anti-inflammation.
PG  - 145-152
LID - 10.4103/2045-9912.266990 [doi]
AB  - Hydrogen sulphide (H(2)S) has been considered as a toxic gas for a long time till 
      new researches discovered the endogenous H(2)S effects on physiological and 
      pathological processes. In virtue of H(2)S's effects on cellular redox imbalance 
      and aspirin's good anticoagulation property, exogenous H(2)S donors, such as 
      H(2)S-releasing aspirin (ACS14), have been explored to attenuate side effects of 
      aspirin on gastrointestinal mucosal damage. However, existing researches mainly 
      focus on the antithrombotic effects. Considering H(2)S role in angiogenesis and 
      vascular-protection progress, we herein focused on if ACS14 further has the 
      ability to attenuate oxidative lesion and inflammation in human umbilical vein 
      endothelial cells (HUVECs) and macrophages. In this study, we synthesized ACS14 
      by 5-(4-methoxyphenyl)-1,2-dithiole-3-thione and o-acetylsalicylic acid 
      (aspirin), and the obtained compounds showed the ability to release H(2)S. Our 
      data illustrated that both aspirin and ACS14 had good cytocompatibility, and 
      could support the proliferation of HUVECs. And, ACS14 was found to be able to 
      promote 1.6 folds increase compared to aspirin. H(2)S released from ACS14 was 
      detected inside cells, wherein H2S fluorescence intensity increased twofold in 5 
      μM and 10 μM ACS14 groups than 1 μM group. Owing to reactive oxygen species 
      inside cells being obviously decreased in ACS14 group, the apoptosis rate of 
      HUVEC herein was reduced as low as 1.6% from 60% of blank group. Meanwhile, the 
      tumour necrosis factor alpha release in macrophage was also declined by 15% in 
      ACS14 groups than the others. Basically, the ACS14 we obtained had the 
      cyto-protective and anti-inflammatory capabilities. Potential applications for 
      vascular intima repair in atherosclerosis are further expected.
FAU - Zhao, An-Sha
AU  - Zhao AS
AD  - Key Laboratory for Advanced Technologies of Materials, Ministry of Education; 
      School of Material Science and Engineering, Southwest Jiaotong University, 
      Chengdu, Sichuan Province, China.
FAU - Zou, Dan
AU  - Zou D
AD  - Key Laboratory for Advanced Technologies of Materials, Ministry of Education; 
      School of Material Science and Engineering, Southwest Jiaotong University, 
      Chengdu, Sichuan Province, China.
FAU - Wang, Hao-Hao
AU  - Wang HH
AD  - Key Laboratory for Advanced Technologies of Materials, Ministry of Education; 
      School of Material Science and Engineering, Southwest Jiaotong University, 
      Chengdu, Sichuan Province, China.
FAU - Han, Xiao
AU  - Han X
AD  - Key Laboratory for Advanced Technologies of Materials, Ministry of Education; 
      School of Material Science and Engineering, Southwest Jiaotong University, 
      Chengdu, Sichuan Province, China.
FAU - Yang, Ping
AU  - Yang P
AD  - Key Laboratory for Advanced Technologies of Materials, Ministry of Education; 
      School of Material Science and Engineering, Southwest Jiaotong University, 
      Chengdu, Sichuan Province, China.
FAU - Huang, Nan
AU  - Huang N
AD  - Key Laboratory for Advanced Technologies of Materials, Ministry of Education; 
      School of Material Science and Engineering, Southwest Jiaotong University, 
      Chengdu, Sichuan Province, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*metabolism/*pharmacology
MH  - Antioxidants/*metabolism/*pharmacology
MH  - Aspirin/*metabolism/*pharmacology
MH  - Human Umbilical Vein Endothelial Cells/drug effects/metabolism
MH  - Humans
MH  - Hydrogen Sulfide/*metabolism
MH  - Mice
MH  - Oxidative Stress/drug effects
MH  - RAW 264.7 Cells
PMC - PMC6779009
OTO - NOTNLM
OT  - ACS14
OT  - H2S donor
OT  - anticoagulation
OT  - atherosclerosis
OT  - endothelial cell
OT  - hydrogen sulphide
OT  - inflammation
OT  - macrophage
OT  - oxidative lesion
COIS- No potential conflict of interest was reported by the authors.
EDAT- 2019/09/26 06:00
MHDA- 2020/05/26 06:00
CRDT- 2019/09/26 06:00
PHST- 2019/09/26 06:00 [entrez]
PHST- 2019/09/26 06:00 [pubmed]
PHST- 2020/05/26 06:00 [medline]
AID - MedGasRes_2019_9_3_145_266990 [pii]
AID - MGR-9-145 [pii]
AID - 10.4103/2045-9912.266990 [doi]
PST - ppublish
SO  - Med Gas Res. 2019 Jul-Sep;9(3):145-152. doi: 10.4103/2045-9912.266990.

PMID- 15471991
OWN - NLM
STAT- MEDLINE
DCOM- 20041122
LR  - 20181113
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 101
IP  - 42
DP  - 2004 Oct 19
TI  - Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a 
      randomized human trial.
PG  - 15178-83
AB  - There is increasing evidence that aspirin initiates biosynthesis of novel 
      antiinflammatory mediators by means of interactions between endothelial cells and 
      leukocytes. These mediators are classified as aspirin-triggered 15-epi-lipoxins. 
      Such compounds may account at least in part for aspirin's clinical benefits, 
      which are distinct from the well appreciated action of aspirin as a platelet 
      inhibitor. Here, we addressed whether aspirin-triggered 15-epilipoxinA4 (ATL) 
      formation is aspirin-dependent in humans and its relationship to aspirin's 
      antiplatelet activity. We conducted a randomized clinical trial among 128 healthy 
      subjects allocated to placebo or to 81-, 325-, or 650-mg daily doses of aspirin 
      for 8 weeks. Plasma thromboxane (TX)B2, an indicator of platelet reactivity, and 
      ATL were assessed from blood collected at baseline and at 8 weeks. Plasma ATL 
      levels significantly increased in the 81-mg aspirin group (0.25 +/- 0.63 ng/ml, P 
      = 0.04), with borderline increases in the 325-mg group (0.16 +/- 0.71 ng/ml) and 
      no apparent significant changes in the 650-mg group (0.01 +/- 0.75 ng/ml, P = 
      0.96). When ATL and TXB2 were compared, levels changed in a statistically 
      significant and opposite direction (P < 0.01) for all three aspirin doses. These 
      results demonstrated that low-dose aspirin (81 mg daily) initiates production of 
      antiinflammatory ATL opposite to the inhibition of TX. Monitoring ATL may 
      represent a simple clinical parameter to verify an individual's vascular 
      leukocyte antiinflammatory response with low-dose aspirin treatment. These 
      results also emphasize the importance of cell-cell interactions in the modulation 
      of hemostatic, thrombotic, and inflammatory processes.
FAU - Chiang, Nan
AU  - Chiang N
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Bermudez, Edmund A
AU  - Bermudez EA
FAU - Ridker, Paul M
AU  - Ridker PM
FAU - Hurwitz, Shelley
AU  - Hurwitz S
FAU - Serhan, Charles N
AU  - Serhan CN
LA  - eng
GR  - R01 GM038765/GM/NIGMS NIH HHS/United States
GR  - GM 38765/GM/NIGMS NIH HHS/United States
GR  - P01-DE13499/DE/NIDCR NIH HHS/United States
GR  - P01 DE013499/DE/NIDCR NIH HHS/United States
GR  - R37 GM038765/GM/NIGMS NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20041007
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Isoenzymes)
RN  - 0 (Lipoxins)
RN  - 0 (Membrane Proteins)
RN  - 0 (lipoxin A4)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2016 Sep 27;316(12):1317-8. PMID: 27673312
CIN - JAMA. 2016 Sep 27;316(12 ):1318. PMID: 27673315
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cyclooxygenase 2
MH  - Female
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Isoenzymes/blood
MH  - Lipoxins/*blood
MH  - Male
MH  - Membrane Proteins
MH  - Middle Aged
MH  - Prostaglandin-Endoperoxide Synthases/blood
MH  - Thromboxane B2/*antagonists & inhibitors/blood
PMC - PMC523452
EDAT- 2004/10/09 09:00
MHDA- 2004/12/16 09:00
CRDT- 2004/10/09 09:00
PHST- 2004/10/09 09:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/10/09 09:00 [entrez]
AID - 0405445101 [pii]
AID - 10115178 [pii]
AID - 10.1073/pnas.0405445101 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15178-83. doi: 
      10.1073/pnas.0405445101. Epub 2004 Oct 7.

PMID- 35411788
OWN - NLM
STAT- MEDLINE
DCOM- 20220421
LR  - 20220920
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 11
IP  - 8
DP  - 2022 Apr 19
TI  - Contextualizing National Policies Regulating Access to Low-Dose Aspirin in 
      America and Europe Using the Full Report of a Transatlantic Patient Survey of 
      Aspirin in Preventive Cardiology.
PG  - e023995
LID - 10.1161/JAHA.121.023995 [doi]
LID - e023995
AB  - Background Aspirin is widely administered to prevent cardiovascular disease 
      (CVD). However, appropriate use of aspirin depends on patient understanding of 
      its risks, benefits, and indications, especially where aspirin is available over 
      the counter (OTC). Methods and Results We did a survey of patient-reported 
      10-year cardiovascular risk; aspirin therapy status; form of aspirin access (OTC 
      versus prescription); and knowledge of the risks, benefits, and role of aspirin 
      in CVD prevention. Consecutive adults aged ≥50 years with ≥1 cardiovascular risk 
      factor attending outpatient clinics in America and Europe were recruited. We also 
      systematically reviewed national policies regulating access to low-dose aspirin 
      for CVD prevention. At each site, 150 responses were obtained (300 total). 
      Mean±SD age was 65±10 years, 40% were women, and 41% were secondary prevention 
      patients. More than half of the participants at both sites did not know (1) their 
      own level of 10-year CVD risk, (2) the expected magnitude of reduction in CVD 
      risk with aspirin, or (3) aspirin's bleeding risks. Only 62% of all participants 
      reported that aspirin was routinely indicated for secondary prevention, whereas 
      47% believed it was routinely indicated for primary prevention (P=0.048). In 
      America, 83.5% participants obtained aspirin OTC compared with 2.5% in Europe 
      (P<0.001). Finally, our review of European national policies found only 2 
      countries where low-dose aspirin was available OTC. Conclusions Many patients 
      have poor insight into their objectively calculated 10-year cardiovascular risk 
      and do not know the risks, benefits, and role of aspirin in CVD prevention. 
      Aspirin is mainly obtained OTC in America in contrast to Europe, where most 
      countries restrict access to low-dose aspirin.
FAU - Jacobsen, Alan P
AU  - Jacobsen AP
AUID- ORCID: 0000-0003-0587-8333
AD  - Ciccarone Center for the Prevention of Cardiovascular Disease Division of 
      Cardiology Department of Medicine Johns Hopkins Medical Institutions Baltimore 
      MD.
FAU - Lim, Zi Lun
AU  - Lim ZL
AD  - National Institute for Prevention and Cardiovascular HealthNational University of 
      Ireland Galway School of Medicine Galway Ireland.
FAU - Chang, Blair
AU  - Chang B
AD  - Ciccarone Center for the Prevention of Cardiovascular Disease Division of 
      Cardiology Department of Medicine Johns Hopkins Medical Institutions Baltimore 
      MD.
FAU - Lambeth, Kaleb D
AU  - Lambeth KD
AD  - Ciccarone Center for the Prevention of Cardiovascular Disease Division of 
      Cardiology Department of Medicine Johns Hopkins Medical Institutions Baltimore 
      MD.
FAU - Das, Thomas M
AU  - Das TM
AUID- ORCID: 0000-0002-4004-023X
AD  - Ciccarone Center for the Prevention of Cardiovascular Disease Division of 
      Cardiology Department of Medicine Johns Hopkins Medical Institutions Baltimore 
      MD.
FAU - Gorry, Colin
AU  - Gorry C
AD  - National Institute for Prevention and Cardiovascular HealthNational University of 
      Ireland Galway School of Medicine Galway Ireland.
FAU - McCague, Michael
AU  - McCague M
AD  - Clinical Research Facility National University of Ireland Galway Galway Ireland.
FAU - Sharif, Faisal
AU  - Sharif F
AD  - School of Medicine National University of Ireland Galway Galway Ireland.
FAU - Mylotte, Darren
AU  - Mylotte D
AD  - School of Medicine National University of Ireland Galway Galway Ireland.
FAU - Wijns, William
AU  - Wijns W
AD  - School of Medicine National University of Ireland Galway Galway Ireland.
FAU - Serruys, Patrick W J C
AU  - Serruys PWJC
AUID- ORCID: 0000-0002-9636-1104
AD  - School of Medicine National University of Ireland Galway Galway Ireland.
FAU - Blumenthal, Roger S
AU  - Blumenthal RS
AUID- ORCID: 0000-0003-1910-3168
AD  - Ciccarone Center for the Prevention of Cardiovascular Disease Division of 
      Cardiology Department of Medicine Johns Hopkins Medical Institutions Baltimore 
      MD.
FAU - Martin, Seth S
AU  - Martin SS
AUID- ORCID: 0000-0002-7021-7622
AD  - Ciccarone Center for the Prevention of Cardiovascular Disease Division of 
      Cardiology Department of Medicine Johns Hopkins Medical Institutions Baltimore 
      MD.
FAU - McEvoy, John W
AU  - McEvoy JW
AUID- ORCID: 0000-0001-6530-5479
AD  - Ciccarone Center for the Prevention of Cardiovascular Disease Division of 
      Cardiology Department of Medicine Johns Hopkins Medical Institutions Baltimore 
      MD.
AD  - National Institute for Prevention and Cardiovascular HealthNational University of 
      Ireland Galway School of Medicine Galway Ireland.
LA  - eng
PT  - Journal Article
DEP - 20220412
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - J Am Heart Assoc. 2022 Sep 20;11(18):e020758. PMID: 36104845
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - *Cardiology
MH  - *Cardiovascular Diseases/chemically induced/epidemiology/prevention & control
MH  - Europe/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Policy
MH  - Primary Prevention/methods
PMC - PMC9238454
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular disease prevention
OT  - guidelines
OT  - patient understanding
OT  - regional variation
EDAT- 2022/04/13 06:00
MHDA- 2022/04/22 06:00
CRDT- 2022/04/12 08:39
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/04/22 06:00 [medline]
PHST- 2022/04/12 08:39 [entrez]
AID - JAH37367 [pii]
AID - 10.1161/JAHA.121.023995 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2022 Apr 19;11(8):e023995. doi: 10.1161/JAHA.121.023995. Epub 
      2022 Apr 12.

PMID- 11470724
OWN - NLM
STAT- MEDLINE
DCOM- 20010823
LR  - 20180330
IS  - 0002-9165 (Print)
IS  - 0002-9165 (Linking)
VI  - 74
IP  - 2
DP  - 2001 Aug
TI  - Aspirin intake and the use of serum ferritin as a measure of iron status.
PG  - 219-26
AB  - BACKGROUND: Atherosclerosis, a primary cause of myocardial infarction (MI), is an 
      inflammatory disease. Aspirin use lowers risk of MI, probably through 
      antithrombotic and antiinflammatory effects. Because serum ferritin (SF) can be 
      elevated spuriously by inflammation, reported associations between elevated SF, 
      used as an indicator of iron stores, and heart disease could be confounded by 
      occult inflammation and aspirin use if they affect SF independently of iron 
      status. OBJECTIVE: We tested the hypothesis that aspirin use is associated with 
      reduced SF. DESIGN: We used analysis of covariance to investigate the relation 
      between SF and categories of aspirin use in 913 elderly participants aged 67-96 y 
      in the Framingham Heart Study. RESULTS: After adjustment for sex, age, body mass 
      index, smoking, alcohol use, concentrations of C-reactive protein and liver 
      enzymes, white blood cell count, and use of nonaspirin nonsteroidal 
      antiinflammatory drugs and other medications, subjects who took >7 aspirins/wk 
      had a significantly lower (by 25%) geometric mean SF than did nonusers, who took 
      <1 aspirin/wk (71 compared with 95 microg/L, respectively; P for trend = 0.004). 
      This effect of aspirin on SF was more marked in diseased subjects than in healthy 
      subjects (mean SF was 50% lower compared with 21% lower, respectively). 
      CONCLUSIONS: Aspirin use is associated with lower SF. We suggest this effect 
      results from possible increased occult blood loss and a cytokine-mediated effect 
      on SF in subjects with inflammation, infection, or liver disease. The relations 
      between aspirin, inflammation, and SF may confound epidemiologic associations 
      between elevated SF, as an indicator of iron stores, and heart disease risk.
FAU - Fleming, D J
AU  - Fleming DJ
AD  - Mineral Bioavailability Laboratory and the Epidemiology Program, Jean Mayer US 
      Department of Agriculture Human Nutrition Research Center on Aging at Tufts 
      University, Boston, MA 02111, USA.
FAU - Jacques, P F
AU  - Jacques PF
FAU - Massaro, J M
AU  - Massaro JM
FAU - D'Agostino, R B Sr
AU  - D'Agostino RB Sr
FAU - Wilson, P W
AU  - Wilson PW
FAU - Wood, R J
AU  - Wood RJ
LA  - eng
GR  - 2-R01-NS-17950-12/NS/NINDS NIH HHS/United States
GR  - N01-HC-38038/HC/NHLBI NIH HHS/United States
GR  - R01-HL-40423-05/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cytokines)
RN  - 9007-73-2 (Ferritins)
RN  - E1UOL152H7 (Iron)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/blood
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cohort Studies
MH  - Cytokines/blood
MH  - Female
MH  - Ferritins/*blood/*drug effects
MH  - Geriatric Assessment
MH  - Health Status
MH  - Humans
MH  - Iron/*blood
MH  - Male
MH  - Myocardial Infarction/*blood/drug therapy/etiology
MH  - Risk Factors
EDAT- 2001/07/27 10:00
MHDA- 2001/08/24 10:01
CRDT- 2001/07/27 10:00
PHST- 2001/07/27 10:00 [pubmed]
PHST- 2001/08/24 10:01 [medline]
PHST- 2001/07/27 10:00 [entrez]
AID - 10.1093/ajcn/74.2.219 [doi]
PST - ppublish
SO  - Am J Clin Nutr. 2001 Aug;74(2):219-26. doi: 10.1093/ajcn/74.2.219.

PMID- 11478391
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20131121
IS  - 0004-069X (Print)
IS  - 0004-069X (Linking)
VI  - 49
IP  - 3
DP  - 2001
TI  - Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of 
      antiinflammation: emergence of the counterregulatory side.
PG  - 177-88
AB  - Eicosanoids are known to play important roles in cell-cell communications and as 
      intracellular signals that are critical components of multi-cellular responses 
      such as acute inflammation and reperfusion injury. Recent findings have given 
      rise to several new concepts that are reviewed here regarding the generation of 
      eicosanoids and their impact in inflammation. Lipoxins (LX) are 
      trihydroxytetraene-containing eicosanoids that can be generated within the 
      vascular lumen during platelet-leukocyte interactions and at mucosal surfaces via 
      leukocyte-epithelial cell interactions. During these cell-cell interactions, 
      transcellular biosynthetic pathways are used as major LX biosynthetic routes, and 
      thus, in humans, LX are formed in vivo during multi-cellular responses such as 
      inflammation, atherosclerosis, and in asthma. This branch of the eicosanoid 
      cascade generates specific tetraene-containing products that serve as stop 
      signals, in that they regulate key steps in leukocyte trafficking and prevent 
      leukocyte-mediated acute tissue injury. Of interest here are recent results 
      indicating that aspirin's mechanism of action also involves the triggering of 
      novel carbon 15 epimers of LX or 15-epi-LX that mimic the bioactions of native 
      LX. Here, an overview of these recent developments is presented, with a focus on 
      the cellular and molecular interactions of these novel antiinflammatory lipid 
      mediators.
FAU - Serhan, C N
AU  - Serhan CN
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Harvard Medical School, Boston, Massachusetts 02115, USA. 
      cnserhan@zeus.bwh.harvard.edu
LA  - eng
GR  - DK50305/DK/NIDDK NIH HHS/United States
GR  - GM38765/GM/NIGMS NIH HHS/United States
GR  - P01-DE13499/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Switzerland
TA  - Arch Immunol Ther Exp (Warsz)
JT  - Archivum immunologiae et therapiae experimentalis
JID - 0114365
RN  - 0 (Eicosanoids)
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - 0 (Lipoxins)
RN  - 0 (Receptors, Leukotriene B4)
RN  - 0 (lipoxin A4)
RN  - 92950-25-9 (lipoxin B4)
RN  - EC 1.13.11.34 (Arachidonate 5-Lipoxygenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonate 5-Lipoxygenase/physiology
MH  - Aspirin/*pharmacology
MH  - Eicosanoids/*physiology
MH  - Humans
MH  - Hydroxyeicosatetraenoic Acids/*physiology
MH  - Inflammation/*prevention & control
MH  - *Lipoxins
MH  - Neutrophils/physiology
MH  - Receptors, Leukotriene B4/physiology
MH  - Signal Transduction
RF  - 65
EDAT- 2001/08/02 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/08/02 10:00
PHST- 2001/08/02 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/08/02 10:00 [entrez]
PST - ppublish
SO  - Arch Immunol Ther Exp (Warsz). 2001;49(3):177-88.

PMID- 1165647
OWN - NLM
STAT- MEDLINE
DCOM- 19751212
LR  - 20131213
IS  - 0025-6196 (Print)
IS  - 0025-6196 (Linking)
VI  - 50
IP  - 10
DP  - 1975 Oct
TI  - Aspirin and gastric ulcer.
PG  - 565-70
AB  - Although acetylsalicylic acid (aspirin) can cause acute damage to human gastric 
      mucosa, its relationship to chronic gastric ulcer has been less documented. A 
      study of the aspirin intake of 61 patients with gastric ulcer revealed that 32 
      (52%) took 15 or more aspirins each week, compared to 6 (10%) age- and 
      sex-matched controls who took such amounts (P less than 0.001). This difference 
      remained significant when patients who took aspirin for relief of alimentary 
      symptoms or when patients whose symptoms preceded aspirin use were excluded. The 
      regular use of aspirin was especially associated with ulcers in the prepyloric 
      region of the stomach. Fewer patients who had combined gastric and duodenal 
      ulcers were regular users of aspirin when compared with patients who had gastric 
      ulcer alone. The findings suggest that aspirin may be a common cause of gastric 
      ulcer in man.
FAU - Cameron, A J
AU  - Cameron AJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects/pharmacology
MH  - Chronic Disease
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastric Mucosa/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rats
MH  - Self Medication
MH  - Stomach
MH  - Ulcer/*chemically induced/epidemiology
MH  - United States
EDAT- 1975/10/01 00:00
MHDA- 1975/10/01 00:01
CRDT- 1975/10/01 00:00
PHST- 1975/10/01 00:00 [pubmed]
PHST- 1975/10/01 00:01 [medline]
PHST- 1975/10/01 00:00 [entrez]
PST - ppublish
SO  - Mayo Clin Proc. 1975 Oct;50(10):565-70.

PMID- 18004254
OWN - NLM
STAT- MEDLINE
DCOM- 20071217
LR  - 20131121
IS  - 1027-6661 (Print)
IS  - 1027-6661 (Linking)
VI  - 13
IP  - 2
DP  - 2007
TI  - [Therapy with aspirin: a new look at the old problem].
PG  - 9-14
AB  - Aspirin is known to be efficient in secondary prevention of atherothrombosis. 
      However, a considerable number of patients despite daily doses of aspirin still 
      experience and suffer from various cardiovascular complications. In the medical 
      literature this phenomenon was described as <<aspirin resistance>>, however, no 
      well-defined criteria for this notion have been developed as yet. The 
      overwhelming majority of researchers take the term <<aspirin resistance>> to mean 
      both inability of the drug to prevent development of secondary thrombotic events, 
      and its failure to adequately inhibit the function of blood platelets according 
      to the findings of various laboratory tests. The incidence of detecting <<aspirin 
      resistance>> varies considerably depending on the pathology involved and the 
      method(s) used, amounting to from 5 to 70% of the cases. Amongst possible 
      mechanisms capable of influencing the aspirin's clinical effect considered 
      (herein, are the following aspects: polymorphism and/or mutation of the 
      cyclooxigenese-1gene, production of thromboxane A2 in macrophages and endothelial 
      cells via cyclooxigenese-2 polymorphism of Ilb/IIIa platelet receptors, 
      competitive interaction with non-steroidal anti-inflammatory drugs for binding 
      with the cyclooxigenese-1 of blood platelets, and platelet activation via other 
      pathways which are not blocked by aspirin.
FAU - Katkova, O V
AU  - Katkova OV
FAU - Laguta, P S
AU  - Laguta PS
FAU - Panchenko, E P
AU  - Panchenko EP
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Russia (Federation)
TA  - Angiol Sosud Khir
JT  - Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery
JID - 9604504
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Fibrinolytic Agents)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/*therapeutic use
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Biological Availability
MH  - Coronary Thrombosis/prevention & control
MH  - Cyclooxygenase 2/genetics
MH  - Drug Resistance
MH  - Fibrinolytic Agents/pharmacology/therapeutic use
MH  - Humans
MH  - Intracranial Thrombosis/prevention & control
MH  - Point Mutation/genetics
MH  - Polymorphism, Genetic/genetics
RF  - 38
EDAT- 2007/11/16 09:00
MHDA- 2007/12/18 09:00
CRDT- 2007/11/16 09:00
PHST- 2007/11/16 09:00 [pubmed]
PHST- 2007/12/18 09:00 [medline]
PHST- 2007/11/16 09:00 [entrez]
PST - ppublish
SO  - Angiol Sosud Khir. 2007;13(2):9-14.

PMID- 2114725
OWN - NLM
STAT- MEDLINE
DCOM- 19900816
LR  - 20160923
IS  - 1784-3227 (Print)
IS  - 1784-3227 (Linking)
VI  - 53
IP  - 1
DP  - 1990 Jan-Feb
TI  - [Sludge, gallstones and aspirin].
PG  - 16-21
AB  - This article reviews our present knowledge concerning the so-called sludge, an 
      echographic entity, which is formed by mucus and cholesterol microcrystals. 
      Several physiological and pathological states are associated with gallbladder 
      sludge. Experimental data suggest that sludge could precede gallstones and that 
      aspirin could be used as a preventive agent against the appearance of gallbladder 
      sludge and stones.
FAU - Heller, F R
AU  - Heller FR
AD  - Service de Médecine Interne, Hôpital de Jolimont, Haine St Paul, Belgique.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Sludge, lithiase biliaire et aspirine.
PL  - Belgium
TA  - Acta Gastroenterol Belg
JT  - Acta gastro-enterologica Belgica
JID - 0414075
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cholelithiasis/physiopathology/*prevention & control
MH  - Energy Intake
MH  - Fasting
MH  - Gallbladder Diseases/physiopathology
MH  - Humans
MH  - Mucus/physiology
MH  - Parenteral Nutrition/adverse effects
RF  - 26
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Gastroenterol Belg. 1990 Jan-Feb;53(1):16-21.

PMID- 35127290
OWN - NLM
STAT- MEDLINE
DCOM- 20230109
LR  - 20230111
IS  - 2167-8359 (Print)
IS  - 2167-8359 (Electronic)
IS  - 2167-8359 (Linking)
VI  - 10
DP  - 2022
TI  - Characterization of transcriptional landscape in bone marrow-derived mesenchymal 
      stromal cells treated with aspirin by RNA-seq.
PG  - e12819
LID - 10.7717/peerj.12819 [doi]
LID - e12819
AB  - INTRODUCTION: Aspirin is a common antipyretic, analgesic, and anti-inflammatory 
      drug, which has been reported to extend life in animal models and application in 
      the treatment of aging-related diseases. However, it remains unclear about the 
      effects of aspirin on bone marrow-derived mesenchymal stromal cells (BM-MSCs). 
      Here, we aimed to analyze the influence of aspirin on senescence and young 
      BM-MSCs. METHODS: BM-MSCs were serially passaged to construct a replicative 
      senescence model. SA-β-gal staining, PCR, western blot, and RNA-sequencing were 
      performed on BM-MSCs with or without aspirin treatment, to examine aspirin's 
      impact on bone marrow-derived mesenchymal stem cells. RESULTS: SA-β-gal staining, 
      PCR, and western blot revealed that aspirin could alleviate the cellular 
      expression of senescence-related indicators of BM-MSCs, including a decrease of 
      SA-β-gal-positive cells and staining intensity, and downregulation of p16, p21, 
      and p53 expression after aspirin treatment. RNA-sequencing results shown in the 
      biological processes related to aging, aspirin could influence cellular immune 
      response and lipid metabolism. CONCLUSION: The efficacy of aspirin for retarding 
      senescence of BM-MSCs was demonstrated. Our study indicated that the mechanisms 
      of this delay might involve influencing immune response and lipid metabolism.
CI  - © 2022 Liu et al.
FAU - Liu, Xinpeng
AU  - Liu X
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
FAU - Zhan, Yuanbo
AU  - Zhan Y
AUID- ORCID: 0000-0003-0416-8911
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
AD  - The Second Affiliated Hospital of Harbin Medical University, Department of 
      Periodontology and Oral Mucosa, Harbin, China.
FAU - Xu, Wenxia
AU  - Xu W
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
FAU - Liu, Lixue
AU  - Liu L
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
FAU - Liu, Xiaoyao
AU  - Liu X
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
FAU - Da, Junlong
AU  - Da J
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
FAU - Zhang, Kai
AU  - Zhang K
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
FAU - Zhang, Xinjian
AU  - Zhang X
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
FAU - Wang, Jianqun
AU  - Wang J
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
FAU - Liu, Ziqi
AU  - Liu Z
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
FAU - Jin, Han
AU  - Jin H
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
FAU - Zhang, Bin
AU  - Zhang B
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
AD  - Heilongjiang Academy of Medical Sciences, Harbin, China.
FAU - Li, Ying
AU  - Li Y
AD  - Heilongjiang Provincial Key Laboratory of Hard Tissue Development and 
      Regeneration, The Second Affiliated Hospital of Harbin Medical University, 
      Harbin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220124
PL  - United States
TA  - PeerJ
JT  - PeerJ
JID - 101603425
RN  - R16CO5Y76E (Aspirin)
RN  - 63231-63-0 (RNA)
MH  - Animals
MH  - *Cellular Senescence/genetics
MH  - Aspirin/pharmacology
MH  - Bone Marrow
MH  - RNA-Seq
MH  - Cells, Cultured
MH  - *Mesenchymal Stem Cells
MH  - RNA/metabolism
PMC - PMC8793730
OTO - NOTNLM
OT  - Aspirin
OT  - BM-MSCs
OT  - Cell senescence
OT  - Immune response
OT  - Lipid metabolism
OT  - RNA-seq
COIS- The authors declare that they have no competing interests.
EDAT- 2022/02/08 06:00
MHDA- 2022/02/08 06:01
CRDT- 2022/02/07 05:33
PHST- 2021/06/03 00:00 [received]
PHST- 2021/12/30 00:00 [accepted]
PHST- 2022/02/07 05:33 [entrez]
PHST- 2022/02/08 06:00 [pubmed]
PHST- 2022/02/08 06:01 [medline]
AID - 12819 [pii]
AID - 10.7717/peerj.12819 [doi]
PST - epublish
SO  - PeerJ. 2022 Jan 24;10:e12819. doi: 10.7717/peerj.12819. eCollection 2022.

PMID- 27149646
OWN - NLM
STAT- MEDLINE
DCOM- 20170502
LR  - 20170502
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 122
IP  - 13
DP  - 2016 Jul 1
TI  - Prediagnostic aspirin use and mortality in women with stage I to III breast 
      cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer 
      Screening Trial.
PG  - 2067-75
LID - 10.1002/cncr.30004 [doi]
AB  - BACKGROUND: There is a body of evidence indicating that aspirin may reduce the 
      risk of cancer mortality. However, to the authors' knowledge, the optimal 
      exposure timing and mechanism of action remain unclear. In the current study, the 
      authors investigated associations between prediagnostic aspirin use and breast 
      cancer-specific mortality in a US population. METHODS: Postmenopausal women 
      diagnosed with stage I to III breast cancer (1993-2009) were identified (2925 
      women with a total of 18,073 person-years) from the National Cancer Institute's 
      Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Prediagnostic 
      aspirin use (1274 women) was identified from study questionnaires. Multivariate 
      Cox proportional hazards models were used to estimate hazard ratios (HRs) with 
      95% confidence intervals (95% CIs) for associations between aspirin use and 
      breast cancer-specific mortality. Effect modification by lymph node status was 
      evaluated. RESULTS: Prediagnostic aspirin use was not found to be associated with 
      lower breast cancer-specific mortality (HR, 0.95; 95% CI, 0.68-1.31 [P = .74]). 
      In analyses stratified by lymph node status, aspirin use was found to be 
      associated with lower breast cancer-specific mortality among women with lymph 
      node-negative tumors (HR, 0.54; 95% CI, 0.32-0.93 [P = 0.02]), but not those with 
      lymph node-positive tumors (HR, 1.41; 95% CI, 0.92-2.16 [P = 0.11]). Tests for 
      interaction were found to be statistically significant (P for interaction =.006). 
      No association was noted between aspirin use and lymph node status. CONCLUSIONS: 
      Prediagnostic aspirin use was not found to be associated with a reduction in 
      breast cancer-specific mortality overall. However, effect modification by lymph 
      node status was observed and mortality was found to be reduced by approximately 
      one-half among aspirin users with lymph node-negative disease. This represents a 
      clinically significant reduction in breast cancer mortality. These findings 
      contribute to the understanding of aspirin's mechanism of action in breast 
      cancer. However, further etiologic research to understand this association is 
      warranted. Cancer 2016;122:2067-75. © 2016 American Cancer Society.
CI  - © 2016 American Cancer Society.
FAU - Bradley, Marie C
AU  - Bradley MC
AD  - Clinical and Translational Epidemiology Branch, Epidemiology and Genomics 
      Research Program, Division of Cancer Control and Population Sciences, National 
      Cancer Institute, Bethesda, Maryland.
FAU - Black, Amanda
AU  - Black A
AD  - Epidemiology and Biostatistics Program, Division of Cancer Epidemiology and 
      Genetics, National Cancer Institute, Bethesda, Maryland.
FAU - Freedman, Andrew N
AU  - Freedman AN
AD  - Clinical and Translational Epidemiology Branch, Epidemiology and Genomics 
      Research Program, Division of Cancer Control and Population Sciences, National 
      Cancer Institute, Bethesda, Maryland.
FAU - Barron, Thomas I
AU  - Barron TI
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, Maryland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20160503
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Breast Neoplasms/*epidemiology/mortality/pathology
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Lymph Nodes/*pathology
MH  - Middle Aged
MH  - Postmenopause
MH  - Proportional Hazards Models
OTO - NOTNLM
OT  - Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
OT  - aspirin
OT  - breast cancer mortality
OT  - lymph node metastasis
OT  - postmenopausal
EDAT- 2016/05/06 06:00
MHDA- 2017/05/04 06:00
CRDT- 2016/05/06 06:00
PHST- 2015/12/15 00:00 [received]
PHST- 2016/03/02 00:00 [revised]
PHST- 2016/03/04 00:00 [accepted]
PHST- 2016/05/06 06:00 [entrez]
PHST- 2016/05/06 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
AID - 10.1002/cncr.30004 [doi]
PST - ppublish
SO  - Cancer. 2016 Jul 1;122(13):2067-75. doi: 10.1002/cncr.30004. Epub 2016 May 3.

PMID- 26230605
OWN - NLM
STAT- MEDLINE
DCOM- 20160425
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 7
DP  - 2015
TI  - The Effect of Aspirin on Bleeding and Transfusion in Contemporary Cardiac 
      Surgery.
PG  - e0134670
LID - 10.1371/journal.pone.0134670 [doi]
LID - e0134670
AB  - OBJECTIVE: Despite evidence that preoperative aspirin improves outcomes in 
      cardiac surgery, recommendations for aspirin use are inconsistent due to 
      aspirin's anti-platelet effect and concern for bleeding. The purpose of this 
      study was to investigate preoperative aspirin use and its effect on bleeding and 
      transfusion in cardiac surgery. METHODS: This retrospective study involved 
      consecutive patients (n=1571) who underwent CABG, valve, or combined CABG and 
      valve surgery at a single center between March 2007 and July 2012. Of all 
      patients, 728 met the inclusion criteria and were divided into two groups: those 
      using (n=603) or not using (n=125) aspirin within 5 days of surgery. Data were 
      collected on chest tube drainage, re-operation for bleeding, and transfusion of 
      red blood cells (RBCs), fresh frozen plasma (FFP), and platelets. RESULTS: No 
      significant difference was observed between the two groups in chest tube drainage 
      or re-operation for bleeding. An increase in patients transfused with RBCs was 
      observed in the aspirin group (61.9 vs 51.2%, adjusted OR 1.77, p=0.027); 
      however, among those transfused RBCs, no significant difference in mean units 
      transfused or massive transfusion was observed. No significant difference was 
      seen in transfusion requirement of FFP or platelets. CONCLUSIONS: In patients 
      undergoing CABG, valve, or combined CABG/valve surgery, preoperative aspirin, 
      within 5 days of surgery, was associated with an increased probability of 
      receiving an RBC transfusion. Preoperative aspirin was not associated with an 
      increase in chest tube drainage, re-operation for bleeding complications, or 
      transfusion of FFP or platelets.
FAU - Goldhammer, Jordan E
AU  - Goldhammer JE
AD  - Department of Anesthesiology, Sidney Kimmel Medical College, Thomas Jefferson 
      University, Philadelphia, Pennsylvania, United States of America.
FAU - Marhefka, Gregary D
AU  - Marhefka GD
AD  - Division of Cardiology, Department of Medicine, Sidney Kimmel Medical College, 
      Thomas Jefferson University, Philadelphia, Pennsylvania, United States of 
      America.
FAU - Daskalakis, Constantine
AU  - Daskalakis C
AD  - Division of Biostatistics, Sidney Kimmel Medical College, Thomas Jefferson 
      University, Philadelphia, Pennsylvania, United States of America.
FAU - Berguson, Mark W
AU  - Berguson MW
AD  - Department of Anesthesiology, Sidney Kimmel Medical College, Thomas Jefferson 
      University, Philadelphia, Pennsylvania, United States of America.
FAU - Bowen, John E
AU  - Bowen JE
AD  - Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, 
      Pennsylvania, United States of America.
FAU - Diehl, James T
AU  - Diehl JT
AD  - Division of Cardiothoracic Surgery, Department of Surgery, Sidney Kimmel Medical 
      College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States 
      of America.
FAU - Sun, Jianzhong
AU  - Sun J
AD  - Department of Anesthesiology, Sidney Kimmel Medical College, Thomas Jefferson 
      University, Philadelphia, Pennsylvania, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20150731
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - *Blood Transfusion
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
PMC - PMC4521851
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/08/01 06:00
MHDA- 2016/04/26 06:00
CRDT- 2015/08/01 06:00
PHST- 2015/04/30 00:00 [received]
PHST- 2015/07/13 00:00 [accepted]
PHST- 2015/08/01 06:00 [entrez]
PHST- 2015/08/01 06:00 [pubmed]
PHST- 2016/04/26 06:00 [medline]
AID - PONE-D-15-18462 [pii]
AID - 10.1371/journal.pone.0134670 [doi]
PST - epublish
SO  - PLoS One. 2015 Jul 31;10(7):e0134670. doi: 10.1371/journal.pone.0134670. 
      eCollection 2015.

PMID- 12700498
OWN - NLM
STAT- MEDLINE
DCOM- 20030606
LR  - 20201208
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 27
IP  - 3 Pt 2
DP  - 2003 Mar
TI  - [Should Helicobacter pylori infection be tested and eradicated in patients 
      treated or about to be treated with aspirin or nonsteroidal anti-inflammatory 
      drugs?].
PG  - 415-26
AB  - Helicobacter pylori (H. pylori) and non-steroidal anti-inflammatory drugs 
      (NSAIDs) are the main causes of gastroduodenal ulcers. Their coexistence is 
      frequent in the elderly and raises the problem of their interaction. In the 
      clinical setting, the question is whether or not H. pylori infection should be 
      eradicated in patients with both risk factors. A number of epidemiological 
      studies and more recently interventional studies have been performed to answer 
      this question. Contradictory results have been reported. According to a 
      meta-analysis, H. pylori and NSAIDs independently and significantly increase the 
      risk of gastroduodenal ulcer and ulcer bleeding. However, these conclusions are 
      not supported by more recent epidemiological and interventional studies. The 
      critical review of these studies indicates that the discrepancy arises mainly 
      from heterogeneity in risk factors, patients and outcome measurements. Among the 
      main confounding factors are the type of treatment, non aspirin NSAIDs or 
      low-dose aspirin, the different strains of H. pylori, the variable host response 
      and the type of ulcer, gastric or duodenal. Based on the critical review of 
      recent studies, recommendations are made about indications of H. pylori 
      eradication in patients treated or about to be treated by NSAIDs or low-dose 
      aspirin.
FAU - Thiéfin, Gérard
AU  - Thiéfin G
AD  - Service d'Hépato-Gastroentérologie, CHU R.-Debré, Rue du Général-Koenig, 51092 
      Reims Cedex. gthiefin@chu-reims.fr
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Faut-il rechercher et éradiquer Helicobacter pylori chez les malades traités ou 
      devant être traités par aspirine ou anti-inflammatoires non stéroïdiens?
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Helicobacter Infections/*complications/*drug therapy
MH  - Helicobacter pylori/*pathogenicity
MH  - Humans
MH  - Middle Aged
MH  - Risk Factors
MH  - Treatment Outcome
RF  - 90
EDAT- 2003/04/18 05:00
MHDA- 2003/06/07 05:00
CRDT- 2003/04/18 05:00
PHST- 2003/04/18 05:00 [pubmed]
PHST- 2003/06/07 05:00 [medline]
PHST- 2003/04/18 05:00 [entrez]
AID - MDOI-GCB-03-2003-27-3-C2-0399-8320-101019-ART8 [pii]
PST - ppublish
SO  - Gastroenterol Clin Biol. 2003 Mar;27(3 Pt 2):415-26.

PMID- 24187753
OWN - NLM
STAT- MEDLINE
DCOM- 20131230
LR  - 20131105
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 9
IP  - 400
DP  - 2013 Oct 2
TI  - [Aspirin ototoxicity: a rare situation today].
PG  - 1785-8
AB  - Aspirin is commonly used most often at low daily doses. We report a case of acute 
      aspirin intoxication resulting in a transitory hearing loss, tinnitus, and 
      vertigo. Such intoxications occur at doses of several grams. The disorders caused 
      by aspirin are fortunately reversible. The mechanisms of ototoxicity appear to 
      involve, in part, electro-mobility of the outer hair cells of the inner ear by 
      inhibiting the movement of prestin.
FAU - Cuffel, C
AU  - Cuffel C
AD  - Service d'ORL et de chirurgie cervico-faciale, Département des neurosciences 
      cliniques, HUG, 1211 Genève 14. cyril.cuffel@hcuge.ch
FAU - Guyot, J-P
AU  - Guyot JP
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Ototoxicité à l'Aspirine: une situation rare de nos jours.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Overdose/complications/diagnosis
MH  - Ear, Inner/*drug effects
MH  - Female
MH  - Hearing Loss/*chemically induced/diagnosis
MH  - Hearing Tests
MH  - Humans
MH  - Young Adult
EDAT- 2013/11/06 06:00
MHDA- 2014/01/01 06:00
CRDT- 2013/11/06 06:00
PHST- 2013/11/06 06:00 [entrez]
PHST- 2013/11/06 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
PST - ppublish
SO  - Rev Med Suisse. 2013 Oct 2;9(400):1785-8.

PMID- 24206142
OWN - NLM
STAT- MEDLINE
DCOM- 20140905
LR  - 20140109
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 15
IP  - 2
DP  - 2014 Feb
TI  - An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, 
      cancers and bleeds.
PG  - 153-7
LID - 10.1517/14656566.2014.853039 [doi]
AB  - Aspirin or acetylsalicylic acid (ASA) is commonly used in the general population 
      for primary prevention of cardiovascular disease (CVD). Strong evidence supports 
      the use of ASA in secondary prevention of CVD; however, for primary prevention, 
      potential benefits are offset by potential harms (primarily major bleeds), with 
      no benefit in overall mortality. Anti-platelet agents, including ASA, are one of 
      the most commonly implicated medications for hospital admissions related to 
      adverse medication events. Studies of primary prevention in patients with risk 
      factors for CVD also fail to show a benefit with ASA. Finally, evidence 
      supporting ASA use for cancer prevention is limited. Health care providers should 
      be aware of the benefits and risks associated with ASA use in primary and 
      secondary prevention and discuss these with their patients in the context of 
      individual patient values and preferences.
FAU - Kolber, Michael R
AU  - Kolber MR
AD  - University of Alberta, Department of Family Medicine , 8215-112 street, Edmonton, 
      Alberta, T6G 2C8 , Canada mkolber@ualberta.ca.
FAU - Korownyk, Christina
AU  - Korownyk C
LA  - eng
PT  - Editorial
DEP - 20131111
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Neoplasms/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Primary Prevention/methods
MH  - Risk Factors
MH  - Secondary Prevention/methods
EDAT- 2013/11/12 06:00
MHDA- 2014/09/06 06:00
CRDT- 2013/11/12 06:00
PHST- 2013/11/12 06:00 [entrez]
PHST- 2013/11/12 06:00 [pubmed]
PHST- 2014/09/06 06:00 [medline]
AID - 10.1517/14656566.2014.853039 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2014 Feb;15(2):153-7. doi: 
      10.1517/14656566.2014.853039. Epub 2013 Nov 11.

PMID- 15166914
OWN - NLM
STAT- MEDLINE
DCOM- 20050216
LR  - 20191210
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 15
IP  - 4
DP  - 2004 Jun
TI  - Assessing aspirin responsiveness in subjects with multiple risk factors for 
      vascular disease with a rapid platelet function analyzer.
PG  - 295-301
AB  - Aspirin, compared with placebo, reduces the risk of cardiovascular events by 25% 
      in populations of patients with and without known arterial vascular disease. 
      However, the phenomena of 'aspirin resistance' that has been described in 5'--50% 
      of this population may critically reduce aspirin's efficacy. One study has 
      suggested that aspirin-resistant patients have a 3.5 times higher risk of 
      cardiovascular death. Presently, there are no established, simple, broadly used 
      methods determining antiplatelet properties of aspirin, while conventional 
      aggregometry requires special equipment and trained personnel. We sought to 
      determine the validity of an Ultegra analyzer with the novel aspirin-sensitive 
      cartridge before and after one pill of non-enteric coated aspirin (325 mg) in 
      subjects with multiple risk factors for coronary artery disease. One hundred and 
      fifty-four volunteers were enrolled into the multicenter study, but six of them 
      were excluded. Data from 148 participants were analyzed. Platelets were assessed 
      twice at baseline (pre-aspirin), and after 2-30 h (post-aspirin). We employed 5 
      micromol/l epinephrine-induced conventional aggregometry, and aspirin response 
      units stimulated by propyl gallate with the point-of-care Ultegra analyzer. A 
      single pill of aspirin reduced platelet-rich plasma aggregation from 72 +/- 21% 
      to 25 +/- 10%, and diminished aspirin reduction units from 647 +/- 95 to 436 +/- 
      69. The overall agreement between the two methods was 87% with 85% sensitivity 
      for Ultegra and 88% for platelet aggregation, respectively. The correlation 
      between the two methods was 0.902. Timely determination of aspirin resistance 
      represents an indispensable application in current medicine. The Ultegra RPFA-ASA 
      analyzer is a novel, fast method that could be used in clinical practice for 
      monitoring efficacy of aspirin, and for triaging the aspirin-resistant 
      population. The clinical implications of these data need to be proven in 
      randomized trials.
FAU - Malinin, Alex
AU  - Malinin A
AD  - Johns Hopkins University, Baltimore, Maryland, USA.
FAU - Spergling, Malcolm
AU  - Spergling M
FAU - Muhlestein, Brent
AU  - Muhlestein B
FAU - Steinhubl, Steven
AU  - Steinhubl S
FAU - Serebruany, Victor
AU  - Serebruany V
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology
MH  - Platelet Function Tests/*instrumentation/standards
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Vascular Diseases/*etiology/mortality
EDAT- 2004/05/29 05:00
MHDA- 2005/02/17 09:00
CRDT- 2004/05/29 05:00
PHST- 2004/05/29 05:00 [pubmed]
PHST- 2005/02/17 09:00 [medline]
PHST- 2004/05/29 05:00 [entrez]
AID - 00001721-200406000-00002 [pii]
AID - 10.1097/00001721-200406000-00002 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2004 Jun;15(4):295-301. doi: 
      10.1097/00001721-200406000-00002.

PMID- 36474449
OWN - NLM
STAT- MEDLINE
DCOM- 20221222
LR  - 20221222
IS  - 1028-768X (Print)
IS  - 1028-768X (Linking)
VI  - 32(1)
DP  - 2023 Mar 30
TI  - Does proton pump inhibitor reduce the antiaggregant efficacy of aspirin in 
      ischemic stroke?
PG  - 9-15
AB  - OBJECTIVE: To evaluate the effect of using acetylsalicylic acid (aspirin) 
      together with lansoprazole in the secondary prevention of ischemic stroke. 
      MATERIALS AND METHODS: 199 patients with a diagnosis of ischemic stroke and 
      transient ischemic attack (TIA) using 100 mg aspirin regularly were included in 
      the study. All patients were evaluated for the presence of aspirin resistance 
      before starting the study. 57 patients with aspirin resistance were excluded from 
      the study. The remaining 142 patients were divided into two groups: the 1st group 
      consisted of those with stomach discomfort and the 2nd group consisted of those 
      without stomach discomfort. Patients in group 1 were given 30 mg of lansoprazole 
      taken before breakfast in addition to aspirin therapy. All patients were 
      re-evaluated for the presence of aspirin resistance at a one-month follow-up. The 
      antiaggregant activity was evaluated by the impedance aggregometry method in both 
      groups. RESULTS: Of 142 patients, 75 were in group 1, and 67 were in group 2. 
      There was no difference between the two groups in terms of age and gender 
      distribution of vascular risk factors. There was no statistically significant 
      difference between the two groups in terms of aspirin efficacy. The dose of 
      aspirin was increased in patients with aspirin resistance (AR). CONCLUSION: The 
      combination of 30 mg lansoprazole and 100 mg aspirin does not cause a decrease in 
      antiaggregant activity in the early period, but chronic use was not evaluated in 
      this study. Patients with AR may benefit from an increase in the dose of aspirin.
FAU - Özel, Tuğba
AU  - Özel T
AD  - Akdeniz University Hospital Neurology Department.
FAU - Ünal, Ali
AU  - Ünal A
AD  - Akdeniz University Hospital Neurology Department.
FAU - Özdem, Sebahat
AU  - Özdem S
AD  - Akdeniz University Hospital Neurology Department.
FAU - Dora, Babur
AU  - Dora B
AD  - Akdeniz University Hospital Neurology Department.
LA  - eng
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Acta Neurol Taiwan
JT  - Acta neurologica Taiwanica
JID - 9815355
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Ischemic Stroke
MH  - *Proton Pump Inhibitors/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - aspirin resistance
OT  - ischemic stroke transient global amnesia.
OT  - proton pump inhibitors
EDAT- 2022/12/08 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/12/07 01:52
PHST- 2022/12/07 01:52 [entrez]
PHST- 2022/12/08 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
AID - 10196099/321009 [pii]
PST - ppublish
SO  - Acta Neurol Taiwan. 2023 Mar 30;32(1):9-15.

PMID- 16465941
OWN - NLM
STAT- MEDLINE
DCOM- 20060228
LR  - 20181203
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 2
IP  - 47
DP  - 2006 Jan 4
TI  - [Haemostasis. Aspirin and clopidogrel platelet resistances].
PG  - 25-9
AB  - Articles on antiplatelet "resistance" or "nonresponder" subjects now appear in 
      the medical literature or in the media on a regular basis. The clinical 
      consequences of such biological resistances are yet uncertain. In this review, we 
      describe the concepts of specific and non specific resistances according to the 
      tests used and summarize the main studies up to now. If antiplatelet drug 
      resistances are shown to be predictive of cardiovascular events in large 
      prospective studies, tailoring antiplatelet drugs could be beneficial and, 
      therefore, warranted. New compounds with a more potent effect are emerging and 
      might be useful in clinically relevant resistances.
FAU - Fontana, P
AU  - Fontana P
AD  - Service d'angiologie et d'hémostase, Département de médecine interne, Faculté de 
      médecine et HUG, 1211 Genève 14. pierre.fontana@medecine.unige.ch
FAU - Berdagué, P
AU  - Berdagué P
FAU - Reny, J L
AU  - Reny JL
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Hémostase. Résistances plaquettaires à l'aspirine et au clopidogrel.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
RF  - 34
EDAT- 2006/02/10 09:00
MHDA- 2006/03/01 09:00
CRDT- 2006/02/10 09:00
PHST- 2006/02/10 09:00 [pubmed]
PHST- 2006/03/01 09:00 [medline]
PHST- 2006/02/10 09:00 [entrez]
PST - ppublish
SO  - Rev Med Suisse. 2006 Jan 4;2(47):25-9.

PMID- 26101955
OWN - NLM
STAT- MEDLINE
DCOM- 20160607
LR  - 20181113
IS  - 1528-3658 (Electronic)
IS  - 1076-1551 (Print)
IS  - 1076-1551 (Linking)
VI  - 21
IP  - 1
DP  - 2015 Jun 18
TI  - Aspirin's Active Metabolite Salicylic Acid Targets High Mobility Group Box 1 to 
      Modulate Inflammatory Responses.
PG  - 526-35
LID - 10.2119/molmed.2015.00148 [doi]
AB  - Salicylic acid (SA) and its derivatives have been used for millennia to reduce 
      pain, fever and inflammation. In addition, prophylactic use of acetylsalicylic 
      acid, commonly known as aspirin, reduces the risk of heart attack, stroke and 
      certain cancers. Because aspirin is rapidly de-acetylated by esterases in human 
      plasma, much of aspirin's bioactivity can be attributed to its primary 
      metabolite, SA. Here we demonstrate that human high mobility group box 1 (HMGB1) 
      is a novel SA-binding protein. SA-binding sites on HMGB1 were identified in the 
      HMG-box domains by nuclear magnetic resonance (NMR) spectroscopic studies and 
      confirmed by mutational analysis. Extracellular HMGB1 is a damage-associated 
      molecular pattern molecule (DAMP), with multiple redox states. SA suppresses both 
      the chemoattractant activity of fully reduced HMGB1 and the increased expression 
      of proinflammatory cytokine genes and cyclooxygenase 2 (COX-2) induced by 
      disulfide HMGB1. Natural and synthetic SA derivatives with greater potency for 
      inhibition of HMGB1 were identified, providing proof-of-concept that new 
      molecules with high efficacy against sterile inflammation are attainable. An 
      HMGB1 protein mutated in one of the SA-binding sites identified by NMR chemical 
      shift perturbation studies retained chemoattractant activity, but lost binding of 
      and inhibition by SA and its derivatives, thereby firmly establishing that SA 
      binding to HMGB1 directly suppresses its proinflammatory activities. 
      Identification of HMGB1 as a pharmacological target of SA/aspirin provides new 
      insights into the mechanisms of action of one of the world's longest and most 
      used natural and synthetic drugs. It may also provide an explanation for the 
      protective effects of low-dose aspirin usage.
FAU - Choi, Hyong Woo
AU  - Choi HW
AD  - Boyce Thompson Institute for Plant Research, Ithaca, New York, United States of 
      America.
FAU - Tian, Miaoying
AU  - Tian M
AD  - Boyce Thompson Institute for Plant Research, Ithaca, New York, United States of 
      America.
FAU - Song, Fei
AU  - Song F
AD  - Center of Advanced Biotechnology and Medicine, Department of Molecular Biology 
      and Biochemistry, and Northeast Structural Genomics Consortium, Rutgers, The 
      State University of New Jersey, Piscataway, New Jersey, United States of America.
FAU - Venereau, Emilie
AU  - Venereau E
AD  - Division of Genetics and Cell Biology, San Raffaele University and Research 
      Institute, Milano, Italy.
FAU - Preti, Alessandro
AU  - Preti A
AD  - Division of Genetics and Cell Biology, San Raffaele University and Research 
      Institute, Milano, Italy.
FAU - Park, Sang-Wook
AU  - Park SW
AD  - Boyce Thompson Institute for Plant Research, Ithaca, New York, United States of 
      America.
FAU - Hamilton, Keith
AU  - Hamilton K
AD  - Center of Advanced Biotechnology and Medicine, Department of Molecular Biology 
      and Biochemistry, and Northeast Structural Genomics Consortium, Rutgers, The 
      State University of New Jersey, Piscataway, New Jersey, United States of America.
FAU - Swapna, G V T
AU  - Swapna GV
AD  - Center of Advanced Biotechnology and Medicine, Department of Molecular Biology 
      and Biochemistry, and Northeast Structural Genomics Consortium, Rutgers, The 
      State University of New Jersey, Piscataway, New Jersey, United States of America.
FAU - Manohar, Murli
AU  - Manohar M
AD  - Boyce Thompson Institute for Plant Research, Ithaca, New York, United States of 
      America.
FAU - Moreau, Magali
AU  - Moreau M
AD  - Boyce Thompson Institute for Plant Research, Ithaca, New York, United States of 
      America.
FAU - Agresti, Alessandra
AU  - Agresti A
AD  - Division of Genetics and Cell Biology, San Raffaele University and Research 
      Institute, Milano, Italy.
FAU - Gorzanelli, Andrea
AU  - Gorzanelli A
AD  - Division of Genetics and Cell Biology, San Raffaele University and Research 
      Institute, Milano, Italy.
FAU - De Marchis, Francesco
AU  - De Marchis F
AD  - Division of Genetics and Cell Biology, San Raffaele University and Research 
      Institute, Milano, Italy.
FAU - Wang, Huang
AU  - Wang H
AD  - Center of Advanced Biotechnology and Medicine, Department of Molecular Biology 
      and Biochemistry, and Northeast Structural Genomics Consortium, Rutgers, The 
      State University of New Jersey, Piscataway, New Jersey, United States of America.
FAU - Antonyak, Marc
AU  - Antonyak M
AD  - Department of Chemistry and Chemical Biology, Department of Molecular Medicine, 
      Cornell University, Ithaca, New York, United States of America.
FAU - Micikas, Robert J
AU  - Micikas RJ
AD  - Boyce Thompson Institute for Plant Research, Ithaca, New York, United States of 
      America.
FAU - Gentile, Daniel R
AU  - Gentile DR
AD  - Boyce Thompson Institute for Plant Research, Ithaca, New York, United States of 
      America.
FAU - Cerione, Richard A
AU  - Cerione RA
AD  - Department of Chemistry and Chemical Biology, Department of Molecular Medicine, 
      Cornell University, Ithaca, New York, United States of America.
FAU - Schroeder, Frank C
AU  - Schroeder FC
AD  - Boyce Thompson Institute for Plant Research, Ithaca, New York, United States of 
      America.
FAU - Montelione, Gaetano T
AU  - Montelione GT
AD  - Center of Advanced Biotechnology and Medicine, Department of Molecular Biology 
      and Biochemistry, and Northeast Structural Genomics Consortium, Rutgers, The 
      State University of New Jersey, Piscataway, New Jersey, United States of America.
AD  - Department of Biochemistry and Molecular Medicine, Robert Wood Johnson Medical 
      School, Rutgers, The State University of New Jersey, Piscataway, New Jersey, 
      United States of America.
FAU - Bianchi, Marco E
AU  - Bianchi ME
AD  - Division of Genetics and Cell Biology, San Raffaele University and Research 
      Institute, Milano, Italy.
FAU - Klessig, Daniel F
AU  - Klessig DF
AD  - Boyce Thompson Institute for Plant Research, Ithaca, New York, United States of 
      America.
LA  - eng
GR  - R01 GM040654/GM/NIGMS NIH HHS/United States
GR  - GM040654/GM/NIGMS NIH HHS/United States
GR  - P41 GM103485/GM/NIGMS NIH HHS/United States
GR  - U54 GM094597/GM/NIGMS NIH HHS/United States
GR  - U54-GM094597/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20150618
PL  - England
TA  - Mol Med
JT  - Molecular medicine (Cambridge, Mass.)
JID - 9501023
RN  - 0 (HMGB1 Protein)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry/*pharmacology
MH  - Cyclooxygenase 2/biosynthesis/genetics
MH  - HMGB1 Protein/biosynthesis/chemistry/*genetics
MH  - Humans
MH  - Inflammation/drug therapy/*genetics/pathology
MH  - Mutation
MH  - Nuclear Magnetic Resonance, Biomolecular
MH  - Salicylic Acid/chemistry/*pharmacology
PMC - PMC4607614
EDAT- 2015/06/24 06:00
MHDA- 2016/06/09 06:00
CRDT- 2015/06/24 06:00
PHST- 2015/06/17 00:00 [received]
PHST- 2015/06/18 00:00 [accepted]
PHST- 2015/06/24 06:00 [entrez]
PHST- 2015/06/24 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - molmed.2015.00148 [pii]
AID - 15_148_choi [pii]
AID - 10.2119/molmed.2015.00148 [doi]
PST - epublish
SO  - Mol Med. 2015 Jun 18;21(1):526-35. doi: 10.2119/molmed.2015.00148.

PMID- 28162291
OWN - NLM
STAT- MEDLINE
DCOM- 20180110
LR  - 20180120
IS  - 2213-2317 (Electronic)
IS  - 2213-2317 (Linking)
VI  - 5
DP  - 2015 Aug
TI  - NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism.
PG  - 421
LID - S2213-2317(15)00144-5 [pii]
LID - 10.1016/j.redox.2015.09.033 [doi]
AB  - BACKGROUND: NOSH-aspirin, a novel hybrid that releases nitric oxide (NO) and 
      hydrogen sulfide (H(2)S) was designed to overcome the potential side effects of 
      aspirin. AIM: We compared the cell growth inhibitory properties of ortho-, meta-, 
      and para-NOSH-aspirins. Effects of electron donating/withdrawing groups on the 
      stability and biological activity of these novel compounds were also evaluated. 
      METHODS: Cell line: HT-29 (Cyclooxygenase, COX-1 & -2 expressing) and HCT 15 (COX 
      null) human colon adenocarcimoa; Cell growth: MTT; Cell cycle phase distribution: 
      Flow cytometry; Apoptosis: subdiploid (sub-G(0)/G(1)) peak in DNA content 
      histograms; Proliferation: PCNA; ROS: measured hydrogen peroxide and super oxide 
      by flow cytometry using DCFDA and DHE dyes. RESULTS: The IC(50)s for growth 
      inhibition in µM at 24h were, HT-29: ortho-NOSH-ASA (0.04±0.011), meta-NOSH-ASA 
      (0.24±0.11), para-NOSH-ASA (0.46±0.17); significance between the groups were: o 
      vs m P>0.05, o vs p P<0.05, m vs p P>0.05; HCT 15: ortho-NOSH-ASA (0.062±0.006), 
      meta-NOSH-ASA (0.092±0.004), para-NOSH-ASA (0.37±0.04); significance between the 
      groups were: o vs m P<0.01, o vs p P<0.001, m vs p P<0.001. Electron 
      donating/withdrawing groups significantly affected these IC(50)s. All positional 
      isomers qualitatively had similar effects on proliferation, apoptosis, and caused 
      G(0)/G(1) cell cycle arrest in both colon cancer cell lines. The underlying 
      mechanism for these observations appeared to be mediated through ROS, as 
      pretreatment of the cells with N-acetylcysteine, partially blocked these effects. 
      CONCLUSIONS: Positional isomerism affects the potency of NOSH-aspirin. The 
      effects appear to be COX independent.
CI  - Copyright © 2015. Published by Elsevier B.V.
FAU - Vannini, Federica
AU  - Vannini F
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, USA.
FAU - Kodela, Ravinder
AU  - Kodela R
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, USA.
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, USA.
FAU - Kashfi, Khosrow
AU  - Kashfi K
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, USA.
LA  - eng
PT  - Journal Article
DEP - 20151230
PL  - Netherlands
TA  - Redox Biol
JT  - Redox biology
JID - 101605639
RN  - 0 (4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate)
RN  - 0 (Disulfides)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Nitrates)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Cell Line, Tumor
MH  - Colonic Neoplasms/*drug therapy/metabolism/pathology
MH  - Cyclooxygenase 1/biosynthesis/genetics
MH  - Cyclooxygenase 2/biosynthesis/genetics
MH  - Disulfides/*chemistry/*pharmacology
MH  - Gene Expression Regulation, Enzymologic/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Neoplasm Proteins/biosynthesis/genetics
MH  - Nitrates/*chemistry/*pharmacology
EDAT- 2015/08/01 00:00
MHDA- 2015/08/01 00:01
CRDT- 2017/02/07 06:00
PHST- 2017/02/07 06:00 [entrez]
PHST- 2015/08/01 00:00 [pubmed]
PHST- 2015/08/01 00:01 [medline]
AID - S2213-2317(15)00144-5 [pii]
AID - 10.1016/j.redox.2015.09.033 [doi]
PST - ppublish
SO  - Redox Biol. 2015 Aug;5:421. doi: 10.1016/j.redox.2015.09.033. Epub 2015 Dec 30.

PMID- 14763349
OWN - NLM
STAT- MEDLINE
DCOM- 20040219
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 32
IP  - 37 Pt 2
DP  - 2003 Nov 22
TI  - [Risk factors for gastrointestinal bleeding associated with low-dose aspirin].
PG  - S9-16
AB  - INTRODUCTION: Low-dose aspirin is the cause of gastro-intestinal and bleeding 
      complications. Different factors may increase the gastro-intestinal (GI) toxicity 
      associated with aspirin. The aim of this review is to attempt to describe these 
      factors. METHODOLOGY: This review is based on an analysis of 24 randomized GI, 
      cardiovascular and neurological studies and 8 case-control and cohort, follow-up 
      studies evaluating GI and bleeding risk factors associated with the ingestion of 
      aspirin at doses of less than 500 mg/day. These studies have been selected based 
      on specific criteria from all works published from 1983 to 2003 (PubMed). 
      RESULTS: The GI toxicity of low-dose aspirin appears to be dose-dependent, 
      apparently starting with 10 mg/day, but this observation has not been confirmed 
      by all studies. The "protective" effect of gastro-resistant coating is debatable. 
      The GI risk is enhanced in the elderly and in particular appears related to 
      concomitant disorders, specifically cardiovascular and neurological disorders, 
      but few studies make it possible to confirm this. A previous history of ulcer or 
      GI bleeding are identified risk factors for GI bleeding, but few studies have 
      been conducted on patients treated with low-dose aspirin to confirm this. Other 
      platelet-inhibiting and anti-coagulant agents potentiate the gastro-intestinal 
      lesional and bleeding risk associated with low-dose aspirin. GI complications are 
      more frequent if aspirin is given in combination with conventional NSAIDs or 
      steroids. In the case of concomitant prescription of low-dose aspirin and an 
      NSAID, the use of a coxib may be considered, but studies are still necessary to 
      evaluate the usefulness of their combination use with low-dose aspirin. In the 
      future, other better tolerated NSAIDs (NO releasing NSAIDs, zwitterion complexes) 
      will be developed. Ongoing studies evaluate the protective risk of misoprostol 
      and proton pump inhibitors in patients at risk for a GI adverse effects, 
      receiving low-dose aspirin. CONCLUSION: The GI risk induced by low-dose aspirin 
      exists and may be increased by different factors related, first to the patient, 
      and second to certain concomitant treatments. Patients at risk must be screened 
      in order to plan a prophylactic strategy. However to date, no compound has been 
      registered for prophylactic treatment of gastro-intestinal risk induced by 
      low-dose aspirin.
FAU - Sibilia, Jean
AU  - Sibilia J
AD  - Service de rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre Strasbourg.
FAU - Ravaud, Philippe
AU  - Ravaud P
FAU - Marck, Géraldine
AU  - Marck G
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Les facteurs de risque des complications digestives et hémorragiques liées à 
      l'aspirine à faibles doses.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Clinical Trials as Topic
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Risk Factors
RF  - 70
EDAT- 2004/02/07 05:00
MHDA- 2004/02/20 05:00
CRDT- 2004/02/07 05:00
PHST- 2004/02/07 05:00 [pubmed]
PHST- 2004/02/20 05:00 [medline]
PHST- 2004/02/07 05:00 [entrez]
PST - ppublish
SO  - Presse Med. 2003 Nov 22;32(37 Pt 2):S9-16.

PMID- 6355137
OWN - NLM
STAT- MEDLINE
DCOM- 19831221
LR  - 20151119
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 57
IP  - 6
DP  - 1983 Dec
TI  - Aspirin causes tissue insensitivity to insulin in normal man.
PG  - 1102-6
AB  - The effect of aspirin on glucose and insulin metabolism was examined with the 
      hyperglycemic clamp technique in 8 normal volunteers. When the plasma glucose 
      concentration was acutely raised and maintained at 125 mg/dl above the basal 
      level after treatment with aspirin (3 g daily for 3 days), acute (0-10 min) and 
      sustained (20-120 min) insulin release were 70% and 45% greater than before 
      treatment. Despite the increased plasma insulin level, the glucose infusion rate 
      remained unchanged (8 +/- 0.9 to 9.1 +/- 1.2 mg/kg X min). Consequently, the 
      ratio of the glucose infusion rate to the plasma insulin level, an index of 
      tissue sensitivity to endogenous insulin, decreased by 30%, indicative of 
      impaired insulin action. Aspirin did not alter fasting levels of FFA. When 
      ibuprofen, another prostaglandin synthesis inhibitor, was given to 10 normal 
      volunteers, only an effect on acute insulin release could be demonstrated. These 
      results demonstrate that aspirin not only enhances beta-cell sensitivity to 
      glucose, but also impairs glucose metabolism in insulin-sensitive tissues. It is 
      not clear whether these effects are related to aspirin's ability to inhibit 
      prostaglandin synthesis.
FAU - Newman, W P
AU  - Newman WP
FAU - Brodows, R G
AU  - Brodows RG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Blood Glucose)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Insulin)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Glucose/metabolism
MH  - Fatty Acids, Nonesterified/blood
MH  - Glucose
MH  - Humans
MH  - Ibuprofen
MH  - Insulin/*blood
MH  - *Insulin Resistance
MH  - Male
EDAT- 1983/12/01 00:00
MHDA- 1983/12/01 00:01
CRDT- 1983/12/01 00:00
PHST- 1983/12/01 00:00 [pubmed]
PHST- 1983/12/01 00:01 [medline]
PHST- 1983/12/01 00:00 [entrez]
AID - 10.1210/jcem-57-6-1102 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 1983 Dec;57(6):1102-6. doi: 10.1210/jcem-57-6-1102.

PMID- 21081908
OWN - NLM
STAT- MEDLINE
DCOM- 20110420
LR  - 20131121
IS  - 1572-0241 (Electronic)
IS  - 0002-9270 (Linking)
VI  - 106
IP  - 2
DP  - 2011 Feb
TI  - Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: 
      a randomized clinical trial.
PG  - 272-7
LID - 10.1038/ajg.2010.436 [doi]
AB  - OBJECTIVES: Relative contributions of local and systemic mechanisms of upper 
      gastrointestinal (GI) injury following aspirin are unknown. Studies suggest that 
      aspirin's GI risk is age related and that gastroprotection may be needed at 
      therapy initiation. We determined acute gastroduodenal erosion and ulceration 
      following low-dose aspirin and aspirin-phosphatidylcholine complex (PL2200) in 
      subjects at risk of aspirin ulcers. METHODS: In a randomized, single blind, 
      multicenter active-controlled study, we compared upper GI damage of aspirin and 
      PL2200 in healthy subjects (n=204, ages 50-74 years) following 7 days of oral 
      325 mg once daily, immediate release aspirin or PL2200. RESULTS: Overall, 42.2% 
      of aspirin-treated subjects developed multiple erosions and/or ulcers, whereas 
      22.2% treated with PL2200 developed such damage (P=0.0027). Gastroduodenal ulcers 
      were observed in 17.6% of aspirin-treated compared with 5.1% of subjects treated 
      with PL2200 (P=0.0069). CONCLUSIONS: Low-dose aspirin induced a surprisingly high 
      incidence of acute gastroduodenal ulcers in at risk subjects, highlighting that 
      aspirin's upper GI risk begins early and may require gastroprotection. Local 
      mechanisms of GI protection are important as aspirin's preassociation with 
      surface-active phospholipids significantly reduced mucosal damage. PL2200 may be 
      an attractive alternative or complement to proton pump inhibitors in older 
      patients who are at risk of aspirin-induced ulceration. Longer-term studies 
      assessing clinical GI events are desirable to confirm the clinical GI safety 
      profile of PL2200.
FAU - Cryer, Byron
AU  - Cryer B
AD  - University of Texas Southwestern and VA North Texas Health Care System, Dallas, 
      Texas 75216-7167, USA. Byron.Cryer@UTSouthwestern.edu
FAU - Bhatt, Deepak L
AU  - Bhatt DL
FAU - Lanza, Frank L
AU  - Lanza FL
FAU - Dong, Jing-fei
AU  - Dong JF
FAU - Lichtenberger, Lenard M
AU  - Lichtenberger LM
FAU - Marathi, Upendra K
AU  - Marathi UK
LA  - eng
GR  - R42 DK063882/DK/NIDDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20101116
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Drug Combinations)
RN  - 0 (Phosphatidylcholines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (aspirin-phosphatidylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phosphatidylcholines/administration & dosage/*adverse effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Prospective Studies
MH  - Single-Blind Method
MH  - Stomach Ulcer/*chemically induced/*prevention & control
EDAT- 2010/11/18 06:00
MHDA- 2011/04/22 06:00
CRDT- 2010/11/18 06:00
PHST- 2010/11/18 06:00 [entrez]
PHST- 2010/11/18 06:00 [pubmed]
PHST- 2011/04/22 06:00 [medline]
AID - ajg2010436 [pii]
AID - 10.1038/ajg.2010.436 [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2011 Feb;106(2):272-7. doi: 10.1038/ajg.2010.436. Epub 2010 
      Nov 16.

PMID- 35729443
OWN - NLM
STAT- MEDLINE
DCOM- 20220720
LR  - 20221207
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Print)
IS  - 0925-4692 (Linking)
VI  - 30
IP  - 4
DP  - 2022 Aug
TI  - A closer look at endothelial injury-induced platelet hyperactivity and the use of 
      aspirin in the treatment of COVID infection.
PG  - 1475-1476
LID - 10.1007/s10787-022-01015-w [doi]
AB  - In this commentary, we make a case that the mechanism of COVID pathogenesis is 
      related to virus-induced endothelial injury resulting in platelet activation and 
      the formation of microthrombi both systemically and in cardiac and pulmnonary 
      circulation which result in major causes of COVID morbidity and mortality. 
      Aspirin by virtue of its irreversible inhibition of platelet COX-1, should 
      reverse these platelet-induced pathogenic changes associated with COVID infection 
      for the 6-9 day lifetime of the platelet. We also cite recent findings of a 
      retrospective analysis that supports the use of low-dose (81 mg) aspirin to treat 
      the symptoms associated with the early stages of COVID infection.
CI  - © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Lichtenberger, Lenard M
AU  - Lichtenberger LM
AUID- ORCID: 0000-0003-2746-1627
AD  - Department of Integrative Biology and Pharmacology, The University of Texas 
      Health Science Center at Houston, Houston, USA. 
      lenard.m.lichtenberger@uth.tmc.edu.
AD  - American University of Health Sciences, Signal Hill/Long Beach, CA, USA. 
      lenard.m.lichtenberger@uth.tmc.edu.
FAU - Szabo, Sandor
AU  - Szabo S
AD  - American University of Health Sciences, Signal Hill/Long Beach, CA, USA.
AD  - University of California, Irvine, Irvine, USA.
LA  - eng
GR  - R42CA171408/RG/CSR NIH HHS/United States
PT  - Journal Article
DEP - 20220622
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets
MH  - Humans
MH  - Platelet Activation
MH  - Retrospective Studies
MH  - *COVID-19 Drug Treatment
PMC - PMC9213171
OTO - NOTNLM
OT  - Aspirin
OT  - COVID
OT  - Endothelial
OT  - Platelet
COIS- Dr. Lichtenberger declares he was Scientific Founder of PLx Pharma Inc that is 
      commercializing a lipid-associated aspirin and has shares in the company.
EDAT- 2022/06/22 06:00
MHDA- 2022/07/22 06:00
CRDT- 2022/06/21 23:33
PHST- 2022/05/28 00:00 [received]
PHST- 2022/05/30 00:00 [accepted]
PHST- 2022/06/22 06:00 [pubmed]
PHST- 2022/07/22 06:00 [medline]
PHST- 2022/06/21 23:33 [entrez]
AID - 10.1007/s10787-022-01015-w [pii]
AID - 1015 [pii]
AID - 10.1007/s10787-022-01015-w [doi]
PST - ppublish
SO  - Inflammopharmacology. 2022 Aug;30(4):1475-1476. doi: 10.1007/s10787-022-01015-w. 
      Epub 2022 Jun 22.

PMID- 1613122
OWN - NLM
STAT- MEDLINE
DCOM- 19920730
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 32
IP  - 2
DP  - 1992 Feb
TI  - Dose-dependent aspirin hydrolysis and platelet aggregation in patients with 
      atherosclerosis.
PG  - 133-5
AB  - In a double blind, randomized trial, the effects of aspirin (1, 5, and 15 mg/kg) 
      were compared with the changes in platelet aggregation at 6 and 24 hours after 
      dosage. It is found that there is a negative correlation between aspirin 
      hydrolysis velocity in blood and capability of aspirin to decrease platelet 
      aggregation with ADP and collagen in patients with atherosclerosis. Relationship 
      between these parameters depends on aspirin dosage. The correlation was more 
      marked for low doses of aspirin. It is suggested that the effect of aspirin in 
      low dosage on platelet aggregation might be ineffective in many patients without 
      control of aspirin hydrolysis velocity in blood.
FAU - Akopov, S S
AU  - Akopov SS
AD  - Department of Pharmacology, Yerevan Medical Institute, Armenia, USSR.
FAU - Grigorian, G S
AU  - Grigorian GS
FAU - Gabrielian, E S
AU  - Gabrielian ES
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Arteriosclerosis/*metabolism
MH  - Aspirin/chemistry/*metabolism/pharmacology
MH  - Collagen/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hydrolysis
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1992.tb03817.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1992 Feb;32(2):133-5. doi: 10.1002/j.1552-4604.1992.tb03817.x.

PMID- 22281116
OWN - NLM
STAT- MEDLINE
DCOM- 20121126
LR  - 20131121
IS  - 1532-8422 (Electronic)
IS  - 1053-0770 (Linking)
VI  - 26
IP  - 4
DP  - 2012 Aug
TI  - Evaluation of aspirin's effect on platelet function early after coronary artery 
      bypass grafting.
PG  - 575-80
LID - 10.1053/j.jvca.2011.12.004 [doi]
AB  - OBJECTIVE: Aspirin therapy decreases mortality and ischemic complication rates 
      after coronary artery bypass grafting (CABG). However, platelet inhibition after 
      oral aspirin seems to be insufficient in the early postoperative period. There 
      are incomplete data reporting aspirin efficacy early after CABG. The aim of this 
      study was to assess the pharmacologic effect of aspirin on platelets in the first 
      postoperative days using the most specific laboratory tests for the evaluation of 
      aspirin efficacy. DESIGN: A prospective study. SETTING: A clinical study in one 
      cardiac surgery center and measurements in two pharmacologic institutions. 
      PARTICIPANTS: Thirty patients. INTERVENTIONS: Postoperative aspirin efficacy (200 
      mg/d) was assessed by the suppression of serum thromboxane B(2) (TxB(2)) and by 
      arachidonic acid-induced aggregometry using the MULTIPLATE analyzer. Samples were 
      collected before surgery and on postoperative days 1-5. METHODS AND MAIN RESULTS: 
      The median baseline value (range) of serum TxB(2) was 1.6 ng/mL (1.4-1.9). The 
      median TxB(2) inhibition >90% (the value required for full platelet inhibition) 
      was not achieved until day 5 (-91%, 0.13 ng/mL [0.08-0.22], p < 0.001) and in 
      only 55% of patients. The median baseline ASPI value was 805 (640-975) 
      aggregation units (AU)*min. A significant decrease in aspirin insufficiency was 
      not seen before postoperative day 5 (390 [243-621], p < 0.003) and only 34% of 
      patients reached an effective platelet inhibition on day 5 (cutoff < 300 AU*min). 
      CONCLUSIONS: The effect of aspirin on inhibition of TxB(2) production and 
      arachidonic acid-induced platelet aggregation is impaired during the first 
      postoperative days after CABG. A more effective antiplatelet strategy presumably 
      could increase early graft patency and improve clinical outcomes after CABG.
CI  - Copyright © 2012. Published by Elsevier Inc.
FAU - Bednar, Frantisek
AU  - Bednar F
AD  - Cardiocentre, 3rd Department of Internal Medicine and Cardiology, 3rd Medical 
      School, Charles University and Kralovske Vinohrady University Hospital, Prague, 
      Czech Republic. fandabednar@email.cz
FAU - Tencer, Tomas
AU  - Tencer T
FAU - Plasil, Petr
AU  - Plasil P
FAU - Paluch, Zoltan
AU  - Paluch Z
FAU - Sadilkova, Lenka
AU  - Sadilkova L
FAU - Prucha, Miroslav
AU  - Prucha M
FAU - Kopa, Milos
AU  - Kopa M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120126
PL  - United States
TA  - J Cardiothorac Vasc Anesth
JT  - Journal of cardiothoracic and vascular anesthesia
JID - 9110208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Cardiothorac Vasc Anesth. 2012 Aug;26(4):e46-7. PMID: 22608470
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Prospective Studies
MH  - Thromboxane B2/biosynthesis
EDAT- 2012/01/28 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/01/28 06:00
PHST- 2011/08/29 00:00 [received]
PHST- 2012/01/28 06:00 [entrez]
PHST- 2012/01/28 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S1053-0770(11)00859-7 [pii]
AID - 10.1053/j.jvca.2011.12.004 [doi]
PST - ppublish
SO  - J Cardiothorac Vasc Anesth. 2012 Aug;26(4):575-80. doi: 
      10.1053/j.jvca.2011.12.004. Epub 2012 Jan 26.

PMID- 31098750
OWN - NLM
STAT- MEDLINE
DCOM- 20190627
LR  - 20200225
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 145
IP  - 7
DP  - 2019 Jul
TI  - Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis 
      of randomized controlled trials.
PG  - 1795-1809
LID - 10.1007/s00432-019-02932-0 [doi]
AB  - BACKGROUND: In the United States, cancer is the second leading cause of 
      mortality, and millions more battle cancer worldwide. As such, primary prevention 
      of cancer is a major interest globally. Aspirin has been studied as a primary 
      prevention method for multiple diseases, mainly cardiovascular disease and 
      various forms of cancer. The role of aspirin as a primary prevention of cancer is 
      still controversial and may be more beneficial in certain cancers over others. 
      With rapidly surfacing large randomized controlled trials (RCTs) studying this 
      subject, we aimed to evaluate the efficacy and safety of aspirin as a primary 
      prophylaxis for cancer. METHODS: A comprehensive electronic database search was 
      conducted for all RCTs that compared aspirin versus placebo for the prevention of 
      any type of disease, and where cancer incidence or mortality was reported. The 
      primary outcome was cancerrelated mortality. Secondary outcomes were cancer 
      incidence, all-cause mortality, major bleeding, any bleeding and gastrointestinal 
      (GI) bleeding. We calculated risk ratios (RRs) and 95% confidence intervals (CIs) 
      using a random-effects model at the longest follow-up period. RESULTS: We 
      included 16 RCTs with 104,018 total patients, mean age of 60.51 years, mean 
      follow-up of 5.48 years, and a male percentage of 38.72%. We found that aspirin 
      was not associated with a significant reduction of cancer-related mortality 
      compared with placebo (RR 0.99; 95% CI: 0.87-1.12; P = 0.85: I(2) = 41%). 
      Compared with placebo, aspirin was not associated with significant reduction of 
      all-cause mortality (RR 0.97; 95% CI: 0.92-1.02; P = 0.19; I(2) = 13%) or cancer 
      incidence (RR: 0.98; 95% CI: 0.92-1.04; P = 0.43; I(2) = 16%). However, aspirin 
      treatment was associated with significantly increased risks of any bleeding (RR 
      1.63; 95% CI: 1.31-2.03; P < 0.01), major bleeding (RR 1.41; 95% CI: 1.26-1.57; P 
      < 0.01), and GI bleeding (RR 1.85; 95% CI: 1.38-2.48; P < 0.01) compared with 
      placebo. CONCLUSION: Our study did not find any significant reductions in 
      cancer-related mortality or cancer incidence when compared aspirin use with 
      placebo or no aspirin. Our study also highlights that the use of aspirin for 
      primary prevention of cancer was found to cause higher rates of bleeding (any 
      bleeding, major bleeding, and GI bleeding) compared to placebo or no aspirin at 
      the longest follow-up period with no significant benefit in cancer primary 
      prevention.
FAU - Haykal, Tarek
AU  - Haykal T
AUID- ORCID: 0000-0002-8637-7292
AD  - Department of Internal Medicine, Hurley Medical Center, Flint, MI, USA. 
      haykaltarek@gmail.com.
AD  - College of Human Medicine, Michigan State University, East Lansing, MI, USA. 
      haykaltarek@gmail.com.
FAU - Barbarawi, Mahmoud
AU  - Barbarawi M
AD  - Department of Internal Medicine, Hurley Medical Center, Flint, MI, USA.
AD  - College of Human Medicine, Michigan State University, East Lansing, MI, USA.
FAU - Zayed, Yazan
AU  - Zayed Y
AD  - Department of Internal Medicine, Hurley Medical Center, Flint, MI, USA.
AD  - College of Human Medicine, Michigan State University, East Lansing, MI, USA.
FAU - Yelangi, Anitha
AU  - Yelangi A
AD  - Department of Internal Medicine, Hurley Medical Center, Flint, MI, USA.
AD  - College of Human Medicine, Michigan State University, East Lansing, MI, USA.
FAU - Dhillon, Harsukh
AU  - Dhillon H
AD  - Department of Internal Medicine, Hurley Medical Center, Flint, MI, USA.
AD  - College of Human Medicine, Michigan State University, East Lansing, MI, USA.
FAU - Goranta, Sowmya
AU  - Goranta S
AD  - Department of Internal Medicine, Hurley Medical Center, Flint, MI, USA.
AD  - College of Human Medicine, Michigan State University, East Lansing, MI, USA.
FAU - Kheiri, Babikir
AU  - Kheiri B
AD  - Department of Internal Medicine, Hurley Medical Center, Flint, MI, USA.
AD  - College of Human Medicine, Michigan State University, East Lansing, MI, USA.
FAU - Chahine, Adam
AU  - Chahine A
AD  - Department of Internal Medicine, Hurley Medical Center, Flint, MI, USA.
AD  - College of Human Medicine, Michigan State University, East Lansing, MI, USA.
FAU - Samji, Varun
AU  - Samji V
AD  - Department of Internal Medicine, Hurley Medical Center, Flint, MI, USA.
AD  - College of Human Medicine, Michigan State University, East Lansing, MI, USA.
FAU - Kerbage, Josiane
AU  - Kerbage J
AD  - Department of Anesthesiology, Lebanese University, Beirut, Lebanon.
FAU - Katato, Khalil
AU  - Katato K
AD  - Genessee Hematology & Oncology, PC, Flint, MI, USA.
FAU - Bachuwa, Ghassan
AU  - Bachuwa G
AD  - Department of Internal Medicine, Hurley Medical Center, Flint, MI, USA.
AD  - College of Human Medicine, Michigan State University, East Lansing, MI, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190516
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Cancer Res Clin Oncol. 2020 Aug;146(8):2173-2175. PMID: 31673755
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Humans
MH  - Neoplasms/mortality/*prevention & control
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Aspirin
OT  - Bleeding
OT  - Cancer
OT  - Primary prevention
EDAT- 2019/05/18 06:00
MHDA- 2019/06/30 06:00
CRDT- 2019/05/18 06:00
PHST- 2019/02/21 00:00 [received]
PHST- 2019/03/28 00:00 [accepted]
PHST- 2019/05/18 06:00 [pubmed]
PHST- 2019/06/30 06:00 [medline]
PHST- 2019/05/18 06:00 [entrez]
AID - 10.1007/s00432-019-02932-0 [pii]
AID - 10.1007/s00432-019-02932-0 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2019 Jul;145(7):1795-1809. doi: 
      10.1007/s00432-019-02932-0. Epub 2019 May 16.

PMID- 29204620
OWN - NLM
STAT- MEDLINE
DCOM- 20171219
LR  - 20210319
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 167
IP  - 11
DP  - 2017 Dec 5
TI  - Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel 
      Deaconess Medical Center.
PG  - 786-793
LID - 10.7326/M17-2162 [doi]
AB  - Aspirin exerts antiplatelet effects through irreversible inhibition of 
      cyclooxygenase-1, whereas its anticancer effects may be due to inhibition of 
      cyclooxygenase-2 and other pathways. In 2009, the U.S. Preventive Services Task 
      Force endorsed aspirin for primary prevention of cardiovascular disease. However, 
      aspirin's role in cancer prevention is still emerging, and no groups currently 
      recommend its use for this purpose. To help physicians balance the benefits and 
      harms of aspirin in primary disease prevention, the Task Force issued a guideline 
      titled, "Aspirin Use for the Primary Prevention of Cardiovascular Disease and 
      Colorectal Cancer" in 2016. In the evidence review conducted for the guideline, 
      cardiovascular disease mortality and colorectal cancer mortality were 
      significantly reduced among persons taking aspirin. However, there was no 
      difference in nonfatal stroke, cardiovascular disease mortality, or all-cause 
      mortality, nor in total cancer mortality, among those taking aspirin. Aspirin 
      users were found to be at increased risk for major gastrointestinal bleeding. In 
      this Beyond the Guidelines, the guideline is reviewed and 2 experts discuss how 
      they would apply it to a 57-year-old man considering starting aspirin for primary 
      prevention. Our experts review the data on which the guideline is based, discuss 
      how they would balance the benefits and harms of aspirin therapy, and explain how 
      they would incorporate shared decision making into clinical practice.
FAU - Burns, Risa B
AU  - Burns RB
AD  - From Beth Israel Deaconess Medical Center, Boston, Massachusetts.
FAU - Graham, Kelly
AU  - Graham K
AD  - From Beth Israel Deaconess Medical Center, Boston, Massachusetts.
FAU - Sawhney, Mandeep S
AU  - Sawhney MS
AD  - From Beth Israel Deaconess Medical Center, Boston, Massachusetts.
FAU - Reynolds, Eileen E
AU  - Reynolds EE
AD  - From Beth Israel Deaconess Medical Center, Boston, Massachusetts.
LA  - eng
PT  - Clinical Conference
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - KXO2KT9N0G (Pravastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticholesteremic Agents/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Hypercholesterolemia/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Pravastatin/therapeutic use
MH  - *Primary Prevention
MH  - Risk Assessment
EDAT- 2017/12/06 06:00
MHDA- 2017/12/20 06:00
CRDT- 2017/12/06 06:00
PHST- 2017/12/06 06:00 [entrez]
PHST- 2017/12/06 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
AID - 2664847 [pii]
AID - 10.7326/M17-2162 [doi]
PST - ppublish
SO  - Ann Intern Med. 2017 Dec 5;167(11):786-793. doi: 10.7326/M17-2162.

PMID- 10904435
OWN - NLM
STAT- MEDLINE
DCOM- 20001013
LR  - 20131121
IS  - 0306-9877 (Print)
IS  - 0306-9877 (Linking)
VI  - 55
IP  - 2
DP  - 2000 Aug
TI  - Peri-operative aspirin can prevent post-operative ischemia and thrombosis.
PG  - 164-7
AB  - Of the 30 million patients in the USA who undergo non-cardiac surgery every year, 
      approximately 1.5 million suffer post-operative cardiovascular events. Surgical 
      trauma and associated catecholamine release leads to platelet activation in the 
      immediate post-operative period, as evidenced by a rise in circulating platelet 
      release products. Platelet activation promotes platelet aggregation and 
      hypercoagulability. Aspirin is widely used for its platelet inhibiting effects to 
      prevent myocardial infarction and stroke. However, aspirin is not routinely 
      started in the immediate peri-operative period, and even in high-risk patients 
      already taking aspirin, aspirin is generally discontinued before elective surgery 
      to improve intra-operative hemostasis. The risk-to-benefit ratios of 
      administering vs withholding aspirin in the immediate peri-operative period have 
      never been assessed and compared. We hypothesize that aspirin given pre-, intra- 
      or immediately post-operatively will reduce post-operative ischemia and 
      thrombotic events, including myocardial infarction and stroke, and that 
      risk-benefit analysis would favor the administration of aspirin. This hypothesis 
      can and should be tested in a prospective, randomized trial.
CI  - Copyright 2000 Harcourt Publishers Ltd.
FAU - Madi, A
AU  - Madi A
AD  - Departments of Preventive Medicine & Internal Medicine, Yale-Griffin Prevention 
      Research Center, Griffin Hospital, Derby, CT 06418, USA.
FAU - Plavec, M
AU  - Plavec M
FAU - Nawaz, H
AU  - Nawaz H
FAU - Katz, D L
AU  - Katz DL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Humans
MH  - Intraoperative Period
MH  - Platelet Activation/drug effects
MH  - Postoperative Complications/*prevention & control
MH  - Thrombosis/*prevention & control
EDAT- 2000/08/06 11:00
MHDA- 2000/10/21 11:01
CRDT- 2000/08/06 11:00
PHST- 2000/08/06 11:00 [pubmed]
PHST- 2000/10/21 11:01 [medline]
PHST- 2000/08/06 11:00 [entrez]
AID - S0306-9877(99)91030-7 [pii]
AID - 10.1054/mehy.1999.1030 [doi]
PST - ppublish
SO  - Med Hypotheses. 2000 Aug;55(2):164-7. doi: 10.1054/mehy.1999.1030.

PMID- 27745943
OWN - NLM
STAT- MEDLINE
DCOM- 20170614
LR  - 20221207
IS  - 2214-8116 (Electronic)
IS  - 0398-0499 (Linking)
VI  - 41
IP  - 6
DP  - 2016 Dec
TI  - [Prevalence and prognosis of aspirin resistance in critical limb ischemia 
      patients].
PG  - 358-364
LID - S0398-0499(16)30076-2 [pii]
LID - 10.1016/j.jmv.2016.08.004 [doi]
AB  - OBJECTIVES: To assess the prevalence and the association between aspirin 
      resistance in critical limb ischemia patients using the VerifyNow(®) bed-side 
      platelet test, and occurrence of cardiovascular morbidity and/or death at one 
      year. MATERIALS AND METHODS: National multicenter prospective observational study 
      related to COPART II centers. From 2010 through 2014, 64 subjects hospitalized 
      for critical limb ischemia and already treated by aspirin before the VerifyNow(®) 
      test were included. A VerifyNow(®) test>550 ARU was defined as aspirin 
      resistance. Critical limb ischemia was defined according to the TASC I criteria. 
      The primary outcome was a composite including death, acute coronary syndrome, 
      stroke and major amputation during the one-year follow-up period. RESULTS: In 
      all, 9/64 patients were aspirin resistant, the status was confirmed in one case. 
      The prevalence of aspirin resistance was 14.06%. There was no significant 
      difference between aspirin resistant and aspirin non-resistant groups in terms of 
      cardiovascular history and glycemia status. Neither was there significant 
      difference between the two groups in terms of survival. CONCLUSION: Aspirin 
      resistance was not predictive of poorer survival in critical limb ischemia 
      patients. However, our population was limited. Considering that a clear 
      definition of aspirin resistance and standardized diagnostic tests are lacking, 
      complementary studies might be useful.
CI  - Copyright Â© 2016 Elsevier Masson SAS. All rights reserved.
FAU - Doly, J-S
AU  - Doly JS
AD  - Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine 
      vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France. 
      Electronic address: jeansimon.doly@gmail.com.
FAU - Lorian, E
AU  - Lorian E
AD  - Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine 
      vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France.
FAU - Desormais, I
AU  - Desormais I
AD  - Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine 
      vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France.
FAU - Constans, J
AU  - Constans J
AD  - Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine 
      vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France.
FAU - Bura Rivière, A
AU  - Bura Rivière A
AD  - Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine 
      vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France.
FAU - Lacroix, P
AU  - Lacroix P
AD  - Service chirurgie thoracique et cardiovasculaire et angiologie, unité de médecine 
      vasculaire, CHU de Limoges, 2, avenue Martin-Luther-King, 87000 Limoges, France.
LA  - fre
PT  - Journal Article
PT  - Multicenter Study
TT  - Prévalence et valeur pronostique de la résistance à l’aspirine chez les patients 
      en ischémie critique chronique des membres inférieurs.
DEP - 20161014
PL  - France
TA  - J Mal Vasc
JT  - Journal des maladies vasculaires
JID - 7707965
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/epidemiology
MH  - Aged
MH  - Aged, 80 and over
MH  - Amputation, Surgical
MH  - Aspirin/*therapeutic use
MH  - *Drug Resistance
MH  - Extremities/*blood supply
MH  - Female
MH  - Humans
MH  - Ischemia/complications/*drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Stroke/epidemiology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Artériopathie oblitérante des membres inférieurs
OT  - Aspirin resistance
OT  - COPART
OT  - Critical limb ischemia
OT  - Ischémie critique des membres inférieurs
OT  - Peripheral arterial disease
OT  - Résistance à l’aspirine
OT  - VerifyNow(®) Aspirin
EDAT- 2016/10/18 06:00
MHDA- 2017/06/15 06:00
CRDT- 2016/10/18 06:00
PHST- 2015/10/06 00:00 [received]
PHST- 2016/07/29 00:00 [accepted]
PHST- 2016/10/18 06:00 [pubmed]
PHST- 2017/06/15 06:00 [medline]
PHST- 2016/10/18 06:00 [entrez]
AID - S0398-0499(16)30076-2 [pii]
AID - 10.1016/j.jmv.2016.08.004 [doi]
PST - ppublish
SO  - J Mal Vasc. 2016 Dec;41(6):358-364. doi: 10.1016/j.jmv.2016.08.004. Epub 2016 Oct 
      14.

PMID- 21061539
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - [Role of proton pump inhibitor in the management of low dose aspirin related 
      ulcerations].
PG  - 2096-101
AB  - Aspirin, as an anti-platelet medication, has been increasingly prescribed to 
      elderly patients for primary and secondary prevention of cardio--and 
      cerebro--vascular events. Nonetheless, aspirin's effectiveness in such disease 
      prevention is limited by the risk of gastrointestinal (GI) complications such as 
      ulceration, hemorrhage and perforation. Aspirin administration is associated with 
      2-fold increase in GI risk in middle-aged users without prior history of peptic 
      ulcer and without concomitant medications. However, the GI risk increases 
      dramatically in patients with a prior history of peptic ulcer disease, advanced 
      age, and concomitant use of NSAIDs, corticosteroids, clopidogrel, or 
      anticoagulants. Mechanisms of aspirin-induced GI injury are believed to be 
      through local effects within the GI mucosa that cause topical injury and through 
      systemic inhibition of cyclo-oxygenase (CO) resulting in depletion of mucosal 
      protective prostaglandins. Herein, we focus on the role of proton pump inhibitor 
      (PPI) in the strategy to prevent and to treat aspirin-induced peptic ulcerations 
      and their complications, based on the scientific evidence.
FAU - Hiraishi, Hideyuki
AU  - Hiraishi H
AD  - Department of Gastroenterology, Dokkyo Medical University.
FAU - Shimada, Tadahito
AU  - Shimada T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Middle Aged
MH  - Peptic Ulcer/*chemically induced/*drug therapy/prevention & control
MH  - Proton Pump Inhibitors/*therapeutic use
EDAT- 2010/11/11 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Nov;68(11):2096-101.

PMID- 12742332
OWN - NLM
STAT- MEDLINE
DCOM- 20030612
LR  - 20191025
IS  - 1470-0328 (Print)
IS  - 1470-0328 (Linking)
VI  - 110
IP  - 5
DP  - 2003 May
TI  - Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the 
      Essai Régional Aspirine Mère-Enfant study (Part 1).
PG  - 475-84
AB  - OBJECTIVE: To reduce the incidence of pre-eclampsia in nulliparous women, in 
      accordance with the suggestion of a recent meta-analysis that low dose aspirin 
      might decrease this incidence by more than half if used early enough in and at a 
      sufficient dose during pregnancy (more than 75 mg). DESIGN: Multicentre 
      randomised double-blinded placebo-controlled trial. SETTING: Twenty eight centres 
      in Northern of France and one in Belgium. POPULATION: Three thousand and two 
      hundred ninety-four nulliparous women recruited between 14 and 20 weeks. METHODS: 
      Randomisation to either 100 mg aspirin or placebo daily from inclusion through 34 
      weeks. MAIN OUTCOME MEASURES: Preeclampsia was defined as hypertension (> or =140 
      and or 90 mmHg) associated with proteinuria (> or =0.5 g/L). RESULTS: The aspirin 
      (n = 1644) and placebo (n = 1650) groups did not differ significantly in the 
      mothers' incidence of pre-eclampsia (28 of 1632 [1.7%] vs 26 of 1637 [1.6%]; 
      relative risk, RR, 1.08, 95% CI 0.64-1.83), hypertension, HELLP syndrome or 
      placental abruption, or in the children's incidence of perinatal deaths or 
      birthweight below the 10th centile. The incidence of babies with birthweight 
      below the third centile was significantly higher in the aspirin group, with no 
      explanation. The incidence of maternal side effects was higher in the aspirin 
      group, principally because of a significantly higher rate of haemorrhage. 
      CONCLUSIONS: Aspirin at a dose of 100 mg does not reduce the incidence of 
      pre-eclampsia in nulliparous women. Aspirin (100 mg) is associated with an 
      increase in bleeding complications.
FAU - Subtil, Damien
AU  - Subtil D
FAU - Goeusse, Patrice
AU  - Goeusse P
FAU - Puech, Francis
AU  - Puech F
FAU - Lequien, Pierre
AU  - Lequien P
FAU - Biausque, Serge
AU  - Biausque S
FAU - Breart, Gérard
AU  - Breart G
FAU - Uzan, Serge
AU  - Uzan S
FAU - Marquis, Pierre
AU  - Marquis P
FAU - Parmentier, Dominique
AU  - Parmentier D
FAU - Churlet, Alain
AU  - Churlet A
CN  - Essai Régional Aspirine Mère-Enfant (ERASME) Collaborative Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BJOG
JT  - BJOG : an international journal of obstetrics and gynaecology
JID - 100935741
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Blood Transfusion
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Parity
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Prospective Studies
EDAT- 2003/05/14 05:00
MHDA- 2003/06/13 05:00
CRDT- 2003/05/14 05:00
PHST- 2003/05/14 05:00 [pubmed]
PHST- 2003/06/13 05:00 [medline]
PHST- 2003/05/14 05:00 [entrez]
AID - S1470032803029963 [pii]
AID - 10.1046/j.1471-0528.2003.02096.x [doi]
PST - ppublish
SO  - BJOG. 2003 May;110(5):475-84. doi: 10.1046/j.1471-0528.2003.02096.x.

PMID- 29969574
OWN - NLM
STAT- MEDLINE
DCOM- 20190218
LR  - 20190219
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 96
IP  - 11
DP  - 2018 Nov
TI  - Ameliorative effects of aspirin against lipopolysaccharide-induced 
      preeclampsia-like symptoms in rats by inhibiting the pro-inflammatory pathway.
PG  - 1084-1091
LID - 10.1139/cjpp-2018-0087 [doi]
AB  - Preeclampsia is an inflammatory disease and has connection with increased 
      pro-inflammatory cytokines. Aspirin reduces the incidence of preeclampsia 
      complications. However, the effects of aspirin on lipopolysaccharide-induced 
      preeclampsia-like symptoms in rats have not been reported and the underlying 
      molecular mechanism has not been illuminated. Hence, we investigated the 
      anti-inflammatory effects of aspirin on lipopolysaccharide-induced 
      preeclampsia-like phenotypes in pregnant rats and elucidated the potential 
      molecular mechanism. Preeclampsia-like phenotypes were induced by tail vein 
      injection of lipopolysaccharide (1 μg/kg) on gestational day 14. Aspirin (2 mg/kg 
      per day) were administered from gestational day 14 to 19. Clinical phenotypes 
      were recorded. Placenta tissues and serum were obtained to measure inflammatory 
      cytokines levels using ELISA kit on gestational day 20. The mRNA expressions of 
      IL-6, IL-1β, and MCP-1 were measured by real-time PCR. Protein expressions 
      including TLR4, MyD88, NF-κBp65, and TLR2 were determined by Western blot 
      analysis in the rat placentas of each group. Aspirin obviously assuaged 
      lipopolysaccharide-induced preeclampsia-like phenotypes in pregnant rats. Aspirin 
      treatment significantly decreased the levels of pro-inflammatory cytokines in 
      serum and placenta tissues of preeclampsia rats. Aspirin also obviously 
      downregulated the mRNA expressions of IL-6, IL-1β, and MCP-1 and assuaged the 
      activation of TLR4, MyD88, NF-κBp65, and TLR2 in the placental tissue. Our 
      results indicated that aspirin could assuage preeclampsia-like phenotypes, and 
      this improvement effect is possibly the result of the suppression of 
      pro-inflammatory cytokines via the TLR4, MyD88, NF-κBp65, and TLR2 signaling 
      pathway.
FAU - Sun, Jieqiong
AU  - Sun J
AD  - Department of Obstetrics, Zhongshan Hospital Affiliated Dalian University, 
      Dalian, China.
AD  - Department of Obstetrics, Zhongshan Hospital Affiliated Dalian University, 
      Dalian, China.
FAU - Zhang, Huimei
AU  - Zhang H
AD  - Department of Obstetrics, Zhongshan Hospital Affiliated Dalian University, 
      Dalian, China.
AD  - Department of Obstetrics, Zhongshan Hospital Affiliated Dalian University, 
      Dalian, China.
FAU - Liu, Fang
AU  - Liu F
AD  - Department of Obstetrics, Zhongshan Hospital Affiliated Dalian University, 
      Dalian, China.
AD  - Department of Obstetrics, Zhongshan Hospital Affiliated Dalian University, 
      Dalian, China.
FAU - Tang, Dongmei
AU  - Tang D
AD  - Department of Obstetrics, Zhongshan Hospital Affiliated Dalian University, 
      Dalian, China.
AD  - Department of Obstetrics, Zhongshan Hospital Affiliated Dalian University, 
      Dalian, China.
FAU - Lu, Xuhong
AU  - Lu X
AD  - Department of Obstetrics, Zhongshan Hospital Affiliated Dalian University, 
      Dalian, China.
AD  - Department of Obstetrics, Zhongshan Hospital Affiliated Dalian University, 
      Dalian, China.
LA  - eng
PT  - Journal Article
DEP - 20180703
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cytokines)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (RNA, Messenger)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cytokines/blood/genetics/immunology/*metabolism
MH  - Disease Models, Animal
MH  - Down-Regulation/drug effects
MH  - Female
MH  - Humans
MH  - Lipopolysaccharides/immunology
MH  - Placenta/pathology
MH  - Pre-Eclampsia/blood/*drug therapy/immunology/pathology
MH  - Pregnancy
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Signal Transduction/*drug effects
OTO - NOTNLM
OT  - aspirin
OT  - aspirine
OT  - inflammation
OT  - lipopolysaccharide
OT  - lipopolysaccharides
OT  - preeclampsia
OT  - pré-éclampsie
EDAT- 2018/07/04 06:00
MHDA- 2019/02/20 06:00
CRDT- 2018/07/04 06:00
PHST- 2018/07/04 06:00 [pubmed]
PHST- 2019/02/20 06:00 [medline]
PHST- 2018/07/04 06:00 [entrez]
AID - 10.1139/cjpp-2018-0087 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2018 Nov;96(11):1084-1091. doi: 10.1139/cjpp-2018-0087. 
      Epub 2018 Jul 3.

PMID- 7638141
OWN - NLM
STAT- MEDLINE
DCOM- 19950911
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 24
IP  - 20
DP  - 1995 Jun 3
TI  - [Use of aspirin in coronary disease].
PG  - 925-7
AB  - The beneficial effect of aspirin in different situations of coronary artery 
      disease has been clearly demonstrated, but prescription remains empirical due to 
      the lack of phase II trials and the incompletely understood mechanism of action. 
      Since the ISIS-2 study was published in 1988, aspirin is indicated in the acute 
      phase of myocardial infarction as mortality can be reduced by 20% and the rate of 
      reocclusions reduced. The beneficial effect of aspirin in unstable angina has 
      also been demonstrated with a reduction of more than 50% in the combined 
      incidence of mortality and myocardial infarction. Stable angina is an ideal 
      application for low-dose aspirin with an improvement in combined incidence of 
      myocardial infarction and sudden death of 34%. The question of dose remains open. 
      When prescribed for primary or secondary prevention, aspirin should be given at 
      low-doses (50-100 mg/d) in a long-term regimen. The dose should be examined 
      differently for treatment of acute thrombotic events including infarction and 
      unstable angina. Doses above 250 mg/d with an initial dose of 500 mg to 1 g are 
      recommended followed by a relay with 50 to 100 mg/d. Irreversible dose-dependent 
      inhibition of platelet cyclooxygenase by aspirin is nearly total for a single 
      dose of 100 mg. The effect is cumulative for smaller doses and since the 
      anucleated platelets cannot resynthesize the enzyme only new platelet can recover 
      enzymatic activity. The duration of the effect thus is a function of normal 
      platelet turn-over (8 days). Currently, aspirin is indicated in all coronary 
      artery patients and should be discussed for "potential" patients i.e. as primary 
      prevention in healthy subjects at risk of coronary artery disease although the 
      threshold of risk requiring prescription remains to be clearly determined.
FAU - Montalescot, G
AU  - Montalescot G
LA  - fre
PT  - Editorial
PT  - English Abstract
TT  - Utilisation de l'aspirine dans la maladie coronaire.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Anticoagulants)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina Pectoris/*drug therapy
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/administration & dosage/metabolism/*therapeutic use
MH  - Coronary Disease/*drug therapy/prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Myocardial Infarction/*drug therapy/mortality
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
EDAT- 1995/06/03 00:00
MHDA- 1995/06/03 00:01
CRDT- 1995/06/03 00:00
PHST- 1995/06/03 00:00 [pubmed]
PHST- 1995/06/03 00:01 [medline]
PHST- 1995/06/03 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1995 Jun 3;24(20):925-7.

PMID- 6825391
OWN - NLM
STAT- MEDLINE
DCOM- 19830415
LR  - 20190511
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 33
IP  - 3
DP  - 1983 Mar
TI  - Aspirin kinetics and platelet aggregation in man.
PG  - 367-74
AB  - Our aims were (1) to determine the effect of six commercially available aspirin 
      (ASA) preparations on in vitro platelet aggregation, and (2) to relate changes in 
      platelet function to ASA kinetics. Each of six subjects took a single dose of one 
      of the following preparations--600 mg Asproclear, 600 mg Bufferin, 600 mg 
      Bi-prin, 600 mg compressed ASA, 650 mg Ecotrin, or 650 mg S.R.A.--in random order 
      every 3 wk. Venous blood was drawn before and at 2, 4, 6, and 24 hr after ASA 
      dosage to measure platelet aggregation in response to collagen and adenosine 
      diphosphate and, at more frequent intervals, to characterize ASA kinetics. 
      Asproclear, Bufferin, Bi-prin, and compressed ASA yielded peak plasma ASA levels 
      of 28 to 56 mumol/l (5 to 10 mg/l) within 15 to 60 min and peak salicylic acid 
      (SA) levels of 72 to 290 mumol/l (10 to 40 mg/l) within 2 hr. Ecotrin and S.R.A. 
      yielded plasma SA levels of 14 to 87 mumol/l (2-12 mg/l) within 4 to 24 hr and no 
      measurable ASA at any time after dosing. Platelet aggregation was inhibited to an 
      equal extent by all preparations. The time course for this inhibition was the 
      same for all preparations but Ecotrin (which led to a more delayed effect). There 
      was significant recovery of collagen-induced platelet aggregation at 24 hr with 
      all preparations but Ecotrin. With Ecotrin and S.R.A. there was inhibition of 
      platelet aggregation in the absence of measurable circulating ASA. We postulate 
      that this was due to acetylation of cyclooxygenase in the portal circulation and 
      that inhibition of peripheral cyclooxygenase may be spared.
FAU - Siebert, D J
AU  - Siebert DJ
FAU - Bochner, F
AU  - Bochner F
FAU - Imhoff, D M
AU  - Imhoff DM
FAU - Watts, S
AU  - Watts S
FAU - Lloyd, J V
AU  - Lloyd JV
FAU - Field, J
AU  - Field J
FAU - Gabb, B W
AU  - Gabb BW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/metabolism/*pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Thromboembolism/prevention & control
EDAT- 1983/03/01 00:00
MHDA- 1983/03/01 00:01
CRDT- 1983/03/01 00:00
PHST- 1983/03/01 00:00 [pubmed]
PHST- 1983/03/01 00:01 [medline]
PHST- 1983/03/01 00:00 [entrez]
AID - 0009-9236(83)90591-X [pii]
AID - 10.1038/clpt.1983.47 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1983 Mar;33(3):367-74. doi: 10.1038/clpt.1983.47.

PMID- 22057729
OWN - NLM
STAT- MEDLINE
DCOM- 20121120
LR  - 20211021
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Print)
IS  - 0925-4692 (Linking)
VI  - 20
IP  - 4
DP  - 2012 Aug
TI  - Dissolution and pharmacokinetics of a novel micronized aspirin formulation.
PG  - 225-31
LID - 10.1007/s10787-011-0099-z [doi]
AB  - Aspirin (acetylsalicylic acid, ASA) has been used as an analgesic, antipyretic 
      and antiinflammatory drug for many years. A new 500 mg aspirin tablet formulation 
      containing micronized active ingredient and an effervescent component has been 
      developed for potential improvement in the onset of action for acute pain 
      treatment. This paper describes the dissolution and the pharmacokinetics of the 
      new formulation in comparison with regular aspirin tablets, aspirin granules and 
      aspirin effervescent tablets. Micronized aspirin tablets dissolve significantly 
      faster over a pH range from 1.2 to 6.8 compared to regular 500 mg aspirin 
      tablets. Plasma concentration time curve comparison to regular 500 mg aspirin 
      tablets showed a substantial improvement in the time to maximum plasma 
      concentrations (T(max)) (ASA 17.5 min vs. 45 min) and an increase in maximum 
      plasma concentration (C(max)) (ASA 13.8 μg/ml vs. 4.4 μg/ml) while the overall 
      extent of exposure (AUC) remains almost unchanged. The data suggest a potential 
      improvement for onset of action in treating acute pain with the new micronized 
      aspirin formulation.
FAU - Voelker, M
AU  - Voelker M
AD  - Bayer Consumer Care, Morristown, NJ, USA. michael.voelker@bayer.com
FAU - Hammer, M
AU  - Hammer M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20111105
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/chemistry/pharmacokinetics
MH  - Chemistry, Pharmaceutical
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Salicylic Acid/pharmacokinetics
MH  - Solubility
MH  - Tablets
PMC - PMC3398252
EDAT- 2011/11/08 06:00
MHDA- 2012/12/10 06:00
CRDT- 2011/11/08 06:00
PHST- 2011/09/13 00:00 [received]
PHST- 2011/10/18 00:00 [accepted]
PHST- 2011/11/08 06:00 [entrez]
PHST- 2011/11/08 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 99 [pii]
AID - 10.1007/s10787-011-0099-z [doi]
PST - ppublish
SO  - Inflammopharmacology. 2012 Aug;20(4):225-31. doi: 10.1007/s10787-011-0099-z. Epub 
      2011 Nov 5.

PMID- 12208460
OWN - NLM
STAT- MEDLINE
DCOM- 20030414
LR  - 20191106
IS  - 0928-0987 (Print)
IS  - 0928-0987 (Linking)
VI  - 16
IP  - 4-5
DP  - 2002 Sep
TI  - Isosorbide-based aspirin prodrugs. II. Hydrolysis kinetics of isosorbide 
      diaspirinate.
PG  - 297-304
AB  - Aspirin prodrugs have been intensively investigated in an effort to produce 
      compounds with lower gastric toxicity, greater stability or enhanced percutaneous 
      absorption, relative to aspirin. This report describes the hydrolysis kinetics 
      and aspirin release characteristics of isosorbide diaspirinate (ISDA), the 
      aspirin diester of isosorbide. ISDA underwent rapid hydrolysis when incubated in 
      phosphate buffered human plasma solutions (pH 7.4) at 37 degrees C, producing 
      appreciable quantities of aspirin. In 30% human plasma solution the half-life was 
      1.1 min and 61% aspirin was liberated relative to the initial ester 
      concentration. The hydrolysis kinetics of ISDA were monitored in aqueous solution 
      at 37 degrees C over the pH range 1.03-9.4. The aqueous hydrolysis followed 
      pseudo-first-order kinetics over several half-lives at all pH values, resulting 
      in a U-shaped pH rate profile. Salicylate esters and salicylic acid were formed 
      during these processes. The hydrolysis characteristics of ISDA were also 
      investigated in pH 7.4 phosphate buffered solutions containing alpha-chymotrypsin 
      [EC 3.1.1.1] (t(1/2)=200.9 min), carboxyl esterase [EC 3.1.1.1] (t(1/2)=31.5 
      min), human serum albumin (t(1/2)=603 min), purified human serum 
      butyrylcholinesterase [EC 3.1.1.8] (80 micro g/ml; t(1/2)=9.4 min; 55% aspirin), 
      purified horse serum butyrylcholinesterase (100 micro g/ml; t(1/2)=1.85 min;11% 
      aspirin) and in 10% human plasma solution in the presence of physostigmine (3 
      micro M). The results indicate that a specific enzyme present in human plasma, 
      probably human butyrylcholinesterase, catalyses aspirin release from isosorbide 
      diaspirinate.
FAU - Gilmer, John F
AU  - Gilmer JF
AD  - Department of Pharmaceutical Chemistry, School of Pharmacy, Trinity College, 2, 
      Dublin, Ireland. gilmerjf@tcd.ie
FAU - Moriarty, Louise M
AU  - Moriarty LM
FAU - Lally, Maeve N
AU  - Lally MN
FAU - Clancy, John M
AU  - Clancy JM
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Prodrugs)
RN  - 0 (isosorbide diaspirinate)
RN  - EC 3.1.1.8 (Butyrylcholinesterase)
RN  - R16CO5Y76E (Aspirin)
RN  - WXR179L51S (Isosorbide)
SB  - IM
MH  - Aspirin/analogs & derivatives/*chemical synthesis/chemistry/*metabolism
MH  - Butyrylcholinesterase/blood
MH  - Catalysis
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - In Vitro Techniques
MH  - Isosorbide/analogs & derivatives/*chemical synthesis/*chemistry/metabolism
MH  - Kinetics
MH  - Male
MH  - Prodrugs/*chemical synthesis/chemistry/metabolism
MH  - Time Factors
EDAT- 2002/09/05 10:00
MHDA- 2003/04/15 05:00
CRDT- 2002/09/05 10:00
PHST- 2002/09/05 10:00 [pubmed]
PHST- 2003/04/15 05:00 [medline]
PHST- 2002/09/05 10:00 [entrez]
AID - S0928098702001240 [pii]
AID - 10.1016/s0928-0987(02)00124-0 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2002 Sep;16(4-5):297-304. doi: 10.1016/s0928-0987(02)00124-0.

PMID- 14970280
OWN - NLM
STAT- MEDLINE
DCOM- 20040303
LR  - 20190513
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Linking)
VI  - 96
IP  - 4
DP  - 2004 Feb 18
TI  - Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
PG  - 316-25
AB  - BACKGROUND: Recent data suggest that nonsteroidal anti-inflammatory drugs, 
      including aspirin, may prevent the progression of Barrett's esophagus to 
      adenocarcinoma. However, use of aspirin is associated with numerous potential 
      complications, including gastrointestinal bleeding and hemorrhagic strokes. We 
      used a modeling approach to determine and compare the effectiveness and 
      cost-effectiveness of aspirin with and without endoscopic surveillance to prevent 
      esophageal adenocarcinoma. METHODS: A Markov Monte Carlo decision model was 
      constructed to compare four strategies for management of Barrett's esophagus: 
      aspirin therapy, endoscopic surveillance with biopsies, both, or neither. 
      Patients who took a daily enteric-coated aspirin were modeled to have a 50% 
      reduction in the incidence of esophageal adenocarcinoma but could have 
      complications related to therapy, at which point the aspirin was discontinued. 
      Potential cardiac benefits of aspirin and its role in the chemoprevention of 
      other cancers were not included in the analysis. The analysis was from a societal 
      perspective from age 55 years until death. Sensitivity analyses were performed to 
      investigate the effects of changes in model parameters on estimated costs and 
      effectiveness outcomes across a wide range of assumptions. RESULTS: Aspirin 
      therapy was more effective and less costly than no therapy, resulting in 0.19 
      more quality-adjusted life years (QALYs). The combination of aspirin and 
      endoscopic surveillance produced 0.27 more QALYs than no therapy at a cost of 
      13,400 U.S. dollars more, for an associated incremental cost-effectiveness ratio 
      of 49,600 U.S. dollars/QALY. Aspirin use in combination with endoscopic 
      surveillance dominated endoscopic surveillance alone, resulting in 0.06 more 
      QALYs and 11,400 U.S. dollars less cost. The model's results were sensitive to 
      increasing age and to decreased benefit or delay in aspirin's chemopreventive 
      efficacy. CONCLUSION: Using published values of parameters, regardless of whether 
      a patient undergoes endoscopic surveillance, aspirin use in the management of 
      Barrett's esophagus appears to be a cost-effective strategy to prevent esophageal 
      adenocarcinoma.
FAU - Hur, Chin
AU  - Hur C
AD  - Gastrointestinal Unit and The Institute for Technology Assessment, Massachusetts 
      General Hospital, Boston, USA. chur@partners.org
FAU - Nishioka, Norman S
AU  - Nishioka NS
FAU - Gazelle, G Scott
AU  - Gazelle GS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Natl Cancer Inst. 2004 Feb 18;96(4):252-3. PMID: 14970267
CIN - J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887. PMID: 15173278
MH  - Aged
MH  - Anticarcinogenic Agents/administration & dosage/*economics
MH  - Aspirin/administration & dosage/*economics
MH  - Barrett Esophagus/complications/*drug therapy/pathology
MH  - Cost-Benefit Analysis
MH  - Drug Costs/statistics & numerical data
MH  - Esophageal Neoplasms/*economics/etiology/pathology/*prevention & control
MH  - Esophagoscopy
MH  - Female
MH  - Humans
MH  - Male
MH  - *Markov Chains
MH  - Massachusetts
MH  - Middle Aged
MH  - *Monte Carlo Method
MH  - Sensitivity and Specificity
EDAT- 2004/02/19 05:00
MHDA- 2004/03/05 05:00
CRDT- 2004/02/19 05:00
PHST- 2004/02/19 05:00 [pubmed]
PHST- 2004/03/05 05:00 [medline]
PHST- 2004/02/19 05:00 [entrez]
AID - 10.1093/jnci/djh039 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2004 Feb 18;96(4):316-25. doi: 10.1093/jnci/djh039.

PMID- 29885857
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20180727
IS  - 1872-7786 (Electronic)
IS  - 0009-2797 (Linking)
VI  - 291
DP  - 2018 Aug 1
TI  - From epidemiology to treatment: Aspirin's prevention of brain and breast-cancer 
      and cardioprotection may associate with its metabolite gentisic acid.
PG  - 29-39
LID - S0009-2797(18)30278-3 [pii]
LID - 10.1016/j.cbi.2018.05.016 [doi]
AB  - BACKGROUND: Epidemiological studies indicate that aspirin consumption reduces the 
      risk of tumors, which is especially relevant for colonic adenoma and carcinoma. 
      Similar observations were made for glial brain tumors and breast cancers, yet the 
      results are inconsistent. Gentisic acid (GA) is a minor catabolite of aspirin; 
      yet humans carrying CYP2C9-variants incapable to catabolize aspirin to GA do not 
      benefit from aspirin in prevention against colonic adenoma. GA blocks binding of 
      Fibroblastic Growth Factor to its receptor and its sulphonate metabolite 
      dobesilic acid blocks growth of C6 glioblastoma in vivo. GA is also an 
      endogenously produced siderophore in mammalians for the transport of iron, a 
      trace element which stimulates tumor growth and enhances anthracycline 
      cardiotoxicity. MATERIALS AND METHODS: In this study, we assessed whether GA 
      exerts direct antitumor activity on C6 glioma cells in vitro (cytotoxicity, 
      colony growth, 3H-thymidine labeling analysis of DNA synthesis); and whether it 
      can modify growth of Ehrlich breast ascites carcinoma (EAC) and solid tumors 
      (EST) in vivo. GA and antitumoral trace element selenium block 12-lipoxygenase 
      activity and aspirin's paradoxical inflammatory effects are seen in 
      selenium-deficient humans; thus, we also investigated antitumor interactions 
      between GA and sodium selenite. Lastly, we evaluated whether GA could protect 
      against doxorubicin cardiotoxicity due to its function to chelate iron. RESULTS: 
      Clinically achievable doses of GA blocked growth, colony formation and DNA 
      synthesis of C6 glioma in vitro with high significance. GA enhanced the survival 
      of EAC-bearing mice at a dosage of 0.4 mg/mice/day, in which 33% of the treated 
      animals survived more than 3-weeks, when all untreated mice succumbed to their 
      tumors. Selenium decreased EST volumes initially, yet increased tumor volumes at 
      later stages in surviving mice. GA alone reduced solid tumor growth and did not 
      modify selenite antineoplasticity initially, but blocked the late 
      tumor-stimulating effects of selenite. Lastly, doxorubicin-induced cardiac 
      myofibrillary and endothelial damage and hyalinization necrosis were attenuated 
      with GA treatment. CONCLUSIONS: GA highly merits to be studied in further animal 
      models as an anticancer and chemoprotective drug.
CI  - Copyright © 2018. Published by Elsevier B.V.
FAU - Altinoz, Meric A
AU  - Altinoz MA
AD  - Neuroacademy Group, Istanbul, Turkey; Department of Psychiatry, Maastricht 
      University, Holland, Netherlands. Electronic address: maltinoz@gmail.com.
FAU - Elmaci, Ilhan
AU  - Elmaci I
AD  - Department of Neurosurgery, Memorial Hospital, Istanbul, Turkey.
FAU - Cengiz, Salih
AU  - Cengiz S
AD  - Insitute of Forensics, Istanbul University, Turkey.
FAU - Emekli-Alturfan, Ebru
AU  - Emekli-Alturfan E
AD  - Department of Biochemistry, Marmara University, Istanbul, Turkey.
FAU - Ozpinar, Aysel
AU  - Ozpinar A
AD  - Department of Medical Biochemistry, Acibadem University, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20180607
PL  - Ireland
TA  - Chem Biol Interact
JT  - Chemico-biological interactions
JID - 0227276
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Gentisates)
RN  - HIW548RQ3W (Sodium Selenite)
RN  - R16CO5Y76E (Aspirin)
RN  - VP36V95O3T (2,5-dihydroxybenzoic acid)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Brain Neoplasms/drug therapy/*epidemiology/*prevention & control
MH  - Breast Neoplasms/drug therapy/*epidemiology/*prevention & control
MH  - Carcinoma, Ehrlich Tumor/drug therapy/pathology
MH  - Cardiotonic Agents/pharmacology/*therapeutic use
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Female
MH  - Gentisates/*metabolism
MH  - Male
MH  - Mice, Inbred BALB C
MH  - Myocardium/pathology/ultrastructure
MH  - S Phase/drug effects
MH  - Sodium Selenite/pharmacology/therapeutic use
MH  - Survival Analysis
OTO - NOTNLM
OT  - Anthracycline cardiotoxicity
OT  - Aspirin
OT  - Cancer chemoprevention
OT  - Cancer treatment
OT  - Gentisic acid
OT  - Selenium
EDAT- 2018/06/11 06:00
MHDA- 2018/07/28 06:00
CRDT- 2018/06/11 06:00
PHST- 2018/03/01 00:00 [received]
PHST- 2018/05/17 00:00 [revised]
PHST- 2018/05/29 00:00 [accepted]
PHST- 2018/06/11 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2018/06/11 06:00 [entrez]
AID - S0009-2797(18)30278-3 [pii]
AID - 10.1016/j.cbi.2018.05.016 [doi]
PST - ppublish
SO  - Chem Biol Interact. 2018 Aug 1;291:29-39. doi: 10.1016/j.cbi.2018.05.016. Epub 
      2018 Jun 7.

PMID- 18175528
OWN - NLM
STAT- MEDLINE
DCOM- 20080110
LR  - 20191110
IS  - 0035-2349 (Print)
IS  - 0035-2349 (Linking)
VI  - 55
IP  - 354
DP  - 2007 Jul
TI  - [From the willow to aspirin].
PG  - 209-16
AB  - At the beginning was the willow bark, which was considered as a medicine by 
      Hippocrates, Dioscorides and Plinus. During the XVIIIth century, the Reverend 
      Edward Stone re-discovered the willow for the cure of agues. In 1829, the french 
      pharmacist Pierre Joseph Leroux isolated salicin. Raffaelle Piria was the first 
      to synthesize salicylic acid from salicin (salicoside). Hermann Kolbe prepared 
      salicylic acid from sodium phenate and carbon dioxide. And then acetylsalicylic 
      acid was first prepared by Charles Gerhardt in 1853, but he did not succeed in 
      identifying its structure. Felix Hoffmann, Arthur Eichengrun and Heinrich Dresen 
      from Bayer Laboratories were at the origin of the use of Aspirin as a medicine. 
      In 1971, John Vane showed that aspirin-like drugs inhibited prostaglandine 
      synthesis.
FAU - Lafont, Olivier
AU  - Lafont O
AD  - Faculté de médecine et de pharmacie de Rouen, 22 boulevard Gambetta, 76183 Rouen 
      1.
LA  - fre
PT  - Historical Article
PT  - Journal Article
PT  - Portrait
TT  - Du saule a l'aspirine.
PL  - France
TA  - Rev Hist Pharm (Paris)
JT  - Revue d'histoire de la pharmacie
JID - 0204315
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*history/therapeutic use
MH  - Chemistry/history
MH  - History of Pharmacy
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Molecular Structure
MH  - Salicylic Acid/chemical synthesis/*history
MH  - *Salix
EDAT- 2008/01/08 09:00
MHDA- 2008/01/11 09:00
CRDT- 2008/01/08 09:00
PHST- 2008/01/08 09:00 [pubmed]
PHST- 2008/01/11 09:00 [medline]
PHST- 2008/01/08 09:00 [entrez]
AID - 10.3406/pharm.2007.6334 [doi]
PST - ppublish
SO  - Rev Hist Pharm (Paris). 2007 Jul;55(354):209-16. doi: 10.3406/pharm.2007.6334.

PMID- 18463514
OWN - NLM
STAT- MEDLINE
DCOM- 20080626
LR  - 20181201
IS  - 0275-004X (Print)
IS  - 0275-004X (Linking)
VI  - 28
IP  - 5
DP  - 2008 May
TI  - Effect of aspirin therapy on photodynamic therapy with verteporfin for choroidal 
      neovascularization.
PG  - 711-6
LID - 10.1097/IAE.0b013e31816079c3 [doi]
AB  - BACKGROUND: Photodynamic therapy (PDT) with verteporfin is used for treatment of 
      choroidal neovascularization in several conditions. Platelet aggregation is one 
      of the mechanisms by which PDT is thought to work. This study sought to examine 
      the hypothesis that systemic use of aspirin, an inhibitor of platelet 
      aggregation, affects the efficacy of PDT. METHODS: A retrospective review was 
      conducted of data for patients treated with PDT at one institution between 2001 
      and 2004. End points included total number of PDT treatments, mean time between 
      PDT treatments, change in visual acuity from baseline to 3 months after last PDT 
      treatment, and concurrent or subsequent treatments other than PDT. RESULTS: A 
      total of 244 eyes of 222 patients met inclusion criteria, of which 102 eyes from 
      92 patients were included in the aspirin taking group. Aspirin takers received an 
      average of 3.11 PDT treatments compared with 2.39 PDT treatments for nonaspirin 
      takers (P = 0.001). Decrease in logMAR visual acuity was greater for aspirin 
      takers (P = 0.0003), and a loss of > or =3 lines was seen in 58% of aspirin 
      takers compared with 35% of nonaspirin takers (P = 0.0003). These differences 
      remained statistically significant after controlling for patient age, lesion 
      type, and lesion size. CONCLUSIONS: Patients taking aspirin required more PDT 
      treatments and had worse visual outcomes than patients not taking aspirin, 
      possibly due to aspirin's ability to inhibit platelet aggregation and thereby 
      diminish the efficacy of PDT.
FAU - Ranchod, Tushar M
AU  - Ranchod TM
AD  - Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, 
      Philadelphia, Pennsylvania, USA.
FAU - Guercio, Jason R
AU  - Guercio JR
FAU - Ying, Gui-Shuang
AU  - Ying GS
FAU - Brucker, Alexander J
AU  - Brucker AJ
FAU - Stoltz, Robert A
AU  - Stoltz RA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Retina
JT  - Retina (Philadelphia, Pa.)
JID - 8309919
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Porphyrins)
RN  - 0X9PA28K43 (Verteporfin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Choroidal Neovascularization/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - *Photochemotherapy
MH  - Photosensitizing Agents/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Porphyrins/*therapeutic use
MH  - Retreatment
MH  - Retrospective Studies
MH  - Verteporfin
MH  - Visual Acuity
EDAT- 2008/05/09 09:00
MHDA- 2008/06/27 09:00
CRDT- 2008/05/09 09:00
PHST- 2008/05/09 09:00 [pubmed]
PHST- 2008/06/27 09:00 [medline]
PHST- 2008/05/09 09:00 [entrez]
AID - 00006982-200805000-00006 [pii]
AID - 10.1097/IAE.0b013e31816079c3 [doi]
PST - ppublish
SO  - Retina. 2008 May;28(5):711-6. doi: 10.1097/IAE.0b013e31816079c3.

PMID- 30189589
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 23
IP  - 9
DP  - 2018 Sep 5
TI  - Separation and Analysis of Aspirin and Metformin HCl Using Green Subcritical 
      Water Chromatography.
LID - 10.3390/molecules23092258 [doi]
LID - 2258
AB  - Organic solvents are widely used in pharmaceutical and chemical industry for 
      chromatographic separations. In recent years, subcritical water chromatography 
      (SBWC) has shown ability in replacing hazardous organic solvents used in 
      traditional high-performance liquid chromatography (HPLC). In this work, a pain 
      killer-aspirin-and an antidiabetic drug-metformin HCl-were successfully separated 
      on an XBridge C18 column using no organic solvents in the subcritical water 
      chromatography mobile phase. Both traditional HPLC and subcritical water 
      chromatography were used for comparison purposes. SBWC separation of metformin 
      HCl and aspirin were achieved at 95 °C and 125 °C, respectively. The recovery for 
      both active pharmaceutical ingredients (APIs) obtained by SBWC is 99% in 
      comparing with the stated content of each drug. The relative standard deviation 
      is less than 1% for SBWC assays developed in this work. This level of accuracy 
      and precision achieved by SBWC is the same as that resulted by the traditional 
      HPLC analysis.
FAU - Doctor, Ninad
AU  - Doctor N
AD  - Department of Chemistry, East Carolina University, Greenville, NC 27858, USA. 
      doctorn11@students.ecu.edu.
FAU - Yang, Yu
AU  - Yang Y
AD  - Department of Chemistry, East Carolina University, Greenville, NC 27858, USA. 
      yangy@ecu.edu.
LA  - eng
PT  - Journal Article
DEP - 20180905
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/*isolation & purification
MH  - Chromatography, High Pressure Liquid
MH  - Metformin/*chemistry/*isolation & purification
PMC - PMC6225179
OTO - NOTNLM
OT  - HPLC
OT  - SBWC
OT  - aspirin
OT  - high performance liquid chromatography
OT  - metformin HCl
OT  - subcritical water chromatography
COIS- The authors declare no conflict of interest.
EDAT- 2018/09/08 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/09/08 06:00
PHST- 2018/08/09 00:00 [received]
PHST- 2018/08/31 00:00 [revised]
PHST- 2018/09/03 00:00 [accepted]
PHST- 2018/09/08 06:00 [entrez]
PHST- 2018/09/08 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
AID - molecules23092258 [pii]
AID - molecules-23-02258 [pii]
AID - 10.3390/molecules23092258 [doi]
PST - epublish
SO  - Molecules. 2018 Sep 5;23(9):2258. doi: 10.3390/molecules23092258.

PMID- 6425869
OWN - NLM
STAT- MEDLINE
DCOM- 19840619
LR  - 20191031
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 13
IP  - 3
DP  - 1984 Mar
TI  - Enteric-coated aspirin, platelet cyclooxygenase activity and function.
PG  - 341-7
AB  - Recent studies evaluating the effect of slow releasing enteric-coated aspirin 
      formulations have reported contradictory findings regarding the bioavailability 
      of the active molecule in the circulating blood and the length of duration of the 
      inhibitory effect on platelet function. In the present study, we have evaluated 
      the effect of a single dose of two commercially available enteric-coated aspirins 
      on platelet arachidonic acid metabolism and function. A single dose of slow 
      releasing aspirin was as effective as fast acting regular aspirin in its effect 
      on cyclooxygenase activity and platelet function in both human and canine 
      platelets. However, in view of its slow releasing property, the onset of 
      inhibition was considerably delayed compared to the action of fast acting aspirin 
      in those subjects who ingested enteric-coated aspirins.
FAU - Rao, G H
AU  - Rao GH
FAU - Radh, E
AU  - Radh E
FAU - Johnson, G J
AU  - Johnson GJ
FAU - White, J G
AU  - White JG
LA  - eng
GR  - CA-21737/CA/NCI NIH HHS/United States
GR  - HL-11880/HL/NHLBI NIH HHS/United States
GR  - HL-16833/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Arachidonic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Biological Availability
MH  - Blood Platelets/drug effects/*enzymology
MH  - *Cyclooxygenase Inhibitors
MH  - Dogs
MH  - Humans
MH  - Prostaglandin-Endoperoxide Synthases/blood
MH  - Tablets, Enteric-Coated
MH  - Thromboxane B2/biosynthesis
MH  - Time Factors
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
AID - 10.1016/0262-1746(84)90049-0 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1984 Mar;13(3):341-7. doi: 
      10.1016/0262-1746(84)90049-0.

PMID- 31096304
OWN - NLM
STAT- MEDLINE
DCOM- 20191211
LR  - 20191217
IS  - 1098-9064 (Electronic)
IS  - 0094-6176 (Linking)
VI  - 45
IP  - 5
DP  - 2019 Jul
TI  - Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than 
      Benefit-A Systematic Review and Meta-Analysis.
PG  - 478-489
LID - 10.1055/s-0039-1687905 [doi]
AB  - Primary prevention of cardiovascular events with aspirin remains controversial, 
      as the risk of bleeding might outweigh the benefits. Recently, new evidence has 
      emerged from the ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events), 
      ASCEND (A Study of Cardiovascular Events in Diabetes), and ASPREE (Effect of 
      Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly) trials. The 
      aim of this study was to perform a systematic review and meta-analysis of 
      aspirin's efficacy and safety in the primary prevention of cardiovascular events 
      in healthy individuals and in individuals with cardiovascular risk factors, and 
      separately in those with diabetes. The Medline database was searched, without 
      time restrictions, for relevant human trials published in English up to December 
      10, 2018, and additional trials were identified from reference lists. Data on 
      efficacy (cardiovascular death and nonfatal myocardial infarction) and safety 
      (major bleeding) were extracted for analysis. In total, 20 randomized trials were 
      identified. Separate meta-analyses were performed on 10 trials including 144,930 
      individuals, who were healthy or had cardiovascular risk factors, and on 4 trials 
      including 20,326 individuals with diabetes. In healthy individuals and 
      individuals with cardiovascular risk factors, aspirin reduced the risk of 
      nonfatal myocardial infarction by 21% (p < 0.001), but had no effect on 
      cardiovascular death (p = 0.52), and increased the risk of major bleeding by 48% 
      (p < 0.001). In individuals with diabetes, aspirin had no effect on nonfatal 
      myocardial infarction (p = 0.93) or cardiovascular death (p = 0.92) and increased 
      the risk of bleeding by 49% (p = 0.13). This meta-analysis suggests that aspirin 
      should not be used on a routine basis in the primary prevention of cardiovascular 
      events, especially in individuals with diabetes.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Christiansen, Mikael
AU  - Christiansen M
AD  - Department of Clinical Biochemistry, Regional Hospital in Horsens, Horsens, 
      Denmark.
FAU - Grove, Erik Lerkevang
AU  - Grove EL
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, 
      Denmark.
FAU - Hvas, Anne-Mette
AU  - Hvas AM
AD  - Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, 
      Denmark.
AD  - Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190516
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/pathology/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Risk Assessment
COIS- AMH reports speaker's fee from CSL Behring and Astellas and fees for congress 
      participation from Bayer A/S, outside the submitted work. ELG has received 
      speaker honoraria or consultancy fees from AstraZeneca, Bayer, Boehringer 
      Ingelheim, Bristol-Myers Squibb, Pfizer, MSD and Roche. MC has no conflict of 
      interest to declare.
EDAT- 2019/05/17 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/05/17 06:00
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/05/17 06:00 [entrez]
AID - 10.1055/s-0039-1687905 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2019 Jul;45(5):478-489. doi: 10.1055/s-0039-1687905. Epub 
      2019 May 16.

PMID- 8708654
OWN - NLM
STAT- MEDLINE
DCOM- 19960910
LR  - 20190501
IS  - 0022-3050 (Print)
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
VI  - 60
IP  - 2
DP  - 1996 Feb
TI  - Aspirin at any dose above 30 mg offers only modest protection after cerebral 
      ischaemia.
PG  - 197-9
AB  - There is continuing debate about the relative efficacy of low (< 100 mg per day), 
      medium (300 to 325 mg per day), and high (> 900 mg per day) doses of aspirin in 
      patients after a transient ischaemic attack or non-disabling stroke. The purpose 
      of this study was to resolve the issue. Thus a minimeta-analysis was performed on 
      data from 10 randomised trials of aspirin only v control treatment in 6171 
      patients after a transient ischaemic attack or nondisabling stroke. The data on 
      the trials were listed in an appendix of the report on the second cycle of the 
      Antiplatelet Trialists' Collaboration. There was virtually no difference in 
      relative risk reduction for low, medium, and high doses of aspirin (13%, 9%, and 
      14% respectively). This equivalence corresponds with the results of the UK-TIA 
      trial in a direct comparison of 300 and 1200 mg. The Dutch TIA trial showed no 
      difference in efficacy of 30 and 283 mg. It is concluded that aspirin at any dose 
      above 30 mg daily prevents 13% (95% confidence interval 4-21) of vascular events 
      and that there is a need for more efficacious drugs.
FAU - Algra, A
AU  - Algra A
AD  - University Department of Neurology, Utrecht, The Netherlands.
FAU - van Gijn, J
AU  - van Gijn J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):255. PMID: 10071120
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Risk Factors
PMC - PMC1073805
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - 10.1136/jnnp.60.2.197 [doi]
PST - ppublish
SO  - J Neurol Neurosurg Psychiatry. 1996 Feb;60(2):197-9. doi: 10.1136/jnnp.60.2.197.

PMID- 27566955
OWN - NLM
STAT- MEDLINE
DCOM- 20170214
LR  - 20190112
IS  - 2352-3964 (Electronic)
IS  - 2352-3964 (Linking)
VI  - 11
DP  - 2016 Sep
TI  - Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription 
      Factor Linked to Cardiovascular Disease and Colon Cancer.
PG  - 157-164
LID - S2352-3964(16)30370-X [pii]
LID - 10.1016/j.ebiom.2016.08.021 [doi]
AB  - Aspirin prevents cardiovascular disease and colon cancer; however aspirin's 
      inhibition of platelet COX-1 only partially explains its diverse effects. We 
      previously identified an aspirin response signature (ARS) in blood consisting of 
      62 co-expressed transcripts that correlated with aspirin's effects on platelets 
      and myocardial infarction (MI). Here we report that 60% of ARS transcripts are 
      regulated by RUNX1 - a hematopoietic transcription factor - and 48% of ARS gene 
      promoters contain a RUNX1 binding site. Megakaryocytic cells exposed to aspirin 
      and its metabolite (salicylic acid, a weak COX-1 inhibitor) showed up regulation 
      in the RUNX1 P1 isoform and MYL9, which is transcriptionally regulated by RUNX1. 
      In human subjects, RUNX1 P1 expression in blood and RUNX1-regulated platelet 
      proteins, including MYL9, were aspirin-responsive and associated with platelet 
      function. In cardiovascular disease patients RUNX1 P1 expression was associated 
      with death or MI. RUNX1 acts as a tumor suppressor gene in gastrointestinal 
      malignancies. We show that RUNX1 P1 expression is associated with colon cancer 
      free survival suggesting a role for RUNX1 in aspirin's protective effect in colon 
      cancer. Our studies reveal an effect of aspirin on RUNX1 and gene expression that 
      may additionally explain aspirin's effects in cardiovascular disease and cancer.
CI  - Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Voora, Deepak
AU  - Voora D
AD  - Duke Center for Applied Genomics & Precision Medicine, Duke University, Durham, 
      NC, United States; Department of Medicine, Duke University, Durham, NC, United 
      States. Electronic address: deepak.voora@duke.edu.
FAU - Rao, A Koneti
AU  - Rao AK
AD  - Department of Medicine and Sol Sherry Thrombosis Research Center, Temple 
      University School of Medicine, Philadelphia, PA, United States.
FAU - Jalagadugula, Gauthami S
AU  - Jalagadugula GS
AD  - Department of Medicine and Sol Sherry Thrombosis Research Center, Temple 
      University School of Medicine, Philadelphia, PA, United States.
FAU - Myers, Rachel
AU  - Myers R
AD  - Duke Center for Applied Genomics & Precision Medicine, Duke University, Durham, 
      NC, United States.
FAU - Harris, Emily
AU  - Harris E
AD  - Duke Center for Applied Genomics & Precision Medicine, Duke University, Durham, 
      NC, United States.
FAU - Ortel, Thomas L
AU  - Ortel TL
AD  - Department of Medicine, Duke University, Durham, NC, United States.
FAU - Ginsburg, Geoffrey S
AU  - Ginsburg GS
AD  - Duke Center for Applied Genomics & Precision Medicine, Duke University, Durham, 
      NC, United States; Department of Medicine, Duke University, Durham, NC, United 
      States. Electronic address: geoffrey.ginsburg@duke.edu.
LA  - eng
GR  - R01 HL109568/HL/NHLBI NIH HHS/United States
GR  - R01 HL118049/HL/NHLBI NIH HHS/United States
GR  - RC1 GM091083/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20160814
PL  - Netherlands
TA  - EBioMedicine
JT  - EBioMedicine
JID - 101647039
RN  - 0 (Core Binding Factor Alpha 2 Subunit)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/metabolism
MH  - Cardiovascular Diseases/*genetics/metabolism
MH  - Cell Line, Tumor
MH  - Colonic Neoplasms/*genetics/metabolism/mortality/pathology
MH  - Core Binding Factor Alpha 2 Subunit/*genetics/metabolism
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation/*drug effects
MH  - *Genetic Predisposition to Disease
MH  - Humans
MH  - Megakaryocytes/drug effects/metabolism
MH  - Neoplasm Staging
MH  - Pharmacogenetics
MH  - Prognosis
PMC - PMC5049978
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Colorectal cancer
OT  - Gene expression profiling
OT  - RUNX1
OT  - Systems pharmacogenomics
EDAT- 2016/08/28 06:00
MHDA- 2017/02/15 06:00
CRDT- 2016/08/28 06:00
PHST- 2016/05/23 00:00 [received]
PHST- 2016/08/10 00:00 [revised]
PHST- 2016/08/12 00:00 [accepted]
PHST- 2016/08/28 06:00 [pubmed]
PHST- 2017/02/15 06:00 [medline]
PHST- 2016/08/28 06:00 [entrez]
AID - S2352-3964(16)30370-X [pii]
AID - 10.1016/j.ebiom.2016.08.021 [doi]
PST - ppublish
SO  - EBioMedicine. 2016 Sep;11:157-164. doi: 10.1016/j.ebiom.2016.08.021. Epub 2016 
      Aug 14.

PMID- 21061520
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - [The present state and problem of gastric ulcer caused by low-dose aspirin].
PG  - 1983-6
AB  - Upper gastrointestinal (GI) injuries induced by non-steroidal anti-inflammatory 
      drugs (NSAID) and low-dose aspirin (LDA) have been increasing, because the number 
      of patients who need to use NSAID, LDA, other anti-platelet drugs and 
      anti-coagulants have been increasing. The aging is one of the most important risk 
      factors of upper GI injuries induced by LDA, such as gastric ulcer. Since 
      atypical symptoms often lead to a delay in diagnosis and treatment in the elderly 
      patients, endoscopic examination should be considered especially in the elderly 
      patients to detect upper GI lesions before using LDA.
FAU - Hirasawa, Tomosuke
AU  - Hirasawa T
AD  - Division of Gastro-enterology, Department of Internal Medicine, Jichi Medical 
      University.
FAU - Satoh, Kiichi
AU  - Satoh K
FAU - Sugano, Kentaro
AU  - Sugano K
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Humans
MH  - Peptic Ulcer/*chemically induced
EDAT- 2010/11/11 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Nov;68(11):1983-6.

PMID- 858010
OWN - NLM
STAT- MEDLINE
DCOM- 19770630
LR  - 20190509
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 59
IP  - 4
DP  - 1977 Apr
TI  - Aspirin at therapeutic concentrations does not affect 5-hydroxytryptamine uptake 
      by platelets.
PG  - 661-2
AB  - Aspirin at therapeutic concentrations does not inhibit the uptake of 
      5-hydroxytryptamine (5-HT) by blood platelets nor induce release of 5-HT from 
      platelets, although platelet aggregation responses to collagen and arachidonic 
      acid (which are dependent on platelet prostaglandin synthesis) are abolished. 
      This does not support an earlier claim that aspirin's effects on platelet 
      function include inhibition of 5-HT transport.
FAU - Drummond, A H
AU  - Drummond AH
FAU - MacIntyre, D E
AU  - MacIntyre DE
FAU - Olverman, H J
AU  - Olverman HJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 333DO1RDJY (Serotonin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/*metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Osmolar Concentration
MH  - Platelet Aggregation/drug effects
MH  - Serotonin/*blood
MH  - Time Factors
PMC - PMC1667754
EDAT- 1977/04/01 00:00
MHDA- 1977/04/01 00:01
CRDT- 1977/04/01 00:00
PHST- 1977/04/01 00:00 [pubmed]
PHST- 1977/04/01 00:01 [medline]
PHST- 1977/04/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1977.tb07735.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1977 Apr;59(4):661-2. doi: 10.1111/j.1476-5381.1977.tb07735.x.

PMID- 9162173
OWN - NLM
STAT- MEDLINE
DCOM- 19970529
LR  - 20181130
IS  - 0397-9148 (Print)
IS  - 0397-9148 (Linking)
VI  - 29
IP  - 2
DP  - 1997 Feb
TI  - [Importance of in vivo and in vitro studies of leukotrienes. Application to the 
      particular instance of aspirin].
PG  - 28-35
AB  - The major role played by leukotrienes in the inflammatory reaction is today 
      clearly demonstrated. These newly-formed mediators show powerful pro-inflammatory 
      activities and their release from various cell types may be induced by agonists 
      including the allergens. Therefore, leukotriene levels in biological fluids may 
      represent a reliable image of the local or systemic inflammatory reaction and 
      their release in vitro after incubation of the blood leukocytes in the presence 
      of a specific allergen is today widely used for allergy diagnosis. Leukotrienes 
      metabolism is deeply involved in aspirin intolerance or so-called pseudo allergy 
      and, in spite of that the exact mechanism involved is still unknown, leukotriene 
      release in vitro by ASA in the presence C5a represent the first reliable test for 
      this diagnosis. The results of the recent clinical trials concerning the activity 
      of anti-leukotrienes in vivo have led to a real therapeutic hope.
FAU - Sainte-Laudy, J
AU  - Sainte-Laudy J
AD  - Unité d'immuno-allergologie clinique, laboratoire Cerba, Cergy-Pontoise, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Intérêt de l'étude in vivo et in vitro des leucotriènes. Application au cas 
      particulier de l'aspirine.
PL  - France
TA  - Allerg Immunol (Paris)
JT  - Allergie et immunologie
JID - 0245775
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Leukotriene Antagonists)
RN  - 0 (Leukotrienes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology
MH  - Aspirin/*adverse effects/pharmacology
MH  - Biomarkers
MH  - Body Fluids/chemistry
MH  - Cells, Cultured
MH  - Drug Hypersensitivity/*physiopathology
MH  - Humans
MH  - Inflammation/*physiopathology
MH  - Leukocytes/drug effects/*metabolism
MH  - Leukotriene Antagonists
MH  - Leukotrienes/analysis/*physiology
RF  - 65
EDAT- 1997/02/01 00:00
MHDA- 1997/02/01 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1997/02/01 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
PST - ppublish
SO  - Allerg Immunol (Paris). 1997 Feb;29(2):28-35.

PMID- 23664596
OWN - NLM
STAT- MEDLINE
DCOM- 20140110
LR  - 20220311
IS  - 1532-2823 (Electronic)
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 89
IP  - 1
DP  - 2013 Jul
TI  - Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in 
      adults with diabetes mellitus.
PG  - 9-18
LID - S0952-3278(13)00054-9 [pii]
LID - 10.1016/j.plefa.2013.03.005 [doi]
AB  - INTRODUCTION: Many diabetics are insensitive to aspirin's platelet 
      anti-aggregation effects. The possible modulating effects of co-administration of 
      aspirin and fish oil in subjects with diabetes are poorly characterized. 
      PARTICIPANTS AND METHODS: Thirty adults with type 2 diabetes mellitus were 
      treated with aspirin 81 mg/d for 7 days, then with fish oil 4 g/day for 28 days, 
      then the combination of fish oil and aspirin for another 7 days. RESULTS: Aspirin 
      alone and in combination with fish oil reduced platelet aggregation in most 
      participants. Five of 7 participants classified as aspirin insensitive 1 week 
      after daily aspirin ingestion were sensitive after the combination. Although some 
      platelet aggregation measures correlated positively after aspirin and fish oil 
      ingestion alone and (in combination) in all individuals, correlation was only 
      observed in those who were aspirin insensitive after ingestion of the 
      combination. CONCLUSIONS: Co-administration of aspirin and fish oil may reduce 
      platelet aggregation more than aspirin alone in adults with diabetes mellitus.
CI  - Copyright © 2013 Elsevier Ltd. All rights reserved.
FAU - Block, Robert C
AU  - Block RC
AD  - Department of Public Health Sciences, The University of Rochester School of 
      Medicine and Dentistry, Rochester, New York, USA. robert_block@urmc.rochester.edu
FAU - Abdolahi, Amir
AU  - Abdolahi A
FAU - Smith, Brian
AU  - Smith B
FAU - Meednu, N
AU  - Meednu N
FAU - Thevenet-Morrison, Kelly
AU  - Thevenet-Morrison K
FAU - Cai, Xueya
AU  - Cai X
FAU - Cui, Huadong
AU  - Cui H
FAU - Mousa, Shaker
AU  - Mousa S
FAU - Brenna, J Thomas
AU  - Brenna JT
FAU - Georas, S
AU  - Georas S
LA  - eng
SI  - ClinicalTrials.gov/NCT01181882
GR  - R01 AT007003/AT/NCCIH NIH HHS/United States
GR  - P30 ES001247/ES/NIEHS NIH HHS/United States
GR  - R01HL071933/HL/NHLBI NIH HHS/United States
GR  - R01 HL071933/HL/NHLBI NIH HHS/United States
GR  - T32 HL007937/HL/NHLBI NIH HHS/United States
GR  - KL2RR024136/RR/NCRR NIH HHS/United States
GR  - R21 HL102582/HL/NHLBI NIH HHS/United States
GR  - 5R21HL102582-02/HL/NHLBI NIH HHS/United States
GR  - P30ES001247/ES/NIEHS NIH HHS/United States
GR  - 1R01AT007003-01/AT/NCCIH NIH HHS/United States
GR  - UL1 RR024160/RR/NCRR NIH HHS/United States
GR  - T32HL007937/HL/NHLBI NIH HHS/United States
GR  - KL2 RR024136/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130507
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Fish Oils)
RN  - 0 (NF-kappa B)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Fish Oils/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - NF-kappa B/*metabolism
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests
PMC - PMC3683095
MID - NIHMS463018
EDAT- 2013/05/15 06:00
MHDA- 2014/01/11 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/29 00:00 [received]
PHST- 2013/03/10 00:00 [revised]
PHST- 2013/03/11 00:00 [accepted]
PHST- 2013/05/14 06:00 [entrez]
PHST- 2013/05/15 06:00 [pubmed]
PHST- 2014/01/11 06:00 [medline]
AID - S0952-3278(13)00054-9 [pii]
AID - 10.1016/j.plefa.2013.03.005 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2013 Jul;89(1):9-18. doi: 
      10.1016/j.plefa.2013.03.005. Epub 2013 May 7.

PMID- 30759035
OWN - NLM
STAT- MEDLINE
DCOM- 20190417
LR  - 20220330
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 30
IP  - 2
DP  - 2019
TI  - Very-low-dose twice-daily aspirin maintains platelet inhibition and improves 
      haemostasis during dual-antiplatelet therapy for acute coronary syndrome.
PG  - 148-157
LID - 10.1080/09537104.2019.1572880 [doi]
AB  - Higher aspirin doses may be inferior in ticagrelor-treated acute coronary 
      syndrome (ACS) patients and reducing bleeding risk whilst maintaining 
      antithrombotic benefits could improve outcomes. We characterized the 
      pharmacodynamics of a novel dual-antiplatelet-therapy regimen consisting of 
      very-low-dose twice-daily (BD) aspirin with standard-dose ticagrelor. A total of 
      20 ticagrelor-treated ACS patients entered a randomized crossover to take aspirin 
      20 mg BD (12-hourly) during one 14-day period and 75 mg once-daily (OD) in the 
      other. After 14 days of treatment, serum thromboxane (TX)B(2) and 
      light-transmittance aggregometry were assessed pre- and 2 h post-morning-dose, 
      bleeding time was measured post-dose, and TXA(2) and prostacyclin stable 
      metabolites were measured in urine collected 2 h post-morning-dose. Data are 
      expressed as mean ± SD. After 14 days treatment, serum TXB(2) levels were 
      significantly greater 2 h post-dosing with aspirin 20 mg BD vs. 75 mg OD (3.0 ± 
      3.6 ng/mL vs. 0.8 ± 1.9 ng/mL; p = 0.018) whereas pre-dosing levels were not 
      significantly different (3.5 ± 4.1 ng/mL vs. 2.5 ± 3.1 ng/mL, p = 0.23). 1-mmol/L 
      arachidonic acid-induced platelet aggregation was similarly inhibited by both 
      regimens pre-dose (8.5 ± 14.3% vs. 5.1 ± 3.6%, p = 0.24) and post-dose (8.7 ± 
      14.2% vs. 6.6 ± 5.3%; p = 0.41). Post-dose bleeding time was shorter with 20 mg 
      BD (680 ± 306 s vs. 834 ± 386 s, p = 0.02). Urinary prostacyclin and TX 
      metabolite excretion were not significantly different. In conclusion, compared to 
      aspirin 75 mg OD, aspirin 20 mg BD provided consistent inhibition of platelet 
      TXA(2) release and aggregation, and improved post-dose hemostasis, in 
      ticagrelor-treated ACS patients. Further studies are warranted to assess whether 
      this regimen improves the balance of clinical efficacy and safety.
FAU - Parker, William A E
AU  - Parker WAE
AUID- ORCID: 0000-0002-7822-8852
AD  - a Department of Infection, Immunity and Cardiovascular Disease , University of 
      Sheffield , Sheffield , United Kingdom.
AD  - b Department of Cardiology , Sheffield Teaching Hospitals NHS Foundation Trust , 
      Sheffield , UK.
FAU - Orme, Rachel C
AU  - Orme RC
AD  - a Department of Infection, Immunity and Cardiovascular Disease , University of 
      Sheffield , Sheffield , United Kingdom.
AD  - b Department of Cardiology , Sheffield Teaching Hospitals NHS Foundation Trust , 
      Sheffield , UK.
FAU - Hanson, Jessica
AU  - Hanson J
AD  - a Department of Infection, Immunity and Cardiovascular Disease , University of 
      Sheffield , Sheffield , United Kingdom.
FAU - Stokes, Hannah M
AU  - Stokes HM
AD  - a Department of Infection, Immunity and Cardiovascular Disease , University of 
      Sheffield , Sheffield , United Kingdom.
FAU - Bridge, Claire M
AU  - Bridge CM
AD  - a Department of Infection, Immunity and Cardiovascular Disease , University of 
      Sheffield , Sheffield , United Kingdom.
FAU - Shaw, Patricia A
AU  - Shaw PA
AD  - a Department of Infection, Immunity and Cardiovascular Disease , University of 
      Sheffield , Sheffield , United Kingdom.
FAU - Sumaya, Wael
AU  - Sumaya W
AD  - a Department of Infection, Immunity and Cardiovascular Disease , University of 
      Sheffield , Sheffield , United Kingdom.
AD  - b Department of Cardiology , Sheffield Teaching Hospitals NHS Foundation Trust , 
      Sheffield , UK.
FAU - Thorneycroft, Kirstie
AU  - Thorneycroft K
AD  - a Department of Infection, Immunity and Cardiovascular Disease , University of 
      Sheffield , Sheffield , United Kingdom.
FAU - Petrucci, Giovanna
AU  - Petrucci G
AD  - c Institute of Pharmacology , Catholic University School of Medicine , Rome , 
      Italy.
FAU - Porro, Benedetta
AU  - Porro B
AD  - d Centro Cardiologico Monzino , Istituto di Ricovero e Cura a Carattere 
      Scientifico Cardiologico Monzino , Milan , Italy.
FAU - Judge, Heather M
AU  - Judge HM
AD  - a Department of Infection, Immunity and Cardiovascular Disease , University of 
      Sheffield , Sheffield , United Kingdom.
FAU - Ajjan, Ramzi A
AU  - Ajjan RA
AD  - e Leeds Institute of Cardiovascular and Metabolic Medicine , University of Leeds 
      , Leeds , UK.
FAU - Rocca, Bianca
AU  - Rocca B
AD  - c Institute of Pharmacology , Catholic University School of Medicine , Rome , 
      Italy.
FAU - Storey, Robert F
AU  - Storey RF
AD  - a Department of Infection, Immunity and Cardiovascular Disease , University of 
      Sheffield , Sheffield , United Kingdom.
AD  - b Department of Cardiology , Sheffield Teaching Hospitals NHS Foundation Trust , 
      Sheffield , UK.
LA  - eng
GR  - FS/15/82/31824/BHF_/British Heart Foundation/United Kingdom
GR  - FS/18/49/33752/BHF_/British Heart Foundation/United Kingdom
GR  - MC_PC_17176/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20190213
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Female
MH  - Hemostasis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
PMC - PMC6425913
OTO - NOTNLM
OT  - Aspirin
OT  - P2Y inhibitors
OT  - bleeding
OT  - thromboxane
OT  - ticagrelor
EDAT- 2019/02/14 06:00
MHDA- 2019/04/18 06:00
CRDT- 2019/02/14 06:00
PHST- 2019/02/14 06:00 [pubmed]
PHST- 2019/04/18 06:00 [medline]
PHST- 2019/02/14 06:00 [entrez]
AID - 1572880 [pii]
AID - 10.1080/09537104.2019.1572880 [doi]
PST - ppublish
SO  - Platelets. 2019;30(2):148-157. doi: 10.1080/09537104.2019.1572880. Epub 2019 Feb 
      13.

PMID- 1159076
OWN - NLM
STAT- MEDLINE
DCOM- 19751204
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 56
IP  - 3
DP  - 1975 Sep
TI  - The mechanism of the effect of aspirin on human platelets. I. Acetylation of a 
      particulate fraction protein.
PG  - 624-32
AB  - Aspirin (acetylsalicylic acid) inhibits platelet prostaglandin synthesis and the 
      ADP- and collagen-induced platelet release reaction. The mechanism of the 
      inhibitory effect is unknown but may involve protein acetylation, since aspirin 
      acetylates a variety of substrates, including platelet protein. We have examined 
      the relationship between protein acetylation and aspirin's physiologic effect on 
      platelets. Suspensions of washed human platelets were incubated at 37 degrees C 
      with (3H)aspirin, and incorporation of radioactivity into protein was analyzed by 
      sodium dodecyl sulfate polyacrylamide gel electrophoresis. Exposure to 
      (acetyl-3H)aspirin but not (aromatic ring-3H)aspirin resulted in radioactive 
      labeling of three platelet proteins, suggesting that the drug acetylates these 
      three proteins. The acetylation of two of the proteins (located in the 
      supernatant fraction) was not saturable, implying that these reactions may not be 
      physiologically significant. Acetylation of the third protein, approximate mol wt 
      85,000 (located in the particulate fraction), saturated at an aspirin 
      concentration of 30 muM and was complete within 20 min. Platelets prepared from 
      aspirin-treated donors did not incorporate any (acetyl-3H)aspirin radioactivity 
      into the particulate protein for 2 days after drug treatment and did not show 
      full pretreatment uptake of radioactivity for 12 days thereafter. The course of 
      increasing incorporation of (acetyl-3H)aspirin radioactivity parralleled that of 
      platelet turnover. Therefore, in addition to its saturability, acetylation of the 
      particulate fraction protein by aspirin was permanent. In two respects, the 
      inhibition of platelet function by aspirin correlates well with the 
      aspirin-mediated acetylation of the particulate fraction protein. Both persist 
      for the life-span of the aspirin-treated platelet, and both occur at a similar 
      saturating aspirin concentration. The evidence suggests that the physiologic 
      effect of aspirin on human platelets is produced by acetylation of a single 
      protein located in the particulate fraction. The acetylated protein may be 
      related to cyclo-oxygenase, the prostaglandin G2 biosynthetic enzyme.
FAU - Roth, G J
AU  - Roth GJ
FAU - Majerus, P W
AU  - Majerus PW
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Acetates)
RN  - 0 (Blood Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/metabolism
MH  - Acetylation
MH  - Aspirin/analogs & derivatives/metabolism/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Blood Proteins/*metabolism
MH  - Depression, Chemical
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Humans
MH  - In Vitro Techniques
MH  - Molecular Weight
MH  - Subcellular Fractions/metabolism
PMC - PMC301910
EDAT- 1975/09/01 00:00
MHDA- 1975/09/01 00:01
CRDT- 1975/09/01 00:00
PHST- 1975/09/01 00:00 [pubmed]
PHST- 1975/09/01 00:01 [medline]
PHST- 1975/09/01 00:00 [entrez]
AID - 10.1172/JCI108132 [doi]
PST - ppublish
SO  - J Clin Invest. 1975 Sep;56(3):624-32. doi: 10.1172/JCI108132.

PMID- 35490093
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20220712
IS  - 2352-3840 (Electronic)
IS  - 1499-2671 (Linking)
VI  - 46
IP  - 4
DP  - 2022 Jun
TI  - Trends and Determinants of Self-reported Aspirin Use Among Patients With Diabetes 
      Stratified by Presence and Risk of Cardiovascular Diseases: A Repeated 
      Pan-Canadian Cross-sectional Study.
PG  - 361-368.e5
LID - S1499-2671(21)00464-0 [pii]
LID - 10.1016/j.jcjd.2021.11.008 [doi]
AB  - OBJECTIVES: Our aim in this study was to quantify the prevalence over time and 
      identify determinants of acetylsalicylic acid (ASA) use in patients with diabetes 
      with and without cardiovascular disease (CVD) in a representative Canadian sample 
      from 2005 to 2014, and to determine whether the use of ASA among patients with 
      diabetes changed after the Diabetes Canada clinical practice guidelines updates. 
      METHODS: Data from the Canadian Community Health Survey were used. Respondents 
      who were at least 35 years of age and diagnosed with diabetes---not during 
      pregnancy---were included and categorized into secondary prevention (previous 
      heart disease or stroke) or primary prevention (high or low CVD risk) groups. A 
      stratified and weighted multivariable logistic regression model was used to 
      quantify ASA use and identify determinants of use. RESULTS: Our sample consisted 
      of 15,100 respondents with diabetes (weighted sample of ∼2,429,900). 
      Approximately 70% and 50% of Canadians with diabetes used ASA for secondary and 
      primary prevention, respectively. Overall, the trend of ASA use was stable over 
      the study period in both the secondary and the primary prevention groups. This 
      trend did not change after the clinical practice guidelines update in 2008. 
      Having a regular doctor and older age were associated with increased use of ASA. 
      Other significant determinants independently associated with ASA use included 
      income, body mass index, smoking, immigration status, gender and chronic 
      diseases. CONCLUSIONS: Among patients with diabetes in Canada, ASA appears to be 
      underutilized in secondary prevention and high-risk primary prevention 
      populations. Future research should address whether regular use of ASA is 
      associated with clinical outcomes among patients with diabetes.
CI  - Copyright © 2021 Canadian Diabetes Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Seng Bong Ing, Nathan
AU  - Seng Bong Ing N
AD  - School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
FAU - Amoud, Razan
AU  - Amoud R
AD  - School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
FAU - Gamble, John-Michael
AU  - Gamble JM
AD  - School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
FAU - Alsabbagh, Mhd Wasem
AU  - Alsabbagh MW
AD  - School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada. 
      Electronic address: wasem.alsabbagh@uwaterloo.ca.
LA  - eng
PT  - Journal Article
DEP - 20211230
PL  - Canada
TA  - Can J Diabetes
JT  - Canadian journal of diabetes
JID - 101148810
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Canada/epidemiology
MH  - *Cardiovascular Diseases/drug therapy/epidemiology/prevention & control
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus/drug therapy/epidemiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Self Report
OTO - NOTNLM
OT  - aspirin
OT  - aspirine
OT  - diabetes mellitus
OT  - diabète sucré
OT  - drug utilization
OT  - primary prevention
OT  - prévention primaire
OT  - prévention secondaire
OT  - secondary prevention
OT  - tendances
OT  - trends
OT  - utilisation de médicaments
EDAT- 2022/05/01 06:00
MHDA- 2022/07/14 06:00
CRDT- 2022/04/30 22:07
PHST- 2020/12/29 00:00 [received]
PHST- 2021/10/16 00:00 [revised]
PHST- 2021/11/13 00:00 [accepted]
PHST- 2022/05/01 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
PHST- 2022/04/30 22:07 [entrez]
AID - S1499-2671(21)00464-0 [pii]
AID - 10.1016/j.jcjd.2021.11.008 [doi]
PST - ppublish
SO  - Can J Diabetes. 2022 Jun;46(4):361-368.e5. doi: 10.1016/j.jcjd.2021.11.008. Epub 
      2021 Dec 30.

PMID- 7468475
OWN - NLM
STAT- MEDLINE
DCOM- 19810421
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 47
IP  - 2
DP  - 1981 Feb
TI  - Lack of effect of aspirin on myocardial infarct size in the dog.
PG  - 258-64
AB  - Pretreatment with platelet-inhibitory doses of aspirin (3 mg/kg body weight) has 
      been shown to augment epicardial collateral flow by more than 50 percent (p less 
      than 0.05) 4 hours after ligation of the left anterior descending coronary artery 
      in dogs. To determine whether this favorable influence of aspirin is sufficient 
      to decrease the amount of infarcted tissue, either intravenous aspirin, 3 mg/kg 
      (n = 17), or saline solution (n = 17) was administered to dogs 10 minutes before 
      occlusion of the left anterior descending coronary artery. Administration of 
      saline solution or aspirin was repeated every 24 hours. By 72 hours, 5 dogs in 
      each treatment group had died. Survivors were killed at 72 hours. The portion of 
      the left ventricle at risk of infarction was delineated by perfusion of the 
      aortic root with Evans blue and simultaneous perfusion of the distal left 
      anterior descending coronary artery with saline solution under equal physiologic 
      pressures. Slices of the stained heart were incubated with triphenyltetrazolium 
      to identify gross infarct (with histologic confirmation). Total mass of left 
      ventricle, myocardium at risk, and infarct size were measured in each dog. A 
      direct relation was found between the mass at risk and the mass infarcted (r = 
      0.84, p less than 0.001). Aspirin-treated dogs did not differ from control dogs 
      in percent ventricle at risk (mean +/- standard error 37 +/- 2 versus 40 +/- 2), 
      percent infarct weight/left ventricle (29 +/- 3 versus 31 +/- 2) or percent 
      infarct weight/weight of ventricle at risk (78 +/- 4 versus 77 +/- 3). Thus, 
      despite aspirin's ability to inhibit platelet aggregation and to increase 
      epicardial collateral flow by more than 50 percent, aspirin treatment failed to 
      reduce infarct size in this dog model.
FAU - Bonow, R O
AU  - Bonow RO
FAU - Lipson, L C
AU  - Lipson LC
FAU - Sheehan, F H
AU  - Sheehan FH
FAU - Capurro, N L
AU  - Capurro NL
FAU - Isner, J M
AU  - Isner JM
FAU - Roberts, W C
AU  - Roberts WC
FAU - Goldstein, R E
AU  - Goldstein RE
FAU - Epstein, S E
AU  - Epstein SE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Coronary Disease/physiopathology
MH  - Coronary Vessels/physiopathology
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Male
MH  - Myocardial Infarction/*drug therapy
MH  - Risk
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
AID - 0002-9149(81)90395-7 [pii]
AID - 10.1016/0002-9149(81)90395-7 [doi]
PST - ppublish
SO  - Am J Cardiol. 1981 Feb;47(2):258-64. doi: 10.1016/0002-9149(81)90395-7.

PMID- 32453611
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 26
DP  - 2020 Jan-Dec
TI  - Interaction Between Low-Dose Aspirin and Nonsteroidal Anti-Inflammatory Drugs Can 
      Compromise Aspirin's Efficacy in Preventing Venous Thrombosis Following Total 
      Joint Arthroplasty.
PG  - 1076029620920373
LID - 10.1177/1076029620920373 [doi]
LID - 1076029620920373
AB  - Total joint arthroplasty is a rapid recovery procedure with patients optimized 
      quickly in preparation for discharge. Two significant postoperative goals are 
      effective pain management and prevention of postoperative venous thromboembolism 
      (VTE). Low-risk patients receive aspirin 81 mg twice daily for VTE prophylaxis; 
      this dosing regimen has been reduced over the past few years from 325 mg to 162 
      mg to 81 mg twice daily. Unless contraindications exist, all patients receive 
      multimodal pain management that includes the use of celecoxib or meloxicam. Upon 
      reduction of the aspirin dose to 81 mg twice daily, we rapidly identified 2 
      patients who developed a pulmonary embolus when celecoxib or meloxicam was 
      administered concurrently with aspirin. The interaction between nonsteroidal 
      anti-inflammatory drugs (NSAIDs) and low-dose aspirin varies among the different 
      NSAIDs. It is also highly dependent on numerous factors, including time of 
      administration, dose of aspirin, and both pharmacodynamics and dose of the NSAID. 
      Real-world outcomes of concomitant administration of NSAIDs with low-dose aspirin 
      led to increased incidence of VTE, possibly due to competitive inhibition of 
      aspirin at platelet receptor sites. This interaction was mitigated by altering 
      the administration times of both agents.
FAU - Krauss, Eugene
AU  - Krauss E
AD  - Syosset Hospital, Northwell Health, New York Orthopaedic and Spine Center, Great 
      Neck, NY, USA.
AD  - Zucker School of Medicine at Hofstra/Northwell, Hofstra University School of 
      Medicine, New York Orthopaedic and Spine Center, Great Neck, NY, USA.
AD  - Syosset Hospital, Northwell Health, Syosset, NY, USA.
FAU - Cronin, MaryAnne
AU  - Cronin M
AUID- ORCID: 0000-0002-7498-1564
AD  - Syosset Hospital, Northwell Health, Syosset, NY, USA.
FAU - Dengler, Nancy
AU  - Dengler N
AD  - Syosset Hospital, Northwell Health, Syosset, NY, USA.
FAU - Segal, Ayal
AU  - Segal A
AD  - Syosset Hospital, Northwell Health, New York Orthopaedic and Spine Center, Great 
      Neck, NY, USA.
AD  - Syosset Hospital, Northwell Health, Syosset, NY, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Arthroplasty, Replacement/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Venous Thrombosis/drug therapy/*physiopathology
PMC - PMC7370567
OTO - NOTNLM
OT  - celecoxib
OT  - drug interaction
OT  - low-dose aspirin
OT  - nonsteroidal anti-inflammatory drug
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/05/27 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
AID - 10.1177_1076029620920373 [pii]
AID - 10.1177/1076029620920373 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620920373. doi: 
      10.1177/1076029620920373.

PMID- 8667182
OWN - NLM
STAT- MEDLINE
DCOM- 19960806
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 277
IP  - 3
DP  - 1996 Jun
TI  - Zwitterionic phospholipids enhance aspirin's therapeutic activity, as 
      demonstrated in rodent model systems.
PG  - 1221-7
AB  - We have recently reported that the Gl toxicity of aspirin is markedly reduced 
      when the drug is preassociated with the zwitterionic phospholipid 
      dipalmitoylphosphatidycholine (DPPC) before intragastric administration. The 
      present study was designed to determine whether the biological availability and 
      therapeutic activity of aspirin were affected by chemically associating the drug 
      with DPPC. To evaluate this, we compared the kinetics of entry of labeled aspirin 
      into the blood, after intragastric administration of the drug in the free and 
      lipid-associated states; we also tested the ability of the above formulations to 
      inhibit fever, inflammation and pain in appropriate rodent model systems. We 
      found that although the Gl absorption of free aspirin and that of the 
      aspirin/DPPC complex were similar, in all three rodent models the complex had 
      significantly greater antipyretic, anti-inflammatory and analgesic efficacy than 
      aspirin alone. Dose-response analyses employing the fever model demonstrated that 
      potency of aspirin to reduce fever was increased 5 to 10-fold when the aspirin 
      was intragastrically administered in the lipid-associated state. We conclude that 
      the therapeutic activity of aspirin to inhibit fever, inflammation and pain is 
      remarkably enhanced when the drug is intragastrically administered in chemical 
      association with the zwitterionic phospholipid DPPC. A number of molecular 
      mechanisms have been proposed to explain the observed phospholipid-dependent 
      increase in aspirin's therapeutic activity.
FAU - Lichtenberger, L M
AU  - Lichtenberger LM
AD  - Department of Integrative Biology, University of Texas-Houston Medical School, 
      USA.
FAU - Ulloa, C
AU  - Ulloa C
FAU - Vanous, A L
AU  - Vanous AL
FAU - Romero, J J
AU  - Romero JJ
FAU - Dial, E J
AU  - Dial EJ
FAU - Illich, P A
AU  - Illich PA
FAU - Walters, E T
AU  - Walters ET
LA  - eng
GR  - DK 33239/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 2644-64-6 (1,2-Dipalmitoylphosphatidylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 1,2-Dipalmitoylphosphatidylcholine/*pharmacology
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Body Temperature/drug effects
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Inflammation/drug therapy
MH  - Male
MH  - Pain/drug therapy
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1996 Jun;277(3):1221-7.

PMID- 31613300
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20200727
IS  - 2050-7518 (Electronic)
IS  - 2050-750X (Linking)
VI  - 7
IP  - 44
DP  - 2019 Nov 28
TI  - Carrier-free self-built aspirin nanorods as anti-aggregation agents towards 
      alpha-crystallin-derived peptide aggregates: potential implications in 
      non-invasive cataract therapy.
PG  - 6945-6954
LID - 10.1039/c9tb01435g [doi]
AB  - The aggregation of the α-crystallin protein is the pathological hallmark of 
      cataract. In the current work, peptide fragments derived from native α-crystallin 
      were synthesized and explored as a peptide-based crystallin aggregation model 
      towards cataract. The anti-aggregation potential of aspirin was evaluated towards 
      these peptide-generated aggregates as well as towards the α-crystallin aggregate. 
      The results demonstrated that aspirin had the capacity to inhibit crystallin and 
      crystallin-derived peptide aggregation and could act as a potential therapeutic 
      agent in mitigating cataract. Computational studies were also carried out to 
      study the interaction between the model peptides and aspirin. The results 
      revealed the existence of molecular interactions between the peptides and 
      aspirin, which had a significant impact on the secondary structure of the 
      peptides and potentially modulated their assembly and aggregation behavior. The 
      formation of self-built aspirin nanorods was also explored and their ability to 
      inhibit the aggregation of model cataract peptides and α-crystallin aggregation 
      was validated. These findings open up the possibility of using small 
      molecule-based nanotherapeutics for cataract merely through topical applications, 
      which can be beneficial to cataract patients.
FAU - Bisht, Anjali
AU  - Bisht A
AD  - Institute of Nano Science and Technology, Mohali, Punjab-160062, India. 
      jyoti@inst.ac.in ehesan.ali@inst.ac.in.
FAU - Sharma, Manju
AU  - Sharma M
FAU - Sharma, Shikha
AU  - Sharma S
FAU - Ali, Md Ehesan
AU  - Ali ME
FAU - Panda, Jiban Jyoti
AU  - Panda JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191015
PL  - England
TA  - J Mater Chem B
JT  - Journal of materials chemistry. B
JID - 101598493
RN  - 0 (Peptide Fragments)
RN  - 0 (Peptides)
RN  - 0 (alpha-Crystallins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*chemistry/*pharmacology
MH  - Cataract/*therapy
MH  - Computer Simulation
MH  - Models, Molecular
MH  - Nanotubes/*chemistry
MH  - Peptide Fragments
MH  - Peptides/*chemistry
MH  - Protein Conformation
MH  - alpha-Crystallins/*chemistry
EDAT- 2019/10/16 06:00
MHDA- 2020/07/28 06:00
CRDT- 2019/10/16 06:00
PHST- 2019/10/16 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2019/10/16 06:00 [entrez]
AID - 10.1039/c9tb01435g [doi]
PST - ppublish
SO  - J Mater Chem B. 2019 Nov 28;7(44):6945-6954. doi: 10.1039/c9tb01435g. Epub 2019 
      Oct 15.

PMID- 26044408
OWN - NLM
STAT- MEDLINE
DCOM- 20170217
LR  - 20191113
IS  - 1875-5704 (Electronic)
IS  - 1567-2018 (Linking)
VI  - 13
IP  - 4
DP  - 2016
TI  - Improving the Efficiency and Safety of Aspirin by Complexation with the Natural 
      Polysaccharide Arabinogalactan.
PG  - 582-9
AB  - BACKGROUND: The main undesirable side effect of the aspirin is the damage to the 
      gastrointestinal mucosa, leading to the formation of erosions, peptic ulcers, and 
      as a result, bleeding. To overcome this problem "host-guest" complexation with 
      natural polysaccharide arabinogalactan could be applied. METHODS: The complex 
      with a weight ratio of ASA:AG = 1:10 was prepared by solid phase method in a 
      rotary mill. Complex was administered orally to mice or rats at doses of 250, 500 
      or 1000 mg/kg. The "acetic acid induced writhing" and "hot plate" tests were used 
      as an in vivo pain models. The antiinflammatory activity was studied using 
      "histamine swelling" test. Also, long-term (30 days) oral introduction of the 
      complex to rats was performed and gastric mucosa damages were evaluated. In all 
      experiments pure aspirin (ASA) was used as a control in appropriate doses. 
      RESULTS: The minimal effective analgesic dose of the complex was 250 mg/kg, 
      equivalent to 23 mg/kg of ASA, a dose in which aspirin itself was not active. The 
      anti-inflammatory effect was found at relatively higher doses: 500 and 1000 mg/kg 
      (46 and 92 mg/kg of ASA respectively) for the complex and only at 100 mg/kg for 
      the ASA. Long-term introduction of the complex at doses of 250 and 500 mg/kg was 
      safe for gastric mucosa, while ASA at the dose of 50 mg/kg showed a strong 
      gastric mucosal damage. CONCLUSION: The effective analgesic and anti-inflammatory 
      doses of 1:10 aspirin complex with arabinogalactan are twice less compared to 
      pure aspirin and safer for the gastrointestinal mucosa.
FAU - Khvostov, Mikhail V
AU  - Khvostov MV
AD  - Laboratory of Pharmacological Research, N.N. Vorozhtsov Novosibirsk Institute of 
      Organic Chemistry SB RAS, 630090, Novosibirsk, Russia. khvostov@nioch.nsc.ru.
FAU - Tolstikova, Tatjana G
AU  - Tolstikova TG
FAU - Borisov, Sergey A
AU  - Borisov SA
FAU - Zhukova, Natalja A
AU  - Zhukova NA
FAU - Dushkin, Alexander V
AU  - Dushkin AV
FAU - Chistyachenko, Yulia S
AU  - Chistyachenko YS
FAU - Polyakov, Nikolay E
AU  - Polyakov NE
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Drug Deliv
JT  - Current drug delivery
JID - 101208455
RN  - 0 (Galactans)
RN  - R16CO5Y76E (Aspirin)
RN  - SL4SX1O487 (arabinogalactan)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/chemistry/*therapeutic use
MH  - Galactans/*chemistry
MH  - Male
MH  - Mice
MH  - Proton Magnetic Resonance Spectroscopy
MH  - Rats
MH  - Rats, Wistar
EDAT- 2015/06/06 06:00
MHDA- 2017/02/18 06:00
CRDT- 2015/06/06 06:00
PHST- 2015/02/02 00:00 [received]
PHST- 2015/04/30 00:00 [revised]
PHST- 2015/06/03 00:00 [accepted]
PHST- 2015/06/06 06:00 [entrez]
PHST- 2015/06/06 06:00 [pubmed]
PHST- 2017/02/18 06:00 [medline]
AID - CDD-EPUB-67894 [pii]
AID - 10.2174/1567201812666150605104944 [doi]
PST - ppublish
SO  - Curr Drug Deliv. 2016;13(4):582-9. doi: 10.2174/1567201812666150605104944.

PMID- 7381741
OWN - NLM
STAT- MEDLINE
DCOM- 19800828
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 69
IP  - 5
DP  - 1980 May
TI  - Aspirin--a national survey III: Determination of impurities in bulk aspirin and 
      aspirin formulations by high-pressure liquid chromatography and 
      spectrophotometry.
PG  - 550-3
AB  - A quantitative high-pressure liquid chromatographic method, using a 
      reversed-phase column and an aqueous acetic acid-methanol solution as the mobile 
      phase, was employed for the determination of O-acetyl-O-salicylsalicylic acid and 
      O-salicylsalicylic acid in pharmaceutical aspirin preparations. The aspirin was 
      dissolved, filtered, and injected into the chromatograph. The absorbance of the 
      impurities was measured at 254 nm. Acetylsalicylic anhydridge was determined by a 
      spectrophotometric method. The aspirin was dissolved in pH 11.3 buffer and 
      extracted with benzene. An aliquot of the benzene was evaporated, and the residue 
      was dissolved in alpha-benzamidocinnamate-pyridine reagent. The acetylsalicylic 
      anhydride was measured using the difference between the absorbance at 362 and 372 
      nm. Possible interference of aspirin with the procedure is discussed. Thirty-four 
      bulk aspirin and 172 tablet formulations were examined. Results for 
      O-acetyl-O-salicylsalicylic acid, O-salicylsalicylic acid and acetylsalicylic 
      anhydride are given.
FAU - Kirchhoefer, R D
AU  - Kirchhoefer RD
FAU - Reepmeyer, J C
AU  - Reepmeyer JC
FAU - Juhl, W E
AU  - Juhl WE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - V9MO595C9I (salicylsalicylic acid)
RN  - VBE72MCP5L (acetylsalicylsalicylic acid)
RN  - XIA5Z82RHB (acetylsalicylic anhydride)
SB  - IM
MH  - Aspirin/analogs & derivatives/*analysis/standards
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Drug Contamination
MH  - Salicylates/analysis
MH  - Spectrophotometry
EDAT- 1980/05/01 00:00
MHDA- 1980/05/01 00:01
CRDT- 1980/05/01 00:00
PHST- 1980/05/01 00:00 [pubmed]
PHST- 1980/05/01 00:01 [medline]
PHST- 1980/05/01 00:00 [entrez]
AID - S0022-3549(15)43191-0 [pii]
AID - 10.1002/jps.2600690519 [doi]
PST - ppublish
SO  - J Pharm Sci. 1980 May;69(5):550-3. doi: 10.1002/jps.2600690519.

PMID- 36500502
OWN - NLM
STAT- MEDLINE
DCOM- 20221216
LR  - 20221221
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 27
IP  - 23
DP  - 2022 Dec 1
TI  - Acetylsalicylic Acid-Primus Inter Pares in Pharmacology.
LID - 10.3390/molecules27238412 [doi]
LID - 8412
AB  - Acetylsalicylic acid (ASA) is one of the first drugs to be obtained by synthesis 
      while being the most used. It has experienced the longest lasting commercial 
      success and is considered the most popular drug of the modern era. ASA, 
      originally used as an anti-inflammatory medication, nowadays is predominantly 
      used as an antiplatelet agent for prophylaxis in cardiac patients. Many studies 
      show that the benefits of using ASA far outweigh the potential risk of side 
      effects. With particular emphasis on the possibility of ASA repositioning for new 
      therapies, extending the indications for use beyond the diseases from the 
      spectrum of atherosclerotic diseases, such as cancer, requires shifting the 
      benefit-risk ratio, although very good, even more towards safety. Interesting 
      activities consisting not only of changing the formulation but also modifying the 
      drug molecule seem to be an important goal of the 21st century. ASA has become a 
      milestone in two important fields: pharmacy and medicine. For a pharmacist, ASA 
      is a long-used drug for which individual indications are practically maintained. 
      For a doctor, acetylsalicylic acid is primarily an antiplatelet drug that saves 
      millions of lives of patients with coronary heart disease or after a stroke. 
      These facts do not exempt us from improving therapeutic methods based on ASA, the 
      main goal of which is to reduce the risk of side effects, as well as to extend 
      effectiveness. Modified acetylsalicylic acid molecules already seem to be a 
      promising therapeutic option.
FAU - Fijałkowski, Łukasz
AU  - Fijałkowski Ł
AUID- ORCID: 0000-0001-6778-8259
AD  - Department of Pharmacometrics and Molecular Modeling, Faculty of Pharmacy, 
      Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 2 dr. A. Jurasza 
      St., 85-094 Bydgoszcz, Poland.
FAU - Skubiszewska, Magdalena
AU  - Skubiszewska M
AUID- ORCID: 0000-0001-7950-5543
AD  - Department of Pharmacometrics and Molecular Modeling, Faculty of Pharmacy, 
      Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 2 dr. A. Jurasza 
      St., 85-094 Bydgoszcz, Poland.
FAU - Grześk, Grzegorz
AU  - Grześk G
AUID- ORCID: 0000-0001-6669-5931
AD  - Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, 
      Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 
      75 Ujejskiego St., 85-168 Bydgoszcz, Poland.
FAU - Koech, Frankline Kiptoo
AU  - Koech FK
AD  - School of Pharmacy, Kabarak University, Nairobi P.O. Box 20157, Kenya.
FAU - Nowaczyk, Alicja
AU  - Nowaczyk A
AUID- ORCID: 0000-0003-4945-2369
AD  - Department of Pharmacometrics and Molecular Modeling, Faculty of Pharmacy, 
      Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 2 dr. A. Jurasza 
      St., 85-094 Bydgoszcz, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221201
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - *Stroke/drug therapy
PMC - PMC9738180
OTO - NOTNLM
OT  - ASA derivatives
OT  - ASA formulations
OT  - aspirin (ASA)
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/12 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/12/11 01:28
PHST- 2022/11/06 00:00 [received]
PHST- 2022/11/24 00:00 [revised]
PHST- 2022/11/27 00:00 [accepted]
PHST- 2022/12/11 01:28 [entrez]
PHST- 2022/12/12 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
AID - molecules27238412 [pii]
AID - molecules-27-08412 [pii]
AID - 10.3390/molecules27238412 [doi]
PST - epublish
SO  - Molecules. 2022 Dec 1;27(23):8412. doi: 10.3390/molecules27238412.

PMID- 8106894
OWN - NLM
STAT- MEDLINE
DCOM- 19940322
LR  - 20191101
IS  - 0889-4655 (Print)
IS  - 0889-4655 (Linking)
VI  - 8
IP  - 1
DP  - 1993 Oct
TI  - The use of aspirin in cardiovascular disease.
PG  - 1-18
AB  - Aspirin has many uses in cardiovascular disease. It is used for primary 
      prophylaxis; as an adjunctive therapy in angina, acute myocardial infarction, and 
      thrombolytic therapy; and to promote vessel patency after angioplasty and 
      coronary artery bypass grafting. This article reviews the recent research 
      findings on the use of aspirin in cardiovascular disease and discusses remaining 
      questions and nursing implications.
FAU - Byers, J F
AU  - Byers JF
AD  - Orlando Regional Medical Center, Florida.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Cardiovasc Nurs
JT  - The Journal of cardiovascular nursing
JID - 8703516
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/nursing/*therapy
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Postoperative Care
MH  - Primary Prevention
MH  - Recurrence
MH  - Thrombolytic Therapy
RF  - 55
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
AID - 10.1097/00005082-199310000-00004 [doi]
PST - ppublish
SO  - J Cardiovasc Nurs. 1993 Oct;8(1):1-18. doi: 10.1097/00005082-199310000-00004.

PMID- 15346640
OWN - NLM
STAT- MEDLINE
DCOM- 20050512
LR  - 20131121
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 50
IP  - 6
DP  - 2004 Jun
TI  - [Clinical importance of aspirin resistance].
PG  - 462-9
AB  - The antiplatelet effect of aspirin is mostly explained by the irreversible 
      cyclooxygenase-1 inhibition resulting in the suppression of thromboxane A2 
      synthesis. The benefit of aspirin was proved in various cardiovascular diseases. 
      However, the inter- and intraindividual variability of its antiplatelet effect is 
      well known. Aspirin resistance can be understood from the clinical point of 
      view--as a failure of the protective effect of aspirin from thrombotic 
      complication or can be defined from the laboratory aspect--as an inability to 
      cause in vitro detectable platelet function inhibition. The cause of this 
      phenomenon has not been completely explained yet and more mechanisms have been 
      proposed, incomplete suppression of thromboxane A2 generation being one of them. 
      Laboratory diagnostics of aspirin resistance is based on the demonstration of the 
      insufficient inhibition of platelet aggregation or the incomplete suppression of 
      thromboxane A2 synthesis (assay for its metabolite, 11-dehydrothromboxane B2 in 
      urine). The results of some trials raise the possibility that aspirin resistance 
      could be a new independent predictor of cardiovascular events.
FAU - Hirmerová, J
AU  - Hirmerová J
AD  - II. interní klinika Lékarské fakulty UK a FN, Plzen.
FAU - Filipovský, J
AU  - Filipovský J
LA  - cze
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Klinický význam aspirinové rezistence.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
RF  - 70
EDAT- 2004/09/07 05:00
MHDA- 2005/05/13 09:00
CRDT- 2004/09/07 05:00
PHST- 2004/09/07 05:00 [pubmed]
PHST- 2005/05/13 09:00 [medline]
PHST- 2004/09/07 05:00 [entrez]
PST - ppublish
SO  - Vnitr Lek. 2004 Jun;50(6):462-9.

PMID- 8918560
OWN - NLM
STAT- MEDLINE
DCOM- 19961218
LR  - 20190512
IS  - 0960-7722 (Print)
IS  - 0960-7722 (Linking)
VI  - 29
IP  - 8
DP  - 1996 Aug
TI  - Aspirin suppresses 1,2-dimethylhydrazine-induced alteration of proliferative 
      parameters in rat colonic crypts.
PG  - 467-73
AB  - Human epidemiological reports and rodent experimental research data indicate a 
      possible chemopreventive effect of regular aspirin use for decreasing risk of 
      colon and rectum cancer incidence and mortality. We have previously demonstrated 
      that aspirin can significantly suppress proliferative parameters in normal rat 
      colonic epithelium when examined 24 h following an acute or chronic course of 
      aspirin administration. To investigate whether aspirin would effectively suppress 
      known carcinogen-induced changes in colonic epithelium, rats were given single 
      s.c. injections of either aspirin (50 mg/kg bw) or saline on days 1-3 and either 
      1,2-dimethylhydrazine (DMH; 12 mg base/kg bw) or DMH vehicle on day 4 of each 
      week for eight consecutive weeks. Rats were sacrificed 4 days after the last 
      aspirin dose and 3 days after the last DMH or DMH vehicle dose. Using the 
      proliferative biomarkers of proliferating cell nuclear antigen positive cells per 
      midaxial crypt section (SCC), crypt proliferative zone height (PZ), crypt 
      differentiated zone height (DZ), and total crypt height (CH), it was found that 
      aspirin does suppress DMH-induced increases in SCC, PZ and CH. The findings 
      demonstrate that aspirin has a long term (i.e. several days) protective effect 
      against early carcinogen-induced proliferative changes in rat colonic crypts 
      which may help account for aspirin's chemopreventive action against colon cancer.
FAU - Barnes, C J
AU  - Barnes CJ
AD  - Department of Cellular and Structural Biology, University of Texas Health Science 
      Center, San Antonio 78284-7762, USA. BARNESC@UTHSCSA.EDU
FAU - Lee, M
AU  - Lee M
FAU - Hardman, W E
AU  - Hardman WE
FAU - Cameron, I L
AU  - Cameron IL
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Cell Prolif
JT  - Cell proliferation
JID - 9105195
RN  - 0 (Dimethylhydrazines)
RN  - IX068S9745 (1,2-Dimethylhydrazine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 1,2-Dimethylhydrazine
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cell Division/*drug effects
MH  - Dimethylhydrazines/*pharmacology
MH  - Intestinal Mucosa/cytology/*drug effects
MH  - Male
MH  - Neoplasms, Experimental/prevention & control
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Time Factors
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - 10.1111/j.1365-2184.1996.tb00989.x [doi]
PST - ppublish
SO  - Cell Prolif. 1996 Aug;29(8):467-73. doi: 10.1111/j.1365-2184.1996.tb00989.x.

PMID- 8829360
OWN - NLM
STAT- MEDLINE
DCOM- 19961016
LR  - 20190516
IS  - 0108-2701 (Print)
IS  - 0108-2701 (Linking)
VI  - 52 ( Pt 2)
DP  - 1996 Feb 15
TI  - 2-bromoacetoxybenzoic acid, a brominated aspirin analog.
PG  - 375-7
AB  - The crystal structure of 2-bromoacetoxybenzoic acid, C9H7BrO4, shows it to be a 
      close structural analog of aspirin. The carboxylic acid moiety is twisted by 7.7 
      (4) degrees out of the plane of the aromatic ring. The acetyl group, like that of 
      aspirin, shows bond-angle distortions from ideal values while remaining 
      essentially planar. The Br atom is rotationally disordered and has been modeled 
      as occupying two sites related by a 13 (1) degree rotation about the C8--C9 bond.
FAU - Loll, P J
AU  - Loll PJ
AD  - Department of Biochemistry and Molecular Biology, University of Chicago, IL 
      60637, USA.
FAU - Garavito, R M
AU  - Garavito RM
FAU - Carrell, C J
AU  - Carrell CJ
FAU - Carrell, H L
AU  - Carrell HL
LA  - eng
GR  - CA-10925/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Acta Crystallogr C
JT  - Acta crystallographica. Section C, Crystal structure communications
JID - 8305826
RN  - 77382-69-5 (bromoaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemistry
MH  - Crystallography, X-Ray
MH  - Molecular Conformation
EDAT- 1996/02/15 00:00
MHDA- 1996/02/15 00:01
CRDT- 1996/02/15 00:00
PHST- 1996/02/15 00:00 [pubmed]
PHST- 1996/02/15 00:01 [medline]
PHST- 1996/02/15 00:00 [entrez]
AID - 10.1107/s0108270195010390 [doi]
PST - ppublish
SO  - Acta Crystallogr C. 1996 Feb 15;52 ( Pt 2):375-7. doi: 10.1107/s0108270195010390.

PMID- 18430462
OWN - NLM
STAT- MEDLINE
DCOM- 20090212
LR  - 20131121
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 123
IP  - 1
DP  - 2008
TI  - Monitoring aspirin treatment in patients with thrombocytosis: comparison of the 
      platelet function analyzer (PFA)-100 with optical aggregometry.
PG  - 100-7
LID - 10.1016/j.thromres.2008.03.008 [doi]
AB  - Aspirin provides satisfactory protection against thrombotic episodes in essential 
      thrombocythemia (ET), but at higher platelet counts has been less effective. Our 
      aim was to compare the platelet function analyzer (PFA)-100 with optical 
      aggregometry in order to determine a reliable method in monitoring aspirin's 
      influence on platelet function in patients with thrombocytosis. We studied 36 
      patients with thrombocytosis. Sixteen of them, receiving aspirin, composed group 
      A, while group B consisted of 20 patients not taking aspirin. In all patients, we 
      compared the platelet function measured by classic optical aggregation tests with 
      closure times (CT) obtained by the PFA-100. The definition of platelet responses 
      as normal or pathological showed that PFA-100 collagen and/or epinephrine (CEPI) 
      CTs and epinephrine-induced aggregometry is the pair of methods with the higher 
      agreement in monitoring of platelet dysfunction due to ASA treatment (a=94%). 
      Satisfactory results were also obtained for group B (a=81%). The comparison 
      between PFA-100 CEPI CTs and arachidonic acid-induced aggregometry exhibited 
      moderate agreement both in the total number of patients and in group A (a=79% and 
      94%, respectively). PFA-100 collagen and/or ADP (CADP) CTs and ADP-induced 
      aggregometry were not concordant. The PFA-100 system appears to be a reliable and 
      rapid method in the assessment of aspirin's antiplatelet effect in patients with 
      thrombocytosis. Regarding aggregometry, the selection of the inducer, its 
      concentration and cut-off points is crucial in defining the response to 
      antiaggregating agents. It still remains to determine whether there is any 
      relevance between the measurements obtained by these methods and clinical outcome 
      in thrombocythemic patients.
FAU - Tsantes, Argirios E
AU  - Tsantes AE
AD  - Laboratory of Haematology & Blood Bank Unit, Attikon General Hospital, School of 
      Medicine, University of Athens, Greece. atsantes@yahoo.com
FAU - Mantzios, Georgios
AU  - Mantzios G
FAU - Giannopoulou, Vassiliki
AU  - Giannopoulou V
FAU - Tsirigotis, Panagiotis
AU  - Tsirigotis P
FAU - Bonovas, Stefanos
AU  - Bonovas S
FAU - Rapti, Evdoxia
AU  - Rapti E
FAU - Mygiaki, Elissavet
AU  - Mygiaki E
FAU - Kartasis, Zafirios
AU  - Kartasis Z
FAU - Sitaras, Nikolaos M
AU  - Sitaras NM
FAU - Dervenoulas, John
AU  - Dervenoulas J
FAU - Travlou, Anthi
AU  - Travlou A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080421
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests/*instrumentation
MH  - Thrombocytosis/blood/*drug therapy
EDAT- 2008/04/24 09:00
MHDA- 2009/02/13 09:00
CRDT- 2008/04/24 09:00
PHST- 2007/12/23 00:00 [received]
PHST- 2008/03/05 00:00 [revised]
PHST- 2008/03/06 00:00 [accepted]
PHST- 2008/04/24 09:00 [pubmed]
PHST- 2009/02/13 09:00 [medline]
PHST- 2008/04/24 09:00 [entrez]
AID - S0049-3848(08)00091-1 [pii]
AID - 10.1016/j.thromres.2008.03.008 [doi]
PST - ppublish
SO  - Thromb Res. 2008;123(1):100-7. doi: 10.1016/j.thromres.2008.03.008. Epub 2008 Apr 
      21.

PMID- 1433426
OWN - NLM
STAT- MEDLINE
DCOM- 19921211
LR  - 20190911
IS  - 0731-3810 (Print)
IS  - 0731-3810 (Linking)
VI  - 30
IP  - 4
DP  - 1992
TI  - The preadministration of activated charcoal and aspirin absorption.
PG  - 549-56
AB  - There is little information describing the effects of activated charcoal 
      preadministration on drug absorption. This study was undertaken to determine the 
      effect of activated charcoal preadministration at two different times on aspirin 
      absorption. Fifteen volunteer subjects completed three study phases: 1) 975 mg 
      aspirin alone, 2) 975 mg aspirin 30 min after 10 g activated charcoal, and 3) 975 
      mg aspirin 60 min after 10 g activated charcoal. Urine was collected for 48 h 
      after the initiation of each study phase, and total aspirin recovery determined 
      by HPLC. The aspirin recovery was 88.8% +/- 4.5% for the control phase, and 84.8% 
      +/- 9.4% (Phase 1) and 85.8% +/- 12.6% (Phase 2) for the activated charcoal 
      treatments (p > 0.05). These results suggest that activated charcoal administered 
      30 and 60 min prior to drug ingestion has little effect on drug absorption. 
      Further studies of the effect of charcoal preadministration on the absorption of 
      other drugs may provide useful information regarding factors important in 
      determining activated charcoal efficacy.
FAU - McKinney, P E
AU  - McKinney PE
AD  - Rocky Mountain Poison and Drug Center, Denver, Colorado.
FAU - Gillilan, R
AU  - Gillilan R
FAU - Watson, W A
AU  - Watson WA
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Toxicol Clin Toxicol
JT  - Journal of toxicology. Clinical toxicology
JID - 8213460
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption/drug effects
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics/urine
MH  - Charcoal/administration & dosage/*pharmacology
MH  - Humans
MH  - Male
MH  - Random Allocation
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.3109/15563659209017940 [doi]
PST - ppublish
SO  - J Toxicol Clin Toxicol. 1992;30(4):549-56. doi: 10.3109/15563659209017940.

PMID- 31152901
OWN - NLM
STAT- MEDLINE
DCOM- 20190815
LR  - 20190815
IS  - 1879-1298 (Electronic)
IS  - 0045-6535 (Linking)
VI  - 232
DP  - 2019 Oct
TI  - Metabolic activity and pathway study of aspirin biodegradation using a microbial 
      electrochemical system supplied by an alternating current.
PG  - 35-44
LID - S0045-6535(19)31101-4 [pii]
LID - 10.1016/j.chemosphere.2019.05.186 [doi]
AB  - The main aim of this study is to investigate the biodegradation of highly 
      concentrated aspirin as an emerging pollutant from aqueous solution using an 
      alternating current microbial electrochemical system. A single-chamber Plexiglas 
      cylindrical reactor equipped with stainless steel mesh electrodes (18 cm 
      height × 16 cm diameter) was applied as the bioreactor in batch mode with an 
      effective volume of 5 L, height of 20 cm, and the diameter about 20 cm by 
      AMPL = 2 V(pp), OFST = 0.1 V, waveform = sinusoidal, frequency = 10 Hz, and 
      pH = 7. The process parameters including initial concentration 
      (100-400 mg L(-1)), chemical oxygen demand (COD), activity of enzymes, biokinetic 
      and pathway studies at very low voltage and very low frequency alternating 
      current were investigated. The specific biodegradation rate of aspirin was 
      calculated based on Michaelis-Menten model. The complete aspirin removal 
      efficiency and the maximum enzymatic activity were achieved at 250 mg L(-1) 
      aspirin, voltage of 2 V(pp) and applied current = 3 mA during 6 h. The bioassay 
      of aspirin concentrations in biofilm of the system using flow cytometry analysis 
      resulted in the live and necrotic cells shares of 96.2%, and 0.44%, respectively. 
      Moreover, the LC and GC-MS analysis showed low molecular weight acids such as 
      oxalic and acetic acid at 6 h time under the optimal conditions using very low 
      applied voltage and frequency. Obtaining low reaction time for degradation, high 
      potential in biodegradation, oxidation and mineralization ability were the 
      novelty of treatment system with high concentration aspirin in the study.
CI  - Copyright © 2019 Elsevier Ltd. All rights reserved.
FAU - Moghiseh, Zohreh
AU  - Moghiseh Z
AD  - Department of Environmental Health Engineering, Faculty of Medical Sciences, 
      Tarbiat Modares University, Tehran, Iran.
FAU - Rezaee, Abbas
AU  - Rezaee A
AD  - Department of Environmental Health Engineering, Faculty of Medical Sciences, 
      Tarbiat Modares University, Tehran, Iran. Electronic address: 
      rezaee@modares.ac.ir.
FAU - Ghanati, Faezeh
AU  - Ghanati F
AD  - Department of Plant Biology, Faculty of Biological Sciences, Tarbiat Modares 
      University, Tehran, Iran.
FAU - Esrafili, Ali
AU  - Esrafili A
AD  - Department of Environmental Health Engineering, School of Public Health, Iran 
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20190523
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - 0 (Water Pollutants, Chemical)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/analysis/*metabolism
MH  - *Biodegradation, Environmental
MH  - Biological Oxygen Demand Analysis
MH  - Bioreactors
MH  - Electrodes
MH  - Oxidation-Reduction
MH  - Water Pollutants, Chemical/analysis/*metabolism
OTO - NOTNLM
OT  - Aspirin
OT  - Emerging pollutants
OT  - Microbial electrochemical system
OT  - Pathway
EDAT- 2019/06/04 06:00
MHDA- 2019/08/16 06:00
CRDT- 2019/06/02 06:00
PHST- 2019/01/28 00:00 [received]
PHST- 2019/05/14 00:00 [revised]
PHST- 2019/05/22 00:00 [accepted]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2019/08/16 06:00 [medline]
PHST- 2019/06/02 06:00 [entrez]
AID - S0045-6535(19)31101-4 [pii]
AID - 10.1016/j.chemosphere.2019.05.186 [doi]
PST - ppublish
SO  - Chemosphere. 2019 Oct;232:35-44. doi: 10.1016/j.chemosphere.2019.05.186. Epub 
      2019 May 23.

PMID- 22104368
OWN - NLM
STAT- MEDLINE
DCOM- 20120601
LR  - 20131121
IS  - 1096-0961 (Electronic)
IS  - 1079-9796 (Linking)
VI  - 48
IP  - 2
DP  - 2012 Feb 15
TI  - Gender-specific antitumor action of aspirin in a murine model of a T-cell 
      lymphoma bearing host.
PG  - 137-44
LID - 10.1016/j.bcmd.2011.10.006 [doi]
AB  - Aspirin is an anti-inflammatory drug demonstrated to possess a tremendous 
      anticancer potential. As progression of some tumors is influenced by sex 
      hormones, we investigated if the antineoplastic action of aspirin shows gender 
      dependence. Using a murine model of T-cell lymphoma, the present investigation 
      was undertaken to study if the antitumor actions of aspirin against lymphoma 
      cells display gender dimorphism. The findings of the present investigation 
      indicate that aspirin administration to male and female tumor-bearing hosts 
      resulted in gender dependent differential tumor growth retardation. Such gender 
      dichotomy of aspirin's antitumor action was associated with a differential impact 
      on cell cycle progression and expression of cell survival regulatory molecules. 
      Aspirin administration was also found to modulate crucial parameters of tumor 
      microenvironment, including contents of glucose, lactate and cell growth 
      regulatory cytokines, in a gender specific manner. Aspirin was found to reverse 
      estrogen-dependent augmentation of tumor cell survival in vitro. Taken together 
      the results of the present study suggest that the antineoplastic action of 
      aspirin is gender-dependent and should be considered in designing of 
      gender-specific therapeutic applications of aspirin.
CI  - Copyright © 2011 Elsevier Inc. All rights reserved.
FAU - Kumar, Anjani
AU  - Kumar A
AD  - School of Biotechnology, Banaras Hindu University, Varanasi, U.P., India.
FAU - Vishvakarma, Naveen Kumar
AU  - Vishvakarma NK
FAU - Bharti, Alok Chandra
AU  - Bharti AC
FAU - Singh, Sukh Mahendra
AU  - Singh SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111121
PL  - United States
TA  - Blood Cells Mol Dis
JT  - Blood cells, molecules & diseases
JID - 9509932
RN  - 0 (Androgens)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Estrogens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Androgens/pharmacology
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cell Cycle/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Disease Models, Animal
MH  - Estrogens/pharmacology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Lymphoma, T-Cell/*drug therapy/genetics/mortality
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Sex Factors
MH  - Tumor Microenvironment/drug effects
EDAT- 2011/11/23 06:00
MHDA- 2012/06/02 06:00
CRDT- 2011/11/23 06:00
PHST- 2011/09/19 00:00 [received]
PHST- 2011/10/25 00:00 [revised]
PHST- 2011/10/25 00:00 [accepted]
PHST- 2011/11/23 06:00 [entrez]
PHST- 2011/11/23 06:00 [pubmed]
PHST- 2012/06/02 06:00 [medline]
AID - S1079-9796(11)00199-9 [pii]
AID - 10.1016/j.bcmd.2011.10.006 [doi]
PST - ppublish
SO  - Blood Cells Mol Dis. 2012 Feb 15;48(2):137-44. doi: 10.1016/j.bcmd.2011.10.006. 
      Epub 2011 Nov 21.

PMID- 17376682
OWN - NLM
STAT- MEDLINE
DCOM- 20070807
LR  - 20171116
IS  - 0960-894X (Print)
IS  - 0960-894X (Linking)
VI  - 17
IP  - 11
DP  - 2007 Jun 1
TI  - Evaluation of nitrate-substituted pseudocholine esters of aspirin as potential 
      nitro-aspirins.
PG  - 3217-20
AB  - Herein we explore some designs for nitro-aspirins, compounds potentially capable 
      of releasing both aspirin and nitric oxide in vivo. A series of nitrate-bearing 
      alkyl esters of aspirin were prepared based on the choline ester template 
      preferred by human plasma butyrylcholinesterase. The degradation kinetics of the 
      compounds were followed in human plasma solution. All compounds underwent 
      hydrolysis rapidly (t(1/2) approximately 1min) but generating exclusively the 
      corresponding nitro-salicylate. The one exception, an N-propyl, N-nitroxyethyl 
      aminoethanol ester produced 9.2% aspirin in molar terms indicating that the 
      nitro-aspirin objective is probably achievable if due cognisance can be paid to 
      the demands of the activating enzyme. Even at this low level of aspirin release, 
      this compound is the most successful nitro-aspirin reported to date in the key 
      human plasma model.
FAU - Gilmer, John F
AU  - Gilmer JF
AD  - School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin 2, 
      Ireland. gilmerjf@tcd.ie
FAU - Moriarty, Louise M
AU  - Moriarty LM
FAU - Clancy, John M
AU  - Clancy JM
LA  - eng
PT  - Journal Article
DEP - 20070312
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (Esters)
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Prodrugs)
RN  - EC 3.1.1.8 (Butyrylcholinesterase)
RN  - N91BDP6H0X (Choline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives
MH  - Butyrylcholinesterase/chemistry
MH  - Choline/chemistry
MH  - *Drug Design
MH  - Esters/chemistry/metabolism
MH  - Humans
MH  - Hydrolysis
MH  - Nitrates/*chemistry/metabolism
MH  - Nitric Oxide Donors/*chemistry/metabolism
MH  - Prodrugs/*chemistry/metabolism
MH  - Serum/chemistry/metabolism
EDAT- 2007/03/23 09:00
MHDA- 2007/08/08 09:00
CRDT- 2007/03/23 09:00
PHST- 2007/02/12 00:00 [received]
PHST- 2007/03/05 00:00 [accepted]
PHST- 2007/03/23 09:00 [pubmed]
PHST- 2007/08/08 09:00 [medline]
PHST- 2007/03/23 09:00 [entrez]
AID - S0960-894X(07)00303-4 [pii]
AID - 10.1016/j.bmcl.2007.03.009 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2007 Jun 1;17(11):3217-20. doi: 10.1016/j.bmcl.2007.03.009. 
      Epub 2007 Mar 12.

PMID- 29425227
OWN - NLM
STAT- MEDLINE
DCOM- 20180402
LR  - 20221207
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 2
DP  - 2018
TI  - Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin 
      use and colorectal cancer risk: A case-control study in unselected white European 
      populations.
PG  - e0192223
LID - 10.1371/journal.pone.0192223 [doi]
LID - e0192223
AB  - Regular aspirin use is associated with reduced risk of colorectal cancer (CRC). 
      Variation in aspirin's chemoprevention efficacy has been attributed to the 
      presence of single nucleotide polymorphisms (SNPs). We conducted a meta-analysis 
      using two large population-based case-control datasets, the UK-Leeds Colorectal 
      Cancer Study Group and the NIH-Colon Cancer Family Registry, having a combined 
      total of 3325 cases and 2262 controls. The aim was to assess 42 candidate SNPs in 
      15 genes whose association with colorectal cancer risk was putatively modified by 
      aspirin use, in the literature. Log odds ratios (ORs) and standard errors were 
      estimated for each dataset separately using logistic regression adjusting for 
      age, sex and study site, and dataset-specific results were combined using random 
      effects meta-analysis. Meta-analysis showed association between SNPs rs6983267, 
      rs11694911 and rs2302615 with CRC risk reduction (All P<0.05). Association for 
      SNP rs6983267 in the CCAT2 gene only was noteworthy after multiple test 
      correction (P = 0.001). Site-specific analysis showed association between SNPs 
      rs1799853 and rs2302615 with reduced colon cancer risk only (P = 0.01 and P = 
      0.004, respectively), however neither reached significance threshold following 
      multiple test correction. Meta-analysis of SNPs rs2070959 and rs1105879 in UGT1A6 
      gene showed interaction between aspirin use and CRC risk (Pinteraction = 0.01 and 
      0.02, respectively); stratification by aspirin use showed an association for 
      decreased CRC risk for aspirin users having a wild-type genotype (rs2070959 OR = 
      0.77, 95% CI = 0.68-0.86; rs1105879 OR = 0.77 95% CI = 0.69-0.86) compared to 
      variant allele cariers. The direction of the interaction however is in contrast 
      to that published in studies on colorectal adenomas. Both SNPs showed potential 
      site-specific interaction with aspirin use and colon cancer risk only 
      (Pinteraction = 0.006 and 0.008, respectively), with the direction of association 
      similar to that observed for CRC. Additionally, they showed interaction between 
      any non-steroidal anti-inflammatory drugs (including aspirin) use and CRC risk 
      (Pinteraction = 0.01 for both). All gene x environment (GxE) interactions however 
      were not significant after multiple test correction. Candidate gene investigation 
      indicated no evidence of GxE interaction between genetic variants in genes 
      involved in aspirin pathways, regular aspirin use and colorectal cancer risk.
FAU - Sheth, Harsh
AU  - Sheth H
AUID- ORCID: 0000-0001-9626-0971
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United 
      Kingdom.
AD  - Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United 
      Kingdom.
FAU - Northwood, Emma
AU  - Northwood E
AD  - Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United 
      Kingdom.
FAU - Ulrich, Cornelia M
AU  - Ulrich CM
AD  - Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United 
      States of America.
FAU - Scherer, Dominique
AU  - Scherer D
AD  - Institute of Medical Biometry and Informatics, University of Heidelberg, 
      Heidelberg, Germany.
FAU - Elliott, Faye
AU  - Elliott F
AD  - Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United 
      Kingdom.
FAU - Barrett, Jennifer H
AU  - Barrett JH
AD  - Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United 
      Kingdom.
FAU - Forman, David
AU  - Forman D
AD  - Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United 
      Kingdom.
FAU - Wolf, C Roland
AU  - Wolf CR
AD  - School of Medicine, University of Dundee, Dundee, United Kingdom.
FAU - Smith, Gillian
AU  - Smith G
AD  - School of Medicine, University of Dundee, Dundee, United Kingdom.
FAU - Jackson, Michael S
AU  - Jackson MS
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United 
      Kingdom.
FAU - Santibanez-Koref, Mauro
AU  - Santibanez-Koref M
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United 
      Kingdom.
FAU - Haile, Robert
AU  - Haile R
AD  - Stanford Cancer Institute, Stanford, California, United States of America.
FAU - Casey, Graham
AU  - Casey G
AD  - Center for Public Health Genomics, University of Virginia, Charlottesville, 
      Virginia, United States of America.
FAU - Jenkins, Mark
AU  - Jenkins M
AD  - Melbourne School of Population and Global Health, The University of Melbourne, 
      Carlton, Australia.
FAU - Win, Aung Ko
AU  - Win AK
AD  - Melbourne School of Population and Global Health, The University of Melbourne, 
      Carlton, Australia.
FAU - Hopper, John L
AU  - Hopper JL
AD  - Melbourne School of Population and Global Health, The University of Melbourne, 
      Carlton, Australia.
FAU - Marchand, Loic Le
AU  - Marchand LL
AD  - University of Hawaii, Manoa, Hawaii, United States of America.
FAU - Lindor, Noralane M
AU  - Lindor NM
AD  - Mayo Clinic, Scottsdale, Arizona, United States of America.
FAU - Thibodeau, Stephen N
AU  - Thibodeau SN
AD  - Mayo Clinic, Rochester, Minnesota, United States of America.
FAU - Potter, John D
AU  - Potter JD
AD  - Centre for Public Health Research, Massey University, Wellington, New Zealand.
FAU - Burn, John
AU  - Burn J
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United 
      Kingdom.
FAU - Bishop, D Timothy
AU  - Bishop DT
AD  - Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United 
      Kingdom.
LA  - eng
GR  - UM1 CA167551/NH/NIH HHS/United States
GR  - U01/U24 CA074783/NH/NIH HHS/United States
GR  - U01/U24 CA074794/NH/NIH HHS/United States
GR  - U24 CA074783/CA/NCI NIH HHS/United States
GR  - R01 CA189184/CA/NCI NIH HHS/United States
GR  - U24 CA074794/CA/NCI NIH HHS/United States
GR  - U01/U24 CA097735/NH/NIH HHS/United States
GR  - R01 CA143237/CA/NCI NIH HHS/United States
GR  - R01 CA207371/CA/NCI NIH HHS/United States
GR  - U01 CA097735/CA/NCI NIH HHS/United States
GR  - U01 CA074783/CA/NCI NIH HHS/United States
GR  - U24 CA097735/CA/NCI NIH HHS/United States
GR  - U01 CA122839/NH/NIH HHS/United States
GR  - U01 CA074794/CA/NCI NIH HHS/United States
GR  - UM1 CA167551/CA/NCI NIH HHS/United States
GR  - R01 CA143237/NH/NIH HHS/United States
GR  - U01 CA122839/CA/NCI NIH HHS/United States
GR  - 10822/CRUK_/Cancer Research UK/United Kingdom
GR  - U01 CA074778/NH/NIH HHS/United States
GR  - 10589/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180209
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*metabolism
MH  - Australia/epidemiology
MH  - Canada/epidemiology
MH  - Case-Control Studies
MH  - Colorectal Neoplasms/*epidemiology/prevention & control
MH  - Humans
MH  - *Polymorphism, Single Nucleotide
MH  - Risk Factors
MH  - United States/epidemiology
MH  - *White People
PMC - PMC5806861
COIS- Competing Interests: John Burn and Cornelia M. Ulrich are consultant/advisory 
      board member of Bayer Pharma who manufacture aspirin. Other authors have declared 
      that no competing interest exist. This does not alter our adherence to PLOS ONE 
      policies on sharing data and materials.
EDAT- 2018/02/10 06:00
MHDA- 2018/04/03 06:00
CRDT- 2018/02/10 06:00
PHST- 2017/05/17 00:00 [received]
PHST- 2018/01/19 00:00 [accepted]
PHST- 2018/02/10 06:00 [entrez]
PHST- 2018/02/10 06:00 [pubmed]
PHST- 2018/04/03 06:00 [medline]
AID - PONE-D-17-10794 [pii]
AID - 10.1371/journal.pone.0192223 [doi]
PST - epublish
SO  - PLoS One. 2018 Feb 9;13(2):e0192223. doi: 10.1371/journal.pone.0192223. 
      eCollection 2018.

PMID- 10947177
OWN - NLM
STAT- MEDLINE
DCOM- 20001130
LR  - 20200313
IS  - 0032-5791 (Print)
IS  - 0032-5791 (Linking)
VI  - 79
IP  - 8
DP  - 2000 Aug
TI  - Effect of dietary aspirin on ascites in broilers raised in a hypobaric chamber.
PG  - 1101-5
AB  - During the course of ascites development in broilers, many factors can interact 
      to cause hypoxia. To counteract hypoxia, birds with ascites develop greatly 
      increased hematocrit and red cell counts. Increasing hematocrits result in more 
      viscous blood. Prostaglandins are involved in the regulation of constriction and 
      dilation of pulmonary blood vessels and in the formation of blood clots. Dietary 
      aspirin, a prostaglandin inhibitor, was used in an attempt to promote 
      vasodilation and inhibit blood clotting in broilers, with the objective of 
      determining the effect of aspirin on ascites progression. The experimental design 
      consisted of two trials with a total of 1,360, 1-d-old male broiler chicks, which 
      were placed at either local altitude (390 m above sea level) or in a hypobaric 
      chamber that simulated an altitude of 2,900 m above sea level. At each elevation, 
      five dietary treatments were employed: [control, 0.025% crystalline 
      acetylsalicylic acid (aspirin), 0.05% aspirin, 0.10% aspirin, and 0.20% aspirin]. 
      Bird and feed weights were recorded weekly. At the end of 5 wk, blood samples and 
      organ weights were collected, and all birds were examined for signs of ascites. 
      In both trials, birds raised at high altitudes were significantly lighter, had a 
      higher incidence of ascites, and had differences in hematology, compared with 
      birds raised at local elevation. Only in Trial 2, however, did dietary aspirin 
      appear to have any effect on ascites incidence. At the 0.20% aspirin level, a 
      reduction in ascites incidence approached significance compared with controls 
      (34% vs. 56%, P < or = 0.06). Unfortunately, birds fed 0.20% aspirin also were 
      significantly (P < or = 0.01) lighter than controls. Because slowing growth rate 
      is known to reduce ascites, this decrease in BW may have been partially 
      responsible for any beneficial effect on ascites development and progression 
      obtained through feeding aspirin.
FAU - Balog, J M
AU  - Balog JM
AD  - USDA, Agricultural Research Service, Poultry Production and Product Safety 
      Research, Center of Excellence for Poultry Science, University of Arkansas, 
      Fayetteville 72701, USA. jbalog@comp.uark.edu
FAU - Huff, G R
AU  - Huff GR
FAU - Rath, N C
AU  - Rath NC
FAU - Huff, W E
AU  - Huff WE
LA  - eng
PT  - Journal Article
PL  - England
TA  - Poult Sci
JT  - Poultry science
JID - 0401150
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Altitude
MH  - Animal Nutritional Physiological Phenomena
MH  - Animals
MH  - Ascites/etiology/prevention & control/*veterinary
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - *Atmospheric Pressure
MH  - Body Weight/drug effects
MH  - *Chickens
MH  - *Diet
MH  - Male
MH  - Poultry Diseases/*prevention & control
EDAT- 2000/08/18 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/18 11:00
PHST- 2000/08/18 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/18 11:00 [entrez]
AID - S0032-5791(19)41594-0 [pii]
AID - 10.1093/ps/79.8.1101 [doi]
PST - ppublish
SO  - Poult Sci. 2000 Aug;79(8):1101-5. doi: 10.1093/ps/79.8.1101.

PMID- 9863744
OWN - NLM
STAT- MEDLINE
DCOM- 19990225
LR  - 20190831
IS  - 0098-6569 (Print)
IS  - 0098-6569 (Linking)
VI  - 45
IP  - 4
DP  - 1998 Dec
TI  - Comparison of enteric-coated aspirin and uncoated aspirin effect on bleeding 
      time.
PG  - 396-9
AB  - Aspirin therapy is an essential part of the drug regimen for patients with acute 
      myocardial infarction (MI), unstable angina, or after coronary angioplasty and 
      coronary stenting. Recognizing this importance, this study sought to compare the 
      bleeding time in two groups of 10 normal volunteers 4 hr after ingestion of 
      either an enteric-coated aspirin or an uncoated aspirin, assuming that a 
      difference between the two groups could be clinically significant. Defining < or 
      = 8 min as normal, 80% of the uncoated group developed abnormal bleeding times, 
      compared to 10% of the enteric-coated group (P < 0.01). The study demonstrates a 
      significant difference between the two types of aspirin preparations on bleeding 
      times in normal individuals. This strongly suggests that some enteric-coated 
      aspirin preparations may not be as effective as uncoated aspirin in acutely 
      decreasing platelet aggregation. Therefore, uncoated aspirin is recommended in 
      the setting of acute MI, unstable angina, or after percutaneous transluminal 
      coronary angioplasty.
FAU - Gantt, A J
AU  - Gantt AJ
AD  - Temple High School, Texas, USA.
FAU - Gantt, S
AU  - Gantt S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Cathet Cardiovasc Diagn
JT  - Catheterization and cardiovascular diagnosis
JID - 7508512
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Tablets, Enteric-Coated
EDAT- 1998/12/24 03:03
MHDA- 2000/06/20 09:00
CRDT- 1998/12/24 03:03
PHST- 1998/12/24 03:03 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1998/12/24 03:03 [entrez]
AID - 10.1002/(SICI)1097-0304(199812)45:4<396::AID-CCD9>3.0.CO;2-J [pii]
AID - 10.1002/(sici)1097-0304(199812)45:4<396::aid-ccd9>3.0.co;2-j [doi]
PST - ppublish
SO  - Cathet Cardiovasc Diagn. 1998 Dec;45(4):396-9. doi: 
      10.1002/(sici)1097-0304(199812)45:4<396::aid-ccd9>3.0.co;2-j.

PMID- 33111589
OWN - NLM
STAT- MEDLINE
DCOM- 20220217
LR  - 20220217
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 32
IP  - 8
DP  - 2021 Nov 17
TI  - Pro-apoptotic properties and mitochondrial functionality in 
      platelet-like-particles generated from low Aspirin-incubated Meg-01 cells.
PG  - 1063-1072
LID - 10.1080/09537104.2020.1839637 [doi]
AB  - Long-term therapy with low Aspirin (ASA) dose is basis to prevent thrombotic 
      acute events. However, the anti-platelet mechanisms of ASA remain not completely 
      known. The aim was to analyze if in vitro exposure of human megakaryocytes to low 
      ASA concentration may alter the apoptotic features of the newly formed platelets. 
      Cultured Meg-01 cells, a human megakaryoblastic cell line, were stimulated to 
      form platelets with 10 nmol/L phorbol 12-myristate-13-acetate (PMA) in the 
      presence and absence of ASA (0.33 mmol/L). Results revealed that platelet-like 
      particles (PLPs) derived from ASA-exposed Meg-01 cells, showed higher content of 
      pro-apoptotic proteins Bax and Bak than PLPs from non-ASA incubated Meg-01 cells. 
      It was accompanied of reduced cytochrome C oxidase activity and higher 
      mitochondrial content of PTEN-induced putative kinase-1 in PLPs from 
      ASA-incubated Meg-01 cells. However, only after calcium ionophore A23187 
      stimulation, caspase-3 activity, the cytosolic cytochrome C content, and 
      reduction of mitochondrial membrane potential were higher in PLPs from 
      ASA-incubated megakaryocytes than in those from Meg-01 without ASA. Nitric oxide 
      synthase 3 content was higher in PLPs from ASA-exposed Meg-01 cells than in PLPs 
      from non-ASA incubated Meg-01 cells. The L-arginine antagonist, 
      NG-Nitro-L-arginine Methyl Ester, reduced caspase-3 activity in A23187-stimulated 
      PLPs generated from ASA-incubated Meg-01 cells. As conclusions exposure of 
      megakaryocyte to ASA promotes that the newly generated PLPs have, under 
      stimulating condition, higher sensitivity to go into apoptosis than those PLPs 
      generated from Meg-01 cells without ASA. It could be associated with differences 
      in mitochondrial functionality and NO formation.
FAU - Freixer, Gala
AU  - Freixer G
AD  - Medicine.
FAU - Zekri-Nechar, Khaoula
AU  - Zekri-Nechar K
AD  - Medicine.
FAU - Zamorano-León, José J
AU  - Zamorano-León JJ
AD  - Public Health and Maternal and Child Health.
FAU - Hugo-Martínez, Carlos
AU  - Hugo-Martínez C
AD  - Medicine.
FAU - Butta, Nora V
AU  - Butta NV
AUID- ORCID: 0000-0003-4601-7150
AD  - Haematology Department, Hospital Universitario La Paz, idiPaz, Madrid, Spain.
FAU - Monzón, Elena
AU  - Monzón E
AD  - Haematology Department, Hospital Universitario La Paz, idiPaz, Madrid, Spain.
FAU - Recio, María-José
AU  - Recio MJ
AD  - Immunology, Ophthalmology and ORL.
FAU - Giner, Manel
AU  - Giner M
AD  - Surgery Departments, School of Medicine, Universidad Complutense, Madrid, Spain.
FAU - López-Farré, Antonio
AU  - López-Farré A
AD  - Medicine.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Humans
MH  - Membrane Potential, Mitochondrial/*immunology
OTO - NOTNLM
OT  - Apoptosis
OT  - Aspirin
OT  - Megakaryocytes
OT  - Mitochondria
OT  - Nitric Oxide
OT  - Platelets
EDAT- 2020/10/29 06:00
MHDA- 2022/02/19 06:00
CRDT- 2020/10/28 08:43
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2020/10/28 08:43 [entrez]
AID - 10.1080/09537104.2020.1839637 [doi]
PST - ppublish
SO  - Platelets. 2021 Nov 17;32(8):1063-1072. doi: 10.1080/09537104.2020.1839637. Epub 
      2020 Oct 28.

PMID- 37352055
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20230701
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 102
IP  - 25
DP  - 2023 Jun 23
TI  - Effect of combination of prophylactic or therapeutic anticoagulation with aspirin 
      on the outcomes of hospitalized COVID-19 patients: An observational retrospective 
      study.
PG  - e34040
LID - 10.1097/MD.0000000000034040 [doi]
LID - e34040
AB  - Regimens for managing thromboembolic complications of COVID-19 are still not very 
      well established. The present study compares the clinical characteristics and 
      outcomes of patients hospitalized with COVID-19 receiving different 
      anticoagulation regimens with and without aspirin. This is a retrospective 
      observational study of 491 patients hospitalized for COVID-19 from August 2020 to 
      April 2021. Data regarding clinical characteristics, laboratory findings, and 
      outcomes of patients receiving different anticoagulation with and without aspirin 
      regimens was collected, according to which 5 patient groups were defined: 
      received no anticoagulation (NAA), prophylactic anticoagulation with (PA) or 
      without aspirin (PAA) and therapeutic anticoagulation with (TA) or without 
      aspirin (TAA). The average age was highest in the TAA group. Desaturation was 
      highest in the TA and TAA groups. Diabetes, hypertension, dyslipidemia and 
      coronary artery disease were the most prevalent in aspirin groups (PAA and TAA) 
      as was heart failure in the TA and TAA groups and cancer in the TA and PAA 
      groups. Elevated troponin was observed in the PAA and TAA groups. TA and TAA 
      patients received oxygen therapy, needed ICU admission overall, and required 
      invasive ventilation and vasopressors the most. Prophylactic anticoagulation 
      groups (PA and PAA) had the highest patient survival rates. Patients with severe 
      COVID-19 infections were more likely to receive higher, therapeutic, 
      anticoagulation doses. Aspirin was given to patients with preexisting 
      comorbidities, but it had no statistically significant impact on the outcomes of 
      the different groups. Groups receiving prophylactic anticoagulation had the best 
      survival outcomes.
CI  - Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Mina, Jonathan
AU  - Mina J
AD  - Department of Internal Medicine, Staten Island University Hospital, Staten 
      Island, NY.
FAU - Fleifel, Mohamad
AU  - Fleifel M
AD  - Department of Internal Medicine, Lebanese American University Medical Centre-Rizk 
      Hospital, Beirut, Lebanon.
AD  - Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, 
      Byblos, Lebanon.
FAU - Haykal, Tony
AU  - Haykal T
AD  - Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, 
      Byblos, Lebanon.
FAU - Dimassi, Hani
AU  - Dimassi H
AD  - School of Pharmacy, Lebanese American University, Byblos, Lebanon.
FAU - Nasr, Janane
AU  - Nasr J
AD  - Department of Internal Medicine, Lebanese American University Medical Centre-Rizk 
      Hospital, Beirut, Lebanon.
AD  - Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, 
      Byblos, Lebanon.
FAU - Harb, Ranime
AU  - Harb R
AD  - School of Pharmacy, Lebanese American University, Byblos, Lebanon.
FAU - Mahdi, Ahmad
AU  - Mahdi A
AD  - Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, 
      Byblos, Lebanon.
FAU - El Hout, Ghida
AU  - El Hout G
AD  - Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, 
      Byblos, Lebanon.
FAU - Franjieh, Elissar
AU  - Franjieh E
AD  - Department of Internal Medicine, Lebanese American University Medical Centre-Rizk 
      Hospital, Beirut, Lebanon.
FAU - Mokhbat, Jacques
AU  - Mokhbat J
AD  - Department of Internal Medicine, Lebanese American University Medical Centre-Rizk 
      Hospital, Beirut, Lebanon.
FAU - Farra, Anna
AU  - Farra A
AD  - Department of Internal Medicine, Lebanese American University Medical Centre-Rizk 
      Hospital, Beirut, Lebanon.
FAU - Husni, Rola
AU  - Husni R
AUID- ORCID: 0000-0002-6893-5027
AD  - Department of Internal Medicine, Lebanese American University Medical Centre-Rizk 
      Hospital, Beirut, Lebanon.
AD  - Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, 
      Byblos, Lebanon.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Humans
MH  - *COVID-19
MH  - Aspirin/therapeutic use/pharmacology
MH  - Retrospective Studies
MH  - SARS-CoV-2
MH  - Blood Coagulation
MH  - Anticoagulants/adverse effects
PMC - PMC10289777
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2023/06/23 19:11
MHDA- 2023/06/26 06:42
CRDT- 2023/06/23 12:33
PHST- 2023/06/26 06:42 [medline]
PHST- 2023/06/23 19:11 [pubmed]
PHST- 2023/06/23 12:33 [entrez]
AID - 00005792-202306230-00036 [pii]
AID - 10.1097/MD.0000000000034040 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2023 Jun 23;102(25):e34040. doi: 
      10.1097/MD.0000000000034040.

PMID- 3772743
OWN - NLM
STAT- MEDLINE
DCOM- 19861208
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 75
IP  - 8
DP  - 1986 Aug
TI  - Extrahepatic metabolism and distribution of aspirin in vascular beds of sheep.
PG  - 731-7
AB  - The dispositions of aspirin, its metabolite, salicylic acid, and its subsequent 
      metabolite, salicyluric acid, were studied in eight anesthetized sheep infused 
      with aspirin (61 and 485 microgram X min-1 X kg-1) for 75 min. Plasma samples 
      were withdrawn from the portal vein, hepatic vein, pulmonary artery, left 
      ventricle, left femoral vein, and left femoral artery. Significant extraction of 
      aspirin occurred across the liver and hind leg, with mean availabilities of 0.75, 
      0.98, and 0.82 observed across the liver, lung, and hind leg, respectively. The 
      extraction of aspirin was not affected by coadministration of sodium salicylate 
      (30-1200 mg equiv salicylic acid). This extraction reflected hydrolysis of 
      aspirin to salicylic acid; the metabolism of aspirin in the hind leg, lung, and 
      liver being confirmed with tissue homogenate studies. The metabolism of aspirin 
      in the extrahepatic tissues is significant in relation to the proposed selective 
      presystemic acetylation of platelet cyclooxygenase by aspirin and the use of 
      low-dose aspirin for thrombotic indications.
FAU - Cossum, P A
AU  - Cossum PA
FAU - Roberts, M S
AU  - Roberts MS
FAU - Kilpatrick, D
AU  - Kilpatrick D
FAU - Yong, A C
AU  - Yong AC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*metabolism
MH  - Hindlimb/blood supply
MH  - Kinetics
MH  - Protein Binding
MH  - Sheep
EDAT- 1986/08/01 00:00
MHDA- 1986/08/01 00:01
CRDT- 1986/08/01 00:00
PHST- 1986/08/01 00:00 [pubmed]
PHST- 1986/08/01 00:01 [medline]
PHST- 1986/08/01 00:00 [entrez]
AID - S0022-3549(15)47191-6 [pii]
AID - 10.1002/jps.2600750802 [doi]
PST - ppublish
SO  - J Pharm Sci. 1986 Aug;75(8):731-7. doi: 10.1002/jps.2600750802.

PMID- 27005850
OWN - NLM
STAT- MEDLINE
DCOM- 20161215
LR  - 20161230
IS  - 1757-6199 (Electronic)
IS  - 1757-6180 (Linking)
VI  - 8
IP  - 8
DP  - 2016 Apr
TI  - Sol-gel approach for extracting highly versatile aspirin and its metabolites 
      using MISPE followed by GC-MS/MS analysis.
PG  - 795-805
LID - 10.4155/bio.16.28 [doi]
AB  - AIM: Aspirin is known to be a salicylate drug widely used as an analgesic, 
      antipyretic and anti-inflammatory drug. METHODOLOGY: Sol-gel based nanosized 
      molecularly imprinted polymer (nMIP) has been synthesized for extraction of 
      aspirin and its metabolites in urine followed by GC-MS/MS analysis. RESULTS: 
      Binding affinity of nMIP and nonimprinted polymer was found to be in the range of 
      70-95% and 29-45%, respectively. LOD and LOQ of aspirin and its metabolites were 
      found to be in the range of 0.63-2.4 ng/ml and 2.07-7.68 ng/ml, respectively. 
      CONCLUSION: The developed method was found to be applicable for routine analysis 
      of aspirin and its metabolites in biological samples.
FAU - Bhatia, Tejasvi
AU  - Bhatia T
AD  - Analytical Chemistry Laboratory, Regulatory Toxicology Group, CSIR-IITR, MG Marg, 
      Lucknow 226001, India.
AD  - Academy of Scientific & Innovative Research (AcSIR), CSIR-IITR, MG Marg, Lucknow 
      226001, India.
FAU - Gupta, Manoj Kumar
AU  - Gupta MK
AD  - Analytical Chemistry Laboratory, Regulatory Toxicology Group, CSIR-IITR, MG Marg, 
      Lucknow 226001, India.
AD  - Academy of Scientific & Innovative Research (AcSIR), CSIR-IITR, MG Marg, Lucknow 
      226001, India.
FAU - Singh, Pratibha
AU  - Singh P
AD  - Analytical Chemistry Laboratory, Regulatory Toxicology Group, CSIR-IITR, MG Marg, 
      Lucknow 226001, India.
FAU - Chauhan, Abhishek
AU  - Chauhan A
AD  - Analytical Chemistry Laboratory, Regulatory Toxicology Group, CSIR-IITR, MG Marg, 
      Lucknow 226001, India.
FAU - Saxena, Prem Narain
AU  - Saxena PN
AD  - CIF Facility, CSIR-IITR, MG Marg, Lucknow 226001, India.
FAU - Mudiam, Mohana Krishna Reddy
AU  - Mudiam MK
AD  - Analytical Chemistry Laboratory, Regulatory Toxicology Group, CSIR-IITR, MG Marg, 
      Lucknow 226001, India.
AD  - Academy of Scientific & Innovative Research (AcSIR), CSIR-IITR, MG Marg, Lucknow 
      226001, India.
AD  - Pesticide Toxicology Laboratory, Regulatory Toxicology Group, CSIR-IITR, M G 
      Marg, Lucknow 226001, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160323
PL  - England
TA  - Bioanalysis
JT  - Bioanalysis
JID - 101512484
RN  - 0 (Gels)
RN  - 0 (Polymers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis/*isolation & purification/metabolism
MH  - Chemistry Techniques, Analytical/*methods
MH  - *Gas Chromatography-Mass Spectrometry
MH  - Gels/*chemistry
MH  - Humans
MH  - Microscopy, Electron, Scanning
MH  - *Molecular Imprinting
MH  - Polymers/chemistry
MH  - *Solid Phase Extraction
OTO - NOTNLM
OT  - GC–MS/MS
OT  - aspirin and its metabolites
OT  - molecular imprinted polymer
OT  - sol-gel polymerization
EDAT- 2016/03/24 06:00
MHDA- 2016/12/16 06:00
CRDT- 2016/03/24 06:00
PHST- 2016/03/24 06:00 [entrez]
PHST- 2016/03/24 06:00 [pubmed]
PHST- 2016/12/16 06:00 [medline]
AID - 10.4155/bio.16.28 [doi]
PST - ppublish
SO  - Bioanalysis. 2016 Apr;8(8):795-805. doi: 10.4155/bio.16.28. Epub 2016 Mar 23.

PMID- 23017325
OWN - NLM
STAT- MEDLINE
DCOM- 20130225
LR  - 20220311
IS  - 1532-2823 (Electronic)
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 87
IP  - 4-5
DP  - 2012 Oct-Nov
TI  - The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet 
      function acutely whereas each alone may not in healthy humans.
PG  - 143-51
LID - S0952-3278(12)00149-4 [pii]
LID - 10.1016/j.plefa.2012.08.007 [doi]
AB  - INTRODUCTION: Aspirin's effectiveness in reducing cardiovascular disease events 
      is inadequate in some individuals, a phenomenon termed aspirin "resistance". The 
      hypothesis that combining low dose aspirin with eicosapentaenoic acid and 
      docosahexaenoic acid (EPA+DHA) reduces platelet function in the acute setting has 
      not been investigated. PATIENTS AND METHODS: We conducted a clinical trial of 
      EPA+DHA and aspirin ingestion in healthy adults. Fasting blood samples were drawn 
      at baseline and 4 h after supplementation with EPA/DHA (3.4 g/d), aspirin (81 
      mg), and both. Platelet function was measured using the Platelet Function 
      Analyzer-100 (PFA-100). Plasma lysophosphatidylcholine (LPC), lysophosphatidic 
      acid (LPA), autotaxin, angiogenesis activators, and cytokines were measured. 
      RESULTS: Platelet function decreased with the combination of aspirin+EPA/DHA 
      (p=0.03) but not with either alone (p>0.05). EPA-LPC increased (p=0.002). 
      DISCUSSION AND CONCLUSIONS: Our results demonstrate that a potentially beneficial 
      effect on platelet function occurred within 4h after ingestion of low-dose 
      aspirin and EPA+DHA in healthy adults.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Block, Robert C
AU  - Block RC
AD  - Department of Community and Preventive Medicine, The University of Rochester 
      School of Medicine and Dentistry, Box 644, Rochester, NY 14642, USA. 
      robert_block@urmc.rochester.edu
FAU - Kakinami, Lisa
AU  - Kakinami L
FAU - Jonovich, Matthew
AU  - Jonovich M
FAU - Antonetti, Illena
AU  - Antonetti I
FAU - Lawrence, Peter
AU  - Lawrence P
FAU - Meednu, Nida
AU  - Meednu N
FAU - CalderonArtero, Pedro
AU  - CalderonArtero P
FAU - Mousa, Shaker A
AU  - Mousa SA
FAU - Brenna, J Thomas
AU  - Brenna JT
FAU - Georas, Steve
AU  - Georas S
LA  - eng
GR  - KL2RR024136/RR/NCRR NIH HHS/United States
GR  - UL1 RR024160/RR/NCRR NIH HHS/United States
GR  - T32 HL007937/HL/NHLBI NIH HHS/United States
GR  - UL1RR024160/RR/NCRR NIH HHS/United States
GR  - KL2 RR024136/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20120925
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Drug Combinations)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Docosahexaenoic Acids/administration & dosage/*pharmacology
MH  - Drug Combinations
MH  - Eicosapentaenoic Acid/administration & dosage/*pharmacology
MH  - Humans
MH  - Platelet Function Tests
PMC - PMC3589139
MID - NIHMS410157
EDAT- 2012/09/29 06:00
MHDA- 2013/02/26 06:00
CRDT- 2012/09/29 06:00
PHST- 2012/06/20 00:00 [received]
PHST- 2012/08/21 00:00 [revised]
PHST- 2012/08/22 00:00 [accepted]
PHST- 2012/09/29 06:00 [entrez]
PHST- 2012/09/29 06:00 [pubmed]
PHST- 2013/02/26 06:00 [medline]
AID - S0952-3278(12)00149-4 [pii]
AID - 10.1016/j.plefa.2012.08.007 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2012 Oct-Nov;87(4-5):143-51. doi: 
      10.1016/j.plefa.2012.08.007. Epub 2012 Sep 25.

PMID- 27383519
OWN - NLM
STAT- MEDLINE
DCOM- 20171025
LR  - 20181202
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 14
IP  - 1
DP  - 2016 Jul 6
TI  - Individualised benefit-harm balance of aspirin as primary prevention measure - a 
      good proof-of-concept, but could have been better….
PG  - 101
LID - 10.1186/s12916-016-0648-9 [doi]
LID - 101
AB  - Guidelines from different organisations regarding the use of aspirin for primary 
      prevention vary despite being based on similar evidence. Translating these in 
      practice presents a further major challenge. The benefit-harm balance tool 
      developed by Puhan et al. (BMC Med 13:250, 2015) for aspirin can overcome some of 
      these difficulties and is therefore an important step towards personalised 
      medicine. Although a good proof-of-concept, this tool has some important 
      limitations that presently preclude its use in practice or for further research. 
      One of the major benefits of aspirin that has become apparent in the last decade 
      or so is its effect in preventing cancer and cancer-related deaths. However, this 
      benefit is clear and consistent in randomised as well as observational evidence 
      only for specific cancers. Additionally, it has long lag-time and carry-over 
      periods. These nuances of aspirin's effects demand a specific and a more 
      sophisticated model such as a time-varying model. Further refinement of this tool 
      with respect to these aspects is merited to make it ready for evaluation in 
      qualitative and quantitative studies with the goal of clinical utility.Please see 
      related article: 
      http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0493-2.
FAU - Thorat, Mangesh A
AU  - Thorat MA
AD  - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen 
      Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. 
      m.thorat@qmul.ac.uk.
AD  - Breast Services, Division of Surgery and Interventional Science, Whittington 
      Hospital, Magdala Avenue, London, N19 5NF, UK. m.thorat@qmul.ac.uk.
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20160706
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - BMC Med. 2015 Oct 01;13:250. PMID: 26423305
MH  - *Aspirin
MH  - *Cardiovascular Diseases
MH  - Humans
MH  - Neoplasms
MH  - Primary Prevention
PMC - PMC4936221
OTO - NOTNLM
OT  - Aspirin
OT  - Benefit–harm balance
OT  - Bleeding
OT  - Cancer
OT  - Cardiovascular disease
OT  - Gastrointestinal
OT  - Modelling
OT  - Personalised medicine
OT  - Prevention
EDAT- 2016/07/08 06:00
MHDA- 2017/10/27 06:00
CRDT- 2016/07/08 06:00
PHST- 2016/05/25 00:00 [received]
PHST- 2016/06/23 00:00 [accepted]
PHST- 2016/07/08 06:00 [entrez]
PHST- 2016/07/08 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
AID - 10.1186/s12916-016-0648-9 [pii]
AID - 648 [pii]
AID - 10.1186/s12916-016-0648-9 [doi]
PST - epublish
SO  - BMC Med. 2016 Jul 6;14(1):101. doi: 10.1186/s12916-016-0648-9.

PMID- 6793630
OWN - NLM
STAT- MEDLINE
DCOM- 19811221
LR  - 20190606
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 68
IP  - 4
DP  - 1981 Oct
TI  - Salicylate-aspirin interaction in the rat. Evidence that salicylate accumulating 
      during aspirin administration may protect vascular prostacyclin from 
      aspirin-induced inhibition.
PG  - 1108-12
AB  - Aspirin inhibits cyclooxygenase, thus preventing thromboxane A2 production in 
      blood platelets and prostacyclin in vascular cells. Aspirin is rapidly hydrolyzed 
      to salicylate in the circulation. The objectives of this study were (a) to 
      evaluate whether administration of salicylate, though ineffective by itself, 
      prevents the inhibitory effect of aspirin on platelet and/or vascular 
      cyclooxygenase activity; (b) to verify whether salicylate accumulating in blood 
      after aspirin administration interferes with the pharmacological activity of 
      further doses of aspirin. Pretreatment of rats with sodium salicylate (25-100 
      mg/kg i.p.) resulted in dose-related prevention of the effect of a subsequent 
      dose of aspirin (2.5-10 mg/kg i.v.) on both platelet and vascular cells. Sodium 
      salicylate appeared to amplify the greater response of platelets to aspirin 
      compared with vessel wall. Pretreatment of rats with repeated high doses of 
      aspirin (200 mg/kg) resulted after 24 h in blood salicylate levels (150-200 
      microgram/ml) that significantly prevented the inhibitory effect of a subsequent 
      dose of aspirin on newly synthesized vascular prostacyclin. Blood salicylate 
      levels obtained after 36 or 48 h (less than 50 microgram/ml) were too low to 
      blunt aspirin's effect. The interference with aspirin of its major endogenous 
      metabolite should be borne in mind when interpreting results obtained with high 
      dose aspirin or during repeated administration of this drug.
FAU - Dejana, E
AU  - Dejana E
FAU - Cerletti, C
AU  - Cerletti C
FAU - de Castellarnau, C
AU  - de Castellarnau C
FAU - Livio, M
AU  - Livio M
FAU - Galletti, F
AU  - Galletti F
FAU - Latini, R
AU  - Latini R
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandins)
RN  - 0 (Salicylates)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/antagonists & inhibitors/*pharmacology
MH  - Biotransformation
MH  - Blood Platelets/enzymology
MH  - Cyclooxygenase Inhibitors
MH  - Epoprostenol/*blood
MH  - Prostaglandin-Endoperoxide Synthases/blood
MH  - Prostaglandins/*blood
MH  - Rats
MH  - Salicylates/*pharmacology
MH  - Salicylic Acid
PMC - PMC370901
EDAT- 1981/10/01 00:00
MHDA- 1981/10/01 00:01
CRDT- 1981/10/01 00:00
PHST- 1981/10/01 00:00 [pubmed]
PHST- 1981/10/01 00:01 [medline]
PHST- 1981/10/01 00:00 [entrez]
AID - 10.1172/jci110336 [doi]
PST - ppublish
SO  - J Clin Invest. 1981 Oct;68(4):1108-12. doi: 10.1172/jci110336.

PMID- 12532116
OWN - NLM
STAT- MEDLINE
DCOM- 20030617
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 111
IP  - 1
DP  - 2003 Jan
TI  - Long-term treatment with aspirin desensitization in asthmatic patients with 
      aspirin-exacerbated respiratory disease.
PG  - 180-6
AB  - BACKGROUND: Aspirin desensitization treatment is an option to decrease disease 
      activity and reduce the need for systemic corticosteroids in patients with 
      aspirin-exacerbated respiratory disease (AERD). OBJECTIVE: This study was 
      designed to determine whether the clinical courses of patients with AERD improved 
      as early as 6 months after starting aspirin desensitization and to compare this 
      with follow-up evaluations after at least a year. METHODS: Between 1995 and 2000, 
      172 patients with AERD were admitted to our General Clinical Research Center, 
      were desensitized to and treated with aspirin, were discharged to their home 
      communities, and participated in follow-up interviews and written assessments of 
      their clinical courses. RESULTS: By the first 6 months of aspirin treatment, 
      there were significant reductions in sinus infections and numbers of short 
      courses of prednisone and improvements in sense of smell and general assessment 
      of nasal-sinus and asthma symptoms (P <.0001). These results persisted for 1 to 5 
      years (P <.0001). Mean prednisone doses decreased from 10.8 mg/d to 8.1 and 3.6 
      mg/d at 6 months and greater than 1 year, respectively. Of the 172 patients, 24 
      (14%) discontinued aspirin treatment because of side effects, and 115 (67%) 
      responded to aspirin treatment. After eliminating those who discontinued aspirin 
      treatment because of side effects, the improvement rate was 115 (78%) of 148 
      patients. Of the 126 patients who completed a year or more of aspirin treatment, 
      110 (87%) experienced improvement. CONCLUSION: Aspirin desensitization followed 
      by daily aspirin is efficacious by at least the first 6 months of treatment and 
      continues to be effective for up to 5 years of follow-up.
FAU - Berges-Gimeno, M Pilar
AU  - Berges-Gimeno MP
AD  - Scripps Research Institute and Scripps Clinic and Scripps Research Institute, La 
      Jolla, Calif 92037, USA.
FAU - Simon, Ronald A
AU  - Simon RA
FAU - Stevenson, Donald D
AU  - Stevenson DD
LA  - eng
GR  - M01RR00833/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Leukotriene Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Inhalation
MH  - Administration, Intranasal
MH  - Adrenal Cortex Hormones/administration & dosage
MH  - Aspirin/adverse effects/*immunology/*therapeutic use
MH  - Asthma/*therapy
MH  - Bronchial Provocation Tests
MH  - Desensitization, Immunologic
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Leukotriene Antagonists/therapeutic use
MH  - Respiratory Tract Diseases/*chemically induced
EDAT- 2003/01/18 04:00
MHDA- 2003/06/18 05:00
CRDT- 2003/01/18 04:00
PHST- 2003/01/18 04:00 [pubmed]
PHST- 2003/06/18 05:00 [medline]
PHST- 2003/01/18 04:00 [entrez]
AID - S0091674902912698 [pii]
AID - 10.1067/mai.2003.7 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2003 Jan;111(1):180-6. doi: 10.1067/mai.2003.7.

PMID- 37491919
OWN - NLM
STAT- MEDLINE
DCOM- 20230727
LR  - 20230727
IS  - 1600-0897 (Electronic)
IS  - 1046-7408 (Linking)
VI  - 90
IP  - 2
DP  - 2023 Aug
TI  - Modulation of the activation of endothelial nitric oxide synthase and nitrosative 
      stress biomarkers by aspirin triggered lipoxins: A possible mechanism of action 
      of aspirin in the antiphospholipid syndrome.
PG  - e13753
LID - 10.1111/aji.13753 [doi]
AB  - PROBLEM: Antiphospholipid syndrome (APS) is characterized by the clinical 
      manifestation of vascular thrombosis (VT) or pregnancy morbidity (PM) and 
      antiphospholipid antibodies (aPL) that can modify the nitric oxide production. 
      Low-dose aspirin is used in the prevention and treatment of diverse alterations 
      of pregnancy. One of the mechanisms of action of aspirin is to induce the 
      production of aspirin-triggered-lipoxins (ATL). The aim of this study was to 
      evaluate the modulatory effect of ATL over the activation of endothelial nitric 
      oxide synthase (eNOS) and nitrosative stress biomarkers induced by aPL. METHODS: 
      We used polyclonal IgG and sera from women with aPL and PM/VT or VT only, and 
      from women with PM only and positive for non-criteria aPL (SN-OAPS). In these 
      sera, biomarkers of nitrosative stress (nitrites and nitrotyrosine) were 
      measured. The protein expression of nitrotyrosine and the phosphorylation of eNOS 
      (at Ser1177) were estimated in human umbilical vein endothelial cells (HUVECs) 
      stimulated with polyclonal IgG with or without ATL. RESULTS: Women with SN-OAPS 
      showed increased circulating levels of nitrites and nitrotyrosine. Likewise, 
      polyclonal IgG from either SN-OAPS or VT patients stimulated nitrotyrosine 
      expression in HUVECs. ATL decreased the nitrotyrosine expression induced by 
      polyclonal IgG from the SN-OAPS group. ATL also recovered the reduced eNOS 
      phosphorylation at Ser1177 in HUVECs stimulated with polyclonal IgG from women 
      with PM/VT or SN-OAPS. CONCLUSIONS: Increased nitrosative stress present in serum 
      of women with SN-OAPS is associated with IgG-mediated impaired endothelial NO 
      synthesis in endothelial cells. ATL prevent these cellular changes.
CI  - © 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Granada-Gómez, Manuel
AU  - Granada-Gómez M
AD  - Grupo Reproducción, Facultad de Medicina, Dpto. Microbiología y Parasitología, 
      Universidad de Antioquia UdeA, Medellín, Colombia.
FAU - Velásquez-Berrío, Manuela
AU  - Velásquez-Berrío M
AUID- ORCID: 0000-0003-3348-9810
AD  - Grupo Reproducción, Facultad de Medicina, Dpto. Microbiología y Parasitología, 
      Universidad de Antioquia UdeA, Medellín, Colombia.
FAU - Molina, Carolina Rúa
AU  - Molina CR
AD  - Grupo de Investigación en Trombosis, Facultad de Medicina, Universidad de 
      Antioquia UdeA, Medellín, Colombia.
FAU - Martín, Sebastián San
AU  - Martín SS
AD  - Biomedical Research Center School of Medicine, Universidad de Valparaiso, 
      Valparaiso, Chile.
AD  - Group of Research and Innovation in Vascular Health (GRIVAS Health), Chillan, 
      Chile.
FAU - Escudero, Carlos
AU  - Escudero C
AUID- ORCID: 0000-0001-7688-4621
AD  - Vascular Physiology Laboratory, Basic Sciences Department, Faculty of Sciences, 
      Universidad del Bio-Bio, Chillán, Chile.
AD  - Group of Research and Innovation in Vascular Health (GRIVAS Health), Chillan, 
      Chile.
AD  - Red Iberoamericana de Alteraciones Vasculares Asociadas a TRanstornos del 
      EMbarazo (RIVATREM).
FAU - Alvarez, Angela M
AU  - Alvarez AM
AD  - Grupo Reproducción, Facultad de Medicina, Dpto. Microbiología y Parasitología, 
      Universidad de Antioquia UdeA, Medellín, Colombia.
FAU - Cadavid, Angela P
AU  - Cadavid AP
AD  - Grupo Reproducción, Facultad de Medicina, Dpto. Microbiología y Parasitología, 
      Universidad de Antioquia UdeA, Medellín, Colombia.
AD  - Grupo de Investigación en Trombosis, Facultad de Medicina, Universidad de 
      Antioquia UdeA, Medellín, Colombia.
AD  - Red Iberoamericana de Alteraciones Vasculares Asociadas a TRanstornos del 
      EMbarazo (RIVATREM).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Lipoxins)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - 0 (Nitrites)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Pregnancy
MH  - Humans
MH  - Female
MH  - *Antiphospholipid Syndrome
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Lipoxins/pharmacology
MH  - Nitric Oxide Synthase Type III
MH  - Nitrosative Stress
MH  - Nitrites
MH  - Human Umbilical Vein Endothelial Cells
MH  - Immunoglobulin G
OTO - NOTNLM
OT  - antiphospholipid antibodies
OT  - antiphospholipid syndrome
OT  - aspirin-triggered lipoxins
OT  - eNOS activation
OT  - nitrosative stress
EDAT- 2023/07/26 06:43
MHDA- 2023/07/27 06:42
CRDT- 2023/07/26 02:53
PHST- 2023/06/20 00:00 [revised]
PHST- 2022/04/09 00:00 [received]
PHST- 2023/07/04 00:00 [accepted]
PHST- 2023/07/27 06:42 [medline]
PHST- 2023/07/26 06:43 [pubmed]
PHST- 2023/07/26 02:53 [entrez]
AID - 10.1111/aji.13753 [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 2023 Aug;90(2):e13753. doi: 10.1111/aji.13753.

PMID- 22963282
OWN - NLM
STAT- MEDLINE
DCOM- 20130805
LR  - 20131121
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Linking)
VI  - 112
IP  - 3
DP  - 2013 Mar
TI  - Evaluation of the in vivo anti-inflammatory and analgesic activity of a highly 
      water-soluble aspirin conjugate.
PG  - 171-4
LID - 10.1111/bcpt.12006 [doi]
AB  - Glucose-aspirin (GA) was synthesized by conjugating aspirin (ASA) to the 3-carbon 
      of glucose to produce a stable water-soluble aspirin derivative. The in vivo 
      activities were compared with those of aspirin. The mouse tail flick assay showed 
      that at 120 min., both aspirin and GA showed the maximum possible effect, and the 
      higher dose (200 mg/kg) generally had less of an effect than the lower dose (100 
      mg/kg). Per cent inhibition of paw oedema was 63% and 69% for ASA and GA at 100 
      mg/kg, respectively. In the tail immersion test, the increase in reaction time 
      was significantly greater with GA as compared to aspirin (100 mg/kg) at 60 min. 
      In conclusion, there was significant anti-inflammatory and analgesic activity for 
      GA at the doses studied under the experimental conditions.
CI  - © 2012 The Authors Basic & Clinical Pharmacology & Toxicology © 2012 Nordic 
      Pharmacological Society.
FAU - Jacob, James N
AU  - Jacob JN
AD  - Organomed Corporation, Coventry, RI 02816, USA. info@organomed.com
FAU - Badyal, Dinesh K
AU  - Badyal DK
FAU - Bala, Suman
AU  - Bala S
LA  - eng
PT  - Journal Article
DEP - 20121009
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - 0 (3-O-(2'-acetoxy)benzoyl-2-glucopyranose)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Glucosides)
RN  - 059QF0KO0R (Water)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemical 
      synthesis/chemistry/pharmacology/*therapeutic use
MH  - Aspirin/*analogs & derivatives/chemical 
      synthesis/chemistry/pharmacology/therapeutic use
MH  - Carrageenan/pharmacology
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Edema/drug therapy
MH  - Glucosides/chemical synthesis/chemistry/pharmacology/*therapeutic use
MH  - Hydrolysis
MH  - Mice
MH  - Molecular Structure
MH  - Pain Threshold/drug effects
MH  - Rats
MH  - Solubility
MH  - Water/*chemistry
EDAT- 2012/09/12 06:00
MHDA- 2013/08/06 06:00
CRDT- 2012/09/12 06:00
PHST- 2012/05/22 00:00 [received]
PHST- 2012/09/02 00:00 [accepted]
PHST- 2012/09/12 06:00 [entrez]
PHST- 2012/09/12 06:00 [pubmed]
PHST- 2013/08/06 06:00 [medline]
AID - 10.1111/bcpt.12006 [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):171-4. doi: 10.1111/bcpt.12006. 
      Epub 2012 Oct 9.

PMID- 18993142
OWN - NLM
STAT- MEDLINE
DCOM- 20081204
LR  - 20131121
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 102
IP  - 10
DP  - 2008 Nov 15
TI  - Relation between aspirin dose, all-cause mortality, and bleeding in patients with 
      recent cerebrovascular or coronary ischemic events (from the BRAVO Trial).
PG  - 1285-90
LID - 10.1016/j.amjcard.2008.07.019 [doi]
AB  - Despite aspirin's established role in the treatment of atherosclerotic vascular 
      disease, considerable controversy exists regarding its most effective dosing 
      strategy. In a retrospective observational study, we examined the relation 
      between prescribed aspirin dose (<162 mg vs > or =162 mg/day aspirin) and 
      clinical outcome in 4,589 placebo-treated patients enrolled in the Blockage of 
      the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial over 
      a median follow-up of 366 days. Standard Cox regression analysis was employed 
      because propensity analysis was not feasible. Compared with lower aspirin doses, 
      higher doses were associated with lower unadjusted all-cause mortality (2.9 vs 
      1.6%, respectively; log rank chi-square 8.6, p = 0.0034). Higher aspirin dose 
      remained independently predictive of lower all-cause mortality in a multivariable 
      Cox proportional hazards model (hazard ratio 0.64, 95% confidence interval 0.42 
      to 0.97, p = 0.037). However, there was no significant difference in the 
      incidence of the composite endpoint death, nonfatal myocardial infarction, or 
      nonfatal stroke (6.1% vs 6.2%, p = 0.74). Higher aspirin dose was a significant 
      independent predictor of any (hazard ratio 1.32, 95% confidence interval 1.12 to 
      1.55, p = 0.001) but not serious bleeding. In conclusion, our findings suggest 
      that aspirin doses of > or =162 mg/day may be more beneficial than those <162 
      mg/day at preventing death.
FAU - Aronow, Herbert D
AU  - Aronow HD
AD  - Clinical Scholars Program, Michigan Heart and Vascular Institute at St Joseph 
      Mercy Hospital, Ann Arbor, MI, USA. haronow@michiganheart.com
FAU - Califf, Robert M
AU  - Califf RM
FAU - Harrington, Robert A
AU  - Harrington RA
FAU - Vallee, Marc
AU  - Vallee M
FAU - Graffagnino, Carmelo
AU  - Graffagnino C
FAU - Shuaib, Ashfaq
AU  - Shuaib A
FAU - Fitzgerald, Desmond J
AU  - Fitzgerald DJ
FAU - Easton, J Donald
AU  - Easton JD
FAU - Van de Werf, Frans
AU  - Van de Werf F
FAU - Diener, Hans-Christoph
AU  - Diener HC
FAU - Ferguson, James
AU  - Ferguson J
FAU - Koudstaal, Peter J
AU  - Koudstaal PJ
FAU - Amarenco, Pierre
AU  - Amarenco P
FAU - Theroux, Pierre
AU  - Theroux P
FAU - Davis, Stephen
AU  - Davis S
FAU - Topol, Eric J
AU  - Topol EJ
LA  - eng
PT  - Journal Article
DEP - 20080915
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cause of Death
MH  - Coronary Disease/*drug therapy/mortality
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Stroke/*drug therapy/mortality
EDAT- 2008/11/11 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/11/11 09:00
PHST- 2008/04/22 00:00 [received]
PHST- 2008/07/09 00:00 [revised]
PHST- 2008/07/09 00:00 [accepted]
PHST- 2008/11/11 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/11/11 09:00 [entrez]
AID - S0002-9149(08)01180-6 [pii]
AID - 10.1016/j.amjcard.2008.07.019 [doi]
PST - ppublish
SO  - Am J Cardiol. 2008 Nov 15;102(10):1285-90. doi: 10.1016/j.amjcard.2008.07.019. 
      Epub 2008 Sep 15.

PMID- 37236757
OWN - NLM
STAT- MEDLINE
DCOM- 20230529
LR  - 20230622
IS  - 1557-8925 (Electronic)
IS  - 1054-3589 (Linking)
VI  - 97
DP  - 2023
TI  - Cyclooxygenases and platelet functions.
PG  - 133-165
LID - S1054-3589(22)00084-9 [pii]
LID - 10.1016/bs.apha.2022.12.001 [doi]
AB  - Cyclooxygenase (COX) isozymes, i.e., COX-1 and COX-2, are encoded by separate 
      genes and are involved in the generation of the same products, prostaglandin 
      (PG)G(2) and PGH(2) from arachidonic acid (AA) by the COX and peroxidase 
      activities of the enzymes, respectively. PGH(2) is then transformed into 
      prostanoids in a tissue-dependent fashion due to the different expression of 
      downstream synthases. Platelets present almost exclusively COX-1, which generates 
      large amounts of thromboxane (TX)A(2), a proaggregatory and vasoconstrictor 
      mediator. This prostanoid plays a central role in atherothrombosis, as shown by 
      the benefit of the antiplatelet agent low-dose aspirin, a preferential inhibitor 
      of platelet COX-1. Recent findings have shown the relevant role played by 
      platelets and TXA(2) in developing chronic inflammation associated with several 
      diseases, including tissue fibrosis and cancer. COX-2 is induced in response to 
      inflammatory and mitogenic stimuli to generate PGE(2) and PGI(2) (prostacyclin), 
      in inflammatory cells. However, PGI(2) is constitutively expressed in vascular 
      cells in vivo and plays a crucial role in protecting the cardiovascular systems 
      due to its antiplatelet and vasodilator effects. Here, platelets' role in 
      regulating COX-2 expression in cells of the inflammatory microenvironment is 
      described. Thus, the selective inhibition of platelet COX-1-dependent TXA(2) by 
      low-dose aspirin prevents COX-2 induction in stromal cells leading to 
      antifibrotic and antitumor effects. The biosynthesis and functions of other 
      prostanoids, such as PGD(2), and isoprostanes, are reported. In addition to 
      aspirin, which inhibits platelet COX-1 activity, possible strategies to affect 
      platelet functions by influencing platelet prostanoid receptors or synthases are 
      discussed.
CI  - Copyright © 2023 Elsevier Inc. All rights reserved.
FAU - Bruno, Annalisa
AU  - Bruno A
AD  - Center for Advanced Studies and Technology (CAST), Chieti, Italy; Department of 
      Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University, Chieti, 
      Italy.
FAU - Tacconelli, Stefania
AU  - Tacconelli S
AD  - Center for Advanced Studies and Technology (CAST), Chieti, Italy; Department of 
      Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University, Chieti, 
      Italy.
FAU - Contursi, Annalisa
AU  - Contursi A
AD  - Center for Advanced Studies and Technology (CAST), Chieti, Italy; Department of 
      Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University, Chieti, 
      Italy.
FAU - Ballerini, Patrizia
AU  - Ballerini P
AD  - Center for Advanced Studies and Technology (CAST), Chieti, Italy; Department of 
      Innovative Technologies in Medicine and Dentistry, "G.d'Annunzio" University, 
      Chieti, Italy.
FAU - Patrignani, Paola
AU  - Patrignani P
AD  - Center for Advanced Studies and Technology (CAST), Chieti, Italy; Department of 
      Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University, Chieti, 
      Italy. Electronic address: ppatrignani@unich.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230511
PL  - United States
TA  - Adv Pharmacol
JT  - Advances in pharmacology (San Diego, Calif.)
JID - 9015397
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 42935-17-1 (Prostaglandin H2)
SB  - IM
MH  - Humans
MH  - Cyclooxygenase 2
MH  - *Prostaglandins
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Thromboxane A2/physiology
MH  - Prostaglandin H2
OTO - NOTNLM
OT  - Atherothrombosis
OT  - Cancer
OT  - Cyclooxygenase
OT  - Eicosanoids
OT  - Fibrosis
OT  - Inflammation
OT  - Low-dose aspirin
OT  - Platelets
OT  - Thromboxane A(2)
COIS- Conflict of interest statement The authors declare no conflict of interest.
EDAT- 2023/05/27 09:42
MHDA- 2023/05/29 06:41
CRDT- 2023/05/26 20:58
PHST- 2023/05/29 06:41 [medline]
PHST- 2023/05/27 09:42 [pubmed]
PHST- 2023/05/26 20:58 [entrez]
AID - S1054-3589(22)00084-9 [pii]
AID - 10.1016/bs.apha.2022.12.001 [doi]
PST - ppublish
SO  - Adv Pharmacol. 2023;97:133-165. doi: 10.1016/bs.apha.2022.12.001. Epub 2023 May 
      11.

PMID- 7358711
OWN - NLM
STAT- MEDLINE
DCOM- 19800530
LR  - 20210210
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 255
IP  - 7
DP  - 1980 Apr 10
TI  - Modification of hemoglobin with analogs of aspirin.
PG  - 2816-21
AB  - A variety of acyl esters of salicyclic acid and 3,5-dibromosalicylic acid have 
      been prepared and examined for their ability to place the acyl group on 
      hemoglobin. In general, short chain acyl groups (C2 and C3) are more reactive 
      than longer chains (C4 to C10), but longer chains may be more effective with 
      intact red cells because of their enhanced ability to permeate the erythrocyte 
      membrane. The brominated salicyl esters also exhibit enhanced permeation of the 
      membrane, as well as increased activity due to activation at the acyl site. 
      Bis(salicyl) esters, nonbrominated and brominated, are more reactive than 
      corresponding monoesters, and those from C4 dicarboxylic acids connect beta 
      subunits by covalent bridges. These double-headed aspirins have the attractive 
      features of being bound selectively by hemoglobin and of forming a covalent 
      cross-link that may influence the conformation of the tetramer.
FAU - Zaugg, R H
AU  - Zaugg RH
FAU - Walder, J A
AU  - Walder JA
FAU - Walder, R Y
AU  - Walder RY
FAU - Steele, J M
AU  - Steele JM
FAU - Klotz, I M
AU  - Klotz IM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Macromolecular Substances)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/blood
MH  - Cross-Linking Reagents
MH  - Erythrocyte Membrane/metabolism
MH  - *Hemoglobins/metabolism
MH  - Macromolecular Substances
MH  - Protein Binding
MH  - Structure-Activity Relationship
EDAT- 1980/04/10 00:00
MHDA- 1980/04/10 00:01
CRDT- 1980/04/10 00:00
PHST- 1980/04/10 00:00 [pubmed]
PHST- 1980/04/10 00:01 [medline]
PHST- 1980/04/10 00:00 [entrez]
AID - S0021-9258(19)85812-X [pii]
PST - ppublish
SO  - J Biol Chem. 1980 Apr 10;255(7):2816-21.

PMID- 19048166
OWN - NLM
STAT- MEDLINE
DCOM- 20090123
LR  - 20131121
IS  - 1359-7345 (Print)
IS  - 1359-7345 (Linking)
IP  - 47
DP  - 2008 Dec 21
TI  - Evaluation of aspirin metabolites as inhibitors of hypoxia-inducible factor 
      hydroxylases.
PG  - 6393-5
LID - 10.1039/b814440k [doi]
AB  - Known and potential aspirin metabolites were evaluated as inhibitors of 
      oxygen-sensing hypoxia-inducible transcription factor (HIF) hydroxylases; some of 
      the metabolites were found to stabilise HIF-alpha in cells.
FAU - Lienard, Benoit M
AU  - Lienard BM
AD  - The Department of Chemistry and the Oxford Centre for Integrative Systems 
      Biology, Chemistry Research Laboratory, University of Oxford, Mansfield Road, 
      Oxford, United Kingdom.
FAU - Conejo-García, Ana
AU  - Conejo-García A
FAU - Stolze, Ineke
AU  - Stolze I
FAU - Loenarz, Christoph
AU  - Loenarz C
FAU - Oldham, Neil J
AU  - Oldham NJ
FAU - Ratcliffe, Peter J
AU  - Ratcliffe PJ
FAU - Schofield, Christopher J
AU  - Schofield CJ
LA  - eng
GR  - Biotechnology and Biological Sciences Research Council/United Kingdom
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081105
PL  - England
TA  - Chem Commun (Camb)
JT  - Chemical communications (Cambridge, England)
JID - 9610838
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - EC 1.13.11.- (Dioxygenases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/metabolism/*pharmacology
MH  - Dioxygenases/*metabolism
MH  - Enzyme Inhibitors/*chemistry/metabolism/*pharmacology
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*antagonists & inhibitors/*metabolism
MH  - Molecular Structure
MH  - Spectrometry, Mass, Electrospray Ionization
EDAT- 2008/12/03 09:00
MHDA- 2009/01/24 09:00
CRDT- 2008/12/03 09:00
PHST- 2008/12/03 09:00 [pubmed]
PHST- 2009/01/24 09:00 [medline]
PHST- 2008/12/03 09:00 [entrez]
AID - 10.1039/b814440k [doi]
PST - ppublish
SO  - Chem Commun (Camb). 2008 Dec 21;(47):6393-5. doi: 10.1039/b814440k. Epub 2008 Nov 
      5.

PMID- 22168568
OWN - NLM
STAT- MEDLINE
DCOM- 20120418
LR  - 20211021
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 12
DP  - 2011 Dec 14
TI  - The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the 
      ASCOLT study: study protocol for a randomized controlled trial.
PG  - 261
LID - 10.1186/1745-6215-12-261 [doi]
AB  - BACKGROUND: High quality evidence indicates that aspirin is effective in reducing 
      colorectal polyps; and numerous epidemiological studies point towards an ability 
      to prevent colorectal cancer. However the role of Aspirin as an adjuvant agent in 
      patients with established cancers remains to be defined. Recently a nested 
      case-control study within the Nurses Health cohort suggested that the initiation 
      of Aspirin after the diagnosis of colon cancer reduced overall colorectal cancer 
      specific mortality. Although this data is supportive of Aspirin's biological 
      activity in this disease and possible role in adjuvant therapy, it needs to be 
      confirmed in a randomized prospective trial. METHODS/DESIGN: We hypothesize 
      through this randomized, placebo-controlled adjuvant study, that Aspirin in 
      patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve 
      survival in this patient population over placebo control. The primary endpoint of 
      this study is Disease Free Survival and the secondary Endpoint is 5 yr Overall 
      Survival. This study will randomize eligible patients with Dukes C or high risk 
      Dukes B colorectal cancer, after completion of surgery and standard adjuvant 
      chemotherapy (+/- radiation therapy for rectal cancer patients) to 200 mg Aspirin 
      or Placebo for 3 years. Stratification factors include study centre, rectal or 
      colon cancer stage, and type of adjuvant chemotherapy (exposed/not exposed to 
      oxaliplatin). After randomization, patient will be followed up with 3 monthly 
      assessments whilst on study drug and for a total of 5 years. Patients with active 
      peptic ulcer disease, bleeding diathesis or on treatment with aspirin or 
      anti-platelet agents will be excluded from the study. DISCUSSION: This study aims 
      to evaluate Aspirin's role as an adjuvant treatment in colorectal cancer. If 
      indeed found to be beneficial, because aspirin is cheap, accessible and easy to 
      administer, it will positively impact the lives of many individuals in Asia and 
      globally. TRIALS REGISTRATION: Clinicaltrials.gov: NCT00565708.
FAU - Ali, Raghib
AU  - Ali R
AD  - INDOX Cancer Research Network, Richard Doll building, University of Oxford 
      OX37LF, UK.
FAU - Toh, Han-Chong
AU  - Toh HC
FAU - Chia, Whay-Kuang
AU  - Chia WK
CN  - ASCOLT Trial Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00565708
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20111214
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - *Clinical Protocols
MH  - Colorectal Neoplasms/*drug therapy
MH  - Cyclooxygenase 2 Inhibitors/therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Sample Size
PMC - PMC3271983
FIR - Deng, Y H
IR  - Deng YH
FIR - Jian, X
IR  - Jian X
FIR - Wang, W
IR  - Wang W
FIR - Roh, J K
IR  - Roh JK
FIR - Bae, A J
IR  - Bae AJ
FIR - Shin, S J
IR  - Shin SJ
FIR - Raj, T A
IR  - Raj TA
FIR - Nathan, E
IR  - Nathan E
FIR - Khong, R
IR  - Khong R
FIR - Lau, F
IR  - Lau F
FIR - Deniel, A
IR  - Deniel A
FIR - Low, J
IR  - Low J
FIR - Tan, D
IR  - Tan D
FIR - Ho, G F
IR  - Ho GF
FIR - Mastura, B M Y
IR  - Mastura BM
FIR - Roslani, A C
IR  - Roslani AC
FIR - Azrif, M
IR  - Azrif M
FIR - Yau, T
IR  - Yau T
FIR - Law, W L
IR  - Law WL
FIR - Kurnianda, J
IR  - Kurnianda J
FIR - Purwanto, I
IR  - Purwanto I
FIR - Widayati, K
IR  - Widayati K
FIR - Soemardi, A
IR  - Soemardi A
FIR - Syafei, S
IR  - Syafei S
FIR - Mellinas, L
IR  - Mellinas L
FIR - Andalusia, R
IR  - Andalusia R
FIR - Noorwati, S
IR  - Noorwati S
FIR - Basir, I
IR  - Basir I
FIR - Abdullah, M
IR  - Abdullah M
FIR - Maengkom, F
IR  - Maengkom F
FIR - Rinaldi, I
IR  - Rinaldi I
FIR - Prajogi, G B
IR  - Prajogi GB
FIR - Lopes, G
IR  - Lopes G
FIR - Ku, G
IR  - Ku G
FIR - Bharwani, L
IR  - Bharwani L
FIR - Chopra, A
IR  - Chopra A
FIR - Chang, A
IR  - Chang A
FIR - Tham, C K
IR  - Tham CK
FIR - Ong, S
IR  - Ong S
FIR - Choo, S P
IR  - Choo SP
FIR - Lo, S K
IR  - Lo SK
FIR - Koo, W H
IR  - Koo WH
FIR - Lim, H Y
IR  - Lim HY
FIR - Tan, I
IR  - Tan I
FIR - Lim, K H
IR  - Lim KH
FIR - Sim, R
IR  - Sim R
FIR - Dasappa, L
IR  - Dasappa L
FIR - Sadashivudu, G
IR  - Sadashivudu G
FIR - Mallath, Mohandas
IR  - Mallath M
FIR - Sharma, A
IR  - Sharma A
FIR - Chacko, R T
IR  - Chacko RT
FIR - Sivanesan, B
IR  - Sivanesan B
FIR - Rajkumar, A
IR  - Rajkumar A
FIR - Ganesan, T S
IR  - Ganesan TS
FIR - Sajeed, A
IR  - Sajeed A
FIR - Ismail, A
IR  - Ismail A
FIR - Hsieh, C I
IR  - Hsieh CI
FIR - Wei, P L
IR  - Wei PL
FIR - Juo, L J
IR  - Juo LJ
FIR - Chao, T Y
IR  - Chao TY
FIR - Chen, C M
IR  - Chen CM
FIR - Hsieh, Y Y
IR  - Hsieh YY
FIR - Chang, T C
IR  - Chang TC
FIR - Lai, G M
IR  - Lai GM
FIR - Su, Y W
IR  - Su YW
FIR - Chou, C M
IR  - Chou CM
FIR - Yen, C C
IR  - Yen CC
FIR - Lin, J K
IR  - Lin JK
FIR - Liu, J H
IR  - Liu JH
FIR - Lin, T C
IR  - Lin TC
FIR - Teng, H W
IR  - Teng HW
FIR - Hua, Chang
IR  - Hua C
FIR - Chen, H C
IR  - Chen HC
FIR - Chang, C S
IR  - Chang CS
FIR - Huang, S Y
IR  - Huang SY
FIR - Wang, C C
IR  - Wang CC
FIR - Lin, S Y
IR  - Lin SY
FIR - Chung, C Y
IR  - Chung CY
FIR - Lin, J T
IR  - Lin JT
FIR - Hsu, S Z
IR  - Hsu SZ
FIR - Huang, I P
IR  - Huang IP
FIR - Chen, C H
IR  - Chen CH
FIR - Chen, C C
IR  - Chen CC
FIR - Huang, K C
IR  - Huang KC
FIR - Lee, J C
IR  - Lee JC
FIR - Lin, P C
IR  - Lin PC
FIR - Su, W C
IR  - Su WC
FIR - Lin, B W
IR  - Lin BW
FIR - Lin, S C
IR  - Lin SC
FIR - Kullathorn, T
IR  - Kullathorn T
FIR - Akewanlop, C
IR  - Akewanlop C
FIR - Dankulchai, P
IR  - Dankulchai P
FIR - Chansilpa, Y
IR  - Chansilpa Y
FIR - Akaraviputh, T
IR  - Akaraviputh T
FIR - Chucheep, S
IR  - Chucheep S
FIR - Jirawat, P A
IR  - Jirawat PA
FIR - Atittharnsakul, P
IR  - Atittharnsakul P
FIR - Tantiplachiva, K
IR  - Tantiplachiva K
FIR - Sacdalan, D L
IR  - Sacdalan DL
FIR - Parreno, D
IR  - Parreno D
EDAT- 2011/12/16 06:00
MHDA- 2012/04/19 06:00
CRDT- 2011/12/16 06:00
PHST- 2011/10/31 00:00 [received]
PHST- 2011/12/14 00:00 [accepted]
PHST- 2011/12/16 06:00 [entrez]
PHST- 2011/12/16 06:00 [pubmed]
PHST- 2012/04/19 06:00 [medline]
AID - 1745-6215-12-261 [pii]
AID - 10.1186/1745-6215-12-261 [doi]
PST - epublish
SO  - Trials. 2011 Dec 14;12:261. doi: 10.1186/1745-6215-12-261.

PMID- 10230767
OWN - NLM
STAT- MEDLINE
DCOM- 19990601
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 57
IP  - 11
DP  - 1999 Jun 1
TI  - An NMR analysis of the reaction of ubiquitin with [acetyl-1-13C]aspirin.
PG  - 1233-44
AB  - The acetylation of ubiquitin by [acetyl-1-13C]aspirin has been studied using 2D 
      NMR methods. Studies performed in a 50:50 H2O:D2O medium show doubling of the 
      acetyl carbonyl resonances, indicating that all of the stable adducts formed 
      involved amide linkages. Assignment of the heteronuclear multiple quantum 
      coherence (HMQC) resonances was accomplished based on comparison of resonance 
      intensities with the results of an Edman degradation analysis, pH titration 
      studies of acetylated ubiquitin, and analysis of two ubiquitin mutants, K33R and 
      K63R. The presence of a single tyrosine residue in close proximity to lysine-48 
      suggested another assignment strategy. Nitration of tyrosine-59 resulted in a 
      small, pH-dependent shift of the resonance assigned to lysine-48, with a pK of 
      7.0, close to that expected for the nitrotyrosyl hydroxyl group. An additional 
      adduct resonance with very low intensity also was observed and tentatively 
      assigned to the acetylated N-terminal methionine residue. The relative rates of 
      acetylation of the various lysine residues were obtained from time-dependent HMQC 
      studies. Since no sample preparation artifacts were introduced, the levels of 
      modification of the various residues could be determined with relatively high 
      accuracy. Based on the time-dependent intensity data, the relative rate constants 
      for modification of K6, K48, K63, K11, K33, and M1 were 1.0, 0.59, 0.43, 0.26, 
      0.23, and 0.03, respectively. These results were in much better agreement with 
      amino accessibility predictions based on the crystal structure of the ubiquitin 
      monomer than with predictions based on the ubiquitin structure in the 
      crystallized dimeric and tetrameric forms. This approach provides a useful basis 
      for understanding how local environmental factors can influence protein adduct 
      formation, as well as for comparing the extent and specificity of various 
      acetylation reagents.
FAU - Macdonald, J M
AU  - Macdonald JM
AD  - Laboratory of Structural Biology, National Institute of Environmental Health 
      Sciences, Research Triangle Park, NC 27709, USA.
FAU - LeBlanc, D A
AU  - LeBlanc DA
FAU - Haas, A L
AU  - Haas AL
FAU - London, R E
AU  - London RE
LA  - eng
GR  - GM 34009/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Carbon Isotopes)
RN  - 0 (Ubiquitins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/chemical synthesis/*chemistry
MH  - Carbon Isotopes
MH  - Kinetics
MH  - Magnetic Resonance Spectroscopy
MH  - Ubiquitins/analogs & derivatives/*chemistry
EDAT- 1999/05/07 00:00
MHDA- 1999/05/07 00:01
CRDT- 1999/05/07 00:00
PHST- 1999/05/07 00:00 [pubmed]
PHST- 1999/05/07 00:01 [medline]
PHST- 1999/05/07 00:00 [entrez]
AID - S0006-2952(99)00039-8 [pii]
AID - 10.1016/s0006-2952(99)00039-8 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1999 Jun 1;57(11):1233-44. doi: 10.1016/s0006-2952(99)00039-8.

PMID- 30802900
OWN - NLM
STAT- MEDLINE
DCOM- 20200107
LR  - 20200107
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 170
IP  - 6
DP  - 2019 Mar 19
TI  - Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of 
      Cardiovascular Disease: A Cohort Study.
PG  - 357-368
LID - 10.7326/M18-2808 [doi]
AB  - BACKGROUND: Many prognostic models for cardiovascular risk can be used to 
      estimate aspirin's absolute benefits, but few bleeding risk models are available 
      to estimate its likely harms. OBJECTIVE: To develop prognostic bleeding risk 
      models among persons in whom aspirin might be considered for the primary 
      prevention of cardiovascular disease (CVD). DESIGN: Prospective cohort study. 
      SETTING: New Zealand primary care. PARTICIPANTS: The study cohort comprised 
      385 191 persons aged 30 to 79 years whose CVD risk was assessed between 2007 and 
      2016. Those with indications for or contraindications to aspirin and those who 
      were already receiving antiplatelet or anticoagulant therapy were excluded. 
      MEASUREMENTS: For each sex, Cox proportional hazards models were developed to 
      predict major bleeding risk; participants were censored at the earliest of the 
      date on which they first met an exclusion criterion, date of death, or study end 
      date (30 June 2017). The main models included the following predictors: 
      demographic characteristics (age, ethnicity, and socioeconomic deprivation), 
      clinical measurements (systolic blood pressure and ratio of total-high-density 
      lipoprotein cholesterol), family history of premature CVD, medical history 
      (smoking, diabetes, bleeding, peptic ulcer disease, cancer, chronic liver 
      disease, chronic pancreatitis, or alcohol-related conditions), and medication use 
      (nonsteroidal anti-inflammatory agents, corticosteroids, and selective serotonin 
      reuptake inhibitors). RESULTS: During 1 619 846 person-years of follow-up, 4442 
      persons had major bleeding events (of which 313 [7%] were fatal). The main models 
      predicted a median 5-year bleeding risk of 1.0% (interquartile range, 0.8% to 
      1.5%) in women and 1.1% (interquartile range, 0.7% to 1.6%) in men. Plots of 
      predicted-against-observed event rates showed good calibration throughout the 
      risk range. LIMITATION: Hemoglobin level, platelet count, and body mass index 
      were excluded from the main models because of high numbers of missing values, and 
      the models were not externally validated in non-New Zealand populations. 
      CONCLUSION: Prognostic bleeding risk models were developed that can be used to 
      estimate the absolute bleeding harms of aspirin among persons in whom aspirin is 
      being considered for the primary prevention of CVD. PRIMARY FUNDING SOURCE: The 
      Health Research Council of New Zealand.
FAU - Selak, Vanessa
AU  - Selak V
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., S.W.).
FAU - Jackson, Rod
AU  - Jackson R
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., S.W.).
FAU - Poppe, Katrina
AU  - Poppe K
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., S.W.).
FAU - Wu, Billy
AU  - Wu B
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., S.W.).
FAU - Harwood, Matire
AU  - Harwood M
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., S.W.).
FAU - Grey, Corina
AU  - Grey C
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., S.W.).
FAU - Pylypchuk, Romana
AU  - Pylypchuk R
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., S.W.).
FAU - Mehta, Suneela
AU  - Mehta S
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., S.W.).
FAU - Kerr, Andrew
AU  - Kerr A
AD  - University of Auckland and Middlemore Hospital, Auckland, New Zealand (A.K.).
FAU - Wells, Sue
AU  - Wells S
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., S.W.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20190226
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2019 Mar 19;170(6):411-413. PMID: 30802898
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Primary Prevention
MH  - *Proportional Hazards Models
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2019/02/26 06:00
MHDA- 2020/01/08 06:00
CRDT- 2019/02/26 06:00
PHST- 2019/02/26 06:00 [pubmed]
PHST- 2020/01/08 06:00 [medline]
PHST- 2019/02/26 06:00 [entrez]
AID - 2726667 [pii]
AID - 10.7326/M18-2808 [doi]
PST - ppublish
SO  - Ann Intern Med. 2019 Mar 19;170(6):357-368. doi: 10.7326/M18-2808. Epub 2019 Feb 
      26.

PMID- 15238606
OWN - NLM
STAT- MEDLINE
DCOM- 20041026
LR  - 20181113
IS  - 0022-1007 (Print)
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Linking)
VI  - 200
IP  - 1
DP  - 2004 Jul 5
TI  - 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin 
      inhibits acute inflammation.
PG  - 69-78
AB  - The established model for the mechanism of action of aspirin is the inhibition of 
      prostaglandin synthesis. However, this has never fully explained aspirin's 
      repertoire of antiinflammatory properties. We found in acute pleuritis that 
      aspirin, but not salicylate, indomethacin, or piroxicam, increased plasma nitric 
      oxide (NO), which correlated with a reduction in inflammation. Inhibiting 
      aspirin-elicited NO pharmacologically in this model nullified the 
      antiinflammatory effects of aspirin. Moreover, aspirin was not antiinflammatory 
      in either constitutive (eNOS) or inducible NO synthase (iNOS) knockout mice with 
      IL-1beta-induced peritonitis. It transpires that aspirin generates NO through its 
      unique ability to trigger the synthesis of 15-epi-lipoxin A(4). Aspirin and 
      15-epi-lipoxin A(4) were shown to inhibit leukocyte trafficking in an 
      NO-dependent manner using intravital microscopy on IL-1beta-stimulated mouse 
      mesentery. Not only did aspirin inhibit leukocyte-endothelial interaction in a 
      manner similar to NO in wild-type mice but both aspirin and 15-epi-lipoxin A(4) 
      had markedly reduced effects on leukocyte-endothelial cell adherence in eNOS- and 
      iNOS-deficient mice compared with wild type. Collectively, these data suggest 
      that aspirin triggers the synthesis of 15-epi-lipoxin A(4), which increases NO 
      synthesis through eNOS and iNOS. This aspirin-elicited NO exerts antiinflammatory 
      effects in the microcirculation by inhibiting leukocyte-endothelium interactions.
FAU - Paul-Clark, Mark J
AU  - Paul-Clark MJ
AD  - Department of Biochemical Pharmacology, William Harvey Research Institute, St. 
      Bartholomew's Hospital and The Royal London School of Medicine and Dentistry, 
      Charterhouse Sq., London EC1M 6BQ, England, UK.
FAU - Van Cao, Thong
AU  - Van Cao T
FAU - Moradi-Bidhendi, Niloufar
AU  - Moradi-Bidhendi N
FAU - Cooper, Dianne
AU  - Cooper D
FAU - Gilroy, Derek W
AU  - Gilroy DW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Interleukin-1)
RN  - 0 (Lipoxins)
RN  - 0 (Nitrites)
RN  - 0 (lipoxin A4)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - EC 1.14.13.39 (Nos2 protein, mouse)
RN  - EC 1.14.13.39 (Nos2 protein, rat)
RN  - EC 1.14.13.39 (Nos3 protein, mouse)
RN  - EC 1.14.13.39 (Nos3 protein, rat)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism/pharmacology
MH  - Aspirin/*metabolism/pharmacology/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Endothelium/metabolism
MH  - Inflammation/drug therapy/*metabolism
MH  - Interleukin-1/metabolism
MH  - Leukocytes/drug effects/metabolism
MH  - Lipoxins/*metabolism/pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Microcirculation
MH  - Nitric Oxide/*metabolism
MH  - Nitric Oxide Synthase/genetics/metabolism
MH  - Nitric Oxide Synthase Type II
MH  - Nitric Oxide Synthase Type III
MH  - Nitrites/blood
MH  - Peritonitis/metabolism
MH  - Rats
MH  - Rats, Wistar
PMC - PMC2213311
EDAT- 2004/07/09 05:00
MHDA- 2004/10/27 09:00
CRDT- 2004/07/09 05:00
PHST- 2004/07/09 05:00 [pubmed]
PHST- 2004/10/27 09:00 [medline]
PHST- 2004/07/09 05:00 [entrez]
AID - jem.20040566 [pii]
AID - 20040566 [pii]
AID - 10.1084/jem.20040566 [doi]
PST - ppublish
SO  - J Exp Med. 2004 Jul 5;200(1):69-78. doi: 10.1084/jem.20040566.

PMID- 30326254
OWN - NLM
STAT- MEDLINE
DCOM- 20190109
LR  - 20190109
IS  - 1638-6183 (Electronic)
IS  - 0300-9084 (Linking)
VI  - 156
DP  - 2019 Jan
TI  - Activation of catalase via co-administration of aspirin and pioglitazone: 
      Experimental and MLSD simulation approaches.
PG  - 100-108
LID - S0300-9084(18)30286-4 [pii]
LID - 10.1016/j.biochi.2018.10.007 [doi]
AB  - Aspirin (ASP) and pioglitazone (PGL) are the most common drugs that are widely 
      used by diabetic patients to control the blood sugar and hinder cardiovascular 
      diseases. The interaction between PGL and ASP is one of the important medical 
      issues to clarify the safety of co-administration of these drugs. In the present 
      study, the effect of co-administered ASP with PGL was investigated on the 
      structure and catalytic function of catalase as a potential target in the liver. 
      Based on our data, co-administration of ASP-PGL significantly enhanced the 
      catalase activity in comparison with PGL alone. However, ASP does not have any 
      effects on the catalytic function of catalase. Moreover, the dialysis measurement 
      and CD spectroscopy study revealed that binding of ASP to catalase could increase 
      the stability of catalase-PGL complex. Based on the obtained data, it is shown 
      that the binding of ASP to catalase led to increase the affinity of catalase to 
      PGL. Binding analysis showed that the association constant of catalase-PGL was 
      reduced considerably in the presence of ASP from 12.19 ± 0.1 × 10(6) M(-1) to 
      6.4 ± 0.2 × 10(6) M(-1) at 298 K. Multiple ligands simultaneous docking (MLSD) 
      also confirmed an increase in the binding affinity of PGL to catalase.
CI  - Copyright © 2018 Elsevier B.V. and Société Française de Biochimie et Biologie 
      Moléculaire (SFBBM). All rights reserved.
FAU - Panahi, Yunes
AU  - Panahi Y
AD  - Pharmacotherapy Department, Baqiyatallah University of Medical Sciences, Tehran, 
      Iran.
FAU - Yekta, Reza
AU  - Yekta R
AD  - Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, 
      Iran.
FAU - Dehghan, Gholamreza
AU  - Dehghan G
AD  - Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, 
      Iran. Electronic address: gdehghan@tabrizu.ac.ir.
FAU - Rashtbari, Samaneh
AU  - Rashtbari S
AD  - Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, 
      Iran.
FAU - Jafari, Nematollah Jonaidi
AU  - Jafari NJ
AD  - Research Centers of Molecular Biology, Baqiyatallah University of Medical 
      Sciences, Tehran, Iran.
FAU - Moosavi-Movahedi, Ali A
AU  - Moosavi-Movahedi AA
AD  - Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran; 
      Center of Excellence in Biothermodynamics, University of Tehran, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20181014
PL  - France
TA  - Biochimie
JT  - Biochimie
JID - 1264604
RN  - EC 1.11.1.6 (Catalase)
RN  - R16CO5Y76E (Aspirin)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Adult
MH  - Aspirin/*chemistry/pharmacology
MH  - Catalase/*chemistry
MH  - Enzyme Activation
MH  - Female
MH  - Humans
MH  - Male
MH  - *Molecular Docking Simulation
MH  - Pioglitazone/*chemistry/pharmacology
OTO - NOTNLM
OT  - Aspirin
OT  - Catalase activation
OT  - Co-administration
OT  - MLSD
OT  - Pioglitazone
EDAT- 2018/10/17 06:00
MHDA- 2019/01/10 06:00
CRDT- 2018/10/17 06:00
PHST- 2018/07/11 00:00 [received]
PHST- 2018/10/11 00:00 [accepted]
PHST- 2018/10/17 06:00 [pubmed]
PHST- 2019/01/10 06:00 [medline]
PHST- 2018/10/17 06:00 [entrez]
AID - S0300-9084(18)30286-4 [pii]
AID - 10.1016/j.biochi.2018.10.007 [doi]
PST - ppublish
SO  - Biochimie. 2019 Jan;156:100-108. doi: 10.1016/j.biochi.2018.10.007. Epub 2018 Oct 
      14.

PMID- 6985998
OWN - NLM
STAT- MEDLINE
DCOM- 19800324
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 243
IP  - 7
DP  - 1980 Feb 15
TI  - A randomized, controlled trial of aspirin in persons recovered from myocardial 
      infarction.
PG  - 661-9
AB  - The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and 
      Blood Institute-sponsored, multicenter, randomized, double-blind, and 
      placebo-controlled trial designed to test whether the regular administration of 
      aspirin to men and women who had experienced at least one documented myocardial 
      infarction (MI) would result in a significant reduction in total mortality over a 
      three-year period. Cause-specific mortality, nonfatal events, and side effects 
      were also evaluated. Over a 13-month period, 4,524 persons between the ages of 30 
      and 69 years were randomized to either 1 g of aspirin per day (2,267 persons) or 
      placebo (2,257 persons). High levels of patient compliance to study protocol were 
      indicated by various measures. Total mortality during the entire follow-up period 
      was 10.8% in the aspirin group and 9.7% in the placebo group. Three-year total 
      mortality was 9.6% in the aspirin group and 8.8% in the placebo group. The 
      percentage of definite nonfatal MI was 8.1% in the placebo group and 6.3% in the 
      aspirin group. Coronary incidence (coronary heart disease mortality or definite 
      nonfatal MI) was 14.1% in the aspirin group and 14.8% in the placebo group. 
      Symptoms suggestive of peptic ulcer, gastritis, or erosion of gastric mucosa 
      occurred in 23.7% of the aspirin group and 14.9% in the placebo group. Based on 
      AMIS results, aspirin is not recommended for routine use in patients who have 
      survived an MI.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/mortality/*rehabilitation
MH  - Platelet Aggregation/drug effects
MH  - Random Allocation
MH  - Recurrence
MH  - Sex Factors
EDAT- 1980/02/15 00:00
MHDA- 1980/02/15 00:01
CRDT- 1980/02/15 00:00
PHST- 1980/02/15 00:00 [pubmed]
PHST- 1980/02/15 00:01 [medline]
PHST- 1980/02/15 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1980 Feb 15;243(7):661-9.

PMID- 7805939
OWN - NLM
STAT- MEDLINE
DCOM- 19950202
LR  - 20131121
IS  - 0011-8532 (Print)
IS  - 0011-8532 (Linking)
VI  - 38
IP  - 4
DP  - 1994 Oct
TI  - Acetylsalicylic acid and acetaminophen.
PG  - 633-44
AB  - Aspirin is the most extensively prescribed analgesic, antipyretic, and 
      anti-inflammatory agent. It is effective against the mild-to-moderate pain of 
      inflammation. The best single dose of aspirin is that which is adequate to 
      relieve pain; the proper dosage interval is that which sustains relief without 
      causing toxicity. It would be unfortunate to withhold aspirin from a patient who 
      desperately requires the relief provided by this most useful analgesic because 
      there have been some adverse effects when it is used improperly. Acetaminophen is 
      a suitable substitute for aspirin for its analgesic or antipyretic uses in 
      patients in whom aspirin is contraindicated (e.g., prepartum patients, children 
      with febrile conditions, patients with asthma, peptic ulcer, gouty arthritis, 
      hyperuricemia, hemophilia or other bleeding disorders, and those taking 
      anticoagulants). However, the general substitution of acetaminophen for aspirin 
      as an analgesic is not recommended.
FAU - Kacso, G
AU  - Kacso G
AD  - Department of Dentistry, Cleveland Clinic Foundation, Ohio.
FAU - Terézhalmy, G T
AU  - Terézhalmy GT
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Dent Clin North Am
JT  - Dental clinics of North America
JID - 0217440
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/pharmacokinetics/pharmacology/*therapeutic use
MH  - Adult
MH  - Aspirin/adverse effects/pharmacokinetics/pharmacology/*therapeutic use
MH  - Child
MH  - Dental Care
MH  - Humans
MH  - Pain/prevention & control
RF  - 36
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
PST - ppublish
SO  - Dent Clin North Am. 1994 Oct;38(4):633-44.

PMID- 18296839
OWN - NLM
STAT- MEDLINE
DCOM- 20080703
LR  - 20190819
IS  - 1346-9843 (Print)
IS  - 1346-9843 (Linking)
VI  - 72
IP  - 3
DP  - 2008 Mar
TI  - Action of aspirin on whole blood-aggregation evaluated by the screen filtration 
      pressure method.
PG  - 420-6
AB  - BACKGROUND: There are few monitoring systems widely used in clinical practice for 
      evaluating the effectiveness of aspirin therapy, so in the present study 
      aspirin's antiplatelet effects we investigated with a whole blood aggregometer 
      using a screen filtration pressure (SFP) method. METHODS AND RESULTS: Thirty-five 
      healthy male volunteers took 100 mg/day aspirin for 14 days. Whole-blood 
      aggregation was analyzed at baseline and on days 7 and 14, using collagen and 
      adenosine diphosphate as the stimuli, and compared with the platelet-rich plasma 
      (PRP) aggregation measured by optical aggregometer. The platelet-aggregation 
      threshold index (PATI) for both methods, which was defined as the putative 
      agonist-concentration giving half-maximal aggregation, and the PRP-maximal 
      aggregation rate were analyzed. The maximal aggregation rate induced by 1.6 mg/L 
      collagen decreased from 85.5% (80.8-92.8) [median (interquartile range)] at 
      baseline to 51.5% (39-63.8) on day 14 (p<0.0001). The PRP-PATI and whole-blood 
      PATI for collagen increased from 0.32 (0.28-0.70) to 1.82 mg/L (1.25-2.89) 
      (p<0.0001) and from 0.28 (0.22-0.3) to 1.06 mg/L (1.01-1.29) (p<0.0001) 
      respectively. CONCLUSIONS: The whole-blood PATI and PRP-PATI for collagen, as 
      well as the maximal PRP aggregation rate, clearly distinguish platelet 
      aggregability before and after aspirin intake. However, whole-blood analysis by 
      the SFP-method is easier to perform, and is a promising method of monitoring 
      aspirin's effects.
FAU - Tabuchi, Arata
AU  - Tabuchi A
AD  - Department of Geriatric Medicine, Graduate School of Medicine, Kyoto University, 
      Kyoto, Japan.
FAU - Taniguchi, Ryoji
AU  - Taniguchi R
FAU - Takahashi, Kanako
AU  - Takahashi K
FAU - Kondo, Hirokazu
AU  - Kondo H
FAU - Kawato, Mitsunori
AU  - Kawato M
FAU - Morimoto, Takeshi
AU  - Morimoto T
FAU - Kimura, Takeshi
AU  - Kimura T
FAU - Kita, Toru
AU  - Kita T
FAU - Horiuchi, Hisanori
AU  - Horiuchi H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets
MH  - Collagen/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Filtration/methods
MH  - Hematologic Tests/methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Pressure
EDAT- 2008/02/26 09:00
MHDA- 2008/07/04 09:00
CRDT- 2008/02/26 09:00
PHST- 2008/02/26 09:00 [pubmed]
PHST- 2008/07/04 09:00 [medline]
PHST- 2008/02/26 09:00 [entrez]
AID - JST.JSTAGE/circj/72.420 [pii]
AID - 10.1253/circj.72.420 [doi]
PST - ppublish
SO  - Circ J. 2008 Mar;72(3):420-6. doi: 10.1253/circj.72.420.

PMID- 724341
OWN - NLM
STAT- MEDLINE
DCOM- 19790226
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 62
IP  - 5 Pt 2 Suppl
DP  - 1978 Nov
TI  - Aspirin overdosage: incidence, diagnosis, and management.
PG  - 890-7
AB  - The importance of aspirin as a cause of poisoning in children has declined 
      dramatically with safety packaging and reductions in the dose of flavored 
      children's aspirin per package. Although flavoring entices children to ingest 
      more tablets, the increment is less than the dose differential between the 
      children's and adults' preparations, and so the latter pose the greater hazard in 
      the individual case. Chronic poisoning of children during therapy with aspirin is 
      aggravated by the peculiar kinetics of the drug, but is preventable and 
      constitutes no essential basis for the substitution of acetaminophen, which may 
      not be devoid of risk factors in sick children. Salicylate levels are essential 
      in the diagnosis and management of intoxication. In treatment, emphasis should be 
      on trapping salicylate in the plasma and eventually the urine--through ionization 
      to prevent its entry into the brain.
FAU - Done, A K
AU  - Done AK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*poisoning/therapeutic use
MH  - Child, Preschool
MH  - Chronic Disease
MH  - Drug Packaging
MH  - Humans
MH  - Safety
MH  - United States
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1978 Nov;62(5 Pt 2 Suppl):890-7.

PMID- 16794200
OWN - NLM
STAT- MEDLINE
DCOM- 20060818
LR  - 20220409
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 37
IP  - 8
DP  - 2006 Aug
TI  - Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy 
      volunteers.
PG  - 2153-8
AB  - BACKGROUND AND PURPOSE: Aspirin resistance may be relatively common and 
      associated with adverse outcome. Meta-analysis has clearly shown that 75 mg plain 
      aspirin is the lowest effective dose; however, it is not known whether the recent 
      increased use of enteric-coated aspirin could account for aspirin resistance. 
      This study was designed to determine whether enteric-coated aspirin is as 
      effective as plain aspirin in healthy volunteers. METHODS: Seventy-one healthy 
      volunteers were enrolled in 3 separate bioequivalence studies. Using a crossover 
      design, each volunteer took 2 different aspirin preparations. Five aspirin 
      preparations were evaluated, 3 different enteric-coated 75-mg aspirins, 
      dispersible aspirin 75 mg and asasantin (25-mg standard release aspirin plus 
      200-mg modified-release dipyridamole given twice daily). Serum thromboxane (TX) 
      B2 levels and arachidonic acid-induced platelet aggregation were measured before 
      and after 14 days of treatment. RESULTS: All other aspirin preparations tested 
      were inferior to dispersible aspirin (P<0.001) in their effect on serum TXB(2) 
      level. Treatment failure (<95% inhibition serum TXB2 formation) occurred in 14 
      subjects, none of whom were taking dispersible aspirin. Mean weight for those 
      demonstrating treatment failure was greater than those with complete TXB2 (>99%) 
      inhibition (P<0.001). Using logistic regression analysis an 80-kg subject had a 
      20% probability of treatment failure. Asasantin was the most potent preparation 
      in terms of inhibition of platelet aggregation. CONCLUSIONS: Equivalent doses of 
      the enteric-coated aspirin were not as effective as plain aspirin. Lower 
      bioavailability of these preparations and poor absorption from the higher pH 
      environment of the small intestine may result in inadequate platelet inhibition, 
      particularly in heavier subjects.
FAU - Cox, Dermot
AU  - Cox D
AD  - Department of Clinical Pharmacology, Royal College of Surgeons, 123 St Stephens 
      Green, Dublin 2, Ireland. dcox@rcsi.ie
FAU - Maree, Andrew O
AU  - Maree AO
FAU - Dooley, Michelle
AU  - Dooley M
FAU - Conroy, Ronán
AU  - Conroy R
FAU - Byrne, Michael F
AU  - Byrne MF
FAU - Fitzgerald, Desmond J
AU  - Fitzgerald DJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20060622
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/*pharmacokinetics/pharmacology
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Body Weight
MH  - Cross-Over Studies
MH  - Dipyridamole/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Humans
MH  - Logistic Models
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & 
      dosage/*pharmacokinetics/pharmacology
MH  - Reference Values
MH  - Tablets, Enteric-Coated
MH  - Therapeutic Equivalency
MH  - Thromboxane B2/blood
MH  - Treatment Outcome
EDAT- 2006/06/24 09:00
MHDA- 2006/08/19 09:00
CRDT- 2006/06/24 09:00
PHST- 2006/06/24 09:00 [pubmed]
PHST- 2006/08/19 09:00 [medline]
PHST- 2006/06/24 09:00 [entrez]
AID - 01.STR.0000231683.43347.ec [pii]
AID - 10.1161/01.STR.0000231683.43347.ec [doi]
PST - ppublish
SO  - Stroke. 2006 Aug;37(8):2153-8. doi: 10.1161/01.STR.0000231683.43347.ec. Epub 2006 
      Jun 22.

PMID- 15820166
OWN - NLM
STAT- MEDLINE
DCOM- 20050524
LR  - 20151119
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 95
IP  - 8
DP  - 2005 Apr 15
TI  - Compliance as a critical consideration in patients who appear to be resistant to 
      aspirin after healing of myocardial infarction.
PG  - 973-5
AB  - The hypothesis that aspirin resistance is often due to noncompliance was 
      investigated. One hundred ninety patients with a history of myocardial infarction 
      were evaluated using arachidonic acid-stimulated light aggregometry at 3 
      different time points: while receiving their usual daily aspirin, after not 
      receiving aspirin for 7 days, and 2 hours after the observed ingestion of aspirin 
      325 mg. At the first time point, 17 patients (9%) failed to show aspirin 
      inhibition of platelet aggregation, but 2 hours after observed aspirin ingestion, 
      aspirin inhibition was observed in all but 1 patient.
FAU - Schwartz, Kenneth A
AU  - Schwartz KA
AD  - Department of Medicine, Michigan State University, East Lansing 48824, USA. 
      schwart7@msu.edu <schwart7@msu.edu>
FAU - Schwartz, Dianne E
AU  - Schwartz DE
FAU - Ghosheh, Khalid
AU  - Ghosheh K
FAU - Reeves, Mathew J
AU  - Reeves MJ
FAU - Barber, Kimberly
AU  - Barber K
FAU - DeFranco, Anthony
AU  - DeFranco A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid
MH  - Aspirin/administration & dosage/*pharmacology/*therapeutic use
MH  - Drug Resistance
MH  - Humans
MH  - Myocardial Infarction
MH  - *Patient Compliance
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/*pharmacology/*therapeutic use
EDAT- 2005/04/12 09:00
MHDA- 2005/05/25 09:00
CRDT- 2005/04/12 09:00
PHST- 2004/09/20 00:00 [received]
PHST- 2004/12/15 00:00 [revised]
PHST- 2004/12/15 00:00 [accepted]
PHST- 2005/04/12 09:00 [pubmed]
PHST- 2005/05/25 09:00 [medline]
PHST- 2005/04/12 09:00 [entrez]
AID - S0002-9149(05)00121-9 [pii]
AID - 10.1016/j.amjcard.2004.12.038 [doi]
PST - ppublish
SO  - Am J Cardiol. 2005 Apr 15;95(8):973-5. doi: 10.1016/j.amjcard.2004.12.038.

PMID- 7648980
OWN - NLM
STAT- MEDLINE
DCOM- 19950928
LR  - 20200304
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 40
IP  - 8
DP  - 1995 Aug
TI  - Effect of aspirin on gallbladder motility in patients with gallstone disease. A 
      randomized, double-blind, placebo-controlled trial of two dosage schedules.
PG  - 1782-5
AB  - Patients with gallstone disease have impaired gallbladder motility. 
      Prostaglandins are thought to be important mediators of gallbladder hypomotility. 
      We assessed the effect of aspirin, a prostaglandin inhibitor on gallbladder 
      resting volume and ejection fraction according to a double-blind study protocol 
      in 20 healthy volunteers and 30 patients with gallstone disease. Healthy 
      volunteers had a higher ejection fraction compared to patients with gallstone 
      disease (73.9 +/- 0.9% vs 60.4 +/- 1.0%, P < 0.05). Aspirin in a dose of 350 
      mg/day for two weeks did not alter gallbladder motility in the healthy 
      volunteers. Thirty patients with gallstone disease were randomized into three 
      treatment groups: group I (placebo), group II (aspirin 350 mg/day), and group III 
      (aspirin 1400 mg/day). After two weeks of treatment, gallbladder ejection 
      fraction was improved in group II (74.0 +/- 1.7% vs 62.0 +/- 1.7%, P < 0.01) and 
      group III (69.8 +/- 3.8% vs 61.2 +/- 1.3%, P < 0.01) but not in group I (60.4 +/- 
      2.6% vs 59.0 +/- 1.9%, P = NS). The higher dose of aspirin did not induce a 
      greater increase in gallbladder emptying. It is concluded that impaired 
      gallbladder motility in patients with gallstone disease is corrected by 
      short-term oral aspirin even in low dosage. This may be clinically useful in 
      secondary prophylaxis after nonsurgical therapy for gallstone disease.
FAU - Das, A
AU  - Das A
AD  - Department of Gastroenterology and Radiodiagnosis, Sanjay Gandhi Postgraduate 
      Institute of Medical Sciences, Lucknow, India.
FAU - Baijal, S S
AU  - Baijal SS
FAU - Saraswat, V A
AU  - Saraswat VA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Cholelithiasis/*physiopathology
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Gallbladder Emptying/*drug effects
MH  - Humans
MH  - Male
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
AID - 10.1007/BF02212702 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1995 Aug;40(8):1782-5. doi: 10.1007/BF02212702.

PMID- 9270062
OWN - NLM
STAT- MEDLINE
DCOM- 19970919
LR  - 20131121
IS  - 0014-4886 (Print)
IS  - 0014-4886 (Linking)
VI  - 146
IP  - 2
DP  - 1997 Aug
TI  - Nitric oxide reverses aspirin antagonism of t-PA thrombolysis in a rabbit model 
      of thromboembolic stroke.
PG  - 513-7
AB  - Randomized trials of thrombolytic therapy in stroke have reported an improvement 
      in neurologic outcome; however, the addition of aspirin has resulted in a 
      significant increase in mortality and antagonism of clot lysis in clinical and 
      animal studies, respectively. This finding is in contradistinction to the known 
      synergy in mortality reduction for aspirin and thrombolytics in myocardial 
      infarction. It is hypothesized that aspirin antagonism of clot lysis is related 
      to inhibition of nitric oxide (NO) and may be reversed by providing a source of 
      NO. Twenty rabbits were treated with aspirin (20 mg/kg, i.v.) prior to internal 
      carotid clot embolization. One-half hour following embolization, rabbits were 
      randomized to receive vehicle (n = 5), the NO precursor L-arginine (300 mg/kg, 
      i.v. bolus at 0.5 and 2.5 h postembolus; n = 5), or a nitric oxide donor 
      (nitroprusside, 1 mg/kg/h, i.a., or nitroglycerin, 10 microg/kg/min, i.v., n = 5 
      each agent). Tissue plasminogen activator (t-PA) (6.3 mg/kg) was administered 
      from 1 to 3 h after embolization. Lysis of the tin-tagged clot was followed with 
      serial X rays and gross examination. No rabbit in the control group experienced 
      complete clot lysis. However, 2 of 5 rabbits in the L-arginine group and 6 of 10 
      rabbits in the nitric oxide donor (nitroprusside and nitroglycerin) groups noted 
      complete clot lysis (P < 0.05, Fisher exact test). Thus, administration of an NO 
      donor (nitroglycerin or nitroprusside) and, to a lesser extent L-arginine, 
      reversed aspirin's antagonism of t-PA thrombolysis. This study may help explain 
      the discrepant results seen with aspirin and thrombolytics.
FAU - Bednar, M M
AU  - Bednar MM
AD  - Division of Neurosurgery, University of Vermont, Burlington 05405, USA.
FAU - Gross, C E
AU  - Gross CE
FAU - Howard, D B
AU  - Howard DB
FAU - Russell, S R
AU  - Russell SR
FAU - Thomas, G R
AU  - Thomas GR
LA  - eng
GR  - NS28708/NS/NINDS NIH HHS/United States
GR  - NS31008/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Exp Neurol
JT  - Experimental neurology
JID - 0370712
RN  - 0 (Antifibrinolytic Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antifibrinolytic Agents/*pharmacology
MH  - Aspirin/*antagonists & inhibitors/*pharmacology
MH  - Cerebrovascular Disorders/*blood/*etiology
MH  - Female
MH  - Male
MH  - Nitric Oxide/*pharmacology
MH  - Rabbits
MH  - Thromboembolism/*complications
MH  - Tissue Plasminogen Activator/*antagonists & inhibitors/pharmacology
EDAT- 1997/08/01 00:00
MHDA- 1997/08/01 00:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 1997/08/01 00:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
AID - S0014-4886(97)96568-7 [pii]
AID - 10.1006/exnr.1997.6568 [doi]
PST - ppublish
SO  - Exp Neurol. 1997 Aug;146(2):513-7. doi: 10.1006/exnr.1997.6568.

PMID- 21617874
OWN - NLM
STAT- MEDLINE
DCOM- 20111024
LR  - 20181201
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 26
IP  - 3
DP  - 2011 Sep
TI  - Activity of aspirin analogues and vanillin in a human colorectal cancer cell 
      line.
PG  - 557-65
LID - 10.3892/or.2011.1320 [doi]
AB  - Colorectal cancer is the third most common cancer and is associated with 
      significant morbidity and mortality. Epidemiological and animal studies indicate 
      that regular acetylsalicylic acid (aspirin) intake is associated with a reduction 
      in the incidence of colorectal cancer. Acetylsalicylic acid (ASA) has also been 
      shown to inhibit colorectal cancer cell proliferation in vitro. The molecular 
      basis for this specific cytotoxicity is an area of considerable debate. To 
      investigate the toxicity of salicylates, the sensitivity of the DNA mismatch 
      repair proficient SW480 human colorectal cancer cell line to four categories of 
      compounds with varying degrees of structural similarity to acetylsalicylic acid 
      was tested. These compounds were: i) salicylic acid analogues with substituents 
      at the 5-position; ii) ASA analogues with extended chain lengths in the acyl 
      group; iii) vanillin (4-hydroxy-3-methoxybenzaldehyde; and iv) 
      bis(2-carboxyphenyl) succinate (BCS) and structurally similar derivatives 
      thereof. It was found that compounds with amino and acetamido substituents at the 
      salicylate 5-position were less toxic than ASA itself. Modifications to the 
      length of the hydrocarbon chain in the acyl groups of ASA analogues also 
      marginally reduced toxicity. Vanillin exhibited relatively limited toxicity 
      against the SW480 colorectal cancer cell line. Commercially available and 
      in-house synthesised BCS (diaspirin) were notably more inhibitory to cell growth 
      than ASA itself, yet retained substantial specificity against colorectal cancer 
      cell lines vs. non-colorectal cancer cell lines. BCS and ASA were toxic to SW480 
      cells through initiation of necrotic and apoptotic pathways. Fumaroyldiaspirin 
      and benzoylaspirin exhibited greater toxicity than ASA against the SW480 cell 
      line. A novel method for synthesis of BCS, a compound that has erratic commercial 
      availability, is described. We propose that the anti-inflammatory and anticancer 
      capacity of BCS and the other analogues described herein is worthy of 
      investigation.
FAU - Deb, Jolly
AU  - Deb J
AD  - School of Applied Sciences, University of Wolverhampton, Wolverhampton WV1 1LY, 
      UK.
FAU - Dibra, Harpreet
AU  - Dibra H
FAU - Shan, Song
AU  - Shan S
FAU - Rajan, Sujith
AU  - Rajan S
FAU - Manneh, Jainaba
AU  - Manneh J
FAU - Kankipati, Chandra S
AU  - Kankipati CS
FAU - Perry, Chris J
AU  - Perry CJ
FAU - Nicholl, Iain D
AU  - Nicholl ID
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110525
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzaldehydes)
RN  - 7673326042 (Irinotecan)
RN  - CHI530446X (vanillin)
RN  - R16CO5Y76E (Aspirin)
RN  - XT3Z54Z28A (Camptothecin)
SB  - IM
MH  - Antineoplastic Agents/chemical synthesis/*pharmacology
MH  - Apoptosis
MH  - Aspirin/*analogs & derivatives/chemical synthesis/*pharmacology
MH  - Benzaldehydes/*pharmacology
MH  - Camptothecin/analogs & derivatives/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Survival
MH  - Colorectal Neoplasms
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Irinotecan
EDAT- 2011/05/28 06:00
MHDA- 2011/10/25 06:00
CRDT- 2011/05/28 06:00
PHST- 2011/02/22 00:00 [received]
PHST- 2011/04/19 00:00 [accepted]
PHST- 2011/05/28 06:00 [entrez]
PHST- 2011/05/28 06:00 [pubmed]
PHST- 2011/10/25 06:00 [medline]
AID - 10.3892/or.2011.1320 [doi]
PST - ppublish
SO  - Oncol Rep. 2011 Sep;26(3):557-65. doi: 10.3892/or.2011.1320. Epub 2011 May 25.

PMID- 15028354
OWN - NLM
STAT- MEDLINE
DCOM- 20040406
LR  - 20131121
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 43
IP  - 6
DP  - 2004 Mar 17
TI  - The effects of nonselective non-aspirin non-steroidal anti-inflammatory 
      medications on the risk of nonfatal myocardial infarction and their interaction 
      with aspirin.
PG  - 985-90
AB  - OBJECTIVES: This study was designed to determine if non-aspirin non-steroidal 
      anti-inflammatory drugs (NANSAIDs) are associated with lower odds of myocardial 
      infarction (MI) and if NANSAIDs, particularly ibuprofen, interfere with aspirin's 
      cardioprotective effect. BACKGROUND: The NANSAIDs may reduce the risk of MI but 
      may also interfere with aspirin's cardioprotective effect. METHODS: A 
      case-control study was conducted, with cases of first, nonfatal MI identified 
      prospectively and controls identified randomly from the community. RESULTS: The 
      use of NANSAIDs was associated with a significant reduction in MI among those not 
      using aspirin (adjusted odds ratio [OR] 0.53; 95% confidence interval [CI]: 0.42 
      to 0.67). This was true for both ibuprofen (adjusted OR 0.52; 95% CI: 0.39 to 
      0.69) and naproxen (adjusted OR 0.48; 95% CI: 0.28 to 0.82). Although aspirin 
      itself was associated with decreased odds of MI in those not also using NANSAIDs 
      (adjusted OR relative to no aspirin use 0.79; 95% CI: 0.63 to 0.98), it was not 
      associated with decreased odds of MI among those who were using NANSAIDs (OR 
      1.28; 95% CI: 0.85 to 1.94; p value for interaction = 0.026). The association of 
      aspirin and reduced odds of MI diminished with increasing frequency of NANSAID 
      use (test for interaction p = 0.006), particularly for ibuprofen (p = 0.018). 
      Among frequent (4 times/week) NANSAID users, the OR for aspirin versus no aspirin 
      was 2.04 (95% CI: 1.06 to 3.94). Users of prophylactic aspirin plus frequent 
      ibuprofen had an OR relative to aspirin-only users of 2.03 (95% CI: 0.60 to 
      6.84). CONCLUSIONS: In the absence of aspirin use, NANSAIDs are associated with 
      reduced odds of MI. In those using aspirin, NANSAIDs do not provide additional 
      protection. Additional study is needed to determine the clinical impact of using 
      NANSAIDs along with aspirin for cardioprotection.
FAU - Kimmel, Stephen E
AU  - Kimmel SE
AD  - Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics 
      and Epidemiology, University of Pennsylvania School of Medicine, 717 Blockley 
      Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA. 
      skimmel@cceb.med.upenn.edu
FAU - Berlin, Jesse A
AU  - Berlin JA
FAU - Reilly, Muredach
AU  - Reilly M
FAU - Jaskowiak, Jane
AU  - Jaskowiak J
FAU - Kishel, Lori
AU  - Kishel L
FAU - Chittams, Jesse
AU  - Chittams J
FAU - Strom, Brian L
AU  - Strom BL
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
CIN - J Am Coll Cardiol. 2004 Mar 17;43(6):991-3. PMID: 15028355
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Case-Control Studies
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Ibuprofen/administration & dosage/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*epidemiology/etiology/*prevention & control
MH  - Pennsylvania/epidemiology
MH  - Prospective Studies
MH  - Risk Factors
EDAT- 2004/03/19 05:00
MHDA- 2004/04/07 05:00
CRDT- 2004/03/19 05:00
PHST- 2003/04/16 00:00 [received]
PHST- 2003/08/11 00:00 [revised]
PHST- 2003/08/19 00:00 [accepted]
PHST- 2004/03/19 05:00 [pubmed]
PHST- 2004/04/07 05:00 [medline]
PHST- 2004/03/19 05:00 [entrez]
AID - S0735109703017273 [pii]
AID - 10.1016/j.jacc.2003.08.064 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2004 Mar 17;43(6):985-90. doi: 10.1016/j.jacc.2003.08.064.

PMID- 1773551
OWN - NLM
STAT- MEDLINE
DCOM- 19920305
LR  - 20181113
IS  - 0312-5963 (Print)
IS  - 0312-5963 (Linking)
VI  - 21
IP  - 5
DP  - 1991 Nov
TI  - Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers.
PG  - 394-9
AB  - The single dose pharmacokinetics of 4 commercially available 100 mg oral aspirin 
      formulations were studied in 6 healthy men and 6 healthy women. Two of the 
      formulations were rapid release ('Cardiprin' 100, 'Platelin') and the other 2 
      were enteric coated formulations ('Astrix' 100, 'Cartia'). There were marked 
      differences in the plasma concentration-time profiles between the rapid release 
      and the enteric coated formulations. There were no significant differences (p 
      greater than 0.05) in the mean time to achieve maximum aspirin concentrations 
      between 'Cardiprin' 100 (0.48 h) and 'Platelin' (0.35 h), but this was 
      significantly prolonged (p less than 0.001) for 'Astrix' 100 (3.73 h) and even 
      more prolonged for 'Cartia' (6.84 h). Similar between-formulation differences 
      were seen in the areas under the plasma concentration-time curves, for which the 
      rank order was 'Cardiprin' 100 (1.60 mg/L.h) = 'Platelin' (1.54 mg/L.h) greater 
      than 'Astrix' 100 (0.73 mg/L.h) greater than 'Cartia' (0.56 mg/L.h). For 
      'Cardiprin' 100, 'Platelin' and 'Astrix' 100 plasma aspirin concentrations were 
      below 5 micrograms/L by 7 h after ingestion, whereas for 'Cartia' aspirin was 
      detectable for up to 16 h, giving the appearance of sustained release. The 
      enteric coated formulations produced the greatest variability in the plasma 
      aspirin concentration vs time profiles. The urinary recovery of salicylate was 
      greater than 80% of the administered dose for all 4 formulations. The clinical 
      significance of the marked pharmacokinetic differences observed with these 4 
      low-dose aspirin formulations is not known.
FAU - Bochner, F
AU  - Bochner F
AD  - Department of Clinical and Experimental Pharmacology, University of Adelaide, 
      South Australia.
FAU - Somogyi, A A
AU  - Somogyi AA
FAU - Wilson, K M
AU  - Wilson KM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Clin Pharmacokinet
JT  - Clinical pharmacokinetics
JID - 7606849
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Dosage Forms)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Delayed-Action Preparations
MH  - Dosage Forms
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Therapeutic Equivalency
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
AID - 10.2165/00003088-199121050-00006 [doi]
PST - ppublish
SO  - Clin Pharmacokinet. 1991 Nov;21(5):394-9. doi: 10.2165/00003088-199121050-00006.

PMID- 17325651
OWN - NLM
STAT- MEDLINE
DCOM- 20070629
LR  - 20181113
IS  - 0007-1188 (Print)
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Linking)
VI  - 150
IP  - 7
DP  - 2007 Apr
TI  - Surface phospholipids in gastric injury and protection when a selective 
      cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin.
PG  - 913-9
AB  - BACKGROUND AND PURPOSE: Clinical studies demonstrate that aspirin consumption 
      reverses the gastrointestinal (GI) benefits of coxibs, by an undefined mechanism. 
      EXPERIMENTAL APPROACH: Rodent models were employed to investigate the effects of 
      combinations of celecoxib and aspirin on gastric ulcerogenesis, bleeding, surface 
      hydrophobicity (by contact angle analysis) and ulcer healing. We also evaluated 
      the effects of phosphatidylcholine (PC)-associated aspirin in these rodent models 
      and confirmed its cyclooxygenase (COX)-inhibitory activity by measuring mucosal 
      prostaglandin E(2) (PGE(2)) concentration. We present evidence that aspirin's 
      ability to induce gastric injury and bleeding in rats, was exacerbated in the 
      presence of a coxib and was dependent on its ability to reduce gastric surface 
      hydrophobicity. In contrast, co-administration of phosphatidylcholine 
      (PC)-associated aspirin and celecoxib induced little or no gastric 
      injury/bleeding and maintained the stomach's hydrophobic properties. 
      Interestingly, aspirin and aspirin/PC equally inhibited gastric mucosal PGE(2) 
      concentration. Aspirin in combination with a coxib retarded the healing of 
      experimentally induced gastric ulcers, whereas healing rates of rats treated with 
      celecoxib in combination with aspirin/PC were comparable to controls. CONCLUSIONS 
      AND IMPLICATIONS: Aspirin's gastric toxicity in combination with a coxib can be 
      dissociated from its ability to inhibit COX-1 and appears to be dependent, in 
      part, on its ability to attenuate the stomach's surface hydrophobic barrier. This 
      adverse drug interaction between aspirin and coxibs, which impacts the treatment 
      of osteoarthritic and cardiac patients requiring cardiovascular prophylaxis, can 
      be circumvented by the administration of phosphatidylcholine (PC)-associated 
      aspirin, to maintain the stomach's hydrophobic properties.
FAU - Lichtenberger, L M
AU  - Lichtenberger LM
AD  - The Department of Integrative Biology and Pharmacology, The University of Texas 
      Health Science Center, Houston, TX 77030, USA. lenard.m.lichtenberger@uth.tmc.edu
FAU - Romero, J J
AU  - Romero JJ
FAU - Dial, E J
AU  - Dial EJ
LA  - eng
GR  - P30 DK056338/DK/NIDDK NIH HHS/United States
GR  - R42 DK063882/DK/NIDDK NIH HHS/United States
GR  - 2 R42 DK 063882/DK/NIDDK NIH HHS/United States
GR  - P30 DK 56338/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20070226
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Phosphatidylcholines)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - JCX84Q7J1L (Celecoxib)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Celecoxib
MH  - Cyclooxygenase Inhibitors/*administration & dosage
MH  - Dinoprostone/metabolism
MH  - Drug Interactions
MH  - Gastric Mucosa/drug effects/metabolism/pathology
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Male
MH  - Phosphatidylcholines/*administration & dosage
MH  - Pyrazoles/*administration & dosage/adverse effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Stomach Ulcer/chemically induced/metabolism/pathology/*prevention & control
MH  - Sulfonamides/*administration & dosage/adverse effects
PMC - PMC2013889
EDAT- 2007/02/28 09:00
MHDA- 2007/06/30 09:00
CRDT- 2007/02/28 09:00
PHST- 2007/02/28 09:00 [pubmed]
PHST- 2007/06/30 09:00 [medline]
PHST- 2007/02/28 09:00 [entrez]
AID - 0707176 [pii]
AID - 10.1038/sj.bjp.0707176 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2007 Apr;150(7):913-9. doi: 10.1038/sj.bjp.0707176. Epub 2007 Feb 
      26.

PMID- 16551714
OWN - NLM
STAT- MEDLINE
DCOM- 20060324
LR  - 20220316
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 295
IP  - 12
DP  - 2006 Mar 22
TI  - Sex differences in platelet reactivity and response to low-dose aspirin therapy.
PG  - 1420-7
AB  - CONTEXT: Recent randomized trials suggest that women may not accrue the same 
      cardioprotective benefits as men do from low-dose aspirin therapy used in primary 
      prevention. Failure of aspirin to suppress platelet aggregation in women is one 
      hypothesized mechanism. OBJECTIVE: To examine differential platelet reactivity to 
      low-dose aspirin therapy by sex. DESIGN, SETTING, AND PARTICIPANTS: A clinical 
      trial of aspirin at 81 mg/d for 14 days was conducted in 571 men and 711 women. 
      Baseline and post-aspirin therapy measures included platelet aggregation to 
      arachidonic acid, adenosine diphosphate, epinephrine, and platelet function 
      analyzer closure time. MAIN OUTCOME MEASURE: Sex differences in cyclooxygenase 1 
      (COX-1) direct and indirect platelet activation pathways before and after 
      administration of aspirin. RESULTS: In 10 of the 12 platelet agonist exposures, 
      women's platelets were significantly more reactive at baseline. However, after 
      aspirin therapy, the percent aggregation to arachidonic acid (the direct COX-1 
      pathway) decreased more in women than in men (P<.001) and demonstrated near total 
      suppression of residual platelet reactivity in both men and women. In COX-1 
      indirect pathways, women experienced the same or more platelet inhibition than 
      men in 8 of the 9 assays yet retained modestly greater platelet reactivity after 
      aspirin therapy. In multivariable analysis, female sex significantly predicted 
      aggregation to 2 muM and 10 muM of adenosine diphosphate (P = .02 and <.001, 
      respectively) and collagen at 5 mug/mL (P<.001) independent of risk factors, age, 
      race, menopausal status, and hormone therapy. CONCLUSIONS: Women experienced the 
      same or greater decreases in platelet reactivity after aspirin therapy, retaining 
      modestly more platelet reactivity compared with men. However, most women achieved 
      total suppression of aggregation in the direct COX-1 pathway, the putative 
      mechanism for aspirin's cardioprotection.
FAU - Becker, Diane M
AU  - Becker DM
AD  - Division of General Internal Medicine, Department of Medicine, The Johns Hopkins 
      University School of Medicine, Baltimore, Md, USA. dbecker@jhmi.edu
FAU - Segal, Jodi
AU  - Segal J
FAU - Vaidya, Dhananjay
AU  - Vaidya D
FAU - Yanek, Lisa R
AU  - Yanek LR
FAU - Herrera-Galeano, J Enrique
AU  - Herrera-Galeano JE
FAU - Bray, Paul F
AU  - Bray PF
FAU - Moy, Taryn F
AU  - Moy TF
FAU - Becker, Lewis C
AU  - Becker LC
FAU - Faraday, Nauder
AU  - Faraday N
LA  - eng
GR  - M01-RR000052/RR/NCRR NIH HHS/United States
GR  - U01 HL72518/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Collagen/pharmacology
MH  - Cyclooxygenase 1/pharmacology
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests
MH  - Regression Analysis
MH  - Sex Factors
EDAT- 2006/03/23 09:00
MHDA- 2006/03/25 09:00
CRDT- 2006/03/23 09:00
PHST- 2006/03/23 09:00 [pubmed]
PHST- 2006/03/25 09:00 [medline]
PHST- 2006/03/23 09:00 [entrez]
AID - 295/12/1420 [pii]
AID - 10.1001/jama.295.12.1420 [doi]
PST - ppublish
SO  - JAMA. 2006 Mar 22;295(12):1420-7. doi: 10.1001/jama.295.12.1420.

PMID- 7359337
OWN - NLM
STAT- MEDLINE
DCOM- 19800514
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 69
IP  - 2
DP  - 1980 Feb
TI  - Synthesis of 1-O-(2'-acetoxy)benzoyl-alpha-D-2-deoxyglucopyranose, a novel 
      aspirin prodrug.
PG  - 231-2
AB  - The synthesis and characterization of 
      1-O-(2'-acetoxy)benzoyl-alpha-D-2-deoxyglucopyranose, a novel aspirin prodrug, 
      are described. 3,4,6-Tri-O-benzyl-alpha-D-2-deoxyglucopyranose was synthesized by 
      methylating the anomeric hydroxyl group of 2-deoxyglucose, benzylating the 3-, 
      4-, and 6-hydroxy functional grups, and cleaving hydrolytically the anomeric 
      methyl group. Reaction of the tribenzylated sugar with the acid chloride of 
      aspirin and subsequent hydrogenolysis of the benzyl groups resulted in the 
      prodrug, mp 128 degrees. The compound was further characterized by elemental 
      analysis and PMR and 13C-NMR spectroscopy. In vitro, the compound cleaved to 
      aspirin with a half-life of 7 min at 37 degrees. Prodrug cleavage was independent 
      of pH over the pH 3--9 range.
FAU - Truelove, J E
AU  - Truelove JE
FAU - Hussain, A A
AU  - Hussain AA
FAU - Kostenbauder, H B
AU  - Kostenbauder HB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Deoxy Sugars)
RN  - 70206-30-3 (1-O-(2'-acetoxy)benzoyl-alpha-deoxyglucopyronse)
RN  - 9G2MP84A8W (Deoxyglucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemical synthesis
MH  - Deoxy Sugars/*chemical synthesis
MH  - Deoxyglucose/analogs & derivatives/*chemical synthesis
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
AID - S0022-3549(15)43038-2 [pii]
AID - 10.1002/jps.2600690237 [doi]
PST - ppublish
SO  - J Pharm Sci. 1980 Feb;69(2):231-2. doi: 10.1002/jps.2600690237.

PMID- 1951559
OWN - NLM
STAT- MEDLINE
DCOM- 19911203
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 165
IP  - 4 Pt 1
DP  - 1991 Oct
TI  - Transfer of aspirin across the perfused human placental cotyledon.
PG  - 939-44
AB  - Pregnancy-induced hypertension is associated with a reduction in prostacyclin 
      synthesis that is relative to normotensive pregnancy, whereas thromboxane A2 
      synthesis is unchanged or increased. The net effect is a decreased 
      prostacyclin/thromboxane ratio that may result in the reduced fetal-placental 
      blood flow seen in pregnancy-induced hypertension because thromboxane is known to 
      constrict this circulation. Low-dose aspirin (acetylsalicylic acid), which is 
      used to treat pregnancy-induced hypertension, selectively inhibits thromboxane 
      synthesis and therefore may alter fetal-placental blood flow. We have 
      investigated the transfer of acetylsalicylic acid in the perfused human placental 
      cotyledon and its effects on fetal-placental perfusion pressure. Human placental 
      cotyledons were perfused with tissue culture medium 199 plus 5% 
      polyvinylpyrrolidone that was gassed with 95% oxygen/5% carbon dioxide at flow 
      rates of 10 ml/min (maternal) and 4 ml/min (fetal). Acetylsalicylic acid (10(-5) 
      mol/L) was added to the maternal circuit, and cotyledons were perfused for 1 hour 
      with aliquots taken from a closed fetal circuit every 5 minutes. Acetylsalicylic 
      acid was assayed by spectrofluorometry at 306/412 nm. Our data indicate an 
      initial rapid transfer of acetylsalicylic acid during the first 5 minutes into 
      the fetal-placental circulation, the concentration then decreased to a steady 
      state at 0.4 x 10(-5) mol/L. Resting perfusion pressure of both maternal and 
      fetal circulation did not change after the addition of acetylsalicylic acid to 
      maternal perfusate and transfer to the fetal circulation.
FAU - Jacobson, R L
AU  - Jacobson RL
AD  - Department of Obstetrics and Gynecology, University of Cincinnati Medical Center, 
      OH 45267-0526.
FAU - Brewer, A
AU  - Brewer A
FAU - Eis, A
AU  - Eis A
FAU - Siddiqi, T A
AU  - Siddiqi TA
FAU - Myatt, L
AU  - Myatt L
LA  - eng
GR  - HL 40029/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Humans
MH  - Perfusion
MH  - Placenta/*metabolism
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
AID - 0002-9378(91)90444-V [pii]
AID - 10.1016/0002-9378(91)90444-v [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1991 Oct;165(4 Pt 1):939-44. doi: 
      10.1016/0002-9378(91)90444-v.

PMID- 24201035
OWN - NLM
STAT- MEDLINE
DCOM- 20141208
LR  - 20190608
IS  - 1880-3873 (Electronic)
IS  - 1340-3478 (Linking)
VI  - 21
IP  - 3
DP  - 2014
TI  - Laboratory aspirin resistance and the risk of major adverse cardiovascular events 
      in patients with coronary heart disease on confirmed aspirin adherence.
PG  - 239-47
AB  - AIM: Previous meta-analyses have demonstrated an increased risk of adverse events 
      in aspirin-resistant patients. In this meta-analysis, we aimed to update clinical 
      evidence regarding the relationship between aspirin resistance and major adverse 
      cardiovascular events (MACEs) in patients with coronary heart disease (CHD) on 
      confirmed aspirin adherence. METHODS: An electronic literature search of PubMed, 
      EMBASE, Web of Science and the Cochrane Library and a hand search of 
      bibliographies through April 2013 were conducted. Studies were included if they 
      prospectively investigated the association between aspirin resistance and the 
      risk of adverse cardiovascular events during follow-up in CHD patients, mentioned 
      confirmed compliance and provided adequate data for a statistical analysis. 
      RESULTS: Nine prospective studies with a total 1,889 CHD patients who were 
      followed for one month to 2.5 years and study sample sizes ranging from 86 to 496 
      patients were identified. Overall, 622 of the 1,889 CHD patients (33.0%) were 
      classified as being aspirin resistant with confirmed aspirin adherence. The 
      aspirin-resistant patients exhibited a significantly higher risk of adverse 
      events than the aspirin-sensitive patients (odds ratio 2.44, 95% confidence 
      interval 1.81 to 3.30; p＜0.00001). CONCLUSIONS: Among CHD patients, approximately 
      one in three individuals can be diagnosed as aspirin resistant on confirmed 
      aspirin adherence. Patients identified as having laboratory aspirin resistance 
      exhibit a 2.4-fold increased risk of MACE compared with aspirin-sensitive 
      patients.
FAU - Li, Jiabei
AU  - Li J
AD  - Institute of Cardiovascular Medicine, Xinqiao Hospital, Third Military Medical 
      University.
FAU - Song, Mingbao
AU  - Song M
FAU - Jian, Zhao
AU  - Jian Z
FAU - Guo, Wenyun
AU  - Guo W
FAU - Chen, Guozhu
AU  - Chen G
FAU - Jiang, Guoyan
AU  - Jiang G
FAU - Wang, Juan
AU  - Wang J
FAU - Wu, Xiaojing
AU  - Wu X
FAU - Huang, Lan
AU  - Huang L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131107
PL  - Japan
TA  - J Atheroscler Thromb
JT  - Journal of atherosclerosis and thrombosis
JID - 9506298
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*epidemiology
MH  - *Drug Resistance
MH  - Humans
MH  - *Patient Compliance
MH  - Risk Factors
EDAT- 2013/11/10 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/11/09 06:00
PHST- 2013/11/09 06:00 [entrez]
PHST- 2013/11/10 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - DN/JST.JSTAGE/jat/19521 [pii]
AID - 10.5551/jat.19521 [doi]
PST - ppublish
SO  - J Atheroscler Thromb. 2014;21(3):239-47. doi: 10.5551/jat.19521. Epub 2013 Nov 7.

PMID- 1793876
OWN - NLM
STAT- MEDLINE
DCOM- 19920409
LR  - 20161020
IS  - 1001-9294 (Print)
IS  - 1001-9294 (Linking)
VI  - 6
IP  - 3
DP  - 1991 Sep
TI  - Secondary prevention of myocardial reinfarction with low dose aspirin.
PG  - 141-4
AB  - A clinical trial of secondary prevention of reinfarction with low dose aspirin is 
      reported. 50 mg aspirin per day was administered in 216 case. 211 cases did not 
      take aspirin or any other antiplatelet agents as a control group. The follow-up 
      periods in the two groups were 19.4 +/- 12.6 mon and 20.7 +/- 13.0 mon, 
      respectively. There were 175 males in the aspirin group and 137 males in the 
      control group. The incidence of reinfarction was reduced by 65% and platelet 
      aggregation was inhibited obviously in the aspirin group as compared to the 
      control group in men, whereas no significant trends were observed in women.
FAU - Chen, Z
AU  - Chen Z
AD  - Cardiovascular Institute, CAMS, Beijing.
FAU - Xu, Y
AU  - Xu Y
FAU - Yu, Q
AU  - Yu Q
FAU - Kou, W
AU  - Kou W
FAU - Lu, Z
AU  - Lu Z
FAU - Yao, K
AU  - Yao K
FAU - Gao, R
AU  - Gao R
FAU - Chen, J
AU  - Chen J
FAU - Jia, Y
AU  - Jia Y
FAU - Duan, B
AU  - Duan B
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - China
TA  - Chin Med Sci J
JT  - Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
JID - 9112559
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Recurrence
MH  - Sex Factors
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
PST - ppublish
SO  - Chin Med Sci J. 1991 Sep;6(3):141-4.

PMID- 1731469
OWN - NLM
STAT- MEDLINE
DCOM- 19920214
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 69
IP  - 3
DP  - 1992 Jan 15
TI  - Rapidity and duration of platelet suppression by enteric-coated aspirin in 
      healthy young men.
PG  - 258-62
AB  - The recent demonstration of aspirin's ability to prevent and reduce the severity 
      of myocardial infarction has led to a marked increase in its use and to a need 
      for information regarding the time-course of onset and offset of its antiplatelet 
      effect. A study of healthy men was conducted to determine (1) the rapidity of 
      onset of inhibition of platelet aggregation in response to adenosine diphosphate, 
      and thromboxane A2 production after chewed enteric-coated aspirin (325 mg, n = 
      10); and (2) the duration of platelet inhibition after cessation of 
      enteric-coated aspirin (325 mg) every other day for 14 days (n = 10). When 
      chewed, enteric-coated aspirin greatly inhibited platelet aggregation response to 
      adenosine diphosphate and thromboxane A2 production within 15 minutes. Complete 
      recovery of platelet aggregation occurred in half of the subjects by day 3, and 
      in 80% of the subjects by day 4; the platelet response was not affected by 
      exercise. This study demonstrates a rapid onset of aspirin's antiplatelet effect 
      and provides information relevant for optimal timing of initiation of aspirin for 
      acute conditions such as myocardial infarction and unstable angina, and cessation 
      of aspirin before surgery.
FAU - Jimenez, A H
AU  - Jimenez AH
AD  - Institute for Prevention of Cardiovascular Disease, New England Deaconess 
      Hospital, Boston, Massachusetts 02215.
FAU - Stubbs, M E
AU  - Stubbs ME
FAU - Tofler, G H
AU  - Tofler GH
FAU - Winther, K
AU  - Winther K
FAU - Williams, G H
AU  - Williams GH
FAU - Muller, J E
AU  - Muller JE
LA  - eng
GR  - MOI-RR02635/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Tablets, Enteric-Coated)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Epinephrine/pharmacology
MH  - Epoprostenol/biosynthesis
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Reference Values
MH  - Tablets, Enteric-Coated
MH  - Thromboxane A2/*biosynthesis
MH  - Time Factors
EDAT- 1992/01/15 00:00
MHDA- 1992/01/15 00:01
CRDT- 1992/01/15 00:00
PHST- 1992/01/15 00:00 [pubmed]
PHST- 1992/01/15 00:01 [medline]
PHST- 1992/01/15 00:00 [entrez]
AID - 0002-9149(92)91316-V [pii]
AID - 10.1016/0002-9149(92)91316-v [doi]
PST - ppublish
SO  - Am J Cardiol. 1992 Jan 15;69(3):258-62. doi: 10.1016/0002-9149(92)91316-v.

PMID- 6842340
OWN - NLM
STAT- MEDLINE
DCOM- 19830623
LR  - 20220408
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 102
IP  - 5
DP  - 1983 May
TI  - Trial of low doses of aspirin as prophylaxis in sickle cell disease.
PG  - 781-4
AB  - The effects of low doses of aspirin on the frequency and severity of painful 
      vaso-occlusive crises were evaluated in children with sickle hemoglobinopathies. 
      Aspirin was compared with placebo in 49 patients in a double-blind crossover 
      study. Careful monitoring of patients revealed an average of 1.1 painful crises 
      per patient year. During the 21 months of study, 70% of patients had a maximum of 
      two painful crises, and 25% experienced four or more. The frequency and severity 
      of crises were not affected by aspirin therapy. In view of aspirin's demonstrated 
      effect on platelet function, we suggest that platelets do not contribute to the 
      initiation or progression of the vaso-occlusive process.
FAU - Greenberg, J
AU  - Greenberg J
FAU - Ohene-Frempong, K
AU  - Ohene-Frempong K
FAU - Halus, J
AU  - Halus J
FAU - Way, C
AU  - Way C
FAU - Schwartz, E
AU  - Schwartz E
LA  - eng
GR  - HL07439/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anemia, Sickle Cell/*drug therapy
MH  - Aspirin/*administration & dosage
MH  - Blood Platelets/drug effects
MH  - Child
MH  - Child, Preschool
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain/drug therapy
MH  - Platelet Count
MH  - Sickle Cell Trait/*drug therapy
EDAT- 1983/05/01 00:00
MHDA- 1983/05/01 00:01
CRDT- 1983/05/01 00:00
PHST- 1983/05/01 00:00 [pubmed]
PHST- 1983/05/01 00:01 [medline]
PHST- 1983/05/01 00:00 [entrez]
AID - S0022-3476(83)80258-3 [pii]
AID - 10.1016/s0022-3476(83)80258-3 [doi]
PST - ppublish
SO  - J Pediatr. 1983 May;102(5):781-4. doi: 10.1016/s0022-3476(83)80258-3.

PMID- 16644316
OWN - NLM
STAT- MEDLINE
DCOM- 20060526
LR  - 20131121
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 151
IP  - 5
DP  - 2006 May
TI  - Lack of effect of enteric coating on aspirin-induced inhibition of platelet 
      aggregation in healthy volunteers.
PG  - 976.e7-11
AB  - BACKGROUND: Aspirin inhibits platelet aggregation and is widely used in the 
      treatment of cardiovascular disease. Some individuals are less responsive to 
      aspirin's antiplatelet effect, a phenomenon termed aspirin resistance. It is not 
      known whether the antiplatelet effect is fully preserved with the enteric-coated 
      (EC) formulation. METHODS: We performed a prospective randomized trial of 50 
      healthy volunteers using a crossover design to compare the EC with the standard 
      aspirin formulations. The subjects received a 7-day course of each aspirin 
      formulation (81-mg) (Bayer Corporation, Morristown, NJ) separated by a 3-week 
      washout period. Platelet function was measured before and after each course using 
      optical aggregometry (with arachidonic acid and adenosine diphosphate as 
      agonists) and a point-of-care platelet assay. RESULTS: The assays were 
      reproducible, and the variation in baseline platelet function was small to 
      moderate between the subjects. There was no difference in the extent of platelet 
      inhibition between the EC and standard formulations with any of the 3 assays. 
      With the point-of-care platelet assay, the mean aspirin effect favoring the 
      standard formulation (more aggregation inhibition) compared with the EC 
      formulation was 1.6% +/- 15.8% (P = .60 for difference between the formulations). 
      The corresponding optical aggregometry values were -3.4% +/- 39.5% (P = .97) and 
      -1.4% +/- 16.6% (P = .75) for arachidonic acid and adenosine diphosphate, 
      respectively. CONCLUSIONS: Compared with standard aspirin, EC aspirin appears to 
      exhibit similar inhibition of platelet aggregation in healthy volunteers. 
      Furthermore, point-of-care platelet assessment correlated well with the gold 
      standard of laboratory-based optical platelet aggregometry.
FAU - Karha, Juhana
AU  - Karha J
AD  - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 
      44195, USA.
FAU - Rajagopal, Vivek
AU  - Rajagopal V
FAU - Kottke-Marchant, Kandice
AU  - Kottke-Marchant K
FAU - Bhatt, Deepak L
AU  - Bhatt DL
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Optics and Photonics
MH  - Platelet Aggregation/*drug effects
MH  - Point-of-Care Systems
MH  - Reference Values
MH  - Reproducibility of Results
MH  - *Tablets, Enteric-Coated
EDAT- 2006/04/29 09:00
MHDA- 2006/05/27 09:00
CRDT- 2006/04/29 09:00
PHST- 2005/08/18 00:00 [received]
PHST- 2006/02/05 00:00 [accepted]
PHST- 2006/04/29 09:00 [pubmed]
PHST- 2006/05/27 09:00 [medline]
PHST- 2006/04/29 09:00 [entrez]
AID - S0002-8703(06)00140-2 [pii]
AID - 10.1016/j.ahj.2006.02.017 [doi]
PST - ppublish
SO  - Am Heart J. 2006 May;151(5):976.e7-11. doi: 10.1016/j.ahj.2006.02.017.

PMID- 21726257
OWN - NLM
STAT- MEDLINE
DCOM- 20111223
LR  - 20181201
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 34
IP  - 5
DP  - 2011 Sep
TI  - Randomised clinical trial: rabeprazole plus aspirin is not inferior to 
      rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer.
PG  - 519-25
LID - 10.1111/j.1365-2036.2011.04760.x [doi]
AB  - BACKGROUND: Clopidogrel does not inhibit prostaglandin synthesis. As a result, 
      clopidogrel's incidence of peptic ulcer disease (PUD) and ulcer bleeding is lower 
      than aspirin's. AIM: To compare the healing rate in aspirin-related dyspeptic 
      ulcer patients who were given proton pump inhibitor (PPI) plus aspirin or PPI 
      plus clopidogrel. METHODS: Patients with aspirin-related nonbleeding symptomatic 
      ulcers were randomised to receive rabeprazole (20 mg/day) plus aspirin (100 
      mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks. The 
      primary endpoint was the successful treatment of PUD as characterised by 
      intention-to-treat at the end of therapy. RESULTS: Two hundred and eighteen 
      patients (109 in the aspirin group and 109 in the clopidogrel group) were 
      enrolled. There were no statistical demographic differences between the group 
      that received aspirin and the group that received clopidogrel. The PUD treatment 
      success rate was also statistically equal between the clopidogrel and aspirin 
      groups (86.2% vs. 90.0%, P = 0.531). Neither group experienced ulcer-related 
      bleeding. Multivariate logistic regression analysis showed that large ulcer size 
      (>10 mm) (OR: 6.29, 95% CI: 2.58-15.37) and past history of PUD (OR: 3.69, 95% 
      CI: 1.24-10.97) were important predictors of unsuccessful therapy for 
      aspirin-related PUD. CONCLUSIONS: Rabeprazole plus aspirin is not inferior to 
      rabeprazole plus clopidogrel in treating aspirin-related symptomatic PUD. Large 
      ulcer size (>10 mm) and past history of PUD are important predictors of 
      unsuccessful therapy (NCT 01037491).
CI  - © 2011 Blackwell Publishing Ltd.
FAU - Luo, J-C
AU  - Luo JC
AD  - Division of Gastroenterology, Taipei Veterans General Hospital, Taiwan. 
      jcluo@vghtpe.gov.tw
FAU - Huang, K-W
AU  - Huang KW
FAU - Leu, H-B
AU  - Leu HB
FAU - Chen, L-C
AU  - Chen LC
FAU - Hou, M-C
AU  - Hou MC
FAU - Li, C-P
AU  - Li CP
FAU - Lu, C-L
AU  - Lu CL
FAU - Lin, H-C
AU  - Lin HC
FAU - Lee, F-Y
AU  - Lee FY
FAU - Lee, S-D
AU  - Lee SD
LA  - eng
SI  - ClinicalTrials.gov/NCT01037491
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110705
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 32828355LL (Rabeprazole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/chemically induced/*drug therapy
MH  - Peptic Ulcer Hemorrhage/prevention & control
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Rabeprazole
MH  - Regression Analysis
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2011/07/06 06:00
MHDA- 2011/12/24 06:00
CRDT- 2011/07/06 06:00
PHST- 2011/07/06 06:00 [entrez]
PHST- 2011/07/06 06:00 [pubmed]
PHST- 2011/12/24 06:00 [medline]
AID - 10.1111/j.1365-2036.2011.04760.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2011 Sep;34(5):519-25. doi: 
      10.1111/j.1365-2036.2011.04760.x. Epub 2011 Jul 5.

PMID- 4129015
OWN - NLM
STAT- MEDLINE
DCOM- 19740226
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 7845
DP  - 1974 Jan 5
TI  - Letter: Aspirin, prostaglandin, and gestation.
PG  - 31
FAU - Horan, A H
AU  - Horan AH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arthritis/drug therapy/metabolism
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Embryo Implantation/drug effects
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/metabolism
MH  - Pregnancy, Prolonged/*drug effects
MH  - Prostaglandins/*metabolism
MH  - Rats
OID - PIP: 002063
OID - POP: 00087409
OAB - Dr. Lewis and Dr. Schulman (November 24, p. 1159) discussed their demonstration 
      that gestation is prolonged in patients with arthritis taking aspirin in terms of 
      prostaglandin metabolism at the end of pregnancy. On the other hand, perhaps the 
      delay came much earlier, during the periimplantation period. For example, when 
      rats were fed a saturated solution of sodium salicylate acid, the development of 
      the decidual cell reaction was much reduced on day 7 of pregnancy (day 0 was the 
      day of sperm in the vagina). This experiment was performed because the decidual 
      cell reaction to the invading blastocyst seemed to resemble the physiology of 
      acute inflammation elsewhere in the body, as evidenced by the suppression of the 
      increased capillary permeability to Evans-blue characteristic of the early hours 
      of nidation by sodium salicylate. It may be that arthritics on aspirin have a 
      decreased rate of deciduoma growth in the early weeks of gestation, as did the 
      rat.
OABL- eng
OTO - PIP
OT  - Biology
OT  - Endocrine System
OT  - Physiology
OT  - Pregnancy
OT  - *Pregnancy, First Trimester
OT  - *Prostaglandins--analysis
OT  - Reproduction
GN  - PIP: TJ: LANCET.
EDAT- 1974/01/05 00:00
MHDA- 1974/01/05 00:01
CRDT- 1974/01/05 00:00
PHST- 1974/01/05 00:00 [pubmed]
PHST- 1974/01/05 00:01 [medline]
PHST- 1974/01/05 00:00 [entrez]
AID - 10.1016/s0140-6736(74)93029-3 [doi]
PST - ppublish
SO  - Lancet. 1974 Jan 5;1(7845):31. doi: 10.1016/s0140-6736(74)93029-3.

PMID- 7143203
OWN - NLM
STAT- MEDLINE
DCOM- 19830119
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 71
IP  - 10
DP  - 1982 Oct
TI  - Solid-state stability of aspirin in the presence of excipients: kinetic 
      interpretation, modeling, and prediction.
PG  - 1096-101
AB  - Salicylsalicylic acid and acetylsalicylsalicylic acid were identified as 
      decomposition products of aspirin when mixtures of the drug, with magnesium 
      stearate, were stored in the solid state of 60 degrees and 75% relative humidity. 
      The effect of increasing the concentration of magnesium stearate and the addition 
      of other alkali stearates on the rate of decomposition of aspirin were studied. 
      The validity of the theory that pH changes induced by the alkali stearates 
      account for the catalytic effect of the lubricants on the decomposition was 
      tested. The changes observed were modeled and the mechanism involved elucidated. 
      The potential use of the melting points of aspirin mixtures in predicting the 
      stability of the drug in such drug-excipient mixtures is demonstrated.
FAU - Mroso, P V
AU  - Mroso PV
FAU - Li Wan Po, A
AU  - Li Wan Po A
FAU - Irwin, W J
AU  - Irwin WJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Excipients)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - V9MO595C9I (salicylsalicylic acid)
RN  - VBE72MCP5L (acetylsalicylsalicylic acid)
SB  - IM
MH  - *Aspirin/analogs & derivatives/analysis
MH  - Chemistry, Pharmaceutical
MH  - Chromatography, High Pressure Liquid/methods
MH  - Drug Stability
MH  - Excipients
MH  - Kinetics
MH  - Models, Chemical
MH  - Salicylates/analysis
EDAT- 1982/10/01 00:00
MHDA- 1982/10/01 00:01
CRDT- 1982/10/01 00:00
PHST- 1982/10/01 00:00 [pubmed]
PHST- 1982/10/01 00:01 [medline]
PHST- 1982/10/01 00:00 [entrez]
AID - S0022-3549(15)44349-7 [pii]
AID - 10.1002/jps.2600711004 [doi]
PST - ppublish
SO  - J Pharm Sci. 1982 Oct;71(10):1096-101. doi: 10.1002/jps.2600711004.

PMID- 20334083
OWN - NLM
STAT- MEDLINE
DCOM- 20100504
LR  - 20131121
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 6
IP  - 234
DP  - 2010 Feb 3
TI  - [Aspirin as primary prevention for diabetic patients].
PG  - 244-8
AB  - Several meta-analysis support the prescription of aspirin for primary prevention 
      of cardiovascular events in patients at risk. Though diabetics are particularly 
      prone to these complications, a review of the literature shows that they have 
      fewer benefits from the protective effects of such treatment. In these patients, 
      controlling dyslipidemia, blood pressure and glycemia remains the main aim. 
      Prescription of aspirin, in combination with an already existing medication, 
      should not be solely based on the presence of diabetes, but on the overall risk 
      profile of the patient, as well as his motivation.
FAU - Fumeaux, David
AU  - Fumeaux D
AD  - Service de médecine interne générale, HUG, 1211 Genève 14.
FAU - Becerra, Maria-Elisa
AU  - Becerra ME
FAU - Philippe, Jacques
AU  - Philippe J
FAU - Louis-Simonet, Martine
AU  - Louis-Simonet M
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - L'aspirine en prévention primaire chez les patients diabétiques.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - *Diabetes Complications
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Primary Prevention
EDAT- 2010/03/26 06:00
MHDA- 2010/05/05 06:00
CRDT- 2010/03/26 06:00
PHST- 2010/03/26 06:00 [entrez]
PHST- 2010/03/26 06:00 [pubmed]
PHST- 2010/05/05 06:00 [medline]
PST - ppublish
SO  - Rev Med Suisse. 2010 Feb 3;6(234):244-8.

PMID- 26599376
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20170817
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 27
IP  - 4
DP  - 2016 Jun
TI  - Evening intake of aspirin is associated with a more stable 24-h platelet 
      inhibition compared to morning intake: a study in chronic aspirin users.
PG  - 351-6
LID - 10.3109/09537104.2015.1107536 [doi]
AB  - Daily generation of novel platelets may compromise aspirin's platelet inhibitory 
      action, especially near the end of the regular 24-h dosing interval. A 
      contributor to this attenuation could be the endogenous circadian rhythm. The 
      primary objective of this study was to assess platelet activity 12 and 24 h after 
      different times of aspirin intake (c.q. 8.00 AM and 8.00 PM). A randomized 
      open-label crossover study was conducted, comprising outpatients with stable 
      cardiovascular disease taking aspirin once daily. We measured platelet 
      aggregation with the platelet function analyzer (PFA)-200(®) and light 
      transmission aggregometry (LTA). The attenuation of aspirin's inhibitory action 
      was most apparent in the 8.00 AM regimen. The platelet function analyzer-closure 
      time was 78 s faster at 24 h than at 12 h after intake in the 8.00 AM regimen 
      (IQR: 166.8-301 vs. 132.8-301; p = 0.006) and 0 s faster at 24 h than at 12 h 
      after intake in the 8.00 PM regimen (IQR: 198.8-837.0 vs. 169.8-301; p = 0.653). 
      The adenosine diphosphate 1.0 µmol/L maximum amplitude was 5.40% higher at 24 h 
      than at 12 h after intake in the 8.00 AM regimen (95% confidence interval (CI): 
      -0.03--10.8; p = 0.040) and was 0.75% higher 24 h than at 12 h after intake in 
      the 8.00 PM regimen (95% CI: -4.83-3.33; p = 0.705). The platelet inhibitory 
      effect of aspirin decreases after 24 h, particularly after intake in the morning. 
      These results suggest that patients might benefit from evening intake or twice 
      daily intake regimens.
FAU - van Diemen, Jeske Joanna Katarina
AU  - van Diemen JJ
AD  - a Internal Medicine , VU University Medical Center , Amsterdam , The Netherlands.
FAU - Fuijkschot, Wessel Willem
AU  - Fuijkschot WW
AD  - a Internal Medicine , VU University Medical Center , Amsterdam , The Netherlands.
FAU - Wessels, Tim Jon
AU  - Wessels TJ
AD  - a Internal Medicine , VU University Medical Center , Amsterdam , The Netherlands.
FAU - Veen, Gerrit
AU  - Veen G
AD  - b Cardiology , VU University Medical Center , Amsterdam , The Netherlands.
FAU - Smulders, Yvo Michiel
AU  - Smulders YM
AD  - a Internal Medicine , VU University Medical Center , Amsterdam , The Netherlands.
FAU - Thijs, Abel
AU  - Thijs A
AD  - a Internal Medicine , VU University Medical Center , Amsterdam , The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20151124
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cardiovascular Diseases/blood/diagnosis/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Function Tests
MH  - Time Factors
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - cardiovascular patients
OT  - circadian rhythm
OT  - platelet aggregation
OT  - randomized crossover trial
EDAT- 2015/11/26 06:00
MHDA- 2017/03/14 06:00
CRDT- 2015/11/25 06:00
PHST- 2015/11/25 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
AID - 10.3109/09537104.2015.1107536 [doi]
PST - ppublish
SO  - Platelets. 2016 Jun;27(4):351-6. doi: 10.3109/09537104.2015.1107536. Epub 2015 
      Nov 24.

PMID- 27393450
OWN - NLM
STAT- MEDLINE
DCOM- 20160906
LR  - 20160709
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 29
IP  - 4
DP  - 2016 Jul
TI  - A study into the genetic basis of aspirin resistance in Pakistani patients with 
      coronary artery disease.
PG  - 1177-82
AB  - Aspirin is a key player in the management and prevention of stroke and myocardial 
      infarction in patients with atherothrombosis. About 12% of Pakistanis suffering 
      from coronary artery disease are resistant to aspirin's effects. Clinical, 
      biochemical and genetic factors are known to be responsible for this phenomenon. 
      We conducted this study to investigate whether previously studied polymorphisms 
      in COX-1, GPIIIa, GPIa and P2RYI genes could be the cause of aspirin resistance 
      in our population. Blood samples were collected from 29 aspirin non-responders 
      and 60 ethnically matched responders. Aspirin response assay was performed on 
      IMPACT-R and DNA prepared from blood using the phenol: chloroform method. 
      Genotyping was carried out for four SNPS including COX-1 C50T (rs3842787), GPIIIA 
      PIA1/A2 polymorphism (rs5918), GPIA C807T (rs1126643) and p2RY1 C893T 
      (rs1065776). No statistically significant differences were observed in the allele 
      or genotype frequencies between the aspirin non responders and responders 
      indicating the possible involvement of different genetic determinants of aspirin 
      resistance in our population. This study paves the way for further research into 
      the field of aspirin resistance in Pakistan.
FAU - Mukarram, Osama
AU  - Mukarram O
AD  - Shifa College of Medicine, Shifa Tameer-e-Millat University, H-8/4, Islamabad.
FAU - Akhtar, Naveed
AU  - Akhtar N
AD  - Department of Cardiology, Shifa International Hospital, H-8/4 Islamabad.
FAU - Junaid, Ayesha
AU  - Junaid A
AD  - Department of Pathology, Shifa International Hospital, H-8/4 Islamabad.
FAU - Mohyuddin, Aisha
AU  - Mohyuddin A
AD  - Shifa College of Medicine, Shifa Tameer-e-Millat University, H-8/4, Islamabad.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - 0 (Integrin beta3)
RN  - 0 (P2RY1 protein, human)
RN  - 0 (Receptors, Purinergic P2Y1)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy
MH  - Cyclooxygenase 1/genetics
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Integrin beta3/genetics
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Receptors, Purinergic P2Y1/genetics
EDAT- 2016/07/10 06:00
MHDA- 2016/09/07 06:00
CRDT- 2016/07/10 06:00
PHST- 2016/07/10 06:00 [entrez]
PHST- 2016/07/10 06:00 [pubmed]
PHST- 2016/09/07 06:00 [medline]
PST - ppublish
SO  - Pak J Pharm Sci. 2016 Jul;29(4):1177-82.

PMID- 24464812
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20180101
IS  - 2211-0690 (Electronic)
IS  - 2211-0682 (Linking)
VI  - 19
IP  - 4
DP  - 2014 Aug
TI  - Automated Dissolution for Enteric-Coated Aspirin Tablets: A Case Study for Method 
      Transfer to a RoboDis II.
PG  - 375-80
LID - 10.1177/2211068213520401 [doi]
AB  - Dissolution method transfer is a complicated yet common process in the 
      pharmaceutical industry. With increased pharmaceutical product manufacturing and 
      dissolution acceptance requirements, dissolution testing has become one of the 
      most labor-intensive quality control testing methods. There is an increased trend 
      for automation in dissolution testing, particularly for large pharmaceutical 
      companies to reduce variability and increase personnel efficiency. There is no 
      official guideline for dissolution testing method transfer from a manual, 
      semi-automated, to automated dissolution tester. In this study, a manual 
      multipoint dissolution testing procedure for an enteric-coated aspirin tablet was 
      transferred effectively and reproducibly to a fully automated dissolution testing 
      device, RoboDis II. Enteric-coated aspirin samples were used as a model 
      formulation to assess the feasibility and accuracy of media pH change during 
      continuous automated dissolution testing. Several RoboDis II parameters were 
      evaluated to ensure the integrity and equivalency of dissolution method transfer 
      from a manual dissolution tester. This current study provides a systematic 
      outline for the transfer of the manual dissolution testing protocol to an 
      automated dissolution tester. This study further supports that automated 
      dissolution testers compliant with regulatory requirements and similar to manual 
      dissolution testers facilitate method transfer.
CI  - © 2014 Society for Laboratory Automation and Screening.
FAU - Ibrahim, Sarah A
AU  - Ibrahim SA
AD  - Division of Pharmaceutical Sciences, College of Pharmacy, University of 
      Cincinnati, Cincinnati, OH, USA Division of Pharmaceutical Sciences, School of 
      Pharmacy, Fairleigh Dickinson University, Florham Park, NJ, USA 
      ibrahisa@mail.uc.edu.
FAU - Martini, Luigi
AU  - Martini L
AD  - Institute of Pharmaceutical Science, King's College London, UK.
LA  - eng
PT  - Journal Article
DEP - 20140124
PL  - United States
TA  - J Lab Autom
JT  - Journal of laboratory automation
JID - 101558509
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/analysis/chemistry
MH  - Automation, Laboratory/*methods
MH  - Chemistry, Pharmaceutical/*methods
MH  - *Drug Liberation
MH  - Reproducibility of Results
MH  - *Tablets, Enteric-Coated/analysis/chemistry
OTO - NOTNLM
OT  - RoboDis II
OT  - automated dissolution
OT  - enteric-coated aspirin
OT  - method transfer
EDAT- 2014/01/28 06:00
MHDA- 2014/01/28 06:01
CRDT- 2014/01/28 06:00
PHST- 2013/08/02 00:00 [received]
PHST- 2014/01/28 06:00 [entrez]
PHST- 2014/01/28 06:00 [pubmed]
PHST- 2014/01/28 06:01 [medline]
AID - 2211068213520401 [pii]
AID - 10.1177/2211068213520401 [doi]
PST - ppublish
SO  - J Lab Autom. 2014 Aug;19(4):375-80. doi: 10.1177/2211068213520401. Epub 2014 Jan 
      24.

PMID- 28705331
OWN - NLM
STAT- MEDLINE
DCOM- 20180522
LR  - 20181202
IS  - 0003-4509 (Print)
IS  - 0003-4509 (Linking)
VI  - 75
IP  - 5
DP  - 2017 Sep
TI  - A non-interventional retrospective cohort study of the interaction between 
      methotrexate and proton pump inhibitors or aspirin.
PG  - 344-348
LID - S0003-4509(17)30020-2 [pii]
LID - 10.1016/j.pharma.2017.06.002 [doi]
AB  - INTRODUCTION: Methotrexate (MTX) is an antifolate drug, which is frequently used 
      in the treatment of cancer. Proton pump inhibitors (PPIs) could delay the 
      elimination of plasma MTX in high-dose MTX therapy by inhibition of tubular 
      secretion, which could lead to MTX toxicity. However, the evidence of the 
      clinical relevance of this drug-drug interaction is inconsistent. No previous 
      studies into the effect of low dose aspirin on the elimination of MTX in 
      high-dose therapy have been performed. Therefore, we evaluated the interaction 
      between MTX and PPIs or aspirin. METHODS: We conducted a non-interventional 
      retrospective cohort study in patients treated with high dose MTX (≥500mg/m(2) or 
      >1000mg), between 2009 and 2016 at the OLVG ("Onze Lieve Vrouwe Gasthuis, Oost") 
      in Amsterdam, the Netherlands. Patients were included if MTX concentrations were 
      determined at 24, 48 or 72hours after high dose MTX treatment. We categorised the 
      cycles of high dose MTX therapy into delayed elimination or normal elimination. 
      Differences in patient characteristics and MTX dosing regimen were compared 
      between all groups by X2-test, Fisher's exact probability test or Mann-Whitney 
      U-test. RESULTS: In total, 89 high dose MTX cycles were included. Delayed MTX 
      elimination was observed in 27 (30.3%) cycles. Co-administration of a PPI was 
      significantly more frequent in the delayed elimination group than in the normal 
      elimination group (P<0.001). There was no statistical effect observed by 
      co-administration of aspirin. CONCLUSION: The use of PPIs during high dose MTX 
      treatment can lead to delayed MTX elimination. Discontinuation of PPIs during 
      high dose MTX treatment is recommended. Co-administration of aspirin did not 
      influence the elimination of MTX, but further research is needed.
CI  - Copyright © 2017 Académie Nationale de Pharmacie. Published by Elsevier Masson 
      SAS. All rights reserved.
FAU - Boerrigter, E
AU  - Boerrigter E
AD  - Division of Clinical Pharmacy, OLVG, Oosterpark 9, 1090HM Amsterdam, Netherlands.
FAU - Crul, M
AU  - Crul M
AD  - Division of Clinical Pharmacy, OLVG, Oosterpark 9, 1090HM Amsterdam, Netherlands. 
      Electronic address: m.crul@olvg.nl.
LA  - eng
PT  - Journal Article
DEP - 20170710
PL  - France
TA  - Ann Pharm Fr
JT  - Annales pharmaceutiques francaises
JID - 2985176R
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Aspirin
MH  - *Drug Interactions
MH  - Humans
MH  - Methotrexate/*chemistry
MH  - Proton Pump Inhibitors/*chemistry
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirine
OT  - Drug–drug interactions
OT  - Inhibiteur de la pompe à protons
OT  - Interaction
OT  - Methotrexate
OT  - Méthotrexate
OT  - Proton pump inhibitor
EDAT- 2017/07/15 06:00
MHDA- 2018/05/23 06:00
CRDT- 2017/07/15 06:00
PHST- 2017/02/08 00:00 [received]
PHST- 2017/06/08 00:00 [revised]
PHST- 2017/06/09 00:00 [accepted]
PHST- 2017/07/15 06:00 [pubmed]
PHST- 2018/05/23 06:00 [medline]
PHST- 2017/07/15 06:00 [entrez]
AID - S0003-4509(17)30020-2 [pii]
AID - 10.1016/j.pharma.2017.06.002 [doi]
PST - ppublish
SO  - Ann Pharm Fr. 2017 Sep;75(5):344-348. doi: 10.1016/j.pharma.2017.06.002. Epub 
      2017 Jul 10.

PMID- 18823461
OWN - NLM
STAT- MEDLINE
DCOM- 20081107
LR  - 20131121
IS  - 1399-6576 (Electronic)
IS  - 0001-5172 (Linking)
VI  - 52
IP  - 9
DP  - 2008 Oct
TI  - Bleeding time prolonged by daily low-dose aspirin is shortened by one medium dose 
      aspirin.
PG  - 1226-30
LID - 10.1111/j.1399-6576.2008.01766.x [doi]
AB  - BACKGROUND: In planning surgery, a low-dose aspirin regimen for prevention of 
      thrombotic events is often discontinued in order to avoid the risk of excessive 
      bleeding during surgery. However, this procedure increases the risk from adverse 
      thrombotic events. We propose a different method, which may normalize the 
      prolonged bleeding time caused by low-dose aspirin. We verified the effectiveness 
      of this method in healthy volunteers. METHODS: Volunteers with bleeding time 
      prolonged by taking 81 mg of aspirin a day for a period of 1 week were randomly 
      divided into two groups. The test group of 18 volunteers received a dose of 660 
      mg of aspirin, while the control group of 16 received placebo. Bleeding time and 
      maximum platelet activity were then evaluated. RESULTS: Before 660 mg of aspirin 
      or placebo, bleeding time was prolonged: in the aspirin group from 3.1 +/- 0.7 to 
      6.1 +/- 1.4 min (n=18), and in the placebo group from 2.9 +/- 0.9 to 6.1 +/- 1.5 
      min (n=16). This prolongation was significant in both groups at the P<0.01 level. 
      In the test group, bleeding time was shortened to 4.5 +/- 1.3 min (P<0.01), which 
      is in the normal range, while it remained prolonged in the control group (6.0 +/- 
      1.2 min). Platelet activity, on the other hand, was suppressed in both groups. 
      CONCLUSION: We conclude that 660 mg of aspirin effectively shortens the bleeding 
      time prolonged by daily low-dose (81 mg) aspirin.
FAU - Yokoyama, T
AU  - Yokoyama T
AD  - Department of Anesthesiology and Critical Care Medicine, Kochi Medical School, 
      Nankoku, Japan. yokoyamt@med.kochi-u.ac.jp
FAU - Yamasaki, F
AU  - Yamasaki F
FAU - Yamashita, K
AU  - Yamashita K
FAU - Manabe, M
AU  - Manabe M
FAU - Suwa, K
AU  - Suwa K
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Acta Anaesthesiol Scand
JT  - Acta anaesthesiologica Scandinavica
JID - 0370270
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
EDAT- 2008/10/01 09:00
MHDA- 2008/11/08 09:00
CRDT- 2008/10/01 09:00
PHST- 2008/10/01 09:00 [pubmed]
PHST- 2008/11/08 09:00 [medline]
PHST- 2008/10/01 09:00 [entrez]
AID - AAS1766 [pii]
AID - 10.1111/j.1399-6576.2008.01766.x [doi]
PST - ppublish
SO  - Acta Anaesthesiol Scand. 2008 Oct;52(9):1226-30. doi: 
      10.1111/j.1399-6576.2008.01766.x.

PMID- 8469865
OWN - NLM
STAT- MEDLINE
DCOM- 19930510
LR  - 20131121
IS  - 0035-290X (Print)
IS  - 0035-290X (Linking)
VI  - 88
IP  - 2
DP  - 1993 Feb
TI  - [Does a preventive treatment of pregnancy toxemia exist: the role of aspirin].
PG  - 63-8
AB  - After studying the risk factors of eclamptic toxemia, the author describes the 
      various methods of prevention proposed. A salt-free diet has no effect. Increased 
      intake of zinc or magnesium has no impact. Calcium (600 to 2,000 mg/d) may reduce 
      the incidence of toxemia among teenagers from 27.9% to 4%. Low dose aspirin 
      appears to be equally effective. Cod liver oil is currently being tested.
FAU - Boog, G
AU  - Boog G
AD  - Service de Gynécologie-Obstétrique, CHU, Hôpital Laennec, Nantes.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Existe-t-il une prévention de la toxémie gravidique: place de l'aspirine.
PL  - France
TA  - Rev Fr Gynecol Obstet
JT  - Revue francaise de gynecologie et d'obstetrique
JID - 0411346
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/diagnosis/*prevention & control
MH  - Pregnancy
MH  - Risk Factors
RF  - 39
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
PST - ppublish
SO  - Rev Fr Gynecol Obstet. 1993 Feb;88(2):63-8.

PMID- 16025889
OWN - NLM
STAT- MEDLINE
DCOM- 20050929
LR  - 20131121
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 1
IP  - 22
DP  - 2005 Jun 1
TI  - [Should we treat all diabetic patients with aspirin in primary prevention?].
PG  - 1500-4
AB  - Patients with diabetes have a higher risk of atherothrombotic disease. These 
      patients have up to 4-fold more coronary artery diseases compared with patients 
      without diabetes. Aspirin is one of the most prescribed treatments in the 
      prevention of cardiovascular diseases. This article focuses on the effect of 
      aspirin in primary prevention with a summary of interventional studies including 
      diabetic patients. The guidelines from different speciality societies, notably 
      the American Diabetes Association, are positive. However, the results of these 
      studies are not conclusive. Cautions recommendations are proposed.
FAU - Righetti, A
AU  - Righetti A
AD  - Service d'endocrinologie, diabétologie et nutrition, Hôpitaux universitaires de 
      Genève, 1211 Genève 14. anne.righetti@hcuge.ch
FAU - De Moerloose, P
AU  - De Moerloose P
FAU - Philippe, J
AU  - Philippe J
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Faut-il donner de l'aspirine en prévention primaire a tous les patients 
      diabétiques?
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
RF  - 23
EDAT- 2005/07/20 09:00
MHDA- 2005/09/30 09:00
CRDT- 2005/07/20 09:00
PHST- 2005/07/20 09:00 [pubmed]
PHST- 2005/09/30 09:00 [medline]
PHST- 2005/07/20 09:00 [entrez]
PST - ppublish
SO  - Rev Med Suisse. 2005 Jun 1;1(22):1500-4.

PMID- 9277122
OWN - NLM
STAT- MEDLINE
DCOM- 19970924
LR  - 20161021
IS  - 1079-7440 (Print)
IS  - 1079-7440 (Linking)
VI  - 51
IP  - 4
DP  - 1997 Jul-Aug
TI  - Total organic carbon method for aspirin cleaning validation.
PG  - 149-52
AB  - Cleaning validation is the process of assuring that cleaning procedures 
      effectively remove the residue from manufacturing equipment/facilities below a 
      predetermined level. This is necessary to assure the quality of future products 
      using the equipment, to prevent cross-contamination, and as a World Health 
      Organization Good Manufacturing Practices requirement. We have applied the Total 
      Organic Carbon (TOC) analysis method to a number of pharmaceutical products. In 
      this article we discuss the TOC method that we developed for measuring residual 
      aspirin on aluminum, stainless steel, painted carbon steel, and plexiglass. These 
      are all surfaces that are commonly found as part of pharmaceutical production 
      equipment. The method offers low detection capability (parts per million levels) 
      and rapid sample analysis time. The recovery values ranged from 25% for aluminum 
      to about 75% for plexiglass with a precision of 13% or less. The results for the 
      plexiglass tended to vary with the age of the surface making the determination of 
      an accurate recovery value difficult for this type of surface. We found that the 
      TOC method is applicable for determining residual aspirin on pharmaceutical 
      surfaces and will be useful for cleaning validation.
FAU - Holmes, A J
AU  - Holmes AJ
AD  - Chemistry Department, Western Michigan University, Kalamazoo, USA.
FAU - Vanderwielen, A J
AU  - Vanderwielen AJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - PDA J Pharm Sci Technol
JT  - PDA journal of pharmaceutical science and technology
JID - 9439538
RN  - 7440-44-0 (Carbon)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/*standards
MH  - Carbon/*analysis
MH  - Drug Compounding/instrumentation/standards
MH  - Quality Control
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
PST - ppublish
SO  - PDA J Pharm Sci Technol. 1997 Jul-Aug;51(4):149-52.

PMID- 20370474
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20131121
IS  - 1525-6073 (Electronic)
IS  - 0742-0528 (Linking)
VI  - 27
IP  - 2
DP  - 2010 Jan
TI  - Sex differences in the administration-time-dependent effects of low-dose aspirin 
      on ambulatory blood pressure in hypertensive subjects.
PG  - 345-62
LID - 10.3109/07420521003624662 [doi]
AB  - Previous studies have revealed sex differences in blood pressure (BP) regulation, 
      pathophysiology of hypertension, and treatment responses to medication. On the 
      other hand, low-dose aspirin has been shown to reduce BP when administered at 
      bedtime, as opposed to upon awakening, in hypertensive subjects and pregnant 
      women at risk for preeclampsia. The purpose of this research was to investigate 
      the potential sex differences in the administration-time-dependent influence of 
      aspirin on BP. We studied 130 men and 186 women with untreated mild hypertension, 
      44.1 +/- 13.2 yrs of age, randomized to receive aspirin (100 mg/day) either on 
      awakening or at bedtime daily for three months. BP was measured for 48 h before 
      and after treatment. With ASA on awakening, ambulatory BP was unchanged in men 
      and slightly but significantly elevated in women (1.7/1.4 mmHg in the 48 h 
      SBP/DBP means, respectively; p < 0.023). BP was significantly reduced after 
      aspirin at bedtime and to a larger extent in women (-8.0/-5.6 mmHg in SBP/DBP) 
      than men (5.5/3.4 mmHg, respectively; p < 0.009 between men and women). Factors 
      influencing a stronger response of BP to aspirin at bedtime included female sex, 
      elevated fasting glucose, and high glomerular filtration rate. This study 
      corroborates the significant administration-time-dependent effect of low-dose 
      aspirin on ambulatory BP in subjects with untreated mild hypertension, while 
      documenting significant sex differences in the BP response to aspirin. 
      Accordingly, results indicate that bedtime is the optimal time for aspirin 
      ingestion in both men and women. This timed administration of low-dose aspirin 
      could provide a cost-effective valuable approach for BP control and potential 
      added cardiovascular protection, especially in hypertensive women.
FAU - Ayala, Diana E
AU  - Ayala DE
AD  - Bioengineering and Chronobiology Laboratories, University of Vigo, Campus 
      Universitario, Vigo 36310, Spain.
FAU - Hermida, Ramón C
AU  - Hermida RC
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Chronobiol Int
JT  - Chronobiology international
JID - 8501362
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Actigraphy
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology/therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pregnancy
MH  - Prospective Studies
MH  - Sex Characteristics
MH  - Time Factors
EDAT- 2010/04/08 06:00
MHDA- 2010/06/16 06:00
CRDT- 2010/04/08 06:00
PHST- 2010/04/08 06:00 [entrez]
PHST- 2010/04/08 06:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
AID - 10.3109/07420521003624662 [doi]
PST - ppublish
SO  - Chronobiol Int. 2010 Jan;27(2):345-62. doi: 10.3109/07420521003624662.

PMID- 7264918
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 7
DP  - 1981 Jul
TI  - Improved delivery through biological membranes VIII: Design, synthesis, and in 
      vivo testing of true prodrugs of aspirin.
PG  - 743-9
AB  - Novel activated ester-type prodrugs of aspirin were designed and synthesized. The 
      methylthiomethyl, methylsulfinymethyl, and methylsulfonylmethyl esters of aspirin 
      (acetylsalicylic acid) were cleaved in vitro in plasma to form aspirin rather 
      than the corresponding salicylates. In vitro studies using dogs indicated that at 
      least one aspirin derivative, methylsulfinylmethyl-2-acetoxybenzoate, is a true 
      aspirin prodrug since aspirin was detected in the blood after prodrug 
      administration.
FAU - Loftsson, T
AU  - Loftsson T
FAU - Kaminski, J J
AU  - Kaminski JJ
FAU - Bodor, N
AU  - Bodor N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/chemical 
      synthesis/metabolism
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Dogs
MH  - Female
MH  - Hydrolysis
MH  - Kinetics
MH  - Membranes/metabolism
EDAT- 1981/07/01 00:00
MHDA- 1981/07/01 00:01
CRDT- 1981/07/01 00:00
PHST- 1981/07/01 00:00 [pubmed]
PHST- 1981/07/01 00:01 [medline]
PHST- 1981/07/01 00:00 [entrez]
AID - S0022-3549(15)43800-6 [pii]
AID - 10.1002/jps.2600700708 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Jul;70(7):743-9. doi: 10.1002/jps.2600700708.

PMID- 3958361
OWN - NLM
STAT- MEDLINE
DCOM- 19860515
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 7
IP  - 5
DP  - 1986 May
TI  - Regional myocardial blood flow in experimental myocardial infarction after 
      pretreatment with aspirin.
PG  - 1057-62
AB  - The effects of aspirin on myocardial blood flow in an area of ischemia were 
      studied in 12 baboons. In each, a diagonal branch of the left anterior descending 
      coronary artery was ligated. Six of the baboons received aspirin (2 X 600 mg 
      orally, 12 hours and 1 hour before ligation); the other six did not receive 
      aspirin and served as a control group. The extent of myocardial ischemia was 
      delineated with an electrode wire grid on the surface of the anterior left 
      ventricular wall. The maximal area circumscribed by electrodes with 2 mV or more 
      ST segment elevation was compared with the area of reduced myocardial blood flow. 
      Myocardial blood flow was measured with the radioactive microspheres method using 
      strontium-85-labeled carbonized spheres. Two areas of reduced myocardial blood 
      flow were noted, one with severely reduced flow in the center of the myocardial 
      infarct (0 to 49% of noninfarcted myocardium) and another with mild to moderately 
      reduced myocardial blood flow at the border of the myocardial infarct (50 to 90% 
      of noninfarcted myocardium). Myocardial blood flow in the border area (margins of 
      ST elevation area) for the total wall was 85 +/- 8% of normal in the 
      aspirin-treated animals and 40 +/- 4% in the control group (p less than 0.01); 
      for the epicardium it was 67 +/- 10% of normal in noninfarcted myocardium after 
      aspirin and 37 +/- 5% for the control group (p less than 0.05); and for the 
      endocardium it was 78 +/- 8% of normal in noninfarcted myocardium after aspirin 
      and 39 +/- 6% in the control group (p less than 0.01).(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Ruf, W
AU  - Ruf W
FAU - Suehiro, G T
AU  - Suehiro GT
FAU - Suehiro, A
AU  - Suehiro A
FAU - McNamara, J J
AU  - McNamara JJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Coronary Circulation/*drug effects
MH  - Electrocardiography
MH  - Heart/physiology
MH  - Myocardial Infarction/*drug therapy
MH  - Papio
EDAT- 1986/05/01 00:00
MHDA- 1986/05/01 00:01
CRDT- 1986/05/01 00:00
PHST- 1986/05/01 00:00 [pubmed]
PHST- 1986/05/01 00:01 [medline]
PHST- 1986/05/01 00:00 [entrez]
AID - S0735-1097(86)80223-6 [pii]
AID - 10.1016/s0735-1097(86)80223-6 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1986 May;7(5):1057-62. doi: 10.1016/s0735-1097(86)80223-6.

PMID- 17457441
OWN - NLM
STAT- MEDLINE
DCOM- 20070731
LR  - 20131121
IS  - 0379-5284 (Print)
IS  - 0379-5284 (Linking)
VI  - 28
IP  - 5
DP  - 2007 May
TI  - Effect of low-dose aspirin therapy on implantation rate in women undergoing 
      in-vitro fertilization cycles.
PG  - 732-6
AB  - OBJECTIVE: To determine the effect of low-dose aspirin on ovarian response, 
      implantation and pregnancy rates in patients undergoing in-vitro fertilization 
      (IVF) cycles. METHODS: We performed a randomized analysis of 145 infertile women 
      with a mean+/-SD age of 29.6 +/- 4.47 years who underwent cycles of IVF. Patients 
      received 100 mg of aspirin (n=72) or placebo (n=73) daily. This study was 
      conducted in Royan Institute, Tehran, Iran from April 2002 to January 2004. 
      Aspirin was started on the 21st of their preceding menstrual cycle and it was 
      continued until menstruation or a negative pregnancy test. Pregnant women 
      received the medication until 12 weeks of pregnancy. The main outcome measures 
      were number of follicles >or=15 mm, number of oocytes retrieved, serum E2 levels, 
      cancellation rate, Ovarian Hyperstimulation Syndrome (OHSS) occurrence, number of 
      embryos transferred, and implantation and pregnancy rates. RESULTS: There were 
      statistically significant differences between the treatment group and the control 
      group in the number of follicles (7.4 +/- 4.1 versus 9.0 +/- 4.8) and OHSS 
      occurrence (5.6% versus 23.3%) but not in the other measures. CONCLUSION: The 
      addition of aspirin low dose (100 mg/daily) to the standard long protocol for 
      oocyte retrieval did not improve implantation and pregnancy rates in unselected 
      patients undergoing IVF cycles.
FAU - Moini, Ashraf
AU  - Moini A
AD  - Department of Endocrinology and Female Infertility, Royan Institute, Tehran 
      University of Medical Sciences, Tehran, Iran. a_moini@royaninstitute.org
FAU - Zafarani, Fatemeh
AU  - Zafarani F
FAU - Haddadian, Sedigheh
AU  - Haddadian S
FAU - Ahmadi, Jila
AU  - Ahmadi J
FAU - Honar, Hooman
AU  - Honar H
FAU - Riazi, Kiarash
AU  - Riazi K
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Saudi Arabia
TA  - Saudi Med J
JT  - Saudi medical journal
JID - 7909441
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Embryo Implantation/*drug effects
MH  - Female
MH  - Fertilization in Vitro/*drug effects
MH  - Humans
EDAT- 2007/04/26 09:00
MHDA- 2007/08/01 09:00
CRDT- 2007/04/26 09:00
PHST- 2007/04/26 09:00 [pubmed]
PHST- 2007/08/01 09:00 [medline]
PHST- 2007/04/26 09:00 [entrez]
AID - 20060911' [pii]
PST - ppublish
SO  - Saudi Med J. 2007 May;28(5):732-6.

PMID- 26606248
OWN - NLM
STAT- MEDLINE
DCOM- 20160627
LR  - 20201215
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 11
DP  - 2015
TI  - Human GAPDH Is a Target of Aspirin's Primary Metabolite Salicylic Acid and Its 
      Derivatives.
PG  - e0143447
LID - 10.1371/journal.pone.0143447 [doi]
LID - e0143447
AB  - The plant hormone salicylic acid (SA) controls several physiological processes 
      and is a key regulator of multiple levels of plant immunity. To decipher the 
      mechanisms through which SA's multiple physiological effects are mediated, 
      particularly in immunity, two high-throughput screens were developed to identify 
      SA-binding proteins (SABPs). Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) 
      from plants (Arabidopsis thaliana) was identified in these screens. Similar 
      screens and subsequent analyses using SA analogs, in conjunction with either a 
      photoaffinity labeling technique or surface plasmon resonance-based technology, 
      established that human GAPDH (HsGAPDH) also binds SA. In addition to its central 
      role in glycolysis, HsGAPDH participates in several pathological processes, 
      including viral replication and neuronal cell death. The anti-Parkinson's drug 
      deprenyl has been shown to suppress nuclear translocation of HsGAPDH, an early 
      step in cell death and the resulting cell death induced by the DNA alkylating 
      agent N-methyl-N'-nitro-N-nitrosoguanidine. Here, we demonstrate that SA, which 
      is the primary metabolite of aspirin (acetyl SA) and is likely responsible for 
      many of its pharmacological effects, also suppresses nuclear translocation of 
      HsGAPDH and cell death. Analysis of two synthetic SA derivatives and two classes 
      of compounds from the Chinese medicinal herb Glycyrrhiza foetida (licorice), 
      glycyrrhizin and the SA-derivatives amorfrutins, revealed that they not only 
      appear to bind HsGAPDH more tightly than SA, but also exhibit a greater ability 
      to suppress translocation of HsGAPDH to the nucleus and cell death.
FAU - Choi, Hyong Woo
AU  - Choi HW
AD  - Boyce Thompson Institute for Plant Research, Cornell University, 533 Tower Road, 
      Ithaca, New York, 14853, United States of America.
FAU - Tian, Miaoying
AU  - Tian M
AD  - Boyce Thompson Institute for Plant Research, Cornell University, 533 Tower Road, 
      Ithaca, New York, 14853, United States of America.
FAU - Manohar, Murli
AU  - Manohar M
AD  - Boyce Thompson Institute for Plant Research, Cornell University, 533 Tower Road, 
      Ithaca, New York, 14853, United States of America.
FAU - Harraz, Maged M
AU  - Harraz MM
AD  - The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School 
      of Medicine, Baltimore, Maryland 21205, United States of America.
FAU - Park, Sang-Wook
AU  - Park SW
AD  - Boyce Thompson Institute for Plant Research, Cornell University, 533 Tower Road, 
      Ithaca, New York, 14853, United States of America.
FAU - Schroeder, Frank C
AU  - Schroeder FC
AD  - Boyce Thompson Institute for Plant Research, Cornell University, 533 Tower Road, 
      Ithaca, New York, 14853, United States of America.
FAU - Snyder, Solomon H
AU  - Snyder SH
AD  - The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School 
      of Medicine, Baltimore, Maryland 21205, United States of America.
FAU - Klessig, Daniel F
AU  - Klessig DF
AD  - Boyce Thompson Institute for Plant Research, Cornell University, 533 Tower Road, 
      Ithaca, New York, 14853, United States of America.
AD  - Department of Plant Pathology and Plant-Microbe Biology, Cornell University, 
      Ithaca, New York, 14853, United States of America.
LA  - eng
GR  - R01 MH018501/MH/NIMH NIH HHS/United States
GR  - R37 MH018501/MH/NIMH NIH HHS/United States
GR  - MH18501/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20151125
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - EC 1.2.1.12 (Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating))
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/chemistry/metabolism/*pharmacology
MH  - Cell Death/drug effects
MH  - Cell Line
MH  - Cell Nucleus/metabolism
MH  - Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)/*antagonists & 
      inhibitors/metabolism
MH  - Humans
MH  - Molecular Structure
MH  - Protein Binding
MH  - Protein Transport/drug effects
MH  - Salicylic Acid/chemistry/metabolism/*pharmacology
PMC - PMC4659538
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/11/26 06:00
MHDA- 2016/06/28 06:00
CRDT- 2015/11/26 06:00
PHST- 2015/08/14 00:00 [received]
PHST- 2015/11/04 00:00 [accepted]
PHST- 2015/11/26 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/06/28 06:00 [medline]
AID - PONE-D-15-35850 [pii]
AID - 10.1371/journal.pone.0143447 [doi]
PST - epublish
SO  - PLoS One. 2015 Nov 25;10(11):e0143447. doi: 10.1371/journal.pone.0143447. 
      eCollection 2015.

PMID- 26323873
OWN - NLM
STAT- MEDLINE
DCOM- 20160617
LR  - 20220311
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Print)
IS  - 0960-894X (Linking)
VI  - 25
IP  - 20
DP  - 2015 Oct 15
TI  - Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin 
      (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid.
PG  - 4677-82
LID - S0960-894X(15)00858-6 [pii]
LID - 10.1016/j.bmcl.2015.08.023 [doi]
AB  - We recently reported the synthesis of NOSH-aspirin, a novel hybrid compound 
      capable of releasing both nitric oxide (NO) and hydrogen sulfide (H2S). In 
      NOSH-aspirin, the two moieties that release NO and H2S are covalently linked at 
      the 1, 2 positions of acetyl salicylic acid, i.e., ortho-NOSH-aspirin. Here we 
      report on the synthesis of meta- and para-NOSH-aspirins. We also made a 
      head-to-head evaluation of the effects of these three positional isomers of 
      NOSH-aspirin on colon cancer cell kinetics and induction of reactive oxygen 
      species, which in recent years has emerged as a key event in causing cancer cell 
      regression. Electron donating/withdrawing groups incorporated about the benzoate 
      moiety significantly affected the potency of these compounds with respect to 
      colon cancer cell growth inhibition.
CI  - Copyright © 2015 Elsevier Ltd. All rights reserved.
FAU - Vannini, Federica
AU  - Vannini F
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, 138th Street 
      and Convent Avenue, New York, NY 10031, USA.
FAU - MacKessack-Leitch, Andrew C
AU  - MacKessack-Leitch AC
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, 138th Street 
      and Convent Avenue, New York, NY 10031, USA; EaStCHEM School of Chemistry, 
      University of St. Andrews, St. Andrews, Fife KY16 9ST, UK.
FAU - Eschbach, Erin K
AU  - Eschbach EK
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, 138th Street 
      and Convent Avenue, New York, NY 10031, USA.
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, 138th Street 
      and Convent Avenue, New York, NY 10031, USA.
FAU - Kodela, Ravinder
AU  - Kodela R
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, 138th Street 
      and Convent Avenue, New York, NY 10031, USA.
FAU - Kashfi, Khosrow
AU  - Kashfi K
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, 138th Street 
      and Convent Avenue, New York, NY 10031, USA; Avicenna Pharmaceuticals Inc., 555 
      West 57th Street, New York, NY 10019, USA. Electronic address: 
      kashfi@med.cuny.edu.
LA  - eng
GR  - R24 DA018055/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150814
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Disulfides)
RN  - 0 (Nitrates)
RN  - 0 (Reactive Oxygen Species)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Antineoplastic Agents/*chemical synthesis/chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*analogs & derivatives/chemical synthesis/chemistry/pharmacology
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Disulfides/chemical synthesis/chemistry/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Screening Assays, Antitumor
MH  - HT29 Cells
MH  - Humans
MH  - Hydrogen Sulfide/*metabolism
MH  - Molecular Structure
MH  - Nitrates/chemical synthesis/chemistry/*pharmacology
MH  - Nitric Oxide/*metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Structure-Activity Relationship
PMC - PMC4592841
MID - NIHMS719763
OTO - NOTNLM
OT  - Cell kinetics
OT  - Colon cancer
OT  - Hydrogen sulfide
OT  - NOSH-aspirin
OT  - Nitric oxide
OT  - Reactive oxygen species
COIS- Conflict of interest: The authors have nothing to disclose except for KK, who has 
      an equity position in Avicenna Pharmaceuticals, Inc. to which these compounds are 
      licensed.
EDAT- 2015/09/02 06:00
MHDA- 2016/06/18 06:00
CRDT- 2015/09/02 06:00
PHST- 2015/07/24 00:00 [received]
PHST- 2015/08/05 00:00 [revised]
PHST- 2015/08/07 00:00 [accepted]
PHST- 2015/09/02 06:00 [entrez]
PHST- 2015/09/02 06:00 [pubmed]
PHST- 2016/06/18 06:00 [medline]
AID - S0960-894X(15)00858-6 [pii]
AID - 10.1016/j.bmcl.2015.08.023 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2015 Oct 15;25(20):4677-82. doi: 
      10.1016/j.bmcl.2015.08.023. Epub 2015 Aug 14.

PMID- 6519349
OWN - NLM
STAT- MEDLINE
DCOM- 19850314
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 12
IP  - 6
DP  - 1984
TI  - A double-blind randomized study of an aspirin/caffeine combination versus 
      acetaminophen/aspirin combination versus acetaminophen versus placebo in patients 
      with moderate to severe post-partum pain.
PG  - 338-45
AB  - In a double-blind, randomized controlled trial among 500 post-partum patients 
      experiencing moderate to severe pain, a single oral dose of an aspirin/caffeine 
      combination (800 mg aspirin, 65 mg caffeine) provided significantly more pain 
      relief at 2 hours than did a higher dose of an acetaminophen/aspirin combination 
      (648 mg acetaminophen, 648 mg aspirin) and a higher dose of acetaminophen alone 
      (1000 mg acetaminophen). At 3 and 4 hours, the acetaminophen/aspirin combination 
      as well as the aspirin/caffeine combination were significantly superior to 
      acetaminophen alone. At all times, all three drugs were significantly superior to 
      placebo. There were no clinically significant adverse reactions. These results 
      provide evidence of a potentiating effect of caffeine on aspirin's analgesic 
      potency.
FAU - Rubin, A
AU  - Rubin A
FAU - Winter, L Jr
AU  - Winter L Jr
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Drug Combinations)
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Caffeine/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Drug Evaluation
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Pain/*drug therapy
MH  - Placebos
MH  - Pregnancy
MH  - Puerperal Disorders/*drug therapy
MH  - Random Allocation
EDAT- 1984/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1177/030006058401200604 [doi]
PST - ppublish
SO  - J Int Med Res. 1984;12(6):338-45. doi: 10.1177/030006058401200604.

PMID- 1518391
OWN - NLM
STAT- MEDLINE
DCOM- 19921008
LR  - 20200304
IS  - 0024-4201 (Print)
IS  - 0024-4201 (Linking)
VI  - 27
IP  - 4
DP  - 1992 Apr
TI  - Liver lipid profiles of adults taking therapeutic doses of aspirin.
PG  - 311-4
AB  - The distributions of lipids of hepatic specimens obtained at autopsy from 7 adult 
      patients who had been taking large amounts of aspirin for arthritis were compared 
      to 7 control samples obtained from livers of autopsied adults without prior liver 
      disease. The total neutral lipid levels of control livers were approximately 
      one-third lower than those observed for livers of patients on aspirin. In 
      addition, the phospholipid content of control specimens was significantly greater 
      than that of livers from adult patients that had been on a high dose of aspirin 
      for a long time. Examination of individual lipid classes showed that the 
      concentrations of free fatty acids, triacylglycerols, and mono- and 
      diacylglycerols were highest in livers of patients with aspirin exposure, and 
      that all phospholipids were diminished. Phosphatidylcholines and 
      phosphatidylethanolamines showed the greatest decrease. These results suggest 
      that the livers of patients taking large amounts of aspirin may accumulate fatty 
      acids and neutral lipids due to an impairment in the oxidation of fatty acids by 
      hepatocytes. The data obtained also suggest that needle biopsy of the liver with 
      measurement of distribution of hepatic lipids, perhaps together with 
      histopathologic examination, may provide useful diagnostic information.
FAU - Rabinowitz, J L
AU  - Rabinowitz JL
AD  - Veterans Affairs Medical Center, Philadelphia, PA 19104.
FAU - Baker, D G
AU  - Baker DG
FAU - Villanueva, T G
AU  - Villanueva TG
FAU - Asanza, A P
AU  - Asanza AP
FAU - Capuzzi, D M
AU  - Capuzzi DM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Lipids
JT  - Lipids
JID - 0060450
RN  - 0 (Lipids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Humans
MH  - Lipids/*analysis
MH  - Liver/*chemistry
MH  - Tissue Distribution
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
AID - 10.1007/BF02536483 [doi]
PST - ppublish
SO  - Lipids. 1992 Apr;27(4):311-4. doi: 10.1007/BF02536483.

PMID- 20065114
OWN - NLM
STAT- MEDLINE
DCOM- 20100326
LR  - 20161125
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
VI  - 184
IP  - 4
DP  - 2010 Feb 15
TI  - NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects 
      through inhibition of I kappa B-alpha degradation in human monocytes.
PG  - 2140-7
LID - 10.4049/jimmunol.0903107 [doi]
AB  - NO-donating aspirins consist of aspirin to which a NO-donating group is 
      covalently linked via a spacer molecule. NCX 4040 and NCX 4016 are positional 
      isomers with respect to the -CH(2)ONO(2) group (para and meta, respectively) on 
      the benzene ring of the spacer. Because positional isomerism is critical for 
      antitumor properties of NO-donating aspirins, we aimed to compare their 
      anti-inflammatory effects with those of aspirin in vitro. Thus, we assessed their 
      impacts on cyclooxygenase-2 activity (by measuring PGE(2) levels), protein 
      expression, and cytokine generation(IL-1beta, IL-18, TNF-alpha, and IL-10) in 
      human whole blood and isolated human monocytes stimulated with LPS. 
      Interestingly, we found that micromolar concentrations of NCX 4040, but not NCX 
      4016 or aspirin, affected cyclooxygenase-2 expression and cytokine generation. We 
      compared the effects of NCX 4040 with those of NCX 4016 or aspirin on 
      IkappaB-alpha stabilization and proteasome activity in the LPS-stimulated human 
      monocytic cell line THP1. Differently from aspirin and NCX 4016, NCX 4040, at a 
      micromolar concentration range, inhibited IkappaB-alpha degradation. In fact, NCX 
      4040 caused concentration-dependent accumulation of IkappaB-alpha and its 
      phosphorylated form. This effect was not reversed by 
      1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, an inhibitor of guanylyl cyclase, 
      thus excluding the contribution of NO-dependent cGMP generation. In contrast, 
      IkappaB-alpha accumulation by NCX 4040 may involve an inhibitory effect on 
      proteasome functions. Indeed, NCX 4040 inhibited 20S proteasome activity when 
      incubated with intact cells but not in the presence of cell lysate supernatants, 
      thus suggesting an indirect inhibitory effect. In conclusion, NCX 4040 is an 
      inhibitor of IkappaB-alpha degradation and proteasome function, and it should be 
      taken into consideration for the development of novel anti-inflammatory and 
      chemopreventive agents.
FAU - Ricciotti, Emanuela
AU  - Ricciotti E
AD  - Department of Medicine and Center of Excellence on Aging, School of Medicine, G. 
      d'Annunzio University, Chieti, Italy.
FAU - Dovizio, Melania
AU  - Dovizio M
FAU - Di Francesco, Luigia
AU  - Di Francesco L
FAU - Anzellotti, Paola
AU  - Anzellotti P
FAU - Salvatore, Tania
AU  - Salvatore T
FAU - Di Francesco, Andrea
AU  - Di Francesco A
FAU - Sciulli, Maria G
AU  - Sciulli MG
FAU - Pistritto, Giuseppa
AU  - Pistritto G
FAU - Monopoli, Angela
AU  - Monopoli A
FAU - Patrignani, Paola
AU  - Patrignani P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100111
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (I-kappa B Proteins)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NCX 4040)
RN  - 0 (NFKBIA protein, human)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Nitro Compounds)
RN  - 139874-52-5 (NF-KappaB Inhibitor alpha)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*pharmacology
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Blood Platelets/drug effects/enzymology
MH  - Cell Line, Tumor
MH  - Cyclooxygenase 1/blood
MH  - Cyclooxygenase 2/blood
MH  - Dinoprostone/biosynthesis/blood
MH  - Humans
MH  - I-kappa B Proteins/*antagonists & inhibitors/*metabolism
MH  - Lipopolysaccharides/antagonists & inhibitors/physiology
MH  - Monocytes/*drug effects/*metabolism
MH  - NF-KappaB Inhibitor alpha
MH  - Nitric Oxide Donors/chemistry/*pharmacology
MH  - Nitro Compounds/chemistry/*pharmacology
MH  - Signal Transduction/drug effects/immunology
EDAT- 2010/01/13 06:00
MHDA- 2010/03/27 06:00
CRDT- 2010/01/13 06:00
PHST- 2010/01/13 06:00 [entrez]
PHST- 2010/01/13 06:00 [pubmed]
PHST- 2010/03/27 06:00 [medline]
AID - jimmunol.0903107 [pii]
AID - 10.4049/jimmunol.0903107 [doi]
PST - ppublish
SO  - J Immunol. 2010 Feb 15;184(4):2140-7. doi: 10.4049/jimmunol.0903107. Epub 2010 
      Jan 11.

PMID- 18094224
OWN - NLM
STAT- MEDLINE
DCOM- 20080418
LR  - 20131121
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 48
IP  - 1
DP  - 2008 Jan
TI  - Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of 
      platelet aggregation: clinical consequences in stroke prophylaxis.
PG  - 117-22
AB  - This study was designed to measure the magnitude and duration of inhibition of 
      platelet aggregation following doses of aspirin or ibuprofen alone or taken in 
      combination in a group of healthy volunteers. Ten normal volunteer subjects 
      underwent 3 randomized treatment sessions: aspirin 325 mg alone, ibuprofen 400 mg 
      alone, and ibuprofen 400 mg, followed by dosing with aspirin 325 mg 2 hours 
      thereafter. In addition, a confirmatory study was performed in patients. Over 27 
      months, a cohort of patients treated with aspirin for secondary stroke 
      prophylaxis while concomitantly taking a nonsteroidal anti-inflammatory drug 
      (NSAID) was identified. A significant reduction was found in both the magnitude 
      and duration of aspirin's inhibitory effect on platelet aggregation when 
      ibuprofen was given prior to aspirin administration in normal volunteer subjects. 
      During a 27-month period, a cohort of 28 patients took regular daily doses of 
      ibuprofen or naproxen. Of these 28 patients, 18 returned for follow-up testing in 
      the absence of this pharmacodynamic interaction. None of these 18 patients 
      demonstrated inhibition of platelet aggregation while on both NSAID and aspirin; 
      however, all showed inhibition of aggregation following discontinuation of the 
      NSAID. Notably, 13 of these 18 patients (72%) had experienced a recurrent 
      ischemic episode while taking aspirin and NSAIDs concomitantly. These data 
      suggest that ibuprofen prevents the irreversible inhibition of platelet 
      aggregation produced by aspirin needed for secondary stroke prophylaxis, and this 
      interaction can have clinical consequences for patients taking aspirin.
FAU - Gengo, Francis M
AU  - Gengo FM
AD  - Department of Neurology, University at Buffalo, Buffalo, NY, USA. 
      fgengo@buffalo.edu
FAU - Rubin, Lisa
AU  - Rubin L
FAU - Robson, Matthew
AU  - Robson M
FAU - Rainka, Michelle
AU  - Rainka M
FAU - Gengo, Michael F
AU  - Gengo MF
FAU - Mager, Donald E
AU  - Mager DE
FAU - Bates, Vernice
AU  - Bates V
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Analysis of Variance
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cohort Studies
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ibuprofen/*pharmacology/therapeutic use
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Single-Blind Method
MH  - Stroke/etiology/prevention & control
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2007/12/21 09:00
MHDA- 2008/04/19 09:00
CRDT- 2007/12/21 09:00
PHST- 2007/12/21 09:00 [pubmed]
PHST- 2008/04/19 09:00 [medline]
PHST- 2007/12/21 09:00 [entrez]
AID - 48/1/117 [pii]
AID - 10.1177/0091270007310379 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2008 Jan;48(1):117-22. doi: 10.1177/0091270007310379.

PMID- 19527929
OWN - NLM
STAT- MEDLINE
DCOM- 20091207
LR  - 20140211
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 19
IP  - 15
DP  - 2009 Aug 1
TI  - Design, synthesis and evaluation of aspirin analogues having an additional 
      carboxylate substituent for antithrombotic activity.
PG  - 4213-6
LID - 10.1016/j.bmcl.2009.05.120 [doi]
AB  - Acetylsalicylic acid (aspirin) is an effective long-term prophylaxis of 
      thrombotic events such as heart attacks and strokes. It covalently inhibits 
      prostaglandin-H-synthase by interacting with Arg120 or Tyr385 at the active site 
      allowing delivery of its acetyl group to Ser530. However the structure has not 
      been optimized to fit the active site. We have designed acetylsalicylate 
      analogues with an additional carboxylate substituent which allows simultaneous 
      interaction with Arg120 and Tyr385 whilst positioning the acetyl group in close 
      proximity to Ser530. One of these, an ester derivative which unlike 
      acetylsalicylic acid is non-acidic, may act as useful lead compound for further 
      exploitation of this approach.
FAU - Alagha, Ahmed
AU  - Alagha A
AD  - Centre for Synthesis and Chemical Biology, Department of Pharmaceutical and 
      Medicinal Chemistry, Royal College of Surgeons in Ireland, 123 St Stephen's 
      Green, Dublin 2, Ireland.
FAU - Moman, Edelmiro
AU  - Moman E
FAU - Adamo, Mauro F A
AU  - Adamo MF
FAU - Nolan, Kevin B
AU  - Nolan KB
FAU - Chubb, Anthony J
AU  - Chubb AJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090613
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (Carboxylic Acids)
RN  - 0 (Esters)
RN  - 42HK56048U (Tyrosine)
RN  - 452VLY9402 (Serine)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Bioorg Med Chem Lett. 2014 Jan 1;24(1):398
MH  - Arginine/chemistry
MH  - Aspirin/*analogs & derivatives/*chemical synthesis/chemistry/pharmacology
MH  - Carboxylic Acids/chemistry
MH  - Catalytic Domain
MH  - Chemistry, Pharmaceutical/methods
MH  - Drug Design
MH  - Esters
MH  - Humans
MH  - Platelet Activation
MH  - Platelet Aggregation
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Serine/chemistry
MH  - Thrombosis/*drug therapy
MH  - Tyrosine/chemistry
EDAT- 2009/06/17 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/06/17 09:00
PHST- 2009/03/18 00:00 [received]
PHST- 2009/05/22 00:00 [revised]
PHST- 2009/05/27 00:00 [accepted]
PHST- 2009/06/17 09:00 [entrez]
PHST- 2009/06/17 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S0960-894X(09)00801-4 [pii]
AID - 10.1016/j.bmcl.2009.05.120 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2009 Aug 1;19(15):4213-6. doi: 10.1016/j.bmcl.2009.05.120. 
      Epub 2009 Jun 13.

PMID- 9866064
OWN - NLM
STAT- MEDLINE
DCOM- 19990330
LR  - 20220317
IS  - 1058-0468 (Print)
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 15
IP  - 10
DP  - 1998 Nov
TI  - A matched study to determine whether low-dose aspirin without heparin improves 
      pregnancy rates following frozen embryo transfer and/or affects endometrial 
      sonographic parameters.
PG  - 579-82
AB  - PURPOSE: The objective of the matched, controlled study was to determine whether 
      low-dose aspirin therapy without heparin improves pregnancy rates following 
      frozen embryo transfer. METHODS: Thirty-six women who did not achieve a pregnancy 
      following fresh embryo transfer and who had frozen embryos available for another 
      transfer were included. Eighteen women were treated with 81 mg aspirin from day 2 
      of the cycle through pregnancy testing. If the beta-human chorionic gonadotropin 
      level was positive, aspirin was continued through the pregnancy. Eighteen women 
      were not given aspirin. The mean outcome variables were pregnancy and 
      implantation rates. RESULTS: The clinical pregnancy rate in the aspirin group was 
      11.1%, compared with 33.3% for the controls, and implantation rates were 2.9 and 
      10.9%, respectively. CONCLUSIONS: No positive effects of low-dose aspirin therapy 
      on pregnancy rates following frozen embryo transfer were observed.
FAU - Check, J H
AU  - Check JH
AD  - University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical 
      School at Camden, Camden, New Jersey, USA.
FAU - Dietterich, C
AU  - Dietterich C
FAU - Lurie, D
AU  - Lurie D
FAU - Nazari, A
AU  - Nazari A
FAU - Chuong, J
AU  - Chuong J
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Chorionic Gonadotropin, beta Subunit, Human)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Antiphospholipid
MH  - Aspirin/administration & dosage/adverse effects/pharmacology/*therapeutic use
MH  - Chorionic Gonadotropin, beta Subunit, Human/blood
MH  - Embryo Implantation/*drug effects
MH  - Embryo Transfer/*methods
MH  - Endometrium/*diagnostic imaging
MH  - Female
MH  - Heparin
MH  - Humans
MH  - Menstrual Cycle
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Ultrasonography
PMC - PMC3454856
EDAT- 1998/12/29 00:00
MHDA- 1998/12/29 00:01
CRDT- 1998/12/29 00:00
PHST- 1998/12/29 00:00 [pubmed]
PHST- 1998/12/29 00:01 [medline]
PHST- 1998/12/29 00:00 [entrez]
AID - 408947 [pii]
AID - 10.1023/a:1020373009043 [doi]
PST - ppublish
SO  - J Assist Reprod Genet. 1998 Nov;15(10):579-82. doi: 10.1023/a:1020373009043.

PMID- 11190906
OWN - NLM
STAT- MEDLINE
DCOM- 20010503
LR  - 20191104
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 7
IP  - 1
DP  - 2001 Jan
TI  - A comparison of every-third-day versus daily low-dose aspirin therapy on serum 
      thromboxane concentrations in healthy men and women.
PG  - 53-7
AB  - Aspirin's antithrombotic effect is mediated predominately by inhibition of 
      platelet cyclooxygenase-1, leading to a decline in serum thromboxane A2 
      concentrations. We performed a placebo-controlled, randomized, double-blind trial 
      to determine whether aspirin could be given at 3-day intervals and still achieve 
      potent serum thromboxane inhibition. One hundred nine healthy men and women with 
      no recent exposure to aspirin and no contraindications to its use participated. 
      Subjects received 325 mg, 81 mg, or 40 mg of plain aspirin every third day, with 
      placebo on other days; 81 mg of aspirin every day; or placebo every day. Serum 
      concentrations of thromboxane B2 (the metabolite of thromboxane A2) were measured 
      at 3-day intervals during a 31-day treatment period, as well as 4, 7, and 14 days 
      after treatment ended. Serum thromboxane B2 concentrations were nearly identical 
      during treatment with 325 mg of aspirin every third day or 81 mg of aspirin per 
      day (86% inhibition [84%, 89%] and 85% inhibition [73%, 96%], respectively). An 
      aspirin dose of 81 mg every third day was nearly as potent (74% inhibition [70%, 
      79%]), whereas 40 mg of aspirin every third day achieved only 50% inhibition 
      (40%, 60%). Every-third-day low-dose aspirin regimens (325 and 81 mg) deserve 
      comparison with daily low-dose aspirin regimens in controlled clinical trials 
      because the former regimens could prove to have equal efficacy with reduced 
      toxicity.
FAU - Feldman, M
AU  - Feldman M
AD  - Medical Service, Dallas Department of Veterans Affairs Medical Center and 
      University of Texas Southwestern Medical School, 75216, USA. 
      feldman.mark@dallas.va.gov
FAU - Cryer, B
AU  - Cryer B
FAU - Rushin, K
AU  - Rushin K
FAU - Betancourt, J
AU  - Betancourt J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Thromboxane B2/blood
MH  - Thromboxanes/*blood
MH  - Time Factors
EDAT- 2001/02/24 12:00
MHDA- 2001/05/05 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/05/05 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
AID - 10.1177/107602960100700111 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2001 Jan;7(1):53-7. doi: 10.1177/107602960100700111.

PMID- 18160359
OWN - NLM
STAT- MEDLINE
DCOM- 20080221
LR  - 20131121
IS  - 1308-0032 (Electronic)
IS  - 1302-8723 (Linking)
VI  - 7 Suppl 2
DP  - 2007 Dec
TI  - [Aspirin in cardiovascular prevention: does the approach differ by gender?].
PG  - 2-4
AB  - Although aspirin is effective in the treatment of acute coronary syndrome and in 
      the secondary prevention of cardiovascular disease among both men and women, its 
      use in primary prevention remains controversial. The gender-specific 
      meta-analysis demonstrates that the specific types of benefit of aspirin therapy 
      differ between women and men in primary prevention. For primary prevention of 
      cardiovascular disease in women, aspirin therapy significantly reduced the risk 
      of the composite of cardiovascular events primarily by its effect on reducing the 
      risk of stroke. In contrast, in men; aspirin therapy significantly reduced the 
      risk of the composite of cardiovascular events predominantly by reducing the risk 
      of myocardial infarction. The reasons for any sex-based differences in the 
      efficacy of aspirin for primary prevention are unclear and require further 
      exploration.
FAU - Temizhan, Ahmet
AU  - Temizhan A
AD  - Türkiye Yüksek Ihtisas Eğitim ve Araştirma Hastanesi Kardiyoloji Kliniği, Ankara, 
      Türkiye. temizhan@hotmail.com
LA  - tur
PT  - English Abstract
PT  - Journal Article
PT  - Meta-Analysis
TT  - Kardiyovasküler korumada aspirin: cinsiyete göre farkli bir yaklaşim var mi?
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - *Gender Identity
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
EDAT- 2008/02/09 09:00
MHDA- 2008/02/22 09:00
CRDT- 2008/02/09 09:00
PHST- 2008/02/09 09:00 [pubmed]
PHST- 2008/02/22 09:00 [medline]
PHST- 2008/02/09 09:00 [entrez]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2007 Dec;7 Suppl 2:2-4.

PMID- 2203555
OWN - NLM
STAT- MEDLINE
DCOM- 19901009
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 82
IP  - 3
DP  - 1990 Sep
TI  - Prevention of early aortocoronary bypass occlusion by low-dose aspirin and 
      dipyridamole. Grupo Español para el Seguimiento del Injerto Coronario (GESIC).
PG  - 765-73
AB  - To analyze the efficacy of low-dose aspirin in preventing early aortocoronary 
      vein graft occlusion, 1,112 consecutive patients were enrolled in a multicenter, 
      randomized, double-blind, placebo-controlled trial comparing 50 mg t.i.d. 
      aspirin, 50 mg aspirin plus 75 mg t.i.d. dipyridamole, and placebo. All patients 
      received 100 mg q.i.d. dipyridamole for 48 hours before surgery, and assigned 
      treatment was started 7 hours after surgery. Vein graft angiography was performed 
      in 927 patients (83%) within 28 days of surgery (mean, 10 days). Aspirin plus 
      dipyridamole significantly (p = 0.017) reduced the occlusion rate of distal 
      anastomoses from 18% (placebo) to 12.9%. Occlusion rate in the aspirin group was 
      14%, which approached statistical significance (p = 0.058). Furthermore, only 
      aspirin plus dipyridamole reduced (p = 0.01) the number of patients with occluded 
      grafts (placebo, 33%; aspirin, 27.1%; aspirin plus dipyridamole, 24.3%). 
      Mediastinal drainage was slightly higher (p = 0.04) in the aspirin plus 
      dipyridamole group (713 +/- 456 ml) than in the other two groups (placebo, 670 
      +/- 437 ml; aspirin, 629 +/- 337 ml), but hospital mortality (average, 4.6%) and 
      early reoperation (average, 3.9%) rates were similar among the three groups. 
      Thus, low-dose aspirin plus dipyridamole safely improves early saphenous vein 
      aortocoronary graft patency; this effect is an added benefit to a preoperative 
      regimen of dipyridamole.
FAU - Sanz, G
AU  - Sanz G
AD  - Unidad Coronaria, Hospital Clínic, University of Barcelona, Spain.
FAU - Pajarón, A
AU  - Pajarón A
FAU - Alegría, E
AU  - Alegría E
FAU - Coello, I
AU  - Coello I
FAU - Cardona, M
AU  - Cardona M
FAU - Fournier, J A
AU  - Fournier JA
FAU - Gómez-Recio, M
AU  - Gómez-Recio M
FAU - Ruano, J
AU  - Ruano J
FAU - Hidalgo, R
AU  - Hidalgo R
FAU - Medina, A
AU  - Medina A
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Drug Combinations)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 1990 Sep;82(3):1046-8. PMID: 2393990
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Drug Combinations
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Vascular Patency
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
AID - 10.1161/01.cir.82.3.765 [doi]
PST - ppublish
SO  - Circulation. 1990 Sep;82(3):765-73. doi: 10.1161/01.cir.82.3.765.

PMID- 10381905
OWN - NLM
STAT- MEDLINE
DCOM- 19990727
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 117
IP  - 1
DP  - 1999 Jul
TI  - Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, 
      and rectal prostaglandin levels and on mucosal injury in healthy humans.
PG  - 17-25
AB  - BACKGROUND & AIMS: The safety of low-dose daily aspirin therapy in the 
      gastrointestinal tract is uncertain. Our objectives were to evaluate the 
      long-term effects of very low daily aspirin doses in the gastrointestinal tract 
      and effects on platelet-derived serum thromboxane levels in volunteers. METHODS: 
      Subjects were randomized to receive 10 mg (n = 8), 81 mg (n = 11), or 325 mg (n = 
      10) aspirin daily for 3 months. Before administration of aspirin, all subjects 
      underwent gastroduodenoscopy, and most underwent proctoscopy for assessment of 
      mucosal injury and prostaglandin content. After 1.5 and 3 months, subjects again 
      underwent gastroduodenoscopy and, at 3 months, another proctoscopy. RESULTS: Each 
      aspirin dose (even 10 mg) significantly reduced gastric mucosal prostaglandin 
      levels, to approximately 40% of the baseline value. All three doses also induced 
      significant gastric injury, and 325 mg caused duodenal injury. Three subjects 
      developed gastric ulcers, 1 while taking 10 mg/day of aspirin. Furthermore, 
      aspirin at 81 mg/day and 325 mg/day (but not 10 mg/day) significantly reduced 
      duodenal mucosal prostaglandin levels to approximately 40% of the baseline value. 
      Only 325 mg of aspirin per day significantly reduced rectal mucosal prostaglandin 
      levels to approximately 60% of the baseline value. Serum thromboxane levels were 
      inhibited 62%, 90%, and 98% with 10, 81, and 325 mg of aspirin. CONCLUSIONS: The 
      findings explain aspirin's predominant gastric toxicity and question the safety 
      of even 10 mg of aspirin daily.
FAU - Cryer, B
AU  - Cryer B
AD  - Medical Service, Dallas VA Medical Center, and Department of Internal Medicine, 
      University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA. 
      bcryer@mednet.swmed.edu
FAU - Feldman, M
AU  - Feldman M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandins)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 1999 Dec;117(6):1505. PMID: 10610340
CIN - Gastroenterology. 1999 Dec;117(6):1505-7. PMID: 10610341
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Cyclooxygenase Inhibitors/*administration & dosage/adverse effects/therapeutic 
      use
MH  - Dose-Response Relationship, Drug
MH  - Duodenum/drug effects/*metabolism
MH  - Endoscopy, Digestive System
MH  - Female
MH  - Gastric Mucosa/drug effects/*metabolism/pathology
MH  - Humans
MH  - Intestinal Mucosa/drug effects/metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Prostaglandins/*biosynthesis
MH  - Rectum/drug effects/*metabolism
MH  - Stomach/drug effects
MH  - Thromboxane B2/blood
MH  - Time Factors
EDAT- 1999/06/26 10:00
MHDA- 2000/03/18 09:00
CRDT- 1999/06/26 10:00
PHST- 1999/06/26 10:00 [pubmed]
PHST- 2000/03/18 09:00 [medline]
PHST- 1999/06/26 10:00 [entrez]
AID - S001650859900013X [pii]
AID - 10.1016/s0016-5085(99)70545-7 [doi]
PST - ppublish
SO  - Gastroenterology. 1999 Jul;117(1):17-25. doi: 10.1016/s0016-5085(99)70545-7.

PMID- 10973674
OWN - NLM
STAT- MEDLINE
DCOM- 20001004
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 99
IP  - 5
DP  - 2000 Sep 1
TI  - Inhibitory activity of aspirin on von Willebrand factor-induced platelet 
      aggregation.
PG  - 461-6
AB  - The effect of aspirin (ASA) on vWF induced platelet - platelet interaction is 
      unknown. We therefore tested the response of platelets to von Willebrand factor 
      (vWF) coated beads induced platelet aggregation before and after i.v. and oral 
      ASA. 1000 mg ASA was infused to 10 healthy individuals and after a wash-out 
      period 7 volunteers received 100 mg ASA orally over a period of 11 days. Prior to 
      ASA and in regular intervals thereafter we tested the reactivity to vWF-coated 
      beads to assess platelet adhesion/aggregation and the fade-out time of ASA 
      effects on platelets. Considerable interindividual variability in response to 
      vWF-coated beads was observed, both before ASA and after treatment with ASA. The 
      maximal response to vWF-coated beads (Tmax), the time lag, and the slope of the 
      curve were significantly affected by i.v. ASA, whereas 100 mg of ASA had only 
      inconstant effect on Tmax and slope. The absolute reduction of Tmax after ASA 
      depended on the pre-ASA level, while the percentage of the reduction was similar 
      in all individuals. Thus, platelet aggregation induced by vWF-coated beads is 
      impaired by ASA. Furthermore, our data indicate a large interindividual 
      variability of the response to ASA shortly after treatment induction, which 
      becomes more constant after prolonged treatment.
FAU - Homoncik, M
AU  - Homoncik M
AD  - Department of Clinical Pharmacology, University Vienna, Austria.
FAU - Jilma, B
AU  - Jilma B
FAU - Eichelberger, B
AU  - Eichelberger B
FAU - Panzer, S
AU  - Panzer S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (von Willebrand Factor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*antagonists & inhibitors/pharmacology
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Microspheres
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Prospective Studies
MH  - Time Factors
MH  - von Willebrand Factor/*pharmacology
EDAT- 2000/09/06 11:00
MHDA- 2000/10/07 11:01
CRDT- 2000/09/06 11:00
PHST- 2000/09/06 11:00 [pubmed]
PHST- 2000/10/07 11:01 [medline]
PHST- 2000/09/06 11:00 [entrez]
AID - S0049-3848(00)00297-8 [pii]
AID - 10.1016/s0049-3848(00)00297-8 [doi]
PST - ppublish
SO  - Thromb Res. 2000 Sep 1;99(5):461-6. doi: 10.1016/s0049-3848(00)00297-8.

PMID- 30500120
OWN - NLM
STAT- MEDLINE
DCOM- 20191028
LR  - 20191028
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 162
DP  - 2018 Nov 21
TI  - [Weight-dependent dosing of aspirin; the pharmacological and cardiological 
      perspective].
LID - D3298 [pii]
AB  - A recent meta-analysis by Rothwell and colleagues, presented in The Lancet, of 
      studies using aspirin as primary prevention showed that the effectiveness of the 
      medication was weight-dependent. We discuss the results from both a 
      pharmacological and cardiological perspective to assess the conclusions of this 
      study. The observed result in the meta-analysis could possibly be explained by 
      applying pharmacological principles; however, from a cardiological point of view 
      the extent to which it has an influence on clinical practice is questionable. 
      Notably, the included studies were conducted relatively long ago and results are, 
      therefore, difficult to translate to a more contemporary population; furthermore, 
      it is important to note that in current cardiology practice aspirin is not 
      indicated as primary prevention. Nonetheless, given the complex interaction 
      between patient-related factors and medication in the current population with 
      multiple comorbidities, the present study provides food for thought regarding 
      personalization of therapy.
FAU - Damen, Sander A J
AU  - Damen SAJ
AD  - Radboudumc, afd. Cardiologie, Nijmegen.
FAU - Brouwer, Marc A
AU  - Brouwer MA
AD  - Radboudumc, afd. Cardiologie, Nijmegen.
FAU - Kramers, C
AU  - Kramers C
AD  - Radboudumc, afd. Interne Geneeskunde, Nijmegen.
AD  - Contact: C. Kramers (kees.kramers@radboudumc.nl).
LA  - dut
PT  - Comment
PT  - Journal Article
TT  - Gewichtsafhankelijk doseren van aspirine.
DEP - 20181121
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Lancet. 2018 Aug 4;392(10145):387-399. PMID: 30017552
MH  - Aspirin
MH  - Body Weight
MH  - *Cardiology
MH  - Humans
MH  - *Neoplasms
MH  - Primary Prevention
EDAT- 2018/12/01 06:00
MHDA- 2019/10/29 06:00
CRDT- 2018/12/01 06:00
PHST- 2018/12/01 06:00 [entrez]
PHST- 2018/12/01 06:00 [pubmed]
PHST- 2019/10/29 06:00 [medline]
AID - D3298 [pii]
PST - epublish
SO  - Ned Tijdschr Geneeskd. 2018 Nov 21;162:D3298.

PMID- 7766717
OWN - NLM
STAT- MEDLINE
DCOM- 19950706
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 13
IP  - 2
DP  - 1995 Feb
TI  - The quantitative determination of aspirin and its degradation products in a model 
      solution aerosol.
PG  - 111-9
AB  - Formulation of pressurized aerosol solutions in propellants for inhalation 
      requires the use of high quantities of surfactants to solubilize the drug. Due to 
      the lipophilic nature of these surfactants, analytical difficulties are created 
      for those wishing to quantify the drug and its degradation products. In order to 
      quantify drug and degradation products by LC it is necessary to separate 
      surfactant and analytes prior to chromatography. To illustrate a typical 
      situation, a method was developed for the analysis of acetylsalicyclic acid 
      (approximately 2.5 x 10(-3) M) and its major degradation products (salicylic 
      acid, acetylsalicylsalicylic acid and salicylsalicylic acid) solubilized in 
      trichloromonofluoromethane (CFC-11) containing 10(-2) M sorbitan trioleate (Span 
      85). Surfactant extraction problems were reviewed experimentally. The 
      presentation of all analytes and the surfactant, dissolved in hexane, to silica 
      solid phase extraction columns, followed by elution in a polar solvent, was found 
      to be an efficient way of separating this lipophilic surfactant from the 
      analytes. The final assay employed propellant evaporation, reconstitution of the 
      non-volatiles in hexane, normal phase solid phase extraction (recoveries of 100 
      +/- 10% were observed for all analytes), elution and dilution with mobile phase, 
      and reversed-phase liquid chromatography (Econosphere C8 5 microns, 4.6 x 250 
      mm). The assay utilized a mobile phase of water, methanol, tetrahydrofuran and 1 
      M phosphoric acid with ultraviolet detection at 275 nm. Using external standards, 
      linear calibration curves of peak height versus concentration were obtained for 
      all analytes in the expected concentration ranges (r > 0.991). As it is 
      described, the assay had a relative standard deviation of < or = 3.7% for all 
      analytes.
FAU - Blondino, F E
AU  - Blondino FE
AD  - Medical College of Virginia/Virginia Commonwealth University, Department of 
      Pharmacy and Pharmaceutics, Richmond 23298-0533, USA.
FAU - Byron, P R
AU  - Byron PR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Aerosols)
RN  - 0 (Salicylates)
RN  - 0 (Solutions)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - V9MO595C9I (salicylsalicylic acid)
RN  - VBE72MCP5L (acetylsalicylsalicylic acid)
SB  - IM
MH  - Administration, Inhalation
MH  - Aerosols
MH  - Aspirin/administration & dosage/analogs & derivatives/*analysis/chemical 
      synthesis/chemistry
MH  - Chemistry, Pharmaceutical
MH  - Chromatography/methods
MH  - Reference Standards
MH  - Salicylates/analysis/chemistry
MH  - Salicylic Acid
MH  - Solutions
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
AID - 0731-7085(94)00131-K [pii]
AID - 10.1016/0731-7085(94)00131-k [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1995 Feb;13(2):111-9. doi: 10.1016/0731-7085(94)00131-k.

PMID- 16960142
OWN - NLM
STAT- MEDLINE
DCOM- 20061128
LR  - 20131121
IS  - 1534-0384 (Print)
IS  - 1534-0384 (Linking)
VI  - 6
IP  - 4
DP  - 2006 Aug
TI  - COX-2 in inflammation and resolution.
PG  - 199-207
AB  - Aspirin and the other NSAIDs have popularized the notion of inhibiting 
      prostaglandins as a common anti-inflammatory strategy based on the erroneous 
      premise that all eicosanoids are, within the context of inflammation, generally 
      detrimental. However, our fascination with aspirin and the emergence of COX-2 has 
      shown a more affable side to lipid mediators based on our increasing interest in 
      the endogenous control of acute inflammation and in factors that mediate its 
      resolution. Epilipoxins, for instance, are produced from aspirin's acetylation of 
      COX-2 and together with Resolvins and COX-2-derived prostaglandins of the D(2) 
      and J(2) series represent an increasingly important family of immunoregulatory 
      lipid mediators with strong implications for disease control and drug discovery.
FAU - Rajakariar, Ravindra
AU  - Rajakariar R
AD  - Department of Experimental Medicine, Nephrology and Critical Care, William Harvey 
      Research Institute, Charterhouse Square, London EC1M6BQ.
FAU - Yaqoob, Muhammad M
AU  - Yaqoob MM
FAU - Gilroy, Derek W
AU  - Gilroy DW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Mol Interv
JT  - Molecular interventions
JID - 101093789
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Prostaglandins)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/pharmacology
MH  - Cyclooxygenase 2/*metabolism
MH  - Cyclooxygenase 2 Inhibitors/*pharmacology/therapeutic use
MH  - Humans
MH  - Inflammation/drug therapy/*metabolism
MH  - Prostaglandins/metabolism
RF  - 67
EDAT- 2006/09/09 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/09/09 09:00
PHST- 2006/09/09 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/09/09 09:00 [entrez]
AID - 6/4/199 [pii]
AID - 10.1124/mi.6.4.6 [doi]
PST - ppublish
SO  - Mol Interv. 2006 Aug;6(4):199-207. doi: 10.1124/mi.6.4.6.

PMID- 9864607
OWN - NLM
STAT- MEDLINE
DCOM- 19990127
LR  - 20171116
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 91
IP  - 11
DP  - 1998 Nov
TI  - [Aspirin, oral anticoagulants, and heart failure].
PG  - 1377-81
AB  - The incidence of thromboembolic complications in patients with cardiac failure is 
      low. The predisposing factors are principally the presence of a left ventricular 
      mural thrombus, atrial fibrillation, a low ejection fraction and a low peak VO2. 
      The risk of cerebral haemorrhage in a patient with cardiac failure treated with 
      oral anticoagulants is about the same as the risk of thromboembolism. Therefore, 
      anticoagulant therapy for patients with cardiac failure is controversial in the 
      absence of a prospective large scale clinical trial demonstrating its benefits. 
      In the meantime, a prudent approach with risk stratification to determine which 
      patients would benefit the most from oral anticoagulation is advised.
FAU - Gibelin, P
AU  - Gibelin P
AD  - Service de cardiologie, CHU Pasteur, Nice.
LA  - fre
PT  - Journal Article
TT  - Aspirine, antivitamines K et insuffisance cardiaque chronique.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anti-Inflammatory Agents/therapeutic use
MH  - *Anticoagulants/therapeutic use
MH  - *Aspirin/therapeutic use
MH  - Contraindications
MH  - Heart Failure/*complications
MH  - Humans
MH  - Risk Factors
MH  - Thromboembolism/etiology/*prevention & control
EDAT- 1998/12/29 00:00
MHDA- 1998/12/29 00:01
CRDT- 1998/12/29 00:00
PHST- 1998/12/29 00:00 [pubmed]
PHST- 1998/12/29 00:01 [medline]
PHST- 1998/12/29 00:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 1998 Nov;91(11):1377-81.

PMID- 59550
OWN - NLM
STAT- MEDLINE
DCOM- 19760823
LR  - 20181113
IS  - 0002-9440 (Print)
IS  - 1525-2191 (Electronic)
IS  - 0002-9440 (Linking)
VI  - 84
IP  - 1
DP  - 1976 Jul
TI  - Gel-filtered human platelets. Ultrastructure, function, and role of proteins in 
      inhibition of aggregation by aspirin.
PG  - 11-24
AB  - Gel filtration of human platelet-rich plasma (PRP) on columns of Sepharose 2B 
      removed at least 99.85% of the plasma proteins from platelets when a column 10 cm 
      in height was used and a plasma volume 11 to 14% of the gel-bed volume was 
      applied. ADP and ATP levels in gel-filtered platelets (GFP) were not 
      significantly different from those in PRP. By transmission electron microscopy, 
      GFP were indistinguishable from PRP. Gel filtration appears to be a highly 
      satisfactory technique of separating platelets from plasma without modifying 
      structure, function, or contents significantly. The roles of several crude 
      protein fractions in platelet aggregation and aspirin's inhibition of aggregation 
      were examined. Fraction I (mostly fibrinogen) enhanced collagen-induced 
      aggregation of gel-filtered platelets; Fraction V (mostly albumin) was 
      inhibitory. Fraction II (mostly gamma-globulin) or gelatin had no significant 
      effect. Aspirin added to gel-filtered platelets inhibited aggregation by 80%. The 
      addition of mixtures of plasma proteins containing albumin increased albumin's 
      inhibitory effect. Incubation of gel-filtered platelets with aspirin labeled in 
      the carboxyl position resulted in no uptake of the label. In contrast, incubation 
      with acetyl-labeled aspirin was followed by uptake of more than 2 X 10(6) acetyl 
      groups per platelet in 1 minute. Incubation for 30 minutes resulted in a five- to 
      sixfold further increase in uptake of the label. Aspirin can acetylate platelets 
      and inhibit aggregation directly. Plasma proteins, in particular albumin or a 
      contaminant of the albumin fraction tested, enhance the inhibitory effect of 
      aspirin on platelet aggregation.
FAU - Fine, K M
AU  - Fine KM
FAU - Ashbrook, P C
AU  - Ashbrook PC
FAU - Brigden, L P
AU  - Brigden LP
FAU - Maldonado, J E
AU  - Maldonado JE
FAU - Didishelm, P
AU  - Didishelm P
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Pathol
JT  - The American journal of pathology
JID - 0370502
RN  - 0 (Blood Proteins)
RN  - 0 (Serum Albumin)
RN  - 0 (gamma-Globulins)
RN  - 9000-70-8 (Gelatin)
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/analysis/*physiology/ultrastructure
MH  - Blood Proteins/*physiology
MH  - Cell Fractionation
MH  - Chromatography, Gel
MH  - Fibrinogen/pharmacology
MH  - Gelatin/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Aggregation/*drug effects
MH  - Serum Albumin/pharmacology
MH  - gamma-Globulins/pharmacology
PMC - PMC2032350
EDAT- 1976/07/01 00:00
MHDA- 1976/07/01 00:01
CRDT- 1976/07/01 00:00
PHST- 1976/07/01 00:00 [pubmed]
PHST- 1976/07/01 00:01 [medline]
PHST- 1976/07/01 00:00 [entrez]
PST - ppublish
SO  - Am J Pathol. 1976 Jul;84(1):11-24.

PMID- 22391539
OWN - NLM
STAT- MEDLINE
DCOM- 20120913
LR  - 20211021
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Print)
IS  - 0066-4804 (Linking)
VI  - 56
IP  - 6
DP  - 2012 Jun
TI  - In vitro interactions between aspirin and amphotericin B against planktonic cells 
      and biofilm cells of Candida albicans and C. parapsilosis.
PG  - 3250-60
LID - 10.1128/AAC.06082-11 [doi]
AB  - The increase in drug resistance and invasion caused by biofilm formation brings 
      enormous challenges to the management of Candida infection. Aspirin's antibiofilm 
      activity in vitro was discovered recently. The spectrophotometric method and the 
      XTT 
      {2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium 
      hydroxide} reduction assay used for data generation make it possible to evaluate 
      fungal biofilm growth accurately. The combined use of the most commonly used 
      methods, the fractional inhibitory concentration index (FICI) and a newly 
      developed method, the ΔE model, which uses the concentration-effect relationship 
      over the whole concentration range instead of using the MIC index alone, makes 
      the interpretation of results more reliable. As an attractive tool for studying 
      the pharmacodynamics of antimicrobial agents, time-kill curves can provide 
      detailed information about antimicrobial efficacy as a function of both time and 
      concentration. In the present study, in vitro interactions between aspirin 
      (acetylsalicylic acid [ASA]) and amphotericin B (AMB) against planktonic cells 
      and biofilm cells of Candida albicans and C. parapsilosis were evaluated by the 
      checkerboard microdilution method and the time-kill test. Synergistic and 
      indifferent effects were found for the combination of ASA and AMB against 
      planktonic cells, while strong synergy was found against biofilm cells analyzed 
      by FICI. The ΔE model gave more consistent results with FICI. The positive 
      interactions in concentration were also confirmed by the time-kill test. 
      Moreover, this approach also revealed the pharmacodynamics changes of ASA and 
      synergistic action on time. Our findings suggest a potential clinical use for 
      combination therapy with ASA and AMB to augment activity against 
      biofilm-associated infections.
FAU - Zhou, Yabin
AU  - Zhou Y
AD  - Department of Microbiology and Key Laboratory for Experimental Teratology of 
      Chinese Ministry of Education, School of Medicine, Shandong University, Jinan, 
      People's Republic of China.
FAU - Wang, Ganggang
AU  - Wang G
FAU - Li, Yutang
AU  - Li Y
FAU - Liu, Yang
AU  - Liu Y
FAU - Song, Yu
AU  - Song Y
FAU - Zheng, Wenshuai
AU  - Zheng W
FAU - Zhang, Ning
AU  - Zhang N
FAU - Hu, Xiaoyan
AU  - Hu X
FAU - Yan, Shikun
AU  - Yan S
FAU - Jia, Jihui
AU  - Jia J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120305
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Antifungal Agents)
RN  - 7XU7A7DROE (Amphotericin B)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amphotericin B/*pharmacology
MH  - Antifungal Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Biofilms/*drug effects
MH  - Candida albicans/*drug effects
MH  - Microbial Sensitivity Tests
PMC - PMC3370722
EDAT- 2012/03/07 06:00
MHDA- 2012/09/14 06:00
CRDT- 2012/03/07 06:00
PHST- 2012/03/07 06:00 [entrez]
PHST- 2012/03/07 06:00 [pubmed]
PHST- 2012/09/14 06:00 [medline]
AID - AAC.06082-11 [pii]
AID - 06082-11 [pii]
AID - 10.1128/AAC.06082-11 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 2012 Jun;56(6):3250-60. doi: 10.1128/AAC.06082-11. 
      Epub 2012 Mar 5.

PMID- 29985735
OWN - NLM
STAT- MEDLINE
DCOM- 20190513
LR  - 20210109
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 30
IP  - 4
DP  - 2019
TI  - Comparison of nine platelet function tests used to determine responses to 
      different aspirin dosages in people with type 2 diabetes.
PG  - 521-529
LID - 10.1080/09537104.2018.1478402 [doi]
AB  - The antiplatelet efficacy of aspirin (ASA) is reduced in type 2 diabetes (T2D). 
      As the best ex vivo method of measuring ASA efficacy remains uncertain, we 
      compared nine platelet function tests to assess responsiveness to three ASA 
      dosing regimens in 24 T2D patients randomized in a three-treatment crossover 
      design to ASA 100 mg/day, 200 mg/day, or 100 mg twice daily for 2-week treatment 
      periods. Platelet function tests compared were as follows: light transmission 
      aggregometry (LTA)-0.5 mg/mL of arachidonic acid (AA) and 10 µM adenosine 
      diphosphate (ADP); multiplate whole blood aggregometry (WBA)-0.5 mM AA and 6.5 µM 
      ADP; platelet function analyzer (PFA)-100™-collagen and ADP (CADP) and collagen 
      and epinephrine (CEPI); VerifyNow™-ASA; and urinary 11-dehydro-thromboxane B2 
      (TxB(2)) and serum TxB(2). All cyclo-oxygenase (COX-1)-dependent tests and some 
      COX-1-independent tests (PFA-CEPI, LTA-ADP) demonstrated significant reductions 
      in platelet reactivity with all ASA doses. Two COX-1-independent tests (WBA-ADP 
      and PFA-CADP) showed no overall reduction in platelet reactivity. Overall 
      classifications for detecting all ASA doses, compared to baseline, were as 
      follows: very good-LTA-AA (k = 0.95) and VerifyNow™-ASA (k = 0.85); good-serum 
      TxB(2) (k = 0.79); moderate-LTA-ADP (k = 0.59), PFA-100™-CEPI (k = 0.56), urinary 
      TxB(2) (k = 0.55), WBA-AA (k = 0.47); and poor-PFA-100™-CADP (k = -0.02) and 
      WBA-ADP (k = -0.07). No significant kappa statistic differences were seen for 
      each test for each ASA dose. Correlations for each test with serum TxB(2) 
      measurements were as follows: very good-VerifyNow™-ASA (k = 0.81, R(2) = 0.56) 
      and LTA-AA (k = 0.85, R(2) = 0.65); good-PFA-100(TM)-CEPI (k = 0.62, 
      R(2) = 0.30); moderate-urinary TxB(2) (k = 0.57, R(2) = 0.51) and LTA-ADP 
      (k = 0.47, R(2) = 0.56); fair-WBA-AA (k = 0.31, R(2) = 0.31); and 
      poor-PFA-100™-CADP (k = 0.04, R(2) = 0.003) and WBA-ADP (k = -0.04, 
      R(2) = 0.0005). The platelet function tests we assessed were not equally 
      effective in measuring the antiplatelet effect of ASA and correlated poorly 
      amongst themselves, but COX-1-dependent tests performed better than 
      non-COX-1-dependent tests.
FAU - Harrison, Paul
AU  - Harrison P
AUID- ORCID: 0000-0003-4610-8909
AD  - a Institute of Inflammation and Ageing , University of Birmingham Medical School 
      , Birmingham , UK.
FAU - Bethel, M Angelyn
AU  - Bethel MA
AD  - b Diabetes Trials Unit , University of Oxford , Oxford , UK.
FAU - Kennedy, Irene
AU  - Kennedy I
AD  - b Diabetes Trials Unit , University of Oxford , Oxford , UK.
AD  - c NIHR Oxford Biomedical Research Centre , Churchill Hospital , Oxford , UK.
FAU - Dinsdale, Robert
AU  - Dinsdale R
AD  - a Institute of Inflammation and Ageing , University of Birmingham Medical School 
      , Birmingham , UK.
FAU - Coleman, Ruth
AU  - Coleman R
AD  - b Diabetes Trials Unit , University of Oxford , Oxford , UK.
AD  - c NIHR Oxford Biomedical Research Centre , Churchill Hospital , Oxford , UK.
FAU - Holman, Rury R
AU  - Holman RR
AD  - b Diabetes Trials Unit , University of Oxford , Oxford , UK.
AD  - c NIHR Oxford Biomedical Research Centre , Churchill Hospital , Oxford , UK.
LA  - eng
GR  - PG/11/29/28852/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
DEP - 20180709
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Function Tests/*methods
OTO - NOTNLM
OT  - Aspirin
OT  - platelet function
OT  - type 2 diabetes
EDAT- 2018/07/10 06:00
MHDA- 2019/05/14 06:00
CRDT- 2018/07/10 06:00
PHST- 2018/07/10 06:00 [pubmed]
PHST- 2019/05/14 06:00 [medline]
PHST- 2018/07/10 06:00 [entrez]
AID - 10.1080/09537104.2018.1478402 [doi]
PST - ppublish
SO  - Platelets. 2019;30(4):521-529. doi: 10.1080/09537104.2018.1478402. Epub 2018 Jul 
      9.

PMID- 2291862
OWN - NLM
STAT- MEDLINE
DCOM- 19910409
LR  - 20191029
IS  - 0904-213X (Print)
IS  - 0904-213X (Linking)
VI  - 44
IP  - 9
DP  - 1990 Oct
TI  - Aspirin prodrugs: synthesis of 2-substituted 2-methyl-4H-1,3-benzodioxin-4-ones 
      and their screening for prodrug potential.
PG  - 952-6
AB  - A series of new 2-substituted 2-methyl-4H-1,3-benzodioxin-4-ones 1 have been 
      synthesized and fully characterized. This study involves fifteen compounds of 
      which fourteen are orthoesters, containing tertiary aliphatic alkoxy groups. One 
      compound contains a tert-butylperoxy group and one a 3 beta-cholesteryloxy group 
      in the 2-position. The hydrolysis of these compounds 1 was followed in enzymatic 
      and non-enzymatic media to clarify whether they are true prodrugs of aspirin. Two 
      compounds 1 were additionally tested in vivo as potential topical keratolytics.
FAU - Nielsen, K K
AU  - Nielsen KK
AD  - Department of Organic Chemistry, University of Aarhus, Denmark.
FAU - Senning, A
AU  - Senning A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Acta Chem Scand (Cph)
JT  - Acta chemica Scandinavica (Copenhagen, Denmark : 1989)
JID - 9012772
RN  - 0 (Dioxins)
RN  - 0 (Keratolytic Agents)
RN  - 0 (Prodrugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/blood/chemical synthesis/*chemistry/pharmacology
MH  - Chromatography, High Pressure Liquid
MH  - Dioxins/*chemical synthesis/chemistry/pharmacology
MH  - Drug Evaluation, Preclinical
MH  - Hydrolysis
MH  - Keratolytic Agents/*chemical synthesis/chemistry
MH  - Kinetics
MH  - Magnetic Resonance Spectroscopy
MH  - Mice
MH  - Prodrugs/*chemical synthesis/chemistry/pharmacology
EDAT- 1990/10/01 00:00
MHDA- 1990/10/01 00:01
CRDT- 1990/10/01 00:00
PHST- 1990/10/01 00:00 [pubmed]
PHST- 1990/10/01 00:01 [medline]
PHST- 1990/10/01 00:00 [entrez]
AID - 10.3891/acta.chem.scand.44-0952 [doi]
PST - ppublish
SO  - Acta Chem Scand (Cph). 1990 Oct;44(9):952-6. doi: 
      10.3891/acta.chem.scand.44-0952.

PMID- 20560642
OWN - NLM
STAT- MEDLINE
DCOM- 20100701
LR  - 20141120
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 52
IP  - 16
DP  - 2009 Aug 27
TI  - (Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing 
      aspirins.
PG  - 5058-68
LID - 10.1021/jm900587h [doi]
AB  - A series of (nitrooxyacyloxy)methyl esters of aspirin were synthesized and 
      evaluated as new NO-donor aspirins. Different amounts of aspirin were released in 
      serum from these products according to the nature of nitrooxyacyloxy moiety 
      present. In the aromatic series, there is a rather good linear correlation 
      between the amount of aspirin released and the potencies of the products in 
      inhibiting platelet aggregation induced by collagen. Both the native compounds 
      and the related nitrooxy-substituted acid metabolites were able to relax rat 
      aorta strips precontracted with phenylephrine, in keeping with a NO-induced 
      activation of the sGC as a mechanism that underlies the vasodilator effect. The 
      products here described are new improved examples of NO-donor aspirins containing 
      nitrooxy groups. They could represent an alternative to the use of aspirin in a 
      variety of clinical applications.
FAU - Lazzarato, Loretta
AU  - Lazzarato L
AD  - Dipartimento di Scienza e Tecnologia del Farmaco, Universita degli Studi di 
      Torino, Via Pietro Giuria 9, 10125 Torino, Italy.
FAU - Donnola, Monica
AU  - Donnola M
FAU - Rolando, Barbara
AU  - Rolando B
FAU - Chegaev, Konstantin
AU  - Chegaev K
FAU - Marini, Elisabetta
AU  - Marini E
FAU - Cena, Clara
AU  - Cena C
FAU - Di Stilo, Antonella
AU  - Di Stilo A
FAU - Fruttero, Roberta
AU  - Fruttero R
FAU - Biondi, Stefano
AU  - Biondi S
FAU - Ongini, Ennio
AU  - Ongini E
FAU - Gasco, Alberto
AU  - Gasco A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Esters)
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta/drug effects/physiology
MH  - Aspirin/*analogs & derivatives/blood/*chemical synthesis/pharmacology
MH  - Drug Stability
MH  - Esters
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - In Vitro Techniques
MH  - Male
MH  - Muscle Contraction/drug effects
MH  - Muscle, Smooth, Vascular/drug effects/physiology
MH  - Nitrates/blood/*chemical synthesis/pharmacology
MH  - Nitric Oxide Donors/blood/*chemical synthesis/pharmacology
MH  - Platelet Aggregation Inhibitors/blood/*chemical synthesis/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Structure-Activity Relationship
MH  - Vasodilator Agents/blood/*chemical synthesis/pharmacology
EDAT- 2010/06/22 06:00
MHDA- 2010/07/02 06:00
CRDT- 2010/06/22 06:00
PHST- 2010/06/22 06:00 [entrez]
PHST- 2010/06/22 06:00 [pubmed]
PHST- 2010/07/02 06:00 [medline]
AID - 10.1021/jm900587h [doi]
PST - ppublish
SO  - J Med Chem. 2009 Aug 27;52(16):5058-68. doi: 10.1021/jm900587h.

PMID- 488131
OWN - NLM
STAT- MEDLINE
DCOM- 19791218
LR  - 20181113
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 4
IP  - 2
DP  - 1979
TI  - Effect of other drugs and chemicals on the degradation of aspirin in vitro: 
      possible extrapolation to in vivo metabolism of aspirin.
PG  - 103-8
AB  - To assess the possible influence of other drugs and chemicals on the metabolic 
      degradation of aspirin in man, their effect on the serum aspirin esterase 
      activity was determined in vitro. The activation or inhibition of the enzyme as 
      observed with these compounds suggest the possibility that simultaneous ingestion 
      of these drugs with aspirin may influence the pharmacology and toxicity of the 
      analgesic.
FAU - Gupta, J D
AU  - Gupta JD
FAU - Gruca, M
AU  - Gruca M
FAU - Ablett, W
AU  - Ablett W
LA  - eng
PT  - Journal Article
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (Anticoagulants)
RN  - 0 (Narcotics)
RN  - 3K9958V90M (Ethanol)
RN  - EC 3.1.- (Esterases)
RN  - I38ZP9992A (Magnesium)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Anticoagulants/pharmacology
MH  - Aspirin/*blood
MH  - Biotransformation
MH  - Calcium/pharmacology
MH  - Drug Interactions
MH  - Drug Stability
MH  - Esterases/blood
MH  - Ethanol/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Magnesium/pharmacology
MH  - Narcotics/pharmacology
OID - PIP: 799023
OID - POP: 00081327
OAB - The action of various drugs and chemicals on the serum aspirin esterase activity 
      was tested as a measure of their possible effect on the metabolic degradation of 
      aspirin in order to elucidate how the interaction between drugs and aspirin may 
      influence aspirin's pharmacology and toxicity. The in vitro test used serum as 
      the source of the enzyme which was incubated with soluble aspirin as substrate 
      followed by treatment with an acidic reagent of mercuric chloride and ferric 
      nitrate, which precipitates the serum proteins. The following drugs were found to 
      act as inhibitors of serum aspirin esterase activity: codeine phosphate (50%), 
      dextropropoxyphene (Doloxen and Digestic both 50%), morphine, methadone, 
      pethidine, papaveretum (all 50%), hydroxychloroquine (Plaquenil 50%), heparin 
      (50%), propanolol (Inderal 50%), cimetidien (Tagamet 50%), alcohol (50%), and 
      ascorbic acid (50%). The following drugs were activators of aspirin esterase: 
      calcium (50%) and magnesium (50%). The following drugs were found inactive: 
      paracetamol, caffeine, phenacetin, phyenylbutazone (Butazolidine), indomethacin 
      (Indocid), cortisone acetate, flufenamic acid (Arlef), mefenamic acid (Ponstan), 
      Ibuprofen (Brufen), dipyridamole (Persantin), warfarin (Coumadin), clofibrate 
      (Atromid), sulphinpyrazone (Anturan), colchincine, allopurinol, diazepam 
      (Valium), oral contraceptives, and sodium cromoglycate (Intal).
OABL- eng
OTO - PIP
OT  - *Analgesia
OT  - Biology
OT  - Clinical Research
OT  - Endocrine System
OT  - *Enzymes
OT  - Enzymes And Enzyme Inhibitors
OT  - *In Vitro
OT  - Physiology
OT  - *Prostaglandins
OT  - Research Methodology
OT  - Treatment
GN  - PIP: TJ: EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS.
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1007/BF03189409 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 1979;4(2):103-8. doi: 10.1007/BF03189409.

PMID- 8060229
OWN - NLM
STAT- MEDLINE
DCOM- 19940913
LR  - 20131121
IS  - 0003-9985 (Print)
IS  - 0003-9985 (Linking)
VI  - 118
IP  - 8
DP  - 1994 Aug
TI  - Population variability in the effect of aspirin on platelet function. 
      Implications for clinical trials and therapy.
PG  - 801-4
AB  - Little or nothing is known about how the inhibitory effect of aspirin on 
      platelets distributes in the general population. We describe a simple whole-blood 
      assay for the extent of aspirin-induced inhibition of platelet aggregation and 
      its application to 31 aspirin-treated subjects. Platelet inhibition to two or 
      more 325-mg aspirin tablets was measured using a newly developed method in 31 
      healthy, young adults. These subjects showed a wide range of variation in their 
      response to aspirin, which in subsequent studies was found to be stable over 
      time. The effect persisted even when the steps of gut absorption and liver 
      metabolism were bypassed. We conclude that the response of platelets to aspirin 
      varies to the extent that a significant proportion of the population may be 
      nonresponsive and that this variability may be intrinsic to platelets and/or 
      their blood environment.
FAU - Pappas, J M
AU  - Pappas JM
AD  - Department of Pathology, Loma Linda (Calif) University Medical Center 92354.
FAU - Westengard, J C
AU  - Westengard JC
FAU - Bull, B S
AU  - Bull BS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Equipment and Supplies
MH  - Female
MH  - Humans
MH  - Male
MH  - Pilot Projects
MH  - Platelet Aggregation/*drug effects
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
PST - ppublish
SO  - Arch Pathol Lab Med. 1994 Aug;118(8):801-4.

PMID- 2510140
OWN - NLM
STAT- MEDLINE
DCOM- 19891219
LR  - 20190818
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 6
IP  - 8
DP  - 1989 Aug
TI  - Route of administration and sex differences in the pharmacokinetics of aspirin, 
      administered as its lysine salt.
PG  - 660-6
AB  - One thousand milligrams of aspirin, as its lysine salt was administered 
      intravenously, orally, and intramuscularly to nine male and nine female young 
      healthy adult volunteers. After intravenous injection mean (+/- SD) values of 
      clearance, steady-state volume of distribution, and terminal half-life were 12.2 
      +/- 2.2 ml/min/kg, 0.219 +/- 0.042 liter/kg, and 15.4 +/- 2.5 min, respectively, 
      with no differences between males and females. Following administration aspirin 
      was absorbed more quickly in females than in males (mean absorption times of 16.4 
      and 21.3 min, respectively although the bioavailability, 54%, was the same in 
      both groups. In contrast, following intramuscular administration, aspirin was 
      absorbed more slowly in females than males (mean absorption time of 97 and 53 
      min, respectively) but again the bioavailability, 89%, was the same in both 
      groups. The data suggest that in the female the intramuscular injection is going 
      into fat. Salicylic acid concentration-time profiles showed a less pronounced sex 
      difference and were comparable among the routes of administration.
FAU - Aarons, L
AU  - Aarons L
AD  - Department of Pharmacy, University of Manchester, U.K.
FAU - Hopkins, K
AU  - Hopkins K
FAU - Rowland, M
AU  - Rowland M
FAU - Brossel, S
AU  - Brossel S
FAU - Thiercelin, J F
AU  - Thiercelin JF
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Absorption
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Injections, Intramuscular
MH  - Lysine/administration & dosage/pharmacology
MH  - Male
MH  - Random Allocation
MH  - Sex Characteristics
MH  - Time Factors
EDAT- 1989/08/01 00:00
MHDA- 1989/08/01 00:01
CRDT- 1989/08/01 00:00
PHST- 1989/08/01 00:00 [pubmed]
PHST- 1989/08/01 00:01 [medline]
PHST- 1989/08/01 00:00 [entrez]
AID - 10.1023/a:1015978104017 [doi]
PST - ppublish
SO  - Pharm Res. 1989 Aug;6(8):660-6. doi: 10.1023/a:1015978104017.

PMID- 7003730
OWN - NLM
STAT- MEDLINE
DCOM- 19810226
LR  - 20131121
IS  - 0038-4348 (Print)
IS  - 0038-4348 (Linking)
VI  - 73
IP  - 12
DP  - 1980 Dec
TI  - Aspirin: four score and more.
PG  - 1630-4
AB  - Pain is a tax levied on man for the privilege of life upon this planet. Some are 
      taxed lightly and others are taxed heavily, but all are taxed. To relieve this 
      stress, from time immemorial man has taken analgesics. In modern times, if home 
      medication fails, professional consultation is available. The important question 
      is the choice of an analgesic. The advantage appears to lie with aspirin because 
      it especially evokes relief of pain caused by inflammation.
FAU - Krantz, J C Jr
AU  - Krantz JC Jr
FAU - White, J M
AU  - White JM
LA  - eng
PT  - Comparative Study
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Prostaglandins)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects
MH  - Aspirin/adverse effects/*history/pharmacology
MH  - Drug Compounding
MH  - Drug Interactions
MH  - Fibrinolytic Agents/pharmacology
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Prostaglandins/biosynthesis
EDAT- 1980/12/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
PST - ppublish
SO  - South Med J. 1980 Dec;73(12):1630-4.

PMID- 25467192
OWN - NLM
STAT- MEDLINE
DCOM- 20160323
LR  - 20181202
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 36
IP  - 12
DP  - 2014 Dec 1
TI  - Role of clinical pharmacology in the development of antiplatelet drugs.
PG  - 2096-2111
LID - S0149-2918(14)00685-7 [pii]
LID - 10.1016/j.clinthera.2014.10.012 [doi]
AB  - PURPOSE: This review discusses the role of clinical pharmacology in the 
      development of low-dose aspirin and other antiplatelet agents during the past 30 
      years, emphasizing the main determinants of several success stories as well as of 
      complete failures in the field. METHODS: The author employs personal appraisal of 
      the literature, with emphasis on personal contributions to the field. FINDINGS: 
      Low-dose aspirin provides an interesting paradigm of the independent development 
      of a "new" antiplatelet agent by the medical/scientific community. Aspirin 
      "resistance," improved dosing regimens for personalized therapy, and 
      chemoprevention of colorectal cancer are thoroughly discussed. The 
      industry-driven development paradigm includes 12 mechanism-based antiplatelet 
      agents. Of those completing Phase 3, only 6 have been approved for the acute 
      treatment or secondary prevention of atherothrombosis. Inadequate Phase 2 studies 
      were largely involved in Phase 3 failures. IMPLICATIONS: The design of 
      mechanism-based pharmacodynamic biomarkers and sophisticated Phase 2 
      investigations appear as an important key to successful drug development in this 
      field. Clinical pharmacology has an excellent track record in this endeavor, and 
      its role needs to be expanded, as suggested by the case studies discussed in this 
      review. Finally, the choice of appropriate platelet-dependent end points and 
      homogeneous clinical settings for Phase 3 trials not only represent desirable 
      objectives for an integrated scientific and regulatory discussion but also 
      deserve proper ethical consideration by all stakeholders to avoid an unacceptable 
      burden of drug toxicity and an unsustainable waste of financial resources.
CI  - Copyright © 2014 Elsevier HS Journals, Inc. All rights reserved.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. 
      Electronic address: carlo.patrono@rm.unicatt.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20141120
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Drug Design
MH  - Humans
MH  - Pharmacology, Clinical
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - GPIIb/IIIa blockers
OT  - P2Y(12) blockers
OT  - PAR-1 antagonists
OT  - TP antagonists
OT  - aspirin
EDAT- 2014/12/04 06:00
MHDA- 2016/03/24 06:00
CRDT- 2014/12/04 06:00
PHST- 2014/07/02 00:00 [received]
PHST- 2014/09/15 00:00 [revised]
PHST- 2014/10/20 00:00 [accepted]
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2016/03/24 06:00 [medline]
AID - S0149-2918(14)00685-7 [pii]
AID - 10.1016/j.clinthera.2014.10.012 [doi]
PST - ppublish
SO  - Clin Ther. 2014 Dec 1;36(12):2096-2111. doi: 10.1016/j.clinthera.2014.10.012. 
      Epub 2014 Nov 20.

PMID- 8346511
OWN - NLM
STAT- MEDLINE
DCOM- 19930909
LR  - 20131121
IS  - 0040-7453 (Print)
IS  - 0040-7453 (Linking)
VI  - 118
IP  - 13
DP  - 1993 Jul 15
TI  - [Analgesics; the use of aspirin in dogs; effects of tablet type and food intake 
      on plasma salicylate level].
PG  - 439-42
AB  - Administration of acetylsalicylic acid (aspirin) in the dog may cause gastric 
      mucosal damage. Enteric-coated tablets protect the canine stomach during oral 
      aspirin medication. A therapeutic plasma salicylate concentration can be attained 
      using enteric-coated aspirin tablets at a dosage of 25 mg/kg TID. In a series 4 
      of experiments using adult beagle and large mixed breed dogs and two types 
      enteric-coated tablets, the influence of food intake on the plasma salicylate 
      concentration was studied. Tablets were administered with 8h intervals and food 
      intake was either once daily or three time daily with 8h intervals. Plasma 
      salicylate concentrations were also studied during fasting. It is concluded that, 
      when using enteric-coated tablets, the plasma salicylate concentration in the dog 
      after oral medication is strongly influenced by the aspirin dosage, the tablet 
      type and the feeding pattern. Large enteric-coated tablets may accumulate in the 
      stomach over several days and are not suitable for use in the dog. The gastric 
      accumulation is caused by the enteric-coating of the large tablets and not by the 
      aspirin medication.
FAU - Nap, R C
AU  - Nap RC
AD  - Vakgroep Geneeskunde van Gezelschapsdieren, Universiteit Utrecht.
FAU - Breen, D J
AU  - Breen DJ
FAU - Lam, T J
AU  - Lam TJ
FAU - Peters, I O
AU  - Peters IO
FAU - Willemsen, A
AU  - Willemsen A
FAU - De Bruyne, J J
AU  - De Bruyne JJ
LA  - dut
PT  - English Abstract
PT  - Journal Article
TT  - Pijnstillers; het gebruik van aspirine bij de hond; invloeden van tablettype en 
      voeropname op de plasma-salicylaatconcentratie.
PL  - Netherlands
TA  - Tijdschr Diergeneeskd
JT  - Tijdschrift voor diergeneeskunde
JID - 0031550
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Dog Diseases/*drug therapy/metabolism
MH  - Dogs
MH  - Food
MH  - Pain/drug therapy/*veterinary
MH  - Salicylates/blood
MH  - Tablets
MH  - Time Factors
EDAT- 1993/07/15 00:00
MHDA- 1993/07/15 00:01
CRDT- 1993/07/15 00:00
PHST- 1993/07/15 00:00 [pubmed]
PHST- 1993/07/15 00:01 [medline]
PHST- 1993/07/15 00:00 [entrez]
PST - ppublish
SO  - Tijdschr Diergeneeskd. 1993 Jul 15;118(13):439-42.

PMID- 3923041
OWN - NLM
STAT- MEDLINE
DCOM- 19850703
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 75
IP  - 5
DP  - 1985 May
TI  - Effects of platelet-modifying drugs on arterial thromboembolism in baboons. 
      Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone 
      by mechanism(s) independent of platelet cyclooxygenase inhibition.
PG  - 1591-9
AB  - To resolve questions of drug actions, efficacy, and interactions for 
      platelet-modifying agents used clinically, we have compared the relative 
      capacities and mechanisms of aspirin, dipyridamole, sulfinpyrazone, and dazoxiben 
      to prevent arterial thromboembolism in a baboon model. In 136 studies the agents 
      were given twice daily by oral administration both singly and in combination. The 
      antithrombotic efficacy of a given therapy was determined by its capacity to 
      interrupt steady-state platelet utilization induced by thrombogenic arteriovenous 
      cannulae. When given alone, dipyridamole and sulfinpyrazone reduced the rate at 
      which platelets were utilized by thrombus formation in a dose-dependent manner 
      with essentially complete interruption by dipyridamole at 10 mg/kg per d. In 
      contrast, neither aspirin (2-100 mg/kg per d) nor dazoxiben (20-100 mg/kg per d) 
      decreased cannula platelet consumption detectably despite the striking reduction 
      in the capacity of platelets to produce thromboxane B2. However, aspirin, but not 
      dazoxiben, potentiated the antithrombotic effects of dipyridamole and 
      sulfinpyrazone in a dose-dependent fashion without changing the pharmacokinetics 
      for any of the agents. Complete potentiation required aspirin at 20 mg/kg per d 
      to be given with each dose of dipyridamole. Because dazoxiben's blockade of 
      platelet thromboxane A2 production was not associated with antithrombotic 
      potentiation, and because complete potentiation by aspirin required a dose that 
      fully inhibited vascular production of prostaglandin I2 (PGI2), we conclude that 
      aspirin's potentiating effect on dipyridamole is independent of PGI2 production 
      or inhibition of thromboxane A2 formation. In addition, because frequent repeated 
      and synchronous dosing of aspirin was necessary, aspirin's potentiating effects 
      appear to be produced by mechanism(s) unrelated to its potent, irreversible 
      inhibition of platelet cyclooxygenase.
FAU - Hanson, S R
AU  - Hanson SR
FAU - Harker, L A
AU  - Harker LA
FAU - Bjornsson, T D
AU  - Bjornsson TD
LA  - eng
GR  - HL-29036/HL/NHLBI NIH HHS/United States
GR  - HL-31469/HL/NHLBI NIH HHS/United States
GR  - HL-31950/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Imidazoles)
RN  - 09ZFC7974Q (dazoxiben)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/enzymology
MH  - Cell Survival/drug effects
MH  - *Cyclooxygenase Inhibitors
MH  - Dipyridamole/blood/*pharmacology
MH  - Drug Synergism
MH  - Femoral Artery
MH  - Fibrinolytic Agents/pharmacology
MH  - Imidazoles/pharmacology
MH  - Male
MH  - Papio
MH  - Sulfinpyrazone/blood/*pharmacology
MH  - Thromboembolism/*drug therapy
PMC - PMC425500
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
AID - 10.1172/JCI111865 [doi]
PST - ppublish
SO  - J Clin Invest. 1985 May;75(5):1591-9. doi: 10.1172/JCI111865.

PMID- 836536
OWN - NLM
STAT- MEDLINE
DCOM- 19770401
LR  - 20141120
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 296
IP  - 10
DP  - 1977 Mar 10
TI  - Increased blood fibrinolytic activity after aspirin ingestion.
PG  - 525-9
AB  - Fibrinolytic activity of whole blood and of platelet-deficient plasma, measured 
      by 125I-fibrin assay in four normal subjects before and after ingestion of 1.8 g 
      of aspirin, increased 33 to 150 per cent at one to three hours, at plasma 
      salicylate levels of 5 to 18 mg per 100 ml. In two, plasma activity also 
      increased. Fibrinolysis in blood, but not in plasma, increased 66 per cent after 
      sodium salicylate. Sodium salicylate increased fibrinolytic activities of blood 
      and of purified polymorphonuclear leukocytes in vitro, whereas aspirin had little 
      effect. These striking effects of aspirin on cellular and fluid phases of blood 
      fibrinolysis are apparently distinct from known aspirin actions on platelets. 
      Plasma fibrinolytic activity accounted for only 18.8 +/- 12.3 per cent (S.D.) and 
      17.4 +/- 10.4 per cent of the activity measured in the corresponding whole blood 
      of 11 normal men and 10 normal women, respectively, indicating the importance of 
      cellular elements in normal blood fibrinolysis.
FAU - Moroz, L A
AU  - Moroz LA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Female
MH  - Fibrinolysis/*drug effects
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Neutrophils/drug effects
MH  - Plasma/drug effects
MH  - Sodium Salicylate/pharmacology
EDAT- 1977/03/10 00:00
MHDA- 1977/03/10 00:01
CRDT- 1977/03/10 00:00
PHST- 1977/03/10 00:00 [pubmed]
PHST- 1977/03/10 00:01 [medline]
PHST- 1977/03/10 00:00 [entrez]
AID - 10.1056/NEJM197703102961001 [doi]
PST - ppublish
SO  - N Engl J Med. 1977 Mar 10;296(10):525-9. doi: 10.1056/NEJM197703102961001.

PMID- 26665660
OWN - NLM
STAT- MEDLINE
DCOM- 20151229
LR  - 20151211
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 11
IP  - 490
DP  - 2015 Oct 14
TI  - [Long term aspirin in stable coronary disease with an indication for 
      anticoagulation: is it reasonable?].
PG  - 1904, 1906-8
AB  - In patients with both stable coronary disease and atrial fibrillation, a baseline 
      treatment of aspirin and an oral anticoagulant is often prescribed due to the 
      proven benefits of each therapy on cardiovascular and thromboembolic events and 
      mortality. However, recent cohort studies in this population have shown that 
      adding aspirin to an oral anticoagulant is not associated with a reduction in 
      recurrence of coronary or thromboembolic events, but significantly increases the 
      bleeding risk. In these patients, in particular when their bleeding risk is high, 
      aspirin withdrawal may be considered.
FAU - Lister, K
AU  - Lister K
FAU - Louis Simonet, M
AU  - Louis Simonet M
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Aspirine à vie et maladie coronarienne stable avec indication à une 
      anticoagulation: est-ce bien raisonnable?
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/complications/drug therapy
MH  - Coronary Disease/*drug therapy
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Risk
MH  - Thromboembolism/etiology/prevention & control
EDAT- 2015/12/17 06:00
MHDA- 2015/12/30 06:00
CRDT- 2015/12/16 06:00
PHST- 2015/12/16 06:00 [entrez]
PHST- 2015/12/17 06:00 [pubmed]
PHST- 2015/12/30 06:00 [medline]
PST - ppublish
SO  - Rev Med Suisse. 2015 Oct 14;11(490):1904, 1906-8.

PMID- 15016937
OWN - NLM
STAT- MEDLINE
DCOM- 20040520
LR  - 20190501
IS  - 0032-5473 (Print)
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 80
IP  - 941
DP  - 2004 Mar
TI  - Antiplatelet therapy in cardiovascular disease.
PG  - 155-64
AB  - Platelet activation and aggregation are considered to be central to arterial 
      thrombus formation. Antiplatelet therapy is therefore important for both the 
      treatment and prevention of cardiovascular disease. Aspirin, the most widely used 
      antiplatelet agent, inhibits platelet cyclo-oxygenase and the conversion of 
      arachidonic acid to the potent platelet agonist thromboxane A(2) but does not 
      prevent platelet activation occurring via various signalling pathways that are 
      independent of thromboxane A(2) release. Therefore a number of other compounds 
      have been developed to complement aspirin's beneficial effect. These include the 
      thienopyridines (clopidogrel and ticlopidine), dipyridamole, and the 
      alpha(IIb)beta(3) (glycoprotein IIb/IIIa) receptor inhibitors.
FAU - Behan, M W H
AU  - Behan MW
AD  - Division of Cardiovascular Medicine, University Hospital, Derby Road, Nottingham 
      NG7 2UH, UK. miles.behan@nottingham.ac.uk
FAU - Storey, R F
AU  - Storey RF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Pyridines/therapeutic use
PMC - PMC1742947
EDAT- 2004/03/16 05:00
MHDA- 2004/05/21 05:00
CRDT- 2004/03/16 05:00
PHST- 2004/03/16 05:00 [pubmed]
PHST- 2004/05/21 05:00 [medline]
PHST- 2004/03/16 05:00 [entrez]
AID - 10.1136/pgmj.2003.007062 [doi]
PST - ppublish
SO  - Postgrad Med J. 2004 Mar;80(941):155-64. doi: 10.1136/pgmj.2003.007062.

PMID- 11625257
OWN - HMD
STAT- MEDLINE
DCOM- 19980325
LR  - 20131121
IS  - 0035-2349 (Print)
IS  - 0035-2349 (Linking)
VI  - 45
IP  - 316
DP  - 1997
TI  - [Two "pharmacists" in the beginning of Aspirin: Charles Gerhardt and Felix 
      Hoffmann].
PG  - 411-4
AB  - The two scholars in the beginning of Aspirin, Charles Gerhardt, who realized, 
      1852, the first synthesis, and Felix Hoffmann, whose researchs permitted, 1899, 
      the deposit of the trade-mark "Aspirin Bayer", where every one stately examinated 
      pharmacists.
FAU - Bachoffner, P
AU  - Bachoffner P
LA  - fre
PT  - Biography
PT  - English Abstract
PT  - Historical Article
PT  - Journal Article
TT  - Les deux "pharmaciens" à l'aube de l'"Aspirine": Charles Gerhardt et Felix 
      Hoffmann.
PL  - France
TA  - Rev Hist Pharm (Paris)
JT  - Revue d'histoire de la pharmacie
JID - 0204315
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*history
MH  - Economics, Pharmaceutical/*history
MH  - France
MH  - Germany
MH  - History, 19th Century
MH  - Humans
MH  - Pharmacists/*history
PS  - Gerhardt C
FPS - Gerhardt, C
PS  - Hoffmann F
FPS - Hoffmann, F
EDAT- 1997/01/01 00:00
MHDA- 2001/11/01 10:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 2001/11/01 10:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Hist Pharm (Paris). 1997;45(316):411-4.

PMID- 15068834
OWN - NLM
STAT- MEDLINE
DCOM- 20040812
LR  - 20151119
IS  - 0361-090X (Print)
IS  - 0361-090X (Linking)
VI  - 28
IP  - 2
DP  - 2004
TI  - Effects of low dose aspirin (81 mg) on proliferating cell nuclear antigen and 
      Amaranthus caudatus labeling in normal-risk and high-risk human subjects for 
      colorectal cancer.
PG  - 107-13
AB  - Epidemiological, experimental, and clinical observations provide support for a 
      colorectal cancer chemopreventive role for aspirin. We have evaluated the effects 
      of aspirin on proliferation biomarkers in normal-risk and high-risk human 
      subjects for colorectal cancer. Colorectal biopsies were obtained at baseline and 
      at 24h after 28 daily doses of 81 mg of aspirin from 13 high-risk and 15 
      normal-risk subjects for colorectal cancer. We evaluated aspirin's effects on 
      proliferating cell nuclear antigen (PCNA) immunohistochemistry and epithelial 
      mucin histochemistry using the lectin, Amaranthus caudatus agglutinin (ACA) in 
      crypt sections from rectal biopsies. The baseline whole crypt PCNA LIs differed 
      significantly between normal-risk and high-risk subjects. PCNA LIs are not 
      affected by 28 days of aspirin at 81 mg daily. ACA LIs are decreased by 28 days 
      of aspirin at 81 mg daily in both normal-risk and high-risk subjects. Aspirin's 
      effects on ACA LIs may have mechanistic and biological implications that deserve 
      further attention. PCNA and ACA LIs are not useful as proliferation biomarkers 
      for aspirin's chemopreventive activity in morphologically normal human colorectal 
      mucosa.
FAU - Krishnan, Koyamangalath
AU  - Krishnan K
AD  - Medical Service, James H. Quillen Veterans Administration Medical Center and 
      Division of Hematology-Oncology, Department of Internal Medicine, East Tennessee 
      State University, Johnson City, TN 37614, USA.
FAU - Aoki, Toshihiro
AU  - Aoki T
FAU - Ruffin, Mack T
AU  - Ruffin MT
FAU - Normolle, Daniel P
AU  - Normolle DP
FAU - Boland, C Richard
AU  - Boland CR
FAU - Brenner, Dean E
AU  - Brenner DE
LA  - eng
GR  - CN-25429/CN/NCI NIH HHS/United States
GR  - M01-RR00042/RR/NCRR NIH HHS/United States
GR  - U01-CA86400/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Cancer Detect Prev
JT  - Cancer detection and prevention
JID - 7704778
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Lectins)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (lectin, Amaranthus caudatus)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticarcinogenic Agents/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cell Division/drug effects
MH  - Colon/cytology/drug effects
MH  - Colorectal Neoplasms/prevention & control
MH  - Epithelial Cells/chemistry/drug effects/metabolism
MH  - Female
MH  - Humans
MH  - *Lectins
MH  - Male
MH  - Middle Aged
MH  - Proliferating Cell Nuclear Antigen/*drug effects/metabolism
MH  - Staining and Labeling
EDAT- 2004/04/08 05:00
MHDA- 2004/08/13 05:00
CRDT- 2004/04/08 05:00
PHST- 2003/12/18 00:00 [received]
PHST- 2004/01/02 00:00 [accepted]
PHST- 2004/04/08 05:00 [pubmed]
PHST- 2004/08/13 05:00 [medline]
PHST- 2004/04/08 05:00 [entrez]
AID - S0361090X04000078 [pii]
AID - 10.1016/j.cdp.2004.01.001 [doi]
PST - ppublish
SO  - Cancer Detect Prev. 2004;28(2):107-13. doi: 10.1016/j.cdp.2004.01.001.

PMID- 9744831
OWN - NLM
STAT- MEDLINE
DCOM- 19981001
LR  - 20190514
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 51
IP  - 3 Suppl 3
DP  - 1998 Sep
TI  - What have we learned from recent antiplatelet trials?
PG  - S36-8
AB  - Aspirin's benefit in preventing vascular outcomes is well established. It reduces 
      the relative risk for stroke, myocardial infarction, and vascular death by about 
      25% compared with placebo. Almost 10 years ago we learned that ticlopidine is 
      more effective than aspirin (about 12% relative risk reduction for stroke or 
      death). However, ticlopidine has important adverse effects. In 1996, the 
      Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial 
      showed that clopidogrel, a new thienopyridine similar to ticlopidine, is also 
      more effective than aspirin (by a similar amount) and is as safe as aspirin. Also 
      in 1996, the European Stroke Prevention Study 2 (ESPS-2) showed that dipyridamole 
      alone prevents stroke and that when combined with aspirin it is more effective, 
      probably comparable to ticlopidine and clopidogrel. Dipyridamole combined with 
      aspirin reduced the relative risk for stroke or death by about 13% compared with 
      aspirin alone. Both clopidogrel and dipyridamole are safe but will cost more than 
      aspirin. Aspirin also appears beneficial for acute stroke treatment. The Chinese 
      Acute Stroke Trial (CAST) and the International Stroke Trial (IST) demonstrated 
      that aspirin given at the time of an acute ischemic stroke reduces the risk for 
      early death (about 5 less/1,000 treated), recurrence or death (about 10 
      less/1,000 treated), and dependence (about 5 less/1,000 treated). Overall, the 
      benefits of aspirin in acute stroke treatment and stroke prevention are definite 
      but modest. Combination therapy with antiplatelet agents that act through 
      different mechanisms is a promising way to maximize the benefits of antiplatelet 
      treatment.
FAU - Easton, J D
AU  - Easton JD
AD  - Department of Clinical Neurosciences, Brown University School of Medicine, Rhode 
      Island Hospital, Providence 02903, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Cerebrovascular Disorders/*drug therapy/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - *Randomized Controlled Trials as Topic
RF  - 21
EDAT- 1998/09/23 00:00
MHDA- 1998/09/23 00:01
CRDT- 1998/09/23 00:00
PHST- 1998/09/23 00:00 [pubmed]
PHST- 1998/09/23 00:01 [medline]
PHST- 1998/09/23 00:00 [entrez]
AID - 10.1212/wnl.51.3_suppl_3.s36 [doi]
PST - ppublish
SO  - Neurology. 1998 Sep;51(3 Suppl 3):S36-8. doi: 10.1212/wnl.51.3_suppl_3.s36.

PMID- 7263127
OWN - NLM
STAT- MEDLINE
DCOM- 19811014
LR  - 20191023
IS  - 0165-5701 (Print)
IS  - 0165-5701 (Linking)
VI  - 3
IP  - 3
DP  - 1981 May
TI  - Aspirin effect on cataract formation in patients with rheumatoid arthritis alone 
      or combined with diabetes.
PG  - 173-7
AB  - The prevalence of cataracts is significantly lower in patients with rheumatoid 
      arthritis receiving aspirin (mean of 2,700 mgs daily for an average of 10.4 
      years) as compared to the matched population not receiving aspirin. Similarly, 
      fewer cataracts were found among a population with diabetes and rheumatoid 
      arthritis receiving aspirin (mean of 2,340 mgs daily for an average of 8.8 years) 
      as compared to the matched population on no aspirin. The effects of aspirin on 
      cataract formation may result from 1) lowering of plasma tryptophan levels and 
      increased excretion of tryptophan metabolites, 2) inhibition of aldose reductase 
      and sorbitol formation in the diabetic lens, 3) inhibition of tryptophan or 
      kynurenine binding to lens protein.
FAU - Cotlier, E
AU  - Cotlier E
LA  - eng
GR  - EY 02905-02/EY/NEI NIH HHS/United States
GR  - NIH 724A-41-48178/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Int Ophthalmol
JT  - International ophthalmology
JID - 7904294
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Cataract/*etiology/metabolism
MH  - Diabetes Complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1981/05/01 00:00
MHDA- 1981/05/01 00:01
CRDT- 1981/05/01 00:00
PHST- 1981/05/01 00:00 [pubmed]
PHST- 1981/05/01 00:01 [medline]
PHST- 1981/05/01 00:00 [entrez]
AID - 10.1007/BF00130701 [doi]
PST - ppublish
SO  - Int Ophthalmol. 1981 May;3(3):173-7. doi: 10.1007/BF00130701.

PMID- 6201446
OWN - NLM
STAT- MEDLINE
DCOM- 19840618
LR  - 20190816
IS  - 0020-5915 (Print)
IS  - 0020-5915 (Linking)
VI  - 74
IP  - 2
DP  - 1984
TI  - Effect of the calcium ionophore A23187 and aspirin on histamine release in vitro 
      from leukocytes of aspirin-intolerant donors.
PG  - 104-7
AB  - In vitro histamine release from leukocytes of 10 aspirin-intolerant donors in 
      response to the calcium ionophore A23187 and aspirin was compared to that of 
      controls. Incubation with A23187 induced a concentration-dependent histamine 
      release from leukocytes of all donors. At 0.1 and 0.2 micrograms/ml A23187, 
      release from leukocytes of aspirin-intolerant donors was significantly less (p 
      less than 0.01) than that of controls. Preincubation with aspirin failed to alter 
      spontaneous or A23187-stimulated histamine release. Leukocytes of 
      aspirin-intolerant donors do not demonstrate an enhanced sensitivity to histamine 
      release stimulated by aspirin or A23187.
FAU - Bochner, B S
AU  - Bochner BS
FAU - Thomas, L L
AU  - Thomas LL
FAU - Godnik, L
AU  - Godnik L
FAU - Samter, M
AU  - Samter M
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int Arch Allergy Appl Immunol
JT  - International archives of allergy and applied immunology
JID - 0404561
RN  - 37H9VM9WZL (Calcimycin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*immunology/pharmacology
MH  - Calcimycin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/*immunology
MH  - Female
MH  - Histamine Release/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1159/000233528 [doi]
PST - ppublish
SO  - Int Arch Allergy Appl Immunol. 1984;74(2):104-7. doi: 10.1159/000233528.

PMID- 2328753
OWN - NLM
STAT- MEDLINE
DCOM- 19900529
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 38
IP  - 1
DP  - 1990
TI  - Pharmacokinetics of aspirin in aged Indians.
PG  - 85-6
AB  - The pharmacokinetics of aspirin (ASA) has been studied in elderly Indians 
      (greater than 60 y) of either sex, composing, apparently healthy subjects 
      controlled hypertensives and NIDDM diabetics, in comparison with healthy young 
      subjects. Serum salicylate levels were estimated a 0, 0.5, 1, 2, 4 & 8 h after 
      ASA. The pharmacokinetics of serum salicylate were not changed in elderly 
      subjects as compared to the young after the first dose or after one week of ASA 
      therapy, although greater variability was observed in the elderly. Various 
      laboratory investigations were unaltered after one week in all the groups, except 
      that one elderly hypertensive patient gained weight, and a young subject showed 
      an increase in SGOT & SGPT.
FAU - Dhasmana, D C
AU  - Dhasmana DC
AD  - Department of Pharmacology, Maulana Azad Medical College, New Delhi, India.
FAU - Chandra, D
AU  - Chandra D
FAU - Mansharamani, G G
AU  - Mansharamani GG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Female
MH  - Humans
MH  - India
MH  - Male
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1007/BF00314810 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1990;38(1):85-6. doi: 10.1007/BF00314810.

PMID- 2934008
OWN - NLM
STAT- MEDLINE
DCOM- 19860123
LR  - 20181113
IS  - 0003-3006 (Print)
IS  - 0003-3006 (Linking)
VI  - 32
IP  - 4
DP  - 1985 Jul-Aug
TI  - Relief of dental surgery pain: a controlled 12-hour comparison of etodolac, 
      aspirin, and placebo.
PG  - 151-6
AB  - Single doses of the study drugs were evaluated for 12 hours by 201 out-patients 
      reporting moderate or severe pain following oral surgery. The results of this 
      double-blind study indicated that 50, 100, and 200 mg of etodolac as well as 650 
      mg of aspirin were significantly more effective than placebo. A dose-response 
      relationship was found for the three doses of etodolac, which was significant for 
      summed pain relief scores for up to 8 hours. In terms of total analgesic effect, 
      etodolac 200 mg was significantly superior to placebo for 8 hours, while aspirin 
      and the two lower doses of etodolac were similarly effective in the range of 3-6 
      hours postdrug. All doses showed a favorable onset of analgesia (½-1 hour). 
      Etodolac 200 mg resulted in a duration of action which was approximately twice as 
      long as aspirin's and also produced a peak pain relief which was significantly 
      greater than the lower doses of etodolac and aspirin. All study medications were 
      well tolerated with no reports of significant adverse side effects. No 
      dose-related effects were observed with etodolac
FAU - Nelson, S L
AU  - Nelson SL
FAU - Bergman, S A
AU  - Bergman SA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Anesth Prog
JT  - Anesthesia progress
JID - 0043533
RN  - 0 (Acetates)
RN  - 0 (Placebos)
RN  - 2M36281008 (Etodolac)
RN  - R16CO5Y76E (Aspirin)
MH  - Acetates/administration & dosage/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Etodolac
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
MH  - Time Factors
MH  - Tooth Extraction
PMC - PMC2148530
EDAT- 1985/07/01 00:00
MHDA- 1985/07/01 00:01
CRDT- 1985/07/01 00:00
PHST- 1985/07/01 00:00 [pubmed]
PHST- 1985/07/01 00:01 [medline]
PHST- 1985/07/01 00:00 [entrez]
PST - ppublish
SO  - Anesth Prog. 1985 Jul-Aug;32(4):151-6.

PMID- 15974943
OWN - NLM
STAT- MEDLINE
DCOM- 20050930
LR  - 20190906
IS  - 1568-0266 (Print)
IS  - 1568-0266 (Linking)
VI  - 5
IP  - 5
DP  - 2005
TI  - Dual COX-inhibitors: the answer is NO?
PG  - 487-92
AB  - Nitric oxide (NO) releasing non-steroidal anti-inflammatory drugs (NSAIDs) are a 
      new class of anti-inflammatory agents obtained by adding an NO releasing moiety 
      to existing NSAIDs. They have also christened as COX inhibiting NO-donating drugs 
      (CINOD). Preclinical and clinical studies suggest that CINOD inhibit COX-1 and 
      COX-2 activities while cause less adverse effects on gastrointestinal tract in 
      comparison to conventional NSAIDs and coxibs and reduce systemic blood pressure. 
      A different class of NO-donating drugs has been obtained by coupling NO to 
      aspirin. These NO-releasing aspirins are new chemical entities that maintain and 
      possibly expands the pharmacological properties of aspirin, but spare the 
      gastrointestinal mucosa. Animal studies have shown that CINOD and NO-aspirins 
      maintain gastric mucosal blood flow and reduce leukocyte-endothelial cell 
      adherence.
FAU - Fiorucci, Stefano
AU  - Fiorucci S
AD  - Clinica di Gastroenterologia ed Epatologia, Dipartimento di Medicina Clinica e 
      Sperimentale, Università degli Studi di Perugia, Italy. fiorucci@unipg.it
FAU - Antonelli, Elisabetta
AU  - Antonelli E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Top Med Chem
JT  - Current topics in medicinal chemistry
JID - 101119673
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Lipoxins)
RN  - 0 (Membrane Proteins)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Gastric Mucosa/drug effects
MH  - Humans
MH  - Kidney/drug effects
MH  - Lipoxins/metabolism
MH  - Membrane Proteins
MH  - Nitric Oxide/*pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
RF  - 48
EDAT- 2005/06/25 09:00
MHDA- 2005/10/01 09:00
CRDT- 2005/06/25 09:00
PHST- 2005/06/25 09:00 [pubmed]
PHST- 2005/10/01 09:00 [medline]
PHST- 2005/06/25 09:00 [entrez]
AID - 10.2174/1568026054201677 [doi]
PST - ppublish
SO  - Curr Top Med Chem. 2005;5(5):487-92. doi: 10.2174/1568026054201677.

PMID- 1026550
OWN - NLM
STAT- MEDLINE
DCOM- 19770723
LR  - 20191210
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 4
IP  - 4
DP  - 1976
TI  - Micro-encapsulated aspirin (Levius) compared with aloxiprin (Palaprin Forte) in 
      the treatment of rheumatoid arthritis.
PG  - 272-5
AB  - A randomized crossover trial of micro-encapsulated aspirin (Levius) and aloxiprin 
      (Palaprin Forte) was carried out on thirty-three hospital outpatients with 
      rheumatoid arthritis. Both preparations improved the clincial status of the 
      patients. The difference in response to the two preparations was not significant, 
      except for effect on functional status where the micro-encapsulated aspirin was 
      found to be significantly better at the 5% level. Apart from six complaints of 
      constipation with aloxiprin compared with only one with Levius, the side-effects 
      were similar. The trial has shown that Levius can be conveniently given in 
      divided doses thrice daily without loss of efficacy.
FAU - Wright, M G
AU  - Wright MG
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Delayed-Action Preparations)
RN  - 6QT214X4XU (aloxiprin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1177/030006057600400410 [doi]
PST - ppublish
SO  - J Int Med Res. 1976;4(4):272-5. doi: 10.1177/030006057600400410.

PMID- 3820103
OWN - NLM
STAT- MEDLINE
DCOM- 19870422
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 75
IP  - 11
DP  - 1986 Nov
TI  - S-acylation of cysteine by O-acetylsalicylic anhydride: a possible mechanism for 
      aspirin hypersensitivity?
PG  - 1081-4
AB  - In order to elucidate the possible reaction pathways for the acylation of protein 
      by O-acetylsalicylic anhydride, the mechanism of the reaction between L-cysteine 
      and O-acetylsalicylic anhydride was studied. O-Acetylsalicylic anhydride reacts 
      with L-cysteine via a consecutive kinetic pathway. The thiol anion first reacts 
      with the anhydride to form an intermediate thiol ester which then undergoes an 
      intramolecular rearrangement to form the stable 
      N-(O-acetylsalicyloyl)-2-amino-3-thiopropionic acid, 5. The importance of the 
      free amino group in the intramolecular reaction was established by the observed 
      stability of the S-(O-acetylsalicyloyl) derivative of N-acetylcysteine under 
      similar reaction conditions. The formation of the thiol ester was pH dependent, 
      suggesting that the thiol anion was the attacking species. The acyl transfer to 
      the adjacent amino group was catalyzed by both phosphate and acetate buffers. The 
      results suggest that the reaction of O-acetylsalicylic anhydride with the 
      thiol-containing amino acids of a protein molecule may proceed via formation of 
      an initial thio ester, followed by an S to N intramolecular acyl transfer to form 
      an immunogenic amide.
FAU - Dannan, H
AU  - Dannan H
FAU - Khawam, M N
AU  - Khawam MN
FAU - Bogardus, J B
AU  - Bogardus JB
FAU - Hussain, A A
AU  - Hussain AA
FAU - Crooks, P A
AU  - Crooks PA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - K848JZ4886 (Cysteine)
RN  - R16CO5Y76E (Aspirin)
RN  - XIA5Z82RHB (acetylsalicylic anhydride)
SB  - IM
MH  - Acylation
MH  - Aspirin/*adverse effects/*analogs & derivatives/analysis
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Chromatography, High Pressure Liquid
MH  - Cysteine/*analysis
MH  - Drug Hypersensitivity/*etiology/metabolism
MH  - Kinetics
EDAT- 1986/11/01 00:00
MHDA- 1986/11/01 00:01
CRDT- 1986/11/01 00:00
PHST- 1986/11/01 00:00 [pubmed]
PHST- 1986/11/01 00:01 [medline]
PHST- 1986/11/01 00:00 [entrez]
AID - S0022-3549(15)47280-6 [pii]
AID - 10.1002/jps.2600751112 [doi]
PST - ppublish
SO  - J Pharm Sci. 1986 Nov;75(11):1081-4. doi: 10.1002/jps.2600751112.

PMID- 10830093
OWN - NLM
STAT- MEDLINE
DCOM- 20000706
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 93
IP  - 2
DP  - 2000 Feb
TI  - [Aspirin, angiotensin converting enzyme inhibitors and cardiac insufficiency].
PG  - 167-71
AB  - The possible negative therapeutic interaction between aspirin and angiotensin 
      converting enzyme inhibitors arose from the conclusions of several experimental 
      studies and retrospective analysis of large scale mortality trials with 
      converting enzyme inhibitors. Some experimental results show inhibition of the 
      vasodilatation of converting enzyme inhibitors, increase in pulmonary pressures, 
      vascular resistances and blood pressure, and degradation of renal function and 
      exercise capacity. However, other studies did not confirm these results. In large 
      scale therapeutic trials, some retrospective analyses, but not all of them, have 
      shown less benefit on morbi-mortality of converting enzyme inhibitors in patients 
      on aspirin. The differences between the doses of aspirin, the type and dosage of 
      the converting enzyme inhibitors and neuro-hormonal activation of the patients 
      could explain the discordant results. The results of randomised trials are 
      awaited but, in the meantime, it is logical to propose small doses of aspirin (< 
      or = 100 mg/day) for patients with cardiac failure and atherosclerosis and to 
      avoid the association in all the other patients.
FAU - de Groote, P
AU  - de Groote P
AD  - Service de cardiologie C, hôpital cardiologique, CHRU, Lille.
FAU - Aumégeat, V
AU  - Aumégeat V
FAU - Meurice, T
AU  - Meurice T
FAU - Millaire, A
AU  - Millaire A
FAU - Lamblin, N
AU  - Lamblin N
FAU - Lablanche, J M
AU  - Lablanche JM
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Aspirine, inhibiteur de l'enzyme de conversion de l'angiotensine et insuffisance 
      cardiaque.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*adverse effects/pharmacokinetics
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacokinetics
MH  - Aspirin/*adverse effects/pharmacokinetics
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Heart Failure/*drug therapy
MH  - Humans
EDAT- 2000/06/01 09:00
MHDA- 2000/07/08 11:00
CRDT- 2000/06/01 09:00
PHST- 2000/06/01 09:00 [pubmed]
PHST- 2000/07/08 11:00 [medline]
PHST- 2000/06/01 09:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 2000 Feb;93(2):167-71.

PMID- 7320839
OWN - NLM
STAT- MEDLINE
DCOM- 19820313
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 12
DP  - 1981 Dec
TI  - Physicochemical property modification strategies based on enzyme substrate 
      specificities I: rationale, synthesis, and pharmaceutical properties of aspirin 
      derivatives.
PG  - 1299-303
AB  - A rationale is developed for drug physicochemical property modification based on 
      making derivatives that are substrates for known enzymes. The approach requires 
      knowledge of the enzyme-substrate specificities to select the appropriate 
      derivative. As a class, the digestive enzymes represent possible reconversion 
      sites. It is shown that by using only known specificities of these enzymes, the 
      physicochemical properties of a drug may be modified in almost any manner desired 
      by appropriate derivative choice, with enzymatic regeneration remaining 
      effective. The strategy is applied to making a stable aspirin derivative that is 
      activated in vivo. Of the derivatives made, aspirin phenylalanine ethyl ester was 
      shown to be stable in suspension form for over 4 years. It was also shown that 
      aspirin is regenerated form the derivative in the presence of the enzymes 
      alpha-chymotrypsin and carboxypeptidase in vitro. This biochemical approach to 
      drug physicochemical property modification offers a new and powerful rationale 
      for improving drug product efficacy.
FAU - Banerjee, P K
AU  - Banerjee PK
FAU - Amidon, G L
AU  - Amidon GL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Amines)
RN  - 47E5O17Y3R (Phenylalanine)
RN  - EC 3.4.- (Carboxypeptidases)
RN  - EC 3.4.17.1 (Carboxypeptidases A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amines
MH  - Aspirin/*analogs & derivatives/metabolism
MH  - Carboxypeptidases/metabolism
MH  - Carboxypeptidases A
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Chromatography, Thin Layer
MH  - Drug Stability
MH  - Phenylalanine
MH  - Solubility
MH  - Substrate Specificity
EDAT- 1981/12/01 00:00
MHDA- 1981/12/01 00:01
CRDT- 1981/12/01 00:00
PHST- 1981/12/01 00:00 [pubmed]
PHST- 1981/12/01 00:01 [medline]
PHST- 1981/12/01 00:00 [entrez]
AID - S0022-3549(15)43972-3 [pii]
AID - 10.1002/jps.2600701202 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Dec;70(12):1299-303. doi: 10.1002/jps.2600701202.

PMID- 21440610
OWN - NLM
STAT- MEDLINE
DCOM- 20120110
LR  - 20161125
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 411
IP  - 1-2
DP  - 2011 Jun 15
TI  - The breakage behaviour of Aspirin under quasi-static indentation and single 
      particle impact loading: effect of crystallographic anisotropy.
PG  - 49-63
LID - 10.1016/j.ijpharm.2011.03.039 [doi]
AB  - The influence of crystallographic structural anisotropy on the breakage behaviour 
      of Aspirin under impact loading is highlighted. Under both quasi-static testing 
      conditions, using nano-indentation, and dynamic impact tests, Aspirin 
      demonstrates clear anisotropy in its slip and fracture behaviour. During 
      nano-indentation on the (100) and (001) faces, cracks were propagated along the 
      [010] direction. While the hardness was found to be comparatively similar for 
      both these faces, it was observed that slip due to plastic deformation occurred 
      more readily on the (100) than the (001) crystal planes suggesting the former as 
      the preferred slip plane. Furthermore, the fracture toughness on the (001) planes 
      was found to be distinctly lower than that of the (100) planes, indicating the 
      former as the preferred cleavage plane. Observations of the crystal morphology of 
      damaged particles after dynamic impact testing showed that both the chipping and 
      fragmentation of Aspirin mostly occurred via cleavage in a manner consistent with 
      the observed fracture behaviour following nano-indentation. This work highlights 
      the importance of cleavage as a dominant factor underpinning the fracture 
      mechanism of Aspirin under both quasi-static and impact loading conditions.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Olusanmi, D
AU  - Olusanmi D
AD  - Institute of Particle Science and Engineering, School of Process, Environmental 
      and Materials Engineering, University of Leeds, Leeds LS2 9JT, United Kingdom. 
      dolapo.olusanmi@bms.com
FAU - Roberts, K J
AU  - Roberts KJ
FAU - Ghadiri, M
AU  - Ghadiri M
FAU - Ding, Y
AU  - Ding Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110403
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Antipyretics)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anisotropy
MH  - Antipyretics/analysis/*chemistry
MH  - Aspirin/analysis/*chemistry
MH  - Crystallization
MH  - Hardness
MH  - *Hardness Tests
MH  - *Materials Testing
MH  - Mechanical Phenomena
MH  - Models, Chemical
MH  - Nanotechnology/*methods
MH  - Surface Properties
MH  - Tablets
EDAT- 2011/03/29 06:00
MHDA- 2012/01/11 06:00
CRDT- 2011/03/29 06:00
PHST- 2011/01/17 00:00 [received]
PHST- 2011/03/18 00:00 [accepted]
PHST- 2011/03/29 06:00 [entrez]
PHST- 2011/03/29 06:00 [pubmed]
PHST- 2012/01/11 06:00 [medline]
AID - S0378-5173(11)00256-0 [pii]
AID - 10.1016/j.ijpharm.2011.03.039 [doi]
PST - ppublish
SO  - Int J Pharm. 2011 Jun 15;411(1-2):49-63. doi: 10.1016/j.ijpharm.2011.03.039. Epub 
      2011 Apr 3.

PMID- 19481896
OWN - NLM
STAT- MEDLINE
DCOM- 20091110
LR  - 20131121
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 50
IP  - 3
DP  - 2009 Oct 15
TI  - Isotopic 13C NMR spectrometry to assess counterfeiting of active pharmaceutical 
      ingredients: site-specific 13C content of aspirin and paracetamol.
PG  - 336-41
LID - 10.1016/j.jpba.2009.04.030 [doi]
AB  - Isotope profiling is a well-established technique to obtain information about the 
      chemical history of a given compound. However, the current methodology using IRMS 
      can only determine the global (13)C content, leading to the loss of much valuable 
      data. The development of quantitative isotopic (13)C NMR spectrometry at natural 
      abundance enables the measurement of the (13)C content of each carbon within a 
      molecule, thus giving simultaneous access to a number of isotopic parameters. 
      When it is applied to active pharmaceutical ingredients, each manufactured batch 
      can be characterized better than by IRMS. Here, quantitative isotopic (13)C NMR 
      is shown to be a very promising and effective tool for assessing the 
      counterfeiting of medicines, as exemplified by an analysis of aspirin 
      (acetylsalicylic acid) and paracetamol (acetaminophen) samples collected from 
      pharmacies in different countries. It is proposed as an essential complement to 
      (2)H NMR and IRMS.
FAU - Silvestre, Virginie
AU  - Silvestre V
AD  - University of Nantes-CNRS, Chemistry and Interdisciplinarity: Synthesis, Analysis 
      and Modeling, UMR6230, 2 rue de la Houssinière, BP 92208, F-44322 Nantes cedex 3, 
      France.
FAU - Mboula, Vanessa Maroga
AU  - Mboula VM
FAU - Jouitteau, Catherine
AU  - Jouitteau C
FAU - Akoka, Serge
AU  - Akoka S
FAU - Robins, Richard J
AU  - Robins RJ
FAU - Remaud, Gérald S
AU  - Remaud GS
LA  - eng
PT  - Journal Article
DEP - 20090507
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Carbon Isotopes)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis/standards
MH  - Aspirin/*analysis/standards
MH  - Carbon Isotopes
MH  - Magnetic Resonance Spectroscopy/*methods
MH  - Quality Control
EDAT- 2009/06/02 09:00
MHDA- 2009/11/11 06:00
CRDT- 2009/06/02 09:00
PHST- 2009/04/02 00:00 [received]
PHST- 2009/04/27 00:00 [revised]
PHST- 2009/04/29 00:00 [accepted]
PHST- 2009/06/02 09:00 [entrez]
PHST- 2009/06/02 09:00 [pubmed]
PHST- 2009/11/11 06:00 [medline]
AID - S0731-7085(09)00273-8 [pii]
AID - 10.1016/j.jpba.2009.04.030 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2009 Oct 15;50(3):336-41. doi: 10.1016/j.jpba.2009.04.030. 
      Epub 2009 May 7.

PMID- 9919990
OWN - NLM
STAT- MEDLINE
DCOM- 19990413
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 18
IP  - 4-5
DP  - 1998 Dec
TI  - Simultaneous determination of salicylic acid and acetylsalicylic acid in aspirin 
      delayed-release tablet formulations by second-derivative UV spectrophotometry.
PG  - 871-5
AB  - A rapid, simple assay procedure was developed for simultaneous analysis of 
      aspirin (ASA) and salicylic acid (SA) in aspirin delayed-release tablet 
      formulation by 'zero crossing' second-derivative UV spectrophotometry. The 
      zero-order absorption spectra and second derivative spectra of ASA and SA were 
      recorded in diluting solution acetonitrile-formic acid (99:1). The accuracy of 
      the method was demonstrated by the determination of ASA and SA in five tablets 
      formulations (each 20 tablets of the same batch) by the described method and by 
      high performance liquid chromatographic method, and the results were in good 
      agreement.
FAU - Kokot, Z
AU  - Kokot Z
AD  - Department of Inorganic and Analytical Chemistry, K. Marcinkowski University of 
      Medical Sciences, Poznan, Poland. Kokotzen@main.amu.edu.pl
FAU - Burda, K
AU  - Burda K
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/*chemistry
MH  - Chromatography, High Pressure Liquid
MH  - Delayed-Action Preparations
MH  - Salicylic Acid/*analysis
MH  - Spectrophotometry, Ultraviolet/*methods
MH  - Tablets/chemistry
EDAT- 1999/01/27 00:00
MHDA- 1999/01/27 00:01
CRDT- 1999/01/27 00:00
PHST- 1999/01/27 00:00 [pubmed]
PHST- 1999/01/27 00:01 [medline]
PHST- 1999/01/27 00:00 [entrez]
AID - S0731-7085(98)00225-8 [pii]
AID - 10.1016/s0731-7085(98)00225-8 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1998 Dec;18(4-5):871-5. doi: 10.1016/s0731-7085(98)00225-8.

PMID- 7264919
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 7
DP  - 1981 Jul
TI  - Improved delivery through biological membranes IX: Kinetics and mechanism of 
      hydrolysis of methylsulfinymethyl 2-acetoxybenzoate and related aspirin prodrugs.
PG  - 750-5
AB  - The complex kinetics and mechanism of the hydrolysis of the methylthiomethyl, 
      methylsulfinylmethyl, and methylsulfonylmethyl 2-acetoxybenzoates, novel aspirin 
      prodrugs, were studied. The pH profiles for the related salicylates and benzoates 
      also were determined. Based on the activation parameters, isotope effects, and 
      other data, it was established that the methylthiomethyl esters hydrolyze via a 
      unimolecular alkyl-oxygen cleavage. The methylsulfinylmethyl and 
      methylsulfonylmethyl 2-acetoxybenzoates undergo neutral hydrolysis of esters at 
      pH greater than 4 to form aspirin, while water acts as a general base; but at 
      lower pH, a different mechanism takes place and the o-acetyl group cleaves first, 
      releasing the corresponding salicylates.
FAU - Loftsson, T
AU  - Loftsson T
FAU - Bodor, N
AU  - Bodor N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 76432-33-2 (methylsulfinylmethyl 2-acetoxybenzoate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*analogs & derivatives/metabolism
MH  - Chemical Phenomena
MH  - Chemistry, Pharmaceutical
MH  - Chemistry, Physical
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - Kinetics
MH  - Salicylates/*metabolism
MH  - Solubility
MH  - Temperature
EDAT- 1981/07/01 00:00
MHDA- 1981/07/01 00:01
CRDT- 1981/07/01 00:00
PHST- 1981/07/01 00:00 [pubmed]
PHST- 1981/07/01 00:01 [medline]
PHST- 1981/07/01 00:00 [entrez]
AID - S0022-3549(15)43799-2 [pii]
AID - 10.1002/jps.2600700709 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Jul;70(7):750-5. doi: 10.1002/jps.2600700709.

PMID- 7097494
OWN - NLM
STAT- MEDLINE
DCOM- 19820910
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 71
IP  - 5
DP  - 1982 May
TI  - Determination of related compounds in aspirin by liquid chromatography.
PG  - 511-4
AB  - A rapid liquid chromatographic procedure has been validated for the determination 
      of salicylic acid, salsalate, acetylsalicylsalicylic acid, and acetylsalicylic 
      anhydride in aspirin. Samples are dissolved in methylene chloride and analyzed 
      directly by adsorption chromatography in a 7-min separation using an isocratic 
      mobile phase. Recoveries averaged 99% over a 200-10,000 ppm concentration range 
      with standard deviations of less than 4% for the four compounds of interest. 
      Detection limits ranged from 5 to 36 ppm. Compared to a recently published 
      reversed-phase liquid chromatographic procedure for analyzing aspirin, this 
      method is twice as fast, more sensitive, and avoids the use of hydroxylic 
      solvents which lead to degradation of aspirin and acetylsalicylic anhydride.
FAU - Pfeiffer, C D
AU  - Pfeiffer CD
FAU - Pankey, J W
AU  - Pankey JW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - V9MO595C9I (salicylsalicylic acid)
RN  - XIA5Z82RHB (acetylsalicylic anhydride)
SB  - IM
MH  - Aspirin/analogs & derivatives/*analysis
MH  - Chromatography, Liquid/methods
MH  - Salicylates/analysis
MH  - Salicylic Acid
MH  - Tablets/analysis
EDAT- 1982/05/01 00:00
MHDA- 1982/05/01 00:01
CRDT- 1982/05/01 00:00
PHST- 1982/05/01 00:00 [pubmed]
PHST- 1982/05/01 00:01 [medline]
PHST- 1982/05/01 00:00 [entrez]
AID - S0022-3549(15)44150-4 [pii]
AID - 10.1002/jps.2600710508 [doi]
PST - ppublish
SO  - J Pharm Sci. 1982 May;71(5):511-4. doi: 10.1002/jps.2600710508.

PMID- 2322188
OWN - NLM
STAT- MEDLINE
DCOM- 19900508
LR  - 20131121
IS  - 0300-8495 (Print)
IS  - 0300-8495 (Linking)
VI  - 19
IP  - 2
DP  - 1990 Feb
TI  - Aspirin and coronary heart disease. Clinical applications.
PG  - 217, 221-3
AB  - Aspirin, which is an effective anti-platelet agent, given in the low dosage of 60 
      to 100 mg per day appears to be beneficial for patients with a history of 
      unstable angina, myocardial infarction, transient ischaemic attacks and stroke.
FAU - Koutts, J
AU  - Koutts J
AD  - Clinical Haematology Unit, Westmead Hospital, New South Wales.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust Fam Physician
JT  - Australian family physician
JID - 0326701
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cerebrovascular Disorders/drug therapy
MH  - Coronary Disease/*drug therapy
MH  - Endothelium, Vascular/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Activation/drug effects
EDAT- 1990/02/01 00:00
MHDA- 1990/02/01 00:01
CRDT- 1990/02/01 00:00
PHST- 1990/02/01 00:00 [pubmed]
PHST- 1990/02/01 00:01 [medline]
PHST- 1990/02/01 00:00 [entrez]
PST - ppublish
SO  - Aust Fam Physician. 1990 Feb;19(2):217, 221-3.

PMID- 2218966
OWN - NLM
STAT- MEDLINE
DCOM- 19901109
LR  - 20131121
IS  - 0040-5930 (Print)
IS  - 0040-5930 (Linking)
VI  - 47
IP  - 8
DP  - 1990 Aug
TI  - [Aspirin against aging? For whom and how much?].
PG  - 648-52
AB  - Aspirin has been successfully used in the secondary prophylaxis of myocardial 
      infarction, cerebral vascular events and peripheral arterial disease. Regular 
      aspirin intake may further be beneficial in asymptomatic healthy male with 
      cardiovascular risk factors over the age of 50. There is no good evidence that 
      aspirin prevents the development of atherosclerosis and thromboembolic events in 
      healthy individuals.
FAU - Oelz, O
AU  - Oelz O
AD  - Departement für Innere Medizin, Universitätsspital Zürich.
FAU - Meier, P J
AU  - Meier PJ
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Aspirin gegen das Altern? Für wen und wieviel?
PL  - Switzerland
TA  - Ther Umsch
JT  - Therapeutische Umschau. Revue therapeutique
JID - 0407224
RN  - 0 (Arachidonic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acids/*antagonists & inhibitors
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Coronary Disease/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention
EDAT- 1990/08/01 00:00
MHDA- 1990/08/01 00:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 1990/08/01 00:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
PST - ppublish
SO  - Ther Umsch. 1990 Aug;47(8):648-52.

PMID- 1202530
OWN - NLM
STAT- MEDLINE
DCOM- 19760301
LR  - 20131121
IS  - 0031-8280 (Print)
IS  - 0031-8280 (Linking)
VI  - 28
IP  - 1
DP  - 1975 Jan-Mar
TI  - [Aspirin as treatment for platelet aggregation].
PG  - 35-6
AB  - The efficacity of therapy against platelet aggregation, as a preventive treatment 
      in cases of venous thrombosis has been questioned : however, some good, little 
      known pieces of work suggest that such treatment is of value.
FAU - Tournay, R
AU  - Tournay R
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - L'aspirine, thérapeutique anti-agrégation plaquettaire.
PL  - France
TA  - Phlebologie
JT  - Phlebologie
JID - 0376212
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Embolism/prevention & control
MH  - Heparin/therapeutic use
MH  - Hip/surgery
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Postoperative Complications/*prevention & control
MH  - Thrombophlebitis/*prevention & control
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
PST - ppublish
SO  - Phlebologie. 1975 Jan-Mar;28(1):35-6.

PMID- 18924327
OWN - NLM
STAT- MEDLINE
DCOM- 20081118
LR  - 20131121
IS  - 0035-2640 (Print)
IS  - 0035-2640 (Linking)
VI  - 58
IP  - 13
DP  - 2008 Sep 15
TI  - [Risk and prevention of gastrointestinal complications due to low-dose aspirin 
      and other antiplatelet agents].
PG  - 1434-6, 1439-40
AB  - Upper and lower gastrointestinal (GI) haemorrhages are the main complications 
      associated with low-dose aspirin or anti-thrombotic drugs. In France, low-dose 
      aspirin or anti-thrombotic agents use has been found in 30% of upper GI and 40% 
      of lower GI bleeding episodes. Main causes of GI bleeding with low-dose aspirin 
      are gastroduodenal peptic ulcer and colonic diverticulosis. Recent cohort studies 
      have shown that the relative risk of GI bleeding with low-dose aspirin was 
      comprised between 2 and 4 and the absolute risk comprised between 1 per 100 and 1 
      per 1000 aspirin users per year. Main risk factors for upper GI bleeding with 
      low-dose aspirin are concomitant antiplatelet agents, anticoagulants, non 
      steroidal anti-inflammatory drugs or steroids use, and recent history of 
      complicated or non-complicated gastroduodenal ulcer. Helicobacter pylori 
      infection increases the risk for upper GI bleeding with low-dose aspirin, but 
      infection should be searched and treated only in patients with peptic ulcer. 
      Despite eradication of H. pylori in the latter patients, gastroprotection with 
      PPI is strongly recommended. In patients presenting with peptic ulcer bleeding 
      with low-dose aspirin, aspirin should be continued in association with PPI rather 
      than replaced with clopidogrel. Discontinuation of low-dose aspirin which exposes 
      to increased cardiovascular complications and mortality should be avoided, even 
      in cases of peptic ulcer bleeding.
FAU - Bretagne, Jean-François
AU  - Bretagne JF
AD  - Service des maladies de l'appareil digestif, hôpital Pontchaillou, Université 
      Rennes 1, 35033 Rennes Cedex, France. jean-francois.bretagne@chu-rennes.fr
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Accidents digestifs dus a la prise d'aspirine a faible dose et autres 
      antiagrégants plaquettaires.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Gastrointestinal Diseases/*chemically induced/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk Factors
EDAT- 2008/10/18 09:00
MHDA- 2008/11/19 09:00
CRDT- 2008/10/18 09:00
PHST- 2008/10/18 09:00 [pubmed]
PHST- 2008/11/19 09:00 [medline]
PHST- 2008/10/18 09:00 [entrez]
PST - ppublish
SO  - Rev Prat. 2008 Sep 15;58(13):1434-6, 1439-40.

PMID- 11029017
OWN - NLM
STAT- MEDLINE
DCOM- 20010215
LR  - 20191104
IS  - 0959-9851 (Print)
IS  - 0959-9851 (Linking)
VI  - 10
IP  - 4
DP  - 2000 Aug
TI  - Acetylsalicylic acid and autonomic modulation.
PG  - 197-201
AB  - Loss of autonomic balance characterized by increased sympathetic activity and 
      decreased vagal activity has been implicated as a major cardiovascular risk 
      factor. Aspirin's cardioprotective abilities involve a multitude of physiologic 
      processes. However, the effects of aspirin on cardiac autonomic activity are 
      unknown. In a double-blind crossover study, 22 subjects randomly received either 
      aspirin or placebo in the amounts of 325 mg with each meal (three times per day) 
      over a 2.5-day period. The total amount of aspirin ingested was 2,275 mg, which 
      resulted in plasma levels of 3.3 mg/dl. At the conclusion of each treatment, 
      subjects were evaluated for autonomic physiology activity using standard 
      autonomic tests. Power spectral analyses of the electrocardiograms were used to 
      delineate autonomic function. A 2 x 4 repeated measures analysis of variance 
      revealed significant and favorable changes in autonomic activity after the use of 
      aspirin. Specifically, at rest high-frequency (HF) power was significantly higher 
      (mean, 1,090 + 1,463.5 msec2) compared with the placebo (mean, 692 742 msec2) (p 
      <0.05). Low-frequency (LF) power was significantly reduced (mean, 963 745 msec2) 
      after aspirin compared with placebo (mean, 1,100 906 msec2). After the aspirin 
      treatment, a significantly lower LF-to-HF power ratio (mean, 1.7 2 msec2) was 
      noted at rest when compared with the placebo (mean, 2.5 2.7 msec2) (p <0.05). 
      Similar significant trends were seen during the sustained isometric contraction 
      after aspirin therapy for HF power (mean 210 2.15 msec2) compared with placebo 
      (mean, 213 184 msec2) (p <0.05). Accordingly, the LF-to-HF power ratio was lower 
      as well when compared to placebo treatment (mean, 2.3 3.5 msec2) (mean, 5.3 8.4 
      msec2) (p <0.05). No differences were found in breathing rates for hemodynamic 
      variables between any of the protocols. The significant reduction of LF-to-HF 
      ratio, a marker of sympathovagal balance, for both protocols appeared to be 
      largely due to a withdrawal of LF modulation and concomitant but lesser increase 
      in HF modulation. Favorable alterations in autonomic outflow through 
      prostaglandin inhibition may be one of the mechanisms by which low therapeutic 
      amounts of aspirin provide prophylactic cardioprotection.
FAU - De Meersman, R E
AU  - De Meersman RE
AD  - Department of Rehabilitation Medicine and Teachers College, Columbia University, 
      New York, New York 10032, USA. red13@columbia.edu
FAU - Zion, A S
AU  - Zion AS
FAU - Lieberman, J S
AU  - Lieberman JS
FAU - Downey, J A
AU  - Downey JA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Auton Res
JT  - Clinical autonomic research : official journal of the Clinical Autonomic Research 
      Society
JID - 9106549
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Autonomic Nervous System/*drug effects
MH  - Baroreflex/drug effects
MH  - Blood Pressure/drug effects
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Electrocardiography/drug effects
MH  - Exercise/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/blood/*pharmacology
MH  - Respiratory Mechanics/physiology
MH  - Rest/physiology
EDAT- 2000/10/12 11:00
MHDA- 2001/03/03 10:01
CRDT- 2000/10/12 11:00
PHST- 2000/10/12 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2000/10/12 11:00 [entrez]
AID - 10.1007/BF02291356 [doi]
PST - ppublish
SO  - Clin Auton Res. 2000 Aug;10(4):197-201. doi: 10.1007/BF02291356.

PMID- 19171224
OWN - NLM
STAT- MEDLINE
DCOM- 20090423
LR  - 20131121
IS  - 0151-9638 (Print)
IS  - 0151-9638 (Linking)
VI  - 136
IP  - 1
DP  - 2009 Jan
TI  - [Safety of reintroducing platelet-inhibitory doses of aspirin in patients with 
      urticaria or angioedema induced by anti-inflammatory doses].
PG  - 15-20
LID - 10.1016/j.annder.2008.10.022 [doi]
AB  - BACKGROUND: Aspirin is one of the most widely prescribed drugs in the world on 
      account of its analgesic, antipyretic, and anti-inflammatory properties. Its 
      effect on platelet aggregation makes it the first choice for prophylaxis in 
      cardiovascular, neurological and obstetric diseases. However, a history of 
      aspirin-induced urticaria and/or angioedema is usually a contraindication for 
      further prescription of the drug. The aim of this article was to demonstrate that 
      patients presenting aspirin-induced cutaneous reactions at anti-inflammatory 
      doses can safely benefit from aspirin reintroduction at platelet-inhibitory 
      doses. PATIENTS AND METHODS: Patients with a history of aspirin-induced urticaria 
      and/or angioedema referred to our department between January 2000 and June 2008 
      for double-blind placebo-controlled reintroduction at platelet-inhibitory doses 
      for a medical indication were enrolled in this study. RESULTS: Seventy patients 
      with aspirin hypersensitivity as well as a medical indication for this therapy 
      were referred to our department. Of these, 38 (54.3%) had a history of 
      aspirin-induced urticaria and/or angioedema, including three laryngeal oedemas 
      (7.9%). All subjects received platelet-inhibitory doses of aspirin (maximal total 
      dose: 400mg/day) in double-blind placebo-controlled fashion during a one-day 
      hospitalization period. None of the patients presented an immediate 
      hypersensitivity reaction. Only one patient, who had received a cumulative dose 
      of 200mg/day, reported diffuse urticaria and facial angioedema of no clinical 
      significance the following day. He had a history of chronic urticaria. 
      CONCLUSION: This article demonstrates the safety of reintroducing 
      platelet-inhibitory doses of aspirin in patients in whom it is indicated and 
      reporting aspirin-induced urticaria and/or angioedema with anti-inflammatory 
      doses. However, patients with a history of chronic urticaria should undergo a 
      challenge with the lowest platelet-inhibitory dose (75mg/day) in order to 
      minimize the risk of aggravating their condition.
FAU - Vial, A
AU  - Vial A
AD  - Service de dermatologie et allergologie, hôpital Tenon, 4, rue de la Chine, 75020 
      Paris, France.
FAU - Mathelier-Fusade, P
AU  - Mathelier-Fusade P
FAU - Gaouar, H
AU  - Gaouar H
FAU - Leynadier, F
AU  - Leynadier F
FAU - Chosidow, O
AU  - Chosidow O
FAU - Aractingi, S
AU  - Aractingi S
FAU - Francès, C
AU  - Francès C
LA  - fre
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Réintroduction de l'aspirine à dose antiagrégante après urticaire ou angio-oedème 
      induits par des doses anti-inflammatoires.
DEP - 20081218
PL  - France
TA  - Ann Dermatol Venereol
JT  - Annales de dermatologie et de venereologie
JID - 7702013
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioedema/chemically induced
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*adverse effects
MH  - Urticaria/chemically induced
EDAT- 2009/01/28 09:00
MHDA- 2009/04/25 09:00
CRDT- 2009/01/28 09:00
PHST- 2008/08/07 00:00 [received]
PHST- 2008/10/24 00:00 [accepted]
PHST- 2009/01/28 09:00 [entrez]
PHST- 2009/01/28 09:00 [pubmed]
PHST- 2009/04/25 09:00 [medline]
AID - S0151-9638(08)00756-4 [pii]
AID - 10.1016/j.annder.2008.10.022 [doi]
PST - ppublish
SO  - Ann Dermatol Venereol. 2009 Jan;136(1):15-20. doi: 10.1016/j.annder.2008.10.022. 
      Epub 2008 Dec 18.

PMID- 9183950
OWN - NLM
STAT- MEDLINE
DCOM- 19970715
LR  - 20131121
IS  - 0035-2640 (Print)
IS  - 0035-2640 (Linking)
VI  - 47
IP  - 7
DP  - 1997 Apr 1
TI  - [Acute paracetamol and aspirin poisoning].
PG  - 736-41
AB  - Liver injury is the main feature of paracetamol poisoning. Early administration 
      of N-acetylcysteine is an effective antidotal treatment. There are also effective 
      treatments for salicylate poisoning and severe cases are always due to delayed 
      diagnosis. Salicylate poisoning should be systematically suspected when several 
      of the following features are observed in a poisoned patient: tinnitus, deafness, 
      hyperventilation, respiratory alkalosis, metabolic acidosis. Diagnosis is readily 
      confirmed by measuring plasma salicylate concentration.
FAU - Garnier, R
AU  - Garnier R
AD  - Centre anti-poisons de Paris Hôpital Fernand-Widal, Paris.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Intoxications aiguës par le paracétamol et l'aspirine.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
MH  - Acetaminophen/metabolism/*poisoning
MH  - Acute Disease
MH  - Analgesics, Non-Narcotic/poisoning
MH  - Anti-Inflammatory Agents, Non-Steroidal/metabolism/*poisoning
MH  - Aspirin/metabolism/*poisoning
MH  - Humans
MH  - Poisoning/diagnosis/therapy
MH  - Prognosis
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
PST - ppublish
SO  - Rev Prat. 1997 Apr 1;47(7):736-41.

PMID- 6643708
OWN - NLM
STAT- MEDLINE
DCOM- 19840107
LR  - 20191023
IS  - 0094-5145 (Print)
IS  - 0094-5145 (Linking)
VI  - 8
IP  - 4
DP  - 1983 Summer
TI  - Public awareness of aspirin and sources of aspirin information in a rural Iowa 
      community.
PG  - 229-39
AB  - One hundren fifty households in a rural Iowa community were surveyed to determine 
      the frequency and reasons for aspirin use, their awareness of aspirin effects, 
      and their sources of aspirin information. Of those surveyed 82 percent used 
      aspirin to some extent and 59 percent used it at least monthly. The frequency of 
      aspirin use was indirectly associated with age. The number of correct aspirin 
      effects mentioned was 1.8 +/- 1.1 with 89 percent mentioning analgesia as an 
      effect of aspirin. Nineteen percent mentioned mental relaxation as an effect of 
      aspirin. The number of correct effects mentioned was associated directly with 
      education and indirectly with age but was not associated with the frequency of 
      aspirin use. The number of information sources mentioned was 1.3 +/- 0.7 with 34 
      percent mentioning television and radio advertising as a source of aspirin 
      information. Awareness of gastrointestinal irritation and antipyretic effects and 
      the number of correct effects mentioned were each associated with mention of 
      television and radio advertising as an information source. Use of aspirin for 
      fever was associated with mention of physicians as an information source. 
      Seventy-two percent of the respondents indicated a desire for more information 
      with physicians mentioned as the desired source of additional information by 69 
      percent of respondents.
FAU - Rubin, R J
AU  - Rubin RJ
FAU - Brown, D J
AU  - Brown DJ
FAU - Taylor, J W
AU  - Taylor JW
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Community Health
JT  - Journal of community health
JID - 7600747
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - *Attitude
MH  - *Drug Information Services
MH  - Drug Interactions
MH  - Humans
MH  - Iowa
MH  - *Rural Health
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1007/BF01666776 [doi]
PST - ppublish
SO  - J Community Health. 1983 Summer;8(4):229-39. doi: 10.1007/BF01666776.

PMID- 6600426
OWN - NLM
STAT- MEDLINE
DCOM- 19830317
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 28
IP  - 1
DP  - 1983 Jan
TI  - Gastric adaptation occurs with aspirin administration in man.
PG  - 1-6
AB  - Endoscopy has become a standard method to evaluate drug-induced damage to the 
      gastroduodenal mucosa; however, studies defining the time course, extent, and 
      duration of the injury in man are unavailable. We report a systematic endoscopic 
      evaluation of the effect of aspirin administration on the gastric mucosa in 
      normal volunteers. Aspirin (2.6 g/ day) or placebo was administered for 1 or 7 
      days. Gastroscopy was performed after 1, 2, 4, and 8 days, and every other day 
      thereafter until the lesions resolved. Submocosal hemorrhages and/or focal 
      erosions were present within 24 hr in all subjects. With continuous aspirin 
      administration, injury was maximal within 3 days and then lessened, ie, damage 
      present after 7 days of aspirin was significantly less than after 1 day of 
      therapy. The time to resolution of the damage was also longer following 1 day 
      than after 7 days of aspirin (median 8 days for 1 day of aspirin vs median 3 days 
      for 7 days of aspirin). Thus, gastric mucosal adaptation occurred and was 
      associated both with less damage and with an accelerated healing process. Acute 
      administration of aspirin produced well-defined areas of submucosal hemorrhages 
      within 2 hr of administration; additional doses increased the area of involvement 
      but not necessarily the severity of involvement.
FAU - Graham, D Y
AU  - Graham DY
FAU - Smith, J L
AU  - Smith JL
FAU - Dobbs, S M
AU  - Dobbs SM
LA  - eng
PT  - Case Reports
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects/pharmacology
MH  - Gastric Mucosa/*drug effects
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Time Factors
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1007/BF01393353 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1983 Jan;28(1):1-6. doi: 10.1007/BF01393353.

PMID- 2010437
OWN - NLM
STAT- MEDLINE
DCOM- 19910509
LR  - 20161026
IS  - 0021-9509 (Print)
IS  - 0021-9509 (Linking)
VI  - 32
IP  - 1
DP  - 1991 Jan-Feb
TI  - A prospective study of aspirin's effect on red blood cell loss in cardiac 
      surgery.
PG  - 1-7
AB  - The effect of aspirin on red blood cell (RBC) loss and blood transfusions was 
      evaluated prospectively in 100 consecutive patients, with normal bleeding times, 
      undergoing elective coronary artery bypass (CABG) surgery. Patients taking 85-325 
      mgm of aspirin daily up to or within 48 hours of surgery (the "aspirin" group) 
      were compared to patients not taking aspirin or those who had discontinued 
      aspirin at least 4 days before surgery (the "no-aspirin" group). RBC loss was 
      determined by measuring preoperative and postoperative RBC volume using RISA and 
      51Cr techniques. There were no significant differences, respectively, between the 
      aspirin and no-aspirin groups for: RBC loss (1158 +/- 67 ml vs 1129 +/- 47 ml, p 
      = 0.737), chest tube drainage (925 +/- 31 ml vs 844 +/- 70 ml, p = 0.553), and 
      gm% discharge Hemoglobin (Hgb) (9.94 +/- 0.32 vs 9.49 +/- 1.4, p = 0.0148). 
      Strict criteria for blood transfusions were employed: (1) intraoperative 
      hematocrit of less than 21%, (2) postoperative Hgb of less than 7 gm% for 
      patients less than 70 years old and (3) postoperative Hgb of less than 8 gm% for 
      patients greater than 70 years old. There were no significant differences, 
      respectively, between the aspirin and no-aspirin groups for units of blood 
      transfused (1.32 +/- vs 1.21 +/- 0.20, p = 0.843) and patients not receiving 
      transfusions during the entire hospitalization (44% vs 50%). Patients taking 
      85-325 mgm of aspirin with a normal bleeding time undergoing elective CABG did 
      not have increased RBC loss or increased transfusion requirements. These results 
      indicate it is not necessary to delay elective CABG surgery for the purpose of 
      discontinuing aspirin.
FAU - Rawitscher, R E
AU  - Rawitscher RE
AD  - Toledo Hospital, Ritter Heart Institute, Ohio.
FAU - Jones, J W
AU  - Jones JW
FAU - McCoy, T A
AU  - McCoy TA
FAU - Lindsley, D A
AU  - Lindsley DA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Italy
TA  - J Cardiovasc Surg (Torino)
JT  - The Journal of cardiovascular surgery
JID - 0066127
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - *Blood Loss, Surgical
MH  - Blood Platelets/drug effects
MH  - *Blood Transfusion
MH  - *Coronary Artery Bypass
MH  - Erythrocyte Volume/*drug effects
MH  - Female
MH  - Hematocrit
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
PST - ppublish
SO  - J Cardiovasc Surg (Torino). 1991 Jan-Feb;32(1):1-7.

PMID- 2667297
OWN - NLM
STAT- MEDLINE
DCOM- 19890830
LR  - 20131121
IS  - 0002-838X (Print)
IS  - 0002-838X (Linking)
VI  - 40
IP  - 2
DP  - 1989 Aug
TI  - Aspirin prophylaxis for cardiovascular disease. U.S. Preventive Services Task 
      Force.
PG  - 117-20
AB  - Low-dose aspirin therapy should be considered for men over age 40 who are at 
      significantly increased risk for myocardial infarction and who lack 
      contraindications to the drug. Patients should understand the potential benefits 
      and risks of aspirin therapy before beginning treatment.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am Fam Physician
JT  - American family physician
JID - 1272646
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - American Heart Association
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Trials as Topic
MH  - Counseling
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - United States
EDAT- 1989/08/01 00:00
MHDA- 1989/08/01 00:01
CRDT- 1989/08/01 00:00
PHST- 1989/08/01 00:00 [pubmed]
PHST- 1989/08/01 00:01 [medline]
PHST- 1989/08/01 00:00 [entrez]
PST - ppublish
SO  - Am Fam Physician. 1989 Aug;40(2):117-20.

PMID- 34732279
OWN - NLM
STAT- MEDLINE
DCOM- 20211210
LR  - 20211214
IS  - 1768-3181 (Electronic)
IS  - 0003-3928 (Linking)
VI  - 70
IP  - 6
DP  - 2021 Dec
TI  - [Résistance à l'aspirine : l'ennemi de mon ami est mon ennemi].
PG  - 401-409
LID - S0003-3928(21)00139-6 [pii]
LID - 10.1016/j.ancard.2021.10.009 [doi]
AB  - Low dose aspirin is an efficient antiplatelet agent to decrease the risk of 
      occlusive arterial events, however it is not infallible. Aspirin resistance 
      describe its inability to block the formation of thromboxane A2 in platelets 
      and/or to produce an inhibitory effect on platelet aggregation. Detection of 
      aspirin resistance relies on the results of various platelet function tests or on 
      blood and urinary thromboxane metabolites concentrations, but these methods show 
      very low correlation and reproducibility. Moreover, light-transmission 
      aggregometry using arachidonic acid, known as the reference functional assay, 
      requires technical expertise. The incidence rate of aspirin resistance amoung 
      populations suffering from cardiovascular diseases is about 25%, however there is 
      a wide variability depending on the specificity of the used test and the clinical 
      features of the considered population. Aspirin resistance is associated with the 
      recurrence of arterial occlusive events: the odds ratio is about 4 all tests 
      combined, therefore it could be considered as a risk marker. Evidence is lacking 
      regarding the relevance of these tests to resort an intensification of the 
      antithrombotic treatment, and experts recommend to reserve their use for 
      high-risk situations. Nevertheless several studies have explored the effect of 
      dose increases or intake frequency increases, and revealed encouraging results 
      regarding pharmacodynamic endpoints. The reasons for aspirin resistance are 
      numerous, often remain debate, and can accumulate to result in poor response to 
      aspirin.
CI  - Copyright © 2021 Elsevier Masson SAS. All rights reserved.
FAU - Perier, Dr Matthieu
AU  - Perier DM
AD  - Service de cardiologie, Hôpital Foch, 40, rue Worth, 92150 Suresnes, France. 
      Electronic address: perier.matthieu@yahoo.fr.
FAU - Seret, Dr Gabriel
AU  - Seret DG
AD  - Service de cardiologie, Hôpital Foch, 40, rue Worth, 92150 Suresnes, France.
FAU - Huang, Dr Florent
AU  - Huang DF
AD  - Service de cardiologie, Hôpital Foch, 40, rue Worth, 92150 Suresnes, France.
FAU - Dillinger, Dr Jean-Guillaume
AU  - Dillinger DJ
AD  - Université de Paris, AP-HP, hôpital Lariboisière, Département de Cardiologie, 2, 
      rue Ambroise Paré, Paris, 75010 France; C.R.E.A.T.I.F. Centre de Référence et 
      d'Éducation aux Antithrombotiques d'Ile de France, hôpital Lariboisière, 
      Département de Cardiologie, 2, rue Ambroise Paré, Paris, 75010 France.
FAU - Henry, Pr Patrick
AU  - Henry PP
AD  - Université de Paris, AP-HP, hôpital Lariboisière, Département de Cardiologie, 2, 
      rue Ambroise Paré, Paris, 75010 France.
FAU - Drouet, Pr Ludovic
AU  - Drouet PL
AD  - Université de Paris, AP-HP, hôpital Lariboisière, Département de Cardiologie, 2, 
      rue Ambroise Paré, Paris, 75010 France; C.R.E.A.T.I.F. Centre de Référence et 
      d'Éducation aux Antithrombotiques d'Ile de France, hôpital Lariboisière, 
      Département de Cardiologie, 2, rue Ambroise Paré, Paris, 75010 France; Service de 
      médecine vasculaire, Hôpital Saint Joseph, 185, rue Raymond Losserand, 
      75014 Paris, France; Professeur émérite de l'université de Paris.
FAU - Benamer, Dr Hakim
AU  - Benamer DH
AD  - Service de cardiologie, Hôpital Foch, 40, rue Worth, 92150 Suresnes, France; 
      Institut Jacques Cartier, Institut cardiovasculaire Paris Sud (ICPS) Ramsay 
      Générale de santé, 6, avenue du Noyer-Lambert, 91300 Massy, France; Membre du 
      Collège de Médecine des Hôpitaux de Paris, France.
LA  - fre
PT  - Journal Article
TT  - Aspirin resistance, the enemy of my friend is my enemy.
DEP - 20211031
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - Drug Resistance
MH  - Humans
MH  - *Platelet Aggregation Inhibitors
MH  - Platelet Function Tests
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - acide acétylsalicylique
OT  - agrégation plaquettaire
OT  - antiagrégant plaquettaire
OT  - antiplatelet agent
OT  - aspirin resistance
OT  - literature review
OT  - platelet aggregation
OT  - revue de littérature
OT  - résistance à l'aspirine
EDAT- 2021/11/05 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/11/04 05:32
PHST- 2021/09/14 00:00 [received]
PHST- 2021/10/02 00:00 [accepted]
PHST- 2021/11/05 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/11/04 05:32 [entrez]
AID - S0003-3928(21)00139-6 [pii]
AID - 10.1016/j.ancard.2021.10.009 [doi]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 2021 Dec;70(6):401-409. doi: 
      10.1016/j.ancard.2021.10.009. Epub 2021 Oct 31.

PMID- 6929324
OWN - NLM
STAT- MEDLINE
DCOM- 19800726
LR  - 20131121
IS  - 0022-3255 (Print)
IS  - 0022-3255 (Linking)
VI  - 38
IP  - 6
DP  - 1980 Jun
TI  - Fibrinolysis in the rat after short-term aspirin therapy.
PG  - 412-6
AB  - Fibrinolytic parameters were compared in blood taken from rats treated with 
      aspirin (10 and 40 mg/kg) or saline solution. Plasma euglobulin fractions 
      prepared from animals treated with the higher dose of aspirin caused increased 
      zones of lysis on plasminogen-rich fibrin plates. Even greater lytic activity was 
      detected in blood from all aspirin-treated rats when euglobulin fractions were 
      augmented with sodium flufenamate and dextran sulfate. The inhibitor index was 
      significantly reduced when calculated for rats treated with the larger dose of 
      drug. Dilute blood clot lysis times for this group were consistently prolonged, 
      most likely reflecting impaired platelet function. Platelet counts, hematocrits, 
      and bleeding times did not differ from controls. Prothrombin times, activated 
      partial thromboplastin times, and plasma clot times were all prolonged, 
      reflecting the sensitivity of the vitamin K-dependent factors to aspirin.
FAU - Housholder, G T
AU  - Housholder GT
FAU - Moorrees, L L
AU  - Moorrees LL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Oral Surg
JT  - Journal of oral surgery (American Dental Association : 1965)
JID - 8302454
RN  - 0 (Serum Globulins)
RN  - 9001-31-4 (Fibrin)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Coagulation Tests
MH  - Fibrin/antagonists & inhibitors
MH  - Fibrinolysis/*drug effects
MH  - Male
MH  - Plasminogen Activators/metabolism
MH  - Rats
MH  - Serum Globulins/analysis
EDAT- 1980/06/01 00:00
MHDA- 1980/06/01 00:01
CRDT- 1980/06/01 00:00
PHST- 1980/06/01 00:00 [pubmed]
PHST- 1980/06/01 00:01 [medline]
PHST- 1980/06/01 00:00 [entrez]
PST - ppublish
SO  - J Oral Surg. 1980 Jun;38(6):412-6.

PMID- 28162289
OWN - NLM
STAT- MEDLINE
DCOM- 20180110
LR  - 20180120
IS  - 2213-2317 (Electronic)
IS  - 2213-2317 (Linking)
VI  - 5
DP  - 2015 Aug
TI  - Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer 
      Agents.
PG  - 420
LID - S2213-2317(15)00141-X [pii]
LID - 10.1016/j.redox.2015.09.030 [doi]
AB  - BACKGROUND: Aspirin is chemopreventive but has significant side effects. We 
      developed NOSH-aspirin a safer, nitric oxide and hydrogen sulfide releasing 
      hybrid. AIM: Here we report on NOSH-aspirin as an anti-inflammatory and its 
      effects on human cancer cell kinetics and various cancer xenografts. METHODS: 
      Anti-inflammatory: Carageenan rat paw edema model. Cancer cell lines: Colon, 
      HT-29, HCT 15, SW 480; breast, MCF-7, MDA-MB-231; pancreas, MIA PaCa2, BxPC3. 
      Normal cell lines: human mammary, HMEpC; pancreatic epithelial, ACBRI 515. 
      Xenografts: nude mice implanted with HT-29, MDA-MB-231, MIA PaCa2 cells, were 
      treated with NOSH-aspirin (100mg/kg/d) or vehicle. After 3 weeks, mice were 
      sacrificed, tumors excised, weighed, and fixed for IHC studies. RESULTS: 
      NOSH-aspirin significantly reduced paw edema as function of time. NOSH-aspirin's 
      IC(50) in nM at 24h for cell growth inhibition ranged from 50±2 to 250±10 in the 
      cancer cell lines and about 400-fold higher in the normal cell lines. The cell 
      growth inhibitory effects were due to a dose-dependent induction of apoptosis and 
      cell cycle arrest (G0/G1), leading to reductions in cell proliferation. In 
      xenografts, NOSH-aspirin had no effect on the weight of the mice. Tumor volume 
      was reduced as a function of treatment time. At sacrifice, tumor mass reductions 
      were colon: 89%, P=0.005; breast: 91%, P=0.006; pancreas: 75%, P=0.0031. Growth 
      inhibition was due to reduced proliferation (decreased PCNA expression), and 
      induction of apoptosis (increased TUNEL positive cells). CONCLUSIONS: 
      NOSH-aspirin is a potent anti-inflammatory, preferentially affecting cancer cells 
      and targets parameters important in determining cellular mass.
CI  - Copyright © 2015. Published by Elsevier B.V.
FAU - Kashfi, Khosrow
AU  - Kashfi K
AD  - City University of New York Medical School, New York, USA.
LA  - eng
PT  - Journal Article
DEP - 20151230
PL  - Netherlands
TA  - Redox Biol
JT  - Redox biology
JID - 101605639
RN  - 0 (4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Disulfides)
RN  - 0 (Nitrates)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Disulfides/*pharmacology
MH  - Humans
MH  - MCF-7 Cells
MH  - Mice
MH  - Neoplasms, Experimental/*drug therapy/metabolism/pathology
MH  - Nitrates/*pharmacology
MH  - Nitric Oxide/*pharmacology
MH  - Rats
MH  - Xenograft Model Antitumor Assays
EDAT- 2015/08/01 00:00
MHDA- 2015/08/01 00:01
CRDT- 2017/02/07 06:00
PHST- 2017/02/07 06:00 [entrez]
PHST- 2015/08/01 00:00 [pubmed]
PHST- 2015/08/01 00:01 [medline]
AID - S2213-2317(15)00141-X [pii]
AID - 10.1016/j.redox.2015.09.030 [doi]
PST - ppublish
SO  - Redox Biol. 2015 Aug;5:420. doi: 10.1016/j.redox.2015.09.030. Epub 2015 Dec 30.

PMID- 7320840
OWN - NLM
STAT- MEDLINE
DCOM- 19820313
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 12
DP  - 1981 Dec
TI  - Physicochemical property modification strategies based on enzyme substrate 
      specificities II: alpha-chymotrypsin hydrolysis of aspirin derivatives.
PG  - 1304-6
AB  - Three aspirin derivatives, aspirin phenylalanine ethyl ester, aspirin 
      phenylalanine amide, and aspirin phenyllactic ethyl ester, were investigated with 
      respect to their hydrolysis by alpha-chymotrypsin. Of the three compounds, 
      aspirin phenylalanine ethyl ester was the best substrate, with kcat = 25 sec-1 
      and Km = 1.3 x 10-6 M at pH 8.0. The results for all substrates were in the range 
      of expectation based on kinetic data for other substrates. The apparent latitude 
      in the nature of the acrylamide substituent of alpha-chymotrypsin substrates 
      makes this enzyme a good potential reconversion site for many drug derivatives.
FAU - Banerjee, P K
AU  - Banerjee PK
FAU - Amidon, G L
AU  - Amidon GL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - EC 3.4.21.1 (Chymotrypsin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/metabolism
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Chymotrypsin/*metabolism
MH  - Hydrolysis
MH  - Kinetics
MH  - Substrate Specificity
OID - NASA: 82100563
EDAT- 1981/12/01 00:00
MHDA- 1981/12/01 00:01
CRDT- 1981/12/01 00:00
PHST- 1981/12/01 00:00 [pubmed]
PHST- 1981/12/01 00:01 [medline]
PHST- 1981/12/01 00:00 [entrez]
AID - S0022-3549(15)43971-1 [pii]
AID - 10.1002/jps.2600701203 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Dec;70(12):1304-6. doi: 10.1002/jps.2600701203.

PMID- 10685133
OWN - NLM
STAT- MEDLINE
DCOM- 20000303
LR  - 20190817
IS  - 0025-7125 (Print)
IS  - 0025-7125 (Linking)
VI  - 84
IP  - 1
DP  - 2000 Jan
TI  - Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic 
      heart disease.
PG  - 163-79, ix
AB  - Antiplatelet and anticoagulant medications play a major role in the secondary 
      prevention of ischemic heart disease. Numerous trials have demonstrated their 
      clinical benefits. Newer agents, such as clopidogrel, have challenged aspirin's 
      role as the premier medication for secondary prevention. Much remains to be 
      learned, however, about the merits of these different drug classes, relative to 
      one another and in combination.
FAU - Bhatt, D L
AU  - Bhatt DL
AD  - Department of Cardiology, Cleveland Clinic Foundation, Ohio, USA.
FAU - Topol, E J
AU  - Topol EJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Med Clin North Am
JT  - The Medical clinics of North America
JID - 2985236R
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Clopidogrel
MH  - Coronary Disease/*prevention & control
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Recurrence
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & derivatives
MH  - Treatment Outcome
RF  - 96
EDAT- 2000/02/24 09:00
MHDA- 2000/03/11 09:00
CRDT- 2000/02/24 09:00
PHST- 2000/02/24 09:00 [pubmed]
PHST- 2000/03/11 09:00 [medline]
PHST- 2000/02/24 09:00 [entrez]
AID - S0025-7125(05)70212-1 [pii]
AID - 10.1016/s0025-7125(05)70212-1 [doi]
PST - ppublish
SO  - Med Clin North Am. 2000 Jan;84(1):163-79, ix. doi: 10.1016/s0025-7125(05)70212-1.

PMID- 7359516
OWN - NLM
STAT- MEDLINE
DCOM- 19800514
LR  - 20190709
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 23
IP  - 1
DP  - 1980 Jan
TI  - Glycerides as prodrugs. 2. 
      1,3-Dialkanoyl-2-(2-methyl-4-oxo-1,3-benzodioxan-2-yl)glycerides (cyclic aspirin 
      triglycerides) as antiinflammatory agents.
PG  - 79-82
AB  - A series of 1,3-dialkanoyl-2-(2-methyl-4-oxo-1,3-benzodioxan-2-yl)glycerides 
      ("cyclic aspirin triglycerides") was synthesized. They demonstrated essentially 
      all the systemic antiinflammatory activity associated with aspirin in the 
      carrageenin-induced rat paw edema test. Examination of the rat stomachs showed 
      that the 1,3-didecanoyl derivative did not cause gastric lesions.
FAU - Paris, G Y
AU  - Paris GY
FAU - Garmaise, D L
AU  - Garmaise DL
FAU - Cimon, D G
AU  - Cimon DG
FAU - Swett, L
AU  - Swett L
FAU - Carter, G W
AU  - Carter GW
FAU - Young, P
AU  - Young P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Salicylates)
RN  - 0 (Triglycerides)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*chemical synthesis
MH  - Aspirin/*analogs & derivatives/chemical synthesis/metabolism/pharmacology
MH  - Carrageenan
MH  - Edema/chemically induced/physiopathology
MH  - Male
MH  - Rats
MH  - Salicylates/blood
MH  - Stomach Ulcer/chemically induced
MH  - Triglycerides/*chemical synthesis/metabolism/pharmacology
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1021/jm00175a015 [doi]
PST - ppublish
SO  - J Med Chem. 1980 Jan;23(1):79-82. doi: 10.1021/jm00175a015.

PMID- 16294543
OWN - NLM
STAT- MEDLINE
DCOM- 20060124
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 98
IP  - 10
DP  - 2005 Oct
TI  - [Intra-individual variability of the platelet anti-aggregation effect of aspirin 
      in coronary patients].
PG  - 979-83
AB  - Several studies have reported a biochemical resistance to aspirin in 5 to 10% of 
      coronary patients. However, the stability of the platelet anti-aggregation effect 
      with aspirin over time remains poorly understood. OBJECTIVE: To study the 
      intra-individual variability at 6 months of the anti-platelet action of aspirin 
      in coronary patients. METHOD: Prospective study including 40 consecutive patients 
      with acute coronary syndrome and taking regular aspirin (250 mg a day). The 
      biochemical impact of aspirin was determined by measuring the time to occlusion 
      (TO) on a collagen/epinephrine cartridge with PFA-100. The determination of the 
      TO was performed 2 months (TO1) and then 8 months (TO2) after starting aspirin. 
      In our population, a resistance to aspirin was defined as a TO < or =125 sec. 
      RESULTS: The median value for TO was generally stable over the two periods, at 
      158 sec for TO1 and 179 sec for TO2 (p = 0.29). Among the 9 initially resistant 
      patients (22.5%), 4 became sensitive to aspirin without changing the dosage, 
      while only one of the 31 initially sensitive patients became biochemically 
      resistant. CONCLUSION: the existence of a medium term intra-individual 
      variability in the antiplatelet response to aspirin in coronary patients 
      underlines the importance of biochemical surveillance in these high vascular risk 
      patients.
FAU - Addad, F
AU  - Addad F
AD  - Service de cardiologie, CHU Fattouma Bourguiba, Tunisie. faouzi.addad@rns.tn
FAU - Hassine, M
AU  - Hassine M
FAU - Ben Farhat, M
AU  - Ben Farhat M
FAU - Abderrazak, F
AU  - Abderrazak F
FAU - Chakroun, T
AU  - Chakroun T
FAU - Gamra, H
AU  - Gamra H
FAU - Hamdi, S
AU  - Hamdi S
FAU - Betbout, F
AU  - Betbout F
FAU - Samama, M
AU  - Samama M
FAU - Elalamy, I
AU  - Elalamy I
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Variabilité intra-individuelle de l'effet antiagrégant plaquettaire de l'aspirine 
      chez le coronarien.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Drug Resistance
MH  - Humans
MH  - Middle Aged
MH  - Observer Variation
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Reproducibility of Results
EDAT- 2005/11/22 09:00
MHDA- 2006/01/25 09:00
CRDT- 2005/11/22 09:00
PHST- 2005/11/22 09:00 [pubmed]
PHST- 2006/01/25 09:00 [medline]
PHST- 2005/11/22 09:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 2005 Oct;98(10):979-83.

PMID- 7524460
OWN - NLM
STAT- MEDLINE
DCOM- 19941110
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 58
IP  - 4
DP  - 1994 Oct
TI  - Aprotinin preserves hemostasis in aspirin-treated patients undergoing 
      cardiopulmonary bypass.
PG  - 1036-9
AB  - Various clinical trials have shown that hemostasis is improved by the 
      administration of aprotinin during cardiopulmonary bypass. However, this effect 
      has not been proved for those patients treated preoperatively with aspirin. 
      Therefore, a double-blind, placebo-controlled study was conducted to test the 
      efficacy of low-dose aprotinin (2 x 10(6) KIU in the pump prime solution) in 
      preserving hemostasis in 40 aspirin-treated (325 mg) patients undergoing coronary 
      artery bypass grafting. Aprotinin brought about a decrease in the postoperative 
      blood loss (p < 0.05). The in vitro bleeding test (Thrombostat) demonstrated that 
      aprotinin preserved the platelet hemostatic function in aspirin-treated patients 
      during cardiopulmonary bypass (p < 0.05). The inhibitory effects of aspirin on 
      collagen-induced platelet aggregation and thromboxane production were not 
      influenced by aprotinin treatment. The findings from the present study indicate 
      that aprotinin preserves hemostasis in aspirin-treated patients during 
      cardiopulmonary bypass, but aspirin's effect on platelets is maintained. 
      Therefore, aprotinin seems to be a useful adjunct treatment in aspirin-treated 
      patients undergoing coronary artery bypass grafting.
FAU - Tabuchi, N
AU  - Tabuchi N
AD  - Thorax Center, University Hospital Groningen, The Netherlands.
FAU - Huet, R C
AU  - Huet RC
FAU - Sturk, A
AU  - Sturk A
FAU - Eijsman, L
AU  - Eijsman L
FAU - Wildevuur, C R
AU  - Wildevuur CR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 54397-85-2 (Thromboxane B2)
RN  - 9087-70-1 (Aprotinin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aprotinin/*pharmacology/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*drug effects/physiology
MH  - *Cardiopulmonary Bypass
MH  - Double-Blind Method
MH  - Hemostasis/*drug effects
MH  - Hemostasis, Surgical
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Thromboxane B2/blood
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 0003-4975(94)90450-2 [pii]
AID - 10.1016/0003-4975(94)90450-2 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1994 Oct;58(4):1036-9. doi: 10.1016/0003-4975(94)90450-2.

PMID- 6531573
OWN - NLM
STAT- MEDLINE
DCOM- 19850508
LR  - 20151119
IS  - 0761-8417 (Print)
IS  - 0761-8417 (Linking)
VI  - 40
IP  - 6
DP  - 1984
TI  - [Indications for the aspirin provocation test in the asthmatic].
PG  - 369-71
AB  - Oral provocation tests using aspirin (n = 55), tartrazine (n = 37) and benzoate 
      (n = 28) were performed in 55 asthmatic patients. A positive aspirin provocation 
      test was observed in 15 patients (27%). These patients often had a past history 
      of aspirin intolerance, 53% of them also had nasal polyposis and 5 out of 12 had 
      associated tartrazine intolerance, while 2 out of 8 had associated benzoate 
      intolerance. The authors consider that these features may help the clinician to 
      detect the asthmatic patient at high risk of aspirin intolerance in whom a 
      provocation test should be performed.
FAU - Michel, O
AU  - Michel O
FAU - Naeije, N
AU  - Naeije N
FAU - Bracamonte, M
AU  - Bracamonte M
FAU - Sergysels, R
AU  - Sergysels R
FAU - Duchateau, J
AU  - Duchateau J
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Indications du test de provocation à l'aspirine chez l'asthmatique.
PL  - France
TA  - Rev Pneumol Clin
JT  - Revue de pneumologie clinique
JID - 8406312
RN  - 0 (Benzoates)
RN  - I753WB2F1M (Tartrazine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Aspirin/adverse effects
MH  - Asthma/*physiopathology
MH  - Benzoates
MH  - Bronchial Provocation Tests/*methods
MH  - Drug Hypersensitivity/*diagnosis
MH  - Female
MH  - Humans
MH  - Lung Volume Measurements
MH  - Male
MH  - Middle Aged
MH  - Tartrazine
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Pneumol Clin. 1984;40(6):369-71.

PMID- 21957617
OWN - NLM
STAT- MEDLINE
DCOM- 20111027
LR  - 20131121
IS  - 0201-7563 (Print)
IS  - 0201-7563 (Linking)
IP  - 4
DP  - 2011 Jul-Aug
TI  - [Thromboelastography as a method for preoperative assessment of hemostasis state 
      in neurosurgical patients on long term aspirin therapy].
PG  - 27-32
AB  - The hemostasis state was assessed by routine tests and TEG in 169 patients on 
      long term aspirin therapy. According to TEG results all the patients were divided 
      into three groups: normo-, hypo- and hypercoagulation. The aspirin therapy was 
      interrupted in normo- and hypercoagulation groups, but the surgery was not 
      postponed. In cases of hypocoagulation the aspirin therapy was also interrupted 
      and the surgery was postponed for 3-5 days until TEG results normalized. Also the 
      frequency of intracranial hemorrhagic complications was analyzed in every group. 
      The results showed that despite the method used the hypocoagulation group had the 
      highest rate of postoperative hemorrhage complications. Thromboelastography 
      enables to assess hemostasis state in neurosurgical patients on long term aspirin 
      therapy promptly and effectively.
FAU - Israelian, L A
AU  - Israelian LA
FAU - Lubnin, A Iu
AU  - Lubnin AIu
FAU - Tseĭtlin, A M
AU  - Tseĭtlin AM
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Anesteziol Reanimatol
JT  - Anesteziologiia i reanimatologiia
JID - 7705399
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Blood Coagulation Disorders/*chemically induced/complications/*diagnosis
MH  - Female
MH  - *Hemostasis
MH  - Humans
MH  - Intracranial Hemorrhages/etiology
MH  - Male
MH  - Middle Aged
MH  - Neurosurgical Procedures
MH  - Perioperative Period
MH  - Postoperative Hemorrhage/etiology
MH  - Thrombelastography/*drug effects
EDAT- 2011/10/01 06:00
MHDA- 2011/10/28 06:00
CRDT- 2011/10/01 06:00
PHST- 2011/10/01 06:00 [entrez]
PHST- 2011/10/01 06:00 [pubmed]
PHST- 2011/10/28 06:00 [medline]
PST - ppublish
SO  - Anesteziol Reanimatol. 2011 Jul-Aug;(4):27-32.

PMID- 7437270
OWN - NLM
STAT- MEDLINE
DCOM- 19810219
LR  - 20190512
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 10 Suppl 2
IP  - Suppl 2
DP  - 1980 Oct
TI  - Clinical pharmacokinetics of salicylates: a re-assessment.
PG  - 285S-290S
AB  - 1 Aspirin is partly hydrolyzed to salicylic acid during absorption. Absorbed 
      aspirin is rapidly hydrolyzed systemically. Salicylic acid elimination kinetics 
      are dependent on drug concentration due to the limited capacity of two major 
      biotransformation pathways: formation of salicyluric acid and of salicylphenolic 
      glucuronide. 2 The time courses of the various pharmacological effects of single 
      doses of aspirin are not directly coincident with the plasma concentrations of 
      either aspirin or salicylic acid but there is reasonably good evidence that the 
      pharmacological effects are related to the concentration of aspirin, salicylic 
      acid, or both. 3 Steady-state plasma salicylate concentrations increase more than 
      proportionally with increasing daily dose; the time required to reach steady 
      state increases with increasing daily dose. Dosage intervals of 8 or even 12 h 
      are usually sufficient to maintain plasma salicylate concentrations in the 
      anti-inflammatory concentration range. Monitoring of plasma salicylate 
      concentrations in this range is facilitated by the relatively small drug 
      concentration fluctuations during a dosing interval at steady-state. 4 Limited 
      data suggest that the pharmacological activity of salicylate is produced by free 
      (unbound) drug. As the plasma protein binding of salicylic acid is 
      concentration-dependent and subject to pronounced interindividual differences, it 
      is preferable, at least in principle, to monitor free rather than total 
      concentrations of salicylate in plasma. Although salicylate concentration in 
      saliva reflects the free rather than total salicylate concentration in plasma or 
      serum, use of saliva for indirect monitoring of plasma salicylate concentrations 
      seems to be impractical for technical reasons.
FAU - Levy, G
AU  - Levy G
LA  - eng
GR  - GM 19568/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Analgesics)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics
MH  - Aspirin/metabolism/pharmacology
MH  - Humans
MH  - Kinetics
MH  - Salicylates/*metabolism
PMC - PMC1430201
EDAT- 1980/10/01 00:00
MHDA- 1980/10/01 00:01
CRDT- 1980/10/01 00:00
PHST- 1980/10/01 00:00 [pubmed]
PHST- 1980/10/01 00:01 [medline]
PHST- 1980/10/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1980.tb01811.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1980 Oct;10 Suppl 2(Suppl 2):285S-290S. doi: 
      10.1111/j.1365-2125.1980.tb01811.x.

PMID- 34983353
OWN - NLM
STAT- MEDLINE
DCOM- 20220728
LR  - 20220728
IS  - 2212-3970 (Electronic)
IS  - 1574-8928 (Linking)
VI  - 17
IP  - 4
DP  - 2022
TI  - The Effect of Acetylsalicylic Acid (Asa) on the Mechanical Properties of Breast 
      Cancer Epithelial Cells.
PG  - 410-415
LID - 10.2174/1574892817666220104094846 [doi]
AB  - BACKGROUND: In most communities, the risk of developing breast cancer is 
      increasing. By affecting the cyclooxygenase 1 and 2 (COX-1 and COX-2) enzymes and 
      actin filaments, acetylsalicylic acid (Aspirin) has been shown to reduce the risk 
      of breast cancer and prevent cell migration in both laboratory and clinical 
      studies. METHODS: The purpose of this study is to determine the mechanical 
      properties of normal and cancerous breast tissue cells, as well as the short-term 
      effect of aspirin on cancer cells. To this end, the mechanical properties and 
      deformation of three cell types were investigated: healthy MCF-10 breast cells, 
      MCF-7 breast cancer cells, and MCF-7 breast cancer cells treated with a 5 μM 
      aspirin solution. Atomic Force Microscopy (AFM) was used to determine the 
      mechanical properties of the cells. Cell deformation was analyzed in all groups, 
      and Young's modulus was calculated using the Hertz model. RESULTS: According to 
      the obtained data, cancer cells deformed at a rate half that of healthy cells. 
      Nonetheless, when aspirin was used, cancer cells deformed similarly to healthy 
      cells. Additionally, healthy cells' Young's modulus was calculated to be 
      approximately three times that of cancer cells, which was placed closer to that 
      of healthy cells by adding aspirin to Young's modulus. CONCLUSION: Cell strength 
      appears to have increased due to aspirin's intervention on actin filaments and 
      cytoskeletons, and the mechanical properties of breast cancer cells have become 
      more similar to those of normal cells. The likelihood of cell migration and 
      metastasis decreases as cell strength increases.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Milani, Dornaz
AU  - Milani D
AD  - Department of Biomedical Engineering, Science and Research Branch, Islamic Azad 
      University, Tehran, Iran.
FAU - Khorramymehr, Siamak
AU  - Khorramymehr S
AD  - Department of Biomedical Engineering, Science and Research Branch, Islamic Azad 
      University, Tehran, Iran.
FAU - Vasaghi-Gharamaleki, Behnoush
AU  - Vasaghi-Gharamaleki B
AD  - Department of Basic Sciences of Rehabilitation, Iran University of Medical 
      Sciences (IUMS), Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Recent Pat Anticancer Drug Discov
JT  - Recent patents on anti-cancer drug discovery
JID - 101266081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - *Breast Neoplasms/drug therapy
MH  - Elastic Modulus
MH  - Epithelial Cells
MH  - Female
MH  - Humans
MH  - Microscopy, Atomic Force
OTO - NOTNLM
OT  - Cell mechanics
OT  - acetylsalicylic acid (ASA)
OT  - atomic force microscopy
OT  - breast cancer
OT  - cancer cell
OT  - cancer drug
EDAT- 2022/01/06 06:00
MHDA- 2022/07/29 06:00
CRDT- 2022/01/05 05:32
PHST- 2021/08/25 00:00 [received]
PHST- 2021/10/31 00:00 [revised]
PHST- 2021/11/24 00:00 [accepted]
PHST- 2022/01/06 06:00 [pubmed]
PHST- 2022/07/29 06:00 [medline]
PHST- 2022/01/05 05:32 [entrez]
AID - PRA-EPUB-119924 [pii]
AID - 10.2174/1574892817666220104094846 [doi]
PST - ppublish
SO  - Recent Pat Anticancer Drug Discov. 2022;17(4):410-415. doi: 
      10.2174/1574892817666220104094846.

PMID- 32238
OWN - NLM
STAT- MEDLINE
DCOM- 19790324
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 30
IP  - 12
DP  - 1978 Dec
TI  - Gastric ulceration and the concentration of salicylate in plasma in rats after 
      administration of 14C-labelled aspirin and its synthetic triglyceride, 
      1,3-dipalmitoyl-2(2'-acetoxy-[14C]carboxylbenzoyl) glycerol.
PG  - 754-8
AB  - Triglycerides containing aspirin in place of one or more fatty acid residues of 
      the molecule have been synthesized. Metabolism of the compound with the labelled 
      (14C) drug residue introduced specifically into the 2-position of the 
      triglyceride is reported. Plasma salicylate concentrations with this synthetic 
      glyceride were determined and compared with those obtained with commercially 
      available aspirin labelled with the 14C-isotope. Both compounds gave a 
      therapeutic concentration of salicylate in the plasma after ingestion. The 
      1,3-di-fatty acyl-2-aspirin glyceride was absorbed through the intestine as 
      2-aspirin monoglyceride, some 20% of which was transported through the 
      thoracic-duct chyle and about 30% through the portal system. Whereas pronounced 
      ulceration of the rat stomach occurred with free aspirin, the above fatty acyl 
      glyceride of aspirin produced no ulceration.
FAU - Kumar, R
AU  - Kumar R
FAU - Billimoria, J D
AU  - Billimoria JD
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Salicylates)
RN  - 0 (Triglycerides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/metabolism/*pharmacology
MH  - Chyle/metabolism
MH  - Male
MH  - Rats
MH  - Salicylates/*blood
MH  - Stomach Ulcer/*chemically induced
MH  - Time Factors
MH  - Triglycerides/pharmacology
EDAT- 1978/12/01 00:00
MHDA- 1978/12/01 00:01
CRDT- 1978/12/01 00:00
PHST- 1978/12/01 00:00 [pubmed]
PHST- 1978/12/01 00:01 [medline]
PHST- 1978/12/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1978.tb13386.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1978 Dec;30(12):754-8. doi: 
      10.1111/j.2042-7158.1978.tb13386.x.

PMID- 37522775
OWN - NLM
STAT- MEDLINE
DCOM- 20230801
LR  - 20230801
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 339
DP  - 2023 Jun
TI  - EVALUATION OF PAIN-KILLING ACTION OF ACETYLSALICYLIC ACID NANOPARTICLES ON 
      THERMAL NOCICEPTION IN MICE.
PG  - 57-61
AB  - Pain is a common experience that can range from mild annoyance to debilitating 
      agony. As such, finding effective ways to relieve pain is a crucial aspect of 
      healthcare. Aspirin, a nonsteroidal anti-inflammatory drug (NSAID), is a commonly 
      used analgesic that works by inhibiting the production of prostaglandins, which 
      are responsible for causing pain. However, the effectiveness of aspirin can be 
      influenced by various factors, including the form in which it is administered. 
      The current study aimed to compare the effects of aspirin's ordinary particles 
      and nanoparticles as an analgesic utilizing the hot plate method in topical 
      formulations (gel, ointment, cream). The study employed 120 albino mice, all 
      males, divided into six groups. In the three groups, aspirin was topically 
      applied using various formulations (gel, cream, and ointment, respectively) and 
      concentrations (0.25, 0.5, and 1%). The same composition and concentration of 
      aspirin nanoparticles were administered to the other three groups. The reaction 
      time was assessed after aspirin was topically applied at 2-, 10-, 20-, 30-, 40-, 
      50- and 60-minute intervals. Extended delay durations in comparison to control 
      values were used to express the ant-nociceptive effects of aspirin. The results 
      of the study showed that aspirin nanoparticles produced the best analgesic 
      impact, followed by the cream and then the ointment, according to the data. This 
      suggests that the form in which aspirin is administered can significantly 
      influence its effectiveness as an analgesic. The use of nanoparticles may 
      increase the bioavailability of aspirin, allowing it to be more efficiently 
      absorbed by the body and produce a more significant analgesic effect. Overall, 
      the study's findings suggest that aspirin nanoparticles may be a more effective 
      form of aspirin for pain relief than ordinary particles. Further research is 
      needed to explore the potential benefits and drawbacks of this form of aspirin 
      and determine its efficacy in human subjects. Nevertheless, the current study 
      provides valuable insights into the factors that can influence the effectiveness 
      of aspirin as an analgesic and may inform future developments in pain management.
FAU - Al-Alsadoon, L
AU  - Al-Alsadoon L
AD  - 1Mosul Technical Institute/Northern Technical University, Iraq.
FAU - Taqa, G
AU  - Taqa G
AD  - 2Dental Basic Sciences Department, College of Dentistry. University of Mosul, 
      Iraq.
FAU - Al-Saffar, M
AU  - Al-Saffar M
AD  - 2Dental Basic Sciences Department, College of Dentistry. University of Mosul, 
      Iraq.
LA  - eng
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Ointments)
SB  - IM
MH  - Mice
MH  - Male
MH  - Animals
MH  - Humans
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Nociception
MH  - Ointments
MH  - Pain/drug therapy
MH  - *Nanoparticles/therapeutic use
EDAT- 2023/07/31 13:07
MHDA- 2023/08/01 06:45
CRDT- 2023/07/31 09:43
PHST- 2023/08/01 06:45 [medline]
PHST- 2023/07/31 13:07 [pubmed]
PHST- 2023/07/31 09:43 [entrez]
PST - ppublish
SO  - Georgian Med News. 2023 Jun;(339):57-61.

PMID- 2234646
OWN - NLM
STAT- MEDLINE
DCOM- 19901204
LR  - 20131121
IS  - 0028-8446 (Print)
IS  - 0028-8446 (Linking)
VI  - 103
IP  - 900
DP  - 1990 Oct 24
TI  - Poor participation of nulliparous women in a low dose aspirin study to prevent 
      preeclampsia.
PG  - 511-2
AB  - Only four of 39 nulliparous women agreed to participate in a placebo controlled 
      study of low dose aspirin therapy to prevent preeclampsia. The major reason for 
      nonparticipation was fear the aspirin would harm the fetus (30 of 35 women). 
      Twenty-four women felt public promotion of a healthy lifestyle influenced their 
      nonparticipation. No woman felt any practical problems related to the study 
      impeded their recruitment and all but one woman felt the study was important and 
      worthwhile. Eleven women considered any drug therapy or research in pregnancy was 
      anathema. As a result of the low response rate a multicentered study was not 
      feasible. Unless new approaches to research are developed, scientific advances in 
      obstetric practice in New Zealand may depend only on research conducted overseas.
FAU - Hutton, J D
AU  - Hutton JD
AD  - Department of Obstetrics and Gynaecology, Wellington School of Medicine.
FAU - Wilkinson, A M
AU  - Wilkinson AM
FAU - Neale, J
AU  - Neale J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - New Zealand
TA  - N Z Med J
JT  - The New Zealand medical journal
JID - 0401067
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Drug Administration Schedule
MH  - Evaluation Studies as Topic
MH  - Fear/physiology
MH  - Female
MH  - Humans
MH  - Parity
MH  - Patient Participation/*psychology
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
EDAT- 1990/10/24 00:00
MHDA- 1990/10/24 00:01
CRDT- 1990/10/24 00:00
PHST- 1990/10/24 00:00 [pubmed]
PHST- 1990/10/24 00:01 [medline]
PHST- 1990/10/24 00:00 [entrez]
PST - ppublish
SO  - N Z Med J. 1990 Oct 24;103(900):511-2.

PMID- 29463423
OWN - NLM
STAT- MEDLINE
DCOM- 20181024
LR  - 20181024
IS  - 1776-2588 (Electronic)
IS  - 0761-8425 (Linking)
VI  - 35
IP  - 2
DP  - 2018 Feb
TI  - [Is celecoxib a safe alternative for the Fernand Widal syndrome?].
PG  - 149-159
LID - S0761-8425(17)31020-3 [pii]
LID - 10.1016/j.rmr.2017.09.007 [doi]
AB  - The Fernand Widal syndrome is a set of associations between asthma, nasal 
      polyposis and aspirin sensitivity. Selective cyclo-oxygenase 2 (COX 2) inhibitors 
      are recognized as being a therapeutic alternative in cases needing analgesic or 
      anti-inflammatory treatment. In a retrospective study, we have compiled data 
      concerning oral provocation tests (OPT) undertaken with celecoxib, one of most 
      the selective COX 2 inhibitors, in eight patients with the Fernand Widal 
      syndrome. They were compared with twenty-seven control patients with sensitivity 
      to aspirin or non-steroidal anti-inflammatories, manifesting as asthma, urticaria 
      or rhino-conjunctivitis. Four patients with the Fernand Widal syndrome developed 
      bronchospasm after taking the usually recommended daily dose of celecoxib while 
      all the control patients tolerated it. The Fernand Widal patients who reacted 
      during the OPT had a lower threshold of reactivity to aspirin, a more severe 
      reaction with aspirin, and/or more severe asthma. In patients with the Fernand 
      Widal syndrome, celecoxib is not always a possible alternative to non-steroidal 
      anti-inflammatory drugs. Its introduction must be carried out in a hospital 
      environment under medical supervision.
CI  - Copyright © 2017 SPLF. Published by Elsevier Masson SAS. All rights reserved.
FAU - Schaller, A
AU  - Schaller A
AD  - Unité d'allergologie, pôle de pathologie thoracique, Nouvel hôpital civil, 1, 
      place de l'Hôpital, 67000, Strasbourg, France. Electronic address: 
      alexandre.schaller@gmail.com.
FAU - Metz-Favre, C
AU  - Metz-Favre C
AD  - Unité d'allergologie, pôle de pathologie thoracique, Nouvel hôpital civil, 1, 
      place de l'Hôpital, 67000, Strasbourg, France.
FAU - Guenard-Bilbaut, L
AU  - Guenard-Bilbaut L
AD  - Unité d'allergologie, pôle de pathologie thoracique, Nouvel hôpital civil, 1, 
      place de l'Hôpital, 67000, Strasbourg, France.
FAU - De Blay, F
AU  - De Blay F
AD  - Unité d'allergologie, pôle de pathologie thoracique, Nouvel hôpital civil, 1, 
      place de l'Hôpital, 67000, Strasbourg, France; EA 3072, fédération de médecine 
      translationnelle, FHU OMICARE, Strasbourg, France.
LA  - fre
PT  - Journal Article
TT  - Célécoxib, une alternative sûre pour les syndromes de Fernand Widal ?
DEP - 20180217
PL  - France
TA  - Rev Mal Respir
JT  - Revue des maladies respiratoires
JID - 8408032
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/complications/diagnosis/*drug therapy
MH  - Case-Control Studies
MH  - Celecoxib/adverse effects/*therapeutic use
MH  - Drug Hypersensitivity/complications/diagnosis/*drug therapy
MH  - Female
MH  - France/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/complications/diagnosis/*drug therapy
MH  - Respiratory Function Tests/methods
MH  - Retrospective Studies
MH  - Syndrome
OTO - NOTNLM
OT  - Aspirin hypersensitivity
OT  - Aspirin-induced asthma
OT  - Celecoxib
OT  - Cyclo-oxygenase 2
OT  - Cyclo-oxygénase 2
OT  - Célécoxib
OT  - Hypersensibilité à l’aspirine
OT  - Oral provocation test
OT  - Syndrome de Fernand Widal
OT  - Test de provocation oral
EDAT- 2018/02/22 06:00
MHDA- 2018/10/26 06:00
CRDT- 2018/02/22 06:00
PHST- 2017/02/14 00:00 [received]
PHST- 2017/09/17 00:00 [accepted]
PHST- 2018/02/22 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
PHST- 2018/02/22 06:00 [entrez]
AID - S0761-8425(17)31020-3 [pii]
AID - 10.1016/j.rmr.2017.09.007 [doi]
PST - ppublish
SO  - Rev Mal Respir. 2018 Feb;35(2):149-159. doi: 10.1016/j.rmr.2017.09.007. Epub 2018 
      Feb 17.

PMID- 15314705
OWN - NLM
STAT- MEDLINE
DCOM- 20041202
LR  - 20191108
IS  - 0720-9355 (Print)
IS  - 0720-9355 (Linking)
VI  - 24
IP  - 3
DP  - 2004 Aug
TI  - [Platelet function tests for monitoring of acetylsalicylic acid: clinical 
      significance in antiplatelet treatment].
PG  - 196-202
AB  - Several studies have demonstrated with the use platelet function tests (PFT) that 
      subgroups of patients under acetylsalicylic acid (ASA) fail to produce the 
      anticipated antiplatelet effect. This phenomenon as well as the clinical failure 
      of ASA to protect patients from thromboembolic complications has been termed ASA 
      resistance (AR) or ASA nonresponsiveness. Several subtypes of AR can be 
      distinguished by PFT. The following PFT were used to characterize AR: optical 
      aggregometry, platelet aggregation in whole blood, platelet function analyzer 
      (PFA-100), platelet reactivity test or platelet aggregate ratio, flow cytometry 
      and thromboxane B(2) generation. All PFT have in common that their widespread 
      clinical use is substantially limited due to complex preanalytic factors, reduced 
      specificity and poor reproducibility. PFT are not interchangeable for monitoring 
      antiplatelet treatment. Three prospective clinical trials revealed a possible 
      relationship between AR and subsequent cardiovascular events. There is a need for 
      a simple and reliable assay for predicting the clinical efficacy of antiplatelet 
      therapy. Recent data demonstrate that none of the currently available assays 
      including the PFA-100 system are capable to accomplish these objectives.
FAU - Haubelt, H
AU  - Haubelt H
AD  - Institut für Hämostaseologie und Transfusionsmedizin, Klinikum der Stadt 
      Ludwigshafen gGmbH, Bremserstrasse 79, 67063 Ludwigshafen.
FAU - Simon, M
AU  - Simon M
FAU - Anders, Ch
AU  - Anders Ch
FAU - Hellstern, P
AU  - Hellstern P
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Plättchenfunktionstests zum Monitoring der Azetylsalizylsäuretherapie acid: 
      Klinische Wertigkeit bei plättchenfunktionshemmender Behandlung.
PL  - Germany
TA  - Hamostaseologie
JT  - Hamostaseologie
JID - 8204531
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacokinetics/pharmacology/therapeutic use
MH  - Drug Monitoring/methods
MH  - Drug Resistance
MH  - Humans
MH  - Monitoring, Physiologic/methods
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/*therapeutic use
MH  - *Platelet Function Tests
RF  - 44
EDAT- 2004/08/18 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/08/18 05:00
PHST- 2004/08/18 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/08/18 05:00 [entrez]
AID - 04030196 [pii]
AID - 10.1267/hamo04030196 [doi]
PST - ppublish
SO  - Hamostaseologie. 2004 Aug;24(3):196-202. doi: 10.1267/hamo04030196.

PMID- 7049782
OWN - NLM
STAT- MEDLINE
DCOM- 19821029
LR  - 20131121
IS  - 0338-1684 (Print)
IS  - 0338-1684 (Linking)
VI  - 8
IP  - 2
DP  - 1982 Jun
TI  - [Controlled clinical trial of the effect of aspirin and aspirin + dipyridamole on 
      the development of diabetic retinopathy. I. General protocol. From the DAMAD 
      Study Group (author's transl)].
PG  - 91-6
AB  - In diabetic patients platelet abnormalities and hemostatic dysfunction have been 
      reported and may play a role on the development of retinopathy. It has been shown 
      that aspirin and dipyridamole modify platelet functions in vitro and in vivo. The 
      aim of this multicenter controlled clinical trial was to investigate the effect 
      of aspirin and aspirin + dipyridamole on the evolution of background retinopathy. 
      In this paper are described the main clinical characteristics of the 450 patients 
      included in the study, the protocol and the major end-points. Patient recruitment 
      started in 1977 and was completed in 1981. Compliance to the protocol is 
      satisfactory, side effects have been minimal and the number of patients lost to 
      follow up is small.
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
TT  - Essai contrôlé de l'aspirine et de l'association aspirine + dipyridamole sur 
      l'évolution de la rétinopathie diabétique I. Protocole général. Groupe d'étude 
      damad.
PL  - France
TA  - Diabete Metab
JT  - Diabete & metabolisme
JID - 7604157
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Blood Platelets/drug effects
MH  - Clinical Trials as Topic
MH  - Diabetic Retinopathy/physiopathology/*prevention & control
MH  - Dipyridamole/*administration & dosage
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Middle Aged
EDAT- 1982/06/01 00:00
MHDA- 2000/03/11 09:00
CRDT- 1982/06/01 00:00
PHST- 1982/06/01 00:00 [pubmed]
PHST- 2000/03/11 09:00 [medline]
PHST- 1982/06/01 00:00 [entrez]
PST - ppublish
SO  - Diabete Metab. 1982 Jun;8(2):91-6.

PMID- 35675970
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20221015
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 198
IP  - 4
DP  - 2022 Aug
TI  - Cytoreductive treatment and association with platelet function and maturity in 
      patients with essential thrombocythaemia.
PG  - 693-702
LID - 10.1111/bjh.18303 [doi]
AB  - Patients with essential thrombocythaemia (ET) have an increased risk of 
      thromboembolic events, which may differ according to different cytoreductive 
      drugs. We investigated the effect of cytoreductive treatment on platelet function 
      and turnover in ET patients. Blood samples were obtained at 1 and 24 h after 
      aspirin intake. Platelet function was evaluated by platelet aggregation and flow 
      cytometry. Platelet turnover was assessed by immature platelet count, immature 
      platelet fraction (IPF) and mean platelet volume (MPV). A total of 47 ET patients 
      were included and grouped into 21 patients not receiving cytoreductive treatment, 
      15 patients receiving hydroxycarbamide and 11 patients receiving pegylated 
      interferon alpha (peg-IFN). Patients receiving peg-IFN had significantly higher 
      IPF and MPV than the other ET groups. Patients not receiving cytoreductive 
      treatment had significantly higher platelet aggregation 24 h after aspirin intake 
      than the other ET groups (p-values from 0.03 to 0.0002). Patients receiving 
      hydroxycarbamide had significantly higher expression of platelet granule makers, 
      P-selectin and CD63, than patients receiving peg-IFN (p-values ≤0.003). 
      Cytoreduction provides more consistent platelet inhibition compared with no 
      cytoreductive treatment. Moreover, peg-IFN provides superior inhibition of 
      platelet activation markers than hydroxycarbamide, which in part may explain 
      differences in risk of thromboembolic events in ET patients.
CI  - © 2022 The Authors. British Journal of Haematology published by British Society 
      for Haematology and John Wiley & Sons Ltd.
FAU - Pedersen, Oliver Buchhave
AU  - Pedersen OB
AUID- ORCID: 0000-0002-7437-270X
AD  - Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, 
      Aarhus University Hospital, Aarhus, Denmark.
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Grove, Erik Lerkevang
AU  - Grove EL
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, 
      Denmark.
FAU - Pasalic, Leonardo
AU  - Pasalic L
AD  - Institute of Clinical Pathology and Medical Research and the Departments of 
      Clinical and Laboratory Haematology, Westmead Hospital, Sydney, Australia.
AD  - Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, 
      Sydney, Australia.
FAU - Ommen, Hans Beier
AU  - Ommen HB
AD  - Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Kristensen, Steen Dalby
AU  - Kristensen SD
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, 
      Denmark.
FAU - Hvas, Anne-Mette
AU  - Hvas AM
AD  - Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, 
      Aarhus University Hospital, Aarhus, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, 
      Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220608
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - R16CO5Y76E (Aspirin)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/metabolism
MH  - Humans
MH  - Hydroxyurea/therapeutic use
MH  - Platelet Aggregation
MH  - Platelet Function Tests
MH  - *Thrombocythemia, Essential
PMC - PMC9540443
OTO - NOTNLM
OT  - essential thrombocythaemia
OT  - hydroxycarbamide
OT  - interferon-alpha
OT  - platelet activation
OT  - platelet function
COIS- None related to this manuscript. The authors report the following general 
      conflicts: Erik Lerkevang Grove has received speaker honoraria or consultancy 
      fees from Alexion Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Myers 
      Squibb, Lundbeck Pharma, Pfizer, MSD, Mundipharma, Organon, and Portola 
      Pharmaceuticals. He is an investigator in studies sponsored by AstraZeneca and 
      Bayer, and has received unrestricted research grants from Boehringer Ingelheim. 
      Anne‐Mette Hvas has received speaker's fees from CSL Behring, Bayer, 
      Boehringer‐Ingelheim, Bristol‐Myers Squibb and Leo Pharma and unrestricted 
      research support from Octapharma, and CSL Behring. Oliver Buchhave Pedersen, Hans 
      Beier Ommen, Leonardo Pasalic, and Steen Dalby Kristensen have no conflicts of 
      interest to declare.
EDAT- 2022/06/09 06:00
MHDA- 2022/08/10 06:00
CRDT- 2022/06/08 20:53
PHST- 2022/05/21 00:00 [revised]
PHST- 2022/03/17 00:00 [received]
PHST- 2022/05/26 00:00 [accepted]
PHST- 2022/06/09 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2022/06/08 20:53 [entrez]
AID - BJH18303 [pii]
AID - 10.1111/bjh.18303 [doi]
PST - ppublish
SO  - Br J Haematol. 2022 Aug;198(4):693-702. doi: 10.1111/bjh.18303. Epub 2022 Jun 8.

PMID- 6761186
OWN - NLM
STAT- MEDLINE
DCOM- 19830407
LR  - 20131121
IS  - 0338-1684 (Print)
IS  - 0338-1684 (Linking)
VI  - 8
IP  - 4
DP  - 1982 Dec
TI  - [Controlled clinical trial of the effect of aspirin and aspirin + dipyridamole on 
      the development of diabetic retinopathy. II. Ophthalmologic protocol].
PG  - 307-11
AB  - A description is given of the ophthalmological protocol of the DAMAD (aspirin and 
      dipyridamole + Aspirin) controlled clinical trial in diabetic retinopathy. The 
      450 patients included in this trial were insulin or noninsulin treated diabetics 
      with an early diabetic retinopathy (i.e. at least five microaneurysms in the 
      posterior pole and/or one zone of capillary non-perfusion). They were randomized 
      in a double blind fashion to treatment with either placebo or aspirin 330 mg or 
      aspirin 330 mg + dipyridamole 75 mg three times daily. A full ophthalmologic 
      examination was performed annually on both eyes of each patient and followed at 
      least three years. Data were recorded on a special form. The main assessment 
      criteria were orientated toward the quantification of the retinal vascular 
      micro-abnormalities, counting of microaneurysm and measurement of the central and 
      peripheral avascular zones. Angiofluorographic photographs were standardized. The 
      two eyes were photographed but only one reference eye was kept for the whole 
      length of this study. A standard reading technique is now used by a technician in 
      charge of coding the quality of the films, the dotting and numbering of the 
      lesions.
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
TT  - Essai contrôlé de l'aspirine et de l'association aspirine + dipyridamole sur 
      l'évolution de la rétinopathie diabétique. II. Protocole ophtalmologique.
PL  - France
TA  - Diabete Metab
JT  - Diabete & metabolisme
JID - 7604157
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Diabetic Retinopathy/diagnosis/*drug therapy
MH  - Dipyridamole/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Fluorescein Angiography
MH  - Humans
EDAT- 1982/12/01 00:00
MHDA- 2000/03/11 09:00
CRDT- 1982/12/01 00:00
PHST- 1982/12/01 00:00 [pubmed]
PHST- 2000/03/11 09:00 [medline]
PHST- 1982/12/01 00:00 [entrez]
PST - ppublish
SO  - Diabete Metab. 1982 Dec;8(4):307-11.

PMID- 485008
OWN - NLM
STAT- MEDLINE
DCOM- 19791128
LR  - 20131121
IS  - 0003-438X (Print)
IS  - 0003-438X (Linking)
VI  - 96
IP  - 4-5
DP  - 1979 Apr-May
TI  - [Nasosinusal polyposis and aspirin intolerance. Fernand Widal-Lermoyez syndrome].
PG  - 229-39
AB  - The authors describe the clinical picture of the aspirin idiosyncrasy and propose 
      to call this peculiar entity: syndrom of Widal and Lermoyez. They compare 25 
      cases of aspirin nasal polyposis with 26 other cases of various etiologies. Other 
      substances than aspirin seem to be charged. The complications are regular with 
      severe asthma and infection. The pathogenesis is discussed, excluding an allergic 
      mechanism; it remain not quite clear. Essentially prophylactic, the treatment is 
      poor and difficult.
FAU - Wayoff, M
AU  - Wayoff M
FAU - Moneret-Vautrin, D
AU  - Moneret-Vautrin D
FAU - Gazel, P
AU  - Gazel P
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Polypose naso-sinusienne et maladie à l'aspirine. Syndrome de Fernand Widal et 
      Lermoyez.
PL  - France
TA  - Ann Otolaryngol Chir Cervicofac
JT  - Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la 
      Societe d'oto-laryngologie des hopitaux de Paris
JID - 9431026
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/pharmacology
MH  - Asthma/etiology
MH  - Diagnosis, Differential
MH  - Drug Hypersensitivity/*complications/diagnosis
MH  - Female
MH  - Humans
MH  - Male
MH  - Nasal Polyps/*etiology/pathology
MH  - Paranasal Sinus Neoplasms/*etiology/pathology
MH  - Syndrome
EDAT- 1979/04/01 00:00
MHDA- 1979/04/01 00:01
CRDT- 1979/04/01 00:00
PHST- 1979/04/01 00:00 [pubmed]
PHST- 1979/04/01 00:01 [medline]
PHST- 1979/04/01 00:00 [entrez]
PST - ppublish
SO  - Ann Otolaryngol Chir Cervicofac. 1979 Apr-May;96(4-5):229-39.

PMID- 33684129
OWN - NLM
STAT- MEDLINE
DCOM- 20210825
LR  - 20210825
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 16
IP  - 3
DP  - 2021
TI  - NMR spectroscopy reveals acetylsalicylic acid metabolites in the human urine for 
      drug compliance monitoring.
PG  - e0247102
LID - 10.1371/journal.pone.0247102 [doi]
LID - e0247102
AB  - Cardiovascular disease is the leading cause of morbidity and mortality worldwide. 
      Long-term use of antiplatelet drugs is a well-studied therapy for the prevention 
      of cardiovascular death. Ensuring compliance with lifelong administration of 
      antiplatelet drugs, in particular acetylsalicylic acid, is one of the challenges 
      of such therapy. The aim of this study is to explore the possibility of using 
      nuclear magnetic resonance spectroscopy to identify acetylsalicylic acid 
      metabolites in urine and to search for characteristic markers that could be used 
      to detect patient compliance with long-term acetylsalicylic acid treatment.
FAU - Kupriyanova, Galina
AU  - Kupriyanova G
AD  - Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
FAU - Rafalskiy, Vladimir
AU  - Rafalskiy V
AUID- ORCID: 0000-0002-2503-9580
AD  - Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
FAU - Mershiev, Ivan
AU  - Mershiev I
AD  - Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
FAU - Moiseeva, Ekaterina
AU  - Moiseeva E
AD  - Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210308
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*metabolism/therapeutic use/*urine
MH  - Humans
MH  - *Magnetic Resonance Spectroscopy
MH  - Medication Adherence/*statistics & numerical data
PMC - PMC7939264
COIS- NO authors have competing interests.
EDAT- 2021/03/09 06:00
MHDA- 2021/08/26 06:00
CRDT- 2021/03/08 17:09
PHST- 2020/04/29 00:00 [received]
PHST- 2021/02/02 00:00 [accepted]
PHST- 2021/03/08 17:09 [entrez]
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/08/26 06:00 [medline]
AID - PONE-D-20-12512 [pii]
AID - 10.1371/journal.pone.0247102 [doi]
PST - epublish
SO  - PLoS One. 2021 Mar 8;16(3):e0247102. doi: 10.1371/journal.pone.0247102. 
      eCollection 2021.

PMID- 8669801
OWN - NLM
STAT- MEDLINE
DCOM- 19960806
LR  - 20131121
IS  - 0003-3928 (Print)
IS  - 0003-3928 (Linking)
VI  - 44
IP  - 8
DP  - 1995 Oct
TI  - [What dose of aspirin should be prescribed in patients with coronary disease?].
PG  - 469-72
AB  - Aspirin is prescribed in almost all coronary patients. However, the prescription 
      modalities tend to vary, partly because of the absence of phase II development of 
      this molecule as an antithrombotic agent in coronary patients. The dose of 162.5 
      mg has been shown to be effective during the acute phase of myocardial 
      infarction, but we do not know whether this is the most effective dose. A higher 
      dose, in particular 500 mg to 1 g, would have the advantage of more rapidly and 
      more completely blocking platelets during an acute thrombotic phase. After this 
      first high dose, lower doses, less than 100 mg, could be administered in the long 
      term. These low doses of aspirin, generally 75 mg, have been demonstrated, in 
      stable angina, to decrease infarction and sudden death by more than 30%. This 
      dose has also been demonstrated to be effective in the long-term in unstable 
      angina, but once again this low dose should be introduced after an initial higher 
      dose for this acute coronary syndrome. A primary prevention study is currently 
      underway using the dose of 75 mg per day following the trial in American 
      physicians using a dose of 320 mg every second day. Long-term low doses have a 
      clearly demonstrated efficacy in chronic prevention and have the advantage of 
      inducing much fewer adverse effects, particularly gastrointestinal haemorrhage. 
      In conclusion, a high initial dose should be recommended in acute coronary 
      syndromes and a low dose, less than 100 mg, should be recommended for chronic 
      prevention. Buffered forms, protecting the stomach, and sustained-release forms 
      are impatiently awaited to further improve the benefit/risk ratio of aspirin, 
      which is nevertheless already excellent.
FAU - Montalescot, G
AU  - Montalescot G
AD  - Service de Cardiologie, Hôpital Pitié-Salpêtrière, Paris.
FAU - Drobinski, G
AU  - Drobinski G
FAU - Thomas, D
AU  - Thomas D
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Quelle dose d'aspirine faut-il prescrire chez les coronariens?
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects/pharmacology
MH  - Blood Platelets/enzymology
MH  - Coronary Disease/*drug therapy
MH  - Cyclooxygenase Inhibitors/*administration & dosage/adverse effects/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Risk Factors
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 1995 Oct;44(8):469-72.

PMID- 34162040
OWN - NLM
STAT- MEDLINE
DCOM- 20211230
LR  - 20211230
IS  - 2768-6698 (Electronic)
IS  - 2768-6698 (Linking)
VI  - 26
IP  - 6
DP  - 2021 May 30
TI  - Acetylsalicylic acid improves cognitive performance in sleep deprived adult 
      Zebrafish (Danio rerio) model.
PG  - 114-124
LID - 10.52586/4928 [doi]
AB  - Sleep deprivation (SD) is commonly associated with decreased attention, reduced 
      responsiveness to external stimuli, and impaired locomotor and cognitive 
      performances. Strong evidence indicates that SD disrupts neuro-immuno-endocrine 
      system which is also linked to cognitive function. Recently Zebrafish have 
      emerged as a powerful model sharing organizational and functional characteristics 
      with other vertebrates, providing great translational relevance with rapid and 
      reliable screening results. In the current study, we examined the effects of 
      acetylsalicylic acid (aspirin) on cognitive and locomotor activity in sleep 
      deprived Zebrafish model. Learning and memory were assessed by T-maze and 
      locomotor activity was assessed by partition preference and swimming time in 
      spinning tasks. Furthermore, brain bioavailability of aspirin was determined by 
      high performance liquid chromatography. Following drug exposure and tasks, 
      histopathology of the brain was performed. It was observed that three-day SD 
      significantly reduces learning and memory and locomotion in the Zebrafish. 
      Aspirin was found to restore SD induced cognitive decline and improve the 
      locomotor functions. Neuro-inflammation and impaired functional network 
      connectivity is linked to cognitive defects, which implicate the possible 
      benefits of immunotherapeutics. In the present study, aspirin decreased 
      neutrophil infiltration, and increased spine density in dentate gyrus granular 
      and shrinkage and basophil in the CA1 neurons of hippocampus. This hints the 
      benefit of aspirin on neuroimmune functions in sleep deprived fish and warrants 
      more studies to establish the clear molecular mechanism behind this protective 
      effect.
CI  - © 2021 The Author(s). Published by BRI.
FAU - Bishir, Muhammed
AU  - Bishir M
AD  - Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher 
      Education & Research, 570015 Mysuru, India.
FAU - Aslam, Muhammed
AU  - Aslam M
AD  - Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher 
      Education & Research, 570015 Mysuru, India.
FAU - Bhat, Abid
AU  - Bhat A
AD  - Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher 
      Education & Research, 570015 Mysuru, India.
AD  - Centre for Experimental Pharmacology & Toxicology, Central Animal Facility, JSS 
      Academy of Higher Education & Research, 570015 Mysuru, India.
FAU - Ray, Bipul
AU  - Ray B
AD  - Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher 
      Education & Research, 570015 Mysuru, India.
AD  - Centre for Experimental Pharmacology & Toxicology, Central Animal Facility, JSS 
      Academy of Higher Education & Research, 570015 Mysuru, India.
FAU - Elumalai, Preetham
AU  - Elumalai P
AD  - Department of Processing Technology (Biochemistry), Kerala University of 
      Fisheries and Ocean Studies, Panangad, 682506 Kochi, Kerala, India.
FAU - R, Jyothi Priya
AU  - R JP
AD  - Regional Research and Educational Centre, Tamil Nadu Veterinary and Animal 
      Sciences University, 622004 Pudukkottai, India.
FAU - Rashan, Luay
AU  - Rashan L
AD  - Biodiversity Research Centre, Dohfar University, 211 Salalah, Sultanate of Oman.
FAU - Yang, Jian
AU  - Yang J
AD  - College of Pharmacy and Nutrition, University of Saskatchewan, 107, Wiggins Road, 
      Saskatoon, SK S7N 5C9, Canada.
FAU - Chang, Sulie L
AU  - Chang SL
AD  - Department of Biological Sciences and Institute of Neuroimmune Pharmacology, 
      Seton Hall University, 400 South Orange Ave South Orange, NJ 07079, USA.
FAU - Essa, Musthafa Mohamed
AU  - Essa MM
AD  - Department of Food Science and Nutrition, CAMS, Sultan Qaboos University, 123 
      Muscat, Oman.
AD  - Ageing and Dementia Research Group, Sultan Qaboos University, 123 Muscat, Oman.
FAU - Sakharkar, Meena Kishore
AU  - Sakharkar MK
AD  - College of Pharmacy and Nutrition, University of Saskatchewan, 107, Wiggins Road, 
      Saskatoon, SK S7N 5C9, Canada.
FAU - Chidambaram, Saravana Babu
AU  - Chidambaram SB
AD  - Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher 
      Education & Research, 570015 Mysuru, India.
AD  - Centre for Experimental Pharmacology & Toxicology, Central Animal Facility, JSS 
      Academy of Higher Education & Research, 570015 Mysuru, India.
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - Front Biosci (Landmark Ed)
JT  - Frontiers in bioscience (Landmark edition)
JID - 101612996
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacokinetics/*pharmacology/toxicity
MH  - Biological Availability
MH  - Cognition/*drug effects
MH  - Male
MH  - *Sleep Deprivation
MH  - Swimming
MH  - Toxicity Tests, Acute
MH  - Zebrafish
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Cognition
OT  - Neuro-immune
OT  - Sleep deprivation
OT  - Spinning task
OT  - Tmaze
OT  - Zebrafish
EDAT- 2021/06/24 06:00
MHDA- 2021/12/31 06:00
CRDT- 2021/06/23 21:09
PHST- 2021/01/03 00:00 [received]
PHST- 2021/02/15 00:00 [accepted]
PHST- 2021/06/23 21:09 [entrez]
PHST- 2021/06/24 06:00 [pubmed]
PHST- 2021/12/31 06:00 [medline]
AID - s1093-9946(21)04612-9 [pii]
AID - 10.52586/4928 [doi]
PST - ppublish
SO  - Front Biosci (Landmark Ed). 2021 May 30;26(6):114-124. doi: 10.52586/4928.

PMID- 3715789
OWN - NLM
STAT- MEDLINE
DCOM- 19860714
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 55
IP  - 2
DP  - 1986 Apr 30
TI  - Peripheral venous plasma aspirin concentrations and platelet aggregation 
      inhibition produced by enteric-coated aspirin formulations.
PG  - 222-7
AB  - In a random cross-over design, six healthy consenting adult volunteers were given 
      on separate occasions single doses of 300-650 mg of 3 different formulations of 
      enteric-coated aspirin. Over various intervals for 48-54 h following dosage, 
      plasma aspirin and salicylate concentrations were measured together with 
      percentage inhibition of platelet aggregation activated by threshold 
      concentrations of sodium arachidonate alone and combined with ADP and collagen. 
      In all subjects each formulation delivered measurable quantities of aspirin to 
      the peripheral circulation, the unchanged drug being detected at various times up 
      to and including 28 h after dosage. Moreover, low aspirin concentrations were 
      found to co-exist with unimpaired platelet aggregation. All 3 formulations 
      yielded statistically significant (P less than 0.01) inhibition of platelet 
      aggregation activated both by arachidonate and by the combination of aggregants 
      when tested 24-29 and 48-54 h after dosage; there were no significant differences 
      (P greater than 0.05) between the 3 formulations in this regard. Two different 
      patterns of delivery of unchanged aspirin to the systemic circulation from these 
      enteric-coated formulations were apparent. These patterns may be important when 
      considering which aspirin formulation might be most appropriate in chronic use 
      for an antiplatelet effect. None of the enteric-coated formulations used in this 
      study may be optimal in this regard.
FAU - Brandon, R A
AU  - Brandon RA
FAU - Emmett, J A
AU  - Emmett JA
FAU - Eadie, M J
AU  - Eadie MJ
FAU - Curran, A C
AU  - Curran AC
FAU - Bunce, I H
AU  - Bunce IH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Arachidonic Acids)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Administration, Oral
MH  - Adult
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Collagen/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Tablets, Enteric-Coated
MH  - Time Factors
EDAT- 1986/04/30 00:00
MHDA- 1986/04/30 00:01
CRDT- 1986/04/30 00:00
PHST- 1986/04/30 00:00 [pubmed]
PHST- 1986/04/30 00:01 [medline]
PHST- 1986/04/30 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1986 Apr 30;55(2):222-7.

PMID- 11878097
OWN - NLM
STAT- MEDLINE
DCOM- 20020424
LR  - 20131121
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 56
IP  - 6
DP  - 2001 Nov-Dec
TI  - [The saga of aspirin: centuries-old ancestors of an old lady who doesn't deserve 
      to die].
PG  - 723-6
AB  - Where do analgics come from? If their ancestors are many centuries old, we 
      observe that the four main drugs of modern analgesia, morphine (1816), codeine 
      (1832), paracetamol (1893) and aspirin (1897) were discovered during the 19th 
      century. And through what 'sagas'! The first known prescriptions, written on 
      earthenware shelves in Mesopotamia 3 centuries BC, already mentioned medications 
      derived from willow to cure headaches. The Greeks dedicated to Asclepios, god of 
      therapeutics, a statue carved in a willow trunk as a symbol! Thus, before 
      becoming a drug, aspirin was born from the willow, which grows with its feet in 
      water 'without suffering', as the ancestors put it. But before it walked on the 
      moon with Neil Armstrong in 1969, the discovery of aspirin as a drug was the 
      consequence of the filial love of a young researcher, Felix Hoffmann, who wanted 
      to decrease the resistant pain of his rheumatic old father.
FAU - Queneau, P
AU  - Queneau P
AD  - Service de Médecine Interne, CHU Hôpital de Bellevue, 42055 Saint-Etienne, 
      France.
LA  - fre
PT  - English Abstract
PT  - Historical Article
PT  - Journal Article
TT  - La 'saga' de l'aspirine: des ancêtres multimillénaires pour une vieille dame 
      indigne ... de mourir.
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*history/therapeutic use
MH  - History, 19th Century
MH  - History, Ancient
MH  - Humans
MH  - Pain/drug therapy/history
MH  - Plants, Medicinal
EDAT- 2002/03/07 10:00
MHDA- 2002/04/25 10:01
CRDT- 2002/03/07 10:00
PHST- 2002/03/07 10:00 [pubmed]
PHST- 2002/04/25 10:01 [medline]
PHST- 2002/03/07 10:00 [entrez]
PST - ppublish
SO  - Therapie. 2001 Nov-Dec;56(6):723-6.

PMID- 12865240
OWN - NLM
STAT- MEDLINE
DCOM- 20040128
LR  - 20131121
IS  - 1000-2588 (Print)
IS  - 1000-2588 (Linking)
VI  - 23
IP  - 7
DP  - 2003 Jul
TI  - Determination of free salicylic acid in chewing aspirin tablets by HPLC.
PG  - 744-7
AB  - OBJECTIVE: To establish a HPLC method for determining the content of free 
      salicylic acid in chewing aspirin tablets. METHOD: The determination was 
      conducted on a HPLC column (C(18), 150 mm x 4.6 mm x 5 microm) with 
      methanol-water-glacial acetic acid (8.0 5.5 1.0) as the mobile phase and the 
      detection wavelength of 302 nm. RESULTS: The calibration curve was linear within 
      the concentration range of 2.65 to 31.77 microg/ml (r=0.999 97) of salicylic 
      acid. The average recovery rate was 100.21% with relative standard deviation of 
      0.53% (n=6). CONCLUSION: HPLC is quick and accurate of determining the content of 
      free salicylic acid for chewing aspirin tablets.
FAU - Tian, Jun
AU  - Tian J
AD  - Department of Pharmacy, General Navy Hospital of PLA, Beijing 100037, China.
FAU - Chen, Xin-shan
AU  - Chen XS
FAU - Wang, Rui-dong
AU  - Wang RD
LA  - eng
PT  - Journal Article
PL  - China
TA  - Di Yi Jun Yi Da Xue Xue Bao
JT  - Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
JID - 9426110
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*analysis/chemistry
MH  - Chromatography, High Pressure Liquid
MH  - Drug Stability
MH  - Mastication
MH  - Salicylic Acid/*analysis
MH  - Tablets
EDAT- 2003/07/17 05:00
MHDA- 2004/01/30 05:00
CRDT- 2003/07/17 05:00
PHST- 2003/07/17 05:00 [pubmed]
PHST- 2004/01/30 05:00 [medline]
PHST- 2003/07/17 05:00 [entrez]
PST - ppublish
SO  - Di Yi Jun Yi Da Xue Xue Bao. 2003 Jul;23(7):744-7.

PMID- 35762565
OWN - NLM
STAT- MEDLINE
DCOM- 20221111
LR  - 20221208
IS  - 1936-086X (Electronic)
IS  - 1936-0851 (Linking)
VI  - 16
IP  - 7
DP  - 2022 Jul 26
TI  - Turning Hot into Cold: Immune Microenvironment Reshaping for Atherosclerosis 
      Attenuation Based on pH-Responsive shSiglec-1 Delivery System.
PG  - 10517-10533
LID - 10.1021/acsnano.2c01778 [doi]
AB  - Current atherosclerosis treatment is based on a combination of 
      cholesterol-lowering medication and low-fat diets; however, the clinical effect 
      is unsatisfactory. It has been shown that the level of immune cell infiltration 
      and pro-inflammatory factors in the atherosclerotic immune microenvironment (AIM) 
      play important roles in the development and progression of atherosclerosis. 
      Therefore, we hypothesized that reshaping "hot AIM" into "cold AIM" could 
      attenuate atherosclerosis. For this purpose, we designed a pH-responsive and 
      charge-reversible nanosystem, referred to as 
      Au-PEI/shSiglec-1/PEI-acetylsalicylic acid (ASPA NPs) to effectively deliver 
      shSiglec-1, which blocked the interactions between macrophages with CD8(+) T/NKT 
      cells, thus inhibiting immune cell infiltration. Further, we demonstrated that 
      acetylsalicylic acid (ASA), detached from the pH-responsive PEI-ASA polymer, and 
      inhibited lipid accumulation in macrophage, thereby decreasing the lipid antigen 
      presentation. Additionally, reduced macrophage-produced inflammatory factors by 
      ASA and low CD8(+) T/NKT cell infiltration levels synergistically inhibit Th17 
      cell differentiation, thus further dramatically attenuating inflammation in AIM 
      by decreasing the IL-17A production. Eventually, ASPA NPs efficiently reshaped 
      AIM by inhibiting immune cell infiltration, lipid antigen presentation, and 
      pro-inflammation, which provided a feasible therapeutic strategy for 
      atherosclerosis immunotherapy.
FAU - Zhou, Yue
AU  - Zhou Y
AD  - Tianjin Key Laboratory of Drug Delivery and High-Efficiency, School of 
      Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
FAU - Wang, Siyu
AU  - Wang S
AD  - Tianjin Key Laboratory of Drug Delivery and High-Efficiency, School of 
      Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
FAU - Liang, Xiaoyang
AU  - Liang X
AD  - Tianjin Key Laboratory of Drug Delivery and High-Efficiency, School of 
      Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
FAU - Heger, Zbynek
AU  - Heger Z
AD  - Department of Chemistry and Biochemistry, Mendel University in Brno, CZ-61300 
      Brno, Czech Republic.
AD  - Central European Institute of Technology, Brno University of Technology, 
      Purkynova 123, CZ-61200 Brno, Czech Republic.
FAU - Xu, Min
AU  - Xu M
AD  - Tianjin Key Laboratory of Drug Delivery and High-Efficiency, School of 
      Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
FAU - Lu, Qiang
AU  - Lu Q
AD  - Tianjin Key Laboratory of Drug Delivery and High-Efficiency, School of 
      Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
FAU - Yu, Meng
AU  - Yu M
AUID- ORCID: 0000-0003-1039-9687
AD  - School of Pharmaceutical Science Guangdong Provincial Key Laboratory of New Drug 
      Screening, Southern Medical University, Guangzhou 510515, China.
FAU - Adam, Vojtech
AU  - Adam V
AUID- ORCID: 0000-0002-8527-286X
AD  - Department of Chemistry and Biochemistry, Mendel University in Brno, CZ-61300 
      Brno, Czech Republic.
AD  - Central European Institute of Technology, Brno University of Technology, 
      Purkynova 123, CZ-61200 Brno, Czech Republic.
FAU - Li, Nan
AU  - Li N
AD  - Tianjin Key Laboratory of Drug Delivery and High-Efficiency, School of 
      Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220628
PL  - United States
TA  - ACS Nano
JT  - ACS nano
JID - 101313589
RN  - 0 (Lipids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Atherosclerosis/drug therapy
MH  - Inflammation
MH  - Lipids
MH  - Hydrogen-Ion Concentration
MH  - Aspirin/pharmacology/therapeutic use
OTO - NOTNLM
OT  - antigen presentation
OT  - atherosclerosis
OT  - atherosclerotic immune microenvironment reshaping
OT  - immune cell recruitment
OT  - shSiglec-1
EDAT- 2022/06/29 06:00
MHDA- 2022/11/15 06:00
CRDT- 2022/06/28 07:44
PHST- 2022/06/29 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/06/28 07:44 [entrez]
AID - 10.1021/acsnano.2c01778 [doi]
PST - ppublish
SO  - ACS Nano. 2022 Jul 26;16(7):10517-10533. doi: 10.1021/acsnano.2c01778. Epub 2022 
      Jun 28.

PMID- 20601992
OWN - NLM
STAT- MEDLINE
DCOM- 20101129
LR  - 20131121
IS  - 1364-548X (Electronic)
IS  - 1359-7345 (Linking)
VI  - 46
IP  - 32
DP  - 2010 Aug 28
TI  - Selective binding and release of aspirin by an encapsulating receptor.
PG  - 5921-3
LID - 10.1039/c0cc00422g [doi]
AB  - The selective binding of aspirin deep inside superbowl synthetic hosts is 
      reported. Evidence for a two-point binding mode of the drug by the host is 
      presented. Both the strength of aspirin binding and the rate of its release are 
      manipulated by altering the substituents about the host's aperture.
FAU - Nguyen, Thanh V
AU  - Nguyen TV
AD  - ARC Centre of Excellence for Free Radical Chemistry and Biotechnology, Research 
      School of Chemistry, Australian National University, Canberra, ACT 0200, 
      Australia.
FAU - Yoshida, Hiroshi
AU  - Yoshida H
FAU - Sherburn, Michael S
AU  - Sherburn MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100705
PL  - England
TA  - Chem Commun (Camb)
JT  - Chemical communications (Cambridge, England)
JID - 9610838
RN  - 0 (Drug Carriers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*chemistry
MH  - Crystallography, X-Ray
MH  - Drug Carriers/chemistry
MH  - Hydrogen Bonding
MH  - Molecular Conformation
EDAT- 2010/07/06 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/07/06 06:00
PHST- 2010/07/06 06:00 [entrez]
PHST- 2010/07/06 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.1039/c0cc00422g [doi]
PST - ppublish
SO  - Chem Commun (Camb). 2010 Aug 28;46(32):5921-3. doi: 10.1039/c0cc00422g. Epub 2010 
      Jul 5.

PMID- 319424
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20131121
IS  - 0301-1518 (Print)
IS  - 0301-1518 (Linking)
VI  - 6
IP  - 4
DP  - 1977 Jan 29
TI  - [Reduction of the effects of indomethacin by aspirin. Value of measurement of the 
      articular index and sigma ESR].
PG  - 255-8
AB  - Two groups, A and B, were selected at random amongst a total of 31 patients 
      suffering from chronic inflammatory rheumatic disorders. The patients in group A 
      (n = 16) received succesively: Placebo (2d), Indomethacin (5d). Indomethacin + 
      aspirin (5d). The order of the 5 day treatment periods was reversed for the 
      patients in group b (n = 15). The daily dose of indomethacin was 150 mg. That of 
      aspirin was 1500 mg. Four parameters were measured at the end of each period of 
      treatment: total serum indomethacin, articular index (Ritchie), ESR (Westergren) 
      and the sigma ESR - a new technique for the measurement of sedimentation rate. No 
      conclusions could be drawn from the analysis of variations in ESR. Concordant and 
      statistically significnat variations in articular index and the sigma ESR showed 
      a reduction in the activity of indomethacin under the influence of aspirin. The 
      inhibitory effect of aspirin. The inhibitory effect of aspirin continues after 
      the drug stopped. This reduction in indomethacin activity is not related to a 
      decrease in serum concentrations of the medication which are not significantly 
      altered when aspirin is taken.
FAU - Pawlotsky, Y
AU  - Pawlotsky Y
FAU - Durand, B
AU  - Durand B
FAU - Delbary, A
AU  - Delbary A
FAU - Le Treut, A
AU  - Le Treut A
FAU - Catheline, M
AU  - Catheline M
FAU - Bourel, M
AU  - Bourel M
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Réduction de l'activité de l'indométacine par l'aspirine. Intérêt des mesures de 
      l'indice articulaire et de la Sigma VS.
PL  - France
TA  - Nouv Presse Med
JT  - La Nouvelle presse medicale
JID - 0312552
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - *Blood Sedimentation
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hematocrit
MH  - Humans
MH  - Indomethacin/administration & dosage/*antagonists & inhibitors/blood/therapeutic 
      use
MH  - Male
MH  - Middle Aged
MH  - Pain
MH  - Placebos
MH  - Rheumatic Diseases/*drug therapy
MH  - Time Factors
EDAT- 1977/01/29 00:00
MHDA- 1977/01/29 00:01
CRDT- 1977/01/29 00:00
PHST- 1977/01/29 00:00 [pubmed]
PHST- 1977/01/29 00:01 [medline]
PHST- 1977/01/29 00:00 [entrez]
PST - ppublish
SO  - Nouv Presse Med. 1977 Jan 29;6(4):255-8.

PMID- 12134590
OWN - NLM
STAT- MEDLINE
DCOM- 20020826
LR  - 20190901
IS  - 0750-7658 (Print)
IS  - 0750-7658 (Linking)
VI  - 21
IP  - 6
DP  - 2002 Jun
TI  - [Does the time between preoperative interruption of aspirin intake and operation 
      influence postoperative blood loss and transfusion requirement in coronary artery 
      bypass graft?].
PG  - 458-63
AB  - OBJECTIVE: Impact of the interval between interruption of aspirin intake and 
      surgery on postoperative bleeding and transfusion in coronary artery bypass graft 
      (CABG), with extracorporeal circulation (ECC). STUDY DESIGN: Retrospective study. 
      PATIENTS AND METHODS: Four hundred and twelve patients having undergone CABG were 
      retrospectively reviewed. Three groups were evaluated according to the length of 
      the interval defined above: Group I (< 3 days), Group II (3-7 days), Group III (> 
      7 days or without aspirin intake). Postoperative blood loss at 3rd, 6th, 12th, 
      and 24th hour and transfusion requirements were assessed for the 3 groups. 
      Aprotinin (low dose, 2 M KIU) was systematically included in the priming of the 
      ECC circuit. RESULTS: There were no significant differences among groups for 
      weight, size, duration of ECC, and number of bypasses. No significant correlation 
      was noted among the 3 groups for postoperative blood loss and transfusion. 
      Multivariate analysis showed that factors associated to a higher risk of 
      excessive bleeding were ECC duration and number of arterial grafts. Factors 
      associated with a higher risk of transfusion were: emergency, minimum patient 
      temperature during ECC, weight and preoperative haemoglobin level. Aspirine 
      intake was not associated with an increase of bleeding or transfusion. 
      CONCLUSION: Our study showed that in our practice using systematic low dose of 
      aprotinin when priming the ECC circuit, aspirin did not significantly increase 
      bleeding or transfusion requirements in CABG with ECC, whatever the interval 
      between interruption of aspirin intake and surgery. Consequently, in our 
      practice, aspirin intake is interrupted on hospitalisation, one day before 
      surgery.
FAU - Chavanon, O
AU  - Chavanon O
AD  - Service de chirurgie cardiaque, CHU Grenoble, 38043 Grenoble, France. 
      ochavanon@wanadoo.fr
FAU - Durand, M
AU  - Durand M
FAU - Romain-Sorin, V
AU  - Romain-Sorin V
FAU - Noirclerc, M
AU  - Noirclerc M
FAU - Cracowski, J L
AU  - Cracowski JL
FAU - Protar, D
AU  - Protar D
FAU - Abdennadher, M
AU  - Abdennadher M
FAU - Blin, D
AU  - Blin D
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - L'intervalle entre l'arrêt préopératoire de l'aspirine et l'intervention 
      chirurgicale a-t-il une influence sur le saignement et la transfusion en 
      chirurgie coronaire?
PL  - France
TA  - Ann Fr Anesth Reanim
JT  - Annales francaises d'anesthesie et de reanimation
JID - 8213275
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood Transfusion
MH  - Body Temperature
MH  - *Coronary Artery Bypass
MH  - Emergency Medical Services
MH  - Extracorporeal Circulation
MH  - Female
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Hemorrhage/chemically induced/*epidemiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
EDAT- 2002/07/24 10:00
MHDA- 2002/08/27 10:01
CRDT- 2002/07/24 10:00
PHST- 2002/07/24 10:00 [pubmed]
PHST- 2002/08/27 10:01 [medline]
PHST- 2002/07/24 10:00 [entrez]
AID - S0750-7658(02)00656-1 [pii]
AID - 10.1016/s0750-7658(02)00656-1 [doi]
PST - ppublish
SO  - Ann Fr Anesth Reanim. 2002 Jun;21(6):458-63. doi: 10.1016/s0750-7658(02)00656-1.

PMID- 21688846
OWN - NLM
STAT- MEDLINE
DCOM- 20111007
LR  - 20131121
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 54
IP  - 15
DP  - 2011 Aug 11
TI  - New nitric oxide or hydrogen sulfide releasing aspirins.
PG  - 5478-84
LID - 10.1021/jm2004514 [doi]
AB  - A new series of (((R-oxy)carbonyl)oxy)methyl esters of aspirin (ASA), bearing 
      nitric oxide (NO) or hydrogen sulfide (H(2)S) releasing groups, was synthesized, 
      and the compounds were evaluated as new ASA co-drugs. All the products were quite 
      stable in buffered solution at pH 1 and 7.4. Conversely, they were all rapidly 
      metabolized, producing ASA and the NO/H(2)S releasing moiety used for their 
      preparation. Consequent on ASA release, the compounds were capable of inhibiting 
      collagen-induced platelet aggregation of human platelet-rich plasma (PRP). The 
      simple NO/H(2)S donor substructures were able to relax contracted rat aorta 
      strips, with a NO- and H(2)S-dependent mechanism, respectively, but they either 
      did not trigger antiaggregatory activity or displayed antiplatelet potency 
      markedly below that of the related co-drug. The new products might provide a 
      safer and improved alternative to the use of ASA principally in its 
      anti-inflammatory and antithrombotic applications.
FAU - Lazzarato, Loretta
AU  - Lazzarato L
AD  - Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di 
      Torino, Torino, Italy.
FAU - Chegaev, Konstantin
AU  - Chegaev K
FAU - Marini, Elisabetta
AU  - Marini E
FAU - Rolando, Barbara
AU  - Rolando B
FAU - Borretto, Emily
AU  - Borretto E
FAU - Guglielmo, Stefano
AU  - Guglielmo S
FAU - Joseph, Sony
AU  - Joseph S
FAU - Di Stilo, Antonella
AU  - Di Stilo A
FAU - Fruttero, Roberta
AU  - Fruttero R
FAU - Gasco, Alberto
AU  - Gasco A
LA  - eng
PT  - Journal Article
DEP - 20110706
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/chemical synthesis
MH  - Aorta, Thoracic/drug effects
MH  - Aspirin/*analogs & derivatives/chemical synthesis/pharmacology
MH  - Humans
MH  - Hydrogen Sulfide/*metabolism
MH  - Male
MH  - Muscle Relaxation/drug effects
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Donors/chemical synthesis/pharmacology
MH  - Platelet Aggregation Inhibitors/chemical synthesis
MH  - Rats
MH  - Rats, Wistar
MH  - Vasodilator Agents/chemical synthesis/pharmacology
EDAT- 2011/06/22 06:00
MHDA- 2011/10/08 06:00
CRDT- 2011/06/22 06:00
PHST- 2011/06/22 06:00 [entrez]
PHST- 2011/06/22 06:00 [pubmed]
PHST- 2011/10/08 06:00 [medline]
AID - 10.1021/jm2004514 [doi]
PST - ppublish
SO  - J Med Chem. 2011 Aug 11;54(15):5478-84. doi: 10.1021/jm2004514. Epub 2011 Jul 6.

PMID- 18845080
OWN - NLM
STAT- MEDLINE
DCOM- 20100408
LR  - 20131121
IS  - 1007-8738 (Print)
IS  - 1007-8738 (Linking)
VI  - 24
IP  - 10
DP  - 2008 Oct
TI  - [The effect of aspirin on human's gammadeltaT cells killing digestive system 
      tumor cell lines].
PG  - 966-8
AB  - AIM: To explore the effect of aspirin on human's gammadeltaT cells killing 
      digestive system tumor cell lines. METHODS: Use the isopentenyl pyrophosphate 
      method to amplify human peripheral blood gammadeltaT cells in vitro. Various 
      concentrations of aspirin were used to induce gammadeltaT cells and digestive 
      system tumor cells SGC-7901, SW-1990, SW-480, SW-1116, LOVO cells lines, LDH 
      assays was used to measure the cytotoxic activity of gammadeltaT cells, flow 
      cytometry analysis the apoptosis percentage of before and after induced 
      gammadeltaT cells and SGC-7901, SW-1990, SW-480, SW-1116, LOVO cell lines. 
      RESULTS: gammadeltaT cells were cultivated for ten days which proliferation ratio 
      increase from 4.21% to 70.35%. When gammadeltaT cells induced via aspirin 
      concentrations rang from 0.4 mmol/L to 0.8 mmol/L which cytotoxic activity on the 
      five kinds of tumor cell lines was the highest, if aspirin's concentration 
      surpassing 3.2 mmol/L, cytotoxic activity of gammadeltaT cells present decrease 
      tendency. SGC-7901, SW-1990, SW-480, SW-1116, LOVO cells lines were induced by 
      different concentrations of aspirin for 24 hours, just SW-480, SW-1116 and LOVO 
      were enhanced as far as the cytotoxic activity of gammadeltaT cells on these cell 
      lines was concerned, other groups and control group have no notable changed. The 
      apoptosis percentage of gammadeltaT cells(52.71%) were induced by aspirin which 
      concentration was 3.2 mmol/L, which was strikingly higher than SGC-7901, SW-1990, 
      SW-480, SW-1116, LOVO cells lines, (respectively 7.88%, 8.89%, 6.21%, 4.47% and 
      3.67%). CONCLUSION: When aspirin's concentration for clinical routine used can 
      enhance the effect of gammadeltaT cells killing the tumor cells, if surpassing 
      this concentration can obvious inhibited the proliferation capacity and cytotoxic 
      activity of gammadeltaT cells and augment apoptosis ratio, however, it is not 
      obvious for digestive tract tumor lines.
FAU - Liu, Jun-Quan
AU  - Liu JQ
AD  - Department of Central Laboratory, 97 th Hospital of PLA, Xuzhou 221004, China.
FAU - Chen, Fu-Xing
AU  - Chen FX
FAU - Zhu, Bin
AU  - Zhu B
FAU - Zhang, Song
AU  - Zhang S
FAU - Zhang, Juan
AU  - Zhang J
FAU - Tao, Zheng-Zhong
AU  - Tao ZZ
FAU - Li, Yi
AU  - Li Y
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
JT  - Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular 
      immunology
JID - 101139110
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Aspirin/*pharmacology
MH  - Cell Line, Tumor
MH  - Digestive System Neoplasms/*drug therapy/*immunology
MH  - Flow Cytometry
MH  - Humans
MH  - T-Lymphocytes/*drug effects/*immunology
EDAT- 2008/10/11 09:00
MHDA- 2010/04/09 06:00
CRDT- 2008/10/11 09:00
PHST- 2008/10/11 09:00 [pubmed]
PHST- 2010/04/09 06:00 [medline]
PHST- 2008/10/11 09:00 [entrez]
PST - ppublish
SO  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008 Oct;24(10):966-8.

PMID- 30507306
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20200701
IS  - 1478-6427 (Electronic)
IS  - 1478-6419 (Linking)
VI  - 34
IP  - 11
DP  - 2020 Jun
TI  - In vitro cytotoxicity evaluation of thiourea derivatives bearing Salix sp. 
      constituent against HK-1 cell lines.
PG  - 1505-1514
LID - 10.1080/14786419.2018.1517120 [doi]
AB  - In searching for drugs from natural product scaffolds has gained interest among 
      researchers. In this study, a series of twelve halogenated thiourea (ATX 1-12) 
      via chemical modification of aspirin (a natural product derivative) and evaluated 
      for cytotoxic activity against nasopharyngeal carcinoma (NPC) cell lines, HK-1 
      via MTS-based colorimetric assay. The cytotoxicity studies demonstrated that 
      halogens at meta position of ATX showed promising activity against HK-1 cells 
      (IC(50) value ≤15 µM) in comparison to cisplatin, a positive cytotoxic drug 
      (IC(50) value =8.9 ± 1.9 µM). ATX 11, bearing iodine at meta position, showed 
      robust cytotoxicity against HK-1 cells with an IC(50) value of 4.7 ± 0.7 µM. 
      Molecular docking interactions between ATX 11 and cyclooxygenase-2 demonstrated a 
      robust binding affinity value of -8.1 kcal/mol as compared to aspirin's binding 
      affinity value of -6.4 kcal/mol. The findings represent a promising lead molecule 
      from natural product with excellent cytotoxic activity against NPC cell lines.
FAU - Nordin, Norsyafikah Asyilla
AU  - Nordin NA
AD  - Faculty of Pharmacy, Universiti Sultan Zainal Abidin, Besut Campus, Terengganu, 
      Malaysia.
AD  - Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, Sarawak, 
      Malaysia.
FAU - Lawai, Vannessa
AU  - Lawai V
AD  - Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, Sarawak, 
      Malaysia.
FAU - Ngaini, Zainab
AU  - Ngaini Z
AD  - Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, Sarawak, 
      Malaysia.
FAU - Abd Halim, Ainaa Nadiah
AU  - Abd Halim AN
AD  - Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, Sarawak, 
      Malaysia.
FAU - Hwang, Siaw San
AU  - Hwang SS
AD  - Faculty of Engineering, Computing and Science, Swinburne University of Technology 
      Sarawak Campus, Sarawak, Malaysia.
FAU - Linton, Reagan Entigu
AU  - Linton RE
AD  - Faculty of Engineering, Computing and Science, Swinburne University of Technology 
      Sarawak Campus, Sarawak, Malaysia.
FAU - Lee, Boon Kiat
AU  - Lee BK
AD  - Faculty of Engineering, Computing and Science, Swinburne University of Technology 
      Sarawak Campus, Sarawak, Malaysia.
FAU - Neilsen, Paul Matthew
AU  - Neilsen PM
AD  - School of Health Medical and Applied Sciences, Central Queensland University, 
      Norman Gardens, Australia.
LA  - eng
PT  - Journal Article
DEP - 20181203
PL  - England
TA  - Nat Prod Res
JT  - Natural product research
JID - 101167924
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Halogens)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - GYV9AM2QAG (Thiourea)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Aspirin/analogs & derivatives/metabolism
MH  - Cell Line, Tumor
MH  - Cyclooxygenase 2/metabolism
MH  - Halogens/chemistry
MH  - Humans
MH  - Molecular Docking Simulation
MH  - Molecular Structure
MH  - Protein Binding
MH  - Salix/chemistry
MH  - Structure-Activity Relationship
MH  - Thiourea/analogs & derivatives/metabolism/*toxicity
OTO - NOTNLM
OT  - Aspirin
OT  - cyclooxygenase-2
OT  - cytotoxicity
OT  - molecular docking
OT  - thiourea
EDAT- 2018/12/07 06:00
MHDA- 2020/07/02 06:00
CRDT- 2018/12/04 06:00
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
PHST- 2018/12/04 06:00 [entrez]
AID - 10.1080/14786419.2018.1517120 [doi]
PST - ppublish
SO  - Nat Prod Res. 2020 Jun;34(11):1505-1514. doi: 10.1080/14786419.2018.1517120. Epub 
      2018 Dec 3.

PMID- 9309270
OWN - NLM
STAT- MEDLINE
DCOM- 19971020
LR  - 20131121
IS  - 0369-8114 (Print)
IS  - 0369-8114 (Linking)
VI  - 45
IP  - 6
DP  - 1997 Jun
TI  - [Comparison between effects of morning and evening administration of effervescent 
      calcium carbasalate (equivalent of 160 mg aspirin) on the gastroduodenal mucosa 
      in healthy volunteers].
PG  - 514-20
AB  - The aim of this randomised, cross-over trial was to compare the gastroduodenal 
      tolerability and anti-aggregating effect of effervescent calcium carbasalate (ECC 
      equivalent to 160 mg aspirin) given once daily either in the morning or in the 
      evening. Twelve healthy volunteers received calcium carbasalate for 2 periods of 
      5 days (21 days of wash-out between the 2 periods). The principal criterion was 
      the gastroduodenal tolerability assessed by the total number of lesions at upper 
      gastro-intestinal endoscopy. The same treatment-blinded endoscopist performed all 
      evaluations. Efficacy was evaluated by thromboxane B2 measurement and 
      collagen-induced platelet aggregation tests. No difference was observed between 
      morning and evening administration of ECC on gastroduodenal tolerability and 
      platelet agregation. ECC was very well tolerated as assessed by upper 
      gastrointestinal endoscopy and almost totally inhibited platelet aggregation.
FAU - Berlin, I
AU  - Berlin I
AD  - Service de pharmacologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
FAU - Decroix, D
AU  - Decroix D
FAU - Molinier, P
AU  - Molinier P
FAU - Herrmann, M A
AU  - Herrmann MA
FAU - Peraudeau, P
AU  - Peraudeau P
FAU - Scheck, F
AU  - Scheck F
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Comparaison de l'effet de la prise matinale et vespérale du carbasalate calcique 
      effervescent (equivalent a 160 mg d'aspirine) sur la muqueuse gastroduodénale 
      chez le volontaire sain.
PL  - France
TA  - Pathol Biol (Paris)
JT  - Pathologie-biologie
JID - 0265365
RN  - 0 (Analgesics)
RN  - 0 (Salicylates)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 8W8T17847W (Urea)
RN  - N667F17JP1 (carbaspirin calcium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analgesics/*administration & dosage/adverse effects/*pharmacology
MH  - Aspirin/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacology
MH  - Chronobiology Phenomena
MH  - Cross-Over Studies
MH  - Drug Tolerance
MH  - Duodenum/*drug effects
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Healthy Worker Effect
MH  - Humans
MH  - Intestinal Mucosa/*drug effects
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Salicylates/blood
MH  - Thromboxane B2/blood
MH  - Urea/administration & dosage/adverse effects/*analogs & derivatives/pharmacology
MH  - Volunteers
EDAT- 1997/06/01 00:00
MHDA- 1997/10/06 00:01
CRDT- 1997/06/01 00:00
PHST- 1997/06/01 00:00 [pubmed]
PHST- 1997/10/06 00:01 [medline]
PHST- 1997/06/01 00:00 [entrez]
PST - ppublish
SO  - Pathol Biol (Paris). 1997 Jun;45(6):514-20.

PMID- 6228913
OWN - NLM
STAT- MEDLINE
DCOM- 19840224
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 12
IP  - 48
DP  - 1983 Dec 29
TI  - [Controlled cooperative trial of secondary prevention of cerebral ischemic 
      accidents caused by atherosclerosis, using aspirin and dipyridamole].
PG  - 3049-57
AB  - Six hundred and four patients with atherothrombotic cerebral ischemic events 
      (transient: 16% or completed: 84%) referable either to the carotid or to the 
      vertebral-basilar circulation were entered into a double blind randomized 
      clinical trial (AICLA) to determine whether aspirin (A) (1 g/day) or aspirin (1 
      g) + dipyridamole (225 mg) (AD) would produce a significant reduction in the 
      subsequent (3 years) occurrence of fatal and non fatal cerebral infarction. 
      Randomization produced remarkably comparable treatment groups and this good 
      comparability was maintained throughout the study. Adherence to the protocol and 
      drug compliance were excellent. Side effects, particularly peptic ulcers and 
      bleedings of various origin, were significantly (p less than 0.03) more frequent 
      in the two treatment groups containing aspirin. At the end of the study (3 
      years), the number of fatal and non fatal cerebral infarction was 31 in the P 
      group (placebo), 17 in the A group and 18 in the AD group. Taking into account 
      the duration of follow up for each patient, these figures correspond to cumulate 
      rates of 18% in the P group and 10.5% in the 2 others. Analysis with the Mantel 
      Method showed: a difference at the 6% level between the 3 groups and between P 
      and AD; a difference at the 5% level between P and A; no difference between A and 
      AD; a difference at the 2% level between the P group and the two treated groups 
      taken together (A + AD).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Bousser, M G
AU  - Bousser MG
FAU - Eschwège, E
AU  - Eschwège E
FAU - Haguenau, M
AU  - Haguenau M
FAU - Lefauconnier, J M
AU  - Lefauconnier JM
FAU - Thibult, N
AU  - Thibult N
FAU - Touboul, D
AU  - Touboul D
FAU - Touboul, P J
AU  - Touboul PJ
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Essai coopératif contrôlé de prévention secondaire des accidents ischémiques 
      cérébraux liés à l'athérosclérose par l'aspirine et le dipyridamole.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Drug Combinations)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arteriosclerosis/complications
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cerebrovascular Disorders/etiology/mortality/*prevention & control
MH  - Clinical Trials as Topic
MH  - Dipyridamole/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
EDAT- 1983/12/29 00:00
MHDA- 1983/12/29 00:01
CRDT- 1983/12/29 00:00
PHST- 1983/12/29 00:00 [pubmed]
PHST- 1983/12/29 00:01 [medline]
PHST- 1983/12/29 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1983 Dec 29;12(48):3049-57.

PMID- 30895834
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20200916
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 31
IP  - 2
DP  - 2020
TI  - Effect of acetylsalicylic acid intake on platelet derived microvesicles in 
      healthy subjects.
PG  - 206-214
LID - 10.1080/09537104.2019.1588242 [doi]
AB  - Platelet-derived microvesicles (pMVs) are released from platelets in 
      physiological and pathological conditions and exhibit a wide range of 
      prothrombotic, antithrombotic, proatherogenic, and pro-inflammatory properties. 
      Antiplatelet agents, such as acetylsalicylic acid (ASA), are widely used for the 
      prevention and treatment of vascular diseases, but their impact on pMV release 
      remains poorly understood and contradictory mainly because of discrepancies in 
      the methodology and lack of well-standardized MV assessment protocols. The 
      present study investigated the effects of ASA not only on total pMV release but 
      also on their phenotypes defined using the surface expression of pro-inflammatory 
      (CD40L, CD62P, CD31) and procoagulant (PS, PAC-1) markers in healthy subjects. 
      Fifty healthy volunteers were enrolled in the study and received a daily dose of 
      150 mg ASA for 3 consecutive days. Circulating pMVs were characterized and 
      quantified before and after the intervention period using flow cytometry. Serum 
      levels of thromboxane B2 (TXB2) and whole blood impedance platelet aggregation 
      under arachidonic acid (AA) stimulation were also investigated to assess ASA 
      compliance. In general, ASA did not effect pMV numbers in healthy subjects 
      despite its effective inhibition of platelet aggregation Moreover, in 
      premenopausal women, we noticed an increase in the number of pMVs. Further 
      studies are needed to assess whether dose modification of ASA or combinations or 
      changes in antiplatelet therapy would reduce pMV formation, especially in 
      patients with cardiovascular risk factors.
FAU - Rosinska, Justyna
AU  - Rosinska J
AUID- ORCID: 0000-0001-5918-0120
AD  - Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
FAU - Maciejewska, Joanna
AU  - Maciejewska J
AD  - Laboratory of Flow Cytometry and Vascular Biology, Department of Neurology, 
      Poznan University of Medical Sciences, Poznan, Poland.
FAU - Narożny, Robert
AU  - Narożny R
AD  - Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
FAU - Osztynowicz, Krystyna
AU  - Osztynowicz K
AD  - Department of Neurochemistry and Neuropathology, Poznan University of Medical 
      Sciences, Poznan, Poland.
FAU - Raczak, Beata
AU  - Raczak B
AD  - Department of Neurochemistry and Neuropathology, Poznan University of Medical 
      Sciences, Poznan, Poland.
FAU - Michalak, Sławomir
AU  - Michalak S
AD  - Department of Neurochemistry and Neuropathology, Poznan University of Medical 
      Sciences, Poznan, Poland.
FAU - Watała, Cezary
AU  - Watała C
AD  - Department of Haemostasis and Haemostatic Disorders, Medical University, Lodz, 
      Poland.
FAU - Kozubski, Wojciech
AU  - Kozubski W
AD  - Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
FAU - Łukasik, Maria
AU  - Łukasik M
AD  - Laboratory of Flow Cytometry and Vascular Biology, Department of Neurology, 
      Poznan University of Medical Sciences, Poznan, Poland.
LA  - eng
PT  - Journal Article
DEP - 20190321
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cell-Derived Microparticles/*drug effects
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - antiplatelet therapy
OT  - microvesicles
OT  - platelet-derived microvesicles
OT  - platelets
EDAT- 2019/03/22 06:00
MHDA- 2020/09/17 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2019/03/22 06:00 [entrez]
AID - 10.1080/09537104.2019.1588242 [doi]
PST - ppublish
SO  - Platelets. 2020;31(2):206-214. doi: 10.1080/09537104.2019.1588242. Epub 2019 Mar 
      21.

PMID- 1277469
OWN - NLM
STAT- MEDLINE
DCOM- 19760823
LR  - 20190722
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 22
IP  - 6
DP  - 1976 Jun
TI  - Assessment of interference by aspirin with some assays commonly done in the 
      clinical laboratory.
PG  - 837-42
AB  - We have assessed the interference of acetylsalicylic acid (aspirin) with some 
      common clinical laboratory assays, because of its widespread use and reported 
      interference. The therapeutic regimens involved ingestion of 10 325-mg tablets 
      daily for three days or eight tablets for five days or two weeks. Twenty-one 
      commonly done determinations were run on control sera, and sera were collected 
      during and after drug therapy. Significant changes in t-test values, indicating 
      the significance of the standard deviation of the difference between controls and 
      specimens drawn after drug therapy, were observed for chloride (increased), and 
      for total protein, calcium, cholesterol, uric acid, bilirubin, and thyroxine 
      (decreased). Aspirin therapy depressed the apparent concentrations of these 
      constituents progressively in the three-day regimen and initially in the 
      long-term regimens, followed by recovery toward zero t-values at the end of the 
      longer regimens.
FAU - Routh, J I
AU  - Routh JI
FAU - Paul, W D
AU  - Paul WD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*blood/therapeutic use
MH  - *Blood Chemical Analysis
MH  - Dose-Response Relationship, Drug
MH  - False Negative Reactions
MH  - False Positive Reactions
MH  - Humans
MH  - Time Factors
EDAT- 1976/06/01 00:00
MHDA- 1976/06/01 00:01
CRDT- 1976/06/01 00:00
PHST- 1976/06/01 00:00 [pubmed]
PHST- 1976/06/01 00:01 [medline]
PHST- 1976/06/01 00:00 [entrez]
PST - ppublish
SO  - Clin Chem. 1976 Jun;22(6):837-42.

PMID- 23450139
OWN - NLM
STAT- MEDLINE
DCOM- 20130910
LR  - 20131121
IS  - 1364-548X (Electronic)
IS  - 1359-7345 (Linking)
VI  - 49
IP  - 28
DP  - 2013 Apr 11
TI  - Making bispirin: synthesis, structure and activity against Helicobacter pylori of 
      bismuth(III) acetylsalicylate.
PG  - 2870-2
LID - 10.1039/c3cc40645h [doi]
AB  - Reaction of Bi(O(t)Bu)3 with aspirin (acetylsalicylic acid = aspH) in dry toluene 
      results in the bismuth(III) complex, [Bi(O2C(C6H4)OAc)3]∞ 1 (O2C(C6H4)OAc = asp), 
      minimum inhibitory concentration (MIC) against Helicobacter pylori ≥ 6.25 μg 
      mL(-1), while the inclusion of a stoichiometric equivalent of KO(t)Bu leads to 
      crystals of the bismuthate salt [KBi(O2C(C6H4)OAc)4]∞ 2.
FAU - Andrews, Philip C
AU  - Andrews PC
AD  - School of Chemistry, Monash University, Clayton, Melbourne, VIC 3800, Australia. 
      phil.andrews@monash.edu
FAU - Blair, Victoria L
AU  - Blair VL
FAU - Ferrero, Richard L
AU  - Ferrero RL
FAU - Junk, Peter C
AU  - Junk PC
FAU - Kumar, Ish
AU  - Kumar I
LA  - eng
PT  - Journal Article
PL  - England
TA  - Chem Commun (Camb)
JT  - Chemical communications (Cambridge, England)
JID - 9610838
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Coordination Complexes)
RN  - 0 (Organometallic Compounds)
RN  - 0 (bismuth(III) acetylsalicylate)
RN  - R16CO5Y76E (Aspirin)
RN  - U015TT5I8H (Bismuth)
SB  - IM
MH  - Anti-Bacterial Agents/*chemical synthesis/chemistry/*pharmacology
MH  - Aspirin/*analogs & derivatives/chemical synthesis/*chemistry/pharmacology
MH  - Bismuth/*chemistry
MH  - Chemistry Techniques, Synthetic
MH  - Coordination Complexes/*chemical synthesis/chemistry/*pharmacology
MH  - Helicobacter pylori/*drug effects
MH  - Microbial Sensitivity Tests
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Organometallic Compounds/*chemical synthesis/chemistry/*pharmacology
MH  - Structure-Activity Relationship
EDAT- 2013/03/02 06:00
MHDA- 2013/09/11 06:00
CRDT- 2013/03/02 06:00
PHST- 2013/03/02 06:00 [entrez]
PHST- 2013/03/02 06:00 [pubmed]
PHST- 2013/09/11 06:00 [medline]
AID - 10.1039/c3cc40645h [doi]
PST - ppublish
SO  - Chem Commun (Camb). 2013 Apr 11;49(28):2870-2. doi: 10.1039/c3cc40645h.

PMID- 29028441
OWN - NLM
STAT- MEDLINE
DCOM- 20180810
LR  - 20180810
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 96
IP  - 2
DP  - 2018 Feb
TI  - Physiological and pharmacological inductors of HSP70 enhance the antioxidative 
      defense mechanisms of the liver and pancreas in diabetic rats.
PG  - 158-164
LID - 10.1139/cjpp-2017-0394 [doi]
AB  - Heat preconditioning (HP) is a powerful adaptive and protective phenomenon and 
      the heat stress proteins (HSPs) it produces are an important determinant for the 
      development of diabetic complications. Aspirin has been reported to modulate heat 
      shock response in different organisms through increased induction of HSPs and is 
      also known to exert antioxidative and radical scavenging effects in diabetes. We 
      estimated the effect of physiological (heat stress: 45 min at 41 ± 0.5 °C) and 
      pharmacological (aspirin treatment) induction of HSP70 on several parameters of 
      oxidative state in the pancreas and liver of diabetic rats. Diabetes increased 
      HSP70 level and decreased poly(ADP) ribose polymerase (PARP), glutathione (GSH), 
      and glutathione peroxidase (GPx) activities in the pancreas. In the liver, there 
      was reduction of HSP70 level, GSH concentration, and CAT activity, while GPx and 
      GR activity were enhanced. HP of diabetic rats caused an additional increase of 
      HSP70, GSH, and antioxidant enzymes in both organs. Pre-treatment of HP-diabetic 
      animals with aspirin led to an additional increase of PARP and HSP70. Both HP and 
      aspirin, as physiological and pharmacological inductors of HSP70, respectively, 
      enhanced the antioxidative defense mechanisms of the liver and pancreas in 
      diabetic rats.
FAU - Dimitrovska, Maja
AU  - Dimitrovska M
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
FAU - Dervisevik, Mirsada
AU  - Dervisevik M
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
FAU - Cipanovska, Natasa
AU  - Cipanovska N
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
FAU - Gerazova, Katerina
AU  - Gerazova K
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
FAU - Dinevska-Kjovkarovska, Suzana
AU  - Dinevska-Kjovkarovska S
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
FAU - Miova, Biljana
AU  - Miova B
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
AD  - Department of Experimental Physiology and Biochemistry, Institute of Biology, 
      Faculty of Natural Sciences and Mathematics, University "St Cyril and Methodius", 
      Skopje, R. Macedonia.
LA  - eng
PT  - Journal Article
DEP - 20171013
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Antioxidants)
RN  - 0 (HSP70 Heat-Shock Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antioxidants/*metabolism
MH  - Aspirin/pharmacology
MH  - Body Temperature/drug effects
MH  - Diabetes Mellitus, Experimental/*metabolism
MH  - HSP70 Heat-Shock Proteins/*metabolism
MH  - Heat-Shock Response/drug effects
MH  - Liver/drug effects/*metabolism
MH  - Male
MH  - Pancreas/drug effects/*metabolism
MH  - Rats, Wistar
OTO - NOTNLM
OT  - HSP70
OT  - aspirin
OT  - aspirine
OT  - diabète expérimental
OT  - experimental diabetes
OT  - heat preconditioning
OT  - oxidative status
OT  - préconditionnement thermique
OT  - état oxydatif
EDAT- 2017/10/14 06:00
MHDA- 2018/08/11 06:00
CRDT- 2017/10/14 06:00
PHST- 2017/10/14 06:00 [pubmed]
PHST- 2018/08/11 06:00 [medline]
PHST- 2017/10/14 06:00 [entrez]
AID - 10.1139/cjpp-2017-0394 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2018 Feb;96(2):158-164. doi: 10.1139/cjpp-2017-0394. 
      Epub 2017 Oct 13.

PMID- 6470944
OWN - NLM
STAT- MEDLINE
DCOM- 19841012
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 73
IP  - 7
DP  - 1984 Jul
TI  - Acylation of hemoglobin by aspirin-like diacyl esters.
PG  - 1013-4
AB  - Aspirin-like diacyl esters of different steric disposition have been prepared and 
      compared with acetylsalicylate in their abilities to modify hemoglobin.
FAU - Massil, S E
AU  - Massil SE
FAU - Shi, G Y
AU  - Shi GY
FAU - Klotz, I M
AU  - Klotz IM
LA  - eng
GR  - HL22719/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acylation
MH  - Aspirin/*analogs & derivatives/analysis/pharmacology
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Hemoglobins/*analysis/metabolism
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
AID - S0022-3549(15)46214-8 [pii]
AID - 10.1002/jps.2600730744 [doi]
PST - ppublish
SO  - J Pharm Sci. 1984 Jul;73(7):1013-4. doi: 10.1002/jps.2600730744.

PMID- 271972
OWN - NLM
STAT- MEDLINE
DCOM- 19780321
LR  - 20190501
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 74
IP  - 12
DP  - 1977 Dec
TI  - Alternative aspirins as antisickling agents: acetyl-3,5-dibromosalicylic acid.
PG  - 5499-503
AB  - Acetyl-3,5-dibromosalicylic acid (dibromoaspirin) is shown to be a potent 
      acylating agent of intracellular hemoglobin in vitro. Transfer of the actyl group 
      of dibromoaspirin to amino groups of hemoglobins A and S seems to occur 
      predominantly at just two or three sites on these proteins. This acetylation 
      produces moderate increases in the oxygen affinities of normal and sickle 
      erythrocytes. Furthermore, treatment of intracellular hemoglobin S with 
      dibromoaspirin directly inhibits erythrocyte sickling. This antisickling effect 
      is paralleled by an increase in the minimum gelling concentration of deoxy 
      hemoglobin S extracted from sickle erythrocytes that had been exposed to low 
      concentrations of dibromoaspirin. These observations suggest that dibromoaspirin 
      might be an effective antisickling agent in vivo.
FAU - Walder, J A
AU  - Walder JA
FAU - Zaugg, R H
AU  - Zaugg RH
FAU - Iwaoka, R S
AU  - Iwaoka RS
FAU - Watkin, W G
AU  - Watkin WG
FAU - Klotz, I M
AU  - Klotz IM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Antisickling Agents)
RN  - 0 (Gels)
RN  - 0 (Hemoglobin, Sickle)
RN  - 0 (Oxyhemoglobins)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - *Antisickling Agents
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Erythrocytes, Abnormal/drug effects
MH  - Gels
MH  - Hemoglobin A
MH  - *Hemoglobin, Sickle
MH  - Kinetics
MH  - Oxyhemoglobins/metabolism
MH  - Solubility
PMC - PMC431780
EDAT- 1977/12/01 00:00
MHDA- 1977/12/01 00:01
CRDT- 1977/12/01 00:00
PHST- 1977/12/01 00:00 [pubmed]
PHST- 1977/12/01 00:01 [medline]
PHST- 1977/12/01 00:00 [entrez]
AID - 10.1073/pnas.74.12.5499 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1977 Dec;74(12):5499-503. doi: 10.1073/pnas.74.12.5499.

PMID- 24789086
OWN - NLM
STAT- MEDLINE
DCOM- 20150122
LR  - 20140529
IS  - 1744-6848 (Electronic)
IS  - 1744-683X (Linking)
VI  - 10
IP  - 24
DP  - 2014 Jun 28
TI  - Acetylsalicylic acid (ASA) increases the solubility of cholesterol when 
      incorporated in lipid membranes.
PG  - 4275-86
LID - 10.1039/c4sm00372a [doi]
AB  - Cholesterol has been well established as a mediator of cell membrane fluidity. By 
      interacting with lipid tails, cholesterol causes the membrane tails to be 
      constrained thereby reducing membrane fluidity, well known as the condensation 
      effect. Acetylsalicylic acid (ASA), the main ingredient in aspirin, has recently 
      been shown to increase fluidity in lipid bilayers by primarily interacting with 
      lipid head groups. We used high-resolution X-ray diffraction to study both ASA 
      and cholesterol coexisting in model membranes of dimyristoylphosphatidylcholine 
      (DMPC). While a high cholesterol concentration of 40 mol% cholesterol leads to 
      the formation of immiscible cholesterol bilayers, as was reported previously, 
      increasing the amount of ASA in the membranes between 0 to 12.5 mol% was found to 
      significantly increase the fluidity of the bilayers and dissolve the cholesterol 
      plaques. We, therefore, present experimental evidence for an interaction between 
      cholesterol and ASA on the level of the cell membrane at elevated levels of 
      cholesterol and ASA.
FAU - Alsop, Richard J
AU  - Alsop RJ
AD  - Department of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.
FAU - Barrett, Matthew A
AU  - Barrett MA
FAU - Zheng, Songbo
AU  - Zheng S
FAU - Dies, Hannah
AU  - Dies H
FAU - Rheinstädter, Maikel C
AU  - Rheinstädter MC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Soft Matter
JT  - Soft matter
JID - 101295070
RN  - 0 (Lipid Bilayers)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
RN  - U86ZGC74V5 (Dimyristoylphosphatidylcholine)
SB  - IM
MH  - Aspirin/*chemistry/pharmacology
MH  - Cholesterol/*chemistry
MH  - Dimyristoylphosphatidylcholine/chemistry
MH  - Lipid Bilayers/*chemistry
MH  - Membrane Fluidity/drug effects
MH  - Solubility
EDAT- 2014/05/03 06:00
MHDA- 2015/01/23 06:00
CRDT- 2014/05/03 06:00
PHST- 2014/05/03 06:00 [entrez]
PHST- 2014/05/03 06:00 [pubmed]
PHST- 2015/01/23 06:00 [medline]
AID - 10.1039/c4sm00372a [doi]
PST - ppublish
SO  - Soft Matter. 2014 Jun 28;10(24):4275-86. doi: 10.1039/c4sm00372a.

PMID- 39013
OWN - NLM
STAT- MEDLINE
DCOM- 19791121
LR  - 20180216
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 19
IP  - 2
DP  - 1979
TI  - Effect of parental aspirin on the gastric mucosal barrier in the rat.
PG  - 93-8
AB  - The purpose of the present study was to determine in the rat whether parenteral 
      aspirin, like topical aspirin, injures the gastric mucosa by diffusely disrupting 
      the gastric mucosal barrier to hydrogen ion back-diffusion. Back-diffusion 
      studies, including the ion fluxes and lumenal potential difference, were 
      performed in control situations and either 0.5 or 4 h after the intraperitoneal 
      administration of sodium acetylsalicylate. Gastric mucosal lesions were scored. 
      After 0.5h, lesions developed but the barrier was intact. However, after 4 h, 
      lesion formation was more severe and changes characteristic of diffuse barrier 
      disruption, fall in potential difference and increased loss of hydrogen ion 
      occurred. Since lesions occurred before evidence of diffuse barrier disruption 
      could be detected, we conclude that in the present model diffuse barrier 
      disruption is a consequence rather than a cause of lesions.
FAU - Guth, P H
AU  - Guth PH
FAU - Paulsen, G
AU  - Paulsen G
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chick Embryo
MH  - Gastric Mucosa/*drug effects
MH  - Hydrogen-Ion Concentration
MH  - Infusions, Parenteral
MH  - Injections, Intraperitoneal
MH  - Male
MH  - Rats
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1159/000198329 [doi]
PST - ppublish
SO  - Digestion. 1979;19(2):93-8. doi: 10.1159/000198329.

PMID- 901317
OWN - NLM
STAT- MEDLINE
DCOM- 19771031
LR  - 20190902
IS  - 0004-945X (Print)
IS  - 0004-945X (Linking)
VI  - 55
IP  - 2
DP  - 1977 Apr
TI  - The effect of aspirin pretreatment on the sweating response of older female 
      subjects.
PG  - 225-8
AB  - Seven healthy female volunteers (aged 50 to 67 years) have been subjected to a 
      thermal stress and their sweat rates evaluated using hygrosensors on five 
      different locations on their body surface. It was found that the sweating rate 
      was highest on the forehead in all but one of the subjects with the chest being 
      the next most prominent site for the response. Five of the subjects were 
      restudied after aspirin pretreatment. In the presence of this drug, resting body 
      temperature was lowered, sweating occurred at a lower oral temperature and the 
      mean sweating rate at a standardized body temperature was significantly higher. 
      These findings are consistent with aspirin's known pharmacological actions, 
      although in this study the increased sweating rate have been demonstrated in 
      afebrile subjects.
FAU - Tam, H S
AU  - Tam HS
FAU - Frewin, D B
AU  - Frewin DB
FAU - Elliott, K
AU  - Elliott K
FAU - Luke, W K
AU  - Luke WK
FAU - Downey, J A
AU  - Downey JA
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust J Exp Biol Med Sci
JT  - The Australian journal of experimental biology and medical science
JID - 0416662
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Body Temperature/drug effects
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Stimulation, Chemical
MH  - Sweating/*drug effects
EDAT- 1977/04/01 00:00
MHDA- 1977/04/01 00:01
CRDT- 1977/04/01 00:00
PHST- 1977/04/01 00:00 [pubmed]
PHST- 1977/04/01 00:01 [medline]
PHST- 1977/04/01 00:00 [entrez]
AID - 10.1038/icb.1977.16 [doi]
PST - ppublish
SO  - Aust J Exp Biol Med Sci. 1977 Apr;55(2):225-8. doi: 10.1038/icb.1977.16.

PMID- 6239255
OWN - NLM
STAT- MEDLINE
DCOM- 19850118
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 13
IP  - 42
DP  - 1984 Nov 24
TI  - [Immunoallergic hemolytic anemia, thrombopenia and acute renal failure induced by 
      aspirin].
PG  - 2567-9
AB  - The first case of haemolytic anaemia with thrombocytopenia and acute renal 
      failure induced by ingestion of aspirin in a 22-year old woman is reported. An 
      IgM anti-aspirin antibody which agglutinated erythrocytes of the patient and of 
      ABO compatible donors in the presence of aspirin was isolated in the serum. In 
      addition, the allergic nature of the patient's hypersensitivity to aspirin was 
      confirmed by positive lymphocyte transformation and basophil degranulation tests 
      in the presence of the drug.
FAU - Hubert, D
AU  - Hubert D
FAU - Habibi, B
AU  - Habibi B
FAU - Krulik, M
AU  - Krulik M
FAU - Debray, J
AU  - Debray J
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Anémie hémolytique immunoallergique, thrombopénie et insuffisance rénale aiguë 
      induites par l'aspirine.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Immunoglobulin M)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Kidney Injury/*chemically induced
MH  - Adult
MH  - Anemia, Hemolytic/*chemically induced/immunology
MH  - Aspirin/*adverse effects/immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin M/analysis
MH  - Thrombocytopenia/*chemically induced
EDAT- 1984/11/24 00:00
MHDA- 1984/11/24 00:01
CRDT- 1984/11/24 00:00
PHST- 1984/11/24 00:00 [pubmed]
PHST- 1984/11/24 00:01 [medline]
PHST- 1984/11/24 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1984 Nov 24;13(42):2567-9.

PMID- 20598402
OWN - NLM
STAT- MEDLINE
DCOM- 20101130
LR  - 20131121
IS  - 1768-3254 (Electronic)
IS  - 0223-5234 (Linking)
VI  - 45
IP  - 9
DP  - 2010 Sep
TI  - Synthesis and bioactivity of sphingosine kinase inhibitors and their novel 
      aspirinyl conjugated analogs.
PG  - 4149-56
LID - 10.1016/j.ejmech.2010.06.005 [doi]
AB  - Sphingosine kinase (SphK) is a lipid kinase with oncogenic activity, and SphK 
      inhibitors (SKIs) are known for their anti-cancer activity. Here, we report 
      highly efficient syntheses of SKIs and their aspirinyl (Asp) analogs. Both SKIs 
      and their Asp analogs were highly cytotoxic towards multiple human cancer cell 
      lines; in several cases the Asp analogs were up to three times more effective. 
      Furthermore, they were equally potent inhibitors of SphK. The pharmacokinetic 
      study indicated that SKI-I-Asp cleaved efficiently to form SKI-I and the 
      half-life of SKI-I was increased from approximately 7 h in SKI-I to approximately 
      10 h in SKI-I-Asp injected mice, thereby prolonging its effect. In summary, the 
      Asp-conjugated SKIs seem to be promising prodrugs of SKIs where delivery in vivo 
      remains a problem.
CI  - 2010 Elsevier Masson SAS. All rights reserved.
FAU - Sharma, Arun K
AU  - Sharma AK
AD  - Department of Pharmacology, Penn State Hershey College of Medicine, Penn State 
      Hershey Cancer Institute, CH72, 500 University Drive, Hershey, PA 17033, USA. 
      aks14@psu.edu
FAU - Sk, Ugir Hossain
AU  - Sk UH
FAU - Gimbor, Melissa A
AU  - Gimbor MA
FAU - Hengst, Jeremy A
AU  - Hengst JA
FAU - Wang, Xujun
AU  - Wang X
FAU - Yun, Jong
AU  - Yun J
FAU - Amin, Shantu
AU  - Amin S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100612
PL  - France
TA  - Eur J Med Chem
JT  - European journal of medicinal chemistry
JID - 0420510
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Prodrugs)
RN  - EC 2.7.1.- (Phosphotransferases (Alcohol Group Acceptor))
RN  - EC 2.7.1.- (sphingosine kinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/*chemical synthesis/metabolism/*pharmacology
MH  - Cell Line, Tumor
MH  - Drug Stability
MH  - Enzyme Inhibitors/*chemical synthesis/chemistry/metabolism/*pharmacology
MH  - Humans
MH  - Mice
MH  - Phosphotransferases (Alcohol Group Acceptor)/*antagonists & inhibitors
MH  - Prodrugs/metabolism
EDAT- 2010/07/06 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/07/06 06:00
PHST- 2010/03/24 00:00 [received]
PHST- 2010/06/03 00:00 [revised]
PHST- 2010/06/04 00:00 [accepted]
PHST- 2010/07/06 06:00 [entrez]
PHST- 2010/07/06 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - S0223-5234(10)00449-6 [pii]
AID - 10.1016/j.ejmech.2010.06.005 [doi]
PST - ppublish
SO  - Eur J Med Chem. 2010 Sep;45(9):4149-56. doi: 10.1016/j.ejmech.2010.06.005. Epub 
      2010 Jun 12.

PMID- 6637302
OWN - NLM
STAT- MEDLINE
DCOM- 19831217
LR  - 20191031
IS  - 0302-4369 (Print)
IS  - 0302-4369 (Linking)
VI  - 37
IP  - 4
DP  - 1983
TI  - Chemical feasibility studies concerning potential prodrugs of acetylsalicylic 
      acid.
PG  - 351-9
AB  - A rationale is developed for aspirin prodrugs based on non-acidic latentiated 
      derivatives. Knowledge of the gastro-intestinal liabilities and pharmacological 
      profile is required for this approach whereby aspirin is built into a common 
      ortho ester function of the type 2-substituted 2-methyl-4H-1,3-benzodioxin-4-one 
      with latentiated carboxyl and acetoxy groups. Twelve compounds of this type, ten 
      substituted with various alkoxy and aryloxy groups and two with arylthio groups, 
      have been isolated and characterized. A new synthetic route, comprising the 
      reaction of 2-acetoxybenzoyl chloride with TMS derivatives of the corresponding 
      alcohols and phenols, has been devised for the preparation of some of the 
      compounds while others were prepared according to known methods. Subsequently, 
      the prodrug candidates have been subjected to non-enzymatic hydrolysis for a 
      first rapid screening in vitro. Only 
      2-tert-butoxy-2-methyl-4H-1,3-benzodioxin-4-one is observed to act as a true 
      proaspirin, releasing aspirin, under these conditions, but analogous compounds 
      with tertiary substituents may display the same behavior, and this chemical 
      approach to aspirin modification may offer a viable rationale for aspirin 
      prodrugs with reduced gastric irritancy or for making "superaspirins".
FAU - Hansen, A B
AU  - Hansen AB
FAU - Senning, A
AU  - Senning A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Denmark
TA  - Acta Chem Scand B
JT  - Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry
JID - 0421265
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemical synthesis
MH  - Hydrolysis
MH  - Kinetics
MH  - Magnetic Resonance Spectroscopy
MH  - Spectrophotometry
MH  - Structure-Activity Relationship
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.3891/acta.chem.scand.37b-0351 [doi]
PST - ppublish
SO  - Acta Chem Scand B. 1983;37(4):351-9. doi: 10.3891/acta.chem.scand.37b-0351.

PMID- 3919888
OWN - NLM
STAT- MEDLINE
DCOM- 19850510
LR  - 20131121
IS  - 0764-4469 (Print)
IS  - 0764-4469 (Linking)
VI  - 300
IP  - 4
DP  - 1985
TI  - [Demonstration of specific platelet function anomaly in asthma induced by 
      aspirin: diagnostic consequences].
PG  - 137-42
AB  - Aspirin-sensitive asthma is a common and severe disorder characterized by 
      asthmatic attacks after oral ingestion of cyclooxygenase inhibiting drugs. Yet 
      its pathophysiology remains unknown, and no specific in vitro abnormality, 
      neither humoral nor cellular, has been detected in these patients. We have 
      recently described a new model of platelet activation--IgE-dependent platelet 
      activation--expressed by the release of cytocidal mediators and oxygen 
      metabolites. We have now investigated whether cyclooxygenase inhibitors induce a 
      similar response in platelets from aspirin-sensitive asthmatics in vitro. Aspirin 
      or indomethacin strikingly activated platelets from 12 aspirin-sensitive 
      asthmatics to the same extent as IgE-dependent stimuli, but had no effect on 
      platelets from 18 controls (p less than 0.0001). Sodium salicylate, which does 
      not inhibit cyclooxygenase, did not trigger platelets from aspirin-sensitive 
      asthmatics. Preincubation with sodium salicylate or prostaglandin endoperoxides 
      (PGH2), selectively prevented further platelet activation by aspirin or 
      indomethacin (90% inhibition), suggesting that this abnormal platelet activation 
      is the consequence of cyclooxygenase inhibition. This represents the first 
      identification of a specific abnormal cellular response in aspirin-sensitive 
      asthma, provides the basis for an in vitro diagnostic test of the disease, and 
      for new insights on its pathogenesis and its prevention.
FAU - Ameisen, J C
AU  - Ameisen JC
FAU - Joseph, M
AU  - Joseph M
FAU - Tonnel, A B
AU  - Tonnel AB
FAU - Vorng, H
AU  - Vorng H
FAU - Pancré, V
AU  - Pancré V
FAU - Fournier, E
AU  - Fournier E
FAU - Wallaert, B
AU  - Wallaert B
FAU - Capron, A
AU  - Capron A
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Mise en évidence d'une anomalie fonctionnelle plaquettaire spécifique dans 
      l'asthme à l'aspirine; conséquences diagnostiques.
PL  - France
TA  - C R Acad Sci III
JT  - Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie
JID - 8503078
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandin Endoperoxides)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aspirin/*adverse effects/pharmacology
MH  - Asthma/blood/*chemically induced/enzymology
MH  - Blood Platelets/drug effects/*enzymology
MH  - *Cyclooxygenase Inhibitors
MH  - Female
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Male
MH  - Prostaglandin Endoperoxides/pharmacology
MH  - Sodium Salicylate/pharmacology
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - C R Acad Sci III. 1985;300(4):137-42.

PMID- 31109107
OWN - NLM
STAT- MEDLINE
DCOM- 20191114
LR  - 20200225
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 24
IP  - 10
DP  - 2019 May 18
TI  - Reconsidering the Role of Cyclooxygenase Inhibition in the Chemotherapeutic Value 
      of NO-Releasing Aspirins for Lung Cancer.
LID - 10.3390/molecules24101924 [doi]
LID - 1924
AB  - Nitric oxide-releasing aspirins (NO-aspirins) are aspirin derivatives that are 
      safer than the parent drug in the gastrointestinal context and have shown 
      superior cytotoxic effects in several cancer models. Despite the rationale for 
      their design, the influence of nitric oxide (NO(•)) on the effects of NO-aspirins 
      has been queried. Moreover, different isomers exhibit varying antitumor activity, 
      apparently related to their ability to release NO(•). Here, we investigated the 
      effects and mode of action of NO-aspirins in non-small-cell lung cancer (NSCLC) 
      cells, comparing two isomers, NCX4016 and NCX4040 (-meta and -para isomers, 
      respectively). NCX4040 was more potent in decreasing NSCLC cell viability and 
      migration and exhibited significant synergistic effects in combination with 
      erlotinib (an epidermal growth factor receptor inhibitor) in erlotinib-resistant 
      cells. We also studied the relationship among the effects of NO-aspirins, NO(•) 
      release, and PGE(2) levels. NCX4040 released more NO(•) and significantly 
      decreased PGE(2) synthesis relative to NCX4016; however, NO(•) scavenger 
      treatment reversed the antiproliferative effects of NCX4016, but not those of 
      NCX4040. By contrast, misoprostol (a PGE(2) receptor agonist) significantly 
      reversed the antiproliferative effect of NCX4040, but not those of NCX4016. 
      Furthermore, misoprostol reversed the antimigratory effects of NCX4040. Overall, 
      these results indicate that PGE(2) inhibition is important in the mode of action 
      of NO-aspirins.
FAU - Martin-Martin, Antonia
AU  - Martin-Martin A
AD  - Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, 
      Universidad Austral de Chile, Valdivia 5090000, Chile. 
      antoniamartinm94@gmail.com.
FAU - Rivera-Dictter, Andrés
AU  - Rivera-Dictter A
AD  - Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, 
      Universidad Austral de Chile, Valdivia 5090000, Chile. ariveradictter@gmail.com.
FAU - Muñoz-Uribe, Matías
AU  - Muñoz-Uribe M
AD  - Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, 
      Universidad Austral de Chile, Valdivia 5090000, Chile. matias.munoz@uach.cl.
FAU - López-Contreras, Freddy
AU  - López-Contreras F
AD  - Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, 
      Universidad Austral de Chile, Valdivia 5090000, Chile. 
      freddy.lopez@postgrado.uach.cl.
AD  - Escuela de Graduados, Facultad de Ciencias Veterinarias, Universidad Austral de 
      Chile, Valdivia 5090000, Chile. freddy.lopez@postgrado.uach.cl.
FAU - Pérez-Laines, Jorge
AU  - Pérez-Laines J
AD  - Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, 
      Universidad Austral de Chile, Valdivia 5090000, Chile. 
      jorgeperezlaines@gmail.com.
FAU - Molina-Berríos, Alfredo
AU  - Molina-Berríos A
AD  - Instituto de Investigación en Ciencias Odontológicas, Facultad de Odontología, 
      Universidad de Chile, Santiago 8380492, Chile. aemolina@u.uchile.cl.
FAU - López-Muñoz, Rodrigo
AU  - López-Muñoz R
AUID- ORCID: 0000-0003-1825-8563
AD  - Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, 
      Universidad Austral de Chile, Valdivia 5090000, Chile. rodrigo.lopez@uach.cl.
LA  - eng
GR  - FONDECYT 1160807/Fondo Nacional de Desarrollo Científico y Tecnológico/
PT  - Journal Article
DEP - 20190518
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (NCX 4040)
RN  - 0 (Nitro Compounds)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*pharmacology
MH  - Aspirin/analogs & derivatives/chemistry/*pharmacology
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Cyclooxygenase Inhibitors/chemistry/*pharmacology
MH  - Dinoprostone/biosynthesis
MH  - Drug Synergism
MH  - Erlotinib Hydrochloride/pharmacology
MH  - Humans
MH  - Lung Neoplasms/metabolism
MH  - Molecular Structure
MH  - Nitric Oxide/*metabolism
MH  - Nitro Compounds/pharmacology
PMC - PMC6572483
OTO - NOTNLM
OT  - NCX4016
OT  - NCX4040
OT  - cyclooxygenase
OT  - erlotinib
OT  - nitric oxide
OT  - non-small-cell lung cancer
OT  - prostaglandin
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript; or in the decision to publish the results.
EDAT- 2019/05/22 06:00
MHDA- 2019/11/15 06:00
CRDT- 2019/05/22 06:00
PHST- 2019/04/23 00:00 [received]
PHST- 2019/05/10 00:00 [revised]
PHST- 2019/05/13 00:00 [accepted]
PHST- 2019/05/22 06:00 [entrez]
PHST- 2019/05/22 06:00 [pubmed]
PHST- 2019/11/15 06:00 [medline]
AID - molecules24101924 [pii]
AID - molecules-24-01924 [pii]
AID - 10.3390/molecules24101924 [doi]
PST - epublish
SO  - Molecules. 2019 May 18;24(10):1924. doi: 10.3390/molecules24101924.

PMID- 3839482
OWN - NLM
STAT- MEDLINE
DCOM- 19850823
LR  - 20190824
IS  - 0306-3623 (Print)
IS  - 0306-3623 (Linking)
VI  - 16
IP  - 3
DP  - 1985
TI  - Aluminum intake from non-prescription drugs and sucralfate.
PG  - 223-8
AB  - The use of non-prescription antacids to control hyperphosphatemia has been 
      implicated as a primary cause of aluminum intoxications in patients with reduced 
      renal function. Additional reports suggest that oral aluminum intake may have 
      adverse effects on mineral metabolism of patients with normal renal function. The 
      non-prescription drugs that contain substantial quantities of aluminum salts 
      include some antacids, buffered aspirins, antidiarrheals, and vaginal douches. 
      Sucralfate, an anti-ulcer drug available by prescription, is the aluminum salt of 
      sucrose sulfate. If taken as directed, the daily aluminum intake from the 
      antacids can be as much as 5,000 mg. When aluminum buffered aspirins are used as 
      part of the drug therapy for rheumatoid arthritis, aluminum intake can be 
      elevated by 700 mg/day. Although aluminum intoxications have been reported among 
      patients with reduced renal function, existing reports are not sufficient to 
      estimate whether the chronic elevation of aluminum intake from drugs is causing 
      adverse health effects among other patient populations.
FAU - Lione, A
AU  - Lione A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gen Pharmacol
JT  - General pharmacology
JID - 7602417
RN  - 0 (Antacids)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Buffers)
RN  - 0 (Nonprescription Drugs)
RN  - 54182-58-0 (Sucralfate)
RN  - CPD4NFA903 (Aluminum)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aluminum/*administration & dosage/adverse effects
MH  - Antacids/administration & dosage
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Aspirin/administration & dosage
MH  - Buffers
MH  - Humans
MH  - *Nonprescription Drugs
MH  - Sucralfate
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 0306-3623(85)90073-4 [pii]
AID - 10.1016/0306-3623(85)90073-4 [doi]
PST - ppublish
SO  - Gen Pharmacol. 1985;16(3):223-8. doi: 10.1016/0306-3623(85)90073-4.

PMID- 2488658
OWN - NLM
STAT- MEDLINE
DCOM- 19910506
LR  - 20131121
IS  - 0246-0831 (Print)
IS  - 0246-0831 (Linking)
VI  - 66
IP  - 3-4
DP  - 1989
TI  - [Treatment of vernal conjunctivitis with aspirin].
PG  - 119-27
AB  - The authors have made a study on 67 cases of vernal keratoconjunctivitis during 4 
      years (1984-1988). These cases were treated by aspirin by oral route, at the rate 
      of 25 to 50 mg/kg. Aspirin and corticoïds make functional signs disappear and 
      make clinical signs decrease. The efficacy of aspirin is better than the efficacy 
      of corticoïds as far as side-effects as extension of the bull period are 
      concerned.
FAU - Lemrini, F
AU  - Lemrini F
FAU - Dafrallah, L
AU  - Dafrallah L
FAU - Sebbahi, F
AU  - Sebbahi F
FAU - Rafi, M
AU  - Rafi M
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Traitement de la conjonctivite printanière par l'aspirine.
PL  - France
TA  - Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique
JT  - Revue internationale du trachome et de pathologie oculaire tropicale et 
      subtropicale et de sante publique : organe de la Ligue contre le trachome avec la 
      collaboration de l'International Organization against Trachoma et des 
      organisation...
JID - 8209867
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Conjunctivitis, Allergic/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Seasons
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique. 1989;66(3-4):119-27.

PMID- 18574022
OWN - NLM
STAT- MEDLINE
DCOM- 20080724
LR  - 20190101
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 65
IP  - 13 Suppl 5
DP  - 2008 Jul 1
TI  - Benefits and limitations of current antiplatelet therapies.
PG  - S5-10; quiz S16-8
LID - 10.2146/ajhp080156 [doi]
AB  - PURPOSE: The benefits and limitations of current antiplatelet therapies in the 
      management of patients experiencing acute coronary syndrome (ACS) are reviewed. 
      SUMMARY: Antiplatelet agents, including aspirin, thienopyridines, and platelet 
      glycoprotein (GP) IIb/IIIa receptor inhibitors, have become the foundation of 
      antithrombotic therapy in the management of patients experiencing ACS. Despite 
      aspirin's ability to reduce the risk for adverse thrombotic events in a broad 
      range of patients, it has variable antiplatelet activity in individual patients. 
      The term "aspirin resistance" describes the inability of aspirin to produce an 
      anticipated effect on one or more tests of platelet function. Because a 
      substantial proportion of patients are "resistant" to the antiplatelet effects of 
      aspirin, and other pathways for platelet aggregation are not inhibited by 
      aspirin, current guidelines recommend a dual antiplatelet regimen with a 
      thienopyridine or GP IIb/IIIa inhibitor in addition to aspirin for patients with 
      ACS, including patients undergoing percutaneous coronary intervention and stent 
      placement. These guidelines are based on observational and randomized clinical 
      trials supporting the effectiveness of dual antiplatelet therapy in reducing 
      mortality, nonfatal myocardial infarction, and the need for urgent 
      revascularization compared with placebo, aspirin therapy alone, or an 
      anticoagulant regimen. Studies in small numbers of patients have also revealed 
      that some patients may be resistant to a thienopyridine, with some suggestion of 
      a genetic etiology. Additional studies are needed to provide more definitive 
      answers. CONCLUSION: Improved awareness by healthcare professionals of the 
      benefits and limitations of various antiplatelet therapies should aid in the 
      development of strategies to ensure patient compliance and thereby reduce the 
      morbidity and mortality associated with premature discontinuation of dual 
      antiplatelet therapy.
FAU - Nappi, Jean
AU  - Nappi J
AD  - South Carolina College of Pharmacy and Professor of Medicine, Medical University 
      of South Carolina, QE 213, 43 Sabin Street, Charleston, SC 29425, USA. 
      nappijm@musc.edu
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Clinical Protocols
MH  - Drug Therapy
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Pyridines/administration & dosage/pharmacology/therapeutic use
MH  - Risk Factors
MH  - Stents/adverse effects
EDAT- 2008/07/02 09:00
MHDA- 2008/07/25 09:00
CRDT- 2008/07/02 09:00
PHST- 2008/07/02 09:00 [pubmed]
PHST- 2008/07/25 09:00 [medline]
PHST- 2008/07/02 09:00 [entrez]
AID - 65/13_Supplement_5/S5 [pii]
AID - 10.2146/ajhp080156 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2008 Jul 1;65(13 Suppl 5):S5-10; quiz S16-8. doi: 
      10.2146/ajhp080156.

PMID- 3134035
OWN - NLM
STAT- MEDLINE
DCOM- 19880812
LR  - 20131121
IS  - 0397-9148 (Print)
IS  - 0397-9148 (Linking)
VI  - 19
IP  - 8 Suppl
DP  - 1987 Oct
TI  - [Blood platelets and asthma caused by aspirin].
PG  - 7-10
AB  - Platelets isolated from patients with aspirin-induced asthma (ASA patients) react 
      abnormally in vitro to aspirin and to non-steroid anti-inflammatory drugs 
      (NSAID), by generating cytocidal molecules, that can kill parasitic larvae and to 
      oxygen-dependent free radicles, which may be detected by chemiluminescence, 
      although these drugs do not have a similar effect on platelets from normal donors 
      or allergic asthmatics. The abnormality appears to be associated with the 
      inhibiting properties of NSAID and aspirin on the cyclo-oxygenase pathway, that 
      leads to a defect of the binding of prostaglandin endoperoxide PGH2 to its 
      receptors on the platelet membrane. In addition, another metabolite from the 
      lipoxygenase pathway which is at present poorly defined seems to participate in 
      the anomaly. Sodium salicylate, a naturally produced catabolite of aspirin, that 
      is well-tolerated by ASA patients, inhibits the abnormal response of the 
      platelets and this opens new perspectives in the management of aspirin-sensitive 
      intolerance.
FAU - Joseph, M
AU  - Joseph M
FAU - Capron, A
AU  - Capron A
FAU - Ameisen, J C
AU  - Ameisen JC
FAU - Martinot, J B
AU  - Martinot JB
FAU - Tonnel, A B
AU  - Tonnel AB
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Plaquettes sanguines et asthme à l'aspirine.
PL  - France
TA  - Allerg Immunol (Paris)
JT  - Allergie et immunologie
JID - 0245775
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/blood/*chemically induced
MH  - Blood Platelets/*drug effects/enzymology/immunology
MH  - *Cyclooxygenase Inhibitors
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/immunology
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - *Lipoxygenase Inhibitors
EDAT- 1987/10/01 00:00
MHDA- 1987/10/01 00:01
CRDT- 1987/10/01 00:00
PHST- 1987/10/01 00:00 [pubmed]
PHST- 1987/10/01 00:01 [medline]
PHST- 1987/10/01 00:00 [entrez]
PST - ppublish
SO  - Allerg Immunol (Paris). 1987 Oct;19(8 Suppl):7-10.

PMID- 1153355
OWN - NLM
STAT- MEDLINE
DCOM- 19751028
LR  - 20131121
IS  - 0301-0244 (Print)
IS  - 0301-0244 (Linking)
VI  - 27
IP  - 2
DP  - 1975 Apr-Jun
TI  - The study of the bioavailability of coated acetylsalicylic acid in suppositories 
      after rectal administration.
PG  - 227-33
AB  - The rate of release of acetylsalicylic acid (ASA) coated and uncoated from 
      suppositories in vitro, and the bioavailability of ASA in vivo were examined. The 
      coating reduces the rate of release of activite drug from suppositories. In vivo 
      the coating delays the obtention of the maximum concentration of salicylates in 
      urine, but doesn't have any essential effect on cummulative amount of salicylates 
      in urine.
FAU - Stozek, T
AU  - Stozek T
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Pol J Pharmacol Pharm
JT  - Polish journal of pharmacology and pharmacy
JID - 0366561
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Suppositories)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*metabolism/urine
MH  - Biological Availability
MH  - Cellulose
MH  - Delayed-Action Preparations
MH  - Humans
MH  - Male
MH  - Rectum
MH  - Solubility
MH  - *Suppositories
EDAT- 1975/04/01 00:00
MHDA- 1975/04/01 00:01
CRDT- 1975/04/01 00:00
PHST- 1975/04/01 00:00 [pubmed]
PHST- 1975/04/01 00:01 [medline]
PHST- 1975/04/01 00:00 [entrez]
PST - ppublish
SO  - Pol J Pharmacol Pharm. 1975 Apr-Jun;27(2):227-33.

PMID- 8281678
OWN - NLM
STAT- MEDLINE
DCOM- 19940217
LR  - 20220317
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 89
IP  - 1
DP  - 1994 Jan
TI  - History of drugs for thrombotic disease. Discovery, development, and directions 
      for the future.
PG  - 432-49
AB  - The history of the antithrombotic agents--aspirin, heparin, warfarin, and the 
      thrombolytics--is a rich and lively odyssey of serendipity, perseverance, vision, 
      and conflict involving a number of striking personalities. The history of aspirin 
      spans ages and continents from Hippocrates' analgesic for women in labor to the 
      rediscovery of the white willow bark by English country scholar Reverend Edward 
      Stone. Bayer chemist Felix Hoffmann reinvented aspirin for his ailing father; 
      suburban physician L.L. Craven pioneered the prophylactic antithrombotic uses of 
      aspirin; and Sir John Vane elucidated aspirin's mechanism of action as the 
      inhibition of prostaglandin synthetase. Heparin was discovered by McLean, working 
      as a medical student in 1915 in search of a pure procoagulant in dog liver. His 
      original impure material differed somewhat from today's heparin, but purified 
      heparin was rapidly accepted for a myriad of clinical uses; to this day, diverse 
      new properties of this complex glycosaminoglycan continue to be elucidated. The 
      oral anticoagulants emerged from veterinary research in the 1920s on a 
      hemorrhagic disorder afflicting cattle that consumed spoiled sweet clover hay. 
      Several chance encounters led Karl Link and his University of Wisconsin team to 
      the identification of dicumarol as the offending agent in 1939 and its widespread 
      therapeutic use by Wright and others in the 1940s. Link later developed warfarin 
      as a rodenticide, but its use in humans soon followed in the 1950s. Vitamin K was 
      discovered in the 1930s; its involvement in the mechanism of the anticoagulant 
      agents was not delineated until the 1970s. The intrinsic ability of clotted blood 
      to liquify and the fibrinolytic properties of normal urine were noted in the 
      1800s. Tillett and Sherry's group stumbled on the fibrinolytic properties of 
      streptokinase in the 1930s and pioneered the therapeutic use of streptokinase in 
      the 1940s and of urokinase in the 1960s. Several teams found tissue-type 
      plasminogen activator in various body sites beginning in the 1940s, leading to 
      its cloning and widespread use in the 1980s; anisoylated 
      plasminogen-streptokinase activator complex is an example of rational drug 
      design. The discoverers of these diverse agents have not only provided physicians 
      with a potent armamentarium of antithrombotic drugs but also helped elucidate 
      much basic science and vividly demonstrated the merits of perseverance, 
      independent thought, and adherance to the scientific method.
FAU - Mueller, R L
AU  - Mueller RL
AD  - Division of Cardiology, New York Hospital-Cornell Medical Center, New York 10021.
FAU - Scheidt, S
AU  - Scheidt S
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Portrait
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/history
MH  - Canada
MH  - Europe
MH  - Fibrinolytic Agents/*history
MH  - Heparin/history
MH  - History, 17th Century
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, Ancient
MH  - Humans
MH  - Thrombosis/drug therapy/*history
MH  - United States
MH  - Warfarin/history
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1161/01.cir.89.1.432 [doi]
PST - ppublish
SO  - Circulation. 1994 Jan;89(1):432-49. doi: 10.1161/01.cir.89.1.432.

PMID- 12558
OWN - NLM
STAT- MEDLINE
DCOM- 19770226
LR  - 20181130
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 11
IP  - 8
DP  - 1976
TI  - The absorption of acetylsalicylic acid from the stomach in relation to 
      intragastric pH.
PG  - 801-5
AB  - A comparative study on the effect of a buffered (pH 6.5) and an unbuffered (pH 
      2.9) solution of acetylsalicylic acid (ASA) on gastric pH, gastric emptying, and 
      gastric absorption of ASA was performed in 10 healthy volunteers. Gastric pH was 
      recorded using radiotelemetry. Gastric emptying and gastric absorption was 
      studied with an aspiration technique and phenol red as nonabsorbable marker. 
      Administration of the unbuffered solution to the fasting subjects resulted in a 
      gastric pH of about 2 and absorption of ASA from the stomach was found to occur. 
      The buffered solution of ASA increased gastric pH to above 5 and gastric 
      absorption of ASA was found to be significantly less than after the unbuffered 
      solution. The buffered solution was emptied from the stomach more rapidly than 
      the unbuffered one.
FAU - Dotevall, G
AU  - Dotevall G
FAU - Ekenved, G
AU  - Ekenved G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Buffers)
RN  - I6G9Y0J1OJ (Phenolsulfonphthalein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*metabolism
MH  - Buffers
MH  - Female
MH  - Gastric Acidity Determination
MH  - *Gastric Juice/analysis
MH  - Gastric Mucosa/*metabolism
MH  - Gastrointestinal Motility
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Phenolsulfonphthalein
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol. 1976;11(8):801-5.

PMID- 9604316
OWN - NLM
STAT- MEDLINE
DCOM- 19980612
LR  - 20191102
IS  - 0014-827X (Print)
IS  - 0014-827X (Linking)
VI  - 53
IP  - 2
DP  - 1998 Feb
TI  - Prodrugs. Part 3. 2-Formylphenyl esters of indomethacin, ketoprofen and ibuprofen 
      and 6-substituted 2-formyl and 2-acylphenyl esters of aspirin.
PG  - 95-101
AB  - The synthesis and study of a novel series of potential prodrugs of indomethacin, 
      ketoprofen, ibuprofen and aspirin are reported. 2-Formylphenyl esters of the 
      NSAIDs, together with two 6-substituted 2-formyl and two 2-acylphenyl aspirins 
      and 4-formylphenyl indomethacin, have been prepared. A study of their alkaline 
      and neutral hydrolysis shows that these compounds, with the exception of 
      2-acetylphenyl aspirin, act as true prodrugs of the NSAIDs, giving the NSAID and 
      acylphenol. The rates of hydrolysis and activation parameters indicate that the 
      2-acylphenyl esters employ an intramolecular catalytic route. The 2-formylphenyl 
      esters were more potent as anti-inflammatory agents than the parent compounds in 
      the carragheenan-induced paw oedema test.
FAU - Abordo, E A
AU  - Abordo EA
AD  - Department of Biological and Chemical Sciences, University of Essex, Colchester, 
      UK.
FAU - Bowden, K
AU  - Bowden K
FAU - Huntington, A P
AU  - Huntington AP
FAU - Powell, S L
AU  - Powell SL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Farmaco
JT  - Farmaco (Societa chimica italiana : 1989)
JID - 8912641
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prodrugs)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemical synthesis/pharmacology
MH  - Aspirin/*chemical synthesis
MH  - Ibuprofen/*chemical synthesis
MH  - Indomethacin/*chemical synthesis
MH  - Ketoprofen/*chemical synthesis
MH  - Male
MH  - Prodrugs/*chemical synthesis/pharmacology
MH  - Rats
MH  - Rats, Wistar
EDAT- 1998/05/30 00:00
MHDA- 1998/05/30 00:01
CRDT- 1998/05/30 00:00
PHST- 1998/05/30 00:00 [pubmed]
PHST- 1998/05/30 00:01 [medline]
PHST- 1998/05/30 00:00 [entrez]
AID - S0014-827X(97)00014-1 [pii]
AID - 10.1016/s0014-827x(97)00014-1 [doi]
PST - ppublish
SO  - Farmaco. 1998 Feb;53(2):95-101. doi: 10.1016/s0014-827x(97)00014-1.

PMID- 538418
OWN - NLM
STAT- MEDLINE
DCOM- 19800523
LR  - 20131121
IS  - 0036-5572 (Print)
IS  - 0036-5572 (Linking)
VI  - 60
IP  - 6
DP  - 1979 Dec
TI  - Tolerance of guaiacolic ester of acetylsalicylic acid by patients with 
      aspirin-asthma.
PG  - 350-4
AB  - The effects of oral administration of the guaiacolic ester of acetylsalicylic 
      acid (ASA-G) on the ventilatory function were studied by means of a body 
      plethysmograph, in a group of nine ASA-asthmatic patients. No differences in 
      specific airway resistance were observed between ASA-G and placebo. It is 
      concluded that ASA-G is tolerated by patients with ASA-induced asthma.
FAU - Bianco, S
AU  - Bianco S
FAU - Petrigni, G
AU  - Petrigni G
FAU - Felisi, E
AU  - Felisi E
FAU - Robuschi, M
AU  - Robuschi M
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Denmark
TA  - Scand J Respir Dis
JT  - Scandinavian journal of respiratory diseases
JID - 0055427
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Airway Resistance/drug effects
MH  - Aspirin/*adverse effects/*analogs & derivatives/pharmacology
MH  - Asthma/*chemically induced
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Plethysmography
MH  - Respiration/drug effects
EDAT- 1979/12/01 00:00
MHDA- 1979/12/01 00:01
CRDT- 1979/12/01 00:00
PHST- 1979/12/01 00:00 [pubmed]
PHST- 1979/12/01 00:01 [medline]
PHST- 1979/12/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Respir Dis. 1979 Dec;60(6):350-4.

PMID- 28169410
OWN - NLM
STAT- MEDLINE
DCOM- 20180305
LR  - 20180305
IS  - 1576-6578 (Electronic)
IS  - 0210-0010 (Linking)
VI  - 64
IP  - 4
DP  - 2017 Feb 16
TI  - [Long-term effect of policosanol on the functional recovery of non-cardioembolic 
      ischemic stroke patients: a one year study].
PG  - 153-161
AB  - INTRODUCTION: Stroke is a leading cause of mortality and disability. Policosanol 
      has been effective in brain ischemia models. The aim of this study is to 
      investigate whether policosanol, added to aspirin therapy within 30 days of 
      stroke onset, is better than placebo + aspirine for the long-term recovery of 
      non-cardioembolic ischemic stroke subjects. PATIENTS AND METHODS: Randomized, 
      double-blind, placebo-controlled study. Eighty patients (mean age: 69 years) 
      within 30 days of onset, with a modified Rankin Scale score (mRS) 2 to 4, were 
      included. They were randomized in two groups (policosanol + aspirine or placebo + 
      aspirine) for 12 months. RESULTS: Policosanol + aspirine decreased significantly 
      mean mRS from the first interim check-up (1.5 months). The treatment even 
      improved after long-term therapy. More policosanol + aspirin (87.5%) than placebo 
      + aspirine (0%) patients achieved mRSs <= 1. Policosanol + aspirine increased 
      significantly Barthel Index, lowered LDL-cholesterol and increased 
      HDL-cholesterol versus placebo + aspirin. CONCLUSIONS: Long-term (12 months) 
      administration of policosanol + aspirin given after suffering non-cardioembolic 
      ischemic stroke was shown to be better than placebo + aspirin in improving 
      functional outcomes when used among patients with non-cardioembolic ischemic 
      stroke of moderate severity.
FAU - Sanchez, J
AU  - Sanchez J
AD  - (CNIC) Centro Nacional de Investigaciones Cientificas, La Habana, Cuba.
FAU - Illnait, J
AU  - Illnait J
AD  - (CNIC) Centro Nacional de Investigaciones Cientificas, La Habana, Cuba.
FAU - Mas, R
AU  - Mas R
AD  - (CNIC) Centro Nacional de Investigaciones Cientificas, La Habana, Cuba.
FAU - Mendoza, S
AU  - Mendoza S
AD  - (CNIC) Centro Nacional de Investigaciones Cientificas, La Habana, Cuba.
FAU - Fernandez, L
AU  - Fernandez L
AD  - (CNIC) Centro Nacional de Investigaciones Cientificas, La Habana, Cuba.
FAU - Mesa, M
AU  - Mesa M
AD  - (CNIC) Centro Nacional de Investigaciones Cientificas, La Habana, Cuba.
FAU - Vega, H
AU  - Vega H
AD  - (CNIC) Centro Nacional de Investigaciones Cientificas, La Habana, Cuba.
FAU - Fernandez, J
AU  - Fernandez J
AD  - (CNIC) Centro Nacional de Investigaciones Cientificas, La Habana, Cuba.
FAU - Reyes, P
AU  - Reyes P
AD  - (CNIC) Centro Nacional de Investigaciones Cientificas, La Habana, Cuba.
FAU - Ruiz, D
AU  - Ruiz D
AD  - (CNIC) Centro Nacional de Investigaciones Cientificas, La Habana, Cuba.
LA  - spa
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Efecto a largo plazo del policosanol en la recuperacion funcional de pacientes 
      con ictus isquemico no cardioembolico: estudio de un año.
PL  - Spain
TA  - Rev Neurol
JT  - Revista de neurologia
JID - 7706841
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Fatty Alcohols)
RN  - 142583-61-7 (policosanol)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticholesteremic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Brain Damage, Chronic/etiology
MH  - Brain Ischemia/blood/*drug therapy
MH  - Cholesterol/blood
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Fatty Alcohols/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hypercholesterolemia/blood/complications/diet therapy
MH  - Male
MH  - Patient Compliance
MH  - Recovery of Function
MH  - Treatment Outcome
EDAT- 2017/02/09 06:00
MHDA- 2018/03/06 06:00
CRDT- 2017/02/08 06:00
PHST- 2017/02/08 06:00 [entrez]
PHST- 2017/02/09 06:00 [pubmed]
PHST- 2018/03/06 06:00 [medline]
AID - rn2016180 [pii]
PST - ppublish
SO  - Rev Neurol. 2017 Feb 16;64(4):153-161.

PMID- 6326301
OWN - NLM
STAT- MEDLINE
DCOM- 19840605
LR  - 20131121
VI  - 60
IP  - 15
DP  - 1984 Apr 5
TI  - [Evaluation of the analgesic activity of a soluble precursor of aspirin in 
      orthopedic surgery].
PG  - 1089-91
AB  - We carried out a randomized double-blind trial to evaluate the analgesic effect, 
      rapidity of action and tolerance of calcium carbasalate relative to a placebo, 
      given in a single dose of 1 gr. aspirin equivalent immediately after an 
      orthopedic surgical procedure. Autoevaluation by the patient using a visual scale 
      and overall evaluation of analgesic effectiveness by the patient and relatives 
      showed that pain was significantly less with the active therapy whose tolerance 
      was excellent.
FAU - Letenneur, J
AU  - Letenneur J
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Evaluation de l'activité antalgique d'un précurseur soluble de l'aspirine en 
      chirurgie orthopédique.
PL  - France
TA  - Sem Hop
JT  - La semaine des hopitaux : organe fonde par l'Association d'enseignement medical 
      des hopitaux de Paris
JID - 9410059
RN  - 0 (Analgesics)
RN  - 8W8T17847W (Urea)
RN  - N667F17JP1 (carbaspirin calcium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Analgesics
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Orthopedics
MH  - Pain, Postoperative/*drug therapy
MH  - Random Allocation
MH  - Urea/*analogs & derivatives/therapeutic use
EDAT- 1984/04/05 00:00
MHDA- 1984/04/05 00:01
CRDT- 1984/04/05 00:00
PHST- 1984/04/05 00:00 [pubmed]
PHST- 1984/04/05 00:01 [medline]
PHST- 1984/04/05 00:00 [entrez]
PST - ppublish
SO  - Sem Hop. 1984 Apr 5;60(15):1089-91.

PMID- 25455452
OWN - NLM
STAT- MEDLINE
DCOM- 20170207
LR  - 20191210
IS  - 1879-3169 (Electronic)
IS  - 0378-4274 (Linking)
VI  - 232
IP  - 1
DP  - 2015 Jan 5
TI  - Effect of lysine acetylsalicylate on aluminium accumulation and 
      (Na(+)/K(+))ATPase activity in rat brain cortex synaptosomes after aluminium 
      ingestion.
PG  - 167-74
LID - S0378-4274(14)01387-3 [pii]
LID - 10.1016/j.toxlet.2014.10.014 [doi]
AB  - Aluminium is neurotoxic in humans and has been implicated in several neurological 
      disorders. Chronic use of buffered aspirins, as aspegic, would likely constitute 
      the major human aluminium uptake source. Low-dose aspirin is beneficial in 
      secondary prevention of cardiovascular events, so it is widely used for long 
      periods of time. We studied if oral administration of aspegic to rats modified 
      the aluminium inhibitory effect on brain (Na(+)/K(+))ATPase due to alteration in 
      synaptosomal membrane aluminium content. Adult male Wistar rats were submitted to 
      sub-acute (1.00g/day during 10 days) and chronic (0.03g/day during 4 months) 
      dietary AlCl3 exposure and/or to aspegic (0.11g/day). The exposure protocol 
      increased the synaptosomal aluminium content especially after a long-term 
      exposure to aluminium and aspegic. Although no alterations were observed in rat 
      body weight gain and adenylate energy charge, the (Na(+)/K(+))ATPase activity was 
      significantly reduced when aluminium was orally administered to rats. The oral 
      administration of aspegic increased the synaptosomal aluminium content and 
      concomitantly enhanced the (Na(+)/K(+))ATPase inhibition. In our exposure 
      protocol the increase in synaptosomal aluminium content correlates with the 
      reduction of the (Na(+)/K(+))ATPase activity.
CI  - Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
FAU - Silva, V S
AU  - Silva VS
AD  - CESAM & Departamento de Biologia, Universidade de Aveiro, 3810-193 Aveiro, 
      Portugal. Electronic address: vsilva@ua.pt.
FAU - Gonçalves, P P
AU  - Gonçalves PP
AD  - CESAM & Departamento de Biologia, Universidade de Aveiro, 3810-193 Aveiro, 
      Portugal. Electronic address: pgoncalves@ua.pt.
LA  - eng
PT  - Journal Article
DEP - 20141017
PL  - Netherlands
TA  - Toxicol Lett
JT  - Toxicology letters
JID - 7709027
RN  - 0 (Aluminum Compounds)
RN  - 0 (Chlorides)
RN  - 3CYT62D3GA (Aluminum Chloride)
RN  - EC 7.2.2.13 (Sodium-Potassium-Exchanging ATPase)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Oral
MH  - Aluminum Chloride
MH  - Aluminum Compounds/administration & dosage/metabolism/*toxicity
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/toxicity
MH  - Cerebral Cortex/*drug effects/enzymology
MH  - Chlorides/administration & dosage/metabolism/*toxicity
MH  - Lysine/administration & dosage/*analogs & derivatives/toxicity
MH  - Male
MH  - Neurotoxicity Syndromes/enzymology/*etiology
MH  - Presynaptic Terminals/*drug effects/enzymology
MH  - Rats, Wistar
MH  - Sodium-Potassium-Exchanging ATPase/*antagonists & inhibitors/metabolism
MH  - Synaptosomes/*drug effects/enzymology
MH  - Time Factors
OTO - NOTNLM
OT  - (Na(+)/K(+))ATPase
OT  - Aluminium
OT  - Aspegic
OT  - Presynaptic nerve terminals
OT  - Rat
EDAT- 2014/12/03 06:00
MHDA- 2017/02/09 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/06/21 00:00 [received]
PHST- 2014/10/09 00:00 [revised]
PHST- 2014/10/09 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
AID - S0378-4274(14)01387-3 [pii]
AID - 10.1016/j.toxlet.2014.10.014 [doi]
PST - ppublish
SO  - Toxicol Lett. 2015 Jan 5;232(1):167-74. doi: 10.1016/j.toxlet.2014.10.014. Epub 
      2014 Oct 17.

PMID- 781789
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20131121
IS  - 0035-2659 (Print)
IS  - 0035-2659 (Linking)
VI  - 43
IP  - 6
DP  - 1976 Jun
TI  - [Interaction of salicyl compounds and other non-steroidal anti-inflammatory 
      agents: pharmacokinetic study of phenylbutazone-aspirin combination in man].
PG  - 425-9
AB  - The pharmacodynamic interaction between phenybutazone and aspirin was studied in 
      9 patients. The levels of phenylbutazone were estimated by gas-chromatography and 
      verified by mass-spectrometry. When phenylbutazone was administered together with 
      salicylates a decrease in the bioavailability of phenylbutazone was demonstrated, 
      but there was no significant variation in the absorption and elimination 
      constants or in the half-life. The variations were much less than those observed 
      with other nonsteroid anti-inflammatory drugs (indometacine, naproxen, 
      fenoprofen). These interactions must be taken into account in the long-term 
      treatment of cases of inflammatory rheumatism.
FAU - Gaucher, A
AU  - Gaucher A
FAU - Netter, P
AU  - Netter P
FAU - Faure, G
AU  - Faure G
FAU - Tamisier, J N
AU  - Tamisier JN
FAU - Pourel, J
AU  - Pourel J
FAU - Maillard, A
AU  - Maillard A
FAU - Royer, R J
AU  - Royer RJ
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - A propos des interactions des salicylés et des autres anti-inflammatoires non 
      stéroidiens; etude pharmacocinétique de l'association phénylbutazone-aspirine 
      chez l'homme.
PL  - France
TA  - Rev Rhum Mal Osteoartic
JT  - Revue du rhumatisme et des maladies osteo-articulaires
JID - 0407211
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/metabolism/*pharmacology
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Drug Antagonism
MH  - *Drug Interactions
MH  - Drug Therapy, Combination
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenylbutazone/metabolism/*pharmacology
EDAT- 1976/06/01 00:00
MHDA- 1976/06/01 00:01
CRDT- 1976/06/01 00:00
PHST- 1976/06/01 00:00 [pubmed]
PHST- 1976/06/01 00:01 [medline]
PHST- 1976/06/01 00:00 [entrez]
PST - ppublish
SO  - Rev Rhum Mal Osteoartic. 1976 Jun;43(6):425-9.

PMID- 32046
OWN - NLM
STAT- MEDLINE
DCOM- 19790324
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 14
IP  - 5
DP  - 1978 Dec 18
TI  - Influence of food on the absorption of acetylsalicylic acid from enteric-coated 
      dosage forms.
PG  - 351-5
AB  - The absorption of acetylsalicylic acid (ASA) from two different enteric-coated 
      dosage forms, tablets (Premaspin) and granules (Reumyl), was studied in healthy 
      volunteers under fasting and non-fasting conditions by following the plasma 
      concentration and urine recovery of salicylates after single doses of ASA 1 g. 
      Conventional tablets (Aspirin) were used as the reference. Under fasting 
      conditions the absorption of ASA from the two different enteric-coated 
      preparations was complete. Taken with food the enteric-coated tablets gave much 
      lower plasma concentrations than under fasting conditions, and absorption was not 
      complete in all subjects. In contrast, absorption from the enteric-coated 
      granules was not influenced by the intake of food. It was concluded that 
      enteric-coated granules of ASA permit more reproducible absorption than 
      enteric-coated tablets.
FAU - Bogentoft, C
AU  - Bogentoft C
FAU - Carlsson, I
AU  - Carlsson I
FAU - Ekenved, G
AU  - Ekenved G
FAU - Magnusson, A
AU  - Magnusson A
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*metabolism
MH  - *Food
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - *Intestinal Absorption
MH  - Male
MH  - Tablets, Enteric-Coated
EDAT- 1978/12/18 00:00
MHDA- 1978/12/18 00:01
CRDT- 1978/12/18 00:00
PHST- 1978/12/18 00:00 [pubmed]
PHST- 1978/12/18 00:01 [medline]
PHST- 1978/12/18 00:00 [entrez]
AID - 10.1007/BF00611905 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1978 Dec 18;14(5):351-5. doi: 10.1007/BF00611905.

PMID- 7240262
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20210210
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 256
IP  - 13
DP  - 1981 Jul 10
TI  - Structural specificities in acylation of hemoglobin and sickle hemoglobin by 
      diaspirins.
PG  - 7046-52
AB  - Double-headed aspirins with bridging groups of different length and molecular 
      structure have been examined for their reactivity with hemoglobin A or S. The 
      compounds constructed are bound in the beta-cleft and show a wide range of 
      beta-beta cross-linking effectiveness. Oxygenation curves of the modified 
      hemoglobins in the presence of inositol hexaphosphate are strikingly modified. 
      Many of the diaspirins also produce substantial changes in the minimum gelling 
      concentration of sickle hemoglobin. These reagents offer possibilities for 
      further enhancement of specificity toward hemoglobin, particularly by taking 
      advantage of stereoselectivities.
FAU - Wood, L E
AU  - Wood LE
FAU - Haney, D N
AU  - Haney DN
FAU - Patel, J R
AU  - Patel JR
FAU - Clare, S E
AU  - Clare SE
FAU - Shi, G Y
AU  - Shi GY
FAU - King, L C
AU  - King LC
FAU - Klotz, I M
AU  - Klotz IM
LA  - eng
GR  - HL22719/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobin, Sickle)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Oxyhemoglobins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 578-19-8 (succinyldisalicylic acid)
RN  - 71337-52-5 (bis(3,5-dibromosalicyl)succinate)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemical synthesis
MH  - *Cross-Linking Reagents
MH  - *Hemoglobin A/metabolism
MH  - *Hemoglobin, Sickle/metabolism
MH  - Humans
MH  - Indicators and Reagents
MH  - Methods
MH  - Oxyhemoglobins/metabolism
MH  - Protein Binding
MH  - Structure-Activity Relationship
EDAT- 1981/07/10 00:00
MHDA- 1981/07/10 00:01
CRDT- 1981/07/10 00:00
PHST- 1981/07/10 00:00 [pubmed]
PHST- 1981/07/10 00:01 [medline]
PHST- 1981/07/10 00:00 [entrez]
AID - S0021-9258(19)69097-6 [pii]
PST - ppublish
SO  - J Biol Chem. 1981 Jul 10;256(13):7046-52.

PMID- 31775803
OWN - NLM
STAT- MEDLINE
DCOM- 20200219
LR  - 20200219
IS  - 1749-8090 (Electronic)
IS  - 1749-8090 (Linking)
VI  - 14
IP  - 1
DP  - 2019 Nov 27
TI  - Dual antiplatelet therapy up to the time of non-elective coronary artery bypass 
      grafting with prophylactic platelet transfusion: is it safe?
PG  - 202
LID - 10.1186/s13019-019-1028-2 [doi]
LID - 202
AB  - BACKGROUND: Guidelines suggest that patients discontinue Clopidogrel at least 
      5 days prior to coronary artery bypass grafting (CABG). Those with acute coronary 
      syndrome (ACS) are at high risk for myocardial infarction (MI) if not treated 
      with dual antiplatelet therapy (DAPT). We sought to assess pre and post-operative 
      outcomes of patients maintained on Clopidogrel and aspirin up to the time of 
      surgery and compare them with those on aspirin alone. METHODS: From the cardiac 
      surgery database, 240 patients were retrospectively registered between January 
      and May 2017. There were 126 patients with ACS who underwent CABG on DAPT 
      (Clopidogrel group [CG]) and 114 patients who underwent elective CABG on aspirin 
      alone (control). The CG received intraoperative prophylactic platelet transfusion 
      (PPT). Demographics, comorbidities, and laboratory data were prospectively 
      entered at the time of surgery and were subsequently retrieved for analysis. Per 
      and postoperative findings were identified and compared between both groups. 
      RESULTS: The cohort consisted of 240 patients (mean age 61 years, 81.3% were 
      male, SD ± 9.58). Patients in the CG were younger (Median 57 vs. 63, P-value 
      0.001), and with male predominance (86% versus 75%, P-value 0.028). In addition, 
      they had less prevalence for diabetes and renal failure as compared to control 
      (P-values 0.003, and 0.005, respectively). There were no significant differences 
      between both groups in number of vessels grafts, duration of on-pump and aortic 
      clamp. Hematologic laboratory data had also similar baseline values. The CG had 
      similar bleeding rate, redo surgery and in-hospital death (P-values 
      non-significant), however more infection and total hospital stay as compared to 
      control (p-values 0.048 and 0.001). CONCLUSION: Patients who are at increased 
      risk for MI can be maintained on DAPT up to the time of CABG because surgery is 
      safe when patients are offered PPT.
FAU - Charif, Fida
AU  - Charif F
AD  - Division of Pulmonary Medicine, Beirut Cardiac Institute, Beirut, Lebanon.
FAU - Hamdan, Righab
AU  - Hamdan R
AD  - Division of Cardiology Medicine, Beirut Cardiac Institute, Beirut, Lebanon. 
      mdrighabh@hotmail.com.
FAU - Youness, Genane
AU  - Youness G
AD  - Department of statistics, ISSAE, Cnam, Beirut, Lebanon.
FAU - El Zein, Ali
AU  - El Zein A
AD  - Department of Anesthesiology, Beirut Cardiac Institute, Beirut, Lebanon.
FAU - Issa, Mohamad
AU  - Issa M
AD  - Department of Anesthesiology, Beirut Cardiac Institute, Beirut, Lebanon.
FAU - Jassar, Yehya
AU  - Jassar Y
AD  - Department of Cardiovascular surgery, Beirut Cardiac Institute, Beirut, Lebanon.
FAU - Younes, Mahmoud
AU  - Younes M
AD  - Medical research center, Beirut Cardiac Institute, Rassoul Aazam Hospital, 
      Beirut, Lebanon.
FAU - Saab, Mohamad
AU  - Saab M
AD  - Department of Cardiovascular surgery, Beirut Cardiac Institute, Beirut, Lebanon.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20191127
PL  - England
TA  - J Cardiothorac Surg
JT  - Journal of cardiothoracic surgery
JID - 101265113
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy/surgery
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Clopidogrel/*administration & dosage/therapeutic use
MH  - Combined Modality Therapy
MH  - *Coronary Artery Bypass
MH  - Drug Administration Schedule
MH  - Dual Anti-Platelet Therapy/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/etiology/prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - *Platelet Transfusion
MH  - Preoperative Care/*methods
MH  - Retrospective Studies
PMC - PMC6880414
OTO - NOTNLM
OT  - ACS
OT  - Aspirine
OT  - CABG
OT  - Clopidogrel
OT  - Platelet transfusion
COIS- The authors declare that they have no competing interests.
EDAT- 2019/11/30 06:00
MHDA- 2020/02/20 06:00
CRDT- 2019/11/29 06:00
PHST- 2019/08/17 00:00 [received]
PHST- 2019/11/18 00:00 [accepted]
PHST- 2019/11/29 06:00 [entrez]
PHST- 2019/11/30 06:00 [pubmed]
PHST- 2020/02/20 06:00 [medline]
AID - 10.1186/s13019-019-1028-2 [pii]
AID - 1028 [pii]
AID - 10.1186/s13019-019-1028-2 [doi]
PST - epublish
SO  - J Cardiothorac Surg. 2019 Nov 27;14(1):202. doi: 10.1186/s13019-019-1028-2.

PMID- 1611062
OWN - NLM
STAT- MEDLINE
DCOM- 19920727
LR  - 20131121
IS  - 0365-9615 (Print)
IS  - 0365-9615 (Linking)
VI  - 113
IP  - 2
DP  - 1992 Feb
TI  - [Anti-ischemic protection of the brain using water-soluble form of 
      aspirin-acelisin].
PG  - 156-9
AB  - The domestic water-soluble aspirin (acelisin) has been used as an anti-ischemic 
      brain protector. The total brain ischemia has been implemented in accordance with 
      an original technique for 17 to 35 min. The doses of acelisin from 25 to 250 
      mg/kg have been tested during experiments. The infusion of solutions has been 
      carried out before ischemia, 15 min before reperfusion and just after the 
      beginning of reperfusion. The functional status and survival of rats have been 
      evaluated during a week. The best result has been reached with 150 mg/kg acelisin 
      injected 30 min before ischaemia. A positive effect was reported when acelisin 
      was used in early postischaemic period.
FAU - Tel'pukhov, V I
AU  - Tel'pukhov VI
FAU - Bilenko, M V
AU  - Bilenko MV
FAU - Tikhomirova, A I
AU  - Tikhomirova AI
FAU - Komarov, P G
AU  - Komarov PG
FAU - Morganov, A A
AU  - Morganov AA
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Protivoishemicheskaia zashchita golovnogo mozga s pomoshch'iu vodorastvorimoĭ 
      formy aspirina-atselizina.
PL  - Russia (Federation)
TA  - Biull Eksp Biol Med
JT  - Biulleten' eksperimental'noi biologii i meditsiny
JID - 0370627
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Brain Ischemia/*prevention & control
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Solubility
MH  - Time Factors
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
PST - ppublish
SO  - Biull Eksp Biol Med. 1992 Feb;113(2):156-9.

PMID- 2011121
OWN - NLM
STAT- MEDLINE
DCOM- 19910508
LR  - 20190824
IS  - 0161-5890 (Print)
IS  - 0161-5890 (Linking)
VI  - 28
IP  - 1-2
DP  - 1991 Jan-Feb
TI  - Acetylsalicylate-human serum albumin interaction as studied by NMR 
      spectroscopy--antigenicity-producing mechanism of acetylsalicylic acid.
PG  - 107-13
AB  - To discover the antigenicity-producing mechanism of acetylsalicylic acid, the 
      interaction of this drug and relevant salicylic acid with human serum albumin 
      (HSA) has been studied by means of nuclear magnetic resonance (NMR) spectroscopy. 
      The determination of spin-lattice relaxation rates (1/T1) of some protons have 
      revealed that one HSA molecule can bind acetylsalicylate and salicylate up to 80 
      and 290 molecules, respectively. The hydrolysis rates of acetylsalicylate were 
      greatly enhanced in the presence of HSA, especially when the drug/HSA mole ratio 
      was small. Thus, the esterase-like activity of HSA was verified. This activity of 
      HSA was effectively inhibited by salicylate; the effect was ascribed to the 
      stronger binding affinity of salicylate toward HSA as compared with that of 
      acetylsalicylate. Based on these results, the antigenicity-producing mechanism of 
      acetylsalicylate and salicylate has been discussed.
FAU - Honma, K
AU  - Honma K
AD  - Department of Immunology, Toho University School of Medicine, Tokyo, Japan.
FAU - Nakamura, M
AU  - Nakamura M
FAU - Ishikawa, Y
AU  - Ishikawa Y
LA  - eng
PT  - Journal Article
PL  - England
TA  - Mol Immunol
JT  - Molecular immunology
JID - 7905289
RN  - 0 (Serum Albumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/immunology
MH  - Humans
MH  - In Vitro Techniques
MH  - Magnetic Resonance Spectroscopy
MH  - Protein Binding
MH  - Serum Albumin/*chemistry
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1016/0161-5890(91)90093-y [doi]
PST - ppublish
SO  - Mol Immunol. 1991 Jan-Feb;28(1-2):107-13. doi: 10.1016/0161-5890(91)90093-y.

PMID- 486423
OWN - NLM
STAT- MEDLINE
DCOM- 19791229
LR  - 20190613
IS  - 0006-2960 (Print)
IS  - 0006-2960 (Linking)
VI  - 18
IP  - 20
DP  - 1979 Oct 2
TI  - Diaspirins that cross-link beta chains of hemoglobin: bis(3,5-dibromosalicyl) 
      succinate and bis(3,5-dibromosalicyl) fumarate.
PG  - 4265-70
AB  - Two double-headed aspirins, bis(3,5-dibromosalicyl) succinate and 
      bis(3,5-dibromosalicyl) fumarate, have been found to be potent acylating agents 
      of intracellular hemoglobin (A or S) in vitro. Furthermore, each of these 
      reagents cross-links beta chains of hemoglobin, probably at the beta cleft. The 
      modified hemoglobins show increased oxygen affinities and reduced gelation or 
      sickling tendencies.
FAU - Walder, J A
AU  - Walder JA
FAU - Zaugg, R H
AU  - Zaugg RH
FAU - Walder, R Y
AU  - Walder RY
FAU - Steele, J M
AU  - Steele JM
FAU - Klotz, I M
AU  - Klotz IM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Fumarates)
RN  - 0 (Hemoglobin, Sickle)
RN  - 0 (Hemoglobins)
RN  - 0 (Macromolecular Substances)
RN  - 0 (Oxyhemoglobins)
RN  - 0 (Succinates)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Acylation
MH  - Aspirin/*analogs & derivatives
MH  - *Cross-Linking Reagents
MH  - Erythrocytes/metabolism
MH  - Fumarates
MH  - Hemoglobin A
MH  - Hemoglobin, Sickle
MH  - *Hemoglobins
MH  - Humans
MH  - Macromolecular Substances
MH  - Oxygen/blood
MH  - Oxyhemoglobins
MH  - Succinates
EDAT- 1979/10/02 00:00
MHDA- 1979/10/02 00:01
CRDT- 1979/10/02 00:00
PHST- 1979/10/02 00:00 [pubmed]
PHST- 1979/10/02 00:01 [medline]
PHST- 1979/10/02 00:00 [entrez]
AID - 10.1021/bi00587a001 [doi]
PST - ppublish
SO  - Biochemistry. 1979 Oct 2;18(20):4265-70. doi: 10.1021/bi00587a001.

PMID- 29466186
OWN - NLM
STAT- MEDLINE
DCOM- 20190305
LR  - 20191113
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 57
IP  - S3
DP  - 2017 Mar
TI  - [Safety and efficacy of long-term treatment with different ASA forms in patients 
      with stable IHD and a high risk for development of gastropathy by data from a 
      cross-sectionals study].
PG  - 24-31
AB  - AIM: To study indexes of efficacy, safety and compliance for different ASA forms 
      (Aspirin-Cardio, Cardiomagnyl, Thrombo ASS) used in stable IHD. MATERIALS AND 
      METHODS: An open, cross-sectional study compared three groups of patients 
      consisting of 200 patients each who had stable IHD and a high risk of 
      gastrointestinal disorders and who received a long-term antiaggregant monotherapy 
      with one of ASA drugs (group 1, Aspirin Cardio; group 2, Thrombo ASS; group 3, 
      Cardiomagnyl). Efficacy, safety and compliance with the treatment were evaluated 
      using standard tests and analogue scales; dyspepsia symptoms were evaluated using 
      a special, additionally developed questionnaire. RESULTS: The Aspirin-Cardio 
      treatment reduced the mean score of GI symptom severity from the questionnaire 
      (1.4-1.6 times, р=0.001), requirement for proton pump inhibitors (р=0.002) and 
      endoscopy during the ASA treatment the mean score of GI symptom questionnaire >3 
      predicted non-compliance or insufficient compliance with a diagnostic sensitivity 
      of 58.9 % and specificity of 56.3 % (р=0.002), which makes this value a threshold 
      for considering a modification of the treatment. CONCLUSION: Aspirin-Cardio is 
      characterized by better safety in respect of GI symptoms and better compliance 
      with the treatment during long-term prophylactic therapy. The proposed 
      questionnaire for evaluation of GI symptoms can be used for specifying 
      indications and modifying the treatment tactics.
FAU - Nekrasov, A A
AU  - Nekrasov AA
AD  - Federal State Budgetary Educational Institution of Higher Education, "Nizhny 
      Novgorod State Medical Academy" of the Ministry of Health of the Russian 
      Federation.
FAU - Timoshchenko, E S
AU  - Timoshchenko ES
AD  - State Budgetary Institution of Health Care of Nizhegorodskaya Region, "Municipal 
      Clinical Hospital #5".
FAU - Petelina, I S
AU  - Petelina IS
AD  - State Budgetary Institution of Health Care of Nizhegorodskaya Region, "Municipal 
      Clinical Hospital #5".
FAU - Karpukhina, E V
AU  - Karpukhina EV
AD  - Federal State Budgetary Educational Institution of Higher Education, "Nizhny 
      Novgorod State Medical Academy" of the Ministry of Health of the Russian 
      Federation.
LA  - rus
PT  - Journal Article
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/*analogs & derivatives/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Long-Term Care
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Ischemia/complications/drug therapy/physiopathology
MH  - Patient Compliance
OTO - NOTNLM
OT  - acetylsalicylic acid preparations, safety, copmliance, gastrointestinal disorders
EDAT- 2018/02/22 06:00
MHDA- 2019/03/06 06:00
CRDT- 2018/02/22 06:00
PHST- 2018/02/22 06:00 [entrez]
PHST- 2018/02/22 06:00 [pubmed]
PHST- 2019/03/06 06:00 [medline]
AID - 10.18087/cardio.2380 [doi]
PST - ppublish
SO  - Kardiologiia. 2017 Mar;57(S3):24-31. doi: 10.18087/cardio.2380.

PMID- 12541957
OWN - NLM
STAT- MEDLINE
DCOM- 20030822
LR  - 20161124
IS  - 1000-8713 (Print)
IS  - 1000-8713 (Linking)
VI  - 20
IP  - 3
DP  - 2002 May
TI  - [Determination of aspirin and free salicylic acid in lysinipirine injection by 
      high performance liquid chromatography].
PG  - 277-8
AB  - The contents of aspirin and free salicylic acid in lysinipirine injection were 
      determined by high performance liquid chromatography (HPLC). A Hypersil BDS C18 
      column was used with the mobile phase of methanol-water-acetic acid (35:65:3, 
      volume ratio) and the detection wavelength of 280 nm. The average recoveries of 
      aspirin and salicylic acid added were 99.27% (RSD = 0.8%) and 99.61%(RSD = 1.3%), 
      respectively. The calibration curves had good linearity in the range of 0.028 g/L 
      -0.141 mg/L and 0.77 mg/L -3.85 mg/L, and the correlation coefficients were 
      0.9999 and 0.9998 for aspirin and salicylic acid respectively.
FAU - Dong, Yu
AU  - Dong Y
AD  - Dalian Institute for Drug Control, Dalian 116021, China.
FAU - Zhao, Yuan-zheng
AU  - Zhao YZ
FAU - Zhang, Yi-na
AU  - Zhang YN
LA  - chi
PT  - Journal Article
PL  - China
TA  - Se Pu
JT  - Se pu = Chinese journal of chromatography
JID - 9424804
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry
MH  - Aspirin/*analogs & derivatives/*analysis/*chemistry
MH  - Calibration
MH  - Chromatography, High Pressure Liquid
MH  - Lysine/*analogs & derivatives/*chemistry
MH  - Salicylic Acid/*analysis
EDAT- 2003/01/25 04:00
MHDA- 2003/08/23 05:00
CRDT- 2003/01/25 04:00
PHST- 2003/01/25 04:00 [pubmed]
PHST- 2003/08/23 05:00 [medline]
PHST- 2003/01/25 04:00 [entrez]
PST - ppublish
SO  - Se Pu. 2002 May;20(3):277-8.

PMID- 3558647
OWN - NLM
STAT- MEDLINE
DCOM- 19870521
LR  - 20190629
VI  - 388
IP  - 1
DP  - 1987 Feb 6
TI  - Quantitative determination by high-performance liquid chromatography of 
      acetylsalicylic acid and related substances in tablets.
PG  - 201-16
AB  - High-performance liquid chromatography on a Zorbax C8 7-micron column (25 cm X 
      0.46 cm I.D.) with methanol-water-1 M phosphoric acid (59:36:5) as the mobile 
      phase has been used for the analysis of several naturally aged batches of 
      fourteen brands of acetylsalicyclic acid tablets. The extraction solvent is 
      methanol, containing 2% v/v of formic acid. Salicylic acid is the main impurity. 
      Acetylsalicylsalicylic acid is the second most important impurity, and the 
      corresponding salicylsalicylic acid is rarely present. Buffered or dispersible 
      tablets contain relatively more of the latter two impurities and eventually also 
      the corresponding higher oligomers. Acetylsalicylic anhydride is always a minor 
      impurity. Comparison is made with classical spectrophotometric methods, which are 
      observed to be selective for salicylic acid.
FAU - Verstraeten, A
AU  - Verstraeten A
FAU - Roets, E
AU  - Roets E
FAU - Hoogmartens, J
AU  - Hoogmartens J
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Chromatogr
JT  - Journal of chromatography
JID - 0427043
RN  - 0 (Indicators and Reagents)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*analysis
MH  - Chromatography, High Pressure Liquid
MH  - Indicators and Reagents
MH  - Pharmacopoeias as Topic
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets
MH  - United Kingdom
MH  - United States
EDAT- 1987/02/06 00:00
MHDA- 1987/02/06 00:01
CRDT- 1987/02/06 00:00
PHST- 1987/02/06 00:00 [pubmed]
PHST- 1987/02/06 00:01 [medline]
PHST- 1987/02/06 00:00 [entrez]
AID - 10.1016/s0021-9673(01)94480-2 [doi]
PST - ppublish
SO  - J Chromatogr. 1987 Feb 6;388(1):201-16. doi: 10.1016/s0021-9673(01)94480-2.

PMID- 314982
OWN - NLM
STAT- MEDLINE
DCOM- 19791220
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 6
IP  - 3
DP  - 1979 May-Jun
TI  - Twice-daily dosing of enteric-coated aspirin in patients with rheumatic diseases.
PG  - 351-9
AB  - To determine the feasibility of twice daily dosing of enteric-coated aspirin 
      (EntrophenR), a preliminary trial on 10 patients with rheumatic diseases was 
      conducted. Three plasma salicylate levels on 2 separate occasions, 1 day apart, 
      were determined. In 9 of the 10 patients studied at steady-state, therapeutic 
      levels were attained (15-30 mg/dl). There were no gastrointestinal side-effects. 
      One case developed tinnitus which resolved with a small reduction in dosage. On 
      the basis of this short-term study, twice-daily EC-ASA appears to be effective in 
      maintaining adequate plasma salicylate levels, and it seems to compare favourably 
      to ASA given in multiple daily doses. On a long-term basis, it may improve 
      patient compliance.
FAU - Bensen, W G
AU  - Bensen WG
FAU - Laskin, C A
AU  - Laskin CA
FAU - Paton, T W
AU  - Paton TW
FAU - Little, H A
AU  - Little HA
FAU - Fam, A G
AU  - Fam AG
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology/therapeutic use
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rheumatic Diseases/*drug therapy
MH  - Tablets, Enteric-Coated
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1979 May-Jun;6(3):351-9.

PMID- 29891331
OWN - NLM
STAT- MEDLINE
DCOM- 20190523
LR  - 20190523
IS  - 2352-3840 (Electronic)
IS  - 1499-2671 (Linking)
VI  - 43
IP  - 1
DP  - 2019 Feb
TI  - Serum Brain-Derived Neurotrophic Factor is Related to Platelet Reactivity and 
      Metformin Treatment in Adult Patients With Type 2 Diabetes Mellitus.
PG  - 19-26
LID - S1499-2671(17)30734-7 [pii]
LID - 10.1016/j.jcjd.2018.01.014 [doi]
AB  - OBJECTIVES: The aim of this study was to investigate the association of serum 
      brain-derived neurotrophic factor (BDNF) levels with platelet reactivity and 
      antidiabetes treatment, as well as serum adipocytokine concentrations. METHODS: 
      This observational, open-label study enrolled 149 patients. Serum BDNF, 
      hematologic, biochemical parameters and platelet reactivity were measured. Blood 
      samples were taken after the last acetylsalicylic acid dose. RESULTS: Patients 
      with high BDNF levels were younger (65.60±8.956 vs. 68.59±8.516) and smoked 
      cigarettes more frequently (14.6% vs. 4.1%); they were more commonly being 
      treated by metformin (77.3% vs. 54%); had higher platelet counts (245.81±68.85 
      10(3)/mm(3) vs. 206.61±44.48 10(3)/mm(3)); had shorter collagen-adenosine 
      diphosphate closure time (CADP-CT) values (104.88±69.73 s vs. 140.93±86.63 s); 
      had higher triglyceride concentrations (140.73±67.5 vs. 121.76±60.49) and had 
      higher concentrations of serum thromboxane B2 (0.938±1.59 vs. 0.364±0.76). In 
      univariate linear regression analyses, predictive factors for serum BDNF levels 
      above the median were metformin treatment, current smoking, platelet count, 
      triglyceride concentration, total cholesterol concentration and CADP-CT >74 s. In 
      multivariate backward stepwise analysis CADP-CT >141 s; adiponectin concentration 
      >4.22 µg/mL; total cholesterol and low-density lipoprotein levels were 
      independently associated with serum BDNF levels above the median. CONCLUSIONS: 
      Our results suggest that BDNF may be associated with lipid metabolism and that 
      increased production of BDNF may be related to metformin treatment. Moreover, we 
      showed an association between BDNF levels and platelet reactivity; we found that 
      serum BDNF levels in patients with type 2 diabetes who had high platelet 
      reactivity were higher than in subjects with normal platelet reactivity despite 
      antiplatelet therapy.
CI  - Copyright © 2018 Diabetes Canada. Published by Elsevier Inc. All rights reserved.
FAU - Eyileten, Ceren
AU  - Eyileten C
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
FAU - Mirowska-Guzel, Dagmara
AU  - Mirowska-Guzel D
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland. 
      Electronic address: dmirowska@wum.edu.pl.
FAU - Milanowski, Lukasz
AU  - Milanowski L
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
FAU - Zaremba, Malgorzata
AU  - Zaremba M
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
FAU - Rosiak, Marek
AU  - Rosiak M
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
FAU - Cudna, Agnieszka
AU  - Cudna A
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
FAU - Kaplon-Cieslicka, Agnieszka
AU  - Kaplon-Cieslicka A
AD  - Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
FAU - Opolski, Grzegorz
AU  - Opolski G
AD  - Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
FAU - Filipiak, Krzysztof J
AU  - Filipiak KJ
AD  - Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
FAU - Malek, Lukasz
AU  - Malek L
AD  - Faculty of Rehabilitation, University of Physical Education, Warsaw, Poland.
FAU - Postula, Marek
AU  - Postula M
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Randomized Controlled Trial
DEP - 20180203
PL  - Canada
TA  - Can J Diabetes
JT  - Canadian journal of diabetes
JID - 101148810
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/therapeutic use
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Male
MH  - Metformin/pharmacology/*therapeutic use
MH  - Middle Aged
MH  - Platelet Activation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - adiponectin
OT  - adiponectine
OT  - aspirin
OT  - aspirine
OT  - diabetes mellitus
OT  - diabète sucré
OT  - metformin
OT  - metformine
OT  - plaquette
OT  - platelet
EDAT- 2018/06/13 06:00
MHDA- 2019/05/24 06:00
CRDT- 2018/06/13 06:00
PHST- 2017/09/02 00:00 [received]
PHST- 2018/01/31 00:00 [accepted]
PHST- 2018/06/13 06:00 [pubmed]
PHST- 2019/05/24 06:00 [medline]
PHST- 2018/06/13 06:00 [entrez]
AID - S1499-2671(17)30734-7 [pii]
AID - 10.1016/j.jcjd.2018.01.014 [doi]
PST - ppublish
SO  - Can J Diabetes. 2019 Feb;43(1):19-26. doi: 10.1016/j.jcjd.2018.01.014. Epub 2018 
      Feb 3.

PMID- 10319419
OWN - NLM
STAT- MEDLINE
DCOM- 19990802
LR  - 20191024
IS  - 1039-9712 (Print)
IS  - 1039-9712 (Linking)
VI  - 47
IP  - 4
DP  - 1999 Apr
TI  - An NMR study of the structural basis of the wide range of pharmacological 
      functions of acetylsalicylic acid.
PG  - 665-71
AB  - The interaction between acetylsalicylic acid (aspirin) and membrane was studied 
      by NMR spectra. (1) NMR spectra showed acetylsalicylic acid did not insert into 
      membrane; (2) 1H NMR spectrum recorded by spin-echo pulse sequence showed protons 
      of the aromatic ring interacted with membrane; (3) the change of spin-lattice 
      relaxation (T1) of 31P was ascribed to the association of acetylsalicylic acid to 
      the polar head of lecithin; (4) the self-diffusion coefficient measured by pulsed 
      field gradients NMR showed the mobility of acetylsalicylic acid was restricted by 
      membrane and that acetylsalicylic acid changed membrane viscosity. Based on the 
      results, the relationship between the interaction and the mechanism of the wide 
      pharmacological functions of acetylsalicylic acid is discussed.
FAU - Li, J
AU  - Li J
AD  - School of Life Science, Wuhan University, P. R. China. jingzhi9@hotmail.com
FAU - Huang, H
AU  - Huang H
FAU - Zhou, M
AU  - Zhou M
FAU - Ning, S
AU  - Ning S
FAU - Jiang, X
AU  - Jiang X
FAU - Peng, Y
AU  - Peng Y
FAU - Zhao, K
AU  - Zhao K
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biochem Mol Biol Int
JT  - Biochemistry and molecular biology international
JID - 9306673
RN  - 0 (Liposomes)
RN  - 0 (Phosphatidylcholines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/metabolism/pharmacology
MH  - Liposomes
MH  - Magnetic Resonance Spectroscopy
MH  - Phosphatidylcholines/metabolism
MH  - Structure-Activity Relationship
EDAT- 1999/05/13 00:00
MHDA- 1999/05/13 00:01
CRDT- 1999/05/13 00:00
PHST- 1999/05/13 00:00 [pubmed]
PHST- 1999/05/13 00:01 [medline]
PHST- 1999/05/13 00:00 [entrez]
AID - 10.1080/15216549900201723 [doi]
PST - ppublish
SO  - Biochem Mol Biol Int. 1999 Apr;47(4):665-71. doi: 10.1080/15216549900201723.

PMID- 15185599
OWN - NLM
STAT- MEDLINE
DCOM- 20040629
LR  - 20131121
IS  - 0041-4131 (Print)
IS  - 0041-4131 (Linking)
VI  - 82
IP  - 2
DP  - 2004 Feb
TI  - [Exploring the effect of aspirin on primary hemostasis through bleeding time. 
      Study of 16 volunteers].
PG  - 219-22
AB  - Strong anti-binding platelets, aspirin is used in the treatment or the prevention 
      of many thrombotic pathologies. We wanted to study the effect of aspirin over the 
      bleeding time of a group of volunteers. It consisted of 16 volunteers aged from 
      20 to 25 years and having no haemorrhagic or thrombotic antecedent. For each of 
      them, we have carried out a blood count by means of an automaton Sysmex K800, 
      followed by a measure of the bleeding time (BT). Immediately after, each 
      volunteer has ingested 250 mg of Aspegic; then, the BT has been measured every 24 
      hours and up to the fifth day. The BT has been carried out by means of IVY 
      technique 3 points, that besides the time, allows to measure the volume of 
      bleeding (microliter). All the check-ups were normal, however, the time and 
      volumes of bleeding were respective by short and weak. After having taken 
      aspirin, the bleeding time has significantly become longer to day 1 and day 2 
      (respectively 48% and 31.5% with regard to day 0) and the volume has increased to 
      day 1, day 2 and day 3 (respectively 122.6%, 74.7% and 38.1% with regard to day 
      0).
FAU - Gargouri, Jalel
AU  - Gargouri J
FAU - Mnif, Hela
AU  - Mnif H
FAU - Sellami, Samia
AU  - Sellami S
FAU - Rekik, Hayet
AU  - Rekik H
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Exploration de l'effet de l'aspirine sur l'hemostase primaire par le temps de 
      saignement. Etude à propos de 16 volontaires.
PL  - Tunisia
TA  - Tunis Med
JT  - La Tunisie medicale
JID - 0413766
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - Hemostasis/*physiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 2004/06/10 05:00
MHDA- 2004/06/30 05:00
CRDT- 2004/06/10 05:00
PHST- 2004/06/10 05:00 [pubmed]
PHST- 2004/06/30 05:00 [medline]
PHST- 2004/06/10 05:00 [entrez]
PST - ppublish
SO  - Tunis Med. 2004 Feb;82(2):219-22.

PMID- 10756785
OWN - NLM
STAT- MEDLINE
DCOM- 20000519
LR  - 20131121
IS  - 0048-7848 (Print)
IS  - 0048-7848 (Linking)
VI  - 101
IP  - 3-4
DP  - 1997 Jul-Dec
TI  - Antirheumatic effects of first-line agents in the treatment of juvenile chronic 
      arthritis.
PG  - 134-8
AB  - The main goal of the present study was to investigate comparatively (in the last 
      8 years) the effects of nonsteroidal antiinflammatory drugs (NSAIDs) on a sample 
      of 100 children diagnosed with juvenile chronic arthritis (JCA). The patients 
      were divided in 3 smaller groups, as follows: group 1--prescribed diclofenac, 
      group 2--paduden and group 3--aspirin. Clinical features and laboratory findings 
      were evaluated after: a 2 months trial, 4 months trial, 6 months trial, 2 years 
      trial, 3 years trial and more than 5 years trial, from the beginning of the 
      NSAIDs therapy. The results were the followings: within the first 12 weeks of 
      therapy with NSAIDs a good response was obtained in 64% (group 1), 59% (group 2) 
      and 53% (group 3) of the managed children, respectively; after 8 years of 
      treatment for the children remained under medical observation in our clinic, the 
      remission was obtained in 68% (diclofenac), 60% (paduden) and 64% (aspirin) of 
      the patients on NSAIDs therapy. The incidence of side-effects in the groups 
      treated with diclofenac and paduden has been present in a smaller percentage and 
      less severe than in the aspirin's group. No child managed with diclofenac had 
      major gastrointestinal, hepatic or renal reactions. These results highlight the 
      superiority of diclofenac as a new drug over aspirin and paduden, in the 
      treatment of JCA.
FAU - Ailioaie, C
AU  - Ailioaie C
AD  - Second Paediatric Clinic, Faculty of Medicine, Gr. T. Popa University of Medicine 
      and Pharmacy, Iassy.
FAU - Lupuşoru-Ailioaie, L M
AU  - Lupuşoru-Ailioaie LM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Romania
TA  - Rev Med Chir Soc Med Nat Iasi
JT  - Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi
JID - 0413735
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antirheumatic Agents)
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - Antirheumatic Agents/*administration & dosage/adverse effects
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/administration & dosage/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Diclofenac/administration & dosage/adverse effects
MH  - Humans
MH  - Infant
MH  - Time Factors
EDAT- 1997/07/01 00:00
MHDA- 2000/06/08 09:00
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 2000/06/08 09:00 [medline]
PHST- 1997/07/01 00:00 [entrez]
PST - ppublish
SO  - Rev Med Chir Soc Med Nat Iasi. 1997 Jul-Dec;101(3-4):134-8.

PMID- 29894671
OWN - NLM
STAT- MEDLINE
DCOM- 20190521
LR  - 20190521
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
IP  - S5
DP  - 2018 SMay
TI  - [Dosage forms and doses of acetylsalicylic acid: significance for clinical 
      practice].
PG  - 4-12
AB  - The article presents a review of pharmacokinetics and pharmacodynamics of 
      different acetylsalicylic acid (ASA) dosage forms. The review showed that 
      efficacy and safety of ASA are determined by its systemic effects and do not 
      depend on the dosage form. Issues of ASA resistance are discussed.
FAU - Tarlovskaya, E I
AU  - Tarlovskaya EI
AD  - Federal State Budgetary Educational Institution of Higher Education, "Nizhny 
      Novgorod State Medical Academy" of the Ministry of Health of the Russian 
      Federation.
LA  - rus
PT  - Journal Article
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
OTO - NOTNLM
OT  - acetylsalicylic acid, aspirin, antithrombotic therapy, аspirin dosage forms, 
      aspirin resistance
EDAT- 2018/06/13 06:00
MHDA- 2019/05/22 06:00
CRDT- 2018/06/13 06:00
PHST- 2018/06/13 06:00 [entrez]
PHST- 2018/06/13 06:00 [pubmed]
PHST- 2019/05/22 06:00 [medline]
PST - ppublish
SO  - Kardiologiia. 2018 SMay;(S5):4-12.

PMID- 10797981
OWN - NLM
STAT- MEDLINE
DCOM- 20000518
LR  - 20131121
IS  - 0049-1101 (Print)
IS  - 0049-1101 (Linking)
VI  - 44
IP  - 1
DP  - 1999
TI  - [Comparative study of the antithrombotic effect of aspirin and Bay U3405, 
      antagonist of a thromboxane A2 receptor].
PG  - 25-7
AB  - The antithrombotic activity of aspirin (acetylsalicylic acid), inhibitor of the 
      synthesis of thromboxane A2 was compared to that of Bay U3405, a thromboxane A2 
      receptor antagonist. A model of experimental thrombosis induced by laser in 
      guinea pig mesenteric arteries was used. Aspirin exhibited a dose-dependent 
      antithrombotic activity with and inhibitory effect of 70% at the high dose of 100 
      mg/kg while Bay U 3405 was efficient at the dose of 10 mg/kg with a percent of 
      inhibition that did not exceed 55%. These results showed that: first, the 
      inhibition of the activity of thromboxane A2 by an antagonist was not more 
      important than that by aspirin and second, the thromboxane A2 way was well 
      implicated in the thrombosis in the guinea pig, suggesting that this species was 
      a good model for the study of the mechanisms using the prostaglandins way in 
      arterial thrombosis.
FAU - Cissé-Thiam, M
AU  - Cissé-Thiam M
AD  - Laboratoire de Bactériologie, CHU de Dakar.
FAU - Drouet, L
AU  - Drouet L
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Etude comparative des effets antithrombotiques de l'aspirine et du Bay U3405, 
      antagoniste d'un récepteur de thromboxane A2.
PL  - Senegal
TA  - Dakar Med
JT  - Dakar medical
JID - 7907630
RN  - 0 (Carbazoles)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Receptors, Thromboxane)
RN  - 0 (Sulfonamides)
RN  - P1ALI72U6C (ramatroban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Carbazoles/administration & dosage/*pharmacology
MH  - Fibrinolytic Agents/*pharmacology
MH  - Guinea Pigs
MH  - Male
MH  - Mesenteric Arteries
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Receptors, Thromboxane/*antagonists & inhibitors
MH  - Sulfonamides/administration & dosage/*pharmacology
MH  - Thrombosis/drug therapy
EDAT- 2000/05/08 09:00
MHDA- 2000/05/20 09:00
CRDT- 2000/05/08 09:00
PHST- 2000/05/08 09:00 [pubmed]
PHST- 2000/05/20 09:00 [medline]
PHST- 2000/05/08 09:00 [entrez]
PST - ppublish
SO  - Dakar Med. 1999;44(1):25-7.

PMID- 6728039
OWN - NLM
STAT- MEDLINE
DCOM- 19840718
LR  - 20190725
IS  - 0028-1298 (Print)
IS  - 0028-1298 (Linking)
VI  - 325
IP  - 3
DP  - 1984 Mar
TI  - Butyl hydroxy toluene antagonizes the gastric toxicity but not the 
      pharmacological activity of acetylsalicylic acid in rats.
PG  - 283-5
AB  - Butyl hydroxy toluene reduced gastric erosion due to acetylsalicylic acid in the 
      rat, but not the antiinflammatory, anti-pyretic and analgesic activity. By 
      itself, BHT exhibited activity only in the test on analgesia.
FAU - van Kolfschoten, A A
AU  - van Kolfschoten AA
FAU - Hagelen, F
AU  - Hagelen F
FAU - van Noordwijk, J
AU  - van Noordwijk J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
RN  - 1P9D0Z171K (Butylated Hydroxytoluene)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesia
MH  - Animals
MH  - Aspirin/*antagonists & inhibitors/therapeutic use/toxicity
MH  - Butylated Hydroxytoluene/*pharmacology
MH  - Carrageenan
MH  - Edema/drug therapy
MH  - Fever/drug therapy
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach/*drug effects
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
AID - 10.1007/BF00495956 [doi]
PST - ppublish
SO  - Naunyn Schmiedebergs Arch Pharmacol. 1984 Mar;325(3):283-5. doi: 
      10.1007/BF00495956.

PMID- 15879390
OWN - NLM
STAT- MEDLINE
DCOM- 20050519
LR  - 20181221
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Print)
IS  - 0959-8138 (Linking)
VI  - 330
IP  - 7499
DP  - 2005 May 7
TI  - Effect of combinations of drugs on all cause mortality in patients with ischaemic 
      heart disease: nested case-control analysis.
PG  - 1059-63
AB  - OBJECTIVE: To determine the effect of combinations of statins, aspirin, beta 
      blockers, and angiotensin converting enzyme inhibitors in the secondary 
      prevention of all cause mortality in patients with ischaemic heart disease. 
      DESIGN: Open prospective cohort study with nested case-control analysis. SETTING: 
      1.18 million patients registered with 89 general practices across 23 strategic 
      health authority areas within the United Kingdom. Practices had longitudinal data 
      for a minimum of eight years and were contributing to QRESEARCH, a new database. 
      PATIENTS: All patients with a first diagnosis of ischaemic heart disease between 
      January 1996 and December 2003. Cases were patients with ischaemic heart disease 
      who died. Controls were patients with ischaemic heart disease who were matched 
      for age, sex, and year of diagnosis and were alive at the time their matched case 
      died. MAIN OUTCOME MEASURES: Odds ratio with 95% confidence interval for risk of 
      death in cases compared with controls. Exposure was current use of different 
      combinations of statins, aspirin, beta blockers, and angiotensin converting 
      enzyme inhibitors before death in cases, or the equivalent date in controls. 
      RESULTS: 13,029 patients had a first diagnosis of ischaemic heart disease 
      (incidence rate 338 per 100,000 person years). 2266 cases were matched to 9064 
      controls. Drug combinations associated with the greatest reduction in all cause 
      mortality were statins, aspirin, and beta blockers (83% reduction, 95% confidence 
      interval 77% to 88%); statins, aspirin, beta blockers, and angiotensin converting 
      enzyme inhibitors (75% reduction, 65% to 82%); and statins, aspirin, and 
      angiotensin converting enzyme inhibitors (71% reduction, 59% to 79%). Treatments 
      associated with the smallest reduction in all cause mortality were beta blockers 
      alone (19% reduction, 37% reduction to 4% increase), angiotensin converting 
      enzyme inhibitors alone (20% reduction, 1% to 35%), and combined statins and 
      angiotensin converting enzyme inhibitors (31% reduction, 57% reduction to 12% 
      increase). CONCLUSIONS: Combinations of statins, aspirins, and beta blockers 
      improve survival in high risk patients with cardiovascular disease, although the 
      addition of an angiotensin converting enzyme inhibitor conferred no additional 
      benefit despite the analysis being adjusted for congestive cardiac failure.
FAU - Hippisley-Cox, Julia
AU  - Hippisley-Cox J
AD  - Division of Primary Care, School of Community Health Sciences, University Park, 
      Nottingham NG2 7RD. julia.hippisley-cox@nottingham.ac.uk
FAU - Coupland, Carol
AU  - Coupland C
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - BMJ. 2006 Apr 15;332(7546):912
CIN - BMJ. 2005 May 7;330(7499):1035-6. PMID: 15879368
CIN - BMJ. 2005 Jul 16;331(7509):159; author reply 160. PMID: 16020860
CIN - BMJ. 2005 Jul 16;331(7509):159; author reply 160. PMID: 16020861
CIN - BMJ. 2005 Jul 16;331(7509):159; author reply 160. PMID: 16020862
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Epidemiologic Methods
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Male
MH  - Myocardial Ischemia/mortality/*prevention & control
MH  - United Kingdom/epidemiology
PMC - PMC557227
EDAT- 2005/05/10 09:00
MHDA- 2005/05/20 09:00
CRDT- 2005/05/10 09:00
PHST- 2005/05/10 09:00 [pubmed]
PHST- 2005/05/20 09:00 [medline]
PHST- 2005/05/10 09:00 [entrez]
AID - 330/7499/1059 [pii]
AID - 3301059 [pii]
AID - 10.1136/bmj.330.7499.1059 [doi]
PST - ppublish
SO  - BMJ. 2005 May 7;330(7499):1059-63. doi: 10.1136/bmj.330.7499.1059.

PMID- 12735559
OWN - NLM
STAT- MEDLINE
DCOM- 20030522
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 75
IP  - 5
DP  - 2003 May
TI  - Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein 
      graft failure.
PG  - 1437-42
AB  - BACKGROUND: A new class of nitric oxide donating aspirin (NO-ASA) drugs may 
      increase the therapeutic impact of aspirin in saphenous vein coronary artery 
      bypass grafting (CABG) not only through the inhibition of thrombosis but also 
      through a reduction of vasospasm and inhibition of vascular smooth muscle cell 
      (VSMC) proliferation (effects that are inhibited by NO but not ASA). In order to 
      test this proposal the effect of three NO-ASA drugs (NCX4040, NCX4050, and 
      NCX4060) on in vitro relaxation and cyclic guanosine monophosphate (cGMP) 
      formation in the human isolated saphenous vein and the proliferation of human 
      VSMCs was investigated. METHODS: Saphenous vein segments were obtained from 30 
      patients undergoing CABG (median age, 59 years; range, 49 to 68). The effect of 
      the NO-ASA adducts, ASA alone, and sodium nitroprusside (NO donor) were 
      investigated on (1) relaxation of phenylephrine-stimulated contraction using an 
      organ bath, (2) cyclic guanosine monophosphate (cGMP) formation using an 
      enzyme-linked immunosorbent assay, and (3) the proliferation of VSMCs derived 
      from saphenous vein using bromo-deoxyuridine (BRDU) incorporation. RESULTS: All 
      three NO-ASA adducts (at concentrations that inhibited responses by 50% [IC50s] 
      between 1 micromol/L and 100 micromol/L) and nitroprusside (at IC50s between 0.5 
      and 10 micromol/L) elicited relaxation of isolated human saphenous vein, promoted 
      cGMP formation, and inhibited VSMC proliferation whereas ASA alone (up to 100 
      micromol/L) had no effect on any variable. CONCLUSIONS: These data indicate that 
      the NO-ASA adducts by virtue of their capacity to release NO and stimulate 
      guanylyl cyclase may be useful not only in the prevention of thrombosis following 
      CABG but also the reduction of saphenous vein graft spasm and neointima 
      formation.
FAU - Shukla, Nilima
AU  - Shukla N
AD  - Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, Bristol, 
      United Kingdom.
FAU - Angelini, Gianni D
AU  - Angelini GD
FAU - Ascione, Raimondo
AU  - Ascione R
FAU - Talpahewa, Sudath
AU  - Talpahewa S
FAU - Capoun, Radek
AU  - Capoun R
FAU - Jeremy, Jamie Y
AU  - Jeremy JY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 169D1260KM (Nitroprusside)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EH04H13L6B (nitroaspirin)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*analogs & derivatives/*pharmacology/therapeutic use
MH  - Cell Division/drug effects
MH  - Cyclic GMP/biosynthesis
MH  - Dose-Response Relationship, Drug
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - L-Lactate Dehydrogenase/metabolism
MH  - Male
MH  - Middle Aged
MH  - Muscle, Smooth, Vascular/cytology/drug effects/enzymology
MH  - Nitric Oxide Donors/pharmacology
MH  - Nitroprusside/pharmacology
MH  - Platelet Aggregation Inhibitors/*pharmacology/*therapeutic use
MH  - Saphenous Vein/*drug effects/*transplantation
MH  - Vasodilation/drug effects
EDAT- 2003/05/09 05:00
MHDA- 2003/05/23 05:00
CRDT- 2003/05/09 05:00
PHST- 2003/05/09 05:00 [pubmed]
PHST- 2003/05/23 05:00 [medline]
PHST- 2003/05/09 05:00 [entrez]
AID - S0003-4975(02)04892-0 [pii]
AID - 10.1016/s0003-4975(02)04892-0 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 2003 May;75(5):1437-42. doi: 10.1016/s0003-4975(02)04892-0.

PMID- 3142657
OWN - NLM
STAT- MEDLINE
DCOM- 19881223
LR  - 20161123
IS  - 0764-4469 (Print)
IS  - 0764-4469 (Linking)
VI  - 307
IP  - 8
DP  - 1988
TI  - [Fluorescence polarization studies of rat gastric surfactant: effects of 
      aspirin].
PG  - 475-8
AB  - Rat gastric surfactant has been studied by fluorescence polarization, both in a 
      basal state and after an aspirin challenge. Gastric surfactant appeared as a very 
      viscous molecular organisation of phospholipids and was disorganised by low, non 
      ulcerogenic, concentrations of aspirin. The method presented herein allows one to 
      study the human gastric surfactant under physiological and pathological condition 
      and should help in the design of synthetic surfactants for a therapeutical 
      purpose.
FAU - Bommelaer, G
AU  - Bommelaer G
AD  - Services de Gastroentérologie et de Biochimie, Hôtel-Dieu, Clermont-Ferrand.
FAU - Delasalle, P
AU  - Delasalle P
FAU - Mosnier, P
AU  - Mosnier P
FAU - Motta, C
AU  - Motta C
LA  - fre
PT  - Comparative Study
PT  - Journal Article
TT  - Etude en polarisation de fluorescence du surfactant gastrique du rat: effets de 
      l'aspirine.
PL  - France
TA  - C R Acad Sci III
JT  - Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie
JID - 8503078
RN  - 0 (Phospholipids)
RN  - 0 (Pulmonary Surfactants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Fluorescence Polarization
MH  - Gastric Mucosa/drug effects/*metabolism
MH  - Male
MH  - Phospholipids/analysis/*metabolism
MH  - Pulmonary Surfactants
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach Ulcer/metabolism
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - C R Acad Sci III. 1988;307(8):475-8.

PMID- 5771601
OWN - NLM
STAT- MEDLINE
DCOM- 19690706
LR  - 20131121
IS  - 0008-1264 (Print)
IS  - 0008-1264 (Linking)
VI  - 110
IP  - 5
DP  - 1969 May
TI  - The clinical pharmacology of salicylates.
PG  - 410-22
AB  - These discussions are selected from the weekly staff conferences in the 
      Department of Medicine, University of California Medical Center, San Francisco. 
      Taken from transcriptions, they are prepared by Drs. Martin J. Cline and Hibbard 
      E. Williams, Associate Professors of Medicine, under the direction of Dr. Lloyd 
      H. Smith, Jr., Professor of Medicine and Chairman of the Department of Medicine.
FAU - Melmon, Kenneth L
AU  - Melmon KL
FAU - Rowland, Malcolm
AU  - Rowland M
FAU - Morrell, Howard
AU  - Morrell H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Calif Med
JT  - California medicine
JID - 0410260
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Humans
MH  - Salicylates/*pharmacology/*therapeutic use
PMC - PMC1503515
EDAT- 1969/05/01 00:00
MHDA- 1969/05/01 00:01
CRDT- 1969/05/01 00:00
PHST- 1969/05/01 00:00 [pubmed]
PHST- 1969/05/01 00:01 [medline]
PHST- 1969/05/01 00:00 [entrez]
PST - ppublish
SO  - Calif Med. 1969 May;110(5):410-22.

PMID- 12555868
OWN - NLM
STAT- MEDLINE
DCOM- 20030624
LR  - 20190922
IS  - 1359-6640 (Print)
IS  - 1359-6640 (Linking)
VI  - 122
DP  - 2003
TI  - In situ neutron diffraction studies of single crystals and powders during 
      microwave irradiation.
PG  - 363-79; discussion 381-93
AB  - Microwave dielectric heating has become an important method in chemical synthesis 
      and materials processing over the past 15 years, and in the case of the reactions 
      in solutions, there is a well-developed understanding of heating mechanisms and 
      their influence on reaction rate. In the solid-state however, there is much less 
      clarity, despite the advantages to be gained from better insight into the way in 
      which such electromagnetic radiation may couple directly to charge carriers, 
      accelerating reactions in good conductors. The related issue of the influence of 
      microwave irradiation on biological systems, in particular, proteins, and the way 
      in which this may pose hazards to health is similarly poorly understood despite 
      the obvious relevance this may have to the current debate on the influence of 
      electromagnetic radiation, in particular, microwave transmission, on human 
      health. One reason for the paucity of fundamental insight in both fields is 
      because most work has been performed with microwave equipment whose design is 
      derived from that of a domestic oven, and which is not ideal for in situ studies 
      of microwave driven processes. We have been developing new methods of irradiating 
      a variety of solid samples while measuring structural parameters through a range 
      of diffraction techniques, and describe apparatus that will enable X-ray or 
      neutron scattering measurements to be performed on powders or single crystals 
      under microwave irradiation with controlled power level. We also describe 
      preliminary studies of a single crystal of the molecular solid aspirin, and a 
      powder of the microwave-susceptible ionic material BaTiO3, during microwave 
      irradiation.
FAU - Harrison, Andrew
AU  - Harrison A
AD  - Department of Chemistry, The University of Edinburgh, The King's Buildings, West 
      Mains Rd, Edinburgh, UK EH9 3JJ.
FAU - Ibberson, Richard
AU  - Ibberson R
FAU - Robb, Graeme
AU  - Robb G
FAU - Whittaker, Gavin
AU  - Whittaker G
FAU - Wilson, Chick
AU  - Wilson C
FAU - Youngson, Douglas
AU  - Youngson D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Faraday Discuss
JT  - Faraday discussions
JID - 9212301
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/radiation effects
MH  - *Microwaves
MH  - Molecular Structure
MH  - Neutron Diffraction
MH  - Temperature
EDAT- 2003/01/31 04:00
MHDA- 2003/06/25 05:00
CRDT- 2003/01/31 04:00
PHST- 2003/01/31 04:00 [pubmed]
PHST- 2003/06/25 05:00 [medline]
PHST- 2003/01/31 04:00 [entrez]
AID - 10.1039/b203379h [doi]
PST - ppublish
SO  - Faraday Discuss. 2003;122:363-79; discussion 381-93. doi: 10.1039/b203379h.

PMID- 1949660
OWN - NLM
STAT- MEDLINE
DCOM- 19911129
LR  - 20150612
IS  - 0042-8450 (Print)
IS  - 0042-8450 (Linking)
VI  - 48
IP  - 3
DP  - 1991 May-Jun
TI  - [Effect of small doses of aspirin on thrombocyte aggregation].
PG  - 211-5
AB  - Aspirin (acetylsalicylic acid--ASA) inhibits pletlets thromboxane (TXA2) 
      synthesis as well as endothelial prostacycline (PGI2) synthesis. Aiming to 
      prevent PGI2 synthesis attempts have been made to reduce ASA doses. Here are 
      presented results of ASA effects in daily dose of 100 mg given to 26 patients 
      with mean age of 54 years who suffered from myocardial infarction and were on 
      rehabilitation. Except for ASA, none had consumed any anti-inflammatory drugs. 
      Platelet aggregation was examined with ADP stimulation and spontaneous platelet 
      aggregation in the circulation. The analyses were performed before ASA intake and 
      10 days after receiving 100 mg ASA each day. The results of the study have shown 
      that both doses of ASA, 100 mg and 500 mg, have the same effects on pletelet 
      aggregation measured by these methods.
FAU - Ciko, Z
AU  - Ciko Z
AD  - Vojnomedicinska akademija, Klinika za hematologiju, Vojni centar za 
      rehabilitaciju i lecenje, Meljine-Herceg-Novi.
FAU - Mijić, R
AU  - Mijić R
FAU - Tanasijević, M
AU  - Tanasijević M
LA  - srp
PT  - English Abstract
PT  - Journal Article
TT  - Efekti malih doza aspirina na agregaciju trombocita.
PL  - Serbia
TA  - Vojnosanit Pregl
JT  - Vojnosanitetski pregled
JID - 21530700R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
PST - ppublish
SO  - Vojnosanit Pregl. 1991 May-Jun;48(3):211-5.

PMID- 6451261
OWN - NLM
STAT- MEDLINE
DCOM- 19810513
LR  - 20161123
IS  - 0037-9026 (Print)
IS  - 0037-9026 (Linking)
VI  - 174
IP  - 6
DP  - 1980
TI  - [Electrophysiology of the peripheral effect of two analgesics: aspirin and 
      dibencozide].
PG  - 1010-5
AB  - The peripheral effect of two analgesics (aspirin and dibencozide) was studied on 
      anaesthetized cats. Several types of neurons and stimulations were performed in 
      this work: traction for periodontal mechanoreceptors connected to small-sized 
      trigeminal fibres, distension for the muscular intestinal mechanoreceptors 
      connected to non-myelinated vagal fibres, chemical stimulation by means of 
      phenyldiguanide for the non-myelinated vagal fibres, electrical stimulation of 
      the myelinated and non-myelinated vagal fibres. In all cases, unitary activities 
      were recorded into corresponding ganglia (nodose or gasserian) with extracellular 
      glass microelectrodes. After injection of analgesics, a decrease of control 
      responses were observed till 30 minutes but the maximum occurred between 1 and 5 
      minutes. This effect concerned the non-myelinated neurones as well as the 
      myelinated ones. It can be explained by a direct action of analgesics on the 
      ending excitability.
FAU - Mei, N
AU  - Mei N
LA  - fre
PT  - Journal Article
TT  - Etude électrophysiologique de l'effet périphérique de deux substances 
      antalgiques: l'aspirine et le dibencozide.
PL  - France
TA  - C R Seances Soc Biol Fil
JT  - Comptes rendus des seances de la Societe de biologie et de ses filiales
JID - 7505439
RN  - 0 (Cobamides)
RN  - F0R1QK73KB (cobamamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cats
MH  - Cobamides/*pharmacology
MH  - Kinetics
MH  - Mechanoreceptors/drug effects/physiology
MH  - Neurons/drug effects/physiology
MH  - Vagus Nerve/drug effects/*physiology
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - C R Seances Soc Biol Fil. 1980;174(6):1010-5.

PMID- 18162262
OWN - NLM
STAT- MEDLINE
DCOM- 20081014
LR  - 20131121
IS  - 0223-5234 (Print)
IS  - 0223-5234 (Linking)
VI  - 43
IP  - 8
DP  - 2008 Aug
TI  - Oligo(3-hydroxybutanoate) conjugates with acetylsalicylic acid and their 
      antitumour activity.
PG  - 1785-90
AB  - In this paper we discuss the anticancer activity of acetylsalicylic acid with 
      oligo(3-hydroxybutanoate) conjugates, their characteristics and in vitro 
      biological evaluation. Acetylsalicylic acid (aspirin) attached via hydrolysable 
      ester bonds to non-toxic well-defined 3-hydroxybutanoic acid oligomers shows 
      novel method of drug modification. The resulting conjugates were more effective 
      than aspirin in growth inhibition of human colon adenocarcinoma cells HT-29 and 
      human colon carcinoma cells HCT 116 in vitro. Treatment of rats with doses as 
      high as 2g of the conjugate (equivalent to 0.6g of pure aspirin) per kg of body 
      weight did not exhibit toxic effects.
FAU - Juzwa, Maria
AU  - Juzwa M
AD  - Centre of Polymer and Carbon Materials, Polish Academy of Sciences, M. 
      Skłodowskiej-Curie 34, Zabrze 41-819, Poland.
FAU - Rusin, Aleksandra
AU  - Rusin A
FAU - Zawidlak-Wegrzyńska, Barbara
AU  - Zawidlak-Wegrzyńska B
FAU - Krawczyk, Zdzisław
AU  - Krawczyk Z
FAU - Obara, Ilona
AU  - Obara I
FAU - Jedliński, Zbigniew
AU  - Jedliński Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071121
PL  - France
TA  - Eur J Med Chem
JT  - European journal of medicinal chemistry
JID - 0420510
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hydroxybutyrates)
RN  - 0 (Polyesters)
RN  - 26063-00-3 (poly-beta-hydroxybutyrate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*chemical synthesis/chemistry/*pharmacology
MH  - Aspirin/*chemical synthesis/chemistry/*pharmacology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Humans
MH  - Hydroxybutyrates/*chemistry
MH  - Magnetic Resonance Spectroscopy
MH  - Molecular Structure
MH  - Polyesters/*chemistry
MH  - Spectrometry, Mass, Electrospray Ionization
MH  - Structure-Activity Relationship
EDAT- 2007/12/29 09:00
MHDA- 2008/10/15 09:00
CRDT- 2007/12/29 09:00
PHST- 2007/06/18 00:00 [received]
PHST- 2007/11/06 00:00 [revised]
PHST- 2007/11/12 00:00 [accepted]
PHST- 2007/12/29 09:00 [pubmed]
PHST- 2008/10/15 09:00 [medline]
PHST- 2007/12/29 09:00 [entrez]
AID - S0223-5234(07)00436-9 [pii]
AID - 10.1016/j.ejmech.2007.11.004 [doi]
PST - ppublish
SO  - Eur J Med Chem. 2008 Aug;43(8):1785-90. doi: 10.1016/j.ejmech.2007.11.004. Epub 
      2007 Nov 21.

PMID- 6527276
OWN - NLM
STAT- MEDLINE
DCOM- 19850410
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 73
IP  - 12
DP  - 1984 Dec
TI  - Electrostatic effects in acylation of hemoglobin by aspirins.
PG  - 1851-3
AB  - Carboxylate substituents added to the salicylate ring increase the effectiveness 
      of a variety of aspirins and diaspirins in acylating hemoglobin. Even more 
      effective are a series of monoesters of dicarboxylate derivatives. 
      Bis(5-carbomethoxysalicyl)fumarate and -succinate at 5 mM concentrations modify 
      approximately 100% of the hemoglobin in solution and should alter the aggregation 
      behavior of sickle hemoglobin.
FAU - Massil, S E
AU  - Massil SE
FAU - Shi, G Y
AU  - Shi GY
FAU - Klotz, I M
AU  - Klotz IM
LA  - eng
GR  - HL-22719/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Hemoglobins)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acylation
MH  - Aspirin/*pharmacology
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Electricity
MH  - Hemoglobins/*metabolism
MH  - Humans
MH  - Salicylates/pharmacology
EDAT- 1984/12/01 00:00
MHDA- 1984/12/01 00:01
CRDT- 1984/12/01 00:00
PHST- 1984/12/01 00:00 [pubmed]
PHST- 1984/12/01 00:01 [medline]
PHST- 1984/12/01 00:00 [entrez]
AID - S0022-3549(15)46496-2 [pii]
AID - 10.1002/jps.2600731255 [doi]
PST - ppublish
SO  - J Pharm Sci. 1984 Dec;73(12):1851-3. doi: 10.1002/jps.2600731255.

PMID- 2086132
OWN - NLM
STAT- MEDLINE
DCOM- 19910522
LR  - 20131121
IS  - 0529-5815 (Print)
IS  - 0529-5815 (Linking)
VI  - 28
IP  - 9
DP  - 1990 Sep
TI  - [Changes in bile components during the formation and prevention of black pigment 
      gallstone in a guinea pig model].
PG  - 558-61, 574
AB  - Black pigment gallstones were found in 22 out of 23 guinea pigs one week after 
      the common bile ducts were partially ligated (S group). The incidence decreased 
      to 11/20 (P less than 0.01) if the animals were fed with a chow containing bile 
      salt mixture, glucurolactone, ane aspirin (S+M group). Three weeks after the 
      ligation the incidence of gallstone in S group and S+M group was 17/18, and 9/10, 
      respectively (P greater than 0.05). Glucuronidase (beta-G) activity in the bile 
      of S group was not higher than that of control group (C group, P greater than 
      0.05), and all the bile samples were sterile. The biliary concentrations of 
      ionized calcium (ICa), unconjugated bilirubin (UCB), total calcium (TCa), total 
      bilirubin (TBr), glycoprotein (GIy. P), and PH significantly fluctuated among 
      guinea pig groups and were parallel to gallstone incidence. The results of this 
      study could hardly be explained by Maki beta-G theory, but were consistent with 
      the assumption that the precipitation-dissolution equilibrium of calcium 
      bilirubinate is the key of pigment gallstone formation, thus the increases of the 
      above mentioned bile components, including beta-G activity, would bias this 
      equilibrium towards calcium bilirubinate precipitation and therefore promote 
      gallstone formation. On the contrary, stone formation would be prevented.
FAU - Xu, Z
AU  - Xu Z
AD  - Third Teaching hospital, Beijing Medical University.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Wai Ke Za Zhi
JT  - Zhonghua wai ke za zhi [Chinese journal of surgery]
JID - 0153611
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Glycoproteins)
RN  - R16CO5Y76E (Aspirin)
RN  - RFM9X3LJ49 (Bilirubin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Bile/*metabolism
MH  - Bile Acids and Salts/therapeutic use
MH  - Bilirubin/*metabolism
MH  - Calcium/*metabolism
MH  - Cholelithiasis/*metabolism/prevention & control
MH  - Glycoproteins/metabolism
MH  - Guinea Pigs
MH  - Male
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Wai Ke Za Zhi. 1990 Sep;28(9):558-61, 574.

PMID- 12899996
OWN - NLM
STAT- MEDLINE
DCOM- 20040413
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 32
IP  - 4-5
DP  - 2003 Aug 8
TI  - Fast drug stability determination by LC variable-parameter kinetic experiments.
PG  - 1073-9
AB  - Variable-parameter kinetic experiments were carried out using HPLC as analytical 
      instrument. The hydrolysis of aspirin was followed both at variable-temperature 
      and at variable-pH conditions. The peak areas relative to salicylic acid were 
      processed by direct fit to a mathematical model and/or by differential method 
      obtaining, by single experiments, the values of the apparent rate constant in the 
      whole range of temperature and pH studied. The results, although the 
      discontinuity of this kind of analysis, are in agreement with those obtained by 
      constant-parameter kinetics but saving experimental time.
FAU - Alibrandi, Giuseppe
AU  - Alibrandi G
AD  - Dipartimento di Chimica Inorganica, Chimica Analitica e Chimica Fisica, 
      Università di Messina, Salita Sperone 31, Villaggio S. Agata, 98166 Messina, 
      Italy. alibrandi@chem.unime.it
FAU - Coppolino, Salvatore
AU  - Coppolino S
FAU - D'Aliberti, Santi
AU  - D'Aliberti S
FAU - Ficarra, Rita
AU  - Ficarra R
FAU - Micali, Norberto
AU  - Micali N
FAU - Villari, Antonino
AU  - Villari A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis/metabolism
MH  - Chromatography, Liquid/methods
MH  - *Drug Stability
MH  - Technology, Pharmaceutical/*methods
EDAT- 2003/08/06 05:00
MHDA- 2004/04/14 05:00
CRDT- 2003/08/06 05:00
PHST- 2003/08/06 05:00 [pubmed]
PHST- 2004/04/14 05:00 [medline]
PHST- 2003/08/06 05:00 [entrez]
AID - S0731708503002115 [pii]
AID - 10.1016/s0731-7085(03)00211-5 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2003 Aug 8;32(4-5):1073-9. doi: 
      10.1016/s0731-7085(03)00211-5.

PMID- 8015917
OWN - NLM
STAT- MEDLINE
DCOM- 19940728
LR  - 20131121
IS  - 0029-1420 (Print)
IS  - 0029-1420 (Linking)
VI  - 109
IP  - 6-7
DP  - 1994
TI  - [Clarification of mechanism of acetylsalicylic acid].
PG  - 202-3, 205
AB  - Acetylsalicylic acid is probably the most widely used of all drugs. Recent data 
      has provided new insights into its mechanism of action and documented its 
      usefulness in cardiovascular prevention. At the same time we now understand 
      better why plants benefit from new production of the mother compound-salicylic 
      acid. Thus very old drugs can be quite newsworthy.
FAU - Fredholm, B
AU  - Fredholm B
AD  - Institutionen för fysiologi och farmakologi, Karolinska Institutet, Stockholm.
LA  - swe
PT  - English Abstract
PT  - Journal Article
TT  - Mekanismen klarnar för acetylsalicylsyra.
PL  - Sweden
TA  - Nord Med
JT  - Nordisk medicin
JID - 0401001
RN  - 0 (Prostaglandin Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism/*pharmacology/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - Prostaglandin Antagonists/pharmacology
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Nord Med. 1994;109(6-7):202-3, 205.

PMID- 15063462
OWN - NLM
STAT- MEDLINE
DCOM- 20041123
LR  - 20181130
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 35
IP  - 2
DP  - 2004 Apr 16
TI  - Chemiluminescence and LC-MS/MS analyses for the study of nitric oxide release and 
      distribution following oral administration of nitroaspirin (NCX 4016) in healthy 
      volunteers.
PG  - 277-87
AB  - The metabolic fate of nitric oxide (NO) released from nitroaspirin, benzoic acid, 
      2-(acetyloxy)-3-[(nitrooxy)methyl]phenyl ester (NCX 4016), the lead compound of a 
      new class of NO-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) has 
      been studied in eight healthy male Caucasian subjects following p.o. 
      administration of 1600 mg (single dose), by monitoring at different times in 
      plasma the bioactive storage forms of NO, S-nitrosothiols (RSNO) and its 
      oxidation products (NOx). Plasma levels of NOx and RSNO and urinary levels of NOx 
      were determined by an ozone-based chemiluminescent assay using a sensitive Nitric 
      Oxide Analyzer (LOQ: 10 pmol NO injected). In parallel plasma samples were 
      analyzed by a newly developed LC-MS/MS method for analysis of NCX 4015, the 
      metabolite bearing the nitrate ester function. Using MS/MS with multiple reaction 
      monitoring (MRM) in negative ion mode for NCX 4015 and the internal standard (NCX 
      4015- 13C-D2) it was possible to detect with sufficient accuracy and precision 
      the metabolite in plasma with a quantification limit of 78.1 ng ml(-1). 
      Concentration versus time profile of plasma NCX 4015 gave a Cmax value of 161.94 
      +/- 47.4 ng ml(-1) and a tmax 4.5 +/- 1 h. The results indicate that both NOx and 
      RSNO (these last for the first time determined in vivo in man following oral 
      administration of a NO-donor drug) are effective plasma markers of NO release in 
      vivo, the latter being an earlier indicator of NO distribution (tmax 2.0 +/- 0.6 
      h versus 5.4 +/- 1.2 h).
FAU - Carini, Marina
AU  - Carini M
AD  - Istituto Chimico Farmaceutico Tossicologico, University of Milan, Viale Abruzzi 
      42, 20131 Milan, Italy. marina.carini@unimi.it
FAU - Aldini, Giancarlo
AU  - Aldini G
FAU - Orioli, Marica
AU  - Orioli M
FAU - Piccoli, Angela
AU  - Piccoli A
FAU - Tocchetti, Paola
AU  - Tocchetti P
FAU - Facino, Roberto Maffei
AU  - Facino RM
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*administration & dosage/*analogs & derivatives/*analysis/chemistry
MH  - Chromatography, Liquid
MH  - Humans
MH  - Luminescent Measurements
MH  - Male
MH  - Mass Spectrometry
MH  - Nitric Oxide/*analysis/*metabolism
EDAT- 2004/04/06 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/04/06 05:00
PHST- 2003/08/05 00:00 [received]
PHST- 2003/08/05 00:00 [revised]
PHST- 2003/09/23 00:00 [accepted]
PHST- 2004/04/06 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/04/06 05:00 [entrez]
AID - S0731708503005314 [pii]
AID - 10.1016/S0731-7085(03)00531-4 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2004 Apr 16;35(2):277-87. doi: 
      10.1016/S0731-7085(03)00531-4.

PMID- 1213854
OWN - NLM
STAT- MEDLINE
DCOM- 19760423
LR  - 20191021
IS  - 0020-7101 (Print)
IS  - 0020-7101 (Linking)
VI  - 6
IP  - 2
DP  - 1975 Apr
TI  - A strategy of approaching the fit of a compartmental model applied to the 
      behaviour of aspirins in humans.
PG  - 131-46
AB  - A compartmental model has been set up with five parts. Formulation and testing of 
      the model have been performed by simultaneous experiments involving measurement 
      of blood levels of ASA and SA for four different preparations of aspirin 
      investigated in four different patients. The hypotheses of the present study had 
      been based upon a four-compartment model. However, such a model did not appear to 
      be adequate and a new model with five compartments has been substituted for the 
      former one. The five-compartment model has led to the formulation and testing of 
      new physiological hypotheses; it has also provided the development of a fitting 
      method using powerful convergence algorithms. A general analytical formulation 
      has been set up which has made it possible to circumscribe the multiple roots of 
      the characteristic polynomial when they have to be taken into consideration.
FAU - Revillard, C
AU  - Revillard C
FAU - Griessen, M
AU  - Griessen M
FAU - Perrier, C V
AU  - Perrier CV
FAU - Scherrer, J R
AU  - Scherrer JR
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Int J Biomed Comput
JT  - International journal of bio-medical computing
JID - 0252005
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Computers
MH  - Humans
MH  - *Models, Biological
EDAT- 1975/04/01 00:00
MHDA- 1975/04/01 00:01
CRDT- 1975/04/01 00:00
PHST- 1975/04/01 00:00 [pubmed]
PHST- 1975/04/01 00:01 [medline]
PHST- 1975/04/01 00:00 [entrez]
AID - 10.1016/0020-7101(75)90032-x [doi]
PST - ppublish
SO  - Int J Biomed Comput. 1975 Apr;6(2):131-46. doi: 10.1016/0020-7101(75)90032-x.

PMID- 9851814
OWN - NLM
STAT- MEDLINE
DCOM- 19990309
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 92
IP  - 5
DP  - 1998 Dec 1
TI  - Some effects of prophylactic aspirins and heparins on concurrent arterial and 
      venous thrombosis in the same animal.
PG  - 229-32
AB  - The antithrombotic effect of unfractionated heparin, a low-molecular weight 
      heparin, oral acetylsalicylic acid, intravenous lysine-aspirin and oral soluble 
      aspirin was measured on platinum wire simultaneously in artery and vein, in 
      groups of 12-20 rats with concurrent untreated controls. Subcutaneous low 
      molecular weight heparin reduced mean thrombus weight by 26% in the artery only. 
      Venous thrombosis was reduced 56% by oral soluble acetylsalicylic acid and 27% by 
      oral aspirin. Other reductions did not reach statistical significance. While 
      thrombus deposition was induced by both 2-cm (upper site) and 1-cm (lower site) 
      wires, the results obtained on the 2-cm wires in the upper vein and artery were 
      more reliable [corrected].
FAU - Iomhair, M M
AU  - Iomhair MM
AD  - Department of Experimental Medicine, Clinical Science Institute, National 
      University of Ireland, Galway.
FAU - Lavelle, S M
AU  - Lavelle SM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Thromb Res 1999 Oct 1;96(1):83-4
MH  - Animals
MH  - Aortic Diseases/blood/complications/*drug therapy
MH  - Aspirin/*pharmacology
MH  - Fibrinolytic Agents/*pharmacology
MH  - Heparin, Low-Molecular-Weight/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thrombosis/blood/complications/drug therapy
MH  - Vena Cava, Inferior
MH  - Venous Thrombosis/blood/complications/*drug therapy
EDAT- 1998/12/16 00:00
MHDA- 1998/12/16 00:01
CRDT- 1998/12/16 00:00
PHST- 1998/12/16 00:00 [pubmed]
PHST- 1998/12/16 00:01 [medline]
PHST- 1998/12/16 00:00 [entrez]
AID - S0049-3848(98)00139-X [pii]
AID - 10.1016/s0049-3848(98)00139-x [doi]
PST - ppublish
SO  - Thromb Res. 1998 Dec 1;92(5):229-32. doi: 10.1016/s0049-3848(98)00139-x.

PMID- 6696450
OWN - NLM
STAT- MEDLINE
DCOM- 19840312
LR  - 20190629
IS  - 0003-9861 (Print)
IS  - 0003-9861 (Linking)
VI  - 228
IP  - 2
DP  - 1984 Feb 1
TI  - Alternative diaspirins for modification of hemoglobin and sickle hemoglobin.
PG  - 627-38
AB  - Studies of modification of hemoglobin and of sickle hemoglobin by alternative 
      aspirins have been extended to a series of new bis esters with a variety of 
      substituted bridging diacids and to a group of mono esters with polar acyl 
      groups. Rates of hydrolysis of these alternative aspirins have also been 
      examined, and they reveal that a careful balance between stability and reactivity 
      is essential for optimal activity. Four-carbon bridging groups have been found to 
      be particularly effective, two of these raising the minimum gelling concentration 
      of sickle hemoglobin by as much as 100%.
FAU - Delaney, E J
AU  - Delaney EJ
FAU - Massil, S E
AU  - Massil SE
FAU - Shi, G Y
AU  - Shi GY
FAU - Klotz, I M
AU  - Klotz IM
LA  - eng
GR  - HL22719/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Biochem Biophys
JT  - Archives of biochemistry and biophysics
JID - 0372430
RN  - 0 (Antisickling Agents)
RN  - 0 (Bridged-Ring Compounds)
RN  - 0 (Hemoglobin, Sickle)
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Antisickling Agents
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Bridged-Ring Compounds/pharmacology
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Hemoglobin, Sickle/*metabolism
MH  - Hemoglobins/*metabolism
MH  - Humans
MH  - Hydrolysis
MH  - Structure-Activity Relationship
EDAT- 1984/02/01 00:00
MHDA- 1984/02/01 00:01
CRDT- 1984/02/01 00:00
PHST- 1984/02/01 00:00 [pubmed]
PHST- 1984/02/01 00:01 [medline]
PHST- 1984/02/01 00:00 [entrez]
AID - 0003-9861(84)90032-8 [pii]
AID - 10.1016/0003-9861(84)90032-8 [doi]
PST - ppublish
SO  - Arch Biochem Biophys. 1984 Feb 1;228(2):627-38. doi: 
      10.1016/0003-9861(84)90032-8.

PMID- 9000115
OWN - NLM
STAT- MEDLINE
DCOM- 19970212
LR  - 20190701
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 60
IP  - 2
DP  - 1997
TI  - Pharmacokinetics of a new nitroderivative of acetylsalicylic acid after a single 
      dose in rats.
PG  - 101-6
AB  - The pharmacokinetics of a new ASA-nitroderivative compound, NCX 4016 (ASA-NO2), 
      was evaluated using an HPLC method. After single equimolar doses of ASA (35 mg 
      kg(-1)) or ASA-NO2 (65 mg kg(-1)), no detectable levels of these compounds have 
      been observed in rat plasma samples. SA peak levels were obtained at 3 h and 6 h 
      after ASA and ASA-NO2 administration respectively. The elimination rate constants 
      of SA were similar after ASA and ASA-NO2, suggesting a similar elimination phase 
      of this metabolite in rats. From these data it is evident that ASA-NO2 is slowly 
      metabolized in ASA, which is rapidly converted to SA.
FAU - Tagliaro, F
AU  - Tagliaro F
AD  - Institutes of Pharmacology and Forensic Medicine, University of Verona, Italy.
FAU - Cuzzolin, L
AU  - Cuzzolin L
FAU - Adami, A
AU  - Adami A
FAU - Scarcella, D
AU  - Scarcella D
FAU - Crivellente, F
AU  - Crivellente F
FAU - Benoni, G
AU  - Benoni G
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - S0024320596005991 [pii]
AID - 10.1016/s0024-3205(96)00599-1 [doi]
PST - ppublish
SO  - Life Sci. 1997;60(2):101-6. doi: 10.1016/s0024-3205(96)00599-1.

PMID- 6541512
OWN - NLM
STAT- MEDLINE
DCOM- 19841218
LR  - 20191023
IS  - 0142-2782 (Print)
IS  - 0142-2782 (Linking)
VI  - 5
IP  - 3
DP  - 1984 Jul-Sep
TI  - Comparison of two enteric-coated acetylsalicylic acid preparations by monitoring 
      steady-state levels of salicylic acid and its metabolites in plasma and urine.
PG  - 251-60
AB  - In a randomized three-way crossover study, 12 healthy male volunteers were given 
      multiple oral doses, i.e. 1.5 g b.i.d. for 7 days, of two different types of 
      enteric-coated acetylsalicylic acid (ASA) preparations, one being a conventional 
      enteric-coated tablet (ET) and the other enteric-coated granules (EG) in a 
      capsule; conventional ASA tablets were used as a reference. Plasma levels and 
      excretion of salicylic acid and some of its metabolites were investigated under 
      steady-state conditions. Plasma salicylic acid (SA) and salicyluric acid (SUA) 
      levels were determined using a liquid chromatographic method. Two separate 
      analyses were done to quantitate the metabolites in urine. SA, SUA, and gentisic 
      acid were each assayed by the method used for plasma. Total salicylate was also 
      determined. There was no significant difference in urinary excretion of total 
      salicylate between the three formulations. A diurnal variation in the excretion 
      of SUA and SA in urine was found. The two enteric-coated formulations provided 
      significantly higher morning plasma concentrations than the conventional aspirin. 
      The AUC was found to be significantly higher for ET than for the other two 
      formulations. EG gave more uniform plasma levels during the studied 12-h 
      intervals and also less inter- and intra-individual variations than ET, 
      indicating that a b.i.d. regimen may be suitable for EG.
FAU - Edgar, B
AU  - Edgar B
FAU - Bogentoft, C
AU  - Bogentoft C
FAU - Lagerström, P O
AU  - Lagerström PO
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Biopharm Drug Dispos
JT  - Biopharmaceutics & drug disposition
JID - 7911226
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*metabolism/toxicity
MH  - Circadian Rhythm
MH  - Humans
MH  - Male
MH  - Salicylates/*analysis
MH  - Tablets, Enteric-Coated
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
AID - 10.1002/bdd.2510050307 [doi]
PST - ppublish
SO  - Biopharm Drug Dispos. 1984 Jul-Sep;5(3):251-60. doi: 10.1002/bdd.2510050307.

PMID- 6683520
OWN - NLM
STAT- MEDLINE
DCOM- 19830811
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 33
IP  - 3
DP  - 1983
TI  - [Comparative studies on the in vitro dissolution and bioavailability of various 
      acetylsalicylic acid preparations].
PG  - 439-45
AB  - For five different brands of acetylsalicylic acid (ASA) preparations the in 
      vitro/in vivo data were determined and tested for comparability. The in vitro 
      dissolution rates were determined by two different methods (Paddle, rotating 
      basket) whereas the in vivo data were obtained from 15 volunteers in a 5-fold 
      cross-over trial. The markedly worse in vitro dissolution (rotating basket) of 
      one preparation is in contrast to the in vivo data which showed bioequivalency of 
      all five preparations. It is doubled that in vitro measurements alone reveal 
      sufficient informations for any predictions of the in vivo characteristics (e.g. 
      bioavailability) of a preparation. It was possible to determine separately ASA 
      and salicylic acid using a highly selective HPLC-method developed by us.
FAU - Nieder, M
AU  - Nieder M
FAU - Rasper, J
AU  - Rasper J
FAU - Gielsdorf, W
AU  - Gielsdorf W
FAU - Russmann, D
AU  - Russmann D
FAU - Jaeger, H
AU  - Jaeger H
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Vergleichende Untersuchungen zur In-vitro-Freisetzung und Bioverfügbarkeit von 
      verschiedenen Acetylsalicylsäure-Fertigarzneimitteln.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/blood/metabolism
MH  - Biological Availability
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Solubility
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1983;33(3):439-45.

PMID- 1296703
OWN - NLM
STAT- MEDLINE
DCOM- 19930423
LR  - 20131121
IS  - 0006-6648 (Print)
IS  - 0006-6648 (Linking)
VI  - 131
IP  - 10
DP  - 1992 Nov
TI  - Effect of continuous, long-term administrations of acetylsalicylic acid on 
      hematological and hemocoagulation changes in the rat.
PG  - 363-8
AB  - Acetylsalicylic acid is currently being widely used either itself or in 
      combination with the other substances for the prevention of thromboembolic 
      events. Its effect is particularly given by the inhibition of the cyclooxygenase 
      enzyme participating in the metabolism of eicosanoids. The recommended doses of 
      acetylsalicylic acid as well as frequency of administrations are very different. 
      The present work is aimed at estimating the effect of the continuous 
      administration of acetylsalicylic acid for 28 days on hematological and 
      hemocoagulation changes in the rat. The experimental results suggest that 
      long-term administrations of acetylsalicylic acid should be used cautiously in 
      human medicine. They signalize the need of long-term, aimed clinical studies of 
      hematological parameters of patients preventively treated with acetylsalicylic 
      acid, also with respect to the producer of this substance. It is also impossible 
      to neglect regular controls of necessary parameters for the estimation of the 
      efficiency of the given therapy in each patient with respect to individual 
      reactions. The dosage should also be adjusted with respect to the age, sex and 
      individual sensitivity of the organism.
FAU - Navrátil, L
AU  - Navrátil L
AD  - Institute of Biophysics, First Medical Faculty, Charles University, Prague.
FAU - Blehová, Z
AU  - Blehová Z
FAU - Drbohlavová, H
AU  - Drbohlavová H
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Boll Chim Farm
JT  - Bollettino chimico farmaceutico
JID - 0372534
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*blood/pharmacology
MH  - Blood Cell Count/*drug effects
MH  - Blood Coagulation/*drug effects
MH  - Female
MH  - Rats
MH  - Rats, Wistar
MH  - Time Factors
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
PST - ppublish
SO  - Boll Chim Farm. 1992 Nov;131(10):363-8.

PMID- 273338
OWN - NLM
STAT- MEDLINE
DCOM- 19780517
LR  - 20131121
IS  - 0078-5334 (Print)
IS  - 0078-5334 (Linking)
VI  - 97
IP  - 2
DP  - 1977 Jul
TI  - Prevention of postoperative ocular hypertension by prostaglandin inhibitors.
PG  - 268-71
AB  - The Pneumatonometer of Langham was used to monitor intraocular pressure in the 
      operating theatre and in the early postoperative period after cataract surgery. 
      Both indomethacin and aspirin were shown to prodcue a significant reduction in 
      the acute ocular hypertension which can be expected to follow 6 hours after 
      routine cataract surgery. It is suggested that the inhibition of prostaglandin 
      synthesis by these drugs is probably responsible for this effect.
FAU - Rich, W J
AU  - Rich WJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Trans Ophthalmol Soc U K (1962)
JT  - Transactions of the ophthalmological societies of the United Kingdom
JID - 0200570
RN  - 0 (Prostaglandin Antagonists)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Cataract Extraction
MH  - Depression, Chemical
MH  - Humans
MH  - Indomethacin/pharmacology/therapeutic use
MH  - Intraocular Pressure/*drug effects
MH  - Postoperative Complications/*prevention & control
MH  - Prostaglandin Antagonists/*therapeutic use
EDAT- 1977/07/01 00:00
MHDA- 1977/07/01 00:01
CRDT- 1977/07/01 00:00
PHST- 1977/07/01 00:00 [pubmed]
PHST- 1977/07/01 00:01 [medline]
PHST- 1977/07/01 00:00 [entrez]
PST - ppublish
SO  - Trans Ophthalmol Soc U K (1962). 1977 Jul;97(2):268-71.

PMID- 5271744
OWN - NLM
STAT- MEDLINE
DCOM- 19701020
LR  - 20190501
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 64
IP  - 4
DP  - 1969 Dec
TI  - Hyperpyrexia and antipyresis owing to sodium acetylsalicylate in intact and 
      decapitate cats.
PG  - 1165-71
AB  - Sodium acetylsalicylate (100 mg/kg) intravenously injected into anaesthetized 
      intact or decapitate cats caused an increase in body temperature. At a dosage of 
      30 mg per kilogram it caused a lowering of body temperature in the intact 
      preparations, but again an increase in decapitate preparations. At a dosage of 10 
      mg per kilogram, no significant temperature change occurred in either type of 
      preparation. Aspirin (in the form of sodium acetylsalicylate) is a systemic 
      pyrogen and a centrally acting antipyretic. When it occurs, aspirin antipyresis 
      must take place in the face of systemic pyrogenesis. Notable is the fact that 
      aspirin (30 mg/kg) in the intact preparation lowers body temperature not only 
      from fever levels, but also from normal and subnormal levels.
FAU - Lloyd, D P
AU  - Lloyd DP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Pyrogens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Body Temperature/*drug effects
MH  - Cats
MH  - Hypothalamus/physiology
MH  - Pyrogens/pharmacology
PMC - PMC223263
EDAT- 1969/12/01 00:00
MHDA- 1969/12/01 00:01
CRDT- 1969/12/01 00:00
PHST- 1969/12/01 00:00 [pubmed]
PHST- 1969/12/01 00:01 [medline]
PHST- 1969/12/01 00:00 [entrez]
AID - 10.1073/pnas.64.4.1165 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1969 Dec;64(4):1165-71. doi: 10.1073/pnas.64.4.1165.

PMID- 7122998
OWN - NLM
STAT- MEDLINE
DCOM- 19821202
LR  - 20151119
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 37
IP  - 1
DP  - 1982 Jul
TI  - Pharmacological actions of diaspirins, potential antisickling agents I: A 
      preliminary study.
PG  - 139-42
AB  - The acute toxicity (LD50) and effects on locomotor activity of three alternative 
      aspirin analogs were determined in mice of both sexes. Dibromoaspirin, 
      bis(dibromosalicyl) succinate and bis(dibromosalicyl) fumarate were administered 
      in oral suspension. The 24-hour LD50 values in both male and female mice were 
      within the same range as that of commercial aspirin (i.e., 1100 mg/kg). The 
      effects of 1/40, 1/20, 1/10 and 1/5 LD50 doses of each compound were tested on 
      locomotor activity of male mice. These compounds decreased locomotor activity in 
      a dose-dependent fashion.
FAU - Thompson, E B
AU  - Thompson EB
FAU - Klotz, I M
AU  - Klotz IM
LA  - eng
GR  - HL 22719/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - 0 (Antisickling Agents)
RN  - 0 (dibromoacetylsalicylic acid)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 71337-52-5 (bis(3,5-dibromosalicyl)succinate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antisickling Agents/*pharmacology/toxicity
MH  - Aspirin/*analogs & derivatives/pharmacology/toxicity
MH  - Lethal Dose 50
MH  - Mice
MH  - Motor Activity/drug effects
EDAT- 1982/07/01 00:00
MHDA- 1982/07/01 00:01
CRDT- 1982/07/01 00:00
PHST- 1982/07/01 00:00 [pubmed]
PHST- 1982/07/01 00:01 [medline]
PHST- 1982/07/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1982 Jul;37(1):139-42.

PMID- 845030
OWN - NLM
STAT- MEDLINE
DCOM- 19770512
LR  - 20131121
IS  - 0017-8470 (Print)
IS  - 0017-8470 (Linking)
VI  - 28
IP  - 2
DP  - 1977 Feb
TI  - [Modern aspects in the pathogenesis of urticaria with special reference to 
      intolerance phenomena].
PG  - 102-10
AB  - The chronic urticaria remains till now a "vexing problem" (Sheldon, 1954), 
      because its etiopathology can be clarified only in about 20-30%. Five different 
      immunologic mechanisms, two nonimmunologic mechanisms and two important 
      manifestation factors are found. The physical triggering (12-17%) and the 
      so-called aspirine/additiva provocation (26%) seem to be the most frequent causes 
      of urticaria. Exogenic antigens are identified only in 3-8% of cases. The 
      unspecific reaction phase of urticaria can be different too, although the 
      degranulation of mast cells with histamine-deliberation is found very often. In 
      hereditary urticaria and in pressure urticaria histamine-deliberation seems not 
      to be important.
FAU - Illig, L
AU  - Illig L
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Moderne Aspekte der Urtikariapathogenese unter besonderer Berücksichtigung des 
      Intderanzphänomens.
PL  - Germany
TA  - Hautarzt
JT  - Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
JID - 0372755
RN  - 0 (Autoantigens)
RN  - 0 (Histamine Antagonists)
RN  - 820484N8I3 (Histamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anaphylaxis
MH  - Antigen-Antibody Reactions
MH  - Aspirin/adverse effects
MH  - Autoantigens/analysis
MH  - Chronic Disease
MH  - Cold Temperature
MH  - Drug Hypersensitivity
MH  - Histamine
MH  - Histamine Antagonists
MH  - Humans
MH  - Pressure
MH  - Recurrence
MH  - Urticaria/*etiology/genetics
EDAT- 1977/02/01 00:00
MHDA- 1977/02/01 00:01
CRDT- 1977/02/01 00:00
PHST- 1977/02/01 00:00 [pubmed]
PHST- 1977/02/01 00:01 [medline]
PHST- 1977/02/01 00:00 [entrez]
PST - ppublish
SO  - Hautarzt. 1977 Feb;28(2):102-10.

PMID- 3366158
OWN - NLM
STAT- MEDLINE
DCOM- 19880620
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 33
IP  - 6
DP  - 1988
TI  - Plasma drug and antiplatelet profiles of the original acetylsalicylic acid 
      preparations used in the AMIS, PARIS and German-Austrian trials for secondary 
      prevention of myocardial infarction.
PG  - 541-7
AB  - In a cross-over study 6 healthy male subjects were given for 9 days the 
      acetylsalicylic acid (ASA) preparations used in the Aspirin Myocardial Infarction 
      Study (AMIS), Persantine-Aspirin Reinfarction Study (PARIS) and German-Austrian 
      secondary heart attack prevention trials, exactly according to the original study 
      protocols. Plasma concentrations of ASA and its main metabolites salicylic acid 
      (SA) and salicyluric acid (SUA), as well as platelet function (collagen-induced 
      platelet aggregation; tissue extract-induced change in platelet shape) were 
      studied repeatedly on the first day of each medication period and were again 
      examined on the sixth and ninth days. Differences in the plasma concentrations of 
      ASA and its metabolites were found only on the first day, probably as a result of 
      different absorption rates. Collagen-induced platelet aggregation was more 
      rapidly inhibited the faster the preparation was absorbed. Each ASA preparation 
      inhibited tissue extract-induced platelet shape change from the first dose, 
      although statistically significant inhibition was seen only with the AMIS 
      preparation. It is concluded that differences in the antithrombotic efficiency of 
      ASA cannot be explained by differences in the pharmacokinetic and antiplatelet 
      profiles of the various ASA preparations tested.
FAU - Simrock, R
AU  - Simrock R
AD  - Department of Internal Medicine, Faculty of Pharmacy and Biochemistry, J. W. 
      Goethe University, Frankfurt, Main, Federal Republic of Germany.
FAU - Rehders, K
AU  - Rehders K
FAU - Spahn, H
AU  - Spahn H
FAU - Mutschler, E
AU  - Mutschler E
FAU - Breddin, H K
AU  - Breddin HK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/metabolism/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Collagen/pharmacology
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation/drug effects
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.1007/BF00542484 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1988;33(6):541-7. doi: 10.1007/BF00542484.

PMID- 8430052
OWN - NLM
STAT- MEDLINE
DCOM- 19930309
LR  - 20190818
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 10
IP  - 1
DP  - 1993 Jan
TI  - Acacia-gelatin microencapsulated liposomes: preparation, stability, and release 
      of acetylsalicylic acid.
PG  - 141-6
AB  - Liposomes of dipalmitoylphosphatidylcholine (DPPC) containing acetylsalicylic 
      acid (ASA) have been microencapsulated by acacia-gelatin using the complex 
      coacervation technique as a potential oral drug delivery system. The 
      encapsulation efficiency of ASA was unaltered by the microencapsulation process. 
      The stability of the microencapsulated liposomes in sodium cholate solutions at 
      pH 5.6 was much greater than the corresponding liposomes. The optimum composition 
      and conditions for stability and ASA release were 3.0% acacia-gelatin and a 1- to 
      2-hr formaldehyde hardening time. Approximately 25% ASA was released in the first 
      6 hr from microencapsulated liposomes at 23 degrees C and the kinetics followed 
      matrix-controlled release (Q varies; is directly proportional to t1/2). At 37 
      degrees C, this increased to 75% released in 30 min followed by a slow constant 
      release, likely due to lowering of the phase transition temperature of DPPC by 
      the acacia-gelatin to near 37 degrees C. At both temperatures, the release from 
      control liposomes was even more rapid. Hardening times of 4 hr and an 
      acacia-gelatin concentration of 5% resulted in a lower stability of liposomes and 
      a faster release of ASA. It is concluded that under appropriate conditions the 
      microencapsulation of liposomes by acacia-gelatin may increase their potential as 
      an oral drug delivery system.
FAU - Dong, C
AU  - Dong C
AD  - Lipopharm Inc., St-Laurent, Quebec, Canada.
FAU - Rogers, J A
AU  - Rogers JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Capsules)
RN  - 0 (Drug Carriers)
RN  - 0 (Liposomes)
RN  - 2644-64-6 (1,2-Dipalmitoylphosphatidylcholine)
RN  - 9000-70-8 (Gelatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 1,2-Dipalmitoylphosphatidylcholine
MH  - Acacia
MH  - Aspirin/*administration & dosage/chemistry/pharmacokinetics
MH  - Capsules
MH  - Chemistry, Pharmaceutical
MH  - Drug Carriers
MH  - Drug Compounding
MH  - Drug Stability
MH  - Gelatin
MH  - Liposomes
MH  - Microscopy, Electron
MH  - Particle Size
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1023/a:1018997602334 [doi]
PST - ppublish
SO  - Pharm Res. 1993 Jan;10(1):141-6. doi: 10.1023/a:1018997602334.

PMID- 522193
OWN - NLM
STAT- MEDLINE
DCOM- 19800317
LR  - 20181130
IS  - 0027-9684 (Print)
IS  - 0027-9684 (Linking)
VI  - 71
IP  - 12
DP  - 1979 Dec
TI  - Dollars: prophylaxis or cure?
PG  - 1236-7
AB  - Much is unknown about the mechanisms by which aspirin causes an increase in 
      bleeding time by diminishing platelet aggregation. Prevailing theories of 
      mechanisms are discussed and analyzed. The author suggests that proposed mass use 
      of aspirin for prevention of cardiovascular diseases be delayed until current 
      studies are fully evaluated.
FAU - Krantz, J C Jr
AU  - Krantz JC Jr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Natl Med Assoc
JT  - Journal of the National Medical Association
JID - 7503090
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandins/metabolism
PMC - PMC2537458
EDAT- 1979/12/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1979/12/01 00:00
PHST- 1979/12/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1979/12/01 00:00 [entrez]
PST - ppublish
SO  - J Natl Med Assoc. 1979 Dec;71(12):1236-7.

PMID- 6193845
OWN - NLM
STAT- MEDLINE
DCOM- 19831123
LR  - 20141120
IS  - 0037-9026 (Print)
IS  - 0037-9026 (Linking)
VI  - 177
IP  - 3
DP  - 1983
TI  - [In vitro aggregation of rat platelets by cumulative doses of ADP: influence of 3 
      antiaggregants and a protease inhibitor, aprotinin].
PG  - 320-31
AB  - The authors describe the aggregation provoked on rat platelets using cumulative 
      doses of ADP on the same sample. This model of aggregation is used to study the 
      effects of three known aggregation inhibitors (aspirine, theophylline, 
      isoproterenol) and one protease inhibitor, aprotinine.
FAU - Mary, A
AU  - Mary A
FAU - Cros, G
AU  - Cros G
FAU - Modat, G
AU  - Modat G
FAU - Lalaurie, M
AU  - Lalaurie M
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Agrégation in vitro des plaquettes de rat par doses cumulées d'ADP: influence de 
      trois antiagrégants et d'un inhibiteur protéasique, l'aprotinine.
PL  - France
TA  - C R Seances Soc Biol Fil
JT  - Comptes rendus des seances de la Societe de biologie et de ses filiales
JID - 7505439
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9087-70-1 (Aprotinin)
RN  - C137DTR5RG (Theophylline)
RN  - L628TT009W (Isoproterenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/*pharmacology
MH  - Animals
MH  - Aprotinin/*pharmacology
MH  - Aspirin/pharmacology
MH  - In Vitro Techniques
MH  - Isoproterenol/pharmacology
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Theophylline/pharmacology
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - C R Seances Soc Biol Fil. 1983;177(3):320-31.

PMID- 1605353
OWN - NLM
STAT- MEDLINE
DCOM- 19920716
LR  - 20190819
IS  - 0003-2654 (Print)
IS  - 0003-2654 (Linking)
VI  - 117
IP  - 5
DP  - 1992 May
TI  - Simultaneous determination of acetylsalicylic acid and its major metabolites in 
      human serum by second-derivative synchronous fluorescence spectrometry.
PG  - 877-82
AB  - A method is described for the simultaneous determination of acetylsalicylic, 
      salicylic, gentisic and salicyluric acids (ASA, SA, GA and SU, respectively) in 
      serum, based on their native fluorescence. The ASA-SA-GA-SU-containing serum 
      samples are extracted with chloroform-1% acetic acid solution; ASA and SA are 
      determined in the organic phase, and GA and SU in the aqueous phase, after 
      removal of protein with trichloroacetic acid, at pH 5.0 and 11.6, respectively. 
      The ASA-SA and GA-SU-SA mixtures are resolved using second-derivative 
      fluorescence spectrometry and the appropriate empirical equations involving the 
      effect of each acid on the signal of the other. Recoveries from sera spiked with 
      ASA (1.0-10 micrograms ml-1), SA (25-50 micrograms ml-1), GA (0.05-0.2 micrograms 
      ml-1) and SU (1.0-5.0 micrograms ml-1) ranged from 100 to 104% (mean 101%), from 
      93 to 99% (mean 97%), from 94 to 104% (mean 99%) and from 94 to 107% (mean 98%), 
      respectively.
FAU - Konstantianos, D G
AU  - Konstantianos DG
AD  - Department of Chemistry, University of Athens, Kouponia, Greece.
FAU - Ioannou, P C
AU  - Ioannou PC
LA  - eng
PT  - Journal Article
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/*blood/metabolism
MH  - Biotransformation
MH  - Humans
MH  - Spectrometry, Fluorescence/methods
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
AID - 10.1039/an9921700877 [doi]
PST - ppublish
SO  - Analyst. 1992 May;117(5):877-82. doi: 10.1039/an9921700877.

PMID- 7017485
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [The use of guacetisal in chronic obstructive bronchopneumopathy. Controlled 
      clinical study].
PG  - 355-62
AB  - A single-blind, between-patients trial was run to compare the fluidifying, 
      expectorant, antitussive, antipyretic and anti-inflammatory activity, and the 
      local and systemic tolerance of guacetisal, an active principle obtained by the 
      esterification of acetylsalicylic acid and guaiacol, and oxolamine phosphate, in 
      which the suspension formulation for adults was administered to 30 presenile and 
      senile patients of both sexes with chronic obstructive bronchopathy. A higher 
      activity on the part of guacetisal was noted. The results obtained are 
      illustrated and discussed.
FAU - Cerqua, R
AU  - Cerqua R
FAU - Trovello, C
AU  - Trovello C
FAU - Infante, G
AU  - Infante G
FAU - Ricciardi, S
AU  - Ricciardi S
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - L'impiego del guacetisal nella broncopneumopatia cronica ostruttiva. Studio 
      clinico controllato.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Oxadiazoles)
RN  - 90BEA145GY (oxolamine)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Aged
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Lung Diseases, Obstructive/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Oxadiazoles/*therapeutic use
MH  - Respiration/drug effects
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):355-62.

PMID- 2778621
OWN - NLM
STAT- MEDLINE
DCOM- 19891019
LR  - 20131121
IS  - 0047-2166 (Print)
IS  - 0047-2166 (Linking)
VI  - 44
IP  - 2
DP  - 1989 Mar-Apr
TI  - [Chromopharmacokinetics of acetylsalicylic acid administered rectally the 
      rabbit].
PG  - 117-20
AB  - Five white rabbits are given by rectal route a single dose of 100 mg of Aspirin 
      at regular hours: 7 a.m.; 10 a.m. and 2 p.m. the 7 a.m. administration results in 
      lowest CMAX and AUC and the slowest elimination, whereas 10 a.m. and 2 p.m. 
      administration results in the highest CMAX and AUC and shortest elimination time.
FAU - Fehri, B
AU  - Fehri B
FAU - Aiache, J M
AU  - Aiache JM
FAU - Boukef, K
AU  - Boukef K
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Chronopharmacocinétique de l'acide acétylsalicylique administré par voie rectale 
      chez le lapin.
PL  - Belgium
TA  - J Pharm Belg
JT  - Journal de pharmacie de Belgique
JID - 0375351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Rectal
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Female
MH  - Rabbits
EDAT- 1989/03/01 00:00
MHDA- 1989/03/01 00:01
CRDT- 1989/03/01 00:00
PHST- 1989/03/01 00:00 [pubmed]
PHST- 1989/03/01 00:01 [medline]
PHST- 1989/03/01 00:00 [entrez]
PST - ppublish
SO  - J Pharm Belg. 1989 Mar-Apr;44(2):117-20.

PMID- 9221624
OWN - NLM
STAT- MEDLINE
DCOM- 19970714
LR  - 20200225
IS  - 0303-8408 (Print)
IS  - 0303-8408 (Linking)
VI  - 42
IP  - 2
DP  - 1997
TI  - [Cost-effectiveness analysis of prevention of reinfarction using low-dose 
      acetylsalicylic acid; model calculation].
PG  - 114-20
AB  - The purpose of this study is to estimate the potential of savings which can be 
      achieved by prophylaxis of myocardial reinfarction with low-dose acetylsalicylic 
      acid (ASA) at 75 mg per day over a treatment period of two years. After secondary 
      analysis of published data, the effectiveness of low-dose ASA is compared to 
      placebo by a model calculation. The difference in the effectiveness between the 
      prophylaxis with ASA and placebo is taken from an international meta-analysis. 
      The economic valuation of this difference is carried out by a cost-effectiveness 
      analysis applying disease costs per case. According to the model calculation, 
      5535 DM can be saved per patient with a history of myocardial infarction with 75 
      mg ASA a day over a treatment period of two years. In 1991 there were around 
      740,000 patients with a history of myocardial infarction in the age group of 
      25-64 in the Old Bundesländer of the Federal Republic of Germany. The application 
      of the results of the model calculation would lead to considerable savings. Even 
      in the sensitivity analysis with different assumptions regarding costs incurred 
      by hospital treatment and costs incurred by premature retirement, the cost 
      advantage of the ASA-prophylaxis remains. Due to the cautious and conservative 
      assumptions in the model calculation the potential of savings is likely 
      underestimated. Nevertheless, there is a distinct advantage for the prophylaxis 
      with low-dose ASA which already occurs in direct costs thus leading to advantages 
      also for cost carriers.
FAU - Schädlich, P K
AU  - Schädlich PK
AD  - InForMed, Gesellschaft für interdisziplinäre Forschung und Beratung im 
      Gesundheitswesen mbH, Hamburg.
FAU - Brecht, J G
AU  - Brecht JG
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Kosten-Wirksamkeits-Analyse der Reinfarktprophylaxe mit niedrig dosierter 
      Acetylsalicylsäure: Modellrechnung.
PL  - Switzerland
TA  - Soz Praventivmed
JT  - Sozial- und Praventivmedizin
JID - 7502479
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*economics/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Middle Aged
MH  - Models, Economic
MH  - Myocardial Infarction/*prevention & control
MH  - Recurrence
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1007/BF01318140 [doi]
PST - ppublish
SO  - Soz Praventivmed. 1997;42(2):114-20. doi: 10.1007/BF01318140.

PMID- 7839324
OWN - NLM
STAT- MEDLINE
DCOM- 19950301
LR  - 20131121
IS  - 0040-5930 (Print)
IS  - 0040-5930 (Linking)
VI  - 51
IP  - 10
DP  - 1994 Oct
TI  - [Primary prevention of coronary heart disease with drugs: wishful thinking or 
      reality?].
PG  - 677-82
AB  - The primary prevention of coronary artery disease remains a controversial issue. 
      Beside the much disputed lipid-lowering drugs we have additional possibilities 
      for a pharmacological intervention, such as the administration of antioxidants 
      (e.g. vitamin E), aspirine or estrogens. In this article the epidemiological data 
      with such treatments are presented. In selected populations the relative risk of 
      cardiovascular events could be reduced 40 to 60% by vitamin-E supplements, 
      low-dose aspirine and estrogen replacement in postmenopausal women. The 
      protective effects are most marked in persons over 50 years with coexistent 
      cardiovascular risk factors. There are, however, also potential dangers of a 
      primary prophylaxis by drugs, such as the increased risk of cerebral and 
      gastrointestinal hemorrhage with aspirine or the induction of endometrial 
      carcinoma or breast cancer with estrogens. For this reason dietary and life style 
      counselling should remain the most important measure in primary prophylaxis. In 
      individuals with cardiovascular risk factors--which should be eliminated, if 
      possible--additional administration of aspirine, estrogens or antioxidants may be 
      considered after a careful evaluation of the overall risk/benefit ratio.
FAU - Follath, F
AU  - Follath F
AD  - Departement für Innere Medizin, Universitätsspital Zürich.
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Medikamentöse Primärprävention der koronaren Herzkrankheit: Wunschtraum oder 
      Realität?
PL  - Switzerland
TA  - Ther Umsch
JT  - Therapeutische Umschau. Revue therapeutique
JID - 0407224
RN  - 0 (Antioxidants)
RN  - 0 (Calcium Channel Blockers)
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antioxidants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Calcium Channel Blockers/therapeutic use
MH  - Coronary Disease/*prevention & control
MH  - Diet
MH  - Estrogen Replacement Therapy
MH  - Female
MH  - Humans
MH  - Life Style
MH  - Male
MH  - Primary Prevention
MH  - Vitamin E/therapeutic use
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
PST - ppublish
SO  - Ther Umsch. 1994 Oct;51(10):677-82.

PMID- 1206970
OWN - NLM
STAT- MEDLINE
DCOM- 19760402
LR  - 20190711
IS  - 0023-2173 (Print)
IS  - 0023-2173 (Linking)
VI  - 53
IP  - 23
DP  - 1975 Dec 1
TI  - [The effect of acetylsalicylic-lysine on platelet function (author's transl)].
PG  - 1125-9
AB  - Fifteen minutes after the intravenous administration of two different doses of 
      acetylsalicylic lysine, a pronounced inhibition of collagen-induced platelet 
      aggregation was observed in healthy volunteers. A proportionate dose response to 
      the differing doses could not be demonstrated. Platelet function investigated by 
      the glass bead filter method according to Hellem decreased however significantly 
      and dose-dependently after the injections. The clot formation in the 
      thromboelastogram was not disturbed after the administration of the drug in spite 
      of decreased platelet function.
FAU - Schöndorf, T H
AU  - Schöndorf TH
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Die Wirkung von Acetylsalicyl-Lysin auf die Thrombocytenfunktion.
PL  - Germany
TA  - Klin Wochenschr
JT  - Klinische Wochenschrift
JID - 2985205R
RN  - 0 (Anticoagulants)
RN  - 9007-34-5 (Collagen)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Anticoagulants
MH  - Aspirin/adverse effects/analogs & derivatives/*pharmacology
MH  - Collagen
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Lysine
MH  - Male
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Thrombelastography
EDAT- 1975/12/01 00:00
MHDA- 1975/12/01 00:01
CRDT- 1975/12/01 00:00
PHST- 1975/12/01 00:00 [pubmed]
PHST- 1975/12/01 00:01 [medline]
PHST- 1975/12/01 00:00 [entrez]
AID - 10.1007/BF01614281 [doi]
PST - ppublish
SO  - Klin Wochenschr. 1975 Dec 1;53(23):1125-9. doi: 10.1007/BF01614281.

PMID- 2613110
OWN - NLM
STAT- MEDLINE
DCOM- 19900301
LR  - 20190828
IS  - 0015-5691 (Print)
IS  - 0015-5691 (Linking)
VI  - 94
IP  - 5
DP  - 1989 Nov
TI  - [Pharmacological study of kako-bushi-matsu: analgesic action and acute toxicity].
PG  - 309-17
AB  - The analgesic effect and the acute toxicity of a medical drug "kako-bushi-matsu" 
      (S-01), which was produced through several processing of raw aconite roots, were 
      examined in comparison with those of ibuprofen, indomethacin and aspirin. S-01 
      (p.o.) inhibited the acetic acid- and phenylquinone-induced writhing 
      dose-dependently. From the ED50 values, indomethacin showed more potent 
      inhibitory action on the phenylquinone-induced writhing than on the acetic 
      acid-induced writhing. Ibuprofen and aspirin showed the same tendency as 
      indomethacin. The potency of the writhing inhibition by S-01 was almost to the 
      same degree in both writhing methods. In the tail pressure method, S-01 raised 
      the pain threshold ratio to almost the same degree as ibuprofen did. In 
      Randall-Selitto's method, the analgesic effect of S-01 on inflamed foot was less 
      than that of ibuprofen. In the normal foot, S-01 raised the pain threshold ratio 
      dose-dependently, but ibuprofen did not influence the pain threshold ratio. On 
      adjuvant-induced arthritic pain, S-01 and ibuprofen had an analgesic action, and 
      this action of S-01 was less than that of ibuprofen. The oral LD50 value of S-01 
      was more than 10,000 mg/kg in mice and rats of both sexes. The above evidence 
      indicates that S-01 has analgesic action and suggests that the mode of the 
      analgesic action of S-01 may differ from those of ibuprofen, indomethacin and 
      aspirin, which inhibit prostaglandin biosynthesis.
FAU - Murayama, M
AU  - Murayama M
AD  - Research Section, Sanwa Shoyaku Co., Ltd., Utsunomiya, Japan.
FAU - Namiki, Y
AU  - Namiki Y
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Yakurigaku Zasshi
JT  - Nihon yakurigaku zasshi. Folia pharmacologica Japonica
JID - 0420550
RN  - 0 (Analgesics)
RN  - 0 (Drugs, Chinese Herbal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - *Analgesics
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drugs, Chinese Herbal/*pharmacology/toxicity
MH  - Female
MH  - Ibuprofen/pharmacology
MH  - Indomethacin/pharmacology
MH  - Lethal Dose 50
MH  - Male
MH  - Mice
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
AID - 10.1254/fpj.94.309 [doi]
PST - ppublish
SO  - Nihon Yakurigaku Zasshi. 1989 Nov;94(5):309-17. doi: 10.1254/fpj.94.309.

PMID- 8787810
OWN - NLM
STAT- MEDLINE
DCOM- 19961023
LR  - 20190719
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 18
IP  - 12
DP  - 1995 Dec
TI  - A deconvolution method for estimating the first-pass metabolism of orally 
      administered drugs.
PG  - 1787-9
AB  - A deconvolution method for estimating the first-pass metabolism of orally 
      administered drugs is proposed. This analysis can be carried out without assuming 
      any pharmacokinetic models. The applicability of the deconvolution method was 
      evaluated by application to the plasma concentration-time courses of aspirin and 
      its metabolite, salicylic acid, reconstructed from pharmacokinetic parameters for 
      orally administered drugs. The estimated absorption profiles for aspirin and 
      salicylic acid were in fairly good agreement with the theoretical ones, although 
      a series of numerical calculations is involved in the procedures. The potential 
      of the present method was also confirmed by applying it to pharmacokinetic data 
      with random errors.
FAU - Yamashita, F
AU  - Yamashita F
AD  - Department of Drug Delivery Research, Kyoto University, Japan.
FAU - Bando, H
AU  - Bando H
FAU - Takakura, Y
AU  - Takakura Y
FAU - Hashida, M
AU  - Hashida M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/blood/*pharmacokinetics
MH  - Humans
MH  - Models, Biological
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
AID - 10.1248/bpb.18.1787 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 1995 Dec;18(12):1787-9. doi: 10.1248/bpb.18.1787.

PMID- 3936727
OWN - NLM
STAT- MEDLINE
DCOM- 19860228
LR  - 20190721
IS  - 0014-4819 (Print)
IS  - 0014-4819 (Linking)
VI  - 61
IP  - 1
DP  - 1985
TI  - The effect of lysine acetylsalicylate on joint capsule mechanoreceptors in rats 
      with polyarthritis.
PG  - 164-8
AB  - Joint capsule mechanoreceptors in arthritic rats are more sensitive to pressure 
      than similar receptors in normal animals. This greater sensitivity was reversed 
      by the intravenous or topical administration of lysine acetylsalicylate in 
      anaesthetised rats in doses of 15 to 50 mgm ASA-equivalent/kg. The reduction in 
      sensitivity began within 5-10 min and reached a minimum mean value of 35% of the 
      control after 35 to 40 min. During this period there was a negative linear or 
      exponential relation between the amplitude of response to a controlled mechanical 
      stimulus and time after administration of lysine acetylsalicylate. Control values 
      of sensitivity were reached about 65-70 min following treatment with lysine 
      acetylsalicylate. The results are interpreted as indicating that the high 
      sensitivity of the arthritic joint capsule receptors is due to locally produced 
      prostaglandins, such as prostacyclin.
FAU - Guilbaud, G
AU  - Guilbaud G
FAU - Iggo, A
AU  - Iggo A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Exp Brain Res
JT  - Experimental brain research
JID - 0043312
RN  - 0 (Analgesics)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Topical
MH  - Analgesics/*therapeutic use
MH  - Animals
MH  - Arthritis/*drug therapy
MH  - Arthritis, Experimental/*drug therapy
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology/therapeutic 
      use
MH  - Injections, Intravenous
MH  - Joints/*innervation
MH  - Lysine/administration & dosage/*analogs & derivatives/pharmacology/therapeutic 
      use
MH  - Mechanoreceptors/*drug effects
MH  - Rats
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1007/BF00235631 [doi]
PST - ppublish
SO  - Exp Brain Res. 1985;61(1):164-8. doi: 10.1007/BF00235631.

PMID- 6462879
OWN - NLM
STAT- MEDLINE
DCOM- 19840911
LR  - 20191111
IS  - 0167-6555 (Print)
IS  - 0167-6555 (Linking)
VI  - 6
IP  - 3
DP  - 1984 Jun 22
TI  - A simple fluorometric method for the determination of salicylic acid in aluminium 
      acetylsalicylate.
PG  - 118-20
AB  - A simple, rapid fluorometric method for the determination of salicylic acid in 
      aluminium acetylsalicylate is presented. The method is based on the dissolution 
      of aluminium acetylsalicylate in sodium fluoride-hydrochloric acid solution, 
      filtration and dilution with buffer solution pH = 4 followed by the fluorometric 
      determination of the liberated salicylic acid. The method was applied 
      successfully to the determination of salicylic acid in aluminium acetylsalicylate 
      tablets.
FAU - Wahbi, A M
AU  - Wahbi AM
FAU - Barary, M H
AU  - Barary MH
FAU - Korany, M A
AU  - Korany MA
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Pharm Weekbl Sci
JT  - Pharmaceutisch weekblad. Scientific edition
JID - 7907992
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 6QT214X4XU (aloxiprin)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/analysis
MH  - Hydrogen-Ion Concentration
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Spectrometry, Fluorescence
MH  - Tablets/analysis
EDAT- 1984/06/22 00:00
MHDA- 1984/06/22 00:01
CRDT- 1984/06/22 00:00
PHST- 1984/06/22 00:00 [pubmed]
PHST- 1984/06/22 00:01 [medline]
PHST- 1984/06/22 00:00 [entrez]
AID - 10.1007/BF01963002 [doi]
PST - ppublish
SO  - Pharm Weekbl Sci. 1984 Jun 22;6(3):118-20. doi: 10.1007/BF01963002.

PMID- 7017482
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Effects of guaiacolic ester of acetylsalicylic acid on spirometric and 
      plethysmographic parameters in subjects with chronic obstructive 
      bronchopneumopathy].
PG  - 333-7
AB  - The effects of oral administration of guaiacolic ester of acetyl salicilic acid 
      in 24 patients with chronic obstructive lung disease have been evaluated. 1.5 g 
      of this drug were given daily into 3 administrations improving both objective and 
      subjective symptomatology in 19 of the 24 patients after 1 or 3 weeks of 
      treatment. Moreover, a statistically significant improvement of FEV 1" (p less 
      than 0.001), Raw (p less than 0.005) and FEV 1"/VC (p less than 0.01) was 
      observed. The remaining 5 patients discontinued the treatment failing the 
      improvement of the subjective symptomatology.
FAU - Bonaduce, D
AU  - Bonaduce D
FAU - Postiglione, M
AU  - Postiglione M
FAU - Ferrara, N
AU  - Ferrara N
FAU - Petretta, M
AU  - Petretta M
FAU - De Caprio, L
AU  - De Caprio L
FAU - Rengo, F
AU  - Rengo F
LA  - ita
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Effetti dell'estere guaiacolico dell'acido acetilsalicilico su alcuni parametri 
      spirometrici e pletismografici in soggetti affetti da broncopneumopatia cronica 
      ostruttiva.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Aged
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Bronchitis/*drug therapy
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Lung Diseases, Obstructive/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Respiration/drug effects
MH  - Respiratory Function Tests
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):333-7.

PMID- 2769581
OWN - NLM
STAT- MEDLINE
DCOM- 19891011
LR  - 20131121
IS  - 0163-9366 (Print)
IS  - 0163-9366 (Linking)
VI  - 8
IP  - 3-4
DP  - 1989
TI  - Acetylsalicylic acid dose fails to affect energy intake of osteoarthritic 
      elderly.
PG  - 79-96
AB  - The objective of the study was to determine the effect on energy intake and 
      appetite of acetylsalicylic acid (ASA), commonly used by the elderly to treat 
      arthritis. In a double blind cross-over study, 23 free-living osteoarthritic 
      patients 60 years of age or older were treated for two-weeks intervals with a 
      mean daily ASA intake of 2.44 and 1.29 grams, respectively. Twenty healthy 
      persons similar in age, taking no medication, and matched in sociocultural 
      characteristics were included as a control group. Appetite was measured directly, 
      using a visual analogue scale, and indirectly by calculating energy intake from 
      three-day food records. Varying the dose of ASA was without effect on appetite 
      and food energy intake; however, as appetite was rated lower by the medicated 
      osteoarthritic than by the healthy group, although the energy intakes were not 
      significantly different, the former should be considered as potentially at 
      nutritional risk.
FAU - Taylor, J
AU  - Taylor J
FAU - Krondl, M
AU  - Krondl M
FAU - Rao, V
AU  - Rao V
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Nutr Elder
JT  - Journal of nutrition for the elderly
JID - 8208739
RN  - R16CO5Y76E (Aspirin)
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Energy Intake/*drug effects
MH  - Humans
MH  - Osteoarthritis/drug therapy
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1300/J052v08n03_06 [doi]
PST - ppublish
SO  - J Nutr Elder. 1989;8(3-4):79-96. doi: 10.1300/J052v08n03_06.

PMID- 2076181
OWN - NLM
STAT- MEDLINE
DCOM- 19910423
LR  - 20161123
IS  - 0884-2884 (Print)
IS  - 0884-2884 (Linking)
VI  - 6
IP  - 3
DP  - 1990 Sep
TI  - Rosin and rosin derivatives as hydrophobic matrix materials for controlled 
      release of drugs.
PG  - 223-7
AB  - The evaluation of rosin, a rosin hard paraffin adduct, and four rosin esters as 
      hydrophobic matrix materials for the controlled release of drugs is reported, 
      using aspirin as a drug model. Aspirin matrix tablets were prepared using a wet 
      granulation (nonaqueous) method, and were evaluated for various pharmaceutical 
      parameters. Dissolution studies in pH 7.2 phosphate buffer showed that all 
      formulations had hardness greater than 6 kg/cm2 and disintegration time greater 
      than 150 min. Release of aspirin from the formulations obeyed a diffusion 
      controlled first order kinetic and linear to the square root of time function. 
      Two of the resin ester formulations had a T80% of more than 4 hr. The results 
      suggest that these esters may find application in the development of sustained 
      release formulations for the local treatment of dental diseases, or--as tablet 
      matrices suitably coated with acid resistant material--in the development of oral 
      sustained release drug delivery systems.
FAU - Pathak, Y V
AU  - Pathak YV
AD  - Department of Pharmaceutical Sciences, Nagpur University, India.
FAU - Dorle, A K
AU  - Dorle AK
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Drug Des Deliv
JT  - Drug design and delivery
JID - 8712388
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Resins, Plant)
RN  - 0 (Tablets)
RN  - 88S87KL877 (rosin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/chemistry
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Delayed-Action Preparations
MH  - Hardness
MH  - Resins, Plant/*chemistry
MH  - Tablets
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
PST - ppublish
SO  - Drug Des Deliv. 1990 Sep;6(3):223-7.

PMID- 1941545
OWN - NLM
STAT- MEDLINE
DCOM- 19911224
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 80
IP  - 6
DP  - 1991 Jun
TI  - Enzymatic and nonenzymatic in vitro hydrolysis of 
      2-methyl-2-[2-(methoxy)phenoxy]-4H-1,3-benzodioxin-4-one and 2-methoxyphenyl 
      O-acetylsalicylate.
PG  - 545-7
AB  - This paper is concerned with the synthesis and physical properties as well as the 
      enzymatic and nonenzymatic in vitro hydrolysis of the potential aspirin prodrug 
      MR 693 (5) and the salicylic acid prodrug guacetisalum (6). The half-lives of 
      both prodrugs and the amount of aspirin regenerated in each hydrolytic run for 5 
      have been estimated over a wide range of pH values.
FAU - Hundewadt, M
AU  - Hundewadt M
AD  - Department of Chemistry, University of Aarhus, Denmark.
FAU - Senning, A
AU  - Senning A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Dioxanes)
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - K43273G1CW (guaimesal)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism
MH  - Aspirin/*analogs & derivatives/chemistry/metabolism
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Dioxanes/chemistry/*metabolism
MH  - Humans
MH  - Hydrolysis
MH  - Mixed Function Oxygenases/metabolism
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
AID - S0022-3549(15)48561-2 [pii]
AID - 10.1002/jps.2600800609 [doi]
PST - ppublish
SO  - J Pharm Sci. 1991 Jun;80(6):545-7. doi: 10.1002/jps.2600800609.

PMID- 825279
OWN - NLM
STAT- MEDLINE
DCOM- 19770129
LR  - 20191021
VI  - 283
IP  - 4
DP  - 1976 Sep 13
TI  - [The effect of prostaglandin F2alpha on pregnancy in rats and attempts to 
      counteract its abortifacient action].
PG  - 353-5
AB  - Prostaglandin F2alpha is not teratogenic in the Rat. The frequency of abortions 
      increases after implantation. Between day 9-14, 100% of abortions are observed. 
      Progesterone, aspirine, or indomethacine are incapable of preventing the 
      abortions induced by prostaglandin F2alpha.
FAU - Mercier-Parot, L
AU  - Mercier-Parot L
FAU - Tuchmann-Duplessis, H
AU  - Tuchmann-Duplessis H
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Action de la prostaglandine F2alpha sur la gestation de la Ratte et essais de 
      prévention du pouvoir abortif.
PL  - France
TA  - C R Acad Hebd Seances Acad Sci D
JT  - Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: 
      Sciences naturelles
JID - 7501107
RN  - 0 (Abortifacient Agents)
RN  - 0 (Prostaglandins F)
RN  - 4G7DS2Q64Y (Progesterone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - *Abortifacient Agents/antagonists & inhibitors
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gestational Age
MH  - Indomethacin/pharmacology
MH  - Pregnancy
MH  - Progesterone/pharmacology
MH  - Prostaglandins F/antagonists & inhibitors/*pharmacology
MH  - Rats
EDAT- 1976/09/13 00:00
MHDA- 1976/09/13 00:01
CRDT- 1976/09/13 00:00
PHST- 1976/09/13 00:00 [pubmed]
PHST- 1976/09/13 00:01 [medline]
PHST- 1976/09/13 00:00 [entrez]
PST - ppublish
SO  - C R Acad Hebd Seances Acad Sci D. 1976 Sep 13;283(4):353-5.

PMID- 987505
OWN - NLM
STAT- MEDLINE
DCOM- 19761201
LR  - 20131121
IS  - 0300-8630 (Print)
IS  - 0300-8630 (Linking)
VI  - 188
IP  - 5
DP  - 1976 Sep
TI  - [Hamostasiological changes induced by platelet-aggregation-inhibitors, tested in 
      children with congenital heart disease (in vitro and in vitro examinations) 
      (author's transl)].
PG  - 424-9
AB  - This report has delt with in vivo and in vitro examinations in the cases of 
      sixteen children suffering from cyanotic congenital heart disease, and who had 
      been placed under extended therapy with platelet-aggregation-inhibitors. The 
      pharmacological effect of acetylsalicylic acid and dipyridamol has been 
      discussed--as far as it is known. The discrepancy between in vivo and in vitro 
      therapy-effect in the treatment with platelet-aggregation-inhibitors has been 
      subjected to criticism. Consistant treatment of all children suffering from 
      cyanotic congenital heart disease with aspirine and persantine has been 
      advocated, however should only be carried out in collaboration with a competent 
      hamostasiological laboratory.
FAU - Schmidt, B
AU  - Schmidt B
FAU - Sutor, H
AU  - Sutor H
FAU - Lorenz, H
AU  - Lorenz H
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Hämostaseveränderungen durch Plättchenaggregationshemmer bei Kindern mit 
      Herzvitien (in vivo- und in vitro-Untersuchungen).
PL  - Germany
TA  - Klin Padiatr
JT  - Klinische Padiatrie
JID - 0326144
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cyanosis
MH  - Dipyridamole/*pharmacology/therapeutic use
MH  - Heart Defects, Congenital/complications/*drug therapy
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Time Factors
EDAT- 1976/09/01 00:00
MHDA- 1976/09/01 00:01
CRDT- 1976/09/01 00:00
PHST- 1976/09/01 00:00 [pubmed]
PHST- 1976/09/01 00:01 [medline]
PHST- 1976/09/01 00:00 [entrez]
PST - ppublish
SO  - Klin Padiatr. 1976 Sep;188(5):424-9.

PMID- 3579047
OWN - NLM
STAT- MEDLINE
DCOM- 19870624
LR  - 20131121
IS  - 0003-1348 (Print)
IS  - 0003-1348 (Linking)
VI  - 53
IP  - 6
DP  - 1987 Jun
TI  - Prevention of postoperative neurologic deficits after carotid endarterectomy. Is 
      platelet inhibition beneficial?
PG  - 329-32
AB  - Aspirin (ASA) and dipyridamole (DIP) have been shown to reduce the incidence of 
      transient ischemic attacks (TIAs), but aspirin's ability to reduce the incidence 
      of postoperative neurologic deficits in patients who require carotid 
      endarterectomy (CE) is controversial. To evaluate the role of adjunctive ASA/DIP 
      in conjunction with CE, 908 CE cases were reviewed. Four hundred sixty-seven 
      patients took ASA (650 mg/day) and DIP (150 mg/day) preoperatively, while 381 
      received no ASA/DIP. There was no statistical difference in the distribution of 
      postoperative neurologic deficits. Twenty-six transient deficits occurred: 14 
      (53%) patients were taking ASA/DIP, whereas 12 (47%) were not. Seventeen 
      permanent deficits occurred: ten (58%) patients were taking ASA/DIP and seven 
      (42%) were not. ASA/DIP are useful medications in combating ischemic 
      cerebrovascular disease, but ASA/DIP cannot replace precise operative technique 
      which affords unequaled protection against a postendarterectomy neurologic 
      deficit.
FAU - Rosenthal, D
AU  - Rosenthal D
FAU - Lamis, P A
AU  - Lamis PA
FAU - Stanton, P E Jr
AU  - Stanton PE Jr
FAU - Clark, M D
AU  - Clark MD
FAU - Ellison, R G Jr
AU  - Ellison RG Jr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Surg
JT  - The American surgeon
JID - 0370522
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Carotid Artery Diseases/*surgery
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Dipyridamole/*therapeutic use
MH  - *Endarterectomy
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/prevention & control
MH  - Male
MH  - Middle Aged
MH  - *Postoperative Complications
MH  - Preoperative Care
MH  - Risk
EDAT- 1987/06/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1987/06/01 00:00
PHST- 1987/06/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1987/06/01 00:00 [entrez]
PST - ppublish
SO  - Am Surg. 1987 Jun;53(6):329-32.

PMID- 7193003
OWN - NLM
STAT- MEDLINE
DCOM- 19810327
LR  - 20141120
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 30
IP  - 11
DP  - 1980
TI  - [On the platelet aggregation inhibiting and analgesic activities of 
      acetylsalicylic acid (author's transl)].
PG  - 1917-22
AB  - Acetylsalicylic acid (ASA)--now the most potent platelet-aggregation 
      inhibitor--is being investigated in combination with glycine (Godamed; text 
      preparation A) and microencapsulated (test preparation B) in view of the plasma 
      total salicylate level and platelet aggregation inhibiting effect. The 
      examination is conducted on 20 patients by the cross-over method. An increase of 
      the plasma total salicylate level of test preparation A compared with test 
      preparation B is highly significant up to 60 min after application of 1000 mg ASA 
      respectively. As in shorter time a higher plasma total salicylate level is 
      reached a significantly higher analgesic effect of the test preparation A may be 
      expected. In certain indications, occurring with pain, as for instance arterial 
      occlusive disease, thrombophlebitis, etc., this is absolutely desired. Additional 
      application of analgetics is then often unnecessary. A differentiated use of ASA 
      preparations as platelet-aggregation inhibitors is therefore required. To 
      investigate the disaggregating effect of both ASA preparations the PAT-III test 
      by Breddin was used. 2 h after the oral application of 1000 mg ASA a complete 
      normalisation by both ASA preparations was reached, whereas before a significant 
      higher platelet aggregation had been recognized. The somewhat faster reached 
      effect of test preparation A is not significant and clinically not relevant. When 
      in the acute phase as well as in the long-term treatment of the above mentioned 
      indications an ASA-containing platelet-aggregation inhibitor is used, that 
      preparation should get preference which is well tolerable and has the same 
      platelet-disaggregating effect but with the higher analgesic effect.
FAU - Schnell, O
AU  - Schnell O
FAU - Lang, E
AU  - Lang E
FAU - Bertholdt, H
AU  - Bertholdt H
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Untersuchungen zur thrombozytenaggregationshemmenden und analgetischen Wirkung 
      der Acetylsalicylsäure.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Analgesics)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - *Analgesics
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Glycine/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Aggregation/*drug effects
MH  - Solubility
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1980;30(11):1917-22.

PMID- 8030422
OWN - NLM
STAT- MEDLINE
DCOM- 19940809
LR  - 20131121
IS  - 0001-6837 (Print)
IS  - 0001-6837 (Linking)
VI  - 50
IP  - 2-3
DP  - 1993
TI  - [Determination of trace amounts of salicylic acid and acetylsalicylic acid in 
      polopirin and other drugs containing acetylsalicylic acid].
PG  - 143-7
AB  - A liquid chromatography procedure has been employed for the quantitative 
      determination of trace amounts of salicylic acid, acetylsalicylic salicylic acid 
      and acetylsalicylic anhydride in several Polish drugs containing aspirin. The 
      results were compared with those obtained by other workers for analogous foreign 
      drugs.
FAU - Gołkiewicz, W
AU  - Gołkiewicz W
AD  - Katedra Chemii Nieorganicznej i Analitycznej, Akademia Medyczna, Lublin.
FAU - Bartos, A
AU  - Bartos A
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Oznaczanie śladowych ilości kwasu salicylowego i kwasu 
      acetylosalicylosalicylowego w polopirynie i innych lekach zawierajacych kwas 
      acetylosalicylowy.
PL  - Poland
TA  - Acta Pol Pharm
JT  - Acta poloniae pharmaceutica
JID - 2985167R
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XIA5Z82RHB (acetylsalicylic anhydride)
SB  - IM
MH  - Aspirin/analogs & derivatives/*analysis
MH  - Chromatography, Liquid/methods
MH  - Salicylates/*analysis
MH  - Salicylic Acid
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Pol Pharm. 1993;50(2-3):143-7.

PMID- 1198081
OWN - NLM
STAT- MEDLINE
DCOM- 19760226
LR  - 20190907
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 4
IP  - 4
DP  - 1975
TI  - Dosage of salicylates for children with juvenile rheumatoid arthritis. A 
      preliminary report.
PG  - 250-2
AB  - The daily dosage of salicylates is traditionally very high for patients with 
      juvenile rheumatoid arthritis. In order to achieve the optimal therapeutic 
      effect, serum salicylate levels are kept at 30-35 mg/100 ml (2175-2540 mumol/l). 
      The recommended daily dosage in the textbooks is about 100 mg/kg of body weight, 
      and the reported dosage/m2 of body surface area has been 3.2 g/m2/day. These 
      dosages are, however, too high in clinical routine. In the present investigation, 
      19 children were treated with salicylates for 15 days with daily check-ups of the 
      serum salicylate levels. Seven of these children had symptoms of salicylate 
      intoxication which corresponded closely to the serum salicylate levels. If the 
      daily dosage of salicylates exceeds 3 g/m2 of body surface area, intoxication can 
      be expected.
FAU - Mäkelä, A L
AU  - Mäkelä AL
FAU - Tryänä, T
AU  - Tryänä T
FAU - Haapasaari, J
AU  - Haapasaari J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/*administration & dosage/blood/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Tablets, Enteric-Coated
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 10.3109/03009747509165266 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 1975;4(4):250-2. doi: 10.3109/03009747509165266.

PMID- 14762891
OWN - NLM
STAT- MEDLINE
DCOM- 20041015
LR  - 20171116
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 93
IP  - 3
DP  - 2004 Mar
TI  - Polymorphism of NCX4016, an NO-releasing derivative of acetylsalicylic acid.
PG  - 521-31
AB  - NCX4016 [2-acetoxybenzoic acid 3'-(nitrooxymethyl)phenyl ester] is a recently 
      developed nitrooxy-derivative of aspirin with improved antiinflammatory, 
      analgesic, and antithrombotic activity as well as increased gastrointestinal 
      safety. Systematic polymorphic screening performed with different solvents and 
      preparation methods resulted in the identification of two polymorphs, designated 
      Forms I and II. They were characterized by scanning electron microscopy, powder 
      X-ray diffraction, thermal analyses, and infrared spectroscopy; the crystal 
      structure of polymorph I was solved by single-crystal X-ray analysis and compared 
      with that of aspirin. Finally, intrinsic dissolution rate studies and 
      calculations according to the melting data method were performed to assess the 
      thermodynamic relationship between the two polymorphs.
CI  - Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association
FAU - Foppoli, A
AU  - Foppoli A
AD  - Università di Milano, Istituto di Chimica Farmaceutica e Tossicologica, viale 
      Abruzzi 42, 20131 Milan, Italy.
FAU - Sangalli, M E
AU  - Sangalli ME
FAU - Maroni, A
AU  - Maroni A
FAU - Gazzaniga, A
AU  - Gazzaniga A
FAU - Caira, M R
AU  - Caira MR
FAU - Giordano, F
AU  - Giordano F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/analysis/*chemistry
MH  - Nitric Oxide/*chemistry/*metabolism
MH  - X-Ray Diffraction/methods
EDAT- 2004/02/06 05:00
MHDA- 2004/10/16 09:00
CRDT- 2004/02/06 05:00
PHST- 2004/02/06 05:00 [pubmed]
PHST- 2004/10/16 09:00 [medline]
PHST- 2004/02/06 05:00 [entrez]
AID - S0022-3549(16)31433-2 [pii]
AID - 10.1002/jps.10547 [doi]
PST - ppublish
SO  - J Pharm Sci. 2004 Mar;93(3):521-31. doi: 10.1002/jps.10547.

PMID- 1242328
OWN - NLM
STAT- MEDLINE
DCOM- 19751218
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 25
IP  - 5
DP  - 1975 May
TI  - Antinociceptive action and plasma levels of acetylsalicylic acid in the dog.
PG  - 801-6
AB  - 1. The analgesic potency of acetylsalicylic acid (ASA) is four times greater when 
      administered intravenously than when administered orally. 2. The onset of the ASA 
      analgesia after oral administration is significantly slower (30-60 min) than 
      after intravenous (5-15 min) application. However, the duration of ASA-analgesia 
      after oral administration is significantly longer (5 h) than after i.v. (2-4 h) 
      application. 3. The onset and duration of ASA-analgesia in dogs after oral and 
      i.v. administration cannot be correlated with plasma levels of ASA. During the 
      period of analgesia, ASA can be detected only in extremely low concentrations, 
      since it appears to be very rapidly hydrolysed to SA. 4. The development of an 
      accurate and reproducible method for the separate determination of ASA and SA in 
      plasma facilitated the direct correlation of plasma levels of these substances 
      with ASA-induced analgesia.
FAU - O'Dea, K
AU  - O'Dea K
FAU - Pütter, J
AU  - Pütter J
FAU - Hoffmeister, F
AU  - Hoffmeister F
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Analgesics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hydrolysis
MH  - Injections, Intravenous
MH  - Male
MH  - Time Factors
EDAT- 1975/05/01 00:00
MHDA- 1975/05/01 00:01
CRDT- 1975/05/01 00:00
PHST- 1975/05/01 00:00 [pubmed]
PHST- 1975/05/01 00:01 [medline]
PHST- 1975/05/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1975 May;25(5):801-6.

PMID- 6732552
OWN - NLM
STAT- MEDLINE
DCOM- 19840720
LR  - 20190829
IS  - 0160-564X (Print)
IS  - 0160-564X (Linking)
VI  - 8
IP  - 2
DP  - 1984 May
TI  - Drug interaction in middle molecule analysis, with special reference to 
      acetylsalicylic acid.
PG  - 226-9
AB  - Concerning the middle molecules in uremia and other diseases, the potential 
      artifact that can impede an accurate quantitation of middle molecules and that is 
      related to the absorption of a very commonly used drug, namely aspirin, is 
      discussed. Peak 7c and peak b 4-2 are two different middle molecules separated by 
      gel permeation chromatography followed by anion-exchange chromatography. Oral 
      ingestion of acetylsalicylic acid modifies the chromatographic pattern of the 
      middle molecule fraction in normal subjects and uremic patients. Peak 7c is 
      increased in the urine of healthy subjects, whereas this is not the case for peak 
      b 4-2: With the b 4-2 technique, ingestion of acetylsalicylic acid produces a 
      higher peak b 5. This is consistent with the previous demonstration that peak 7c 
      was eluted as peak b 5. Structural analogies between salicylate metabolites and 
      orthohydroxyhippuric acid beta-glucuronate (i.e., the main component of peak 7c) 
      could explain this drug-related artifact.
FAU - Faguer, P
AU  - Faguer P
FAU - Man, N K
AU  - Man NK
FAU - Cueille, G
AU  - Cueille G
FAU - Funck-Brentano, J L
AU  - Funck-Brentano JL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Artif Organs
JT  - Artificial organs
JID - 7802778
RN  - 0 (Toxins, Biological)
RN  - 0 (uremia middle molecule toxins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/metabolism
MH  - Chromatography, Gel
MH  - Chromatography, Ion Exchange
MH  - Drug Interactions
MH  - Humans
MH  - Toxins, Biological/*analysis
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
AID - 10.1111/j.1525-1594.1984.tb04277.x [doi]
PST - ppublish
SO  - Artif Organs. 1984 May;8(2):226-9. doi: 10.1111/j.1525-1594.1984.tb04277.x.

PMID- 3696143
OWN - NLM
STAT- MEDLINE
DCOM- 19880212
LR  - 20151119
IS  - 0301-4894 (Print)
IS  - 0301-4894 (Linking)
VI  - 88
IP  - 10
DP  - 1987 Oct
TI  - [Quantitative study of platelet deposition on expanded polytetrafluoroethylene 
      grafts using 111indium-labeled platelets].
PG  - 1485-93
AB  - The count of platelets deposited on expanded polytetrafluoroethylene grafts (2 cm 
      long, 3 mm internal diameter, implanted into thoracic aortae of 59 rabbits) was 
      measured using 111Indium-labeled autologous platelets. The changes due to the 
      time courses after implantation, the effect of aspirin and the differences of the 
      platelet deposition on the thrombus and thrombus free surface were studied. In 
      non-treated grafts, platelet deposition on the thrombus free surface was 
      significantly and repeatedly decreased on the 3rd (42.3 +/- 16.6 X 10(4)/mm2, 
      mean +/- S.D.), 9th (17.7 +/- 5.3 X 10(4)/mm2), and 30th (6.8 +/- 3.2 X 10(4) 
      mm2) days after the implantation (p less than 0.05). In treated grafts, platelet 
      deposition on the thrombus free surface was significantly inhibited by aspirin on 
      the 3rd day (20.5 +/- 8.4 X 10(4)/mm2) after implantation (p less than 0.03), 
      while significant inhibition of platelet deposition by aspirin was not noted on 
      the 9th (13.4 +/- 3.8 X 10(4)/mm2) and 30th (13.1 +/- 4.5 X 10(4)/mm2) days after 
      the implantation. Platelet deposition on the thrombus was not inhibited by 
      aspirin. (3600 +/- 2400 X 10(4)/mm2, non-treated grafts. 3500 +/- 520 X 
      10(4)/mm2, treated grafts). It is concluded that administration of aspirin is 
      necessary immediately after implantation, and its effect is not noted at the time 
      when the deposition of the platelet decreased, and the effect of aspirin cannot 
      be expected in tissues where easy platelet aggregation occurs.
FAU - Imai, K
AU  - Imai K
AD  - Second Department of Surgery, Yamagata University School of Medicine, Japan.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Geka Gakkai Zasshi
JT  - Nihon Geka Gakkai zasshi
JID - 0405405
RN  - 0 (Indium Radioisotopes)
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology
MH  - *Blood Vessel Prosthesis
MH  - Indium Radioisotopes
MH  - *Platelet Aggregation/drug effects
MH  - *Polytetrafluoroethylene
MH  - Rabbits
EDAT- 1987/10/01 00:00
MHDA- 1987/10/01 00:01
CRDT- 1987/10/01 00:00
PHST- 1987/10/01 00:00 [pubmed]
PHST- 1987/10/01 00:01 [medline]
PHST- 1987/10/01 00:00 [entrez]
PST - ppublish
SO  - Nihon Geka Gakkai Zasshi. 1987 Oct;88(10):1485-93.

PMID- 7008184
OWN - NLM
STAT- MEDLINE
DCOM- 19810421
LR  - 20190909
IS  - 0036-553X (Print)
IS  - 0036-553X (Linking)
VI  - 26
IP  - 1
DP  - 1981 Jan
TI  - Acetylsalicylic acid-induced prolongation of bleeding time in healthy men.
PG  - 50-6
AB  - Bleeding times were determined in 25 healthy men using the Thrombolette bleeding 
      time device. The median bleeding times prior to low and high doses of 
      acetylsalicylic acid (ASA), 245 and 230 s, were not significantly different (P = 
      0.12). 2 h after randomized ingestion of 0.44 and 3.96 g ASA, the median bleeding 
      times rose to 450 and 430 s, respectively. Both increased in bleeding time were 
      significant (P less than 0.001), but the difference was not significant (P = 
      0.29). The maximum increase in bleeding time was estimated to occur 2.6 h after 
      ingestion of a single low ASA dose, and 2.4 h after a single high dose. Following 
      ingestion of 0.44 as well as 3.96 g ASA the bleeding time returned to basal 
      levels within 5-6 d. Compared to the younger ones, volunteers with a higher age 
      showed a tendency to have lower plasma salicylate levels as well as smaller 
      increases in bleeding times following ASA ingestion.
FAU - Dybdahl, J H
AU  - Dybdahl JH
FAU - Daae, L N
AU  - Daae LN
FAU - Eika, C
AU  - Eika C
FAU - Godal, H C
AU  - Godal HC
FAU - Larsen, S
AU  - Larsen S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Denmark
TA  - Scand J Haematol
JT  - Scandinavian journal of haematology
JID - 0404507
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aspirin/administration & dosage/*adverse effects/blood
MH  - Bleeding Time
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1981.tb01623.x [doi]
PST - ppublish
SO  - Scand J Haematol. 1981 Jan;26(1):50-6. doi: 10.1111/j.1600-0609.1981.tb01623.x.

PMID- 7243036
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Clinico-functional data concerning chronic asthmatic bronchitis patients treated 
      wih guacetisal].
PG  - 321-4
AB  - Guacetisal was administered to a group of patients suffering from chronic 
      asthmatic bronchitis. The drug in question was shown to possess a good 
      fluidifying, expectorant and indirect anti-cough action, by means of an initial 
      increase of the bronchial secretions and a subsequent progressive decrease of 
      secretions towards the end of the treatment. The analysis of the respiratory 
      parameters examined showed no modifications of statistical significance.
FAU - Bande, G
AU  - Bande G
FAU - Coghe, M
AU  - Coghe M
FAU - Meloni, M
AU  - Meloni M
FAU - Nonne, G
AU  - Nonne G
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Rilievi clinico-funzionali in bronchitici cronici asmatici trattati con 
      guacetisal.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Bronchial Spasm/drug therapy
MH  - Bronchitis/*drug therapy
MH  - Cough/drug therapy
MH  - Dyspnea/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiration/drug effects
MH  - Respiratory Function Tests
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):321-4.

PMID- 17985450
OWN - NLM
STAT- MEDLINE
DCOM- 20080114
LR  - 20131121
IS  - 1049-510X (Print)
IS  - 1049-510X (Linking)
VI  - 17
IP  - 2 Suppl 3
DP  - 2007 Summer
TI  - Health issues in the Arab American community. The use of glucose-lowering agents 
      and aspirin among Arab Americans with diabetes.
PG  - S3-42-S3-45
AB  - OBJECTIVE: Little is known about the health outcomes or the quality of care among 
      Arab American patients with diabetes. The objective of this study is to examine 
      the use of glucose-lowering agents and aspirin therapy in this population 
      compared to the drug utilization patterns reported in nationally representative 
      surveys. RESEARCH DESIGN AND METHODS: A random sample of adult Arab American 
      patients with self-reported diabetes was selected. Complete medication histories 
      were recorded during a face-to-face interview. Medication utilization of the 
      glucose-lowering agents and aspirin were compared to data from the Third National 
      Health and Nutrition Examination Survey (NHANES) and the Behavioral Risk Factor 
      Surveillance System (BRFSS). RESULTS: The study sample consisted of 53 
      participants (20 males, 33 females) with mean age +/- SD of 59.4 +/- 12 years and 
      A1C levels of 8.0 +/- 2%. Compared to US adults, Arab American patients with 
      diabetes were less likely to be treated with insulin (27% vs 17%) and more likely 
      to receive oral hypoglycemic agents (65% vs 81%). Similar proportions of 
      participants were maintained on insulin-oral hypoglycemic-combined therapy (10% 
      US adults vs 9% Arab Americans). Aspirin use was significantly lower among the 
      study participants (23%) compared to the reported national prevalence of aspirin 
      intake (64%). CONCLUSION: The therapeutic management of diabetes in the 
      Arab-American patients with diabetes is suboptimal. The use of insulin and 
      aspirin was lower than that reported by participants in the NHANES and BRFSS 
      national databases. More aggressive approaches for the management of 
      hyperglycemia and the prevention of cardiovascular diseases are needed to improve 
      health outcomes in the Arab-American community.
FAU - Berlie, Helen D
AU  - Berlie HD
AD  - Department of Pharmacy Practice, Wayne State University Detroit, Michigan, USA.
FAU - Hammad, Adnan
AU  - Hammad A
FAU - Jaber, Linda A
AU  - Jaber LA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ethn Dis
JT  - Ethnicity & disease
JID - 9109034
RN  - 0 (Blood Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Arabs
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Blood Glucose/*drug effects
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus/*drug therapy
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Michigan
MH  - Middle Aged
MH  - Middle East/ethnology
EDAT- 2007/11/07 09:00
MHDA- 2008/01/15 09:00
CRDT- 2007/11/07 09:00
PHST- 2007/11/07 09:00 [pubmed]
PHST- 2008/01/15 09:00 [medline]
PHST- 2007/11/07 09:00 [entrez]
PST - ppublish
SO  - Ethn Dis. 2007 Summer;17(2 Suppl 3):S3-42-S3-45.

PMID- 874749
OWN - NLM
STAT- MEDLINE
DCOM- 19770812
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 66
IP  - 5
DP  - 1977 May
TI  - Antipyretic testing of commercial aspirin formulations in rats.
PG  - 674-6
AB  - Four commercial aspirin formulations and aspirin powder USP were assayed in 
      yeast-fevered rats for antipyretic activity. Tablets allowed to disintegrate 
      spontaneously prior to dosing yielded aggregates of various sizes which failed to 
      produce uniform patterns of antipyresis. When tested at smaller, more uniform 
      particle sizes of total product, consistent, statistically significant 
      antipyresis was observed with no significant variation among formulations. The 
      ED50 values and parallel line assays were homogeneous.
FAU - Loux, J J
AU  - Loux JJ
FAU - DePalma, P D
AU  - DePalma PD
FAU - Eby, R Z
AU  - Eby RZ
FAU - Yankell, S L
AU  - Yankell SL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Analgesics)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesics
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Body Temperature/drug effects
MH  - Male
MH  - Particle Size
MH  - Rats
MH  - Tablets
MH  - Therapeutic Equivalency
MH  - Time Factors
EDAT- 1977/05/01 00:00
MHDA- 1977/05/01 00:01
CRDT- 1977/05/01 00:00
PHST- 1977/05/01 00:00 [pubmed]
PHST- 1977/05/01 00:01 [medline]
PHST- 1977/05/01 00:00 [entrez]
AID - S0022-3549(15)39335-7 [pii]
AID - 10.1002/jps.2600660516 [doi]
PST - ppublish
SO  - J Pharm Sci. 1977 May;66(5):674-6. doi: 10.1002/jps.2600660516.

PMID- 30381068
OWN - NLM
STAT- MEDLINE
DCOM- 20200226
LR  - 20200226
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 27
IP  - 1
DP  - 2020
TI  - The Structural Details of Aspirin Molecules and Crystals.
PG  - 99-120
LID - 10.2174/0929867325666181031132823 [doi]
AB  - We revisit, in the key of structural chemistry, one of the most known and 
      important drugs: the aspirin. Although apparently simple, the factors determining 
      the molecular structure and supramolecular association in crystals are not 
      trivial. We addressed the problem from experimental and theoretical sides, 
      considering issues from X-ray measurements and results of first-principle 
      reconstruction of molecule and lattices by ab initio calculations. Some puzzling 
      problems can give headaches to specialists and intrigue the general public. Thus, 
      the reported polymorphism of aspirin is disputed, a so-called form II being 
      alleged as a result of misinterpretation. At the same time, were presented 
      evidences that the structure of common form I can be disrupted by domains where 
      the regular packing is changed to the pattern of form II. The problems appear 
      even at the level of independent molecule: the most stable conformation computed 
      by various techniques of electronic structure differs from those encountered in 
      crystals. Because the energy difference between the related conformational 
      isomers (computed as most stable vs. the experimental structure) is small, about 
      1 kcal/mol, comprised in the error bars of used methods, the unresting question 
      is whether the modelling is imprecise, or the supramolecular factors are mutating 
      the conformational preferences. By a detective following of the issue, the 
      intermolecular effects were made responsible for the conformation of the molecule 
      in crystal. The presented problems were gathered from literature results, 
      debates, glued with modelling and analysis redone by ourselves, in order to 
      secure the unitary view of the considered prototypic topic.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Toader, Ana Maria
AU  - Toader AM
AD  - Institute of Physical Chemistry, Bucharest, Romania.
FAU - Zarić, Snezana D
AU  - Zarić SD
AD  - Department of Chemistry, University of Belgrade, Belgrade, Serbia.
AD  - Department of Chemistry, Texas A&M University at Qatar, Doha, Qatar.
FAU - Zalaru, Christina M
AU  - Zalaru CM
AD  - Department of Organic Chemistry, Biochemistry and Catalysis, Faculty of 
      Chemistry, University of Bucharest, Bucharest, Romania.
FAU - Ferbinteanu, Marilena
AU  - Ferbinteanu M
AD  - Department of Inorganic Chemistry, Faculty of Chemistry, University of Bucharest, 
      Bucharest, Romania.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Models, Molecular
MH  - Molecular Structure
OTO - NOTNLM
OT  - Aspirin
OT  - computational modelling
OT  - intermolecular effects
OT  - molecular structure
OT  - polymorphism
OT  - supramolecular structure.
EDAT- 2018/11/02 06:00
MHDA- 2020/02/27 06:00
CRDT- 2018/11/02 06:00
PHST- 2017/05/17 00:00 [received]
PHST- 2018/01/29 00:00 [revised]
PHST- 2018/02/06 00:00 [accepted]
PHST- 2018/11/02 06:00 [pubmed]
PHST- 2020/02/27 06:00 [medline]
PHST- 2018/11/02 06:00 [entrez]
AID - CMC-EPUB-94152 [pii]
AID - 10.2174/0929867325666181031132823 [doi]
PST - ppublish
SO  - Curr Med Chem. 2020;27(1):99-120. doi: 10.2174/0929867325666181031132823.

PMID- 3620667
OWN - NLM
STAT- MEDLINE
DCOM- 19871009
LR  - 20131121
IS  - 0365-9615 (Print)
IS  - 0365-9615 (Linking)
VI  - 104
IP  - 8
DP  - 1987 Aug
TI  - [Local prevention of thrombosis in the dog carotid artery using magnetically 
      concentrated erythrocytes loaded with aspirin].
PG  - 153-5
AB  - Thrombosis was induced in both canine carotid arteries by means of vascular wall 
      flap inversion into their lumens. A red, completely occluding thrombus was formed 
      inside the vessel 4 to 5 hours later. SmCo5 magnet was secured externally to one 
      of the arteries. The constant magnetic field produced by the magnet had no 
      influence on the clot formation. Autologous red cells loaded with ferromagnetic 
      colloid compound and aspirin were administered intravenously through the hind paw 
      route; total aspirin pool was 20 micrograms. Circulating magnetically-charged red 
      cells have been earlier shown to concentrate in a canine artery in the constant 
      magnet area. The administration of magnetically-charged red cells loaded with 
      aspirin completely prevented arterial thrombosis in the magnet-supplied artery, 
      having no detrimental effect on clot formation in the control artery.
FAU - Orekhov, A N
AU  - Orekhov AN
FAU - Beliaev, A A
AU  - Beliaev AA
FAU - Orekhova, N M
AU  - Orekhova NM
FAU - Samokhin, G P
AU  - Samokhin GP
FAU - Ragimov, S E
AU  - Ragimov SE
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Lokal'noe predotvrashchenie tromboza v sonnoĭ arterii sobake s pomoshch'iu 
      magnitnogo kontsentrirovaniia éritrotsitov, nagruzhennykh aspirinom.
PL  - Russia (Federation)
TA  - Biull Eksp Biol Med
JT  - Biulleten' eksperimental'noi biologii i meditsiny
JID - 0370627
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Carotid Artery Thrombosis/*prevention & control
MH  - Dogs
MH  - *Erythrocytes
MH  - *Magnetics
MH  - Male
EDAT- 1987/08/01 00:00
MHDA- 1987/08/01 00:01
CRDT- 1987/08/01 00:00
PHST- 1987/08/01 00:00 [pubmed]
PHST- 1987/08/01 00:01 [medline]
PHST- 1987/08/01 00:00 [entrez]
PST - ppublish
SO  - Biull Eksp Biol Med. 1987 Aug;104(8):153-5.

PMID- 21056102
OWN - NLM
STAT- MEDLINE
DCOM- 20110406
LR  - 20131121
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 42
IP  - 1-2
DP  - 2011 Jan 18
TI  - An integrated Quality by Design (QbD) approach towards design space definition of 
      a blending unit operation by Discrete Element Method (DEM) simulation.
PG  - 106-15
LID - 10.1016/j.ejps.2010.10.013 [doi]
AB  - A combined Quality by Design (QbD) and Discrete Element Model (DEM) 
      simulation-approach is presented to characterize a blending unit operation by 
      evaluating the impact of formulation parameters and process variables on the 
      blending quality and blending end point. Understanding the variability of both 
      the API and the excipients, as well as their impact on the blending process are 
      critical elements for blending QbD. In a first step, the QbD-methodology is 
      systematically used to (1) establish the critical quality attribute content 
      uniformity and to link this CQA to its surrogate blend homogeneity, (2) identify 
      potentially critical input factors that may affect blending operation quality and 
      (3) risk-rank these factors to define activities for process characterization. 
      Subsequently, a DEM-simulation-based characterization of the blending process is 
      performed. A statistical evaluation is finally presented, relating blend 
      homogeneity of systems with low particle number to the regulatory requirements. 
      Data are then used to map out a three-dimensional knowledge space, providing 
      parameters to define a design space and set up an appropriate control strategy.
CI  - Copyright © 2010 Elsevier B.V. All rights reserved.
FAU - Adam, Siegfried
AU  - Adam S
AD  - Research Center Pharmaceutical Engineering GmbH, Graz, Austria.
FAU - Suzzi, Daniele
AU  - Suzzi D
FAU - Radeke, Charles
AU  - Radeke C
FAU - Khinast, Johannes G
AU  - Khinast JG
LA  - eng
PT  - Journal Article
DEP - 20101104
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Excipients)
RN  - 0 (Pharmaceutical Preparations)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/chemistry/standards
MH  - Chemistry, Pharmaceutical/methods/*standards
MH  - *Drug Design
MH  - Endpoint Determination
MH  - Excipients/chemistry
MH  - Hydrodynamics
MH  - Lactose/chemistry
MH  - *Models, Chemical
MH  - *Pharmaceutical Preparations/administration & dosage/chemistry/standards
MH  - Quality Control
EDAT- 2010/11/09 06:00
MHDA- 2011/04/07 06:00
CRDT- 2010/11/09 06:00
PHST- 2010/04/30 00:00 [received]
PHST- 2010/09/27 00:00 [revised]
PHST- 2010/10/27 00:00 [accepted]
PHST- 2010/11/09 06:00 [entrez]
PHST- 2010/11/09 06:00 [pubmed]
PHST- 2011/04/07 06:00 [medline]
AID - S0928-0987(10)00358-1 [pii]
AID - 10.1016/j.ejps.2010.10.013 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2011 Jan 18;42(1-2):106-15. doi: 10.1016/j.ejps.2010.10.013. 
      Epub 2010 Nov 4.

PMID- 18472019
OWN - NLM
STAT- MEDLINE
DCOM- 20080917
LR  - 20161020
IS  - 1089-8611 (Electronic)
IS  - 1089-8603 (Linking)
VI  - 19
IP  - 2
DP  - 2008 Sep
TI  - NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms 
      of action in cancer cells.
PG  - 225-36
LID - 10.1016/j.niox.2008.04.007 [doi]
AB  - Non-steroidal anti-inflammatory drugs (NSAIDs) have repeatedly shown to be 
      effective in tumor prevention, but important side-effects limit their wide 
      clinical use. Nitric oxide-releasing derivatives (NO-NSAIDs) are a promising 
      class of compounds synthesized by combining a classic NSAID molecule with an 
      NO-releasing moiety to counteract side-effects. These new chemical entities 
      exhibit a significantly higher activity and much lower toxicity with respect to 
      the parental drug. In the present paper, we report the results obtained from in 
      in vitro experimental systems aimed to evaluate the activity and mechanisms of 
      action of the novel NO-releasing aspirin derivative, NCX 4040. The in vitro 
      studies were carried out on a panel of human colon (LoVo, LoVo Dx, WiDr, LRWZ), 
      bladder (HT1376, MCR), and pancreatic (Capan-2, MIA PaCa-2, T3M4) cancer cell 
      lines. With regard to colon cancer, NCX 4040 activity was also investigated in 
      vitro in combination with drugs currently used in clinical practice and was 
      validated in vivo on tumor-bearing mice xenografted with the aforementioned colon 
      cancer cell lines. The in vitro studies showed a high cytotoxic activity of NCX 
      4040 in all tumor histotypes and demonstrated the pivotal role of the NO 
      component in drug activity. It was also observed that NCX 4040 exerts a 
      pro-apoptotic activity via a mitochondria-dependent pathway. Moreover, the in 
      vivo studies on xenografted mice further confirmed the antitumor efficacy and low 
      toxicity of NCX 4040 in colon cancer and highlighted its role as sensitizing 
      agent of oxaliplatin cytotoxicity.
FAU - Tesei, Anna
AU  - Tesei A
AD  - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Via Maroncelli 
      40, 47014 Meldola, FC, Italy. anna.tesei@ausl.fo.it
FAU - Zoli, Wainer
AU  - Zoli W
FAU - Fabbri, Francesco
AU  - Fabbri F
FAU - Leonetti, Carlo
AU  - Leonetti C
FAU - Rosetti, Marco
AU  - Rosetti M
FAU - Bolla, Manlio
AU  - Bolla M
FAU - Amadori, Dino
AU  - Amadori D
FAU - Silvestrini, Rosella
AU  - Silvestrini R
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20080422
PL  - United States
TA  - Nitric Oxide
JT  - Nitric oxide : biology and chemistry
JID - 9709307
RN  - 0 (NCX 4040)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Nitro Compounds)
RN  - 0 (Organoplatinum Compounds)
RN  - 0 (Pyridines)
RN  - 0 (oxiplatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Humans
MH  - Mice
MH  - Neoplasms/*drug therapy/pathology
MH  - Nitric Oxide Donors
MH  - Nitro Compounds/pharmacology/*therapeutic use
MH  - Organoplatinum Compounds/therapeutic use
MH  - Pyridines/therapeutic use
RF  - 77
EDAT- 2008/05/13 09:00
MHDA- 2008/09/18 09:00
CRDT- 2008/05/13 09:00
PHST- 2008/01/30 00:00 [received]
PHST- 2008/04/14 00:00 [revised]
PHST- 2008/04/14 00:00 [accepted]
PHST- 2008/05/13 09:00 [pubmed]
PHST- 2008/09/18 09:00 [medline]
PHST- 2008/05/13 09:00 [entrez]
AID - S1089-8603(08)00050-5 [pii]
AID - 10.1016/j.niox.2008.04.007 [doi]
PST - ppublish
SO  - Nitric Oxide. 2008 Sep;19(2):225-36. doi: 10.1016/j.niox.2008.04.007. Epub 2008 
      Apr 22.

PMID- 12652150
OWN - NLM
STAT- MEDLINE
DCOM- 20030909
LR  - 20191106
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 14
IP  - 1
DP  - 2002 Aug
TI  - Aspirin resistance and genetic polymorphisms.
PG  - 51-8
AB  - Differences in genetic makeup or polymorphisms can affect individual drug 
      response. Detecting genetic variation may help predict how a patient will respond 
      to a drug and could be used as a tool to select optimal therapy, tailor dosage 
      regimens, and improve clinical outcomes. The data are replete relative to the 
      therapeutic efficacy of aspirin (ASA) for the prevention of ischemic events. 
      However, there is a paucity of published data on the relationship between 
      polymorphisms and the clinical effects on ASA. Prothrombotic genetic variations 
      that may contribute to ASA resistance, and increased risk of cardiovascular 
      events may involve: (1) a polymorphism on the cyclooxygenase-1 (COX-1) gene 
      affecting Ser529; (2) overexpression of COX-2 mRNA on platelets and endothelial 
      cells; (3) polymorphism PLA1/A2 of the gene encoding glycoprotein IIIa (GPIIIa); 
      and (4) the homozygous 807T (873A) polymorphism allied with increased density of 
      platelet GP Ia/IIa collagen-receptor gene. Because of the possible increased risk 
      of ischemic vascular events, carriers of these genetic polymorphisms may be 
      resistant to the antithrombotic effects of ASA and should be considered for 
      additional or alternative treatment.
FAU - Cambria-Kiely, Josie A
AU  - Cambria-Kiely JA
AD  - Massachusetts College of Pharmacy and Health Sciences-Worcester, Worcester, MA 
      01608, USA.
FAU - Gandhi, Pritesh J
AU  - Gandhi PJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Drug Resistance/genetics
MH  - Drug Tolerance/genetics
MH  - Humans
MH  - Polymorphism, Genetic/*genetics
RF  - 51
EDAT- 2003/03/26 04:00
MHDA- 2003/09/10 05:00
CRDT- 2003/03/26 04:00
PHST- 2003/03/26 04:00 [pubmed]
PHST- 2003/09/10 05:00 [medline]
PHST- 2003/03/26 04:00 [entrez]
AID - 5112412 [pii]
AID - 10.1023/a:1022066305399 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2002 Aug;14(1):51-8. doi: 10.1023/a:1022066305399.

PMID- 19580619
OWN - NLM
STAT- MEDLINE
DCOM- 20100315
LR  - 20131121
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 39
IP  - 6
DP  - 2009 Jun
TI  - Aspirin for primary prevention: do potential benefits outweigh the risks?
PG  - 401-7
LID - 10.1111/j.1445-5994.2008.01888.x [doi]
AB  - The role of aspirin for primary prevention in healthy individuals has been the 
      subject of clinical trials for more than a quarter of a century. Because of this 
      evidence, or sometimes despite it, many individuals self-administer aspirin to 
      prevent cardiovascular events. This article reviews the published work for 
      aspirin in primary prevention of cardiovascular and malignant diseases and 
      considers whether aspirin would be approved by regulatory authorities for this 
      use if it were to be marketed for this indication today.
FAU - Shakib, S
AU  - Shakib S
AD  - Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South 
      Australia, Australia. sepehr.shakib@health.sa.gov.au
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/economics/*therapeutic use
MH  - Cardiovascular Diseases/economics/prevention & control
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Neoplasms/economics/prevention & control
MH  - Primary Prevention/*methods
MH  - Risk Assessment
MH  - Risk Factors
RF  - 50
EDAT- 2009/07/08 09:00
MHDA- 2010/03/17 06:00
CRDT- 2009/07/08 09:00
PHST- 2009/07/08 09:00 [entrez]
PHST- 2009/07/08 09:00 [pubmed]
PHST- 2010/03/17 06:00 [medline]
AID - IMJ1888 [pii]
AID - 10.1111/j.1445-5994.2008.01888.x [doi]
PST - ppublish
SO  - Intern Med J. 2009 Jun;39(6):401-7. doi: 10.1111/j.1445-5994.2008.01888.x.

PMID- 21842865
OWN - NLM
STAT- MEDLINE
DCOM- 20120119
LR  - 20211020
IS  - 1520-6904 (Electronic)
IS  - 0022-3263 (Print)
IS  - 0022-3263 (Linking)
VI  - 76
IP  - 19
DP  - 2011 Oct 7
TI  - An n→π* interaction in aspirin: implications for structure and reactivity.
PG  - 7933-7
LID - 10.1021/jo201389d [doi]
AB  - Stereoelectronic effects modulate molecular structure, reactivity, and 
      conformation. We find that the interaction between the ester and carboxyl 
      moieties of aspirin has a previously unappreciated quantum mechanical character 
      that arises from the delocalization of an electron pair (n) of a donor group into 
      the antibonding orbital (π*) of an acceptor group. This interaction affects the 
      physicochemical attributes of aspirin and could have implications for its 
      pharmacology.
FAU - Choudhary, Amit
AU  - Choudhary A
AD  - Graduate Program in Biophysics, University of Wisconsin-Madison, Madison, 
      Wisconsin 53706, United States.
FAU - Kamer, Kimberli J
AU  - Kamer KJ
FAU - Raines, Ronald T
AU  - Raines RT
LA  - eng
GR  - R01 AR044276/AR/NIAMS NIH HHS/United States
GR  - R01 AR044276-16/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20110906
PL  - United States
TA  - J Org Chem
JT  - The Journal of organic chemistry
JID - 2985193R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Physical Phenomena
PMC - PMC3184772
MID - NIHMS319274
EDAT- 2011/08/17 06:00
MHDA- 2012/01/20 06:00
CRDT- 2011/08/17 06:00
PHST- 2011/08/17 06:00 [entrez]
PHST- 2011/08/17 06:00 [pubmed]
PHST- 2012/01/20 06:00 [medline]
AID - 10.1021/jo201389d [doi]
PST - ppublish
SO  - J Org Chem. 2011 Oct 7;76(19):7933-7. doi: 10.1021/jo201389d. Epub 2011 Sep 6.

PMID- 7899379
OWN - NLM
STAT- MEDLINE
DCOM- 19950425
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 24
IP  - 5
DP  - 1995 Feb 4
TI  - [Efficacy and tolerance of an effervescent aspirin-metoclopramide combination in 
      the treatment of a migraine attack. Randomized double-blind study using a 
      placebo].
PG  - 254-8
AB  - OBJECTIVES: A double blind, randomized, multicenter, parallel group study was 
      carried out to compare the efficacy and tolerance of aspirin 900 
      mg-metoclopramide 10 mg effervescent association (AAM) with those of placebo in 
      the treatment of acute migraine attack. All patients were selected according to 
      the International Headache Society criteria. METHODS: A total of 303 out-patients 
      with an acute migraine attack were treated orally with either AAM (n = 152) or 
      placebo (n = 151). RESULTS: The aspirin-metoclopramide association was 
      significantly more effective than placebo at relieving headache (principal 
      criterion) within 2 h of treatment (54.3% versus 25.9% : p < 0.001), producing 
      entire resolution of acute migraine attack (14.2% versus 5.3% : p = 0.017), 
      reducing the percentage of patients requiring rescue medication (44.3% versus 
      63.2% : p = 0.001) and increasing the percentage of patients able to resume their 
      usual activities (44.1% versus 22.1% : p = 0.003). AAM also provided more 
      frequent relief from associated symptoms as compared with placebo (37.4% versus 
      22.1% : p = 0.006). The therapeutic efficacy was rated as good or excellent by 
      39.7% of patients in the AAM group compared with 20.7% in the placebo group (p < 
      0.001). Moreover 64.2% of AAM treated patients said they would be prepared to 
      take the treatment again compared with 46.4% who received placebo (p < 0.001). 
      The percentage of patients reporting adverse events was not different between the 
      two treatments (20.4% AAM versus 18.5% placebo : p = 0.684). The most commonly 
      reported symptoms were gastro-intestinal disorders. Similar number of gastralgia 
      occurred with AAM (n = 4) and placebo (n = 3). CONCLUSION: It is concluded that 
      the aspirin-metoclopramide association may be used as a first intention treatment 
      of acute migraine attack in out-patients.
FAU - Henry, P
AU  - Henry P
AD  - Service de Neurologie, Hôpital Pellegrin Tripode, Bordeaux.
FAU - Hiesse-Provost, O
AU  - Hiesse-Provost O
FAU - Dillenschneider, A
AU  - Dillenschneider A
FAU - Ganry, H
AU  - Ganry H
FAU - Insuasty, J
AU  - Insuasty J
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Efficacité et tolérance de l'association effervescente aspirine-métoclopramide 
      dans le traitement de la crise de migraine sans aura. Essai randomisé en double 
      aveugle contre placebo.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Drug Combinations)
RN  - 0 (Placebos)
RN  - 0 (Tablets)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Family Practice
MH  - Female
MH  - Humans
MH  - Male
MH  - Metoclopramide/administration & dosage/*therapeutic use
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Placebos
MH  - Surveys and Questionnaires
MH  - Tablets
EDAT- 1995/02/04 00:00
MHDA- 1995/02/04 00:01
CRDT- 1995/02/04 00:00
PHST- 1995/02/04 00:00 [pubmed]
PHST- 1995/02/04 00:01 [medline]
PHST- 1995/02/04 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1995 Feb 4;24(5):254-8.

PMID- 600324
OWN - NLM
STAT- MEDLINE
DCOM- 19780329
LR  - 20190725
IS  - 0028-1298 (Print)
IS  - 0028-1298 (Linking)
VI  - 301
IP  - 2
DP  - 1977 Dec
TI  - Effect of acetylsalicylic acid on experimentally induced arterial thrombosis in 
      rats.
PG  - 115-9
AB  - Acetylsalicylic acid (ASA) was tested for its antithrombotic activity in the 
      arterial system after prophylactic administration to rats, using a new 
      standardized method. Damage of the vessel wall was produced by chilling a small 
      segment of the left carotid artery. Dose related, significant results were 
      obtained after 3 mg/kg orally. If higher doses (10 and 30 mg/kg) are 
      administered, the formation of non-occlusive thrombi is inhibited by 70--90% on 
      the basis of thrombus weight. As the frequency distributions show, there are 
      significantly more zero-values in the ASA treated groups (total 50%) than in the 
      control groups. However, the incidence of occlusive thrombi was not changed by 
      ASA. The long-lasting effect of ASA in inhibition of platelet aggregation was 
      confirmed. The formation of arterial thrombi is significantly inhibited after 
      prophylactic administration of 30 and 10 mg/kg up to 48 h before initiation of 
      thrombosis. After administration of 3 mg/kg orally, only insignificant effects 
      were observed. Thus the duration of action depends on the dose used.
FAU - Meng, K
AU  - Meng K
FAU - Seuter, F
AU  - Seuter F
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arterial Occlusive Diseases/*prevention & control
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Rats
MH  - Thrombosis/*prevention & control
MH  - Time Factors
EDAT- 1977/12/01 00:00
MHDA- 1977/12/01 00:01
CRDT- 1977/12/01 00:00
PHST- 1977/12/01 00:00 [pubmed]
PHST- 1977/12/01 00:01 [medline]
PHST- 1977/12/01 00:00 [entrez]
AID - 10.1007/BF00501425 [doi]
PST - ppublish
SO  - Naunyn Schmiedebergs Arch Pharmacol. 1977 Dec;301(2):115-9. doi: 
      10.1007/BF00501425.

PMID- 6873151
OWN - NLM
STAT- MEDLINE
DCOM- 19830909
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 24
IP  - 5
DP  - 1983
TI  - Systemic availability of acetylsalicylic acid in normal men and women and its 
      effect on in vitro platelet aggregability.
PG  - 679-82
AB  - The systemic availability of acetylsalicylic acid (ASA) after oral ingestion of 1 
      g in an effervescent formulation was 16.3 +/- 2.0% and 16.9 +/- 3.2% of the 
      ingested dose in normal women and men, respectively. The average plasma half-life 
      of ASA in each sex was also identical at 18.5 +/- 1.4 and 18.1 +/- 1.2 min, 
      respectively. The inhibitory effect of ASA on collagen-induced platelet 
      aggregation in vitro on blood from both sexes was studied. The IC50 was 23.9 +/- 
      2.9 micrograms/ml in females and 22.5 +/- 2.7 micrograms/ml in males, which did 
      not differ significantly. The inhibition by salicylic acid (SA) of the 
      antiaggregatory effect of ASA was similar in both sexes with increases in IC50 to 
      33.5 +/- 5.1 micrograms/ml in females (p less than 0.02) and to 29.5 +/- 3.8 
      micrograms/ml in males (p less than 0.05). It is concluded that the observed 
      sex-difference in the antithrombotic effect of ASA cannot be explained neither by 
      differences between females and males in the pharmacokinetic properties of ASA 
      after oral ingestion, nor by differences in the in vitro effect of ASA on the 
      platelet aggregation induced by collagen.
FAU - Husted, S E
AU  - Husted SE
FAU - Pedersen, A K
AU  - Pedersen AK
FAU - Petersen, T
AU  - Petersen T
FAU - Geday, E
AU  - Geday E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*metabolism/pharmacology
MH  - Biological Availability
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Sex Factors
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1007/BF00542222 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1983;24(5):679-82. doi: 10.1007/BF00542222.

PMID- 32163237
OWN - NLM
STAT- MEDLINE
DCOM- 20211019
LR  - 20211019
IS  - 1939-005X (Electronic)
IS  - 1939-5094 (Print)
IS  - 1939-005X (Linking)
VI  - 12
IP  - 5
DP  - 2020 Sep
TI  - Aspirin and the chemoprevention of cancers: A mathematical and evolutionary 
      dynamics perspective.
PG  - e1487
LID - 10.1002/wsbm.1487 [doi]
AB  - Epidemiological data indicate that long-term low dose aspirin administration has 
      a protective effect against the occurrence of colorectal cancer, both in sporadic 
      and in hereditary forms of the disease. The mechanisms underlying this protective 
      effect, however, are incompletely understood. The molecular events that lead to 
      protection have been partly defined, but remain to be fully characterized. So 
      far, however, approaches based on evolutionary dynamics have not been discussed 
      much, but can potentially offer important insights. The aim of this review is to 
      highlight this line of investigation and the results that have been obtained. A 
      core observation in this respect is that aspirin has a direct negative impact on 
      the growth dynamics of the cells, by influencing the kinetics of tumor cell 
      division and death. We discuss the application of mathematical models to 
      experimental data to quantify these parameter changes. We then describe further 
      mathematical models that have been used to explore how these aspirin-mediated 
      changes in kinetic parameters influence the probability of successful colony 
      growth versus extinction, and how they affect the evolution of the tumor during 
      aspirin administration. Finally, we discuss mathematical models that have been 
      used to investigate the selective forces that can lead to the rise of 
      mismatch-repair deficient cells in an inflammatory environment, and how this 
      selection can be potentially altered through aspirin-mediated interventions. This 
      article is categorized under: Models of Systems Properties and Processes > 
      Mechanistic Models Analytical and Computational Methods > Analytical Methods 
      Analytical and Computational Methods > Computational Methods.
CI  - © 2020 Wiley Periodicals, Inc.
FAU - Komarova, Natalia L
AU  - Komarova NL
AUID- ORCID: 0000-0003-4876-0343
AD  - Department of Mathematics, University of California Irvine, Irvine, California, 
      USA.
FAU - Boland, C Richard
AU  - Boland CR
AD  - Department of Medicine, UCSD School of Medicine, San Diego, California, USA.
FAU - Goel, Ajay
AU  - Goel A
AD  - Department of Molecular Diagnostics and Experimental Therapeutics, Beckman 
      Research Institute, City of Hope Comprehensive Cancer Center, Biomedical Research 
      Center, Monrovia, California, USA.
FAU - Wodarz, Dominik
AU  - Wodarz D
AD  - Department of Population Health and Disease Prevention, Program in Public Health, 
      Susan and Henry Samueli College of Health Sciences, University of California 
      Irvine, Irvine, California, USA.
LA  - eng
GR  - U01 CA187956/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200312
PL  - United States
TA  - Wiley Interdiscip Rev Syst Biol Med
JT  - Wiley interdisciplinary reviews. Systems biology and medicine
JID - 101516550
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Cell Cycle Checkpoints/drug effects
MH  - Cell Proliferation/drug effects
MH  - Evolution, Molecular
MH  - Humans
MH  - *Models, Theoretical
MH  - Neoplasms/metabolism/pathology/*prevention & control
PMC - PMC7486281
MID - NIHMS1574234
OTO - NOTNLM
OT  - aspirin
OT  - cancer prevention
OT  - evolutionary dynamics
OT  - lunchsyndrome
OT  - mathematical modeling of cancer
OT  - mutations
OT  - mutator phenotype
EDAT- 2020/03/13 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/03/13 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2020/02/10 00:00 [revised]
PHST- 2020/02/19 00:00 [accepted]
PHST- 2020/03/13 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2020/03/13 06:00 [entrez]
AID - 10.1002/wsbm.1487 [doi]
PST - ppublish
SO  - Wiley Interdiscip Rev Syst Biol Med. 2020 Sep;12(5):e1487. doi: 
      10.1002/wsbm.1487. Epub 2020 Mar 12.

PMID- 6623020
OWN - NLM
STAT- MEDLINE
DCOM- 19831123
LR  - 20190908
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 12
IP  - 3
DP  - 1983
TI  - Comparison of three slow-release acetylsalicylic acid preparations in rheumatoid 
      arthritis.
PG  - 305-9
AB  - Nine patients suffering from chronic rheumatoid arthritis were each given single 
      doses of 1 g acetylsalicylic acid, in the form of each of the preparations 
      studied: an enteric-coated tablet, a microcrystalline tablet, and a capsule 
      containing enterosoluble granules. Absorption from each preparation was good in 
      all patients. Onset of absorption varied to some degree, but similar salicylate 
      levels were reached within 5 hours with all preparations. In the case of 
      enteric-coated tablets, relatively high salicylate levels persisted 12 hours 
      after dosing, which would seem to permit twice daily dosage, regardless of the 
      total daily dose.
FAU - Martio, J
AU  - Martio J
FAU - Kahela, P
AU  - Kahela P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Capsules)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Tablets)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/blood/*metabolism
MH  - Capsules
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Tablets
MH  - Tablets, Enteric-Coated
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.3109/03009748309098554 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 1983;12(3):305-9. doi: 10.3109/03009748309098554.

PMID- 26314861
OWN - NLM
STAT- MEDLINE
DCOM- 20170127
LR  - 20181113
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 37
IP  - 2
DP  - 2016 Feb
TI  - Aspirin and salicylic acid decrease c-Myc expression in cancer cells: a potential 
      role in chemoprevention.
PG  - 1727-38
LID - 10.1007/s13277-015-3959-0 [doi]
AB  - Epidemiological studies have demonstrated a significant correlation between 
      regular aspirin use and reduced colon cancer incidence and mortality; however, 
      the pathways by which it exerts its anti-cancer effects are still not fully 
      explored. We hypothesized that aspirin's anti-cancer effect may occur through 
      downregulation of c-Myc gene expression. Here, we demonstrate that aspirin and 
      its primary metabolite, salicylic acid, decrease the c-Myc protein levels in 
      human HCT-116 colon and in few other cancer cell lines. In total cell lysates, 
      both drugs decreased the levels of c-Myc in a concentration-dependent fashion. 
      Greater inhibition was observed in the nucleus than the cytoplasm, and 
      immunofluorescence studies confirmed these observations. Pretreatment of cells 
      with lactacystin, a proteasome inhibitor, partially prevented the downregulatory 
      effect of both aspirin and salicylic acid, suggesting that 26S proteasomal 
      pathway is involved. Both drugs failed to decrease exogenously expressed 
      DDK-tagged c-Myc protein levels; however, under the same conditions, the 
      endogenous c-Myc protein levels were downregulated. Northern blot analysis showed 
      that both drugs caused a decrease in c-Myc mRNA levels in a 
      concentration-dependent fashion. High-performance liquid chromatography (HPLC) 
      analysis showed that aspirin taken up by cells was rapidly metabolized to 
      salicylic acid, suggesting that aspirin's inhibitory effect on c-Myc may occur 
      through formation of salicylic acid. Our result suggests that salicylic acid 
      regulates c-Myc level at both transcriptional and post-transcription levels. 
      Inhibition of c-Myc may represent an important pathway by which aspirin exerts 
      its anti-cancer effect and decrease the occurrence of cancer in epithelial 
      tissues.
FAU - Ai, Guoqiang
AU  - Ai G
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Avera Health and Sciences Center, Brookings, SD, 57007, USA.
FAU - Dachineni, Rakesh
AU  - Dachineni R
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Avera Health and Sciences Center, Brookings, SD, 57007, USA.
FAU - Muley, Pratik
AU  - Muley P
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Avera Health and Sciences Center, Brookings, SD, 57007, USA.
FAU - Tummala, Hemachand
AU  - Tummala H
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Avera Health and Sciences Center, Brookings, SD, 57007, USA.
FAU - Bhat, G Jayarama
AU  - Bhat GJ
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Avera Health and Sciences Center, Brookings, SD, 57007, USA. 
      Jayarama.gunaje@sdstate.edu.
LA  - eng
PT  - Journal Article
DEP - 20150828
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Blotting, Northern
MH  - Blotting, Western
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Chemoprevention
MH  - Chromatography, High Pressure Liquid
MH  - Down-Regulation
MH  - Fluorescent Antibody Technique
MH  - Gene Expression/drug effects
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Humans
MH  - Neoplasms/pathology/*prevention & control
MH  - Proto-Oncogene Proteins c-myc/*biosynthesis
MH  - Salicylates/*pharmacology
OTO - NOTNLM
OT  - Aspirin
OT  - Colon cancer
OT  - Proteasome
OT  - Salicylic acid
OT  - c-Myc
EDAT- 2015/09/01 06:00
MHDA- 2017/01/28 06:00
CRDT- 2015/08/29 06:00
PHST- 2015/07/30 00:00 [received]
PHST- 2015/08/19 00:00 [accepted]
PHST- 2015/08/29 06:00 [entrez]
PHST- 2015/09/01 06:00 [pubmed]
PHST- 2017/01/28 06:00 [medline]
AID - 10.1007/s13277-015-3959-0 [pii]
AID - 10.1007/s13277-015-3959-0 [doi]
PST - ppublish
SO  - Tumour Biol. 2016 Feb;37(2):1727-38. doi: 10.1007/s13277-015-3959-0. Epub 2015 
      Aug 28.

PMID- 9653928
OWN - NLM
STAT- MEDLINE
DCOM- 19980821
LR  - 20190831
IS  - 1387-2273 (Print)
IS  - 1387-2273 (Linking)
VI  - 709
IP  - 1
DP  - 1998 May 8
TI  - Gas chromatographic-tandem mass spectrometric determination of acetylsalicylic 
      acid in human plasma after oral administration of low-dose aspirin and guaimesal.
PG  - 79-88
AB  - A fully validated gas chromatographic-tandem mass spectrometric (GC-MS-MS) method 
      is described for the accurate determination of acetylsalicylic acid (ASA) in 
      human plasma after a single low-dose oral administration of aspirin or guaimesal, 
      an ASA releasing prodrug. ASA and the newly prepared O-[2H3]-acetylsalicylic acid 
      (d3-ASA) used as internal standard were determined in 100-microl aliquots of 
      plasma by extractive pentafluorobenzyl (PFB) esterification using PFB bromide and 
      tetrabutylammoniumhydrogen sulphate as the esterifying and ion-pairing agent, 
      respectively, and by GC-MS-MS analysis in the negative-ion chemical ionization 
      mode. The overall relative standard deviations were below 8% for ASA levels in 
      the range 0-1 microg/ml plasma. Mean accuracy was 3.8% for ASA levels within the 
      range 0-100 ng/ml. The limit of quantitation of the method was determined as 200 
      pg/ml ASA at an accuracy of 5.5% and a precision of 15.2%. The limit of detection 
      was determined as 546 amol of ASA at a signal-to-noise ratio of 10:1.
FAU - Tsikas, D
AU  - Tsikas D
AD  - Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover, Germany.
FAU - Tewes, K S
AU  - Tewes KS
FAU - Gutzki, F M
AU  - Gutzki FM
FAU - Schwedhelm, E
AU  - Schwedhelm E
FAU - Greipel, J
AU  - Greipel J
FAU - Frölich, J C
AU  - Frölich JC
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Chromatogr B Biomed Sci Appl
JT  - Journal of chromatography. B, Biomedical sciences and applications
JID - 9714109
RN  - 0 (Dioxanes)
RN  - 0 (Prodrugs)
RN  - K43273G1CW (guaimesal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/blood/pharmacokinetics
MH  - Dioxanes/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Gas Chromatography-Mass Spectrometry/*methods
MH  - Humans
MH  - Magnetic Resonance Spectroscopy
MH  - Prodrugs/*administration & dosage
MH  - Sensitivity and Specificity
EDAT- 1998/07/08 00:00
MHDA- 1998/07/08 00:01
CRDT- 1998/07/08 00:00
PHST- 1998/07/08 00:00 [pubmed]
PHST- 1998/07/08 00:01 [medline]
PHST- 1998/07/08 00:00 [entrez]
AID - 10.1016/s0378-4347(98)00049-8 [doi]
PST - ppublish
SO  - J Chromatogr B Biomed Sci Appl. 1998 May 8;709(1):79-88. doi: 
      10.1016/s0378-4347(98)00049-8.

PMID- 6967685
OWN - NLM
STAT- MEDLINE
DCOM- 19801021
LR  - 20190825
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 10
IP  - 3
DP  - 1980 Jun
TI  - Pharmacological studies in the rat with 
      [2-(1,3-didecanoyloxy)-propyl]2-acetyloxybenzoate (A-45474): an aspirin pro-drug 
      with negligible gastric irritation.
PG  - 240-5
AB  - A triglyceride of aspirin, A-45474: 
      [2-(1,3-didecanoyloxy)-propyl]2-acetyloxybenzoate, was developed to reduce the 
      direct gastric irritant properties of aspirin. Studies in the rat show that oral 
      administration of A-45474 produces anti-inflammatory activity comparable to 
      aspirin with negligible gastric irritation. Compared with aspirin, plasma 
      salicylate levels of A-45474 appeared less rapidly and were more sustained. It is 
      concluded that incorporation of aspirin in the 2-position of a triglyceride 
      bearing n-decanoyl groups in the 1- and 3-positions markedly reduces the gastric 
      irritating properties of aspirin while maintaining its pharmacological effects.
FAU - Carter, G W
AU  - Carter GW
FAU - Young, P R
AU  - Young PR
FAU - Swett, L R
AU  - Swett LR
FAU - Paris, G Y
AU  - Paris GY
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Salicylates)
RN  - 0 (Triglycerides)
RN  - 70540-33-9 ((2-(1,3-didecanoyloxy)-propyl)2-acetyloxybenzoate)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/adverse effects/*analogs & derivatives/metabolism/pharmacology
MH  - Biological Availability
MH  - Carrageenan/antagonists & inhibitors
MH  - Delayed-Action Preparations
MH  - Edema/drug therapy
MH  - Injections, Intravenous
MH  - Intestinal Absorption
MH  - Male
MH  - Rats
MH  - Salicylates/blood
MH  - Stomach/*drug effects
MH  - Time Factors
MH  - Triglycerides/metabolism
EDAT- 1980/06/01 00:00
MHDA- 1980/06/01 00:01
CRDT- 1980/06/01 00:00
PHST- 1980/06/01 00:00 [pubmed]
PHST- 1980/06/01 00:01 [medline]
PHST- 1980/06/01 00:00 [entrez]
AID - 10.1007/BF02025942 [doi]
PST - ppublish
SO  - Agents Actions. 1980 Jun;10(3):240-5. doi: 10.1007/BF02025942.

PMID- 24779202
OWN - NLM
STAT- MEDLINE
DCOM- 20140605
LR  - 20140430
IS  - 0001-6837 (Print)
IS  - 0001-6837 (Linking)
VI  - 71
IP  - 1
DP  - 2014 Jan-Feb
TI  - Interaction analysis of aspirin with selective amino acids.
PG  - 139-43
AB  - This study was conducted to assess the compatibility of aspirin with selective 
      amino acids by studying the effect of amino acids on the solubility of aspirin, 
      so that the attention could be paid towards the use of proteinous foods along 
      with aspirin. Two different types of dissolution media, i.e., 0.5% solution of 
      each amino acid and 100 mL of distilled water (100 mL each), were prepared. Then, 
      1 g of aspirin was added in both media and shaked gently. Ten milliliters of 
      sample was withdrawn at different time intervals, i.e., 10, 20, 30, 40, 50 and 60 
      min and analyzed spectrophotometrically at 265 nm. It is evident from results 
      that the absorbance of aspirin increased with the addition of amino acids and 
      this increase was significant (p < 0.05). Absorbance after adding amino acid like 
      glycine, tyrosine, glutamic acid, tartaric acid and aspartic acid was observed to 
      be 2.98, 2.96, 2.92, 3.23 and 3.28, respectively, as compared to that of aspirin 
      alone. The increase in absorbance of aspirin in the presence of tartaric acid and 
      aspartic acid was non-significantly (p > 0.05) greater than that in the presence 
      of other amino acids like glycine, tyrosine and glutamic acid. The absorbance of 
      aspirin in the presence of tartaric acid and aspartic acid was 3.23 and 3.28, 
      respectively, while the absorbance of aspirin in the presence of glycine, 
      tyrosine and glutamic acid was 2.98, 2.96 and 2.92, respectively. This study 
      elaborates that the solubility of aspirin increases with concomitant 
      administration of amino acids, thus the use of amino acids (proteinous foods) 
      with aspirin should be prohibited or low dose of aspirin should be recommended in 
      such situation.
FAU - Murtaza, Ghulam
AU  - Murtaza G
FAU - Karim, Sabiha
AU  - Karim S
FAU - Najam-ul-Haq, Muhammad
AU  - Najam-ul-Haq M
FAU - Ahmad, Mahmood
AU  - Ahmad M
FAU - Ismail, Tariq
AU  - Ismail T
FAU - Khan, Shujaat Ali
AU  - Khan SA
FAU - Bin Asad, Muhammad Hassham Hassan
AU  - Bin Asad MH
FAU - Hussain, Izhar
AU  - Hussain I
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Acta Pol Pharm
JT  - Acta poloniae pharmaceutica
JID - 2985167R
RN  - 0 (Amino Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acids/*chemistry
MH  - Aspirin/*chemistry
MH  - Solubility
MH  - Spectrophotometry
EDAT- 2014/05/02 06:00
MHDA- 2014/06/06 06:00
CRDT- 2014/05/01 06:00
PHST- 2014/05/01 06:00 [entrez]
PHST- 2014/05/02 06:00 [pubmed]
PHST- 2014/06/06 06:00 [medline]
PST - ppublish
SO  - Acta Pol Pharm. 2014 Jan-Feb;71(1):139-43.

PMID- 7320841
OWN - NLM
STAT- MEDLINE
DCOM- 19820313
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 12
DP  - 1981 Dec
TI  - Physicochemical property modification strategies based on enzyme substrate 
      specificities III: carboxypeptidase A hydrolysis of aspirin derivatives.
PG  - 1307-9
AB  - The aspirin derivatives aspirin phenylalanine and aspirin phenyllactic acid were 
      studied as substrates for carboxypeptidase A. The phenyllactic acid derivative 
      (an ester) was the best substrate but showed considerable product inhibition. The 
      kinetic parameters for both substrates were in the range expected on the basis of 
      other known substrates. The results indicate that the acylamide substituent 
      (drug) has only a small effect on the enzyme kinetic parameters. Consequently, 
      carboxypeptidase A may serve as a reconversion site for many drug derivatives.
FAU - Banerjee, P K
AU  - Banerjee PK
FAU - Amidon, G L
AU  - Amidon GL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 47E5O17Y3R (Phenylalanine)
RN  - 55X04QC32I (Sodium Hydroxide)
RN  - EC 3.4.- (Carboxypeptidases)
RN  - EC 3.4.17.1 (Carboxypeptidases A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/metabolism
MH  - Carboxypeptidases/*metabolism
MH  - Carboxypeptidases A
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Hydrolysis
MH  - Kinetics
MH  - Phenylalanine
MH  - Sodium Hydroxide
MH  - Substrate Specificity
EDAT- 1981/12/01 00:00
MHDA- 1981/12/01 00:01
CRDT- 1981/12/01 00:00
PHST- 1981/12/01 00:00 [pubmed]
PHST- 1981/12/01 00:01 [medline]
PHST- 1981/12/01 00:00 [entrez]
AID - S0022-3549(15)43970-X [pii]
AID - 10.1002/jps.2600701204 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Dec;70(12):1307-9. doi: 10.1002/jps.2600701204.

PMID- 17243147
OWN - NLM
STAT- MEDLINE
DCOM- 20070531
LR  - 20131121
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 96
IP  - 4
DP  - 2007 Apr
TI  - Understanding the polymorphism of aspirin with electronic calculations.
PG  - 755-60
AB  - This report presents electronic calculations of two aspirin polymorphs in order 
      to understand the origin of polymorphism in aspirin crystals. Analysis of the 
      calculated electronic structures, particularly the nuclear Fukui functions, 
      reveals a structural tension between the carboxylic and acetyloxy groups, which 
      may play a key role in the formation of aspirin polymorphs. Calculations of the 
      lattice energies of the two polymorphs indicate that aspirin crystals may be 
      enantiotropic.
CI  - (c) 2006 Wiley-Liss, Inc.
FAU - Li, Tonglei
AU  - Li T
AD  - Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Models, Molecular
MH  - Molecular Conformation
EDAT- 2007/01/24 09:00
MHDA- 2007/06/01 09:00
CRDT- 2007/01/24 09:00
PHST- 2007/01/24 09:00 [pubmed]
PHST- 2007/06/01 09:00 [medline]
PHST- 2007/01/24 09:00 [entrez]
AID - S0022-3549(16)32226-2 [pii]
AID - 10.1002/jps.20819 [doi]
PST - ppublish
SO  - J Pharm Sci. 2007 Apr;96(4):755-60. doi: 10.1002/jps.20819.

PMID- 2329445
OWN - NLM
STAT- MEDLINE
DCOM- 19900525
LR  - 20151119
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 7
IP  - 2
DP  - 1990 Apr-Jun
TI  - Release kinetic study of RHPC coated aspirin microcapsules.
PG  - 185-90
AB  - The present communication deals with the study of the effect of pH on the drug 
      release characteristics and the drug release kinetic from the RHPC (Rosin Hard 
      Paraffin Combination) coated aspirin microcapsules. For the purpose of the 
      present study the aspirin microcapsules were prepared by pan coating method 
      imparting 15 coats using 10 per cent RHPC solution in acetone. A standard coating 
      procedure was used to coat the aspirin granules. Dissolution studies were carried 
      out in media with different pH. To get a clear picture drug release studies were 
      conducted in each media for 3 h. The results showed that the RHPC films were 
      resistant to acidic pH releasing less than 5 per cent and 15 per cent drug in 3 h 
      in pH 1.2 and 3.0 respectively. The T 50% in pH 5.0 media was 163 min. The drug 
      was released very quickly in pH 7.2 and 8.0. The release kinetic study showed 
      that the release followed the classical first order pattern though the coated 
      microcapsules used to be intact during the dissolution process, in case of the 
      acidic pH media. The release kinetic was changed when the pH of the dissolution 
      media was 7.2 and above. It was found that during the dissolution process the 
      granules undergo erosion and the release mechanism does not follow a single 
      process.
FAU - Pathak, Y V
AU  - Pathak YV
AD  - College of Pharmacy, Manipal, India.
FAU - Dorle, A K
AU  - Dorle AK
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Resins, Plant)
RN  - 8002-74-2 (Paraffin)
RN  - 88S87KL877 (rosin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Delayed-Action Preparations
MH  - Hydrogen-Ion Concentration
MH  - Paraffin
MH  - Resins, Plant
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
AID - 10.3109/02652049009021831 [doi]
PST - ppublish
SO  - J Microencapsul. 1990 Apr-Jun;7(2):185-90. doi: 10.3109/02652049009021831.

PMID- 8367238
OWN - NLM
STAT- MEDLINE
DCOM- 19931005
LR  - 20131121
IS  - 0031-5125 (Print)
IS  - 0031-5125 (Linking)
VI  - 77
IP  - 1
DP  - 1993 Aug
TI  - Aspirin (acetylsalicylic acid) effects on behavioral thermoregulation with 
      microwave radiation.
PG  - 187-91
AB  - Aspirin is a widely used over-the-counter drug in our society which has wide 
      therapeutic value, yet not all of the behavioral side effects have been studied. 
      Different doses of aspirin solutions were administered (ip) prior to 
      fixed-interval 2-min. schedules of microwave reinforcement in rats tested in a 
      cold environment. Four Sprague-Dawley rats were conditioned to regulate their 
      thermal environment with 5-sec. exposures of MW reinforcement. Friedman's 
      nonparametric test showed significant differences among aspirin and 
      saline-control doses. Post hoc sign tests showed that a moderate dose of aspirin 
      increased operant behavior reinforced by MW radiation, yet lower and higher doses 
      decreased and then increased the rate of responding which resulted in an inverted 
      U-shaped trend. Possible multiple effects of aspirin in terms of its 
      thermoregulatory as well as its pain-tolerance properties, and implications for 
      hypothalamic "set point" are discussed.
FAU - Vitulli, W F
AU  - Vitulli WF
AD  - Department of Psychology, University of South Alabama, Mobile 36688-0001.
FAU - Laconsay, K L
AU  - Laconsay KL
FAU - Agnew, A C
AU  - Agnew AC
FAU - Henderson, M E
AU  - Henderson ME
FAU - Quinn, J M
AU  - Quinn JM
FAU - Holland, B E
AU  - Holland BE
FAU - DePace, A N 3rd
AU  - DePace AN 3rd
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Percept Mot Skills
JT  - Perceptual and motor skills
JID - 0401131
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*pharmacology
MH  - Behavior, Animal/*drug effects
MH  - Body Temperature Regulation/*drug effects
MH  - Conditioning, Operant
MH  - Female
MH  - Male
MH  - *Microwaves
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
AID - 10.2466/pms.1993.77.1.187 [doi]
PST - ppublish
SO  - Percept Mot Skills. 1993 Aug;77(1):187-91. doi: 10.2466/pms.1993.77.1.187.

PMID- 11395668
OWN - NLM
STAT- MEDLINE
DCOM- 20010816
LR  - 20131121
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 25
IP  - 3
DP  - 2001 Mar
TI  - [Upper gastrointestinal bleeding in patients treated by low-dose aspirin].
PG  - 233-8
AB  - AIM OF THE STUDY: To estimate the number of people treated by low-dose aspirin 
      (<330 mg daily) in France and to evaluate the risk of upper gastrointestinal 
      bleeding associated with low-dose aspirin treatment. SUBJECTS AND METHODS: One 
      thousand six hundred and two patients with upper gastrointestinal bleeding were 
      included between January and June 1996 in 4 French areas. Data about patients 
      characteristics, drugs recently used, and bleeding lesions were prospectively 
      collected. Five hundred seventy five cases were matched for sex, age and area 
      with control people without previous upper gastrointestinal bleeding. Low-dose 
      aspirin intake in the population was estimated from the control group. Aspirin 
      intake in the previous 7 days in cases and in controls was compared by logistic 
      regression, adjusted for other gastrotoxic drugs intake. RESULTS: Low-dose 
      aspirin is taken by about 1.2 millions adults in France. In 1 602 patients, 
      gastrointestinal bleeding was related to a peptic ulcer in 34%. Aspirin was 
      associated with higher risk of upper gastrointestinal bleeding: OR=1.68 
      (1.03-2.74) with low-dose, and OR 1.42 (0.91-2.21) with higher doses. CONCLUSION: 
      About 2.8% of the population is exposed to low-dose aspirin in France. This 
      treatment seems to be associated with a high risk of upper gastrointestinal 
      bleeding.
FAU - Capet, C
AU  - Capet C
AD  - Groupe de Recherche sur l'Appareil Digestif, l'Environnement et la Nutrition 
      (ADEN EA 1296), Rouen.
FAU - Czernichow, P
AU  - Czernichow P
FAU - Dupas, J L
AU  - Dupas JL
FAU - Goria, O
AU  - Goria O
FAU - Gouérou, H
AU  - Gouérou H
FAU - Hochain, P
AU  - Hochain P
FAU - Amouretti, M
AU  - Amouretti M
FAU - Herman, H
AU  - Herman H
FAU - Colin, R
AU  - Colin R
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Hémorragies digestives hautes et aspirine à faible dose.
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Duodenal Ulcer/chemically induced/epidemiology
MH  - Female
MH  - France/epidemiology
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Stomach Ulcer/chemically induced/epidemiology
EDAT- 2001/06/08 10:00
MHDA- 2001/08/17 10:01
CRDT- 2001/06/08 10:00
PHST- 2001/06/08 10:00 [pubmed]
PHST- 2001/08/17 10:01 [medline]
PHST- 2001/06/08 10:00 [entrez]
AID - MDOI-GCB-03-2001-25-3-0399-8320-101019-ART2 [pii]
PST - ppublish
SO  - Gastroenterol Clin Biol. 2001 Mar;25(3):233-8.

PMID- 35905195
OWN - NLM
STAT- MEDLINE
DCOM- 20220802
LR  - 20220817
IS  - 1555-8576 (Electronic)
IS  - 1538-4047 (Print)
IS  - 1538-4047 (Linking)
VI  - 23
IP  - 1
DP  - 2022 Dec 31
TI  - Colorectal cancer chemoprevention: is aspirin still in the game?
PG  - 446-461
LID - 10.1080/15384047.2022.2104561 [doi]
AB  - Screening strategies have demonstrated their potential for decreasing the 
      incidence and mortality of cancers, particularly that of colorectal cancer (CRC). 
      Another strategy that has been developed to reduce CRC occurrence is the use of 
      chemoprevention agents. Among them, aspirin is the most promising. Aspirin acts 
      in colorectal tumourigenesis through several mechanisms, either directly in tumor 
      cells or in their microenvironment, such as through its anti-inflammatory 
      activity or its effect on the modulation of platelet function. Many retrospective 
      studies, as well as follow-up of large cohorts from trials with primary 
      cardiovascular end points, have shown that long-term treatment with daily 
      low-dose aspirin decreases the incidence of adenomas and colorectal cancers. 
      Therefore, aspirin is currently recommended by the United States Preventive 
      Services Task Force (USPSTF) for primary prevention of CRC in all patients aged 
      50 to 59 with a 10-y risk of cardiovascular events greater than 10%. Furthermore, 
      several studies have also reported that long-term aspirin treatment taking after 
      CRC resection decreases recurrence risk and increases overall survival, 
      especially in patients with PIK3CA-mutated tumors. This review summarizes current 
      knowledge on the pathophysiological mechanisms of aspirin chemoprevention, 
      discusses the primary clinical results on CRC prevention and highlights the 
      potential biomarkers identified to predict aspirin efficacy.
FAU - Grancher, Adrien
AU  - Grancher A
AUID- ORCID: 0000-0003-2338-891X
AD  - Normandy Centre for Genomic and Personalized Medicine and Department of 
      Hepatogastroenterology, Normandie Univ, Iron Group, Rouen University Hospital, 
      Rouen, France.
FAU - Michel, Pierre
AU  - Michel P
AD  - Normandy Centre for Genomic and Personalized Medicine and Department of 
      Hepatogastroenterology, Normandie Univ, Iron Group, Rouen University Hospital, 
      Rouen, France.
FAU - Di Fiore, Frederic
AU  - Di Fiore F
AD  - Normandy Centre for Genomic and Personalized Medicine, Department of 
      Hepatogastroenterology and Department of Medical Oncology, Henri Becquerel 
      Centre, Normandie Univ, IRON group, Rouen University Hospital, Rouen, France.
FAU - Sefrioui, David
AU  - Sefrioui D
AD  - Normandy Centre for Genomic and Personalized Medicine and Department of 
      Hepatogastroenterology, Normandie Univ, Iron Group, Rouen University Hospital, 
      Rouen, France.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Biol Ther
JT  - Cancer biology & therapy
JID - 101137842
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Adenoma
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/pharmacology/therapeutic use
MH  - Chemoprevention
MH  - *Colorectal Neoplasms/pathology
MH  - Humans
MH  - Retrospective Studies
MH  - Tumor Microenvironment
PMC - PMC9341367
OTO - NOTNLM
OT  - Aspirin
OT  - PIK3CA mutation
OT  - colorectal cancer
COIS- None
EDAT- 2022/07/30 06:00
MHDA- 2022/08/03 06:00
CRDT- 2022/07/29 14:03
PHST- 2022/07/29 14:03 [entrez]
PHST- 2022/07/30 06:00 [pubmed]
PHST- 2022/08/03 06:00 [medline]
AID - 2104561 [pii]
AID - 10.1080/15384047.2022.2104561 [doi]
PST - ppublish
SO  - Cancer Biol Ther. 2022 Dec 31;23(1):446-461. doi: 10.1080/15384047.2022.2104561.

PMID- 32105246
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 1897-9483 (Electronic)
IS  - 0032-3772 (Linking)
VI  - 130
IP  - 2
DP  - 2020 Feb 27
TI  - Aspirin for primary cardiovascular prevention: why the wonder drug should not be 
      precipitously dismissed.
PG  - 121-129
LID - 10.20452/pamw.15215 [doi]
AB  - Primary cardiovascular prevention is the combined set of actions aimed at 
      reducing the likelihood of symptomatic atherosclerotic disease or major adverse 
      cardiovascular events (MACEs) in currently asymptomatic individuals. Older 
      studies on aspirin for primary prevention were positive or neutral as to the 
      primary ischemic endpoint (often represented by MACE), but the reduction in 
      nonfatal ischemic events seemed largely counterbalanced by an increase in 
      bleeding events. The 3 latest large randomized controlled trials on aspirin in 
      primary prevention, all published in 2018, reached basically similar conclusions, 
      leading to an intense debate on whether aspirin therapy is warranted in 
      asymptomatic patients and whether there are subgroups that may benefit. In the 
      present review, we provide an overview of the available evidence on aspirin for 
      primary cardiovascular prevention, focusing on the results of meta‑analyses and 
      on strengths and pitfalls of meta‑analytic assessments. Based on a 
      meta‑regression of the benefits and harm of aspirin therapy in primary prevention 
      as a function of the 10‑year risk of MACE, which is an alternative type of pooled 
      analysis of available evidence, we propose a treatment algorithm acknowledging 
      differences among patients and emphasizing the need for an individualized 
      assessment of benefits and risks. Following general preventive measures (physical 
      exercise, smoking cessation, treatment of hypertension and hypercholesterolemia, 
      etc), a tailored approach to aspirin prescription is warranted. When patients are 
      younger than 70 years of age, clinicians should assess the 10‑year cardiovascular 
      risk: when such risk is high and bleeding risk is low, aspirin treatment should 
      still be considered, also taking patients' preferences into account.
FAU - Aimo, Alberto
AU  - Aimo A
AD  - University of Pisa and Pisa University Hospital, Pisa, Italy; Institute of Life 
      Sciences, Sant’Anna School of Advanced Studies, Pisa, Italy
FAU - De Caterina, Raffaele
AU  - De Caterina R
AD  - University of Pisa and Pisa University Hospital, Pisa, Italy; Fondazione 
      VillaSerena per la Ricerca, Città Sant’Angelo, Pescara, Italy. 
      raffaele.decaterina@unipi.it
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200227
PL  - Poland
TA  - Pol Arch Intern Med
JT  - Polish archives of internal medicine
JID - 101700960
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Primary Prevention
EDAT- 2020/02/28 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/02/28 06:00
PHST- 2020/02/28 06:00 [entrez]
PHST- 2020/02/28 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
AID - 10.20452/pamw.15215 [doi]
PST - ppublish
SO  - Pol Arch Intern Med. 2020 Feb 27;130(2):121-129. doi: 10.20452/pamw.15215. Epub 
      2020 Feb 27.

PMID- 25600173
OWN - NLM
STAT- MEDLINE
DCOM- 20160129
LR  - 20181113
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 5
DP  - 2015 Jan 20
TI  - Mapping sites of aspirin-induced acetylations in live cells by quantitative 
      acid-cleavable activity-based protein profiling (QA-ABPP).
PG  - 7896
LID - 10.1038/srep07896 [doi]
LID - 7896
AB  - Target-identification and understanding of mechanism-of-action (MOA) are 
      challenging for development of small-molecule probes and their application in 
      biology and drug discovery. For example, although aspirin has been widely used 
      for more than 100 years, its molecular targets have not been fully characterized. 
      To cope with this challenge, we developed a novel technique called quantitative 
      acid-cleavable activity-based protein profiling (QA-ABPP) with combination of the 
      following two parts: (i) activity-based protein profiling (ABPP) and iTRAQ™ 
      quantitative proteomics for identification of target proteins and (ii) 
      acid-cleavable linker-based ABPP for identification of peptides with specific 
      binding sites. It is known that reaction of aspirin with its target proteins 
      leads to acetylation. We thus applied the above technique using aspirin-based 
      probes in human cancer HCT116 cells. We identified 1110 target proteins and 2775 
      peptides with exact acetylation sites. By correlating these two sets of data, 523 
      proteins were identified as targets of aspirin. We used various biological assays 
      to validate the effects of aspirin on inhibition of protein synthesis and 
      induction of autophagy which were elicited from the pathway analysis of Aspirin 
      target profile. This technique is widely applicable for target identification in 
      the field of drug discovery and biology, especially for the covalent drugs.
FAU - Wang, Jigang
AU  - Wang J
AD  - Department of Biological Sciences, 14 Science Drive 4, National University of 
      Singapore, Singapore, 117543.
FAU - Zhang, Chong-Jing
AU  - Zhang CJ
AD  - Tropical Crops Genetic Resources Institute, Chinese Academy of Tropical 
      Agricultural Science, Baodao Xincun, Danzhou, Hainan, P.R. China, 571737.
FAU - Zhang, Jianbin
AU  - Zhang J
AD  - Department of Physiology, Yong Loo Lin School of Medicine, Block MD9, 2 Medical 
      Drive, National University of Singapore, Singapore 117597.
FAU - He, Yingke
AU  - He Y
AD  - Department of Anaesthesiology, Singapore General Hospital, Outram Road, 
      Singapore, 169608.
FAU - Lee, Yew Mun
AU  - Lee YM
AD  - Department of Biological Sciences, 14 Science Drive 4, National University of 
      Singapore, Singapore, 117543.
FAU - Chen, Songbi
AU  - Chen S
AD  - Tropical Crops Genetic Resources Institute, Chinese Academy of Tropical 
      Agricultural Science, Baodao Xincun, Danzhou, Hainan, P.R. China, 571737.
FAU - Lim, Teck Kwang
AU  - Lim TK
AD  - Department of Biological Sciences, 14 Science Drive 4, National University of 
      Singapore, Singapore, 117543.
FAU - Ng, Shukie
AU  - Ng S
AD  - Department of Physiology, Yong Loo Lin School of Medicine, Block MD9, 2 Medical 
      Drive, National University of Singapore, Singapore 117597.
FAU - Shen, Han-Ming
AU  - Shen HM
AD  - Department of Physiology, Yong Loo Lin School of Medicine, Block MD9, 2 Medical 
      Drive, National University of Singapore, Singapore 117597.
FAU - Lin, Qingsong
AU  - Lin Q
AD  - Department of Biological Sciences, 14 Science Drive 4, National University of 
      Singapore, Singapore, 117543.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150120
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Peptides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation/drug effects
MH  - Aspirin/*chemistry/metabolism
MH  - Binding Sites
MH  - Drug Discovery
MH  - Humans
MH  - Peptides/*chemistry/isolation & purification/metabolism
MH  - Protein Array Analysis
MH  - *Proteomics
PMC - PMC5379034
COIS- The authors declare no competing financial interests.
EDAT- 2015/01/21 06:00
MHDA- 2016/01/30 06:00
CRDT- 2015/01/21 06:00
PHST- 2014/09/09 00:00 [received]
PHST- 2014/12/16 00:00 [accepted]
PHST- 2015/01/21 06:00 [entrez]
PHST- 2015/01/21 06:00 [pubmed]
PHST- 2016/01/30 06:00 [medline]
AID - srep07896 [pii]
AID - 10.1038/srep07896 [doi]
PST - epublish
SO  - Sci Rep. 2015 Jan 20;5:7896. doi: 10.1038/srep07896.

PMID- 17491210
OWN - NLM
STAT- MEDLINE
DCOM- 20070605
LR  - 20131121
IS  - 1565-1088 (Print)
VI  - 9
IP  - 4
DP  - 2007 Apr
TI  - Aspirin--issues in daily practice: an update.
PG  - 221-6
AB  - We have summarized current knowledge regarding primary and secondary prevention 
      of cardiovasular disease, with an emphasis on aspirin resistance and adverse 
      effects. The use of combined therapy of aspirin and warfarin was discussed and 
      the role of aspirin in patients with AF was reviewed according to the latest 
      guidelines /Table 3/. The issue of primary prevention remains only partially 
      resolved, though it would seem that male patients at moderate to high risk for 
      CVD may benefit. On the other hand, the role of aspirin for secondary prevention 
      in high risk populations and in ACS is well established. A dose of 75-150 mg/day 
      has been validated in numerous studies with higher doses showing no additional 
      effects. Aspirin should not be regarded as an innocent drug, since prolonged use 
      in low risk populations carries the risk of serious adverse events, primarily 
      bleeding. Adverse events seem to increase linearly with increased doses. Patient 
      compliance remains a major issue regarding treatment failure and achieving 
      clinical benefit and should be stressed at every physician-patient encounter. 
      Further research is required to develop testing methods that are reliable, 
      standardized and accurate for aspirin resistance, and currently such testing is 
      not recommended. Withdrawal of aspirin treatment should not be considered an 
      innocent act as it may cause susceptibility to atherothrombotic events.
FAU - Beigel, Roy
AU  - Beigel R
AD  - Department of Medicine E, Sheba Medical Center, Tel Hashomer, Israel. 
      beigelr@post.tau.ac.il
FAU - Matetzky, Shlomi
AU  - Matetzky S
FAU - Fefer, Paul
AU  - Fefer P
FAU - Dvir, Danny
AU  - Dvir D
FAU - Hod, Hanoch
AU  - Hod H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Israel
TA  - Isr Med Assoc J
JT  - The Israel Medical Association journal : IMAJ
JID - 100930740
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Drug Resistance
MH  - Humans
MH  - Treatment Outcome
RF  - 40
EDAT- 2007/05/12 09:00
MHDA- 2007/06/06 09:00
CRDT- 2007/05/12 09:00
PHST- 2007/05/12 09:00 [pubmed]
PHST- 2007/06/06 09:00 [medline]
PHST- 2007/05/12 09:00 [entrez]
PST - ppublish
SO  - Isr Med Assoc J. 2007 Apr;9(4):221-6.

PMID- 8494138
OWN - NLM
STAT- MEDLINE
DCOM- 19930617
LR  - 20190703
IS  - 0003-2409 (Print)
IS  - 0003-2409 (Linking)
VI  - 48
IP  - 4
DP  - 1993 Apr
TI  - The effect of low dose aspirin on bleeding times.
PG  - 331-3
AB  - This double-blind, controlled study assessed the effect of low-dose aspirin on 
      bleeding times. Thirty patients, in the last trimester of their first pregnancy, 
      who were also taking part in a trial to evaluate the effect of low-dose aspirin 
      on the development and progress of pregnancy-induced hypertension, had their 
      bleeding times measured using the Simplate 11 Bleeding Device. Our study showed 
      there was no significant difference between the bleeding times of the two groups 
      and all measurements fell within the normal range.
FAU - Williams, H D
AU  - Williams HD
AD  - Queen Elizabeth Hospital, Birmingham.
FAU - Howard, R
AU  - Howard R
FAU - O'Donnell, N
AU  - O'Donnell N
FAU - Findley, I
AU  - Findley I
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Anaesthesia
JT  - Anaesthesia
JID - 0370524
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Anaesthesia. 1993 Oct;48(10):915-6. PMID: 8305048
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation/*drug effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Trimester, Third
MH  - Prospective Studies
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
AID - 10.1111/j.1365-2044.1993.tb06956.x [doi]
PST - ppublish
SO  - Anaesthesia. 1993 Apr;48(4):331-3. doi: 10.1111/j.1365-2044.1993.tb06956.x.

PMID- 6974303
OWN - NLM
STAT- MEDLINE
DCOM- 19811122
LR  - 20131121
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 2
IP  - 1
DP  - 1981 Jul 11
TI  - Enteric-coated pelletized aspirin. Gastrointestinal blood loss and 
      bioavailability.
PG  - 39-40
AB  - Eleven patients suffering from arthritis received, in a randomized cross-over 
      study, anti-inflammatory doses of two aspirin formulations: Enpryn, capsules 
      containing enteric-coated pellets; Rhusal, an enteric-coated tablet. No 
      significant difference was found between the two formulations with respect to 
      gastrointestinal microbleeding, plasma salicylate levels and urinary recovery of 
      salicylate. Bioavailability studies carried out on 10 healthy male volunteers 
      demonstrated that absorption from the enteric-coated pellet capsules was 
      sustained and complete.
FAU - Portek, I
AU  - Portek I
FAU - Graham, G
AU  - Graham G
FAU - Fleming, A
AU  - Fleming A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects/metabolism
MH  - Biological Availability
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Salicylates/blood
MH  - Tablets, Enteric-Coated
EDAT- 1981/07/11 00:00
MHDA- 1981/07/11 00:01
CRDT- 1981/07/11 00:00
PHST- 1981/07/11 00:00 [pubmed]
PHST- 1981/07/11 00:01 [medline]
PHST- 1981/07/11 00:00 [entrez]
PST - ppublish
SO  - Med J Aust. 1981 Jul 11;2(1):39-40.

PMID- 8960238
OWN - NLM
STAT- MEDLINE
DCOM- 19970109
LR  - 20181130
IS  - 0001-6837 (Print)
IS  - 0001-6837 (Linking)
VI  - 52
IP  - 1
DP  - 1995 Jan-Feb
TI  - Tensides from the group of propylene oxide and ethylene oxide copolymers. Part 
      XI. Solubilization of acetylsalicylic acid (ASA) by monomethoxypoly(ethylene 
      glycol) (M-PEG) micelles.
PG  - 61-5
AB  - The process of structural solubilization of acetyl salicylic acid (ASA) in a 
      balanced system (weight-balanced) by micelles of monomethoxypoly(ethylene 
      glycol)-s-CH3OCH2[CH2OCH2]n-CH2OH (M(r) = 350-5000) types and, for comparison, by 
      those of F-68 and F-108 Pluronics, was investigated. The determined viscosity and 
      hydrodynamic parameters ([eta], KH, M eta, Robs, omega) allowed for the 
      calculation of solubilizing activity of monomethoxypoly(ethylene glycol) 
      micelles-pi s(ASA). The results of the investigation point at 
      monomethoxypoly(ethylene glycol)s as an excipient, which may help to obtain new 
      drug delivery systems.
FAU - Zgoda, M M
AU  - Zgoda MM
AD  - Department of Applied Pharmacy, Faculty of Pharmacy, School of Medicine, Lódź, 
      Poland.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Acta Pol Pharm
JT  - Acta poloniae pharmaceutica
JID - 2985167R
RN  - 0 (Micelles)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 9004-74-4 (monomethoxypolyethylene glycol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*chemistry
MH  - Micelles
MH  - Polyethylene Glycols/*administration & dosage
MH  - Solubility
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Pol Pharm. 1995 Jan-Feb;52(1):61-5.

PMID- 10439430
OWN - NLM
STAT- MEDLINE
DCOM- 19991022
LR  - 20131121
IS  - 0161-6412 (Print)
IS  - 0161-6412 (Linking)
VI  - 21
IP  - 5
DP  - 1999 Jul
TI  - Aspirin reduces experimental cerebral blood flow in vivo.
PG  - 488-90
AB  - Aspirin therapy for stroke prophylaxis in low risk patients has paradoxically 
      demonstrated an increased risk of ischemic stroke in several studies. Moreover, 
      the MAST-Italy trial reported a near doubling of mortality with the addition of 
      aspirin to thrombolytics while experimentally, we have noted that aspirin 
      antagonizes t-PA-mediated clot lysis. The mechanisms responsible for these 
      observations is unclear. Of interest, few studies have examined the effect of 
      aspirin on cerebral blood flow (CBF). The objective of this study was to examine 
      the acute effect of high dose aspirin on CBF in a rabbit model. Mean arterial 
      pressure, arterial blood gases, and core and brain temperature were controlled 
      throughout the protocol. CBF, measured by the technique of hydrogen clearance 
      using Platinum-Iridium flow probes, was measured before and 20 min following 
      aspirin administration (20 mg kg-1 i.v.) in a cohort of 50 rabbits and compared 
      to rabbits receiving vehicle (n = 19). Following aspirin therapy, CBF (cc/100 g-1 
      min-1) was reduced from 80.8 +/- 27.4 to 65.1 +/- 31.7 (mean +/- SD), a reduction 
      to 80.4 +/- 21.3% of baseline (p < 0.00001, t-test), whereas CBF in the control 
      group remained unchanged (81.0 +/- 25.4 vs. 77.5 +/- 24.0, mean +/- SD). Thus 
      aspirin acutely reduced CBF by approximately 20% in a rabbit model, perhaps 
      related to inhibitory effects on prostacyclin and/or nitric oxide. This result 
      may help explain the possible increase in ischemic stroke seen in low risk 
      patients on aspirin therapy. A reduction in CBF by aspirin may also assist in 
      understanding the antagonism of t-PA-mediated clot lysis by aspirin seen in our 
      rabbit model of thromboembolic stroke, particularly since all agents which share 
      the ability to reverse this antagonism (nitric oxide donors, beta blockers, 
      hydralazine, prostacyclin) also increase CBF by approximately 20%. Future 
      strategies for 'antiplatelet' therapy may benefit from using agents which do not 
      adversely affect CBF.
FAU - Bednar, M M
AU  - Bednar MM
AD  - Division of Neurosurgery, University of Vermont, Burlington 05405, USA.
FAU - Gross, C E
AU  - Gross CE
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/toxicity
MH  - Brain Ischemia/chemically induced
MH  - Cerebrovascular Circulation/*drug effects
MH  - Depression, Chemical
MH  - Female
MH  - Male
MH  - Rabbits
MH  - Risk
EDAT- 1999/08/10 00:00
MHDA- 1999/08/10 00:01
CRDT- 1999/08/10 00:00
PHST- 1999/08/10 00:00 [pubmed]
PHST- 1999/08/10 00:01 [medline]
PHST- 1999/08/10 00:00 [entrez]
PST - ppublish
SO  - Neurol Res. 1999 Jul;21(5):488-90.

PMID- 24942808
OWN - NLM
STAT- MEDLINE
DCOM- 20150403
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 12
IP  - 8
DP  - 2014 Aug
TI  - Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel 
      direct and traditional indirect biomarkers of drug action.
PG  - 1320-30
LID - 10.1111/jth.12637 [doi]
AB  - BACKGROUND: Even though the acetylation of platelet cyclooxygenase (COX)-1 at 
      serine-529 is the direct mechanism of action of low-dose aspirin, its 
      antiplatelet effect has been characterized using indirect indexes of COX-1 
      activity. OBJECTIVES: We performed a clinical study with enteric-coated low-dose 
      aspirin (EC-aspirin), in healthy subjects, to evaluate the effects on the extent 
      and duration of platelet COX-1 acetylation, using a novel proteomic strategy for 
      absolute protein quantification (termed AQUA), as compared with traditional 
      pharmacokinetic and pharmacodynamic parameters. SUBJECTS AND METHODS: In a phase 
      I, single-arm, open-label study of EC aspirin (100 mg day(-1) ) administered to 
      24 healthy subjects, we compared, over a 24 h-period on day 1 and 7, % platelet 
      acetylated COX-1 (AceCOX-1) with traditional pharmacokinetic and pharmacodynamics 
      [i.e. serum thromboxane (TX) B2 , platelet function by monitoring 
      CEPI(collagen/epinephrine) closure time (CT) using whole-blood PFA-100 and 
      urinary excretion of 11-dehydro-TXB2 ] parameters. RESULTS: Acetylation of 
      platelet COX-1 was measurable before detection of aspirin levels in the systemic 
      circulation and increased in a cumulative fashion upon repeated dosing. After the 
      last dose of EC-aspirin, %AceCOX-1, serum TXB2 and CEPI-CT values were maximally 
      and persistently modified throughout 24 h; they averaged 76 ± 2%, 99.0 ± 0.4% and 
      271 ± 5 s, respectively. EC-aspirin caused 75% reduction in urinary 
      11-dehydro-TXB2 excretion. After chronic dosing with aspirin, the 
      pharmacokinetics of acetylsalicylic acid was completely dissociated from 
      pharmacodynamics. CONCLUSIONS: The demonstrated feasibility of quantifying the 
      extent and duration of platelet COX-1 acetylation will allow characterizing the 
      genetic, pharmacokinetic and pharmacodynamic determinants of the inter-individual 
      variability in the antiplatelet response to low-dose aspirin as well as 
      identifying extra-platelet sites of drug action.
CI  - © 2014 International Society on Thrombosis and Haemostasis.
FAU - Patrignani, P
AU  - Patrignani P
AD  - Section of Cardiovascular and Pharmacological Sciences, Department of 
      Neuroscience, Imaging and Clinical Science, Center of Excellence on Aging (CeSI), 
      'G. d'Annunzio' University, Chieti, Italy; Center of Excellence on Aging (CeSI), 
      "G. d'Annunzio" University, Chieti, Italy.
FAU - Tacconelli, S
AU  - Tacconelli S
FAU - Piazuelo, E
AU  - Piazuelo E
FAU - Di Francesco, L
AU  - Di Francesco L
FAU - Dovizio, M
AU  - Dovizio M
FAU - Sostres, C
AU  - Sostres C
FAU - Marcantoni, E
AU  - Marcantoni E
FAU - Guillem-Llobat, P
AU  - Guillem-Llobat P
FAU - Del Boccio, P
AU  - Del Boccio P
FAU - Zucchelli, M
AU  - Zucchelli M
FAU - Patrono, C
AU  - Patrono C
FAU - Lanas, A
AU  - Lanas A
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140718
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Biomarkers)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Biomarkers/*blood
MH  - Cyclooxygenase 1/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Thromboxane B2/blood
OTO - NOTNLM
OT  - 11-dehydro-thromboxane B2
OT  - acetylsalicylic acid
OT  - antiplatelet drugs
OT  - cyclooxygenase-1
OT  - proteomics
OT  - thromboxane A2
EDAT- 2014/06/20 06:00
MHDA- 2015/04/04 06:00
CRDT- 2014/06/20 06:00
PHST- 2014/04/09 00:00 [received]
PHST- 2014/06/10 00:00 [accepted]
PHST- 2014/06/20 06:00 [entrez]
PHST- 2014/06/20 06:00 [pubmed]
PHST- 2015/04/04 06:00 [medline]
AID - S1538-7836(22)04022-3 [pii]
AID - 10.1111/jth.12637 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2014 Aug;12(8):1320-30. doi: 10.1111/jth.12637. Epub 2014 Jul 
      18.

PMID- 3885174
OWN - NLM
STAT- MEDLINE
DCOM- 19850509
LR  - 20190912
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 5
IP  - 1
DP  - 1985 Jan-Feb
TI  - Nonsteroidal antiinflammatory drugs and aspirin--analyzing the scores.
PG  - 30-8
AB  - We reviewed 103 controlled clinical trials that compared the antiarthritic 
      efficacy and tolerance of previously and currently marketed nonsteroidal 
      antiinflammatory drugs (NSAIDs) and aspirin. Of 52 studies, 35 had data 
      sufficient to calculate an NSAID efficacy index (the ratio of mean improvement in 
      NSAID-treated patients to that in aspirin-treated patients) based on subjective 
      and/or objective criteria. The mean indexes (obtained from all studies from which 
      an index could be calculated) indicated no statistically significant difference 
      in efficacy between aspirin and the NSAIDs as a group; the indexes tended to 
      become less variable as the number of study subjects increased. Tolerance, 
      assessed from the percentage of patients who discontinued the drug because of 
      side effects, was significantly greater for NSAIDs than for aspirin. The NSAIDs 
      had greater efficacy but not greater toxicity at increased doses. Efficacy 
      differences described among NSAIDs in some studies were attributable either to 
      comparisons at nonequivalent doses or to chance.
FAU - Heller, C A
AU  - Heller CA
FAU - Ingelfinger, J A
AU  - Ingelfinger JA
FAU - Goldman, P
AU  - Goldman P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Drug Tolerance
MH  - Humans
RF  - 110
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1002/j.1875-9114.1985.tb04454.x [doi]
PST - ppublish
SO  - Pharmacotherapy. 1985 Jan-Feb;5(1):30-8. doi: 10.1002/j.1875-9114.1985.tb04454.x.

PMID- 18478192
OWN - NLM
STAT- MEDLINE
DCOM- 20090112
LR  - 20131121
IS  - 0163-4984 (Print)
IS  - 0163-4984 (Linking)
VI  - 124
IP  - 3
DP  - 2008 Sep
TI  - Pharmacokinetic study of copper (II) acetylsalicylate.
PG  - 283-8
LID - 10.1007/s12011-008-8146-3 [doi]
AB  - This study was aimed at determination of pharmacokinetic parameters of copper 
      (II) acetylsalicylate (CAS). Ten volunteers received a 60-mg dose of CAS. Blood 
      samples were collected just before and after 0.25, 0.5, 0.75, 1.0, 1.5, 2.5, 3.0, 
      3.5, 4.0, 4.5, 5.5, 7.0, 10, and 12.0 h of administration of the drug. The plasma 
      samples were analyzed for CAS and its metabolites by a validated high-performance 
      liquid chromatography method having a suitable lower limit of quantification. The 
      dose of 60 mg was well tolerated without any adverse effect. The maximum plasma 
      concentration of CAS was found to be 0.38 mg L(-1) with t (max) of 0.72 h. The 
      plasma half-life, clearance, and volume of distribution of CAS were 8.67 h, 66.30 
      L h(-1) and 829 L kg(-1), respectively. The elimination of CAS, acetylsalicylic 
      acid, copper salicylate, and salicylic acid follows the first order kinetics with 
      r (2) 0.979, 0.880, 0.991, and 0.998, respectively. The study provided for the 
      first time the pharmacokinetic data for CAS after oral administration of CAS. The 
      data were found to be useful in understanding the claimed enhanced 
      anti-inflammatory activity of the drug as compared with that of acetylsalicylic 
      acid.
FAU - Iqbal, Mohammad S
AU  - Iqbal MS
AD  - Department of Chemistry, GC University, Lahore, Pakistan. saeediq50@hotmail.com
FAU - Sher, Muhammad
AU  - Sher M
FAU - Pervez, Humayun
AU  - Pervez H
FAU - Saeed, Maryiam
AU  - Saeed M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20080514
PL  - United States
TA  - Biol Trace Elem Res
JT  - Biological trace element research
JID - 7911509
RN  - 0 (Organometallic Compounds)
RN  - 0 (Salicylates)
RN  - 16048-96-7 (copper salicylate complex)
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*analogs & derivatives/blood/pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Humans
MH  - Male
MH  - Organometallic Compounds/blood
MH  - Salicylates/blood
MH  - Young Adult
EDAT- 2008/05/15 09:00
MHDA- 2009/01/13 09:00
CRDT- 2008/05/15 09:00
PHST- 2008/04/07 00:00 [received]
PHST- 2008/04/15 00:00 [accepted]
PHST- 2008/05/15 09:00 [pubmed]
PHST- 2009/01/13 09:00 [medline]
PHST- 2008/05/15 09:00 [entrez]
AID - 10.1007/s12011-008-8146-3 [doi]
PST - ppublish
SO  - Biol Trace Elem Res. 2008 Sep;124(3):283-8. doi: 10.1007/s12011-008-8146-3. Epub 
      2008 May 14.

PMID- 24441590
OWN - NLM
STAT- MEDLINE
DCOM- 20140812
LR  - 20190724
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 134
IP  - 4
DP  - 2014
TI  - [Evaluation of drug information service available for physicians regarding 
      low-dose aspirin-induced gastrointestinal lesions].
PG  - 545-53
AB  - Low-dose aspirin-induced gastrointestinal lesions are becoming an important 
      problem in clinical practice. In our investigation of such adverse effects, we 
      obtained 4 important findings considered useful for physicians, as follows; 1) 
      even when aspirin was given at a dose, the incidence rate of gastrointestinal 
      lesions was higher than with other non-steroidal anti-inflammatory drugs 
      (NSAIDs), 2) the odds ratios for gastrointestinal lesions induced by aspirin with 
      a histamine H2 receptor antagonist and proton pump inhibitor were 0.6 and 0.4, 
      respectively, as compared with aspirin alone, 3) it is difficult to administer 
      aspirin, which exerts an antiplatelet effect, without inducing gastrointestinal 
      lesions, and 4) these gastrointestinal lesions appears early, especially within 2 
      years after administration. We distributed a questionnaire to 41 physicians to 
      confirm our findings, and compared high (n=20) and low (n=21) frequency aspirin 
      prescription groups. The recognition rate of points 1 and 3 noted above in the 
      high group was significantly elevated as compared to the low group, whereas there 
      no significant difference in regard to the information in point 4 between the 
      groups and the rate of recognition was low. Moreover, only 27% of the surveyed 
      physicians were familiar with all 4 points. Prior to receiving this information, 
      17% of the physicians gave no related instructions their patients, which was 
      reduced to 0% after receiving this information. Furthermore, 98% of those 
      surveyed found the information to be useful. Our results suggest that these 4 
      points of information regarding potential adverse gastrointestinal effects of 
      low-dose aspirin are useful for physicians.
FAU - Suzuki, Yuji
AU  - Suzuki Y
AD  - Department of Pharmacy, Tokai University of Oiso Hospital.
FAU - Yokoyama, Haruko
AU  - Yokoyama H
FAU - Soeda, Shinji
AU  - Soeda S
FAU - Tokuoka, Kentaro
AU  - Tokuoka K
FAU - Watanabe, Masayuki
AU  - Watanabe M
FAU - Kitagawa, Yasuhisa
AU  - Kitagawa Y
FAU - Yamada, Yasuhiko
AU  - Yamada Y
LA  - jpn
PT  - English Abstract
PT  - Journal Article
DEP - 20140118
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*adverse effects
MH  - *Drug Information Services
MH  - Drug Synergism
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Humans
MH  - Surveys and Questionnaires
EDAT- 2014/01/21 06:00
MHDA- 2014/08/13 06:00
CRDT- 2014/01/21 06:00
PHST- 2014/01/21 06:00 [entrez]
PHST- 2014/01/21 06:00 [pubmed]
PHST- 2014/08/13 06:00 [medline]
AID - DN/JST.JSTAGE/yakushi/13-00193 [pii]
AID - 10.1248/yakushi.13-00193 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2014;134(4):545-53. doi: 10.1248/yakushi.13-00193. Epub 2014 Jan 
      18.

PMID- 36378010
OWN - NLM
STAT- MEDLINE
DCOM- 20230126
LR  - 20230202
IS  - 2191-0286 (Electronic)
IS  - 0792-6855 (Linking)
VI  - 34
IP  - 1
DP  - 2023 Jan 1
TI  - Effect of aspirin on the TNF-α-mediated cell survival and death pathways in 
      breast cancer.
PG  - 91-102
LID - 10.1515/jbcpp-2022-0112 [doi]
AB  - OBJECTIVES: Aspirin is an anti-inflammatory drug commonly used as an analgesic 
      and in cardiovascular disorders. However, many studies have highlighted its 
      anti-cancer properties, especially in colorectal, lung, head and neck, and breast 
      cancers. In this work, we tried to study the effect of aspirin on the 
      TNF-α-mediated cell survival and death pathways in two cell lines representing 
      two different subtypes of breast cancer. TNF-α-mediated stimulation of a cell can 
      result in its proliferation via the NF-κB pathway or its death via either 
      apoptosis or a programmed form of necrosis called necroptosis. The latter is 
      believed to come into the picture only when apoptosis is inhibited. METHODS: In 
      this work, we studied the effect of aspirin on the TNF-α-mediated cell survival 
      pathway and observed a decrease in expression of the NF-κB pathway regulators, 
      its nuclear translocation, and phosphorylation in a dose-dependent manner. The 
      effect of aspirin on the TNF-α-mediated cell death showed significant 
      cytotoxicity at the higher doses (5-20 mM) of aspirin in both the breast cancer 
      cell lines. The effect of aspirin on necroptosis was investigated after 
      stimulating the cells with TNF-α and inhibiting apoptosis using Z-VAD-FMK. 
      RESULTS: Though no significant effect was noted in breast cancer cell lines, the 
      above protocol successfully induced necroptosis in L929, i.e., a positive control 
      cell line for necroptosis having an intact necroptosis machinery. Even when 
      combined with the chemotherapeutic drugs, the above regime failed to induce any 
      significant necroptosis in breast cancer cells but was found effective in L929. 
      CONCLUSIONS: Overall, the findings show that while aspirin has the potential to 
      inhibit the TNF-α-mediated cell survival pathway, it does not help sensitize 
      breast cancer cells to necroptotic cell death induction.
CI  - © 2022 Walter de Gruyter GmbH, Berlin/Boston.
FAU - Thakur, Banita
AU  - Thakur B
AUID- ORCID: 0000-0002-3807-3446
AD  - Department of Experimental Medicine and Biotechnology, Postgraduate Institute of 
      Medical Education and Research, Chandigarh, India.
FAU - Saha, Lekha
AU  - Saha L
AUID- ORCID: 0000-0001-5925-7159
AD  - Department of Pharmacology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Dahiya, Divya
AU  - Dahiya D
AD  - Department of General Surgery, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Bhatia, Alka
AU  - Bhatia A
AUID- ORCID: 0000-0002-7976-0824
AD  - Department of Experimental Medicine and Biotechnology, Postgraduate Institute of 
      Medical Education and Research, Chandigarh, India.
LA  - eng
PT  - Journal Article
DEP - 20221110
PL  - Germany
TA  - J Basic Clin Physiol Pharmacol
JT  - Journal of basic and clinical physiology and pharmacology
JID - 9101750
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (NF-kappa B)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Tumor Necrosis Factor-alpha
MH  - NF-kappa B/metabolism
MH  - *Breast Neoplasms/drug therapy
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cell Survival
MH  - Apoptosis
MH  - MCF-7 Cells
OTO - NOTNLM
OT  - aspirin treatment
OT  - breast cancer cell lines
OT  - chemotherapeutic drugs
OT  - estrogen receptor
OT  - necroptosis
OT  - triple-negative
EDAT- 2022/11/16 06:00
MHDA- 2023/01/27 06:00
CRDT- 2022/11/15 09:29
PHST- 2022/04/25 00:00 [received]
PHST- 2022/10/17 00:00 [accepted]
PHST- 2022/11/16 06:00 [pubmed]
PHST- 2023/01/27 06:00 [medline]
PHST- 2022/11/15 09:29 [entrez]
AID - jbcpp-2022-0112 [pii]
AID - 10.1515/jbcpp-2022-0112 [doi]
PST - epublish
SO  - J Basic Clin Physiol Pharmacol. 2022 Nov 10;34(1):91-102. doi: 
      10.1515/jbcpp-2022-0112. eCollection 2023 Jan 1.

PMID- 15760636
OWN - NLM
STAT- MEDLINE
DCOM- 20050503
LR  - 20131121
IS  - 0022-510X (Print)
IS  - 0022-510X (Linking)
VI  - 229-230
DP  - 2005 Mar 15
TI  - Aspirin resistance in stroke: 2004.
PG  - 163-9
AB  - Aspirin is a well-established medication in the treatment of atherothrombotic 
      vascular disease. However, despite aspirin treatment a substantial number of 
      patients experience recurring ischaemic episodes. Aspirin resistance denotes 
      those situations when it is unable to protect individuals from thrombotic 
      complications, or when it fails to produce an anticipated effect in laboratory 
      tests of platelet function. There are various laboratory techniques with which to 
      evaluate the effectiveness of aspirin and other antiplatelet drugs. It has been 
      estimated that in 5-60% of patients, aspirin does not achieve adequate efficacy 
      in various measures of platelet activity. Some studies have revealed that 
      vascular patients shown by laboratory tests to be aspirin-resistant are at an 
      increased risk of major vascular events. The suggested mechanisms of aspirin 
      resistance, among others, include genetic polymorphisms, alternate pathways of 
      platelet activation, aspirin-insensitive thromboxane biosynthesis, drug 
      interactions, or low aspirin dose. An increase in the dosage of aspirin or 
      conversion to clopidogrel or clopidogrel plus aspirin might be beneficial in the 
      management of those patients who are aspirin resistant. Additional work is 
      required to improve and validate laboratory tests of platelet function, so that 
      they may become useful tools for selecting the most appropriate antiplatelet 
      therapy for an individual patient. Improvements in antiplatelet treatment 
      strategies in the future should lead to a reduction in premature vascular events.
FAU - Sztriha, Laszlo K
AU  - Sztriha LK
AD  - Department of Neurology, Albert Szent-Györgyi Medical and Pharmaceutical Center, 
      University of Szeged, Szeged, Hungary.
FAU - Sas, Katalin
AU  - Sas K
FAU - Vecsei, Laszlo
AU  - Vecsei L
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20041223
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism/*therapeutic use
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/metabolism/*therapeutic use
MH  - Stroke/*prevention & control
MH  - Treatment Outcome
RF  - 55
EDAT- 2005/03/12 09:00
MHDA- 2005/05/04 09:00
CRDT- 2005/03/12 09:00
PHST- 2005/03/12 09:00 [pubmed]
PHST- 2005/05/04 09:00 [medline]
PHST- 2005/03/12 09:00 [entrez]
AID - S0022-510X(04)00446-0 [pii]
AID - 10.1016/j.jns.2004.11.023 [doi]
PST - ppublish
SO  - J Neurol Sci. 2005 Mar 15;229-230:163-9. doi: 10.1016/j.jns.2004.11.023. Epub 
      2004 Dec 23.

PMID- 11333459
OWN - NLM
STAT- MEDLINE
DCOM- 20010906
LR  - 20190607
IS  - 1470-2118 (Print)
IS  - 1473-4893 (Electronic)
IS  - 1470-2118 (Linking)
VI  - 1
IP  - 2
DP  - 2001 Mar-Apr
TI  - Aspirin: past, present and future.
PG  - 132-7
AB  - Many folk remedies used since pre-historic times have depended upon salicylates 
      for their effect. One hundred years ago aspirin was formulated from salicylic and 
      acetic acids. It was the first drug to be synthesised and its formulation is 
      regarded as the foundation of the modern pharmaceutical industry. The benefit of 
      low-dose aspirin as a prophylactic after a thrombotic event was first reported 25 
      years ago. Its use after coronary or cerebral thrombosis is virtually mandatory, 
      unless there are signs of intolerance. A 'loading dose' of soluble aspirin should 
      be given on first contact with a patient who may be suffering from myocardial 
      infarction. Patients considered to be at increased risk of a vascular event 
      should also be advised to carry their own aspirin and, if they experience sudden 
      severe chest pain, to chew and swallow a 300 mg tablet or a soluble preparation 
      immediately. The current phase of the aspirin story is, however, not over, and 
      its possible value in a variety of conditions, including dementia and certain 
      cancers, seems likely to ensure that it will long continue to play a remarkable 
      part in clinical practice.
FAU - Elwood, P C
AU  - Elwood PC
AD  - University of Wales, College of Medicine, Cardiff. pelwood@doctors.org.uk
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - England
TA  - Clin Med (Lond)
JT  - Clinical medicine (London, England)
JID - 101092853
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*history/therapeutic use
MH  - Aspirin/*history/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Female
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Male
MH  - Preventive Medicine
PMC - PMC4952474
EDAT- 2001/05/03 10:00
MHDA- 2001/09/08 10:01
CRDT- 2001/05/03 10:00
PHST- 2001/05/03 10:00 [pubmed]
PHST- 2001/09/08 10:01 [medline]
PHST- 2001/05/03 10:00 [entrez]
AID - clinmedicine [pii]
AID - 10.7861/clinmedicine.1-2-132 [doi]
PST - ppublish
SO  - Clin Med (Lond). 2001 Mar-Apr;1(2):132-7. doi: 10.7861/clinmedicine.1-2-132.

PMID- 17323609
OWN - NLM
STAT- MEDLINE
DCOM- 20070327
LR  - 20131121
IS  - 0008-7335 (Print)
IS  - 0008-7335 (Linking)
VI  - 145
IP  - 12
DP  - 2006
TI  - [Milestones of cardivascular pharmacotherapy: salicylates and aspirin].
PG  - 901-4
AB  - The analgesic and antipyretic effect of the bark of willow has been known in 
      Egypt and Greece for canturies. The modem era of salicylates starts with a letter 
      sent 1758 by Reverend Edward Stone to The Royal Society in London. He described 
      "an account of the success of the bark of willow in the cure of agues". His 
      report. erroneously attributed to Edmond Stone. was published five years later. 
      The active ingredient of willow bark. "salicine". was first isolated 1828 by 
      Joseph Buchner, then by Henri Leroux, and also prepared from the oil of 
      wintergreen (Gaultheria) and meadowsweet (Spirea ulmaria) by J. W. Lowig 1833. 
      and called "Spirsäure", which was already pure acetylsalicylic acid. It was also 
      synthetised 1853 by Ch. Gerhardt and finally 1897 in Bayer's laboratoires by 
      Felix Hoffman, who also demonstrated its antiinflammatory efficacy. After two 
      years of clinical trials with low doses, Bayer's management decided to start the 
      productions and launched Aspirin as an analgetic worldwide in summer 1899. The 
      first ASPIRIN ERA bagun. A completely new epoch started when J. N. Vane and 
      Priscilla Piner demonstrated 1971 that the main mechanism of action of 
      aspirin-like drugs is the inhibition of prostaglandin synthesis. In later studies 
      the potency to inhibit platelet aggregation with small doses of aspirin (30-125 
      mg) was demonstrated. The Physicians'Health Study 1988 confirmed this effect: 
      aspirin significantly reduced the risk of both, fatal and non-fatal myocardial 
      infarction. and is now used in primary and secondary prevention of 
      atherosclerosis. However the idea was not new: The use of salicylates and aspirin 
      was throughly discussed more than 50 years ago: Paul C. Gibson published 1949 a 
      well-documented case report on efficacy of aspirin in patients with angina, and 
      Kl. Weber and P. Klein in Prague used Gibson's mixture successfully for patients 
      with acute myocardial infarction (1951). Recently, the efficacy and security, the 
      interactions and side-effects of low-dose aspirin have been studied and 
      discussed. In chronic treatment, any combination of two specific platelet 
      antiaggregants should be avoided.
FAU - Jerie, P
AU  - Jerie P
LA  - cze
PT  - English Abstract
PT  - Historical Article
PT  - Journal Article
TT  - Milníky kardiovaskulární terapie. I. Salicyláty a aspirin.
PL  - Czech Republic
TA  - Cas Lek Cesk
JT  - Casopis lekaru ceskych
JID - 0004743
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*history/therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*history
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Salicylates/*history/therapeutic use
EDAT- 2007/02/28 09:00
MHDA- 2007/03/28 09:00
CRDT- 2007/02/28 09:00
PHST- 2007/02/28 09:00 [pubmed]
PHST- 2007/03/28 09:00 [medline]
PHST- 2007/02/28 09:00 [entrez]
PST - ppublish
SO  - Cas Lek Cesk. 2006;145(12):901-4.

PMID- 8365757
OWN - NLM
STAT- MEDLINE
DCOM- 19931007
LR  - 20131121
IS  - 0019-4832 (Print)
IS  - 0019-4832 (Linking)
VI  - 45
IP  - 2
DP  - 1993 Mar-Apr
TI  - Aspirin in ischemic heart disease--an overview.
PG  - 73-9
AB  - Aspirin is one of the oldest and most commonly used nonprescription drugs in the 
      world. Although commonly it is used for relief from common headache and muscular 
      pain, its use in the prevention and treatment of platelet related complications 
      in cardiovascular diseases (CVD) and cerebrovascular disease (CBVD) is quite 
      controversial. A brief review of the major aspirin trials indicated that a full 
      strength aspirin taken daily had no significant beneficial effect in reducing 
      mortality of patients with CVD/CBVD. However, two major trials (ISIS-2, PHS) in 
      which either low dose aspirin (160 mg) or one aspirin administered every other 
      day, have demonstrated significant reduction in fatal and nonfatal cardiovascular 
      events. Even a dose as low as 1 mg aspirin per day significantly lowers platelet 
      thromboxane synthesis. As a result of these studies, low dose aspirin should be 
      the choice of prophylactic therapy aimed at the inhibition of platelet 
      cyclooxygenase activity. Controlled-release low dose aspirin may favorably reduce 
      platelet thromboxane production and spare vascular prostacyclin synthesis. At 
      least 100 mgs of aspirin per day are essential to completely inhibit steady state 
      thromboxane formation. Low dose aspirin (160 mgs) has been shown to be as 
      effective as the full strength aspirin (325 mgs) in reducing clinical 
      complications related to platelet activation. The antithrombotic effect of 
      aspirin is well established and improved formulations, well thought out 
      therapeutic protocols, customized dosage, appropriate timing of delivery, a 
      better understanding of platelet function and pathophysiology of CUD/CBUD will 
      facilitate maximization of the beneficial effects of aspirin.
FAU - Rao, G H
AU  - Rao GH
AD  - Department of Laboratory Medicine and Pathology, University of Minnesota Medical 
      School, Minneapolis 55455.
FAU - Rao, A S
AU  - Rao AS
FAU - White, J G
AU  - White JG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian Heart J
JT  - Indian heart journal
JID - 0374675
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy/metabolism/prevention & control
RF  - 30
EDAT- 1993/03/01 00:00
MHDA- 1993/03/01 00:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 1993/03/01 00:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
PST - ppublish
SO  - Indian Heart J. 1993 Mar-Apr;45(2):73-9.

PMID- 16961726
OWN - NLM
STAT- MEDLINE
DCOM- 20070205
LR  - 20171116
IS  - 0897-5957 (Print)
IS  - 0897-5957 (Linking)
VI  - 24
IP  - 2
DP  - 2006 Summer
TI  - Pharmacologic profile and therapeutic potential of NCX 4016, a nitric 
      oxide-releasing aspirin, for cardiovascular disorders.
PG  - 148-68
AB  - NCX 4016, 2-(acetyloxy)benzoic acid 3-[(nitrooxy)methyl]phenyl ester, is a new 
      molecule in which a nitric oxide (NO)-releasing moiety is covalently linked to 
      aspirin. After enzymatic metabolism, NCX 4016 releases both components. In vitro 
      and in some animal models, these components exert their pharmacologic effects 
      simultaneously. Nitric oxide (NO) is a small gaseous molecule that exerts several 
      activities which may prevent atherothrombotic disorders. Moreover, it displays a 
      protective activity on the gastric mucosa. NCX 4016 has been shown to inhibit 
      platelet activation in vitro more effectively than aspirin, to inhibit smooth 
      muscle cell proliferation, to exert an endothelial cell protective activity and 
      to suppress the function of several inflammatory cells potentially involved in 
      atherothrombosis. In animal models, NCX 4016 protected from platelet 
      thromboembolism, prevented restenosis in atherosclerosis-prone animals, protected 
      the heart from ischemia/reperfusion injury, and induced neoangiogenesis in 
      critically ischemic limbs. Moreover, it displayed little or no gastric toxicity 
      and appeared to protect stomach from noxious stimuli, including aspirin. NCX 4016 
      has been evaluated in healthy volunteers and found to inhibit platelet 
      cyclo-oxygenase-1 (COX-1) similarly to or slightly less than aspirin, to raise 
      the circulating levels of NO-degradation products, and to have little or no 
      gastric toxicity in short term studies. In particular, in phase II studies, NCX 
      4016 had favorable effects on effort-induced endothelial dysfunction in 
      intermittent claudication and on platelet-activation parameters elicited by 
      short-term hyperglycemia in type II diabetics. In patients with type II diabetes 
      the effects of NCX 4016 on microalbuminuria and on some hemodynamic parameters 
      were promising. The pharmacokinetics of in vivo aspirin- and NO- released by NCX 
      4016, as well as the bioavailability of the two molecules, were not yet 
      adequately studied. Also, the long-term tolerability of NCX 4016, as well as its 
      possible effectiveness in preventing ischemic cardiovascular events and 
      progression of atherosclerosis, should be explored.
FAU - Gresele, Paolo
AU  - Gresele P
AD  - Department of Internal Medicine, Division of Internal and Cardiovascular 
      Medicine, University of Perugia, Perugia, Italy. grespa@unipg.it
FAU - Momi, Stefania
AU  - Momi S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiovasc Drug Rev
JT  - Cardiovascular drug reviews
JID - 9006912
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology/therapeutic use
MH  - Atherosclerosis/pathology/*prevention & control
MH  - Endothelium, Vascular/drug effects/physiopathology
MH  - Humans
MH  - Molecular Structure
MH  - Myocardial Ischemia/pathology/*prevention & control
MH  - Nitric Oxide Donors/chemistry/pharmacology/therapeutic use
MH  - Platelet Aggregation Inhibitors/chemistry/pharmacology/therapeutic use
MH  - Treatment Outcome
RF  - 106
EDAT- 2006/09/12 09:00
MHDA- 2007/02/06 09:00
CRDT- 2006/09/12 09:00
PHST- 2006/09/12 09:00 [pubmed]
PHST- 2007/02/06 09:00 [medline]
PHST- 2006/09/12 09:00 [entrez]
AID - CDR148 [pii]
AID - 10.1111/j.1527-3466.2006.00148.x [doi]
PST - ppublish
SO  - Cardiovasc Drug Rev. 2006 Summer;24(2):148-68. doi: 
      10.1111/j.1527-3466.2006.00148.x.

PMID- 3516407
OWN - NLM
STAT- MEDLINE
DCOM- 19860616
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 6
IP  - 1
DP  - 1986 Mar
TI  - A new formulation of aspirin: bioavailability and analgesic efficacy in migraine 
      attacks.
PG  - 19-27
AB  - Plasma aspirin and salicylate concentrations were followed after 600 mg of a new 
      palatable glycinated preparation of aspirin was given to six healthy male 
      volunteers in an attempt to investigate whether pre-gastric absorption of aspirin 
      could occur. In each subject the drug was administered by three different routes, 
      viz. (i) swallowed with water, (ii) dissolved sublingually and retained in the 
      mouth, and (iii) allowed to disperse on the tongue, and then swallowed without 
      water intake. Using the latter route of administration and the same aspirin 
      formulation, plasma aspirin and salicylate concentrations were also followed in 
      10 patients during acute migraine attacks. These results were compared with those 
      from another 10 migraineurs given 600 mg of soluble aspirin swallowed with water 
      during attacks. Aspirin and salicylate pharmacokinetic parameters (Cmax, tmax, 
      t1/2, Kabs and AUC) in the normal volunteers were not significantly different (p 
      greater than 0.05) whether glycinated aspirin was swallowed with water or 
      swallowed without water after dispersion in the mouth. However, negligible 
      aspirin was absorbed when the glycinated preparation was retained in the mouth. 
      In migraine patients, there was no significant difference (p greater than 0.05) 
      between the bioavailabilities of soluble aspirin swallowed with water (AUC = 5.7 
      +/- 2.3 mg h/l) and glycinated aspirin swallowed without water (AUC = 4.4 +/- 1.6 
      mg h/l). There also was no significant difference (p greater than 0.05) when the 
      time courses of pain relief were compared, both treatments being associated with 
      a significant (p less than 0.01) analgesic effect. The glycinated aspirin was 
      thus bioequivalent to swallowed aspirin but has no advantages for migraineurs 
      over soluble aspirin if water is readily available for self-administration.
FAU - Brandon, R A
AU  - Brandon RA
FAU - Eadie, M J
AU  - Eadie MJ
FAU - Curran, A C
AU  - Curran AC
FAU - Nolan, P C
AU  - Nolan PC
FAU - Presneill, J J
AU  - Presneill JJ
FAU - Patterson, M C
AU  - Patterson MC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*metabolism/therapeutic use
MH  - Biological Availability
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Migraine Disorders/*drug therapy
MH  - Random Allocation
MH  - Time Factors
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
AID - 10.1046/j.1468-2982.1986.0601019.x [doi]
PST - ppublish
SO  - Cephalalgia. 1986 Mar;6(1):19-27. doi: 10.1046/j.1468-2982.1986.0601019.x.

PMID- 12945292
OWN - NLM
STAT- MEDLINE
DCOM- 20040317
LR  - 20131121
IS  - 1000-0593 (Print)
IS  - 1000-0593 (Linking)
VI  - 21
IP  - 4
DP  - 2001 Aug
TI  - [Determination of lead and arsenic in copper aspirinate by graphite furnace 
      atomic absorption spectrometry].
PG  - 555-7
AB  - A graphite furnace atomic absorption spectrometric method has been established to 
      determine trace lead and arsenic in copper aspirinate, a new anti-inflammatory 
      and anti-thrombotic agent. The sample is pretreated by ashing at 530 degrees C in 
      the presence of Ni (NO3)2, followed by dissolution with HNO3. The method is 
      simple and has a low detection limit. The relative standard deviation is 11%-15%, 
      the recovery is 92%-112% for lead and 86%-119% for arsenic.
FAU - Qiu, H
AU  - Qiu H
AD  - Kunming Instiute of Precious Metals, 650221 Kunming.
FAU - Liu, J
AU  - Liu J
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Guang Pu Xue Yu Guang Pu Fen Xi
JT  - Guang pu xue yu guang pu fen xi = Guang pu
JID - 9424805
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - 2P299V784P (Lead)
RN  - N712M78A8G (Arsenic)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Arsenic/*analysis
MH  - Aspirin/*analogs & derivatives/*chemistry
MH  - Lead/*analysis
MH  - Spectrophotometry, Atomic/methods
EDAT- 2003/08/30 05:00
MHDA- 2004/03/18 05:00
CRDT- 2003/08/30 05:00
PHST- 2003/08/30 05:00 [pubmed]
PHST- 2004/03/18 05:00 [medline]
PHST- 2003/08/30 05:00 [entrez]
PST - ppublish
SO  - Guang Pu Xue Yu Guang Pu Fen Xi. 2001 Aug;21(4):555-7.

PMID- 6857178
OWN - NLM
STAT- MEDLINE
DCOM- 19830708
LR  - 20190909
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 12
IP  - 2
DP  - 1983
TI  - Decreasing serum salicylate concentrations during long-term administration of 
      acetylsalicylic acid in healthy volunteers. Discussion of possible clinical 
      implications.
PG  - 81-4
AB  - The suitability for multiple dosing of two acetylsalicylic acid (ASA) 
      preparations was compared in 8 healthy volunteers. During this study a marked 
      decrease in serum salicylate concentrations with time was observed in 7 of the 
      subjects. These results are presented here. On day 16 of medications, levels were 
      60-80% of those on day 6. On day 38, when the study was discontinued, the levels 
      had fallen to 50-65% of the values on day 6. The decrease in salicylate 
      concentrations is probably due to induction of the salicyluric acid formation, 
      one of the saturable pathways of salicylate elimination. Because of a narrow 
      therapeutic range and large interindividual differences in salicylate 
      concentrations with the same dose, determination of serum salicylate levels is an 
      important tool in the adjustment of optimum individual ASA therapy. Our findings 
      further emphasize this fact. They indicate that serum salicylate determinations 
      should preferably be repeated a few times after initiation of ASA therapy.
FAU - Olsson, B
AU  - Olsson B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*blood/metabolism
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Random Allocation
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.3109/03009748309102889 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 1983;12(2):81-4. doi: 10.3109/03009748309102889.

PMID- 12742333
OWN - NLM
STAT- MEDLINE
DCOM- 20030612
LR  - 20191025
IS  - 1470-0328 (Print)
IS  - 1470-0328 (Linking)
VI  - 110
IP  - 5
DP  - 2003 May
TI  - Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo 
      in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 2).
PG  - 485-91
AB  - OBJECTIVE: To assess the effectiveness of a pre-eclampsia prevention strategy 
      based on routine uterine artery Doppler flow velocity waveform examination during 
      the second trimester of pregnancy, followed by a prescription for 100 mg aspirin 
      in the case of abnormal Doppler findings. DESIGN: Multicentre randomised 
      controlled trial. SETTING: Eleven centres in the north of France and one in 
      Belgium. POPULATION: One thousand and eight hundred and fifty-three nulliparous 
      women recruited between 14 and 20 weeks of gestation. METHODS: Randomisation 
      either to undergo a uterine Doppler examination between 22 and 24 week of 
      gestation or to take a placebo. Women with abnormal Doppler waveforms received 
      100 mg of aspirin daily from Doppler examination through 36 weeks. MAIN OUTCOME 
      MEASURES: Pre-eclampsia was defined as hypertension (> or = 140 and/or 90 mmHg) 
      associated with proteinuria (> or = 0.5 g/L). RESULTS: One thousand two hundred 
      and fifty-three women (67%) were randomised into the systematic Doppler group and 
      617 (33%) into the placebo group. Of the 1175 patients in the Doppler group who 
      underwent this examination, 239 (20.3%) had abnormal uterine artery Doppler and 
      received a prescription for aspirin. Despite the aspirin prescription, the 
      frequency of pre-eclampsia did not differ between the systematic Doppler group 
      and the placebo group (28 of 1237 [2.3%] vs 9 of 616 [1.5%]; RR = 1.55, 95% CI 
      0.7-3.3). Furthermore, the groups did not differ in the frequency of children who 
      were very small for their gestational age (< or =3rd centile) or for perinatal 
      deaths. Compared with patients with normal Doppler findings, those with abnormal 
      Doppler were at high risk of pre-eclampsia (RR = 5.5, 95% CI 2.5-12.2) and of 
      giving birth to a small-for-gestational-age child (RR = 3.6, 95% CI 1.6-8.1). 
      CONCLUSION: Despite its sensitivity in screening for pre-eclampsia, routine 
      uterine Doppler in the second trimester cannot be recommended for nulliparous 
      patients.
FAU - Subtil, Damien
AU  - Subtil D
FAU - Goeusse, Patrice
AU  - Goeusse P
FAU - Houfflin-Debarge, Véronique
AU  - Houfflin-Debarge V
FAU - Puech, Francis
AU  - Puech F
FAU - Lequien, Pierre
AU  - Lequien P
FAU - Breart, Gérard
AU  - Breart G
FAU - Uzan, Serge
AU  - Uzan S
FAU - Quandalle, Florence
AU  - Quandalle F
FAU - Delcourt, Yves Marie
AU  - Delcourt YM
FAU - Malek, Yves Marie
AU  - Malek YM
CN  - Essai Régional Aspirine Mère-Enfant (ERASME) Collaborative Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - BJOG
JT  - BJOG : an international journal of obstetrics and gynaecology
JID - 100935741
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arteries/physiology
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fetal Growth Retardation/etiology
MH  - Humans
MH  - Placental Circulation/physiology
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/diagnostic imaging/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Pregnancy Trimester, Second
MH  - Sensitivity and Specificity
MH  - Ultrasonography, Doppler/methods
MH  - Ultrasonography, Prenatal/methods
MH  - Uterus/*blood supply
EDAT- 2003/05/14 05:00
MHDA- 2003/06/13 05:00
CRDT- 2003/05/14 05:00
PHST- 2003/05/14 05:00 [pubmed]
PHST- 2003/06/13 05:00 [medline]
PHST- 2003/05/14 05:00 [entrez]
AID - S1470032803029975 [pii]
AID - 10.1046/j.1471-0528.2003.t01-1-02097.x [doi]
PST - ppublish
SO  - BJOG. 2003 May;110(5):485-91. doi: 10.1046/j.1471-0528.2003.t01-1-02097.x.

PMID- 35051864
OWN - NLM
STAT- MEDLINE
DCOM- 20220322
LR  - 20220322
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 147
DP  - 2022 Mar
TI  - High on-treatment platelet reactivity to aspirin in patients after myocardial 
      infarction.
PG  - 112618
LID - S0753-3322(22)00006-3 [pii]
LID - 10.1016/j.biopha.2022.112618 [doi]
AB  - Aspirin (ASA) is widely used as an antiplatelet therapeutic drug in secondary 
      prevention. Last years brought many reports on ASA resistance or high 
      on-treatment platelet reactivity (HTPR) to aspirin.This study is a post-hoc 
      prospective analysis with 30 patients evaluated during follow up on average of 
      6.3 years after hospitalization from myocardial infarction. The examined 
      population was divided into two subgroups according to the response to ASA. In 
      order to estimate the function of blood platelets and their responsiveness to 
      acetylsalicylic acid therapy, ASPI-test was used. The measurements were performed 
      by the method of whole blood impedance aggregometry. During long-term follow up 
      significantly higher percentage of high platelet reactivity was observed, 
      compared with previous visits (p = 0.00001). Considering clinical endpoints of 
      the research that were connected with coronary disease, no differences were 
      obtained.The frequency of HTPR to aspirin in this study was higher than data 
      reported in literature among subjects with CV diseases. In long-term observation 
      the highest percentage of ASA non-responders was reported (58.6%). HTPR to 
      aspirin did not affect the presence of the clinical endpoints for the study.
CI  - Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Stolarek, Wioleta
AU  - Stolarek W
AD  - Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium 
      Medicum, Nicolaus Copernicus University, 9 Sklodowskiej, Curie Street, Bydgoszcz, 
      Poland. Electronic address: wioletaplazuk@o2.pl.
FAU - Kasprzak, Michał
AU  - Kasprzak M
AD  - Department of Cardiology and Internal Medicine, Faculty of Medicine, Collegium 
      Medicum, Nicolaus Copernicus University, 9 Sklodowskiej, Curie Street, Bydgoszcz, 
      Poland. Electronic address: medkas@o2.pl.
FAU - Sikora, Joanna
AU  - Sikora J
AD  - Department of Transplantology and General Surgery, Faculty of Medicine, Collegium 
      Medicum, Nicolaus Copernicus University, 9 Sklodowskiej, Curie Street, Bydgoszcz, 
      Poland. Electronic address: wojcikiewicz.j@gmail.com.
FAU - Siemińska, Emilia
AU  - Siemińska E
AD  - Department of Transplantology and General Surgery, Faculty of Medicine, Collegium 
      Medicum, Nicolaus Copernicus University, 9 Sklodowskiej, Curie Street, Bydgoszcz, 
      Poland. Electronic address: e.m.sieminska@gmail.com.
FAU - Grześk, Grzegorz
AU  - Grześk G
AD  - Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, 
      Collegium Medicum, Nicolaus Copernicus University, 75 Ujejskiego Street, 
      Bydgoszcz, Poland. Electronic address: ggrzesk@cm.umk.pl.
LA  - eng
PT  - Journal Article
DEP - 20220117
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/therapeutic 
      use
MH  - Prospective Studies
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Aspirin resistance
OT  - Coronary artery disease
OT  - High-on treatment platelet reactivity
OT  - Myocardial infarction
EDAT- 2022/01/21 06:00
MHDA- 2022/03/23 06:00
CRDT- 2022/01/20 20:27
PHST- 2021/10/24 00:00 [received]
PHST- 2021/12/22 00:00 [revised]
PHST- 2022/01/02 00:00 [accepted]
PHST- 2022/01/21 06:00 [pubmed]
PHST- 2022/03/23 06:00 [medline]
PHST- 2022/01/20 20:27 [entrez]
AID - S0753-3322(22)00006-3 [pii]
AID - 10.1016/j.biopha.2022.112618 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2022 Mar;147:112618. doi: 10.1016/j.biopha.2022.112618. Epub 
      2022 Jan 17.

PMID- 12830718
OWN - NLM
STAT- MEDLINE
DCOM- 20040420
LR  - 20161124
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 38
IP  - 3
DP  - 2003 Mar
TI  - [Separation of salicylic acid drugs by aqueous and nonaqueous capillary 
      electrophoresis with conductance detector].
PG  - 207-10
AB  - AIM: To develop a method for separating salicylic acid drugs by aqueous and 
      nonaqueous capillary electrophoresis with conductance detector. METHODS: 
      Fused-silica capillary (55 cm x 50 microns ID) was used. The effects of 
      concentration and pH of the running buffer, running voltage and injection time 
      were studied. Salicylic acid (SA), acetylsalicylic acid (ASA) and sulfosalicylic 
      acid (SSA) can be separated in a 10 mmol.L-1 Tris-30 mmol.L-1 H3BO3 buffer (pH 
      8.0), the separation voltage and injection time were 24 kV and 10 s, 
      respectively. But tailing peaks appeared. In order to improve the separation 
      efficiency and the sensitivity, ethanol was used as nonaqueous solvent. RESULTS: 
      High sensitivity and resolution for SA, ASA and SSA were obtained in ethanol 
      media, and there was excellent linearity between peak area and concentration of 
      the analytes in the concentration range of 0.05-100 mg.L-1, 5.0-250 mg.L-1 and 
      0.08-100 mg.L-1 for SA, ASA and SSA, respectively. All the correlation 
      coefficients were over 0.995. CONCLUSION: The analysis of SA and ASA in aspirin 
      tablets was tried and good results were obtained in ethanol media. There was 
      higher sensitivity and separation efficiency than in aqueous media.
FAU - Wei, Shou-lian
AU  - Wei SL
AD  - Department of Light Industry and Chemistry, Zhaoqing University, Zhaoqing 526061, 
      China.
FAU - Mo, Jin-yuan
AU  - Mo JY
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 0 (Benzenesulfonates)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 059QF0KO0R (Water)
RN  - 3K9958V90M (Ethanol)
RN  - L8XED79U3U (sulfosalicylic acid)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis/*chemistry/*isolation & purification
MH  - Benzenesulfonates
MH  - Electrophoresis, Capillary/*methods
MH  - Ethanol
MH  - Salicylates/isolation & purification
MH  - Salicylic Acid/*isolation & purification
MH  - Sensitivity and Specificity
MH  - Tablets
MH  - Water
EDAT- 2003/07/02 05:00
MHDA- 2004/04/21 05:00
CRDT- 2003/07/02 05:00
PHST- 2003/07/02 05:00 [pubmed]
PHST- 2004/04/21 05:00 [medline]
PHST- 2003/07/02 05:00 [entrez]
PST - ppublish
SO  - Yao Xue Xue Bao. 2003 Mar;38(3):207-10.

PMID- 37513173
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230801
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 28
IP  - 14
DP  - 2023 Jul 9
TI  - Dietary Supplementation of Aspirin Promotes Drosophila Defense against Viral 
      Infection.
LID - 10.3390/molecules28145300 [doi]
LID - 5300
AB  - Aspirin, also known as acetylsalicylic acid, is widely consumed as a pain 
      reliever and an anti-inflammatory as well as anti-platelet agent. Recently, our 
      studies using the animal model of Drosophila demonstrated that the dietary 
      supplementation of aspirin renovates age-onset intestinal dysfunction and delays 
      organismal aging. Nevertheless, it remains probable that aspirin plays functional 
      roles in other biological activities, for instance antiviral defense reactions. 
      Intriguingly, we observed that the replications of several types of viruses were 
      drastically antagonized in Drosophila macrophage-like S2 cells with the addition 
      of aspirin. Further in vivo experimental approaches illustrate that adult flies 
      consuming aspirin harbor higher resistances to viral infections with respect to 
      flies without aspirin treatment. Mechanistically, aspirin positively contributes 
      to the Drosophila antiviral defense largely through mediating the STING 
      (stimulator of interferon genes) but not the IMD (immune deficiency) signaling 
      pathway. Collectively, our studies uncover a novel biological function of aspirin 
      in modulating Drosophila antiviral immunity and provide theoretical bases for 
      exploring new antiviral treatments in clinical trials.
FAU - Kong, Fanrui
AU  - Kong F
AD  - Center for Developmental Biology, School of Life Sciences, Anhui Agricultural 
      University, Hefei 230036, Anhui, China.
FAU - Qadeer, Abdul
AU  - Qadeer A
AD  - Center for Developmental Biology, School of Life Sciences, Anhui Agricultural 
      University, Hefei 230036, Anhui, China.
FAU - Xie, Yali
AU  - Xie Y
AD  - Center for Developmental Biology, School of Life Sciences, Anhui Agricultural 
      University, Hefei 230036, Anhui, China.
FAU - Jin, Yiheng
AU  - Jin Y
AD  - Center for Developmental Biology, School of Life Sciences, Anhui Agricultural 
      University, Hefei 230036, Anhui, China.
FAU - Li, Qingyang
AU  - Li Q
AD  - Center for Developmental Biology, School of Life Sciences, Anhui Agricultural 
      University, Hefei 230036, Anhui, China.
FAU - Xiao, Yihua
AU  - Xiao Y
AD  - Center for Developmental Biology, School of Life Sciences, Anhui Agricultural 
      University, Hefei 230036, Anhui, China.
FAU - She, Kan
AU  - She K
AD  - Center for Developmental Biology, School of Life Sciences, Anhui Agricultural 
      University, Hefei 230036, Anhui, China.
FAU - Zheng, Xianrui
AU  - Zheng X
AD  - Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou 363000, 
      Fujian, China.
FAU - Li, Jiashu
AU  - Li J
AD  - Université de Strasbourg, 67000 Strasbourg, France.
FAU - Ji, Shanming
AU  - Ji S
AD  - Center for Developmental Biology, School of Life Sciences, Anhui Agricultural 
      University, Hefei 230036, Anhui, China.
AD  - Université de Strasbourg, 67000 Strasbourg, France.
FAU - Zhu, Yangyang
AU  - Zhu Y
AD  - Center for Developmental Biology, School of Life Sciences, Anhui Agricultural 
      University, Hefei 230036, Anhui, China.
LA  - eng
GR  - 32100702/National Natural Science Foundation of China/
GR  - 2008085J14/Anhui Provincial Natural Science Foundation/
PT  - Journal Article
DEP - 20230709
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Animals
MH  - *Drosophila
MH  - Aspirin/pharmacology/metabolism
MH  - Immunity, Innate
MH  - *Virus Diseases
MH  - Antiviral Agents/metabolism
MH  - Dietary Supplements
MH  - Drosophila melanogaster/metabolism
PMC - PMC10385701
OTO - NOTNLM
OT  - Drosophila
OT  - IMD pathway
OT  - STING signaling
OT  - antiviral immunity
OT  - aspirin
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/29 11:45
MHDA- 2023/07/31 06:42
CRDT- 2023/07/29 01:34
PHST- 2023/05/03 00:00 [received]
PHST- 2023/06/28 00:00 [revised]
PHST- 2023/07/07 00:00 [accepted]
PHST- 2023/07/31 06:42 [medline]
PHST- 2023/07/29 11:45 [pubmed]
PHST- 2023/07/29 01:34 [entrez]
AID - molecules28145300 [pii]
AID - molecules-28-05300 [pii]
AID - 10.3390/molecules28145300 [doi]
PST - epublish
SO  - Molecules. 2023 Jul 9;28(14):5300. doi: 10.3390/molecules28145300.

PMID- 8612758
OWN - NLM
STAT- MEDLINE
DCOM- 19960605
LR  - 20190621
IS  - 0014-5793 (Print)
IS  - 0014-5793 (Linking)
VI  - 382
IP  - 1-2
DP  - 1996 Mar 11
TI  - Aspirin-DNA interaction studied by FTIR and laser Raman difference spectroscopy.
PG  - 26-30
AB  - The interaction of calf-thymus DNA with aspirin is investigated in aqueous 
      solution at pH 7-6 with drug/DNA (phosphate) molar ratios of r = 1/40, 1/20, 
      1/10, 1/5, 1/2, 1 and 2. Fourier transform infrared (FTIR) and laser Raman 
      difference spectroscopy are used to determine drug binding sites, sequence 
      preference and DNA secondary structure, as well as the structural variations of 
      aspirin-DNA complexes in aqueous solution. Spectroscopic evidence showed that at 
      low aspirin concentration (r =1/40), drug-DNA interaction is mainly through the 
      backbone PO2 groups and the A-T base pairs. Such interaction largely perturbs the 
      phosphate vibration at 1222 cm(-1) and the A-T bands at 1663 and 1609 cm(-1) with 
      no major helix destabilization. At higher drug concentration (r > 1/20), the 
      participation of the G-C bases in drug-DNA complexation was evident by strong 
      perturbations of the guanine and cytosine vibrations at 1717 and 1494 cm(-1), 
      with a partial helix destabilization. A major alteration of the B-DNA structure 
      towards A-DNA occurs on drug complexation. The aspirin interaction was through 
      anion CO and COOCH3 donor atoms with those of the backbone PO2 group and DNA 
      bases donor sites (directly or indirectly via H2O molecules).
FAU - Neault, J F
AU  - Neault JF
AD  - Department of Chemistry and Biology, University of Québec, Canada.
FAU - Naoui, M
AU  - Naoui M
FAU - Manfait, M
AU  - Manfait M
FAU - Tajmir-Riahi, H A
AU  - Tajmir-Riahi HA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - FEBS Lett
JT  - FEBS letters
JID - 0155157
RN  - 059QF0KO0R (Water)
RN  - 9007-49-2 (DNA)
RN  - R16CO5Y76E (Aspirin)
RN  - Y4S76JWI15 (Methanol)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry/*metabolism
MH  - Binding Sites
MH  - Cattle
MH  - DNA/*chemistry/*metabolism
MH  - Methanol
MH  - Nucleic Acid Conformation
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Spectrum Analysis, Raman
MH  - Water
EDAT- 1996/03/11 00:00
MHDA- 1996/03/11 00:01
CRDT- 1996/03/11 00:00
PHST- 1996/03/11 00:00 [pubmed]
PHST- 1996/03/11 00:01 [medline]
PHST- 1996/03/11 00:00 [entrez]
AID - 0014-5793(96)00093-2 [pii]
AID - 10.1016/0014-5793(96)00093-2 [doi]
PST - ppublish
SO  - FEBS Lett. 1996 Mar 11;382(1-2):26-30. doi: 10.1016/0014-5793(96)00093-2.

PMID- 353659
OWN - NLM
STAT- MEDLINE
DCOM- 19780915
LR  - 20131121
IS  - 0369-8114 (Print)
IS  - 0369-8114 (Linking)
VI  - 25 Suppl
DP  - 1977 Dec
TI  - Comparision of low dose heparin and low dose heparin combined with aspirin in 
      prevention of deep vein thrombosis after total hip replacement.
PG  - 55-8
AB  - In a prospective randomised trial, two groups of 20 patients each were compared. 
      The first group received low dose heparin (t.i.d.) and the second group received 
      low dose heparin (t.i.d.) combined with aspirin. The incidence of deep vein 
      thrombosis (DVT) were determined using both radioactive fibrinogen uptake test 
      and venography. The correlation between the two methods of diagnosis was better 
      than 90%. There was no significant difference in the incidence of DVT between the 
      two prophylactic regimen. A significant tendancy towards increased bleeding in 
      observed with the combination of low dose heparin and aspirin.
FAU - Flicoteaux, H
AU  - Flicoteaux H
FAU - Kher, A
AU  - Kher A
FAU - Jean, N
AU  - Jean N
FAU - Blery, M
AU  - Blery M
FAU - Judet, T
AU  - Judet T
FAU - Honnart, F
AU  - Honnart F
FAU - Pasteyer, J
AU  - Pasteyer J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - France
TA  - Pathol Biol (Paris)
JT  - Pathologie-biologie
JID - 0265365
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastrointestinal Hemorrhage/etiology
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - *Joint Prosthesis
MH  - Male
MH  - Middle Aged
MH  - Platelet Adhesiveness/drug effects
MH  - Thrombophlebitis/prevention & control
EDAT- 1977/12/01 00:00
MHDA- 1977/12/01 00:01
CRDT- 1977/12/01 00:00
PHST- 1977/12/01 00:00 [pubmed]
PHST- 1977/12/01 00:01 [medline]
PHST- 1977/12/01 00:00 [entrez]
PST - ppublish
SO  - Pathol Biol (Paris). 1977 Dec;25 Suppl:55-8.

PMID- 26759138
OWN - NLM
STAT- MEDLINE
DCOM- 20161219
LR  - 20220317
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 31
IP  - 3
DP  - 2016 Mar
TI  - Expanded findings from a randomized controlled trial of preconception low-dose 
      aspirin and pregnancy loss.
PG  - 657-65
LID - 10.1093/humrep/dev329 [doi]
AB  - STUDY QUESTION: What is the association between daily preconception-initiated 
      low-dose aspirin (LDA) treatment and very early pregnancy losses or euploid 
      (chromosomally normal) losses among women with one to two prior losses? SUMMARY 
      ANSWER: Daily LDA initiated preconception was not associated with the rate or 
      type of pregnancy loss among women with a history of one to two prior pregnancy 
      losses. WHAT IS KNOWN ALREADY: LDA is often used to treat recurrent pregnancy 
      loss with reductions in pregnancy loss generally only observed among women with 
      antiphospholipid antibodies, and null associations observed among women without 
      antiphospholipid antibodies. We previously evaluated the association between LDA 
      and pregnancy loss overall among women with one to two prior losses in the 
      Effects of Aspirin in Gestation and Reproduction (EAGeR) trial and found no 
      association, though did not distinguish between potential effects at different 
      stages of pregnancy loss, including implantation failure, or between euploid and 
      aneuploid losses. STUDY DESIGN, SIZE, DURATION: The EAGeR trial was a multi-site 
      prospective block-randomized double-blind placebo-controlled trial. In total, 
      1228 women were randomized to daily LDA (81 mg/day) plus folic acid (400 
      mcg/day), or placebo plus folic acid. Participants were assigned study drug for 
      less than or equal to six menstrual cycles or if they conceived, throughout 
      pregnancy with study drug discontinued at 36 weeks gestation. This analysis 
      includes additional outcome information obtained from chart abstractions after 
      the completion of the trial, as well as testing of stored urine for measurement 
      of hCG and detection of very early pregnancy losses, and karyotyping of the 
      products of conception for assessment of aneuploidy of the losses. PARTICIPANTS, 
      SETTING, METHODS: Women aged 18-40 with a history of one to two prior losses and 
      actively trying to conceive were randomized (n = 615 LDA and n = 613 placebo) at 
      four clinical centers in the USA (2007-2011). Log-binomial regression was used to 
      estimate risk ratios under the intent-to-treat approach. MAIN RESULTS AND THE 
      ROLE OF CHANCE: Daily LDA initiated preconception was not associated with 
      clinically recognized pregnancy losses or implantation failures among women with 
      proved fecundity and a history of one to two prior losses. Specifically, 1088 
      (88.6%) women completed the trial with 797 having an hCG detected pregnancy 
      (64.9%). Overall there were 133 clinical losses (12.7% LDA versus 11.8% placebo, 
      P = 0.71) and 55 implantation failures (5.2% LDA versus 4.9% placebo, P = 0.89). 
      No differences were found in rate of euploid losses (RR 1.11, 95% confidence 
      interval: 0.99, 1.26). LIMITATIONS, REASONS FOR CAUTION: Generalizability of 
      these findings is limited to women with a history of one to two prior losses, and 
      may further be limited to women of white race with higher socioeconomic status as 
      given the rigors of the study protocol participants tended to be white and have 
      higher incomes and more education. We were also missing karyotype information on 
      approximately one-third of the clinically recognized pregnancy losses, which may 
      limit our power to detect effects on euploid losses, though detailed sensitivity 
      analysis showed similar results. WIDER IMPLICATIONS OF THE FINDINGS: Our data do 
      not support the general use of LDA to decrease pregnancy loss and further 
      demonstrate no increased risk of loss for women on LDA treatment. STUDY 
      FUNDING/COMPETING INTERESTS: This research was supported by the Intramural 
      Research Program of the Eunice Kennedy Shriver National Institute of Child Health 
      and Human Development, National Institutes of Health, Bethesda, Maryland 
      (Contract Nos. HHSN267200603423, HHSN267200603424, HHSN267200603426). The authors 
      have no conflicts of interest. TRIAL REGISTRATION NUMBER: The trial was 
      registered at ClinicalTrials.gov #NCT00467363. TRIAL REGISTRATION DATE: 27 April 
      2007. DATE OF FIRST PATIENT'S ENROLLMENT: 15 June 2007.
CI  - Published by Oxford University Press on behalf of the European Society of Human 
      Reproduction and Embryology 2016. This work is written by (a) US Government 
      employee(s) and is in the public domain in the US.
FAU - Mumford, Sunni L
AU  - Mumford SL
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 6100 
      Executive Blvd. 7B03, Rockville, MD 20852, USA mumfords@mail.nih.gov.
FAU - Silver, Robert M
AU  - Silver RM
AD  - Department of Obstetrics and Gynecology, University of Utah Health Sciences 
      Center, Room 2B200 SOM, 50 North Medical Drive, Salt Lake City, UT 84132, USA.
FAU - Sjaarda, Lindsey A
AU  - Sjaarda LA
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 6100 
      Executive Blvd. 7B03, Rockville, MD 20852, USA.
FAU - Wactawski-Wende, Jean
AU  - Wactawski-Wende J
AD  - Department of Epidemiology and Environmental Health, University at Buffalo, 270 
      Farber Hall, Buffalo, NY 14214, USA.
FAU - Townsend, Janet M
AU  - Townsend JM
AD  - Department of Family, Community and Rural Health, Commonwealth Medical College, 
      525 East Pine Street, Scranton, PA 18509, USA.
FAU - Lynch, Anne M
AU  - Lynch AM
AD  - Department of Obstetrics and Gynecology, University of Colorado, 12700 East 19th 
      Avenue, Aurora, CO 80045, USA.
FAU - Galai, Noya
AU  - Galai N
AD  - Department of Statistics, University of Haifa, Mt Carmel, Haifa 31905, Israel.
FAU - Lesher, Laurie L
AU  - Lesher LL
AD  - Department of Obstetrics and Gynecology, University of Utah Health Sciences 
      Center, Room 2B200 SOM, 50 North Medical Drive, Salt Lake City, UT 84132, USA.
FAU - Faraggi, David
AU  - Faraggi D
AD  - Department of Statistics, University of Haifa, Mt Carmel, Haifa 31905, Israel.
FAU - Perkins, Neil J
AU  - Perkins NJ
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 6100 
      Executive Blvd. 7B03, Rockville, MD 20852, USA.
FAU - Schliep, Karen C
AU  - Schliep KC
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 6100 
      Executive Blvd. 7B03, Rockville, MD 20852, USA.
FAU - Zarek, Shvetha M
AU  - Zarek SM
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 6100 
      Executive Blvd. 7B03, Rockville, MD 20852, USA.
FAU - Schisterman, Enrique F
AU  - Schisterman EF
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 6100 
      Executive Blvd. 7B03, Rockville, MD 20852, USA.
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Intramural
DEP - 20160111
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Spontaneous/*prevention & control
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Regression Analysis
PMC - PMC4755442
OTO - NOTNLM
OT  - conception
OT  - fertility
OT  - live birth
OT  - low-dose aspirin
OT  - pregnancy loss
EDAT- 2016/01/14 06:00
MHDA- 2016/12/20 06:00
PMCR- 2017/03/01
CRDT- 2016/01/14 06:00
PHST- 2015/06/03 00:00 [received]
PHST- 2015/11/20 00:00 [accepted]
PHST- 2017/03/01 00:00 [pmc-release]
PHST- 2016/01/14 06:00 [entrez]
PHST- 2016/01/14 06:00 [pubmed]
PHST- 2016/12/20 06:00 [medline]
AID - dev329 [pii]
AID - 10.1093/humrep/dev329 [doi]
PST - ppublish
SO  - Hum Reprod. 2016 Mar;31(3):657-65. doi: 10.1093/humrep/dev329. Epub 2016 Jan 11.

PMID- 23907141
OWN - NLM
STAT- MEDLINE
DCOM- 20141020
LR  - 20211021
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 34
IP  - 44
DP  - 2013 Nov
TI  - Is aspirin useful in primary prevention?
PG  - 3412-8
LID - 10.1093/eurheartj/eht287 [doi]
AB  - There is no evidence that aspirin is effective for the primary prevention of 
      cardiovascular events, although it may change the way that they present. Indeed, 
      there is no evidence that long-term aspirin should be given to patients even with 
      known cardiovascular disease. Theoretical arguments that aspirin can prevent 
      cardiovascular events by reducing the propagation of thrombus are countered by 
      evidence that plaque haemorrhage from vasa vasorum may also cause plaque growth 
      and instability. There is evidence that aspirin causes serious bleeding into the 
      brain and the gut. Aspirin may also detract from the benefits of drugs that have 
      definite cardiovascular benefits, such as angiotensin-converting enzyme 
      inhibitors. Meta-analysis is prone to multiple biases in favour of aspirin, 
      including publication bias, bias due to trial and endpoint selection and bias due 
      to interpretation. Meta-analysis should not be relied on in preference to 
      adequately powered clinical trials. Unfortunately, the benefits of aspirin, if 
      they exist, may be so small that a very large study indeed would be required to 
      demonstrate that its benefits outweigh its risks. The evidence that aspirin might 
      reduce cancer is intriguing but relies on data from trials conducted many decades 
      ago using a wide range of aspirin doses. There is no reliable evidence that 
      aspirin used in the current fashionable doses of 50-100 mg/day is of any benefit 
      in any common clinical setting.
FAU - Cleland, John G F
AU  - Cleland JG
AD  - Imperial College London (Royal Brompton & Harefield Hospitals), London, UK and 
      Department of Cardiology, Castle Hill Hospital, Hull and York Medical School, 
      University of Hull, Kingston-upon-Hull HU6 5JQ, UK.
LA  - eng
GR  - 08/53/36/DH_/Department of Health/United Kingdom
GR  - HTA/08/53/36/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20130801
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects/pharmacology
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Primary Prevention
MH  - Publication Bias
MH  - Secondary Prevention
OTO - NOTNLM
OT  - Aspirin
OT  - Primary prevention
EDAT- 2013/08/03 06:00
MHDA- 2014/10/21 06:00
CRDT- 2013/08/03 06:00
PHST- 2013/08/03 06:00 [entrez]
PHST- 2013/08/03 06:00 [pubmed]
PHST- 2014/10/21 06:00 [medline]
AID - eht287 [pii]
AID - 10.1093/eurheartj/eht287 [doi]
PST - ppublish
SO  - Eur Heart J. 2013 Nov;34(44):3412-8. doi: 10.1093/eurheartj/eht287. Epub 2013 Aug 
      1.

PMID- 25842298
OWN - NLM
STAT- MEDLINE
DCOM- 20150828
LR  - 20161126
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1855
IP  - 2
DP  - 2015 Apr
TI  - Chemopreventive effects of aspirin at a glance.
PG  - 254-63
LID - S0304-419X(15)00022-0 [pii]
LID - 10.1016/j.bbcan.2015.03.007 [doi]
AB  - Experimental, epidemiological, and clinical data from the last two decades have 
      each supported the hypothesis that aspirin possesses anticancer properties, and 
      that its use may also reduce the lifetime probability of developing or dying from 
      a number of cancers. Aspirin's ability to act on multiple key metabolic and 
      signaling pathways via inhibition of the cyclooxygenase (COX) enzyme, as well as 
      through COX-independent mechanisms, makes it particularly relevant in the fight 
      against cancer. A growing body of evidence indicates that aspirin may not only 
      reduce cancer risk, but also prevent metastasis and angiogenesis while slowing 
      the rate of mutation-inducing DNA damage. These emerging benefits of aspirin are 
      offset to some extent by the known risks of treatment, such as cardiovascular 
      events and gastrointestinal bleeding. However, it has been shown that 
      pre-treatment risk assessment of individual patients and the use of proton pump 
      inhibitors or Helicobacter pylori eradication therapy concomitantly with aspirin 
      treatment can reduce these potential risks. Thus, the significant benefits of 
      aspirin treatment, coupled with recent data concerning its risks, may prove to 
      tip the balance in favor of aspirin use in cancer prevention.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Usman, Muhammad Waqas
AU  - Usman MW
AD  - Cancer Institute, Second Affiliated Hospital, Dalian Medical University, Dalian, 
      Liaoning, China; Institute of Cancer Stem Cell, Dalian Medical University, 
      Dalian, Liaoning, China.
FAU - Luo, Fuwen
AU  - Luo F
AD  - Department of Acute Abdomen Surgery, Second Affiliated Hospital, Dalian Medical 
      University, Dalian, Liaoning, China.
FAU - Cheng, Hailing
AU  - Cheng H
AD  - Cancer Institute, Second Affiliated Hospital, Dalian Medical University, Dalian, 
      Liaoning, China; Department of Cancer Biology, Dana-Farber Cancer Institute 
      Harvard Medical School, Boston, MA, USA; Department of Surgery, Brigham and 
      Women's Hospital Harvard Medical School, Boston, MA, USA. Electronic address: 
      hailing_cheng@dfci.harvard.edu.
FAU - Zhao, Jean J
AU  - Zhao JJ
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute Harvard Medical 
      School, Boston, MA, USA; Department of Surgery, Brigham and Women's Hospital 
      Harvard Medical School, Boston, MA, USA; Department of Biological Chemistry and 
      Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. Electronic 
      address: Jean_zhao@dfci.harvard.edu.
FAU - Liu, Pixu
AU  - Liu P
AD  - Cancer Institute, Second Affiliated Hospital, Dalian Medical University, Dalian, 
      Liaoning, China; Institute of Cancer Stem Cell, Dalian Medical University, 
      Dalian, Liaoning, China; Department of Cancer Biology, Dana-Farber Cancer 
      Institute Harvard Medical School, Boston, MA, USA. Electronic address: 
      Pixu_liu@dlmedu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150402
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cyclooxygenase 1/biosynthesis
MH  - Cyclooxygenase Inhibitors/therapeutic use
MH  - DNA Damage/*drug effects
MH  - Humans
MH  - Neoplasms/*drug therapy/genetics/pathology
MH  - Neovascularization, Pathologic/drug therapy/pathology
MH  - Risk Assessment
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer
OT  - Chemoprevention
OT  - Cyclooxygenase
EDAT- 2015/04/07 06:00
MHDA- 2015/09/01 06:00
CRDT- 2015/04/06 06:00
PHST- 2014/12/13 00:00 [received]
PHST- 2015/03/05 00:00 [revised]
PHST- 2015/03/21 00:00 [accepted]
PHST- 2015/04/06 06:00 [entrez]
PHST- 2015/04/07 06:00 [pubmed]
PHST- 2015/09/01 06:00 [medline]
AID - S0304-419X(15)00022-0 [pii]
AID - 10.1016/j.bbcan.2015.03.007 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2015 Apr;1855(2):254-63. doi: 10.1016/j.bbcan.2015.03.007. 
      Epub 2015 Apr 2.

PMID- 2092574
OWN - NLM
STAT- MEDLINE
DCOM- 19910610
LR  - 20131121
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 25
IP  - 9
DP  - 1990
TI  - [The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in 
      rats].
PG  - 664-9
AB  - Guaiacol acetylsalicylate (GASL) has been shown to possess significant 
      anti-inflammatory, antipyretic and expectorant activities and has been used 
      clinically in chronic bronchitis with fairly good results. In the present work, 
      the absorption, distribution and excretion of metabolites of the drug were 
      studied in rats using quantitative TLC scanning technique. GASL was shown to be 
      unstable in rat gastrointestinal tract and guaiacol salicylate (GSLT) and 
      salicylic acid (SLA) were found in plasma. The plasma SLA concentration-time 
      curve obtained after oral administration of GASL to rats was shown to fit a one 
      compartment open model with the following pharmacokinetic parameters: T1/2ka = 
      1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 
      331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h The SLA concentration was 
      found to be high in muscle, moderate in spleen, testicle, kidney, lung, plasma, 
      heart and liver and low in brain. The GSLT concentration was found to be low in 
      plasma and organs. Within 24 h following ig administration of GASL the total SLA 
      excreted in urine and feces was 10.9 and 0.41 of the GASL dose, respectively.
FAU - Qu, S Y
AU  - Qu SY
AD  - Academy of Traditional Chinese Medicine, Changchun.
FAU - Li, W
AU  - Li W
FAU - Chen, Y L
AU  - Chen YL
FAU - Sun, Y
AU  - Sun Y
FAU - Zhang, Y Q
AU  - Zhang YQ
FAU - Hong, T
AU  - Hong T
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 0 (Salicylates)
RN  - 6JKA7MAH9C (Guaiacol)
RN  - 87-16-1 (guaiacol salicylate)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/metabolism/pharmacokinetics
MH  - Female
MH  - Guaiacol/analogs & derivatives
MH  - Male
MH  - Rats
MH  - Salicylates/metabolism
MH  - Tissue Distribution
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - Yao Xue Xue Bao. 1990;25(9):664-9.

PMID- 7930659
OWN - NLM
STAT- MEDLINE
DCOM- 19941116
LR  - 20131121
IS  - 0019-5847 (Print)
IS  - 0019-5847 (Linking)
VI  - 92
IP  - 6
DP  - 1994 Jun
TI  - A study of use of low dose aspirin in prevention of pregnancy induced 
      hypertension.
PG  - 188-91
AB  - Forty-six nulliparous women in third trimester of pregnancy with a raised blood 
      pressure of 30 mm Hg (systolic) or/and 15 mm Hg (diastolic) or both, over 
      baseline values were treated with 75 mg of aspirin per day. The results are 
      compared with another 48 age, height, weight, and gestational period matched 
      nulliparaous women with similar condition for trial selection, who were treated 
      as control. There is considerable more number of cases in the control group than 
      in aspirin treated group showing subsequent rise of BP, appearance of 
      proteinuria, and severe pre-eclamptic toxaemia. The aspirin treated group showed 
      increased mean gestational age at termination 39.4 +/- 2.6 weeks as against 38.2 
      +/- 3.4, increased foetal weight 2860 +/- 552 g as against 2540 +/- 720 g. No 
      case of neonatal haemorrhagic manifestations or congenital malformations were 
      seen. However not much result is obtained with aspirin therapy in cases with 
      established pregnancy induced hypertension or with proteinuria. Hence it is 
      concluded that aspirin therapy should be given to prevent pregnancy induced 
      hypertension. As predictability of other screening tests are not unequivocal, 
      criterion used in this series for screening may be used.
FAU - Roy, U K
AU  - Roy UK
AD  - Department of Obstetrics and Gynaecology, Sambhunath Pandit Hospital, Calcutta.
FAU - Pan, S
AU  - Pan S
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - India
TA  - J Indian Med Assoc
JT  - Journal of the Indian Medical Association
JID - 7505608
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hypertension/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*prevention & control
MH  - Pregnancy Trimester, Third
MH  - Treatment Outcome
EDAT- 1994/06/01 00:00
MHDA- 1994/06/01 00:01
CRDT- 1994/06/01 00:00
PHST- 1994/06/01 00:00 [pubmed]
PHST- 1994/06/01 00:01 [medline]
PHST- 1994/06/01 00:00 [entrez]
PST - ppublish
SO  - J Indian Med Assoc. 1994 Jun;92(6):188-91.

PMID- 1993051
OWN - NLM
STAT- MEDLINE
DCOM- 19910308
LR  - 20190612
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 174
IP  - 2
DP  - 1991 Jan 31
TI  - Thermal stability of hemoglobin crosslinked in the T-state by 
      bis(3,5-dibromosalicyl) fumarate.
PG  - 518-23
AB  - Bis(3,5-dibromosalicyl) fumarate was used to crosslink oxyhemoglobin between Lys 
      82 beta 1 and Lys 82 beta 2 (Walder, J. A., et al. (1979) Biochemistry 18, 4265) 
      and deoxyhemoglobin between Lys 99 alpha 1 and Lys 99 alpha 2 (Chatterjee R.Y., 
      et al. (1986) J. Biol. Chem. 261, 9929). Thermal denaturations demonstrated that 
      alpha crosslinked hemoglobin (alpha 99XLHb A) has the same stability as the beta 
      crosslinked one (beta 82XLHb A). Both alpha and beta crosslinked methemoglobins 
      have a denaturation temperature in 0.9 M guanidine of 57 degrees C compared to 41 
      degrees C of Hb A. The second product from the T-state crosslinking reaction was 
      found to be crosslinked between the beta chains by chain separation and amino 
      acid analysis. The possible positions for this crosslink are limited to the 
      bisphosphoglycerate binding site in the three-dimensional structure. Its 
      stability is comparable to that of the alpha 99XLHb A or beta 82XLHb A. These 
      modified hemoglobins are potential blood substitutes.
FAU - Yang, T
AU  - Yang T
AD  - Department of Chemistry, Loyola University of Chicago, Chicago, IL 60626.
FAU - Olsen, K W
AU  - Olsen KW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Amino Acids)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Macromolecular Substances)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 9004-22-2 (Globins)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acids/analysis
MH  - Aspirin/*analogs & derivatives/chemical synthesis/metabolism
MH  - Cross-Linking Reagents/*metabolism
MH  - Drug Stability
MH  - Globins/*metabolism
MH  - Hemoglobin A/metabolism
MH  - Hemoglobins/*metabolism
MH  - Humans
MH  - Macromolecular Substances
MH  - Protein Denaturation
MH  - Thermodynamics
EDAT- 1991/01/31 00:00
MHDA- 1991/01/31 00:01
CRDT- 1991/01/31 00:00
PHST- 1991/01/31 00:00 [pubmed]
PHST- 1991/01/31 00:01 [medline]
PHST- 1991/01/31 00:00 [entrez]
AID - 0006-291X(91)91447-K [pii]
AID - 10.1016/0006-291x(91)91447-k [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1991 Jan 31;174(2):518-23. doi: 
      10.1016/0006-291x(91)91447-k.

PMID- 1927946
OWN - NLM
STAT- MEDLINE
DCOM- 19911029
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 68
IP  - 9
DP  - 1991 Oct 1
TI  - Effects of low-dose aspirin on restenosis after coronary angioplasty.
PG  - 874-8
AB  - After angioplasty of a previously untreated native coronary artery and after 2 
      weeks of aspirin therapy, 216 subjects (aged less than 70 years without acute 
      infarction) were randomized to treatment with soluble aspirin, 100 mg/day, or 
      placebo to study the effect on restenosis. Follow-up, defined as angiography at 6 
      months, earlier angiographic restenosis or coronary bypass surgery was completed 
      by 108 aspirin- and 104 placebo-treated patients. Restenosis (stenosis greater 
      than or equal to 50% plus loss of greater than or equal to 50% of gain, or 
      surgery) occurred in 38 (35%) aspirin- and 45 (43%) placebo-treated subjects (p = 
      not significant). No patient died. Restenosis occurred in 42 of 168 (25%) 
      aspirin- and 51 of 135 (38%) placebo-treated lesions (p less than 0.025). 
      Aspirin-treated lesions (n = 163) had lost 16 +/- 22% (mean +/- standard 
      deviation) of lumen and placebo-treated lesions 22 +/- 25% of lumen (n = 134) at 
      angiography (p less than 0.01). There were more left anterior descending lesions 
      in the placebo group and these had a higher recurrence rate than other lesions. 
      The beneficial effect of aspirin was not dependent on this, although significance 
      was reduced in subgroup analysis. Loss of lumen in left anterior descending 
      lesions was 20 +/- 24% (n = 57) in the aspirin-treated and 27 +/- 25% (n = 70) in 
      the placebo-treated lesions (p less than 0.1). It is concluded that there is a 
      small beneficial effect of low-dose aspirin on restenosis after coronary 
      angioplasty.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Taylor, R R
AU  - Taylor RR
AD  - Department of Cardiology, Royal Perth Hospital, Western Australia.
FAU - Gibbons, F A
AU  - Gibbons FA
FAU - Cope, G D
AU  - Cope GD
FAU - Cumpston, G N
AU  - Cumpston GN
FAU - Mews, G C
AU  - Mews GC
FAU - Luke, P
AU  - Luke P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Constriction, Pathologic/prevention & control
MH  - Coronary Angiography
MH  - Coronary Disease/diagnostic imaging/*prevention & control/therapy
MH  - Coronary Vessels/pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Vascular Patency/*drug effects
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
AID - 0002-9149(91)90402-7 [pii]
AID - 10.1016/0002-9149(91)90402-7 [doi]
PST - ppublish
SO  - Am J Cardiol. 1991 Oct 1;68(9):874-8. doi: 10.1016/0002-9149(91)90402-7.

PMID- 8031939
OWN - NLM
STAT- MEDLINE
DCOM- 19940812
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 12
IP  - 3
DP  - 1994 Mar
TI  - Comparison of assay methods by second-derivative spectroscopy, colorimetry and 
      fluorescence spectroscopy of salicylic acid in aspirin preparations with a 
      high-performance liquid chromatographic method.
PG  - 383-7
AB  - Second-derivative spectroscopy, colorimetry and fluorescence spectroscopy have 
      been compared with a high-performance liquid chromatographic (HPLC) method for 
      the assay of salicylic acid in preparations of aspirin. Results are presented for 
      the linearity, sensitivity and reproducibility of these methods. The 
      second-derivative spectroscopic and the HPLC methods were acceptable in terms of 
      linearity, sensitivity and inter-day reproducibility and were convenient for the 
      routine analysis of salicylic acid in aspirin preparations.
FAU - Torrado, S
AU  - Torrado S
AD  - Department of Pharmaceutical Technology, Faculty of Pharmacy, Complutense 
      University, Madrid, Spain.
FAU - Torrado, S
AU  - Torrado S
FAU - Cadórniga, R
AU  - Cadórniga R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis/*chemistry
MH  - *Chromatography, High Pressure Liquid
MH  - Colorimetry
MH  - Reproducibility of Results
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Spectrometry, Fluorescence
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets/chemistry
EDAT- 1994/03/01 00:00
MHDA- 1994/03/01 00:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 1994/03/01 00:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
AID - 0731-7085(94)90015-9 [pii]
AID - 10.1016/0731-7085(94)90015-9 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1994 Mar;12(3):383-7. doi: 10.1016/0731-7085(94)90015-9.

PMID- 18983514
OWN - NLM
STAT- MEDLINE
DCOM- 20090209
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 6
IP  - 12
DP  - 2008 Dec
TI  - Aspirin 'resistance': role of pre-existent platelet reactivity and correlation 
      between tests.
PG  - 2035-44
LID - 10.1111/j.1538-7836.2008.03184.x [doi]
AB  - BACKGROUND: Aspirin 'resistance' is a widely used term for hyporesponsiveness to 
      aspirin in a platelet function test. Serum thromboxane (TX) B(2) is the most 
      specific test of aspirin's effect on platelets. OBJECTIVES: (i) To examine the 
      role of pre-existent platelet hyperreactivity in aspirin 'resistance'. (ii) To 
      determine the correlation between aspirin resistance defined by serum TXB(2) and 
      other assays of platelet function. METHODS: To enable pre-aspirin samples to be 
      drawn, platelet function was measured in normal subjects (n = 165) before and 
      after aspirin 81 mg daily for seven days. RESULTS: The proportion of the 
      post-aspirin platelet function predicted by the pre-aspirin platelet function was 
      28.3 +/- 7.5% (mean +/- asymptotic standard error) for serum TXB(2), 39.3 +/- 
      6.8% for urinary 11-dehydro TXB(2), 4.4 +/- 7.7% for arachidonic acid-induced 
      platelet aggregation, 40.4 +/- 7.1% for adenosine diphosphate-induced platelet 
      aggregation, 26.3 +/- 9.2% for the VerifyNow Aspirin Assay, and 45.0 +/- 10.9% 
      for the TEG PlateletMapping System with arachidonic acid. There was poor 
      agreement between aspirin-resistant subjects identified by serum TXB(2) vs. 
      aspirin-resistant subjects identified by the other five assays, irrespective of 
      whether the analysis was based on categorical or continuous variables. Platelet 
      count correlated with pre-aspirin serum TXB(2) and VerifyNow Aspirin Assay, but 
      not with any post-aspirin platelet function test. CONCLUSIONS: (i) Aspirin 
      'resistance' (i.e. hyporesponsiveness to aspirin in a laboratory test) is in part 
      unrelated to aspirin but is the result of underlying platelet hyperreactivity 
      prior to the institution of aspirin therapy. (ii) Aspirin resistance defined by 
      serum TXB(2) shows a poor correlation with aspirin resistance defined by other 
      commonly used assays.
FAU - Frelinger, A L
AU  - Frelinger AL
AD  - Department of Pediatrics, Center for Platelet Function Studies, University of 
      Massachusetts Medical School, Worcester, MA 01655, USA.
FAU - Li, Y
AU  - Li Y
FAU - Linden, M D
AU  - Linden MD
FAU - Tarnow, I
AU  - Tarnow I
FAU - Barnard, M R
AU  - Barnard MR
FAU - Fox, M L
AU  - Fox ML
FAU - Michelson, A D
AU  - Michelson AD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081007
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacokinetics
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - *Platelet Activation
MH  - Platelet Function Tests/methods/*standards
MH  - Sensitivity and Specificity
MH  - Thromboxane A2/pharmacology
MH  - Young Adult
EDAT- 2008/11/06 09:00
MHDA- 2009/02/10 09:00
CRDT- 2008/11/06 09:00
PHST- 2008/11/06 09:00 [pubmed]
PHST- 2009/02/10 09:00 [medline]
PHST- 2008/11/06 09:00 [entrez]
AID - S1538-7836(22)13326-X [pii]
AID - 10.1111/j.1538-7836.2008.03184.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2008 Dec;6(12):2035-44. doi: 10.1111/j.1538-7836.2008.03184.x. 
      Epub 2008 Oct 7.

PMID- 6378231
OWN - NLM
STAT- MEDLINE
DCOM- 19840913
LR  - 20190511
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 17
IP  - 6
DP  - 1984 Jun
TI  - Aspirin metabolism and efficacy in postoperative dental pain.
PG  - 697-701
AB  - Aspirin 1200 mg was compared with placebo in a randomised, double-blind, 
      crossover study in 15 patients with postoperative pain after removal of impacted 
      lower third molars. Over a 5 h investigation period, patients reported 
      significantly less pain (P less than 0.01) after treatment with aspirin, than 
      after treatment with placebo. Peak concentrations of aspirin occurred at 15 min 
      after dosage. Significant negative correlations were observed between plasma 
      aspirin esterase activity and both AUC aspirin (r = -0.904, P less than 0.001) 
      and AUC analgesia (r = -0.91, P less than 0.001). Similarly, a significant 
      correlation was observed between AUC aspirin and AUC analgesia (r = 0.96, P less 
      than 0.001). Evidence from this study would suggest that an individual's pain 
      relief in postoperative dental pain is determined by the rate of aspirin 
      hydrolysis to salicylate.
FAU - Seymour, R A
AU  - Seymour RA
FAU - Williams, F M
AU  - Williams FM
FAU - Ward, A
AU  - Ward A
FAU - Rawlins, M D
AU  - Rawlins MD
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.- (acetylsalicylic acid hydrolase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/blood/metabolism/*therapeutic use
MH  - Carboxylic Ester Hydrolases/blood
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Pain, Postoperative/*drug therapy
MH  - Random Allocation
MH  - Time Factors
MH  - *Tooth Extraction
MH  - Tooth, Impacted/surgery
PMC - PMC1463421
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1984.tb02406.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1984 Jun;17(6):697-701. doi: 
      10.1111/j.1365-2125.1984.tb02406.x.

PMID- 1404679
OWN - NLM
STAT- MEDLINE
DCOM- 19921106
LR  - 20190819
IS  - 0741-5214 (Print)
IS  - 0741-5214 (Linking)
VI  - 16
IP  - 4
DP  - 1992 Oct
TI  - Adverse effects of aspirin in the treatment of asymptomatic carotid artery 
      stenosis. The VA Cooperative Asymptomatic Carotid Artery Stenosis Study Group.
PG  - 588-97; discussion 597-600
AB  - We prospectively analyzed adverse effects of aspirin in a multicentered 
      cooperative study undertaken to determine the role of endarterectomy in the 
      treatment of asymptomatic carotid artery stenosis. Persons with active peptic 
      ulcer disease or known intolerance to aspirin were excluded from the study. 
      Patients initially received 650 mg aspirin twice daily. After a 54-month 
      recruitment period, 444 patients in 11 centers were followed up for as many as 8 
      years (mean 47.9 +/- 27.9 months). Patients intolerant to 650 mg aspirin twice 
      daily could be switched to enteric-coated aspirin or "low-dose" aspirin (80 to 
      325 mg daily). At the conclusion of the study, we performed a cross-sectional 
      analysis of aspirin usage and complications. Overall, there were 757 episodes 
      reported wherein adjustments in study medications were made, including cessation 
      and change in formulation or dosage. At the conclusion of the study, at the time 
      of death, or at occurrence of a neurologic end point, 16% of patients were off 
      medication entirely, 51% had been converted to enteric-coated aspirin, and only 
      33% were taking regular aspirin with 27% of those having been placed on a reduced 
      dosage. Adverse reactions were ascertained from 4954 patient visit records. In 
      all there were a total of 837 adverse reactions reported, or one in every 5.9 
      visits. The most frequently reported reaction was heartburn or stomach pain for 
      which 372 episodes were reported in 184 (42%) patients. Nausea or vomiting 
      occurred on 79 occasions in 58 patients, and bloody stools were reported 52 times 
      in 41 patients. We conclude that high-dose aspirin therapy for asymptomatic 
      carotid artery stenosis is poorly tolerated and that adverse reactions even to 
      low-dose enteric-coated aspirin are common even in patients screened for aspirin 
      intolerance.
FAU - Krupski, W C
AU  - Krupski WC
AD  - VA Cooperative Studies Program Coordinating Center (CSPCC), Perry Point, Md.
FAU - Weiss, D G
AU  - Weiss DG
FAU - Rapp, J H
AU  - Rapp JH
FAU - Corson, J D
AU  - Corson JD
FAU - Hobson, R W 2nd
AU  - Hobson RW 2nd
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Carotid Stenosis/*drug therapy/surgery
MH  - Chi-Square Distribution
MH  - Combined Modality Therapy
MH  - Endarterectomy, Carotid
MH  - Humans
MH  - Middle Aged
MH  - Prospective Studies
MH  - Tablets, Enteric-Coated
EDAT- 1992/10/01 00:00
MHDA- 2001/09/06 10:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 2001/09/06 10:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - S0741521492005330 [pii]
AID - 10.1067/mva.1992.39246 [doi]
PST - ppublish
SO  - J Vasc Surg. 1992 Oct;16(4):588-97; discussion 597-600. doi: 
      10.1067/mva.1992.39246.

PMID- 10808182
OWN - NLM
STAT- MEDLINE
DCOM- 20000607
LR  - 20131121
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 105
IP  - 5
DP  - 2000 May
TI  - Rapid oral challenge-desensitization for patients with aspirin-related 
      urticaria-angioedema.
PG  - 997-1001
AB  - BACKGROUND: Acetylsalicylic acid (ASA), commonly known as aspirin, is indicated 
      in the treatment of coronary artery disease (CAD). Many patients are denied 
      treatment with ASA because of a history of ASA or nonsteroidal anti-inflammatory 
      drug (NSAID)-induced urticaria or angioedema. OBJECTIVE: We sought to develop a 
      safe and practical protocol to allow the administration of ASA to patients with a 
      history of ASA- or NSAID-induced urticaria-angioedema. METHODS: Eleven subjects 
      with a history of ASA- or NSAID-induced urticaria-angioedema were 
      challenged-desensitized by oral protocols based on rapidly escalating doses of 
      ASA. Most had CAD, one had a history of pulmonary embolism, and one had 
      refractory chronic sinusitis and asthma. Starting doses ranged from 0.1 to 10 mg 
      and were administered at intervals of 10 to 30 minutes. Dosing was individualized 
      for each patient but followed this general sequence (in milligrams): 0.1, 0.3, 1, 
      3, 10, 20, 40, 81, 162, 325. RESULTS: Nine patients tolerated the procedure 
      without adverse effects and continued taking ASA for periods ranging from 1 to 24 
      months, without development of urticaria or angioedema. A patient who had a 
      history of chronic idiopathic urticaria in addition to aspirin-induced urticaria 
      had chest tightness during the protocol. Another patient who had continuing 
      urticaria and angioedema associated with antithyroid antibodies developed 
      angioedema several hours after completing the protocol. CONCLUSION: In patients 
      with historical ASA- or NSAID-induced urticaria-angioedema reactions but who did 
      not have urticaria and angioedema independent of ASA/NSAID, rapid oral 
      challenge-desensitization to ASA was performed safely and permitted patients with 
      CAD and other diseases to receive treatment with ASA.
FAU - Wong, J T
AU  - Wong JT
AD  - Clinical Immunology and Allergy Units, Massachusetts General Hospital, Boston, MA 
      02114, USA.
FAU - Nagy, C S
AU  - Nagy CS
FAU - Krinzman, S J
AU  - Krinzman SJ
FAU - Maclean, J A
AU  - Maclean JA
FAU - Bloch, K J
AU  - Bloch KJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angioedema/*chemically induced
MH  - Aspirin/*adverse effects/immunology/therapeutic use
MH  - Coronary Disease/drug therapy
MH  - Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Urticaria/*chemically induced
EDAT- 2000/05/16 09:00
MHDA- 2000/06/10 09:00
CRDT- 2000/05/16 09:00
PHST- 2000/05/16 09:00 [pubmed]
PHST- 2000/06/10 09:00 [medline]
PHST- 2000/05/16 09:00 [entrez]
AID - S0091-6749(00)80024-X [pii]
AID - 10.1067/mai.2000.104571 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2000 May;105(5):997-1001. doi: 10.1067/mai.2000.104571.

PMID- 20394106
OWN - NLM
STAT- MEDLINE
DCOM- 20100910
LR  - 20131121
IS  - 1860-7187 (Electronic)
IS  - 1860-7179 (Linking)
VI  - 5
IP  - 6
DP  - 2010 Jun 7
TI  - Fragment-based lead discovery: screening and optimizing fragments for thermolysin 
      inhibition.
PG  - 930-40
LID - 10.1002/cmdc.201000084 [doi]
AB  - Fragment-based drug discovery has gained a foothold in today's lead 
      identification processes. We present the application of in silico fragment-based 
      screening for the discovery of novel lead compounds for the metalloendoproteinase 
      thermolysin. We have chosen thermolysin to validate our screening approach as it 
      is a well-studied enzyme and serves as a model system for other proteases. A 
      protein-targeted virtual library was designed and screening was carried out using 
      the program AutoDock. Two fragment hits could be identified. For one of them, the 
      crystal structure in complex with thermolysin is presented. This compound was 
      selected for structure-based optimization of binding affinity and improvement of 
      ligand efficiency, while concomitantly keeping the fragment-like properties of 
      the initial hit. Redesigning the zinc coordination group revealed a novel class 
      of fragments possessing K(i) values as low as 128 microM, thus they provide a 
      good starting point for further hit evolution in a tailored lead design.
FAU - Englert, Lisa
AU  - Englert L
AD  - Philipps-Universität Marburg, Institut für Pharmazeutische Chemie, Marbacher Weg 
      6, 35032 Marburg, Germany.
FAU - Silber, Katrin
AU  - Silber K
FAU - Steuber, Holger
AU  - Steuber H
FAU - Brass, Sascha
AU  - Brass S
FAU - Over, Björn
AU  - Over B
FAU - Gerber, Hans-Dieter
AU  - Gerber HD
FAU - Heine, Andreas
AU  - Heine A
FAU - Diederich, Wibke E
AU  - Diederich WE
FAU - Klebe, Gerhard
AU  - Klebe G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - ChemMedChem
JT  - ChemMedChem
JID - 101259013
RN  - 0 (Protease Inhibitors)
RN  - EC 3.4.24.27 (Thermolysin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/chemical synthesis/pharmacology
MH  - Binding Sites
MH  - Computer Simulation
MH  - Crystallography, X-Ray
MH  - Databases, Protein
MH  - Drug Design
MH  - Protease Inhibitors/*chemistry
MH  - Protein Structure, Tertiary
MH  - Software
MH  - Thermolysin/*antagonists & inhibitors/metabolism
EDAT- 2010/04/16 06:00
MHDA- 2010/09/11 06:00
CRDT- 2010/04/16 06:00
PHST- 2010/04/16 06:00 [entrez]
PHST- 2010/04/16 06:00 [pubmed]
PHST- 2010/09/11 06:00 [medline]
AID - 10.1002/cmdc.201000084 [doi]
PST - ppublish
SO  - ChemMedChem. 2010 Jun 7;5(6):930-40. doi: 10.1002/cmdc.201000084.

PMID- 2724047
OWN - NLM
STAT- MEDLINE
DCOM- 19890629
LR  - 20131121
IS  - 0047-2166 (Print)
IS  - 0047-2166 (Linking)
VI  - 44
IP  - 1
DP  - 1989 Jan-Feb
TI  - [Bioavailability of acetylsalicylic acid administered orally or rectally in the 
      rabbit].
PG  - 5-10
AB  - The aim of this study is to compare the bioavailability of acetylsalicylic acid 
      administered rectally in suppositories form and orally in tablets form to the 
      rabbit. Acetylsalicylic acid was given to 8 males rabbits rectally and orally in 
      a balanced crossover design with 15 days of interval between each study. In blood 
      samples, acetylsalicylic acid is determined by Trinder's method. It has been 
      established that the rectal route has a faster absorption than the oral route 
      however it displayed a more intense first pass effect than that of the oral 
      route.
FAU - Fehri, B
AU  - Fehri B
FAU - Aiache, J M
AU  - Aiache JM
FAU - Boukef, K
AU  - Boukef K
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Biodisponibilité de l'acide acétylsalicylique administré par voie orale et 
      rectale chez le lapin.
PL  - Belgium
TA  - J Pharm Belg
JT  - Journal de pharmacie de Belgique
JID - 0375351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Administration, Rectal
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Biological Availability
MH  - Male
MH  - Rabbits
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - J Pharm Belg. 1989 Jan-Feb;44(1):5-10.

PMID- 14963632
OWN - NLM
STAT- MEDLINE
DCOM- 20050630
LR  - 20160512
IS  - 1618-2642 (Print)
IS  - 1618-2642 (Linking)
VI  - 378
IP  - 7
DP  - 2004 Apr
TI  - Kinetic method for acetylsalicylic acid determination based on its inhibitory 
      effect upon the catalytic decomposition of H(2)O(2).
PG  - 1868-72
AB  - The catalytic reaction of catalase was investigated, by means of a Clark oxygen 
      sensor, in the presence of various concentrations of acetylsalicylic acid. 
      Michaelis-Menten kinetic parameters were determined from Lineweaver-Burk plots, 
      obtained in the absence and in the presence of the inhibitor. The inhibition 
      pattern, suggested by the Lineweave-Burk plots, corresponds to a fully mixed 
      inhibition mechanism. A kinetic method, based on the indicator reaction: 
      [Formula: see text], was developed for the quantitative determination of 
      acetylsalicylic acid. Calibration graphs of the reciprocal value of first-order 
      rate constant versus acetylsalicylic concentration covered the concentration 
      range (2.99-19.98)x10(-4) mol/L, while the detection limit was 4.12x10(-4) mol/L 
      acetylsalicylic acid with a standard deviation of 2.1x10(-5) mol/L.
FAU - Mureşanu, Claudia
AU  - Mureşanu C
AD  - Faculty of Chemistry and Chemical Engineering, Babeş-Bolyai University, 11 Arany 
      Janos Street, 3400, Cluj-Napoca, Romania. muresanu@ptc.tu-graz.ac.at
FAU - Copolovici, Lucian
AU  - Copolovici L
LA  - eng
PT  - Journal Article
DEP - 20040212
PL  - Germany
TA  - Anal Bioanal Chem
JT  - Analytical and bioanalytical chemistry
JID - 101134327
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - EC 1.11.1.6 (Catalase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/pharmacology
MH  - Catalase/antagonists & inhibitors/chemistry
MH  - Catalysis
MH  - Hydrogen Peroxide/*chemistry
MH  - Kinetics
EDAT- 2004/02/14 05:00
MHDA- 2005/07/01 09:00
CRDT- 2004/02/14 05:00
PHST- 2003/07/11 00:00 [received]
PHST- 2003/12/09 00:00 [revised]
PHST- 2003/12/10 00:00 [accepted]
PHST- 2004/02/14 05:00 [pubmed]
PHST- 2005/07/01 09:00 [medline]
PHST- 2004/02/14 05:00 [entrez]
AID - 10.1007/s00216-003-2470-4 [doi]
PST - ppublish
SO  - Anal Bioanal Chem. 2004 Apr;378(7):1868-72. doi: 10.1007/s00216-003-2470-4. Epub 
      2004 Feb 12.

PMID- 11712638
OWN - NLM
STAT- MEDLINE
DCOM- 20020509
LR  - 20191105
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 23
IP  - 5
DP  - 2001 Jun
TI  - Modeling drug absorption from enteric-coated granules.
PG  - 213-7
AB  - A system-approach-based method is proposed for modeling drug absorption from 
      enteric-coated granules. This method was exemplified using enteric-coated 
      granules of aspirin given to healthy subjects. Based on the results obtained, it 
      can be concluded that absorption of salicylate from the granules can be 
      sufficiently described using a first-order linear model with an absorption rate 
      constant of salicylate similar to that reported for an aqueous solution of 
      aspirin administered orally to healthy subjects. The method proposed in this 
      study may contribute to the working library of modeling techniques in 
      pharmacokinetics since it allows direct modeling of the drug absorption process 
      and estimates the absorption rate constant of a drug when its behavior in the 
      body is significantly influenced by a gastric emptying process. i.e., when the 
      absorption rate constant of the drug cannot be estimated on the basis of its 
      cumulative absorption-time profile.
FAU - Dedík, L
AU  - Dedík L
AD  - Faculty of Mechanical Engineering, Slovak University of Technology, Bratislava.
FAU - Durisová, M
AU  - Durisová M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - 0 (Delayed-Action Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Delayed-Action Preparations
MH  - Humans
MH  - *Intestinal Absorption
MH  - Models, Biological
EDAT- 2001/11/20 10:00
MHDA- 2002/05/10 10:01
CRDT- 2001/11/20 10:00
PHST- 2001/11/20 10:00 [pubmed]
PHST- 2002/05/10 10:01 [medline]
PHST- 2001/11/20 10:00 [entrez]
AID - 662114 [pii]
AID - 10.1358/mf.2001.23.5.662114 [doi]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 2001 Jun;23(5):213-7. doi: 
      10.1358/mf.2001.23.5.662114.

PMID- 2390952
OWN - NLM
STAT- MEDLINE
DCOM- 19901002
LR  - 20131121
IS  - 0012-835X (Print)
IS  - 0012-835X (Linking)
VI  - 67
IP  - 5
DP  - 1990 May
TI  - Acetylsalicylic acid or paracetamol?
PG  - 302-10
AB  - Paracetamol, a widely used non-narcotic analgesic, has the same analgesic, and 
      antipyretic efficacy as acetylsalicylic acid (ASA). In contrast to ASA, 
      paracetamol has traditionally been claimed to have little or no anti-inflammatory 
      effect. There is, however, increasing support for the view that paracetamol has 
      anti-inflammatory activity and reduces pain and swelling in inflammatory 
      conditions other than rheumatoid arthritis. Overall, paracetamol seems to be 
      equally effective as ASA. Since ASA has a greater potential for adverse effects, 
      paracetamol is increasingly preferred to ASA, particularly in children.
FAU - Mburu, D N
AU  - Mburu DN
AD  - Department of Public Health, Pharmacology and Toxicology, Faculty of Veterinary 
      Medicine, College of Agriculture and Veterinary Sciences, University of Nairobi, 
      Kabete.
FAU - Maitho, T E
AU  - Maitho TE
FAU - Lökken, P
AU  - Lökken P
LA  - eng
PT  - Journal Article
PL  - Kenya
TA  - East Afr Med J
JT  - East African medical journal
JID - 0372766
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/pharmacokinetics/*pharmacology
MH  - Adult
MH  - Aspirin/adverse effects/pharmacokinetics/*pharmacology
MH  - Child
MH  - Humans
EDAT- 1990/05/01 00:00
MHDA- 1990/05/01 00:01
CRDT- 1990/05/01 00:00
PHST- 1990/05/01 00:00 [pubmed]
PHST- 1990/05/01 00:01 [medline]
PHST- 1990/05/01 00:00 [entrez]
PST - ppublish
SO  - East Afr Med J. 1990 May;67(5):302-10.

PMID- 22893203
OWN - NLM
STAT- MEDLINE
DCOM- 20121108
LR  - 20211021
IS  - 0080-0015 (Print)
IS  - 0080-0015 (Linking)
VI  - 191
DP  - 2013
TI  - Aspirin in prevention of sporadic colorectal cancer: current clinical evidence 
      and overall balance of risks and benefits.
PG  - 121-42
LID - 10.1007/978-3-642-30331-9_7 [doi]
AB  - In addition to longstanding evidence from observational studies, evidence from 
      randomised trials of the effectiveness of aspirin for chemoprevention of 
      colorectal cancer has increased substantially in recent years. Trials have shown 
      that daily aspirin reduces the risk of any recurrent colorectal adenoma by 17 % 
      and advanced adenoma by 28 %, and that daily aspirin for about 5 years reduces 
      incidence and mortality due to colorectal cancer by 30-40 % after 20 years of 
      follow-up, and reduces the 20-year risk of all-cause cancer mortality by about 20 
      %. Recent evidence also shows that the risk of major bleeding on aspirin 
      diminishes with prolonged use, suggesting that the balance of risk and benefit 
      favours the use of daily aspirin in primary prevention of colorectal and other 
      cancers. Updated clinical guidelines are currently awaited.
FAU - Rothwell, Peter M
AU  - Rothwell PM
AD  - Nuffield Department of Clinical Neuroscience, John Radcliffe Hospital, Oxford, 
      OX39DU, UK. peter.rothwell@clneuro.ox.ac.uk
LA  - eng
GR  - 095626/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Recent Results Cancer Res
JT  - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans 
      les recherches sur le cancer
JID - 0044671
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Colorectal Neoplasms/*prevention & control
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Risk
EDAT- 2012/08/16 06:00
MHDA- 2012/11/09 06:00
CRDT- 2012/08/16 06:00
PHST- 2012/08/16 06:00 [entrez]
PHST- 2012/08/16 06:00 [pubmed]
PHST- 2012/11/09 06:00 [medline]
AID - 10.1007/978-3-642-30331-9_7 [doi]
PST - ppublish
SO  - Recent Results Cancer Res. 2013;191:121-42. doi: 10.1007/978-3-642-30331-9_7.

PMID- 16168276
OWN - NLM
STAT- MEDLINE
DCOM- 20051222
LR  - 20131121
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 46
IP  - 6
DP  - 2005 Sep 20
TI  - Aspirin use in chronic heart failure: what should we recommend to the 
      practitioner?
PG  - 963-6
AB  - There has been ongoing controversy as to whether aspirin should be used in 
      patients with chronic heart failure (CHF). The argument for aspirin is that many 
      patients have underlying coronary disease, and aspirin prevents reinfarction and 
      other vascular events. Arguments against the routine use of aspirin are that many 
      CHF patients do not have underlying coronary disease, and that the benefit of 
      aspirin lessens after the first 6 to 12 months after infarction. Also, several 
      analyses suggest that aspirin may actually worsen outcomes in CHF patients, 
      possibly because it inhibits prostaglandins, with resulting adverse hemodynamic 
      and renal effects. Two recent prospective randomized studies have found that 
      aspirin is associated with more frequent hospitalizations for worsening heart 
      failure, although it did not have an adverse effect on vascular events. These 
      results suggest that aspirin should not be routinely used in CHF patients and be 
      avoided in those with refractory CHF, but that it may be beneficial in patients 
      with recent infarction or multiple vascular risk factors.
FAU - Massie, Barry M
AU  - Massie BM
AD  - Department of Medicine and Cardiovascular Research Institute, University of 
      California, San Francisco, California, USA. barry.massie@med.va.gov
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Practice Guidelines as Topic
EDAT- 2005/09/20 09:00
MHDA- 2005/12/24 09:00
CRDT- 2005/09/20 09:00
PHST- 2004/08/02 00:00 [received]
PHST- 2004/10/14 00:00 [revised]
PHST- 2004/10/25 00:00 [accepted]
PHST- 2005/09/20 09:00 [pubmed]
PHST- 2005/12/24 09:00 [medline]
PHST- 2005/09/20 09:00 [entrez]
AID - S0735-1097(05)01516-0 [pii]
AID - 10.1016/j.jacc.2004.10.082 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2005 Sep 20;46(6):963-6. doi: 10.1016/j.jacc.2004.10.082.

PMID- 26503631
OWN - NLM
STAT- MEDLINE
DCOM- 20170710
LR  - 20220330
IS  - 1468-3288 (Electronic)
IS  - 0017-5749 (Print)
IS  - 0017-5749 (Linking)
VI  - 66
IP  - 2
DP  - 2017 Feb
TI  - Spectral biomarkers for chemoprevention of colonic neoplasia: a 
      placebo-controlled double-blinded trial with aspirin.
PG  - 285-292
LID - 10.1136/gutjnl-2015-309996 [doi]
AB  - OBJECTIVE: A major impediment to translating chemoprevention to clinical practice 
      has been lack of intermediate biomarkers. We previously reported that rectal 
      interrogation with low-coherence enhanced backscattering spectroscopy (LEBS) 
      detected microarchitectural manifestations of field carcinogenesis. We now wanted 
      to ascertain if reversion of two LEBS markers spectral slope (SPEC) and fractal 
      dimension (FRAC) could serve as a marker for chemopreventive efficacy. DESIGN: We 
      conducted a multicentre, prospective, randomised, double-blind 
      placebo-controlled, clinical trial in subjects with a history of colonic 
      neoplasia who manifested altered SPEC/FRAC in histologically normal colonic 
      mucosa. Subjects (n=79) were randomised to 325 mg aspirin or placebo. The primary 
      endpoint changed in FRAC and SPEC spectral markers after 3 months. Mucosal levels 
      of prostaglandin E2 (PGE2) and UDP-glucuronosyltransferase (UGT)1A6 genotypes 
      were planned secondary endpoints. RESULTS: At 3 months, the aspirin group 
      manifested alterations in SPEC (48.9%, p=0.055) and FRAC (55.4%, p=0.200) with 
      the direction towards non-neoplastic status. As a measure of aspirin's 
      pharmacological efficacy, we assessed changes in rectal PGE2 levels and noted 
      that it correlated with SPEC and FRAC alterations (R=-0.55, p=0.01 and R=0.57, 
      p=0.009, respectively) whereas there was no significant correlation in placebo 
      specimens. While UGT1A6 subgroup analysis did not achieve statistical 
      significance, the changes in SPEC and FRAC to a less neoplastic direction 
      occurred only in the variant consonant with epidemiological evidence of 
      chemoprevention. CONCLUSIONS: We provide the first proof of concept, albeit 
      somewhat underpowered, that spectral markers reversion mirrors antineoplastic 
      efficacy providing a potential modality for titration of agent type/dose to 
      optimise chemopreventive strategies in clinical practice. TRIAL NUMBER: 
      NCT00468910.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://www.bmj.com/company/products-services/rights-and-licensing/.
FAU - Roy, Hemant K
AU  - Roy HK
AD  - Department of Medicine, Boston University Medical Center, Boston, Massachusetts, 
      USA.
FAU - Turzhitsky, Vladimir
AU  - Turzhitsky V
AD  - Department of Biomedical Engineering, Robert H. Lurie Cancer Center, Northwestern 
      University, Chicago, Illinois, USA.
FAU - Wali, Ramesh
AU  - Wali R
AD  - Department of Medicine, Boston University Medical Center, Boston, Massachusetts, 
      USA.
FAU - Radosevich, Andrew J
AU  - Radosevich AJ
AD  - Department of Biomedical Engineering, Robert H. Lurie Cancer Center, Northwestern 
      University, Chicago, Illinois, USA.
FAU - Jovanovic, Borko
AU  - Jovanovic B
AD  - Department of Preventive Medicine, Robert H. Lurie Cancer Center, Northwestern 
      University, Chicago, Illinois, USA.
FAU - Della'Zanna, Gary
AU  - Della'Zanna G
AD  - Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, 
      USA.
FAU - Umar, Asad
AU  - Umar A
AD  - Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, 
      USA.
FAU - Rubin, David T
AU  - Rubin DT
AD  - Department of Medicine, The University of Chicago Medical Center, Chicago, 
      Illinois, USA.
FAU - Goldberg, Michael J
AU  - Goldberg MJ
AD  - Department of Medicine, NorthShore University Health Systems, Evanston, Illinois, 
      USA.
FAU - Bianchi, Laura
AU  - Bianchi L
AD  - Department of Medicine, NorthShore University Health Systems, Evanston, Illinois, 
      USA.
FAU - De La Cruz, Mart
AU  - De La Cruz M
AD  - Department of Medicine, Boston University Medical Center, Boston, Massachusetts, 
      USA.
FAU - Bogojevic, Andrej
AU  - Bogojevic A
AD  - Department of Medicine, NorthShore University Health Systems, Evanston, Illinois, 
      USA.
FAU - Helenowski, Irene B
AU  - Helenowski IB
AD  - Department of Preventive Medicine, Robert H. Lurie Cancer Center, Northwestern 
      University, Chicago, Illinois, USA.
FAU - Rodriguez, Luz
AU  - Rodriguez L
AD  - Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, 
      USA.
FAU - Chatterton, Robert
AU  - Chatterton R
AD  - Department of Obstetrics and Gynecology, Robert H. Lurie Cancer Center, 
      Northwestern University, Chicago, Illinois, USA.
FAU - Skripkauskas, Silvia
AU  - Skripkauskas S
AD  - Department of Medicine, Robert H. Lurie Cancer Center, Northwestern University, 
      Chicago, Illinois, USA.
FAU - Page, Katherine
AU  - Page K
AD  - Department of Medicine, Robert H. Lurie Cancer Center, Northwestern University, 
      Chicago, Illinois, USA.
FAU - Weber, Christopher R
AU  - Weber CR
AD  - Department of Pathology, The University of Chicago Medical Center, Chicago, 
      Illinois, USA.
FAU - Huang, Xiaoke
AU  - Huang X
AD  - Department of Medicine, Robert H. Lurie Cancer Center, Northwestern University, 
      Chicago, Illinois, USA.
FAU - Richmond, Ellen
AU  - Richmond E
AD  - Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, 
      USA.
FAU - Bergan, Raymond C
AU  - Bergan RC
AD  - Department of Medicine, Robert H. Lurie Cancer Center, Northwestern University, 
      Chicago, Illinois, USA.
FAU - Backman, Vadim
AU  - Backman V
AD  - Department of Biomedical Engineering, Robert H. Lurie Cancer Center, Northwestern 
      University, Chicago, Illinois, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00468910
GR  - N01 CN035157/CN/NCI NIH HHS/United States
GR  - N01CN35157/CA/NCI NIH HHS/United States
GR  - P30 CA060553/CA/NCI NIH HHS/United States
GR  - UL1 TR001422/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20151026
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.4.1.- (UDP-glucuronosyltransferase, UGT1A6)
RN  - EC 2.4.1.17 (Glucuronosyltransferase)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Biomarkers, Tumor
MH  - Chemoprevention
MH  - Colonic Neoplasms/*prevention & control
MH  - Dinoprostone/metabolism
MH  - Double-Blind Method
MH  - Female
MH  - Genotype
MH  - Glucuronosyltransferase/genetics
MH  - Humans
MH  - Intestinal Mucosa/metabolism
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Rectum/metabolism
MH  - Spectrum Analysis/*methods
PMC - PMC5108693
MID - NIHMS739798
OTO - NOTNLM
OT  - COLORECTAL NEOPLASIA
EDAT- 2015/10/28 06:00
MHDA- 2017/07/14 06:00
CRDT- 2015/10/28 06:00
PHST- 2015/05/15 00:00 [received]
PHST- 2015/09/22 00:00 [revised]
PHST- 2015/09/23 00:00 [accepted]
PHST- 2015/10/28 06:00 [pubmed]
PHST- 2017/07/14 06:00 [medline]
PHST- 2015/10/28 06:00 [entrez]
AID - gutjnl-2015-309996 [pii]
AID - 10.1136/gutjnl-2015-309996 [doi]
PST - ppublish
SO  - Gut. 2017 Feb;66(2):285-292. doi: 10.1136/gutjnl-2015-309996. Epub 2015 Oct 26.

PMID- 21933761
OWN - NLM
STAT- MEDLINE
DCOM- 20120125
LR  - 20180815
IS  - 2241-5955 (Electronic)
IS  - 1109-9666 (Linking)
VI  - 52
IP  - 4
DP  - 2011 Jul-Aug
TI  - Rapid desensitisation of patients with aspirin allergy who undergo coronary 
      angioplasty.
PG  - 307-10
AB  - INTRODUCTION: Although aspirin is the cornerstone of medication in patients with 
      coronary artery disease, a minority of these patients have aspirin sensitivity. 
      The aim of this study was to evaluate the efficacy and safety of an aspirin 
      desensitisation protocol in patients scheduled for coronary angioplasty and 
      stenting. METHODS: We used a challenge-desensitisation protocol in 11 patients (6 
      men, mean age 56 ± 9.6 years) who reported allergy to aspirin and were to undergo 
      percutaneous coronary intervention with stent implantation. Eight had a history 
      of cutaneous sensitivity, 1 had rhinitis, 1 reported urticaria and rhinitis, 
      while another patient showed a respiratory response in the form of an asthma 
      attack after taking aspirin in the past. Eight successive doses of aspirin were 
      given (0.1, 0.3, 10, 30, 40, 81, 162, 325 mg) at intervals of 15-25 min over a 
      total period of 2 h 15 min. RESULTS: All patients with aspirin sensitivity 
      completed the desensitisation therapy successfully, without adverse effects, and 
      subsequently underwent angioplasty and stenting. During follow up, the patients 
      continued to take aspirin over 6-19 months without any problems. CONCLUSIONS: 
      Rapid aspirin desensitisation is an effective and safe procedure for patients 
      with aspirin allergy who are to undergo coronary angioplasty and stenting, 
      allowing them to receive the optimum treatment.
FAU - Christou, Apostolos
AU  - Christou A
AD  - Cardiology Department, Konstantopoulio General Hospital, Nea Ionia, Athens, 
      Greece. christouapostolos@yahoo.com
FAU - Kafkas, Nikolaos
AU  - Kafkas N
FAU - Marinakos, Athanasios
AU  - Marinakos A
FAU - Katsanos, Spyridon
AU  - Katsanos S
FAU - Papanikitas, Kimon
AU  - Papanikitas K
FAU - Patsilinakos, Sotirios
AU  - Patsilinakos S
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Hellenic J Cardiol
JT  - Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
JID - 101257381
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/*adverse effects/*analogs & derivatives/therapeutic use
MH  - Drug Hypersensitivity/*drug therapy/*etiology
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - *Tachyphylaxis
EDAT- 2011/09/22 06:00
MHDA- 2012/01/26 06:00
CRDT- 2011/09/22 06:00
PHST- 2011/09/22 06:00 [entrez]
PHST- 2011/09/22 06:00 [pubmed]
PHST- 2012/01/26 06:00 [medline]
PST - ppublish
SO  - Hellenic J Cardiol. 2011 Jul-Aug;52(4):307-10.

PMID- 17631383
OWN - NLM
STAT- MEDLINE
DCOM- 20080408
LR  - 20131121
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 121
IP  - 4
DP  - 2008
TI  - Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 
      protein levels and polymorphisms.
PG  - 509-17
AB  - Aspirin's inhibitory effect on platelet function has been shown to be highly 
      heterogeneous. However, due to the considerable individual variation in 
      pharmacokinetics after aspirin intake, it has been difficult to investigate the 
      mechanism of aspirin resistance empirically. Our objective was to examine whether 
      platelet responsiveness to in vitro aspirin treatment could be affected by 
      cyclooxygenase (COX)-1/2 protein levels in platelets or single-nucleotide 
      polymorphisms (SNPs), which could possibly change specific activity of enzymes 
      and/or aspirin susceptibility. Collagen/epinephrine closure time (CEPI-CT) of 
      PFA-100 in blood from 178 healthy males was assessed with/without aspirin. 
      Platelet COX-1 protein levels and the sequences of COX-1 gene exons were examined 
      in three groups categorized by CEPI-CT: PR (Poor responders to aspirin), 10 
      people showing the shortest CEPI-CT under aspirin; GR-High or GR-Low (good 
      responders to aspirin with high or low platelet basal reactivity), 10 people 
      showing CEPI-CT over 300 s under aspirin and having the shortest or longest basal 
      CEPI-CT, respectively. We analyzed the three groups, representing phenotypic 
      extremes, aiming to increase statistical power to investigate the possible 
      relevance of COXs to platelet response to aspirin. Western blot analysis revealed 
      that COX-1 was abundantly expressed in platelets at comparable levels among the 
      three groups, whereas COX-2 was undetectable. The frequencies of nonsynonymous 
      COX-1/2 SNPs were unlikely to explain the difference in aspirin responsiveness 
      considering the observed genotype frequencies and wide individual variation in 
      platelet response. These results suggest that heterogeneity in platelet 
      responsiveness to in vitro aspirin is independent of COX-1/2 protein levels and 
      SNPs.
FAU - Takahashi, Shinichi
AU  - Takahashi S
AD  - The Keio-Daiichi Project on Genetics of Thrombosis, Keio University, Tokyo 
      160-8582, Japan.
FAU - Ushida, Miho
AU  - Ushida M
FAU - Komine, Risa
AU  - Komine R
FAU - Shimodaira, Aya
AU  - Shimodaira A
FAU - Uchida, Toshihiro
AU  - Uchida T
FAU - Ishihara, Hiroaki
AU  - Ishihara H
FAU - Shibano, Toshiro
AU  - Shibano T
FAU - Watanabe, Gentaro
AU  - Watanabe G
FAU - Ikeda, Yasuo
AU  - Ikeda Y
FAU - Murata, Mitsuru
AU  - Murata M
LA  - eng
PT  - Journal Article
DEP - 20070713
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/enzymology
MH  - Cyclooxygenase 1/*blood/*genetics
MH  - Cyclooxygenase 2/*blood/*genetics
MH  - Exons
MH  - Humans
MH  - Introns
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
EDAT- 2007/07/17 09:00
MHDA- 2008/04/09 09:00
CRDT- 2007/07/17 09:00
PHST- 2006/11/15 00:00 [received]
PHST- 2007/04/27 00:00 [revised]
PHST- 2007/05/22 00:00 [accepted]
PHST- 2007/07/17 09:00 [pubmed]
PHST- 2008/04/09 09:00 [medline]
PHST- 2007/07/17 09:00 [entrez]
AID - S0049-3848(07)00231-9 [pii]
AID - 10.1016/j.thromres.2007.05.017 [doi]
PST - ppublish
SO  - Thromb Res. 2008;121(4):509-17. doi: 10.1016/j.thromres.2007.05.017. Epub 2007 
      Jul 13.

PMID- 11754803
OWN - NLM
STAT- MEDLINE
DCOM- 20020826
LR  - 20190916
IS  - 0300-8932 (Print)
IS  - 0300-8932 (Linking)
VI  - 54
IP  - 12
DP  - 2001 Dec
TI  - [Should coronary patients chronically taking a low-dose of aspirin receive 
      gastroprotective agents?].
PG  - 1361-4
AB  - The use of low-dose aspirin (75-300 mg/day) is associated with an increased risk 
      of gastrointestinal bleeding, which is lower than that observed with common 
      NSAIDs. Risk factors for the development of GI bleeding in patients taking 
      low-dose aspirin are not well defined, although patients with a previous history 
      of peptic ulcer, concomitant NSAID use and serious diseases should receive 
      gastroprotection. Among the available drugs, proton pump inhibitors associated, 
      when present, to Helicobacter pylori erradication, have shown the highest 
      efficacy. The best cost-effectiveness treatment is still undefined.
FAU - Lanas A, A
AU  - Lanas A A
AD  - Servicio de Aparato Digestivo, Hospital Clínico Universitario, Zaragoza. 
      alanas@doymanet.es
FAU - Ferrández A, A
AU  - Ferrández A A
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Deben administrarse protectores gástricos a los pacientes coronarios que toman 
      dosis bajas de aspirina de forma crónica?
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Coronary Disease/*prevention & control
MH  - Gastrointestinal Diseases/*chemically induced/*prevention & control
MH  - Humans
RF  - 27
EDAT- 2002/01/05 10:00
MHDA- 2002/08/27 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/08/27 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
AID - 13023026 [pii]
AID - 10.1016/s0300-8932(01)76517-7 [doi]
PST - ppublish
SO  - Rev Esp Cardiol. 2001 Dec;54(12):1361-4. doi: 10.1016/s0300-8932(01)76517-7.

PMID- 8010451
OWN - NLM
STAT- MEDLINE
DCOM- 19940719
LR  - 20190704
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 79
IP  - 1
DP  - 1994 Jul
TI  - Aspirin does not increase homologous blood requirements in elective coronary 
      bypass surgery.
PG  - 4-8
AB  - Studies have demonstrated increased homologous blood product requirements in 
      patients on aspirin (ASA) undergoing cardiac surgery. We reexamined the influence 
      of ASA therapy on hemorrhage and transfusion requirements in patients undergoing 
      elective coronary artery bypass (CAB) surgery in light of recent 
      transfusion-sparing practices and autologous cell salvaging techniques. Records 
      from 197 patients who underwent reinfusion of postoperatively shed mediastinal 
      autologous whole blood were retrospectively reviewed, including 87 patients who 
      received ASA within 1 wk prior to surgery and 110 control patients. Patients 
      undergoing repeat cardiac operations were excluded from the study. 
      Cardiopulmonary bypass (CPB) duration, procedure length, aortic cross-clamp time, 
      and number of grafts performed did not differ significantly between groups. None 
      of the patients required reexploration for bleeding. There was significantly more 
      mediastinal tube drainage in the ASA group (27%), but it did not affect 
      homologous blood component requirements because this blood was autotransfused. In 
      addition, there were no significant differences in platelet, fresh frozen plasma, 
      and cryoprecipitate use between the groups. Thus, ASA did increase bleeding but 
      did not increase homologous blood transfusion requirements in elective CAB 
      surgery.
FAU - Reich, D L
AU  - Reich DL
AD  - Department of Anesthesiology, Mount Sinai Medical Center, New York, New York 
      10029-6574.
FAU - Patel, G C
AU  - Patel GC
FAU - Vela-Cantos, F
AU  - Vela-Cantos F
FAU - Bodian, C
AU  - Bodian C
FAU - Lansman, S
AU  - Lansman S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Anesth Analg. 1994 Jul;79(1):1-3. PMID: 8010417
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Loss, Surgical
MH  - *Blood Transfusion
MH  - Blood Transfusion, Autologous
MH  - Blood Volume
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
EDAT- 1994/07/01 00:00
MHDA- 1994/07/01 00:01
CRDT- 1994/07/01 00:00
PHST- 1994/07/01 00:00 [pubmed]
PHST- 1994/07/01 00:01 [medline]
PHST- 1994/07/01 00:00 [entrez]
AID - 10.1213/00000539-199407000-00002 [doi]
PST - ppublish
SO  - Anesth Analg. 1994 Jul;79(1):4-8. doi: 10.1213/00000539-199407000-00002.

PMID- 15884703
OWN - NLM
STAT- MEDLINE
DCOM- 20050630
LR  - 20181201
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 60
IP  - 3
DP  - 2005 Mar
TI  - [Aspirin and cardiovascular prevention: last minute information].
PG  - 198-200
AB  - Just a few days after the publication in this journal of a review on aspirin and 
      cardiovascular prevention, a significant article appeared in the international 
      literature; it provides new information and deserves a brief presentation. This 
      paper is concerned with patients who took aspirin to prevent vascular diseases 
      and who presented with ulcer bleeding. After the ulcers had healed and after 
      eradication of Helicobacter pylori had, if necessary, been achieved, 320 patients 
      were randomly assigned to receive either 75 mg of clopidogrel daily or 80 mg of 
      aspirin daily + 20 mg of esomeprazole twice daily. Recurrent ulcer bleeding 
      occurred in 13 of the 161 patients assigned to receive clopidogrel and in 1 of 
      the 159 who received aspirin plus esomeprazole. The cumulative incidence of 
      recurrent bleeding during the 12 months of follow up was 8.6% in the clopidogrel 
      group and 0.7% in the aspirin-esomeprazole group (p = 0.001). These findings do 
      not support a current American recommendation that patients with major 
      gastrointestinal intolerance of aspirin should be given clopidogrel instead.
FAU - Kulbertus, H
AU  - Kulbertus H
AD  - l'ULg.
LA  - fre
PT  - Journal Article
TT  - Aspirine et prévention cardiovasculaire, dernière minute: prise en charge des 
      effets secondaires gastro-duodénaux.
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Peptic Ulcer Hemorrhage/chemically induced/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Secondary Prevention
MH  - Ticlopidine/*administration & dosage/adverse effects/*analogs & derivatives
EDAT- 2005/05/12 09:00
MHDA- 2005/07/01 09:00
CRDT- 2005/05/12 09:00
PHST- 2005/05/12 09:00 [pubmed]
PHST- 2005/07/01 09:00 [medline]
PHST- 2005/05/12 09:00 [entrez]
PST - ppublish
SO  - Rev Med Liege. 2005 Mar;60(3):198-200.

PMID- 20654075
OWN - NLM
STAT- MEDLINE
DCOM- 20110913
LR  - 20211020
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 38
IP  - 4
DP  - 2010 Apr
TI  - [Effects of low-dose aspirin on primary prevention of cardiovascular events: a 
      systematic review].
PG  - 315-20
AB  - OBJECTIVE: To evaluate the effect and safety of low-dose aspirin for primary 
      prevention of cardiovascular events. METHODS: We searched for randomized 
      controlled trials (RCT) in the following electronic databases: MEDLINE, EMbase, 
      the Cochrane Library (Issue 3, 2008), CBM, CNKI. Quality assessment and data 
      extraction were conducted by two reviewers independently. All data were analyzed 
      using Review Manager 4.2. RESULTS: Six studies (TPT, HOT, PPP, WHS, POPADAD, 
      J-PAD) involving a total of 72,466 participants met the inclusion criteria. 
      Meta-analysis results showed that: (1) Compared with placebo, the incidences of 
      total cardiovascular events (RR = 0.85, 95% CI: 0.80-0.92), stroke (RR = 0.87, 
      95% CI: 0.77-0.98), nonfatal stroke (RR = 0.81, 95% CI: 0.70-0.95) and transient 
      ischemic attack (RR = 0.76, 95% CI: 0.64-0.90) were significantly lower in 
      low-dose aspirin group than those in placebo control group (all P < 0.05). (2) 
      Nonfatal myocardial infarction (RR = 0.89, 95% CI: 0.77-1.02), death from 
      cardiovascular causes (RR = 0.98, 95% CI: 0.86-1.13) and death from any cause (RR 
      = 0.95, 95% CI: 0.88-1.02) were similar between the 2 groups (all P > 0.05). (3) 
      The risk of coronary heart disease was reduced in low-dose aspirin group in the 
      elderly (RR = 0.81, 95% CI: 0.70-0.94, P < 0.05). (4) The risk of bleeding was 
      higher in low aspirin group compared to placebo group (RR = 1.15, 95% CI: 
      1.12-1.18, P < 0.01). CONCLUSIONS: Low-dose aspirin use could reduce the 
      incidences of total cardiovascular events, stroke, nonfatal stroke and transient 
      ischemic attack but increase the risk of bleeding, the incidence of nonfatal 
      myocardial infarction, death from cardiovascular causes and death from any cause 
      was not affected by low-dose aspirin use. Low-dose aspirin use was also 
      significantly reduced the risk of coronary heart disease in the elderly.
FAU - Tang, Hai-qin
AU  - Tang HQ
AD  - Department of Geriatrics, First Affiliated Hospital of Anhui Medical University, 
      Hefei 230022, China. tanghq898@sina.com.cn
FAU - Yang, Lin-lin
AU  - Yang LL
FAU - Hu, Shi-lian
AU  - Hu SL
FAU - Shen, Gan
AU  - Shen G
FAU - Sun, Ye-huan
AU  - Sun YH
FAU - Huang, Xiao-hui
AU  - Huang XH
FAU - Li, Jie-hua
AU  - Li JH
FAU - Xu, Ting-juan
AU  - Xu TJ
LA  - chi
GR  - G9534799/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/*therapeutic use
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2010/07/27 06:00
MHDA- 2011/09/14 06:00
CRDT- 2010/07/27 06:00
PHST- 2010/07/27 06:00 [entrez]
PHST- 2010/07/27 06:00 [pubmed]
PHST- 2011/09/14 06:00 [medline]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Apr;38(4):315-20.

PMID- 7131273
OWN - NLM
STAT- MEDLINE
DCOM- 19821218
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 71
IP  - 9
DP  - 1982 Sep
TI  - Aspirin--a national survey V: Determination of aspirin and impurities in enteric 
      coated tablets and suppository formulations and in vitro dissolution of enteric 
      coated tablets.
PG  - 1049-52
AB  - The results of a national survey on the quality of enteric coated aspirin tablets 
      and aspirin suppositories are presented. The tablets were analyzed for strength, 
      salicylic acid content, in vitro dissolution rate, and related aspirin 
      impurities. The suppositories were analyzed for strength and salicylic acid 
      content. The methods of analysis and validation of data are also presented.
FAU - Kirchhoefer, R D
AU  - Kirchhoefer RD
FAU - Jefferson, E
AU  - Jefferson E
FAU - Flinn, P E
AU  - Flinn PE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 0 (Suppositories)
RN  - 0 (Tablets, Enteric-Coated)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/standards
MH  - Chromatography, Thin Layer
MH  - Drug Contamination/analysis
MH  - Salicylates/analysis
MH  - Salicylic Acid
MH  - Solubility
MH  - Suppositories/analysis
MH  - Tablets, Enteric-Coated/analysis
MH  - United States
EDAT- 1982/09/01 00:00
MHDA- 1982/09/01 00:01
CRDT- 1982/09/01 00:00
PHST- 1982/09/01 00:00 [pubmed]
PHST- 1982/09/01 00:01 [medline]
PHST- 1982/09/01 00:00 [entrez]
AID - S0022-3549(15)44315-1 [pii]
AID - 10.1002/jps.2600710923 [doi]
PST - ppublish
SO  - J Pharm Sci. 1982 Sep;71(9):1049-52. doi: 10.1002/jps.2600710923.

PMID- 10486668
OWN - NLM
STAT- MEDLINE
DCOM- 19991022
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 92
IP  - 8
DP  - 1999 Aug
TI  - [Effect of intensive antihypertensive treatment and of aspirin in a low dose in 
      the hypertensive. The HOT (Hypertension Optimal Treatment) study].
PG  - 1073-8
AB  - The aim of the HOT Study (Hypertension Optimal Treatment) was to determine the 
      optimal diastolic blood pressure decrease and to assess the effect of the acetyl 
      salicylic acid as a primary prevention on the cardiovascular morbidity and 
      mortality in hypertensive patients. The HOT Study is an open, prospective, 
      randomised, international trial with blinded end points. This study included 
      18,790 patients, 50 to 80 years old (mean 61.5 years) in 26 countries (1,574 
      patients in France) with a primary hypertension (100 < or = PAD < or = 115 mmHg). 
      The patients were randomised in 3 target diastolic blood pressure: < or = 80 mmHg 
      (n = 6,262), < or = 85 mmHg (n = 6,264), < or = 90 mmHg (n = 6,264). The 
      felodipine LP, a long acting dihydropyridine, was selected as a first line 
      therapy, other hypertension drugs combined if necessary. The lowest incidence of 
      cardiovascular events was observed at a diastolic blood pressure level of 82.6 
      mmHg. There was no increased risk below this level even in the hypertensive 
      patients with medical history of coronary heart disease or stroke. In the 
      diabetic population, the diastolic blood pressure decrease from 90 to 80 reduced 
      the incidence of the major cardiovascular events by 51%. The acetyl salicylic 
      acid reduced the myocardial infarction risk in the blood pressure well-controlled 
      population.
FAU - Mallion, J M
AU  - Mallion JM
AD  - Service médecine interne et cardiologie, CHU Grenoble.
FAU - Benkritly, A
AU  - Benkritly A
FAU - Hansson, L
AU  - Hansson L
FAU - Zanchetti, A
AU  - Zanchetti A
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Effet du traitement antihypertenseur intensif et de l'aspirine à faible dose chez 
      l'hypertendu. Etude HOT (Hypertension Optimal Treatment).
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Antihypertensive Agents)
RN  - OL961R6O2C (Felodipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antihypertensive Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Europe
MH  - Felodipine/*therapeutic use
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Middle Aged
EDAT- 1999/09/16 00:00
MHDA- 1999/09/16 00:01
CRDT- 1999/09/16 00:00
PHST- 1999/09/16 00:00 [pubmed]
PHST- 1999/09/16 00:01 [medline]
PHST- 1999/09/16 00:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 1999 Aug;92(8):1073-8.

PMID- 20565050
OWN - NLM
STAT- MEDLINE
DCOM- 20101123
LR  - 20131121
IS  - 1520-510X (Electronic)
IS  - 0020-1669 (Linking)
VI  - 49
IP  - 14
DP  - 2010 Jul 19
TI  - Experimental electron density study of 
      tetrakis-mu-(acetylsalicylate)dicopper(II): a polymeric structure with Cu...Cu 
      short contacts.
PG  - 6443-52
LID - 10.1021/ic100090h [doi]
AB  - The electron density, its topological features, and the electrostatic potential 
      of tetrakis-mu-(acetylsalicylate)dicopper(II), Cu[C(9)H(7)O(4)](2), have been 
      derived from an accurate high-resolution diffraction experiment at 100 K. This 
      complex exhibits a polymeric structure involving one acetyl oxygen atom as a 
      bridge in the solid state. Only van der Waals interactions between the polymeric 
      chains are observed. The copper cation is octahedrally coordinated with five 
      oxygen atoms of the aspirinate ligands and one adjacent Cu with short Cu...Cu 
      contact distances in the range of 2.6054(1) A. The Cu-O bond lengths are equal to 
      1.96 A except the apical one which is 2.2183(7) A. The multipole refinements were 
      carried out using the Hansen-Coppens model coded in the MOPRO computer program. 
      Starting from the 3d(10)4s(1) copper electron configuration, the electron density 
      analysis and Cu d-orbital populations reveal that the observed configuration is 
      close to being [Ar]3d(9)4s(1). As expected from the ligand field theory, the most 
      depopulated 3d-orbital is the d(x(2)-y(2)) (1.17 e) one with lobes pointing 
      toward the carboxylic oxygen atoms. Conversely, the d(z(2)) is the most populated 
      orbital for a z-axis directed along the Cu...Cu bond. The atomic charges were 
      derived from a kappa-refinement and yielded a metal net charge of +1.20(3) e. 
      Deficits of +0.72(6) and +0.59(7) e are obtained for the acetyl carbon atoms of 
      the aspirinate ligands, those involved in the drug activity of aspirin. 
      Comparisons are made to the results of our previous work on the zinc-aspirinate 
      complex.
FAU - Bouhmaida, Nouzha
AU  - Bouhmaida N
AD  - Laboratoire des Sciences des Matériaux (LSM), Université Cadi Ayyad, Faculté des 
      Sciences Semlalia, Boulevard Prince Moulay Abdallah, BP 2390, 40000 Marrakech, 
      Morocco.
FAU - Méndez-Rojas, Miguel A
AU  - Méndez-Rojas MA
FAU - Pérez-Benítez, Aarón
AU  - Pérez-Benítez A
FAU - Merino, Gabriel
AU  - Merino G
FAU - Fraisse, Bernard
AU  - Fraisse B
FAU - Ghermani, Nour Eddine
AU  - Ghermani NE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Inorg Chem
JT  - Inorganic chemistry
JID - 0366543
RN  - 0 (Coordination Complexes)
RN  - 0 (Ligands)
RN  - 0 (Polymers)
RN  - 0 (tetrakis-mu-(acetylsalicylate)dicopper(II))
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - 789U1901C5 (Copper)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/chemistry
MH  - Coordination Complexes/*chemistry
MH  - Copper/*chemistry
MH  - Ligands
MH  - Models, Molecular
MH  - Polymers/chemistry
MH  - *Quantum Theory
EDAT- 2010/06/23 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/06/23 06:00
PHST- 2010/06/23 06:00 [entrez]
PHST- 2010/06/23 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.1021/ic100090h [doi]
PST - ppublish
SO  - Inorg Chem. 2010 Jul 19;49(14):6443-52. doi: 10.1021/ic100090h.

PMID- 6351216
OWN - NLM
STAT- MEDLINE
DCOM- 19831028
LR  - 20131121
IS  - 0035-3787 (Print)
IS  - 0035-3787 (Linking)
VI  - 139
IP  - 5
DP  - 1983
TI  - [The A.I.C.L.A. controlled cooperative trial. Secondary prevention of cerebral 
      ischemic accidents due to atherosclerosis by aspirin and dipyridamole. 3: 
      Results].
PG  - 335-48
AB  - As decided in the protocol, the AICLA study ended when all the 604 patients had 
      completed a follow up of three years. Adhesion to the protocol and drug 
      compliance were excellent. Side effects, particularly peptic ulcers and bleedings 
      of various origins were more frequent in the 2 treatment groups containing 
      aspirin. The number of fatal and non fatal cerebral infarction was 31 in the P 
      group, 17 in the ASA group, and 18 in the ASA + D group. Taking into account the 
      duration of follow up for each patient, these figures correspond to cummulate 
      rates of 18 p. 100 in the P group and 10.5 p. 100 in the 2 others. Analysis with 
      the Mantel Method showed: 1 - a difference at the 6 p. 100 level between the 3 
      groups and between P an AD; 2 - A difference at the 5 p. 100 level between P and 
      A; 3 - No difference between A and AD; 4 - A difference at the 2 p. 100 level 
      between the P group and the two treated groups taken together. Among other 
      diseases occurring during the trial, the only significant difference concerned 
      myocardial infarction, less frequent in the 2 treated groups (p less than 0.05). 
      Subgroup analysis failed to show a significant sex difference in the efficacy of 
      aspirin. It is concluded that, in patients such as those defined in the protocol, 
      Aspirin (1 g) has a significant beneficial effect in the secondary prevention of 
      atherothrombotic cerebral infarction.
FAU - Bousser, M G
AU  - Bousser MG
FAU - Eschwege, E
AU  - Eschwege E
FAU - Haguenau, M
AU  - Haguenau M
FAU - Lefauconnier, J M
AU  - Lefauconnier JM
FAU - Thibult, N
AU  - Thibult N
FAU - Touboul, D
AU  - Touboul D
FAU - Touboul, P J
AU  - Touboul PJ
LA  - fre
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Essai coopératif contrôle "A.I.C.L.A.". Prévention secondaire des accidents 
      ischémiques cérébraux liés à l'athérosclérose par l'aspirine et le dipyridamole. 
      3e partie: Résultats.
PL  - France
TA  - Rev Neurol (Paris)
JT  - Revue neurologique
JID - 2984779R
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/*prevention & control
MH  - Cerebral Infarction/mortality/*prevention & control
MH  - Clinical Trials as Topic
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Intracranial Arteriosclerosis/*complications
MH  - Male
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Neurol (Paris). 1983;139(5):335-48.

PMID- 14576595
OWN - NLM
STAT- MEDLINE
DCOM- 20031112
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 32
IP  - 33
DP  - 2003 Oct 11
TI  - [Prevention of preeclampsia].
PG  - 1559-65
AB  - THE CURRENT SITUATION: Preeclampsia is associated with increased risk of adverse 
      maternal (abruptio placentae, HELLP syndrome, eclampsia.) and perinatal death. 
      Its prevention, therefore, is of particular importance. The latter must be 
      determined together with the group of women who would benefit from it. THE 
      INTEREST OF ASPIRIN: The best studied preventive treatment is low dose aspirin. 
      The various studies on low-dose aspirin have confirmed its safety in pregnant 
      women. These studies, in small cohorts of selected patients at risk or in large 
      series of women with moderate risk, show that the use of aspirin is associated 
      with a 15% reduction in the risk of preeclampsia. OTHER THAN ASPIRIN: Other 
      preventive treatments, such as calcium have not demonstrated their efficacy, or 
      their effect requires confirmation, such as with anti-oxidants or low molecular 
      weight heparin. IN PRACTICE: The prevention of preeclampsia currently relies on 
      low-dose aspirin started at the beginning of pregnancy. The moderate benefit of 
      such prevention justifies its administration in patients at high risk, selected 
      on their obstetrical past history.
FAU - Desvaux, Dominique
AU  - Desvaux D
AD  - Département de pathologie et service de néphrologie, AP-HP, Hôpital Henri Mondor, 
      Créteil. dominique.desvaux@hmn.ap-hop-paris.fr
FAU - Haddad, Bassam
AU  - Haddad B
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Prévention de la prééclampsie.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Presse Med. 2004 Jul 31;33(13):903. PMID: 15387392
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Fetal Diseases/chemically induced
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Pre-Eclampsia/physiopathology/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications/*prevention & control
MH  - Pregnancy Trimester, First
MH  - Randomized Controlled Trials as Topic
EDAT- 2003/10/25 05:00
MHDA- 2003/11/13 05:00
CRDT- 2003/10/25 05:00
PHST- 2003/10/25 05:00 [pubmed]
PHST- 2003/11/13 05:00 [medline]
PHST- 2003/10/25 05:00 [entrez]
AID - MDOI-PM-10-2003-32-33-0755-4982-101019-ART6 [pii]
PST - ppublish
SO  - Presse Med. 2003 Oct 11;32(33):1559-65.

PMID- 27567928
OWN - NLM
STAT- MEDLINE
DCOM- 20170615
LR  - 20170922
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1866
IP  - 2
DP  - 2016 Dec
TI  - Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials.
PG  - 163-176
LID - S0304-419X(16)30060-9 [pii]
LID - 10.1016/j.bbcan.2016.08.002 [doi]
AB  - Pancreatic cancer is one of the most aggressive malignancies with dismal 
      prognosis. Recently, aspirin has been found to be an effective chemopreventive 
      agent for many solid tumors. However, the function of aspirin use in pancreatic 
      cancer largely remains unknown. We herein argued that aspirin could also lower 
      the risk of pancreatic cancer. Importantly, aspirin assumes pleiotropic effects 
      by targeting multiple molecules. It could further target the unique tumor biology 
      of pancreatic cancer and modify the cancer microenvironment, thus showing 
      remarkable therapeutic potentials. Besides, aspirin could reverse the 
      chemoradiation resistance by repressing tumor repopulation and exert synergistic 
      potentials with metformin on pancreatic cancer chemoprevention. Moreover, aspirin 
      secondarily benefits pancreatic cancer patients through modestly reducing cancer 
      pain and the risk of venous thromboembolism. Furthermore, new aspirin derivatives 
      and delivery systems might help to improve risk-to-benefit ratio. In brief, 
      aspirin is a promising chemopreventive agent and exerts significant therapeutic 
      potentials in pancreatic cancer.
CI  - Copyright Â© 2016 Elsevier B.V. All rights reserved.
FAU - Jiang, Ming-Jie
AU  - Jiang MJ
AD  - Institute of Translational Medicine, Shanghai General Hospital, Shanghai Jiao 
      Tong University School of Medicine, Shanghai 201620, China; Shanghai Key 
      Laboratory of Pancreatic Diseases, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai 201620, China.
FAU - Dai, Juan-Juan
AU  - Dai JJ
AD  - Institute of Translational Medicine, Shanghai General Hospital, Shanghai Jiao 
      Tong University School of Medicine, Shanghai 201620, China; Shanghai Key 
      Laboratory of Pancreatic Diseases, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai 201620, China.
FAU - Gu, Dian-Na
AU  - Gu DN
AD  - Institute of Translational Medicine, Shanghai General Hospital, Shanghai Jiao 
      Tong University School of Medicine, Shanghai 201620, China; Shanghai Key 
      Laboratory of Pancreatic Diseases, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai 201620, China.
FAU - Huang, Qian
AU  - Huang Q
AD  - Shanghai Key Laboratory of Pancreatic Diseases, Shanghai General Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China; 
      Comprehensive Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai 201620, China.
FAU - Tian, Ling
AU  - Tian L
AD  - Institute of Translational Medicine, Shanghai General Hospital, Shanghai Jiao 
      Tong University School of Medicine, Shanghai 201620, China; Shanghai Key 
      Laboratory of Pancreatic Diseases, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai 201620, China. Electronic address: 
      TL09168@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160824
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Anticarcinogenic Agents)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticarcinogenic Agents/*pharmacology
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cancer Pain/prevention & control
MH  - Humans
MH  - Metformin/pharmacology
MH  - Pancreatic Neoplasms/*prevention & control
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer biology
OT  - Cancer chemoprevention
OT  - Cancer microenvironment
OT  - Cancer therapy
OT  - Pancreatic cancer
EDAT- 2016/10/25 06:00
MHDA- 2017/06/16 06:00
CRDT- 2016/08/29 06:00
PHST- 2016/05/18 00:00 [received]
PHST- 2016/08/04 00:00 [revised]
PHST- 2016/08/23 00:00 [accepted]
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/06/16 06:00 [medline]
PHST- 2016/08/29 06:00 [entrez]
AID - S0304-419X(16)30060-9 [pii]
AID - 10.1016/j.bbcan.2016.08.002 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2016 Dec;1866(2):163-176. doi: 10.1016/j.bbcan.2016.08.002. 
      Epub 2016 Aug 24.

PMID- 35412629
OWN - NLM
STAT- MEDLINE
DCOM- 20220414
LR  - 20220621
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 5
IP  - 4
DP  - 2022 Apr 1
TI  - Analysis of Aspirin Use and Cardiovascular Events and Mortality Among Adults With 
      Hypertension and Controlled Systolic Blood Pressure.
PG  - e226952
LID - 10.1001/jamanetworkopen.2022.6952 [doi]
LID - e226952
AB  - This cohort study investigates the association of aspirin use with risk of 
      cardiovascular events among adults with hypertension and controlled systolic 
      blood pressure.
FAU - Del Pinto, Rita
AU  - Del Pinto R
AD  - Department of Clinical Medicine, Public Health, Life and Environmental Sciences, 
      University of L'Aquila, L'Aquila, Italy.
AD  - Division of Internal Medicine and Nephrology, Center for Hypertension and 
      Cardiovascular Prevention, San Salvatore Hospital, L'Aquila, Italy.
FAU - Pietropaoli, Davide
AU  - Pietropaoli D
AD  - Department of Clinical Medicine, Public Health, Life and Environmental Sciences, 
      University of L'Aquila, L'Aquila, Italy.
FAU - Desideri, Giovambattista
AU  - Desideri G
AD  - Department of Clinical Medicine, Public Health, Life and Environmental Sciences, 
      University of L'Aquila, L'Aquila, Italy.
AD  - Geriatrics Unit, SS Filippo e Nicola Hospital, Avezzano, Italy.
FAU - Ferri, Claudio
AU  - Ferri C
AD  - Department of Clinical Medicine, Public Health, Life and Environmental Sciences, 
      University of L'Aquila, L'Aquila, Italy.
AD  - Division of Internal Medicine and Nephrology, Center for Hypertension and 
      Cardiovascular Prevention, San Salvatore Hospital, L'Aquila, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220401
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antihypertensive Agents/pharmacology/therapeutic use
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Blood Pressure/physiology
MH  - Humans
MH  - *Hypertension/drug therapy/epidemiology
PMC - PMC9006111
COIS- Conflict of Interest Disclosures: None reported.
EDAT- 2022/04/13 06:00
MHDA- 2022/04/15 06:00
CRDT- 2022/04/12 12:13
PHST- 2022/04/12 12:13 [entrez]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/04/15 06:00 [medline]
AID - 2790994 [pii]
AID - zld220056 [pii]
AID - 10.1001/jamanetworkopen.2022.6952 [doi]
PST - epublish
SO  - JAMA Netw Open. 2022 Apr 1;5(4):e226952. doi: 10.1001/jamanetworkopen.2022.6952.

PMID- 28645644
OWN - NLM
STAT- MEDLINE
DCOM- 20180719
LR  - 20181202
IS  - 1953-8022 (Electronic)
IS  - 1246-7820 (Linking)
VI  - 24
IP  - 3
DP  - 2017 Sep
TI  - [Antiplatelet agents and transfusion].
PG  - 160-165
LID - S1246-7820(17)30076-9 [pii]
LID - 10.1016/j.tracli.2017.05.014 [doi]
AB  - Antiplatelet agents are at risk for bleeding complications, the management of 
      which differs depending on the clinical situation and on the antiplatelet agent 
      itself. Neutralization of antiplatelets is sometimes necessary, most often 
      leading to platelet transfusion, although the benefit of this strategy is poorly 
      documented. In addition, if platelet transfusion corrects the platelet inhibition 
      induced by aspirin and probably by clopidogrel and prasugrel, it does not 
      neutralize ticagrelor, as a consequence of its pharmacological properties. The 
      clinical benefit of platelet transfusion is limited, and the most recent studies 
      are challenging it. However, it is indicated on a perioperative basis for 
      surgeries with high hemorrhagic risk and is discussed in severe hemorrhages. The 
      neutralization of ticagrelor is a concern and the antidote currently under 
      development may be a solution. In all cases, other therapeutic solutions may be 
      considered, such as administration of desmopressin, tranexamic acid or activated 
      factor VII.
CI  - Copyright © 2017 Elsevier Masson SAS. All rights reserved.
FAU - Gaussem, P
AU  - Gaussem P
AD  - Service d'hématologie biologique, hôpital européen Georges-Pompidou, AP-HP, 20, 
      rue Leblanc, 75908 Paris cedex 15, France; Université Paris Descartes, Sorbonne 
      Paris Cité, 75006 Paris, France; Inserm UMR-S1140, faculté de pharmacie, 75006 
      Paris, France. Electronic address: pascale.gaussem@aphp.fr.
FAU - Martin, A-C
AU  - Martin AC
AD  - Inserm UMR-S1140, faculté de pharmacie, 75006 Paris, France; Service de 
      cardiologie, service de santé des armées, hôpital d'instruction des Armées-Percy, 
      92140 Clamart, France. Electronic address: ac.martin75@gmail.com.
FAU - Belleville-Rolland, T
AU  - Belleville-Rolland T
AD  - Service d'hématologie biologique, hôpital européen Georges-Pompidou, AP-HP, 20, 
      rue Leblanc, 75908 Paris cedex 15, France; Université Paris Descartes, Sorbonne 
      Paris Cité, 75006 Paris, France; Inserm UMR-S1140, faculté de pharmacie, 75006 
      Paris, France. Electronic address: tiphaine.belleville-rolland@aphp.fr.
FAU - Helley, D
AU  - Helley D
AD  - Service d'hématologie biologique, hôpital européen Georges-Pompidou, AP-HP, 20, 
      rue Leblanc, 75908 Paris cedex 15, France; Université Paris Descartes, Sorbonne 
      Paris Cité, 75006 Paris, France; Inserm UMR-S970, 75015 Paris, France. Electronic 
      address: dominique.helley@aphp.fr.
FAU - Bachelot-Loza, C
AU  - Bachelot-Loza C
AD  - Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France; Inserm 
      UMR-S1140, faculté de pharmacie, 75006 Paris, France. Electronic address: 
      christilla.bachelot-loza@parisdescartes.fr.
FAU - Godier, A
AU  - Godier A
AD  - Inserm UMR-S1140, faculté de pharmacie, 75006 Paris, France; Service 
      d'anesthésie-réanimation, Fondation Adolphe-de-Rothschild, 75019 Paris, France. 
      Electronic address: annegodier@yahoo.fr.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Antiplaquettaires et transfusion.
DEP - 20170620
PL  - France
TA  - Transfus Clin Biol
JT  - Transfusion clinique et biologique : journal de la Societe francaise de 
      transfusion sanguine
JID - 9423846
RN  - 0 (Antidotes)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine/adverse effects/analogs & derivatives/therapeutic use
MH  - Antidotes
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Hemorrhage/chemically induced/*therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - *Platelet Transfusion
MH  - Prasugrel Hydrochloride/adverse effects/therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
MH  - Risk
MH  - Ticagrelor
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Antidote
OT  - Antiplatelet agents
OT  - Aspirine
OT  - Bleeding
OT  - Clopidogrel
OT  - Hémorragie
OT  - Médicaments antiplaquettaires
OT  - P2Y12
OT  - Platelet transfusion
OT  - Prasugrel
OT  - Ticagrelor
OT  - Transfusion plaquettaire
EDAT- 2017/06/25 06:00
MHDA- 2018/07/20 06:00
CRDT- 2017/06/25 06:00
PHST- 2017/05/30 00:00 [received]
PHST- 2017/05/30 00:00 [accepted]
PHST- 2017/06/25 06:00 [pubmed]
PHST- 2018/07/20 06:00 [medline]
PHST- 2017/06/25 06:00 [entrez]
AID - S1246-7820(17)30076-9 [pii]
AID - 10.1016/j.tracli.2017.05.014 [doi]
PST - ppublish
SO  - Transfus Clin Biol. 2017 Sep;24(3):160-165. doi: 10.1016/j.tracli.2017.05.014. 
      Epub 2017 Jun 20.

PMID- 7771997
OWN - NLM
STAT- MEDLINE
DCOM- 19950706
LR  - 20190830
IS  - 0004-8666 (Print)
IS  - 0004-8666 (Linking)
VI  - 35
IP  - 1
DP  - 1995 Feb
TI  - Aspirin and prevention of preeclampsia. Position statement of the use of low-dose 
      aspirin in pregnancy by the Australasian Society for the Study of Hypertension in 
      Pregnancy.
PG  - 38-41
AB  - 1. A heterogeneous group of randomized trials have been conducted using low-dose 
      aspirin to prevent preeclampsia. The results do not support widespread use of 
      low-dose aspirin to prevent preeclampsia. 2. On the basis of existing literature, 
      it is reasonable to use prophylactic low-dose aspirin from early pregnancy in the 
      following groups: (i) Women with prior fetal loss after the first trimester, with 
      placental insufficiency (ii) Women with severe fetal growth retardation in a 
      preceding pregnancy either due to preeclampsia or unexplained (iii) Women with 
      severe early-onset preeclampsia in a previous pregnancy necessitating delivery at 
      or before 32 weeks' gestation. 3. On the basis of existing literature, it is 
      recommended that aspirin not be used in the following groups: (i) Healthy 
      nulliparous women (ii) Women with mild chronic hypertension (iii) Women with 
      established preeclampsia. 4. The data are sufficient to support further trials in 
      more homogeneous select subgroups of women considered at risk of developing 
      preeclampsia.
FAU - Brennecke, S P
AU  - Brennecke SP
AD  - Department of Perinatal Medicine, Royal Women's Hospital, Melbourne, Australia.
FAU - Brown, M A
AU  - Brown MA
FAU - Crowther, C A
AU  - Crowther CA
FAU - Hague, W M
AU  - Hague WM
FAU - King, J
AU  - King J
FAU - McCowan, L
AU  - McCowan L
FAU - Morris, J
AU  - Morris J
FAU - North, R
AU  - North R
FAU - Pattison, N
AU  - Pattison N
FAU - Tippett, C
AU  - Tippett C
AU  - et al.
LA  - eng
PT  - Guideline
PT  - Journal Article
PT  - Practice Guideline
PL  - Australia
TA  - Aust N Z J Obstet Gynaecol
JT  - The Australian & New Zealand journal of obstetrics & gynaecology
JID - 0001027
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Patient Selection
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Primary Prevention/methods
MH  - Randomized Controlled Trials as Topic
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
AID - 10.1111/j.1479-828x.1995.tb01827.x [doi]
PST - ppublish
SO  - Aust N Z J Obstet Gynaecol. 1995 Feb;35(1):38-41. doi: 
      10.1111/j.1479-828x.1995.tb01827.x.

PMID- 7167043
OWN - NLM
STAT- MEDLINE
DCOM- 19830527
LR  - 20170214
IS  - 0272-989X (Print)
IS  - 0272-989X (Linking)
VI  - 2
IP  - 2
DP  - 1982
TI  - Evaluation for colon cancer in patients with occult fecal blood loss while taking 
      aspirin: a Bayesian viewpoint.
PG  - 147-60
AB  - This paper examines the implications of occult fecal blood loss in patients 
      taking aspirin (at least 2 grams daily). Although such patients do have a 
      somewhat higher probability of colonic carcinoma than do members of the general 
      population, their risk is far lower than that of patients who have 
      gastrointestinal blood loss when not taking aspirin. This difference in risk 
      exists because aspirin itself can provoke occult blood loss in stool. Patients 
      who manifest gastrointestinal blood loss while taking aspirin can be separated 
      into two groups, based on whether or not that blood loss continues after aspirin 
      is discontinued. Although patients who continue to bleed are at high risk for 
      colonic carcinoma, those who cease having any blood loss are at lower risk than 
      are members of the general population. Further diagnostic studies to detect 
      colonic carcinoma should be pursued in the former group, but not in the latter, 
      low-risk group.
FAU - Doubilet, P
AU  - Doubilet P
FAU - Donowitz, M
AU  - Donowitz M
FAU - Pauker, S G
AU  - Pauker SG
LA  - eng
GR  - 1K04-GM00349/GM/NIGMS NIH HHS/United States
GR  - AM20700/AM/NIADDK NIH HHS/United States
GR  - AM26523/AM/NIADDK NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Med Decis Making
JT  - Medical decision making : an international journal of the Society for Medical 
      Decision Making
JID - 8109073
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Bayes Theorem
MH  - Colonic Neoplasms/*diagnosis
MH  - Feces/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Occult Blood
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1177/0272989X8200200206 [doi]
PST - ppublish
SO  - Med Decis Making. 1982;2(2):147-60. doi: 10.1177/0272989X8200200206.

PMID- 1576068
OWN - NLM
STAT- MEDLINE
DCOM- 19920611
LR  - 20190509
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 33
IP  - 4
DP  - 1992 Apr
TI  - An evaluation of buffered aspirin and aspirin tablets in postoperative pain after 
      third molar surgery.
PG  - 395-9
AB  - 1. Single doses (500 and 1000 mg) of both buffered aspirin and aspirin tablets 
      were compared with placebo in a randomised double-blind trial of parallel design 
      in patients with postoperative pain after third molar surgery. 2. Only buffered 
      aspirin 500 mg provided significant pain relief (P = 0.016) during the 5 h 
      investigation period. 3. A significant correlation (P = 0.004) was observed 
      between overall pain scores after the various aspirin treatments and aspirin 
      esterase activity. 4. Buffered aspirin preparations afforded a slight advantage 
      over aspirin tablets in the control of postoperative pain after third molar 
      surgery. However, the duration of analgesia was short (approximately 2 h). 5. 
      Aspirin esterase activity appears to be an important determinant of the drug's 
      efficacy in postoperative dental pain.
FAU - Seymour, R A
AU  - Seymour RA
AD  - Department of Operative Dentistry, Dental School, Newcastle upon Tyne.
FAU - Weldon, M
AU  - Weldon M
FAU - Kelly, P
AU  - Kelly P
FAU - Nicholson, E
AU  - Nicholson E
FAU - Hawkesford, J E
AU  - Hawkesford JE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Buffers)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Buffers
MH  - Female
MH  - Humans
MH  - Male
MH  - Molar, Third/*surgery
MH  - Pain, Postoperative/*drug therapy
MH  - Tablets
PMC - PMC1381328
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1992.tb04057.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1992 Apr;33(4):395-9. doi: 
      10.1111/j.1365-2125.1992.tb04057.x.

PMID- 7017495
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Clinical study of a preparation with bronchomucotropic activity: guacetisal].
PG  - 429-33
AB  - An open clinical study has been carried out on 40 patients of both sexes 
      suffering from prevalently chronic bronchopneumopathy, with a suspension of 
      guacetisal for adults. The drug is a new bronchomucotropic synthesized by the 
      Bayer Italia S.p.A. Research Laboratories. The improvement in the clinical 
      picture was very evident in 55% of cases and is in favour of an overall positive 
      opinion of the drug's activity bearing in mind that the pathology considered 
      would not in any case have permitted the achievement of complete resolution. The 
      drug was very well tolerated and presented marked mucopoietic and 
      anti-inflammatory properties at a dose of 1 spoonful (10 ml) 2-3 times a day.
FAU - Rubegni, M
AU  - Rubegni M
FAU - De Mauro, G
AU  - De Mauro G
LA  - ita
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Studio clinico di un preparato ad attività broncomucotropica: il guacetisal.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Bronchitis/drug therapy
MH  - Clinical Trials as Topic
MH  - Cough/drug therapy
MH  - Female
MH  - Humans
MH  - Lung Diseases, Obstructive/*drug therapy
MH  - Male
MH  - Pulmonary Emphysema/drug therapy
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):429-33.

PMID- 19936921
OWN - NLM
STAT- MEDLINE
DCOM- 20100720
LR  - 20221207
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 55
IP  - 8
DP  - 2010 Aug
TI  - Clinical features of gastroduodenal ulcer in Japanese patients taking low-dose 
      aspirin.
PG  - 2270-4
LID - 10.1007/s10620-009-1009-8 [doi]
AB  - BACKGROUND AND AIM: The risks of peptic ulcer complications increase in 
      association with low-dose aspirin (LDA) use. The endoscopic findings and clinical 
      features of gastroduodenal ulcer have not been thoroughly investigated in 
      patients taking LDA. METHOD: We classified 1,041 gastroduodenal ulcer patients 
      into three groups [patients taking LDA (group A), patients taking nonaspirin 
      nonsteroidal anti-inflammatory drug (NSAID) (group N), and patients taking 
      neither aspirin nor nonaspirin NSAID (group C)] and 241 bleeding gastroduodenal 
      ulcer patients into three corresponding groups (groups a, n, and c). We 
      investigated the clinical features, endoscopic characteristics, and endoscopic 
      treatment of the hemorrhagic lesion in the gastroduodenal ulcer patients taking 
      LDA and compared them with those of the other groups. RESULTS: The frequency of 
      bleeding events such as hematemesis, melena, and anemia was significantly higher 
      in group A and N than in group C. The percentage of ulcers located in the antrum 
      was higher in group A and N than in group C, and also higher in group a and n 
      than in group c. The percentage of ulcers located in the body, fundus, and cardia 
      was significantly higher in the bleeding patients than in all gastroduodenal 
      ulcer patients. The percentage of cases that required additional endoscopic 
      treatment in group a was higher than in group c. Duration of hospitalization of 
      group a was significantly longer than that of group c. CONCLUSION: These results 
      indicate that it is very important to prevent LDA-induced gastroduodenal ulcer 
      complications, including bleeding.
FAU - Iwamoto, Junichi
AU  - Iwamoto J
AD  - Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, 
      Ibaraki, Japan. junnki@dg.mbn.or.jp
FAU - Mizokami, Yuji
AU  - Mizokami Y
FAU - Shimokobe, Koichi
AU  - Shimokobe K
FAU - Ito, Masanori
AU  - Ito M
FAU - Hirayama, Takeshi
AU  - Hirayama T
FAU - Saito, Yoshifumi
AU  - Saito Y
FAU - Ikegami, Tadashi
AU  - Ikegami T
FAU - Honda, Akira
AU  - Honda A
FAU - Matsuzaki, Yasushi
AU  - Matsuzaki Y
LA  - eng
PT  - Journal Article
DEP - 20091120
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Asian People
MH  - Aspirin/*administration & dosage/*adverse effects/therapeutic use
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*chemically induced/pathology
EDAT- 2009/11/26 06:00
MHDA- 2010/07/21 06:00
CRDT- 2009/11/26 06:00
PHST- 2009/06/16 00:00 [received]
PHST- 2009/09/24 00:00 [accepted]
PHST- 2009/11/26 06:00 [entrez]
PHST- 2009/11/26 06:00 [pubmed]
PHST- 2010/07/21 06:00 [medline]
AID - 10.1007/s10620-009-1009-8 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2010 Aug;55(8):2270-4. doi: 10.1007/s10620-009-1009-8. Epub 2009 Nov 
      20.

PMID- 2182244
OWN - NLM
STAT- MEDLINE
DCOM- 19900516
LR  - 20190510
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - Suppl 5
DP  - 1990 Mar
TI  - Aspirin in chronic cardiovascular disease and acute myocardial infarction.
PG  - V62-6; discussion V67-72
AB  - The ability of low-dose aspirin to irreversibly inhibit platelet-dependent 
      cyclooxygenase provides a biologic mechanism to explain why this drug may 
      decrease the risk of thrombotic cardiovascular events. Observational 
      epidemiologic studies, both case-control and cohort, have suggested that aspirin 
      might reduce the risk of cardiovascular disease by approximately 20 to 30%. An 
      overview of 25 randomized trials of aspirin among individuals with a history of 
      prior cardiovascular disease demonstrated that those receiving aspirin 
      experienced a significant 25% reduction in the occurrence of "important vascular 
      events," an endpoint that combines nonfatal myocardial infarction (MI), nonfatal 
      stroke, and cardiovascular death. There were also significant 32% reductions in 
      subsequent nonfatal MI, 27% reductions in nonfatal stroke, and 15% reductions in 
      vascular mortality. Thus, individuals with a history of MI, stroke, transient 
      ischemic attack, or unstable angina clearly benefit from aspirin. The Second 
      International Study of Infarct Survival (ISIS-2) sought to determine if benefits 
      would accrue if aspirin was given within the first 24 hours of suspected evolving 
      MI. The aspirin group experienced a significant 23% reduction in 5-week vascular 
      mortality compared with those receiving placebo. Aspirin was also associated with 
      significantly fewer reinfarctions and strokes. Thus, among those with suspected 
      evolving MI, aspirin significantly reduces the risk of reinfarction, stroke, and 
      vascular mortality. These analyses indicate that aspirin is of proven value in 
      the therapy of most patients who have survived MI, stroke, or unstable angina, as 
      well as those evolving a suspected MI.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Hennekens, C H
AU  - Hennekens CH
AD  - Channing Laboratory, Department of Medicine, Harvard Medical School, Boston, 
      Massachusetts 02146.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Chronic Disease
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
RF  - 12
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
AID - 10.1002/clc.4960131314 [doi]
PST - ppublish
SO  - Clin Cardiol. 1990 Mar;Suppl 5:V62-6; discussion V67-72. doi: 
      10.1002/clc.4960131314.

PMID- 16168280
OWN - NLM
STAT- MEDLINE
DCOM- 20051222
LR  - 20131121
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 46
IP  - 6
DP  - 2005 Sep 20
TI  - Aspirin resistance and atherothrombotic disease.
PG  - 986-93
AB  - Acute coronary syndromes and other manifestations of atherothrombotic disease are 
      primarily caused by atherosclerotic plaque rupture or fissuring and subsequent 
      occlusive or subocclusive thrombus formation. Platelets play a critical role in 
      the pathophysiology of atherothrombotic disease, and aspirin is the most commonly 
      used antiplatelet agent. Clinical trials have demonstrated the efficacy of 
      aspirin in both primary and secondary prevention of myocardial infarction, 
      stroke, and cardiovascular death. Despite its proven benefit, the absolute risk 
      of recurrent vascular events among patients taking aspirin remains relatively 
      high, an estimated 8% to 18% after two years. Therapeutic resistance to aspirin 
      might explain a portion of this risk. Although formal diagnostic criteria and a 
      validated method of measurement are lacking, aspirin resistance may affect 
      between 5% and 45% of the population. Given the prevalence of cardiovascular 
      disease, the potential impact of aspirin resistance is large. Currently, however, 
      there are many unanswered questions regarding the biological mechanism, 
      diagnosis, population prevalence, clinical relevance, and optimal therapeutic 
      intervention for aspirin resistance.
FAU - Mason, Peter J
AU  - Mason PJ
AD  - Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston 
      University School of Medicine, Boston, Massachusetts, USA. pjmason@partners.org
FAU - Jacobs, Alice K
AU  - Jacobs AK
FAU - Freedman, Jane E
AU  - Freedman JE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2006 Aug 15;48(4):846-7; author reply 847. PMID: 16904562
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Atherosclerosis/*complications/*drug therapy
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Thrombosis/*complications/*drug therapy
RF  - 66
EDAT- 2005/09/20 09:00
MHDA- 2005/12/24 09:00
CRDT- 2005/09/20 09:00
PHST- 2004/06/08 00:00 [received]
PHST- 2004/08/10 00:00 [revised]
PHST- 2004/08/23 00:00 [accepted]
PHST- 2005/09/20 09:00 [pubmed]
PHST- 2005/12/24 09:00 [medline]
PHST- 2005/09/20 09:00 [entrez]
AID - S0735-1097(05)01558-5 [pii]
AID - 10.1016/j.jacc.2004.08.070 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2005 Sep 20;46(6):986-93. doi: 10.1016/j.jacc.2004.08.070.

PMID- 1304946
OWN - NLM
STAT- MEDLINE
DCOM- 19930713
LR  - 20161018
IS  - 0100-879X (Print)
IS  - 0100-879X (Linking)
VI  - 25
IP  - 1
DP  - 1992
TI  - Comparison of the anti-inflammatory effects of topically applied aspirin and 
      indomethacin following photocoagulation of the rabbit iris.
PG  - 67-73
AB  - 1. A comparative study of the inhibitory action of topically applied indomethacin 
      and aspirin (1% (w/v) 2 h before and immediately after trauma, totaling 4 mg 
      each) on myosis, increase in intraocular pressure and breakdown of the blood 
      aqueous barrier was performed. 2. Argon laser photocoagulation on the anterior 
      surface of the left iris of pigmented rabbits, totaling 2,250 mJ, was used as 
      traumatic stimulus. The untraumatized eye was used as a reference for 
      measurements. 3. Four groups of 10 animals each (control, photocoagulated, 
      photocoagulated plus indomethacin and photocoagulated plus aspirin) were studied. 
      4. Both drugs similarly inhibited the increase in the total protein concentration 
      in aqueous humor and in intraocular pressure at 10, 20 and 40 min. Only aspirin 
      showed some inhibitory action on the pupillary response 10 min after 
      photocoagulation.
FAU - Guimarães-Filho, S R
AU  - Guimarães-Filho SR
AD  - Departamento de Oftalmologia e Otorrinolaringologia, Faculdade de Medicina, 
      Universidade Federal de Minas Gerais, Belo Horizonte, Brasil.
FAU - Simal, C J
AU  - Simal CJ
FAU - Almeida, H G
AU  - Almeida HG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Brazil
TA  - Braz J Med Biol Res
JT  - Brazilian journal of medical and biological research = Revista brasileira de 
      pesquisas medicas e biologicas
JID - 8112917
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Indomethacin/administration & dosage/*pharmacology
MH  - Iris/*drug effects
MH  - Light Coagulation
MH  - Rabbits
MH  - Time Factors
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Braz J Med Biol Res. 1992;25(1):67-73.

PMID- 21665159
OWN - NLM
STAT- MEDLINE
DCOM- 20111102
LR  - 20131121
IS  - 1878-013X (Electronic)
IS  - 1878-013X (Linking)
VI  - 19
IP  - 3
DP  - 2011 Jul
TI  - What every emergency nurse needs to know about aspirin: an update.
PG  - 152-3
LID - 10.1016/j.ienj.2010.07.003 [doi]
AB  - In 2005, we presented a manuscript about the use of aspirin (ASA) in the setting 
      of the Emergency Department (ED). We now write to report recent developments in 
      our understanding about ASA and individual responses to the medication. The 
      phenomenon of aspirin resistance is explored.
CI  - Copyright © 2010 Elsevier Ltd. All rights reserved.
FAU - Turris, Sheila A
AU  - Turris SA
AD  - Affiliate Faculty, University of British Columbia, Central Health Center, 6th 
      Floor - 132 West Esplanade, North Vancouver, British Columbia, Canada V7M 1A2.
FAU - Finamore, Sheila
AU  - Finamore S
LA  - eng
PT  - Journal Article
DEP - 20100810
PL  - England
TA  - Int Emerg Nurs
JT  - International emergency nursing
JID - 101472191
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects/pharmacokinetics/*therapeutic use
MH  - Drug Interactions
MH  - *Drug Resistance
MH  - Emergency Nursing/organization & administration
MH  - Humans
MH  - *Nurse's Role
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Platelet Function Tests
MH  - Risk Factors
EDAT- 2011/06/15 06:00
MHDA- 2011/11/04 06:00
CRDT- 2011/06/14 06:00
PHST- 2010/04/25 00:00 [received]
PHST- 2010/06/23 00:00 [revised]
PHST- 2010/07/03 00:00 [accepted]
PHST- 2011/06/14 06:00 [entrez]
PHST- 2011/06/15 06:00 [pubmed]
PHST- 2011/11/04 06:00 [medline]
AID - S1755-599X(10)00054-6 [pii]
AID - 10.1016/j.ienj.2010.07.003 [doi]
PST - ppublish
SO  - Int Emerg Nurs. 2011 Jul;19(3):152-3. doi: 10.1016/j.ienj.2010.07.003. Epub 2010 
      Aug 10.

PMID- 10175978
OWN - NLM
STAT- MEDLINE
DCOM- 19980226
LR  - 20181113
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 12
IP  - 6
DP  - 1997 Dec
TI  - Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to 
      a New Zealand ischaemic stroke cost analysis.
PG  - 667-74
AB  - The aim of this study was to apply the findings of the European Stroke Prevention 
      Study 2 (ESPS-2) to a paper that quantified and described the annual cost of 
      ischaemic stroke in New Zealand, and to compare the cost of alternative drug 
      regimens in the secondary prevention of ischaemic stroke. Comparisons were made 
      between the costs of low-dosage aspirin (acetylsalicylic acid) monotherapy and a 
      combination of modified-release dipyridamole and low-dosage aspirin. Differences 
      in undiscounted costs were calculated over a 2-year period. The New Zealand cost 
      per stroke event was multiplied by the ESPS-2 incremental reduction in stroke 
      events to derive the cost of strokes avoided. As the focus of the paper was on 
      direct medical costs, the primary perspective adopted was that of a healthcare 
      provider or funder, but a societal perspective was also considered by evaluation 
      of direct nonmedical and indirect costs. Compared with aspirin monotherapy, 
      combination therapy generated incremental net direct costs of 18.22 New Zealand 
      dollars ($NZ) per patient or $NZ18,223 per 1000 patients. However, individually, 
      each treatment regimen resulted in direct cost savings when compared with 
      placebo: combination therapy $NZ905.16 per patient; aspirin monotherapy $NZ923.39 
      per patient (a difference between the 2 regimens of $NZ18.22 per patient). Total 
      direct and indirect incremental cost savings were $NZ40.96 per patient, and 
      $NZ40,963 per 1000 patients, for the combination therapy. The analysis 
      demonstrates that changing patients from low-dosage aspirin to a combination 
      therapy of modified-release dipyridamole plus low-dosage aspirin would result in 
      a small rise in incremental direct costs (using our conservative assumptions 
      relating to hospital and continuing institutional care costs). If less 
      conservative unit cost assumptions were adopted, a more likely outcome would be a 
      saving in direct incremental costs of up to $NZ400 per patient treated.
FAU - Scott, G
AU  - Scott G
AD  - W. Guy Scott and Associates Limited, Wellington, New Zealand. ghscott@xtra.co.nz
FAU - Scott, H M
AU  - Scott HM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Brain Ischemia/*prevention & control
MH  - Costs and Cost Analysis
MH  - Dipyridamole/administration & dosage
MH  - *Health Care Costs
MH  - Humans
EDAT- 1997/11/03 00:00
MHDA- 1997/11/03 00:01
CRDT- 1997/11/03 00:00
PHST- 1997/11/03 00:00 [pubmed]
PHST- 1997/11/03 00:01 [medline]
PHST- 1997/11/03 00:00 [entrez]
AID - 10.2165/00019053-199712060-00006 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 1997 Dec;12(6):667-74. doi: 10.2165/00019053-199712060-00006.

PMID- 10174319
OWN - NLM
STAT- MEDLINE
DCOM- 19971201
LR  - 20181113
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 12
IP  - 5
DP  - 1997 Nov
TI  - Is aspirin underused in myocardial infarction?
PG  - 524-32
AB  - This article reviews the relevant published literature in order to assess whether 
      aspirin (acetylsalicylic acid; ASA) is underused in myocardial infarction (MI), 
      taking into account: (i) the evidence of efficacy and safety from clinical 
      trials; (ii) authoritative recommendations about its use; and (iii) published 
      drug-utilisation studies. The use of low-dosage aspirin in the acute phase of MI, 
      and as secondary prevention, should be recommended to all patients who do not 
      have contraindications to the drug. This is a solid evidence-based recommendation 
      with potential benefits that are, at least, similar to those obtained with other 
      standard treatments. As this treatment is well tolerated and inexpensive, it is 
      also assumed that net savings can be achieved. No conventionally used 
      prophylactic aspirin regimen seems to be free from the risk of serious 
      gastrointestinal toxicity. This is especially important in primary prevention, in 
      which the benefits are small; there is, as yet, no clear evidence that aspirin is 
      indicated for routine use in patients at low risk of occlusive vascular events. 
      We have identified 21 published drug-utilisation studies, and the potential 
      underuse of aspirin in MI was not properly assessed in most of them. In these 
      studies, fairly high aspirin prescription rates were usually documented. However, 
      it seems clear that there is room for improvement, and that a significant 
      proportion of patients who could have benefited from aspirin did not receive it 
      or received less well-studied and more costly drugs. The prescription rates for 
      other drugs with proven efficacy have been lower, and the potential underuse 
      greater, than those documented for aspirin.
FAU - Arnau, J M
AU  - Arnau JM
AD  - Institut Català de Farmacologia, Service of Clinical Pharmacology, CSU Vall 
      d'Hebron, Barcelona, Spain. JMA@ICF.UAB.ES
FAU - Agustí, A
AU  - Agustí A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Utilization
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
RF  - 54
EDAT- 1997/10/04 00:00
MHDA- 1997/10/04 00:01
CRDT- 1997/10/04 00:00
PHST- 1997/10/04 00:00 [pubmed]
PHST- 1997/10/04 00:01 [medline]
PHST- 1997/10/04 00:00 [entrez]
AID - 10.2165/00019053-199712050-00003 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 1997 Nov;12(5):524-32. doi: 10.2165/00019053-199712050-00003.

PMID- 22486810
OWN - NLM
STAT- MEDLINE
DCOM- 20130305
LR  - 20131121
IS  - 1526-4610 (Electronic)
IS  - 0017-8748 (Linking)
VI  - 52
IP  - 8
DP  - 2012 Sep
TI  - Aspirin's effect on platelet inhibition in migraineurs.
PG  - 1207-18
LID - 10.1111/j.1526-4610.2012.02143.x [doi]
AB  - OBJECTIVE: To assess the effect of aspirin on platelet reactivity in migraineurs. 
      BACKGROUND: Migraineurs, particularly women with aura and high monthly migraine 
      frequency, are at risk for ischemic stroke and myocardial infarction (MI). High 
      on-aspirin platelet reactivity (HAPR), or aspirin resistance, has been reported 
      in females and patients with coronary artery disease, and is associated with 
      adverse outcomes. METHODS: Using a single group, pretest/posttest design, 50 
      migraineurs without prior history of stroke or MI were prospectively treated for 
      14 to 21 consecutive days with 325 mg generic enteric-coated aspirin, after 
      undergoing a 14-day aspirin washout. Platelet reactivity was measured after 
      aspirin washout and following aspirin treatment. Subjects were screened for HAPR 
      using the VerifyNow™ Aspirin Assay (Accumetrics, San Diego, CA, USA). HAPR was 
      defined as ≥ 460 Aspirin Reaction Units (ARU; primary endpoint). RESULTS: Fifty 
      subjects, 44 (88%) female, aged (mean ± standard deviation) 43 ± 12 years were 
      enrolled. Twelve (24%; 95% CI 12-36%) subjects, all female, had HAPR and were 
      classified as aspirin resistant. Subjects with HAPR had lower baseline hemoglobin 
      levels than those without HAPR (P = .03). Baseline hemoglobin was significantly 
      correlated with final ARU (r = -0.39, P = .005). CONCLUSIONS: Findings of this 
      exploratory study suggest that migraineurs have a higher prevalence of HAPR than 
      healthy volunteers or patients with coronary artery disease taking aspirin 325 
      mg. The clinical implications of HAPR in migraine warrant further exploration due 
      to the risk of stroke and MI and the potential need for antiplatelet therapy in 
      this population.
CI  - © 2012 American Headache Society.
FAU - Jesurum, Jill T
AU  - Jesurum JT
AD  - The Swedish Heart & Vascular Institute, Swedish Medical Center, Seattle, WA 
      98122, USA. jill.jesurum@swedish.org
FAU - Fuller, Cindy J
AU  - Fuller CJ
FAU - Murinova, Natalia
AU  - Murinova N
FAU - Truva, Colleen M
AU  - Truva CM
FAU - Lucas, Sylvia M
AU  - Lucas SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120405
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*blood/complications
MH  - Myocardial Infarction/etiology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Risk Factors
MH  - Stroke/etiology
EDAT- 2012/04/11 06:00
MHDA- 2013/03/06 06:00
CRDT- 2012/04/11 06:00
PHST- 2012/04/11 06:00 [entrez]
PHST- 2012/04/11 06:00 [pubmed]
PHST- 2013/03/06 06:00 [medline]
AID - 10.1111/j.1526-4610.2012.02143.x [doi]
PST - ppublish
SO  - Headache. 2012 Sep;52(8):1207-18. doi: 10.1111/j.1526-4610.2012.02143.x. Epub 
      2012 Apr 5.

PMID- 6794584
OWN - NLM
STAT- MEDLINE
DCOM- 19820128
LR  - 20190515
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 53
IP  - 10
DP  - 1981 Oct
TI  - Injectable aspirin as a postoperative analgesic.
PG  - 1069-71
AB  - The effectiveness of lysine acetyl salicylate (LAS) 1.8 g, equivalent to aspirin 
      1 g, in relieving severe, immediate, postoperative pain has been compared with 
      that of morphine 10 mg in comparable groups of patients. A single injection of 
      LAS 1.8 did not give effective or consistent relief of pain, while morphine was 
      both effective and consistent in its action. However, LAS was shown to have some 
      analgesic activity.
FAU - McAteer, E
AU  - McAteer E
FAU - Dundee, J W
AU  - Dundee JW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Analgesics)
RN  - 76I7G6D29C (Morphine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - *Analgesics
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Morphine/therapeutic use
MH  - Pain, Postoperative/*drug therapy
EDAT- 1981/10/01 00:00
MHDA- 1981/10/01 00:01
CRDT- 1981/10/01 00:00
PHST- 1981/10/01 00:00 [pubmed]
PHST- 1981/10/01 00:01 [medline]
PHST- 1981/10/01 00:00 [entrez]
AID - S0007-0912(17)42934-5 [pii]
AID - 10.1093/bja/53.10.1069 [doi]
PST - ppublish
SO  - Br J Anaesth. 1981 Oct;53(10):1069-71. doi: 10.1093/bja/53.10.1069.

PMID- 36634762
OWN - NLM
STAT- MEDLINE
DCOM- 20230411
LR  - 20230411
IS  - 2174-2030 (Electronic)
IS  - 0870-2551 (Linking)
VI  - 42
IP  - 4
DP  - 2023 Apr
TI  - Adherence to European guidelines for the use of aspirin in primary health care.
PG  - 307-313
LID - S0870-2551(23)00050-1 [pii]
LID - 10.1016/j.repc.2022.03.007 [doi]
AB  - INTRODUCTION AND OBJECTIVES: Cardiovascular disease remains a leading cause of 
      global morbidity and mortality. The administration of low doses of aspirin in 
      secondary prevention of atherosclerotic cardiovascular disease (ASCVD) has been 
      clearly established. However, the most recent guidelines do not recommend aspirin 
      in primary prevention, reserving it for high-risk patients and after a 
      risk/benefit assessment. The aim of this study was to assess adherence to 
      European guidelines for the use of aspirin in primary and secondary prevention of 
      ASCVD in primary health care. METHODS: The study population consisted of 
      individuals aged >50 years registered at two primary health care units without 
      (primary prevention) and with previous ASCVD events (secondary prevention). 
      RESULTS: We studied a total of 1262 individuals, 720 in primary prevention and 
      542 in secondary prevention. A total of 61 individuals (8.5%) were under aspirin 
      therapy in primary prevention, most of them taking 150 mg/day (57%). In secondary 
      prevention, 195 patients (27%) were receiving aspirin only, most taking 150 
      mg/day (52%), and 166 patients (31%) were not under any antithrombotic or 
      anticoagulant therapy. The 100 mg dosage was predominant in patients with 
      ischemic heart disease with (64%) and without (64%) angina, as well as those with 
      myocardial infarction (61.5%) and peripheral vascular disease (62%). CONCLUSIONS: 
      In this study, the prevalence of aspirin use in primary prevention was 8.5%. We 
      found that 30% of patients were not taking either antithrombotic or 
      anticoagulation therapy in secondary prevention. In both primary and secondary 
      prevention, the 150 mg dosage was predominant.
CI  - Copyright © 2023. Publicado por Elsevier España, S.L.U.
FAU - Ferreira Moita, Catarina
AU  - Ferreira Moita C
AD  - USF S. Martinho de Alcabideche, ACES Cascais, Cascais, Portugal. Electronic 
      address: catarina.moita@gmail.com.
FAU - Marau, Gonçalo
AU  - Marau G
AD  - USF S. Julião, ACES Lisboa Ocidental e Oeiras, Oeiras, Portugal.
FAU - Corte-Real, Susana
AU  - Corte-Real S
AD  - USF S. Julião, ACES Lisboa Ocidental e Oeiras, Oeiras, Portugal.
FAU - Dantas, Ana
AU  - Dantas A
AD  - USF S. Martinho de Alcabideche, ACES Cascais, Cascais, Portugal.
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20230109
PL  - Portugal
TA  - Rev Port Cardiol
JT  - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de 
      Cardiologia = Portuguese journal of cardiology : an official journal of the 
      Portuguese Society of Cardiology
JID - 8710716
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
CIN - Rev Port Cardiol. 2023 Apr;42(4):315-317. PMID: 36639109
MH  - Humans
MH  - Aspirin/therapeutic use/adverse effects
MH  - *Cardiovascular Diseases/prevention & control
MH  - Fibrinolytic Agents
MH  - *Myocardial Infarction
MH  - Anticoagulants
MH  - *Atherosclerosis
MH  - Primary Health Care
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Primary Prevention
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiometabolic risk factors
OT  - Cuidados de saúde primários
OT  - Fatores de risco cardiovascular
OT  - Prevenção primária
OT  - Prevenção secundária
OT  - Primary health care
OT  - Primary prevention
OT  - Secondary prevention
OT  - Ácido acetilsalicílico
EDAT- 2023/01/13 06:00
MHDA- 2023/04/11 06:41
CRDT- 2023/01/12 19:20
PHST- 2021/12/17 00:00 [received]
PHST- 2022/02/24 00:00 [revised]
PHST- 2022/03/27 00:00 [accepted]
PHST- 2023/04/11 06:41 [medline]
PHST- 2023/01/13 06:00 [pubmed]
PHST- 2023/01/12 19:20 [entrez]
AID - S0870-2551(23)00050-1 [pii]
AID - 10.1016/j.repc.2022.03.007 [doi]
PST - ppublish
SO  - Rev Port Cardiol. 2023 Apr;42(4):307-313. doi: 10.1016/j.repc.2022.03.007. Epub 
      2023 Jan 9.

PMID- 18215480
OWN - NLM
STAT- MEDLINE
DCOM- 20080903
LR  - 20191210
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 355
IP  - 1-2
DP  - 2008 May 1
TI  - Solid-state compatibility studies using a high-throughput and automated forced 
      degradation system.
PG  - 164-73
LID - 10.1016/j.ijpharm.2007.12.002 [doi]
AB  - As the number of pharmaceutical candidate compounds increases, so does the need 
      for development workflow that is capable of handling more compounds in shorter 
      times. In this paper, the establishment of a high-throughput automated powder 
      compatibility testing system is reported. The integrated robotic system 
      automatically dispenses, weighs, and stores powder samples, and extracts and 
      analyses drug substance using ultra-performance liquid chromatography (UPLC). 
      Although automation of powder testing systems is generally accompanied by 
      difficulties in accuracy and precision, mass tracking at every unit operation 
      allowed the system to be validated. In a standard procedure, drug substance and 
      an excipient were dispensed 1:1 (w/w), stored at 70 degrees C for 9 days, 
      dissolved in solvents, and analyzed to examine the degradation of drug substance 
      and the increases in related substances. The robot quantitatively discriminate 
      between initial conditions of the incompatible powder mixtures of aspirin and 
      magnesium stearate (Mg-St) prepared with or without the use of a whisk and shaker 
      system, demonstrating the capability for evaluating powder mixtures with varying 
      degrees of homogeneity where the contact area between excipient and drug 
      substance differs. Differential scanning calorimetry (DSC), however, did not 
      clearly distinguish between those powder samples, indicating that DSC is less 
      sensitive to powder conditions. The incompatibility results of aspirin and Mg-St 
      were comparable to those reported previously, demonstrating that the automated 
      testing system is reliable. The robot reduced manual work to one sixth and cut 
      down on the costs of outsourcing. An extensive impact is anticipated on 
      development workflows because this system is applicable not only to compatibility 
      testing but also to analytical method development for drug products.
FAU - Wakasawa, Tatsuyoshi
AU  - Wakasawa T
AD  - Pharmaceutical Analysis, Pharmaceutical Research and Technology Laboratories, 
      Astellas Pharma Inc., 180 Ozumi, Yaizu, Shizuoka 425-0072, Japan.
FAU - Sano, Kyoko
AU  - Sano K
FAU - Hirakura, Yutaka
AU  - Hirakura Y
FAU - Toyo'oka, Toshimasa
AU  - Toyo'oka T
FAU - Kitamura, Satoshi
AU  - Kitamura S
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20071214
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Excipients)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/chemistry
MH  - Automation
MH  - Calorimetry, Differential Scanning
MH  - Chemistry, Pharmaceutical/*methods
MH  - Drug Compounding/instrumentation
MH  - *Drug Incompatibility
MH  - Excipients
MH  - Reproducibility of Results
MH  - Software
EDAT- 2008/01/25 09:00
MHDA- 2008/09/04 09:00
CRDT- 2008/01/25 09:00
PHST- 2007/09/20 00:00 [received]
PHST- 2007/11/05 00:00 [revised]
PHST- 2007/12/05 00:00 [accepted]
PHST- 2008/01/25 09:00 [pubmed]
PHST- 2008/09/04 09:00 [medline]
PHST- 2008/01/25 09:00 [entrez]
AID - S0378-5173(07)01007-1 [pii]
AID - 10.1016/j.ijpharm.2007.12.002 [doi]
PST - ppublish
SO  - Int J Pharm. 2008 May 1;355(1-2):164-73. doi: 10.1016/j.ijpharm.2007.12.002. Epub 
      2007 Dec 14.

PMID- 36301649
OWN - NLM
STAT- MEDLINE
DCOM- 20221031
LR  - 20221031
IS  - 2379-3961 (Electronic)
IS  - 1098-1861 (Linking)
VI  - 121
IP  - 3
DP  - 2022 Oct
TI  - Interdisciplinary Deprescribing of Aspirin Through Prescriber Education and 
      Provision of Patient-Specific Recommendations.
PG  - 220-225
AB  - BACKGROUND: Inappropriate aspirin use can lead to increased frequency of bleeding 
      events and poor patient outcomes. OBJECTIVES: Compare current aspirin prescribing 
      to guideline recommendations and analyze the impact of pharmacist education for 
      clinicians with provision of patient-specific recommendations. METHODS: Internal 
      medicine residents received 1 educational session on appropriate aspirin use. 
      Over a 5-month period post-education, 100 patients on aspirin with a clinic 
      appointment were screened and their charts reviewed. Aspirin use was classified 
      based on guideline recommendations as follows: (1) recommended, (2) weigh the 
      risk and benefits, (3) not recommended, (4) dose change recommended, or (5) 
      outside of guideline recommendation. A recommendation for aspirin deprescribing 
      was then communicated to the clinician prior to the patient's appointment. 
      Prescriber practice following the appointment was collected and analyzed. 
      RESULTS: Inappropriate aspirin use occurred in 29% (n = 29) of patients prior to 
      their appointment. Of these, aspirin was not recommended in 65.5% (n = 19), and a 
      dose reduction from 325 mg to 81 mg was recommended in 34.5% (n = 10). Of the 81 
      patients who kept their appointment, pharmacist recommendations to deprescribe 
      aspirin were communicated to the clincian for 20 patients (24.7%) and resulted in 
      a 55% aspirin deprescription. CONCLUSIONS: The majority of patients identified as 
      using aspirin inappropriately fell into 3 groups: (1) patients taking 325 mg 
      aspirin, (2) patients taking aspirin for primary prevention, and (3) patients 
      taking aspirin concomitantly with an anticoagulant. Strategies that may lead to 
      optimization of aspirin use include lectures and patient-specific chart reviews 
      with pharmacist recommendation.
CI  - Copyright© Board of Regents of the University of Wisconsin System and The Medical 
      College of Wisconsin, Inc.
FAU - Draeger, Cameron
AU  - Draeger C
AD  - Pharmacy Residency, Marshfield Medical Medical Center, Marshfield, Wisconsin.
FAU - Lodhi, Fahad
AU  - Lodhi F
FAU - Geissinger, Nicole
AU  - Geissinger N
AD  - Department of Internal Medicine, Marshfield Health Clinic System, Marshfield, 
      Wisconsin.
FAU - Larson, Tonja
AU  - Larson T
AD  - Department of Clinical Pharmacy, Marshfield Clinic Health System, Marshfield, 
      Wisconsin.
FAU - Griesbach, Sara
AU  - Griesbach S
AD  - Department of Clinical Pharmacy, Marshfield Clinic Health System, Marshfield, 
      Wisconsin, griesbach.sara@marshfieldclinic.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - WMJ
JT  - WMJ : official publication of the State Medical Society of Wisconsin
JID - 9716054
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - *Deprescriptions
MH  - Pharmacists
EDAT- 2022/10/28 06:00
MHDA- 2022/11/01 06:00
CRDT- 2022/10/27 12:03
PHST- 2022/10/27 12:03 [entrez]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/11/01 06:00 [medline]
PST - ppublish
SO  - WMJ. 2022 Oct;121(3):220-225.

PMID- 3281822
OWN - NLM
STAT- MEDLINE
DCOM- 19880516
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 35
IP  - 2
DP  - 1988 Feb
TI  - Aspirin in cardiovascular disease.
PG  - 154-76
AB  - Although other mechanisms may be contributory, the antithrombotic properties of 
      aspirin derive predominantly from its platelet-inhibitory effects. These are 
      mediated via irreversible acetylation of platelet cyclo-oxygenase with subsequent 
      blockade of platelet thromboxane synthesis. Long term administration of doses of 
      aspirin as low as 20mg daily depresses platelet thromboxane formation by more 
      than 90%; however, higher doses appear to be necessary to prevent 
      thromboxane-dependent platelet activation in vivo. While there is evidence of 
      biochemical selectivity with low doses of aspirin, significant reduction of the 
      platelet-inhibitory eicosenoid, prostacyclin, occurs even at dosages ranging from 
      20 to 40mg daily. The ability of aspirin to prevent the occurrence or recurrence 
      of vaso-occlusion has been extensively investigated. In the secondary prevention 
      of myocardial infarction 7 placebo-controlled trials involving more than 15,000 
      patients have been completed. The dose of aspirin varied from 300 to 1500mg 
      daily. Although none of the individual trials produced statistically significant 
      reductions in total or coronary mortality, taken together the results are highly 
      suggestive of a beneficial effect of aspirin. Similarly, 2 recent studies in 
      patients with unstable angina demonstrated a protective effect of aspirin against 
      acute myocardial infarction and death. While each study employed widely different 
      doses of aspirin (324mg and 1250mg daily) similar reductions in mortality were 
      reported. The effects of aspirin on the prevention of coronary artery bypass 
      graft occlusion have been evaluated in 9 trials. Aspirin in doses of 100 to 975mg 
      daily was shown to be of benefit in preventing early (less than 6 months) graft 
      occlusion, particularly when therapy was started within 24 hours of operation. In 
      patients with prosthetic vascular grafts of the lower limbs, aspirin has been 
      shown to reduce platelet deposition, however further controlled trials will be 
      required to establish the patient population most likely to benefit and, as in 
      all these studies, the optimum dose of aspirin to employ. In patients with 
      prosthetic heart valves it is clear that aspirin alone is insufficient to prevent 
      thromboembolic complications and when administered as an adjunct to anticoagulant 
      therapy it is associated with a high incidence of bleeding. In contrast, there is 
      convincing evidence from several studies for the efficacy of aspirin in doses of 
      990 to 1300mg daily in the prevention of stroke and death in patients with 
      transient ischaemic attacks.(ABSTRACT TRUNCATED AT 400 WORDS)
FAU - Reilly, I A
AU  - Reilly IA
AD  - Division of Clinical Pharmacology, Vanderbilt University, Nashville.
FAU - FitzGerald, G A
AU  - FitzGerald GA
LA  - eng
GR  - HL 30400/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
RF  - 181
EDAT- 1988/02/01 00:00
MHDA- 1988/02/01 00:01
CRDT- 1988/02/01 00:00
PHST- 1988/02/01 00:00 [pubmed]
PHST- 1988/02/01 00:01 [medline]
PHST- 1988/02/01 00:00 [entrez]
AID - 10.2165/00003495-198835020-00005 [doi]
PST - ppublish
SO  - Drugs. 1988 Feb;35(2):154-76. doi: 10.2165/00003495-198835020-00005.

PMID- 22582636
OWN - NLM
STAT- MEDLINE
DCOM- 20150708
LR  - 20181201
IS  - 1000-0593 (Print)
IS  - 1000-0593 (Linking)
VI  - 32
IP  - 3
DP  - 2012 Mar
TI  - [Study of aspirin and its interaction with DNA by Raman and UV spectroscopies].
PG  - 699-702
AB  - Normal Raman spectroscopy and surface-enhanced Raman spectroscopy of aspirin and 
      aspirin tablet were reported, and the vibrational and enhanced peaks were 
      assigned; the interaction of aspirin with DNA was investigated by SERS and UV. 
      The results showed that NRS and SERS of aspirin and aspirin tablet were 
      consistent basically, which indicated that excipient hardly affected the 
      detection of aspirin; in SERS, aspirin was absorbed perpendicularly on silver 
      colloid through the carboxyl group and the benzene ring; The interaction was 
      mainly caused by the inserting-action mode between aspirin and DNA, and the 
      benzene ring and C=O of aspirin were inserted between the base pair of the double 
      helix structure of DNA, which provided important information and useful reference 
      for understanding deeply the mechanism of action of this kind of drug.
FAU - Kang, Qian-qian
AU  - Kang QQ
AD  - Key Laboratory of Luminescence and Real-Time Analysis (Southwest University), 
      Ministry of Education, and School of Chemistry and Chemical Engineering, 
      Southwest University, Chongqing 400715, China. lanqianer@163.com
FAU - Zhou, Guang-ming
AU  - Zhou GM
LA  - chi
PT  - Journal Article
PL  - China
TA  - Guang Pu Xue Yu Guang Pu Fen Xi
JT  - Guang pu xue yu guang pu fen xi = Guang pu
JID - 9424805
RN  - 9007-49-2 (DNA)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - DNA/*chemistry
MH  - Spectrophotometry, Ultraviolet
MH  - Spectrum Analysis, Raman
EDAT- 2012/05/16 06:00
MHDA- 2015/07/15 06:00
CRDT- 2012/05/16 06:00
PHST- 2012/05/16 06:00 [entrez]
PHST- 2012/05/16 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
PST - ppublish
SO  - Guang Pu Xue Yu Guang Pu Fen Xi. 2012 Mar;32(3):699-702.

PMID- 9622040
OWN - NLM
STAT- MEDLINE
DCOM- 19980811
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 89
IP  - 3
DP  - 1998 Feb 1
TI  - Thromboembolic complications several days after a single-dose administration of 
      aspirin.
PG  - 123-7
AB  - The antithrombotic properties of acetyl salicylic acid (ASA) used at current 
      doses are largely demonstrated. However, our previous study showed unexpected 
      thrombotic potencies associated with the use of this drug. In this study we 
      investigate the effect of aspirin on an experimental thrombosis induced by laser 
      beams, according to its in vivo plasma concentration. Experiments were done on 
      nine groups of seven Wistar male rats. The groups are defined by the delay 
      between aspirin administration time and the laser-induced thrombosis time. 
      Results from this study showed an enhancement of thromboembolic complications 
      when thrombosis was induced 8 or 10 days after aspirin administration; the number 
      of emboli and the duration of embolization are increased, compared to the control 
      group. The prothrombotic properties of ASA demonstrated in this study, might 
      limit its therapeutic benefit and might explain thromboembolic complications 
      observed in some ASA-treated patients. These results also suggest a biological 
      monitoring several days after aspirin administration to patients.
FAU - Aguejouf, O
AU  - Aguejouf O
AD  - Laboratoire d'Hématologie, Faculté de Pharmacie, Université de Bordeaux II, 
      France.
FAU - Belougne-Malfatti, E
AU  - Belougne-Malfatti E
FAU - Doutremepuich, F
AU  - Doutremepuich F
FAU - Belon, P
AU  - Belon P
FAU - Doutremepuich, C
AU  - Doutremepuich C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Cutaneous
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Lasers
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Thromboembolism/*chemically induced
MH  - Time Factors
EDAT- 1998/06/11 00:00
MHDA- 1998/06/11 00:01
CRDT- 1998/06/11 00:00
PHST- 1998/06/11 00:00 [pubmed]
PHST- 1998/06/11 00:01 [medline]
PHST- 1998/06/11 00:00 [entrez]
AID - S0049384897003022 [pii]
AID - 10.1016/s0049-3848(97)00302-2 [doi]
PST - ppublish
SO  - Thromb Res. 1998 Feb 1;89(3):123-7. doi: 10.1016/s0049-3848(97)00302-2.

PMID- 2519257
OWN - NLM
STAT- MEDLINE
DCOM- 19911122
LR  - 20191029
IS  - 0385-0137 (Print)
IS  - 0385-0137 (Linking)
VI  - 31
IP  - 1
DP  - 1989 Feb
TI  - Hypocalcemic action of the several types of salicylic acid analogues.
PG  - 89-94
AB  - The present study was performed to see the structure-activity relationships on 
      the aspirin-induced hypocalcemia. Several kinds of salicylic acid (SA) analogues 
      administered orally with a stomach tube. In general, the drugs were suspended in 
      the 2% CMC solution. At the scheduled times after the treatment, 60 microliters 
      of the blood was collected to determine the level of calcium. Aspirin, sodium 
      salt of o-hydroxybenzoic acid (Na-salicylate), sodium salt of m- and 
      p-hydroxybenzoic acid (HBA), 2,5-dihydroxybenzoic acid (DHBA), PAS sodium 
      dihydrate (PAS-Na), salicylamide (SAM) and 2% CMC control were used. Hypocalcemia 
      was induced by aspirin and Na-salicylate but not by m- and p-HBA-Na. In addition, 
      DHBA and PAS caused hypocalcemia when they were administered intravenously but 
      not orally. These results suggest that the carboxyl group must be adjacent to the 
      hydroxyl group on the benzene ring to induce this type of hypocalcemia and that 
      the SA structure would be able to induce hypocalcemia, even in the presence of 
      the additional third substituent on the same ring. On the comparison between 
      aspirin-DL lysine (water soluble aspirin) and SA-DL lysine, SA-DL lysine, which 
      is not an inhibitor of PG synthetase, was more effective on the hypocalcemic 
      action than ASP-DL lysine. The phenomenon was observed at the stage especially 
      immediately after intravenous injection, when the acetyl group may be more 
      responsible to acetylate the PG synthetase in the aspirin-DL lysine group. The 
      present results seems to be consistent with the previous hypothesis that PGs are 
      not involved in the process of aspirin-induced hypocalcemia in the rat.
FAU - Kato, Y
AU  - Kato Y
FAU - Nishishita, K
AU  - Nishishita K
FAU - Sakai, H
AU  - Sakai H
FAU - Tatsumi, M
AU  - Tatsumi M
FAU - Yamamoto, K
AU  - Yamamoto K
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Shika Kiso Igakkai Zasshi
JT  - Shika Kiso Igakkai zasshi = Japanese journal of oral biology
JID - 7506047
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Salicylamides)
RN  - EM8BM710ZC (salicylamide)
RN  - R16CO5Y76E (Aspirin)
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Hydroxybenzoates/pharmacology
MH  - Hypocalcemia/*chemically induced
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Salicylamides/pharmacology
EDAT- 1989/02/01 00:00
MHDA- 1989/02/01 00:01
CRDT- 1989/02/01 00:00
PHST- 1989/02/01 00:00 [pubmed]
PHST- 1989/02/01 00:01 [medline]
PHST- 1989/02/01 00:00 [entrez]
AID - 10.2330/joralbiosci1965.31.89 [doi]
PST - ppublish
SO  - Shika Kiso Igakkai Zasshi. 1989 Feb;31(1):89-94. doi: 
      10.2330/joralbiosci1965.31.89.

PMID- 933973
OWN - NLM
STAT- MEDLINE
DCOM- 19760901
LR  - 20131121
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 1
IP  - 17
DP  - 1976 Apr 24
TI  - Single-dose evaluation of a new enteric-coated aspirin preparation.
PG  - 617-9
AB  - The bioavailability of a new enteric-coated tablet of aspirin (Ecotrin, Smith, 
      Kline and French) was evaluated after single doses to eight volunteers. One 
      tablet was administered to each subject on four occasions--twice after a light 
      breakfast, once after a heavy breakfast and once after pretreatment with 
      metoclopramide. The study utilized non-invasive techniques. The rate of 
      absorption of aspirin was estimated by the time course of concentrations of 
      salicylate in saliva, while the total bioavailability was determined by the 
      recovery of total salicylate in urine. The urinary recovery of aspirin from all 
      32 trials was 575 +/- 25 mg (mean +/- standard error), representing 89% +/- 4% of 
      the administered dose. The different treatments did not significantly alter the 
      urinary recovery. The absorption of aspirin from the enteric-coated tablets was 
      delayed and slow. Absorption was retarded by a heavy meal and hastened by 
      pretreatment with metoclopramide. The effect of metoclopramide is consistent with 
      the release of aspirin in the small intestine. Overall, the single-dose tests 
      indicated satisfactory functioning of the enteric coating.
FAU - Paull, P
AU  - Paull P
FAU - Day, R
AU  - Day R
FAU - Graham, G
AU  - Graham G
FAU - Champion, D
AU  - Champion D
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Tablets, Enteric-Coated)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*metabolism/urine
MH  - Biological Availability
MH  - Eating
MH  - Humans
MH  - Intestinal Absorption/drug effects
MH  - Male
MH  - Metoclopramide/pharmacology
MH  - Saliva/metabolism
MH  - Tablets, Enteric-Coated
EDAT- 1976/04/24 00:00
MHDA- 1976/04/24 00:01
CRDT- 1976/04/24 00:00
PHST- 1976/04/24 00:00 [pubmed]
PHST- 1976/04/24 00:01 [medline]
PHST- 1976/04/24 00:00 [entrez]
PST - ppublish
SO  - Med J Aust. 1976 Apr 24;1(17):617-9.

PMID- 8983259
OWN - NLM
STAT- MEDLINE
DCOM- 19970107
LR  - 20181113
IS  - 0960-1643 (Print)
IS  - 0960-1643 (Linking)
VI  - 46
IP  - 407
DP  - 1996 Jun
TI  - Who needs antiplatelet therapy?
PG  - 367-70
AB  - A series of overviews or meta-analyses of randomized clinical trials prepared by 
      the Antiplatelet Trialists' Collaboration were published in the British Medical 
      Journal in January 1994. They demonstrated that prolonged courses of medium-dose 
      aspirin were very effective at preventing both fatal and non-fatal myocardial 
      infarction and stroke in patients at high risk of occlusive vascular disease. The 
      aim of this review is to provide the general practitioner with a practical guide 
      to the use of aspirin in patients at high and low risk of occlusive vascular 
      disease and to discuss appropriate dosages and contraindications to treatment in 
      the light of all the recent evidence.
FAU - Moher, M
AU  - Moher M
AD  - ICRF General Practice Research Group, University Department of Public Health and 
      Primary Care, Oxford.
FAU - Lancaster, T
AU  - Lancaster T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of 
      General Practitioners
JID - 9005323
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br J Gen Pract. 1996 Aug;46(409):494-5. PMID: 8949338
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
PMC - PMC1239672
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
PST - ppublish
SO  - Br J Gen Pract. 1996 Jun;46(407):367-70.

PMID- 17241655
OWN - NLM
STAT- MEDLINE
DCOM- 20070919
LR  - 20131121
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 120
IP  - 3
DP  - 2007
TI  - Aspirin resistance.
PG  - 337-46
AB  - Aspirin resistance refers to less than expected suppression of thromboxane A(2) 
      production by aspirin and has been reported to be independently associated with 
      an increased risk of adverse cardiovascular events. Possible causes of aspirin 
      resistance include poor compliance, drug interaction, inadequate aspirin dose, 
      increase turnover of platelets, genetic polymorphisms of cyclo-oxygenase-1, and 
      upregulation of alternate (non-platelet) pathways of thromboxane production. 
      Laboratory methods used to detect aspirin resistance include those that measure 
      thromboxane A(2) production and thromboxane A(2)-dependent platelet function. 
      However, since there is currently no standardised approach to the diagnosis and 
      there are no proven effective treatments for aspirin resistance that improve 
      outcome, patients with cardiovascular disease receiving aspirin should not be 
      routinely tested for aspirin resistance. Instead physicians should be aware of 
      the factors that may impair aspirin function, ensure that they use an appropriate 
      dose of aspirin and optimise compliance with aspirin therapy. Further research 
      exploring the mechanisms of aspirin resistance is needed in order to better 
      define and develop a standardised test for aspirin resistance that is specific, 
      reliable, can be readily applied in routine laboratories and correlate with an 
      increased risk of cardiovascular events.
FAU - Tran, Huyen A
AU  - Tran HA
AD  - Department of Clinical Haematology, Monash Medical Centre, Clayton, Victoria, 
      Australia. huyen.tran@southernhealth.org.au
FAU - Anand, Sonia S
AU  - Anand SS
FAU - Hankey, Graeme J
AU  - Hankey GJ
FAU - Eikelboom, John W
AU  - Eikelboom JW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20070122
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Forecasting
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests/methods
MH  - Thromboxanes/biosynthesis
RF  - 76
EDAT- 2007/01/24 09:00
MHDA- 2007/09/20 09:00
CRDT- 2007/01/24 09:00
PHST- 2006/07/31 00:00 [received]
PHST- 2006/07/31 00:00 [revised]
PHST- 2006/08/10 00:00 [accepted]
PHST- 2007/01/24 09:00 [pubmed]
PHST- 2007/09/20 09:00 [medline]
PHST- 2007/01/24 09:00 [entrez]
AID - S0049-3848(06)00501-9 [pii]
AID - 10.1016/j.thromres.2006.08.014 [doi]
PST - ppublish
SO  - Thromb Res. 2007;120(3):337-46. doi: 10.1016/j.thromres.2006.08.014. Epub 2007 
      Jan 22.

PMID- 8968267
OWN - NLM
STAT- MEDLINE
DCOM- 19970114
LR  - 20190706
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 24
IP  - 12
DP  - 1996 Dec
TI  - Phase I study of the safety and pharmacologic effects of diaspirin cross-linked 
      hemoglobin solution.
PG  - 1993-2000
AB  - OBJECTIVE: To evaluate the safety, pharmacokinetics, and pharmacodynamics of 
      diaspirin cross-linked hemoglobin solution (DCLHb) in normal, healthy volunteers. 
      DESIGN: Randomized, double-blind, controlled, crossover study. SETTING: Phase I 
      research facility of a contract research organization. PATIENTS: Twenty-four 
      healthy adult volunteers. INTERVENTIONS: Diaspirin cross-linked hemoglobin 
      solution (25, 50, or 100 mg/kg) or equal volume of lactated Ringer's solution was 
      infused on day 1; the alternate solution was infused 6 days later. Laboratory 
      analyses, electrocardiograms, and Holter and telemetry monitoring were performed 
      to assess organ function, pharmacokinetics, and potential toxicity. Vital signs, 
      pulse oximetry, laser Doppler flowmetry, and toe temperature were measured to 
      evaluate diaspirin cross-linked hemoglobin solution's pharmacodynamic effects. 
      MEASUREMENTS AND MAIN RESULTS: There were no serious adverse events associated 
      with diaspirin cross-linked hemoglobin solution infusion. Abdominal pain occurred 
      in three subjects after control infusion and in six subjects after diaspirin 
      cross-linked hemoglobin solution infusion; no treatment was required. A 
      dose-related increase in lactic dehydrogenase (LDH)-5 isoenzyme concentrations 
      was observed in 12 subjects after diaspirin cross-linked hemoglobin solution 
      infusion. There were no associated increases in the circulating concentrations of 
      total LDH, aspartate aminotransferase, alanine aminotransferase, or alkaline 
      phosphatase. Total serum creatine kinase concentrations increased significantly 
      after infusion of 100 mg/kg of diaspirin cross-linked hemoglobin solution; the 
      isoenzyme creatine kinase-myocardial band (CK-MB) was not increased, nor were 
      there any abnormal electrocardiogram findings. There were no differences in laser 
      Doppler, pulse oximetry, or toe temperature measurements during or after either 
      infusion. The half-life of diaspirin cross-linked hemoglobin solution was 2.5 hrs 
      for the 25- and 50-mg/kg doses and 3.3 hrs for the 100-mg/kg dose. A dose-related 
      increase in blood pressure occurred with diaspirin cross-linked hemoglobin 
      solution. CONCLUSIONS: Diaspirin cross-linked hemoglobin solution doses of 25, 
      50, and 100 mg/kg are well tolerated, without evidence of organ dysfunction or 
      toxicity. Diaspirin cross-linked hemoglobin solution's pressor effect is without 
      evidence of decreased peripheral perfusion. Further investigations of its use in 
      certain patient populations are warranted.
FAU - Przybelski, R J
AU  - Przybelski RJ
AD  - Substitutes Division, Baxter Healthcare Corporation, Round Lake IL, USA.
FAU - Daily, E K
AU  - Daily EK
FAU - Kisicki, J C
AU  - Kisicki JC
FAU - Mattia-Goldberg, C
AU  - Mattia-Goldberg C
FAU - Bounds, M J
AU  - Bounds MJ
FAU - Colburn, W A
AU  - Colburn WA
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*analogs & 
      derivatives/pharmacokinetics/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/administration & dosage/*pharmacokinetics/*pharmacology
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Safety
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - 10.1097/00003246-199612000-00011 [doi]
PST - ppublish
SO  - Crit Care Med. 1996 Dec;24(12):1993-2000. doi: 10.1097/00003246-199612000-00011.

PMID- 10992168
OWN - NLM
STAT- MEDLINE
DCOM- 20001010
LR  - 20131121
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 183
IP  - 3
DP  - 2000 Sep
TI  - Preeclampsia prevention: lessons from the low-dose aspirin therapy trials.
PG  - 523-8
AB  - The ability of low-dose aspirin therapy to prevent preeclampsia is controversial. 
      The 19 randomized, placebo-controlled trials of low-dose aspirin therapy reported 
      in the literature were categorized according to the risk factors of the women 
      studied-nulliparity, underlying medical illness, poor obstetric history, and 
      multiple gestation. Low-dose aspirin therapy reduced the incidences of 
      preeclampsia among women with poor obstetric histories and among high-risk 
      nulliparous women but was ineffective among women with underlying medical 
      illness. It was marginally effective among low-risk nulliparous women, and 
      benefits for women with multiple gestations are unclear. More research is needed 
      to better identify high-risk nulliparous women who might benefit from the use of 
      low-dose aspirin therapy and to define potential benefits for women with multiple 
      gestations. The differential effects of low-dose aspirin therapy in the various 
      risk groups are probably a result of varying roles in the groups of abnormal 
      arachidonic acid metabolism in mediating preeclampsia. It is premature to abandon 
      the use of low-dose aspirin therapy for preeclampsia prevention.
FAU - Heyborne, K D
AU  - Heyborne KD
AD  - Division of Maternal-Fetal Medicine, Swedish Medical Center, Englewood, CO 80110, 
      USA.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Review
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Female
MH  - Humans
MH  - MEDLINE
MH  - Placebos
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications
MH  - Risk Factors
RF  - 25
EDAT- 2000/09/19 11:00
MHDA- 2000/10/14 11:01
CRDT- 2000/09/19 11:00
PHST- 2000/09/19 11:00 [pubmed]
PHST- 2000/10/14 11:01 [medline]
PHST- 2000/09/19 11:00 [entrez]
AID - S0002-9378(00)71214-2 [pii]
AID - 10.1067/mob.2000.106757 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2000 Sep;183(3):523-8. doi: 10.1067/mob.2000.106757.

PMID- 14607016
OWN - NLM
STAT- MEDLINE
DCOM- 20040210
LR  - 20171116
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 55
IP  - 10
DP  - 2003 Oct
TI  - Single oral dose study of two isosorbide-based aspirin prodrugs in the dog.
PG  - 1351-7
AB  - The objective of this study was to compare two aspirin prodrugs, isosorbide 
      diaspirinate (ISDA) and a nitroaspirin (ISMNA), with aspirin in terms of effects 
      on dog platelet function after administration of a single oral dose. Groups of 
      six dogs were administered ISDA (2mg kg(-1)), ISMNA (4 mg kg(-1)) or aspirin (2mg 
      kg(-1)). Blood was sampled at 1, 2, 4, 8, 12 and 24 h post-dosing and evaluated 
      for capacity to generate post-clotting thromboxane (TX)B2. The aggregation 
      response to arachidonic acid (AA) (100 microM), ADP (30 microM) or collagen (10 
      microg mL(-1)) was estimated at each time-point using the whole blood impedance 
      method. Plasma ISMN following oral administration of ISMNA was also measured and 
      compared with plasma ISMN following administration of a physical mixture of ISMN 
      and aspirin. ISDA administration (2 mg kg(-1)) was associated with a significant 
      reduction (P < 0.05) in serum TXB2 at 12 and 24 h (>90%) post-dosing and 
      persistent inhibition of AA-induced platelet aggregation. ISDA administration 
      caused a more marked depression of post-clotting TXB2 levels than aspirin in this 
      study, although its ability to inhibit platelet aggregation was less consistent 
      than that of aspirin. The nitroaspirin ISMNA was least effective at inhibiting 
      platelet aggregation response or TXB2 production. The ISMN AUC(0-24 h) for the 
      ISMNA-treated dogs was 77% of that for the physical mix-treated dogs and the tmax 
      was delayed. This study indicates that the two aspirin esters cause aspirin-like 
      effects on platelet function, probably through aspirin release, when administered 
      orally to dogs.
FAU - Gilmer, John F
AU  - Gilmer JF
AD  - Department of Pharmaceutical Chemistry, Trinity College, Dublin 2, Ireland. 
      gilmerjf@tcd.ie
FAU - Murphy, Michael A
AU  - Murphy MA
FAU - Shannon, Jean A
AU  - Shannon JA
FAU - Breen, Colm G
AU  - Breen CG
FAU - Ryder, Sheila A
AU  - Ryder SA
FAU - Clancy, John M
AU  - Clancy JM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (isosorbide diaspirinate)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 9007-34-5 (Collagen)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
RN  - WXR179L51S (Isosorbide)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*administration & dosage/*analogs & derivatives/*pharmacology
MH  - Collagen/pharmacology
MH  - Dogs
MH  - Female
MH  - Isosorbide/*analogs & derivatives
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*pharmacology
MH  - Platelet Function Tests
EDAT- 2003/11/11 05:00
MHDA- 2004/02/11 05:00
CRDT- 2003/11/11 05:00
PHST- 2003/11/11 05:00 [pubmed]
PHST- 2004/02/11 05:00 [medline]
PHST- 2003/11/11 05:00 [entrez]
AID - 10.1211/0022357022007 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2003 Oct;55(10):1351-7. doi: 10.1211/0022357022007.

PMID- 7328486
OWN - NLM
STAT- MEDLINE
DCOM- 19820420
LR  - 20190913
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 4
IP  - 11
DP  - 1981 Nov
TI  - The bioavailabilities of aspirin from an aspirin aluminum and an aspirin tablet 
      and the effects of food and aluminum hydroxide gel.
PG  - 860-4
AB  - The bioavailability of aspirin from an aspirin aluminum tablet was compared with 
      that from an aspirin tablet in humans by determining total salicylate excreted in 
      the urine. The effects of concomitant intakes of antacid or food on the 
      bioavailability of aspirin were also investigated. The bioavailability of aspirin 
      from an aspirin aluminum tablet was nearly 60% of that from an aspirin tablet. 
      The low bioavailability of aspirin from an aspirin aluminum tablet was caused by 
      slow release of aspirin from the aluminum complex, and not increased by 
      concomitant intake of food. Intake of food, however, reduced both rate and extent 
      of bioavailability of aspirin from an aspirin tablet, but dried aluminum 
      hydroxide gel granules had no effect on the bioavailability of it.
FAU - Kaniwa, N
AU  - Kaniwa N
FAU - Ogata, H
AU  - Ogata H
FAU - Aoyagi, N
AU  - Aoyagi N
FAU - Ejima, A
AU  - Ejima A
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Tablets)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - CPD4NFA903 (Aluminum)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aluminum
MH  - Aluminum Hydroxide/*pharmacology
MH  - Aspirin/administration & dosage/*metabolism
MH  - Biological Availability
MH  - *Food
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Middle Aged
MH  - Solubility
MH  - Tablets
MH  - Time Factors
EDAT- 1981/11/01 00:00
MHDA- 1981/11/01 00:01
CRDT- 1981/11/01 00:00
PHST- 1981/11/01 00:00 [pubmed]
PHST- 1981/11/01 00:01 [medline]
PHST- 1981/11/01 00:00 [entrez]
AID - 10.1248/bpb1978.4.860 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1981 Nov;4(11):860-4. doi: 10.1248/bpb1978.4.860.

PMID- 28011944
OWN - NLM
STAT- MEDLINE
DCOM- 20170523
LR  - 20170523
IS  - 1899-1505 (Electronic)
IS  - 0867-5910 (Linking)
VI  - 67
IP  - 5
DP  - 2016 Oct
TI  - Bioavailability of aspirin in rats comparing the drug's uptake into 
      gastrointestinal tissue and vascular and lymphatic systems: implications on 
      aspirin's chemopreventive action.
PG  - 635-642
AB  - Aspirin is an effective analgesic and antiplatelet drug that in addition to its 
      ability to reduce pain, inflammation and fever, appears to have efficacy in the 
      prevention/treatment of a range of diseases including heart disease, numerous 
      cancers and Alzheimer's. It is important to understand the bioavailability of 
      aspirin and its major metabolite, salicylic acid, since dosage and route of 
      administration can vary for treating differing diseases, and the major 
      side-effects of aspirin, upper gastrointestinal ulceration and bleeding, are 
      dose-dependent. We examined the time course for gastroduodenal uptake of aspirin 
      and the appearance of its major metabolite salicylic acid in blood and lymph 
      after intragastric (to simulate oral) and intraduodenal (to simulate 
      enteric-coating) dosing in rats. Results show that after intragastric dosing, 
      intact aspirin is absorbed primarily by the gastric mucosa and to a lesser extent 
      by the duodenal mucosa. When aspirin is dosed intragastrically or 
      intraduodenally, a much greater concentration of aspirin enters the lymph than 
      the blood. In contrast, the concentration of salicylic acid was higher in blood 
      than in lymph. Lymph levels of both aspirin and salicylic acid were sufficiently 
      high so as to perform a pharmacologic function there, possibly as a 
      chemopreventive agent against colon cancer and potentially the metastatic spread 
      of non-gastrointestinal cancers.
FAU - Lichtenberger, L M
AU  - Lichtenberger LM
AD  - Department of Integrative Biology and Pharmacology, The University of Texas 
      Health Science Center at Houston - McGovern Medical School, Houston, TX, USA. 
      lenard.m.lichtenberger@uth.tmc.edu.
FAU - Phan, T
AU  - Phan T
AD  - Department of Integrative Biology and Pharmacology, The University of Texas 
      Health Science Center at Houston - McGovern Medical School, Houston, TX, USA.
FAU - Fang, D
AU  - Fang D
AD  - Department of Integrative Biology and Pharmacology, The University of Texas 
      Health Science Center at Houston - McGovern Medical School, Houston, TX, USA.
FAU - Edler, S
AU  - Edler S
AD  - Department of Integrative Biology and Pharmacology, The University of Texas 
      Health Science Center at Houston - McGovern Medical School, Houston, TX, USA.
FAU - Philip, J
AU  - Philip J
AD  - Department of Integrative Biology and Pharmacology, The University of Texas 
      Health Science Center at Houston - McGovern Medical School, Houston, TX, USA.
FAU - Li-Geng, T
AU  - Li-Geng T
AD  - Department of Integrative Biology and Pharmacology, The University of Texas 
      Health Science Center at Houston - McGovern Medical School, Houston, TX, USA.
FAU - Dial, E J
AU  - Dial EJ
AD  - Department of Integrative Biology and Pharmacology, The University of Texas 
      Health Science Center at Houston - McGovern Medical School, Houston, TX, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Poland
TA  - J Physiol Pharmacol
JT  - Journal of physiology and pharmacology : an official journal of the Polish 
      Physiological Society
JID - 9114501
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/blood/*pharmacokinetics
MH  - Anticarcinogenic Agents/administration & dosage/blood/*pharmacokinetics
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Biological Availability
MH  - Drug Administration Routes
MH  - Intestinal Mucosa/*metabolism
MH  - Lymphatic System/*metabolism
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Salicylic Acid/administration & dosage/blood/*pharmacokinetics
EDAT- 2016/12/25 06:00
MHDA- 2017/05/24 06:00
CRDT- 2016/12/25 06:00
PHST- 2016/08/02 00:00 [received]
PHST- 2016/10/31 00:00 [accepted]
PHST- 2016/12/25 06:00 [entrez]
PHST- 2016/12/25 06:00 [pubmed]
PHST- 2017/05/24 06:00 [medline]
PST - ppublish
SO  - J Physiol Pharmacol. 2016 Oct;67(5):635-642.

PMID- 29433703
OWN - NLM
STAT- MEDLINE
DCOM- 20180417
LR  - 20180417
IS  - 1751-486X (Electronic)
IS  - 1751-4851 (Linking)
VI  - 22
IP  - 1
DP  - 2018 Feb
TI  - Low-Dose Aspirin for the Prevention of Preeclampsia.
PG  - 87-92
LID - S1751-4851(17)30332-X [pii]
LID - 10.1016/j.nwh.2017.12.002 [doi]
AB  - Preeclampsia is a hypertensive disorder specific to pregnancy that remains a 
      significant cause of maternal and neonatal morbidity and mortality. 
      Identification of women who are most at risk for preeclampsia is imprecise. 
      Because of the potential negative health consequences of preeclampsia for women 
      and newborns and the lack of effective screening mechanisms preventing 
      preeclampsia is an important component of prenatal care. Researchers have 
      documented that low-dose aspirin, taken daily after the first trimester, can 
      decrease the development of preeclampsia and reduce the incidence of preterm 
      birth and birth of small-for-gestational-age infants. This column includes an 
      overview of low-dose aspirin in pregnancy and a review of current recommendations 
      from leading national organizations.
CI  - © 2018 AWHONN, the Association of Women’s Health, Obstetric and Neonatal Nurses.
FAU - Fantasia, Heidi Collins
AU  - Fantasia HC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nurs Womens Health
JT  - Nursing for women's health
JID - 101304602
RN  - R16CO5Y76E (Aspirin)
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*drug therapy/physiopathology/*prevention & control
MH  - Pregnancy
MH  - Risk Factors
OTO - NOTNLM
OT  - aspirin
OT  - hypertension
OT  - preeclampsia
OT  - pregnancy
EDAT- 2018/02/13 06:00
MHDA- 2018/04/18 06:00
CRDT- 2018/02/14 06:00
PHST- 2017/08/12 00:00 [received]
PHST- 2017/10/13 00:00 [revised]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/13 06:00 [pubmed]
PHST- 2018/04/18 06:00 [medline]
AID - S1751-4851(17)30332-X [pii]
AID - 10.1016/j.nwh.2017.12.002 [doi]
PST - ppublish
SO  - Nurs Womens Health. 2018 Feb;22(1):87-92. doi: 10.1016/j.nwh.2017.12.002.

PMID- 27687643
OWN - NLM
STAT- MEDLINE
DCOM- 20170509
LR  - 20171203
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
VI  - 122
DP  - 2016 Dec 15
TI  - Reduced metabolic activity of gut microbiota by antibiotics can potentiate the 
      antithrombotic effect of aspirin.
PG  - 72-79
LID - S0006-2952(16)30306-9 [pii]
LID - 10.1016/j.bcp.2016.09.023 [doi]
AB  - In this study, we investigated the effects of antibiotics on the pharmacological 
      effects of aspirin. The antithrombotic activity of aspirin was evaluated after 
      antibiotic treatment using tail bleeding assay. The pyrosequencing analysis and 
      selective medium culture assay were performed to investigate the alterations in 
      gut microbiota. In addition, the in vitro metabolism assay with fecal suspension 
      and in vivo pharmacokinetic experiments with antibiotic treatment were conducted. 
      Ampicillin treatment significantly prolonged the bleeding time in aspirin-dosed 
      rats. Oral administration of ampicillin significantly reduced gut microbial 
      aspirin-metabolizing activity by 67.0% in rats. Furthermore, systemic exposure to 
      aspirin and its primary metabolite (M1) was significantly increased in 
      ampicillin-treated rats. The results from the pyrosequencing and selective medium 
      culture with rat fecal samples revealed that ampicillin treatment led to the 
      changes of the amounts and composition profile of gut microbiota. These findings 
      suggest that co-administration of antibiotics can modulate the metabolism and 
      pharmacokinetics of aspirin via suppression of metabolic activity of gut 
      microbiota, which could potentiate the therapeutic potency of aspirin.
CI  - Copyright Â© 2016 Elsevier Inc. All rights reserved.
FAU - Kim, In Sook
AU  - Kim IS
AD  - Institute of Pharmaceutical Science and Technology and College of Pharmacy, 
      Hanyang University, Ansan, Gyeonggi-do 426-791, Republic of Korea.
FAU - Yoo, Dae-Hyeong
AU  - Yoo DH
AD  - Department of Life and Nanopharmaceutical Sciences and Department of Pharmacy, 
      Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of 
      Korea.
FAU - Jung, Il-Hoon
AU  - Jung IH
AD  - Department of Life and Nanopharmaceutical Sciences and Department of Pharmacy, 
      Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of 
      Korea.
FAU - Lim, Sumin
AU  - Lim S
AD  - Department of Life and Nanopharmaceutical Sciences and Department of Pharmacy, 
      Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of 
      Korea.
FAU - Jeong, Jin-Ju
AU  - Jeong JJ
AD  - Department of Life and Nanopharmaceutical Sciences and Department of Pharmacy, 
      Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of 
      Korea.
FAU - Kim, Kyeong-A
AU  - Kim KA
AD  - Institute of Pharmaceutical Science and Technology and College of Pharmacy, 
      Hanyang University, Ansan, Gyeonggi-do 426-791, Republic of Korea.
FAU - Bae, Ok-Nam
AU  - Bae ON
AD  - Institute of Pharmaceutical Science and Technology and College of Pharmacy, 
      Hanyang University, Ansan, Gyeonggi-do 426-791, Republic of Korea.
FAU - Yoo, Hye Hyun
AU  - Yoo HH
AD  - Institute of Pharmaceutical Science and Technology and College of Pharmacy, 
      Hanyang University, Ansan, Gyeonggi-do 426-791, Republic of Korea. Electronic 
      address: yoohh@hanyang.ac.kr.
FAU - Kim, Dong-Hyun
AU  - Kim DH
AD  - Department of Life and Nanopharmaceutical Sciences and Department of Pharmacy, 
      Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of 
      Korea. Electronic address: dhkim@khu.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20160926
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Aspirin/administration & dosage/metabolism/*pharmacology
MH  - Bacteria/*drug effects
MH  - Carboxylic Ester Hydrolases/metabolism
MH  - Feces
MH  - Female
MH  - Fibrinolytic Agents/metabolism/*pharmacology
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Young Adult
OTO - NOTNLM
OT  - Antibiotics
OT  - Antithrombotic effect
OT  - Aspirin
OT  - Gut microbiota
OT  - Metabolism
EDAT- 2016/10/01 06:00
MHDA- 2017/05/10 06:00
CRDT- 2016/10/01 06:00
PHST- 2016/08/17 00:00 [received]
PHST- 2016/09/23 00:00 [accepted]
PHST- 2016/10/01 06:00 [pubmed]
PHST- 2017/05/10 06:00 [medline]
PHST- 2016/10/01 06:00 [entrez]
AID - S0006-2952(16)30306-9 [pii]
AID - 10.1016/j.bcp.2016.09.023 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2016 Dec 15;122:72-79. doi: 10.1016/j.bcp.2016.09.023. Epub 
      2016 Sep 26.

PMID- 7230728
OWN - NLM
STAT- MEDLINE
DCOM- 19810709
LR  - 20190711
IS  - 0023-2173 (Print)
IS  - 0023-2173 (Linking)
VI  - 59
IP  - 6
DP  - 1981 Mar 16
TI  - Does chronic aspirin treatment increase blood pressure in man?
PG  - 297-9
AB  - In postmyocardial infarction patients longterm aspirin treatment with 1.5 g/day 
      led to a significant increase in systolic and diastolic blood pressure after 6 
      months. This could not be found in the placebo- and the phenprocoumon-treated 
      patients. After one year the blood pressure behaviour was the same in all three 
      treatment groups. As nonsteroidal antirheumatic drugs can produce hypertension in 
      animals, probably due to inhibition of prostaglandin synthesis, blood pressure 
      control in longterm aspirin treatment is advisable.
FAU - Walter, E
AU  - Walter E
FAU - Kaufmann, W
AU  - Kaufmann W
FAU - Oster, P
AU  - Oster P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Klin Wochenschr
JT  - Klinische Wochenschrift
JID - 2985205R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Myocardial Infarction/therapy
MH  - Platelet Aggregation
EDAT- 1981/03/16 00:00
MHDA- 1981/03/16 00:01
CRDT- 1981/03/16 00:00
PHST- 1981/03/16 00:00 [pubmed]
PHST- 1981/03/16 00:01 [medline]
PHST- 1981/03/16 00:00 [entrez]
AID - 10.1007/BF01478209 [doi]
PST - ppublish
SO  - Klin Wochenschr. 1981 Mar 16;59(6):297-9. doi: 10.1007/BF01478209.

PMID- 19595490
OWN - NLM
STAT- MEDLINE
DCOM- 20100211
LR  - 20161018
IS  - 1768-3122 (Electronic)
IS  - 0248-8663 (Linking)
VI  - 30
IP  - 12
DP  - 2009 Dec
TI  - [The concept of aspirin "resistance": mechanisms and clinical relevance].
PG  - 1020-9
LID - 10.1016/j.revmed.2009.02.028 [doi]
AB  - Aspirin, a 110-year-old molecule, is a cornerstone in the treatment of 
      atherothrombotic patients. The concept of aspirin "resistance" emerged 
      approximately 15 years ago and is of growing interest. Aspirin resistance, 
      defined as a lack of inhibition of cyclo-oxygenase-1 (COX-1), is a rare 
      phenomenon and its clinical relevance can hardly be studied. On the contrary, 
      residual platelet hyperactivity is more common and affects 20 to 30% of 
      aspirin-treated patients. This latter phenomenon corresponds to sustained 
      platelet reactivity despite a proper inhibition of COX-1 by aspirin. Several 
      meta-analyses suggest that residual platelet hyperactivity could be a risk factor 
      for the recurrence of ischemic events in aspirin-treated patients. Causes of 
      biological non-responsiveness to aspirin are discussed, including the role of 
      compliance, drug-drug interactions, genetic polymorphisms and diabetes mellitus. 
      Ongoing studies are designed to find out the mechanisms of residual platelet 
      hyperactivity, determine its potential clinical relevance and delineate the more 
      appropriate assays in order to identify patients who may benefit of a tailored 
      antiplatelet therapy.
FAU - Reny, J-L
AU  - Reny JL
AD  - Laboratoire et service de cardiologie, département de médecine interne, centre 
      hospitalier de Béziers, 2, rue Valentin-Hauÿ, BP 740, 34525 Béziers cedex, 
      France. jean-luc.reny@ch-beziers.fr
FAU - Bonvini, R F
AU  - Bonvini RF
FAU - Barazer, I
AU  - Barazer I
FAU - Berdagué, P
AU  - Berdagué P
FAU - de Moerloose, P
AU  - de Moerloose P
FAU - Schved, J-F
AU  - Schved JF
FAU - Gris, J-C
AU  - Gris JC
FAU - Fontana, P
AU  - Fontana P
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Le concept de "résistance" à l'aspirine: mécanismes et pertinence clinique.
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cardiovascular Diseases/genetics/prevention & control
MH  - Cyclooxygenase 1/*drug effects/genetics
MH  - Cyclooxygenase Inhibitors/administration & dosage/*pharmacology
MH  - *Drug Resistance/genetics
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Myocardial Ischemia/etiology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Polymorphism, Genetic
MH  - Recurrence
MH  - Risk Factors
MH  - Thrombosis/genetics/prevention & control
EDAT- 2009/07/15 09:00
MHDA- 2010/02/12 06:00
CRDT- 2009/07/15 09:00
PHST- 2008/09/16 00:00 [received]
PHST- 2009/02/03 00:00 [revised]
PHST- 2009/02/15 00:00 [accepted]
PHST- 2009/07/15 09:00 [entrez]
PHST- 2009/07/15 09:00 [pubmed]
PHST- 2010/02/12 06:00 [medline]
AID - S0248-8663(09)00614-6 [pii]
AID - 10.1016/j.revmed.2009.02.028 [doi]
PST - ppublish
SO  - Rev Med Interne. 2009 Dec;30(12):1020-9. doi: 10.1016/j.revmed.2009.02.028.

PMID- 1809699
OWN - NLM
STAT- MEDLINE
DCOM- 19920527
LR  - 20131121
IS  - 0251-1649 (Print)
IS  - 0251-1649 (Linking)
VI  - 11
IP  - 3
DP  - 1991
TI  - Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) 
      formulation in comparison with plain ASA in healthy volunteers.
PG  - 129-35
AB  - A single-blind, randomized, crossover pharmacokinetic study was carried out to 
      investigate the bioavailability of a new oral buffered 325 mg acetylsalicylic 
      acid (ASA) formulation (ASPIRINA 03) in comparison with a 325 mg plain tablet. 
      Twelve healthy volunteers of both sexes, aged between 20 and 37 years, received 
      buffered or plain ASA on two separate occasions with a wash-out interval of at 
      least two weeks. ASA and salicylic acid (SA) plasma levels were determined by a 
      chromatographic method. The results showed no difference between the area under 
      concentration time curve (AUC0-infinity) ASA values of both formulations (p = 
      0.19), and buffered ASA relative bioavailability was 102.49% (= bioequivalence). 
      A significant difference was found between the AUC0-30 min ASA values: 90.5 
      micrograms. min/ml with buffered and 67.7 micrograms. min/ml with the plain 
      tablet (p less than 0.05). The buffered ASA time of maximum concentration was 
      shorter (28 +/- 8 min) than the plain one (38 +/- 19 min, p less than 0.05). The 
      plasma concentrations and pharmacokinetic parameters of SA were not significantly 
      different after the administration of the two ASA formulations. The plain ASA 
      tablet had a significantly lower (p less than 0.05) dissolution rate than 
      buffered ASA tablet. Moreover, the buffered ASA tablet significantly (p less than 
      0.01) increased the pH by 0.5 units. In conclusion, the bioavailability of the 
      new oral buffered ASA was equivalent to that of plain ASA, but the plasma 
      concentration peak was reached in a shorter time.
FAU - Viganò, G
AU  - Viganò G
AD  - Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
FAU - Garagiola, U
AU  - Garagiola U
FAU - Gaspari, F
AU  - Gaspari F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Int J Clin Pharmacol Res
JT  - International journal of clinical pharmacology research
JID - 8110183
RN  - 0 (Buffers)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Biological Availability
MH  - Buffers
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Random Allocation
MH  - Solubility
MH  - Tablets
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Res. 1991;11(3):129-35.

PMID- 3792435
OWN - NLM
STAT- MEDLINE
DCOM- 19870212
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 31
IP  - 3
DP  - 1986
TI  - Correlation between dosage and antipyretic effect of aspirin in children.
PG  - 359-61
AB  - One hundred and forty-five children aged 3 months to 11.5 years, with rectal 
      temperatures greater than 38.9 degrees C, were randomly treated with aspirin 5, 
      10 or 15 mg/kg p.o. Temperatures were recorded just before medication, every 30 
      min thereafter for 4 h and subsequently hourly up to 6 h. In all dosage regimens 
      the average temperature was significantly reduced in the time interval 1-6 h 
      after drug administration; the antipyretic effect, however, was significantly 
      greater with the 10 and 15 mg/kg doses. Both had significantly better and 
      comparable clinical efficacy, defined as reduction in fever below 38.9 degrees C. 
      The duration of the clinical effect was not dose-related. A dose of 10 mg/kg 
      appears rational for the treatment of children with fever.
FAU - Vigano, A
AU  - Vigano A
FAU - Dalla Villa, A
AU  - Dalla Villa A
FAU - Cecchini, I
AU  - Cecchini I
FAU - Biasini, G C
AU  - Biasini GC
FAU - Principi, N
AU  - Principi N
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fever/*drug therapy
MH  - Humans
MH  - Infant
MH  - Male
MH  - Random Allocation
MH  - Time Factors
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1007/BF00981138 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1986;31(3):359-61. doi: 10.1007/BF00981138.

PMID- 6404714
OWN - NLM
STAT- MEDLINE
DCOM- 19830617
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 13
IP  - 1
DP  - 1983
TI  - The influence of dose, time of administration, body temperature and salicylate 
      kinetics on the antithrombotic action of acetylsalicylic acid in male rats.
PG  - 42-52
AB  - Acetylsalicylic acid (ASA), given i.v. to male rats 10 min before electrical 
      injury to the carotid artery, was found to reduce rate and extent of thrombosis 
      at 3.3 and 10.0 mg/kg but not at 1.7, 20 or 100 mg/kg, indicating a narrow, 
      low-dose window for antithrombotic effect. ASA was more effective in rats in 
      which body temperature was allowed to fall greater than 0.5 degrees C but 
      protection was lost if injury was delayed 15 min or more after ASA 
      administration. Serum salicylate studies did not support the view that loss of 
      protection was due to competition between salicylate and ASA for 
      cyclooxygenase-binding sites. ASA was also protective at 200 mg/kg i.v., possibly 
      through non-specific toxic effects.
FAU - Philp, R B
AU  - Philp RB
FAU - Paul, M L
AU  - Paul ML
FAU - Killackey, J J
AU  - Killackey JJ
FAU - Killackey, B A
AU  - Killackey BA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/metabolism/*pharmacology/therapeutic use
MH  - Body Temperature
MH  - Cyclooxygenase Inhibitors
MH  - Disease Models, Animal
MH  - Kinetics
MH  - Male
MH  - Microscopy, Electron, Scanning
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Sodium Salicylate/pharmacology
MH  - Thrombosis/drug therapy/enzymology/metabolism/*prevention & control
MH  - Time Factors
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1159/000214702 [doi]
PST - ppublish
SO  - Haemostasis. 1983;13(1):42-52. doi: 10.1159/000214702.

PMID- 9082487
OWN - NLM
STAT- MEDLINE
DCOM- 19970403
LR  - 20131121
IS  - 0300-8932 (Print)
IS  - 0300-8932 (Linking)
VI  - 49
IP  - 11
DP  - 1996 Nov
TI  - [Should individuals without evidence of coronary disease and with risk factors 
      receive continuous treatment with aspirin? Arguments against].
PG  - 788-92
AB  - There is a widespread opinion, above the non-scientific press, of the fact that 
      it is demonstrated the aspirin usefulness in the primary prevention of the 
      ischemic heart disease. This feeling is based on the results of the Physicians' 
      Health Study. This wrong position is stablished on the significant reduction of 
      the risk of myocardial infarction, since even though this study demonstrated a 
      very significant, but there were also a non significant excess of hemorrhagic 
      strokes and of sudden death among the physicians on aspirin treatment. For this 
      reason the Physicians' Health Study demonstrated no effect on the cardiovascular 
      mortality neither on the total mortality, that was the main objective of this 
      study. On the other hand, all the primary prevention trials employing aspirin, 
      have demonstrated also a significant excess of gastrointestinal bleeding 
      complications. While is unquestionable the beneficial effect of the aspirin in 
      the secondary prevention of patients with previous ischemic heart disease, the 
      complications that aspirin may produce with its employment in healthy subjects, 
      counterbalance the possible beneficial effect of the reduction of the incidence 
      of myocardial infarction in a low-risk population. There are several ongoing 
      trials, yet not concluded, that attempt to determine the usefulness of aspirin in 
      primary prevention in high risk populations in order to clarify if there is a 
      place in the employment of the aspirin in the primary prevention of ischemic 
      heart disease.
FAU - López de Sá, E
AU  - López de Sá E
AD  - Departamento de Cardiología, Hospital General Universitario Gregorio Marañón, 
      Madrid.
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Deben recibir tratamiento continuado con aspirina los individuos sin evidencia de 
      enfermedad coronaria y con factores de riesgo? Argumentos en contra.
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Ischemia/*prevention & control
MH  - Risk Factors
EDAT- 1996/11/01 00:00
MHDA- 1996/11/01 00:01
CRDT- 1996/11/01 00:00
PHST- 1996/11/01 00:00 [pubmed]
PHST- 1996/11/01 00:01 [medline]
PHST- 1996/11/01 00:00 [entrez]
PST - ppublish
SO  - Rev Esp Cardiol. 1996 Nov;49(11):788-92.

PMID- 20171274
OWN - NLM
STAT- MEDLINE
DCOM- 20100616
LR  - 20220309
IS  - 1873-4596 (Electronic)
IS  - 0891-5849 (Linking)
VI  - 48
IP  - 9
DP  - 2010 May 1
TI  - Modulation of thiol homeostasis induced by H2S-releasing aspirin.
PG  - 1263-72
LID - 10.1016/j.freeradbiomed.2010.02.014 [doi]
AB  - The H(2)S-releasing aspirin (ACS14) containing a dithiolethione moiety has been 
      demonstrated to maintain the thromboxane-suppressing activity of the parent 
      compound, but it seems to spare the gastric mucosa by affecting redox imbalance 
      through increased H(2)S/glutathione (GSH) formation. Nevertheless, the mechanisms 
      by which ACS14 is able to elevate the levels of these agents has not been fully 
      elucidated so far. In this manuscript the effect of an acute ip administration of 
      ACS14 and of its dithiolethione moiety 
      (5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione, ADTOH) on the overall thiol 
      content of rat tissues and on the main enzymes involved in the maintenance of 
      thiol homeostasis is reported. ACS14 and ADTOH treatments were shown to induce a 
      significant increase not only of GSH but also of cysteine in plasma and in 
      several rat tissues as well as of H(2)S plasma levels. Conversely, a significant 
      decrease of homocysteine in most rat organs and in plasma was observed. Most of 
      these phenomena are supposed to be linked to the elevated intracellular levels of 
      cysteine induced by treatments with either ACS14 or ADTOH.
CI  - (c) 2010 Elsevier Inc. All rights reserved.
FAU - Giustarini, Daniela
AU  - Giustarini D
AD  - Department of Evolutionary Biology, Laboratory of Pharmacology and Toxicology, 
      University of Siena, Siena, Italy.
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Sparatore, Anna
AU  - Sparatore A
FAU - Rossi, Ranieri
AU  - Rossi R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100217
PL  - United States
TA  - Free Radic Biol Med
JT  - Free radical biology & medicine
JID - 8709159
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Sulfhydryl Compounds)
RN  - GAN16C9B8O (Glutathione)
RN  - QUY32964DJ (Anethole Trithione)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Anethole Trithione/pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/metabolism/*pharmacology
MH  - Chromatography, High Pressure Liquid
MH  - Glutathione/drug effects/metabolism
MH  - Homeostasis/*drug effects
MH  - Hydrogen Sulfide/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sulfhydryl Compounds/*analysis
EDAT- 2010/02/23 06:00
MHDA- 2010/06/17 06:00
CRDT- 2010/02/23 06:00
PHST- 2009/12/15 00:00 [received]
PHST- 2010/02/04 00:00 [revised]
PHST- 2010/02/10 00:00 [accepted]
PHST- 2010/02/23 06:00 [entrez]
PHST- 2010/02/23 06:00 [pubmed]
PHST- 2010/06/17 06:00 [medline]
AID - S0891-5849(10)00101-2 [pii]
AID - 10.1016/j.freeradbiomed.2010.02.014 [doi]
PST - ppublish
SO  - Free Radic Biol Med. 2010 May 1;48(9):1263-72. doi: 
      10.1016/j.freeradbiomed.2010.02.014. Epub 2010 Feb 17.

PMID- 9225654
OWN - NLM
STAT- MEDLINE
DCOM- 19970806
LR  - 20131121
IS  - 0300-8835 (Print)
IS  - 0300-8835 (Linking)
VI  - 164
DP  - 1997
TI  - Medical prevention of pre-eclampsia.
PG  - 111-5
AB  - There is no clear evidence that any of the antihypertensive drugs available can 
      defer or prevent the occurrence of proteinuric pre-eclampsia or associated 
      problems such as fetal growth retardation or perinatal death. When 
      antihypertensive treatment is indicated, there seems to be no reason to prefer 
      any of the tested beta-blockers, or to prefer labetalol to a pure beta-blocker, 
      or indeed, to prefer beta-blockers to methyldopa. The increased maternal, fetal 
      and infant mortality and morbidity associated with hypertension in pregnancy 
      justify careful evaluation of the risks of the more severe forms of hypertension 
      at an early stage in all pregnancies. A careful family and medical history are 
      benchmarks in pregnancy surveillance, followed by meticulous monitoring of the 
      pregnant mother in a well organized maternity health care system where high 
      maternal compliance is necessary together with use of appropriate methods to 
      predict hypertension early. Prophylactic treatment with medication causing least 
      harm to the mother and fetus to prevent serious complication due to hypertension 
      in pregnancy when increased risk is identified would be of value and further 
      improve maternal and fetal outcome.
FAU - Montan, S
AU  - Montan S
AD  - Department of Obstetrics and Gynecology, County Hospital, Angelholm, Sweden.
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Acta Obstet Gynecol Scand Suppl
JT  - Acta obstetricia et gynecologica Scandinavica. Supplement
JID - 0337655
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/diagnosis/*prevention & control
MH  - Pregnancy
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Obstet Gynecol Scand Suppl. 1997;164:111-5.

PMID- 26932276
OWN - NLM
STAT- MEDLINE
DCOM- 20170724
LR  - 20181202
IS  - 1542-4758 (Electronic)
IS  - 1492-7535 (Linking)
VI  - 20
IP  - 4
DP  - 2016 Oct
TI  - Low-dose aspirin for prevention of cardiovascular disease in patients on 
      hemodialysis: A 5-y prospective cohort study.
PG  - 548-557
LID - 10.1111/hdi.12409 [doi]
AB  - Introduction Aspirin is an effective antiplatelet drug for preventing 
      cardiovascular events in high-risk subjects. However, for patients with chronic 
      kidney disease and undergoing hemodialysis (HD), its preventive efficacy remains 
      controversial. The present study aimed to determine whether aspirin therapy 
      reduces the risk of cardiovascular disease (CVD) and all-cause mortality in 
      patients on HD. Methods We conducted a 5-y prospective cohort study involving 
      patients on HD. Major exposure variables included prescription of aspirin (100 
      mg/d) and no aspirin (nonaspirin). The primary outcomes included all-cause death, 
      cardiovascular events, hemorrhage, and ischemic stroke. The secondary outcome 
      included bleeding events defined by the requirement of hospitalization. Findings 
      In this study, 406 patients on regular HD were involved during a 5-y follow-up. 
      Among these, 152 and 254 propensity-matched patients were enrolled in the aspirin 
      and nonaspirin cohort, respectively. The cumulative survival rate was not 
      significantly higher in the aspirin than in the nonaspirin users (log rank χ(2) 
       = 1.080, P = 0.299). Aspirin use was not significantly associated with reduced 
      all-cause mortality, fatal and nonfatal congestive heart failure, as well as 
      acute myocardial infarction and ischemic stroke. The risk of fatal cerebral 
      hemorrhage was not significantly increased in the aspirin users (HR = 1.795, 95% 
      CI 0.666-4.841, P = 0.174). After adjustment for other confounders, aspirin use 
      was also not associated with decreased risk of all-cause mortality and CVD. 
      Discussion The present prospective cohort study suggests that low-dose aspirin 
      use is not associated with a significant decrease in the risks of all-cause 
      mortality, CVD, and stroke in population undergoing HD (ClinicalTrials.gov 
      number, NCT02261025).
CI  - © 2016 International Society for Hemodialysis.
FAU - Liu, Jun
AU  - Liu J
AD  - Division of Nephrology, Shanghai No. 1 People's Hospital, Shanghai Jiao Tong 
      University, Shanghai, China.
FAU - Pan, Yu
AU  - Pan Y
AD  - Division of Nephrology, The Ninth People's Hospital, School of Medicine, Shanghai 
      Jiao Tong University, Shanghai, China.
FAU - Chen, Lei
AU  - Chen L
AD  - Division of Nephrology, Shanghai No. 1 People's Hospital, Shanghai Jiao Tong 
      University, Shanghai, China.
FAU - Qiao, Qing Yan
AU  - Qiao QY
AD  - Division of Nephrology, Shanghai Pudong Hospital, Fudan University, Pudong 
      Medical Center, Shanghai, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Division of Nephrology, Shanghai No. 1 People's Hospital, Shanghai Jiao Tong 
      University, Shanghai, China.
FAU - Pan, Li Hua
AU  - Pan LH
AD  - Division of Nephrology, Shanghai Pudong Hospital, Fudan University, Pudong 
      Medical Center, Shanghai, China.
FAU - Gu, Yan Hong
AU  - Gu YH
AD  - Division of Nephrology, Shanghai Pudong Hospital, Fudan University, Pudong 
      Medical Center, Shanghai, China.
FAU - Gu, Hui Fang
AU  - Gu HF
AD  - Division of Nephrology, Shanghai Pudong Hospital, Fudan University, Pudong 
      Medical Center, Shanghai, China.
FAU - Fu, Shun Kun
AU  - Fu SK
AD  - Division of Nephrology, Shanghai Pudong Hospital, Fudan University, Pudong 
      Medical Center, Shanghai, China.
FAU - Jin, Hui Min
AU  - Jin HM
AD  - Division of Nephrology, Shanghai Pudong Hospital, Fudan University, Pudong 
      Medical Center, Shanghai, China. hmjgli@163.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT02261025
PT  - Journal Article
DEP - 20160301
PL  - Canada
TA  - Hemodial Int
JT  - Hemodialysis international. International Symposium on Home Hemodialysis
JID - 101093910
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/mortality/prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors
MH  - Prospective Studies
MH  - Renal Dialysis/*methods
OTO - NOTNLM
OT  - Aspirin
OT  - all-cause mortality
OT  - bleeding
OT  - cardiovascular disease
OT  - hemodialysis
EDAT- 2016/03/05 06:00
MHDA- 2017/07/25 06:00
CRDT- 2016/03/03 06:00
PHST- 2016/03/05 06:00 [pubmed]
PHST- 2017/07/25 06:00 [medline]
PHST- 2016/03/03 06:00 [entrez]
AID - 10.1111/hdi.12409 [doi]
PST - ppublish
SO  - Hemodial Int. 2016 Oct;20(4):548-557. doi: 10.1111/hdi.12409. Epub 2016 Mar 1.

PMID- 2781669
OWN - NLM
STAT- MEDLINE
DCOM- 19891017
LR  - 20131121
IS  - 0041-5782 (Print)
IS  - 0041-5782 (Linking)
VI  - 151
IP  - 35
DP  - 1989 Aug 28
TI  - [Tardive anaphylactic shock caused by intolerance to aspirin].
PG  - 2211-2
AB  - A case of tardive anaphylactic shock resulting from intolerance of acetyl 
      salicylic acid is presented. The precipitating mechanism of ASA-intolerance is 
      complex and not yet fully elucidated but possibly involves anaphylate toxins 
      activated by mast cells. The symptoms may occur immediately or after a prolonged 
      latent period and are dependent on the dosage. Patients with asthma and chronic 
      urticaria/angiooedema show increased prevalence of ASA-intolerance and these 
      patients should be advised to be careful with ASA/NSAID preparations.
FAU - Flarup, M
AU  - Flarup M
FAU - Udholm, S
AU  - Udholm S
LA  - dan
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Tardivt anafylaktisk shock som følge af acetylsalicylsyreintolerans.
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anaphylaxis/*immunology
MH  - Aspirin/*adverse effects/immunology
MH  - Drug Hypersensitivity/immunology
MH  - Female
MH  - Humans
EDAT- 1989/08/28 00:00
MHDA- 1989/08/28 00:01
CRDT- 1989/08/28 00:00
PHST- 1989/08/28 00:00 [pubmed]
PHST- 1989/08/28 00:01 [medline]
PHST- 1989/08/28 00:00 [entrez]
PST - ppublish
SO  - Ugeskr Laeger. 1989 Aug 28;151(35):2211-2.

PMID- 1421534
OWN - NLM
STAT- MEDLINE
DCOM- 19921127
LR  - 20191028
IS  - 1056-8719 (Print)
IS  - 1056-8719 (Linking)
VI  - 27
IP  - 4
DP  - 1992 Jul
TI  - Gastric mucosal damage due to aspirin and copper aspirinate assessed by gastric 
      mucosal potential difference changes.
PG  - 245-50
AB  - When the gastric mucosa is damaged by antiinflammatory agents, such as aspirin, 
      gastric mucosal potential difference (GPD) decreases and may or may not return to 
      predamage values after the agent is removed. The magnitude and time course of the 
      gastric potential difference changes have been suggested as a measure of mucosal 
      damage. Male Sprague-Dawley rats were fasted, anesthetized, and surgically 
      prepared for measurement of GPD by placement of electrodes in the gastric lumen 
      and spleen. Test mixtures of aspirin, copper aspirinate, copper sulfate, or 
      mixtures of aspirin and copper sulfate were administered by gavage, and 
      subsequent changes in GPD were recorded. The area between the extrapolated 
      control (baseline) GPD and the damage GPD was determined. The product of this 
      area and the maximum change in GPD, the Reizindex (RI), was calculated. Values 
      for all copper (II)-containing systems, including those with no aspirin, were 
      significantly greater than aspirin alone. It was concluded that factors other 
      than mucosal damage may contribute to a reduction in GPD and, therefore, an 
      increase in Reizindex.
FAU - Alich, A A
AU  - Alich AA
AD  - Department of Chemistry, College of St. Scholastica, Duluth, Minnesota 55811.
FAU - Wittmers, L E Jr
AU  - Wittmers LE Jr
FAU - Anderson, L A
AU  - Anderson LA
FAU - Rieschl, E M
AU  - Rieschl EM
FAU - Peterson, P L
AU  - Peterson PL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharmacol Toxicol Methods
JT  - Journal of pharmacological and toxicological methods
JID - 9206091
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*toxicity
MH  - Dose-Response Relationship, Drug
MH  - Electrophysiology
MH  - Gastric Mucosa/*drug effects
MH  - Male
MH  - Numerical Analysis, Computer-Assisted
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1992/07/11 19:15
MHDA- 2001/03/28 10:01
CRDT- 1992/07/11 19:15
PHST- 1992/07/11 19:15 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1992/07/11 19:15 [entrez]
AID - 1056-8719(92)90047-5 [pii]
AID - 10.1016/1056-8719(92)90047-5 [doi]
PST - ppublish
SO  - J Pharmacol Toxicol Methods. 1992 Jul;27(4):245-50. doi: 
      10.1016/1056-8719(92)90047-5.

PMID- 11226331
OWN - NLM
STAT- MEDLINE
DCOM- 20010913
LR  - 20181113
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 98
IP  - 5
DP  - 2001 Feb 27
TI  - Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in 
      hypercholesterolemic mice.
PG  - 2860-4
AB  - Restenosis is due to neointimal hyperplasia, which occurs in the coronary artery 
      after percutaneous transluminal coronary angioplasty (PTCA). During restenosis, 
      an impairment of nitric oxide (NO)-dependent pathways may occur. Concomitant 
      hypercholesterolemia may exacerbate restenosis in patients undergoing PTCA. Here, 
      we show that a NO-releasing aspirin derivative (NCX-4016) reduces the degree of 
      restenosis after balloon angioplasty in low-density lipoprotein 
      receptor-deficient mice and this effect is associated with reduced vascular 
      smooth muscle cell (VSMC) proliferation and macrophage deposition at the site of 
      injury. Drugs were administered following both therapeutic or preventive 
      protocols. We demonstrate that NCX-4016 is effective both in prevention and 
      treatment of restenosis in the presence of hypercholesterolemia. These data 
      indicate that impairment of NO-dependent mechanisms may be involved in the 
      development of restenosis in hypercholesterolemic mice. Although experimental 
      models of restenosis may not reflect restenosis in humans in all details, we 
      suggest that a NO-releasing aspirin derivative could be an effective drug in 
      reducing restenosis following PTCA, especially in the presence of 
      hypercholesterolemia and/or gastrointestinal damage.
FAU - Napoli, C
AU  - Napoli C
AD  - Department of Medicine, Federico II University of Naples, 80131 Naples, Italy.
FAU - Cirino, G
AU  - Cirino G
FAU - Del Soldato, P
AU  - Del Soldato P
FAU - Sorrentino, R
AU  - Sorrentino R
FAU - Sica, V
AU  - Sica V
FAU - Condorelli, M
AU  - Condorelli M
FAU - Pinto, A
AU  - Pinto A
FAU - Ignarro, L J
AU  - Ignarro LJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Receptors, LDL)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/*pharmacology/therapeutic use
MH  - Constriction, Pathologic/drug therapy/*prevention & control
MH  - Hypercholesterolemia/*complications
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Nitric Oxide/*metabolism
MH  - Receptors, LDL/genetics/physiology
MH  - Recurrence
PMC - PMC30230
EDAT- 2001/02/28 10:00
MHDA- 2001/09/14 10:01
CRDT- 2001/02/28 10:00
PHST- 2001/02/28 10:00 [pubmed]
PHST- 2001/09/14 10:01 [medline]
PHST- 2001/02/28 10:00 [entrez]
AID - 98/5/2860 [pii]
AID - 041602898 [pii]
AID - 6028 [pii]
AID - 10.1073/pnas.041602898 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2860-4. doi: 10.1073/pnas.041602898.

PMID- 8725731
OWN - NLM
STAT- MEDLINE
DCOM- 19970121
LR  - 20141120
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 75
IP  - 5
DP  - 1996 May
TI  - Reduced effect of aspirin on thrombus formation at high shear and disturbed 
      laminar blood flow.
PG  - 827-32
AB  - Aspirin is the most commonly used antithrombotic drug in primary and secondary 
      prophylaxis against cardio- and cerebrovascular disease. In previous studies from 
      our laboratory it was demonstrated that the effect of aspirin on collagen-induced 
      thrombus formation in a parallel- plate perfusion device with laminar blood flow 
      is shear rate dependent. Although aspirin did not affect collagen-induced 
      thrombus formation at 650 s-1 (medium sized arteries), a significant inhibition 
      of thrombus formation by approximately 38% at 2,600 s-1 (moderately stenoses in 
      medium sized arteries) was observed. At present we have extended these studies to 
      thrombus formation at the apex of eccentric stenoses in a parallel-plate 
      perfusion chamber device. The stenoses reduced the cross-sectional area of the 
      blood flow channel of the perfusion chambers by 60 or 80%, introducing disturbed 
      laminar flow and apex wall shear rates of 2,600 and 10,500 s-1, respectively. The 
      corresponding wall shear stresses were 80 and 315 dynes/cm2, respectively. 
      Aspirin reduced the platelet thrombus volume at the 60% stenosis by 45% (p < 
      0.03), and the fibrin deposition by 70% (p < 0.004). However, none of these 
      parameters were affected by aspirin at the 80% stenosis. These observations may 
      at least partly explain why aspirin has a limited clinical effect in preventing 
      arterial thrombus formation in atherosclerotic vessels at high shear and 
      disturbed blood flow. In contrast, thrombus formation in blood from one patient 
      with Glanzmann's thrombasthenia and two patients with von Willebrand disease 
      subtype 2M was almost abolished at this blood flow condition. Thus, blocking the 
      function of either von Willebrand factor or glycoprotein IIb/IIIa may represent 
      better antithrombotic approaches for such critical events than blocking the 
      prostaglandin metabolism by aspirin. The lack of effect of aspirin on thrombus 
      formation at the 80% stenosis may reflect shear-induced platelet activation at 
      the stenosis inlet region, since shear-induced platelet aggregation in rotational 
      viscometers is not affected by aspirin at shear stresses exceeding 100 dynes/cm2.
FAU - Barstad, R M
AU  - Barstad RM
AD  - Nycomed Pharma AS, Oslo, Norway.
FAU - Orvim, U
AU  - Orvim U
FAU - Hamers, M J
AU  - Hamers MJ
FAU - Tjønnfjord, G E
AU  - Tjønnfjord GE
FAU - Brosstad, F R
AU  - Brosstad FR
FAU - Sakariassen, K S
AU  - Sakariassen KS
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Flow Velocity
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Stress, Mechanical
MH  - Thrombosis/*drug therapy/physiopathology
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1996 May;75(5):827-32.

PMID- 25406385
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20181113
IS  - 1752-1947 (Electronic)
IS  - 1752-1947 (Linking)
VI  - 8
DP  - 2014 Nov 19
TI  - Multiple episodes of aspirin overdose in an individual patient: a case report.
PG  - 374
LID - 10.1186/1752-1947-8-374 [doi]
AB  - INTRODUCTION: Aspirin overdose, though now infrequently encountered, nevertheless 
      continues to contribute to significant morbidity and mortality. The patient 
      described in this case report intentionally ingested overdoses of aspirin on 
      repeated occasions. The case provided an unusual and possibly one-of-a-kind 
      opportunity to focus on the variability in the time course of plasma salicylate 
      concentrations with current treatment modalities of aspirin overdose in an 
      individual patient. CASE PRESENTATION: A 75-year-old Caucasian man who weighed 45 
      kg and had an extensive history of various drug overdoses and stage 3 chronic 
      kidney disease presented to a tertiary university hospital on three occasions 
      within 2 months after successive overdoses of aspirin. During his third 
      admission, he overdosed with aspirin, while on the ward recovering from the 
      previous aspirin overdose. The overdoses were categorized as "potentially lethal" 
      on two occasions and as "serious" in the other two, based on the alleged dose of 
      aspirin ingested (over 500 mg/kg in the first two overdoses, and 320 mg/kg and 
      498 mg/kg in the other two, respectively). However, as assessed by the observed 
      salicylate concentrations, the ingestions would more appropriately have been 
      categorized as being of "moderate" severity for the first and second overdose and 
      "mild" severity for each of the others. This categorization was more consistent 
      with the clinical severity of his admissions. A single dose of activated charcoal 
      was administered only after the second overdose. On each occasion, he was given 
      intravenous fluid with the aim of achieving euvolemia. Urinary alkalization was 
      not attempted during the first admission, which was associated with the longest 
      apparent elimination half-life of salicylate (30 hours). A plasma potassium 
      concentration of approximately 4 mmol/L appeared to be needed for adequate 
      urinary alkalization. CONCLUSION: In a patient with impaired renal function, 
      intravenous fluid and urinary alkalization are the mainstays of treatment of 
      aspirin overdose. Correction of hypokalemia is recommended. Repeated doses of 
      charcoal may be a worthwhile intervention when there is no risk of aspiration. 
      Our experience in this case also revealed considerable unexplained variation in 
      management despite the availability of guidelines. It is, therefore, important to 
      monitor the implementation of available guidelines.
FAU - Ghosh, Debasish
AU  - Ghosh D
FAU - Williams, Kenneth M
AU  - Williams KM
FAU - Graham, Garry G
AU  - Graham GG
FAU - Nair, Priya
AU  - Nair P
FAU - Buscher, Hergen
AU  - Buscher H
FAU - Day, Richard O
AU  - Day RO
AD  - Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, 390 
      Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia. r.day@unsw.edu.au.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141119
PL  - England
TA  - J Med Case Rep
JT  - Journal of medical case reports
JID - 101293382
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/blood/pharmacokinetics/*poisoning
MH  - Drug Overdose/*blood
MH  - Humans
MH  - Hypokalemia/chemically induced/therapy
MH  - Male
PMC - PMC4275751
EDAT- 2014/11/20 06:00
MHDA- 2015/07/21 06:00
CRDT- 2014/11/20 06:00
PHST- 2014/07/23 00:00 [received]
PHST- 2014/08/28 00:00 [accepted]
PHST- 2014/11/20 06:00 [entrez]
PHST- 2014/11/20 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - 1752-1947-8-374 [pii]
AID - 10.1186/1752-1947-8-374 [doi]
PST - epublish
SO  - J Med Case Rep. 2014 Nov 19;8:374. doi: 10.1186/1752-1947-8-374.

PMID- 17109209
OWN - NLM
STAT- MEDLINE
DCOM- 20070126
LR  - 20181113
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 24
IP  - 1
DP  - 2007 Jan
TI  - Rational design of a dual-mode optical and chemical prodrug.
PG  - 194-200
AB  - PURPOSE: The purpose of this study is to demonstrate the rational design and 
      behaviour of the first dual-mode optical and chemical prodrug, exemplified by an 
      acetyl salicylic acid-based system. METHODS: A cyclic 1,4-benzodioxinone prodrug 
      was synthesised by reaction of 3,5-dimethoxybenzoin and acetyl salicoyl chloride 
      with pyridine. After purification by column chromatography and recrystallization, 
      characterization was achieved using infrared and NMR spectroscopies, mass 
      spectrometry, elemental analysis and single crystal X-ray diffraction. 
      Light-triggered drug liberation was characterised via UV-visible spectroscopy 
      following low-power 365 nm irradiation for controlled times. Chemical drug 
      liberation was characterised via UV-visible spectroscopy in pH 5.5 solution. 
      RESULTS: The synthetic method yielded pure prodrug, with full supporting 
      characterisation. Light-triggered drug liberation proceeded at a rate of 
      8.30x10(-2) s-1, while chemical, hydrolytic liberation proceeded independently at 
      1.89x10(-3) s-1. The photochemical and hydrolytic reactions were both 
      quantitative. CONCLUSIONS: This study demonstrates the first rational dual-mode 
      optical and chemical prodrug, using acetyl salicylic acid as a model, acting as a 
      paradigm for future dual-mode systems. Photochemical drug liberation proceeds 44 
      times faster than chemical liberation, suggesting potential use in drug-eluting 
      medical devices where an additional burst of drug is required at the onset of 
      infection.
FAU - McCoy, Colin P
AU  - McCoy CP
AD  - School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK. 
      c.mccoy@qub.ac.uk
FAU - Rooney, Clare
AU  - Rooney C
FAU - Jones, David S
AU  - Jones DS
FAU - Gorman, Sean P
AU  - Gorman SP
FAU - Nieuwenhuyzen, Mark
AU  - Nieuwenhuyzen M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061116
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Indicators and Reagents)
RN  - 0 (Prodrugs)
RN  - 0 (Pyridines)
RN  - NH9L3PP67S (pyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/analogs & derivatives/pharmacokinetics
MH  - Crystallography, X-Ray
MH  - *Drug Design
MH  - Hydrolysis
MH  - Indicators and Reagents
MH  - Light
MH  - Models, Molecular
MH  - Photochemistry
MH  - Prodrugs/*chemical synthesis/chemistry/radiation effects
MH  - Pyridines/chemistry
MH  - Spectrophotometry, Ultraviolet
EDAT- 2006/11/17 09:00
MHDA- 2007/01/27 09:00
CRDT- 2006/11/17 09:00
PHST- 2006/05/31 00:00 [received]
PHST- 2006/08/02 00:00 [accepted]
PHST- 2006/11/17 09:00 [pubmed]
PHST- 2007/01/27 09:00 [medline]
PHST- 2006/11/17 09:00 [entrez]
AID - 10.1007/s11095-006-9145-8 [doi]
PST - ppublish
SO  - Pharm Res. 2007 Jan;24(1):194-200. doi: 10.1007/s11095-006-9145-8. Epub 2006 Nov 
      16.

PMID- 34168274
OWN - NLM
STAT- MEDLINE
DCOM- 20220815
LR  - 20230210
IS  - 1476-5527 (Electronic)
IS  - 0950-9240 (Linking)
VI  - 36
IP  - 8
DP  - 2022 Aug
TI  - The preventive effects of aspirin on preeclampsia based on network pharmacology 
      and bioinformatics.
PG  - 753-759
LID - 10.1038/s41371-021-00568-7 [doi]
AB  - This study aimed to reveal the key targets and molecular mechanisms of aspirin in 
      preventing preeclampsia. We used bioinformatics databases to collect the 
      candidate targets for aspirin and preeclampsia. The biological functions and 
      signaling pathways of the intersecting targets were analyzed by Gene Ontology 
      (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Then, the hub targets 
      were identified by cytoscape plugin cytoHubba from the protein-protein 
      interaction network. We collected 90 targets for aspirin in preventing 
      preeclampsia. The biological processes of the intersecting targets are mainly 
      involved in xenobiotic metabolic process, inflammatory response, negative 
      regulation of apoptotic process, and protein phosphorylation. The highly enriched 
      pathways were FoxO signaling pathway, circadian rhythm, insulin resistance, 
      arachidonic acid metabolism, and drug metabolism-cytochrome P450. The hub targets 
      for aspirin in preventing preeclampsia were tumor protein p53 (TP53), C-X-C motif 
      chemokine ligand 8 (CXCL8), mitogen-activated protein kinase 3 (MAPK3), 
      mitogen-activated protein kinase 1 (MAPK1), mitogen-activated protein kinase 14 
      (MAPK14), epidermal growth factor receptor (EGFR), estrogen receptor (ESR1), and 
      prostaglandin-endoperoxide synthase 2 (PTGS2). Molecular docking results showed 
      good bindings between the proteins and aspirin. In conclusion, these findings 
      highlight the key targets and molecular mechanisms of aspirin in preventing 
      preeclampsia.
CI  - © 2021. The Author(s), under exclusive licence to Springer Nature Limited.
FAU - Zhang, Jiejie
AU  - Zhang J
AD  - Department of Obstetrics, Xiangya Hospital, Central South University, Changsha, 
      China.
AD  - Hunan Engineering Research Center of Early Life Development and Disease 
      Prevention, Changsha, China.
FAU - Huang, Jingrui
AU  - Huang J
AD  - Department of Obstetrics, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Zhao, Yanhua
AU  - Zhao Y
AD  - Department of Obstetrics, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Zhang, Weishe
AU  - Zhang W
AUID- ORCID: 0000-0002-3767-5998
AD  - Department of Obstetrics, Xiangya Hospital, Central South University, Changsha, 
      China. zhangweishe@yeah.net.
AD  - Hunan Engineering Research Center of Early Life Development and Disease 
      Prevention, Changsha, China. zhangweishe@yeah.net.
LA  - eng
GR  - 81903696/National Natural Science Foundation of China (National Science 
      Foundation of China)/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210624
PL  - England
TA  - J Hum Hypertens
JT  - Journal of human hypertension
JID - 8811625
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Computational Biology/methods
MH  - Female
MH  - Gene Regulatory Networks
MH  - Humans
MH  - Molecular Docking Simulation
MH  - Network Pharmacology
MH  - *Pre-Eclampsia/genetics/prevention & control
MH  - Pregnancy
EDAT- 2021/06/26 06:00
MHDA- 2022/08/16 06:00
CRDT- 2021/06/25 06:41
PHST- 2021/02/21 00:00 [received]
PHST- 2021/06/14 00:00 [accepted]
PHST- 2021/06/03 00:00 [revised]
PHST- 2021/06/26 06:00 [pubmed]
PHST- 2022/08/16 06:00 [medline]
PHST- 2021/06/25 06:41 [entrez]
AID - 10.1038/s41371-021-00568-7 [pii]
AID - 10.1038/s41371-021-00568-7 [doi]
PST - ppublish
SO  - J Hum Hypertens. 2022 Aug;36(8):753-759. doi: 10.1038/s41371-021-00568-7. Epub 
      2021 Jun 24.

PMID- 2013838
OWN - NLM
STAT- MEDLINE
DCOM- 19910513
LR  - 20191022
IS  - 0090-466X (Print)
IS  - 0090-466X (Linking)
VI  - 19
IP  - 2
DP  - 1991 Apr
TI  - The pharmacokinetics of aspirin in rats and the effect of buffer.
PG  - 157-73
AB  - Aspirin (acetylsalicyclic acid) was administered to rats intravenously, orally, 
      and intraintestinally at different doses or in different dosage forms. The 
      distribution and elimination kinetics of aspirin in rats following intravenous 
      administration were best described by a two-compartmental open system and were 
      dose independent up to 15 mg/kg. The terminal elimination half-life following 
      intravenous dosing (10 mg/kg) was 3.36 +/- 0.85 min (n = 15) with the clearance 
      being 8.40 +/- 1.24 L/(kg.hr). Intravenous distribution and elimination kinetics 
      of aspirin in rats were not influenced by an orally administered buffered 
      solution with a buffer capacity of 0.933 mEq ANC (acid neutralizing capacity) per 
      kg of body weight. However, this orally buffered solution did change the 
      gastrointestinal absorption kinetics of aspirin in rats. The absolute 
      bioavailable dose of aspirin was 56.6 +/- 10.4% (n = 6) following its 
      administration in an unbuffered solution while it was only 31.8 +/- 8.0% (n = 6) 
      following administration in the buffered solution. The corresponding values of 
      the absolute bioavailable doses were 43.4 +/- 3.7% and 25.5 +/- 1.8% following 
      intraintestinal administration. The lower systemic availability of aspirin in the 
      presence of buffer is attributed to a greater fraction of the administered dose 
      becoming available for absorption from the intestine where the extraction 
      efficiency is higher than that in the stomach.
FAU - Fu, C J
AU  - Fu CJ
AD  - Pharmacokinetics Laboratory, School of Pharmacy, University of Missouri-Kansas 
      City 64108.
FAU - Melethil, S
AU  - Melethil S
FAU - Mason, W D
AU  - Mason WD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacokinet Biopharm
JT  - Journal of pharmacokinetics and biopharmaceutics
JID - 0357115
RN  - 0 (Buffers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - *Buffers
MH  - Gastrointestinal Contents
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1991/04/01 00:00
MHDA- 1991/04/01 00:01
CRDT- 1991/04/01 00:00
PHST- 1991/04/01 00:00 [pubmed]
PHST- 1991/04/01 00:01 [medline]
PHST- 1991/04/01 00:00 [entrez]
AID - 10.1007/BF01073867 [doi]
PST - ppublish
SO  - J Pharmacokinet Biopharm. 1991 Apr;19(2):157-73. doi: 10.1007/BF01073867.

PMID- 4043367
OWN - NLM
STAT- MEDLINE
DCOM- 19851108
LR  - 20131121
IS  - 0014-8318 (Print)
IS  - 0014-8318 (Linking)
VI  - 48
IP  - 4
DP  - 1985 Jul-Aug
TI  - [Utilization of the pharmacokinetic parameters of acetylsalicylic acid for 
      optimizing its use with people of different ages].
PG  - 69-73
AB  - Nomograms for application of acetylsalicylic acid in persons of different age are 
      presented. The nomograms are based on pharmacokinetic parameters of 
      acetylsalicylic acid with regard to the age. Proceeding from the known constants 
      of absorption and elimination, the nomograms are made use of to screen the 
      loading and maintenance doses, to determine the time of administering the first 
      maintenance dose and the maximal amount of the drug in the body, which was built 
      up as a result of the use of the accepted treatment schedule. While using the 
      nomograms one should be guided by the known therapeutic dose and the dosage 
      intervals or by the therapeutic or maximal allowable dose. The nomograms are 
      unsophisticated, fairly convenient, and help determine the optimal regimen of the 
      use of acetylsalicylic acid in persons of different age.
FAU - Zapadniuk, V I
AU  - Zapadniuk VI
FAU - Korkushko, O V
AU  - Korkushko OV
FAU - Bezverkhaia, I S
AU  - Bezverkhaia IS
FAU - Belyĭ, A A
AU  - Belyĭ AA
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Ispol'zovanie farmakokineticheskikh parametrov atsetilsalitsilovoĭ kisloty dlia 
      optimizatsii ee primeneniia u liudeĭ raznogo vozrasta.
PL  - Russia (Federation)
TA  - Farmakol Toksikol
JT  - Farmakologiia i toksikologiia
JID - 16920420R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aging/*drug effects
MH  - Aspirin/administration & dosage/*metabolism
MH  - Humans
MH  - Kinetics
MH  - Mathematics
MH  - Middle Aged
MH  - Models, Biological
MH  - Time Factors
EDAT- 1985/07/01 00:00
MHDA- 1985/07/01 00:01
CRDT- 1985/07/01 00:00
PHST- 1985/07/01 00:00 [pubmed]
PHST- 1985/07/01 00:01 [medline]
PHST- 1985/07/01 00:00 [entrez]
PST - ppublish
SO  - Farmakol Toksikol. 1985 Jul-Aug;48(4):69-73.

PMID- 17879379
OWN - NLM
STAT- MEDLINE
DCOM- 20080513
LR  - 20131121
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 97
IP  - 4
DP  - 2008 Apr
TI  - The confusion of indexing aspirin crystals.
PG  - 1361-7
AB  - Much of the existing literature dealing with crystalline aspirin is vague or 
      ambiguous with regard to indexing of the crystal faces. The inconsistency with 
      which the indices of the dominant faces have been assigned leads to confusion in 
      analysis of surface properties. To clarify this, we have conducted crystal growth 
      experiments on aspirin, and indexed the crystal faces with X-ray diffraction 
      (XRD), paying special attention to the placement of symmetry elements. The space 
      group was confirmed as P2(1)/c, and the dominant face was (100). Contact angle 
      measurements made on the two major faces of aspirin indicate the (100) face to be 
      more hydrophobic than the (001) face, likely due to the acetyloxy moiety, not the 
      carboxyl, exposed on the (100).
CI  - 2007 Wiley-Liss, Inc
FAU - Aubrey-Medendorp, Clare
AU  - Aubrey-Medendorp C
AD  - Department of Pharmaceutical Sciences, University of Kentucky, Lexington, 
      Kentucky 40536-0082.
FAU - Parkin, Sean
AU  - Parkin S
FAU - Li, Tonglei
AU  - Li T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Wettability
MH  - X-Ray Diffraction
EDAT- 2007/09/20 09:00
MHDA- 2008/05/14 09:00
CRDT- 2007/09/20 09:00
PHST- 2007/09/20 09:00 [pubmed]
PHST- 2008/05/14 09:00 [medline]
PHST- 2007/09/20 09:00 [entrez]
AID - S0022-3549(16)32542-4 [pii]
AID - 10.1002/jps.21055 [doi]
PST - ppublish
SO  - J Pharm Sci. 2008 Apr;97(4):1361-7. doi: 10.1002/jps.21055.

PMID- 32919225
OWN - NLM
STAT- MEDLINE
DCOM- 20210412
LR  - 20210412
IS  - 1877-783X (Electronic)
IS  - 1877-7821 (Linking)
VI  - 69
DP  - 2020 Dec
TI  - Use of metformin and aspirin is associated with delayed cancer incidence.
PG  - 101808
LID - S1877-7821(20)30142-9 [pii]
LID - 10.1016/j.canep.2020.101808 [doi]
AB  - BACKGROUND: While the chemoprevention effect of aspirin is well-established, the 
      effects of metformin in cancer prevention is still controversial. This study is 
      to investigate the use of aspirin, metformin, or the combination of both is 
      associated with delayed cancer incidence. METHOD: This dataset is based on the 
      electronic medical record of public hospitals in Hong Kong. Patients were 
      classified into 1. aspirin user, 2. metformin user, 3. both aspirin and metformin 
      user and 4. control group with neither aspirin nor metformin used. Aspirin and/or 
      metformin must have been taken for over 6 months in the treatment group and 
      cancer incidences was counted at least 6 months after exposure to such 
      medications. The primary outcome of this study was overall incidence of cancer 
      during the follow-up period. The secondary outcomes were cancer incidences of 
      specific sites, including colon/rectum, liver, oesophagus, pancreas, stomach, 
      lung, breast, kidney, bladder and prostate. Cox proportional hazards regression 
      models were fitted to estimate hazard ratios of cancer risks. Inverse probability 
      of treatment weighting was used to control for the medication effects. RESULTS: A 
      total of 120,971 aspirin users, 11,365 metformin users, and 6630 aspirin plus 
      metformin users, were identified. Compare to the control groups, those who used 
      aspirin alone demonstrated a significant reduction in overall cancer risk (HR 
      0.80, 95% CI 0.73-0.87). Similarly, those who used metformin alone also showed an 
      overall reduction in cancer risk (HR 0.79, 95% CI 0.71-0.88). Patients who 
      received both aspirin and metformin showed the most significant reduction in 
      overall cancer risk (HR 0.53, 95% CI 0.45-0.63). Metformin showed a significant 
      reduction in cancer risk of lung, oesophagus and bladder. CONCLUSION: There is a 
      similar decrease in overall cancer rate with the use of aspirin or metformin 
      alone. A more significant reduction in overall cancer risk was found with the use 
      of both agents.
CI  - Copyright © 2020 Elsevier Ltd. All rights reserved.
FAU - Sung, Joseph Jy
AU  - Sung JJ
AD  - Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of 
      Hong Kong, Hong Kong, China; Department of Medicine and Therapeutics, The Chinese 
      University of Hong Kong, Hong Kong, China.
FAU - Ho, Jason Mw
AU  - Ho JM
AD  - JC School of Public Health and Primary Care, The Chinese University of Hong Kong, 
      Hong Kong, China.
FAU - Lam, Amy Sm
AU  - Lam AS
AD  - Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of 
      Hong Kong, Hong Kong, China.
FAU - Yau, Sarah Ty
AU  - Yau ST
AD  - Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of 
      Hong Kong, Hong Kong, China; JC School of Public Health and Primary Care, The 
      Chinese University of Hong Kong, Hong Kong, China.
FAU - Tsoi, Kelvin Kf
AU  - Tsoi KK
AD  - Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of 
      Hong Kong, Hong Kong, China; JC School of Public Health and Primary Care, The 
      Chinese University of Hong Kong, Hong Kong, China. Electronic address: 
      kelvintsoi@cuhk.edu.hk.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - Netherlands
TA  - Cancer Epidemiol
JT  - Cancer epidemiology
JID - 101508793
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Delayed Diagnosis
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Metformin/pharmacology/*therapeutic use
MH  - Middle Aged
MH  - Neoplasms/epidemiology
MH  - Retrospective Studies
OTO - NOTNLM
OT  - aspirin
OT  - cancer
OT  - metformin
EDAT- 2020/09/13 06:00
MHDA- 2021/04/13 06:00
CRDT- 2020/09/12 20:13
PHST- 2020/07/21 00:00 [received]
PHST- 2020/08/21 00:00 [revised]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2021/04/13 06:00 [medline]
PHST- 2020/09/12 20:13 [entrez]
AID - S1877-7821(20)30142-9 [pii]
AID - 10.1016/j.canep.2020.101808 [doi]
PST - ppublish
SO  - Cancer Epidemiol. 2020 Dec;69:101808. doi: 10.1016/j.canep.2020.101808. Epub 2020 
      Sep 9.

PMID- 11067652
OWN - NLM
STAT- MEDLINE
DCOM- 20001019
LR  - 20181113
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 18
IP  - 2
DP  - 2000 Aug
TI  - Economic assessment of the secondary prevention of ischaemic events with lysine 
      acetylsalicylate.
PG  - 185-200
AB  - OBJECTIVE: To analyse the economic benefits, in comparison with placebo, of the 
      secondary prevention of ischaemic stroke and myocardial infarction (MI) with 
      lysine acetylsalicylate (Kardégic) in patients with a history of ischaemic 
      stroke, MI or stable and unstable angina pectoris. DESIGN AND SETTING: This was a 
      modelling study from the perspectives of direct medical costs, the social 
      security system and society in France. METHODS: Efficacy data for the secondary 
      prevention of ischaemic events were derived from the Antiplatelet Trialists' 
      Collaboration meta-analysis on antithrombotics. The rates and costs of ischaemic 
      disease and of serious gastrointestinal adverse affects arising from long term 
      aspirin treatment, as well as the costs of treatment with lysine 
      acetylsalicylate, were taken from published sources, using French data where 
      possible. RESULTS: From the social security perspective, the estimated 
      cost-effectiveness ratios show that the prevention of MI in patients with a 
      history of unstable angina (with a 1-year follow-up) is a cost-saving strategy, 
      with net benefits ranging from $US5703 (1996 prices) per avoided MI for lysine 
      acetylsalicylate 300 mg/day to $US5761 per avoided MI for lysine acetylsalicylate 
      75 mg/day. The prevention of MI and stroke is also a cost-saving strategy in 
      patients with prior MI [net benefits in a 2-year follow-up (5% discount rate) 
      ranging from $US15 to $US494 per avoided MI and from $US37 to $US1170 per avoided 
      stroke]. This was also true in patients with prior ischaemic stroke (net benefits 
      in a 3-year follow-up ranging from $US610 to $US2082 per avoided MI and from 
      $US176 to $US599 per avoided stroke). Finally, a 4-year follow-up in patients 
      with a history of stable angina pectoris shows that prophylactic treatment with 
      lysine acetylsalicylate is associated with net costs per avoided MI, ranging from 
      $US4375 to $US3608 per avoided event. Sensitivity analysis confirmed that 
      prophylaxis with lysine acetylsalicylate in patients at high risk of 
      cardiovascular and cerebrovascular events results in savings in social security 
      expenditure. CONCLUSIONS: Our results underline the high economic benefit of 
      using lysine acetylsalicylate to prevent secondary ischaemic stroke and MI in 
      patients at high risk of cardiovascular and/or cerebrovascular events, leading to 
      savings for the social security system and society.
FAU - Marissal, J P
AU  - Marissal JP
AD  - Department of Health Economics, Catholic University of Lille, France. 
      jp.marissal@cresge.fupl.asso.fr
FAU - Selke, B
AU  - Selke B
FAU - Lebrun, T
AU  - Lebrun T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
MH  - Aspirin/*analogs & derivatives/economics/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Lysine/*analogs & derivatives/economics/therapeutic use
MH  - Myocardial Ischemia/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/*prevention & control
EDAT- 2000/11/07 11:00
MHDA- 2000/11/07 11:01
CRDT- 2000/11/07 11:00
PHST- 2000/11/07 11:00 [pubmed]
PHST- 2000/11/07 11:01 [medline]
PHST- 2000/11/07 11:00 [entrez]
AID - 10.2165/00019053-200018020-00008 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2000 Aug;18(2):185-200. doi: 10.2165/00019053-200018020-00008.

PMID- 28667787
OWN - NLM
STAT- MEDLINE
DCOM- 20180629
LR  - 20180629
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Linking)
VI  - 121
IP  - 6
DP  - 2017 Dec
TI  - Global Trends in Aspirin Resistance-Related Research from 1990 to 2015: A 
      Bibliometric Analysis.
PG  - 512-519
LID - 10.1111/bcpt.12840 [doi]
AB  - Aspirin resistance can be defined as the inability of the usual dose of aspirin 
      medication to produce its antithrombotic effect. Patients with diabetes or 
      cardiovascular disease are at higher risk of stroke, myocardial infarction or 
      cardiovascular death due to aspirin resistance. The aim of this bibliometric 
      study was to identify and analyse the status and trends of aspirin resistance 
      research production at global level through publications indexed in the Scopus 
      database; this will shed new light on future research trends and help researchers 
      predict dynamic direction of research. Literature search using the Scopus 
      database was conducted to assess publications related to aspirin resistance. The 
      selected publications included the terms related to aspirin resistance in the 
      title, abstract or keywords. The searching was accomplished on 20 March 2016 and 
      can be considered to include all publications up to 31 December 2015. Global 
      cumulative publication output on aspirin resistance consists of 986 papers during 
      1990-2015. Among the 986 documents, 19 (1.9%) were published before 2000, 567 
      (57.5%) were published from 2000 to 2009 and 400 (40.6%) were published from 2010 
      to 2015, with peak of publications on this topic in 2008. The leading country in 
      the field of aspirin resistance was the United States, which had the greatest 
      counts of independent articles (165) and international collaboration articles 
      (44). Turkey was in the second rank with 78 articles, followed by Italy (68), the 
      UK (62) and Poland (60). The total number of citations for all documents was 
      26,342, and the average citations per document were 26.7. The h-index for all 
      aspirin resistance publications was 82. This study presents the results of the 
      first bibliometric study (including quantitative and qualitative analysis) of 
      scientific publications in the field of aspirin renitence at global level. 
      Aspirin resistance-related researches have notably increased in the last years, 
      especially from 2000 to 2015. The United States is the most prolific country, not 
      only in research quantity but also in quality. Furthermore, Turkey and European 
      countries provided more research related to aspirin resistance than other regions 
      such as the developing countries.
CI  - © 2017 Nordic Association for the Publication of BCPT (former Nordic 
      Pharmacological Society).
FAU - Al-Jabi, Samah W
AU  - Al-Jabi SW
AD  - Department of Clinical and Community Pharmacy, Faulty of Medicine and Health 
      Sciences, An-Najah National University, Nablus, Palestine.
LA  - eng
PT  - Journal Article
DEP - 20170725
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Bibliometrics
MH  - Databases, Bibliographic
MH  - Drug Resistance
MH  - Europe
MH  - Fibrinolytic Agents/*pharmacology/therapeutic use
MH  - Humans
MH  - Italy
MH  - Publishing
MH  - Qualitative Research
MH  - Research
MH  - Turkey
MH  - United States
EDAT- 2017/07/02 06:00
MHDA- 2018/06/30 06:00
CRDT- 2017/07/02 06:00
PHST- 2017/05/10 00:00 [received]
PHST- 2017/06/27 00:00 [accepted]
PHST- 2017/07/02 06:00 [pubmed]
PHST- 2018/06/30 06:00 [medline]
PHST- 2017/07/02 06:00 [entrez]
AID - 10.1111/bcpt.12840 [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2017 Dec;121(6):512-519. doi: 10.1111/bcpt.12840. 
      Epub 2017 Jul 25.

PMID- 26501118
OWN - NLM
STAT- MEDLINE
DCOM- 20160912
LR  - 20210109
IS  - 2352-3964 (Print)
IS  - 2352-3964 (Electronic)
IS  - 2352-3964 (Linking)
VI  - 2
IP  - 9
DP  - 2015 Sep
TI  - The Helicobacter Eradication Aspirin Trial (HEAT): A Large Simple Randomised 
      Controlled Trial Using Novel Methodology in Primary Care.
PG  - 1200-4
LID - 10.1016/j.ebiom.2015.07.012 [doi]
AB  - BACKGROUND: Clinical trials measuring the effect of an intervention on clinical 
      outcomes are more influential than those investigating surrogate measures but are 
      costly. We developed methods to reduce costs substantially by using existing data 
      in primary care systems, to ask whether Helicobacter pylori eradication would 
      reduce the incidence of hospitalisation for ulcer bleeding in aspirin users. 
      METHODS: The Helicobacter Eradication Aspirin Trial (HEAT) is a National 
      Institute of Health Research-funded, double-blind placebo controlled randomised 
      trial of the effects of H. pylori eradication on subsequent ulcer bleeding in 
      infected individuals taking aspirin daily, conducted in practices across the 
      whole of England, Wales and Northern Ireland. A bespoke web-based trial 
      management system developed for the trial (and housed within the secure NHS Data 
      Network) communicates directly with the HEAT Toolkit software downloaded at 
      participating practices, which issues queries searching entry criteria 
      (≥ 60 years, on chronic aspirin ≤ 325 mg daily, not on anti-ulcer therapy or 
      non-steroidal anti-inflammatory drugs) for GP review of eligibility. Trial 
      participation is invited using a highly secure automated online mail management 
      system. Interested patients are seen once for consent and breath testing. Those 
      with a positive test are randomised to eradication treatment (lansoprazole, 
      clarithromycin, metronidazole) or placebo, with drug sent by post. Events are 
      tracked by upload of accumulating information in the GP database, patient 
      contact, review of National Hospital Episode Statistics and Office of National 
      Statistics data. RESULTS: HEAT is the largest Clinical Research Network-supported 
      drug trial, with 115,660 invitation letters sent from 850 practices, 22,922 
      volunteers, and 3038 H. pylori positive patients randomised to active or placebo 
      treatment after 2.5 years of recruitment. 178 practices have performed their 
      first follow-up data search to identify 21 potential endpoints to date. 
      DISCUSSION: HEAT is important medically, because aspirin is so widely used, and 
      methodologically, as a successful trial would show that large-scale studies of 
      important clinical outcomes can be conducted at a fraction of the cost of those 
      conducted by industry, which in turn will help to ensure that trials of primarily 
      medical rather than commercial interest can be conducted successfully in the UK.
FAU - Dumbleton, Jennifer S
AU  - Dumbleton JS
AD  - University of Nottingham, UK.
FAU - Avery, Anthony J
AU  - Avery AJ
AD  - University of Nottingham, UK.
FAU - Coupland, Carol
AU  - Coupland C
AD  - University of Nottingham, UK.
FAU - Hobbs, F D Richard
AU  - Hobbs FD
AD  - University of Oxford, UK.
FAU - Kendrick, Denise
AU  - Kendrick D
AD  - University of Nottingham, UK.
FAU - Moore, Michael V
AU  - Moore MV
AD  - University of Southampton, UK.
FAU - Morris, Clive
AU  - Morris C
AD  - TCR Nottingham Ltd., UK.
FAU - Rubin, Greg P
AU  - Rubin GP
AD  - University of Durham, UK.
FAU - Smith, Murray D
AU  - Smith MD
AD  - University of Nottingham, UK.
FAU - Stevenson, Diane J
AU  - Stevenson DJ
AD  - University of Nottingham, UK.
FAU - Hawkey, Chris J
AU  - Hawkey CJ
AD  - University of Nottingham, UK.
LA  - eng
GR  - 09/55/52/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150710
PL  - Netherlands
TA  - EBioMedicine
JT  - EBioMedicine
JID - 101647039
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Disease Eradication
MH  - Helicobacter/*drug effects
MH  - Humans
MH  - Patient Compliance
MH  - *Primary Health Care
MH  - Sample Size
MH  - Treatment Outcome
PMC - PMC4588401
OTO - NOTNLM
OT  - Aspirin
OT  - Bleed
OT  - Clinical trial
OT  - Helicobacter pylori
OT  - Ulcer
EDAT- 2015/10/27 06:00
MHDA- 2015/10/27 06:01
CRDT- 2015/10/27 06:00
PHST- 2015/06/12 00:00 [received]
PHST- 2015/07/06 00:00 [revised]
PHST- 2015/07/07 00:00 [accepted]
PHST- 2015/10/27 06:00 [entrez]
PHST- 2015/10/27 06:00 [pubmed]
PHST- 2015/10/27 06:01 [medline]
AID - S2352-3964(15)30067-0 [pii]
AID - 10.1016/j.ebiom.2015.07.012 [doi]
PST - epublish
SO  - EBioMedicine. 2015 Jul 10;2(9):1200-4. doi: 10.1016/j.ebiom.2015.07.012. 
      eCollection 2015 Sep.

PMID- 18728372
OWN - NLM
STAT- MEDLINE
DCOM- 20081231
LR  - 20140530
IS  - 1598-6535 (Print)
IS  - 1598-6535 (Linking)
VI  - 28
IP  - 4
DP  - 2008 Aug
TI  - [Incidence of aspirin resistance in the patient group of a university hospital in 
      Korea].
PG  - 251-7
LID - 10.3343/kjlm.2008.28.4.251 [doi]
AB  - BACKGROUND: Aspirin is the most common drug used for the prevention of arterial 
      thrombosis. However, platelet responsiveness to aspirin is variable among 
      individuals and it is important to detect aspirin resistance to improve clinical 
      outcome. We analyzed the changes of platelet reactivity before and after aspirin 
      treatment. We also investigated the incidence and influencing factors of aspirin 
      resistance in Korean. METHODS: We tested platelet function in 198 patients who 
      had been treated with aspirin in a Korean university hospital, and 59 of these 
      patients were tested for platelet function before and after aspirin treatment. We 
      also analyzed platelet reactivity in 136 patients who had not been treated with 
      aspirin. Platelet function was tested using the VerifyNow Aspirin Assay 
      (Accumetrics, USA). Platelet reactivity was expressed as aspirin reaction unit 
      (ARU) and > or =550 ARU was defined as aspirin resistance. RESULTS: Platelet 
      reactivity of 136 patients who had not been treated with aspirin was 
      632.2plusmn;46.3 ARU (meanplusmn;SD) (range, 462-675). Platelet reactivity of 198 
      patients who had been treated with aspirin was 472.5plusmn;60.0 (338-666) ARU, 
      and 10.1% of patients were aspirin-resistant. The difference of platelet 
      reactivity before and after aspirin treatment was 128.3plusmn;68.7 (-40-248) ARU. 
      Hb level was lower and platelet count was higher in aspirin-resistant group than 
      in aspirin-sensitive group (P<0.05). CONCLUSIONS: We demonstrated the 
      distribution of platelet reactivity before and after aspirin treatment using the 
      VerifyNow Aspirin Assay. The incidence of aspirin resistance was 10.1%, and low 
      Hb level and high platelet count were related with aspirin resistance.
FAU - Lee, Young Kyung
AU  - Lee YK
AD  - Department of Laboratory Medicine, Hallym University College of Medicine, 
      Chuncheon, Korea. lyoungk@hallym.or.kr
FAU - Kim, Han-Sung
AU  - Kim HS
FAU - Park, Ji-Young
AU  - Park JY
FAU - Kang, Hee Jung
AU  - Kang HJ
LA  - kor
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PL  - Korea (South)
TA  - Korean J Lab Med
JT  - The Korean journal of laboratory medicine
JID - 101322822
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Drug Resistance
MH  - Female
MH  - Hospitals, University
MH  - Humans
MH  - Korea/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests
MH  - Predictive Value of Tests
EDAT- 2008/08/30 09:00
MHDA- 2009/01/01 09:00
CRDT- 2008/08/30 09:00
PHST- 2008/08/30 09:00 [pubmed]
PHST- 2009/01/01 09:00 [medline]
PHST- 2008/08/30 09:00 [entrez]
AID - 200808251 [pii]
AID - 10.3343/kjlm.2008.28.4.251 [doi]
PST - ppublish
SO  - Korean J Lab Med. 2008 Aug;28(4):251-7. doi: 10.3343/kjlm.2008.28.4.251.

PMID- 1389819
OWN - NLM
STAT- MEDLINE
DCOM- 19921029
LR  - 20190515
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 69
IP  - 2
DP  - 1992 Aug
TI  - Thrombelastography after aspirin ingestion in pregnant and non-pregnant subjects.
PG  - 159-61
AB  - The thrombelastograph (TEG) and bleeding time were performed before and 6 h after 
      a single oral dose of aspirin 600 mg in a group of eight healthy volunteers and 
      12 pregnant patients. Measured TEG variables (r, k, r+k times and maximum 
      amplitude) were unaltered after aspirin although there was a significant 
      prolongation of the bleeding time in both groups. Although the TEG appeared not 
      to detect aspirin-induced changes in platelet function, the TEG measures all 
      phases of coagulation and the unaltered TEG after aspirin suggested a functioning 
      coagulation system.
FAU - Orlikowski, C E
AU  - Orlikowski CE
AD  - Department of Anaesthetics, Faculty of Medicine, University of Natal, Durban, 
      South Africa.
FAU - Payne, A J
AU  - Payne AJ
FAU - Moodley, J
AU  - Moodley J
FAU - Rocke, D A
AU  - Rocke DA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation/*drug effects
MH  - Blood Platelets/drug effects
MH  - Female
MH  - Humans
MH  - Pregnancy/*blood
MH  - Thrombelastography
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
AID - S0007-0912(17)46495-6 [pii]
AID - 10.1093/bja/69.2.159 [doi]
PST - ppublish
SO  - Br J Anaesth. 1992 Aug;69(2):159-61. doi: 10.1093/bja/69.2.159.

PMID- 8728890
OWN - NLM
STAT- MEDLINE
DCOM- 19960919
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 25
IP  - 1
DP  - 1996 Jan 6-13
TI  - [Aspirin during pregnancy. Indications and modalities of prescription after the 
      publication of the later trials].
PG  - 31-6
AB  - Aspirin, an inhibitor of cyclo-oxygenase, is prescribed in a number of conditions 
      related to abnormal production of prostaglandins including gravidic hypertension. 
      Results of the most recent trials demonstrate that in patients with a past 
      history of pre-eclampsia or intra-uterine growth retardation, a pathological 
      Doppler examination of the uterus, a pathological angiotensin test or an 
      antiphospholipid syndrome, prescription of aspirin at the dose of 100 mg/day can 
      prevent recurrence or development of pre-eclampsia or intra-uterine growth 
      retardation. Treatment should begin as soon as possible during pregnancy, 
      certainly before development of clinical manifestations. After history taking and 
      identification of possible contraindications, bleeding time (Ivy method) is 
      recorded before and after prescription and should be lower than 8 minutes. In 
      case bleeding time exceeds 10 minutes 10 to 15 days after initiating aspirin, 
      doses may be reduced to 50 mg per day or even 50 mg every two or three days to 
      reach the target level. Treatment should generally be continued up to 36 weeks 
      gestation.
FAU - Uzan, S
AU  - Uzan S
AD  - Service de Gynécologie-Obstétrique, Hôpital Tenon, Paris.
FAU - Merviel, P
AU  - Merviel P
FAU - Beaufils, M
AU  - Beaufils M
FAU - Bréart, G
AU  - Bréart G
FAU - Salat-Baroux, J
AU  - Salat-Baroux J
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Aspirine pendant la grossesse indications et modalités de prescription après la 
      publication des derniers essais.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 11128-99-7 (Angiotensin II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin II/analysis
MH  - Antiphospholipid Syndrome/*prevention & control
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Female
MH  - Fetal Growth Retardation/diagnostic imaging/*prevention & control
MH  - Humans
MH  - Infant, Newborn
MH  - Pre-Eclampsia/diagnosis/diagnostic imaging/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications
MH  - Pregnancy Trimester, First
MH  - Pregnancy Trimester, Second
MH  - Pregnancy, High-Risk
MH  - Ultrasonography
RF  - 30
EDAT- 1996/01/06 00:00
MHDA- 1996/01/06 00:01
CRDT- 1996/01/06 00:00
PHST- 1996/01/06 00:00 [pubmed]
PHST- 1996/01/06 00:01 [medline]
PHST- 1996/01/06 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1996 Jan 6-13;25(1):31-6.

PMID- 11244807
OWN - NLM
STAT- MEDLINE
DCOM- 20010322
LR  - 20151119
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 55
IP  - 10
DP  - 2000 Oct
TI  - [Pharma-clinics. The drug of the month. Dipyridamole-acetylsalicylic acid 
      combination (Aggrenox)].
PG  - 957-9
AB  - Aggrenox, launched in Belgium by Boehringer Ingelheim, is a fixed-dose 
      combination of extended-release dipyridamole (200 mg) and aspirin (25 mg), two 
      antiplatelet agents with different and complementary mechanisms of action. It is 
      recommended, twice daily, in the protection against secondary stroke and 
      transient ischaemic attacks. The placebo-controlled European study ESPS 2 
      (European Stroke Prevention Study 2) demonstrated that the administration of this 
      combination was twice as effective as either agent alone in the secondary 
      prevention of stroke in patients with prior stroke or transient ischaemic attack.
FAU - Scheen, A J
AU  - Scheen AJ
AD  - Université de Liège, Service de Médecine interne générale et Service de 
      Diabétologie, Nutrition et Maladies métaboliques, Département de Médecine.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Pharma-clinics. Le médicament du mois. La combinaison fixe dipyridamole--acide 
      acétylsalicylique (Aggrenox).
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Dipyridamole/pharmacology/*therapeutic use
MH  - Drug Combinations
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Primary Prevention
MH  - Stroke/*prevention & control
MH  - Treatment Outcome
RF  - 10
EDAT- 2001/03/14 10:00
MHDA- 2001/03/27 10:01
CRDT- 2001/03/14 10:00
PHST- 2001/03/14 10:00 [pubmed]
PHST- 2001/03/27 10:01 [medline]
PHST- 2001/03/14 10:00 [entrez]
PST - ppublish
SO  - Rev Med Liege. 2000 Oct;55(10):957-9.

PMID- 10837790
OWN - NLM
STAT- MEDLINE
DCOM- 20000718
LR  - 20191104
IS  - 0169-409X (Print)
IS  - 0169-409X (Linking)
VI  - 40
IP  - 3
DP  - 2000 Feb 28
TI  - Site-specific modifications and toxicity of blood substitutes. The case of 
      diaspirin cross-linked hemoglobin.
PG  - 199-212
AB  - Safe and effective hemoglobin-based blood substitutes may be advantageous over 
      conventional therapies for certain clinical settings requiring short term blood 
      replacement such as emergency resuscitation and hemodilution in surgery. Many 
      advances have been made in developing these oxygen therapeutics, however safety 
      concerns continue to slow their clinical progress. An important and often 
      overlooked consideration in evaluating the safety of modified hemoglobins is the 
      impact of chemical and/or genetic modifications on the redox chemistry of these 
      proteins. Diaspirin cross-linked hemoglobin (DBBF-Hb) has been extensively 
      evaluated in vitro and in animal models, and thus represents a useful model to 
      explore possible correlations between structural-functional alterations and 
      toxicity of hemoglobin-based blood substitutes.
FAU - D'Agnillo, F
AU  - D'Agnillo F
AD  - Laboratory of Plasma Derivatives, Division of Hematology, Center for Biologics 
      Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.
FAU - Alayash, A I
AU  - Alayash AI
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Netherlands
TA  - Adv Drug Deliv Rev
JT  - Advanced drug delivery reviews
JID - 8710523
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/toxicity
MH  - Blood Substitutes/*chemistry/*toxicity
MH  - Hemoglobins/*chemistry/*toxicity
MH  - Humans
MH  - Oxidation-Reduction
RF  - 74
EDAT- 2000/06/06 09:00
MHDA- 2000/07/25 11:00
CRDT- 2000/06/06 09:00
PHST- 2000/06/06 09:00 [pubmed]
PHST- 2000/07/25 11:00 [medline]
PHST- 2000/06/06 09:00 [entrez]
AID - S0169-409X(99)00050-2 [pii]
AID - 10.1016/s0169-409x(99)00050-2 [doi]
PST - ppublish
SO  - Adv Drug Deliv Rev. 2000 Feb 28;40(3):199-212. doi: 
      10.1016/s0169-409x(99)00050-2.

PMID- 2400264
OWN - NLM
STAT- MEDLINE
DCOM- 19901016
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 50
IP  - 3
DP  - 1990 Sep
TI  - Low-dose preoperative aspirin therapy, postoperative blood loss, and transfusion 
      requirements.
PG  - 424-8
AB  - The effects of three low-dose regimens of preoperative aspirin therapy on 
      postoperative blood loss, transfusion requirements, and length of hospital stay 
      were recorded in a prospective cohort study of 202 patients undergoing elective 
      coronary artery bypass grafting. One hundred one patients had been prescribed 
      daily aspirin by the referring cardiologist (44 at 75 mg, 28 at 150 mg, and 29 at 
      300 mg); the remaining 101 patients who had not been prescribed aspirin acted as 
      a control group. A median postoperative blood loss of 870 mL in the control group 
      was increased by 280 mL in the 75-mg aspirin group (p less than 0.001), by 490 mL 
      in the 150-mg aspirin group (p less than 0.001), and by 230 mL in the 300-mg 
      aspirin group (p = 0.03). The median requirement for blood transfusion of 2 U red 
      blood cell concentrates in the control group was increased by 2 U in the 75-mg 
      aspirin group (p less than 0.001), 2 U in the 150-mg aspirin group (p less than 
      0.001), and 1 U in the 300-mg aspirin group (p = 0.05). Hemostatic "packs" (fresh 
      frozen plasma, platelets, and cryoprecipitate) were required in 20 patients in 
      the aspirin groups as compared with 5 in the control group (p less than 0.01 by 
      chi 2 test). The mean postoperative hospital stay was 8 days for all groups. 
      Regular daily low-dose aspirin therapy produces significant increases in 
      postoperative blood loss, resulting in a substantial increase in blood 
      transfusion and hemostatic pack requirements, but does not prolong postoperative 
      hospital stay.
FAU - Taggart, D P
AU  - Taggart DP
AD  - Department of Cardiac Surgery, Royal Infirmary, Glasgow, Scotland.
FAU - Siddiqui, A
AU  - Siddiqui A
FAU - Wheatley, D J
AU  - Wheatley DJ
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Thorac Surg. 1991 Apr;51(4):693-4. PMID: 2012439
CIN - Ann Thorac Surg. 1990 Sep;50(3):345. PMID: 2400251
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Transfusion
MH  - *Coronary Artery Bypass
MH  - Coronary Disease/*drug therapy
MH  - Erythrocyte Transfusion
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - *Premedication
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
AID - 10.1016/0003-4975(90)90488-r [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1990 Sep;50(3):424-8. doi: 10.1016/0003-4975(90)90488-r.

PMID- 7711618
OWN - NLM
STAT- MEDLINE
DCOM- 19950517
LR  - 20220310
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 310
IP  - 6983
DP  - 1995 Apr 1
TI  - Prophylactic aspirin and risk of peptic ulcer bleeding.
PG  - 827-30
AB  - OBJECTIVE: To determine the risks of hospitalisation for bleeding peptic ulcer 
      with the current prophylactic aspirin regimens of 300 mg daily or less. DESIGN: A 
      case-control study with hospital and community controls. SETTING: Hospitals in 
      Glasgow, Newcastle, Nottingham, Oxford, and Portsmouth. SUBJECTS: 1121 patients 
      with gastric or duodenal ulcer bleeding matched with hospital and community 
      controls. RESULTS: 144 (12.8%) cases had been regular users of aspirin (taken at 
      least five days a week for at least the previous month) compared with 101 (9.0%) 
      hospital and 77 (7.8%) community controls. Odds ratios were raised for all doses 
      of aspirin taken, whether compared with hospital or community controls (compared 
      with combined controls: 75 mg, 2.3 (95% confidence interval 1.2 to 4.4); 150 mg, 
      3.2 (1.7 to 6.5); 300 mg, 3.9 (2.5 to 6.3)). Results were not explained by 
      confounding influences of age, sex, prior ulcer history or dyspepsia, or 
      concurrent non-aspirin non-steroidal anti-inflammatory drug use. Risks seemed 
      particularly high in patients who took non-aspirin non-steroidal 
      anti-inflammatory drugs concurrently. CONCLUSION: No conventionally used 
      prophylactic aspirin regimen seems free of the risk of peptic ulcer 
      complications.
FAU - Weil, J
AU  - Weil J
AD  - West Midlands Regional Health Authority, Birmingham.
FAU - Colin-Jones, D
AU  - Colin-Jones D
FAU - Langman, M
AU  - Langman M
FAU - Lawson, D
AU  - Lawson D
FAU - Logan, R
AU  - Logan R
FAU - Murphy, M
AU  - Murphy M
FAU - Rawlins, M
AU  - Rawlins M
FAU - Vessey, M
AU  - Vessey M
FAU - Wainwright, P
AU  - Wainwright P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 1995 Jul 22;311(6999):259-60. PMID: 7627061
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/*adverse effects/chemistry/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Case-Control Studies
MH  - Chemistry, Pharmaceutical
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Hospitalization/*statistics & numerical data
MH  - Humans
MH  - Peptic Ulcer Hemorrhage/*chemically induced
MH  - Risk Factors
PMC - PMC2549215
EDAT- 1995/04/01 00:00
MHDA- 1995/04/01 00:01
CRDT- 1995/04/01 00:00
PHST- 1995/04/01 00:00 [pubmed]
PHST- 1995/04/01 00:01 [medline]
PHST- 1995/04/01 00:00 [entrez]
AID - 10.1136/bmj.310.6983.827 [doi]
PST - ppublish
SO  - BMJ. 1995 Apr 1;310(6983):827-30. doi: 10.1136/bmj.310.6983.827.

PMID- 18097547
OWN - NLM
STAT- MEDLINE
DCOM- 20080320
LR  - 20131121
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 32
IP  - 1
DP  - 2008 Jan
TI  - The novel phenylester anticancer compounds: Study of a derivative of aspirin 
      (phoshoaspirin).
PG  - 97-100
AB  - We have synthesized a series of novel phenylester compounds and present our 
      assessment of such a derivative of aspirin, 
      3-((diethoxyphosphoryloxy)methyl)phenyl 2-acetoxybenzoate, provisionally named 
      phosphoaspirin. We determined its anticancer activity both in vitro and in vivo. 
      Phosphoaspirin inhibited the growth of HT-29 human colon adenocarcinoma cells 
      (IC(50) = 276.6+/-12.3 microM (mean +/- SEM)] through a combined 
      antiproliferative and mainly proapoptotic effect. Phosphoaspirin (100 mg/kg body 
      weight intraperitoneally daily for 21 days) also inhibited the growth of HT-29 
      tumors grown as xenografts in nude mice. The size of the tumors decreased 
      progressively in the phosphoaspirin treated group, compared to controls, being 
      reduced by 57% (p<0.001) on day 21. Phosphoaspirin achieved this effect by 
      modulating cell kinetics; the proliferation index of cancer cells was reduced by 
      18.13% compared to controls (p<0.001) and the apoptosis index was increased by 
      94.6% (p<0.003). There was no apparent toxicity from phosphoaspirin. We conclude 
      that phosphoaspirin is a promising agent for the control of cancer that deserves 
      further evaluation.
FAU - Rigas, Basil
AU  - Rigas B
AD  - Division of Cancer Prevention, Stony Brook University, Stony Brook, NY 
      11794-5200, USA. basil.rigas@stonybrook.edu
FAU - Kozoni, Vasiliki
AU  - Kozoni V
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Organophosphates)
RN  - 0 (phosphoaspirin)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - HT29 Cells
MH  - Humans
MH  - Mice
MH  - Neoplasm Transplantation
MH  - Nitric Oxide/physiology
MH  - Organophosphates/*pharmacology
MH  - Transplantation, Heterologous
EDAT- 2007/12/22 09:00
MHDA- 2008/03/21 09:00
CRDT- 2007/12/22 09:00
PHST- 2007/12/22 09:00 [pubmed]
PHST- 2008/03/21 09:00 [medline]
PHST- 2007/12/22 09:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2008 Jan;32(1):97-100.

PMID- 32838616
OWN - NLM
STAT- MEDLINE
DCOM- 20211228
LR  - 20211228
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 32
IP  - 6
DP  - 2021 Aug 18
TI  - Evening aspirin intake results in higher levels of platelet inhibition and a 
      reduction in reticulated platelets - a window of opportunity for patients with 
      cardiovascular disease?
PG  - 821-827
LID - 10.1080/09537104.2020.1809643 [doi]
AB  - Cardiovascular events occur most frequently in the early morning. Similarly, the 
      release of reticulated platelets (RP) by megakaryocytes has a peak in the late 
      night and early morning. Which aspirin regimen most effectively inhibits 
      platelets during these critical hours is unknown. Hence, the primary objective of 
      this trial was to assess platelet function and RP levels at 8.00 AM, in stable 
      cardiovascular (CVD) patients, during three different aspirin regimens. In this 
      open-label randomized cross-over study subjects were allocated to three 
      sequential aspirin regimens: once-daily (OD) 80 mg morning; OD-evening, and 
      twice-daily (BID) 40 mg. Platelet function was measured at 8.00 AM & 8.00 PM by 
      serum Thromboxane B(2) (sTxB(2)) levels, the Platelet Function Analyzer 
      (PFA)-200® Closure Time (CT), Aspirin Reaction Units (ARU, VerifyNow®), and RP 
      levels. In total, 22 patients were included. At 8.00 AM, sTxB(2) levels were the 
      lowest after OD-evening in comparison with OD-morning (p = <0.01), but not in 
      comparison with BID. Furthermore, RP levels were similar at 8.00 AM, but 
      statistically significantly reduced at 8.00 PM after OD-evening (p = .01) and BID 
      (p = .02) in comparison with OD-morning. OD-evening aspirin intake results in 
      higher levels of platelet inhibition during early morning hours and results in a 
      reduction of RP levels in the evening. These findings may, if confirmed by larger 
      studies, be relevant to large groups of patients taking aspirin to reduce 
      cardiovascular risk.
FAU - van Diemen, J J K
AU  - van Diemen JJK
AD  - Department of Internal Medicine, Amsterdam UMC, Location VU University, 
      Amsterdam, The Netherlands.
FAU - Madsen, M C
AU  - Madsen MC
AD  - Department of Internal Medicine, Amsterdam UMC, Location VU University, 
      Amsterdam, The Netherlands.
FAU - Vrancken, P
AU  - Vrancken P
AD  - Department of Internal Medicine, Amsterdam UMC, Location VU University, 
      Amsterdam, The Netherlands.
FAU - de Bie, K
AU  - de Bie K
AD  - Department of Internal Medicine, Amsterdam UMC, Location VU University, 
      Amsterdam, The Netherlands.
FAU - van der Bom, J G
AU  - van der Bom JG
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, 
      The Netherlands.
AD  - JJ Van Rood Center for Clinical Transfusion Research, Sanquin Research, Leiden, 
      The Netherlands.
FAU - Veen, G
AU  - Veen G
AD  - Department of Cardiology, Amsterdam UMC, Location VU University, Amsterdam, The 
      Netherlands.
FAU - Bonten, T N
AU  - Bonten TN
AD  - Department of Public Health & Primary Care, Leiden University Medical Center, 
      Leiden, The Netherlands.
FAU - Fuijkschot, W W
AU  - Fuijkschot WW
AD  - Department of Internal Medicine, Amsterdam UMC, Location VU University, 
      Amsterdam, The Netherlands.
FAU - Smulders, Y M
AU  - Smulders YM
AD  - Department of Internal Medicine, Amsterdam UMC, Location VU University, 
      Amsterdam, The Netherlands.
FAU - Thijs, A
AU  - Thijs A
AD  - Department of Internal Medicine, Amsterdam UMC, Location VU University, 
      Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200825
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*blood/*drug therapy
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*physiology
MH  - Platelet Count/*methods
MH  - Time Factors
OTO - NOTNLM
OT  - Aspirin
OT  - chronotherapy
OT  - circadian rhythm
OT  - cross-over trial
OT  - platelet aggregation
EDAT- 2020/08/26 06:00
MHDA- 2021/12/29 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/12/29 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1080/09537104.2020.1809643 [doi]
PST - ppublish
SO  - Platelets. 2021 Aug 18;32(6):821-827. doi: 10.1080/09537104.2020.1809643. Epub 
      2020 Aug 25.

PMID- 17323349
OWN - NLM
STAT- MEDLINE
DCOM- 20070928
LR  - 20131121
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 96
IP  - 8
DP  - 2007 Aug
TI  - Quantifying solubility enhancement due to particle size reduction and crystal 
      habit modification: case study of acetyl salicylic acid.
PG  - 1967-73
AB  - The poor solubility of potential drug molecules is a significant problem in the 
      design of pharmaceutical formulations. It is well known, however, that the 
      solubility of crystalline materials is enhanced when the particle size is reduced 
      to submicron levels and this factor can be expected to enhance drug product 
      bioavailability. Direct estimation of solubility enhancement, as calculated via 
      the Gibbs-Thompson relationship, demands reasonably accurate values for the 
      particle/solution interfacial tension and, in particular, its anisotropy with 
      respect to the crystal product's habit and morphology. In this article, an 
      improved, more molecule-centered, approach is presented towards the calculation 
      of solubility enhancement factors in which molecular modeling techniques are 
      applied, and the effects associated with both crystal habit modification and 
      solvent choice are examined. A case study for facetted, acetyl salicylic acid 
      (aspirin) crystals in equilibrium with saturated aqueous ethanol solution reveals 
      that their solubility will be enhanced in the range (7-58%) for a crystal size of 
      0.02 microm, with significantly higher enhancement for crystal morphologies in 
      which the hydrophobic crystal faces are more predominant than the hydrophilic 
      faces and for solvents in which the solubility is smaller.
CI  - (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.
FAU - Hammond, Robert B
AU  - Hammond RB
AD  - Institute of Particle Science and Engineering, School of Process Environmental 
      and Materials Engineering University of Leeds, Leeds, LS2 9JT, UK.
FAU - Pencheva, Klimentina
AU  - Pencheva K
FAU - Roberts, Kevin J
AU  - Roberts KJ
FAU - Auffret, Tony
AU  - Auffret T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Solvents)
RN  - 059QF0KO0R (Water)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/*chemistry
MH  - Chemistry, Pharmaceutical/*methods
MH  - Crystallization
MH  - Ethanol/chemistry
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Nanotechnology/methods
MH  - Particle Size
MH  - Solubility
MH  - Solvents/chemistry
MH  - Water/chemistry
EDAT- 2007/02/27 09:00
MHDA- 2007/09/29 09:00
CRDT- 2007/02/27 09:00
PHST- 2007/02/27 09:00 [pubmed]
PHST- 2007/09/29 09:00 [medline]
PHST- 2007/02/27 09:00 [entrez]
AID - S0022-3549(16)32313-9 [pii]
AID - 10.1002/jps.20869 [doi]
PST - ppublish
SO  - J Pharm Sci. 2007 Aug;96(8):1967-73. doi: 10.1002/jps.20869.

PMID- 11244821
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 30
IP  - 2
DP  - 2001 Jan 20
TI  - [Prevention of cardiovascular diseases in type 2 diabetes with aspirin].
PG  - 87-91
AB  - THEORY AND REALITY: Diabetes mellitus is known to be associated with excess 
      cardiovascular risk. Prescription of antiplatelet agents such as acetylsalicylic 
      acid would thus appear to be warranted. That is the theory, but the reality is 
      much different. A review of the literature provides evidence on the use of 
      acetylsalicylic acid for primary and secondary preventive care, but conclusions 
      are often extrapolated from studies conducted in the general population. EVIDENCE 
      OF A BENEFICIAL EFFECT IN DIABETICS: The HOT study, conducted in hypertensive 
      patients) demonstrated that acetylsalicylic acid at the dose of 75 mg a day, 
      reduced the rate of major cardiovascular events by 15% (p = 0.03) and of 
      myocardial infarction by 36% (p = 0.02) with no effect on stroke. In diabetic 
      patients (n = 1500), the benefit was even more pronounced. RISKS: The risk of 
      bleeding must be balanced against the beneficial cardiovascular effect. Diabetic 
      retinopathy is not aggravated by aspirin. The data reported in the literature do 
      not however enable any evidenced-based decision on dosing for the diabetic 
      population with numerous cardiovascular risks.
FAU - Duly-Bouhanick, B
AU  - Duly-Bouhanick B
AD  - Service de Médecine B, Centre Hospitalier Universitaire d'Angers. 
      BeBouhanick@chu-angers.fr
FAU - Menard, S
AU  - Menard S
FAU - Hadjadj, S
AU  - Hadjadj S
FAU - Soares-Barbosa, S
AU  - Soares-Barbosa S
FAU - Plun-Favreau, J
AU  - Plun-Favreau J
FAU - Guilloteau, G
AU  - Guilloteau G
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - L'aspirine chez le diabétique de type 2 pour prévenir les maladies 
      cardio-vasculaires.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Drug Prescriptions
MH  - Evidence-Based Medicine
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention/methods
MH  - Risk Factors
RF  - 17
EDAT- 2001/03/14 10:00
MHDA- 2001/04/03 10:01
CRDT- 2001/03/14 10:00
PHST- 2001/03/14 10:00 [pubmed]
PHST- 2001/04/03 10:01 [medline]
PHST- 2001/03/14 10:00 [entrez]
PST - ppublish
SO  - Presse Med. 2001 Jan 20;30(2):87-91.

PMID- 9327189
OWN - NLM
STAT- MEDLINE
DCOM- 19971106
LR  - 20190909
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 13
IP  - 10
DP  - 1997
TI  - The influence of dosage form on aspirin kinetics: implications for acute 
      cardiovascular use.
PG  - 547-53
AB  - In this study, the pharmacokinetics of several formulations of aspirin were 
      examined: soluble aspirin, mouth-dispersible aspirin, plain aspirin and 
      enteric-coated aspirin granules. Blood samples were taken at frequent intervals 
      for 24 hours after single dosing in 12 healthy volunteers and Tmax, Cmax and t1/2 
      measured. Cmax was significantly higher for soluble aspirin than for the other 
      formulations and the t1/2 was shorter. The results show the rapid absorption of 
      aspirin from a soluble formulation compared with that from plain aspirin or 
      enteric-coated aspirin granules. Recommendations to treat patients suspected of 
      having a heart attack as soon as possible with aspirin are now widely accepted 
      and the present study would suggest that soluble aspirin should be the aspirin of 
      choice in this situation.
FAU - Muir, N
AU  - Muir N
AD  - Reckitt and Colman plc, HULL, UK.
FAU - Nichols, J D
AU  - Nichols JD
FAU - Clifford, J M
AU  - Clifford JM
FAU - Stillings, M R
AU  - Stillings MR
FAU - Hoare, R C
AU  - Hoare RC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*chemistry/*pharmacokinetics/therapeutic use
MH  - Biological Availability
MH  - Chemistry, Pharmaceutical
MH  - Cross-Over Studies
MH  - Drug Monitoring
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy
MH  - Platelet Aggregation Inhibitors/*chemistry/*pharmacokinetics/therapeutic use
MH  - Solubility
MH  - Tablets, Enteric-Coated
MH  - Time Factors
EDAT- 1997/01/01 00:00
MHDA- 1997/11/04 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/11/04 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1185/03007999709113328 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1997;13(10):547-53. doi: 10.1185/03007999709113328.

PMID- 18057595
OWN - NLM
STAT- MEDLINE
DCOM- 20080108
LR  - 20131121
IS  - 1600-5759 (Electronic)
IS  - 0108-2701 (Linking)
VI  - 63
IP  - Pt 12
DP  - 2007 Dec
TI  - Lithium aspirinate hemihydrate.
PG  - m563-5
AB  - The title compound {systematic name: 
      catena-poly[lithium(I)-mu3-acetylsalicylato-hemi-mu2-aqua]}, {[Li(C9H7O4)] x 0.5 
      H2O}n, is the hemihydrate of the lithium salt of aspirin. The carboxylate groups 
      and water molecules bridge between Li atoms to form a one-dimensional 
      coordination chain composed of two distinct ring types. The water O atom lies on 
      a twofold axis. Hydrogen bonding between water donors and carbonyl acceptors 
      further links the coordination chains to form a sheet structure.
FAU - Arlin, Jean-Baptiste
AU  - Arlin JB
AD  - WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, 
      295 Cathedral Street, Glasgow G1 1XL, Scotland. jeanbaptiste.arlin@strath.ac.uk
FAU - Addison, Fiona
AU  - Addison F
FAU - Kennedy, Alan R
AU  - Kennedy AR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071114
PL  - United States
TA  - Acta Crystallogr C
JT  - Acta crystallographica. Section C, Crystal structure communications
JID - 8305826
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 059QF0KO0R (Water)
RN  - 2BMD2GNA4V (Lithium Carbonate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry
MH  - Aspirin/*chemical synthesis/*chemistry
MH  - Crystallography, X-Ray
MH  - Hydrogen Bonding
MH  - Lithium Carbonate/*chemistry
MH  - Models, Molecular
MH  - Molecular Structure
MH  - Solubility
MH  - Water/*chemistry
EDAT- 2007/12/07 09:00
MHDA- 2008/01/09 09:00
CRDT- 2007/12/07 09:00
PHST- 2007/09/05 00:00 [received]
PHST- 2007/10/16 00:00 [accepted]
PHST- 2007/12/07 09:00 [pubmed]
PHST- 2008/01/09 09:00 [medline]
PHST- 2007/12/07 09:00 [entrez]
AID - S0108270107051104 [pii]
AID - 10.1107/S0108270107051104 [doi]
PST - ppublish
SO  - Acta Crystallogr C. 2007 Dec;63(Pt 12):m563-5. doi: 10.1107/S0108270107051104. 
      Epub 2007 Nov 14.

PMID- 7994392
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Enzymatic protection from autoxidation for crosslinked hemoglobins.
PG  - 709-17
AB  - The autoxidation rates of hemoglobins crosslinked between the alpha subunits 
      (alpha 99XLHb A) and between the beta subunits (beta 82XLHb A) were reduced in 
      the presence of catalase and/or superoxide dismutase. In the presence of catalase 
      the rate for alpha 99XLHb A decreased 2.3 fold and for beta 82XLHb A, 1.9 fold. 
      Superoxide dismutase reduced the rate 1.6 fold for alpha 99XLHb A and 1.8 fold 
      for beta 82XLHb A. In the presence of both catalase and superoxide dismutase the 
      rate of autoxidation decreased by 3.0 fold in alpha 99XLHb A and 4.0 fold in beta 
      82XLHb A. The presence of catalase and superoxide dismutase or both in the 
      crosslinked hemoglobin samples increases the autoxidation half-life of 
      oxyhemoglobins. This suggests that crosslinked hemoglobins to be used as blood 
      substitutes could be protected from oxidation in storage by these enzymes.
FAU - Yang, T
AU  - Yang T
AD  - Department of Chemistry, Loyola University of Chicago, IL 60626.
FAU - Olsen, K W
AU  - Olsen KW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Solutions)
RN  - 0 (hemoglobin XL99alpha)
RN  - 9008-37-1 (Methemoglobin)
RN  - EC 1.11.1.6 (Catalase)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/chemistry/isolation & purification/metabolism
MH  - Blood Substitutes/*chemistry/isolation & purification/metabolism
MH  - Catalase
MH  - Cross-Linking Reagents
MH  - Drug Storage
MH  - Half-Life
MH  - Hemoglobins/*chemistry/isolation & purification/metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Methemoglobin/metabolism
MH  - Oxidation-Reduction
MH  - Solutions
MH  - Superoxide Dismutase
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117902 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):709-17. doi: 
      10.3109/10731199409117902.

PMID- 7864551
OWN - NLM
STAT- MEDLINE
DCOM- 19950323
LR  - 20131121
IS  - 0003-3928 (Print)
IS  - 0003-3928 (Linking)
VI  - 43
IP  - 10
DP  - 1994 Dec
TI  - [Characteristics of patients with coronary disease and aspirin prescription in 
      Haute-Garonne].
PG  - 588-93
AB  - The MONICA Haute-Garonne Centre studied the incidence of myocardial infarction 
      and death from coronary heart disease in 1,762 cases between 1985 and 1989. 
      Changes in treatment were analysed in the subgroup of 416 patients admitted to 
      hospital for myocardial infarction in 1986 and in 1989. The incidence of 
      myocardial infarction decreased in men from 218.4 to 183.9 per 100,000 
      inhabitants (p < 0.01) and decreased nonsignificantly in women from 19.3 to 23.2 
      per 100,000 inhabitants (NS). The decreased incidence of myocardial infarction in 
      men was exclusively due to a decrease by one-third of the incidence of infarction 
      in patients with diagnosed coronary heart disease. Although the community 
      mortality remained stable, the hospital mortality decreased by one half in man 
      between 1985 and 1989 (21% versus 10%, respectively, p < 0.001). Between 1986 and 
      1989, the prescription of acetylsalicylic acid during the acute phase increased 
      threefold (26.4% versus 72.9%, p < 0.001) and increased fivefold when 
      coprescribed with fibrinolytics. Similarly, the prescription of aspirin on 
      discharge from hospital doubled (from 32.6% to 69.5%, p < 0.001). The dosage of 
      aspirin decreased from 500 mg or more per day in 1986 to a daily dose of 
      approximately 250 mg in 1989. Lysine acetylsalicylate was the form most widely 
      prescribed. In this population, patients treated by antithrombotics (aspirin or 
      fibrinolytics) had a more favourable prognosis than patients not receiving any of 
      these treatments. The changes observed in this study population are in line with 
      the published results of therapeutic trials on antithrombotics in the acute phase 
      of myocardial infarction and in the postinfarction phase (GISSI2, ISIS2).
FAU - Cambou, J P
AU  - Cambou JP
AD  - INSERM U-326, ORSMIP, CHU Purpan, Toulouse.
FAU - Lablache-Combier, B
AU  - Lablache-Combier B
FAU - Marques-Vidal, P
AU  - Marques-Vidal P
FAU - Ruidavets, J B
AU  - Ruidavets JB
FAU - Branchu, M P
AU  - Branchu MP
FAU - Ferrières, J
AU  - Ferrières J
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Caractéristiques des coronariens et prescription d'aspirine en Haute-Garonne.
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Disease/drug therapy/*epidemiology/mortality
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - France/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/epidemiology/physiopathology
MH  - Registries
MH  - Time Factors
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 1994 Dec;43(10):588-93.

PMID- 11039549
OWN - NLM
STAT- MEDLINE
DCOM- 20010215
LR  - 20190915
IS  - 0002-9645 (Print)
IS  - 0002-9645 (Linking)
VI  - 61
IP  - 10
DP  - 2000 Oct
TI  - Evaluation of the ability of orally administered aspirin to mitigate effects of 
      3-methylindole in feedlot cattle.
PG  - 1209-13
AB  - OBJECTIVE: To evaluate the ability of orally administered aspirin to mitigate 
      3-methylindole (3MI)-induced respiratory tract disease and reduced rate of gain 
      in feedlot cattle. ANIMALS: 244 beef cattle. PROCEDURE: In a masked, randomized, 
      controlled field trial, calves were untreated (controls) or received a single 
      orally administered dose of aspirin (31.2 g) on entry into a feedlot. Serum 3MI 
      concentrations were measured on days 0, 3, and 6. Rumen 3MI concentration was 
      measured on day 3. Cattle were observed daily for clinical signs of respiratory 
      tract disease. Lungs were evaluated at slaughter for gross pulmonary lesions. 
      RESULTS: Mean daily gain (MDG) in cattle treated with aspirin, compared with 
      control cattle, was 0.06 kg greater in the backgrounding unit and 0.03 kg greater 
      for the overall feeding period. Neither serum nor rumen 3MI concentrations 
      appeared to modify this effect. Cattle treated with aspirin were more likely to 
      be treated for respiratory tract disease. Mortality rate, gross pulmonary 
      lesions, and serum and rumen 3MI concentrations were similar between groups. 
      Increased rumen 3MI concentration was associated with a small difference in risk 
      of lung fibrosis. CONCLUSIONS AND CLINICAL RELEVANCE: Cattle given a single 
      orally administered dose of aspirin on feedlot entry had higher MDG in the 
      backgrounding unit and for the overall feeding period, but this finding could not 
      be attributed to mitigation of effects of 3MI. This may have been influenced by 
      low peak 3MI production and slow rates of gain.
FAU - Bingham, H R
AU  - Bingham HR
AD  - Department of Veterinary Preventive Medicine, College of Veterinary Medicine, The 
      Ohio State University, Columbus 43210, USA.
FAU - Wittum, T E
AU  - Wittum TE
FAU - Morley, P S
AU  - Morley PS
FAU - Bray, T M
AU  - Bray TM
FAU - Sarver, C F
AU  - Sarver CF
FAU - Queen, W G
AU  - Queen WG
FAU - Shulaw, W P
AU  - Shulaw WP
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 9W945B5H7R (Skatole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animal Husbandry/*methods
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cattle
MH  - Cattle Diseases/chemically induced/*prevention & control
MH  - *Skatole
MH  - Weight Gain/drug effects
EDAT- 2000/10/20 11:00
MHDA- 2001/03/03 10:01
CRDT- 2000/10/20 11:00
PHST- 2000/10/20 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2000/10/20 11:00 [entrez]
AID - 10.2460/ajvr.2000.61.1209 [doi]
PST - ppublish
SO  - Am J Vet Res. 2000 Oct;61(10):1209-13. doi: 10.2460/ajvr.2000.61.1209.

PMID- 20299485
OWN - NLM
STAT- MEDLINE
DCOM- 20100831
LR  - 20181113
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 33
IP  - 6
DP  - 2010 Jun
TI  - Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to 
      aspirin but not to a nitric oxide-donating agent.
PG  - 1262-8
LID - 10.2337/dc09-2013 [doi]
AB  - OBJECTIVE: Acute, short-term hyperglycemia enhances high shear stress-induced 
      platelet activation in type 2 diabetes. Several observations suggest that 
      platelets in type 2 diabetes are resistant to inhibition by aspirin. Our aim was 
      to assess comparatively the effect of aspirin, a nitric oxide-donating agent (NCX 
      4016), their combination, or placebo on platelet activation induced by acute 
      hyperglycemia in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a double-blind, 
      placebo-controlled, randomized trial, 40 type 2 diabetic patients were allocated 
      to 100 mg aspirin once daily, 800 mg NCX 4016 b.i.d., both of them, or placebo 
      for 15 days. On day 15, 1 h after the morning dose, a 4-h hyperglycemic clamp 
      (plasma glucose 13.9 mmol/l) was performed, and blood samples were collected 
      before and immediately after it for platelet activation and cyclooxygenase-1 
      (COX-1) inhibition studies. RESULTS Acute hyperglycemia enhanced shear 
      stress-induced platelet activation in placebo-treated patients (basal closure 
      time 63 +/- 7.1 s, after hyperglycemia 49.5 +/- 1.4 s, -13.5 +/- 6.3 s, P < 
      0.048). Pretreatment with aspirin, despite full inhibition of platelet COX-1, did 
      not prevent it (-12.7 +/- 6.9 s, NS vs. placebo). On the contrary, pretreatment 
      with the NO donor NCX 4016, alone or in combination with aspirin, suppressed 
      platelet activation induced by acute hyperglycemia (NCX 4016 +10.5 +/- 8.3 s; NCX 
      4016 plus aspirin: +12.0 +/- 10.7 s, P < 0.05 vs. placebo for both). Other 
      parameters of shear stress-dependent platelet activation were also more inhibited 
      by NCX 4016 than by aspirin, despite lesser inhibition of COX-1. CONCLUSIONS: 
      Acute hyperglycemia-induced enhancement of platelet activation is resistant to 
      aspirin; a NO-donating agent suppresses it. Therapeutic approaches aiming at a 
      wider platelet inhibitory action than that exerted by aspirin may prove useful in 
      patients with type 2 diabetes.
FAU - Gresele, Paolo
AU  - Gresele P
AD  - Section of Internal and Cardiovascular Medicine, Department of Internal Medicine, 
      University of Perugia, Perugia, Italy. grespa@unipg.it
FAU - Marzotti, Stefania
AU  - Marzotti S
FAU - Guglielmini, Giuseppe
AU  - Guglielmini G
FAU - Momi, Stefania
AU  - Momi S
FAU - Giannini, Silvia
AU  - Giannini S
FAU - Minuz, Pietro
AU  - Minuz P
FAU - Lucidi, Paola
AU  - Lucidi P
FAU - Bolli, Geremia B
AU  - Bolli GB
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100318
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*analogs & derivatives/pharmacology/*therapeutic use
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Hyperglycemia/*drug therapy/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide Donors/pharmacology/*therapeutic use
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - *Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Young Adult
PMC - PMC2875435
EDAT- 2010/03/20 06:00
MHDA- 2010/09/02 06:00
CRDT- 2010/03/20 06:00
PHST- 2010/03/20 06:00 [entrez]
PHST- 2010/03/20 06:00 [pubmed]
PHST- 2010/09/02 06:00 [medline]
AID - dc09-2013 [pii]
AID - 2013 [pii]
AID - 10.2337/dc09-2013 [doi]
PST - ppublish
SO  - Diabetes Care. 2010 Jun;33(6):1262-8. doi: 10.2337/dc09-2013. Epub 2010 Mar 18.

PMID- 19095331
OWN - NLM
STAT- MEDLINE
DCOM- 20091029
LR  - 20161018
IS  - 0248-8663 (Print)
IS  - 0248-8663 (Linking)
VI  - 30
IP  - 8
DP  - 2009 Aug
TI  - [Indications of vitamin K antagonists and aspirin in the atrial fibrillation of 
      the elderly].
PG  - 671-7
LID - 10.1016/j.revmed.2008.10.338 [doi]
AB  - Non valvular atrial fibrillation is a public health concern because of the 
      frequency and the severity of its embolic complications, particularly strokes. 
      The aim of this paper is to analyze the recent recommendations for the prevention 
      of embolic events and their application in the elderly. The recommendations for 
      the prevention of stroke, published in 2001 on the basis of the results of 
      randomized studies comparing vitamin K antagonists (VKA) and aspirin versus 
      placebo, have been modified in August 2006. VKA are recommended in patients at 
      high risk of stroke. In patients considered at moderate risk, the choice is now 
      possible between VKA and aspirin, with a reduced dosage of aspirin (75 to 325 
      mg). The absolute risk of stroke related to age, hypertension, heart failure or 
      diabetes is not yet evaluated. Further studies would be necessary in order to 
      precise the recommendations for patients with only one of these risk factors: 
      aspirin or VKA? In geriatric patients with several risk factors, VKA are under 
      prescribed. A better knowledge of the embolic risk of atrial fibrillation, of the 
      often overestimated hemorrhagic risk of VKA, of the quite underestimated 
      hemorrhagic risk of aspirin and of the recommendations for prevention would be 
      necessary.
FAU - Gentric, A
AU  - Gentric A
AD  - Service de gériatrie aiguë, CHU La Cavale Blanche, 29285 Brest cedex, France. 
      armelle.gentric@chu-brest.fr
FAU - Estivin, S
AU  - Estivin S
FAU - Jestin, C
AU  - Jestin C
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Indications des antivitamines K et de l'aspirine chez les sujets âgés en 
      fibrillation atriale.
DEP - 20081217
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thromboembolism/etiology/*prevention & control
MH  - Vitamin K/*antagonists & inhibitors
EDAT- 2008/12/20 09:00
MHDA- 2009/10/30 06:00
CRDT- 2008/12/20 09:00
PHST- 2008/06/06 00:00 [received]
PHST- 2008/09/16 00:00 [revised]
PHST- 2008/10/05 00:00 [accepted]
PHST- 2008/12/20 09:00 [entrez]
PHST- 2008/12/20 09:00 [pubmed]
PHST- 2009/10/30 06:00 [medline]
AID - S0248-8663(08)01292-7 [pii]
AID - 10.1016/j.revmed.2008.10.338 [doi]
PST - ppublish
SO  - Rev Med Interne. 2009 Aug;30(8):671-7. doi: 10.1016/j.revmed.2008.10.338. Epub 
      2008 Dec 17.

PMID- 7157193
OWN - NLM
STAT- MEDLINE
DCOM- 19830311
LR  - 20141120
IS  - 0040-3709 (Print)
IS  - 0040-3709 (Linking)
VI  - 26
IP  - 2
DP  - 1982 Oct
TI  - Sodium salicylate teratogenicity in vitro.
PG  - 167-71
AB  - Rat embryos were exposed to sodium salicylate in vitro at concentrations 
      comparable to those used to produce terata in vivo. Embryos treated with 400, 
      600, or 800 micrograms Na salicylate/ml were compared with embryos treated with 
      an equimolar concentration of NaCl. When compared to growth of the controls, a 
      significant dose-dependent decrease in growth parameters was observed. The 
      incidence of abnormal embryos characterized by generalized swelling (particularly 
      in the area of the rhombencephalon) was also dose dependent. This study 
      demonstrates the teratogenicity of salicylate in the rat independent of maternal 
      factors.
FAU - Greenaway, J C
AU  - Greenaway JC
FAU - Shepard, T H
AU  - Shepard TH
FAU - Fantel, A G
AU  - Fantel AG
FAU - Juchau, M R
AU  - Juchau MR
LA  - eng
GR  - HD00836/HD/NICHD NIH HHS/United States
GR  - HD04839/HD/NICHD NIH HHS/United States
GR  - HD12717/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Teratology
JT  - Teratology
JID - 0153257
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced/*etiology
MH  - Animals
MH  - Aspirin/*adverse effects/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - In Vitro Techniques
MH  - Pregnancy
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1982/10/01 00:00
MHDA- 1982/10/01 00:01
CRDT- 1982/10/01 00:00
PHST- 1982/10/01 00:00 [pubmed]
PHST- 1982/10/01 00:01 [medline]
PHST- 1982/10/01 00:00 [entrez]
AID - 10.1002/tera.1420260209 [doi]
PST - ppublish
SO  - Teratology. 1982 Oct;26(2):167-71. doi: 10.1002/tera.1420260209.

PMID- 32538826
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20201120
IS  - 1875-8622 (Electronic)
IS  - 1386-0291 (Linking)
VI  - 76
IP  - 1
DP  - 2020
TI  - Performance comparison of platelet function analyzers in cardiology patients: 
      VerifyNow and Anysis-200 aspirin assays.
PG  - 33-42
LID - 10.3233/CH-200822 [doi]
AB  - BACKGROUND: Analysis of responsiveness to antiplatelet therapy is crucial in the 
      management of patients with cardiovascular diseases. OBJECTIVE: This study aimed 
      to evaluate a new platelet function analysis system (Anysis-200) and to compare 
      it with VerifyNow (Accumetrics, San Diego, CA, USA) in cardiology patients. 
      METHODS: Overall, 125 citrated blood samples were collected from 85 cardiology 
      patients referred for platelet function testing. In Anysis-200, platelet function 
      was measured as blood migration distance (MD) until clogging of flow passage, 
      which is comparable to aspirin resistance units obtained using VerifyNow. The two 
      devices were simultaneously used and compared. RESULTS: The MDs before and after 
      taking aspirin were 175±51 and 247±27 mm, respectively (p < 0.0001). Compared 
      with VerifyNow (reference), the sensitivity and specificity of Anysis-200 was 
      91.5% and 75.5%, respectively (area under the curve, 0.829). Further, the true 
      positive rate in patients newly taking aspirin was 85% for VerifyNow and 92.5% 
      for Anysis-200, respectively. The Cohen's kappa coefficient between the two 
      devices was 0.682, indicating a relatively high agreement. CONCLUSIONS: 
      Anysis-200, a novel system for assessing platelet aggregation, has accuracy and 
      precision equivalent to that of, and significant agreement with, VerifyNow. 
      Anysis-200 may be useful in screening patients with abnormal platelet reactivity 
      and aspirin nonresponsiveness.
FAU - Chung, Young Hak
AU  - Chung YH
AD  - Department of Internal Medicine, Division of Cardiology, College of Medicine, 
      Yonsei University, Seoul, Korea.
FAU - Lee, Kyung Ah
AU  - Lee KA
AD  - Department of Laboratory Medicine, College of Medicine, Yonsei University, Seoul, 
      Korea.
FAU - Cho, Minhee
AU  - Cho M
AD  - Department of Internal Medicine, Division of Cardiology, College of Medicine, 
      Yonsei University, Seoul, Korea.
FAU - Shin, Sehyun
AU  - Shin S
AD  - Department of Mechanical Engineering, Korea University, Seoul, Korea.
FAU - Lee, Byoung Kwon
AU  - Lee BK
AD  - Department of Internal Medicine, Division of Cardiology, College of Medicine, 
      Yonsei University, Seoul, Korea.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Function Tests/*methods
OTO - NOTNLM
OT  - Anysis-200 analyzer
OT  - Platelet function
OT  - VerifyNow
OT  - aspirin
EDAT- 2020/06/17 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
PHST- 2020/06/16 06:00 [entrez]
AID - CH200822 [pii]
AID - 10.3233/CH-200822 [doi]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 2020;76(1):33-42. doi: 10.3233/CH-200822.

PMID- 19355950
OWN - NLM
STAT- MEDLINE
DCOM- 20090616
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 15
IP  - 10
DP  - 2009
TI  - Aspirin resistance in cardiovascular disease: pathogenesis, diagnosis and 
      clinical impact.
PG  - 1085-94
AB  - Aspirin is the cornerstone of treatment in patients with coronary artery disease. 
      However, several studies investigating the in vitro response of platelets to the 
      administration of aspirin showed this response to be variable, with some patients 
      exhibiting non-responsiveness or resistance. Aspirin resistance may be 
      categorised as either 'laboratory' or 'clinical'. Laboratory aspirin resistance 
      is defined as the failure of aspirin to inhibit the production of thromboxane 
      A(2) (TxA(2)) by platelets or to inhibit platelet activation that depends on 
      TxA(2) production. Clinical aspirin resistance is defined as the failure to 
      prevent the occurrence of atherothrombotic ischaemic episodes in patients to whom 
      it is administered. So far, there is no generally accepted method for the ex vivo 
      evaluation of platelet activation or for assessing the degree of platelet 
      activation following aspirin administration and data concerning the clinical 
      impact of aspirin resistance are conflicting. For these reasons it is not 
      possible to suggest specific guidelines for the treatment of patients who show 
      high levels of platelet activation or a low level of platelet inhibition after 
      treatment with aspirin. The aim of this review is to present data from laboratory 
      and clinical studies that are related to resistance to aspirin, and to discuss 
      the possible causes, the clinical significance, and the ways of managing such 
      resistance at a clinical level.
FAU - Papathanasiou, Athanasios
AU  - Papathanasiou A
AD  - Cardiology Department, Ioannina University Hospital, Greece.
FAU - Goudevenos, John
AU  - Goudevenos J
FAU - Tselepis, Alexandros D
AU  - Tselepis AD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Curr Pharm Des. 2009;15(10):1034-7. PMID: 19355945
MH  - Acute Coronary Syndrome/diagnosis/pathology/prevention & control
MH  - Animals
MH  - Aspirin/pharmacokinetics/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/diagnosis/*pathology/*prevention & control
MH  - Drug Interactions
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/pharmacology/*therapeutic use
MH  - Primary Prevention
RF  - 122
EDAT- 2009/04/10 09:00
MHDA- 2009/06/17 09:00
CRDT- 2009/04/10 09:00
PHST- 2009/04/10 09:00 [entrez]
PHST- 2009/04/10 09:00 [pubmed]
PHST- 2009/06/17 09:00 [medline]
AID - 10.2174/138161209787846964 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2009;15(10):1085-94. doi: 10.2174/138161209787846964.

PMID- 2810261
OWN - NLM
STAT- MEDLINE
DCOM- 19891213
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 16
IP  - 10
DP  - 1989 Oct
TI  - Correction of thrombocytopenia with small dose aspirin in the primary 
      antiphospholipid syndrome.
PG  - 1359-61
AB  - We describe 2 patients with primary antiphospholipid syndrome in whom 
      thrombocytopenia, which had not responded to high dose prednisone treatment, was 
      promptly corrected after they started taking small doses (100 mg/day) of aspirin. 
      This effect has been sustained despite subsequent prednisone withdrawal. 
      Theoretical reasons for such an apparent therapeutic effect of aspirin in these 
      patients are discussed.
FAU - Alarcón-Segovia, D
AU  - Alarcón-Segovia D
AD  - Department of Immunology and Rheumatology, Instituto Nacional de la Nutrición 
      Salvador Zubirán, Mexico City, Mexico.
FAU - Sánchez-Guerrero, J
AU  - Sánchez-Guerrero J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antibodies)
RN  - 0 (Phospholipids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies/*analysis
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Phospholipids/*immunology
MH  - Syndrome
MH  - Thrombocytopenia/*drug therapy
EDAT- 1989/10/01 00:00
MHDA- 1989/10/01 00:01
CRDT- 1989/10/01 00:00
PHST- 1989/10/01 00:00 [pubmed]
PHST- 1989/10/01 00:01 [medline]
PHST- 1989/10/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1989 Oct;16(10):1359-61.

PMID- 16408865
OWN - NLM
STAT- MEDLINE
DCOM- 20060406
LR  - 20181113
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 6
IP  - 4
DP  - 2005 Dec 12
TI  - Functionality comparison of 3 classes of superdisintegrants in promoting aspirin 
      tablet disintegration and dissolution.
PG  - E634-40
AB  - The aims of this study are (1) to compare the disintegration efficiency, and (2) 
      to develop a discriminating test model for the 3 classes of superdisintegrants 
      represented by Ac-Di-Sol, Primojel, and Polyplasdone XL10. Using a digital video 
      camera to examine the disintegration process of tablets containing the same wt/wt 
      percentage concentration of the disintegrants, Ac-Di-Sol was found to 
      disintegrate tablets rapidly into apparently primary particles; Primojel also 
      apparently disintegrated tablets into primary particles but more slowly; 
      Polyplasdone XL10 disintegrated tablets rapidly but into larger masses of 
      aggregated particles. The differences in the size distribution generated in the 
      disintegrated tablets likely contribute to the drug dissolution rate differences 
      found for aspirin tablets with similar disintegration rates. The aspirin tablet 
      matrix is proposed as a model formulation for disintegrant efficiency comparison 
      and performance consistency testing for quality control purposes.
FAU - Zhao, Na
AU  - Zhao N
AD  - University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.
FAU - Augsburger, Larry L
AU  - Augsburger LL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051212
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Excipients)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry/*pharmacokinetics
MH  - Excipients/chemistry/*classification/*pharmacokinetics
MH  - Solubility
PMC - PMC2750612
EDAT- 2006/01/18 09:00
MHDA- 2006/04/07 09:00
CRDT- 2006/01/18 09:00
PHST- 2006/01/18 09:00 [pubmed]
PHST- 2006/04/07 09:00 [medline]
PHST- 2006/01/18 09:00 [entrez]
AID - 64634 [pii]
AID - 10.1208/pt060479 [doi]
PST - epublish
SO  - AAPS PharmSciTech. 2005 Dec 12;6(4):E634-40. doi: 10.1208/pt060479.

PMID- 18253960
OWN - NLM
STAT- MEDLINE
DCOM- 20080731
LR  - 20131121
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 51
IP  - 1
DP  - 2008 Jul
TI  - Low prevalence and assay discordance of "aspirin resistance" in children.
PG  - 86-92
LID - 10.1002/pbc.21465 [doi]
AB  - BACKGROUND: Although "aspirin resistance" (AR-inadequate platelet inhibition as 
      suggested by in vitro testing of aspirin-treated patients) has been widely 
      studied in adults and linked to increased risk of adverse outcomes, its 
      prevalence and clinical significance are largely unknown in children. PROCEDURE: 
      To determine AR prevalence in children and its relationship to assay methodology, 
      we undertook a cross-sectional study of 44 children (1-17 years, 24 male) on 
      aspirin for various indications and considered three published definitions of AR 
      in adults: platelet aggregation >/=70% to 10 microM adenosine diphosphate and 
      >/=20% to 0.5 mg/ml arachidonic acid (AA), normal PFA-100(R) closure time and 
      elevated urinary 11-dehydro thromboxane B(2) (11dhTxB(2)) concentration. RESULTS: 
      Six subjects exhibited AR according to at least one of the criteria (5 by 
      PFA-100(R), 1 by aggregometry and 11dhTxB(2) criteria); nearly all subjects had 
      low levels of 11dhTxB(2) compared with controls. Subjects studied prior to 
      therapy showed pronounced changes in AR parameters after aspirin dosing (e.g., 
      mean aggregation to AA decreased from 82% to 6%, P < 0.001), confirming an 
      aspirin effect. Subjects with AR did not differ from aspirin responsive subjects 
      in terms of age, race, platelet count, or aspirin dose, indication or therapy 
      duration. There was minimal correlation between assays. CONCLUSIONS: In this 
      initial prevalence study of a clinically diverse group of pediatric patients, 
      frequencies of AR were assay-dependent; however, the prevalence of true AR is 
      likely low in children (2.3%; 95% CI 0.1-10.7%), in agreement with adult studies. 
      To better define the clinical relevance of AR in children, multicenter, 
      prospective cohort studies are imperative.
CI  - (c) 2008 Wiley-Liss, Inc.
FAU - Yee, D L
AU  - Yee DL
AD  - Department of Pediatrics, Hematology-Oncology Section, Baylor College of 
      Medicine, One Baylor Plaza, Houston, Texas, USA. dlyee@txccc.org
FAU - Dinu, B R
AU  - Dinu BR
FAU - Sun, C W
AU  - Sun CW
FAU - Edwards, R M
AU  - Edwards RM
FAU - Justino, H
AU  - Justino H
FAU - Teruya, J
AU  - Teruya J
FAU - Bray, P F
AU  - Bray PF
FAU - Bomgaars, L
AU  - Bomgaars L
LA  - eng
GR  - HL81539/HL/NHLBI NIH HHS/United States
GR  - RR00188/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - *Drug Resistance
MH  - Epidemiologic Measurements
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Prevalence
MH  - Risk Factors
EDAT- 2008/02/07 09:00
MHDA- 2008/08/01 09:00
CRDT- 2008/02/07 09:00
PHST- 2008/02/07 09:00 [pubmed]
PHST- 2008/08/01 09:00 [medline]
PHST- 2008/02/07 09:00 [entrez]
AID - 10.1002/pbc.21465 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2008 Jul;51(1):86-92. doi: 10.1002/pbc.21465.

PMID- 37196887
OWN - NLM
STAT- MEDLINE
DCOM- 20230614
LR  - 20230711
IS  - 1559-2030 (Electronic)
IS  - 1551-7144 (Print)
IS  - 1551-7144 (Linking)
VI  - 130
DP  - 2023 Jul
TI  - Health Characteristics and Aspirin Use in Participants at the Baseline of the 
      ASPirin in Reducing Events in the Elderly - eXTension (ASPREE-XT) Observational 
      Study.
PG  - 107231
LID - S1551-7144(23)00154-4 [pii]
LID - 10.1016/j.cct.2023.107231 [doi]
AB  - BACKGROUND: Aspirin as a primary preventative in healthy older adults did not 
      prolong disability-free survival in the ASPREE randomized trial. Observational 
      studies following randomized trials allow assessment of benefits and harms which 
      may not appear during the trial. We describe health characteristics, physical 
      function, and aspirin use in the ASPREE-eXTension (ASPREE-XT) observational study 
      cohort. METHODS: Descriptive statistics compared health characteristics of those 
      consented to ASPREE-XT at their first post-trial baseline (XT01) to corresponding 
      ASPREE baseline values, and to those not consented. Likelihood of an indication 
      for aspirin was assessed in participants reporting aspirin use at XT01. RESULTS: 
      16,317 (93%) of the remaining and eligible 17,546 ASPREE participants were 
      consented into ASPREE-XT; 14,894 completed XT01. Mean participant age had 
      increased from 74.9 to 80.6 years. Overall health and physical function declined 
      from the original ASPREE baseline; more participants were living alone, there was 
      higher prevalence of chronic kidney disease, diabetes, and frailty, grip strength 
      was lower and gait speed slower. Those not consented into ASPREE-XT were slightly 
      older, and had lower cognitive scores and higher prevalence of age-related 
      conditions than those who continued. 1015/11,717 (8.7%) participants without an 
      apparent indication for aspirin reported using aspirin at XT01. CONCLUSIONS: The 
      ASPREE-XT cohort was slightly less healthy at the XT01 visit than at ASPREE trial 
      initiation, and rates of aspirin use without indication were similar to ASPREE 
      baseline. Participants will be followed long-term to investigate aspirin's 
      potential legacy towards dementia and cancer prevention and explore determinants 
      of healthy aging.
CI  - Copyright © 2023 Elsevier Inc. All rights reserved.
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - Department of Pharmacy Practice and Science, College of Pharmacy, The University 
      of Iowa, Iowa City, IA, United States of America; Department of Family Medicine, 
      Carver College of Medicine, The University of Iowa, Iowa City, IA, United States 
      of America. Electronic address: michael-ernst@uiowa.edu.
FAU - Broder, Jonathan C
AU  - Broder JC
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia; Menzies Institute for Medical Research, University of Tasmania, 
      Hobart, Australia.
FAU - Ryan, Joanne
AU  - Ryan J
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
FAU - Shah, Raj C
AU  - Shah RC
AD  - Department of Family and Preventive Medicine and the Rush Alzheimer's Disease 
      Center, Rush University Medical Center, Chicago, IL, United States of America.
FAU - Orchard, Suzanne G
AU  - Orchard SG
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and 
      Harvard Medical School, Boston, MA, United States of America.
FAU - Espinoza, Sara E
AU  - Espinoza SE
AD  - Division of Geriatrics, Gerontology & Palliative Medicine, and Sam and Ann 
      Barshop Institute for Longevity and Aging Studies, University of Texas Health 
      Science Center at San Antonio, San Antonio, TX, United States of America; 
      Geriatric Research Education & Clinical Center, South Texas Veterans Health Care 
      System, San Antonio, TX, United States of America.
FAU - Wilson, Michelle
AU  - Wilson M
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
FAU - Kirpach, Brenda
AU  - Kirpach B
AD  - Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Minneapolis, MN, United States of America.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia; School of Population Health, Curtin University; Perth, WA, 
      Australia.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
FAU - Williamson, Jeff D
AU  - Williamson JD
AD  - Sticht Centre on Health Aging and Alzheimer's Prevention, Section on Gerontology 
      and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of 
      Medicine, Winston-Salem, NC, United States of America.
FAU - Murray, Anne M
AU  - Murray AM
AD  - Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Minneapolis, MN, United States of America; Division of Geriatrics, 
      Department of Medicine, Hennepin Healthcare, Minneapolis, MN, United States of 
      America.
CN  - ASPREE Investigator Group
LA  - eng
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U19 AG062682/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20230515
PL  - United States
TA  - Contemp Clin Trials
JT  - Contemporary clinical trials
JID - 101242342
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aspirin
MH  - Double-Blind Method
MH  - *Cognition
PMC - PMC10330669
MID - NIHMS1904145
OTO - NOTNLM
OT  - ASPREE
OT  - Aspirin
OT  - Healthy aging
OT  - Observational
COIS- Declaration of Competing Interest All authors declare no conflicts of interest in 
      the publication of this manuscript.
EDAT- 2023/05/18 01:07
MHDA- 2023/06/14 06:42
PMCR- 2024/07/01
CRDT- 2023/05/17 19:27
PHST- 2022/12/08 00:00 [received]
PHST- 2023/04/18 00:00 [revised]
PHST- 2023/05/11 00:00 [accepted]
PHST- 2024/07/01 00:00 [pmc-release]
PHST- 2023/06/14 06:42 [medline]
PHST- 2023/05/18 01:07 [pubmed]
PHST- 2023/05/17 19:27 [entrez]
AID - S1551-7144(23)00154-4 [pii]
AID - 10.1016/j.cct.2023.107231 [doi]
PST - ppublish
SO  - Contemp Clin Trials. 2023 Jul;130:107231. doi: 10.1016/j.cct.2023.107231. Epub 
      2023 May 15.

PMID- 21890814
OWN - NLM
STAT- MEDLINE
DCOM- 20120216
LR  - 20161125
IS  - 1468-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 61
IP  - 2
DP  - 2012 Feb
TI  - Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year 
      results of the APACC randomised trial.
PG  - 255-61
LID - 10.1136/gutjnl-2011-300113 [doi]
AB  - BACKGROUND: Aspirin inhibits colorectal carcinogenesis. In a randomised 
      double-blind placebo-controlled trial, daily soluble aspirin significantly 
      reduced recurrence of colorectal adenomas at 1-year follow-up. In this study the 
      results of daily intake of low-dose aspirin on polyp recurrence at 4-year 
      follow-up are presented. METHODS: 272 patients (naive for chronic aspirin use) 
      with colorectal adenomas were randomly assigned to treatment with lysine 
      acetylsalicylate 160 mg/day (n=73) or 300 mg/day (n=67) or placebo (n=132) for 4 
      years. The primary endpoints were adenoma recurrence and adenomatous polyp burden 
      at year 4, comparing aspirin at either dose with placebo. The same endpoints were 
      also assessed at year 1 or 4 (last colonoscopy performed for each patient). 
      RESULTS: At the final year 4 colonoscopy the analysis included 185 patients (55 
      receiving aspirin 160 mg/day, 47 aspirin 300 mg/day and 83 placebo). There was no 
      difference in the proportion of patients with at least one recurrent adenoma 
      between patients receiving aspirin at either dose and those treated with placebo 
      (42/102 (41%) vs 33/83 (40%); NS) or in the adenomatous polyp burden (3.1 ± 5.8 
      mm vs 3.4 ± 6.2 mm; NS). Also, the proportion of patients with at least one 
      advanced recurrent adenoma did not differ (10/102 [corrected] (10%) in the 
      aspirin group vs 7/83 (8.4%) [corrected] in the placebo group; NS). CONCLUSION: 
      Daily low-dose aspirin decreased adenoma recurrence significantly at 1 year but 
      not at year 4. This discrepancy might be explained by a differential effect of 
      aspirin according to the natural history of the polyp. TRIAL REGISTRATION NUMBER: 
      NCT 00224679.
FAU - Benamouzig, Robert
AU  - Benamouzig R
AD  - Department of Gastroenterology, AP-HP, Avicenne Hospital, Paris-13 University, 
      Bobigny, France. robert.benamouzig@avc.aphp.fr
FAU - Uzzan, Bernard
AU  - Uzzan B
FAU - Deyra, Jacques
AU  - Deyra J
FAU - Martin, Antoine
AU  - Martin A
FAU - Girard, Bernard
AU  - Girard B
FAU - Little, Julian
AU  - Little J
FAU - Chaussade, Stanislas
AU  - Chaussade S
CN  - Association pour la Prévention par l'Aspirine du Cancer Colorectal Study Group 
      (APACC)
LA  - eng
SI  - ClinicalTrials.gov/NCT00224679
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110902
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
EIN - Gut. 2012 Mar;61(3):472
MH  - Adenoma/prevention & control
MH  - Adenomatous Polyps/pathology/*prevention & control
MH  - Aged
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Colonoscopy
MH  - Colorectal Neoplasms/pathology/*prevention & control
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Secondary Prevention
MH  - Treatment Outcome
FIR - Attar, A
IR  - Attar A
FIR - Barakrok, N
IR  - Barakrok N
FIR - Beaujard, E
IR  - Beaujard E
FIR - Bejou, B
IR  - Bejou B
FIR - Benamouzig, R
IR  - Benamouzig R
FIR - Benazzouz, A P
IR  - Benazzouz AP
FIR - Benoit, R
IR  - Benoit R
FIR - Berthelemy, B
IR  - Berthelemy B
FIR - Blondon, H
IR  - Blondon H
FIR - Bordet, E
IR  - Bordet E
FIR - Boulant, J
IR  - Boulant J
FIR - Bour, B
IR  - Bour B
FIR - Cassan, P
IR  - Cassan P
FIR - Chaussade, S
IR  - Chaussade S
FIR - Ciribilli, J-M
IR  - Ciribilli JM
FIR - Coudert, P
IR  - Coudert P
FIR - Couturier, D
IR  - Couturier D
FIR - Courillon-Mallet, A
IR  - Courillon-Mallet A
FIR - Danielou, J-Y
IR  - Danielou JY
FIR - Degoy, J
IR  - Degoy J
FIR - Delasalle, P
IR  - Delasalle P
FIR - Delchier, J-C
IR  - Delchier JC
FIR - Dieumegard, B
IR  - Dieumegard B
FIR - Dreyfus, G
IR  - Dreyfus G
FIR - Dupas, J-L
IR  - Dupas JL
FIR - Durney, D
IR  - Durney D
FIR - Dusoleil, A
IR  - Dusoleil A
FIR - Flamenbaum, M
IR  - Flamenbaum M
FIR - Flaubert, G
IR  - Flaubert G
FIR - Fontanges, T
IR  - Fontanges T
FIR - Fourgeaud, J-L
IR  - Fourgeaud JL
FIR - Gatineau-Saillant, G
IR  - Gatineau-Saillant G
FIR - Godeberge, P
IR  - Godeberge P
FIR - Goldfain, D
IR  - Goldfain D
FIR - Gouffier, E
IR  - Gouffier E
FIR - Grobost, O
IR  - Grobost O
FIR - Heyman, B
IR  - Heyman B
FIR - Heyries, L
IR  - Heyries L
FIR - Humeau, B
IR  - Humeau B
FIR - Kalinsky, E
IR  - Kalinsky E
FIR - Kerneis, J
IR  - Kerneis J
FIR - Klewansky, M
IR  - Klewansky M
FIR - Kusielewicz, D
IR  - Kusielewicz D
FIR - Lagneau, M
IR  - Lagneau M
FIR - Lamarque, D
IR  - Lamarque D
FIR - Lepage, M
IR  - Lepage M
FIR - Loiseau, D
IR  - Loiseau D
FIR - Macaigne, O
IR  - Macaigne O
FIR - Malka, D
IR  - Malka D
FIR - Marill, J-L
IR  - Marill JL
FIR - Marti, R
IR  - Marti R
FIR - Mitry, E
IR  - Mitry E
FIR - Nalet, B
IR  - Nalet B
FIR - Nizou, C
IR  - Nizou C
FIR - Pariente, E A
IR  - Pariente EA
FIR - Paupard, T
IR  - Paupard T
FIR - Perrot, S
IR  - Perrot S
FIR - Pigot, F
IR  - Pigot F
FIR - Pouderoux, P
IR  - Pouderoux P
FIR - Rampal, P
IR  - Rampal P
FIR - Rautureau, J
IR  - Rautureau J
FIR - Renou, C
IR  - Renou C
FIR - Ribiere, O
IR  - Ribiere O
FIR - Roche, H
IR  - Roche H
FIR - Rotenberg, A
IR  - Rotenberg A
FIR - Rougier, P
IR  - Rougier P
FIR - Ruszniewski, P
IR  - Ruszniewski P
FIR - Schneider, S
IR  - Schneider S
FIR - Souillac, P
IR  - Souillac P
FIR - Stremsdoerfer, N
IR  - Stremsdoerfer N
FIR - Tainturier, M-H
IR  - Tainturier MH
FIR - Travers, B
IR  - Travers B
FIR - Vergeau, B
IR  - Vergeau B
FIR - Zamora, C
IR  - Zamora C
FIR - Zummer, K
IR  - Zummer K
FIR - Abarah, B
IR  - Abarah B
FIR - Aillet, G
IR  - Aillet G
FIR - Anger, E
IR  - Anger E
FIR - Balaton, A
IR  - Balaton A
FIR - Barhoum, K
IR  - Barhoum K
FIR - Baron, V
IR  - Baron V
FIR - Benderitter-Giovo, E
IR  - Benderitter-Giovo E
FIR - Bertrand, G
IR  - Bertrand G
FIR - Besnard-Bernadac, M-C
IR  - Besnard-Bernadac MC
FIR - Bonnafous, F
IR  - Bonnafous F
FIR - Bouc, M
IR  - Bouc M
FIR - Bougaran, J
IR  - Bougaran J
FIR - Bringeon, B
IR  - Bringeon B
FIR - Cales, V
IR  - Cales V
FIR - Calvet, E
IR  - Calvet E
FIR - Carayon, M-J
IR  - Carayon MJ
FIR - Carnot, F
IR  - Carnot F
FIR - Chamlian, A
IR  - Chamlian A
FIR - Chassaigne, C
IR  - Chassaigne C
FIR - Chatelain, D
IR  - Chatelain D
FIR - Chomarat, C
IR  - Chomarat C
FIR - Cloup, N
IR  - Cloup N
FIR - Coppe, P
IR  - Coppe P
FIR - Costes-Chalret, N
IR  - Costes-Chalret N
FIR - Cousin-Maignan, C
IR  - Cousin-Maignan C
FIR - Degott, C
IR  - Degott C
FIR - Dubois-Gordeff, A
IR  - Dubois-Gordeff A
FIR - Durand, L
IR  - Durand L
FIR - Fabiani-Caetz, B
IR  - Fabiani-Caetz B
FIR - Forest, E
IR  - Forest E
FIR - Giglio, L
IR  - Giglio L
FIR - de Pinieux, G
IR  - de Pinieux G
FIR - Gros, P
IR  - Gros P
FIR - Hofman-Guilaine, C
IR  - Hofman-Guilaine C
FIR - Homsi, T
IR  - Homsi T
FIR - Jeandel, R
IR  - Jeandel R
FIR - Journel, B
IR  - Journel B
FIR - Kalifat, R
IR  - Kalifat R
FIR - Karkouche, B
IR  - Karkouche B
FIR - Kerlo, P
IR  - Kerlo P
FIR - Lab, P
IR  - Lab P
FIR - Languille-Mimoune, O
IR  - Languille-Mimoune O
FIR - Lesec, G
IR  - Lesec G
FIR - Longchampt, E
IR  - Longchampt E
FIR - Louis, B
IR  - Louis B
FIR - Marquet, M
IR  - Marquet M
FIR - Martin, A
IR  - Martin A
FIR - Marty-Double, C
IR  - Marty-Double C
FIR - Medioni, L-D
IR  - Medioni LD
FIR - Molas, G
IR  - Molas G
FIR - Monnier, P
IR  - Monnier P
FIR - Mosnier-Damet, M
IR  - Mosnier-Damet M
FIR - Nenert, N
IR  - Nenert N
FIR - Petit, J
IR  - Petit J
FIR - Rey, C
IR  - Rey C
FIR - Richard-Coulet, E
IR  - Richard-Coulet E
FIR - Rolachon, J
IR  - Rolachon J
FIR - Romeo, J-M
IR  - Romeo JM
FIR - Roucayrol, A-M
IR  - Roucayrol AM
FIR - Roux, F
IR  - Roux F
FIR - Saint-Paul, M-C
IR  - Saint-Paul MC
FIR - Schill, H
IR  - Schill H
FIR - Schlund-Schoettel, E
IR  - Schlund-Schoettel E
FIR - Staroz, S
IR  - Staroz S
FIR - Trincard, M-D
IR  - Trincard MD
FIR - Tulliez, M
IR  - Tulliez M
FIR - Valade, S
IR  - Valade S
FIR - Verdier, V
IR  - Verdier V
FIR - Verriele, V
IR  - Verriele V
FIR - Zafrani, E
IR  - Zafrani E
EDAT- 2011/09/06 06:00
MHDA- 2012/02/18 06:00
CRDT- 2011/09/06 06:00
PHST- 2011/09/06 06:00 [entrez]
PHST- 2011/09/06 06:00 [pubmed]
PHST- 2012/02/18 06:00 [medline]
AID - gutjnl-2011-300113 [pii]
AID - 10.1136/gutjnl-2011-300113 [doi]
PST - ppublish
SO  - Gut. 2012 Feb;61(2):255-61. doi: 10.1136/gutjnl-2011-300113. Epub 2011 Sep 2.

PMID- 8372735
OWN - NLM
STAT- MEDLINE
DCOM- 19931014
LR  - 20131121
IS  - 0379-0363 (Print)
IS  - 0379-0363 (Linking)
VI  - 44
DP  - 1993
TI  - Biliary elimination of aspirin after oral and intravenous administration in 
      patients.
PG  - 51-7
AB  - Five patients suffering from various diseases were investigated for biliary 
      elimination of aspirin given i.v. (500 mg, n = 3; 1500 mg, n = 1) or orally (500 
      mg, n = 2). Two bile draining systems, t-tube and naso-biliary tube, were used to 
      collect the bile fluid. The analysis of biliary secretion of salicylates revealed 
      only small amounts of salicylic acid and its conjugates undergoing biliary 
      elimination and subsequent enterohepatic circulation ranging between 0.02 and 
      1.89% of the given dose (median 0.18%). Urinary recovery was calculated between 
      22.4 and 101.78% (median 92.27%). From these data it is concluded that biliary 
      elimination and subsequent enterohepatic circulation plays no (aspirin) or only a 
      minor role (salicylic acid) in the excretion of aspirin in man.
FAU - Brune, K
AU  - Brune K
AD  - Department of Pharmacology and Toxicology, University of Erlangen-Nürnberg, FRG.
FAU - Nuernberg, B
AU  - Nuernberg B
FAU - Schneider, H T
AU  - Schneider HT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Agents Actions Suppl
JT  - Agents and actions. Supplements
JID - 7801014
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Bile/*metabolism
MH  - Biological Availability
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Agents Actions Suppl. 1993;44:51-7.

PMID- 22320344
OWN - NLM
STAT- MEDLINE
DCOM- 20120706
LR  - 20131121
IS  - 1520-5207 (Electronic)
IS  - 1520-5207 (Linking)
VI  - 116
IP  - 10
DP  - 2012 Mar 15
TI  - Inactivation of ovine cyclooxygenase-1 by bromoaspirin and aspirin: a quantum 
      chemistry description.
PG  - 3270-9
LID - 10.1021/jp206397z [doi]
AB  - The resulting noncovalent bonding of the salicylic acid to ovine COX-1 after 
      bromoaspirin and aspirin acetylation by Ser530 is investigated within the scope 
      of density functional theory considering a 6.5 Å radius binding pocket. We have 
      not only took full advantage of published X-ray structural data for the ovine 
      COX-1 cocrystallized with bromoaspirin, but we also have improved that data 
      through computation, finding good estimates for the hydrogen atom positions at 
      the residues of the binding pocket, and repositioning the Ser530Ac[Br;H] lateral 
      chain and salicylic acid by total energy minimization procedures employing LDA 
      and GGA+D exchange-correlation functionals. Using bromoaspirin as a template, we 
      have simulated the positioning of aspirin in the binding pocket, estimating its 
      interaction energy with each of its neighbor COX-1 residues. We demonstrate that 
      the binding energies of bromoaspirin and aspirin to COX-1 are very close when 
      second-order quantum refinements of the structural data are performed, which 
      points to an explanation on why the IC(50) values for the 126 μM COX-1 activity 
      of both bromoaspirin and aspirin are practically the same. Attracting and 
      repelling residues were identified, being shown that Arg120 is the most effective 
      residue attracting the salicylic acid, followed by Ala527, Leu531, Leu359, and 
      Ser353. On the other hand, Glu524 was found the most effective repulsive residue 
      (strength interaction comparable to Arg120).
CI  - © 2012 American Chemical Society
FAU - Barroso-Neto, Ito L
AU  - Barroso-Neto IL
AD  - Department of Biochemistry, Universidade Federal do Ceará, Fortaleza 60455-760, 
      Ceará, Brazil.
FAU - Marques, João Paulo C
AU  - Marques JP
FAU - da Costa, Roner F
AU  - da Costa RF
FAU - Caetano, Ewerton W S
AU  - Caetano EW
FAU - Cavada, Benildo S
AU  - Cavada BS
FAU - Gottfried, Carmem
AU  - Gottfried C
FAU - Freire, Valder N
AU  - Freire VN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120306
PL  - United States
TA  - J Phys Chem B
JT  - The journal of physical chemistry. B
JID - 101157530
RN  - 77382-69-5 (bromoaspirin)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*chemistry
MH  - Binding Sites
MH  - Crystallography, X-Ray
MH  - Cyclooxygenase 1/chemistry/*metabolism
MH  - Protein Structure, Tertiary
MH  - *Quantum Theory
MH  - Sheep/metabolism
EDAT- 2012/02/11 06:00
MHDA- 2012/07/07 06:00
CRDT- 2012/02/11 06:00
PHST- 2012/02/11 06:00 [entrez]
PHST- 2012/02/11 06:00 [pubmed]
PHST- 2012/07/07 06:00 [medline]
AID - 10.1021/jp206397z [doi]
PST - ppublish
SO  - J Phys Chem B. 2012 Mar 15;116(10):3270-9. doi: 10.1021/jp206397z. Epub 2012 Mar 
      6.

PMID- 3989690
OWN - NLM
STAT- MEDLINE
DCOM- 19850612
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 74
IP  - 2
DP  - 1985 Feb
TI  - Preparation and analysis of deuterium-labeled aspirin: application to 
      pharmacokinetic studies.
PG  - 188-92
AB  - Inhibition of endogenous prostacyclin and thromboxane biosynthesis by aspirin is 
      critically dose-dependent in humans. Gastrointestinal and hepatic hydrolysis may 
      limit systemic availability of aspirin, especially in low doses, perhaps 
      contributing to the biochemical selectivity of aspirin. Existing analytical 
      methods do not permit determination of systemic bioavailability when low (less 
      than 100 mg) doses of aspirin are administered. Deuterium-labeled aspirin 
      (2-acetoxy[3,4,5,6-2H4]benzoic acid) was synthesized from salicylic acid by 
      catalytic exchange and subsequent acetylation. Analysis of the compounds as 
      benzyl esters by GC-MS followed extractive alkylation from plasma. 
      Heptadeuterated compounds were used as internal standards. Simultaneous 
      administration of tetradeuterated aspirin intravenously with native aspirin 
      orally to anesthetized dogs permitted kinetic studies of both aspirin and 
      salicylic acid. The sensitivity of the method is superior to published methods 
      using HPLC and, thus, more applicable to studies of low dose aspirin. Pulse 
      administration of stable isotope-labeled aspirin permits detailed and repeated 
      studies of dose-related aspirin pharmacokinetics in humans.
FAU - Pedersen, A K
AU  - Pedersen AK
FAU - FitzGerald, G A
AU  - FitzGerald GA
LA  - eng
GR  - GM 15431/GM/NIGMS NIH HHS/United States
GR  - HL 30400/HL/NHLBI NIH HHS/United States
GR  - RR 05424/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - AR09D82C7G (Deuterium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*metabolism
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid
MH  - *Deuterium
MH  - Dogs
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Isotope Labeling/*methods
MH  - Kinetics
MH  - Male
EDAT- 1985/02/01 00:00
MHDA- 1985/02/01 00:01
CRDT- 1985/02/01 00:00
PHST- 1985/02/01 00:00 [pubmed]
PHST- 1985/02/01 00:01 [medline]
PHST- 1985/02/01 00:00 [entrez]
AID - S0022-3549(15)46572-4 [pii]
AID - 10.1002/jps.2600740217 [doi]
PST - ppublish
SO  - J Pharm Sci. 1985 Feb;74(2):188-92. doi: 10.1002/jps.2600740217.

PMID- 10695091
OWN - NLM
STAT- MEDLINE
DCOM- 20000313
LR  - 20190513
IS  - 0007-1420 (Print)
IS  - 0007-1420 (Linking)
VI  - 55
IP  - 1
DP  - 1999
TI  - Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions.
PG  - 277-98
AB  - The problems posed by transfusion of homologous blood have led to the development 
      of substances able to replace the gas transporting properties of blood. 
      Perfluorocarbons (PFCs) emulsions and modified haemoglobin (Hb) solutions have 
      been developed for this goal and are now tested in clinical assays. PFCs are 
      synthetic fluorinated hydrocarbons, capable of dissolving large quantities of 
      oxygen (O2; without binding) at high inspired concentrations of O2, and of 
      delivering this O2 to the tissues. They are administered as emulsions containing 
      particles with a diameter of approximately 0.2 micron, capable of entering the 
      microcirculation. They are eliminated unchanged by the lungs within several days. 
      Fluosol-DA 20% was the first PFC emulsion used in clinical practice. Currently, 
      Oxygent, a second generation PFC emulsion, is being evaluated in clinical 
      studies. The PFCs are not blood substitutes, but rather a means to ensure tissue 
      oxygenation during extreme haemodilution. Solutions of free Hb do not have the 
      antigenic characteristics of the blood groups, and do not require compatibility 
      testing. They are fully saturated with O2 at ambient FiO2. The Hbs used are 
      derived from either human or bovine sources, or via recombinant DNA technology. 
      In order to maintain satisfactory intravascular half-life and O2 affinity, the Hb 
      molecules are modified by adding internal crosslinks, by polymerization, and/or 
      by encapsulation. After promising animal studies, several of these modified Hb 
      solutions are now being studied in Phase III clinical trials. Among them, 
      diaspirin cross-linked haemoglobin (DCLHb) has been used in cardiac and 
      orthopaedic surgery, and for resuscitation of traffic accident victims. The 
      initial results of multicentre trials are now being analysed.
FAU - Remy, B
AU  - Remy B
AD  - Department of Anaesthesia and Intensive Care Medicine, University of Liège, 
      Belgium.
FAU - Deby-Dupont, G
AU  - Deby-Dupont G
FAU - Lamy, M
AU  - Lamy M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br Med Bull
JT  - British medical bulletin
JID - 0376542
RN  - 0 (Blood Substitutes)
RN  - 0 (Fluorocarbons)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - Fluorocarbons/*therapeutic use
MH  - Hemoglobins/*therapeutic use
MH  - Humans
RF  - 77
EDAT- 2000/03/01 09:00
MHDA- 2000/03/18 09:00
CRDT- 2000/03/01 09:00
PHST- 2000/03/01 09:00 [pubmed]
PHST- 2000/03/18 09:00 [medline]
PHST- 2000/03/01 09:00 [entrez]
AID - 10.1258/0007142991902259 [doi]
PST - ppublish
SO  - Br Med Bull. 1999;55(1):277-98. doi: 10.1258/0007142991902259.

PMID- 6638687
OWN - NLM
STAT- MEDLINE
DCOM- 19831217
LR  - 20131121
IS  - 0003-0805 (Print)
IS  - 0003-0805 (Linking)
VI  - 128
IP  - 5
DP  - 1983 Nov
TI  - Aspirin desensitization in aspirin-sensitive asthma: failure to maintain a 
      desensitized state during prolonged therapy.
PG  - 953-5
AB  - A patient with a history of asthma induced by acetylsalicylic acid (ASA) was 
      found to be ASA sensitive when orally challenged with ASA. She was successfully 
      desensitized using incremental doses of ASA given orally and maintained on ASA or 
      other nonsteroidal antiinflammatory (NSAI) agents for the treatment of arthritis. 
      After 6 months of uninterrupted therapy the patient developed asthmatic symptoms 
      that were related to ASA and NSAI drug therapy. Although desensitization may be 
      achieved in patients with ASA-sensitive asthma, sensitivity may recur despite 
      continuous therapy.
FAU - Dankner, R E
AU  - Dankner RE
FAU - Wedner, H J
AU  - Wedner HJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am Rev Respir Dis
JT  - The American review of respiratory disease
JID - 0370523
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*chemically induced
MH  - Desensitization, Immunologic
MH  - Female
MH  - Humans
EDAT- 1983/11/01 00:00
MHDA- 1983/11/01 00:01
CRDT- 1983/11/01 00:00
PHST- 1983/11/01 00:00 [pubmed]
PHST- 1983/11/01 00:01 [medline]
PHST- 1983/11/01 00:00 [entrez]
AID - 10.1164/arrd.1983.128.5.953 [doi]
PST - ppublish
SO  - Am Rev Respir Dis. 1983 Nov;128(5):953-5. doi: 10.1164/arrd.1983.128.5.953.

PMID- 7719448
OWN - NLM
STAT- MEDLINE
DCOM- 19950522
LR  - 20191031
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 23
IP  - 1
DP  - 1995
TI  - Diaspirin crosslinked hemoglobin (DCLHb) does not affect the anesthetic potency 
      of isoflurane in rats.
PG  - 89-99
AB  - Hemoglobin solutions are being developed as oxygen carrying fluids for multiple 
      clinical indications. Despite an early report of accentuation of ether 
      anesthesia, the effect of hemoglobin on anesthetic potency has not been assessed. 
      We assessed the effect of alpha-alpha diaspirin crosslinked hemoglobin (DCLHb) on 
      the anesthetic requirement of isoflurane necessary to keep rats unresponsive to 
      noxious stimuli (1.0 MAC [minimum alveolar concentration]). During isoflurane 
      administration, each rat received one of the following fluid regimens: 
      44Hct/N-normal hematocrit and volume; 44Hct/H-8.0 ml of donor blood given as a 
      hypervolemic bolus; 30Hct/H-5.0 ml of DCLHb given as an exchange transfusion and 
      8.0 ml as a hypervolemic bolus; or 16Hct/H-15.0 ml of DCLHb given as an exchange 
      transfusion and 8.0 ml as a hypervolemic bolus. MAC was determined using a 
      standard tail clamp technique. The isoflurane requirement to achieve 1.0 MAC was 
      not different between the four groups. These results are consistent with a 
      hypothesis that DCLHb does not change the anesthetic state.
FAU - Cole, D J
AU  - Cole DJ
AD  - Department of Anesthesiology, Loma Linda University, California 92354, U.S.A.
FAU - Przybelski, R J
AU  - Przybelski RJ
FAU - Schell, R M
AU  - Schell RM
FAU - Martin, R D
AU  - Martin RD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Hemoglobins)
RN  - CYS9AKD70P (Isoflurane)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anesthesia, Inhalation
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Drug Interactions
MH  - Hemoglobins/*pharmacology
MH  - Isoflurane/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Inbred SHR
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.3109/10731199509117670 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1995;23(1):89-99. doi: 
      10.3109/10731199509117670.

PMID- 8122187
OWN - NLM
STAT- MEDLINE
DCOM- 19940407
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 72
IP  - 1
DP  - 1993 Oct 1
TI  - In vitro and ex vivo effects of aspirin in patients on a low-dose aspirin 
      therapy.
PG  - 49-57
AB  - In 19 patients on a low-dose aspirin therapy with 100 mg/d, an insufficient 
      effect of aspirin was observed in five patients (aggregations induced by 
      arachidonic acid and collagen, thromboxane B2-formation in serum and after 
      collagen). Aspirin added in vitro increased the inhibition to a degree comparable 
      to that seen in the other 14 patients, i.e. the insufficient effect could be due 
      to a lack of compliance or to a reduced availability of the drug. In another 20 
      patients there was a good inhibitory effect of aspirin; additional aspirin did 
      not increase the inhibition of arachidonic acid-induced aggregation and 
      serum-thromboxane B2, but slightly increased collagen-induced aggregation and 
      thromboxane B2 formation. The effect was the same, whether the aspirin was given 
      in vivo or added in vitro.
FAU - Voss, R
AU  - Voss R
AD  - Department of Internal Medicine, Justus-Liebig-University, Giessen, Germany.
FAU - Geissler, B S
AU  - Geissler BS
FAU - Tillmanns, H
AU  - Tillmanns H
FAU - Matthias, F R
AU  - Matthias FR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Collagen/pharmacology
MH  - Coronary Disease/blood/drug therapy
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane B2/biosynthesis
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
AID - 0049-3848(93)90172-K [pii]
AID - 10.1016/0049-3848(93)90172-k [doi]
PST - ppublish
SO  - Thromb Res. 1993 Oct 1;72(1):49-57. doi: 10.1016/0049-3848(93)90172-k.

PMID- 2918521
OWN - NLM
STAT- MEDLINE
DCOM- 19890406
LR  - 20190709
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 32
IP  - 3
DP  - 1989 Mar
TI  - Evaluation of glycolamide esters and various other esters of aspirin as true 
      aspirin prodrugs.
PG  - 727-34
AB  - A series of glycolamide, glycolate, (acyloxy)methyl, alkyl, and aryl esters of 
      acetylsalicylic acid (aspirin) were synthesized and evaluated as potential 
      prodrug forms of aspirin. N,N-Disubstituted glycolamide esters were found to be 
      rapidly hydrolyzed in human plasma, resulting in the formation of aspirin as well 
      as the corresponding salicylate esters. These in turn hydrolyzed rapidly to 
      salicylic acid. The largest amount of aspirin formed from the esters were 50 and 
      55% in case of the N,N-dimethyl- and N,N-diethylglycolamide esters, respectively. 
      Similar results were obtained in blood with the N,N-dimethyl- and 
      N,N-diethylglycolamide esters. Unsubstituted and monosubstituted glycolamide 
      esters as well as most other esters previously suggested to be aspirin prodrugs 
      were shown to hydrolyze exclusively to the corresponding salicylic acid esters. 
      Lipophilicity parameters and water solubilities of the esters were determined, 
      and structural factors favoring ester prodrug hydrolysis at the expense of 
      deacetylation to yield salicylate ester are discussed. The properties of some 
      N,N-disubstituted glycolamide esters of aspirin are highlighted with respect to 
      their use as potential aspirin prodrugs.
FAU - Nielsen, N M
AU  - Nielsen NM
AD  - Royal Danish School of Pharmacy, Department of Pharmaceutical Chemistry AD, 
      Copenhagen.
FAU - Bundgaard, H
AU  - Bundgaard H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Esters)
RN  - 0 (Glycolates)
RN  - 0 (Prodrugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemical synthesis/pharmacokinetics
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Esters/chemical synthesis/pharmacokinetics
MH  - Glycolates/chemical synthesis/pharmacokinetics
MH  - Humans
MH  - Hydrolysis
MH  - Prodrugs/*chemical synthesis/pharmacokinetics
MH  - Solubility
MH  - Structure-Activity Relationship
EDAT- 1989/03/01 00:00
MHDA- 1989/03/01 00:01
CRDT- 1989/03/01 00:00
PHST- 1989/03/01 00:00 [pubmed]
PHST- 1989/03/01 00:01 [medline]
PHST- 1989/03/01 00:00 [entrez]
AID - 10.1021/jm00123a040 [doi]
PST - ppublish
SO  - J Med Chem. 1989 Mar;32(3):727-34. doi: 10.1021/jm00123a040.

PMID- 15545617
OWN - NLM
STAT- MEDLINE
DCOM- 20050405
LR  - 20131121
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 114
IP  - 6
DP  - 2004 Dec
TI  - Treatment of acute Kawasaki disease: aspirin's role in the febrile stage 
      revisited.
PG  - e689-93
AB  - OBJECTIVE: To evaluate the effect of treatment without aspirin in the acute phase 
      of Kawasaki disease (KD) and to determine whether it is necessary to expose 
      children to high- or medium-dose aspirin. METHODS: A total of 162 patients who 
      fulfilled the established criteria of acute KD between 1993 and 2003 were 
      included in this retrospective study. All patients were treated with high-dose 
      intravenous immunoglobulin (IVIG; 2 g/kg) as a single infusion without 
      concomitant aspirin treatment. Low-dose aspirin (3-5 mg/kg per day) was 
      subsequently prescribed when fever subsided. Patients who had defervescence 
      within 3 days after the completion of IVIG treatment were classified as the 
      IVIG-responsive group, and those whose fever persisted for >3 days were 
      classified as the IVIG-nonresponsive group. The 162 patients were divided further 
      into 2 groups: those who were treated with IVIG before illness day 5, and those 
      who were treated after illness day 5. We compared the response rate of IVIG 
      therapy, duration of fever, and incidence of coronary artery abnormalities (CAAs) 
      between these groups. RESULTS: A total of 153 patients were classified into the 
      IVIG-responsive group, and 128 (83.66%) of them had defervescence within 24 hours 
      after completion of IVIG therapy. Nine (5.56%) patients were classified into the 
      IVIG nonresponsive group, and all received additional IVIG (2 g/kg) without 
      aspirin. Six (66.67%) had defervescence within 3 days after additional therapy. 
      Patients in the IVIG-nonresponsive group had a significantly higher incidence of 
      CAAs than those in the IVIG-responsive group (25% vs 2.92%). In the group that 
      was treated before illness day 5 (n = 16), all patients had defervescence within 
      3 days after IVIG therapy and 13 (81.25%) had defervescence within 24 hours. In 
      the group that was treated after illness day 5 (n = 146), 137 (93.84%) patients 
      had defervescence within 3 days and 115 (78.77%) had defervescence within 24 
      hours. One (6.67%) patient in the group that was treated before illness day 5 got 
      a new onset of CAAs, as did 5 (3.85%) in the group that was treated after illness 
      day 5. There was no statistically significant difference in the response rate of 
      IVIG therapy, duration of fever, and incidence of CAAs between these 2 groups. 
      CONCLUSION: The results of our study indicate that the treatment without aspirin 
      in acute stage of KD had no effect on the response rate of IVIG therapy, duration 
      of fever, or incidence of CAAs when children were treated with high-dose (2 g/kg) 
      IVIG as a single infusion, despite treatment before or after day 5 of illness. We 
      conclude that it seems unnecessary to expose children to high- or medium-dose 
      aspirin therapy in acute KD when the available data show no appreciable benefit 
      in preventing the failure of IVIG therapy, formation of CAAs, or shortening the 
      duration of fever.
FAU - Hsieh, Kai-Sheng
AU  - Hsieh KS
AD  - Department of Pediatrics, Veterans General Hospital-Kaohsiung, National Yang-Ming 
      University, Kaohsiung, Taiwan.
FAU - Weng, Ken-Pen
AU  - Weng KP
FAU - Lin, Chu-Chuan
AU  - Lin CC
FAU - Huang, Ta-Cheng
AU  - Huang TC
FAU - Lee, Cheng-Liang
AU  - Lee CL
FAU - Huang, Shih-Ming
AU  - Huang SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20041115
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Coronary Disease/etiology/*prevention & control
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fever/*drug therapy/etiology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/complications/*drug therapy
MH  - Retrospective Studies
EDAT- 2004/11/17 09:00
MHDA- 2005/04/06 09:00
CRDT- 2004/11/17 09:00
PHST- 2004/11/17 09:00 [pubmed]
PHST- 2005/04/06 09:00 [medline]
PHST- 2004/11/17 09:00 [entrez]
AID - peds.2004-1037 [pii]
AID - 10.1542/peds.2004-1037 [doi]
PST - ppublish
SO  - Pediatrics. 2004 Dec;114(6):e689-93. doi: 10.1542/peds.2004-1037. Epub 2004 Nov 
      15.

PMID- 2326776
OWN - NLM
STAT- MEDLINE
DCOM- 19900524
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 57
IP  - 4
DP  - 1990 Feb 15
TI  - Local prevention of thrombosis in animal arteries by means of magnetic targeting 
      of aspirin-loaded red cells.
PG  - 611-6
AB  - Thrombosis was induced in 18 dog and 16 rabbit arteries by surgically inverting a 
      vascular wall flap into its lumen. A completely occluding red thrombus was formed 
      inside the vessel 4 to 5 hours later in 80% of cases. SmCo5 magnet was secured 
      externally to one of the arteries. The constant magnetic field produced by the 
      magnet had no influence on the clot formation. Autologous red cells loaded with 
      ferromagnetic colloid compound and aspirin were administered intravenously and 
      completely aborted arteriothrombosis on magnet-supplied side with no 
      deterioratory effect on clot formation in the control artery.
FAU - Orekhova, N M
AU  - Orekhova NM
AD  - Institute of Experimental Cardiology, USSR Cardiology Research Center, Academy of 
      Medical Sciences, Moscow.
FAU - Akchurin, R S
AU  - Akchurin RS
FAU - Belyaev, A A
AU  - Belyaev AA
FAU - Smirnov, M D
AU  - Smirnov MD
FAU - Ragimov, S E
AU  - Ragimov SE
FAU - Orekhov, A N
AU  - Orekhov AN
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Drug Carriers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Dogs
MH  - Drug Carriers
MH  - Erythrocyte Transfusion
MH  - *Magnetics
MH  - Male
MH  - Rabbits
MH  - Thrombosis/etiology/*prevention & control
MH  - Vascular Surgical Procedures
EDAT- 1990/02/15 00:00
MHDA- 1990/02/15 00:01
CRDT- 1990/02/15 00:00
PHST- 1990/02/15 00:00 [pubmed]
PHST- 1990/02/15 00:01 [medline]
PHST- 1990/02/15 00:00 [entrez]
AID - 10.1016/0049-3848(90)90078-q [doi]
PST - ppublish
SO  - Thromb Res. 1990 Feb 15;57(4):611-6. doi: 10.1016/0049-3848(90)90078-q.

PMID- 31098917
OWN - NLM
STAT- MEDLINE
DCOM- 20200403
LR  - 20200403
IS  - 1179-1942 (Electronic)
IS  - 0114-5916 (Linking)
VI  - 42
IP  - 9
DP  - 2019 Sep
TI  - Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care 
      Unit: A Systematic Review and Meta-Analysis.
PG  - 1035-1044
LID - 10.1007/s40264-019-00829-y [doi]
AB  - INTRODUCTION: There is an increased risk of potential drug-drug interactions 
      (pDDIs) in critically ill patients based on the number of drugs received. The 
      occurrence of pDDIs and clinical significance is not well described. OBJECTIVE: 
      The aim was to provide insight into important clinical issues and offer guidance 
      on drug-drug interaction (DDI) surveillance through the performance of a 
      systematic review. METHODS: Five targeted objectives were developed, a priori, 
      which guided study selection and data abstraction. Two independent reviewers 
      extracted the definition, frequency, type, and clinical significance of pDDIs. A 
      meta-analysis was performed to evaluate the proportion of patients exposed to a 
      pDDI. Three data sources (PubMed, Embase, and Scopus) were utilized for the 
      search to include studies that evaluated pDDIs in adult critically ill patients. 
      Included studies in the systematic review and meta-analysis were required to be 
      full text. RESULTS: A total of 39 studies met inclusion criteria. Definitions of 
      pDDIs were diverse. Frequency of pDDIs varied by study, but was most commonly 
      between one and five pDDIs per patient. Fifty-eight percent of patients were 
      exposed to at least one pDDI during their intensive care unit admission. Types of 
      pDDIs identified were numerous, with aspirin being the most common drug involved. 
      As expected, not all pDDIs were clinically significant. Clinical significance was 
      determined by varied definitions and sources. CONCLUSIONS: Improving the 
      understanding of clinically significant pDDIs and alerts that clinicians 
      encounter may guide better development of surveillance through clinical decision 
      support and decrease alert fatigue.
FAU - Fitzmaurice, Mary Grace
AU  - Fitzmaurice MG
AD  - Department of Pharmacy and Therapeutics, University of Pittsburgh, 303 Baum, 4B- 
      4, 5607, Baum Boulevard, Pittsburgh, PA, 15206, USA.
FAU - Wong, Adrian
AU  - Wong A
AD  - Department of Pharmacy and Therapeutics, University of Pittsburgh, 303 Baum, 4B- 
      4, 5607, Baum Boulevard, Pittsburgh, PA, 15206, USA.
AD  - Department of Pharmacy and Therapeutics, MCPHS University, 179 Longwood Avenue, 
      Boston, MA, USA.
FAU - Akerberg, Hannah
AU  - Akerberg H
AD  - Department of Pharmacy and Therapeutics, University of Pittsburgh, 303 Baum, 4B- 
      4, 5607, Baum Boulevard, Pittsburgh, PA, 15206, USA.
FAU - Avramovska, Simona
AU  - Avramovska S
AD  - Department of Pharmacy and Therapeutics, University of Pittsburgh, 303 Baum, 4B- 
      4, 5607, Baum Boulevard, Pittsburgh, PA, 15206, USA.
FAU - Smithburger, Pamela L
AU  - Smithburger PL
AD  - Department of Pharmacy and Therapeutics, University of Pittsburgh, 303 Baum, 4B- 
      4, 5607, Baum Boulevard, Pittsburgh, PA, 15206, USA.
AD  - Department of Pharmacy, UPMC Presbyterian, 200 Lothrop Street, Pittsburgh, PA, 
      USA.
FAU - Buckley, Mitchell S
AU  - Buckley MS
AD  - Department of Pharmacy, Banner-University Medical Center Phoenix, 1111 E. 
      McDowell Road, Phoenix, AZ, USA.
FAU - Kane-Gill, Sandra L
AU  - Kane-Gill SL
AUID- ORCID: 0000-0001-7523-4846
AD  - Department of Pharmacy, UPMC Presbyterian, 200 Lothrop Street, Pittsburgh, PA, 
      USA. kane-gill@pitt.edu.
AD  - Department of Pharmacy and Therapeutics, Critical Care Medicine, Biomedical 
      Informatics and Clinical Translational Science Institute, University of 
      Pittsburgh, 638 Salk Hall, 3501 Terrace Street, Pittsburgh, PA, 15213, USA. 
      kane-gill@pitt.edu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Drug Saf. 2020 Feb;43(2):193. PMID: 31997287
CIN - Drug Saf. 2020 Feb;43(2):195-196. PMID: 31997288
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects
MH  - *Decision Support Systems, Clinical
MH  - *Drug Interactions
MH  - Humans
MH  - *Intensive Care Units
EDAT- 2019/05/18 06:00
MHDA- 2020/04/04 06:00
CRDT- 2019/05/18 06:00
PHST- 2019/05/18 06:00 [pubmed]
PHST- 2020/04/04 06:00 [medline]
PHST- 2019/05/18 06:00 [entrez]
AID - 10.1007/s40264-019-00829-y [pii]
AID - 10.1007/s40264-019-00829-y [doi]
PST - ppublish
SO  - Drug Saf. 2019 Sep;42(9):1035-1044. doi: 10.1007/s40264-019-00829-y.

PMID- 1057921
OWN - NLM
STAT- MEDLINE
DCOM- 19751122
LR  - 20190823
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 5
IP  - 2
DP  - 1975 Apr
TI  - Reduction of platelet/fibrin deposition in haemodialysers by aspirin 
      administration.
PG  - 117-22
AB  - Aspirin, a drug known to inhibit the platelet release reaction, was evaluated for 
      its potential in reducing platelet/fibrin deposition in hollow fibre dialysers. 
      Twelve patients with endstage renal failure were given the drug under controlled 
      conditions while being treated by regular maintenance haemodialysis. After 
      base-line data were collected during a mean number of 11.7 dialysers per study, 
      observations were repeated for a mean of 9.3 dialysers, during which time each 
      patient took 600 mg of aspirin by mouth every morning. Thrombus deposition, 
      measured by volume loss of the blood compartment of the dialyser fibre bundle, 
      was significantly reduced (P less than 0.05) during aspirin administration in six 
      of the 12 studies. The mean volume loss of the fibre bundle in these six studies 
      (responders) was 25% per dialysis during the control period, and 13% with 
      aspirin; in the other six studies (non-responders), the mean values were 8% and 
      6% respectively. Aspirin prolonged the bleeding time in all patients, and 
      significantly (p less than 0.05) impaired platelet aggregation in both responders 
      and non-responders.
FAU - Stewart, J H
AU  - Stewart JH
FAU - Farrell, P C
AU  - Farrell PC
FAU - Dixon, M
AU  - Dixon M
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 9001-31-4 (Fibrin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Tests
MH  - *Blood Platelets
MH  - Depression, Chemical
MH  - Female
MH  - *Fibrin
MH  - Humans
MH  - *Kidneys, Artificial
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Renal Dialysis
MH  - Time Factors
EDAT- 1975/04/01 00:00
MHDA- 1975/04/01 00:01
CRDT- 1975/04/01 00:00
PHST- 1975/04/01 00:00 [pubmed]
PHST- 1975/04/01 00:01 [medline]
PHST- 1975/04/01 00:00 [entrez]
AID - 10.1111/j.1445-5994.1975.tb03639.x [doi]
PST - ppublish
SO  - Aust N Z J Med. 1975 Apr;5(2):117-22. doi: 10.1111/j.1445-5994.1975.tb03639.x.

PMID- 3799752
OWN - NLM
STAT- MEDLINE
DCOM- 19870217
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 156
IP  - 1
DP  - 1987 Jan
TI  - Effect of low-dose aspirin on angiotensin II pressor response in human pregnancy.
PG  - 193-4
AB  - Recent clinical studies have reported a significant reduction in the incidence of 
      pregnancy-induced hypertension after the ingestion of low-dose aspirin. The 
      effect of 80 mg of acetylsalicylic acid on vascular sensitivity to exogenous 
      angiotensin II (Hypertensin, Ciba-Geigy Limited, Basel, Switzerland) was examined 
      in 13 normotensive pregnant patients. The effective pressor dose before treatment 
      (17.4 +/- 2.2 ng/kg/min) (mean +/- SE) was significantly less (p less than 0.001) 
      than that after treatment (35.1 +/- 4.2 ng/kg/min). Low-dose aspirin therapy 
      resulted in an enhancement of the pregnancy-acquired refractoriness to 
      angiotensin II. It can be speculated that prostaglandin synthetase inhibitors at 
      a low dose may alter the thromboxane A2/prostacyclin ratio in favor of the 
      latter.
FAU - Sanchez-Ramos, L
AU  - Sanchez-Ramos L
FAU - O'Sullivan, M J
AU  - O'Sullivan MJ
FAU - Garrido-Calderon, J
AU  - Garrido-Calderon J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 11128-99-7 (Angiotensin II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin II/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Female
MH  - Humans
MH  - Pregnancy/*physiology
MH  - Time Factors
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 0002-9378(87)90236-5 [pii]
AID - 10.1016/0002-9378(87)90236-5 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1987 Jan;156(1):193-4. doi: 10.1016/0002-9378(87)90236-5.

PMID- 30411180
OWN - NLM
STAT- MEDLINE
DCOM- 20190507
LR  - 20200227
IS  - 1573-2649 (Electronic)
IS  - 0962-9343 (Print)
IS  - 0962-9343 (Linking)
VI  - 28
IP  - 4
DP  - 2019 Apr
TI  - Quality of Life for 19,114 participants in the ASPREE (ASPirin in Reducing Events 
      in the Elderly) study and their association with sociodemographic and modifiable 
      lifestyle risk factors.
PG  - 935-946
LID - 10.1007/s11136-018-2040-z [doi]
AB  - PURPOSE: To explore the relationship between sociodemographic and lifestyle 
      variables with health-related quality of life (HRQoL) of a large cohort of 
      'healthy' older individuals. METHODS: The sample included individuals aged 65+ 
      years from Australia (N = 16,703) and the USA (N = 2411) enrolled in the ASPirin 
      in Reducing Events in the Elderly (ASPREE) multicentre placebo-controlled trial 
      study and free of cardiovascular disease, dementia, serious physical disabilities 
      or 'fatal' illnesses. The associations with the physical (PCS) and mental 
      component scores (MCS) of HRQoL (SF-12 questionnaire) were explored using 
      multiple linear regression models from data collected at baseline (2010-2014). 
      RESULTS: The adjusted PCS mean was slightly higher in the USA (49.5 ± 9.1) than 
      Australia (48.2 ± 11.6; p < 0.001), but MCS was similar in both samples 
      (55.7 ± 7.5 and 55.7 ± 9.6, respectively; p = 0.603). Males, younger 
      participants, better educated, more active individuals, or those currently 
      drinking 1-2 alcoholic drinks/day showed a better HRQoL (results more evident for 
      PCS than MCS), while current heavy smokers had the lowest physical HRQoL in both 
      countries. Neither age, walking time, nor alcohol intake was associated with MCS 
      in either cohort. CONCLUSIONS: Baseline HRQoL of ASPREE participants was higher 
      than that reported in population-based studies of older individuals, but the 
      associations between sociodemographic and lifestyle variables were consistent 
      with the published literature. As the cohort ages and develops chronic diseases, 
      ASPREE will be able to document HRQoL changes.
FAU - Stocks, Nigel P
AU  - Stocks NP
AD  - Discipline of General Practice, Adelaide Medical School, The University of 
      Adelaide, Level 1, Helen Mayo North, Frome Road, North Tce Campus, Adelaide, SA, 
      5005, Australia. nigel.stocks@adelaide.edu.au.
FAU - González-Chica, David A
AU  - González-Chica DA
AUID- ORCID: 0000-0002-7153-2878
AD  - Discipline of General Practice, Adelaide Medical School, The University of 
      Adelaide, Level 1, Helen Mayo North, Frome Road, North Tce Campus, Adelaide, SA, 
      5005, Australia.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
FAU - Lockery, Jessica E
AU  - Lockery JE
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
FAU - Wolfe, Rory S J
AU  - Wolfe RSJ
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
FAU - Murray, Anne M
AU  - Murray AM
AD  - Berman Center for Outcomes and Clinical Research, Minneapolis Medical Research 
      Foundation, Hennepin County Medical Center, Minneapolis, MN, USA.
FAU - Kirpach, Brenda
AU  - Kirpach B
AD  - Berman Center for Outcomes and Clinical Research, Minneapolis Medical Research 
      Foundation, Hennepin County Medical Center, Minneapolis, MN, USA.
FAU - Shah, Raj C
AU  - Shah RC
AD  - Department of Family Medicine and Rush Alzheimer's Disease Center, Rush 
      University Medical Center, Chicago, IL, USA.
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 
      Australia.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
AD  - School of Public Health, Curtin University, Perth, WA, Australia.
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - Department of Pharmacy Practice and Science, College of Pharmacy, Department of 
      Family Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, 
      USA.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
CN  - ASPREE Investigator Group
LA  - eng
GR  - U19 AG062682/AG/NIA NIH HHS/United States
GR  - 1127060/National Health and Medical Research Council of Australia (AU)/
GR  - U01AG029824/AG/NIA NIH HHS/United States
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - 334047/National Health and Medical Research Council of Australia (AU)/
PT  - Journal Article
PT  - Multicenter Study
DEP - 20181108
PL  - Netherlands
TA  - Qual Life Res
JT  - Quality of life research : an international journal of quality of life aspects of 
      treatment, care and rehabilitation
JID - 9210257
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Life Style
MH  - Male
MH  - Quality of Life/*psychology
MH  - Risk Factors
MH  - Surveys and Questionnaires
PMC - PMC6924574
MID - NIHMS1051549
OTO - NOTNLM
OT  - Global health
OT  - Health status
OT  - Health-related quality of life
OT  - Mental health
OT  - Social Determinants of Health
COIS- Conflict of interest The authors declare that they have no conflict of interest.
EDAT- 2018/11/10 06:00
MHDA- 2019/05/08 06:00
CRDT- 2018/11/10 06:00
PHST- 2018/10/31 00:00 [accepted]
PHST- 2018/11/10 06:00 [pubmed]
PHST- 2019/05/08 06:00 [medline]
PHST- 2018/11/10 06:00 [entrez]
AID - 10.1007/s11136-018-2040-z [pii]
AID - 10.1007/s11136-018-2040-z [doi]
PST - ppublish
SO  - Qual Life Res. 2019 Apr;28(4):935-946. doi: 10.1007/s11136-018-2040-z. Epub 2018 
      Nov 8.

PMID- 3501162
OWN - NLM
STAT- MEDLINE
DCOM- 19880202
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 117
IP  - 43
DP  - 1987 Oct 24
TI  - [Dipyridamole and low-dose aspirin in patients with aortocoronary 
      bypass--comparison with anticoagulation].
PG  - 1688-92
AB  - The effects of antiplatelet therapy (AP; dipyridamole 400 mg [beginning 2 days 
      preoperatively] + aspirin 50 mg/day) and anticoagulation (AC) were compared 
      prospectively in 251 patients with coronary artery bypass grafting (CABG). Two 
      weeks postoperatively, 85.2% of AP and 81% of AC patients had all grafts patent 
      with graft patency rates of 93.6% and 91.3% respectively (p = n.s.) Significant 
      differences in favour of AP therapy were found in subgroups with multiple grafts 
      and with low intraoperative graft flow. Up to 3 months postoperatively, severe 
      complications occurred in 22 AC patients (11 bleedings) but only in 9 patients on 
      AP therapy (p less than 0.01). Overall, AP therapy should therefore be preferred 
      to AC in patients with CABG surgery.
FAU - Pfisterer, M
AU  - Pfisterer M
AD  - Department für Innere Medizin, Universitätsspital Basel.
FAU - Jockers, G
AU  - Jockers G
FAU - Burkart, F
AU  - Burkart F
FAU - Schmitt, H E
AU  - Schmitt HE
FAU - Wolff, G
AU  - Wolff G
FAU - Skarvan, K
AU  - Skarvan K
FAU - Stulz, P
AU  - Stulz P
FAU - Hasse, J
AU  - Hasse J
FAU - Grädel, E
AU  - Grädel E
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Dipyridamol und niedrig dosiertes Aspirin bei Patienten mit aortokoronarem 
      Bypass--Vergleich mit der Antikoagulation.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 0 (Anticoagulants)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Postoperative Care
EDAT- 1987/10/24 00:00
MHDA- 1987/10/24 00:01
CRDT- 1987/10/24 00:00
PHST- 1987/10/24 00:00 [pubmed]
PHST- 1987/10/24 00:01 [medline]
PHST- 1987/10/24 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1987 Oct 24;117(43):1688-92.

PMID- 18160361
OWN - NLM
STAT- MEDLINE
DCOM- 20080221
LR  - 20131121
IS  - 1308-0032 (Electronic)
IS  - 1302-8723 (Linking)
VI  - 7 Suppl 2
DP  - 2007 Dec
TI  - [Aspirin in patients undergoing percutaneous coronary intervention].
PG  - 9-13
AB  - Prophylactic use of aspirin at doses between 75 to 162 mg/d is a class I 
      indication for all patients with stable coronary artery disease unless there is a 
      contraindication. However, some studies suggest that long-term treatment with low 
      dose aspirin is associated with a progressive reduction in platelet sensitivity 
      to this drug. Given that percutaneous coronary stent implantation causes vascular 
      injury with a subsequent activation of platelets and proinflammatory cytokines, 
      some investigators suggest that higher aspirin doses should be considered for 
      patients undergoing stent implantation. However, randomized clinical studies 
      failed to show any benefit of additional high dose aspirin on top of standard low 
      dose regimen before elective stent implantation. On the other hand, for those 
      treated with drug-eluting stents aspirin is recommended at relatively higher 
      doses (325 mg/d) started before the procedure and continue for up to 6 months 
      after the intervention. Although, 325 mg/d is the dose preferred in clinical 
      trials one may argue that lower doses can be as effective. Indeed, subgroup 
      analysis of CURE trial demonstrated that aspirin at doses >100 mg/d increases 
      bleeding complications without any additional reduction in cardiovascular events. 
      In summary, although aspirin is recommended for every patient with coronary 
      artery disease, its optimal dose for patients who underwent stent implantation is 
      still not clear.
FAU - Güleç, Sadi
AU  - Güleç S
AD  - Ankara Universitesi Tip Fakültesi Kardiyoloji Anabilim Dali, Ankara, Türkiye. 
      gulec99@yahoo.com
LA  - tur
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Perkütan koroner girişim uygulanan hastalarda aspirin.
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Drug Administration Schedule
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/*therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - *Stents
RF  - 30
EDAT- 2008/02/09 09:00
MHDA- 2008/02/22 09:00
CRDT- 2008/02/09 09:00
PHST- 2008/02/09 09:00 [pubmed]
PHST- 2008/02/22 09:00 [medline]
PHST- 2008/02/09 09:00 [entrez]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2007 Dec;7 Suppl 2:9-13.

PMID- 6436507
OWN - NLM
STAT- MEDLINE
DCOM- 19841219
LR  - 20190919
IS  - 0140-7783 (Print)
IS  - 0140-7783 (Linking)
VI  - 7
IP  - 3
DP  - 1984 Sep
TI  - Gastro-intestinal motor disturbances induced by lysine-acetylsalicylate treatment 
      in sheep.
PG  - 189-95
AB  - The effects of intravenous (i.v.), intramuscular (i.m.) and oral administration 
      of lysine-acetylsalicylate (Lys-ASA) on gastro-intestinal motility were 
      investigated in sheep using electromyography. A dose of 20 mg/kg Lys-ASA 
      intravenously reduced the frequency of reticular contractions for 86 +/- 18 min, 
      produced abomasal hypomotility and caused a disruption of the cyclical pattern of 
      intestinal motility for at least 120 min. The frequency of reticular contractions 
      measured from 20 to 30 min after Lys-ASA administration was negatively correlated 
      (r = 0.97; P less than 0.01) to the log of the dose used for doses varying from 
      10 to 40 mg/kg. Similar effects were observed with intramuscular and oral dose 
      rates of 40 and 80 mg/kg, respectively. Previous i.v. administration of 
      phentolamine (0.1 mg/kg) or tolazoline (2 mg/kg) abolished the effects of Lys-ASA 
      (20 mg/kg) administered intravenously on both reticular contractions and 
      abomaso-intestinal motility. It was concluded that Lys-ASA administered at 
      therapeutic doses in sheep produced gastro-intestinal motor disturbances and that 
      alpha- and alpha 2-adrenergic antagonists are able to block them.
FAU - Honde, C
AU  - Honde C
FAU - Buéno, L
AU  - Buéno L
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - CHH9H12AQ3 (Tolazoline)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - Z468598HBV (Phentolamine)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology/therapeutic 
      use
MH  - Electromyography
MH  - Female
MH  - Gastrointestinal Motility/*drug effects
MH  - Lysine/administration & dosage/*analogs & derivatives/pharmacology/therapeutic 
      use
MH  - Phentolamine/administration & dosage/pharmacology
MH  - Sheep
MH  - Sheep Diseases/*chemically induced
MH  - Tolazoline/administration & dosage/pharmacology
EDAT- 1984/09/01 00:00
MHDA- 1984/09/01 00:01
CRDT- 1984/09/01 00:00
PHST- 1984/09/01 00:00 [pubmed]
PHST- 1984/09/01 00:01 [medline]
PHST- 1984/09/01 00:00 [entrez]
AID - 10.1111/j.1365-2885.1984.tb00899.x [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 1984 Sep;7(3):189-95. doi: 
      10.1111/j.1365-2885.1984.tb00899.x.

PMID- 34808706
OWN - NLM
STAT- MEDLINE
DCOM- 20220325
LR  - 20220630
IS  - 2055-5822 (Electronic)
IS  - 2055-5822 (Linking)
VI  - 9
IP  - 1
DP  - 2022 Feb
TI  - Aspirin use is associated with increased risk for incident heart failure: a 
      patient-level pooled analysis.
PG  - 685-694
LID - 10.1002/ehf2.13688 [doi]
AB  - AIMS: Recent trials evaluating the effect of aspirin in the primary prevention of 
      cardiovascular disease showed little or no benefit. However, the role of aspirin 
      on the risk of incident heart failure (HF) remains elusive. This study aimed to 
      evaluate the role of aspirin use on HF incidence in primary and secondary 
      prevention and whether aspirin use increases the risk of incident HF in patients 
      at risk. METHODS AND RESULTS: Data from 30 827 patients at risk for HF enrolled 
      in six observational studies were analysed [women 33.9%, mean age (±standard 
      deviation) 66.8 ± 9.2 years]. Cardiovascular risk factors and aspirin use were 
      recorded at baseline, and patients were followed up for the first incident of 
      fatal or non-fatal HF. The association of incident HF with aspirin use was 
      assessed using multivariable-adjusted proportional hazard regression, which 
      accounted for study and cardiovascular risk factors. Over 5.3 years (median; 
      5th-95th percentile interval, 2.1-11.7 years), 1330 patients experienced HF. The 
      fully adjusted hazard ratio (HR) associated with aspirin use was 1.26 [95% 
      confidence interval (CI) 1.12-1.41; P ≤ 0.001]. Further, in a 
      propensity-score-matched analysis, the HR was 1.26 (95% CI 1.10-1.44; P ≤ 0.001). 
      In 22 690 patients (73.6%) without history of cardiovascular disease, the HR was 
      1.27 (95% CI 1.10-1.46; P = 0.001). CONCLUSIONS: In patients, at risk, aspirin 
      use was associated with incident HF, independent of other risk factors. In the 
      absence of conclusive trial evidence, our observations suggest that aspirins 
      should be prescribed with caution in patients at risk of HF or having HF.
CI  - © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on 
      behalf of European Society of Cardiology.
FAU - Mujaj, Blerim
AU  - Mujaj B
AUID- ORCID: 0000-0001-5831-0800
AD  - Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular 
      Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of 
      Leuven, Leuven, Belgium.
AD  - Department of Diagnostic and Interventional Radiology, University Centre, Faculty 
      of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Zhang, Zhen-Yu
AU  - Zhang ZY
AUID- ORCID: 0000-0002-3785-7417
AD  - Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular 
      Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of 
      Leuven, Leuven, Belgium.
FAU - Yang, Wen-Yi
AU  - Yang WY
AUID- ORCID: 0000-0003-1279-0866
AD  - Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular 
      Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of 
      Leuven, Leuven, Belgium.
FAU - Thijs, Lutgarde
AU  - Thijs L
AUID- ORCID: 0000-0002-8108-2356
AD  - Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular 
      Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of 
      Leuven, Leuven, Belgium.
FAU - Wei, Fang-Fei
AU  - Wei FF
AUID- ORCID: 0000-0002-9135-1660
AD  - Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular 
      Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of 
      Leuven, Leuven, Belgium.
FAU - Verhamme, Peter
AU  - Verhamme P
AUID- ORCID: 0000-0001-8698-2858
AD  - Centre for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular 
      Sciences, University of Leuven, Leuven, Belgium.
FAU - Delles, Christian
AU  - Delles C
AUID- ORCID: 0000-0003-2238-2612
AD  - Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular 
      Research Centre, University of Glasgow, Glasgow, UK.
FAU - Butler, Javed
AU  - Butler J
AUID- ORCID: 0000-0001-7683-4720
AD  - Department of Medicine, University of Mississippi Medical Centre, Jackson, MS, 
      USA.
FAU - Sever, Peter
AU  - Sever P
AUID- ORCID: 0000-0003-0421-2409
AD  - International Centre for Circulatory Health and National Heart and Lung 
      Institute, Imperial College London, London, UK.
FAU - Latini, Roberto
AU  - Latini R
AUID- ORCID: 0000-0002-3729-4650
AD  - Department of Cardiovascular Medicine, IRCCS - Istituto di Ricerche 
      Farmacologiche "Mario Negri", Milan, Italy.
FAU - Gf Cleland, John
AU  - Gf Cleland J
AUID- ORCID: 0000-0002-1471-7016
AD  - Cardiology Department, Castle Hill Hospital, University of Hull and Imperial 
      College London, London, UK.
FAU - Zannad, Faiez
AU  - Zannad F
AUID- ORCID: 0000-0001-7456-1570
AD  - INSERM, Centre d'Investigations Cliniques Plurithe'matique 1433, INSERM U1116, 
      CHRU de Nancy, F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.
FAU - Staessen, Jan A
AU  - Staessen JA
AUID- ORCID: 0000-0002-3026-1637
AD  - Research Institute Alliance for the Promotion of Preventive Medicine (APPREMED), 
      Mechelen, Belgium.
AD  - Biomedical Science Group, University of Leuven, Leuven, Belgium.
CN  - Heart Omics in Ageing Investigators
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20211122
PL  - England
TA  - ESC Heart Fail
JT  - ESC heart failure
JID - 101669191
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circ Heart Fail. 2022 Jun;15(6):e009511. PMID: 35727884
MH  - Aged
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/complications/epidemiology/prevention & control
MH  - Female
MH  - *Heart Failure/complications/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Observational Studies as Topic
MH  - Risk Factors
PMC - PMC8787993
OTO - NOTNLM
OT  - Aspirin use
OT  - Cardiovascular diseases
OT  - Heart failure
OT  - Primary prevention
OT  - Secondary prevention
COIS- None declared.
EDAT- 2021/11/23 06:00
MHDA- 2022/03/26 06:00
CRDT- 2021/11/22 20:33
PHST- 2021/10/05 00:00 [revised]
PHST- 2021/01/09 00:00 [received]
PHST- 2021/10/14 00:00 [accepted]
PHST- 2021/11/23 06:00 [pubmed]
PHST- 2022/03/26 06:00 [medline]
PHST- 2021/11/22 20:33 [entrez]
AID - EHF213688 [pii]
AID - 10.1002/ehf2.13688 [doi]
PST - ppublish
SO  - ESC Heart Fail. 2022 Feb;9(1):685-694. doi: 10.1002/ehf2.13688. Epub 2021 Nov 22.

PMID- 21062358
OWN - NLM
STAT- MEDLINE
DCOM- 20110613
LR  - 20181201
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 26
IP  - 3
DP  - 2011 Mar
TI  - Aspirin: old drug, new uses and challenges.
PG  - 426-31
LID - 10.1111/j.1440-1746.2010.06569.x [doi]
AB  - Salicylates have been used since antiquity to relieve pain and inflammation. 
      However, it has been only in the last half century that evidence has emerged that 
      aspirin causes reproducible acute and superficial injury to the gastric and 
      duodenal mucosa, and is an important cause of complicated and uncomplicated 
      peptic ulcer. Superficial damage to the mucosa occurs rapidly and reproducibly 
      and acid and pepsin then produce a second wave of deeper injury. Most of the time 
      this heals rapidly, but some focal deeper mucosal lesions (erosions) occur 
      frequently and the point prevalence of frank ulcers in low dose aspirin users is 
      around 10%. It is even more recently that aspirin's unique antiplatelet action 
      has been recognized, with long-lasting inhibition of platelet aggregation due to 
      irreversible inactivation of the cyclooxygenase-1 mediated production of 
      thromboxane. It has now become the mainstay of pharmacological reduction of 
      thrombotic risk in patients with cardiovascular diseases. In addition, evidence 
      is accumulating about the cancer-reducing effects of blocking cyclooxygenase in a 
      number of tissues. For example, recent data indicate that even at a 75-mg/day 
      dose, it may reduce colorectal cancer risk after a lag of a year or so. Because 
      of its widespread use for cardiovascular protection, aspirin is now one of the 
      most frequently prescribed drugs-and gastroenterologists regularly need to deal 
      with its ulcerative complications along the whole length of the gastrointestinal 
      tract. Strategies that can be used to reduce these risks include using the lowest 
      effective aspirin dose and co-prescribing acid suppressants.
CI  - © 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell 
      Publishing Asia Pty Ltd.
FAU - Yeomans, Neville D
AU  - Yeomans ND
AD  - School of Medicine, University of Western Sydney, Sydney, New South Wales, 
      Australia. n.yeomans@uws.edu.au
LA  - eng
PT  - Lecture
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Anticarcinogenic Agents/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cyclooxygenase Inhibitors/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/drug effects/pathology
MH  - Humans
MH  - Intestines/drug effects/pathology
MH  - Peptic Ulcer/chemically induced/pathology/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2010/11/11 06:00
MHDA- 2011/06/15 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
AID - 10.1111/j.1440-1746.2010.06569.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2011 Mar;26(3):426-31. doi: 
      10.1111/j.1440-1746.2010.06569.x.

PMID- 35780223
OWN - NLM
STAT- MEDLINE
DCOM- 20220706
LR  - 20220804
IS  - 1420-9071 (Electronic)
IS  - 1420-682X (Print)
IS  - 1420-682X (Linking)
VI  - 79
IP  - 7
DP  - 2022 Jul 2
TI  - Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms 
      revisited.
PG  - 393
LID - 10.1007/s00018-022-04430-y [doi]
LID - 393
AB  - PIK3CA mutations are amongst the most prevalent somatic mutations in cancer and 
      are associated with resistance to first-line treatment along with low survival 
      rates in a variety of malignancies. There is evidence that patients carrying 
      PIK3CA mutations may benefit from treatment with acetylsalicylic acid, commonly 
      known as aspirin, particularly in the setting of colorectal cancer. In this 
      regard, it has been clarified that Class IA Phosphatidylinositol 3-kinases 
      (PI3K), whose catalytic subunit p110α is encoded by the PIK3CA gene, are involved 
      in signal transduction that regulates cell cycle, cell growth, and metabolism 
      and, if disturbed, induces carcinogenic effects. Although PI3K is associated with 
      pro-inflammatory cyclooxygenase-2 (COX-2) expression and signaling, and COX-2 is 
      among the best-studied targets of aspirin, the mechanisms behind this clinically 
      relevant phenomenon are still unclear. Indeed, there is further evidence that the 
      protective, anti-carcinogenic effect of aspirin in this setting may be mediated 
      in a COX-independent manner. However, until now the understanding of aspirin's 
      prostaglandin-independent mode of action is poor. This review will provide an 
      overview of the current literature on this topic and aims to analyze possible 
      mechanisms and targets behind the aspirin sensitivity of PIK3CA-mutated cancers.
CI  - © 2022. The Author(s).
FAU - Hall, Daniella C N
AU  - Hall DCN
AD  - Department of Clinical Pharmacy and Pharmacotherapy, Institute of Pharmacy, 
      Martin-Luther-University Halle-Wittenberg, Kurt-Mothes-Str. 3, 06120, Halle 
      (Saale), Germany.
FAU - Benndorf, Ralf A
AU  - Benndorf RA
AUID- ORCID: 0000-0001-6493-4521
AD  - Department of Clinical Pharmacy and Pharmacotherapy, Institute of Pharmacy, 
      Martin-Luther-University Halle-Wittenberg, Kurt-Mothes-Str. 3, 06120, Halle 
      (Saale), Germany. ralf.benndorf@pharmazie.uni-halle.de.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220702
PL  - Switzerland
TA  - Cell Mol Life Sci
JT  - Cellular and molecular life sciences : CMLS
JID - 9705402
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - *Class I Phosphatidylinositol 3-Kinases/genetics
MH  - *Colorectal Neoplasms/drug therapy/genetics
MH  - Cyclooxygenase 2/genetics
MH  - Humans
MH  - Mutation/genetics
PMC - PMC9250486
OTO - NOTNLM
OT  - AKT
OT  - Acetylsalicylic acid
OT  - COX
OT  - Cyclooxygenases
OT  - NSAID
OT  - PI3 kinases
OT  - PKB
OT  - Prostaglandin
OT  - Tumor Biology
OT  - Wnt
OT  - mTOR
OT  - β-catenin
COIS- The authors declare that they have no conflict of interest.
EDAT- 2022/07/03 06:00
MHDA- 2022/07/07 06:00
CRDT- 2022/07/02 23:26
PHST- 2022/03/15 00:00 [received]
PHST- 2022/06/14 00:00 [accepted]
PHST- 2022/06/01 00:00 [revised]
PHST- 2022/07/02 23:26 [entrez]
PHST- 2022/07/03 06:00 [pubmed]
PHST- 2022/07/07 06:00 [medline]
AID - 10.1007/s00018-022-04430-y [pii]
AID - 4430 [pii]
AID - 10.1007/s00018-022-04430-y [doi]
PST - epublish
SO  - Cell Mol Life Sci. 2022 Jul 2;79(7):393. doi: 10.1007/s00018-022-04430-y.

PMID- 28341753
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20181202
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 48
IP  - 5
DP  - 2017 May
TI  - Aspirin and Risk of Subarachnoid Hemorrhage: Systematic Review and Meta-Analysis.
PG  - 1210-1217
LID - 10.1161/STROKEAHA.116.015674 [doi]
AB  - BACKGROUND AND PURPOSE: Recent studies have suggested that the use of low-dose 
      aspirin may reduce the risk of aneurysmal subarachnoid hemorrhage (aSAH). We 
      aimed to evaluate any association between aspirin use and risk of aSAH based on 
      the literature, and whether this is influenced by duration or frequency of 
      aspirin use. METHODS: A search of electronic databases was done from inception to 
      September 2016. For each study, data on risk of aSAH in aspirin versus nonaspirin 
      users were used to generate odds ratios and 95% confidence intervals, and 
      combined using inverse variance-weighted averages of logarithmic odds ratios in a 
      random-effects models. RESULTS: From 7 included studies, no significant 
      difference was noted between aspirin use of any duration or frequency and 
      nonaspirin users (odds ratio, 1.00; 95% confidence interval, 0.81-1.24; P=0.99). 
      We found a significant association between short-term use of aspirin (<3 months) 
      and the risk of aSAH (odds ratio, 1.61; 95% confidence interval, 1.20-2.18; 
      P=0.002). No significant difference was found in terms of risk of aSAH for 3 to 
      12 months, 1 to 3 years, and >3 years of durations of use. No significant 
      association was found between infrequent aspirin use (≤2× per week) or frequent 
      use (≥3× per week) with risk of aSAH. CONCLUSIONS: Current evidence suggests that 
      short-term (<3 months) use of aspirin is associated with increased risk of aSAH. 
      Limitations include substantial heterogenity of the included studies. The role of 
      long-term aspirin in reducing risk of aSAH remains unclear and ideally should be 
      addressed by an appropriately designed randomized controlled trial.
CI  - © 2017 American Heart Association, Inc.
FAU - Phan, Kevin
AU  - Phan K
AD  - From the NeuroSpine Surgery Research Group (NSURG), Prince of Wales Private 
      Hospital, Sydney, New South Wales, Australia (K.P.); Sydney Medical School, 
      University of Sydney, New South Wales, Australia (K.P.); Department of 
      Neurosurgery, Stanford University School of Medicine, CA (J.M.M.); and 
      Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA (J.M.M., C.J.G., C.S.O., A.J.T.). kphan.vc@gmail.com.
FAU - Moore, Justin M
AU  - Moore JM
AD  - From the NeuroSpine Surgery Research Group (NSURG), Prince of Wales Private 
      Hospital, Sydney, New South Wales, Australia (K.P.); Sydney Medical School, 
      University of Sydney, New South Wales, Australia (K.P.); Department of 
      Neurosurgery, Stanford University School of Medicine, CA (J.M.M.); and 
      Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA (J.M.M., C.J.G., C.S.O., A.J.T.).
FAU - Griessenauer, Christoph J
AU  - Griessenauer CJ
AD  - From the NeuroSpine Surgery Research Group (NSURG), Prince of Wales Private 
      Hospital, Sydney, New South Wales, Australia (K.P.); Sydney Medical School, 
      University of Sydney, New South Wales, Australia (K.P.); Department of 
      Neurosurgery, Stanford University School of Medicine, CA (J.M.M.); and 
      Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA (J.M.M., C.J.G., C.S.O., A.J.T.).
FAU - Ogilvy, Christopher S
AU  - Ogilvy CS
AD  - From the NeuroSpine Surgery Research Group (NSURG), Prince of Wales Private 
      Hospital, Sydney, New South Wales, Australia (K.P.); Sydney Medical School, 
      University of Sydney, New South Wales, Australia (K.P.); Department of 
      Neurosurgery, Stanford University School of Medicine, CA (J.M.M.); and 
      Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA (J.M.M., C.J.G., C.S.O., A.J.T.).
FAU - Thomas, Ajith J
AU  - Thomas AJ
AD  - From the NeuroSpine Surgery Research Group (NSURG), Prince of Wales Private 
      Hospital, Sydney, New South Wales, Australia (K.P.); Sydney Medical School, 
      University of Sydney, New South Wales, Australia (K.P.); Department of 
      Neurosurgery, Stanford University School of Medicine, CA (J.M.M.); and 
      Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA (J.M.M., C.J.G., C.S.O., A.J.T.).
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20170324
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 2017 Jul;48(7):e184-e185. PMID: 28536171
MH  - Aspirin/*adverse effects/*pharmacology
MH  - Humans
MH  - Subarachnoid Hemorrhage/*chemically induced/*prevention & control
OTO - NOTNLM
OT  - aspirin
OT  - randomized controlled trial
OT  - stroke
OT  - subarachnoid hemorrhage
OT  - thromboembolism
EDAT- 2017/03/28 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/03/26 06:00
PHST- 2016/10/06 00:00 [received]
PHST- 2017/01/15 00:00 [revised]
PHST- 2017/02/01 00:00 [accepted]
PHST- 2017/03/28 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
PHST- 2017/03/26 06:00 [entrez]
AID - STROKEAHA.116.015674 [pii]
AID - 10.1161/STROKEAHA.116.015674 [doi]
PST - ppublish
SO  - Stroke. 2017 May;48(5):1210-1217. doi: 10.1161/STROKEAHA.116.015674. Epub 2017 
      Mar 24.

PMID- 8317687
OWN - NLM
STAT- MEDLINE
DCOM- 19930729
LR  - 20131121
IS  - 0003-2417 (Print)
IS  - 0003-2417 (Linking)
VI  - 42
IP  - 5
DP  - 1993 May
TI  - [Prolongation and normalization of bleeding time during therapy with different 
      doses of acetylsalicylic acid].
PG  - 300-4
AB  - The present study investigated whether there is a statistically significant 
      correlation between platelet aggregation inhibition (TAI) and prolongation of 
      subaqueous bleeding time (SBT) under therapy with 40 mg (n = 20) and 500 mg (n = 
      20) acetylsalicylic acid (ASA) daily and when parameters return to normal after 
      discontinuation of long-term (4 weeks) and short-term (1 week) treatment. The 
      results of this study may be helpful in clinical practice when deciding upon 
      indications for certain operative or anaesthetic procedures. RESULTS. Under ASA 
      treatment, neither TAI nor prolongation of SBT was dependent on dosage or time 
      (Figs. 1-4). After discontinuation of ASA, platelet aggregation returned to 
      normal 1-4 days later than SBT, depending on the dosage and duration of 
      medication. SBT declined to its initial value on the 3rd day following 
      discontinuation of ASA in both dosage groups (Figs. 2 and 4). Normalisation of 
      platelet aggregation depended on dosage: in those groups with 40 mg ASA, 
      thrombocyte aggregation had normalised on the 4th day irrespective of duration of 
      medication; in groups with 500 mg aggregation capacity was completely restored on 
      the 5th day after 1-week therapy and on the 7th day after 4-week therapy (Figs. 1 
      and 3). Considering these results, an important factor is the time of 
      discontinuation of ASA intake. Prior to scheduled operative procedures or 
      regional anaesthetics near the spinal cord, ASA should be discontinued, depending 
      on the dosage, 2-3 days ahead. At this time SBT has reached the initial value, 
      however, the aggregation capacity of thrombocytes is still reduced for a few 
      days.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Epp, K
AU  - Epp K
AD  - Abteilung für Laboratoriumsmedizin, Medizinische Klinik Minden.
FAU - Nolte, H
AU  - Nolte H
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Blutungszeitverlängerung und -normalisierung unter der Therapie mit 
      unterschiedlich dosierter Azetylsalicylsäure.
PL  - Germany
TA  - Anaesthesist
JT  - Der Anaesthesist
JID - 0370525
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Bleeding Time
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Time Factors
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
PST - ppublish
SO  - Anaesthesist. 1993 May;42(5):300-4.

PMID- 2737909
OWN - NLM
STAT- MEDLINE
DCOM- 19890804
LR  - 20190912
IS  - 0363-0269 (Print)
IS  - 0363-0269 (Linking)
VI  - 13
IP  - 2
DP  - 1989
TI  - Thermal stability and cross-linking of Hb New York [beta 113(G15)Val----Glu].
PG  - 147-56
AB  - Hb New York [beta 113(G15)Val----Glu] has been cross-linked with bis 
      (3,5-dibromosalicyl) fumarate, a reagent known to cross-link Lys 82 beta 1 and 
      Lys 82 beta 2. Thermal denaturations of met Hb New York and its derivative have 
      been compared to those of the corresponding Hb A samples. The structural 
      transitions, observed as absorbance changes at 418 nm, were at 40.2 degrees C for 
      Hb New York, 42.2 degrees C for Hb A, 53.7 degrees C for cross-linked Hb New 
      York, and 56.2 degrees C for cross-linked Hb A. Transitions observed at 280 nm 
      were approximately 2 degrees C higher. Thus, a single inter-subunit cross-link 
      can stabilize an abnormal hemoglobin. A model of Hb New York in which Glu beta 
      113 forms a salt bridge to His beta 117 can explain the small changes in both the 
      stability and the electrophoretic mobility of this protein.
FAU - Yang, T
AU  - Yang T
AD  - Department of Chemistry, Loyola University of Chicago, IL 60626.
FAU - Olsen, K W
AU  - Olsen KW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Hemoglobin
JT  - Hemoglobin
JID - 7705865
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins, Abnormal)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 9035-15-8 (hemoglobin New York)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Chromatography, Ion Exchange
MH  - Cross-Linking Reagents/*pharmacology
MH  - Drug Stability
MH  - Electrophoresis
MH  - Hemoglobins, Abnormal/*analysis
MH  - *Hot Temperature
MH  - Humans
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.3109/03630268908998064 [doi]
PST - ppublish
SO  - Hemoglobin. 1989;13(2):147-56. doi: 10.3109/03630268908998064.

PMID- 22470078
OWN - NLM
STAT- MEDLINE
DCOM- 20120612
LR  - 20220410
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 255
IP  - 5
DP  - 2012 May
TI  - Should more patients continue aspirin therapy perioperatively?: clinical impact 
      of aspirin withdrawal syndrome.
PG  - 811-9
LID - 10.1097/SLA.0b013e318250504e [doi]
AB  - OBJECTIVE: To provide an evidence-based focused review of aspirin use in the 
      perioperative period along with an in-depth discussion of the considerations and 
      risks associated with its preoperative withdrawal. BACKGROUND: For patients with 
      established cardiovascular disease, taking aspirin is considered a critical 
      therapy. The cessation of aspirin can cause a platelet rebound phenomenon and 
      prothrombotic state leading to major adverse cardiovascular events. Despite the 
      risks of aspirin withdrawal, which are exacerbated during the perioperative 
      period, standard practice has been to stop aspirin before elective surgery for 
      fear of excessive bleeding. Mounting evidence suggests that this practice should 
      be abandoned. METHODS: We performed a PubMed and Medline literature search using 
      the keywords aspirin, withdrawal, and perioperative. We manually reviewed 
      relevant citations for inclusion. RESULTS/CONCLUSIONS: Clinicians should employ a 
      patient-specific strategy for perioperative aspirin management that weighs the 
      risks of stopping aspirin with those associated with its continuation. Most 
      patients, especially those taking aspirin for secondary cardiovascular 
      prevention, should have their aspirin continued throughout the perioperative 
      period. When aspirin is held preoperatively, the aspirin withdrawal syndrome may 
      significantly increase the risk of a major thromboembolic complication. For many 
      operative procedures, the risk of perioperative bleeding while continuing aspirin 
      is minimal, as compared with the concomitant thromboembolic risks associated with 
      aspirin withdrawal. Those cases where aspirin should be stopped include patients 
      undergoing intracranial, middle ear, posterior eye, intramedullary spine, and 
      possibly transurethral prostatectomy surgery.
FAU - Gerstein, Neal Stuart
AU  - Gerstein NS
AD  - Department of Anesthesiology and Critical Care Medicine, University of New Mexico 
      School of Medicine, Albuquerque, New Mexico 87131, USA. ngerstein@gmail.com
FAU - Schulman, Peter Mark
AU  - Schulman PM
FAU - Gerstein, Wendy Hawks
AU  - Gerstein WH
FAU - Petersen, Timothy Randal
AU  - Petersen TR
FAU - Tawil, Isaac
AU  - Tawil I
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Surg. 2012 May;255(5):820. PMID: 22504186
CIN - J Urol. 2012 Nov;188(5):1810. PMID: 23059227
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiac Surgical Procedures
MH  - Cardiovascular Diseases/prevention & control
MH  - Hemorrhage/*etiology
MH  - Humans
MH  - Mohs Surgery
MH  - Orthopedic Procedures
MH  - *Perioperative Care
MH  - Perioperative Period
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Thrombosis/prevention & control
MH  - Urologic Surgical Procedures
MH  - Vascular Surgical Procedures
EDAT- 2012/04/04 06:00
MHDA- 2012/06/13 06:00
CRDT- 2012/04/04 06:00
PHST- 2012/04/04 06:00 [entrez]
PHST- 2012/04/04 06:00 [pubmed]
PHST- 2012/06/13 06:00 [medline]
AID - 10.1097/SLA.0b013e318250504e [doi]
PST - ppublish
SO  - Ann Surg. 2012 May;255(5):811-9. doi: 10.1097/SLA.0b013e318250504e.

PMID- 9142418
OWN - NLM
STAT- MEDLINE
DCOM- 19971203
LR  - 20190512
IS  - 0007-1188 (Print)
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Linking)
VI  - 120
IP  - 4 Suppl
DP  - 1997 Feb
TI  - Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. 
      1973.
PG  - 401-12; discussion 399-400
AB  - 1. Resting splenic venous outflow from anaesthetized dogs contains 
      prostaglandin-like material: the concentration increases after intra-arterial 
      injections of bradykinin into the spleen, and is abolished by treatment with 
      indomethacin. 2. Intra-arterial injections of bradykinin into the spleen of 
      lightly anaesthetized dogs elicit a dose-dependent reflex increase in the blood 
      pressure, which is reduced but not abolished by treatment with indomethacin. 3. 
      Addition of prostaglandin E(1) or E(2) either by injections or by infusions 
      restores the reflex increase in the blood pressure due to bradykinin injections 
      after indomethacin treatment. 4. The sensitizing action of endogenously released 
      prostaglandins at or near the afferent nerve endings is discussed. 5. The 
      analgesic activity of aspirin-like drugs is explained in terms of the removal of 
      the sensitizing activity of prostaglandins.
FAU - Ferreira, S H
AU  - Ferreira SH
FAU - Moncada, S
AU  - Moncada S
FAU - Vane, J R
AU  - Vane JR
LA  - eng
PT  - Biography
PT  - Classical Article
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesia/*history
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*history/pharmacology
MH  - Aspirin/analogs & derivatives/*history/pharmacology
MH  - Dogs
MH  - Female
MH  - History, 20th Century
MH  - Male
MH  - Prostaglandins/*history/metabolism
MH  - Spleen/drug effects/metabolism
PS  - Ferreira SH
FPS - Ferreira, S H
PS  - Moncada S
FPS - Moncada, S
PS  - Vane JR
FPS - Vane, J R
PMC - PMC3224318
EDAT- 1997/02/01 00:00
MHDA- 1997/02/01 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1997/02/01 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1997.tb06823.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1997 Feb;120(4 Suppl):401-12; discussion 399-400. doi: 
      10.1111/j.1476-5381.1997.tb06823.x.

PMID- 1133735
OWN - NLM
STAT- MEDLINE
DCOM- 19750905
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 64
IP  - 6
DP  - 1975 Jun
TI  - Bioavailability of aspirin from commercial suppositories.
PG  - 1064-6
AB  - A comparison of the bioavailability of salicylate from five brands of 
      commercially available aspirin rectal suppositories in an adult panel is 
      presented. All brands show slow absorption compared to oral administration of the 
      drug in tablet form. At best, about 40% of the dose (on the average) was absorbed 
      when retention time in the bowel was limited to 2 hr. However, four out of the 
      five brands give substantially lower absorption rates so that only about 20% of 
      the aspirin is available.
FAU - Gibaldi, M
AU  - Gibaldi M
FAU - Grundhofer, B
AU  - Grundhofer B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Suppositories)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*metabolism/urine
MH  - *Biological Availability
MH  - *Biopharmaceutics
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Rectum/metabolism
MH  - Suppositories
EDAT- 1975/06/01 00:00
MHDA- 1975/06/01 00:01
CRDT- 1975/06/01 00:00
PHST- 1975/06/01 00:00 [pubmed]
PHST- 1975/06/01 00:01 [medline]
PHST- 1975/06/01 00:00 [entrez]
AID - S0022-3549(15)40212-6 [pii]
AID - 10.1002/jps.2600640649 [doi]
PST - ppublish
SO  - J Pharm Sci. 1975 Jun;64(6):1064-6. doi: 10.1002/jps.2600640649.

PMID- 7127458
OWN - NLM
STAT- MEDLINE
DCOM- 19821216
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 2
IP  - 2
DP  - 1982 Jun
TI  - Aspirin treatment of migraine attacks: clinical observations.
PG  - 71-6
AB  - A retrospective study of the efficacy of soluble aspirin in migraine has been 
      carried out. Data were available for 61 patients. These patients differed in only 
      relatively minor ways from the remainder of the population of migraine sufferers 
      referred to a neurological consultative practice. Soluble aspirin usually or 
      always relieved migraine attacks in 44% of these patients, and sometimes relieved 
      the disorder in another 25%. Adverse effects mainly nausea and vomiting, were 
      reported by 16% of patients only, and in some cases nausea and vomiting may have 
      been due to migraine rather than to the drug. Response to aspirin was unrelated 
      to factors such as the patient's age, sex and duration of migraine history, and 
      to the severity of migraine or occurrence of nausea and vomiting during attacks. 
      However, the presence of a migraine aura appeared to improve the chances of a 
      response to aspirin. The aura may have permitted earlier recognition that 
      migraine was present, and thus allowed earlier aspirin intake at a stage when it 
      had a better chance of influencing migraine mechanisms.
FAU - Ross-Lee, L
AU  - Ross-Lee L
FAU - Eadie, M J
AU  - Eadie MJ
FAU - Tyrer, J H
AU  - Tyrer JH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Research Design
MH  - Retrospective Studies
EDAT- 1982/06/01 00:00
MHDA- 1982/06/01 00:01
CRDT- 1982/06/01 00:00
PHST- 1982/06/01 00:00 [pubmed]
PHST- 1982/06/01 00:01 [medline]
PHST- 1982/06/01 00:00 [entrez]
AID - 10.1046/j.1468-2982.1982.0202071.x [doi]
PST - ppublish
SO  - Cephalalgia. 1982 Jun;2(2):71-6. doi: 10.1046/j.1468-2982.1982.0202071.x.

PMID- 7994391
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Diaspirin crosslinked hemoglobin (DCLHb): characterization of the process and the 
      product manufactured under GMP requirements for clinical studies.
PG  - 701-8
AB  - Initiation of Clinical Trials in 1992 necessitated product manufacture under FDA 
      Good Manufacturing Practice (GMP) requirements. To this end, all product 
      components used were characterized to meet established requirements and processes 
      and analytical methods were validated to confirm and document their utility and 
      reproductibility. Manufacture of multiple 50+ liter lots of 10%g DCLHb under GMP 
      requirements resulted in a pure and homogeneous product which reproducibly met a 
      rigorous and complete set of product specifications. Final release testing of 
      five consecutive GMP lots showed hemoglobin concentrations of 10.2 +/- 0.2g%, pH 
      of 7.33 +/- 0.02 (37 degrees C), methemoglobin concentrations of 3.2 +/- 0.6%, 
      degree of crosslinking of 99.8 +/- 0.1% and a P50 of 32.4 +/- 1.0 mmHg (37 
      degrees C). The mean overall yield for production of these five lots was 55 +/- 
      2%. Products were all endotoxin free as indicated by rabbit, cytokine and LAL 
      testing (< 0.06 EU/mL); a critical characteristic for a molecule which may bind 
      endotoxin. All lots were sterile as indicated by compendial testing.
FAU - Azari, M
AU  - Azari M
AD  - Blood Substitutes Program, Baxter Healthcare Corporation, Round Lake, Illinois 
      60073.
FAU - Rohn, K
AU  - Rohn K
FAU - Picken, J
AU  - Picken J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Endotoxins)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/isolation & purification/standards
MH  - Blood Substitutes/chemistry/*isolation & purification/standards
MH  - Drug Contamination/prevention & control
MH  - Endotoxins/analysis
MH  - Hemoglobins/chemistry/*isolation & purification/standards
MH  - Humans
MH  - Quality Control
MH  - Rabbits
MH  - Reproducibility of Results
MH  - Safety
MH  - United States
MH  - United States Food and Drug Administration
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117901 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):701-8. doi: 
      10.3109/10731199409117901.

PMID- 36609866
OWN - NLM
STAT- MEDLINE
DCOM- 20230511
LR  - 20230824
IS  - 1099-1573 (Electronic)
IS  - 0951-418X (Linking)
VI  - 37
IP  - 5
DP  - 2023 May
TI  - Antiplatelet effect of ginkgo diterpene lactone meglumine injection in acute 
      ischemic stroke: A randomized, double-blind, placebo-controlled clinical trial.
PG  - 1986-1996
LID - 10.1002/ptr.7720 [doi]
AB  - This study was designed to evaluate antiplatelet effect and therapeutic effect of 
      ginkgo diterpene lactone meglumine injection (GDLI) in acute ischemic stroke 
      (AIS) patients. In this randomized, double-blind, placebo-controlled trial, we 
      randomly assigned 70 inpatients within 48 hr after the onset of AIS to 
      combination therapy with GDLI and aspirin (GDLI at a dose of 25 mg/d for 14 days 
      plus aspirin at a dose of 100 mg/d for 90 days) or to placebo plus aspirin in a 
      ratio of 1:1. Platelet function, the National Institute of Health Stroke Scale 
      (NIHSS), and the modified Rankin Scale (mRS) were evaluated. A good outcome was 
      defined as NIHSS scores decrease ≥5 or mRS scores decrease ≥2. Results showed 
      that arachidonic acid induced maximum platelet aggregation rate (AA-MAR) and mean 
      platelet volume (MPV) of the GDLI-aspirin group were much lower than that of the 
      aspirin group (p = 0.013 and p = 0.034, respectively) after the 14-day therapy. 
      The combination of GDLI and aspirin was superior to aspirin alone, and had 
      significant impact on the good outcome at day 90 (ORadj 7.21 [95%CI, 1.03-50.68], 
      p = 0.047). In summary, GDLI has antiplatelet effect and can improve the 
      prognosis of AIS patients.
CI  - © 2023 John Wiley & Sons Ltd.
FAU - Chen, Chunxiang
AU  - Chen C
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Lv, Huihui
AU  - Lv H
AUID- ORCID: 0000-0002-1371-1376
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Shan, Lili
AU  - Shan L
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Long, Xie
AU  - Long X
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Guo, Cen
AU  - Guo C
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Huo, Yajing
AU  - Huo Y
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Lu, Lingdan
AU  - Lu L
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Zhou, Yinting
AU  - Zhou Y
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Liu, Mingyuan
AU  - Liu M
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Wu, Haibo
AU  - Wu H
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Zhu, Desheng
AU  - Zhu D
AD  - Department of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong 
      University, Shanghai, China.
FAU - Han, Yan
AU  - Han Y
AUID- ORCID: 0000-0002-7654-0906
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
LA  - eng
GR  - 81771288/National Natural Science Foundation of China/
GR  - 81904014/National Natural Science Foundation of China/
GR  - SHDC2020CR 2046B/Clinical Research Plan of SHDC/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20230106
PL  - England
TA  - Phytother Res
JT  - Phytotherapy research : PTR
JID - 8904486
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Phytother Res. 2023 Aug 23;:. PMID: 37612843
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - *Stroke/drug therapy
MH  - *Ischemic Stroke/drug therapy
MH  - Ginkgo biloba
MH  - Aspirin/pharmacology/therapeutic use
OTO - NOTNLM
OT  - acute ischemic stroke
OT  - antiplatelet agent
OT  - ginkgo diterpene lactone meglumine injection
OT  - platelet function
EDAT- 2023/01/08 06:00
MHDA- 2023/05/11 06:42
CRDT- 2023/01/07 16:58
PHST- 2022/11/01 00:00 [revised]
PHST- 2022/06/02 00:00 [received]
PHST- 2022/12/18 00:00 [accepted]
PHST- 2023/05/11 06:42 [medline]
PHST- 2023/01/08 06:00 [pubmed]
PHST- 2023/01/07 16:58 [entrez]
AID - 10.1002/ptr.7720 [doi]
PST - ppublish
SO  - Phytother Res. 2023 May;37(5):1986-1996. doi: 10.1002/ptr.7720. Epub 2023 Jan 6.

PMID- 11362292
OWN - NLM
STAT- MEDLINE
DCOM- 19950509
LR  - 20161123
IP  - no 16
DP  - 1995 Jan
TI  - Salasalate for HIV.
PG  - 7
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Newspaper Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Treat Rev
JT  - Treatment review
JID - 9507417
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Double-Blind Method
MH  - HIV Infections/*complications
MH  - Humans
MH  - Inflammation/*drug therapy/etiology
MH  - Placebos
OAB - A newly opened trial is examining the use of salasalate, an aspirin-related drug 
      without the adverse side effects to the stomach lining, for treatment of HIV 
      infection. Participants will either be treated with the drug or a placebo, but 
      neither the patient's doctor nor the participant will be told which is being 
      administered. Participants must be HIV positive and be willing to visit the 
      clinic conducting the trial every other week for the first two months and once a 
      month after that until the end of the study. Information can be obtained by 
      calling Project for Aspirin Research and Education at (310) 659-6965.
OABL- eng
EDAT- 1995/01/01 00:00
MHDA- 2001/05/22 10:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 2001/05/22 10:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Treat Rev. 1995 Jan;(no 16):7.

PMID- 1615514
OWN - NLM
STAT- MEDLINE
DCOM- 19920728
LR  - 20131121
IS  - 0029-2001 (Print)
IS  - 0029-2001 (Linking)
VI  - 112
IP  - 12
DP  - 1992 May 10
TI  - [Preventive low dosage treatment and pre-eclampsia].
PG  - 1597-9
AB  - Pregnancy-induced hypertension and pre-eclampsia occur in 10% of pregnancies and 
      are recognised as important and prevalent sources of risk to both mother and 
      foetus. Although the exact cause of the disease is unknown, several mechanisms 
      have been suggested, including enhanced sensitivity to vasopressors and imbalance 
      in the production of prostaglandins. This may lead to vasoconstriction of small 
      arteries, activation of platelets and uteroplacental insufficiency. Since 
      thromboxane A2 and prostacyclin are derived from arachidonic acid through the 
      action of cyclooxygenase, low dose aspirin selectively inhibits the synthesis of 
      platelet thromboxane A2 without affecting production of endothelium-derived 
      prostacyclin. Data available from clinical trials suggest that, when given to 
      high risk patients, low dose aspirin reduces risk of preeclampsia and 
      intrauterine growth retardation by 50%, with no observed risk of adverse effects 
      to either mother or foetus.
FAU - Oian, P
AU  - Oian P
AD  - Kvinneklinikken, Regionsykehuset, Tromsø.
FAU - Aune, B
AU  - Aune B
LA  - nor
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Profylaktisk lavdose acetylsalisylsyrebehandling og preeklampsi.
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny 
      raekke
JID - 0413423
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Tidsskr Nor Laegeforen. 1993 Apr 20;113(10):1256. PMID: 8493659
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
RF  - 25
EDAT- 1992/05/10 00:00
MHDA- 1992/05/10 00:01
CRDT- 1992/05/10 00:00
PHST- 1992/05/10 00:00 [pubmed]
PHST- 1992/05/10 00:01 [medline]
PHST- 1992/05/10 00:00 [entrez]
PST - ppublish
SO  - Tidsskr Nor Laegeforen. 1992 May 10;112(12):1597-9.

PMID- 364400
OWN - NLM
STAT- MEDLINE
DCOM- 19790226
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 62
IP  - 5 Pt 2 Suppl
DP  - 1978 Nov
TI  - Aspirin and acetaminophen: a comparative view of their antipyretic and analgesic 
      activity.
PG  - 904-9
AB  - Aspirin and acetaminophen have excellent and essentially similar antipyretic 
      activity. For the child, lowering of temperature will be indicated for 
      excessively high temperature and when there is a history of febrile seizures. 
      Specific clinical contraindications will often dictate the selection of one drug 
      over the other. Aspirin has some advantage over acetaminophen for analgesia. The 
      need for either drug for analgesia in the pediatric patient, however, will be 
      infrequent; when required, a drug with greater analgesic activity than either 
      aspirin or acetaminophen may be indicated.
FAU - Lovejoy, F H Jr
AU  - Lovejoy FH Jr
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/pharmacology/*therapeutic use
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Body Temperature/drug effects
MH  - Fever/*drug therapy/etiology
MH  - Humans
MH  - Hypothalamus/drug effects
MH  - Pain/*drug therapy
RF  - 12
EDAT- 1978/11/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1978 Nov;62(5 Pt 2 Suppl):904-9.

PMID- 11362298
OWN - NLM
STAT- MEDLINE
DCOM- 19950509
LR  - 20131121
IP  - no 17
DP  - 1995 Mar-Apr
TI  - Aspirin study stopped.
PG  - 4
LA  - eng
PT  - Newspaper Article
PL  - United States
TA  - Treat Rev
JT  - Treatment review
JID - 9507417
RN  - R16CO5Y76E (Aspirin)
MH  - Anemia/*chemically induced
MH  - Aspirin/*adverse effects/therapeutic use
MH  - HIV Infections/*drug therapy
MH  - Humans
MH  - Liver/enzymology
OAB - A study using high-dose aspirin treatment for HIV infection was stopped due to 
      side effects, including reduction in red blood cells and a modest increase in 
      liver enzymes. When treatment stopped, lab values returned to normal. Material 
      strongly cautioning people about trying aspirin on their own was released in 
      connection to the study. A related drug, salasalate, is being tested in a 
      clinical trial as well, but it is still not known whether it is safe or effective 
      for treatment of HIV disease. The Community Research Initiative has other studies 
      that are enrolling, such as one using U-90, also known as delavirdine. Results 
      from this drug appear promising.
OABL- eng
EDAT- 1995/03/01 00:00
MHDA- 2001/05/22 10:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 2001/05/22 10:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
PST - ppublish
SO  - Treat Rev. 1995 Mar-Apr;(no 17):4.

PMID- 582676
OWN - NLM
STAT- MEDLINE
DCOM- 19791121
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 28
IP  - 10
DP  - 1978
TI  - [Promoting and inhibitory influences of tribenoside and acetylsalicylic acid on 
      spontaneous arthrosis in the mouse (author's transl)].
PG  - 1724-6
AB  - Tribenoside administered in moderate doses over periods of three or ten months, 
      inhibited the development of spontaneous arthrosis in mice of the C 57 black 
      strain. Acetylsalicylic acid administered once daily in oral doses of 50 and 150 
      mg/kg for five months, had a distinctly promoting effect on the development of 
      the same arthrosis. Attention is drawn to certain common features in the activity 
      spectra of the two drugs, but especially also to their opposite effects on 
      mucopolysaccharide metabolism and on regenerative processes which are promoted by 
      tribenoside but inhibited by acetylsalicylic acid.
FAU - Wilhelmi, G
AU  - Wilhelmi G
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Fördernde und hemmende Einflüsse von Tribenosid und Acetylsalicylsäure auf die 
      spontane Arthrose der Maus.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Glycosides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Glycosides/administration & dosage/*therapeutic use
MH  - Joint Diseases/*drug therapy
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Time Factors
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1978;28(10):1724-6.

PMID- 21062249
OWN - NLM
STAT- MEDLINE
DCOM- 20110325
LR  - 20190823
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 17
IP  - 36
DP  - 2010
TI  - Anti-platelet therapy and aspirin resistance - clinically and chemically 
      relevant?
PG  - 4578-86
AB  - Platelets play a central role in the pathogenesis of the atherothrombosis which 
      ultimately causes myocardial infarction, stroke and peripheral vascular disease. 
      Commonly used oral anti-platelet drugs include aspirin (an irreversible inhibitor 
      of cyclo-oxygenase), clopidogrel (an ADP receptor antagonist), other 
      thienopyridines such as ticlopidine and prasgruel, and dipyridamole (an inhibitor 
      of adenosine reuptake and platelet phosphodiesterase). Newer agents are in 
      development and one, ticagrelor, a reversible ADP receptor antagonist has shown 
      promise. Despite their proven benefit, recurrent vascular events still occur in 
      those taking anti-platelet drugs. This has led to the concept of anti-platelet 
      resistance, most commonly aspirin resistance as this drug is the cornerstone of 
      most regimens. The causes of aspirin resistance are numerous but potential 
      mechanisms include lack of patient adherence, non COX-1 mediated thromboxane A2 
      synthesis, increased activity of alternate platelet activation pathways, 
      interference of aspirin action by other drugs and probably pharmacogenetic 
      factors. Measurement of platelet response to aspirin is made possible using a 
      number of in-vitro laboratory assays of platelet function which include 
      measurement of thromboxane A2 metabolites as well as newer point-of-care assays 
      of platelet aggregation. The phenomenon of aspirin resistance is important as it 
      raises the possibility of developing strategies to identify those who respond 
      best to a particular anti-platelet regimen, or to development of newer 
      anti-platelet therapies to which more patients respond. This review discusses 
      important aspects of aspirin resistance both in terms of clinical medicine, 
      alternative anti-platelet strategies, and the potential to overcome its various 
      causes.
FAU - Rafferty, M
AU  - Rafferty M
AD  - Acute Stroke Unit, Institute of Cardiovascular and Medical Sciences, College of 
      Medicine, Veterinary & Life Sciences, University of Glasgow, Western Infirmary, 
      Glasgow, G11 6NT, UK.
FAU - Walters, M R
AU  - Walters MR
FAU - Dawson, J
AU  - Dawson J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects/metabolism
MH  - Clinical Medicine
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Thromboxane A2/metabolism
EDAT- 2010/11/11 06:00
MHDA- 2011/03/26 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/07/28 00:00 [received]
PHST- 2010/10/19 00:00 [accepted]
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/03/26 06:00 [medline]
AID - BSP/CMC/E-Pub/ 286 [pii]
AID - 10.2174/092986710794182962 [doi]
PST - ppublish
SO  - Curr Med Chem. 2010;17(36):4578-86. doi: 10.2174/092986710794182962.

PMID- 2487506
OWN - NLM
STAT- MEDLINE
DCOM- 19900308
LR  - 20131121
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 37
IP  - 4
DP  - 1989 Apr
TI  - Effect of variable doses of aspirin on platelet functions.
PG  - 269-70
AB  - Serial platelet functions were studied after various single doses of aspirin (75 
      mg, 150 mg, 300 mg, and 600 mg) in 20 males. Clotting time and platelet counts 
      remained unchanged. Significant deaggregation of platelets occurred only with 600 
      mg of aspirin. This persisted on day '3'. Platelet factor-3 release time was 
      prolonged till day '3' with only 150 mg and 600 mg doses of aspirin. In view of 
      these findings it appears that 600 mg aspirin given every 4th day is more suited 
      for significant antiplatelet effect.
FAU - Jha, S
AU  - Jha S
FAU - Chandra, M
AU  - Chandra M
FAU - Kumar, A
AU  - Kumar A
FAU - Kumar, A
AU  - Kumar A
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 37270-93-2 (Platelet Factor 3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Platelets/*drug effects/physiology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors
MH  - Platelet Factor 3/drug effects
EDAT- 1989/04/01 00:00
MHDA- 1989/04/01 00:01
CRDT- 1989/04/01 00:00
PHST- 1989/04/01 00:00 [pubmed]
PHST- 1989/04/01 00:01 [medline]
PHST- 1989/04/01 00:00 [entrez]
PST - ppublish
SO  - J Assoc Physicians India. 1989 Apr;37(4):269-70.

PMID- 7213053
OWN - NLM
STAT- MEDLINE
DCOM- 19810521
LR  - 20131121
IS  - 0098-6127 (Print)
IS  - 0098-6127 (Linking)
VI  - 8
IP  - 5
DP  - 1980
TI  - Biphasic initial phase of platelet aggregation inhibition after oral aspirin.
PG  - 501-6
AB  - For one hour after the ingestion of 1 g aspirin the pharmacodynamics of 
      acetylsalicylic acid with regard to the inhibition of platelet aggregation were 
      studied in nine healthy male volunteers. Plasma salicylic acid (SA) and 
      acetylsalicylic acid (ASA) levels were measured, and platelet aggregation was 
      controlled by the collagen-induced aggregation. It took 12 - 24 minutes till the 
      maximum of platelet aggregation inhibition was reached; maximal inhibition was 
      only observed with ASA levels above 4.5 /microgram/ml and total ASA levels above 
      10 /microgram/ml. At that time already more than 50% of the total ASA were 
      hydrolysed to minimally active SA. In spite of further increasing ASA levels 
      inhibition of platelet aggregation decreased again. The different sensitivity of 
      platelet- and vessel wall cyclooxygenase to aspirin does not explain our 
      findings.
FAU - Walter, E
AU  - Walter E
FAU - Zimmermann, R
AU  - Zimmermann R
FAU - Siess, R
AU  - Siess R
FAU - Staiger, C
AU  - Staiger C
FAU - Weber, E
AU  - Weber E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Artery
JT  - Artery
JID - 7508494
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Collagen/pharmacology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Count
MH  - Time Factors
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Artery. 1980;8(5):501-6.

PMID- 29039130
OWN - NLM
STAT- MEDLINE
DCOM- 20180724
LR  - 20190118
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 77
IP  - 17
DP  - 2017 Nov
TI  - Aspirin for Prevention of Preeclampsia.
PG  - 1819-1831
LID - 10.1007/s40265-017-0823-0 [doi]
AB  - Aspirin is currently the most widely prescribed treatment in the prevention of 
      cardiovascular complications. The indications for the use of aspirin during 
      pregnancy are, however, the subject of much controversy. Since the first evidence 
      of the obstetric efficacy of aspirin in 1985, numerous studies have tried to 
      determine the effect of low-dose aspirin on the incidence of preeclampsia, with 
      very controversial results. Large meta-analyses including individual patient data 
      have demonstrated that aspirin is effective in preventing preeclampsia in 
      high-risk patients, mainly those with a history of preeclampsia. However, 
      guidelines regarding the usage of aspirin to prevent preeclampsia differ 
      considerably from one country to another. Screening modalities, target 
      population, and aspirin dosage are still a matter of debate. In this review, we 
      report the pharmacodynamics of aspirin, its main effects according to dosage and 
      gestational age, and the evidence-based indications for primary and secondary 
      prevention of preeclampsia.
FAU - Atallah, A
AU  - Atallah A
AD  - Hospices Civils de Lyon, Department of Obstetrics and Gynecology, Femme Mère 
      Enfant Hospital, University Hospital Center, 59 boulevard Pinel, 69500, Bron, 
      France.
AD  - Claude-Bernard University Lyon1, Lyon, France.
FAU - Lecarpentier, E
AU  - Lecarpentier E
AD  - Assistance Publique-Hôpital de Paris, Department of Obstetrics and Gynecology, 
      Port-Royal Maternity, University Hospital Center Cochin Broca Hôtel Dieu, Groupe 
      Hospitalier Universitaire Ouest, 53, Avenue de l'Observatoire, 75014, Paris, 
      France.
AD  - PRES Sorbonne Paris Cité, Université Paris Descartes, Paris, France.
AD  - PremUP Foundation, Paris, France.
AD  - DHU Risques et Grossesse, Paris, France.
FAU - Goffinet, F
AU  - Goffinet F
AD  - Assistance Publique-Hôpital de Paris, Department of Obstetrics and Gynecology, 
      Port-Royal Maternity, University Hospital Center Cochin Broca Hôtel Dieu, Groupe 
      Hospitalier Universitaire Ouest, 53, Avenue de l'Observatoire, 75014, Paris, 
      France.
AD  - PRES Sorbonne Paris Cité, Université Paris Descartes, Paris, France.
AD  - PremUP Foundation, Paris, France.
AD  - DHU Risques et Grossesse, Paris, France.
FAU - Doret-Dion, M
AU  - Doret-Dion M
AD  - Hospices Civils de Lyon, Department of Obstetrics and Gynecology, Femme Mère 
      Enfant Hospital, University Hospital Center, 59 boulevard Pinel, 69500, Bron, 
      France.
AD  - Claude-Bernard University Lyon1, Lyon, France.
FAU - Gaucherand, P
AU  - Gaucherand P
AD  - Hospices Civils de Lyon, Department of Obstetrics and Gynecology, Femme Mère 
      Enfant Hospital, University Hospital Center, 59 boulevard Pinel, 69500, Bron, 
      France.
AD  - Claude-Bernard University Lyon1, Lyon, France.
FAU - Tsatsaris, V
AU  - Tsatsaris V
AD  - Assistance Publique-Hôpital de Paris, Department of Obstetrics and Gynecology, 
      Port-Royal Maternity, University Hospital Center Cochin Broca Hôtel Dieu, Groupe 
      Hospitalier Universitaire Ouest, 53, Avenue de l'Observatoire, 75014, Paris, 
      France. vassilis.tsatsaris@aphp.fr.
AD  - PRES Sorbonne Paris Cité, Université Paris Descartes, Paris, France. 
      vassilis.tsatsaris@aphp.fr.
AD  - PremUP Foundation, Paris, France. vassilis.tsatsaris@aphp.fr.
AD  - DHU Risques et Grossesse, Paris, France. vassilis.tsatsaris@aphp.fr.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Pre-Eclampsia/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Primary Prevention
MH  - Risk Factors
MH  - Secondary Prevention
PMC - PMC5681618
COIS- CONFLICT OF INTEREST: VT is a consultant for Roche Diagnostics and principal 
      investigator of the PRECOG study, a study partly funded by Roche Diagnostics. AA, 
      EL, FG, MD-D and PG declare that they have no conflict of interest. FUNDING: 
      Payment for open access is provided by the Pierre Budin Association, a French 
      association promoting research and teaching in perinatology.
EDAT- 2017/10/19 06:00
MHDA- 2018/07/25 06:00
CRDT- 2017/10/18 06:00
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2018/07/25 06:00 [medline]
PHST- 2017/10/18 06:00 [entrez]
AID - 10.1007/s40265-017-0823-0 [pii]
AID - 823 [pii]
AID - 10.1007/s40265-017-0823-0 [doi]
PST - ppublish
SO  - Drugs. 2017 Nov;77(17):1819-1831. doi: 10.1007/s40265-017-0823-0.

PMID- 23819347
OWN - NLM
STAT- MEDLINE
DCOM- 20130722
LR  - 20131121
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 85
IP  - 5
DP  - 2013
TI  - [Aspirin resistance candidate genes and their association with the risk of fatal 
      cardiovascular events].
PG  - 95-100
AB  - The review presents the current data available in the world literature on the 
      most likely gene polymorphisms, such as cyclooxygenase, glycoproteins (GP) 
      Ib/IIIa, GP Iba, GP VI, adenosine diphosphate receptor P2Y1 and P2Y12 
      polymorphisms that may lead to aspirin resistance. The frequency of these 
      polymorphisms in laboratory aspirin resistance and their association with the 
      development of adverse cardiovascular events from the use of aspirin are 
      considered.
FAU - Grinshtein, Yu I
AU  - Grinshtein YI
FAU - Kosinova, A A
AU  - Kosinova AA
FAU - Grinshtein, I Yu
AU  - Grinshtein IY
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*pharmacology
MH  - Cardiovascular Diseases/*etiology/genetics
MH  - Drug Resistance/genetics
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacology
MH  - Polymorphism, Genetic
EDAT- 2013/07/04 06:00
MHDA- 2013/07/23 06:00
CRDT- 2013/07/04 06:00
PHST- 2013/07/04 06:00 [entrez]
PHST- 2013/07/04 06:00 [pubmed]
PHST- 2013/07/23 06:00 [medline]
PST - ppublish
SO  - Ter Arkh. 2013;85(5):95-100.

PMID- 17694222
OWN - NLM
STAT- MEDLINE
DCOM- 20071004
LR  - 20191110
IS  - 0720-9355 (Print)
IS  - 0720-9355 (Linking)
VI  - 27
IP  - 3
DP  - 2007 Aug
TI  - [Control of aspirin effect in chronic cardiovascular patients using two whole 
      blood platelet function assays. PFA-100 and Multiplate].
PG  - 155-60; quiz 161-2
AB  - In this study two aspirin sensitive platelet function tests which are based on 
      the analysis of whole blood were evaluated and correlated with each other. In 
      vitro bleeding time was determined using the PFA-100 analyzer (Dade Behring, 
      Marburg, Germany) using the collagen/epinephrine cartridge and citrated blood. 
      Whole blood aggregometry was performed using the Multiplate analyzer (Dynabyte 
      medical, Munich, Germany) using hirudin blood (25 mug/ml). Aggregatin was 
      triggered using arachidonic acid (ASPItest), collagen (COLtest) or TRAP-6 
      (thrombin receptor activating peptide, TRAPtest). Following informed consent 
      citrated blood and hirudin blood was drawn from 76 cardiovascular patients which 
      were on long-term aspirin therapy (aspirin patients). In addition hirudin blood 
      was drawn from 57 healthy blood donors for assessment of whole blood 
      aggregometry. PFA-100 closure times of the aspirin patients were 273 +/- 49 s. 
      Based on the cut-off of 170 s a non response to the aspirin therapy was detected 
      in 5 of 76 patients. Whole blood aggregation was comparable in the aspirin 
      patients vs the blood donors AUC values in the TRAP test, whereas in COLtest and 
      ASPItest significantly reduced aggregations were detected (p < 0.05). Of the five 
      patients that had a normal PFA-100 closure time only one had normal aggregation 
      in ASPItest, and also only one had a normal aggregation in COLtest. The high rate 
      of response to the aspirin therapy which was found in PFA-100 and ASPItest can be 
      explained by the assumed high level of compliance of the cohort. In the applied 
      tests different patients were stratified as aspirin-non-responders. This 
      highlights the importance of the assay conditions for the diagnosis of an 
      aspirin-non-response.
FAU - von Pape, K-W
AU  - von Pape KW
AD  - Institut für Laboratoriumsmedizin, Klinikum Fulda gAG, Pacelliallee 4, 63043 
      Fulda. vonpape@klinikum-fulda.de
FAU - Dzijan-Horn, M
AU  - Dzijan-Horn M
FAU - Bohner, J
AU  - Bohner J
FAU - Spannagl, M
AU  - Spannagl M
FAU - Weisser, H
AU  - Weisser H
FAU - Calatzis, A
AU  - Calatzis A
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Vollblutaggregometrie zur Kontrolle der Wirksamkeit von Azetylsalizylsäure bei 
      Patienten mit koronarer Herzkrankheit. Vergleich von PFA-100 und Multiplate.
PL  - Germany
TA  - Hamostaseologie
JT  - Hamostaseologie
JID - 8204531
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Blood Donors
MH  - Blood Platelets/drug effects/*physiology
MH  - Cardiovascular Diseases/*drug therapy
MH  - Chronic Disease
MH  - Humans
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Reference Values
EDAT- 2007/08/19 09:00
MHDA- 2007/10/05 09:00
CRDT- 2007/08/19 09:00
PHST- 2007/08/19 09:00 [pubmed]
PHST- 2007/10/05 09:00 [medline]
PHST- 2007/08/19 09:00 [entrez]
AID - 07030155 [pii]
AID - 10.1007/978-3-540-36715-4_49 [doi]
PST - ppublish
SO  - Hamostaseologie. 2007 Aug;27(3):155-60; quiz 161-2. doi: 
      10.1007/978-3-540-36715-4_49.

PMID- 3095220
OWN - NLM
STAT- MEDLINE
DCOM- 19861217
LR  - 20191029
IS  - 0144-5952 (Print)
IS  - 0144-5952 (Linking)
VI  - 5
IP  - 5
DP  - 1986 Sep
TI  - Comparison of effects of lysine aspirin, soluble aspirin and conventional aspirin 
      on buccal potential difference in healthy volunteer subjects.
PG  - 329-31
AB  - The effects of aspirin, soluble aspirin and lysine aspirin on buccal mucosal 
      potential difference (p.d.) were compared in a double-blind trial. Placebo and 
      three doses of each preparation containing 150, 300 and 600 mg of aspirin were 
      allocated according to a latin square design. Six volunteer subjects were 
      studied; each received a total of 10 treatments at least 24 h apart. All doses of 
      each preparation considered, a significant treatment effect was seen [F (d.f. = 
      2,306) = 6.2, P less than 0.003]. Lysine aspirin showed the least effect of the 
      active treatments on buccal p.d. with a change from baseline of +8.5 mV compared 
      with +13.3 for soluble aspirin +14.4 for conventional aspirin and -5.2 mV for 
      placebo.
FAU - Shah, K
AU  - Shah K
FAU - Jackson, S H
AU  - Jackson SH
FAU - Hedges, A
AU  - Hedges A
FAU - Turner, P
AU  - Turner P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Toxicol
JT  - Human toxicology
JID - 8206759
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects/*analogs & derivatives
MH  - Cheek
MH  - Electrophysiology
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Male
MH  - Mouth Mucosa/*drug effects/physiology
MH  - Solubility
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
AID - 10.1177/096032718600500506 [doi]
PST - ppublish
SO  - Hum Toxicol. 1986 Sep;5(5):329-31. doi: 10.1177/096032718600500506.

PMID- 10902139
OWN - NLM
STAT- MEDLINE
DCOM- 20000809
LR  - 20131121
IS  - 0761-8425 (Print)
IS  - 0761-8425 (Linking)
VI  - 17
IP  - 1 Pt 2
DP  - 2000 Feb
TI  - [Asthma and aspirin intolerance].
PG  - 255-64
AB  - Undesirable reactions to aspirin and other non-steroidal antiinflammatory drugs 
      compose a diverse group of clinical manifestations with different pathogenic 
      mechanisms. In this review we describe one particular type of manifestation: 
      aspirin-induced asthma. This syndrome describes a straightforward situation with 
      typical clinical signs. The distinctive sign is asthma triggered by aspirin and 
      NSAID. Data has accumulated over recent years concerning the interference of 
      these drugs with arachidonic acid metabolism in the bronchi and lungs. In 
      patients sensitive to aspirin inhibition of cyclooxygenase is accompanied by 
      overproduction of cysteinyl leucotrienes. The clinical course of this condition, 
      the pathogenic mechanisms of the undesirable reactions to aspirin, and treatment 
      are discussed.
FAU - Nizankowska, E
AU  - Nizankowska E
AD  - Département de Médecine, Université Jagellonne, Krakow, Pologne.
FAU - Szczeklik, A
AU  - Szczeklik A
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Asthme et intolérance à l'aspirine.
PL  - France
TA  - Rev Mal Respir
JT  - Revue des maladies respiratoires
JID - 8408032
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced/diagnosis/epidemiology/*immunology
MH  - Drug Hypersensitivity/*complications
MH  - Humans
MH  - Prevalence
RF  - 78
EDAT- 2000/07/21 11:00
MHDA- 2000/08/12 11:00
CRDT- 2000/07/21 11:00
PHST- 2000/07/21 11:00 [pubmed]
PHST- 2000/08/12 11:00 [medline]
PHST- 2000/07/21 11:00 [entrez]
PST - ppublish
SO  - Rev Mal Respir. 2000 Feb;17(1 Pt 2):255-64.

PMID- 1777943
OWN - NLM
STAT- MEDLINE
DCOM- 19920311
LR  - 20190705
IS  - 0009-2363 (Print)
IS  - 0009-2363 (Linking)
VI  - 39
IP  - 7
DP  - 1991 Jul
TI  - Atomic force microscope images of the surfaces of aspirin crystals at 
      submolecular resolution.
PG  - 1899-901
AB  - The atomic force microscope has been developed and used to image arrays of 
      molecules at the (001) and (100) faces of aspirin crystals in water and in air. 
      Lattice spacings composed of methyl groups and the part of the phenyl groups on 
      the surface of the (001) in water, are consistent with X-ray diffraction data. 
      The surface of (100) face which shows most perfect cleavage in bulk, is more 
      difficult to image. This initial success in imaging at drug crystal surfaces 
      clarified the different structural behavior at the submolecular level for three 
      crystal faces, and the close relationship to the differences in the dissolution 
      velocity.
FAU - Masaki, N
AU  - Masaki N
AD  - Faculty of Pharmaceutical Sciences, Kyoto University, Japan.
FAU - Machida, K
AU  - Machida K
FAU - Kado, H
AU  - Kado H
FAU - Yokoyama, K
AU  - Yokoyama K
FAU - Tohda, T
AU  - Tohda T
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Crystallization
MH  - Microscopy, Electron
EDAT- 1991/07/01 00:00
MHDA- 1991/07/01 00:01
CRDT- 1991/07/01 00:00
PHST- 1991/07/01 00:00 [pubmed]
PHST- 1991/07/01 00:01 [medline]
PHST- 1991/07/01 00:00 [entrez]
AID - 10.1248/cpb.39.1899 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 1991 Jul;39(7):1899-901. doi: 10.1248/cpb.39.1899.

PMID- 33111628
OWN - NLM
STAT- MEDLINE
DCOM- 20211001
LR  - 20211001
IS  - 1557-9891 (Electronic)
IS  - 1557-9883 (Print)
IS  - 1557-9883 (Linking)
VI  - 14
IP  - 5
DP  - 2020 Sep-Oct
TI  - Efficacy of Aspirin for Vasculogenic Erectile Dysfunction in Men: A Meta-Analysis 
      of Randomized Control Trials.
PG  - 1557988320969082
LID - 10.1177/1557988320969082 [doi]
LID - 1557988320969082
AB  - One of the major causes of erectile dysfunction (ED) is an endothelial vascular 
      disorder. This meta-analysis is performed to determine the efficacy of aspirin on 
      erectile function in men with vasculogenic ED. For this purpose, CENTRAL, 
      MEDLINE, and reference lists of articles up to November 2019 were searched. 
      Randomized controlled trials (RCTs) were selected that compared aspirin with 
      placebo in men of any ethnicity with vasculogenic ED. A total of 58 trials were 
      retrieved. Finally, two trials of 214 men fulfilled our selection criteria. High 
      selection and detection bias were identified for one trial. The participants 
      showed a significant improvement in erectile function when they took aspirin 
      (mean difference: 5.14, 95% CI [3.89, 6.40], and I(2) = 0%). Although the present 
      meta-analysis suggested that aspirin has a significant effect on the improvement 
      of erectile function, there were limited RCTs available on this topic and doses 
      of aspirin varied. Additional studies are needed to support findings from this 
      meta-analysis. Aspirin needs to be considered by practitioners when prescribing 
      drugs for vasculogenic ED.
FAU - Irfan, Muhammad
AU  - Irfan M
AUID- ORCID: 0000-0002-5308-2359
AD  - Women's Health Development Unit, Universiti Sains Malaysia, Kelantan, Malaysia.
AD  - Department of Zoology, Pir Mehr Ali Shah, Arid Agriculture University, 
      Rawalpindi, Pakistan.
FAU - Ismail, Shaiful Bahari
AU  - Ismail SB
AD  - Department of Family Medicine, School of Medical Sciences, Universiti Sains 
      Malaysia, Kelantan, Malaysia.
FAU - Noor, Norhayati Mohd
AU  - Noor NM
AD  - Department of Family Medicine, School of Medical Sciences, Universiti Sains 
      Malaysia, Kelantan, Malaysia.
FAU - Hussain, Nik Hazlina Nik
AU  - Hussain NHN
AUID- ORCID: 0000-0002-9476-062X
AD  - Women's Health Development Unit, Universiti Sains Malaysia, Kelantan, Malaysia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Am J Mens Health
JT  - American journal of men's health
JID - 101287723
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Erectile Dysfunction/*drug therapy
MH  - Humans
MH  - Male
MH  - Penile Erection/*drug effects/physiology
MH  - *Randomized Controlled Trials as Topic
MH  - Vascular Diseases
PMC - PMC7607788
OTO - NOTNLM
OT  - Aspirin
OT  - cardiovascular diseases
OT  - endothelial dysfunction
OT  - erectile dysfunction
OT  - nitric oxide
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/10/29 06:00
MHDA- 2021/10/02 06:00
CRDT- 2020/10/28 08:44
PHST- 2020/10/28 08:44 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/10/02 06:00 [medline]
AID - 10.1177_1557988320969082 [pii]
AID - 10.1177/1557988320969082 [doi]
PST - ppublish
SO  - Am J Mens Health. 2020 Sep-Oct;14(5):1557988320969082. doi: 
      10.1177/1557988320969082.

PMID- 11153137
OWN - NLM
STAT- MEDLINE
DCOM- 20010215
LR  - 20131121
IS  - 0006-3347 (Print)
IS  - 0006-3347 (Linking)
VI  - 47
IP  - 5
DP  - 2000 Nov
TI  - Aspirin--the first hundred years.
PG  - 269-71
AB  - 'Take two aspirin and call me in the morning', may be an old cliché deriding the 
      medical profession, but the story of the first 100 years of aspirin suggests that 
      this drug may be of benefit for a far greater range of ailments than those who 
      synthesised it 100 years ago could have imagined.
FAU - Stanley, P
AU  - Stanley P
AD  - David Game College, Royal Free Hospital School of Medicine.
FAU - Hegedus, R
AU  - Hegedus R
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - England
TA  - Biologist (London)
JT  - Biologist (London, England)
JID - 9108399
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*history/pharmacology/therapeutic use
MH  - Anticoagulants/history/therapeutic use
MH  - Aspirin/*history/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/history/prevention & control
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Pain/drug therapy/history
EDAT- 2001/01/12 11:00
MHDA- 2001/03/03 10:01
CRDT- 2001/01/12 11:00
PHST- 2001/01/12 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2001/01/12 11:00 [entrez]
PST - ppublish
SO  - Biologist (London). 2000 Nov;47(5):269-71.

PMID- 22607190
OWN - NLM
STAT- MEDLINE
DCOM- 20121005
LR  - 20131121
IS  - 1520-5207 (Electronic)
IS  - 1520-5207 (Linking)
VI  - 116
IP  - 22
DP  - 2012 Jun 7
TI  - Calorimetric determination of rate constants and enthalpy changes for zero-order 
      reactions.
PG  - 6356-60
LID - 10.1021/jp302933f [doi]
AB  - Calorimetry is a general method for determination of the rates of zero-order 
      processes, but analysis of the data for the rate constant and reaction enthalpy 
      is difficult because these occur as a product in the rate equation so evaluation 
      of one requires knowledge of the other. Three methods for evaluation of both 
      parameters, without prior knowledge, are illustrated with examples and compared 
      with literature data. Method 1 requires the reaction to be studied in two buffers 
      with different enthalpies of ionization. Method 2 is based on calculation of 
      reaction enthalpy from group additivity functions. Method 3 applies when reaction 
      progresses to completion. The methods are applied to the enzymatic hydrolysis of 
      urea, the hydrolysis of acetylsalicylic acid, and the photodegradation of 
      nifedipine, respectively.
FAU - Almeida e Sousa, Luis
AU  - Almeida e Sousa L
AD  - UCL School of Pharmacy, University College London, 29-39 Brunswick Square, 
      London, WC1N 1AX, UK.
FAU - Beezer, Anthony E
AU  - Beezer AE
FAU - Hansen, Lee D
AU  - Hansen LD
FAU - Clapham, David
AU  - Clapham D
FAU - Connor, Joseph A
AU  - Connor JA
FAU - Gaisford, Simon
AU  - Gaisford S
LA  - eng
PT  - Journal Article
DEP - 20120529
PL  - United States
TA  - J Phys Chem B
JT  - The journal of physical chemistry. B
JID - 101157530
RN  - 8W8T17847W (Urea)
RN  - EC 3.5.1.5 (Urease)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry/*metabolism
MH  - Calorimetry
MH  - Hydrolysis
MH  - Nifedipine/*chemistry
MH  - Photochemical Processes
MH  - *Thermodynamics
MH  - Urea/chemistry/*metabolism
MH  - Urease/chemistry/*metabolism
EDAT- 2012/05/23 06:00
MHDA- 2012/10/06 06:00
CRDT- 2012/05/22 06:00
PHST- 2012/05/22 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2012/10/06 06:00 [medline]
AID - 10.1021/jp302933f [doi]
PST - ppublish
SO  - J Phys Chem B. 2012 Jun 7;116(22):6356-60. doi: 10.1021/jp302933f. Epub 2012 May 
      29.

PMID- 2473539
OWN - NLM
STAT- MEDLINE
DCOM- 19890825
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 61
IP  - 2
DP  - 1989 Apr 25
TI  - The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a 
      prostacyclin analogue.
PG  - 286-8
AB  - The reduced fibrinolytic response after aspirin intake may be due to prevention 
      of prostacyclin production. The effect of iloprost (a stable prostacyclin 
      analogue) was tested on the fibrinolytic activity (euglobulin lysis area on 
      fibrin plate [E.L.A.], t-PA antigen, PAI activity and PAI-1 antigen) of plasma 
      drawn after venous stasis test from six healthy male volunteers, who each 
      received all the following treatments according to a single-blind randomized 
      cross-over design: placebo, iloprost, aspirin + placebo, aspirin + iloprost. The 
      mean E.L.A. value after venous occlusion was significantly higher than the basal 
      level after every treatment but aspirin. Within each treatment group the t-PA 
      antigen levels in response to venous stasis were significantly higher than the 
      basal ones. PAI-1 antigen levels did not change significantly before and after 
      venous stasis either within or among the treatment groups. These data are 
      consistent with the hypothesis that the mechanism related to aspirin's effect on 
      fibrinolysis is mediated by suppression of vessel wall prostacyclin production. 
      Aspirin's inhibitory effect on fibrinolysis was in fact prevented by replacing 
      endogenous prostacyclin with iloprost. Iloprost enhances fibrinolytic activity 
      reduced by aspirin, but not by promoting t-PA release or by inhibiting release of 
      the specific inhibitor, PAI-1.
FAU - Bertelé, V
AU  - Bertelé V
AD  - Clinica Medica Generale of Milan University, L. Sacco Hospital, Italy.
FAU - Mussoni, L
AU  - Mussoni L
FAU - Pintucci, G
AU  - Pintucci G
FAU - del Rosso, G
AU  - del Rosso G
FAU - Romano, G
AU  - Romano G
FAU - de Gaetano, G
AU  - de Gaetano G
FAU - Libretti, A
AU  - Libretti A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Antigens)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Glycoproteins)
RN  - 0 (Plasminogen Inactivators)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - JED5K35YGL (Iloprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antigens/analysis
MH  - Aspirin/*antagonists & inhibitors
MH  - Cardiovascular Agents/*pharmacology
MH  - Epoprostenol/*pharmacology/physiology
MH  - Fibrinolysis/*drug effects
MH  - Glycoproteins/analysis
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Iloprost
MH  - Male
MH  - Plasminogen Activators/antagonists & inhibitors
MH  - Plasminogen Inactivators
MH  - Tissue Plasminogen Activator/immunology
EDAT- 1989/04/25 00:00
MHDA- 1989/04/25 00:01
CRDT- 1989/04/25 00:00
PHST- 1989/04/25 00:00 [pubmed]
PHST- 1989/04/25 00:01 [medline]
PHST- 1989/04/25 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1989 Apr 25;61(2):286-8.

PMID- 2251993
OWN - NLM
STAT- MEDLINE
DCOM- 19910111
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 66
IP  - 20
DP  - 1990 Dec 15
TI  - Low-dose aspirin versus anticoagulants for prevention of coronary graft 
      occlusion.
PG  - 1464-8
AB  - The prevention of graft occlusion by aspirin (100 mg/day) or heparin followed by 
      phenprocoumon was investigated in a randomized trial in 235 patients after 
      aortocoronary bypass operation. Aspirin treatment started 24 hours before, and 
      heparin 6 hours and phenprocoumon 2 days after surgery. The results of the vein 
      graft angiography and the clinical outcome 3 months postoperatively did not 
      differ: 22% of 218 vein graft distal anastomoses in the aspirin group and 20% of 
      272 in the anticoagulant group were occluded. At least 1 occluded distal 
      anastomosis was present in 38% of 74 patients in the aspirin-treated group and in 
      39% of 86 in the anticoagulant group. Worst-case analysis of all randomized 
      patients showed graft occlusions, cardiovascular complications or lost to 
      follow-up in 42% of 122 aspirin-treated patients compared with 41% of 113 
      patients treated with anticoagulants. For grafts with endarterectomy the 
      occlusion rate was lower in the aspirin (12% of 49) than in the anticoagulant 
      (22% of 41) group (p less than or equal to 0.05). Increased perioperative blood 
      loss in the aspirin group (1,211 +/- 814 ml in the first 48 hours vs 874 +/- 818 
      ml in the anticoagulant group [p less than or equal to 0.001]) without a higher 
      reoperation rate indicates effective platelet inhibition with low-dose aspirin. 
      Because occlusion rates were equal but high in these patients with advanced stage 
      of coronary artery disease, a combination of low-dose aspirin and anticoagulation 
      should be investigated to reduce graft occlusion rates further.
FAU - Weber, M A
AU  - Weber MA
AD  - Medizinische Klinik Innenstadt, Universität, München, Federal Republic of 
      Germany.
FAU - Hasford, J
AU  - Hasford J
FAU - Taillens, C
AU  - Taillens C
FAU - Zitzmann, A
AU  - Zitzmann A
FAU - Hahalis, G
AU  - Hahalis G
FAU - Seggewiss, H
AU  - Seggewiss H
FAU - Langbehn, A F
AU  - Langbehn AF
FAU - Fassbender, D
AU  - Fassbender D
FAU - Buchwalsky, R
AU  - Buchwalsky R
FAU - Theisen, K
AU  - Theisen K
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 9005-49-6 (Heparin)
RN  - Q08SIO485D (Phenprocoumon)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Artery Bypass
MH  - Female
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenprocoumon/*therapeutic use
MH  - Postoperative Care
EDAT- 1990/12/15 00:00
MHDA- 1990/12/15 00:01
CRDT- 1990/12/15 00:00
PHST- 1990/12/15 00:00 [pubmed]
PHST- 1990/12/15 00:01 [medline]
PHST- 1990/12/15 00:00 [entrez]
AID - 0002-9149(90)90535-9 [pii]
AID - 10.1016/0002-9149(90)90535-9 [doi]
PST - ppublish
SO  - Am J Cardiol. 1990 Dec 15;66(20):1464-8. doi: 10.1016/0002-9149(90)90535-9.

PMID- 18543581
OWN - NLM
STAT- MEDLINE
DCOM- 20080710
LR  - 20211020
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 33
IP  - 1
DP  - 2008 Jan-Mar
TI  - Effect of aminophylline on aspirin penetration into the central nervous system in 
      rats.
PG  - 23-30
AB  - This study investigated with the effect of aminophylline on the penetration of 
      aspirin through the blood-brain barrier (BBB) into the central nervous system 
      (CNS) in rats. Acetylsalycylic was injected into the right axillary artery, to 
      avoid the drug affecting the peripheral organs before it reached the CNS. The 
      test animals received subcutaneously (s.c.) aminophylline 30 min before aspirin 
      injection, while the control animals received an equimolar dose of physiological 
      solution s.c. At time intervals of 30, 60, 90, 120, and 240 s after aspirin 
      injection, the animals were decapitated and blood samples from the left jugular 
      vein, as well as samples from the brainstem, cerebellum and left and right 
      cerebral hemispheres, were taken to determine aspirin concentrations in all of 
      them by a standard method. It was found that aspirin concentrations in the CNS 
      were even 30 times lower than in the blood, with the concentrations being higher 
      in the brainstem and cerebellum than in the left and right hemispheres. The 
      presence of aminophylline did not alter aspirin concentrations either in the 
      blood or the brain, and therefore did not affect significantly the aspirin 
      penetration through the BBB into the CNS.
FAU - Vasović, Velibor
AU  - Vasović V
AD  - Department of Pharmacology and Toxicology, Faculty of Medicine, University of 
      Novi Sad, Republic of Serbia.
FAU - Banić, Branko
AU  - Banić B
FAU - Jakovljević, Vida
AU  - Jakovljević V
FAU - Tomic, Zdenko
AU  - Tomic Z
FAU - Milic-Djordjevic, Vukica
AU  - Milic-Djordjevic V
LA  - eng
PT  - Journal Article
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 27Y3KJK423 (Aminophylline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aminophylline/*pharmacology
MH  - Animals
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Biological Transport
MH  - Blood-Brain Barrier/metabolism
MH  - Brain/*metabolism
MH  - Capillary Permeability
MH  - Drug Interactions
MH  - Female
MH  - Injections, Intra-Arterial
MH  - Male
MH  - Rats
MH  - Rats, Wistar
EDAT- 2008/06/12 09:00
MHDA- 2008/07/11 09:00
CRDT- 2008/06/12 09:00
PHST- 2008/06/12 09:00 [pubmed]
PHST- 2008/07/11 09:00 [medline]
PHST- 2008/06/12 09:00 [entrez]
AID - 10.1007/BF03191015 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 2008 Jan-Mar;33(1):23-30. doi: 
      10.1007/BF03191015.

PMID- 27752166
OWN - NLM
STAT- MEDLINE
DCOM- 20170922
LR  - 20181202
IS  - 1671-167X (Print)
IS  - 1671-167X (Linking)
VI  - 48
IP  - 5
DP  - 2016 Oct 18
TI  - [Dose-response of aspirin on platelet function in very elderly patients].
PG  - 835-840
AB  - OBJECTIVE: To assess the consequences of switching aspirin dosage from 100 mg/d 
      to 40 mg/d on cardiovascular benefit, bleeding risk and platelet aggregation in 
      very elderly patients. METHODS: Arachidonic acid induced platelet 
      aggregation(AA-Ag) was measured in 537 patients aged 80 or older treated with 
      aspirin (100 mg/d). In the study, 100 patients with low on-treatment platelet 
      aggregation and at high risk of bleeding and low risk of cardiovascular events, 
      were switched to aspirin (40 mg/d) and their platelet aggregation was measured 
      again 7 days later.Their bleeding and upper gastrointestinal symptoms were also 
      recorded in following 3 months. RESULTS: The study observed a heterogeneous 
      distributed aspirin 100 mg/d AA-Ag (range: 0.42% to 28.78%)in the 537 very 
      elderly patients.Aspirin 100 mg/d AA-Ag before the switch in aspirin 40 mg/d 
      group was 5.00%±2.32% and the rate of the patients with low on-treatment platelet 
      aggregation was 71.00%. The rates of melena or occult blood positive, other 
      minimal bleeding,upper gastrointestinal symptoms and a history of 
      gastrointestinal bleeding in 40 mg/d group were higher than those in 100 mg/d 
      group. On a regimen of aspirin 40 mg/d, AA-Ag increased to 11.21%±4.95%(range: 
      2.12% to 28.84%) with 95.00%of the patients with AA-Ag<20% and the rate of the 
      patients with low on-treatment platelet aggregation was 15.00%. Multiple variable 
      analysis revealed that aspirin 40 mg/d AA-Ag was significantly influenced by 
      aspirin 100 mg/d AA-Ag, BMI and platelet counts. The rate of gastrointestinal 
      bleeding decreased from 12.00% to 5.00%,and upper gastrointestinal symptoms 
      decreased from 59.00% to 21.00% after the switch in 40 mg/d group. CONCLUSION: 
      Switching aspirin dosage from 100 mg/d to 40 mg/d reduces the bleeding events and 
      improves upper gastrointestinal symptoms, thus inhibiting platelet aggregation 
      effectively in very elderly patients.
FAU - Feng, X R
AU  - Feng XR
AD  - Department of Geriatrics, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Liu, M L
AU  - Liu ML
AD  - Department of Geriatrics, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Liu, F
AU  - Liu F
AD  - Department of Geriatrics, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Fan, Y
AU  - Fan Y
AD  - Department of Geriatrics, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Tian, Q P
AU  - Tian QP
AD  - Department of Geriatrics, Peking University First Hospital, Beijing 100034, 
      China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Beijing Da Xue Xue Bao Yi Xue Ban
JT  - Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health 
      sciences
JID - 101125284
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged, 80 and over
MH  - Arachidonic Acid/adverse effects/blood
MH  - Aspirin/*administration & dosage/*adverse effects/*blood/pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Platelet Function Tests
EDAT- 2016/10/19 06:00
MHDA- 2017/09/25 06:00
CRDT- 2016/10/19 06:00
PHST- 2016/10/19 06:00 [pubmed]
PHST- 2017/09/25 06:00 [medline]
PHST- 2016/10/19 06:00 [entrez]
PST - ppublish
SO  - Beijing Da Xue Xue Bao Yi Xue Ban. 2016 Oct 18;48(5):835-840.

PMID- 4425854
OWN - NLM
STAT- MEDLINE
DCOM- 19750122
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 4
IP  - 5939
DP  - 1974 Nov 2
TI  - Absorption of effervescent aspirin during migraine.
PG  - 265-8
AB  - The absorption of effervescent aspirin was studied in 42 patients during acute 
      attacks of migraine. When compared with normal controls and with themselves 
      between attacks 19 out of the 42 patients showed impairment of absorption. 
      Impairment of absorption seemed to correlate with the severity of the headache 
      and the gastro-intestinal symptoms at the time of treatment but not with the 
      duration of the attack or with the type of migraine. This study probably 
      underestimated the prevalence of impairment of absorption in migraine attacks, 
      and it is concluded that the treatment of acute migraine symptoms by oral drugs 
      should use those formulations which are rapidly absorbed under normal conditions.
FAU - Volans, G N
AU  - Volans GN
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Dosage Forms)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*blood/therapeutic use
MH  - Digestive System/physiopathology
MH  - Dosage Forms
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Migraine Disorders/*blood/drug therapy/physiopathology
MH  - Time Factors
PMC - PMC1612218
EDAT- 1974/11/02 00:00
MHDA- 1974/11/02 00:01
CRDT- 1974/11/02 00:00
PHST- 1974/11/02 00:00 [pubmed]
PHST- 1974/11/02 00:01 [medline]
PHST- 1974/11/02 00:00 [entrez]
AID - 10.1136/bmj.4.5939.265 [doi]
PST - ppublish
SO  - Br Med J. 1974 Nov 2;4(5939):265-8. doi: 10.1136/bmj.4.5939.265.

PMID- 31442897
OWN - NLM
STAT- MEDLINE
DCOM- 20200505
LR  - 20200505
IS  - 1532-2823 (Electronic)
IS  - 0952-3278 (Linking)
VI  - 149
DP  - 2019 Oct
TI  - Evaluation of commonly used tests to measure the effect of single-dose aspirin on 
      mouse hemostasis.
PG  - 46-51
LID - S0952-3278(19)30074-2 [pii]
LID - 10.1016/j.plefa.2019.08.002 [doi]
AB  - Discrepancies in preclinical studies of aspirin (ASA) antiplatelet activity in 
      mouse models of bleeding and arterial thrombosis led us to evaluate commonly 
      reported methods in order to propose a procedure for reliably measuring the 
      effects of single dose ASA on mouse hemostasis. FVB and C57Bl6 mice received 
      100 mg/kg of ASA or vehicle orally 30 min or 3 h prior to investigate either 
      hemostasis using the tail bleeding assay or carotid thrombosis induced by 
      FeCl(3), or to blood sampling for isolated platelet aggregation and TXB(2) 
      generation. Expected inhibition of COX1 by ASA was ascertained by a strong 
      decrease in TXB(2) production, and its effect on platelet function and 
      hemostasis, by decreased collagen-induced aggregation and increased bleeding 
      time, respectively. Strikingly, we determined that anti-hemostatic effects of ASA 
      were more predictable 30 min after administration than 3 h later. Conversely, ASA 
      did not alter time to arterial occlusion of the carotid upon FeCl(3)-induced 
      thrombosis, suggesting ASA not to be used as reference inhibitor drug in this 
      model of arterial thrombosis.
CI  - Copyright © 2019 Elsevier Ltd. All rights reserved.
FAU - Decouture, Benoit
AU  - Decouture B
AD  - Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, 
      France.
FAU - Leuci, Alexandre
AU  - Leuci A
AD  - Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, 
      France.
FAU - Dizier, Blandine
AU  - Dizier B
AD  - Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, 
      France.
FAU - Belleville-Rolland, Tiphaine
AU  - Belleville-Rolland T
AD  - Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, 
      France; Service d'Hématologie Biologique, AH-HP, Georges Pompidou European 
      Hospital, F-75015 Paris, France.
FAU - Mansour, Alexandre
AU  - Mansour A
AD  - Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, 
      France.
FAU - Martin, Fanny
AU  - Martin F
AD  - Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, 
      France.
FAU - Pidard, Dominique
AU  - Pidard D
AD  - Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, 
      France.
FAU - Gaussem, Pascale
AU  - Gaussem P
AD  - Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, 
      France; Service d'Hématologie Biologique, AH-HP, Georges Pompidou European 
      Hospital, F-75015 Paris, France. Electronic address: pascale.gaussem@aphp.fr.
FAU - Bachelot-Loza, Christilla
AU  - Bachelot-Loza C
AD  - Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, 
      France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190808
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/*pharmacology/therapeutic use
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical/*methods
MH  - Hemorrhage/drug therapy
MH  - Hemostasis/*drug effects
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & 
      dosage/*pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Thrombosis/drug therapy
OTO - NOTNLM
OT  - Aspirin
OT  - Hemostasis
OT  - Platelets
OT  - Preclinical study
OT  - Thrombosis
EDAT- 2019/08/24 06:00
MHDA- 2020/05/06 06:00
CRDT- 2019/08/24 06:00
PHST- 2019/04/08 00:00 [received]
PHST- 2019/07/26 00:00 [revised]
PHST- 2019/08/07 00:00 [accepted]
PHST- 2019/08/24 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
PHST- 2019/08/24 06:00 [entrez]
AID - S0952-3278(19)30074-2 [pii]
AID - 10.1016/j.plefa.2019.08.002 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2019 Oct;149:46-51. doi: 
      10.1016/j.plefa.2019.08.002. Epub 2019 Aug 8.

PMID- 7402059
OWN - NLM
STAT- MEDLINE
DCOM- 19801024
LR  - 20131121
IS  - 0195-9131 (Print)
IS  - 0195-9131 (Linking)
VI  - 12
IP  - 3
DP  - 1980
TI  - Reflections on a 100-mile run: effects of aspirin therapy.
PG  - 212-5
AB  - I finished a 100-mile competitive run in hot, humid weather. Because of knee 
      pain, I took therapeutic amounts of aspirin before and throughout the race. Based 
      on empirical evidence, I conclude that aspirin increased by sweat rate, body 
      temperature, and urinary output; inhibited my thirst; abolished my knee pain; and 
      blunted my sense of fatigue. The overall effect was detrimental and predisposed 
      me to heat illness. From the information presented, two potential effects of 
      aspirin have become evident. First, aspirin therapy (approximately 10 or more 
      tablets daily) may be dangerous when combined with physical exertion in the heat. 
      Second, aspirin therapy might reduce the extreme thirst sometimes associated with 
      hyperreninemia. Both hypotheses deserve further study.
FAU - Fred, H L
AU  - Fred HL
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Med Sci Sports Exerc
JT  - Medicine and science in sports and exercise
JID - 8005433
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Knee Injuries/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Physical Endurance/*drug effects
MH  - *Running
MH  - Sports Medicine
MH  - Sweating/drug effects
MH  - Thirst/drug effects
MH  - Urination/drug effects
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Med Sci Sports Exerc. 1980;12(3):212-5.

PMID- 19094419
OWN - NLM
STAT- MEDLINE
DCOM- 20090224
LR  - 20131121
IS  - 1479-1072 (Print)
IS  - 1479-1064 (Linking)
VI  - 16
IP  - 6
DP  - 2008
TI  - Ethical considerations in relation to aspirin prophylaxis.
PG  - 433-40
AB  - Low-dose aspirin prophylaxis, 75-150 mg per day, reduces the risk of vascular 
      events and there is also promising evidence that it may also reduce the risk of 
      cancer. Increased use of aspirin may confer considerable benefits to the 
      population, but the risk of causing a gastric bleed is certainly a major concern. 
      There are ethical considerations related to the potential increased use of 
      aspirin in the population. These include the balance of benefit and risk of the 
      medicine, possible undesirable effects such as 'risk compensation' and 
      'iatrogenesis', as well as a potential impact on health inequalities. More 
      research is therefore needed on aspirin, particularly to define and describe the 
      population use of the drug. More evidence on aspirin, including an ongoing 
      randomised controlled trial on vascular events, will allow appropriate policy 
      responses to be made.
FAU - Morgan, Gareth
AU  - Morgan G
AD  - Welsh Aspirin Group Secretary, Swansea, Wales, UK. morgan@fforrdbeck.fsnet.co.uk
LA  - eng
PT  - Journal Article
PL  - England
TA  - Qual Prim Care
JT  - Quality in primary care
JID - 101182136
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - *Ethics, Medical
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Neoplasms/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Risk Assessment
MH  - Socioeconomic Factors
EDAT- 2008/12/20 09:00
MHDA- 2009/02/25 09:00
CRDT- 2008/12/20 09:00
PHST- 2008/12/20 09:00 [entrez]
PHST- 2008/12/20 09:00 [pubmed]
PHST- 2009/02/25 09:00 [medline]
PST - ppublish
SO  - Qual Prim Care. 2008;16(6):433-40.

PMID- 8548891
OWN - NLM
STAT- MEDLINE
DCOM- 19960220
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 93
IP  - 2
DP  - 1996 Jan 15
TI  - A randomized comparison of combined ticlopidine and aspirin therapy versus 
      aspirin therapy alone after successful intravascular ultrasound-guided stent 
      implantation.
PG  - 215-22
AB  - BACKGROUND: Previous studies have shown that it is feasible to withhold 
      anticoagulation after a successful intracoronary stent procedure with a low 
      incidence of stent thrombosis. The importance of specific antiplatelet agents 
      when stenting is performed without anticoagulation is unknown. METHODS AND 
      RESULTS: After successful intravascular ultrasound-guided stenting, 226 patients 
      were randomly assigned to receive either aspirin therapy alone (n = 103) or a 
      combination of ticlopidine and short-term aspirin therapy (n = 123). Primary 
      angiographic and clinical end points were stent thrombosis, death, myocardial 
      infarction, the need for postprocedure coronary artery bypass surgery or repeated 
      angioplasty, and significant medication side effects requiring termination of the 
      medication within the first month of a successful procedure. At 1 month, the rate 
      of stent thrombosis was 2.9% in the aspirin only group and 0.8% in the 
      ticlopidine-aspirin group (P = .2). Cumulative major clinical events after 
      successful stenting occurred in 3.9% of the patients in the aspirin group and in 
      0.8% in the ticlopidine-aspirin group (P = .1). There were no medication side 
      effects in the aspirin group; in the combined ticlopidine-aspirin group, 
      medication side effects occurred in 3 patients (P = .2). CONCLUSIONS: At 1 month, 
      there was no difference in the incidence of stent thrombosis or other clinical 
      end points between the two poststent antiplatelet regimens. However, the 
      relatively small size of the study and the low incidence of thrombosis events may 
      have contributed to the failure to detect differences in angiographic and 
      clinical end points between the two groups.
FAU - Hall, P
AU  - Hall P
AD  - Centro Cuore Columbus, Milan, Italy.
FAU - Nakamura, S
AU  - Nakamura S
FAU - Maiello, L
AU  - Maiello L
FAU - Itoh, A
AU  - Itoh A
FAU - Blengino, S
AU  - Blengino S
FAU - Martini, G
AU  - Martini G
FAU - Ferraro, M
AU  - Ferraro M
FAU - Colombo, A
AU  - Colombo A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 1996 Dec 1;94(11):2993-4. PMID: 8941139
MH  - Aged
MH  - Angiography
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Stents
MH  - Thrombosis/*prevention & control
MH  - Ticlopidine/administration & dosage/pharmacology/*therapeutic use
MH  - Ultrasonics
EDAT- 1996/01/15 00:00
MHDA- 1996/01/15 00:01
CRDT- 1996/01/15 00:00
PHST- 1996/01/15 00:00 [pubmed]
PHST- 1996/01/15 00:01 [medline]
PHST- 1996/01/15 00:00 [entrez]
AID - 10.1161/01.cir.93.2.215 [doi]
PST - ppublish
SO  - Circulation. 1996 Jan 15;93(2):215-22. doi: 10.1161/01.cir.93.2.215.

PMID- 8498423
OWN - NLM
STAT- MEDLINE
DCOM- 19930622
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 168
IP  - 5
DP  - 1993 May
TI  - Effects of maternal ingestion of low-dose aspirin on the fetal cardiovascular 
      system.
PG  - 1430-7
AB  - OBJECTIVE: Our purpose was to assess fetal central and regional hemodynamics in 
      normal fetuses using two-dimensional, range-gated pulsed Doppler echocardiography 
      in pregnant women on chronic baby aspirin regimen (87 mg). STUDY DESIGN: Fifteen 
      fetuses exposed to maternal chronic ingestion of baby aspirin were compared with 
      26 control fetuses. Longitudinal studies of the umbilical artery waveform and 
      blood flow through the fetal right and left ventricles were obtained every 4 
      weeks during gestation in a group of fetuses exposed to daily maternal intake of 
      87 mg of aspirin. Pulsed Doppler waveforms were obtained below the tricuspid and 
      mitral valves, at the level of the descending aorta (below the ductus), and at 
      the level of the fetal renal artery as it enters the kidney. All tracings were 
      recorded on a strip chart and analyzed with a digital light-pen and graphic 
      overlay system. Peak systolic velocity and minimal diastolic velocity were 
      obtained for the umbilical and fetal renal artery. Peak flow velocity and 
      velocity time integral of the pulsed Doppler waveforms of the atrioventricular 
      valves were calculated. Acceleration time/ejection time ratio was obtained for 
      the descending aorta. RESULTS: No significant differences were found among the 
      two groups in either central or regional circulation. CONCLUSION: Chronic daily 
      maternal ingestion of baby aspirin does not significantly affect the central and 
      regional circulation of the fetus.
FAU - Veille, J C
AU  - Veille JC
AD  - Department of Obstetrics and Gynecology, Bowman Gray School of Medicine, Wake 
      Forest University, Winston-Salem, NC 27157.
FAU - Hanson, R
AU  - Hanson R
FAU - Sivakoff, M
AU  - Sivakoff M
FAU - Swain, M
AU  - Swain M
FAU - Henderson, L
AU  - Henderson L
LA  - eng
GR  - HL38296/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Flow Velocity/drug effects
MH  - Coronary Circulation/drug effects
MH  - Echocardiography, Doppler
MH  - Female
MH  - Fetus/*drug effects
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Pregnancy
MH  - Ultrasonography, Prenatal
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
AID - S0002-9378(11)90777-7 [pii]
AID - 10.1016/s0002-9378(11)90777-7 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1993 May;168(5):1430-7. doi: 10.1016/s0002-9378(11)90777-7.

PMID- 24879431
OWN - NLM
STAT- MEDLINE
DCOM- 20150115
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 5
DP  - 2014
TI  - A short-term effect of low-dose aspirin on major hemorrhagic risks in primary 
      prevention: a case-crossover design.
PG  - e98326
LID - 10.1371/journal.pone.0098326 [doi]
LID - e98326
AB  - BACKGROUND: Very few studies have examined the risk of short-term adverse 
      hemorrhage of low-dose aspirin use in primary prevention. This case-crossover 
      study examined the transient effect of low-dose aspirin use on major hemorrhagic 
      risks. METHODS: A representative database of 1,000,000 patients randomly sampled 
      from the Taiwan's National Health Insurance Research Database in 2000 was 
      analyzed. The study cohort consisted of a total of 501,946 individuals, aged 
      30-95 years old, at risk of a major bleeding event in 2000. A case-crossover 
      study was used to retrieve data on 10,905 incident patients with major 
      hemorrhagic complications (3,781 cerebral and 7,124 gastrointestinal) and 
      prescribed low-dose aspirin (≤300 mg/day) from 2000-2008. A 56-day time window 
      (∼2 months) was used as the case period for which the odds ratio (OR) was 
      estimated using the ratio of patients exposed during the 56-day case period only 
      (1-56 days before the index date) compared to its corresponding 56-day control 
      period only (57-112 days before the index date). RESULTS: Four hundred 
      eighty-nine (4.5%) of the 10,905 hemorrhagic patients had used low-dose aspirin 
      during the 56-day case only period; 294 (2.7%) of the same patients had used 
      low-dose aspirin during control only period. Low-dose aspirin use increase the 
      risk of developing a major hemorrhage 1.33-fold (95% CI = 1.13-1.55, P<0.0001). 
      Significance was found prominent in 4,453 non-hypertensive and non-diabetic 
      subjects (Adjusted odds ratio = 1.88, 95% CI = 1.21-2.91). CONCLUSION: Transient 
      low-dose aspirin use increases risk for major hemorrhagic events in Han Chinese.
FAU - Wu, I-Chen
AU  - Wu IC
AD  - Kaohsiung Medical University, Kaohsiung, Taiwan; Kaohsiung Medical University 
      Hospital, Kaohsiung, Taiwan.
FAU - Lin, Ming-Yen
AU  - Lin MY
AD  - Kaohsiung Medical University, Kaohsiung, Taiwan.
FAU - Yu, Fang-Jung
AU  - Yu FJ
AD  - Kaohsiung Medical University, Kaohsiung, Taiwan; Kaohsiung Medical University 
      Hospital, Kaohsiung, Taiwan.
FAU - Hsieh, Hui-Min
AU  - Hsieh HM
AD  - Kaohsiung Medical University, Kaohsiung, Taiwan.
FAU - Chiu, Kuei-Fen
AU  - Chiu KF
AD  - Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
FAU - Wu, Ming-Tsang
AU  - Wu MT
AD  - Kaohsiung Medical University, Kaohsiung, Taiwan; Kaohsiung Medical University 
      Hospital, Kaohsiung, Taiwan; Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, 
      Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140530
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/pharmacology
MH  - Cross-Over Studies
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention/*methods
MH  - Risk
MH  - Time Factors
PMC - PMC4039487
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/06/01 06:00
MHDA- 2015/01/16 06:00
CRDT- 2014/06/01 06:00
PHST- 2014/02/03 00:00 [received]
PHST- 2014/05/01 00:00 [accepted]
PHST- 2014/06/01 06:00 [entrez]
PHST- 2014/06/01 06:00 [pubmed]
PHST- 2015/01/16 06:00 [medline]
AID - PONE-D-14-05023 [pii]
AID - 10.1371/journal.pone.0098326 [doi]
PST - epublish
SO  - PLoS One. 2014 May 30;9(5):e98326. doi: 10.1371/journal.pone.0098326. eCollection 
      2014.

PMID- 25001974
OWN - NLM
STAT- MEDLINE
DCOM- 20141104
LR  - 20170328
IS  - 1759-5053 (Electronic)
IS  - 1759-5045 (Linking)
VI  - 11
IP  - 8
DP  - 2014 Aug
TI  - PPI therapy. The small bowel, low-dose aspirin and PPIs--should we be concerned?
PG  - 458-60
LID - 10.1038/nrgastro.2014.120 [doi]
AB  - A new study suggests that co-prescription of low-dose aspirin and PPIs increases 
      the incidence of small-bowel mucosal breaks. Should we be concerned about the 
      potential negative interactions of these drugs? Or is the balance of evidence 
      still substantially tipped towards the need for PPIs to protect against 
      aspirin-induced upper gastrointestinal damage?
FAU - Lanas, Angel
AU  - Lanas A
AD  - University Clinic Hospital, University of Zaragoza, CIBERehd, IIS Aragón, Calle 
      de San Juan Bosco 15, 5009 Zaragoza, Spain.
FAU - Sostres, Carlos
AU  - Sostres C
AD  - University Clinic Hospital, University of Zaragoza, CIBERehd, IIS Aragón, Calle 
      de San Juan Bosco 15, 5009 Zaragoza, Spain.
LA  - eng
PT  - Journal Article
DEP - 20140708
PL  - England
TA  - Nat Rev Gastroenterol Hepatol
JT  - Nature reviews. Gastroenterology & hepatology
JID - 101500079
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Humans
MH  - Intestinal Mucosa/drug effects
MH  - Intestine, Small/*drug effects
MH  - Proton Pump Inhibitors/*administration & dosage
EDAT- 2014/07/09 06:00
MHDA- 2014/11/05 06:00
CRDT- 2014/07/09 06:00
PHST- 2014/07/09 06:00 [entrez]
PHST- 2014/07/09 06:00 [pubmed]
PHST- 2014/11/05 06:00 [medline]
AID - nrgastro.2014.120 [pii]
AID - 10.1038/nrgastro.2014.120 [doi]
PST - ppublish
SO  - Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):458-60. doi: 
      10.1038/nrgastro.2014.120. Epub 2014 Jul 8.

PMID- 305202
OWN - NLM
STAT- MEDLINE
DCOM- 19780417
LR  - 20161123
IS  - 0002-9289 (Print)
IS  - 0002-9289 (Linking)
VI  - 35
IP  - 3
DP  - 1978 Mar
TI  - Aspirin hepatotoxicity.
PG  - 330-6
AB  - A case of aspirin hepatotoxicity in a 46-year-old male with rheumatoid arthritis 
      is discussed, and this adverse reaction is reviewed. The patient was started on 
      900 mg aspirin four times daily; five days later the dose was increased to 1200 
      mg four times daily. After six days' therapy of 4.8 g aspirin daily, the serum 
      salicylate level rose to 25 mg/100 ml and liver enzymes became elevated. Aspirin 
      was discontinued and ibuprofen, 600 mg four times daily, begun. Eight days after 
      cessation of aspirin therapy, the patient's liver enzyme values returned to 
      normal. Previous case reports and studies of aspirin-induced hepatotoxicity are 
      reviewed. It is concluded that aspirin-induced hepatotoxicity occurs much more 
      frequently in patients with rheumatoid arthritis and other connective tissue 
      disorders than previously recognized.
FAU - Kanada, S A
AU  - Kanada SA
FAU - Kolling, W M
AU  - Kolling WM
FAU - Hindin, B I
AU  - Hindin BI
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Hosp Pharm
JT  - American journal of hospital pharmacy
JID - 0370474
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aging
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Chemical and Drug Induced Liver Injury/*etiology
MH  - Child
MH  - Female
MH  - Humans
MH  - Liver Function Tests
MH  - Lupus Erythematosus, Systemic/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Rheumatic Diseases/drug therapy
MH  - Sex Factors
EDAT- 1978/03/01 00:00
MHDA- 1978/03/01 00:01
CRDT- 1978/03/01 00:00
PHST- 1978/03/01 00:00 [pubmed]
PHST- 1978/03/01 00:01 [medline]
PHST- 1978/03/01 00:00 [entrez]
PST - ppublish
SO  - Am J Hosp Pharm. 1978 Mar;35(3):330-6.

PMID- 1151748
OWN - NLM
STAT- MEDLINE
DCOM- 19751030
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 194
IP  - 1
DP  - 1975 Jul
TI  - Effects of sodium acetylsalicylate on body temperature of monkeys under heat 
      exposure.
PG  - 165-70
AB  - Exposure of Taiwan monkeys to 38 degrees C ambient temperature caused: a) raised 
      body temperature, b) restlessness and struggling, c) increased evaporative heat 
      loss and d) increase in tail skin temperature. After the administration of sodium 
      acetylsalicylate, 100 to 250 mg/kg intraperitoneally or 4 to 15 mg 
      intracerebroventricularly (third ventricle) the same heat load caused: a) less 
      increase in body temperature, b) no restlessness or struggling, c) an initially 
      higher rate of evaporative heat loss and d) higher tail skin temperature. Larger 
      doses of acetylsalicylate caused greater antihyperthermic effects. 
      Intracerebroventricular injection was more effective than the intraperitoneal 
      route. These data show that acetylsalicylate improved tolerance of animals to 
      external heat loads. The magnitude of body temperature elevation during heat 
      exposure was reduced in the presence of acetylsalicylate by activation of 
      heat-dissipating mechanisms, presumably through the central nervous system.
FAU - Lin, M T
AU  - Lin MT
FAU - Chai, C Y
AU  - Chai CY
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Body Temperature/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fever
MH  - *Hot Temperature
MH  - Injections, Intraperitoneal
MH  - Macaca
MH  - Male
MH  - Time Factors
EDAT- 1975/07/01 00:00
MHDA- 1975/07/01 00:01
CRDT- 1975/07/01 00:00
PHST- 1975/07/01 00:00 [pubmed]
PHST- 1975/07/01 00:01 [medline]
PHST- 1975/07/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1975 Jul;194(1):165-70.

PMID- 2390880
OWN - NLM
STAT- MEDLINE
DCOM- 19901004
LR  - 20131121
IS  - 0412-4057 (Print)
IS  - 0412-4057 (Linking)
VI  - 23
IP  - 2
DP  - 1990 Apr
TI  - [Research on the critical dose for antithrombotic effectiveness of aspirin in the 
      Chinese].
PG  - 94-5, 127
AB  - We studied 345 cases taking aspirin due to increased platelet aggregation. 220 
      were male and 125 were female. They were divided into five groups (0, 30 mg, 50 
      mg, 300 mg, 500 mg, daily) with double-blind method. Platelet aggregation tests 
      were performed before and after medication. The result shows that the response in 
      male is good. For female, the benefit in menopausal women and contraceptive taker 
      is more prominent than that in adolescent and middle aged women. From our 
      clinical trial we suggest 50 mg of aspirin daily as the optimal dosage.
FAU - Pang, S
AU  - Pang S
AD  - Beijing Xuan-wu Hospital.
LA  - chi
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Shen Jing Jing Shen Ke Za Zhi
JT  - Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and 
      psychiatry
JID - 16210510R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arteriosclerosis/drug therapy
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1990 Apr;23(2):94-5, 127.

PMID- 9538376
OWN - NLM
STAT- MEDLINE
DCOM- 19980422
LR  - 20131121
IS  - 0003-410X (Print)
IS  - 0003-410X (Linking)
VI  - 148
IP  - 6
DP  - 1997
TI  - Aspirin for prevention of myocardial infarction. A double-edged sword.
PG  - 430-3
AB  - BACKGROUND: The use of low dose aspirin is associated with upper gastrointestinal 
      bleeding, especially in the elderly. Anemia is one of the risk factors of acute 
      myocardial infarction especially in patients with ischemic heart disease. METHODS 
      AND RESULTS: We present a series of fifteen patients treated with low dose 
      aspirin for secondary prevention of ischemic heart disease who had upper GI 
      bleeding and were admitted to our hospital because of unstable angina or 
      myocardial infarction. Nine patients had acute myocardial infarction and six 
      patients had unstable angina. The mean age of the patient was 72 +/- 9 years. 
      Only two patients had a previous history of duodenal ulcer before their 
      admission. The duration of aspirin therapy ranged from a few days to more than a 
      year. Weakness, abdominal pain and melena were present in most of the patients 
      between 2-7 days before the appearance of chest pain, and syncope was the chief 
      complaint in 5 patients. CONCLUSIONS: We conclude that aspirin which is given to 
      patients in order to prevent myocardial infarction might cause myocardial 
      infarction as a sequella of upper gastrointestinal bleeding. Lack of patient 
      education was the primary cause of the delayed diagnosis of this complication. 
      Instruction of patients treated by aspirin to seek medical advise because of 
      symptoms of gastrointestinal bleeding could prevent acute myocardial infarction 
      in patients treated by aspirin who have upper gastrointestinal bleeding.
FAU - Bar-Dayan, Y
AU  - Bar-Dayan Y
AD  - Department of Medicine 'B', Research Unit of Autoimmune Diseases, Sheba Medical 
      Center, Tel-Hashomer, Israel.
FAU - Levy, Y
AU  - Levy Y
FAU - Amital, H
AU  - Amital H
FAU - Shoenfeld, Y
AU  - Shoenfeld Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Ann Med Interne (Paris)
JT  - Annales de medecine interne
JID - 0171744
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia/etiology
MH  - Angina, Unstable/etiology
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/physiopathology
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Risk Factors
EDAT- 1997/01/01 00:00
MHDA- 1998/04/16 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1998/04/16 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Ann Med Interne (Paris). 1997;148(6):430-3.

PMID- 12120413
OWN - NLM
STAT- MEDLINE
DCOM- 20020730
LR  - 20171116
IS  - 1474-1776 (Print)
IS  - 1474-1776 (Linking)
VI  - 1
IP  - 5
DP  - 2002 May
TI  - Potential cardioprotective actions of no-releasing aspirin.
PG  - 375-82
AB  - The use of low doses of aspirin on a daily basis has increased greatly in the 
      past 20 years, based on observations that it can significantly reduce the risk of 
      heart attacks and strokes. However, aspirin can also cause severe damage to the 
      stomach. A modified version of aspirin that releases nitric oxide has been 
      developed that seems to offer important advantages over its 103-year-old 
      parent--namely, improved protection for the heart without the unwanted effects on 
      the stomach.
FAU - Wallace, John L
AU  - Wallace JL
AD  - Department of Pharmacology & Therapeutics, University of Calgary, Calgary, 
      Alberta, T2N 4N1 Canada. wallacej@ucalgary.ca
FAU - Ignarro, Louis J
AU  - Ignarro LJ
FAU - Fiorucci, Stefano
AU  - Fiorucci S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Nat Rev Drug Discov
JT  - Nature reviews. Drug discovery
JID - 101124171
RN  - 0 (Caspase Inhibitors)
RN  - 0 (Cytokines)
RN  - EH04H13L6B (nitroaspirin)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Arteriosclerosis/drug therapy
MH  - Aspirin/analogs & derivatives/*pharmacology/therapeutic use
MH  - Caspase Inhibitors
MH  - Cell Adhesion/drug effects
MH  - Cyclic GMP/physiology
MH  - Cytokines/biosynthesis
MH  - Heart/*drug effects
MH  - Humans
MH  - Hypertension/drug therapy
MH  - Myocardial Infarction/*prevention & control
MH  - Stroke/*prevention & control
RF  - 105
EDAT- 2002/07/18 10:00
MHDA- 2002/07/31 10:01
CRDT- 2002/07/18 10:00
PHST- 2002/07/18 10:00 [pubmed]
PHST- 2002/07/31 10:01 [medline]
PHST- 2002/07/18 10:00 [entrez]
AID - 10.1038/nrd794 [doi]
PST - ppublish
SO  - Nat Rev Drug Discov. 2002 May;1(5):375-82. doi: 10.1038/nrd794.

PMID- 7742804
OWN - NLM
STAT- MEDLINE
DCOM- 19950615
LR  - 20190719
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 18
IP  - 2
DP  - 1995 Feb
TI  - Modeling of controlled release of aspirin derivatives from human erythrocytes.
PG  - 310-4
AB  - The transport of aspirin (ASP) and its derivatives (m- or p-acetoxybenzoic acid 
      (m- or p-AcOHBA), o-propionyloxybenzoic acid (PrOHBA), o-butyryloxybenzoic acid 
      (BuOHBA), o-acetoxyhippuric acid (AcOHPA), and o-acetoxy-N-benzoyl-beta-alanine 
      (AcONBA)) through human erythrocyte membrane was investigated. ASP derivatives 
      were transported into the erythrocytes where they were hydrolyzed and then 
      released, although the derivatives varied in the rate of transport. In different 
      binding positions, the hydrolyzed derivatives were released rapidly in the order 
      of p- > m- > o-AcOHBA (ASP). The rates of derivatives were accelerated by 
      lengthening of the side chain of the acetoxyl group (BuOHBA > PrOHBA > ASP). The 
      rate of release of o-, m- or p-AcOHBA, BuOHBA and PrOHBA was related to 
      hydrolysis rate in erythrocytes but not to partition coefficient (log P). In 
      different amino acids in a carboxyl group of ASP, the release of AcONBA was 
      slower and about 2 h was required to attain equilibrium. The release of AcOHPA 
      was also slower and increased gradually during an incubation of 3 h. The rate of 
      release of AcOHPA and AcONBA was not related to hydrolysis rate in the 
      erythrocytes. The rates were equivalent values with the predicted values 
      calculated by log P of tested drugs. It was suggested from these results that ASP 
      derivatives were able to control the release from human erythrocytes.
FAU - Ohsako, M
AU  - Ohsako M
AD  - Department of Pharmacy, Daiichi College of Pharmaceutical Sciences, Fukuoka, 
      Japan.
FAU - Oka, Y
AU  - Oka Y
FAU - Tsuzuki, O
AU  - Tsuzuki O
FAU - Matsumoto, Y
AU  - Matsumoto Y
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/*pharmacokinetics
MH  - Biological Transport
MH  - Erythrocyte Membrane/*metabolism
MH  - Humans
MH  - Hydrolysis
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Models, Biological
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
AID - 10.1248/bpb.18.310 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 1995 Feb;18(2):310-4. doi: 10.1248/bpb.18.310.

PMID- 1572459
OWN - NLM
STAT- MEDLINE
DCOM- 19920602
LR  - 20191021
IS  - 0950-821X (Print)
IS  - 0950-821X (Linking)
VI  - 6
IP  - 2
DP  - 1992 Mar
TI  - Aspirin usage and its influence on femoro-popliteal vein graft patency. The 
      Femoro-popliteal Bypass Trial Participants.
PG  - 185-8
AB  - As part of the Femoro-popliteal Bypass Trial patients undergoing femoro-popliteal 
      vein bypass were randomised to aspirin 300 mg and dipyridamole 150 mg twice daily 
      or identical placebo tablets. Blood was taken from a subgroup of 145 patients 
      (mean age 66.3 years) with patent grafts at 6 months. Serum salicylate analysis 
      revealed that of the 65 randomised to receive placebo 18 (28%) had evidence of 
      salicylate in their sample (greater than 50 ng ml-1). Similarly, in those 
      randomised to active treatment and considered to be good compliers 16/61 (26%) 
      had no evidence of salicylate in their serum sample (less than 50 ng ml-1). 
      Analysis of primary graft patency by "intention to treat" failed to detect a 
      difference by life table, the risk being slightly higher in the group assigned to 
      placebo (RR = 1.33, 95% confidence internal C.I. 0.64-2.78, p = 0.438). When 
      comparing patients with no detectable serum concentration (less than 50 ng ml-1) 
      with patients with serum salicylate over 50 ng ml-1 there was a significant 
      difference in graft patency at 66 versus 83% respectively at 3 years (RR = 2.38, 
      95%C.I. 1.08-5.26, p = 0.024). When corrected for a number of possible risk 
      factors this significant difference was maintained (RR = 2.78, 95%C.I. 1.15-6.67, 
      p = 0.017). Although these findings are based on observational data they provide 
      indirect evidence of an improvement in graft patency with aspirin. This result 
      combined with the finding of a significant reduction in cardiovascular events in 
      the main trial results support the use of aspirin and dipyridamole in patients 
      undergoing femoro-popliteal vein bypass.
FAU - Franks, P J
AU  - Franks PJ
AD  - Department of Surgery, Charing Cross and Westminster Medical School, London, U.K.
FAU - Sian, M
AU  - Sian M
FAU - Kenchington, G F
AU  - Kenchington GF
FAU - Alexander, C E
AU  - Alexander CE
FAU - Powell, J T
AU  - Powell JT
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Vasc Surg
JT  - European journal of vascular surgery
JID - 8709440
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anastomosis, Surgical
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Femoral Vein/drug effects/*surgery
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Compliance
MH  - Popliteal Vein/drug effects/*surgery
MH  - Vascular Patency/*drug effects
EDAT- 1992/03/01 00:00
MHDA- 1992/03/01 00:01
CRDT- 1992/03/01 00:00
PHST- 1992/03/01 00:00 [pubmed]
PHST- 1992/03/01 00:01 [medline]
PHST- 1992/03/01 00:00 [entrez]
AID - 10.1016/s0950-821x(05)80238-5 [doi]
PST - ppublish
SO  - Eur J Vasc Surg. 1992 Mar;6(2):185-8. doi: 10.1016/s0950-821x(05)80238-5.

PMID- 1352567
OWN - NLM
STAT- MEDLINE
DCOM- 19920813
LR  - 20190610
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 340
IP  - 8812
DP  - 1992 Jul 18
TI  - Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' 
      Health Study.
PG  - 143-5
AB  - In the US Physicians' Health Study the early termination of the aspirin arm has 
      provided the opportunity to test the hypothesis that low-dose aspirin (325 mg on 
      alternate days) might affect the subsequent occurrence of peripheral arterial 
      surgery. In the study, a randomised double-blind placebo-controlled trial among 
      22,071 healthy US male physicians aged 40-84, there were, during an average of 
      60.2 months of treatment and follow-up, 56 participants who underwent peripheral 
      arterial surgery (20 aspirin, 36 placebo). The relative risk of peripheral artery 
      surgery in the aspirin group was 0.54 (95% confidence intervals 0.30-0.95; p = 
      0.03). These data indicate that chronic administration of low-dose aspirin to 
      apparently healthy men reduced the need for peripheral arterial surgery.
FAU - Goldhaber, S Z
AU  - Goldhaber SZ
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
FAU - Manson, J E
AU  - Manson JE
FAU - Stampfer, M J
AU  - Stampfer MJ
FAU - LaMotte, F
AU  - LaMotte F
FAU - Rosner, B
AU  - Rosner B
FAU - Buring, J E
AU  - Buring JE
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA-34944/CA/NCI NIH HHS/United States
GR  - HL-26490/HL/NHLBI NIH HHS/United States
GR  - HL-34595/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/*prevention & control/surgery
MH  - Risk Factors
EDAT- 1992/07/18 00:00
MHDA- 1992/07/18 00:01
CRDT- 1992/07/18 00:00
PHST- 1992/07/18 00:00 [pubmed]
PHST- 1992/07/18 00:01 [medline]
PHST- 1992/07/18 00:00 [entrez]
AID - 0140-6736(92)93216-A [pii]
AID - 10.1016/0140-6736(92)93216-a [doi]
PST - ppublish
SO  - Lancet. 1992 Jul 18;340(8812):143-5. doi: 10.1016/0140-6736(92)93216-a.

PMID- 24925393
OWN - NLM
STAT- MEDLINE
DCOM- 20150406
LR  - 20140613
IS  - 1662-2898 (Electronic)
IS  - 0079-6034 (Linking)
VI  - 100
DP  - 2014
TI  - Aspirin hypersensitivity.
PG  - 132-9
LID - 10.1159/000358618 [doi]
AB  - Hypersensitivity reactions to acetylsalicylic acid and non-steroidal 
      anti-inflammatory drugs constitute a major medical concern worldwide. This 
      article presents an overview of the observations that led to the discovery of 
      cyclooxygenase inhibitors, as a prerequisite to better understand the basic 
      concepts supporting seminal investigations carried out in order to elucidate the 
      clinical features, pathogenic mechanisms, diagnosis and modern management of 
      these common conditions. There are some unmet needs in this clinical area which 
      will have to be solved in the future, especially concerning the pathogenesis of 
      these reactions and the availability of novel in vitro diagnostic methods sparing 
      both patient and physician of the risks inherent to in vivo provocation tests.
CI  - © 2014 S. Karger AG, Basel.
FAU - Sánchez-Borges, Mario
AU  - Sánchez-Borges M
AD  - Allergy and Clinical Immunology Department, Centro Médico-Docente 'la Trinidad' 
      and Clínica El Avila, Caracas, Venezuela.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20140522
PL  - Switzerland
TA  - Chem Immunol Allergy
JT  - Chemical immunology and allergy
JID - 101183835
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/history
MH  - Aspirin/*adverse effects/chemical synthesis/history
MH  - Cyclooxygenase 1/chemistry/metabolism
MH  - Drug Hypersensitivity/*etiology
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, Ancient
MH  - Humans
EDAT- 2014/06/14 06:00
MHDA- 2015/04/07 06:00
CRDT- 2014/06/14 06:00
PHST- 2014/06/14 06:00 [entrez]
PHST- 2014/06/14 06:00 [pubmed]
PHST- 2015/04/07 06:00 [medline]
AID - 000358618 [pii]
AID - 10.1159/000358618 [doi]
PST - ppublish
SO  - Chem Immunol Allergy. 2014;100:132-9. doi: 10.1159/000358618. Epub 2014 May 22.

PMID- 2795423
OWN - NLM
STAT- MEDLINE
DCOM- 19891103
LR  - 20131121
IS  - 0047-2166 (Print)
IS  - 0047-2166 (Linking)
VI  - 44
IP  - 3
DP  - 1989 May-Jun
TI  - [The effect of certain active principles and excipients on the biodisposition of 
      rectally administered acetylsalicylic acid in the rabbit].
PG  - 197-209
AB  - In this work, we have studied in the rabbit, bioavailability of acetylsalicylic 
      acid contained respectively in three forms of suppositories which are made as 
      follows: for the first by only acetylsalicyclic acid (0.1 g); for the second by 
      the association: acetylsalicylic acid (0.1 g) and phenobarbital (0.01 g); and for 
      the third by acetylsalicylic acid (0.01 g), ascorbic acid (0.02 g) and thiamine 
      chloride (0.002 g). It has been shown that ascorbic acid and thiamine chloride do 
      not change the bioavailability of acetylsalicylic acid, while phenobarbital 
      decreases it. In this work we have also compared two pharmaceutical forms of 
      suppositories containing acetylsalicylic acid, ascorbic acid and thiamine 
      chloride. In one of the two forms, acetylsalicylic acid is buffered by 
      glycocolle. The study which consisted in giving the two forms to the rabbit 
      rectally was concerned with the effect of glycocolle on the bioavailability of 
      acetylsalicylic acid. It was shown that making glycocolle a buffer to 
      acetylsalicylic acid resulted in an improved absorption as well as a delayed 
      elimination of acetylsalicyclic acid. In this study too, we have evaluated the 
      bioavailability of acetylsalicylic acid which is released from two types of 
      suppositories containing respectively base witepsol W31 and base cocoa butter. In 
      order to study this bioavailability whole suppositories were administered by 
      rectal route to the rabbits after 24 hours of fasting (balanced crossover design 
      with 15 days of interval after each study). Statistical analysis does not reveal 
      any significant difference between the two forms of suppositories.
FAU - Fehri, B
AU  - Fehri B
FAU - Aiache, J M
AU  - Aiache JM
FAU - Boukef, K
AU  - Boukef K
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Influence de certains principes actifs et excipients sur la biodisponibilité de 
      l'acide acétylsalicylique administré par voie rectale chez le lapin.
PL  - Belgium
TA  - J Pharm Belg
JT  - Journal de pharmacie de Belgique
JID - 0375351
RN  - 0 (Excipients)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Rectal
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Excipients
MH  - Male
MH  - Rabbits
MH  - Tissue Distribution
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
PST - ppublish
SO  - J Pharm Belg. 1989 May-Jun;44(3):197-209.

PMID- 10714657
OWN - NLM
STAT- MEDLINE
DCOM- 20000323
LR  - 20210503
IS  - 0003-9942 (Print)
IS  - 0003-9942 (Linking)
VI  - 57
IP  - 3
DP  - 2000 Mar
TI  - Aspirin for the primary prevention of stroke and other major vascular events: 
      meta-analysis and hypotheses.
PG  - 326-32
AB  - BACKGROUND: Aspirin therapy reduces stroke by about 25% for persons with 
      atherosclerotic vascular disease, but the effect in those without clinically 
      apparent vascular disease is distinctly different. OBJECTIVE: To define the 
      effect of aspirin use on stroke and other major vascular events when given for 
      primary prevention to persons without clinically recognized vascular disease. 
      DATA SOURCES AND EXTRACTION: Systematic review of randomized clinical trials and 
      large prospective observational cohort studies examining the relation between 
      aspirin use and stroke in persons at low intrinsic risk. Studies were identified 
      by a computerized search of the English-language literature. DATA SYNTHESIS: Five 
      randomized trials of primary prevention included 52 251 participants randomized 
      to aspirin doses ranging from 75 to 650 mg/d; the mean overall stroke rate was 
      0.3% per year during an average follow-up of 4.6 years. Meta-analysis revealed no 
      significant effect on stroke (relative risk = 1.08; 95% confidence interval, 
      0.95-1.24) contrasting with a decrease in myocardial infarction (relative risk = 
      0.74; 95% confidence interval, 0.68-0.82). The lack of reduction of stroke by 
      aspirin for primary prevention was incompatible with its protective effect 
      against stroke in patients with manifest vascular disease (P = .001). 
      Intracranial hemorrhage was increased by the regular use of aspirin (relative 
      risk = 1.35; P = .03), similarly for both primary and secondary prevention. In 4 
      large observational studies, self-selected use of aspirin was consistently 
      associated with higher rates of stroke. CONCLUSIONS: The effect of aspirin 
      therapy on stroke differs between individuals based on the presence or absence of 
      overt vascular disease, in contrast with the consistent reduction in myocardial 
      infarction by aspirin therapy observed in all populations. We hypothesize that 
      the effect of aspirin therapy on stroke for persons with major risk factors for 
      vascular disease may be intermediate between a substantial decrease for those 
      with manifest vascular disease and a possible small increase for healthy persons 
      due to accentuated intracranial hemorrhage. When aspirin is given for primary 
      prevention of vascular events, available data support using 75 to 81 mg/d.
FAU - Hart, R G
AU  - Hart RG
AD  - Department of Medicine (Neurology), University of Texas Health Science Center, 
      San Antonio 78284, USA. hartr@uthscsa.edu
FAU - Halperin, J L
AU  - Halperin JL
FAU - McBride, R
AU  - McBride R
FAU - Benavente, O
AU  - Benavente O
FAU - Man-Son-Hing, M
AU  - Man-Son-Hing M
FAU - Kronmal, R A
AU  - Kronmal RA
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Arch Neurol
JT  - Archives of neurology
JID - 0372436
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Neurol. 2000 Mar;57(3):306-8. PMID: 10714652
MH  - Adult
MH  - Aged
MH  - Arteriosclerosis/*prevention & control
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Intracranial Hemorrhages/*etiology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Preventive Medicine
MH  - Risk Factors
MH  - Sex Factors
MH  - Stroke/*prevention & control
EDAT- 2000/03/14 09:00
MHDA- 2000/03/25 09:00
CRDT- 2000/03/14 09:00
PHST- 2000/03/14 09:00 [pubmed]
PHST- 2000/03/25 09:00 [medline]
PHST- 2000/03/14 09:00 [entrez]
AID - 10.1001/archneur.57.3.326 [doi]
PST - ppublish
SO  - Arch Neurol. 2000 Mar;57(3):326-32. doi: 10.1001/archneur.57.3.326.

PMID- 3199298
OWN - NLM
STAT- MEDLINE
DCOM- 19890125
LR  - 20161123
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 5
IP  - 1
DP  - 1988 Jan-Mar
TI  - Examination of parameters determining particle size distribution: acetylsalicylic 
      acid microcapsules.
PG  - 21-5
AB  - A method of preparation of acetylsalicylic acid microcapsules has been 
      elaborated. The active ingredient was made suitable for microencapsulation by 
      recrystallization before phase separation coating. Experiments were performed on 
      the basis of factorial design, and parameters which influence the particle size 
      and particle size distribution of microcapsules were characterized 
      quantitatively.
FAU - Dévay, A
AU  - Dévay A
AD  - Pharmaceutical Institute, Semmelweis Medical University, Budapest, Hungary.
FAU - Rácz, I
AU  - Rácz I
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Capsules)
RN  - 7Z8S9VYZ4B (ethyl cellulose)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - Capsules
MH  - Cellulose/analogs & derivatives
MH  - Crystallization
MH  - Particle Size
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.3109/02652048809036719 [doi]
PST - ppublish
SO  - J Microencapsul. 1988 Jan-Mar;5(1):21-5. doi: 10.3109/02652048809036719.

PMID- 350604
OWN - NLM
STAT- MEDLINE
DCOM- 19780828
LR  - 20190629
IS  - 0014-4754 (Print)
IS  - 0014-4754 (Linking)
VI  - 34
IP  - 5
DP  - 1978 May 15
TI  - Effect of pretreatment with acetylsalicylate on surgical bleeding and 
      peroperative mortality in rats undergoing kidney transplantation.
PG  - 664-5
AB  - 42 rats were pretreated with L-ASA before kidney transplantation, 43 rats acted 
      as controls. 9 rats with L-ASA, but no control rats, died with i.p. haemorrhage. 
      However, in animals surviving the operation, the intraoperative blood loss did 
      not differ significantly between the 2 groups.
FAU - Reyers, I
AU  - Reyers I
FAU - Donati, M B
AU  - Donati MB
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Experientia
JT  - Experientia
JID - 0376547
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Clinical Trials as Topic
MH  - Hemorrhage/*mortality
MH  - *Kidney Transplantation
MH  - Lysine/*analogs & derivatives
MH  - Male
MH  - Preoperative Care
MH  - Rats
MH  - Transplantation, Homologous
EDAT- 1978/05/15 00:00
MHDA- 1978/05/15 00:01
CRDT- 1978/05/15 00:00
PHST- 1978/05/15 00:00 [pubmed]
PHST- 1978/05/15 00:01 [medline]
PHST- 1978/05/15 00:00 [entrez]
AID - 10.1007/BF01937021 [doi]
PST - ppublish
SO  - Experientia. 1978 May 15;34(5):664-5. doi: 10.1007/BF01937021.

PMID- 92668
OWN - NLM
STAT- MEDLINE
DCOM- 19800228
LR  - 20220330
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8156-8157
DP  - 1979 Dec 22-29
TI  - Aspirin and secondary mortality after myocardial infarction.
PG  - 1313-5
AB  - A randomised controlled double-blind trial of aspirin in the prevention of death 
      was conducted in 1682 patients (including 248 women) who had had a confirmed 
      myocardial infarct (MI). 25% of the patients were admitted to the trial within 3 
      days of the infarction and 50% within 7 days. Aspirin, 300 mg three times daily, 
      was given for 1 yr. Total mortality was 12.3% in patients given aspirin and 14.8% 
      in those given placebo, a reduction by aspirin of 17%, which was not 
      statistically significant at p less than 0.05. The reduction in specific 
      ischaemic-heart-disease (IHD) mortality was 22% and in total mortality plus IHD 
      morbidity (readmission to hospital for MI in survivors) was 28%.
FAU - Elwood, P C
AU  - Elwood PC
FAU - Sweetnam, P M
AU  - Sweetnam PM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Death, Sudden/*epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*mortality
MH  - Patient Dropouts
MH  - Placebos
MH  - Prospective Studies
MH  - Research Design
MH  - Time Factors
EDAT- 1979/12/22 00:00
MHDA- 1979/12/22 00:01
CRDT- 1979/12/22 00:00
PHST- 1979/12/22 00:00 [pubmed]
PHST- 1979/12/22 00:01 [medline]
PHST- 1979/12/22 00:00 [entrez]
AID - S0140-6736(79)92808-3 [pii]
AID - 10.1016/s0140-6736(79)92808-3 [doi]
PST - ppublish
SO  - Lancet. 1979 Dec 22-29;2(8156-8157):1313-5. doi: 10.1016/s0140-6736(79)92808-3.

PMID- 32196623
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20221207
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 24
IP  - 5
DP  - 2020 Mar
TI  - Effect of low-dose aspirin on serum uric acid levels in Chinese individuals over 
      60: subanalysis of a multicentre randomized clinical trial.
PG  - 2719-2724
LID - 20544 [pii]
LID - 10.26355/eurrev_202003_20544 [doi]
AB  - OBJECTIVE: Uric acid is considered a biomarker for cardiovascular risk. Only a 
      few studies have investigated the effect of aspirin on serum uric acid (SUA) 
      levels with contradictory results. The present study evaluated the effect of 
      aspirin on SUA levels in Chinese individuals over 60 years of age. PATIENTS AND 
      METHODS: Subjects over 60 with coronary artery disease or multiple cardiovascular 
      risk factors were enrolled in a multicentre randomized clinical trial. Eligible 
      subjects were randomized to receive 50 mg or 100 mg aspirin daily. Levels of 
      arachidonic acid-induced platelet aggregation performed by light transmission 
      aggregometry (LTA-AA) and SUA were measured at randomization and two weeks 
      thereafter. In this subanalysis, subjects without aspirin use prior to enrolment 
      were chosen. RESULTS: A total of 446 subjects were analysed, of which 151 
      subjects took 50 mg aspirin, and 295 took 100 mg aspirin. Hyperuricaemia was 
      present in 23.3% (104/446) of subjects at baseline. LTA-AA levels were 
      significantly reduced in subjects after taking aspirin for two weeks (both 50 mg 
      and 100 mg, p < 0.001). SUA levels were decreased after aspirin administration 
      (311 μmol/L vs. 302 μmol/L, p < 0.001). Further analysis showed SUA levels were 
      unchanged in normouricaemic subjects (284 μmol/L vs. 280 μmol/L, p > 0.05), while 
      slightly decreased in hyperuricaemic subjects (429 μmol/L vs. 392 μmol/L, p < 
      0.001). CONCLUSIONS: Our study showed that both 50 mg and 100 mg aspirin 
      significantly inhibited platelet aggregation. Aspirin treatment for two weeks 
      showed no hyperuricaemic effect in people over 60. SUA levels were unchanged 
      after taking aspirin in normouricaemic subjects but decreased in hyperuricaemic 
      subjects. This trial was registered at www. chictr.org.cn as ChiCTR1800018517.
FAU - Zhang, P
AU  - Zhang P
AD  - Department of Geriatrics, Peking University First Hospital, Beijing, China. 
      liumeilin@hotmail.com.
FAU - Wang, H
AU  - Wang H
FAU - Chen, X-H
AU  - Chen XH
FAU - Liang, W-Y
AU  - Liang WY
FAU - Liu, W-W
AU  - Liu WW
FAU - Liu, M-L
AU  - Liu ML
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 268B43MJ25 (Uric Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - *Asian People
MH  - Aspirin/*administration & dosage/blood/*pharmacology
MH  - Cardiovascular Diseases/*blood/drug therapy
MH  - China
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Risk Factors
MH  - Uric Acid/*blood
EDAT- 2020/03/21 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/03/21 06:00
PHST- 2020/03/21 06:00 [entrez]
PHST- 2020/03/21 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - 20544 [pii]
AID - 10.26355/eurrev_202003_20544 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2020 Mar;24(5):2719-2724. doi: 
      10.26355/eurrev_202003_20544.

PMID- 21250412
OWN - NLM
STAT- MEDLINE
DCOM- 20110301
LR  - 20140730
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 149
IP  - 11
DP  - 2010 Nov
TI  - [Aspirin for primary prevention of cardiovascular diseases--lessons from recent 
      studies].
PG  - 712-4, 749, 748
AB  - Aspirin is recommended as a primary prevention treatment of cardiovascular 
      disease for the population at risk. The American Heart Association guidelines of 
      2002 recommended aspirin as primary prevention for patients with a cardiovascular 
      risk of over 10% per decade (according to the Framingham study). Over the last 
      few years, several double-blind controlled studies analyzed the affect of aspirin 
      for primary prevention in several population groups. For example, while the 
      effect of aspirin in men is mainly in lowering myocardial infarction risk, the 
      effect in women is mainly in lowering the risk of cerebrovascular accident. In 
      view of those studies, the U.S. Preventive Services Task Force (USPSTF) published 
      a gender-based set of guidelines for the use of aspirin as primary prevention. 
      Despite the studies and the USPSTF guidelines, controversy still persists 
      regarding aspirin as a primary prevention therapy. The available use of other 
      therapeutics as a measure for primary prevention and the different harm-benefit 
      ratio scaling for the aspirin effect, all contribute to the controversy. These 
      considerations have led some of the authors of articles in this edition to 
      recommend against administering aspirin as primary prevention. Studies in 
      diabetic patients have shown inferior results compared to the general population. 
      CONCLUSION: Despite tens of thousands of patients over the years, controversy 
      over aspirin as a primary prevention measure still prevails. Therefore, the 
      physician who decides on aspirin for primary prevention has to base his decision 
      on the unique characteristics of each specific patient.
FAU - Balmor, Gingy Ronen
AU  - Balmor GR
FAU - Shoenfeld, Yehuda
AU  - Shoenfeld Y
LA  - heb
PT  - Editorial
PT  - English Abstract
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Controlled Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Assessment
EDAT- 2011/01/22 06:00
MHDA- 2011/03/02 06:00
CRDT- 2011/01/22 06:00
PHST- 2011/01/22 06:00 [entrez]
PHST- 2011/01/22 06:00 [pubmed]
PHST- 2011/03/02 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2010 Nov;149(11):712-4, 749, 748.

PMID- 30325305
OWN - NLM
STAT- MEDLINE
DCOM- 20190409
LR  - 20210109
IS  - 2046-4924 (Electronic)
IS  - 1366-5278 (Print)
IS  - 1366-5278 (Linking)
VI  - 22
IP  - 55
DP  - 2018 Oct
TI  - AVURT: aspirin versus placebo for the treatment of venous leg ulcers - a Phase II 
      pilot randomised controlled trial.
PG  - 1-138
LID - 10.3310/hta22550 [doi]
AB  - BACKGROUND: Venous leg ulcers (VLUs) are the most common cause of leg ulceration, 
      affecting 1 in 100 adults. VLUs may take many months to heal (25% fail to heal). 
      Estimated prevalence is between 1% and 3% of the elderly population. Compression 
      is the mainstay of treatment and few additional therapies exist to improve 
      healing. Two previous trials have indicated that low-dose aspirin, as an adjunct 
      to standard care, may improve healing time, but these trials were insufficiently 
      robust. Aspirin is an inexpensive, widely used medication but its safety and 
      efficacy in the treatment of VLUs remains to be established. OBJECTIVES: Primary 
      objective - to assess the effects of 300 mg of aspirin (daily) versus placebo on 
      the time to healing of the reference VLU. Secondary objectives - to assess the 
      feasibility of leading into a larger pragmatic Phase III trial and the safety of 
      aspirin in this population. DESIGN: A multicentred, pilot, Phase II randomised 
      double-blind, parallel-group, placebo-controlled efficacy trial. SETTING: 
      Community leg ulcer clinics or services, hospital outpatient clinics, leg ulcer 
      clinics, tissue viability clinics and wound clinics in England, Wales and 
      Scotland. PARTICIPANTS: Patients aged ≥ 18 years with a chronic VLU (i.e. the VLU 
      is > 6 weeks in duration or the patient has a history of VLU) and who are not 
      regularly taking aspirin. INTERVENTIONS: 300 mg of daily oral aspirin versus 
      placebo. All patients were offered care in accordance with Scottish 
      Intercollegiate Guidelines Network (SIGN) guidance with multicomponent 
      compression therapy aiming to deliver 40 mmHg at the ankle when possible. 
      RANDOMISATION: Participants were allocated in a 1 : 1 (aspirin : placebo) ratio 
      by the Research Pharmacy, St George's University Hospitals NHS Foundation Trust, 
      using a randomisation schedule generated in advance by the investigational 
      medicinal product manufacturer. Randomisation was stratified according to ulcer 
      size (≤ 5cm(2) or > 5cm(2)). MAIN OUTCOME MEASURE: The primary outcome was time 
      to healing of the largest eligible ulcer (reference ulcer). FEASIBILITY RESULTS – 
      RECRUITMENT: 27 patients were recruited from eight sites over a period of 8 
      months. The target of 100 patients was not achieved and two sites did not 
      recruit. Barriers to recruitment included a short recruitment window and a large 
      proportion of participants failing to meet the eligibility criteria. RESULTS: The 
      average age of the 27 randomised participants (placebo, n = 13; aspirin, n = 14) 
      was 62 years (standard deviation 13 years), and two-thirds were male (n = 18). 
      Participants had their reference ulcer for a median of 15 months, and the median 
      size of ulcer was 17.1 cm(2). There was no evidence of a difference in time to 
      healing of the reference ulcer between groups in an adjusted analysis for 
      log-ulcer area and duration (hazard ratio 0.58, 95% confidence interval 0.18 to 
      1.85; p = 0.357). One expected, related serious adverse event was recorded for a 
      participant in the aspirin group. LIMITATIONS: The trial under-recruited because 
      many patients did not meet the eligibility criteria. CONCLUSIONS: There was no 
      evidence that aspirin was efficacious in hastening the healing of chronic VLUs. 
      It can be concluded that a larger Phase III (effectiveness) trial would not be 
      feasible. TRIAL REGISTRATION: Clinical Trials.gov NCT02333123; European Clinical 
      Trials Database (EudraCT) 2014-003979-39. FUNDING: This project was funded by the 
      National Institute for Health Research (NIHR) Health Technology Assessment 
      programme and will be published in full in Health Technology Assessment; Vol. 22, 
      No. 55. See the NIHR Journals Library website for further project information.
FAU - Tilbrook, Helen
AU  - Tilbrook H
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Clark, Laura
AU  - Clark L
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Cook, Liz
AU  - Cook L
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Bland, Martin
AU  - Bland M
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Buckley, Hannah
AU  - Buckley H
AD  - Cancer Division, Clinical Trials Research Unit, Leeds Institute of Clinical 
      Trials Research, University of Leeds, Leeds, UK.
FAU - Chetter, Ian
AU  - Chetter I
AD  - Academic Vascular Surgical Unit, Hull Royal Infirmary, Hull, UK.
FAU - Dumville, Jo
AU  - Dumville J
AD  - Division of Nursing, Midwifery and Social Work, School of Health Sciences, 
      Faculty of Biology, Medicine and Health, University of Manchester, Manchester, 
      UK.
FAU - Fenner, Chris
AU  - Fenner C
AD  - Orthopaedic Department, West Middlesex Hospital, Isleworth, UK.
FAU - Forsythe, Rachael
AU  - Forsythe R
AD  - Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
FAU - Gabe, Rhian
AU  - Gabe R
AD  - Hull York Medical School and York Trials Unit, Department of Health Sciences, 
      University of York, York, UK.
FAU - Harding, Keith
AU  - Harding K
AD  - Wound Healing, School of Medicine, Cardiff University, Cardiff, UK.
FAU - Layton, Alison
AU  - Layton A
AD  - Harrogate and District NHS Foundation Trust, Harrogate, UK.
FAU - Lindsay, Ellie
AU  - Lindsay E
AD  - The Lindsay Leg Club Foundation, Ipswich, UK.
FAU - McDaid, Catriona
AU  - McDaid C
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Moffatt, Christine
AU  - Moffatt C
AD  - School of Health Sciences, University of Nottingham, Royal Derby Hospital, Derby, 
      UK.
FAU - Rolfe, Debbie
AU  - Rolfe D
AD  - Joint Research and Enterprise Office, St George's University of London, London, 
      UK.
FAU - Sbizzera, Illary
AU  - Sbizzera I
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Stansby, Gerard
AU  - Stansby G
AD  - Freeman Hospital, Newcastle upon Tyne, UK.
FAU - Torgerson, David
AU  - Torgerson D
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Vowden, Peter
AU  - Vowden P
AD  - Bradford Teaching Hospitals NHS Foundation Trust, Bradford Royal Infirmary, 
      Bradford, UK.
FAU - Williams, Laurie
AU  - Williams L
AD  - Lay representative.
FAU - Hinchliffe, Robert
AU  - Hinchliffe R
AD  - Bristol Centre for Surgical Research, National Institute for Health Research 
      (NIHR) Biomedical Research Centre, University of Bristol, Bristol, UK.
LA  - eng
SI  - EudraCT/2014-003979-39
SI  - ClinicalTrials.gov/NCT02333123
GR  - HTA/13/87/08/DH_/Department of Health/United Kingdom
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Health Technol Assess
JT  - Health technology assessment (Winchester, England)
JID - 9706284
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Compression Bandages
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Pilot Projects
MH  - United Kingdom
MH  - Varicose Ulcer/*drug therapy/therapy
MH  - Wound Healing/*drug effects
PMC - PMC6204573
COIS- Catriona McDaid is a member of the National Institute for Health Research Health 
      Technology Assessment and Efficacy and Mechanism Evaluation Editorial Board. 
      Christine Moffatt has received grant funding from 3M UK PLC and Smith and Nephew, 
      two health science-based technology companies, outside the submitted work.
EDAT- 2018/10/17 06:00
MHDA- 2019/04/10 06:00
CRDT- 2018/10/17 06:00
PHST- 2018/10/17 06:00 [entrez]
PHST- 2018/10/17 06:00 [pubmed]
PHST- 2019/04/10 06:00 [medline]
AID - 10.3310/hta22550 [doi]
PST - ppublish
SO  - Health Technol Assess. 2018 Oct;22(55):1-138. doi: 10.3310/hta22550.

PMID- 31556777
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20221207
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 31
IP  - 5
DP  - 2020 Jul 3
TI  - Effects of cigarette smoking on older chinese men treated with clopidogrel 
      monotherapy or aspirin monotherapy: a prospective study.
PG  - 667-673
LID - 10.1080/09537104.2019.1667494 [doi]
AB  - We investigated the comparative effects of smoking status on outcomes in older 
      Chinese men receiving aspirin or clopidogrel monotherapy. This was a prospective 
      observational study of outcomes in 668 men aged ≥ 60 years undergoing annual 
      health examination in the Chinese People's Liberation Army General Hospital from 
      March-April 2017. All patients received regular treatment with aspirin or 
      clopidogrel. Platelet aggregation and phenotyping for rs762551 were measured in 
      all patients. We recorded all major adverse cardiovascular and cerebrovascular 
      events; namely, all-cause death, myocardial infarction, stroke, transient 
      ischemic attack, and unstable angina. In the clopidogrel subgroup, homozygous 
      carriers (AA) of the CYP1A2*1F gene (rs762551, 163C>A) appeared more frequently 
      in smokers than in nonsmokers (45.6% vs 32.7%, p = .035). Adenosine 
      diphosphate-induced platelet aggregation using light transmittance aggregometry 
      was lower in smokers compared with nonsmokers (44.97 ± 20.05% vs 51.98 ± 19.38%, 
      respectively; p = .0018). Smokers (n = 103) had a decreased risk of major adverse 
      cardiovascular and cerebrovascular events, compared with nonsmokers [n = 159; 
      hazard ratio, 0.466; 95% confidence interval: 0.262-0.829, p = .008]. In the 
      aspirin subgroup, AA-induced platelet aggregation showed no significant 
      difference regarding smoking vs nonsmoking status (30.90 ± 32.21 vs 
      29.78 ± 31.47, respectively; p = .771). However, we saw a significant increase in 
      adverse clinical events in the smoking group (n = 148) compared with the 
      nonsmoking group (n = 258; hazard ratio = 1.907, 95% confidence interval: 
      1.128-3.225; p = .016). In older Chinese men, active smokers benefitted from 
      clopidogrel therapy compared with aspirin. Long-term cigarette smoking may 
      contribute to increased variations in CYP1A2*1F, but the variations do not fully 
      explain the smoking paradox.
FAU - Cai, Yulun
AU  - Cai Y
AD  - Geriatric Cardiology Department of The Second Medical Center & National Clinical 
      Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing, 
      China.
FAU - Xu, Weihao
AU  - Xu W
AD  - Geriatric Cardiology Department of The Second Medical Center & National Clinical 
      Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing, 
      China.
FAU - Liu, Hongbin
AU  - Liu H
AD  - Geriatric Cardiology Department of The Second Medical Center & National Clinical 
      Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing, 
      China.
FAU - Wang, Fan
AU  - Wang F
AD  - Geriatric Cardiology Department of The Second Medical Center & National Clinical 
      Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing, 
      China.
FAU - Duan, Lei
AU  - Duan L
AD  - Geriatric Cardiology Department of The Second Medical Center & National Clinical 
      Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing, 
      China.
FAU - Li, Huiying
AU  - Li H
AD  - Geriatric Cardiology Department of The Second Medical Center & National Clinical 
      Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing, 
      China.
FAU - Li, Man
AU  - Li M
AD  - Geriatric Cardiology Department of The Second Medical Center & National Clinical 
      Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing, 
      China.
FAU - Li, Yuerui
AU  - Li Y
AD  - Geriatric Cardiology Department of The Second Medical Center & National Clinical 
      Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing, 
      China.
FAU - Han, Lina
AU  - Han L
AD  - Geriatric Cardiology Department of The Second Medical Center & National Clinical 
      Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing, 
      China.
FAU - Xiao, Hunan
AU  - Xiao H
AD  - Geriatric Cardiology Department of The Second Medical Center & National Clinical 
      Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20190926
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Asian People
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Clopidogrel/pharmacology/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Smoking/*adverse effects
OTO - NOTNLM
OT  - Aspirin
OT  - Chinese
OT  - Smoking
OT  - clopidogrel
OT  - cytochrome p450
EDAT- 2019/09/27 06:00
MHDA- 2021/02/09 06:00
CRDT- 2019/09/27 06:00
PHST- 2019/09/27 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2019/09/27 06:00 [entrez]
AID - 10.1080/09537104.2019.1667494 [doi]
PST - ppublish
SO  - Platelets. 2020 Jul 3;31(5):667-673. doi: 10.1080/09537104.2019.1667494. Epub 
      2019 Sep 26.

PMID- 731412
OWN - NLM
STAT- MEDLINE
DCOM- 19790324
LR  - 20191021
IS  - 0090-466X (Print)
IS  - 0090-466X (Linking)
VI  - 6
IP  - 6
DP  - 1978 Dec
TI  - Effects of concomitant aspirin administration on the pharmacokinetics of 
      indomethacin in man.
PG  - 451-76
AB  - Ten healthy volunteers each received single and multiple 50-mg doses of 
      indomethacin orally and a single 25-mg dose of [14C]indomethacin intravenously in 
      the absence of and concomitantly with 1200 mg of aspirin as a single dose and in 
      a chronic t.i.d. regimen. Systematic analysis of the data resulted in the 
      isolation and quantification of aspirin's effects on the absorption, 
      distribution, biotransformation, excretion, enterohepatic circulation, and 
      accumulation of indomethacin. The effects of chronic aspirin were to suppress the 
      renal clearance, to increase the biliary clearance, to decrease the efficiency of 
      gastrointestinal absorption, and to enhance the enterohepatic circulation of 
      indomethacin. On concomitant administration of 1200 mg of aspirin t.i.d., mean 
      plasma levels of indomethacin were depressed by 20% after a single oral dose, by 
      a smaller margin after multiple oral doses, and not at all after a single 
      intravenous dose of indomethacin. The mean plasma concentration of orally 
      administered indomethacin was decreased by 8% when given concurrently with a 
      single 1200 mg dose of aspirin. Concomitant chronic therapeutic dosages of 
      indomethacin had no effect on salicylate accumulation from repetitive doses of 
      aspirin.
FAU - Kwan, K C
AU  - Kwan KC
FAU - Breault, G O
AU  - Breault GO
FAU - Davis, R L
AU  - Davis RL
FAU - Lei, B W
AU  - Lei BW
FAU - Czerwinski, A W
AU  - Czerwinski AW
FAU - Besselaar, G H
AU  - Besselaar GH
FAU - Duggan, D E
AU  - Duggan DE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacokinet Biopharm
JT  - Journal of pharmacokinetics and biopharmaceutics
JID - 0357115
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Biotransformation
MH  - Drug Interactions
MH  - Half-Life
MH  - Humans
MH  - Indomethacin/blood/*metabolism/urine
MH  - Intestinal Absorption
MH  - Kinetics
MH  - Male
MH  - Salicylates/blood
MH  - Statistics as Topic
MH  - Tissue Distribution
EDAT- 1978/12/01 00:00
MHDA- 1978/12/01 00:01
CRDT- 1978/12/01 00:00
PHST- 1978/12/01 00:00 [pubmed]
PHST- 1978/12/01 00:01 [medline]
PHST- 1978/12/01 00:00 [entrez]
AID - 10.1007/BF01062103 [doi]
PST - ppublish
SO  - J Pharmacokinet Biopharm. 1978 Dec;6(6):451-76. doi: 10.1007/BF01062103.

PMID- 25789633
OWN - NLM
STAT- MEDLINE
DCOM- 20160429
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 3
DP  - 2015
TI  - Risk threshold for starting low dose aspirin in pregnancy to prevent 
      preeclampsia: an opportunity at a low cost.
PG  - e0116296
LID - 10.1371/journal.pone.0116296 [doi]
LID - e0116296
AB  - BACKGROUND: Preeclampsia (PE) increases maternal and perinatal morbidity and 
      mortality. Based on a multitude of data from randomized clinical trials, clinical 
      practice guidelines endorse using ASA to prevent PE in women who are "at risk." 
      However, data are lacking about the level of absolute risk to warrant starting 
      ASA prophylaxis. METHODS AND FINDINGS: We present two approaches for objectively 
      determining the minimum absolute risk for PE at which ASA prophylaxis is 
      justified. The first is a new approach-the minimum control event rate (CERmin). 
      The second approach uses a pre-existing concept-the minimum event rate for 
      treatment (MERT). Here we show how the CERmin is derived, and then use the CERmin 
      and the MERT to guide us to a reasonable risk threshold for starting a woman on 
      ASA prophylaxis against PE based on clinical risk assessment. We suggest that 
      eligible women need not be at "high risk" for preeclampsia to warrant ASA, but 
      rather at some modestly elevated absolute risk of 6-10%. CONCLUSIONS: Given its 
      very low cost, its widespread availability, ease of administration and its safety 
      profile, ASA is a highly attractive agent for the prevention of maternal and 
      perinatal morbidity worldwide.
FAU - Bartsch, Emily
AU  - Bartsch E
AD  - Western University, London, Ontario, Canada.
FAU - Park, Alison L
AU  - Park AL
AD  - Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
FAU - Kingdom, John C
AU  - Kingdom JC
AD  - Department of Obstetrics and Gynaecology, University of Toronto, Toronto, 
      Ontario, Canada.
FAU - Ray, Joel G
AU  - Ray JG
AD  - Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, 
      Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150319
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Risk
PMC - PMC4366221
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/03/20 06:00
MHDA- 2016/04/30 06:00
CRDT- 2015/03/20 06:00
PHST- 2014/11/03 00:00 [received]
PHST- 2014/11/28 00:00 [accepted]
PHST- 2015/03/20 06:00 [entrez]
PHST- 2015/03/20 06:00 [pubmed]
PHST- 2016/04/30 06:00 [medline]
AID - PONE-D-14-48807 [pii]
AID - 10.1371/journal.pone.0116296 [doi]
PST - epublish
SO  - PLoS One. 2015 Mar 19;10(3):e0116296. doi: 10.1371/journal.pone.0116296. 
      eCollection 2015.

PMID- 30355919
OWN - NLM
STAT- MEDLINE
DCOM- 20190314
LR  - 20190314
IS  - 1423-0313 (Electronic)
IS  - 0031-7012 (Linking)
VI  - 103
IP  - 1-2
DP  - 2019
TI  - Malondialdehyde Assay in the Evaluation of Aspirin Antiplatelet Effects.
PG  - 23-29
LID - 10.1159/000493754 [doi]
AB  - Aspirin is essential in secondary prevention of patients after myocardial 
      infarction and with coronary artery disease. However, impaired pharmacodynamic 
      response to aspirin is frequent (high on-treatment platelet reactivity [HTPR]). 
      This leads to an enhanced prevalence of cardiovascular events and to an impaired 
      clinical outcome. The current specific assays to evaluate aspirin antiplatelet 
      effects are complex, time-consuming and demand for a high laboratory expertise. 
      Therefore, we developed a potentially bedside assay based on the determination of 
      malondialdehyde (MDA). MDA is a by-product of the thromboxane (TX) formation, 
      which is synthesized in equimolar concentrations. In this study, we compared this 
      MDA assay to the conventional assays in determination of pharmacodynamic aspirin 
      response. For this, aspirin antiplatelet effects were measured in 22 healthy 
      individuals and 63 aspirin treated patients using TX B2 formation enzyme-linked 
      antibody assay, arachidonic acid induced light transmission aggregometry (LTA) 
      and the new fluorometric MDA assay. In patients, MDA levels correlated well with 
      TX formation (R = 0.81; 95% CI 0.69-0.88; p < 0.001) and LTA (R = 0.84; CI 
      0.74-0.91; p < 0.001). Receiver operating characteristic analyses revealed that 
      the MDA assay does detect HTPR to aspirin sufficiently (area under the curve: 
      0.965; p < 0.001). The optimal cut-off was > 128 nmol/L (sensitivity of 100%, 
      specificity of 91%). The new MDA assay is reliable in detecting HTPR. It is 
      highly specific in the evaluation of antiplatelet effects by aspirin. This 
      promising and potential bedside assay needs to be evaluated in clinical practice.
CI  - © 2018 S. Karger AG, Basel.
FAU - Polzin, Amin
AU  - Polzin A
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, 
      Germanyamin.polzin@med.uni-duesseldorf.de.
FAU - Dannenberg, Lisa
AU  - Dannenberg L
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Schneider, Theresa
AU  - Schneider T
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Knoop, Betül
AU  - Knoop B
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Naguib, David
AU  - Naguib D
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Helten, Carolin
AU  - Helten C
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Pöhl, Martin
AU  - Pöhl M
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Kelm, Malte
AU  - Kelm M
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Zeus, Tobias
AU  - Zeus T
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Hohlfeld, Thomas
AU  - Hohlfeld T
AD  - Institute for Pharmacology and Clinical Pharmacology, Heinrich Heine University, 
      Düsseldorf, Germany.
LA  - eng
PT  - Journal Article
DEP - 20181024
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/blood/pharmacokinetics/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Malondialdehyde/*blood
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Platelet Function Tests
MH  - Thromboxane B2/blood
OTO - NOTNLM
OT  - Aspirin
OT  - High on-treatment platelet reactivity
OT  - Malondialdehyde
EDAT- 2018/10/26 06:00
MHDA- 2019/03/15 06:00
CRDT- 2018/10/26 06:00
PHST- 2018/09/10 00:00 [received]
PHST- 2018/09/11 00:00 [accepted]
PHST- 2018/10/26 06:00 [pubmed]
PHST- 2019/03/15 06:00 [medline]
PHST- 2018/10/26 06:00 [entrez]
AID - 000493754 [pii]
AID - 10.1159/000493754 [doi]
PST - ppublish
SO  - Pharmacology. 2019;103(1-2):23-29. doi: 10.1159/000493754. Epub 2018 Oct 24.

PMID- 22731119
OWN - NLM
STAT- MEDLINE
DCOM- 20130222
LR  - 20211021
IS  - 1758-3284 (Electronic)
IS  - 1758-3284 (Linking)
VI  - 4
DP  - 2012 Jun 25
TI  - Feasibility of recruitment to an oral dysplasia trial in the United Kingdom.
PG  - 40
AB  - BACKGROUND: Oral epithelial dysplasia (OED) has a malignant potential. 
      Therapeutic options for OED remain both limited and without good evidence. 
      Despite surgery being the most common method of treating OED, recurrence and 
      potentially significant morbidity remain problematic. Consequently, there has 
      been much interest in non-surgical treatments for OED. Cyclo-oxygenase (COX) 
      up-regulation is known to occur in the dysplasia-carcinoma sequence and evidence 
      now exists that COX-2 is a prognostic marker of malignant transformation in OED. 
      COX-inhibitors are therefore considered a potential therapeutic strategy for 
      treating this condition. We aimed to provide both proof of principal evidence 
      supporting the effect of topical COX inhibition, and determine the feasibility of 
      recruitment to an OED chemoprevention trial in the UK. METHODS: Recruitment of 40 
      patients with oral leukoplakia to 4 study arms was planned. The total daily dose 
      of Aspirin would increase in each group and be used in the period between initial 
      diagnostic and follow-up biopsies. RESULTS: During the 15-month recruitment 
      period, 15/50 screened patients were eligible for recruitment, and 13 (87%) 
      consented. Only 1 had OED diagnosed on biopsy. 16 patients were intolerant of, or 
      already taking Aspirin and 16 patients required no biopsy. Initial recruitment 
      was slow, as detection relied on clinicians identifying potentially eligible 
      patients. Pre-screening new patient letters and directly contacting patients 
      listed for biopsies improved screening of potentially eligible patients. However, 
      as the incidence of OED was so low, it had little impact on trial recruitment. 
      The trial was terminated, as recruitment was unlikely to be achieved in a single 
      centre. CONCLUSION: This feasibility trial has demonstrated the low incidence of 
      OED in the UK and the difficulties in conducting a study because of this. With an 
      incidence of around 1.5/100,000/year and a high proportion of those patients 
      already taking or intolerant of Aspirin, a large multi-centred trial would be 
      required to fulfil the recruitment for this study. The ability of topical 
      non-steroidal anti-inflammatory drugs to modify COX and prostaglandin expression 
      remains an important but unanswered question. Collaboration with centres in other 
      parts of the world with higher incidences of the disease may be required to 
      ensure adequate recruitment. ISRCTN: 31503555.
FAU - Nankivell, Paul
AU  - Nankivell P
AD  - Institute of Head and Neck Studies and Education, University Hospitals Coventry 
      and Warwickshire, Clifford Bridge Road, Coventry, CV2 2DX, UK.
FAU - Dunn, Janet
AU  - Dunn J
FAU - Langman, Michael
AU  - Langman M
FAU - Mehanna, Hisham
AU  - Mehanna H
LA  - eng
SI  - ISRCTN/ISRCTN31503555
PT  - Clinical Trial, Phase I
PT  - Journal Article
DEP - 20120625
PL  - England
TA  - Head Neck Oncol
JT  - Head & neck oncology
JID - 101479704
RN  - R16CO5Y76E (Aspirin)
SB  - IM
ECI - BMC Med. 2014 Feb 05;12 :24. PMID: 24499430
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clinical Trials, Phase I as Topic/*methods
MH  - Feasibility Studies
MH  - Humans
MH  - Leukoplakia, Oral/*drug therapy/pathology
MH  - *Patient Selection
MH  - United Kingdom
PMC - PMC3448506
EDAT- 2012/06/27 06:00
MHDA- 2013/02/23 06:00
CRDT- 2012/06/27 06:00
PHST- 2012/05/31 00:00 [received]
PHST- 2012/06/06 00:00 [accepted]
PHST- 2012/06/27 06:00 [entrez]
PHST- 2012/06/27 06:00 [pubmed]
PHST- 2013/02/23 06:00 [medline]
AID - 1758-3284-4-40 [pii]
AID - 10.1186/1758-3284-4-40 [doi]
PST - epublish
SO  - Head Neck Oncol. 2012 Jun 25;4:40. doi: 10.1186/1758-3284-4-40.

PMID- 31792942
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 189
IP  - 2
DP  - 2020 Apr
TI  - Unexpected low expression of platelet fibrinogen receptor in patients with 
      chronic myeloproliferative neoplasms: how does it change with aspirin?
PG  - 335-338
LID - 10.1111/bjh.16335 [doi]
AB  - This study was conducted to evaluate the expression of fibrinogen receptors on 
      platelets of Philadelphia-negative chronic myeloproliferative neoplasm (MPN) 
      patients. We collected blood samples from 40 consecutive MPN patients and healthy 
      volunteers. We performed flow cytometry analysis of P-selectin expression and 
      integrin beta-3, activation of glycoprotein (GP) IIb/IIIa and fibrinogen receptor 
      exposure (PAC-1 binding). Surprisingly, we found a very low PAC-1 binding 
      capacity in MPN patients; however, the expression of PAC-1 was almost completely 
      recovered with aspirin intake. We hypothesize that the hypercoagulable states 
      observed in MPN patients could depend on a primarily plasma-driven impairment of 
      fibrin turnover and thrombin generation.
CI  - © 2019 The Authors. British Journal of Haematology published by British Society 
      for Haematology and John Wiley & Sons Ltd.
FAU - Lucchesi, Alessandro
AU  - Lucchesi A
AUID- ORCID: 0000-0002-0624-5311
AD  - Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei 
      Tumori (IRST) IRCCS, Meldola, Italy.
FAU - Carloni, Silvia
AU  - Carloni S
AD  - Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura 
      dei Tumori (IRST) IRCCS, Meldola, Italy.
FAU - De Matteis, Serena
AU  - De Matteis S
AUID- ORCID: 0000-0001-9219-4081
AD  - Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura 
      dei Tumori (IRST) IRCCS, Meldola, Italy.
FAU - Ghetti, Martina
AU  - Ghetti M
AD  - Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura 
      dei Tumori (IRST) IRCCS, Meldola, Italy.
FAU - Musuraca, Gerardo
AU  - Musuraca G
AD  - Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei 
      Tumori (IRST) IRCCS, Meldola, Italy.
FAU - Poggiaspalla, Monica
AU  - Poggiaspalla M
AD  - Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei 
      Tumori (IRST) IRCCS, Meldola, Italy.
FAU - Augello, Accursio F
AU  - Augello AF
AD  - Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei 
      Tumori (IRST) IRCCS, Meldola, Italy.
FAU - Giordano, Giulio
AU  - Giordano G
AD  - Internal Medicine Division, Hematology Service, Regional Hospital "A. 
      Cardarelli", Campobasso, Italy.
FAU - Fattori, Pier P
AU  - Fattori PP
AD  - Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei 
      Tumori (IRST) IRCCS, Meldola, Italy.
FAU - Martinelli, Giovanni
AU  - Martinelli G
AD  - Scientific Directorate, Istituto Scientifico Romagnolo per lo Studio e la Cura 
      dei Tumori (IRST) IRCCS, Meldola, Italy.
FAU - Napolitano, Roberta
AU  - Napolitano R
AUID- ORCID: 0000-0003-3682-9606
AD  - Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura 
      dei Tumori (IRST) IRCCS, Meldola, Italy.
LA  - eng
PT  - Journal Article
DEP - 20191202
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets
MH  - Chronic Disease
MH  - Fibrinogen/pharmacology/*therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Myeloproliferative Disorders/*drug therapy
PMC - PMC7187459
OTO - NOTNLM
OT  - PAC-1
OT  - aspirin
OT  - myeloproliferative neoplasms
OT  - platelet fibrinogen receptor
COIS- The authors declare no potential conflicts of interest.
EDAT- 2019/12/04 06:00
MHDA- 2020/12/15 06:00
CRDT- 2019/12/04 06:00
PHST- 2019/07/09 00:00 [received]
PHST- 2019/09/09 00:00 [accepted]
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2019/12/04 06:00 [entrez]
AID - BJH16335 [pii]
AID - 10.1111/bjh.16335 [doi]
PST - ppublish
SO  - Br J Haematol. 2020 Apr;189(2):335-338. doi: 10.1111/bjh.16335. Epub 2019 Dec 2.

PMID- 9725760
OWN - NLM
STAT- MEDLINE
DCOM- 19981104
LR  - 20190726
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 138
IP  - 3-4
DP  - 1998 Aug
TI  - The influence of acetylsalicylic acid on cognitive processing: an event-related 
      potentials study.
PG  - 369-74
AB  - The central effects of acetylsalicylic acid (ASA) are discussed controversially. 
      In animal models, it has been shown that ASA can interact with the central 
      serotonergic and catecholaminergic neuronal system. However, the relevance of 
      this interaction for humans is still unknown. We performed a study on the 
      influence of ASA on central cognitive processing. In 25 healthy subjects (age 
      21-56 years), visually evoked event-related potentials (ERP) and reaction time 
      under IV ASA medication were recorded. ERP were evoked by an oddball paradigm. As 
      compared to placebo, ASA decreased the latency of the P3 component significantly 
      in a time interval of 20-40 min after administration. The latency of the N2 
      component was significantly decreased about 25 min after administration; the 
      latency of the exogenous P2 component was not influenced by ASA. The mean choice 
      reaction time was significantly decreased by ASA 35 min after administration. At 
      this time point, there was a significant correlation between decrease in reaction 
      time and increase in ASA plasma level. The data show that IV administration of 
      ASA has an accelerating effect on the endogenous components of visual ERP and on 
      reaction time. This finding suggests that ASA can influence central cognitive 
      processing, possibly by ASA induced changes of neurotransmitters. Since serotonin 
      can be released by ASA and serotonin release leads to a decrease of ERP 
      latencies. we assume that ASA most likely influences cognitive processing via the 
      central serotonergic transmitter system.
FAU - Austermann, M
AU  - Austermann M
AD  - Department of Neurology, University of Münster, Germany.
FAU - Grotemeyer, K H
AU  - Grotemeyer KH
FAU - Evers, S
AU  - Evers S
FAU - Rödding, D
AU  - Rödding D
FAU - Husstedt, I W
AU  - Husstedt IW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Neurotransmitter Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/metabolism/*pharmacology
MH  - Cognition/*drug effects
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Evoked Potentials, Visual/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neurotransmitter Agents/metabolism
MH  - Reaction Time/drug effects
EDAT- 1998/09/02 00:00
MHDA- 1998/09/02 00:01
CRDT- 1998/09/02 00:00
PHST- 1998/09/02 00:00 [pubmed]
PHST- 1998/09/02 00:01 [medline]
PHST- 1998/09/02 00:00 [entrez]
AID - 10.1007/s002130050683 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 1998 Aug;138(3-4):369-74. doi: 10.1007/s002130050683.

PMID- 32011329
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20201117
IS  - 2149-2271 (Electronic)
IS  - 2149-2263 (Print)
IS  - 2149-2263 (Linking)
VI  - 23
IP  - 2
DP  - 2020 Jan
TI  - Aspirin for primary prevention of cardiovascular disease: Advice for a decisional 
      strategy based on risk stratification.
PG  - 70-78
LID - 10.14744/AnatolJCardiol.2019.89916 [doi]
AB  - The need for aspirin therapy as part of primary prevention of cardiovascular (CV) 
      disease is currently being highly debated, especially after 3 studies in 
      different settings reported that a reduction in ischemic events is largely 
      counterbalanced by an increase in bleeding events. One possible explanation for 
      these results is the progressive reduction in the risk of major adverse 
      cardiovascular events (MACE) as a result of primary prevention, which has 
      accompanied global education programs that have led to patients smoking less, 
      exercising more, and increasingly undertaking lipid-lowering therapies. Based on 
      a meta-regression of the benefits and harmful effects of aspirin therapy in 
      primary prevention as a function of the 10-year risk of MACE, we favor a 
      differentiated and personalized approach that acknowledged differences between 
      patients and emphasized an individualized assessment of benefits and risks. 
      Following general preventive measures (physical exercise, cessation of smoking, 
      treatment of hypertension and hypercholesterolemia, etc.), an individualized 
      approach to prescribing aspirin is still warranted. When patients are less than 
      70 years of age, clinicians should assess the 10-year CV risk. Aspirin treatment 
      should be considered only when the CV risk is very high and the bleeding risk is 
      low, after taking into account the patient's preferences.
FAU - Aimo, Alberto
AU  - Aimo A
AD  - Department of Cardiology, University Hospital of Pisa; Pisa-Italy.
FAU - De Caterina, Raffaele
AU  - De Caterina R
AD  - Department of Cardiology, University Hospital of Pisa; Pisa-Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Turkey
TA  - Anatol J Cardiol
JT  - Anatolian journal of cardiology
JID - 101652981
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Decision Support Techniques
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Risk
PMC - PMC7040875
COIS- Conflict of interest: R.D.C. reports personal fees and non-financial support from 
      Bayer, outside the submitted work.
EDAT- 2020/02/06 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/02/04 06:00
PHST- 2020/02/04 06:00 [entrez]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - AJC-23-70 [pii]
AID - 10.14744/AnatolJCardiol.2019.89916 [doi]
PST - ppublish
SO  - Anatol J Cardiol. 2020 Jan;23(2):70-78. doi: 10.14744/AnatolJCardiol.2019.89916.

PMID- 6637899
OWN - NLM
STAT- MEDLINE
DCOM- 19831221
LR  - 20190511
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 80
IP  - 6
DP  - 1983 Dec
TI  - Self-poisoning with enteric-coated aspirin.
PG  - 888-90
AB  - A case of self-poisoning by enteric-coated aspirin tablets is described. 
      Absorption of salicylate was delayed, resulting in serum kinetics different from 
      that obtained with regular aspirin. When the ingested aspirin is enteric coated, 
      the use of Done's nomogram may be inappropriate.
FAU - Kwong, T C
AU  - Kwong TC
FAU - Laczin, J
AU  - Laczin J
FAU - Baum, J
AU  - Baum J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/metabolism/*poisoning
MH  - Female
MH  - Humans
MH  - Intestinal Absorption/drug effects
MH  - Tablets, Enteric-Coated/*adverse effects
MH  - Time Factors
EDAT- 1983/12/01 00:00
MHDA- 1983/12/01 00:01
CRDT- 1983/12/01 00:00
PHST- 1983/12/01 00:00 [pubmed]
PHST- 1983/12/01 00:01 [medline]
PHST- 1983/12/01 00:00 [entrez]
AID - 10.1093/ajcp/80.6.888 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1983 Dec;80(6):888-90. doi: 10.1093/ajcp/80.6.888.

PMID- 16938230
OWN - NLM
STAT- MEDLINE
DCOM- 20070103
LR  - 20131121
IS  - 0300-8932 (Print)
IS  - 0300-8932 (Linking)
VI  - 59
IP  - 8
DP  - 2006 Aug
TI  - [Health economic evaluation of low-dose acetylsalicylic acid in the primary 
      prevention of cardiovascular disease].
PG  - 807-15
AB  - INTRODUCTION AND OBJECTIVES: Low-dose aspirin is standard treatment for patients 
      with a history of cardiovascular disease. Its use in primary prevention is more 
      controversial. However, recent studies also support the use of aspirin in 
      high-risk individuals with no history of cardiovascular disease. This study 
      investigated the health economic implications of using low-dose aspirin in the 
      primary prevention of cardiovascular disease in Spain. METHODS: A model was 
      developed to predict the cost-effectiveness of low-dose aspirin in the primary 
      prevention of cardiovascular disease over a period of 10 years. The direct costs 
      used were those of the Spanish National Health Service (NHS). Results were 
      expressed as cost per life-year gained and per quality-adjusted life-year gained. 
      RESULTS: Administering low-dose aspirin to an individual with a 10-year risk of 
      coronary heart disease > or =15% resulted in an average net saving of e 797 (95% 
      CI, e 263-1331) over the 10-year period, with savings starting in the first year. 
      For an annual risk > or =0.24%, this form of treatment would reduce NHS costs. 
      Treating all at-risk individuals in the Spanish population with aspirin would 
      save e 26.5 million from the healthcare budget, starting in the first year. 
      CONCLUSIONS: Administering low-dose aspirin to individuals with a 10-year risk of 
      coronary heart disease > or =15% would result in significant cost savings for the 
      Spanish NHS. Sensitivity analysis confirmed the robustness of these findings.
FAU - Lamotte, Mark
AU  - Lamotte M
AD  - Health Economics and Disease Management Unit. IMS Health. Bruselas. Bélgica.
FAU - Piñol, Carme
AU  - Piñol C
FAU - Brotons, Carlos
AU  - Brotons C
FAU - Annemans, Lieven
AU  - Annemans L
FAU - Guardiola, Elena
AU  - Guardiola E
FAU - Evers, Thomas
AU  - Evers T
FAU - Kubin, Maria
AU  - Kubin M
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Evaluación económica del tratamiento con ácido acetilsalicílico en dosis bajas en 
      la prevención primaria de enfermedades cardiovasculares.
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*economics
MH  - Budgets
MH  - Cardiovascular Diseases/*economics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Models, Economic
MH  - Spain
EDAT- 2006/08/30 09:00
MHDA- 2007/01/04 09:00
CRDT- 2006/08/30 09:00
PHST- 2006/08/30 09:00 [pubmed]
PHST- 2007/01/04 09:00 [medline]
PHST- 2006/08/30 09:00 [entrez]
AID - 13091885 [pii]
PST - ppublish
SO  - Rev Esp Cardiol. 2006 Aug;59(8):807-15.

PMID- 26356085
OWN - NLM
STAT- MEDLINE
DCOM- 20160927
LR  - 20151223
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 12
IP  - 1
DP  - 2016 Jan
TI  - Drug delivery and therapeutic impact of extended-release acetylsalicylic acid.
PG  - 45-58
LID - 10.2217/fca.15.60 [doi]
AB  - Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid 
      (ASA; aspirin) for secondary prevention of cardiovascular events. However, the 
      anti-thrombotic benefits of traditional ASA formulations may not extend over a 
      24-h period, especially in patients at high risk for a recurrent cardiovascular 
      event. A next-generation, extended-release ASA formulation (ER-ASA) has been 
      developed to provide 24-h anti-thrombotic coverage with once-daily dosing. The 
      pharmacokinetics of ER-ASA indicates slower absorption and prolonged ASA release 
      versus immediate-release ASA, with a favorable safety profile. ER-ASA minimizes 
      systemic ASA absorption and provides sustained antiplatelet effects over a 24-h 
      period.
FAU - Bliden, Kevin P
AU  - Bliden KP
AD  - Sinai Center for Thrombosis Research, Baltimore, MD, USA.
FAU - Patrick, Jeff
AU  - Patrick J
AD  - New Haven Pharmaceuticals, Inc., North Haven, CT, USA.
FAU - Pennell, Andrew T
AU  - Pennell AT
AD  - New Haven Pharmaceuticals, Inc., North Haven, CT, USA.
FAU - Tantry, Udaya S
AU  - Tantry US
AD  - Sinai Center for Thrombosis Research, Baltimore, MD, USA.
FAU - Gurbel, Paul A
AU  - Gurbel PA
AD  - Sinai Center for Thrombosis Research, Baltimore, MD, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150910
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Delayed-Action Preparations/pharmacology/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - *Secondary Prevention
OTO - NOTNLM
OT  - Durlaza
OT  - acetylsalicylic acid
OT  - antiplatelet
OT  - cardiovascular disease
OT  - diabetes
OT  - extended-release
OT  - microcapsule
OT  - secondary prevention
OT  - thrombosis
EDAT- 2015/09/12 06:00
MHDA- 2016/09/28 06:00
CRDT- 2015/09/11 06:00
PHST- 2015/09/11 06:00 [entrez]
PHST- 2015/09/12 06:00 [pubmed]
PHST- 2016/09/28 06:00 [medline]
AID - 10.2217/fca.15.60 [doi]
PST - ppublish
SO  - Future Cardiol. 2016 Jan;12(1):45-58. doi: 10.2217/fca.15.60. Epub 2015 Sep 10.

PMID- 20334450
OWN - NLM
STAT- MEDLINE
DCOM- 20100608
LR  - 20131121
IS  - 1175-3277 (Print)
IS  - 1175-3277 (Linking)
VI  - 10
IP  - 2
DP  - 2010
TI  - Low-dose aspirin therapy for cardiovascular prevention: quantification and 
      consequences of poor compliance or discontinuation.
PG  - 125-41
LID - 10.2165/11318440-000000000-00000 [doi]
AB  - Long-term therapy with low-dose aspirin (acetylsalicylic acid; ASA), 75-325 mg, 
      is highly effective for the secondary prevention of cardiovascular (CV) events. 
      For high-CV-risk patients to attain the full benefits of this therapy, it is 
      important that treatment is continuous and that good compliance is maintained 
      over the long term. We aimed to quantify the level of, and investigate the 
      reasons for, patient-driven non-compliance and treatment discontinuation among 
      patients taking low-dose ASA for the prevention of CV events. We therefore 
      performed a systematic search of the PubMed, Embase, and Cochrane databases using 
      the terms 'aspirin' AND 'patient compliance' OR 'withdrawal', with no 
      restrictions on the start date and up to July 2008. A total of 32 studies, 
      summarizing >144 800 patients, were selected from over 400 results for inclusion. 
      Poor compliance (defined differently among the studies included) with low-dose 
      ASA therapy ranged from approximately 10% to over 50%, and patient-initiated 
      discontinuation of therapy occurred in up to 30% of patients. Common predictors 
      of both non-compliance and treatment discontinuation were lower education level, 
      female sex, or a history of depression, diabetes mellitus, or cigarette smoking. 
      Adverse events were cited as the reason for low-dose ASA discontinuation in 
      almost 50% of patients. The findings of this review suggest that poor compliance 
      is common among patients receiving low-dose ASA therapy, placing them at 
      substantial risk of CV events. By addressing barriers to compliance with low-dose 
      ASA therapy, healthcare professionals can improve CV risk management for such 
      patients.
FAU - Herlitz, Johan
AU  - Herlitz J
AD  - Sahlgrenska University Hospital, Gothenburg, Sweden. johan.herlitz@gu.se
FAU - Tóth, Peter P
AU  - Tóth PP
FAU - Naesdal, Jørgen
AU  - Naesdal J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Medication Adherence
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Risk Factors
MH  - Risk Management/methods
MH  - Sex Factors
RF  - 92
EDAT- 2010/03/26 06:00
MHDA- 2010/06/09 06:00
CRDT- 2010/03/26 06:00
PHST- 2010/03/26 06:00 [entrez]
PHST- 2010/03/26 06:00 [pubmed]
PHST- 2010/06/09 06:00 [medline]
AID - 6 [pii]
AID - 10.2165/11318440-000000000-00000 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2010;10(2):125-41. doi: 10.2165/11318440-000000000-00000.

PMID- 15122378
OWN - NLM
STAT- MEDLINE
DCOM- 20050208
LR  - 20190605
IS  - 0034-8910 (Print)
IS  - 0034-8910 (Linking)
VI  - 38
IP  - 2
DP  - 2004 Apr
TI  - [Level of knowledge of the compositions of analgesic medication containing 
      aspirin].
PG  - 223-7
AB  - OBJECTIVE: To evaluate the knowledge of the generic designation, use and 
      composition of analgesic medications containing aspirin. METHODS: A total of 124 
      interviews were carried out between December 1999 and January 2000, in two 
      neighborhoods of the city of Porto Alegre, southern Brazil. The interview was 
      held with the person who came to answer the door at each of the homes that was 
      drawn. The data collection instruments comprised a set of five different 
      pharmaceutical specialties containing acetylsalicylic acid, and an interview 
      consisting of two open questions concerning the differences and similarities 
      between the products. RESULTS: Three major knowledge-level groups were 
      characterized on the basis of the information that the interviewees were able to 
      provide. The group that was knowledgeable about the matter comprised 14 
      individuals (11%). The group with limited knowledge contained 61 people (49)%. 
      Those who had no knowledge of the matter at all formed a group of 49 people 
      (40%). CONCLUSIONS: Taking the results as a whole, they indicate that most people 
      (about 90% of the sample investigated) are simply not aware of what the active 
      substance is, even in pharmaceutical specialties that they use frequently.
FAU - Tierling, Vera L
AU  - Tierling VL
AD  - Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, 
      RS, Brasil.
FAU - Paulino, Marco Antonio
AU  - Paulino MA
FAU - Fernandes, Luciana C
AU  - Fernandes LC
FAU - Schenkel, Eloir P
AU  - Schenkel EP
FAU - Mengue, Sotero S
AU  - Mengue SS
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Nível de conhecimento sobre a composição de analgésicos com ácido 
      acetilsalicílico.
DEP - 20040426
PL  - Brazil
TA  - Rev Saude Publica
JT  - Revista de saude publica
JID - 0135043
RN  - 0 (Analgesics, Non-Narcotic)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics, Non-Narcotic/*chemistry/pharmacology
MH  - Aspirin/*chemistry/pharmacology
MH  - Chemistry, Pharmaceutical
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Interviews as Topic
MH  - Pilot Projects
EDAT- 2004/05/04 05:00
MHDA- 2005/02/09 09:00
CRDT- 2004/05/04 05:00
PHST- 2004/05/04 05:00 [pubmed]
PHST- 2005/02/09 09:00 [medline]
PHST- 2004/05/04 05:00 [entrez]
AID - S0034-89102004000200011 [pii]
AID - 10.1590/s0034-89102004000200011 [doi]
PST - ppublish
SO  - Rev Saude Publica. 2004 Apr;38(2):223-7. doi: 10.1590/s0034-89102004000200011. 
      Epub 2004 Apr 26.

PMID- 20725815
OWN - NLM
STAT- MEDLINE
DCOM- 20101222
LR  - 20211020
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 92
IP  - 2
DP  - 2010 Sep
TI  - Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary 
      artery disease patients with diabetes.
PG  - 296-301
LID - 10.1007/s12185-010-0652-3 [doi]
AB  - The aim of this pilot study was to compare the effect of two different regimens 
      of aspirin dosage on platelet of coronary artery disease (CAD) diabetic patients. 
      Twenty-five CAD diabetic patients were included. Initially, all patients received 
      aspirin 100 mg/day for 10 days. At day 10, aspirin antiplatelet effect was 
      determined by measuring the collagen/epinephrine closure time (CT) 2 h after the 
      last aspirin dosage and the next morning at 8 a.m.. The aspirin regimen was 
      modified to 100 mg twice daily for patients showing a non-optimal 
      platelet-inhibitory effect (CT < 298 s at 8 a.m.). Persistent high platelet 
      reactivity (HPR) was defined by a CT < 160 s. During the 100 mg/day aspirin 
      regimen, the prevalence of HPR at 8 a.m. was 48%, and only 7 patients (28%) had 
      showed an optimal platelet-inhibitory effect. Bridging to the twice-daily 
      regimen, the HPR was significantly reduced (p=0.025), and the optimal 
      platelet-inhibitory effect was reached for 3 other patients. Our results showed 
      that 100 mg aspirin twice-daily dosing rather than a once-daily dose 
      significantly improves the aspirin effect on platelet of CAD diabetic patients. 
      However, large prospective studies were needed to confirm whether this strategy 
      will be clinically relevant and safe.
FAU - Addad, Faouzi
AU  - Addad F
AD  - Department of Cardiology A, Fattouma Bourguiba University Hospital, Monastir, 
      Tunisia. faouzi.addad@rns.tn
FAU - Chakroun, Tahar
AU  - Chakroun T
FAU - Elalamy, Ismail
AU  - Elalamy I
FAU - Abderazek, Fatma
AU  - Abderazek F
FAU - Chouchene, Saoussen
AU  - Chouchene S
FAU - Dridi, Zohra
AU  - Dridi Z
FAU - Gerotziafas, Gregoris T
AU  - Gerotziafas GT
FAU - Hatmi, Mohamed
AU  - Hatmi M
FAU - Hassine, Mohsen
AU  - Hassine M
FAU - Gamra, Habib
AU  - Gamra H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100820
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Chemoprevention/methods
MH  - Coronary Artery Disease/*drug therapy
MH  - Diabetes Mellitus/drug therapy
MH  - Diabetic Angiopathies/*drug therapy
MH  - Drug Administration Schedule
MH  - Humans
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Treatment Outcome
EDAT- 2010/08/21 06:00
MHDA- 2010/12/24 06:00
CRDT- 2010/08/21 06:00
PHST- 2009/12/01 00:00 [received]
PHST- 2010/07/21 00:00 [accepted]
PHST- 2010/07/13 00:00 [revised]
PHST- 2010/08/21 06:00 [entrez]
PHST- 2010/08/21 06:00 [pubmed]
PHST- 2010/12/24 06:00 [medline]
AID - 10.1007/s12185-010-0652-3 [doi]
PST - ppublish
SO  - Int J Hematol. 2010 Sep;92(2):296-301. doi: 10.1007/s12185-010-0652-3. Epub 2010 
      Aug 20.

PMID- 8570531
OWN - NLM
STAT- MEDLINE
DCOM- 19960305
LR  - 20190818
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 12
IP  - 9
DP  - 1995 Sep
TI  - New evaluation method for in vitro/in vivo correlation of enteric-coated multiple 
      unit dosage forms.
PG  - 1333-7
AB  - PURPOSE: To establish the evaluating method for drug dissolution profiles in the 
      gastrointestinal (GI) tract based on in vitro data for the enteric-coated 
      multiple unit. METHODS: Dissolution profile in the GI tract was calculated by the 
      convolution procedure using an in vitro dissolution profile as a weighting 
      function, and the gastric-emptying (GE) process as an input function 
      (GE-convolution method). A computer program, GECONV, was developed for numerical 
      execution of the convolution integral. RESULTS: The in vivo dissolution profile 
      of enteric-coated aspirin granules estimated by GE-convolution was in good 
      agreement with the in vivo cumulative absorption profile calculated by the 
      Wagner-Nelson method using the plasma concentration data after oral 
      administration to healthy subjects. The in vitro/in vivo correlation improved 
      markedly by taking the GE process into consideration. CONCLUSIONS: These findings 
      indicated that this convolution method is useful for estimating the in vivo 
      dissolution profile of drugs, when they are administered in an enteric-coated 
      multiple unit type dosage form, because the gastric emptying process is a 
      determinant process for the in vivo drug dissolution.
FAU - Hayashi, T
AU  - Hayashi T
AD  - Developmental Research Laboratories, Shionogi & Co., Ltd., Hyogo, Japan.
FAU - Ogura, T
AU  - Ogura T
FAU - Takagishi, Y
AU  - Takagishi Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Dosage Forms)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/blood/pharmacokinetics
MH  - Dosage Forms
MH  - Evaluation Studies as Topic
MH  - Gastric Emptying
MH  - Humans
MH  - In Vitro Techniques
MH  - Intestinal Absorption
MH  - Male
MH  - Models, Biological
MH  - Software
MH  - Tablets, Enteric-Coated/*pharmacokinetics
MH  - Therapeutic Equivalency
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
AID - 10.1023/a:1016277724645 [doi]
PST - ppublish
SO  - Pharm Res. 1995 Sep;12(9):1333-7. doi: 10.1023/a:1016277724645.

PMID- 359216
OWN - NLM
STAT- MEDLINE
DCOM- 19781229
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 24
IP  - 5
DP  - 1978 Nov
TI  - Oral nefopam and aspirin.
PG  - 555-9
AB  - Analgesia through nefopam (30 mg, 60 mg, 90 mg), aspirin (325 mg, 650 mg), and 
      placebo were compared in 122 hospitalized patients with moderate to severe 
      postoperative, fracture, or other somatic pain. A double-blind noncrossover study 
      design was used, and patients were evaluated for pain intensity and pain relief 
      over a 6-hr period. Based on sum of pain intensity differences (SPID) scores, 
      treatment effects were consistent and indicative of good dose response to both 
      active medications. Pain relief scores were more variable but were generally in 
      accordance with SPID values. Time-effect curves were similar. Estimated relative 
      potency of nefopam to aspirin was 10.4 with a 95% confidence interval of 6.3 to 
      20.8 for SPID, indicating that the analgesic potency of nefopam, 60 mg, was 
      equivalent to that of aspirin, 650 mg. Side effects were minimal.
FAU - Sunshine, A
AU  - Sunshine A
FAU - Laska, E
AU  - Laska E
FAU - Slafta, J
AU  - Slafta J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Analgesics)
RN  - 0 (Oxazocines)
RN  - 0 (Placebos)
RN  - 4UP8060B7J (Nefopam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - *Analgesics
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nefopam/administration & dosage/adverse effects/*pharmacology
MH  - Oxazocines/*pharmacology
MH  - Placebos
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
AID - 0009-9236(78)90346-6 [pii]
AID - 10.1002/cpt1978245555 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1978 Nov;24(5):555-9. doi: 10.1002/cpt1978245555.

PMID- 12728491
OWN - NLM
STAT- MEDLINE
DCOM- 20030808
LR  - 20131121
IS  - 0021-4892 (Print)
IS  - 0021-4892 (Linking)
VI  - 52
IP  - 4
DP  - 2003 Apr
TI  - Aspirin reversal--an incremental administration of aspirin shortens the bleeding 
      time prolonged by low-dose aspirin.
PG  - 399-401
AB  - In summary, an incremental dosage of aspirin (660 mg) shortens the bleeding time 
      prolonged by daily low-dosage aspirin (81 mg) in healthy subjects. The "Aspirin 
      Reversal" phenomenon might be useful to control excessive bleeding during surgery 
      in patients taking daily low-dosage aspirin as anti-coagulants.
FAU - Yokoyama, Takeshi
AU  - Yokoyama T
AD  - Department of Anesthesiology and Resuscitology, Kochi Medical School, Nankoku 
      783-8505.
FAU - Yamashita, Koichi
AU  - Yamashita K
FAU - Yamasaki, Fumiyasu
AU  - Yamasaki F
FAU - Ueta, Tadashi
AU  - Ueta T
FAU - Manabe, Masanobu
AU  - Manabe M
FAU - Nishiyama, Tomoki
AU  - Nishiyama T
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Masui
JT  - Masui. The Japanese journal of anesthesiology
JID - 0413707
RN  - 0 (Analgesics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analgesics/*administration & dosage
MH  - Aspirin/*administration & dosage/pharmacology
MH  - *Bleeding Time
MH  - Humans
MH  - Male
MH  - Partial Thromboplastin Time
MH  - Platelet Count
MH  - Prothrombin Time
EDAT- 2003/05/06 05:00
MHDA- 2003/08/09 05:00
CRDT- 2003/05/06 05:00
PHST- 2003/05/06 05:00 [pubmed]
PHST- 2003/08/09 05:00 [medline]
PHST- 2003/05/06 05:00 [entrez]
PST - ppublish
SO  - Masui. 2003 Apr;52(4):399-401.

PMID- 29775202
OWN - NLM
STAT- MEDLINE
DCOM- 20191029
LR  - 20191029
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 58
IP  - 9
DP  - 2018 Sep
TI  - The Development of an In Vitro Assay for the Prospective Determination of Aspirin 
      Sensitivity.
PG  - 1150-1156
LID - 10.1002/jcph.1260 [doi]
AB  - Aspirin remains the standard for stroke prophylaxis. However, as many as 20%-25% 
      of patients may fail to show a full response to aspirin. Ideally, patients who 
      are resistant to aspirin could be identified, then receive an increased dose of 
      aspirin or be changed to an alternative therapy more efficiently. We have 
      developed an in vitro assay that may make this possible. Healthy volunteers (n = 
      13) between 18 and 50 years of age were tested for both ex vivo and in vivo 
      responses to aspirin. Dimethyl sulfoxide (DMSO) was selected as the solvent for 
      aspirin in the assay. DMSO can exhibit antiplatelet effects, necessitating the 
      use of a concentration low enough to avoid such antiplatelet effects. Blood 
      samples were tested against DMSO 0%, 0.05%, 0.5%, and 1% w/v with and without 
      aspirin 0, 50, and 100 μM. The effects of both agents were measured via 
      whole-blood aggregometry. A 3-dimensional response model described the data well, 
      quantifying the combinatorial effect of DMSO and aspirin on platelet aggregation. 
      Across all participants, baseline aggregation stimulated with collagen 1 μM or 
      arachidonate 0.5 mM was approximately 18 and 13 Ω, respectively. The response 
      model showed that 0.05% DMSO with 100 μM aspirin would provide platelet 
      aggregation of 3.4 Ω. A DMSO concentration of 0.05% in the absence of aspirin 
      would result in no discernable effects on platelet aggregation (17.7 Ω). Overall, 
      the use of 100 μM of aspirin in 0.05% DMSO provides a robust method to test for 
      ex vivo inhibition of platelet aggregation.
CI  - © 2018, The American College of Clinical Pharmacology.
FAU - Westphal, Erica S
AU  - Westphal ES
AD  - Dent Neurologic Institute, Amherst, NY, USA.
FAU - Wisniewski, Caitlin
AU  - Wisniewski C
AD  - School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, 
      NY, USA.
FAU - Rainka, Michelle
AU  - Rainka M
AD  - Dent Neurologic Institute, Amherst, NY, USA.
AD  - School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, 
      NY, USA.
FAU - Smith, Nicholas M
AU  - Smith NM
AD  - School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, 
      NY, USA.
AD  - NYS Center for Excellence in Bioinformatics and Life Sciences, Buffalo, NY, USA.
FAU - Bates, Vernice
AU  - Bates V
AD  - Dent Neurologic Institute, Amherst, NY, USA.
FAU - Gengo, Fran M
AU  - Gengo FM
AD  - Dent Neurologic Institute, Amherst, NY, USA.
AD  - School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, 
      NY, USA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180518
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology
MH  - Platelet Function Tests
MH  - Young Adult
OTO - NOTNLM
OT  - TIA
OT  - aspirin prophylaxis
OT  - aspirin resistance assay
OT  - pharmacodynamic resistance
OT  - pharmacokinetic resistance
OT  - stroke
OT  - stroke prevention
EDAT- 2018/05/19 06:00
MHDA- 2019/10/30 06:00
CRDT- 2018/05/19 06:00
PHST- 2018/02/07 00:00 [received]
PHST- 2018/04/16 00:00 [accepted]
PHST- 2018/05/19 06:00 [pubmed]
PHST- 2019/10/30 06:00 [medline]
PHST- 2018/05/19 06:00 [entrez]
AID - 10.1002/jcph.1260 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2018 Sep;58(9):1150-1156. doi: 10.1002/jcph.1260. Epub 2018 May 
      18.

PMID- 10407155
OWN - NLM
STAT- MEDLINE
DCOM- 19990820
LR  - 20190610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1432
IP  - 2
DP  - 1999 Jul 13
TI  - NMR study of the sites of human hemoglobin acetylated by aspirin.
PG  - 333-49
AB  - Acetylation of hemoglobin by aspirin and other acetylating agents has been used 
      to generate hemoglobin analogs with altered structural and functional properties, 
      and may prove useful in the treatment of sickle cell disease. We have studied the 
      acetylation of human hemoglobin using [1'-(13)C]acetylsalicylic acid in 
      combination with two-dimensional HMQC and HSQC NMR analysis. The spectra of the 
      acetylated hemoglobin exhibit a number of well resolved resonances. Several 
      spectral assignment strategies were used: blocking the 2, 3-DPG binding site 
      non-covalently with inositol hexaphosphate or covalently with a cross-linking 
      agent, selective carbamylation of the N-terminal valine amino groups with 
      cyanate, spin-labeling the hemoglobin at betaCys93, and analysis of a hemoglobin 
      triple mutant: betaV1MH2DeltaK144R, in which betaLys144 is replaced by an 
      arginine residue. These studies support the conclusion that the most rapidly 
      acetylated residue is betaLys82 rather than betaLys144, as previously reported. 
      Further, it is apparent that acetyl betaLys82 can give rise to several resonances 
      due to additional acetylation of betaLys82' or other nearby residues. An 
      additional assignment strategy involving comparison of the chemical shifts of the 
      acetyl resonances observed for adducts of diamagnetic carbonmonoxyhemoglobin with 
      the shifts observed in paramagnetic cyanomethemoglobin provides information about 
      the location of the acetyl derivatives relative to the heme irons. This approach 
      is limited, however, by the lack of well defined structural information for the 
      lysine residues on the protein surface. Additional tentative assignments have 
      also been made, using the above approaches.
FAU - Xu, A S
AU  - Xu AS
AD  - Laboratory of Structural Biology, National Institute of Environmental Health 
      Sciences, P.O. Box 12233, Research Triangle Park, NC 27709-2233, USA.
FAU - Macdonald, J M
AU  - Macdonald JM
FAU - Labotka, R J
AU  - Labotka RJ
FAU - London, R E
AU  - London RE
LA  - eng
GR  - 5RO1 HL57604/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Carbon Isotopes)
RN  - 0 (Hemoglobins)
RN  - 0 (Spin Labels)
RN  - 0 (acetylated hemoglobin)
RN  - 0 (cyanomethemoglobin)
RN  - 106044-07-9 (bis(2,3-dibromosalicyl)fumarate)
RN  - 138-81-8 (2,3-Diphosphoglycerate)
RN  - 7IGF0S7R8I (Phytic Acid)
RN  - 9008-37-1 (Methemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2,3-Diphosphoglycerate/chemistry
MH  - Aspirin/analogs & derivatives/chemical synthesis/*chemistry
MH  - Binding Sites
MH  - Carbon Isotopes
MH  - Hemoglobins/*chemistry/isolation & purification
MH  - Humans
MH  - Magnetic Resonance Spectroscopy
MH  - Methemoglobin/analogs & derivatives/chemistry
MH  - Mutation
MH  - Phytic Acid/chemistry
MH  - Spin Labels
EDAT- 1999/07/17 00:00
MHDA- 1999/07/17 00:01
CRDT- 1999/07/17 00:00
PHST- 1999/07/17 00:00 [pubmed]
PHST- 1999/07/17 00:01 [medline]
PHST- 1999/07/17 00:00 [entrez]
AID - S0167-4838(99)00094-1 [pii]
AID - 10.1016/s0167-4838(99)00094-1 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 1999 Jul 13;1432(2):333-49. doi: 
      10.1016/s0167-4838(99)00094-1.

PMID- 1163602
OWN - NLM
STAT- MEDLINE
DCOM- 19751120
LR  - 20190627
IS  - 0002-9394 (Print)
IS  - 0002-9394 (Linking)
VI  - 80
IP  - 3 Pt 2
DP  - 1975 Sep
TI  - The effect of aspirin on rebleeding in traumatic hyphema.
PG  - 543-5
AB  - Often used as an oral analgesic in the management of pain associated with 
      traumatic hyphema, aspirin has an inhibitory effect on the blood clotting 
      mechamism by its action on platelets. We carried out a retrospective study of 
      patients with traumatic hyphema treated with aspirin and showed that the 
      incidence of rebleeding significantly increased with aspirin administration.
FAU - Crawford, J S
AU  - Crawford JS
FAU - Lewandowski, R L
AU  - Lewandowski RL
FAU - Chan, W
AU  - Chan W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Eye Injuries/*drug therapy
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Hyphema/*drug therapy
MH  - Platelet Adhesiveness/drug effects
MH  - Recurrence
EDAT- 1975/09/01 00:00
MHDA- 1975/09/01 00:01
CRDT- 1975/09/01 00:00
PHST- 1975/09/01 00:00 [pubmed]
PHST- 1975/09/01 00:01 [medline]
PHST- 1975/09/01 00:00 [entrez]
AID - 0002-9394(75)90224-X [pii]
AID - 10.1016/0002-9394(75)90224-x [doi]
PST - ppublish
SO  - Am J Ophthalmol. 1975 Sep;80(3 Pt 2):543-5. doi: 10.1016/0002-9394(75)90224-x.

PMID- 8015355
OWN - NLM
STAT- MEDLINE
DCOM- 19940725
LR  - 20190701
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 55
IP  - 2
DP  - 1994
TI  - Prazosin blocks the pressor but not the regional circulatory effects of diaspirin 
      crosslinked hemoglobin.
PG  - 121-30
AB  - Diaspirin crosslinked hemoglobin (DCLHb) (400 mg/kg, i.v.) produces an increase 
      in blood pressure and blood flow to the heart, spleen, stomach, small intestine, 
      skin, mesentery and pancreas when administered to rats. The present study was 
      conducted to determine (1) whether prazosin, an alpha 1-adrenergic antagonist, 
      can block the pressor effect of DCLHb and (2) the effect of prazosin pretreatment 
      on regional circulatory changes induced by DCLHb in rats. DCLHb (400 mg/kg, i.v.) 
      produced an increase in blood pressure (64%), cardiac output (20%) and total 
      peripheral resistance (65%) when administered to control rats. Infusion of DCLHb 
      in prazosin (1 mg/kg, i.v.) treated rats did not show any significant pressor 
      effect, but reversed the hypotensive effect of prazosin. Cardiac output and 
      stroke volume were significantly increased and total peripheral resistance 
      decreased in prazosin treated rats as compared to control (untreated) rats. DCLHb 
      significantly increased blood flow to the heart, gastrointestinal tract, portal 
      system (spleen), and skin of control rats. Blood flow to the brain, kidneys, and 
      musculo-skeletal system was not altered following the infusion of DCLHb in 
      controls rats. Infusion of DCLHb in prazosin treated rats produced a significant 
      increase in blood flow to the brain, heart, kidneys, gastrointestinal tract, 
      portal system, skin and musculoskeletal system. In summary, prazosin pretreatment 
      blocked the pressor effect of DCLHb, however, blood flow to the heart, brain, 
      gastrointestinal tract, portal system, kidneys, skin and musculoskeletal system 
      was increased by DCLHb. It is concluded that blood flow to most of the organs is 
      increased by DCLHb but the pressor effect of DCLHb is blocked by prazosin 
      pretreatment.
FAU - Gulati, A
AU  - Gulati A
AD  - Department of Pharmaceutics and Pharmacodynamics, University of Illinois at 
      Chicago 60612.
FAU - Sharma, A C
AU  - Sharma AC
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - XM03YJ541D (Prazosin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/antagonists & inhibitors/pharmacology
MH  - Blood Pressure/*drug effects
MH  - Drug Interactions
MH  - Hemodynamics/*drug effects
MH  - Hemoglobins/*antagonists & inhibitors/*pharmacology
MH  - Male
MH  - Prazosin/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/drug effects
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 0024-3205(94)90103-1 [pii]
AID - 10.1016/0024-3205(94)90103-1 [doi]
PST - ppublish
SO  - Life Sci. 1994;55(2):121-30. doi: 10.1016/0024-3205(94)90103-1.

PMID- 12032100
OWN - NLM
STAT- MEDLINE
DCOM- 20021011
LR  - 20190515
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 25
IP  - 6
DP  - 2002 Jun
TI  - Aspirin use and counseling about aspirin among patients with diabetes.
PG  - 965-70
AB  - OBJECTIVE: Despite being a safe, effective therapy for lowering cardiovascular 
      risk, only 20% of diabetic patients were using aspirin in the early 1990s. This 
      study examines current physician practices and the use of aspirin therapy by 
      individuals with diabetes. RESEARCH DESIGN AND METHODS: A random sample of 
      diabetic patients receiving care in the Department of Veterans Affairs health 
      care system were surveyed during January-March 2000. The association between 
      aspirin counseling, aspirin use, and reported coronary vascular disease (CVD) and 
      classical CVD risk factors were examined using logistic regression. The effect of 
      increasing aspirin use on risk of myocardial infarction (MI) and cardiovascular 
      mortality was demonstrated by simulation. RESULTS: Seventy-one percent of 
      respondents reported being counseled about aspirin use, and 66% were taking daily 
      aspirin. Individuals with known CVD were more likely to be counseled (odds ratio 
      [OR] 4.9, 95% CI 2.9-8.1) and to use aspirin (2.1, 1.2-3.7). The factor most 
      strongly associated with aspirin use was having been counseled about aspirin 
      therapy by a doctor. We estimate that for this population, increasing daily 
      aspirin use to 90% could prevent an additional 11,000 MIs and potentially save 
      >8,000 lives. CONCLUSIONS: Compared with previous reports, a substantial 
      proportion of these diabetic patients have been counseled about and use aspirin. 
      Most clinicians recognize aspirin as an important treatment for patients with 
      preexisting coronary disease. However, since diabetes is now considered a CVD 
      equivalent, it is imperative that clinicians include counseling about aspirin 
      therapy as a care priority for all their diabetic patients, as this simple 
      intervention may prevent many cardiovascular events and deaths.
FAU - Krein, Sarah L
AU  - Krein SL
AD  - Department of Veterans Affairs' Center for Practice Management and Outcomes 
      Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan 48113, 
      USA.skrein@umich.edu
FAU - Vijan, Sandeep
AU  - Vijan S
FAU - Pogach, Leonard M
AU  - Pogach LM
FAU - Hogan, Mary M
AU  - Hogan MM
FAU - Kerr, Eve A
AU  - Kerr EA
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*epidemiology/prevention & control
MH  - *Diabetes Mellitus
MH  - Diabetic Angiopathies/*epidemiology
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Hospitals, Veterans
MH  - Humans
MH  - Male
MH  - Risk Factors
MH  - United States
EDAT- 2002/05/29 10:00
MHDA- 2002/10/12 04:00
CRDT- 2002/05/29 10:00
PHST- 2002/05/29 10:00 [pubmed]
PHST- 2002/10/12 04:00 [medline]
PHST- 2002/05/29 10:00 [entrez]
AID - 10.2337/diacare.25.6.965 [doi]
PST - ppublish
SO  - Diabetes Care. 2002 Jun;25(6):965-70. doi: 10.2337/diacare.25.6.965.

PMID- 2768694
OWN - NLM
STAT- MEDLINE
DCOM- 19890929
LR  - 20190708
IS  - 0002-8177 (Print)
IS  - 0002-8177 (Linking)
VI  - 119
IP  - 2
DP  - 1989 Aug
TI  - Mucosal burn resulting from chewable aspirin: report of case.
PG  - 279-80
AB  - A 4-year-old female patient with juvenile rheumatoid arthritis received a mucosal 
      burn from chewable-aspirin therapy. She was given five chewable aspirin tablets 
      before bedtime, and fell asleep before swallowing them. Mucosal burns from 
      incomplete aspirin ingestion can be prevented by not administering aspirin at 
      bedtime, and by cleaning the buccal vestibules with a cotton swab to ensure 
      complete removal of all aspirin.
FAU - Maron, F S
AU  - Maron FS
AD  - Albert Einstein College of Medicine, Montefiore Division, Bronx, NY.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Juvenile/drug therapy
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Burns, Chemical/*etiology
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Mouth Mucosa/*injuries
MH  - Tablets
EDAT- 1989/08/01 00:00
MHDA- 1989/08/01 00:01
CRDT- 1989/08/01 00:00
PHST- 1989/08/01 00:00 [pubmed]
PHST- 1989/08/01 00:01 [medline]
PHST- 1989/08/01 00:00 [entrez]
AID - S0002-8177(89)92013-8 [pii]
AID - 10.14219/jada.archive.1989.0195 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 1989 Aug;119(2):279-80. doi: 10.14219/jada.archive.1989.0195.

PMID- 7994419
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20211203
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Diaspirin crosslinked hemoglobin (DCLHb) polymerization.
PG  - 923-31
AB  - By employing proprietary polymerization agents possessing specific binding groups 
      and by completing diaspirin crosslinked hemoglobin (DCLHb) polymerization under 
      specific conditions, we have selectively achieved the following objectives: (1) 
      the P50 was adjusted to the physiologic range or left- or right-shifted; (2) the 
      surface of DCLHb was modified ("decorated"); (3) DCLHb was polymerized but not 
      decorated; (4) DCLHb was polymerized and decorated; or (5) DCLHb was 
      site-specifically modified and polymerized.
FAU - Hai, T T
AU  - Hai TT
AD  - Blood Substitutes Program, Baxter Healthcare Corporation, Round Lake, IL 60073.
FAU - Nelson, D
AU  - Nelson D
FAU - Pereira, D
AU  - Pereira D
FAU - Srnak, A
AU  - Srnak A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Amino Acids, Diamino)
RN  - 0 (Blood Substitutes)
RN  - 0 (Cyanobacteria Toxins)
RN  - 0 (Hemoglobins)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Polymers)
RN  - 108SA6URTV (beta-N-methylamino-L-alanine)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Amino Acids, Diamino
MH  - Aspirin/*analogs & derivatives/chemistry/isolation & purification/metabolism
MH  - Binding Sites
MH  - Blood Substitutes/chemistry/*isolation & purification/metabolism
MH  - Cyanobacteria Toxins
MH  - Hemoglobins/chemistry/*isolation & purification/metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Indicators and Reagents
MH  - Oxygen/metabolism
MH  - Polyethylene Glycols
MH  - Polymers/chemistry/isolation & purification
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117931 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):923-31. doi: 
      10.3109/10731199409117931.

PMID- 11170020
OWN - NLM
STAT- MEDLINE
DCOM- 20010628
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 90
IP  - 3
DP  - 2001 Mar
TI  - Variable pH kinetics: an easy determination of pH-rate profile.
PG  - 270-4
AB  - The complete pH-rate profile of the hydrolysis reaction of aspirin, requiring 
      many experiments in the past, was obtained by a single variable-parameter kinetic 
      experiment carried out by varying the hydrogen ion concentration. The experiment 
      was carried out spectrophotometrically, reading automatically absorbance, pH, and 
      temperature inside the reaction vessel. The results obtained by the fast 
      processing of the kinetic profile are identical to those obtained under the same 
      conditions but using traditional constant-pH kinetic runs. This method provides 
      the possibility of reducing the amount of time and chemicals usually spent in 
      collecting kinetic data in such mechanistic studies by nearly two orders of 
      magnitude.
FAU - Alibrandi, G
AU  - Alibrandi G
AD  - Dipartimento di Chimica Inorganica, Chimica Analitica e Chimica Fisica, 
      Università di Messina, Salita Sperone 31, Villaggio S. Agata, 98166 Messina, 
      Italy. alibrandi@chem.unime.it
FAU - Coppolino, S
AU  - Coppolino S
FAU - Micali, N
AU  - Micali N
FAU - Villari, A
AU  - Villari A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - *Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - *Kinetics
MH  - Spectrophotometry
EDAT- 2001/02/15 11:00
MHDA- 2001/06/29 10:01
CRDT- 2001/02/15 11:00
PHST- 2001/02/15 11:00 [pubmed]
PHST- 2001/06/29 10:01 [medline]
PHST- 2001/02/15 11:00 [entrez]
AID - S0022-3549(16)30727-4 [pii]
AID - 10.1002/1520-6017(200103)90:3<270::aid-jps2>3.0.co;2-# [doi]
PST - ppublish
SO  - J Pharm Sci. 2001 Mar;90(3):270-4. doi: 
      10.1002/1520-6017(200103)90:3<270::aid-jps2>3.0.co;2-#.

PMID- 4463276
OWN - NLM
STAT- MEDLINE
DCOM- 19750913
LR  - 20190725
IS  - 0021-5198 (Print)
IS  - 0021-5198 (Linking)
VI  - 24
IP  - 6
DP  - 1974 Dec
TI  - Influence of L-glutamine on aspirin-induced gastric lesions and absorptions as 
      well as antipyretic, analgesic and anti-inflammatory effects of aspirin in rats 
      and mice.
PG  - 903-10
AB  - L-glutamine markedly suppressed the development of the gastric lesions induced by 
      aspirin in pylorus-ligated rats. In non-ligated normal rats, aspirin was absorbed 
      rapidly after administration and was maintained in the blood in high salicylate 
      concentration thereafter. When aspirin was administered in combination with 
      L-glutamine, the absorption of aspirin was at nearly the same level as when 
      aspirin had been given alone. In pylorus-ligated rats, administration of aspirin 
      was followed by slow increment in blood salicylate concentration. Blood 
      salicylate level in these rats was higher when aspirin was administered in 
      combination with L-glutamine than when it had been given alone. Combined 
      administration of aspirin and L-glutamine produced little influence on the 
      antipyretic, analgesic and anti-inflammatory effects of aspirin in non-ligated 
      normal rats.
FAU - Tanaka, H
AU  - Tanaka H
FAU - Kiyohara, A
AU  - Kiyohara A
FAU - Orima, H
AU  - Orima H
FAU - Suzuki, Y
AU  - Suzuki Y
FAU - Takagi, K
AU  - Takagi K
FAU - Okabe, S
AU  - Okabe S
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Jpn J Pharmacol
JT  - Japanese journal of pharmacology
JID - 2983305R
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0RH81L854J (Glutamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - *Analgesics/*pharmacology
MH  - Animals
MH  - *Anti-Inflammatory Agents
MH  - Aspirin/administration & dosage/metabolism/*pharmacology
MH  - Glutamine/administration & dosage/*pharmacology
MH  - Intestinal Absorption
MH  - Male
MH  - Mice
MH  - Rats
MH  - Stomach/drug effects
MH  - Stomach Ulcer/chemically induced/*prevention & control
EDAT- 1974/12/01 00:00
MHDA- 1974/12/01 00:01
CRDT- 1974/12/01 00:00
PHST- 1974/12/01 00:00 [pubmed]
PHST- 1974/12/01 00:01 [medline]
PHST- 1974/12/01 00:00 [entrez]
AID - 10.1254/jjp.24.903 [doi]
PST - ppublish
SO  - Jpn J Pharmacol. 1974 Dec;24(6):903-10. doi: 10.1254/jjp.24.903.

PMID- 37564983
OWN - NLM
STAT- MEDLINE
DCOM- 20230814
LR  - 20230814
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - The underlying regulatory mechanisms of colorectal carcinoma by combining Vitexin 
      and Aspirin: based on systems biology, molecular docking, molecular dynamics 
      simulation, and in vitro study.
PG  - 1147132
LID - 10.3389/fendo.2023.1147132 [doi]
LID - 1147132
AB  - INTRODUCTION: Colorectal cancer (CRC) is a highly prevalent digestive system 
      malignancy. Aspirin is currently one of the most promising chemopreventive agents 
      for CRC, and the combination of aspirin and natural compounds helps to enhance 
      the anticancer activity of aspirin. Natural flavonoids like vitexin have an 
      anticancer activity focusing on colorectal carcinoma. METHODS: This study 
      investigated the potential mechanism of action of the novel combination of 
      vitexin and aspirin against colorectal cancer through network pharmacology, 
      molecular docking, molecular dynamics simulation, and in vitro experiments. 
      RESULTS: The results of network pharmacology suggested that vitexin and aspirin 
      regulate multiple signaling pathways through various target proteins such as 
      NFKB1, PTGS2 (COX-2), MAPK1, MAPK3, and TP53. Cellular experiments revealed that 
      the combined effect of vitexin and aspirin significantly inhibited HT-29 cell 
      growth. Vitexin dose-dependently inhibited COX-2 expression in cells and enhanced 
      the down-regulation of COX-2 and NF-κB expression in colorectal cancer cells by 
      aspirin. DISCUSSION: This study provides a pharmacodynamic material and 
      theoretical basis for applying agents against colorectal cancer to delay the 
      development of drug resistance and improve the prognosis of cancer patients.
CI  - Copyright © 2023 Chen, Chen, Huang, Zhang, Zhou and Xu.
FAU - Chen, Dengsheng
AU  - Chen D
AD  - Department of Clinical Pharmacy, Sanming First Hospital, Affiliated Hospital of 
      Fujian Medical University, Sanming, Fujian, China.
FAU - Chen, Ying
AU  - Chen Y
AD  - Department of Clinical Pharmacy, Sanming First Hospital, Affiliated Hospital of 
      Fujian Medical University, Sanming, Fujian, China.
FAU - Huang, Fang
AU  - Huang F
AD  - Department of Clinical Pharmacy, Sanming First Hospital, Affiliated Hospital of 
      Fujian Medical University, Sanming, Fujian, China.
FAU - Zhang, Xiaoling
AU  - Zhang X
AD  - Department of Clinical Pharmacy, Sanming First Hospital, Affiliated Hospital of 
      Fujian Medical University, Sanming, Fujian, China.
FAU - Zhou, Yulv
AU  - Zhou Y
AD  - Department of Chinese Medicine and Anorectology, Sanming First Hospital, 
      Affiliated Hospital of Fujian Medical University, Sanming, Fujian, China.
FAU - Xu, Luning
AU  - Xu L
AD  - Department of Clinical Pharmacy, Sanming First Hospital, Affiliated Hospital of 
      Fujian Medical University, Sanming, Fujian, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230726
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - R16CO5Y76E (Aspirin)
RN  - 9VP70K75OK (vitexin)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
SB  - IM
MH  - Humans
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Molecular Docking Simulation
MH  - Cyclooxygenase 2
MH  - Molecular Dynamics Simulation
MH  - *Colorectal Neoplasms/drug therapy/pathology
MH  - Molecular Biology
PMC - PMC10410442
OTO - NOTNLM
OT  - Aspirin
OT  - colorectal cancer
OT  - experimental verification
OT  - molecular docking
OT  - network pharmacology
OT  - vitexin
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/11 06:43
MHDA- 2023/08/14 06:42
CRDT- 2023/08/11 04:08
PHST- 2023/01/18 00:00 [received]
PHST- 2023/07/03 00:00 [accepted]
PHST- 2023/08/14 06:42 [medline]
PHST- 2023/08/11 06:43 [pubmed]
PHST- 2023/08/11 04:08 [entrez]
AID - 10.3389/fendo.2023.1147132 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Jul 26;14:1147132. doi: 
      10.3389/fendo.2023.1147132. eCollection 2023.

PMID- 18047255
OWN - NLM
STAT- MEDLINE
DCOM- 20080103
LR  - 20211020
IS  - 1176-9092 (Print)
IS  - 1178-1998 (Electronic)
IS  - 1176-9092 (Linking)
VI  - 1
IP  - 1
DP  - 2006
TI  - Improving the gastrointestinal tolerability of aspirin in older people.
PG  - 33-9
AB  - Interventions to reduce mortality and disability in older people are vital. 
      Aspirin is cheap and effective and known to prevent cardiovascular and 
      cerebrovascular disease, many cancers, and Alzheimer dementia. The widespread use 
      of aspirin in older people is limited by its gastrointestinal side effects. 
      Understanding age-related changes in gastrointestinal physiology that could put 
      older people at risk of the side effects of aspirin may direct strategies to 
      improve tolerance and hence lead to greater numbers of older people being able to 
      take this effective intervention.
FAU - Newton, Julia L
AU  - Newton JL
AD  - Institute for Ageing and Health, University of Newcastle upon Tyne, Care of the 
      Elderly Offices, Royal Victoria Infirmary, Newcastle upon Tyne, UK. 
      julianewton@blueyonder.co.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Clin Interv Aging
JT  - Clinical interventions in aging
JID - 101273480
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Gastrointestinal Diseases/*chemically induced/*epidemiology
MH  - Humans
MH  - Peptic Ulcer/*chemically induced/*epidemiology
PMC - PMC2682452
EDAT- 2007/12/01 09:00
MHDA- 2008/01/04 09:00
CRDT- 2007/12/01 09:00
PHST- 2007/12/01 09:00 [pubmed]
PHST- 2008/01/04 09:00 [medline]
PHST- 2007/12/01 09:00 [entrez]
AID - 10.2147/ciia.2006.1.1.33 [doi]
PST - ppublish
SO  - Clin Interv Aging. 2006;1(1):33-9. doi: 10.2147/ciia.2006.1.1.33.

PMID- 23905373
OWN - NLM
STAT- MEDLINE
DCOM- 20140418
LR  - 20161018
IS  - 1003-5370 (Print)
IS  - 1003-5370 (Linking)
VI  - 33
IP  - 5
DP  - 2013 May
TI  - [Treatment of aspirin resistance patients at transient ischemic attack by buyang 
      huanwu decoction combination with aspirin: a randomized control observation].
PG  - 594-7
AB  - OBJECTIVE: To investigate the curative effect and safety of buyang huanwu 
      decoction (BHD) combined aspirin (ASP) in treatment of aspirin resistance (AR) 
      patients at transient ischemic attack (TIA). METHODS: Recruited were 86 AR 
      patients at TIA who took ASP as the secondary prevention. Two cases were rejected 
      due to poor compliance. The rest 84 patients were randomly assigned to the 
      treatment group and the control group. Those in the treatment group were treated 
      with BHD and ASP, while those in the control group took Clopidogrel and ASP. 
      After 30-, 60-, and 90-day of treatment, arachidonic acid (AA) and adenosine 
      diphosphate (ADP) induced platelet aggregation rate (PAG) were detected using 
      turbidimetry. After treatment of 90 days, the case numbers of TIA recurrence or 
      of progressing to cerebral infarction were counted. The incidence of adverse 
      events was also observed. RESULTS: The ADP-and AA-induced PAG showed similar 
      decreasing tendency in the treatment group and the control group at each time 
      point (P >0.05). There was no statistical difference in the risk control of end 
      point events (including ischemic cerebrovascular diseases, TIA recurrence, 
      cerebral infarction) between the two groups (P >0.05). One patient suffered from 
      bleeding (mild gastrointestinal bleeding) in the treatment group, while 4 
      patients suffered from bleeding (3 due to skin and mucous membrane bleeding and 1 
      to stool bleeding). The bleeding risk was lowered by 76.29% in the treatment 
      group when compared with the control group. CONCLUSIONS: BHD combined ASP showed 
      similar efficacy in treating AR and controlling endpoint events. Besides, they 
      lowered bleeding risk.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, 
      Urumqi 830000, China. zhang30lei@tom.com
FAU - Liu, Tao
AU  - Liu T
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhongguo Zhong Xi Yi Jie He Za Zhi
JT  - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese 
      journal of integrated traditional and Western medicine
JID - 9211576
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (buyang huanwu)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Drug Resistance
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
EDAT- 2013/08/03 06:00
MHDA- 2014/04/20 06:00
CRDT- 2013/08/03 06:00
PHST- 2013/08/03 06:00 [entrez]
PHST- 2013/08/03 06:00 [pubmed]
PHST- 2014/04/20 06:00 [medline]
PST - ppublish
SO  - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 May;33(5):594-7.

PMID- 2894232
OWN - NLM
STAT- MEDLINE
DCOM- 19880420
LR  - 20220330
IS  - 0267-0623 (Print)
IS  - 0267-0623 (Linking)
VI  - 296
IP  - 6618
DP  - 1988 Jan 30
TI  - United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim 
      results. UK-TIA Study Group.
PG  - 316-20
AB  - From 1979 to 1985, 2435 patients thought to have had a transient ischaemic attack 
      or minor ischaemic stroke were allocated at random to receive long term blind 
      treatment with either aspirin 600 mg twice daily (n = 815), aspirin 300 mg once 
      daily (806), or placebo (814). Treatment continued with about 85% compliance 
      until September 1986 (mean four years). The odds of suffering one or more of four 
      categories of event--namely, non-fatal myocardial infarction, non-fatal major 
      stroke, vascular death, or non-vascular death--were 18% less in the two groups 
      allocated to receive aspirin than in the group allocated to receive placebo (2p = 
      0.01). The more relevant but less frequent composite event of disabling stroke or 
      vascular death was reduced by only 7%; this reduction was not significantly 
      different from zero, but nor was it significantly different from a 25% reduction. 
      There was no definite difference between responses to the 300 mg and 1200 mg 
      daily doses, except that the lower dose was significantly less gastrotoxic.
CN  - Uk-Tia Study Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br Med J (Clin Res Ed)
JT  - British medical journal (Clinical research ed.)
JID - 8302911
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/mortality
MH  - Cerebrovascular Disorders/mortality/*prevention & control
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
PMC - PMC2544832
EDAT- 1988/01/30 00:00
MHDA- 1988/01/30 00:01
CRDT- 1988/01/30 00:00
PHST- 1988/01/30 00:00 [pubmed]
PHST- 1988/01/30 00:01 [medline]
PHST- 1988/01/30 00:00 [entrez]
PST - ppublish
SO  - Br Med J (Clin Res Ed). 1988 Jan 30;296(6618):316-20.

PMID- 1001131
OWN - NLM
STAT- MEDLINE
DCOM- 19770216
LR  - 20131121
IS  - 0009-4722 (Print)
IS  - 0009-4722 (Linking)
VI  - 47
IP  - 12
DP  - 1976 Dec
TI  - [Double-blind study for the prevention of postoperative thrombosis].
PG  - 670-3
AB  - In a double-blind study a randomized group of 96 patients with abdominal 
      operations received a placebo, dipyridamol/acetylsalicylic acid or ASA alone. 
      Thrombi were verified by the 125-I-fibrinogen test. In 38% of the placebo group 
      deep venous thrombosis (DVT) was found, while only 10% of the dipyridamol/ASA 
      group (P less than 0,05) and 28% of the ASA treated patients (not significant) 
      showed radioactive thrombi. DVT were localized in 83.8% in the calf region. 48.6% 
      of increasend activities were registered up to the end of the first postoperative 
      day, 78.3% up to the third day. The results emphasize the importance of a general 
      antithrombotic prophylaxis. Dipyridamol/ASA seems to be efficient in this regard 
      for abdominal procedures.
FAU - Encke, A
AU  - Encke A
FAU - Stock, C
AU  - Stock C
FAU - Dumke, H O
AU  - Dumke HO
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Doppelblindstudie zur postoperativen Thromboseprophylaxe mit 
      Dipyridamol/Acetylsalicylsäure.
PL  - Germany
TA  - Chirurg
JT  - Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
JID - 16140410R
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdomen/surgery
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Dipyridamole/pharmacology/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Postoperative Complications/*prevention & control
MH  - Thrombosis/*prevention & control
EDAT- 1976/12/01 00:00
MHDA- 1976/12/01 00:01
CRDT- 1976/12/01 00:00
PHST- 1976/12/01 00:00 [pubmed]
PHST- 1976/12/01 00:01 [medline]
PHST- 1976/12/01 00:00 [entrez]
PST - ppublish
SO  - Chirurg. 1976 Dec;47(12):670-3.

PMID- 29874836
OWN - NLM
STAT- MEDLINE
DCOM- 20181022
LR  - 20181207
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 23
IP  - 6
DP  - 2018 Jun 5
TI  - Aspirin Derivative 5-(Bis(3-methylbut-2-enyl)amino)-2-hydroxybenzoic Acid 
      Improves Thermotolerance via Stress Response Proteins in Caenorhabditis elegans.
LID - 10.3390/molecules23061359 [doi]
LID - 1359
AB  - Aging is a major risk factor for many prevalent diseases. Pharmacological 
      intervention to improve the health span and extend the lifespan could be a 
      preventive elixir for aging and age-related diseases. The non-steroid 
      anti-inflammation medicine aspirin was reported to delay aging in Caenorhabditis 
      elegans (C. elegans) and mice. We are wondering if the analogues of aspirin could 
      also present antiaging activity. Here, we synthesized several aspirin derivatives 
      and investigated their thermotolerance and antiaging effect in C. elegans. One of 
      the compounds, 5-(bis(3-methylbut-2-en-1-yl)amino)-2-hydroxybenzoic acid, 
      moderately increased the survival of C. elegans under heat stress, but could not 
      extend the lifespan under optimum conditions. This compound could increase the 
      mRNA level of stress response gene gst-4, and the mRNA and protein expression 
      level of heat shock protein hsp-16.2 under heat stress. The failure of activating 
      the transcription factor DAF-16 might explain why this compound could not act as 
      aspirin to extend the lifespan of C. elegans. Our results would help further the 
      investigation of the pharmacological activity of aspirin analogues and the 
      relationship between structures and activity.
FAU - Huang, Xiao-Bing
AU  - Huang XB
AD  - State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming 
      Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China. 
      hxb@swmu.edu.cn.
AD  - Key Laboratory for Aging and Regenerative Medicine, Department of Pharmacology, 
      School of Pharmacy, Southwest Medical University, Luzhou 646000, China. 
      hxb@swmu.edu.cn.
AD  - Key Laboratory of Medical Electrophysiology of Ministry of Education, 
      Collaborative Innovation Center for Prevention and Treatment of Cardiovascular 
      Disease, Southwest Medical University, Luzhou 646000, China. hxb@swmu.edu.cn.
FAU - Wu, Gui-Sheng
AU  - Wu GS
AD  - Key Laboratory for Aging and Regenerative Medicine, Department of Pharmacology, 
      School of Pharmacy, Southwest Medical University, Luzhou 646000, China. 
      wgs@swmu.edu.cn.
AD  - Key Laboratory of Medical Electrophysiology of Ministry of Education, 
      Collaborative Innovation Center for Prevention and Treatment of Cardiovascular 
      Disease, Southwest Medical University, Luzhou 646000, China. wgs@swmu.edu.cn.
FAU - Ke, Lei-Yu
AU  - Ke LY
AD  - Key Laboratory of Economic Plants and Biotechnology, and Yunnan Key Laboratory 
      for Wild Plant Resources, Kunming Institute of Botany, Chinese Academy of 
      Sciences, Kunming 650201, China. keleiyu@mail.kib.ac.cn.
AD  - Southeast Asia Biodiversity Research Institute, Chinese Academy of Sciences, 
      Yezin, Nay Pyi Taw 05282, Myanmar. keleiyu@mail.kib.ac.cn.
FAU - Zhou, Xiao-Gang
AU  - Zhou XG
AD  - Key Laboratory for Aging and Regenerative Medicine, Department of Pharmacology, 
      School of Pharmacy, Southwest Medical University, Luzhou 646000, China. 
      zxg@swmu.edu.cn.
AD  - Key Laboratory of Medical Electrophysiology of Ministry of Education, 
      Collaborative Innovation Center for Prevention and Treatment of Cardiovascular 
      Disease, Southwest Medical University, Luzhou 646000, China. zxg@swmu.edu.cn.
FAU - Wang, Yue-Hu
AU  - Wang YH
AD  - Key Laboratory of Economic Plants and Biotechnology, and Yunnan Key Laboratory 
      for Wild Plant Resources, Kunming Institute of Botany, Chinese Academy of 
      Sciences, Kunming 650201, China. wangyuehu@mail.kib.ac.cn.
AD  - Southeast Asia Biodiversity Research Institute, Chinese Academy of Sciences, 
      Yezin, Nay Pyi Taw 05282, Myanmar. wangyuehu@mail.kib.ac.cn.
FAU - Luo, Huai-Rong
AU  - Luo HR
AD  - State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming 
      Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China. 
      luohuairong@mail.kib.ac.cn.
AD  - Key Laboratory for Aging and Regenerative Medicine, Department of Pharmacology, 
      School of Pharmacy, Southwest Medical University, Luzhou 646000, China. 
      luohuairong@mail.kib.ac.cn.
AD  - Key Laboratory of Medical Electrophysiology of Ministry of Education, 
      Collaborative Innovation Center for Prevention and Treatment of Cardiovascular 
      Disease, Southwest Medical University, Luzhou 646000, China. 
      luohuairong@mail.kib.ac.cn.
LA  - eng
PT  - Journal Article
DEP - 20180605
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (5-(bis(3-methylbut-2-en-1-yl)amino)-2-hydroxybenzoic acid)
RN  - 0 (Helminth Proteins)
RN  - 0 (RNA, Messenger)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adaptation, Physiological/*drug effects
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Caenorhabditis elegans/*drug effects/metabolism/physiology
MH  - *Heat-Shock Response
MH  - Helminth Proteins/genetics/*metabolism
MH  - *Hot Temperature
MH  - Longevity
MH  - RNA, Messenger/genetics
PMC - PMC6099645
OTO - NOTNLM
OT  - Caenorhabditis elegans
OT  - aging
OT  - aspirin
OT  - lifespan
OT  - thermotolerance
COIS- The authors declare no conflict of interest.
EDAT- 2018/06/08 06:00
MHDA- 2018/10/23 06:00
CRDT- 2018/06/08 06:00
PHST- 2018/04/12 00:00 [received]
PHST- 2018/05/30 00:00 [revised]
PHST- 2018/06/04 00:00 [accepted]
PHST- 2018/06/08 06:00 [entrez]
PHST- 2018/06/08 06:00 [pubmed]
PHST- 2018/10/23 06:00 [medline]
AID - molecules23061359 [pii]
AID - molecules-23-01359 [pii]
AID - 10.3390/molecules23061359 [doi]
PST - epublish
SO  - Molecules. 2018 Jun 5;23(6):1359. doi: 10.3390/molecules23061359.

PMID- 36232618
OWN - NLM
STAT- MEDLINE
DCOM- 20221017
LR  - 20221019
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 19
DP  - 2022 Sep 26
TI  - Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need 
      for Improved Point-of-Care Testing and Personalized Therapy.
LID - 10.3390/ijms231911317 [doi]
LID - 11317
AB  - Aspirin resistance describes a phenomenon where patients receiving aspirin 
      therapy do not respond favorably to treatment, and is categorized by continued 
      incidence of adverse cardiovascular events and/or the lack of reduced platelet 
      reactivity. Studies demonstrate that one in four patients with vascular disease 
      are resistant to aspirin therapy, placing them at an almost four-fold increased 
      risk of major adverse limb and adverse cardiovascular events. Despite the 
      increased cardiovascular risk incurred by aspirin resistant patients, strategies 
      to diagnose or overcome this resistance are yet to be clinically validated and 
      integrated. Currently, five unique laboratory assays have shown promise for 
      aspirin resistance testing: Light transmission aggregometry, Platelet Function 
      Analyzer-100, Thromboelastography, Verify Now, and Platelet Works. Newer 
      antiplatelet therapies such as Plavix and Ticagrelor have been tested as an 
      alternative to overcome aspirin resistance (used both in combination with aspirin 
      and alone) but have not proven to be superior to aspirin alone. A recent 
      breakthrough discovery has demonstrated that rivaroxaban, an anticoagulant which 
      functions by inhibiting active Factor X when taken in combination with aspirin, 
      improves outcomes in patients with vascular disease. Current studies are 
      determining how this new regime may benefit those who are considered aspirin 
      resistant.
FAU - Khan, Hamzah
AU  - Khan H
AD  - Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON M5B 1W8, 
      Canada.
FAU - Kanny, Omar
AU  - Kanny O
AD  - Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of 
      St. Michael's Hospital, Toronto, ON M5B 1T8, Canada.
FAU - Syed, Muzammil H
AU  - Syed MH
AUID- ORCID: 0000-0003-4697-5260
AD  - Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON M5B 1W8, 
      Canada.
FAU - Qadura, Mohammad
AU  - Qadura M
AD  - Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON M5B 1W8, 
      Canada.
AD  - Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of 
      St. Michael's Hospital, Toronto, ON M5B 1T8, Canada.
AD  - Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220926
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9001-29-0 (Factor X)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - A74586SNO7 (Clopidogrel)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Factor X
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Point-of-Care Testing
MH  - Rivaroxaban
MH  - Ticagrelor
MH  - *Vascular Diseases/chemically induced/diagnosis/drug therapy
PMC - PMC9570127
OTO - NOTNLM
OT  - aggregation
OT  - antiplatelet
OT  - aspirin
OT  - platelet
OT  - point-of-care
OT  - resistance
OT  - vascular
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/15 06:00
MHDA- 2022/10/18 06:00
CRDT- 2022/10/14 02:08
PHST- 2022/08/11 00:00 [received]
PHST- 2022/09/17 00:00 [revised]
PHST- 2022/09/21 00:00 [accepted]
PHST- 2022/10/14 02:08 [entrez]
PHST- 2022/10/15 06:00 [pubmed]
PHST- 2022/10/18 06:00 [medline]
AID - ijms231911317 [pii]
AID - ijms-23-11317 [pii]
AID - 10.3390/ijms231911317 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Sep 26;23(19):11317. doi: 10.3390/ijms231911317.

PMID- 16950199
OWN - NLM
STAT- MEDLINE
DCOM- 20061025
LR  - 20131121
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 98
IP  - 6
DP  - 2006 Sep 15
TI  - Effect of aspirin dose, preparation, and withdrawal on platelet response in 
      normal volunteers.
PG  - 838-41
AB  - A significant difference in individual response to aspirin therapy has been 
      described, and studies have shown that a minimal response to aspirin may be 
      associated with increased risk for some cardiovascular events. However, it 
      remains unclear if aspirin dose, coating, or termination alters the antiplatelet 
      effects of aspirin. Normal volunteers were randomly assigned to enteric-coated or 
      uncoated aspirin 81 or 325 mg and monitored over 12 days with a point-of-care 
      aspirin assay that incorporates the platelet agonist arachidonic acid. The 
      antiplatelet response was greater with a 325-mg dose than with an 81-mg dose. A 
      coating slowed the antiplatelet response to the 81-mg dose only. There were no 
      differences among the groups after maximum response was achieved between days 4 
      and 7. There was significant recovery of platelet aggregation <48 hours after the 
      cessation of aspirin, with a return to baseline values by the fifth day. A 
      significant interpatient variation in response to the 4 dosing regimes was 
      observed. In conclusion, the antiplatelet response was more rapid to a 325-mg/day 
      dose of aspirin compared with an 81-mg/day dose. An enteric-coated preparation 
      delayed the time of response to an 81-mg/day dose. These results suggest that 
      aspirin dose and preparation may be important mediators of the antiplatelet 
      effects of aspirin in some patients.
FAU - Coleman, Jacqueline L
AU  - Coleman JL
AD  - Atlantis Laboratory Systems, San Diego, California, USA. jcoleman@san.rr.com
FAU - Alberts, Mark J
AU  - Alberts MJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20060802
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Tablets, Enteric-Coated
EDAT- 2006/09/05 09:00
MHDA- 2006/10/26 09:00
CRDT- 2006/09/05 09:00
PHST- 2005/12/17 00:00 [received]
PHST- 2006/03/30 00:00 [revised]
PHST- 2006/03/30 00:00 [accepted]
PHST- 2006/09/05 09:00 [pubmed]
PHST- 2006/10/26 09:00 [medline]
PHST- 2006/09/05 09:00 [entrez]
AID - S0002-9149(06)01088-5 [pii]
AID - 10.1016/j.amjcard.2006.03.071 [doi]
PST - ppublish
SO  - Am J Cardiol. 2006 Sep 15;98(6):838-41. doi: 10.1016/j.amjcard.2006.03.071. Epub 
      2006 Aug 2.

PMID- 2739536
OWN - NLM
STAT- MEDLINE
DCOM- 19890802
LR  - 20131121
IS  - 0392-6516 (Print)
IS  - 0392-6516 (Linking)
VI  - 9
IP  - 1
DP  - 1989 Jan-Mar
TI  - [Reye's syndrome in an adult following therapy with salicylates in Still's 
      disease].
PG  - 64-5
AB  - Reye's syndrome or encephalopathy with fatty infiltration of the liver occurs 
      mainly in childhood and to a lesser degree in adult age. Salicylate may play a 
      role in the pathogenesis of this syndrome. Still's disease is a form of juvenile 
      rheumatoid arthritis very rare in the adult. A case is reported of a 39-year old 
      woman who developed Reye's syndrome while on aspirin therapy for the treatment of 
      a classical adult Still's disease.
FAU - Tumiati, B
AU  - Tumiati B
FAU - Azzalito, C
AU  - Azzalito C
FAU - Veneziani, M
AU  - Veneziani M
LA  - ita
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Sindrome di Reye dell'adulto secondaria a terapia con salicilati per morbo di 
      Still.
PL  - Italy
TA  - Medicina (Firenze)
JT  - Medicina (Florence, Italy)
JID - 8813280
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Reye Syndrome/*chemically induced
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Medicina (Firenze). 1989 Jan-Mar;9(1):64-5.

PMID- 32222319
OWN - NLM
STAT- MEDLINE
DCOM- 20210715
LR  - 20210715
IS  - 1535-6280 (Electronic)
IS  - 0146-2806 (Linking)
VI  - 46
IP  - 3
DP  - 2021 Mar
TI  - Aspirin for Primary Prevention of Coronary Artery Disease.
PG  - 100553
LID - S0146-2806(20)30030-X [pii]
LID - 10.1016/j.cpcardiol.2020.100553 [doi]
AB  - Primary prevention of coronary artery disease (CAD) is an important means to 
      reduce the burden of the disease. Aspirin has been widely prescribed over the 
      last several decades as part of primary CAD prevention strategy. However, 3 
      recent hallmark trials - ARRIVE, ASCEND and ASPREE have raised serious questions 
      about this common practice. Although, aspirin reduced incidence of non-fatal MI 
      and stroke in these recent studies, bleeding risk was higher. In the present era, 
      where regular exercise, healthy diet, smoking cessation, and statins are used to 
      manage the risk factors of CAD, additional prescription of aspirin seems more 
      harmful than beneficial. The guidelines of major societies such as European 
      Society of Cardiology (ESC), American College of Cardiology (ACC), and American 
      Heart Association (AHA) also reflect this shift. In this article, the authors aim 
      to highlight the current evidence on aspirin use for primary prevention of CAD, 
      in the context of evolving contrasting clinical trial data from the last 2 
      decades. We also highlight the pertinent sections of the most recent clinical 
      guidelines of European Society of Cardiology, American College of Cardiology, and 
      American Heart Association in this article.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Ujjawal, Aditi
AU  - Ujjawal A
FAU - Gupta, Manasvi
AU  - Gupta M
FAU - Ghosh, Raktim K
AU  - Ghosh RK
FAU - Jain, Vardhmaan
AU  - Jain V
FAU - Bandyopadhyay, Dhrubajyoti
AU  - Bandyopadhyay D
FAU - Qamar, Arman
AU  - Qamar A
FAU - Aronow, Wilbert S
AU  - Aronow WS
FAU - Deedwania, Prakash
AU  - Deedwania P
FAU - Kapadia, Samir
AU  - Kapadia S
FAU - Lavie, Carl J
AU  - Lavie CJ
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200214
PL  - Netherlands
TA  - Curr Probl Cardiol
JT  - Current problems in cardiology
JID - 7701802
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage/adverse effects
MH  - *Coronary Artery Disease/prevention & control
MH  - Humans
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
EDAT- 2020/03/31 06:00
MHDA- 2021/07/16 06:00
CRDT- 2020/03/31 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/02/05 00:00 [accepted]
PHST- 2020/03/31 06:00 [pubmed]
PHST- 2021/07/16 06:00 [medline]
PHST- 2020/03/31 06:00 [entrez]
AID - S0146-2806(20)30030-X [pii]
AID - 10.1016/j.cpcardiol.2020.100553 [doi]
PST - ppublish
SO  - Curr Probl Cardiol. 2021 Mar;46(3):100553. doi: 10.1016/j.cpcardiol.2020.100553. 
      Epub 2020 Feb 14.

PMID- 15449806
OWN - NLM
STAT- MEDLINE
DCOM- 20041021
LR  - 20131121
IS  - 0385-0005 (Print)
IS  - 0385-0005 (Linking)
VI  - 29
IP  - 1
DP  - 2004 Apr
TI  - Platelet inhibition by single low-dose aspirin, using the newly developed 
      aggregometry with the laser light scattering method.
PG  - 7-12
AB  - Low-dose aspirin (acetylsalicylic acid 81 mg/day, LDA) is often used as an 
      antiplatelet drug in the treatment of cardiovascular and cerebrovascular diseases 
      as well as for patients with anti-phospholipid antibody syndrome. In this study, 
      we explored the duration of the inhibitory effect of a single LDA on platelet 
      aggregation, using the newly developed aggregometry with the laser light 
      scattering method. Five healthy volunteers (females between 23 and 30 years old) 
      ingested 81 mg of buffered aspirin. Platelet aggregation was measured with 
      adenosine 5'-diphosphate before the ingestion and at the 1st, 2nd, 4th, 6th, and 
      8th day thereafter. The results showed that the effect of 81 mg of aspirin 
      continues for at least 8 days, which suggested that the intermittent 
      administration of 81 mg of aspirin (a few times a week) might be an alternative 
      way to induce the anti-platelet effect.
FAU - Haque, Shanta Fahmida
AU  - Haque SF
AD  - Department of Obstetrics and Gynecology, Specialized Clinical Science, Tokai 
      University School of Medicine, Kanagawa, Japan.
FAU - Izumi, Shun-Ichiro
AU  - Izumi S
FAU - Hotta, Akiko
AU  - Hotta A
FAU - Matsubayashi, Hidehiko
AU  - Matsubayashi H
FAU - Awaji, Hideo
AU  - Awaji H
FAU - Murano, Takayo
AU  - Murano T
FAU - Yoshitake, Tomoko
AU  - Yoshitake T
FAU - Yoshikata, Kikuo
AU  - Yoshikata K
FAU - Sugi, Toshitaka
AU  - Sugi T
FAU - Nakazawa, Hiroyuki
AU  - Nakazawa H
FAU - Ly, Cai
AU  - Ly C
FAU - Makino, Tsunehisa
AU  - Makino T
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Tokai J Exp Clin Med
JT  - The Tokai journal of experimental and clinical medicine
JID - 7704186
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Female
MH  - Humans
MH  - Needles
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - *Platelet Function Tests
MH  - Time Factors
EDAT- 2004/09/29 05:00
MHDA- 2004/10/22 09:00
CRDT- 2004/09/29 05:00
PHST- 2004/09/29 05:00 [pubmed]
PHST- 2004/10/22 09:00 [medline]
PHST- 2004/09/29 05:00 [entrez]
PST - ppublish
SO  - Tokai J Exp Clin Med. 2004 Apr;29(1):7-12.

PMID- 6519122
OWN - NLM
STAT- MEDLINE
DCOM- 19850227
LR  - 20181113
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 9
IP  - 3
DP  - 1984 Jul-Sep
TI  - The metabolism of aspirin in rats; localization, absorption, distribution and 
      excretion.
PG  - 205-14
AB  - By the use of acetylsalicylic acid (aspirin) 14C-labelled in either the acetyl or 
      the carboxyl group, the metabolic pathway and the degree of degradation of the 
      substance were studied. The change in aspirin concentration and the rate of 
      degradation occurring in major tissues and organs after oral administration was 
      measured by radioactivity techniques. The degree of degradation for the period 
      10-30 minutes was found to be about 38% in the stomach wall, 64% in the liver and 
      86% in the lung, and less than 10% in the circulating portion of aspirin itself 
      in blood, under conditions of equilibrium concentration of substrate. A technique 
      measuring 14CO2 in expired air and using 14C-acetyl aspirin allowed for 
      determination of the kinetics of the transformation of this compound into 
      salicylic acid. The effective period for aspirin for unstrained and 
      unanesthetized rats given orally was determined to be 90 min. The metabolic fates 
      of the two kinds of 14C-labelled aspirin given orally were found to be very 
      different and characteristic by counting and autoradiographic techniques. The 
      distribution of [carboxyl-14C] aspirin was rather uniform, but [acetyl-14C] 
      aspirin preferentially accumulated in the bone cortex portion.
FAU - Hatori, A
AU  - Hatori A
FAU - Shigematsu, A
AU  - Shigematsu A
FAU - Tsuya, A
AU  - Tsuya A
LA  - eng
PT  - Journal Article
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (Carbon Radioisotopes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/blood/*metabolism
MH  - Autoradiography
MH  - Breath Tests
MH  - Carbon Radioisotopes
MH  - Intestinal Absorption
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Tissue Distribution
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
AID - 10.1007/BF03189643 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 1984 Jul-Sep;9(3):205-14. doi: 
      10.1007/BF03189643.

PMID- 33132371
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210505
IS  - 1347-5223 (Electronic)
IS  - 0009-2363 (Linking)
VI  - 68
IP  - 11
DP  - 2020
TI  - Impact of Magnesium Stearate Content: Modeling of Drug Degradation Using a 
      Modified Arrhenius Equation.
PG  - 1049-1054
LID - 10.1248/cpb.c20-00443 [doi]
AB  - To accelerate drug development, the pharmaceutical industry is working to shorten 
      and improve studies on stability. The Accelerated Stability Assessment Program 
      (ASAP) incorporating the humidity-corrected Arrhenius equation as an accelerated 
      methodology has been proposed for both drug substances and drug products. In this 
      study, the effect of magnesium stearate (MgSt) content on the chemical stability 
      of acetylsalicylic acid was evaluated as a model system of drug-excipient 
      compatibility studies using ASAP. In the acetylsalicylic acid powder blends, 
      temperature and humidity showed a first-order linear response to the natural 
      logarithm of the reaction rate constant, and MgSt content also showed a 
      first-order linear response. A polynomial model was built in which temperature, 
      humidity, and MgSt content were independent each other. The fitting index of the 
      model, the coefficient of determination, was 0.9567, which was a good fit. In the 
      long-term stability study (25 °C/60% relative humidity, 6 months), there was good 
      agreement in total between measured values and model-predicted values. Using this 
      model, we inferred that the degradation rates were depended on MgSt content at 
      the fixed temperature and humidity because the micro-environmental pH of the 
      excipient was catalytically affected. Applying this model equation can 
      significantly reduce the duration of formulation design and stability studies and 
      save time and costs in drug development.
FAU - Tamura, Kousuke
AU  - Tamura K
AD  - Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd.
FAU - Ono, Makoto
AU  - Ono M
AD  - Quality Assurance Department, Daiichi Sankyo Co., Ltd.
FAU - Kawabe, Takefumi
AU  - Kawabe T
AD  - Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd.
FAU - Yonemochi, Etsuo
AU  - Yonemochi E
AD  - Graduate School of Pharmaceutical Sciences, Hoshi University.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Powders)
RN  - 0 (Stearic Acids)
RN  - 4ELV7Z65AP (stearic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis/metabolism
MH  - Drug Stability
MH  - Humidity
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - *Models, Theoretical
MH  - Pharmaceutical Preparations/analysis/*metabolism
MH  - Powders/chemistry
MH  - Stearic Acids/*chemistry
MH  - Temperature
OTO - NOTNLM
OT  - chemical stability
OT  - drug–excipient interaction
OT  - kinetics
OT  - mathematical model
OT  - solid-state
EDAT- 2020/11/03 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/11/02 06:11
PHST- 2020/11/02 06:11 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
AID - 10.1248/cpb.c20-00443 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 2020;68(11):1049-1054. doi: 10.1248/cpb.c20-00443.

PMID- 22452804
OWN - NLM
STAT- MEDLINE
DCOM- 20121030
LR  - 20131121
IS  - 1473-0790 (Electronic)
IS  - 1368-5538 (Linking)
VI  - 15
IP  - 3
DP  - 2012 Sep
TI  - The prevalence, risk factors and prognosis of aspirin resistance in elderly male 
      patients with cardiovascular disease.
PG  - 140-7
LID - 10.3109/13685538.2012.666584 [doi]
AB  - AIM: Aspirin resistance is recognized in different population. However, the 
      prevalence and clinical events of aspirin resistance in elderly male patients 
      with cardiovascular disease (CVD) have not been reported. METHODS: We enrolled 
      304 elderly male patients with CVD receiving daily aspirin therapy (≥ 75 mg) more 
      than 1 month. Platelet aggregation was measured by light transmission 
      aggregometry (LTA) and thrombelastography platelet mapping assay (TEG). The 
      median follow-up time was 1.8 years. The primary outcome was the composite of 
      death, myocardial infarction, unstable angina, stroke and transient ischemic 
      attack. RESULTS: By LTA, 25 (8.2%) of elderly patients were aspirin resistant and 
      106 (34.9%) patients were semiresponders. According to TEG, 62 patients (20.4%) 
      were found to be resistant to aspirin therapy. Of the 62 patients with aspirin 
      resistance by TEG, 21 patients were aspirin resistant by LTA. Twenty-two of the 
      106 semiresponders by LTA were aspirin resistant by TEG. Patients with aspirin 
      resistance or aspirin semiresponders were at increased risk of the composite 
      outcome compared with aspirin-sensitive patients by LTA (18.3% vs 9.8%, Hazard 
      ratio (HR) = 1.864, 95% confidence interval (CI): 1.046-3.324 p = 0.039). 
      However, aspirin resistance was not associated with an increased risk of clinical 
      vascular events compared to aspirin-sensitive patients by TEG (17.7% vs 10.9%, p 
      = 0.452). In addition, Cox proportional hazard regression modeling demonstrated 
      that aspirin resistance or semiresponders (HR = 3.050, 95% CI: 1.464-6.354, p = 
      0.003) and diabetes (HR = 2.055, 95% CI: 1.060-3.981, p = 0.033) were associated 
      with major adverse long-term outcomes. CONCLUSIONS: Aspirin resistance or 
      semiresponders, defined by LTA, are associated with an increased risk of adverse 
      clinical events in elderly male patients with CVD.
FAU - Cao, Jian
AU  - Cao J
AD  - First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, 
      China.
FAU - Liu, Lin
AU  - Liu L
FAU - Fan, Li
AU  - Fan L
FAU - Chen, Tianmeng
AU  - Chen T
FAU - Hu, Guoliang
AU  - Hu G
FAU - Hu, Yixin
AU  - Hu Y
FAU - Zhu, Bingpo
AU  - Zhu B
FAU - Li, Jian
AU  - Li J
FAU - Wang, Hao
AU  - Wang H
FAU - Li, Xiaoli
AU  - Li X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120327
PL  - England
TA  - Aging Male
JT  - The aging male : the official journal of the International Society for the Study 
      of the Aging Male
JID - 9808210
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Diabetes Mellitus
MH  - Drug Resistance
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Prevalence
MH  - Prognosis
MH  - Risk Factors
EDAT- 2012/03/29 06:00
MHDA- 2012/10/31 06:00
CRDT- 2012/03/29 06:00
PHST- 2012/03/29 06:00 [entrez]
PHST- 2012/03/29 06:00 [pubmed]
PHST- 2012/10/31 06:00 [medline]
AID - 10.3109/13685538.2012.666584 [doi]
PST - ppublish
SO  - Aging Male. 2012 Sep;15(3):140-7. doi: 10.3109/13685538.2012.666584. Epub 2012 
      Mar 27.

PMID- 14747600
OWN - NLM
STAT- MEDLINE
DCOM- 20040602
LR  - 20191108
IS  - 0957-4832 (Print)
IS  - 0957-4832 (Linking)
VI  - 25
IP  - 4
DP  - 2003 Dec
TI  - Prophylactic aspirin use in the adult general population.
PG  - 377-80
AB  - BACKGROUND: The aim of the study was to establish the prevalence and patterns of 
      aspirin use in people with vascular problems. METHODS: A cross-sectional 
      population survey was carried out on a stratified random sample of 10,000 adults 
      aged 35 and over in North Staffordshire. RESULTS: A total of 6322 adults replied 
      to the questionnaire (adjusted response 67 percent). The prevalence of vascular 
      problems was 12.9 percent, and 67.6 per cent of respondents were using aspirin. 
      The main association with aspirin use was previous advice about aspirin: adults 
      who recalled being given advice were more likely to be using aspirin. Increasing 
      age, disease severity and level of deprivation were also associated with 
      increased aspirin use. Of adults without vascular problems, 7.1 percent also 
      reported using aspirin regularly. CONCLUSIONS: There is still potential to 
      increase aspirin use in those with vascular problems. The extent and quality of 
      health care professionals' advice may be an important area to target. The reasons 
      why some people without vascular problems take regular aspirin is an area for 
      further investigation.
FAU - Trinder, P
AU  - Trinder P
AD  - Department of Public Health, North Staffordshire Health, Heron House, Great 
      Fenton Business Park, Grove Road, Stoke-on-Trent ST4 4LX, UK. 
      Paul.Trinder@nsha.wmids.nhs.uk
FAU - Rajaratnam, G
AU  - Rajaratnam G
FAU - Lewis, M
AU  - Lewis M
FAU - Croft, P
AU  - Croft P
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Public Health Med
JT  - Journal of public health medicine
JID - 9011205
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cross-Sectional Studies
MH  - Drug Utilization
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Vascular Diseases/*prevention & control
EDAT- 2004/01/30 05:00
MHDA- 2004/06/03 05:00
CRDT- 2004/01/30 05:00
PHST- 2004/01/30 05:00 [pubmed]
PHST- 2004/06/03 05:00 [medline]
PHST- 2004/01/30 05:00 [entrez]
AID - 10.1093/pubmed/fdg079 [doi]
PST - ppublish
SO  - J Public Health Med. 2003 Dec;25(4):377-80. doi: 10.1093/pubmed/fdg079.

PMID- 20166339
OWN - NLM
STAT- MEDLINE
DCOM- 20100305
LR  - 20131121
IS  - 1565-1088 (Print)
VI  - 11
IP  - 12
DP  - 2009 Dec
TI  - Aspirin promotes low density lipoprotein susceptibility to oxidative modification 
      in healthy volunteers.
PG  - 730-4
AB  - BACKGROUND: Low density lipoprotein oxidation is a major pathogenic pathway in 
      atherosclerosis. Previous studies suggested that aspirin, a commonly prescribed 
      drug in patients with atherosclerosis, when given in a dose of 300 mg/day may 
      decrease LDL susceptibility to oxidative modification. However, the effect of the 
      more common lower dose aspirin on LDL oxidation is not known. OBJECTIVES: To 
      examine the effect of aspirin administration (low dosage) on the susceptibility 
      of LDL to oxidative modification in healthy volunteers. METHODS: Aspirin 75 mg 
      was administered daily for 2 weeks to 10 healthy volunteers selected from the 
      medical staff and students at the faculty of medicine. The main outcome measure 
      was ex vivo oxidation of LDL by ultraviolet C irradiation or by peroxyl free 
      radicals generated by AAPH (2,2'-azobis 2-amidinopropane hydrochloride). The 
      extent of LDL oxidation was determined by measuring the formed amounts of 
      thiobarbituric acid-reactive substances, lipid peroxides and conjugated dienes. 
      RESULTS: Following exposure to UVc irradiation there was a significant (P 0.01) 
      increase (10.8%) in TBARS concentrations and a significant (P < 0.05) increase 
      (5.4%) in PD concentrations in LDL withdrawn after aspirin treatment as compared 
      to LDL withdrawn before aspirin treatment. Following incubation with AAPH there 
      was a significant (P < 0.05) increase (15%) in PD concentrations and a 
      significant (P < 0.05) reduction (10%) of the LDL oxidation lag time in LDL 
      withdrawn after aspirin intake as compared to LDL withdrawn before aspirin 
      treatment. CONCLUSIONS: Aspirin treatment given to healthy volunteers at a dose 
      of 75 mg/day increased the susceptibility of their plasma LDL to oxidative 
      modification ex vivo. Our study provides, for the first time, in vivo evidence of 
      pro-oxidative properties of aspirin already suggested by previous in vitro 
      trials.
FAU - Waterman, Matti
AU  - Waterman M
AD  - Department of Internal Medicine A, Rappaport Faculty of Medicine, Technion-Israel 
      Institute of Technology, Haifa, Israel. m_waterman@rambam.health.gov.il
FAU - Fuhrman, Bianca
AU  - Fuhrman B
FAU - Keidar, Shlomo
AU  - Keidar S
FAU - Hayek, Tony
AU  - Hayek T
LA  - eng
PT  - Journal Article
PL  - Israel
TA  - Isr Med Assoc J
JT  - The Israel Medical Association journal : IMAJ
JID - 100930740
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipoproteins, LDL)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Humans
MH  - Lipoproteins, LDL/*metabolism/radiation effects
MH  - Male
MH  - Oxidation-Reduction
MH  - Ultraviolet Rays
EDAT- 2010/02/20 06:00
MHDA- 2010/03/06 06:00
CRDT- 2010/02/20 06:00
PHST- 2010/02/20 06:00 [entrez]
PHST- 2010/02/20 06:00 [pubmed]
PHST- 2010/03/06 06:00 [medline]
PST - ppublish
SO  - Isr Med Assoc J. 2009 Dec;11(12):730-4.

PMID- 16808476
OWN - NLM
STAT- MEDLINE
DCOM- 20070426
LR  - 20181201
IS  - 0003-2700 (Print)
IS  - 0003-2700 (Linking)
VI  - 78
IP  - 13
DP  - 2006 Jul 1
TI  - Chemical characterization of diaspirin cross-linked hemoglobin polymerized with 
      poly(ethylene glycol).
PG  - 4634-41
AB  - A lack of specificity associated with chemical modification methods used in the 
      preparation of certain hemoglobin (Hb)-based oxygen carriers (HBOCs) may alter Hb 
      structure and function, as amino acids located in critical regions (e.g., 
      alpha-beta interfaces and the 2,3-DPG binding pocket) may unintentionally be 
      targeted. Hb protein surface modifications with various poly(ethylene glycol) 
      (PEG) derivatives have been used as conjugating and polymerizing agents with the 
      intent of improving reaction site specificity/reproducibility and ultimately 
      reducing the untoward hypertensive response due to nitric oxide scavenging by 
      smaller molecular size tetrameric species (i.e., 64 kDa) in HBOC solutions. 
      Previous experiments performed in our laboratory have evaluated the influence of 
      polymerization of diaspirin alpha-alpha cross-linked Hb (alphaalpha-DBBF-Hb) with 
      a bifunctional modified PEG, bis(maleoylglycylamide) PEG (BMAA-PEG), in terms of 
      oxygen carrying capacity, redox properties, hypertensive response, and renal 
      clearance in rats. The data presented in this paper specifically evaluate the 
      influence of BMAA-PEG on alphaalpha-DBBF-Hb (Poly-alphaalpha-DBBF-Hb) to identify 
      molecular weight distribution, protein conformation, and site-specific 
      modification, as well as to provide insight into the previously determined in 
      vitro and in vivo functional and vasoactive characteristics of this HBOC. 
      Chemical analysis performed herein reveals nonspecific modifications induced by 
      BMAA-PEG that result in the full modification of alphaalpha-DBBF-Hb leaving no 
      tetrameric cross-linked starting material in solution. These data are 
      inconsistent with the continuing assumption that molecular size (i.e., 64 kDa) 
      has a direct influence on HBOC-mediated vasoactivity and that other protective 
      strategies should be considered to control blood pressure imbalances.
FAU - Buehler, Paul W
AU  - Buehler PW
AD  - Laboratory of Biochemistry and Vascular Biology, Division of Hematology, Center 
      for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 
      Bethesda, Maryland 20892, USA.
FAU - Boykins, Robert A
AU  - Boykins RA
FAU - Norris, Scott
AU  - Norris S
FAU - Alayash, Abdu I
AU  - Alayash AI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
RN  - 0 (Polymers)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 578-19-8 (succinyldisalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemistry
MH  - Chromatography, Gel
MH  - Circular Dichroism
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Polyethylene Glycols/*chemistry
MH  - Polymers/*chemistry
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
EDAT- 2006/07/01 09:00
MHDA- 2007/04/27 09:00
CRDT- 2006/07/01 09:00
PHST- 2006/07/01 09:00 [pubmed]
PHST- 2007/04/27 09:00 [medline]
PHST- 2006/07/01 09:00 [entrez]
AID - 10.1021/ac060188q [doi]
PST - ppublish
SO  - Anal Chem. 2006 Jul 1;78(13):4634-41. doi: 10.1021/ac060188q.

PMID- 3942122
OWN - NLM
STAT- MEDLINE
DCOM- 19860218
LR  - 20131121
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 81
IP  - 1
DP  - 1986 Jan
TI  - A comparison of enteric-coated aspirin granules with plain and buffered aspirin: 
      a report of two studies.
PG  - 26-8
AB  - Reported herein are two endoscopic studies performed to compare the 
      gastrointestinal mucosal effects of encapsulated enteric-coated aspirin granules 
      with several other well-known aspirin products. The first study compared the 
      effects of Ascriptin A/D, Bayer, Bufferin, and 325 mg enteric-coated aspirin 
      granules (325 mg Ecotrin capsules); the second study compared Anacin Arthritis 
      Pain Formula, Arthritis Strength Bufferin, Ascriptin A/D, Bayer, and 500 mg 
      enteric-coated aspirin granules (500 mg Ecotrin capsule). In both of these 
      studies the Ecotrin capsule induced less stomach damage than did any of the other 
      aspirin products tested. The Ecotrin capsule was also shown to cause less damage 
      to the proximal duodenum than did Bayer.
FAU - Petroski, D
AU  - Petroski D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Buffers)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Buffers
MH  - Duodenum/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Stomach/drug effects
MH  - Tablets, Enteric-Coated
MH  - Time Factors
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Am J Gastroenterol. 1986 Jan;81(1):26-8.

PMID- 26148076
OWN - NLM
STAT- MEDLINE
DCOM- 20151106
LR  - 20181203
IS  - 1016-5169 (Print)
IS  - 1016-5169 (Linking)
VI  - 43
IP  - 5
DP  - 2015 Jul
TI  - Assessment of efficacy of single dose acetylsalicylic acid over a 24-hour period.
PG  - 443-9
LID - 10.5543/tkda.2015.78380 [doi]
AB  - OBJECTIVE: Acetylsalicylic acid (ASA) has a half-life of less than 30 minutes in 
      the human body. This study aimed to test whether the effects of a single dose of 
      ASA wane over a 24-hour period due to the daily release of new reactive blood 
      platelets into the bloodstream. METHODS: The study included 30 patients (10 
      female and 20 male, mean age: 62.8±9.0). Each took a single dose of 300 mg 
      enteric coated ASA orally. Platelet aggregation was determined using VerifyNow® 
      Aspirin kits immediately prior to intake, and at 12 and 24 hours following 
      intake. Laboratory parameters such as serum CRP and CBC were also examined before 
      ASA intake. Patients were included irrespective of routine ASA and/or clopidogrel 
      use. RESULTS: Aspirin reaction unit (ARU) values were lower than 550 at 24 hours 
      after drug intake in 26 (86.7%) patients. Values lower than 550 indicate 
      therapeutic range of ASA on platelet function. Two (6.7%) patients were found to 
      be responsive to ASA at 12 hours after intake, but unresponsive at 24 hours. 
      Aspirin resistance was found in another 2 (6.7%) patients. CONCLUSION: Although 
      ASA was found to be effective on platelet inhibition over a 24-hour period in 
      most of the patients, there was a considerable number who were resistant to ASA, 
      and who had developed unresponsiveness to ASA by the end of 24 hours. There is 
      evidence in the literature regarding the clinical importance of ASA resistance, 
      but the importance of loss ASA's effectiveness during a day warrants further 
      studies.
FAU - Baha, Reşat Mehmet
AU  - Baha RM
AD  - Department of Cardiology, Ministry of Health of Turkey Diskapi Training and 
      Research Hospital, Ankara, Turkey. drreshat@gmail.com.
FAU - Özdöl, Çağdaş
AU  - Özdöl Ç
AD  - Department of Cardiology, Ankara University Faculty of Medicine, Ankara, Turkey.
FAU - Güleç, Sadi
AU  - Güleç S
AD  - Department of Cardiology, Ankara University Faculty of Medicine, Ankara, Turkey.
FAU - Erol, Çetin
AU  - Erol Ç
AD  - Department of Cardiology, Ankara University Faculty of Medicine, Ankara, Turkey.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Turkey
TA  - Turk Kardiyol Dern Ars
JT  - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
JID - 9426239
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacokinetics/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & 
      dosage/pharmacokinetics/*pharmacology/therapeutic use
MH  - Ticlopidine/analogs & derivatives/pharmacokinetics
EDAT- 2015/07/07 06:00
MHDA- 2015/11/07 06:00
CRDT- 2015/07/07 06:00
PHST- 2015/07/07 06:00 [entrez]
PHST- 2015/07/07 06:00 [pubmed]
PHST- 2015/11/07 06:00 [medline]
AID - 10.5543/tkda.2015.78380 [doi]
PST - ppublish
SO  - Turk Kardiyol Dern Ars. 2015 Jul;43(5):443-9. doi: 10.5543/tkda.2015.78380.

PMID- 6839001
OWN - NLM
STAT- MEDLINE
DCOM- 19830617
LR  - 20191023
IS  - 0142-2782 (Print)
IS  - 0142-2782 (Linking)
VI  - 4
IP  - 1
DP  - 1983 Jan-Mar
TI  - Human platelet response to three salicylate dosage forms.
PG  - 43-51
AB  - Acetylsalicylic acid (ASA) inhibition of platelet aggregation as evaluated by 
      collagen-induced 14C-serotonin release, has been measured in 12 healthy male 
      subjects. Each subject received a single oral dose (650 mg) of enteric-coated ASA 
      (ecASA) and compressed ASA tablets (cASA), or ecASA and sodium salicylate (578 
      mg) separated by a minimum of 5 weeks. The platelet response was related to 
      plasma ASA and salicyclic acid determined by high-pressure liquid chromatography. 
      Both ecASA and cASA inhibited 14C-serotonin release; no significant difference 
      was observed in the maximum effect between these two products (p less than 0.05). 
      No relationship was found between the maximum observed plasma ASA level and the 
      maximum effect. Further, no correlation was found between the maximum inhibition 
      of 14C-serotonin release in vivo and the release predicted from in vitro 
      experiments wherein the effect was measured after incubating plasma containing 
      specified ASA concentrations.
FAU - Thiessen, J J
AU  - Thiessen JJ
FAU - Grad, H
AU  - Grad H
FAU - Macleod, S M
AU  - Macleod SM
FAU - Spino, M
AU  - Spino M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Biopharm Drug Dispos
JT  - Biopharmaceutics & drug disposition
JID - 7911226
RN  - 0 (Tablets, Enteric-Coated)
RN  - 333DO1RDJY (Serotonin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/blood/pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Aggregation/drug effects
MH  - Serotonin/metabolism
MH  - Tablets, Enteric-Coated
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1002/bdd.2510040107 [doi]
PST - ppublish
SO  - Biopharm Drug Dispos. 1983 Jan-Mar;4(1):43-51. doi: 10.1002/bdd.2510040107.

PMID- 299888
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 66
IP  - 1
DP  - 1977 Jan
TI  - Physical form as a determinant of effect of buffered acetylsalicylate 
      formulations on gi microbleeding.
PG  - 124-7
AB  - During a 48-day period, 12 male dogs received four buffered sodium 
      acetylsalicylate formulations, quantitatively virtually identical (a homogenenous 
      disintegrating swallow tablet, a swallow tablet in which the sodium 
      acetylsalicylate was contained in a dissolving core, an encapsulated powder, and 
      an aqueous suspension), at 650-mg aspirin equivalent doses twice daily during 
      four 7-day treatment periods (each preceded by a 5-day period of no treatment) in 
      a complete changeover fashion. Mean daily fecal blood losses of 0.75, 1.37, 1.43, 
      and 2.89 ml were observed in the 12 dogs during treatment with the aqueous 
      suspension, the homogeneous tablet, the encapsulated powder, and the core tablet, 
      respectively. These findings indicate that the physical form of buffered 
      acetylsalicylate formulations is a critical factor in the effect of such 
      formulations on GI microbleeding.
FAU - Phillips, B M
AU  - Phillips BM
FAU - Palermo, B T
AU  - Palermo BT
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Buffers)
RN  - 0 (Powders)
RN  - 0 (Suspensions)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Buffers
MH  - Dogs
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Male
MH  - Powders
MH  - Suspensions
MH  - Tablets
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - S0022-3549(15)39139-5 [pii]
AID - 10.1002/jps.2600660136 [doi]
PST - ppublish
SO  - J Pharm Sci. 1977 Jan;66(1):124-7. doi: 10.1002/jps.2600660136.

PMID- 29611656
OWN - NLM
STAT- MEDLINE
DCOM- 20190802
LR  - 20190802
IS  - 1505-1773 (Print)
IS  - 1505-1773 (Linking)
VI  - 20
IP  - 4
DP  - 2017 Dec
TI  - The effect of acetylosalicylic acid and berberis on ascites syndrome parameters 
      in broiler chickens.
PG  - 835-837
LID - 10.1515/pjvs-2017-0107 [doi]
AB  - One-hundred and thirty day-old broiler chickens were kept for 6 days and on the 
      seventh day, 120 chickens were selected and randomly divided into 5 groups with 2 
      replicates. To cause ascites, an amount of 0.12% sodium was added to the drinking 
      water of 4 groups of chickens. On the fourteenth day, the amount of sodium was 
      increased to 0.24% and at the same time, treatment with acetylosalicylic acid and 
      berberis was started. At the age of 14 and 21 days, random sample chickens from 
      each replicate were necropsied and were examined in terms of the factors 
      associated with ascites. The results showed that the ratio of the weight of the 
      right ventricle (RV) to the weight of the total ventricles (TV) and all other 
      factors on 14th day revealed no significant difference between the groups 
      (p>0.05). On 21st day, the RV/TV ratio in the ascites control group was 
      significantly higher than that in the control group (p<0.05). The RV/TV ratio in 
      the groups receiving acetylosalicylic acid and berberis were lower than those in 
      the ascites control group; however, this reduction was not significant (p>0.05). 
      The rate of mortality in the groups receiving acetylosalicylic acid and berberis 
      was lower than that in ascites control group. Considering the results obtained, 
      it can be suggested that the treatment with acetylosalicylic acid and berberis is 
      effective to prevent ascites.
CI  - Copyright© by the Polish Academy of Sciences.
FAU - Hormozi, M
AU  - Hormozi M
AD  - Graduated student of School of Veterinary Medicine, University of Zabol, Zabol, 
      P.O.Box 98615-538, Zabol 9861335856, Iran.
FAU - Jahantigh, M
AU  - Jahantigh M
AD  - Department of Poultry Diseases, School of Veterinary Medicine, University of 
      Zabol, Zabol, P.O.Box 98615-538, Zabol 9861335856, Iran.
FAU - Jahantigh, M
AU  - Jahantigh M
AD  - Department of Clinical Sciences, School of Veterinary Medicine, University of 
      Zabol, Zabol, P.O.Box 98615-538, Zabol 9861335856, Iran.
LA  - eng
PT  - Clinical Trial, Veterinary
PT  - Journal Article
PL  - Germany
TA  - Pol J Vet Sci
JT  - Polish journal of veterinary sciences
JID - 101125473
RN  - R16CO5Y76E (Aspirin)
MH  - Animals
MH  - Ascites/prevention & control/*veterinary
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Berberis
MH  - *Chickens
MH  - Male
MH  - Poultry Diseases/*prevention & control
OTO - NOTNLM
OT  - acetylosalicylic acid
OT  - ascites
OT  - berberis
OT  - broilers
OT  - sodium chloride
EDAT- 2018/04/04 06:00
MHDA- 2019/08/03 06:00
CRDT- 2018/04/04 06:00
PHST- 2018/04/04 06:00 [entrez]
PHST- 2018/04/04 06:00 [pubmed]
PHST- 2019/08/03 06:00 [medline]
AID - 10.1515/pjvs-2017-0107 [doi]
PST - ppublish
SO  - Pol J Vet Sci. 2017 Dec;20(4):835-837. doi: 10.1515/pjvs-2017-0107.

PMID- 7748895
OWN - NLM
STAT- MEDLINE
DCOM- 19950619
LR  - 20190610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1248
IP  - 2
DP  - 1995 Apr 27
TI  - Effects of polymerization on the oxygen carrying and redox properties of 
      diaspirin cross-linked hemoglobin.
PG  - 135-42
AB  - Human hemoglobin site specifically cross-linked with 
      bis(3,5-dibromosalicyl)fumarate results in a low oxygen affinity hemoglobin-based 
      red cell substitute (alpha-DBBF). Polymerization of alpha-DBBF by 
      bis(maleoylglycylamide) polyethylene glycol (BMAA-PEG) yields poly alpha-DBBF 
      which offers the added benefits of reduced renal clearance and increased 
      retention in the vascular circulation. Oxygen equilibrium curves for poly 
      alpha-DBBF are slightly left-shifted (higher O2 affinity) compared to those of 
      alpha-DBBF; with a diminished cooperativity and a reduced Bohr effect. In rapid 
      mixing experiments (oxygen dissociation and carbon monoxide binding), poly 
      alpha-DBBF exhibits a several fold increase in the overall rate of deoxygenation 
      and carbon monoxide binding kinetics over its cross-linked counterpart. The rate 
      of nitric oxide binding to the oxidized form of poly alpha-DBBF shows little or 
      no change compared to the intramolecularly cross-linked derivative. The reduction 
      of cyanomet poly alpha-DBBF by dithionite is several fold faster than that of 
      HbA0 and alpha-DBBF whereas the slow subsequent cyanide dissociation from the 
      ferrous iron remained unchanged among all proteins. The propensity of poly 
      alpha-DBBF for auto-oxidation is slightly enhanced over alpha-DBBF whereas the 
      extent of oxidative modification by hydrogen peroxide is very similar. 
      Polymerization appears to selectively modify ligand interactions and redox 
      kinetics of the tetrameric cross-linked form which reflects a possibly more open 
      heme pocket. The data suggests that changes in oxygenation properties of 
      hemoglobin brought about by a given modification are not necessarily predictive 
      of other functional changes.
FAU - Rogers, M S
AU  - Rogers MS
AD  - Center for Biologics Evaluation and Research, Food and Drug Administration, 
      Bethesda, MD 20892, USA.
FAU - Ryan, B B
AU  - Ryan BB
FAU - Cashon, R E
AU  - Cashon RE
FAU - Alayash, A I
AU  - Alayash AI
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Polymers)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 7U1EE4V452 (Carbon Monoxide)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemistry
MH  - Carbon Monoxide/chemistry
MH  - Cross-Linking Reagents/chemistry
MH  - Hemoglobins/*chemistry
MH  - Oxidation-Reduction
MH  - Oxygen/*chemistry
MH  - Polymers
EDAT- 1995/04/27 00:00
MHDA- 1995/04/27 00:01
CRDT- 1995/04/27 00:00
PHST- 1995/04/27 00:00 [pubmed]
PHST- 1995/04/27 00:01 [medline]
PHST- 1995/04/27 00:00 [entrez]
AID - 0167-4838(95)00017-O [pii]
AID - 10.1016/0167-4838(95)00017-o [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 1995 Apr 27;1248(2):135-42. doi: 
      10.1016/0167-4838(95)00017-o.

PMID- 724343
OWN - NLM
STAT- MEDLINE
DCOM- 19790226
LR  - 20161123
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 62
IP  - 5 Pt 2 Suppl
DP  - 1978 Nov
TI  - Chronic salicylate administration in juvenile rheumatoid arthritis: aspirin 
      "hepatitis" and its clinical significance.
PG  - 916-25
AB  - Salicylates provide the backbone of therapy in juvenile rheumatoid arthritis. 
      They are effective in controlling the disease approximately 75% of the time if 
      they are properly used. Salicylate administration is relatively safe if carefully 
      done. Serum salicylate levels should not exceed 30 mg/dl routinely. Patients, 
      physicians, and parents should be alert to early clinical signs of toxicity. 
      Chief hazards of chronic salicylate administration other than salicylism (which 
      should be uniformly preventable) include gastric irritation with questionable 
      relationship to peptic ulcer disease, and rare serious hepatotoxicity, bleeding 
      diatheses, or hypersensitivity reactions.
FAU - Schaller, J G
AU  - Schaller JG
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Chemical and Drug Induced Liver Injury/*etiology
MH  - Child
MH  - Child, Preschool
MH  - Digestive System/drug effects
MH  - Female
MH  - Humans
MH  - Liver/*drug effects
MH  - Male
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1978 Nov;62(5 Pt 2 Suppl):916-25.

PMID- 10563770
OWN - NLM
STAT- MEDLINE
DCOM- 20000106
LR  - 20191024
IS  - 1043-1802 (Print)
IS  - 1043-1802 (Linking)
VI  - 10
IP  - 6
DP  - 1999 Nov-Dec
TI  - Polymerization of diaspirin cross-linked hemoglobin (DCLHb) with water-soluble, 
      nonimmunogenic polyamide cross-linking agents.
PG  - 1013-20
AB  - Diaspirin cross-linked hemoglobin (DCLHb), a human hemoglobin that is 
      intramolecularly cross-linked between the alpha chains (lysine 
      99(alpha)(1)-lysine 99(alpha)(2)), was polymerized with a number of 
      water-soluble, nonimmunogenic polyamide cross-linking agents. The degree of 
      polymerization and the oxygen-carrying capacity depended upon the polyamide 
      reagent, the starting concentration of DCLHb, the molar ratio of the polyamide 
      reagent to DCLHb used, the reaction pH, and whether oxy- or deoxy-DCLHb was used 
      in the polymerization reaction.
FAU - Hai, T T
AU  - Hai TT
AD  - Corporate Research and Technical Services, Baxter Healthcare Corporation, Round 
      Lake, Illinois 60073-9799, USA. ton_hait@baxter.com
FAU - Pereira, D E
AU  - Pereira DE
FAU - Nelson, D J
AU  - Nelson DJ
FAU - Srnak, A
AU  - Srnak A
FAU - Catarello, J
AU  - Catarello J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bioconjug Chem
JT  - Bioconjugate chemistry
JID - 9010319
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Nylons)
RN  - 0 (Oxyhemoglobins)
RN  - 0 (Polymers)
RN  - 059QF0KO0R (Water)
RN  - 9008-02-0 (deoxyhemoglobin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemistry/metabolism
MH  - Cross-Linking Reagents
MH  - Hemoglobins/*chemistry/metabolism
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Indicators and Reagents
MH  - Molecular Weight
MH  - Nylons/*chemistry
MH  - Oxygen/metabolism
MH  - Oxyhemoglobins/chemistry
MH  - Polymers/chemistry
MH  - Solubility
MH  - Water
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
AID - bc9900486 [pii]
AID - 10.1021/bc9900486 [doi]
PST - ppublish
SO  - Bioconjug Chem. 1999 Nov-Dec;10(6):1013-20. doi: 10.1021/bc9900486.

PMID- 1206822
OWN - NLM
STAT- MEDLINE
DCOM- 19760305
LR  - 20190918
IS  - 0047-1909 (Print)
IS  - 0047-1909 (Linking)
VI  - 5
IP  - 1
DP  - 1975 Mar
TI  - Prophylactic administrations of aspirin for the prevention of thrombo-embolic 
      complications in postoperative reactive thrombocytosis.
PG  - 20-8
AB  - Hyperfunctioning platelets in the thrombocytotic patients after major surgery 
      were satisfactorily controlled by a small dose of aspirin ingestion. Since 
      aspirin is well documented as a potent inhibitor of platelet aggregation, a small 
      dose of prophylactic administration of aspirin appeared to be a legitimate 
      approach to a possible life-threatening thrombo-embolic complication after 
      surgery, particularly when the platelets are excessively produced and 
      hyperfunctioning.
FAU - Matsuda, M
AU  - Matsuda M
FAU - Wakabayshi, K
AU  - Wakabayshi K
FAU - Yamanaka, M
AU  - Yamanaka M
FAU - Uekane, K
AU  - Uekane K
FAU - Uetake, M
AU  - Uetake M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - Jpn J Surg
JT  - The Japanese journal of surgery
JID - 1302176
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Postoperative Complications/*prevention & control
MH  - Thrombocytosis/*complications
MH  - Thromboembolism/*prevention & control
EDAT- 1975/03/01 00:00
MHDA- 1975/03/01 00:01
CRDT- 1975/03/01 00:00
PHST- 1975/03/01 00:00 [pubmed]
PHST- 1975/03/01 00:01 [medline]
PHST- 1975/03/01 00:00 [entrez]
AID - 10.1007/BF02469466 [doi]
PST - ppublish
SO  - Jpn J Surg. 1975 Mar;5(1):20-8. doi: 10.1007/BF02469466.

PMID- 34854685
OWN - NLM
STAT- MEDLINE
DCOM- 20220328
LR  - 20220328
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 19
IP  - 1
DP  - 2022 Jan 3
TI  - New Insights into the Crystallographic Disorder in the Polymorphic Forms of 
      Aspirin from Low-Frequency Vibrational Analysis.
PG  - 227-234
LID - 10.1021/acs.molpharmaceut.1c00727 [doi]
AB  - Terahertz time-domain spectroscopy (THz-TDS) is applied to two polymorphs of 
      acetylsalicylic acid (aspirin), and the experimental spectra are compared to 
      lattice dynamical calculations using high accuracy density functional theory. The 
      calculations confirm that forms I and II have very close energetic and 
      thermodynamic properties and also that they show similar spectral features in the 
      far-infrared region, reflecting the high degree of similarity in their crystal 
      structures. Unique vibrational modes are identified for each polymorph which 
      allow them to be distinguished using THz-TDS measurements. The observation of 
      spectral features attributable to both polymorphic forms in a single sample, 
      however, provides further evidence to support the hypothesis that crystalline 
      aspirin typically comprises intergrown domains of forms I and II. Differences 
      observed in the baseline of the measured THz-TDS spectra indicate a greater 
      degree of structural disorder in the samples of form II. Calculated Gibbs 
      free-energy curves show a turning point at 75 K, inferring that form II is 
      expected to be more stable than form I above this temperature as a result of its 
      greater vibrational entropy. The calculations do not account for any differences 
      in configurational entropy that may arise from expected structural defects. 
      Further computational work on these structures, such as ab initio molecular 
      dynamics, would be very useful to further explore this perspective. Here, aspirin 
      is a model system to show how the additional insight from the low-frequency 
      vibrational information complements the structural data and allows for 
      quantitative thermodynamic information of pharmaceutical polymorphs to be 
      extracted. The methodology is directly applicable to other polymorphic systems.
FAU - Li, Qi
AU  - Li Q
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge, 
      Philippa Fawcett Drive, Cambridge CB3 0AS, U.K.
FAU - Bond, Andrew D
AU  - Bond AD
AUID- ORCID: 0000-0002-1744-0489
AD  - Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, 
      Cambridge CB2 1EW, U.K.
FAU - Korter, Timothy M
AU  - Korter TM
AUID- ORCID: 0000-0002-0398-5680
AD  - Department of Chemistry, Syracuse University, 1-014 Center for Science and 
      Technology, Syracuse, New York 13244, United States.
FAU - Zeitler, J Axel
AU  - Zeitler JA
AUID- ORCID: 0000-0002-4958-0582
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge, 
      Philippa Fawcett Drive, Cambridge CB3 0AS, U.K.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211202
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Terahertz Spectroscopy/methods
MH  - Thermodynamics
MH  - Vibration
OTO - NOTNLM
OT  - DFT simulations
OT  - THz-TDS
OT  - XRPD
OT  - aspirin
OT  - polymorphism
EDAT- 2021/12/03 06:00
MHDA- 2022/03/29 06:00
CRDT- 2021/12/02 12:13
PHST- 2021/12/03 06:00 [pubmed]
PHST- 2022/03/29 06:00 [medline]
PHST- 2021/12/02 12:13 [entrez]
AID - 10.1021/acs.molpharmaceut.1c00727 [doi]
PST - ppublish
SO  - Mol Pharm. 2022 Jan 3;19(1):227-234. doi: 10.1021/acs.molpharmaceut.1c00727. Epub 
      2021 Dec 2.

PMID- 3190996
OWN - NLM
STAT- MEDLINE
DCOM- 19881228
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 26
IP  - 4
DP  - 1988 Oct
TI  - An evaluation of different doses of soluble aspirin and aspirin tablets in 
      postoperative dental pain.
PG  - 463-8
AB  - 1. The efficacy of three different single doses (600, 900 and 1200 mg of soluble 
      aspirin and aspirin tablets) was determined in a randomized placebo-controlled 
      parallel study in 140 patients (70 females) with postoperative pain after removal 
      of impacted third molars. 2. Patients treated with soluble aspirin 600 mg, 900 
      mg, 1200 mg and aspirin tablet 1200 mg reported significantly less pain (P less 
      than 0.01) throughout the investigation period than those treated with placebo. 
      3. Overall pain scores after treatment with aspirin tablets 600 and 900 mg did 
      not differ significantly from those after treatment with placebo (P greater than 
      0.05). 4. On a comparative dose basis, soluble aspirin was significantly more 
      potent (P less than 0.05) than aspirin tablets.
FAU - Holland, I S
AU  - Holland IS
AD  - Department of Oral and Maxillofacial Surgery, Sunderland District General 
      Hospital.
FAU - Seymour, R A
AU  - Seymour RA
FAU - Ward-Booth, R P
AU  - Ward-Booth RP
FAU - Ord, R A
AU  - Ord RA
FAU - Lim, K L
AU  - Lim KL
FAU - Hoare, R C
AU  - Hoare RC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Solutions)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/blood
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Solutions
MH  - Tablets
MH  - *Tooth Extraction
PMC - PMC1386569
EDAT- 1988/10/01 00:00
MHDA- 1988/10/01 00:01
CRDT- 1988/10/01 00:00
PHST- 1988/10/01 00:00 [pubmed]
PHST- 1988/10/01 00:01 [medline]
PHST- 1988/10/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1988.tb03406.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1988 Oct;26(4):463-8. doi: 
      10.1111/j.1365-2125.1988.tb03406.x.

PMID- 12503945
OWN - NLM
STAT- MEDLINE
DCOM- 20030424
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 37
IP  - 1
DP  - 2003 Jan
TI  - Aspirin dose for prevention of cardiovascular disease in diabetics.
PG  - 116-21
AB  - OBJECTIVE: To determine whether a specific dose of aspirin can be recommended for 
      prevention of cardiovascular disease in patients with diabetes. DATA SOURCE: 
      Biomedical literature was accessed through MEDLINE (1990-February 2002). Key 
      terms included diabetes, cardiovascular protection, and aspirin. DATA SYNTHESIS: 
      Pharmacologic and clinical studies focusing on the dose-response relationship of 
      aspirin therapy were reviewed. Evidence supports the benefit of low-dose aspirin 
      therapy in reducing vascular events in secondary and primary prevention trials in 
      various patient populations; however, some studies suggest larger doses of 
      aspirin may be needed in certain patients. CONCLUSIONS: Review of the evidence 
      does not support a particular dose of aspirin for cardiovascular protection in 
      diabetic patients. Clinical guidelines recommend aspirin therapy in the range of 
      81-325 mg/d. However, due to an increased prevalence of cardiovascular morbidity 
      and disturbances in coagulation in diabetic patients, the dose of aspirin for 
      prevention of cardiovascular disease in these individuals may be different from 
      that in other populations and requires further evaluation.
FAU - Nowak, Sandra N
AU  - Nowak SN
AD  - Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health 
      Sciences, Wayne State University, Detroit, MI 48201, USA.
FAU - Jaber, Linda A
AU  - Jaber LA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/etiology
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/complications
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*therapeutic use
RF  - 24
EDAT- 2002/12/31 04:00
MHDA- 2003/04/25 05:00
CRDT- 2002/12/31 04:00
PHST- 2002/12/31 04:00 [pubmed]
PHST- 2003/04/25 05:00 [medline]
PHST- 2002/12/31 04:00 [entrez]
AID - 10.1345/aph.1C101 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2003 Jan;37(1):116-21. doi: 10.1345/aph.1C101.

PMID- 14665439
OWN - NLM
STAT- MEDLINE
DCOM- 20040209
LR  - 20171116
IS  - 0193-1857 (Print)
IS  - 0193-1857 (Linking)
VI  - 286
IP  - 1
DP  - 2004 Jan
TI  - Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 
      inhibitors to aggravate gastric damage and inflammation.
PG  - G76-81
AB  - Aceylation of cyclooxygenase (COX)-2 by aspirin can trigger the formation of 
      15(R)-epilipoxin A4, or aspirin-triggered lipoxin (ATL). ATL exerts protective 
      effects in the stomach. Selective COX-2 inhibitors block ATL synthesis and 
      exacerbate aspirin-induced gastric damage. Nitric oxide-releasing aspirins, 
      including NCX-4016, have antiplatelet effects similar to aspirin but do not cause 
      gastric damage. In the present study, we examined whether or not NCX-4016 
      triggers ATL synthesis and/or upregulates gastric COX-2 expression and the 
      effects of coadministration of NCX-4016 with a selective COX-2 inhibitor on 
      gastric mucosal injury and inflammation. Rats were given aspirin or NCX-4016 
      orally and either vehicle or a selective COX-2 inhibitor (celecoxib) 
      intraperitoneally. Gastric damage was blindly scored, and granulocyte 
      infiltration into gastric tissue was monitored through measurement of 
      myeloperoxidase activity. Gastric PG and ATL synthesis was measured as was COX-2 
      expression. Whereas celecoxib inhibited gastric ATL synthesis and increased the 
      severity of aspirin-induced gastric damage and inflammation, coadministration of 
      celecoxib and NCX-4016 did not result in damage or inflammation. NCX-4016 did not 
      upregulate gastric COX-2 expression nor did it trigger ATL synthesis (in contrast 
      to aspirin). Daily administration of aspirin for 5 days resulted in significantly 
      less gastric damage than that seen with a single dose, as well as augmented ATL 
      synthesis. Celecoxib reversed this effect. In contrast, repeated administration 
      of NCX-4016 failed to cause gastric damage, whether given alone or with 
      celecoxib. These studies support the notion that NCX-4016 may be an attractive 
      alternative to aspirin for indications such as cardioprotection, including in 
      individuals also taking selective COX-2 inhibitors.
FAU - Wallace, John L
AU  - Wallace JL
AD  - Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta, 
      Canada T2N 4N1. wallacej@ucalgary.ca
FAU - Zamuner, Stella R
AU  - Zamuner SR
FAU - McKnight, Webb
AU  - McKnight W
FAU - Dicay, Michael
AU  - Dicay M
FAU - Mencarelli, Andrea
AU  - Mencarelli A
FAU - del Soldato, Piero
AU  - del Soldato P
FAU - Fiorucci, Stefano
AU  - Fiorucci S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Physiol Gastrointest Liver Physiol
JT  - American journal of physiology. Gastrointestinal and liver physiology
JID - 100901227
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EH04H13L6B (nitroaspirin)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Can J Gastroenterol. 2004 Nov;18(11):697-8. PMID: 15565212
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Dinoprostone/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Gastric Mucosa/drug effects/enzymology/*pathology
MH  - Gastritis/*pathology
MH  - Isoenzymes/biosynthesis/*metabolism
MH  - Lipoxins/biosynthesis
MH  - Male
MH  - Neutropenia/metabolism
MH  - Neutrophil Infiltration/drug effects
MH  - Nitric Oxide/*metabolism
MH  - Peroxidase/metabolism
MH  - Prostaglandin-Endoperoxide Synthases/biosynthesis/*metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2003/12/11 05:00
MHDA- 2004/02/11 05:00
CRDT- 2003/12/11 05:00
PHST- 2003/12/11 05:00 [pubmed]
PHST- 2004/02/11 05:00 [medline]
PHST- 2003/12/11 05:00 [entrez]
AID - 286/1/G76 [pii]
AID - 10.1152/ajpgi.00295.2003 [doi]
PST - ppublish
SO  - Am J Physiol Gastrointest Liver Physiol. 2004 Jan;286(1):G76-81. doi: 
      10.1152/ajpgi.00295.2003.

PMID- 21319963
OWN - NLM
STAT- MEDLINE
DCOM- 20110615
LR  - 20151119
IS  - 1752-0371 (Electronic)
IS  - 1752-0363 (Linking)
VI  - 5
IP  - 1
DP  - 2011 Feb
TI  - Functional testing methods for the antiplatelet effects of aspirin.
PG  - 31-42
LID - 10.2217/bmm.10.122 [doi]
AB  - At antiplatelet doses of 75-325 mg/day, aspirin irreversibly inhibits the 
      platelet cyclooxygenase (COX)-1-dependent thromboxane A(2) (TXA(2)) formation. 
      This is the pharmacological mode of action of aspirin, and it can be predicted 
      that if aspirin does not inhibit COX-1 sufficiently, patients will not benefit 
      from its antiplatelet effects. A pharmacodynamic failure of aspirin occurs in 
      1-2% of patients. The vast majority of atherothrombotic events in patients 
      treated with aspirin result from mechanisms that are dependent on residual 
      (non-COX-1-dependent) platelet reactivity. Global tests of platelet activation in 
      vitro may identify patients with high residual platelet reactivity but are not 
      sufficiently specific to test the pharmacological effect of aspirin. A further 
      problem is the absence of standardized normal ranges for many assays and the fact 
      that different equipment measures different signals, which are also influenced by 
      the agonist and the anticoagulant used. Similar considerations apply for the 
      determination of platelet-derived biomarkers such as circulating P-selectin, 
      soluble CD40 ligand and others. The direct measurement of inhibition of 
      thromboxane-forming capacity is the most specific pharmacological assay for 
      aspirin. However, there is no linear correlation between inhibition of TXA(2) 
      formation and inhibition of platelet function. Measurement of urinary levels of 
      the TXB(2) metabolite, 11-dehydro-thromboxane B(2), represents an index of TXA(2) 
      biosynthesis in vivo, but is also sensitive to other cellular sources of TXA(2). 
      One general problem of all assays is the relationship with clinical outcome, 
      which is still unclear. Monitoring aspirin treatment by testing platelet function 
      or measuring biomarkers in clinical practice should not be recommended until a 
      clear relationship for the predictive value of these assays for clinical outcome 
      has been established.
FAU - Schrör, Karsten
AU  - Schrör K
AD  - Institut für Pharmakologie und Klinische Pharmakologie, 
      Heinrich-Heine-Universität Düsseldorf, Universitätsklinikum, Germany. 
      karsten.schroer@uni-duesseldorf.de
FAU - Huber, Kurt
AU  - Huber K
FAU - Hohlfeld, Thomas
AU  - Hohlfeld T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Biomark Med
JT  - Biomarkers in medicine
JID - 101312535
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Biomarkers/blood
MH  - Blood Platelets/drug effects/physiology
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests/*methods
EDAT- 2011/02/16 06:00
MHDA- 2011/06/16 06:00
CRDT- 2011/02/16 06:00
PHST- 2011/02/16 06:00 [entrez]
PHST- 2011/02/16 06:00 [pubmed]
PHST- 2011/06/16 06:00 [medline]
AID - 10.2217/bmm.10.122 [doi]
PST - ppublish
SO  - Biomark Med. 2011 Feb;5(1):31-42. doi: 10.2217/bmm.10.122.

PMID- 8330469
OWN - NLM
STAT- MEDLINE
DCOM- 19930819
LR  - 20190512
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 54
IP  - 1
DP  - 1993 Jul
TI  - Adverse effects of low-dose aspirin in a healthy elderly population.
PG  - 84-9
AB  - The adverse effects of low-dose aspirin (100 mg daily) in the elderly were 
      studied over a 12-month period in a double-blind, randomized, placebo-controlled 
      trial of 400 subjects who were 70 years of age or older and had no preexisting 
      major vascular diseases at the time of entry. Subjects were randomized so that 
      200 subjects received low-dose enteric-coated aspirin (100 mg daily) and 200 
      subjects received placebo. Compliance with medication, assessed by pill count, 
      was 86%. Gastrointestinal symptoms were reported by 18% (n = 36) of participants 
      receiving aspirin and 13% (n = 26) of those receiving placebo. Clinically evident 
      gastrointestinal bleeding occurred in 3% (n = 6) of subjects receiving aspirin 
      and none receiving placebo. Aspirin-treated subjects had a significant decrease 
      in mean hemoglobin levels of 0.33 gm/dl during the 12-month study period, which 
      was significantly greater than the decrease in the placebo-treated group (0.11 
      gm/dl; p < 0.05). These rates of unwanted symptoms are comparable with previous 
      studies that used higher doses of aspirin. Until the risk-benefit trade-off from 
      the use of low-dose aspirin in the elderly is established with an appropriate 
      clinical trial, caution should be exercised when this compound is used for 
      primary prevention of cardiovascular disease in this age group.
FAU - Silagy, C A
AU  - Silagy CA
AD  - Department of Social and Preventive Medicine, Monash University, Prahran, 
      Victoria, Australia.
FAU - McNeil, J J
AU  - McNeil JJ
FAU - Donnan, G A
AU  - Donnan GA
FAU - Tonkin, A M
AU  - Tonkin AM
FAU - Worsam, B
AU  - Worsam B
FAU - Campion, K
AU  - Campion K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Cerebrovascular Disorders/prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Hematologic Tests
MH  - Humans
MH  - Male
MH  - Tablets, Enteric-Coated
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
AID - 10.1038/clpt.1993.115 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1993 Jul;54(1):84-9. doi: 10.1038/clpt.1993.115.

PMID- 3677978
OWN - NLM
STAT- MEDLINE
DCOM- 19880107
LR  - 20190515
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 10
IP  - 5
DP  - 1987 Sep-Oct
TI  - Is aspirin usage associated with diabetic retinopathy?
PG  - 600-3
AB  - The relationship between the history of aspirin usage and diabetic retinopathy is 
      examined in this report. The study population consists of a sample of people (n = 
      1370) who developed diabetes mellitus after 30 yr of age, who lived in 
      south-central Wisconsin, and who participated in the Wisconsin Epidemiologic 
      Study of Diabetic Retinopathy. These participants were questioned about recent 
      and past use of aspirin. There was no association between the number of aspirin 
      used in the month before the exam and the severity of diabetic retinopathy. Three 
      hundred thirty-eight of these individuals reported taking aspirin daily for at 
      least 3 mo since they were diagnosed as having diabetes. There was no association 
      between the severity of retinopathy and having used aspirin in this way. These 
      analyses suggest that aspirin usage, as herein described, is unrelated to the 
      severity of diabetic retinopathy in older-onset diabetic patients.
FAU - Klein, B E
AU  - Klein BE
AD  - University of Wisconsin Medical School, Department of Ophthalmology, Madison.
FAU - Klein, R
AU  - Klein R
FAU - Moss, S E
AU  - Moss SE
LA  - eng
GR  - EY-03083/EY/NEI NIH HHS/United States
GR  - P30-AM-AC-26659/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Diabetic Retinopathy/*chemically induced/epidemiology
MH  - Humans
MH  - Wisconsin
EDAT- 1987/09/01 00:00
MHDA- 1987/09/01 00:01
CRDT- 1987/09/01 00:00
PHST- 1987/09/01 00:00 [pubmed]
PHST- 1987/09/01 00:01 [medline]
PHST- 1987/09/01 00:00 [entrez]
AID - 10.2337/diacare.10.5.600 [doi]
PST - ppublish
SO  - Diabetes Care. 1987 Sep-Oct;10(5):600-3. doi: 10.2337/diacare.10.5.600.

PMID- 778989
OWN - NLM
STAT- MEDLINE
DCOM- 19760823
LR  - 20191028
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - 15
IP  - 2
DP  - 1976 May
TI  - A trial of micro-encapsulated and enteric-coated aspirin in rheumatoid arthritis.
PG  - 77-80
AB  - In a trial of 48 patients with rheumatoid arthritis, enteric-coated aspirin (4.55 
      g daily( and micro-encapsulated aspirin (4.50 g daily) proved to be equally 
      effective in reducing morning stiffness, relieving pain, increasing grip 
      strength, reducing ESR, and reducing the need for additional analgesic tablets, 
      compared with placebo. Reduction of joint tenderness was also found, but this was 
      not statistically significant. Proximal interphalangeal joint circumference 
      altered little during the trial. Tinnitus and deafness were commoner with 
      enteric-coated aspirin, but gastric side-effects were similar. Of 39 patients 
      completing the trial, there was an equal patient preference for enteric-coated 
      aspirin and micro-encapsulated aspirin. Salicylate side-effects necessitated 
      withdrawal of six patients from the trial and dose reduction in nine patients. It 
      was concluded that the efficacy and side-effects in rheumatoid arthritis of both 
      aspirin preparations were similar.
FAU - Dippy, J E
AU  - Dippy JE
FAU - Pritchard, M H
AU  - Pritchard MH
FAU - Lloyd, K N
AU  - Lloyd KN
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Placebos)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clinical Trials as Topic
MH  - Delayed-Action Preparations
MH  - Drug Evaluation
MH  - Humans
MH  - Placebos
MH  - Tablets, Enteric-Coated
EDAT- 1976/05/01 00:00
MHDA- 1976/05/01 00:01
CRDT- 1976/05/01 00:00
PHST- 1976/05/01 00:00 [pubmed]
PHST- 1976/05/01 00:01 [medline]
PHST- 1976/05/01 00:00 [entrez]
AID - 10.1093/rheumatology/15.2.77 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1976 May;15(2):77-80. doi: 10.1093/rheumatology/15.2.77.

PMID- 23998633
OWN - NLM
STAT- MEDLINE
DCOM- 20140421
LR  - 20180411
IS  - 1520-5126 (Electronic)
IS  - 0002-7863 (Linking)
VI  - 135
IP  - 39
DP  - 2013 Oct 2
TI  - An alkyne-aspirin chemical reporter for the detection of aspirin-dependent 
      protein modification in living cells.
PG  - 14568-73
LID - 10.1021/ja408322b [doi]
AB  - Aspirin (acetylsalicylic acid) is widely used for the acute treatment of 
      inflammation and the management of cardiovascular disease. More recently, it has 
      also been shown to reduce the risk of a variety of cancers. The anti-inflammatory 
      properties of aspirin in pain-relief, cardio-protection, and chemoprevention are 
      well-known to result from the covalent inhibition of cyclooxygenase enzymes 
      through nonenzymatic acetylation of key serine residues. However, any additional 
      molecular mechanisms that may contribute to the beneficial effects of aspirin 
      remain poorly defined. Interestingly, studies over the past 50 years using 
      radiolabeled aspirin demonstrated that other proteins are acetylated by aspirin 
      and enrichment with antiacetyl-lysine antibodies identified 33 potential targets 
      of aspirin-dependent acetylation. Herein we describe the development of an 
      alkyne-modified aspirin analogue (AspAlk) as a chemical reporters of 
      aspirin-dependent acetylation in living cells. When combined with the 
      Cu(I)-catalyzed [3 + 2] azide-alkyne cycloaddition, this chemical reporter 
      allowed for the robust in-gel fluorescent detection of acetylation and the 
      subsequent enrichment and identification of 120 proteins, 112 of which have not 
      been previously reported to be acetylated by aspirin in cellular or in vivo 
      contexts. Finally, AspAlk was shown to modify the core histone proteins, 
      implicating aspirin as a potential chemical-regulator of transcription.
FAU - Bateman, Leslie A
AU  - Bateman LA
AD  - Department of Chemistry and ‡Department of Molecular and Computational Biology, 
      University of Southern California , Los Angeles, California, United States.
FAU - Zaro, Balyn W
AU  - Zaro BW
FAU - Miller, Stephanie M
AU  - Miller SM
FAU - Pratt, Matthew R
AU  - Pratt MR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130918
PL  - United States
TA  - J Am Chem Soc
JT  - Journal of the American Chemical Society
JID - 7503056
RN  - 0 (Alkynes)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Azides)
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - J Am Chem Soc. 2018 Apr 11;140(14 ):4954. PMID: 29589917
MH  - Acetylation/*drug effects
MH  - Alkynes/*chemistry
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Azides/chemistry
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Fluorescent Dyes/chemistry
MH  - Humans
MH  - Proteins/*metabolism
EDAT- 2013/09/04 06:00
MHDA- 2014/04/22 06:00
CRDT- 2013/09/04 06:00
PHST- 2013/09/04 06:00 [entrez]
PHST- 2013/09/04 06:00 [pubmed]
PHST- 2014/04/22 06:00 [medline]
AID - 10.1021/ja408322b [doi]
PST - ppublish
SO  - J Am Chem Soc. 2013 Oct 2;135(39):14568-73. doi: 10.1021/ja408322b. Epub 2013 Sep 
      18.

PMID- 420719
OWN - NLM
STAT- MEDLINE
DCOM- 19790428
LR  - 20190717
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 22
IP  - 3
DP  - 1979 Mar
TI  - Apparent acute renal failure associated with therapeutic aspirin and ibuprofen 
      administration.
PG  - 281-5
AB  - Aspirin and ibuprofen may cause a decrease in renal function which, although 
      statistically significant, is usually small. We report a patient with active 
      systemic lupus erythematosus and apparent acute renal failure associated with the 
      administration of these drugs. Renal biopsy revealed no light microscopic 
      evidence of drug nephrotoxicity although patchy nonspecific ultrastructural 
      changes in the tubular epithelium were seen. The renal failure reversed rapidly 
      when the drugs were withdrawn.
FAU - Kimberly, R P
AU  - Kimberly RP
FAU - Sherman, R L
AU  - Sherman RL
FAU - Mouradian, J
AU  - Mouradian J
FAU - Lockshin, M D
AU  - Lockshin MD
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acute Kidney Injury/*chemically induced/pathology
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Ibuprofen/administration & dosage/*adverse effects/therapeutic use
MH  - Kidney/ultrastructure
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
AID - 10.1002/art.1780220311 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1979 Mar;22(3):281-5. doi: 10.1002/art.1780220311.

PMID- 1682177
OWN - NLM
STAT- MEDLINE
DCOM- 19911205
LR  - 20190819
IS  - 0020-7292 (Print)
IS  - 0020-7292 (Linking)
VI  - 35
IP  - 4
DP  - 1991 Aug
TI  - Low dose acetyl salicylic acid in severe preeclampsia.
PG  - 311-7
AB  - Twenty pregnant patients in the third trimester with severe preeclampsia were 
      allocated at random into two equal groups. The first group was treated for 10 
      days with a low dose (75 mg/day) of acetyl salicylic acid (ASA) then with 
      conventional therapy for another 10 days. The second group received the same 
      regimen but conventional therapy in the first 10 days and ASA in the second 10 
      days. Changes in systolic and diastolic blood pressure, albuminuria, lower limb 
      edema and urinary output were closely monitored and recorded. This comparative 
      crossover study indicated that both the low dose ASA and conventional therapy 
      significantly reduced systolic and diastolic blood pressure which was more 
      pronounced with ASA and in group I. Crossover from one treatment to the other 
      maintained the response but was more beneficial when ASA was given first.
FAU - Toppozada, M
AU  - Toppozada M
AD  - Department of Obstetrics and Gynaecology, Shatby Hospital, University of 
      Alexandria, Egypt.
FAU - Darwish, E A
AU  - Darwish EA
FAU - Osman, Y F
AU  - Osman YF
FAU - Abd-Rabbo, M S
AU  - Abd-Rabbo MS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Albuminuria/drug therapy
MH  - Aspirin/*administration & dosage/pharmacology/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Edema/drug therapy
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*drug therapy/physiopathology/urine
MH  - Pregnancy
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
AID - 10.1016/0020-7292(91)90663-p [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 1991 Aug;35(4):311-7. doi: 10.1016/0020-7292(91)90663-p.

PMID- 17669925
OWN - NLM
STAT- MEDLINE
DCOM- 20070831
LR  - 20131121
IS  - 1569-9285 (Electronic)
IS  - 1569-9285 (Linking)
VI  - 6
IP  - 4
DP  - 2007 Aug
TI  - Does enteric-coated aspirin result in a lower incidence of gastrointestinal 
      complications compared to normal aspirin?
PG  - 519-22
AB  - A best evidence topic in cardiac surgery was written according to a structured 
      protocol. The question addressed was whether enteric-coated aspirin results in a 
      lower incidence of gastrointestinal complications compared to normal aspirin in 
      CABG surgery. Using the reported search, 340 papers were identified. Nine papers 
      represented the best evidence on the subject. The author, journal, date and 
      country of publication, patient group studied, study type, relevant outcomes, 
      weaknesses, results and study comments were tabulated. Five randomised controlled 
      trials of healthy volunteers undergoing endoscopy after a period of either 
      enteric-coated aspirin or plain aspirin administration all demonstrated a clear 
      reduction of gastric mucosal injury. However, these trials on healthy volunteers 
      taking short-term aspirin have not been supported by clinical studies in older 
      age-group adults taking lower doses of aspirin for long periods. No clinical 
      benefits in terms of reduction of gastrointestinal bleeding or ulceration with 
      enteric coating have, therefore, been successfully demonstrated, although the 
      endoscopic studies show that potentially these benefits could exist.
FAU - Walker, Jay
AU  - Walker J
AD  - Department of Cardiothoracic Surgery, James Cook University Hospital, 
      Middlesbrough, UK.
FAU - Robinson, James
AU  - Robinson J
FAU - Stewart, Jamie
AU  - Stewart J
FAU - Jacob, Samuel
AU  - Jacob S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20070406
PL  - England
TA  - Interact Cardiovasc Thorac Surg
JT  - Interactive cardiovascular and thoracic surgery
JID - 101158399
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Coronary Artery Bypass
MH  - Evidence-Based Medicine
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Postoperative Care
MH  - Stomach Diseases/*chemically induced
MH  - Tablets, Enteric-Coated
EDAT- 2007/08/03 09:00
MHDA- 2007/09/01 09:00
CRDT- 2007/08/03 09:00
PHST- 2007/08/03 09:00 [pubmed]
PHST- 2007/09/01 09:00 [medline]
PHST- 2007/08/03 09:00 [entrez]
AID - icvts.2007.155788 [pii]
AID - 10.1510/icvts.2007.155788 [doi]
PST - ppublish
SO  - Interact Cardiovasc Thorac Surg. 2007 Aug;6(4):519-22. doi: 
      10.1510/icvts.2007.155788. Epub 2007 Apr 6.

PMID- 3903519
OWN - NLM
STAT- MEDLINE
DCOM- 19851218
LR  - 20190617
IS  - 0028-0836 (Print)
IS  - 0028-0836 (Linking)
VI  - 318
IP  - 6042
DP  - 1985 Nov 14-20
TI  - Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin 
      production in man.
PG  - 186-8
AB  - Acetylsalicylic acid (aspirin) inhibits prostanoid synthesis by irreversible 
      acetylation of fatty acid cyclooxygenase (EC 1.14.99.1). It thereby inhibits 
      synthesis of pro-aggregatory thromboxane A2 (TXA2) by platelets and is widely 
      used in the treatment and prophylaxis of vascular disease. Its efficacy, however, 
      may be reduced since it also inhibits formation of prostacyclin (PGI2) which is a 
      vasodilator and anti-aggregatory agent. There is uncertainty over the optimum 
      dose regimen for aspirin since although it inhibits platelet thromboxane 
      production for many days, the magnitude and duration of its effect on PGI2 
      production by vascular endothelium in vivo is unknown. Resting plasma 
      concentrations of PGI2 (measured as the stable hydrolysis product 6-oxo-PGF1 
      alpha) are at or below the limit of sensitivity of the most sensitive assays and 
      cannot therefore be used to demonstrate a reduction in production. Bradykinin 
      stimulates PGI2 synthesis by cultured human vascular endothelial cells and we 
      have shown that it stimulates PGI2 production by man in vivo. We report here that 
      an oral dose of aspirin (600 mg) causes rapid and substantial inhibition of 
      bradykinin-stimulated PGI2 production, but recovery occurs within 6 hours; this 
      implies that endothelial PGI2 synthesis would be spared most of the time during 
      dosing once daily with even this relatively large dose of aspirin.
FAU - Heavey, D J
AU  - Heavey DJ
FAU - Barrow, S E
AU  - Barrow SE
FAU - Hickling, N E
AU  - Hickling NE
FAU - Ritter, J M
AU  - Ritter JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bradykinin/*pharmacology
MH  - Epoprostenol/*biosynthesis
MH  - Humans
MH  - Male
MH  - Time Factors
EDAT- 1985/11/14 00:00
MHDA- 1985/11/14 00:01
CRDT- 1985/11/14 00:00
PHST- 1985/11/14 00:00 [pubmed]
PHST- 1985/11/14 00:01 [medline]
PHST- 1985/11/14 00:00 [entrez]
AID - 10.1038/318186a0 [doi]
PST - ppublish
SO  - Nature. 1985 Nov 14-20;318(6042):186-8. doi: 10.1038/318186a0.

PMID- 3379589
OWN - NLM
STAT- MEDLINE
DCOM- 19880727
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 77
IP  - 4
DP  - 1988 Apr
TI  - Decomposition of aspirin in the solid state in the presence of limited amounts of 
      moisture III: Effect of temperature and a possible mechanism.
PG  - 318-21
AB  - In a previous study, we showed that aspirin in the presence of limited amounts of 
      moisture falls to follow Leeson-Mattocks kinetics at 62.5 degrees C. This system 
      has been tested at a series of temperatures, and several plausible models have 
      been tested. It is shown that the data are explained by a model in which the 
      reaction is limited to a surface interaction between aspirin and water from the 
      sorbed bulk moisture layer.
FAU - Carstensen, J T
AU  - Carstensen JT
AD  - School of Pharmacy, University of Wisconsin, Madison 53706.
FAU - Attarchi, F
AU  - Attarchi F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chemistry, Pharmaceutical
MH  - Drug Stability
MH  - Models, Biological
MH  - Temperature
EDAT- 1988/04/01 00:00
MHDA- 1988/04/01 00:01
CRDT- 1988/04/01 00:00
PHST- 1988/04/01 00:00 [pubmed]
PHST- 1988/04/01 00:01 [medline]
PHST- 1988/04/01 00:00 [entrez]
AID - S0022-3549(15)47665-8 [pii]
AID - 10.1002/jps.2600770407 [doi]
PST - ppublish
SO  - J Pharm Sci. 1988 Apr;77(4):318-21. doi: 10.1002/jps.2600770407.

PMID- 22538532
OWN - NLM
STAT- MEDLINE
DCOM- 20120820
LR  - 20131121
IS  - 1875-8622 (Electronic)
IS  - 1386-0291 (Linking)
VI  - 50
IP  - 1-2
DP  - 2012
TI  - Influence of acetylsalicylic acid (Aspirin) on cutaneous microcirculation.
PG  - 25-34
LID - 10.3233/CH-2011-1440 [doi]
AB  - BACKGROUND: The protective effect of acetylsalicylic acid (aspirin) in primary 
      and secondary prophylaxis of cardiovascular events is attributed to the 
      inhibition of platelet cyclooxygenase (COX). However, a recent animal study found 
      a vasodilating and blood pressure lowering effect of aspirin independent of COX, 
      but mediated by inhibition of the RhoA/Rho kinase signaling pathway. METHOD: 
      Prospective, randomized, double-blind, placebo-controlled cross-over study. In 
      each instance 5 healthy volunteers received either aspirin 500 mg/d or placebo 
      for 7 days. Capillary red blood cell velocity (vRBC) at rest and after 
      postischemic hyperemia was determined on day 1 and 7 by means of nailfold 
      capillary microscopy. RESULTS: In the aspirin group after 7 days a significant 
      increase of vRBC was found at rest and during hyperemia. In the placebo group 
      vRBC did not change. The finding was confirmed by the cross-over design of the 
      study. CONCLUSION: Aspirin at a dosage of 500 mg/d has an impact on 
      vasoregulation in the microcirculation. At present, the underlying mode of action 
      in humans is unknown.
FAU - Leithäuser, B
AU  - Leithäuser B
AD  - Asklepios Klinik Harburg, 1st Medical Department, Cardiology, Hamburg, Germany. 
      b.leithaeuser@asklepios.com
FAU - Mrowietz, C
AU  - Mrowietz C
FAU - Park, J-W
AU  - Park JW
FAU - Jung, F
AU  - Jung F
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Flow Velocity
MH  - Cell Movement/drug effects
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Erythrocytes/drug effects
MH  - Humans
MH  - Microcirculation/*drug effects
MH  - Nails/*blood supply/drug effects
EDAT- 2012/04/28 06:00
MHDA- 2012/08/21 06:00
CRDT- 2012/04/28 06:00
PHST- 2012/04/28 06:00 [entrez]
PHST- 2012/04/28 06:00 [pubmed]
PHST- 2012/08/21 06:00 [medline]
AID - T6731WPN58144277 [pii]
AID - 10.3233/CH-2011-1440 [doi]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 2012;50(1-2):25-34. doi: 10.3233/CH-2011-1440.

PMID- 11794965
OWN - NLM
STAT- MEDLINE
DCOM- 20020205
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 94
IP  - 11 Suppl
DP  - 2001 Nov
TI  - [Primary prevention of coronary thrombosis by antithrombotic agents].
PG  - 1243-50
AB  - At the start of the eighties, in the wake of the good results obtained with 
      aspirin in secondary prevention, two studies were launched aimed at testing the 
      effect of aspirin on the primary prevention of myocardial infarction. The results 
      published in 1988 and 1989 were divergent: the study conducted by British doctors 
      showed no benefit with aspirin, that conducted by American doctors showed a very 
      distinct benefit concerning myocardial infarction but no advantage for cerebral 
      vascular accidents. Besides, in both studies an additional risk of haemorrhagic 
      cerebral vascular accident was described. Methodological reasons were the origin 
      of these facts, but it resulted in a certain confusion as to the practical 
      conduct to adopt. Ten years later it is much more clear after the publication of 
      three supplementary trials. The benefits of aspirin in terms of prevention of 
      myocardial infarction are certain and considerable, at the price of a 
      haemorrhagic risk equally certain but moderate. On the other hand, questions 
      remain concerning the preventive effect of aspirin on cerebral vascular accidents 
      and also on the expected benefits in the female sex. In practice, the 
      prescription of aspirin with the objective of primary prevention must take into 
      account the absolute benefit which can be expected. This is a function of the 
      individual absolute risk before treatment which therefore signifies an evaluation 
      based on the risk factors. Only subjects exposed to a substantial risk before 
      treatment are likely to benefit from aspirin. For the others, the risks linked 
      with aspirin could counterbalance its preventive advantages.
FAU - Milon, H
AU  - Milon H
AD  - Service de cardiologie, hôpital de la Croix-Rousse, 103, Grande Rue de la 
      Croix-Rousse, 69317 Lyon.
FAU - Lantelme, P
AU  - Lantelme P
FAU - Khettab, F
AU  - Khettab F
FAU - Mestre-Fernandes, C
AU  - Mestre-Fernandes C
FAU - Lasserre-Remy, S
AU  - Lasserre-Remy S
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Prévention primaire de la thrombose coronaire par les antithrombotiques.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Fibrinolytic Agents/*pharmacology/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Preventive Medicine
MH  - Risk Factors
EDAT- 2002/01/25 10:00
MHDA- 2002/02/06 10:01
CRDT- 2002/01/25 10:00
PHST- 2002/01/25 10:00 [pubmed]
PHST- 2002/02/06 10:01 [medline]
PHST- 2002/01/25 10:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1243-50.

PMID- 26523769
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20170917
IS  - 1520-6017 (Electronic)
IS  - 0022-3549 (Linking)
VI  - 105
IP  - 2
DP  - 2016 Feb
TI  - Effect of Calcium Ions on the Disintegration of Enteric-Coated Solid Dosage 
      Forms.
PG  - 509-511
LID - S0022-3549(15)00119-7 [pii]
LID - 10.1002/jps.24700 [doi]
AB  - To investigate the effect of calcium ions on the disintegration of enteric-coated 
      dosage forms, disintegration testing was performed on enteric-coated aspirin 
      tablets in the presence and absence of calcium in the test media. The results 
      show that the presence of calcium ions retards the disintegration of 
      enteric-coated dosage forms. This finding, which has not been reported in 
      scientific literature, sheds light on the importance of conducting well-designed 
      detailed investigations into the potential of calcium from dietary sources, 
      calcium supplements, antacids, and/or phosphate binders affecting the absorption 
      of drugs formulated into enteric-coated dosage forms. Moreover, it shows the 
      necessity to investigate the potential of the occurrence of additional 
      nutrient-excipient interactions.
CI  - Copyright © 2016 American Pharmacists Association®. Published by Elsevier Inc. 
      All rights reserved.
FAU - Al-Gousous, Jozef
AU  - Al-Gousous J
AD  - Institute of Pharmacy and Biochemistry, Johannes Gutenberg University Mainz, 
      Mainz, Germany.
FAU - Langguth, Peter
AU  - Langguth P
AD  - Institute of Pharmacy and Biochemistry, Johannes Gutenberg University Mainz, 
      Mainz, Germany. Electronic address: langguth@uni-mainz.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160111
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Dosage Forms)
RN  - 0 (Tablets, Enteric-Coated)
RN  - M4I0D6VV5M (Calcium Chloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry/metabolism
MH  - Calcium Chloride/*chemistry/*metabolism
MH  - Dosage Forms
MH  - Drug Liberation
MH  - Solubility
MH  - Tablets, Enteric-Coated/*chemistry/*metabolism
OTO - NOTNLM
OT  - bioavailability
OT  - calcium
OT  - disintegration
OT  - dissolution
OT  - enteric coating
OT  - excipient
OT  - interaction
OT  - nutrient
EDAT- 2015/11/03 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/11/03 06:00
PHST- 2015/09/01 00:00 [received]
PHST- 2015/09/30 00:00 [revised]
PHST- 2015/10/01 00:00 [accepted]
PHST- 2015/11/03 06:00 [entrez]
PHST- 2015/11/03 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S0022-3549(15)00119-7 [pii]
AID - 10.1002/jps.24700 [doi]
PST - ppublish
SO  - J Pharm Sci. 2016 Feb;105(2):509-511. doi: 10.1002/jps.24700. Epub 2016 Jan 11.

PMID- 24361050
OWN - NLM
STAT- MEDLINE
DCOM- 20140918
LR  - 20140204
IS  - 2212-4934 (Electronic)
IS  - 2212-4926 (Linking)
VI  - 54
DP  - 2014 Jan
TI  - An aspirin a day.
PG  - 231-41
LID - S2212-4926(13)00085-7 [pii]
LID - 10.1016/j.jbior.2013.09.011 [doi]
AB  - The title of this article is also its punch line. The thesis that I will prove is 
      that every adult, with a few exceptions, should take one 325 mg aspirin tablet 
      each day. The drug is extraordinary and is beneficial in myriad ways. In this 
      dosage the toxicity of the treatment is minimal. Since the drug is sold "over the 
      counter", not requiring prescription, it is cheap and its benefits are easily 
      underestimated. I do not use extensive reference citations; but just tell the 
      story of aspirin.
CI  - Copyright © 2013. Published by Elsevier Ltd.
FAU - Majerus, Philip W
AU  - Majerus PW
AD  - Division of Hematology, Washington University, School of Medicine, St. Louis, MO 
      63110, USA. Electronic address: PHIL@dom.wustl.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131204
PL  - England
TA  - Adv Biol Regul
JT  - Advances in biological regulation
JID - 101572336
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Humans
MH  - Neoplasms/*prevention & control
EDAT- 2013/12/24 06:00
MHDA- 2014/09/19 06:00
CRDT- 2013/12/24 06:00
PHST- 2013/09/26 00:00 [received]
PHST- 2013/09/27 00:00 [accepted]
PHST- 2013/12/24 06:00 [entrez]
PHST- 2013/12/24 06:00 [pubmed]
PHST- 2014/09/19 06:00 [medline]
AID - S2212-4926(13)00085-7 [pii]
AID - 10.1016/j.jbior.2013.09.011 [doi]
PST - ppublish
SO  - Adv Biol Regul. 2014 Jan;54:231-41. doi: 10.1016/j.jbior.2013.09.011. Epub 2013 
      Dec 4.

PMID- 15819094
OWN - NLM
STAT- MEDLINE
DCOM- 20100618
LR  - 20191210
IS  - 1000-0593 (Print)
IS  - 1000-0593 (Linking)
VI  - 19
IP  - 3
DP  - 1999 Jun
TI  - [New solution of simultaneous equations in spectrophotometry for the 
      determination of aspirin and acetaminophen in xiaoer tuishao pian].
PG  - 468-70
AB  - The contents of aspirin and acetaminophen in xiaoer tuishao pian were determined 
      by using the new solution of simultaneous equations without any preliminary 
      separation. The average recoveries and variation coefficients of the analysis are 
      99.95% and 1.74% for aspirin and 100.1% and 0.93% for acetaminophen, 
      respectively. The method was simple, rapid and accurate.
FAU - Huang, X
AU  - Huang X
AD  - Department of Pharmacy, Hebei Medical University, 50017 Shijiazhuang.
FAU - Zhang, Z
AU  - Zhang Z
FAU - Zhang, Z
AU  - Zhang Z
FAU - Liu, W
AU  - Liu W
FAU - Tang, S
AU  - Tang S
FAU - Han, X
AU  - Han X
LA  - chi
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Guang Pu Xue Yu Guang Pu Fen Xi
JT  - Guang pu xue yu guang pu fen xi = Guang pu
JID - 9424805
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis/therapeutic use
MH  - Aspirin/*analysis/therapeutic use
MH  - Fever/drug therapy
MH  - Spectrophotometry/*methods
EDAT- 2005/04/12 09:00
MHDA- 2010/06/19 06:00
CRDT- 2005/04/12 09:00
PHST- 2005/04/12 09:00 [pubmed]
PHST- 2010/06/19 06:00 [medline]
PHST- 2005/04/12 09:00 [entrez]
PST - ppublish
SO  - Guang Pu Xue Yu Guang Pu Fen Xi. 1999 Jun;19(3):468-70.

PMID- 8401340
OWN - NLM
STAT- MEDLINE
DCOM- 19931118
LR  - 20131121
IS  - 0867-7077 (Print)
IS  - 0867-7077 (Linking)
VI  - 61
IP  - 7-8
DP  - 1993
TI  - [Chemotactic activity of serum granulocytes after aspirin in patients with 
      aspirin-sensitive urticaria who find themselves in a state of tolerance for this 
      drug].
PG  - 357-61
AB  - The increase in neutrophil chemotactic activity (NCA) is related to degranulation 
      of mast cells. The study included 10 patients in whom aspirin-induced urticaria 
      was related to NCA increase. Tolerance state to ASA was achieved by administering 
      this drug in incremental doses. In none of the examined patients after 600 mg of 
      ASA given during induced tolerance state, the increase of NCA was observed. The 
      authors conclude that in patients with ASA-urticaria, after ASA desensitization, 
      mast cells degranulation does not occur.
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
AD  - Kliniki Pneumonologii i Alergologii IMW AM, Lodzi.
FAU - Szmidt, M
AU  - Szmidt M
FAU - Grzegorczyk, J
AU  - Grzegorczyk J
FAU - Rozniecki, J
AU  - Rozniecki J
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Aktywność chemotaktyczna surowicy dla granulocytów po aspirynie u chorych z 
      pokrzywkowo-obrzekowa postacia nadwrazliwości na aspiryne znajdujacych sie w 
      stanie tolerancji na ten lek.
PL  - Poland
TA  - Pneumonol Alergol Pol
JT  - Pneumonologia i alergologia polska
JID - 9302892
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Chemotaxis, Leukocyte/*physiology
MH  - Drug Hypersensitivity/*blood
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neutrophils/physiology
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Pneumonol Alergol Pol. 1993;61(7-8):357-61.

PMID- 1803794
OWN - NLM
STAT- MEDLINE
DCOM- 19920428
LR  - 20191028
IS  - 1042-9611 (Print)
IS  - 1042-9611 (Linking)
VI  - 25
IP  - 10
DP  - 1991 Oct
TI  - Long-term, low-dose aspirin is safe in glucose-6-phosphate dehydrogenase 
      deficiency.
PG  - 1074-5
AB  - Forty-four patients with Mediterranean-type glucose-6-phosphate dehydrogenase 
      (G-6-PD) deficiency receiving long-term, low-dose aspirin were monitored over 
      three months for evidence of hemolysis. Complete blood count, reticulocyte count 
      and serum bilirubin were normal in all patients before treatment and upon 
      periodic retesting. We conclude that there is sufficient current evidence to 
      remove the hemolytic stigma of aspirin in G-6-PD deficiency, thereby establishing 
      its safety for long-term therapy in this condition.
FAU - Shalev, O
AU  - Shalev O
AD  - Department of Medicine, Hadassah University Hospital, Mount Scopus, Jerusalem, 
      Israel.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - DICP
JT  - DICP : the annals of pharmacotherapy
JID - 8904338
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Glucosephosphate Dehydrogenase Deficiency/*metabolism
MH  - Hemolysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Safety
MH  - Time Factors
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
AID - 10.1177/106002809102501010 [doi]
PST - ppublish
SO  - DICP. 1991 Oct;25(10):1074-5. doi: 10.1177/106002809102501010.

PMID- 25766664
OWN - NLM
STAT- MEDLINE
DCOM- 20160310
LR  - 20220311
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 24
IP  - 7
DP  - 2015 Jul
TI  - The Role of Colchicine in Pericarditis--A Systematic Review and Meta-analysis of 
      Randomised Trials.
PG  - 660-6
LID - S1443-9506(15)00048-7 [pii]
LID - 10.1016/j.hlc.2015.01.010 [doi]
AB  - INTRODUCTION: Colchicine has been used in diverse clinical settings. Primary 
      idiopathic pericarditis is complicated by recurrence in 15 to 30% of cases. 
      Aspirin, non-steroidal anti-inflammatory drugs, colchicine and steroids are the 
      commonly prescribed medications. We synthesised the available evidence from the 
      randomised trials to assess the efficacy and safety of colchicine in primary and 
      recurrent pericarditis. METHODS: A systematic search was conducted using MEDLINE, 
      PubMed, EMBASE, Current Contents Connect, Cochrane library, Google Scholar, 
      Science Direct, and Web of Science. Original data was abstracted from each study 
      and used to calculate an odds ratio (OR) and 95% confidence interval (95% CI). 
      RESULTS: Seven randomised trials comprising 1275 patients met full criteria for 
      analysis. Two open label randomised controlled trials and five double-blind 
      randomised controlled trials were included. Colchicine was useful in reducing the 
      incidence of primary pericarditis (OR: 0.38, 95% CI: 0.22- 0.65) as well as 
      recurrent pericarditis (OR: 0.31, 95% CI: 0.22-0.44). The most common 
      side-effects were related to the gastrointestinal system and no severe adverse 
      events were observed. Colchicine cessation either by patient or physician was 
      similar in both groups (OR: 1.53, 95% CI: 0.86-2.71). CONCLUSION: Colchicine is 
      effective in preventing both primary and recurrent episodes of pericarditis. The 
      number needed to treat for preventing recurrent pericarditis was five. 
      Gastrointestinal side-effects were the most common adverse events.
CI  - Copyright © 2015 Australian and New Zealand Society of Cardiac and Thoracic 
      Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). 
      Published by Elsevier B.V. All rights reserved.
FAU - Raval, Jwalant
AU  - Raval J
AD  - Department of Cardiology, Blacktown Hospital, Sydney, NSW, Australia. Electronic 
      address: jwalant_21@yahoo.com.
FAU - Nagaraja, Vinayak
AU  - Nagaraja V
AD  - Prince of Wales Hospital, Randwick, NSW Australia.
FAU - Eslick, Guy D
AU  - Eslick GD
AD  - The Whiteley-Martin Research Centre, Discipline of Surgery, The University of 
      Sydney, Nepean Hospital, Sydney, NSW, Australia.
FAU - Denniss, A Robert
AU  - Denniss AR
AD  - Department of Cardiology, Blacktown Hospital, Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20150209
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Colchicine/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Pericarditis/*drug therapy
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Colchicine
OT  - Meta-analysis
OT  - Primary pericarditis
OT  - Randomised controlled trials
OT  - Recurrent pericarditis
OT  - Systematic reviews
EDAT- 2015/03/15 06:00
MHDA- 2016/03/11 06:00
CRDT- 2015/03/14 06:00
PHST- 2013/11/18 00:00 [received]
PHST- 2014/08/31 00:00 [revised]
PHST- 2015/01/19 00:00 [accepted]
PHST- 2015/03/14 06:00 [entrez]
PHST- 2015/03/15 06:00 [pubmed]
PHST- 2016/03/11 06:00 [medline]
AID - S1443-9506(15)00048-7 [pii]
AID - 10.1016/j.hlc.2015.01.010 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2015 Jul;24(7):660-6. doi: 10.1016/j.hlc.2015.01.010. Epub 2015 
      Feb 9.

PMID- 3864170
OWN - NLM
STAT- MEDLINE
DCOM- 19851125
LR  - 20191030
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 19
IP  - 3
DP  - 1985 Sep
TI  - Plasma concentrations and anti-platelet effects after low dose acetylsalicylic 
      acid.
PG  - 289-300
AB  - The present study has investigated whether low-dose acetylsalicylic acid (ASA) 
      can inhibit platelet aggregation locally at its site of gastrointestinal 
      absorption without concentrations in the systemic circulation high enough for 
      inhibition of cyclooxygenase. For this purpose platelet aggregation, thromboxane 
      formation as well as ASA plasma concentrations were measured in 8 volunteers 
      before oral intake of 100 mg ASA as well as 20 to 300 minutes thereafter. At each 
      time 5 ml of blood were mixed with 5 ml of blood obtained from a second, 
      untreated volunteer. Aggregation and thromboxane formation were also determined 
      in these mixed blood samples. The same protocol was performed with 4 volunteers 
      after administration of 1500 mg ASA as well as after no drug intake. In a 
      separate experiment the concentration-effect-relationship of ASA was assessed in 
      vitro. One hundred and forty minutes after administration of 100 mg ASA 
      aggregation and thromboxane formation were significantly decreased to 49.4 and 
      4.5% of the initial values, respectively, whereas in the mixed blood sample 
      aggregation was not impaired. Inhibition of thromboxane formation was constantly 
      73% of the inhibition observed in the unmixed sample throughout the study period 
      and thus most probably was caused by dilution of the platelets of the untreated 
      volunteer by the inactivated platelets of the ASA-treated volunteer. These data 
      suggest the absence of pharmacologically active drug concentrations in the 
      peripheral blood. ASA plasma concentration was highest after 40 minutes (2.2 +/- 
      1.6 microgram/ml; n = 5). After the 1500 mg ASA dose platelet function and 
      thromboxane formation decreased to 29.8 and 2.0% of the initial values, 
      respectively. Furthermore, aggregation and thromboxane formation in the mixed 
      blood sample were markedly reduced. Thus, after the high dose of ASA effective 
      plasma concentrations were present in the peripheral circulation. Highest ASA 
      plasma concentrations were 21.1 +/- 8.9 micrograms/ml. IC50 values were 1.00 +/- 
      0.36 and 0.30 +/- 0.05 microgram/ml for aggregation and thromboxane formation in 
      vitro, respectively. It is concluded that low dose ASA can effectively inhibit 
      platelet function without producing pharmacologically active concentrations in 
      the peripheral circulation.
FAU - Rosenkranz, B
AU  - Rosenkranz B
FAU - Frölich, J C
AU  - Frölich JC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane B2/blood
MH  - Time Factors
EDAT- 1985/09/01 00:00
MHDA- 1985/09/01 00:01
CRDT- 1985/09/01 00:00
PHST- 1985/09/01 00:00 [pubmed]
PHST- 1985/09/01 00:01 [medline]
PHST- 1985/09/01 00:00 [entrez]
AID - 10.1016/0262-1746(85)90142-8 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1985 Sep;19(3):289-300. doi: 
      10.1016/0262-1746(85)90142-8.

PMID- 1754994
OWN - NLM
STAT- MEDLINE
DCOM- 19920127
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 63
IP  - 4
DP  - 1991 Aug 15
TI  - Could proteolytic enzyme modulate the interaction platelets/vessel wall in 
      presence of ASA at ultra low doses?
PG  - 419-26
AB  - Acetylsalicylic acid (ASA) is known to act on platelets and vessel walls. At 
      ultra low doses it reverses the inhibitory effects produced by a vascular 
      fragment. Use of papain on normal platelets in vitro led to the appearance of 
      platelet aggregation without collagen induction with a range of 20.25 +/- 28.91%. 
      In the presence of vascular fragments (without ASA), this "spontaneous" 
      aggregation remained but was reduced (13.26 +/- 27.73%). This effect was reversed 
      by ASA treatment (29.41 +/- 24.17%). Reversion of vascular inhibition by ASA was 
      not modified by papain.
FAU - Lalanne, M C
AU  - Lalanne MC
AD  - CJF Inserm 88/13, Laboratoire d'Hématologie, Bordeaux, France.
FAU - de Seze, O
AU  - de Seze O
FAU - Doutremepuich, C
AU  - Doutremepuich C
FAU - Belon, P
AU  - Belon P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Solutions)
RN  - EC 3.4.22.2 (Papain)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Blood Vessels/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - In Vitro Techniques
MH  - Papain/*physiology
MH  - Platelet Aggregation/drug effects
MH  - Solutions
EDAT- 1991/08/15 00:00
MHDA- 1991/08/15 00:01
CRDT- 1991/08/15 00:00
PHST- 1991/08/15 00:00 [pubmed]
PHST- 1991/08/15 00:01 [medline]
PHST- 1991/08/15 00:00 [entrez]
AID - 0049-3848(91)90228-O [pii]
AID - 10.1016/0049-3848(91)90228-o [doi]
PST - ppublish
SO  - Thromb Res. 1991 Aug 15;63(4):419-26. doi: 10.1016/0049-3848(91)90228-o.

PMID- 1290386
OWN - NLM
STAT- MEDLINE
DCOM- 19930322
LR  - 20131121
IS  - 0003-4509 (Print)
IS  - 0003-4509 (Linking)
VI  - 50
IP  - 3
DP  - 1992
TI  - [HPLC used in the validation of simple methods for research of degradation 
      products in essential drug tablets].
PG  - 167-76
AB  - HPLC have been used to validate simple methods to be employed in developing 
      countries (DC) for the quality control of drugs. As the important lack of 
      analytical material in DC, colorimetric methods have been used. These are 
      subjected to visual appreciation of the color intensity. Two essential drugs have 
      been selected: aspirin, hydrochlorothiazide. For each compound, standardization 
      of concentration's degradation product by colorimetry and HPLC have been achieved 
      in proximity of the restricted norms of pharmacopoeia. These results have been 
      applied to tablets exposed to stressed conditions (t(0) = 60 and humidity = 75%). 
      The results obtained by colorimetric method were similar to HPLC's ones.
FAU - Smahi, Z
AU  - Smahi Z
AD  - Centre Universitaire de Mesure et d'Analyse, Laboratoire de Pharmacotechnie 
      Industrielle, Faculté de Pharmacie, Lille.
FAU - Huvenne, J P
AU  - Huvenne JP
FAU - Traisnel, M
AU  - Traisnel M
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Validation par HPLC de méthodes simples pour la recherche de produits de 
      dégradation dans les comprimés de médicaments essentiels.
PL  - France
TA  - Ann Pharm Fr
JT  - Annales pharmaceutiques francaises
JID - 2985176R
RN  - 0 (Tablets)
RN  - 0J48LPH2TH (Hydrochlorothiazide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/analysis/*metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Colorimetry/*methods
MH  - *Developing Countries
MH  - Drug and Narcotic Control
MH  - Humans
MH  - Hydrochlorothiazide/administration & dosage/analysis/*metabolism
MH  - Quality Control
MH  - Tablets
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Ann Pharm Fr. 1992;50(3):167-76.

PMID- 3051530
OWN - NLM
STAT- MEDLINE
DCOM- 19881102
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 19
IP  - 10
DP  - 1988 Oct
TI  - Danish very-low-dose aspirin after carotid endarterectomy trial.
PG  - 1211-5
AB  - The effect of very-low-dose aspirin as an antithrombotic agent was evaluated 
      blindly in 301 patients who had recently undergone carotid endarterectomy. After 
      randomization, 150 patients received aspirin and 151 received placebo. The two 
      groups were comparable with regard to age, sex, blood pressure, previous 
      cerebrovascular events, and smoking habits. The effect of the study medication on 
      platelet aggregation was measured twice in each patient during the first 2 months 
      and at each follow-up visit; the dose was individually adjusted. In 76% of the 
      patients receiving aspirin, 50 mg/day gave satisfactory platelet inhibition, 13% 
      needed 60 mg/day, 8% needed 70 mg/day, and 3% needed 100 mg/day. Platelet 
      aggregation was found to be inhibited in only 1.2% of the measurements in the 
      patients receiving placebo. Observation during treatment averaged 21 months; 
      total intention-to-treat follow-up averaged 25 months. For the combined outcome 
      events of transient ischemic attack, stroke, acute myocardial infarction, and 
      vascular death, aspirin reduced risk by 11% (95% confidence limits: -38% to 48%, 
      p greater than 0.1). Thus, there was no significant effect of very-low-dose 
      aspirin in our trial.
FAU - Boysen, G
AU  - Boysen G
AD  - Department of Neurology, Rigshospitalet, Copenhagen, Denmark.
FAU - Sørensen, P S
AU  - Sørensen PS
FAU - Juhler, M
AU  - Juhler M
FAU - Andersen, A R
AU  - Andersen AR
FAU - Boas, J
AU  - Boas J
FAU - Olsen, J S
AU  - Olsen JS
FAU - Joensen, P
AU  - Joensen P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Carotid Arteries/*surgery
MH  - Clinical Trials as Topic
MH  - *Endarterectomy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Platelet Aggregation/drug effects
MH  - Random Allocation
MH  - Thrombosis/*prevention & control
EDAT- 1988/10/01 00:00
MHDA- 1988/10/01 00:01
CRDT- 1988/10/01 00:00
PHST- 1988/10/01 00:00 [pubmed]
PHST- 1988/10/01 00:01 [medline]
PHST- 1988/10/01 00:00 [entrez]
AID - 10.1161/01.str.19.10.1211 [doi]
PST - ppublish
SO  - Stroke. 1988 Oct;19(10):1211-5. doi: 10.1161/01.str.19.10.1211.

PMID- 2672131
OWN - NLM
STAT- MEDLINE
DCOM- 19890929
LR  - 20131121
IS  - 0889-857X (Print)
IS  - 0889-857X (Linking)
VI  - 15
IP  - 3
DP  - 1989 Aug
TI  - Aspirin and the treatment of rheumatoid arthritis.
PG  - 439-54
AB  - The recent development of other nonsteroidal anti-inflammatory agents (NSAIDs) 
      has challenged the role of aspirin in the initial treatment of rheumatoid 
      arthritis. The ready availability of aspirin as "an over-the-counter" preparation 
      has contributed to its low esteem among both patients and physicians as a truly 
      potent anti-inflammatory agent. But whether these newer, more expensive NSAIDs 
      are more efficacious in the treatment of rheumatoid arthritis than aspirin 
      remains to be proven. Most clinical trials of the newer agents have compared 
      their efficacy against fixed doses of aspirin which were almost always too small 
      to produce optimal anti-inflammatory serum salicylate levels. In our experience, 
      individually tailored doses of aspirin remains the most predictable and 
      consistently effective NSAID available for the initial treatment of rheumatoid 
      arthritis. We also want to make it clear that we almost never rely on aspirin or 
      other NSAIDs to control seropositive rheumatoid arthritis. Their chief advantage 
      is rapidity of action. We do rely on the use of remittive agents to control 
      rheumatoid joint inflammation, in conjunction with aspirin or other NSAID.
FAU - Csuka, M E
AU  - Csuka ME
AD  - Department of Medicine, Medical College of Wisconsin, Milwaukee.
FAU - McCarty, D J
AU  - McCarty DJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Rheum Dis Clin North Am
JT  - Rheumatic diseases clinics of North America
JID - 8708093
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Bleeding Time
MH  - Chemistry, Pharmaceutical
MH  - Digestive System/drug effects
MH  - Drug Hypersensitivity/etiology
MH  - Humans
MH  - Kidney/drug effects
RF  - 105
EDAT- 1989/08/01 00:00
MHDA- 1989/08/01 00:01
CRDT- 1989/08/01 00:00
PHST- 1989/08/01 00:00 [pubmed]
PHST- 1989/08/01 00:01 [medline]
PHST- 1989/08/01 00:00 [entrez]
PST - ppublish
SO  - Rheum Dis Clin North Am. 1989 Aug;15(3):439-54.

PMID- 2327383
OWN - NLM
STAT- MEDLINE
DCOM- 19900511
LR  - 20131121
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 85
IP  - 4
DP  - 1990 Apr
TI  - Overt gastrointestinal bleeding in the course of chronic low-dose aspirin 
      administration for secondary prevention of arterial occlusive disease.
PG  - 408-11
AB  - We describe 13 patients who developed erosive gastritis with overt 
      gastrointestinal bleeding while receiving 75-250 mg nonbuffered aspirin per day 
      for the secondary prevention of cardiac or cerebrovascular events. The bleeding 
      occurred despite good initial tolerance to aspirin for several months or years. 
      All patients were elderly and had severe atherosclerotic cardiovascular disease. 
      Our data suggest that, contrary to common belief, very low doses of nonbuffered 
      aspirin are attendant with clinically apparent gastrointestinal complications.
FAU - Naschitz, J E
AU  - Naschitz JE
AD  - Department of Medicine A, Bnai Zion Medical Center, Haifa, Israel.
FAU - Yeshurun, D
AU  - Yeshurun D
FAU - Odeh, M
AU  - Odeh M
FAU - Bassan, H
AU  - Bassan H
FAU - Rosner, I
AU  - Rosner I
FAU - Stermer, E
AU  - Stermer E
FAU - Levy, N
AU  - Levy N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Gastroenterol. 1991 Sep;86(9):1279-80. PMID: 1882816
MH  - Aged
MH  - Arterial Occlusive Diseases/*prevention & control
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Female
MH  - Gastritis/*chemically induced
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Stomach Ulcer/chemically induced
MH  - Time Factors
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
PST - ppublish
SO  - Am J Gastroenterol. 1990 Apr;85(4):408-11.

PMID- 8140884
OWN - NLM
STAT- MEDLINE
DCOM- 19940428
LR  - 20131121
IS  - 0300-9009 (Print)
IS  - 0300-9009 (Linking)
VI  - 94
IP  - 1
DP  - 1994
TI  - Secondary prevention of stroke: does dipyridamole add to aspirin?
PG  - 24-34
AB  - BACKGROUND AND PURPOSE: The purpose of this paper is to evaluate, in the light of 
      all available evidence, the place of aspirin alone and of aspirin combined with 
      dipyridamole in the secondary prevention of cerebrovascular accidents. METHODS: 
      We performed a meta-analysis of all identified double blind, controlled, studies 
      in secondary prevention of cerebrovascular accidents for the following 
      categories: studies comparing aspirin with placebo; studies comparing aspirin 
      plus dipyridamole with placebo; studies comparing aspirin plus dipyridamole with 
      aspirin alone. An indirect comparison was carried out to compare the results 
      obtained with aspirin alone and those obtained with aspirin combined with 
      dipyridamole. RESULTS: The meta-analysis of trials involving aspirin alone 
      against placebo showed a risk reduction on strokes (17% reduction, p = 0.02), 
      "important vascular events", i.e. a combination of vascular deaths, non-fatal 
      strokes and non-fatal myocardial infarction (18% reduction, p = 0.003). Fatal 
      vascular events (vascular deaths and fatal strokes) did not seem to be reduced at 
      all. The overall mortality was reduced by 10%, but this reduction failed to reach 
      statistical significance (p = 0.23). The meta-analysis of trials involving 
      aspirin combined with dipyridamole showed more important risk reductions on every 
      outcome whether fatal or not. Strokes were reduced by 42% (p < 0.001), fatal 
      strokes by 43% (p = 0.02) and vascular deaths by 24% (p = 0.07, not significant). 
      The overall mortality was reduced by 30% (p = 0.004). Direct comparisons of 
      aspirin with aspirin plus dipyridamole did not indicate differences between the 
      two treatment regimens. However the sample sizes involved in these comparisons 
      were far too small to be informative. Indirect comparisons yielded statistically 
      significant results in favour of the combination in terms of "important vascular 
      events" (p = 0.007), all strokes (p = 0.007) and fatal strokes (p = 0.03). The 
      results were also in favour of the combination but not statistically significant 
      in terms of all deaths (p = 0.10) and vascular deaths (p = 0.08). CONCLUSIONS: 
      Aspirin used alone reduces secondary occurrence of vascular events in 
      cerebrovascular patients. There is no evidence, however, of a reduction of fatal 
      events (vascular deaths and fatal strokes). In contrast, aspirin in combination 
      with dipyridamole reduces non-fatal as well as fatal events. These results as 
      well as the indirect comparisons of the risk reductions suggest that the 
      combination of aspirin with dipyridamole may be superior to aspirin alone; this 
      hypothesis is presently tested in a large randomized trial.
FAU - Lowenthal, A
AU  - Lowenthal A
AD  - Algemeen Ziekenhuis Middelheim, Antwerp.
FAU - Buyse, M
AU  - Buyse M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Acta Neurol Belg
JT  - Acta neurologica Belgica
JID - 0247035
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cerebrovascular Disorders/mortality/*prevention & control
MH  - Dipyridamole/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Randomized Controlled Trials as Topic
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Neurol Belg. 1994;94(1):24-34.

PMID- 7131233
OWN - NLM
STAT- MEDLINE
DCOM- 19821218
LR  - 20190913
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 5
IP  - 7
DP  - 1982 Jul
TI  - Electrophysiological approach to the action of taurine on rat gastric mucosa.
PG  - 495-500
AB  - The effect of taurine on isolated rat gastric mucosa was examined 
      electrophysiologically in order to clarify the mechanism of taurine-induced 
      effect on drug absorption. Although taurine itself had little effect on the 
      electrical parameters, potential difference (PD), short-circuit current (Isc), 
      and tissue electrical resistance (R), of the gastric mucosa, sodium lauryl 
      sulfate, an anionic surfactant, was shown to reduce these parameters remarkably. 
      On the other hand, when aspirin was present, taurine showed different effects on 
      the gastric mucosa depending on the concentrations of aspirin. Taurine decreased 
      Isc significantly in the presence of aspirin at low concentration (1 mM), which 
      has in itself no influence on the electric parameters. In contrast, aspirin at 
      higher concentration (10 mM) was shown to act as barrier breaker of the gastric 
      mucosa resulting in a marked decline of PD and Isc. When taurine was added, 
      however, these parameters were reasonably recovered. It seems to be likely that 
      taurine acts as a protector against the aspirin-induced damage in the gastric 
      mucosa.
FAU - Kimura, T
AU  - Kimura T
FAU - Yamashita, S
AU  - Yamashita S
FAU - Kim, K S
AU  - Kim KS
FAU - Sezaki, H
AU  - Sezaki H
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 1EQV5MLY3D (Taurine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Animals
MH  - Aspirin/metabolism/pharmacology
MH  - Electrophysiology
MH  - Gastric Mucosa/*drug effects/physiology
MH  - In Vitro Techniques
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Taurine/*pharmacology
EDAT- 1982/07/01 00:00
MHDA- 1982/07/01 00:01
CRDT- 1982/07/01 00:00
PHST- 1982/07/01 00:00 [pubmed]
PHST- 1982/07/01 00:01 [medline]
PHST- 1982/07/01 00:00 [entrez]
AID - 10.1248/bpb1978.5.495 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1982 Jul;5(7):495-500. doi: 10.1248/bpb1978.5.495.

PMID- 11484519
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20191025
IS  - 0284-4311 (Print)
IS  - 0284-4311 (Linking)
VI  - 35
IP  - 2
DP  - 2001 Jun
TI  - Effect of high dose and low dose aspirin on survival of random pattern flaps in 
      rats.
PG  - 117-21
AB  - This paper studies which of the physiological effects of aspirin is responsible 
      for increasing the survival of random flaps in rats, found in an earlier 
      experiment. We wished to confirm that the antiaggregating--antithrombotic effect 
      was responsible for the increased survival of flaps without microvascular 
      anastomosis. Three groups of rats with standardised random pattern flaps were 
      used. The first two were given aspirin 200 mg/kg (high dose, n = 27) or 40 mg/kg 
      (low dose, n = 21) and the third (n = 28) acted as controls. The beneficial 
      effects of aspirin were restricted to the high dose group. Since the low dose 
      group also showed antiaggregation of platelets, but without the anti-inflammatory 
      or vasodilatory effects, the results indicate that the antiaggregating effect 
      alone was not responsible for the increased survival of the flaps.
FAU - Shalom, A
AU  - Shalom A
AD  - Department of Plastic Surgery, Assaf Harofeh Medical Center, Zerifin, Israel.
FAU - Westreich, M
AU  - Westreich M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Plast Reconstr Surg Hand Surg
JT  - Scandinavian journal of plastic and reconstructive surgery and hand surgery
JID - 8707869
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Graft Survival/*drug effects
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Rats
MH  - Rats, Wistar
MH  - Surgical Flaps
EDAT- 2001/08/04 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/08/04 10:00
PHST- 2001/08/04 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/08/04 10:00 [entrez]
AID - 10.1080/028443101300165237 [doi]
PST - ppublish
SO  - Scand J Plast Reconstr Surg Hand Surg. 2001 Jun;35(2):117-21. doi: 
      10.1080/028443101300165237.

PMID- 997151
OWN - NLM
STAT- MEDLINE
DCOM- 19770128
LR  - 20131121
IS  - 0042-4625 (Print)
IS  - 0042-4625 (Linking)
VI  - 117
IP  - 9
DP  - 1976 Sep
TI  - [Role of drugs with disaggregative effect in the prevention of thrombosis in 
      reconstructive operations on the veins of the limbs].
PG  - 9-13
AB  - With the aim of prophylaxis of early postoperative thrombosis in reparative 
      operations on veins of the lower extremities acetyl salicylic acid (aspirin) was 
      used. Diminishing of adhesion and aggregation of thrombocytes, a reduced 
      fibrinase activity and lessening of clot density were noted.
FAU - Klement, A A
AU  - Klement AA
FAU - Khanina, T M
AU  - Khanina TM
FAU - Kotovshchikova, M A
AU  - Kotovshchikova MA
FAU - Osipov, S N
AU  - Osipov SN
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - O roli preparatov dezagregiruiushchego deĭstviia v preduprezhdenii trombozov pri 
      rekonstruktivnykh operatsiiakh na venakh konechnostei.
PL  - Russia (Federation)
TA  - Vestn Khir Im I I Grek
JT  - Vestnik khirurgii imeni I. I. Grekova
JID - 0411377
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Humans
MH  - Leg/blood supply
MH  - Platelet Aggregation/*drug effects
MH  - Postoperative Complications/*prevention & control
MH  - Thrombophlebitis/*prevention & control
MH  - Varicose Veins/surgery
MH  - Venous Insufficiency/surgery
EDAT- 1976/09/01 00:00
MHDA- 1976/09/01 00:01
CRDT- 1976/09/01 00:00
PHST- 1976/09/01 00:00 [pubmed]
PHST- 1976/09/01 00:01 [medline]
PHST- 1976/09/01 00:00 [entrez]
PST - ppublish
SO  - Vestn Khir Im I I Grek. 1976 Sep;117(9):9-13.

PMID- 8645878
OWN - NLM
STAT- MEDLINE
DCOM- 19960723
LR  - 20191101
IS  - 1056-8719 (Print)
IS  - 1056-8719 (Linking)
VI  - 35
IP  - 1
DP  - 1996 Feb
TI  - A ferret model of electrical-induction of arterial thrombosis that is sensitive 
      to aspirin.
PG  - 3-10
AB  - An experimental model of acute thrombosis was developed in pentobarbital- 
      anesthetized ferrets. A 10-min anodal electrical stimulation of 1 mA was 
      delivered to the external surface of the carotid artery while measuring carotid 
      blood flow (CBF). This produced an occlusive thrombus in all vehicle-treated 
      ferrets within 41 +/- 3 min with an average weight of 8 +/- 1 mg (n = 7). These 
      thrombi were enriched in both platelets and fibrin and were adherent at the site 
      of transmural vascular injury as determined by light and electron microscopy. To 
      determine the model's sensitivity to antiplatelet drugs, aspirin or a thromboxane 
      (TxA2) receptor antagonist (ifetroban) were administered 15 min before electrical 
      stimulation. Thrombus weight was reduced 58% by aspirin (10 mg/kg, i.v.) and 74% 
      by ifetroban (1 mg/kg + 1 mg/kg per hr, i.v.). Both drugs also improved CBF and 
      decreased vascular occlusion. Ferrets were more sensitive than rats to aspirin's 
      inhibition of collagen-induced platelet aggregation as determined ex vivo in 
      whole blood. Separate in vitro platelet aggregation studies revealed species 
      differences in reactivity to U-46619 (TxA2 receptor agonist) and collagen in the 
      order of human > ferret > rat, with relatively lesser variations in ADP 
      responses. These studies identify the ferret as a useful species for evaluating 
      antithrombotic drugs in a model in which aspirin is efficacious.
FAU - Schumacher, W A
AU  - Schumacher WA
AD  - Department of Pharmacology, Bristol-Myers Squibb Research Institute, Princeton, 
      New Jersey, USA.
FAU - Steinbacher, T E
AU  - Steinbacher TE
FAU - Megill, J R
AU  - Megill JR
FAU - Durham, S K
AU  - Durham SK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Toxicol Methods
JT  - Journal of pharmacological and toxicological methods
JID - 9206091
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Oxazoles)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prostaglandin Endoperoxides, Synthetic)
RN  - 0 (Vasoconstrictor Agents)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 76898-47-0 (15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid)
RN  - 9001-31-4 (Fibrin)
RN  - 9007-34-5 (Collagen)
RN  - E833KT807K (ifetroban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Blood Platelets/cytology
MH  - Bridged Bicyclo Compounds, Heterocyclic/administration & 
      dosage/pharmacology/therapeutic use
MH  - Carotid Arteries/drug effects/ultrastructure
MH  - Carotid Artery Injuries
MH  - Collagen/toxicity
MH  - Disease Models, Animal
MH  - Electric Stimulation/adverse effects
MH  - Ferrets
MH  - Fibrin/metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Microscopy, Electron
MH  - Microscopy, Electron, Scanning
MH  - Oxazoles/administration & dosage/pharmacology/therapeutic use
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Prostaglandin Endoperoxides, Synthetic/pharmacology
MH  - Prothrombin Time
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/drug effects
MH  - Species Specificity
MH  - Thrombosis/*drug therapy/physiopathology
MH  - Thromboxane A2/analogs & derivatives/pharmacology
MH  - Vasoconstrictor Agents/pharmacology
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - 1056-8719(95)00099-2 [pii]
AID - 10.1016/1056-8719(95)00099-2 [doi]
PST - ppublish
SO  - J Pharmacol Toxicol Methods. 1996 Feb;35(1):3-10. doi: 
      10.1016/1056-8719(95)00099-2.

PMID- 21873632
OWN - NLM
STAT- MEDLINE
DCOM- 20120104
LR  - 20220316
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 107
IP  - 6
DP  - 2011 Dec
TI  - Impact of preoperative maintenance or interruption of aspirin on thrombotic and 
      bleeding events after elective non-cardiac surgery: the multicentre, randomized, 
      blinded, placebo-controlled, STRATAGEM trial.
PG  - 899-910
LID - 10.1093/bja/aer274 [doi]
AB  - BACKGROUND: Patients receiving anti-platelet agents for secondary cardiovascular 
      prevention frequently require non-cardiac surgery. A substantial proportion of 
      these patients have their anti-platelet drug discontinued before operation; 
      however, there is uncertainty about the impact of this practice. The aim of this 
      study was to compare the effect of maintenance or interruption of aspirin before 
      surgery, in terms of major thrombotic and bleeding events. METHODS: Patients 
      treated with anti-platelet agents for secondary prevention and undergoing 
      intermediate- or high-risk non-cardiac surgery were included in this multicentre, 
      randomized, placebo-controlled, trial. We substituted non-aspirin anti-platelets 
      with aspirin (75 mg daily) or placebo starting 10 days before surgery. The 
      primary outcome was a composite score evaluating both major thrombotic and 
      bleeding adverse events occurring within the first 30 postoperative days weighted 
      by their severity (weights were established a priori using a Delphi consensus 
      process). Analyses followed the intention-to-treat principle. RESULTS: We 
      randomized 291 patients (n=145, aspirin group, and n=146, placebo group). The 
      most frequent surgical procedures were orthopaedic surgery (52.2%), abdominal 
      surgery (20.6%), and urologic surgery (15.5%). No significant difference was 
      observed neither in the primary outcome score [mean values (SD)=0.67 (2.05) in 
      the aspirin group vs 0.65 (2.04) in the placebo group, P=0.94] nor at day 30 in 
      the number of major complications between groups. CONCLUSIONS: In these at-risk 
      patients undergoing elective non-cardiac surgery, we did not find any difference 
      in terms of occurrence of major thrombotic or bleeding events between 
      preoperative maintenance or interruption of aspirin.
FAU - Mantz, J
AU  - Mantz J
AD  - APHP, Hôpital Beaujon, Service d'Anesthésie Réanimation et SMUR, Clichy F-92110, 
      France. jean.mantz@bjn.aphp.fr
FAU - Samama, C M
AU  - Samama CM
FAU - Tubach, F
AU  - Tubach F
FAU - Devereaux, P J
AU  - Devereaux PJ
FAU - Collet, J-P
AU  - Collet JP
FAU - Albaladejo, P
AU  - Albaladejo P
FAU - Cholley, B
AU  - Cholley B
FAU - Nizard, R
AU  - Nizard R
FAU - Barré, J
AU  - Barré J
FAU - Piriou, V
AU  - Piriou V
FAU - Poirier, N
AU  - Poirier N
FAU - Mignon, A
AU  - Mignon A
FAU - Schlumberger, S
AU  - Schlumberger S
FAU - Longrois, D
AU  - Longrois D
FAU - Aubrun, F
AU  - Aubrun F
FAU - Farèse, M E
AU  - Farèse ME
FAU - Ravaud, P
AU  - Ravaud P
FAU - Steg, P G
AU  - Steg PG
CN  - Stratagem Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT00190307
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110827
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br J Anaesth. 2012 Apr;108(4):699; author reply 699. PMID: 22419627
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Elective Surgical Procedures
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Hemorrhage/*chemically induced
MH  - *Preoperative Care
MH  - Thrombosis/*prevention & control
FIR - Granry
IR  - Granry
FIR - Denantes
IR  - Denantes
FIR - Dahmani
IR  - Dahmani
FIR - Mantz
IR  - Mantz
FIR - Pilly-Floury
IR  - Pilly-Floury
FIR - Samain
IR  - Samain
FIR - Ferrier
IR  - Ferrier
FIR - Bazin
IR  - Bazin
FIR - Ozier
IR  - Ozier
FIR - Marty
IR  - Marty
FIR - Fischler
IR  - Fischler
FIR - Bonnet
IR  - Bonnet
FIR - Bourgain
IR  - Bourgain
FIR - Payen, D
IR  - Payen D
FIR - Lefebvre
IR  - Lefebvre
FIR - Vallet
IR  - Vallet
FIR - Pierre
IR  - Pierre
FIR - Lehot
IR  - Lehot
FIR - Capel
IR  - Capel
FIR - Jeannes
IR  - Jeannes
FIR - Ripart
IR  - Ripart
FIR - Malinovsky
IR  - Malinovsky
FIR - Dessieux
IR  - Dessieux
FIR - Ecoffey
IR  - Ecoffey
FIR - Becq
IR  - Becq
FIR - Jacob
IR  - Jacob
FIR - Eurin
IR  - Eurin
FIR - Le Hétêt
IR  - Le Hétêt
FIR - Marret
IR  - Marret
FIR - Bonnet
IR  - Bonnet
EDAT- 2011/08/30 06:00
MHDA- 2012/01/05 06:00
CRDT- 2011/08/30 06:00
PHST- 2011/08/30 06:00 [entrez]
PHST- 2011/08/30 06:00 [pubmed]
PHST- 2012/01/05 06:00 [medline]
AID - S0007-0912(17)32567-9 [pii]
AID - 10.1093/bja/aer274 [doi]
PST - ppublish
SO  - Br J Anaesth. 2011 Dec;107(6):899-910. doi: 10.1093/bja/aer274. Epub 2011 Aug 27.

PMID- 7185512
OWN - NLM
STAT- MEDLINE
DCOM- 19831008
LR  - 20131121
IS  - 0278-2677 (Print)
IS  - 0278-2677 (Linking)
VI  - 1
IP  - 2
DP  - 1982 Mar-Apr
TI  - Evaluation of activated charcoal and magnesium citrate in the prevention of 
      aspirin absorption in humans.
PG  - 154-6
AB  - Inhibition of aspirin absorption by activated charcoal and magnesium citrate 
      solution was compared with the inhibition produced by activated charcoal alone. 
      Following an overnight fast, eight healthy male volunteers were given three 
      325-mg aspirin tablets under four study regimens: (1) water 360 ml; (2) water 300 
      ml and activated charcoal 10 g in water 60 ml; (3) water 105 ml, activated 
      charcoal 10 g in water 60 ml, and magnesium citrate solution 200 ml; and (4) same 
      as (3) except that administration of magnesium citrate was delayed 30 minutes. At 
      least one week separated each regimen. Urine samples were collected at 0, 2, 4, 
      8, 12, 24, 36, and 48 hours, and percent of the aspirin dose excreted in the 
      urine was determined. The data were analyzed using analysis of variance for 
      Latin-square design and Newman-Keuls test. The salicylate excreted with regimens 
      2, 3, and 4 was each significantly less compared with that excreted following 
      regimen 1 (p less than 0.001). Salicylate excretion percentages when magnesium 
      citrate was given with activated charcoal in regimens 3 and 4 were not 
      significantly different from each other or the salicylate excretion with 
      activated charcoal alone (p greater than 0.05). These findings apply only to the 
      dose of aspirin tested, and it is possible that magnesium citrate and activated 
      charcoal may decrease aspirin absorption to a greater extent when aspirin is 
      taken in overdose. Hence, it is recommended that this study not be used to 
      justify discontinuing the combined use of magnesium citrate and activated 
      charcoal to treat aspirin overdose.
FAU - Easom, J M
AU  - Easom JM
FAU - Caraccio, T R
AU  - Caraccio TR
FAU - Lovejoy, F H Jr
AU  - Lovejoy FH Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharm
JT  - Clinical pharmacy
JID - 8207437
RN  - 0 (Citrates)
RN  - 16291-96-6 (Charcoal)
RN  - 2968PHW8QP (Citric Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*metabolism/urine
MH  - Charcoal/*pharmacology
MH  - Citrates/*pharmacology
MH  - Citric Acid
MH  - Humans
MH  - Intestinal Absorption/*drug effects
MH  - Male
MH  - Time Factors
EDAT- 1982/03/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1982/03/01 00:00
PHST- 1982/03/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1982/03/01 00:00 [entrez]
PST - ppublish
SO  - Clin Pharm. 1982 Mar-Apr;1(2):154-6.

PMID- 15974885
OWN - NLM
STAT- MEDLINE
DCOM- 20051026
LR  - 20191109
IS  - 1568-0169 (Print)
IS  - 1568-0169 (Linking)
VI  - 3
IP  - 3
DP  - 2005 Jul
TI  - Aspirin and clopidogrel: a sweeping combination in cardiology.
PG  - 203-19
AB  - Platelets play a pivotal role in the pathogenesis of atherothrombosis, believed 
      to be integrally involved in both the development and progression of 
      atherosclerotic heart disease, as well as in its acute thrombotic complications. 
      Antiplatelet therapy constitutes the cornerstone in the management of patients 
      with acute coronary syndromes and generally high-risk patients with 
      atherothrombosis. Until recently, long-term antiplatelet therapy for the 
      treatment and prevention of the complications of atherothrombotic disease was 
      traditionally limited to aspirin. The availability of the thienopyridines, in 
      particular clopidogrel, represents an important addition to the physician's 
      armamentarium. Clopidogrel is currently one of the most widely prescribed drugs 
      for the treatment of symptomatic coronary artery disease. Aspirin and clopidogrel 
      interfere with platelet activation in complementary, but separate pathways. 
      Aspirin irreversibly inhibits cyclooxygenase, thus preventing the production of 
      thromboxane A(2), which is a prothrombotic and vasoconstrictive substance. 
      Clopidogrel, a newer thienopyridine which has largely supplanted ticlopidine due 
      to a more favorable safety profile, irreversibly prevents platelet activation by 
      blocking one of the three known adenosine 5'-diphosphate (ADP) receptors (the 
      P2Y(12) receptor) on the platelet surface, thus interfering with platelet 
      activation, degranulation and aggregation. Both these antiplatelet agents have a 
      potent protective effect against adverse vascular events, but the combination of 
      these two agents has an even stronger antiplatelet effect translating into 
      superior antithrombotic protection in coronary, cerebral or peripheral arterial 
      disease, without an inordinate increase in bleeding complications. A number of 
      seminal clinical trials have demonstrated and confirmed the incremental benefit 
      and efficacy of the combination of clopidogrel and aspirin therapy above and 
      beyond that of aspirin alone, with multiple other important large-scale clinical 
      trials currently ongoing. Newer data are being accumulated from studies where 
      indications for the use of clopidogrel and aspirin continue to expand into other 
      patient groups, rendering this dual antiplatelet drug therapy a sweeping 
      combination in Cardiology. However, important issues remain to be further and 
      more thoroughly explored about the benefit of this antiplatelet drug combination 
      in these other patient groups, such as in patients with heart failure, where 
      preliminary data indicate a favorable effect on thrombotic vascular events, in 
      patients with atrial fibrillation, where there is hope that this combination may 
      replace or be an alternative treatment modality to coumadin in certain 
      subpopulations, in patients undergoing demanding catheter ablation procedures, 
      where data point to a protective effect from thromboembolic events. Another 
      pertaining issue to be further investigated is the occurrence of drug-resistance 
      observed in some patients for both these antithrombotic agents. This article is a 
      comprehensive review of all these data and the landmark trials on the two 
      antiplatelet agents, the issues involved and the current recommendations for 
      their use in patients with atherosclerotic heart disease and other cardiovascular 
      disorders and procedures.
FAU - Manolis, Antonis S
AU  - Manolis AS
AD  - First Department of Cardiology, Evagelismos General Hospital of Athens, Greece. 
      asmanol@otenet.gr
FAU - Tzeis, Stylianos
AU  - Tzeis S
FAU - Andrikopoulos, George
AU  - Andrikopoulos G
FAU - Koulouris, Spyros
AU  - Koulouris S
FAU - Melita, Helen
AU  - Melita H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem Cardiovasc Hematol Agents
JT  - Current medicinal chemistry. Cardiovascular and hematological agents
JID - 101157213
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use
MH  - Cardiology
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Clopidogrel
MH  - Humans
MH  - Ticlopidine/adverse effects/*analogs & 
      derivatives/pharmacokinetics/pharmacology/therapeutic use
RF  - 201
EDAT- 2005/06/25 09:00
MHDA- 2005/10/27 09:00
CRDT- 2005/06/25 09:00
PHST- 2005/06/25 09:00 [pubmed]
PHST- 2005/10/27 09:00 [medline]
PHST- 2005/06/25 09:00 [entrez]
AID - 10.2174/1568016054368188 [doi]
PST - ppublish
SO  - Curr Med Chem Cardiovasc Hematol Agents. 2005 Jul;3(3):203-19. doi: 
      10.2174/1568016054368188.

PMID- 8038469
OWN - NLM
STAT- MEDLINE
DCOM- 19940825
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 28
IP  - 4
DP  - 1994 Apr
TI  - Suicide attempt by means of aspirin enema.
PG  - 467-9
AB  - OBJECTIVE: To report a suicide attempt with an aspirin enema. CASE SUMMARY: A 
      patient presented to the emergency room after self-administering, in enema form, 
      approximately 700 aspirin tablets dissolved in water. Over the next 12 hours the 
      patient became progressively acidemic with eventual cardiac arrest and subsequent 
      chronic hypoxic encephalopathy. DISCUSSION: This patient's poor outcome was the 
      result of retained aspirin products in the rectal vault combined with the failure 
      to recognize the delayed absorption properties of rectally administered aspirin. 
      CONCLUSIONS: In rectal aspirin overdoses, aspirin absorption from the rectum may 
      occur over a long period of time. It is important to remove as much aspirin from 
      the rectum as possible and to closely monitor these patients so that appropriate 
      therapy may be started quickly. Activated charcoal given both in enema and oral 
      form may help decrease aspirin absorption. Hemodialysis should be available and 
      performed without delay should the patient require it.
FAU - Watson, J E
AU  - Watson JE
AD  - Department of Internal Medicine, Medical University of South Carolina, Charleston 
      29425.
FAU - Tagupa, E T
AU  - Tagupa ET
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Rectal
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*poisoning
MH  - Coma/chemically induced
MH  - *Enema
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Rectum/physiopathology
MH  - *Suicide, Attempted
MH  - Tachycardia, Supraventricular/chemically induced
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
AID - 10.1177/106002809402800409 [doi]
PST - ppublish
SO  - Ann Pharmacother. 1994 Apr;28(4):467-9. doi: 10.1177/106002809402800409.

PMID- 314764
OWN - NLM
STAT- MEDLINE
DCOM- 19791129
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 91
IP  - 4
DP  - 1979 Oct
TI  - Incidence of gastric lesions in patients with rheumatic disease on chronic 
      aspirin therapy.
PG  - 517-20
AB  - Endoscopy was done in 82 patients with rheumatic disease who were receiving 
      chronic aspirin therapy. Fifty-eight patients were taking at least eight aspirin 
      tablets daily for 3 or more months; 24 patients were taking, in addition to the 
      aspirin, a maximum of one other antiinflammatory, nonsteroidal medication. 
      Endoscopy in 45 normal subjects not taking aspirin showed no ulcers or erosions 
      and a 4% incidence of gastric erythema. In the 82 patients with rheumatic 
      disease, 14 (17%) had gastric ulcers, 33 (40%) had gastric erosions, and 62 (76%) 
      had gastric erythema. Regular aspirin and buffered aspirin users had an ulcer 
      incidence of 23% and 31% respectively, compared with a 6% incidence in 
      enteric-coated aspirin users (P less than 0.05). One third of all patients with 
      gastric ulcer had no gastrointestinal symptoms. Patients taking chronic aspirin 
      therapy for rheumatic diseases have a higher than suspected incidence of gastric 
      ulcer and erosions. Gastric ulcer may exist without symptoms in such patients.
FAU - Silvoso, G R
AU  - Silvoso GR
FAU - Ivey, K J
AU  - Ivey KJ
FAU - Butt, J H
AU  - Butt JH
FAU - Lockard, O O
AU  - Lockard OO
FAU - Holt, S D
AU  - Holt SD
FAU - Sisk, C
AU  - Sisk C
FAU - Baskin, W N
AU  - Baskin WN
FAU - Mackercher, P A
AU  - Mackercher PA
FAU - Hewett, J
AU  - Hewett J
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Buffers)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects/blood
MH  - Buffers
MH  - Female
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rheumatic Diseases/blood/*drug therapy
MH  - Stomach Diseases/*chemically induced/diagnosis
MH  - Stomach Ulcer/chemically induced
MH  - Tablets, Enteric-Coated
EDAT- 1979/10/01 00:00
MHDA- 1979/10/01 00:01
CRDT- 1979/10/01 00:00
PHST- 1979/10/01 00:00 [pubmed]
PHST- 1979/10/01 00:01 [medline]
PHST- 1979/10/01 00:00 [entrez]
AID - 10.7326/0003-4819-91-4-517 [doi]
PST - ppublish
SO  - Ann Intern Med. 1979 Oct;91(4):517-20. doi: 10.7326/0003-4819-91-4-517.

PMID- 6716908
OWN - NLM
STAT- MEDLINE
DCOM- 19840608
LR  - 20190711
IS  - 0023-2173 (Print)
IS  - 0023-2173 (Linking)
VI  - 62
IP  - 5
DP  - 1984 Mar 1
TI  - [Effects of acetylsalicylic acid on partial functions of human thrombocytes are 
      not inhibited in vivo by salicylic acid].
PG  - 225-30
AB  - Acetylsalicylic acid inhibits platelet function. In plasma acetylsalicylic acid 
      is rapidly deacetylated to salicylic acid which is slowly eliminated and has no 
      direct inhibitory effects on platelet function. However, salicylic acid prevents 
      the inhibition by acetylsalicylic acid of collagen-induced aggregation of human 
      thrombocytes in vitro. It was suggested that salicylic acid might inhibit the 
      antiplatelet effects of acetylsalicylic acid in vivo and therefore low-dose 
      acetylsalicylic acid would be more effective for antithrombotic therapy. A 500-mg 
      tablet of acetylsalicylic acid applied 90 min after oral administration of 500 mg 
      salicylic acid to six healthy male volunteers led to the same inhibition of 
      collagen-induced platelet aggregation and tissue-extract-induced platelet 
      stimulation as 500 mg acetylsalicylic acid alone. These results cannot give 
      additional support to the recommendation of low-dose acetylsalicylic acid in the 
      prevention of thromboembolic disease.
FAU - Simrock, R
AU  - Simrock R
FAU - Lischke, V
AU  - Lischke V
FAU - Missalla, A
AU  - Missalla A
FAU - Schwidtal, P
AU  - Schwidtal P
FAU - Breddin, H K
AU  - Breddin HK
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Die Acetylsalicylsäurewirkung auf Partialfunktionen menschlicher Thrombozyten 
      wird in vivo durch Salicylsäure nicht gehemmt.
PL  - Germany
TA  - Klin Wochenschr
JT  - Klinische Wochenschrift
JID - 2985205R
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*antagonists & inhibitors/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Salicylates/administration & dosage/*pharmacology
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
AID - 10.1007/BF01721048 [doi]
PST - ppublish
SO  - Klin Wochenschr. 1984 Mar 1;62(5):225-30. doi: 10.1007/BF01721048.

PMID- 22201268
OWN - NLM
STAT- MEDLINE
DCOM- 20121107
LR  - 20220331
IS  - 1557-900X (Electronic)
IS  - 0892-7790 (Linking)
VI  - 26
IP  - 7
DP  - 2012 Jul
TI  - Preoperative aspirin is safe in patients undergoing urologic robot-assisted 
      surgery.
PG  - 852-6
LID - 10.1089/end.2011.0491 [doi]
AB  - PURPOSE: To determine the impact of preoperative aspirin on bleeding and other 
      complications in patients undergoing robot-assisted radical prostatectomy and 
      nephrectomy. PATIENTS AND METHODS: We identified all patients who underwent 
      robot-assisted radical prostatectomy or robot-assisted nephrectomy by a single 
      surgeon between August 2008 and August 2010. We compared patients in whom aspirin 
      had not been administered for 7 days with those who received aspirin the morning 
      of surgery. Patients on other antiplatelet agents or anticoagulants were 
      excluded. RESULTS: Forty-four patients underwent prostatectomy without recent 
      aspirin, and 51 received preoperative aspirin. There were no significant 
      differences between the two groups in terms of age, body mass index, American 
      Society of Anesthesiologists score, prostate-specific antigen level, or highest 
      Gleason score. Operative time (182 vs 174 min, P=0.19), median blood loss (175 vs 
      100 mL, P=0.12), and duration of hospital stay (1 vs 1 day, P=0.08) were similar 
      between the two groups, respectively. No patient received a transfusion. Three 
      patients who had not received aspirin and one who had were readmitted within 30 
      days. In the nephrectomy cohort, 12 patients had not received aspirin and 14 had. 
      There were no differences in median blood loss (65 vs 50 mL, P=0.96), median 
      operative time (176 vs 140 min, P=0.14), or median hospital stay (2 vs 2 days, 
      P=0.74). No patient received a transfusion. CONCLUSIONS: The administration of 
      aspirin to patients undergoing robot-assisted radical prostatectomy and 
      nephrectomy appears to be safe. The risk of cardiovascular complications 
      resulting from stopping aspirin may exceed the risk of perioperative bleeding and 
      associated complications.
FAU - Parikh, Ankur
AU  - Parikh A
AD  - Department of Urology, Geisinger Medical Center, Danville, Pennsylvania, USA. 
      amparikh@geisinger.edu
FAU - Toepfer, Nicholas
AU  - Toepfer N
FAU - Baylor, Kelly
AU  - Baylor K
FAU - Henry, Yvette
AU  - Henry Y
FAU - Berger, Peter
AU  - Berger P
FAU - Rukstalis, Daniel
AU  - Rukstalis D
LA  - eng
PT  - Journal Article
DEP - 20120405
PL  - United States
TA  - J Endourol
JT  - Journal of endourology
JID - 8807503
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nephrectomy
MH  - *Preoperative Care
MH  - Prostate/surgery
MH  - Robotics/*methods
MH  - Urologic Surgical Procedures/*methods
EDAT- 2011/12/29 06:00
MHDA- 2012/11/08 06:00
CRDT- 2011/12/29 06:00
PHST- 2011/12/29 06:00 [entrez]
PHST- 2011/12/29 06:00 [pubmed]
PHST- 2012/11/08 06:00 [medline]
AID - 10.1089/end.2011.0491 [doi]
PST - ppublish
SO  - J Endourol. 2012 Jul;26(7):852-6. doi: 10.1089/end.2011.0491. Epub 2012 Apr 5.

PMID- 20956485
OWN - NLM
STAT- MEDLINE
DCOM- 20101108
LR  - 20131121
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 96
IP  - 21
DP  - 2010 Nov
TI  - Dual antiplatelet therapy in cardiovascular disease: does aspirin increase 
      clinical risk in the presence of potent P2Y12 receptor antagonists?
PG  - 1693-4
LID - 10.1136/hrt.2010.205724 [doi]
AB  - Aspirin is now widely accepted as the first-line antithrombotic platelet therapy 
      for at-risk individuals. During the last decade or so it has also become 
      established that co-administering antagonists of the ADP receptor P2Y(12) with 
      aspirin further reduces the risk of acute thrombotic events. By the nature of its 
      evolution, this therapeutic approach assumes that P2Y(12) receptor antagonists 
      will be added to aspirin, and this therefore dominates the design of clinical 
      trials. This strategy has resulted in the generation of a large body of clinical 
      evidence showing the benefit of aspirin plus P2Y(12) receptor antagonists, 
      largely from studies with clopidogrel and more recently from those with prasugrel 
      and ticagrelor, but with obvious limitations in terms of residual ischaemic event 
      rates and bleeding complications. It is our hypothesis, however, that when 
      administered in the presence of potent P2Y(12) receptor antagonists, aspirin 
      could actually increase total cardiovascular risk, although this has never been 
      tested in large outcome studies. Clearly, this potentially negative interaction 
      could be of relevance to millions of patients.
FAU - Warner, Timothy D
AU  - Warner TD
AD  - The William Harvey Research Institute, Barts and the London School of Medicine 
      and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 
      6BQ, UK. t.d.warner@qmul.ac.uk
FAU - Armstrong, Paul C J
AU  - Armstrong PC
FAU - Curzen, Nicholas P
AU  - Curzen NP
FAU - Mitchell, Jane A
AU  - Mitchell JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (P2RY12 protein, human)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2 Receptor Antagonists)
RN  - 0 (Receptors, Purinergic P2Y12)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Heart. 2011 Feb;97(3):263-4; author reply 264. PMID: 21189314
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*chemically induced/prevention & control
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - *Purinergic P2 Receptor Antagonists
MH  - Receptors, Purinergic P2Y12
EDAT- 2010/10/20 06:00
MHDA- 2010/11/09 06:00
CRDT- 2010/10/20 06:00
PHST- 2010/10/20 06:00 [entrez]
PHST- 2010/10/20 06:00 [pubmed]
PHST- 2010/11/09 06:00 [medline]
AID - 96/21/1693 [pii]
AID - 10.1136/hrt.2010.205724 [doi]
PST - ppublish
SO  - Heart. 2010 Nov;96(21):1693-4. doi: 10.1136/hrt.2010.205724.

PMID- 22491884
OWN - NLM
STAT- MEDLINE
DCOM- 20120820
LR  - 20211021
IS  - 1433-0458 (Electronic)
IS  - 0017-6192 (Linking)
VI  - 60
IP  - 4
DP  - 2012 Apr
TI  - [Aspirin desensitization: therapy options in patients with aspirin-exacerbated 
      respiratory disease].
PG  - 369-83
LID - 10.1007/s00106-011-2444-3 [doi]
AB  - Aspirin desensitization has established itself as an additional therapy option in 
      the treatment of aspirin- exacerbated respiratory disease, recurrent chronic 
      rhinosinusitis and nasal polyps. Inpatient treatment is strongly recommended due 
      to the risk of life-threatening side effects. In addition, the necessary 
      requirements, indications and contraindications should be carefully considered 
      from a medicolegal perspective. A maintenance dose of 300 (-500) mg ASS is 
      currently recommended. Indications include persisting symptoms despite intensive 
      medical care and/or recurrent nasal polyps, leading to recurrent sinus operations 
      and/or the need to take systemic corticosteroids in order to control nasal 
      symptoms or asthma. If ASS intake is interrupted for more than 48 h, aspirin 
      desensitization should be resumed to prevent renewed intolerance reactions.
FAU - Weber, R
AU  - Weber R
AD  - Nasennebenhöhlen- und Schädelbasischirurgie, Traumatologie, HNO-Klinik, 
      Städtisches Klinikum Karlsruhe, Moltkestr. 90, 76133, Karlsruhe, Deutschland. 
      rainerweber@rainerweber.de
FAU - Trautmann, A
AU  - Trautmann A
FAU - Randerath, W
AU  - Randerath W
FAU - Heppt, W
AU  - Heppt W
FAU - Hosemann, W
AU  - Hosemann W
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - ASS-Toleranzinduktion: Therapieoption bei Patienten mit analgetikainduzierter 
      Erkrankung der Atemwege.
PL  - Germany
TA  - HNO
JT  - HNO
JID - 2985099R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*etiology/*prevention & control
MH  - Humans
MH  - Respiration Disorders/*chemically induced/*prevention & control
EDAT- 2012/04/12 06:00
MHDA- 2012/08/21 06:00
CRDT- 2012/04/12 06:00
PHST- 2012/04/12 06:00 [entrez]
PHST- 2012/04/12 06:00 [pubmed]
PHST- 2012/08/21 06:00 [medline]
AID - 10.1007/s00106-011-2444-3 [doi]
PST - ppublish
SO  - HNO. 2012 Apr;60(4):369-83. doi: 10.1007/s00106-011-2444-3.

PMID- 1087831
OWN - NLM
STAT- MEDLINE
DCOM- 19770315
LR  - 20190823
IS  - 0002-9211 (Print)
IS  - 0002-9211 (Linking)
VI  - 21
IP  - 12
DP  - 1976 Dec
TI  - The influence of aspirin on gastrointestinal microbleeding in dogs with gastric 
      ulcers.
PG  - 1029-32
AB  - Fecal blood volume was determined daily in 11 dogs with single gastric ulcers. 
      Beginning 11 days after production of the ulcers and dogs received, in crossover 
      fashion, 2 placebo or ordinary 325-mg aspirin tablets orally twice daily during 
      two 7-day treatment periods separated and followed by 5-day periods of no 
      treatment. Mean daily fecal blood volumes of 0.52 and 3.25 ml were observed 
      during periods of treatment with placebo and aspirin, respectively. However, in 7 
      previous studies in this laboratory a total of 24 normal dogs have received 7-day 
      courses of treatment with 650 mg ordinary aspirin twice daily on 105 occasions; 
      during these 105 treatment periods fecal blood volume averaged 2.90 ml/day. Thus, 
      it is concluded that the effect of ordinary aspirin in dogs with gastric ulcers 
      is essentially the same as the effect in normal dogs, and that there is no 
      tendency for dogs with gastric ulcers to bleed massively in response to aspirin.
FAU - Phillips, B M
AU  - Phillips BM
FAU - Quiring, J N
AU  - Quiring JN
FAU - Hurley, J W
AU  - Hurley JW
FAU - Myers, C E
AU  - Myers CE
FAU - Hartnagel, R E
AU  - Hartnagel RE
FAU - Kowalski, R L
AU  - Kowalski RL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Dig Dis
JT  - The American journal of digestive diseases
JID - 0404011
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dogs
MH  - Gastrointestinal Hemorrhage/*chemically induced/etiology
MH  - Male
MH  - Stomach Ulcer/*complications
EDAT- 1976/12/01 00:00
MHDA- 1976/12/01 00:01
CRDT- 1976/12/01 00:00
PHST- 1976/12/01 00:00 [pubmed]
PHST- 1976/12/01 00:01 [medline]
PHST- 1976/12/01 00:00 [entrez]
AID - 10.1007/BF01071858 [doi]
PST - ppublish
SO  - Am J Dig Dis. 1976 Dec;21(12):1029-32. doi: 10.1007/BF01071858.

PMID- 16978891
OWN - NLM
STAT- MEDLINE
DCOM- 20070227
LR  - 20161020
IS  - 1089-8603 (Print)
IS  - 1089-8603 (Linking)
VI  - 16
IP  - 1
DP  - 2007 Feb
TI  - Wound healing activity of NOE-aspirin: a pre-clinical study.
PG  - 150-6
AB  - Aspirin, one of the oldest non-steroidal anti-inflammatory drugs, impedes tissue 
      repair by virtue of retarding inflammation. The present study was undertaken to 
      find out if linking of nitrooxyethyl ester to aspirin reverses its 
      healing-depressant propensity. Nitrooxyethyl ester of aspirin (NOE-Asp) was 
      synthesized in our laboratory through well-established synthetic pathway, 
      starting from aspirin through esterification with ethylene glycol and nitration 
      with a mixture of nitric and sulfuric acids at 0 degrees C. The effect of NOE-Asp 
      on phases of healing such as collagenation, wound contraction and 
      epithelialization and on scar size of healed wound was evaluated in three wound 
      models-incision, dead space, and excision wounds. To assess its influence on the 
      oxidative stress, the levels of glutathione (GSH) and thiobarbiturate reactive 
      species (TBARS) were also determined in 10-day-old granulation tissue. NOE-Asp 
      was further screened for its anti-inflammatory activity in rat paw edema model. 
      NOE-Asp promoted collagenation (increase in breaking strength, granulation 
      weight, and collagen content), wound contraction, and epithelialization phases of 
      healing. NOE-Asp also showed a significant antioxidant effect in 10-day-old 
      granulation tissue as compared to aspirin. The results vindicate our assumption 
      that the esterification of aspirin with nirooxyethyl group reverses the 
      healing-suppressant effect of aspirin. The compound also showed equipotent 
      anti-inflammatory activity as aspirin.
FAU - Kaushal, Mandeep
AU  - Kaushal M
AD  - Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal 
      576 104, India. kaushalman@hotmail.com <kaushalman@hotmail.com>
FAU - Gopalan Kutty, N
AU  - Gopalan Kutty N
FAU - Mallikarjuna Rao, C
AU  - Mallikarjuna Rao C
LA  - eng
PT  - Journal Article
DEP - 20060805
PL  - United States
TA  - Nitric Oxide
JT  - Nitric oxide : biology and chemistry
JID - 9709307
RN  - 0 (Thiobarbituric Acid Reactive Substances)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
RN  - RMB44WO89X (Hydroxyproline)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Glutathione/metabolism
MH  - Hydroxyproline/metabolism
MH  - Male
MH  - Oxidative Stress
MH  - Rats
MH  - Rats, Wistar
MH  - Thiobarbituric Acid Reactive Substances/metabolism
MH  - Wound Healing/*drug effects
EDAT- 2006/09/19 09:00
MHDA- 2007/02/28 09:00
CRDT- 2006/09/19 09:00
PHST- 2006/04/21 00:00 [received]
PHST- 2006/07/06 00:00 [revised]
PHST- 2006/07/20 00:00 [accepted]
PHST- 2006/09/19 09:00 [pubmed]
PHST- 2007/02/28 09:00 [medline]
PHST- 2006/09/19 09:00 [entrez]
AID - S1089-8603(06)00391-0 [pii]
AID - 10.1016/j.niox.2006.07.004 [doi]
PST - ppublish
SO  - Nitric Oxide. 2007 Feb;16(1):150-6. doi: 10.1016/j.niox.2006.07.004. Epub 2006 
      Aug 5.

PMID- 848248
OWN - NLM
STAT- MEDLINE
DCOM- 19770520
LR  - 20131121
IS  - 0300-970X (Print)
IS  - 0300-970X (Linking)
VI  - 24
IP  - 1
DP  - 1977 Feb
TI  - Effect of lysine-acetylsalicylate on serum gastrin levels.
PG  - 52-4
AB  - The effect on serum gastrin levels of lysin-acetylsalicylate (LAS), water soluble 
      derivative of acetylsalicylic acid, was investigated in mice. Intragastrically 
      administered LAS did not at all alter serum gastrin values while--when given via 
      the intravenous route--LAS not earlier than at the very high dose of 450 mug/g 
      caused a short-lived significant increase in serum gastrin. These results are in 
      keeping with the view that salicylates do not owe their potential ulcerogenic 
      properties to stimulation the gastrin-gastric secrection mechanism.
FAU - Estler, C J
AU  - Estler CJ
FAU - Mitznegg, P
AU  - Mitznegg P
FAU - Domschke, W
AU  - Domschke W
FAU - Demling, L
AU  - Demling L
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Acta Hepatogastroenterol (Stuttg)
JT  - Acta hepato-gastroenterologica
JID - 0340734
RN  - 0 (Gastrins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Gastrins/*blood
MH  - Male
MH  - Mice
MH  - Peptic Ulcer/chemically induced
EDAT- 1977/02/01 00:00
MHDA- 1977/02/01 00:01
CRDT- 1977/02/01 00:00
PHST- 1977/02/01 00:00 [pubmed]
PHST- 1977/02/01 00:01 [medline]
PHST- 1977/02/01 00:00 [entrez]
PST - ppublish
SO  - Acta Hepatogastroenterol (Stuttg). 1977 Feb;24(1):52-4.

PMID- 7014935
OWN - NLM
STAT- MEDLINE
DCOM- 19810709
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 245
IP  - 18
DP  - 1981 May 8
TI  - Aspirin-induced prolongation of bleeding time and perioperative blood loss.
PG  - 1825-8
AB  - One hundred twenty-nine patients undergoing total hip replacement were treated 
      with aspirin at a level of either 300 mg four times a day (1.2 g/day) or 900 mg 
      four times a day (3.6 g/day). Baseline bleeding times before aspirin treatment 
      averaged 4.18 +/- 1.44 minutes. Two hours after 300 mg and 900 mg of aspirin, the 
      bleeding times were 5.83 +/- 1.88 and 5.72 +/- 1.57 minutes, respectively. After 
      three to five days of aspirin therapy at 1.2 g/day and 3.6 g/day, the bleeding 
      times were 6.27 +/- 2.27 and 6.43 +/- 2.11 minutes, respectively. The bleeding 
      times for all the aspirin-treated groups were longer than baseline times. No 
      paradoxical shortening of the bleeding time was noted at the 3.6-g/day dose. 
      Perioperative blood loss for those receiving aspirin was not increased in six of 
      eight subsets by operation and anesthesia when compared with historical control 
      subjects. Neither a bleeding time greater than ten minutes nor a prolongation of 
      the bleeding time by aspirin of more than four minutes over baseline bleeding 
      times was associated with increased perioperative blood loss.
FAU - Amrein, P C
AU  - Amrein PC
FAU - Ellman, L
AU  - Ellman L
FAU - Harris, W H
AU  - Harris WH
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Bleeding Time
MH  - Clinical Trials as Topic
MH  - Female
MH  - Hip Prosthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
EDAT- 1981/05/08 00:00
MHDA- 1981/05/08 00:01
CRDT- 1981/05/08 00:00
PHST- 1981/05/08 00:00 [pubmed]
PHST- 1981/05/08 00:01 [medline]
PHST- 1981/05/08 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1981 May 8;245(18):1825-8.

PMID- 857671
OWN - NLM
STAT- MEDLINE
DCOM- 19770622
LR  - 20131121
IS  - 0002-9289 (Print)
IS  - 0002-9289 (Linking)
VI  - 34
IP  - 3
DP  - 1977 Mar
TI  - Stability of aspirin in propoxyphene compound dosage forms.
PG  - 267-9
AB  - The stability of aspirin in propoxyphene compound capsules made by three 
      manufacturers, stored under a variety of temperature and humidity conditions, was 
      compared. The cotton packing was removed from 100-capsule bottles, and the 
      containers were stored (capped) under the following conditions: 25 c37 C and 50 C 
      at both high (90%) and low (10%) humidity. No desiccant was removed from the 
      bottles if originally present. The products tested were Darvon Compound-65 (two 
      formulations) (Lilly), SK-65 Compound (Smith Kline & French) and Dolene 
      Compound-65 (Lederle). Under all conditions, the stability of aspirin in the 
      SK-65 Compound product was greater than that of Darvon Compound-65 which in turn 
      was greater than Dolene Compound-65. Further, the rate of aspirin decomposition 
      was greater in the latter product than in the others.
FAU - Goldberg, R
AU  - Goldberg R
FAU - Nightingale, C H
AU  - Nightingale CH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Hosp Pharm
JT  - American journal of hospital pharmacy
JID - 0370474
RN  - 0 (Capsules)
RN  - 0 (Drug Combinations)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
SB  - IM
MH  - Aspirin/administration & dosage/*analysis
MH  - Capsules/analysis
MH  - Dextropropoxyphene/*administration & dosage
MH  - Drug Combinations
MH  - Drug Stability
MH  - Drug Storage
MH  - Half-Life
MH  - Humidity
MH  - Salicylates/analysis
MH  - Time Factors
EDAT- 1977/03/01 00:00
MHDA- 1977/03/01 00:01
CRDT- 1977/03/01 00:00
PHST- 1977/03/01 00:00 [pubmed]
PHST- 1977/03/01 00:01 [medline]
PHST- 1977/03/01 00:00 [entrez]
PST - ppublish
SO  - Am J Hosp Pharm. 1977 Mar;34(3):267-9.

PMID- 9629510
OWN - NLM
STAT- MEDLINE
DCOM- 19980828
LR  - 20181113
IS  - 0169-4197 (Print)
IS  - 0169-4197 (Linking)
VI  - 23
IP  - 2
DP  - 1998 Apr
TI  - Different dosages of acetylsalicylic acid lead to adverse modifications of the 
      reaction of rat pancreas to ethanol.
PG  - 125-36
AB  - CONCLUSION: Acetylsalicylic acid (aspirin, ASA) in a therapeutic dose prevents 
      lipid peroxidation and damage of cell organelles in pancreatic tissue of rats 
      chronically fed with ethanol. In contrast, higher ASA dosages lead to enhanced 
      biochemical and morphological signs of pancreatic damage different from findings 
      in rats fed by ethanol alone. METHODS: Two groups of rats received 20% alcohol as 
      drinking fluid plus a diet containing either 6 (S6) or 10 g/kg (S10) ASA. Two 
      control groups received no ASA (CA) and neither ASA nor alcohol (CW), 
      respectively. Feeding was performed by the interrupted feeding regimen with four 
      18-h periods of food and fluid withdrawal weekly. After 7 mo, pancreatic tissue 
      was examined by light and electron microscopy. In pancreas homogenates, the 
      contents of malondialdehyde (MDA), protein, trypsinogen, lipase, pancreatic 
      secretory trypsin inhibitor, acid phosphatase (AcPh), cathepsin B, 
      beta-glucuronidase, and desoxyribonucleic acid were determined. RESULTS: In the 
      pancreas of group CA, we found a 100% increase of MDA compared with group CW, 
      increased fat deposition, as well as damaged mitochondria (Mito) and endoplasmic 
      reticula (ER) in acinar cells, decreased protein content, decreased AcPh 
      activity, and unchanged secretory parameters. The ASA-fed groups showed MDA 
      contents indistinguishable from group CW. Protein and secretory parameters were 
      decreased. Lysosomal enzymes were decreased in S6, but in S10, they were always 
      higher than in group S6 and mostly as high as in group CW. Fat deposits were as 
      frequent as in group CA. Mito and ER were mostly well preserved, but more 
      autophagosomes and residual bodies occurred, particularly in group S10.
FAU - Siegmund, E
AU  - Siegmund E
AD  - Institute of Clinical Chemistry and Pathobiochemistry, Faculty of Medicine, 
      University of Rostock, Germany.
FAU - Jonas, L
AU  - Jonas L
FAU - Borisch, I
AU  - Borisch I
FAU - Fechner, U
AU  - Fechner U
FAU - Käding, U
AU  - Käding U
FAU - Schröder, H
AU  - Schröder H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Pancreatol
JT  - International journal of pancreatology : official journal of the International 
      Association of Pancreatology
JID - 8703511
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Ethanol/*pharmacology
MH  - Female
MH  - Microscopy, Electron
MH  - Pancreas/*drug effects/metabolism/pathology
MH  - Rats
MH  - Rats, Wistar
EDAT- 1998/06/18 00:00
MHDA- 1998/06/18 00:01
CRDT- 1998/06/18 00:00
PHST- 1998/06/18 00:00 [pubmed]
PHST- 1998/06/18 00:01 [medline]
PHST- 1998/06/18 00:00 [entrez]
AID - 10.1385/IJGC:23:2:125 [doi]
PST - ppublish
SO  - Int J Pancreatol. 1998 Apr;23(2):125-36. doi: 10.1385/IJGC:23:2:125.

PMID- 31927808
OWN - NLM
STAT- MEDLINE
DCOM- 20200117
LR  - 20200117
IS  - 1565-1088 (Print)
VI  - 22
IP  - 1
DP  - 2020 Jan
TI  - The Aspirin Primary Prevention Conundrum.
PG  - 60-63
AB  - In this review, the authors re-examine the role of aspirin in the primary 
      prevention of cardiovascular disease. They discuss the history of the use of 
      aspirin in primary prevention, the current guidelines, and the recent evidence 
      surrounding aspirin use as primary prevention in special populations such as 
      those with moderate cardiovascular risk, diabetes mellitus, and the elderly.
FAU - Schamroth Pravda, Miri
AU  - Schamroth Pravda M
AD  - Department of Internal Medicine A, Meir Medical Center, Kfar Saba, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Schamroth Pravda, Nili
AU  - Schamroth Pravda N
AD  - Department of Internal Medicine B, Rabin Medical Center (Beilinson Campus), Petah 
      Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Beigel, Yitzhak
AU  - Beigel Y
AD  - Clalit health services, Central Region, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Matetzky, Shlomi
AU  - Matetzky S
AD  - Department of Cardiology and Intensive Cardiac Care Unit, Sheba Medical Center, 
      Tel Hashomer, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Beigel, Roy
AU  - Beigel R
AD  - Department of Cardiology and Intensive Cardiac Care Unit, Sheba Medical Center, 
      Tel Hashomer, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Israel
TA  - Isr Med Assoc J
JT  - The Israel Medical Association journal : IMAJ
JID - 100930740
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Primary Prevention/methods
EDAT- 2020/01/14 06:00
MHDA- 2020/01/18 06:00
CRDT- 2020/01/14 06:00
PHST- 2020/01/14 06:00 [entrez]
PHST- 2020/01/14 06:00 [pubmed]
PHST- 2020/01/18 06:00 [medline]
PST - ppublish
SO  - Isr Med Assoc J. 2020 Jan;22(1):60-63.

PMID- 11975816
OWN - NLM
STAT- MEDLINE
DCOM- 20020607
LR  - 20191105
IS  - 1521-737X (Print)
IS  - 1521-737X (Linking)
VI  - 3
IP  - 5
DP  - 2001 Sep-Oct
TI  - Aggrenox: an aspirin and extended-release dipyridamole combination.
PG  - 340-6
AB  - Stroke is one of the leading causes of death in the United States. The risk of 
      experiencing a recurrent stroke remains elevated for several years after an 
      initial stroke or a transient ischemic attack (TIA), therefore secondary 
      prevention is crucial in reducing the risk of stroke and the complications and 
      costs associated with stroke. Aggrenox, a combination of low-dose aspirin and 
      extended-release dipyridamole, is a new agent that is effective in the secondary 
      prevention of stroke and transient ischemia of the brain. The clinical effect of 
      its two antiplatelet agents are additive and significantly better than either 
      aspirin or dipyridamole alone, although it has not been shown to be more 
      effective than aspirin alone in preventing death. Aggrenox is much more expensive 
      than aspirin alone but has been shown to be more cost-effective. At this point, 
      much of the pharmacologic information concerning this combination agent is based 
      on previous data about aspirin and immediate-release dipyridamole. This 
      combination of aspirin and extended-release dipyridamole may play a significant 
      role in secondary stroke and TIA prevention.
FAU - Wong, N N
AU  - Wong NN
AD  - Montefiore Medical Center, Department of Family Medicine/Department of Pharmacy, 
      Bronx, New York 10467, USA. nwong@montefiore.org
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Heart Dis
JT  - Heart disease (Hagerstown, Md.)
JID - 100887299
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/economics/*pharmacology/*therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Cardiovascular Diseases/drug therapy/economics/epidemiology
MH  - Cost-Benefit Analysis/economics
MH  - Dipyridamole/economics/*pharmacology/*therapeutic use
MH  - Drug Combinations
MH  - Humans
MH  - Platelet Aggregation Inhibitors/economics/*pharmacology/*therapeutic use
MH  - Stroke/drug therapy/economics/epidemiology
MH  - Treatment Outcome
MH  - United States/epidemiology
EDAT- 2002/04/27 10:00
MHDA- 2002/06/12 10:01
CRDT- 2002/04/27 10:00
PHST- 2002/04/27 10:00 [pubmed]
PHST- 2002/06/12 10:01 [medline]
PHST- 2002/04/27 10:00 [entrez]
AID - 10.1097/00132580-200109000-00011 [doi]
PST - ppublish
SO  - Heart Dis. 2001 Sep-Oct;3(5):340-6. doi: 10.1097/00132580-200109000-00011.

PMID- 24026956
OWN - NLM
STAT- MEDLINE
DCOM- 20140430
LR  - 20151119
IS  - 2194-9379 (Print)
IS  - 2194-9379 (Linking)
VI  - 64
IP  - 2
DP  - 2014 Feb
TI  - Spray drying as a fast and simple technique for the preparation of extended 
      release dipyridamole (DYP) microparticles in a fixed dose combination (FDC) 
      product with aspirin.
PG  - 104-12
LID - 10.1055/s-0033-1354364 [doi]
AB  - INTRODUCTION: Recent advances have proven that the combinational therapy of 
      extended release dipyridamole (DYP) and fast release aspirin (ASP) can improve 
      clinical indices of heart failure in several vascular disorders. Although 
      pharmaceutical industries always supported fast, simple and cost saving 
      techniques in their productions, there is no simple reported method available for 
      this purpose. The aim of this study was to check the possibility of preparing a 
      FDC product, containing individual dosage units of extended release DYP 
      microparticles and fast release ASP, using the spray-drying technique as a 
      practice compatible with pharmaceutical industries. MATERIALS AND METHOD: Solid 
      dispersions of DYP in different polymeric substances (ethyl cellulose, carnauba 
      wax, and Eudragit PO 100), were prepared using the spray-drying method. The 
      physicochemical properties and structure of the prepared microparticles were 
      analyzed using different techniques, such as the particle size analyzer (PSA), 
      differential scanning calorimetry (DSC), scanning electron microscopy (SEM), X 
      ray diffraction (XRD), and USP dissolution tester. ASP tablets were prepared 
      individually and tested according to pharmacopeia. RESULTS AND DISCUSSION: 
      Results showed that prepared microparticles measured about 2.3 µm in size. 
      Statistical analysis of the release data revealed that there is no significant 
      difference in the mean release amount of the selected formulation compared to the 
      innovative brand (Aggrenox®). CONCLUSION: Findings proposed a new formulation 
      (F7) as an alternative to innovative brand and proved spray drying as a practice 
      compatible with pharmaceutical industries and as a successful method for 
      sustaining the DYP release rate from prepared microparticles in a FDC dosage 
      form.
CI  - © Georg Thieme Verlag KG Stuttgart · New York.
FAU - Hamishehkar, H
AU  - Hamishehkar H
AD  - Pharmaceutical Technology Laboratory, Drug Applied Research Center, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Valizadeh, H
AU  - Valizadeh H
AD  - Biotechnology Research Center and Faculty of Pharmacy, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
FAU - Alasty, P
AU  - Alasty P
AD  - Students' Research Committee, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Monajjemzadeh, F
AU  - Monajjemzadeh F
AD  - Pharmaceutical Technology Laboratory, Drug Applied Research Center, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
DEP - 20130911
PL  - Germany
TA  - Drug Res (Stuttg)
JT  - Drug research
JID - 101602406
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Calorimetry, Differential Scanning
MH  - Chemistry, Pharmaceutical
MH  - Delayed-Action Preparations
MH  - Dipyridamole/*chemistry
MH  - Drug Combinations
MH  - Microscopy, Electron, Scanning
MH  - Particle Size
MH  - Solubility
MH  - *Technology, Pharmaceutical
MH  - X-Ray Diffraction
EDAT- 2013/09/13 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/09/13 06:00
PHST- 2013/09/13 06:00 [entrez]
PHST- 2013/09/13 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - 10.1055/s-0033-1354364 [doi]
PST - ppublish
SO  - Drug Res (Stuttg). 2014 Feb;64(2):104-12. doi: 10.1055/s-0033-1354364. Epub 2013 
      Sep 11.

PMID- 15291188
OWN - NLM
STAT- MEDLINE
DCOM- 20040922
LR  - 20190513
IS  - 0026-4075 (Print)
IS  - 0026-4075 (Linking)
VI  - 169
IP  - 7
DP  - 2004 Jul
TI  - A prospective trial of diaspirin cross-linked hemoglobin solution in patients 
      after elective repair of abdominal aortic aneurysm.
PG  - 546-50
AB  - We evaluated the safety, pharmacokinetics, and pharmacodynamics of diaspirin 
      cross-linked hemoglobin (DCLHb) solution in patients after repair of abdominal 
      aortic aneurysm. We performed a randomized, single-blind controlled study with 10 
      patients in the surgical intensive care unit of a tertiary care facility. Within 
      24 hours after repair of an abdominal aortic aneurysm, each patient received an 
      infusion of DCLHb (50 mg/kg or 35 mL for a 70-kg patient) or an equal volume of 
      hetastarch. Variables were measured before infusion, at 15 and 30 minutes 
      postinfusion, and at hourly intervals up to 72 hours. Compared with controls, the 
      experimental group had significantly greater mean pulmonary artery pressure at 30 
      minutes (mean +/- SD, 26.4 +/- 3.18 vs. 22.8 +/- 2.86 mm Hg), greater mean 
      arterial pressure through 30 minutes (100.8 +/- 8.67 vs. 81.6 +/- 13.8 mm Hg), 
      and greater plasma hemoglobin through 2 hours (69.3 +/- 6.08 vs. 1.8 +/- 0 g/dL). 
      Cardiac output was significantly less in the DCLHb group at 2 hours (5.34 +/- 
      7.92 vs. 6.18 +/- 0.54 L/minute), levels of serum bilirubin were significantly 
      less at 24 and 48 hours (94 +/- 0.26 vs. 1.56 +/- 0.73 mg/dL), and platelet 
      counts were significantly greater at 24 hours (128 +/- 35.8 vs. 101 +/- 55.7 
      mg/dL). The two groups did not differ in oxygen delivery or consumption. One 
      patient treated with DCLHb had a myocardial infarction 36 hours postinfusion. No 
      patient had antibodies to DCLHb. At this dosage, DCLHb was well tolerated without 
      severe organ dysfunction or toxicity. However, its use may lead to decreases in 
      cardiac output because of increases in afterload, which may pose serious problems 
      with left ventricular function.
FAU - Bloomfield, Eric L
AU  - Bloomfield EL
AD  - Division of Anesthesiology and Critical Care Medicine, Cleveland Clinic 
      Foundation, Cleveland, OH, USA.
FAU - Rady, Mohamed Y
AU  - Rady MY
FAU - Esfandiari, Shahpour
AU  - Esfandiari S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Mil Med
JT  - Military medicine
JID - 2984771R
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Solutions)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aortic Aneurysm, Abdominal/*surgery
MH  - Aspirin/administration & dosage/*analogs & derivatives/*pharmacology/therapeutic 
      use
MH  - Blood Pressure/*drug effects
MH  - Blood Substitutes/administration & dosage/*pharmacology/therapeutic use
MH  - *Elective Surgical Procedures
MH  - Hemoglobins/administration & dosage/*pharmacology/therapeutic use
MH  - Humans
MH  - Prospective Studies
MH  - Pulmonary Artery/drug effects
MH  - Solutions
EDAT- 2004/08/05 05:00
MHDA- 2004/09/24 05:00
CRDT- 2004/08/05 05:00
PHST- 2004/08/05 05:00 [pubmed]
PHST- 2004/09/24 05:00 [medline]
PHST- 2004/08/05 05:00 [entrez]
AID - 10.7205/milmed.169.7.546 [doi]
PST - ppublish
SO  - Mil Med. 2004 Jul;169(7):546-50. doi: 10.7205/milmed.169.7.546.

PMID- 14561103
OWN - NLM
STAT- MEDLINE
DCOM- 20040401
LR  - 20220330
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 20
IP  - 13
DP  - 2003
TI  - Aspirin for the prevention of cardiovascular events in the elderly.
PG  - 999-1010
AB  - Aspirin (acetylsalicylic acid), the most widely used antiplatelet drug, is 
      clinically effective for the prevention of vascular ischaemic events. Very few 
      primary or secondary prevention trials address the benefit-risk ratio of aspirin 
      in the elderly. In secondary prevention, it is generally accepted that the 
      beneficial effect of aspirin in the general patient population, demonstrated by 
      randomised controlled trials, can be extrapolated to the elderly. Elderly 
      patients are at relatively high risk for the development of vascular disease and 
      might also be expected to derive substantial benefit from regular aspirin 
      administration. However, there is no consensus about the definition of elderly 
      and no specific prospective trial conducted in elderly subjects is available. 
      Retrospective studies in the elderly found that the benefit provided by aspirin 
      in older patients was similar or increased compared with younger individuals. In 
      primary prevention, the potential benefit of antiplatelet agents must be balanced 
      against the risk of bleeding, which is higher in older patients. The risk-benefit 
      trade-off from the use of low-dose aspirin in the elderly is not yet established 
      and caution should be exercised when using aspirin in primary prevention. In 
      conclusion, aspirin should only be given for primary and secondary prevention in 
      the elderly after a comprehensive evaluation of an individual patient's 
      thrombotic and haemorrhagic risk has been conducted.
FAU - Mahé, Isabelle
AU  - Mahé I
AD  - Service Médecine A, Hôpital Lariboisière, Paris, France. 
      isabelle.mahe@lrb.ap-hop-paris.fr
FAU - Leizorovicz, Alain
AU  - Leizorovicz A
FAU - Caulin, Charles
AU  - Caulin C
FAU - Bergmann, Jean-François
AU  - Bergmann JF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention/methods
MH  - Randomized Controlled Trials as Topic
RF  - 69
EDAT- 2003/10/17 05:00
MHDA- 2004/04/02 05:00
CRDT- 2003/10/17 05:00
PHST- 2003/10/17 05:00 [pubmed]
PHST- 2004/04/02 05:00 [medline]
PHST- 2003/10/17 05:00 [entrez]
AID - 20134 [pii]
AID - 10.2165/00002512-200320130-00004 [doi]
PST - ppublish
SO  - Drugs Aging. 2003;20(13):999-1010. doi: 10.2165/00002512-200320130-00004.

PMID- 28058428
OWN - NLM
STAT- MEDLINE
DCOM- 20180613
LR  - 20180613
IS  - 1463-9084 (Electronic)
IS  - 1463-9076 (Linking)
VI  - 19
IP  - 3
DP  - 2017 Jan 18
TI  - Incorporation of aspirin modulates the dynamical and phase behavior of the 
      phospholipid membrane.
PG  - 2514-2524
LID - 10.1039/c6cp06202d [doi]
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used 
      medications in the world for their analgesic, antipyretic, and anti-inflammatory 
      actions, despite a well-known incidence of a wide spectrum of their adverse 
      effects. To a great extent, beneficial action and side effects of NSAIDs are 
      associated with the interaction of these drugs at the cell membrane level. Here, 
      we use neutron scattering to combine elastic intensity scans, quasielastic and 
      neutron spin echo (NSE) measurements to understand the effect of aspirin, a 
      commonly used NSAID, on the dynamical and phase behavior of the membrane of 
      dimyristoylphosphatidylcholine (DMPC), a prominent representative of 
      phospholipids residing in the outer leaflet of the human erythrocyte membrane. 
      Elastic intensity scans reveal that addition of aspirin not only eliminates the 
      pre-transition (solid gel to ripple phase), but also broadens the main phase 
      transition (ripple to fluid phase) in the membrane. Moreover, the main phase 
      transition becomes shifted toward a lower temperature. These results are found to 
      be consistent with our differential scanning calorimetry measurements. Elastic 
      intensity scans further suggest that aspirin inhibits the membrane from going 
      into the ordered phase and overall induces disorder in the membrane, thus 
      indicating enhancement in the fluidity of the membrane. Quasielastic neutron 
      scattering (QENS) data show that aspirin affects both lateral lipid motion within 
      the leaflet and the localized internal motion of the lipid. Aspirin accelerates 
      both lateral and internal motions, with the more pronounced effect observed for 
      the ordered phase of the neat membrane. Intermediate scattering function as 
      observed by NSE has been analyzed using the Zilman Granek model, which indicates 
      that addition of aspirin alters the bending modulus of the membrane to make the 
      membrane softer. Our study provides a quantitative description of the effect of 
      an archetypal NSAID, aspirin, on the various physical properties of the model 
      biological membrane, which is essential for understanding the complex 
      drug-membrane interaction.
FAU - Sharma, V K
AU  - Sharma VK
AUID- ORCID: 0000-0002-9077-5904
AD  - Solid State Physics Division, Bhabha Atomic Research Centre, Mumbai 400085, 
      India. sharmavk@barc.gov.in vksphy@gmail.com.
FAU - Mamontov, E
AU  - Mamontov E
AD  - Chemical and Engineering Materials Division, Neutron Sciences Directorate, Oak 
      Ridge National Laboratory, Oak Ridge, TN 37831, USA.
FAU - Ohl, M
AU  - Ohl M
AD  - Jülich Center for Neutron Science, Oak Ridge, Tennessee 37831, USA.
FAU - Tyagi, M
AU  - Tyagi M
AD  - National Institute of Standards and Technology Center for Neutron Research, 
      Gaithersburg, Maryland 20899, USA and Department of Materials Science and 
      Engineering, University of Maryland, College Park, Maryland 20742, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Phys Chem Chem Phys
JT  - Physical chemistry chemical physics : PCCP
JID - 100888160
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipid Bilayers)
RN  - R16CO5Y76E (Aspirin)
RN  - U86ZGC74V5 (Dimyristoylphosphatidylcholine)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry
MH  - Aspirin/*chemistry/*metabolism
MH  - Biological Transport
MH  - Calorimetry, Differential Scanning/methods
MH  - Dimyristoylphosphatidylcholine/*chemistry
MH  - Kinetics
MH  - Lipid Bilayers/chemistry
MH  - Motion
MH  - Neutron Diffraction/methods
MH  - Phase Transition
EDAT- 2017/01/07 06:00
MHDA- 2018/06/14 06:00
CRDT- 2017/01/07 06:00
PHST- 2017/01/07 06:00 [pubmed]
PHST- 2018/06/14 06:00 [medline]
PHST- 2017/01/07 06:00 [entrez]
AID - 10.1039/c6cp06202d [doi]
PST - ppublish
SO  - Phys Chem Chem Phys. 2017 Jan 18;19(3):2514-2524. doi: 10.1039/c6cp06202d.

PMID- 10995215
OWN - NLM
STAT- MEDLINE
DCOM- 20001121
LR  - 20191025
IS  - 1043-1802 (Print)
IS  - 1043-1802 (Linking)
VI  - 11
IP  - 5
DP  - 2000 Sep-Oct
TI  - Surface modification of diaspirin cross-linked hemoglobin (DCLHb) with 
      chondroitin-4-sulfate derivatives. Part 1.
PG  - 705-13
AB  - Synthetic methodology was developed for the preparation of chondrotin-4-sulfate 
      reagents that could be specifically attached to the surface of diaspirin 
      cross-linked hemoglobin (DCLHb), a chemically stabilized human hemoglobin. The 
      surface-modified hemoglobin solutions had a significantly higher colloidal 
      osmotic pressures (COP) than DCLHb. The P(50) of the modified DCLHb was dependent 
      upon the reactive end group of the chondrotin-4-sulfate reagents that was used 
      for the protein modification. Modification of DCLHb with the 
      chondroitin-4-sulfate derivatives containing the maleimide end group 23 provided 
      a hemoglobin with a P(50) value of 23 mmHg, while the P(50) of hemoglobins 
      prepared from chondroitin-4-sulfate derivatives containing the aldehyde end group 
      13 and 18 remained unchanged from that of DCLHb.
FAU - Hai, T T
AU  - Hai TT
AD  - Corporate Research and Technical Services, Baxter Healthcare Corporation, 25212 
      West State Route 120, Round Lake, Illinois 60073-9799, USA. ton_hai@baxter.com
FAU - Pereira, D E
AU  - Pereira DE
FAU - Nelson, D J
AU  - Nelson DJ
FAU - Catarello, J
AU  - Catarello J
FAU - Srnak, A
AU  - Srnak A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bioconjug Chem
JT  - Bioconjugate chemistry
JID - 9010319
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 9007-28-7 (Chondroitin Sulfates)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Blood Substitutes/chemistry/pharmacology
MH  - Carbohydrate Sequence
MH  - Chondroitin Sulfates/*chemistry/*pharmacology
MH  - Erythrocyte Aggregation/drug effects
MH  - Hemoglobins/*chemistry/*pharmacology
MH  - Humans
MH  - Molecular Sequence Data
MH  - Structure-Activity Relationship
MH  - Surface Properties
EDAT- 2000/09/20 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/20 11:00
PHST- 2000/09/20 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/20 11:00 [entrez]
AID - bc000021i [pii]
AID - 10.1021/bc000021i [doi]
PST - ppublish
SO  - Bioconjug Chem. 2000 Sep-Oct;11(5):705-13. doi: 10.1021/bc000021i.

PMID- 7211578
OWN - NLM
STAT- MEDLINE
DCOM- 19810513
LR  - 20190825
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 10
IP  - 5
DP  - 1980 Nov
TI  - Bio-distribution in rats of some salicylates with low gastric ulcerogenicity.
PG  - 457-64
AB  - The distribution of three radioactively labelled salicylate derivatives with low 
      ulcerogenic activity was compared with that of acetylsalicylic acid (ASA) and 
      salicylic acid using whole body autoradiography and liquid scintillation counting 
      techniques in rats. The methyl ester of ASA (AME) was distributed in vivo very 
      similarly to that observed with ASA and salicylic acid. AME is rapidly 
      demethylated following absorption from the stomach and is subsequently converted 
      to ASA and salicylate. Salicylate is the main metabolite produced from both AME 
      and ASA, which specifically accumulates in inflamed tissues. The 3-methyl- and 
      6-methyl-substituted salicylic acids are not as rapidly absorbed as either ASA or 
      salicylic acid and do not pass readily into the brain or bone marrow. These 
      results show that the methyl (ester) group of AME (which adequately protects the 
      gastric mucosa from damage caused by ASA itself) does not impair the quantity of 
      pharmacologically active form of drug (salicylate and ASA) generated in vivo. 
      However, insertion of the methyl group at the 3- and 6-position of salicylic acid 
      markedly affects both absorption, distribution and pharmaco-activity of these 
      acids.
FAU - Rainsford, K D
AU  - Rainsford KD
FAU - Schweitzer, A
AU  - Schweitzer A
FAU - Green, P
AU  - Green P
FAU - Whitehouse, M W
AU  - Whitehouse MW
FAU - Brune, K
AU  - Brune K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Salicylates)
RN  - 580-02-9 (methyl acetylsalicylic acid)
RN  - L5352FE23Y (6-methylsalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/metabolism/toxicity
MH  - Male
MH  - Rats
MH  - Salicylates/*metabolism/toxicity
MH  - Stomach Ulcer/*chemically induced
MH  - Tissue Distribution
EDAT- 1980/11/01 00:00
MHDA- 1980/11/01 00:01
CRDT- 1980/11/01 00:00
PHST- 1980/11/01 00:00 [pubmed]
PHST- 1980/11/01 00:01 [medline]
PHST- 1980/11/01 00:00 [entrez]
AID - 10.1007/BF01968047 [doi]
PST - ppublish
SO  - Agents Actions. 1980 Nov;10(5):457-64. doi: 10.1007/BF01968047.

PMID- 6882040
OWN - NLM
STAT- MEDLINE
DCOM- 19830923
LR  - 20190503
IS  - 0003-4967 (Print)
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 42
IP  - 4
DP  - 1983 Aug
TI  - Assessment of nonsteroidal anti-inflammatory drug combinations by the 
      polyurethane sponge implantation model in the rat.
PG  - 439-42
AB  - The anti-inflammatory effect of single doses and combinations of aspirin and 
      commonly used nonsteroidal anti-inflammatory drugs was investigated by the 
      polyurethane sponge implantation model of acute inflammation. Dose response 
      curves were performed to delineate a suppressive (high) and nonsuppressive (low) 
      dose of each drug prior to studying these doses in combination with aspirin. The 
      results suggest that a combination of aspirin in either high or low dose does not 
      increase the anti-inflammatory effect of other nonsteroidal anti-inflammatory 
      drugs in this model of inflammation.
FAU - Garrett, R
AU  - Garrett R
FAU - Manthey, B
AU  - Manthey B
FAU - Vernon-Roberts, B
AU  - Vernon-Roberts B
FAU - Brooks, P M
AU  - Brooks PM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Polyurethanes)
RN  - 9009-54-5 (polyurethane foam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Aspirin/administration & dosage/therapeutic use
MH  - *Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Inflammation/*drug therapy
MH  - Polyurethanes
MH  - Rats
MH  - Rats, Inbred Strains
PMC - PMC1001259
EDAT- 1983/08/01 00:00
MHDA- 1983/08/01 00:01
CRDT- 1983/08/01 00:00
PHST- 1983/08/01 00:00 [pubmed]
PHST- 1983/08/01 00:01 [medline]
PHST- 1983/08/01 00:00 [entrez]
AID - 10.1136/ard.42.4.439 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 1983 Aug;42(4):439-42. doi: 10.1136/ard.42.4.439.

PMID- 671239
OWN - NLM
STAT- MEDLINE
DCOM- 19780925
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 67
IP  - 8
DP  - 1978 Aug
TI  - Correlation of aspirin excretion with parameters from different dissolution 
      methods.
PG  - 1070-3
AB  - The cumulative urinary excretion of four different aspirin products (two tablets, 
      a capsule, and a timed-release tablet) was determined in a crossover study using 
      five subjects. Comparison of in vivo results showed a significant difference in 
      cumulative urinary excretion levels at only 1 hr. The excretion from the two 
      regular tablets was significantly different from the timed-release tablet, but 
      the capsule showed no significant difference from the other three products. Each 
      product was tested in the USP, Levy beaker, and the regular and large magnetic 
      basket dissolution apparatus. Analysis of variance of the in vitro results showed 
      a significant difference between the aspirin products and the dissolution methods 
      at selected times. In vitro comparison with in vivo results for the four products 
      showed that a regression analysis can be used to determined which dissolution 
      methods produce a significant correlation with urinary excretion.
FAU - Needham, T E
AU  - Needham TE
FAU - Shah, K
AU  - Shah K
FAU - Kotzan, J
AU  - Kotzan J
FAU - Zia, H
AU  - Zia H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Capsules)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*urine
MH  - Capsules
MH  - Chemistry, Pharmaceutical/instrumentation/methods
MH  - Delayed-Action Preparations
MH  - Humans
MH  - Male
MH  - Solubility
MH  - Tablets
EDAT- 1978/08/01 00:00
MHDA- 1978/08/01 00:01
CRDT- 1978/08/01 00:00
PHST- 1978/08/01 00:00 [pubmed]
PHST- 1978/08/01 00:01 [medline]
PHST- 1978/08/01 00:00 [entrez]
AID - S0022-3549(15)42183-5 [pii]
AID - 10.1002/jps.2600670812 [doi]
PST - ppublish
SO  - J Pharm Sci. 1978 Aug;67(8):1070-3. doi: 10.1002/jps.2600670812.

PMID- 31518069
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20200601
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 9
IP  - 12
DP  - 2019 Dec
TI  - Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory 
      disease: a systematic review and meta-analysis.
PG  - 1409-1419
LID - 10.1002/alr.22428 [doi]
AB  - BACKGROUND: Aspirin desensitization is increasingly recommended for the treatment 
      of aspirin-exacerbated respiratory disease (AERD). The objective of this study is 
      to systematically review the efficacy and safety of aspirin desensitization in 
      patients with AERD. METHODS: We searched MEDLINE, EMBASE, the Cochrane Central 
      Register of Controlled Trials, and World Health Organization (WHO) International 
      Clinical Trials Registry Platform from inception to January 5, 2019. We included 
      randomized trials and comparative observational studies in any language. Data 
      extraction and risk of bias assessment were performed in duplicate independently. 
      RESULTS: Five randomized controlled trials (RCTs) enrolled 233 patients with 
      AERD. Compared to placebo, aspirin desensitization (mean daily dose 800 mg) 
      improved quality of life (risk ratio [RR] 2.00; 95% confidence interval [CI], 
      1.31 to 3.06; heterogeneity measure [I(2) ] = 0%; risk difference [RD] +24%; 
      22-item Sino-Nasal Outcome Test [SNOT-22] scale [0 to 110, higher worse]; mean 
      difference [MD] -10.27 [95% CI, -6.39 to -14.15]; moderate-certainty); and 
      respiratory symptoms (RR 2.20 [95% CI, 1.55 to 2.73], I(2) = 34%, RD +36%; 
      American Academy of Otolaryngology (AAO) scale [0 to 20, higher worse]; MD -2.56 
      [95% CI,-1.12 to -3.92]; high-certainty). Aspirin desensitization increased 
      adverse events severe enough to cause treatment discontinuation (major bleeding, 
      gastritis, asthma exacerbation, or rash causing drug discontinuation, RR 4.39 
      [95% CI, 1.43 to 13.50], I(2) = 0%, RD +11%, moderate-certainty), and gastritis 
      (RR 3.84 [95% CI, 1.12 to 13.19], I(2) = 0%, RD +9%, low-certainty). Findings 
      were robust to sensitivity analyses. Two available observational studies were not 
      informative because they lacked adjustment for confounders and/or contemporaneous 
      controls. CONCLUSION: In patients with AERD, moderate-certainty and 
      high-certainty evidence shows that aspirin desensitization meaningfully reduces 
      symptoms of rhinosinusitis and improves quality of life, but results in a 
      significant increase in adverse events.
CI  - © 2019 ARS-AAOA, LLC.
FAU - Chu, Derek K
AU  - Chu DK
AUID- ORCID: 0000-0001-8269-4496
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
FAU - Lee, Daniel J
AU  - Lee DJ
AUID- ORCID: 0000-0003-4057-2858
AD  - Department of Otolaryngology-Head & Neck Surgery, St. Michael's Hospital, 
      University of Toronto, Toronto, ON, Canada.
FAU - Lee, Keith M
AU  - Lee KM
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Schünemann, Holger J
AU  - Schünemann HJ
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
AD  - Department of Health Research Methods, Evidence & Impact (formerly, Clinical 
      Epidemiology & Biostatistics), McMaster University, Hamilton, ON, Canada.
FAU - Szczeklik, Wojciech
AU  - Szczeklik W
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
AD  - Department of Health Research Methods, Evidence & Impact (formerly, Clinical 
      Epidemiology & Biostatistics), McMaster University, Hamilton, ON, Canada.
AD  - Department of Intensive Care and Perioperative Medicine, Jagiellonian University 
      Medical College, Kraków, Poland.
FAU - Lee, John M
AU  - Lee JM
AD  - Department of Otolaryngology-Head & Neck Surgery, St. Michael's Hospital, 
      University of Toronto, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190913
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Asthma, Aspirin-Induced/*therapy
MH  - *Desensitization, Immunologic
MH  - Humans
MH  - Observational Studies as Topic
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - AERD
OT  - NSAIDs
OT  - aspirin
OT  - aspirin-induced asthma
OT  - meta-analysis
OT  - sinusitis
OT  - systematic review
EDAT- 2019/09/14 06:00
MHDA- 2020/06/02 06:00
CRDT- 2019/09/14 06:00
PHST- 2019/05/13 00:00 [received]
PHST- 2019/08/05 00:00 [revised]
PHST- 2019/08/13 00:00 [accepted]
PHST- 2019/09/14 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2019/09/14 06:00 [entrez]
AID - 10.1002/alr.22428 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2019 Dec;9(12):1409-1419. doi: 10.1002/alr.22428. Epub 
      2019 Sep 13.

PMID- 30929989
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20200603
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Jan
TI  - Vein Graft Patency Rates With Aspirin Plus Clopidogrel Following Coronary Artery 
      Bypass Grafting.
PG  - 162-163
LID - S1443-9506(19)30269-0 [pii]
LID - 10.1016/j.hlc.2019.02.191 [doi]
AB  - A best evidence topic in cardiac surgery was written according to a structured 
      protocol. The question addressed was, "In patients who have undergone Coronary 
      Artery Bypass Grafting, does aspirin plus clopidogrel postoperatively improve 
      vein graft patency when compared to aspirin alone?" Altogether, 165 papers were 
      found using the reported search, of which five represented the best evidence to 
      answer the clinical question. Overall analysis of these papers demonstrated 
      similar rates of vein graft patency between the two groups. There was no 
      difference between the groups with regard to mortality, adverse bleeding-related 
      outcomes, or composite vascular events.
CI  - Copyright © 2019 Australian and New Zealand Society of Cardiac and Thoracic 
      Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). 
      Published by Elsevier B.V. All rights reserved.
FAU - De Bono, Joshua A
AU  - De Bono JA
AD  - Department of Cardiothoracics, St Vincent's Hospital Melbourne, Melbourne, Vic, 
      Australia.
FAU - Conte, Sean M
AU  - Conte SM
AD  - Department of Cardiology, St Vincent's Hospital Sydney, NSW, Australia. 
      Electronic address: sean.m.conte@gmail.com.
FAU - Florisson, Daniel S
AU  - Florisson DS
AD  - Department of Cardiothoracics, St Vincent's Hospital Melbourne, Melbourne, Vic, 
      Australia.
FAU - Davies, Reece A
AU  - Davies RA
AD  - Department of Cardiothoracics, John Hunter Hospital, Newcastle, NSW, Australia.
FAU - Newcomb, Andrew E
AU  - Newcomb AE
AD  - Department of Cardiothoracics, St Vincent's Hospital Melbourne, Melbourne, Vic, 
      Australia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20190318
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Middle Aged
OTO - NOTNLM
OT  - Aspirin
OT  - Clopidogrel
OT  - Coronary artery bypass grafting
OT  - Graft patency
EDAT- 2019/04/02 06:00
MHDA- 2020/06/04 06:00
CRDT- 2019/04/02 06:00
PHST- 2018/11/30 00:00 [received]
PHST- 2019/01/03 00:00 [revised]
PHST- 2019/02/17 00:00 [accepted]
PHST- 2019/04/02 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
PHST- 2019/04/02 06:00 [entrez]
AID - S1443-9506(19)30269-0 [pii]
AID - 10.1016/j.hlc.2019.02.191 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2020 Jan;29(1):162-163. doi: 10.1016/j.hlc.2019.02.191. Epub 
      2019 Mar 18.

PMID- 1030815
OWN - NLM
STAT- MEDLINE
DCOM- 19770611
LR  - 20161021
IS  - 0035-0915 (Print)
IS  - 0035-0915 (Linking)
VI  - 35
IP  - 4
DP  - 1976 Dec
TI  - [Action of acetylsalicylic acid administered by different routes on the blood and 
      buccal tissues of rats].
PG  - 193-7
AB  - Sixty female Sprague-Dawley rats, with an average weight of 120 g, have been used 
      in this study. The experimental groups received twice a day 1 ml of a 2% 
      acetyl-salicylic acid suspension in methyl-cellulose either per os or i.p. The 
      control groups received methyl-cellulose without asprin. The blood was collected 
      before any treatment and each day during the week for the purpose of counting 
      cells. The experimental animals and their control were killed after 2, 4 and 8 
      days. A piece of endobuccal epithelium with its deeper tissues was cut off and 
      frozen for histochemistry. The tissue sections were treated to show the basic 
      enzymatic reactions of the cell. It was observed that: 1. most of the changes 
      appear between the 4th and 8th day of the treatment: 2. depending on the 
      administration route, certain blood cells show a peak. Microphages between the 
      4th and 6th day in injected animals. Lymphocytes at the same time, in the gavage 
      group; 3. oral epithelium lesions are limited and appear lately; 4. underlying 
      muscles are a constant target. The lesions are seen in both experimental groups 
      as soon as the 2nd day. After a week, the lesions are more numerous. They are 
      characterized by enzymatic inbalances with or without macrophages. The muscular 
      cell is a real target for acetyl salicylic acid.
FAU - Mascrès, C
AU  - Mascrès C
FAU - Bonner, M
AU  - Bonner M
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Action de l'acide acétyl-salicylique administré par différentes voies sur les 
      tissus sanguin et buccaux du rat.
PL  - Canada
TA  - Rev Can Biol
JT  - Revue canadienne de biologie
JID - 8214595
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*toxicity
MH  - Blood Cells/*drug effects
MH  - Cheek
MH  - Female
MH  - Injections, Intraperitoneal
MH  - Mouth Mucosa/*drug effects
EDAT- 1976/12/01 00:00
MHDA- 1976/12/01 00:01
CRDT- 1976/12/01 00:00
PHST- 1976/12/01 00:00 [pubmed]
PHST- 1976/12/01 00:01 [medline]
PHST- 1976/12/01 00:00 [entrez]
PST - ppublish
SO  - Rev Can Biol. 1976 Dec;35(4):193-7.

PMID- 1680084
OWN - NLM
STAT- MEDLINE
DCOM- 19911024
LR  - 20190819
IS  - 0020-7292 (Print)
IS  - 0020-7292 (Linking)
VI  - 35
IP  - 2
DP  - 1991 Jun
TI  - Low-dose aspirin and vascular response in pregnant patients sensitive to 
      angiotensin II.
PG  - 123-8
AB  - The angiotensin sensitivity test was performed in 25 high risk pregnant women 
      before and after administration of low-dose aspirin (100 mg/day for 7 days). 
      After aspirin administration there was a significant decrease in AII sensitivity 
      in sensitive patients with no change in nonsensitive patients. Low-dose aspirin 
      favorably affects sensitivity to AII in sensitive patients, thus indicating a 
      reduced vascular reactivity as a consequence of this regimen.
FAU - Caruso, A
AU  - Caruso A
AD  - Department of Obstetrics and Gynaecology, Catholic University, Rome, Italy.
FAU - Ferrazzani, S
AU  - Ferrazzani S
FAU - De Carolis, S
AU  - De Carolis S
FAU - Lanzone, A
AU  - Lanzone A
FAU - Mancuso, S
AU  - Mancuso S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - 11128-99-7 (Angiotensin II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angiotensin II
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Hypertension/*physiopathology
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*physiopathology
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
AID - 0020-7292(91)90814-L [pii]
AID - 10.1016/0020-7292(91)90814-l [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 1991 Jun;35(2):123-8. doi: 10.1016/0020-7292(91)90814-l.

PMID- 20332350
OWN - NLM
STAT- MEDLINE
DCOM- 20100831
LR  - 20220716
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 33
IP  - 6
DP  - 2010 Jun
TI  - Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 
      diabetes.
PG  - 1193-9
LID - 10.2337/dc09-1888 [doi]
AB  - OBJECTIVE: To assess the long-term cost-effectiveness of aspirin use among adults 
      aged >or=40 years with newly diagnosed type 2 diabetes. RESEARCH DESIGN AND 
      METHODS: We used a validated cost-effectiveness model of type 2 diabetes to 
      assess the lifetime health and cost consequences of use or nonuse of aspirin. The 
      model simulates the progression of diabetes and accompanying complications for a 
      cohort of subjects with type 2 diabetes. The model predicts the outcomes of type 
      2 diabetes along five disease paths (nephropathy, neuropathy, retinopathy, 
      coronary heart disease, and stroke) from the time of diagnosis until age 94 years 
      or until death. RESULTS: Over a lifetime, aspirin users gained 0.31 life-years 
      (LY) or 0.19 quality-adjusted LYs (QALYs) over nonaspirin users, at an 
      incremental cost of $1,700; the incremental cost-effectiveness ratio (ICER) of 
      aspirin use was $5,428 per LY gained or $8,801 per QALY gained. In probabilistic 
      sensitivity analyses, the ICER was <$30,000 per QALY in all of 2,000 realizations 
      in two scenarios. CONCLUSIONS: Regular use of aspirin among people with newly 
      diagnosed diabetes is cost-effective.
FAU - Li, Rui
AU  - Li R
AD  - Division of Diabetes Translation, Centers for Disease Control and Prevention, 
      Atlanta, Georgia, USA. rli2@cdc.gov
FAU - Zhang, Ping
AU  - Zhang P
FAU - Barker, Lawrence E
AU  - Barker LE
FAU - Hoerger, Thomas J
AU  - Hoerger TJ
LA  - eng
PT  - Journal Article
DEP - 20100323
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Hypoglycemic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*economics/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/diagnosis/*drug therapy
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*economics/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Time Factors
PMC - PMC2875422
EDAT- 2010/03/25 06:00
MHDA- 2010/09/02 06:00
CRDT- 2010/03/25 06:00
PHST- 2010/03/25 06:00 [entrez]
PHST- 2010/03/25 06:00 [pubmed]
PHST- 2010/09/02 06:00 [medline]
AID - dc09-1888 [pii]
AID - 1888 [pii]
AID - 10.2337/dc09-1888 [doi]
PST - ppublish
SO  - Diabetes Care. 2010 Jun;33(6):1193-9. doi: 10.2337/dc09-1888. Epub 2010 Mar 23.

PMID- 31515060
OWN - NLM
STAT- MEDLINE
DCOM- 20200710
LR  - 20200710
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 297
DP  - 2019 Dec 15
TI  - The effect of low-dose aspirin on colorectal cancer prevention and 
      gastrointestinal bleeding according to bodyweight and body mass index: Analysis 
      of UK primary care data.
PG  - 135-139
LID - S0167-5273(19)32235-1 [pii]
LID - 10.1016/j.ijcard.2019.08.001 [doi]
AB  - BACKGROUND: Meta-analysis of trial data suggests that in primary cardiovascular 
      disease (CVD) prevention bodyweight modifies low-dose aspirin's effects on 
      colorectal cancer (CRC) and major bleeding risk. We sought to investigate whether 
      these effects are seen in patients with or without CVD in routine clinical 
      practice by undertaking sub-analyses of data from two cohort studies with 
      nested-case-control analyses. METHODS: We followed ~200,000 new users of low-dose 
      aspirin (75-300 mg/day) and a matched cohort of non-users to identify incident 
      cases of CRC/upper gastrointestinal bleeding (UGIB). Adjusted relative risks 
      (RRs) with 95% confidence intervals (CIs) were calculated for current vs. non-use 
      of low-dose aspirin using logistic regression stratified by bodyweight/body mass 
      index (BMI) strata. RESULTS: RRs (95% CIs) for CRC by bodyweight were: 0.60 
      (0.50-0.72) for ≤70 kg, 0.68 (0.60-0.76) for >70 kg; and by BMI were 0.60 
      (0.52-0.68) for ≤28 kg/m(2), 0.76 (0.64-0.89) for >28 kg/m(2). For UGIB, 
      estimates were: 1.49 (1.28-1.74) for ≤90 kg, 1.78 (1.29-2.45) for >90 kg/m(2), 
      1.44 (1.21-1.72) for ≤28 kg/m(2), 1.72 (1.38-2.16) for >28 kg/m(2). Results were 
      similar in the primary CVD prevention population. CONCLUSION: Our findings 
      suggest that the effects of low-dose aspirin in reducing CRC risk and increasing 
      UGIB risk are not modified by bodyweight/BMI.
CI  - Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Cea Soriano, Lucía
AU  - Cea Soriano L
AD  - Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain; 
      Department of Public Health and Maternal and Child Health, Faculty of Medicine, 
      Complutense University of Madrid, Spain. Electronic address: 
      luciaceife@gmail.com.
FAU - Vora, Pareen
AU  - Vora P
AD  - Epidemiology, Bayer AG, Berlin, Germany.
FAU - Soriano-Gabarró, Montse
AU  - Soriano-Gabarró M
AD  - Epidemiology, Bayer AG, Berlin, Germany.
FAU - García Rodríguez, Luis A
AU  - García Rodríguez LA
AD  - Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20190826
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - *Body Mass Index
MH  - *Body Weight
MH  - Colorectal Neoplasms/*epidemiology
MH  - Female
MH  - Gastrointestinal Hemorrhage/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Health Care
MH  - United Kingdom
OTO - NOTNLM
OT  - Aspirin
OT  - Body mass index
OT  - Bodyweight
OT  - Colorectal cancer
OT  - Gastrointestinal bleeding
OT  - Observational
EDAT- 2019/09/14 06:00
MHDA- 2020/07/11 06:00
CRDT- 2019/09/14 06:00
PHST- 2019/04/30 00:00 [received]
PHST- 2019/06/17 00:00 [revised]
PHST- 2019/08/02 00:00 [accepted]
PHST- 2019/09/14 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
PHST- 2019/09/14 06:00 [entrez]
AID - S0167-5273(19)32235-1 [pii]
AID - 10.1016/j.ijcard.2019.08.001 [doi]
PST - ppublish
SO  - Int J Cardiol. 2019 Dec 15;297:135-139. doi: 10.1016/j.ijcard.2019.08.001. Epub 
      2019 Aug 26.

PMID- 2216216
OWN - NLM
STAT- MEDLINE
DCOM- 19901119
LR  - 20190818
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 76
IP  - 5 Pt 1
DP  - 1990 Nov
TI  - Low-dose aspirin does not influence the clinical course of women with mild 
      pregnancy-induced hypertension.
PG  - 742-4
AB  - The effect of low doses of aspirin on women with mild pregnancy-induced 
      hypertension was investigated by means of a prospective, randomized, double-blind 
      trial. Forty-seven women hospitalized at 30-36 weeks' gestation because of mild 
      pregnancy-induced hypertension were treated by a daily dose of either 100 mg 
      aspirin or placebo. The mean blood pressure values, rates of development of 
      severe preeclampsia, gestational ages at delivery, newborn weights, and 5-minute 
      Apgar scores were similar in the aspirin-treated and the placebo-treated groups. 
      We conclude that low-dose aspirin is not curative but is essentially a preventive 
      treatment which, in order to be effective, should be started weeks before 
      clinical signs of preeclampsia are present.
FAU - Schiff, E
AU  - Schiff E
AD  - Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Sackler 
      School of Medicine, Tel Aviv University, Tel Hashomer, Israel.
FAU - Barkai, G
AU  - Barkai G
FAU - Ben-Baruch, G
AU  - Ben-Baruch G
FAU - Mashiach, S
AU  - Mashiach S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*drug therapy
MH  - Prospective Studies
EDAT- 1990/11/01 00:00
MHDA- 1990/11/01 00:01
CRDT- 1990/11/01 00:00
PHST- 1990/11/01 00:00 [pubmed]
PHST- 1990/11/01 00:01 [medline]
PHST- 1990/11/01 00:00 [entrez]
AID - 10.1097/00006250-199011000-00002 [doi]
PST - ppublish
SO  - Obstet Gynecol. 1990 Nov;76(5 Pt 1):742-4. doi: 10.1097/00006250-199011000-00002.

PMID- 7029423
OWN - NLM
STAT- MEDLINE
DCOM- 19820128
LR  - 20210111
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 11
IP  - 1
DP  - 1981 Aug
TI  - Age-associated changes of responses to acetylsalicylic acid.
PG  - 1-8
LID - 10.1016/0304-3959(81)90134-2 [doi]
AB  - Aspirin can be an effective antipyretic, analgesic and anti-inflammatory agent, 
      but unfortunately, its use in the elderly is often excessive [43]. In a survey by 
      Gillies and Skyring, the overall prevalence of daily aspirin intake was greater 
      in middle-age and older-age groups than for those of less than 40 years of age 
      [16]. The elderly are susceptible to the advertising of non-prescription drugs 
      and aspirin is frequently self-prescribed [8,31]. Age-related physiological 
      changes modify the response to aspirin in the elderly. A higher incidence of drug 
      reactions and interactions has been evidenced in this age group. The cases cited 
      throughout this report substantiate the need for caution on the part of the 
      geriatric patient and the physician in regard to aspirin therapy for the elderly.
FAU - Baskin, Steven I
AU  - Baskin SI
AD  - Department of Pharmacology, Medical College of Pennsylvania, 3300 Henry Avenue, 
      Philadelphia, Pa. 19129, U.S.A.
FAU - Smith, Lester
AU  - Smith L
FAU - Hoey, Leslie A
AU  - Hoey LA
FAU - Levy, Perri I
AU  - Levy PI
FAU - Goldfarb, Allan H
AU  - Goldfarb AH
LA  - eng
GR  - AG00003/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Drug Interactions
MH  - Humans
MH  - Pain/drug therapy
MH  - Stomach Ulcer/chemically induced
RF  - 44
EDAT- 1981/08/01 00:00
MHDA- 1981/08/01 00:01
CRDT- 1981/08/01 00:00
PHST- 1981/08/01 00:00 [pubmed]
PHST- 1981/08/01 00:01 [medline]
PHST- 1981/08/01 00:00 [entrez]
AID - 00006396-198108000-00001 [pii]
AID - 10.1016/0304-3959(81)90134-2 [doi]
PST - ppublish
SO  - Pain. 1981 Aug;11(1):1-8. doi: 10.1016/0304-3959(81)90134-2.

PMID- 31544224
OWN - NLM
STAT- MEDLINE
DCOM- 20200415
LR  - 20200415
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
VI  - 19
IP  - 10
DP  - 2019 Sep 23
TI  - Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of 
      the Evidence.
PG  - 107
LID - 10.1007/s11892-019-1206-6 [doi]
AB  - PURPOSE OF REVIEW: People with diabetes are at a higher risk of atherosclerotic 
      cardiovascular disease (ASCVD) compared with those without diabetes. Though 
      aspirin has been shown to have an overall net clinical benefit when used for 
      secondary prevention of ASCVD in people with and without diabetes, the evidence 
      for primary prevention, especially in those with diabetes, remains inconsistent. 
      In this article, we review the latest studies examining the risks and benefits of 
      aspirin use for primary prevention of ASCVD in adults with diabetes, discuss key 
      aspects in assessing the risk-benefit ratio of aspirin use for primary prevention 
      of ASCVD, and summarize current guidelines from professional societies on aspirin 
      use for primary prevention in adults with diabetes. RECENT FINDINGS: In the 
      general population, past studies have shown no difference in the beneficial 
      effect of aspirin for primary cardiovascular disease prevention by diabetes 
      status. However, several randomized controlled studies and meta-analyses in 
      adults with diabetes have shown lack of net clinical benefit of aspirin use for 
      primary prevention of ASCVD. The recent ASCEND trial documented cardiovascular 
      benefit of aspirin for primary prevention in adults with diabetes but suggested 
      that the increased risk of bleeding may outweigh the cardiovascular benefit. The 
      decision to initiate aspirin for primary prevention of ASCVD must be considered 
      carefully on an individual basis to balance the cardiovascular benefit and 
      bleeding risk in all patients, especially those with diabetes. A multifactorial 
      approach that focuses on managing ASCVD risk factors such as hypertension, 
      dyslipidemia, dysglycemia, and smoking is recommended in all patients. More 
      research is needed to identify subgroups of people with diabetes who are more 
      likely to benefit from aspirin use for primary prevention of ASCVD and develop 
      better antithrombotic strategies that shift the risk-benefit balance toward an 
      overall net clinical benefit.
FAU - Al-Sofiani, Mohammed E
AU  - Al-Sofiani ME
AD  - Division of Endocrinology, Diabetes & Metabolism, The Johns Hopkins University, 
      1830 East Monument Street, Suite 333, Baltimore, MD, 21287, USA.
AD  - Endocrinology Division, College of Medicine, King Saud University, Riyadh, Saudi 
      Arabia.
FAU - Derenbecker, Robert
AU  - Derenbecker R
AD  - General Internal Medicine, The Johns Hopkins University, Baltimore, MD, USA.
FAU - Quartuccio, Michael
AU  - Quartuccio M
AD  - Division of Endocrinology, Diabetes & Metabolism, The Johns Hopkins University, 
      1830 East Monument Street, Suite 333, Baltimore, MD, 21287, USA.
FAU - Kalyani, Rita R
AU  - Kalyani RR
AD  - Division of Endocrinology, Diabetes & Metabolism, The Johns Hopkins University, 
      1830 East Monument Street, Suite 333, Baltimore, MD, 21287, USA. 
      rrastogi@jhmi.edu.
LA  - eng
GR  - R03 DK109163/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190923
PL  - United States
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Diabetes Complications/*complications
MH  - Humans
MH  - Primary Prevention
MH  - Risk Assessment
OTO - NOTNLM
OT  - Aspirin
OT  - Atherosclerotic cardiovascular disease
OT  - Diabetes
OT  - Primary cardiovascular prevention
EDAT- 2019/09/24 06:00
MHDA- 2020/04/16 06:00
CRDT- 2019/09/24 06:00
PHST- 2019/09/24 06:00 [entrez]
PHST- 2019/09/24 06:00 [pubmed]
PHST- 2020/04/16 06:00 [medline]
AID - 10.1007/s11892-019-1206-6 [pii]
AID - 10.1007/s11892-019-1206-6 [doi]
PST - epublish
SO  - Curr Diab Rep. 2019 Sep 23;19(10):107. doi: 10.1007/s11892-019-1206-6.

PMID- 20739873
OWN - NLM
STAT- MEDLINE
DCOM- 20101210
LR  - 20131121
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
VI  - 340
IP  - 5
DP  - 2010 Nov
TI  - Aspirin desensitization/challenge in 3 patients with unstable angina.
PG  - 418-20
LID - 10.1097/MAJ.0b013e3181eecfc7 [doi]
AB  - Aspirin sensitivity is relatively frequent and can be a major problem in patients 
      who need percutaneous coronary intervention and stenting with subsequent dual 
      antiplatelet therapy. Desensitization is often the therapy in these patients, but 
      this can prolong the time to revascularization significantly. Rapid oral aspirin 
      desensitization protocols have been described since 2000. However, data are 
      lacking on the optimal strategy for aspirin desensitization and determining which 
      patients are mostly benefited from this desensitization. The authors describe the 
      use of a Wong-modified protocol in 3 patients who had known aspirin sensitivity 
      and who had unstable angina and an indication for percutaneous coronary 
      intervention.
FAU - Ortega-Loayza, Alex G
AU  - Ortega-Loayza AG
AD  - Department of Internal Medicine, Virginia Commonwealth University, Richmond, 
      Virginia 23298, USA. aortegaloayza2@mcvh-vcu.edu
FAU - Raza, Syed
AU  - Raza S
FAU - Minisi, Anthony J
AU  - Minisi AJ
FAU - Topaz, On
AU  - Topaz O
FAU - Heller, Andrew
AU  - Heller A
FAU - Jovin, Ion S
AU  - Jovin IS
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/*drug therapy
MH  - Aspirin/*immunology/*therapeutic use
MH  - *Desensitization, Immunologic
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*immunology/*therapeutic use
EDAT- 2010/08/27 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/08/27 06:00
PHST- 2010/08/27 06:00 [entrez]
PHST- 2010/08/27 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - S0002-9629(15)31460-9 [pii]
AID - 10.1097/MAJ.0b013e3181eecfc7 [doi]
PST - ppublish
SO  - Am J Med Sci. 2010 Nov;340(5):418-20. doi: 10.1097/MAJ.0b013e3181eecfc7.

PMID- 35373259
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220715
IS  - 1940-6215 (Electronic)
IS  - 1940-6215 (Linking)
VI  - 15
IP  - 4
DP  - 2022 Apr 1
TI  - Role of Aspirin in Gastric Cancer Prevention.
PG  - 213-215
LID - 10.1158/1940-6207.CAPR-22-0014 [doi]
AB  - The role of aspirin in cancer prevention has been well described for multiple 
      cancers, with strong data for gastrointestinal cancers. Studies, primarily 
      conducted in colorectal cancer, suggest that aspirin exerts its cancer-preventive 
      effects through the inhibition of gastrointestinal inflammation. Compared with 
      colorectal cancer, the role of aspirin in gastric cancer prevention is less well 
      described, however it stands to reason that aspirin and/or other nonsteroidal 
      anti-inflammatory drugs may inhibit gastric cancer progression through the 
      inhibition of COX-2. As discussed in this issue of Cancer Prevention Research, 
      aspirin may prevent gastric cancer, albeit it appears to exert a disparate effect 
      in men and women, the reason for which remain unclear. These results expand upon 
      prior studies by prospectively examining aspirin use at a wider range of doses 
      and durations in non-Asian participants and lend support to observations from 
      previously conducted studies in Asian populations. See related article, p. 265.
CI  - ©2022 American Association for Cancer Research.
FAU - Umar, Asad
AU  - Umar A
AUID- ORCID: 0000-0002-6239-8494
AD  - Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, 
      NCI, NIH, Rockville, Maryland.
FAU - Loomans-Kropp, Holli A
AU  - Loomans-Kropp HA
AUID- ORCID: 0000-0002-9681-8725
AD  - Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, 
      NCI, NIH, Rockville, Maryland.
AD  - Cancer Prevention Fellowship Program, Division of Cancer Prevention, NCI, NIH, 
      Rockville, Maryland.
LA  - eng
PT  - Comment
PT  - Editorial
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Cancer Prev Res (Phila). 2022 Apr 1;15(4):265-272. PMID: 34980677
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cyclooxygenase 2
MH  - Female
MH  - *Gastrointestinal Neoplasms/prevention & control
MH  - Humans
MH  - Male
MH  - *Stomach Neoplasms/prevention & control
EDAT- 2022/04/05 06:00
MHDA- 2022/04/06 06:00
CRDT- 2022/04/04 05:36
PHST- 2022/01/07 00:00 [received]
PHST- 2022/01/19 00:00 [revised]
PHST- 2022/02/17 00:00 [accepted]
PHST- 2022/04/04 05:36 [entrez]
PHST- 2022/04/05 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
AID - 682290 [pii]
AID - 10.1158/1940-6207.CAPR-22-0014 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2022 Apr 1;15(4):213-215. doi: 
      10.1158/1940-6207.CAPR-22-0014.

PMID- 30417794
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20200707
IS  - 2212-3938 (Electronic)
IS  - 1574-8847 (Print)
IS  - 1574-8847 (Linking)
VI  - 14
IP  - 2
DP  - 2019
TI  - The Cytotoxicity and Synergistic Potential of Aspirin and Aspirin Analogues 
      Towards Oesophageal and Colorectal Cancer.
PG  - 141-151
LID - 10.2174/1574884713666181112141151 [doi]
AB  - BACKGROUND: Oesophageal cancer (OC) is a deadly cancer because of its aggressive 
      nature with survival rates that have barely improved in decades. Epidemiologic 
      studies have shown that low-dose daily intake of aspirin can decrease the 
      incidence of OC. METHODS: The toxicity of aspirin and aspirin derivatives to OC 
      and a CRC cell line were investigated in the presence and absence of platins. 
      RESULTS: The data in this study show the effects of a number of aspirin analogues 
      and aspirin on OC cell lines that originally presented as squamous cell carcinoma 
      (SSC) and adenocarcinoma (ADC). The aspirin analogues fumaryldiaspirin (PN517) 
      and the benzoylsalicylates (PN524, PN528 and PN529), were observed to be more 
      toxic against the OC cell lines than aspirin. Both quantitative and qualitative 
      apoptosis experiments reveal that these compounds largely induce apoptosis, 
      although some necrosis was evident with PN528 and PN529. Failure to recover 
      following the treatment with these analogues emphasized that these drugs are 
      largely cytotoxic in nature. The OE21 (SSC) and OE33 (ADC) cell lines were more 
      sensitive to the aspirin analogues compared to the Flo-1 cell line (ADC). A 
      non-cancerous oesophageal primary cells NOK2101, was used to determine the 
      specificity of the aspirin analogues and cytotoxicity assays revealed that 
      analogues PN528 and PN529 were selectively toxic to cancer cell lines, whereas 
      PN508, PN517 and PN524 also induced cell death in NOK2101. In combination index 
      testing synergistic interactions of the most promising compounds, including 
      aspirin, with cisplatin, oxaliplatin and carboplatin against the OE33 cell line 
      and the SW480 colorectal cancer (CRC) cell line were investigated. Compounds 
      PN517 and PN524, and to a lesser extent PN528, synergised with cisplatin against 
      OE33 cells. Cisplatin and oxaliplatin synergised with aspirin and PN517 when 
      tested against the SW480 cell line. CONCLUSION: These findings indicate the 
      potential and limitations of aspirin and aspirin analogues as chemotherapeutic 
      agents against OC and CRC when combined with platins.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Kilari, Rajagopal S
AU  - Kilari RS
AD  - Research Institute in Healthcare Science, University of Wolverhampton, 
      Wolverhampton WV1 1 LY, United Kingdom.
FAU - Bashir, Asma'u I J
AU  - Bashir AIJ
AD  - Research Institute in Healthcare Science, University of Wolverhampton, 
      Wolverhampton WV1 1 LY, United Kingdom.
AD  - Department of Pharmacology, Faculty of Pharmaceutical Sciences, Gombe State 
      University, Gombe, Nigeria.
FAU - Devitt, Andreue
AU  - Devitt A
AD  - School of Life & Health Sciences, Aston University, Birmingham B4 7ET, United 
      Kingdom.
FAU - Perry, Christopher J
AU  - Perry CJ
AD  - Research Institute in Healthcare Science, University of Wolverhampton, 
      Wolverhampton WV1 1 LY, United Kingdom.
FAU - Safrany, Stephen T
AU  - Safrany ST
AD  - RCSI Bahrain, P.O. Box 15503, Adliya, Bahrain.
FAU - Nicholl, Iain D
AU  - Nicholl ID
AD  - Research Institute in Healthcare Science, University of Wolverhampton, 
      Wolverhampton WV1 1 LY, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Clin Pharmacol
JT  - Current clinical pharmacology
JID - 101273158
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Organoplatinum Compounds)
RN  - 04ZR38536J (Oxaliplatin)
RN  - Q20Q21Q62J (Cisplatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/*analogs & derivatives/*pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cisplatin/pharmacology/therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Drug Synergism
MH  - Esophageal Neoplasms/*drug therapy
MH  - Humans
MH  - Organoplatinum Compounds/pharmacology
MH  - Oxaliplatin/pharmacology/therapeutic use
PMC - PMC7040498
OTO - NOTNLM
OT  - Oesophageal cancer
OT  - apoptosis
OT  - aspirin
OT  - aspirin analogues
OT  - morbidity
OT  - platins.
EDAT- 2018/11/13 06:00
MHDA- 2020/07/08 06:00
CRDT- 2018/11/13 06:00
PHST- 2018/04/13 00:00 [received]
PHST- 2018/10/24 00:00 [revised]
PHST- 2018/10/31 00:00 [accepted]
PHST- 2018/11/13 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
PHST- 2018/11/13 06:00 [entrez]
AID - CCP-EPUB-94452 [pii]
AID - CP-14-141 [pii]
AID - 10.2174/1574884713666181112141151 [doi]
PST - ppublish
SO  - Curr Clin Pharmacol. 2019;14(2):141-151. doi: 10.2174/1574884713666181112141151.

PMID- 3955197
OWN - NLM
STAT- MEDLINE
DCOM- 19860507
LR  - 20191022
IS  - 0142-2782 (Print)
IS  - 0142-2782 (Linking)
VI  - 7
IP  - 1
DP  - 1986 Jan-Feb
TI  - Acetylsalicylic acid metabolites in blood and urine after plain and 
      enteric-coated tablets.
PG  - 21-5
AB  - Acetylsalicylic acid (ASA) was administered orally as a single dose to 7 healthy 
      male volunteers as plain or enteric-coated (Entrophen) tablets using a crossover 
      design. Blood and urine samples were collected and analysed for ASA metabolites 
      by high performance liquid chromatography. Labile and stable glucuronide 
      conjugates of salicylic acid (SA) were measured in urine after differential 
      hydrolysis with glucuronidase. Plasma kinetic parameters for the ASA metabolites 
      SA and salicyluric acid were not different for the 2 formulations, apart from the 
      delayed appearance after the enteric-coated tablets. Total urinary recovery, and 
      recovery of salicyluric acid and the two SA glucuronides were not different, thus 
      confirming the equivalent bioavailability and metabolite profile of the 2 ASA 
      formulations.
FAU - Montgomery, P R
AU  - Montgomery PR
FAU - Sitar, D S
AU  - Sitar DS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Biopharm Drug Dispos
JT  - Biopharmaceutics & drug disposition
JID - 7911226
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*metabolism/urine
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid
MH  - Hippurates/blood
MH  - Humans
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Tablets, Enteric-Coated
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1002/bdd.2510070104 [doi]
PST - ppublish
SO  - Biopharm Drug Dispos. 1986 Jan-Feb;7(1):21-5. doi: 10.1002/bdd.2510070104.

PMID- 4127544
OWN - NLM
STAT- MEDLINE
DCOM- 19740115
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 7839
DP  - 1973 Nov 24
TI  - Influence of acetylsalicylic acid, an inhibitor of prostaglandin synthesis, on 
      the duration of human gestation and labour.
PG  - 1159-61
FAU - Lewis, R B
AU  - Lewis RB
FAU - Schulman, J D
AU  - Schulman JD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Birth Weight
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Labor, Obstetric/*drug effects
MH  - Postpartum Hemorrhage/chemically induced
MH  - Pregnancy/*drug effects
MH  - *Prostaglandin Antagonists
MH  - Prostaglandins/biosynthesis
MH  - Retrospective Studies
OID - PIP: 000996
OID - POP: 00086537
OAB - A retrospective survey of 103 patients taking high-dose acetylsalicylic acid for 
      at least the last 6 months of pregnancy has been carried out and comparisons were 
      made with control populations. Aspirin administration was associated with a 
      highly significant increase in the average length of gestation, in the frequency 
      of postmaturity, and in the mean duration of spontaneous labor. These 
      observations are compatible with the known capacity of aspirin to inhibit the 
      synthesis of (PG) prostaglandins, and suggest that endogenous PGs are important 
      regulators of the duration of human gestation and labor. The possibility is 
      raised that aberrations in PG metabolism could be responsible for certain 
      instances of postmaturity or prolonged labor.
OABL- eng
OTO - PIP
OT  - Age Factors
OT  - Biology
OT  - *Birth Weight--statistics
OT  - Body Weight
OT  - *Control Groups
OT  - *Delivery--statistics
OT  - Endocrine System
OT  - Parity
OT  - Physiology
OT  - Population Characteristics
OT  - *Pregnancy
OT  - *Pregnancy Outcomes
OT  - *Prostaglandins
OT  - Reproduction
OT  - Research Methodology
OT  - *Retrospective Studies
OT  - Studies
OT  - Surveys
GN  - PIP: TJ: LANCET.
EDAT- 1973/11/24 00:00
MHDA- 1973/11/24 00:01
CRDT- 1973/11/24 00:00
PHST- 1973/11/24 00:00 [pubmed]
PHST- 1973/11/24 00:01 [medline]
PHST- 1973/11/24 00:00 [entrez]
AID - S0140-6736(73)92934-6 [pii]
AID - 10.1016/s0140-6736(73)92934-6 [doi]
PST - ppublish
SO  - Lancet. 1973 Nov 24;2(7839):1159-61. doi: 10.1016/s0140-6736(73)92934-6.

PMID- 9091911
OWN - NLM
STAT- MEDLINE
DCOM- 19970409
LR  - 20220318
IS  - 0032-1052 (Print)
IS  - 0032-1052 (Linking)
VI  - 99
IP  - 4
DP  - 1997 Apr
TI  - Effect of low dose aspirin on thrombus formation at arterial and venous 
      microanastomoses and on the tissue microcirculation.
PG  - 1112-21
AB  - In free flap/replantation surgery, failure is usually associated with thrombotic 
      occlusion of a microvascular anastomosis (risk zone I) or, on occasion, flow 
      impairment in the microcirculation of the transferred or replanted tissue (risk 
      zone II). The objective of this study is to describe the effect of low dose 
      aspirin on blood flow at both risk zones in microvascular surgery. Risk zone I: 
      In rat femoral arteries and veins, thrombus formation was measured at the 
      anastomoses using transillumination and videomicroscopy. Forty male Wistar rats 
      were assigned in equal numbers to four groups: either arterial or venous injury 
      with either aspirin (5 mg/kg systemically) or saline treatment. We found that 
      aspirin significantly reduces thrombus formation at the venous anastomosis (p = 
      0.001). Risk zone II: In the isolated rat cremaster muscle downstream from an 
      arterial anastomosis, we measured capillary perfusion, arteriolar diameters, and 
      the appearance of platelet emboli for 6 hours in the muscle microcirculation. 
      Sixteen male Wistar rats in two equal groups received either aspirin (5 mg/kg 
      systemically) or saline. We found that in aspirin-treated animals, capillary 
      perfusion is significantly (p = 0.002) improved, whereas arteriolar diameters and 
      emboli only slightly increased. In conclusion, low dose aspirin inhibits 
      anastomotic venous thrombosis and improves microcirculatory perfusion in our rat 
      model. These studies provide quantitative data confirming and clarifying the 
      beneficial effects of low dose aspirin in microvascular surgery.
FAU - Peter, F W
AU  - Peter FW
AD  - Department of Physiology and Biophysics, University of Louisville School of 
      Medicine, Kentucky, USA.
FAU - Franken, R J
AU  - Franken RJ
FAU - Wang, W Z
AU  - Wang WZ
FAU - Anderson, G L
AU  - Anderson GL
FAU - Schuschke, D A
AU  - Schuschke DA
FAU - O'Shaughnessy, M M
AU  - O'Shaughnessy MM
FAU - Banis, J C
AU  - Banis JC
FAU - Steinau, H U
AU  - Steinau HU
FAU - Barker, J H
AU  - Barker JH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Plast Reconstr Surg
JT  - Plastic and reconstructive surgery
JID - 1306050
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anastomosis, Surgical/adverse effects
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Male
MH  - Microcirculation/*drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Thrombosis/etiology/*prevention & control
MH  - Vascular Surgical Procedures/*adverse effects
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - 10.1097/00006534-199704000-00030 [doi]
PST - ppublish
SO  - Plast Reconstr Surg. 1997 Apr;99(4):1112-21. doi: 
      10.1097/00006534-199704000-00030.

PMID- 698392
OWN - NLM
STAT- MEDLINE
DCOM- 19781220
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 52
IP  - 5
DP  - 1978 Nov
TI  - Sex differences in the antithrombotic effects of aspirin.
PG  - 1073-6
AB  - Aspirin inhibits platelet function by acetylating platelet cyclooxygenase. Recent 
      clinical trials indicate that aspirin is a promising antithrombotic agent against 
      both venous and arterial thrombosis, but somewhat surprisingly this protective 
      effect appears to be limited to males. To examine the potential sex-related 
      differences in response to aspirin, we developed an animal model for quantitating 
      fibrin accretion into an injury-induced thrombus and used it to study the effects 
      of aspirin on thrombus size in male and female rabbits. Platelet prostaglandin 
      synthesis was estimated by assay of platelet malondialdehyde and was 
      significantly decreased in both male and female rabbits following treatment with 
      10 mg/kg aspirin (p less than 0.001). This inhibitory effect was not different 
      for platelets from male and female rabbits. Thrombus size was significantly 
      decreased in aspirin-treated male rabbits when compared to controls (p less than 
      0.05), but this aspirin effect was not apparent in female rabbits or rabbits of 
      either sex treated with 10 mg/kg sodium salicylate. These findings support the 
      results of clinical trials that were obtained by retrospective subgroup analysis. 
      The reason for the sex difference is not known, but the findings raise an 
      important issue in relationship to this mechanism of the antithrombotic effect of 
      aspirin.
FAU - Kelton, J G
AU  - Kelton JG
FAU - Hirsh, J
AU  - Hirsh J
FAU - Carter, C J
AU  - Carter CJ
FAU - Buchanan, M R
AU  - Buchanan MR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Female
MH  - *Fibrinolytic Agents
MH  - Male
MH  - Rabbits
MH  - *Sex
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
AID - S0006-4971(20)82965-6 [pii]
PST - ppublish
SO  - Blood. 1978 Nov;52(5):1073-6.

PMID- 6436696
OWN - NLM
STAT- MEDLINE
DCOM- 19841128
LR  - 20220225
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 311
IP  - 19
DP  - 1984 Nov 8
TI  - Dose-related kinetics of aspirin. Presystemic acetylation of platelet 
      cyclooxygenase.
PG  - 1206-11
AB  - When aspirin is administered by mouth in low doses, poor systemic bioavailability 
      may contribute to its apparent dose-related "selective inhibition" of thromboxane 
      A2 formation. Systemic bioavailability of orally administered aspirin is 
      necessary to inhibit prostacyclin synthesis by systemic vascular endothelium, 
      whereas cumulative inhibition of thromboxane A2 formation by platelets may occur 
      in the presystemic (portal) circulation. We simultaneously administered unlabeled 
      aspirin orally and deuterium-labeled aspirin intravenously in five healthy 
      volunteers. This permitted an estimation of the bioavailability of an oral dose 
      from the ratio of plasma drug concentration-time curves for the labeled and the 
      unlabeled species. Systemic bioavailability ranged from 46 to 51 per cent of 
      single oral doses of 20, 40, 325, and 1300 mg of aspirin. Bioavailability was 
      similar after single-dose and long-term oral administration of 325 mg. 
      Thromboxane B2 formation in serum ex vivo after oral administration of 20 mg of 
      unlabeled aspirin was reduced 39 per cent before aspirin was detected in the 
      systemic circulation. Furthermore, incubation of simulated peak plasma aspirin 
      concentrations in whole blood in vitro underestimated the inhibition of 
      thromboxane B2 ex vivo after oral administration of 20 or 40 mg of unlabeled 
      aspirin. These data are consistent with presystemic inhibition of platelets by 
      aspirin and suggest that biochemical "selectivity" might be enhanced by slow 
      administration of very low doses of aspirin, thereby optimizing conditions for 
      cumulative, presystemic acetylation of platelet cyclooxygenase and inhibition of 
      thromboxane formation.
FAU - Pedersen, A K
AU  - Pedersen AK
FAU - FitzGerald, G A
AU  - FitzGerald GA
LA  - eng
GR  - GM-15431/GM/NIGMS NIH HHS/United States
GR  - HL-30400/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 54397-85-2 (Thromboxane B2)
RN  - AR09D82C7G (Deuterium)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*metabolism/pharmacology
MH  - Biological Availability
MH  - Blood Platelets/drug effects/*enzymology
MH  - Deuterium
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Injections, Intravenous
MH  - Kinetics
MH  - Male
MH  - Prostaglandin-Endoperoxide Synthases/*blood
MH  - Thromboxane B2/biosynthesis
EDAT- 1984/11/08 00:00
MHDA- 1984/11/08 00:01
CRDT- 1984/11/08 00:00
PHST- 1984/11/08 00:00 [pubmed]
PHST- 1984/11/08 00:01 [medline]
PHST- 1984/11/08 00:00 [entrez]
AID - 10.1056/NEJM198411083111902 [doi]
PST - ppublish
SO  - N Engl J Med. 1984 Nov 8;311(19):1206-11. doi: 10.1056/NEJM198411083111902.

PMID- 25126928
OWN - NLM
STAT- MEDLINE
DCOM- 20150529
LR  - 20140816
IS  - 1079-7114 (Electronic)
IS  - 0031-9007 (Linking)
VI  - 113
IP  - 5
DP  - 2014 Aug 1
TI  - Role of dispersion interactions in the polymorphism and entropic stabilization of 
      the aspirin crystal.
PG  - 055701
AB  - Aspirin has been used and studied for over a century but has only recently been 
      shown to have an additional polymorphic form, known as form II. Since the two 
      observed solid forms of aspirin are degenerate in terms of lattice energy, 
      kinetic effects have been suggested to determine the metastability of the less 
      abundant form II. Here, first-principles calculations provide an alternative 
      explanation based on free-energy differences at room temperature. The explicit 
      consideration of many-body van der Waals interactions in the free energy 
      demonstrates that the stability of the most abundant form of aspirin is due to a 
      subtle coupling between collective electronic fluctuations and quantized lattice 
      vibrations. In addition, a systematic analysis of the elastic properties of the 
      two forms of aspirin rules out mechanical instability of form II as making it 
      metastable.
FAU - Reilly, Anthony M
AU  - Reilly AM
AD  - Fritz-Haber-Institut der Max-Planck-Gesellschaft, Faradayweg 4-6, 14195 Berlin, 
      Germany.
FAU - Tkatchenko, Alexandre
AU  - Tkatchenko A
AD  - Fritz-Haber-Institut der Max-Planck-Gesellschaft, Faradayweg 4-6, 14195 Berlin, 
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140730
PL  - United States
TA  - Phys Rev Lett
JT  - Physical review letters
JID - 0401141
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Elastic Modulus
MH  - Elasticity
MH  - Kinetics
MH  - Models, Molecular
MH  - Thermodynamics
EDAT- 2014/08/16 06:00
MHDA- 2015/05/30 06:00
CRDT- 2014/08/16 06:00
PHST- 2014/04/03 00:00 [received]
PHST- 2014/08/16 06:00 [entrez]
PHST- 2014/08/16 06:00 [pubmed]
PHST- 2015/05/30 06:00 [medline]
AID - 10.1103/PhysRevLett.113.055701 [doi]
PST - ppublish
SO  - Phys Rev Lett. 2014 Aug 1;113(5):055701. doi: 10.1103/PhysRevLett.113.055701. 
      Epub 2014 Jul 30.

PMID- 18437592
OWN - NLM
STAT- MEDLINE
DCOM- 20080722
LR  - 20211203
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 36
IP  - 2
DP  - 2008
TI  - DBBF modified human placenta hemoglobin through the alpha chains.
PG  - 156-65
LID - 10.1080/10731190801932140 [doi]
AB  - Hemoglobin-based blood substitute is widely studied. As the starting materials, 
      hemoglobin (Hb) is mainly supplied from outdated human blood and animal sources. 
      But there are many disadvantages. As the alternative source, human placenta 
      hemoglobin (PHb) has its own advantages. We take the lead in being occupied in 
      the research of blood substitutes based on the placenta blood. Purified PHb 
      readily undergoes dissociation to form two dimers that are easily filtered by the 
      kidneys and have high 02 affinity (low P50), failing to transport 02 to tissues. 
      As a first step, to enhance PHb stability and P50, we first adopted DBBF to 
      modify deoxyPHb leading to DBBF-alpha PHb. According to detection, we knew that 
      the PHb stability was improved, 02 affinity of the PHb solution was reduced, 
      DBBF-alpha PHb had the appropriate capacity of oxygen-carrying and 
      oxygen-unloading, and DBBF-alpha PHb kept the biological activity well. On the 
      whole DBBF-alpha PHb could be considered as a first step toward the synthesis of 
      a potential blood substitute.
FAU - Huang, Lei
AU  - Huang L
AD  - College of Material Science and Chemical Engineering, Tianjin Polytechnic 
      University, Tianjin, China.
FAU - Wang, Bing
AU  - Wang B
FAU - Wang, Xiang
AU  - Wang X
FAU - Liang, Wei-Guang
AU  - Liang WG
FAU - Yang, Cheng-Min
AU  - Yang CM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (PHB protein, human)
RN  - 0 (Phb protein, rat)
RN  - 0 (Prohibitins)
RN  - 0 (Protein Subunits)
RN  - 0 (bis(3,5-dibromosalicyl)fumarate-crosslinked hemoglobin A(0))
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & 
      derivatives/chemistry/metabolism/pharmacokinetics
MH  - *Blood Substitutes
MH  - Enzyme Stability
MH  - Female
MH  - Hemoglobin A/administration & dosage/chemistry/metabolism/pharmacokinetics
MH  - Hemoglobins/*chemistry/isolation & purification/*metabolism
MH  - Humans
MH  - Multiprotein Complexes/isolation & purification/metabolism
MH  - Placenta/*metabolism
MH  - Pregnancy
MH  - Prohibitins
MH  - Protein Subunits/chemistry/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2008/04/26 09:00
MHDA- 2008/07/23 09:00
CRDT- 2008/04/26 09:00
PHST- 2008/04/26 09:00 [pubmed]
PHST- 2008/07/23 09:00 [medline]
PHST- 2008/04/26 09:00 [entrez]
AID - 792553923 [pii]
AID - 10.1080/10731190801932140 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 2008;36(2):156-65. doi: 
      10.1080/10731190801932140.

PMID- 3527555
OWN - NLM
STAT- MEDLINE
DCOM- 19861020
LR  - 20131121
IS  - 0010-8650 (Print)
IS  - 0010-8650 (Linking)
VI  - 28
IP  - 3
DP  - 1986
TI  - Improvement of aortocoronary bypass patency by antiplatelet drug administration. 
      Preliminary communication.
PG  - 177-80
AB  - Patients with aortocoronary bypass whose peroperatively measured blood flow 
      amounted to 40 ml/min or less were divided into two groups. The treated group was 
      from postoperative day 0 given 2 X 500 mg acetylsalicylic acid and 3 X 75 mg 
      dipyridamole per day; the control group was without this medication. One month 
      and one year after surgery the patients were examined by coronarography. The 
      first follow-up examination revealed in the treated group 34 patent and 7 
      occluded bypasses, in the control group 17 patent and 20 occluded bypasses. On 
      late follow-up examination there were in the treated group 24 patent and 13 
      occluded and in the control group 8 patent and 30 occluded bypasses (p less than 
      0.001).
FAU - Pirk, J
AU  - Pirk J
FAU - Vojácek, J
AU  - Vojácek J
FAU - Kovác, J
AU  - Kovác J
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Czech Republic
TA  - Cor Vasa
JT  - Cor et vasa
JID - 0372614
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Clinical Trials as Topic
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/pharmacology/therapeutic use
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Cor Vasa. 1986;28(3):177-80.

PMID- 16419075
OWN - NLM
STAT- MEDLINE
DCOM- 20060614
LR  - 20171116
IS  - 0006-3525 (Print)
IS  - 0006-3525 (Linking)
VI  - 81
IP  - 6
DP  - 2006 Apr 15
TI  - Competition of cytarabine and aspirin in binding to serum albumin in multidrug 
      therapy.
PG  - 464-72
AB  - The aim of this study was to describe a competition between cytarabine (araC) and 
      aspirin (ASA) in binding with bovine serum albumin (BSA). High-affinity binding 
      sites for both drugs were determined using a spectrofluorimetric method. 
      Cytarabine as well as aspirin binds in the IIA hydrophobic subdomain of the 
      transporting protein. Binding constants for araC-BSA and ASA-BSA were calculated 
      by the Scatchard method. Analysis of ultraviolet (UV) difference spectra showed 
      that araC, which has a higher affinity to BSA in comparison to ASA [Ka(araC) > 
      Ka(ASA)] displaces ASA in high-affinity binding sites. The competition between 
      drugs in low-affinity binding sites was investigated using (1)H nuclear magnetic 
      resonance (NMR) and 13C-NMR spectra. We concluded that in the low-affinity 
      binding sites cytarabine decreases the affinity of albumin toward aspirin. 
      However, the interaction between araC and BSA becomes more difficult in the 
      presence of aspirin.
CI  - Copyright 2006 Wiley Periodicals, Inc.
FAU - Sułkowska, Anna
AU  - Sułkowska A
AD  - Medical University of Silesia, Department of Physical Pharmacy, Jagiellońska 4, 
      Sosnowiec, 41-200, Poland. annasulkowska@yahoo.com
FAU - Bojko, Barbara
AU  - Bojko B
FAU - Równicka, Joanna
AU  - Równicka J
FAU - Sułkowski, Wiesław W
AU  - Sułkowski WW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biopolymers
JT  - Biopolymers
JID - 0372525
RN  - 04079A1RDZ (Cytarabine)
RN  - 27432CM55Q (Serum Albumin, Bovine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/metabolism
MH  - *Binding, Competitive
MH  - Cytarabine/*chemistry/metabolism
MH  - Drug Interactions
MH  - *Drug Therapy, Combination
MH  - Magnetic Resonance Spectroscopy
MH  - Serum Albumin, Bovine/*chemistry/metabolism
EDAT- 2006/01/19 09:00
MHDA- 2006/06/15 09:00
CRDT- 2006/01/19 09:00
PHST- 2006/01/19 09:00 [pubmed]
PHST- 2006/06/15 09:00 [medline]
PHST- 2006/01/19 09:00 [entrez]
AID - 10.1002/bip.20445 [doi]
PST - ppublish
SO  - Biopolymers. 2006 Apr 15;81(6):464-72. doi: 10.1002/bip.20445.

PMID- 7960314
OWN - NLM
STAT- MEDLINE
DCOM- 19941130
LR  - 20131121
IS  - 0172-4622 (Print)
IS  - 0172-4622 (Linking)
VI  - 15
IP  - 5
DP  - 1994 Jul
TI  - Aspirin does not affect exercise performance.
PG  - 224-7
AB  - A single-blind, cross-over study was carried out to evaluate the effects of 
      acetylsalicylic acid (ASA) on cardiorespiratory performance during exercise. 
      Eighteen young men, 9 athletes and 9 untrained but active subjects, performed a 
      progressive maximal exercise test on a cycle ergometer (30 watt, 3 min steps, 
      starting at 60 watt) on three different occasions, after a single administration 
      of plain aspirin (1000mg of ASA), chewable buffered aspirin (1000mg of ASA and 
      600 mg of calcium carbonate) and placebo. Continuous measurement of 
      breath-by-breath ventilation, oxygen consumption, carbon dioxide output, 
      respiratory frequency and heart rate was carried-out at rest and during the 
      exercise test. Blood lactate concentration was measured just before the start of 
      exercise and at the third minute of each step in order to detect the anaerobic 
      threshold. The pharmacokinetics of aspirin during exercise was also investigated 
      in ten of the eighteen participants. The analysis of all investigated variables 
      did not show any statistically significant difference between treatments, 
      suggesting that a single dose of 1000mg of aspirin does not affect physical 
      performance during submaximal and maximal exercise.
FAU - Roi, G S
AU  - Roi GS
AD  - Dipartimento di Scienze e Tecnologie Biomediche, Università degli Studi di 
      Milano, Ospedale San Raffaele, Segrate.
FAU - Garagiola, U
AU  - Garagiola U
FAU - Verza, P
AU  - Verza P
FAU - Spadari, G
AU  - Spadari G
FAU - Radice, D
AU  - Radice D
FAU - Zecca, L
AU  - Zecca L
FAU - Cerretelli, P
AU  - Cerretelli P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int J Sports Med
JT  - International journal of sports medicine
JID - 8008349
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anaerobic Threshold/drug effects
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Cross-Over Studies
MH  - Exercise/physiology
MH  - Humans
MH  - Male
MH  - Physical Exertion/*drug effects
MH  - Single-Blind Method
EDAT- 1994/07/01 00:00
MHDA- 1994/07/01 00:01
CRDT- 1994/07/01 00:00
PHST- 1994/07/01 00:00 [pubmed]
PHST- 1994/07/01 00:01 [medline]
PHST- 1994/07/01 00:00 [entrez]
AID - 10.1055/s-2007-1021050 [doi]
PST - ppublish
SO  - Int J Sports Med. 1994 Jul;15(5):224-7. doi: 10.1055/s-2007-1021050.

PMID- 24553145
OWN - NLM
STAT- MEDLINE
DCOM- 20150724
LR  - 20140711
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 64
IP  - 1
DP  - 2014 Jul
TI  - Assessment methods for aspirin-mediated platelet antiaggregation in type 2 
      diabetic patients: degree of correlation between 2 point-of-care methods.
PG  - 16-20
LID - 10.1097/FJC.0000000000000084 [doi]
AB  - AIMS: Impaired response to antiplatelet therapy in diabetic patients results in a 
      higher incidence of drug-eluting stent thrombosis. This study determined the 
      prevalence of high on-aspirin (AS) platelet reactivity in type 2 diabetic 
      patients treated with percutaneous coronary intervention (PCI) using the 
      VerifyNow Aspirin Assay (VN) and platelet function analyzer PFA-100 (PFA-100) and 
      analyzed the correlation between both methods. METHODS: Type 2 diabetic patients 
      (100) with non-ST-elevation acute coronary syndrome who underwent PCI and Xience 
      V drug-eluting stent implantation were included in this study. After PCI, 
      platelet antiaggregation mediated by acetylsalicylic acid was assessed by VN and 
      PFA-100. The degree of correlation and concordance was then determined. RESULTS: 
      When assayed with VN, 7% of the patients were nonresponders to aspirin (aspirin 
      reaction units >550), and when assayed with PFA-10, 41% were nonresponders 
      (closure time <193 seconds). Of the patients, 4% were nonresponders to aspirin 
      according to VN but were sensitive to aspirin according to PFA-100, and 38% were 
      sensitive to aspirin according to VN and nonresponders according to PFA-100. 
      Overall, 55% of the patients were aspirin-sensitive in both methods. The 
      Spearman's coefficient between VN and PFA-100 results was r = 0.09 (P = 0.35). 
      The kappa index value was 0.0062 (P = 0.91). CONCLUSIONS: There is no concordance 
      or correlation between the VN and PFA-100 results. Therefore, the use of these 
      analyses should be restricted to clinical research, which limits its application 
      in clinical practice.
FAU - Cubero Gómez, Jose M
AU  - Cubero Gómez JM
AD  - *Department of Cardiology, Hospital Universitario Virgen del Rocio, Seville, 
      Spain; and Departments of †Internal Medicine, ‡Investigation, and §Cardiology, 
      Hospital Universitario Virgen de Valme, Seville, Spain.
FAU - Navarro Puerto, María A
AU  - Navarro Puerto MA
FAU - Acosta Martínez, Juan
AU  - Acosta Martínez J
FAU - De Mier Barragán, María I
AU  - De Mier Barragán MI
FAU - Pérez Santigosa, Pastor L
AU  - Pérez Santigosa PL
FAU - Sánchez Burguillos, Francisco
AU  - Sánchez Burguillos F
FAU - Molano Casimiro, Francisco
AU  - Molano Casimiro F
FAU - Pastor Torres, Luis
AU  - Pastor Torres L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Drug-Eluting Stents
MH  - Female
MH  - Humans
MH  - Male
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests
MH  - *Point-of-Care Systems
MH  - Prospective Studies
MH  - Statistics, Nonparametric
EDAT- 2014/02/21 06:00
MHDA- 2015/07/25 06:00
CRDT- 2014/02/21 06:00
PHST- 2014/02/21 06:00 [entrez]
PHST- 2014/02/21 06:00 [pubmed]
PHST- 2015/07/25 06:00 [medline]
AID - 10.1097/FJC.0000000000000084 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2014 Jul;64(1):16-20. doi: 10.1097/FJC.0000000000000084.

PMID- 1026515
OWN - NLM
STAT- MEDLINE
DCOM- 19770718
LR  - 20131121
IS  - 0014-8318 (Print)
IS  - 0014-8318 (Linking)
VI  - 39
IP  - 3
DP  - 1976 May-Jun
TI  - [Anti-inflammatory effect of methylmethionine sulfonium chloride (vitamin U)].
PG  - 316-9
AB  - Tests conducted on mice demonstrated that methylmethionine-sulfonium chloride 
      (vitamin U) is capable of lowering the permeability of the skin capillaries 
      following the action of stimulants. It greatly potentiates the antiphlogistic 
      effect of acetylsalicylic acid, this action being more pronounced with vitamin U 
      administered one hour before intake of acetlsaliclic acid than when both are 
      taken simultaneously. Given in a dose of 1000 mg/kg vitamin U helps reduce 
      exudation in aseptic serosites in rats. The antiphlogistic effect of vitamin U 
      comes in conjunction with its ability to exercise a protective action against 
      lesion of the gastric mucosa produced by acetylsalicylic acid.
FAU - Urazaeva, L G
AU  - Urazaeva LG
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Farmakol Toksikol
JT  - Farmakologiia i toksikologiia
JID - 16920420R
RN  - 0 (Vitamins)
RN  - 3485Y39925 (Vitamin U)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Capillary Permeability/drug effects
MH  - Drug Evaluation
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Mice
MH  - Rats
MH  - Serositis/*drug therapy
MH  - Skin/blood supply
MH  - Vitamin U/administration & dosage/pharmacology/*therapeutic use
MH  - Vitamins/*therapeutic use
EDAT- 1976/05/01 00:00
MHDA- 1976/05/01 00:01
CRDT- 1976/05/01 00:00
PHST- 1976/05/01 00:00 [pubmed]
PHST- 1976/05/01 00:01 [medline]
PHST- 1976/05/01 00:00 [entrez]
PST - ppublish
SO  - Farmakol Toksikol. 1976 May-Jun;39(3):316-9.

PMID- 4036917
OWN - NLM
STAT- MEDLINE
DCOM- 19851003
LR  - 20190716
IS  - 0002-922X (Print)
IS  - 0002-922X (Linking)
VI  - 139
IP  - 9
DP  - 1985 Sep
TI  - Reye syndrome and juvenile rheumatoid arthritis in Michigan.
PG  - 870-2
AB  - Reye syndrome (RS) is believed to occur infrequently among children receiving 
      long-term aspirin therapy. We reviewed all cases of RS reported to the Michigan 
      Department of Public Health during 1982 and 1983. Three of the 36 patients were 
      receiving aspirin for the treatment of juvenile rheumatoid arthritis. All three 
      patients had clinical courses characteristic of RS and two had supportive 
      histologic findings on liver biopsy. The incidence of RS among children with 
      juvenile rheumatoid arthritis is significantly greater than the incidence of RS 
      among children who do not have juvenile rheumatoid arthritis. These findings 
      support previous studies that showed that the use of aspirin during the 
      antecedent illness may be a risk factor for the development of RS. Physicians 
      should be aware of the potential for the development of RS among children who are 
      receiving long-term aspirin therapy for the treatment of systemic inflammatory 
      illnesses.
FAU - Remington, P L
AU  - Remington PL
FAU - Shabino, C L
AU  - Shabino CL
FAU - McGee, H
AU  - McGee H
FAU - Preston, G
AU  - Preston G
FAU - Sarniak, A P
AU  - Sarniak AP
FAU - Hall, W N
AU  - Hall WN
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Dis Child
JT  - American journal of diseases of children (1960)
JID - 0370471
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Male
MH  - Michigan
MH  - Reye Syndrome/*chemically induced
EDAT- 1985/09/01 00:00
MHDA- 1985/09/01 00:01
CRDT- 1985/09/01 00:00
PHST- 1985/09/01 00:00 [pubmed]
PHST- 1985/09/01 00:01 [medline]
PHST- 1985/09/01 00:00 [entrez]
AID - 10.1001/archpedi.1985.02140110024021 [doi]
PST - ppublish
SO  - Am J Dis Child. 1985 Sep;139(9):870-2. doi: 10.1001/archpedi.1985.02140110024021.

PMID- 8750369
OWN - NLM
STAT- MEDLINE
DCOM- 19961029
LR  - 20190826
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 35
IP  - 12
DP  - 1995 Dec
TI  - Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in 
      healthy male volunteers.
PG  - 1181-6
AB  - Data describing the pharmacokinetics and pharmacodynamics of low dose aspirin 
      (acetylsalicylic acid; ASA) are limited. This single-center study was designed to 
      determine the rate and extent of oral absorption of 80-mg ASA tablets in healthy, 
      young male subjects and to assess the intra- and inter-subject variability of ASA 
      pharmacokinetics and platelet aggregation effects. Ten subjects each received a 
      single, open-label, oral 80-mg ASA dose on three separate days. Each dose was 
      separated by a 2-week washout interval. Blood samples for pharmacokinetic 
      determinations of ASA and its metabolite, salicylic acid (SA) and platelet 
      aggregation studies were obtained at scheduled timepoints before and up to 24 
      hours after each dose. Peak plasma ASA levels of 1 microgram/mL were achieved 
      within 30 minutes. Peak plasma SA levels of approximately 4 micrograms/mL were 
      attained in 1 hour. The terminal half-lives (t1/2) of ASA and SA were 0.4 and 2.1 
      hours, respectively. Both ASA and SA pharmacokinetics and the platelet 
      aggregation response to ASA exhibited considerable intra- and inter-subject 
      variability. Inhibition of platelet aggregation was found to relate with ASA area 
      under the plasma concentration versus time curve (AUC).
FAU - Benedek, I H
AU  - Benedek IH
AD  - Clinical Research and Development Department, The DuPont Merck Pharmaceutical 
      Company, Newark, Delaware 19714, USA.
FAU - Joshi, A S
AU  - Joshi AS
FAU - Pieniaszek, H J
AU  - Pieniaszek HJ
FAU - King, S Y
AU  - King SY
FAU - Kornhauser, D M
AU  - Kornhauser DM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics/pharmacology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacokinetics
MH  - Salicylates/pharmacokinetics
MH  - Salicylic Acid
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1995.tb04044.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1995 Dec;35(12):1181-6. doi: 
      10.1002/j.1552-4604.1995.tb04044.x.

PMID- 1651564
OWN - NLM
STAT- MEDLINE
DCOM- 19910916
LR  - 20220331
IS  - 0040-6376 (Print)
IS  - 1468-3296 (Electronic)
IS  - 0040-6376 (Linking)
VI  - 46
IP  - 1
DP  - 1991 Jan
TI  - Digital gangrene in small cell lung cancer: response to aspirin treatment.
PG  - 63-4
AB  - A patient who had small cell lung cancer complicated by symmetrical peripheral 
      gangrene, secondary to spontaneous platelet aggregation, improved dramatically 
      after starting aspirin treatment.
FAU - Arrowsmith, J E
AU  - Arrowsmith JE
AD  - Department of Thoracic Medicine, St. George's Hospital, London.
FAU - Woodhead, M A
AU  - Woodhead MA
FAU - Bevan, D H
AU  - Bevan DH
FAU - Nanson, E M
AU  - Nanson EM
FAU - Cummin, A R
AU  - Cummin AR
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Thorax
JT  - Thorax
JID - 0417353
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelet Disorders/drug therapy/*etiology
MH  - Carcinoma, Small Cell/*complications
MH  - Fingers/*pathology
MH  - Gangrene
MH  - Humans
MH  - Lung Neoplasms/*complications
MH  - Male
MH  - Middle Aged
MH  - *Platelet Aggregation/drug effects
PMC - PMC1020918
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1136/thx.46.1.63 [doi]
PST - ppublish
SO  - Thorax. 1991 Jan;46(1):63-4. doi: 10.1136/thx.46.1.63.

PMID- 3475538
OWN - NLM
STAT- MEDLINE
DCOM- 19870909
LR  - 20191029
IS  - 0742-2814 (Print)
IS  - 0742-2814 (Linking)
VI  - 7
IP  - 2
DP  - 1986 Mar-Apr
TI  - Aspirin desensitization.
PG  - 101-4
AB  - Aspirin desensitization can be carried out in all aspirin sensitive patients in 
      whom the reaction is confined to the respiratory tract. Because only a few 
      patients with urticarial reactions to ASA have been studied and the results are 
      inconsistent, desensitization of urticaria patients cannot be recommended at this 
      time. In asthmatic patients with aspirin sensitivity, who undergo ASA 
      desensitization, continuous treatment with ASA or NSAIDs is realistic. Such 
      treatment maintains the desensitized state indefinitely while allowing the 
      beneficial anti-inflammatory effects of these drugs to participate in the 
      treatment of various diseases, including arthritis, thromboembolic diseases, and 
      probably inflammation in the respiratory tract.
FAU - Stevenson, D D
AU  - Stevenson DD
LA  - eng
GR  - AI-10386/AI/NIAID NIH HHS/United States
GR  - RR-0083/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl Reg Allergy Proc
JT  - New England and regional allergy proceedings
JID - 8306562
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug Hypersensitivity/*therapy
MH  - Drug Tolerance
MH  - Humans
MH  - Respiratory Hypersensitivity/chemically induced/*therapy
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
AID - 10.2500/108854186779047708 [doi]
PST - ppublish
SO  - N Engl Reg Allergy Proc. 1986 Mar-Apr;7(2):101-4. doi: 
      10.2500/108854186779047708.

PMID- 845804
OWN - NLM
STAT- MEDLINE
DCOM- 19770520
LR  - 20191210
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 66
IP  - 3
DP  - 1977 Mar
TI  - Application of gluconolactone in direct tablet compression.
PG  - 370-9
AB  - Gluconolactone was evaluated as an excipient for tablets prepared by direct 
      compression using various drugs known to be difficult to compress. The physical 
      properties of the tablets were evaluated after compression and after storage and 
      were satisfactory. Comparative studies were conducted between gluconolactone and 
      anhydrous lactose, a common direct compression diluent, for development of static 
      charges during blending, flow, drug distribution, drug stratification, color 
      distribution, compressibility, and preservation against mold growth. 
      Gluconolactone possesses those properties necessary to produce high quality 
      tablets by the direct compression process. Separate powdered mixtures of aspirin 
      USP with gluconolactone, anhydrous lactose, spray-dried lactose, mannitol, and 
      sorbitol were stored at various humidities and temperatures for specified periods 
      and tested for the integrity of aspirin. Gluconolactone contributed least to the 
      degradation of the drug as compared to other excipients studied. A preliminary in 
      vivo study also was conducted on the bioavailability of aspirin from separate and 
      similar mixtures with gluconolactone, anhydrous lactose, and starch. 
      Gluconolactone did not show any inhibitory effect on aspirin absorption.
FAU - Nasir, S S
AU  - Nasir SS
FAU - Wilken, L O Jr
AU  - Wilken LO Jr
FAU - Akhtar, B
AU  - Akhtar B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Excipients)
RN  - 0 (Gluconates)
RN  - 0 (Lactones)
RN  - 0 (Pharmaceutical Vehicles)
RN  - 0 (Tablets)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
RN  - WQ29KQ9POT (beta-glucono-1,5-lactone)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/metabolism
MH  - Biological Availability
MH  - Chemistry, Pharmaceutical
MH  - Color
MH  - Drug Compounding
MH  - Drug Stability
MH  - *Excipients
MH  - *Gluconates
MH  - Lactones
MH  - Male
MH  - Particle Size
MH  - *Pharmaceutical Vehicles
MH  - Solubility
MH  - *Tablets/analysis
MH  - Water/analysis
EDAT- 1977/03/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1977/03/01 00:00
PHST- 1977/03/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1977/03/01 00:00 [entrez]
AID - S0022-3549(15)39240-6 [pii]
AID - 10.1002/jps.2600660316 [doi]
PST - ppublish
SO  - J Pharm Sci. 1977 Mar;66(3):370-9. doi: 10.1002/jps.2600660316.

PMID- 327585
OWN - NLM
STAT- MEDLINE
DCOM- 19770812
LR  - 20140912
IS  - 0256-9574 (Print)
VI  - 51
IP  - 22
DP  - 1977 May 28
TI  - A comparison of tolmetin with aspirin in the treatment of osteo-arthritis of the 
      knee.
PG  - 794-6
AB  - A randomized, double-blind crossover study conducted on 55 patients showed 
      tolmetin (Tolectin; Ethnor) (900 mg daily) to be as effective as aspirin (4 500 
      mg daily) in relieving the symptoms and signs of osteo-arthritis of the knee. 
      Overall, aspirin produced significantly more side-effects, but the incidence of 
      gastro-intestinal side-effects did not differ significantly. In almost every 
      comparison tolmetin had the better score, but differences were not statistically 
      significant; the only exception was the evaluation of the patients' well-being at 
      mid-therapy, which significanlty favoured tolmetin.
FAU - Müller, F O
AU  - Müller FO
FAU - Gosling, J A
AU  - Gosling JA
FAU - Erdmann, G H
AU  - Erdmann GH
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - 0 (Pyrroles)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - *Knee Joint
MH  - Osteoarthritis/*drug therapy
MH  - Pyrroles/*therapeutic use
MH  - Tolmetin/adverse effects/*therapeutic use
EDAT- 1977/05/28 00:00
MHDA- 1977/05/28 00:01
CRDT- 1977/05/28 00:00
PHST- 1977/05/28 00:00 [pubmed]
PHST- 1977/05/28 00:01 [medline]
PHST- 1977/05/28 00:00 [entrez]
PST - ppublish
SO  - S Afr Med J. 1977 May 28;51(22):794-6.

PMID- 6761371
OWN - NLM
STAT- MEDLINE
DCOM- 19830407
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 22
IP  - 11-12
DP  - 1982 Nov-Dec
TI  - Quantitative differences in aspirin analgesia in three models of clinical pain.
PG  - 531-42
AB  - An analysis was made of data from over 4000 postepisiotomy, uterine cramping, and 
      postsurgical patients complaining of moderate or severe pain. They had received 
      325, 650, or 1300 mg aspirin or placebo while they were subjects in 10 analgesic 
      clinical trials. On the average, for the same verbally expressed pain intensity 
      level and the same treatment, more relief was obtained by a patient with uterine 
      cramping than one with episiotomy pain, who in turn obtained more relief than a 
      patient with surgical pain. A new mathematical model which characterizes the 
      probability that an analgesic provides complete relief as a function of dose, 
      severity of pain intensity, and pain etiology is developed. The model utilizes 
      the data itself to estimate the numerical score corresponding to verbal pain 
      intensities. The results indicate that the numerical score quantifying severe 
      surgical pain is 1.4 times greater than the score for severe episiotomy pain, 
      which in turn is 3.2 times greater than the score for severe uterine cramping. 
      Clinical trials must be designed to take these differences into account. Also, 
      clinicians must be cognizant of such differences when choosing among drugs and 
      dosages for patients with different pain intensity and etiology.
FAU - Laska, E M
AU  - Laska EM
FAU - Sunshine, A
AU  - Sunshine A
FAU - Wanderling, J A
AU  - Wanderling JA
FAU - Meisner, M J
AU  - Meisner MJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Models, Biological
MH  - Pain/*drug therapy
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1982.tb02646.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1982 Nov-Dec;22(11-12):531-42. doi: 
      10.1002/j.1552-4604.1982.tb02646.x.

PMID- 7697845
OWN - NLM
STAT- MEDLINE
DCOM- 19950504
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 91
IP  - 8
DP  - 1995 Apr 15
TI  - Comparison of effects of high-dose and low-dose aspirin on restenosis after 
      femoropopliteal percutaneous transluminal angioplasty.
PG  - 2167-73
AB  - BACKGROUND: Long-term treatment with aspirin is recommended in patients with 
      large-vessel peripheral arterial disease since these patients have a high risk of 
      death from cardiovascular causes. Recent studies have demonstrated the 
      prophylactic effect of low-dose aspirin in reducing the risk of cardiovascular 
      events. Since aspirin is also recommended for prevention of late recurrence after 
      peripheral angioplasty, the present study was undertaken to compare the effects 
      of high-dose (1000 mg/d) and low-dose (100 mg/d) aspirin on long-term patency 
      after femoropopliteal angioplasty. METHODS AND RESULTS: Two hundred sixteen 
      patients treated successfully by percutaneous transluminal angioplasty for 
      femoropopliteal lesions were randomly allocated to therapy with either 1000 or 
      100 mg aspirin daily. The follow-up was 24 months. The long-term results were 
      analyzed using the Kaplan-Meier method, and differences between curves of 
      cumulative patency were determined with the Wilcoxon and log-rank statistics. 
      Complete follow-up information (patency after 24 months, restenosis, and death) 
      was obtained in 207 patients. During the 2-year follow-up period, 72 patients--36 
      in the high-dose and 36 in the low-dose aspirin group, respectively--developed 
      angiographically verified reobstruction within the recanalized segment. By 
      intention-to-treat analysis, the cumulative patency rates at 24 months were 62.5% 
      in the high-dose and 62.6% in the low-dose aspirin group (Wilcoxon, P = .97; 
      log-rank, P = .97). The cumulative survival at 24 months of follow-up was 86.6% 
      in the high-dose and 87.7% in the low-dose aspirin group. The number of patients 
      discontinuing therapy was 30 in the high-dose and 11 in the low-dose aspirin 
      group (P < .01). Fewer patients receiving 100 mg of aspirin discontinued therapy 
      because of gastrointestinal symptoms (4 versus 20). CONCLUSIONS: The data 
      indicate that 100 mg aspirin is no less effective in the prevention of restenosis 
      after femoropopliteal PTA than a 1000-mg dose and has fewer side effects.
FAU - Minar, E
AU  - Minar E
AD  - Department of Angiology, University Clinic Vienna, Währingergürtel, Austria.
FAU - Ahmadi, A
AU  - Ahmadi A
FAU - Koppensteiner, R
AU  - Koppensteiner R
FAU - Maca, T
AU  - Maca T
FAU - Stümpflen, A
AU  - Stümpflen A
FAU - Ugurluoglu, A
AU  - Ugurluoglu A
FAU - Ehringer, H
AU  - Ehringer H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon
MH  - Arterial Occlusive Diseases/epidemiology/prevention & control/*therapy
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Combined Modality Therapy
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - *Femoral Artery
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Multivariate Analysis
MH  - Peripheral Vascular Diseases/epidemiology/prevention & control/*therapy
MH  - *Popliteal Artery
MH  - Recurrence
MH  - Survival Analysis
MH  - Time Factors
MH  - Vascular Patency/drug effects
EDAT- 1995/04/15 00:00
MHDA- 1995/04/15 00:01
CRDT- 1995/04/15 00:00
PHST- 1995/04/15 00:00 [pubmed]
PHST- 1995/04/15 00:01 [medline]
PHST- 1995/04/15 00:00 [entrez]
AID - 10.1161/01.cir.91.8.2167 [doi]
PST - ppublish
SO  - Circulation. 1995 Apr 15;91(8):2167-73. doi: 10.1161/01.cir.91.8.2167.

PMID- 21647746
OWN - NLM
STAT- MEDLINE
DCOM- 20120209
LR  - 20211020
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Print)
IS  - 0884-8734 (Linking)
VI  - 26
IP  - 11
DP  - 2011 Nov
TI  - Effect of aspirin dose on mortality and cardiovascular events in people with 
      diabetes: a meta-analysis.
PG  - 1336-44
LID - 10.1007/s11606-011-1757-y [doi]
AB  - OBJECTIVES: Pharmacologic evidence suggests adequate antiplatelet activity in 
      diabetic patients requires >100 mg aspirin daily, yet recent trials have used 
      ≤100 mg daily. This meta-analysis explored the relationship between aspirin dose 
      and prevention of cardiovascular events. DATA SOURCES: Six electronic databases 
      were searched using database-appropriate terms for aspirin, diabetes, and 
      comparative study from inception until February 2010. REVIEW METHODS: Randomized 
      controlled trials and cohort studies comparing aspirin to no antiplatelet therapy 
      were included if they reported cardiovascular events as pre-specified outcomes, 
      aspirin dose, and number of diabetic patients. Studies were stratified by daily 
      aspirin dose (≤100 mg; 101-325 mg; >325 mg) and pooled risk ratios (RR) were 
      calculated using random effects models. All-cause mortality was the primary 
      outcome of interest. Cardiovascular-related mortality, myocardial infarction, and 
      stroke were secondary outcomes. RESULTS: Data for diabetic patients were 
      available from 21 studies (n = 17,522). Overall, 1,172 (15.4%) of 7,592 aspirin 
      users and 1,520 (18.4%) of 8,269 controls died (p = 0.31). The pooled RRs were 
      0.89 (95% CI: 0.72-1.10; p = 0.27) from 13 studies using ≤100 mg (I(2) = 64%); 
      0.89 (95% CI: 0.61-1.30; p = 0.55) from four studies using 101-325 mg (I(2) = 
      83%); and 0.96 (95% CI: 0.85-1.08; p = 0.50) from eight studies using >325 mg 
      (I(2) = 0%). Aspirin use was associated with a significantly lower risk of 
      mortality (RR: 0.82; 95% CI: 0.69-0.98; p = 0.03) in 13 secondary prevention 
      studies (I(2) = 27%), whereas aspirin use in seven primary prevention studies 
      (I(2) = 0%) was not (RR: 1.01; 95% CI 0.85-1.19; p = 0.94). A substantial amount 
      of heterogeneity was observed amongst studies in all outcomes. Although inclusion 
      of cohort studies was a major source of heterogeneity, stratification by study 
      design did not reveal a significant dose-response relationship. 
      CONCLUSIONS/INTERPRETATION: This summary of available data does not support an 
      aspirin dose-response effect for prevention of cardiovascular events in diabetic 
      patients. However, the systematic review identified an important gap in 
      randomized controlled trial evidence for using 101-325 mg aspirin daily in 
      diabetes.
FAU - Simpson, Scot H
AU  - Simpson SH
AD  - Faculty of Pharmacy & Pharmaceutical Sciences, 3126 Dentistry / Pharmacy Centre, 
      University of Alberta, Edmonton, AB, Canada, T6G 2N8. 
      ssimpson@pharmacy.ualberta.ca
FAU - Gamble, John-Michael
AU  - Gamble JM
FAU - Mereu, Laurie
AU  - Mereu L
FAU - Chambers, Thane
AU  - Chambers T
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20110607
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*mortality
MH  - Diabetes Mellitus/*pathology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Primary Prevention
MH  - Stroke
PMC - PMC3208465
EDAT- 2011/06/08 06:00
MHDA- 2012/02/10 06:00
CRDT- 2011/06/08 06:00
PHST- 2010/09/18 00:00 [received]
PHST- 2011/05/03 00:00 [accepted]
PHST- 2011/03/09 00:00 [revised]
PHST- 2011/06/08 06:00 [entrez]
PHST- 2011/06/08 06:00 [pubmed]
PHST- 2012/02/10 06:00 [medline]
AID - 1757 [pii]
AID - 10.1007/s11606-011-1757-y [doi]
PST - ppublish
SO  - J Gen Intern Med. 2011 Nov;26(11):1336-44. doi: 10.1007/s11606-011-1757-y. Epub 
      2011 Jun 7.

PMID- 27843305
OWN - NLM
STAT- MEDLINE
DCOM- 20170213
LR  - 20181113
IS  - 1178-1998 (Electronic)
IS  - 1176-9092 (Print)
IS  - 1176-9092 (Linking)
VI  - 11
DP  - 2016
TI  - Does the use of acetylsalicylic acid have an influence on our vision?
PG  - 1567-1574
AB  - PURPOSE: Acetylsalicylic acid (ASA) is one of the most commonly used drugs in the 
      world due to its anti-inflammatory, analgesic, and antipyretic properties. This 
      review aims to describe the relationship between acetylsalicylic acid and 
      age-related macular degeneration (AMD) - a chronic disease that causes 
      deterioration of visual acuity and is one of the most common ophthalmological 
      diseases these days. METHODS: Data presented in this review were collected from 
      both research and review articles concerning ophthalmology and pharmacology. 
      RESULTS: The results of the studies analyzed in this review are not unambiguous. 
      Moreover, the studies are not homogenous. They differed from one another in terms 
      of the number of patients, the age criteria, the ASA dose, and the duration of 
      control period. The reviewed studies revealed that ASA therapy, which is applied 
      as a protection in cardiovascular diseases in patients with early forms of AMD 
      and geographic atrophy, should not be discontinued. CONCLUSION: On the basis of 
      the present studies, it cannot be unequivocally said whether ASA influences 
      people's vision and if people endangered with AMD progression or who are 
      diagnosed with AMD should use this drug. It may increase the risk of AMD, but it 
      can also reduce the risk of life-threatening conditions. The authors suggest that 
      in order to avoid possible risks of AMD development, people who frequently take 
      ASA should have their vision checked regularly.
FAU - Michalska-Małecka, Katarzyna
AU  - Michalska-Małecka K
AD  - Department of Ophthalmology, School of Medicine in Katowice, Medical University 
      of Silesia, Katowice, Poland; University Clinical Center, University Hospital 
      Medical University of Silesia, Katowice, Poland.
FAU - Regucka, Agnieszka
AU  - Regucka A
AD  - University Clinical Center, University Hospital Medical University of Silesia, 
      Katowice, Poland.
FAU - Śpiewak, Dorota
AU  - Śpiewak D
AD  - University Clinical Center, University Hospital Medical University of Silesia, 
      Katowice, Poland.
FAU - Sosnowska-Pońska, Magdalena
AU  - Sosnowska-Pońska M
AD  - University Clinical Center, University Hospital Medical University of Silesia, 
      Katowice, Poland.
FAU - Niewiem, Alfred
AU  - Niewiem A
AD  - University Clinical Center, University Hospital Medical University of Silesia, 
      Katowice, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161103
PL  - New Zealand
TA  - Clin Interv Aging
JT  - Clinical interventions in aging
JID - 101273480
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Disease Progression
MH  - Humans
MH  - Macular Degeneration/*epidemiology
MH  - Retinal Pigment Epithelium/*drug effects
MH  - Visual Acuity/*drug effects
PMC - PMC5098504
OTO - NOTNLM
OT  - AMD
OT  - acetylsalicylic acid
OT  - drusen genesis
OT  - geographic atrophy
OT  - lipofuscin genesis
OT  - retinal pigment epithelium cells
COIS- The authors report no conflicts of interest in this work.
EDAT- 2016/11/16 06:00
MHDA- 2017/02/14 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/02/14 06:00 [medline]
AID - cia-11-1567 [pii]
AID - 10.2147/CIA.S115234 [doi]
PST - epublish
SO  - Clin Interv Aging. 2016 Nov 3;11:1567-1574. doi: 10.2147/CIA.S115234. eCollection 
      2016.

PMID- 11336435
OWN - NLM
STAT- MEDLINE
DCOM- 20010906
LR  - 20181130
IS  - 0832-610X (Print)
IS  - 0832-610X (Linking)
VI  - 48
IP  - 4 Suppl
DP  - 2001 Apr
TI  - Oxygen therapeutics--current concepts.
PG  - S32-40
AB  - PURPOSE: In an effort to develop agents that enhance the oxygen-delivery 
      capability of blood without the risks associated with allogeneic blood 
      transfusions, several products are undergoing development and clinical trials. 
      These oxygen transport agents can be divided into two main groups, 
      perfluorocarbon (PFC) emulsions and modified hemoglobin solutions. SOURCE: 
      Articles from the literature on the development and clinical trials of oxygen 
      therapeutic agents were reviewed. PRINCIPAL FINDING: PFCs are synthetic 
      fluorinated hydrocarbons that increase dissolved oxygen in the fluid phase of the 
      blood without binding the oxygen molecule. They enhance oxygen delivery 
      significantly and may be used to augment the technique of intraoperative 
      autologous donation. Two PFC products have been tested in Phase III clinical 
      trials. Hemoglobin-based oxygen carriers (HBOCs) are either cross-linked or 
      microencapsulated hemoglobin molecules. Modification of the human hemoglobin 
      molecule with intra- and inter-molecular cross-linking eliminates renal toxicity 
      and improves the oxygen dissociation characteristics of the molecule. These 
      modifications are necessary because stroma-free hemoglobin (Hb) does not release 
      oxygen in the physiologic range and dissociates into dimers which can be rapidly 
      filtered by the kidney, leading to renal toxicity. In addition to human Hb, 
      bovine hemoglobin is another source of raw material for HBOC products. 
      Recombinant human Hb has also been produced, using an E. coli expression system, 
      for HBOC manufacturing. Four cross-linked hemoglobin products have been tested in 
      Phase III clinical trials. CONCLUSION: While no product has yet been approved for 
      clinical use, preliminary studies with oxygen therapeutics show promising 
      results, with effective oxygen carrying capacity and acceptable side effect 
      profiles. In the future, the formation of a hybrid product which combines the 
      best features from several of the products currently undergoing development may 
      yield the ideal oxygen therapeutic agent.
FAU - Hill, S E
AU  - Hill SE
AD  - Department of Anesthesiology, Duke University Medical Center, Durham, North 
      Carolina 27710, USA. hill0012@mc.duke.edu
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Can J Anaesth
JT  - Canadian journal of anaesthesia = Journal canadien d'anesthesie
JID - 8701709
RN  - 0 (Blood Substitutes)
RN  - 0 (Fluorocarbons)
RN  - 0 (Hemoglobins)
RN  - 1XQE66T19H (HBOC 201)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Aspirin/analogs & derivatives/*therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - Fluorocarbons/*therapeutic use
MH  - Hemoglobins/*therapeutic use
MH  - Humans
MH  - Oxygen/*metabolism
EDAT- 2001/05/05 10:00
MHDA- 2001/09/08 10:01
CRDT- 2001/05/05 10:00
PHST- 2001/05/05 10:00 [pubmed]
PHST- 2001/09/08 10:01 [medline]
PHST- 2001/05/05 10:00 [entrez]
PST - ppublish
SO  - Can J Anaesth. 2001 Apr;48(4 Suppl):S32-40.

PMID- 17347160
OWN - NLM
STAT- MEDLINE
DCOM- 20070817
LR  - 20220311
IS  - 1355-4786 (Print)
IS  - 1355-4786 (Linking)
VI  - 13
IP  - 4
DP  - 2007 Jul-Aug
TI  - Low-dose aspirin for in vitro fertilization: a systematic review and 
      meta-analysis.
PG  - 357-64
AB  - Despite recent advances in ovarian stimulation regimens and laboratory 
      techniques, the pregnancy rate of assisted reproduction remains relatively low. 
      New methods that would potentially improve implantation rates are needed. One 
      proposed strategy involves enhancement of blood flow at the implantation site 
      with the use of low-dose aspirin. We conducted a systematic review and 
      meta-analysis to investigate the effect of low-dose aspirin on likelihood of 
      pregnancy in women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm 
      injection (ICSI). An electronic search of the literature was conducted targeting 
      reports published over the last 26 years. Only randomized controlled trials 
      (RCTs) comparing aspirin with placebo or no treatment in IVF/ICSI women were 
      included in the meta-analysis. A number of relevant outcomes including pregnancy 
      and live birth (LB) rates were investigated. Pooled relative risk (RR) and 95% 
      confidence interval (CI) were calculated using a random-effects model. 
      Inter-study heterogeneity among the trials was assessed using the Cochran's Q 
      test. Ten RCTs were identified from the literature search, six of which met the 
      criteria for inclusion in the meta-analysis. Clinical pregnancy (CP) rate per 
      embryo transfer (ET) was not found to be significantly different between patients 
      who received low-dose aspirin and those who received placebo or no treatment (RR 
      1.09, 95% CI 0.92-1.29). None of the other outcomes, including CP per cycle, 
      spontaneous abortion or ectopic pregnancy per CP and LB rate per cycle or ET was 
      found to differ significantly between the compared groups. On the basis of 
      up-to-date evidence, low-dose aspirin has no substantial positive effect on 
      likelihood of pregnancy and, therefore, it should not be routinely recommended 
      for women undergoing IVF/ICSI.
FAU - Gelbaya, T A
AU  - Gelbaya TA
AD  - Department of Obstetrics and Gynaecology, Royal Bolton Hospital, Bolton, UK.
FAU - Kyrgiou, M
AU  - Kyrgiou M
FAU - Li, T C
AU  - Li TC
FAU - Stern, C
AU  - Stern C
FAU - Nardo, L G
AU  - Nardo LG
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20070308
PL  - England
TA  - Hum Reprod Update
JT  - Human reproduction update
JID - 9507614
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Hum Reprod Update. 2008 May-Jun;14(3):289; author reply 289-91. PMID: 18258788
CIN - Hum Reprod Update. 2009 Mar-Apr;15(2):262-3. PMID: 19008242
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Embryo Transfer
MH  - Female
MH  - Fertilization in Vitro/*drug effects
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - *Pregnancy Rate
MH  - Probability
MH  - Randomized Controlled Trials as Topic
RF  - 73
EDAT- 2007/03/10 09:00
MHDA- 2007/08/19 09:00
CRDT- 2007/03/10 09:00
PHST- 2007/03/10 09:00 [pubmed]
PHST- 2007/08/19 09:00 [medline]
PHST- 2007/03/10 09:00 [entrez]
AID - dmm005 [pii]
AID - 10.1093/humupd/dmm005 [doi]
PST - ppublish
SO  - Hum Reprod Update. 2007 Jul-Aug;13(4):357-64. doi: 10.1093/humupd/dmm005. Epub 
      2007 Mar 8.

PMID- 9884205
OWN - NLM
STAT- MEDLINE
DCOM- 19990507
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 17
IP  - 6-7
DP  - 1998 Sep 1
TI  - Assay of acetylsalicylic acid and three of its metabolites in human plasma and 
      urine using non-aqueous capillary electrophoresis with reversed electroosmotic 
      flow.
PG  - 1155-60
AB  - The separation of acetylsalicylic acid and three of its metabolites--salicylic 
      acid, salicyluric acid and gentisic acid--is demonstrated in a non-aqueous 
      capillary electrophoresis system with reversed electroosmotic flow. Solvent 
      mixtures of methanol and acetonitrile are used for the electrophoresis media and 
      different electrolytes have been investigated. The flow is reversed by the 
      addition of the polycation hexadimethrine bromide and thus a negative voltage is 
      used. This system provides a fast and effective separation of the four analytes. 
      The separation method was applied to the assay of acetylsalicylic acid and its 
      major metabolites in plasma and urine and the limits of quantification for all of 
      these compounds are about 5 microg ml(-1) in plasma and 25 microg ml(-1) in 
      urine.
FAU - Hansen, S H
AU  - Hansen SH
AD  - Department of Analytical and Pharmaceutical Chemistry, The Royal Danish School of 
      Pharmacy, Copenhagen. shh@mail.dfh.dk
FAU - Jensen, M E
AU  - Jensen ME
FAU - Bjørnsdottir, I
AU  - Bjørnsdottir I
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Acetonitriles)
RN  - 0 (Gentisates)
RN  - 0 (Hippurates)
RN  - 0 (Hydroxybenzoates)
RN  - 487-54-7 (salicylurate)
RN  - 4C905MSK4W (Hexadimethrine Bromide)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - VP36V95O3T (2,5-dihydroxybenzoic acid)
RN  - Y4S76JWI15 (Methanol)
RN  - Z072SB282N (acetonitrile)
SB  - IM
MH  - Acetonitriles/chemistry
MH  - Aspirin/*analysis/blood/metabolism/urine
MH  - Electrophoresis, Capillary/*methods
MH  - *Gentisates
MH  - Hexadimethrine Bromide/chemistry
MH  - Hippurates/*analysis
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Hydroxybenzoates/*analysis
MH  - In Vitro Techniques
MH  - Methanol/chemistry
MH  - Osmosis
MH  - Reproducibility of Results
MH  - Salicylic Acid/*analysis
MH  - Temperature
EDAT- 1999/01/12 00:00
MHDA- 1999/01/12 00:01
CRDT- 1999/01/12 00:00
PHST- 1999/01/12 00:00 [pubmed]
PHST- 1999/01/12 00:01 [medline]
PHST- 1999/01/12 00:00 [entrez]
AID - S0731-7085(98)00081-8 [pii]
AID - 10.1016/s0731-7085(98)00081-8 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1998 Sep 1;17(6-7):1155-60. doi: 
      10.1016/s0731-7085(98)00081-8.

PMID- 6607157
OWN - NLM
STAT- MEDLINE
DCOM- 19840305
LR  - 20190913
IS  - 0012-6578 (Print)
IS  - 0012-6578 (Linking)
VI  - 18
IP  - 1
DP  - 1984 Jan
TI  - The argument for aspirin as the NSAID of choice in the management of rheumatoid 
      arthritis.
PG  - 34-8
AB  - In view of their costliness, the use of newer NSAIDs is justified if they are 
      demonstrably more effective, less toxic, or better tolerated than aspirin (ASA). 
      However, there is no evidence that any is more effective than ASA, and their 
      widely assumed comparable effectiveness has not been demonstrated convincingly. 
      In terms of clinically meaningful overt and even occult gastrointestinal blood 
      loss, ASA is indistinguishable from the newer NSAIDs. Most NSAIDs evoke fewer 
      unpleasant gastrointestinal symptoms than ASA does, although current recording of 
      such symptoms has magnified the ASA experience. Prescribing a new NSAID before 
      ASA requires a heuristic assertion of comparable effectiveness, misconception of 
      overt toxicities, and belief in the meaningfulness of data demonstrating 
      differential tolerance. The trade-off is increased expense and unknown long-term 
      toxicity.
FAU - Hadler, N M
AU  - Hadler NM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Drug Intell Clin Pharm
JT  - Drug intelligence & clinical pharmacy
JID - 0212457
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Gastroscopy
MH  - Humans
MH  - Occult Blood
MH  - Time Factors
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1177/106002808401800104 [doi]
PST - ppublish
SO  - Drug Intell Clin Pharm. 1984 Jan;18(1):34-8. doi: 10.1177/106002808401800104.

PMID- 9500486
OWN - NLM
STAT- MEDLINE
DCOM- 19980319
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 178
IP  - 2
DP  - 1998 Feb
TI  - Aspirin pretreatment potentiates hyperthermia-induced teratogenesis in the mouse.
PG  - 270-9
AB  - OBJECTIVE: Our purpose was to investigate the effect of aspirin pretreatment on 
      hyperthermia-induced teratogenesis. The rationale for the study was based on the 
      growing evidence that prostaglandin pathway may be involved in the cellular 
      response to the thermic injury. STUDY DESIGN: On gestation day 8.5 Swiss mice 
      were treated with 0 or 200 mg/kg of aspirin and 1 hour later exposed to a single 
      10-minute thermostatic bath treatment at 38 degrees C, 41 degrees C, 42 degrees 
      C, or 43 degrees C. On gestation day 18 uterine contents were evaluated for 
      developmental disorders, including prenatal mortality, intrauterine growth 
      restriction, and external, visceral, and skeletal abnormalities. RESULTS: 
      Consistent with expectations, hyperthermia impaired morphogenesis in a 
      dose-related manner. Although aspirin alone did not reveal embryotoxicity, its 
      administration potentiated hyperthermia-induced teratogenesis. A statistically 
      significant interaction (p < 0.05) was observed at 42 degrees C, where the 
      incidence of fetuses per litter with axial skeletal malformations increased from 
      20.3% to 55.7%. CONCLUSION: A nonteratogenic dose of aspirin enhanced the 
      teratogenic response to hyperthermia. This result fits the hypothesis that 
      prostaglandins may play a protective role in hyperthermia-induced teratogenesis.
FAU - Tiboni, G M
AU  - Tiboni GM
AD  - Clinica Ginecologica e Ostetrica, Facoltà di Medicina e Chirurgia, Universita G. 
      d'Annunzio, Chieti, Italy.
FAU - Iammarrone, E
AU  - Iammarrone E
FAU - Piccirillo, G
AU  - Piccirillo G
FAU - Liberati, M
AU  - Liberati M
FAU - Bellati, U
AU  - Bellati U
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/toxicity
MH  - Body Temperature
MH  - Bone and Bones/abnormalities
MH  - Congenital Abnormalities/*etiology
MH  - Female
MH  - Fever/*complications
MH  - Gestational Age
MH  - Hot Temperature
MH  - Mice
MH  - Morphogenesis
MH  - Pregnancy
EDAT- 1998/03/21 00:00
MHDA- 1998/03/21 00:01
CRDT- 1998/03/21 00:00
PHST- 1998/03/21 00:00 [pubmed]
PHST- 1998/03/21 00:01 [medline]
PHST- 1998/03/21 00:00 [entrez]
AID - S0002-9378(98)80012-4 [pii]
AID - 10.1016/s0002-9378(98)80012-4 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1998 Feb;178(2):270-9. doi: 10.1016/s0002-9378(98)80012-4.

PMID- 27309035
OWN - NLM
STAT- MEDLINE
DCOM- 20170227
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 17
IP  - 13
DP  - 2016 Sep
TI  - Dual antiplatelet therapy after coronary stenting.
PG  - 1775-87
LID - 10.1080/14656566.2016.1202924 [doi]
AB  - INTRODUCTION: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor 
      inhibitor represents the mainstay of pharmacotherapy in patients undergoing 
      coronary stenting. Currently, three P2Y12 receptor inhibitors are approved for 
      clinical use, including clopidogrel, prasugrel, and ticagrelor, with the latter 
      two being preferred in patients presenting with an acute coronary syndrome. The 
      introduction into clinical practice of newer-generation drug-eluting stent (DES) 
      with safer profiles (i.e. less stent thrombosis) compared with earlier platforms 
      have led recent guideline updates to re-evaluate the optimal duration of DAPT 
      therapy, which are now based on evidence of a multitude of randomized clinical 
      trials, registries, and meta-analysis and take into consideration the ischemic 
      and bleeding risk profile of the patients. AREAS COVERED: Most recent updates on 
      DAPT duration from professional societies in the United States and Europe are 
      discussed. Moreover, an assessment of clinical trials, registries, and 
      meta-analysis leading to changes on practice guidelines analyzed. EXPERT OPINION: 
      The widespread introduction into clinical practice of newer-generation DES allows 
      for shortening DAPT duration as also endorsed by practice guidelines. However, 
      the optimal duration of DAPT therapy varies according to the individuals' risk of 
      ischemic and bleeding complications, with longer or shorter durations of 
      treatment, respectively, that may be considered.
FAU - Park, Yongwhi
AU  - Park Y
AD  - a Division of Cardiology, University of Florida College of Medicine - 
      Jacksonville , Jacksonville , FL , USA.
AD  - b Department of Internal Medicine , Gyeongsang National University School of 
      Medicine and Gyeongsang National University Hospital , Jinju , Korea.
FAU - Franchi, Francesco
AU  - Franchi F
AD  - a Division of Cardiology, University of Florida College of Medicine - 
      Jacksonville , Jacksonville , FL , USA.
FAU - Rollini, Fabiana
AU  - Rollini F
AD  - a Division of Cardiology, University of Florida College of Medicine - 
      Jacksonville , Jacksonville , FL , USA.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - a Division of Cardiology, University of Florida College of Medicine - 
      Jacksonville , Jacksonville , FL , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160628
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - *Drug-Eluting Stents/adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Time Factors
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - coronary artery disease
OT  - coronary stent
OT  - duration of antiplatelet therapy
EDAT- 2016/06/17 06:00
MHDA- 2017/02/28 06:00
CRDT- 2016/06/17 06:00
PHST- 2016/06/17 06:00 [entrez]
PHST- 2016/06/17 06:00 [pubmed]
PHST- 2017/02/28 06:00 [medline]
AID - 10.1080/14656566.2016.1202924 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2016 Sep;17(13):1775-87. doi: 
      10.1080/14656566.2016.1202924. Epub 2016 Jun 28.

PMID- 1880688
OWN - NLM
STAT- MEDLINE
DCOM- 19910927
LR  - 20161123
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 8
IP  - 1
DP  - 1991 Jan-Mar
TI  - Biopharmaceutical evaluation of a tablet dosage form made from ethyl cellulose 
      encapsulated aspirin particles.
PG  - 21-8
AB  - Ethyl cellulose encapsulated aspirin particles, suitable for preparation of 
      direct compression tablets were prepared by the solvent evaporation method. Ethyl 
      acetate was used as a solvent for the polymer in combination with a saturated 
      solution of aspirin as the dispersing medium to prevent partitioning and drug 
      loss. This resulted in a high yield of free-flowing, non-aggregated particles. In 
      vitro-in vivo evaluations of the experimental aspirin tablets (made by direct 
      compression of ethyl cellulose encapsulated particles) and three different 
      commercial aspirin products (a conventional tablet, a timed-release tablet, and a 
      timed-release caplet) were undertaken. Comparison of the dissolution in acidic 
      media at pH 1.2 showed different release profiles for these products. While the 
      conventional tablet and the timed-release caplet showed the highest and the 
      lowest rate of release, respectively; the timed-release tablet and the 
      experimentally made tablet revealed an intermediate rate and very similar release 
      profiles. The cumulative urinary excretion data collected in a complete crossover 
      study, using five healthy subjects further indicated that the experimental tablet 
      has an in vivo availability identical to that of the timed-release tablet.
FAU - Zia, H
AU  - Zia H
AD  - School of Pharmacy, University of Isfahan.
FAU - Falamarzian, M
AU  - Falamarzian M
FAU - Raisi, A
AU  - Raisi A
FAU - Montaseri, H
AU  - Montaseri H
FAU - Needham, T E
AU  - Needham TE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Tablets)
RN  - 7Z8S9VYZ4B (ethyl cellulose)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/chemistry/*pharmacokinetics
MH  - Biological Availability
MH  - Cellulose/administration & dosage/*analogs & derivatives/chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - Drug Compounding
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Tablets
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.3109/02652049109021854 [doi]
PST - ppublish
SO  - J Microencapsul. 1991 Jan-Mar;8(1):21-8. doi: 10.3109/02652049109021854.

PMID- 11834769
OWN - NLM
STAT- MEDLINE
DCOM- 20020405
LR  - 20190513
IS  - 1460-2725 (Print)
IS  - 1460-2393 (Linking)
VI  - 95
IP  - 1
DP  - 2002 Jan
TI  - Costs of aspirin and statins in general practice.
PG  - 23-6
AB  - BACKGROUND: Aspirin and statins are the two drugs most commonly indicated for 
      secondary prevention of atherosclerotic disease in the UK. Statin treatment, 
      which is more expensive, is under-prescribed. AIM: To assess the expenditure in 
      Greater Manchester general practices on aspirin and statins. DESIGN: Survey of 
      general practice records. METHODS: Practice registers were searched for patients 
      receiving regular prescriptions for aspirin. For each patient, the next patient 
      of the same sex, aged within +/- 5 years, not on aspirin, acted as a control. 
      Details of all medications were recorded. In a sub-study, records of 100 patients 
      on aspirin were studied to determine indications for aspirin prescription. 
      RESULTS: There were 1003 (511 men, 492 women) in each group; mean age was 70 
      years in both groups. In the sub-study, 79% of patients received aspirin for 
      established vascular disease, 9% for hypertension, 5% for diabetes mellitus, 5% 
      for unknown reasons and 2% for arthritis. Of the patients on aspirin, 67% 
      received dispersible aspirin 75 mg/day. The rest were on higher doses (10%) or on 
      more expensive preparations (22%), costing up to 22.4 p/day. The mean daily cost 
      of aspirin was 1.7p. Dyspepsia treatment was received by 266 patients and 194 
      controls (p<0.001). There was a wide range of dyspepsia medications 
      (10-306p/day), averaging in the groups as a whole 15.5p/day in patients and 
      12.5p/day in controls. Of the patients on aspirin, 28% received statins, compared 
      to 4% of controls. Mean daily expenditure on statins in patients was 23.4p. 
      CONCLUSION: Assuming the difference in the use of medication for dyspepsia 
      between patients and controls was due to aspirin, the full cost of aspirin 
      treatment was 4.7p/day. Statins were probably under-prescribed in aspirin-takers, 
      many of whom would have been at high CHD risk.
FAU - Drummond, A
AU  - Drummond A
AD  - Department of Medicine, Manchester Royal Infirmary, Manchester, UK.
FAU - Kwok, S
AU  - Kwok S
FAU - Morgan, J
AU  - Morgan J
FAU - Durrington, P N
AU  - Durrington PN
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - QJM
JT  - QJM : monthly journal of the Association of Physicians
JID - 9438285
RN  - 0 (Hypolipidemic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*economics
MH  - Drug Administration Schedule
MH  - *Drug Costs
MH  - Dyspepsia/chemically induced/drug therapy/economics
MH  - England
MH  - Family Practice/*economics
MH  - Female
MH  - Humans
MH  - Hypolipidemic Agents/administration & dosage/*economics
MH  - Male
MH  - Middle Aged
EDAT- 2002/02/09 10:00
MHDA- 2002/04/06 10:01
CRDT- 2002/02/09 10:00
PHST- 2002/02/09 10:00 [pubmed]
PHST- 2002/04/06 10:01 [medline]
PHST- 2002/02/09 10:00 [entrez]
AID - 10.1093/qjmed/95.1.23 [doi]
PST - ppublish
SO  - QJM. 2002 Jan;95(1):23-6. doi: 10.1093/qjmed/95.1.23.

PMID- 997672
OWN - NLM
STAT- MEDLINE
DCOM- 19770128
LR  - 20131121
IS  - 0323-5580 (Print)
IS  - 0323-5580 (Linking)
VI  - 9
IP  - 1
DP  - 1976
TI  - [Thromboelastography and inhibitors of aggregation].
PG  - 36-40
AB  - The effect of maintained treatment with salicylo-acetic acid (1.5 g/day) on the 
      thrombelastogram was examined in the venous blood from 18 accidental patients. In 
      the prevention of thrombembolia, resulting values of the thrombelastograph are 
      not sufficient to show functional changes of platelets. Some of the patients 
      revealed prolonged times for reaction and formation of coagula, thus discreet 
      influencing the thrombelastogram might be supposed.
FAU - Maess, M
AU  - Maess M
FAU - Nugel, E
AU  - Nugel E
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Thrombelastogramm und Aggregationshemmer.
PL  - Germany
TA  - Z Exp Chir
JT  - Zeitschrift fur experimentelle Chirurgie
JID - 0154510
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Cell Count
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Reaction Time/drug effects
MH  - *Thrombelastography
MH  - Thromboembolism/prevention & control
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Exp Chir. 1976;9(1):36-40.

PMID- 6853924
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 71
IP  - 6
DP  - 1983 Jun
TI  - Improvement in aspirin-sensitive asthmatic subjects after rapid aspirin 
      desensitization and aspirin maintenance (ADAM) treatment.
PG  - 560-7
AB  - Twelve ASA-sensitive (AS) asthmatics, including nine over age 35 years and three 
      under age 19, were successfully desensitized to the adverse effects of ASA in an 
      average of 322 min without any serious untoward sequelae. Six subjects (50%) 
      experienced subjective improvement, three (25%) no change, and three (25%) 
      worsening in their asthma while on a daily maintenance dose of ASA (mean = 539 
      mg) for an average follow-up period of 115 days. Six subjects (50%) were able to 
      discontinue one or more antiasthma medications, including systemic steroid in one 
      (8%) and aerosol steroid in three (25%). The incidence of subjective improvement 
      in asthma status (67% vs. 44%) was higher in those under 19 than in those over 
      35, and none of the younger vs. 30% of the older subgroup experienced worsening 
      in their asthma. ASA desensitization (AD) followed by an ASA maintenance program 
      (ADAM) therefore appeared to be beneficial in approximately 50% of AS asthmatics. 
      In this study an improvement in postdesensitization peak expiratory flow rate 
      with a repeat ASA challenge appeared to correlate best with subjective 
      improvement in asthma and/or reduction in antiasthma medication requirement after 
      AD. However, the number of subjects studied was relatively small and the 
      conclusions drawn will require confirmation.
FAU - Chiu, J T
AU  - Chiu JT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*immunology/therapeutic use
MH  - Asthma/*immunology
MH  - Bronchial Provocation Tests
MH  - Desensitization, Immunologic
MH  - Forced Expiratory Flow Rates
MH  - Humans
MH  - Middle Aged
EDAT- 1983/06/01 00:00
MHDA- 1983/06/01 00:01
CRDT- 1983/06/01 00:00
PHST- 1983/06/01 00:00 [pubmed]
PHST- 1983/06/01 00:01 [medline]
PHST- 1983/06/01 00:00 [entrez]
AID - 0091-6749(83)90437-2 [pii]
AID - 10.1016/0091-6749(83)90437-2 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1983 Jun;71(6):560-7. doi: 10.1016/0091-6749(83)90437-2.

PMID- 3093269
OWN - NLM
STAT- MEDLINE
DCOM- 19861031
LR  - 20161123
IS  - 0014-8318 (Print)
IS  - 0014-8318 (Linking)
VI  - 49
IP  - 4
DP  - 1986 Jul-Aug
TI  - [Antiaggregation action and pharmacokinetics of lysine acetylsalicylate].
PG  - 58-62
AB  - Lysine acetylsalicylate, a water-soluble salt of acetylsalicylic acid, 
      administered intravenously to rabbits (15 and 100 mg/kg) and also in vitro (2-10 
      mg/ml) produced antiaggregational and anticoagulant effects pertaining to 
      acetylsalicylic acid. Pharmacokinetics of acetylsalicylic acid injected 
      intravenously to rabbits in the form of lysine acetylsalicylate is formalized by 
      a biexponential equation for a two-compartment model. The main pharmacokinetic 
      constants of acetylsalicylic acid in these experiments were found to be similar 
      to those in humans.
FAU - Khadzhaĭ, Ia I
AU  - Khadzhaĭ IaI
FAU - Chaĭka, L A
AU  - Chaĭka LA
FAU - Kosheleva, L P
AU  - Kosheleva LP
FAU - Libina, V V
AU  - Libina VV
FAU - Pichugin, V V
AU  - Pichugin VV
LA  - rus
PT  - Comparative Study
PT  - Journal Article
TT  - Antiagregatsionnoe deĭstvie i farmakokinetika atsetilsalitsilata lizina.
PL  - Russia (Federation)
TA  - Farmakol Toksikol
JT  - Farmakologiia i toksikologiia
JID - 16920420R
RN  - 0 (Solutions)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/blood/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Lysine/*analogs & derivatives/blood/pharmacology
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
MH  - Solutions
MH  - Time Factors
EDAT- 1986/07/01 00:00
MHDA- 1986/07/01 00:01
CRDT- 1986/07/01 00:00
PHST- 1986/07/01 00:00 [pubmed]
PHST- 1986/07/01 00:01 [medline]
PHST- 1986/07/01 00:00 [entrez]
PST - ppublish
SO  - Farmakol Toksikol. 1986 Jul-Aug;49(4):58-62.

PMID- 31926190
OWN - NLM
STAT- MEDLINE
DCOM- 20200515
LR  - 20200515
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 160
DP  - 2020 Feb
TI  - Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: 
      A new perspective.
PG  - 108008
LID - S0168-8227(20)30007-3 [pii]
LID - 10.1016/j.diabres.2020.108008 [doi]
AB  - Although the improved control of hyperglycaemia and other cardiovascular risk 
      factors was associated with a parallel decline of atherosclerotic cardiovascular 
      disease (ASCVD) and death in both type 1 (T1) and type 2 (T2) diabetes mellitus 
      (DM), the burden of death and hospitalization for ASCVD remains significantly 
      higher by about 2-fold versus the matched non-DM population. Life style 
      interventions, such as physical activity and healthy diet, and drugs, such as 
      statins and low-dose aspirin, may have beneficial effects by targeting one or 
      multiple pathways responsible for accelerated atherosclerosis and its thrombotic 
      complications. The debate on the benefit-risk balance of primary cardiovascular 
      prevention with aspirin has been especially vivacious over the past two years, 
      following the publication of three large randomized, placebo-controlled, primary 
      prevention trials in different settings, spanning from healthy elderly to DM 
      subjects. The aim of this review is to discuss the pathophysiological, 
      pharmacological and clinical evidence supporting the appropriate use of low-dose 
      aspirin in DM, within the context of the current multifactorial approach to 
      primary cardiovascular prevention.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Rocca, Bianca
AU  - Rocca B
AD  - Institute of Pharmacology, Catholic University School of Medicine, and Fondazione 
      Policlinico Universitario "A. Gemelli" Istituto di Ricovero e Cura a Carattere 
      Scientifico (IRCCS), Rome, Italy. Electronic address: bianca.rocca@unicatt.it.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - Institute of Pharmacology, Catholic University School of Medicine, and Fondazione 
      Policlinico Universitario "A. Gemelli" Istituto di Ricovero e Cura a Carattere 
      Scientifico (IRCCS), Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200108
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Primary Prevention/*methods
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular prevention
OT  - Diabetes mellitus
OT  - Platelets
COIS- Declaration of Competing Interest BR reports lecture fees from Bayer AG, Medscape 
      and Novartis and research funding from the Italian Drug Agency (AIFA). CP reports 
      consulting and lecture fees from Acticor Biotech, Amgen, Bayer, GlaxoSmithKline 
      and Zambon and institutional research grants from Bayer, Cancer Research UK 
      (Catalyst Award Aspirin for Cancer Prevention Collaboration), the European 
      Commission and the Italian Drug Agency (AIFA); he serves as chairperson of the 
      Scientific Advisory Board of the International Aspirin Foundation. The authors 
      received no funding from an external source.
EDAT- 2020/01/12 06:00
MHDA- 2020/05/16 06:00
CRDT- 2020/01/12 06:00
PHST- 2020/01/02 00:00 [received]
PHST- 2020/01/06 00:00 [accepted]
PHST- 2020/01/12 06:00 [pubmed]
PHST- 2020/05/16 06:00 [medline]
PHST- 2020/01/12 06:00 [entrez]
AID - S0168-8227(20)30007-3 [pii]
AID - 10.1016/j.diabres.2020.108008 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2020 Feb;160:108008. doi: 10.1016/j.diabres.2020.108008. 
      Epub 2020 Jan 8.

PMID- 25636606
OWN - NLM
STAT- MEDLINE
DCOM- 20151117
LR  - 20150218
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 84
IP  - 3
DP  - 2015 Mar
TI  - NOSH aspirin may have a protective role in Alzheimer's disease.
PG  - 262-7
LID - S0306-9877(15)00020-1 [pii]
LID - 10.1016/j.mehy.2015.01.008 [doi]
AB  - Evidence indicates that inflammation, oxidative stress, and the disruption of 
      normal conformation of proteins might be directly linked to Alzheimer's disease 
      (AD). The present study was undertaken using literature data to find a possible 
      drug to address the multiple disorders involved in AD-associated Aβ accumulation 
      and plaque formation. We consider NOSH-aspirin a drug of choice for reducing the 
      inflammatory areas in the brain (aspirin moiety), removing the noxious heavy 
      metals from plaques (hydrogen sulfide), and increasing the oxygen supply to 
      neurons since nitrogen oxide is a potent vasodilator and an anti-inflammatory 
      agent. Several confirmatory data in literature and possible mechanisms for 
      cellular defence as well as novel therapeutical pathways are discussed.
CI  - Copyright © 2015 Elsevier Ltd. All rights reserved.
FAU - Drochioiu, Gabi
AU  - Drochioiu G
AD  - Faculty of Chemistry, Al. I. Cuza University of Iasi, 11 Carol I, Iasi 700506, 
      Romania.
FAU - Tudorachi, Lucia
AU  - Tudorachi L
AD  - Faculty of Chemistry, Al. I. Cuza University of Iasi, 11 Carol I, Iasi 700506, 
      Romania.
FAU - Murariu, Manuela
AU  - Murariu M
AD  - Petru Poni Institute of Macromolecular Chemistry, Romanian Academy, 41A Grigore 
      Ghica Voda Alee, Iasi 700487, Romania. Electronic address: manuelam@icmpp.ro.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150114
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate)
RN  - 0 (Disulfides)
RN  - 0 (Nitrates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alzheimer Disease/*prevention & control
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Disulfides/*therapeutic use
MH  - Encephalitis/*drug therapy
MH  - Humans
MH  - *Models, Biological
MH  - Nitrates/*therapeutic use
EDAT- 2015/02/01 06:00
MHDA- 2015/11/18 06:00
CRDT- 2015/02/01 06:00
PHST- 2014/08/16 00:00 [received]
PHST- 2014/12/26 00:00 [revised]
PHST- 2015/01/06 00:00 [accepted]
PHST- 2015/02/01 06:00 [entrez]
PHST- 2015/02/01 06:00 [pubmed]
PHST- 2015/11/18 06:00 [medline]
AID - S0306-9877(15)00020-1 [pii]
AID - 10.1016/j.mehy.2015.01.008 [doi]
PST - ppublish
SO  - Med Hypotheses. 2015 Mar;84(3):262-7. doi: 10.1016/j.mehy.2015.01.008. Epub 2015 
      Jan 14.

PMID- 21554056
OWN - NLM
STAT- MEDLINE
DCOM- 20120109
LR  - 20131121
IS  - 1502-7686 (Electronic)
IS  - 0036-5513 (Linking)
VI  - 71
IP  - 5
DP  - 2011 Sep
TI  - Laboratory signs of aspirin response in haemodialysis patients.
PG  - 426-31
LID - 10.3109/00365513.2011.581388 [doi]
AB  - INTRODUCTION: Aspirin is effective in the secondary prevention and high-risk 
      primary prevention of cardiovascular events. However, clinical and laboratory 
      evidence demonstrates diminished or no response to aspirin in some patients. This 
      study was designed to assess aspirin response in haemodialysis patients. METHODS: 
      We prospectively enrolled 78 haemodialysis patients (28 female; 58.4 ± 12.6 years 
      old) and 79 patients (29 female; 58.4 ± 10.6 years old) with normal renal 
      function (glomerular filtration rate (GFR) >60 mL/min/1.73 m(2)). All subjects in 
      both the haemodialysis patient group and the control group were taking aspirin 
      (80-300 mg) for at least 30 days and were not taking other antiplatelet agents. 
      Platelet function was assessed by arachidonic acid-induced aggregometry with a 
      Multiplate analyser (Dynabyte Medical, Munich, Germany). Multiplate electrode 
      aggregometry values below 300 AU were applied as a cut-off for response to 
      aspirin. RESULTS: Aspirin non-response was two-fold more prevalent in 
      haemodialysis patients (42.3%) than in patients with normal renal function 
      (21.5%), and this difference was statistically significant (p = 0.005). The two 
      groups were similar in terms of sex, age, tobacco use, the presence of diabetes 
      mellitus, and platelet count. CONCLUSIONS: The frequency of aspirin non-response 
      as defined in this study was higher in haemodialysis patients than in patients 
      with normal renal function. However, larger subsets of patients are needed to 
      confirm the present study.
FAU - Kilickesmez, Kadriye O
AU  - Kilickesmez KO
AD  - Department of Cardiology, Istanbul University Institute of Cardiology, Turkey. 
      kadriye11@yahoo.com
FAU - Kocas, Cuneyt
AU  - Kocas C
FAU - Okcun, Baris
AU  - Okcun B
FAU - Abaci, Okay
AU  - Abaci O
FAU - Kaya, Aysem
AU  - Kaya A
FAU - Arat, Alev
AU  - Arat A
FAU - Gorcin, Bilal
AU  - Gorcin B
FAU - Gurmen, Tevfik
AU  - Gurmen T
LA  - eng
PT  - Journal Article
DEP - 20110509
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Kidney Failure, Chronic/*therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - *Renal Dialysis
MH  - Treatment Failure
EDAT- 2011/05/11 06:00
MHDA- 2012/01/10 06:00
CRDT- 2011/05/11 06:00
PHST- 2011/05/11 06:00 [entrez]
PHST- 2011/05/11 06:00 [pubmed]
PHST- 2012/01/10 06:00 [medline]
AID - 10.3109/00365513.2011.581388 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2011 Sep;71(5):426-31. doi: 
      10.3109/00365513.2011.581388. Epub 2011 May 9.

PMID- 6979740
OWN - NLM
STAT- MEDLINE
DCOM- 19820826
LR  - 20131121
IS  - 0391-5387 (Print)
IS  - 0391-5387 (Linking)
VI  - 3
IP  - 2-3
DP  - 1981 Mar-Jun
TI  - [Gastrointestinal bleeding after low doses of aspirin: gastroscopic and clinical 
      patterns in two pediatric patients (author's transl)].
PG  - 225-7
AB  - Two cases of gastrointestinal bleeding (haematemesis-melena) after ingestion of 
      low doses of aspirin are described. Gastroscopic examinations suddenly performed 
      (until 24 hours) have shown the typical gastric alterations due to this drug. The 
      Authors, besides calling the attention on the possible gastrointestinal accidents 
      following salicylates ingestion, suggest that these events may easier occur with 
      familial predisposition and with contemporary assumption of other gastrolesive 
      drugs.
FAU - Venier, D
AU  - Venier D
FAU - Torre, G
AU  - Torre G
FAU - Ventura, A
AU  - Ventura A
LA  - ita
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Ematemesi e melena dopo assunzione di piccole dosi di aspirina: osservazioni 
      clinico-anamnestiche e gastroscopiche in due bambine.
PL  - Italy
TA  - Pediatr Med Chir
JT  - La Pediatria medica e chirurgica : Medical and surgical pediatrics
JID - 8100625
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/diagnosis
MH  - Gastroscopy
MH  - Humans
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
PST - ppublish
SO  - Pediatr Med Chir. 1981 Mar-Jun;3(2-3):225-7.

PMID- 885664
OWN - NLM
STAT- MEDLINE
DCOM- 19770922
LR  - 20131121
IS  - 0340-0026 (Print)
IS  - 0340-0026 (Linking)
VI  - 15
IP  - 2
DP  - 1977 Feb
TI  - Absorption, and effect on gastric mucosa, of buffered and non-buffered tablets of 
      acetylsalicylic acid.
PG  - 61-4
AB  - The effect of buffered and non-buffered acetylsalicylic acid tablets on gastric 
      mucosa and gastric distress was investigated in healthy volunteers and in 
      patients with rheumatoid arthritis. The absorption of acetylsalicylic and 
      salicylic acids was also measured. The absorption of salicylic acid was not 
      affected in clinically significant amounts by buffering the tablets. Buffered 
      tablets containing aluminum subacetate showed a slightly delayed absorption of 
      salicylic acid. Damage to the gastric mucosa tended to be less after the 
      preparation buffered by magnesium hydroxide. Subjective feelings to gastric 
      distress were not affected by buffering.
FAU - Linnoila, M
AU  - Linnoila M
FAU - Lehtola, J
AU  - Lehtola J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Biopharm
JT  - International journal of clinical pharmacology and biopharmacy
JID - 7505527
RN  - 0 (Buffers)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/blood/pharmacology
MH  - Buffers
MH  - Double-Blind Method
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - *Intestinal Absorption
MH  - Salicylates/blood
MH  - Stomach/drug effects
MH  - Tablets
MH  - Time Factors
EDAT- 1977/02/01 00:00
MHDA- 1977/02/01 00:01
CRDT- 1977/02/01 00:00
PHST- 1977/02/01 00:00 [pubmed]
PHST- 1977/02/01 00:01 [medline]
PHST- 1977/02/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Biopharm. 1977 Feb;15(2):61-4.

PMID- 29956671
OWN - NLM
STAT- MEDLINE
DCOM- 20181001
LR  - 20181001
IS  - 0231-5882 (Print)
IS  - 0231-5882 (Linking)
VI  - 37
IP  - 4
DP  - 2018 Jul
TI  - Asthma exacerbation by aspirin and chemical additives: use of a nucleotide 
      template model to investigate potential mechanisms.
PG  - 461-468
LID - 10.4149/gpb_2018003 [doi]
AB  - Aspirin exacerbated asthma (AEA) affects approximately 10% of the asthmatic 
      population. Clinical studies with a focus on abnormalities in arachidonate 
      metabolism do not adequately account for susceptibility. Other pharmacological 
      targets of aspirin receive less attention. Further investigation is required to 
      elucidate mechanisms, improve on diagnosis and treatment. This study employs a 
      molecular modeling approach, based on use of a nucleotide template, to 
      standardise and compare molecular structures of compounds known to induce or 
      prevent asthma. Results identify relative molecular similarity within the 
      structures of drugs and cell mediators relevant to AEA and intolerance reactions. 
      The investigated compounds provide equivalent fits to ligand structures for GABA, 
      glycine, NMDA and nicotinic receptors. Chloride and ligand-gated ion channels are 
      a common link between agents responsible for the induction and control of AEA. 
      The methodology is applicable to compounds responsible for chemical-induced 
      intolerance reactions..
FAU - Williams, Wynford R
AU  - Williams WR
AD  - Faculty of Life Sciences and Education, University of South Wales, Cardiff, 
      United Kingdom. Robert.Williams2@southwales.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20180629
PL  - Slovakia
TA  - Gen Physiol Biophys
JT  - General physiology and biophysics
JID - 8400604
RN  - 0 (Nucleotides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/chemistry
MH  - Asthma/*chemically induced/*metabolism
MH  - *Models, Molecular
MH  - Molecular Conformation
MH  - Nucleotides/chemistry/*metabolism
EDAT- 2018/06/30 06:00
MHDA- 2018/10/03 06:00
CRDT- 2018/06/30 06:00
PHST- 2017/11/20 00:00 [received]
PHST- 2018/01/17 00:00 [accepted]
PHST- 2018/06/30 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
PHST- 2018/06/30 06:00 [entrez]
AID - 10.4149/gpb_2018003 [doi]
PST - ppublish
SO  - Gen Physiol Biophys. 2018 Jul;37(4):461-468. doi: 10.4149/gpb_2018003. Epub 2018 
      Jun 29.

PMID- 7205593
OWN - NLM
STAT- MEDLINE
DCOM- 19810526
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 69
IP  - 6
DP  - 1980 Jun
TI  - Hydrolysis of tetrakis-mu-acetylsalicylato-dicopper(II).
PG  - 725-7
AB  - Hydrolysis rates of acetylsalicylate in the free acid and anion forms and in the 
      dilute solution of the copper complex, tetrakis-mu-acetylsalicylato-dicopper(II), 
      were compared. The hydrolysis rate was unaffected by the presence of copper(II). 
      The pH-dependent rate was 3.64 x 10(-4) mmole/liter/min per pH unit at 37 degrees 
      in Ringer's solution. The synthetic procedures commonly used for the preparation 
      of this compound yield a product contaminated with salicylate. This contamination 
      is avoided by synthesis of the compound in methanol, which yields a complex 
      containing no measurable salicylate.
FAU - Alich, A A
AU  - Alich AA
FAU - Wittmers, L E
AU  - Wittmers LE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
EDAT- 1980/06/01 00:00
MHDA- 1980/06/01 00:01
CRDT- 1980/06/01 00:00
PHST- 1980/06/01 00:00 [pubmed]
PHST- 1980/06/01 00:01 [medline]
PHST- 1980/06/01 00:00 [entrez]
AID - S0022-3549(15)43272-1 [pii]
AID - 10.1002/jps.2600690631 [doi]
PST - ppublish
SO  - J Pharm Sci. 1980 Jun;69(6):725-7. doi: 10.1002/jps.2600690631.

PMID- 32371645
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20210125
IS  - 1473-6500 (Electronic)
IS  - 0952-7907 (Linking)
VI  - 33
IP  - 3
DP  - 2020 Jun
TI  - Perioperative management of antiplatelet therapy in noncardiac surgery.
PG  - 454-462
LID - 10.1097/ACO.0000000000000875 [doi]
AB  - PURPOSE OF REVIEW: Perioperative management of antiplatelet agents (APAs) in the 
      setting of noncardiac surgery is a controversial topic of balancing bleeding 
      versus thrombotic risks. RECENT FINDINGS: Recent data do not support a clear 
      association between continuation or discontinuation of APAs and rates of ischemic 
      events, bleeding complications, and mortality up to 6 months after surgery. 
      Clinical factors, such as indication and urgency of the operation, time since 
      stent placement, invasiveness of the procedure, preoperative cardiac 
      optimization, underlying functional status, as well as perioperative control of 
      supply-demand mismatch and bleeding may be more responsible for adverse outcome 
      than antiplatelet management. SUMMARY: Perioperative management of antiplatelet 
      therapy (APT) should be individually tailored based on consensus among the 
      anesthesiologist, cardiologist, surgeon, and patient to minimize both 
      ischemic/thrombotic and bleeding risks. Where possible, surgery should be delayed 
      for a minimum of 1 month but ideally for 3-6 months from the index cardiac event. 
      If bleeding risk is acceptable, dual APT (DAPT) should be continued 
      perioperatively; otherwise P2Y12 inhibitor therapy should be discontinued for the 
      minimum amount of time possible and aspirin monotherapy continued. If bleeding 
      risk is prohibitive, both aspirin and P2Y12 inhibitor therapy should be 
      interrupted and bridging therapy may be considered in patients with high 
      thrombotic risk.
FAU - Filipescu, Daniela C
AU  - Filipescu DC
AD  - Department of Anaesthesiology and Intensive Care Medicine, Carol Davila 
      University of Medicine and Pharmacy.
AD  - Department of Cardiac Anaeshesia and Intensive Care II.
FAU - Stefan, Mihai G
AU  - Stefan MG
AD  - Department of Cardiac Anaeshesia and Intensive Care II.
FAU - Valeanu, Liana
AU  - Valeanu L
AD  - Department of Anaesthesiology and Intensive Care Medicine, Carol Davila 
      University of Medicine and Pharmacy.
AD  - Department of Cardiac Anaeshesia and Intensive Care I, Emergency Institute for 
      Cardiovascular Diseases, 'Prof. Dr C. C. Iliescu', Bucharest, Romania.
FAU - Popescu, Wanda M
AU  - Popescu WM
AD  - Thoracic and Vascular Anesthesia Section, Yale School of Medicine, New Haven, 
      Connecticut, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Anaesthesiol
JT  - Current opinion in anaesthesiology
JID - 8813436
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Elective Surgical Procedures
MH  - Hemorrhage/*prevention & control
MH  - Humans
MH  - Perioperative Care/*methods
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Surgical Procedures, Operative/methods
EDAT- 2020/05/07 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 00001503-202006000-00030 [pii]
AID - 10.1097/ACO.0000000000000875 [doi]
PST - ppublish
SO  - Curr Opin Anaesthesiol. 2020 Jun;33(3):454-462. doi: 
      10.1097/ACO.0000000000000875.

PMID- 35854767
OWN - NLM
STAT- MEDLINE
DCOM- 20220721
LR  - 20220822
IS  - 1555-4317 (Electronic)
IS  - 1555-4309 (Print)
IS  - 1555-4309 (Linking)
VI  - 2022
DP  - 2022
TI  - The Effect of Off-Pump Coronary Artery Bypass Grafting in Patients on Aspirin 
      Therapy until Surgery Day.
PG  - 8674401
LID - 10.1155/2022/8674401 [doi]
LID - 8674401
AB  - Coronary artery bypass grafting (CABG) is widely used to treat coronary artery 
      disease, and intraoperative and postoperative bleeding is one of the major 
      factors affecting the efficacy and mortality of CABG. To overcome the adverse 
      effects of extracorporeal circulation (CPB), nonextracorporeal coronary artery 
      bypass grafting (OPCABG) has become the main modality of CABG but is still prone 
      to thromboembolic events. Whether antiplatelet agents should be clinically 
      applied before CABG, especially OPCABG, remains controversial. Aspirin is 
      currently the most important perioperative oral antiplatelet agent for coronary 
      artery bypass graft surgery. In this study, we evaluated the effect of continuing 
      aspirin therapy before OPCABG and observed perioperative performance and 
      physiological indicators to find evidence for continuing aspirin therapy before 
      surgery in China. The study showed that preoperative aspirin application had a 
      positive effect on enhancing early postoperative platelet inhibition without 
      increasing the incidence of adverse effects such as cardiovascular events. This 
      provides an important clinical reference for whether antiplatelet agents should 
      be applied before CABG, especially OPCABG.
CI  - Copyright © 2022 Zhishuo Liu et al.
FAU - Liu, Zhishuo
AU  - Liu Z
AD  - Department of Cardiovascular Surgery, HeBei PetroChina Central Hospital, Langfang 
      065000, China.
AD  - Department of Cardiovascular Surgery, General Hospital of Northern Theatre 
      Command, Shenyang 110000, China.
FAU - Yang, Zhonglu
AU  - Yang Z
AD  - Department of Cardiovascular Surgery, General Hospital of Northern Theatre 
      Command, Shenyang 110000, China.
FAU - Ge, Yuguang
AU  - Ge Y
AD  - Department of Cardiovascular Surgery, General Hospital of Northern Theatre 
      Command, Shenyang 110000, China.
FAU - Wang, Lu
AU  - Wang L
AD  - Department of Cardiovascular Surgery, General Hospital of Northern Theatre 
      Command, Shenyang 110000, China.
FAU - Jiang, Hui
AU  - Jiang H
AUID- ORCID: 0000-0002-4430-9902
AD  - Department of Cardiovascular Surgery, General Hospital of Northern Theatre 
      Command, Shenyang 110000, China.
LA  - eng
PT  - Journal Article
DEP - 20220708
PL  - England
TA  - Contrast Media Mol Imaging
JT  - Contrast media & molecular imaging
JID - 101286760
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Coronary Artery Bypass
MH  - *Coronary Artery Bypass, Off-Pump
MH  - *Coronary Artery Disease/drug therapy/surgery
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Treatment Outcome
PMC - PMC9286924
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/07/21 06:00
MHDA- 2022/07/22 06:00
CRDT- 2022/07/20 02:04
PHST- 2022/05/08 00:00 [received]
PHST- 2022/06/02 00:00 [revised]
PHST- 2022/06/03 00:00 [accepted]
PHST- 2022/07/20 02:04 [entrez]
PHST- 2022/07/21 06:00 [pubmed]
PHST- 2022/07/22 06:00 [medline]
AID - 10.1155/2022/8674401 [doi]
PST - epublish
SO  - Contrast Media Mol Imaging. 2022 Jul 8;2022:8674401. doi: 10.1155/2022/8674401. 
      eCollection 2022.

PMID- 2072775
OWN - NLM
STAT- MEDLINE
DCOM- 19910822
LR  - 20131121
IS  - 0025-7753 (Print)
IS  - 0025-7753 (Linking)
VI  - 96
IP  - 18
DP  - 1991 May 11
TI  - [Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular 
      pathology].
PG  - 689-91
AB  - BACKGROUND: The metaanalysis of clinical trials on the secondary prevention of 
      myocardial infarction and cerebrovascular disease with antiplatelet drugs 
      suggests that low doses of acetylsalicylic acid (ASA) reduce cardiovascular 
      mortality and morbidity. The ideal galenic formulation should contain a low dose 
      of ASA, should be enteric-coated--to reduce gastrointestinal toxicity--and should 
      be slowly absorbed--to facilitate selective inhibition of thromboxane synthesis 
      by platelets. METHODS: The kinetics of a single dose of an enteric-coated 
      sustained-release preparation containing 300 mg of ASA were studied in 6 healthy 
      volunteers. Plasma concentrations of ASA and salicylic acid (SA) were measured 
      during 12 hours after its administration. RESULTS: The time elapsed to achieve 
      maximum plasma concentrations in the systemic circulation was 1 to 4 hours, as 
      compared with 0.25 to 1.5 hours with other conventional preparations of ASA. The 
      maximum plasma concentration recorded in one subject was 1.2 micrograms/ml, as 
      compared with 4.8, 12, and 14 micrograms/ml with other preparations. CONCLUSIONS: 
      The pharmacokinetic profile of this new preparation fits that proposed by others 
      to produce a selective inhibition of thromboxane synthesis by platelets.
FAU - Castel, J M
AU  - Castel JM
AD  - Unitat de Farmacologia Clínica, Universitat Autónoma de Barcelona.
FAU - Artaza, M A
AU  - Artaza MA
FAU - Laporte, J R
AU  - Laporte JR
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Farmacocinética del ácido acetilsalicílico para la profilaxis de patología 
      cardiovascular.
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacokinetics/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Tablets, Enteric-Coated
EDAT- 1991/05/11 00:00
MHDA- 1991/05/11 00:01
CRDT- 1991/05/11 00:00
PHST- 1991/05/11 00:00 [pubmed]
PHST- 1991/05/11 00:01 [medline]
PHST- 1991/05/11 00:00 [entrez]
PST - ppublish
SO  - Med Clin (Barc). 1991 May 11;96(18):689-91.

PMID- 31856631
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 31
IP  - 8
DP  - 2020 Nov 16
TI  - The distinct effects of aspirin on platelet aggregation induced by infectious 
      bacteria.
PG  - 1028-1038
LID - 10.1080/09537104.2019.1704717 [doi]
AB  - Bacteria induce platelet aggregation triggered by several mechanisms. The goal of 
      this work was to characterize platelet aggregates induced by different bacterial 
      strains and to quantify the effect of aspirin treatment using aggregation tests, 
      as well as a novel approach based on confocal analysis. Blood samples were 
      obtained from either healthy donors (n = 27) or patients treated with long-term 
      aspirin (n = 15). The bacterial species included were Staphylococcus aureus, 
      Enterococcus faecalis, and Streptococcus sanguinis. The different aggregate's 
      ultrastructures depending on the bacterial strain were analyzed using Scanning 
      electron microscopy. Quantification of the size of the platelet aggregates, their 
      mean number as well as the bacterial impregnation within the aggregates was 
      performed using confocal laser scanning light microscopy. Light Transmission 
      Aggregometry was also performed. Our results reported distinct characteristics of 
      platelet aggregates depending on the bacterial strain. Using confocal analysis, 
      we have shown that aspirin significantly reduced platelet aggregation induced by 
      S. aureus (p = .003) and E. faecalis (p = .006) with no effect in the case of S. 
      sanguinis (p = .529). The results of the aggregometry were concordant with those 
      of the confocal technique in the case of S. aureus and S. sanguinis. 
      Interestingly, aggregation induced by E. faecalis was detected only with confocal 
      analysis. In conclusion, our confocal scanning microscopy allowed a detailed 
      study of the platelet aggregation induced by bacteria. We showed that aspirin 
      acts on bacterial-induced platelet aggregation depending on the species. These 
      results are in favor of the use of aspirin considering the species and the 
      bacterial strain involved.
FAU - Hannachi, Nadji
AU  - Hannachi N
AD  - Département d'infectiologie, MEPHI, IHU Méditerranée infection, Aix Marseille 
      Univ, IRD, AP-HM , Marseille, France.
FAU - Baudoin, Jean-Pierre
AU  - Baudoin JP
AD  - Département d'infectiologie, MEPHI, IHU Méditerranée infection, Aix Marseille 
      Univ, IRD, AP-HM , Marseille, France.
FAU - Prasanth, Arsha
AU  - Prasanth A
AD  - Département d'infectiologie, MEPHI, IHU Méditerranée infection, Aix Marseille 
      Univ, IRD, AP-HM , Marseille, France.
FAU - Habib, Gilbert
AU  - Habib G
AD  - Département d'infectiologie, MEPHI, IHU Méditerranée infection, Aix Marseille 
      Univ, IRD, AP-HM , Marseille, France.
AD  - Département de cardiologie, la Timone Hospital, AP-HM , Marseille, France.
FAU - Camoin-Jau, Laurence
AU  - Camoin-Jau L
AD  - Département d'infectiologie, MEPHI, IHU Méditerranée infection, Aix Marseille 
      Univ, IRD, AP-HM , Marseille, France.
AD  - Laboratoire d'Hématologie, La Timone Hospital, APHM , Marseille, France.
LA  - eng
PT  - Journal Article
DEP - 20191219
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Bacteremia/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
OTO - NOTNLM
OT  - Aggregation
OT  - Aspirin
OT  - Enterococcus faecalis
OT  - Platelets
OT  - Staphylococcus aureus
OT  - Streptococcus sanguinis
EDAT- 2019/12/21 06:00
MHDA- 2021/08/11 06:00
CRDT- 2019/12/21 06:00
PHST- 2019/12/21 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
PHST- 2019/12/21 06:00 [entrez]
AID - 10.1080/09537104.2019.1704717 [doi]
PST - ppublish
SO  - Platelets. 2020 Nov 16;31(8):1028-1038. doi: 10.1080/09537104.2019.1704717. Epub 
      2019 Dec 19.

PMID- 181404
OWN - NLM
STAT- MEDLINE
DCOM- 19761001
LR  - 20181130
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 57
IP  - 4
DP  - 1976 Apr
TI  - Effect of aspirin on normal and cholera toxin-stimulated intestinal electrolyte 
      transport.
PG  - 916-24
AB  - The effect of aspirin on normal and cholera toxin-stimulated electrolyte 
      transport has been investigated in vitro, because this drug appears to inhibit 
      cholera toxin-induced intestinal secretion in in vivo animal models. In the 
      Ussing chamber, 10 mM aspirin decreased the control rabbit ileal potential 
      difference and short-circuit current by 50% and increased conductance by 28%. 
      Bidirectional electrolyte flux determinations showed that aspirin significantly 
      increased both Na and Cl absorption and reduced flux (which probably represents 
      HCO3 secretion) to zero. This effect of aspirin appears to be identical to that 
      reported to others with catecholamines as determined with similar techniques. 
      However, alpha-adrenergic blockers did not prevent the electrical effects of 
      aspirin, suggesting that aspirin does not have its effect through release of 
      tissue stores of catecholamines. In the presence of aspirin, cholera toxin 
      increased the potential difference and short-circuit current, and decreased the 
      conductance of rabbit ileum in a fashion qualitatively similar to control 
      tissues. However, aspirin reversed cholera toxin-stimulated Na transport from 
      secretion to absorption, inhibited cholera toxin, induced Cl secretion by 58% and 
      partially, but not significantly, inhibited HCO3 secretion. Thus, the inhibitory 
      effect of aspirin on cholera toxin-induced electrolyte secretion appears to be 
      due to aspirin-stimulated Na and Cl absorption. Although aspirin reduced tissue 
      cyclic AMP concentrations in normal and cholera toxin-stimulated ileum, it also 
      inhibited the electrolyte secretion induced by exogenous cyclic AMP. Thus, if 
      aspirin's stimulatory effect on sodium and anion absorption in normal tissue and 
      its inhibitory effect on cholera toxin-stimulated sodium and anion secretion 
      involves a cyclic AMP-mediated system, the effect must be a step distal to cyclic 
      AMP production or degradation. The exact mechanism of aspirin's effect on normal 
      and cholera toxin-induced electrolyte transport, and its possible usefulness in 
      the treatment of cholera diarrhea, remains to be determined.
FAU - Farris, R K
AU  - Farris RK
FAU - Tapper, E J
AU  - Tapper EJ
FAU - Powell, D W
AU  - Powell DW
FAU - Morris, S M
AU  - Morris SM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Electrolytes)
RN  - 0 (Ions)
RN  - 0 (Toxins, Biological)
RN  - 0TTZ664R7Z (Phenoxybenzamine)
RN  - E0399OZS9N (Cyclic AMP)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W3ENH1CV (Norepinephrine)
RN  - YKH834O4BH (Epinephrine)
RN  - Z468598HBV (Phentolamine)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Biological Transport/drug effects
MH  - *Cholera
MH  - Cyclic AMP/metabolism
MH  - Cyclic GMP/metabolism
MH  - Electrolytes/*metabolism
MH  - Electrophysiology
MH  - Epinephrine/pharmacology
MH  - Ileum/metabolism
MH  - Intestinal Absorption
MH  - Intestinal Mucosa/*metabolism
MH  - Ions
MH  - Male
MH  - Norepinephrine/pharmacology
MH  - Phenoxybenzamine/pharmacology
MH  - Phentolamine/pharmacology
MH  - Rabbits
MH  - Stimulation, Chemical
MH  - Toxins, Biological/*pharmacology
PMC - PMC436735
EDAT- 1976/04/01 00:00
MHDA- 1976/04/01 00:01
CRDT- 1976/04/01 00:00
PHST- 1976/04/01 00:00 [pubmed]
PHST- 1976/04/01 00:01 [medline]
PHST- 1976/04/01 00:00 [entrez]
AID - 10.1172/JCI108368 [doi]
PST - ppublish
SO  - J Clin Invest. 1976 Apr;57(4):916-24. doi: 10.1172/JCI108368.

PMID- 22195684
OWN - NLM
STAT- MEDLINE
DCOM- 20120423
LR  - 20161020
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 32
IP  - 5
DP  - 2011 Sep-Oct
TI  - Aspirin therapy in aspirin-exacerbated respiratory disease: a risk-benefit 
      analysis for the practicing allergist.
PG  - 335-40
LID - 10.2500/aap.2011.32.3457 [doi]
AB  - This study was designed to investigate the risks associated with aspirin (ASA) 
      therapy that is used in high doses for the treatment of ASA-exacerbated 
      respiratory disease (AERD) and to review therapeutic strategies for the 
      prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced side effects. A 
      PubMed search was performed using the key words "aspirin" and "adverse effects." 
      Additional citations were generated by surveying the reference lists of the 
      pulled articles. More than 120 articles were reviewed and references were 
      selected based on their relevance to the subject matter. Prevalence rates of ASA 
      hypersensitivity in the general population have been reported to be 0.6-2.5%. 
      Asthmatic patients have higher rates of ASA hypersensitivity. The 
      allergy/immunology specialty is unique in the use of prolonged high-dose ASA 
      therapy for the treatment of AERD. ASA use is associated with an increased risk 
      for the development of serious gastrointestinal (GI) events including GI 
      bleeding, ulcers, and perforation. Established risk factors for GI ulcer 
      development include advanced age, history of ulcer or GI bleed, concomitant use 
      of corticosteroids or anticoagulants, high-dose ASA/NSAID therapy, and possibly 
      concomitant Helicobacter pylori infection. Effective strategies to prevent GI 
      complications include initiation of a proton pump inhibitor (PPI), misoprostol, 
      or double dose H(2)-receptor antagonists (H(2)RAs) at the start of ASA therapy. 
      Allergist/immunologists are involved in treatment decisions regarding high-dose 
      ASA use in AERD. The primary risk of using ASA therapy is the development of GI 
      complications. Cotherapy with a PPI, misoprostol, or double dose H(2)RAs can 
      reduce GI complications associated with high-dose ASA therapy.
FAU - Baker, Troy W
AU  - Baker TW
AD  - Wilford Hall Medical Center, U.S. Air Force, Lackland Air Force Base, Texas, USA. 
      troy.baker@us.af.mil
FAU - Quinn, James M
AU  - Quinn JM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Allergy Asthma Proc. 2011 Sep-Oct;32(5):333-4. PMID: 22195683
MH  - Aspirin/administration & dosage/*adverse effects/*therapeutic use
MH  - Desensitization, Immunologic
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Gastrointestinal Tract/drug effects
MH  - Humans
MH  - Mucous Membrane/drug effects
MH  - Respiratory Hypersensitivity/*chemically induced/*drug therapy
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2011/12/27 06:00
MHDA- 2012/04/24 06:00
CRDT- 2011/12/27 06:00
PHST- 2011/12/27 06:00 [entrez]
PHST- 2011/12/27 06:00 [pubmed]
PHST- 2012/04/24 06:00 [medline]
AID - 10.2500/aap.2011.32.3457 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2011 Sep-Oct;32(5):335-40. doi: 10.2500/aap.2011.32.3457.

PMID- 22542150
OWN - NLM
STAT- MEDLINE
DCOM- 20130320
LR  - 20181201
IS  - 1532-1916 (Electronic)
IS  - 1521-6918 (Linking)
VI  - 26
IP  - 2
DP  - 2012 Apr
TI  - Role of ASA in the primary and secondary prevention of cardiovascular events.
PG  - 113-23
LID - 10.1016/j.bpg.2012.01.013 [doi]
AB  - Cardiovascular disease, which includes coronary heart disease, cerebrovascular 
      disease and peripheral artery disease, is the leading cause of death in developed 
      countries. Evidence from basic research, clinical investigations, observational 
      epidemiologic studies and randomized clinical trials has provided strong support 
      for the benefits of aspirin in decreasing the risk of cardiovascular events in a 
      wide range of pathologies in secondary prevention. Data in primary prevention 
      have far more uncertainties. An overview for the evidence supporting the efficacy 
      of aspirin in primary and secondary prevention of cardiovascular disease is 
      discussed, including the relative and absolute benefit and the risks of side 
      effects. Finally, future developments in the field directed towards 
      individualized treatment strategies and novel antiplatelet agents are examined.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Casado-Arroyo, Rubén
AU  - Casado-Arroyo R
AD  - Heart Rhythm Management Center, Cardiovascular Center, Free University of 
      Brussels (UZ Brussel) VUB, Brussels, Belgium. rbcasado@gmail.com
FAU - Bayrak, Fatih
AU  - Bayrak F
FAU - Sarkozy, Andrea
AU  - Sarkozy A
FAU - Chierchia, Gian-Battista
AU  - Chierchia GB
FAU - de Asmundis, Carlo
AU  - de Asmundis C
FAU - Brugada, Pedro
AU  - Brugada P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Gastroenterol
JT  - Best practice & research. Clinical gastroenterology
JID - 101120605
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention
MH  - Secondary Prevention
MH  - Sex Factors
EDAT- 2012/05/01 06:00
MHDA- 2013/03/21 06:00
CRDT- 2012/05/01 06:00
PHST- 2011/11/08 00:00 [received]
PHST- 2012/01/19 00:00 [accepted]
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
AID - S1521-6918(12)00014-5 [pii]
AID - 10.1016/j.bpg.2012.01.013 [doi]
PST - ppublish
SO  - Best Pract Res Clin Gastroenterol. 2012 Apr;26(2):113-23. doi: 
      10.1016/j.bpg.2012.01.013.

PMID- 23918470
OWN - NLM
STAT- MEDLINE
DCOM- 20140327
LR  - 20220408
IS  - 1098-1136 (Electronic)
IS  - 0894-1491 (Linking)
VI  - 61
IP  - 10
DP  - 2013 Oct
TI  - NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing 
      hybrid, attenuates neuroinflammation induced by microglial and astrocytic 
      activation: a new candidate for treatment of neurodegenerative disorders.
PG  - 1724-34
LID - 10.1002/glia.22553 [doi]
AB  - Hydrogen sulfide (H2 S) and nitric oxide (NO) have been described as 
      gasotransmitters. Anti-inflammatory activity in the central and peripheral 
      nervous systems may be one of their functions. Previously we demonstrated that 
      several SH(-) donors including H2 S-releasing aspirin (S-ASA) exhibited 
      anti-inflammatory and neuroprotective activity in vitro against toxins released 
      by activated microglia and astrocytes. Here we report that NOSH-ASA, an NO- and 
      H2 S-releasing hybrid of aspirin, has a significantly greater anti-inflammatory 
      and neuroprotective effect than S-ASA or NO-ASA. When activated by LPS/IFNγ, 
      human microglia and THP-1 cells release materials that are toxic to 
      differentiated SH-SY5Y cells. These phenomena also occur with IFNγ-stimulated 
      human astroglia and U373 cells. When the cells were treated with the S-ASA or 
      NO-ASA, there was a significant enhancement of neuroprotection. However, NOSH-ASA 
      had significantly more potent protection properties than NO-ASA or S-ASA. The 
      effect was concentration-dependent, as well as incubation time-dependent. Such 
      treatment not only reduced the release of the TNFα and IL-6, but also attenuated 
      activation of P38 MAPK and NFκB proteins. All the compounds tested were not 
      harmful when applied directly to SH-SY5Y cells. These data suggest that NOSH-ASA 
      has significant anti-inflammatory properties and may be a new candidate for 
      treating neurodegenerative disorders that have a prominent neuroinflammatory 
      component such as Alzheimer disease and Parkinson disease.
CI  - Copyright © 2013 Wiley Periodicals, Inc.
FAU - Lee, Moonhee
AU  - Lee M
AD  - Kinsmen Laboratory of Neurological Research, University of British Columbia, 
      Vancouver, BC V6T 1Z3, Canada.
FAU - McGeer, Edith
AU  - McGeer E
FAU - Kodela, Ravinder
AU  - Kodela R
FAU - Kashfi, Khosrow
AU  - Kashfi K
FAU - McGeer, Patrick L
AU  - McGeer PL
LA  - eng
GR  - R24 DA018055/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130805
PL  - United States
TA  - Glia
JT  - Glia
JID - 8806785
RN  - 0 (4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Disulfides)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (Nitrates)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Astrocytes/*drug effects
MH  - Astrocytoma/pathology
MH  - Cell Line, Tumor
MH  - Cells, Cultured
MH  - Disulfides/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Interferon-gamma/pharmacology
MH  - Interleukin-6/metabolism
MH  - Lipopolysaccharides/pharmacology
MH  - Microglia/*drug effects
MH  - NF-kappa B/metabolism
MH  - Nitrates/*pharmacology
MH  - Signal Transduction/drug effects
MH  - Temporal Lobe/cytology
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - p38 Mitogen-Activated Protein Kinases/metabolism
OTO - NOTNLM
OT  - Alzheimer disease
OT  - IL-6
OT  - NO-aspirin
OT  - NOSH-aspirin
OT  - Parkinson disease
OT  - S-aspirin
OT  - tumor necrosis factor-α
EDAT- 2013/08/07 06:00
MHDA- 2014/03/29 06:00
CRDT- 2013/08/07 06:00
PHST- 2013/03/19 00:00 [received]
PHST- 2013/06/27 00:00 [revised]
PHST- 2013/06/27 00:00 [accepted]
PHST- 2013/08/07 06:00 [entrez]
PHST- 2013/08/07 06:00 [pubmed]
PHST- 2014/03/29 06:00 [medline]
AID - 10.1002/glia.22553 [doi]
PST - ppublish
SO  - Glia. 2013 Oct;61(10):1724-34. doi: 10.1002/glia.22553. Epub 2013 Aug 5.

PMID- 19423529
OWN - NLM
STAT- MEDLINE
DCOM- 20090625
LR  - 20211020
IS  - 1055-9965 (Print)
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
VI  - 18
IP  - 5
DP  - 2009 May
TI  - No effect of aspirin on mammographic density in a randomized controlled clinical 
      trial.
PG  - 1524-30
LID - 10.1158/1055-9965.EPI-08-1088 [doi]
AB  - BACKGROUND: Epidemiologic studies suggest a reduced risk of breast cancer among 
      women who regularly use aspirin; a plausible mechanism is through aspirin effect 
      on mammographic breast density, a breast cancer risk factor, possibly mediated 
      through aspirin interference with estrogen synthesis. METHODS: In a 2-arm 
      randomized placebo-controlled clinical trial, we evaluated the effects of 6-month 
      administration of 325 mg/day aspirin on total mammographic breast dense area and 
      percent of the mammographic breast image occupied by dense areas (% density) in 
      143 postmenopausal women. Eligible women, recruited from 2005 to 2007, were 
      healthy, not taking hormone therapy, with elevated mammographic breast density 
      (American College of Radiology Breast Imaging Reporting and Data System density 
      category 2, 3, or 4) within 6 months before enrollment. RESULTS: Women were a 
      mean (SD) 59.5 (5.5) years. Geometric mean baseline percent density was 17.6% 
      (95% confidence interval, 14.8-20.9) in women randomized to aspirin and 19.2% 
      (95% confidence interval, 16.3-22.7) in women randomized to placebo. Percent 
      density decreased in women randomized to aspirin by an absolute 0.8% versus an 
      absolute decrease of 1.2% in controls (P = 0.84). Total breast area and dense 
      area decreased to a similar degree in women assigned to aspirin and in those 
      assigned to placebo, with no statistically significant differences between trial 
      arms. CONCLUSIONS: A single daily administration of adult-dose aspirin for 6 
      months had no effect on mammographic density in postmenopausal women. If aspirin 
      affects breast cancer risk in postmenopausal women, it may do so through 
      alternative pathways than mammographic breast density.
FAU - McTiernan, Anne
AU  - McTiernan A
AD  - Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. 
      amctiern@fhcrc.org
FAU - Wang, C Y
AU  - Wang CY
FAU - Sorensen, Bess
AU  - Sorensen B
FAU - Xiao, Liren
AU  - Xiao L
FAU - Buist, Diana S M
AU  - Buist DS
FAU - Aiello Bowles, Erin J
AU  - Aiello Bowles EJ
FAU - White, Emily
AU  - White E
FAU - Rossing, Mary Anne
AU  - Rossing MA
FAU - Potter, John
AU  - Potter J
FAU - Urban, Nicole
AU  - Urban N
LA  - eng
GR  - P50 CA083636/CA/NCI NIH HHS/United States
GR  - P50 CA083636-10/CA/NCI NIH HHS/United States
GR  - P50 CA83636/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Breast Neoplasms/*diagnostic imaging
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Linear Models
MH  - Mammography
MH  - Middle Aged
MH  - Postmenopause
MH  - Risk Factors
PMC - PMC2689709
MID - NIHMS116968
EDAT- 2009/05/09 09:00
MHDA- 2009/06/26 09:00
CRDT- 2009/05/09 09:00
PHST- 2009/05/09 09:00 [entrez]
PHST- 2009/05/09 09:00 [pubmed]
PHST- 2009/06/26 09:00 [medline]
AID - 18/5/1524 [pii]
AID - 10.1158/1055-9965.EPI-08-1088 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1524-30. doi: 
      10.1158/1055-9965.EPI-08-1088.

PMID- 7849445
OWN - NLM
STAT- MEDLINE
DCOM- 19950316
LR  - 20191101
IS  - 0941-0198 (Print)
IS  - 0941-0198 (Linking)
VI  - 72
IP  - 9
DP  - 1994 Sep
TI  - Controlled trial of high- versus low-dose aspirin treatment after percutaneous 
      transluminal angioplasty in patients with peripheral vascular disease.
PG  - 673-80
AB  - Percutaneous transluminal angioplasty of aortoiliac and femoropopliteal 
      atherosclerotic lesions can provide long-lasting hemodynamic improvement. 
      High-dose aspirin is commonly prescribed as reocclusion prophylaxis, but low 
      doses would be preferable because of fewer adverse effects. We performed a 
      double-blind, randomized, controlled clinical trial in patients with peripheral 
      vascular disease with lesions appropriate for angioplasty. We compared the 
      efficacy and side effects of two doses of aspirin (50 mg vs. 900 mg daily) during 
      a period of 12 months after angioplasty. A total of 359 patients were evaluated: 
      175 were randomly assigned to treatment with 900 mg aspirin daily and 184 to 50 
      mg aspirin daily. Thirty-nine patients developed restenosis at the angioplasty 
      site; the cumulative percentage of event-free survival after 1 year (patency 
      rate) was 85% in 900 mg group and 84% in 50 mg group. An equivalence test showed 
      the two groups equivalent with respect to restenosis rates (P = 0.0003 for an 
      equivalence region of < 10% difference. Nine patients (5%) in the 900 mg group 
      had serious gastrointestinal side effects (peptic ulcer, 8; erosive gastritis 
      requiring transfusion, 1) compared to two ( peptic ulcer) in the 50 mg group (P = 
      0.03). The results of our study show that a dose of 50 mg aspirin a day is as 
      effective as 900 mg for the prevention of restenoses after lower limb 
      angioplasty, and that severe gastrointestinal side effects are less frequent.
FAU - Ranke, C
AU  - Ranke C
AD  - Abteilung Angiologie, Medizinische Hochsule Hannover, Germany.
FAU - Creutzig, A
AU  - Creutzig A
FAU - Luska, G
AU  - Luska G
FAU - Wagner, H H
AU  - Wagner HH
FAU - Galanski, M
AU  - Galanski M
FAU - Bode-Böger, S
AU  - Bode-Böger S
FAU - Frölich, J
AU  - Frölich J
FAU - Avenarius, H J
AU  - Avenarius HJ
FAU - Hecker, H
AU  - Hecker H
FAU - ALexander, K
AU  - ALexander K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Clin Investig
JT  - The Clinical investigator
JID - 9207154
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/drug therapy/*therapy
MH  - Prognosis
EDAT- 1994/09/01 00:00
MHDA- 1994/09/01 00:01
CRDT- 1994/09/01 00:00
PHST- 1994/09/01 00:00 [pubmed]
PHST- 1994/09/01 00:01 [medline]
PHST- 1994/09/01 00:00 [entrez]
AID - 10.1007/BF00212985 [doi]
PST - ppublish
SO  - Clin Investig. 1994 Sep;72(9):673-80. doi: 10.1007/BF00212985.

PMID- 8024235
OWN - NLM
STAT- MEDLINE
DCOM- 19940803
LR  - 20131121
IS  - 0003-3928 (Print)
IS  - 0003-3928 (Linking)
VI  - 43
IP  - 4
DP  - 1994 Apr
TI  - [Coronary disease: benefits of aspirin. What dose for which disease?].
PG  - 204-10
AB  - Thrombotic occlusion is one of the chief complications of coronary 
      atherosclerosis. The search for an effective method to prevent coronary 
      thrombosis has thus been an active research area for several years. The 
      anti-thrombotic drug most studied during the past twenty years has been aspirin. 
      Many studies have shown the usefulness of aspirin in the secondary prevention of 
      recurrences of cardiovascular disease: during the acute phase of myocardial 
      infarction, post-infarction, in unstable angina, and following angioplasty or 
      aortocoronary bypass. While the benefits of this platelet anti-aggregant are now 
      unanimously recognised, since aspirin reduces by approximately 25% the risk of a 
      further coronary event after a first episode, the question today concerns the 
      optimal dose to be used in each pathological context. Analysis of data from major 
      clinical trials of aspirin as secondary prevention reveals the usefulness of a 
      daily dose of aspirin of between 160 and 300 mg, with many studies undertaken at 
      the dose of 300 mg/day. In the special case of the acute phase of myocardial 
      infarction, the dose of 160 mg/day appears most suitable, as shown by the results 
      of the vast ISIS II study.
FAU - Michel, P L
AU  - Michel PL
AD  - Service de Cardiologie, Hôpital Tenon, Paris.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Pathologie coronaire: les bénéfices de l'aspirine. Quelles doses pour quelles 
      pathologies?
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angina, Unstable/prevention & control
MH  - Aspirin/*administration & dosage
MH  - Coronary Disease/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy
MH  - Recurrence
RF  - 26
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 1994 Apr;43(4):204-10.

PMID- 23597106
OWN - NLM
STAT- MEDLINE
DCOM- 20131231
LR  - 20191112
IS  - 1875-6182 (Electronic)
IS  - 1871-5257 (Linking)
VI  - 11
IP  - 2
DP  - 2013 Jun
TI  - Combined antiplatelet therapy: still a sweeping combination in cardiology.
PG  - 136-67
AB  - Platelets play a key role in the pathogenesis of atherothrombosis, involved in 
      both the development and progression of atherosclerotic heart disease, and the 
      attendant acute thrombotic complications. Antiplatelet therapy constitutes a 
      mainstay therapy for patients with acute coronary syndromes and generally 
      high-risk patients with atherothrombosis. Until recently, dual antiplatelet 
      therapy (DAPT) for the treatment and prevention of the complications of 
      atherothrombotic disease was traditionally limited to aspirin plus clopidogrel. 
      However, a most important pertaining issue emerged, that of the occurrence of 
      drug-resistance or tolerance observed in some patients for both these 
      antithrombotic agents, which limited the efficacy and applicability of this 
      combined therapy.The availability of the newer thienopyridine, prasugrel, and the 
      cyclopentyl-triazolopyrimidine, ticagrelor, represents an important addition to 
      the physician's armamentarium. Dual antiplatelet therapy with aspirin and 
      clopidogrel or one of the newer agents interferes with platelet activation in 
      complementary, but separate pathways. Aspirin irreversibly inhibits 
      cyclooxygenase, thus preventing the production of thromboxane A2, which is a 
      prothrombotic and vasoconstrictive substance. Thienopyridines 
      (clopidogrel/prasugrel) irreversibly and ticagrelor reversibly prevent and 
      inhibit platelet activation by blocking one of the three known adenosine 
      5'-diphosphate (ADP) receptors (the P2Y12 receptor) on the platelet surface, thus 
      interfering with platelet activation, degranulation and aggregation. Each of 
      these antiplatelet agents has a protective effect against adverse vascular 
      events; classical DAPT with aspirin and clopidogrel has an even stronger 
      antiplatelet effect compared with either agent alone, however DAPT combining 
      aspirin with one of the newer more potent agents translates into superior 
      antithrombotic protection in atherothrobotic vascular disease, albeit at an 
      increased, though not inordinately, risk for bleeding complications. A number of 
      randomized clinical trials have demonstrated and confirmed the incremental 
      benefit and efficacy of DAPT with use of either classical or newer agents, above 
      and beyond that of each antiplatelet agent alone. Data have also been obtained 
      from studies where indications for the use of DAPT continue to expand into other 
      patient groups, rendering and maintaining DAPT a sweeping combination in 
      Cardiology. This article is a comprehensive review of all these data and the 
      landmark trials on the two classical and also the newer antiplatelet agents, the 
      issues involved and the current recommendations for their use in patients with 
      atherosclerotic heart disease and other cardiovascular disorders and procedures.
FAU - Manolis, Antonis S
AU  - Manolis AS
AD  - First Department of Cardiology, Evagelismos General Hospital of Athens, Athens, 
      Greece. asmanol@otenet.gr
FAU - Manolis, Theodora A
AU  - Manolis TA
FAU - Papadimitriou, Prokopis
AU  - Papadimitriou P
FAU - Koulouris, Spyros
AU  - Koulouris S
FAU - Melita, Helen
AU  - Melita H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cardiovasc Hematol Agents Med Chem
JT  - Cardiovascular & hematological agents in medicinal chemistry
JID - 101266881
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination/standards/trends
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
EDAT- 2013/04/20 06:00
MHDA- 2014/01/01 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/03/20 00:00 [received]
PHST- 2013/04/03 00:00 [revised]
PHST- 2013/04/04 00:00 [accepted]
PHST- 2013/04/20 06:00 [entrez]
PHST- 2013/04/20 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
AID - CMCCHA-EPUB-20130408-1 [pii]
AID - 10.2174/1871525711311020009 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Agents Med Chem. 2013 Jun;11(2):136-67. doi: 
      10.2174/1871525711311020009.

PMID- 868818
OWN - NLM
STAT- MEDLINE
DCOM- 19770729
LR  - 20190716
IS  - 0002-922X (Print)
IS  - 0002-922X (Linking)
VI  - 131
IP  - 6
DP  - 1977 Jun
TI  - Aspirin-induced hepatotoxicity and its effect on juvenile rheumatoid arthritis.
PG  - 659-63
AB  - Evidence of hepatic disease was sought in 102 children with juvenile rheumatoid 
      arthritis (JRA) who were treated with aspirin. Serum glutamic oxaloacetic 
      transaminase level was elevated (greater than 39 IU/liter) in 59% of the 
      children. The degree and prevalence of SGOT elevations correlated with aspirin 
      dose and serum salicylate level. Nevertheless, increased SGOT values were 
      frequently present in children receiving moderate aspirin doses and having serum 
      salicylate levels less than 25 mg/100 ml. Elevated SGOT values decreased in 
      proportion to the degree of reduction in aspirin dose. The SGOT values above the 
      100 IU/liter were statistically associated with reduced sedimentation rates. 
      Concomitant improvement in the clinical manifestations of JRA was noted in some 
      children.
FAU - Bernstein, B H
AU  - Bernstein BH
FAU - Singsen, B H
AU  - Singsen BH
FAU - King, K K
AU  - King KK
FAU - Hanson, V
AU  - Hanson V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Dis Child
JT  - American journal of diseases of children (1960)
JID - 0370471
RN  - 0 (Salicylates)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspartate Aminotransferases/blood
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Chemical and Drug Induced Liver Injury/*etiology
MH  - Child
MH  - Female
MH  - Humans
MH  - Liver/*drug effects
MH  - Male
MH  - Salicylates/blood
EDAT- 1977/06/01 00:00
MHDA- 1977/06/01 00:01
CRDT- 1977/06/01 00:00
PHST- 1977/06/01 00:00 [pubmed]
PHST- 1977/06/01 00:01 [medline]
PHST- 1977/06/01 00:00 [entrez]
AID - 10.1001/archpedi.1977.02120190053012 [doi]
PST - ppublish
SO  - Am J Dis Child. 1977 Jun;131(6):659-63. doi: 
      10.1001/archpedi.1977.02120190053012.

PMID- 7823260
OWN - NLM
STAT- MEDLINE
DCOM- 19950216
LR  - 20190920
IS  - 0300-5577 (Print)
IS  - 0300-5577 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Low-dose aspirin to pregnant women: single dose pharmacokinetics and influence of 
      short term treatment on bleeding time.
PG  - 205-11
AB  - Single dose pharmacokinetics of 75 mg aspirin was investigated in two groups of 
      ten women with clinically normal pregnancies. Eleven non-pregnant subjects in the 
      same age were controls. In group A, gestational age was 27-30 completed weeks, 
      and in group B, 36-39 weeks. Venous blood samples were taken before and up to 240 
      minutes after the intake of the aspirin. Liquid chromatographic assays for 
      acetylsalicylic acid (ASA) and its metabolite, salicylic acid (SA), was 
      performed. The pharmacokinetics of ASA and SA were similar in group A and B but 
      pregnant subjects had a slower uptake and a lower peak level than controls. The 
      late elimination phase for their compound did not differ between the groups. Nine 
      pregnant women with normal pregnancies had their bleeding time measured by a 
      modified Ivy technique using a Simplate II device before, at the end of, and two 
      weeks after daily administration of 75 mg ASA for two weeks. All had a normal 
      bleeding time before and two weeks after the end of the medication. Eight of the 
      nine subjects had an increased bleeding time by Ivy tests, (p < 0.01) whereas the 
      bleeding time assessed by Duke's method was within normal limits. These studies 
      suggest that during pregnancy changes of the uptake rate and distribution volume 
      modulate the pharmacokinetics of ASA and that this drug given in low dosage to 
      gravidae marginally alters their platelet function.
FAU - Rymark, P
AU  - Rymark P
AD  - Department of Obstetrics and Gynaecology, University of Lund, Malmoe General 
      Hospital, Sweden.
FAU - Berntorp, E
AU  - Berntorp E
FAU - Nordsjö, P
AU  - Nordsjö P
FAU - Liedholm, H
AU  - Liedholm H
FAU - Melander, A
AU  - Melander A
FAU - Gennser, G
AU  - Gennser G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Bleeding Time
MH  - Female
MH  - Humans
MH  - Male
MH  - Pregnancy/*metabolism/physiology
MH  - Pregnancy Trimester, Third
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1515/jpme.1994.22.3.205 [doi]
PST - ppublish
SO  - J Perinat Med. 1994;22(3):205-11. doi: 10.1515/jpme.1994.22.3.205.

PMID- 21121897
OWN - NLM
STAT- MEDLINE
DCOM- 20110603
LR  - 20190911
IS  - 1875-5305 (Electronic)
IS  - 0929-8665 (Linking)
VI  - 18
IP  - 3
DP  - 2011 Mar
TI  - Investigating the antagonistic action between aspirin and tamoxifen with HSA: 
      identification of binding sites in binary and ternary drug-protein systems by 
      spectroscopic and molecular modeling approaches.
PG  - 305-17
AB  - The combination of several drugs is often necessary, especially during long-term 
      therapy. A competitive binding of the drugs can cause a decrease of the amount of 
      drugs actually bound to the protein and increase the biologically active fraction 
      of the drug. The aim of this study has been to analyze the interactions of 
      tamoxifen (TMX) and aspirin (ASA) with human serum albumin (HSA) and to evaluate 
      the mechanism of a simultaneous binding of TMX and ASA to the protein. 
      Fluorescence analysis was used to estimate the effect of the drugs on the protein 
      fluorescence and to define the binding and quenching properties of drug-HSA 
      complexes. The binding sites for TMX and ASA were identified in ternary 
      structures of HSA by means of spectrofluroscence. The analysis of the 
      fluorescence quenching of HSA in binary and ternary systems pointed at TMX and 
      ASA having an effect on the HSA-ASA and HSA-TMX complexes. Furthermore, the 
      results of synchronous fluorescence, resonance light scattering and circular 
      dichroism of the binary and ternary systems showed that the binding of TMX and 
      ASA to HSA could induce conformational changes in HSA. Moreover, the simultaneous 
      presence of TMX and ASA during binding to HSA should be taken into account in 
      multi-drug therapy, as it induces the necessity of a monitoring therapy owing to 
      the possible increase of uncontrolled toxic effects. Competitive site marker 
      experiments demonstrated that the binding site of ASA and TMX to HSA differed in 
      the binary system as opposed to in its ternary counterpart. Finally, molecular 
      modeling of the possible binding sites of TMX and ASA in binary and ternary 
      systems to HSA confirmed the experimental results.
FAU - Pourgonabadi, Sanaz
AU  - Pourgonabadi S
AD  - Department of Biology, Faculty of Sciences, Islamic Azad University-Mashhad 
      Branch, Mashhad, Iran.
FAU - Saberi, Mohammad Reza
AU  - Saberi MR
FAU - Chamani, Jamshid Khan
AU  - Chamani JK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Protein Pept Lett
JT  - Protein and peptide letters
JID - 9441434
RN  - 0 (Serum Albumin)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/antagonists & inhibitors/*metabolism/pharmacology
MH  - Binding Sites
MH  - *Drug Antagonism
MH  - Humans
MH  - *Models, Molecular
MH  - Protein Binding
MH  - Protein Conformation/drug effects
MH  - Serum Albumin/*chemistry/*metabolism
MH  - *Spectrum Analysis
MH  - Tamoxifen/antagonists & inhibitors/*metabolism/pharmacology
EDAT- 2010/12/03 06:00
MHDA- 2011/06/04 06:00
CRDT- 2010/12/03 06:00
PHST- 2010/09/09 00:00 [received]
PHST- 2010/11/17 00:00 [accepted]
PHST- 2010/12/03 06:00 [entrez]
PHST- 2010/12/03 06:00 [pubmed]
PHST- 2011/06/04 06:00 [medline]
AID - BSP/ PPL/ E pub/0245 [pii]
AID - 10.2174/092986611794578350 [doi]
PST - ppublish
SO  - Protein Pept Lett. 2011 Mar;18(3):305-17. doi: 10.2174/092986611794578350.

PMID- 8501577
OWN - NLM
STAT- MEDLINE
DCOM- 19930629
LR  - 20191210
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 122
IP  - 6
DP  - 1993 Jun
TI  - Toxic reaction to salicylate in a newborn infant: similarities to neonatal 
      sepsis.
PG  - 955-8
AB  - A newborn infant had metabolic acidosis, tachypnea, and hypoglycemia. After the 
      initial diagnosis of neonatal sepsis, she was given antibiotics but failed to 
      respond. Further investigation revealed that her mother had taken aspirin 
      throughout pregnancy. This case illustrates the similarities between symptoms of 
      neonatal sepsis and those of a toxic reaction to salicylate.
FAU - Buck, M L
AU  - Buck ML
AD  - Department of Pharmacy, University of Virginia Health Sciences Center, 
      Charlottesville 22908.
FAU - Grebe, T A
AU  - Grebe TA
FAU - Bond, G R
AU  - Bond GR
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*poisoning/therapeutic use
MH  - Diagnosis, Differential
MH  - Female
MH  - Fetus/drug effects
MH  - Headache/drug therapy
MH  - Humans
MH  - Infant, Newborn
MH  - Infections/*diagnosis
MH  - Poisoning/congenital/diagnosis
MH  - Pregnancy
MH  - Pregnancy Complications/drug therapy
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - S0022-3476(09)90027-0 [pii]
AID - 10.1016/s0022-3476(09)90027-0 [doi]
PST - ppublish
SO  - J Pediatr. 1993 Jun;122(6):955-8. doi: 10.1016/s0022-3476(09)90027-0.

PMID- 3662541
OWN - NLM
STAT- MEDLINE
DCOM- 19871112
LR  - 20190629
IS  - 0003-9861 (Print)
IS  - 0003-9861 (Linking)
VI  - 258
IP  - 1
DP  - 1987 Oct
TI  - Effects of crosslinking on the thermal stability of hemoglobin. I. The use of 
      bis(3,5-dibromosalicyl) fumarate.
PG  - 51-7
AB  - The double-headed aspirin, bis(3,5-dibromosalicyl) fumarate, has been used to 
      crosslink hemoglobin A between Lys 82 beta 1 and Lys 82 beta 2 (J. A. Walder et 
      al. (1979) Biochemistry 18,4265). Denaturation experiments were used to compare 
      the stability of this crosslinked protein to that of hemoglobin A. Thermal 
      denaturations, done in 0.01 M 4-morpholine-propanesulfonic acid, pH 7, containing 
      0.9 M guanidine to prevent precipitation at high temperatures, were monitored by 
      changes in absorbance between 190 and 650 nm using a diode array 
      spectrophotometer. The sample was heated from 25 to 70 degrees C at 0.3 degrees 
      C/min. The data were analyzed by using both a two-state model and a novel first 
      derivative method. As expected, methemoglobin A had a single, broad transition 
      with a midpoint of 40.7 degrees C. The crosslinked methemoglobin showed a 
      transition at 57.1 degrees C. Two minor transitions, one of which was apparently 
      due to residual unmodified hemoglobin, were also observed in the crosslinked 
      sample. Thus, a single crosslink between only two of the four subunits can lead 
      to a significantly more stable molecule. These results can be explained by Le 
      Chatelier's principle, since crosslinking prevents dissociation of the 
      beta-subunits and, thereby, holds the entire tetramer together.
FAU - White, F L
AU  - White FL
AD  - Department of Chemistry, Loyola University of Chicago, Illinois 60626.
FAU - Olsen, K W
AU  - Olsen KW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Biochem Biophys
JT  - Archives of biochemistry and biophysics
JID - 0372430
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Macromolecular Substances)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 9008-37-1 (Methemoglobin)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cross-Linking Reagents/pharmacology
MH  - Electrophoresis, Polyacrylamide Gel
MH  - *Hemoglobin A
MH  - *Hot Temperature
MH  - Humans
MH  - Macromolecular Substances
MH  - Methemoglobin
MH  - Protein Denaturation/drug effects
MH  - Spectrophotometry
EDAT- 1987/10/01 00:00
MHDA- 1987/10/01 00:01
CRDT- 1987/10/01 00:00
PHST- 1987/10/01 00:00 [pubmed]
PHST- 1987/10/01 00:01 [medline]
PHST- 1987/10/01 00:00 [entrez]
AID - 0003-9861(87)90321-3 [pii]
AID - 10.1016/0003-9861(87)90321-3 [doi]
PST - ppublish
SO  - Arch Biochem Biophys. 1987 Oct;258(1):51-7. doi: 10.1016/0003-9861(87)90321-3.

PMID- 7243038
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Clinical considerations on a new synthetic compound with antipyretic and 
      anticatarrhal action].
PG  - 367-9
AB  - A Broncaspin suspension was administered for an average of 6-7 days (1/2 
      teaspoonful twice a day to patients up to 3 yr old; 1 teaspoonful twice a day to 
      those over 3) in the treatment of acute febrile diseases of the upper airways in 
      16 male and 14 female children aged 5 months to 5 and 3/12 yr. Satisfactory 
      results were obtained in all cases.
FAU - D'Urso, G
AU  - D'Urso G
FAU - Lax, I
AU  - Lax I
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Considerazioni cliniche su un nuovo composto di sintesi ad azione antipiretica ed 
      anticatarrale.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Bronchitis/drug therapy
MH  - Child, Preschool
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Nasopharyngitis/drug therapy
MH  - Otitis/drug therapy
MH  - Pharyngitis/drug therapy
MH  - Respiratory Tract Infections/*drug therapy
MH  - Tracheitis/drug therapy
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):367-9.

PMID- 20410547
OWN - NLM
STAT- MEDLINE
DCOM- 20100729
LR  - 20190101
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 67
IP  - 9
DP  - 2010 May 1
TI  - Safety of fixed-dose aspirin-extended-release dipyridamole in patients with 
      ischemic heart disease.
PG  - 728-33
LID - 10.2146/ajhp080645 [doi]
AB  - PURPOSE: The safety of fixed-dose combination aspirin-extended-release (ER) 
      dipyridamole for stroke prevention in patients with ischemic heart disease is 
      reviewed. SUMMARY: Randomized controlled trials have established the superiority 
      of aspirinER dipyridamole over aspirin alone for secondary stroke prevention. One 
      limitation of this product is the potential risk of worsening angina in patients 
      with coronary artery disease. The English-language medical literature was 
      searched for articles describing the cardiac safety of oral dipyridamole alone or 
      in combination with aspirin. Meta-analyses, randomized controlled trials, 
      observational studies, and case reports presenting information on the cardiac 
      safety of oral dipyridamole were also reviewed. Four meta-analyses described 
      vascular events with dipyridamole using various dosing strategies. Three trials 
      included the endpoint of myocardial infarction in patients receiving ER 
      dipyridamole. The meta-analyses and randomized controlled trials specifically 
      evaluating aspirin-ER dipyridamole did not provide evidence of increased risk of 
      vascular events. One post hoc analysis of a randomized controlled trial 
      specifically assessed the cardiac safety of fixed-dose aspirin-ER dipyridamole 
      and found that dipyridamole was not associated with a higher number of cardiac 
      events compared with aspirin alone. One randomized controlled trial evaluated the 
      efficacy of ER dipyridamole in patients with preexisting ischemic heart disease 
      and found no evidence of increased risk of cardiac events in this population. No 
      published reports were located describing angina with the combination product. 
      CONCLUSION: A literature review revealed that fixed-dose aspirin-ER dipyridamole 
      was not associated with an increased risk of cardiovascular events in patients 
      with ischemic heart disease. However, individual patient factors merit 
      consideration when choosing an antiplatelet agent for stroke prevention.
FAU - Crown, Natalie
AU  - Crown N
AD  - Pharmacy Services, London Health Sciences Centre, London, Ontario, Canada.
FAU - Mysak, Tania
AU  - Mysak T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Dipyridamole/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Combinations
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Myocardial Ischemia/*drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/prevention & control
RF  - 28
EDAT- 2010/04/23 06:00
MHDA- 2010/07/30 06:00
CRDT- 2010/04/23 06:00
PHST- 2010/04/23 06:00 [entrez]
PHST- 2010/04/23 06:00 [pubmed]
PHST- 2010/07/30 06:00 [medline]
AID - 67/9/728 [pii]
AID - 10.2146/ajhp080645 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2010 May 1;67(9):728-33. doi: 10.2146/ajhp080645.

PMID- 7876370
OWN - NLM
STAT- MEDLINE
DCOM- 19950406
LR  - 20191023
IS  - 0269-4727 (Print)
IS  - 0269-4727 (Linking)
VI  - 19
IP  - 6
DP  - 1994 Dec
TI  - Omission of aspirin in patients following coronary artery bypass graft surgery.
PG  - 381-6
AB  - Graft patency is a major factor contributing to the long-term results of coronary 
      artery bypass graft (CABG) surgery. The systematic overview of the Antiplatelet 
      Trialists' Collaboration provides unequivocal evidence that antiplatelet therapy 
      reduces by nearly one-half the odds of coronary graft occlusion following CABG. 
      We retrospectively reviewed patients undergoing CABG during 1993 at the 
      Cardiothoracic Unit, Northern General Hospital, to determine the incidence of, 
      and indications for, aspirin omission following CABG: 462 patients with isolated 
      CABG, 75 patients with a combined CABG and a heart valve procedure and 21 
      patients with a combined CABG and other non-valve procedure. Thirty-six patients 
      (7.5%) with isolated CABG and CABG combined with a non-valve procedure were not 
      prescribed aspirin. The reasons for aspirin omission were categorized into three 
      groups depending on whether omission was fully justified (group 1), possibly 
      justified (group 2) or unjustified (group 3). Twenty-one patients were in groups 
      2 and 3, nine of whom were started on aspirin 2-6 weeks after discharge without 
      any ill effect. Forty-two patients were discharged from hospital on a three month 
      course of warfarin. Four months later four patients had died, 24 had changed to 
      aspirin, 10 were still on warfarin and four were on neither drug. Aspirin was 
      sometimes omitted without clear indications. Better provisions for supervision 
      should be made by either the General Practitioner or Hospital Practitioner during 
      the change-over period from oral anticoagulation to antiplatelet therapy in 
      patients on a short course of warfarin.
FAU - Galea, J
AU  - Galea J
AD  - Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield, U.K.
FAU - Manché, A
AU  - Manché A
FAU - Goiti, J J
AU  - Goiti JJ
FAU - Locke, T J
AU  - Locke TJ
FAU - Wilkinson, G A
AU  - Wilkinson GA
FAU - Smith, G H
AU  - Smith GH
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Drug Administration Schedule
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - *Vascular Patency
MH  - Warfarin/therapeutic use
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
AID - 10.1111/j.1365-2710.1994.tb00697.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 1994 Dec;19(6):381-6. doi: 10.1111/j.1365-2710.1994.tb00697.x.

PMID- 9290896
OWN - NLM
STAT- MEDLINE
DCOM- 19971118
LR  - 20190221
IS  - 1079-2082 (Print)
IS  - 1079-2082 (Linking)
VI  - 54
IP  - 17
DP  - 1997 Sep 1
TI  - ASHP therapeutic position statement on the use of aspirin for prophylaxis of 
      myocardial infarction.
PG  - 1984-7
AB  - In patients without contraindications, aspirin is an effective, low-cost, and 
      relatively safe but underused option for preventing MI. Given the possible 
      complications of long-term therapy, careful patient selection is warranted. ASHP 
      believes that pharmacists should become actively involved in educating health 
      care professionals about the benefits of using aspirin for the prophylaxis of MI 
      and assisting in the identification of appropriate patients. Pharmacists should 
      encourage patients to modify controllable risk factors for coronary artery 
      disease (smoking, hypercholesterolemia, and hypertension) and to view aspirin as 
      an adjunct, not a replacement for these efforts. ASHP strongly believes that 
      well-controlled clinical trials are needed to determine the benefit of aspirin 
      prophylaxis of MI in women.
LA  - eng
PT  - Guideline
PT  - Journal Article
PT  - Practice Guideline
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/complications
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/complications/*prevention & control
MH  - Patient Selection
MH  - Pharmacists
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use
EDAT- 1997/09/18 00:00
MHDA- 1997/09/18 00:01
CRDT- 1997/09/18 00:00
PHST- 1997/09/18 00:00 [pubmed]
PHST- 1997/09/18 00:01 [medline]
PHST- 1997/09/18 00:00 [entrez]
AID - 10.1093/ajhp/54.17.1984 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 1997 Sep 1;54(17):1984-7. doi: 10.1093/ajhp/54.17.1984.

PMID- 3715407
OWN - NLM
STAT- MEDLINE
DCOM- 19860717
LR  - 20190908
IS  - 0036-553X (Print)
IS  - 0036-553X (Linking)
VI  - 36
IP  - 4
DP  - 1986 Apr
TI  - The effects of different doses of some acetylsalicylic acid formulations on 
      platelet function and bleeding times in healthy subjects.
PG  - 379-84
AB  - In an attempt to find the most appropriate dose and formulation(s) of 
      acetylsalicylic acid (ASA) for thrombosis prophylaxis, healthy volunteers were 
      given doses of ASA for 1 wk daily ranging from 50 to 3900 mg as either 
      Aspro-Clear (soluble), Astrix (enteric coated pellets) or Ecotrin (enteric coated 
      tablets). Platelet function and bleeding times were monitored. All doses of ASA 
      significantly inhibited platelet function (p less than 0.05) and increased 
      bleeding times (p less than 0.05) relative to control values. Irrespective of the 
      formulation, maximum increases in bleeding time and platelet dysfunction were 
      obtained with daily doses of about 100 mg, and no further changes were observed 
      with higher doses.
FAU - McLeod, L J
AU  - McLeod LJ
FAU - Roberts, M S
AU  - Roberts MS
FAU - Cossum, P A
AU  - Cossum PA
FAU - Vial, J H
AU  - Vial JH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Scand J Haematol
JT  - Scandinavian journal of haematology
JID - 0404507
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/drug effects/*physiology
MH  - Delayed-Action Preparations
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Tablets, Enteric-Coated
EDAT- 1986/04/01 00:00
MHDA- 1986/04/01 00:01
CRDT- 1986/04/01 00:00
PHST- 1986/04/01 00:00 [pubmed]
PHST- 1986/04/01 00:01 [medline]
PHST- 1986/04/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1986.tb01753.x [doi]
PST - ppublish
SO  - Scand J Haematol. 1986 Apr;36(4):379-84. doi: 10.1111/j.1600-0609.1986.tb01753.x.

PMID- 25402445
OWN - NLM
STAT- MEDLINE
DCOM- 20150928
LR  - 20150202
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 45
IP  - 1
DP  - 2015 Jan
TI  - Absorption kinetics of low-dose chewable aspirin--implications for acute coronary 
      syndromes.
PG  - 13-7
LID - 10.1111/eci.12373 [doi]
AB  - BACKGROUND: This study describes the implications of the pharmacokinetics of 
      low-dose chewable aspirin for acute coronary syndromes. Current guidelines 
      recommend the administration of 162-325 mg aspirin chewing tablets for the 
      treatment of acute myocardial infarction. Although aspirin is widely used and a 
      cornerstone in myocardial infarction, there is no information available on the 
      pharmacokinetics of low doses of chewable aspirin. MATERIALS AND METHODS: This 
      prospective trial assessed the pharmacokinetics of acetylsalicylic acid and its 
      metabolite salicylic acid after intake of 162 mg chewable low-dose aspirin in 35 
      healthy volunteers. Plasma drug and metabolite levels were analysed using 
      high-performance liquid chromatography, and corresponding pharmacodynamics were 
      determined by impedance aggregometry. RESULTS: Acetylsalicylic acid was rapidly 
      absorbed with a mean Tmax of 27 ± 8 min. Tmax of salicylic acid was 69 ± 21 min. 
      Mean Cmax was 1·8 ± 0·6 mg/L and 7·6 ± 1·4 for acetylsalicylic acid and salicylic 
      acid, respectively. Arachidonic acid-induced aggregation showed maximum platelet 
      inhibition 30 min after drug ingestion. CONCLUSIONS: The characterization of the 
      plasma-time profile fills the gap between the lack of data on pharmacokinetics 
      and the pharmacodynamics and the recommendation for using low-dose chewable 
      aspirin for acute coronary syndromes. We describe for the first time that a 
      162-mg dose of chewable aspirin is rapidly absorbed and achieves plasma 
      concentrations of the active metabolite salicylic acid required to maximally 
      inhibit platelet aggregation. However, a 162-mg dose is truly a minimum, and 
      doubling this dose might be better for patients with myocardial infarction.
CI  - © 2014 Stichting European Society for Clinical Investigation Journal Foundation.
FAU - Hobl, Eva-Luise
AU  - Hobl EL
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
FAU - Schmid, Rainer W
AU  - Schmid RW
FAU - Stimpfl, Thomas
AU  - Stimpfl T
FAU - Ebner, Josef
AU  - Ebner J
FAU - Jilma, Bernd
AU  - Jilma B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Chewing Gum)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacokinetics/pharmacology
MH  - Chewing Gum
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/*pharmacokinetics/pharmacology
MH  - Prospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - acute coronary syndromes
OT  - low-dose chewable aspirin
OT  - pharmacokinetics
EDAT- 2014/11/18 06:00
MHDA- 2015/09/29 06:00
CRDT- 2014/11/18 06:00
PHST- 2014/07/28 00:00 [received]
PHST- 2014/11/10 00:00 [accepted]
PHST- 2014/11/18 06:00 [entrez]
PHST- 2014/11/18 06:00 [pubmed]
PHST- 2015/09/29 06:00 [medline]
AID - 10.1111/eci.12373 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2015 Jan;45(1):13-7. doi: 10.1111/eci.12373.

PMID- 3892659
OWN - NLM
STAT- MEDLINE
DCOM- 19850812
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 115
IP  - 20
DP  - 1985 May 18
TI  - [Controversy on platelet-inhibiting drugs].
PG  - 703-7
AB  - The only well established, clinically useful platelet inhibiting drug is aspirin, 
      though the optimal dose is unknown. Experimental findings, the virtual absence of 
      side effects and, so far, four clinical studies favour a dose of 100-300 mg per 
      day. The majority of clinical studies, however, and particularly those involving 
      patients with cerebrovascular diseases, have employed doses of aspirin of 
      1000-1200 mg per day. Aspirin reduces mortality and infarction rates in patients 
      who have already had myocardial infarction by 0-30%. The efficacy of additional 
      dipyridamol or of sulfinpyrazone is not proven either. So far the effects of 
      aspirin in patients with unstable angina and in patients after aortocoronary 
      bypass surgery are more favourable. The best evidenced indication for aspirin 
      treatment is transient ischemic attacks and status post stroke. The beneficial 
      effect of aspirin in these conditions may also extend to women. Additional 
      dipyridamol is also useless in this condition.
FAU - Oelz, O
AU  - Oelz O
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Kontroversen um Plättchenhemmer.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Angina, Unstable/drug therapy
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Cerebrovascular Disorders/drug therapy
MH  - Clinical Trials as Topic
MH  - Coronary Artery Bypass
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Postoperative Care
MH  - Random Allocation
MH  - Sulfinpyrazone/therapeutic use
RF  - 36
EDAT- 1985/05/18 00:00
MHDA- 1985/05/18 00:01
CRDT- 1985/05/18 00:00
PHST- 1985/05/18 00:00 [pubmed]
PHST- 1985/05/18 00:01 [medline]
PHST- 1985/05/18 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1985 May 18;115(20):703-7.

PMID- 11624864
OWN - HMD
STAT- MEDLINE
DCOM- 19961105
LR  - 20181130
IS  - 0035-2349 (Print)
IS  - 0035-2349 (Linking)
VI  - 43
IP  - 310
DP  - 1996
TI  - [Clarification on publications concerning the synthesis of acetylsalicylic acid].
PG  - 269-73
AB  - Charles Frédéric Gerhardt (1816-1856) mentioned in his Traité de chimie Organique 
      (1854) a publication, in French (realized in 1852 but published in 1853) entitled 
      "Researches on anhydrous organic acids" in which, was reported the reaction of 
      sodium salicylate with acetyl chloride. He thought that the reaction product was 
      an acid anhydride, but obtained really crude acetylsalicylic acid. Later on, but 
      also in 1853, a publication in german, by the same author related the same 
      experiments. Surprisingly only the second publication has been mentioned in most 
      of the historical studies on the subject. Acetyl salicylic acid was identified 
      and synthesised in 1859 by von Gilm by another method and the product obtained by 
      Gerhardt was identified to it in 1869.
FAU - Lafont, O
AU  - Lafont O
AD  - Faculté de médecine et pharmacie de Rouen, Saint-Etienne-de-Rouvray cedex.
LA  - fre
PT  - Biography
PT  - Historical Article
PT  - Journal Article
TT  - Mise au point sur les publications relatives à la synthèse de l'acide 
      acétylsalicylique.
PL  - France
TA  - Rev Hist Pharm (Paris)
JT  - Revue d'histoire de la pharmacie
JID - 0204315
RN  - 0 (Acids)
RN  - R16CO5Y76E (Aspirin)
MH  - Acids/history
MH  - Aspirin/*history
MH  - France
MH  - *History of Pharmacy
MH  - History, 19th Century
PS  - Gerhardt CF
FPS - Gerhardt, C F
EDAT- 1996/01/01 00:00
MHDA- 2001/10/31 10:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 2001/10/31 10:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Hist Pharm (Paris). 1996;43(310):269-73.

PMID- 33313989
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 21
IP  - 4
DP  - 2021 Jul
TI  - Aspirin Therapy in Cardiovascular Disease with Glucose-6-Phosphate Dehydrogenase 
      Deficiency, Safe or Not?
PG  - 377-382
LID - 10.1007/s40256-020-00460-8 [doi]
AB  - Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human 
      enzyme defect, which may present as acute hemolysis, neonatal jaundice, or 
      chronic hemolysis. Ingestion of fava beans, as well as infection and certain 
      drugs, are the most typical causes of acute hemolysis in people with G6PD 
      deficiency. Aspirin, the cornerstone in current therapies for the prevention of 
      cardiovascular disease (CVD), is occasionally reported to induce acute hemolysis 
      in G6PD-deficient individuals. G6PD deficiency is typically asymptomatic and many 
      CVD patients with this enzyme defect start to take long-term aspirin therapy 
      without G6PD activity examination; however, no consensus on the safety of aspirin 
      in this population has been reached. A few studies have reported on this issue 
      and produced contradictory results. In this review, we discuss the possible 
      mechanisms of aspirin-induced hemolysis, and summarize clinical evidence 
      regarding the safety of aspirin in subjects with G6PD deficiency.
FAU - Li, Jianle
AU  - Li J
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; 
      Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major 
      Neurological Diseases, National Key Clinical Department and Key Discipline of 
      Neurology, Southern China International Cooperation Base for Early Intervention 
      and Functional Rehabilitation of Neurological Diseases, No. 58 Zhongshan Road 2, 
      Guangzhou, 510080, China.
FAU - Chen, Yicong
AU  - Chen Y
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; 
      Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major 
      Neurological Diseases, National Key Clinical Department and Key Discipline of 
      Neurology, Southern China International Cooperation Base for Early Intervention 
      and Functional Rehabilitation of Neurological Diseases, No. 58 Zhongshan Road 2, 
      Guangzhou, 510080, China.
FAU - Ou, Zilin
AU  - Ou Z
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; 
      Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major 
      Neurological Diseases, National Key Clinical Department and Key Discipline of 
      Neurology, Southern China International Cooperation Base for Early Intervention 
      and Functional Rehabilitation of Neurological Diseases, No. 58 Zhongshan Road 2, 
      Guangzhou, 510080, China.
FAU - Ouyang, Fubing
AU  - Ouyang F
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; 
      Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major 
      Neurological Diseases, National Key Clinical Department and Key Discipline of 
      Neurology, Southern China International Cooperation Base for Early Intervention 
      and Functional Rehabilitation of Neurological Diseases, No. 58 Zhongshan Road 2, 
      Guangzhou, 510080, China.
FAU - Liang, Jiahui
AU  - Liang J
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; 
      Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major 
      Neurological Diseases, National Key Clinical Department and Key Discipline of 
      Neurology, Southern China International Cooperation Base for Early Intervention 
      and Functional Rehabilitation of Neurological Diseases, No. 58 Zhongshan Road 2, 
      Guangzhou, 510080, China.
FAU - Jiang, Zimu
AU  - Jiang Z
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; 
      Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major 
      Neurological Diseases, National Key Clinical Department and Key Discipline of 
      Neurology, Southern China International Cooperation Base for Early Intervention 
      and Functional Rehabilitation of Neurological Diseases, No. 58 Zhongshan Road 2, 
      Guangzhou, 510080, China.
FAU - Chen, Chunyong
AU  - Chen C
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; 
      Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major 
      Neurological Diseases, National Key Clinical Department and Key Discipline of 
      Neurology, Southern China International Cooperation Base for Early Intervention 
      and Functional Rehabilitation of Neurological Diseases, No. 58 Zhongshan Road 2, 
      Guangzhou, 510080, China.
FAU - Li, Pingping
AU  - Li P
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; 
      Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major 
      Neurological Diseases, National Key Clinical Department and Key Discipline of 
      Neurology, Southern China International Cooperation Base for Early Intervention 
      and Functional Rehabilitation of Neurological Diseases, No. 58 Zhongshan Road 2, 
      Guangzhou, 510080, China.
FAU - Chen, Jiaxin
AU  - Chen J
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; 
      Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major 
      Neurological Diseases, National Key Clinical Department and Key Discipline of 
      Neurology, Southern China International Cooperation Base for Early Intervention 
      and Functional Rehabilitation of Neurological Diseases, No. 58 Zhongshan Road 2, 
      Guangzhou, 510080, China.
FAU - Wei, Jiating
AU  - Wei J
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; 
      Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major 
      Neurological Diseases, National Key Clinical Department and Key Discipline of 
      Neurology, Southern China International Cooperation Base for Early Intervention 
      and Functional Rehabilitation of Neurological Diseases, No. 58 Zhongshan Road 2, 
      Guangzhou, 510080, China.
FAU - Zeng, Jinsheng
AU  - Zeng J
AUID- ORCID: 0000-0003-4280-0439
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; 
      Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major 
      Neurological Diseases, National Key Clinical Department and Key Discipline of 
      Neurology, Southern China International Cooperation Base for Early Intervention 
      and Functional Rehabilitation of Neurological Diseases, No. 58 Zhongshan Road 2, 
      Guangzhou, 510080, China. zengjs@pub.guangzhou.gd.cn.
LA  - eng
GR  - 2017YFC1307500/National Key R&D Program of China/
GR  - 81571107/Natural Science Foundation of China/
GR  - 81771137/Natural Science Foundation of China/
GR  - 81971103/Natural Science Foundation of China/
GR  - 81901077/Natural Science Foundation of China/
GR  - 2019A030317006/Scientific and Technical Project of Guangdong Province/
GR  - 2018001/Sun Yat-sen University Clinical Research 5010 Program/
GR  - 2015B050501003/the Southern China International Cooperation Base for Early 
      Intervention and Functional Rehabilitation of Neurological Diseases/
PT  - Journal Article
PT  - Review
DEP - 20201214
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects/pharmacology
MH  - Cardiovascular Diseases/*epidemiology/mortality/*prevention & control
MH  - Glucosephosphate Dehydrogenase Deficiency/*epidemiology/physiopathology
MH  - Hemoglobins/drug effects
MH  - Hemolysis/*drug effects
MH  - Hemorrhage/chemically induced
MH  - Humans
EDAT- 2020/12/15 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/12/14 11:04
PHST- 2020/11/20 00:00 [accepted]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/12/14 11:04 [entrez]
AID - 10.1007/s40256-020-00460-8 [pii]
AID - 10.1007/s40256-020-00460-8 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2021 Jul;21(4):377-382. doi: 10.1007/s40256-020-00460-8. 
      Epub 2020 Dec 14.

PMID- 31521369
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 1578-8989 (Electronic)
IS  - 0025-7753 (Linking)
VI  - 153
IP  - 8
DP  - 2019 Oct 25
TI  - The role of aspirin as antiaggregant therapy in primary prevention. An update.
PG  - 326-331
LID - S0025-7753(19)30439-7 [pii]
LID - 10.1016/j.medcli.2019.05.024 [doi]
AB  - Aspirin indication in primary prevention has been questioned in the last ten 
      years due to the publication of several trials with neutral outcomes. In the last 
      year, three research studies discussed in this review (ASCEND, ARRIVE, ASPREE) 
      have weighed the benefit (cardiovascular events reduction) against the adverse 
      effects (especially bleeding) in several situations such as general population 
      with moderate cardiovascular risk, diabetics and elderly population. This review 
      performs a detailed analysis of these trials and it also comments on a recent 
      metanalysis that includes these projects along with others undertaken in the last 
      30 years. In addition, the current position of aspirin in primary prevention is 
      established based on the latest evidence reviewed.
CI  - Copyright © 2019 Elsevier España, S.L.U. All rights reserved.
FAU - Jiménez-García, Nicolás
AU  - Jiménez-García N
AD  - Servicio de Medicina Interna, Agencia Sanitaria Costa del Sol, Marbella, Málaga, 
      España. Electronic address: nijimenez93@gmail.com.
FAU - de la Torre Lima, Javier
AU  - de la Torre Lima J
AD  - Servicio de Medicina Interna, Agencia Sanitaria Costa del Sol, Marbella, Málaga, 
      España.
FAU - García Alegría, Javier
AU  - García Alegría J
AD  - Servicio de Medicina Interna, Agencia Sanitaria Costa del Sol, Marbella, Málaga, 
      España; Red de Investigación en Servicios de Salud en Enfermedades Crónicas 
      (REDISSEC).
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Papel de la Aspirina® como tratamiento antiagregante en prevención primaria. 
      Puesta al día.
DEP - 20190911
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Decision-Making
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention/*methods
OTO - NOTNLM
OT  - Antiaggregation
OT  - Antiagregación
OT  - Aspirin
OT  - Aspirina®
OT  - Bleedings
OT  - Cardiovascular events
OT  - Eventos cardiovasculares
OT  - Hemorragias
OT  - Prevención primaria
OT  - Primary prevention
EDAT- 2019/09/16 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/09/16 06:00
PHST- 2019/04/03 00:00 [received]
PHST- 2019/05/21 00:00 [revised]
PHST- 2019/05/21 00:00 [accepted]
PHST- 2019/09/16 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/09/16 06:00 [entrez]
AID - S0025-7753(19)30439-7 [pii]
AID - 10.1016/j.medcli.2019.05.024 [doi]
PST - ppublish
SO  - Med Clin (Barc). 2019 Oct 25;153(8):326-331. doi: 10.1016/j.medcli.2019.05.024. 
      Epub 2019 Sep 11.

PMID- 19642589
OWN - NLM
STAT- MEDLINE
DCOM- 20090917
LR  - 20131121
IS  - 0869-2092 (Print)
IS  - 0869-2092 (Linking)
VI  - 72
IP  - 3
DP  - 2009 May-Jun
TI  - [Experimental study of the pharmacokinetics of acetylsalicylic acid upon 
      transdermal administration].
PG  - 29-32
AB  - A comparative analysis of the concentrations of acetylsalicylic acid (ASA) and 
      its metabolite, salicylic acid (SA), in the blood was performed and the other 
      pharmacokinetic parameters were studied after conventional intragastric and 
      transdermal administration in rabbits. It is established that the ASA 
      concentration in the blood upon transdermal administration in a dose of 100 mg/kg 
      is above the minimum therapeutic level during 24 h. Prolonged action of a 
      transdermal therapeutic system (TTS) in comparison to intragastric administration 
      was proved. After the transdermal administration via TTS, the ASA 
      half-elimination time and the mean retention time increased in comparison to the 
      values upon intragastric administration. The ASA bioavailability upon the 
      transdermal administration increased by a factor of 4.5 in comparison to the case 
      of peroral administration.
FAU - Polukhina, O S
AU  - Polukhina OS
FAU - Basok, Iu B
AU  - Basok IuB
FAU - Salomatina, L A
AU  - Salomatina LA
FAU - Sevast'ianov, V I
AU  - Sevast'ianov VI
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Eksp Klin Farmakol
JT  - Eksperimental'naia i klinicheskaia farmakologiia
JID - 9215981
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Cutaneous
MH  - Animals
MH  - Aspirin/*administration & dosage/metabolism/pharmacokinetics
MH  - Platelet Aggregation Inhibitors/*administration & 
      dosage/metabolism/pharmacokinetics
MH  - Rabbits
MH  - Salicylic Acid/*metabolism
EDAT- 2009/08/01 09:00
MHDA- 2009/09/18 06:00
CRDT- 2009/08/01 09:00
PHST- 2009/08/01 09:00 [entrez]
PHST- 2009/08/01 09:00 [pubmed]
PHST- 2009/09/18 06:00 [medline]
PST - ppublish
SO  - Eksp Klin Farmakol. 2009 May-Jun;72(3):29-32.

PMID- 4023420
OWN - NLM
STAT- MEDLINE
DCOM- 19850923
LR  - 20151119
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 48
IP  - 3
DP  - 1985 Jun
TI  - Pharmacological actions of diaspirins, potential antisickling agents: analgesic 
      and anti-inflammatory effects.
PG  - 381-8
AB  - Three aspirin analogs, dibromoaspirin, bis(3,5-dibromosalicyl) succinate and 
      bis(3,5-dibromosalicyl) fumarate, potential antisickling agents, were compared 
      with acetylsalicylic acid (aspirin) for their analgesic, body temperature and 
      anti-inflammatory effects in the laboratory mouse and rat. In the analgesic 
      assay, using the "writhing method", only a 200 mg/kg dose of the diaspirin 
      succinate significantly reduced the writhing response induced by phenylacetic 
      acid. Only a dose of 800 mg/kg of acetylsalicylic acid significantly decreased 
      writhing. These analog compounds had only slight hypothermic effects, the 
      reduction in body temperature not being appreciable. On the other hand, they were 
      effective anti-inflammatory agents, comparable to aspirin; a dose of 200 mg/kg 
      very significantly reduced the paw edema due to injected carrageenan.
FAU - Thompson, E B
AU  - Thompson EB
FAU - Klotz, I M
AU  - Klotz IM
LA  - eng
GR  - HL 22719/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antisickling Agents)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 71337-52-5 (bis(3,5-dibromosalicyl)succinate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Antisickling Agents/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Body Temperature/drug effects
MH  - Male
MH  - Mice
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1985/06/01 00:00
MHDA- 1985/06/01 00:01
CRDT- 1985/06/01 00:00
PHST- 1985/06/01 00:00 [pubmed]
PHST- 1985/06/01 00:01 [medline]
PHST- 1985/06/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1985 Jun;48(3):381-8.

PMID- 7017481
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Clinical evaluation of the therapeutic effectiveness of a new drug with 
      anti-inflammatory-balsamic action, guacetisal, in respiratory tract diseases].
PG  - 325-32
AB  - In 40 patients with bronchopulmonary diseases, in prevalence of chronic type, the 
      therapeutic value of a new antiphlogistic-balsamic compound was evaluated. The 
      favourable results obtained, particularly as far as the rapidity of regression of 
      signs and symptoms is concerned, showed that this drug may have a significant 
      role in a combined scheme of treatment.
FAU - Bartolucci, L
AU  - Bartolucci L
FAU - Canini, F
AU  - Canini F
FAU - Fioroni, E
AU  - Fioroni E
FAU - Pinchi, G
AU  - Pinchi G
FAU - Carosi, M
AU  - Carosi M
LA  - ita
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Valutazione clinica dell'efficacia terapeutica di un nuovo farmaco ad azione 
      antiflogistico-balsamica, il guacetisal, nelle affezioni delle vie respiratorie.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Bronchitis/drug therapy
MH  - Bronchopneumonia/drug therapy
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Cough/drug therapy
MH  - Drug Evaluation
MH  - Dyspnea/drug therapy
MH  - Fever/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiration/drug effects
MH  - Respiratory Tract Diseases/*drug therapy
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):325-32.

PMID- 3188
OWN - NLM
STAT- MEDLINE
DCOM- 19760415
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 25
IP  - 12
DP  - 1975
TI  - [Influence of ethanol on the in vitro and in vivo drug release from some 
      sustained release tablets (author's transl)].
PG  - 1958-64
AB  - The in vitro and in vivo liberation of acetylsalicylic acid from sustained 
      release tablets in presence of ethanol is described. Simultaneous uptake of 120 
      ml commercial brandy resulted in a faster release of the active substance from 
      the tablets prepared with Eudragit ret-l (PM), as has been proved by urinary 
      excretion data. These results were supported by experiments with a pH-endoaradio 
      transmitter and by radiography.
FAU - Frömming, K H
AU  - Frömming KH
FAU - Topaloglu, Y
AU  - Topaloglu Y
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Beeinflussung der In-vitro- und In-vivo-Pharmakonfreisetzung aus einigen 
      peroralen Depotformen unter Athanolbelastung.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Bicarbonates)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Tablets)
RN  - 25BB7EKE2E (Barium Sulfate)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*metabolism/urine
MH  - Barium Sulfate/metabolism
MH  - Bicarbonates/metabolism
MH  - Delayed-Action Preparations
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Ethanol/*metabolism/pharmacology
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Middle Aged
MH  - Radiography
MH  - Solubility
MH  - Tablets
MH  - Time Factors
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1975;25(12):1958-64.

PMID- 32721423
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210202
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 85
DP  - 2020 Nov
TI  - Aspirin: Bitter pill or miracle drug?
PG  - 1-4
LID - S0009-9120(20)30792-X [pii]
LID - 10.1016/j.clinbiochem.2020.07.003 [doi]
AB  - Acetylsalicylic acid (ASA) or brand name Aspirin is a widely available medication 
      used to relieve inflammation, fever and pain. It has also been frequently 
      prescribed as prevention for cardiovascular disease due to its anti-thrombotic 
      qualities. However, ASA is also connected to increased internal bleeding, leading 
      to concerns that this harmful side effect may outweigh its cardioprotective 
      properties in some populations. In this review, we summarize data from several 
      recent, large-scale clinical trials that put into the question the long-standing 
      recommendations about prescribing ASA for primary cardiovascular disease. We also 
      provide a detailed overview of the role of ASA in cancer, surgery and female 
      reproductive health. Finally, we discuss the ASA prescription guidelines of 
      several major medical organizations and suggest that this new evidence may lead 
      to updates to these influential and longstanding recommendations.
CI  - Copyright © 2020 The Canadian Society of Clinical Chemists. Published by Elsevier 
      Inc. All rights reserved.
FAU - Fiala, Clare
AU  - Fiala C
AD  - Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, 
      Ontario, Canada.
FAU - Pasic, Maria D
AU  - Pasic MD
AD  - Department of Laboratory Medicine, Unity Health Toronto, Toronto, Ontario, 
      Canada; Department of Laboratory Medicine and Pathobiology, University of 
      Toronto, Toronto, Ontario, Canada. Electronic address: 
      maria.pasic@unityhealth.to.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200725
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Trials as Topic
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*adverse effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acetylsalicyclic acid
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Internal bleeding
OT  - Preventative medicine
OT  - Stroke
EDAT- 2020/07/30 06:00
MHDA- 2021/02/03 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/06/01 00:00 [received]
PHST- 2020/07/20 00:00 [revised]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - S0009-9120(20)30792-X [pii]
AID - 10.1016/j.clinbiochem.2020.07.003 [doi]
PST - ppublish
SO  - Clin Biochem. 2020 Nov;85:1-4. doi: 10.1016/j.clinbiochem.2020.07.003. Epub 2020 
      Jul 25.

PMID- 27235915
OWN - NLM
STAT- MEDLINE
DCOM- 20170531
LR  - 20170531
IS  - 1557-9832 (Electronic)
IS  - 0272-2712 (Linking)
VI  - 36
IP  - 2
DP  - 2016 Jun
TI  - Aspirin for the Prevention of Preeclampsia and Intrauterine Growth Restriction.
PG  - 319-29
LID - S0272-2712(16)30013-0 [pii]
LID - 10.1016/j.cll.2016.01.013 [doi]
AB  - Low-dose aspirin (LDA) has been used for several years for the prevention of 
      preeclampsia (PE). LDA started in early pregnancy is associated with improvement 
      of placental implantation. The best evidence suggest that LDA can prevent more 
      than half of PE cases in high-risk women when started before 16 weeks of 
      gestation. Moreover, LDA started in early pregnancy reduces the risk of other 
      placenta-mediated complications such as intrauterine growth restriction (IUGR) 
      and perinatal death. The efficacy of LDA has been demonstrated in women with 
      abnormal first-trimester uterine artery Doppler or with prior history of chronic 
      hypertension or preeclampsia.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Roberge, Stephanie
AU  - Roberge S
AD  - Department of Social and Preventive Medicine, Faculty of Medicine, Université 
      Laval, 2705 Boulevard Laurier, Quebec G1V 4G2, Canada.
FAU - Odibo, Anthony O
AU  - Odibo AO
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, 
      University of South Florida Morsani College of Medicine, 2 Tampa General Circle, 
      6th Floor, Tampa, FL 33606, USA.
FAU - Bujold, Emmanuel
AU  - Bujold E
AD  - Department of Social and Preventive Medicine, Faculty of Medicine, Université 
      Laval, 2705 Boulevard Laurier, Quebec G1V 4G2, Canada; Department of Obstetrics 
      and Gynecology, Faculty of Medicine, Université Laval, 2705 Boulevard Laurier, 
      Québec City, Quebec G1V 4G2, Canada. Electronic address: 
      emmanuel.bujold@crchudequebec.ulaval.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160308
PL  - United States
TA  - Clin Lab Med
JT  - Clinics in laboratory medicine
JID - 8100174
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - Aspirin
OT  - Intrauterine growth restriction
OT  - Placenta
OT  - Preeclampsia
OT  - Pregnancy
EDAT- 2016/05/29 06:00
MHDA- 2017/06/01 06:00
CRDT- 2016/05/29 06:00
PHST- 2016/05/29 06:00 [entrez]
PHST- 2016/05/29 06:00 [pubmed]
PHST- 2017/06/01 06:00 [medline]
AID - S0272-2712(16)30013-0 [pii]
AID - 10.1016/j.cll.2016.01.013 [doi]
PST - ppublish
SO  - Clin Lab Med. 2016 Jun;36(2):319-29. doi: 10.1016/j.cll.2016.01.013. Epub 2016 
      Mar 8.

PMID- 30296406
OWN - NLM
STAT- MEDLINE
DCOM- 20191021
LR  - 20191022
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 132
IP  - 2
DP  - 2019 Feb
TI  - Aspirin to Prevent Sudden Cardiac Death in Athletes with High Coronary Artery 
      Calcium Scores.
PG  - 138-141
LID - S0002-9343(18)30938-0 [pii]
LID - 10.1016/j.amjmed.2018.09.015 [doi]
AB  - While proficient cardiac resuscitation has improved survival following cardiac 
      arrest during road races in Japan, this accomplishment does not address coronary 
      artery disease as the underlying cause of an increasing frequency of cardiac 
      arrest in middle-aged men during marathons and ironman triathlons in the United 
      States since the year 2000. Based on the high prevalence of subclinical coronary 
      artery disease by cardiac computed tomography in endurance athletes with low 
      conventional cardiac risk-factor profiles, we recommend coronary artery calcium 
      scores as a more reliable and independent predictor of incident cardiac events, 
      including death, as validated among adults aged 30-46 years. Scores of over 100 
      Agatston units indicate a 10-year cardiac risk of 7.5%, at which additional 
      measures for primary prevention are recommended, including aspirin, as shown 
      conclusively to reduce first myocardial infarctions in same-aged men in a 
      prospective double-blind controlled trial. Targeted screening for subclinical 
      coronary atherosclerosis with coronary artery calcium scores is prudent to guide 
      appropriately dosed aspirin use to mitigate the increasing frequency of 
      sports-related sudden cardiac death due to plaque rupture.
CI  - Copyright © 2018 Elsevier Inc. All rights reserved.
FAU - Siegel, Arthur J
AU  - Siegel AJ
AD  - Division of General Internal Medicine, Massachusetts General Hospital, Boston; 
      Department of Internal Medicine, McLean Hospital, Belmont, Mass; Harvard Medical 
      School, Boston, Mass. Electronic address: asiegel@partners.org.
FAU - Noakes, Timothy D
AU  - Noakes TD
AD  - Department of Human Biology, University of Cape Town, South Africa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181005
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*pharmacology
MH  - *Athletes
MH  - Coronary Artery Disease/*complications
MH  - Death, Sudden, Cardiac/etiology/*prevention & control
MH  - Humans
OTO - NOTNLM
OT  - Aspirin prophylaxis
OT  - Cardiac arrest
OT  - Coronary artery calcium scores
OT  - Marathons
EDAT- 2018/10/09 06:00
MHDA- 2019/10/23 06:00
CRDT- 2018/10/09 06:00
PHST- 2018/09/04 00:00 [received]
PHST- 2018/09/20 00:00 [revised]
PHST- 2018/09/20 00:00 [accepted]
PHST- 2018/10/09 06:00 [pubmed]
PHST- 2019/10/23 06:00 [medline]
PHST- 2018/10/09 06:00 [entrez]
AID - S0002-9343(18)30938-0 [pii]
AID - 10.1016/j.amjmed.2018.09.015 [doi]
PST - ppublish
SO  - Am J Med. 2019 Feb;132(2):138-141. doi: 10.1016/j.amjmed.2018.09.015. Epub 2018 
      Oct 5.

PMID- 16317615
OWN - NLM
STAT- MEDLINE
DCOM- 20060110
LR  - 20131121
IS  - 0012-0472 (Print)
IS  - 0012-0472 (Linking)
VI  - 130
IP  - 49
DP  - 2005 Dec 9
TI  - [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
PG  - 2847-52
AB  - BACKGROUND AND OBJECTIVE: Although the benefit of aspirin for patients with known 
      cardiovascular disease is well established, the protective effect in primary 
      prevention remains the subject of a controversial discussion. This meta-analysis 
      was undertaken to ascertain whether a risk reduction regarding mortality and/or 
      cardiovascular events can be achievement with aspirin in persons without known 
      cardiovascular disease? METHODS: A systematic literature search for randomized 
      controlled trials and meta-analyses was done. RESULTS: Six relevant primary 
      trials and three meta-analyses were found. The validity of three of the trials 
      and thus also the meta-analyses was limited by inclusion of patients with known 
      cardiovascular disease. Therapy with aspirin showed no reduction in terms of 
      overall mortality rate or rate of cardiovascular death. In men the primary 
      prevention with aspirin reduced the risk of a non-fatal myocardial infarction 
      with an annual numbers needed to treat of about 670. There was no equivalent 
      effect in women (except for women (3) 65 years). A reduction of stroke events was 
      only seen in the Women's Health Study, which included only female participants. 
      The effect was quite small, the annual numbers needed to treat were about 3890. 
      An equivalent benefit for men was not proven in any of the other trials. 
      CONCLUSION: In view of the absence of life prolonging effect and no possibility 
      of determining a definite risk group, that would have a special or accessory 
      effect from a primary prevention with aspirin, there is no indication for such a 
      scheme.
FAU - Waltering, A
AU  - Waltering A
AD  - DieM-Institut für evidenzbasierte Medizin. a.waltering@di-em.de
FAU - Hemkens, L
AU  - Hemkens L
FAU - Florack, C
AU  - Florack C
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Primäre Prävention kardiovaskulärer Erkrankungen mit Acetylsalicylsäure.
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention/*methods
MH  - Risk Factors
RF  - 30
EDAT- 2005/12/01 09:00
MHDA- 2006/01/13 09:00
CRDT- 2005/12/01 09:00
PHST- 2005/12/01 09:00 [pubmed]
PHST- 2006/01/13 09:00 [medline]
PHST- 2005/12/01 09:00 [entrez]
AID - 10.1055/s-2005-923318 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2005 Dec 9;130(49):2847-52. doi: 10.1055/s-2005-923318.

PMID- 22724484
OWN - NLM
STAT- MEDLINE
DCOM- 20131210
LR  - 20191027
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 11
IP  - 3
DP  - 2013 May
TI  - Anti-platelet treatment of middle-sized abdominal aortic aneurysms.
PG  - 305-13
AB  - The physiological transport in the aortic wall occurs mainly by centrifugal 
      convection from the lumen to the adventitia through the arterial wall. 
      Enlargement of an abdominal aortic aneurysm (AAA) is usually associated with the 
      development of an intraluminal mural thrombus (ILT). The interface between the 
      luminal side of the thrombus and flowing blood is a site of constant thrombus 
      renewal, which is linked to platelet aggregation-induced fibrin generation and 
      accumulation. In addition, red blood cells are entrapped causing an oxidative 
      response. Through centrifugal convection are factors increasing the inflammatory 
      and degenerative response transported from the ILT to media and adventitia. Two 
      experimental studies on rats with experimental AAA have shown that aneurysmal 
      progression can be impaired by antiplatelet agents. By a systematic literature 
      search, 4 human cohorts were identified analysing the effect of antiplatelet 
      treatment on the progression of AAA. The two largest cohorts couldn´t detect any 
      significant difference. However, the cohorts included very small AAA, in which 
      ILT seldom is present. In the two other trials, only testing AAA sized above 35 
      and 39 mm, respectively, use of low dose aspirin was associated with 
      significantly lower expansion rates and less need for later surgical repair. 
      Size-based subgroup analyses from relevant existing cohorts ought to be conducted 
      for confirmation. Finally, low dose aspirin is recommend as general 
      cardiovascular secondary prevention, however, large-scaled trials comparing low 
      dose aspirin with more potent antiplatelets would be relevant.
FAU - Lindholt, Jes S
AU  - Lindholt JS
AD  - Department of Thoracic, Lung, and Vascular Surgery, University Hospital of 
      Odense, Denmark. Jes.s.lindholt@viborg.rm.dk
FAU - Björck, Martin
AU  - Björck M
FAU - Michel, Jean B
AU  - Michel JB
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aortic Aneurysm, Abdominal/*drug therapy/physiopathology
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Rats
MH  - Thrombosis/*pathology
EDAT- 2012/06/26 06:00
MHDA- 2013/12/16 06:00
CRDT- 2012/06/26 06:00
PHST- 2011/08/17 00:00 [received]
PHST- 2011/09/18 00:00 [revised]
PHST- 2011/10/01 00:00 [accepted]
PHST- 2012/06/26 06:00 [entrez]
PHST- 2012/06/26 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - CVP-EPUB-20120622-24 [pii]
AID - 10.2174/1570161111311030005 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2013 May;11(3):305-13. doi: 10.2174/1570161111311030005.

PMID- 31656245
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20200819
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 140
IP  - 1
DP  - 2020 Jan 1
TI  - [The Analgesic Effect of Aspirin on Inflammatory Pain in Rats Is Affected by Pain 
      Intensity and Administration Timing].
PG  - 91-97
LID - 10.1248/yakushi.19-00168 [doi]
AB  - Non-steroidal anti-inflammatory drugs (NSAIDs) are widely known as painkillers. 
      The analgesic action of NSAIDs is attributable to the inhibition of prostaglandin 
      synthesis that occurs in response to blocking cyclooxygenase activity. The 
      effective dose of NSAIDs can vary depending on pain intensity and administration 
      timing; however, there are few studies on this. This study aimed to elucidate 
      whether the analgesic effect of NSAIDs changes depending on the situation in 
      which they are taken and we focused on the NSAID, aspirin (ASP). In a rat model 
      of brewer's yeast-induced inflammation, pain caused by 20% (w/v) brewer's 
      yeast-treatment was defined as "strong pain" and that caused by 2.5% (w/v) was 
      defined as "weak pain". The analgesic effect of ASP (low-dose; 44 mg/kg or 
      high-dose; 66 mg/kg) against strong pain was dose-dependent, but that against 
      weak pain was the same. Furthermore, we defined drug administration after 3 h of 
      brewer's yeast-treatment as "late administration" and that after 20 min as "early 
      administration". In the case of strong pain, the analgesic effect of "late ASP 
      administration" was dose-dependent, but that of "early ASP administration" was 
      the same. These results suggest that low-dose NSAIDs have an analgesic effect 
      against weak pain or when taken early.
FAU - Kitahara, Miu
AU  - Kitahara M
AD  - Pharmaceutical Research Laboratories, Research & Development Headquarters, Lion 
      Corporation.
FAU - Seki, Keiko
AU  - Seki K
AD  - Pharmaceutical Research Laboratories, Research & Development Headquarters, Lion 
      Corporation.
FAU - Midorikawa, Tatsuyuki
AU  - Midorikawa T
AD  - Pharmaceutical Research Laboratories, Research & Development Headquarters, Lion 
      Corporation.
FAU - Arita, Junya
AU  - Arita J
AD  - Pharmaceutical Research Laboratories, Research & Development Headquarters, Lion 
      Corporation.
FAU - Uchiyama, Akira
AU  - Uchiyama A
AD  - Pharmaceutical Research Laboratories, Research & Development Headquarters, Lion 
      Corporation.
LA  - jpn
PT  - Journal Article
DEP - 20191025
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Analgesics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesics
MH  - Animals
MH  - Aspirin/*administration & dosage/*pharmacology
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Pain/*drug therapy
MH  - Rats, Wistar
MH  - Severity of Illness Index
MH  - Time Factors
OTO - NOTNLM
OT  - administration timing
OT  - analgesic effect
OT  - aspirin
OT  - inflammatory pain
OT  - non-steroidal anti-inflammatory drug
OT  - pain intensity
EDAT- 2019/10/28 06:00
MHDA- 2020/08/20 06:00
CRDT- 2019/10/29 06:00
PHST- 2019/10/28 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
PHST- 2019/10/29 06:00 [entrez]
AID - 10.1248/yakushi.19-00168 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2020 Jan 1;140(1):91-97. doi: 10.1248/yakushi.19-00168. Epub 
      2019 Oct 25.

PMID- 30252883
OWN - NLM
STAT- MEDLINE
DCOM- 20190304
LR  - 20190304
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 9
DP  - 2018
TI  - Systematic review update of observational studies further supports aspirin role 
      in cancer treatment: Time to share evidence and decision-making with patients?
PG  - e0203957
LID - 10.1371/journal.pone.0203957 [doi]
LID - e0203957
AB  - BACKGROUND: Evidence is growing that low-dose aspirin used as an adjuvant 
      treatment of cancer is associated with an increased survival and a reduction in 
      metastatic spread. We therefore extended up to August 2017 an earlier systematic 
      search and meta-analyses of published studies of low-dose aspirin taken by 
      patients with a diagnosis of cancer. METHODS: Searches were completed in Medline 
      and Embase to August 2017 using a pre-defined search strategy to identify reports 
      of relevant studies. References in all the selected papers were scanned. Two 
      reviewers independently applied pre-determined eligibility criteria and extracted 
      data on cause-specific cancer deaths, overall mortality and the occurrence of 
      metastatic spread. Meta-analyses were then conducted for different cancers and 
      heterogeneity and publication bias assessed. Sensitivity analyses and attempts to 
      reduce heterogeneity were conducted. RESULTS: Analyses of 29 studies reported 
      since an earlier review up to April 2015 are presented in this report, and these 
      are then pooled with the 42 studies in our earlier publication. Overall 
      meta-analyses of the 71 studies are presented, based on a total of over 120 
      thousand patients taking aspirin. Ten of the studies also give evidence on the 
      incidence of metastatic cancer spread. There are now twenty-nine observational 
      studies describing colorectal cancer (CRC) and post-diagnostic aspirin. Pooling 
      the estimates of reduction by aspirin which are reported as hazard ratios (HR), 
      gives an overall HR for aspirin and CRC mortality 0.72 (95% CI 0.64-0.80). 
      Fourteen observational studies have reported on aspirin and breast cancer 
      mortality and pooling those that report the association with aspirin as a hazard 
      ratio gives HR 0.69 (0.53-0.90). Sixteen studies report on aspirin and prostate 
      cancer mortality and a pooled estimate yields an HR of 0.87 (95% CI 0.73-1.05). 
      Data from 12 reports relating to other cancers are also listed. Ten studies give 
      evidence of a reduction in metastatic spread; four give a pooled HR 0.31 (95% CI 
      0.18, 0.54) and five studies which reported odds ratio of metastatic spread give 
      OR 0.79 (0.66 to 0.95). CONCLUSION: Being almost entirely from observational 
      studies, the evidence of benefit from aspirin is limited. There is heterogeneity 
      between studies and the results are subject to important biases, only some of 
      which can be identified. Nevertheless, the evidence would seem to merit wide 
      discussion regarding whether or not it is adequate to justify the recommendation 
      of low-dose therapeutic aspirin, and if it is, for which cancers?
FAU - Elwood, Peter C
AU  - Elwood PC
AUID- ORCID: 0000-0003-4352-1570
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
FAU - Pickering, Janet E
AU  - Pickering JE
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
AD  - Institute of Food, Nutrition and Health, University of Reading, Reading, United 
      Kingdom.
FAU - Morgan, Gareth
AU  - Morgan G
AD  - Hywel Dda University Health Board, Llanelli, United Kingdom.
FAU - Galante, Julieta
AU  - Galante J
AD  - Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom.
FAU - Weightman, Alison L
AU  - Weightman AL
AD  - Specialist Unit for Review Evidence, Cardiff University, Cardiff, United Kingdom.
FAU - Morris, Delyth
AU  - Morris D
AD  - Specialist Unit for Review Evidence, Cardiff University, Cardiff, United Kingdom.
FAU - Longley, Marcus
AU  - Longley M
AD  - Health Policy, University of South Wales, Pontypridd, United Kingdom.
FAU - Mason, Malcolm
AU  - Mason M
AD  - Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, 
      United Kingdom.
FAU - Adams, Richard
AU  - Adams R
AD  - Institute of Cancer & Genetics Cardiff University, Cardiff, United Kingdom.
FAU - Dolwani, Sunil
AU  - Dolwani S
AD  - Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, 
      United Kingdom.
FAU - Chia W K, John
AU  - Chia W K J
AD  - Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
FAU - Lanas, Angel
AU  - Lanas A
AD  - University of Zaragoza, IIS Aragón, CIBERehd, Zaragoza, Spain.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20180925
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Adjuvants, Pharmaceutic)
RN  - 0 (Antineoplastic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adjuvants, Pharmaceutic/administration & dosage/*therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Decision Making
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Observational Studies as Topic
MH  - Treatment Outcome
PMC - PMC6155524
COIS- We have the following interests. PE was a member of the International Aspirin 
      Foundation until Sept 2015. He had received occasional expenses from Bayer for 
      attendance at Conferences organised by the Foundation, but nothing in recent 
      years. MM received personal payments for advisory boards: Sanofi, Bayer, Takeda 
      Lecture fees: Bayer, Janssen, Sanofi. JC: Ownership of Stocks - QuantumDx, 
      Biomark, AstraZeneca, Roche Holdings, Pfizer, Bristol-MeyerSquibb, 
      SeattleGenetics, Natera, Nektar, Spark Therapeutics, Biocept, Nanostring 
      Technologies, Incyte 2. Consultancy/ Paid employment - Tessa Therapeutics 3. 
      Research grants - BMS (drug supply for Investigator Trial) - Bayer (drug supply – 
      Aspirin, for Investigator Trial) - Oncoquest (drug supply – Oregovomab, for 
      Investigator Trial, and study expenses) 4. Travel Grants - AstraZeneca, Bristol 
      Meyer Squibb, MSD 5. Travel grants and honoraria for speaking or participation at 
      meetings - AstraZeneca (speakership). Membership in a government or other 
      advisory board o Board member, Singapore Gynaecologic Oncology Group Council 
      member, College of Clinician Scientist Singapore Scientific advisory board, 
      Aspirin Foundation. AL is n advisor to Bayer A.G. There are no patents, products 
      in development or marketed products to declare. This does not alter our adherence 
      to all the PLOS ONE policies on sharing data and materials, as detailed online in 
      the guide for authors.
EDAT- 2018/09/27 06:00
MHDA- 2019/03/05 06:00
CRDT- 2018/09/26 06:00
PHST- 2018/03/28 00:00 [received]
PHST- 2018/08/30 00:00 [accepted]
PHST- 2018/09/26 06:00 [entrez]
PHST- 2018/09/27 06:00 [pubmed]
PHST- 2019/03/05 06:00 [medline]
AID - PONE-D-18-08743 [pii]
AID - 10.1371/journal.pone.0203957 [doi]
PST - epublish
SO  - PLoS One. 2018 Sep 25;13(9):e0203957. doi: 10.1371/journal.pone.0203957. 
      eCollection 2018.

PMID- 28065221
OWN - NLM
STAT- MEDLINE
DCOM- 20170308
LR  - 20191113
IS  - 1001-9294 (Print)
IS  - 1001-9294 (Linking)
VI  - 31
IP  - 4
DP  - 2016 Nov 20
TI  - Meta-analysis of aspirin-heparin therapy for un-explained recurrent miscarriage.
PG  - 239-246
AB  - Objective This study was designed to evaluate the efficacy and safety of 
      aspirin-heparin treatment for un-explained recurrent spontaneous abortion (URSA). 
      Methods Literatures reporting the studies on the aspirin-heparin treatment of 
      un-explained recurrent miscarriage with randomized controlled trials (RCTs) were 
      collected from the major publication databases. The live birth rate was used as 
      primary indicator, preterm delivery, preeclampsia, intrauterine growth 
      restriction, and adverse reactions (thrombocytopenia ) were used as the secondary 
      indicators. The quality of the included studies was evaluated using RCT bias risk 
      assessment tool in the Cochrane Handbook (v5.1.0). Meta-analysis was conducted 
      using RevMan (v5.3) software. Subgroup analyses were conducted with an 
      appropriately combined model according to the type of the treatments if 
      heterogeneity among the selected studies was detected. Results Six publications 
      of RCTs were included in this study. There were a total of 907 pregnant women 
      with diagnosis of URSA, 367 of them were pooled in the study group with 
      aspirin-heparin therapy and 540 women in the control group with placebo, aspirin 
      or progesterone therapy. Meta-analysis showed that the live birth rate in the 
      study group was significantly different from that in the control group [RR = 
      1.18, 95% CI (1.00-1.39), P=0.04]. Considering the clinical heterogeneity among 
      the six studies, subgroup analysis were performed. Live birth rates in the 
      aspirin-heparin treated groups and placebo groups were compared and no 
      significant difference was found. There were no significant differences found 
      between the two groups in the incidence of preterm delivery [RR=1.22, 95% CI 
      (0.54-2.76), P=0.64], preeclampsia [RR=0.52, 95% CI (0.25-1.07), P=0.08], 
      intrauterine growth restriction [RR=1.19, 95% CI (0.56-2.52), P=0.45] and 
      thrombocytopenia [RR=1.17, 95% CI (0.09-14.42), P=0.90]. Conclusion This 
      meta-analysis did not provide evidence that aspirin-heparin therapy had 
      beneficial effect on un-explained recurrent miscarriage in terms of live birth 
      rate, but it was relatively safe for it did not increase incidence of adverse 
      pregnancy and adverse events. More well-designed and stratified double-blind RCT, 
      individual-based meta-analysis regarding aspirin-heparin therapy are needed in 
      future.
FAU - Tong, Ling
AU  - Tong L
AD  - Department of Gynaecology and Obstetrics, XiXi Hospital of Hangzhou, Hangzhou, 
      310023, China.
FAU - Wei, Xianjiang
AU  - Wei X
AD  - Department of Gynaecology and Obstetrics, Hangzhou Red Cross Hospital, Hangzhou 
      310000, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - China
TA  - Chin Med Sci J
JT  - Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
JID - 9112559
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*drug therapy
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Heparin/*administration & dosage/adverse effects
MH  - Humans
MH  - Pregnancy
MH  - Publication Bias
EDAT- 2017/01/10 06:00
MHDA- 2017/03/09 06:00
CRDT- 2017/01/10 06:00
PHST- 2017/01/10 06:00 [entrez]
PHST- 2017/01/10 06:00 [pubmed]
PHST- 2017/03/09 06:00 [medline]
AID - 10.1016/s1001-9294(17)30007-x [doi]
PST - ppublish
SO  - Chin Med Sci J. 2016 Nov 20;31(4):239-246. doi: 10.1016/s1001-9294(17)30007-x.

PMID- 23454710
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20131121
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 108
DP  - 2013 May
TI  - A rapid method for the simultaneous determination of L-ascorbic acid and 
      acetylsalicylic acid in aspirin C effervescent tablet by ultra performance liquid 
      chromatography-tandem mass spectrometry.
PG  - 20-5
LID - S1386-1425(13)00108-X [pii]
LID - 10.1016/j.saa.2013.01.070 [doi]
AB  - In present study, a rapid and sensitive method using ultra performance liquid 
      chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed for the 
      simultaneous determination of L-ascorbic acid and acetylsalicylic acid in aspirin 
      C effervescent tablet. The optimum chromatographic separation was carried out on 
      a reversed phase Waters® Acquity UPLC BEH C18 column (1.7 μm particle size, 100 
      mm × 2.1 mm ID) with an isocratic elution profile and mobile phase consisting of 
      0.1% formic acid in water and acetonitrile (75:25, v/v, pH 3.5) at flow rate of 
      0.5 mL min(-1). The influences of mobile phase composition, flow rate and pH on 
      chromatographic resolution were investigated. The total chromatographic analysis 
      time was as short as 2 min with excellent resolution. Detection and 
      quantification of the target compounds were carried out with a triple quadrupole 
      mass spectrometer using negative electrospray ionization (ESI) and multiple 
      reaction monitoring (MRM) modes. The performance of the method was evaluated and 
      very low limits of detection less than 0.09 μg g(-1), excellent coefficient 
      correlation (r(2)>0.999) with liner range over a concentration range of 0.1-1.0 
      μg g(-1) for both L-ascorbic acid and acetylsalicylic acid, and good intraday and 
      interday precisions (relative standard deviations (R.S.D.) <3%), were obtained. 
      Comparison of system performance with traditional liquid chromatography-photo 
      diode array detector (HPLC-PDA) was made with respect to analysis time, 
      sensitivity, linearity and precisions. The proposed UPLC-MS/MS method was found 
      to be reproducible and appropriate for quantitative analysis of L-ascorbic acid 
      and acetylsalicylic acid in aspirin C effervescent tablet.
CI  - Copyright © 2013 Elsevier B.V. All rights reserved.
FAU - Wabaidur, Saikh Mohammad
AU  - Wabaidur SM
AD  - Advanced Materials Research Chair, Department of Chemistry, College of Science, 
      King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia. 
      swabaidur@ksu.edu.sa
FAU - Alothman, Zeid Abdullah
AU  - Alothman ZA
FAU - Khan, Mohammad Rizwan
AU  - Khan MR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130206
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 0 (Tablets)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/*analysis/chemistry
MH  - Aspirin/*analysis/chemistry
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Limit of Detection
MH  - Reference Standards
MH  - Reproducibility of Results
MH  - Spectrometry, Mass, Electrospray Ionization
MH  - Tablets
MH  - Tandem Mass Spectrometry/*methods
MH  - Time Factors
EDAT- 2013/03/05 06:00
MHDA- 2013/10/18 06:00
CRDT- 2013/03/05 06:00
PHST- 2012/12/01 00:00 [received]
PHST- 2013/01/21 00:00 [revised]
PHST- 2013/01/27 00:00 [accepted]
PHST- 2013/03/05 06:00 [entrez]
PHST- 2013/03/05 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - S1386-1425(13)00108-X [pii]
AID - 10.1016/j.saa.2013.01.070 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2013 May;108:20-5. doi: 
      10.1016/j.saa.2013.01.070. Epub 2013 Feb 6.

PMID- 31060409
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20210109
IS  - 1532-2394 (Electronic)
IS  - 0898-2104 (Linking)
VI  - 30
IP  - 2
DP  - 2020 Jun
TI  - Development of transferrin-bearing vesicles encapsulating aspirin for cancer 
      therapy.
PG  - 174-181
LID - 10.1080/08982104.2019.1614054 [doi]
AB  - Originally developed for the treatment of inflammatory disorders, the 
      non-steroidal anti-inflammatory drug aspirin was shown to have a preventive 
      effect against cancer in the past decades. Most importantly, recent studies 
      suggested that it might also provide a therapeutic benefit in the treatment of 
      cancer in vitro. However, this drug failed to specifically reach tumors at a 
      therapeutic concentration following intravenous administration, thus resulting in 
      lack of efficacy on tumors. In this work, we demonstrated that aspirin could be 
      formulated in transferrin-bearing vesicles and that this tumor-targeted 
      formulation could lead to an increase in the anti-proliferative efficacy of the 
      drug in three cancer cell lines in vitro. The in vitro therapeutic efficacy of 
      aspirin was significantly improved when formulated in transferrin-bearing 
      vesicles, by about 2-fold compared to that of drug solution. These results are 
      promising and support the optimization of this delivery system to further improve 
      its potential as a therapeutic tool in combination with other anti-cancer 
      therapies.
FAU - Sakpakdeejaroen, Intouch
AU  - Sakpakdeejaroen I
AD  - Strathclyde Institute of Pharmacy and Biomedical Sciences, University of 
      Strathclyde, Glasgow, UK.
FAU - Somani, Sukrut
AU  - Somani S
AD  - Strathclyde Institute of Pharmacy and Biomedical Sciences, University of 
      Strathclyde, Glasgow, UK.
FAU - Mullin, Margaret
AU  - Mullin M
AD  - College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, 
      UK.
FAU - Dufès, Christine
AU  - Dufès C
AUID- ORCID: 0000-0002-7963-6364
AD  - Strathclyde Institute of Pharmacy and Biomedical Sciences, University of 
      Strathclyde, Glasgow, UK.
LA  - eng
GR  - R463/0216/DMT_/The Dunhill Medical Trust/United Kingdom
PT  - Journal Article
DEP - 20190605
PL  - England
TA  - J Liposome Res
JT  - Journal of liposome research
JID - 9001952
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Capsules)
RN  - 0 (Drug Carriers)
RN  - 0 (Transferrin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/chemistry/pharmacology
MH  - Aspirin/*administration & dosage/chemistry/pharmacology
MH  - Capsules/chemistry
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Carriers/*chemistry
MH  - Drug Delivery Systems
MH  - *Drug Development
MH  - Drug Liberation
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Mice
MH  - Molecular Structure
MH  - Structure-Activity Relationship
MH  - Transferrin/*chemistry
MH  - Tumor Cells, Cultured
OTO - NOTNLM
OT  - Aspirin
OT  - cancer therapy
OT  - drug delivery
OT  - transferrin
OT  - tumor targeting
EDAT- 2019/05/08 06:00
MHDA- 2020/12/30 06:00
CRDT- 2019/05/08 06:00
PHST- 2019/05/08 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
PHST- 2019/05/08 06:00 [entrez]
AID - 10.1080/08982104.2019.1614054 [doi]
PST - ppublish
SO  - J Liposome Res. 2020 Jun;30(2):174-181. doi: 10.1080/08982104.2019.1614054. Epub 
      2019 Jun 5.

PMID- 12552716
OWN - NLM
STAT- MEDLINE
DCOM- 20040224
LR  - 20131121
IS  - 1001-5515 (Print)
IS  - 1001-5515 (Linking)
VI  - 16
IP  - 4
DP  - 1999 Dec
TI  - [A water-soluble synthetic polymer, alpha,beta-poly(hydroxyalkyl)-DL-asparamide, 
      and conjugating drug].
PG  - 429-34
AB  - A water-soluble polymer alpha,beta-poly (hydroxyalkyl)-DL-asparamide was 
      synthesized by polysuccinimide(PSI) and different lengths of hydroxyalkyls, 
      including alpha,beta-poly(hydroxyethyl)-DL-asparamide(PHEA), 
      alpha,beta-poly(hydroxypropyl)-DL-asparamide(PHPA), and 
      alpha,beta-poly(hydroxybutyl)-DL-asparamide(PHBA). These polymers were 
      characterized by differential scanning calorimetry(DSC) and infrared 
      spectrophotometry(IR). Stability and acutetoxicity of these polymers were 
      studied. The experiment indicated that these materials were of low-toxicity and 
      high stability. Acetylsalicylic acid, as a model drug, was conjugated into 
      polymers; the drug loadings were 38.63%, 37.68% and 38.70% respectively. Polymer 
      drugs were made into cylinder, and in-vivo release in rabbits was set out. It 
      showed that the longer the spacer was linked into the polymer, the faster the 
      drug was released.
FAU - Zhang, Z
AU  - Zhang Z
AD  - Department of Pharmacy, Zhejiang Medical University, Hangzhou 310031.
FAU - Tang, G
AU  - Tang G
FAU - Chen, Q
AU  - Chen Q
FAU - Wang, B
AU  - Wang B
FAU - Ma, M
AU  - Ma M
FAU - Zhang, X
AU  - Zhang X
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
JT  - Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = 
      Shengwu yixue gongchengxue zazhi
JID - 9426398
RN  - 0 (Drug Carriers)
RN  - 0 (Peptides)
RN  - 0 (alpha,beta-poly((2-hydroxyethyl)-aspartamide))
RN  - 30KYC7MIAI (Aspartic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspartic Acid
MH  - Aspirin/chemical synthesis/*pharmacokinetics
MH  - Drug Carriers
MH  - Female
MH  - Male
MH  - Materials Testing
MH  - Mice
MH  - Peptides/*chemical synthesis
MH  - Rabbits
EDAT- 2003/01/30 04:00
MHDA- 2004/02/26 05:00
CRDT- 2003/01/30 04:00
PHST- 2003/01/30 04:00 [pubmed]
PHST- 2004/02/26 05:00 [medline]
PHST- 2003/01/30 04:00 [entrez]
PST - ppublish
SO  - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 1999 Dec;16(4):429-34.

PMID- 29486728
OWN - NLM
STAT- MEDLINE
DCOM- 20181002
LR  - 20200225
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Feb 27
TI  - Low-dose aspirin use and survival in colorectal cancer: results from a 
      population-based cohort study.
PG  - 228
LID - 10.1186/s12885-018-4142-y [doi]
LID - 228
AB  - BACKGROUND: Aspirin has been proposed as a novel adjuvant agent in colorectal 
      cancer (CRC). Six observational studies have reported CRC-specific survival 
      outcomes in patients using aspirin after CRC diagnosis but the results from these 
      studies have been conflicting. Using a population-based cohort design this study 
      aimed to assess if low-dose aspirin use after diagnosis reduced CRC-specific 
      mortality. METHODS: A cohort of 8391 patients with Dukes' A-C CRC (2009-2012) was 
      identified from the Scottish Cancer Registry and linked to national prescribing 
      and death records. Adjusted hazard ratios (HRs) and 95% confidence intervals 
      (CIs) for CRC-specific mortality were calculated using time-dependent Cox 
      regression. RESULTS: There were 1064 CRC-specific deaths after a median follow-up 
      of 3.6 years. Post-diagnostic low-dose aspirin use was not associated with a 
      reduction in CRC-specific mortality either before or after adjustment for 
      confounders (adjusted HR = 1.17, 95% CI 1.00-1.36). In sensitivity analysis 
      pre-diagnostic low-dose aspirin was also not associated with reduced CRC-specific 
      mortality (adjusted HR = 0.96, 95% CI 0.88-1.05). CONCLUSION: Low-dose aspirin 
      use, either before or after diagnosis, did not prolong survival in this 
      population-based CRC cohort.
FAU - Gray, Ronan T
AU  - Gray RT
AD  - Cancer Epidemiology and Health Services Research Group, Centre for Public Health, 
      Queen's University Belfast, Royal Victoria Hospital, Belfast, Northern Ireland, 
      BT12 6BA, UK. rgray05@qub.ac.uk.
FAU - Coleman, Helen G
AU  - Coleman HG
AD  - Cancer Epidemiology and Health Services Research Group, Centre for Public Health, 
      Queen's University Belfast, Royal Victoria Hospital, Belfast, Northern Ireland, 
      BT12 6BA, UK.
FAU - Hughes, Carmel
AU  - Hughes C
AD  - School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, 
      Northern Ireland, BT9 7BL, UK.
FAU - Murray, Liam J
AU  - Murray LJ
AD  - Cancer Epidemiology and Health Services Research Group, Centre for Public Health, 
      Queen's University Belfast, Royal Victoria Hospital, Belfast, Northern Ireland, 
      BT12 6BA, UK.
FAU - Cardwell, Chris R
AU  - Cardwell CR
AD  - Cancer Epidemiology and Health Services Research Group, Centre for Public Health, 
      Queen's University Belfast, Royal Victoria Hospital, Belfast, Northern Ireland, 
      BT12 6BA, UK.
LA  - eng
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180227
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cohort Studies
MH  - Colorectal Neoplasms/*drug therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Scotland
PMC - PMC6389196
OTO - NOTNLM
OT  - Aspirin
OT  - Colorectal cancer
OT  - Pharmaco-epidemiology
OT  - Survival
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This cohort study used 
      non-identifiable information from routinely collected administrative healthcare 
      datasets in Scotland and had approval from the NHS National Services Scotland 
      Privacy Advisory committee (ref: PAC 36/14). CONSENT FOR PUBLICATION: Approval to 
      use anonymous routinely collected patient data has been obtained as described 
      above. COMPETING INTERESTS: The authors declare that they have no competing 
      interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to 
      jurisdictional claims in published maps and institutional affiliations.
EDAT- 2018/03/01 06:00
MHDA- 2018/10/03 06:00
CRDT- 2018/03/01 06:00
PHST- 2016/04/19 00:00 [received]
PHST- 2018/02/19 00:00 [accepted]
PHST- 2018/03/01 06:00 [entrez]
PHST- 2018/03/01 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
AID - 10.1186/s12885-018-4142-y [pii]
AID - 4142 [pii]
AID - 10.1186/s12885-018-4142-y [doi]
PST - epublish
SO  - BMC Cancer. 2018 Feb 27;18(1):228. doi: 10.1186/s12885-018-4142-y.

PMID- 21805049
OWN - NLM
STAT- MEDLINE
DCOM- 20111101
LR  - 20211020
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 4
IP  - 5
DP  - 2011 Sep-Oct
TI  - Structure-activity relationship study of novel anticancer aspirin-based 
      compounds.
PG  - 891-9
LID - 10.3892/mmr.2011.534 [doi]
AB  - We performed a structure-activity relationship (SAR) study of a novel aspirin 
      (ASA) derivative, which shows strong anticancer activity in vitro and in vivo. A 
      series of ASA-based benzyl esters (ABEs) were synthesized and their inhibitory 
      activity against human colon (HT-29 and SW480) and pancreatic (BxPC-3 and MIA 
      PaCa-2) cancer cell lines was evaluated. The ABEs that we studied largely 
      comprise organic benzyl esters bearing an ASA or acyloxy group (X) at the meta or 
      para position of the benzyl ring and one of four different leaving groups. The 
      nature of the salicyloyl/acyloxy function, the leaving group, and the additional 
      substituents affecting the electron density of the benzyl ring, all were 
      influential determinants of the inhibitory activity on cancer cell growth for 
      each ABE. Positional isomerism also played a significant role in this effect. The 
      mechanism of action of these compounds appears consistent with the notion that 
      they generate either a quinone methide or an m-oxybenzyl zwitterion (or an 
      m-hydroxybenzyl cation), which then reacts with a nucleophile, mediating their 
      biological effect. Our SAR study provides an insight into the biological 
      properties of this novel class of compounds and underscores their potential as 
      anticancer agents.
FAU - Joseph, Stancy
AU  - Joseph S
AD  - Division of Cancer Prevention, Department of Medicine, Stony Brook University, 
      Health Sciences Center T17-080, Stony Brook, NY 11794-8173, USA.
FAU - Nie, Ting
AU  - Nie T
FAU - Huang, Liqun
AU  - Huang L
FAU - Zhou, Hui
AU  - Zhou H
FAU - Atmakur, Krishnaiah
AU  - Atmakur K
FAU - Gupta, Ramesh C
AU  - Gupta RC
FAU - Johnson, Francis
AU  - Johnson F
FAU - Rigas, Basil
AU  - Rigas B
LA  - eng
GR  - R01 CA092423/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20110706
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Antineoplastic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*chemistry/*pharmacology
MH  - Aspirin/*chemistry/*pharmacology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Drug Screening Assays, Antitumor
MH  - Flow Cytometry
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Isomerism
MH  - Static Electricity
MH  - Structure-Activity Relationship
PMC - PMC3565583
MID - NIHMS435712
EDAT- 2011/08/02 06:00
MHDA- 2011/11/02 06:00
CRDT- 2011/08/02 06:00
PHST- 2011/05/30 00:00 [received]
PHST- 2011/07/06 00:00 [accepted]
PHST- 2011/08/02 06:00 [entrez]
PHST- 2011/08/02 06:00 [pubmed]
PHST- 2011/11/02 06:00 [medline]
AID - 10.3892/mmr.2011.534 [doi]
PST - ppublish
SO  - Mol Med Rep. 2011 Sep-Oct;4(5):891-9. doi: 10.3892/mmr.2011.534. Epub 2011 Jul 6.

PMID- 18061948
OWN - NLM
STAT- MEDLINE
DCOM- 20080501
LR  - 20151119
IS  - 1552-4957 (Electronic)
IS  - 1552-4949 (Linking)
VI  - 74
IP  - 2
DP  - 2008 Mar
TI  - Flow cytometric assessment of platelet aspirin resistance using light scattering.
PG  - 110-7
AB  - BACKGROUND: A simple and reliable assay is needed for the prediction of the 
      clinical efficacy of antiplatelet aspirin therapy. We have devised another method 
      for the evaluation of platelet function and aspirin resistance (AR), via 
      conventional flow cytometry (FCM). METHODS: To devise an optimized protocol for 
      the assessment of platelet AR, various analytic variables of FCM were 
      investigated. Using this devised protocol, AR was assessed in healthy subjects as 
      an example. RESULTS: The protocol utilized herein is as follows: 
      citrate-anticoagulated platelet-rich plasma was mixed 1:1 with HEPES-buffered 
      saline in two tubes, one of which is treated with aspirin. During the acquisition 
      of FCM, arachidonate is added to the tube. The response of the aspirin-treated 
      platelets is then compared with those of nontreated ones on a time/forward 
      scatter plot. In the 61 total subjects, none was identified as aspirin resistant 
      by this assay. CONCLUSIONS: Using light scattering, platelet aggregation and 
      aspirin's antiplatelet effects can be readily and cost-effectively detected. 
      According to this assay, biochemical AR appears to be rare. This new protocol may 
      prove useful in a clinical setting or as a research tool.
CI  - (c) 2007 Clinical Cytometry Society
FAU - Won, Dong Il
AU  - Won DI
AD  - Department of Clinical Pathology, Kyungpook National University School of 
      Medicine, Daegu, Korea. wondi@knu.ac.kr
FAU - Yang, Dong Heon
AU  - Yang DH
FAU - Kim, Dong Hyun
AU  - Kim DH
FAU - Chae, Shung Chull
AU  - Chae SC
FAU - Suh, Jang Soo
AU  - Suh JS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cytometry B Clin Cytom
JT  - Cytometry. Part B, Clinical cytometry
JID - 101235690
RN  - 0 (Buffers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid
MH  - Aspirin/*pharmacology
MH  - Biological Assay/instrumentation/methods
MH  - Buffers
MH  - Drug Resistance/*physiology
MH  - Flow Cytometry/instrumentation/*methods
MH  - Humans
MH  - *Light
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Platelet Count/instrumentation/*methods
MH  - Predictive Value of Tests
MH  - Reproducibility of Results
MH  - *Scattering, Radiation
EDAT- 2007/12/07 09:00
MHDA- 2008/05/02 09:00
CRDT- 2007/12/07 09:00
PHST- 2007/12/07 09:00 [pubmed]
PHST- 2008/05/02 09:00 [medline]
PHST- 2007/12/07 09:00 [entrez]
AID - 10.1002/cyto.b.20377 [doi]
PST - ppublish
SO  - Cytometry B Clin Cytom. 2008 Mar;74(2):110-7. doi: 10.1002/cyto.b.20377.

PMID- 33356730
OWN - NLM
STAT- MEDLINE
DCOM- 20220304
LR  - 20220304
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 33
IP  - 1
DP  - 2022 Jan 2
TI  - Recovery of platelet reactivity following cessation of either aspirin or 
      ticagrelor in patients treated with dual antiplatelet therapy following 
      percutaneous coronary intervention: a GLOBAL LEADERS substudy.
PG  - 141-146
LID - 10.1080/09537104.2020.1863937 [doi]
AB  - Cessation of one component of dual antiplatelet therapy (DAPT) following 
      percutaneous coronary intervention (PCI) has been associated with increased risk 
      of ischemic events but it is uncertain whether discontinuation of aspirin is 
      preferable to discontinuation of the oral P2Y(12) inhibitor. The GLOBAL LEADERS 
      study compared two antiplatelet strategies following PCI, cessation of aspirin at 
      1 month with continued ticagrelor monotherapy for 23 months versus standard DAPT 
      for 12 months followed by aspirin monotherapy for a further 12 months. We 
      assessed recovery of platelet reactivity after withdrawal of either aspirin or 
      ticagrelor at 1 month and 12 months, respectively, in this study. Platelet 
      aggregation (PA) was assessed before cessation of DAPT ('baseline') and after 2, 
      7, and 14 days post-cessation using Multiplate whole-blood aggregometry with 
      collagen, thrombin-receptor-activating peptide (TRAP), adenosine diphosphate 
      (ADP) and arachidonic acid (AA) as agonists. Following cessation of aspirin at 
      1 month, there was marked recovery of PA induced by AA (baseline [mean ± SD]: 
      11.1 ± 7.4 U vs. 14 days: 64.9 ± 19.6 U, p < .0001) and collagen (37.4 ± 22.9 U 
      vs. 79.8 ± 13.8 U, p < .0001), whereas PA induced by ADP (18.6 ± 6.6 vs. 
      69.1 ± 20.5, p < .0001) and collagen (34.4 ± 18.7 U vs. 43.0 ± 21.0, p = .0018) 
      recovered following cessation of ticagrelor at 12 months. There were no 
      significant changes in TRAP-induced PA in either group. In conclusion, cessation 
      of either component of DAPT leads to substantial increase in platelet reactivity 
      with differential effects on different pathways of platelet activation when 
      aspirin or the P2Y(12) inhibitor is stopped. Further work is required to 
      determine which patients receive net benefit from long-term continuation of DAPT.
FAU - Hennigan, Barry W
AU  - Hennigan BW
AD  - Department of Cardiology, Golden Jubilee National Hospital, Glasgow, UK.
FAU - Good, Richard
AU  - Good R
AD  - Department of Cardiology, Golden Jubilee National Hospital, Glasgow, UK.
FAU - Adamson, Carly
AU  - Adamson C
AD  - Department of Cardiology, Golden Jubilee National Hospital, Glasgow, UK.
FAU - Parker, William A E
AU  - Parker WAE
AUID- ORCID: 0000-0002-7822-8852
AD  - Cardiovascular Research Unit, Department of Infection, Immunity and 
      Cardiovascular Disease, University of Sheffield, Sheffield, UK.
FAU - Martin, Lynn
AU  - Martin L
AD  - Department of Cardiology, Golden Jubilee National Hospital, Glasgow, UK.
FAU - Anderson, Lynne
AU  - Anderson L
AD  - Department of Cardiology, Golden Jubilee National Hospital, Glasgow, UK.
FAU - Campbell, Michael
AU  - Campbell M
AD  - Department of Cardiology, Golden Jubilee National Hospital, Glasgow, UK.
FAU - Serruys, Patrick W
AU  - Serruys PW
AD  - Department of Cardiology, National University of Ireland, University Road, 
      Galway, Ireland.
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
FAU - Storey, Robert F
AU  - Storey RF
AD  - Cardiovascular Research Unit, Department of Infection, Immunity and 
      Cardiovascular Disease, University of Sheffield, Sheffield, UK.
FAU - Oldroyd, Keith G
AU  - Oldroyd KG
AD  - Department of Cardiology, Golden Jubilee National Hospital, Glasgow, UK.
LA  - eng
GR  - FS/18/49/33752/BHF_/British Heart Foundation/United Kingdom
GR  - PG/14/97/31263/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
DEP - 20201226
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Dual Anti-Platelet Therapy/*methods
MH  - Humans
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Ticagrelor/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - percutaneous coronary intervention
OT  - platelet aggregation
OT  - ticagrelor
EDAT- 2020/12/29 06:00
MHDA- 2022/03/05 06:00
CRDT- 2020/12/28 10:10
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2022/03/05 06:00 [medline]
PHST- 2020/12/28 10:10 [entrez]
AID - 10.1080/09537104.2020.1863937 [doi]
PST - ppublish
SO  - Platelets. 2022 Jan 2;33(1):141-146. doi: 10.1080/09537104.2020.1863937. Epub 
      2020 Dec 26.

PMID- 423116
OWN - NLM
STAT- MEDLINE
DCOM- 19790523
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 68
IP  - 3
DP  - 1979 Mar
TI  - Beneficial effects of methionine and histidine in aspirin solutions on gastric 
      mucosal damage in rats.
PG  - 295-8
AB  - Amino acids methionine and histidine, which are soluble in propylene glycol, were 
      investigated for their purported beneficial effects on aspirin-induced gastric 
      mucosal damage in the rat. The pathognomonic changes observed microscopically in 
      the fundic region of the stomach of animals administered daily doses (100 mg/kg), 
      for up to 15 days, of aspirin solutions (0.36 M) in propylene glycol incorporated 
      with the amino acids were compared with those of animals given equivalent 
      quantities of aspirin in an aqueous suspension combined with an aluminum 
      hydroxide antacid. A "delayed" onset of aspirin-induced cellular damage due to 
      the presence of amino acids, analogous to that associated with the use of 
      antacids, was found as determined partly by differences in the staining ability 
      of injured cells with hematoxylin and eosin.
FAU - Lim, J K
AU  - Lim JK
FAU - Narang, P K
AU  - Narang PK
FAU - Overman, D O
AU  - Overman DO
FAU - Jacknowitz, A I
AU  - Jacknowitz AI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Drug Combinations)
RN  - 0 (Solutions)
RN  - 4QD397987E (Histidine)
RN  - AE28F7PNPL (Methionine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects/metabolism
MH  - Drug Combinations
MH  - Gastric Mucosa/drug effects/pathology
MH  - Histidine/*pharmacology
MH  - Male
MH  - Methionine/*pharmacology
MH  - Rats
MH  - Solutions
MH  - Stomach Ulcer/chemically induced/*prevention & control
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
AID - S0022-3549(15)42546-8 [pii]
AID - 10.1002/jps.2600680310 [doi]
PST - ppublish
SO  - J Pharm Sci. 1979 Mar;68(3):295-8. doi: 10.1002/jps.2600680310.

PMID- 7705877
OWN - NLM
STAT- MEDLINE
DCOM- 19950511
LR  - 20131121
IS  - 0019-5499 (Print)
IS  - 0019-5499 (Linking)
VI  - 39
IP  - 1
DP  - 1995 Jan
TI  - Aspirin and anticonvulsant interaction.
PG  - 77-9
AB  - Aspirin (360 mg/kg, po) per se had anticonvulsant activity in MES model. No 
      effect was observed at lower doses and in other models. Aspirin 216 mg/kg, po (a 
      subanticonvulsant dose) protected animals, receiving subanticonvulsant doses of 
      phenytoin, phenobarbitone and carbamazepine against MES.
FAU - Wali, R S
AU  - Wali RS
AD  - Department of Pharmacology, Jawaharlal Nehru Medical College, Belgaum.
FAU - Patil, P A
AU  - Patil PA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - India
TA  - Indian J Physiol Pharmacol
JT  - Indian journal of physiology and pharmacology
JID - 0374707
RN  - 33CM23913M (Carbamazepine)
RN  - 6158TKW0C5 (Phenytoin)
RN  - R16CO5Y76E (Aspirin)
RN  - YQE403BP4D (Phenobarbital)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Carbamazepine/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Drug Synergism
MH  - Electroshock/adverse effects
MH  - Female
MH  - Male
MH  - Phenobarbital/pharmacology/*therapeutic use
MH  - Phenytoin/pharmacology/*therapeutic use
MH  - Rats
MH  - Seizures/*drug therapy/prevention & control
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Physiol Pharmacol. 1995 Jan;39(1):77-9.

PMID- 15976365
OWN - NLM
STAT- MEDLINE
DCOM- 20051201
LR  - 20131121
IS  - 8750-7587 (Print)
IS  - 0161-7567 (Linking)
VI  - 99
IP  - 4
DP  - 2005 Oct
TI  - Cathodal current-induced vasodilation to single application and the amplified 
      response to repeated application in humans rely on aspirin-sensitive mechanisms.
PG  - 1538-44
AB  - Assumed to rely on an axon reflex, the current-induced vasodilation (CIV) 
      interferes with the microvascular response to iontophoretic drug delivery. 
      Mechanisms resulting in CIV are likely different at the anode and at the cathode. 
      While studies have been conducted to understand anodal CIV, little information is 
      available on cathodal CIV. The present study investigates CIV observed following 
      0.1-mA cathodal applications on forearms of healthy volunteers and the possible 
      mechanisms involved. Results are expressed in percentage of the cutaneous 
      heat-induced maximal vascular conductance [%MVC (means +/- SE)]. 1) The amplitude 
      of CIV was proportional to the duration of cathodal currents for periods of <1 
      min: r = 0.99. 2) Two current applications of 10 s, with 10-min interstimulation 
      interval, induced a higher peak value of CIV (79.1 +/- 8.6% MVC) than the one 
      obtained with all-at-once 20-s current application (39.5 +/- 4.3% MVC, P < 0.05). 
      This amplified vascular response due to segmental application was observed for 
      all tested interstimulation intervals (up to 40 min). 3) Two hours and 3 days 
      following pretreatment with 1-g oral aspirin, the CIV observed following cathodal 
      application, as well as the difference of cathodal CIV amplitude between 
      all-at-once and segmented applications, were reduced. These findings suggest a 
      role of prostaglandins, not only released from endothelial or smooth muscle 
      cells, as direct vasodilator and/or as a sensitizer. Thus aspirin pretreatment 
      could be used to decrease CIV resulting from all-at-once and repeated cathodal 
      application and facilitate the study of the specific vascular effect induced by 
      the drug delivered.
FAU - Tartas, M
AU  - Tartas M
AD  - Laboratory of Vascular Investigations, University Hospital, Angers, France.
FAU - Bouyé, P
AU  - Bouyé P
FAU - Koïtka, A
AU  - Koïtka A
FAU - Jaquinandi, V
AU  - Jaquinandi V
FAU - Tan, L
AU  - Tan L
FAU - Saumet, J L
AU  - Saumet JL
FAU - Abraham, P
AU  - Abraham P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050623
PL  - United States
TA  - J Appl Physiol (1985)
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Electric Stimulation/methods
MH  - Electrodes
MH  - Forearm
MH  - Humans
MH  - Male
MH  - Regional Blood Flow
MH  - Skin/blood supply
MH  - Time Factors
MH  - Vasodilation/*drug effects/*physiology
EDAT- 2005/06/25 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/06/25 09:00
PHST- 2005/06/25 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/06/25 09:00 [entrez]
AID - 00258.2005 [pii]
AID - 10.1152/japplphysiol.00258.2005 [doi]
PST - ppublish
SO  - J Appl Physiol (1985). 2005 Oct;99(4):1538-44. doi: 
      10.1152/japplphysiol.00258.2005. Epub 2005 Jun 23.

PMID- 1750721
OWN - NLM
STAT- MEDLINE
DCOM- 19920123
LR  - 20161123
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 67
IP  - 6
DP  - 1991 Dec
TI  - Intranasal treatment with lysine acetylsalicylate in patients with nasal 
      polyposis.
PG  - 588-92
AB  - Forty-three patients suffering from nasal polyposis underwent intranasal 
      treatment with increasing doses of lysine acetylsalicylate (LAS) corresponding to 
      20, 200, and 2000 micrograms of aspirin (ASA), until a maximal dose of 2000 
      micrograms weekly was reached. The patients were divided in two groups: a group 
      of 28 patients with ASA intolerance, including 20 with ASA triad, and a group of 
      15 patients without ASA intolerance. The local treatment was usually started 1 
      month after polypectomy and was well tolerated without side effects. A control 
      group included 191 subjects with nasal polyposis, 130 of whom had ASA 
      intolerance. After polypectomy the controls received no further medical 
      treatment. Patients were examined every 3 months and radiographs of the paranasal 
      sinuses were obtained every 6 months. After 24 months 34 of 43 patients (79.1%) 
      treated with topical LAS had suffered no relapse of polyposis. Only 45 of 191 
      control patients (23.6%) failed to relapse after 24 months (P less than .0001). 
      Nine of 28 (32.1%) ASA-intolerant patients treated with LAS and 105 of the 130 
      (80.77%) control subjects relapsed (P less than .0001). None of the 15 
      ASA-tolerant patients treated with LAS relapsed, but 41 of the 61 (67.21%) 
      nontreated control subjects relapsed (P less than .00001). These data indicate 
      topical LAS is effective in preventing recurrence of nasal polyps after 
      polypectomy.
FAU - Patriarca, G
AU  - Patriarca G
AD  - Department of Allergology, Catholic University of Rome, Italy.
FAU - Bellioni, P
AU  - Bellioni P
FAU - Nucera, E
AU  - Nucera E
FAU - Schiavino, D
AU  - Schiavino D
FAU - Papa, G
AU  - Papa G
FAU - Schinco, G
AU  - Schinco G
FAU - Fais, G
AU  - Fais G
FAU - Pirotta, L R
AU  - Pirotta LR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
EIN - Ann Allergy 1999 Jun;82(6):542
MH  - Administration, Intranasal
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic 
      use
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/*drug therapy/prevention & control/surgery
MH  - Paranasal Sinuses/diagnostic imaging
MH  - Radiography
MH  - Time Factors
EDAT- 1991/12/01 00:00
MHDA- 2000/03/01 00:00
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 2000/03/01 00:00 [medline]
PHST- 1991/12/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1991 Dec;67(6):588-92.

PMID- 37058400
OWN - NLM
STAT- MEDLINE
DCOM- 20230605
LR  - 20230605
IS  - 1469-0705 (Electronic)
IS  - 0960-7692 (Linking)
VI  - 61
IP  - 6
DP  - 2023 Jun
TI  - ASPRE trial: effects of aspirin on mean arterial blood pressure and uterine 
      artery pulsatility index trajectories in pregnancy.
PG  - 691-697
LID - 10.1002/uog.26222 [doi]
AB  - OBJECTIVES: The mechanism by which aspirin prevents pre-eclampsia is poorly 
      understood, and its effects on biomarkers throughout pregnancy are unknown. We 
      aimed to investigate the effects of aspirin on mean arterial pressure (MAP) and 
      mean uterine artery pulsatility index (UtA-PI) using repeated measures from women 
      at increased risk of preterm pre-eclampsia. METHODS: This was a longitudinal 
      secondary analysis of the Combined Multimarker Screening and Randomized Patient 
      Treatment with Aspirin for Evidence-Based Pre-eclampsia Prevention (ASPRE) trial 
      using repeated measures of MAP and UtA-PI. In the trial, 1620 women at increased 
      risk of preterm pre-eclampsia were identified using the Fetal Medicine Foundation 
      algorithm at 11 + 0 to 13 + 6 weeks, of whom 798 were randomly assigned to 
      receive 150 mg/day aspirin and 822 were assigned to receive placebo daily from 
      11-14 weeks to 36 weeks of gestation or delivery, whichever came first. MAP and 
      UtA-PI were measured at baseline and follow-up visits at 19-24, 32-34 and 
      36 weeks of gestation. Generalized additive mixed models with treatment by 
      gestational age interaction terms were used to investigate the effects of aspirin 
      on MAP and UtA-PI trajectories over time. RESULTS: Among 798 participants in the 
      aspirin group and 822 in the placebo group, there were 5951 MAP and 5942 UtA-PI 
      measurements. Trajectories of raw and multiples of the median (MoM) values of MAP 
      did not differ significantly between the two groups (MAP MoM analysis: P-value 
      for treatment by gestational age interaction, 0.340). In contrast, trajectories 
      of raw and MoM values of UtA-PI showed a significantly steeper decline in the 
      aspirin group than in the placebo group, with the difference mainly driven by a 
      more pronounced reduction before 20 weeks of gestation (UtA-PI MoM analysis: 
      P-value for treatment by gestational age interaction, 0.006). CONCLUSIONS: In 
      women at increased risk of preterm pre-eclampsia, 150 mg/day aspirin initiated in 
      the first trimester does not affect MAP but is associated with a significant 
      decrease in mean UtA-PI, particularly before 20 weeks of gestation. © 2023 The 
      Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd 
      on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
CI  - © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley 
      & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and 
      Gynecology.
FAU - Rolnik, D L
AU  - Rolnik DL
AUID- ORCID: 0000-0002-2263-3592
AD  - Department of Obstetrics and Gynaecology, Monash University, Melbourne, 
      Australia.
FAU - Syngelaki, A
AU  - Syngelaki A
AUID- ORCID: 0000-0001-5856-6072
AD  - Fetal Medicine Research Institute, King's College Hospital, London, UK.
FAU - O'Gorman, N
AU  - O'Gorman N
AD  - Coombe Women and Infants University Hospital, Dublin, Ireland.
FAU - Wright, D
AU  - Wright D
AD  - Institute of Health Research, University of Exeter, Exeter, UK.
FAU - Poon, L C
AU  - Poon LC
AUID- ORCID: 0000-0002-3944-4130
AD  - Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, 
      Hong Kong SAR.
FAU - Nicolaides, K H
AU  - Nicolaides KH
AD  - Fetal Medicine Research Institute, King's College Hospital, London, UK.
LA  - eng
GR  - UK Charity number 1037116/Fetal Medicine Foundation/
GR  - FP7-HEALTH-2013-INNOVATION-2; ASPRE Project number/FP7 Health/
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Ultrasound Obstet Gynecol
JT  - Ultrasound in obstetrics & gynecology : the official journal of the International 
      Society of Ultrasound in Obstetrics and Gynecology
JID - 9108340
RN  - R16CO5Y76E (Aspirin)
RN  - 144589-93-5 (Placenta Growth Factor)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Pregnancy
MH  - Infant, Newborn
MH  - Female
MH  - Humans
MH  - *Aspirin/pharmacology/therapeutic use
MH  - *Pre-Eclampsia/drug therapy/prevention & control
MH  - Arterial Pressure/physiology
MH  - Uterine Artery
MH  - Placenta Growth Factor
MH  - Pregnancy Trimester, First
MH  - Biomarkers
MH  - Pulsatile Flow/physiology
OTO - NOTNLM
OT  - ASPRE trial
OT  - aspirin
OT  - first trimester
OT  - mean arterial pressure
OT  - pre-eclampsia
OT  - prevention
OT  - uterine artery Doppler
EDAT- 2023/04/15 06:00
MHDA- 2023/06/05 06:42
CRDT- 2023/04/14 12:33
PHST- 2023/03/24 00:00 [revised]
PHST- 2023/02/02 00:00 [received]
PHST- 2023/03/31 00:00 [accepted]
PHST- 2023/06/05 06:42 [medline]
PHST- 2023/04/15 06:00 [pubmed]
PHST- 2023/04/14 12:33 [entrez]
AID - 10.1002/uog.26222 [doi]
PST - ppublish
SO  - Ultrasound Obstet Gynecol. 2023 Jun;61(6):691-697. doi: 10.1002/uog.26222.

PMID- 8215751
OWN - NLM
STAT- MEDLINE
DCOM- 19931119
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 153
IP  - 21
DP  - 1993 Nov 8
TI  - A reevaluation of aspirin therapy in rheumatoid arthritis.
PG  - 2465-71
AB  - BACKGROUND: Aspirin therapy has been largely superseded by prescription 
      nonsteroidal anti-inflammatory drug (NSAID) therapy in rheumatoid arthritis, in 
      part because of premarketing studies suggesting lesser toxic effects for NSAIDs 
      than for aspirin. This study evaluates these toxic effects in a postmarketing 
      population of patients with rheumatoid arthritis. METHODS: We studied 1521 
      consecutive courses of aspirin and 4860 courses of NSAIDs in patients with 
      rheumatoid arthritis from eight Arthritis, Rheumatism, and Aging Medical 
      Information System Post-marketing Surveillance Centers. Toxicity index scores 
      were generated from symptoms, laboratory abnormalities, and hospitalizations, 
      weighted for variable severity and severity of side effect. RESULTS: The toxicity 
      index was only 1.37 (SE = 0.10) for aspirin and 1.87 to 2.90 for selected 
      nonsalicylate NSAIDs. These differences were consistent across centers and 
      remained after statistical adjustment for differing patient characteristics. 
      There was a different toxicity with different aspirin preparations, with a score 
      for plain aspirin of 1.36 (SE = 0.23), for buffered aspirin of 1.10 (0.20), and 
      for enteric-coated aspirin preparations of 0.92 (0.14). Most important, there 
      were strong dose effects, with a score of 0.73 (0.09) for 651 to 2600 mg daily, 
      1.08 (0.17) for 2601 to 3900 mg, and 1.91 (0.38) for more than 3900 mg. The 
      average aspirin dose taken was only 2665 mg/d, approximately eight "tablets," 
      compared with 3600 to 4800 mg/d used in the 16 pivotal premarketing studies 
      reviewed. Average NSAID doses were, on the other hand, lower in premarketing 
      trials (eg, naproxen 500 mg/d vs 773 mg/d in the Arthritis, Rheumatism, and Aging 
      Medical System clinical practices). CONCLUSIONS: Aspirin therapy, in doses 
      commonly employed in practice, has an excellent safety profile in rheumatoid 
      arthritis, and it is the least costly NSAID. The safety advantage is explained 
      primarily by a dose effect and secondarily by possible differences between 
      formulations. Newer management strategies for rheumatoid arthritis emphasize 
      NSAID use as symptomatic therapy and use of disease-modifying anti-rheumatic drug 
      therapy for anti-inflammatory objectives. Thus, the original recommendation for 
      "anti-inflammatory" doses of aspirin now is less easily justified. Aspirin 
      therapy merits reconsideration as adjunctive therapy for the management of 
      rheumatoid arthritis.
FAU - Fries, J F
AU  - Fries JF
AD  - Department of Medicine, University School of Medicine, Stanford, Calif.
FAU - Ramey, D R
AU  - Ramey DR
FAU - Singh, G
AU  - Singh G
FAU - Morfeld, D
AU  - Morfeld D
FAU - Bloch, D A
AU  - Bloch DA
FAU - Raynauld, J P
AU  - Raynauld JP
LA  - eng
GR  - AM 21393/AM/NIADDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1993/11/08 00:00
MHDA- 1993/11/08 00:01
CRDT- 1993/11/08 00:00
PHST- 1993/11/08 00:00 [pubmed]
PHST- 1993/11/08 00:01 [medline]
PHST- 1993/11/08 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1993 Nov 8;153(21):2465-71.

PMID- 19302313
OWN - NLM
STAT- MEDLINE
DCOM- 20100511
LR  - 20220318
IS  - 1365-2672 (Electronic)
IS  - 1364-5072 (Linking)
VI  - 107
IP  - 1
DP  - 2009 Jul
TI  - The assessment of the antibacterial and antifungal activities of aspirin, EDTA 
      and aspirin-EDTA combination and their effectiveness as antibiofilm agents.
PG  - 280-6
LID - 10.1111/j.1365-2672.2009.04205.x [doi]
AB  - AIMS: To evaluate the antimicrobial activities of aspirin, EDTA and an 
      aspirin-EDTA (A-EDTA) combination against Pseudomonas aeruginosa, Escherichia 
      coli and Candida albicans in planktonic and biofilm cultures. METHODS AND 
      RESULTS: Minimal inhibitory concentrations (MIC) and minimal biocidal 
      concentrations (MBC) were determined using twofold broth microdilution and viable 
      counting methods, respectively. Aspirin's recorded MIC values ranged from 1.2 to 
      2.7 mg ml(-1). Checkerboard assay demonstrated a synergism in antimicrobial 
      activity upon combination. Aspirin's minimal biofilm eradication concentration 
      values (MBEC) against the established biofilms ranged between 1.35 and 3.83 mg 
      ml(-1). A complete eradication of bacterial biofilms was achieved after a 4-h 
      treatment with the A-EDTA combination. CONCLUSION: Both aspirin and EDTA possess 
      broad-spectrum antimicrobial activity for both planktonic and biofilm cultures. 
      Aspirin used at the MBEC for 24 h was successful in eradicating P. aeruginosa, E. 
      coli and C. albicans biofilms established on abiotic surfaces. Moreover, the 
      exposure to the A-EDTA combination (4 h) effected complete bacterial biofilm 
      eradication. SIGNIFICANCE AND IMPACT OF THE STUDY: There is a continuous need for 
      the discovery of new antimicrobial agents. Aspirin and EDTA are 'nonantibiotic 
      drugs', the combination of which can be used successfully to treat and eradicate 
      biofilms established on abiotic surfaces.
FAU - Al-Bakri, A G
AU  - Al-Bakri AG
AD  - University of Jordan, Faculty of Pharmacy, Amman-11942, Jordan. agbakri@ju.edu.jo
FAU - Othman, G
AU  - Othman G
FAU - Bustanji, Y
AU  - Bustanji Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090310
PL  - England
TA  - J Appl Microbiol
JT  - Journal of applied microbiology
JID - 9706280
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Disinfectants)
RN  - 9G34HU7RV0 (Edetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Infective Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Biofilms/*drug effects/growth & development
MH  - Candida albicans/*drug effects/growth & development
MH  - Colony Count, Microbial
MH  - Disinfectants/pharmacology
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Edetic Acid/*pharmacology
MH  - Escherichia coli/drug effects/growth & development
MH  - Gram-Negative Bacteria/*drug effects/growth & development
MH  - Microbial Sensitivity Tests
MH  - Plankton/*drug effects/growth & development
MH  - Pseudomonas aeruginosa/drug effects/growth & development
EDAT- 2009/03/24 09:00
MHDA- 2010/05/12 06:00
CRDT- 2009/03/24 09:00
PHST- 2009/03/24 09:00 [entrez]
PHST- 2009/03/24 09:00 [pubmed]
PHST- 2010/05/12 06:00 [medline]
AID - JAM4205 [pii]
AID - 10.1111/j.1365-2672.2009.04205.x [doi]
PST - ppublish
SO  - J Appl Microbiol. 2009 Jul;107(1):280-6. doi: 10.1111/j.1365-2672.2009.04205.x. 
      Epub 2009 Mar 10.

PMID- 27125773
OWN - NLM
STAT- MEDLINE
DCOM- 20170127
LR  - 20170127
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 54
IP  - 8
DP  - 2016 Aug
TI  - Acetylsalicylic acid (ASA) - How much, how often, and when? A 
      clinical-pharmacological perspective.
PG  - 634-9
LID - 10.5414/CP202539 [doi]
AB  - The dose of acetylsalicylic acid (ASA) commonly used in the prevention and 
      treatment of arteriosclerotic angiopathies is equal to or less than 100 mg daily. 
      This choice of dose is predominantly based on molecular-pharmacological findings 
      showing an inhibition in synthesis of the prothrombotic thromboxane (TXB2) and an 
      irreversible inhibition in blood platelet aggregation. However, an analysis of 
      ASA dose-effect relationships for doses of 50 - 500 mg (PO and IV) shows that 
      doses of ASA up to 100 mg daily produce only a small or moderate inhibition in 
      collagen/epinephrine-induced platelet aggregation and have no significant effect 
      on the important platelet factors, PF3 and PF4. Doses of ASA 300 - 500 mg, on the 
      other hand, inhibit platelet aggregation almost completely and, in addition, 
      produce a 50 - 70% inhibition in PF3 and PF4 lasting at least 24 hours. There is 
      also evidence that doses of ASA above 100 mg daily markedly inhibit thromboxane 
      synthesis for up to 24 hours and that doses of 500 mg daily produce a clinically 
      relevant inhibition in platelet adhesion to vessel walls for up 72 hours and 
      prevent procoagulatory shape changes for up to 12 hours. These findings suggest 
      that a dose of ≥ 300 mg at intervals of 2 - 3 days would be more appropriate for 
      primary and secondary prophylaxis of arteriosclerotic angiopathies and that the 
      benefit-risk ratio would be greater because of the increased availability of 
      mucoprotective prostaglandins, PGI2 (prostacyclin) and the gastroprotective, 
      PGE2. Our viewpoint, predominantly based on findings with biomarkers, could serve 
      as a basis for further randomized controlled studies.
FAU - Loew, Dieter
AU  - Loew D
FAU - Belz, Gustav G
AU  - Belz GG
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Hemostatics)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis/prevention & control
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Hemostatics/pharmacology
MH  - Humans
MH  - Pharmacology, Clinical
MH  - Platelet Aggregation Inhibitors/pharmacology
EDAT- 2016/04/30 06:00
MHDA- 2017/01/28 06:00
CRDT- 2016/04/30 06:00
PHST- 2016/07/12 00:00 [accepted]
PHST- 2016/04/30 06:00 [entrez]
PHST- 2016/04/30 06:00 [pubmed]
PHST- 2017/01/28 06:00 [medline]
AID - 14364 [pii]
AID - 10.5414/CP202539 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2016 Aug;54(8):634-9. doi: 10.5414/CP202539.

PMID- 3708124
OWN - NLM
STAT- MEDLINE
DCOM- 19860630
LR  - 20191022
IS  - 0142-2782 (Print)
IS  - 0142-2782 (Linking)
VI  - 7
IP  - 2
DP  - 1986 Mar-Apr
TI  - A pharmacokinetic approach to the establishment of biopharmaceutic 
      characteristics of different acetylsalicylic acid formulations in man.
PG  - 183-95
AB  - Eleven acetylsalicylic acid (ASA) formulations were administered to 26 healthy 
      volunteers in a cross-over design. The properties of the preparations differed 
      from conventional, effervescent, buffered to buccal. The objectives of this study 
      were: Consideration of the general aspects of a biopharmaceutical study: which 
      parameter for which biopharmaceutic characteristic? Measurement of the kinetic 
      parameters of ASA: first-pass effect, mean residence time, mean appearance time, 
      total body clearance, apparent volume of distribution, half-lives, etc. 
      Comparison of the formulations. Most of the formulations yield mean residence 
      times for ASA of 0.3-1.0 h, which do not differ significantly (p greater than 
      0.05). For most of the products the first-pass effect is about 40 per cent; the 
      average values of the apparent volume of distribution and whole body clearance, 
      corrected for the first-pass effect, are about 201 and 650 ml min-1, 
      respectively. Peak levels are reached slowly for the buccal formulations, and 
      rapidly for the buffered products. It is difficult, especially for ASA, to 
      characterize the gastro-intestinal absorption with pharmacokinetic model 
      parameters, because the first-pass effect is large and often elimination of ASA 
      is faster than absorption. The model-independent approach has the special 
      advantages of calculating reliable pharmacokinetic parameters, and creating 
      theoretical possibilities to characterize the absorption patterns of the 
      different formulations in a quantitative way. No significant differences in the 
      values of the parameters are found between most of the formulations. The ASA 
      first-pass effect is reasonably constant and buccal application has no advantage. 
      Enteric coating of the outer layer of ASA formulations causes inconsistent 
      absorption and may be categorized under 'artificial mistakes'.
FAU - Raghoebar, M
AU  - Raghoebar M
FAU - Vrancx, F
AU  - Vrancx F
FAU - Van Ginneken, C A
AU  - Van Ginneken CA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Biopharm Drug Dispos
JT  - Biopharmaceutics & drug disposition
JID - 7911226
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/blood/*metabolism
MH  - Half-Life
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Metabolic Clearance Rate
MH  - Tablets
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
AID - 10.1002/bdd.2510070209 [doi]
PST - ppublish
SO  - Biopharm Drug Dispos. 1986 Mar-Apr;7(2):183-95. doi: 10.1002/bdd.2510070209.

PMID- 24453035
OWN - NLM
STAT- MEDLINE
DCOM- 20140930
LR  - 20140207
IS  - 1521-3773 (Electronic)
IS  - 1433-7851 (Linking)
VI  - 53
IP  - 7
DP  - 2014 Feb 10
TI  - The prodrug platin-A: simultaneous release of cisplatin and aspirin.
PG  - 1963-7
LID - 10.1002/anie.201308899 [doi]
AB  - Cancer-associated inflammation induces tumor progression to the metastatic stage, 
      thus indicating that a chemo-anti-inflammatory strategy is of interest for the 
      management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed 
      to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity 
      caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory 
      properties which are better than a combination of cisplatin and aspirin. These 
      findings highlight the advantages of combining anti-inflammatory treatment with 
      chemotherapy when both the drugs are delivered in the form of a single prodrug.
CI  - Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Pathak, Rakesh K
AU  - Pathak RK
AD  - NanoTherapeutics Research Laboratory, Department of Chemistry, University of 
      Georgia, Athens, GA 30602 (USA) http://shanta.chem.uga.edu.
FAU - Marrache, Sean
AU  - Marrache S
FAU - Choi, Joshua H
AU  - Choi JH
FAU - Berding, Trenton B
AU  - Berding TB
FAU - Dhar, Shanta
AU  - Dhar S
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20140122
PL  - Germany
TA  - Angew Chem Int Ed Engl
JT  - Angewandte Chemie (International ed. in English)
JID - 0370543
RN  - 0 (Prodrugs)
RN  - Q20Q21Q62J (Cisplatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Intravenous
MH  - Aspirin/*administration & dosage/chemistry/pharmacokinetics
MH  - Cisplatin/*administration & dosage/chemistry/pharmacokinetics
MH  - Humans
MH  - Inflammation/drug therapy/metabolism
MH  - Neoplasms/drug therapy/metabolism
MH  - Prodrugs/*administration & dosage/chemistry/pharmacokinetics
OTO - NOTNLM
OT  - antitumor agents
OT  - drug design
OT  - inflammation
OT  - platinum
OT  - prodrugs
EDAT- 2014/01/24 06:00
MHDA- 2014/10/01 06:00
CRDT- 2014/01/24 06:00
PHST- 2013/10/12 00:00 [received]
PHST- 2014/01/24 06:00 [entrez]
PHST- 2014/01/24 06:00 [pubmed]
PHST- 2014/10/01 06:00 [medline]
AID - 10.1002/anie.201308899 [doi]
PST - ppublish
SO  - Angew Chem Int Ed Engl. 2014 Feb 10;53(7):1963-7. doi: 10.1002/anie.201308899. 
      Epub 2014 Jan 22.

PMID- 6771948
OWN - NLM
STAT- MEDLINE
DCOM- 19800923
LR  - 20180216
IS  - 0001-5792 (Print)
IS  - 0001-5792 (Linking)
VI  - 63
IP  - 4
DP  - 1980
TI  - Effect of aspirin and aspirin lysinate on platelet function in smokers and 
      non-smokers.
PG  - 177-84
AB  - When administered orally, both acetylsalicylic acid and acetylsalicylic acid 
      lysinate produced an increased bleeding time, reduced platelet adhesiveness and 
      inhibition of the second phase of ADP-induced platelet aggregation in the 
      majority of subjects. The effects on bleeding time and adhesiveness were similar 
      for both drugs. Platelet aggregation studies demonstrated slight differences 
      between smokers and non-smokers, in both control samples and in response to the 
      two drugs. It is concluded that aspirin lysinate should provide a good candidate 
      for clinical investigation, to assess its value in the treatment of thrombotic 
      disease.
FAU - Morgan, K T
AU  - Morgan KT
FAU - Duchosal, F
AU  - Duchosal F
FAU - Rogg, C
AU  - Rogg C
FAU - Miescher, P A
AU  - Miescher PA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adenosine Diphosphate/antagonists & inhibitors
MH  - Adult
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Bleeding Time
MH  - Blood Platelets/*physiology
MH  - Humans
MH  - Lysine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Smoking/*physiopathology
MH  - Thrombosis/drug therapy
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1159/000207395 [doi]
PST - ppublish
SO  - Acta Haematol. 1980;63(4):177-84. doi: 10.1159/000207395.

PMID- 11442268
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190818
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 18
IP  - 3
DP  - 2001 Mar
TI  - An in situ dissolution study of aspirin crystal planes (100) and (001) by atomic 
      force microscopy.
PG  - 299-303
AB  - PURPOSE: To observe in situ and on individual aspirin crystal faces the 
      comparative rates and processes of dissolution of the dominant faces. METHODS: 
      The kinetics of the dissolution rate of two aspirin crystal planes (001) and 
      (100) under 0.05M HCl are studied in situ at room temperature using Atomic Force 
      Microscopy. The dissolution process of each crystal plane was followed by 
      observed changes in topographic features. RESULTS: The results revealed that 
      crystal plane (001) dissolves by receding step edges, and has a dissolution rate 
      of 0.45 nm s(-1). Conversely. plane (100) displays crystal terrace sinking at an 
      average rate of 2.93 nm s(-1). Calculated intrinsic dissolution values (g s(-1) 
      cm(-2)) for planes (001) and (100) are 1.37 x 10(-7) gs(-1) cm(-2) and 8.36 x 
      10(-7) gs(-1) cm(-2), respectively. CONCLUSIONS: These values indicate that the 
      rate of flux of material from plane (100) is approximately six times greater than 
      that from plane (001), under 0.05M HCl. Interpretation of the data, based upon 
      intrinsic dissolution rates and dissolution rate velocities, correlate with 
      reported variations in the dissolution behavior of commercial aspirin products. 
      These observations illustrate the suitability of the technique for characterizing 
      the dissolution behavior of crystalline drugs.
FAU - Danesh, A
AU  - Danesh A
AD  - School of Pharmaceutical Sciences, The University of Nottingham, UK.
FAU - Connell, S D
AU  - Connell SD
FAU - Davies, M C
AU  - Davies MC
FAU - Roberts, C J
AU  - Roberts CJ
FAU - Tendler, S J
AU  - Tendler SJ
FAU - Williams, P M
AU  - Williams PM
FAU - Wilkins, M J
AU  - Wilkins MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Kinetics
MH  - Microscopy, Atomic Force
MH  - Solubility
MH  - Surface Properties
EDAT- 2001/07/10 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/07/10 10:00
PHST- 2001/07/10 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/07/10 10:00 [entrez]
AID - 10.1023/a:1011046728622 [doi]
PST - ppublish
SO  - Pharm Res. 2001 Mar;18(3):299-303. doi: 10.1023/a:1011046728622.

PMID- 8071834
OWN - NLM
STAT- MEDLINE
DCOM- 19940927
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 83
IP  - 5
DP  - 1994 May
TI  - Comparison of three new spectrophotometric methods for simultaneous determination 
      of aspirin and salicylic acid in tablets without separation of pharmaceutical 
      excipients.
PG  - 751-7
AB  - Simultaneous analysis of aspirin (ASA) and salicylic acid (SA) in pharmaceutical 
      tablet preparations was performed by two multicomponent UV-spectrophotometric 
      methods utilizing principal component regression and classical least square 
      algorithm. Additionally, an assay procedure based on second-derivative 
      spectroscopy was developed. The analysis was performed in turbid solutions 
      without separation of interfering excipients. The range, as determined by the 
      second-derivative methods, was 0.2 to 103.2 micrograms/mL for ASA and 0.07 to 
      44.5 micrograms/mL for SA. Sensitivity for determination of SA was 0.004% of ASA 
      content for the second-derivative method and 0.2% of ASA content for both 
      multicomponent methods. The methods were applied to laboratory mixtures and 
      commercial tablet formulations containing ASA and SA. The advantage of the 
      second-derivative method in determining small amounts of SA in commercial tablet 
      preparations is shown in comparison with a conventional HPLC method. All 
      UV-spectrophotometric methods are rapid, accurate, and reproducible.
FAU - Glombitza, B W
AU  - Glombitza BW
AD  - Department of Pharmaceutical Technology, Eberhard-Karls-University Tübingen, 
      Germany.
FAU - Schmidt, P C
AU  - Schmidt PC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Excipients)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Aspirin/*analysis/chemistry
MH  - Chemistry, Pharmaceutical/*methods
MH  - Excipients/chemistry
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - Kinetics
MH  - Salicylates/*analysis/chemistry
MH  - Spectrophotometry, Ultraviolet/methods
MH  - Tablets
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
AID - S0022-3549(15)49449-3 [pii]
AID - 10.1002/jps.2600830532 [doi]
PST - ppublish
SO  - J Pharm Sci. 1994 May;83(5):751-7. doi: 10.1002/jps.2600830532.

PMID- 881098
OWN - NLM
STAT- MEDLINE
DCOM- 19770917
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 5
IP  - 4
DP  - 1977
TI  - A comparison of a new slow release aspirin ("slow aspirin") with plain aspirin in 
      the treatment of rheumatoid disease.
PG  - 270-5
AB  - In a single centre double-blind crossover study in eighteen patients with 
      established rheumatoid disease, a new slow release aspirin ("slow aspirin") was 
      compared with plain aspirin with respect to patient tolerability and gastric 
      mucosal damage as observed at gastroscopy. "Slow aspirin" was significantly 
      better than plain aspirin with regard to gastroscopic findings. With "slow 
      aspirin", the gastric mucosal appearances were definitely better in eight 
      patients, worse in two, and eight showed no difference. There was a high 
      incidence of gastric ulceration or erosions in the groups as a whole (39%) but 
      few patients complained of dyspepsia. There was little difference in the ability 
      of both plain and "slow aspirin" in controlling the patients' joint symptoms. 
      Evidence has been provided to suggest that "slow aspirin" is less injurious to 
      the gastric mucosa. In an attempt to reduce gastric mucosal damage due to 
      prolonged aspirin treatment it is therefore concluded that "slow aspirin" merits 
      consideration in the management of chronic rheumatoid disease.
FAU - Clarke, D N
AU  - Clarke DN
FAU - Mowat, N A
AU  - Mowat NA
FAU - Brunt, P W
AU  - Brunt PW
FAU - Bain, L S
AU  - Bain LS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Delayed-Action Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Delayed-Action Preparations
MH  - Double-Blind Method
MH  - Drug Tolerance
MH  - Dyspepsia/chemically induced
MH  - Gastric Mucosa/drug effects/pathology
MH  - Gastroscopy
MH  - Humans
MH  - Middle Aged
MH  - Stomach Ulcer/chemically induced/pathology
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1177/030006057700500408 [doi]
PST - ppublish
SO  - J Int Med Res. 1977;5(4):270-5. doi: 10.1177/030006057700500408.

PMID- 6476484
OWN - NLM
STAT- MEDLINE
DCOM- 19841022
LR  - 20131121
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 53
IP  - 3
DP  - 1984 Sep
TI  - Effects of chronic aspirin ingestion in aspirin-intolerant asthmatic patients.
PG  - 262-4
AB  - The effects of regular aspirin ingestion after aspirin-desensitization were 
      evaluated in 10 aspirin-intolerant asthmatic patients. Chronic aspirin ingestion 
      was not observed to be associated with either a significant improvement of mean 
      FEV1 values or with a decrease in daily corticosteroid requirements. This study 
      suggests that regular aspirin ingestion in aspirin-intolerant asthmatic patients 
      does not induce a measurable improvement of the respiratory status.
FAU - Naeije, N
AU  - Naeije N
FAU - Bracamonte, M
AU  - Bracamonte M
FAU - Michel, O
AU  - Michel O
FAU - Sergysels, R
AU  - Sergysels R
FAU - Duchateau, J
AU  - Duchateau J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*chemically induced
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/etiology
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Time Factors
EDAT- 1984/09/01 00:00
MHDA- 1984/09/01 00:01
CRDT- 1984/09/01 00:00
PHST- 1984/09/01 00:00 [pubmed]
PHST- 1984/09/01 00:01 [medline]
PHST- 1984/09/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1984 Sep;53(3):262-4.

PMID- 2910232
OWN - NLM
STAT- MEDLINE
DCOM- 19890201
LR  - 20131121
IS  - 0003-9985 (Print)
IS  - 0003-9985 (Linking)
VI  - 113
IP  - 1
DP  - 1989 Jan
TI  - Fatal iatrogenic salicylate intoxication in a long-term user of enteric-coated 
      aspirin.
PG  - 89-90
AB  - A 64-year-old woman, who was taking long-term enteric-coated aspirin therapy for 
      rheumatoid arthritis, was prescribed approximately twice her normal dosage (7.1 g 
      daily) during a ten-day convalescence following surgery. Although she presented 
      with features mimicking sepsis, biochemical analysis, ie, a spuriously high 
      carbon dioxide content, suggested salicylate intoxication (admission salicylate 
      concentration, 5.13 mmol/L). She died on the third day after admission. Autopsy 
      showed no major source of infection except for bronchopneumonia. Long-term users 
      of a high-dose aspirin are at risk for potential salicylate intoxication. The 
      metabolism of salicylate, particularly its excretion kinetics, can make small 
      upward dosage adjustments hazardous. Salicylate has widespread metabolic effects 
      that can mimic other medical conditions, leading to delayed diagnosis of 
      salicylate intoxication. Increased mortality and morbidity may result.
FAU - Shkrum, M J
AU  - Shkrum MJ
AD  - Department of Pathology, Victoria Hospital, London, Ontario, Canada.
FAU - Gay, R M
AU  - Gay RM
FAU - Hudson, P
AU  - Hudson P
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Pathol Lab Med. 1989 Jul;113(7):711. PMID: 2742453
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/administration & dosage/*poisoning
MH  - Female
MH  - Humans
MH  - *Medication Errors
MH  - Middle Aged
MH  - Tablets, Enteric-Coated
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Arch Pathol Lab Med. 1989 Jan;113(1):89-90.

PMID- 29149707
OWN - NLM
STAT- MEDLINE
DCOM- 20180720
LR  - 20180720
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 160
DP  - 2017 Dec
TI  - Over-expression of cyclooxygenase-2 in increased reticulated platelets leads to 
      aspirin resistance after elective off-pump coronary artery bypass surgery.
PG  - 114-118
LID - S0049-3848(17)30546-7 [pii]
LID - 10.1016/j.thromres.2017.11.003 [doi]
AB  - INTRODUCTION: Aspirin resistance (AR) has been reported to present after coronary 
      artery bypass graft causing saphenous vein graft failure. We aimed to investigate 
      the factors that affect the anti-platelet effect of aspirin after off-pump 
      coronary artery bypass surgery (OPCAB). MATERIALS AND METHODS: Thirty OPCAB 
      candidates were successively recruited. Platelet count, platelet aggregation, 
      reticulated platelet (RP), platelets' cyclooxygenase (COX)-1 and COX-2 
      expressions were determined during the peri-operative period. Besides, 10 healthy 
      volunteers were enrolled to determine the onset of the anti-platelet effect of 
      aspirin as comparison. RESULTS AND CONCLUSIONS: The arachidonic acid-induced 
      platelet aggregation (PL(AA)) decreased to <20% within 8h after taking 100mg 
      aspirin in healthy volunteers. However, in the OPCAB patients, PL(AA) levels 
      remained over 20% in 16 (53.3%) patients after resuming aspirin for 24h. The 
      surgical bleeding volumes were higher in the AR patients compared to the normal 
      responders (512.5±192.8 vs. 314.3±94.9, p=0.002). The platelet count on Day 8, RP 
      proportions on Days 1, 4, 8, and COX-2 level on Day 4 were significantly 
      increased compared to their baseline levels in AR group but not in AS group. 
      Platelet count on Day 8, RP proportion and COX-2 on Day 4 were all significantly 
      higher in AR group than those in AS group. The surgical bleeding volume and COX-2 
      over-expression were predictors of post-OPCAB AR. As a conclusion, the inability 
      of aspirin to inhibit the COX-2 created by increased RP would account for the 
      post-OPCAB AR.
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - Gong, Xiaoxuan
AU  - Gong X
AD  - Department of Cardiology, the First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu, China; Department of Cardiology, Huai'an First 
      People's Hospital, Nanjing Medical University, Huai'an, Jiangsu, China.
FAU - Wang, Xuezhong
AU  - Wang X
AD  - Department of Cardiology, Maanshan People's Hospital, Maanshan, Anhui, China.
FAU - Xu, Zhuowen
AU  - Xu Z
AD  - Department of Cardiology, Jiangyin People's Hospital, Jiangyin, Jiangsu, China.
FAU - Zhu, Tiantian
AU  - Zhu T
AD  - Department of Cardiology, Jiangning People's Hospital, Nanjing, Jiangsu, China.
FAU - Zhang, Qiu
AU  - Zhang Q
AD  - Department of Cardiology, the Second People's Hospital of Changzhou City, 
      Changzhou, Jiangsu, China.
FAU - Zhang, Jinying
AU  - Zhang J
AD  - Department of Oncology, the First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu. China.
FAU - Wang, Xiaowei
AU  - Wang X
AD  - Department of Cardiac-thoracic Surgery, the First Affiliated Hospital, Nanjing 
      Medical University, Nanjing, Jiangsu. China.
FAU - Li, Chunjian
AU  - Li C
AD  - Department of Cardiology, the First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu, China. Electronic address: lijay@njmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20171109
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Coronary Artery Bypass, Off-Pump/*methods
MH  - Coronary Artery Disease/*drug therapy
MH  - Cyclooxygenase 2/*metabolism
MH  - Drug Resistance/*physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - Aspirin resistance (AR)
OT  - Coronary artery disease (CAD)
OT  - Cyclooxygenase (COX)
OT  - Off-pump coronary artery bypass (OPCAB)
EDAT- 2017/11/18 06:00
MHDA- 2018/07/22 06:00
CRDT- 2017/11/18 06:00
PHST- 2017/07/19 00:00 [received]
PHST- 2017/10/06 00:00 [revised]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2018/07/22 06:00 [medline]
PHST- 2017/11/18 06:00 [entrez]
AID - S0049-3848(17)30546-7 [pii]
AID - 10.1016/j.thromres.2017.11.003 [doi]
PST - ppublish
SO  - Thromb Res. 2017 Dec;160:114-118. doi: 10.1016/j.thromres.2017.11.003. Epub 2017 
      Nov 9.

PMID- 10472431
OWN - NLM
STAT- MEDLINE
DCOM- 19991021
LR  - 20131121
IS  - 0753-3322 (Print)
IS  - 0753-3322 (Linking)
VI  - 53
IP  - 7
DP  - 1999 Aug
TI  - Aspirin induced apoptosis in gastric cancer cells.
PG  - 315-8
AB  - Aspirin has been well known for its anti-pyretic and anti-inflammatory action 
      over the past century. Its main action in the gastro-intestinal tract has always 
      been associated with erosion and ulceration. However in recent years, there has 
      been evidence suggesting that aspirin and the more potent non-steroidal 
      anti-inflammatory drugs (NSAIDs), could reduce the risk of gastric and colon 
      cancer. One of the possible mechanisms in chemo-prevention is the ability to 
      induce apoptosis in epithelial cells of the gastro-intestinal origin. This 
      article introduces the role of apoptosis in the body and the gastro-intestinal 
      tract. Evidence on the chemo-preventive role of aspirin and NSAIDs are listed, 
      and the mechanisms of action discussed.
FAU - Wong, B C
AU  - Wong BC
AD  - Department of Medicine, University of Hong Kong, Queen Mary Hospital, China.
FAU - Zhu, G H
AU  - Zhu GH
FAU - Lam, S K
AU  - Lam SK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Apoptosis/*drug effects
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Humans
MH  - Isoenzymes/metabolism
MH  - Membrane Proteins
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Stomach Neoplasms/*prevention & control
RF  - 32
EDAT- 1999/09/03 00:00
MHDA- 1999/09/03 00:01
CRDT- 1999/09/03 00:00
PHST- 1999/09/03 00:00 [pubmed]
PHST- 1999/09/03 00:01 [medline]
PHST- 1999/09/03 00:00 [entrez]
AID - S0753-3322(00)88503-0 [pii]
AID - 10.1016/S0753-3322(00)88503-0 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 1999 Aug;53(7):315-8. doi: 10.1016/S0753-3322(00)88503-0.

PMID- 35471507
OWN - NLM
STAT- MEDLINE
DCOM- 20220428
LR  - 20220616
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 327
IP  - 16
DP  - 2022 Apr 26
TI  - Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated 
      Evidence Report and Systematic Review for the US Preventive Services Task Force.
PG  - 1585-1597
LID - 10.1001/jama.2022.3337 [doi]
AB  - IMPORTANCE: Low-dose aspirin is used for primary cardiovascular disease 
      prevention and may have benefits for colorectal cancer prevention. OBJECTIVE: To 
      review the benefits and harms of aspirin in primary cardiovascular disease 
      prevention and colorectal cancer prevention to inform the US Preventive Services 
      Task Force. DATA SOURCES: MEDLINE, PubMed, Embase, and the Cochrane Central 
      Register of Controlled Trials through January 2021; literature surveillance 
      through January 21, 2022. STUDY SELECTION: English-language randomized clinical 
      trials (RCTs) of low-dose aspirin (≤100 mg/d) compared with placebo or no 
      intervention in primary prevention populations. DATA EXTRACTION AND SYNTHESIS: 
      Single extraction, verified by a second reviewer. Quantitative synthesis using 
      Peto fixed-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Cardiovascular 
      disease events and mortality, all-cause mortality, colorectal cancer incidence 
      and mortality, major bleeding, and hemorrhagic stroke. RESULTS: Eleven RCTs 
      (N = 134 470) and 1 pilot trial (N = 400) of low-dose aspirin for primary 
      cardiovascular disease prevention were included. Low-dose aspirin was associated 
      with a significant decrease in major cardiovascular disease events (odds ratio 
      [OR], 0.90 [95% CI, 0.85-0.95]; 11 RCTs [n = 134 470]; I2 = 0%; range in absolute 
      effects, -2.5% to 0.1%). Results for individual cardiovascular disease outcomes 
      were significant, with similar magnitude of benefit. Aspirin was not 
      significantly associated with reductions in cardiovascular disease mortality or 
      all-cause mortality. There was limited trial evidence on benefits for colorectal 
      cancer, with the findings highly variable by length of follow-up and 
      statistically significant only when considering long-term observational follow-up 
      beyond randomized trial periods. Low-dose aspirin was associated with significant 
      increases in total major bleeding (OR, 1.44 [95% CI, 1.32-1.57]; 10 RCTs 
      [n = 133 194]; I2 = 4.7%; range in absolute effects, 0.1% to 1.0%) and in 
      site-specific bleeding, with similar magnitude. CONCLUSIONS AND RELEVANCE: 
      Low-dose aspirin was associated with small absolute risk reductions in major 
      cardiovascular disease events and small absolute increases in major bleeding. 
      Colorectal cancer results were less robust and highly variable.
FAU - Guirguis-Blake, Janelle M
AU  - Guirguis-Blake JM
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
AD  - Department of Family Medicine, University of Washington, Tacoma.
FAU - Evans, Corinne V
AU  - Evans CV
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
FAU - Perdue, Leslie A
AU  - Perdue LA
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
FAU - Bean, Sarah I
AU  - Bean SI
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
FAU - Senger, Caitlyn A
AU  - Senger CA
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - JAMA. 2022 Jun 14;327(22):2249. PMID: 35522266
MH  - *Aspirin/adverse effects/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - *Colorectal Neoplasms/prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
EDAT- 2022/04/27 06:00
MHDA- 2022/04/29 06:00
CRDT- 2022/04/26 12:52
PHST- 2022/04/26 12:52 [entrez]
PHST- 2022/04/27 06:00 [pubmed]
PHST- 2022/04/29 06:00 [medline]
AID - 2791401 [pii]
AID - 10.1001/jama.2022.3337 [doi]
PST - ppublish
SO  - JAMA. 2022 Apr 26;327(16):1585-1597. doi: 10.1001/jama.2022.3337.

PMID- 25301295
OWN - NLM
STAT- MEDLINE
DCOM- 20160224
LR  - 20150603
IS  - 1538-0254 (Electronic)
IS  - 0739-1102 (Linking)
VI  - 33
IP  - 8
DP  - 2015
TI  - Spectroscopic and DFT investigation of interactions between cyclophosphamide and 
      aspirin with lysozyme as binary and ternary systems.
PG  - 1669-81
LID - 10.1080/07391102.2014.967299 [doi]
AB  - Multi-spectroscopic and density functional theory (DFT) calculations was used to 
      study the interaction between cyclophosphamide (CYP) and aspirin (ASA) with 
      lysozyme (LYS). The experimental results showed that fluorescence quenching of 
      LYS by drug was a result of the formation of drug-LYS complex; static quenching 
      was confirmed to result in fluorescence quenching. Modified Stern-Volmer plots of 
      interaction between CYP and ASA with protein in the binary and ternary systems 
      were used to determine the binding parameters. Molecular distances between the 
      donor (LYS) and acceptor (CYP and ASA) for all systems were estimated according 
      to Forster's theory. The quantitative analysis obtained by CD spectra suggested 
      that the presence of ASA and CYP decreased the α-helical content of LYS and 
      induced the destabilizing of it. Theoretical studies on the interaction between 
      LYS with ASA and CYP have been carried out using DFT at the B3LYP/6-31G level in 
      the solvent phase. Binding energy of the mentioned complexes was calculated. It 
      showed that tryptophan (Trp) 62 had the most affinity toward ASA and CYP. 
      Analyzing the calculated results revealed that the five member ring of Trp has a 
      key role in interaction of LYS with ASA and CYP.
FAU - Bozorgmehr, Mohammad Reza
AU  - Bozorgmehr MR
AD  - a Department of Chemistry , Mashhad Branch, Islamic Azad University , Mashhad , 
      Iran.
FAU - Chamani, Jamshidkhan
AU  - Chamani J
FAU - Moslehi, Ghodsiye
AU  - Moslehi G
LA  - eng
PT  - Journal Article
DEP - 20141010
PL  - England
TA  - J Biomol Struct Dyn
JT  - Journal of biomolecular structure & dynamics
JID - 8404176
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - EC 3.2.1.17 (Muramidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Aspirin/*chemistry/metabolism
MH  - Cyclophosphamide/*chemistry/metabolism
MH  - *Models, Molecular
MH  - Molecular Conformation
MH  - Muramidase/*chemistry/metabolism
MH  - Protein Binding
MH  - Spectrum Analysis/methods
OTO - NOTNLM
OT  - aspirin
OT  - cyclophosphamide
OT  - density functional theory
OT  - drug binding
OT  - lysozyme
OT  - spectroscopy
EDAT- 2014/10/11 06:00
MHDA- 2016/02/26 06:00
CRDT- 2014/10/11 06:00
PHST- 2014/10/11 06:00 [entrez]
PHST- 2014/10/11 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
AID - 10.1080/07391102.2014.967299 [doi]
PST - ppublish
SO  - J Biomol Struct Dyn. 2015;33(8):1669-81. doi: 10.1080/07391102.2014.967299. Epub 
      2014 Oct 10.

PMID- 18160364
OWN - NLM
STAT- MEDLINE
DCOM- 20080221
LR  - 20131121
IS  - 1308-0032 (Electronic)
IS  - 1302-8723 (Linking)
VI  - 7 Suppl 2
DP  - 2007 Dec
TI  - Aspirin and gastrointestinal toxicity.
PG  - 27-30
AB  - Aspirin is the main actor in primary and secondary preventive treatments in 
      cardiovascular diseases. However, it has several side effects including 
      gastrointestinal toxicity (peptic ulcer formation, bleeding). Although lower 
      doses are relatively safe, we should keep in mind that even the lowest dose may 
      cause gastrointestinal bleeding. Gastrointestinal toxicity profile does not 
      differ between conventional and enteric-coated aspirin use. In patients who have 
      cardiovascular disease but are at high risk for gastrointestinal bleeding, 
      eradication of Helicobacter pylori infection and concurrent proton pump inhibitor 
      therapy may help to reduce the risk of gastrointestinal toxicity.
FAU - Törüner, Murat
AU  - Törüner M
AD  - Department of Gastroenterology, Ibni-Sina Hospital, Ankara University Medical 
      School, Sihhiye, Ankara, Turkey. murattoruner@yahoo.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Ulcer Agents/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Gastrointestinal Hemorrhage/*chemically induced/microbiology/prevention & control
MH  - Helicobacter pylori
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
RF  - 39
EDAT- 2008/02/09 09:00
MHDA- 2008/02/22 09:00
CRDT- 2008/02/09 09:00
PHST- 2008/02/09 09:00 [pubmed]
PHST- 2008/02/22 09:00 [medline]
PHST- 2008/02/09 09:00 [entrez]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2007 Dec;7 Suppl 2:27-30.

PMID- 18346781
OWN - NLM
STAT- MEDLINE
DCOM- 20080728
LR  - 20131121
IS  - 0141-8130 (Print)
IS  - 0141-8130 (Linking)
VI  - 42
IP  - 4
DP  - 2008 May 1
TI  - Changes of serum albumin affinity for aspirin induced by fatty acid.
PG  - 314-23
LID - 10.1016/j.ijbiomac.2007.11.002 [doi]
AB  - Saturated fatty acids such as myristic acid play an important role in the 
      pathogenesis of cardiovascular disorders. Using the quenching fluorescence method 
      we examined the influence of myristate on the changes of transporting protein 
      affinity towards aspirin-the most popular anticoagulant. Our results showed that 
      the presence of the myristic acid alters the stability of the 
      anticoagulant-albumin complex. The ranges of [myristate]/[albumin] molar ratio at 
      which the stability of drug-protein complex increases or decreases were 
      determined. The differences in interaction between ligands and human or bovine 
      serum albumins were identified. The competition in binding of ligands with these 
      albumins was also described.
FAU - Bojko, B
AU  - Bojko B
AD  - Department of Physical Pharmacy, Faculty of Pharmacy, Medical University of 
      Silesia, Sosnowiec, Poland. bbojko@slam.katowice.pl
FAU - Sułkowska, A
AU  - Sułkowska A
FAU - Maciazek, M
AU  - Maciazek M
FAU - Równicka, J
AU  - Równicka J
FAU - Njau, F
AU  - Njau F
FAU - Sułkowski, W W
AU  - Sułkowski WW
LA  - eng
PT  - Journal Article
DEP - 20071119
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
RN  - 0 (Albumins)
RN  - 0 (Anticoagulants)
RN  - 0 (Fatty Acids)
RN  - 0 (Ligands)
RN  - 0 (Serum Albumin)
RN  - 0I3V7S25AW (Myristic Acid)
RN  - 8DUH1N11BX (Tryptophan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Albumins/chemistry
MH  - Animals
MH  - Anticoagulants/pharmacology
MH  - Aspirin/chemistry/*pharmacology
MH  - Binding Sites
MH  - Cattle
MH  - Fatty Acids/*chemistry
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Ligands
MH  - Myristic Acid/chemistry
MH  - Protein Binding
MH  - Serum Albumin/*metabolism
MH  - Tryptophan/chemistry
EDAT- 2008/03/19 09:00
MHDA- 2008/07/29 09:00
CRDT- 2008/03/19 09:00
PHST- 2007/08/03 00:00 [received]
PHST- 2007/11/08 00:00 [revised]
PHST- 2007/11/09 00:00 [accepted]
PHST- 2008/03/19 09:00 [pubmed]
PHST- 2008/07/29 09:00 [medline]
PHST- 2008/03/19 09:00 [entrez]
AID - S0141-8130(07)00276-0 [pii]
AID - 10.1016/j.ijbiomac.2007.11.002 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2008 May 1;42(4):314-23. doi: 
      10.1016/j.ijbiomac.2007.11.002. Epub 2007 Nov 19.

PMID- 22287037
OWN - NLM
STAT- MEDLINE
DCOM- 20121120
LR  - 20211021
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Print)
IS  - 0925-4692 (Linking)
VI  - 20
IP  - 4
DP  - 2012 Aug
TI  - Evaluation of onset of pain relief from micronized aspirin in a dental pain 
      model.
PG  - 233-42
LID - 10.1007/s10787-012-0121-0 [doi]
AB  - A new formulation of a micronized acetylsalicylic acid swallowable tablet with an 
      effervescent component (FR-aspirin) was evaluated in two independent studies 
      using the dental impaction pain model. These clinical studies were performed to 
      confirm the results of preclinical dissolution studies and human pharmacokinetic 
      studies, which indicated an improved onset of analgesia without compromising 
      duration of effect or safety. Study 1 evaluated a 650-mg dose of aspirin and 
      Study 2 evaluated a 1,000-mg dose of aspirin. Both studies were double-blinded, 
      parallel group and compared to regular aspirin (R-aspirin) and placebo. Speed of 
      onset was measured by the double stopwatch method for time to both first 
      perceptible relief and meaningful relief. In both studies, the FR-aspirin was 
      significantly faster (p<0.038-0.001) than both R-aspirin and placebo for both 
      onset measures. There were no significant differences between FR-aspirin and 
      R-aspirin for peak or total effects and both treatments were significantly better 
      than placebo. For first perceptible relief, FR-aspirin onset was 19.8 and 16.3 
      min for 650 mg and 1,000 mg, respectively, compared to 23.7 and 20.0 for 
      R-aspirin. For meaningful relief, FR-aspirin onset was 48.9 and 49.4 min for 650 
      mg and 1,000 mg, respectively, compared to 119.2 and 99.2 for R-aspirin. These 
      efficacy studies clearly demonstrate that the onset of analgesic efficacy is 
      dramatically improved by adding an effervescent component and micronized active 
      ingredient to the swallowable tablet aspirin formulation. The enhanced onset did 
      not adversely impact either the peak effect or duration of effect or tolerability 
      compared to regular aspirin.
FAU - Cooper, S A
AU  - Cooper SA
AD  - Clinical Trial Consultant, Palm Beach Gardens, FL, USA.
FAU - Voelker, M
AU  - Voelker M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Chemistry, Pharmaceutical
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Tablets
MH  - Tooth, Impacted/physiopathology
MH  - Toothache/*drug therapy
MH  - Young Adult
PMC - PMC3398251
EDAT- 2012/01/31 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/01/31 06:00
PHST- 2011/09/13 00:00 [received]
PHST- 2012/01/07 00:00 [accepted]
PHST- 2012/01/31 06:00 [entrez]
PHST- 2012/01/31 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 121 [pii]
AID - 10.1007/s10787-012-0121-0 [doi]
PST - ppublish
SO  - Inflammopharmacology. 2012 Aug;20(4):233-42. doi: 10.1007/s10787-012-0121-0.

PMID- 24212980
OWN - NLM
STAT- MEDLINE
DCOM- 20140902
LR  - 20181202
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 19
IP  - 1
DP  - 2014 Jan
TI  - Safety and efficacy outcomes of preoperative aspirin in patients undergoing 
      coronary artery bypass grafting: a systematic review and meta-analysis.
PG  - 97-113
LID - 10.1177/1074248413509026 [doi]
AB  - BACKGROUND: The administration of aspirin is traditionally discontinued prior to 
      coronary artery bypass grafting (CABG), given a potential risk of excessive 
      postoperative bleeding. Few studies have previously suggested the benefits of 
      continuing aspirin until the time of surgery. The primary aim of this review is 
      to evaluate the effects of preoperative aspirin therapy on several clinically 
      important outcomes in patients undergoing CABG. METHODS: A meta-analysis of 
      eligible studies of patients undergoing CABG, reporting preoperative aspirin in 
      comparison with no aspirin/placebo and our outcomes, was carried out. The safety 
      outcomes included postoperative bleeding, packed red blood cell (PRBC) 
      transfusion requirements, and reoperation for bleeding. The efficacy outcomes 
      included perioperative myocardial infarction (MI), cerebrovascular accidents 
      (CVAs), and mortality. RESULTS: In 8 randomized controlled trials (RCTs; n = 
      1538), preoperative aspirin increased postoperative bleeding (difference in means 
      = 132.30 mL; 95 % confidence interval [CI] 47.10-217.51; P = .002), PRBC 
      transfusion requirements (difference in means = 0.67 units; 95% CI 0.10-1.24; P = 
      .02), and reoperation for bleeding (odds ratio [OR] = 1.76; 95% CI 1.05-2.93; P = 
      .03). In 19 observational studies (n = 19551), preoperative aspirin increased 
      postoperative bleeding (difference in means = 132.74 mL; 95% CI 45.77-219.72; P = 
      .003) and PRBC transfusion requirements (difference in means = 0.19 units; 95% CI 
      0.02-0.35; P = .02) but not reoperation for bleeding (OR = 1.13; 95% CI 
      0.91-1.42; P = .27). Subgroup analyses for RCTs demonstrated that aspirin given 
      at doses ≤ 100 mg/d might not increase the postoperative bleeding, and the dose 
      of 325 mg/d might not be a cutoff value that has clinical and statistical 
      significance. No statistically significant differences in the rate of 
      perioperative MI, CVAs, or mortality were seen between the 2 groups. CONCLUSIONS: 
      Preoperative aspirin therapy is associated with increased postoperative bleeding, 
      PRBC transfusion requirements, and reoperation for bleeding in patients 
      undergoing CABG. Doses lower than 100 mg/d may minimize the risk of bleeding. 
      Additional RCTs are needed to assess the effects of preoperative aspirin on the 
      safety and efficacy outcomes in patients undergoing CABG.
FAU - Ma, Xiaochun
AU  - Ma X
AD  - 1Shandong University School of Medicine, Jinan, Shandong, China.
FAU - Ma, Chi
AU  - Ma C
FAU - Yun, Yan
AU  - Yun Y
FAU - Zhang, Qian
AU  - Zhang Q
FAU - Zheng, Xia
AU  - Zheng X
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20131107
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Cardiovasc Pharmacol Ther. 2016 Mar;21(2):157-8. PMID: 26254244
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Coronary Artery Bypass/*methods
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Postoperative Hemorrhage/chemically induced/epidemiology
MH  - Premedication
MH  - Randomized Controlled Trials as Topic
MH  - Reoperation/statistics & numerical data
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin
OT  - coronary artery bypass graft
OT  - efficacy
OT  - safety
EDAT- 2013/11/12 06:00
MHDA- 2014/09/03 06:00
CRDT- 2013/11/12 06:00
PHST- 2013/11/12 06:00 [entrez]
PHST- 2013/11/12 06:00 [pubmed]
PHST- 2014/09/03 06:00 [medline]
AID - 1074248413509026 [pii]
AID - 10.1177/1074248413509026 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):97-113. doi: 
      10.1177/1074248413509026. Epub 2013 Nov 7.

PMID- 31051121
OWN - NLM
STAT- MEDLINE
DCOM- 20200224
LR  - 20200224
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 221
IP  - 3
DP  - 2019 Sep
TI  - A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of 
      aspirin in pregnancy.
PG  - 255.e1-255.e9
LID - S0002-9378(19)30612-X [pii]
LID - 10.1016/j.ajog.2019.04.027 [doi]
AB  - BACKGROUND: The benefit of aspirin in preventing preeclampsia is well 
      established; however, studies over the years have demonstrated variability in 
      outcomes with its use. Potential contributing factors to this variation in 
      efficacy include dosing, time of dosing, and preparation of aspirin. OBJECTIVE: 
      We aimed to compare the difference in pharmacokinetics of aspirin, through its 
      major active metabolite, salicylic acid, in pregnant women and nonpregnant women, 
      and to examine the effect of dose (100 mg vs 150 mg), preparation (enteric coated 
      vs non-enteric-coated), and chronotherapy of aspirin (morning vs evening) between 
      the 2 groups. MATERIALS AND METHODS: Twelve high-risk pregnant women and 3 
      nonpregnant women were enrolled in this study. Pregnant women were in 1 of 4 
      groups (100 mg enteric coated, 100 mg non-enteric-coated, 150 mg 
      non-enteric-coated morning dosing, and 150 mg non-enteric-coated evening dosing), 
      whereas nonpregnant women undertook each of the 4 dosing schedules with at least 
      a 30-day washout period. Blood samples were collected at baseline (before 
      ingestion) and at 1, 2, 4, 6, 12, and 24 hours after ingestion of aspirin. Plasma 
      obtained was analyzed for salicylic acid levels by means of liquid 
      chromatography-mass spectrometry. Pharmacokinetic values of area under the curve 
      from time point 0 to 24 hours point of maximum concentration, time of maximum 
      concentration, volume of distribution, clearance, and elimination half-life were 
      analyzed for statistical significance with SPSS v25 software. RESULTS: Pregnant 
      women had a 40% ± 4% reduction in area under the curve from time point 0 to 24 
      hours (P < .01) and 29% ± 3% reduction in point of maximum concentration (P < 
      .01) with a 44% ± 8% increase in clearance (P < .01) in comparison to that in 
      nonpregnant women when 100 mg aspirin was administered. The reduction in the area 
      under the curve from time point 0 to 24 hours, however, was minimized with the 
      use of 150 mg aspirin in pregnant women, with which the area under the curve from 
      time point 0 to 24 hours was closer to that achieved with the use of 100 mg 
      aspirin in nonpregnant women. There was a 4-hour delay (P < .01) in the time of 
      maximum concentration, a 47% ± 3% reduction in point of maximum concentration (P 
      < .01) and a 48% ± 1% increase in volume of distribution (P < .01) with the use 
      of 100 mg enteric-coated aspirin compared to non-enteric-coated aspirin, with no 
      difference in the overall area under the curve. There was no difference in the 
      pharmacokinetics of aspirin between morning and evening dosing. CONCLUSION: There 
      is a reduction in the total drug metabolite concentration of aspirin in 
      pregnancy, and therefore a dose adjustment is potentially required in pregnant 
      women. This is likely due to the altered pharmacokinetics of aspirin in 
      pregnancy, with an increase in clearance. There was no difference in the total 
      drug metabolite concentration of aspirin between enteric-coated and 
      non-enteric-coated aspirin and between morning and evening dosing of aspirin. 
      Further pharmacodynamic and clinical studies are required to examine the clinical 
      relevance of these pharmacokinetic findings.
CI  - Crown Copyright © 2019. Published by Elsevier Inc. All rights reserved.
FAU - Shanmugalingam, Renuka
AU  - Shanmugalingam R
AD  - School of Medicine, Western Sydney University, NSW, Australia; Department of 
      Renal Medicine, South Western Sydney Local Health District, NSW, Australia; Heart 
      Research Institute, University of Sydney, NSW, Australia; Women's Health 
      Initiative Translational Unit (WHITU), South Western Sydney Local Health 
      District, NSW, Australia. Electronic address: 
      Renuka.shanmugalingam@health.nsw.gov.au.
FAU - Wang, XiaoSuo
AU  - Wang X
AD  - Bosch Mass Spectrometry Facility, Bosch Institute, Faculty of Medicine and 
      Health, University of Sydney, NSW, Australia.
FAU - Münch, Gerald
AU  - Münch G
AD  - Pharmacology Unit, School of Medicine, Western Sydney University, NSW, Australia.
FAU - Fulcher, Ian
AU  - Fulcher I
AD  - Department of Obstetrics and Gynaecology, Liverpool Hospital, NSW, Australia.
FAU - Lee, Gaksoo
AU  - Lee G
AD  - Department of Renal Medicine, South Western Sydney Local Health District, NSW, 
      Australia; Women's Health Initiative Translational Unit (WHITU), South Western 
      Sydney Local Health District, NSW, Australia.
FAU - Chau, Katrina
AU  - Chau K
AD  - Heart Research Institute, University of Sydney, NSW, Australia.
FAU - Xu, Bei
AU  - Xu B
AD  - Heart Research Institute, University of Sydney, NSW, Australia.
FAU - Kumar, Roshika
AU  - Kumar R
AD  - Department of Obstetrics and Gynaecology, Liverpool Hospital, NSW, Australia.
FAU - Hennessy, Annemarie
AU  - Hennessy A
AD  - School of Medicine, Western Sydney University, NSW, Australia; Department of 
      Renal Medicine, South Western Sydney Local Health District, NSW, Australia; Heart 
      Research Institute, University of Sydney, NSW, Australia; Women's Health 
      Initiative Translational Unit (WHITU), South Western Sydney Local Health 
      District, NSW, Australia.
FAU - Makris, Angela
AU  - Makris A
AD  - School of Medicine, Western Sydney University, NSW, Australia; Department of 
      Renal Medicine, South Western Sydney Local Health District, NSW, Australia; Heart 
      Research Institute, University of Sydney, NSW, Australia; Women's Health 
      Initiative Translational Unit (WHITU), South Western Sydney Local Health 
      District, NSW, Australia.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190430
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/*pharmacokinetics/therapeutic use
MH  - Case-Control Studies
MH  - Dose-Response Relationship, Drug
MH  - *Drug Chronotherapy
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/*pharmacokinetics/therapeutic use
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy/*physiology
MH  - Tablets, Enteric-Coated
OTO - NOTNLM
OT  - aspirin
OT  - dose
OT  - pharmacokinetics
OT  - preeclampsia
OT  - pregnancy
EDAT- 2019/05/06 06:00
MHDA- 2020/02/25 06:00
CRDT- 2019/05/04 06:00
PHST- 2019/01/08 00:00 [received]
PHST- 2019/04/16 00:00 [revised]
PHST- 2019/04/24 00:00 [accepted]
PHST- 2019/05/06 06:00 [pubmed]
PHST- 2020/02/25 06:00 [medline]
PHST- 2019/05/04 06:00 [entrez]
AID - S0002-9378(19)30612-X [pii]
AID - 10.1016/j.ajog.2019.04.027 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2019 Sep;221(3):255.e1-255.e9. doi: 
      10.1016/j.ajog.2019.04.027. Epub 2019 Apr 30.

PMID- 22100851
OWN - NLM
STAT- MEDLINE
DCOM- 20120514
LR  - 20131121
IS  - 1899-1505 (Electronic)
IS  - 0867-5910 (Linking)
VI  - 62
IP  - 4
DP  - 2011 Aug
TI  - Aspirin's ability to induce intestinal injury in rats is dependent on bile and 
      can be reversed if pre-associated with phosphatidylcholine.
PG  - 491-6
AB  - Clinical evidence suggests that aspirin and particularly enteric-coated aspirin 
      induce significant injury to the lower gut. We have reported that NSAID injury to 
      the small bowel is exacerbated by bile acids and that phosphatidylcholine (PC) 
      can protect against this damage. Using a recently described method, we 
      intra-duodenally administered either: saline, aspirin or aspirin pre-associated 
      with PC. The rats were euthanized 90 minutes later at which time we assessed: 
      tissue injury morphologically, vascular permeability with i.v. administered 
      Evan's blue and intestinal bleeding by measuring luminal hemoglobin. In a 
      separate experiment, aspirin-induced injury was studied in rats whose bile duct 
      was ligated either alone or in the presence of rat bile (collected from donor 
      animals). Intra-duodenal administration of aspirin induced mucosal injury 
      (observed histologically), an increase in vascular permeability and blood loss 
      into the intestinal lumen, all of which could be attenuated if the NSAID was 
      pre-associated with PC. Furthermore, using 100 mg/kg dose of aspirin it was 
      determined that bile duct ligation (BDL) significantly reduced aspirin-induced 
      intestinal bleeding which was not different from control rats. Lastly, it was 
      determined that intestinal bleeding was significantly increased in rats with BDL 
      if the aspirin was administered in rodent bile. Aspirin-induced intestinal injury 
      and bleeding in the rat is dependent on the presence of luminal bile, which is 
      likely attributable to it's constituent bile acids. Pre-association of aspirin 
      with PC provides a novel therapeutic approach to significantly reduce 
      aspirin-induced small intestinal injury and bleeding, as may occur with 
      enteric-coated aspirin.
FAU - Lichtenberger, L M
AU  - Lichtenberger LM
AD  - Department of Integrative Biology and Pharmacology, The University of Texas 
      Health Sciences Center at Houston, Houston, TX 77030, USA. 
      lenard.m.lichtenberger@uth.tmc.edu
FAU - Phan, T
AU  - Phan T
FAU - Okabe, S
AU  - Okabe S
LA  - eng
GR  - P30 DK56338/DK/NIDDK NIH HHS/United States
GR  - RC1 DK086304/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - Poland
TA  - J Physiol Pharmacol
JT  - Journal of physiology and pharmacology : an official journal of the Polish 
      Physiological Society
JID - 9114501
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Phosphatidylcholines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - *Bile/chemistry
MH  - Bile Acids and Salts/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Hemorrhage/chemically induced/pathology/*prevention & control
MH  - Intestinal Mucosa/drug effects/injuries/pathology
MH  - Intestine, Small/*drug effects/injuries/pathology
MH  - Male
MH  - Phosphatidylcholines/*administration & dosage
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2011/11/22 06:00
MHDA- 2012/05/15 06:00
CRDT- 2011/11/22 06:00
PHST- 2011/07/29 00:00 [received]
PHST- 2011/08/17 00:00 [accepted]
PHST- 2011/11/22 06:00 [entrez]
PHST- 2011/11/22 06:00 [pubmed]
PHST- 2012/05/15 06:00 [medline]
PST - ppublish
SO  - J Physiol Pharmacol. 2011 Aug;62(4):491-6.

PMID- 29429226
OWN - NLM
STAT- MEDLINE
DCOM- 20180312
LR  - 20181202
IS  - 1002-0098 (Print)
IS  - 1002-0098 (Linking)
VI  - 53
IP  - 2
DP  - 2018 Feb 9
TI  - [Effect of low dose aspirin on osseointegration around titanium implants in 
      osteoporotic rats].
PG  - 92-96
LID - 10.3760/cma.j.issn.1002-0098.2018.02.004 [doi]
AB  - Objective: To investigate the effect of aspirin on osseointegration around 
      titanium implants in ostoeporotic rats and to provide evidence for future 
      researches and clinical application. Methods: A total of 60 female SD rats, aged 
      3-4 months, were divided into ovariectomy group (Ovx group, n=48) and 
      sham-ovariectomy group (Sham group, n=12). The rats in Ovx group received 
      ovariectomy and those in Sham group underwent sham-ovariectomy. Twelve weeks 
      later, six rats in each group were randomly selected to confirm the osteoporosis 
      models. The Ovx group was divided into 4 subgroups with 12 rats in each group, 
      namely the osteoporosis group (OP group), and Aspirin groups (A1, A2, A3 group). 
      Pure screw titanium implants were placed in the right tibia near metaphysis of 
      all rats. Three days after implant surgery, aspirin groups were intragastrically 
      administered aspirin at a dose of 2.06, 4.11, 8.21 mg·kg(-1)·d(-1) (A1, A2, A3), 
      and OP group and Sham group were fed the same amount of normal saline. Four and 
      12 weeks following implantations surgery, half of the rats in each group were 
      randomly chosen and sacrificed. Implant bone contact rate (IBCR), combined bone 
      lamella width (CBLW) and trabercular width (TW) were observed and calculated 
      using histomorphometric measurement. Results: Four weeks after implantations 
      surgery, the TW and CBLW of rats in A1 group [(39.60±2.77) and (27.56±4.14) μm] 
      and the IBCR, TW and CBLW of rats in A2 group and A3 group [A2: (47.21±4.19)%, 
      (48.74±3.20) and (35.91±3.79) μm; A3: (47.35±6.07)%, (50.27±5.25) and 
      (40.66±2.11) μm] were much higher than those in OP group [(33.89±7.17)%, 
      (32.20±6.10) and (19.77±6.80) μm](P<0.05). In term of CBLW, there were no 
      difference between A3 group and Sham group [(46.11±5.87) μm](P>0.05). Twelve 
      weeks after implantations surgery, the IBCR and CBLW of rats in A1 group [ 
      (85.86±3.64) %, (53.12±8.68) μm], and the IBCR, TW and CBLW of rats in A2 group 
      and A3 group [A2: (85.64±3.97)%, (69.42±6.78) and (54.19±3.12) μm; A3: 
      (86.22±3.48)%, (75.43±3.50) and (55.79±5.60) μm] were much higher than those in 
      OP group [(77.20±7.14)%, (55.10±2.26) and (41.77±3.13) μm](P<0.05). In term of 
      IBCR, there were no difference among A1 group, A2 group, A3 group and Sham group 
      [(90.09±2.21)%](P>0.05). Conclusions: The low dose aspirin could promote IBCR, 
      CBLW and TW of osteoporotic rats implants.
FAU - Yang, Q
AU  - Yang Q
AD  - Department of Prosthodontics, Affiliated People's Hospital, Shanxi Medical 
      University, Taiyuan 030012, China (Present address: Department of Oral Medicine, 
      Shanxi Medical University, Taiyuan 030000, China).
FAU - Li, F L
AU  - Li FL
AD  - Department of Prosthodontics, Affiliated People's Hospital, Shanxi Medical 
      University, Taiyuan 030012, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Kou Qiang Yi Xue Za Zhi
JT  - Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese 
      journal of stomatology
JID - 8711066
RN  - 451W47IQ8X (Sodium Chloride)
RN  - D1JT611TNE (Titanium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - *Bone Screws
MH  - Female
MH  - Osseointegration/*drug effects
MH  - Osteoporosis/*therapy
MH  - *Ovariectomy
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sodium Chloride
MH  - Tibia
MH  - *Titanium
OTO - NOTNLM
OT  - Aspirin
OT  - Dental implants
OT  - Osseointegration
OT  - Osteoporosis
EDAT- 2018/02/13 06:00
MHDA- 2018/03/13 06:00
CRDT- 2018/02/13 06:00
PHST- 2018/02/13 06:00 [entrez]
PHST- 2018/02/13 06:00 [pubmed]
PHST- 2018/03/13 06:00 [medline]
AID - 10.3760/cma.j.issn.1002-0098.2018.02.004 [doi]
PST - ppublish
SO  - Zhonghua Kou Qiang Yi Xue Za Zhi. 2018 Feb 9;53(2):92-96. doi: 
      10.3760/cma.j.issn.1002-0098.2018.02.004.

PMID- 22541221
OWN - NLM
STAT- MEDLINE
DCOM- 20120712
LR  - 20131121
IS  - 1552-6259 (Electronic)
IS  - 0003-4975 (Linking)
VI  - 93
IP  - 5
DP  - 2012 May
TI  - How an aspirin, a throat swab from a chicken, and four Guinea pigs changed 
      thoracic surgery.
PG  - 1753-60
LID - 10.1016/j.athoracsur.2011.11.079 [doi]
AB  - The development of antituberculous drugs changed thoracic surgery and also 
      markedly lowered the morbidity and mortality of a disease that had epidemic 
      proportions. This article summarizes aspects from 3 important articles that led 
      to the discovery of these drugs.
CI  - Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All 
      rights reserved.
FAU - Odell, John A
AU  - Odell JA
AD  - Division of Cardiovascular and Thoracic Surgery, Mayo Clinic, Jacksonville, 
      Florida 32224, USA. odell.john@mayo.edu
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antitubercular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/history/pharmacology
MH  - Antitubercular Agents/history/*pharmacology
MH  - Aspirin/history/*pharmacology
MH  - Chickens
MH  - Drug Design
MH  - Guinea Pigs
MH  - History, 20th Century
MH  - Humans
MH  - Pharynx/*microbiology
MH  - Thoracic Surgical Procedures/*history
EDAT- 2012/05/01 06:00
MHDA- 2012/07/13 06:00
CRDT- 2012/05/01 06:00
PHST- 2011/09/01 00:00 [received]
PHST- 2011/10/27 00:00 [revised]
PHST- 2011/11/02 00:00 [accepted]
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2012/07/13 06:00 [medline]
AID - S0003-4975(12)00414-6 [pii]
AID - 10.1016/j.athoracsur.2011.11.079 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 2012 May;93(5):1753-60. doi: 10.1016/j.athoracsur.2011.11.079.

PMID- 1587637
OWN - NLM
STAT- MEDLINE
DCOM- 19920623
LR  - 20180216
IS  - 1018-2438 (Print)
IS  - 1018-2438 (Linking)
VI  - 97
IP  - 3
DP  - 1992
TI  - In vitro study of platelets and circulating mononuclear cells of subjects 
      presenting an intolerance to aspirin.
PG  - 233-6
AB  - Aspirine-sensitive asthma (ASA) is a disease defined only by clinical criteria. 
      It is an intrinsic asthma related to a hypersensitivity to aspirin. The illness 
      is linked to abnormalities in platelet and macrophage arachidonic acid 
      metabolism. We assessed in vitro the platelet chemoluminescence (CL) and 
      lymphocyte proliferative response of ASA patients. We observed that platelets 
      from patients and control do not generate any CL in the presence of aspirin. 
      Concerning the proliferative response of lymphocytes, the in vitro effect of 
      aspirin depends upon the origin of the lymphocytes tested. Thus aspirin clearly 
      enhances the proliferative response of lymphocytes from normal subjects but 
      diminishes the thymidine uptake by lymphocytes from ASA patients. This 
      discrepancy in the in vitro response of lymphocytes from normal subjects and 
      patients might be useful for in vitro diagnosis of ASA.
FAU - Guez, S
AU  - Guez S
AD  - Service de Médecine interne et Maladies allergiques, Hôpital Pellegrin, Bordeaux, 
      France.
FAU - Gualde, N
AU  - Gualde N
FAU - Bezian, J H
AU  - Bezian JH
FAU - Cabanieu, G
AU  - Cabanieu G
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (Salicylamides)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 90Y4QC304K (Ketoprofen)
RN  - EM8BM710ZC (salicylamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/*immunology
MH  - Asthma/chemically induced/pathology
MH  - Blood Platelets/*drug effects
MH  - Drug Hypersensitivity/*pathology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Ketoprofen/pharmacology
MH  - Leukocytes, Mononuclear/*drug effects
MH  - Luminescent Measurements
MH  - Lymphocyte Activation/drug effects
MH  - Male
MH  - Middle Aged
MH  - Salicylamides/pharmacology
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1159/000236125 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 1992;97(3):233-6. doi: 10.1159/000236125.

PMID- 17870554
OWN - NLM
STAT- MEDLINE
DCOM- 20080410
LR  - 20161209
IS  - 2213-0276 (Electronic)
IS  - 0755-4982 (Linking)
VI  - 35 Suppl 1
DP  - 2006 Sep
TI  - [Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?].
PG  - 53-60
LID - 10.1016/S0755-4982(06)74941-7 [doi]
AB  - OBJECTIVES: Some studies have recently suggested a potential pharmacodynamic 
      interaction between aspirin and some non-selective non-steroidal 
      anti-inflammatory drugs (NSAIDs). We have evaluated the reality of this 
      pharmacodynamic interaction and analyse its clinical pertinence. METHODS: 
      Literature review (Medline search - December 2005). RESULTS: Several ex vivo 
      studies show that some non-selective NSAIDs can block the active site of Cox1 
      thus preventing aspirin from exerting its platelet anti-aggregating 
      cardio-preventive action. Cox2 selective molecules do not act at this site. The 
      few studies, mainly case reports, have analysed the potential loss of the 
      cardiovascular preventive benefit of aspirin in patients receiving concomitantly 
      non-selective anti-inflammatory drugs with controversial results. IN PRACTICE: It 
      seems necessary to know the existence of this pharmacodynamic interaction between 
      aspirin at a low dose and some non-selective anti-inflammatory drugs notably 
      ibuprofen and naproxen. In the absence of a clear clinical demonstration, it is 
      advisable to avoid the non-selective NSAIDs in patients treated with a low dose 
      of aspirin. It might be advisable to switch to an anti-aggregating treatment 
      other than aspirin (clopidrogel, etc.) in these cases. At the present time, 
      however, there are no data on which to base such a recommendation.
FAU - Flipo, René-Marc
AU  - Flipo RM
AD  - Service de Rhumatologie,CHU Roger Salengro, Lille.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Les AINS sont-ils susceptibles de compromettre l'efficacité cardiopréventive de 
      l'aspirine?
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*therapeutic use
MH  - Cyclooxygenase Inhibitors/*adverse effects
MH  - Drug Interactions
MH  - Heart Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
EDAT- 2008/03/20 09:00
MHDA- 2008/04/11 09:00
CRDT- 2008/03/20 09:00
PHST- 2008/03/20 09:00 [pubmed]
PHST- 2008/04/11 09:00 [medline]
PHST- 2008/03/20 09:00 [entrez]
AID - S0755-4982(06)74941-7 [pii]
AID - 10.1016/S0755-4982(06)74941-7 [doi]
PST - ppublish
SO  - Presse Med. 2006 Sep;35 Suppl 1:53-60. doi: 10.1016/S0755-4982(06)74941-7.

PMID- 26323750
OWN - NLM
STAT- MEDLINE
DCOM- 20160706
LR  - 20181113
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 40
IP  - 4
DP  - 2015 Nov
TI  - Aspirin dosing in cardiovascular disease prevention and management: an update.
PG  - 499-511
LID - 10.1007/s11239-015-1267-6 [doi]
AB  - Aspirin has been in use for prevention and management of cardiovascular diseases 
      for several decades. Clinical and epidemiological literature suggests that while 
      net benefits of aspirin in primary prevention of CVDs are less clear, the 
      benefits of aspirin in acute scenarios and secondary prevention settings are well 
      established. However, its optimum dosing requirements have been up for debate 
      especially in various settings of acute coronary syndrome and stable ischemic 
      heart disease. The role of clinician in stratifying individual risk score to 
      achieve net clinical benefit is an important determinant of initiating aspirin 
      therapy. The purpose of this article is to review association of aspirin and CVD 
      in general, and to review its dosing regimens in acute settings as well as 
      primary and secondary prevention as suggested by various established guidelines. 
      We also aim to provide the readers an update on recent changes and current 
      evidence based practice trends.
FAU - Ganjehei, Leila
AU  - Ganjehei L
AD  - Division of Cardiovascular Health and Disease, University of Cincinnati Medical 
      Center, 231 Albert Sabin Way, MLC 0542, Cincinnati, OH, 45267-0542, USA. 
      Leila.Ganjehei@uc.edu.
FAU - Becker, Richard C
AU  - Becker RC
AD  - Division of Cardiovascular Health and Disease, University of Cincinnati Medical 
      Center, 231 Albert Sabin Way, MLC 0542, Cincinnati, OH, 45267-0542, USA.
AD  - Lung and Vascular Institute, University of Cincinnati Medical Center, Cincinnati, 
      OH, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*prevention & control
MH  - Aspirin/*therapeutic use
MH  - Humans
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular diseases
OT  - Dosage
OT  - Primary prevention
OT  - Secondary prevention
EDAT- 2015/09/02 06:00
MHDA- 2016/07/07 06:00
CRDT- 2015/09/02 06:00
PHST- 2015/09/02 06:00 [entrez]
PHST- 2015/09/02 06:00 [pubmed]
PHST- 2016/07/07 06:00 [medline]
AID - 10.1007/s11239-015-1267-6 [pii]
AID - 10.1007/s11239-015-1267-6 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2015 Nov;40(4):499-511. doi: 10.1007/s11239-015-1267-6.

PMID- 32488906
OWN - NLM
STAT- MEDLINE
DCOM- 20210702
LR  - 20210802
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 86
IP  - 8
DP  - 2020 Aug
TI  - Effect of low-dose aspirin on health outcomes: An umbrella review of systematic 
      reviews and meta-analyses.
PG  - 1465-1475
LID - 10.1111/bcp.14310 [doi]
AB  - AIMS: This study aimed to use an umbrella review methodology to capture the range 
      of outcomes that were associated with low-dose aspirin and to systematically 
      assess the credibility of this evidence. METHODS: Aspirin is associated with 
      several health outcomes, but the overall benefit/risk balance related to aspirin 
      use is unclear. We searched three major databases up to 15 August 2019 for 
      meta-analyses of observational studies and randomized controlled trials (RCTs) 
      including low-dose aspirin compared to placebo or other treatments. Based on 
      random-effects summary effect sizes, 95% prediction intervals, heterogeneity, 
      small-study effects and excess significance, significant meta-analyses of 
      observational studies were classified from convincing (class I) to weak (class 
      IV). For meta-analyses of RCTs, outcomes with random effects P-value < .005 and a 
      moderate/high GRADE assessment, were classified as strong evidence. From 6802 
      hits, 67 meta-analyses (156 outcomes) were eligible. RESULTS: Observational data 
      showed highly suggestive evidence for aspirin use and increased risk of upper 
      gastrointestinal bleeding (RR = 2.28, 95% CI: 1.97-2.64). In RCTs of low-dose 
      aspirin, we observed strong evidence for lower risk of CVD in people without CVD 
      (RR = 0.83; 95% CI: 0.79-0.87) and in general population (RR = 0.83; 95% CI: 
      0.79-0.89), higher risk of major gastrointestinal (RR = 1.47; 95% CI: 1.26-1.72) 
      and intracranial bleeding (RR = 1.34; 95% CI: 1.18-1.53), and of major bleedings 
      in people without CVD (RR = 1.62; 95% CI: 1.26-2.08). CONCLUSION: Compared to 
      other active medications, low-dose aspirin had strong evidence for lower risk of 
      bleeding, but also lower comparative efficacy. Low-dose aspirin significantly 
      lowers CVD risk and increases risk of bleeding. Evidence for multiple other 
      health outcomes is limited.
CI  - © 2020 The British Pharmacological Society.
FAU - Veronese, Nicola
AU  - Veronese N
AD  - National Research Council, Neuroscience Institute, Aging Branch, Padua, Italy.
AD  - Geriatrics Unit, Department of Geriatric Care, Ortho Geriatrics and 
      Rehabilitation, Frailty Area, E.O. Galliera Hospital, Genoa, Italy.
FAU - Demurtas, Jacopo
AU  - Demurtas J
AD  - Primary Care Department, Azienda USL Toscana Sud Est, Grosseto, Italy.
AD  - Clinical and Experimental Medicine PhD Program, University of Modena and Reggio 
      Emilia, Modena, Italy.
FAU - Thompson, Trevor
AU  - Thompson T
AD  - Faculty of Health, Social Care and Education, Anglia Ruskin University, 
      Chelmsford, UK.
FAU - Solmi, Marco
AU  - Solmi M
AD  - Department of Neuroscience, University of Padova, Padua, Italy.
FAU - Pesolillo, Gabriella
AU  - Pesolillo G
AD  - Primary Care Service, ASL 02, Chieti, Italy.
FAU - Celotto, Stefano
AU  - Celotto S
AD  - Primary Care Department, Alto Friuli-Collinare-Medio Friuli, Udine, Italy.
FAU - Barnini, Tommaso
AU  - Barnini T
AD  - Primary Care Service, AUSL Toscana Centro, Florence, Italy.
FAU - Stubbs, Brendon
AU  - Stubbs B
AD  - Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark 
      Hill, London, UK.
AD  - Department of Psychological Medicine, Institute of Psychiatry, Psychology and 
      Neuroscience, King's College London, De Crespigny Park, London, UK.
FAU - Maggi, Stefania
AU  - Maggi S
AD  - National Research Council, Neuroscience Institute, Aging Branch, Padua, Italy.
FAU - Pilotto, Alberto
AU  - Pilotto A
AD  - Geriatrics Unit, Department of Geriatric Care, Ortho Geriatrics and 
      Rehabilitation, Frailty Area, E.O. Galliera Hospital, Genoa, Italy.
FAU - Onder, Graziano
AU  - Onder G
AD  - Fondazione Policlinico Universitario A. Gemelli, IRCCS and Università Cattolica 
      del Sacro Cuore, Rome, Italy.
FAU - Theodoratou, Evropi
AU  - Theodoratou E
AD  - Centre for Global Health Research, Usher Institute of Population Health Sciences 
      and Informatics, University of Edinburgh, Edinburgh, UK.
AD  - Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, 
      University of Edinburgh, Edinburgh, UK.
FAU - Vaona, Alberto
AU  - Vaona A
AD  - Primary Care Department, Azienda ULSS20 Verona, Verona, Italy.
FAU - Firth, Joseph
AU  - Firth J
AD  - NICM Health Research Institute, University of Western Sydney, Penrith, Australia.
AD  - Division of Psychology and Mental Health, University of Manchester, Manchester, 
      UK.
FAU - Smith, Lee
AU  - Smith L
AUID- ORCID: 0000-0003-0890-7566
AD  - The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, 
      Cambridge, UK.
FAU - Koyanagi, Ai
AU  - Koyanagi A
AD  - Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud 
      Mental, CIBERSAM, Madrid, Spain.
AD  - Research and Development Unit, Parc Sanitari Sant Joan de Déu, Universitat de 
      Barcelona, Barcelona, Spain.
FAU - Ioannidis, John P A
AU  - Ioannidis JPA
AD  - Stanford Prevention Research Center, Department of Medicine, Stanford University 
      Medical School, Stanford, California, USA.
AD  - Department of Health Research and Policy, Stanford University School of Medicine, 
      Stanford, California, USA.
AD  - Department of Statistics, Stanford University School of Humanities and Sciences, 
      Stanford, California, USA.
AD  - Department of Biomedical Data Science, Stanford University School of Medicine, 
      Stanford, California, USA.
FAU - Tzoulaki, Ioanna
AU  - Tzoulaki I
AD  - Centre for Global Health Research, Usher Institute of Population Health Sciences 
      and Informatics, University of Edinburgh, Edinburgh, UK.
AD  - MRC-PHE Centre for Environment, School of Public Health, Imperial College London, 
      UK.
LA  - eng
GR  - 22804/CRUK_/Cancer Research UK/United Kingdom
GR  - ICA-CL-2017-03-001/DH_/Department of Health/United Kingdom
GR  - C31250/A22804/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200602
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage/therapeutic use
MH  - Gastrointestinal Hemorrhage/chemically induced/epidemiology/prevention & control
MH  - Humans
MH  - Risk Assessment
PMC - PMC7373714
OTO - NOTNLM
OT  - aspirin
OT  - cancer
OT  - cardiovascular disease
OT  - meta-analysis
OT  - umbrella review
COIS- Dr Demurtas received an honorary consultancy from Bayer; Dr Stubbs is supported 
      by Health Education England and the National Institute for Health Research 
      HEE/NIHR ICA Programme Clinical Lectureship (ICA‐CL‐2017‐03‐001), and is part 
      supported by the National Institute for Health Research (NIHR) Collaboration for 
      Leadership in Applied Health Research and Care South London at King's College 
      Hospital NHS Foundation Trust. The views expressed in this publication are those 
      of the author(s) and not necessarily those of the NHS, the National Institute for 
      Health Research or the Department of Health and Social Care; Dr Firth is 
      supported by a Blackmores Institute Fellowship; Dr Koyanagi's work was supported 
      by the Miguel Servet contract financed by the CP13/00150 and PI15/00862 projects, 
      integrated into the National R+D+I and funded by the ISCIII – General Branch 
      Evaluation and Promotion of Health Research – and the European Regional 
      Development Fund (ERDF‐FEDER); Dr Theodoratou is supported by a Cancer Research 
      UK (CRUK) Career Development Fellowship (C31250/A22804). The other authors don't 
      have any financial arrangements, organizational affiliations or other 
      relationships that might give rise to any conflict of interest regarding the 
      subject matter of the manuscript submitted.
EDAT- 2020/06/04 06:00
MHDA- 2021/07/03 06:00
CRDT- 2020/06/04 06:00
PHST- 2019/10/30 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/07/03 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - BCP14310 [pii]
AID - 10.1111/bcp.14310 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2020 Aug;86(8):1465-1475. doi: 10.1111/bcp.14310. Epub 2020 
      Jun 2.

PMID- 10741808
OWN - NLM
STAT- MEDLINE
DCOM- 20000707
LR  - 20181130
IS  - 0391-3988 (Print)
IS  - 0391-3988 (Linking)
VI  - 23
IP  - 2
DP  - 2000 Feb
TI  - Blood profile during and after hemoglobin substitute administration.
PG  - 119-24
AB  - The in vivo effects of Diaspirin Crosslinked Hemoglobin (DCLHb, Baxter Healthcare 
      Corp.) on hematology and biochemistry are unknown. This study includes 6 calves 
      (71.2+/-1.3 kg). In each animal a total of 2 litres of blood was exchanged for 
      the same amount of hydroxylethyl starch (Haes, Fresenius) (n=3) or DCLHb (n=3), 
      which is equivalent to 28cc/kg of blood substitute, over a period of 5 hours. The 
      animals were allowed to survive 7 days. Blood samples were taken hourly during 
      the perfusion protocol, at postoperative day (POD) 1, 2 and 7. ANOVA test was 
      used for repeated measurements. Blood cell profiles were similar in both groups. 
      Peak methemoglobinemia was 4.2% in the DCLHb group. Osmolarity was significantly 
      higher in the DCLHb group with the greatest difference at POD 1 and 2. Postmortem 
      analysis of the major organs did not show any sign of hemoglobin deposit in the 
      DCLHb group. In the given setup DCLHb can be administered in a large quantity 
      with good hematological tolerance and without any deposits in major organs. A 
      prolonged plasma expander effect was observed.
FAU - Mueller, X M
AU  - Mueller XM
AD  - Clinic for Cardiovascular Surgery, Centre Hospitalier Universitaire Vaudois, 
      Lausanne, Switzerland.
FAU - Tevaearai, H T
AU  - Tevaearai HT
FAU - Gardaz, J P
AU  - Gardaz JP
FAU - Jegger, D
AU  - Jegger D
FAU - von Segesser, L K
AU  - von Segesser LK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Artif Organs
JT  - The International journal of artificial organs
JID - 7802649
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Cell Count
MH  - Blood Substitutes/*pharmacology
MH  - *Cardiopulmonary Bypass
MH  - Cattle
MH  - Hemoglobins/*pharmacology
MH  - Methemoglobinemia/etiology
MH  - Osmolar Concentration
EDAT- 2000/03/31 09:00
MHDA- 2000/07/15 11:00
CRDT- 2000/03/31 09:00
PHST- 2000/03/31 09:00 [pubmed]
PHST- 2000/07/15 11:00 [medline]
PHST- 2000/03/31 09:00 [entrez]
PST - ppublish
SO  - Int J Artif Organs. 2000 Feb;23(2):119-24.

PMID- 2107595
OWN - NLM
STAT- MEDLINE
DCOM- 19900425
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 57
IP  - 3
DP  - 1990 Feb 1
TI  - Differential inhibition of thromboxane A2 and prostacyclin synthesis by low dose 
      acetylsalicylic acid in atherosclerotic patients.
PG  - 437-44
AB  - Differential inhibition of thromboxane A2 (TxA2) and prostacyclin (PGI2) 
      biosynthesis has an antithrombotic potential, since it may change the TxA2/PGI2 
      formation ratio in a favourable direction. Very low doses of acetylsalicylic acid 
      (ASA) have been demonstrated to elicit differential inhibition of TxA2 and PGI2 
      formation in healthy subjects; whether a similar effect can be obtained in 
      patients with atherosclerosis is still an open question. We addressed this by 
      analyzing the urinary excretion of the 2,3-dinor-metabolites of TxA2 (Tx-M) and 
      PGI2 (PGI-M) in 10 patients with severe atherosclerosis during 10 consecutive 
      days. The first three days were a basal period, under which no treatment was 
      given. During the subsequent seven days a daily 50 mg oral dose of ASA was 
      administered. In the basal state urinary Tx-M did not differ from that of PGI-M, 
      the median excretion rates of the two eicosanoid metabolites being 526 (range 
      68-1490) and 562 (range 93-1970) pg/mg creatinine, respectively. During ASA 
      treatment urinary Tx-M fell to a lower (p less than 0.001) level than PGI-M. 
      Thus, during the last 5 days of ASA treatment the median excretion of Tx-M was 
      depressed (p less than 0.001) to 148 (range 48-428) pg/mg creatinine, while that 
      of PGI-M was decreased (p less than 0.01) to 313 (range 42-2658) pg/mg 
      creatinine. These data indicate that a daily 50 mg dose of ASA inhibits 
      cardiovascular formation of eicosanoids in patients with severe atherosclerosis 
      and increased platelet TxA2 formation. Furthermore, this dose of ASA inhibits the 
      formation of TxA2 more than that of PGI2.
FAU - Carlsson, I
AU  - Carlsson I
AD  - Geriatric Clinic, Boo Hospital, Nacka, Sweden.
FAU - Benthin, G
AU  - Benthin G
FAU - Petersson, A S
AU  - Petersson AS
FAU - Wennmalm, A
AU  - Wennmalm A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Arteriosclerosis/*urine
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Cyclooxygenase Inhibitors
MH  - Epoprostenol/*biosynthesis
MH  - Female
MH  - Humans
MH  - Male
MH  - Thromboxane A2/*biosynthesis
EDAT- 1990/02/01 00:00
MHDA- 1990/02/01 00:01
CRDT- 1990/02/01 00:00
PHST- 1990/02/01 00:00 [pubmed]
PHST- 1990/02/01 00:01 [medline]
PHST- 1990/02/01 00:00 [entrez]
AID - 10.1016/0049-3848(90)90259-f [doi]
PST - ppublish
SO  - Thromb Res. 1990 Feb 1;57(3):437-44. doi: 10.1016/0049-3848(90)90259-f.

PMID- 1750820
OWN - NLM
STAT- MEDLINE
DCOM- 19920123
LR  - 20190718
IS  - 0004-8682 (Print)
IS  - 0004-8682 (Linking)
VI  - 61
IP  - 11
DP  - 1991 Nov
TI  - Inhibition of human endothelial prostacyclin synthesis by different aspirin 
      formulations.
PG  - 849-52
AB  - The availability of different formulations of low-dose aspirin for use as 
      anti-thrombotic agents merits a comparison of their effects on vessel wall 
      biochemistry. We compared the effect of ingestion of an enteric-coated 
      slow-release aspirin (Astrix) with that of soluble aspirin (Cardiprin) on human 
      endothelial prostacyclin synthesis. Patients undergoing varicose vein surgery (10 
      per group) ingested 100 mg aspirin per day as Astrix or Cardiprin for 7 days 
      prior to surgery. A control group ingested no aspirin. Prostacyclin synthesis by 
      the endothelial surface of the great saphenous vein was determined in vitro. Both 
      aspirin formulations caused significant inhibition of endothelial prostacyclin 
      synthesis compared with the control group. Using the median values, the 
      enteric-coated slow-release aspirin caused 76% inhibition, whereas the soluble 
      formulation caused significantly greater inhibition (95%). If differential 
      inhibition of platelet thromboxane synthesis with 'sparing' of endothelial 
      prostacyclin synthesis is necessary for an optimum anti-thrombotic effect of 
      aspirin, the results suggest that a lower dose of soluble aspirin than 
      enteric-coated slow-release aspirin may be preferred.
FAU - James, M J
AU  - James MJ
AD  - Rheumatology Unit, Royal Adelaide Hospital, South Australia.
FAU - Foreman, R K
AU  - Foreman RK
FAU - Burnett, J R
AU  - Burnett JR
FAU - Cleland, L G
AU  - Cleland LG
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust N Z J Surg
JT  - The Australian and New Zealand journal of surgery
JID - 0373115
RN  - 0 (Tablets, Enteric-Coated)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Endothelium, Vascular/drug effects/*metabolism
MH  - Epoprostenol/*biosynthesis
MH  - Humans
MH  - Solubility
MH  - Tablets, Enteric-Coated
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
AID - 10.1111/j.1445-2197.1991.tb00170.x [doi]
PST - ppublish
SO  - Aust N Z J Surg. 1991 Nov;61(11):849-52. doi: 10.1111/j.1445-2197.1991.tb00170.x.

PMID- 36971054
OWN - NLM
STAT- MEDLINE
DCOM- 20230518
LR  - 20230624
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 63 Suppl 3
DP  - 2023 May
TI  - Hemostatics in patients with inhibited coagulation-A viscoelastic in-vitro 
      analysis.
PG  - S159-S167
LID - 10.1111/trf.17333 [doi]
AB  - BACKGROUND: The military has used topical hemostatic agents to successfully treat 
      life-threatening external bleeding for years. In contrast to the military 
      environment, the general population are increasingly prescribed anticoagulants. 
      There are only few comparative evaluations of topical hemostatic agents with 
      anticoagulated human blood. It is important to understand the impact of these 
      agents on those who take anticoagulants. STUDY DESIGN AND METHODS: Citrated blood 
      of patients treated with enoxaparin, heparin, and acetylsalicylic acid, apixaban 
      or phenprocoumon was incubated with different hemostatic agents (QuikClot Gauze, 
      Celox Granules, Celox Gauze, Chito SAM 100, WoundClot Trauma Gauze, QuikClot 
      Gauze Moulage Trainer and Kerlix) and rotational thromboelastometry was performed 
      with non-activated thromboelastometry (NATEM reagent). RESULTS: All tested agents 
      improved the onset of coagulation in all anticoagulants, mostly to a significant 
      degree. Most significant improvements were produced by QuikClot Gauze and 
      QuikClot Gauze Moulage Trainer, followed by the tested chitosans (Celox Granules, 
      Celox Gauze, Chito SAM 100). Of the anticoagulant groups, the most significant 
      improvements were seen in enoxaparin. This was followed in order by apixaban, 
      heparin, and acetylsalicylic acid, and phenprocoumon. DISCUSSION: All the 
      hemostatic agents tested were able to activate the clotting cascade earlier and 
      initiate faster clot formation in anticoagulated blood. A definitive head-to-head 
      comparison is not feasible, because of the limitations of an in-vitro analysis. 
      However, the sometimes-presented hypothesis that kaolin-based hemostatic agents 
      are ineffective in anticoagulated blood is inaccurate according to our data. 
      Hemostasis with hemostatic agents appears most challenging with phenprocoumon.
CI  - © 2023 AABB.
FAU - Lechner, Raimund
AU  - Lechner R
AUID- ORCID: 0000-0002-5961-335X
AD  - Bundeswehr Hospital Ulm, Department of Anesthesiology, Intensive Care Medicine, 
      Emergency Medicine, and Pain Therapy, Ulm, Germany.
FAU - Hanke, Katharina
AU  - Hanke K
AD  - Bundeswehr Hospital Ulm, Department of Anesthesiology, Intensive Care Medicine, 
      Emergency Medicine, and Pain Therapy, Ulm, Germany.
FAU - Schmid, Anna
AU  - Schmid A
AD  - Bundeswehr Hospital Ulm, Department of Anesthesiology, Intensive Care Medicine, 
      Emergency Medicine, and Pain Therapy, Ulm, Germany.
FAU - Mayer, Benjamin
AU  - Mayer B
AUID- ORCID: 0000-0003-1042-9006
AD  - Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
FAU - Helm, Matthias
AU  - Helm M
AD  - Bundeswehr Hospital Ulm, Department of Anesthesiology, Intensive Care Medicine, 
      Emergency Medicine, and Pain Therapy, Ulm, Germany.
FAU - Kulla, Martin
AU  - Kulla M
AUID- ORCID: 0000-0001-7454-0876
AD  - Bundeswehr Hospital Ulm, Department of Anesthesiology, Intensive Care Medicine, 
      Emergency Medicine, and Pain Therapy, Ulm, Germany.
FAU - Hossfeld, Björn
AU  - Hossfeld B
AUID- ORCID: 0000-0002-5048-2533
AD  - Bundeswehr Hospital Ulm, Department of Anesthesiology, Intensive Care Medicine, 
      Emergency Medicine, and Pain Therapy, Ulm, Germany.
LA  - eng
PT  - Journal Article
DEP - 20230426
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Hemostatics)
RN  - Q08SIO485D (Phenprocoumon)
RN  - 0 (Enoxaparin)
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Hemostatics/pharmacology
MH  - Phenprocoumon
MH  - Enoxaparin/pharmacology
MH  - Anticoagulants/pharmacology/therapeutic use
MH  - Heparin/pharmacology
MH  - Aspirin/pharmacology/therapeutic use
OTO - NOTNLM
OT  - NATEM reagent
OT  - anticoagulation
OT  - bleeding control
OT  - hemostatic agent
OT  - viscoelastic testing
EDAT- 2023/03/28 06:00
MHDA- 2023/05/18 06:42
CRDT- 2023/03/27 05:15
PHST- 2023/02/16 00:00 [revised]
PHST- 2022/11/17 00:00 [received]
PHST- 2023/02/16 00:00 [accepted]
PHST- 2023/05/18 06:42 [medline]
PHST- 2023/03/28 06:00 [pubmed]
PHST- 2023/03/27 05:15 [entrez]
AID - 10.1111/trf.17333 [doi]
PST - ppublish
SO  - Transfusion. 2023 May;63 Suppl 3:S159-S167. doi: 10.1111/trf.17333. Epub 2023 Apr 
      26.

PMID- 2191636
OWN - NLM
STAT- MEDLINE
DCOM- 19900718
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 150
IP  - 6
DP  - 1990 Jun
TI  - Does multiple-dose charcoal therapy enhance salicylate excretion?
PG  - 1281-3
AB  - Multiple-dose charcoal therapy has been shown to increase the excretion of some 
      drugs. This study assesses the effects of this intervention on salicylate 
      excretion in the postabsorptive phase. Ten human volunteers participated in this 
      randomized, controlled, crossover, two-limbed protocol. On two occasions each 
      volunteer ingested 2880 mg of aspirin. During the experimental limb, 25 g of 
      activated charcoal was ingested at 4, 6, 8, and 10 hours after drug ingestion. 
      Pharmacokinetic data were derived from serial serum salicylate concentrations, 
      and urinary salicylate excretion was quantified. Treatment effects were 9% and 
      18%, respectively. Although both are significant, they are clinically modest, 
      making multiple-dose charcoal therapy of questionable value for acute salicylate 
      poisoning. Controlled data demonstrating the clinical efficacy of this therapy 
      are required to validate it as an intervention for this condition.
FAU - Kirshenbaum, L A
AU  - Kirshenbaum LA
AD  - Department of Pharmacology, University of Manitoba, Winnipeg, Canada.
FAU - Mathews, S C
AU  - Mathews SC
FAU - Sitar, D S
AU  - Sitar DS
FAU - Tenenbein, M
AU  - Tenenbein M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*urine
MH  - Charcoal/*administration & dosage
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Reference Values
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1990 Jun;150(6):1281-3.

PMID- 785986
OWN - NLM
STAT- MEDLINE
DCOM- 19761101
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 92
IP  - 1
DP  - 1976 Jul
TI  - Aspirin therapy in angina pectoris: effects on platelet aggregation, exercise 
      tolerance, and electrocardiographic manifestations of ischemia.
PG  - 3-10
AB  - If altered platelet function contributes to poorly perfused zones of myocardium 
      in patients with angina pectoris, then specific antiplatelet therapy might 
      improve cardiovascular function and exercise performance. Exercise tolerance on a 
      bicycle ergometer, heart rate-blood pressure product, and ischemic ECG changes at 
      exercise end-point were compared before and during oral aspirin therapy (2.4 Gm. 
      per day for 2 weeks) in 11 normal subjecs and in 11 patients with stable angina 
      pectoris. Platelet aggregation threshold in response to ADP and epinephrine was 
      measured. Untreated patients had increased platelet aggregability when compared 
      to normal subjects...
FAU - Frishman, W H
AU  - Frishman WH
FAU - Christodoulou, J
AU  - Christodoulou J
FAU - Weksler, B
AU  - Weksler B
FAU - Smithen, C
AU  - Smithen C
FAU - Killip, T
AU  - Killip T
FAU - Scheidt, S
AU  - Scheidt S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Angina Pectoris/*drug therapy
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/drug therapy
MH  - Female
MH  - Heart Function Tests
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Exertion
MH  - Platelet Aggregation/*drug effects
EDAT- 1976/07/01 00:00
MHDA- 1976/07/01 00:01
CRDT- 1976/07/01 00:00
PHST- 1976/07/01 00:00 [pubmed]
PHST- 1976/07/01 00:01 [medline]
PHST- 1976/07/01 00:00 [entrez]
AID - S0002-8703(76)80397-3 [pii]
AID - 10.1016/s0002-8703(76)80397-3 [doi]
PST - ppublish
SO  - Am Heart J. 1976 Jul;92(1):3-10. doi: 10.1016/s0002-8703(76)80397-3.

PMID- 313448
OWN - NLM
STAT- MEDLINE
DCOM- 19790917
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 6
IP  - 2
DP  - 1979 Mar-Apr
TI  - Salicylate-induced gastrointestinal bleeding: comparison between soluble 
      buffered, enteric-coated, and intravenous administration.
PG  - 210-8
AB  - Serum salicylate levels and blood loss in stools were compared in 94 patients 
      after intake of various forms of acetylsalicylate. Four different oral soluble 
      forms, an enteric-coated variety and an intravenous form were evaluated. Analysis 
      of the results of blood loss measurement in stools showed that salicylate users 
      could be divided into "bleeders" and "non-bleeders". Administration of 
      enteric-coated and intravenous forms of salicylates showed less blood less than 
      ingestion of soluble forms. Only after administration of enteric-coated or 
      intravenous forms of salicylates was a relationship between serum salicylate 
      level and blood loss in stools observed in "bleeders". This suggests a similar 
      mode of action of both these preparations on gastric mucosa. We conclude that 
      enteric-coated forms of salicylates cause gastrointestinal bleeding by a systemic 
      action on gastric mucosa.
FAU - Mielants, H
AU  - Mielants H
FAU - Verbruggen, G
AU  - Verbruggen G
FAU - Schelstraete, K
AU  - Schelstraete K
FAU - Veys, E M
AU  - Veys EM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Buffers)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/blood
MH  - Buffers
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Tablets, Enteric-Coated
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1979 Mar-Apr;6(2):210-8.

PMID- 8185620
OWN - NLM
STAT- MEDLINE
DCOM- 19940616
LR  - 20190612
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 200
IP  - 3
DP  - 1994 May 16
TI  - Stability of a potential blood substitute, HbXL99 alpha, under high pressure.
PG  - 1635-40
AB  - One important criteria for a plasma circulating hemoglobin blood substitute is 
      resistance to subunit dissociation. For this reason, cross-linked hemoglobins 
      (with low oxygen affinities) are being specifically designed to serve as 
      potential blood substitutes. An example is HbXL99 alpha, cross-linked between the 
      alpha-subunits [PNAS (1987) 84:7280]. In the study presented here, the effects of 
      up to 2 kilobars of pressure on the intrinsic fluorescence of HbXL99 alpha, HbA, 
      and myoglobin were compared. Hemoglobin solutions were studied between 0.01-0.1g% 
      in potassium phosphate or Hepes buffers, pH 7.4. Results show HbA exhibits a 
      decrease in fluorescence intensity as a function of pressure. In contrast, HbXL99 
      alpha as well myoglobin (a monomer) show essentially no significant intrinsic 
      fluorescence changes as a function of pressure. These results suggest that HbXL99 
      alpha is stable as a tetramer up to approximately 2 kilobars of pressure. In 
      addition, high pressure intrinsic fluorescence studies provide a suitable 
      technique for determining the subunit stability of hemoglobins.
FAU - Hirsch, R E
AU  - Hirsch RE
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461.
FAU - Friedman, J M
AU  - Friedman JM
FAU - Harrington, J R
AU  - Harrington JR
FAU - Scarlata, S F
AU  - Scarlata SF
FAU - Harrington, J P
AU  - Harrington JP
LA  - eng
GR  - GM 44343/GM/NIGMS NIH HHS/United States
GR  - HL 38655/HL/NHLBI NIH HHS/United States
GR  - R01 DK41253/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Hemoglobins)
RN  - 0 (Myoglobin)
RN  - 0 (hemoglobin XL99alpha)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Biochem Biophys Res Commun 1994 Jul 15;202(1):645
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry
MH  - Hemoglobin A/chemistry
MH  - Hemoglobins/*chemistry
MH  - Humans
MH  - Hydrostatic Pressure
MH  - In Vitro Techniques
MH  - Myoglobin/chemistry
MH  - Spectrometry, Fluorescence
MH  - Whales
EDAT- 1994/05/16 00:00
MHDA- 1994/05/16 00:01
CRDT- 1994/05/16 00:00
PHST- 1994/05/16 00:00 [pubmed]
PHST- 1994/05/16 00:01 [medline]
PHST- 1994/05/16 00:00 [entrez]
AID - S0006291X84716391 [pii]
AID - 10.1006/bbrc.1994.1639 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1994 May 16;200(3):1635-40. doi: 
      10.1006/bbrc.1994.1639.

PMID- 35030453
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220401
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 16
IP  - 1
DP  - 2022 Jan
TI  - Low-doses aspirin in the primary prevention of cardiovascular disease in patients 
      with diabetes: Meta-analysis stratified by baseline cardiovascular risk.
PG  - 102391
LID - S1871-4021(22)00005-4 [pii]
LID - 10.1016/j.dsx.2022.102391 [doi]
AB  - BACKGROUND AND AIM: The aim of this meta-analysis was to analyze the risks and 
      benefits of low-dose aspirin in patients with T2D without cardiovascular 
      conditions according to the baseline cardiovascular risk. METHODS: We performed a 
      meta-analysis including randomized clinical trials that evaluated the use of 
      low-dose aspirin (75-100 mg/day) versus placebo/usual care in patients with T2D. 
      Studies were classified as low, moderate and high risk based on the number of 
      events in the placebo/control arms or by cardiovascular risk score when reported. 
      The incidence of MACE, cardiovascular mortality and bleeding were evaluated. 
      RESULTS: Ten eligible trials (34069 patients) were considered eligible for the 
      analyses. According to the stratified analysis, low-dose aspirin use was 
      associated with reduced risk for MACE in the moderate/high-risk group (OR: 0.88; 
      95% CI, 0.80-0.97; I(2) = 0%) but not in the low-risk group (OR: 0.89; 95% CI, 
      0.77-1.01; I(2) = 0%). Likewise, low-dose aspirin use was associated with more 
      bleeding in the low-risk group, showing a non-significant trend in the 
      moderate/high-risk group. There was no reduction in cardiovascular mortality in 
      either group. Beyond the different findings in each stratum, the differences 
      between the subgroups were not statistically significant. CONCLUSION: This study 
      showed that low-dose aspirin in patients with T2D reduces MACE and increases 
      bleeding. Based on the within-subgroups results, the baseline cardiovascular risk 
      does not modify the effect of aspirin therapy. However, few studies were included 
      and the comparison between subgroups showed a trend in favor to the highest risk 
      group, these results should be confirmed in future studies.
CI  - Copyright © 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.
FAU - Masson, Walter
AU  - Masson W
AD  - Council of Epidemiology and Cardiovascular Prevention, Argentine Society of 
      Cardiology, Azcuenaga 980, Buenos Aires, Argentina; Cardiology Department, 
      Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. Electronic address: 
      walter.masson@hospitalitaliano.org.ar.
FAU - Barbagelata, Leandro
AU  - Barbagelata L
AD  - Cardiology Department, Hospital Italiano de Buenos Aires, Buenos Aires, 
      Argentina.
FAU - Lavalle-Cobo, Augusto
AU  - Lavalle-Cobo A
AD  - Council of Epidemiology and Cardiovascular Prevention, Argentine Society of 
      Cardiology, Azcuenaga 980, Buenos Aires, Argentina; Cardiology Department, 
      Sanatorio Finochietto, Av. Córdoba, 2678, Buenos Aires, Argentina.
FAU - Lobo, Martín
AU  - Lobo M
AD  - Council of Epidemiology and Cardiovascular Prevention, Argentine Society of 
      Cardiology, Azcuenaga 980, Buenos Aires, Argentina; Cardiology Department, 
      Hospital Militar Campo de Mayo, Buenos Aires, Argentina.
FAU - Masson, Gerardo
AU  - Masson G
AD  - Council of Epidemiology and Cardiovascular Prevention, Argentine Society of 
      Cardiology, Azcuenaga 980, Buenos Aires, Argentina; Cardiology Department, 
      Instituto Cardiovascular San Isidro-Sanatorio Las Lomas, Von Wernicke, 3031, San 
      Isidro, Argentina.
FAU - Nogueira, Juan P
AU  - Nogueira JP
AD  - Centro de Investigación en Endocrinología, Nutrición y Metabolismo (CIENM), 
      Facultad de Ciencias de la Salud, Universidad Nacional de Formosa, Argentina.
FAU - Vergès, Bruno
AU  - Vergès B
AD  - Service Endocrinologie, Diabétologie, et Maladies Métaboliques, Centre 
      Hospitalier Universitaire (CHU), Institut National de la Santé et de la Recherche 
      Médicale (INSERM) Lipides, Nutrition, Cancer (LNC)-Unité Mixte de Recherche (UMR) 
      1231, University of Burgundy, 21000, Dijon, France.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220108
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - *Cardiovascular Diseases/epidemiology/etiology/prevention & control
MH  - *Diabetes Mellitus/drug therapy
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - Primary Prevention/methods
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular risk
OT  - Major cardiovascular events
OT  - Type 2 diabetes
COIS- Declaration of competing interest None declared.
EDAT- 2022/01/15 06:00
MHDA- 2022/04/01 06:00
CRDT- 2022/01/14 20:14
PHST- 2021/11/10 00:00 [received]
PHST- 2021/12/30 00:00 [revised]
PHST- 2022/01/06 00:00 [accepted]
PHST- 2022/01/15 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2022/01/14 20:14 [entrez]
AID - S1871-4021(22)00005-4 [pii]
AID - 10.1016/j.dsx.2022.102391 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2022 Jan;16(1):102391. doi: 10.1016/j.dsx.2022.102391. Epub 
      2022 Jan 8.

PMID- 3794991
OWN - NLM
STAT- MEDLINE
DCOM- 19870219
LR  - 20190912
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 9
IP  - 9
DP  - 1986 Sep
TI  - Effect of concanavalin A on the aspirin concentration and distribution in the 
      brain and plasma of rats.
PG  - 704-14
AB  - The effects of concanavalin A (Con A) on plasma and brain concentration of 
      aspirin (Asp) were investigated in rats. When Asp was administered in rats 
      treated with Con A, the plasma and brain concentration of Asp and its metabolites 
      (salicylic acid (SA), salicyluric acid (SU) and gentisic acid (GA)) were 
      increased. Distribution of Asp and its metabolites into the hippocampus, striatum 
      and hypothalamus were increased by treatment with Con A. Asp esterase activities 
      in the small intestinal mucosa, liver and brain were increased by pretreatment 
      with Con A, but these enzyme activities were decreased by a high dose of Con A. 
      The inhibitory effect of Asp, SA, SU and GA on the writhing induced by acetic 
      acid in Con A-pretreated mice was stronger than that in the control. A lowering 
      of rectal temperature, after the administration of Asp, was stronger in Con 
      A-treated rats than in control rats. These results suggested that Con A 
      facilitated the absorption of Asp and enhanced the transfer of SA into the brain, 
      and increased Asp esterase activities in various tissues.
FAU - Miyagi, N
AU  - Miyagi N
FAU - Kondoh, H
AU  - Kondoh H
FAU - Sakurai, E
AU  - Sakurai E
FAU - Hikichi, N
AU  - Hikichi N
FAU - Niwa, H
AU  - Niwa H
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Analgesics)
RN  - 11028-71-0 (Concanavalin A)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.- (acetylsalicylic acid hydrolase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics
MH  - Animals
MH  - Aspirin/*metabolism/pharmacology
MH  - Body Temperature/drug effects
MH  - Brain/drug effects/*metabolism
MH  - Carboxylic Ester Hydrolases/metabolism
MH  - Concanavalin A/*pharmacology
MH  - Drug Synergism
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Male
MH  - Rats
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
AID - 10.1248/bpb1978.9.704 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1986 Sep;9(9):704-14. doi: 10.1248/bpb1978.9.704.

PMID- 2252288
OWN - NLM
STAT- MEDLINE
DCOM- 19910117
LR  - 20131121
IS  - 0302-4342 (Print)
IS  - 0302-4342 (Linking)
VI  - 33
IP  - 1
DP  - 1990 Jul
TI  - [Kawasaki disease. Report of two cases].
PG  - 54-7
AB  - We present two reports of Kawasaki's disease. The first a five months old male, 
      which was diagnosed through autopsy developed cardiovascular complications 
      (myocarditis, coronary aneurysms, myocardial infarction) which led to death. The 
      second one a two years and ten months old female, which was diagnosed at the 
      fifth day of illness, was treated with aspirin at rate of 100 mg/kg/day and 
      healed without consequences. It is interesting to emphasize the different 
      development as a function of age, sex and precocity of diagnosis.
FAU - Sánchez Lorente, A
AU  - Sánchez Lorente A
AD  - Servicio de Pediatría, Hospital Doctor Peset, Valencia.
FAU - Sanchís Calvo, A
AU  - Sanchís Calvo A
FAU - Ferrer Giménez, R
AU  - Ferrer Giménez R
FAU - Marquina Vila, A
AU  - Marquina Vila A
LA  - spa
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Enfermedad de Kawasaki. Presentación de dos casos.
PL  - Spain
TA  - An Esp Pediatr
JT  - Anales espanoles de pediatria
JID - 0420463
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Child, Preschool
MH  - Female
MH  - Heart Diseases/etiology
MH  - Humans
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*complications/drug therapy
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
PST - ppublish
SO  - An Esp Pediatr. 1990 Jul;33(1):54-7.

PMID- 15306525
OWN - NLM
STAT- MEDLINE
DCOM- 20040921
LR  - 20191210
IS  - 1364-503X (Print)
IS  - 1364-503X (Linking)
VI  - 362
IP  - 1815
DP  - 2004 Feb 15
TI  - Applications of terahertz spectroscopy to pharmaceutical sciences.
PG  - 351-63; discussion 363-4
AB  - The application of terahertz pulsed spectroscopy within the US Food and Drug 
      Administration's (FDA's) recent process analytical technology (PAT) initiative is 
      considered. As a case study the potency levels in paracetamol (4-acetamidophenol) 
      and aspirin (acetylsalicylic acid) test tablets have been recovered from the 
      terahertz absorption spectra using a multivariate partial-least-squares (PLS) 
      calibration model. Root-mean-square errors of cross-validation (RMSECVs) of 2.85% 
      and 3.90% were obtained for paracetamol and aspirin, respectively. Information 
      about other excipients can also be obtained; for example, using the strong 
      lactose absorption lines in the tablets, RMSECVs of 3.65% and 4.30% could be 
      recovered from the paracetamol and aspirin samples, respectively. As active 
      ingredients may also change their solid-state form during formulation processing 
      or storage and as this can adversely affect the final dosage performance, 
      monitoring of pharmaceutical ingredients is essential for a 'right-first-time' 
      philosophy within the industry. Terahertz pulse spectroscopy is a high-throughput 
      technique with many areas of potential exploitation in the pharmaceutical 
      industry; these issues are discussed in this paper.
FAU - Taday, Philip F
AU  - Taday PF
AD  - TeraView Limited, 302/304 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, 
      UK. philip.taday@teraview.com
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Validation Study
PL  - England
TA  - Philos Trans A Math Phys Eng Sci
JT  - Philosophical transactions. Series A, Mathematical, physical, and engineering 
      sciences
JID - 101133385
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis/chemistry/standards
MH  - *Algorithms
MH  - Aspirin/*analysis/chemistry/standards
MH  - Chemistry, Pharmaceutical/instrumentation/*methods
MH  - Drug Contamination/*prevention & control
MH  - Infrared Rays
MH  - Microwaves
MH  - Quality Assurance, Health Care/methods
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Spectrophotometry, Infrared/instrumentation/*methods
EDAT- 2004/08/13 05:00
MHDA- 2004/09/24 05:00
CRDT- 2004/08/13 05:00
PHST- 2004/08/13 05:00 [pubmed]
PHST- 2004/09/24 05:00 [medline]
PHST- 2004/08/13 05:00 [entrez]
AID - 31MLVVN0CEAU3Y14 [pii]
AID - 10.1098/rsta.2003.1321 [doi]
PST - ppublish
SO  - Philos Trans A Math Phys Eng Sci. 2004 Feb 15;362(1815):351-63; discussion 363-4. 
      doi: 10.1098/rsta.2003.1321.

PMID- 7076011
OWN - NLM
STAT- MEDLINE
DCOM- 19820719
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 23
IP  - 4
DP  - 1982 Apr
TI  - Aspirin, paracetamol, and haematemesis and melaena.
PG  - 340-4
AB  - Aspirin and paracetamol consumption have been compared in 346 matched pairs of 
      patients with haematemesis and melaena, and control individuals in the general 
      community. Both aspirin and paracetamol intake were more common in patients than 
      in controls, but the association for aspirin was stronger and was apparent with 
      both recent and habitual intake, whereas for paracetamol the association was not 
      detectable for habitual intake. The results for paracetamol suggests that 
      patients with bleeding take analgesic drugs in part because of symptoms 
      associated with bleeding, and such intake is not necessarily causal of bleeding. 
      Failure to control investigations to take account of this point has exaggerated 
      the possible risks of aspirin consumption.
FAU - Coggon, D
AU  - Coggon D
FAU - Langman, M J
AU  - Langman MJ
FAU - Spiegelhalter, D
AU  - Spiegelhalter D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Female
MH  - Hematemesis/*etiology
MH  - Humans
MH  - Male
MH  - Melena/*etiology
MH  - Middle Aged
MH  - Risk
PMC - PMC1419746
EDAT- 1982/04/01 00:00
MHDA- 1982/04/01 00:01
CRDT- 1982/04/01 00:00
PHST- 1982/04/01 00:00 [pubmed]
PHST- 1982/04/01 00:01 [medline]
PHST- 1982/04/01 00:00 [entrez]
AID - 10.1136/gut.23.4.340 [doi]
PST - ppublish
SO  - Gut. 1982 Apr;23(4):340-4. doi: 10.1136/gut.23.4.340.

PMID- 25918851
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181023
IS  - 0717-6384 (Electronic)
IS  - 0717-6384 (Linking)
VI  - 15
IP  - 3
DP  - 2015 Apr 9
TI  - Does aspirin reduce recurrence after completing anticoagulant treatment for an 
      idiopathic thromboembolic event?
PG  - e6118
LID - 10.5867/medwave.2015.03.6118 [doi]
AB  - Idiopathic thromboembolic disease presents a high risk of recurrence. There is 
      controversy about the effects of aspirin in reducing this risk after the 
      completion of anticoagulant treatment. Searching in Epistemonikos database, which 
      screens 30 databases, we identified four systematic reviews that together include 
      two randomized trials. We combined the evidence using meta-analysis and generated 
      a summary of findings table following the GRADE approach. We concluded that 
      aspirin administered after having completed anticoagulation reduces the risk of 
      recurrence, probably without importantly increasing the risk of hemorrhage.
FAU - Valenzuela, Andrés
AU  - Valenzuela A
AD  - Programa de Salud Basada en Evidencia, Facultad de Medicina, Pontificia 
      Universidad Católica de Chile, Santiago, Chile; Departamento de Medicina Interna, 
      Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 
      Address: Facultad de Medicina, Pontificia Universidad Católica de Chile, Lira 63, 
      Santiago Centro, Chile. Email: andresaizman@gmail.com.
FAU - Aizman, Andrés
AU  - Aizman A
AD  - Programa de Salud Basada en Evidencia, Facultad de Medicina, Pontificia 
      Universidad Católica de Chile, Santiago, Chile; Departamento de Medicina Interna, 
      Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20150409
PL  - Chile
TA  - Medwave
JT  - Medwave
JID - 101581949
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Thromboembolism/drug therapy/*prevention & control
EDAT- 2015/04/29 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/04/29 06:00
PHST- 2015/04/29 06:00 [entrez]
PHST- 2015/04/29 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - e6118 [pii]
AID - 10.5867/medwave.2015.03.6118 [doi]
PST - epublish
SO  - Medwave. 2015 Apr 9;15(3):e6118. doi: 10.5867/medwave.2015.03.6118.

PMID- 9377584
OWN - NLM
STAT- MEDLINE
DCOM- 19971110
LR  - 20131121
IS  - 0362-5664 (Print)
IS  - 0362-5664 (Linking)
VI  - 16
IP  - 6
DP  - 1993 Dec
TI  - Low- versus high-dose aspirin in prevention of ischemic stroke.
PG  - 485-500
AB  - Aspirin is the most extensively studied drug for the prevention of ischemic 
      vascular disease. Meta-analyses confirm that aspirin is effective in prevention 
      of ischemic events, including stroke. Recently, there has been considerable 
      discussion about the best dose of aspirin to prevent stroke. Several studies 
      tested aspirin in a daily dose of 975 mg or more alone or in combination with 
      another drug, most commonly dipyridamole, and noted that aspirin was effective. 
      Successively lower doses of aspirin were tested and recent studies demonstrate 
      that low doses (< 100 mg/day) are effective. Only one study, enrolling patients 
      with transient ischemic attack or minor stroke, has examined aspirin in a daily 
      dose of approximately 325 mg. Side effects of aspirin are dose related; 
      gastrointestinal bleeding and epigastric pain are less with low doses. Available 
      data cannot confirm that low doses (< 100 mg/day) of aspirin are either more or 
      less effective than larger (975 mg/day) doses. A direct comparison of the 
      usefulness of low doses (< 100 mg/day) or large doses (approximately 1,000 
      mg/day) in patients at high risk of stroke is needed. Until the results of such a 
      study are known, the better safety profile of low doses favors aspirin in a daily 
      dose of 100 mg or less.
FAU - Adams, H P Jr
AU  - Adams HP Jr
AD  - Department of Neurology, University of Iowa College of Medicine, Iowa City, USA.
FAU - Bendixen, B H
AU  - Bendixen BH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Neuropharmacol
JT  - Clinical neuropharmacology
JID - 7607910
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Brain Ischemia/*prevention & control
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*therapeutic use
RF  - 104
EDAT- 1993/12/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
PST - ppublish
SO  - Clin Neuropharmacol. 1993 Dec;16(6):485-500.

PMID- 34762964
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220413
IS  - 1096-0260 (Electronic)
IS  - 0091-7435 (Print)
IS  - 0091-7435 (Linking)
VI  - 154
DP  - 2022 Jan
TI  - Aspirin use for cancer prevention: A systematic review of public, patient and 
      healthcare provider attitudes and adherence behaviours.
PG  - 106872
LID - S0091-7435(21)00445-X [pii]
LID - 10.1016/j.ypmed.2021.106872 [doi]
LID - 106872
AB  - We undertook a systematic review to synthesise the data on attitudes and 
      behaviour towards the use of aspirin for cancer prevention, and healthcare 
      providers' attitudes towards implementing aspirin in practice. Searches were 
      carried out across 12 databases (e.g. MEDLINE, EMBASE). We used the Mixed Methods 
      Appraisal Tool to evaluate study quality, and conducted a narrative synthesis of 
      the data. The review was pre-registered (PROSPERO: CRD42018093453). Thirty-eight 
      studies were identified. Uptake and adherence data were all from trials. Trials 
      recruited healthy participants, those at higher risk of cancer, and those with 
      cancer. Four studies reported moderate to high (40.9-77.7%) uptake to an aspirin 
      trial among people who were eligible. Most trials (18/22) reported high 
      day-to-day adherence (≥80%). Three trials observed no association between gender 
      and adherence. One trial found no association between adherence and colorectal 
      cancer risk. Three studies reported moderate to high (43.6-76.0%) hypothetical 
      willingness to use aspirin. Two studies found that a high proportion of 
      healthcare providers (72.0-76.0%) perceived aspirin to be a suitable cancer 
      prevention option. No qualitative studies were identified. The likelihood that 
      eligible users of aspirin would participate in a trial evaluating the use of 
      aspirin for preventive therapy was moderate to high. Among participants in a 
      trial, day-to-day adherence was high. Further research is needed to identify 
      uptake and adherence rates in routine care, the factors affecting aspirin use, 
      and the barriers to implementing aspirin into clinical care.
CI  - Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Lloyd, Kelly E
AU  - Lloyd KE
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. Electronic 
      address: umkel@leeds.ac.uk.
FAU - Hall, Louise H
AU  - Hall LH
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
FAU - King, Natalie
AU  - King N
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
FAU - Thorneloe, Rachael J
AU  - Thorneloe RJ
AD  - Centre for Behavioural Science & Applied Psychology, Sheffield Hallam University, 
      Sheffield, UK.
FAU - Rodriguez-Lopez, Rocio
AU  - Rodriguez-Lopez R
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
FAU - Ziegler, Lucy
AU  - Ziegler L
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
FAU - Taylor, David G
AU  - Taylor DG
AD  - School of Pharmacy, University College London, London, UK.
FAU - MacKenzie, Mairead
AU  - MacKenzie M
AD  - Independent Cancer Patients' Voice, UK.
FAU - Smith, Samuel G
AU  - Smith SG
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
CN  - AsCaP Group
LA  - eng
GR  - C569/A24991/CRUK_/Cancer Research UK/United Kingdom
GR  - NIHR300588/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20211109
PL  - United States
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Attitude of Health Personnel
MH  - Health Personnel
MH  - Humans
MH  - *Neoplasms/prevention & control
PMC - PMC8803547
OTO - NOTNLM
OT  - Aspirin
OT  - Chemoprevention
OT  - Decision-making
OT  - NSAID
OT  - Preventive therapy
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2021/11/12 06:00
MHDA- 2022/04/14 06:00
CRDT- 2021/11/11 20:13
PHST- 2021/04/15 00:00 [received]
PHST- 2021/09/08 00:00 [revised]
PHST- 2021/11/04 00:00 [accepted]
PHST- 2021/11/12 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
PHST- 2021/11/11 20:13 [entrez]
AID - S0091-7435(21)00445-X [pii]
AID - 106872 [pii]
AID - 10.1016/j.ypmed.2021.106872 [doi]
PST - ppublish
SO  - Prev Med. 2022 Jan;154:106872. doi: 10.1016/j.ypmed.2021.106872. Epub 2021 Nov 9.

PMID- 21854539
OWN - NLM
STAT- MEDLINE
DCOM- 20120313
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 9
IP  - 11
DP  - 2011 Nov
TI  - Genetic determinants of platelet reactivity during acetylsalicylic acid therapy 
      in diabetic patients: evaluation of 27 polymorphisms within candidate genes.
PG  - 2291-301
LID - 10.1111/j.1538-7836.2011.04482.x [doi]
AB  - AIMS: Decreased platelet responsiveness to acetylsalicylic acid (ASA) reported 
      previously in diabetic patients could be attributed to patient-based, clinical, 
      genetic and cellular factors. The objective of the present study was to 
      investigate the effect of the genomic polymorphism on the platelet reactivity in 
      diabetic patients treated with ASA. METHODS AND RESULTS: The study cohort 
      consisted of 295 Caucasians with diabetes type 2 who had been taking ASA tablets 
      at the dose of 75 mg per day for at least 3 months for primary or secondary 
      prevention of myocardial infarction (MI). Platelet reactivity analyzes were 
      performed using VerifyNow ASA and PFA-100 assays. Genotyping for the selected 27 
      single nucleotide polymorphisms (SNPs) within 19 genes was performed using a 
      Sequenom iPLEX platform. The results indicate that the statistically significant 
      differences in platelet reactivity were observed in the PFA-100 assay for SNPs in 
      following genes: TXBA2R (rs1131882), ADRA2A (rs4311994), PLA2G7 (rs7756935) and 
      9p21.3 (rs10120688) (P = 0.02, P = 0.03, P = 0.02, P = 0.03, respectively, all 
      significance levels corrected for multiple comparisons). When using the VerifyNow 
      ASA test, a weak nominal statistical significance (i.e. before multiple 
      comparison testing) was observed for two SNPs in the GPVI gene: rs1671152 and 
      rs1613662 [P = 0.025 (0.5) for both SNPs, corrected for multiple comparisons 
      test]. CONCLUSIONS: The results from the present study suggest that the four 
      analyzed genes may contribute to platelet reactivity measured with the PFA-100 
      assay in the diabetic population treated with ASA.
CI  - © 2011 International Society on Thrombosis and Haemostasis.
FAU - Postula, M
AU  - Postula M
AD  - Department of Cardiology, Medical University of Warsaw, Poland. 
      mpostula@wum.edu.pl
FAU - Kaplon-Cieslicka, A
AU  - Kaplon-Cieslicka A
FAU - Rosiak, M
AU  - Rosiak M
FAU - Kondracka, A
AU  - Kondracka A
FAU - Serafin, A
AU  - Serafin A
FAU - Filipiak, K J
AU  - Filipiak KJ
FAU - Czlonkowski, A
AU  - Czlonkowski A
FAU - Opolski, G
AU  - Opolski G
FAU - Janicki, P K
AU  - Janicki PK
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Mutant Proteins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Diabetes Mellitus/*drug therapy/*genetics
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutant Proteins
MH  - Platelet Activation/drug effects/*genetics
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Platelet Function Tests
MH  - *Polymorphism, Genetic
MH  - Polymorphism, Single Nucleotide
EDAT- 2011/08/23 06:00
MHDA- 2012/03/14 06:00
CRDT- 2011/08/23 06:00
PHST- 2011/08/23 06:00 [entrez]
PHST- 2011/08/23 06:00 [pubmed]
PHST- 2012/03/14 06:00 [medline]
AID - S1538-7836(22)07435-9 [pii]
AID - 10.1111/j.1538-7836.2011.04482.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2011 Nov;9(11):2291-301. doi: 10.1111/j.1538-7836.2011.04482.x.

PMID- 25096559
OWN - NLM
STAT- MEDLINE
DCOM- 20171215
LR  - 20171215
IS  - 1603-6824 (Electronic)
IS  - 0041-5782 (Linking)
VI  - 176
IP  - 9
DP  - 2014 Apr 28
TI  - [Enteric-coated aspirin does not reduce the risk of gastrointestinal side 
      effects].
LID - V09130544 [pii]
AB  - Enteric-coated aspirin has been developed in order to decrease the risk of 
      gastrointestinal side effects. When reviewing the existing literature on the 
      effects of the coating on the incidence of gastrointestinal side effects we find 
      that enteric-coated aspirin causes significantly less minor gastrointestinal 
      lesions compared to plain aspirin evaluated by endoscopy after short-term 
      treatment, but there seems to be no effect of enteric-coating on the incidence of 
      dyspepsia or gastrointestinal bleeding of clinical relevance. In conclusion 
      enteric-coated aspirin is not superior to plain aspirin.
FAU - Haastrup, Peter
AU  - Haastrup P
AD  - Forskningsenheden for Almen Praksis, J.B. Winsløws Vej 9A, 5000 Odense C. 
      phaastrup@health.sdu.dk.
FAU - Jarbøl, Dorte Ejg
AU  - Jarbøl DE
LA  - dan
PT  - Journal Article
PT  - Review
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage/adverse effects
MH  - Dyspepsia/chemically induced
MH  - Gastric Mucosa/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Risk Factors
MH  - *Tablets, Enteric-Coated
EDAT- 2014/08/07 06:00
MHDA- 2014/08/07 06:01
CRDT- 2014/08/07 06:00
PHST- 2014/08/07 06:00 [entrez]
PHST- 2014/08/07 06:00 [pubmed]
PHST- 2014/08/07 06:01 [medline]
AID - V09130544 [pii]
PST - ppublish
SO  - Ugeskr Laeger. 2014 Apr 28;176(9):V09130544.

PMID- 24042256
OWN - NLM
STAT- MEDLINE
DCOM- 20140707
LR  - 20221207
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 77
IP  - 12
DP  - 2013
TI  - Effect of low-dose aspirin on primary prevention of cardiovascular events in 
      Japanese diabetic patients at high risk.
PG  - 3023-8
AB  - BACKGROUND: Benefit of low-dose aspirin for primary prevention of cardiovascular 
      events in diabetes remains controversial. The American Diabetes Association 
      (ADA), the American Heart Association (AHA), and the American College of 
      Cardiology Foundation (ACCF) recommend aspirin for high-risk diabetic patients: 
      older patients with additional cardiovascular risk factors. We evaluated 
      aspirin's benefit in Japanese diabetic patients stratified by cardiovascular 
      risk. METHODS AND RESULTS: In the JPAD trial, we enrolled 2,539 Japanese patients 
      with type 2 diabetes and no history of cardiovascular disease. We randomly 
      assigned them to aspirin (81-100 mg daily) or no aspirin groups. The median 
      follow-up period was 4.4 years. We stratified the patients into high-risk or 
      low-risk groups, according to the US recommendation: age (older; younger) and 
      coexisting cardiovascular risk factors. The risk factors included smoking, 
      hypertension, dyslipidemia, family history of coronary artery disease, and 
      proteinuria. Most of the patients were classified into the high-risk group, 
      consisting of older patients with risk factors (n=1,804). The incidence of 
      cardiovascular events was higher in this group, but aspirin did not reduce 
      cardiovascular events (hazard ratio [HR], 0.83; 95% confidence interval [CI]: 
      0.58-1.17). In the low-risk group, consisting of older patients without risk 
      factors and younger patients (n=728), aspirin did not reduce cardiovascular 
      events (HR, 0.55; 95% CI: 0.23-1.21). These results were unchanged after 
      adjusting for potential confounding factors. CONCLUSIONS: Low-dose aspirin is not 
      beneficial in Japanese diabetic patients at high risk.
FAU - Okada, Sadanori
AU  - Okada S
AD  - First Department of Internal Medicine, Nara Medical University.
FAU - Morimoto, Takeshi
AU  - Morimoto T
FAU - Ogawa, Hisao
AU  - Ogawa H
FAU - Sakuma, Mio
AU  - Sakuma M
FAU - Soejima, Hirofumi
AU  - Soejima H
FAU - Nakayama, Masafumi
AU  - Nakayama M
FAU - Sugiyama, Seigo
AU  - Sugiyama S
FAU - Jinnouchi, Hideaki
AU  - Jinnouchi H
FAU - Waki, Masako
AU  - Waki M
FAU - Doi, Naofumi
AU  - Doi N
FAU - Horii, Manabu
AU  - Horii M
FAU - Kawata, Hiroyuki
AU  - Kawata H
FAU - Somekawa, Satoshi
AU  - Somekawa S
FAU - Soeda, Tsunenari
AU  - Soeda T
FAU - Uemura, Shiro
AU  - Uemura S
FAU - Saito, Yoshihiko
AU  - Saito Y
CN  - investigators for the Japanese Primary Prevention of Atherosclerosis with Aspirin 
      for Diabetes (JPAD) trial
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130913
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Asian People
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Complications/*drug therapy
MH  - Female
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Prospective Studies
MH  - Risk Factors
FIR - Ogawa, Hisao
IR  - Ogawa H
FIR - Saito, Yoshihiko
IR  - Saito Y
FIR - Nakayama, Masafumi
IR  - Nakayama M
FIR - Kanauchi, Masao
IR  - Kanauchi M
FIR - Uemura, Shiro
IR  - Uemura S
FIR - Morimoto, Takeshi
IR  - Morimoto T
FIR - Soejima, Hirofumi
IR  - Soejima H
FIR - Sakuma, Mio
IR  - Sakuma M
FIR - Okada, Sadanori
IR  - Okada S
FIR - Masuda, Izuru
IR  - Masuda I
FIR - Nakayama, Masafumi
IR  - Nakayama M
FIR - Kanauchi, Masao
IR  - Kanauchi M
FIR - Imura, Hiroo
IR  - Imura H
FIR - Kimura, Kazuo
IR  - Kimura K
FIR - Morimoto, Takeshi
IR  - Morimoto T
FIR - Sakuma, Mio
IR  - Sakuma M
FIR - Ohtorii, Makiko
IR  - Ohtorii M
FIR - Miyake, Eri
IR  - Miyake E
FIR - Mizutani, Ai
IR  - Mizutani A
FIR - Sakai, Mika
IR  - Sakai M
FIR - Morimoto, Takeshi
IR  - Morimoto T
FIR - Jinnouchi, Hideaki
IR  - Jinnouchi H
FIR - Hanaoka, Yoichi
IR  - Hanaoka Y
FIR - Waki, Masako
IR  - Waki M
FIR - Kawamura, Kyousuke
IR  - Kawamura K
FIR - Shimabukuro, Michio
IR  - Shimabukuro M
FIR - Nishiura, Kimiaki
IR  - Nishiura K
FIR - Kawano, Takahiro
IR  - Kawano T
FIR - Kyoda, Yusuke
IR  - Kyoda Y
FIR - Hashiguchi, Jun
IR  - Hashiguchi J
FIR - Kagoshima, Tadashi
IR  - Kagoshima T
FIR - Hanatani, Masakazu
IR  - Hanatani M
FIR - Matsumura, Norihiko
IR  - Matsumura N
FIR - Doi, Naofumi
IR  - Doi N
FIR - Nakai, Kenji
IR  - Nakai K
FIR - Kobayashi, Yoshiyuki
IR  - Kobayashi Y
FIR - Suzuki, Megumi
IR  - Suzuki M
FIR - Soeda, Tsunenari
IR  - Soeda T
FIR - Morikawa, Yoshinobu
IR  - Morikawa Y
FIR - Horimoto, Masashi
IR  - Horimoto M
FIR - Hasegawa, Atsushi
IR  - Hasegawa A
FIR - Yamano, Shigeru
IR  - Yamano S
FIR - Matsuo, Syuichi
IR  - Matsuo S
FIR - Sakamoto, Yasuhiro
IR  - Sakamoto Y
FIR - Masuda, Izuru
IR  - Masuda I
FIR - Yasuno, Akiko
IR  - Yasuno A
FIR - Fujinaga, Yuriko
IR  - Fujinaga Y
FIR - Horii, Kazuko
IR  - Horii K
FIR - Koga, Takeshi
IR  - Koga T
FIR - Ogawa, Hiroshi
IR  - Ogawa H
FIR - Ozaki, Ken
IR  - Ozaki K
FIR - Ikemura, Makoto
IR  - Ikemura M
FIR - Hayashi, Motomu
IR  - Hayashi M
FIR - Yabuta, Ikuo
IR  - Yabuta I
FIR - Sughihara, Kiyotaka
IR  - Sughihara K
FIR - Yazaki, Akihiro
IR  - Yazaki A
FIR - Masuda, Joji
IR  - Masuda J
FIR - Nishitani, Yoshiharu
IR  - Nishitani Y
FIR - Naito, Masaki
IR  - Naito M
FIR - Ote, Shigenobu
IR  - Ote S
FIR - Yamada, Kazuhiko
IR  - Yamada K
FIR - Wakabayashi, Chikashi
IR  - Wakabayashi C
FIR - Fukuoka, Yoshiaki
IR  - Fukuoka Y
FIR - Mahara, Keiji
IR  - Mahara K
FIR - Kan, Hirofumi
IR  - Kan H
FIR - Oshima, Eiji
IR  - Oshima E
FIR - Sutani, Toshio
IR  - Sutani T
FIR - Hoda, Koichi
IR  - Hoda K
FIR - Sawai, Koryo
IR  - Sawai K
FIR - Yamaga, Kenichi
IR  - Yamaga K
FIR - Nakamura, Tomoki
IR  - Nakamura T
FIR - Okamoto, Shinya
IR  - Okamoto S
FIR - Horie, Hiroaki
IR  - Horie H
FIR - Ashihara, Kenichi
IR  - Ashihara K
FIR - Miki, Hiroshi
IR  - Miki H
FIR - Makino, Hisaharu
IR  - Makino H
FIR - Odo, Takafumi
IR  - Odo T
FIR - Iseri, Yoshihisa
IR  - Iseri Y
FIR - Tanaka, Hiroyuki
IR  - Tanaka H
FIR - Marutsuka, Kousuke
IR  - Marutsuka K
FIR - Nakatani, Akira
IR  - Nakatani A
FIR - Murakami, Hironori
IR  - Murakami H
FIR - Shioya, Yoshiko
IR  - Shioya Y
FIR - Horio, Yutaka
IR  - Horio Y
FIR - Ikeda, Tsuneo
IR  - Ikeda T
FIR - Machii, Kazuo
IR  - Machii K
FIR - Kamura, Masanori
IR  - Kamura M
FIR - Ban, Keiichiro
IR  - Ban K
FIR - Fujii, Yoshihiro
IR  - Fujii Y
FIR - Nishimoto, Kazuo
IR  - Nishimoto K
FIR - Misugi, Susumu
IR  - Misugi S
FIR - Munakata, Tetsuo
IR  - Munakata T
FIR - Yoshimura, Katsutoshi
IR  - Yoshimura K
FIR - Minami, Shigetoshi
IR  - Minami S
FIR - Nakashima, Takao
IR  - Nakashima T
FIR - Ogata, Hirofumi
IR  - Ogata H
FIR - Hifumi, Atuko
IR  - Hifumi A
FIR - Sakurai, Nobuko
IR  - Sakurai N
FIR - Tsurusaki, Ryuichiro
IR  - Tsurusaki R
FIR - Yamanaka, Yoshito
IR  - Yamanaka Y
FIR - Yokota, Hiromitsu
IR  - Yokota H
FIR - Ichihara, Seishi
IR  - Ichihara S
FIR - Yoshinari, Motoki
IR  - Yoshinari M
FIR - Sawada, Yoko
IR  - Sawada Y
FIR - Kawashima, Eiji
IR  - Kawashima E
FIR - Goto, Kazuo
IR  - Goto K
FIR - Kinoshita, Yoshimi
IR  - Kinoshita Y
FIR - Kikukawa, Masao
IR  - Kikukawa M
FIR - Yamada, Hiroharu
IR  - Yamada H
FIR - Tanaka, Yuya
IR  - Tanaka Y
FIR - Kiyota, Mayumi
IR  - Kiyota M
FIR - Kimura, Yoshihiro
IR  - Kimura Y
FIR - Morikami, Yasuhiro
IR  - Morikami Y
FIR - Fukuda, Masahiro
IR  - Fukuda M
FIR - Takami, Takeshi
IR  - Takami T
FIR - Nakatani, Fumihiko
IR  - Nakatani F
FIR - Naomi, Shojiro
IR  - Naomi S
FIR - Nasu, Toshiaki
IR  - Nasu T
FIR - Sawada, Tomohiro
IR  - Sawada T
FIR - Minagawa, Fuyuki
IR  - Minagawa F
FIR - Haraguchi, Osamu
IR  - Haraguchi O
FIR - Kondo, Norifumi
IR  - Kondo N
FIR - Shono, Hiroyuki
IR  - Shono H
FIR - Sugiyama, Hiromichi
IR  - Sugiyama H
FIR - Matsuo, Takeshi
IR  - Matsuo T
FIR - Takaoka, Minoru
IR  - Takaoka M
FIR - Nakajima, Tamio
IR  - Nakajima T
FIR - Toihata, Masamitsu
IR  - Toihata M
FIR - Matsuyama, Kozaburo
IR  - Matsuyama K
FIR - Komori, Kenichi
IR  - Komori K
FIR - Tsubokura, Toshio
IR  - Tsubokura T
FIR - Taguchi, Madoka
IR  - Taguchi M
FIR - Hiramori, Yuko
IR  - Hiramori Y
FIR - Okubo, Hiroto
IR  - Okubo H
FIR - Iemura, Akihiro
IR  - Iemura A
FIR - Doi, Osamu
IR  - Doi O
FIR - Ogihara, Masayuki
IR  - Ogihara M
FIR - Misumi, Kenji
IR  - Misumi K
FIR - Seo, Koji
IR  - Seo K
FIR - Iwai, Ken
IR  - Iwai K
FIR - Naito, Masatoshi
IR  - Naito M
FIR - Ozawa, Seiji
IR  - Ozawa S
FIR - Minoda, Kotaro
IR  - Minoda K
FIR - Fujii, Hiromi
IR  - Fujii H
FIR - Miwa, Kimiaki
IR  - Miwa K
FIR - Egusa, Genshi
IR  - Egusa G
FIR - Yasuda, Isao
IR  - Yasuda I
FIR - Ueda, Michiaki
IR  - Ueda M
FIR - Miyata, Junichi
IR  - Miyata J
FIR - Yoshimura, Midori
IR  - Yoshimura M
FIR - Uemyama, Masakuni
IR  - Uemyama M
FIR - Watanabe, Katumi
IR  - Watanabe K
FIR - Haraguchi, Yoshikuni
IR  - Haraguchi Y
FIR - Tanazawa, Satoshi
IR  - Tanazawa S
FIR - Osamura, Yoshiaki
IR  - Osamura Y
FIR - Shibata, Junji
IR  - Shibata J
FIR - Ono, Takashi
IR  - Ono T
FIR - Kamijikkoku, Syuichi
IR  - Kamijikkoku S
FIR - Yoshimoto, Kazumi
IR  - Yoshimoto K
FIR - Kinuwaki, Etsuo
IR  - Kinuwaki E
FIR - Kozuma, Kazuo
IR  - Kozuma K
FIR - Onoue, Kenji
IR  - Onoue K
FIR - Nakano, Yukitaka
IR  - Nakano Y
FIR - Abe, Nanami
IR  - Abe N
FIR - Araki, Haruo
IR  - Araki H
FIR - Takaoka, Kyoji
IR  - Takaoka K
FIR - Imamoto, Chieko
IR  - Imamoto C
FIR - Suefuji, Hisakazu
IR  - Suefuji H
FIR - Sugimoto, Keisuke
IR  - Sugimoto K
FIR - Matsunaga, Terufumi
IR  - Matsunaga T
FIR - Oya, Akiko
IR  - Oya A
FIR - Onishi, Yoko
IR  - Onishi Y
FIR - Kajiwara, Keizo
IR  - Kajiwara K
FIR - Ikuno, Tetsuo
IR  - Ikuno T
FIR - Doi, Michiaki
IR  - Doi M
FIR - Igaki, Toshiro
IR  - Igaki T
FIR - Bando, Hiroshi
IR  - Bando H
FIR - Ogura, Tateo
IR  - Ogura T
FIR - Doijiri, Kenichi
IR  - Doijiri K
FIR - Iwaoka, Taisuke
IR  - Iwaoka T
FIR - Akahoshi, Kazunobu
IR  - Akahoshi K
FIR - Obata, Kenji
IR  - Obata K
FIR - Shimono, Hisashi
IR  - Shimono H
FIR - Tsuda, Kaoru
IR  - Tsuda K
FIR - Yumoto, Shinya
IR  - Yumoto S
FIR - Oka, Keishiro
IR  - Oka K
FIR - Hasegawa, Hironori
IR  - Hasegawa H
FIR - Fujimoto, Hisao
IR  - Fujimoto H
FIR - Atsumi, Toshiya
IR  - Atsumi T
FIR - Matsutani, Akira
IR  - Matsutani A
FIR - Katsuyama, Yohiyuki
IR  - Katsuyama Y
FIR - Fukami, Ryo
IR  - Fukami R
FIR - Iseri, Yoshihisa
IR  - Iseri Y
FIR - Ishibashi, Yutaka
IR  - Ishibashi Y
FIR - Kudou, Kiyotaka
IR  - Kudou K
FIR - Kuwahara, Tetsuo
IR  - Kuwahara T
FIR - Maeda, Kazutaka
IR  - Maeda K
FIR - Maki, Akira
IR  - Maki A
FIR - Manda, Naiki
IR  - Manda N
FIR - Yasue, Hirofumi
IR  - Yasue H
FIR - Mizuno, Yuji
IR  - Mizuno Y
FIR - Momosaki, Sueo
IR  - Momosaki S
FIR - Tokube, Koji
IR  - Tokube K
FIR - Tomita, Fumishi
IR  - Tomita F
FIR - Tsuchiya, Tatsuaki
IR  - Tsuchiya T
FIR - Yabuta, Matahiro
IR  - Yabuta M
FIR - Hidei
IR  - Hidei
FIR - Yamada
IR  - Yamada
EDAT- 2013/09/18 06:00
MHDA- 2014/07/08 06:00
CRDT- 2013/09/18 06:00
PHST- 2013/09/18 06:00 [entrez]
PHST- 2013/09/18 06:00 [pubmed]
PHST- 2014/07/08 06:00 [medline]
AID - DN/JST.JSTAGE/circj/CJ-13-0307 [pii]
AID - 10.1253/circj.cj-13-0307 [doi]
PST - ppublish
SO  - Circ J. 2013;77(12):3023-8. doi: 10.1253/circj.cj-13-0307. Epub 2013 Sep 13.

PMID- 580735
OWN - NLM
STAT- MEDLINE
DCOM- 19780724
LR  - 20190902
IS  - 0340-5761 (Print)
IS  - 0340-5761 (Linking)
VI  - 40
IP  - 2
DP  - 1978 Apr 27
TI  - Selective cytotoxic actions of aspirin on parietal cells: a principal factor in 
      the early stages of aspirin-induced gastric damage.
PG  - 143-50
AB  - Electronmicroscopic observations are reported on the effects of orally 
      administered aspirin on the rat gastric mucosa to establish the cytotoxic events 
      that occur during the early stages of the development of gastric damage induced 
      by this drug. The results show that aspirin, apart from damaging superficial 
      mucous cells, causes selective damage to the acid-secreting parietal cells 
      located deep in the fundic mucosa. It is suggested that the selective 
      accumulation of salicylates in the parietal cells may account for the specific 
      cytotoxic actions of aspirin on these cells.
FAU - Rainsford, K D
AU  - Rainsford KD
FAU - Brune, K
AU  - Brune K
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arch Toxicol
JT  - Archives of toxicology
JID - 0417615
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*pharmacology
MH  - Cell Survival/drug effects
MH  - Gastric Mucosa/cytology/*drug effects/ultrastructure
MH  - Male
MH  - Rats
MH  - Time Factors
EDAT- 1978/04/27 00:00
MHDA- 1978/04/27 00:01
CRDT- 1978/04/27 00:00
PHST- 1978/04/27 00:00 [pubmed]
PHST- 1978/04/27 00:01 [medline]
PHST- 1978/04/27 00:00 [entrez]
AID - 10.1007/BF01891969 [doi]
PST - ppublish
SO  - Arch Toxicol. 1978 Apr 27;40(2):143-50. doi: 10.1007/BF01891969.

PMID- 1489290
OWN - NLM
STAT- MEDLINE
DCOM- 19930223
LR  - 20190824
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 22
IP  - 6
DP  - 1992 Dec
TI  - The role of dipyridamole in addition to low dose aspirin in the prevention of 
      occlusion of coronary artery bypass grafts.
PG  - 665-70
AB  - One hundred and one subjects were randomised to receive either aspirin 100 mg or 
      aspirin 100 mg + dipyridamole 300 mg daily before undergoing coronary bypass 
      surgery. The drugs were commenced at least 36 hours before operation and patients 
      were followed for one year. There were three perioperative deaths and 37 
      withdrawals, of which 14 were drug related (aspirin four, aspirin + dipyridamole 
      ten). Cineangiocardiograms at nine weeks and one year showed vein graft patency 
      rates of 93% and 87% for subjects treated with aspirin alone; and 90% and 89% in 
      those who received aspirin+dipyridamole. During the follow-up period 14% of 232 
      coronary lesions in the aspirin treated group advanced by more than two grades 
      compared with 15% of 315 lesions in the aspirin+dipyridamole group. The study did 
      not establish superiority of one regimen over another in terms of graft patency 
      or progress of lesions in native vessels. However, low dose aspirin was better 
      tolerated than combination therapy.
FAU - Agnew, T M
AU  - Agnew TM
AD  - Cardiology Department, Green Lane Hospital, Auckland, New Zealand.
FAU - French, J K
AU  - French JK
FAU - Neutze, J M
AU  - Neutze JM
FAU - Whitlock, R M
AU  - Whitlock RM
FAU - Brandt, P W
AU  - Brandt PW
FAU - Kerr, A R
AU  - Kerr AR
FAU - Webber, B J
AU  - Webber BJ
FAU - Rutherford, J D
AU  - Rutherford JD
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Cardiac Catheterization
MH  - Cineangiography
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/administration & dosage/pharmacology/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/diagnostic imaging/epidemiology/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - New Zealand/epidemiology
MH  - Postoperative Complications/diagnostic imaging/epidemiology/*prevention & control
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
AID - 10.1111/j.1445-5994.1992.tb04868.x [doi]
PST - ppublish
SO  - Aust N Z J Med. 1992 Dec;22(6):665-70. doi: 10.1111/j.1445-5994.1992.tb04868.x.

PMID- 27766542
OWN - NLM
STAT- MEDLINE
DCOM- 20170918
LR  - 20181113
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
VI  - 11
IP  - 8
DP  - 2016 Dec
TI  - The 2016 American College of Chest Physicians treatment guidelines for venous 
      thromboembolism: a review and critical appraisal.
PG  - 1031-1035
AB  - The American College of Chest Physicians recently updated their practice 
      guidelines for the treatment of patients with venous thromboembolism, comprising 
      deep vein thrombosis and pulmonary embolism. The 2016 guidelines represent the 
      tenth iteration of these guidelines, which are widely used, and are considered as 
      the reference standard for practice guidelines related to venous thromboembolism. 
      The objectives of this review are to highlight the key recommendations that are 
      new in these guidelines, to address recommendations that may be considered 
      controversial, and to touch on areas of ongoing research that may better inform 
      some of these recommendations.
FAU - Douketis, James Demetrios
AU  - Douketis JD
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada. 
      jdouket@mcmaster.ca.
AD  - St. Joseph's Healthcare Hamilton, Room F-544, 50 Charlton Ave. East, Hamilton, 
      ON, L8N 4A6, Canada. jdouket@mcmaster.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161020
PL  - Italy
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Guidelines as Topic/*standards
MH  - Humans
MH  - Thoracic Surgery/*methods
MH  - Venous Thromboembolism/*drug therapy
MH  - Venous Thrombosis/drug therapy
OTO - NOTNLM
OT  - Anticoagulants
OT  - Practice guideline
OT  - Treatment
OT  - Venous thromboembolism
EDAT- 2016/10/22 06:00
MHDA- 2017/09/19 06:00
CRDT- 2016/10/22 06:00
PHST- 2016/09/03 00:00 [received]
PHST- 2016/10/08 00:00 [accepted]
PHST- 2016/10/22 06:00 [pubmed]
PHST- 2017/09/19 06:00 [medline]
PHST- 2016/10/22 06:00 [entrez]
AID - 10.1007/s11739-016-1553-0 [pii]
AID - 10.1007/s11739-016-1553-0 [doi]
PST - ppublish
SO  - Intern Emerg Med. 2016 Dec;11(8):1031-1035. doi: 10.1007/s11739-016-1553-0. Epub 
      2016 Oct 20.

PMID- 15388526
OWN - NLM
STAT- MEDLINE
DCOM- 20050531
LR  - 20181201
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
VI  - 24
IP  - 11
DP  - 2004 Nov
TI  - Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance.
PG  - 1980-7
AB  - Aspirin and the thienopyridines ticlopidine and clopidogrel are antiplatelet 
      agents that display good antithrombotic activity. In the past few years, the 
      concept of aspirin resistance has been largely emphasized in the medical 
      literature, although its definition is still uncertain. I suggest that 
      "aspirin-resistant" should be considered as a description for those individuals 
      in whom aspirin fails to inhibit thromboxane A2 production, irrespective of the 
      results of unspecific tests of platelet function, such as the bleeding time, 
      platelet aggregation, or the PFA-100 system. Less well known than aspirin 
      resistance, but certainly better characterized, is the issue of "clopidogrel 
      resistance," which is probably mostly caused by inefficient metabolism of the 
      prodrug clopidogrel to its active metabolite. At present, aspirin and clopidogrel 
      resistance should not be looked for in the clinical setting, because there is no 
      definite demonstration of an association with clinical events conditioning 
      cost-effective changes in patient management.
FAU - Cattaneo, Marco
AU  - Cattaneo M
AD  - Unità di Ematologia e Trombosi, Ospedale San Paolo, Università di Milano, Via di 
      Rudinì, 8, 20142 Milano, Italy. marco.cattaneo@unimi.it
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20040923
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/metabolism/*therapeutic use
MH  - Clopidogrel
MH  - Drug Resistance/*physiology
MH  - Humans
MH  - Ticlopidine/*adverse effects/*analogs & derivatives/metabolism/*therapeutic use
MH  - Treatment Failure
MH  - Treatment Outcome
MH  - Venous Thrombosis/prevention & control
RF  - 91
EDAT- 2004/09/25 05:00
MHDA- 2005/06/01 09:00
CRDT- 2004/09/25 05:00
PHST- 2004/09/25 05:00 [pubmed]
PHST- 2005/06/01 09:00 [medline]
PHST- 2004/09/25 05:00 [entrez]
AID - 01.ATV.0000145980.39477.a9 [pii]
AID - 10.1161/01.ATV.0000145980.39477.a9 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):1980-7. doi: 
      10.1161/01.ATV.0000145980.39477.a9. Epub 2004 Sep 23.

PMID- 16886197
OWN - NLM
STAT- MEDLINE
DCOM- 20070104
LR  - 20161124
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 95
IP  - 11
DP  - 2006 Nov
TI  - A new solution for a chronic problem; aqueous enteric coating.
PG  - 2432-7
AB  - In this research, we have reconsidered the current enteric coating techniques and 
      offered a new solution using both theoretical and practical approaches. This 
      approach is based on the fact that salt formation can solubilize the pH-sensitive 
      polymers in water. However, having applied the polymer solution onto the dosage 
      form's surface, the polymer should be converted to the nonionized form for 
      delayed release action. Ammonium hydrogen carbonate (AHC) is used as a buffering 
      agent with dual actions of salting in and desalting the polymer. Following the 
      application of the coating medium onto the dosage form's surface and drying, AHC 
      dissociate completely to ammonia, carbon dioxide, and water converting the 
      polymer to its nonionized form. FT-IR studies on free film samples further 
      confirmed the proposed mechanism. A range of pH-sensitive polymers and other 
      ingredients in water have been successfully applied at the surface of a model ASA 
      tablets, using pan coating technique. According to the SEM observation, the 
      coating layer is very dense and rigid, despite the fact that, the coated amount 
      of the polymers is quit small. The enteric tablets maintain their shapes in acid 
      medium and passed the USP dissolution test for DR ASA tablets.
CI  - Copyright 2006 Wiley-Liss, Inc. and the American Pharmacists Association
FAU - Rafati, Hasan
AU  - Rafati H
AD  - Medicinal Plants and Drugs Research Institute (MPDRI), Shahid Beheshti 
      University, Evin 19835-389, Tehran, Iran. rafati@sina.tums.ac.ir
FAU - Ghassempour, Alireza
AU  - Ghassempour A
FAU - Barzegar-Jalali, Mohammad
AU  - Barzegar-Jalali M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Polymethacrylic Acids)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 059QF0KO0R (Water)
RN  - 25086-15-1 (methylmethacrylate-methacrylic acid copolymer)
RN  - 71138-97-1 (hydroxypropylmethylcellulose acetate succinate)
RN  - 9004-67-5 (Methylcellulose)
RN  - 9050-31-1 (hydroxypropyl methylcellulose phthalate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/chemistry
MH  - Chemical Phenomena
MH  - Chemistry, Pharmaceutical
MH  - Chemistry, Physical
MH  - Methylcellulose/analogs & derivatives
MH  - Microscopy, Electron, Scanning
MH  - Polymethacrylic Acids
MH  - Solubility
MH  - Surface Properties
MH  - *Tablets, Enteric-Coated
MH  - Water
EDAT- 2006/08/04 09:00
MHDA- 2007/01/05 09:00
CRDT- 2006/08/04 09:00
PHST- 2006/08/04 09:00 [pubmed]
PHST- 2007/01/05 09:00 [medline]
PHST- 2006/08/04 09:00 [entrez]
AID - S0022-3549(16)32138-4 [pii]
AID - 10.1002/jps.20693 [doi]
PST - ppublish
SO  - J Pharm Sci. 2006 Nov;95(11):2432-7. doi: 10.1002/jps.20693.

PMID- 6975739
OWN - NLM
STAT- MEDLINE
DCOM- 19820222
LR  - 20180216
IS  - 0304-324X (Print)
IS  - 0304-324X (Linking)
VI  - 27
IP  - 6
DP  - 1981
TI  - Increased serum salicylate metabolites with age in patients receiving chronic 
      acetylsalicylic acid therapy.
PG  - 329-33
AB  - A high pressure liquid chromatographic method was used to measure the serum 
      concentrations of salicylic, salicyluric and gentisic acids in patients receiving 
      chronic acetylsalicylic acid therapy. There was good correlation between this 
      method and the established colorimetric assay for salicylic acid. The 
      concentration of gentisic and salicyluric acids were increased in patients older 
      than 60 years. No correlation was found with sex, concomitant ingestion of other 
      drugs, serum creatinine or serum albumin.
FAU - Montgomery, P R
AU  - Montgomery PR
FAU - Sitar, D S
AU  - Sitar DS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Gerontology
JT  - Gerontology
JID - 7601655
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aspirin/metabolism/*therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Rheumatic Diseases/drug therapy
MH  - Salicylates/*blood
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1159/000212493 [doi]
PST - ppublish
SO  - Gerontology. 1981;27(6):329-33. doi: 10.1159/000212493.

PMID- 23639709
OWN - NLM
STAT- MEDLINE
DCOM- 20131118
LR  - 20131121
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 33
IP  - 2
DP  - 2013 May
TI  - Aspirin desensitization in aspirin-exacerbated respiratory disease.
PG  - 211-22
LID - S0889-8561(12)00140-3 [pii]
LID - 10.1016/j.iac.2012.10.013 [doi]
AB  - Although aspirin desensitization was discovered in 1922, it was not until 1979 
      that a therapeutic use for aspirin treatment, under the protection of 
      desensitization, was discovered. In the last 33 years, details of aspirin 
      treatment have been refined to the point where it is now recognized and accepted 
      as a major therapeutic intervention in the treatment of aspirin-exacerbated 
      respiratory disease, with therapeutic efficacy in approximately two-thirds of 
      patients. It is only effective in patients who have aspirin-exacerbated 
      respiratory disease and none of the other nonsteroidal anti-inflammatory drugs, 
      despite their cross-reactive inhibition of cyclooxygenase-1, can effectively take 
      the place of aspirin.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - White, Andrew A
AU  - White AA
AD  - Division of Allergy and Immunology, The Scripps Research Institute, Scripps 
      Clinic, San Diego, CA 92130, USA. White.Andrew@scrippshealth.org
FAU - Stevenson, Donald D
AU  - Stevenson DD
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20121127
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/history
MH  - Aspirin/*administration & dosage/adverse effects/history
MH  - *Desensitization, Immunologic/history
MH  - Drug Hypersensitivity/drug therapy
MH  - History, 20th Century
MH  - Humans
MH  - Respiratory Tract Diseases/chemically induced/*therapy
MH  - Treatment Outcome
EDAT- 2013/05/04 06:00
MHDA- 2013/11/19 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/05/04 06:00 [entrez]
PHST- 2013/05/04 06:00 [pubmed]
PHST- 2013/11/19 06:00 [medline]
AID - S0889-8561(12)00140-3 [pii]
AID - 10.1016/j.iac.2012.10.013 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2013 May;33(2):211-22. doi: 
      10.1016/j.iac.2012.10.013. Epub 2012 Nov 27.

PMID- 18254152
OWN - NLM
STAT- MEDLINE
DCOM- 20080905
LR  - 20191210
IS  - 0269-3879 (Print)
IS  - 0269-3879 (Linking)
VI  - 22
IP  - 6
DP  - 2008 Jun
TI  - Determination of acetylsalicylic acid and its major metabolite, salicylic acid, 
      in human plasma using liquid chromatography-tandem mass spectrometry: application 
      to pharmacokinetic study of Astrix in Korean healthy volunteers.
PG  - 590-5
LID - 10.1002/bmc.973 [doi]
AB  - The first liquid chromatography-tandem mass spectrometry (LC/MS/MS) method for 
      determination of acetylsalicylic acid (aspirin, ASA) and one of its major 
      metabolites, salicylic acid (SA), in human plasma using simvastatin as an 
      internal standard has been developed and validated. For ASA analysis, a plasma 
      sample containing potassium fluoride was extracted using a mixture of ethyl 
      acetate and diethyl ether in the presence of 0.5% formic acid. SA, a major 
      metabolite of ASA, was extracted from plasma using protein precipitation with 
      acetonitrile. The compounds were separated on a reversed-phase column with an 
      isocratic mobile phase consisting of acetonitrile and water containing 0.1% 
      formic acid (8:2, v/v). The ion transitions recorded in multiple reaction 
      monitoring mode were m/z 179 --> 137, 137 --> 93 and 435 --> 319 for ASA, SA and 
      IS, respectively. The coefficient of variation of the assay precision was less 
      than 9.3%, and the accuracy exceeded 86.5%. The lower limits of quantification 
      for ASA and SA were 5 and 50 ng/mL, respectively. The developed assay method was 
      successfully applied for the evaluation of pharmacokinetics of ASA and SA after 
      single oral administration of Astrix (entero-coated pellet, 100 mg of aspirin) to 
      10 Korean healthy male volunteers.
CI  - Copyright (c) 2008 John Wiley & Sons, Ltd.
FAU - Bae, Soo Kyung
AU  - Bae SK
AD  - Department of Clinical Pharmacology and Clinical Trial Center, Inje University 
      Busan Paik Hospital, Busan, Korea.
FAU - Seo, Kyung Ah
AU  - Seo KA
FAU - Jung, Eun Ji
AU  - Jung EJ
FAU - Kim, Ho-Sook
AU  - Kim HS
FAU - Yeo, Chang-Woo
AU  - Yeo CW
FAU - Shon, Ji-Hong
AU  - Shon JH
FAU - Park, Kyung-Mi
AU  - Park KM
FAU - Liu, Kwang-Hyeon
AU  - Liu KH
FAU - Shin, Jae-Gook
AU  - Shin JG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*blood/pharmacokinetics
MH  - Humans
MH  - Korea
MH  - Reference Standards
MH  - Reference Values
MH  - Reproducibility of Results
MH  - Salicylic Acid/*blood
MH  - Sensitivity and Specificity
MH  - Tandem Mass Spectrometry/*methods
EDAT- 2008/02/07 09:00
MHDA- 2008/09/06 09:00
CRDT- 2008/02/07 09:00
PHST- 2008/02/07 09:00 [pubmed]
PHST- 2008/09/06 09:00 [medline]
PHST- 2008/02/07 09:00 [entrez]
AID - 10.1002/bmc.973 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2008 Jun;22(6):590-5. doi: 10.1002/bmc.973.

PMID- 33657423
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 898
DP  - 2021 May 5
TI  - Mechanisms of the antiangiogenic effects of aspirin in cancer.
PG  - 173989
LID - S0014-2999(21)00142-4 [pii]
LID - 10.1016/j.ejphar.2021.173989 [doi]
AB  - Aspirin is an old drug extracted from willow bark and is widely used for the 
      prevention and treatment of cardiovascular diseases. Accumulating evidence has 
      shown that aspirin use may significantly reduce the angiogenesis of cancer; 
      however, the mechanism of the association between angiogenesis and aspirin is 
      complex. Although COX-1 is widely known as a target of aspirin, several studies 
      reveal other antiangiogenic targets of aspirin, such as angiotensin II, glucose 
      transporter 1, heparanase, and matrix metalloproteinase. In addition, some data 
      indicates that aspirin may produce antiangiogenic effects after acting in 
      different cell types, such as endothelial cells, platelets, pericytes, and 
      macrophages. In this review, we concentrate on research regarding the 
      antiangiogenic effects of aspirin in cancer, and we discuss the molecular 
      mechanisms of aspirin and its metabolites. Moreover, we discuss some mechanisms 
      through which aspirin treatment may normalize existing blood vessels, including 
      preventing the disintegration of endothelial adheres junctions and the 
      recruitment of pericytes. We also address the antiangiogenic effects and the 
      underlying mechanisms of aspirin derivatives, which are aimed at improving safety 
      and efficacy.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Xie, Shiyuan
AU  - Xie S
AD  - College of Pharmacy, Guangxi Medical University, Nanning, 530021, Guangxi, PR 
      China.
FAU - Wang, Youqiong
AU  - Wang Y
AD  - College of Pharmacy, Guangxi Medical University, Nanning, 530021, Guangxi, PR 
      China.
FAU - Huang, Yixuan
AU  - Huang Y
AD  - College of Pharmacy, Guangxi Medical University, Nanning, 530021, Guangxi, PR 
      China.
FAU - Yang, Bin
AU  - Yang B
AD  - College of Pharmacy, Guangxi Medical University, Nanning, 530021, Guangxi, PR 
      China. Electronic address: 81960722@qq.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210228
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Angiogenesis Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiogenesis Inhibitors/adverse effects/*therapeutic use
MH  - Animals
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Humans
MH  - Neoplasms/*drug therapy/metabolism/pathology
MH  - *Neovascularization, Pathologic
MH  - Signal Transduction
OTO - NOTNLM
OT  - Antiangiogenesis
OT  - Aspirin
OT  - Cancer therapy
OT  - Cyclooxygenase
EDAT- 2021/03/04 06:00
MHDA- 2021/05/20 06:00
CRDT- 2021/03/03 20:06
PHST- 2020/06/28 00:00 [received]
PHST- 2021/02/14 00:00 [revised]
PHST- 2021/02/22 00:00 [accepted]
PHST- 2021/03/04 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
PHST- 2021/03/03 20:06 [entrez]
AID - S0014-2999(21)00142-4 [pii]
AID - 10.1016/j.ejphar.2021.173989 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2021 May 5;898:173989. doi: 10.1016/j.ejphar.2021.173989. Epub 
      2021 Feb 28.

PMID- 8873848
OWN - NLM
STAT- MEDLINE
DCOM- 19970123
LR  - 20191024
IS  - 0269-4727 (Print)
IS  - 0269-4727 (Linking)
VI  - 21
IP  - 3
DP  - 1996 Jun
TI  - Effect of tablet integrity on the dissolution rate of sustained-release 
      preparations.
PG  - 155-7
AB  - The objective of this study was to evaluate the effect of tablet integrity on the 
      dissolution rate. The model drug used for this study was aspirin. A dissolution 
      study was performed with three commercially-available aspirin tablets (ZORprin, 
      Bayer 8-h aspirin and Bayer aspirin), two of which were sustained-release 
      tablets. For ZORprin, the average dissolution data indicated that the in vitro 
      release rate of aspirin was consistent with the intended design of the 
      sustained-release wax matrix tablets only when the tablets were intact. The split 
      tablets showed a consistently higher release profile over time, with a 50% higher 
      release at 6 h. However, the Bayer 8-h aspirin and plain aspirin tablet data 
      showed that tablet integrity had no significant impact on the dissolution rate, 
      because the intact and split tablets showed similar drug release profiles over 
      time. In conclusion, care should be taken to administer sustained-release 
      tablets, avoiding any breaking or crushing of the tablets unless this is directed 
      by the manufacturer.
FAU - Mandal, T K
AU  - Mandal TK
AD  - College of Pharmacy, Xavier University of Louisiana, New Orleans 70125, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/chemistry
MH  - Aspirin/administration & dosage/chemistry
MH  - Delayed-Action Preparations/*chemistry
MH  - Drug Compounding
MH  - Kinetics
MH  - Solubility
MH  - Spectrophotometry, Ultraviolet
MH  - *Tablets
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2710.1996.tb00015.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 1996 Jun;21(3):155-7. doi: 10.1111/j.1365-2710.1996.tb00015.x.

PMID- 36923554
OWN - NLM
STAT- MEDLINE
DCOM- 20230808
LR  - 20230808
IS  - 2767-9764 (Electronic)
IS  - 2767-9764 (Linking)
VI  - 2
IP  - 6
DP  - 2022 Jun
TI  - Efficacy of Low-Dose Aspirin in Colorectal Cancer Risk Prevention is Dependent on 
      ADH1B and ALDH2 Genotype in Japanese Familial Adenomatous Polyposis Patients.
PG  - 483-488
LID - 10.1158/2767-9764.CRC-22-0088 [doi]
AB  - Aspirin has gained great attention as a cancer preventive agent. Our previous 
      study revealed that the low-dose aspirin prevents colorectal tumor recurrence in 
      Japanese patients with colorectal adenomas and/or adenocarcinomas, whereas 
      aspirin increases risks in smokers and has no effects on regular drinkers. Our 
      recent study revealed that aspirin reduces polyp growth in Japanese patients with 
      familial adenomatous polyposis (FAP). In this study, we have studied the 
      association of genotypes of alcohol metabolizing enzymes (ADH1B and ALDH2) on 
      aspirin's efficacy of suppressing polyp growth (≥5 mm) in a total of 81 Japanese 
      patients with FAP. Our study revealed that aspirin showed significant preventive 
      effects for patients with ADH1B-AA and AA+GA types [OR = 0.21; 95% confidence 
      interval (CI), 0.05-0.95, and OR = 0.31; 95% CI, 0.10-0.95, respectively], and 
      for patients with ALDH2-GG and GG+GA types (OR = 0.10; 95% CI, 0.01-0.92, and OR 
      = 0.29; 95% CI, 0.09-0.94, respectively), but not for patients with ADH1B-GG and 
      GA+GG types, and ALDH2-AA and GA+AA types. In addition, substantial preventive 
      effects of aspirin were seen for patients with ADH1B-AA type who do not drink 
      regularly (<3 times/week, OR = 0.11; 95% CI, 0.02-0.78), where a statistically 
      significant interaction between aspirin and ADH1B was observed (P (interaction) = 
      0.036). Results from this exploratory study strongly indicate that aspirin is 
      beneficial in prevention of polyp growth for patients with FAP with ADH1B-AA and 
      AA+GA types, and ALDH2-GG and GG+GA types. Taken together, we propose ADH1B and 
      ALDH2 as candidate markers for the personalized prevention by aspirin. 
      SIGNIFICANCE: Aspirin is beneficial to patients with FAP with ADH1B-AA and AA+GA 
      types or ALDH2-GG and GG+GA types. ADH1B and ALDH2 genotypes can be the markers 
      for the personalized prevention of colorectal cancer by aspirin.
CI  - © 2022 The Authors; Published by the American Association for Cancer Research.
FAU - Mure, Kanae
AU  - Mure K
AUID- ORCID: 0000-0002-1395-0983
AD  - Department of Public Health, Wakayama Medical University School of Medicine, 
      Wakayama, Japan.
FAU - Ishikawa, Hideki
AU  - Ishikawa H
AD  - Department of Molecular-Targeting Prevention, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan.
AD  - Ishikawa Gastroenterology Clinic, Osaka, Japan.
FAU - Mutoh, Michihiro
AU  - Mutoh M
AD  - Department of Molecular-Targeting Prevention, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan.
AD  - Epidemiology and Prevention Group, Research Center for Cancer Prevention and 
      Screening/Center for Public Health Sciences, National Cancer Center, Tokyo, 
      Japan.
FAU - Horinaka, Mano
AU  - Horinaka M
AD  - Department of Drug Discovery Medicine, Kyoto Prefectural University of Medicine, 
      Kyoto, Japan.
FAU - Otani, Takahiro
AU  - Otani T
AD  - Department of Public Health, Nagoya City University Graduate School of Medical 
      Sciences, Aichi, Japan.
FAU - Suzuki, Sadao
AU  - Suzuki S
AUID- ORCID: 0000-0001-5988-4849
AD  - Department of Public Health, Nagoya City University Graduate School of Medical 
      Sciences, Aichi, Japan.
FAU - Wakabayashi, Keiji
AU  - Wakabayashi K
AD  - Graduate Division of Nutritional and Environmental Sciences, University of 
      Shizuoka, Shizuoka, Japan.
FAU - Sakai, Toshiyuki
AU  - Sakai T
AD  - Department of Drug Discovery Medicine, Kyoto Prefectural University of Medicine, 
      Kyoto, Japan.
CN  - J-FAPP Study IV group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220623
PL  - United States
TA  - Cancer Res Commun
JT  - Cancer research communications
JID - 9918281580506676
RN  - EC 1.1.1.1 (ADH1B protein, human)
RN  - EC 1.2.1.3 (Aldehyde Dehydrogenase, Mitochondrial)
RN  - EC 1.2.1.3 (ALDH2 protein, human)
RN  - R16CO5Y76E (Aspirin)
MH  - Humans
MH  - *Adenomatous Polyposis Coli/drug therapy/genetics/prevention & control
MH  - Aldehyde Dehydrogenase, Mitochondrial/genetics
MH  - *Aspirin/administration & dosage/therapeutic use
MH  - Colorectal Neoplasms/genetics/prevention & control
MH  - East Asian People
MH  - Genotype
MH  - Neoplasm Recurrence, Local
MH  - Polymorphism, Genetic
PMC - PMC10010329
COIS- K. Mure, H. Ishikawa, M. Mutoh, K. Wakabayashi, T. Sakai, and S. Tanaka report a 
      grant from Japan Agency for Medical Research and Development during the conduct 
      of the study. Y. Takeuchi reports personal fees from Olympus, Boston Scientific 
      Japan, Daiichi-Sankyo, Miyarisan Pharmaceutical, Asuka Pharmacoceutical, 
      AstraZeneca, EA Pharma, Zeria Pharmaceutical, Fujifilm, Kaneka Medical, and 
      Kyorin Pharmaceutical outside the submitted work. No other disclosures were 
      reported.
FIR - Sato, Yasushi
IR  - Sato Y
FIR - Doyama, Hisashi
IR  - Doyama H
FIR - Tajika, Masahiro
IR  - Tajika M
FIR - Tanaka, Shinji
IR  - Tanaka S
FIR - Horimatsu, Takahiro
IR  - Horimatsu T
FIR - Takeuchi, Yoji
IR  - Takeuchi Y
FIR - Kashida, Hiroshi
IR  - Kashida H
FIR - Tashiro, Jun
IR  - Tashiro J
FIR - Ezoe, Yasumasa
IR  - Ezoe Y
FIR - Nakajima, Takeshi
IR  - Nakajima T
FIR - Ikematsu, Hiroaki
IR  - Ikematsu H
FIR - Hori, Shinichiro
IR  - Hori S
FIR - Takayama, Tetsuji
IR  - Takayama T
FIR - Ohda, Yoshio
IR  - Ohda Y
EDAT- 2023/03/17 06:00
MHDA- 2023/03/17 06:01
CRDT- 2023/03/16 02:25
PHST- 2022/02/19 00:00 [received]
PHST- 2022/03/24 00:00 [revised]
PHST- 2022/05/25 00:00 [accepted]
PHST- 2023/03/16 02:25 [entrez]
PHST- 2023/03/17 06:00 [pubmed]
PHST- 2023/03/17 06:01 [medline]
AID - CRC-22-0088 [pii]
AID - 10.1158/2767-9764.CRC-22-0088 [doi]
PST - epublish
SO  - Cancer Res Commun. 2022 Jun 23;2(6):483-488. doi: 10.1158/2767-9764.CRC-22-0088. 
      eCollection 2022 Jun.

PMID- 712608
OWN - NLM
STAT- MEDLINE
DCOM- 19790124
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 67
IP  - 11
DP  - 1978 Nov
TI  - Aspirin stability in solid dispersion binary systems.
PG  - 1631-3
AB  - The stability of aspirin in its solid dispersion with urea or povidone was 
      investigated at two accelerated storage conditions. The observed aspirin 
      degradation in both systems followed the first-order rate equation. The water 
      sorption ability of the two carriers as well as the alkalinity imparted by urea 
      could possibly be the most important factors responsible for the observed 
      acceleration of aspirin decomposition. The results also showed that the 
      temperature effect was more pronounced than the humidity effect. Generally, 
      coprecipitated samples exhibited slightly higher degradation rates than 
      physically mixed ones.
FAU - El-Banna, H M
AU  - El-Banna HM
FAU - Daabis, N A
AU  - Daabis NA
FAU - El-Fattah, S A
AU  - El-Fattah SA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Suspensions)
RN  - 8W8T17847W (Urea)
RN  - FZ989GH94E (Povidone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/analysis
MH  - Drug Stability
MH  - Povidone
MH  - Suspensions
MH  - Urea
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
AID - S0022-3549(15)42351-2 [pii]
AID - 10.1002/jps.2600671135 [doi]
PST - ppublish
SO  - J Pharm Sci. 1978 Nov;67(11):1631-3. doi: 10.1002/jps.2600671135.

PMID- 14965484
OWN - NLM
STAT- MEDLINE
DCOM- 20040520
LR  - 20151119
IS  - 1540-3408 (Print)
IS  - 1540-3408 (Linking)
VI  - 3
IP  - 2
DP  - 2004 Mar
TI  - Overcoming blood shortages: red blood cell and platelet substitutes and membrane 
      modifications.
PG  - 92-6
AB  - Blood shortages are increasingly common as the donor base declines and extensive 
      restrictions on blood donation disqualify many donors. Red blood cell (RBC) and 
      platelet substitutes have long been anticipated as alternatives to standard 
      transfusions. However, difficulties in manufacturing, efficacy, and safety have 
      slowed the development of these products. New understanding of the relationship 
      between blood viscosity, oxygen transport, and vasoactivity have led to more 
      effective RBC substitutes, several of which are in advanced clinical trials. In 
      addition, creative approaches to RBC membrane modification, such as the enzymatic 
      cleavage of ABH glycoproteins, may lead to a universal RBC. Advances in the 
      understanding of platelet membrane behavior at low temperatures may lead to 
      extended platelet storage at refrigerator temperatures. Standard transfusions of 
      human RBCs and platelets will not be replaced soon. However, these new products 
      will be a useful alternative for selected clinical applications and will lessen 
      our dependence on our marginally adequate blood supply.
FAU - Davey, Richard J
AU  - Davey RJ
AD  - New York Blood Center, 310 East 67th Street, New York, NY 10021, USA. 
      rdavey@nybloodcenter.org
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Hematol Rep
JT  - Current hematology reports
JID - 101151358
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Drug Combinations)
RN  - 0 (Fluorocarbons)
RN  - 0 (Hemoglobins)
RN  - 0 (Hydroxyethyl Starch Derivatives)
RN  - 0 (hemoglobin XL99alpha)
RN  - 0 (polyhemoglobin)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 75216-20-5 (glucose, glycerol, hydroxyethyl starch, perfluorodecalin, 
      perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug 
      combination)
RN  - EC 3.2.1.- (Glycoside Hydrolases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*analogs & derivatives/pharmacology/therapeutic use
MH  - Blood Donors/*supply & distribution
MH  - Blood Platelets/chemistry
MH  - Blood Preservation
MH  - Blood Substitutes
MH  - Blood Transfusion/*statistics & numerical data
MH  - Cattle
MH  - Clinical Trials as Topic
MH  - Cross-Linking Reagents/pharmacology
MH  - Cryopreservation
MH  - Drug Combinations
MH  - Erythrocyte Membrane/drug effects
MH  - Fluorocarbons/therapeutic use
MH  - Glycoside Hydrolases/pharmacology
MH  - Hemoglobins/adverse effects/chemistry/drug effects/therapeutic use
MH  - Humans
MH  - Hydroxyethyl Starch Derivatives
RF  - 30
EDAT- 2004/02/18 05:00
MHDA- 2004/05/21 05:00
CRDT- 2004/02/18 05:00
PHST- 2004/02/18 05:00 [pubmed]
PHST- 2004/05/21 05:00 [medline]
PHST- 2004/02/18 05:00 [entrez]
PST - ppublish
SO  - Curr Hematol Rep. 2004 Mar;3(2):92-6.

PMID- 23299823
OWN - NLM
STAT- MEDLINE
DCOM- 20130624
LR  - 20211021
IS  - 1534-6293 (Electronic)
IS  - 1528-4042 (Linking)
VI  - 13
IP  - 2
DP  - 2013 Feb
TI  - Aspirin and clopidogrel for prevention of ischemic stroke.
PG  - 327
LID - 10.1007/s11910-012-0327-y [doi]
AB  - This review examines the role of platelets in ischemic stroke, platelet 
      activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's 
      appearance on the stage, a possible role for combination therapy, antiplatelet 
      resistance, practical considerations, and future directions. Reviewed in this 
      chapter are issues central to optimal antiplatelet therapy: efficacy, safety, 
      resistance, and biochemical/laboratory testing. Current guidelines do not 
      recommend combination aspirin and clopidogrel use, however recent research 
      indicates dual antiplatelet therapy with combined aspirin and clopidogrel may 
      have specific roles in secondary prevention of ischemic stroke. A cautious and 
      analytical interpretation of the literature is advised before application of this 
      knowledge to clinical practice. The best recommendation at this time is to follow 
      the published guidelines for secondary prevention of ischemic stroke.
FAU - Thomson, Ruth M
AU  - Thomson RM
AD  - Department of Neurology, University of Minnesota, 420 Delaware St. SE, MMC 295, 
      Minneapolis, MN 55455, USA. Thom1824@umn.edu
FAU - Anderson, David C
AU  - Anderson DC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Neurol Neurosci Rep
JT  - Current neurology and neuroscience reports
JID - 100931790
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Brain Ischemia/drug therapy/*prevention & control
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Secondary Prevention
MH  - Stroke/drug therapy/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2013/01/10 06:00
MHDA- 2013/06/26 06:00
CRDT- 2013/01/10 06:00
PHST- 2013/01/10 06:00 [entrez]
PHST- 2013/01/10 06:00 [pubmed]
PHST- 2013/06/26 06:00 [medline]
AID - 10.1007/s11910-012-0327-y [doi]
PST - ppublish
SO  - Curr Neurol Neurosci Rep. 2013 Feb;13(2):327. doi: 10.1007/s11910-012-0327-y.

PMID- 9559
OWN - NLM
STAT- MEDLINE
DCOM- 19761121
LR  - 20181130
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 1
IP  - 23
DP  - 1976 Jun 5
TI  - Role of the parietal cell in gastric damage induced by aspirin and related drugs: 
      implications for safer therapy.
PG  - 881-3
AB  - The proton-secreting parietal cell is shown, from recent evidence, to be the 
      principal focus for the actions of aspirin (and related drugs) in damaging the 
      gastric mucosa. It is suggested that the selective damage to the parietal cells 
      is due to the ph gradient favouring a high rate of aspirin uptake and subsequent 
      entrapment of drug anions inside these cells. This concept may serve as a useful 
      basis for developing procedures to minimize the gastric damage by aspirin and 
      related acidic drugs.
FAU - Rainsford, K D
AU  - Rainsford KD
FAU - Brune, K
AU  - Brune K
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*adverse effects
MH  - Aspirin/*adverse effects/metabolism
MH  - Gastric Juice/metabolism
MH  - *Gastric Mucosa/metabolism
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Stomach Diseases/*chemically induced/metabolism
EDAT- 1976/06/05 00:00
MHDA- 1976/06/05 00:01
CRDT- 1976/06/05 00:00
PHST- 1976/06/05 00:00 [pubmed]
PHST- 1976/06/05 00:01 [medline]
PHST- 1976/06/05 00:00 [entrez]
PST - ppublish
SO  - Med J Aust. 1976 Jun 5;1(23):881-3.

PMID- 7503066
OWN - NLM
STAT- MEDLINE
DCOM- 19960116
LR  - 20190815
IS  - 0272-6386 (Print)
IS  - 0272-6386 (Linking)
VI  - 26
IP  - 6
DP  - 1995 Dec
TI  - Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis 
      patients.
PG  - 918-23
AB  - Various hemoglobin compounds have been evaluated as potential oxygen-carrying, 
      blood volume expanders, but toxicity has prevented clinical application. 
      Diaspirin cross-linked hemoglobin (DCLHb) represents a modified hemoglobin 
      compound that is derived from human red blood cells and maintained in a 
      tetrameric configuration by cross-linkages between the two alpha chains of the 
      hemoglobin molecule. In a randomized, placebo-controlled, single-blind, 
      cross-over trial, DCLHb's safety and pharmacologic parameters were evaluated in 
      18 subjects receiving chronic hemodialytic therapy. A 30-minute infusion of 25, 
      50, or 100 mg/kg DCLHb or placebo was given at the start of routine hemodialysis. 
      One week later, the alternate treatment (placebo or DCLHb) was administered. 
      Maximum plasma hemoglobin concentrations and terminal half-life values were 
      calculated for each dosage group. Dialysate was collected and assayed for 
      hemoglobin. Changes in systolic and diastolic blood pressure from baseline and 
      the volume of hypertonic saline administered for treatment of hypotension during 
      hemodialysis were measured. The maximum plasma hemoglobin concentrations 
      increased with DCLHb dose and occurred at the end of DCLHb infusion. The mean 
      (+/- SD) terminal half-life ranged from 2.1 +/- 1.0 hours in the 25 mg/kg DCLHb 
      group to 4.3 +/- 1.4 hours in the 100 mg/kg group, but did not differ 
      significantly between groups. Mean baseline plasma hemoglobin corrected areas 
      under the plasma concentration-time curves increased from 89 to 1,136 mg/hr/dL 
      across the fourfold dose range. Diaspirin cross-linked hemoglobin was not 
      dialyzable as none was detected in dialysate. The maximum increase in systolic 
      blood pressure from baseline increased significantly with DCLHb dose compared 
      with placebo (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Swan, S K
AU  - Swan SK
AD  - Division of Nephrology, Hennepin County Medical Center, Minneapolis, MN 55415, 
      USA.
FAU - Halstenson, C E
AU  - Halstenson CE
FAU - Collins, A J
AU  - Collins AJ
FAU - Colburn, W A
AU  - Colburn WA
FAU - Blue, J
AU  - Blue J
FAU - Przybelski, R J
AU  - Przybelski RJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*analogs & derivatives/pharmacokinetics/pharmacology
MH  - Blood Pressure/drug effects
MH  - Cross-Over Studies
MH  - Half-Life
MH  - Hemoglobins/analysis/pharmacokinetics/*pharmacology
MH  - Humans
MH  - Middle Aged
MH  - Renal Dialysis
MH  - Single-Blind Method
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
AID - S0272638695002526 [pii]
AID - 10.1016/0272-6386(95)90056-x [doi]
PST - ppublish
SO  - Am J Kidney Dis. 1995 Dec;26(6):918-23. doi: 10.1016/0272-6386(95)90056-x.

PMID- 3453142
OWN - NLM
STAT- MEDLINE
DCOM- 19880812
LR  - 20131121
IS  - 0397-9148 (Print)
IS  - 0397-9148 (Linking)
VI  - 19
IP  - 8 Suppl
DP  - 1987 Oct
TI  - [Intolerance to metabisulfites in asthma induced by aspirin].
PG  - 19-23
AB  - 38% of subjects who presented with aspirin (Acetyl-salicylic acid AAS)-included 
      asthma were also found to be intolerant to metabisulphites (MBS). The diagnosis 
      was based on interrogation and an oral provocation test (TPO), to which the 
      majority of the responses were similar, immediate and/or delayed. Atopy and other 
      immunological tests are not involved in this type of asthma, which like AAS is 
      has an intolerance mechanism.
FAU - Sabbah, A
AU  - Sabbah A
FAU - Drouet, M
AU  - Drouet M
FAU - Bonneau, J C
AU  - Bonneau JC
FAU - Le Sellin, J
AU  - Le Sellin J
FAU - Ernoult, C
AU  - Ernoult C
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Intolérance aux métabisulfites dans l'asthme induit par l'aspirine.
PL  - France
TA  - Allerg Immunol (Paris)
JT  - Allergie et immunologie
JID - 0245775
RN  - 0 (Immunoglobulin G)
RN  - 0 (Sulfites)
RN  - 7992SO049K (metabisulfite)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced/immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/analysis
MH  - Male
MH  - Middle Aged
MH  - Skin Tests
MH  - Sulfites/administration & dosage/*adverse effects
EDAT- 1987/10/01 00:00
MHDA- 1987/10/01 00:01
CRDT- 1987/10/01 00:00
PHST- 1987/10/01 00:00 [pubmed]
PHST- 1987/10/01 00:01 [medline]
PHST- 1987/10/01 00:00 [entrez]
PST - ppublish
SO  - Allerg Immunol (Paris). 1987 Oct;19(8 Suppl):19-23.

PMID- 307109
OWN - NLM
STAT- MEDLINE
DCOM- 19780814
LR  - 20131121
IS  - 0025-8458 (Print)
IS  - 0025-8458 (Linking)
VI  - 73
IP  - 22
DP  - 1978 Jun 2
TI  - [Complications of antithrombotic prophylaxis with acetylsalicylic acid (ASS) in 
      polycythemia (author's transl)].
PG  - 839-42
AB  - Eight patients with polycythemia whose main complaints resulted from vascular 
      complications were prophylactically treated with ASS. 4 patients tolerated the 
      treatment without any side effects, 4 patients had an acute upper 
      gastrointestinal hemorrhage, which was fatal in 2 cases. Correlations between the 
      thrombohemorrhagical syndrome in polycythemia on one hand and the side effects of 
      ASS on the other hand are discussed. As a result of this antithrombotic 
      prophylaxis with ASS is not indicated in polycythemia even in predominance of 
      vascular complications and absence of bleeding tendency. In life-threatening 
      situations antithrombotic therapy with heparine should be preferred.
FAU - Ranft, K
AU  - Ranft K
FAU - Brands, W
AU  - Brands W
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Komplikationen der Thromboseprophylaxe mit Acetylsalicylsäure bei Polycythaemia 
      vera.
PL  - Germany
TA  - Med Klin
JT  - Medizinische Klinik
JID - 0376637
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Male
MH  - Polycythemia Vera/*complications
MH  - Thrombosis/*prevention & control
EDAT- 1978/06/02 00:00
MHDA- 2000/03/22 09:00
CRDT- 1978/06/02 00:00
PHST- 1978/06/02 00:00 [pubmed]
PHST- 2000/03/22 09:00 [medline]
PHST- 1978/06/02 00:00 [entrez]
PST - ppublish
SO  - Med Klin. 1978 Jun 2;73(22):839-42.

PMID- 779534
OWN - NLM
STAT- MEDLINE
DCOM- 19760823
LR  - 20131121
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 36
IP  - 5
DP  - 1976 May
TI  - Inhibition of gill cilial activity and of Proteus vulgaris motility as tests for 
      aspirin idiosyncrasy.
PG  - 299-301
AB  - Aspirin ingestion is likely to result in severe asthmatic attacks in patients 
      with aspirin idiosyncrasy. There is no in vitro test for the condition. Gill 
      cilia and Proteus vulgaris motility studies showed no differences between 
      asthmatics with aspirin idiosyncrasy and control patients.
FAU - Delaney, J C
AU  - Delaney JC
FAU - Crawfurd, M D
AU  - Crawfurd MD
FAU - Roberts, C
AU  - Roberts C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/*chemically induced
MH  - Bivalvia
MH  - Cilia
MH  - Drug Hypersensitivity/*diagnosis/immunology
MH  - Humans
MH  - Proteus vulgaris
EDAT- 1976/05/01 00:00
MHDA- 1976/05/01 00:01
CRDT- 1976/05/01 00:00
PHST- 1976/05/01 00:00 [pubmed]
PHST- 1976/05/01 00:01 [medline]
PHST- 1976/05/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1976 May;36(5):299-301.

PMID- 1307083
OWN - NLM
STAT- MEDLINE
DCOM- 19930823
LR  - 20131121
IS  - 0019-4832 (Print)
IS  - 0019-4832 (Linking)
VI  - 44
IP  - 6
DP  - 1992 Nov-Dec
TI  - Influence of low dose enteric-coated aspirin on platelet function.
PG  - 365-70
AB  - Little is known about the effect of low dose, enteric-coated aspirin on human 
      blood platelet function. This study was conducted to evaluate the acute effects 
      of a single daily dose of commercially available enteric-coated aspirin on 
      platelet biochemistry, physiology and function. Blood for these studies was 
      obtained from drug-free volunteer donors prior to ingestion of aspirin or 
      following ingestion, either before breakfast or following lunch. Response of 
      platelets to the action of weak agonists was evaluated. In addition, ability of 
      platelets to convert radiolabeled arachidonic acid to thromboxane was monitored. 
      Results of our studies show that a single daily dose of 50 mg of aspirin taken 
      either before breakfast or after lunch effectively prevented the secondary wave 
      aggregation response, as well as secretion of dense body contents when stimulated 
      by agonists such as epinephrine and ADP. Aspirin ingestion caused a 
      dose-dependent inhibition of platelet cyclooxygenase activity as evidenced by the 
      extent of arachidonic acid converted to thromboxane by platelets exposed to 
      aspirin for different time periods. Based on these observations, it is suggested 
      that low dose aspirin may be very useful and desirable to restrain platelet 
      activity in clinical situations in which increased thromboxane formation may 
      initiate vascular hypertension and platelet hyperactivity.
FAU - Rao, G H
AU  - Rao GH
AD  - Department of Laboratory Medicine and Pathology, University of Minnesota Medical 
      School, Minneapolis 55455.
FAU - Rao, A S
AU  - Rao AS
FAU - White, J G
AU  - White JG
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian Heart J
JT  - Indian heart journal
JID - 0374675
RN  - 0 (Tablets, Enteric-Coated)
RN  - 0 (Thromboxanes)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Tablets, Enteric-Coated
MH  - Thromboxanes/metabolism
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
PST - ppublish
SO  - Indian Heart J. 1992 Nov-Dec;44(6):365-70.

PMID- 37164750
OWN - NLM
STAT- MEDLINE
DCOM- 20230512
LR  - 20230512
IS  - 1349-6867 (Electronic)
IS  - 1343-1420 (Linking)
VI  - 70
IP  - 1.2
DP  - 2023
TI  - Inhibitory Effects of Aspirin and Cilostazol on Intracellular Ca(2+) Mobilization 
      and Aggregation in Thrombin-activated Human Platelets.
PG  - 94-100
LID - 10.2152/jmi.70.94 [doi]
AB  - Platelets play an important role in physiological hemostatic mechanisms. In 
      contrast, platelet activation has been implicated in pathological conditions, 
      such as atherosclerosis, angiogenesis, and inflammation. Thrombin is considered 
      to be of particular pathological importance as a platelet-activating substance, 
      and thrombin-activated platelets are detected in the blood of patients with 
      advanced occlusive arterial disease. Ca(2+) acts as a second messenger in 
      platelet activation, and the regulation of intracellular Ca(2+) concentrations 
      ([Ca(2+)]i) is important for controlling platelet functions. However, changes in 
      [Ca(2+)]i by antiplatelet agents remain unclear. Therefore, we herein 
      investigated the relationship between [Ca(2+)]i and the intensity of platelet 
      aggregation after a thrombin stimulation, the relationship between [Ca(2+)]i and 
      the intensity of platelet aggregation by antiplatelet agents, and the effects of 
      antiplatelet agents on thrombin-activated platelets as a surrogate platelet model 
      for arterial occlusive disease. Fura2-loaded platelets were treated with 
      phosphate-buffered saline or a low concentration of thrombin (0.005 U/mL), 
      followed by antiplatelet agents (aspirin or cilostazol), and changes in [Ca(2+)]i 
      and the intensity of platelet aggregation by the thrombin stimulation were 
      measured using fluorescence spectrophotometry. Changes in [Ca(2+)]i and the 
      intensity of platelet aggregation after the thrombin stimulation as well as the 
      relationship between [Ca(2+)]i and the intensity of platelet aggregation by 
      antiplatelet agents indicated that cilostazol exerted stronger antiplatelet 
      effects than aspirin and also that antiplatelet effects may be attenuated in 
      thrombin-activated platelets. The present results also suggest the utility of 
      thrombin-activated platelets as a surrogate platelet model for arterial occlusive 
      disease. These results may contribute to future drug development for antiplatelet 
      therapy. J. Med. Invest. 70 : 94-100, February, 2023.
FAU - Sone, Atsumi
AU  - Sone A
AD  - Subdivision of Biomedical Laboratory Sciences, Graduate School of Health 
      Sciences, Tokushima University, Tokushima, Japan.
FAU - Aki, Kensaku
AU  - Aki K
AD  - Department of Cells and Immunity Analytics, Institute of Biomedical Sciences, 
      Tokushima University Graduate School, Tokushima, Japan.
FAU - Yasui, Toshiyuki
AU  - Yasui T
AD  - Department of Reproductive and Menopausal Medicine, Institute of Biomedical 
      Sciences, Tokushima University Graduate School, Tokushima, Japan.
FAU - Hosoi, Eiji
AU  - Hosoi E
AD  - Department of Cells and Immunity Analytics, Institute of Biomedical Sciences, 
      Tokushima University Graduate School, Tokushima, Japan.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Med Invest
JT  - The journal of medical investigation : JMI
JID - 9716841
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - N7Z035406B (Cilostazol)
RN  - EC 3.4.21.5 (Thrombin)
SB  - IM
MH  - Humans
MH  - *Blood Platelets/metabolism
MH  - *Aspirin/pharmacology/metabolism/therapeutic use
MH  - Platelet Aggregation Inhibitors/pharmacology/metabolism/therapeutic use
MH  - Cilostazol/pharmacology/metabolism
MH  - Thrombin/pharmacology/metabolism
OTO - NOTNLM
OT  - aspirin
OT  - cilostazol
OT  - intensity of platelet aggregation
OT  - intracellular Ca2+ concentration
OT  - thrombin
EDAT- 2023/05/11 00:41
MHDA- 2023/05/12 07:06
CRDT- 2023/05/10 21:43
PHST- 2023/05/12 07:06 [medline]
PHST- 2023/05/11 00:41 [pubmed]
PHST- 2023/05/10 21:43 [entrez]
AID - 10.2152/jmi.70.94 [doi]
PST - ppublish
SO  - J Med Invest. 2023;70(1.2):94-100. doi: 10.2152/jmi.70.94.

PMID- 21280515
OWN - NLM
STAT- MEDLINE
DCOM- 20110519
LR  - 20131121
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 93 Suppl 6
DP  - 2010 Nov
TI  - Prevalence of aspirin resistance in stroke patients in Phramongkutklao Hospital.
PG  - S51-4
AB  - OBJECTIVE: To study the prevalence of aspirin resistance in cerebrovascular 
      disease patients in Phramongutklao hospital. MATERIAL AND METHOD: The acute 
      ischemic and stable stroke patients who received aspirin at least 60 mg, at least 
      7 days and the last dose of aspirin at least 24 hours before blood test for 
      platelet aggregation. ADP and Collagen were used as platelet aggregator. RESULTS: 
      During July 2007- December 2008, 141 cases of ischemic stroke were enrolled. 
      "Aspirin resistant" was defined as mean aggregation more than 60% both ADP and 
      Collagen. "Aspirin semi-responder" was mean aggregation less than 60% for ADP or 
      Collagen. CONCLUSION: Prevalence of aspirin resistance in Phramonkutklao hospital 
      is 56 % (79/141), and there are relationship between aspirin resistance and 
      timing in the first episode of stroke.
FAU - Nidhinandana, Samart
AU  - Nidhinandana S
AD  - Department of Neurology and Psychiatry, College of Medicine, Phramongkutklao 
      Hospital, Bangkok, Thailand. msani@pmk.ac.th
FAU - Changchit, Siriprang
AU  - Changchit S
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - *Drug Resistance
MH  - Female
MH  - Hospitals, Teaching
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Prevalence
MH  - Stroke/*drug therapy
MH  - Thailand/epidemiology
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2011/02/02 06:00
MHDA- 2011/05/20 06:00
CRDT- 2011/02/02 06:00
PHST- 2011/02/02 06:00 [entrez]
PHST- 2011/02/02 06:00 [pubmed]
PHST- 2011/05/20 06:00 [medline]
PST - ppublish
SO  - J Med Assoc Thai. 2010 Nov;93 Suppl 6:S51-4.

PMID- 9648425
OWN - NLM
STAT- MEDLINE
DCOM- 19980716
LR  - 20131121
IS  - 1048-9886 (Print)
IS  - 1048-9886 (Linking)
VI  - 9
IP  - 2
DP  - 1998
TI  - Use and safety of aspirin in the chemoprevention of colorectal cancer.
PG  - 40-4
AB  - Colorectal cancer is the third leading cause of cancer-related mortality and a 
      significant public health problem in the United States. Aspirin and other 
      nonsteroidal anti-inflammatory drugs reduced the incidence of colorectal cancers 
      and related mortality by 30% to 60% as well as the incidence of colonic adenomas. 
      This effect is presumably due to an inhibition of cyclooxygenase 2, an inducible 
      enzyme involved in the synthesis of prostaglandins. Prostaglandins are increased 
      in colorectal neoplasms. Aspirin's effect appears to be dose related and enhanced 
      by long-term exposure. Two prospective studies, however, failed to show a 
      protective benefit of aspirin in colorectal cancer. When used long term, aspirin 
      has significant adverse effects and is poorly tolerated. The gastrointestinal 
      toxicity of aspirin is dose related, but even low doses of aspirin (75 mg per 
      day) when used regularly result in significantly higher gastrointestinal 
      toxicity, manifested by melena, hematemesis, and peptic ulcer disease, in aspirin 
      users compared with nonusers. Furthermore, some studies indicate an increased 
      risk of hemorrhagic strokes in aspirin users. Presently, aspirin should not be 
      recommended for the primary chemoprevention of colorectal cancer in the general 
      population due to significant risks of serious cerebrovascular and 
      gastrointestinal adverse effects associated with long-term aspirin use.
FAU - Singh, A K
AU  - Singh AK
AD  - Department of Medicine, UMDNJ-University Hospital, Newark, New Jersey 07103-2714, 
      USA.
FAU - Trotman, B W
AU  - Trotman BW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Assoc Acad Minor Phys
JT  - Journal of the Association for Academic Minority Physicians : the official 
      publication of the Association for Academic Minority Physicians
JID - 9113765
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cerebral Hemorrhage/chemically induced
MH  - Colorectal Neoplasms/mortality/*prevention & control
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Peptic Ulcer/chemically induced
MH  - Prostaglandins/biosynthesis
RF  - 43
EDAT- 1998/07/02 00:00
MHDA- 1998/07/02 00:01
CRDT- 1998/07/02 00:00
PHST- 1998/07/02 00:00 [pubmed]
PHST- 1998/07/02 00:01 [medline]
PHST- 1998/07/02 00:00 [entrez]
PST - ppublish
SO  - J Assoc Acad Minor Phys. 1998;9(2):40-4.

PMID- 21057579
OWN - NLM
STAT- MEDLINE
DCOM- 20101203
LR  - 20220409
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Print)
IS  - 1176-6344 (Linking)
VI  - 6
DP  - 2010 Oct 21
TI  - Risk assessment and aspirin use in Asian and Western populations.
PG  - 943-56
LID - 10.2147/VHRM.S9400 [doi]
AB  - OBJECTIVE: The aim of this review was to examine aspirin utilization, 
      cardiovascular risk estimation, and clinical evidence for aspirin prophylaxis in 
      Asian versus Western countries. METHODS: A literature search was performed using 
      PubMed and the key terms "aspirin" and "Asia" or "Western". RESULTS: Despite the 
      growing burden of cardiovascular disease (CVD), aspirin is underutilized in 
      high-risk patients in both Asian and Western countries. A number of risk 
      estimation scores are available; however, validation is needed in countries such 
      as Japan, India, and in South Asia. Underutilization of aspirin in Asia may be 
      linked to an overestimation of bleeding risks. It is possible that a higher 
      prevalence of Helicobacter pylori infection and genetic differences may make 
      Asians more susceptible to gastrointestinal bleeding. Very low aspirin doses and 
      even the wider use of gastroprotective agents may be the optimal approach to 
      high-risk patients in Asia. CONCLUSIONS: Based on the current evidence, aspirin 
      should be used for CVD prevention when the risk:benefit ratio is favorable. A 
      number of trials are underway, including the Diabetic Atherosclerosis Prevention 
      by Cilostazol and Japanese Primary Prevention Project, which will provide key 
      data on the benefits of aspirin in Asian patients at risk of CVD, and may improve 
      aspirin utilization and risk estimation.
FAU - Gao, Runlin
AU  - Gao R
AD  - Department of Cardiology, Cardiovascular Institute and Fuwai Hospital, Chinese 
      Academy of Medical Sciences, Beijing, PR China. gaorunlin@263.net
FAU - Li, Xiaoying
AU  - Li X
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20101021
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Asia/epidemiology
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Coronary Disease/*prevention & control
MH  - Drug Therapy, Combination
MH  - Europe/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
MH  - United States/epidemiology
PMC - PMC2964947
OTO - NOTNLM
OT  - Asia
OT  - Western
OT  - aspirin
OT  - cardiovascular risk estimation
EDAT- 2010/11/09 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/11/09 06:00
PHST- 2010/11/09 06:00 [entrez]
PHST- 2010/11/09 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - vhrm-6-943 [pii]
AID - 10.2147/VHRM.S9400 [doi]
PST - epublish
SO  - Vasc Health Risk Manag. 2010 Oct 21;6:943-56. doi: 10.2147/VHRM.S9400.

PMID- 745307
OWN - NLM
STAT- MEDLINE
DCOM- 19790526
LR  - 20191210
IS  - 0021-5198 (Print)
IS  - 0021-5198 (Linking)
VI  - 28
IP  - 6
DP  - 1978 Dec
TI  - Studies on combination dosing (III). Aspirin and ethenzamide.
PG  - 829-35
AB  - In our studies with drug combinations, we search for mixtures which would enhance 
      the effectiveness of the related active substances. Ethenzamide was found to 
      possess a specific suppressive effect on the gastric damage induced by aspirin. 
      Such effect could not be demonstrated in analgesic agents such as salicylamide, 
      bucetin, acetaminophen and phenacetin. The combination of aspirin with 
      ethenzamide had a potentiating effect on analgesic activity and reduced motor 
      incoordination and loss of righting reflex. We calculated the safety margins of 
      various ratios of combinations and concluded that the best was aspirin and 
      ethenzamide at a ratio of 2:3.
FAU - Kawano, O
AU  - Kawano O
FAU - Sawabe, T
AU  - Sawabe T
FAU - Misaki, N
AU  - Misaki N
FAU - Fukawa, K
AU  - Fukawa K
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Jpn J Pharmacol
JT  - Japanese journal of pharmacology
JID - 2983305R
RN  - 0 (Analgesics)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Salicylamides)
RN  - L929ZCK4BF (ethenzamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/administration & dosage
MH  - Animals
MH  - Anti-Ulcer Agents/administration & dosage
MH  - Aspirin/*administration & dosage/adverse effects/toxicity
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Male
MH  - Mice
MH  - Motor Activity/drug effects
MH  - Reflex/drug effects
MH  - Salicylamides/*administration & dosage/pharmacology
MH  - Stomach/drug effects
EDAT- 1978/12/01 00:00
MHDA- 1978/12/01 00:01
CRDT- 1978/12/01 00:00
PHST- 1978/12/01 00:00 [pubmed]
PHST- 1978/12/01 00:01 [medline]
PHST- 1978/12/01 00:00 [entrez]
AID - 10.1254/jjp.28.829 [doi]
PST - ppublish
SO  - Jpn J Pharmacol. 1978 Dec;28(6):829-35. doi: 10.1254/jjp.28.829.

PMID- 10383561
OWN - NLM
STAT- MEDLINE
DCOM- 19990903
LR  - 20190513
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 48
IP  - 1
DP  - 1999 Jul
TI  - Comparison of antiplatelet activity of microencapsulated aspirin 162.5 Mg (Caspac 
      XL), with enteric coated aspirin 75 mg and 150 mg in patients with 
      atherosclerosis.
PG  - 57-62
AB  - AIMS: A new formulation, low dose microencapsulated aspirin, permits slow 
      absorption of aspirin and presystemic acetylation of platelet cyclo-oxygenase 
      within the portal circulation, potentially avoiding deleterious effects on 
      gastric and systemic prostaglandin synthesis. The objective of this study was to 
      determine whether the administration of microencapsulated aspirin was as 
      effective as enteric coated (EC) aspirin as an inhibitor of platelet function in 
      patients with atherosclerosis. METHODS: One hundred and four patients were 
      enrolled and randomised after a run in period of at least 14 days on aspirin EC 
      75 mg (day 0), to receive either microencapsulated aspirin 162.5 mg (n=34), 
      aspirin EC 150 mg (n=36) or continue on aspirin EC 75 mg (n=34) for 28 days. 
      Serum thromboxane B2 and collagen-induced platelet aggregation and release of 
      5-hydroxytryptamine (EC50 values) were measured on days 0 and 28. 
      Aggregation/release EC50s were then repeated in the presence of a large dose of 
      aspirin added in vitro to determine the EC50 at the maximum level of platelet 
      inhibition. RESULTS: Median thromboxane B2 levels were low after 14 days run-in 
      therapy with aspirin EC 75 mg, but significant further reductions were seen on 
      day 28 in patients randomised to microencapsulated aspirin 162.5 mg (P=0.0368) 
      and aspirin EC 150 mg (P=0.0004) compared with those remaining on aspirin EC 75 
      mg. Median EC50 s on day 28 showed small but significant increases from baseline 
      (day 0) in aggregation in patients randomised to microencapsulated aspirin 162.5 
      mg (0.62-0.85, P=0.0482) and in both aggregation and release in patients 
      randomised to aspirin EC 150 mg (0.95-1.20, P=0.0002, 8.4-11.7, P<0. 0001, 
      respectively) signifying enhanced antiplatelet activity. No changes were seen in 
      patients continuing on aspirin EC 75 mg. Results following addition of high dose 
      aspirin in vitro suggest that mechanisms other than thromboxane synthesis may be 
      operative in the long term effects of microencapsulated aspirin 162.5 mg and 
      aspirin EC 150 mg over aspirin EC 75 mg. CONCLUSIONS: The results show good 
      inhibition of thromboxane B2 synthesis and subsequent platelet activity by all 
      preparations of aspirin, although both microencapsulated aspirin 162.5 mg and 
      aspirin EC 150 mg are slightly more effective than aspirin EC 75 mg. A randomised 
      trial is now required to determine whether microencapsulated aspirin is 
      associated with fewer gastric side-effects.
FAU - Brown, N
AU  - Brown N
AD  - Cardiovascular Medicine, University of Nottingham, Nottingham NG7 2UH, UK.
FAU - May, J A
AU  - May JA
FAU - Wilcox, R G
AU  - Wilcox RG
FAU - Allan, L M
AU  - Allan LM
FAU - Wilson, A M
AU  - Wilson AM
FAU - Kiff, P S
AU  - Kiff PS
FAU - Heptinstall, S
AU  - Heptinstall S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Capsules)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis/*drug therapy/metabolism
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Platelets/drug effects/metabolism
MH  - Capsules
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Single-Blind Method
MH  - Thromboxane B2/metabolism
PMC - PMC2014875
EDAT- 1999/06/26 00:00
MHDA- 1999/06/26 00:01
CRDT- 1999/06/26 00:00
PHST- 1999/06/26 00:00 [pubmed]
PHST- 1999/06/26 00:01 [medline]
PHST- 1999/06/26 00:00 [entrez]
AID - bcp947 [pii]
AID - 10.1046/j.1365-2125.1999.00947.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1999 Jul;48(1):57-62. doi: 10.1046/j.1365-2125.1999.00947.x.

PMID- 33275727
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210504
IS  - 1520-4383 (Electronic)
IS  - 1520-4391 (Print)
IS  - 1520-4383 (Linking)
VI  - 2020
IP  - 1
DP  - 2020 Dec 4
TI  - Does aspirin prevent venous thromboembolism?
PG  - 634-641
LID - 10.1182/hematology.2020000150 [doi]
AB  - Venous thromboembolism (VTE; deep vein thrombosis and/or pulmonary embolism) is a 
      well-established cause of morbidity and mortality in the medical and surgical 
      patient populations. Clinical research in the prevention and treatment of VTE has 
      been a dynamic field of study, with investigations into various treatment 
      modalities ranging from mechanical prophylaxis to the direct oral anticoagulants. 
      Aspirin has long been an inexpensive cornerstone of arterial vascular disease 
      therapy, but its role in the primary or secondary prophylaxis of VTE has been 
      debated. Risk-benefit tradeoffs between aspirin and anticoagulants have changed, 
      in part due to advances in surgical technique and postoperative care, and in part 
      due to the development of safe, easy-to-use oral anticoagulants. We review the 
      proposed mechanisms in which aspirin may act on venous thrombosis, the evidence 
      for aspirin use in the primary and secondary prophylaxis of VTE, and the risk of 
      bleeding with aspirin as compared with anticoagulation.
CI  - © 2020 by The American Society of Hematology.
FAU - Diep, Robert
AU  - Diep R
AD  - Division of Hematology, Department of Medicine, University of Washington, 
      Seattle, WA.
FAU - Garcia, David
AU  - Garcia D
AD  - Division of Hematology, Department of Medicine, University of Washington, 
      Seattle, WA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hematology Am Soc Hematol Educ Program
JT  - Hematology. American Society of Hematology. Education Program
JID - 100890099
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Male
MH  - Venous Thromboembolism/*prevention & control
PMC - PMC7727539
COIS- Conflict-of-interest disclosure: The authors declare no competing financial 
      interests.
EDAT- 2020/12/05 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/12/04 17:10
PHST- 2020/12/04 17:10 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
AID - 474338 [pii]
AID - 2020000150C [pii]
AID - 10.1182/hematology.2020000150 [doi]
PST - ppublish
SO  - Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):634-641. doi: 
      10.1182/hematology.2020000150.

PMID- 20678066
OWN - NLM
STAT- MEDLINE
DCOM- 20110601
LR  - 20191111
IS  - 2212-4063 (Electronic)
IS  - 1871-529X (Linking)
VI  - 10
IP  - 3
DP  - 2010 Sep 1
TI  - New insight in antiplatelet therapy monitoring in cardiovascular patients: from 
      aspirin to thienopyridine.
PG  - 224-33
AB  - Antiplatelet therapy is used to reduce the risk of ischemic events in patients 
      with cardiovascular disease. The balance of benefits and risks of antiplatelet 
      drugs in cardiovascular disease has been evaluated in large-scale randomised 
      trials, however the absolute benefit for an individual patient and a specific 
      platelet-active drug needs further evaluation. Several well-conducted studies 
      have demonstrated a substantial inter-individual variability in platelet 
      responsiveness to drugs. The historical "gold standard" test of platelet function 
      (optical aggregation) has been extensively used for measuring the effect of 
      antiplatelet drugs, but has limitations. New tests developed (i.e. PFA-100®, 
      VerifyNow®) may overcome some of these limitations but they do not correlate well 
      with each other. Despite these unresolved methodological questions, several 
      recent clinical studies, but not all, suggest a significant correlation between 
      antiplatelet resistance status and serious vascular events. In these conditions, 
      laboratory monitoring for antiplatelet therapies raises several questions: (i) 
      the necessity of a consensus regarding the definition of resistance and the 
      relevant test, (ii) the demonstration that biological resistance has clinical 
      significance, and (iii) the clinical impact of individually adjusting the 
      antiplatelet therapy. Therefore, it is not currently appropriate to test patients 
      or to change therapy on the basis of such tests, other than in prospective and 
      adequately powered clinical trials.
FAU - Hezard, N
AU  - Hezard N
AD  - Laboratoire d'Hématologie, CHU Angers, France.
FAU - Tessier-Marteau, A
AU  - Tessier-Marteau A
FAU - Macchi, L
AU  - Macchi L
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Cardiovasc Hematol Disord Drug Targets
JT  - Cardiovascular & hematological disorders drug targets
JID - 101269160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Pyridines/adverse effects/*therapeutic use
EDAT- 2010/08/04 06:00
MHDA- 2011/06/02 06:00
CRDT- 2010/08/04 06:00
PHST- 2010/03/13 00:00 [received]
PHST- 2010/06/10 00:00 [accepted]
PHST- 2010/08/04 06:00 [entrez]
PHST- 2010/08/04 06:00 [pubmed]
PHST- 2011/06/02 06:00 [medline]
AID - BSP/CHDDT/E-Pub/00017 [pii]
AID - 10.2174/1871529x11006030224 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Disord Drug Targets. 2010 Sep 1;10(3):224-33. doi: 
      10.2174/1871529x11006030224.

PMID- 34761666
OWN - NLM
STAT- MEDLINE
DCOM- 20230714
LR  - 20230718
IS  - 2724-5772 (Electronic)
IS  - 2724-5683 (Linking)
VI  - 71
IP  - 4
DP  - 2023 Aug
TI  - Dual pathway inhibition in atherothrombosis prevention: yes, now we can!
PG  - 363-373
LID - 10.23736/S2724-5683.21.05867-1 [doi]
AB  - Despite ongoing developments, prevention and treatment of atherothrombotic 
      cardiovascular disease remains a common challenge. Antithrombotic options for 
      cardiocerebrovascular disease prevention involves a choice between dual 
      antiplatelet therapy (DAPT) and dual pathway inhibition (DPI), which includes an 
      antiplatelet agent and a reduced dose anticoagulant agent. In selected patients 
      at high risk of event and low risk of bleeding, especially those undergoing 
      recent and complex coronary revascularization using drug-eluting stents (DES) 
      ("revascularization-driven effect"), DAPT is superior to single antiplatelet 
      therapy with aspirin. DPI involves a wider potential range of treatment and is 
      superior to single antiplatelet therapy with aspirin, particularly in patients 
      with atherothrombotic involvement in different vascular beds both previously 
      revascularized and not ("no revascularization-driven effect"). After nearly 
      thirty years of randomized trials and observational registries, we have 
      sufficient data to customize antithrombotic therapy in patients at high 
      cardiovascular risk. Therefore, "atherothrombosis stakeholders" must identify the 
      right patient for the right therapy to ensure high levels of efficacy and safety 
      with the best of current therapeutic opportunities.
FAU - Summaria, Francesco
AU  - Summaria F
AD  - Division of Cardiology, San Eugenio Hospital, Rome, Italy - f.summaria@gmail.com.
FAU - Biondi-Zoccai, Giuseppe
AU  - Biondi-Zoccai G
AD  - Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, 
      Latina, Italy.
AD  - Mediterranea Cardiocentro, Naples, Italy.
FAU - Romagnoli, Enrico
AU  - Romagnoli E
AD  - Division of Cardiology, Sacred Heart Catholic University, Rome, Italy.
FAU - Mamas, Mamas A
AU  - Mamas MA
AD  - Keele University, Keele, UK.
FAU - Franchi, Francesco
AU  - Franchi F
AD  - Division of Cardiology, University of Florida College of Medicine Jacksonville, 
      Jacksonville, FL, USA.
FAU - Severino, Paolo
AU  - Severino P
AD  - Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 
      Sapienza University, Rome, Italy.
FAU - Lavalle, Carlo
AU  - Lavalle C
AD  - Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 
      Sapienza University, Rome, Italy.
FAU - Versaci, Francesco
AU  - Versaci F
AD  - Division of Cardiology, Santa Maria Goretti Hospital, Latina, Italy.
FAU - Gaspardone, Achille
AU  - Gaspardone A
AD  - Division of Cardiology, San Eugenio Hospital, Rome, Italy.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 
      Boston, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20211111
PL  - Italy
TA  - Minerva Cardiol Angiol
JT  - Minerva cardiology and angiology
JID - 101776555
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Aspirin/therapeutic use/adverse effects
MH  - Hemorrhage/chemically induced/prevention & control
MH  - *Cardiovascular Diseases/drug therapy/prevention & control/chemically induced
MH  - *Drug-Eluting Stents/adverse effects
EDAT- 2021/11/12 06:00
MHDA- 2023/07/14 13:06
CRDT- 2021/11/11 07:39
PHST- 2023/07/14 13:06 [medline]
PHST- 2021/11/12 06:00 [pubmed]
PHST- 2021/11/11 07:39 [entrez]
AID - S2724-5683.21.05867-1 [pii]
AID - 10.23736/S2724-5683.21.05867-1 [doi]
PST - ppublish
SO  - Minerva Cardiol Angiol. 2023 Aug;71(4):363-373. doi: 
      10.23736/S2724-5683.21.05867-1. Epub 2021 Nov 11.

PMID- 15078587
OWN - NLM
STAT- MEDLINE
DCOM- 20040729
LR  - 20191108
IS  - 1061-5377 (Print)
IS  - 1061-5377 (Linking)
VI  - 12
IP  - 3
DP  - 2004 May-Jun
TI  - Should people on aspirin avoid Ibuprofen? A review of the literature.
PG  - 174-6
AB  - Aspirin reduces the secondary incidence of myocardial infarction and vascular 
      death, but some people on aspirin sustain a subsequent vascular event, suggesting 
      the phenomenon of aspirin resistance. Based on epidemiologic data, some people 
      have recommended avoiding ibuprofen in patients taking aspirin and suggested that 
      ibuprofen reverses the cardioprotection offered by aspirin. We review the related 
      literature. Although the interaction between aspirin and ibuprofen is 
      pharmacologically plausible as shown by in vivo studies, the clinical 
      implications of this observation are unknown. There are no randomized, controlled 
      trials addressing this particular issue. The data obtained from observational and 
      epidemiologic studies is scanty, conflicting, and limited. Therefore, the advice 
      to avoid ibuprofen in patients taking aspirin to avoid the reversal of 
      cardioprotection offered by aspirin seems premature.
FAU - Cheema, Aamir A
AU  - Cheema AA
AD  - Department of Internal Medicine, St. John Hospital, Detroit, Michigan 48225, USA. 
      aamircheema2@eudoramail.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiol Rev
JT  - Cardiology in review
JID - 9304686
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/antagonists & inhibitors/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Drug Antagonism
MH  - Humans
MH  - Ibuprofen/*therapeutic use
RF  - 22
EDAT- 2004/04/14 05:00
MHDA- 2004/07/30 05:00
CRDT- 2004/04/14 05:00
PHST- 2004/04/14 05:00 [pubmed]
PHST- 2004/07/30 05:00 [medline]
PHST- 2004/04/14 05:00 [entrez]
AID - 00045415-200405000-00010 [pii]
AID - 10.1097/01.crd.0000107892.83612.9d [doi]
PST - ppublish
SO  - Cardiol Rev. 2004 May-Jun;12(3):174-6. doi: 10.1097/01.crd.0000107892.83612.9d.

PMID- 17622933
OWN - NLM
STAT- MEDLINE
DCOM- 20070919
LR  - 20161019
IS  - 1744-6872 (Print)
IS  - 1744-6872 (Linking)
VI  - 17
IP  - 8
DP  - 2007 Aug
TI  - UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin.
PG  - 571-9
AB  - OBJECTIVES: In vivo, aspirin (acetylsalicylic acid) is rapidly deacetylated to 
      form salicylic acid, which then undergoes primary or secondary glucuronidation 
      catalyzed by UDP-glucuronosyltransferases (UGTs). The variant UGT1A6*2 (T181A, 
      R184S) is associated with altered enzyme function. Our objective was to compare 
      salicylic acid glucuronidation in individuals with different UGT1A6 genotypes. 
      METHODS: Following orally dosing with 650 mg aspirin, saliva and urine samples 
      were collected over a period of 24 h from healthy individuals with homozygous 
      wild-type UGT1A6 *1/*1 (n=19) and homozygous variant UGT1A6 *2/*2 (T181A, R184S) 
      (n=9) genotypes. RESULTS: No statistically significant differences were observed 
      in salivary pharmacokinetic parameters. Urinary excretion of the sum of aspirin 
      and its metabolites (salicyluric acid, salicyluric acid phenolic glucuronide, 
      salicyl phenolic glucuronide, salicyl acyl glucuronide, salicylic acid) during 
      the early period of 2-4 h of collection was significantly lower in UGT1A6 *1/*1 
      than in UGT1A6 *2/*2 individuals. Further, UGT1A6 *1/*1 individuals excreted a 
      lower percentage of aspirin and its metabolites in the first 12 h and a greater 
      percentage after 12 h than UGT1A6 *2/*2 individuals. CONCLUSIONS: The variant 
      UGT1A6*2 or polymorphisms in other UGTs that are in linkage disequilibrium with 
      UGT1A6*2 may confer more rapid glucuronidation of salicylic acid than the 
      wild-type UGT1A6 *1/*1.
FAU - Chen, Yu
AU  - Chen Y
AD  - University of Washington, Seattle, WA, USA.
FAU - Kuehl, Gwendolyn E
AU  - Kuehl GE
FAU - Bigler, Jeannette
AU  - Bigler J
FAU - Rimorin, Christine F
AU  - Rimorin CF
FAU - Schwarz, Yvonne
AU  - Schwarz Y
FAU - Shen, Danny D
AU  - Shen DD
FAU - Lampe, Johanna W
AU  - Lampe JW
LA  - eng
GR  - T32 CA080416/CA/NCI NIH HHS/United States
GR  - R01 CA92288/CA/NCI NIH HHS/United States
GR  - T32 CA77116/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Pharmacogenet Genomics
JT  - Pharmacogenetics and genomics
JID - 101231005
RN  - 0 (Glucuronides)
RN  - EC 2.4.1.- (UDP-glucuronosyltransferase, UGT1A6)
RN  - EC 2.4.1.17 (Glucuronosyltransferase)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/chemistry/*pharmacology/urine
MH  - Genotype
MH  - Glucuronides/*metabolism
MH  - Glucuronosyltransferase/*genetics
MH  - Humans
MH  - Middle Aged
MH  - Pharmacogenetics
MH  - Polymorphism, Genetic/*genetics
MH  - Salicylic Acid/chemistry/*metabolism/*pharmacokinetics
MH  - Saliva/chemistry
EDAT- 2007/07/12 09:00
MHDA- 2007/09/20 09:00
CRDT- 2007/07/12 09:00
PHST- 2007/07/12 09:00 [pubmed]
PHST- 2007/09/20 09:00 [medline]
PHST- 2007/07/12 09:00 [entrez]
AID - 01213011-200708000-00001 [pii]
AID - 10.1097/01.fpc.0000236339.79916.07 [doi]
PST - ppublish
SO  - Pharmacogenet Genomics. 2007 Aug;17(8):571-9. doi: 
      10.1097/01.fpc.0000236339.79916.07.

PMID- 7752618
OWN - NLM
STAT- MEDLINE
DCOM- 19950621
LR  - 20131121
IS  - 0023-6764 (Print)
IS  - 0023-6764 (Linking)
VI  - 45
IP  - 1
DP  - 1995 Feb
TI  - Disposition kinetics of aspirin in female New Zealand white rabbits.
PG  - 67-9
AB  - Limited information exists on the disposition of aspirin in rabbits. Such 
      information is of value not only for treatment but also for development of 
      experimental protocols with human applications. We evaluated the pharmacokinetics 
      of aspirin at different doses by monitoring serum concentrations of the major 
      metabolite, salicylic acid (SA). Four groups of six female New Zealand white 
      rabbits received 2.5, 10, 20, or 50 mg of aspirin/kg of body weight. Aspirin was 
      given once daily via the oral-gastric route, and blood samples were obtained 
      after the third dose. Samples were collected before the last dose, then at 0.25, 
      0.50, 0.75, 1.0, 1.5, 2, 3, 4, 6, 8, 12, and 24 h after dosing. Analysis of SA 
      was completed by a validated assay on a high-performance liquid chromatography 
      system. Mean maximal serum SA concentration was 7.54, 22.65, 43.2, and 70 
      micrograms/ml for the 2.5, 10, 20, and 50 mg/kg doses respectively. The total 
      systemic clearance of SA was not altered by increasing doses of aspirin, but 
      statistically significant differences were noted in the volume of distribution. 
      The SA elimination half-life also increased proportionally with the aspirin dose. 
      Bleeding tendency was associated with the highest dose of aspirin. Results of 
      this study suggest that the 20 and 50 mg/kg dosages produced serum SA 
      concentrations that simulate those observed in humans after 600-mg and 1.2-g 
      aspirin doses respectively.
FAU - Marangos, M N
AU  - Marangos MN
AD  - Department of Pharmacy, Hartford Hospital, CT 06102, USA.
FAU - Onyeji, C O
AU  - Onyeji CO
FAU - Nicolau, D P
AU  - Nicolau DP
FAU - Nightingale, C H
AU  - Nightingale CH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Lab Anim Sci
JT  - Laboratory animal science
JID - 1266503
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Body Weight
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Kinetics
MH  - Rabbits/*metabolism
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
PST - ppublish
SO  - Lab Anim Sci. 1995 Feb;45(1):67-9.

PMID- 32325408
OWN - NLM
STAT- MEDLINE
DCOM- 20210415
LR  - 20210415
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 236
DP  - 2020 Aug 5
TI  - Interaction between aspirin and vitamin C with human serum albumin as binary and 
      ternary systems.
PG  - 118356
LID - S1386-1425(20)30334-6 [pii]
LID - 10.1016/j.saa.2020.118356 [doi]
AB  - Foods generally contain special ingredients which easily to interact with drugs 
      human intaking, thus affecting drug efficacy and excretion, and even cause 
      adverse reactions. Vitamin C (Vit. C) is abundant in fresh fruits and vegetables. 
      It plays a regulatory role in redox metabolism, and its absence can cause scurvy. 
      Aspirin (ASP) can be used to treat many diseases, is the earliest, common and 
      widely used as antipyretic, analgesic and antirheumatic medicine. Human serum 
      albumin (HSA) is the most abundant protein in vertebrate plasma and has the 
      property of combining and transporting endogenous and exogenous substances. In 
      this paper, the effects of Vit. C on the combination of ASP and HSA were studied 
      by multi-spectra and voltammetric approaches. Fluorescence spectra showed that 
      the quenching mode between Vit. C and HSA is dynamic, and the main binding force 
      is hydrophobic force. The quenching mode between ASP and HSA is static one, and 
      the main binding force is hydrogen bond and van der Waals force. For ternary 
      biological system of (HSA-ASP)-Vit. C, the binding constant decreases compared 
      with HSA-Vit. C system. However, for (HSA-Vit. C)-ASP system, the binding 
      constant does not change when compared with binary system of HSA-ASP. Based on 
      the technology combination of voltammetry, infrared, three-dimensional 
      fluorescence and circular dichroism (CD), it is proved that the existence of ASP 
      will influence the binding process of Vit. C to HSA. It could be concluded that 
      taking Vit. C first doesn't affect the absorption of ASP and may be good for 
      health; in contrast, it is not good to take Vit. C immediately as one have just 
      taken ASP, because the existence of ASP reduce the absorption of Vit. C for human 
      body.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Zhang, Qiulan
AU  - Zhang Q
AD  - School of Chemistry, Nanchang University, Nanchang 330031, China. Electronic 
      address: qlzhang@ncu.edu.cn.
FAU - Zhu, Zhi
AU  - Zhu Z
AD  - School of Chemistry, Nanchang University, Nanchang 330031, China.
FAU - Ni, Yongnian
AU  - Ni Y
AD  - School of Chemistry, Nanchang University, Nanchang 330031, China.
LA  - eng
PT  - Journal Article
DEP - 20200413
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - ZIF514RVZR (Serum Albumin, Human)
SB  - IM
MH  - Ascorbic Acid/chemistry/*metabolism/pharmacokinetics
MH  - Aspirin/*chemistry/*metabolism/pharmacokinetics
MH  - Binding Sites
MH  - Circular Dichroism
MH  - Electrochemical Techniques
MH  - Food-Drug Interactions
MH  - Humans
MH  - Hydrogen Bonding
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Serum Albumin, Human/*chemistry/*metabolism
MH  - Spectrometry, Fluorescence
MH  - Spectroscopy, Fourier Transform Infrared
OTO - NOTNLM
OT  - Aspirin
OT  - Human serum albumin
OT  - Interaction effect
OT  - Multi-spectroscopy
OT  - Vitamin C
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/04/24 06:00
MHDA- 2021/04/16 06:00
CRDT- 2020/04/24 06:00
PHST- 2019/12/20 00:00 [received]
PHST- 2020/04/02 00:00 [revised]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2021/04/16 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
AID - S1386-1425(20)30334-6 [pii]
AID - 10.1016/j.saa.2020.118356 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2020 Aug 5;236:118356. doi: 
      10.1016/j.saa.2020.118356. Epub 2020 Apr 13.

PMID- 7116757
OWN - NLM
STAT- MEDLINE
DCOM- 19821203
LR  - 20190512
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 32
IP  - 4
DP  - 1982 Oct
TI  - Kinetics of the digoxin-aspirin combination.
PG  - 428-30
AB  - Digoxin interacts kinetically with many drugs in man. These interactions may 
      result in digoxin toxicity. Aspirin has been shown to raise serum digoxin levels 
      in the dog. We evaluated the effect of aspirin on digoxin single-dose kinetics in 
      eight healthy adults. Aspirin induced no change in digoxin total body clearance, 
      volume of distribution, elimination half-life, or renal or creatinine clearance. 
      Trough serum salicylate levels ranged from 93 to 163 microgram/ml. We conclude 
      that no alteration is required in digoxin dosing when aspirin is used.
FAU - Fenster, P E
AU  - Fenster PE
FAU - Comess, K A
AU  - Comess KA
FAU - Hanson, C D
AU  - Hanson CD
FAU - Finley, P R
AU  - Finley PR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 73K4184T59 (Digoxin)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Aspirin/blood/*pharmacology
MH  - Creatinine/metabolism
MH  - Digoxin/*metabolism
MH  - Dogs
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Middle Aged
EDAT- 1982/10/01 00:00
MHDA- 1982/10/01 00:01
CRDT- 1982/10/01 00:00
PHST- 1982/10/01 00:00 [pubmed]
PHST- 1982/10/01 00:01 [medline]
PHST- 1982/10/01 00:00 [entrez]
AID - 0009-9236(82)90085-6 [pii]
AID - 10.1038/clpt.1982.184 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1982 Oct;32(4):428-30. doi: 10.1038/clpt.1982.184.

PMID- 21295071
OWN - NLM
STAT- MEDLINE
DCOM- 20110722
LR  - 20220331
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 130
IP  - 2
DP  - 2011 May
TI  - Aspirin resistance: effect of clinical, biochemical and genetic factors.
PG  - 213-25
LID - 10.1016/j.pharmthera.2011.01.011 [doi]
AB  - Aspirin is one of the cornerstones of treatment for cardiovascular disease. 
      However, some patients may be 'resistant' to its effect: this is associated with 
      adverse cardiovascular outcomes and increased mortality. Measuring response to 
      aspirin is often difficult and there is no accepted definition of aspirin 
      resistance. Many assays are available to test aspirin sensitivity but most are 
      not specific to aspirin and the degree of agreement between different assays is 
      poor. Each assay has its own advantages and disadvantages, and there is currently 
      no one assay that can be recommended for routine clinical practise. There are 
      also many potential modifiers of aspirin response including aspirin dose, 
      non-compliance, disease severity, genetic factors, inflammation, diabetes 
      mellitus, hyperlipidaemia, smoking and interacting drugs. Treating the underlying 
      cause may improve aspirin sensitivity but current data are contradictory with no 
      large clinical trials that have addressed this. Further work is required in this 
      area to determine whether and how aspirin resistance is important clinically, 
      what the best measurement is phenotypically and how this should be used in 
      clinical practise, and whether there are any genetic predisposing factors. This 
      will require well designed prospective studies which take into account the 
      numerous confounding factors that can modify aspirin resistance.
CI  - Copyright © 2011 Elsevier Inc. All rights reserved.
FAU - Fitzgerald, Richard
AU  - Fitzgerald R
AD  - The Wolfson Centre for Personalised Medicine, Department of Pharmacology, 
      University of Liverpool, Block A: Waterhouse Buildings, 1-5 Brownlow Street, 
      Liverpool L693GL, United Kingdom.
FAU - Pirmohamed, Munir
AU  - Pirmohamed M
LA  - eng
GR  - Department of Health/United Kingdom
GR  - Medical Research Council/United Kingdom
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110202
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Drug Evaluation/*methods
MH  - Drug Resistance/*genetics/*physiology
MH  - Humans
MH  - Models, Biological
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Platelet Function Tests/*methods
MH  - Risk Factors
EDAT- 2011/02/08 06:00
MHDA- 2011/07/23 06:00
CRDT- 2011/02/08 06:00
PHST- 2011/01/18 00:00 [received]
PHST- 2011/01/18 00:00 [accepted]
PHST- 2011/02/08 06:00 [entrez]
PHST- 2011/02/08 06:00 [pubmed]
PHST- 2011/07/23 06:00 [medline]
AID - S0163-7258(11)00035-0 [pii]
AID - 10.1016/j.pharmthera.2011.01.011 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2011 May;130(2):213-25. doi: 10.1016/j.pharmthera.2011.01.011. 
      Epub 2011 Feb 2.

PMID- 31420787
OWN - NLM
STAT- MEDLINE
DCOM- 20200310
LR  - 20200310
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 48
IP  - 4
DP  - 2019 Nov
TI  - Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical 
      lipid-aspirin complex: results of a randomized, crossover, bioequivalence study.
PG  - 554-562
LID - 10.1007/s11239-019-01933-7 [doi]
AB  - Aspirin (acetylsalicylic acid, ASA) can lead to gastrointestinal mucosal injury 
      through disruption of its protective phospholipid bilayer. A liquid formulation 
      of a novel pharmaceutical lipid-aspirin complex (PL-ASA) was designed to prevent 
      this disruption. We sought to determine the pharmacokinetic (PK)/pharmacodynamic 
      (PD) characteristics of PL-ASA compared with immediate release aspirin (IR-ASA). 
      In this active-control crossover study, 32 healthy volunteers were randomized to 
      receive 1 of 2 dose levels (a single dose of 325 mg or 650 mg) of either PL-ASA 
      or IR-ASA. After a 2-week washout period between treatment assignments, subjects 
      received a single dose of the alternative treatment, at the same dose level. The 
      primary objectives of the study were to assess, for PL-ASA and IR-ASA at 325 mg 
      and 650 mg dose levels, PK and PD bioequivalence, and safety, over a 24-h period 
      after administration of both drugs. PK parameters were similar for PL-ASA and 
      IR-ASA, and met FDA-criteria for bioequivalence. Regarding PD, both drugs also 
      showed C(min) TxB2 values below 3.1 ng/mL (cut-off associated with decreased 
      cardiovascular events) and > 99% inhibition of serum TxB2 ( ≥ 95% inhibition 
      represents the cut-off for aspirin responders) along with similar results in 
      several secondary PK/PD parameters. There were no serious adverse events or 
      changes from baseline in vital signs or laboratory values in either of the 2 
      treatment groups. PL-ASA's novel liquid formulation has similar PK and PD 
      performance compared with IR-ASA, supporting functional and clinical equivalence. 
      These data coupled with the improved gastric safety of PL-ASA suggest that this 
      novel formulation may exhibit an improved benefit-risk profile, warranting 
      evaluation in future trials.Clinical trial registration: 
      http://www.clinicaltrials.gov . Unique Identifier: NCT04008979.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AUID- ORCID: 0000-0001-8451-2131
AD  - Division of Cardiology, University of Florida College of Medicine, 655 West 8th 
      street, Jacksonville, FL, 32209, USA. dominick.angiolillo@jax.ufl.edu.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, 
      Boston, MA, USA.
FAU - Lanza, Frank
AU  - Lanza F
AD  - Houston Institute for Clinical Research, Houston, TX, USA.
FAU - Cryer, Byron
AU  - Cryer B
AD  - University of Texas Southwestern Medical School, Dallas, TX, USA.
FAU - Dong, Jin-Fei
AU  - Dong JF
AD  - Division of Hematology, Department of Medicine, University of Washington, Member, 
      BloodWorks NW Research Institute, Seattle, WA, USA.
FAU - Jeske, Walter
AU  - Jeske W
AD  - Cardiovascular Research Institute, Loyola University Chicago Health Sciences 
      Division, Maywood, IL, USA.
FAU - Zimmerman, Ronald R
AU  - Zimmerman RR
AD  - PLx Pharma, Sparta, NJ, USA.
FAU - von Chong, Estela
AU  - von Chong E
AD  - PLx Pharma, Sparta, NJ, USA.
FAU - Prats, Jayne
AU  - Prats J
AD  - Elysis LLC, Carlisle, MA, USA.
FAU - Deliargyris, Efthymios N
AU  - Deliargyris EN
AD  - PLx Pharma, Sparta, NJ, USA.
FAU - Marathi, Upendra
AU  - Marathi U
AD  - 7 Hills Pharma, Houston, TX, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04008979
GR  - R42DK063882/National Institute of Diabetes and Digestive and Kidney Diseases/
GR  - R42DK063882/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Drug Carriers)
RN  - 0 (Lipids)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects/pharmacokinetics
MH  - Cross-Over Studies
MH  - Drug Carriers/*chemistry
MH  - Gastrointestinal Tract/pathology
MH  - Humans
MH  - Lipids/*therapeutic use
MH  - Middle Aged
MH  - Mucous Membrane/injuries
MH  - Therapeutic Equivalency
MH  - Thromboxane B2/antagonists & inhibitors
MH  - Young Adult
PMC - PMC6800884
OTO - NOTNLM
OT  - Aspirin
OT  - Bioequivalence
OT  - Pharmacodynamic
OT  - Pharmacokinetic
OT  - Platelet
COIS- Dr Angiolillo declares that he has received consulting fees or honoraria from 
      Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, 
      Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, 
      Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company and has 
      received payments for participation in review activities from CeloNova and St 
      Jude Medical. D.J.A. also declares that his institution has received research 
      grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, 
      Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical 
      Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions. Dr. 
      Deepak L. Bhatt discloses the following relationships—Advisory Board: Cardax, 
      Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, 
      PhaseBio, Regado Biosciences; Board of Directors: Boston VA Research Institute, 
      Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart 
      Association Quality Oversight Committee; Data Monitoring Committees: Baim 
      Institute for Clinical Research (formerly Harvard Clinical Research Institute, 
      for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic 
      (including for the ExCEED trial, funded by Edwards), Duke Clinical Research 
      Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, 
      funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: 
      American College of Cardiology (Senior Associate Editor, Clinical Trials and 
      News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for 
      Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI 
      clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II 
      executive committee funded by CSL Behring), Belvoir Publications (Editor in 
      Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial 
      steering committees), HMP Global (Editor in Chief, Journal of Invasive 
      Cardiology), Journal of the American College of Cardiology (Guest Editor; 
      Associate Editor), Medtelligence/ReachMD (CME steering committees), Population 
      Health Research Institute (for the COMPASS operations committee, publications 
      committee, steering committee, and USA national co-leader, funded by Bayer), 
      Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), 
      Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering 
      committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry 
      Steering Committee (Chair), VA CART Research and Publications Committee (Chair); 
      Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer 
      Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Ferring 
      Pharmaceuticals, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, 
      Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The 
      Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A 
      Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston 
      Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of 
      Cardiology; Unfunded Research: FlowCo, Fractyl, Merck, Novo Nordisk, PLx Pharma, 
      Takeda. Dr Cryer is a consultant for Horizon Pharma, PLx Pharma, and Ritter. 
      Pharmaceuticals.Dr. Jeske is the principal investigator on a research grant to 
      Loyola University Chicago from KinMaster Produtos Quimicos and has been a 
      consultant to PLx Pharma Inc., Machaon Diagnostics, and Repros Therapeutics. Dr. 
      Deliargyris, Mr, Zimmerman, and Ms, von Chong are employees of PLx Pharma. Dr. 
      Prats is a consultant to PLx Pharma. Dr. Marathi was an employee of PLx Pharma at 
      the time of the study, and is an investor, option holder, and a co-inventor of 
      the PL-ASA delivery technology. All other authors report no conflicts related to 
      the current study.
EDAT- 2019/08/20 06:00
MHDA- 2020/03/11 06:00
CRDT- 2019/08/18 06:00
PHST- 2019/08/20 06:00 [pubmed]
PHST- 2020/03/11 06:00 [medline]
PHST- 2019/08/18 06:00 [entrez]
AID - 10.1007/s11239-019-01933-7 [pii]
AID - 1933 [pii]
AID - 10.1007/s11239-019-01933-7 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2019 Nov;48(4):554-562. doi: 10.1007/s11239-019-01933-7.

PMID- 3563969
OWN - NLM
STAT- MEDLINE
DCOM- 19870506
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 56
IP  - 3
DP  - 1986 Dec 15
TI  - Role of red blood cells in the early stages of platelet activation by collagen.
PG  - 376-81
AB  - Red blood cells (RBC) increase the proaggregatory capacity of a cell-free 
      supernatant obtained by stimulating platelet-rich plasma (PRP) samples with 
      collagen (1 microgram/ml) as measured by the BASIC wave; this effect increases 
      with the number of RBC and is proportionally greater with a lower number of 
      platelets or when lower collagen concentrations are used. Aspirin (ASA) modifies 
      the RBC behaviour in relation to their platelet-collagen interaction. This is 
      demonstrated by the fact that when PRP and RBC obtained from the same subjects 
      before and two hours after the ingestion of ASA (0.5 g) were mixed, it was found 
      that non-ASA-RBC stimulate ASA-PRP, probably through a platelet cyclooxygenase 
      independent pathway; ASA-RBC, however, stimulate non-ASA-PRP, but not ASA-PRP, 
      which suggests that they may need an active platelet cyclooxygenase system for 
      their action. This effect of ASA on RBC is not transient and was also observable 
      48 h after ASA ingestion. In addition, it was found that ASA-RBC greatly increase 
      the activation of a mixture containing a small proportion of non-ASA-PRP in 
      ASA-PRP, a situation that is expected to be encountered "in vivo" after ASA 
      treatment. This effect of ASA-RBC on platelet activation may help to explain the 
      sometimes contradictory clinical effect of aspirin as an antithrombotic drug.
FAU - Santos, M T
AU  - Santos MT
FAU - Vallés, J
AU  - Vallés J
FAU - Aznar, J
AU  - Aznar J
FAU - Pérez-Requejo, J L
AU  - Pérez-Requejo JL
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Physiological Phenomena
MH  - Cell Communication/drug effects
MH  - Collagen/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Erythrocytes/drug effects/*physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Count
EDAT- 1986/12/15 00:00
MHDA- 1986/12/15 00:01
CRDT- 1986/12/15 00:00
PHST- 1986/12/15 00:00 [pubmed]
PHST- 1986/12/15 00:01 [medline]
PHST- 1986/12/15 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1986 Dec 15;56(3):376-81.

PMID- 18506010
OWN - NLM
STAT- MEDLINE
DCOM- 20080723
LR  - 20131121
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 117
IP  - 22
DP  - 2008 Jun 3
TI  - Cost-effectiveness of aspirin treatment in the primary prevention of 
      cardiovascular disease events in subgroups based on age, gender, and varying 
      cardiovascular risk.
PG  - 2875-83
LID - 10.1161/CIRCULATIONAHA.107.735340 [doi]
AB  - BACKGROUND: Aspirin is effective for the primary prevention of cardiovascular 
      events, but it remains unclear for which subgroups of individuals aspirin is 
      beneficial. We assessed the cost-effectiveness of aspirin separately for men and 
      women of different ages with various levels of cardiovascular disease risk. 
      METHODS AND RESULTS: A Markov model was developed to predict the number of 
      cardiovascular events prevented, quality-adjusted life-years, and costs over a 
      10-year period. Event rates were taken from Dutch population data, and the 
      relative effectiveness of aspirin was taken from a gender-specific meta-analysis. 
      Sensitivity analyses and Monte Carlo simulations were conducted to evaluate the 
      robustness of the results. In 55-year-old persons, aspirin prevented myocardial 
      infarctions in men (127 events per 100,000 person-years) and ischemic strokes in 
      women (17 events per 100,000 person-years). Aspirin implies a net investment and 
      a quality-adjusted life-year gain in men 55 years of age; the incremental 
      cost-effectiveness ratio was 111,949 euros per quality-adjusted life-year (1 
      euro=$1.27 as of June 2007). Aspirin was cost-effective for 55- and 65-year-old 
      men with moderate cardiovascular risk and men 75 years of age (10-year 
      cardiovascular disease risk >10%). Conversely, aspirin was beneficial for women 
      65 years of age with high cardiovascular risk and women 75 years of age with 
      moderate cardiovascular risk (10-year cardiovascular disease risk >15%). Results 
      were sensitive to drug treatment costs, effectiveness of aspirin treatment, and 
      utility of taking aspirin. CONCLUSIONS: Aspirin treatment for primary prevention 
      is cost-effective for men with a 10-year cardiovascular disease risk of >10% and 
      for women with a risk of >15%. This occurs much later in life for women than men. 
      Therefore, opportunities for the primary prevention of aspirin seem limited in 
      women, and a differentiated preventive strategy seems warranted.
FAU - Greving, Jacoba P
AU  - Greving JP
AD  - Julius Center for Health Sciences and Primary Care, Department of Neurology and 
      Neurosurgery, University Medical Center Utrecht, Utrecht, Netherlands. 
      J.P.Greving@umcutrecht.nl
FAU - Buskens, Erik
AU  - Buskens E
FAU - Koffijberg, Hendrik
AU  - Koffijberg H
FAU - Algra, Ale
AU  - Algra A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080527
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 2008 Jun 3;117(22):2844-6. PMID: 18519859
MH  - Age Factors
MH  - Aged
MH  - Aspirin/*economics/therapeutic use
MH  - Cardiovascular Diseases/*epidemiology/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Monte Carlo Method
MH  - Primary Prevention/*methods
MH  - Risk Assessment
MH  - Sex Factors
EDAT- 2008/05/29 09:00
MHDA- 2008/07/24 09:00
CRDT- 2008/05/29 09:00
PHST- 2008/05/29 09:00 [pubmed]
PHST- 2008/07/24 09:00 [medline]
PHST- 2008/05/29 09:00 [entrez]
AID - CIRCULATIONAHA.107.735340 [pii]
AID - 10.1161/CIRCULATIONAHA.107.735340 [doi]
PST - ppublish
SO  - Circulation. 2008 Jun 3;117(22):2875-83. doi: 10.1161/CIRCULATIONAHA.107.735340. 
      Epub 2008 May 27.

PMID- 30992471
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20210109
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Apr 16
TI  - Aspirin impairs acetyl-coenzyme A metabolism in redox-compromised yeast cells.
PG  - 6152
LID - 10.1038/s41598-019-39489-4 [doi]
LID - 6152
AB  - Aspirin is a widely used anti-inflammatory and antithrombotic drug also known in 
      recent years for its promising chemopreventive antineoplastic properties, thought 
      to be mediated in part by its ability to induce apoptotic cell death. However, 
      the full range of mechanisms underlying aspirin's cancer-preventive properties is 
      still elusive. In this study, we observed that aspirin impaired both the 
      synthesis and transport of acetyl-coenzyme A (acetyl-CoA) into the mitochondria 
      of manganese superoxide dismutase (MnSOD)-deficient Saccharomyces cerevisiae 
      EG110 yeast cells, but not of the wild-type cells, grown aerobically in ethanol 
      medium. This occurred at both the gene level, as indicated by microarray and 
      qRT-PCR analyses, and at the protein level as indicated by enzyme assays. These 
      results show that in redox-compromised MnSOD-deficient yeast cells, but not in 
      wild-type cells, aspirin starves the mitochondria of acetyl-CoA and likely causes 
      energy failure linked to mitochondrial damage, resulting in cell death. Since 
      acetyl-CoA is one of the least-studied targets of aspirin in terms of the 
      latter's propensity to prevent cancer, this work may provide further mechanistic 
      insight into aspirin's chemopreventive behavior with respect to early stage 
      cancer cells, which tend to have downregulated MnSOD and are also 
      redox-compromised.
FAU - Farrugia, Gianluca
AU  - Farrugia G
AD  - Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta.
AD  - Department of Physiology & Biochemistry, University of Malta, Msida, Malta.
FAU - Azzopardi, Maria
AU  - Azzopardi M
AD  - Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta.
AD  - Department of Physiology & Biochemistry, University of Malta, Msida, Malta.
FAU - Saliba, Christian
AU  - Saliba C
AD  - Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta.
FAU - Grech, Godfrey
AU  - Grech G
AD  - Department of Pathology, University of Malta, Msida, Malta.
FAU - Gross, Angelina S
AU  - Gross AS
AUID- ORCID: 0000-0002-8096-0831
AD  - Institute of Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria.
FAU - Pistolic, Jelena
AU  - Pistolic J
AD  - Genomics Core Facility, European Molecular Biology Laboratory, Heidelberg, 
      Germany.
FAU - Benes, Vladimir
AU  - Benes V
AUID- ORCID: 0000-0002-0352-2547
AD  - Genomics Core Facility, European Molecular Biology Laboratory, Heidelberg, 
      Germany.
FAU - Vassallo, Neville
AU  - Vassallo N
AD  - Department of Physiology & Biochemistry, University of Malta, Msida, Malta.
FAU - Borg, Joseph
AU  - Borg J
AUID- ORCID: 0000-0002-2220-5651
AD  - Department of Applied Biomedical Science, University of Malta, Msida, Malta.
FAU - Madeo, Frank
AU  - Madeo F
AD  - Institute of Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria.
AD  - BioTechMed Graz, Graz, Austria.
FAU - Eisenberg, Tobias
AU  - Eisenberg T
AUID- ORCID: 0000-0003-3559-1130
AD  - Institute of Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria.
AD  - BioTechMed Graz, Graz, Austria.
AD  - Central Lab Gracia, NAWI Graz, University of Graz, Graz, Austria.
FAU - Balzan, Rena
AU  - Balzan R
AD  - Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta. 
      rena.balzan@um.edu.mt.
AD  - Department of Physiology & Biochemistry, University of Malta, Msida, Malta. 
      rena.balzan@um.edu.mt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190416
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Fibrinolytic Agents)
RN  - 72-89-9 (Acetyl Coenzyme A)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetyl Coenzyme A/*metabolism
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Biosynthetic Pathways/drug effects
MH  - Fibrinolytic Agents/*pharmacology
MH  - Mitochondria/drug effects/metabolism
MH  - Oxidation-Reduction/drug effects
MH  - Saccharomyces cerevisiae/*drug effects/enzymology/metabolism
MH  - Superoxide Dismutase/metabolism
PMC - PMC6468118
COIS- The authors declare no competing interests.
EDAT- 2019/04/18 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/04/18 06:00
PHST- 2018/07/09 00:00 [received]
PHST- 2018/12/20 00:00 [accepted]
PHST- 2019/04/18 06:00 [entrez]
PHST- 2019/04/18 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1038/s41598-019-39489-4 [pii]
AID - 39489 [pii]
AID - 10.1038/s41598-019-39489-4 [doi]
PST - epublish
SO  - Sci Rep. 2019 Apr 16;9(1):6152. doi: 10.1038/s41598-019-39489-4.

PMID- 14763350
OWN - NLM
STAT- MEDLINE
DCOM- 20040219
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 32
IP  - 37 Pt 2
DP  - 2003 Nov 22
TI  - [Digestive and hemorrhage complications of low-dose aspirin].
PG  - S17-28
AB  - INTRODUCTION: The gastro-intestinal (GI) toxicity associated with high dose 
      aspirin has been fully demonstrated, but remains poorly elucidated at low doses 
      i.e., less than 500 mg/day. Such toxicity is relatively difficult to study 
      because lesional and/or bleeding GI complications are not always well described 
      in studies. The objective of this review is to compile a documented inventory of 
      GI complications induced by low-dose aspirin. METHODOLOGY: This review is based 
      on a detailed review of randomized studies, case-control and cohort studies which 
      aim to study the GI toxicity of low-dose aspirin. These studies have been 
      selected based on specific criteria from works published from 1983 to 2003 
      (PubMed). RESULTS: In 8 randomized, placebo-controlled or group-controlled 
      studies, erosions, in particular gastric erosions, are more frequent in the 
      elderly than in younger subjects. On the other hand, the prevalence of gastric 
      and duodenal ulcers does not appear to be significantly increased except in 
      specific cases. The most significant complications are GI bleeding described only 
      in 3% of cases. Among randomized studies which have evaluated the cardiovascular 
      and neurological usefulness of low-dose aspirin, 16 have evaluated GI safety and 
      tolerability as a secondary end-point. These studies demonstrated a 
      non-significant increase in esophageal, gastric and duodenal ulcers during 
      treatment with low-dose aspirin (Odds Ratio = 1.22, P = 0.08), but a significant 
      increase in bleeding ulcers (Odds Ratio = 1.77, P = 0.04). These complications 
      seem to occur in rare cases (less than 3% of patients) and often seem minor. 
      Nevertheless, ulcers have been less studied than bleeding because few endoscopic 
      analyses have been performed in these studies. The gastro-duodenal bleeding 
      related to erosions or ulcers are significantly more frequent with Odds Ratios 
      between 1.3 and 3.3 (P < 0.05). There are 8 case-controlled studies and 1 cohort 
      follow-up study which confirm the increased GI risk with low-dose aspirin. GI 
      bleeding adverse effects related mainly to gastro-duodenal ulcers are more 
      frequent in case of the regular use of aspirin. CONCLUSION: The GI risk exists, 
      starting with the lowest doses and appears to be dose-dependent. The lesional 
      complications consist mainly of erosive lesions, most often gastric, and rarely 
      true ulcers. Cases of bleeding appear more frequent, but generally are minor. 
      This risk should be taken into account by the prescribing physician and the 
      patient should be informed when treatment with low-dose aspirin is initiated.
FAU - Sibilia, Jean
AU  - Sibilia J
AD  - Service de rhumatologie, CHU de Strasbourg, Hôpital de Hautepierre, Strasbourg.
FAU - Ravaud, Philippe
AU  - Ravaud P
FAU - Marck, Géraldine
AU  - Marck G
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Les complications digestives et hémorragiques de l'aspirine à faible dose.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Duodenal Ulcer/*chemically induced
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Stomach Ulcer/*chemically induced
RF  - 74
EDAT- 2004/02/07 05:00
MHDA- 2004/02/20 05:00
CRDT- 2004/02/07 05:00
PHST- 2004/02/07 05:00 [pubmed]
PHST- 2004/02/20 05:00 [medline]
PHST- 2004/02/07 05:00 [entrez]
PST - ppublish
SO  - Presse Med. 2003 Nov 22;32(37 Pt 2):S17-28.

PMID- 6829384
OWN - NLM
STAT- MEDLINE
DCOM- 19830415
LR  - 20131121
IS  - 0002-838X (Print)
IS  - 0002-838X (Linking)
VI  - 27
IP  - 3
DP  - 1983 Mar
TI  - Treatment of juvenile arthritis.
PG  - 133-9
AB  - Aspirin remains the cornerstone of treatment for juvenile arthritis, although 
      tolmetin may be more effective in controlling the fever of systemic-onset 
      disease. Tolmetin and naproxen appear to be more effective in HLA-B27 positive 
      males with pauciarticular disease. When the nonsteroidal anti-inflammatory drugs 
      fail, gold, penicillamine and, occasionally, immunosuppressive agents may be used 
      in the polyarticular forms. Prosthetic joint replacement may be beneficial for 
      patients with extensive disease. The emotional and sexual problems of children 
      with chronic disease require recognition and help.
FAU - Baum, J
AU  - Baum J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Fam Physician
JT  - American family physician
JID - 1272646
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 7440-57-5 (Gold)
RN  - GNN1DV99GX (Penicillamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Arthritis, Juvenile/*therapy
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Child
MH  - Female
MH  - Gold/therapeutic use
MH  - Humans
MH  - Hydroxychloroquine/therapeutic use
MH  - Joint Prosthesis
MH  - Male
MH  - Penicillamine/therapeutic use
MH  - Psychotherapy
MH  - Reye Syndrome/chemically induced
MH  - Synovitis/surgery
MH  - Tablets, Enteric-Coated
EDAT- 1983/03/01 00:00
MHDA- 1983/03/01 00:01
CRDT- 1983/03/01 00:00
PHST- 1983/03/01 00:00 [pubmed]
PHST- 1983/03/01 00:01 [medline]
PHST- 1983/03/01 00:00 [entrez]
PST - ppublish
SO  - Am Fam Physician. 1983 Mar;27(3):133-9.

PMID- 112475
OWN - NLM
STAT- MEDLINE
DCOM- 19791017
LR  - 20220316
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 301
IP  - 11
DP  - 1979 Sep 13
TI  - Prevention of thrombosis in patients on hemodialysis by low-dose aspirin.
PG  - 577-9
AB  - Since platelet cyclo-oxygenase is much more sensitive to inactivation by aspirin 
      than is the enzyme in the arterial wall and low doses of aspirin may prevent 
      thrombosis by blocking thromboxane synthesis, we conducted a randomized, 
      double-blind trial of aspirin (160 mg per day) vs. placebo in 44 patients on 
      chronic hemodialysis. The study was continued until there were 24 patients with 
      thrombi and both groups had been under observation for a mean of nearly five 
      months. Thrombi occurred in 18 of 25 (72 per cent) of patients given placebo and 
      16 of 19 (32 per cent) of those given aspirin (P less than 0.01). The incidence 
      of thrombosis was reduced from 0.46 thrombi per patient month in the placebo 
      group to 0.16 thrombi per patient month in the aspirin group (p less than 0.005). 
      A dose of 160 mg of aspirin per day is an effective, nontoxic antithrombotic 
      regimen in patients on hemodialysis.
FAU - Harter, H R
AU  - Harter HR
FAU - Burch, J W
AU  - Burch JW
FAU - Majerus, P W
AU  - Majerus PW
FAU - Stanford, N
AU  - Stanford N
FAU - Delmez, J A
AU  - Delmez JA
FAU - Anderson, C B
AU  - Anderson CB
FAU - Weerts, C A
AU  - Weerts CA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Adult
MH  - Arteriovenous Shunt, Surgical/adverse effects
MH  - Aspirin/*administration & dosage/pharmacology/therapeutic use
MH  - Blood Platelets/enzymology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostaglandin-Endoperoxide Synthases/blood
MH  - Renal Dialysis/*adverse effects
MH  - Sex Factors
MH  - Thrombosis/enzymology/epidemiology/*prevention & control
MH  - Time Factors
EDAT- 1979/09/13 00:00
MHDA- 1979/09/13 00:01
CRDT- 1979/09/13 00:00
PHST- 1979/09/13 00:00 [pubmed]
PHST- 1979/09/13 00:01 [medline]
PHST- 1979/09/13 00:00 [entrez]
AID - 10.1056/NEJM197909133011103 [doi]
PST - ppublish
SO  - N Engl J Med. 1979 Sep 13;301(11):577-9. doi: 10.1056/NEJM197909133011103.

PMID- 1096275
OWN - NLM
STAT- MEDLINE
DCOM- 19750929
LR  - 20191028
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - 14
IP  - 2
DP  - 1975 May
TI  - A double-blind cross-over trail of Prenazone and aspirin in the management of 
      rheumatoid arthritis.
PG  - 61-70
AB  - A double-blind cross-over trial of Prenazone 600 mg and Aspirin 4 g daily was 
      carried out on 20 patients suffering with rheumatoid arthritis. The analgesic and 
      anti-inflammmatory activity was indistinguishable from that of aspirin under the 
      conditions of the trail. Twelve patients expressed a general preference for 
      Prenazone and six for aspirin. Prenazone appeared to be well tolerated and free 
      from serious side-effects. These results suggest that it will be a useful drug in 
      the management of rheumatoid arthritis.
FAU - Billings, R
AU  - Billings R
FAU - Burry, H C
AU  - Burry HC
FAU - Grahame, R
AU  - Grahame R
FAU - Berry, D J
AU  - Berry DJ
FAU - Donovan, B
AU  - Donovan B
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1975/05/01 00:00
MHDA- 1975/05/01 00:01
CRDT- 1975/05/01 00:00
PHST- 1975/05/01 00:00 [pubmed]
PHST- 1975/05/01 00:01 [medline]
PHST- 1975/05/01 00:00 [entrez]
AID - 10.1093/rheumatology/14.2.61 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1975 May;14(2):61-70. doi: 10.1093/rheumatology/14.2.61.

PMID- 2931045
OWN - NLM
STAT- MEDLINE
DCOM- 19851007
LR  - 20131121
IS  - 0003-438X (Print)
IS  - 0003-438X (Linking)
VI  - 102
IP  - 5
DP  - 1985
TI  - [Mechanisms of aspirin intolerance].
PG  - 357-63
AB  - Aspirin intolerance brings on cutaneous and/or respiratory reactions. The 
      mechanisms are to be elucidated precisely, but are not IgE-mediated. 193 patients 
      with nasal polyps are studied. With systematic aspirin oral challenge, 27% belong 
      to the classical triad: asthma, polyps and aspirin sensitivity. Other drugs or 
      chemicals intolerance are associated in 42%: alcohol, metabisulfites, benzoates, 
      tartrazine, codeine... A link with the non-allergic eosinophilic rhinitis is 
      suggested. A short review of several pathogenic hypothesis is discussed. Among a 
      comparative study, the authors showed that the aspirin-intolerant patients' 
      platelets have a quite normal arachidonic acid metabolism. The clue is probably 
      towards an abnormal instability of cells membranes and excessive receptors 
      sensitivity to leukotrienes.
FAU - Moneret-Vautrin, D A
AU  - Moneret-Vautrin DA
FAU - Wayoff, M
AU  - Wayoff M
FAU - Bonne, C
AU  - Bonne C
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Les mécanismes de l'intolérance à l'aspirine.
PL  - France
TA  - Ann Otolaryngol Chir Cervicofac
JT  - Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la 
      Societe d'oto-laryngologie des hopitaux de Paris
JID - 9431026
RN  - 0 (Arachidonic Acids)
RN  - 0 (Free Radicals)
RN  - 0 (Membrane Lipids)
RN  - 0 (Phospholipids)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/*adverse effects
MH  - Bronchial Diseases/chemically induced
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Drug Eruptions/etiology
MH  - Drug Hypersensitivity/*physiopathology
MH  - Free Radicals
MH  - Humans
MH  - Membrane Lipids/metabolism
MH  - Nasal Polyps/chemically induced
MH  - Otorhinolaryngologic Diseases/chemically induced
MH  - Phospholipids/metabolism
MH  - Prostaglandins/metabolism
RF  - 41
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Ann Otolaryngol Chir Cervicofac. 1985;102(5):357-63.

PMID- 22292958
OWN - NLM
STAT- MEDLINE
DCOM- 20121031
LR  - 20131121
IS  - 1538-0254 (Electronic)
IS  - 0739-1102 (Linking)
VI  - 29
IP  - 5
DP  - 2012
TI  - Probing the interaction of human serum albumin with bilirubin in the presence of 
      aspirin by multi-spectroscopic, molecular modeling and zeta potential techniques: 
      insight on binary and ternary systems.
PG  - 1013-50
AB  - Here, we report on the effect of aspirin (ASA), on the binding parameters with 
      regard to bilirubin (BR) to human serum albumin (HSA). Two different classes of 
      binding sites were detected. Binding to the first and second classes of the 
      binding sites was dominated by hydrophobic forces in the case of HSA-BR, whereas 
      in the case of the ternary system, binding to the first and second classes of the 
      binding sites was achieved by electrostatic interaction. The binding constant 
      (K(a)) and number of binding site (n) obtained were 1.6 × 10(6)M(-1) and 0.98, 
      respectively, for the primary binding site in the case of HSA-BR, and 3.7 × 
      10(6)M(-1) and 0.84, respectively, in the presence of ASA (ternary complex) at 
      λ(ex)= 280 nm. The progressive quenching of the protein fluorescence as the BR 
      concentration increased indicated an arrangement of the domain IIA in HSA. 
      Changes in the environment of the aromatic residues were also observed by 
      synchronous fluorescence spectroscopy (SFS). Changes of the secondary structure 
      of HSA involving a decrease of α-helical and β-sheet contents and increased 
      amounts of turns and unordered conformations were mainly found at high 
      concentrations of BR. For the first time, the relationship between the structural 
      parameters of HSA-BR by RLS for determining the critical induced aggregation 
      concentration (C(CIAC)) of BR in the absence and presence of ASA was 
      investigated, and there was a more significant enhancement in the case of the 
      ternary mixture as opposed to the binary one. Changes in the zeta potential of 
      HSA and the HSA-ASA complex in the presence of BR demonstrated a hydrophobic 
      adsorption of this anionic ligand onto the surface of HSA in the binary system as 
      well as both electrostatic and hydrophobic adsorption in the case of the ternary 
      complex. By performing docking experiments, it was found that the acting forces 
      between BR and HSA were mainly hydrophobic > hydrogen bonding > electrostatic 
      interactions, and consequently BR had a long storage time in blood plasma, 
      especially in the presence of ASA. This was due to the electrostatic interaction 
      force between the BR and HSA being stronger in (HSA-ASA) BR than in the HSA-BR 
      complex. In addition, it was demonstrated that, in the presence of ASA, the first 
      binding site of BR on HSA was altered, but the parameters of binding did not 
      become significantly modified, and thus the affinity of BR barely changed with 
      and without ASA.
FAU - Hosainzadeh, Akram
AU  - Hosainzadeh A
AD  - Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad 
      University, Mashhad, Iran.
FAU - Gharanfoli, Mohsen
AU  - Gharanfoli M
FAU - Saberi, Mohammad
AU  - Saberi M
FAU - Chamani, JamshidKhan
AU  - Chamani J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Biomol Struct Dyn
JT  - Journal of biomolecular structure & dynamics
JID - 8404176
RN  - 0 (Serum Albumin)
RN  - 42HK56048U (Tyrosine)
RN  - 8DUH1N11BX (Tryptophan)
RN  - R16CO5Y76E (Aspirin)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Aspirin/chemistry/*metabolism/pharmacology
MH  - Bilirubin/chemistry/*metabolism
MH  - Binding Sites
MH  - Circular Dichroism
MH  - Humans
MH  - Hydrogen Bonding
MH  - Hydrophobic and Hydrophilic Interactions
MH  - *Models, Molecular
MH  - Protein Conformation
MH  - Protein Structure, Secondary
MH  - Serum Albumin/*chemistry/*metabolism
MH  - Spectrometry, Fluorescence
MH  - Static Electricity
MH  - Tryptophan
MH  - Tyrosine/chemistry
EDAT- 2012/02/02 06:00
MHDA- 2012/11/01 06:00
CRDT- 2012/02/02 06:00
PHST- 2012/02/02 06:00 [entrez]
PHST- 2012/02/02 06:00 [pubmed]
PHST- 2012/11/01 06:00 [medline]
AID - c4318/Probing-the-Interaction-of-Human-Serum-Albumin-With-Bilirubin-in-the-Presence-of-Aspirin-by-Multi-Spectroscopic-Molecular-Modeling-and-Zeta-Potential-Techniques-Insight-on-Binary-and-Ternary-Systems-p18395.html 
      [pii]
AID - 10.1080/073911012010525029 [doi]
PST - ppublish
SO  - J Biomol Struct Dyn. 2012;29(5):1013-50. doi: 10.1080/073911012010525029.

PMID- 18242733
OWN - NLM
STAT- MEDLINE
DCOM- 20081010
LR  - 20181201
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 128
IP  - 2
DP  - 2008 Aug 18
TI  - Residual platelet reactivity on aspirin therapy and recurrent cardiovascular 
      events--a meta-analysis.
PG  - 166-71
LID - 10.1016/j.ijcard.2007.12.010 [doi]
AB  - BACKGROUND: Recently, a growing body of evidence on the possible role of residual 
      platelet reactivity (RPR) in affecting clinical events has accumulated. The aim 
      of this study was to systematically assess the relationship between RPR on 
      acetylic salicylic acid (ASA) therapy and the occurrence of recurrent events in a 
      meta-analysis of prospective studies. METHODS: A systematic literature search of 
      MEDLINE, EMBASE, Science Citation Index, the Cochrane Systematic Review Database 
      and bibliographies of retrieved articles through May 2007 was conducted. Studies 
      were included if they analysed RPR in coronary heart disease patients in relation 
      to the occurrence of adverse coronary events during follow-up. RESULTS: Eleven 
      prospective studies, incorporating 1952 patients with coronary heart disease 
      followed for a time ranging from 6 days to 4 years, met the inclusion criteria. 
      The pooled analysis demonstrated a significantly increased relative risk of 
      adverse clinical events during follow-up for patients with RPR on ASA therapy 
      (RR: 3.11, 95%CI 1.88-5.15; p<0.0001). Moreover, the association between RPR and 
      cardiovascular recurrences remained to be statistically significant even when 
      subgroup analyses performed according to the duration of follow-up, ASA dosage, 
      characteristics of the study population, and laboratory method were conducted. 
      CONCLUSIONS: The present meta-analysis documents a significant association 
      between RPR on ASA treatment and recurrent cardiovascular events. More 
      prospective studies are needed to determine the independent prognostic importance 
      of RPR during aspirin therapy and possible benefit of individually tailored 
      anti-platelet treatment strategies in these patients.
FAU - Sofi, Francesco
AU  - Sofi F
AD  - Department of Medical and Surgical Critical Care, Thrombosis Centre, University 
      of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 
      francescosofi@gmail.com
FAU - Marcucci, Rossella
AU  - Marcucci R
FAU - Gori, Anna Maria
AU  - Gori AM
FAU - Abbate, Rosanna
AU  - Abbate R
FAU - Gensini, Gian Franco
AU  - Gensini GF
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20080201
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*metabolism
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Coronary Disease/*drug therapy
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Recurrence
RF  - 27
EDAT- 2008/02/05 09:00
MHDA- 2008/10/11 09:00
CRDT- 2008/02/05 09:00
PHST- 2007/08/24 00:00 [received]
PHST- 2007/12/04 00:00 [revised]
PHST- 2007/12/11 00:00 [accepted]
PHST- 2008/02/05 09:00 [pubmed]
PHST- 2008/10/11 09:00 [medline]
PHST- 2008/02/05 09:00 [entrez]
AID - S0167-5273(07)02145-6 [pii]
AID - 10.1016/j.ijcard.2007.12.010 [doi]
PST - ppublish
SO  - Int J Cardiol. 2008 Aug 18;128(2):166-71. doi: 10.1016/j.ijcard.2007.12.010. Epub 
      2008 Feb 1.

PMID- 20472328
OWN - NLM
STAT- MEDLINE
DCOM- 20101124
LR  - 20211020
IS  - 1578-1275 (Electronic)
IS  - 0212-6567 (Print)
IS  - 0212-6567 (Linking)
VI  - 42
IP  - 9
DP  - 2010 Sep
TI  - [Primary prevention of cardiovascular disease with aspirin: what do the 
      guidelines say?].
PG  - 470-81
LID - 10.1016/j.aprim.2010.01.024 [doi]
AB  - OBJECTIVE: To review the guideline recommendations on aspirin use in primary 
      prevention of cardiovascular diseases. DESIGN: Systematic review. The search was 
      made by condition, treatment and type of prevention. DATA SOURCES: Science 
      Citation Index, SCOPUS, PubMed, Spanish Ministry of Health, World Health 
      Organisation, web sites of national and international scientific societies. DATA 
      EXTRACTION: Two investigators independently reviewed all the guidelines. Specific 
      topics assessed: a) use of antiplatelet treatment in primary prevention b) 
      identification of target population c) identification of recommended dosage, d) 
      identification of criteria of aspirin use, e) publications in English and/or 
      Spanish, f) dissemination at national (Spain) or international level. RESULTS: 
      Nine guidelines on primary prevention and 5 guidelines on diabetes were reviewed. 
      Most of them recommended low dose aspirin ranging between 75mg and 325mg per day. 
      All the guidelines recommend a specifc level of coronary risk to define the 
      target population to be treated, showing high variability in risk tables used and 
      in the level of risk which should be used to recommend treatment. The diabetes 
      guidelines do not define any level of risk. Three guidelines recommend the use of 
      aspirin when blood pressure is well controlled. CONCLUSIONS: There is high 
      variability among guidelines in terms of the level of risk from which patients 
      should be treated, and also in dosages. Most of the guidelines recommend the use 
      aspirin in diabetics, although some discrepancies exist among international 
      panels, and even in different documents of the same scientific society.
CI  - 2009 Elsevier España, S.L. All rights reserved.
FAU - Brotons Cuixart, Carlos
AU  - Brotons Cuixart C
AD  - Unidad de Investigación, Equipo de Atención Primaria Sardenya, Barcelona, España. 
      cbrotons@eapsardenya.cat
FAU - Moral Peláez, Irene
AU  - Moral Peláez I
LA  - spa
PT  - Journal Article
PT  - Review
PT  - Systematic Review
TT  - Prevención primaria de la enfermedad cardiovascular con aspirina: ¿qué dicen las 
      guías de práctica clínica?
DEP - 20100515
PL  - Spain
TA  - Aten Primaria
JT  - Atencion primaria
JID - 9111075
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - *Practice Guidelines as Topic
MH  - Primary Prevention
PMC - PMC7024482
EDAT- 2010/05/18 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/05/18 06:00
PHST- 2009/12/04 00:00 [received]
PHST- 2010/01/28 00:00 [revised]
PHST- 2010/01/29 00:00 [accepted]
PHST- 2010/05/18 06:00 [entrez]
PHST- 2010/05/18 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - S0212-6567(10)00145-9 [pii]
AID - 10.1016/j.aprim.2010.01.024 [doi]
PST - ppublish
SO  - Aten Primaria. 2010 Sep;42(9):470-81. doi: 10.1016/j.aprim.2010.01.024. Epub 2010 
      May 15.

PMID- 7120026
OWN - NLM
STAT- MEDLINE
DCOM- 19821202
LR  - 20190913
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 5
IP  - 4
DP  - 1982 Apr
TI  - Studies on aspirin derivatives with very little side effects. III. Absorption, 
      distribution, excretion and metabolism of tritium-labeled 
      aspirin-isopropylantipyrine (AIA) in rats.
PG  - 252-8
AB  - The absorption, distribution, excretion, metabolism and protein binding of orally 
      administered tritium-labeled aspirin-isopropylantipyrine (AIA) were demonstrated 
      in rats. 3H-AIA having 0.1 micro Ci/mg of specific activity and 93.2% of 
      radiochemical purity was prepared by the Wilzbach's method. When 3H-AIA was 
      administered orally to rats, about 20% of the given 3H was absorbed from 
      gastro-intestinal tracts in 30 min and about 50% in 3 h, 72% of the dose was 
      excreted in the feces and urine during 5 d, and 10% was excreted in the bile in 
      24 h. The highest accumulation of 3H in most organs was found in one to three hr 
      after oral administration and 3H was concentrated in the liver. THe major 
      metabolites excreted in urine within 24 h after administration were salicylic 
      acid-isopropylantipyrine (SIA) sulfate (57.7%) and SIA glucuronide (30.5%). The 
      amount of free SIA excreted in urine was 1.2%. The carboxylamide bond of AIA was 
      never cleaved in vivo to give salicylic acid and 
      3-aminomethylisopropylantipyrine. About 58% of 3H in blood 1 h after the 
      administration was found with serum protein.
FAU - Aonuma, S
AU  - Aonuma S
FAU - Kohama, Y
AU  - Kohama Y
FAU - Fujimoto, S
AU  - Fujimoto S
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Blood Proteins)
RN  - 0 (N-3'a-propylphenazonyl-2-acetoxybenzamide)
RN  - 10028-17-8 (Tritium)
RN  - R16CO5Y76E (Aspirin)
RN  - T3CHA1B51H (Antipyrine)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*metabolism
MH  - Antipyrine/adverse effects/*analogs & derivatives/metabolism
MH  - Aspirin/adverse effects/*analogs & derivatives/metabolism
MH  - Blood Proteins/metabolism
MH  - Intestinal Absorption
MH  - Male
MH  - Protein Binding
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Tissue Distribution
MH  - Tritium
EDAT- 1982/04/01 00:00
MHDA- 1982/04/01 00:01
CRDT- 1982/04/01 00:00
PHST- 1982/04/01 00:00 [pubmed]
PHST- 1982/04/01 00:01 [medline]
PHST- 1982/04/01 00:00 [entrez]
AID - 10.1248/bpb1978.5.252 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1982 Apr;5(4):252-8. doi: 10.1248/bpb1978.5.252.

PMID- 1285867
OWN - NLM
STAT- MEDLINE
DCOM- 19930318
LR  - 20190918
IS  - 1046-7408 (Print)
IS  - 1046-7408 (Linking)
VI  - 28
IP  - 3-4
DP  - 1992 Oct-Dec
TI  - The use of low dose aspirin in pregnancy.
PG  - 153-6
AB  - Pregnancy-induced hypertension (PIH) in general and preeclampsia in particular 
      are major causes of maternal and perinatal morbidity. Data from our studies and 
      from a number of prospective controlled trials have suggested that aspirin in 
      doses of 60-150 md/day during the second and third trimester reduces the risk of 
      PIH and improves maternal and neonatal outcomes. The number of patients enrolled 
      in these studies is relatively small. However, meta-analysis of existing trials 
      suggests that low dose aspirin reduces the risk of PIH and severe low birth 
      weight. Although no maternal or neonatal adverse effects associated with aspirin 
      were observed, the use of aspirin in the third trimester has been reported to 
      cause hemostatic abnormalities in both mother and neonate. Other complications 
      associated with prostaglandin synthetase inhibitors include premature closure of 
      the ductus and neonatal primary pulmonary hypertension. The use of aspirin in the 
      first trimester is not associated with increased risk of structural 
      malformations. On the basis of these findings and pending the results of ongoing 
      large-scale randomized multicenter trials, we suggest that daily low dose aspirin 
      (1 to 2 mg/kg/day) be recommended only for select women at high risk for 
      developing PIH and its associated complications.
FAU - Schiff, E
AU  - Schiff E
AD  - Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, 
      Tel-Aviv University, Israel.
FAU - Mashiach, S
AU  - Mashiach S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced/etiology
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Evaluation
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Infant, Newborn
MH  - Meta-Analysis as Topic
MH  - Odds Ratio
MH  - Platelet Activation/drug effects
MH  - Pre-Eclampsia/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Thromboxane A2/metabolism
RF  - 25
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 10.1111/j.1600-0897.1992.tb00779.x [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 1992 Oct-Dec;28(3-4):153-6. doi: 
      10.1111/j.1600-0897.1992.tb00779.x.

PMID- 6505391
OWN - NLM
STAT- MEDLINE
DCOM- 19850115
LR  - 20131121
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 46
IP  - 1
DP  - 1984 Oct
TI  - Teratogenicity of aspirin and its metabolite, salicylic acid, in cultured rat 
      embryos.
PG  - 77-91
AB  - Rat embryos were exposed to aspirin or its metabolite, salicylic acid in culture. 
      In these embryos acute reduction of heart beat was observed during 4 hours of 
      administration compared to that in non-treated one. Protein contents and 
      crown-rump length of cultured embryos were significantly decreased in 
      aspirin-treated group, but were not so decreased in salicylic acid-treated one. 
      The predominant defects of the embryos exposed to aspirin were edematous facial 
      malformations and abnormality of tail. On the other hand, facial anomalies such 
      as cleft lip and curly tail were observed in the embryos cultured with salicylic 
      acid. Anomalies induced by aspirin were systemic, while salicylic acid induced 
      localized malformations. These results might be due to the differences between 
      aspirin and its metabolite, salicylic acid in their teratogenicity.
FAU - Yokoyama, A
AU  - Yokoyama A
FAU - Takakubo, F
AU  - Takakubo F
FAU - Eto, K
AU  - Eto K
FAU - Ueno, K
AU  - Ueno K
FAU - Igarashi, T
AU  - Igarashi T
FAU - Satoh, T
AU  - Satoh T
FAU - Kitagawa, H
AU  - Kitagawa H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abnormalities, Drug-Induced
MH  - Animals
MH  - Aspirin/metabolism/*toxicity
MH  - Embryo, Mammalian/drug effects
MH  - Female
MH  - Organ Culture Techniques
MH  - Pregnancy
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Salicylates/*toxicity
EDAT- 1984/10/01 00:00
MHDA- 1984/10/01 00:01
CRDT- 1984/10/01 00:00
PHST- 1984/10/01 00:00 [pubmed]
PHST- 1984/10/01 00:01 [medline]
PHST- 1984/10/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1984 Oct;46(1):77-91.

PMID- 19069170
OWN - NLM
STAT- MEDLINE
DCOM- 20090128
LR  - 20181201
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 60
IP  - 11
DP  - 2008 Nov
TI  - [Aspirin resistance].
PG  - 1357-64
AB  - Aspirin inhibits platelet activation through the permanent inactivation of the 
      cyclooxygenase (COX) activity of prostaglandin H synthase-1 (referred to as 
      COX-1), and consequently inhibits the biosynthesis of thromboxane A2 (TXA2), a 
      platelet agonist. Recent meta-analysis has revealed that long-term aspirin 
      administration has clear benefits for the secondary prevention of cardiovascular 
      diseases with an odds reduction of 23% and an absolute risk reduction of 3.1% 
      over 2 years. However, this indicates that not all individuals respond equally to 
      aspirin therapy and cardiovascular events may occur during aspirin therapy, this 
      is often denoted as "clinical aspirin resistance". Several reports have, indeed, 
      suggested that the effect of aspirin administration varies considerably among the 
      patients at high risk for cardiovascular events. Approximately one forth of the 
      patients showed persistent platelet reactivity in vitro despite the use of 
      aspirin (denoted "laboratory aspirin resistance"), this was determined by 
      laboratory tests including the test for arachidonic acid-induced platelet 
      aggregation and the assays using point-of-care devices. Recent clinical studies 
      have proposed that resistance to aspirin (laboratory aspirin resistance) can 
      relate to the cardiovascular outcomes in patients treated with aspirin (clinical 
      aspirin resistance). A systematic review and meta-analysis on aspirin resistance 
      have indicated that patients who are resistant to aspirin are at a greater risk 
      (odds ratio: 3.85) of clinically important cardiovascular morbidity than patients 
      who are sensitive to aspirin. However, many issues are yet to be resolved in 
      order to apply the concept of "aspirin resistance" to actual clinical practice. 
      The relevance of the various ex vivo functional indexes of platelet capacity to 
      in vivo platelet activation and the precise mechanisms underlying aspirin 
      resistance are still largely unknown. To assess what kind of laboratory assays is 
      the best predictor for cardiovascular events and the risk factors of aspirin 
      resistance, including non-compliance, concurrent intake of other drugs such as 
      nonsteroid anti-inflammatory drugs, and polymorphism of COX-1, we have conducted 
      a multicenter, prospective cohort study (ProGEAR study). We hope that these 
      results will contribute to an individualized antiplatelet therapy through the 
      identification of aspirin nonresponders as a high-risk group for cardiovascular 
      events.
FAU - Miyata, Shigeki
AU  - Miyata S
AD  - Division of Transfusion Medicine, National Cardiovascular Center, 5-7-1 
      Fujishirodai Suita-shi, Osaka 565-8565, Japan
FAU - Miyata, Toshiyuki
AU  - Miyata T
FAU - Kada, Akiko
AU  - Kada A
FAU - Nagatsuka, Kazuyuki
AU  - Nagatsuka K
LA  - jpn
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage/pharmacology
MH  - Cardiovascular Diseases/prevention & control
MH  - Cyclooxygenase 1/genetics
MH  - Cyclooxygenase Inhibitors
MH  - *Drug Resistance/genetics
MH  - Humans
MH  - Pharmacogenetics
MH  - Platelet Activation
MH  - *Platelet Aggregation Inhibitors/pharmacology
RF  - 28
EDAT- 2008/12/17 09:00
MHDA- 2009/01/29 09:00
CRDT- 2008/12/17 09:00
PHST- 2008/12/17 09:00 [entrez]
PHST- 2008/12/17 09:00 [pubmed]
PHST- 2009/01/29 09:00 [medline]
PST - ppublish
SO  - Brain Nerve. 2008 Nov;60(11):1357-64.

PMID- 30862734
OWN - NLM
STAT- MEDLINE
DCOM- 20190520
LR  - 20200309
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 116
IP  - 13
DP  - 2019 Mar 26
TI  - Aspirin-triggered proresolving mediators stimulate resolution in cancer.
PG  - 6292-6297
LID - 10.1073/pnas.1804000116 [doi]
AB  - Inflammation in the tumor microenvironment is a strong promoter of tumor growth. 
      Substantial epidemiologic evidence suggests that aspirin, which suppresses 
      inflammation, reduces the risk of cancer. The mechanism by which aspirin inhibits 
      cancer has remained unclear, and toxicity has limited its clinical use. Aspirin 
      not only blocks the biosynthesis of prostaglandins, but also stimulates the 
      endogenous production of anti-inflammatory and proresolving mediators termed 
      aspirin-triggered specialized proresolving mediators (AT-SPMs), such as 
      aspirin-triggered resolvins (AT-RvDs) and lipoxins (AT-LXs). Using genetic and 
      pharmacologic manipulation of a proresolving receptor, we demonstrate that 
      AT-RvDs mediate the antitumor activity of aspirin. Moreover, treatment of mice 
      with AT-RvDs (e.g., AT-RvD1 and AT-RvD3) or AT-LXA(4) inhibited primary tumor 
      growth by enhancing macrophage phagocytosis of tumor cell debris and 
      counter-regulating macrophage-secreted proinflammatory cytokines, including 
      migration inhibitory factor, plasminogen activator inhibitor-1, and C-C motif 
      chemokine ligand 2/monocyte chemoattractant protein 1. Thus, the pro-resolution 
      activity of AT-resolvins and AT-lipoxins may explain some of aspirin's broad 
      anticancer activity. These AT-SPMs are active at considerably lower 
      concentrations than aspirin, and thus may provide a nontoxic approach to 
      harnessing aspirin's anticancer activity.
FAU - Gilligan, Molly M
AU  - Gilligan MM
AD  - Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, 
      Harvard Medical School, Boston, MA 02215.
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA 02215.
AD  - Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 
      Boston, MA 02215.
FAU - Gartung, Allison
AU  - Gartung A
AD  - Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, 
      Harvard Medical School, Boston, MA 02215.
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA 02215.
AD  - Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 
      Boston, MA 02215.
FAU - Sulciner, Megan L
AU  - Sulciner ML
AD  - Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, 
      Harvard Medical School, Boston, MA 02215.
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA 02215.
AD  - Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 
      Boston, MA 02215.
FAU - Norris, Paul C
AU  - Norris PC
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Harvard Medical School, Boston, MA 02115.
FAU - Sukhatme, Vikas P
AU  - Sukhatme VP
AD  - Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 
      Boston, MA 02215.
AD  - Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA 02115.
AD  - Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322.
FAU - Bielenberg, Diane R
AU  - Bielenberg DR
AD  - Vascular Biology Program, Boston Children's Hospital, Boston, MA 02115.
FAU - Huang, Sui
AU  - Huang S
AUID- ORCID: 0000-0002-3545-4665
AD  - Institute for Systems Biology, Seattle, WA 98109.
FAU - Kieran, Mark W
AU  - Kieran MW
AD  - Division of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical 
      School, Boston, MA 02115.
AD  - Department of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard 
      Medical School, Boston, MA 02115.
FAU - Serhan, Charles N
AU  - Serhan CN
AUID- ORCID: 0000-0003-4627-8545
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Harvard Medical School, Boston, MA 02115; cserhan@bwh.harvard.edu 
      dpanigra@bidmc.harvard.edu.
FAU - Panigrahy, Dipak
AU  - Panigrahy D
AD  - Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, 
      Harvard Medical School, Boston, MA 02215; cserhan@bwh.harvard.edu 
      dpanigra@bidmc.harvard.edu.
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA 02215.
AD  - Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 
      Boston, MA 02215.
LA  - eng
GR  - P01 GM095467/GM/NIGMS NIH HHS/United States
GR  - R01 CA148633/CA/NCI NIH HHS/United States
GR  - R01 CA170549/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190312
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (Eicosanoids)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Lipoxins)
RN  - 0 (MINP protein, mouse)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Plasminogen Inactivators)
RN  - 0 (Prostaglandins)
RN  - 0 (lipoxin A4)
RN  - 0 (resolvin D1)
RN  - 0 (resolvin D3)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chemokine CCL2/metabolism
MH  - Chemokines/metabolism
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Docosahexaenoic Acids/metabolism
MH  - Eicosanoids/metabolism
MH  - Fatty Acids, Unsaturated/metabolism
MH  - Female
MH  - Inflammation/drug therapy
MH  - Lipoxins/metabolism
MH  - Macrophages/drug effects/metabolism
MH  - Metabolomics
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Microtubule-Associated Proteins/metabolism
MH  - Neoplasm Metastasis/drug therapy/prevention & control
MH  - Neoplasms/*drug therapy/*prevention & control
MH  - Nerve Tissue Proteins/metabolism
MH  - Phagocytosis/drug effects
MH  - Plasminogen Inactivators/metabolism
MH  - Prostaglandins/metabolism
PMC - PMC6442621
OTO - NOTNLM
OT  - eicosanoids
OT  - inflammation
OT  - metabolomics
OT  - metastasis
OT  - resolvins
COIS- Conflict of interest statement: M.W.K. is now an employee of Bristol-Myers 
      Squibb. His position at Bristol-Myers Squibb is not related to this work.
EDAT- 2019/03/14 06:00
MHDA- 2019/05/21 06:00
CRDT- 2019/03/14 06:00
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/05/21 06:00 [medline]
PHST- 2019/03/14 06:00 [entrez]
AID - 1804000116 [pii]
AID - 201804000 [pii]
AID - 10.1073/pnas.1804000116 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6292-6297. doi: 
      10.1073/pnas.1804000116. Epub 2019 Mar 12.

PMID- 35994769
OWN - NLM
STAT- MEDLINE
DCOM- 20220824
LR  - 20220930
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 71
IP  - 6
DP  - 2022 Jul
TI  - USPSTF updates recommendations on aspirin and CVD.
PG  - 262-264
LID - 10.12788/jfp.0452 [doi]
AB  - New evidence is reshaping the role of low-dose aspirin in primary prevention. 
      More selective decisions are now urged.
FAU - Campos-Outcalt, Doug
AU  - Campos-Outcalt D
AD  - University of Arizona, Phoenix.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/drug therapy/prevention & control
MH  - Humans
MH  - Primary Prevention
EDAT- 2022/08/23 06:00
MHDA- 2022/08/25 06:00
CRDT- 2022/08/22 17:42
PHST- 2022/08/22 17:42 [entrez]
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/08/25 06:00 [medline]
AID - jfp.0452 [pii]
AID - 10.12788/jfp.0452 [doi]
PST - ppublish
SO  - J Fam Pract. 2022 Jul;71(6):262-264. doi: 10.12788/jfp.0452.

PMID- 26838092
OWN - NLM
STAT- MEDLINE
DCOM- 20170112
LR  - 20181202
IS  - 2169-141X (Electronic)
IS  - 2169-1401 (Linking)
VI  - 44
IP  - 4
DP  - 2016 Jun
TI  - Polymerization of modified diaspirin cross-linked hemoglobin (DCLHb) with 
      1,6-bismaleimic-hexane.
PG  - 1069-74
LID - 10.3109/21691401.2016.1138488 [doi]
AB  - Increasing the size of hemoglobin (Hb) by polymerization offers the benefits of 
      reduced renal clearance and increased duration in the vascular circulation. With 
      this goal, diaspirin cross-linked hemoglobin (DCLHb) was modified in order to 
      keep one thiol group on the surface and then polymerized with 
      1,6-bismaleimic-hexane (1,6-BMH) to increase the molecular weight. The HPLC 
      results indicated that approximate 20% dimers to tetramers of DCLHb desired were 
      achieved after the polymerization. It was also demonstrated that the 
      oxygen-carrying capacity of the products was similar to natural heme. The present 
      study is expected to improve the efficacy of the DCLHb as an oxygen therapeutic 
      agent.
FAU - Qi, Donglai
AU  - Qi D
AD  - a School of Environment and Chemical Engineering, Tianjin Polytechnic University 
      , Tianjin , P.R. China.
FAU - Wang, Pei
AU  - Wang P
AD  - a School of Environment and Chemical Engineering, Tianjin Polytechnic University 
      , Tianjin , P.R. China.
FAU - Chen, Chen
AU  - Chen C
AD  - a School of Environment and Chemical Engineering, Tianjin Polytechnic University 
      , Tianjin , P.R. China.
FAU - Guo, Song
AU  - Guo S
AD  - a School of Environment and Chemical Engineering, Tianjin Polytechnic University 
      , Tianjin , P.R. China.
FAU - Wang, Xiang
AU  - Wang X
AD  - a School of Environment and Chemical Engineering, Tianjin Polytechnic University 
      , Tianjin , P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20160202
PL  - England
TA  - Artif Cells Nanomed Biotechnol
JT  - Artificial cells, nanomedicine, and biotechnology
JID - 101594777
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemistry
MH  - Blood Substitutes/*chemical synthesis/*chemistry
MH  - Cross-Linking Reagents/*chemistry
MH  - Hemoglobins/*chemistry
MH  - Humans
OTO - NOTNLM
OT  - Cross-linking agent
OT  - DCLHb
OT  - oxygen affinity
OT  - thiol group
EDAT- 2016/02/04 06:00
MHDA- 2017/01/14 06:00
CRDT- 2016/02/04 06:00
PHST- 2016/02/04 06:00 [entrez]
PHST- 2016/02/04 06:00 [pubmed]
PHST- 2017/01/14 06:00 [medline]
AID - 10.3109/21691401.2016.1138488 [doi]
PST - ppublish
SO  - Artif Cells Nanomed Biotechnol. 2016 Jun;44(4):1069-74. doi: 
      10.3109/21691401.2016.1138488. Epub 2016 Feb 2.

PMID- 28605890
OWN - NLM
STAT- MEDLINE
DCOM- 20180409
LR  - 20220310
IS  - 2233-4521 (Electronic)
IS  - 1975-8375 (Print)
IS  - 1975-8375 (Linking)
VI  - 50
IP  - 3
DP  - 2017
TI  - Risk of Hemorrhage Attributed to Underlying Chronic Diseases and Uninterrupted 
      Aspirin Therapy of Patients Undergoing Minor Oral Surgical Procedures: A 
      Retrospective Cohort Study.
PG  - 165-176
LID - 10.3961/jpmph.16.121 [doi]
AB  - OBJECTIVES: This study aimed to estimate the risk of bleeding following minor 
      oral surgical procedures and uninterrupted aspirin therapy in high-risk patients 
      or patients with existing chronic diseases compared to patients who did not use 
      aspirin during minor oral surgery at a public hospital. METHODS: This 
      retrospective cohort study analyzed the data of 2912 patients, aged 20 years or 
      older, who underwent 5251 minor oral surgical procedures at a district hospital 
      in Thailand. The aspirin group was comprised of patients continuing aspirin 
      therapy during oral surgery. The non-aspirin group (reference) included all those 
      who did not use aspirin during surgery. Immediate and late-onset bleeding was 
      evaluated in each procedure. The risk ratio of bleeding was estimated using a 
      multilevel Poisson regression. RESULTS: The overall cumulative incidence of 
      immediate bleeding was 1.3% of total procedures. No late-onset bleeding was 
      found. A significantly greater incidence of bleeding was found in the aspirin 
      group (5.8% of procedures, p<0.001). After adjusting for covariates, a multilevel 
      Poisson regression model estimated that the bleeding risk in the aspirin group 
      was 4.5 times higher than that of the non-aspirin group (95% confidence interval, 
      2.0 to 10.0; p<0.001). However, all bleeding events were controlled by simple 
      hemostatic measures. CONCLUSIONS: High-risk patients or patients with existing 
      chronic diseases who continued aspirin therapy following minor oral surgery were 
      at a higher risk of hemorrhage than general patients who had not used aspirin. 
      Nonetheless, bleeding complications were not life-threatening and could be 
      promptly managed by simple hemostatic measures. The procedures could therefore be 
      provided with an awareness of increased bleeding risk, prepared hemostatic 
      measures, and postoperative monitoring, without the need for discontinuing 
      aspirin, which could lead to more serious complications.
FAU - Rojanaworarit, Chanapong
AU  - Rojanaworarit C
AD  - Department of Epidemiology, Faculty of Public Health, Mahidol University, 
      Bangkok, Thailand.
FAU - Limsawan, Soontaree
AU  - Limsawan S
AD  - Department of Epidemiology, Faculty of Public Health, Mahidol University, 
      Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - J Prev Med Public Health
JT  - Journal of preventive medicine and public health = Yebang Uihakhoe chi
JID - 101242972
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Chronic Disease/*drug therapy
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oral Surgical Procedures/*adverse effects
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thailand
MH  - Young Adult
PMC - PMC5495684
OTO - NOTNLM
OT  - Dentistry
OT  - Epidemiology
OT  - Hemorrhage
OT  - Oral surgery
OT  - Platelet aggregation inhibitors
OT  - Aspirin
COIS- CONFLICT OF INTEREST The authors have no conflicts of interest associated with 
      the material presented in this paper.
EDAT- 2017/06/14 06:00
MHDA- 2018/04/10 06:00
CRDT- 2017/06/14 06:00
PHST- 2016/12/25 00:00 [received]
PHST- 2017/03/31 00:00 [accepted]
PHST- 2017/06/14 06:00 [entrez]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2018/04/10 06:00 [medline]
AID - jpmph.16.121 [pii]
AID - jpmph-50-3-165 [pii]
AID - 10.3961/jpmph.16.121 [doi]
PST - ppublish
SO  - J Prev Med Public Health. 2017;50(3):165-176. doi: 10.3961/jpmph.16.121.

PMID- 6784035
OWN - NLM
STAT- MEDLINE
DCOM- 19810613
LR  - 20161123
IS  - 0375-9393 (Print)
IS  - 0375-9393 (Linking)
VI  - 47
IP  - 1-2
DP  - 1981 Jan-Feb
TI  - [Lysine acetylsalicylate in the treatment of postoperative pain in obstetric and 
      gynecological surgery].
PG  - 33-6
AB  - The analgesic activity of acetylsalicylate of lysine (ASL) was evaluated in 
      postoperative pain. Acetylsalicylate of lysine was administered i.v. to 345 
      patients submitted to obstetrical and gynaecological surgery. Excellent results 
      were obtained in 77.4% of the cases and no severe side-effects were observed.
FAU - Ramella, G
AU  - Ramella G
FAU - Poggi, A
AU  - Poggi A
FAU - Zaninetta, G
AU  - Zaninetta G
LA  - ita
PT  - Journal Article
TT  - L'acetilsalicilato di lisina nel trattamento del dolore post-operatorio in 
      chirurgia ostetrica e ginecologica.
PL  - Italy
TA  - Minerva Anestesiol
JT  - Minerva anestesiologica
JID - 0375272
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Cesarean Section
MH  - Female
MH  - Genital Diseases, Female/surgery
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Pain, Postoperative/*drug therapy
MH  - Pregnancy
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Minerva Anestesiol. 1981 Jan-Feb;47(1-2):33-6.

PMID- 369874
OWN - NLM
STAT- MEDLINE
DCOM- 19790516
LR  - 20190629
IS  - 0014-4754 (Print)
IS  - 0014-4754 (Linking)
VI  - 35
IP  - 1
DP  - 1979 Jan 15
TI  - Effect of acetylsalicylate on surgical bleeding, postoperative mortality and 
      allograft survival in rats undergoing heart transplantation.
PG  - 117-8
AB  - 18 rats were treated with L-ASA before heart transplantation and daily thereafter 
      until death or rejection. 22 animals acted as controls. A significantly higher 
      post-operative mortality rate, without any significant modification of the 
      transplant survival time, was found in L-ASA-treated group.
FAU - Reyers, I
AU  - Reyers I
FAU - Di Minno, G
AU  - Di Minno G
FAU - Donati, M B
AU  - Donati MB
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Experientia
JT  - Experientia
JID - 0376547
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Female
MH  - Graft Rejection/*drug effects
MH  - *Heart Transplantation
MH  - Hemorrhage/*chemically induced
MH  - Myocardium/immunology
MH  - Postoperative Complications/*chemically induced/prevention & control
MH  - Rats
MH  - Transplantation, Homologous
EDAT- 1979/01/15 00:00
MHDA- 1979/01/15 00:01
CRDT- 1979/01/15 00:00
PHST- 1979/01/15 00:00 [pubmed]
PHST- 1979/01/15 00:01 [medline]
PHST- 1979/01/15 00:00 [entrez]
AID - 10.1007/BF01917914 [doi]
PST - ppublish
SO  - Experientia. 1979 Jan 15;35(1):117-8. doi: 10.1007/BF01917914.

PMID- 6668187
OWN - NLM
STAT- MEDLINE
DCOM- 19840403
LR  - 20190913
IS  - 0363-0269 (Print)
IS  - 0363-0269 (Linking)
VI  - 7
IP  - 6
DP  - 1983
TI  - Formation of cross-linked asymmetrical hybrid hemoglobins by double-headed 
      aspirin.
PG  - 533-53
AB  - Double-headed aspirin [bis(3,5-dibromosalicyl)fumarate] selectively cross-links 
      hemoglobin molecules between Lys 82 beta 1 and Lys 82 beta 2 and increases 
      solubility of deoxy-Hb S (Walder et al., J. Mol. Biol., 141:195, 1980 and 
      Kikugawa et al., J. Biol. Chem., 257:7525, 1982). We reacted this reagent with 
      the mixture of Hb A and Hb S and the mixture of Hb S and Hb York (beta 146His 
      replaced by Pro). Cross-linked asymmetrical hybrid hemoglobins (alpha 2 beta - 
      beta S and alpha 2 beta Y - beta S) were produced in high yields in addition to 
      the cross-linked parent hemoglobin molecules. Results on electrophoresis, gel 
      electrofocusing, ion exchange column chromatography, mechanical stability and 
      oxygen binding properties showed that the cross-linked asymmetrical hybrid 
      hemoglobins had properties intermediate between those of the cross-linked parent 
      hemoglobins. Oxygen affinities of the cross-linked asymmetrical hybrids were not 
      affected by the addition of 2,3-diphosphoglycerate (DPG) or inositol 
      hexaphosphate, probably due to the presence of a fumaryl group at the DPG binding 
      site.
FAU - Kikugawa, K
AU  - Kikugawa K
FAU - Adachi, K
AU  - Adachi K
FAU - Kosugi, H
AU  - Kosugi H
FAU - Asakura, T
AU  - Asakura T
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hemoglobin
JT  - Hemoglobin
JID - 7705865
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobin, Sickle)
RN  - 0 (Hemoglobins)
RN  - 0 (Hemoglobins, Abnormal)
RN  - 0 (Oxyhemoglobins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 59355-66-7 (hemoglobin York)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Protein Electrophoresis
MH  - Chromatography, Gel
MH  - Chromatography, Ion Exchange
MH  - Cross-Linking Reagents/pharmacology
MH  - Electrophoresis, Cellulose Acetate
MH  - Hemoglobin A
MH  - Hemoglobin, Sickle
MH  - *Hemoglobins
MH  - Hemoglobins, Abnormal
MH  - Humans
MH  - Oxyhemoglobins/analysis
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.3109/03630268309027934 [doi]
PST - ppublish
SO  - Hemoglobin. 1983;7(6):533-53. doi: 10.3109/03630268309027934.

PMID- 28826212
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20210428
IS  - 1520-5827 (Electronic)
IS  - 0743-7463 (Linking)
VI  - 33
IP  - 38
DP  - 2017 Sep 26
TI  - Self-Assembled Lipid Cubic Phase and Cubosomes for the Delivery of Aspirin as a 
      Model Drug.
PG  - 9907-9915
LID - 10.1021/acs.langmuir.7b02486 [doi]
AB  - Three-dimensionally organized lipid cubic self-assemblies and derived 
      oil-in-water emulsions called "cubosomes" are attractive for various 
      biotechnological applications due to their ability to be loaded with functional 
      molecules and their associated sustained release properties. Here, we employed 
      both of these lipid-based systems for the delivery of a model drug, aspirin, 
      under comparable conditions. Studies were performed by varying drug-to-lipid 
      ratio and the type of release medium, water and phosphate buffer saline (PBS). 
      Release rates were determined using UV-vis spectroscopy, and small-angle X-ray 
      scattering was used to confirm the type of self-assembled nanostructures formed 
      in these lipid systems. The release from the bulk lipid cubic phase was sustained 
      as compared to that of dispersed cubosomes, and the release in PBS was more 
      efficient than in water. The tortuosity of the architecture, length of the 
      diffusion pathway, type of nanostructure, and physicochemical interaction with 
      the release media evidently contribute to these observations. This work is 
      particularly important as it is the first report where both of these 
      nanostructured lipid systems have been studied together under similar conditions. 
      This work provides important insights into understanding and therefore 
      controlling the release behavior of lipid-based drug nanocarriers.
FAU - Kulkarni, Chandrashekhar V
AU  - Kulkarni CV
AUID- ORCID: 0000-0002-5621-4791
FAU - Vishwapathi, Vinod Kumar
AU  - Vishwapathi VK
FAU - Quarshie, Abraham
AU  - Quarshie A
FAU - Moinuddin, Zeinab
AU  - Moinuddin Z
FAU - Page, James
AU  - Page J
FAU - Kendrekar, Pravin
AU  - Kendrekar P
AD  - Unit for Drug Discovery Research, Faculty of Health and Environmental Sciences, 
      Central University of Technology (CUT) , Bloemfontein 9300, Free State, South 
      Africa.
FAU - Mashele, Samson S
AU  - Mashele SS
AD  - Unit for Drug Discovery Research, Faculty of Health and Environmental Sciences, 
      Central University of Technology (CUT) , Bloemfontein 9300, Free State, South 
      Africa.
LA  - eng
GR  - G12 MD007602/MD/NIMHD NIH HHS/United States
GR  - R25 MD007589/MD/NIMHD NIH HHS/United States
PT  - Journal Article
DEP - 20170905
PL  - United States
TA  - Langmuir
JT  - Langmuir : the ACS journal of surfaces and colloids
JID - 9882736
RN  - 0 (Lipids)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Diffusion
MH  - Drug Delivery Systems
MH  - Lipids
MH  - Nanostructures
MH  - Water
EDAT- 2017/08/23 06:00
MHDA- 2019/01/29 06:00
CRDT- 2017/08/23 06:00
PHST- 2017/08/23 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2017/08/23 06:00 [entrez]
AID - 10.1021/acs.langmuir.7b02486 [doi]
PST - ppublish
SO  - Langmuir. 2017 Sep 26;33(38):9907-9915. doi: 10.1021/acs.langmuir.7b02486. Epub 
      2017 Sep 5.

PMID- 19167101
OWN - NLM
STAT- MEDLINE
DCOM- 20090707
LR  - 20131121
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 132
IP  - 2
DP  - 2009 Feb 20
TI  - Aspirin resistance: what the cardiologist needs to know?
PG  - 153-6
LID - 10.1016/j.ijcard.2008.12.074 [doi]
AB  - "Aspirin resistance" can be defined as the inability of aspirin to inhibit 
      cyclooxygenase (COX)-1 dependent thromboxane (TX) A2 production, and consequently 
      TX A2-dependent platelet functions. Several laboratory methods have been 
      proposed, to evaluate platelets' resistance to antiplatelet treatment (bleeding 
      time, light transmission aggregation, impedance aggregation, platelet function 
      analyser, rapid platelet function assay, TXB2, flow cytometry). However, all 
      these methods have their advantages intrinsic limitations. Although aspirin 
      resistance appears to be linked to worse long-term outcomes in cardiovascular 
      disease patients, clinical treatment of aspirin resistance, including an 
      increased aspirin dose or the addition of other antiplatelet drugs, is not often 
      effective. Further studies needed to elucidate the appropriate management of 
      aspirin resistance.
FAU - Tousoulis, Dimitris
AU  - Tousoulis D
FAU - Siasos, Gerasimos
AU  - Siasos G
FAU - Stefanadis, Christodoulos
AU  - Stefanadis C
LA  - eng
PT  - Editorial
DEP - 20090122
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Cardiology
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2009/01/27 09:00
MHDA- 2009/07/08 09:00
CRDT- 2009/01/27 09:00
PHST- 2008/09/19 00:00 [received]
PHST- 2008/12/13 00:00 [accepted]
PHST- 2009/01/27 09:00 [entrez]
PHST- 2009/01/27 09:00 [pubmed]
PHST- 2009/07/08 09:00 [medline]
AID - S0167-5273(08)01513-1 [pii]
AID - 10.1016/j.ijcard.2008.12.074 [doi]
PST - ppublish
SO  - Int J Cardiol. 2009 Feb 20;132(2):153-6. doi: 10.1016/j.ijcard.2008.12.074. Epub 
      2009 Jan 22.

PMID- 8620101
OWN - NLM
STAT- MEDLINE
DCOM- 19960618
LR  - 20180216
IS  - 1018-2438 (Print)
IS  - 1018-2438 (Linking)
VI  - 109
IP  - 3
DP  - 1996 Mar
TI  - Incomplete aspirin desensitization in an aspirin-sensitive asthmatic.
PG  - 298-300
AB  - Aspirin desensitization is a valuable treatment for aspirin-sensitive sinusitis. 
      We present a case where long-term desensitization failed. While undergoing 
      desensitization, our patient had prolonged severe asthmatic reactions and 
      therefore received high intravenous doses of prednisone. We hypothesize that high 
      steroid doses administered at the time of desensitization may have raised the 
      threshold of intolerance to a point where the administered aspirin doses were 
      tolerated. Consequently, symptoms of intolerance subsided during the procedure. 
      Subsequent tapering down of the daily prednisone dose caused a re-emergence of 
      the symptoms of intolerance, apparently due to a decrease in the intolerance 
      threshold.
FAU - Rothe, T
AU  - Rothe T
AD  - Luzerner Höhenklinik, Montana, Switzerland.
FAU - Achermann, R
AU  - Achermann R
FAU - Hug, J
AU  - Hug J
FAU - Karrer, W
AU  - Karrer W
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Bronchial Spasm/*chemically induced/*drug therapy
MH  - Desensitization, Immunologic/*adverse effects
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Middle Aged
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
AID - 10.1159/000237254 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 1996 Mar;109(3):298-300. doi: 10.1159/000237254.

PMID- 6480889
OWN - NLM
STAT- MEDLINE
DCOM- 19841106
LR  - 20191023
IS  - 0094-5145 (Print)
IS  - 0094-5145 (Linking)
VI  - 9
IP  - 3
DP  - 1984 Spring
TI  - Aspirin and its expensive substitutes: prescribing patterns and cost 
      implications.
PG  - 216-21
AB  - Relatively expensive nonsteroidal anti-inflammatory drugs (NSAIDs) are among the 
      most commonly prescribed products, although many rheumatologists continue to 
      recommend aspirin as the initial drug of choice for a variety of musculoskeletal 
      problems. We reviewed 100 charts of patients given NSAIDs in a VA clinic to see 
      how many had relative contraindications for aspirin, such as previous salicylate 
      intolerance, peptic ulcer disease, gastrointestinal bleeding, or failure to 
      respond to aspirin. Only 28% of patients on the expensive preparations had any of 
      these problems noted in their charts. With an average retail cost difference of 
      $14 to $29 per month, large potential savings exist for those who purchase 
      anti-inflammatory products, if physicians would initially prescribe aspirin for 
      appropriate patients.
FAU - Read, J L
AU  - Read JL
FAU - Epstein, A M
AU  - Epstein AM
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Community Health
JT  - Journal of community health
JID - 7600747
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Boston
MH  - Drug Prescriptions/*economics/standards
MH  - Humans
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1007/BF01326702 [doi]
PST - ppublish
SO  - J Community Health. 1984 Spring;9(3):216-21. doi: 10.1007/BF01326702.

PMID- 16371762
OWN - NLM
STAT- MEDLINE
DCOM- 20060302
LR  - 20191109
IS  - 1061-5377 (Print)
IS  - 1061-5377 (Linking)
VI  - 14
IP  - 1
DP  - 2006 Jan-Feb
TI  - Aspirin resistance: mechanisms and clinical implications.
PG  - 18-25
AB  - Acetylsalicylic acid (aspirin) has been shown to irreversibly interfere with 
      platelet function, an effect that is associated with a reduction in morbid and 
      mortal arterial thrombotic events in multiple clinical studies. This clinical 
      benefit appears to be attenuated by resistance to the antiplatelet effects of 
      aspirin in up to 35% of patients. The mechanisms for aspirin resistance are 
      multifactorial and include noncompliance with aspirin therapy, diabetes mellitus, 
      cell-cell and drug-drug interactions, genetic polymorphisms, and coronary artery 
      disease. It has not been determined what the best laboratory procedure is to 
      screen for aspirin resistance. Those individuals at high risk for aspirin 
      resistance might best be treated with an additional oral antiplatelet drug (eg, 
      clopidogrel) to achieve maximal protection against arterial thrombotic events.
FAU - Hanjis, Costas
AU  - Hanjis C
AD  - Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical 
      Center, Bronx, New York, USA.
FAU - Frishman, William H
AU  - Frishman WH
FAU - Lerner, Robert G
AU  - Lerner RG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiol Rev
JT  - Cardiology in review
JID - 9304686
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 83
EDAT- 2005/12/24 09:00
MHDA- 2006/03/03 09:00
CRDT- 2005/12/24 09:00
PHST- 2005/12/24 09:00 [pubmed]
PHST- 2006/03/03 09:00 [medline]
PHST- 2005/12/24 09:00 [entrez]
AID - 00045415-200601000-00004 [pii]
AID - 10.1097/01.crd.0000148175.60718.69 [doi]
PST - ppublish
SO  - Cardiol Rev. 2006 Jan-Feb;14(1):18-25. doi: 10.1097/01.crd.0000148175.60718.69.

PMID- 2733398
OWN - NLM
STAT- MEDLINE
DCOM- 19890727
LR  - 20190510
IS  - 0146-4760 (Print)
IS  - 0146-4760 (Linking)
VI  - 13
IP  - 2
DP  - 1989 Mar-Apr
TI  - Detection of a novel compound after overdoses of aspirin and amoxapine.
PG  - 97-9
AB  - The identification of a novel by-product in the tissue and fluid extracts of a 
      victim of fatal overdoses of the tricyclic antidepressant amoxapine and aspirin 
      is presented. Gas chromatography/mass spectrometry suggested that amoxapine was 
      transacetylated by aspirin to form N-acetylated amoxapine. When standard 
      N-acetylated amoxapine was prepared and subjected to the same analytical testing 
      as extracted tissues and fluids, the metabolite was identified as 
      N-acetylamoxapine. Quantitation of N-acetylamoxapine was obtained by gas 
      chromatography. Concentrations of N-acetylamoxapine compared to those of 
      amoxapine and salicylates in blood, liver, stomach, and small bowel are given.
FAU - Osiewicz, R J
AU  - Osiewicz RJ
AD  - Tidewater Regional Forensic Laboratory, Norfolk, Virginia 23507.
FAU - Middleberg, R
AU  - Middleberg R
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - J Anal Toxicol
JT  - Journal of analytical toxicology
JID - 7705085
RN  - 0 (Dibenzoxazepines)
RN  - 126588-76-9 (N-acetylamoxapine)
RN  - R16CO5Y76E (Aspirin)
RN  - R63VQ857OT (Amoxapine)
SB  - IM
MH  - Acetylation
MH  - Amoxapine/analogs & derivatives/*analysis/pharmacology/*poisoning
MH  - Aspirin/analysis/pharmacology/*poisoning
MH  - Brain Chemistry
MH  - Dibenzoxazepines/*analysis/*poisoning
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Intestine, Small/analysis
MH  - Liver/analysis
MH  - Middle Aged
MH  - Stomach/analysis
EDAT- 1989/03/01 00:00
MHDA- 1989/03/01 00:01
CRDT- 1989/03/01 00:00
PHST- 1989/03/01 00:00 [pubmed]
PHST- 1989/03/01 00:01 [medline]
PHST- 1989/03/01 00:00 [entrez]
AID - 10.1093/jat/13.2.97 [doi]
PST - ppublish
SO  - J Anal Toxicol. 1989 Mar-Apr;13(2):97-9. doi: 10.1093/jat/13.2.97.

PMID- 3733281
OWN - NLM
STAT- MEDLINE
DCOM- 19860916
LR  - 20131121
IS  - 0174-4879 (Print)
IS  - 0174-4879 (Linking)
VI  - 24
IP  - 6
DP  - 1986 Jun
TI  - Comparative bioavailability of aspirin from buffered, enteric-coated and plain 
      preparations.
PG  - 313-8
AB  - The bioavailability and pharmacokinetics of acetylsalicylic acid were studied in 
      6 volunteers, under a cross-over design, using plain compressed aspirin, two 
      buffered preparations and an enteric-coated tablet. Absorption, calculated from 
      urinary excretion, was complete for all the formulations. The buffered forms gave 
      higher peak concentrations and AUC for acetylsalicylic acid than the other forms. 
      Absorption from the enteric-coated tablet was the slowest. Acetylsalicylic acid 
      was not measurable in plasma (less than 0.1 micrograms/ml) at any time in 3 
      subjects after plain and in 2 after enteric-coated aspirin. Acetylsalicylic acid 
      was no longer measurable in plasma after 4 hours, irrespective of the preparation 
      given.
FAU - Latini, R
AU  - Latini R
FAU - Cerletti, C
AU  - Cerletti C
FAU - de Gaetano, G
AU  - de Gaetano G
FAU - Dejana, E
AU  - Dejana E
FAU - Galletti, F
AU  - Galletti F
FAU - Urso, R
AU  - Urso R
FAU - Marzot, M
AU  - Marzot M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther Toxicol
JT  - International journal of clinical pharmacology, therapy, and toxicology
JID - 8003415
RN  - 0 (Buffers)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 0 (Tablets, Enteric-Coated)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*administration & dosage/blood/urine
MH  - Biological Availability
MH  - Buffers
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Random Allocation
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Tablets
MH  - Tablets, Enteric-Coated
EDAT- 1986/06/01 00:00
MHDA- 1986/06/01 00:01
CRDT- 1986/06/01 00:00
PHST- 1986/06/01 00:00 [pubmed]
PHST- 1986/06/01 00:01 [medline]
PHST- 1986/06/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther Toxicol. 1986 Jun;24(6):313-8.

PMID- 781233
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 2
DP  - 1976
TI  - Double-blind crossover study of fenoprofen and aspirin in osteoarthritis.
PG  - 67-70
AB  - In a randomized, double-blind, six-week, crossover comparison, fenoprofen (200 mg 
      to 600 mg every six hours) had similar efficacy to aspirin (325 mg to 975 mg 
      every six hours) in the treatment of patients with osteoarthritis affecting the 
      spine, hip, knee, or shoulder. Both fenoprofen and aspirin had greater efficacy 
      than placebo. The overall incidence of side effects was similar during aspirin 
      and fenoprofen therapy.
FAU - Diamond, H S
AU  - Diamond HS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Fenoprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Phenylpropionates/*therapeutic use
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1976;2:67-70.

PMID- 6348804
OWN - NLM
STAT- MEDLINE
DCOM- 19830923
LR  - 20191031
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 11
IP  - 2
DP  - 1983 Jun
TI  - Low-dose aspirin (ASA) renders human platelets more vulnerable to inhibition of 
      aggregation by prostacyclin (PGI2).
PG  - 131-42
AB  - Pre-treatment of human, platelet-rich plasma with concentrations of aspirin that 
      produced 50% or less inhibition of aggregation induced by collagen, arachidonic 
      acid or adenosine diphosphate, significantly increased the % inhibition of 
      platelet aggregation by a low concentration of authentic prostacyclin or by 
      prostacyclin-like activity generated by incubation of rat aorta rings in human 
      platelet-poor plasma. Similarly a single aspirin tablet (325 mg) taken orally by 
      human volunteers significantly increased the sensitivity of their platelets to 
      inhibition of aggregation by authentic prostacyclin (8.1 X 10(-10) M) for 2-48 h 
      after ingestion. Statistical significance was lost at 72 h but the trend was 
      still evident. These results support the contention that low doses of aspirin may 
      be efficacious in the therapy of arterial thromboembolism since this could 
      preserve some arterial prostacyclin-generating activity which might be sufficient 
      to inhibit adhesion and aggregation of the aspirin-treated platelets.
FAU - Philp, R B
AU  - Philp RB
FAU - Paul, M L
AU  - Paul ML
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Prostaglandins)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Aorta/metabolism
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Drug Synergism
MH  - Epoprostenol/biosynthesis/*pharmacology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Prostaglandins/*pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Thromboembolism/drug therapy
EDAT- 1983/06/01 00:00
MHDA- 1983/06/01 00:01
CRDT- 1983/06/01 00:00
PHST- 1983/06/01 00:00 [pubmed]
PHST- 1983/06/01 00:01 [medline]
PHST- 1983/06/01 00:00 [entrez]
AID - 10.1016/0262-1746(83)90013-6 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1983 Jun;11(2):131-42. doi: 
      10.1016/0262-1746(83)90013-6.

PMID- 29181519
OWN - NLM
STAT- MEDLINE
DCOM- 20180723
LR  - 20180723
IS  - 1945-1997 (Electronic)
IS  - 0098-6151 (Linking)
VI  - 117
IP  - 12
DP  - 2017 Dec 1
TI  - Role of Antiplatelet Therapy in Stroke Prevention in Patients With Atrial 
      Fibrillation.
PG  - 761-771
LID - 10.7556/jaoa.2017.148 [doi]
AB  - Patients with atrial fibrillation are at increased risk of having a cardioembolic 
      stroke. The use of oral anticoagulation is now well established to prevent 
      strokes in patients with atrial fibrillation and a CHA2DS2-VASc (congestive heart 
      failure, hypertension, age ≥75 years [2 points], diabetes mellitus, prior 
      stroke/transient ischemic attack or thromboembolism [2 points], vascular disease, 
      age 65 to 74 years, and sex category) score of greater than 1, beyond sex. 
      However, the role of antiplatelet therapy, specifically aspirin in low-risk 
      patients or as an alternative to oral anticoagulation, remains controversial. The 
      most recent US guidelines conflict with the European guidelines, which do not 
      recommend antiplatelet monotherapy for stroke prevention irrespective of stroke 
      risk. The aim of this review is to summarize published studies that question the 
      role of aspirin in preventing strokes associated with atrial fibrillation. 
      Overall, aspirin is found to play a limited role in the prevention of stroke in 
      patients with atrial fibrillation and is associated with a similar risk of 
      hemorrhagic events compared with anticoagulants. The benefit of dual antiplatelet 
      therapy as an alternative to oral anticoagulation requires further study.
FAU - Manaktala, Rohini
AU  - Manaktala R
FAU - Kluger, Jeffrey
AU  - Kluger J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Osteopath Assoc
JT  - The Journal of the American Osteopathic Association
JID - 7503065
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Stroke/etiology/*prevention & control
EDAT- 2017/11/29 06:00
MHDA- 2018/07/24 06:00
CRDT- 2017/11/29 06:00
PHST- 2017/11/29 06:00 [entrez]
PHST- 2017/11/29 06:00 [pubmed]
PHST- 2018/07/24 06:00 [medline]
AID - 2664816 [pii]
AID - 10.7556/jaoa.2017.148 [doi]
PST - ppublish
SO  - J Am Osteopath Assoc. 2017 Dec 1;117(12):761-771. doi: 10.7556/jaoa.2017.148.

PMID- 34978850
OWN - NLM
STAT- MEDLINE
DCOM- 20220207
LR  - 20220207
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 175
IP  - 1
DP  - 2022 Jan
TI  - In persons at intermediate risk for CVD, polypills reduce a composite of CV 
      events at 5 y.
PG  - JC2
LID - 10.7326/J21-0004 [doi]
AB  - Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and 
      without aspirin for primary prevention of cardiovascular disease: an individual 
      participant data meta-analysis. Lancet. 2021;398:1133-46. 34469765.
FAU - Brown, Krysta
AU  - Brown K
AD  - Tower Health/Reading Hospital, West Reading, Pennsylvania, USA (K.B., A.A.D.).
FAU - Donato, Anthony A
AU  - Donato AA
AD  - Tower Health/Reading Hospital, West Reading, Pennsylvania, USA (K.B., A.A.D.).
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20220104
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Lancet. 2021 Sep 25;398(10306):1133-1146. PMID: 34469765
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Drug Combinations
MH  - Humans
MH  - Primary Prevention
EDAT- 2022/01/04 06:00
MHDA- 2022/02/08 06:00
CRDT- 2022/01/03 17:10
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/02/08 06:00 [medline]
PHST- 2022/01/03 17:10 [entrez]
AID - 10.7326/J21-0004 [doi]
PST - ppublish
SO  - Ann Intern Med. 2022 Jan;175(1):JC2. doi: 10.7326/J21-0004. Epub 2022 Jan 4.

PMID- 19788350
OWN - NLM
STAT- MEDLINE
DCOM- 20091229
LR  - 20191210
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 25
IP  - 11
DP  - 2009 Nov
TI  - Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with 
      non-steroidal anti-inflammatory drugs.
PG  - 2785-93
LID - 10.1185/03007990903212682 [doi]
AB  - BACKGROUND: Low-dose acetylsalicylic acid (ASA; aspirin; 75-325 mg/day) is 
      effective for the prevention of cardiovascular events, and its use in this 
      indication is rapidly increasing. However, the use of ASA and, indeed, other 
      non-steroidal anti-inflammatory drugs (NSAIDs) is limited by the incidence of 
      adverse gastroduodenal events. OBJECTIVES AND SCOPE: To review the clinical 
      evidence for, and the pharmacodynamic basis of, ASA-induced gastroduodenal 
      toxicity in comparison with NSAIDs, and address the question of whether low-dose 
      ASA is 'safe' from a gastroduodenal perspective. This was a narrative, 
      descriptive review, rather than a formal systematic review. FINDINGS: Adverse 
      gastroduodenal effects, which are well known to occur with NSAIDs, are also 
      prevalent in patients receiving low-dose ASA for cardiovascular protection even 
      at doses as low as 75 mg/day. The risk of gastroduodenal toxicity is particularly 
      high among 'at-risk' low-dose ASA patients (aged >70 years, previous ulcer or 
      upper gastrointestinal bleeding and users of antiplatelets or NSAIDs). There are 
      important differences in the mechanism of ASA-induced gastroduodenal toxicity, 
      relative to NSAIDs. These differences include the effects on the cyclooxygenase 
      (COX)-1 isoenzyme, local effects on the gastroduodenal mucosa specific to ASA and 
      a reduction in platelet aggregation. CONCLUSION: Data suggest that ASA causes 
      significant gastroduodenal damage even at the low doses used for cardiovascular 
      protection. These effects (both systemic and possibly local) may be 
      pharmacodynamically distinct from the gastroduodenal toxicity seen with NSAIDs. 
      Studies are required to establish strategies for improving the tolerability of 
      low-dose ASA, allowing patients to continue to benefit from the cardiovascular 
      protection associated with such therapy.
FAU - Yeomans, Neville D
AU  - Yeomans ND
AD  - School of Medicine, University of Western Sydney, Penrith South DC, NSW 1797, 
      Australia. N.Yeomans@uws.edu.au
FAU - Hawkey, Christopher J
AU  - Hawkey CJ
FAU - Brailsford, Wayne
AU  - Brailsford W
FAU - Naesdal, Jørgen
AU  - Naesdal J
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/administration & dosage/*adverse effects/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Duodenal Diseases/*chemically induced
MH  - Gastric Mucosa/drug effects
MH  - Humans
MH  - Models, Biological
RF  - 125
EDAT- 2009/10/01 06:00
MHDA- 2009/12/30 06:00
CRDT- 2009/10/01 06:00
PHST- 2009/10/01 06:00 [entrez]
PHST- 2009/10/01 06:00 [pubmed]
PHST- 2009/12/30 06:00 [medline]
AID - 10.1185/03007990903212682 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2009 Nov;25(11):2785-93. doi: 10.1185/03007990903212682.

PMID- 3288070
OWN - NLM
STAT- MEDLINE
DCOM- 19880714
LR  - 20131121
IS  - 0003-4886 (Print)
IS  - 0003-4886 (Linking)
VI  - 20
IP  - 4
DP  - 1988 Apr
TI  - Aspirin and secondary bleeding after traumatic hyphema.
PG  - 157-8
AB  - A randomized, controlled study was conducted in 51 patients to investigate the 
      effect of aspirin administration on traumatic hyphema. Aspirin tablets 500 mg tid 
      were administered for seven days. Rebleeding was found in three of 23 eyes of 
      patients who had received aspirin and in two of 28 eyes of control patients. This 
      difference was not statistically significant (P = .405), proving that aspirin is 
      not an important factor in rebleeding in patients with hyphema.
FAU - Marcus, M
AU  - Marcus M
AD  - Department of Ophthalmology, Soroka University Hospital, Beer-Sheba, Israel.
FAU - Biedner, B
AU  - Biedner B
FAU - Lifshitz, T
AU  - Lifshitz T
FAU - Yassur, Y
AU  - Yassur Y
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Ann Ophthalmol
JT  - Annals of ophthalmology
JID - 0210137
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Eye Injuries/*complications
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Hyphema/*drug therapy/etiology
MH  - Recurrence
MH  - Wounds, Nonpenetrating
EDAT- 1988/04/01 00:00
MHDA- 1988/04/01 00:01
CRDT- 1988/04/01 00:00
PHST- 1988/04/01 00:00 [pubmed]
PHST- 1988/04/01 00:01 [medline]
PHST- 1988/04/01 00:00 [entrez]
PST - ppublish
SO  - Ann Ophthalmol. 1988 Apr;20(4):157-8.

PMID- 31492014
OWN - NLM
STAT- MEDLINE
DCOM- 20200128
LR  - 20200128
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 20
IP  - 18
DP  - 2019 Sep 5
TI  - Molecular Targets of Aspirin and Prevention of Preeclampsia and Their Potential 
      Association with Circulating Extracellular Vesicles during Pregnancy.
LID - 10.3390/ijms20184370 [doi]
LID - 4370
AB  - Uncomplicated healthy pregnancy is the outcome of successful fertilization, 
      implantation of embryos, trophoblast development and adequate placentation. Any 
      deviation in these cascades of events may lead to complicated pregnancies such as 
      preeclampsia (PE). The current incidence of PE is 2-8% in all pregnancies 
      worldwide, leading to high maternal as well as perinatal mortality and morbidity 
      rates. A number of randomized controlled clinical trials observed the association 
      between low dose aspirin (LDA) treatment in early gestational age and significant 
      reduction of early onset of PE in high-risk pregnant women. However, a 
      substantial knowledge gap exists in identifying the particular mechanism of 
      action of aspirin on placental function. It is already established that the 
      placental-derived exosomes (PdE) are present in the maternal circulation from 6 
      weeks of gestation, and exosomes contain bioactive molecules such as proteins, 
      lipids and RNA that are a "fingerprint" of their originating cells. 
      Interestingly, levels of exosomes are higher in PE compared to normal 
      pregnancies, and changes in the level of PdE during the first trimester may be 
      used to classify women at risk for developing PE. The aim of this review is to 
      discuss the mechanisms of action of LDA on placental and maternal physiological 
      systems including the role of PdE in these phenomena. This review article will 
      contribute to the in-depth understanding of LDA-induced PE prevention.
FAU - Dutta, Suchismita
AU  - Dutta S
AD  - Exosome Biology Laboratory, Centre for Clinical Diagnostics, University of 
      Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, The 
      University of Queensland, Brisbane, QLD 4029, Australia. 
      suchismita.sarker@uq.net.au.
FAU - Kumar, Sathish
AU  - Kumar S
AD  - Departments of Comparative Biosciences and Obstetrics and Gynecology, University 
      of Wisconsin, Madison, WI 53792, USA. sathish.kumar@wisc.edu.
FAU - Hyett, Jon
AU  - Hyett J
AD  - Royal Prince Alfred Hospital Sydney, University of Sydney, Camperdown, NSW 2050, 
      Australia. Jon.Hyett@health.nsw.gov.au.
FAU - Salomon, Carlos
AU  - Salomon C
AD  - Exosome Biology Laboratory, Centre for Clinical Diagnostics, University of 
      Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, The 
      University of Queensland, Brisbane, QLD 4029, Australia. 
      c.salomongallo@uq.edu.au.
AD  - Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Ochsner Clinic 
      Foundation, New Orleans, LA 70124, USA. c.salomongallo@uq.edu.au.
AD  - Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, 
      University of Concepción, Concepción, Region Bio-Bio 4070386, Chile. 
      c.salomongallo@uq.edu.au.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190905
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Biomarkers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Biomarkers
MH  - Exosomes/metabolism
MH  - Extracellular Vesicles/*metabolism
MH  - Female
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Placenta/drug effects/metabolism
MH  - Pre-Eclampsia/etiology/*metabolism/*prevention & control
MH  - Pregnancy
MH  - Treatment Outcome
PMC - PMC6769718
OTO - NOTNLM
OT  - exosomes
OT  - low dose aspirin
OT  - placentation
OT  - preeclampsia
OT  - pregnancy
COIS- The authors declare no conflict of interest.
EDAT- 2019/09/08 06:00
MHDA- 2020/01/29 06:00
CRDT- 2019/09/08 06:00
PHST- 2019/05/19 00:00 [received]
PHST- 2019/07/30 00:00 [revised]
PHST- 2019/08/26 00:00 [accepted]
PHST- 2019/09/08 06:00 [entrez]
PHST- 2019/09/08 06:00 [pubmed]
PHST- 2020/01/29 06:00 [medline]
AID - ijms20184370 [pii]
AID - ijms-20-04370 [pii]
AID - 10.3390/ijms20184370 [doi]
PST - epublish
SO  - Int J Mol Sci. 2019 Sep 5;20(18):4370. doi: 10.3390/ijms20184370.

PMID- 20689403
OWN - NLM
STAT- MEDLINE
DCOM- 20110209
LR  - 20131121
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 21
IP  - 7
DP  - 2010 Oct
TI  - Effects of different doses, enteric-coated preparation of aspirin, and sex on 
      urinary 11-dehydrothromboxane B2 in healthy volunteers.
PG  - 649-52
LID - 10.1097/MBC.0b013e32833cea2c [doi]
AB  - There is scarce information about the effects of different doses and 
      enteric-coated preparation of aspirin on platelet function, especially in Asian 
      people, evaluated by the measurement of urinary 11-dehydrothromboxane B2 (dTXB2). 
      The objective of the present study was to assess the effects of different doses, 
      enteric-coated preparation of aspirin, sex and also the effects of timing of 
      urine collection on urinary dTXB2 level in healthy volunteers. Thirty healthy 
      volunteers were included. Each volunteer took three preparations of aspirin 
      (aspirin 81 mg, enteric-coated aspirin 300 mg and aspirin 300 mg) for 7 days. 
      Urine dTXB2 level was measured at baseline, day 3, and day 7 after taking each 
      preparation of aspirin. There was no significant difference in the effects of 
      different doses of aspirin (81 vs. 300 mg, 50.7 vs. 61.8 ng/mmol creatinine, P = 
      0.248), preparations (enteric-coated vs. nonenteric-coated aspirin, 61.8 vs. 67.9 
      ng/mmol creatinine, P = 0.527) and time of urine collection (day 3 vs. day 7, 
      51.7 vs. 49.9 ng/mmol creatinine, P = 0.448). Female volunteers showed a trend to 
      have higher urinary dTXB2 than male volunteers at baseline and after taking 
      aspirin. This study showed no significant difference in urinary dTXB2 level after 
      taking different doses and enteric-coated preparation of aspirin in healthy 
      volunteers.
FAU - Dharmasaroja, Pornpatr A
AU  - Dharmasaroja PA
AD  - Division of Neurology, Faculty of Medicine, Department of Internal Medicine, 
      Thammasat University, Klong Luang, Pathumthani, Thailand. pornpatr1@hotmail.com
FAU - Sae-Lim, Suvaraporn
AU  - Sae-Lim S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Sex Factors
MH  - Tablets, Enteric-Coated/administration & dosage/pharmacokinetics/pharmacology
MH  - Thromboxane B2/*analogs & derivatives/urine
MH  - Time Factors
EDAT- 2010/08/07 06:00
MHDA- 2011/02/10 06:00
CRDT- 2010/08/07 06:00
PHST- 2010/08/07 06:00 [entrez]
PHST- 2010/08/07 06:00 [pubmed]
PHST- 2011/02/10 06:00 [medline]
AID - 10.1097/MBC.0b013e32833cea2c [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2010 Oct;21(7):649-52. doi: 
      10.1097/MBC.0b013e32833cea2c.

PMID- 430508
OWN - NLM
STAT- MEDLINE
DCOM- 19790629
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 68
IP  - 5
DP  - 1979 May
TI  - Amino acid effect on aspirin stability in propylene glycol.
PG  - 645-8
AB  - Temperature stability studies were conducted on 0.36 M (6.5% W/V) aspirin 
      solutions including either 0.02 M L-methionine or 0.02 M histidine in propylene 
      glycol. Aspirin was determined spectrophoto-fluorometrically as salicylic acid 
      content at 412 nm. A 0.36 M aspirin in polyethylene glycol 400 solution was 
      studied concurrently. Aspirin degradation rate constants, k, obtained from 
      semilogarithmic plots of percent drug remaining versus time at 30-70 +/- 0.5 
      degrees were used for preparing Arrhenius plots. Good correlation was seen 
      between predicted aspirin stability and experimental k25 degrees values. 
      L-Methionine and histidine markedly reduced aspirin stability.
FAU - Narang, P K
AU  - Narang PK
FAU - Lim, J K
AU  - Lim JK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Amino Acids)
RN  - 0 (Propylene Glycols)
RN  - 0 (Solvents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Amino Acids
MH  - *Aspirin/analysis
MH  - Drug Stability
MH  - *Propylene Glycols
MH  - Solvents
MH  - Spectrometry, Fluorescence
MH  - Temperature
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
AID - S0022-3549(15)42617-6 [pii]
AID - 10.1002/jps.2600680536 [doi]
PST - ppublish
SO  - J Pharm Sci. 1979 May;68(5):645-8. doi: 10.1002/jps.2600680536.

PMID- 9389827
OWN - NLM
STAT- MEDLINE
DCOM- 19971222
LR  - 20220419
IS  - 0015-0282 (Print)
IS  - 0015-0282 (Linking)
VI  - 68
IP  - 5
DP  - 1997 Nov
TI  - Low-dose aspirin for oocyte donation recipients with a thin endometrium: 
      prospective, randomized study.
PG  - 927-30
AB  - OBJECTIVE: To evaluate the effect of low-dose aspirin use in oocyte donation 
      recipients with an endometrial thickness of < 8 mm. DESIGN: A prospective, 
      randomized study. SETTING: An oocyte donation program in a private infertility 
      practice. PATIENT(S): Twenty-eight recipients undergoing oocyte donation who 
      failed to develop an endometrial thickness of at least 8 mm in a previous 
      evaluation cycle. INTERVENTION(S): Fifteen recipients received low-dose aspirin 
      (81 mg/d) in addition to standard hormone replacement for an oocyte donation 
      cycle. The remaining 13 recipients did not receive aspirin. MAIN OUTCOME 
      MEASURE(S): Clinical pregnancy rates, delivery rates, implantation rates, and 
      change in endometrial thickness were compared in the aspirin and nonaspirin 
      groups. RESULT(S): There was no demonstrable increase in endometrial thickness in 
      the aspirin-treated group. However, there was a statistically significant 
      increase in implantation rates in the aspirin-treated group (24% versus 9%) and 
      in implantation rates and clinical pregnancy rates in the aspirin-treated group 
      when the final endometrial thickness was < 8 mm. CONCLUSION(S): Low-dose aspirin 
      therapy improves implantation rates in oocyte donation recipients with a thin 
      endometrium.
FAU - Weckstein, L N
AU  - Weckstein LN
AD  - Reproductive Science Center of the Bay Area Fertility and Gynecology Medical 
      Group, San Ramon, California, USA.
FAU - Jacobson, A
AU  - Jacobson A
FAU - Galen, D
AU  - Galen D
FAU - Hampton, K
AU  - Hampton K
FAU - Hammel, J
AU  - Hammel J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Fertil Steril. 1998 Sep;70(3):599-600. PMID: 9757908
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Embryo Implantation
MH  - Embryo Transfer
MH  - Endometrium/*pathology
MH  - Female
MH  - Fertilization in Vitro
MH  - Humans
MH  - Infertility, Female/*pathology
MH  - *Oocyte Donation
MH  - Pregnancy
MH  - Pregnancy, Multiple
MH  - Prospective Studies
EDAT- 1997/12/09 00:00
MHDA- 1997/12/09 00:01
CRDT- 1997/12/09 00:00
PHST- 1997/12/09 00:00 [pubmed]
PHST- 1997/12/09 00:01 [medline]
PHST- 1997/12/09 00:00 [entrez]
AID - S0015028297003300 [pii]
AID - 10.1016/s0015-0282(97)00330-0 [doi]
PST - ppublish
SO  - Fertil Steril. 1997 Nov;68(5):927-30. doi: 10.1016/s0015-0282(97)00330-0.

PMID- 3448453
OWN - NLM
STAT- MEDLINE
DCOM- 19880527
LR  - 20131121
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 9
IP  - 11
DP  - 1987 Nov
TI  - In vivo-in vitro correlations with various aspirin formulations.
PG  - 761-7
AB  - In vivo evaluation of gastric irritation as determined by gastric transmural 
      potential difference (GPD) and in vitro characterization of four formulations 
      have been made. The four formulations were: (A) highly buffered, (B) 
      cytoprotective, (C) microencapsulated and (D) a plain tablet. The GPD results 
      showed C to be much less irritating than A or D, and slightly less-irritating 
      than B. The release from all formulations was well represented by dissolution 
      efficiency (DE%) and mean time of dissolution. When correlation coefficients were 
      calculated, significant relationships were found between DE% and the GPD 
      parameters area under the baseline (AUB) and the Reiz Index (RI), and between the 
      mean time of dissolution and the GPD parameters AUB, mean potential drop (MD) and 
      RI.
FAU - Alcorn, G J
AU  - Alcorn GJ
AD  - Division of Pharmaceutics and Drug Delivery Systems, University of Cincinnati, 
      OH.
FAU - Lücker, P W
AU  - Lücker PW
FAU - Procaccini, R L
AU  - Procaccini RL
FAU - Ritschel, W A
AU  - Ritschel WA
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - 0 (Buffers)
RN  - 0 (Capsules)
RN  - 0 (Dosage Forms)
RN  - 0 (Irritants)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Buffers
MH  - Capsules
MH  - Dosage Forms
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Irritants
MH  - Membrane Potentials/drug effects
MH  - Random Allocation
MH  - Solubility
MH  - Tablets
EDAT- 1987/11/01 00:00
MHDA- 1987/11/01 00:01
CRDT- 1987/11/01 00:00
PHST- 1987/11/01 00:00 [pubmed]
PHST- 1987/11/01 00:01 [medline]
PHST- 1987/11/01 00:00 [entrez]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 1987 Nov;9(11):761-7.

PMID- 3047723
OWN - NLM
STAT- MEDLINE
DCOM- 19881027
LR  - 20131121
IS  - 0032-5473 (Print)
IS  - 0032-5473 (Linking)
VI  - 64 Suppl 1
DP  - 1988
TI  - Aspirin-induced gastroduodenal injury and its prevention by prostaglandins.
PG  - 12-4
AB  - It appears likely that aspirin injury and thus bleeding is due to both inhibition 
      of the mucosal synthesis of protective endogenous prostanoids and to a local 
      irritant effect. This injury can be abolished in humans by acid-inhibitory doses 
      of prostaglandins and can probably be ameliorated by 'cytoprotective' doses. It 
      has yet to be shown that the gastropathy seen in patients taking long-term 
      aspirin-like drugs can be prevented or treated by prostaglandins. The clinical 
      relevance of such protection has not yet been established.
FAU - Cohen, M M
AU  - Cohen MM
AD  - Department of Surgery, University of Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/antagonists & inhibitors
MH  - Gastric Mucosa/drug effects
MH  - Gastrointestinal Diseases/*chemically induced/prevention & control
MH  - Humans
MH  - Intestinal Mucosa/drug effects
MH  - Prostaglandins/*therapeutic use
MH  - Rats
RF  - 16
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Postgrad Med J. 1988;64 Suppl 1:12-4.

PMID- 28301951
OWN - NLM
STAT- MEDLINE
DCOM- 20180529
LR  - 20180529
IS  - 1615-7109 (Electronic)
IS  - 1203-4754 (Linking)
VI  - 21
IP  - 4
DP  - 2017 Jul/Aug
TI  - Continuous Aspirin Use Does Not Increase Bleeding Risk of Split-Thickness Skin 
      Transplantation Repair to Chronic Wounds.
PG  - 316-319
LID - 10.1177/1203475417697652 [doi]
AB  - BACKGROUND: Discontinuation of aspirin therapy before cutaneous surgery may cause 
      serious complications. OBJECTIVES: The aim of this prospective study was to 
      evaluate the bleeding risk of split-thickness skin transplantation repair to 
      chronic wounds in patients on aspirin therapy. METHODS: A total of 97 patients 
      who underwent split-thickness skin transplantation surgery of chronic wounds 
      during a 2-year period were enrolled. They were categorized on the basis of 
      aspirin therapies. The primary outcome was postoperative bleeding and bleeding 
      complications. Univariate analysis was performed to examine the association 
      between aspirin and bleeding complications. Among the 26 patients taking aspirin 
      continuously in group A, there were 5 bleeding complications (19.23%). Among the 
      55 nonusers in group B, there were 10 bleeding complications (18.18%). Among the 
      16 discontinuous patients in group C, there were 3 bleeding complications 
      (18.75%). No statistical differences were found among the groups ( P = .956). 
      Univariate analysis showed that continuous aspirin use was not significantly 
      associated with bleeding complications (odds ratio, 0.933; 95% confidence 
      interval, 0.283-3.074; P = .910 in the aspirin and control groups) and that 
      discontinuous aspirin use was not significantly associated with bleeding 
      complications (odds ratio, 0.963; 95% confidence interval, 0.230-4.025; P = .959 
      in the aspirin and control groups; odds ratio, 0.969; 95% confidence interval, 
      0.198-4.752; P = .969 in the aspirin and discontinuous groups). CONCLUSIONS: 
      Continuous aspirin use does not produce an additional bleeding risk in patients 
      who undergo split-thickness skin transplantation repair of chronic wounds.
FAU - Sun, Yanwei
AU  - Sun Y
AD  - 1 Department of Burns & Plastic Surgery, Shandong Provincial Hospital Affiliated 
      to Shandong University, Jinan, China.
AD  - 2 Department of Burns & Plastic Surgery, Central Hospital of Zibo, Zibo, Shandong 
      Province, China.
FAU - Wang, Yibing
AU  - Wang Y
AD  - 1 Department of Burns & Plastic Surgery, Shandong Provincial Hospital Affiliated 
      to Shandong University, Jinan, China.
FAU - Li, Liang
AU  - Li L
AD  - 2 Department of Burns & Plastic Surgery, Central Hospital of Zibo, Zibo, Shandong 
      Province, China.
FAU - Zhang, Zheng
AU  - Zhang Z
AD  - 2 Department of Burns & Plastic Surgery, Central Hospital of Zibo, Zibo, Shandong 
      Province, China.
FAU - Wang, Ning
AU  - Wang N
AD  - 2 Department of Burns & Plastic Surgery, Central Hospital of Zibo, Zibo, Shandong 
      Province, China.
FAU - Wu, Dan
AU  - Wu D
AD  - 2 Department of Burns & Plastic Surgery, Central Hospital of Zibo, Zibo, Shandong 
      Province, China.
LA  - eng
PT  - Journal Article
DEP - 20170316
PL  - United States
TA  - J Cutan Med Surg
JT  - Journal of cutaneous medicine and surgery
JID - 9614685
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Postoperative Hemorrhage/*epidemiology
MH  - Prospective Studies
MH  - Skin/*injuries
MH  - Skin Transplantation/methods/*statistics & numerical data
OTO - NOTNLM
OT  - aspirin
OT  - bleeding
OT  - chronic wound
OT  - skin transplantation
EDAT- 2017/03/18 06:00
MHDA- 2018/05/31 06:00
CRDT- 2017/03/18 06:00
PHST- 2017/03/18 06:00 [pubmed]
PHST- 2018/05/31 06:00 [medline]
PHST- 2017/03/18 06:00 [entrez]
AID - 10.1177/1203475417697652 [doi]
PST - ppublish
SO  - J Cutan Med Surg. 2017 Jul/Aug;21(4):316-319. doi: 10.1177/1203475417697652. Epub 
      2017 Mar 16.

PMID- 19437331
OWN - NLM
STAT- MEDLINE
DCOM- 20090910
LR  - 20131121
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 20
IP  - 3
DP  - 2009 May
TI  - The impact of intravenous aspirin administration on platelet aspirin resistance 
      after on-pump coronary artery bypass surgery.
PG  - 150-7
LID - 10.1080/09537100902780650 [doi]
AB  - Aspirin resistance continues to be a major challenge in patients after coronary 
      artery bypass grafting (CABG). We investigated the impact of intravenous aspirin 
      on platelet function in this clinical setting. Forty-two patients received 100 mg 
      of oral aspirin once daily, beginning on day 1 after the operation. Between day 6 
      and 8 post operation one oral dose was replaced by an intravenous dose of 300 mg. 
      Platelet function analyzer (PFA-100) closure times (CT), turbidimetric platelet 
      aggregation (TPA) and impedance platelet aggregation (IPA) induced by arachidonic 
      acid (AA), collagen and ADP were measured prior to and 1 h and 24 h after 
      intravenous aspirin. Results obtained prior to the intravenous aspirin were 
      compared with respective values from 120 healthy individuals. Despite the 
      postoperative oral aspirin that was given once daily, ADP-induced TPA (ADPTPA) 
      and IPA values induced by AA, ADP or collagen were significantly greater in 
      patients than in controls, while PFA-100 CT were significantly shorter. 
      Intravenous aspirin induced a significant reduction of platelet aggregability as 
      measured by collagen/epinephrine (CEPI) CT, TPA and IPA induced by AA and 
      collagen 1 h and 24 h after administration. Intravenous aspirin was not found to 
      influence collagen/ADP (CADP) CT and IPA induced by ADP. Concomitantly, the 
      number of patients with laboratory aspirin resistance as measured by CEPI-CT and 
      TPA but not by IPA induced by AA or collagen dropped significantly. Agreement in 
      the detection of aspirin responders and non-responders among platelet function 
      tests was poor. Our findings indicate that the intravenous aspirin appears to be 
      a promising approach for reducing laboratory aspirin resistance during the 
      postoperative phase of CABG.
FAU - Bach, Jürgen
AU  - Bach J
AD  - Institute of Hemostaseology and Transfusion Medicine, Academic City Hospital, 
      Ludwigshafen/Germany.
FAU - Kammerer, Inna
AU  - Kammerer I
FAU - Isgro, Frank
AU  - Isgro F
FAU - Haubelt, Hannelore
AU  - Haubelt H
FAU - Vogt, Anette
AU  - Vogt A
FAU - Saggau, Werner
AU  - Saggau W
FAU - Hellstern, Peter
AU  - Hellstern P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Collagen/pharmacology
MH  - *Coronary Artery Bypass
MH  - Drug Resistance/*drug effects
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/therapeutic 
      use
MH  - Platelet Function Tests
EDAT- 2009/05/14 09:00
MHDA- 2009/09/11 06:00
CRDT- 2009/05/14 09:00
PHST- 2009/05/14 09:00 [entrez]
PHST- 2009/05/14 09:00 [pubmed]
PHST- 2009/09/11 06:00 [medline]
AID - 911118964 [pii]
AID - 10.1080/09537100902780650 [doi]
PST - ppublish
SO  - Platelets. 2009 May;20(3):150-7. doi: 10.1080/09537100902780650.

PMID- 15860386
OWN - NLM
STAT- MEDLINE
DCOM- 20050830
LR  - 20131121
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 101
IP  - 1
DP  - 2005 May 11
TI  - Prevalence of aspirin resistance measured by PFA-100.
PG  - 71-6
AB  - BACKGROUND: Aspirin protects from cardiovascular events. However, a number of 
      patients who take this drug suffer events, probably due to aspirin resistance. 
      Our objective was to determine the prevalence of aspirin resistance in patients 
      taking this drug and to test if resistance is related to different variables. 
      METHODS: Platelet function was studied in 113 patients (90 men) aged 63+/-9 (80 
      with stable ischaemic heart disease) who took aspirin (100 to 300 mg/day). By a 
      platelet function analyzer, called PFA-100, the epinephrine closure time was 
      studied. We also analysed the possible relationship between epinephrine closure 
      time and the following variables: total cholesterol, LDL, HDL cholesterol, 
      total/HDL cholesterol, triglycerides, lipoprotein(a), and C reactive protein. The 
      possible association between aspirin resistance (epinephrine closure time <161 s) 
      and different variables was also analyzed with the SPSS statistical package. 
      Results are expressed in median (interquartile range). RESULTS: Aspirin 
      resistance was found in 32% of cases. Ischaemic heart disease, smoking habit, and 
      treatment with statins were associated with a significantly greater percent of 
      resistance (p=0.049, 0.009, and 0.043, respectively). Patients with aspirin 
      resistance had higher levels of total/HDL cholesterol: 4.46 (3.76-5.55) vs. 3.97 
      (3.20-4.75) (p = 0.023); and lipoprotein(a): 57.2 (24.8-85.0) mg/dl vs. 13.1 
      (3.7-38.0) mg/dl (p = 0.007). CONCLUSIONS: Aspirin resistance is frequent and 
      easily detected by PFA-100. It occurs more frequently in smokers. A mild 
      association is found with ischaemic heart disease, some lipids, and treatment 
      with statins. Our results support the applicability of this method to clinical 
      practice.
FAU - Coma-Canella, Isabel
AU  - Coma-Canella I
AD  - Department of Cardiology and Cardiovascular Surgery, Facultad de Medicina, 
      Clínica Universitaria de Navarra, Avenida de Pio XII, 36. 31008 Pamplona, Spain. 
      icoma@unav.es
FAU - Velasco, Amelia
AU  - Velasco A
FAU - Castano, Sara
AU  - Castano S
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Brain Ischemia/prevention & control
MH  - Cross-Sectional Studies
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/prevention & control
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - *Platelet Function Tests
MH  - Prevalence
MH  - Time Factors
EDAT- 2005/04/30 09:00
MHDA- 2005/09/01 09:00
CRDT- 2005/04/30 09:00
PHST- 2003/12/25 00:00 [received]
PHST- 2004/02/19 00:00 [revised]
PHST- 2004/03/05 00:00 [accepted]
PHST- 2005/04/30 09:00 [pubmed]
PHST- 2005/09/01 09:00 [medline]
PHST- 2005/04/30 09:00 [entrez]
AID - S0167-5273(04)00424-3 [pii]
AID - 10.1016/j.ijcard.2004.03.069 [doi]
PST - ppublish
SO  - Int J Cardiol. 2005 May 11;101(1):71-6. doi: 10.1016/j.ijcard.2004.03.069.

PMID- 9230157
OWN - NLM
STAT- MEDLINE
DCOM- 19970807
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 80
IP  - 2
DP  - 1997 Jul 15
TI  - Effect of aspirin dosage and enteric coating on platelet reactivity.
PG  - 189-93
AB  - Although aspirin is effective in the prevention and treatment of cardiovascular 
      diseases, the optimal dose remains uncertain. The purpose of this study was to 
      compare the platelet inhibitory and prostacyclin-sparing effects of 2 doses (81 
      and 325 mg) and forms (enteric-coated and regular) of aspirin. Since platelet 
      reactivity has been reported to increase after strenuous exercise, a known 
      trigger of myocardial infarction, subjects were studied following maximal 
      treadmill exercise as well as at rest. Forty male healthy subjects were evaluated 
      using a randomized, double-blind, parallel study design. Blood samples were 
      obtained before and after maximal treadmill exercise at baseline and after 7 days 
      on aspirin therapy. Both enteric and regular aspirin in 81- and 325-mg dosages 
      markedly inhibited adenosine diphosphate and epinephrine-induced aggregation at 
      rest and after exercise. Aspirin also inhibited the platelet response to collagen 
      as assessed by a longer lag time to aggregation. The prolongation of lag time was 
      greater for 325 mg than for 81 mg (100 +/- 7 vs 91 +/- 7; p = 0.04, after 
      exercise). There were no significant dose-related differences in plasma 
      6-keto-prostaglandin F1alpha level; however, enteric-coated aspirin inhibited the 
      exercise-induced increase in 6-keto-prostaglandin F1alpha to a lesser extent than 
      regular aspirin. Although both doses (81 and 325 mg) and types (regular and 
      enteric-coated) of aspirin inhibited adenosine diphosphate and 
      epinephrine-induced aggregation equally, the 325-mg dose inhibited 
      collagen-induced aggregation to a greater extent than 81 mg. The greater platelet 
      inhibition observed with 325 mg may be clinically relevant in acute coronary 
      syndromes characterized by plaque rupture with extensive collagen exposure and 
      platelet activation.
FAU - Feng, D
AU  - Feng D
AD  - Institute for Prevention of Cardiovascular Disease, Cardiovascular Division, Beth 
      Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 
      02215, USA.
FAU - McKenna, C
AU  - McKenna C
FAU - Murillo, J
AU  - Murillo J
FAU - Mittleman, M A
AU  - Mittleman MA
FAU - Gebara, O C
AU  - Gebara OC
FAU - Lipinska, I
AU  - Lipinska I
FAU - Muller, J E
AU  - Muller JE
FAU - Tofler, G H
AU  - Tofler GH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Tablets, Enteric-Coated)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Tablets, Enteric-Coated
EDAT- 1997/07/15 00:00
MHDA- 1997/07/15 00:01
CRDT- 1997/07/15 00:00
PHST- 1997/07/15 00:00 [pubmed]
PHST- 1997/07/15 00:01 [medline]
PHST- 1997/07/15 00:00 [entrez]
AID - S0002914997003160 [pii]
AID - 10.1016/s0002-9149(97)00316-0 [doi]
PST - ppublish
SO  - Am J Cardiol. 1997 Jul 15;80(2):189-93. doi: 10.1016/s0002-9149(97)00316-0.

PMID- 27571053
OWN - NLM
STAT- MEDLINE
DCOM- 20170417
LR  - 20200225
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 21
IP  - 9
DP  - 2016 Aug 25
TI  - Aspirination of α-Aminoalcohol (Sarpogrelate M1).
LID - 10.3390/molecules21091126 [doi]
LID - 1126
AB  - Aspirination of α-aminoalcohol (sarpogrelate M1) has been performed under various 
      general esterification conditions. In most cases, the desired aspirinate ester 
      was obtained at a low yield with unexpected byproducts, the formation of which 
      was mostly derived from the chemical properties of the tertiary α-amino group. 
      After systematic analysis of those methods, the aspirinated sarpogrelate M1 was 
      prepared using a two-step approach combining salicylate ester formation and 
      acetylation.
FAU - Park, Sunhwa
AU  - Park S
AD  - Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, 
      The Catholic University of Korea, Bucheon-si, Gyeonggi-do 420-743, Korea. 
      sunalovegs@catholic.ac.kr.
FAU - Lee, Jiyun
AU  - Lee J
AD  - Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, 
      The Catholic University of Korea, Bucheon-si, Gyeonggi-do 420-743, Korea. 
      ljiy727@catholic.ac.kr.
FAU - Shin, Kye Jung
AU  - Shin KJ
AD  - Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, 
      The Catholic University of Korea, Bucheon-si, Gyeonggi-do 420-743, Korea. 
      kyejung@catholic.ac.kr.
FAU - Seo, Jae Hong
AU  - Seo JH
AD  - Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, 
      The Catholic University of Korea, Bucheon-si, Gyeonggi-do 420-743, Korea. 
      jaehongseo@catholic.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20160825
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Amino Alcohols)
RN  - 0 (Succinates)
RN  - 19P708E787 (sarpogrelate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Alcohols/*chemistry
MH  - Aspirin/*chemistry
MH  - Esterification
MH  - Succinates/*chemistry
PMC - PMC6274198
OTO - NOTNLM
OT  - aspirin
OT  - esterification
OT  - sarpogrelate
OT  - α-aminoalcohol
COIS- The authors declare no conflict of interest.
EDAT- 2016/08/30 06:00
MHDA- 2017/04/18 06:00
CRDT- 2016/08/30 06:00
PHST- 2016/08/03 00:00 [received]
PHST- 2016/08/23 00:00 [revised]
PHST- 2016/08/24 00:00 [accepted]
PHST- 2016/08/30 06:00 [entrez]
PHST- 2016/08/30 06:00 [pubmed]
PHST- 2017/04/18 06:00 [medline]
AID - molecules21091126 [pii]
AID - molecules-21-01126 [pii]
AID - 10.3390/molecules21091126 [doi]
PST - epublish
SO  - Molecules. 2016 Aug 25;21(9):1126. doi: 10.3390/molecules21091126.

PMID- 18466797
OWN - NLM
STAT- MEDLINE
DCOM- 20080613
LR  - 20131121
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 51
IP  - 19
DP  - 2008 May 13
TI  - The role of aspirin in cardiovascular prevention: implications of aspirin 
      resistance.
PG  - 1829-43
LID - 10.1016/j.jacc.2007.11.080 [doi]
AB  - Aspirin is well recognized as an effective antiplatelet drug for secondary 
      prevention in subjects at high risk of cardiovascular events. However, most 
      patients receiving long-term aspirin therapy still remain at substantial risk of 
      thrombotic events due to insufficient inhibition of platelets, specifically via 
      the thromboxane A2 pathway. Although the exact prevalence is unknown, estimates 
      suggest that between 5.5% and 60% of patients using this drug may exhibit a 
      degree of "aspirin resistance," depending upon the definition used and parameters 
      measured. To date, only a limited number of clinical studies have convincingly 
      investigated the importance of aspirin resistance. Of these, few are of a 
      sufficient scale, well designed, and prospective, with aspirin used at standard 
      doses. Also, most studies do not sufficiently address the issue of noncompliance 
      to aspirin as a frequent, yet easily preventable cause of resistance to this 
      antiplatelet drug. This review article provides a comprehensive overview of 
      aspirin resistance, discussing its definition, prevalence, diagnosis, and 
      therapeutic approaches. Moreover, the clinical implications of aspirin resistance 
      are explored in various cardiovascular disease states, including diabetes 
      mellitus, hypertension, heart failure, and other similar disorders where platelet 
      reactivity is enhanced.
FAU - Gasparyan, Armen Yuri
AU  - Gasparyan AY
AD  - Haemostasis Thrombosis and Vascular Biology Unit, University Department of 
      Medicine, City Hospital, Birmingham, United Kingdom.
FAU - Watson, Timothy
AU  - Watson T
FAU - Lip, Gregory Y H
AU  - Lip GY
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2008 Oct 7;52(15):1276; author reply 1277. PMID: 18926334
CIN - J Am Coll Cardiol. 2008 Oct 7;52(15):1276-7; author reply 1277. PMID: 18926335
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/*physiopathology
MH  - Diabetes Mellitus/physiopathology
MH  - Drug Resistance/*drug effects
MH  - Heart Failure/physiopathology
MH  - Humans
MH  - Hypertension/physiopathology
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Rheumatic Diseases/physiopathology
RF  - 131
EDAT- 2008/05/10 09:00
MHDA- 2008/06/14 09:00
CRDT- 2008/05/10 09:00
PHST- 2007/09/13 00:00 [received]
PHST- 2007/10/19 00:00 [revised]
PHST- 2007/11/10 00:00 [accepted]
PHST- 2008/05/10 09:00 [pubmed]
PHST- 2008/06/14 09:00 [medline]
PHST- 2008/05/10 09:00 [entrez]
AID - S0735-1097(08)00570-6 [pii]
AID - 10.1016/j.jacc.2007.11.080 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2008 May 13;51(19):1829-43. doi: 10.1016/j.jacc.2007.11.080.

PMID- 7489937
OWN - NLM
STAT- MEDLINE
DCOM- 19960104
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 37
IP  - 4
DP  - 1995 Oct
TI  - Risks of gastrointestinal bleeding during secondary prevention of vascular events 
      with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial.
PG  - 509-11
AB  - From 1979 to 1985 2435 patients having had transient ischaemic attacks (TIAs) or 
      minor ischaemic strokes, were enrolled in the UK TIA trial and were randomised to 
      receive either aspirin 300 mg, daily or aspirin 1200 mg or placebo. Analysis of 
      reported upper gastrointestinal bleeding events (defined as haematemesis or 
      melaena, or both) showed a risk of bleeding in a dose dependent manner, odds 
      ratios (95% CI) for 300 mg of aspirin = 3.3 (1.2 to 9.0) and for 1200 mg = 6.4 
      (2.5 to 16.5) and, as would be expected, an increased risk of hospitalisation 
      because of bleeding also in a dose dependent manner, odds ratio = 3.6 (0.7 to 
      17.2) for 300 mg and 8.7 (2.0 to 37.6) for 1200 mg. Further analysis suggested 
      greater risks of bleeding from duodenal ulcers than gastric ulcers and that 
      bleeding is more likely early in the course of treatment with aspirin used as 
      secondary prevention. There was also an increased risk of lower gastrointestinal 
      bleeding, defined as fresh blood per rectum for both doses of aspirin, odds ratio 
      1.8 (0.5 to 6.1) for 300 mg of aspirin, and 1.5 (0.4 to 5.3) for 1200 mg of 
      aspirin.
FAU - Slattery, J
AU  - Slattery J
AD  - Department of Clinical Neurosciences, Western General Hospital, Edinburgh.
FAU - Warlow, C P
AU  - Warlow CP
FAU - Shorrock, C J
AU  - Shorrock CJ
FAU - Langman, M J
AU  - Langman MJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Odds Ratio
MH  - Risk
PMC - PMC1382902
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - 10.1136/gut.37.4.509 [doi]
PST - ppublish
SO  - Gut. 1995 Oct;37(4):509-11. doi: 10.1136/gut.37.4.509.

PMID- 1193452
OWN - NLM
STAT- MEDLINE
DCOM- 19760209
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 4
IP  - 1
DP  - 1975
TI  - Influence of intravenously administered acetylsalicylic acid on platelet 
      functions. A pharmacodynamic and pharmacokinetic study.
PG  - 12-22
AB  - The influence of intravenously administered acetylsalicylic acid (ASA) on the 
      kinetics of platelet function was examined in 10 patients. Simultaneously, assays 
      of salicylate in plasma were performed. A significant inhibition of platelet 
      aggregation as well as PF 3 and PF 4 availabilities could be demonstrated 2 min 
      after injection. A decrease of platelet adhesion was significant after 15 min. 
      The inhibition of platelet functions was still present after 24 h and was 
      partially demonstrable after 72 h. The concentration of salicylate in plasma 2 
      min after injection of ASA was only about two thirds of the level calculated from 
      mere distribution in circulation. After 1 h, half of the initial salicylate had 
      disappeared from plasma. No salicylate could be found after 24 hours. ASA also 
      depressed platelet functions when added to platelet-rich plasma in vitro in a 
      concentration of 100 mug/ml. Inhibition of platelet aggregation and of PF 4 
      availability were dependent on the time of incubation. Their onset was much 
      slower in vitro than in vivo. No inhibition of the PF 3 availability could be 
      found in vitro. The inhibition of platelet functions by ASA is demonstrable 
      almost immediately after injection while the duration of this inhibition is 
      considerably longer than the elimination time of salicylate from plasma. This 
      allows the conclusion that a direct intravascular reaction between ASA and 
      platelets occurs and that the inhibition of platelet functions is irreversible.
FAU - Vinazzer, H
AU  - Vinazzer H
FAU - Pütter, J
AU  - Pütter J
FAU - Loew, D
AU  - Loew D
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 37270-93-2 (Platelet Factor 3)
RN  - 37270-94-3 (Platelet Factor 4)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Collagen/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Factor 3/analysis
MH  - Platelet Factor 4/analysis
MH  - Time Factors
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 10.1159/000214084 [doi]
PST - ppublish
SO  - Haemostasis. 1975;4(1):12-22. doi: 10.1159/000214084.

PMID- 7341460
OWN - NLM
STAT- MEDLINE
DCOM- 19820719
LR  - 20131121
IS  - 0019-5499 (Print)
IS  - 0019-5499 (Linking)
VI  - 25
IP  - 4
DP  - 1981 Oct-Dec
TI  - Failure of acetyl salicylic acid (aspirin) to reduce experimental myocardial 
      ischaemic damage.
PG  - 325-30
AB  - Rats fed on acetylsalicylic acid (aspirin) 1.5 mg/100 g body weight for a period 
      of three weeks were subjected to myocardial infarction by s.c. administration 
      isoprenaline hydrochloride 8.5 mg/100 g of body weight on two consecutive days. 
      Heart specimens were taken for histological examination at 24 hr, on 5th day and 
      12th day. An equal number of rats were given saline to serve as control. As 
      compared to controls aspirin-treated rats were found to have macroscopically 
      bigger infarcts and microscopically showed persistent oedema on the 12th day. 
      Further, no histological evidence of favourable action of aspirin was seen on the 
      fifth day and after twenty-four hr.
FAU - Sharma, S
AU  - Sharma S
FAU - Arora, S
AU  - Arora S
FAU - Sanan, S
AU  - Sanan S
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Physiol Pharmacol
JT  - Indian journal of physiology and pharmacology
JID - 0374707
RN  - L628TT009W (Isoproterenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Female
MH  - Isoproterenol
MH  - Male
MH  - Myocardial Infarction/chemically induced/*drug therapy/pathology
MH  - Rats
EDAT- 1981/10/01 00:00
MHDA- 1981/10/01 00:01
CRDT- 1981/10/01 00:00
PHST- 1981/10/01 00:00 [pubmed]
PHST- 1981/10/01 00:01 [medline]
PHST- 1981/10/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Physiol Pharmacol. 1981 Oct-Dec;25(4):325-30.

PMID- 32612056
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20200921
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 140
IP  - 7
DP  - 2020
TI  - [Prediction of the Crystal Growth Mechanism of Aspirin Using Molecular 
      Simulations].
PG  - 913-921
LID - 10.1248/yakushi.20-00014 [doi]
AB  - Controlling the physicochemical properties of a drug formulation is important for 
      proper drug efficacy, since in the gastrointestinal tract many drugs undergo 
      dissolution, limiting their efficacy. Factors affecting a drug's physicochemical 
      properties include its crystal habit. Therefore, we predicted the crystal habit 
      by molecular simulation for the purpose of controlling crystal morphology. In 
      this study, we used aspirin as a model compound. By performing simulations based 
      on known crystal structure data, we trained the simulation algorithm to produce 
      the cubic and plate-like morphologies of crystals actually obtained. By these 
      methods, we showed that the crystal plane of the crystal form actually obtained 
      coincides with the characteristic crystal plane obtained by simulation. 
      Furthermore, to consider the influence of the crystallization solvent on crystal 
      growth, we simulated adsorption of solvent molecules on characteristic crystal 
      planes. The difference in adsorption energy of the solvent molecules prevents the 
      aspirin molecules from attaching to the crystal plane. As a result, we concluded 
      that the crystal habit was caused by the difference in growth rate of the crystal 
      plane. By applying the methods developed in this research, the growth of crystal 
      planes can be predicted by molecular simulation, making it possible to 
      efficiently obtain crystal forms with optimal physical properties for drug 
      development. We believe that further development of this approach will lead to 
      dramatic decreases in the cost and duration of drug development.
FAU - Hatanaka, Toshiaki
AU  - Hatanaka T
AD  - Tsumura Co. Ltd.
FAU - Yoshihashi, Yasuo
AU  - Yoshihashi Y
AD  - Faculty of Pharmaceutical Sciences, Toho University.
FAU - Ito, Masataka
AU  - Ito M
AD  - Faculty of Pharmaceutical Sciences, Toho University.
FAU - Terada, Katsuhide
AU  - Terada K
AD  - Faculty of Pharmacy, Takasaki University of Health and Welfare.
FAU - Yonemochi, Etsuo
AU  - Yonemochi E
AD  - School of Pharmacy and Pharmaceutical Sciences, Hoshi University.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Solvents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Aspirin/*chemistry
MH  - Chemical Phenomena
MH  - Crystallization
MH  - Drug Compounding
MH  - Forecasting
MH  - Models, Molecular
MH  - Solvents/chemistry
OTO - NOTNLM
OT  - adsorption energy
OT  - aspirin
OT  - crystal growth
OT  - crystal habit
OT  - crystal plane
OT  - simulation
EDAT- 2020/07/03 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1248/yakushi.20-00014 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2020;140(7):913-921. doi: 10.1248/yakushi.20-00014.

PMID- 22674769
OWN - NLM
STAT- MEDLINE
DCOM- 20130603
LR  - 20131121
IS  - 1099-0801 (Electronic)
IS  - 0269-3879 (Linking)
VI  - 27
IP  - 2
DP  - 2013 Feb
TI  - Simultaneous determination of carisoprodol and aspirin in human plasma using 
      liquid chromatography-tandem mass spectrometry in polarity switch mode: 
      application to a human pharmacokinetic study.
PG  - 179-85
LID - 10.1002/bmc.2766 [doi]
AB  - A simple, sensitive and rapid LC-MS/MS-ESI method has been developed and 
      validated for simultaneous quantification of the carisoprodol and aspirin in 
      human plasma. Carisoprodol was detected in positive ion mode, whereas aspirin was 
      detected in negative ion mode. Carbamazepine and furosemide were used as internal 
      standards (IS) for quantification of carisoprodol and aspirin, respectively. The 
      extraction procedure involves a liquid-liquid extraction method with ter-butyl 
      methyl ether. Chromatographic separation was achieved on a Zorbax XDB-Phenyl (4.6 
      × 75 mm, 3.5 µm) column using an isocratic mobile phase (5 mm ammonium 
      acetate:methanol, 20:80, v/v) at a flow rate of 0.8 mL/min with a total run time 
      of 2.2 min. A detailed method validation was performed as per the FDA guidelines. 
      The standard curves found to be linear in the range of 25.5-4900 and 15.3-3000 
      ng/mL for carisoprodol and aspirin, respectively. The results met the acceptance 
      criteria. Carisoprodol and aspirin were found to be stable in various stability 
      studies. The validated method was successfully applied to a pharmacokinetic study 
      following co-administration of carisoprodol (250 mg) and aspirin (75 mg) tablets 
      by oral route to human volunteers.
CI  - Copyright © 2012 John Wiley & Sons, Ltd.
FAU - Sreenivasulu, Vudagandla
AU  - Sreenivasulu V
AD  - Department of Chemistry, Sri Venkateswara University, Tirupathi, AP, India.
FAU - Ramesh, Mullangi
AU  - Ramesh M
FAU - Kumar, Inamadugu Jaswanth
AU  - Kumar IJ
FAU - Babu, Ravi Vasu
AU  - Babu RV
FAU - Pilli, Nageswara Rao
AU  - Pilli NR
FAU - Krishnaiah, Abburi
AU  - Krishnaiah A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120605
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - 21925K482H (Carisoprodol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*blood/chemistry/pharmacokinetics
MH  - Carisoprodol/*blood/chemistry/pharmacokinetics
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Drug Stability
MH  - Humans
MH  - Least-Squares Analysis
MH  - Liquid-Liquid Extraction
MH  - Male
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Tandem Mass Spectrometry/*methods
EDAT- 2012/06/08 06:00
MHDA- 2013/06/05 06:00
CRDT- 2012/06/08 06:00
PHST- 2012/04/04 00:00 [received]
PHST- 2012/05/01 00:00 [accepted]
PHST- 2012/06/08 06:00 [entrez]
PHST- 2012/06/08 06:00 [pubmed]
PHST- 2013/06/05 06:00 [medline]
AID - 10.1002/bmc.2766 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2013 Feb;27(2):179-85. doi: 10.1002/bmc.2766. Epub 2012 Jun 5.

PMID- 1777842
OWN - NLM
STAT- MEDLINE
DCOM- 19920310
LR  - 20190720
IS  - 0008-4212 (Print)
IS  - 0008-4212 (Linking)
VI  - 69
IP  - 10
DP  - 1991 Oct
TI  - Bioavailability of aspirin and salicylamide following oral co-administration in 
      human volunteers.
PG  - 1436-42
AB  - BC powder (I) is a commercially available analgesic containing the active 
      ingredients aspirin and salicylamide. The kinetics of I, BC powder minus aspirin 
      (II), and BC powder minus salicylamide (III) were evaluated in 13 volunteers. Ten 
      minutes after administration of I, aspirin reached a maximum concentration of 
      12.9 micrograms/mL, while salicylamide concentration reached a peak value of 3.4 
      micrograms/mL. However, when III was administered, aspirin was not detected at 10 
      min and only reached a concentration of 0.4 microgram/mL at 2 and 6 h. 
      Furthermore, the area under the plasma concentration versus time curve for 
      aspirin when III was administered was sixfold less compared with treatment with 
      I. The area under the curve for aspirin metabolites was significantly different 
      in I versus III. After treatment with II, a delay in salicylamide peak 
      concentration was observed. Gentisamide was not detected throughout the study. 
      This study demonstrates that salicylamide significantly enhances plasma levels of 
      aspirin with potential therapeutic implications.
FAU - Abdel-Rahman, M S
AU  - Abdel-Rahman MS
AD  - Department of Pharmacology and Toxicology, New Jersey Medical School, University 
      of Medicine and Dentistry of New Jersey 07103.
FAU - Reddi, A S
AU  - Reddi AS
FAU - Curro, F A
AU  - Curro FA
FAU - Turkall, R M
AU  - Turkall RM
FAU - Kadry, A M
AU  - Kadry AM
FAU - Hansrote, J A
AU  - Hansrote JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Drug Combinations)
RN  - 0 (Powders)
RN  - 0 (Salicylamides)
RN  - EM8BM710ZC (salicylamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Biological Availability
MH  - Drug Combinations
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Powders
MH  - Salicylamides/administration & dosage/*pharmacokinetics
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
AID - 10.1139/y91-215 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 1991 Oct;69(10):1436-42. doi: 10.1139/y91-215.

PMID- 26573589
OWN - NLM
STAT- MEDLINE
DCOM- 20161101
LR  - 20181113
IS  - 1590-3478 (Electronic)
IS  - 1590-1874 (Linking)
VI  - 37
IP  - 2
DP  - 2016 Feb
TI  - Aspirin resistance and other aspirin-related concerns.
PG  - 181-9
LID - 10.1007/s10072-015-2412-x [doi]
AB  - Aspirin is a widely used medication and has become a cornerstone for treating 
      cardiovascular disease. Aspirin can significantly reduce the incidence of 
      cardiovascular ischemic events, recurrence and mortality, thereby improving the 
      long-term prognosis of patients. However, there has been a staggering increase in 
      the volume of literature addressing the issue of so-called "aspirin resistance" 
      in recent years, and for some patients, it is difficult to avoid adverse 
      reactions to aspirin. In this review, we present both the historical aspects of 
      aspirin use and contemporary developments in its clinical use.
FAU - Cai, Gaoyu
AU  - Cai G
AD  - Department of Neurology and Institute of Neurology, Rui Jin Hospital, School of 
      Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China.
FAU - Zhou, Weijun
AU  - Zhou W
AD  - Department of Emergency, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, 200025, China.
FAU - Lu, Ya
AU  - Lu Y
AD  - Shanghai Wusong Street Community Health Service Center, Shanghai, 200940, China.
FAU - Chen, Peili
AU  - Chen P
AD  - Department of Emergency, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong 
      University, Shanghai, 200025, China.
FAU - Lu, Zhongjiao
AU  - Lu Z
AD  - Department of Neurology and Institute of Neurology, Rui Jin Hospital, School of 
      Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China.
FAU - Fu, Yi
AU  - Fu Y
AD  - Department of Neurology and Institute of Neurology, Rui Jin Hospital, School of 
      Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China. 
      fuyiki@sina.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20151114
PL  - Italy
TA  - Neurol Sci
JT  - Neurological sciences : official journal of the Italian Neurological Society and 
      of the Italian Society of Clinical Neurophysiology
JID - 100959175
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/*therapeutic use
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - *Drug Resistance
MH  - Humans
MH  - Neoplasms/prevention & control
MH  - Risk Factors
OTO - NOTNLM
OT  - Adverse effects
OT  - Aspirin
OT  - Clinical use
OT  - Resistance phenomenon
EDAT- 2015/11/18 06:00
MHDA- 2016/11/02 06:00
CRDT- 2015/11/18 06:00
PHST- 2015/07/13 00:00 [received]
PHST- 2015/10/26 00:00 [accepted]
PHST- 2015/11/18 06:00 [entrez]
PHST- 2015/11/18 06:00 [pubmed]
PHST- 2016/11/02 06:00 [medline]
AID - 10.1007/s10072-015-2412-x [pii]
AID - 10.1007/s10072-015-2412-x [doi]
PST - ppublish
SO  - Neurol Sci. 2016 Feb;37(2):181-9. doi: 10.1007/s10072-015-2412-x. Epub 2015 Nov 
      14.

PMID- 12527994
OWN - NLM
STAT- MEDLINE
DCOM- 20030409
LR  - 20141120
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 250
IP  - 1
DP  - 2003 Jan
TI  - Aspirin non-responder status in patients with recurrent cerebral ischemic 
      attacks.
PG  - 63-6
AB  - BACKGROUND: Antiplatelet agents such as acetylsalicylic acid (aspirin) reduce the 
      relative risk for cerebrovascular events in patients with cardiovascular or 
      cerebrovascular disorders by approximately 23 %. Recent observations raise the 
      possibility that aspirin resistance may contribute to the failure of aspirin 
      treatment in a significant proportion of patients (aspirin non-responders). To 
      evaluate the clinical relevance of aspirin non-responder status, we analysed 
      platelet functions in symptomatic and asymptomatic patients treated with aspirin 
      for secondary prevention of cardiovascular and cerebrovascular events. METHODS: A 
      total of 53 patients on 100 mg aspirin daily for secondary prevention (mean 
      treatment duration > 60 months) were included. Patients were categorized as 
      asymptomatic if they were free of cerebrovascular incidents for at least 24 
      months (n = 18). Symptomatic patients had suffered ischemic strokes or transient 
      ischemic attacks within the previous 3 days (n = 35). Platelet function was 
      assessed using the PFA-100 system that allows for quantitative assessment of 
      platelet function, reporting platelet aggregatability as the time required to 
      close a small aperture in a biologically active membrane. RESULTS: 
      Collagen/epinephrine closure times were significantly shorter in symptomatic 
      patients than in asymptomatic patients (p < 0.01). Individual closing times were 
      normal in 12 of 35 symptomatic patients (34 % non-responders) whereas all 
      asymptomatic patients had prolonged closure times. CONCLUSIONS: Aspirin 
      non-responder status may contribute to failure of aspirin therapy in the 
      secondary prevention of cerebrovascular incidents in as much as 30-40 % of 
      patients. Quantitative assessment of platelet functions may provide a means to 
      predict aspirin treatment failure in individual patients and to re-direct 
      therapeutic strategies.
FAU - Grundmann, K
AU  - Grundmann K
AD  - Department of Neurology, University of Tübingen, Tübingen, Germany.
FAU - Jaschonek, K
AU  - Jaschonek K
FAU - Kleine, B
AU  - Kleine B
FAU - Dichgans, J
AU  - Dichgans J
FAU - Topka, H
AU  - Topka H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Secondary Prevention
EDAT- 2003/01/16 04:00
MHDA- 2003/04/10 05:00
CRDT- 2003/01/16 04:00
PHST- 2003/01/16 04:00 [pubmed]
PHST- 2003/04/10 05:00 [medline]
PHST- 2003/01/16 04:00 [entrez]
AID - 10.1007/s00415-003-0954-y [doi]
PST - ppublish
SO  - J Neurol. 2003 Jan;250(1):63-6. doi: 10.1007/s00415-003-0954-y.

PMID- 29757761
OWN - NLM
STAT- MEDLINE
DCOM- 20200205
LR  - 20200205
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
VI  - 26
IP  - 5
DP  - 2019 Sep/Oct
TI  - Aspirin Resistance: Cardiovascular Risk Game Changer.
PG  - 593-599
LID - 10.1097/MJT.0000000000000780 [doi]
AB  - BACKGROUND: Aspirin (ASA) is the most used medication on the globe. ASA is a 
      primary pillar of the secondary prevention of cardiovascular atherothromboembolic 
      events. However, a fraction of the population does not respond to ASA as expected 
      in a unique phenomenon called ASA resistance. Multiple mechanisms were described 
      and studied in the literature to explain this phenomenon. AREA OF UNCERTAINTY: 
      ASA resistance is an interesting phenomenon that is worth studying and reviewing. 
      Mechanisms behind this resistance are various and although the rarity of some, it 
      is crucial for the modern health provider to be aware of such phenomenon and its 
      possible explanations to provide more efficient preventive cardiology practice. 
      Our study aimed to review and conclude the evidence behind ASA resistance and its 
      implication on the cardiovascular health. DATA SOURCES: We searched databases 
      like PubMed, EMBASE, Ovid by midline, and Google Scholar for published articles 
      and abstracts. RESULTS: Our systemic search revealed more than 100 articles in 
      relation to ASA resistance. We selected 40 articles, which were relevant for this 
      review. Various mechanisms were described in the literature, with few of them 
      very well documented and understood. Main mechanisms include medication 
      nonadherence, interaction with proton pump inhibitors, esterase-mediated ASA 
      inactivation, post-coronary artery bypass grafting (CABG) MRP-4-mediated ASA 
      consumption, cyclooxygenase-1 (COX-1) polymorphisms, high platelet 
      turnover-associated regeneration of platelet COX-1, and the documented platelet 
      ability of de novo COX-1 synthesis in response to thrombin and fibrinogen. 
      CONCLUSION: Multiple mechanisms of ASA resistance were described in the 
      literature. Awareness of such interaction is important for medical practitioners. 
      Bottom line, further studies and reviews are needed to further study this 
      phenomenon and its implication on the cardiovascular health and hence reaching a 
      valid evidence-based conclusion that might change the practice and improve the 
      patient preventive health care.
FAU - Yassin, Ahmed S
AU  - Yassin AS
AD  - Department of Internal Medicine, Wayne State University, Detroit, MI.
FAU - Abubakar, Hossam
AU  - Abubakar H
AD  - Department of Internal Medicine, Wayne State University, Detroit, MI.
FAU - Mishra, Tushar
AU  - Mishra T
AD  - Department of Internal Medicine, Wayne State University, Detroit, MI.
FAU - Subahi, Ahmed
AU  - Subahi A
AD  - Department of Internal Medicine, Wayne State University, Detroit, MI.
FAU - Hartman, Melanie
AU  - Hartman M
AD  - Radboud University, School of Medicine, Nijmegen, The Netherlands.
FAU - Ahmed, Abdelrahman
AU  - Ahmed A
AD  - Department of Internal Medicine, Wayne State University, Detroit, MI.
FAU - Ibrahim, Walid
AU  - Ibrahim W
AD  - Department of Internal Medicine, Wayne State University, Detroit, MI.
FAU - Singh, Manmohan
AU  - Singh M
AD  - Department of Internal Medicine, Wayne State University, Detroit, MI.
FAU - Pahuja, Mohit
AU  - Pahuja M
AD  - Department of Cardiovascular Medicine, Wayne State University, Detroit, MI.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Resistance
MH  - Evidence-Based Medicine/standards
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Risk Factors
MH  - Secondary Prevention/*standards
EDAT- 2018/05/15 06:00
MHDA- 2020/02/06 06:00
CRDT- 2018/05/15 06:00
PHST- 2018/05/15 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
PHST- 2018/05/15 06:00 [entrez]
AID - 10.1097/MJT.0000000000000780 [doi]
PST - ppublish
SO  - Am J Ther. 2019 Sep/Oct;26(5):593-599. doi: 10.1097/MJT.0000000000000780.

PMID- 16840949
OWN - NLM
STAT- MEDLINE
DCOM- 20060908
LR  - 20191110
IS  - 0398-0499 (Print)
IS  - 0398-0499 (Linking)
VI  - 31
IP  - 3
DP  - 2006 Jul
TI  - [Prevention of major ischemic events in lower limb arterial disease: does aspirin 
      play a role?].
PG  - 129-34
AB  - OBJECTIVE: To determine the effect of aspirin among patients with lower limb 
      occlusive arterial disease. DESIGN: Meta-analysis of trials issuing from a 
      collaborative meta-analysis of randomized trials of anti-platelet therapy for 
      prevention of death, myocardial infarction, and stroke in high risk patients. 
      Five trials were identified as comparing aspirin (with or without dipyridamole) 
      to placebo, in 1 029 patients with lower limb occlusive arterial disease. There 
      was no new publication found comparing aspirin and placebo in lower limb 
      occlusive arterial disease. MAIN OUTCOME MEASURE: As in the main meta-analysis, 
      "serious vascular event": non fatal myocardial infarction, non fatal stroke or 
      vascular death. RESULTS: Among these 1 029 patients, allocation to aspirin did 
      not reduce the outcome of serious vascular event, nor of any of the individual 
      events. This result, as opposed to the enhancement of 23% +/- 8% announced in the 
      main meta-analysis, clearly demonstrate that the beneficial effect cannot be 
      attributable to aspirin. DISCUSSION: In the collaborative meta-analysis, aspirin 
      was the most widely used product (75% of the trials) and it showed its beneficial 
      effect when administered at doses ranging from 75 to 150 mg/day, as compared to 
      placebo. Among the other anti-platelet treatments analyzed, clopidogrel was the 
      only product for which large scale randomized evidence versus aspirin was 
      available. Various national health institutions, in the United States as well as 
      in Europe, show a major concern regarding the use of anti-platelet treatments, in 
      peripheral arterial occlusive disease as well as in other manifestations of 
      cardiovascular disease. Their guidelines take of course the patient's health into 
      account but the economical aspect of this prevention is increasingly hard to 
      circumvent. Based on the results of the collaborative meta-analysis, these 
      guidelines all recommend a lifetime use of low doses of aspirin, reserving 
      clopidogrel for patients intolerant to aspirin, mainly because they do not 
      consider the additional benefit recognized with clopidogrel as important enough 
      to counterbalance the cost of the treatment. While aspirin as a first choice 
      antiplatelet therapy cannot be discussed in coronary disease, after a myocardial 
      infarction, or in cerebrovascular disease, its use in lower limb occlusive 
      arterial disease does not enable a reduction in morbi-mortality. From an 
      economical point of view, the use of a cheap but inefficient preventive treatment 
      could also lead to an increased cost for curing the complications expected with 
      an uncontrolled widely spread disease as chronic lower limb ischemia.
FAU - Lechat, P
AU  - Lechat P
AD  - Service de Pharmacologie, Hôpital de la Salpêtrière, 47-83, boulevard de 
      l'Hôpital, 75651 Paris Cedex 13.
FAU - Priollet, P
AU  - Priollet P
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Meta-Analysis
TT  - Prévention des évènements ischémiques majeurs au cours de l'artériopathie 
      oblitérante des membres inférieurs: l'aspirine a-t-elle un rôle?
PL  - France
TA  - J Mal Vasc
JT  - Journal des maladies vasculaires
JID - 7707965
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Ischemia/epidemiology/*prevention & control
MH  - Leg/*blood supply
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Factors
MH  - Smoking/adverse effects
MH  - Treatment Outcome
EDAT- 2006/07/15 09:00
MHDA- 2006/09/09 09:00
CRDT- 2006/07/15 09:00
PHST- 2006/07/15 09:00 [pubmed]
PHST- 2006/09/09 09:00 [medline]
PHST- 2006/07/15 09:00 [entrez]
AID - MDOI-JMV-07-2006-31-3-0398-0499-101019-200518810 [pii]
AID - 10.1016/s0398-0499(06)76531-3 [doi]
PST - ppublish
SO  - J Mal Vasc. 2006 Jul;31(3):129-34. doi: 10.1016/s0398-0499(06)76531-3.

PMID- 3283661
OWN - NLM
STAT- MEDLINE
DCOM- 19880602
LR  - 20210112
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 32
IP  - 2
DP  - 1988 Feb
TI  - Measurement of the analgesic effects of aspirin with a new experimental 
      algesimetric procedure.
PG  - 215-222
LID - 10.1016/0304-3959(88)90070-X [doi]
AB  - Using controlled long lasting noxious squeeze stimuli applied to the interdigital 
      webs we have tried to develop experimental methods allowing us to measure the 
      effects of peripherally acting analgesics. In the present double-blind cross-over 
      study with 12 subjects we tested the effects of aspirin (1000 and 1500 mg) vs. 
      placebo on subjective pain induced by alternately applied 12 N (Newton) and 8 N 
      stimuli. During the sessions blood samples were taken in regular intervals to 
      measure acetylsalicylate (ASA)- and salicylate (SA)-plasma levels. Analyses of 
      variance were computed with several psychophysical parameters. Both the '12 N' 
      and the '8 N' ratings discriminated between placebo and aspirin, however, only 
      the ratings obtained from the stronger stimuli discriminated between two doses of 
      aspirin. Subsequently we computed analyses of covariance with the ASA- and 
      SA-plasma levels as covariates. Significant (negative) correlations of pain 
      ratings and SA-plasma levels were found for the high dose of aspirin, but there 
      were no significant correlations of ASA levels and ratings.
FAU - Forster, C
AU  - Forster C
AD  - II. Institute of Physiology, University of Heidelberg, D-6900 HeidelbergF.R.G. 
      Laboratory of Clinical Pharmacology, University of Heidelberg, D-6900 
      HeidelbergF.R.G.
FAU - Anton, F
AU  - Anton F
FAU - Reeh, P W
AU  - Reeh PW
FAU - Weber, E
AU  - Weber E
FAU - Handwerker, H O
AU  - Handwerker HO
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesia
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Pain/*drug therapy
MH  - *Pain Measurement
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1988/02/01 00:00
MHDA- 1988/02/01 00:01
CRDT- 1988/02/01 00:00
PHST- 1988/02/01 00:00 [pubmed]
PHST- 1988/02/01 00:01 [medline]
PHST- 1988/02/01 00:00 [entrez]
AID - 00006396-198802000-00010 [pii]
AID - 10.1016/0304-3959(88)90070-X [doi]
PST - ppublish
SO  - Pain. 1988 Feb;32(2):215-222. doi: 10.1016/0304-3959(88)90070-X.

PMID- 781235
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 2
DP  - 1976
TI  - Controlled evaluation of fenoprofen in geriatric patients with osteoarthritis.
PG  - 76-82
AB  - A double-blind, crossover study compared the use of fenoprofen to aspirin in 
      patients with osteoarthritis of large joints, most of them with knee involvement. 
      A total of 24 patients participated in the study. Their ages ranged from 48 to 75 
      years, with an average age of 63 years. The mean daily dose was 1.8 gm of 
      fenoprofen and 3.1 gm of aspirin in divided doses. Efficacy parameters showed 
      that fenoprofen and aspirin provided significantly greater relief of 
      osteoarthritis symptoms than placebo, and that the two active drugs were 
      essentially equal in effectiveness. Fenoprofen was well tolerated in this group 
      of patients. Only one patient discontinued the study during fenoprofen therapy 
      because of side effects. The overall incidence of adverse reactions with 
      fenoprofen compared favorably to that with placebo; the highest incidence was 
      associated with aspirin therapy.
FAU - McMahon, F G
AU  - McMahon FG
FAU - Jain, A
AU  - Jain A
FAU - Onel, A
AU  - Onel A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Fenoprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Phenylpropionates/*therapeutic use
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1976;2:76-82.

PMID- 781234
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 2
DP  - 1976
TI  - Fenoprofen therapy in large-joint osteoarthritis: double-blind comparison with 
      aspirin and longterm experience.
PG  - 71-5
AB  - This study, designed to evaluate fenoprofen in patients with osteoarthritis, 
      consisted of two phases: I. A double-blind crossover comparison of fenoprofen, 
      200 to 600 mg every six hours, to aspirin, 325 to 975 mg every six hours; II. 
      Longterm use of fenoprofen in an open study design. During the first part of the 
      study, both fenoprofen and aspirin were significantly better than placebo in 
      relieving the severity and duration of pain, and in reducing stiffness. In most 
      of the variables fenoprofen was also slightly better than aspirin. The most 
      frequently observed side effects were abdominal discomfort, headache, pruritus, 
      nervousness, and tinnitus. Longterm administration demonstrated the safety of 
      fenoprofen or periods exceeding two years. Fenoprofen did not precipitate or 
      aggravate chronic disorders, nor did it mask the symptoms of any developing 
      disease. No interaction with concomitant drug therapy was observed.
FAU - Brooke, J W
AU  - Brooke JW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Fenoprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - Time Factors
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1976;2:71-5.

PMID- 2293289
OWN - NLM
STAT- MEDLINE
DCOM- 19910411
LR  - 20171116
IS  - 0035-3639 (Print)
IS  - 0035-3639 (Linking)
VI  - 11
IP  - 10
DP  - 1990 Dec
TI  - [Current aspects of arterial anti-thrombosis prophylaxis].
PG  - 503-11
AB  - New prophylactic strategies for arterial thrombosis are built up following new 
      discoveries about the thrombo-resistance of the vascular endothelium. To cope 
      with the complexity of the interactions between platelets, erythrocytes and 
      endothelium, it is logical to propose a multivalent prophylaxis, potent enough to 
      control the multiple thombogenic factors. In this prospect, the combination 
      acetyl-salicylic acid with dipyridamole presents an obvious complementarity, 
      until confirmation of the clinical activity of other combinations.
FAU - Sternon, J
AU  - Sternon J
AD  - Service de Médecine Interne, Hôpital Erasme, U.L.B.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Un nouveau regard sur la prophylaxie anti-thrombotique artérielle.
PL  - Belgium
TA  - Rev Med Brux
JT  - Revue medicale de Bruxelles
JID - 8003474
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Contraindications
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Thrombosis/*prevention & control
RF  - 25
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
PST - ppublish
SO  - Rev Med Brux. 1990 Dec;11(10):503-11.

PMID- 7017486
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [The use of a new balsamic expectorant in bronchopulmonary pathology in 
      children].
PG  - 363-6
AB  - The therapeutic effectiveness of a new antiinflammatory-expectorant drug, 
      guacetisal (Broncaspin) has been compared with that of a well known mucolytic, 
      bromexine, already available for therapy, in the paediatric suspension formula. 
      The study was carried out on 26 children in the 1st Paediatrics clinic of Milan 
      University. The children were suffering from inflammation of the respiratory 
      apparatus. It is concluded that the new drug possesses greated clinical 
      effectiveness.
FAU - Daroda, C
AU  - Daroda C
FAU - Galluzzo, C
AU  - Galluzzo C
FAU - Porzia, R
AU  - Porzia R
FAU - Riva, E
AU  - Riva E
FAU - Giovannini, M
AU  - Giovannini M
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Osservazioni sull'impiego di un nuovo espettorante balsamico nella patologia 
      broncopolmonare del bambino.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - Q1J152VB1P (Bromhexine)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Bromhexine/*therapeutic use
MH  - Bronchitis/*drug therapy
MH  - Bronchopneumonia/*drug therapy
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Tracheitis/drug therapy
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):363-6.

PMID- 29175435
OWN - NLM
STAT- MEDLINE
DCOM- 20180817
LR  - 20180817
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 161
DP  - 2018 Jan
TI  - Antiplatelet effect of aspirin during 24h in patients with type 2 diabetes 
      without cardiovascular disease.
PG  - 1-6
LID - S0049-3848(17)30563-7 [pii]
LID - 10.1016/j.thromres.2017.11.013 [doi]
AB  - INTRODUCTION: The antiplatelet effect of low-dose aspirin in patients with type 2 
      diabetes (T2DM) without cardiovascular disease (CVD) has not been thoroughly 
      explored. We investigated if platelet aggregation increased during the standard 
      24-hour aspirin dosing interval in patients with T2DM compared to non-diabetic 
      controls. Furthermore, we evaluated baseline platelet aggregation, the acute 
      effects of aspirin on platelet aggregation and platelet turnover. MATERIALS AND 
      METHODS: We included 21 patients with T2DM and 21 age and sex-matched controls. 
      Platelet aggregation was measured by impedance aggregometry (Multiplate® 
      Analyzer) and markers of platelet turnover by flow cytometry (Sysmex® XE-5000). 
      Blood samples were obtained at baseline and 1h after administration of 75mg of 
      aspirin. Participants were then treated for 6days with once-daily aspirin, and 
      blood sampling was repeated 1h and 24h after aspirin intake. RESULTS: After 6days 
      of treatment, platelet aggregation levels increased during the 24-hour aspirin 
      dosing interval in both patients and controls (p<0.001) with no difference 
      between patients and controls. At baseline, patients with diabetes had increased 
      platelet aggregation compared to controls (p=0.03). Platelet aggregation was 
      reduced after the first dose of aspirin and significantly further reduced after 
      six days of treatment (p<0.001). Patients with T2DM had numerically higher 
      immature platelet count compared to controls (p=0.09), indicating an increased 
      platelet turnover. CONCLUSION: Patients with T2DM without a history of CVD and 
      controls had increased platelet aggregation at the end of the standard 24-hour 
      dosing interval of aspirin. Further, aspirin-naïve T2DM patients had increased 
      platelet aggregation compared to controls.
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - Vernstrøm, Liv
AU  - Vernstrøm L
AD  - Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 
      Aarhus, Denmark. Electronic address: lvh@clin.au.dk.
FAU - Funck, Kristian Løkke
AU  - Funck KL
AD  - Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 
      Aarhus, Denmark. Electronic address: klf@clin.au.dk.
FAU - Grove, Erik Lerkevang
AU  - Grove EL
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department 
      of Clinical Medicine, Institute of Health, Aarhus University, Denmark. Electronic 
      address: erikgrove@dadlnet.dk.
FAU - Laugesen, Esben
AU  - Laugesen E
AD  - Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 
      Aarhus, Denmark. Electronic address: esben.laugesen@clin.au.dk.
FAU - Baier, Jonathan Mathias
AU  - Baier JM
AD  - Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 
      Aarhus, Denmark. Electronic address: baier@clin.au.dk.
FAU - Hvas, Anne-Mette
AU  - Hvas AM
AD  - Department of Clinical Medicine, Institute of Health, Aarhus University, Denmark; 
      Department of Clinical Biochemistry, Centre of Haemophilia and Thrombosis, Aarhus 
      University Hospital, Aarhus, Denmark. Electronic address: annehvas@rm.dk.
FAU - Poulsen, Per Løgstrup
AU  - Poulsen PL
AD  - Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 
      Aarhus, Denmark. Electronic address: perpouls@rm.dk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171120
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Time Factors
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - Aspirin
OT  - Platelet aggregation
OT  - Platelet turnover
OT  - Type 2 diabetes mellitus
EDAT- 2017/11/28 06:00
MHDA- 2018/08/18 06:00
CRDT- 2017/11/28 06:00
PHST- 2017/08/17 00:00 [received]
PHST- 2017/11/15 00:00 [revised]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2018/08/18 06:00 [medline]
PHST- 2017/11/28 06:00 [entrez]
AID - S0049-3848(17)30563-7 [pii]
AID - 10.1016/j.thromres.2017.11.013 [doi]
PST - ppublish
SO  - Thromb Res. 2018 Jan;161:1-6. doi: 10.1016/j.thromres.2017.11.013. Epub 2017 Nov 
      20.

PMID- 32492080
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210604
IS  - 2168-6238 (Electronic)
IS  - 2168-622X (Print)
IS  - 2168-622X (Linking)
VI  - 77
IP  - 10
DP  - 2020 Oct 1
TI  - Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A 
      Randomized Clinical Trial.
PG  - 1012-1020
LID - 10.1001/jamapsychiatry.2020.1214 [doi]
AB  - IMPORTANCE: Depression is associated with increased inflammation, which may 
      precede its onset, especially in older people. Some preclinical data suggest 
      potential antidepressant effects of aspirin, supported by limited observational 
      data suggesting lower rates of depression in individuals treated with aspirin. 
      There currently appears to be no evidence-based pharmacotherapies for the primary 
      prevention of depression. OBJECTIVE: To determine whether low-dose aspirin (100 
      mg) reduces the risk of depression in healthy older adults. DESIGN, SETTING, AND 
      PARTICIPANTS: This double-blinded, placebo-controlled randomized clinical trial 
      was a substudy of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, 
      which examined if aspirin increased healthy life span, defined as survival free 
      of dementia and disability. The prespecified secondary outcome was depression. 
      Individuals of all races/ethnicities older than 70 years in Australia, as well as 
      white individuals older than 70 years and black and Hispanic individuals older 
      than 65 years in the United States, were included. INTERVENTIONS: Participants 
      were randomized to aspirin (100 mg daily) or placebo, with a median 
      (interquartile range) follow-up of 4.7 (3.5-5.6) years. MAIN OUTCOMES AND 
      MEASURES: The primary outcome was a proxy measure of major depressive disorder 
      defined as a score of 8 or more on the Center for Epidemiologic Studies 
      Depression 10-item (CES-D-10) scale. RESULTS: Of the 19 114 participants enrolled 
      in the trial, 9525 received aspirin and 9589 received a placebo. The mean (SD) 
      age was 75.2 (4.0) years in the aspirin group and 75.1 (4.5) years in the placebo 
      group; 9531 (56.4%) were women. Participants' demographics and clinical 
      characteristics at baseline were similar between groups. A total of 79 886 annual 
      CES-D-10 measurements were taken, with a mean of 4.2 measurements per 
      participant. There were no significant differences at annual visits in the 
      proportions of CES-D-10 scores of 8 or more between the aspirin and placebo 
      groups. The incidence rate of new CES-D-10 scores of 8 or more was 70.4 events 
      per 1000 person-years in the aspirin group and 69.1 in the placebo group (hazard 
      ratio, 1.02 [95% CI, 0.96-1.08]; P = .54). CONCLUSIONS AND RELEVANCE: Low-dose 
      aspirin did not prevent depression in this large-scale study of otherwise healthy 
      older adults. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01038583.
FAU - Berk, Michael
AU  - Berk M
AD  - The Institute for Mental and Physical Health and Clinical Translation Strategy 
      Research Centre, Deakin University School of Medicine, Geelong, Australia.
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia.
AD  - Department of Psychiatry, University of Melbourne, Parkville, Australia.
AD  - Orygen Youth Health Research Centre, Parkville, Australia.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia.
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, 
      Australia.
FAU - Shah, Raj C
AU  - Shah RC
AD  - Rush Alzheimer's Disease Center, Department of Family Medicine, Rush University 
      Medical Center, Chicago, Illinois.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia.
AD  - School of Public Health, Curtin University, Perth, Australia.
FAU - Storey, Elsdon
AU  - Storey E
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia.
FAU - Fitzgerald, Sharyn
AU  - Fitzgerald S
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia.
FAU - Lockery, Jessica E
AU  - Lockery JE
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia.
FAU - Mohebbi, Mohammadreza
AU  - Mohebbi M
AD  - The Institute for Mental and Physical Health and Clinical Translation Strategy 
      Research Centre, Deakin University School of Medicine, Geelong, Australia.
AD  - Biostatistics Unit, Faculty of Health, Deakin University, Geelong, Australia.
FAU - Dodd, Seetal
AU  - Dodd S
AD  - The Institute for Mental and Physical Health and Clinical Translation Strategy 
      Research Centre, Deakin University School of Medicine, Geelong, Australia.
FAU - Murray, Anne M
AU  - Murray AM
AD  - Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Minneapolis, Minnesota.
FAU - Stocks, Nigel
AU  - Stocks N
AD  - Discipline of General Practice, Adelaide Medical School, University of Adelaide, 
      Australia.
FAU - Fitzgerald, Paul B
AU  - Fitzgerald PB
AD  - Epworth Centre for Innovation in Mental Health, the Epworth Clinic, Epworth 
      Healthcare, Camberwell, Australia.
AD  - Monash Alfred Psychiatry Research Centre, Central Clinical School, Monash 
      University, Melbourne, Australia.
FAU - Mazza, Catherine
AU  - Mazza C
AD  - The Institute for Mental and Physical Health and Clinical Translation Strategy 
      Research Centre, Deakin University School of Medicine, Geelong, Australia.
FAU - Agustini, Bruno
AU  - Agustini B
AD  - The Institute for Mental and Physical Health and Clinical Translation Strategy 
      Research Centre, Deakin University School of Medicine, Geelong, Australia.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia.
LA  - eng
SI  - ClinicalTrials.gov/NCT01038583
GR  - P30 AG024824/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA Psychiatry
JT  - JAMA psychiatry
JID - 101589550
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Depressive Disorder, Major/*prevention & control/psychology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Risk Factors
PMC - PMC7271558
COIS- Conflict of Interest Disclosures: Dr Berk has received grant/research support 
      from the National Institutes of Health, Cooperative Research Centre, Simons 
      Autism Foundation, Cancer Council of Victoria, Stanley Medical Research 
      Foundation, Medical Benefits Fund, National Health and Medical Research Council, 
      Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 Milk Company, Meat 
      and Livestock Board, Woolworths, Avant, and the Harry Windsor Foundation, as well 
      as a National Health and Medical Research Council senior principal research 
      fellowship during the conduct of the study; has been a speaker for AstraZeneca, 
      Lundbeck, Merck, and Pfizer; has served as a consultant to Allergan, Astra 
      Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck 
      Merck, Pfizer and Servier; has received personal fees from Grunbiotics, Livanova, 
      Norwegian Psychiatry Association, Janssen Cilag, Otsuka, Medisquire, HealthEd, 
      Medplan Communications, and Royal Australian and New Zealand College of 
      Psychiatrists outside the submitted work; and has a patent to modulation of 
      physiological processes and agents useful for the same pending, a patent to 
      modulation of diseases of the central nervous system and related disorders 
      pending, and a patent to xanthone-rich plant extracts or compounds therefrom for 
      modulating diseases of the central nervous system and related disorders, issued. 
      Dr Shah receives research support from Eli Lilly and Co Inc, Genentech Inc, Merck 
      and Co Inc, H. Lundbeck A/S, Navidea Biopharmaceuticals, Takeda Development 
      Center Americas Inc, and Toyama Chemical Co, Ltd, as a site principal 
      investigator or a site subinvestigator. Dr Nelson has participated in trials that 
      have received funding from SmithKline Beecham, AstraZeneca, Bayer, 
      Sanofi-Aventis, Merck Sharp & Dohme, Pfizer, Servier Laboratories, and 
      Bristol-Myers Squibb; has served on advisory boards for Sanofi-Aventis, Novartis, 
      Schering-Plough Solvay Pharmaceuticals, and Amgen; has prepared educational 
      material for Servier Laboratories, AstraZeneca, Bristol-Myers Squibb, and 
      MediMark; and has received conference and travel support from Bayer HealthCare 
      AG, Merck Sharpe and Dohme, Novartis, and Sanofi-Aventis. Dr Fitzgerald is 
      supported by a National Health and Medical Research Council practitioner 
      fellowship (1078567); has received equipment for research from MagVenture A/S, 
      Medtronic Ltd, Neuronetics, and Brainsway Ltd, and funding for research from 
      Neuronetics; is on scientific advisory boards for Bionomics Ltd and LivaNova; and 
      is a founder of TMS Clinics Australia. Dr Woods reported grants from the National 
      Institutes of Health, National Health and Medical Research Council, and Victorian 
      Cancer Agency and nonfinancial support from Monash University during the conduct 
      of the study. Dr Nelson reported personal fees from Bayer Healthcare outside the 
      submitted work. Dr Shah reported grants from National Institutes of Health during 
      the conduct of the study. Dr Reid reported grants from National Health and 
      Medical Research Council and the National Institute on Aging during the conduct 
      of the study. Dr Storey reported grants from the National Institutes of Health 
      and National Health and Medical Research Council during the conduct of the study. 
      Dr Wolfe reported grants from the National Institutes on Aging and National 
      Health and Medical Research Council during the conduct of the study. Dr Dodd 
      reported grants from Harry Windsor Foundation and grants from National Health and 
      Medical Research Council outside the submitted work. No other disclosures were 
      reported.
EDAT- 2020/06/04 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - 2766709 [pii]
AID - yoi200029 [pii]
AID - 10.1001/jamapsychiatry.2020.1214 [doi]
PST - ppublish
SO  - JAMA Psychiatry. 2020 Oct 1;77(10):1012-1020. doi: 
      10.1001/jamapsychiatry.2020.1214.

PMID- 1576570
OWN - NLM
STAT- MEDLINE
DCOM- 19920610
LR  - 20131121
IS  - 0749-0690 (Print)
IS  - 0749-0690 (Linking)
VI  - 8
IP  - 1
DP  - 1992 Feb
TI  - Prophylactic aspirin and the elderly population.
PG  - 119-26
AB  - A wide array of clinical trials over the past two decades has established that 
      aspirin is indicated to prevent myocardial infarction in patients with clinically 
      evident coronary artery disease, and to prevent stroke in patients with a history 
      of stroke or TIAs. The most likely mechanism by which aspirin decreases the 
      incidence of myocardial infarction is by preventing coronary thrombosis in 
      patients with obstructive coronary artery disease. This protective effect of 
      aspirin should occur in patients with both clinically silent and clinically 
      evident coronary artery disease. For this reason, it has been recommended that 
      patients with risk factors for coronary artery disease also should be treated 
      with prophylactic aspirin. Advanced age is one of the strongest risk factors for 
      coronary artery disease, and the mortality of myocardial infarction rises steeply 
      with increased age. A prospective randomized study of US male physicians without 
      a history of myocardial infarction demonstrated a 44% reduction in myocardial 
      infarction in those treated with 325 mg aspirin every other day. The treatment 
      effect occurred only in those aged 50 or older. A prospective study of US nurses 
      aged 34 to 65, without a history of diagnosed coronary artery disease, 
      demonstrated a 32% decrease in those who took one to six aspirin per week. Again, 
      the treatment effect was seen only in those aged 50 or older. Given these 
      findings, the authors believe that prophylactic aspirin is indicated in men and 
      women aged 50 or older who do not have contraindications to its use. The authors 
      recommend a dose of 325 mg of aspirin every other day, a dose with minimal side 
      effects.
FAU - Dalen, J E
AU  - Dalen JE
AD  - College of Medicine, University of Arizona, Tucson.
FAU - Goldberg, R J
AU  - Goldberg RJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Geriatr Med
JT  - Clinics in geriatric medicine
JID - 8603766
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Coronary Disease/prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Risk Factors
MH  - United States
RF  - 32
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
PST - ppublish
SO  - Clin Geriatr Med. 1992 Feb;8(1):119-26.

PMID- 8730644
OWN - NLM
STAT- MEDLINE
DCOM- 19960917
LR  - 20190830
IS  - 0022-3999 (Print)
IS  - 0022-3999 (Linking)
VI  - 40
IP  - 1
DP  - 1996 Jan
TI  - Is aspirin, as used for antithrombosis, an emotion-modulating agent?
PG  - 53-8
AB  - Antiplatelet substances, generally aspirin, have become widely used for secondary 
      prevention of ischemic heart disease. Used in relatively small doses, it is 
      generally assumed that aspirin has no psychoactive effect. The present study took 
      advantage of a sample of 174 males undergoing coronary angiography to see if 
      regular aspirin use as prophylactic therapy for ischemic heart disease was 
      associated with one or more of a number of measures of emotional distress. 
      Aspirin use was found to be associated with less depression and anxiety or worry, 
      as reported by the patient and as perceived by a significant other. Despite a 
      significant association of aspirin use with the presence of documented coronary 
      artery disease, the association of aspirin use and diminished distress could not 
      be accounted for by the previously observed high prevalence of depressed/anxious 
      individuals among patients with negative or nominal results on angiography, or by 
      a number of other demographic or clinical variables such as age and socioeconomic 
      status. Although only correlational in nature, present results raise the question 
      of whether aspirin may have a beneficial mood-modulating effect.
FAU - Ketterer, M W
AU  - Ketterer MW
AD  - Department of Psychiatry, Henry Ford Health Sciences Center, Case Western Reserve 
      University School of Medicine, Detroit, MI, USA.
FAU - Brymer, J
AU  - Brymer J
FAU - Rhoads, K
AU  - Rhoads K
FAU - Kraft, P
AU  - Kraft P
FAU - Lovallo, W R
AU  - Lovallo WR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Psychosom Res
JT  - Journal of psychosomatic research
JID - 0376333
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Affect/*drug effects
MH  - Aspirin/administration & dosage/*pharmacology/*therapeutic use
MH  - Coronary Angiography
MH  - Coronary Thrombosis/diagnosis/*drug therapy
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/prevention & control
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 0022399995005242 [pii]
AID - 10.1016/0022-3999(95)00524-2 [doi]
PST - ppublish
SO  - J Psychosom Res. 1996 Jan;40(1):53-8. doi: 10.1016/0022-3999(95)00524-2.

PMID- 29257747
OWN - NLM
STAT- MEDLINE
DCOM- 20181024
LR  - 20181024
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 44
IP  - 3
DP  - 2018 Jun
TI  - Low-dose aspirin for primary prevention of cardiovascular events in patients with 
      diabetes: Benefit or risk?
PG  - 217-225
LID - S1262-3636(17)30575-X [pii]
LID - 10.1016/j.diabet.2017.11.002 [doi]
AB  - Primary prevention aims to avert the onset of cardiovascular disease (CVD) by 
      targeting its natural causes and risk factors; secondary prevention includes 
      strategies and therapies that address preclinical or clinical evidence of CVD 
      progression. The value of aspirin for primary CVD prevention is controversial 
      because of increased bleeding, which may offset the overall modest benefits in 
      patients with no overt CVD. In contrast, the benefits of aspirin for secondary 
      prevention have been repeatedly and convincingly demonstrated to outweigh the 
      risk of bleeding. Diabetes mellitus is a strong risk factor for cardiovascular 
      events, and has been associated with an increased risk of both first and 
      recurrent atherothrombotic events. Therefore, prevention of CVD, the major cause 
      of mortality in patients with diabetes, is one of the most important therapeutic 
      goals. Although the benefit of low-dose aspirin for secondary prevention of CVD 
      is well established, its role for primary prevention remains inconclusive and 
      controversial in diabetes patients. The benefit of aspirin for patients with CVD 
      clearly exceeds the risk of bleeding, and even though a modest benefit has also 
      been demonstrated in primary prevention, the trade-off for aspirin initiation 
      against the increased risk of intracranial and gastrointestinal bleeding is more 
      uncertain. Thus, aspirin for primary CVD prevention should be highly 
      individualized, based on a benefit-risk ratio assessment for the given patient. 
      In conclusion, the mere presence of diabetes is apparently not enough for aspirin 
      to confer a benefit that clearly outweighs the risk of bleeding, and further 
      evidence to the contrary is now needed.
CI  - Copyright © 2017. Published by Elsevier Masson SAS.
FAU - Leggio, M
AU  - Leggio M
AD  - Department of Medicine and Rehabilitation, Cardiac Rehabilitation Operative Unit, 
      San Filippo Neri Hospital-Salus Infirmorum Clinic, Rome, Italy. Electronic 
      address: mleggio@libero.it.
FAU - Bendini, M G
AU  - Bendini MG
AD  - Cardiology Division, Santa Maria della Stella Hospital, Orvieto, Italy.
FAU - Caldarone, E
AU  - Caldarone E
AD  - Physical Medicine and Neurorehabilitation Operative Unit, Salus Infirmorum 
      Clinic, Rome, Italy.
FAU - Lombardi, M
AU  - Lombardi M
AD  - Physical Medicine and Neurorehabilitation Operative Unit, Salus Infirmorum 
      Clinic, Rome, Italy.
FAU - Severi, P
AU  - Severi P
AD  - Department of Medicine and Rehabilitation, Cardiac Rehabilitation Operative Unit, 
      San Filippo Neri Hospital-Salus Infirmorum Clinic, Rome, Italy; Physical Medicine 
      and Neurorehabilitation Operative Unit, Salus Infirmorum Clinic, Rome, Italy.
FAU - D'Emidio, S
AU  - D'Emidio S
AD  - Physical Medicine and Neurorehabilitation Operative Unit, Salus Infirmorum 
      Clinic, Rome, Italy.
FAU - Stavri, D C
AU  - Stavri DC
AD  - Physical Medicine and Neurorehabilitation Operative Unit, Salus Infirmorum 
      Clinic, Rome, Italy.
FAU - Armeni, M
AU  - Armeni M
AD  - Department of Research, EDUCAM (C.R.O.M.O.N., S.Os.I., A.I.R.O.P.), Rome, Italy.
FAU - Bravi, V
AU  - Bravi V
AD  - Still Osteopathic Institute, Rome, Italy.
FAU - Mazza, A
AU  - Mazza A
AD  - Cardiology Division, Santa Maria della Stella Hospital, Orvieto, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171114
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Complications/*prevention & control
MH  - Fibrinolytic Agents/*administration & dosage/therapeutic use
MH  - Humans
MH  - Primary Prevention
MH  - Risk Factors
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Diabetes mellitus
OT  - Low-dose aspirin
OT  - Primary prevention
EDAT- 2017/12/20 06:00
MHDA- 2018/10/26 06:00
CRDT- 2017/12/20 06:00
PHST- 2017/06/28 00:00 [received]
PHST- 2017/09/05 00:00 [revised]
PHST- 2017/11/05 00:00 [accepted]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
PHST- 2017/12/20 06:00 [entrez]
AID - S1262-3636(17)30575-X [pii]
AID - 10.1016/j.diabet.2017.11.002 [doi]
PST - ppublish
SO  - Diabetes Metab. 2018 Jun;44(3):217-225. doi: 10.1016/j.diabet.2017.11.002. Epub 
      2017 Nov 14.

PMID- 25577589
OWN - NLM
STAT- MEDLINE
DCOM- 20160609
LR  - 20150904
IS  - 1578-8989 (Electronic)
IS  - 0025-7753 (Linking)
VI  - 145
IP  - 6
DP  - 2015 Sep 21
TI  - [Acetylsalicylic acid desensitization in the new era of percutaneous coronary 
      intervention].
PG  - 253-7
LID - S0025-7753(14)00806-9 [pii]
LID - 10.1016/j.medcli.2014.10.014 [doi]
AB  - Dual antiplatelet therapy is essential in patients undergoing percutaneous 
      coronary intervention with stent implantation. Hypersensitivity to 
      acetylsalicylic acid (ASA) limits treatment options. Desensitization to ASA has 
      classically been studied in patients with respiratory tract disease. Over the 
      last years, many protocols have been described about ASA desensitization in 
      patients with ischemic heart disease, including acute coronary syndrome and the 
      need for coronary stent implantation. It is important to know the efficacy and 
      safety of ASA desensitization in these patients.
CI  - Copyright © 2014 Elsevier España, S.L.U. All rights reserved.
FAU - Fuertes Ferre, Georgina
AU  - Fuertes Ferre G
AD  - Unidad de Hemodinámica, Servicio de Cardiología, Hospital Universitario Miguel 
      Servet, Zaragoza, España. Electronic address: georginaff@hotmail.com.
FAU - Ferrer Gracia, Maria Cruz
AU  - Ferrer Gracia MC
AD  - Unidad de Hemodinámica, Servicio de Cardiología, Hospital Universitario Miguel 
      Servet, Zaragoza, España.
FAU - Calvo Cebollero, Isabel
AU  - Calvo Cebollero I
AD  - Unidad de Hemodinámica, Servicio de Cardiología, Hospital Universitario Miguel 
      Servet, Zaragoza, España.
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Desensibilización al ácido acetil salicílico en la nueva era del intervencionismo 
      coronario percutáneo.
DEP - 20150108
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/complications/*surgery
MH  - Aspirin/*adverse effects/immunology/therapeutic use
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/complications/diagnosis/*therapy
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*adverse effects/immunology/therapeutic use
OTO - NOTNLM
OT  - Acetylsalicylic acid desensitization
OT  - Acetylsalicylic acid hypersensitivity
OT  - Cardiopatía isquémica
OT  - Coronary percutaneous intervention
OT  - Desensibilización al ácido acetil salicílico
OT  - Hipersensibilidad al ácido acetil salicílico
OT  - Intervencionismo coronario percutáneo
OT  - Ischemic cardiomyopathy
EDAT- 2015/01/13 06:00
MHDA- 2016/06/10 06:00
CRDT- 2015/01/12 06:00
PHST- 2014/06/16 00:00 [received]
PHST- 2014/09/29 00:00 [revised]
PHST- 2014/10/15 00:00 [accepted]
PHST- 2015/01/12 06:00 [entrez]
PHST- 2015/01/13 06:00 [pubmed]
PHST- 2016/06/10 06:00 [medline]
AID - S0025-7753(14)00806-9 [pii]
AID - 10.1016/j.medcli.2014.10.014 [doi]
PST - ppublish
SO  - Med Clin (Barc). 2015 Sep 21;145(6):253-7. doi: 10.1016/j.medcli.2014.10.014. 
      Epub 2015 Jan 8.

PMID- 7379449
OWN - NLM
STAT- MEDLINE
DCOM- 19800828
LR  - 20190512
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 27
IP  - 6
DP  - 1980 Jun
TI  - Effects of aspirin on platelet aggregation as a function of dosage and time.
PG  - 803-9
AB  - There are reports on the effects of high doses of aspirin on the alteration of 
      platelet aggregation. In our study single doses of aspirin ranging from 81 to 325 
      mg were given orally to 7 normal subjects. In vitro measurement of platelet 
      aggregation was carried out as a function of time. Based on our data we conclude 
      that low-dose aspirin (81 mg) inhibits platelet aggregation. Both the rate and 
      extent of platelet aggregation are impaired with low-dose aspirin, but neither 
      the rate nor extent of platelet aggregation depends on the size of the dose. 
      Platelet aggregation inhibition by a single dose of aspirin orally (greater than 
      or equal to 81 mg) may be expected to persist for the life of the platelets 
      affected.
FAU - Paccioretti, M J
AU  - Paccioretti MJ
FAU - Block, L H
AU  - Block LH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Prostaglandin Antagonists/pharmacology
MH  - Prostaglandins/biosynthesis
MH  - Regression Analysis
MH  - Time Factors
EDAT- 1980/06/01 00:00
MHDA- 1980/06/01 00:01
CRDT- 1980/06/01 00:00
PHST- 1980/06/01 00:00 [pubmed]
PHST- 1980/06/01 00:01 [medline]
PHST- 1980/06/01 00:00 [entrez]
AID - 0009-9236(80)90302-1 [pii]
AID - 10.1038/clpt.1980.114 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1980 Jun;27(6):803-9. doi: 10.1038/clpt.1980.114.

PMID- 16887404
OWN - NLM
STAT- MEDLINE
DCOM- 20060905
LR  - 20220409
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 119
IP  - 8
DP  - 2006 Aug
TI  - Systematic review and meta-analysis of adverse events of low-dose aspirin and 
      clopidogrel in randomized controlled trials.
PG  - 624-38
AB  - PURPOSE: We performed a systematic review to define the relative and absolute 
      risk of clinically relevant adverse events with the antiplatelet agents, aspirin 
      and clopidogrel. MATERIALS AND METHODS: Databases were searched for randomized 
      controlled trials of low-dose aspirin (75-325 mg/day) or clopidogrel administered 
      for cardiovascular prophylaxis. Relative risks (RR) were determined by 
      meta-analysis of 22 trials for aspirin versus placebo and from single studies for 
      aspirin versus clopidogrel, aspirin versus aspirin/clopidogrel, and clopidogrel 
      versus aspirin/clopidogrel. Absolute risk increase was calculated by multiplying 
      RR increase by the pooled weighted incidence of the control. RESULTS: Aspirin 
      increased the risk of major bleeding (RR=1.71; 95% confidence interval [CI], 
      1.41-2.08), major gastrointestinal (GI) bleeding (RR=2.07; 95% CI, 1.61-2.66), 
      and intracranial bleeding (RR=1.65; 95% CI, 1.06-5.99) versus placebo. No 
      difference between 75-162.5 mg/day and >162.5-325 mg/day aspirin versus placebo 
      was seen. The absolute annual increases attributable to aspirin were major 
      bleeding: 0.13% (95% CI, 0.08-0.20); major GI bleeding: 0.12% (95% CI, 
      0.07-0.19), intracranial bleeding: 0.03% (95% CI, 0.01-0.08). No study compared 
      clopidogrel with placebo. One study showed increased major GI bleeding (but not 
      non-GI bleeding endpoints) with aspirin versus clopidogrel (RR=1.45; 95% CI, 
      1.00-2.10). The absolute annual increase was 0.12% (95% CI, 0.00-0.28). 
      CONCLUSIONS: Low-dose aspirin increases the risk of major bleeding by 
      approximately 70%, but the absolute increase is modest: 769 patients (95% CI, 
      500-1250) need to be treated with aspirin to cause one additional major bleeding 
      episode annually. Compared with clopidogrel, aspirin increases the risk of GI 
      bleeding but not other bleeding; however, 883 patients (95% CI, 357-infinity) 
      would need to be treated with clopidogrel versus aspirin to prevent one major GI 
      bleeding episode annually at a cost of over 1 million dollars.
FAU - McQuaid, Kenneth R
AU  - McQuaid KR
AD  - Veterans Affairs Medical Center, San Francisco, Ca 94121, USA. 
      enneth.mcquaid@med.va.gov
FAU - Laine, Loren
AU  - Laine L
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects/economics
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*adverse effects
MH  - Ticlopidine/adverse effects/*analogs & derivatives/economics
RF  - 91
EDAT- 2006/08/05 09:00
MHDA- 2006/09/06 09:00
CRDT- 2006/08/05 09:00
PHST- 2005/07/07 00:00 [received]
PHST- 2005/10/20 00:00 [revised]
PHST- 2005/10/22 00:00 [accepted]
PHST- 2006/08/05 09:00 [pubmed]
PHST- 2006/09/06 09:00 [medline]
PHST- 2006/08/05 09:00 [entrez]
AID - S0002-9343(05)01043-0 [pii]
AID - 10.1016/j.amjmed.2005.10.039 [doi]
PST - ppublish
SO  - Am J Med. 2006 Aug;119(8):624-38. doi: 10.1016/j.amjmed.2005.10.039.

PMID- 8879422
OWN - NLM
STAT- MEDLINE
DCOM- 19970218
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 24
IP  - 5
DP  - 1996 Sep
TI  - Resuscitation with increasing doses of diaspirin crosslinked hemoglobin in swine.
PG  - 469-87
AB  - This study examined the effects of administering 0.5, 4, 10, and 30 mL/kg of 
      Diaspirin Crosslinked Hemoglobin (DCLHb) in a swine model of non-lethal 
      hemorrhagic shock. Thirty unanesthetized animals were bled (30 mL/kg, 1 
      mL/kg/min) and either recovered without treatment (Untreated Control, UC) or 
      infused with 10 g/dL DCLHb (0.5, 4.0, 10 or 30 mL/kg at 1 mL/kg/min) or Lactated 
      Ringer (LR, 90 mL/kg at 3 mL/kg/min). DCLHb caused dose-related increases in MAP. 
      Both the 10 and 30 mL/kg doses of DCLHb increased MAP more than UC or LR. Lower 
      doses of DCLHb and LR had effects on MAP similar to UC. After hemorrhage, CO 
      increased in all groups. The effect of DCLHb on CO was dose-related. Only LR and 
      30 mL/kg of DCLHb transiently (through 90 min) increased CO more than UC. CO in 
      animals given lower doses of DCLHb was comparable to UC. DCLHb (10 and 30 mL/kg) 
      improved base excess and lactate concentrations, two indices of global perfusion, 
      more rapidly and to a greater extent than either UC or LR. In this swine model of 
      hemorrhage, even small doses of DCLHb exerted measurable beneficial effects on 
      blood pressure and perfusion.
FAU - Marchand, G
AU  - Marchand G
AD  - Corporate Research and Technical Services, Baxter Healthcare Corporation Round 
      Lake, Illinois 60073, USA.
FAU - Dunlap, E
AU  - Dunlap E
FAU - Farrell, L
AU  - Farrell L
FAU - Nigro, C
AU  - Nigro C
FAU - Burhop, K
AU  - Burhop K
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Chemical Analysis
MH  - Blood Substitutes/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Hemodynamics
MH  - Hemoglobins/*therapeutic use
MH  - Male
MH  - Resuscitation
MH  - Shock, Hemorrhagic/*drug therapy
MH  - Swine
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - 10.3109/10731199609117440 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1996 Sep;24(5):469-87. doi: 
      10.3109/10731199609117440.

PMID- 10493274
OWN - NLM
STAT- MEDLINE
DCOM- 19991029
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 58
IP  - 3
DP  - 1999 Sep
TI  - Extended-release dipyridamole/aspirin.
PG  - 469-75; discussion 476-7
AB  - The fixed-dose combination of extended-release dipyridamole/aspirin 
      (Aggrenox/Asasantin Retard) combines 2 antiplatelet agents with different 
      mechanisms of action. The combination reduced thrombus formation in human and 
      animal models. Coadministration of extended-release dipyridamole and aspirin in 
      healthy volunteers had no significant effects on the plasma concentrations of 
      either agent. Twice-daily oral extended-release dipyridamole/aspirin (400/50 
      mg/day) was twice as effective as either agent alone in the secondary prevention 
      of stroke in a large clinical trial involving patients with prior stroke or 
      transient ischaemic attack. The rate of the combined end-point of stroke and 
      death tended to be lower with the combination than with other treatments. The 
      incidence of death was not significantly reduced by any treatment. Most adverse 
      events with extended-release dipyridamole/aspirin were mild and similar to those 
      with either agent alone. Bleeding was more common with the combination than with 
      extended-release dipyridamole alone, as was headache when compared with aspirin 
      alone. Limited pharmacoeconomic analyses suggest that treatment with 
      extended-release dipyridamole/aspirin was cost saving and was cost effective 
      compared with aspirin monotherapy for the secondary prevention of stroke.
FAU - Hervey, P S
AU  - Hervey PS
AD  - Adis International Limited, Mairangi Bay, Auckland, New Zealand.
FAU - Goa, K L
AU  - Goa KL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacokinetics/pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Delayed-Action Preparations/pharmacokinetics/pharmacology/*therapeutic use
MH  - Dipyridamole/pharmacokinetics/pharmacology/*therapeutic use
MH  - Drug Combinations
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/pharmacology/therapeutic use
RF  - 19
EDAT- 1999/09/24 00:00
MHDA- 1999/09/24 00:01
CRDT- 1999/09/24 00:00
PHST- 1999/09/24 00:00 [pubmed]
PHST- 1999/09/24 00:01 [medline]
PHST- 1999/09/24 00:00 [entrez]
AID - 10.2165/00003495-199958030-00007 [doi]
PST - ppublish
SO  - Drugs. 1999 Sep;58(3):469-75; discussion 476-7. doi: 
      10.2165/00003495-199958030-00007.

PMID- 3978896
OWN - NLM
STAT- MEDLINE
DCOM- 19850514
LR  - 20170112
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 3
IP  - 1
DP  - 1985 Jan-Mar
TI  - Indoprofen in juvenile chronic arthritis.
PG  - 59-62
AB  - Indoprofen at 10-12 mg/kg body weight was compared with aloxiprin at 80 mg/kg 
      body weight in children suffering from juvenile chronic arthritis. Indoprofen was 
      significantly superior to aloxiprin in reducing soft tissue swelling and joint 
      limitation and was effective in relieving pain and morning slowness and improving 
      grip strength. The drug was well tolerated and is a satisfactory agent for the 
      treatment of chronic arthritis in children.
FAU - Price, T
AU  - Price T
FAU - Venning, H
AU  - Venning H
FAU - Ansell, B M
AU  - Ansell BM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Phenylpropionates)
RN  - 6QT214X4XU (aloxiprin)
RN  - CPE46ZU14N (Indoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Juvenile/*drug therapy/physiopathology
MH  - Aspirin/adverse effects/analogs & derivatives/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Drug Evaluation
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Indoprofen/adverse effects/*therapeutic use
MH  - Phenylpropionates/*therapeutic use
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Rheumatol. 1985 Jan-Mar;3(1):59-62.

PMID- 19836360
OWN - NLM
STAT- MEDLINE
DCOM- 20100223
LR  - 20211020
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 79
IP  - 5
DP  - 2010 Mar 1
TI  - Reaction of human albumin with aspirin in vitro: mass spectrometric 
      identification of acetylated lysines 199, 402, 519, and 545.
PG  - 784-91
LID - 10.1016/j.bcp.2009.10.007 [doi]
AB  - The aspirin esterase activity of human plasma is due to butyrylcholinesterase and 
      albumin. Our goal was to identify the amino acid residues involved in the aspirin 
      esterase activity of albumin. Fatty acid-free human albumin and human plasma were 
      treated with aspirin for 5 min-24 h. Acetylated residues were identified by 
      LC/MS/MS and MALDI-TOF/TOF mass spectrometry of tryptic peptides. Treatment with 
      0.3 mM aspirin resulted in acetylation of Lys-199, Lys-402, Lys-519, and Lys-545. 
      Treatment with 20 mM aspirin resulted in acetylation of 26 lysines. There was no 
      acetylation of Tyr-411, under any conditions. Acetylated lysine was stable for at 
      least 21 days at pH 7.4, 37 degrees C. Albumin acetylated by aspirin had reduced 
      esterase activity with beta-naphthyl acetate as shown on gels stained for 
      esterase activity. It was concluded that the aspirin esterase activity of albumin 
      is a pseudo-esterase activity in which aspirin stably acetylates lysines and 
      releases salicylate.
CI  - 2009 Elsevier Inc. All rights reserved.
FAU - Liyasova, Mariya S
AU  - Liyasova MS
AD  - University of Nebraska Medical Center, Department of Environmental, Agricultural 
      & Occupational Health, Omaha, NE 68198-6805, USA.
FAU - Schopfer, Lawrence M
AU  - Schopfer LM
FAU - Lockridge, Oksana
AU  - Lockridge O
LA  - eng
GR  - CA36727/CA/NCI NIH HHS/United States
GR  - U01 NS058056-03/NS/NINDS NIH HHS/United States
GR  - P30 CA036727/CA/NCI NIH HHS/United States
GR  - P30 CA036727-24S5/CA/NCI NIH HHS/United States
GR  - U01 NS058056/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20091027
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Serum Albumin)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.- (acetylsalicylic acid hydrolase)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/*chemistry/pharmacology
MH  - Carboxylic Ester Hydrolases/chemistry
MH  - Chromatography, High Pressure Liquid
MH  - Humans
MH  - In Vitro Techniques
MH  - Lysine/*chemistry/drug effects
MH  - Models, Molecular
MH  - Peptide Mapping
MH  - Serum Albumin/*chemistry/drug effects
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/*methods
MH  - Tandem Mass Spectrometry
PMC - PMC2812595
MID - NIHMS152716
EDAT- 2009/10/20 06:00
MHDA- 2010/02/24 06:00
CRDT- 2009/10/20 06:00
PHST- 2009/09/08 00:00 [received]
PHST- 2009/10/07 00:00 [revised]
PHST- 2009/10/07 00:00 [accepted]
PHST- 2009/10/20 06:00 [entrez]
PHST- 2009/10/20 06:00 [pubmed]
PHST- 2010/02/24 06:00 [medline]
AID - S0006-2952(09)00901-0 [pii]
AID - 10.1016/j.bcp.2009.10.007 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2010 Mar 1;79(5):784-91. doi: 10.1016/j.bcp.2009.10.007. Epub 
      2009 Oct 27.

PMID- 19228483
OWN - NLM
STAT- MEDLINE
DCOM- 20090515
LR  - 20211020
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Linking)
VI  - 11
IP  - 2
DP  - 2009 Mar
TI  - Aspirin resistance: an update.
PG  - 105-10
AB  - Aspirin resistance (AR) still lacks a universally accepted definition, but it may 
      be discussed as either a laboratory phenomenon or a clinical presentation. 
      Laboratory resistance is mainly defined as abnormal platelet response to aspirin, 
      whereas the clinical manifestation is the failure of aspirin to prevent 
      cardiovascular events. Although there is evidence of an association, it appears 
      that a laboratory abnormality in platelet function is not the only risk factor 
      for the clinical manifestation of AR. Therapies for primary and secondary 
      prevention of AR still need to be elucidated, but there are some data to suggest 
      that in an acute episode of aspirin failure because of AR, different therapeutic 
      interventions need to be considered.
FAU - Lancaster, Gilead I
AU  - Lancaster GI
AD  - Department of Medicine, Yale University School of Medicine, Bridgeport Hospital, 
      267 Grant Street, Bridgeport, CT 06610, USA. pglanc@bpthosp.org
FAU - Srinivasan, Janardhan
AU  - Srinivasan J
FAU - Jain, Hitender
AU  - Jain H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Drug Resistance
MH  - Humans
RF  - 45
EDAT- 2009/02/21 09:00
MHDA- 2009/05/16 09:00
CRDT- 2009/02/21 09:00
PHST- 2009/02/21 09:00 [entrez]
PHST- 2009/02/21 09:00 [pubmed]
PHST- 2009/05/16 09:00 [medline]
AID - 10.1007/s11883-009-0017-7 [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2009 Mar;11(2):105-10. doi: 10.1007/s11883-009-0017-7.

PMID- 7466908
OWN - NLM
STAT- MEDLINE
DCOM- 19810421
LR  - 20190727
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 21
IP  - 1
DP  - 1981 Jan-Feb
TI  - Acetylation of erythrocytic membrane peptides by aspirin.
PG  - 55-8
AB  - Acetylation of erythrocytic membranes by aspirin has not been reported. When 
      erythrocytes or erythrocytic membranes are incubated with [acetyl-14C]aspirin, 
      there is good evidence of very tight binding to membrane peptides in 
      concentrations known to occur in vivo, 20 to 200 microM. No such evidence is 
      observed with [carboxy-14C] aspirin. This indicates acetylation of membrane 
      peptides. Although pronounced selectivity is not observed among the different 
      peptides by gel filtration on Bio-Gel A-5M and sodium dodecyl sulfate 
      polyacrylamide gel electrophoresis, there is overall saturation with a 
      half-maximum at about 10 mM. The clinical significance of acetylation of membrane 
      peptides of erythrocytes is unclear.
FAU - Green, F A
AU  - Green FA
FAU - Jung, C Y
AU  - Jung CY
LA  - eng
GR  - AM 13376/AM/NIADDK NIH HHS/United States
GR  - HL 24009/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Hemoglobins)
RN  - 0 (Peptides)
RN  - 0 (Serum Albumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/blood/*pharmacology
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Erythrocyte Membrane/*metabolism
MH  - Erythrocytes/*metabolism
MH  - Hemoglobins
MH  - Humans
MH  - Peptides/*metabolism
MH  - Serum Albumin/metabolism
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1046/j.1537-2995.1981.21181127484.x [doi]
PST - ppublish
SO  - Transfusion. 1981 Jan-Feb;21(1):55-8. doi: 
      10.1046/j.1537-2995.1981.21181127484.x.

PMID- 27262845
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20181113
IS  - 1466-1268 (Electronic)
IS  - 1355-8145 (Print)
IS  - 1355-8145 (Linking)
VI  - 21
IP  - 5
DP  - 2016 Sep
TI  - Aspirin-induced heat stress resistance in chicken myocardial cells can be 
      suppressed by BAPTA-AM in vitro.
PG  - 817-27
LID - 10.1007/s12192-016-0706-4 [doi]
AB  - Our recent studies have displayed the protective functions of aspirin against 
      heat stress (HS) in chicken myocardial cells, and it may be associated with heat 
      shock proteins (HSPs). In this study, we further investigated the potential role 
      of HSPs in the aspirin-induced heat stress resistance. Four of the most important 
      HSPs including HspB1 (Hsp27), Hsp60, Hsp70, and Hsp90 were induced by aspirin 
      pretreatment and were suppressed by BAPTA-AM. When HSPs were induced by aspirin, 
      much slighter HS injury was detected. But more serious damages were observed when 
      HSPs were suppressed by BAPTA-AM than those cells exposed to HS without BAPTA-AM, 
      even the myocardial cells have been treated with aspirin in prior. Comparing to 
      other HSPs, HspB1 presented the largest increase after aspirin treatments, 
      86-fold higher than the baseline (the level before HS). These findings suggested 
      that multiple HSPs participated in aspirin's anti-heat stress function but HspB1 
      may contribute the most. Interestingly, during the experiments, we also found 
      that apoptosis rate as well as the oxidative stress indicators (T-SOD and MDA) 
      was not consistently responding to heat stress injury as expected. By selecting 
      from a series of candidates, myocardial cell damage-related enzymes (CK-MB and 
      LDH), cytopathological tests, and necrosis rate (measured by flow cytometry 
      assays) are believed to be reliable indicators to evaluate heat stress injury in 
      chicken's myocardial cells and they will be used in our further investigations.
FAU - Wu, Di
AU  - Wu D
AD  - College of Veterinary Medicine, Nanjing Agricultural University, Weigang 1, 
      Nanjing, 210095, China.
FAU - Zhang, Miao
AU  - Zhang M
AD  - College of Animal Science and Technology, Jinling Institute of Technology, 
      Nanjing, 210038, China.
FAU - Lu, Yinjun
AU  - Lu Y
AD  - College of Veterinary Medicine, Nanjing Agricultural University, Weigang 1, 
      Nanjing, 210095, China.
FAU - Tang, Shu
AU  - Tang S
AD  - College of Veterinary Medicine, Nanjing Agricultural University, Weigang 1, 
      Nanjing, 210095, China.
FAU - Kemper, N
AU  - Kemper N
AD  - Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour, 
      University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
FAU - Hartung, J
AU  - Hartung J
AD  - Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour, 
      University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
FAU - Bao, Endong
AU  - Bao E
AD  - College of Veterinary Medicine, Nanjing Agricultural University, Weigang 1, 
      Nanjing, 210095, China. b_endong@njau.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160604
PL  - Netherlands
TA  - Cell Stress Chaperones
JT  - Cell stress & chaperones
JID - 9610925
RN  - 0 (Avian Proteins)
RN  - 0 (Heat-Shock Proteins)
RN  - 139890-68-9 (1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid 
      acetoxymethyl ester)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 526U7A2651 (Egtazic Acid)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Avian Proteins/metabolism
MH  - Cells, Cultured
MH  - Chickens
MH  - Drug Evaluation, Preclinical
MH  - Egtazic Acid/*analogs & derivatives/pharmacology
MH  - Heat-Shock Proteins/metabolism
MH  - Heat-Shock Response/*drug effects
MH  - Malondialdehyde/metabolism
MH  - Myocytes, Cardiac/*drug effects/metabolism
MH  - Superoxide Dismutase/metabolism
PMC - PMC5003798
OTO - NOTNLM
OT  - Aspirin
OT  - BAPTA-AM
OT  - HSPs
OT  - Heat stress
OT  - Inhibitor
OT  - Myocardial cell
EDAT- 2016/06/06 06:00
MHDA- 2017/03/11 06:00
PMCR- 2017/03/01
CRDT- 2016/06/06 06:00
PHST- 2016/03/29 00:00 [received]
PHST- 2016/05/27 00:00 [accepted]
PHST- 2016/05/09 00:00 [revised]
PHST- 2017/03/01 00:00 [pmc-release]
PHST- 2016/06/06 06:00 [entrez]
PHST- 2016/06/06 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
AID - 10.1007/s12192-016-0706-4 [pii]
AID - 706 [pii]
AID - 10.1007/s12192-016-0706-4 [doi]
PST - ppublish
SO  - Cell Stress Chaperones. 2016 Sep;21(5):817-27. doi: 10.1007/s12192-016-0706-4. 
      Epub 2016 Jun 4.

PMID- 7469622
OWN - NLM
STAT- MEDLINE
DCOM- 19810413
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 141
IP  - 3 Spec No
DP  - 1981 Feb 23
TI  - Therapeutic implications of drug interactions with acetaminophen and aspirin.
PG  - 301-4
AB  - Only drug-drug interactions that are believed clinically important and that are 
      primarily pharmacokinetic in nature are discussed in this article. Drugs reported 
      to interact with aspirin are oral anticoagulants, methotrexate, probenecid, and 
      sulfinpyrazone; those that are believed to interact with acetaminophen are 
      propantheline bromide, narcotics, and metoclopramide hydrochloride, as well as 
      food (carbohydrates). Ethyl alcohol, ammonium chloride, antacids, oral 
      antidiabetic agents, corticosteroids, and heparin sodium probably interact with 
      aspirin. Fenoprofen calcium, gold sodium thiomalate, indomethacin, naproxen, 
      penicillin, phenylbutazone, phenytoin sodium, and spironolactone may also cause 
      such interactions. Ethyl alcohol, beta-adrenergic blockers, oral anticoagulants, 
      chlorpromazine hydrochloride, and miscellaneous mutual toxicities may cause 
      interactions with acetaminophen. The concomitant use of drugs that are believed 
      to interact importantly with either aspirin or acetaminophen should be avoided 
      when designing a treatment regimen. The remaining agents discussed here (of 
      doubtful importance in man) demand careful monitoring in difficult clinical 
      situations and must be submitted to further controlled studies.
FAU - Hayes, A H Jr
AU  - Hayes AH Jr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Antacids)
RN  - 0 (Anticoagulants)
RN  - 1306V2B0Q8 (Propantheline)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Acetaminophen/*administration & dosage/pharmacology
MH  - Antacids/metabolism
MH  - Anticoagulants/metabolism
MH  - Aspirin/*administration & dosage/metabolism/pharmacology
MH  - Drug Interactions
MH  - Humans
MH  - Methotrexate/metabolism
MH  - Propantheline/metabolism
MH  - Sulfinpyrazone/metabolism
EDAT- 1981/02/23 00:00
MHDA- 2001/03/28 10:01
CRDT- 1981/02/23 00:00
PHST- 1981/02/23 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1981/02/23 00:00 [entrez]
AID - 10.1001/archinte.141.3.301 [doi]
PST - ppublish
SO  - Arch Intern Med. 1981 Feb 23;141(3 Spec No):301-4. doi: 
      10.1001/archinte.141.3.301.

PMID- 6805489
OWN - NLM
STAT- MEDLINE
DCOM- 19820807
LR  - 20221207
IS  - 0037-8771 (Print)
IS  - 0037-8771 (Linking)
VI  - 58
IP  - 7
DP  - 1982 Apr 15
TI  - [Action of salicylates on the disappearance of bacteria (Lactobacillus casei) 
      phagocytized by polymorphonuclear cells].
PG  - 371-7
AB  - This is a study of the modifications caused by acetylsalicylic acid and CuII 
      (aspirinate)4 in the speed with which phagocytized bacteria disappear from 
      polymorphonuclears (PMN) of the peritoneal exudate of guinea pigs. 
      Acetylsalicylic acid inhibits the normal processes that cause the disappearance 
      of the phagocytized bacteria; CuII (aspirinate)4, on the contrary, at low 
      concentration (5 10(-6)) and during the first 45 minutes, causes an evident 
      increase in the speed of disappearance of bacteria from PMN.
FAU - Cassone, M C
AU  - Cassone MC
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Azione di salicilati sulla scomparsa di batteri (Lactobacillus casei) fagocitati 
      da polimorfonucleati.
PL  - Italy
TA  - Boll Soc Ital Biol Sper
JT  - Bollettino della Societa italiana di biologia sperimentale
JID - 7506962
RN  - 0 (Anti-Inflammatory Agents)
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Guinea Pigs
MH  - *Lacticaseibacillus casei
MH  - Neutrophils/drug effects/*immunology
MH  - *Phagocytosis
EDAT- 1982/04/15 00:00
MHDA- 1982/04/15 00:01
CRDT- 1982/04/15 00:00
PHST- 1982/04/15 00:00 [pubmed]
PHST- 1982/04/15 00:01 [medline]
PHST- 1982/04/15 00:00 [entrez]
PST - ppublish
SO  - Boll Soc Ital Biol Sper. 1982 Apr 15;58(7):371-7.

PMID- 7017489
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Clinico-functional observations on the use of guacetisal in the treatment of 
      chronic obstructive bronchopneumopathy].
PG  - 387-92
AB  - The results of an approximately 14-day treatment with 500 mg broncaspin capsules 
      in 25 patients with recrudescent chronic bronchitis are presented. There was a 
      marked, constant improvement in the subjective and objective symptomatology, and 
      in respiratory function indices. The expectoration cell parameters displayed 
      changes consonant with the therapeutic effect. Local and general tolerance were 
      good overall.
FAU - Lappa, B
AU  - Lappa B
FAU - Di Caterina, N
AU  - Di Caterina N
FAU - Perna, A
AU  - Perna A
FAU - Di Fraia, C
AU  - Di Fraia C
FAU - Verdoliva, A
AU  - Verdoliva A
FAU - Margarita, A
AU  - Margarita A
LA  - ita
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Osservazioni clinico-funzionali sull'impiego del guacetisal nel trattamento delle 
      broncopneumopatie croniche ostruttive.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Bronchitis/*drug therapy
MH  - Clinical Trials as Topic
MH  - Cough/drug therapy
MH  - Humans
MH  - Lung Diseases, Obstructive/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Respiration/drug effects
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):387-92.

PMID- 32163816
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1768-3254 (Electronic)
IS  - 0223-5234 (Linking)
VI  - 192
DP  - 2020 Apr 15
TI  - True or false? Challenges and recent highlights in the development of aspirin 
      prodrugs.
PG  - 112200
LID - S0223-5234(20)30167-7 [pii]
LID - 10.1016/j.ejmech.2020.112200 [doi]
AB  - Aspirin is a widely used medicine for a variety of indications. It is unique 
      amongst non-steroidal anti-inflammatory drugs (NSAIDs) in that it causes 
      irreversible acetylation of COX enzymes. Like all NSAIDs however, aspirin causes 
      severe gastrointestinal side-effects, in particular with chronic administration. 
      Prodrugs of aspirin have been proposed as a solution to these side-effects. 
      However, identifying true prodrugs of aspirin, rather than salicylic acid, has 
      proven challenging. This review details the challenges and highlights recent 
      progress in the development of such prodrugs.
CI  - Copyright © 2020 Elsevier Masson SAS. All rights reserved.
FAU - Willetts, Steffan
AU  - Willetts S
AD  - Medicines Discovery Institute, Cardiff University, Cardiff, CF10 3AT, UK.
FAU - Foley, David W
AU  - Foley DW
AD  - Medicines Discovery Institute, Cardiff University, Cardiff, CF10 3AT, UK. 
      Electronic address: foleyd4@cardiff.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200303
PL  - France
TA  - Eur J Med Chem
JT  - European journal of medicinal chemistry
JID - 0420510
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Prodrugs)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/chemistry/*pharmacology
MH  - Antineoplastic Agents/adverse effects/chemistry/*pharmacology
MH  - Aspirin/adverse effects/chemistry/*pharmacology
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Nitric Oxide/metabolism
MH  - Prodrugs/adverse effects/chemistry/*pharmacology
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer
OT  - DMPK
OT  - Gastrointestinal toxicity
OT  - Prodrug
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/03/13 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/03/13 06:00
PHST- 2019/11/15 00:00 [received]
PHST- 2019/12/18 00:00 [revised]
PHST- 2020/02/28 00:00 [accepted]
PHST- 2020/03/13 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/03/13 06:00 [entrez]
AID - S0223-5234(20)30167-7 [pii]
AID - 10.1016/j.ejmech.2020.112200 [doi]
PST - ppublish
SO  - Eur J Med Chem. 2020 Apr 15;192:112200. doi: 10.1016/j.ejmech.2020.112200. Epub 
      2020 Mar 3.

PMID- 25998572
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20150730
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 127
IP  - 6
DP  - 2015 Aug
TI  - A randomized trial to assess the pharmacodynamics and pharmacokinetics of a 
      single dose of an extended-release aspirin formulation.
PG  - 573-80
LID - 10.1080/00325481.2015.1050341 [doi]
AB  - AIMS: Low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention 
      reduces cardiovascular disease mortality risk. ASA acetylates cyclooxygenase in 
      the portal circulation and is rapidly (half-life, 20 min) hydrolyzed. Certain 
      patients with cardiovascular disease may exhibit high on-therapy platelet 
      reactivity as a result of high platelet turnover, a process whereby platelets are 
      produced and are active beyond the duration of antiplatelet coverage provided by 
      once-daily immediate-release (IR) ASA. A once-daily, extended-release (ER) ASA 
      formulation using ER microcapsule technology was developed to release ASA over 
      the 24-h dosing interval and reduce maximal plasma concentrations to spare 
      peripheral endogenous endothelial prostacyclin production. METHODS: Healthy 
      adults (n = 50) were randomized in a crossover study to receive two different 
      ER-ASA single doses (up to 325 mg) and two different IR-ASA single doses (up to 
      81 mg) in four periods, each separated by ≥14 days. Pharmacodynamics was assessed 
      by measuring serum thromboxane B2 (TXB2), urine 11-dehydro-TXB2, and arachidonic 
      acid-induced platelet aggregation. Pharmacokinetics was determined for ASA and 
      salicylic acid (SA). RESULTS: Both formulations produced dose-dependent 
      inhibition on all pharmacodynamic parameters. Marked inhibition of TXB2 and 
      11-dehydro-TXB2 was maintained over the 24-h dosing interval after a dose of ≥81 
      mg ER-ASA or ≥40 mg IR-ASA. The dose required to achieve 50% of maximum TXB2 
      inhibition with ER-ASA was 49.9 mg versus 29.6 mg for IR-ASA, for a similar 
      maximum pharmacodynamic effect (98.9% TXB2 inhibition). This suggests that an 
      approximately twofold greater ER-ASA dose (162.5 mg) is necessary to obtain the 
      same response as that of IR-ASA 81 mg. Peak ASA concentrations were lower and 
      Tmax was longer with ER-ASA versus IR-ASA. Administration of IR-ASA resulted in a 
      dose-normalized mean Cmax of ASA that was approximately sixfold higher than that 
      for ER-ASA and a Cmax of SA approximately two- to threefold higher than that for 
      ER-ASA. CONCLUSION: Both ASA formulations showed dose-dependent antiplatelet 
      activity. Compared with the IR-ASA, ER-ASA released active drug more slowly, 
      resulting in prolonged absorption and lower systemic drug concentrations, which 
      is expected for an ER (24-h) formulation.
FAU - Patrick, Jeff
AU  - Patrick J
AD  - New Haven Pharmaceuticals, Inc. , North Haven, CT , USA.
FAU - Dillaha, Larry
AU  - Dillaha L
FAU - Armas, Danielle
AU  - Armas D
FAU - Sessa, William C
AU  - Sessa WC
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20150522
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Capsules)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Capsules
MH  - Cross-Over Studies
MH  - Delayed-Action Preparations
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/pharmacokinetics/*pharmacology
MH  - Therapeutic Equivalency
MH  - Young Adult
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - aspirin
OT  - extended release
OT  - platelets
OT  - thromboxane
EDAT- 2015/05/23 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/05/23 06:00
PHST- 2015/05/23 06:00 [entrez]
PHST- 2015/05/23 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - 10.1080/00325481.2015.1050341 [doi]
PST - ppublish
SO  - Postgrad Med. 2015 Aug;127(6):573-80. doi: 10.1080/00325481.2015.1050341. Epub 
      2015 May 22.

PMID- 3322248
OWN - NLM
STAT- MEDLINE
DCOM- 19880202
LR  - 20190718
IS  - 0004-8682 (Print)
IS  - 0004-8682 (Linking)
VI  - 57
IP  - 10
DP  - 1987 Oct
TI  - Effect of 50 mg enteric-coated aspirin (Astrix) on thromboxane and prostacyclin 
      synthesis.
PG  - 763-6
AB  - Although low-dose soluble aspirin can be recommended as a useful anti-thrombotic 
      drug regimen in patients with vascular disease, enteric-coated preparations have 
      a theoretical advantage for aspirin preparations which are to be ingested daily 
      for many years. We have demonstrated that a 50 mg enteric-coated aspirin 
      formulation (Astrix) which has an absorption rate much lower than soluble 
      aspirin, is sufficient to inhibit platelet thromboxane synthesis while causing no 
      major decrease in vascular prostacyclin synthesis.
FAU - James, M J
AU  - James MJ
AD  - Department of Surgery, Flinders Medical Centre, Bedford Park, South Australia.
FAU - Walsh, J A
AU  - Walsh JA
FAU - Foreman, R K
AU  - Foreman RK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Aust N Z J Surg
JT  - The Australian and New Zealand journal of surgery
JID - 0373115
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Fibrinolytic Agents)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Delayed-Action Preparations
MH  - Epoprostenol/*biosynthesis
MH  - *Fibrinolytic Agents
MH  - Humans
MH  - Thromboxane A2/*biosynthesis
EDAT- 1987/10/01 00:00
MHDA- 1987/10/01 00:01
CRDT- 1987/10/01 00:00
PHST- 1987/10/01 00:00 [pubmed]
PHST- 1987/10/01 00:01 [medline]
PHST- 1987/10/01 00:00 [entrez]
AID - 10.1111/j.1445-2197.1987.tb01257.x [doi]
PST - ppublish
SO  - Aust N Z J Surg. 1987 Oct;57(10):763-6. doi: 10.1111/j.1445-2197.1987.tb01257.x.

PMID- 31891783
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1876-7737 (Electronic)
IS  - 1874-3919 (Linking)
VI  - 215
DP  - 2020 Mar 20
TI  - Plasma metabonomics and proteomics studies on the anti-thrombosis mechanism of 
      aspirin eugenol ester in rat tail thrombosis model.
PG  - 103631
LID - S1874-3919(19)30403-8 [pii]
LID - 10.1016/j.jprot.2019.103631 [doi]
AB  - Aspirin eugenol eater (AEE), a new drug compound, was synthesized through the 
      combination of aspirin and eugenol. Antithrombotic effects of AEE have been 
      confirmed in carrageenan-induced rat tail thrombosis model. However, its 
      mechanism is unclear. With the application of integrated approach combining 
      proteomics and metabolomics, the profilings of protein and metabolite in plasma 
      were examined in thrombosis rat pretreated with AEE, aspirin and eugenol, 
      respectively. A clear separation of the plasma metabolic profiles from different 
      groups was found in score plots. 15 metabolites related with the metabolism of 
      fatty acid, energy and amino acid were found. A total of 144, 38, 41 and 54 
      differentially abundant proteins (DAPs) were identified in control, AEE, aspirin 
      and eugenol group, respectively. Proteomic results showed that aspirin modulated 
      7 proteins in amino acid metabolism and 4 proteins in complement system; eugenol 
      regulated the 8 proteins related with coagulation cascades and fibrinogen; AEE 
      improved 3 proteins in TCA cycle and 3 in lipid metabolism. Integrated analysis 
      suggested that AEE improved fatty acid, energy and lipid metabolism to against 
      thrombosis. Results of this study indicated AEE had different action mechanism on 
      thrombosis from aspirin and eugenol, and contribute to understanding the 
      mechanisms of AEE on thrombosis. SIGNIFICANCE: Thrombosis is a threat to human 
      health, and there is an urgent need for new drug. In this study, compared with 
      the model group, plasma metabolic profiles in AEE-treated rats were clearly 
      separated; 15 metabolites and 38 proteins were picked out. These metabolites and 
      proteins may assist in understanding the action mechanism of AEE on thrombosis. 
      The results of plasma metabonomics and proteomics also revealed the different 
      action mechanism among AEE, aspirin and eugenol on thrombosis. This study 
      established the foundation to further evaluate the druggability of AEE on 
      thrombosis treatment.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Ma, Ning
AU  - Ma N
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, PR China; College of Veterinary Medicine, Agricultural University 
      of Hebei, Baoding, Hebei 071000, PR China.
FAU - Yang, Yajun
AU  - Yang Y
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, PR China.
FAU - Liu, Xiwang
AU  - Liu X
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, PR China.
FAU - Li, Shihong
AU  - Li S
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, PR China.
FAU - Qin, Zhe
AU  - Qin Z
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, PR China.
FAU - Li, Jianyong
AU  - Li J
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, PR China. Electronic address: lijy1971@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191228
PL  - Netherlands
TA  - J Proteomics
JT  - Journal of proteomics
JID - 101475056
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Eugenol/analogs & derivatives/pharmacology
MH  - Metabolomics
MH  - *Pharmaceutical Preparations
MH  - Proteomics
MH  - Rats
MH  - Tail
MH  - *Thrombosis/drug therapy
OTO - NOTNLM
OT  - Aspirin eugenol ester
OT  - Carrageenan
OT  - Omics
OT  - Thrombosis
OT  - iTRAQ
COIS- Declaration of Competing Interest The authors declare that they have no competing 
      interests.
EDAT- 2020/01/01 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/01/01 06:00
PHST- 2019/09/23 00:00 [received]
PHST- 2019/12/10 00:00 [revised]
PHST- 2019/12/27 00:00 [accepted]
PHST- 2020/01/01 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/01/01 06:00 [entrez]
AID - S1874-3919(19)30403-8 [pii]
AID - 10.1016/j.jprot.2019.103631 [doi]
PST - ppublish
SO  - J Proteomics. 2020 Mar 20;215:103631. doi: 10.1016/j.jprot.2019.103631. Epub 2019 
      Dec 28.

PMID- 36326423
OWN - NLM
STAT- MEDLINE
DCOM- 20221215
LR  - 20221221
IS  - 1552-3365 (Electronic)
IS  - 0363-5465 (Print)
IS  - 0363-5465 (Linking)
VI  - 50
IP  - 14
DP  - 2022 Dec
TI  - Venous Thromboembolism Chemoprophylaxis in Knee Arthroscopy: A Break-Even 
      Analysis of Cost.
PG  - 3832-3837
LID - 10.1177/03635465221130990 [doi]
AB  - BACKGROUND: Symptomatic venous thromboembolism (VTE) is a serious and costly 
      complication after knee arthroscopy. There continues to be debate regarding the 
      use of VTE prophylaxis after knee arthroscopy, and minimal research has explored 
      its cost-effectiveness. HYPOTHESIS: Both aspirin and enoxaparin would be 
      cost-effective in preventing symptomatic VTE. STUDY DESIGN: Economic and decision 
      analysis; Level of evidence, 3. METHODS: The literature was searched and the 
      TriNetX research database was queried to determine a range of initial rates of 
      VTE. An open-access retail database was used to determine the mean retail price 
      for aspirin (325 mg) and enoxaparin (30 mg and 40 mg). Our institutional records 
      were used to determine the cost of treating VTE. A "break-even" analysis was then 
      performed to determine the absolute risk reduction necessary to make these drugs 
      cost-effective. This value was then used to calculate the number of patients who 
      would need to be treated (NNT) to prevent a single VTE while still breaking even 
      on cost. RESULTS: The cost of treating VTE was $9407 (US Dollars). Aspirin (325 
      mg), enoxaparin (30 mg), and enoxaparin (40 mg) were found to cost $1.86, 
      $188.72, and $99.99, respectively. The low, TriNetX, and high rates of VTE were 
      0.34%, 0.86%, and 10.9%, respectively. Aspirin was cost-effective at all 3 rates 
      if the initial rate decreased by 0.02% (NNT = 5058). Both formulations of 
      enoxaparin were cost-effective at the high initial rate if they decreased by 
      2.01% (NNT = 50) and 1.06% (NNT = 94), respectively. However, at the low and 
      TriNetX rates, the 2 doses of enoxaparin were not cost-effective because their 
      final break-even rate exceeded the initial VTE rate. CONCLUSION: Aspirin and, in 
      some cases, enoxaparin are cost-effective treatments for VTE prophylaxis after 
      knee arthroscopy.
FAU - Martinazzi, Brandon J
AU  - Martinazzi BJ
AD  - Penn State Health, Milton S. Hershey Medical Center, Department of Orthopaedics & 
      Rehabilitation, Hershey, Pennsylvania, USA.
FAU - Kirchner, Gregory J
AU  - Kirchner GJ
AD  - Penn State Health, Milton S. Hershey Medical Center, Department of Orthopaedics & 
      Rehabilitation, Hershey, Pennsylvania, USA.
FAU - Lorenz, F Jeffrey
AU  - Lorenz FJ
AD  - Penn State Health, Milton S. Hershey Medical Center, Department of Orthopaedics & 
      Rehabilitation, Hershey, Pennsylvania, USA.
FAU - Bonaddio, Vincenzo
AU  - Bonaddio V
AD  - Penn State Health, Milton S. Hershey Medical Center, Department of Orthopaedics & 
      Rehabilitation, Hershey, Pennsylvania, USA.
FAU - Hines, Shawn
AU  - Hines S
AD  - Penn State Health, Milton S. Hershey Medical Center, Department of Orthopaedics & 
      Rehabilitation, Hershey, Pennsylvania, USA.
FAU - Kim, Raymond Y
AU  - Kim RY
AD  - Penn State Health, Milton S. Hershey Medical Center, Department of Orthopaedics & 
      Rehabilitation, Hershey, Pennsylvania, USA.
FAU - Gallo, Robert A
AU  - Gallo RA
AD  - Penn State Health, Milton S. Hershey Medical Center, Department of Orthopaedics & 
      Rehabilitation, Hershey, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221103
PL  - United States
TA  - Am J Sports Med
JT  - The American journal of sports medicine
JID - 7609541
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Venous Thromboembolism/prevention & control
MH  - Aspirin/therapeutic use
PMC - PMC9729969
OTO - NOTNLM
OT  - economic and decision analysis
OT  - knee ligaments
OT  - venous thromboembolism
COIS- One or more of the authors has declared the following potential conflict of 
      interest or source of funding: R.A.G. holds stock in Kalibur Labs and has 
      received research support from Aesculap Biologics. AOSSM checks author 
      disclosures against the Open Payments Database (OPD). AOSSM has not conducted an 
      independent investigation on the OPD and disclaims any liability or 
      responsibility relating thereto.
EDAT- 2022/11/04 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/11/03 09:32
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
PHST- 2022/11/03 09:32 [entrez]
AID - 10.1177_03635465221130990 [pii]
AID - 10.1177/03635465221130990 [doi]
PST - ppublish
SO  - Am J Sports Med. 2022 Dec;50(14):3832-3837. doi: 10.1177/03635465221130990. Epub 
      2022 Nov 3.

PMID- 25296945
OWN - NLM
STAT- MEDLINE
DCOM- 20150708
LR  - 20141009
IS  - 1502-7686 (Electronic)
IS  - 0036-5513 (Linking)
VI  - 74
IP  - 7
DP  - 2014 Oct
TI  - Monitoring ASA and P2Y12-specific platelet inhibition--comparison of conventional 
      (single) and multiple electrode aggregometry.
PG  - 568-74
LID - 10.3109/00365513.2014.913305 [doi]
AB  - OBJECTIVE: Several platelet function test systems exist for the evaluation of the 
      platelet inhibitory effect in patients on P2Y12 inhibitors and/or acetylsalicylic 
      acid (ASA, aspirin) therapy. Studies comparing different available assays found 
      only a poor correlation. The objective of the present study was to evaluate the 
      correlation and agreement between single electrode (SEA) and multiple electrode 
      (MEA) aggregometry. METHODS AND RESULTS: In whole blood arachidonic acid (AA) and 
      adenosine diphosphate (ADP)-induced platelet aggregation was measured 
      simultaneously using SEA (Chrono-Log) and MEA (Multiplate). We analyzed a total 
      of 226 measurements taken from 58 patients on single ASA therapy or dual 
      antiplatelet therapy with ASA and a thienopyridine. A cut-off value for 
      clopidogrel/prasugrel high on-treatment platelet reactivity (HPR) of > 47 units 
      (U) was chosen for MEA testing using hirudin and > 5 Ohm for SEA with citrate 
      anticoagulated blood samples. The respective cut-off values for ASA HPR were > 30 
      U for the MEA assay and > 1 Ohm for SEA testing. There was a good correlation of 
      the prevalence of thienopyridine-HPR in both whole blood assays (Spearman rank 
      correlation coefficient r = 0.698) and a good inter-rate accordance (Cohen's 
      Kappa statistic κ = 0.648). For AA-induced aggregation, the correlation of the 
      results obtained was significant (r = 0.536; p < 0.001) and detecting ASA-HPR 
      revealed a moderate (κ = 0.482) correlation between both impedance aggregometry 
      assays. CONCLUSION: Platelet function testing using SEA and MEA provided both 
      good accordance and correlation and therefore study results obtained by these two 
      assays similarly enabled the detection of HPR of thienopyridine (and ASA) 
      therapy.
FAU - Krüger, Jan-Christopher
AU  - Krüger JC
AD  - Cardiovascular Center.
FAU - Meves, Saskia H
AU  - Meves SH
FAU - Kara, Kaffer
AU  - Kara K
FAU - Mügge, Andreas
AU  - Mügge A
FAU - Neubauer, Horst
AU  - Neubauer H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Electrodes
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests/*methods
MH  - Purinergic P2Y Receptor Antagonists/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - clopidogrel
OT  - impedance aggregometry
OT  - multiplate
OT  - multiple electrode aggregometry
OT  - platelet function test
OT  - residual platelet reactivity
OT  - whole blood platelet aggregation
EDAT- 2014/10/10 06:00
MHDA- 2015/07/15 06:00
CRDT- 2014/10/10 06:00
PHST- 2014/10/10 06:00 [entrez]
PHST- 2014/10/10 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - 10.3109/00365513.2014.913305 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2014 Oct;74(7):568-74. doi: 
      10.3109/00365513.2014.913305.

PMID- 23861151
OWN - NLM
STAT- MEDLINE
DCOM- 20140707
LR  - 20181202
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 3
IP  - 11
DP  - 2013 Nov
TI  - Aspirin desensitization for aspirin-exacerbated respiratory disease (Samter's 
      Triad): a systematic review of the literature.
PG  - 915-20
LID - 10.1002/alr.21202 [doi]
AB  - OBJECTIVES: To critically review the current literature regarding aspirin 
      desensitization treatment for nasal polyposis in patients with 
      Aspirin-Exacerbated Respiratory Disease (AERD). STUDY DESIGN: Systematic review 
      of the literature. METHODS: All English literature published between January 1995 
      and February 2013 reporting specifically nasal outcomes following aspirin 
      desensitization in AERD patients were eligible for inclusion. Exclusion criteria 
      were non-investigative, non-human, and ex-vivo studies. Studies were categorized 
      by level of evidence and evaluated for quality using the Downs and Black scale. 
      RESULTS: A total of 614 citations were retrieved and eleven studies met the 
      criteria for analysis. Outcome measurements included self-reported symptom 
      scores, amount of corticosteroid use, rate of revision surgery, and quantitative 
      measurements such as rhinomanometry. Overall, most studies reported a significant 
      improvement in symptom scores, decrease in corticosteroid use, and decrease in 
      revision surgery. A few studies showed promising results with quantitative 
      outcomes. However, most studies were of Level 2 evidence with small samples 
      sizes. Rates of adverse events ranged from 12.5% to 23%. CONCLUSIONS: Unlike 
      traditional treatments for nasal polyposis, aspirin desensitization targets AERD 
      etiology rather than phenotype and can be an effective therapeutic option. While 
      the current literature shows encouraging results, additional studies are needed 
      to better define clinical benefits.
CI  - © 2013 ARS-AAOA, LLC.
FAU - Xu, Jason J
AU  - Xu JJ
AD  - Schulich School of Medicine & Dentistry, University of Western Ontario, London, 
      Ontario, Canada.
FAU - Sowerby, Leigh
AU  - Sowerby L
FAU - Rotenberg, Brian W
AU  - Rotenberg BW
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20130716
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*prevention & control
MH  - Humans
MH  - Nasal Polyps/chemically induced/*immunology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - ASA triad
OT  - aspirin desensitization
OT  - aspirin exacerbated respiratory disease
OT  - nasal polyps
OT  - samter's triad
OT  - systematic review
EDAT- 2013/07/19 06:00
MHDA- 2014/07/08 06:00
CRDT- 2013/07/18 06:00
PHST- 2013/02/22 00:00 [received]
PHST- 2013/05/16 00:00 [revised]
PHST- 2013/06/06 00:00 [accepted]
PHST- 2013/07/18 06:00 [entrez]
PHST- 2013/07/19 06:00 [pubmed]
PHST- 2014/07/08 06:00 [medline]
AID - 10.1002/alr.21202 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2013 Nov;3(11):915-20. doi: 10.1002/alr.21202. Epub 
      2013 Jul 16.

PMID- 26779603
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 2325-7237 (Electronic)
IS  - 2325-7237 (Linking)
VI  - 6
IP  - 2
DP  - 2016 Jan 15
TI  - Acute Retroperitoneal Hematoma After Psoas Catheter Placement in a Patient with 
      Myeloproliferative Thrombocytosis and Aspirin Therapy.
PG  - 28-30
LID - 10.1213/XAA.0000000000000261 [doi]
AB  - Retroperitoneal hematoma is a rare complication of psoas catheter placement, 
      typically occurring several days after placement and in the setting of 
      anticoagulation. We present the case of a patient with a history of 
      myeloproliferative thrombocytosis receiving aspirin therapy who underwent total 
      hip arthroplasty with preoperative psoas catheter placement complicated by 
      immediate development of a large retroperitoneal hematoma. It is likely that the 
      combination of aspirin therapy and thrombocytosis paradoxically placed the 
      patient at increased risk for hemorrhagic complications. Regional techniques 
      should be used cautiously in patients with myeloproliferative disorders, even in 
      the presence of supraphysiologic platelet counts.
FAU - Warner, Nafisseh S
AU  - Warner NS
AD  - From the Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota.
FAU - Duncan, Christopher M
AU  - Duncan CM
FAU - Kopp, Sandra L
AU  - Kopp SL
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - A A Case Rep
JT  - A & A case reports
JID - 101637720
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects
MH  - Catheters/*adverse effects
MH  - Gastrointestinal Hemorrhage/*etiology
MH  - Hematoma/*etiology
MH  - Humans
MH  - Male
MH  - Myeloproliferative Disorders/complications
MH  - Thrombocytosis/surgery
EDAT- 2016/01/19 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/01/19 06:00
PHST- 2016/01/19 06:00 [entrez]
PHST- 2016/01/19 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 01720097-201601150-00005 [pii]
AID - 10.1213/XAA.0000000000000261 [doi]
PST - ppublish
SO  - A A Case Rep. 2016 Jan 15;6(2):28-30. doi: 10.1213/XAA.0000000000000261.

PMID- 8895078
OWN - NLM
STAT- MEDLINE
DCOM- 19970204
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 15
IP  - 1
DP  - 1996 Oct
TI  - Development and validation of a reversed-phase liquid chromatographic method for 
      analysis of aspirin and warfarin in a combination tablet formulation.
PG  - 73-82
AB  - A stability-indicating liquid chromatographic method for the simultaneous 
      analysis of aspirin and warfarin in warfarin sodium/aspirin combination (DuP 647) 
      tablets has been developed and validated. This paper presents linearity, 
      accuracy, precision, robustness, recovery, limits of detection and quantitation, 
      and cross-validation data. The method has been shown to be specific and 
      stability-indicating, and to give results comparable to existing methods for the 
      individual components. Solution stability has been optimized for routine 
      analysis.
FAU - Montgomery, E R
AU  - Montgomery ER
AD  - DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE 
      19880-0353, USA.
FAU - Taylor, S
AU  - Taylor S
FAU - Segretario, J
AU  - Segretario J
FAU - Engler, E
AU  - Engler E
FAU - Sebastian, D
AU  - Sebastian D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Drug Combinations)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis
MH  - Anticoagulants/*analysis
MH  - Aspirin/analogs & derivatives/*analysis
MH  - Chromatography, Liquid/*methods
MH  - Drug Combinations
MH  - Drug Stability
MH  - Reproducibility of Results
MH  - Structure-Activity Relationship
MH  - Warfarin/analogs & derivatives/*analysis
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - 0731-7085(96)01813-4 [pii]
AID - 10.1016/0731-7085(96)01813-4 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1996 Oct;15(1):73-82. doi: 10.1016/0731-7085(96)01813-4.

PMID- 2257796
OWN - NLM
STAT- MEDLINE
DCOM- 19910131
LR  - 20131121
IS  - 0012-1029 (Print)
IS  - 0012-1029 (Linking)
VI  - 45
IP  - 1
DP  - 1990 Jan
TI  - [The efficacy of paracetamol (Tylenol) and acetyl salicylic acid (Aspirin) in 
      treating postoperative pain].
PG  - 23-6
AB  - In a randomized, double-center, double-blind, parallel group study the analgesic 
      effect of a single dose of paracetamol (1000 mg) and acetyl salicylic acid (1000 
      mg) was compared with placebo in patients with moderate to severe postoperative 
      pain following the surgical removal of a wisdom tooth. The most important finding 
      was the statistically significantly shorter period until the onset of the action 
      of paracetamol as against acetyl salicylic acid.
FAU - Lehnert, S
AU  - Lehnert S
AD  - Poliklinik für Chirurgische Zahn-, Mund- und Kieferheilkunde der Universität 
      Bonn.
FAU - Reuther, J
AU  - Reuther J
FAU - Wahl, G
AU  - Wahl G
FAU - Barthel, K
AU  - Barthel K
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Wirksamkeit von Paracetamol (Tylenol) und Acetylsalizylsäure (Aspirin) bei 
      postoperativen Schmerzen.
PL  - Germany
TA  - Dtsch Zahnarztl Z
JT  - Deutsche zahnarztliche Zeitschrift
JID - 2984745R
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
MH  - Acetaminophen/pharmacology/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Molar, Third/surgery
MH  - Pain, Postoperative/*drug therapy
MH  - Tooth Extraction
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - Dtsch Zahnarztl Z. 1990 Jan;45(1):23-6.

PMID- 30302763
OWN - NLM
STAT- MEDLINE
DCOM- 20190325
LR  - 20190325
IS  - 1365-2885 (Electronic)
IS  - 0140-7783 (Linking)
VI  - 42
IP  - 2
DP  - 2019 Mar
TI  - Investigation into the causes of aspirin resistance in healthy dogs.
PG  - 160-170
LID - 10.1111/jvp.12725 [doi]
AB  - Antiplatelet effects of acetylsalicylic acid (ASA, aspirin) may be poor in some 
      individuals. Additionally, no method exists for predicting poor ASA response 
      (resistance) in individual dogs. This study's main objective was to determine 
      whether poor ASA response results from pharmacodynamic or pharmacokinetic causes. 
      ASA concentrations causing 50% inhibition of platelet aggregation (in vitro IC50) 
      were determined using whole blood collected from 21 drug-free healthy dogs to 
      evaluate intrinsic sensitivity of platelets to ASA. Dogs were then administered 
      ASA at 4 mg/kg once orally. Percent decrease in platelet aggregation from 
      baseline, and plasma ASA and salicylic acid (SA) concentrations (expressed as AUC 
      values) were measured for up to 3 hr. By 3 hr, 13/21 (62%) dogs showed >50% 
      aggregation inhibition, while 8/21 (38%) dogs showed <50% inhibition. Aggregation 
      inhibition values were negatively correlated with in vitro IC50 values 
      (Rs = -0.49; p = 0.028) and positively correlated with ASA concentrations 
      (Rs = 0.48; p = 0.03). Furthermore, ASA concentrations were strongly negatively 
      correlated (Rs = -0.88; p < 0.001) with SA/ASA concentration ratios, an index of 
      ASA metabolism to SA by esterase enzymes. Multiple linear regression analysis 
      indicated that 59% (p < 0.001) of interindividual variability in aggregation 
      inhibition was explained by in vitro IC50 values (29% of variability) and ASA 
      concentrations (29% of variability). Consequently, poor in vivo ASA response in 
      these dogs resulted from both pharmacodynamic (decreased platelet sensitivity) 
      and pharmacokinetic (lower ASA concentrations) causes. Lower ASA concentrations 
      may be explained by reduced bioavailability associated with higher esterase 
      activities.
CI  - © 2018 John Wiley & Sons Ltd.
FAU - Haines, Jillian M
AU  - Haines JM
AUID- ORCID: 0000-0002-8066-838X
AD  - Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical 
      Sciences, College of Veterinary Medicine, Washington State University, Pullman, 
      Washington.
FAU - Lee, Pamela M
AU  - Lee PM
AUID- ORCID: 0000-0001-6003-0496
AD  - Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical 
      Sciences, College of Veterinary Medicine, Washington State University, Pullman, 
      Washington.
FAU - Hegedus, Rachel M
AU  - Hegedus RM
AD  - Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical 
      Sciences, College of Veterinary Medicine, Washington State University, Pullman, 
      Washington.
FAU - Hwang, Julianne K
AU  - Hwang JK
AD  - Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical 
      Sciences, College of Veterinary Medicine, Washington State University, Pullman, 
      Washington.
FAU - Court, Michael H
AU  - Court MH
AD  - Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical 
      Sciences, College of Veterinary Medicine, Washington State University, Pullman, 
      Washington.
LA  - eng
GR  - Washington State University College of Veterinary Medicine Intramural Grant/
PT  - Journal Article
DEP - 20181009
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/blood/pharmacokinetics/*pharmacology
MH  - Chromatography, High Pressure Liquid/veterinary
MH  - Dogs/blood/*metabolism
MH  - Drug Resistance
MH  - Female
MH  - Inhibitory Concentration 50
MH  - Male
MH  - Mass Spectrometry/veterinary
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/pharmacokinetics/*pharmacology
OTO - NOTNLM
OT  - aggregation
OT  - aspirin
OT  - fluoride
OT  - platelet
OT  - thrombosis
EDAT- 2018/10/12 06:00
MHDA- 2019/03/26 06:00
CRDT- 2018/10/11 06:00
PHST- 2018/03/06 00:00 [received]
PHST- 2018/09/13 00:00 [revised]
PHST- 2018/09/13 00:00 [accepted]
PHST- 2018/10/12 06:00 [pubmed]
PHST- 2019/03/26 06:00 [medline]
PHST- 2018/10/11 06:00 [entrez]
AID - 10.1111/jvp.12725 [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 2019 Mar;42(2):160-170. doi: 10.1111/jvp.12725. Epub 2018 
      Oct 9.

PMID- 22508698
OWN - NLM
STAT- MEDLINE
DCOM- 20130212
LR  - 20150330
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Linking)
VI  - 9
IP  - 4
DP  - 2012 Oct
TI  - Primary and secondary prevention of cardiovascular disease in diabetes with 
      aspirin.
PG  - 245-55
AB  - Diabetes is associated with an increased cardiovascular risk. The role for 
      aspirin in diabetes is of high clinical interest. Guidelines recommend that 
      primary prevention of cardiovascular disease (CVD) in diabetes with aspirin 
      should be based on the individual risk for CVD. New mechanistic studies suggest 
      that enhanced platelet turnover may partly contribute to the fact the primary 
      prevention studies found unequivocal results in diabetes. There is initial 
      evidence that a potential future modification of dosages in diabetes may 
      counteract the enhancement in platelet turnover in diabetes. The use of aspirin 
      in diabetic patients for secondary prevention of CVD is supported by key 
      evidence. The aim of the review is to present recent studies on aspirin for 
      prevention of CVD in diabetes and to highlight its role also in view of new 
      mechanistic and clinical studies with aspirin. Novel aspects of aspirin, e.g. its 
      potential role for the prevention of cancer, are also presented.
FAU - Schnell, Oliver
AU  - Schnell O
AD  - Diabetes Research Group, Helmholtz Centre Munich, Neuherberg, Germany. 
      oliver.schnell@lrz.uni-muenchen.de
FAU - Erbach, Michael
AU  - Erbach M
FAU - Hummel, Michael
AU  - Hummel M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120416
PL  - England
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research
JID - 101234011
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Diab Vasc Dis Res. 2012 Oct;9(4):243-4. PMID: 22942227
MH  - Animals
MH  - Anticarcinogenic Agents/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/blood/*prevention & control
MH  - Diabetes Complications/blood/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - *Primary Prevention
MH  - *Secondary Prevention
MH  - Treatment Outcome
EDAT- 2012/04/18 06:00
MHDA- 2013/02/13 06:00
CRDT- 2012/04/18 06:00
PHST- 2012/04/18 06:00 [entrez]
PHST- 2012/04/18 06:00 [pubmed]
PHST- 2013/02/13 06:00 [medline]
AID - 1479164112441486 [pii]
AID - 10.1177/1479164112441486 [doi]
PST - ppublish
SO  - Diab Vasc Dis Res. 2012 Oct;9(4):245-55. doi: 10.1177/1479164112441486. Epub 2012 
      Apr 16.

PMID- 37187127
OWN - NLM
STAT- MEDLINE
DCOM- 20230616
LR  - 20230706
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 120
DP  - 2023 Jul
TI  - Aspirin ameliorates atherosclerotic immuno-inflammation through regulating the 
      Treg/Th17 axis and CD39-CD73 adenosine signaling via remodeling the gut 
      microbiota in ApoE(-/-) mice.
PG  - 110296
LID - S1567-5769(23)00619-7 [pii]
LID - 10.1016/j.intimp.2023.110296 [doi]
AB  - The gut microbiome has been implicated in the development of cardiovascular 
      disease (CVD) and atherosclerosis (AS), a chronic inflammatory condition. Aspirin 
      may improve the immuno-inflammatory status in AS by regulating microbiota 
      dysbiosis. However, the potential role of aspirin in modulating gut microbiota 
      and microbial-derived metabolites remains less explored. In this study, we 
      investigated the effect of aspirin treatment on AS progression by modulating gut 
      microbiota and microbial-derived metabolites in apolipoprotein E-deficient 
      (ApoE(-/-)) mice. We analyzed the fecal bacterial microbiome and targeted 
      metabolites, including short-chain fatty acids (SCFAs) and bile acids (BAs). The 
      immuno-inflammatory status of AS was evaluated by analyzing regulatory T cells 
      (Tregs), Th17 cells, and the CD39-CD73 adenosine signaling pathway involved in 
      purinergic signaling. Our results indicated that aspirin altered gut microbiota, 
      leading to an increase in the phylum Bacteroidetes and a decrease in the 
      Firmicutes to Bacteriodetes (F/B) ratio. Aspirin treatment also increased levels 
      of targeted SCFA metabolites, such as propionic acid, valeric acid, isovaleric 
      acid, and isobutyric acid. Furthermore, aspirin impacted BAs by reducing the 
      level of harmful deoxycholic acid (DCA) and increasing the levels of beneficial 
      isoalloLCA and isoLCA. These changes were accompanied by a rebalancing of the 
      ratio of Tregs to Th17 cells and an increase in the expression of 
      ectonucleotidases CD39 and CD73, thereby ameliorating inflammation. These 
      findings suggest that aspirin has an athero-protective effect with an improved 
      immuno-inflammatory profile, partially attributed to its manipulation of the gut 
      microbiota.
CI  - Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Bai, Zhixia
AU  - Bai Z
AD  - Clinical Medical College, Ningxia Medical University, Yinchuan, Ningxia, China; 
      Heart Centre & Department of Cardiovascular Diseases, General Hospital of Ningxia 
      Medical University, Yinchuan, Ningxia, China.
FAU - Liu, Yajuan
AU  - Liu Y
AD  - Clinical Medical College, Ningxia Medical University, Yinchuan, Ningxia, China; 
      Heart Centre & Department of Cardiovascular Diseases, General Hospital of Ningxia 
      Medical University, Yinchuan, Ningxia, China.
FAU - Zhao, Yang
AU  - Zhao Y
AD  - Department of Surgical Oncology II, General Hospital of Ningxia Medical 
      University, Yinchuan, Ningxia, China.
FAU - Yan, Ru
AU  - Yan R
AD  - Heart Centre & Department of Cardiovascular Diseases, General Hospital of Ningxia 
      Medical University, Yinchuan, Ningxia, China.
FAU - Yang, Libo
AU  - Yang L
AD  - Heart Centre & Department of Cardiovascular Diseases, General Hospital of Ningxia 
      Medical University, Yinchuan, Ningxia, China.
FAU - Ma, Huiyan
AU  - Ma H
AD  - Clinical Medical College, Ningxia Medical University, Yinchuan, Ningxia, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Heart Centre & Department of Cardiovascular Diseases, General Hospital of Ningxia 
      Medical University, Yinchuan, Ningxia, China.
FAU - Wang, Ting
AU  - Wang T
AD  - School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, 
      China.
FAU - Li, Yiwei
AU  - Li Y
AD  - School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, 
      China.
FAU - Zhang, Guoshan
AU  - Zhang G
AD  - Heart Centre & Department of Cardiovascular Diseases, General Hospital of Ningxia 
      Medical University, Yinchuan, Ningxia, China.
FAU - Zhang, Xiaoxia
AU  - Zhang X
AD  - College of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, 
      Ningxia, China. Electronic address: zxx1216@163.com.
FAU - Jia, Shaobin
AU  - Jia S
AD  - Heart Centre & Department of Cardiovascular Diseases, General Hospital of Ningxia 
      Medical University, Yinchuan, Ningxia, China. Electronic address: jsbxn@163.com.
FAU - Wang, Hao
AU  - Wang H
AD  - School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, 
      China. Electronic address: wanghaograduate@126.com.
LA  - eng
PT  - Journal Article
DEP - 20230513
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - R16CO5Y76E (Aspirin)
RN  - K72T3FS567 (Adenosine)
RN  - 0 (Apolipoproteins E)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Gastrointestinal Microbiome
MH  - Aspirin/pharmacology/therapeutic use
MH  - Th17 Cells
MH  - Adenosine
MH  - T-Lymphocytes, Regulatory
MH  - *Atherosclerosis/drug therapy
MH  - Inflammation/drug therapy
MH  - Apolipoproteins E/genetics
MH  - Signal Transduction
OTO - NOTNLM
OT  - Aspirin
OT  - Atherosclerosis
OT  - CD39-CD73 adenosine signaling
OT  - Gut microbiota
OT  - Inflammation
OT  - Regulatory T cells
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/05/16 01:09
MHDA- 2023/06/16 06:42
CRDT- 2023/05/15 18:08
PHST- 2023/02/27 00:00 [received]
PHST- 2023/04/28 00:00 [revised]
PHST- 2023/05/04 00:00 [accepted]
PHST- 2023/06/16 06:42 [medline]
PHST- 2023/05/16 01:09 [pubmed]
PHST- 2023/05/15 18:08 [entrez]
AID - S1567-5769(23)00619-7 [pii]
AID - 10.1016/j.intimp.2023.110296 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2023 Jul;120:110296. doi: 10.1016/j.intimp.2023.110296. Epub 
      2023 May 13.

PMID- 14691786
OWN - NLM
STAT- MEDLINE
DCOM- 20040423
LR  - 20191108
IS  - 1090-3127 (Print)
IS  - 1090-3127 (Linking)
VI  - 8
IP  - 1
DP  - 2004 Jan-Mar
TI  - The effect of simple interventions on paramedic aspirin administration rates.
PG  - 41-5
AB  - OBJECTIVE: To determine the baseline rate of aspirin administration by paramedics 
      and to assess the effect of two interventions (protocol change and brief 
      educational intervention) on that rate. METHODS: The advanced life support 
      transport provider's clinical database was retrospectively queried to identify 
      calls involving adult patients with chest pain or paramedic impression of 
      suspected cardiac event (possible acute coronary syndrome [ACS]). The study 
      includes data from January 1, 1999, to June 30, 2002, which was divided into 
      three distinct periods. Period 1 was the baseline, period 2 was after the 
      protocol change intervention, and period 3 was after the brief educational 
      intervention. The chest pain protocol indicates patients with chest pain should 
      be treated with aspirin. RESULTS: During period 1, 548 of 3,635 (15.1%) patients 
      with possible ACS received aspirin. During period 2, 1,941 of 7,236 (26.8%) 
      patients with possible ACS received aspirin (chi(2) p<0.0001; odds ratio 
      [OR]=2.06; 95% confidence interval [CI]=1.86-2.29). During period 3, 749 of 2,026 
      (37%) patients with possible ACS received aspirin (chi(2) p<0.0001; OR=1.60; 95% 
      CI=1.44-1.78). Comparing period 1 with period 3, after both interventions, there 
      was a 22% absolute improvement in aspirin administration rates (chi(2) p<0.0001; 
      OR=3.30; 95% CI=2.91-3.76). CONCLUSION: Aspirin is underutilized in treating 
      patients with suspected ACS. Two brief interventions can lead to modest increases 
      in aspirin administration rates. Even after these interventions, aspirin 
      administration rates remain low.
FAU - Snider, Jason B
AU  - Snider JB
AD  - American Medical Response Northwest, Portland, Oregon 97214, USA. 
      jason_snider@amr-ems.com
FAU - Moreno, Raymond
AU  - Moreno R
FAU - Fuller, David J
AU  - Fuller DJ
FAU - Schmidt, Terri A
AU  - Schmidt TA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Prehosp Emerg Care
JT  - Prehospital emergency care
JID - 9703530
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Chest Pain/*drug therapy
MH  - Clinical Protocols
MH  - Emergency Medical Technicians/*education
MH  - Female
MH  - Health Services Research
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Oregon
EDAT- 2003/12/24 05:00
MHDA- 2004/04/24 05:00
CRDT- 2003/12/24 05:00
PHST- 2003/12/24 05:00 [pubmed]
PHST- 2004/04/24 05:00 [medline]
PHST- 2003/12/24 05:00 [entrez]
AID - S1090312703002211 [pii]
AID - 10.1080/312703002211 [doi]
PST - ppublish
SO  - Prehosp Emerg Care. 2004 Jan-Mar;8(1):41-5. doi: 10.1080/312703002211.

PMID- 3817057
OWN - NLM
STAT- MEDLINE
DCOM- 19870422
LR  - 20131121
IS  - 0106-4339 (Print)
IS  - 0106-4339 (Linking)
VI  - 69
IP  - 4
DP  - 1986 Oct
TI  - Clinical efficacy of aspirin in "desensitised" aspirin-sensitive asthmatics.
PG  - 219-25
AB  - The effect of daily aspirin (ASA) administration after "desensitisation" was 
      studied in 16 aspirin-sensitive asthmatics. Fourteen patients completed the 
      trial; 12 of them also had perennial rhinitis and eight in addition suffered from 
      chronic headache. During 4 weeks of daily treatment with 600 mg of ASA a marked 
      reduction of the nasal symptoms score was noticed in 8/12 patients and head pain 
      score was significantly decreased in 6/8 patients when compared with the 4-week 
      non-ASA period. Daily aspirin resulted in decreases in both the mean asthma score 
      and in daily beta-agonist usage in 7/14 patients, and 10/13 patients showed a 
      decrease in bronchial responsiveness to inhaled histamine (geometric mean of 
      provocative concentration of histamine 1.8 and 5.8 mg/ml, respectively. In four 
      patients we noticed untoward epigastric symptoms. A decrease in thrombocyte 
      counts was observed during ASA treatment. Our study suggests that daily aspirin 
      administration after "desensitisation" may be helpful in the management of some 
      ASA-sensitive asthmatics.
FAU - Kowalski, M L
AU  - Kowalski ML
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
FAU - Szmidt, M
AU  - Szmidt M
FAU - Rozniecki, J
AU  - Rozniecki J
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Eur J Respir Dis
JT  - European journal of respiratory diseases
JID - 8006891
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/immunology/*therapeutic use
MH  - Asthma/drug therapy/*immunology
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1986/10/01 00:00
MHDA- 1986/10/01 00:01
CRDT- 1986/10/01 00:00
PHST- 1986/10/01 00:00 [pubmed]
PHST- 1986/10/01 00:01 [medline]
PHST- 1986/10/01 00:00 [entrez]
PST - ppublish
SO  - Eur J Respir Dis. 1986 Oct;69(4):219-25.

PMID- 18603541
OWN - NLM
STAT- MEDLINE
DCOM- 20100309
LR  - 20131121
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 15
IP  - 5
DP  - 2009 Oct
TI  - Prothrombotic and hemorrhagic effects of aspirin.
PG  - 523-8
LID - 10.1177/1076029608319945 [doi]
AB  - Aspirin remains the most widely used drug for prevention of vascular events. 
      Recent observational epidemiological evidence has raised the concern that aspirin 
      withdrawal for treatment noncompliance, surgery, or side effects can carry an 
      increased thrombotic risk. The delay to the thrombotic event was between 7 to 30 
      days in most reports and most frequently 7 to 10 days. The mechanism underlying 
      this effect remains poorly understood. Using an in vivo model of laser-induced 
      thrombosis, aspirin injected in 1 single dose of 100 mg/kg body weight has also 
      shown a prothrombotic activity in the rat 8 to 10 days after injection in the 
      normal rat. The hypothesis was made that minimal concentrations of aspirin or 
      ultra-low dose aspirin (ULDA) could induce this effect. ULDA showed prothrombotic 
      properties in the same model of induced thrombosis that were very similar to 
      those described after aspirin withdrawal, but the effect was observed only 1 hour 
      after aspirin administration. This prothrombotic effect of ULDA is very similar 
      to the effect observed after COX 2 selective inhibition with NS 398. The 
      administration of both the selective COX 2 inhibitor and ULDA did not produce 
      further changes. In conclusion, the prothrombotic effects described in recent 
      observational studies are likely produced by a direct effect of aspirin, whose 
      putative mechanism involving COX 2 inhibition remains poorly understood.
FAU - Aguejouf, Omar
AU  - Aguejouf O
AD  - Laboratoire d'Hématologie Université Victor Segalen Bordeaux 2, Bordeaux, France.
FAU - Eizayaga, Francisco
AU  - Eizayaga F
FAU - Desplat, Vanessa
AU  - Desplat V
FAU - Belon, Philippe
AU  - Belon P
FAU - Doutremepuich, Christian
AU  - Doutremepuich C
LA  - eng
PT  - Journal Article
DEP - 20080703
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Hemorrhage/*chemically induced/drug therapy
MH  - Rats
MH  - Substance Withdrawal Syndrome/etiology
MH  - Thrombosis/*chemically induced/drug therapy
EDAT- 2008/07/08 09:00
MHDA- 2010/03/10 06:00
CRDT- 2008/07/08 09:00
PHST- 2008/07/08 09:00 [pubmed]
PHST- 2010/03/10 06:00 [medline]
PHST- 2008/07/08 09:00 [entrez]
AID - 1076029608319945 [pii]
AID - 10.1177/1076029608319945 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2009 Oct;15(5):523-8. doi: 10.1177/1076029608319945. 
      Epub 2008 Jul 3.

PMID- 7415074
OWN - NLM
STAT- MEDLINE
DCOM- 19801125
LR  - 20190819
IS  - 0042-9007 (Print)
IS  - 0042-9007 (Linking)
VI  - 38
IP  - 5
DP  - 1980
TI  - Presence of aspirin in blood units.
PG  - 284-7
AB  - 2,655 blood units collected from healthy voluntary donors selected according to 
      the criteria of the International Society of Blood Transfusion were tested for 
      the presence of aspirin. This drug was found in 6% of the samples at 
      concentrations ranging from 10 to 200 microgram/ml. The clinical implications of 
      these findings are discussed. We also report a case of allergic reaction which 
      could probably be related to the transfusion of blood containing aspirin.
FAU - Sharon, R
AU  - Sharon R
FAU - Kidroni, G
AU  - Kidroni G
FAU - Michel, J
AU  - Michel J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Vox Sang
JT  - Vox sanguinis
JID - 0413606
RN  - 0 (Allergens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Allergens/immunology
MH  - Aspirin/*blood/immunology
MH  - Blood Banks/standards
MH  - Blood Donors
MH  - Blood Specimen Collection/standards
MH  - Blood Transfusion
MH  - Female
MH  - Humans
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1111/j.1423-0410.1980.tb02368.x [doi]
PST - ppublish
SO  - Vox Sang. 1980;38(5):284-7. doi: 10.1111/j.1423-0410.1980.tb02368.x.

PMID- 25469781
OWN - NLM
STAT- MEDLINE
DCOM- 20151103
LR  - 20150216
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Linking)
VI  - 116
IP  - 3
DP  - 2015 Mar
TI  - Enteric coating can lead to reduced antiplatelet effect of low-dose 
      acetylsalicylic acid.
PG  - 212-5
LID - 10.1111/bcpt.12362 [doi]
AB  - Low-dose acetylsalicylic acid (ASA) is widely used as antithrombotic prophylaxis. 
      Enteric-coated ASA has been developed to decrease the risk of gastrointestinal 
      side effects. The consequences of enteric coating on pharmacokinetics and 
      antiplatelet effect of ASA have not systematically been assessed. This MiniReview 
      demonstrates that data from clinical trials indicate that enteric coating can 
      reduce the antiplatelet effect of ASA compared to plain ASA. This is possibly due 
      to decreased bioavailability of ASA caused by prolonged solvation and absorption 
      of the enteric-coated formulations. Therefore, low-dose enteric-coated ASA might 
      not be bioequivalent to plain ASA, entailing the risk of insufficient 
      cardiovascular prophylaxis.
CI  - © 2014 Nordic Association for the Publication of BCPT (former Nordic 
      Pharmacological Society).
FAU - Haastrup, Peter Fentz
AU  - Haastrup PF
AD  - Research Unit of General Practice, Department of Public Health, University of 
      Southern Denmark, Odense C, Denmark.
FAU - Grønlykke, Thor
AU  - Grønlykke T
FAU - Jarbøl, Dorte Ejg
AU  - Jarbøl DE
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141223
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Biological Availability
MH  - Blood Platelets/drug effects/metabolism
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/pharmacokinetics/*pharmacology
MH  - Tablets, Enteric-Coated
EDAT- 2014/12/04 06:00
MHDA- 2015/11/04 06:00
CRDT- 2014/12/04 06:00
PHST- 2014/09/30 00:00 [received]
PHST- 2014/11/25 00:00 [accepted]
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2015/11/04 06:00 [medline]
AID - 10.1111/bcpt.12362 [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2015 Mar;116(3):212-5. doi: 10.1111/bcpt.12362. 
      Epub 2014 Dec 23.

PMID- 7293702
OWN - NLM
STAT- MEDLINE
DCOM- 19811222
LR  - 20190814
IS  - 0001-5172 (Print)
IS  - 0001-5172 (Linking)
VI  - 25
IP  - 1
DP  - 1981 Feb
TI  - Bioavailability of rectal aspirin in neurosurgical patients.
PG  - 25-6
AB  - Serum salicylate levels were determined fluorimetrically in 12 neurosurgical 
      patients after rectal and oral administration of 1.0 g aspirin. There was no 
      significant difference in the AUC-value between the two routes of administration, 
      but a slower rate of absorption with no clear peak effect was found after rectal 
      administration. Rectal aspirin is useful in clinical situations in which 
      mediation is difficult by the oral route, e.g. after neurosurgical and open-heart 
      surgical interventions.
FAU - Kanto, J
AU  - Kanto J
FAU - Klossner, J
AU  - Klossner J
FAU - Mäntylä, R
AU  - Mäntylä R
FAU - Yrjänä, T
AU  - Yrjänä T
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Anaesthesiol Scand
JT  - Acta anaesthesiologica Scandinavica
JID - 0370270
RN  - 0 (Suppositories)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/blood
MH  - Biological Availability
MH  - Brain Diseases/surgery
MH  - Female
MH  - Fever/prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/prevention & control
MH  - Suppositories
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
AID - 10.1111/j.1399-6576.1981.tb01600.x [doi]
PST - ppublish
SO  - Acta Anaesthesiol Scand. 1981 Feb;25(1):25-6. doi: 
      10.1111/j.1399-6576.1981.tb01600.x.

PMID- 14581886
OWN - NLM
STAT- MEDLINE
DCOM- 20040301
LR  - 20131121
IS  - 0026-4784 (Print)
IS  - 0026-4784 (Linking)
VI  - 55
IP  - 5
DP  - 2003 Oct
TI  - Recurrent spontaneous early pregnancy loss and low dose aspirin.
PG  - 441-9
AB  - Miscarriage is the most common complication of pregnancy, occurring in 10-15% of 
      pregnant women. Accurate figures on prevalence are not available but it has been 
      estimated that 2-5% of women have 3 or more miscarriages. The lack of 
      methodological rigour in controlled trials of treatment efficacy in women with 
      recurrent miscarriage makes it difficult to estimate the efficacy of treatment 
      for this condition. To date, there is no evidence of improved outcome with 
      aspirin compared to placebo or no treatment. Furthermore, animal data and limited 
      human data suggest that prenatal use of aspirin may be associated with increased 
      bleeding tendency, congenital malformations and cognitive and behavioural defects 
      in the offspring. Seen and considered the lack of efficacy of low-dose aspirin 
      and the potential for harm to the female and her offspring, the practice of 
      recommending aspirin to women with recurrent miscarriage should be discontinued.
FAU - Daya, S
AU  - Daya S
AD  - Department of Obstetrics and Gynaecology, McMaster University, Hamilton, Ontario, 
      Canada. dayas@mcmaster.ca
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Minerva Ginecol
JT  - Minerva ginecologica
JID - 0400731
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/etiology/*prevention & control
MH  - Antiphospholipid Syndrome/complications
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Placenta/physiology
MH  - Risk Factors
RF  - 47
EDAT- 2003/10/29 05:00
MHDA- 2004/03/03 05:00
CRDT- 2003/10/29 05:00
PHST- 2003/10/29 05:00 [pubmed]
PHST- 2004/03/03 05:00 [medline]
PHST- 2003/10/29 05:00 [entrez]
PST - ppublish
SO  - Minerva Ginecol. 2003 Oct;55(5):441-9.

PMID- 2742967
OWN - NLM
STAT- MEDLINE
DCOM- 19890822
LR  - 20151119
IS  - 0067-8856 (Print)
IS  - 0067-8856 (Linking)
VI  - 25
DP  - 1989
TI  - Sustained delivery of aspirin by means of ALCAP ceramics.
PG  - 203-11
AB  - Research conducted at the University of Dayton has shown that 
      alumino-calcium-phosphorous (ALCAP) ceramics impregnated with polylactic acid 
      (PLA) are capable of sustained delivery of polypeptides and steroids. Recent 
      experiments conducted at the university have shown that ALCAP ceramics are 
      capable of delivering aspirin in vitro. Based on this work, ALCAP ceramics 
      containing 25 mg, 50 mg, or 75, mg aspirin were implanted subcutaneously in 
      random bred albino male rats. There were eight rats in each dosage group. Six 
      rats were implanted with empty ceramics (sham-operated). Eight nonimplanted rats 
      served as controls. Levels of analgesia among the groups were determined using a 
      pressure analgesia meter. The data collected showed that aspirin delivered by 
      ALCAP was capable of producing analgesia in rats as early as 24 hours after 
      surgery. The level of analgesia increased over the first seven days before 
      declining gradually over a period of one month. Levels of analgesia were directly 
      related to the amount of aspirin stored initially within the ceramic.
FAU - Snow, K R
AU  - Snow KR
FAU - Muzina, D J
AU  - Muzina DJ
FAU - Bajpai, P K
AU  - Bajpai PK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biomed Sci Instrum
JT  - Biomedical sciences instrumentation
JID - 0140524
RN  - 0 (Capsules)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Implants)
RN  - 0 (Oxides)
RN  - 27YLU75U4W (Phosphorus)
RN  - CPD4NFA903 (Aluminum)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - *Aluminum
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - *Calcium
MH  - Capsules
MH  - *Ceramics
MH  - Delayed-Action Preparations
MH  - *Drug Implants
MH  - Male
MH  - Nociceptors/*drug effects
MH  - Oxides
MH  - *Phosphorus
MH  - Rats
MH  - Sensory Thresholds/drug effects
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Biomed Sci Instrum. 1989;25:203-11.

PMID- 4049312
OWN - NLM
STAT- MEDLINE
DCOM- 19851028
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 53
IP  - 3
DP  - 1985 Jun 24
TI  - Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for 
      a solution of the "aspirin dilemma".
PG  - 415-8
AB  - Six healthy male volunteers received aspirin (ASA) in a compressed (320 mg) and 
      an enteric-coated (800 mg) formulation as single oral doses ten days apart. Ten 
      plasma samples were obtained from each volunteer between 5 and 120 min after 
      compressed ASA, and seven between 10 and 240 min after enteric-coated ASA. ASA 
      was undetectable (less than 100 ng/ml) in plasma from three subjects receiving 
      compressed ASA and two receiving the enteric-coated preparation. Plasma levels 
      and kinetic parameters of salicylate were the same in subjects with undetectable 
      and detectable ASA plasma levels. More than 98% inhibition of pre-drug serum TXB2 
      was noted in all samples collected one and four hours after either ASA 
      preparation. TXB2 generation recovered on average by 3.5% at 24 hr with both 
      preparations. Thus inhibition of platelet TXB2 generation occurred independently 
      of the amount of ASA reaching the peripheral circulation. If this is due to 
      inhibition of platelet function in the enterohepatic circulation followed by 
      extensive first-pass deacetylation of ASA, vascular PGI2 synthesis could be 
      spared. A better knowledge of the kinetic parameters of ASA for each of the 
      formulations used in thrombosis prevention trials might help in solving the 
      "aspirin dilemma".
FAU - Cerletti, C
AU  - Cerletti C
FAU - Latini, R
AU  - Latini R
FAU - Del Maschio, A
AU  - Del Maschio A
FAU - Galletti, F
AU  - Galletti F
FAU - Dejana, E
AU  - Dejana E
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Capsules)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 54397-85-2 (Thromboxane B2)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*blood/pharmacology
MH  - Blood Platelets/drug effects/*metabolism
MH  - Capsules
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Tablets
MH  - Thromboxane B2/*blood
EDAT- 1985/06/24 00:00
MHDA- 1985/06/24 00:01
CRDT- 1985/06/24 00:00
PHST- 1985/06/24 00:00 [pubmed]
PHST- 1985/06/24 00:01 [medline]
PHST- 1985/06/24 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1985 Jun 24;53(3):415-8.

PMID- 12598144
OWN - NLM
STAT- MEDLINE
DCOM- 20030304
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 361
IP  - 9357
DP  - 2003 Feb 15
TI  - Effect of ibuprofen on cardioprotective effect of aspirin.
PG  - 573-4
AB  - Treatment with ibuprofen might limit the cardioprotective effects of aspirin. We 
      aimed to assess whether patients with known cardiovascular disease who take 
      low-dose aspirin and ibuprofen have increased risk of cardiovascular mortality. 
      We studied 7107 patients who were discharged after first admission for 
      cardiovascular disease between April, 1989, and April, 1997, and who were 
      prescribed low-dose aspirin (<325 mg/day) and survived for at least 1 month. 
      Compared with those who used aspirin alone, patients taking aspirin plus 
      ibuprofen had an increased risk of all-cause mortality (adjusted hazard ratio 
      1.93, 95% CI 1.30-2.87, p=0.0011) and cardiovascular mortality (1.73, 1.05-2.84, 
      p=0.0305). Our finding lends support to the hypothesis that ibuprofen may 
      interact with the cardioprotective effects of aspirin, at least in patients with 
      established cardiovascular disease.
FAU - MacDonald, T M
AU  - MacDonald TM
AD  - Medicines Monitoring Unit, Department of Clinical Pharmacology and Therapeutics, 
      Ninewells Hospital and Medical School, DD1 9SY, Dundee, UK. 
      t.m.macdonald@dundee.ac.uk
FAU - Wei, L
AU  - Wei L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
CIN - Lancet. 2003 Feb 15;361(9357):542-4. PMID: 12598136
CIN - Lancet. 2003 May 3;361(9368):1558-9; author reply 1559. PMID: 12737885
CIN - Lancet. 2003 May 3;361(9368):1559; author reply 1559. PMID: 12737887
CIN - Lancet. 2003 May 3;361(9368):1560; author reply 1561. PMID: 12737889
CIN - Lancet. 2003 May 3;361(9368):1560; author reply 1561. PMID: 12737890
CIN - Lancet. 2003 May 3;361(9368):1560-1; author reply 1561. PMID: 12737891
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/antagonists & inhibitors/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/mortality
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Ibuprofen/*adverse effects
MH  - Male
MH  - Middle Aged
EDAT- 2003/02/25 04:00
MHDA- 2003/03/05 04:00
CRDT- 2003/02/25 04:00
PHST- 2003/02/25 04:00 [pubmed]
PHST- 2003/03/05 04:00 [medline]
PHST- 2003/02/25 04:00 [entrez]
AID - S0140673603125093 [pii]
AID - 10.1016/s0140-6736(03)12509-3 [doi]
PST - ppublish
SO  - Lancet. 2003 Feb 15;361(9357):573-4. doi: 10.1016/s0140-6736(03)12509-3.

PMID- 29463025
OWN - NLM
STAT- MEDLINE
DCOM- 20180813
LR  - 20181207
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 23
IP  - 2
DP  - 2018 Feb 18
TI  - Inhibitory Influence of Panax notoginseng Saponins on Aspirin Hydrolysis in Human 
      Intestinal Caco-2 Cells.
LID - 10.3390/molecules23020455 [doi]
LID - 455
AB  - Herb-drug interactions are important safety concerns in clinical practice. The 
      interactions occur firstly in the intestinal absorption for orally administered 
      drugs. Aspirin and Panax notoginseng saponins (PNS)-based drugs are often 
      combined in China to prevent larger-artery atherosclerosis. Here, we aimed to 
      characterize the aspirin transport across Caco-2 cell monolayers, a model of the 
      intestinal absorption, and further to evaluate the influence of PNS on aspirin 
      hydrolysis and the relating mechanisms. Transcellular transport of aspirin and 
      the influence of PNS were explored using Caco-2 cell monolayers. The protein 
      expression of human carboxylesterase 1 (hCE1) and hCE2 in Caco-2 cells after PNS 
      treatment was analyzed by ELISA, and the mRNA level were determined by qRT-PCR. 
      In the study, Caco-2 cells showed high level of hydrolase activity, and most 
      aspirin was hydrolyzed inside the cells during the transport process. 
      Interestingly, PNS were demonstrated to inhibit the esterase activities 
      responsible for aspirin hydrolysis in Caco-2 cells. PNS could also decrease the 
      protein expression of hCE1 and hCE2, whereas exhibited minor effect on the mRNA 
      expression. These results indicated that oral administration of PNS-based drugs 
      might inhibit the hydrolysis of aspirin during intestinal absorption thus 
      promoting its bioavailability.
FAU - Sun, Zongxi
AU  - Sun Z
AUID- ORCID: 0000-0002-8187-6236
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 
      100029, China. zongxisun@163.com.
FAU - Wu, Yali
AU  - Wu Y
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 
      100029, China. wuyali1993@163.com.
FAU - Yang, Bing
AU  - Yang B
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 
      100029, China. yangbing1028@163.com.
FAU - Zhu, Baochen
AU  - Zhu B
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 
      100029, China. zhaobowua@163.com.
FAU - Hu, Shaonan
AU  - Hu S
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 
      100029, China. hushaonan8980@126.com.
FAU - Lu, Yang
AU  - Lu Y
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 
      100029, China. landocean28@163.com.
FAU - Zhao, Bo
AU  - Zhao B
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 
      100029, China. zbcbock123@sina.com.
FAU - Du, Shouying
AU  - Du S
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 
      100029, China. dushouying@263.net.
LA  - eng
PT  - Journal Article
DEP - 20180218
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Saponins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/antagonists & inhibitors/*chemistry
MH  - Caco-2 Cells
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Hydrolysis/drug effects
MH  - Intestinal Absorption/*drug effects
MH  - Intestines/chemistry/drug effects
MH  - Panax notoginseng/*chemistry
MH  - Saponins/*chemistry/pharmacology
PMC - PMC6016969
OTO - NOTNLM
OT  - Caco-2 cells
OT  - Panax notoginseng saponins
OT  - aspirin
OT  - carboxylesterase
OT  - intestinal absorption
COIS- The authors declare no conflict of interest.
EDAT- 2018/02/22 06:00
MHDA- 2018/08/14 06:00
CRDT- 2018/02/22 06:00
PHST- 2018/02/01 00:00 [received]
PHST- 2018/02/15 00:00 [revised]
PHST- 2018/02/15 00:00 [accepted]
PHST- 2018/02/22 06:00 [entrez]
PHST- 2018/02/22 06:00 [pubmed]
PHST- 2018/08/14 06:00 [medline]
AID - molecules23020455 [pii]
AID - molecules-23-00455 [pii]
AID - 10.3390/molecules23020455 [doi]
PST - epublish
SO  - Molecules. 2018 Feb 18;23(2):455. doi: 10.3390/molecules23020455.

PMID- 7437274
OWN - NLM
STAT- MEDLINE
DCOM- 19810219
LR  - 20190512
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 10 Suppl 2
IP  - Suppl 2
DP  - 1980 Oct
TI  - Comparison of intravenous acetylsalicylic acid and dipyrone in postoperative 
      pain: an interim report.
PG  - 339S-341S
AB  - 1 In 17 gynaecological patients with postoperative pain the analgesic efficacy of 
      intravenous lysine salicylate 1.8 g (corresponding to acetylsalicylic acid (ASA) 
      1.0 g) and dipyrone 1.0 g were compared in a double-blind randomized study. 2 In 
      the ASA group, mean pain relief and pain intensity difference scores reached a 
      maximum 30 min after drug administration and remained at this level for the next 
      90 minutes. 3 In the dipyrone group, these scores reached their peak 60 min after 
      drug administration and seemed to fall off during the next hour. 4 The mean pain 
      relief and intensity difference scores were greater following aspirin than 
      dipyrone. However, firm conclusions cannot be drawn from the results of this 
      small study.
FAU - Blendinger, I
AU  - Blendinger I
FAU - Eberlein, H J
AU  - Eberlein HJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 01704YP3MO (Aminopyrine)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aminopyrine/*analogs & derivatives
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Dipyrone/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Pain, Postoperative/*drug therapy
PMC - PMC1430189
EDAT- 1980/10/01 00:00
MHDA- 1980/10/01 00:01
CRDT- 1980/10/01 00:00
PHST- 1980/10/01 00:00 [pubmed]
PHST- 1980/10/01 00:01 [medline]
PHST- 1980/10/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1980.tb01819.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1980 Oct;10 Suppl 2(Suppl 2):339S-341S. doi: 
      10.1111/j.1365-2125.1980.tb01819.x.

PMID- 32835720
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220308
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 226
IP  - 2S
DP  - 2022 Feb
TI  - Prevention of preeclampsia with aspirin.
PG  - S1108-S1119
LID - S0002-9378(20)30873-5 [pii]
LID - 10.1016/j.ajog.2020.08.045 [doi]
AB  - Preeclampsia is defined as hypertension arising after 20 weeks of gestational age 
      with proteinuria or other signs of end-organ damage and is an important cause of 
      maternal and perinatal morbidity and mortality, particularly when of early onset. 
      Although a significant amount of research has been dedicated in identifying 
      preventive measures for preeclampsia, the incidence of the condition has been 
      relatively unchanged in the last decades. This could be attributed to the fact 
      that the underlying pathophysiology of preeclampsia is not entirely understood. 
      There is increasing evidence suggesting that suboptimal trophoblastic invasion 
      leads to an imbalance of angiogenic and antiangiogenic proteins, ultimately 
      causing widespread inflammation and endothelial damage, increased platelet 
      aggregation, and thrombotic events with placental infarcts. Aspirin at doses 
      below 300 mg selectively and irreversibly inactivates the cyclooxygenase-1 
      enzyme, suppressing the production of prostaglandins and thromboxane and 
      inhibiting inflammation and platelet aggregation. Such an effect has led to the 
      hypothesis that aspirin could be useful for preventing preeclampsia. The first 
      possible link between the use of aspirin and the prevention of preeclampsia was 
      suggested by a case report published in 1978, followed by the first randomized 
      controlled trial published in 1985. Since then, numerous randomized trials have 
      been published, reporting the safety of the use of aspirin in pregnancy and the 
      inconsistent effects of aspirin on the rates of preeclampsia. These 
      inconsistencies, however, can be largely explained by a high degree of 
      heterogeneity regarding the selection of trial participants, baseline risk of the 
      included women, dosage of aspirin, gestational age of prophylaxis initiation, and 
      preeclampsia definition. An individual patient data meta-analysis has indicated a 
      modest 10% reduction in preeclampsia rates with the use of aspirin, but later 
      meta-analyses of aggregate data have revealed a dose-response effect of aspirin 
      on preeclampsia rates, which is maximized when the medication is initiated before 
      16 weeks of gestational age. Recently, the Aspirin for Evidence-Based 
      Preeclampsia Prevention trial has revealed that aspirin at a daily dosage of 150 
      mg, initiated before 16 weeks of gestational age, and given at night to a 
      high-risk population, identified by a combined first trimester screening test, 
      reduces the incidence of preterm preeclampsia by 62%. A secondary analysis of the 
      Aspirin for Evidence-Based Preeclampsia Prevention trial data also indicated a 
      reduction in the length of stay in the neonatal intensive care unit by 68% 
      compared with placebo, mainly because of a reduction in births before 32 weeks of 
      gestational age with preeclampsia. The beneficial effect of aspirin has been 
      found to be similar in subgroups according to different maternal characteristics, 
      except for the presence of chronic hypertension, where no beneficial effect is 
      evident. In addition, the effect size of aspirin has been found to be more 
      pronounced in women with good compliance to treatment. In general, randomized 
      trials are underpowered to investigate the treatment effect of aspirin on the 
      rates of other placental-associated adverse outcomes such as fetal growth 
      restriction and stillbirth. This article summarizes the evidence around aspirin 
      for the prevention of preeclampsia and its complications.
CI  - Copyright © 2020. Published by Elsevier Inc.
FAU - Rolnik, Daniel L
AU  - Rolnik DL
AD  - Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash 
      University, Melbourne, Victoria, Australia.
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
AD  - Fetal Medicine Research Institute, Harris Birthright Centre, King's College 
      Hospital, London, United Kingdom.
FAU - Poon, Liona C
AU  - Poon LC
AD  - Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, 
      Shatin, the Hong Kong Special Administrative Region of the People's Republic of 
      China. Electronic address: liona.poon@cuhk.edu.hk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200821
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Pre-Eclampsia/economics/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications/prevention & control
MH  - Pregnancy, Multiple
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Aspirin for Evidence-Based Preeclampsia Prevention
OT  - Fetal Medicine Foundation
OT  - abruption
OT  - adverse pregnancy outcome
OT  - algorithm
OT  - aspirin
OT  - blood pressure
OT  - competing risk
OT  - fetal growth restriction
OT  - first trimester
OT  - hypertension
OT  - intrauterine growth restriction
OT  - mean arterial pressure
OT  - morbidity
OT  - mortality
OT  - number needed to screen
OT  - number needed to treat
OT  - perinatal
OT  - placental growth factor
OT  - placental insufficiency
OT  - prediction
OT  - preeclampsia
OT  - pregnancy
OT  - pregnancy complications
OT  - prematurity
OT  - preterm
OT  - prevention
OT  - prophylaxis
OT  - pulsatility index
OT  - resistant index
OT  - risk factor
OT  - safety
OT  - stillbirth
OT  - uterine artery
OT  - uterine artery mean pulsatility index
EDAT- 2020/08/25 06:00
MHDA- 2022/03/09 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/06/02 00:00 [received]
PHST- 2020/08/17 00:00 [revised]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - S0002-9378(20)30873-5 [pii]
AID - 10.1016/j.ajog.2020.08.045 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2022 Feb;226(2S):S1108-S1119. doi: 
      10.1016/j.ajog.2020.08.045. Epub 2020 Aug 21.

PMID- 26939106
OWN - NLM
STAT- MEDLINE
DCOM- 20160718
LR  - 20160304
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 141
IP  - 5
DP  - 2016 Mar
TI  - [ASA - from cardiovascular to cancer prevention].
PG  - 347-51
LID - 10.1055/s-0041-107935 [doi]
AB  - Cardiovascular disease and cancer are the leading causes of morbidity and 
      mortality worldwide. Low-dose ASA has been shown to effectively prevent about one 
      fifth of atherothrombotic vascular complications in patients with previous 
      myocardial infarction, peripheral arterial occlusive disease (PAOD), or stroke 2. 
      In secondary prevention, the benefits of antiplatelet therapy substantially 
      exceed its risk 2. By contrast, recommendations for the use of ASA in primary 
      prevention are still a matter of controversy. The aim of this article is to 
      review the current evidence for the efficacy of low-dose ASA in primary and 
      secondary prevention of cardiovascular diseases as well as to discuss its 
      potential additional chemopreventive action.
CI  - © Georg Thieme Verlag KG Stuttgart · New York.
FAU - Sanin, Veronika
AU  - Sanin V
FAU - Pfetsch, Vanessa
AU  - Pfetsch V
FAU - Koenig, Wolfgang
AU  - Koenig W
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Acetylsalicylsäure - von der kardiovaskulären zur Karzinomprävention.
DEP - 20160303
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Carcinoma/*prevention & control
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Sex Factors
EDAT- 2016/03/05 06:00
MHDA- 2016/07/19 06:00
CRDT- 2016/03/04 06:00
PHST- 2016/03/04 06:00 [entrez]
PHST- 2016/03/05 06:00 [pubmed]
PHST- 2016/07/19 06:00 [medline]
AID - 10.1055/s-0041-107935 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2016 Mar;141(5):347-51. doi: 10.1055/s-0041-107935. Epub 
      2016 Mar 3.

PMID- 37071955
OWN - NLM
STAT- MEDLINE
DCOM- 20230516
LR  - 20230517
IS  - 1532-3102 (Electronic)
IS  - 0143-4004 (Linking)
VI  - 137
DP  - 2023 Jun
TI  - Low dose acetyl salicylic acid (LDA) mediates epigenetic changes in preeclampsia 
      placental mesenchymal stem cells similar to cells from healthy pregnancy.
PG  - 49-58
LID - S0143-4004(23)00081-4 [pii]
LID - 10.1016/j.placenta.2023.04.010 [doi]
AB  - INTRODUCTION: Preeclampsia (PE) affects 2-8% of all pregnancies, and is the 
      leading cause of maternal and fetal morbidity and mortality. We reported on 
      pathophysiological changes in placenta mesenchymal stem cells (P-MSCs) in PE. 
      P-MSCs can be isolated from different layers of the placenta at the interface 
      between the fetus and mother. The ability of MSCs from other sources to be immune 
      licensed as immune suppressor cells indicated that P-MSCs could mitigate fetal 
      rejection. Acetylsalicylic acid (aspirin) is indicated for treating PE. Indeed, 
      low-dose aspirin is recommended to prevent PE in high risk patients. METHODS: We 
      conducted robust computational analyses to study changes in gene expression in 
      P-MSCs from PE and healthy term pregnancies as compared with PE-MSCs treated with 
      low dose acetyl salicylic acid (LDA). Confocal microscopy studied phospho-H2AX 
      levels in P-MSCs. RESULTS: We identified changes in >400 genes with LDA, similar 
      to levels of healthy pregnancy. The top canonical pathways that incorporate these 
      genes were linked to DNA repair damage - Basic excision repair (BER), Nucleotide 
      excision repair (NER) and DNA replication. A role for the sumoylation (SUMO) 
      pathway, which could regulate gene expression and protein stabilization was 
      significant although reduced as compared to BER and NER pathways. Labeling for 
      phopho-H2AX indicated no evidence of double strand break in PE P-MSCs. 
      DISCUSSION: The overlapping of key genes within each pathway suggested a major 
      role for LDA in the epigenetic landscape of PE P-MSCs. Overall, this study showed 
      a new insight into how LDA reset the P-MSCs in PE subjects around the DNA.
CI  - Copyright © 2023 Elsevier Ltd. All rights reserved.
FAU - Krishnamoorthy, Kaila
AU  - Krishnamoorthy K
AD  - Dept of Obstetrics, Gynecology and Reproductive Health, D - Maternal Fetal 
      Medicine, Rutgers New Jersey Medical School, Newark, NJ, 07103, USA.
FAU - Sherman, Lauren S
AU  - Sherman LS
AD  - Dept of Medicine - Hematology/Oncology, Rutgers New Jersey Medical School, 
      Newark, NJ, USA; Rutgers School of Graduate Studies at New Jersey Medical School, 
      Newark, NJ, USA.
FAU - Romagano, Matthew P
AU  - Romagano MP
AD  - Dept of Obstetrics, Gynecology and Reproductive Health, D - Maternal Fetal 
      Medicine, Rutgers New Jersey Medical School, Newark, NJ, 07103, USA.
FAU - El Far, Markos
AU  - El Far M
AD  - Dept of Medicine - Hematology/Oncology, Rutgers New Jersey Medical School, 
      Newark, NJ, USA.
FAU - Etchegaray, Jean-Pierre
AU  - Etchegaray JP
AD  - Rutgers University, Dept of Biology, Newark, NJ, USA.
FAU - Williams, Shauna F
AU  - Williams SF
AD  - Dept of Obstetrics, Gynecology and Reproductive Health, D - Maternal Fetal 
      Medicine, Rutgers New Jersey Medical School, Newark, NJ, 07103, USA. Electronic 
      address: williash@njms.rutgers.edu.
FAU - Rameshwar, Pranela
AU  - Rameshwar P
AD  - Dept of Medicine - Hematology/Oncology, Rutgers New Jersey Medical School, 
      Newark, NJ, USA. Electronic address: rameshwa@njms.rutgers.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230413
PL  - Netherlands
TA  - Placenta
JT  - Placenta
JID - 8006349
RN  - R16CO5Y76E (Aspirin)
RN  - O414PZ4LPZ (Salicylic Acid)
SB  - IM
MH  - Humans
MH  - Female
MH  - Pregnancy
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Pre-Eclampsia/metabolism
MH  - Placenta/metabolism
MH  - Epigenesis, Genetic
MH  - *Mesenchymal Stem Cells/metabolism
MH  - Salicylic Acid/metabolism
COIS- Declaration of competing interest PR consults for WR Biotech, Morristown, NJ. The 
      other authors declare no conflict of interest.
EDAT- 2023/04/18 18:41
MHDA- 2023/05/16 06:42
CRDT- 2023/04/18 18:01
PHST- 2023/01/16 00:00 [received]
PHST- 2023/03/29 00:00 [revised]
PHST- 2023/04/07 00:00 [accepted]
PHST- 2023/05/16 06:42 [medline]
PHST- 2023/04/18 18:41 [pubmed]
PHST- 2023/04/18 18:01 [entrez]
AID - S0143-4004(23)00081-4 [pii]
AID - 10.1016/j.placenta.2023.04.010 [doi]
PST - ppublish
SO  - Placenta. 2023 Jun;137:49-58. doi: 10.1016/j.placenta.2023.04.010. Epub 2023 Apr 
      13.

PMID- 1103765
OWN - NLM
STAT- MEDLINE
DCOM- 19760117
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 135
IP  - 11
DP  - 1975 Nov
TI  - Clinical experience with naproxen in rheumatoid arthritis.
PG  - 1429-35
AB  - A total of 42 patients participated in three controlled clinical trials, each of 
      different design, to demonstrate the efficacy and safety of naproxen in the 
      treatment of rheumatodi arthritis. First, a double-blind comparison of aspirin 
      and naproxen was made in 24 patients. As judged by objective and subjective 
      measurements of disease activity, naproxen was at least as effective as aspirin 
      and the incidence of severity of side effects were less with naproxen than with 
      aspirin. Second, the safety and efficacy of naproxen administration was followed 
      in 42 patients for up to two years. Third, the continued efficacy of naproxen 
      during these two years was tested by interspersing a short period of double-blind 
      placebo administration for some patients. The observations made in this clinical 
      study suggest that naproxen is an effective and well-tolerated drug in the 
      long-term treatment of rheumatoid arthritis.
FAU - Alexander, S J
AU  - Alexander SJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Naphthaleneacetic Acids)
RN  - 0 (Placebos)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naphthaleneacetic Acids/*therapeutic use
MH  - Naproxen/administration & dosage/adverse effects/*therapeutic use
MH  - Placebos
EDAT- 1975/11/01 00:00
MHDA- 1975/11/01 00:01
CRDT- 1975/11/01 00:00
PHST- 1975/11/01 00:00 [pubmed]
PHST- 1975/11/01 00:01 [medline]
PHST- 1975/11/01 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1975 Nov;135(11):1429-35.

PMID- 26481090
OWN - NLM
STAT- MEDLINE
DCOM- 20170516
LR  - 20181202
IS  - 1469-0705 (Electronic)
IS  - 0960-7692 (Linking)
VI  - 47
IP  - 5
DP  - 2016 May
TI  - Prevention of pre-eclampsia by low-molecular-weight heparin in addition to 
      aspirin: a meta-analysis.
PG  - 548-53
LID - 10.1002/uog.15789 [doi]
AB  - OBJECTIVE: To estimate the impact of adding low-molecular-weight heparin (LMWH) 
      or unfractionated heparin to low-dose aspirin started ≤ 16 weeks' gestation on 
      the prevalence of pre-eclampsia (PE) and the delivery of a 
      small-for-gestational-age (SGA) neonate. METHODS: A systematic review and 
      meta-analysis of randomized controlled trials (RCTs) was performed by searching 
      the medical databases PubMed, EMBASE, Web of Science and Cochrane Central. 
      Pregnant women randomized to receive LMWH or unfractionated heparin in addition 
      to low-dose aspirin were compared with those who received low-dose aspirin alone. 
      Outcome measures were PE, severe PE, early-onset PE and SGA. Pooled relative 
      risks (RRs) with 95% CI were calculated using a random-effects model. RESULTS: 
      Eight RCTs met the inclusion criteria; the indication for recruitment was 
      previous recurrent miscarriage in five studies (three included women with 
      thrombophilia) and a history of severe or early-onset PE in three studies 
      (including women with thrombophilia in one). LMWH was administered in seven 
      studies and unfractionated heparin in one. In women with a history of PE, 
      treatment with LMWH and aspirin, compared with aspirin alone, was associated with 
      a significant reduction in development of PE (three trials (n = 379); RR, 0.54 
      (95% CI, 0.31-0.92); P = 0.03) and in delivery of SGA neonates (two trials (n = 
      363); RR, 0.54 (95% CI, 0.32-0.91); P = 0.02). These outcomes were not 
      significantly reduced in women with recurrent miscarriage who received LMWH and 
      aspirin, compared with aspirin alone. The small number of studies precluded 
      sensitivity analyses and the evaluation of publication biases. Blinding to the 
      allocation treatment was absent in all RCTs. CONCLUSIONS: Based on limited 
      evidence, the addition of LMWH to low-dose aspirin could reduce the prevalence of 
      PE and SGA in women with a history of PE. This observation should be the basis of 
      a well-conducted future trial rather than a recommendation for immediate clinical 
      application. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.
CI  - Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.
FAU - Roberge, S
AU  - Roberge S
AD  - Department of Social and Preventive Medicine, Université Laval, Québec, Canada.
FAU - Demers, S
AU  - Demers S
AD  - Department of Social and Preventive Medicine, Université Laval, Québec, Canada.
AD  - Department of Obstetrics and Gynecology, Université Laval, Québec, Canada.
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, 
      London, UK.
FAU - Nicolaides, K H
AU  - Nicolaides KH
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, 
      London, UK.
FAU - Bureau, M
AU  - Bureau M
AD  - Department of Obstetrics and Gynecology, Université Laval, Québec, Canada.
FAU - Côté, S
AU  - Côté S
AD  - Department of Medicine, Université Laval, Québec, Canada.
FAU - Bujold, E
AU  - Bujold E
AD  - Department of Social and Preventive Medicine, Université Laval, Québec, Canada.
AD  - Department of Obstetrics and Gynecology, Université Laval, Québec, Canada.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160403
PL  - England
TA  - Ultrasound Obstet Gynecol
JT  - Ultrasound in obstetrics & gynecology : the official journal of the International 
      Society of Ultrasound in Obstetrics and Gynecology
JID - 9108340
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Drug Therapy, Combination/methods
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/therapeutic use
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin
OT  - heparin
OT  - meta-analysis
OT  - pre-eclampsia
OT  - small-for-gestational age
EDAT- 2015/10/21 06:00
MHDA- 2017/05/17 06:00
CRDT- 2015/10/21 06:00
PHST- 2015/07/15 00:00 [received]
PHST- 2015/09/23 00:00 [revised]
PHST- 2015/10/08 00:00 [accepted]
PHST- 2015/10/21 06:00 [entrez]
PHST- 2015/10/21 06:00 [pubmed]
PHST- 2017/05/17 06:00 [medline]
AID - 10.1002/uog.15789 [doi]
PST - ppublish
SO  - Ultrasound Obstet Gynecol. 2016 May;47(5):548-53. doi: 10.1002/uog.15789. Epub 
      2016 Apr 3.

PMID- 35108049
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20230403
IS  - 2375-2548 (Electronic)
IS  - 2375-2548 (Linking)
VI  - 8
IP  - 5
DP  - 2022 Feb 4
TI  - Aspirin activates resolution pathways to reprogram T cell and macrophage 
      responses in colitis-associated colorectal cancer.
PG  - eabl5420
LID - 10.1126/sciadv.abl5420 [doi]
LID - eabl5420
AB  - Inflammation is linked with carcinogenesis in many types of cancer including 
      colorectal cancer (CRC). Aspirin is recommended for the prevention of CRC, 
      although the mechanism(s) mediating its immunomodulatory actions remain 
      incompletely understood. Here, we demonstrate that aspirin increased 
      concentrations of the immune-regulatory aspirin-triggered specialized 
      proresolving mediators (AT-SPMs), including AT-lipoxin A(4) and AT-resolvin D1, 
      in colonic tissues during inflammation-associated CRC (I-CRC). Aspirin also 
      down-regulated the expression of the checkpoint protein programmed cell death 
      protein-1 in macrophages and CD8(+) T cells from the colonic mucosa. Inhibition 
      of AT-SPM biosynthesis or knockout of the AT-SPM receptor Alx/Fpr2 reversed the 
      immunomodulatory actions of aspirin on macrophages and CD8(+) T cells and 
      abrogated its protective effects during I-CRC. Furthermore, treatment of mice 
      with AT-SPM recapitulated the immune-directed actions of aspirin during I-CRC. 
      Together, these findings elucidate a central role for AT-SPM in mediating the 
      immune-directed actions of aspirin in regulating I-CRC progression.
FAU - De Matteis, Roberta
AU  - De Matteis R
AUID- ORCID: 0000-0002-2304-5979
AD  - William Harvey Research Institute, Barts and The London School of Medicine and 
      Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, 
      UK.
FAU - Flak, Magdalena B
AU  - Flak MB
AUID- ORCID: 0000-0002-8238-9835
AD  - Centre for Experimental Medicine and Rheumatology, William Harvey Research 
      Institute, Barts and The London School of Medicine and Dentistry, Queen Mary 
      University of London, London, UK.
FAU - Gonzalez-Nunez, Maria
AU  - Gonzalez-Nunez M
AUID- ORCID: 0000-0002-7741-571X
AD  - William Harvey Research Institute, Barts and The London School of Medicine and 
      Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, 
      UK.
FAU - Austin-Williams, Shani
AU  - Austin-Williams S
AUID- ORCID: 0000-0002-8255-583X
AD  - William Harvey Research Institute, Barts and The London School of Medicine and 
      Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, 
      UK.
FAU - Palmas, Francesco
AU  - Palmas F
AUID- ORCID: 0000-0001-8578-6871
AD  - William Harvey Research Institute, Barts and The London School of Medicine and 
      Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, 
      UK.
FAU - Colas, Romain A
AU  - Colas RA
AD  - William Harvey Research Institute, Barts and The London School of Medicine and 
      Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, 
      UK.
FAU - Dalli, Jesmond
AU  - Dalli J
AUID- ORCID: 0000-0001-6328-3640
AD  - William Harvey Research Institute, Barts and The London School of Medicine and 
      Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, 
      UK.
AD  - Centre for Inflammation and Therapeutic Innovation, Queen Mary University of 
      London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220202
PL  - United States
TA  - Sci Adv
JT  - Science advances
JID - 101653440
RN  - 0 (Receptors, Formyl Peptide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Aspirin/pharmacology/therapeutic use
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - *Colitis-Associated Neoplasms
MH  - Inflammation/metabolism
MH  - Macrophages/metabolism
MH  - Mice
MH  - Receptors, Formyl Peptide/metabolism
PMC - PMC8809687
EDAT- 2022/02/03 06:00
MHDA- 2022/04/20 06:00
CRDT- 2022/02/02 17:14
PHST- 2022/02/02 17:14 [entrez]
PHST- 2022/02/03 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
AID - abl5420 [pii]
AID - 10.1126/sciadv.abl5420 [doi]
PST - ppublish
SO  - Sci Adv. 2022 Feb 4;8(5):eabl5420. doi: 10.1126/sciadv.abl5420. Epub 2022 Feb 2.

PMID- 23421723
OWN - NLM
STAT- MEDLINE
DCOM- 20130930
LR  - 20131121
IS  - 1751-2980 (Electronic)
IS  - 1751-2972 (Linking)
VI  - 14
IP  - 5
DP  - 2013 May
TI  - Role of aspirin in chemoprevention of esophageal adenocarcinoma: a meta-analysis.
PG  - 222-30
LID - 10.1111/1751-2980.12047 [doi]
AB  - OBJECTIVE: To identify whether regular aspirin use protects against esophageal 
      adenocarcinoma (EA) and if so, the effect of the duration and frequency of drug 
      exposure. METHODS: Studies were selected from five journal/trial databases based 
      on defined inclusion and exclusion criteria; most notably, the provision of 
      multivariate EA odds ratios (ORs) in those taking regular aspirin. A subgroup 
      analysis was then performed by stratifying the results according to the frequency 
      and duration of aspirin use. The reliability of these investigations was assessed 
      by calculating study heterogeneity and observing any elements of publication 
      bias. RESULTS: Nine studies were selected for the main analysis, of which five 
      were included in the frequency analysis and three assessed the duration of 
      aspirin use. Data pooling revealed a statistically significant EA OR of 0.671 
      (95% CI 0.526-0.856, P = 0.001) among all aspirin users, suggesting a protective 
      effect. The results for duration and frequency did not reach statistical 
      significance but nonetheless suggested possible benefits of longer, more frequent 
      drug regimens that may be statistically confirmed by studies of larger sample 
      sizes. Funnel plots and statistical tests demonstrated a minimal impact of 
      publication bias on our results. CONCLUSION: Aspirin use confers a significant 
      protective effect against EA with a suggestion that the degree of protection may 
      be increased by the longer duration and higher frequency of usage.
CI  - © 2013 The Authors. Journal of Digestive Diseases © 2013 Chinese Medical 
      Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital 
      Affiliated to Shanghai Jiaotong University School of Medicine and Wiley 
      Publishing Asia Pty Ltd.
FAU - Sivarasan, Nishanth
AU  - Sivarasan N
AD  - Imperial College London, Charing Cross Hospital, London, United Kingdom. 
      nishanth.siva@gmail.com
FAU - Smith, Geoff
AU  - Smith G
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Australia
TA  - J Dig Dis
JT  - Journal of digestive diseases
JID - 101302699
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticarcinogenic Agents/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drug Administration Schedule
MH  - Esophageal Neoplasms/*prevention & control
MH  - Humans
MH  - Publication Bias
EDAT- 2013/02/21 06:00
MHDA- 2013/10/01 06:00
CRDT- 2013/02/21 06:00
PHST- 2013/02/21 06:00 [entrez]
PHST- 2013/02/21 06:00 [pubmed]
PHST- 2013/10/01 06:00 [medline]
AID - 10.1111/1751-2980.12047 [doi]
PST - ppublish
SO  - J Dig Dis. 2013 May;14(5):222-30. doi: 10.1111/1751-2980.12047.

PMID- 9062845
OWN - NLM
STAT- MEDLINE
DCOM- 19970530
LR  - 20191024
IS  - 0276-3478 (Print)
IS  - 0276-3478 (Linking)
VI  - 21
IP  - 2
DP  - 1997 Mar
TI  - Use of aspirin to facilitate vomiting in a young woman with bulimia nervosa: a 
      case report.
PG  - 201-3
AB  - A 25-year-old female patient with a 9-year history of bulimia nervosa gave a 
      2-year history of regularly ingesting up to 24 x 300 mg aspirin tablets to 
      facilitate vomiting after a binge. Awareness of this dangerous practice is 
      important when asking for an eating disorder history. Assessing for the possible 
      physical sequelae of aspirin misuse and educating the patient about the risks 
      would be an important part of the overall treatment.
FAU - Gordon, J
AU  - Gordon J
AD  - Professor Gerald Russel Eating Disorder Unit, Bethlem Royal Hospital, Beckenham, 
      Kent, United Kingdom.
FAU - Ramsay, R
AU  - Ramsay R
FAU - Treasure, J
AU  - Treasure J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Int J Eat Disord
JT  - The International journal of eating disorders
JID - 8111226
RN  - 0 (Cathartics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Bulimia/*psychology
MH  - Cathartics/administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Vomiting/*chemically induced/psychology
EDAT- 1997/03/01 00:00
MHDA- 2000/06/20 09:00
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1997/03/01 00:00 [entrez]
AID - 10.1002/(SICI)1098-108X(199703)21:2<201::AID-EAT12>3.0.CO;2-4 [pii]
AID - 10.1002/(sici)1098-108x(199703)21:2<201::aid-eat12>3.0.co;2-4 [doi]
PST - ppublish
SO  - Int J Eat Disord. 1997 Mar;21(2):201-3. doi: 
      10.1002/(sici)1098-108x(199703)21:2<201::aid-eat12>3.0.co;2-4.

PMID- 98976
OWN - NLM
STAT- MEDLINE
DCOM- 19781027
LR  - 20190823
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 8
IP  - 4
DP  - 1978 Jun
TI  - Aspirin and prostaglandins: some recent developments.
PG  - 427-9
AB  - The results of experiments designed to test the validity of the hypothesis that 
      the anti-inflammatory and anti-rheumatic actions of aspirin are due to the 
      inhibition of prostaglandin synthetase activity are reviewed.
FAU - Smith, M J
AU  - Smith MJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics
MH  - Animals
MH  - Anti-Inflammatory Agents
MH  - Aspirin/metabolism/*pharmacology
MH  - *Cyclooxygenase Inhibitors
MH  - Humans
MH  - Rheumatic Diseases/physiopathology
MH  - Salicylates/metabolism/pharmacology
RF  - 23
EDAT- 1978/06/01 00:00
MHDA- 1978/06/01 00:01
CRDT- 1978/06/01 00:00
PHST- 1978/06/01 00:00 [pubmed]
PHST- 1978/06/01 00:01 [medline]
PHST- 1978/06/01 00:00 [entrez]
AID - 10.1007/BF01968670 [doi]
PST - ppublish
SO  - Agents Actions. 1978 Jun;8(4):427-9. doi: 10.1007/BF01968670.

PMID- 9155612
OWN - NLM
STAT- MEDLINE
DCOM- 19970604
LR  - 20220311
IS  - 1355-6037 (Print)
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 77
IP  - 4
DP  - 1997 Apr
TI  - Aspirin protects low density lipoprotein from oxidative modification.
PG  - 333-7
AB  - OBJECTIVE: To examine the effects of aspirin on the potential for oxidative 
      modification of low density lipoprotein (LDL). DESIGN: Before and after trial. 
      SETTING: University department of medicine within a district general hospital 
      campus. PATIENTS: Ten healthy normolipidaemic volunteers drawn from laboratory 
      and medical staff. INTERVENTIONS: Aspirin (enteric coated) 300 mg daily for two 
      weeks. MAIN OUTCOME MEASURES: In vitro oxidation of LDL following ultraviolet C 
      (UVC) irradiation with measurements made of malondialdehyde, conjugated dienes, 
      and electrophoretic mobility. RESULTS: There was a significant decrease in 
      malondialdehyde production from LDL modified by aspirin in vivo following 
      exposure to UVC irradiation for 90 minutes, culminating in a 30% decrease by 240 
      minutes (mean (SD) 64.2 (9.12) v 89.6 (11.6) nmol/mg LDL protein, P = 0.029). 
      These observations were borne out using LDL modified by aspirin in vitro. The UVC 
      induced increase in relative electrophoretic mobility of LDL was also 
      significantly reduced following aspirin treatment (mean (SD) 2.17 (0.16) v 2.66 
      (0.24), P = 0.012). CONCLUSIONS: Aspirin, both in vivo and in vitro, protects LDL 
      against subsequent oxidative modification, providing an additional mechanism 
      whereby aspirin may protect against atherosclerosis.
FAU - Steer, K A
AU  - Steer KA
AD  - Department of Medicine, University of Bristol.
FAU - Wallace, T M
AU  - Wallace TM
FAU - Bolton, C H
AU  - Bolton CH
FAU - Hartog, M
AU  - Hartog M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Electrophoresis
MH  - Female
MH  - Humans
MH  - Lipoproteins, LDL/*metabolism/physiology/radiation effects
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Oxidation-Reduction
MH  - Tablets, Enteric-Coated
MH  - Time Factors
MH  - Ultraviolet Rays
PMC - PMC484727
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - 10.1136/hrt.77.4.333 [doi]
PST - ppublish
SO  - Heart. 1997 Apr;77(4):333-7. doi: 10.1136/hrt.77.4.333.

PMID- 8377686
OWN - NLM
STAT- MEDLINE
DCOM- 19931021
LR  - 20131121
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 159
IP  - 6
DP  - 1993 Sep 20
TI  - Placebo-controlled trial of enteric coated aspirin in coronary bypass graft 
      patients. Effect on graft patency.
PG  - 376-8
AB  - OBJECTIVE: To determine whether slow-release enteric coated aspirin (100 mg 
      daily), commenced before operation, improves the patency of saphenous vein (SV) 
      coronary artery bypass grafts at six months. DESIGN AND SETTING: Double-blind, 
      randomised, placebo-controlled study at a teaching hospital. RESULTS: One hundred 
      and forty patients were randomly allocated to receive enteric coated aspirin or 
      matching placebo. Similar groups of 50 (aspirin) and 52 (placebo) subjects 
      completed the six months follow-up and had an angiogram to assess patency. Five 
      patients treated with aspirin and nine who received placebo had at least one 
      occluded SV graft; the distal ends of 6 of 128 SV grafts in aspirin-treated 
      patients (4.7%) and 13 of 145 SV grafts in patients in the placebo group (9.0%) 
      were occluded--the difference was not significant. An arterial graft was occluded 
      in one other patient in each group (3% of arterial grafts). There was more 
      postoperative blood loss, on average, in patients treated with aspirin, but the 
      difference was not significant. Only one patient was withdrawn from long-term 
      therapy because of possible gastrointestinal symptoms; most withdrawals from the 
      trial were necessitated by commencement of aspirin or non-steroidal 
      anti-inflammatory therapy for musculo-skeletal disorders. CONCLUSIONS: The 
      coronary bypass graft occlusion rate six months after surgery was low, and was 
      lower on average in aspirin treated subjects but not significantly so. Long-term 
      treatment with low-dose aspirin is recommended unless contraindicated.
FAU - Hockings, B E
AU  - Hockings BE
AD  - Department of Cardiology, Royal Perth Hospital, WA.
FAU - Ireland, M A
AU  - Ireland MA
FAU - Gotch-Martin, K F
AU  - Gotch-Martin KF
FAU - Taylor, R R
AU  - Taylor RR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Tablets, Enteric-Coated)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Premedication
MH  - Saphenous Vein/transplantation
MH  - Tablets, Enteric-Coated
EDAT- 1993/09/20 00:00
MHDA- 1993/09/20 00:01
CRDT- 1993/09/20 00:00
PHST- 1993/09/20 00:00 [pubmed]
PHST- 1993/09/20 00:01 [medline]
PHST- 1993/09/20 00:00 [entrez]
PST - ppublish
SO  - Med J Aust. 1993 Sep 20;159(6):376-8.

PMID- 22634074
OWN - NLM
STAT- MEDLINE
DCOM- 20130108
LR  - 20131121
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 161
IP  - 3
DP  - 2012 Aug 10
TI  - Magnetic Active Agent Release System (MAARS): evaluation of a new way for a 
      reproducible, externally controlled drug release into the small intestine.
PG  - 722-7
LID - 10.1016/j.jconrel.2012.04.047 [doi]
AB  - Human absorption studies are used to test new drug candidates for their 
      bioavailability in different regions of the gastrointestinal tract. In order to 
      replace invasive techniques (e.g. oral or rectal intubation) a variety of 
      externally controlled capsule-based drug release systems has been developed. Most 
      of these use ionizing radiation, internal batteries, heating elements or even 
      chemicals for the localization and disintegration process of the capsule. This 
      embodies potential harms for volunteers and patients. We report about a novel 
      technique called "Magnetic Active Agent Release System" (MAARS), which uses 
      purely magnetic effects for this purpose. In our trial thirteen healthy 
      volunteers underwent a complete monitoring and release procedure of 250 mg 
      acetylsalicylic acid (ASA) targeting the flexura duodenojejunalis and the 
      mid-part of the jejunum. During all experiments MAARS initiated a sufficient drug 
      release and was well tolerated. Beside this we also could show that the 
      absorption of ASA is about two times faster in the more proximal region of the 
      flexura duodenojejunalis with a tmax of 47±13 min compared to the more distal 
      jejunum with tmax values of 100±10 min (p=0.031).
CI  - Copyright © 2012 Elsevier B.V. All rights reserved.
FAU - Dietzel, Christian T
AU  - Dietzel CT
AD  - Department of Clinical Pharmacology, Jena University Hospital, Drackendorfer 
      Strasse 1, 07747 Jena, Germany.
FAU - Richert, Hendryk
AU  - Richert H
FAU - Abert, Sandra
AU  - Abert S
FAU - Merkel, Ute
AU  - Merkel U
FAU - Hippius, Marion
AU  - Hippius M
FAU - Stallmach, Andreas
AU  - Stallmach A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20120522
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - *Drug Delivery Systems
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Intestine, Small/*metabolism
MH  - Magnetic Phenomena
MH  - Male
MH  - Young Adult
EDAT- 2012/05/29 06:00
MHDA- 2013/01/09 06:00
CRDT- 2012/05/29 06:00
PHST- 2012/02/02 00:00 [received]
PHST- 2012/04/19 00:00 [revised]
PHST- 2012/04/20 00:00 [accepted]
PHST- 2012/05/29 06:00 [entrez]
PHST- 2012/05/29 06:00 [pubmed]
PHST- 2013/01/09 06:00 [medline]
AID - S0168-3659(12)00439-7 [pii]
AID - 10.1016/j.jconrel.2012.04.047 [doi]
PST - ppublish
SO  - J Control Release. 2012 Aug 10;161(3):722-7. doi: 10.1016/j.jconrel.2012.04.047. 
      Epub 2012 May 22.

PMID- 10911579
OWN - NLM
STAT- MEDLINE
DCOM- 20001116
LR  - 20190515
IS  - 1058-0468 (Print)
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 17
IP  - 3
DP  - 2000 Mar
TI  - Low-dose aspirin for infertile women with thin endometrium receiving intrauterine 
      insemination: a prospective, randomized study.
PG  - 174-7
AB  - PURPOSE: The objective was to evaluate the effect of aspirin on infertile women 
      with thin endometrium. METHODS: Patients who had thin endometrium (< or = 8 mm) 
      and intrauterine insemination were divided into the aspirin and nonaspirin 
      groups. Endometrial pattern (trilaminar and nontrilaminar) and thickness, the 
      pulsatility index (PI) and resistance index (RI) of the uterine artery, spiral 
      artery, and ovarian dominant follicles, and pregnancy rates of both groups were 
      measured. RESULTS: A total of 114 and 122 women were included in the aspirin and 
      nonaspirin groups, respectively. There were significantly higher percentages of 
      trilaminar endometrium (46.5% vs. 26.2%) and pregnancy rate (18.4% vs. 9.0%) 
      after aspirin therapy. There was nonsignificant difference in the endometrial 
      thickness, and PI/RI values of the uterine artery, spiral artery, and ovarian 
      dominant follicle between both groups. CONCLUSIONS: Higher pregnancy rate and 
      better endometrial pattern were achieved in patients with thin endometrium after 
      aspirin administration. Aspirin therapy could not significantly increase the 
      endometrial thickness and the resistance of uterine and ovarian flow.
FAU - Hsieh, Y Y
AU  - Hsieh YY
AD  - Department of Obstetrics and Gynecology, China Medical College Hospital, 
      Taichung, Taiwan.
FAU - Tsai, H D
AU  - Tsai HD
FAU - Chang, C C
AU  - Chang CC
FAU - Lo, H Y
AU  - Lo HY
FAU - Chen, C L
AU  - Chen CL
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Endometrium/*pathology
MH  - Female
MH  - Humans
MH  - Infertility, Female/*drug therapy/pathology
MH  - Insemination, Artificial, Homologous
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Prospective Studies
PMC - PMC3455661
EDAT- 2000/07/27 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/07/27 11:00
PHST- 2000/07/27 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/07/27 11:00 [entrez]
AID - 222133 [pii]
AID - 10.1023/a:1009474307376 [doi]
PST - ppublish
SO  - J Assist Reprod Genet. 2000 Mar;17(3):174-7. doi: 10.1023/a:1009474307376.

PMID- 26702086
OWN - NLM
STAT- MEDLINE
DCOM- 20160913
LR  - 20190110
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 4
IP  - 12
DP  - 2015 Dec 23
TI  - Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary 
      Prevention of Cardiovascular Disease.
LID - 10.1161/JAHA.115.002321 [doi]
LID - e002321
AB  - BACKGROUND: The U.S. Preventive Services Task Force in 2009 recommended increased 
      aspirin use for primary prevention of cardiovascular disease (CVD) in men ages 45 
      to 79 years and women ages 55 to 79 years for whom benefit outweighs risk. This 
      study estimated the clinical efficacy and cost-effectiveness of a statewide 
      public and health professional awareness campaign to increase regular aspirin use 
      among the target population in Minnesota to reduce first CVD events. METHODS AND 
      RESULTS: A state-transition Markov model was developed, adopting a payer 
      perspective and lifetime time horizon. The main outcomes of interest were 
      quality-adjusted life years, costs, and the number of CVD events averted among 
      those without a prior CVD history. The model was based on real-world data about 
      campaign effectiveness from representative state-specific aspirin use and event 
      rates, and estimates from the scholarly literature. Implementation of a campaign 
      was predicted to avert 9874 primary myocardial infarctions in men and 1223 
      primary ischemic strokes in women in the target population. Increased aspirin use 
      was associated with as many as 7222 more major gastrointestinal bleeding 
      episodes. The cost-effectiveness analysis indicated cost-saving results for both 
      the male and female target populations. CONCLUSIONS: Using current U.S. 
      Preventive Services Task Force recommendations, a state public and health 
      professional awareness campaign would likely provide clinical benefit and be 
      economically attractive. With clinician adjudication of individual benefit and 
      risk, mechanisms can be made available that would facilitate achievement of 
      aspirin's beneficial impact on lowering risk of primary CVD events, with 
      minimization of adverse outcomes.
CI  - © 2015 The Authors. Published on behalf of the American Heart Association, Inc., 
      by Wiley Blackwell.
FAU - Michaud, Tzeyu L
AU  - Michaud TL
AD  - Center for Reducing Health Disparities, College of Public Health, University of 
      Nebraska Medical Center, Omaha, NE (T.L.M.) Department of Health Promotion, 
      Social and Behavioral Health, College of Public Health, University of Nebraska 
      Medical Center, Omaha, NE (T.L.M.).
FAU - Abraham, Jean
AU  - Abraham J
AD  - Division of Health Policy and Management, University of Minnesota, Minneapolis, 
      MN (J.A.).
FAU - Jalal, Hawre
AU  - Jalal H
AD  - Department of Health Policy and Management, University of Pittsburgh, PA (H.J.).
FAU - Luepker, Russell V
AU  - Luepker RV
AD  - Division of Epidemiology and Community Health, University of Minnesota, 
      Minneapolis, MN (R.V.L., A.T.H.) Lillehei Heart Institute and Cardiovascular 
      Division, University of Minnesota, Minneapolis, MN (R.V.L., S.D., A.T.H.).
FAU - Duval, Sue
AU  - Duval S
AD  - Lillehei Heart Institute and Cardiovascular Division, University of Minnesota, 
      Minneapolis, MN (R.V.L., S.D., A.T.H.).
FAU - Hirsch, Alan T
AU  - Hirsch AT
AD  - Division of Epidemiology and Community Health, University of Minnesota, 
      Minneapolis, MN (R.V.L., A.T.H.) Lillehei Heart Institute and Cardiovascular 
      Division, University of Minnesota, Minneapolis, MN (R.V.L., S.D., A.T.H.).
LA  - eng
GR  - R01 HL126041/HL/NHLBI NIH HHS/United States
GR  - 1R01HL126041-01/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151223
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Heart Assoc. 2015 Dec;4(12). pii: e002927. doi: 10.1161/JAHA.115.002927. 
      PMID: 26702080
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/economics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Health Promotion/*economics
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Minnesota
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention/economics/methods
MH  - Quality-Adjusted Life Years
PMC - PMC4845274
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular diseases
OT  - cost–effectiveness analysis
OT  - epidemiology
OT  - myocardial infarction
OT  - prevention
OT  - stroke
EDAT- 2015/12/25 06:00
MHDA- 2016/09/14 06:00
CRDT- 2015/12/25 06:00
PHST- 2015/12/25 06:00 [entrez]
PHST- 2015/12/25 06:00 [pubmed]
PHST- 2016/09/14 06:00 [medline]
AID - JAHA.115.002321 [pii]
AID - JAH31214 [pii]
AID - 10.1161/JAHA.115.002321 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2015 Dec 23;4(12):e002321. doi: 10.1161/JAHA.115.002321.

PMID- 6459443
OWN - NLM
STAT- MEDLINE
DCOM- 19820322
LR  - 20190913
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 4
IP  - 10
DP  - 1981 Oct
TI  - Studies on aspirin derivatives with very little side effect. II. Potent platelet 
      anti-aggregant activity and no mutagenicity of aspirin-isopropylantipyrine (AIA).
PG  - 803-11
AB  - The effect of a new aspirin derivative, aspirin-isopropylantipyrine (AIA), with 
      very little gastric ulcerogenic activity and very slight acute toxicity and with 
      analgesic, antipyretic anti-inflammatory, and platelet aggregation inhibitory 
      activities was evaluated in vitro and ex vivo and compared with those of aspirin 
      and isopropylantipyrine (IA). In vitro, AIA, aspirin and IA (50-200 microM) 
      caused concentration-dependent inhibition of collagen-induced aggregation in 
      rabbit platelets although AIA was several-fold more active than the others 
      Arachidonic acid-induced aggregation was inhibited by all three agents (200 
      microM) in the following magnitude; IA greater than aspirin greater than AIA. 
      Three agents did not influence primary ADP-induced aggregation. The in vitro 
      effects on the release-inducing aggregants were confirmed by ex vivo experiments 
      in rats. These demonstrated that AIA and aspirin (50 mg/kg) exhibited almost 
      identical inhibitory potencies in the extent and the rate of collagen-induced 
      aggregation 4 h after subcutaneous injection. AIA was still effective 24 h after 
      administration as well as aspirin. IA was less effective, differing from the 
      results in vitro. AIA had no effect on plasmin activity and blood flow through 
      the common carotid artery. AIA (1 mM) maintained spreading and beating of 
      myocardial cells in a serum-free culture. As special toxicity trials on AIA 
      mutagenecity tests were made by the Rec-assay with Bacillus subtilis, by the 
      plate culture with Escherichia coli, and by the Ames system with Salmonella 
      typhimurium. AIA was found to have no mutagenic effect under any of those methods 
      and to have no effect on the mutagenic action of 3, 4-benzopyrene under the liver 
      microsome test using the Ames system.
FAU - Aonuma, S
AU  - Aonuma S
FAU - Kohama, Y
AU  - Kohama Y
FAU - Fujimoto, S
AU  - Fujimoto S
FAU - Makino, T
AU  - Makino T
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Mutagens)
RN  - 0 (N-3'a-propylphenazonyl-2-acetoxybenzamide)
RN  - EC 3.4.21.7 (Fibrinolysin)
RN  - R16CO5Y76E (Aspirin)
RN  - T3CHA1B51H (Antipyrine)
SB  - IM
MH  - Animals
MH  - Antipyrine/*analogs & derivatives/pharmacology/toxicity
MH  - Aspirin/*analogs & derivatives/pharmacology/toxicity
MH  - Fibrinolysin/metabolism
MH  - Fibrinolysis/drug effects
MH  - Male
MH  - Microsomes, Liver/metabolism
MH  - Mutagenicity Tests
MH  - *Mutagens
MH  - Platelet Aggregation/*drug effects
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Regional Blood Flow/drug effects
EDAT- 1981/10/01 00:00
MHDA- 1981/10/01 00:01
CRDT- 1981/10/01 00:00
PHST- 1981/10/01 00:00 [pubmed]
PHST- 1981/10/01 00:01 [medline]
PHST- 1981/10/01 00:00 [entrez]
AID - 10.1248/bpb1978.4.803 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1981 Oct;4(10):803-11. doi: 10.1248/bpb1978.4.803.

PMID- 6346519
OWN - NLM
STAT- MEDLINE
DCOM- 19830811
LR  - 20140912
IS  - 0256-9574 (Print)
VI  - 64
IP  - 2
DP  - 1983 Jul 9
TI  - The effect of low-dose aspirin and platelet aggregation in familial 
      hypercholesterolaemia.
PG  - 49-52
AB  - Since the platelets of patients with familial hypercholesterolaemia (FH) are 
      hyperaggregable, the inhibitory effect of low-dose aspirin on platelet 
      aggregation in response to adenosine diphosphate, collagen, adrenaline and 
      arachidonic acid was tested in 9 young adult patients with FH and compared with 
      that in 9 normal subjects. After a single oral dose (150 mg) of aspirin the 
      degree of inhibition of platelet aggregation was the same in the two groups, as 
      was the recovery time (in days) for full restoration of platelet aggregation . In 
      a second experiment in which 162 mg aspirin was administered daily for 28 days, 
      inhibition of platelet aggregation was sustainable in both the patient and the 
      control groups. These results suggest that despite the recognized 
      hyperaggregability of platelets from patients with FH, daily low-dose aspirin 
      ingestion effectively inhibits their in vitro aggregation and may therefore prove 
      beneficial as supplemental therapy to reduce the rate of myocardial infarction in 
      this high-risk group.
FAU - Shires, R
AU  - Shires R
FAU - Chetty, N
AU  - Chetty N
FAU - Baker, S G
AU  - Baker SG
FAU - Bradlow, B A
AU  - Bradlow BA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Hyperlipoproteinemia Type II/*blood
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Time Factors
EDAT- 1983/07/09 00:00
MHDA- 1983/07/09 00:01
CRDT- 1983/07/09 00:00
PHST- 1983/07/09 00:00 [pubmed]
PHST- 1983/07/09 00:01 [medline]
PHST- 1983/07/09 00:00 [entrez]
PST - ppublish
SO  - S Afr Med J. 1983 Jul 9;64(2):49-52.

PMID- 25604474
OWN - NLM
STAT- MEDLINE
DCOM- 20151214
LR  - 20150218
IS  - 1521-3773 (Electronic)
IS  - 1433-7851 (Linking)
VI  - 54
IP  - 9
DP  - 2015 Feb 23
TI  - The biological activity of Zeise's salt and its derivatives.
PG  - 2834-7
LID - 10.1002/anie.201410357 [doi]
AB  - With the aim to design new biologically active bioinorganic drugs of aspirin, 
      whose mode of action is based on the inhibition of the cyclooxygenase(COX) 
      enzymes, derivatives of Zeise's salt were synthesized in this structure-activity 
      relationship study. Surprisingly, not only these Zeise-aspirin compounds but also 
      Zeise's salt itself showed high inhibitory potency against COX enzymes in 
      in vitro assays. In contrast, potassium tetrachloroplatinate and cisplatin did 
      not influence the enzyme activity at equimolar concentrations. It was 
      demonstrated by LC-ESI tandem-mass spectrometry that Zeise's salt platinates the 
      essential amino acids Tyr385 (active site of the enzyme) and Ser516 (will be 
      acetylated by aspirin) of COX-1, thereby strongly impairing the function of the 
      enzyme. This finding demonstrates for the first time that Zeise's salt is 
      pharmacologically active and is a potent enzyme inhibitor.
CI  - © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Meieranz, Sandra
AU  - Meieranz S
AD  - Institute of Pharmacy, Freie Universität Berlin, 14195 Berlin (Germany).
FAU - Stefanopoulou, Maria
AU  - Stefanopoulou M
FAU - Rubner, Gerhard
AU  - Rubner G
FAU - Bensdorf, Kerstin
AU  - Bensdorf K
FAU - Kubutat, Dominic
AU  - Kubutat D
FAU - Sheldrick, William S
AU  - Sheldrick WS
FAU - Gust, Ronald
AU  - Gust R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150121
PL  - Germany
TA  - Angew Chem Int Ed Engl
JT  - Angewandte Chemie (International ed. in English)
JID - 0370543
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Organoplatinum Compounds)
RN  - 0 (Salts)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cyclooxygenase 1/*metabolism
MH  - Cyclooxygenase Inhibitors/chemical synthesis/*chemistry/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Enzyme Activation/drug effects
MH  - Humans
MH  - MCF-7 Cells
MH  - Models, Molecular
MH  - Molecular Structure
MH  - Organoplatinum Compounds/chemistry/*pharmacology
MH  - Salts/*chemistry
MH  - Structure-Activity Relationship
OTO - NOTNLM
OT  - COX inhibition
OT  - Zeise’s salt
OT  - cellular distribution
OT  - cytotoxicity
OT  - stability
EDAT- 2015/01/22 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/01/22 06:00
PHST- 2014/10/22 00:00 [received]
PHST- 2015/01/22 06:00 [entrez]
PHST- 2015/01/22 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1002/anie.201410357 [doi]
PST - ppublish
SO  - Angew Chem Int Ed Engl. 2015 Feb 23;54(9):2834-7. doi: 10.1002/anie.201410357. 
      Epub 2015 Jan 21.

PMID- 2148033
OWN - NLM
STAT- MEDLINE
DCOM- 19910129
LR  - 20161122
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 21
IP  - 12 Suppl
DP  - 1990 Dec
TI  - Thromboxane A2/prostaglandin H2 receptor antagonists. A new therapeutic 
      principle.
PG  - IV139-42
AB  - Neither low- nor very-low-dose Aspirin suppresses thromboxane A2 biosynthesis 
      without inhibiting the formation of its functional antagonist prostacyclin. 
      Although thromboxane synthase inhibitors selectively inhibit thromboxane A2 
      biosynthesis and increase prostacyclin formation in vivo, thromboxane synthase 
      inhibitors can lead to an accumulation of prostaglandin H2 that substitutes for 
      thromboxane A2 at their common receptors in platelets and smooth muscle. In 
      contrast to those inhibitors of thromboxane A2 biosynthesis, thromboxane 
      A2/prostaglandin H2 receptor antagonists do not affect the synthesis of 
      prostacyclin and other prostaglandins but prevent thromboxane A2 and 
      prostaglandin H2 from activating platelets and inducing vasoconstriction. The 
      available thromboxane A2/prostaglandin H2 receptor antagonists are competitive 
      antagonists. However, some of them, such as daltroban, S-145, GR 32.191, and Bay 
      U 3405, produce a noncompetitive antagonism in human platelets due to their low 
      dissociation rate. As a consequence, agonists equilibrate with the 
      antagonist-occupied receptor pool so slowly that they fail to induce platelet 
      activation. This property of some antagonists strongly increases their potency 
      and the duration of their inhibitory effect. Therefore, a low dissociation rate 
      is an important measure of the effectiveness of a thromboxane A2/prostaglandin H2 
      receptor antagonist in addition to its receptor affinity. Another approach in 
      thromboxane A2 pharmacology is a combination of thromboxane synthase inhibition 
      with thromboxane receptor antagonism in one drug, such as ridogrel. Such dual 
      inhibitors present a very high inhibitory potential and prolong the skin bleeding 
      time to a greater extent than Aspirin, thromboxane synthase inhibitors, or 
      thromboxane A2/prostaglandin H2 receptor antagonists.
FAU - Patscheke, H
AU  - Patscheke H
AD  - Institute for Clinical Chemistry, University of Heidelberg, Mannheim, FRG.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Receptors, Prostaglandin)
RN  - 0 (Receptors, Thromboxane)
RN  - 0 (Receptors, Thromboxane A2, Prostaglandin H2)
RN  - EC 5.3.99.5 (Thromboxane-A Synthase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/physiology
MH  - Humans
MH  - Receptors, Prostaglandin/*antagonists & inhibitors
MH  - Receptors, Thromboxane
MH  - Receptors, Thromboxane A2, Prostaglandin H2
MH  - Thromboxane-A Synthase/antagonists & inhibitors
RF  - 27
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
PST - ppublish
SO  - Stroke. 1990 Dec;21(12 Suppl):IV139-42.

PMID- 32984948
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 148
IP  - 6
DP  - 2021 Mar 15
TI  - Aspirin and the risk of nondigestive tract cancers: An updated meta-analysis to 
      2019.
PG  - 1372-1382
LID - 10.1002/ijc.33311 [doi]
AB  - Aspirin has been associated with a reduced risk of colorectal and other selected 
      digestive tract cancers, but the evidence for other neoplasms is still 
      controversial. To provide an up-to-date quantification of the role of aspirin on 
      lung, breast, endometrium, ovary, prostate, bladder, and kidney cancer, we 
      conducted a systematic review and meta-analysis of all observational studies 
      published up to March 2019. We estimated pooled relative risk (RR) of cancer or 
      cancer death for regular aspirin use vs non-use by using random-effects models, 
      and, whenever possible, we investigated dose- and duration-risk relations. A 
      total of 148 studies were considered. Regular aspirin use was associated to a 
      reduced risk of lung (RR = 0.88, 95% confidence interval [CI] = 0.79-0.98), 
      breast (RR = 0.90, 95% CI = 0.85-0.95), endometrial (RR = 0.91, 95% CI = 
      0.84-0.98), ovarian (RR = 0.91, 95% CI = 0.85-0.97) and prostate (RR = 0.93, 95% 
      CI = 0.89-0.96) cancer. However, for most neoplasms, nonsignificant risk 
      reductions were reported in cohort and nested case-control studies and there was 
      between-study heterogeneity. No association was reported for bladder and kidney 
      cancer. No duration-risk relations were observed for most neoplasms, except for 
      an inverse duration-risk relation for prostate cancer. The present meta-analysis 
      confirms the absence of appreciable effect of regular aspirin use on cancers of 
      the bladder and kidney and quantifies small and heterogeneous inverse 
      associations for other cancers considered.
CI  - © 2020 Union for International Cancer Control.
FAU - Santucci, Claudia
AU  - Santucci C
AD  - Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 
      Milan, Italy.
AD  - Department of Clinical Sciences and Community Health, Università degli Studi di 
      Milano, Milan, Italy.
FAU - Gallus, Silvano
AU  - Gallus S
AUID- ORCID: 0000-0002-8967-0400
AD  - Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche 
      Mario Negri IRCCS, Milan, Italy.
FAU - Martinetti, Marco
AU  - Martinetti M
AD  - Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 
      Milan, Italy.
FAU - La Vecchia, Carlo
AU  - La Vecchia C
AUID- ORCID: 0000-0003-1441-897X
AD  - Department of Clinical Sciences and Community Health, Università degli Studi di 
      Milano, Milan, Italy.
FAU - Bosetti, Cristina
AU  - Bosetti C
AUID- ORCID: 0000-0003-2090-4608
AD  - Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 
      Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201006
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Neoplasms/*epidemiology
MH  - Observational Studies as Topic
OTO - NOTNLM
OT  - aspirin
OT  - duration-risk relation
OT  - meta-analysis
OT  - neoplasm
OT  - risk factor
EDAT- 2020/09/29 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/09/28 05:49
PHST- 2020/07/01 00:00 [received]
PHST- 2020/09/07 00:00 [revised]
PHST- 2020/09/18 00:00 [accepted]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/09/28 05:49 [entrez]
AID - 10.1002/ijc.33311 [doi]
PST - ppublish
SO  - Int J Cancer. 2021 Mar 15;148(6):1372-1382. doi: 10.1002/ijc.33311. Epub 2020 Oct 
      6.

PMID- 10836736
OWN - NLM
STAT- MEDLINE
DCOM- 20000913
LR  - 20190915
IS  - 0253-6269 (Print)
IS  - 0253-6269 (Linking)
VI  - 23
IP  - 2
DP  - 2000 Apr
TI  - Synthesis and biological activity of aspirin derivatives.
PG  - 116-20
AB  - Aspirin has been widely used as analgesic and anti-inflammatory drug. Recently, 
      it was elucidated that aspirin have anti-coaggregatory effect in low dose. This 
      study was carried out to investigate the synthesis of aspirin derivatives from 
      aspirin and aromatic compound of antioxidant and its biological activities. 
      Synthesis of aspirin derivatives was prepared by esterification in the presence 
      of 1,1-carbonyldiimidazole. Biological activities was examined using effect of 
      anti-coagulant on bleeding time, effect of antioxidant and effect of 
      anti-platelet aggregation. As a result, SJ-101 showed strong antioxidative 
      activity and anti-coagulant activity among four compounds. Anti-platelet 
      aggregation of SJ-101 was examined by collagen, ADP, PAF method. SJ-101 exhibited 
      more stronger activity to aspirin at collagen aggregation reaction. These finding 
      demonstrates that SJ-101 is useful as care drug of aging and old-disease because 
      of its has antioxidant activity, anti-coagulant activity and anti-platelet 
      activity.
FAU - Cha, B C
AU  - Cha BC
AD  - Department of Applied Animal Sciences, College of Life Sciences and Natural 
      Resources, Sangji University, Wonju, Korea. bccha@chiak.sangji.ac.kr
FAU - Lee, S B
AU  - Lee SB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Korea (South)
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Phenols)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemical synthesis/*pharmacology
MH  - Antioxidants/chemical synthesis/pharmacology
MH  - Aspirin/*analogs & derivatives/chemical synthesis/*pharmacology
MH  - Bleeding Time
MH  - In Vitro Techniques
MH  - Indicators and Reagents
MH  - Magnetic Resonance Spectroscopy
MH  - Mass Spectrometry
MH  - Phenols/chemical synthesis/pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
MH  - Rats
MH  - Spectrophotometry, Ultraviolet
EDAT- 2000/06/03 09:00
MHDA- 2000/09/19 11:01
CRDT- 2000/06/03 09:00
PHST- 2000/06/03 09:00 [pubmed]
PHST- 2000/09/19 11:01 [medline]
PHST- 2000/06/03 09:00 [entrez]
AID - 10.1007/BF02975499 [doi]
PST - ppublish
SO  - Arch Pharm Res. 2000 Apr;23(2):116-20. doi: 10.1007/BF02975499.

PMID- 1106936
OWN - NLM
STAT- MEDLINE
DCOM- 19760320
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 19
IP  - 1
DP  - 1976 Jan
TI  - Assay of aspirin and naproxen analgesia.
PG  - 18-23
AB  - To establish the relative potency of naproxen and aspirin for oral analgesia, a 
      4-point, noncrossover bioassay with placebo control was undertaken with 197 
      patients. Subjective-response methods were used to determine two measures of 
      postoperative analgesia over a period of 6 hr. With reasonable confidence for an 
      oral analgesic assay, we found 220 mg of naproxen to be equivalent to 600 mg of 
      aspirin for pain relief and 330 mg of naproxen to be equivalent to 600 mg of 
      aspirin for decreased pain intensity.
FAU - Mahler, D L
AU  - Mahler DL
FAU - Forrest, W H Jr
AU  - Forrest WH Jr
FAU - Brown, C R
AU  - Brown CR
FAU - Shroff, P F
AU  - Shroff PF
FAU - Gordon, H E
AU  - Gordon HE
FAU - Brown, B W Jr
AU  - Brown BW Jr
FAU - James, K E
AU  - James KE
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Naphthaleneacetic Acids)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Naphthaleneacetic Acids/*therapeutic use
MH  - Naproxen/administration & dosage/adverse effects/*therapeutic use
MH  - Pain, Postoperative/*drug therapy
MH  - Time Factors
EDAT- 1976/01/11 19:15
MHDA- 2001/03/28 10:01
CRDT- 1976/01/11 19:15
PHST- 1976/01/11 19:15 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1976/01/11 19:15 [entrez]
AID - 0009-9236(76)90101-6 [pii]
AID - 10.1002/cpt197619118 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1976 Jan;19(1):18-23. doi: 10.1002/cpt197619118.

PMID- 8669424
OWN - NLM
STAT- MEDLINE
DCOM- 19960808
LR  - 20190815
IS  - 0272-6386 (Print)
IS  - 0272-6386 (Linking)
VI  - 28
IP  - 1 Suppl 1
DP  - 1996 Jul
TI  - Therapeutic uses of aspirin in renal diseases.
PG  - S20-3
AB  - Inhibition, by aspirin, of platelet aggregation, prostaglandin synthesis, smooth 
      muscle cell proliferation, and thromboxane genesis has potential therapeutic uses 
      in renal diseases. Clinically, some benefit from aspirin has been shown in some 
      forms of glomerulonephritis but not in others, such as renovascular hypertension, 
      pregnancy-induced hypertension, and diabetic nephropathy. Experimentally, aspirin 
      aided in amelioration of cyclosporine toxicity and in preservation of explanted 
      kidneys being prepared for transplantation.
FAU - Winchester, J F
AU  - Winchester JF
AD  - Department of Medicine, Georgetown University Medical Center, Washington, DC 
      20007, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Humans
MH  - Kidney Diseases/*drug therapy/physiopathology
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
RF  - 44
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
AID - S0272-6386(96)90564-8 [pii]
AID - 10.1016/s0272-6386(96)90564-8 [doi]
PST - ppublish
SO  - Am J Kidney Dis. 1996 Jul;28(1 Suppl 1):S20-3. doi: 
      10.1016/s0272-6386(96)90564-8.

PMID- 6735140
OWN - NLM
STAT- MEDLINE
DCOM- 19840817
LR  - 20190825
IS  - 0306-3623 (Print)
IS  - 0306-3623 (Linking)
VI  - 15
IP  - 3
DP  - 1984
TI  - Adsorption, distribution and elimination of chloroquine in the presence of 
      aspirin when administered into rabbits.
PG  - 259-61
AB  - The absorption, distribution and elimination of chloroquine were studied in 
      rabbits upon oral administration of chloroquine with aspirin. The time-lag, 
      half-life of absorption and absorption rate constant obtained in both cases were 
      significantly different (P less than 0.01) whereas the half-life of elimination 
      and the elimination rate constant were not significantly different (P greater 
      than 0.01). The results showed that absorption was delayed when aspirin was 
      simultaneously administered with chloroquine but the distribution and elimination 
      of chloroquine were not affected by the presence of aspirin.
FAU - Adelusi, S A
AU  - Adelusi SA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gen Pharmacol
JT  - General pharmacology
JID - 7602417
RN  - 886U3H6UFF (Chloroquine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adsorption
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chloroquine/administration & dosage/blood/*metabolism
MH  - Half-Life
MH  - Kinetics
MH  - Male
MH  - Rabbits
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 0306-3623(84)90171-X [pii]
AID - 10.1016/0306-3623(84)90171-x [doi]
PST - ppublish
SO  - Gen Pharmacol. 1984;15(3):259-61. doi: 10.1016/0306-3623(84)90171-x.

PMID- 21360514
OWN - NLM
STAT- MEDLINE
DCOM- 20130124
LR  - 20131121
IS  - 1529-0131 (Electronic)
IS  - 0004-3591 (Linking)
VI  - 63
IP  - 3
DP  - 2011 Mar
TI  - Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy 
      subjects: recommendations to minimize the functional consequences.
PG  - 850-9
LID - 10.1002/art.30175 [doi]
AB  - OBJECTIVE: To investigate whether low-dose naproxen sodium (220 mg twice a day) 
      interferes with aspirin's antiplatelet effect in healthy subjects. METHODS: We 
      performed a crossover, open-label study in 9 healthy volunteers. They received 
      for 6 days 3 different treatments separated by 14 days of washout: 1) naproxen 2 
      hours before aspirin, 2) aspirin 2 hours before naproxen, and 3) aspirin alone. 
      The primary end point was the assessment of serum thromboxane B(2) (TXB(2)) 24 
      hours after the administration of naproxen 2 hours before aspirin on day 6 of 
      treatment. In 5 volunteers, the rate of recovery of TXB(2) generation (up to 72 
      hours after drug discontinuation) was assessed in serum and in platelet-rich 
      plasma stimulated with arachidonic acid (AA) or collagen. RESULTS: Twenty-four 
      hours after the last dosing on day 6 in volunteers receiving aspirin alone or 
      aspirin before naproxen, serum TXB(2) was almost completely inhibited (median 
      [range] 99.1% [97.4-99.4%] and 99.1% [98.0-99.7%], respectively). Naproxen given 
      before aspirin caused a slightly lower inhibition of serum TXB(2) (median [range] 
      98.0% [90.6-99.4%]) than aspirin alone (P = 0.0007) or aspirin before naproxen (P 
      = 0.0045). All treatments produced a maximal inhibition of AA-induced platelet 
      aggregation. At 24 hours, compared with baseline, collagen-induced platelet 
      aggregation was still inhibited by aspirin alone (P = 0.0003), but not by aspirin 
      given 2 hours before or after naproxen. Compared with administration of aspirin 
      alone, the sequential administration of naproxen and aspirin caused a significant 
      parallel upward shift of the regression lines describing the recovery of platelet 
      TXB(2). CONCLUSION: Sequential administration of 220 mg naproxen twice a day and 
      low-dose aspirin interferes with the irreversible inhibition of platelet 
      cyclooxygenase 1 afforded by aspirin. The interaction was smaller when giving 
      naproxen 2 hours after aspirin. The clinical consequences of these 2 schedules of 
      administration of aspirin with naproxen remain to be studied in randomized 
      clinical trials.
CI  - Copyright © 2011 by the American College of Rheumatology.
FAU - Anzellotti, Paola
AU  - Anzellotti P
AD  - G. d'Annunzio University-Chieti and G. d'Annunzio University Foundation, Chieti, 
      Italy. ppatrignani@unich.it
FAU - Capone, Marta L
AU  - Capone ML
FAU - Jeyam, Anita
AU  - Jeyam A
FAU - Tacconelli, Stefania
AU  - Tacconelli S
FAU - Bruno, Annalisa
AU  - Bruno A
FAU - Tontodonati, Paola
AU  - Tontodonati P
FAU - Di Francesco, Luigia
AU  - Di Francesco L
FAU - Grossi, Linda
AU  - Grossi L
FAU - Renda, Giulia
AU  - Renda G
FAU - Merciaro, Gabriele
AU  - Merciaro G
FAU - Di Gregorio, Patrizia
AU  - Di Gregorio P
FAU - Price, Thomas S
AU  - Price TS
FAU - Garcia Rodriguez, Luis A
AU  - Garcia Rodriguez LA
FAU - Patrignani, Paola
AU  - Patrignani P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57Y76R9ATQ (Naproxen)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/blood
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*administration & dosage/adverse effects/blood
MH  - Blood Platelets/*drug effects
MH  - Collagen/pharmacology
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Naproxen/*administration & dosage/adverse effects/blood
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects/blood
MH  - Platelet-Rich Plasma/drug effects
MH  - Reference Values
MH  - Thromboxane B2/blood
MH  - Young Adult
EDAT- 2011/03/02 06:00
MHDA- 2013/01/25 06:00
CRDT- 2011/03/02 06:00
PHST- 2011/03/02 06:00 [entrez]
PHST- 2011/03/02 06:00 [pubmed]
PHST- 2013/01/25 06:00 [medline]
AID - 10.1002/art.30175 [doi]
PST - ppublish
SO  - Arthritis Rheum. 2011 Mar;63(3):850-9. doi: 10.1002/art.30175.

PMID- 8808777
OWN - NLM
STAT- MEDLINE
DCOM- 19970124
LR  - 20131121
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 13
IP  - 4
DP  - 1996 Jul-Aug
TI  - Combined dipyridamole and aspirin pellet formulation for improved oral drug 
      delivery. Part 2: In-vivo evaluation and stability.
PG  - 395-405
AB  - Hard capsules containing 150 mg dipyridamole and 100 mg aspirin containing 
      pellets were compared in 12 humans against the equivalent dose of conventional 
      products given twice daily. The new product gave extended and more uniform levels 
      of dipyridamole in the steady-state, with a lower incidence of undesirable 
      side-effects, whereas aspirin levels were similar. The new product also had 
      acceptable long-term stability provided it was stored under cool conditions and 
      low humidity.
FAU - Murtagh, P W
AU  - Murtagh PW
AD  - Department of Pharmaceutics, Trinity College, University of Dublin, Ireland.
FAU - Deasy, P B
AU  - Deasy PB
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Capsules)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects/*pharmacokinetics
MH  - Capsules
MH  - Dipyridamole/*administration & dosage/adverse effects/*pharmacokinetics
MH  - Drug Combinations
MH  - Drug Stability
MH  - Drug Storage
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/*pharmacokinetics
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
AID - 10.3109/02652049609026026 [doi]
PST - ppublish
SO  - J Microencapsul. 1996 Jul-Aug;13(4):395-405. doi: 10.3109/02652049609026026.

PMID- 404672
OWN - NLM
STAT- MEDLINE
DCOM- 19770622
LR  - 20190823
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 13
IP  - 4
DP  - 1977 Apr
TI  - Lack of covalent modification of prostaglandin synthetase (cyclo-oxygenase) by 
      indomethacin.
PG  - 669-75
AB  - We have previously shown that aspirin irreversibly inhibits prostaglandin 
      synthetase (cyclo-oxygenase) by acetylating the active site of the enzyme. By 
      utilizing 14C-labeled indomethacin and a close analogue, we now show that 
      indomethacin, unlike aspirin, does not covalently modify cyclo-oxygenase. 
      Furthermore, indomethacin binding to the enzyme may be reversible since even 
      though indomethacin can inhibit acetylation by aspirin, when enzyme inhibited by 
      indomethacin (1 micronM) is treated with 200 micronM aspirin 3 times for 1 hour 
      each, complete acetylation of cyclo-oxygenase is achieved.
FAU - Stanford, N
AU  - Stanford N
FAU - Roth, G J
AU  - Roth GJ
FAU - Shen, T Y
AU  - Shen TY
FAU - Majerus, P W
AU  - Majerus PW
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/metabolism/pharmacology
MH  - Binding Sites/drug effects
MH  - Drug Synergism
MH  - Indomethacin/*analogs & derivatives/metabolism/*pharmacology
MH  - Mixed Function Oxygenases/*metabolism
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - Protein Binding/drug effects
EDAT- 1977/04/01 00:00
MHDA- 1977/04/01 00:01
CRDT- 1977/04/01 00:00
PHST- 1977/04/01 00:00 [pubmed]
PHST- 1977/04/01 00:01 [medline]
PHST- 1977/04/01 00:00 [entrez]
AID - 0090-6980(77)90237-4 [pii]
AID - 10.1016/0090-6980(77)90237-4 [doi]
PST - ppublish
SO  - Prostaglandins. 1977 Apr;13(4):669-75. doi: 10.1016/0090-6980(77)90237-4.

PMID- 8442934
OWN - NLM
STAT- MEDLINE
DCOM- 19930402
LR  - 20131121
IS  - 0278-2626 (Print)
IS  - 0278-2626 (Linking)
VI  - 21
IP  - 2
DP  - 1993 Mar
TI  - Visual field effects of classical migraine.
PG  - 181-91
AB  - Although classical migraine is known to produce lateralized sensory disturbances 
      (e.g., visual "fortification" structures), its effect on higher order processes 
      is unknown. Here four lateralized visual tasks were repeatedly presented to a 
      single subject (the author) over a 2 1/2-year span, during both classical 
      migraine attacks and headache-free periods. Attacks varied as to inferred 
      hemispheric locus. All four tasks ("words," "typing," "bar graphs," and 
      "locations") produced significant or marginally significant visual field (VF) by 
      condition interactions, results generally consistent with a phasic impairment of 
      function in the migrainous hemisphere. A content analysis of notes made during 
      the attacks suggests that among other symptoms, alphabetic indistinctiveness and 
      spatial disturbances are characteristics of left and right hemisphere attacks, 
      respectively. Aspects of the results argue against any major influence of demand 
      characteristics.
FAU - Boles, D B
AU  - Boles DB
AD  - Department of Psychology, Rensselaer Polytechnic Institute, Troy, NY 12065.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Brain Cogn
JT  - Brain and cognition
JID - 8218014
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Brain/*physiopathology
MH  - Functional Laterality
MH  - Humans
MH  - Male
MH  - Migraine Disorders/drug therapy/*physiopathology
MH  - Photic Stimulation
MH  - *Visual Fields
EDAT- 1993/03/01 00:00
MHDA- 1993/03/01 00:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 1993/03/01 00:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
AID - S0278-2626(83)71014-6 [pii]
AID - 10.1006/brcg.1993.1014 [doi]
PST - ppublish
SO  - Brain Cogn. 1993 Mar;21(2):181-91. doi: 10.1006/brcg.1993.1014.

PMID- 1095133
OWN - NLM
STAT- MEDLINE
DCOM- 19751010
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 3
IP  - 5975
DP  - 1975 Jul 12
TI  - Indomethacin--aspirin interaction: a clinical appraisal.
PG  - 69-71
AB  - Plasma profiles of indomethacin after a 50-mg oral dose were constructed in six 
      healthy volunteers before and after a week of aspirin treatment. Aspirin did not 
      interfere with indomethacin plasma levels. To examine the clinical effect of 
      concurrent indomethacin and aspirin treatment 20 patients with seropositive 
      rheumatoid arthritis were given indomethacin 100 mg/day, aspirin soluble 4 g/day, 
      and the two drugs taken together in random order. Analysis of the clinical 
      indices of inflammation--articular index and mean pain score--and of the efficacy 
      of each treatment showed no significant differences between the three treatment 
      groups. With the proliferation in the number of anti-rheumatic drugs available, 
      the case for giving two or more nonsteroidal anti-inflammatory drugs concurrently 
      remains unproved.
FAU - Brooks, P M
AU  - Brooks PM
FAU - Walker, J J
AU  - Walker JJ
FAU - Bell, M A
AU  - Bell MA
FAU - Buchanan, W W
AU  - Buchanan WW
FAU - Rhymer, A R
AU  - Rhymer AR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Interactions
MH  - Humans
MH  - Indomethacin/*blood/therapeutic use
MH  - Inflammation/drug therapy
MH  - Middle Aged
MH  - Placebos
PMC - PMC1673635
EDAT- 1975/07/12 00:00
MHDA- 1975/07/12 00:01
CRDT- 1975/07/12 00:00
PHST- 1975/07/12 00:00 [pubmed]
PHST- 1975/07/12 00:01 [medline]
PHST- 1975/07/12 00:00 [entrez]
AID - 10.1136/bmj.3.5975.69 [doi]
PST - ppublish
SO  - Br Med J. 1975 Jul 12;3(5975):69-71. doi: 10.1136/bmj.3.5975.69.

PMID- 1199984
OWN - NLM
STAT- MEDLINE
DCOM- 19760209
LR  - 20190716
IS  - 0002-922X (Print)
IS  - 0002-922X (Linking)
VI  - 129
IP  - 12
DP  - 1975 Dec
TI  - Aspirin hepatitis.
PG  - 1433-4
AB  - Adverse reactions to aspirin, a potentially hepatotoxic drug, are believed to be 
      dose related. This article reviews the medical literature and described two 
      children with aspirin hepatitis. Hepatic dysfunction recurred in one of these 
      patients at salicylate concentrations in serum previously considered nontoxic.
FAU - Zucker, P
AU  - Zucker P
FAU - Daum, F
AU  - Daum F
FAU - Cohen, M I
AU  - Cohen MI
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Dis Child
JT  - American journal of diseases of children (1960)
JID - 0370471
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anemia, Sickle Cell/complications
MH  - Arthritis, Juvenile/complications/*drug therapy
MH  - Aspartate Aminotransferases/blood
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Chemical and Drug Induced Liver Injury/*etiology
MH  - Child
MH  - Female
MH  - Humans
MH  - Lupus Erythematosus, Systemic/*drug therapy
MH  - Male
MH  - Time Factors
EDAT- 1975/12/01 00:00
MHDA- 1975/12/01 00:01
CRDT- 1975/12/01 00:00
PHST- 1975/12/01 00:00 [pubmed]
PHST- 1975/12/01 00:01 [medline]
PHST- 1975/12/01 00:00 [entrez]
AID - 10.1001/archpedi.1975.02120490045014 [doi]
PST - ppublish
SO  - Am J Dis Child. 1975 Dec;129(12):1433-4. doi: 
      10.1001/archpedi.1975.02120490045014.

PMID- 3130280
OWN - NLM
STAT- MEDLINE
DCOM- 19880614
LR  - 20131121
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 11
IP  - 12
DP  - 1987 Dec
TI  - [Effects of enprostil on changes in the gastric transepithelial potential 
      differential induced by aspirin].
PG  - 886-90
AB  - Enprostil (E), is a semisynthetic E2 prostaglandin with wide-range antisecretory 
      properties. Administered orally E reduced mucosal injury in rats exposed to NSAID 
      and gastric acid. The aim of the present study was to analyze the cytoprotective 
      effect of 7 micrograms of E on the aspirin-induced (500 mg) decrease in gastric 
      transepithelial difference of potential (DP) in a) five healthy volunteers and b) 
      five patients with epigastric heartburn, normal endoscopy and a low gastric DP 
      (mucosal barrier weakness). Aspirin-induced decrease of gastric DP was measured 
      during two four hour periods separated by an interval of two days: a) during a 
      one hour basal period and after three hours after 7 micrograms of E, and b) 
      during a second basal period and one hour after aspirin, E, and then aspirin 
      again. The following parameters were analyzed: maximal drop of DP DP Max (mV), 
      area under the curve of DP drop, AUC (mV.min), and time to return to basal 
      values, TRB (min). In the control group, when E was administered after aspirin, 
      the decrease in DP Max (11.4 +/- 2.3 vs 6.6 +/- 2.1) and in AUC (68 +/- 22 vs 35 
      +/- 11) was significant (p less than 0.05) as compared with values obtained after 
      aspirin alone. In the patient group, E produced a significant decrease in 
      aspirin-induced DP Max (11.8 +/- 1.9 vs 6.8 +/- 2.4) (p less than 0.003) and in 
      AUC (117 +/- vs 48 less than 22) (p less than 0.006) as well as in TRB (52 +/- 2 
      vs 37 +/- 10) (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Florent, C
AU  - Florent C
AD  - Hôpital Saint-Antoine, Paris.
FAU - Desaint, B
AU  - Desaint B
FAU - Joubert, M
AU  - Joubert M
FAU - Maurel, M
AU  - Maurel M
FAU - Bernier, J J
AU  - Bernier JJ
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Effets de l'enprostil sur les modifications de la différence de potentiel 
      transépithéliale gastrique induites par l'aspirine.
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - 0 (Prostaglandins E, Synthetic)
RN  - J4IP5Z9DAU (Enprostil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Action Potentials/drug effects
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Enprostil
MH  - Female
MH  - Gastric Mucosa/*drug effects/physiology/physiopathology
MH  - Humans
MH  - Male
MH  - Prostaglandins E, Synthetic/*pharmacology
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
PST - ppublish
SO  - Gastroenterol Clin Biol. 1987 Dec;11(12):886-90.

PMID- 713432
OWN - NLM
STAT- MEDLINE
DCOM- 19790124
LR  - 20190711
IS  - 0023-2173 (Print)
IS  - 0023-2173 (Linking)
VI  - 56
IP  - 22
DP  - 1978 Nov 15
TI  - Pharmacokinetic investigations in adult humans after parenteral administration of 
      the lysine salt of acetyl-salicylic acid.
PG  - 1119-23
AB  - The lysine salt of acetylsalicylic acid was administered intravenously to four 
      volunteers and intramuscularly to three of them. The drug was tolerated without 
      any observed side effects. Immediately after intravenous application most of the 
      plasma salicylate was acetylsalicylic acid. The highest concentration of 
      acetylsalicylic acid was found after 2 minutes, highest levels of salicylic acid 
      after 60 minutes. Elimination of acetylsalicylic acid was relatively quick within 
      the first period after intravenous administration according to a half-life of 8 
      minutes. Half-life of salicylic acid was determined to be 3 hours. Intramuscular 
      application results in a constant blood level for a longer period. 
      Bioavailability of acetylsalicylic acid was slightly lower after intramuscular 
      application than after intravenous administration.
FAU - von Voss, H
AU  - von Voss H
FAU - Göbel, U
AU  - Göbel U
FAU - Petrich, C
AU  - Petrich C
FAU - Pütter, J
AU  - Pütter J
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Klin Wochenschr
JT  - Klinische Wochenschrift
JID - 2985205R
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/metabolism
MH  - Drug Tolerance
MH  - Half-Life
MH  - Humans
MH  - Infusions, Parenteral
MH  - Injections, Intramuscular
MH  - Kinetics
MH  - Lysine/administration & dosage/*metabolism
EDAT- 1978/11/15 00:00
MHDA- 1978/11/15 00:01
CRDT- 1978/11/15 00:00
PHST- 1978/11/15 00:00 [pubmed]
PHST- 1978/11/15 00:01 [medline]
PHST- 1978/11/15 00:00 [entrez]
AID - 10.1007/BF01477134 [doi]
PST - ppublish
SO  - Klin Wochenschr. 1978 Nov 15;56(22):1119-23. doi: 10.1007/BF01477134.

PMID- 32469305
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 58
IP  - 8
DP  - 2020 Aug
TI  - Bioavailability study of two 81-mg coated tablet formulations of acetylsalicylic 
      acid in fed healthy subjects .
PG  - 457-464
LID - 10.5414/CP203575 [doi]
AB  - OBJECTIVE: To perform a comparative bioavailability study between a test 
      (re-formulation) and a reference acetylsalicylic acid formulation (Ecasil-81, 
      81 mg coated tablet) in healthy subjects under fed condition. MATERIALS AND 
      METHODS: Healthy subjects (n = 48) were included in this monocentric, open-label, 
      randomized, two-way crossover pharmacokinetic study. They received a single 81-mg 
      oral dose of a test or a reference formulation of acetylsalicylic acid under fed 
      condition, with a 7-day washout period between the treatments. Blood samples were 
      collected over a period of 36 hours. The salicylic acid plasma concentration was 
      measured by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). 
      Pharmacokinetic analysis was performed using WinNonlin software. RESULTS: The 
      geometric mean and 90% confidence interval of test/reference formulation ratios 
      were 109.32% (102.54 - 116.54%) and 106.94% (102.97 - 111.07%) for salicylic acid 
      C(max) and AUC(0-last), respectively. Food decreased the AUC and C(max) 
      (p < 0.001) and delayed the t(max) (p = 0.0077). The investigated women presented 
      higher AUC(0-∞) and C(max) values (p < 0.001) than men. The clinical and 
      laboratory exams did not show significant alterations. CONCLUSION: The 
      re-formulation is bioequivalent to the reference formulation regarding the 
      absorption extent and rate in fed healthy subjects. The administration of 
      acetylsalicylic acid with food decreased its bioavailability. Moreover, 
      differences in salicylic acid disposition related to sex were observed. The 
      treatments were well tolerated by the investigated subjects.
FAU - Dolores, Raul Cleverson
AU  - Dolores RC
FAU - Antunes, Natalícia de Jesus
AU  - Antunes NJ
FAU - Czezacki, Alexandre Scremin
AU  - Czezacki AS
FAU - Previato, Carolina
AU  - Previato C
FAU - Campos, Rafael
AU  - Campos R
FAU - Moreno, Ronilson A
AU  - Moreno RA
FAU - Mendes, Gustavo D
AU  - Mendes GD
FAU - De Nucci, Gilberto
AU  - De Nucci G
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Area Under Curve
MH  - Aspirin/adverse effects/*pharmacology
MH  - Biological Availability
MH  - Chromatography, Liquid
MH  - Cross-Over Studies
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Tablets
MH  - Tandem Mass Spectrometry
MH  - Therapeutic Equivalency
EDAT- 2020/05/30 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 186739 [pii]
AID - 10.5414/CP203575 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2020 Aug;58(8):457-464. doi: 10.5414/CP203575.

PMID- 2757664
OWN - NLM
STAT- MEDLINE
DCOM- 19890901
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 39
IP  - 3
DP  - 1989 Mar
TI  - [Absolute bioavailability of a special sustained-release acetylsalicylic acid 
      formulation].
PG  - 391-4
AB  - Absolute Bioavailability of a Special Acetylsalicylic Acid Sustained Release 
      Formulation. The absolute bioavailability of an acetylsalicylic acid (ASA) 
      sustained release formulation (Contrheuma retard), containing 300 mg ASA as 
      initial dose and 350 mg in a retard formulation, was determined in comparison to 
      a standard ASA solution for intravenous administration in a two-treatment, 
      two-period cross-over trial with 6 healthy male volunteers by comparing the areas 
      under the plasma-fluctuation-time curves of the primary metabolite. In addition, 
      it was examined by comparison of the mean times after administration of both 
      formulations, whether the test formulation meets the requirements of a sustained 
      release formulation. The investigations led to the following results: The 
      absolute bioavailability of the test formulation was 95%. The statistical 
      comparison of the areas under the concentration-time courses allowed no decision 
      (neither for equivalence nor difference). The maximal concentration of SA after 
      intravenous administration of the standard formulation was reached after 0.4 h on 
      an average and amounted to 62 micrograms/ml. After oral administration of the 
      test formulation, a mean concentration maximum of 28 micrograms/ml was 
      calculated, which had been reached after about 2 h. The differences are 
      statistically significant. The mean time for SA was 6 h after the standard 
      formulation, whereas after administration of the test compound, a mean of 11.5 h 
      was calculated. 24 h following administration, the concentration of SA was 1.3 
      micrograms/ml after intravenous administration of the standard formulation and 
      5.5 micrograms/ml after administration of the test formulation. These 
      differences, too, are statistically significant. From the comparison of the mean 
      time for SA, a retard factor of 1.9 was calculated.
FAU - Lücker, P W
AU  - Lücker PW
AD  - Institut für klinische Pharmakologie Bobenheim, Grünstadt.
FAU - Swoboda, M
AU  - Swoboda M
FAU - Wetzelsberger, N
AU  - Wetzelsberger N
LA  - ger
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Absolute Bioverfügbarkeit einer speziellen, retardierten 
      Acetylsalicylsäure-Zubereitung.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Delayed-Action Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid
MH  - Delayed-Action Preparations
MH  - Humans
MH  - Male
MH  - Random Allocation
EDAT- 1989/03/01 00:00
MHDA- 1989/03/01 00:01
CRDT- 1989/03/01 00:00
PHST- 1989/03/01 00:00 [pubmed]
PHST- 1989/03/01 00:01 [medline]
PHST- 1989/03/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1989 Mar;39(3):391-4.

PMID- 2487727
OWN - NLM
STAT- MEDLINE
DCOM- 19910327
LR  - 20131121
IS  - 1019-9128 (Print)
IS  - 1019-9128 (Linking)
VI  - 60
IP  - 4
DP  - 1989 Dec
TI  - Pharmacokinetics of aspirin and its application in canine veterinary medicine.
PG  - 191-4
AB  - In preliminary investigation of the pharmacokinetics of aspirin in dogs it became 
      apparent that the drug was well absorbed following oral ingestion with food. 
      Multiple dosing appeared to lead to a substantial increase in half-life; a twice 
      daily dosage regimen would, therefore, be adequate for maintenance of therapeutic 
      levels in dogs. The marked variation in pharmacokinetic parameters observed 
      suggested that therapeutic drug monitoring would be benefit in the control of 
      canine inflammatory conditions using aspirin. Therapeutic monitoring of dogs (n = 
      20) showed that clinical improvement paralleled plasma salicylate concentrations 
      and the therapeutic concentrations so determined were within the range considered 
      therapeutic in humans. No overt gastric irritation was noted in this study over a 
      period of a year which suggests that aspirin can be successfully used to treat 
      canine inflammatory disorders, routine monitoring of plasma salicylate being 
      recommended to ensure therapeutic success.
FAU - Morton, D J
AU  - Morton DJ
AD  - Department of Pharmacy, Faculty of Medicine, University of Zimbabwe.
FAU - Knottenbelt, D C
AU  - Knottenbelt DC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - South Africa
TA  - J S Afr Vet Assoc
JT  - Journal of the South African Veterinary Association
JID - 7503122
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arthritis, Rheumatoid/drug therapy/*veterinary
MH  - Aspirin/administration & dosage/*pharmacokinetics/therapeutic use
MH  - Dog Diseases/*drug therapy
MH  - Dogs/metabolism
MH  - Female
MH  - Male
MH  - Salicylates/blood
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
PST - ppublish
SO  - J S Afr Vet Assoc. 1989 Dec;60(4):191-4.

PMID- 24783984
OWN - NLM
STAT- MEDLINE
DCOM- 20150102
LR  - 20140521
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 13
IP  - 6
DP  - 2014 Jun
TI  - Aspirin and age-related macular degeneration: positives versus negatives.
PG  - 687-90
LID - 10.1517/14740338.2014.915939 [doi]
AB  - The anti-inflammatory, analgesic, antipyretic and antithrombotic activities of 
      aspirin confer its wide therapeutic application. The three former activities 
      require higher doses of aspirin, whereas the latter can be achieved through a 
      lower, thus safer dose of the drug. Low-dose, long-term aspirin is used as an 
      antithrombotic therapy to prevent cardiovascular disease. Such therapy is used by 
      millions of people worldwide, including those suffering from age-related macular 
      degeneration (AMD); thus, questions have arisen as to whether such treatment has 
      any impact on the development and course of AMD. This editorial addresses the 
      important issue of possible beneficial and adverse effects of long-term, low-dose 
      aspirin treatment of AMD patients. Special emphasis is given to the ability of 
      aspirin to acetylate cyclooxygenases (especially COX-2) and thus to initiate a 
      biochemical pathway leading to the generation of anti-inflammatory pro-resolving 
      mediators synthesized from both ω-3 and ω-6 long-chain polyunsaturated fatty 
      acids. Such mediators (e.g., resolvins, lipoxins) may be of therapeutic value in 
      retarding the development of dry form AMD.
FAU - Nowak, Jerzy Z
AU  - Nowak JZ
AD  - Medical University, Department of Pharmacology and Toxicology, Interfaculty Chair 
      of General and Clinical Pharmacology , Lodz , Poland.
LA  - eng
PT  - Journal Article
DEP - 20140430
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Lipoxins)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology/*therapeutic 
      use
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Cyclooxygenase 2/drug effects/metabolism
MH  - Fatty Acids, Unsaturated/metabolism
MH  - Humans
MH  - Lipoxins/metabolism
MH  - Macular Degeneration/*drug therapy/pathology
OTO - NOTNLM
OT  - age-related macular degeneration
OT  - aspirin
OT  - lipoxins
OT  - long-term therapy
OT  - protectins
OT  - resolvins
EDAT- 2014/05/03 06:00
MHDA- 2015/01/03 06:00
CRDT- 2014/05/03 06:00
PHST- 2014/05/03 06:00 [entrez]
PHST- 2014/05/03 06:00 [pubmed]
PHST- 2015/01/03 06:00 [medline]
AID - 10.1517/14740338.2014.915939 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2014 Jun;13(6):687-90. doi: 10.1517/14740338.2014.915939. 
      Epub 2014 Apr 30.

PMID- 7560825
OWN - NLM
STAT- MEDLINE
DCOM- 19951023
LR  - 20131121
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 21
IP  - 1
DP  - 1995 Jul
TI  - Gastrointestinal bleeding during low-dose aspirin administration for prevention 
      of arterial occlusive events. A critical analysis.
PG  - 13-6
AB  - Low-dose aspirin has been recommended for primary and secondary prevention of 
      myocardial infarction and for the maintenance of aortocoronary bypass patency. 
      Doses as low as 75 mg/day significantly lessen the risk of stroke or death in 
      patients who experience cerebrovascular and ischemic events. Aspirin in 
      antiinflammatory doses has been associated with gastrointestinal bleeding, and 
      the bleeding potential of even 75 mg aspirin has been established. I assessed the 
      role of low-dose aspirin in gastrointestinal bleeding by combining the results of 
      nine studies that dealt with the prevention of ischemic, thromboembolic, or 
      cerebrovascular events. The combination of the results showed that the occurrence 
      of bleeding was 1.5 times higher in patients treated with low-dose aspirin in 
      doses of 75-325 mg/day as compared with placebo (odds ratio 1.52; 95% CI 
      1.32-1.75). The monthly probability of gastrointestinal bleeding per 1,000 
      patients treated with low-dose aspirin ranged between 0 and 2.1.
FAU - Stalnikowicz-Darvasi, R
AU  - Stalnikowicz-Darvasi R
AD  - Department of Internal Medicine, Hadassah University Hospital, Mount Scopus, 
      Jerusalem, Israel.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arterial Occlusive Diseases/*prevention & control
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clinical Trials as Topic
MH  - Drug Administration Schedule
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
RF  - 20
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
PST - ppublish
SO  - J Clin Gastroenterol. 1995 Jul;21(1):13-6.

PMID- 7980214
OWN - NLM
STAT- MEDLINE
DCOM- 19941201
LR  - 20190825
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 24
IP  - 3
DP  - 1994 Jun
TI  - Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat 
      animal model.
PG  - 301-3
AB  - BACKGROUND: Epidemiological studies in humans suggest that regular use of 
      non-steroidal anti-inflammatory drugs (NSAIDS) especially aspirin significantly 
      decreases the risk of developing colorectal cancer. AIMS: The purpose of this 
      study was to investigate the effect of aspirin on colonic carcinogenesis using 
      the dimethylhydrazine (DMH) colonic cancer model in rats. METHODS: Groups of 
      animals were given daily doses of aspirin either 0, 5, 30 or 60 mg/kg for 18 
      weeks. Half of each group also received 18 x 30 mg/kg/wk injections of DMH. 
      RESULTS: Aspirin at doses of 5, 30 or 60 mg/kg/dy had a progressive effect on the 
      reduction of tumour numbers and the percentage of tumours greater or equal to 5 
      mm in diameter. Aspirin at doses of 30 and 60 mg/kg/dy significantly reduced 
      tumour incidence. CONCLUSION: These findings support the epidemiological studies 
      in humans. The rat DMH model would appear to be suitable for investigating the 
      mechanism of action of aspirin in reducing colonic tumour formation.
FAU - Davis, A E
AU  - Davis AE
AD  - Department of Gastroenterology, Prince of Wales Hospital, Sydney, NSW, Australia.
FAU - Patterson, F
AU  - Patterson F
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 0 (Dimethylhydrazines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Colonic Neoplasms/chemically induced/*prevention & control
MH  - Dimethylhydrazines
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Male
MH  - Rats
MH  - Rats, Wistar
EDAT- 1994/06/01 00:00
MHDA- 1994/06/01 00:01
CRDT- 1994/06/01 00:00
PHST- 1994/06/01 00:00 [pubmed]
PHST- 1994/06/01 00:01 [medline]
PHST- 1994/06/01 00:00 [entrez]
AID - 10.1111/j.1445-5994.1994.tb02176.x [doi]
PST - ppublish
SO  - Aust N Z J Med. 1994 Jun;24(3):301-3. doi: 10.1111/j.1445-5994.1994.tb02176.x.

PMID- 9495978
OWN - NLM
STAT- MEDLINE
DCOM- 19980312
LR  - 20131121
IS  - 0254-1769 (Print)
IS  - 0254-1769 (Linking)
VI  - 32
IP  - 9
DP  - 1997 Sep
TI  - [Clinical study of using aspirin at various times to reduce adverse reactions of 
      alpha-IFN].
PG  - 505-6
AB  - This article takes the records of an experiment on the effects of using aspirin 
      in different times. Two groups of patients were formed. The control group took 
      the medicine by traditional routines, the experiment group had the medicine 
      preventively according to the specialty of the alpha-IFN adverse reaction. The 
      latter was proved to be much more affective. It was concluded that it was more 
      effective to use aspirin before adverse reaction appear than after that.
FAU - Yue, J R
AU  - Yue JR
AD  - Shenzhen Donghu Hospital, Guangdong.
LA  - chi
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Hu Li Za Zhi
JT  - Zhonghua hu li za zhi = Chinese journal of nursing
JID - 8201928
RN  - 0 (Interferon-alpha)
RN  - R16CO5Y76E (Aspirin)
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Female
MH  - Humans
MH  - Interferon-alpha/*adverse effects/antagonists & inhibitors
MH  - Male
MH  - Middle Aged
MH  - Time Factors
EDAT- 1998/03/13 00:00
MHDA- 1998/03/13 00:01
CRDT- 1998/03/13 00:00
PHST- 1998/03/13 00:00 [pubmed]
PHST- 1998/03/13 00:01 [medline]
PHST- 1998/03/13 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Hu Li Za Zhi. 1997 Sep;32(9):505-6.

PMID- 1521715
OWN - NLM
STAT- MEDLINE
DCOM- 19921014
LR  - 20180216
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 51
IP  - 3
DP  - 1992
TI  - Cell-kinetic alterations induced by aspirin in human gastric mucosa and their 
      prevention by a cytoprotective agent.
PG  - 146-51
AB  - The effect on gastric epithelial cell proliferation of a short-term, low-dose 
      treatment with aspirin was evaluated in 9 healthy volunteers. Nine days before 
      and during aspirin administration, the subjects assumed sulglycotide, a sulfated 
      glycopeptide with cytoprotective properties. Endoscopic biopsies were collected 
      in each subject from the gastric body and antrum before and after treatment. The 
      specimens were incubated in a culture medium containing bromodeoxyuridine (BrdU). 
      The proliferative activity was evaluated by immunohistochemical detection of BrdU 
      uptake. A decrease in BrdU-labelled cells together with a shortening of the 
      length of gastric columns were observed after treatment with aspirin and placebo 
      in biopsies of both body and antrum (p less than 0.05). On the contrary, no 
      modifications were observed after treatment with aspirin and sulglycotide. We 
      conclude that a decrease in the proliferative activity of the epithelial cells 
      could be one of the mechanisms by which aspirin affects the defensive properties 
      of gastric mucosa. The treatment with a cytoprotective drug seems to be effective 
      in preventing this alteration.
FAU - Biasco, G
AU  - Biasco G
AD  - Istituto di Clinica Medica e Gastroenterologia, Università di Bologna, Italia.
FAU - Paganelli, G M
AU  - Paganelli GM
FAU - Di Febo, G
AU  - Di Febo G
FAU - Siringo, S
AU  - Siringo S
FAU - Barbara, L
AU  - Barbara L
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Culture Media)
RN  - 0 (Sialoglycoproteins)
RN  - 26473073GC (sulglicotide)
RN  - G34N38R2N1 (Bromodeoxyuridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Ulcer Agents/*pharmacology
MH  - Aspirin/administration & dosage/antagonists & inhibitors/*pharmacology
MH  - Bromodeoxyuridine/metabolism
MH  - Cell Division
MH  - Culture Media
MH  - Double-Blind Method
MH  - Epithelial Cells
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Pyloric Antrum/cytology/drug effects
MH  - Sialoglycoproteins/*pharmacology
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1159/000200890 [doi]
PST - ppublish
SO  - Digestion. 1992;51(3):146-51. doi: 10.1159/000200890.

PMID- 1783914
OWN - NLM
STAT- MEDLINE
DCOM- 19920319
LR  - 20220330
IS  - 0022-3050 (Print)
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
VI  - 54
IP  - 12
DP  - 1991 Dec
TI  - The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final 
      results.
PG  - 1044-54
AB  - From 1979-85, 2435 patients with a transient ischaemic attack or minor ischaemic 
      stroke were randomly allocated to receive long term "blind" treatment with 
      aspirin 600 mg twice daily (n = 815), aspirin 300 mg once daily (n = 806) or 
      placebo (n = 814). No patient was lost to follow up. The "intention to treat" 
      comparison included all the serious vascular events and deaths which occurred 
      before the end of the follow up period on 30 September 1986. There was no 
      difference in efficacy between the 300 mg and 1200 mg daily doses of aspirin, but 
      the lower dose was undoubtedly less gastrotoxic. Also, there was no definite 
      difference in the response of males and females to aspirin. The odds of suffering 
      a major stroke, myocardial infarction or vascular death were 15% less in the 
      combined aspirin groups compared with the placebo group (95% confidence interval 
      29% reduction to 3% increase in odds) which is compatible with the continuing 
      overview of all the similar trials of antiplatelet drugs where the relative 
      reduction in odds was 25%. There was no statistically significant reduction in 
      the likelihood of either disabling major stroke and vascular death or vascular 
      death occurring.
FAU - Farrell, B
AU  - Farrell B
FAU - Godwin, J
AU  - Godwin J
FAU - Richards, S
AU  - Richards S
FAU - Warlow, C
AU  - Warlow C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - United Kingdom
PMC - PMC1014676
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
AID - 10.1136/jnnp.54.12.1044 [doi]
PST - ppublish
SO  - J Neurol Neurosurg Psychiatry. 1991 Dec;54(12):1044-54. doi: 
      10.1136/jnnp.54.12.1044.

PMID- 34193948
OWN - NLM
STAT- MEDLINE
DCOM- 20211105
LR  - 20211105
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Jun 30
TI  - Low-dose aspirin for primary and secondary prevention of cardiovascular events in 
      Denmark 1998-2018.
PG  - 13603
LID - 10.1038/s41598-021-93179-8 [doi]
LID - 13603
AB  - Randomised controlled trials have shown a neutral or even unfavourable 
      risk-benefit balance of aspirin for primary prevention of cardiovascular events. 
      Using Danish nationwide registries, we investigated aspirin use and associated 
      risks during the past two decades (1998-2018). We linked individual patient data 
      on repeated aspirin redemptions with registered hospital ICD-10 diagnoses of 
      atherosclerotic cardiovascular disease and bleedings. The prevalence of aspirin 
      use among 1.1 million Danish adults fluctuated over the 20-year study period 
      peaking in 2008 with 8.5% (5.4% primary prevention) and dropping to 5.1% (3.1% 
      primary prevention) in 2018. Aspirin use showed strong age dependency, and 21% of 
      individuals > 80 years were treated with aspirin for primary prevention in 2018. 
      Medication adding to bleeding risk was used concurrently by 21% of all aspirin 
      users in 2018. The incidence of major bleedings were similar with primary and 
      secondary prevention aspirin use and highest in elderly (2 per 100 patient years 
      among individuals > 80 years in 2018). In conclusion, low-dose aspirin use for 
      primary prevention of cardiovascular events remains prevalent. The widespread use 
      of aspirin, especially among older adults, and substantial concomitant use of 
      medications adding to bleeding risk warrant increased focus on discontinuation of 
      inappropriate aspirin use.
FAU - Christensen, Mikkel B
AU  - Christensen MB
AUID- ORCID: 0000-0002-8774-1797
AD  - Department of Clinical Pharmacology, Bispebjerg Hospital, University of 
      Copenhagen, Bispebjerg Bakke 23, 2400, Copenhagen, Denmark. 
      mikkel.bring.christensen@regionh.dk.
AD  - Department of Clinical Medicine, University of Copenhagen, 2100, Copenhagen, 
      Denmark. mikkel.bring.christensen@regionh.dk.
AD  - Copenhagen Center for Translational Research, Bispebjerg Hospital, University of 
      Copenhagen, 2400, Copenhagen, Denmark. mikkel.bring.christensen@regionh.dk.
FAU - Jimenez-Solem, Espen
AU  - Jimenez-Solem E
AD  - Department of Clinical Pharmacology, Bispebjerg Hospital, University of 
      Copenhagen, Bispebjerg Bakke 23, 2400, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, 2100, Copenhagen, 
      Denmark.
FAU - Ernst, Martin T
AU  - Ernst MT
AD  - Clinical Pharmacology and Pharmacy, Department of Public Health, University of 
      Southern Denmark, 5000, Odense, Denmark.
FAU - Schmidt, Morten
AU  - Schmidt M
AD  - Department of Cardiology, Aarhus University Hospital, 8200, Aarhus, Denmark.
AD  - Department of Clinical Epidemiology, Aarhus University Hospital, 8200, Aarhus, 
      Denmark.
FAU - Pottegård, Anton
AU  - Pottegård A
AD  - Clinical Pharmacology and Pharmacy, Department of Public Health, University of 
      Southern Denmark, 5000, Odense, Denmark.
FAU - Grove, Erik L
AU  - Grove EL
AUID- ORCID: 0000-0002-1466-0865
AD  - Department of Cardiology, Aarhus University Hospital, 8200, Aarhus, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health, Aarhus University, 8200, 
      Aarhus, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20210630
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - *Cardiovascular Diseases/epidemiology/prevention & control
MH  - Denmark/epidemiology
MH  - Female
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
PMC - PMC8245534
COIS- All authors have completed the ICMJE uniform disclosure form at 
      www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation 
      for the submitted work. Authors MC, EJS, and MTE have no conflicts of interest in 
      relation to this manuscript. Author MS reports grant from Novo Nordisk 
      Foundation, outside the submitted work (NNF19OC0054908). Author AP reports 
      participation in research projects funded by Alcon, Almirall, Astellas, 
      Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier and LEO Pharma, all 
      with funds paid to the institution where he was employed (no personal fees) and 
      with no relation to the work reported in this paper. Outside this manuscript, ELG 
      has received speaker honoraria or consultancy fees from AstraZeneca, Bayer, 
      Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, MSD, Lundbeck Pharma, 
      MundiPharma, Portola Pharmaceuticals and Roche. HELG is an investigator in the 
      SATELLITE, FLAVOUR and ETESIAN studies (AstraZeneca) and has received research 
      grants from Boehringer Ingelheim.
EDAT- 2021/07/02 06:00
MHDA- 2021/11/06 06:00
CRDT- 2021/07/01 06:44
PHST- 2021/01/17 00:00 [received]
PHST- 2021/06/18 00:00 [accepted]
PHST- 2021/07/01 06:44 [entrez]
PHST- 2021/07/02 06:00 [pubmed]
PHST- 2021/11/06 06:00 [medline]
AID - 10.1038/s41598-021-93179-8 [pii]
AID - 93179 [pii]
AID - 10.1038/s41598-021-93179-8 [doi]
PST - epublish
SO  - Sci Rep. 2021 Jun 30;11(1):13603. doi: 10.1038/s41598-021-93179-8.

PMID- 19672841
OWN - NLM
STAT- MEDLINE
DCOM- 20100204
LR  - 20131121
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 18
IP  - 12
DP  - 2009 Dec
TI  - Aspirin increases mortality in diabetic patients without cardiovascular disease: 
      a Swedish record linkage study.
PG  - 1143-9
LID - 10.1002/pds.1828 [doi]
AB  - PURPOSE: Aspirin is effective in secondary prevention of cardiovascular disease. 
      The results are less convincing when aspirin is used for primary prevention even 
      in high-risk patients (i.e., patients with diabetes). We therefore analyzed the 
      effect of aspirin on mortality and serious bleeding in diabetic patients with and 
      without cardiovascular disease. METHODS: We performed a record linkage study of 
      the patient registry of the Västra Götaland region in south-western Sweden, the 
      Swedish mortality register and the Swedish register of dispensed drugs. All 
      diabetic patients (n = 58 465) from 1 July 2005 to 30 June 2006 were followed up 
      with respect to bleeding until 31 October 2006, and mortality until 31 December 
      2006. RESULTS: When 19 confounding factors (diseases and interventions) were 
      assessed, aspirin significantly increased mortality in diabetic patients without 
      cardiovascular disease from 17% (95% confidence interval; 95%CI, 1-36) at age 50 
      years to 29% (16-43) at age 85 years. In contrast aspirin tended to decrease 
      mortality among elderly diabetic patients with cardiovascular disease. 
      Theoretical calculations indicated that aspirin caused 107 excess deaths among 
      diabetic patients without cardiovascular disease and prevented 164 deaths among 
      diabetic patients with cardiovascular disease. Aspirin also increased the risk of 
      serious bleeding by 46% (95%CI, 22-75) in diabetic patients without 
      cardiovascular disease but decreased the risk among those with cardiovascular 
      disease. CONCLUSION: Aspirin use in diabetes patients without cardiovascular 
      disease remains controversial and current guidelines should be revised until 
      results from ongoing large randomized controlled trials become available.
CI  - Copyright (c) 2009 John Wiley & Sons, Ltd.
FAU - Welin, Lennart
AU  - Welin L
AD  - Department of Medicine, Lidköping Hospital, Lidköping, Sweden. 
      lennart.x.welin@vgregion.se
FAU - Wilhelmsen, Lars
AU  - Wilhelmsen L
FAU - Björnberg, Arne
AU  - Björnberg A
FAU - Odén, Anders
AU  - Odén A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*mortality/prevention & control
MH  - Diabetes Complications/*mortality/prevention & control
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - *Medical Record Linkage
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Secondary Prevention
MH  - Sweden
EDAT- 2009/08/13 09:00
MHDA- 2010/02/05 06:00
CRDT- 2009/08/13 09:00
PHST- 2009/08/13 09:00 [entrez]
PHST- 2009/08/13 09:00 [pubmed]
PHST- 2010/02/05 06:00 [medline]
AID - 10.1002/pds.1828 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1143-9. doi: 10.1002/pds.1828.

PMID- 2393892
OWN - NLM
STAT- MEDLINE
DCOM- 19901010
LR  - 20131121
IS  - 0008-7335 (Print)
IS  - 0008-7335 (Linking)
VI  - 129
IP  - 26
DP  - 1990 Jun 29
TI  - [Treatment of chronic glomerulonephritis with small doses of acetylsalicylic 
      acid].
PG  - 820-3
AB  - The purpose of the investigation was to evaluate the long-term administration of 
      100 mg acetylsalicylic acid in patients with chronic proliferative 
      glomerulonephritis. Two 12-month periods are compared in the same patients (n = 
      19) without and with treatment. Glomerular filtration and quantitative 
      proteinuria did not change significantly one year prior to treatment. During 
      treatment glomerular filtration increased from 1.22 +/- 0.37 to 1.70 + 0.55 ml/s 
      (p less than 0.01) and proteinuria declined from 2.6 + 1.1 to 1.6 +/- 1.0 g/24 h 
      (p less than 0.01). Treatment did not influence the excretion of the metabolite 
      prostacyclin 186 +/- 56 and 189 + 75 ng/24 h resp., and significantly reduced the 
      thromboxane excretion from 565 +/- 267 to 348 + 123 ng/24 h, p less than 0.01). 
      The authors assume that long-term treatment could influence in a favourable way 
      the course of chronic proliferative glomerulonephritis.
FAU - Petrů, I
AU  - Petrů I
AD  - II. interní katedra I. lékarské fakulty, Univerzity Karlovy, Praha.
FAU - Knotková, V
AU  - Knotková V
FAU - Nĕmecek, K
AU  - Nĕmecek K
FAU - Jáchymová, M
AU  - Jáchymová M
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Lécba chronické glomerulonefritidy malými dávkami acetylosalicylové kyseliny.
PL  - Czech Republic
TA  - Cas Lek Cesk
JT  - Casopis lekaru ceskych
JID - 0004743
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Chronic Disease
MH  - Female
MH  - Glomerulonephritis/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1990/06/29 00:00
MHDA- 1990/06/29 00:01
CRDT- 1990/06/29 00:00
PHST- 1990/06/29 00:00 [pubmed]
PHST- 1990/06/29 00:01 [medline]
PHST- 1990/06/29 00:00 [entrez]
PST - ppublish
SO  - Cas Lek Cesk. 1990 Jun 29;129(26):820-3.

PMID- 24374649
OWN - NLM
STAT- MEDLINE
DCOM- 20141022
LR  - 20131230
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 25
IP  - 1
DP  - 2014 Jan
TI  - In-vitro study of homocysteine and aspirin effects on fibrinolysis: measuring 
      fibrinolysis parameters.
PG  - 1-5
LID - 10.1097/MBC.0b013e3283657795 [doi]
AB  - Some studies suggest that increased homocysteine in blood leads to alterations in 
      coagulation and fibrinolysis; however, the precise mechanism is not clear. The 
      aim of this study was to compare different concentrations of homocysteine and 
      aspirin on fibrinolysis in the plasma of healthy individuals in vitro. Different 
      concentrations of homocysteine (200, 100, and 50 μmol/l) and aspirin (100, 10, 
      and 1 mg/l) were added to the healthy people plasma citrate. They were incubated 
      at 37°C for 24 h. Then, fibrinolysis parameters were analyzed by the 
      turbidimetric procedure at 405 nm. The independent-samples t-test was utilized to 
      compare them (P < 0.05). Findings revealed that homocysteine at 200 μmol/l with 
      aspirin 100 ml/g had significant changes in the lysis maximum velocity 
      (0.150 ± 0.002), half-lysis time (218 ± 5.77), the total lysis time (446 ± 5.77), 
      and lag time in lysis (119 ± 3.60), compared to homocysteine at 200 μmol/l lysis 
      maximum velocity (0.110 ± 0.002), half-lysis time (278 ± 7.63), the total lysis 
      time (515 ± 14.29), and lag time in lysis (176 ± 3.60), respectively (P < 0.05). 
      Homocysteine at 200 μmol/l with aspirin 1 ml/g did not significantly change in 
      either parameter (P > 0.05). Homocysteine at 50 μmol/l with aspirin (100, 10, and 
      1 mg/l) had significant changes in all fibrinolysis parameters (P < 0.05), 
      compared to homocysteine at 50 μmol/l. The other concentrations were compared in 
      the same way. Aspirin (more than 1 mg/l) had more effect on higher concentrations 
      of homocysteine. Aspirin increased velocity of clot lysis and decreased lysis 
      time of clot in the presence of homocysteine.
FAU - Zavar-Reza, Javad
AU  - Zavar-Reza J
AD  - Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
FAU - Pouya, Fahima Danesh
AU  - Pouya FD
FAU - Jalali, Beman Ali
AU  - Jalali BA
FAU - Gholami, Farangis
AU  - Gholami F
FAU - Pouya, Naser Danesh
AU  - Pouya ND
LA  - eng
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Blood Coagulation Tests/*methods
MH  - Dose-Response Relationship, Drug
MH  - Fibrinolysis/*drug effects
MH  - Homocysteine/blood/*pharmacology
MH  - Humans
EDAT- 2014/01/01 06:00
MHDA- 2014/10/23 06:00
CRDT- 2013/12/31 06:00
PHST- 2013/12/31 06:00 [entrez]
PHST- 2014/01/01 06:00 [pubmed]
PHST- 2014/10/23 06:00 [medline]
AID - 00001721-201401000-00001 [pii]
AID - 10.1097/MBC.0b013e3283657795 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2014 Jan;25(1):1-5. doi: 10.1097/MBC.0b013e3283657795.

PMID- 269932
OWN - NLM
STAT- MEDLINE
DCOM- 19771229
LR  - 20131121
IS  - 0022-3255 (Print)
IS  - 0022-3255 (Linking)
VI  - 35
IP  - 11
DP  - 1977 Nov
TI  - Comparative analgesic potency of aspirin and ibuprofen.
PG  - 898-903
AB  - The object of a study was to evaluate the analgesic efficacy of ibuprofen for 
      dental pain. The subjects were outpatients who were undergoing surgical removal 
      of impacted teeth. We compared aspirin, 325 mg; aspirin, 650 mg; ibuprofen, 200 
      mg; ibuprofen, 400 mg; and placebo. Each patient received a single dose of one of 
      the test medications; there was a minimum of 37 patients in each treatment group. 
      Patients recorded pain intensity before receiving medication; then hourly, for 
      four hours after medication, they recorded pain intensity, amount of relief, and 
      side effects. Time-effect and dose-response curves were generated from the relief 
      and change in pain-intensity scores. First-hour scores, peak scores, and total 
      scores were analyzed. All active medications were significantly better than 
      placebo and the mean effect for ibuprofen was significantly more than for 
      aspirin.
FAU - Cooper, S A
AU  - Cooper SA
FAU - Needle, S E
AU  - Needle SE
FAU - Kruger, G O
AU  - Kruger GO
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Oral Surg
JT  - Journal of oral surgery (American Dental Association : 1965)
JID - 8302454
RN  - 0 (Analgesics)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Analgesics
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drug Evaluation
MH  - Humans
MH  - Ibuprofen/administration & dosage/*therapeutic use
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
MH  - Tooth, Impacted/*surgery
EDAT- 1977/11/01 00:00
MHDA- 1977/11/01 00:01
CRDT- 1977/11/01 00:00
PHST- 1977/11/01 00:00 [pubmed]
PHST- 1977/11/01 00:01 [medline]
PHST- 1977/11/01 00:00 [entrez]
PST - ppublish
SO  - J Oral Surg. 1977 Nov;35(11):898-903.

PMID- 6631688
OWN - NLM
STAT- MEDLINE
DCOM- 19831217
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 72
IP  - 9
DP  - 1983 Sep
TI  - Effect of water deprivation on aspirin disposition kinetics.
PG  - 1030-4
AB  - Temporary water deprivation results in serious stress causing significant 
      physiological, hormonal, and enzymatic changes in the body which can affect the 
      disposition kinetics, toxicity, and activity of drugs. This study attempts to 
      recognize the effect of water deprivation on drug disposition kinetics using 
      aspirin. No significant effects were noted following 36-hr water deprivation in 
      rats on the metabolism of aspirin; there was also no effect of heparinization on 
      aspirin disposition kinetics. The disposition of salicylic acid, however, was 
      altered significantly, with the half-life increased by approximately 72% 
      concomitant with decreased total body clearance. The effect of two dose levels, 5 
      and 10 mg/kg, was also studied to elucidate nonlinearity in the disposition 
      kinetic model. Almost complete urinary recovery of aspirin was obtained in the 
      intact form or as metabolites. At the 10-mg/kg dose, the fraction of salicyluric 
      acid excreted decreased significantly compared with the 5-mg/kg dose. However, 
      the effect of water deprivation was uniform at the two dose levels without any 
      effect on the excretion of salicyluric acid. It is suggested that, in view of the 
      significant changes in the disposition characteristics of salicylates with water 
      deprivation, due care must be exercised in adjusting doses giving proper 
      consideration to body hydration levels.
FAU - Bakar, S K
AU  - Bakar SK
FAU - Niazi, S
AU  - Niazi S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 9005-49-6 (Heparin)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*metabolism
MH  - Biotransformation
MH  - Heparin/pharmacology
MH  - Injections, Intravenous
MH  - Kinetics
MH  - Male
MH  - Rats
MH  - Salicylates/metabolism
MH  - Salicylic Acid
MH  - Water Deprivation/*physiology
EDAT- 1983/09/01 00:00
MHDA- 1983/09/01 00:01
CRDT- 1983/09/01 00:00
PHST- 1983/09/01 00:00 [pubmed]
PHST- 1983/09/01 00:01 [medline]
PHST- 1983/09/01 00:00 [entrez]
AID - S0022-3549(15)44749-5 [pii]
AID - 10.1002/jps.2600720916 [doi]
PST - ppublish
SO  - J Pharm Sci. 1983 Sep;72(9):1030-4. doi: 10.1002/jps.2600720916.

PMID- 3413717
OWN - NLM
STAT- MEDLINE
DCOM- 19881003
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 50
IP  - 4
DP  - 1988 May 15
TI  - Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of 
      platelet thrombus formation in stenosed canine coronary arteries.
PG  - 507-16
AB  - In 18 anesthetized dogs with a 70% mechanically produced coronary artery 
      stenosis, blood flow measured with an electromagnetic flowmeter showed cyclical 
      reductions in flow due to periodic acute platelet thrombus formation. These were 
      abolished in eight of nine dogs with 2.5 mg/kg of aspirin given intravenously and 
      in nine of nine dogs with 5 mg/kg of aspirin. However in 14 of 18 dogs the 
      cyclical flow reductions were temporarily renewed with the infusion of 
      epinephrine 0.4 microgram/kg/min. Human platelets inhibited with aspirin can be 
      reactivated with physiologic amounts of epinephrine. We postulate that in 
      patients with atherosclerotic stenotic lesions the use of aspirin to inhibit 
      arterial thrombus formation may be less effective when they have elevated 
      catecholamines.
FAU - Folts, J D
AU  - Folts JD
AD  - Section of Cardiology, University of Wisconsin Hospital, Madison 53792.
FAU - Rowe, G G
AU  - Rowe GG
LA  - eng
GR  - HL 29586-04/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Animals
MH  - Aspirin/*antagonists & inhibitors/pharmacology/therapeutic use
MH  - Blood Flow Velocity/drug effects
MH  - Blood Pressure/drug effects
MH  - Coronary Disease/complications/*drug therapy
MH  - Coronary Thrombosis/*drug therapy/physiopathology
MH  - Dogs
MH  - Epinephrine/*pharmacology
MH  - Female
MH  - Heart Rate/drug effects
MH  - Male
MH  - Platelet Aggregation/*drug effects
EDAT- 1988/05/15 00:00
MHDA- 1988/05/15 00:01
CRDT- 1988/05/15 00:00
PHST- 1988/05/15 00:00 [pubmed]
PHST- 1988/05/15 00:01 [medline]
PHST- 1988/05/15 00:00 [entrez]
AID - 10.1016/0049-3848(88)90199-5 [doi]
PST - ppublish
SO  - Thromb Res. 1988 May 15;50(4):507-16. doi: 10.1016/0049-3848(88)90199-5.

PMID- 7408527
OWN - NLM
STAT- MEDLINE
DCOM- 19801124
LR  - 20190909
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 6
IP  - 9
DP  - 1980
TI  - A double-blind, crossover comparison between indoprofen and aspirin in rheumatoid 
      arthritis.
PG  - 598-605
AB  - Twenty in-patients with rheumatoid arthritis took part in a double-blind, 
      crossover clinical trial to compare the effectiveness and tolerance of 400 mg 
      indoprofen with 1000 mg aspirin each given 3-times a day for 1 week, with an 
      interval of 2 days during which patients received an indistinguishable placebo. 
      At the start and at the end of each treatment period several subjective and 
      objective indices were measured. Both indoprofen and aspirin to remable 
      improvement in patient conditions, with no significant differences between drugs 
      in overall pain, number of swollen joints, grip strength and functional index. 
      Indoprofen, however, was significantly superior to aspirin with regard to the 
      number of painful joints (p < 0.01), duration of morning stiffness (p < 0.05) and 
      articular index (p < 0.05). Moreover, both patients' and investigators' opinion 
      of overall response favoured indoprofen. Small but significant decreases were 
      recorded in ertythrocyte sedimentation rate and seromucoid levels in both 
      treatment periods. Adverse reactions, mainly as gastric pyrosis and/or 
      gastralgia, occurred in 6 patients while on aspirin, in 2 while on indoprofen, 
      and in a further 2 while on both drugs. No statistically significant changes were 
      observed in safety laboratory tests.
FAU - Loizzi, P
AU  - Loizzi P
FAU - Muratore, M
AU  - Muratore M
FAU - Bruni, G
AU  - Bruni G
FAU - Sacchetti, G
AU  - Sacchetti G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Phenylpropionates)
RN  - CPE46ZU14N (Indoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/blood/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Indoprofen/adverse effects/blood/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Phenylpropionates/*therapeutic use
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1185/03007998009109495 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1980;6(9):598-605. doi: 10.1185/03007998009109495.

PMID- 834212
OWN - NLM
STAT- MEDLINE
DCOM- 19770321
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 296
IP  - 8
DP  - 1977 Feb 24
TI  - Aspirin-induced depression of renal function.
PG  - 418-24
AB  - We observed elevation of serum creatinine and blood urea nitrogen and decrease in 
      creatine clearance in patients taking anti-inflammatory doses of aspirin. In 13 
      of 23 patients with systemic lupus erythematosus increases in serum creatinine 
      ranged from 27 to 163 per cent, and those in urea nitrogen from 42 to 270 per 
      cent. Sequential creatinine-clearance studies, available in 11 of the 13 
      patients, demonstrated decreases up to 58 per cent. Patients with aspirin-induced 
      changes in renal function were more likely to have active renal disease (P 
      =0.035) or hypocomplementemia (P =0.030). Four of 22 patients with rheumatoid 
      arthritis and two of three normal volunteers also demonstrated biochemical 
      changes. The rate of aspirin-induced alterations was significantly higher in 
      systemic lupus erythematosus (P =0.007) than in rheumatoid arthritis. Aspirin, 
      and other nonsteroidal anti-inflammatory agents, can have a major reversible 
      effect on renal function that may influence the interpretation of clinical data.
FAU - Kimberly, R P
AU  - Kimberly RP
FAU - Plotz, P H
AU  - Plotz PH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Complement C3)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arthritis/drug therapy
MH  - Arthritis, Rheumatoid/complications
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Blood Urea Nitrogen
MH  - Complement C3/analysis
MH  - Creatinine/blood
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Kidney/*drug effects
MH  - Lupus Erythematosus, Systemic/complications
MH  - Male
MH  - Middle Aged
MH  - Nephritis/complications
EDAT- 1977/02/24 00:00
MHDA- 1977/02/24 00:01
CRDT- 1977/02/24 00:00
PHST- 1977/02/24 00:00 [pubmed]
PHST- 1977/02/24 00:01 [medline]
PHST- 1977/02/24 00:00 [entrez]
AID - 10.1056/NEJM197702242960803 [doi]
PST - ppublish
SO  - N Engl J Med. 1977 Feb 24;296(8):418-24. doi: 10.1056/NEJM197702242960803.

PMID- 9260666
OWN - NLM
STAT- MEDLINE
DCOM- 19970924
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 15
IP  - 11
DP  - 1997 Jul
TI  - Spectrofluorometric estimation of aspirin and dipyridamole in pure admixtures and 
      in dosage forms.
PG  - 1703-8
AB  - Aspirin and dipyridamole in pure admixtures and in dosage forms have been 
      estimated by spectrofluorometry. Aspirin (2-12 mcg ml-1) was estimated in 1% v/v 
      glacial acetic acid in chloroform using 246 and 345 nm for excitation and 
      emission respectively. Dipyridamole (2-12 mcg ml-1) has been estimated in 
      chloroform using 420 nm for excitation and 475 nm for emission. The 
      non-interference of the excipients as well as the drugs in the estimation of each 
      other, as evidenced by the results, indicate that this method may be used for the 
      routine estimation of aspirin and dipyridamole in tablet preparations.
FAU - Umapathi, P
AU  - Umapathi P
AD  - Department of Pharmacy, Birla Institute of Technology and Science, Pilani 
      Rajasthan, India.
FAU - Parimoo, P
AU  - Parimoo P
FAU - Thomas, S K
AU  - Thomas SK
FAU - Agarwal, V
AU  - Agarwal V
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Drug Combinations)
RN  - 0 (Vasodilator Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Dipyridamole/*analysis
MH  - Drug Combinations
MH  - Spectrometry, Fluorescence
MH  - Vasodilator Agents/*analysis
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - S0731-7085(96)01918-8 [pii]
AID - 10.1016/s0731-7085(96)01918-8 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1997 Jul;15(11):1703-8. doi: 10.1016/s0731-7085(96)01918-8.

PMID- 29388864
OWN - NLM
STAT- MEDLINE
DCOM- 20191001
LR  - 20191001
IS  - 1557-7732 (Electronic)
IS  - 1080-7683 (Linking)
VI  - 34
IP  - 3
DP  - 2018 Apr
TI  - The Effect of Low-Dose Aspirin on Dry Eye Parameters and Ocular Surface Disease 
      Index Questionnaire.
PG  - 256-259
LID - 10.1089/jop.2017.0064 [doi]
AB  - PURPOSE: To evaluate the effects of acetylsalicylic acid (aspirin) on tear film 
      parameters and dry eye disease. METHODS: Fifty-seven patients using low-dose 
      aspirin regularly for antiaggregant purposes as well as 49 controls, who required 
      antiaggregant treatment but who had not yet started, were included in the study. 
      Tear osmolarity, tear break-up time (TBUT), Schirmer and Oxford grading of ocular 
      surface staining were performed on all patients and dry eye symptomatology was 
      assessed using the ocular surface disease index questionnaire (OSDI). RESULTS: 
      The mean osmolarity was 302.11 ± 16.22 mOsm/L in the aspirin group and 
      313.88 ± 19.57 mOsm/L in the control group (P < 0.01). The mean Schirmer's score 
      was 24.16 ± 10.52 mm and 21.94 ± 10.11 mm (P = 0.232), TBUT was 13.61 ± 3.31 s 
      and 10.39 ± 4.46 s (P < 0.01), OSDI score was 5.15 ± 5.98 and 16.94 ± 14.17 
      (P < 0.01), and Oxford score was 0.12 ± 0.33 and 0.12 ± 0.44 in aspirin and 
      control groups, respectively (P = 0.99). Dry eye diagnosis was lower in the 
      aspirin group, but statistical significance was present only in TBUT and 
      osmolarity-based dry eye diagnosis (P ≤ 0.01). In terms of symptom-based dry eye 
      diagnosis with the threshold of OSDI ≥23, none of the aspirin group had dry eye 
      diagnosis, whereas 32.6% of the control group had the diagnosis (P < 0.01). 
      CONCLUSIONS: The use of low-dose aspirin might be great option for treatment of 
      ocular surface inflammatory disease through increasing TBUT and decreasing tear 
      osmolarity with a resultant symptomatic satisfaction.
FAU - Yazıcı, Alper
AU  - Yazıcı A
AD  - 1 Department of Opthalmology, Armedica Goz Eye Hospital , Kocaeli, Turkey .
FAU - Sarı, Esin
AU  - Sarı E
AD  - 2 Department of Opthalmology, Dunya Goz Eye Hospital , Bursa, Turkey .
FAU - Ayhan, Erkan
AU  - Ayhan E
AD  - 3 Department of Cardiology, Edremit Korfez Hospital , Balikesir, Turkey .
FAU - Şahin, Gözde
AU  - Şahin G
AD  - 4 Department of Opthalmology, Balikesir University , Balikesir, Turkey .
FAU - Tıskaoğlu, Nesime Setge
AU  - Tıskaoğlu NS
AD  - 5 Department of Opthalmology, Canakkale State Hospital , Canakkale, Turkey .
FAU - Gürbüzer, Taha
AU  - Gürbüzer T
AD  - 6 Department of Cardiology, Kutahya İsmail Karakuyu Simav State Hospital , 
      Kutahya, Turkey .
FAU - Kurt, Hüseyin
AU  - Kurt H
AD  - 7 Department of Internal Medicine, Hospital Park Hospital , Kocaeli, Turkey .
FAU - Ermiş, Sıtkı Samet
AU  - Ermiş SS
AD  - 8 Department of Opthalmology, Duzey Goz Eye Hospital , Istanbul, Turkey .
LA  - eng
PT  - Journal Article
DEP - 20180201
PL  - United States
TA  - J Ocul Pharmacol Ther
JT  - Journal of ocular pharmacology and therapeutics : the official journal of the 
      Association for Ocular Pharmacology and Therapeutics
JID - 9511091
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & 
      dosage/metabolism/*therapeutic use
MH  - Aspirin/*administration & dosage/metabolism/*therapeutic use
MH  - Corneal Diseases/diagnosis/*drug therapy
MH  - Cross-Sectional Studies
MH  - Dose-Response Relationship, Drug
MH  - Dry Eye Syndromes/diagnosis/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osmolar Concentration
MH  - *Surveys and Questionnaires
OTO - NOTNLM
OT  - OSDI
OT  - Schirmer
OT  - TBUT
OT  - aspirin
OT  - tear osmolarity
EDAT- 2018/02/02 06:00
MHDA- 2019/10/02 06:00
CRDT- 2018/02/02 06:00
PHST- 2018/02/02 06:00 [pubmed]
PHST- 2019/10/02 06:00 [medline]
PHST- 2018/02/02 06:00 [entrez]
AID - 10.1089/jop.2017.0064 [doi]
PST - ppublish
SO  - J Ocul Pharmacol Ther. 2018 Apr;34(3):256-259. doi: 10.1089/jop.2017.0064. Epub 
      2018 Feb 1.

PMID- 26722003
OWN - NLM
STAT- MEDLINE
DCOM- 20170328
LR  - 20170328
IS  - 2048-8734 (Electronic)
IS  - 2048-8726 (Linking)
VI  - 5
IP  - 5
DP  - 2016 Sep
TI  - Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY 
      and HORIZONS-AMI trials.
PG  - 449-54
LID - 10.1177/2048872615624848 [doi]
AB  - BACKGROUND: Aspirin is promptly administered to patients presenting with acute 
      coronary syndromes. It is not known whether aspirin pretreatment in acute 
      coronary syndrome patients is beneficial, particularly because some, but not all, 
      prior studies identified aspirin pretreatment as an independent risk factor for 
      adverse ischemic events. OBJECTIVE: To study the effect of aspirin pretreatment 
      in patients with acute coronary syndromes enrolled in two large randomized 
      clinical trials. METHODS: Patients enrolled in the ACUITY and HORIZONS-AMI trials 
      were analyzed according to aspirin pretreatment within 5-7 days before acute 
      coronary syndromes. We evaluated the incidence of death, myocardial infarction, 
      target vessel revascularization, stent thrombosis and bleeding at 30 days and 1 
      year. Multivariable regression analysis was performed for all-cause and cardiac 
      death. RESULTS: Among 17,387 patients, 10,587 (60.9%) were pretreated with 
      aspirin. Pretreated patients were significantly older and more likely to have 
      diabetes mellitus, hypertension and prior revascularization, and receive only 
      medical therapy without revascularization. Aspirin pretreatment was associated 
      with reduced 48-hour cardiac death (adjusted hazard ratio 0.50, 95% confidence 
      interval 0.26-0.97; P=0.04) and 30-day death (adjusted hazard ratio 0.68, 95% 
      confidence interval 0.49-0.94; P=0.04). Myocardial infarction was more frequent 
      in the aspirin pretreatment group at 30 days (P<0.0001), while stent thrombosis 
      was less frequent (P=0.01). A strong interaction was present such that aspirin 
      pretreatment was associated with reduced 30-day death in patients with 
      non-ST-segment elevation acute coronary syndrome (NSTEACS), but not in those with 
      ST-segment elevation myocardial infarction (P=0.001). CONCLUSIONS: Among patients 
      with acute coronary syndromes in these two large prospective studies, aspirin 
      pretreatment identified a higher risk cohort and was an independent predictor of 
      reduced mortality at 30 days, especially in patients with NSTEACS.
CI  - © The European Society of Cardiology 2015.
FAU - Brener, Sorin J
AU  - Brener SJ
AD  - Department of Medicine, Cardiac Catheterization Laboratory, New York Methodist 
      Hospital, USA Department of Medicine, Cardiovascular Research Foundation, USA 
      sjb9005@nyp.org.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - Department of Medicine, Cardiovascular Research Foundation, USA Mount Sinai 
      Medical Center, USA.
FAU - Lansky, Alexandra J
AU  - Lansky AJ
AD  - Yale University Medical Center, USA.
FAU - Ayele, Girma M
AU  - Ayele GM
AD  - Department of Medicine, Cardiovascular Research Foundation, USA.
FAU - Stone, Gregg W
AU  - Stone GW
AD  - Department of Medicine, Cardiovascular Research Foundation, USA Columbia 
      University Medical Center, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20151231
PL  - England
TA  - Eur Heart J Acute Cardiovasc Care
JT  - European heart journal. Acute cardiovascular care
JID - 101591369
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*mortality/prevention & control
MH  - Aged
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*epidemiology
OTO - NOTNLM
OT  - Acute coronary syndromes
OT  - aspirin
OT  - outcomes
OT  - percutaneous coronary intervention
EDAT- 2016/01/02 06:00
MHDA- 2017/03/30 06:00
CRDT- 2016/01/02 06:00
PHST- 2015/05/27 00:00 [received]
PHST- 2015/12/09 00:00 [accepted]
PHST- 2016/01/02 06:00 [entrez]
PHST- 2016/01/02 06:00 [pubmed]
PHST- 2017/03/30 06:00 [medline]
AID - 2048872615624848 [pii]
AID - 10.1177/2048872615624848 [doi]
PST - ppublish
SO  - Eur Heart J Acute Cardiovasc Care. 2016 Sep;5(5):449-54. doi: 
      10.1177/2048872615624848. Epub 2015 Dec 31.

PMID- 2287558
OWN - NLM
STAT- MEDLINE
DCOM- 19910325
LR  - 20131121
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 10
IP  - 6
DP  - 1990
TI  - Evaluation of aspirin, caffeine, and their combination in postoperative oral 
      surgery pain.
PG  - 387-93
AB  - Three hundred fifty outpatients with postoperative pain after the surgical 
      removal of impacted third molars were randomly assigned, on a double-blind basis, 
      to receive a single oral dose of aspirin 650 or 1000 mg, caffeine 65 mg, a 
      combination of aspirin 650 mg with caffeine 65 mg, or placebo. Using a 
      self-rating record, subjects rated their pain and its relief hourly for 6 hours 
      after medicating. Estimates of summed pain intensity difference, peak pain 
      intensity difference, total relief, peak relief, and hours of 50% relief were 
      derived from these subjective reports. All active treatments except caffeine were 
      significantly superior to placebo. Pairwise comparisons indicated the 
      aspirin-caffeine combination was statistically superior to aspirin 650 mg alone 
      for hours of 50% relief among patients who had severe baseline pain. Adverse 
      effects were transitory and none were serious.
FAU - Forbes, J A
AU  - Forbes JA
AD  - Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, 
      MD.
FAU - Jones, K F
AU  - Jones KF
FAU - Kehm, C J
AU  - Kehm CJ
FAU - Smith, W K
AU  - Smith WK
FAU - Gongloff, C M
AU  - Gongloff CM
FAU - Zeleznock, J R
AU  - Zeleznock JR
FAU - Smith, J W
AU  - Smith JW
FAU - Beaver, W T
AU  - Beaver WT
FAU - Kroesen, M
AU  - Kroesen M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Caffeine/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Molar, Third
MH  - Pain, Postoperative/*drug therapy
MH  - *Tooth Extraction
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - Pharmacotherapy. 1990;10(6):387-93.

PMID- 10350458
OWN - NLM
STAT- MEDLINE
DCOM- 19990609
LR  - 20151119
IS  - 0006-2960 (Print)
IS  - 0006-2960 (Linking)
VI  - 38
IP  - 20
DP  - 1999 May 18
TI  - UV resonance Raman spectra reveal a structural basis for diminished proton and 
      CO2 binding to alpha,alpha-cross-linked hemoglobin.
PG  - 6406-10
AB  - UV resonance Raman difference spectra between ligated and deoxyhemoglobin contain 
      tryptophan and tyrosine signals which arise from quaternary H-bonds in the T 
      state, which are broken in the R state. These H-bonds are unaffected by 
      bis(3,5-dibromosalicyl) fumarate cross-linking at the Lys alpha 99 residues, 
      which prevents dissociation of Hb tetramers to dimers. However, when the pH is 
      lowered from 9.0, or when NaCl is added, intensity is diminished for the tyrosine 
      Y8 and tryptophan W3 bands of cross-linked deoxyHb, but not of native deoxyHb. 
      This effect is attributed to weakening of tertiary H-bonds involving Tyr alpha 
      140 and Trp alpha 14, when the T state salt bridge between Val alpha 1 and Arg 
      alpha 141 is formed via protonation of the terminal amino group and anion 
      binding. The Tyr alpha 140-Val alpha 93 H-bond connects the Arg alpha 141-bearing 
      H helix with the Lys alpha 99-bearing G helix. Weakening of the H-bond reflects a 
      tension between the fumarate linker and the salt-bridge. This tension inhibits 
      protonation of the Val alpha 1 amino terminus, thus accounting for the diminution 
      of both proton [Bohr effect] and CO2 binding in the T state as a result of 
      cross-linking.
FAU - Dick, L A
AU  - Dick LA
AD  - Chemistry Department, Princeton University, New Jersey 08544, USA.
FAU - Heibel, G
AU  - Heibel G
FAU - Moore, E G
AU  - Moore EG
FAU - Spiro, T G
AU  - Spiro TG
LA  - eng
GR  - GM 25158/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 0 (Anions)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Protons)
RN  - 0 (hemoglobin XL99alpha)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 142M471B3J (Carbon Dioxide)
RN  - 9008-02-0 (deoxyhemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anions
MH  - Aspirin/*analogs & derivatives/chemistry/metabolism
MH  - Binding Sites
MH  - Carbon Dioxide/blood/*chemistry
MH  - Cross-Linking Reagents/*chemistry
MH  - Hemoglobins/*chemistry/metabolism
MH  - Humans
MH  - Hydrogen Bonding
MH  - Protein Conformation
MH  - Protein Structure, Tertiary
MH  - *Protons
MH  - Spectrophotometry, Ultraviolet
MH  - Spectrum Analysis, Raman
EDAT- 1999/06/03 00:00
MHDA- 1999/06/03 00:01
CRDT- 1999/06/03 00:00
PHST- 1999/06/03 00:00 [pubmed]
PHST- 1999/06/03 00:01 [medline]
PHST- 1999/06/03 00:00 [entrez]
AID - bi981760d [pii]
AID - 10.1021/bi981760d [doi]
PST - ppublish
SO  - Biochemistry. 1999 May 18;38(20):6406-10. doi: 10.1021/bi981760d.

PMID- 653293
OWN - NLM
STAT- MEDLINE
DCOM- 19780724
LR  - 20131121
IS  - 0035-2659 (Print)
IS  - 0035-2659 (Linking)
VI  - 45
IP  - 3
DP  - 1978 Mar
TI  - [Kinetics of salicylates from the blood to the articular fluid].
PG  - 165-9
AB  - A study was made of the salicylate concentrations in samples of blood and 
      articular fluid from 30 patients treated with acetylsalicylic acid. The data were 
      divided in groups according to the diagnosis of the articular diseases and showed 
      no significant differences as regards the salicylate kinetics in the blood. A 
      concentration of 0.3 mg/1 was reached in 6 minutes on the average and the "near 
      maximum" concentration was 23.0 mg/1 on the average. In the articular fluid a 
      concentration of 0.3 mg/1 the salicylates was reached in 10 to 31 minutes. The 
      average maximum concentration as 14.8 mg/1. The findings support the hypothesis 
      that diffusion was the dominant factor in the passage of salicylates from the 
      blood to the articular fluid. The transport varied with the characteristics of 
      the articular diseases. Histopathological changes in the various types of 
      synovitis would alter the biophysical properties of the internal part of the 
      articularcapsule and would thus alter the kinetics of salicylates.
FAU - Soren, A
AU  - Soren A
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Cinétique des salicylés du sang vers le liquide articulaire.
PL  - France
TA  - Rev Rhum Mal Osteoartic
JT  - Revue du rhumatisme et des maladies osteo-articulaires
JID - 0407211
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis/drug therapy/metabolism
MH  - Aspirin/blood/metabolism/therapeutic use
MH  - Humans
MH  - Salicylates/blood/*metabolism
MH  - Synovial Fluid/*metabolism
EDAT- 1978/03/01 00:00
MHDA- 1978/03/01 00:01
CRDT- 1978/03/01 00:00
PHST- 1978/03/01 00:00 [pubmed]
PHST- 1978/03/01 00:01 [medline]
PHST- 1978/03/01 00:00 [entrez]
PST - ppublish
SO  - Rev Rhum Mal Osteoartic. 1978 Mar;45(3):165-9.

PMID- 24935248
OWN - NLM
STAT- MEDLINE
DCOM- 20150604
LR  - 20141224
IS  - 1099-0801 (Electronic)
IS  - 0269-3879 (Linking)
VI  - 29
IP  - 1
DP  - 2015 Jan
TI  - In vivo and in vitro metabolism of aspirin eugenol ester in dog by liquid 
      chromatography tandem mass spectrometry.
PG  - 129-37
LID - 10.1002/bmc.3249 [doi]
AB  - Aspirin eugenol ester (AEE) is a promising drug candidate for treatment of 
      inflammation, pain and fever and prevention of cardiovascular diseases with fewer 
      side effects than its precursor, aspirin. Investigation into its metabolic 
      process in target animal species will help to illustrate its mechanism of action 
      and to establish its residual mark compound to formulate its dosage. Six beagle 
      dogs were orally given a dose of 20 mg kg(-1) of AEE and one dog was used to 
      prepare blank liver microsomes. Their liver microsomes were prepared for in vitro 
      study and their plasma and urine were collected for in vivo metabolic analysis 
      using liquid chromatography tandem mass spectrometry. In this study we identified 
      10 metabolites, M1, M2, M3, M4, M5 in phase I and M6, M7, M8, M9, M10 in phase 
      II. Based on the metabolites of AEE, the pathways of AEE metabolism in dog were 
      demonstrated.
CI  - Copyright © 2014 John Wiley & Sons, Ltd.
FAU - Shen, Youming
AU  - Shen Y
AD  - Key Laboratory of New Animal Drug Project of Gansu Province and Key Laboratory of 
      Veterinary Pharmaceutical Development, Ministry of Agriculture, Gansu Provincial 
      Engineering Research Center for New Animal Drug, Lanzhou Institute of Husbandry 
      and Pharmaceutical Science of CAAS, Lanzhou, 730050, People's Republic of China.
FAU - Liu, Xiwang
AU  - Liu X
FAU - Yang, Yajun
AU  - Yang Y
FAU - Li, Jianyong
AU  - Li J
FAU - Ma, Ning
AU  - Ma N
FAU - Li, Bing
AU  - Li B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140616
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/blood/chemistry/metabolism/urine
MH  - Chromatography, Liquid/*methods
MH  - Dogs
MH  - Eugenol/*analogs & derivatives/blood/chemistry/metabolism/urine
MH  - Female
MH  - Male
MH  - Metabolic Networks and Pathways
MH  - Microsomes, Liver/*chemistry/*metabolism
MH  - Tandem Mass Spectrometry/*methods
OTO - NOTNLM
OT  - aspirin eugenol ester
OT  - liquid chromatography tandem mass spectrometry
OT  - metabolism
EDAT- 2014/06/18 06:00
MHDA- 2015/06/05 06:00
CRDT- 2014/06/18 06:00
PHST- 2014/02/13 00:00 [received]
PHST- 2014/04/03 00:00 [revised]
PHST- 2014/04/17 00:00 [accepted]
PHST- 2014/06/18 06:00 [entrez]
PHST- 2014/06/18 06:00 [pubmed]
PHST- 2015/06/05 06:00 [medline]
AID - 10.1002/bmc.3249 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2015 Jan;29(1):129-37. doi: 10.1002/bmc.3249. Epub 2014 Jun 
      16.

PMID- 30339946
OWN - NLM
STAT- MEDLINE
DCOM- 20190308
LR  - 20190308
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 553
IP  - 1-2
DP  - 2018 Dec 20
TI  - A study of the impact of excipient shielding on initial drug release using UV 
      imaging.
PG  - 229-237
LID - S0378-5173(18)30775-0 [pii]
LID - 10.1016/j.ijpharm.2018.10.040 [doi]
AB  - Knowledge on the dissolution behaviour of a drug is critical for efficient and 
      effective product development. As the drug has almost always to be formulated 
      with excipients in the design of a dosage form, it is important to examine the 
      implications of the choice of excipients on the dissolution of the drug, among 
      others, especially in the case of an immediate release dosage form. The objective 
      of this study was to explore the potential of using an ultraviolet (UV) imaging 
      technique to examine the effect of drug-excipient ratio on the initial 
      dissolution of the drug, when formulated with a hydrophilic, water insoluble 
      excipient. A series of drug-excipient binary blends with different ratios were 
      prepared and compacted into 2 mm compacts, and their dissolution profiles 
      captured with a UV imager. Chemical imaging via Raman spectroscopy was also 
      performed on the compacts to quantify the fraction of drug presented on the 
      compact surface. At low drug concentrations, a suppression in drug dissolution 
      was observed, but beyond a critical drug-excipient ratio, the concentration of 
      the excipient no longer played a role in affecting drug dissolution rates. Drug 
      particle size was found to affect the critical drug-excipient ratio required to 
      negate the shielding effect exerted by the excipient, such that a higher 
      proportion of drug was required. It is postulated that the excipient served as a 
      physical barrier, as well as competitor for water required for wetting during 
      initial dissolution, thereby causing a delay in the wetting and dissolution of 
      the drug.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Hiew, Tze Ning
AU  - Hiew TN
AD  - GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, 
      National University of Singapore, 18 Science Drive 4, Singapore 117543, 
      Singapore.
FAU - Alaudin, Muhammad Ismail Bin
AU  - Alaudin MIB
AD  - GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, 
      National University of Singapore, 18 Science Drive 4, Singapore 117543, 
      Singapore.
FAU - Chua, Siang Meng
AU  - Chua SM
AD  - Meggle Singapore, 45 Jalan Pemimpin, #06-00 Foo Wah Industrial Building, 
      Singapore 577197, Singapore.
FAU - Heng, Paul Wan Sia
AU  - Heng PWS
AD  - GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, 
      National University of Singapore, 18 Science Drive 4, Singapore 117543, 
      Singapore. Electronic address: phapaulh@nus.edu.sg.
LA  - eng
PT  - Journal Article
DEP - 20181016
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Excipients)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/chemistry
MH  - Chemistry, Pharmaceutical/*methods
MH  - Drug Compounding/methods
MH  - Drug Liberation
MH  - Excipients/*chemistry
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Particle Size
MH  - Solubility
MH  - Spectrum Analysis, Raman
MH  - *Ultraviolet Rays
OTO - NOTNLM
OT  - Excipient shielding
OT  - Initial dissolution
OT  - Raman mapping
OT  - Surface dissolution
OT  - UV imaging
EDAT- 2018/10/20 06:00
MHDA- 2019/03/09 06:00
CRDT- 2018/10/20 06:00
PHST- 2018/06/22 00:00 [received]
PHST- 2018/08/26 00:00 [revised]
PHST- 2018/10/15 00:00 [accepted]
PHST- 2018/10/20 06:00 [pubmed]
PHST- 2019/03/09 06:00 [medline]
PHST- 2018/10/20 06:00 [entrez]
AID - S0378-5173(18)30775-0 [pii]
AID - 10.1016/j.ijpharm.2018.10.040 [doi]
PST - ppublish
SO  - Int J Pharm. 2018 Dec 20;553(1-2):229-237. doi: 10.1016/j.ijpharm.2018.10.040. 
      Epub 2018 Oct 16.

PMID- 26808136
OWN - NLM
STAT- MEDLINE
DCOM- 20160713
LR  - 20220408
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 1
DP  - 2016
TI  - Is Long-Term Low-Dose Aspirin Therapy Associated with Renal Dysfunction in 
      Patients with Type 2 Diabetes? JPAD2 Cohort Study.
PG  - e0147635
LID - 10.1371/journal.pone.0147635 [doi]
LID - e0147635
AB  - BACKGROUND: Low-dose aspirin is widely recommended for patients at high risk for 
      cardiovascular disease (CVD); however, it remains uncertain whether long-term 
      treatment adversely affects renal function in patients with diabetes. We 
      investigated whether long-term low-dose aspirin affects renal dysfunction in 
      patients with diabetes. METHODS: We conducted a randomized controlled trial 
      (RCT), the Japanese Primary Prevention of Atherosclerosis with Aspirin for 
      Diabetes (JPAD) trial, to evaluate low-dose aspirin as primary prevention for CVD 
      in patients with type 2 diabetes. We followed the patients with negative urine 
      dipstick albumin of the JPAD trial in a cohort study after the RCT period was 
      completed. Patients were randomly allocated to receive aspirin (81 mg or 100 mg 
      daily, aspirin group) or no aspirin (no aspirin group). After the RCT, the 
      treating physician decided whether to administer aspirin. We evaluated the 
      incidence of positive urine dipstick albumin and annual changes in estimated 
      glomerular filtration rate (eGFR). RESULTS: Positive urine dipstick albumin 
      developed in 297 patients in the aspirin group (n = 1,075) and 270 patients in 
      the no aspirin group (n = 1,098) during follow-up (median, 8.5 years). 
      Intention-to-treat analysis showed low-dose aspirin did not increase the 
      incidence of positive urine dipstick albumin (hazard ratio [HR], 1.17; 95% 
      confidence interval [CI], 0.995-1.38). On-treatment analysis yielded similar 
      results (HR, 1.08; 95% CI, 0.92-1.28). Multivariable analysis showed the 
      incidence of positive urine dipstick albumin was higher among the elderly and 
      those with elevated serum creatinine, high hemoglobin A1c, or high blood 
      pressure; however, low-dose aspirin did not increase the risk of positive urine 
      dipstick albumin. There were no significant differences in annual changes in eGFR 
      between the groups (aspirin, -0.8 ± 2.9; no aspirin, -0.9 ± 2.5 ml/min/1.73 
      m(2)/year). CONCLUSION: Long-term low-dose aspirin does not affect eGFR and 
      positive urine dipstick albumin in patients with type 2 diabetes.
FAU - Okada, Sadanori
AU  - Okada S
AD  - Department of Diabetology, Nara Medical University, Kashihara, Nara, Japan.
AD  - First Department of Internal Medicine, Nara Medical University, Kashihara, Nara, 
      Japan.
FAU - Morimoto, Takeshi
AU  - Morimoto T
AD  - Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, 
      Hyogo, Japan.
FAU - Ogawa, Hisao
AU  - Ogawa H
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Science, 
      Kumamoto University, Kumamoto, Japan.
FAU - Sakuma, Mio
AU  - Sakuma M
AD  - Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, 
      Hyogo, Japan.
FAU - Soejima, Hirofumi
AU  - Soejima H
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Science, 
      Kumamoto University, Kumamoto, Japan.
FAU - Nakayama, Masafumi
AU  - Nakayama M
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Science, 
      Kumamoto University, Kumamoto, Japan.
FAU - Jinnouchi, Hideaki
AU  - Jinnouchi H
AD  - Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
FAU - Waki, Masako
AU  - Waki M
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Shizuoka City Hospital, Shizuoka, Japan.
FAU - Akai, Yasuhiro
AU  - Akai Y
AD  - Department of Diabetology, Nara Medical University, Kashihara, Nara, Japan.
FAU - Ishii, Hitoshi
AU  - Ishii H
AD  - Department of Diabetology, Nara Medical University, Kashihara, Nara, Japan.
FAU - Saito, Yoshihiko
AU  - Saito Y
AD  - First Department of Internal Medicine, Nara Medical University, Kashihara, Nara, 
      Japan.
AD  - Department of Regulatory Medicine of Blood Pressure, Nara Medical University, 
      Kashihara, Nara, Japan.
CN  - Investigators for the Japanese Primary Prevention of Atherosclerosis with Aspirin 
      for Diabetes trial
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160125
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/*physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Kidney/*drug effects/physiopathology
MH  - Male
MH  - Middle Aged
PMC - PMC4726501
COIS- Competing Interests: Dr. TM reports receiving research grants from Bayer 
      HealthCare and lecturer’s fees from Daiichi-Sankyo, Eisai, Kowa Pharmaceutical, 
      Kyorin Pharmaceutical, and Pfizer Japan for the past three years. Dr. HO reports 
      receiving research grants from AstraZeneca Pharmaceutical, Astellas Pharma, Bayer 
      HealthCare, Boehringer Ingelheim Pharmaceutical, Bristol-Myers, Chugai 
      Pharmaceutical, Daiichi Sankyo, Sumitomo Dainippon Pharma, Kowa Pharmaceutical, 
      MSD, Novartis, Otsuka Pharmaceutical, Pfizer Japan, Sanofi, and Takeda 
      Pharmaceutical and lecturer’s fees from AstraZeneca Pharmaceutical, Bayer 
      HealthCare, Daiichi-Sankyo, MSD, Pfizer Japan, Sanofi, and Taisho Pharmaceutical 
      for the past three years. Dr. HI reports receiving research grant support from 
      Novo Nordisk and Mitsubishi Tanabe Pharma and lecturer’s fees from AstraZeneca 
      Pharmaceutical, Eli Lilly Japan, Sanofi, Daiichi Sankyo, Sumitomo Dainippon 
      Pharma, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Novo 
      Nordisk, Boehringer Ingelheim Pharmaceutical, and MSD. Dr. YS reports receiving 
      research grant support from Ono Pharmaceutical, MSD, Mitsubishi Tanabe Pharma, 
      Daiichi Sankyo, Takeda Pharmaceutical, Novartis Pharma, Shionogi, Astellas 
      Pharma, Otsuka Pharmaceutical, St. Jude Medical Japan, and Kyowa Hakko Kirin; 
      lecturer’s fees from MSD, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, 
      Daiichi Sankyo, Otsuka Pharmaceutical, and Pfizer Japan; and consulting fees from 
      Ono Pharmaceutical for the past three years. The rest of the authors have 
      declared that no competing interests exist. Our competing interests do not alter 
      our adherence to PLOS ONE policies on sharing data and materials
EDAT- 2016/01/26 06:00
MHDA- 2016/07/14 06:00
CRDT- 2016/01/26 06:00
PHST- 2015/09/14 00:00 [received]
PHST- 2016/01/04 00:00 [accepted]
PHST- 2016/01/26 06:00 [entrez]
PHST- 2016/01/26 06:00 [pubmed]
PHST- 2016/07/14 06:00 [medline]
AID - PONE-D-15-37459 [pii]
AID - 10.1371/journal.pone.0147635 [doi]
PST - epublish
SO  - PLoS One. 2016 Jan 25;11(1):e0147635. doi: 10.1371/journal.pone.0147635. 
      eCollection 2016.

PMID- 19390498
OWN - NLM
STAT- MEDLINE
DCOM- 20090824
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 100
IP  - 2
DP  - 2009 Apr
TI  - The preventive and therapeutic impact of antiplatelet agents: past and present.
PG  - 133-6
AB  - Already more than two thousands years ago the Greek physician Hippocrates (V-IV 
      century B.C.) used the extracts of the willow bark to fight fever. At the end of 
      the eighteen hundreds the German chemist Felix Hoffmann obtained acetylsalicylic 
      acid in stable and pure form, and from then on Aspirin (where A is the 
      abbreviation of acetyl and Spir stands for Spirsaure, the German name of 
      salicylic acid) has had enormous diffusion. In 1953 Lawrence Craven reported that 
      he had successfully prescribed aspirin to hundreds of adult male patients for the 
      non-specific prophylaxis of coronary thrombosis. Aspirin is now one of the most 
      well-known drugs in the world, and in the last decades a large body of scientific 
      evidence has appeared with regard to the preventive and therapeutic effects of 
      aspirin and those of other antiplatelet agents. In fact, antiplatelet agents 
      constitute a cornerstone in current pharmacological treatment and prophylaxis. 
      Among the most interesting recent and beneficial areas of impact of aspirin and 
      of other antiplatelet drugs, there are those of stroke and of coronary artery 
      disease, and today targeted pharmacological and non-pharmacological interventions 
      should be carefully combined to deal, preventively and therapeutically, with the 
      cardiovascular epidemic.
FAU - Gensini, G F
AU  - Gensini GF
FAU - Conti, A A
AU  - Conti AA
LA  - eng
PT  - Editorial
PT  - Historical Article
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/history/*therapeutic use
MH  - Coronary Artery Disease/*prevention & control
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, Ancient
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/history/*therapeutic use
MH  - Stroke/*prevention & control
EDAT- 2009/04/25 09:00
MHDA- 2009/08/25 09:00
CRDT- 2009/04/25 09:00
PHST- 2009/04/25 09:00 [entrez]
PHST- 2009/04/25 09:00 [pubmed]
PHST- 2009/08/25 09:00 [medline]
PST - ppublish
SO  - Minerva Med. 2009 Apr;100(2):133-6.

PMID- 2816381
OWN - NLM
STAT- MEDLINE
DCOM- 19891220
LR  - 20131121
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 24
IP  - 3
DP  - 1989
TI  - [Simultaneous determination of aspirin and phenobarbital in infantile 
      co-phenobarbital powder by dual wavelength K-ratio spectrophotometry].
PG  - 229-33
AB  - Aspirin (I) and phenobarbital (II) in infantile co-phenobarbital powder were 
      determined simultaneously using dual wavelength K-ratio spectrophotometry. I and 
      II were analyzed with dual wavelength K-ratio spectrophotometry at 255, 244 and 
      236 nm. This method showed a mean recovery of 101.3% and a coefficient of 
      variation of 1.6% for (I). The mean recovery and CV of II were 99.21% and 1.90% 
      (n = 6) respectively. The method is simple, rapid and accurate.
FAU - Yu, S M
AU  - Yu SM
FAU - Lai, X P
AU  - Lai XP
FAU - Zhang, Y
AU  - Zhang Y
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 0 (Drug Combinations)
RN  - 0 (Powders)
RN  - R16CO5Y76E (Aspirin)
RN  - YQE403BP4D (Phenobarbital)
SB  - IM
MH  - Aspirin/*analysis
MH  - Drug Combinations
MH  - Phenobarbital/*analysis
MH  - Powders
MH  - Spectrophotometry/methods
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Yao Xue Xue Bao. 1989;24(3):229-33.

PMID- 29276386
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20220331
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 12
DP  - 2017
TI  - Guided bone regeneration with asymmetric collagen-chitosan membranes containing 
      aspirin-loaded chitosan nanoparticles.
PG  - 8855-8866
LID - 10.2147/IJN.S148179 [doi]
AB  - INTRODUCTION: Membranes allowing the sustained release of drugs that can achieve 
      cell adhesion are very promising for guided bone regeneration. Previous studies 
      have suggested that aspirin has the potential to promote bone regeneration. The 
      purpose of this study was to prepare a local drug delivery system with 
      aspirin-loaded chitosan nanoparticles (ACS) contained in an asymmetric 
      collagen-chitosan membrane (CCM). METHODS: In this study, the ACS were fabricated 
      using different concentrations of aspirin (5 mg, 25 mg, 50 mg, and 75 mg). The 
      drug release behavior of ACS was studied. Transmission electron microscopy (TEM) 
      and scanning electron microscopy (SEM) were used to examine the micromorphology 
      of ACS and aspirin-loaded chitosan nanoparticles contained in chitosan-collagen 
      membranes (ACS-CCM). In vitro bone mesenchymal stem cells (BMSCs) were cultured 
      and critical-sized cranial defects on Sprague-Dawley rats were made to evaluate 
      the effect of the ACS-CCM on bone regeneration. RESULTS: Drug release behavior 
      results of ACS showed that the nanoparticles fabricated in this study could 
      successfully sustain the release of the drug. TEM showed the morphology of the 
      nanoparticles. SEM images indicated that the asymmetric membrane comprised a 
      loose collagen layer and a dense chitosan layer. In vitro studies showed that 
      ACS-CCM could promote the proliferation of BMSCs, and that the degree of 
      differentiated BMSCs seeded on CCMs containing 50 mg of ACS was higher than that 
      of other membranes. Micro-computed tomography showed that 50 mg of ACS-CCM 
      resulted in enhanced bone regeneration compared with the control group. 
      CONCLUSION: This study shows that the ACS-CCM would allow the sustained release 
      of aspirin and have further osteogenic potential. This membrane is a promising 
      therapeutic approach to guiding bone regeneration.
FAU - Zhang, Jiayu
AU  - Zhang J
AD  - School of Dentistry, Hospital of Stomatology, Tianjin Medical University, 
      Tianjin.
FAU - Ma, Shiqing
AU  - Ma S
AD  - School of Dentistry, Hospital of Stomatology, Tianjin Medical University, 
      Tianjin.
FAU - Liu, Zihao
AU  - Liu Z
AD  - School of Dentistry, Hospital of Stomatology, Tianjin Medical University, 
      Tianjin.
FAU - Geng, Hongjuan
AU  - Geng H
AD  - School of Dentistry, Hospital of Stomatology, Tianjin Medical University, 
      Tianjin.
FAU - Lu, Xin
AU  - Lu X
AD  - School of Dentistry, Hospital of Stomatology, Tianjin Medical University, 
      Tianjin.
FAU - Zhang, Xi
AU  - Zhang X
AD  - School of Dentistry, Hospital of Stomatology, Tianjin Medical University, 
      Tianjin.
FAU - Li, Hongjie
AU  - Li H
AD  - School of Dentistry, Hospital of Stomatology, Tianjin Medical University, 
      Tianjin.
FAU - Gao, Chenyuan
AU  - Gao C
AD  - Beijing Laboratory of Biomedical Materials, Beijing University of Chemical 
      Technology, Beijing, People's Republic of China.
FAU - Zhang, Xu
AU  - Zhang X
AD  - School of Dentistry, Hospital of Stomatology, Tianjin Medical University, 
      Tianjin.
FAU - Gao, Ping
AU  - Gao P
AD  - School of Dentistry, Hospital of Stomatology, Tianjin Medical University, 
      Tianjin.
LA  - eng
PT  - Journal Article
DEP - 20171215
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (Membranes, Artificial)
RN  - 9007-34-5 (Collagen)
RN  - 9012-76-4 (Chitosan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacokinetics/pharmacology
MH  - *Bone Regeneration/drug effects
MH  - Chitosan/chemistry
MH  - Collagen/chemistry
MH  - Drug Delivery Systems/*methods
MH  - Drug Liberation
MH  - Materials Testing
MH  - Membranes, Artificial
MH  - Mesenchymal Stem Cells
MH  - Microscopy, Electron, Scanning
MH  - Microscopy, Electron, Transmission
MH  - Nanoparticles/*administration & dosage/chemistry
MH  - Osteogenesis/drug effects
MH  - Rats, Sprague-Dawley
MH  - X-Ray Microtomography
PMC - PMC5733920
OTO - NOTNLM
OT  - aspirin
OT  - drug release
OT  - guided bone regeneration
OT  - membrane
OT  - nanoparticle
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/12/26 06:00
MHDA- 2018/03/27 06:00
CRDT- 2017/12/26 06:00
PHST- 2017/12/26 06:00 [entrez]
PHST- 2017/12/26 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
AID - ijn-12-8855 [pii]
AID - 10.2147/IJN.S148179 [doi]
PST - epublish
SO  - Int J Nanomedicine. 2017 Dec 15;12:8855-8866. doi: 10.2147/IJN.S148179. 
      eCollection 2017.

PMID- 10763201
OWN - NLM
STAT- MEDLINE
DCOM- 20000427
LR  - 20190826
IS  - 0248-8663 (Print)
IS  - 0248-8663 (Linking)
VI  - 21 Suppl 1
DP  - 2000 Mar
TI  - [Pharmacology of aspirin].
PG  - 18s-26s
AB  - Aspirin (acetylsalicylic acid) is the best-known salicylate and belongs to the 
      non steroid anti-inflammatory drug class. Despite wide use being made since more 
      than 100 years, knowledge about mechanism of action and therapeutic issues 
      continually evolves. The main mechanism of action is prostaglandin synthesis 
      inhibition. This is achieved through inhibition of prostaglandin endoperoxide 
      synthase (PGHS) or cyclooxygenase (COX) synthesis. Most of the therapeutic uses 
      of aspirin are explained by this mechanism. Nevertheless aspirin uses change as 
      time goes by: if the main one during the first fifty years was an analgesic, 
      anti-pyretic and anti-inflammatory one, the last fifty years saw aspirin being 
      used mainly as an anti-thrombotic agent, in primary and secondary thrombo-embolic 
      prevention. Better knowledge of mechanism of action points today at, on one hand, 
      more selective and therefore better tolerated molecules, and, on the other hand, 
      at new therapeutic applications, such as anti-cancer and neurodegenerative 
      diseases prevention.
FAU - Tanasescu, S
AU  - Tanasescu S
AD  - Service de pharmacologie, CHU de Rouen-Boisguillaume, France.
FAU - Lévesque, H
AU  - Lévesque H
FAU - Thuillez, C
AU  - Thuillez C
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Pharmacologie de l'aspirine.
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angina Pectoris/drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology/therapeutic 
      use
MH  - Arteriosclerosis/drug therapy
MH  - Aspirin/adverse effects/*pharmacology/therapeutic use
MH  - Breast Feeding
MH  - Child
MH  - Cyclooxygenase Inhibitors/adverse effects/*pharmacology/therapeutic use
MH  - Drug Hypersensitivity/etiology
MH  - Drug Interactions
MH  - Female
MH  - Fetus/drug effects
MH  - Fibrinolytic Agents/adverse effects/*pharmacology/therapeutic use
MH  - Humans
MH  - Kidney/drug effects
MH  - Liver/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacology/therapeutic use
MH  - Pregnancy
MH  - Reye Syndrome/chemically induced
MH  - Risk Factors
RF  - 48
EDAT- 2000/04/14 09:00
MHDA- 2000/04/29 09:00
CRDT- 2000/04/14 09:00
PHST- 2000/04/14 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/04/14 09:00 [entrez]
AID - S0248-8663(00)88721-4 [pii]
AID - 10.1016/s0248-8663(00)88721-4 [doi]
PST - ppublish
SO  - Rev Med Interne. 2000 Mar;21 Suppl 1:18s-26s. doi: 10.1016/s0248-8663(00)88721-4.

PMID- 3963030
OWN - NLM
STAT- MEDLINE
DCOM- 19860502
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 80
IP  - 3A
DP  - 1986 Mar 24
TI  - Treatment of osteoarthritis of the knee. A comparison of flurbiprofen and 
      aspirin.
PG  - 97-102
AB  - The analgesic efficacy of flurbiprofen (Ansaid, Upjohn) and aspirin were compared 
      in a 12-week, double-blind, randomized, parallel, multicenter study of 147 
      patients with osteoarthritis of the knee. Flurbiprofen (73 patients) was 
      administered two, three, or four times a day in total daily doses of 100, 150, or 
      200 mg; aspirin (74 patients) was also given two, three, or four times a day in 
      total daily doses of 2,000, 3,000, or 4,000 mg. Flurbiprofen was found effective 
      in controlling pain and other symptoms of osteoarthritis. In general, the 
      flurbiprofen group showed greater improvement in efficacy variables than did the 
      aspirin group. Statistically significant improvements were noted in the 
      flurbiprofen-treated patients for disability at week 12, and in the clinicians' 
      assessment of response to therapy and disability at the final evaluation. Many 
      flurbiprofen-treated patients (46 percent) completing the trial followed a 
      relatively low dosage regimen of 50 mg twice daily for more than half the study. 
      Flurbiprofen was well tolerated, and no significant laboratory abnormalities were 
      detected.
FAU - Lomen, P L
AU  - Lomen PL
FAU - Lamborn, K R
AU  - Lamborn KR
FAU - Porter, G H
AU  - Porter GH
FAU - Turner, L F
AU  - Turner LF
FAU - Brinn, E L
AU  - Brinn EL
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Evaluation
MH  - Female
MH  - Flurbiprofen/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - *Knee Joint
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Propionates/*therapeutic use
EDAT- 1986/03/24 00:00
MHDA- 1986/03/24 00:01
CRDT- 1986/03/24 00:00
PHST- 1986/03/24 00:00 [pubmed]
PHST- 1986/03/24 00:01 [medline]
PHST- 1986/03/24 00:00 [entrez]
AID - 0002-9343(86)90122-1 [pii]
AID - 10.1016/0002-9343(86)90122-1 [doi]
PST - ppublish
SO  - Am J Med. 1986 Mar 24;80(3A):97-102. doi: 10.1016/0002-9343(86)90122-1.

PMID- 10923603
OWN - NLM
STAT- MEDLINE
DCOM- 20000808
LR  - 20161124
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 85
IP  - 1
DP  - 2000 Jul
TI  - Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin 
      challenges in aspirin-sensitive asthmatics.
PG  - 40-5
AB  - BACKGROUND: Leukotrienes (LTs) have been implicated as major mediators of 
      aspirin-(ASA)-induced respiratory reactions. It was therefore logical to assume 
      that an inhibitor of 5-lipoxygenase (5-LO), such as zileuton, given before and 
      during oral challenges with ASA, might prevent ASA-induced respiratory reactions. 
      Indeed, in prior studies, pretreatment of ASA-sensitive respiratory disease 
      patients with leukotriene modifiers eliminated or attenuated respiratory 
      reactions upon re-challenge with the previously established provoking dose of 
      ASA. However, doses higher than the provoking doses were not administered during 
      these reported studies. OBJECTIVE: We wished to determine whether zileuton 
      pretreatment could prevent ASA-induced respiratory reactions in our six 
      volunteers with aspirin-sensitive respiratory disease when ASA challenge doses 
      were started below the usual provoking dose of 60 mg and then increased until a 
      respiratory reaction occurred. METHOD: Aspirin sensitivity was established 
      previously in all six patients during a prior ASA oral challenge. In this study, 
      pretreatment with zileuton 600 mg qid was initiated 7 days prior to, and 
      continued during oral ASA challenges. Patients underwent single-blind oral ASA 
      challenges with escalating doses of ASA, every 3 hours, according to our standard 
      protocol. RESULTS: All six patients reacted to doses of ASA between 45 and 325 
      mg. Four patients experienced bronchospasm (FEV1 declined 19% to 53%) while 
      receiving zileuton. All six had naso-ocular reactions. Concentrations of urine 
      LTE4 also increased significantly (mean 334 pg/mg Cr at baseline, increasing to 
      1024 pg/mg Cr at respiratory reactions). CONCLUSIONS: During ASA challenges, 
      zileuton, in standard doses of 600 mg qid was associated with increased synthesis 
      of LTs in five of six patients and naso-ocular reactions in all six patients, as 
      well as bronchospasm in four patients.
FAU - Pauls, J D
AU  - Pauls JD
AD  - Allergy Associates Medical Group, San Diego, California, USA.
FAU - Simon, R A
AU  - Simon RA
FAU - Daffern, P J
AU  - Daffern PJ
FAU - Stevenson, D D
AU  - Stevenson DD
LA  - eng
GR  - M01RR00833/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Leukotrienes)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - V1L22WVE2S (zileuton)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*adverse effects/immunology
MH  - Asthma/chemically induced/prevention & control
MH  - Desensitization, Immunologic
MH  - Humans
MH  - Hydroxyurea/*analogs & derivatives/pharmacology
MH  - Leukotrienes/urine
MH  - *Lipoxygenase Inhibitors/*pharmacology
EDAT- 2000/08/03 11:00
MHDA- 2000/08/12 11:00
CRDT- 2000/08/03 11:00
PHST- 2000/08/03 11:00 [pubmed]
PHST- 2000/08/12 11:00 [medline]
PHST- 2000/08/03 11:00 [entrez]
AID - S1081-1206(10)62432-5 [pii]
AID - 10.1016/S1081-1206(10)62432-5 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2000 Jul;85(1):40-5. doi: 
      10.1016/S1081-1206(10)62432-5.

PMID- 34080629
OWN - NLM
STAT- MEDLINE
DCOM- 20220316
LR  - 20220429
IS  - 1613-9860 (Electronic)
IS  - 1869-6716 (Print)
IS  - 1613-9860 (Linking)
VI  - 11
IP  - 10
DP  - 2021 Oct 23
TI  - News coverage about aspirin as a countervailing force against low-dose aspirin 
      campaign promotion.
PG  - 1941-1946
LID - 10.1093/tbm/ibab065 [doi]
AB  - Organized health promotion efforts sometimes compete with news media, social 
      media, and other sources when providing recommendations for healthy behavior. In 
      recent years, patients have faced a complicated information environment regarding 
      aspirin use as a prevention tool for heart health. We explored the possibility 
      that campaign promotion of low-dose aspirin use might have been undermined by 
      news coverage in the USA detailing controversies regarding aspirin use. Using 
      time series data on low-dose aspirin sales in Minnesota, USA, we assessed whether 
      news coverage of aspirin or audience engagement with the Ask About Aspirin 
      campaign website predicted subsequent changes in low-dose aspirin sales, over and 
      above any secular trend. News coverage predicted actual low-dose aspirin 
      purchases whereas exposure to a state-level campaign did not. While a campaign 
      effort to encourage people at risk to discuss low-dose aspirin use with their 
      health care providers did not generate substantive changes in low-dose aspirin 
      tablet sales in the areas of Minnesota monitored for this study, past news 
      coverage about aspirin use, including news about negative side effects, may have 
      suppressed low-dose aspirin sales during this same period. The extent of news 
      coverage about aspirin and heart health had a negative effect on tablet sales 
      recorded in greater Minnesota approximately a month later in an ARIMA time series 
      model, coefficient = -.014, t = -2.33, p = .02. Presented evidence of news 
      coverage effect suggests health campaign assessment should consider trends in the 
      public information environment as potential countervailing forces.
CI  - © Society of Behavioral Medicine 2021. All rights reserved. For permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Southwell, Brian G
AU  - Southwell BG
AUID- ORCID: 0000-0001-5091-8782
AD  - RTI International, Research Triangle Park, NC, USA.
FAU - Duval, Sue
AU  - Duval S
AD  - University of Minnesota, Minneapolis, MN, USA.
FAU - Luepker, Russell V
AU  - Luepker RV
AD  - University of Minnesota, Minneapolis, MN, USA.
FAU - Oldenburg, Niki
AU  - Oldenburg N
AD  - University of Minnesota, Minneapolis, MN, USA.
FAU - Van't Hof, Jeremy
AU  - Van't Hof J
AD  - University of Minnesota, Minneapolis, MN, USA.
FAU - Eder, Milton
AU  - Eder M
AD  - University of Minnesota, Minneapolis, MN, USA.
FAU - Russell, Carol
AU  - Russell C
AD  - Russell Herder, Minneapolis, MN, USA.
FAU - Graves, Robert N
AU  - Graves RN
AD  - Russell Herder, Minneapolis, MN, USA.
FAU - Finnegan, John
AU  - Finnegan J
AD  - University of Minnesota, Minneapolis, MN, USA.
LA  - eng
GR  - R01 HL126041/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Transl Behav Med
JT  - Translational behavioral medicine
JID - 101554668
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Health Behavior
MH  - Health Promotion
MH  - Humans
MH  - Mass Media
MH  - *Social Media
PMC - PMC9034327
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Health promotion
OT  - News coverage
OT  - Time series
EDAT- 2021/06/04 06:00
MHDA- 2022/03/17 06:00
CRDT- 2021/06/03 08:47
PHST- 2021/06/04 06:00 [pubmed]
PHST- 2022/03/17 06:00 [medline]
PHST- 2021/06/03 08:47 [entrez]
AID - 6291576 [pii]
AID - ibab065 [pii]
AID - 10.1093/tbm/ibab065 [doi]
PST - ppublish
SO  - Transl Behav Med. 2021 Oct 23;11(10):1941-1946. doi: 10.1093/tbm/ibab065.

PMID- 8572405
OWN - NLM
STAT- MEDLINE
DCOM- 19960306
LR  - 20190830
IS  - 0750-7658 (Print)
IS  - 0750-7658 (Linking)
VI  - 14
IP  - 5
DP  - 1995
TI  - [Comparison of the effects of ketorolac and aspirin on hemostasis in the rabbit].
PG  - 393-8
AB  - OBJECTIVE: Comparison of ketorolac with aspirin and placebo for the 
      antithrombotic activity using the Folts' model of experimental arterial 
      thrombosis and the perioperative blood loss. STUDY DESIGN: Experimental 
      randomized blinded study anaesthetized, tracheotomized and mechanically 
      ventilated. Carotid blood flow variations were detected by a probe directly 
      inserted around the artery and monitored by an electromagnetic flowmeter. A 
      segment of the exposed carotid artery was de-endothelialized by gently squeezing 
      the artery with a needle holder forceps, and an external constrictor was placed 
      around it (stenosis 60%), to induce cyclic flow reductions (CFR). During 20 min, 
      CFR rate was assessed. Animals were then randomized in 3 groups of 9: ketorolac 
      (K) 1 mg.kg-1, aspirin (A) 10 mg.kg-1 or saline (S), injected intravenously 
      (peripheral ear vein). After drug administration, CFR rate was assessed over 20 
      min, to determine the potential antithrombotic activity of the drug (curative 
      phase). Thereafter, the opposite carotid artery was injured and stenosed and the 
      occurrence of CFR was assessed over 20 min (preventive phase). The amount of 
      blood loss of a xipho-pubic laparotomy with a spleen section was also measured 30 
      min after drug administration. RESULTS: In all untreated animals, CFRs developed 
      with a mean rate of 4 cycles/20 min. Aspirin completely abolished CFR during the 
      curative phase in all rabbits, except in one. No effect was observed during this 
      phase with ketorolac or saline. During the preventive phase, a partial inhibition 
      of CFRs was induced by ketorolac and aspirin. Peri-operative bleeding was not 
      increased significantly by ketorolac or aspirin. Postinjection bleeding-time did 
      not differ between the three groups. CONCLUSIONS: Ketorolac (1mg.kg-1) has not a 
      strong antithrombotic activity. Ketorolac and aspirin do not increase 
      peri-operative blood loss, and therefore do not seem to strongly interfere with 
      haemostasis in the rabbit.
FAU - Samama, C M
AU  - Samama CM
AD  - Département d'Anesthésie-Réanimation, GH Pitié-Salpétrière, Paris.
FAU - Daghfous, M
AU  - Daghfous M
FAU - Delaporte-Cerceau, S
AU  - Delaporte-Cerceau S
FAU - Nafziger, J
AU  - Nafziger J
FAU - Drouet, L
AU  - Drouet L
FAU - Riou, B
AU  - Riou B
FAU - Coriat, P
AU  - Coriat P
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Comparaison des effets du kétorolac et de l'aspirine sur l'hémostase chez le 
      lapin.
PL  - France
TA  - Ann Fr Anesth Reanim
JT  - Annales francaises d'anesthesie et de reanimation
JID - 8213275
RN  - 0 (Anticoagulants)
RN  - 0 (Hemoglobins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
RN  - YZI5105V0L (Ketorolac)
SB  - IM
MH  - Animals
MH  - Anticoagulants/pharmacology
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - Double-Blind Method
MH  - Hemoglobins/analysis
MH  - Hemostasis/*drug effects
MH  - Ketorolac
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Count
MH  - Rabbits
MH  - Tolmetin/*analogs & derivatives/pharmacology
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - S0750-7658(05)80391-0 [pii]
AID - 10.1016/s0750-7658(05)80391-0 [doi]
PST - ppublish
SO  - Ann Fr Anesth Reanim. 1995;14(5):393-8. doi: 10.1016/s0750-7658(05)80391-0.

PMID- 20188076
OWN - NLM
STAT- MEDLINE
DCOM- 20100504
LR  - 20131121
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
VI  - 79
IP  - 12
DP  - 2010 Jun 15
TI  - Modulation of stress genes expression profile by nitric oxide-releasing aspirin 
      in Jurkat T leukemia cells.
PG  - 1759-71
LID - 10.1016/j.bcp.2010.02.011 [doi]
AB  - NO-donating aspirin (NO-ASA, para isomer) has been reported to exhibit strong 
      growth inhibitory effect in Jurkat T-acute lymphoblastic leukemia (T-ALL) cells 
      mediated in part by beta-catenin degradation and caspase activation, but the 
      mechanism(s) still remains unclear. In this study, DNA oligoarrays with 263 genes 
      were used to examine the gene expression profiles relating to stress and drug 
      metabolism, and characterize the stress responses at IC(50) and subIC(50) 
      concentrations of p-NO-ASA (20 and 10microM, respectively) in Jurkat T cells. A 
      total of 22 genes related to heat shock response, apoptosis signaling, 
      detoxifiers and Phase II enzymes, and regulators of cell growth were altered in 
      expression by array analysis based on the expression fold change criteria of > or 
      =1.5-fold or < or =0.65-fold. Real time quantitative RT-PCR confirmed that 
      20microM p-NO-ASA strongly upregulated the mRNA levels of two heat shock genes 
      HSPA1A (41.5+/-7.01-fold) and HSPA6 (100.4+/-8.11-fold), and FOS 
      (16.2+/-3.2-fold), moderately upregulated HSPH1 (1.71+/-0.43-fold), FMO4 
      (4.5+/-1.67-fold), CASP9 (1.77+/-0.03-fold), DDIT3 (5.6+/-0.51-fold), and 
      downregulated NF-kappaB1 (0.54+/-0.01-fold) and CCND1 (0.69+/-0.06-fold). Protein 
      levels of Hsp70, the product of HSPA1A, and fos were increased in 
      p-NO-ASA-treated Jurkat T and HT-29 colon cancer cells in a dose-dependent 
      manner. Silencing of Hsp70 enhanced the growth inhibitory effect of p-NO-ASA at 
      low concentrations. The altered gene expression patterns by NO-ASA in Jurkat T 
      cells suggest mechanisms for carcinogen metabolism, anti-proliferative activity 
      and possible chemoprotective activity in T-ALL.
CI  - Copyright 2010 Elsevier Inc. All rights reserved.
FAU - Nath, Niharika
AU  - Nath N
AD  - Department of Life Sciences, New York Institute of Technology, New York, NY 
      10023, USA. nnath@nyit.edu
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
FAU - Kodela, Ravinder
AU  - Kodela R
FAU - Tian, Song
AU  - Tian S
FAU - Vlismas, Peter
AU  - Vlismas P
FAU - Boring, Daniel
AU  - Boring D
FAU - Crowell, James A
AU  - Crowell JA
FAU - Kashfi, Khosrow
AU  - Kashfi K
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100224
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Antineoplastic Agents)
RN  - 0 (HSP70 Heat-Shock Proteins)
RN  - 0 (HSPA1A protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/chemistry/*pharmacology
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Gene Silencing
MH  - HSP70 Heat-Shock Proteins/genetics/metabolism
MH  - Humans
MH  - Jurkat Cells
MH  - Leukemia, T-Cell/*drug therapy
MH  - Molecular Structure
MH  - Neoplasm Proteins/genetics/metabolism
MH  - RNA Interference
EDAT- 2010/03/02 06:00
MHDA- 2010/05/05 06:00
CRDT- 2010/03/02 06:00
PHST- 2010/02/13 00:00 [received]
PHST- 2010/02/16 00:00 [accepted]
PHST- 2010/03/02 06:00 [entrez]
PHST- 2010/03/02 06:00 [pubmed]
PHST- 2010/05/05 06:00 [medline]
AID - S0006-2952(10)00105-X [pii]
AID - 10.1016/j.bcp.2010.02.011 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2010 Jun 15;79(12):1759-71. doi: 10.1016/j.bcp.2010.02.011. 
      Epub 2010 Feb 24.

PMID- 19300042
OWN - NLM
STAT- MEDLINE
DCOM- 20090515
LR  - 20131121
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
VI  - 16
IP  - 2
DP  - 2009 Mar-Apr
TI  - Targeting the inflammatory response in secondary stroke prevention: a role for 
      combining aspirin and extended-release dipyridamole.
PG  - 164-70
LID - 10.1097/MJT.0b013e31814b17bf [doi]
AB  - The recognition that stroke and other ischemic events are manifestations of 
      chronic progressive inflammation has had a great impact on the development of 
      prevention strategies. The most recent American Heart Association guidelines 
      recommend combination aspirin and extended-release dipyridamole over aspirin 
      alone for patients with prior ischemic stroke or transient ischemic attack. 
      Although aspirin and extended-release dipyridamole have long been recognized for 
      their antiplatelet activities, there is now evidence that these drugs also have 
      complementary antiinflammatory properties that contribute to improved outcomes 
      when used to prevent secondary stroke. In the Second European Stroke Prevention 
      Study (ESPS-2), the addition of extended-release dipyridamole to low-dose aspirin 
      significantly reduced the risk of recurrent ischemic stroke without significantly 
      increasing bleeding. Also, in the recent European/Australasian Stroke Prevention 
      in Reversible Ischaemia Trial (ESPRIT), a combination of aspirin and 
      extended-release dipyridamole was superior to aspirin alone for reducing the 
      occurrence of the primary combined end point of vascular death, nonfatal stroke, 
      nonfatal myocardial infarction, and major bleeding complications. The added 
      benefit without worsening bleeding may be attributable, in part, to the 
      antiinflammatory actions of this combination therapy.
FAU - Weyrich, Andrew S
AU  - Weyrich AS
AD  - Department of Internal Medicine, University of Utah, Salt Lake City, UT 84112, 
      USA. andy.weyrich@hmbg.utah.edu
FAU - Skalabrin, Elaine J
AU  - Skalabrin EJ
FAU - Kraiss, Larry W
AU  - Kraiss LW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyridamole/administration & dosage/*pharmacology/therapeutic use
MH  - Disease Progression
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Inflammation/drug therapy/physiopathology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/therapeutic 
      use
MH  - Practice Guidelines as Topic
MH  - Stroke/etiology/*prevention & control
RF  - 30
EDAT- 2009/03/21 09:00
MHDA- 2009/05/16 09:00
CRDT- 2009/03/21 09:00
PHST- 2009/03/21 09:00 [entrez]
PHST- 2009/03/21 09:00 [pubmed]
PHST- 2009/05/16 09:00 [medline]
AID - 00045391-200903000-00010 [pii]
AID - 10.1097/MJT.0b013e31814b17bf [doi]
PST - ppublish
SO  - Am J Ther. 2009 Mar-Apr;16(2):164-70. doi: 10.1097/MJT.0b013e31814b17bf.

PMID- 27161407
OWN - NLM
STAT- MEDLINE
DCOM- 20170522
LR  - 20181202
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 23
IP  - 6
DP  - 2016 Jun 1
TI  - The mixture of Salvia miltiorrhiza-Carthamus tinctorius (Danhong injection) 
      alleviates low-dose aspirin induced gastric mucosal damage in rats.
PG  - 662-71
LID - S0944-7113(16)30012-5 [pii]
LID - 10.1016/j.phymed.2016.03.006 [doi]
AB  - BACKGROUND: Danhong injection (DHI) is quite often used in combination with 
      low-dose aspirin (ASA, 75-325mg daily) in clinic, particularly for the treatment 
      of cardiovascular diseases. Exploring their interaction profile is of great 
      clinical importance. PURPOSE: The current study aims to explore the interaction 
      between DHI and low-dose ASA in rats. METHODS: Sixty four rats were randomly 
      divided into eight groups. Stomach and other four vital organs were collected for 
      histological evaluation. Organs which exhibited histological changes were 
      selected for a further study to evaluate the damage score and mode of action. We 
      tested the protective effect of DHI on gastric mucosal damage in different 
      regimes of administration. COX activity, gastric mucus secretion, pepsin 
      activity, antioxidant activity and ROS level were assayed to reflect the 
      protective effect of DHI on gastric mucosal damage induced by ASA. RESULTS: 
      Stomach was the target organ of interaction when DHI and ASA were used in 
      combination. DHI alleviated gastric mucosal damage by 55.8% when DHI was injected 
      before ASA (Group E) and by 53.5% when DHI was injected 2h after ASA 
      administration (Group F). Additionally, if DHI treatment was appended to the 
      long-term administration of ASA, DHI still decreased the gastric mucosal damage 
      score in 52.0% from 2.50 to 1.20. DHI improved gastric mucus secretion, as well 
      as decreased pepsin activity to maintain the integrity of gastric mucosal barrier 
      (P<0.05). Furthermore, DHI recovered antioxidant activity which was impaired by 
      ASA. In details, DHI decreased gastric mucosal ROS level, increased CAT, GSH-Px 
      and SOD activity, and reduced MDA concentration (P<0.05). When ASA (71.9µM) was 
      used in combination with DHI (23-fold dilution, presented in terms of 
      concentrations of DSS, PA, SaD RA, SaB and SaA were 6.45-6.92, 1.10-1.14, 
      1.09-1.10, 0.86-0.90, 16.76-19.38 and 1.83-1.94µg/ml, respectively) in vitro, the 
      inhibition rate of ASA increased from 38.6% (ASA alone) to 62.8% (ASA-DHI) on 
      COX-1 and from 28.9% (ASA alone) to 38.8% (ASA-DHI) on COX-2 (P<0.05). DHI 
      strengthened the inhibition activity of ASA on both COX-1 and COX-2, which showed 
      that DHI alleviated ASA induced gastric mucosal damage but not antagonized 
      anti-COX effect of ASA. CONCLUSIONS: Gastric protective benefits were clearly 
      produced when DHI and ASA were used in combination, which provided rational 
      guidance for clinical combined application of DHI and ASA.
CI  - Copyright © 2016 Elsevier GmbH. All rights reserved.
FAU - Li, Jian-Ping
AU  - Li JP
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China.
FAU - Guo, Jian-Ming
AU  - Guo JM
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China.
FAU - Hua, Yong-Qing
AU  - Hua YQ
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China.
FAU - Zhu, Kevin Yue
AU  - Zhu KY
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China.
FAU - Tang, Yu-Ping
AU  - Tang YP
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China.
FAU - Zhao, Bu-Chang
AU  - Zhao BC
AD  - Buchang Pharma, Xi'an 710000, China.
FAU - Jia, Li-Fu
AU  - Jia LF
AD  - Buchang Pharma, Xi'an 710000, China.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Buchang Pharma, Xi'an 710000, China.
FAU - Tang, Zhi-Shu
AU  - Tang ZS
AD  - Shanxi University of Chinese Medicine, Xianyang 712000, China.
FAU - Duan, Jin-Ao
AU  - Duan JA
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China. Electronic address: 
      dja@njucm.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20160401
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 0 (Drug Combinations)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Plant Extracts)
RN  - 0 (danhong)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/pharmacology/therapeutic use
MH  - Carthamus tinctorius/chemistry
MH  - China
MH  - Drug Combinations
MH  - Drug Interactions
MH  - Drugs, Chinese Herbal/*adverse effects/*pharmacology
MH  - Gastric Mucosa/*drug effects/*injuries
MH  - Male
MH  - Plant Extracts/*pharmacology
MH  - Rats
MH  - Salvia miltiorrhiza/chemistry
OTO - NOTNLM
OT  - Aspirin
OT  - Cyclooxygenase
OT  - Danhong injection
OT  - Drug combination
OT  - Drug interaction
OT  - Gastric mucosal damage
EDAT- 2016/05/11 06:00
MHDA- 2017/05/23 06:00
CRDT- 2016/05/11 06:00
PHST- 2015/09/10 00:00 [received]
PHST- 2016/03/02 00:00 [revised]
PHST- 2016/03/09 00:00 [accepted]
PHST- 2016/05/11 06:00 [entrez]
PHST- 2016/05/11 06:00 [pubmed]
PHST- 2017/05/23 06:00 [medline]
AID - S0944-7113(16)30012-5 [pii]
AID - 10.1016/j.phymed.2016.03.006 [doi]
PST - ppublish
SO  - Phytomedicine. 2016 Jun 1;23(6):662-71. doi: 10.1016/j.phymed.2016.03.006. Epub 
      2016 Apr 1.

PMID- 11776412
OWN - NLM
STAT- MEDLINE
DCOM- 20020402
LR  - 20170214
IS  - 0960-3271 (Print)
IS  - 0960-3271 (Linking)
VI  - 20
IP  - 9
DP  - 2001 Sep
TI  - Three case reports of the use of haemodiafiltration in the treatment of 
      salicylate overdose.
PG  - 491-5
AB  - Aspirin (acetylsalicylic acid) is widely available without prescription. Although 
      self-poisoning is rare, if severe it may be life threatening. Haemodialysis has 
      been recommended in severe cases when salicylate levels exceed 7.3 mmol l(-1). We 
      describe three cases of severe salicylate poisoning, which were treated with 
      continuous veno-venous haemodiafiltration (CVVHDF). All patients survived. The 
      first case had already undergone haemodialysis before transfer to the ICU, where 
      CVVHDF was commenced because salicylism persisted at 3 mmol l(-1). A small 
      reduction in serum salicylate was noted. In the second case, serum salicylate 
      decreased from 8.5 to 3.5 mmol l(-1) after 3 h of CVVHDF even though only minimal 
      urine was produced. Our third case is a chronic overdose in whom serum salicylate 
      decreased from 6.2 to 4 mmol l(-1) after 4 h and to 1.4 mmol l(-1) after a 
      further 7 h. No bicarbonate was administered to this patient and elimination can 
      only be attributed to CVVHDF and urinary clearance, which is known to be slow. We 
      discuss the pathogenesis of severe salicylate toxicity and postulate that CVVHDF, 
      which is widely used in the intensive care setting, may be a useful therapy in 
      severely poisoned patients who are unstable and cannot undergo haemodialysis or 
      in situations where haemodialysis is unavailable.
FAU - Wrathall, G
AU  - Wrathall G
AD  - Frenchay Hospital, Bristol, UK.
FAU - Sinclair, R
AU  - Sinclair R
FAU - Moore, A
AU  - Moore A
FAU - Pogson, D
AU  - Pogson D
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - England
TA  - Hum Exp Toxicol
JT  - Human & experimental toxicology
JID - 9004560
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/blood/*poisoning
MH  - Drug Overdose/therapy
MH  - *Hemodiafiltration
MH  - Humans
MH  - Middle Aged
RF  - 11
EDAT- 2002/01/05 10:00
MHDA- 2002/04/03 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/04/03 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
AID - 10.1191/096032701682693071 [doi]
PST - ppublish
SO  - Hum Exp Toxicol. 2001 Sep;20(9):491-5. doi: 10.1191/096032701682693071.

PMID- 10171961
OWN - NLM
STAT- MEDLINE
DCOM- 19941017
LR  - 20151119
IS  - 0017-9132 (Print)
IS  - 0017-9132 (Linking)
VI  - 26
IP  - 1
DP  - 1994
TI  - The use of aspirin in children under 12 years old attending a paediatric 
      dentistry department in a dental hospital.
PG  - 31-2
AB  - For several years it has been recommended that aspirin should be avoided in 
      children under the age of 12 years because of the risk of Reye's Syndrome. In 
      this study we investigated the reported use of analgesics among children who 
      attended the Children's Department of the Dental Hospital in Newcastle upon Tyne. 
      In addition the study also investigated the complaints that led to use of 
      analgesics, the dose and frequency of administration of the analgesic, and past 
      and current contact with medical services. Of 179 children investigated, 129 were 
      under 12 years-old; of these 129 children under 12 years-of-age, 72 (56%) had 
      taken an analgesic within the previous six months, 12 (17%) of whom took aspirin. 
      Three of these children who had taken aspirin were reported to have had a serious 
      illness in their lives, and would therefore have had significant contact with 
      medical services. One-quarter of all children who had taken an analgesic did so 
      for toothache. Inappropriate use of aspirin in children under 12 years-of-age 
      indicates that health education about the possible risks of Reye's Syndrome needs 
      to be improved.
FAU - Nunn, J
AU  - Nunn J
AD  - Department of Child Dental Health, The Dental School, Newcastle-upon-Tyne.
FAU - Lowry, L
AU  - Lowry L
FAU - Lowry, R
AU  - Lowry R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Health Trends
JT  - Health trends
JID - 0233525
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Dental Service, Hospital/*standards
MH  - England
MH  - Humans
MH  - Pediatric Dentistry/*standards
MH  - Reye Syndrome/etiology
MH  - Surveys and Questionnaires
EDAT- 1993/12/09 00:00
MHDA- 1993/12/09 00:01
CRDT- 1993/12/09 00:00
PHST- 1993/12/09 00:00 [pubmed]
PHST- 1993/12/09 00:01 [medline]
PHST- 1993/12/09 00:00 [entrez]
PST - ppublish
SO  - Health Trends. 1994;26(1):31-2.

PMID- 27637302
OWN - NLM
STAT- MEDLINE
DCOM- 20170529
LR  - 20170529
IS  - 1558-1977 (Electronic)
IS  - 0889-8588 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Oct
TI  - The History of Antithrombotic Therapy: The Discovery of Heparin, the Vitamin K 
      Antagonists, and the Utility of Aspirin.
PG  - 987-93
LID - S0889-8588(16)30074-0 [pii]
LID - 10.1016/j.hoc.2016.06.002 [doi]
AB  - The administration of intravenous heparin to postoperative patients by Barritt 
      and Jordan reduced the incidence of fatal and nonfatal pulmonary embolism and 
      established heparin as the standard for parenteral anticoagulation. The coumarin 
      family of vitamin K antagonists quickly became the standard for long-term oral 
      anticoagulation. Aspirin became a widely used antithrombotic agent after the 
      discovery that chronic oral administration reduced the incidence of secondary 
      strokes and myocardial infarction. This article gives a brief history of 
      antithrombotic therapy, including the discovery of heparin, the vitamin k 
      antagonists, and the utility of aspirin.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Handin, Robert I
AU  - Handin RI
AD  - Hematology Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 
      02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: 
      rhandin@partners.org.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20160727
PL  - United States
TA  - Hematol Oncol Clin North Am
JT  - Hematology/oncology clinics of North America
JID - 8709473
RN  - 0 (Fibrinolytic Agents)
RN  - 12001-79-5 (Vitamin K)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/history/therapeutic use
MH  - *Fibrinolytic Agents/history/therapeutic use
MH  - *Heparin/history/therapeutic use
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Vitamin K/*antagonists & inhibitors
OTO - NOTNLM
OT  - Antithrombotic therapy
OT  - Aspirin
OT  - Heparin
OT  - Vitamin K antagonists
EDAT- 2016/09/18 06:00
MHDA- 2017/05/30 06:00
CRDT- 2016/09/18 06:00
PHST- 2016/09/18 06:00 [entrez]
PHST- 2016/09/18 06:00 [pubmed]
PHST- 2017/05/30 06:00 [medline]
AID - S0889-8588(16)30074-0 [pii]
AID - 10.1016/j.hoc.2016.06.002 [doi]
PST - ppublish
SO  - Hematol Oncol Clin North Am. 2016 Oct;30(5):987-93. doi: 
      10.1016/j.hoc.2016.06.002. Epub 2016 Jul 27.

PMID- 6685916
OWN - NLM
STAT- MEDLINE
DCOM- 19840127
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 113
IP  - 44
DP  - 1983 Nov 5
TI  - [Prevention of vascular complications in polycythemia vera and primary 
      thrombocythemia treated with low doses of acetylsalicylic acid].
PG  - 1622-7
AB  - 22 patients (13 with polycythaemia vera and 9 with primary thrombocythemia) were 
      treated with 250 mg acetylsalicylic acid (ASA) daily for an average of 25 months. 
      Before therapy was started, 3 patients had arterial thromboses, 3 had venous 
      thromboses, 3 had spontaneous hemorrhage, 3 had acral circulatory disorders and 
      13 had dizziness, whereas under ASA treatment neither arterial nor venous 
      thromboses occurred and only 4 mild spontaneous hemorrhages were recorded. Under 
      ASA the circulatory disorders of the extremities disappeared completely in 11 
      patients and recurred intermittently in milder form in 2 patients. Dizziness was 
      completely abolished in 12 of the 13 patients. Discontinuation of therapy was 
      followed by prompt recurrence of symptoms. No correlation could be established 
      between symptoms and extent of platelet disease either before or during ASA 
      therapy. Low-dose salicylates are highly effective in the prevention and 
      treatment of vascular complications in polycythaemia vera and primary 
      thrombocythemia. Thanks to ASA, potentially leukemogenic cytostatic agents and 
      radiophosphorus can be used more sparingly.
FAU - Fröhli, P
AU  - Fröhli P
FAU - Graf, C
AU  - Graf C
FAU - Rhyner, K
AU  - Rhyner K
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Die Prophylaxe vaskulärer Komplikationen bei Polycythaemia vera und primärer 
      Thrombozythämie mit niedrig dosierter Acetylsalicylsäure.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polycythemia Vera/*complications/drug therapy
MH  - Thrombocythemia, Essential/*complications/drug therapy
MH  - Vascular Diseases/etiology/*prevention & control
EDAT- 1983/11/05 00:00
MHDA- 1983/11/05 00:01
CRDT- 1983/11/05 00:00
PHST- 1983/11/05 00:00 [pubmed]
PHST- 1983/11/05 00:01 [medline]
PHST- 1983/11/05 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1983 Nov 5;113(44):1622-7.

PMID- 7773087
OWN - NLM
STAT- MEDLINE
DCOM- 19950711
LR  - 20161123
IS  - 0869-2092 (Print)
IS  - 0869-2092 (Linking)
VI  - 58
IP  - 2
DP  - 1995 Mar-Apr
TI  - [The pharmacokinetics and pharmacodynamics of prophylactic doses of aspirin in 
      pregnant women from a group at risk for placental insufficiency].
PG  - 35-9
AB  - The pharmacokinetics and pharmacodynamics of small-dose aspirin (60 mg/day) were 
      studied during the second to the third trimesters in pregnant females at a high 
      risk of placental insufficiency. In the group of pregnant women with 
      uncomplicated pregnancies (n = 16), the aspirin kinetic changes which presented 
      with a lower concentration-time index, higher total clearance and larger 
      distribution volume were associated with the gestational age. Similar changes 
      were revealed in the group of pregnant women (n = 4) with advanced placental 
      insufficiency. The findings suggest that the optimal therapeutical aspirin doses 
      should be chosen by the gestational age rather than by the severity of placental 
      insufficiency.
FAU - Asymbekova, G U
AU  - Asymbekova GU
FAU - Banartsev, P D
AU  - Banartsev PD
FAU - Ochan, T B
AU  - Ochan TB
FAU - Rozenfel'd, B E
AU  - Rozenfel'd BE
FAU - Sariev, A K
AU  - Sariev AK
FAU - Folomeeva, I Iu
AU  - Folomeeva IIu
FAU - Pavlovich, S V
AU  - Pavlovich SV
LA  - rus
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Farmakokinetika i farmakodinamika profilakticheskikh doz aspirina u beremennykh 
      gruppy riska po platsentarnoĭ nedostatochnosti.
PL  - Russia (Federation)
TA  - Eksp Klin Farmakol
JT  - Eksperimental'naia i klinicheskaia farmakologiia
JID - 9215981
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics/pharmacology
MH  - Blood Platelets/drug effects/ultrastructure
MH  - Blood Viscosity/drug effects
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Placental Insufficiency/blood/diagnostic imaging/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Trimester, Second
MH  - Pregnancy Trimester, Third
MH  - Risk Factors
MH  - Time Factors
MH  - Ultrasonography, Prenatal
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
PST - ppublish
SO  - Eksp Klin Farmakol. 1995 Mar-Apr;58(2):35-9.

PMID- 22724630
OWN - NLM
STAT- MEDLINE
DCOM- 20141029
LR  - 20211021
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Print)
IS  - 1543-8384 (Linking)
VI  - 9
IP  - 8
DP  - 2012 Aug 6
TI  - Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and 
      immobilized TRAIL and E-selectin.
PG  - 2219-27
LID - 10.1021/mp300073j [doi]
AB  - Though metastasis is considered an inefficient process, over 90% of cancer 
      related deaths are attributed to the formation of secondary tumors. Thus, 
      eliminating circulating cancer cells could lead to improved patient survival. 
      This study was aimed at exploiting the interactions of cancer cells with 
      selectins under flow to selectively kill captured colon cancer cells. Microtubes 
      functionalized with E-selectin and TRAIL were perfused with colon cancer cell 
      line Colo205 either treated with 1 mM aspirin or untreated for 1 or 2 h. Cells 
      were collected from the microtube and analyzed by flow cytometry. Aspirin 
      treatment alone killed only 3% cells in culture. A 95% difference in the number 
      of cells killed between control and TRAIL + ES surfaces was seen when aspirin 
      treated cells were perfused over the functionalized surface for 2 h. We have 
      demonstrated a novel biomimetic method to capture and neutralize cancer cells in 
      flow, thus reducing the chances for the formation of secondary tumors.
FAU - Rana, Kuldeepsinh
AU  - Rana K
AD  - Department of Biomedical Engineering, Cornell University, Ithaca, New York 14853, 
      United States.
FAU - Reinhart-King, Cynthia A
AU  - Reinhart-King CA
FAU - King, Michael R
AU  - King MR
LA  - eng
GR  - U54 CA143876/CA/NCI NIH HHS/United States
GR  - U54CA143876/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120702
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 0 (E-Selectin)
RN  - 0 (TNF-Related Apoptosis-Inducing Ligand)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Aspirin/chemistry/*pharmacology
MH  - Cell Line, Tumor
MH  - E-Selectin/chemistry/*pharmacology
MH  - Humans
MH  - Neoplastic Cells, Circulating/drug effects
MH  - TNF-Related Apoptosis-Inducing Ligand/chemistry/*pharmacology
PMC - PMC3412427
EDAT- 2012/06/26 06:00
MHDA- 2014/10/30 06:00
CRDT- 2012/06/26 06:00
PHST- 2012/06/26 06:00 [entrez]
PHST- 2012/06/26 06:00 [pubmed]
PHST- 2014/10/30 06:00 [medline]
AID - 10.1021/mp300073j [doi]
PST - ppublish
SO  - Mol Pharm. 2012 Aug 6;9(8):2219-27. doi: 10.1021/mp300073j. Epub 2012 Jul 2.

PMID- 9099173
OWN - NLM
STAT- MEDLINE
DCOM- 19970508
LR  - 20131121
IS  - 0820-3946 (Print)
IS  - 1488-2329 (Electronic)
IS  - 0820-3946 (Linking)
VI  - 156
IP  - 7
DP  - 1997 Apr 1
TI  - Acetylsalicylic-acid-containing drugs and nonsteroidal anti-inflammatory drugs 
      available in Canada.
PG  - 1025-8
AB  - A large number of drugs containing acetylsalicylic acid (ASA) and nonsteroidal 
      anti-inflammatory drugs (NSAIDs) are available by prescription and over the 
      counter in Canada. The possibility of serious side effects and drug interactions 
      is therefore high. The authors have compiled a comprehensive list of products 
      containing these drugs from information supplied by pharmaceutical databases, 
      independent marketing researchers and Health Canada's Drug Directorate. 
      Physicians should ensure that additional ASA-containing drugs or NSAIDs are not 
      inadvertently taken by patients, especially those receiving oral anticoagulant 
      therapy or those with a qualitative platelet defect. Patients at risk should be 
      cautioned to check with their physician before taking any new medication, even 
      over-the-counter products.
FAU - Brigden, M
AU  - Brigden M
AD  - Penticton Regional Hospital, BC.
FAU - Smith, R E
AU  - Smith RE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Canada
TA  - CMAJ
JT  - CMAJ : Canadian Medical Association journal = journal de l'Association medicale 
      canadienne
JID - 9711805
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*supply & distribution
MH  - Aspirin/pharmacology/*supply & distribution
MH  - Canada
MH  - Drug Interactions
MH  - Humans
MH  - Terminology as Topic
PMC - PMC1227121
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
PST - ppublish
SO  - CMAJ. 1997 Apr 1;156(7):1025-8.

PMID- 3350203
OWN - NLM
STAT- MEDLINE
DCOM- 19880506
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 16
IP  - 1
DP  - 1988 Jan-Feb
TI  - Platelet deposition on human atherosclerotic lesions is decreased by low-dose 
      aspirin in combination with dipyridamole.
PG  - 39-43
AB  - Eighteen patients with ischaemic peripheral vascular disease were treated for a 
      5-week period with either 20 mg aspirin daily, 75 mg dipyridamole three times 
      daily or a combination of these two treatments. Before and after 4 weeks' 
      treatment autologous platelet labelling with 111In was carried out and sites of 
      active vascular platelet uptake monitored, and platelet half-life measured. 
      Neither aspirin nor dipyridamole alone had any effect on platelet uptake or on 
      platelet half-life. The combination of aspirin and dipyridamole resulted in a 
      significant decrease in platelet uptake and a nonsignificant trend towards 
      prolongation of platelet half-life. These findings suggest that this combined 
      therapy may be of benefit in the treatment of atherosclerosis in man.
FAU - Sinzinger, H
AU  - Sinzinger H
AD  - Department of Nuclear Medicine, University of Vienna, Austria.
FAU - O'Grady, J
AU  - O'Grady J
FAU - Fitscha, P
AU  - Fitscha P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Indium Radioisotopes)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arteriosclerosis/*drug therapy
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/metabolism
MH  - Dipyridamole/administration & dosage/*pharmacology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Indium Radioisotopes
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.1177/030006058801600104 [doi]
PST - ppublish
SO  - J Int Med Res. 1988 Jan-Feb;16(1):39-43. doi: 10.1177/030006058801600104.

PMID- 781227
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 2
DP  - 1976
TI  - Fenoprofen in rheumatoid arthritis: a controlled crossover multi-centre study.
PG  - 26-31
AB  - The pooled data of a multi-clinic, double-blind, crossover study (16 weeks' 
      duration), comparing fenoprofen and aspirin in 116 patients with active 
      rheumatoid arthritis are reported. Each patient received fenoprofen (400 mg Q6H) 
      and aspirin (1,000 mg Q6H) for six-week periods, in random fashion. Usual 
      objective and subjective parameters were used to evaluate rheumatic activity. 
      Side effects were obtained by daily telephone interviews, and appropriate 
      laboratory tests were performed during weekly out-patient evaluations. Both 
      fenoprofen and aspirin were significantly more effective than placebo in 
      controlling rheumatoid activity. At the dosage level employed, no significant 
      differences were noted between the two anti-inflammatory agents in regard to 
      efficacy. However, fewer side effects were observed with fenoprofen than with 
      aspirin. The data indicate that fenoprofen is an additional valuable agent for 
      rheumatoid arthritis.
FAU - Gum, O B
AU  - Gum OB
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Fenoprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenylpropionates/*therapeutic use
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1976;2:26-31.

PMID- 7123514
OWN - NLM
STAT- MEDLINE
DCOM- 19821202
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 27
IP  - 1
DP  - 1982 Jul 1
TI  - Dosage frequency for suppression of platelet function by low dose aspirin 
      therapy.
PG  - 99-110
AB  - A study of platelet aggregation and MDA production after an oral dose of 300 mg 
      aspirin indicated that partial recovery of platelet function occurred when 
      approximately one third of the circulating platelets had been replaced by new 
      (uninhibited) platelets. In vitro studies on mixtures of normal and aspirin 
      inhibited platelets indicated partial restoration of platelet aggregation and 
      thromboxane B2 production with as little as 10% of normal platelets in some 
      subjects. Restoration of full function required a higher proportion of normal 
      platelets. There was considerable variation between subjects. These data suggest 
      that complete suppression of platelet functions in all normal subjects requires 
      daily administration of the drug.
FAU - Bradlow, B A
AU  - Bradlow BA
FAU - Chetty, N
AU  - Chetty N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Cell Survival/drug effects
MH  - Collagen/pharmacology
MH  - Depression, Chemical
MH  - Dose-Response Relationship, Drug
MH  - Epinephrine/pharmacology
MH  - Humans
MH  - Malondialdehyde/biosynthesis
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Function Tests
MH  - Thrombosis/drug therapy
MH  - Thromboxane B2/biosynthesis
EDAT- 1982/07/01 00:00
MHDA- 1982/07/01 00:01
CRDT- 1982/07/01 00:00
PHST- 1982/07/01 00:00 [pubmed]
PHST- 1982/07/01 00:01 [medline]
PHST- 1982/07/01 00:00 [entrez]
AID - 0049-3848(82)90283-3 [pii]
AID - 10.1016/0049-3848(82)90283-3 [doi]
PST - ppublish
SO  - Thromb Res. 1982 Jul 1;27(1):99-110. doi: 10.1016/0049-3848(82)90283-3.

PMID- 30158069
OWN - NLM
STAT- MEDLINE
DCOM- 20181102
LR  - 20220408
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 392
IP  - 10152
DP  - 2018 Sep 22
TI  - Use of aspirin to reduce risk of initial vascular events in patients at moderate 
      risk of cardiovascular disease (ARRIVE): a randomised, double-blind, 
      placebo-controlled trial.
PG  - 1036-1046
LID - S0140-6736(18)31924-X [pii]
LID - 10.1016/S0140-6736(18)31924-X [doi]
AB  - BACKGROUND: The use of aspirin in the primary prevention of cardiovascular events 
      remains controversial. We aimed to assess the efficacy and safety of aspirin 
      versus placebo in patients with a moderate estimated risk of a first 
      cardiovascular event. METHODS: ARRIVE is a randomised, double-blind, 
      placebo-controlled, multicentre study done in seven countries. Eligible patients 
      were aged 55 years (men) or 60 years (women) and older and had an average 
      cardiovascular risk, deemed to be moderate on the basis of the number of specific 
      risk factors. We excluded patients at high risk of gastrointestinal bleeding or 
      other bleeding, or diabetes. Patients were randomly assigned (1:1) with a 
      computer-generated randomisation code to receive enteric-coated aspirin tablets 
      (100 mg) or placebo tablets, once daily. Patients, investigators, and others 
      involved in treatment or data analysis were masked to treatment allocation. The 
      primary efficacy endpoint was a composite outcome of time to first occurrence of 
      cardiovascular death, myocardial infarction, unstable angina, stroke, or 
      transient ischaemic attack. Safety endpoints were haemorrhagic events and 
      incidence of other adverse events, and were analysed in the intention-to-treat 
      population. This study is registered with ClinicalTrials.gov, number NCT00501059. 
      FINDINGS: Between July 5, 2007, and Nov 15, 2016, 12 546 patients were enrolled 
      and randomly assigned to receive aspirin (n=6270) or placebo (n=6276) at 501 
      study sites. Median follow-up was 60 months. In the intention-to-treat analysis, 
      the primary endpoint occurred in 269 (4·29%) patients in the aspirin group versus 
      281 (4·48%) patients in the placebo group (hazard ratio [HR] 0·96; 95% CI 
      0·81-1·13; p=0·6038). Gastrointestinal bleeding events (mostly mild) occurred in 
      61 (0·97%) patients in the aspirin group versus 29 (0·46%) in the placebo group 
      (HR 2·11; 95% CI 1·36-3·28; p=0·0007). The overall incidence rate of serious 
      adverse events was similar in both treatment groups (n=1266 [20·19%] in the 
      aspirin group vs n=1311 [20·89%] in the placebo group. The overall incidence of 
      adverse events was similar in both treatment groups (n=5142 [82·01%] vs n=5129 
      [81·72%] in the placebo group). The overall incidence of treatment-related 
      adverse events was low (n=1050 [16·75%] vs n=850 [13·54%] in the placebo group; 
      p<0·0001). There were 321 documented deaths in the intention-to-treat population 
      (n=160 [2·55%] vs n=161 [2·57%] of 6276 patients in the placebo group). 
      INTERPRETATION: The event rate was much lower than expected, which is probably 
      reflective of contemporary risk management strategies, making the study more 
      representative of a low-risk population. The role of aspirin in primary 
      prevention among patients at moderate risk could therefore not be addressed. 
      Nonetheless, the findings with respect to aspirin's effects are consistent with 
      those observed in the previously published low-risk primary prevention studies. 
      FUNDING: Bayer.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Gaziano, J Michael
AU  - Gaziano JM
AD  - Brigham and Women's Hospital, Department of Medicine, Division of Aging, Boston, 
      MA, USA; Harvard Medical School, Boston, MA, USA; VA Boston Healthcare System, 
      Boston, MA, USA. Electronic address: jmgaziano@partners.org.
FAU - Brotons, Carlos
AU  - Brotons C
AD  - Sardenya Primary Health Care Center, EAP Sardenya-Biomedical Research Institute 
      Sant Pau (IIB Sant Pau), Barcelona, Spain.
FAU - Coppolecchia, Rosa
AU  - Coppolecchia R
AD  - Bayer HealthCare LLC, Whippany, NJ, USA.
FAU - Cricelli, Claudio
AU  - Cricelli C
AD  - Società Italiana di Medicina Generale, Florence, Italy.
FAU - Darius, Harald
AU  - Darius H
AD  - Department of Cardiology, Angiology, Nephrology and Intensive Care Medicine, 
      Vivantes Neukoelln Medical Center, Berlin, Germany.
FAU - Gorelick, Philip B
AU  - Gorelick PB
AD  - Department of Translational Science & Molecular Medicine, Michigan State 
      University College of Human Medicine, Grand Rapids, MI, USA; Vascular Neurology 
      Program, Mercy Health Hauenstein Neurosciences, Grand Rapids, Michigan Grand 
      Rapids, MI, USA.
FAU - Howard, George
AU  - Howard G
AD  - Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, 
      USA.
FAU - Pearson, Thomas A
AU  - Pearson TA
AD  - Department of Epidemiology and Medicine, University of Florida Health Science 
      Center, Gainsville, FL, USA.
FAU - Rothwell, Peter M
AU  - Rothwell PM
AD  - Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
FAU - Ruilope, Luis Miguel
AU  - Ruilope LM
AD  - Internal Medicine, Complutense University, Head of the Hypertension Unit, 12 de 
      Octubre Hospital, Madrid, Spain.
FAU - Tendera, Michal
AU  - Tendera M
AD  - Department of Cardiology and Structural Heart Disease, School of Medicine in 
      Katowice, Medical University of Silesia, Katowice, Poland.
FAU - Tognoni, Gianni
AU  - Tognoni G
AD  - IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Department of 
      Cardiovascular Research, IRCSS, Milan, Italy.
CN  - ARRIVE Executive Committee
LA  - eng
SI  - ClinicalTrials.gov/NCT00501059
GR  - 104040/WT_/Wellcome Trust/United Kingdom
GR  - P30 DK079626/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180826
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2018 Sep 22;392(10152):988-990. PMID: 30158070
CIN - Internist (Berl). 2019 Feb;60(2):209-216. PMID: 30645666
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Intention to Treat Analysis
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Stroke/epidemiology/*prevention & control
PMC - PMC7255888
MID - EMS86375
COIS- Declaration of interests All voting members of the ARRIVE Executive Committee 
      (JMG, CB, CC, HD, PBG, GH, TAP, PMR, LMR, MT, and GT) received personal fees from 
      Bayer during the conduct of the study. RC is an employee of Bayer and was a 
      non-voting member of the Executive Committee. PMR reports personal fees from 
      Bristol-Myers Squibb. LMR reports personal fees from Novartis, Sanofi, Medtronic, 
      Daiichi-Sankyo, and grant funding from AstraZeneca. MT reports personal fees from 
      Celyad, Janssen Cilag, Kowa, Perfuse Group, and Servier, outside the submitted 
      work.
EDAT- 2018/08/31 06:00
MHDA- 2018/11/06 06:00
CRDT- 2018/08/31 06:00
PHST- 2018/07/31 00:00 [received]
PHST- 2018/08/08 00:00 [revised]
PHST- 2018/08/10 00:00 [accepted]
PHST- 2018/08/31 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
PHST- 2018/08/31 06:00 [entrez]
AID - S0140-6736(18)31924-X [pii]
AID - 10.1016/S0140-6736(18)31924-X [doi]
PST - ppublish
SO  - Lancet. 2018 Sep 22;392(10152):1036-1046. doi: 10.1016/S0140-6736(18)31924-X. 
      Epub 2018 Aug 26.

PMID- 26263219
OWN - NLM
STAT- MEDLINE
DCOM- 20161005
LR  - 20200715
IS  - 1873-4367 (Electronic)
IS  - 0927-7765 (Linking)
VI  - 135
DP  - 2015 Nov 1
TI  - Structure, molecular simulation, and release of aspirin from intercalated 
      Zn-Al-layered double hydroxides.
PG  - 339-345
LID - S0927-7765(15)30103-X [pii]
LID - 10.1016/j.colsurfb.2015.07.069 [doi]
AB  - Aspirin or acetylsalicylic acid (AA), a non-steroidal anti-inflammatory drug, is 
      intercalated into Zn-Al-layered double hydroxides (ZnAl-LDHs) by co-precipitation 
      and reconstruction methods. The composition, structure, and morphology of the 
      intercalated products as well as their release behavior are determined 
      experimentally and theoretically by Material Studio 5.5. Experimental results 
      disclose the strong interaction between the LDHs sheets and AA in the 
      intercalated ZnAl-LDHs produced by co-precipitation and slow release of AA from 
      the intercalated ZnAl-LDHs in both phosphate buffered saline (PBS) and borate 
      buffered saline (BBS) solutions. The percentage of AA released from the ZnAl-LDHs 
      prepared by both methods in PBS (96.87% and 98.12%) are much more than those in 
      BBS (68.59% and 81.22%) implying that both H4BO4(-) and H2PO4(-) can exchange 
      with AA in the ZnAl-LDHs. After AA is released to PBS, ZnAl-LDHs break into small 
      pieces. The experimental results are explained theoretically based on the 
      calculation of the bonding energy between the anions and LDHs sheets as well as 
      the AlO bond length change in the LDHs sheets.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Meng, Zilin
AU  - Meng Z
AD  - Beijing Key Laboratory of Materials Utilization of Nonmetallic Minerals and Solid 
      Wastes, National Laboratory of Mineral Materials, School of Materials Science and 
      Technology, China University of Geosciences, Beijing 100083, China.
FAU - Li, Xiaowei
AU  - Li X
AD  - Beijing Key Laboratory of Materials Utilization of Nonmetallic Minerals and Solid 
      Wastes, National Laboratory of Mineral Materials, School of Materials Science and 
      Technology, China University of Geosciences, Beijing 100083, China.
FAU - Lv, Fengzhu
AU  - Lv F
AD  - Beijing Key Laboratory of Materials Utilization of Nonmetallic Minerals and Solid 
      Wastes, National Laboratory of Mineral Materials, School of Materials Science and 
      Technology, China University of Geosciences, Beijing 100083, China. Electronic 
      address: lfz619@cugb.edu.cn.
FAU - Zhang, Qian
AU  - Zhang Q
AD  - Beijing Key Laboratory of Materials Utilization of Nonmetallic Minerals and Solid 
      Wastes, National Laboratory of Mineral Materials, School of Materials Science and 
      Technology, China University of Geosciences, Beijing 100083, China.
FAU - Chu, Paul K
AU  - Chu PK
AD  - Department of Physics & Materials Science, City University of Hong Kong, Tat Chee 
      Avenue, Kowloon, Hong Kong, China.
FAU - Zhang, Yihe
AU  - Zhang Y
AD  - Beijing Key Laboratory of Materials Utilization of Nonmetallic Minerals and Solid 
      Wastes, National Laboratory of Mineral Materials, School of Materials Science and 
      Technology, China University of Geosciences, Beijing 100083, China. Electronic 
      address: zyh@cugb.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20150730
PL  - Netherlands
TA  - Colloids Surf B Biointerfaces
JT  - Colloids and surfaces. B, Biointerfaces
JID - 9315133
RN  - 0 (Anions)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Hydroxides)
RN  - 0 (Intercalating Agents)
RN  - 0 (Zinc Compounds)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - OXK3V8KJ7L (zinc hydroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aluminum Hydroxide/*chemistry
MH  - Anions/chemistry
MH  - Aspirin/*administration & dosage/*chemistry
MH  - Computer Simulation
MH  - Delayed-Action Preparations
MH  - Hydroxides/*chemistry
MH  - Intercalating Agents
MH  - Kinetics
MH  - Spectroscopy, Fourier Transform Infrared
MH  - X-Ray Diffraction
MH  - Zinc Compounds/*chemistry
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Molecular simulation
OT  - Release
OT  - Zn–Al-layered double hydroxides
EDAT- 2015/08/12 06:00
MHDA- 2016/10/07 06:00
CRDT- 2015/08/12 06:00
PHST- 2015/04/21 00:00 [received]
PHST- 2015/07/24 00:00 [revised]
PHST- 2015/07/26 00:00 [accepted]
PHST- 2015/08/12 06:00 [entrez]
PHST- 2015/08/12 06:00 [pubmed]
PHST- 2016/10/07 06:00 [medline]
AID - S0927-7765(15)30103-X [pii]
AID - 10.1016/j.colsurfb.2015.07.069 [doi]
PST - ppublish
SO  - Colloids Surf B Biointerfaces. 2015 Nov 1;135:339-345. doi: 
      10.1016/j.colsurfb.2015.07.069. Epub 2015 Jul 30.

PMID- 1150906
OWN - NLM
STAT- MEDLINE
DCOM- 19751106
LR  - 20190823
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 15
IP  - 7
DP  - 1975 Jul
TI  - Assessment of aspirin absorption rate from urinary excretion rate measurements.
PG  - 525-9
AB  - It is shown on the basis of pharmacokinetic simulations and experimental data 
      that adequate evaluation of aspirin dosage forms with different absorption rates 
      by urinary excretion measurements in man requires that such measurements be made 
      during the first hour after drug administration. Measurements made only after 3 
      hours are totally inadequate for that purpose. An assessment of the completeness 
      of absorption obviously does not require serial measurements but needs only a 
      determination of the total amount excreted.
FAU - Levy, G
AU  - Levy G
FAU - Yacobi, A
AU  - Yacobi A
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Aspirin/*metabolism/urine
MH  - Computers
MH  - Half-Life
MH  - Humans
MH  - Kinetics
MH  - Salicylates/urine
EDAT- 1975/07/01 00:00
MHDA- 1975/07/01 00:01
CRDT- 1975/07/01 00:00
PHST- 1975/07/01 00:00 [pubmed]
PHST- 1975/07/01 00:01 [medline]
PHST- 1975/07/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1975.tb01475.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1975 Jul;15(7):525-9. doi: 10.1002/j.1552-4604.1975.tb01475.x.

PMID- 15876009
OWN - NLM
STAT- MEDLINE
DCOM- 20051018
LR  - 20181201
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 22 Suppl 4
DP  - 2004
TI  - The value of clopidogrel versus aspirin in reducing atherothrombotic events: the 
      CAPRIE study.
PG  - 19-27
AB  - Atherothrombotic disease is a growing health problem, and is increasingly more 
      costly to manage. Clopidogrel is an advanced, specific adenosine diphosphate 
      receptor antagonist, which has been shown to be a highly potent antiplatelet 
      agent. Data from the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic 
      Events (CAPRIE) study have demonstrated the significantly superior clinical 
      benefit of clopidogrel over aspirin for secondary prevention of atherothrombotic 
      disease, with a relative risk reduction in myocardial infarction, stroke or 
      vascular death of 8.7% (95% confidence interval 0.3, 16.5; P = 0.043). Moreover, 
      clopidogrel demonstrated an amplified clinical benefit versus aspirin in patients 
      at high risk of atherothrombotic events, such as those with a previous history of 
      symptomatic atherothrombotic disease or with major risk factors such as diabetes 
      mellitus or hypercholesterolaemia. On the basis of commonly accepted threshold 
      criteria (Euros 20000 per life-year gained; LYG), clopidogrel in comparison with 
      aspirin is cost-effective for the secondary prevention of atherothrombotic 
      disease (cost per LYG ranging from Euros 19462 to Euros 3256). Economic analyses 
      have demonstrated consistent cost-effectiveness results with clopidogrel in 
      different countries. Moreover, in high-risk patient subgroups the 
      cost-effectiveness of clopidogrel in comparison with aspirin was evenbetter (cost 
      per LYG ranging from Euros 5900 to Euros 6310). Compared with other treatment 
      strategies used for the prevention of ischaemic or atherothrombotic events, the 
      cost-effectiveness of clopidogrel in comparison with aspirin based on CAPRIE is 
      favourable, with most analyses in the intermediate range of cost-effectiveness. 
      The available data thus support the use of clopidogrel as a clinically efficient 
      and cost-effective option for secondary prevention of atherothrombotic disease, 
      particularly in high-risk patients.
FAU - Durand-Zaleski, Isabelle
AU  - Durand-Zaleski I
AD  - Public Health Service, Henri Mondor Hospital, Assistance Publique-Hôpitaux de 
      Paris, Paris, France. i.durand-zaleski@anaes.fr
FAU - Bertrand, Michel
AU  - Bertrand M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - Arterial Occlusive Diseases/drug therapy/economics/*prevention & control
MH  - Aspirin/economics/pharmacology/*therapeutic use
MH  - Clopidogrel
MH  - Cost-Benefit Analysis/*economics
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/*analogs & derivatives/economics/pharmacology/therapeutic use
RF  - 35
EDAT- 2005/05/07 09:00
MHDA- 2005/10/19 09:00
CRDT- 2005/05/07 09:00
PHST- 2005/05/07 09:00 [pubmed]
PHST- 2005/10/19 09:00 [medline]
PHST- 2005/05/07 09:00 [entrez]
AID - 10.2165/00019053-200422004-00005 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2004;22 Suppl 4:19-27. doi: 10.2165/00019053-200422004-00005.

PMID- 16442756
OWN - NLM
STAT- MEDLINE
DCOM- 20060602
LR  - 20141120
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 310
IP  - 1-2
DP  - 2006 Mar 9
TI  - Synthesis and transdermal properties of acetylsalicylic acid and selected esters.
PG  - 31-6
AB  - The primary aim of this study was to determine the transdermal penetration of 
      acetylsalicylic acid and some of its derivatives, to establish a correlation, if 
      any, with selected physicochemical properties and to determine if transdermal 
      application of acetylsalicylic acid and its derivatives will give therapeutic 
      drug concentrations with respect to transdermal flux. Ten derivatives of 
      acetylsalicylic acid were prepared by esterification of acetylsalicyloyl chloride 
      with ten different alcohols. The experimental aqueous solubility, logD and 
      transdermal flux values were determined for acetylsalicylic acid and its 
      derivatives at pH 4.5. In vitro penetration was measured through excised female 
      human abdominal skin in diffusion cells. The experimental aqueous solubility of 
      acetylsalicylic acid (6.56 mg/ml) was higher than that of the synthesised 
      acetylsalicylate derivatives (ranging from 1.76 x 10(-3) to 3.32 mg/ml), and the 
      logD of acetylsalicylic acid (-0.85) was lower than that of its derivatives 
      (ranging from -0.25 to 1.95). There was thus an inverse correlation between the 
      aqueous solubility data and the logD values. The experimental transdermal flux of 
      acetylsalicylic acid (263.83 nmol/cm(2)h) was much higher than that of its 
      derivatives (ranging from 0.12 to 136.02 nmol/cm(2)h).
FAU - Gerber, Minja
AU  - Gerber M
AD  - Pharmaceutical Chemistry, School of Pharmacy, North-West University, 
      Potchefstroom 2520, South Africa. fchmg@puknet.puk.ac.za
FAU - Breytenbach, Jaco C
AU  - Breytenbach JC
FAU - Hadgraft, Jonathan
AU  - Hadgraft J
FAU - du Plessis, Jeanetta
AU  - du Plessis J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060126
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Esters)
RN  - 059QF0KO0R (Water)
RN  - 580-02-9 (methyl acetylsalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis/*metabolism
MH  - Aspirin/analogs & derivatives/chemical synthesis/*metabolism
MH  - Esters/chemical synthesis/metabolism
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - *Skin Absorption
MH  - Solubility
MH  - Structure-Activity Relationship
MH  - Water/chemistry
EDAT- 2006/01/31 09:00
MHDA- 2006/06/03 09:00
CRDT- 2006/01/31 09:00
PHST- 2005/05/11 00:00 [received]
PHST- 2005/11/02 00:00 [revised]
PHST- 2005/11/02 00:00 [accepted]
PHST- 2006/01/31 09:00 [pubmed]
PHST- 2006/06/03 09:00 [medline]
PHST- 2006/01/31 09:00 [entrez]
AID - S0378-5173(05)00766-0 [pii]
AID - 10.1016/j.ijpharm.2005.11.018 [doi]
PST - ppublish
SO  - Int J Pharm. 2006 Mar 9;310(1-2):31-6. doi: 10.1016/j.ijpharm.2005.11.018. Epub 
      2006 Jan 26.

PMID- 29270857
OWN - NLM
STAT- MEDLINE
DCOM- 20180906
LR  - 20181113
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 45
IP  - 2
DP  - 2018 Feb
TI  - Prior exposure to aspirin in acute coronary syndrome patients: a cardiovascular 
      risk marker or a predictor of adverse outcome? A contemporary data of a national 
      registry.
PG  - 213-221
LID - 10.1007/s11239-017-1603-0 [doi]
AB  - Despite the known protective cardiovascular effect of aspirin, former studies 
      identified its prior exposure to an acute coronary syndrome (ACS) as an 
      independent risk factor for adverse events. However, those studies did not 
      reflect contemporary approaches. In the current study, we determine whether 
      patients exposed to aspirin before an ACS have a worse cardiovascular risk 
      profile and if it predicts higher risk of recurrent cardiovascular events or 
      mortality. A cohort of patients enrolled in a national registry of ACS was 
      analyzed according to prior exposure to aspirin. A propensity score standardized 
      patients according to baseline comorbidities. Multivariable COX regression 
      analysis was performed in unmatched and matched populations for a primary 
      endpoint (composite of all-cause mortality and/or cardiovascular 
      rehospitalization) and two secondary endpoints (all-cause mortality and 
      cardiovascular rehospitalization, separately) at 1-year follow-up. Among 5533 ACS 
      patients, 1763 were previously exposed to aspirin. They were older and had more 
      comorbidities; contemporary approaches, both coronary angiography and 
      percutaneous coronary angioplasty were less likely to be performed. Before 
      matching the population, prior exposure to aspirin was an independent predictor 
      of primary composite endpoint (p = 0.002) and cardiovascular rehospitalization as 
      the secondary endpoint (p = 0.001). There were no statistically significant 
      differences between both groups in the multivariable model for the primary or 
      secondary endpoints after matching. Previous exposure to aspirin identified ACS 
      patients with worse baseline characteristics, establishing its role as a 
      cardiovascular risk marker. However, our data do not support including aspirin 
      pretreatment in risk stratification scores as an adverse prognostic variable.
FAU - Ruivo, Catarina
AU  - Ruivo C
AUID- ORCID: 0000-0002-9105-2409
AD  - Cardiology Department, Leiria Hospital Center, Hospital de Santo André, Rua das 
      Olhalvas, 2410-197, Leiria, Portugal. catarina.ruivo.cardio@gmail.com.
FAU - Sá, Fernando Montenegro
AU  - Sá FM
AD  - Cardiology Department, Leiria Hospital Center, Hospital de Santo André, Rua das 
      Olhalvas, 2410-197, Leiria, Portugal.
FAU - Santos, Luís Graça
AU  - Santos LG
AD  - Cardiology Department, Leiria Hospital Center, Hospital de Santo André, Rua das 
      Olhalvas, 2410-197, Leiria, Portugal.
FAU - Correia, Joana
AU  - Correia J
AD  - Cardiology Department, Leiria Hospital Center, Hospital de Santo André, Rua das 
      Olhalvas, 2410-197, Leiria, Portugal.
FAU - Belo, Adriana
AU  - Belo A
AD  - National Center for Data Collection in Cardiology, Portuguese Society of 
      Cardiology, Coimbra, Portugal.
FAU - Morais, João
AU  - Morais J
AD  - Cardiology Department, Leiria Hospital Center, Hospital de Santo André, Rua das 
      Olhalvas, 2410-197, Leiria, Portugal.
CN  - Portuguese National Registry of Acute Coronary Syndromes, Portuguese Society of 
      Cardiology
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*diagnosis
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/diagnosis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Propensity Score
MH  - Registries
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Aspirin
OT  - Cardiovascular rehospitalization
OT  - Coronary intervention
OT  - Mortality post-acute coronary syndrome
OT  - Risk stratification post-acute coronary syndrome
EDAT- 2017/12/23 06:00
MHDA- 2018/09/07 06:00
CRDT- 2017/12/23 06:00
PHST- 2017/12/23 06:00 [pubmed]
PHST- 2018/09/07 06:00 [medline]
PHST- 2017/12/23 06:00 [entrez]
AID - 10.1007/s11239-017-1603-0 [pii]
AID - 10.1007/s11239-017-1603-0 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2018 Feb;45(2):213-221. doi: 10.1007/s11239-017-1603-0.

PMID- 31356330
OWN - NLM
STAT- MEDLINE
DCOM- 20200309
LR  - 20200309
IS  - 1538-7488 (Electronic)
IS  - 0002-936X (Linking)
VI  - 119
IP  - 8
DP  - 2019 Aug
TI  - Caution Regarding Low-Dose Aspirin for Primary Prevention of Cardiovascular 
      Events.
PG  - 49
LID - 10.1097/01.NAJ.0000577440.62103.d9 [doi]
AB  - According to this study.
FAU - Rosenberg, Karen
AU  - Rosenberg K
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Am J Nurs
JT  - The American journal of nursing
JID - 0372646
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Humans
MH  - Intracranial Hemorrhages/*chemically induced
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention/*methods
MH  - Risk Factors
EDAT- 2019/07/30 06:00
MHDA- 2020/03/10 06:00
CRDT- 2019/07/30 06:00
PHST- 2019/07/30 06:00 [entrez]
PHST- 2019/07/30 06:00 [pubmed]
PHST- 2020/03/10 06:00 [medline]
AID - 00000446-201908000-00030 [pii]
AID - 10.1097/01.NAJ.0000577440.62103.d9 [doi]
PST - ppublish
SO  - Am J Nurs. 2019 Aug;119(8):49. doi: 10.1097/01.NAJ.0000577440.62103.d9.

PMID- 18992230
OWN - NLM
STAT- MEDLINE
DCOM- 20090506
LR  - 20131121
IS  - 1872-7786 (Electronic)
IS  - 0009-2797 (Linking)
VI  - 179
IP  - 2-3
DP  - 2009 May 15
TI  - Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following 
      oral gavage and diet dosing in rats.
PG  - 233-9
LID - 10.1016/j.cbi.2008.10.008 [doi]
AB  - Aspirin is one of the oldest drugs and has been purported to have multiple 
      beneficial effects, including prevention of cardiovascular disease and cancer, in 
      addition to its original indication for treatment of inflammation, fever and 
      pain. In cancer chemoprevention studies using animal models, two methods of 
      aspirin administration have been employed: oral gavage and diet. The untested 
      assumption was that exposure and the resultant pharmacological effects are 
      similar for these two administration methods when dosing is normalized on the 
      basis of mg/kg body weight/day. This study examined and compared time-dependent 
      plasma and colon mucosal concentrations of aspirin metabolite salicylate (aspirin 
      concentrations were below level of quantification), plasma thromboxane B(2) 
      concentrations, and colon mucosal prostaglandin E(2) concentration following 
      these two different dosing paradigms in rats. Diet dosing yielded relatively 
      constant plasma and colon salicylate concentration vs. time profiles. On the 
      other hand, oral gavage dosing led to a rapid peak followed by a fast decline in 
      salicylate concentration in both plasma and colon. Nevertheless, the exposure as 
      measured by the area under plasma or colon concentration-time curve of salicylate 
      was linearly related to dose irrespective of the dosing method. Linear 
      relationships were also observed between colon and plasma salicylate areas under 
      the curve and between colon prostaglandin E(2) and plasma thromboxane B(2) areas 
      under the curve. Therefore, more easily accessible plasma salicylate and 
      thromboxane B(2) concentrations were representative of the salicylate exposure 
      and prostaglandin E(2) pharmacodynamic biomarker in the target colon, 
      respectively.
FAU - Kapetanovic, Izet M
AU  - Kapetanovic IM
AD  - Chemopreventive Agent Development Research Group, Division of Cancer Prevention, 
      National Cancer Institute, 6130 Executive Blvd., Rm. 2116, Bethesda, MD 20892, 
      United States. kapetani@mail.nih.gov
FAU - Bauer, Kenneth S
AU  - Bauer KS
FAU - Tessier, Daniel M
AU  - Tessier DM
FAU - Lindeblad, Matthew O
AU  - Lindeblad MO
FAU - Zakharov, Alexander D
AU  - Zakharov AD
FAU - Lubet, Ronald
AU  - Lubet R
FAU - Lyubimov, Alexander
AU  - Lyubimov A
LA  - eng
GR  - N01-CN-43306/CN/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20081017
PL  - Ireland
TA  - Chem Biol Interact
JT  - Chemico-biological interactions
JID - 0227276
RN  - 0 (Salicylates)
RN  - 54397-85-2 (Thromboxane B2)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage/metabolism/*pharmacokinetics
MH  - Colon/chemistry/metabolism
MH  - *Diet
MH  - Dinoprostone/analysis
MH  - Dose-Response Relationship, Drug
MH  - Male
MH  - Rats
MH  - Rats, Inbred F344
MH  - Salicylates/analysis
MH  - Thromboxane B2/blood
MH  - Time Factors
EDAT- 2008/11/11 09:00
MHDA- 2009/05/07 09:00
CRDT- 2008/11/11 09:00
PHST- 2008/09/05 00:00 [received]
PHST- 2008/09/30 00:00 [revised]
PHST- 2008/10/01 00:00 [accepted]
PHST- 2008/11/11 09:00 [pubmed]
PHST- 2009/05/07 09:00 [medline]
PHST- 2008/11/11 09:00 [entrez]
AID - S0009-2797(08)00546-2 [pii]
AID - 10.1016/j.cbi.2008.10.008 [doi]
PST - ppublish
SO  - Chem Biol Interact. 2009 May 15;179(2-3):233-9. doi: 10.1016/j.cbi.2008.10.008. 
      Epub 2008 Oct 17.

PMID- 33260948
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 23
DP  - 2020 Nov 27
TI  - New Formulation of a Methylseleno-Aspirin Analog with Anticancer Activity towards 
      Colon Cancer.
LID - 10.3390/ijms21239017 [doi]
LID - 9017
AB  - Aspirin (ASA) has attracted wide interest of numerous scientists worldwide thanks 
      to its chemopreventive and chemotherapeutic effects, particularly in colorectal 
      cancer (CRC). Incorporation of selenium (Se) atom into ASA has greatly increased 
      their anti-tumoral efficacy in CRC compared with the organic counterparts without 
      the Se functionality, such as the promising antitumoral methylseleno-ASA analog 
      (1a). Nevertheless, the efficacy of compound 1a in cancer cells is compromised 
      due to its poor solubility and volatile nature. Thus, 1a has been formulated with 
      native α-, β- and γ-cyclodextrin (CD), a modified β-CD (hydroxypropyl β-CD, 
      HP-β-CD) and Pluronic F127, all of them non-toxic, biodegradable and FDA 
      approved. Water solubility of 1a is enhanced with β- and HP- β-CDs and Pluronic 
      F127. Compound 1a forms inclusion complexes with the CDs and was incorporated in 
      the hydrophobic core of the F127 micelles. Herein, we evaluated the cytotoxic 
      potential of 1a, alone or formulated with β- and HP- β-CDs or Pluronic F127, 
      against CRC cells. Remarkably, 1a formulations demonstrated more sustained 
      antitumoral activity toward CRC cells. Hence, β-CD, HP-β-CD and Pluronic F127 
      might be excellent vehicles to improve pharmacological properties of 
      organoselenium compounds with solubility issues and volatile nature.
FAU - Ruberte, Ana Carolina
AU  - Ruberte AC
AUID- ORCID: 0000-0001-8818-3136
AD  - Department of Pharmaceutical Technology and Chemistry, University of Navarra, 
      Irunlarrea 1, E-31008 Pamplona, Spain.
AD  - Instituto de Investigación Sanitaria de Navarra (IdiSNA), Irunlarrea 3, E-31008 
      Pamplona, Spain.
FAU - González-Gaitano, Gustavo
AU  - González-Gaitano G
AUID- ORCID: 0000-0002-1477-6710
AD  - Department of Chemistry, University of Navarra, 31080 Pamplona, Spain.
FAU - Sharma, Arun K
AU  - Sharma AK
AD  - Department of Pharmacology, Penn State Cancer Institute, CH72, Penn State College 
      of Medicine, Hershey, PA 17036, USA.
FAU - Aydillo, Carlos
AU  - Aydillo C
AUID- ORCID: 0000-0002-0542-967X
AD  - Department of Pharmaceutical Technology and Chemistry, University of Navarra, 
      Irunlarrea 1, E-31008 Pamplona, Spain.
AD  - Instituto de Investigación Sanitaria de Navarra (IdiSNA), Irunlarrea 3, E-31008 
      Pamplona, Spain.
FAU - Encío, Ignacio
AU  - Encío I
AUID- ORCID: 0000-0003-1732-1989
AD  - Instituto de Investigación Sanitaria de Navarra (IdiSNA), Irunlarrea 3, E-31008 
      Pamplona, Spain.
AD  - Department of Health Sciences, Public University of Navarra, Avda. Barañain s/n, 
      E-31008 Pamplona, Spain.
FAU - Sanmartín, Carmen
AU  - Sanmartín C
AUID- ORCID: 0000-0003-3431-7826
AD  - Department of Pharmaceutical Technology and Chemistry, University of Navarra, 
      Irunlarrea 1, E-31008 Pamplona, Spain.
AD  - Instituto de Investigación Sanitaria de Navarra (IdiSNA), Irunlarrea 3, E-31008 
      Pamplona, Spain.
FAU - Plano, Daniel
AU  - Plano D
AUID- ORCID: 0000-0002-8266-0445
AD  - Department of Pharmaceutical Technology and Chemistry, University of Navarra, 
      Irunlarrea 1, E-31008 Pamplona, Spain.
AD  - Instituto de Investigación Sanitaria de Navarra (IdiSNA), Irunlarrea 3, E-31008 
      Pamplona, Spain.
LA  - eng
GR  - 2018-21/Universidad de Navarra (PIUNA)/
GR  - P/12/19/Universidad Nacional de Educación a Distancia (UNED)/
PT  - Journal Article
DEP - 20201127
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Micelles)
RN  - 0 (beta-Cyclodextrins)
RN  - 059QF0KO0R (Water)
RN  - 106392-12-5 (Poloxamer)
RN  - JV039JZZ3A (betadex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/chemistry/pharmacology/*therapeutic use
MH  - Aspirin/chemistry/pharmacology/*therapeutic use
MH  - Cell Proliferation/drug effects
MH  - Colonic Neoplasms/*drug therapy
MH  - Drug Liberation
MH  - HT29 Cells
MH  - Humans
MH  - Micelles
MH  - Poloxamer/chemistry
MH  - Proton Magnetic Resonance Spectroscopy
MH  - Solubility
MH  - Spectrometry, Fluorescence
MH  - Water/chemistry
MH  - beta-Cyclodextrins/chemistry
PMC - PMC7730823
OTO - NOTNLM
OT  - Pluronic
OT  - aspirin
OT  - colorectal cancer
OT  - cyclodextrins
OT  - cytotoxicity
OT  - selenium
COIS- The authors declare no conflict of interest.
EDAT- 2020/12/03 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/12/02 01:03
PHST- 2020/10/26 00:00 [received]
PHST- 2020/11/23 00:00 [revised]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2020/12/02 01:03 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - ijms21239017 [pii]
AID - ijms-21-09017 [pii]
AID - 10.3390/ijms21239017 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Nov 27;21(23):9017. doi: 10.3390/ijms21239017.

PMID- 29891025
OWN - NLM
STAT- MEDLINE
DCOM- 20191024
LR  - 20191024
IS  - 1482-1826 (Electronic)
IS  - 1482-1826 (Linking)
VI  - 21
IP  - 1s
DP  - 2018
TI  - Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal 
      Anti-Inflammatory Drugs: A Systematic Review.
PG  - 29854
LID - 10.18433/jpps29854 [doi]
AB  - PURPOSE: Concomitant use of some non-Aspirin nonsteroidal anti-inflammatory drugs 
      (NANSAIDs) reduces the extent of platelet aggregation of Aspirin (acetylsalicylic 
      acid). This is while many observational studies and clinical trials suggest that 
      Aspirin reduces cardiovascular (CV) risk attributed to the use of NANSAIDs. Thus, 
      the therapeutic outcome of the interaction needs to be assessed. METHODS: We 
      searched various databases up to October 2017 for molecular interaction studies 
      between the drugs and long-term clinical outcomes based on randomized clinical 
      trials and epidemiological observations that reported the effect estimates of CV 
      risks (OR, RR or HR; 95% CI) of the interacting drugs alone or in combinations. 
      Comparisons were made between outcomes after Aspirin alone, NANSAIDs alone and 
      Aspirin with naproxen, ibuprofen, celecoxib, meloxicam, diclofenac or rofecoxib. 
      RESULTS: In total, 32 eligible studies (20 molecular interactions studies and 12 
      observational trials) were found. Conflicting in vitro/in vivo/ex vivo platelet 
      aggregation data were found for ibuprofen, naproxen and celecoxib. Nevertheless, 
      for naproxen, the interaction at the aggregation level did not amount to a loss 
      of cardioprotective effects of Aspirin. Similarly, for ibuprofen, the results 
      overwhelmingly suggest no negative clinical CV outcomes following the combination 
      therapy. Meloxicam and rofecoxib neither interacted with Aspirin at the level of 
      platelet aggregation nor altered clinical outcomes. The clinical outcomes data 
      for celecoxib and diclofenac are in conflict. CONCLUSION: Aspirin appears to 
      maintain its cardioprotective effect in the presence of naproxen, ibuprofen, 
      meloxicam and rofecoxib. The limited available data suggest that the effect of 
      interaction at the platelet aggregation level may dissipate shortly, or the 
      reduced platelet aggregation yielded by the interaction may be sufficient for 
      cardioprotection; i.e., no need for near complete aggregation. In addition, 
      cardioprotective effect of Aspirin, despite reduced platelet aggregation caused 
      by NANSAIDs, may be through its involvement in other mechanisms such as the 
      renin-angiotensin system and/or metabolism of arachidonic acid to biologically 
      active compounds mediated by cytochrome P450. This article is open to 
      POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by 
      clicking on ABSTRACT on the issue's contents page.
FAU - Alqahtani, Zuhair
AU  - Alqahtani Z
AD  - Faculty of Pharmacy and Pharmaceutical Science, University of Alberta, Edmonton, 
      Alberta, Canada.
FAU - Jamali, Fakhreddin
AU  - Jamali F
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - Switzerland
TA  - J Pharm Pharm Sci
JT  - Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian 
      Society for Pharmaceutical Sciences, Societe canadienne des sciences 
      pharmaceutiques
JID - 9807281
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cardiovascular Diseases/*drug therapy
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Treatment Outcome
EDAT- 2018/06/13 06:00
MHDA- 2019/10/28 06:00
CRDT- 2018/06/13 06:00
PHST- 2018/06/13 06:00 [entrez]
PHST- 2018/06/13 06:00 [pubmed]
PHST- 2019/10/28 06:00 [medline]
AID - 10.18433/jpps29854 [doi]
PST - ppublish
SO  - J Pharm Pharm Sci. 2018;21(1s):29854. doi: 10.18433/jpps29854.

PMID- 309032
OWN - NLM
STAT- MEDLINE
DCOM- 19781220
LR  - 20220330
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 76
IP  - 5
DP  - 1978 Nov
TI  - Relation of preoperative use of aspirin to increased mediastinal blood loss after 
      coronary artery bypass graft surgery.
PG  - 694-7
AB  - To evaluate the potential effect of aspirin, a platelet inhibitory agent, on 
      postoperative bleeding complications after coronary artery bypass graft surgery, 
      we compared each of nine patients who had taken aspirin within 7 days prior to 
      operation to one or two control subjects (total 16 patients) matched for age, 
      sex, extent of coronary disease, number of grafts placed total operative time, 
      bypass time, and preoperative use of propranolol. Preoperative prothrombin time, 
      partial thromboplastin time, and platelet counts were normal for all patients. 
      Mean mediastinal blood loss was significantly greater in the aspirin group (919 
      +/- 164 ml., S.E.) than in the control group (437 +/- 61 ml., p less than 0.001). 
      The degree of mediastinal blood loss did not correlate with patient age, total 
      operative time, bypass time, number of vessels diseased, or grafts placed. In 
      addition, compared to controls the aspirin group required prolonged chest tube 
      drainage (33 +/- 5 hours versus 19 +/- 1 hour, p less than 0.001).
FAU - Michelson, E L
AU  - Michelson EL
FAU - Morganroth, J
AU  - Morganroth J
FAU - Torosian, M
AU  - Torosian M
FAU - Mac Vaugh, H 3rd
AU  - Mac Vaugh H 3rd
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - *Coronary Artery Bypass
MH  - Drainage
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Mediastinal Diseases/*chemically induced
MH  - Middle Aged
MH  - Postoperative Care
MH  - Postoperative Complications/prevention & control
MH  - Preoperative Care
MH  - Thromboembolism/prevention & control
MH  - Time Factors
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1978 Nov;76(5):694-7.

PMID- 28823937
OWN - NLM
STAT- MEDLINE
DCOM- 20180618
LR  - 20181202
IS  - 1878-1632 (Electronic)
IS  - 1529-9430 (Linking)
VI  - 17
IP  - 12
DP  - 2017 Dec
TI  - Risk of aspirin continuation in spinal surgery: a systematic review and 
      meta-analysis.
PG  - 1939-1946
LID - S1529-9430(17)30912-9 [pii]
LID - 10.1016/j.spinee.2017.08.238 [doi]
AB  - BACKGROUND CONTEXT: Aspirin is typically discontinued in spinal surgery because 
      of increased risk of hemorrhagic complications. The risk of perioperative 
      continuation of aspirin in neurosurgery needed to be evaluated. PURPOSE: This 
      study aimed to evaluate all available evidence about continuation of aspirin and 
      to compare peri- and postoperative blood loss and complication rates between 
      patients that continued aspirin and those who discontinued aspirin 
      perioperatively in spinal surgery. STUDY SETTING: Systematic review and 
      meta-analysis were carried out. METHOD: A meta-analysis was conducted according 
      to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
      (PRISMA) guidelines. Studies comparing aspirin continuation with discontinuation 
      were included. Studies using a combination of anticlotting agents or non-spinal 
      procedures were excluded. Operative outcomes (blood loss and operative length) 
      and different complications (surgical site infection [SSI]), stroke, myocardial 
      infarction within 30 days postoperatively) were extracted. Overall prevalence and 
      means were calculated for the reported outcomes in fixed-effects models with 
      heterogeneity (I-squared [I(2)]) and effect modification (P-interaction) 
      assessment. RESULTS: Out of 1,339 studies, three case series were included in the 
      meta-analysis. No significant differences in mean operating time were seen 
      between the aspirin-continuing group (mean=201.8 minutes, 95% confidence interval 
      [CI]=193.3; 210.3; I(2)=95.4%; 170 patients) and the aspirin-discontinuing group 
      (mean=178.4 minutes, 95% CI=119.1; 237.6; I(2)=93.5%; 200 patients); 
      (P-interaction=0.78). No significant differences in mean perioperative blood loss 
      were seen between the aspirin-continuing group (mean=553.9 milliliters, 95% 
      CI=468.0; 639.9; I(2)=83.4%; 170 patients) and the aspirin-discontinuing group 
      (mean=538.7 milliliters, 95% CI=427.6; 649.8; I(2)=985.5%; 200 patients); 
      (P-interaction=0.96). Similar non-significant differences between the two groups 
      were found for cardiac events, stroke, and surgical site infections. CONCLUSIONS: 
      This meta-analysis showed an absence of significant differences in perioperative 
      complications between aspirin continuation and discontinuation. Because of the 
      paucity of included studies, further well-designed prospective trials are 
      imperative to demonstrate potential benefit and safety.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Goes, Rik
AU  - Goes R
AD  - Department of Neurosurgery, Haaglanden Medical Center, Lijnbaan 32, 2512VA, The 
      Hague, The Netherlands. Electronic address: rikgoes@gmail.com.
FAU - Muskens, Ivo S
AU  - Muskens IS
AD  - Department of Neurosurgery, Brain Center Rudolf Magnus, University Medical Center 
      Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands; Cushing 
      Neurosurgery Outcomes Center (CNOC), Department of Neurosurgery, Brigham and 
      Woman's Hospital, 60 Fenwood Road, 1st Floor, Boston, MA, USA.
FAU - Smith, Timothy R
AU  - Smith TR
AD  - Cushing Neurosurgery Outcomes Center (CNOC), Department of Neurosurgery, Brigham 
      and Woman's Hospital, 60 Fenwood Road, 1st Floor, Boston, MA, USA.
FAU - Mekary, Rania A
AU  - Mekary RA
AD  - Cushing Neurosurgery Outcomes Center (CNOC), Department of Neurosurgery, Brigham 
      and Woman's Hospital, 60 Fenwood Road, 1st Floor, Boston, MA, USA; Department of 
      Pharmaceutical Business and Administrative Sciences, MCPHS University, 179 
      Longwood Ave, Boston, MA, 02115, USA.
FAU - Broekman, Marike L D
AU  - Broekman MLD
AD  - Department of Neurosurgery, Brain Center Rudolf Magnus, University Medical Center 
      Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands; Cushing 
      Neurosurgery Outcomes Center (CNOC), Department of Neurosurgery, Brigham and 
      Woman's Hospital, 60 Fenwood Road, 1st Floor, Boston, MA, USA; Department of 
      Neurology, Massachusetts General Hospital, 15 Parkman Street 835, Boston, MA, 
      02114, USA.
FAU - Moojen, Wouter A
AU  - Moojen WA
AD  - Department of Neurosurgery, Haaglanden Medical Center, Lijnbaan 32, 2512VA, The 
      Hague, The Netherlands; Department of Neurosurgery, Haga Teaching Hospital, Els 
      Borst-Eilersplein 275, 2545AA, The Hague, The Netherlands; Department of 
      Neurosurgery, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, 
      The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20170817
PL  - United States
TA  - Spine J
JT  - The spine journal : official journal of the North American Spine Society
JID - 101130732
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Humans
MH  - Neurosurgical Procedures/*adverse effects/methods
MH  - Postoperative Hemorrhage/*etiology
MH  - Risk
MH  - Spinal Diseases/*surgery
OTO - NOTNLM
OT  - Continuation
OT  - Low-dose aspirin
OT  - Meta-analysis
OT  - Neurosurgery
OT  - Perioperative complications
OT  - Spinal surgery
EDAT- 2017/08/22 06:00
MHDA- 2018/06/19 06:00
CRDT- 2017/08/22 06:00
PHST- 2017/02/04 00:00 [received]
PHST- 2017/07/25 00:00 [revised]
PHST- 2017/08/09 00:00 [accepted]
PHST- 2017/08/22 06:00 [pubmed]
PHST- 2018/06/19 06:00 [medline]
PHST- 2017/08/22 06:00 [entrez]
AID - S1529-9430(17)30912-9 [pii]
AID - 10.1016/j.spinee.2017.08.238 [doi]
PST - ppublish
SO  - Spine J. 2017 Dec;17(12):1939-1946. doi: 10.1016/j.spinee.2017.08.238. Epub 2017 
      Aug 17.

PMID- 10618952
OWN - NLM
STAT- MEDLINE
DCOM- 20000106
LR  - 20190515
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 83
IP  - 2
DP  - 1999 Aug
TI  - Pro-coagulant effect of in vitro haemodilution is not inhibited by aspirin.
PG  - 330-2
AB  - We have conducted an in vitro coagulation study, using the thrombelastograph 
      (TEG), to determine if the enhanced coagulability of whole blood after 
      haemodilution with normal saline can still be demonstrated after administration 
      of an antiplatelet agent. Aspirin inhibits the platelet-endothelial interaction 
      that is part of the coagulation process. We investigated the role of aspirin in 
      the phenomenon of haemodilution-induced coagulability to identify if the 
      platelet-endothelial system is involved in the process. Previous work showed that 
      the TEG is not altered by oral ingestion of aspirin. Blood from 20 volunteers was 
      divided into two aliquots of 4 ml each. One sample was diluted by 20% by addition 
      of 0.9% saline 1 ml while the other was not diluted and served as a control. 
      Coagulation studies were performed using the TEG and enhanced coagulation was 
      seen in the saline diluted samples. Subjects then received soluble aspirin 375 mg 
      daily for 3 days, after which the tests were repeated. There was no difference in 
      the control TEG values and saline enhancement of coagulation was preserved in all 
      subjects after 3 days of aspirin administration. We conclude that aspirin had no 
      effect on the observation that haemodilution with saline enhances the 
      coagulability of whole blood.
FAU - Ruttmann, T G
AU  - Ruttmann TG
AD  - Department of Anaesthesia, University of Cape Town Medical School, South Africa.
FAU - James, M F
AU  - James MF
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - *Blood Coagulation
MH  - *Hemodilution
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thrombelastography
EDAT- 2000/01/05 00:00
MHDA- 2000/01/05 00:01
CRDT- 2000/01/05 00:00
PHST- 2000/01/05 00:00 [pubmed]
PHST- 2000/01/05 00:01 [medline]
PHST- 2000/01/05 00:00 [entrez]
AID - S0007-0912(17)38401-5 [pii]
AID - 10.1093/bja/83.2.330 [doi]
PST - ppublish
SO  - Br J Anaesth. 1999 Aug;83(2):330-2. doi: 10.1093/bja/83.2.330.

PMID- 30359442
OWN - NLM
STAT- MEDLINE
DCOM- 20190410
LR  - 20190410
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 10
DP  - 2018
TI  - Anti-atherogenic properties of vitamin E, aspirin, and their combination.
PG  - e0206315
LID - 10.1371/journal.pone.0206315 [doi]
LID - e0206315
AB  - The present study was designed to assess the extent to which vitamin E and 
      aspirin individually or in combination prevent and/or reverse bone loss and 
      atherosclerotic lesion formation in orchidectomized aged rats. Forty-nine 
      12-month old male Sprague-Dawley rats were either sham-operated (Sham, one group) 
      or orchidectomized (Orx, four groups) and fed a control diet for 120 days to 
      establish bone loss and atherosclerotic lesions. Thereafter, rats were assigned 
      to the various treatment groups (n = 9 to 10 per group): 1) Sham and 2) Orx 
      groups received AIN93M, containing 75 IU vitamin E and served as control, and the 
      other three Orx groups received either 3) 500 IU vitamin E, 4) 500 mg aspirin, or 
      5) 500 IU vitamin E + 500 mg aspirin per kg diet for 90 days. After 90 days of 
      treatment, rats were sacrificed, necropsied, and tissues were collected for 
      analyses. Results show that 500 IU vitamin E was able to reduce the development 
      of atherosclerosis lesion formation and aortic streak area compared to Orx 
      control. More importantly, 500 mg aspirin completely reversed the fatty streak 
      area and made the atherosclerotic lesions disappear. Vitamin E and aspirin were 
      not able to reverse bone loss as shown by whole body, lumbar and femoral bone 
      mineral content and bone mineral density due to gonadal hormone deficiency. 
      Instead, 500 mg aspirin somewhat increased the trabecular separation while 
      decreased trabecular thickness compared to Orx control. Our findings suggest that 
      both, vitamin E and aspirin exert anti-atherogenic effects and aspirin is more 
      effective than vitamin E in preventing atherosclerosis lesions in Orx rats.
FAU - Chai, Sheau C
AU  - Chai SC
AUID- ORCID: 0000-0003-3969-8912
AD  - Department of Behavioral Health and Nutrition, College of Health Sciences, 
      University of Delaware, Newark, DE, United State of America.
FAU - Foley, Elizabeth M
AU  - Foley EM
AD  - Department of Nutrition, Food and Exercise Sciences, College of Human Sciences, 
      Florida State University, Tallahassee, FL, United State of America.
AD  - Center for Advancing Exercise and Nutrition Research on Aging (CAENRA), College 
      of Human Sciences, Florida State University, Tallahassee, FL, United State of 
      America.
FAU - Arjmandi, Bahram H
AU  - Arjmandi BH
AD  - Department of Nutrition, Food and Exercise Sciences, College of Human Sciences, 
      Florida State University, Tallahassee, FL, United State of America.
AD  - Center for Advancing Exercise and Nutrition Research on Aging (CAENRA), College 
      of Human Sciences, Florida State University, Tallahassee, FL, United State of 
      America.
LA  - eng
PT  - Journal Article
DEP - 20181025
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Atherosclerosis/*drug therapy
MH  - Bone Density/drug effects
MH  - Drug Therapy, Combination
MH  - Male
MH  - Osteoporosis/*drug therapy
MH  - Rats, Sprague-Dawley
MH  - Vitamin E/administration & dosage/*pharmacology
PMC - PMC6201936
COIS- The authors have declared that no competing interests exist.
EDAT- 2018/10/26 06:00
MHDA- 2019/04/11 06:00
CRDT- 2018/10/26 06:00
PHST- 2018/03/27 00:00 [received]
PHST- 2018/10/10 00:00 [accepted]
PHST- 2018/10/26 06:00 [entrez]
PHST- 2018/10/26 06:00 [pubmed]
PHST- 2019/04/11 06:00 [medline]
AID - PONE-D-18-09333 [pii]
AID - 10.1371/journal.pone.0206315 [doi]
PST - epublish
SO  - PLoS One. 2018 Oct 25;13(10):e0206315. doi: 10.1371/journal.pone.0206315. 
      eCollection 2018.

PMID- 19247655
OWN - NLM
STAT- MEDLINE
DCOM- 20090916
LR  - 20131121
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 88
IP  - 10
DP  - 2009 Oct
TI  - Variability of non-response to aspirin in patients with peripheral arterial 
      occlusive disease during long-term follow-up.
PG  - 979-88
LID - 10.1007/s00277-009-0708-8 [doi]
AB  - Non-responsiveness to aspirin as detected by laboratory tests may identify 
      patients at high risk for future vascular events. The aim of this prospective 
      study was to evaluate whether non-responsiveness to aspirin is stable over time. 
      Ninety-eight patients with stable peripheral arterial occlusive disease (PAOD) 
      treated with 100 mg/d aspirin were followed over a median timeframe of 17 months. 
      Platelet function tests were performed initially and at follow-up using 
      arachidonic acid-induced light transmittance aggregometry (LTA) in native 
      platelet-rich plasma with the Behring Coagulation Timer and by measuring the 
      collagen-epinephrine closure time (CT) on a Platelet Function Analyzer (PFA-100). 
      When determining platelet function using LTA, four patients (4.1%) had residual 
      platelet function (i.e., MaxAggr > or =78%) despite aspirin treatment, whereas, 
      according to the PFA-100 results, 12 patients (12.2%) were identified as 
      non-responders (i.e., CT <192 s). Fifty-seven patients who were still under 
      treatment with 100 mg/d aspirin at the time of follow-up provided a second blood 
      sample. Further platelet function tests with the PFA-100 system identified a 
      persistent non-responsiveness to aspirin over time in three patients (5.3%) 
      whereas four (7.0%) and 15 (26.3%) patients had changes in response status when 
      platelet function was assessed by LTA and on the PFA-100(R), respectively. We 
      conclude that true non-responsiveness to aspirin is a rare phenomenon in stable 
      PAOD patients. Furthermore, we conclude that in a number of patients, aspirin 
      non-responsiveness is not stable over time.
FAU - Linnemann, Birgit
AU  - Linnemann B
AD  - Department of Internal Medicine, Division of Vascular Medicine, J.W. Goethe 
      University Hospital, Theodor-Stern-Kai 7, D-60590, Frankfurt/Main, Germany. 
      Birgit.Linnemann@kgu.de
FAU - Prochnow, Stephanie
AU  - Prochnow S
FAU - Mani, Helen
AU  - Mani H
FAU - Schwonberg, Jan
AU  - Schwonberg J
FAU - Lindhoff-Last, Edelgard
AU  - Lindhoff-Last E
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20090227
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arterial Occlusive Diseases/*drug therapy
MH  - Aspirin/administration & dosage/*pharmacology
MH  - *Drug Resistance
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/*drug therapy
MH  - Platelet Function Tests/methods
MH  - Prevalence
EDAT- 2009/02/28 09:00
MHDA- 2009/09/17 06:00
CRDT- 2009/02/28 09:00
PHST- 2008/09/03 00:00 [received]
PHST- 2009/01/26 00:00 [accepted]
PHST- 2009/02/28 09:00 [entrez]
PHST- 2009/02/28 09:00 [pubmed]
PHST- 2009/09/17 06:00 [medline]
AID - 10.1007/s00277-009-0708-8 [doi]
PST - ppublish
SO  - Ann Hematol. 2009 Oct;88(10):979-88. doi: 10.1007/s00277-009-0708-8. Epub 2009 
      Feb 27.

PMID- 1376585
OWN - NLM
STAT- MEDLINE
DCOM- 19920710
LR  - 20191021
IS  - 0272-4936 (Print)
IS  - 0272-4936 (Linking)
VI  - 12
IP  - 1
DP  - 1992
TI  - Hepatotoxicity of high dose salicylate therapy in acute rheumatic fever.
PG  - 37-40
AB  - Liver function tests, including serum alanine aminotransferase (ALT) activity, 
      serum bilirubin, alkaline phosphatase, serum proteins, blood ammonia levels and 
      intravenous glucose utilization, were monitored in 50 children with acute 
      rheumatic fever receiving anti-rheumatic doses of aspirin. There was a 
      significant increase in blood ammonia levels and serum ALT after aspirin therapy. 
      A significant fall in glucose utilization coefficient was also recorded. Serum 
      alkaline phosphatase, bilirubin and total proteins did not change significantly. 
      Twenty-two of the 50 children recorded a rise in serum ALT; in 12, the rise was 
      five- to tenfold. These 12 children developed adverse symptoms to aspirin. Also, 
      all had a marked rise in blood ammonia levels. The children improved clinically 
      and biochemically on withdrawal of aspirin. There was no constant relationship 
      between hepatocellular function and serum salicylate levels.
FAU - Singh, H
AU  - Singh H
AD  - Department of Paediatrics, Al Arab Medical University, Benghazi, Libya.
FAU - Chugh, J C
AU  - Chugh JC
FAU - Shembesh, A H
AU  - Shembesh AH
FAU - Ben-Musa, A A
AU  - Ben-Musa AA
FAU - Mehta, H C
AU  - Mehta HC
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ann Trop Paediatr
JT  - Annals of tropical paediatrics
JID - 8210625
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - *Chemical and Drug Induced Liver Injury
MH  - Child
MH  - Child, Preschool
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Liver/cytology/drug effects/metabolism
MH  - Liver Diseases/metabolism
MH  - Liver Function Tests
MH  - Male
MH  - Prospective Studies
MH  - Rheumatic Fever/blood/*drug therapy
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1080/02724936.1992.11747544 [doi]
PST - ppublish
SO  - Ann Trop Paediatr. 1992;12(1):37-40. doi: 10.1080/02724936.1992.11747544.

PMID- 27045959
OWN - NLM
STAT- MEDLINE
DCOM- 20170913
LR  - 20170913
IS  - 1520-5207 (Electronic)
IS  - 1520-5207 (Linking)
VI  - 120
IP  - 16
DP  - 2016 Apr 28
TI  - Born-Oppenheimer Molecular Dynamics Study on Proton Dynamics of Strong Hydrogen 
      Bonds in Aspirin Crystals, with Emphasis on Differences between Two Crystal 
      Forms.
PG  - 3854-62
LID - 10.1021/acs.jpcb.6b01601 [doi]
AB  - In this study, the proton dynamics of hydrogen bonds for two forms of crystalline 
      aspirin was investigated by the Born-Oppenheimer molecular dynamics (BOMD) 
      method. Analysis of the geometrical parameters of hydrogen bonds using BOMD 
      reveals significant differences in hydrogen bonding between the two crystalline 
      forms of aspirin, Form I and Form II. Analysis of the trajectory for Form I shows 
      spontaneous proton transfer in cyclic dimers, which is absent in Form II. 
      Quantization of the O-H stretching modes allows a detailed discussion on the 
      strength of hydrogen-bonding interactions. The focal point of our study is 
      examination of the hydrogen bond characteristics in the crystal structure and 
      clarification of the influence of hydrogen bonding on the presence of the two 
      crystalline forms of aspirin. In the BOMD method, thermal motions were taken into 
      account. Solving the Schrödinger equation for the snapshots of 2D proton 
      potentials, extracted from MD, gives the best agreement with IR spectra. The 
      character of medium-strong hydrogen bonds in Form I of aspirin was compared with 
      that of weaker hydrogen bonds in aspirin Form II. Two proton minima are present 
      in the potential function for the hydrogen bonds in Form I. The band contours, 
      calculated by using one- and two-dimensional O-H quantization, reflect the 
      differences in the hydrogen bond strengths between the two crystalline forms of 
      aspirin, as well as the strong hydrogen bonding in the cyclic dimers of Form I 
      and the medium-strong hydrogen bonding in Form II.
FAU - Brela, Mateusz Z
AU  - Brela MZ
AD  - Faculty of Chemistry, Jagiellonian University , Ingardena 3, 30-060 Krakow, 
      Poland.
FAU - Wójcik, Marek J
AU  - Wójcik MJ
AD  - Faculty of Chemistry, Jagiellonian University , Ingardena 3, 30-060 Krakow, 
      Poland.
FAU - Witek, Łukasz J
AU  - Witek ŁJ
AD  - Faculty of Chemistry, Jagiellonian University , Ingardena 3, 30-060 Krakow, 
      Poland.
FAU - Boczar, Marek
AU  - Boczar M
AD  - Faculty of Chemistry, Jagiellonian University , Ingardena 3, 30-060 Krakow, 
      Poland.
FAU - Wrona, Ewa
AU  - Wrona E
AD  - Faculty of Chemistry, Jagiellonian University , Ingardena 3, 30-060 Krakow, 
      Poland.
FAU - Hashim, Rauzah
AU  - Hashim R
AD  - Department of Chemistry, University of Malaya , 50603 Kuala Lumpur, Malaysia.
FAU - Ozaki, Yukihiro
AU  - Ozaki Y
AD  - Department of Chemistry, School of Science and Technology, Kwansei Gakuin 
      University , Sanda, Hyogo 669-1337, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160420
PL  - United States
TA  - J Phys Chem B
JT  - The journal of physical chemistry. B
JID - 101157530
RN  - 0 (Protons)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Crystallography, X-Ray
MH  - Hydrogen Bonding
MH  - *Molecular Dynamics Simulation
MH  - *Protons
EDAT- 2016/04/06 06:00
MHDA- 2017/09/14 06:00
CRDT- 2016/04/06 06:00
PHST- 2016/04/06 06:00 [entrez]
PHST- 2016/04/06 06:00 [pubmed]
PHST- 2017/09/14 06:00 [medline]
AID - 10.1021/acs.jpcb.6b01601 [doi]
PST - ppublish
SO  - J Phys Chem B. 2016 Apr 28;120(16):3854-62. doi: 10.1021/acs.jpcb.6b01601. Epub 
      2016 Apr 20.

PMID- 12846441
OWN - NLM
STAT- MEDLINE
DCOM- 20031202
LR  - 20191107
IS  - 1590-8658 (Print)
IS  - 1590-8658 (Linking)
VI  - 35 Suppl 2
DP  - 2003 May
TI  - NO-NSAIDs and cancer: promising novel agents.
PG  - S27-34
AB  - Three potential applications of NO-donating NSAIDs in human cancer include their 
      use: as chemopreventive agents; against already developed cancers (chemotherapy); 
      and for the control of cancer symptoms, notably cancer pain. The evidence to date 
      of greater safety and enhanced efficacy of NO-donating NSAIDs underscores their 
      potential to prevent colon cancer and overcome the limitations of traditional 
      NSAIDs. NO-donating NSAIDs affect several pathways critical to colon 
      carcinogenesis and this may explain in part their greater efficacy in colon 
      cancer prevention as assessed in preclinical models.
FAU - Rigas, B
AU  - Rigas B
AD  - American Health Foundation, 1 Dana Road, Valhalla, NY 10595, USA. brigas@ahf.org
FAU - Kalofonos, H
AU  - Kalofonos H
FAU - Lebovics, E
AU  - Lebovics E
FAU - Vagenakis, A G
AU  - Vagenakis AG
LA  - eng
GR  - N01-CN-05112/CN/NCI NIH HHS/United States
GR  - R01-CA92423/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (naproxen-n-butyl nitrate)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 57Y76R9ATQ (Naproxen)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animal Experimentation
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Aspirin/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Humans
MH  - In Vitro Techniques
MH  - Naproxen/*analogs & derivatives/therapeutic use
MH  - Nitric Oxide/administration & dosage/*therapeutic use
MH  - Rats
RF  - 35
EDAT- 2003/07/09 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/07/09 05:00
PHST- 2003/07/09 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/07/09 05:00 [entrez]
AID - S1590-8658(03)00049-5 [pii]
AID - 10.1016/s1590-8658(03)00049-5 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2003 May;35 Suppl 2:S27-34. doi: 10.1016/s1590-8658(03)00049-5.

PMID- 31359682
OWN - NLM
STAT- MEDLINE
DCOM- 20190924
LR  - 20190925
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 44
IP  - 13
DP  - 2019 Jul
TI  - [Network pharmacology-based study on mechanisms of Danhong Injection in treatment 
      of aspirin resistance].
PG  - 2719-2726
LID - 10.19540/j.cnki.cjcmm.20190215.001 [doi]
AB  - This paper aims to discuss the potential targets,pathways and possible mechanisms 
      of Danhong Injection in treatment of aspirin resistance by using network 
      pharmacology concept and network analysis technique. Active ingredients and 
      potential targets of Danhong Injection were collected from TCMSP database and the 
      ingredients were further screened based on their topological characteristics. The 
      active ingredients with nodal degree of freedom≥9 were selected as the main 
      active ingredients. Targets related to aspirin resistance were collected from 
      Genecards database. Drug-active ingredient-target-disease network was constructed 
      by using Cytoscape3. 7. 0,and Funrich 3. 1. 3 software was used for gene 
      enrichment analysis. Sixty main active ingredients were screened out from 110 
      active ingredients of Danhong Injection,including 51 ingredients in Salviae 
      Miltiorrhizae Radix et Rhizoma and 11 ingredients in Carthami Flos,2 of which 
      were both in Salviae Miltiorrhizae Radix et Rhizoma and Carthami Flos. In 
      addition,159 potential targets were collected. The results of gene enrichment 
      analysis showed that Danhong Injection could improve aspirin resistance mainly 
      through21 pathways involving coagulation process,inflammatory response and 
      metabolism. This study revealed the effects of Danhong Injection for improving 
      aspirin resistance in multi-component,multi-target and multi-pathway means mainly 
      through regulation in coagulation process,inflammatory response and 
      metabolism,providing more abundant information and basis for subsequent research 
      and experimental work.
FAU - Lai, Run-Min
AU  - Lai RM
AD  - Graduate School,Beijing University of Chinese Medicine Beijing 100029,China.
FAU - Ju, Jian-Qing
AU  - Ju JQ
AD  - Graduate School,Beijing University of Chinese Medicine Beijing 100029,China.
FAU - Zhao, Yi-Han
AU  - Zhao YH
AD  - Graduate School,Beijing University of Chinese Medicine Beijing 100029,China.
FAU - Xu, Hao
AU  - Xu H
AD  - Xiyuan Hospital,China Academy of Chinese Medical Sciences Beijing 100091,China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese 
      materia medica
JID - 8913656
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (danhong)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - *Drug Resistance
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Medicine, Chinese Traditional
MH  - Rhizome
OTO - NOTNLM
OT  - Carthami Flos
OT  - Danhong Injection
OT  - Salviae Miltiorrhizae Radix et Rhizoma
OT  - aspirin resistance
OT  - network pharmacology
EDAT- 2019/07/31 06:00
MHDA- 2019/09/26 06:00
CRDT- 2019/07/31 06:00
PHST- 2019/07/31 06:00 [entrez]
PHST- 2019/07/31 06:00 [pubmed]
PHST- 2019/09/26 06:00 [medline]
AID - 10.19540/j.cnki.cjcmm.20190215.001 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2019 Jul;44(13):2719-2726. doi: 
      10.19540/j.cnki.cjcmm.20190215.001.

PMID- 20887554
OWN - NLM
STAT- MEDLINE
DCOM- 20101027
LR  - 20211020
IS  - 1365-2184 (Electronic)
IS  - 0960-7722 (Print)
IS  - 0960-7722 (Linking)
VI  - 43
IP  - 5
DP  - 2010 Oct
TI  - Combination of photodynamic therapy with aspirin in human-derived lung 
      adenocarcinoma cells affects proteasome activity and induces apoptosis.
PG  - 480-93
LID - 10.1111/j.1365-2184.2010.00698.x [doi]
AB  - OBJECTIVES: Photodynamic treatment (PDT) of human lung carcinoma cells A549 
      (p53(+/+)) and H1299 (p53(-/-)) induces fast but transient stalling of proteasome 
      activity. We have explored the possibility of prolonging this effect by combining 
      PDT with drugs capable of sustaining the stall, and promote apoptosis of 
      surviving cells. We show that aspirin can be used to accomplish this. MATERIALS 
      AND METHODS: Cells were irradiated at doses ranging from 0.54 to 1.10 J cm(-2), 
      and subsequently were incubated with aspirin at either high (10 and 5 mm) or low 
      concentration (2.5 and 1.5 mm). Photofrin concentration and incubation time were 
      constant (2.5 μg/ml and 16 h). Under these conditions, we analysed cell 
      viability, colony-forming efficiency, cycle profile, expression patterns of 
      specific proteins and ubiquitination state, after individual or combined 
      administration. RESULTS: Treatment with either PDT or aspirin, rapidly induced 
      proteasome malfunction and accumulation of cells in G(2)M, but did not induce 
      apoptosis. However, when aspirin was added to cells (even at low concentrations) 
      after PDT, the proteasome block was sustained. Moreover, significant cytotoxic 
      effects, including apoptosis, were observed along with cytostatic effects (G(2)M 
      accumulation/decreased colony formation). CONCLUSIONS: Combination of PDT and 
      low-toxicity drugs (such as aspirin) resulted in protracted inhibition of 
      proteasome activity and induced apoptosis even in apoptosis-resistant cancer 
      cells.
FAU - Chiaviello, A
AU  - Chiaviello A
AD  - Department of Molecular and Cellular Biology and Pathology L. Califano, 
      University of Naples Federico II, Naples, Italy.
FAU - Paciello, I
AU  - Paciello I
FAU - Postiglione, I
AU  - Postiglione I
FAU - Crescenzi, E
AU  - Crescenzi E
FAU - Palumbo, G
AU  - Palumbo G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cell Prolif
JT  - Cell proliferation
JID - 9105195
RN  - EC 3.4.25.1 (Proteasome Endopeptidase Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Photochemotherapy/*methods
MH  - Proteasome Endopeptidase Complex/*metabolism
PMC - PMC6495995
EDAT- 2010/10/05 06:00
MHDA- 2010/10/28 06:00
CRDT- 2010/10/05 06:00
PHST- 2010/10/05 06:00 [entrez]
PHST- 2010/10/05 06:00 [pubmed]
PHST- 2010/10/28 06:00 [medline]
AID - CPR698 [pii]
AID - 10.1111/j.1365-2184.2010.00698.x [doi]
PST - ppublish
SO  - Cell Prolif. 2010 Oct;43(5):480-93. doi: 10.1111/j.1365-2184.2010.00698.x.

PMID- 12784774
OWN - NLM
STAT- MEDLINE
DCOM- 20040217
LR  - 20131121
IS  - 1129-471X (Print)
IS  - 1129-471X (Linking)
VI  - 4
IP  - 4
DP  - 2003 Apr
TI  - Low-dose aspirin in the primary prevention of cardiovascular disease: how to 
      balance the benefits and the risks.
PG  - 228-31
AB  - The favorable clinical experience with aspirin in the secondary prevention of 
      cardiovascular disease, which has now clearly established the indications for the 
      use of the drug in this context, has been the driving force behind the extension 
      of its use to primary prevention. Here, however, the balance between the benefits 
      and risks is substantially different from that of secondary prevention. In view 
      of this, health authorities have been more reluctant to approve the generalized 
      use of aspirin in primary prevention. We will here review the reasoning which 
      should be at the basis of a set of recommendations, as recently expressed by two 
      American expert opinion panels.
FAU - De Caterina, Raffaele
AU  - De Caterina R
AD  - G. d'Annunzio University, Chieti, Italy. rdecater@unich.it
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Ital Heart J
JT  - Italian heart journal : official journal of the Italian Federation of Cardiology
JID - 100909716
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/etiology/*prevention & control
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Coronary Disease/complications/*drug therapy
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Risk Assessment
RF  - 15
EDAT- 2003/06/06 05:00
MHDA- 2004/02/18 05:00
CRDT- 2003/06/06 05:00
PHST- 2003/06/06 05:00 [pubmed]
PHST- 2004/02/18 05:00 [medline]
PHST- 2003/06/06 05:00 [entrez]
PST - ppublish
SO  - Ital Heart J. 2003 Apr;4(4):228-31.

PMID- 33143725
OWN - NLM
STAT- MEDLINE
DCOM- 20211026
LR  - 20211026
IS  - 1868-7083 (Electronic)
IS  - 1868-7075 (Print)
IS  - 1868-7075 (Linking)
VI  - 12
IP  - 1
DP  - 2020 Nov 3
TI  - Longitudinal analysis of healthy colon establishes aspirin as a suppressor of 
      cancer-related epigenetic aging.
PG  - 164
LID - 10.1186/s13148-020-00956-9 [doi]
LID - 164
AB  - BACKGROUND: Colon cancer (CC) is the third most common cancer worldwide, 
      highlighting the importance of developing effective prevention strategies. 
      Accumulating evidence supports that aspirin use reduces CC incidence. We reported 
      previously that aspirin suppresses age-associated and CC-relevant DNA methylation 
      (DNAm) in healthy colon. Here we addressed the aspirin's effectiveness in 
      longitudinal cohort. METHODS: We measured genome-wide DNAm in 124 healthy normal 
      mucosa samples taken at baseline (time point 1, t1) and after 10-years follow-up 
      (time point 2, t2) from a longitudinal female screening cohort. We investigated 
      the time-dependent methylation drift in aspirin users and nonusers using 
      multivariable regression and related the modulatory effect of aspirin to colonic 
      epigenome-aging and CC. RESULTS: Over time, compared to nonusers, long-term 
      (≥ 2 years) aspirin users showed less hypermethylated CpGs (proximal: 17% vs. 
      87%; distal: 16% vs. 70%) and more hypomethylated CpGs (proximal: 83% vs. 13%; 
      distal: 84% vs. 30%). Overall, users showed 2% (P = 0.02) less mean methylation 
      levels than nonusers in proximal colon and displayed repressed methylation age 
      (mAge). Methylation loss in users occurred at several CC-specific tumor 
      suppressors that gained methylation in nonusers. Methylation loss in users 
      effected genes involved in immune system and inflammation, while methylation gain 
      in nonusers effected genes involved in metabolism. CONCLUSIONS: This is the first 
      longitudinal study demonstrating effectiveness of aspirin-use in suppression of 
      age-related and CC-relevant hypermethylation in the normal colon. These findings 
      provide a rationale for future studies to evaluate loci that may serve as markers 
      to identify individuals that will benefit most from aspirin and hence increase 
      its efficiency in CC prevention and therapy.
FAU - Noreen, Faiza
AU  - Noreen F
AUID- ORCID: 0000-0002-1668-7316
AD  - Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058, Basel, 
      Switzerland. faiza.noreen@unibas.ch.
AD  - Swiss Institute of Bioinformatics, 4053, Basel, Switzerland. 
      faiza.noreen@unibas.ch.
FAU - Chaber-Ciopinska, Anna
AU  - Chaber-Ciopinska A
AD  - Department of Gastroenterology, Medical Center for Postgraduate Education, Maria 
      Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland.
FAU - Regula, Jaroslaw
AU  - Regula J
AD  - Department of Gastroenterology, Medical Center for Postgraduate Education, Maria 
      Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland.
FAU - Schär, Primo
AU  - Schär P
AD  - Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058, Basel, 
      Switzerland.
FAU - Truninger, Kaspar
AU  - Truninger K
AD  - Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058, Basel, 
      Switzerland. k.truninger@gastroenterologie-oberaargau.ch.
AD  - Gastroenterologie Oberaargau, 4900, Langenthal, Switzerland. 
      k.truninger@gastroenterologie-oberaargau.ch.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201103
PL  - Germany
TA  - Clin Epigenetics
JT  - Clinical epigenetics
JID - 101516977
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/drug effects/*genetics
MH  - Aspirin/chemistry/*metabolism
MH  - Case-Control Studies
MH  - Colon/metabolism
MH  - Colonic Neoplasms/epidemiology/*genetics/pathology/prevention & control
MH  - CpG Islands
MH  - Cyclooxygenase Inhibitors/chemistry/*metabolism
MH  - DNA Methylation
MH  - Early Detection of Cancer/methods
MH  - Epigenesis, Genetic/drug effects
MH  - Epigenomics
MH  - Female
MH  - Follow-Up Studies
MH  - Genome-Wide Association Study
MH  - Healthy Volunteers
MH  - Humans
MH  - Incidence
MH  - Longitudinal Studies
MH  - Middle Aged
PMC - PMC7607658
OTO - NOTNLM
OT  - Aging
OT  - Aspirin
OT  - Colon cancer
OT  - DNA methylation
OT  - Epigenetics
COIS- The authors declare that they have no competing interests.
EDAT- 2020/11/05 06:00
MHDA- 2021/10/27 06:00
CRDT- 2020/11/04 05:31
PHST- 2020/08/17 00:00 [received]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/11/04 05:31 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2021/10/27 06:00 [medline]
AID - 10.1186/s13148-020-00956-9 [pii]
AID - 956 [pii]
AID - 10.1186/s13148-020-00956-9 [doi]
PST - epublish
SO  - Clin Epigenetics. 2020 Nov 3;12(1):164. doi: 10.1186/s13148-020-00956-9.

PMID- 14763803
OWN - NLM
STAT- MEDLINE
DCOM- 20040921
LR  - 20190720
IS  - 0021-9673 (Print)
IS  - 0021-9673 (Linking)
VI  - 1025
IP  - 2
DP  - 2004 Feb 6
TI  - Characterisation of reversed-phase liquid-chromatographic columns by 
      chromatographic tests comparing column classification based on chromatographic 
      parameters and column performance for the separation of acetylsalicylic acid and 
      related compounds.
PG  - 189-200
AB  - Selection of RP-LC columns with suitable selectivity for a given analysis is 
      difficult. For example, the European Pharmacopoeia (Ph. Eur.) and other official 
      compendia for drug analysis only give a general description of the stationary 
      phase in the operating procedure of a liquid chromatographic method. The need for 
      a general test method to characterise RP-LC columns has been rising since the 
      1970s. A project to define a chromatographic procedure characterising RP-LC 
      columns was started earlier. A procedure to measure test parameters was 
      introduced and a classification of the columns, based on a minimal number of 
      parameters, was obtained. This paper focuses on correlating the column 
      classification with the selectivity obtained for a real separation. The 
      separation of acetylsalicylic acid (aspirin) and related compounds was performed 
      according to the Ph. Eur. monograph on the stationary phases previously 
      characterised chromatographically. It was examined whether the classes of 
      columns, determined using test parameter results, contain either suitable or 
      unsuitable supports for the aspirin separation. The system suitability test 
      prescribed by the Ph. Eur. in order to distinguish between suitable or unsuitable 
      columns for this separation was also evaluated.
FAU - Dehouck, Pieter
AU  - Dehouck P
AD  - Katholieke Universiteit Leuven, Laboratorium voor Farmaceutische Chemie en 
      Analyse van Geneesmiddelen, Van Evenstraat 4, B-3000 Leuven, Belgium.
FAU - Visky, Dóra
AU  - Visky D
FAU - Vander Heyden, Yvan
AU  - Vander Heyden Y
FAU - Adams, Erwin
AU  - Adams E
FAU - Kovács, Zsuzsanna
AU  - Kovács Z
FAU - Noszál, Béla
AU  - Noszál B
FAU - Massart, Désiré L
AU  - Massart DL
FAU - Hoogmartens, Jos
AU  - Hoogmartens J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Chromatogr A
JT  - Journal of chromatography. A
JID - 9318488
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*isolation & purification
MH  - Chromatography, Liquid/instrumentation/*methods
EDAT- 2004/02/07 05:00
MHDA- 2004/09/24 05:00
CRDT- 2004/02/07 05:00
PHST- 2004/02/07 05:00 [pubmed]
PHST- 2004/09/24 05:00 [medline]
PHST- 2004/02/07 05:00 [entrez]
AID - S0021-9673(03)01965-4 [pii]
AID - 10.1016/j.chroma.2003.10.089 [doi]
PST - ppublish
SO  - J Chromatogr A. 2004 Feb 6;1025(2):189-200. doi: 10.1016/j.chroma.2003.10.089.

PMID- 10431716
OWN - NLM
STAT- MEDLINE
DCOM- 19990923
LR  - 20210112
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 81
IP  - 3
DP  - 1999 Jun
TI  - Oral aspirin in postoperative pain: a quantitative systematic review.
PG  - 289-297
LID - 10.1016/S0304-3959(99)00022-6 [doi]
AB  - OBJECTIVES: A systematic review of the analgesic efficacy and adverse effects of 
      single-dose aspirin compared with placebo in postoperative pain. DESIGN: 
      Published studies were identified from systematic searching of bibliographic 
      databases and reference lists of retrieved reports. Summed pain intensity and 
      pain relief data were extracted and converted into dichotomous information to 
      yield the number of patients with at least 50% pain relief. This was used to 
      calculate the relative benefit and number-needed-to-treat for one patient to 
      achieve at least 50% pain relief. For adverse effects, relative risk and 
      number-needed-to-harm were calculated. Sensitivity analyses were planned to test 
      the impact of different pain models, pain measurements, sample sizes, quality of 
      study design, and study duration on the results. RESULTS: Seventy-two randomized 
      single-dose trials met our inclusion criteria, with 3253 patients given aspirin, 
      and 3297 placebo. Significant benefit of aspirin over placebo was shown for 
      aspirin 600/650 mg, 1000 mg and 1200 mg, with numbers-needed-to-treat for at 
      least 50% pain relief of 4.4 (4.0-4.9), 4.0 (3.2-5.4) and 2.4 (1.9-3.2) 
      respectively. Single-dose aspirin 600/650 mg produced significantly more 
      drowsiness and gastric irritation than placebo, with numbers-needed-to-harm of 28 
      (19-52) and 38 (22-174) respectively. Type of pain model, pain measurement, 
      sample size, quality of study design, and study duration had no significant 
      impact on the results. CONCLUSIONS: There was a clear dose-response for pain 
      relief with aspirin, even though these were single dose studies. Adverse effects, 
      drowsiness and gastric irritation were also evident in the single dose studies. 
      The pain relief achieved with aspirin was very similar milligram for milligram to 
      that seen with paracetamol.
FAU - Edwards, Jayne E
AU  - Edwards JE
AD  - Pain Research and Nuffield Department of Anaesthetics, University of Oxford, 
      Oxford Radcliffe NHS Trust, The Churchill, Headington, Oxford OX3 7LJ, UK.
FAU - Oldman, Anna D
AU  - Oldman AD
FAU - Smith, Lesley A
AU  - Smith LA
FAU - Carroll, Dawn
AU  - Carroll D
FAU - Wiffen, Philip J
AU  - Wiffen PJ
FAU - McQuay, Henry J
AU  - McQuay HJ
FAU - Moore, Andrew R
AU  - Moore AR
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Pain. 2000 Dec 1;88(3):309-11. PMID: 11221654
MH  - Administration, Oral
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Confidence Intervals
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Pain Measurement
MH  - Pain, Postoperative/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Risk
EDAT- 1999/08/04 00:00
MHDA- 1999/08/04 00:01
CRDT- 1999/08/04 00:00
PHST- 1999/08/04 00:00 [pubmed]
PHST- 1999/08/04 00:01 [medline]
PHST- 1999/08/04 00:00 [entrez]
AID - 00006396-199906010-00007 [pii]
AID - 10.1016/S0304-3959(99)00022-6 [doi]
PST - ppublish
SO  - Pain. 1999 Jun;81(3):289-297. doi: 10.1016/S0304-3959(99)00022-6.

PMID- 6291695
OWN - NLM
STAT- MEDLINE
DCOM- 19830107
LR  - 20190501
IS  - 0267-0623 (Print)
IS  - 0267-0623 (Linking)
VI  - 285
IP  - 6352
DP  - 1982 Nov 13
TI  - Diuresis or urinary alkalinisation for salicylate poisoning?
PG  - 1383-6
AB  - Forty-four adults with aspirin poisoning were treated with oral fluids only, 
      standard forced alkaline diuresis, forced diuresis alone, or sodium bicarbonate 
      (alkali) alone. Alkali alone was at least as effective and possibly more 
      effective than forced alkaline diuresis in enhancing salicylate removal. Unlike 
      the diuresis regimens it did not cause fluid retention or biochemical 
      disturbances. The renal excretion of salicylate depends much more on urine pH 
      than flow rate, and forced diuresis alone had little useful effect. In overdosage 
      aspirin causes sodium and fluid retention and may impair renal function. Attempts 
      to force a diuresis are potentially hazardous and the spurious fall in plasma 
      salicylate concentration caused by haemodilution gives a false impression of 
      efficacy. Further studies are required to determine the optimum treatment for 
      salicylate poisoning.
FAU - Prescott, L F
AU  - Prescott LF
FAU - Balali-Mood, M
AU  - Balali-Mood M
FAU - Critchley, J A
AU  - Critchley JA
FAU - Johnstone, A F
AU  - Johnstone AF
FAU - Proudfoot, A T
AU  - Proudfoot AT
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Med J (Clin Res Ed)
JT  - British medical journal (Clinical research ed.)
JID - 8302911
RN  - 0 (Bicarbonates)
RN  - 0 (Diuretics)
RN  - 8MDF5V39QO (Sodium Bicarbonate)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/blood/*poisoning/urine
MH  - Bicarbonates/*therapeutic use
MH  - Body Weight
MH  - Diuretics/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Middle Aged
MH  - Sodium/blood
MH  - Sodium Bicarbonate
MH  - Urodynamics
PMC - PMC1500395
EDAT- 1982/11/13 00:00
MHDA- 1982/11/13 00:01
CRDT- 1982/11/13 00:00
PHST- 1982/11/13 00:00 [pubmed]
PHST- 1982/11/13 00:01 [medline]
PHST- 1982/11/13 00:00 [entrez]
AID - 10.1136/bmj.285.6352.1383 [doi]
PST - ppublish
SO  - Br Med J (Clin Res Ed). 1982 Nov 13;285(6352):1383-6. doi: 
      10.1136/bmj.285.6352.1383.

PMID- 31145484
OWN - NLM
STAT- MEDLINE
DCOM- 20200121
LR  - 20200121
IS  - 1099-0801 (Electronic)
IS  - 0269-3879 (Linking)
VI  - 33
IP  - 10
DP  - 2019 Oct
TI  - Stability-indicating HPLC method for simultaneous quantification of 14 impurities 
      in excedrin tablet formulations and identification of new impurity by LC-MS in 
      accelerated stability studies.
PG  - e4608
LID - 10.1002/bmc.4608 [doi]
AB  - We developed novel stability-indicating HPLC method for simultaneous estimation 
      of 14 impurities in excedrin tablet, a formulation with a combination of 
      acetaminophen, aspirin, and caffeine. In addition, a new impurity that was 
      generated through degradation of aspirin at high temperatures during the 
      accelerated stability conditions was positively identified and confirmed, using 
      liquid chromatography-mass spectrometry technique. The HPLC method was optimized 
      using the Inertsustain C(18) , 250 × 4.6 mm, 5.0 μm column, employing simple 
      gradient method. Forced degradation studies were performed under acidic, basic, 
      oxidative and thermal conditions to prove the scope and stability-indicating the 
      nature of the method. The optimized method was validated as per the International 
      Conference on Harmonization guidelines. The HPLC method showed linearity from LOQ 
      concentration to 21 μg mL(-1) . Precision and intermediate precision values 
      were <5% RSD. The validated HPLC method is currently applied for the routine 
      testing of excedrin tablet formulations in quality control laboratories.
CI  - © 2019 John Wiley & Sons, Ltd.
FAU - Dongala, Thirupathi
AU  - Dongala T
AUID- ORCID: 0000-0001-8251-5005
AD  - Aurex Laboratories LLC, NJ, USA.
AD  - Department of Chemistry, GITAM deemed to be University, Hyderabad, Telangana, 
      India.
FAU - Katari, Naresh Kumar
AU  - Katari NK
AUID- ORCID: 0000-0002-5737-8528
AD  - Department of Chemistry, GITAM deemed to be University, Hyderabad, Telangana, 
      India.
AD  - School of Chemistry and Physics, College of Agriculture, Engineering and Science, 
      Westville Campus, University of KwaZulu-Natal, Durban, South Africa.
FAU - Palakurthi, Ashok Kumar
AU  - Palakurthi AK
AD  - Aurex Laboratories LLC, NJ, USA.
FAU - Jonnalagadda, Sreekantha B
AU  - Jonnalagadda SB
AD  - School of Chemistry and Physics, College of Agriculture, Engineering and Science, 
      Westville Campus, University of KwaZulu-Natal, Durban, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20190627
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - 0 (Drug Combinations)
RN  - 0 (acetaminophen, aspirin, caffeine drug combination)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis/*chemistry
MH  - Aspirin/*analysis/*chemistry
MH  - Caffeine/*analysis/*chemistry
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Drug Combinations
MH  - *Drug Contamination
MH  - Limit of Detection
MH  - Linear Models
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - HPLC
OT  - LC-MS
OT  - acetaminophen
OT  - aspirin
OT  - caffeine
OT  - excedrin
OT  - impurities
EDAT- 2019/05/31 06:00
MHDA- 2020/01/22 06:00
CRDT- 2019/05/31 06:00
PHST- 2019/03/03 00:00 [received]
PHST- 2019/04/26 00:00 [revised]
PHST- 2019/05/23 00:00 [accepted]
PHST- 2019/05/31 06:00 [pubmed]
PHST- 2020/01/22 06:00 [medline]
PHST- 2019/05/31 06:00 [entrez]
AID - 10.1002/bmc.4608 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2019 Oct;33(10):e4608. doi: 10.1002/bmc.4608. Epub 2019 Jun 
      27.

PMID- 8119471
OWN - NLM
STAT- MEDLINE
DCOM- 19940407
LR  - 20190816
IS  - 0301-2115 (Print)
IS  - 0301-2115 (Linking)
VI  - 52
IP  - 1
DP  - 1993 Nov
TI  - Low-dose aspirin in pregnancy: changes in patterns of prescription in The 
      Netherlands.
PG  - 29-33
AB  - OBJECTIVE: To describe patterns of prescription in the Netherlands of low-dose 
      aspirin in pregnancy. DESIGN: Anonymous written inquiry in 1989 and 1991. 
      SUBJECTS: Gynecologists in the Netherlands (619 in 1989 and 618 in 1991), 
      practicing in training and non-training hospitals. MAIN OUTCOME MEASURES: 
      Prescription rates for prevention of pregnancy-induced hypertension and fetal 
      growth retardation, or for intention to treat. RESULTS: The response rates were 
      52% in 1989 and 58% in 1991, covering approximately 61% and 62%, respectively, of 
      the practicing gynecologists in the Netherlands. The use for prevention increased 
      from 53% to 79% and for therapeutic intentions from 25% to 48%. CONCLUSION: The 
      prescription rate for low-dose aspirin increased markedly from 1989 to 1991, 
      without evidence for its benefit from the literature published in the same time 
      period.
FAU - Bremer, H A
AU  - Bremer HA
AD  - Institute of Obstetrics and Gynecology, Erasmus University School of Medicine and 
      Health Sciences, Rotterdam, The Netherlands.
FAU - Wallenburg, H C
AU  - Wallenburg HC
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Humans
MH  - Hypertension/*prevention & control
MH  - Netherlands
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications/*prevention & control
MH  - *Pregnancy Outcome
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
AID - 0028-2243(93)90221-W [pii]
AID - 10.1016/0028-2243(93)90221-w [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 1993 Nov;52(1):29-33. doi: 
      10.1016/0028-2243(93)90221-w.

PMID- 30249529
OWN - NLM
STAT- MEDLINE
DCOM- 20190123
LR  - 20190123
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 151
IP  - 3
DP  - 2018 Dec
TI  - Use of paracetamol, low-dose aspirin, or non-aspirin non-steroidal 
      anti-inflammatory drugs and risk of ovarian borderline tumors in Denmark.
PG  - 513-518
LID - S0090-8258(18)31242-3 [pii]
LID - 10.1016/j.ygyno.2018.09.022 [doi]
AB  - OBJECTIVE: Few studies have examined ovarian borderline tumor (BOT) risk 
      associated with analgesics, and with inconclusive findings. The aim was to 
      examine serous borderline tumor (SBT) or mucinous borderline tumor (MBT) risk 
      associated with use of paracetamol, low-dose aspirin, or non-aspirin 
      non-steroidal anti-inflammatory drugs (NSAIDs). METHODS: We identified all women 
      with SBTs or MBTs in the Danish Pathology Data Bank, 1997-2015. Using risk-set 
      sampling, we randomly selected 15 controls per case. We excluded women with 
      previous cancer (except non-melanoma skin cancer) and controls with bilateral 
      oophorectomy/salpingo-oophorectomy. Information on redeemed prescriptions of 
      medications/confounders was identified from nationwide registries. We used 
      conditional logistic regression to estimate adjusted odds ratios (ORs) and 95% 
      confidence intervals (CIs). RESULTS: We observed a decreased MBT risk among 
      recent paracetamol users (OR = 0.77; 95% CI: 0.60-0.98), but no association with 
      SBTs. Regarding non-aspirin NSAIDs, we found an increased SBT risk with recent 
      (OR = 1.29; 95% CI: 1.11-1.51) and former use (OR = 1.19; 95% CI: 1.04-1.37), and 
      an elevated MBT risk with recent use (OR = 1.14; 95% CI: 0.97-1.33). Low-dose 
      aspirin use did not seem related with SBT risk, and the association with MBTs was 
      unclear. CONCLUSIONS: No strong associations between the examined medications and 
      BOTs were observed. However, our nationwide case-control study may suggest that 
      recent paracetamol use could have a chemopreventive effect on MBTs, whereas 
      neither low-dose aspirin nor non-aspirin NSAIDs use seem to protect against SBTs 
      or MBTs. Larger studies are needed to firmly establish a potential association 
      between these medications and BOT risk.
CI  - Copyright © 2018. Published by Elsevier Inc.
FAU - Hannibal, Charlotte Gerd
AU  - Hannibal CG
AD  - Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 
      Strandboulevarden 49, 2100 Copenhagen, Denmark.
FAU - Dehlendorff, Christian
AU  - Dehlendorff C
AD  - Unit of Statistics and Pharmaco-epidemiology, Danish Cancer Society Research 
      Center, Strandboulevarden 49, 2100 Copenhagen, Denmark.
FAU - Kjaer, Susanne K
AU  - Kjaer SK
AD  - Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 
      Strandboulevarden 49, 2100 Copenhagen, Denmark; Department of Gynecology, Juliane 
      Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, 
      Denmark. Electronic address: susanne@cancer.dk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180921
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/pharmacology/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Denmark
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Risk Factors
OTO - NOTNLM
OT  - Low-dose aspirin
OT  - Non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs)
OT  - Ovarian borderline tumor (BOT)
OT  - Paracetamol
OT  - Population-based case-control study
OT  - Risk factor
EDAT- 2018/09/27 06:00
MHDA- 2019/01/24 06:00
CRDT- 2018/09/26 06:00
PHST- 2018/07/12 00:00 [received]
PHST- 2018/09/11 00:00 [revised]
PHST- 2018/09/19 00:00 [accepted]
PHST- 2018/09/27 06:00 [pubmed]
PHST- 2019/01/24 06:00 [medline]
PHST- 2018/09/26 06:00 [entrez]
AID - S0090-8258(18)31242-3 [pii]
AID - 10.1016/j.ygyno.2018.09.022 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2018 Dec;151(3):513-518. doi: 10.1016/j.ygyno.2018.09.022. Epub 
      2018 Sep 21.

PMID- 15955733
OWN - NLM
STAT- MEDLINE
DCOM- 20060524
LR  - 20131121
IS  - 1471-4892 (Print)
IS  - 1471-4892 (Linking)
VI  - 5
IP  - 4
DP  - 2005 Aug
TI  - Aspirin and steroids: new mechanistic findings and avenues for drug discovery.
PG  - 405-11
AB  - The inflammatory response is a life-saving protective process mounted by the body 
      to overcome pathogen infection and injury; however, in chronic inflammatory 
      pathologies, this response can become deregulated. Aspirin and glucocorticoids 
      are two examples of drugs developed over the years to rectify deregulated 
      inflammatory reactions. Interestingly, both these prototypes of anti-inflammatory 
      therapeutics have been 'borrowed' from Mother Nature, identified from the plant 
      and animal world, respectively. In the past century, systematic organic chemistry 
      has been the major approach for producing new drugs, and vast quantities of 
      aspirin and prednisolone have been synthesized, packaged and sold. However, the 
      fascination provoked by these often life-saving drugs has not subsided, and 
      recent work into the endogenous control of the host inflammatory response has 
      revitalized these compounds. Thus, epi-lipoxins, produced after aspirin 
      acetylation of inducible cyclooxygenase-2, and glucocorticoid-regulated annexin 1 
      appear to be important endogenous mediators of their respective anti-inflammatory 
      effects. In addition, aspirin-triggered epi-lipoxins and glucocorticoid-regulated 
      annexin 1 might act on the same G-protein-coupled receptor, thus rendering this 
      shared receptor a more likely and worthwhile target for fruitful drug discovery.
FAU - Gilroy, Derek W
AU  - Gilroy DW
AD  - Centre for Clinical Pharmacology and Therapeutics, BHF Laboratories, Department 
      of Medicine, University College London, 5 University Street, London WC1E 6JJ, UK. 
      d.gilroy@ucl.ac.uk
FAU - Perretti, Mauro
AU  - Perretti M
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Curr Opin Pharmacol
JT  - Current opinion in pharmacology
JID - 100966133
RN  - 0 (Anti-Inflammatory Agents)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/chemical synthesis/therapeutic use
MH  - Aspirin/chemical synthesis/*therapeutic use
MH  - *Drug Design
MH  - Humans
MH  - Prednisolone/chemical synthesis/*therapeutic use
MH  - Technology, Pharmaceutical/*methods/trends
RF  - 39
EDAT- 2005/06/16 09:00
MHDA- 2006/05/25 09:00
CRDT- 2005/06/16 09:00
PHST- 2005/02/24 00:00 [received]
PHST- 2005/02/24 00:00 [accepted]
PHST- 2005/06/16 09:00 [pubmed]
PHST- 2006/05/25 09:00 [medline]
PHST- 2005/06/16 09:00 [entrez]
AID - S1471-4892(05)00081-0 [pii]
AID - 10.1016/j.coph.2005.02.006 [doi]
PST - ppublish
SO  - Curr Opin Pharmacol. 2005 Aug;5(4):405-11. doi: 10.1016/j.coph.2005.02.006.

PMID- 12888273
OWN - NLM
STAT- MEDLINE
DCOM- 20031029
LR  - 20190910
IS  - 0162-0134 (Print)
IS  - 0162-0134 (Linking)
VI  - 96
IP  - 2-3
DP  - 2003 Aug 1
TI  - Low-temperature (180 K) crystal structure, electron paramagnetic resonance 
      spectroscopy, and propitious anticonvulsant activities of 
      CuII2(aspirinate)4(DMF)2 and other CuII2(aspirinate)4 chelates.
PG  - 375-85
AB  - The purpose of this research was to characterize by X-ray crystallography the 
      ternary dimethylformamide (DMF) Cu(II) complex of acetylsalicylic acid (aspirin), 
      in an effort to compare the structure-activity relationships for the 
      anticonvulsant activity of this and other Cu(II)aspirinate chelates. The ternary 
      DMF Cu(II) complex of aspirin was synthesized and crystals grown from a DMF 
      solution were characterized by single crystal X-ray diffraction. This crystalline 
      material was analyzed for anticonvulsant activity in the Maximal Electroshock 
      (MES) Grand Mal and subcutaneous Metrazol (scMET) Petit Mal models of seizure 
      used to detect anticonvulsant activity. The ternary DMF complex was found to be a 
      monomolecular binuclear complex, 
      tetrakis-mu-(acetylsalicylato)bis(dimethylformamido)dicopper(II) 
      [Cu(II)(2)(aspirinate)(4)(DMF)(2)] with the following parameters: monoclinic, 
      space group P2(1)/n, a=12.259 (1), b=10.228 (1), c=16.987 (1) A, beta=92.07 (1) 
      degrees; V=2128.5 (3) A(3); Z=2. The structure was determined at 180 K from 2903 
      unique reflections (I>1sigma(I)) to the final values of R=0.030 and wR=0.033 
      using F. This binuclear complex contains four acetylsalicylate bridging ligands 
      which are related to each other in a two by two symmetry center. The four nearest 
      O atoms around each Cu atom form a closely square planar arrangement with the 
      square pyramidal coordination completed by the dimethylformamide oxygen atom 
      occupying an apical position at a distance of 2.154 (1) A. Each Cu atom is 
      displaced towards the DMF ligand by 0.187 A from the plane of the four O atoms. 
      Electron paramagnetic resonance (EPR) spectra of 
      [Cu(II)(2)(aspirinate)(4)(DMF)(2)] crystals show a strong antiferromagnetic 
      coupling of the copper atoms, similar to that observed with other binuclear 
      copper(II)salicylate compounds. Studies used to detect anticonvulsant activity 
      revealed that [Cu(II)(2)(aspirinate)(4)(DMF)(2)] was an effective anticonvulsant 
      in the MES model of seizure but ineffective against scMET-induced seizures. The 
      monomolecular ternary binuclear [Cu(II)(2)(aspirinate)(4)(DMF)(2)] complex is 
      more effective in inhibiting MES-induced seizures than other binuclear or 
      mononuclear Cu(II) chelates of aspirin including: binuclear polymeric 
      [Cu(II)(2)(aspirinate)(4)], [Cu(II)(2)(aspirinate)(4)(H(2)O)], which is 
      anticipated to be less polymeric, and monomolecular ternary 
      [Cu(II)(2)(aspirinate)(4)(DMSO)(2)] and [Cu(II)(aspirinate)(2)(Pyr)(2)]. These 
      and other chelates appear to be more effective in the scMET model of seizure than 
      [Cu(II)(2)(aspirinate)(4)(DMF)(2)]. These structure-activity relationships 
      support the potential efficacy of Cu chelates of aspirin in treating epilepsies.
FAU - Viossat, Bernard
AU  - Viossat B
AD  - Laboratoire de Chimie Générale, Faculté de Médecine et de Pharmacie, Poitiers, 
      France.
FAU - Daran, Jean Claude
AU  - Daran JC
FAU - Savouret, Grégoire
AU  - Savouret G
FAU - Morgant, Georges
AU  - Morgant G
FAU - Greenaway, Frederick T
AU  - Greenaway FT
FAU - Dung, Nguyen Huy
AU  - Dung NH
FAU - Pham-Tran, Van Anh
AU  - Pham-Tran VA
FAU - Sorenson, John R J
AU  - Sorenson JR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Inorg Biochem
JT  - Journal of inorganic biochemistry
JID - 7905788
RN  - 0 (Anticonvulsants)
RN  - 0 (Organometallic Compounds)
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - 789U1901C5 (Copper)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticonvulsants/administration & dosage/*chemistry/pharmacology
MH  - Aspirin/*analogs & derivatives/*chemistry/pharmacology
MH  - Cold Temperature
MH  - Copper/*chemistry
MH  - Crystallization
MH  - Crystallography, X-Ray
MH  - Drug Evaluation, Preclinical
MH  - Electron Spin Resonance Spectroscopy
MH  - Male
MH  - Mice
MH  - Molecular Structure
MH  - Organometallic Compounds/administration & dosage/*chemistry/pharmacology
MH  - Rats
MH  - Seizures/prevention & control
MH  - Structure-Activity Relationship
MH  - Temperature
EDAT- 2003/07/31 05:00
MHDA- 2003/10/30 05:00
CRDT- 2003/07/31 05:00
PHST- 2003/07/31 05:00 [pubmed]
PHST- 2003/10/30 05:00 [medline]
PHST- 2003/07/31 05:00 [entrez]
AID - S0162013403001533 [pii]
AID - 10.1016/s0162-0134(03)00153-3 [doi]
PST - ppublish
SO  - J Inorg Biochem. 2003 Aug 1;96(2-3):375-85. doi: 10.1016/s0162-0134(03)00153-3.

PMID- 12438552
OWN - NLM
STAT- MEDLINE
DCOM- 20021224
LR  - 20180301
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 303
IP  - 3
DP  - 2002 Dec
TI  - Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of 
      various cultured human cancer cells: evidence of a tissue type-independent 
      effect.
PG  - 1273-82
AB  - The novel nitric oxide (NO)-donating nonsteroidal anti-inflammatory drugs 
      (NO-NSAIDs), which are safer than their NSAID counterparts, inhibit the growth of 
      colon cancer cells with far greater potency than traditional NSAIDs. We examined 
      whether NO-NSAIDs inhibit the growth of cancer cells arising from other human 
      tissues. Human pancreatic, colon, prostate, lung, and tongue cancer cell lines 
      were treated with NO-aspirin, -sulindac, -ibuprofen, and -indomethacin or their 
      traditional counterparts. We determined IC(50) values, cell proliferation, 
      apoptosis, cell cycle, cyclooxygenase (COX) protein levels, and morphological 
      changes (light and electron microscopy). All NO-NSAIDs inhibited the growth of 
      all cancer cell lines studied. The potency of NO-NSAIDs was 11- to 6000-fold 
      greater than that of their counterparts (except for the effect of sulindac on 
      lung cancer cells). NO-aspirin was consistently the most potent NO-NSAID in all 
      cell lines tested (except for the lung cancer cell line), sometimes in excess of 
      100-fold over the other three NO-NSAIDs. NO-NSAIDs inhibited cell proliferation, 
      induced apoptosis, and altered cell cycle phase distribution (G2/M to G0/G1 
      block). All altered cellular morphology, whereas NO-aspirin induced nuclear 
      disintegration ("atypical" cells) established by electron microscopy. NO-aspirin 
      showed similar effects on two pancreatic cancer cell lines, BxPC-3 (expresses 
      COX) and MIA PaCa-2 (no COX expression), suggesting a COX-independent effect. 
      NO-NSAIDs showed a tissue-type-independent effect. Their pleiotropic effects 
      involve cell renewal, cell death, and cell cycle phase transitions. These results 
      raise the possibility that NO-NSAIDs possess chemopreventive and/or 
      chemotherapeutic activity against a wide variety of human cancers.
FAU - Kashfi, Khosrow
AU  - Kashfi K
AD  - American Health Foundation, Valhalla, New York, USA.
FAU - Rayyan, Yassir
AU  - Rayyan Y
FAU - Qiao, Leon L
AU  - Qiao LL
FAU - Williams, Jennie L
AU  - Williams JL
FAU - Chen, Jie
AU  - Chen J
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Traganos, Frank
AU  - Traganos F
FAU - Rigas, Basil
AU  - Rigas B
FAU - Ryann, Yassir
AU  - Ryann Y
LA  - eng
GR  - CA92423/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Growth Inhibitors)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - J Pharmacol Exp Ther. 2003 Jul;306(1):421. Ryann Yaser [corrected to Ryan Yassir]
EIN - J Pharmacol Exp Ther. 2003 Nov;307(2):829. Ryan Yassir [corrected to Rayyan 
      Yassir]
EIN - J Pharmacol Exp Ther. 2018 Apr;365(1):139. PMID: 29491148
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*pharmacology
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/drug effects/physiology
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Cell Division/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Growth Inhibitors/chemistry/*pharmacology
MH  - Humans
MH  - Nitric Oxide Donors/chemistry/*pharmacology
MH  - Tumor Cells, Cultured/drug effects/ultrastructure
EDAT- 2002/11/20 04:00
MHDA- 2002/12/27 04:00
CRDT- 2002/11/20 04:00
PHST- 2002/11/20 04:00 [pubmed]
PHST- 2002/12/27 04:00 [medline]
PHST- 2002/11/20 04:00 [entrez]
AID - 10.1124/jpet.102.042754 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2002 Dec;303(3):1273-82. doi: 10.1124/jpet.102.042754.

PMID- 16335259
OWN - NLM
STAT- MEDLINE
DCOM- 20060124
LR  - 20131121
IS  - 0008-7335 (Print)
IS  - 0008-7335 (Linking)
VI  - 144 Suppl 3
DP  - 2005
TI  - [Acetylsalicylic acid (ASA) resistance in patients with ischemic heart disease 
      (IHD) as bioindicator of the treatment strategy].
PG  - 23-9
AB  - BACKGROUND: The interest in aspirin resistance has been increasing during the 
      last few years, with researchers earnestly pursuing alternative anti-platelet 
      therapies and devices for measuring platelet aggregation. The recent studies 
      suggest that 5-45% of patients taking aspirin do not experience adequate 
      anti-platelet effects. METHODS AND RESULTS: There is scant evidence proving that 
      aspirin resistance has some clinical consequences. To assess the prevalence of 
      aspirin resistance in patients with ischemic heart disease (IHD) two independent 
      methods were used: platelet aggregation in platelet rich plasma (PRP) after 
      induction by propylgallate (CPG), and assessment of platelet function by PFA 100 
      method. The study population consisted of 424 patients treated for IHD on the 2nd 
      Dept. of Medicine, Teaching Hospital, Hradec Kralove. The age, gender, diagnosis 
      and effect of therapy were characterized in this group of the patients. Daily ASA 
      dose was 100 mg. We used two methods to monitor ASA treatment efficacy: a) 
      thrombocyte aggregation after induction by CPG, b) the assessment of platelet 
      function by PFA 100 method. a) Of the patients studied by CPG platelet 
      aggregation, 51 (12.1%) pts were resistant to ASA dose 100 mg/day, and 32 (7.6%) 
      pts remained resistant even after increasig the dose to 200 mg/day. In 80 (20%) 
      pts, the daily ASA dose of less than 100 mg was sufficient to inhibit platelet 
      function. b) Although the PFA-100 system is not able to detect the difference 
      between low and high ASA dose, we found 53 (15.2%) patients aspirin resistant 
      using this method. CONCLUSIONS: In the patients with IHD treated with 100 mg of 
      ASA per day, our study has shown that the prevalence of aspirin resistance was 
      12.1% using CPG method, and 15.2% using PFA-100 method. Aspirin resistance was 
      dose dependent. Prevalence of ASA resistance in patients treated with 200 mg of 
      ASA per day was only 7.6% using the CPG method.
FAU - Malý, J
AU  - Malý J
AD  - Katedra internich oborů LF UK a FN, Hradec Králové. maly@fnhk.cz
FAU - Pecka, M
AU  - Pecka M
FAU - Gregor, J
AU  - Gregor J
FAU - Dulícek, P
AU  - Dulícek P
FAU - Blazek, M
AU  - Blazek M
FAU - Malý, R
AU  - Malý R
FAU - Pudil, R
AU  - Pudil R
FAU - Bláha, M
AU  - Bláha M
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Rezistence na kyselinu acetylosalicylovou u nemocných s ischemickou chorobou 
      srdecní jako bioindikátor lécebné strategie.
PL  - Czech Republic
TA  - Cas Lek Cesk
JT  - Casopis lekaru ceskych
JID - 0004743
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/blood/*drug therapy
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests
EDAT- 2005/12/13 09:00
MHDA- 2006/01/25 09:00
CRDT- 2005/12/13 09:00
PHST- 2005/12/13 09:00 [pubmed]
PHST- 2006/01/25 09:00 [medline]
PHST- 2005/12/13 09:00 [entrez]
PST - ppublish
SO  - Cas Lek Cesk. 2005;144 Suppl 3:23-9.

PMID- 18046964
OWN - NLM
STAT- MEDLINE
DCOM- 20071212
LR  - 20131121
IS  - 0326-4815 (Print)
IS  - 0326-4815 (Linking)
VI  - 20
IP  - 1
DP  - 2007
TI  - Effect of transdermic acetylsalicylic acid on hemostasis in healthy volunteers.
PG  - 3-8
AB  - Acetylsalicylic acid (ASA) exerts an antiaggregatory effect on platelets by 
      irreversible inhibition of the enzyme thrombocyte cyclooxigenase when it is 
      administered orally at doses above 80 mg/day. For several years ASA has been 
      available as a solution that can be topically applied on the skin. It is widely 
      used by athletes and individuals with chronic rheumatic disorders. However, it 
      has not been established to date whether the plasma levels that result from these 
      doses of ASA affect hemostasis during odontological procedures that involve 
      bleeding, causing platelet dysfunction. The aim of the present study was to 
      evaluate whether topical application is capable of affecting hemostasis. Three 
      studies were conducted: A, B y C. Each of the 3 groups included 12 healthy 
      volunteers of both sexes. The aim of study A was to evaluate if the formulation 
      for topical application resulted in plasma levels of ASA that resembled those 
      observed for the oral formulation and affect hemostasis. In experiment A, plasma 
      levels of salicylic acid (SA) were assessed for each volunteer at 30 minutes, 60 
      minutes, 6 hours, 12 hours and 24 hours after oral administration of a dose of 
      500 mg ASA. Experiment B was identical to experiment A except for the fact that 
      ASA was topically applied employing a commercial preparation Aspirub in a 
      predetermined area at a rate of 2 ml/day over a period of 15 days. Experiment C 
      was designed in the same way as experiment B, for a higher dose and a longer 
      period of time (4 ml/day over a period of 30 days). One of the volunteers 
      exhibited detectable salicylemia that could affect hemostasis as occurs with the 
      oral formulation. The following two studies (C1 and C2) employed doses of Aspirub 
      of 8 and 16 ml/day respectively, over a period of 30 days. We measured 
      biochemical parameters associated to platelet function. The dose of 8 ml/day 
      induced moderate alterations in all the parameters related to platelet function 
      and the daily dose of 16 ml inhibited platelet aggregation in all the volunteers 
      involved.
FAU - Martínez, Adriana B
AU  - Martínez AB
AD  - Department of Pharmacology, Faculty of Dentistry, National University of Rosario, 
      Argentina. adrianabmartinez@yahoo.com.ar
FAU - Funosas, Esteban
AU  - Funosas E
FAU - Maestri, Lorella
AU  - Maestri L
FAU - Lucena, Perla Hermida
AU  - Lucena PH
LA  - eng
PT  - Journal Article
PL  - Argentina
TA  - Acta Odontol Latinoam
JT  - Acta odontologica latinoamericana : AOL
JID - 8610218
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Administration, Cutaneous
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*administration & dosage/blood/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/blood/*pharmacology
MH  - Platelet-Rich Plasma/drug effects
EDAT- 2007/12/01 09:00
MHDA- 2007/12/13 09:00
CRDT- 2007/12/01 09:00
PHST- 2007/12/01 09:00 [pubmed]
PHST- 2007/12/13 09:00 [medline]
PHST- 2007/12/01 09:00 [entrez]
PST - ppublish
SO  - Acta Odontol Latinoam. 2007;20(1):3-8.

PMID- 8083901
OWN - NLM
STAT- MEDLINE
DCOM- 19941012
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 37
IP  - 3
DP  - 1994 Sep
TI  - The efficacy of diaspirin crosslinked hemoglobin solution resuscitation in a 
      model of uncontrolled hemorrhage.
PG  - 408-12
AB  - Controversy exists whether early aggressive fluid therapy in the setting of 
      uncontrolled hemorrhage worsens outcome by increasing blood loss from injured 
      vessels. Since diaspirin crosslinked hemoglobin (DCLHb) is a vasoactive, 
      oxygen-carrying solution, we compared the effects of DCLHb with other 
      resuscitative fluids on blood loss, hemodynamics, and tissue oxygen delivery in a 
      model of uncontrolled hemorrhage. Anesthetized rats (250-350 g) were subjected to 
      a 50% tail transection and resuscitated 15 minutes later with 1:1 DCLHb, 3:1 
      lactated Ringer's solution (LR), 1:1 hypertonic saline (7.5% HTS), or 1:1 human 
      serum albumin (8.3% HSA) based on initial volume of blood loss (average 4.7 +/- 
      0.3 mL/kg). An unresuscitated group served as a control. Cumulative blood loss 
      was measured at 5 hours postresuscitation. By 15 minutes after tail transection, 
      mean arterial pressure (MAP) decreased 19.2 +/- 3.8 mm Hg from the baseline value 
      (102 +/- 5 mm Hg). The DCLHb solution restored and maintained MAP and 
      subcutaneous tissue oxygen tension at baseline values better than all other 
      resuscitative fluids. Although blood loss in DCLHb-treated animals was greater 
      than in unresuscitated animals, it was no different from other resuscitative 
      fluids and less than with HSA. There was no difference in 24-hour survival 
      between all treatment groups. In conclusion, DCLHb elevates MAP but does not 
      exacerbate blood loss or compromise tissue oxygen delivery compared with other 
      resuscitative fluids in this model of uncontrolled hemorrhage.
FAU - Schultz, S C
AU  - Schultz SC
AD  - Department of Surgery, F. Edward Hebert School of Medicine, Uniformed Services 
      University of the Health Sciences, Bethesda, Maryland.
FAU - Powell, C C
AU  - Powell CC
FAU - Burris, D G
AU  - Burris DG
FAU - Nguyen, H
AU  - Nguyen H
FAU - Jaffin, J
AU  - Jaffin J
FAU - Malcolm, D S
AU  - Malcolm DS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Hemoglobins)
RN  - 0 (Isotonic Solutions)
RN  - 0 (Saline Solution, Hypertonic)
RN  - 0 (Serum Albumin)
RN  - 8026-10-6 (Ringer's Solution)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Disease Models, Animal
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/*pharmacology/therapeutic use
MH  - Hemorrhage/*drug therapy/physiopathology
MH  - Isotonic Solutions/pharmacology
MH  - Male
MH  - Oxygen/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - *Resuscitation
MH  - Ringer's Solution
MH  - Saline Solution, Hypertonic/pharmacology
MH  - Serum Albumin/pharmacology
EDAT- 1994/09/01 00:00
MHDA- 1994/09/01 00:01
CRDT- 1994/09/01 00:00
PHST- 1994/09/01 00:00 [pubmed]
PHST- 1994/09/01 00:01 [medline]
PHST- 1994/09/01 00:00 [entrez]
AID - 10.1097/00005373-199409000-00013 [doi]
PST - ppublish
SO  - J Trauma. 1994 Sep;37(3):408-12. doi: 10.1097/00005373-199409000-00013.

PMID- 1996795
OWN - NLM
STAT- MEDLINE
DCOM- 19910322
LR  - 20190717
IS  - 0196-0644 (Print)
IS  - 0196-0644 (Linking)
VI  - 20
IP  - 2
DP  - 1991 Feb
TI  - The adsorption of salicylates by a milk chocolate-charcoal mixture.
PG  - 143-6
AB  - STUDY OBJECTIVE: To evaluate the adsorptive capacity of a milk chocolate-charcoal 
      mixture to aspirin, compared with superactivated charcoal and conventional 
      activated charcoal. DESIGN: A prospective, randomized, crossover study. SETTING: 
      The Massachusetts Poison Control Center office in The Children's Hospital, 
      Boston. TYPE OF PARTICIPANTS: Six healthy adult volunteers with no known 
      allergies to aspirin or chocolate, bleeding disorders, or peptic ulcer disease. 
      INTERVENTIONS: Each participant ingested 975 mg of crushed aspirin on separate 
      days, followed by either water; 10 g milk chocolate-charcoal mixture; 10 g 
      SuperChar Liquid; or 10 g Actidose Aqua activated charcoal. Total serum 
      salicylate concentrations were determined by high-performance liquid 
      chromatography at zero, one, two, four, eight, and 24 hours after ingestion. 
      MEASUREMENTS AND MAIN RESULTS: Neuman-Keuls analysis was used to measure 
      time-to-peak concentration, which was reduced by SuperChar Liquid, 67%; milk 
      chocolate-charcoal mixture, 106%; and activated charcoal, 56%. Aspirin absorption 
      was calculated using Neuman-Keuls analysis to measure area under the 
      concentration-time curve. Total aspirin absorption was reduced by SuperChar, 67%; 
      milk chocolate-charcoal mixture, 50%; and activated charcoal, 2%. There was no 
      difference in serum salicylate concentrations between SuperChar and milk 
      chocolate-charcoal mixture at all time intervals. Also, all serum salicylate 
      concentrations with milk chocolate-charcoal mixture were consistently lower than 
      with activated charcoal. CONCLUSION: Although the formulation of milk chocolate 
      with activated charcoal reduces its adsorptive capacity compared with 
      superactivated charcoal, it is still able to bind aspirin effectively and is 
      superior to conventional activated charcoal. Further research may improve the 
      binding and palatability of milk chocolate-charcoal mixture, especially for home 
      use.
FAU - Eisen, T F
AU  - Eisen TF
AD  - Division of Clinical Pharmacology/Toxicology, Children's Hospital, Boston, 
      Massachusetts.
FAU - Grbcich, P A
AU  - Grbcich PA
FAU - Lacouture, P G
AU  - Lacouture PG
FAU - Shannon, M W
AU  - Shannon MW
FAU - Woolf, A
AU  - Woolf A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Adult
MH  - Aspirin/blood/*pharmacokinetics
MH  - *Cacao
MH  - *Charcoal
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Prospective Studies
EDAT- 1991/02/01 00:00
MHDA- 1991/02/01 00:01
CRDT- 1991/02/01 00:00
PHST- 1991/02/01 00:00 [pubmed]
PHST- 1991/02/01 00:01 [medline]
PHST- 1991/02/01 00:00 [entrez]
AID - S0196-0644(05)81212-0 [pii]
AID - 10.1016/s0196-0644(05)81212-0 [doi]
PST - ppublish
SO  - Ann Emerg Med. 1991 Feb;20(2):143-6. doi: 10.1016/s0196-0644(05)81212-0.

PMID- 6973525
OWN - NLM
STAT- MEDLINE
DCOM- 19811014
LR  - 20131121
IS  - 0015-5691 (Print)
IS  - 0015-5691 (Linking)
VI  - 77
IP  - 1
DP  - 1981 Jan
TI  - [The antipyretic effects of aminopyrine and sodium acetylsalicylate on 
      endotoxin-induced fever in rabbits (author's transl)].
PG  - 9-13
AB  - The antipyretic effects of aminopyrine and sodium acetylsalicylate on 
      endotoxin-induced fever in rabbits were studied relative to the route and dose of 
      administration. Intravenous administration of aminopyrine produced a marked 
      antipyretic effect, intracisternal administration produced a lesser effect and 
      i.v. was the effective route. Similar results were obtained in the nonfebrile 
      rabbits. On the contrary, the intracisternal administration of sodium 
      acetylsalicylate reduced the body temperature to the same degree both in febrile 
      and nonfebrile rabbits, but sodium acetylsalicylate given i.v. to nonfebrile 
      rabbits did not reduce the body temperature. 4-aminoantipyrine and 
      N-acetyl-4-aminoantipyrine, the major metabolites of aminopyrine had a lesser 
      effect in the febrile rabbits. Antipyretic effects of sodium salicylate, the 
      metabolite of sodium acetylsalicylate were similar to the effects of sodium 
      acetylsalicylate. These data suggest that the antipyretic effects of aminopyrine 
      may not be involved in the CNS, while the antipyretic effects of salicylate may 
      be due to a direct action on the CNS.
FAU - Nishio, A
AU  - Nishio A
FAU - Kanoh, S
AU  - Kanoh S
LA  - jpn
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Yakurigaku Zasshi
JT  - Nihon yakurigaku zasshi. Folia pharmacologica Japonica
JID - 0420550
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Endotoxins)
RN  - 01704YP3MO (Aminopyrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aminopyrine/metabolism/*pharmacology
MH  - Animals
MH  - *Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/metabolism/*pharmacology
MH  - Body Temperature/drug effects
MH  - *Endotoxins
MH  - Fever/*chemically induced
MH  - Male
MH  - Rabbits
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Nihon Yakurigaku Zasshi. 1981 Jan;77(1):9-13.

PMID- 9166175
OWN - NLM
STAT- MEDLINE
DCOM- 19970612
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 176
IP  - 5
DP  - 1997 May
TI  - Do low-risk pregnant women with antiphospholipid antibodies need to be treated? 
      Organizing Group of the Antiphospholipid Antibody Treatment Trial.
PG  - 1099-100
AB  - We identified 19 women who had persistently positive test results for 
      antiphospholipid antibodies who were considered to be at low risk because they 
      had none of the associated signs or symptoms of the antiphospholipid antibody 
      syndrome. They had had no (10/19, 53%) or just one prior spontaneous abortion and 
      did not have a history of thrombosis or thrombocytopenia. Many (8/19, 42%) had 
      had a prior uncomplicated pregnancy ending in a live birth. These women were 
      randomly assigned to receive low-dose aspirin (81 mg daily) or usual care. There 
      were few obstetric complications recorded in either treatment group. One woman in 
      the aspirin group had a fetal death, and one in the usual care group had a 
      low-birth-weight infant. The frequency of complications was so low that > 600 
      such women would need to be entered into a randomized trial to evaluate whether 
      low-dose aspirin would be beneficial treatment during a pregnancy. We concluded 
      that treatment of pregnant women with antiphospholipid antibodies who are 
      otherwise at low risk cannot be justified on the basis of the available evidence.
FAU - Cowchock, S
AU  - Cowchock S
AD  - Jefferson Medical College, Thomas Jefferson University, Philadelphia, 
      Pennsylvania, USA.
FAU - Reece, E A
AU  - Reece EA
LA  - eng
GR  - 080-02154/PHS HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Antibodies, Antiphospholipid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Antiphospholipid/*blood
MH  - Antiphospholipid Syndrome/*drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Risk Factors
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - S0002-9378(97)70409-5 [pii]
AID - 10.1016/s0002-9378(97)70409-5 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1997 May;176(5):1099-100. doi: 
      10.1016/s0002-9378(97)70409-5.

PMID- 29305829
OWN - NLM
STAT- MEDLINE
DCOM- 20181127
LR  - 20181202
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 218
IP  - 5
DP  - 2018 May
TI  - Meta-analysis on the effect of aspirin use for prevention of preeclampsia on 
      placental abruption and antepartum hemorrhage.
PG  - 483-489
LID - S0002-9378(17)32812-0 [pii]
LID - 10.1016/j.ajog.2017.12.238 [doi]
AB  - OBJECTIVE DATA: Impaired placentation in the first 16 weeks of pregnancy is 
      associated with increased risk of subsequent development of preeclampsia, birth 
      of small-for-gestational-age neonates, and placental abruption. Previous studies 
      reported that prophylactic use of aspirin reduces the risk of preeclampsia and 
      small-for-gestational-age neonates with no significant effect on placental 
      abruption. However, meta-analyses of randomized controlled trials that examined 
      the effect of aspirin in relation to gestational age at onset of therapy and 
      dosage of the drug reported that significant reduction in the risk of 
      preeclampsia and small-for-gestational-age neonates is achieved only if the onset 
      of treatment is at ≤16 weeks of gestation and the daily dosage of the drug is 
      ≥100 mg. STUDY: We aimed to estimate the effect of aspirin on the risk of 
      placental abruption or antepartum hemorrhage in relation to gestational age at 
      onset of therapy and the dosage of the drug. STUDY APPRAISAL AND SYNTHESIS 
      METHODS: To perform a systematic review and meta-analysis of randomized 
      controlled trials that evaluated the prophylactic effect of aspirin during 
      pregnancy, we used PubMed, Cinhal, Embase, Web of Science and Cochrane library 
      from 1985 to September 2017. Relative risks of placental abruption or antepartum 
      hemorrhage with their 95% confidence intervals were calculated with the use of 
      random effect models. Analyses were stratified according to daily dose of aspirin 
      (<100 and ≥100 mg) and the gestational age at the onset of therapy (≤16 and >16 
      weeks of gestation) and compared with the use of subgroup difference analysis. 
      RESULTS: The entry criteria were fulfilled by 20 studies on a combined total of 
      12,585 participants. Aspirin at a dose of <100 mg per day had no impact on the 
      risk of placental abruption or antepartum hemorrhage, irrespective of whether it 
      was initiated at ≤16 weeks of gestation (relative risk, 1.11; 95% confidence 
      interval, 0.52-2.36) or at >16 weeks of gestation (relative risk, 1.32; 95% 
      confidence interval, 0.73-2.39). At ≥100 mg per day, aspirin was not associated 
      with a significant change on the risk of placental abruption or antepartum 
      hemorrhage, whether the treatment was initiated at ≤16 weeks of gestation 
      (relative risk, 0.62, 95% confidence interval, 0.31-1.26), or at >16 weeks of 
      gestation (relative risk, 2.08; 95% confidence interval, 0.86-5.06), but the 
      difference between the subgroups was significant (P=.04). CONCLUSION: Aspirin at 
      a daily dose of ≥100 mg for prevention of preeclampsia that is initiated at ≤16 
      weeks of gestation, rather than >16 weeks, may decrease the risk of placental 
      abruption or antepartum hemorrhage.
CI  - Copyright © 2018 Elsevier Inc. All rights reserved.
FAU - Roberge, Stephanie
AU  - Roberge S
AD  - Harris Birthright Research Centre of Fetal Medicine, Fetal Medicine Research 
      Institute, King's College Hospital, London, UK. Electronic address: 
      stephanie.g.roberge@gmail.com.
FAU - Bujold, Emmanuel
AU  - Bujold E
AD  - Department of Obstetrics and Gynecology & Department of Social and Preventive 
      Medicine, Faculty of Medicine, Université Laval, Quebec City, Qc, Canada.
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
AD  - Harris Birthright Research Centre of Fetal Medicine, Fetal Medicine Research 
      Institute, King's College Hospital, London, UK.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20180103
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abruptio Placentae/*chemically induced
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - aspirin
OT  - placental abruption
OT  - preeclampsia
OT  - pregnancy
EDAT- 2018/01/07 06:00
MHDA- 2018/11/28 06:00
CRDT- 2018/01/07 06:00
PHST- 2017/11/13 00:00 [received]
PHST- 2017/12/23 00:00 [revised]
PHST- 2017/12/28 00:00 [accepted]
PHST- 2018/01/07 06:00 [pubmed]
PHST- 2018/11/28 06:00 [medline]
PHST- 2018/01/07 06:00 [entrez]
AID - S0002-9378(17)32812-0 [pii]
AID - 10.1016/j.ajog.2017.12.238 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2018 May;218(5):483-489. doi: 10.1016/j.ajog.2017.12.238. 
      Epub 2018 Jan 3.

PMID- 2009817
OWN - NLM
STAT- MEDLINE
DCOM- 19910507
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 99
IP  - 4 Suppl
DP  - 1991 Apr
TI  - The pharmacology of aspirin, heparin, coumarin, and thrombolytic agents. 
      Implications for therapeutic use in cardiopulmonary disease.
PG  - 97S-112S
AB  - The modern treatment of cardiopulmonary disease is increasingly predicated on the 
      goal of dissolving the offending clot to establish vascular patency as rapidly as 
      possible and then preventing rethrombosis. The availability of thrombolytic 
      agents has made this therapeutic approach possible and the adjunctive use of 
      heparin, coumarin, and aspirin has increased the efficacy of lytic drugs. The 
      administration of any of these medications is associated with inherent risks, 
      which are enhanced when they are used concomitantly. An understanding of 
      coagulation and an appreciation of the pathophysiologic processes of the 
      thrombotic events occurring in cardiopulmonary disease states are critical to the 
      formulation of innovative therapeutic regimens that maximize efficacy and safety. 
      Furthermore, knowledge of the comparative pharmacology of the various 
      thrombolytic agents is useful in explaining the benefits and complications 
      observed in clinical trials.
FAU - Kessler, C M
AU  - Kessler CM
AD  - Division of Hematology-Oncology, George Washington University Medical Center, 
      Washington, DC.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Coumarins)
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - A4VZ22K1WT (coumarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Coumarins/*pharmacology/therapeutic use
MH  - Fibrinolytic Agents/*pharmacology/therapeutic use
MH  - Heparin/*pharmacology/therapeutic use
MH  - Humans
MH  - Thromboembolism/therapy
MH  - *Thrombolytic Therapy
MH  - Thrombosis/therapy
RF  - 67
EDAT- 1991/04/01 00:00
MHDA- 1991/04/01 00:01
CRDT- 1991/04/01 00:00
PHST- 1991/04/01 00:00 [pubmed]
PHST- 1991/04/01 00:01 [medline]
PHST- 1991/04/01 00:00 [entrez]
AID - 10.1378/chest.99.4.97s [doi]
PST - ppublish
SO  - Chest. 1991 Apr;99(4 Suppl):97S-112S. doi: 10.1378/chest.99.4.97s.

PMID- 3988614
OWN - NLM
STAT- MEDLINE
DCOM- 19850531
LR  - 20191030
IS  - 0146-2776 (Print)
IS  - 0146-2776 (Linking)
VI  - 11
IP  - 2
DP  - 1985 Mar
TI  - Intraocular lenses and anticoagulation and antiplatelet therapy.
PG  - 165-8
AB  - Questionnaires were sent to 200 members of the American Intra-Ocular Implant 
      Society to assess the preoperative, intraoperative, and postoperative management 
      trends with intraocular lens implant patients on warfarin sodium and aspirin 
      therapy. Responses were received from 135 members. A sizable majority of 
      practitioners (75%) withhold warfarin sodium both prior to and following surgery. 
      In many cases, the medicine is withheld for longer than is necessary, increasing 
      the risk of medical complications. Respondents slightly favored (53%) 
      discontinuing aspirin, which is perceived to be less harmful than warfarin 
      sodium, preoperatively. Although management decisions must be individualized, 
      according to both the surgeon's technique and the particular patient, certain 
      general guidelines are applicable.
FAU - Stone, L S
AU  - Stone LS
FAU - Kline, O R Jr
AU  - Kline OR Jr
FAU - Sklar, C
AU  - Sklar C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Am Intraocul Implant Soc
JT  - Journal - American Intra-Ocular Implant Society
JID - 7701858
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Hemorrhage/etiology
MH  - Humans
MH  - *Lenses, Intraocular
MH  - Surveys and Questionnaires
MH  - Warfarin/adverse effects/therapeutic use
EDAT- 1985/03/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1985/03/01 00:00
PHST- 1985/03/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1985/03/01 00:00 [entrez]
AID - 10.1016/s0146-2776(85)80013-6 [doi]
PST - ppublish
SO  - J Am Intraocul Implant Soc. 1985 Mar;11(2):165-8. doi: 
      10.1016/s0146-2776(85)80013-6.

PMID- 1425318
OWN - NLM
STAT- MEDLINE
DCOM- 19921223
LR  - 20131121
IS  - 0341-6593 (Print)
IS  - 0341-6593 (Linking)
VI  - 99
IP  - 10
DP  - 1992 Oct
TI  - Acetylsalicylic acid and blood coagulation in the horse.
PG  - 410-2
AB  - Equine blood may contain salicylic acid (SA) taken up as free acid or represents 
      the metabolite of acetylsalicylic acid (ASA). To obtain information of SA in race 
      horses we screened blood samples of trotting-horses routinely drawn to be 
      analyzed for doping substances. The individual values determined followed a 
      Gaussian distribution displaying a geometric mean of 19 ng SA per ml serum. A 
      probit analysis revealed linear relationship (r = 0.995). Additional studies 
      examined the antithrombotic efficacy of ASA in the horse. An oral dose of 300 mg 
      ASA considerably elevated the bleeding time for more than 2 hours with 
      concomitant SA serum levels between 800 and 1000 ng/ml. It is concluded that 
      salicylate levels even below 1 microgram/ml serum bring about considerable 
      pharmacologic effects such as prolongation of bleeding time, decrease in blood 
      viscosity and possibly dilatation of blood vessels. These effects may improve the 
      tissue supply with blood including oxygen.
FAU - Hagedorn, H W
AU  - Hagedorn HW
AD  - Institute of Pharmacology, Toxicology and Pharmacy, Klinikum Grosshadern, 
      University of Munich.
FAU - Böck, M
AU  - Böck M
FAU - Schulz, R
AU  - Schulz R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Dtsch Tierarztl Wochenschr
JT  - DTW. Deutsche tierarztliche Wochenschrift
JID - 7706565
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*blood/pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Gas Chromatography-Mass Spectrometry
MH  - Horses/*blood
MH  - Platelet Aggregation/*drug effects
MH  - Reference Values
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
PST - ppublish
SO  - Dtsch Tierarztl Wochenschr. 1992 Oct;99(10):410-2.

PMID- 7162386
OWN - NLM
STAT- MEDLINE
DCOM- 19830407
LR  - 20190830
IS  - 0195-9131 (Print)
IS  - 0195-9131 (Linking)
VI  - 14
IP  - 6
DP  - 1982
TI  - Effects of aspirin treatment on kidney function in exercising man.
PG  - 419-23
AB  - The effects of aspirin treatment on kidney excretory function were investigated 
      in treadmill-exercised men. Six individuals ran for 30 min at 70% of their 
      maximal oxygen consumption. Exercise tests were conducted for control and 
      aspirin-treated conditions. Aspirin (3.25 g/d) was administered for 3 d prior to 
      testing. Experiments were carried out with the subjects non-hydrated and hydrated 
      (4 ml H2O/kg body weight). Aspirin treatment did not influence the alterations in 
      creatinine clearance, urine volume, osmolar clearance, and/or sodium and 
      potassium excretion seen with exercise. The only effect of aspirin was observed 
      in the recovery samples of the non-hydrated tests in which aspirin treatment 
      significantly decreased urine volume and increased urine specific gravity, 
      osmolality, and the urine/plasma osmolality ratio. These results suggest that 
      aspirin treatment does not have any significant effects on the renal excretory 
      response to short-term moderate exercise.
FAU - Zambraski, E J
AU  - Zambraski EJ
FAU - Rofrano, T A
AU  - Rofrano TA
FAU - Ciccone, C D
AU  - Ciccone CD
LA  - eng
GR  - HL 25255/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Med Sci Sports Exerc
JT  - Medicine and science in sports and exercise
JID - 8005433
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Kidney/*drug effects/physiology
MH  - Male
MH  - *Physical Exertion
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1249/00005768-198206000-00002 [doi]
PST - ppublish
SO  - Med Sci Sports Exerc. 1982;14(6):419-23. doi: 10.1249/00005768-198206000-00002.

PMID- 31467716
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20200622
IS  - 2090-2735 (Electronic)
IS  - 2090-2727 (Print)
IS  - 2090-2727 (Linking)
VI  - 2019
DP  - 2019
TI  - Evidence-Based Prevention of Preeclampsia: Commonly Asked Questions in Clinical 
      Practice.
PG  - 2675101
LID - 10.1155/2019/2675101 [doi]
LID - 2675101
AB  - In this review, we discuss the recent literature regarding the prevention of 
      preeclampsia and aim to answer common questions that arise in the routine 
      antenatal care of pregnant women. Prescription of low-dose aspirin for high-risk 
      patients has been shown to reduce the risk of preeclampsia (PE). A daily dose 
      between 100 and 150 mg taken in the evening should be initiated prior to 16 weeks 
      of gestation and can be continued until delivery. Calcium supplementation seems 
      to be advantageous but currently it is only considered for patients with poor 
      dietary intake and high risk for PE. Recent data about heparin are still 
      conflicting, and therefore, heparin can currently not be recommended in the 
      prevention of PE.
FAU - Wertaschnigg, Dagmar
AU  - Wertaschnigg D
AUID- ORCID: 0000-0002-1874-5778
AD  - Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, 
      Australia.
AD  - Department of Obstetrics and Gynecology, Paracelsus Medical University, Salzburg, 
      Austria.
FAU - Reddy, Maya
AU  - Reddy M
AD  - Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, 
      Australia.
AD  - Monash Women's, Monash Health, Clayton Victoria, Australia.
FAU - Mol, Ben W J
AU  - Mol BWJ
AUID- ORCID: 0000-0001-8337-550X
AD  - Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, 
      Australia.
AD  - Monash Women's, Monash Health, Clayton Victoria, Australia.
FAU - da Silva Costa, Fabricio
AU  - da Silva Costa F
AUID- ORCID: 0000-0003-0693-7032
AD  - Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, 
      Australia.
AD  - Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, 
      University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
FAU - Rolnik, Daniel L
AU  - Rolnik DL
AUID- ORCID: 0000-0002-2263-3592
AD  - Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, 
      Australia.
AD  - Monash Women's, Monash Health, Clayton Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190801
PL  - Egypt
TA  - J Pregnancy
JT  - Journal of pregnancy
JID - 101553823
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Evidence-Based Medicine
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Prenatal Care/*methods
MH  - Risk Assessment
PMC - PMC6699262
COIS- Ben W. J. Mol is supported by a NHMRC Practitioner Fellowship [GNT1082548]. Ben 
      W. J. Mol reports consultancy for ObsEva, Merck Merck KGaA, and Guerbet. The 
      other authors report no conflicts of interest.
EDAT- 2019/08/31 06:00
MHDA- 2020/06/23 06:00
CRDT- 2019/08/31 06:00
PHST- 2019/02/11 00:00 [received]
PHST- 2019/07/11 00:00 [accepted]
PHST- 2019/08/31 06:00 [entrez]
PHST- 2019/08/31 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
AID - 10.1155/2019/2675101 [doi]
PST - epublish
SO  - J Pregnancy. 2019 Aug 1;2019:2675101. doi: 10.1155/2019/2675101. eCollection 
      2019.

PMID- 35410433
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220531
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 23
IP  - 1
DP  - 2022 Apr 11
TI  - Efficacy and safety of lumbrokinase plus aspirin versus aspirin alone for acute 
      ischemic stroke (LUCENT): study protocol for a multicenter randomized controlled 
      trial.
PG  - 285
LID - 10.1186/s13063-022-06200-4 [doi]
LID - 285
AB  - BACKGROUND: Lumbrokinase has been widely used for patients with acute ischemic 
      stroke (AIS) in China; however, because rigorously designed studies are lacking, 
      safety and efficacy of lumbrokinase in the treatment of acute ischemic stroke 
      remains largely unknown. In this multicenter, randomized, and controlled trial, 
      we aim to compare lumbrokinase plus aspirin versus aspirin alone in patients with 
      acute ischemic stroke. METHODS: A total of 220 eligible participants will be 
      randomized to either the intervention or control group with a 1:1 ratio. These 
      participants must be diagnosed with acute ischemic stroke for the first time, 
      whose symptoms appear within 72 h. Their NIHSS score must be greater than 5 and 
      less than 15, and their age must be between 35 and 85 years old. They must have 
      not received intravenous thrombolysis, arterial thrombolysis, or intravascular 
      intervention. Participants in the intervention group will be treated with 
      lumbrokinase plus aspirin for the first 90 days. Participants in the control 
      group will use placebo plus aspirin for the first 90 days. Then, all participants 
      will be treated with aspirin only and followed up for another 90 days (180-day 
      follow-up). The primary outcome is the modified Rankin Scale (mRS) score. The 
      secondary outcomes are National Institutes of Health Stroke Scale (NIHSS) score, 
      Activity of Daily Living (ADL) Scale score, coagulation function, and serum 
      hypersensitive C-reactive protein. The exploratory outcomes are fasting lipid 
      panel, recurrence rate, the occurrence of cardiovascular and cerebrovascular 
      events, and the mortality rate. Safety evaluations include liver function and 
      kidney function, serum fibrinogen, adverse events, serious adverse events, and 
      bleeding events. Adherence of participants will also be assessed. DISCUSSION: 
      This trial will investigate the efficacy and safety of lumbrokinase plus aspirin 
      as compared to aspirin alone in the treatment of acute ischemic stroke. TRIAL 
      REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2000032952 . Registered on 
      May 16, 2020.
CI  - © 2022. The Author(s).
FAU - Chen, Ying
AU  - Chen Y
AUID- ORCID: 0000-0001-6334-3113
AD  - Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen 
      Hospital, Beijing University of Chinese Medicine, No.5 Haiyuncang, Dongcheng 
      District, Beijing, 100700, China.
AD  - Beijing University of Chinese Medicine, Beijing, 100029, China.
FAU - Liu, Yan
AU  - Liu Y
AD  - Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen 
      Hospital, Beijing University of Chinese Medicine, No.5 Haiyuncang, Dongcheng 
      District, Beijing, 100700, China.
FAU - Zhang, Jingjing
AU  - Zhang J
AD  - Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen 
      Hospital, Beijing University of Chinese Medicine, No.5 Haiyuncang, Dongcheng 
      District, Beijing, 100700, China.
AD  - Beijing University of Chinese Medicine, Beijing, 100029, China.
FAU - Zhou, Kehua
AU  - Zhou K
AD  - Department of Hospital Medicine, ThedaCare Regional Medical Center-Appleton, 
      Appleton, WI, 54911, USA.
FAU - Zhang, Xuecheng
AU  - Zhang X
AD  - Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen 
      Hospital, Beijing University of Chinese Medicine, No.5 Haiyuncang, Dongcheng 
      District, Beijing, 100700, China.
AD  - Beijing University of Chinese Medicine, Beijing, 100029, China.
FAU - Dai, Hengheng
AU  - Dai H
AD  - Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen 
      Hospital, Beijing University of Chinese Medicine, No.5 Haiyuncang, Dongcheng 
      District, Beijing, 100700, China.
AD  - Beijing University of Chinese Medicine, Beijing, 100029, China.
FAU - Yang, Baolin
AU  - Yang B
AD  - Department of Encephalopathy, Dongzhimen Hospital, Beijing University of Chinese 
      Medicine, Beijing, 100700, China.
FAU - Shang, Hongcai
AU  - Shang H
AD  - Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen 
      Hospital, Beijing University of Chinese Medicine, No.5 Haiyuncang, Dongcheng 
      District, Beijing, 100700, China. shanghongcai@126.com.
LA  - eng
GR  - 81725024/National Science Fund for Distinguished Young Scholars, China/
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20220411
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - EC 3.4.- (Endopeptidases)
RN  - EC 3.4.99.- (lumbrokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aspirin/adverse effects/therapeutic use
MH  - Drug Therapy, Combination/adverse effects
MH  - *Endopeptidases/therapeutic use
MH  - Humans
MH  - *Ischemic Stroke/drug therapy
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
PMC - PMC8996506
OTO - NOTNLM
OT  - Acute ischemic stroke
OT  - Aspirin
OT  - Lumbrokinase
OT  - Multicenter randomized controlled trial
OT  - Trial protocol
COIS- The authors declare that they have no competing interests.
EDAT- 2022/04/13 06:00
MHDA- 2022/04/14 06:00
CRDT- 2022/04/12 05:22
PHST- 2020/12/08 00:00 [received]
PHST- 2022/03/26 00:00 [accepted]
PHST- 2022/04/12 05:22 [entrez]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
AID - 10.1186/s13063-022-06200-4 [pii]
AID - 6200 [pii]
AID - 10.1186/s13063-022-06200-4 [doi]
PST - epublish
SO  - Trials. 2022 Apr 11;23(1):285. doi: 10.1186/s13063-022-06200-4.

PMID- 3454169
OWN - NLM
STAT- MEDLINE
DCOM- 19880919
LR  - 20131121
IS  - 0397-9148 (Print)
IS  - 0397-9148 (Linking)
VI  - 19
IP  - 1
DP  - 1987 Jan
TI  - [Reactions to metabisulfites in aspirin-induced asthma].
PG  - 25-8
AB  - We have observed in some patients that some Aspirin sensitive asthmatic present 
      also a dyspnea after wine or foods containing sulfites ingestion. Owing to a 
      study using ingestion test, with spirometric control, we show that sulfite 
      sensitive asthma is more frequent in patients with Aspirin sensitive asthma than 
      in the others. In the two cases, these molecules trigger off an asthma attack 
      with same symptomatology, same severity, that is to say, frequently of IV type, 
      with corticodependance. Diagnosis allow to an adapted treatment and so a better 
      prognosis of these asthma.
FAU - Sabbah, A
AU  - Sabbah A
AD  - Laboratoire d'Immuno-Allergologie, C.H.R., Angers.
FAU - Drouet, M
AU  - Drouet M
FAU - Bonneau, J C
AU  - Bonneau JC
FAU - Le Sellin, J
AU  - Le Sellin J
LA  - fre
PT  - Case Reports
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Réactions aux métabisulfites dans l'asthme induit par l'aspirine.
PL  - France
TA  - Allerg Immunol (Paris)
JT  - Allergie et immunologie
JID - 0245775
RN  - 0 (Food Additives)
RN  - 0 (Sulfites)
RN  - 7992SO049K (metabisulfite)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced/diagnosis
MH  - Drug Hypersensitivity/diagnosis/*etiology
MH  - Female
MH  - Food Additives/*adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Spirometry
MH  - Sulfites/*adverse effects
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Allerg Immunol (Paris). 1987 Jan;19(1):25-8.

PMID- 17568403
OWN - NLM
STAT- MEDLINE
DCOM- 20071127
LR  - 20161124
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 96
IP  - 9
DP  - 2007 Sep
TI  - A solid-state chemist's view of the crystal polymorphism of organic compounds.
PG  - 2232-41
AB  - In a survey of some structural and energetic aspects of crystal polymorphism, 
      definitions are proposed, and a method for generating an unequivocal fingerprint 
      of the cohesive pattern of an organic crystal structure is presented. The method 
      identifies the electronic nature of molecule-molecule interactions in crystals, 
      and its application requires a minimal training in basic crystallography and 
      molecular modeling. The analysis suggests that thermodynamic and physical 
      properties of polymorphs of organic crystals are quite often very similar, and 
      sometimes depend on morphology as well as on crystal structure. It is also 
      suggested that real polymorphism should be distinguished from the many defective 
      or modulated structural variations often appearing in the crystallization of 
      weakly bound molecular materials.
CI  - (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.
FAU - Gavezzotti, Angelo
AU  - Gavezzotti A
AD  - Department of Structural Chemistry and Faculty of Pharmacy, The University of 
      Milano, Italy. angelo.gavezzotti@unimi.it
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Organic Chemicals)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - *Crystallization
MH  - Organic Chemicals/*chemistry
MH  - Terminology as Topic
MH  - Thermodynamics
EDAT- 2007/06/15 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/06/15 09:00
PHST- 2007/06/15 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/06/15 09:00 [entrez]
AID - S0022-3549(16)32335-8 [pii]
AID - 10.1002/jps.20870 [doi]
PST - ppublish
SO  - J Pharm Sci. 2007 Sep;96(9):2232-41. doi: 10.1002/jps.20870.

PMID- 7444376
OWN - NLM
STAT- MEDLINE
DCOM- 19810224
LR  - 20190909
IS  - 0036-553X (Print)
IS  - 0036-553X (Linking)
VI  - 25
IP  - 1
DP  - 1980 Jul
TI  - Dosage of acetylsalicylic acid for inhibition of platelet function.
PG  - 76-80
AB  - In normal males, platelet prostaglandin synthesis as measured by malondialdehyde 
      (MDA) production is blocked by more than 90% after administration of 600 mg of 
      calciumacetylsalicylic acid and by more than 50% after 100 mg. Repeated doses of 
      100 mg at 12 h intervals progressively decrease MDA production to below 10% of 
      the basic value. Bleeding time increases from 3.38 +/- 0.36 min to 7.73 0.91 min 
      (mean +/- SEM). The data indicate that 12 h 100 mg doses of 
      calciumacetylsalicylic acid (equal to 80 mg of aspirin) adequately inhibit 
      platelet function.
FAU - Huijgens, P C
AU  - Huijgens PC
FAU - van den Berg, C A
AU  - van den Berg CA
FAU - van der Meer, C
AU  - van der Meer C
FAU - Imandt, L M
AU  - Imandt LM
FAU - Langenhuijsen, M M
AU  - Langenhuijsen MM
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Denmark
TA  - Scand J Haematol
JT  - Scandinavian journal of haematology
JID - 0404507
RN  - 0 (Prostaglandins)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - Malondialdehyde/biosynthesis
MH  - Prostaglandins/*biosynthesis/blood
MH  - Thrombin
EDAT- 1980/07/01 00:00
MHDA- 1980/07/01 00:01
CRDT- 1980/07/01 00:00
PHST- 1980/07/01 00:00 [pubmed]
PHST- 1980/07/01 00:01 [medline]
PHST- 1980/07/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1981.tb01368.x [doi]
PST - ppublish
SO  - Scand J Haematol. 1980 Jul;25(1):76-80. doi: 10.1111/j.1600-0609.1981.tb01368.x.

PMID- 1957663
OWN - NLM
STAT- MEDLINE
DCOM- 19911230
LR  - 20131121
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 26
IP  - 3
DP  - 1991
TI  - [Derivative spectrophotometric--signal multiplier method and its application to 
      the determination of aspirin in Xiaoer Tuishao Pian].
PG  - 219-24
AB  - A Microcomputer was used to process the spectral data measured on a manual 
      spectrophotometer (UV-7520) for the determination of aspirin and acetaminophen in 
      Xiaoer Tuishao Pian, using the derivative spectrophotometric-signal multiplier 
      method. The method is simple and rapid. The mean recovery (%) of aspirin was 
      99.74 +/- 0.46. Dual wavelength method was used for the determination of 
      acetaminophen and the recovery was 99.54 +/- 0.52%.
FAU - Lu, R G
AU  - Lu RG
AD  - Guangxi Liuzhou Perfecture Pharmaceutical Factory, Liucheng.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Aspirin/*analysis
MH  - Drug Combinations
MH  - Mathematics
MH  - Microcomputers
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
PST - ppublish
SO  - Yao Xue Xue Bao. 1991;26(3):219-24.

PMID- 35653338
OWN - NLM
STAT- MEDLINE
DCOM- 20220802
LR  - 20230202
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 15
IP  - 8
DP  - 2022 Aug 1
TI  - Plasma Metabolomics Analysis of Aspirin Treatment and Risk of Colorectal 
      Adenomas.
PG  - 521-531
LID - 10.1158/1940-6207.CAPR-21-0555 [doi]
AB  - Despite substantial observational and experimental evidence that aspirin use can 
      provide protection against the development of colorectal neoplasia, our 
      understanding of the molecular mechanisms involved is inadequate and limits our 
      ability to use this drug effectively and safely for chemoprevention. We employed 
      an untargeted plasma metabolomics approach using liquid chromatography with 
      high-resolution mass spectroscopy to explore novel metabolites that may 
      contribute to the chemopreventive effects of aspirin. Associations between levels 
      of metabolic features in plasma and aspirin treatment were investigated among 523 
      participants in a randomized placebo-controlled clinical trial of two doses of 
      aspirin (81 or 325 mg/day) and were linked to risk of colorectal adenoma 
      occurrence over 3 years of follow-up. Metabolic pathways that were altered with 
      aspirin treatment included linoleate and glycerophospholipid metabolism for the 
      81-mg dose and carnitine shuttle for both doses. Metabolites whose levels 
      increased with 81 mg/day aspirin treatment and were also associated with 
      decreased risk of adenomas during follow-up included certain forms of 
      lysophosphatidylcholine and lysophosphatidylethanolamine as well as 
      trihydroxyoctadecenoic acid, which is a derivative of linoleic acid and is 
      upstream of cyclooxygenase inhibition by aspirin in the linoleate and arachidonic 
      acid metabolism pathways. In conclusion, our findings regarding lysophospholipids 
      and metabolites in the linoleate metabolism pathway may provide novel insights 
      into the chemopreventive effects of aspirin in the colorectum, although they 
      should be considered hypothesis-generating at this time. PREVENTION RELEVANCE: 
      This research used metabolomics, an innovative discovery-based approach, to 
      identify molecular changes in human blood that may help to explain how aspirin 
      use reduces the risk of colorectal neoplasia in some individuals. Ultimately, 
      this work could have important implications for optimizing aspirin use in the 
      prevention of colorectal cancer.
CI  - ©2022 American Association for Cancer Research.
FAU - Barry, Elizabeth L
AU  - Barry EL
AUID- ORCID: 0000-0001-9637-3036
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New 
      Hampshire.
FAU - Fedirko, Veronika
AU  - Fedirko V
AUID- ORCID: 0000-0002-7805-9913
AD  - Department of Epidemiology, University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
AD  - Department of Epidemiology, Rollins School of Public Health, Emory University, 
      Atlanta, Georgia.
FAU - Jin, Yutong
AU  - Jin Y
AUID- ORCID: 0000-0002-8996-4812
AD  - Department of Biostatistics and Bioinformatics, Rollins School of Public Health, 
      Emory University, Atlanta, Georgia.
FAU - Liu, Ken
AU  - Liu K
AUID- ORCID: 0000-0002-9736-5828
AD  - Department of Medicine, Emory University, Atlanta, Georgia.
FAU - Mott, Leila A
AU  - Mott LA
AUID- ORCID: 0000-0001-8972-7692
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New 
      Hampshire.
FAU - Peacock, Janet L
AU  - Peacock JL
AUID- ORCID: 0000-0002-0310-2518
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New 
      Hampshire.
FAU - Passarelli, Michael N
AU  - Passarelli MN
AUID- ORCID: 0000-0002-6804-2528
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New 
      Hampshire.
FAU - Baron, John A
AU  - Baron JA
AUID- ORCID: 0000-0003-3461-1056
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New 
      Hampshire.
AD  - Department of Medicine, University of North Carolina at Chapel Hill, School of 
      Medicine, Chapel Hill, North Carolina.
FAU - Jones, Dean P
AU  - Jones DP
AUID- ORCID: 0000-0002-2090-0677
AD  - Department of Medicine, Emory University, Atlanta, Georgia.
LA  - eng
GR  - R01 CA188038/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - 9KJL21T0QJ (Linoleic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Adenoma/drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - *Anticarcinogenic Agents/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Colorectal Neoplasms/epidemiology
MH  - Humans
MH  - Linoleic Acid/therapeutic use
MH  - Metabolomics
PMC - PMC9357068
MID - NIHMS1814670
COIS- Conflicts of Interest: Together with the Trustees of Dartmouth College, John A. 
      Baron holds a use patent, not currently licensed, for the chemopreventive use of 
      aspirin for colorectal cancer. All the other authors declare no potential 
      conflicts of interest.
EDAT- 2022/06/03 06:00
MHDA- 2022/08/03 06:00
CRDT- 2022/06/02 13:33
PHST- 2021/11/07 00:00 [received]
PHST- 2022/03/10 00:00 [revised]
PHST- 2022/05/26 00:00 [accepted]
PHST- 2022/06/03 06:00 [pubmed]
PHST- 2022/08/03 06:00 [medline]
PHST- 2022/06/02 13:33 [entrez]
AID - 699304 [pii]
AID - 10.1158/1940-6207.CAPR-21-0555 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2022 Aug 1;15(8):521-531. doi: 
      10.1158/1940-6207.CAPR-21-0555.

PMID- 11416989
OWN - NLM
STAT- MEDLINE
DCOM- 20011101
LR  - 20191104
IS  - 1083-7450 (Print)
IS  - 1083-7450 (Linking)
VI  - 6
IP  - 2
DP  - 2001
TI  - The influence of excipients on the stability of the moisture sensitive drugs 
      aspirin and niacinamide: comparison of tablets containing lactose monohydrate 
      with tablets containing anhydrous lactose.
PG  - 159-66
AB  - The purpose of this study is to test the hypothesis that in tablet formulations, 
      moisture-sensitive drugs formulated with lactose monohydrate have the same 
      stability as formulations containing anhydrous lactose, and to characterize the 
      kinetics of niacinamide degradation in the solid state. Aspirin and niacinamide 
      decomposition were used as indicators of stability. Aspirin and niacinamide 
      tablets containing either lactose monohydrate or anhydrous lactose were 
      separately investigated at different temperatures and relative humidities; the 
      stability tests were done at 25 degrees C--60% RH, 40 degrees C--80% RH, 60 
      degrees C--60% RH, 60 degrees C--80% RH, and 80 degrees C--80% RH. Official U.S. 
      Pharmacopeia methods were used for the aspirin and niacinamide assays. 
      Statistical analysis showed that tablets containing lactose monohydrate have the 
      same stability as tablets containing anhydrous lactose, which means that even 
      though water is present in the crystal structure, the bound water does not 
      influence the reaction rate. In addition, niacinamide degradation in the 
      solid-state can be described by a third order rate equation.
FAU - Du, J
AU  - Du J
AD  - School of Pharmacy, University of Maryland, Baltimore, 20 N. Pine Street, 
      Baltimore, MD 21201, USA.
FAU - Hoag, S W
AU  - Hoag SW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharm Dev Technol
JT  - Pharmaceutical development and technology
JID - 9610932
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - 25X51I8RD4 (Niacinamide)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/chemistry
MH  - Drug Stability
MH  - Excipients
MH  - Lactose/*administration & dosage
MH  - Niacinamide/*administration & dosage/chemistry
MH  - Tablets
MH  - Temperature
MH  - Volatilization
EDAT- 2001/06/22 10:00
MHDA- 2001/11/03 10:01
CRDT- 2001/06/22 10:00
PHST- 2001/06/22 10:00 [pubmed]
PHST- 2001/11/03 10:01 [medline]
PHST- 2001/06/22 10:00 [entrez]
AID - 10.1081/pdt-100000742 [doi]
PST - ppublish
SO  - Pharm Dev Technol. 2001;6(2):159-66. doi: 10.1081/pdt-100000742.

PMID- 21718240
OWN - NLM
STAT- MEDLINE
DCOM- 20120502
LR  - 20190911
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Linking)
VI  - 12
IP  - 12
DP  - 2011 Nov
TI  - Historical observations on the discovery of platelets, platelet function testing 
      and the first antiplatelet agent.
PG  - 1792-804
AB  - An understanding of the historical paths that have lead to our current state of 
      knowledge in the field of platelet studies can be both illuminating and 
      inspiring. Considering that the existence and function of platelets were 
      initially described just barely over 100 years ago it is exciting to recognize 
      how far our knowledge has advanced in such a relatively short period of time. 
      Within 20 years of Giulio Bizzozero's definitive description of blood platelets 
      investigators began to develop tests that could quantitate the relationship 
      between platelets, hemostasis and bleeding, and these tests have continued to be 
      refined ever since. At the same time, and well before the role of platelets and 
      antiplatelet agents in cardiovascular disease was appreciated, several clinicians 
      started using aspirin for the prevention of heart attacks. All three of these 
      paths of research - platelet biology, platelet function testing and antiplatelet 
      therapies - all converge on what is arguably one of the most important questions 
      in clinical medicine today: how to best prevent arterial thrombosis. For the 
      current and future pioneers of platelet research an understanding of how we got 
      to where we are today will hopefully allow for a clearer and inspired vision of 
      where we will go next.
FAU - Steinhubl, Steven R
AU  - Steinhubl SR
AD  - The Geisinger Health System, Danville, PA 17822, USA. srsteinhubl@geisinger.edu
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/history/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/*physiology
MH  - Hematology/*history/methods
MH  - History, 17th Century
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*history/pharmacology/therapeutic use
MH  - Platelet Function Tests/*history/instrumentation
MH  - Thrombosis/drug therapy/pathology/physiopathology
EDAT- 2011/07/02 06:00
MHDA- 2012/05/04 06:00
CRDT- 2011/07/02 06:00
PHST- 2010/07/08 00:00 [received]
PHST- 2010/12/10 00:00 [revised]
PHST- 2010/12/10 00:00 [accepted]
PHST- 2011/07/02 06:00 [entrez]
PHST- 2011/07/02 06:00 [pubmed]
PHST- 2012/05/04 06:00 [medline]
AID - BSP/CDT/E-Pub/00322 [pii]
AID - 10.2174/138945011797635858 [doi]
PST - ppublish
SO  - Curr Drug Targets. 2011 Nov;12(12):1792-804. doi: 10.2174/138945011797635858.

PMID- 3610517
OWN - NLM
STAT- MEDLINE
DCOM- 19870828
LR  - 20131121
IS  - 0250-0868 (Print)
IS  - 0250-0868 (Linking)
VI  - 9
IP  - 2
DP  - 1987
TI  - Benzydamine, an unique model of anti-inflammatory activity.
PG  - 87-91
AB  - Benzydamine is an anti-inflammatory drug with unique medical uses, namely the 
      topical treatment of oro-pharyngeal and gynaecological conditions. This paper 
      illustrates the rationale for the medical use of benzydamine. Its differences 
      from aspirin-like drugs are pointed out, and evidence is presented that 
      benzydamine does not primarily affect the PGs system, but rather reduces the cell 
      response to injury.
FAU - Silvestrini, B
AU  - Silvestrini B
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int J Tissue React
JT  - International journal of tissue reactions
JID - 8302116
RN  - 0 (Anesthetics, Local)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pyrazoles)
RN  - 4O21U048EF (Benzydamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anesthetics, Local
MH  - Animals
MH  - *Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/pharmacology/toxicity
MH  - Benzydamine/*pharmacology/toxicity
MH  - Inflammation/metabolism
MH  - Platelet Aggregation/drug effects
MH  - Pyrazoles/*pharmacology
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Tissue React. 1987;9(2):87-91.

PMID- 22517822
OWN - NLM
STAT- MEDLINE
DCOM- 20120920
LR  - 20220408
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 23
IP  - 6
DP  - 2012 Jun
TI  - Aspirin and cancer risk: a quantitative review to 2011.
PG  - 1403-15
LID - 10.1093/annonc/mds113 [doi]
AB  - BACKGROUND: Aspirin has been associated to a reduced risk of colorectal and 
      possibly of a few other common cancers. METHODS: To provide an up-to-date 
      quantification of this association, we conducted a meta-analysis of all 
      observational studies on aspirin and 12 selected cancer sites published up to 
      September 2011. RESULTS: Regular aspirin is associated with a statistically 
      significant reduced risk of colorectal cancer [summary relative risk (RR) from 
      random effects models = 0.73, 95% confidence interval (CI) 0.67-0.79], and of 
      other digestive tract cancers (RR = 0.61, 95% CI = 0.50-0.76, for squamous cell 
      esophageal cancer; RR = 0.64, 95% CI = 0.52-0.78, for esophageal and gastric 
      cardia adenocarcinoma; and RR = 0.67, 95% CI = 0.54-0.83, for gastric cancer), 
      with somewhat stronger reductions in risk in case-control than in cohort studies. 
      Modest inverse associations were also observed for breast (RR = 0.90, 95% CI = 
      0.85-0.95) and prostate cancer (RR = 0.90, 95% CI = 0.85-0.96), while lung cancer 
      was significantly reduced in case-control studies (0.73, 95% CI = 0.55-0.98) but 
      not in cohort ones (RR = 0.98, 95% CI = 0.92-1.05). No meaningful overall 
      associations were observed for cancers of the pancreas, endometrium, ovary, 
      bladder, and kidney. CONCLUSIONS: Observational studies indicate a beneficial 
      role of aspirin on colorectal and other digestive tract cancers; modest risk 
      reductions were also observed for breast and prostate cancer. Results are, 
      however, heterogeneous across studies and dose-risk and duration-risk 
      relationships are still unclear.
FAU - Bosetti, C
AU  - Bosetti C
AD  - Department of Epidemiology, Istituto di Ricerche Farmacologiche, Mario Negri, 
      Milan, Italy. cristina.bosetti@marionegri.it
FAU - Rosato, V
AU  - Rosato V
FAU - Gallus, S
AU  - Gallus S
FAU - Cuzick, J
AU  - Cuzick J
FAU - La Vecchia, C
AU  - La Vecchia C
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120419
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Neoplasms/*prevention & control
MH  - Risk
EDAT- 2012/04/21 06:00
MHDA- 2012/09/21 06:00
CRDT- 2012/04/21 06:00
PHST- 2012/04/21 06:00 [entrez]
PHST- 2012/04/21 06:00 [pubmed]
PHST- 2012/09/21 06:00 [medline]
AID - S0923-7534(19)38735-6 [pii]
AID - 10.1093/annonc/mds113 [doi]
PST - ppublish
SO  - Ann Oncol. 2012 Jun;23(6):1403-15. doi: 10.1093/annonc/mds113. Epub 2012 Apr 19.

PMID- 10726022
OWN - NLM
STAT- MEDLINE
DCOM- 20000407
LR  - 20191103
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 5
IP  - 4
DP  - 1999 Oct
TI  - Aspirin and platelet-lowering agents for the prevention of vascular complications 
      in essential thrombocythemia.
PG  - 247-51
AB  - Low-risk essential thrombocythemia patients include patients aged 18 to < 80 
      years with no vascular risk factor or previous thrombosis, no associated disease, 
      a normal life expectancy, and a platelet count between 400 and 1,000 x 10(9)/L up 
      to 1,500 x 10(9)/L. Asymptomatic essential thrombocythemia patients may be at 
      risk for microvascular circulation disturbances. The indication for low-dose 
      aspirin in asymptomatic essential thrombocythemia patients is uncertain, 
      therefore randomization for aspirin 50 mg versus placebo is recommended. 
      Symptomatic essential thrombocythemia patients with erythromelalgia and its 
      ischemic complications, atypical transient ischemic attacks, minor stroke, visual 
      disturbances and "superficial thrombophlebitis" in the absence of bleeding, 
      vascular risk factors, or vascular disease have a clear indication for aspirin in 
      a regular dose. To determine whether 50 mg/day is as effective as 100 mg/day for 
      the prophylaxis of microvascular circulation disturbances in essential 
      thrombocythemia, a randomized trial comparing low-dose aspirin 50 mg versus 100 
      mg at platelet counts between 400 and 1,000 up to 1,500 x 10(9)/L is recommended. 
      To address the question whether reduction of the platelet count to normal (< 350 
      x 10(9)/L) is as effective as low-dose aspirin for the long-term relief of 
      microvascular circulation disturbances, a randomized study comparing low-dose 
      aspirin with the correction of platelet count to normal by anagrelide is 
      recommended. High-risk essential thrombocythemia patients have a clear indication 
      for platelet reductive therapy, including: (a) platelets > 1,500 x 10(9)/L, 
      history of major thrombosis (myocardial infarction, stroke, peripheral occlusive 
      vascular disease), or presence of vascular disease (e.g., arteriosclerosis); (b) 
      history or presence of spontaneous or major bleedings, bleedings elicited by 
      low-dose aspirin for the secondary prevention of vascular complications in 
      essential thrombocythemia at platelet counts < 1500 x 10(9)/L, and side effects 
      of long-term aspirin treatment such as gastritis; and progression from low- to 
      high-risk essential thrombocythemia patients during follow-up or progressive 
      myeloproliferative disease such as significant splenomegaly, myelofibrosis, 
      leukocytosis, etc. To address the question of optimal treatment of high-risk 
      essential thrombocythemia patients, randomization for anagrelide versus 
      interferon at < 65 years of age and anagrelide versus hydroxyurea at an age > 65 
      years is recommended.
FAU - Michiels, J J
AU  - Michiels JJ
AD  - Thrombocythemia Vera Study Group, Goodheart Institute Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - *Platelet Count/drug effects
MH  - Randomized Controlled Trials as Topic
MH  - Thrombocytosis/*complications
MH  - Vascular Diseases/*etiology/*prevention & control
RF  - 42
EDAT- 2000/03/22 00:00
MHDA- 2000/03/22 00:01
CRDT- 2000/03/22 00:00
PHST- 2000/03/22 00:00 [pubmed]
PHST- 2000/03/22 00:01 [medline]
PHST- 2000/03/22 00:00 [entrez]
AID - 10.1177/107602969900500408 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 1999 Oct;5(4):247-51. doi: 10.1177/107602969900500408.

PMID- 3799892
OWN - NLM
STAT- MEDLINE
DCOM- 19870219
LR  - 20190627
IS  - 0002-9610 (Print)
IS  - 0002-9610 (Linking)
VI  - 153
IP  - 1
DP  - 1987 Jan
TI  - Protective effect of exogenous phospholipid on aspirin-induced gastric mucosal 
      injury.
PG  - 48-53
AB  - The protective effects of exogenous phospholipid on aspirin-induced gastric 
      mucosal injury were examined in a canine chamber model which provided two 
      separate segments of mucosa supplied by a single vascular pedicle. In each dog, 
      one segment was treated with a suspension of surface-active phospholipid, similar 
      in composition to that normally present in the gastric mucosa, whereas the other 
      segment served as the control. Pretreatment of the test segments significantly 
      prevented aspirin-induced disruption of the mucosal barrier as evidenced by an 
      increase in potential difference and a decrease in acid back-diffusion and sodium 
      ion and potassium ion flux. These findings were associated with a marked 
      reduction in the degree of mucosal injury. Our results support the recent 
      hypothesis that surface-active phospholipid plays an important role in gastric 
      mucosal defense against the damaging effects to luminal acid.
FAU - Swarm, R A
AU  - Swarm RA
FAU - Ashley, S W
AU  - Ashley SW
FAU - Soybel, D I
AU  - Soybel DI
FAU - Ordway, F S
AU  - Ordway FS
FAU - Cheung, L Y
AU  - Cheung LY
LA  - eng
GR  - 2-T32-GM07602-07/GM/NIGMS NIH HHS/United States
GR  - R01 AM25998-07/AM/NIADDK NIH HHS/United States
GR  - R01 AM35191-01/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Surg
JT  - American journal of surgery
JID - 0370473
RN  - 0 (Phospholipids)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/antagonists & inhibitors
MH  - Dogs
MH  - Gastric Mucosa/*drug effects
MH  - Hydrogen-Ion Concentration
MH  - Phospholipids/*pharmacology
MH  - Potassium/metabolism
MH  - Potentiometry
MH  - Sodium/metabolism
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 0002-9610(87)90200-5 [pii]
AID - 10.1016/0002-9610(87)90200-5 [doi]
PST - ppublish
SO  - Am J Surg. 1987 Jan;153(1):48-53. doi: 10.1016/0002-9610(87)90200-5.

PMID- 6719042
OWN - NLM
STAT- MEDLINE
DCOM- 19840607
LR  - 20190908
IS  - 0036-553X (Print)
IS  - 0036-553X (Linking)
VI  - 32
IP  - 4
DP  - 1984 Apr
TI  - The effect of acetylsalicylic acid in 3 different formulations on in vitro and in 
      vivo platelet function tests. An experimental study on healthy male volunteers.
PG  - 379-84
AB  - The template bleeding time (TBT), ADP-induced platelet aggregation, and serum 
      production of TXB2 were measured in healthy young male subjects immediately 
      before, and on days 1, 4 and 6 after the ingestion of 1 single dose of 500 mg 
      acetylsalicylic acid (ASA) in 3 different formulations: Aspirin (Bayer), and the 
      2 enteric-coated formulations Reumyl (Hässle) and Premaspin (Lääke). The 
      ingestion of Aspirin resulted in a significant prolongation of the TBT over a 
      period of 6 d. However, after the ingestion of the same amount of ASA in the 2 
      enteric coated formulations, the TBT as measured on day 6 had become normalized. 
      After the ingestion of Aspirin, there was no reappearance of the second wave of 
      ADP-induced platelet aggregation during the study period; however, after the 
      ingestion of the 2 enteric-coated formulations, secondary platelet aggregation 
      occasionally returned on day 6. In response to the intake of each of the 3 ASA 
      formulations, the serum TXB2 production as measured 24 h later was almost 
      completely inhibited. In each of the 3 study groups, the TXB2 formation as 
      measured on day 6 was still significantly impaired.
FAU - Kutti, J
AU  - Kutti J
FAU - Safai-Kutti, S
AU  - Safai-Kutti S
FAU - Sigvaldason, A
AU  - Sigvaldason A
FAU - Edgar, B
AU  - Edgar B
FAU - Lundborg, P
AU  - Lundborg P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Scand J Haematol
JT  - Scandinavian journal of haematology
JID - 0404507
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Dosage Forms)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects
MH  - Delayed-Action Preparations
MH  - Dosage Forms
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Thromboxane B2/blood
EDAT- 1984/04/01 00:00
MHDA- 1984/04/01 00:01
CRDT- 1984/04/01 00:00
PHST- 1984/04/01 00:00 [pubmed]
PHST- 1984/04/01 00:01 [medline]
PHST- 1984/04/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1984.tb00692.x [doi]
PST - ppublish
SO  - Scand J Haematol. 1984 Apr;32(4):379-84. doi: 10.1111/j.1600-0609.1984.tb00692.x.

PMID- 3501902
OWN - NLM
STAT- MEDLINE
DCOM- 19880404
LR  - 20190919
IS  - 0036-5580 (Print)
IS  - 0036-5580 (Linking)
VI  - 21
IP  - 3
DP  - 1987
TI  - Failure of combined acetylsalicylic acid and dipyridamole to prevent occlusion of 
      aortocoronary venous bypass graft.
PG  - 215-20
AB  - Patients scheduled to receive at least three aortocoronary venous bypass grafts 
      were randomized to active medication or to placebo. The former were given 
      dipyridamole (DP) preoperatively and acetylsalicylic acid (ASA) was added after 
      the operation. For the next 3 months they received DP 75 mg and ASA 325 mg thrice 
      daily. The placebo regimen was identical and the study was conducted with 
      double-blind technique. One patient in each group died. DP-ASA was discontinued 
      in six patients because of gastrointestinal side effects (bleeding peptic ulcer 
      in 2 cases). Angiography after 3 months revealed the patency rate of individual 
      grafts to be 68% in the DP-ASA group and 77% in the placebo group. DP-ASA 
      therefore did not prevent occlusion of aortocoronary venous bypass grafts.
FAU - Thaulow, E
AU  - Thaulow E
AD  - Medical Department B, Rikshospitalet, Oslo, Norway.
FAU - Frøysaker, T
AU  - Frøysaker T
FAU - Dale, J
AU  - Dale J
FAU - Vatne, K
AU  - Vatne K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Sweden
TA  - Scand J Thorac Cardiovasc Surg
JT  - Scandinavian journal of thoracic and cardiovascular surgery
JID - 0121343
RN  - 0 (Drug Combinations)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Coronary Angiography
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Drug Combinations
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Middle Aged
MH  - Postoperative Complications
MH  - Random Allocation
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.3109/14017438709106027 [doi]
PST - ppublish
SO  - Scand J Thorac Cardiovasc Surg. 1987;21(3):215-20. doi: 
      10.3109/14017438709106027.

PMID- 2783118
OWN - NLM
STAT- MEDLINE
DCOM- 19891020
LR  - 20190612
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 163
IP  - 2
DP  - 1989 Sep 15
TI  - The effect of crosslinking by bis(3,5-dibromosalicyl) fumarate on the 
      autoxidation of hemoglobin.
PG  - 733-8
AB  - Bis(3,5-dibromosalicyl) fumarate was used to crosslink hemoglobin both in the oxy 
      and deoxy states. This double headed diaspirin was known to crosslink oxy Hb A 
      selectively between Lys 82 beta 1 and Lys 82 beta 2 (Walder, J. A., et al. (1979) 
      Biochemistry 18, 4265) and deoxy Hb A between Lys 99 alpha 1 and Lys 99 alpha 2 
      (Chatterjee R. Y., et al. (1986) J. Biol. Chem. 261, 9929). The autoxidation at 
      37 degrees C of oxy alpha 99 crosslinked hemoglobin was found to be 1.8 times as 
      fast as that of Hb A while that of the oxy beta 82 crosslinked hemoglobin was 
      only 1.2 times as fast. After 5 hours the formation of methemoglobin in the alpha 
      crosslinked Hb A is 21.3% compared to 10.8% in beta crosslinked Hb A and 6.4% in 
      Hb A. These results may effect the proposed use of alpha 99 crosslinked 
      hemoglobin as a blood substitute by demonstrating the need for protection from 
      autoxidation during storage.
FAU - Yang, T
AU  - Yang T
AD  - Department of Chemistry Loyola University of Chicago, IL 60626.
FAU - Olsen, K W
AU  - Olsen KW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Oxyhemoglobins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 9008-37-1 (Methemoglobin)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cross-Linking Reagents/*pharmacology
MH  - Hemoglobin A/*metabolism
MH  - Kinetics
MH  - Methemoglobin/metabolism
MH  - Oxidation-Reduction
MH  - Oxyhemoglobins/metabolism
EDAT- 1989/09/15 00:00
MHDA- 1989/09/15 00:01
CRDT- 1989/09/15 00:00
PHST- 1989/09/15 00:00 [pubmed]
PHST- 1989/09/15 00:01 [medline]
PHST- 1989/09/15 00:00 [entrez]
AID - 0006-291X(89)92284-5 [pii]
AID - 10.1016/0006-291x(89)92284-5 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1989 Sep 15;163(2):733-8. doi: 
      10.1016/0006-291x(89)92284-5.

PMID- 21415156
OWN - NLM
STAT- MEDLINE
DCOM- 20110526
LR  - 20211020
IS  - 1533-3450 (Electronic)
IS  - 1046-6673 (Print)
IS  - 1046-6673 (Linking)
VI  - 22
IP  - 4
DP  - 2011 Apr
TI  - Use of aspirin associates with longer primary patency of hemodialysis grafts.
PG  - 773-81
LID - 10.1681/ASN.2010060582 [doi]
AB  - Extended-release dipyridamole plus low-dose aspirin (ERDP/ASA) prolongs primary 
      unassisted graft patency of newly created hemodialysis arteriovenous grafts, but 
      the individual contributions of each component are unknown. Here, we analyzed 
      whether use of aspirin at baseline associated with primary unassisted graft 
      patency among participants in a randomized trial that compared ERDP/ASA and 
      placebo in newly created grafts. We used Cox proportional hazards regression, 
      adjusting for prespecified baseline comorbidities and covariates. Of all 
      participants, 43% reported use of aspirin at baseline; of these, 82% remained on 
      nonstudy aspirin (i.e., excluding ERDP/ASA) at 1 year. After 1 year of follow-up, 
      the incidence of primary unassisted patency among participants using aspirin at 
      baseline was 30% (95% CI: 24 to 35%) and among those not using aspirin was 23% 
      (95% CI: 18 to 27%). Use of aspirin at baseline associated with a dose-dependent 
      prolongation of primary unassisted graft patency that approached statistical 
      significance (adjusted HR, 0.83; 95% CI: 0.68 to 1.01; P=0.06). Use of aspirin at 
      baseline did not associate with prolongation of cumulative graft patency or 
      participant survival. In conclusion, use of aspirin associates with a trend 
      toward longer primary unassisted patency of newly placed hemodialysis grafts 
      similar to that observed for ERDP/ASA.
CI  - Copyright © 2011 by the American Society of Nephrology
FAU - Dixon, Bradley S
AU  - Dixon BS
AD  - Division of Nephrology, University of Iowa College of Medicine, E-300D GH, 200 
      Hawkins Drive, Iowa City, IA 52242-1081, USA. bradley-dixon@uiowa.edu
FAU - Beck, Gerald J
AU  - Beck GJ
FAU - Dember, Laura M
AU  - Dember LM
FAU - Vazquez, Miguel A
AU  - Vazquez MA
FAU - Greenberg, Arthur
AU  - Greenberg A
FAU - Delmez, James A
AU  - Delmez JA
FAU - Allon, Michael
AU  - Allon M
FAU - Himmelfarb, Jonathan
AU  - Himmelfarb J
FAU - Hu, Bo
AU  - Hu B
FAU - Greene, Tom
AU  - Greene T
FAU - Radeva, Milena K
AU  - Radeva MK
FAU - Davidson, Ingemar J
AU  - Davidson IJ
FAU - Ikizler, T Alp
AU  - Ikizler TA
FAU - Braden, Gregory L
AU  - Braden GL
FAU - Lawson, Jeffrey H
AU  - Lawson JH
FAU - Cotton, James R Jr
AU  - Cotton JR Jr
FAU - Kusek, John W
AU  - Kusek JW
FAU - Feldman, Harold I
AU  - Feldman HI
CN  - Dialysis Access Consortium (DAC) Study Group
LA  - eng
GR  - U01 DK058982/DK/NIDDK NIH HHS/United States
GR  - U01 DK058986/DK/NIDDK NIH HHS/United States
GR  - U01DK058978/DK/NIDDK NIH HHS/United States
GR  - U01DK058985/DK/NIDDK NIH HHS/United States
GR  - U01DK058986/DK/NIDDK NIH HHS/United States
GR  - U01 DK058973/DK/NIDDK NIH HHS/United States
GR  - U01DK058966/DK/NIDDK NIH HHS/United States
GR  - U01 DK058966/DK/NIDDK NIH HHS/United States
GR  - U01 DK058981/DK/NIDDK NIH HHS/United States
GR  - U01DK058982/DK/NIDDK NIH HHS/United States
GR  - U01 DK058968/DK/NIDDK NIH HHS/United States
GR  - U01DK058973/DK/NIDDK NIH HHS/United States
GR  - U01 DK058978/DK/NIDDK NIH HHS/United States
GR  - U01DK058981/DK/NIDDK NIH HHS/United States
GR  - U01 DK058985/DK/NIDDK NIH HHS/United States
GR  - U01DK058968/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20110317
PL  - United States
TA  - J Am Soc Nephrol
JT  - Journal of the American Society of Nephrology : JASN
JID - 9013836
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Soc Nephrol. 2011 Apr;22(4):595-7. PMID: 21415154
MH  - Adult
MH  - Aged
MH  - *Arteriovenous Shunt, Surgical/adverse effects
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Chronic Disease
MH  - Dipyridamole/adverse effects/pharmacology/therapeutic use
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kidney Diseases/*therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Proportional Hazards Models
MH  - Renal Dialysis/*methods
MH  - Thrombosis/etiology/prevention & control
MH  - Treatment Outcome
MH  - *Vascular Patency/drug effects
PMC - PMC3065232
FIR - Dember, L
IR  - Dember L
FIR - Kaufman, J
IR  - Kaufman J
FIR - Hawley, M
IR  - Hawley M
FIR - Lauer, A
IR  - Lauer A
FIR - LeSage, P
IR  - LeSage P
FIR - Nathan, R
IR  - Nathan R
FIR - Holmberg, E
IR  - Holmberg E
FIR - Braden, G
IR  - Braden G
FIR - Ryan, M
IR  - Ryan M
FIR - Berkowitz, A
IR  - Berkowitz A
FIR - Rahman, A
IR  - Rahman A
FIR - Lucas, B Jr
IR  - Lucas B Jr
FIR - Santos, R
IR  - Santos R
FIR - Reyes, B
IR  - Reyes B
FIR - Greenberg, A
IR  - Greenberg A
FIR - Berkoben, M
IR  - Berkoben M
FIR - Kovalik, E
IR  - Kovalik E
FIR - Lawson, J
IR  - Lawson J
FIR - Middleton, J
IR  - Middleton J
FIR - Schumm, D
IR  - Schumm D
FIR - Adams, S
IR  - Adams S
FIR - Gitter, K
IR  - Gitter K
FIR - Cantaffa, T
IR  - Cantaffa T
FIR - Quarles, A
IR  - Quarles A
FIR - Work, J
IR  - Work J
FIR - Rhodes, S
IR  - Rhodes S
FIR - Himmelfarb, J
IR  - Himmelfarb J
FIR - Whiting, J
IR  - Whiting J
FIR - Kane, J
IR  - Kane J
FIR - Freedman, S
IR  - Freedman S
FIR - Violette, R
IR  - Violette R
FIR - Cyr-Alves, H
IR  - Cyr-Alves H
FIR - Garrison, K
IR  - Garrison K
FIR - Martin, K
IR  - Martin K
FIR - Schmitz, P
IR  - Schmitz P
FIR - Jenkins, V
IR  - Jenkins V
FIR - Cotton, J Jr
IR  - Cotton J Jr
FIR - Husband, E
IR  - Husband E
FIR - Allon, M
IR  - Allon M
FIR - Robbin, M
IR  - Robbin M
FIR - Lockhart, M
IR  - Lockhart M
FIR - Casey, B
IR  - Casey B
FIR - Newsome, J
IR  - Newsome J
FIR - Dixon, B
IR  - Dixon B
FIR - Franzwa, B
IR  - Franzwa B
FIR - Hunsicker, L
IR  - Hunsicker L
FIR - Hoballah, J
IR  - Hoballah J
FIR - Katz, D
IR  - Katz D
FIR - Sharp, W
IR  - Sharp W
FIR - Kresowik, T
IR  - Kresowik T
FIR - Wu, Y
IR  - Wu Y
FIR - Rayhill, S
IR  - Rayhill S
FIR - Pflederer, T
IR  - Pflederer T
FIR - DuPage, K
IR  - DuPage K
FIR - Welch, K
IR  - Welch K
FIR - Darras, F
IR  - Darras F
FIR - Banqero, A
IR  - Banqero A
FIR - Ketel, B
IR  - Ketel B
FIR - Wounded Arrow, A
IR  - Wounded Arrow A
FIR - Grant, C
IR  - Grant C
FIR - Deeb, J
IR  - Deeb J
FIR - Pyszka, L
IR  - Pyszka L
FIR - Slavin, M
IR  - Slavin M
FIR - Wedeking, D
IR  - Wedeking D
FIR - Vazquez, M
IR  - Vazquez M
FIR - Davidson, I
IR  - Davidson I
FIR - Toto, R
IR  - Toto R
FIR - Littmon, L
IR  - Littmon L
FIR - Ying, C
IR  - Ying C
FIR - Lightfoot, T
IR  - Lightfoot T
FIR - Quinones, H
IR  - Quinones H
FIR - Saxena, R
IR  - Saxena R
FIR - Clagett, P
IR  - Clagett P
FIR - Valentine, J
IR  - Valentine J
FIR - Dolmatch, B
IR  - Dolmatch B
FIR - Thompson, J
IR  - Thompson J
FIR - Fenves, A
IR  - Fenves A
FIR - Pearl, G
IR  - Pearl G
FIR - Ikizler, A
IR  - Ikizler A
FIR - Egbert, P
IR  - Egbert P
FIR - McNeil, J
IR  - McNeil J
FIR - Holmes, D
IR  - Holmes D
FIR - Freiberger, W
IR  - Freiberger W
FIR - Delmez, J
IR  - Delmez J
FIR - Windus, D
IR  - Windus D
FIR - Coyne, D
IR  - Coyne D
FIR - Rothstein, M
IR  - Rothstein M
FIR - Shenoy, S
IR  - Shenoy S
FIR - Creaghan, R
IR  - Creaghan R
FIR - Lluka, B
IR  - Lluka B
FIR - Kusek, J
IR  - Kusek J
FIR - Meyers, C
IR  - Meyers C
FIR - Feldman, H
IR  - Feldman H
FIR - Beck, G
IR  - Beck G
FIR - Gassman, J
IR  - Gassman J
FIR - Greene, T
IR  - Greene T
FIR - Hu, B
IR  - Hu B
FIR - Bi, S
IR  - Bi S
FIR - Liu, A
IR  - Liu A
FIR - Radeva, M
IR  - Radeva M
FIR - Tuason, L
IR  - Tuason L
FIR - Weiss, B
IR  - Weiss B
FIR - Levin, N
IR  - Levin N
FIR - Besarab, A
IR  - Besarab A
FIR - Chertow, G
IR  - Chertow G
FIR - Diener-West, M
IR  - Diener-West M
FIR - Louis, T
IR  - Louis T
FIR - McClellan, W
IR  - McClellan W
FIR - Stehman-Breen, C
IR  - Stehman-Breen C
EDAT- 2011/03/19 06:00
MHDA- 2011/05/27 06:00
CRDT- 2011/03/19 06:00
PHST- 2011/03/19 06:00 [entrez]
PHST- 2011/03/19 06:00 [pubmed]
PHST- 2011/05/27 06:00 [medline]
AID - ASN.2010060582 [pii]
AID - 2010060582 [pii]
AID - 10.1681/ASN.2010060582 [doi]
PST - ppublish
SO  - J Am Soc Nephrol. 2011 Apr;22(4):773-81. doi: 10.1681/ASN.2010060582. Epub 2011 
      Mar 17.

PMID- 11703529
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20190722
IS  - 0011-9059 (Print)
IS  - 0011-9059 (Linking)
VI  - 40
IP  - 8
DP  - 2001 Aug
TI  - A randomized parallel trial of topical aspirin-moisturizer solution vs. oral 
      aspirin for acute herpetic neuralgia.
PG  - 535-8
AB  - BACKGROUND: In this study, the efficacy of oral aspirin vs. topical aspirin in 
      moisturizer (Vaseline Intensive Care Lotion) was studied in an open, randomized, 
      parallel trial in patients with acute herpetic neuralgia. METHODS: Thirty 
      patients were evaluated in the trial, with 15 in each group. The patients were 
      randomized to receive either oral aspirin, 375-750 mg three times a day, or 75 mg 
      topical aspirin/mL of moisturizer (5-10 mL, depending on the extent of 
      involvement), three times a day, for 21 days. Pain was assessed daily by means of 
      a self-rating visual analog scale and physician assessment. In addition, the skin 
      and plasma levels of aspirin were measured in both groups. RESULTS: The mean time 
      to onset of pain relief was 44 min with topical aspirin and 110 min with oral 
      aspirin. The mean duration of pain relief after a single application of topical 
      aspirin was 5.4 h, whereas it was 3.5 h with oral aspirin. The mean visual analog 
      scale scores for pain with oral aspirin decreased from 68.2 +/- 6.1 on day zero 
      to 43.1 +/- 8.7 on day 21, which was not significant compared with the baseline 
      score. With topical aspirin, the baseline pain score was 77.5 +/- 3.7 and 
      decreased to 6.8 +/- 3 on day 21 (P < 0.001 compared to the baseline score and 
      compared to oral aspirin). The mean plasma and skin levels of aspirin following 
      oral administration were 16.21 +/- 1.1 microg/mL and 1.97 +/- 0.3 microg/mm2, 
      respectively. After topical administration, the mean plasma level of aspirin was 
      2.29 +/- 0.5 microg/mL (P < 0.01 vs. oral aspirin) and the skin level was 5.96 
      +/- 0.4 microg/mm2 (P < 0.05 vs. oral aspirin). Treatment tolerance was excellent 
      in both groups. CONCLUSIONS: This trial has demonstrated that topical aspirin in 
      moisturizer is clearly superior to oral aspirin in relieving the pain of acute 
      herpetic neuralgia, and that the analgesic activity of aspirin is largely due to 
      its local effect.
FAU - Balakrishnan, S
AU  - Balakrishnan S
AD  - Department of Pharmacology and Dermatology, Postgraduate Institute of Medical 
      Education and Research, Chandigarh-160 012, India.
FAU - Bhushan, K
AU  - Bhushan K
FAU - Bhargava, V K
AU  - Bhargava VK
FAU - Pandhi, P
AU  - Pandhi P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Administration, Topical
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Herpes Zoster/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2001/11/13 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/13 10:00
PHST- 2001/11/13 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/13 10:00 [entrez]
AID - 1265 [pii]
AID - 10.1046/j.1365-4362.2001.01265.x [doi]
PST - ppublish
SO  - Int J Dermatol. 2001 Aug;40(8):535-8. doi: 10.1046/j.1365-4362.2001.01265.x.

PMID- 10369118
OWN - NLM
STAT- MEDLINE
DCOM- 19990813
LR  - 20181201
IS  - 1434-6621 (Print)
IS  - 1434-6621 (Linking)
VI  - 37
IP  - 4
DP  - 1999 Apr
TI  - Multiple regression analysis of interference effects from a hemoglobin-based 
      oxygen carrier solution.
PG  - 453-64
AB  - The use of hemoglobin-based oxygen carrier solutions in patients requiring blood 
      transfusion will necessitate that clinical laboratories have mechanisms in place 
      to evaluate the potential interference effect of these substances on testing 
      methods. Because these oxygen carrier solutions contain acellular hemoglobin, but 
      do not contain many of the intracellular enzymes and ions present in 
      erythrocytes, interference effects from blood substitutes may be quite different 
      when compared to in vivo or in vitro lysis of erythrocytes. We evaluated the 
      potential interference effect of Diaspirin Cross-linked Hemoglobin on 29 
      different clinical laboratory analytes. Various combinations of these analytes 
      were tested using the Hitachi 747 and 911 systems, a Beckman CX3, an Abbott 
      AxSym, a Bayer Immuno I, and a Dade ACA IV; a total of 60 analyte/instrument 
      combinations. We used the method of multiple regression analysis to classify 
      interferences as analyte-dependent, analyte-independent, or a combination of the 
      first two types. The presence of clinically significant test interference was 
      derived by using the criteria for maximum allowable error specified in the 
      Clinical Laboratory Improvement Amendments of 1988. Using these criteria, we 
      found significant interference from Diaspirin Cross-linked Hemoglobin with 13 of 
      29 analytes tested. Interference was noted with the Hitachi 747 and 911 methods 
      for albumin, alkaline phosphatase, total and conjugated bilirubin, cholesterol, 
      total carbon dioxide, iron, lactate dehydrogenase, magnesium, total protein, and 
      triglyceride. In addition, Diaspirin Cross-linked Hemoglobin interfered with 
      measurement of L-lactate using the ACA IV and minor interference was noted with 
      glucose measured using the Beckman CX3. Data from the interference studies was 
      graphically displayed in the form of interference plots. These plots show the 
      maximum allowable test error, due to Diaspirin Cross-linked Hemoglobin, as a 
      function of analyte and interferent concentrations. Evaluation of the potential 
      interference effect of hemoglobin-based oxygen carrier solutions with use of 
      multiple regression analysis and graphical display of the resultant data in the 
      form of interference plots allows for more reliable reporting of test results 
      from specimens containing these products.
FAU - Kazmierczak, S C
AU  - Kazmierczak SC
AD  - East Carolina University School of Medicine, Department of Pathology and 
      Laboratory Medicine, Greenville, NC 27858, USA. kaz@brody.med.ecu.edu
FAU - Catrou, P G
AU  - Catrou PG
FAU - Best, A E
AU  - Best AE
FAU - Sullivan, S W
AU  - Sullivan SW
FAU - Briley, K P
AU  - Briley KP
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine
JID - 9806306
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/analysis
MH  - Bilirubin/analysis
MH  - Blood Chemical Analysis/*methods
MH  - Dose-Response Relationship, Drug
MH  - Hemoglobins/*analysis
MH  - Humans
MH  - *Regression Analysis
EDAT- 1999/06/16 00:00
MHDA- 1999/06/16 00:01
CRDT- 1999/06/16 00:00
PHST- 1999/06/16 00:00 [pubmed]
PHST- 1999/06/16 00:01 [medline]
PHST- 1999/06/16 00:00 [entrez]
AID - 10.1515/CCLM.1999.074 [doi]
PST - ppublish
SO  - Clin Chem Lab Med. 1999 Apr;37(4):453-64. doi: 10.1515/CCLM.1999.074.

PMID- 1301850
OWN - NLM
STAT- MEDLINE
DCOM- 19930609
LR  - 20161018
IS  - 1003-5370 (Print)
IS  - 1003-5370 (Linking)
VI  - 12
IP  - 11
DP  - 1992 Nov
TI  - [Clinical and experimental study of Ligusticum wallichii and aspirin in the 
      treatment of transient ischemic attack].
PG  - 672-4, 645-6
AB  - This paper reports the results of the treatment of 158 cases with transient 
      ischemic attack (TIA). They were randomly divided into Ligusticum wallichii group 
      (111 cases) and Aspirin group (47 cases). The results showed that the total 
      effective rate in Ligusticum wallichii group and in Aspirin group were 89.2% and 
      61.7% respectively. The effect of former on the treatment of TIA was superior to 
      latter, and the difference between them was significant (P < 0.01). Experimental 
      study showed that Ligusticum wallichii has the effects of increasing cerebral 
      blood flow, accelerating the velocity of blood flow, dilating the spastic artery 
      and decreasing peripheral arterial resistance. Both of them has the functions of 
      decreasing the levels of thromboxane B2(TXB2), beta-thromboglobulin (beta-TG) and 
      platelet factor IV (PF4) in plasma and increasing the concentration of 
      6-keto-prostaglandin F1 alpha (6 keto-PGF1 alpha) in plasma, the effect of 
      Ligusticum wallichii was significantly better than Aspirin (P < 0.05).
FAU - Chen, D R
AU  - Chen DR
AD  - Dept. of Neurology, Changhai Hospital, 2nd Military Medical College, Shanghai.
LA  - chi
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhongguo Zhong Xi Yi Jie He Za Zhi
JT  - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese 
      journal of integrated traditional and Western medicine
JID - 9211576
RN  - 0 (Drugs, Chinese Herbal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drugs, Chinese Herbal/administration & dosage/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
PST - ppublish
SO  - Zhongguo Zhong Xi Yi Jie He Za Zhi. 1992 Nov;12(11):672-4, 645-6.

PMID- 630676
OWN - NLM
STAT- MEDLINE
DCOM- 19780508
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 57
IP  - 4
DP  - 1978 Apr
TI  - Antiarrhythmic effects of aspirin during nonthrombotic coronary occlusion.
PG  - 681-4
AB  - To study the action of aspirin upon the myocardium per se, independent of 
      thrombosis, coronary occlusion with a balloon catheter was induced in 53 
      anesthetized dogs divided into two groups. One group (N = 20) was treated daily 
      with aspirin (600 mg/dog) for seven days and another (N = 33) was untreated. Left 
      ventricular hemodynamics and precordial ECG mapping were used to assess the 
      influence of myocardial ischemia over a four hour period. There were no 
      significant differences in left ventricular function or extent of injury as 
      judged by ECG mapping between the two groups. However, there was a significant 
      decrease in the incidence of ventricular fibrillation in the treated dogs (5% vs 
      39%). Serial plasma samples for free fatty acid determination showed a 
      significant rise in the untreated group. Aspirin blocked the FFA increment in the 
      treated animals. Tissue samples from the ischemic area of left ventricle 
      exhibited a significant reduction of the sodium and water increments, as well as 
      a lesser potassium loss in the treated animals compared to the controls and may 
      have been the basis for the lower incidence of arrhythmias. Since infusion of 
      51Cr labelled platelets showed no myocardial accumulation of platelets in either 
      group, microthrombi did not appear to contribute to the observed differences.
FAU - Moschos, C B
AU  - Moschos CB
FAU - Haider, B
AU  - Haider B
FAU - De La Cruz, C Jr
AU  - De La Cruz C Jr
FAU - Lyons, M M
AU  - Lyons MM
FAU - Regan, T J
AU  - Regan TJ
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Arrhythmia Agents/pharmacology
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Pressure
MH  - Coronary Disease/*drug therapy
MH  - Dogs
MH  - Fatty Acids, Nonesterified/blood
MH  - Heart/drug effects
MH  - Heart Rate
MH  - Male
MH  - Microcirculation
MH  - Ventricular Fibrillation/*prevention & control
MH  - Water-Electrolyte Balance
EDAT- 1978/04/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1978/04/01 00:00
PHST- 1978/04/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1978/04/01 00:00 [entrez]
AID - 10.1161/01.cir.57.4.681 [doi]
PST - ppublish
SO  - Circulation. 1978 Apr;57(4):681-4. doi: 10.1161/01.cir.57.4.681.

PMID- 15358033
OWN - NLM
STAT- MEDLINE
DCOM- 20040921
LR  - 20171116
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 44
IP  - 3
DP  - 2004 Aug 4
TI  - Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents 
      platelet and monocyte activation and protects against gastric damage induced by 
      aspirin in humans.
PG  - 635-41
AB  - OBJECTIVES: The goal of this study was to test the hypothesis that NCX-4016 may 
      have broader anti-inflammatory and antithrombotic effects as well as better 
      gastric tolerability than aspirin in humans. BACKGROUND: NCX-4016 is an aspirin 
      derivative containing a nitric oxide-releasing moiety that prevents platelet 
      activation and modulates tissue factor (TF) expression and cytokine release from 
      lipopolysaccharide (LPS)-stimulated monocytes. METHODS: This was a 
      blind-observer, placebo-controlled, parallel-group study in which 48 healthy 
      subjects were randomized to receive NCX-4016 800 mg twice a day, NCX-4016 800 mg 
      twice a day plus aspirin 325 mg, aspirin 325 mg, or placebo for 21 days. RESULTS: 
      Similar to aspirin alone, NCX-4016 effectively inhibited platelet aggregation 
      induced by 0.6 mmol/ arachidonic acid, clot-stimulated thromboxane (TX) B2 
      generation in whole blood, and urinary excretion of 11-dehydro-TXB2. Unlike 
      aspirin alone, the administration of NCX-4016 significantly inhibited TF 
      expression in monocytes stimulated ex vivo with 10 micromol/l LPS (determined by 
      flow-cytometry analysis of TF on CD14 positive cells). NCX-4016 also inhibited 
      the rapid TF expression induced in monocytes by a proteinase activated receptor 
      agonist (thrombin receptor activator protein, 2 micromol/l) as well as 
      LPS-induced expression of CD11b . Ex vivo, release of MCP-1 and interleukin-6 
      were significantly inhibited by NCX-4016, but not by aspirin. NCX-4016 was not 
      associated with gastric damage, and significantly reduced gastric injury when 
      co-administered with aspirin, although both drugs reduced gastric PGE2 production 
      to the same extent. CONCLUSIONS: NCX-4016 is equally effective as aspirin in 
      inhibiting cyclooxygenase activity. However, NCX-4016 causes less gastric damage 
      and prevents monocyte activation. Larger multicenter trials are warranted to 
      establish clinical efficacy and safety of NCX-4016.
FAU - Fiorucci, Stefano
AU  - Fiorucci S
AD  - Clinica di Gastroenterologia ed Epatologia, Department of Clinical and 
      Experimental Medicine, University of Perugia, Perugia, Italy.
FAU - Mencarelli, Andrea
AU  - Mencarelli A
FAU - Meneguzzi, Alessandra
AU  - Meneguzzi A
FAU - Lechi, Alessandro
AU  - Lechi A
FAU - Renga, Barbara
AU  - Renga B
FAU - del Soldato, Piero
AU  - del Soldato P
FAU - Morelli, Antonio
AU  - Morelli A
FAU - Minuz, Pietro
AU  - Minuz P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2004 Aug 4;44(3):642-3. PMID: 15358034
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects/analogs & 
      derivatives/*pharmacology
MH  - Drug Administration Schedule
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Duodenum/drug effects
MH  - Flow Cytometry
MH  - Gastric Mucosa/drug effects
MH  - Humans
MH  - Intestinal Mucosa/drug effects
MH  - Male
MH  - Monocytes/*drug effects
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/pharmacology
MH  - Reference Values
MH  - Single-Blind Method
MH  - Stomach/*drug effects
MH  - Thromboxane A2/metabolism
MH  - Thromboxane B2/urine
EDAT- 2004/09/11 05:00
MHDA- 2004/09/24 05:00
CRDT- 2004/09/11 05:00
PHST- 2004/01/30 00:00 [received]
PHST- 2004/02/27 00:00 [revised]
PHST- 2004/03/02 00:00 [accepted]
PHST- 2004/09/11 05:00 [pubmed]
PHST- 2004/09/24 05:00 [medline]
PHST- 2004/09/11 05:00 [entrez]
AID - S0735109704010022 [pii]
AID - 10.1016/j.jacc.2004.03.079 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2004 Aug 4;44(3):635-41. doi: 10.1016/j.jacc.2004.03.079.

PMID- 7355437
OWN - NLM
STAT- MEDLINE
DCOM- 19800417
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 11
IP  - 1
DP  - 1980 Jan-Feb
TI  - Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity 
      following plain and enteric-coated aspirin.
PG  - 9-13
AB  - Compressed and enteric-coated acetylsalicylate (ASA) tablets have been compared 
      in normal healthy subjects. Plasma ASA and salicylate (SA) were measured by high 
      pressure liquid chromatography (HPLC). Platelet cyclooxygenase activity in vitro 
      was studied by a radiometric technique. Following ingestion of 650 mg of ASA in 
      the form of compressed tablets, cyclooxygenase activity was inhibited 95% within 
      45 min. Enzyme activity was observed to increase within 8 h and reached 10% of 
      control level by 24 h. The pattern suggests that only circulating platelets are 
      affected by ASA ingestion. Following the administration of 650 mg of ASA as 
      enteric-coated tablets comparable inhibition of cyclooxygenase activity was 
      observed, although the effect was delayed, reflecting the delayed appearance of 
      ASA in the plasma. Return to control levels followed a pattern similar to that 
      observed with the compressed tablet.
FAU - Ali, M
AU  - Ali M
FAU - McDonald, J W
AU  - McDonald JW
FAU - Thiessen, J J
AU  - Thiessen JJ
FAU - Coates, P E
AU  - Coates PE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - EC 1.13.- (Oxygenases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Blood Platelets/*enzymology
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Humans
MH  - Male
MH  - Oxygenases/antagonists & inhibitors/*blood
MH  - Salicylates/*blood
MH  - Tablets, Enteric-Coated
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1161/01.str.11.1.9 [doi]
PST - ppublish
SO  - Stroke. 1980 Jan-Feb;11(1):9-13. doi: 10.1161/01.str.11.1.9.

PMID- 11098344
OWN - NLM
STAT- MEDLINE
DCOM- 20010308
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 34
IP  - 11
DP  - 2000 Nov
TI  - Aggrenox: a fixed-dose combination of aspirin and dipyridamole.
PG  - 1283-90
AB  - OBJECTIVE: To describe the pharmacology, pharmacokinetics, efficacy, and safety 
      of a fixed-dose combination of aspirin and extended-release (ER) dipyridamole 
      indicated for the secondary prevention of stroke. DATA SOURCES: Published 
      articles and abstracts were identified from a MEDLINE search (1966-December 1999) 
      using the search terms dipyridamole, aspirin, antiplatelet, antiaggregation, and 
      stroke prevention. Pertinent articles written in English were considered for 
      review. Additional articles were identified from the references of retrieved 
      literature. STUDY SELECTION AND DATA EXTRACTION: Studies including a combination 
      of aspirin/dipyridamole in human subjects were evaluated. Emphasis was placed on 
      randomized, controlled trials. DATA SYNTHESIS: Aspirin is a platelet inhibitor 
      that works by inhibiting platelet cyclooxygenase, which reduces the production of 
      thromboxane A2. Dipyridamole is a platelet inhibitor that is thought to work in 
      part by inhibiting platelet cyclic-3',5'-adenosine monophosphate and 
      cyclic-3',5'-guanosine monophosphate phosphodiesterase. The active metabolite of 
      aspirin, salicylic acid, is highly bound to plasma protein and has a plasma 
      half-life of two to three hours. Dipyridamole is also highly bound to plasma 
      proteins, and the ER formulation has a plasma half-life of 13 hours. The first 
      European Stroke Prevention Study (ESPS-1) found the combination of 
      aspirin/dipyridamole to be superior to placebo in the prevention of stroke and 
      transient ischemic attack (TIA). The ESPS-1, however, did not include an 
      aspirin-only treatment arm. Therefore, it was unclear whether the combination of 
      aspirin/dipyridamole was superior to aspirin alone. As a result, a second trial 
      was conducted that included treatment arms of aspirin alone, ER dipyridamole 
      alone, combination therapy, and placebo. The combination of aspirin 25 mg plus ER 
      dipyridamole 200 mg twice daily was shown in the ESPS-2 to be significantly 
      better than either agent given individually in preventing stroke and TIAs (p < 
      0.001). CONCLUSIONS: The American College of Chest Physicians (ACCP) recommends 
      aspirin 50-325 mg/d to be the initial antiplatelet of choice for the prevention 
      of atherothrombotic cerebral ischemic events. However, with the favorable results 
      of the ESPS-2, it may be appropriate to substitute aspirin/ER dipyridamole for 
      aspirin alone as the drug of choice. This combination appears to have a favorable 
      adverse effect profile. The relative effectiveness of aspirin/ER dipyridamole 
      compared with clopidogrel and ticlopidine has yet to be determined. If 
      alternative antiplatelet therapy is needed, the ACCP recommends clopidogrel 
      rather than ticlopidine because of its lower incidence of adverse effects. The 
      ACCP further states that the combination of aspirin plus dipyridamole may be more 
      effective than clopidogrel; these agents have a similarly favorable adverse 
      effect profile.
FAU - Lenz, T L
AU  - Lenz TL
AD  - Cardiac Center of Creighton University, Omaha, NE 68131, USA. 
      tllenz@cardiac.creighton.edu
FAU - Hilleman, D E
AU  - Hilleman DE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anti-Inflammatory Agents, Non-Steroidal/adverse 
      effects/pharmacokinetics/therapeutic use
MH  - *Aspirin/adverse effects/pharmacokinetics/pharmacology/therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Clinical Trials as Topic
MH  - *Dipyridamole/adverse effects/pharmacokinetics/pharmacology/therapeutic use
MH  - *Drug Combinations
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/adverse 
      effects/pharmacokinetics/pharmacology/therapeutic use
MH  - Stroke/*prevention & control
RF  - 38
EDAT- 2000/12/01 11:00
MHDA- 2001/03/10 10:01
CRDT- 2000/12/01 11:00
PHST- 2000/12/01 11:00 [pubmed]
PHST- 2001/03/10 10:01 [medline]
PHST- 2000/12/01 11:00 [entrez]
AID - 10.1345/aph.10079 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2000 Nov;34(11):1283-90. doi: 10.1345/aph.10079.

PMID- 2980760
OWN - NLM
STAT- MEDLINE
DCOM- 19920819
LR  - 20190817
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 10
IP  - 3
DP  - 1988 Jun
TI  - Effects of microencapsulated vs. enteric-coated acetylsalicylic acid on gastric 
      and duodenal mucosa: an endoscopic study.
PG  - 269-72
AB  - Two preparations of acetylsalicylic acid (ASA) were tested for their effects on 
      gastroduodenal mucosa in a randomized crossover double-blind study that involved 
      12 healthy volunteers. Medication M (Monobeltin) consisted of 1,050 mg ASA 
      provided with an enteric coat and medication C (Colfarit) consisted of 1,000 mg 
      of a microencapsulated ASA preparation. Both drugs were taken for 6 consecutive 
      days each. Upper gastrointestinal endoscopy was performed before and 2 and 6 days 
      after each medication. An interval of 10 days elapsed between one treatment and 
      the other. Gastric lesions occurred in 10 of 12 subjects taking medication M and 
      in 11 of 12 subjects taking medication C after 2 days and were present in all 
      subject after 6 days. Duodenal lesions were seen only in subjects taking 
      medication C. The degree of gastric mucosal lesions based on two grading scales 
      was not significantly different between the two treatments. Neither of the two 
      pharmaceutical formulations of ASA provided sufficient protection for the gastric 
      mucosa.
FAU - Malfertheiner, P
AU  - Malfertheiner P
AD  - Department of Gastroenterology, University of Ulm, F.R.G.
FAU - Stanescu, A
AU  - Stanescu A
FAU - Rogatti, W
AU  - Rogatti W
FAU - Ditschuneit, H
AU  - Ditschuneit H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*pharmacology
MH  - Drug Compounding
MH  - Duodenoscopy
MH  - Duodenum/*drug effects
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Gastroscopy
MH  - Humans
MH  - Intestinal Mucosa/*drug effects
MH  - Male
MH  - Tablets, Enteric-Coated
EDAT- 1988/06/01 00:00
MHDA- 1988/06/01 00:01
CRDT- 1988/06/01 00:00
PHST- 1988/06/01 00:00 [pubmed]
PHST- 1988/06/01 00:01 [medline]
PHST- 1988/06/01 00:00 [entrez]
AID - 10.1097/00004836-198806000-00008 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 1988 Jun;10(3):269-72. doi: 
      10.1097/00004836-198806000-00008.

PMID- 6356461
OWN - NLM
STAT- MEDLINE
DCOM- 19831220
LR  - 20191031
IS  - 0896-0569 (Print)
IS  - 0896-0569 (Linking)
VI  - 4
DP  - 1983
TI  - Aspirin: plasma concentration and effects.
PG  - 105-11
AB  - The antithrombotic effect of acetylsalicylic acid is intimately linked to its 
      reactivity. The labile acetyl moiety irreversibly acetylates not only 
      cyclo-oxygenase, but other biological components. The presence off ubiquitous 
      esterases leads to the rapid disappearance of ASA from the body. The 
      pharmacokinetics of ASA is affected by the dosage form used and the presence of 
      food. Despite the absence of a definable relationship between plasma ASA levels 
      and response, recent data would suggest a dose of about 0.5 mg/kg/day adequately 
      suppresses platelet aggregation without affecting prostacyclin formation.
FAU - Thiessen, J J
AU  - Thiessen JJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Thromb Res Suppl
JT  - Thrombosis research. Supplement
JID - 8309239
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*pharmacology
MH  - *Fibrinolytic Agents
MH  - Half-Life
MH  - Humans
MH  - Salicylates/blood
MH  - Salicylic Acid
RF  - 20
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1016/0049-3848(83)90365-1 [doi]
PST - ppublish
SO  - Thromb Res Suppl. 1983;4:105-11. doi: 10.1016/0049-3848(83)90365-1.

PMID- 28297635
OWN - NLM
STAT- MEDLINE
DCOM- 20180726
LR  - 20181202
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 592
DP  - 2017 Aug 15
TI  - OH-initiated transformation and hydrolysis of aspirin in AOPs system: DFT and 
      experimental studies.
PG  - 33-40
LID - S0048-9697(17)30545-4 [pii]
LID - 10.1016/j.scitotenv.2017.03.041 [doi]
AB  - Advanced oxidation processes (AOPs) are widely used in wastewater treatment of 
      pharmaceutical and personal care products (PPCPs). In this work, the OH-initiated 
      transformation as well as the hydrolysis of a typical PPCPs, aspirin, was 
      investigated using density functional theory (DFT) calculations and laboratory 
      experiments. For DFT calculations, the frontier electron densities and bond 
      dissociation energies were analyzed. Profiles of the potential energy surface 
      were constructed, and all the possible pathways were discussed. Additionally, 
      rate constants for each pathway were calculated with transition state theory 
      (TST) method. UV/H(2)O(2) experiments of aspirin were performed and degradation 
      intermediates were identified by UPLC-MS-MS analysis. Different findings from 
      previous experimental works were reported that the H-abstraction pathways at 
      methyl position were dominated and OH-addition pathways on benzene ring were also 
      favored. Meantime, hydroxyl ASA was confirmed as the main stable intermediate. 
      Moreover, it was the first time to use DFT method to investigate the hydrolysis 
      mechanisms of organic ester compound.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - He, Lin
AU  - He L
AD  - Shandong Key Laboratory of Water Pollution Control and Resource Reuse, School of 
      Environmental Science and Engineering, Shandong University, Jinan 250100, PR 
      China.
FAU - Sun, Xiaomin
AU  - Sun X
AD  - Environment Research Institute, Shandong University, Jinan 250100, PR China. 
      Electronic address: sxmwch@sdu.edu.cn.
FAU - Zhu, Fanping
AU  - Zhu F
AD  - Shandong Key Laboratory of Water Pollution Control and Resource Reuse, School of 
      Environmental Science and Engineering, Shandong University, Jinan 250100, PR 
      China.
FAU - Ren, Shaojie
AU  - Ren S
AD  - Shandong Key Laboratory of Water Pollution Control and Resource Reuse, School of 
      Environmental Science and Engineering, Shandong University, Jinan 250100, PR 
      China.
FAU - Wang, Shuguang
AU  - Wang S
AD  - Shandong Key Laboratory of Water Pollution Control and Resource Reuse, School of 
      Environmental Science and Engineering, Shandong University, Jinan 250100, PR 
      China. Electronic address: sgw@sdu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20170312
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
RN  - 3352-57-6 (Hydroxyl Radical)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Hydrogen Peroxide
MH  - Hydrolysis
MH  - Hydroxyl Radical
MH  - Kinetics
MH  - Oxidation-Reduction
OTO - NOTNLM
OT  - Advanced oxidation processes
OT  - Aspirin
OT  - DFT
OT  - Hydrolysis
OT  - Transformation mechanism
EDAT- 2017/03/16 06:00
MHDA- 2018/07/27 06:00
CRDT- 2017/03/16 06:00
PHST- 2017/01/08 00:00 [received]
PHST- 2017/02/27 00:00 [revised]
PHST- 2017/03/05 00:00 [accepted]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2018/07/27 06:00 [medline]
PHST- 2017/03/16 06:00 [entrez]
AID - S0048-9697(17)30545-4 [pii]
AID - 10.1016/j.scitotenv.2017.03.041 [doi]
PST - ppublish
SO  - Sci Total Environ. 2017 Aug 15;592:33-40. doi: 10.1016/j.scitotenv.2017.03.041. 
      Epub 2017 Mar 12.

PMID- 3459122
OWN - NLM
STAT- MEDLINE
DCOM- 19860703
LR  - 20190712
IS  - 0030-4220 (Print)
IS  - 0030-4220 (Linking)
VI  - 61
IP  - 5
DP  - 1986 May
TI  - Aspirin-intolerance syndrome. Report of a case.
PG  - 463-5
AB  - Maxillofacial pain is often managed by the use of mild analgesics, such as 
      acetylsalicylic acid and nonsteroidal anti-inflammatory agents. The following is 
      a review of an idiosyncratic phenomenon that could prove life-threatening 
      following ingestion of these pharmaceuticals. A thorough review of the patient's 
      past medical history with an understanding of this syndrome may alleviate such a 
      danger.
FAU - Fridrich, H H
AU  - Fridrich HH
FAU - Zach, G A
AU  - Zach GA
FAU - Fridrich, K L
AU  - Fridrich KL
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Oral Surg Oral Med Oral Pathol
JT  - Oral surgery, oral medicine, and oral pathology
JID - 0376406
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Asthma/*chemically induced
MH  - Drug Hypersensitivity/*etiology
MH  - Facial Pain/drug therapy
MH  - Humans
MH  - Male
MH  - Nasal Polyps/*chemically induced
MH  - Syndrome
EDAT- 1986/05/01 00:00
MHDA- 1986/05/01 00:01
CRDT- 1986/05/01 00:00
PHST- 1986/05/01 00:00 [pubmed]
PHST- 1986/05/01 00:01 [medline]
PHST- 1986/05/01 00:00 [entrez]
AID - 10.1016/0030-4220(86)90388-9 [doi]
PST - ppublish
SO  - Oral Surg Oral Med Oral Pathol. 1986 May;61(5):463-5. doi: 
      10.1016/0030-4220(86)90388-9.

PMID- 798559
OWN - NLM
STAT- MEDLINE
DCOM- 19770415
LR  - 20201209
IS  - 0003-9055 (Print)
IS  - 0003-9055 (Linking)
VI  - 30
IP  - 6
DP  - 1976
TI  - [Effect of acetylsalicylic acid on experimentally induced endotoxin reactions in 
      swine].
PG  - 951-7
AB  - The time and severity of clinical responses to endotoxin depend on dosage, 
      Administration of acetylsalicyclic acid and Indometacin prior to endotoxin 
      application may delay or moderate the clinical phenomena that are likely to 
      result from certain endotoxin amounts.
FAU - Schimmel, D
AU  - Schimmel D
FAU - Schimmel, I
AU  - Schimmel I
FAU - Lutter, K
AU  - Lutter K
FAU - Putsche, R
AU  - Putsche R
LA  - ger
PT  - Journal Article
TT  - Zur Wirkung von Azetylsalizylsäure auf experimentell ausgelöste 
      Endtoxinreaktionen beim Schwein.
PL  - Germany
TA  - Arch Exp Veterinarmed
JT  - Archiv fur experimentelle Veterinarmedizin
JID - 0372410
RN  - 0 (Endotoxins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Drug Interactions
MH  - Endotoxins/adverse effects
MH  - Escherichia coli
MH  - Indomethacin/pharmacology/therapeutic use
MH  - Shock, Septic/drug therapy/*veterinary
MH  - Swine
MH  - Swine Diseases/*drug therapy
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Arch Exp Veterinarmed. 1976;30(6):951-7.

PMID- 1780803
OWN - NLM
STAT- MEDLINE
DCOM- 19920312
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 63
IP  - 6
DP  - 1991 Sep 15
TI  - Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in 
      a subpopulation of treated patients.
PG  - 587-93
AB  - Platelet reactivity (PR) was tested two and 12 hours after acetylsalicylic acid 
      (ASA) intake in 82 stroke patients, aged 59 +/- 14 years (33 female and 49 male). 
      10% of these patients showed a pathologically enhanced PR at least two hours 
      after intake of 500 mg ASA (= primary ASA-nonresponder (PNR)). Only 10 hours 
      later, a further 26% of these ASA treated patients exhibited a pathological 
      platelet reactivity (greater than 1.25) (= secondary ASA-nonresponder (SNR)). 
      Single ASA dosages of 500 mg or 200 mg were of identical effectiveness. 
      Additional administration of metoclopramide in combination with 100 mg ASA was 
      more effective as compared to a single dosage of 1000 mg ASA. Those who were SNR 
      at onset of ASA therapy remained SNR as well 28 days later. The change from a 
      normal, ASA corrected PR, to pathological PR values before a period of 12 hours 
      ended seemed a sudden and irreversible event that could only be corrected by the 
      next ASA application.
FAU - Grotemeyer, K H
AU  - Grotemeyer KH
AD  - Department of Neurology, University of Münster, Germany.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cerebrovascular Disorders/blood/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1991/09/15 00:00
MHDA- 1991/09/15 00:01
CRDT- 1991/09/15 00:00
PHST- 1991/09/15 00:00 [pubmed]
PHST- 1991/09/15 00:01 [medline]
PHST- 1991/09/15 00:00 [entrez]
AID - 0049-3848(91)90085-B [pii]
AID - 10.1016/0049-3848(91)90085-b [doi]
PST - ppublish
SO  - Thromb Res. 1991 Sep 15;63(6):587-93. doi: 10.1016/0049-3848(91)90085-b.

PMID- 22638974
OWN - NLM
STAT- MEDLINE
DCOM- 20120904
LR  - 20131121
IS  - 1097-0231 (Electronic)
IS  - 0951-4198 (Linking)
VI  - 26
IP  - 13
DP  - 2012 Jul 15
TI  - Probing the mechanisms of ambient ionization by laser-induced fluorescence 
      spectroscopy.
PG  - 1567-72
LID - 10.1002/rcm.6264 [doi]
AB  - The ionization mechanisms of several atmospheric pressure ion sources based on 
      desorption and ionization of samples deposited on a surface were studied. 
      Home-built desorption electrospray ionization (DESI), laserspray ionization 
      (LSI), and atmospheric pressure matrix-assisted laser desorption/ionization 
      (AP-MALDI) sources were characterized using low-molecular-weight compounds, in 
      particular fluorescent dyes. Detection of the desorbed and ionized species was 
      performed by laser-induced fluorescence and ion cyclotron resonance mass 
      spectrometry. The dependences of the signal intensities on various experimental 
      parameters were studied. The data obtained reveals common features, such as 
      formation of solvated species and clusters in the ionization processes, in all of 
      the techniques considered.
CI  - Copyright © 2012 John Wiley & Sons, Ltd.
FAU - Frankevich, V
AU  - Frankevich V
AD  - Swiss Federal Institute of Technology, Wolfgang Pauli Str. 10, 8093 Zurich, 
      Switzerland.
FAU - Nieckarz, R J
AU  - Nieckarz RJ
FAU - Sagulenko, P N
AU  - Sagulenko PN
FAU - Barylyuk, K
AU  - Barylyuk K
FAU - Zenobi, R
AU  - Zenobi R
FAU - Levitsky, L I
AU  - Levitsky LI
FAU - Agapov, A Yu
AU  - Agapov AY
FAU - Perlova, T Y
AU  - Perlova TY
FAU - Gorshkov, M V
AU  - Gorshkov MV
FAU - Tarasova, I A
AU  - Tarasova IA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Rapid Commun Mass Spectrom
JT  - Rapid communications in mass spectrometry : RCM
JID - 8802365
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Ions)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis/chemistry
MH  - Fluorescent Dyes
MH  - Ions/analysis/chemistry
MH  - Spectrometry, Fluorescence/instrumentation/*methods
MH  - Spectrometry, Mass, Electrospray Ionization/instrumentation/*methods
MH  - Spectrometry, Mass, Matrix-Assisted Laser 
      Desorption-Ionization/instrumentation/*methods
EDAT- 2012/05/29 06:00
MHDA- 2012/09/05 06:00
CRDT- 2012/05/29 06:00
PHST- 2012/05/29 06:00 [entrez]
PHST- 2012/05/29 06:00 [pubmed]
PHST- 2012/09/05 06:00 [medline]
AID - 10.1002/rcm.6264 [doi]
PST - ppublish
SO  - Rapid Commun Mass Spectrom. 2012 Jul 15;26(13):1567-72. doi: 10.1002/rcm.6264.

PMID- 30178075
OWN - NLM
STAT- MEDLINE
DCOM- 20190621
LR  - 20200225
IS  - 1863-4362 (Electronic)
IS  - 0021-1265 (Linking)
VI  - 188
IP  - 2
DP  - 2019 May
TI  - Oral antiplatelets in primary and secondary prevention of myocardial infarction: 
      a review.
PG  - 453-467
LID - 10.1007/s11845-018-1897-8 [doi]
AB  - There are a number of guidelines and articles available for the use of oral 
      antiplatelets for primary and secondary prevention of myocardial infarction (MI). 
      Antiplatelet medications inhibit platelet activation, aggregation, and other 
      pathways eventually inhibiting clot formation. Aspirin and clopidogrel have been 
      the mainstay in the management of acute coronary syndrome for about a decade. We 
      have discussed the role of aspirin, clopidogrel, ticagrelor, and prasugrel which 
      are the most commonly used oral antiplatelet medications in the current era. We 
      have also considered the role of newer thrombin inhibitor vorapaxar, and dual 
      antiplatelet therapy. In this review paper, we have summarized the continuing 
      controversy about the use of oral antiplatelet therapy and their role in primary 
      as well as secondary prevention of MI by describing results from major clinical 
      trials. The safety and the efficacy of the above medications have been reviewed 
      and described in this paper.
FAU - Doshi, Rajkumar
AU  - Doshi R
AUID- ORCID: 0000-0002-5618-2750
AD  - Department of Internal Medicine, Renown Regional Medical Centre, University of 
      Nevada Reno School of Medicine, 1155 Mill St, W-11, Reno, NV, 89502, USA. 
      rdoshi@med.unr.edu.
FAU - Vadher, Abhishek
AU  - Vadher A
AD  - Department of Cardiology, North Shore University Hospital, Hofstra Northwell 
      School of Medicine, Manhasset, NY, USA.
FAU - Mithawala, Priyam
AU  - Mithawala P
AD  - Department of Pharmacy, Presbyterian College School of Pharmacy, Clinton, SC, 
      USA.
FAU - Shah, Priyank
AU  - Shah P
AD  - Department of Cardiology, Phoebe Putney Memorial Hospital, Albany, GA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180903
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/pathology/*prevention & control
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Secondary Prevention/*methods
OTO - NOTNLM
OT  - Aspirin
OT  - Oral antiplatelets
OT  - P2Y12 inhibitors
OT  - Prevention
EDAT- 2018/09/05 06:00
MHDA- 2019/06/22 06:00
CRDT- 2018/09/05 06:00
PHST- 2018/07/13 00:00 [received]
PHST- 2018/08/24 00:00 [accepted]
PHST- 2018/09/05 06:00 [pubmed]
PHST- 2019/06/22 06:00 [medline]
PHST- 2018/09/05 06:00 [entrez]
AID - 10.1007/s11845-018-1897-8 [pii]
AID - 10.1007/s11845-018-1897-8 [doi]
PST - ppublish
SO  - Ir J Med Sci. 2019 May;188(2):453-467. doi: 10.1007/s11845-018-1897-8. Epub 2018 
      Sep 3.

PMID- 1699581
OWN - NLM
STAT- MEDLINE
DCOM- 19901220
LR  - 20191021
IS  - 0163-4984 (Print)
IS  - 0163-4984 (Linking)
VI  - 25
IP  - 2
DP  - 1990 May
TI  - Effects of copper aspirinate and aspirin on tissue copper, zinc, and iron 
      concentrations following chronic oral treatment in the adjuvant arthritic rat.
PG  - 123-35
AB  - Concentrations of copper, zinc, and iron were analyzed and compared in a number 
      of tissues of adjuvant arthritic rats following 22 d of chronic treatment (per 
      os) with either vehicle, aspirin or copper aspirinate, at doses of 100 mg/kg, 200 
      mg/kg, or 400 mg/kg. Such chronic treatment resulted in a negative balance in 
      copper, zinc, and iron in many tissues. Among the tissues examined, liver and 
      kidney exhibited the greatest changes in metal concentrations; brain and skeletal 
      muscle exhibited the least. Arthritis-induced changes in the concentrations of 
      all three metals in the liver were reversed upon treatment with aspirin. 
      Treatment with copper aspirinate, on the other hand, resulted in an extremely 
      high accumulation of copper in the liver. Arthritis-induced changes in copper, 
      zinc, and iron concentrations in the pancreas and copper concentration in the 
      plasma were generally not reversed upon treatment with either aspirin or copper 
      aspirinate. Among the three metals examined, the degree of change observed as a 
      result of drug treatments was greatest for iron and least for zinc. Finally, it 
      appeared that the effects of aspirin and copper aspirinate on tissue metal 
      concentrations were independent of the antiarthritic effects of these compounds.
FAU - Kishore, V
AU  - Kishore V
AD  - College of Pharmacy, Xavier University of Louisiana, New Orleans 70125.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biol Trace Elem Res
JT  - Biological trace element research
JID - 7911509
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - 789U1901C5 (Copper)
RN  - E1UOL152H7 (Iron)
RN  - J41CSQ7QDS (Zinc)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Arthritis, Experimental/blood/drug therapy/*metabolism
MH  - Aspirin/administration & dosage/*analogs & derivatives/*pharmacology/therapeutic 
      use
MH  - Body Weight/drug effects
MH  - Copper/blood/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Iron/*metabolism
MH  - Kidney/metabolism
MH  - Liver/metabolism
MH  - Male
MH  - Pancreas/metabolism
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Zinc/*metabolism
EDAT- 1990/05/01 00:00
MHDA- 1990/05/01 00:01
CRDT- 1990/05/01 00:00
PHST- 1990/05/01 00:00 [pubmed]
PHST- 1990/05/01 00:01 [medline]
PHST- 1990/05/01 00:00 [entrez]
AID - 10.1007/BF02990273 [doi]
PST - ppublish
SO  - Biol Trace Elem Res. 1990 May;25(2):123-35. doi: 10.1007/BF02990273.

PMID- 2375880
OWN - NLM
STAT- MEDLINE
DCOM- 19900904
LR  - 20170214
IS  - 0960-3271 (Print)
IS  - 0960-3271 (Linking)
VI  - 9
IP  - 3
DP  - 1990 May
TI  - Metabolism of aspirin after therapeutic and toxic doses.
PG  - 131-6
AB  - 1 The urinary recovery of metabolites of aspirin (ASA) was studied in 45 
      volunteers who took a therapeutic dose (600 mg) of ASA by mouth and in 37 
      patients who took ASA in overdose. 2 The main metabolite recovered from the 
      volunteers was the glycine conjugate, salicyluric acid (SUA), which accounted for 
      75.01 +/- 1.19% of total urinary metabolites, whereas salicylic acid (SA) 
      accounted for 8.82 +/- 0.56%. Recovery of SUA was negatively correlated with that 
      of SA (r = -0.8625, P less than 0.001). 3. In 24 patients with admission plasma 
      salicylate concentrations of 240-360 mg l-1, SUA accounted for 46.66 +/- 3.22% 
      and SA for 31.88 +/- 4.02%. 4. In 13 patients with admission plasma salicylate 
      concentrations of 715-870 mg l-1, SUA accounted for 21.57 +/- 3.65% and SA for 
      64.72 +/- 4.82%. 5. Reduced excretion of salicylate as SUA was also accompanied 
      by increased elimination as gentisic acid and salicylic acid phenolic glucuronide 
      indicating that the unsaturated processes that lead to the formation of these 
      metabolites contribute significantly (22-23%) to the inactivation of large doses 
      of salicylate. 6. While the Michalis-Menten kinetics of ASA have been well 
      demonstrated at lower doses, our findings illustrate the progressive saturation 
      of SUA formation under conditions of increasing ASA load to toxic amounts and 
      raise issues about the in-vivo glycine pool when ASA is taken in overdose.
FAU - Patel, D K
AU  - Patel DK
AD  - Medicinal Biochemistry Department, Burroughs Wellcome Co., Research Triangle 
      Park, North Carolina 27709.
FAU - Hesse, A
AU  - Hesse A
FAU - Ogunbona, A
AU  - Ogunbona A
FAU - Notarianni, L J
AU  - Notarianni LJ
FAU - Bennett, P N
AU  - Bennett PN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Exp Toxicol
JT  - Human & experimental toxicology
JID - 9004560
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*metabolism/poisoning/therapeutic use
MH  - Child
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hippurates/urine
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Middle Aged
MH  - Salicylates/urine
MH  - Salicylic Acid
EDAT- 1990/05/01 00:00
MHDA- 1990/05/01 00:01
CRDT- 1990/05/01 00:00
PHST- 1990/05/01 00:00 [pubmed]
PHST- 1990/05/01 00:01 [medline]
PHST- 1990/05/01 00:00 [entrez]
AID - 10.1177/096032719000900302 [doi]
PST - ppublish
SO  - Hum Exp Toxicol. 1990 May;9(3):131-6. doi: 10.1177/096032719000900302.

PMID- 796954
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20191028
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - Suppl
DP  - 1976
TI  - Comparative study of intravenous ketoprofen versus aspirin.
PG  - 83-4
AB  - In order to assess the analgesic effect of an injectable preparation of 
      ketoprofen, a double-blind comparative study was conducted against a soluble form 
      of acetylsalicylic acid of known efficacy, widely used in the clinic. Only one 
      indication was considered for inclusion in the trial, namely discogenic sciatica. 
      We found no significant statistical difference between these two products, 
      considering the criteria used. The time of onset of effect was, on average, 30 
      minutes and the mean duration of activity was 4 hours. The two products were well 
      tolerated.
FAU - Vignon, G
AU  - Vignon G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Analgesics)
RN  - 0 (Benzophenones)
RN  - 0 (Placebos)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Analgesics
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Benzophenones/*administration & dosage
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Ketoprofen/*administration & dosage/adverse effects/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Sciatica/*drug therapy
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1093/rheumatology/15.5.83 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1976;Suppl:83-4. doi: 10.1093/rheumatology/15.5.83.

PMID- 1643923
OWN - NLM
STAT- MEDLINE
DCOM- 19920908
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 102
IP  - 2
DP  - 1992 Aug
TI  - Effect of inhaled furosemide on the bronchial response to lysine-aspirin 
      inhalation in asthmatic subjects.
PG  - 408-11
AB  - It has been demonstrated recently that inhaled furosemide inhibits 
      bronchoconstriction induced by cold air, physical exercise, various antigens, and 
      metabisulfite. The goal of the present study was to determine if the inhalation 
      of furosemide would inhibit the bronchoconstriction resulting from the inhalation 
      of lysine-aspirin in aspirin-sensitive asthmatics. Six female subjects with known 
      hypersensitivity to aspirin participated in this crossover study comparing 20 mg 
      of inhaled furosemide and placebo. The volunteers inhaled increasing 
      concentrations of lysine-aspirin after the inhalation of furosemide or placebo. 
      The geometric mean provocative dose causing a 20 percent decrease in the FEV1 
      (PD20) after the inhalation of placebo was 30.4 mg/ml and the PD20 was equal or 
      below 90 mg/ml in all patients. In contrast, the FEV1 did not decrease by 20 
      percent in any of the patients pretreated with furosemide when the inhaled 
      concentration was increased to 360 mg/ml. From this study, we conclude that the 
      administration of furosemide blocks the bronchospasm induced by the inhalation of 
      lysine-aspirin in aspirin-sensitive asthmatics.
FAU - Vargas, F S
AU  - Vargas FS
AD  - Instituto do Coraçao, University of Sao Paulo, Brazil.
FAU - Croce, M
AU  - Croce M
FAU - Teixeira, L R
AU  - Teixeira LR
FAU - Terra-Filho, M
AU  - Terra-Filho M
FAU - Cukier, A
AU  - Cukier A
FAU - Light, R W
AU  - Light RW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*analogs & 
      derivatives/antagonists & inhibitors
MH  - Asthma/*diagnosis/physiopathology
MH  - Bronchial Provocation Tests/*methods
MH  - Bronchoconstriction/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Furosemide/*administration & dosage/pharmacology
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives/antagonists & inhibitors
MH  - Spirometry
MH  - Time Factors
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
AID - S0012-3692(16)34034-X [pii]
AID - 10.1378/chest.102.2.408 [doi]
PST - ppublish
SO  - Chest. 1992 Aug;102(2):408-11. doi: 10.1378/chest.102.2.408.

PMID- 9083628
OWN - NLM
STAT- MEDLINE
DCOM- 19970605
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 25
IP  - 1-2
DP  - 1997 Jan-Mar
TI  - Dose response effect of diaspirin crosslinked hemoglobin (DCLHb) on systemic 
      hemodynamics and regional blood circulation in rats.
PG  - 75-84
AB  - Diaspirin crosslinked hemoglobin (DCLHb, Baxter Healthcare Corporation) a 
      hemoglobin-based blood substitute has been found to increase mean arterial 
      pressure (MAP) in a dose limiting manner. The present study was undertaken to 
      determine dose-dependent effects of DCLHb on systemic hemodynamics and regional 
      blood circulation. DCLHb (10% solution) in doses of 133, 400 and 1200 mg/kg i.v. 
      was given to urethane anaesthetized rats. Normal saline (12 ml/kg) served as a 
      control. Cardiovascular parameters were determined using a radioactive 
      microsphere technique. DCLHb in the doses of 133, 400 and 1200 mg/kg i.v. 
      produced a 46%, 67% and 65% increase in MAP, respectively. Total peripheral 
      resistance (TPR) increased significantly with 133 and 400 mg/kg dose, while 
      cardiac output increased significantly with 400 and 1200 mg/kg dose. There was no 
      change in heart rate. A dose of 133 mg/kg of DCLHb produced a significant 
      decrease in blood flow to the musculoskeletal system, kidney and liver. DCLHb in 
      the dose of 400 and 1200 mg/kg significantly increased blood flow to the heart, 
      gastrointestinal tract (GIT), mesentery & pancreas and skin. All doses of DCLHb 
      produced a significant increase in vascular resistance to the musculoskeletal 
      system and liver. DCLHb in the dose of 133 mg/kg increased resistance to the GIT. 
      heart, skin and kidneys, while the dose of 400 mg/kg increased resistance to the 
      kidneys. A dose of 1200 mg/kg decreased coronary vascular resistance. It is 
      concluded that cardiovascular effects appear to be different with higher (1200 
      mg/kg) and lower (133 mg/kg) doses of DCLHb.
FAU - Barve, A
AU  - Barve A
AD  - Department of Pharmaceutics & Pharmacodynamics, University of Illinois at Chicago 
      60612, USA.
FAU - Sen, A P
AU  - Sen AP
FAU - Saxena, P R
AU  - Saxena PR
FAU - Gulati, A
AU  - Gulati A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Blood Substitutes/chemistry/*pharmacology
MH  - Cross-Linking Reagents/chemistry/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Hemodynamics/*physiology
MH  - Hemoglobins/chemistry/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/drug effects/physiology
MH  - Vascular Resistance/drug effects/physiology
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.3109/10731199709118899 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1997 Jan-Mar;25(1-2):75-84. doi: 
      10.3109/10731199709118899.

PMID- 19596100
OWN - NLM
STAT- MEDLINE
DCOM- 20091117
LR  - 20181201
IS  - 0003-4509 (Print)
IS  - 0003-4509 (Linking)
VI  - 67
IP  - 4
DP  - 2009 Jul
TI  - [Study of variability in response to aspirin and clopidogrel: clinical and/or 
      biological resistance?].
PG  - 265-71
LID - 10.1016/j.pharma.2009.05.002 [doi]
AB  - Millions of people in France are taking long-term treatments with the two main 
      antiplatelet drugs, aspirin and/or clopidogrel. Most of these people are on a 
      secondary preventive regimen after arterial thrombotic events such as myocardial 
      infarction, stroke, or ischemic complications of lower limb arteriopathy. The 
      term resistance is often a source of confusion. When used, its definition should 
      be explicit. It would be probably be wiser to use a term such as "variable 
      response" which is more widely accepted by specialists and researchers. It would 
      be better to use the term variable platelet response since true pharmacological 
      resistance is rare. The distinction may have clinical pertinence in terms of 
      prognosis. An abundant amount of biological and clinical work in the literature 
      has improved our understanding of the topic. Diverse tests for exploring platelet 
      functions can be used to evaluate the biological impact of treatment. They 
      should, in the near future, contribute to the implementation of guidelines or 
      suggestions for optimal therapeutic modalities. Upcoming results of ongoing 
      large-scale prospective studies will be needed before confirming the potential 
      usefulness and clinical pertinence of these tests.
FAU - Samama, M-M
AU  - Samama MM
AD  - Service d'hématologie biologique, Hôtel-Dieu, 75004 Paris, France. 
      mmsamama@aol.com
FAU - Elalamy, I
AU  - Elalamy I
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Etude de la variabilité de réponse à l'aspirine et au clopidogrel: résistance 
      clinique et/ou biologique?
DEP - 20090703
PL  - France
TA  - Ann Pharm Fr
JT  - Annales pharmaceutiques francaises
JID - 2985176R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/blood/*prevention & control
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
RF  - 27
EDAT- 2009/07/15 09:00
MHDA- 2009/11/18 06:00
CRDT- 2009/07/15 09:00
PHST- 2009/02/25 00:00 [received]
PHST- 2009/05/05 00:00 [revised]
PHST- 2009/05/07 00:00 [accepted]
PHST- 2009/07/15 09:00 [entrez]
PHST- 2009/07/15 09:00 [pubmed]
PHST- 2009/11/18 06:00 [medline]
AID - S0003-4509(09)00080-7 [pii]
AID - 10.1016/j.pharma.2009.05.002 [doi]
PST - ppublish
SO  - Ann Pharm Fr. 2009 Jul;67(4):265-71. doi: 10.1016/j.pharma.2009.05.002. Epub 2009 
      Jul 3.

PMID- 12582467
OWN - NLM
STAT- MEDLINE
DCOM- 20030304
LR  - 20191106
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 38
IP  - 7
DP  - 2002 Jul
TI  - Nonplatelet-mediated effects of aspirin.
PG  - 501-7
AB  - Aspirin has nonplatelet-mediated effects that contribute to its efficacy in the 
      primary and secondary prevention of coronary events. These include antiarrhythmic 
      effects, as shown in animal studies, and antiatherosclerotic effects related to 
      increase in nitric oxide synthesis/activity and reduction in inflammatory 
      mediators. Epidemiological studies have also shown primary antiinflammatory 
      properties. Aspirin is known to inhibit vascular smooth muscle cell proliferation 
      and to produce an endothelial stabilizing effect. Other observed outcomes from 
      the administration of this compound include a modest anticoagulant activity, 
      angiogenesis reduction and a decrease in oxidant stress. We believe that these 
      results complement the antiplatelet effect and make this agent unique in the 
      management of ischemic heart disease.
CI  - Copyright 2002 Prous Science
FAU - Aude, Y Wady
AU  - Aude YW
AD  - Department of Medicine, University of Arkansas and Central Arkansas Veterans 
      Health Care System, Little Rock, AR, USA.
FAU - Mehta, J L
AU  - Mehta JL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Arteriosclerosis/prevention & control
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Humans
MH  - Inflammation/drug therapy
MH  - Muscle, Smooth, Vascular/drug effects
MH  - Neoplasms/prevention & control
MH  - Oxidative Stress/drug effects
RF  - 54
EDAT- 2003/02/13 04:00
MHDA- 2003/03/05 04:00
CRDT- 2003/02/13 04:00
PHST- 2003/02/13 04:00 [pubmed]
PHST- 2003/03/05 04:00 [medline]
PHST- 2003/02/13 04:00 [entrez]
AID - 820117 [pii]
AID - 10.1358/dot.2002.38.7.820117 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2002 Jul;38(7):501-7. doi: 10.1358/dot.2002.38.7.820117.

PMID- 11532311
OWN - NLM
STAT- MEDLINE
DCOM- 20011011
LR  - 20190915
IS  - 0168-3659 (Print)
IS  - 0168-3659 (Linking)
VI  - 76
IP  - 1-2
DP  - 2001 Sep 11
TI  - Investigation of the influence of mean HPMC particle size and number of polymer 
      particles on the release of aspirin from swellable hydrophilic matrix tablets.
PG  - 39-49
AB  - The effects of hydroxypropyl methylcellulose (HPMC) of different particle size 
      ranges, size distributions and concentrations on the release behaviour of aspirin 
      from a swellable matrix tablet system were studied. A mean HPMC (Methocel K15M 
      Premium) particle size of 113 microm was identified as a critical threshold in 
      this study. Drug release rate increased markedly when polymer particle size was 
      increased above 113 microm. Release rate was much less sensitive to changes in 
      particle size below 113 microm. Aspirin release mechanism followed first order 
      kinetics where mean HPMC particle size was below 113 microm. Release mechanism 
      deviated from first order kinetics when the mean particle size was above 113 
      microm. Polymer fractions with similar mean particle size but differing size 
      distribution were also observed to influence drug release rate but not release 
      mechanism. First order release constant K(1) was found to be quantitatively 
      related to the reciprocal of the cube root of both mean polymer particle size and 
      number of polymer particles in the matrix.
FAU - Heng, P W
AU  - Heng PW
AD  - Department of Pharmacy, National University of Singapore, 10, 119260, Kent Ridge 
      Crescent, Singapore. phapaulh@nus.edu.sg
FAU - Chan, L W
AU  - Chan LW
FAU - Easterbrook, M G
AU  - Easterbrook MG
FAU - Li, X
AU  - Li X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Oxazines)
RN  - 0 (Tablets)
RN  - 9004-67-5 (Methylcellulose)
RN  - 99705-65-4 (MK 458)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/chemistry
MH  - Lactose/*administration & dosage/analogs & derivatives
MH  - Methylcellulose/*administration & dosage/analogs & derivatives
MH  - Oxazines
MH  - Particle Size
MH  - Solubility
MH  - Tablets
EDAT- 2001/09/05 10:00
MHDA- 2001/10/12 10:01
CRDT- 2001/09/05 10:00
PHST- 2001/09/05 10:00 [pubmed]
PHST- 2001/10/12 10:01 [medline]
PHST- 2001/09/05 10:00 [entrez]
AID - S0168365901004102 [pii]
AID - 10.1016/s0168-3659(01)00410-2 [doi]
PST - ppublish
SO  - J Control Release. 2001 Sep 11;76(1-2):39-49. doi: 10.1016/s0168-3659(01)00410-2.

PMID- 1342877
OWN - NLM
STAT- MEDLINE
DCOM- 19940222
LR  - 20131121
IS  - 1018-9068 (Print)
IS  - 1018-9068 (Linking)
VI  - 2
IP  - 1
DP  - 1992 Jan-Feb
TI  - Topical acetylsalicylic acid in the treatment of allergic pollinosic 
      conjunctivitis.
PG  - 15-8
AB  - The pharmacological treatment of allergic conjunctivitis includes the use of 
      topical antiinflammatory drugs, i.e. steroids and NSAIDs (nonsteroidal 
      antiinflammatory drugs), such as acetylsalicylic acid (ASA). However, steroids 
      are not suitable in prolonged treatment, as well as in pollinosis in the 
      Mediterranean area, because of their side effects. The present double-blind study 
      evaluates the topical use of acetylsalicylic acid eye drops (1% solution) 
      compared to placebo in the treatment of patients with seasonal allergic 
      conjunctivitis during the period June-July 1990. The patients were randomized and 
      treated with ASA eye drops or placebo eye drops, both applied as one drop in each 
      eye q.i.d. for 14 days. The severity of symptoms was evaluated before and after 
      treatment by the investigator and the patient. An overall judgement of 
      therapeutic response was expressed independently by the patient and the 
      investigator at the end of the treatment. The ASA-treated group improved 
      significantly compared to the placebo-treated group. No serious side effects were 
      observed. The results confirm the clinical efficacy and safety of topical ASA in 
      the treatment of pollen-induced allergic conjunctivitis.
FAU - Ciprandi, G
AU  - Ciprandi G
AD  - Department of Internal Medicine, University of Genoa, Italy.
FAU - Buscaglia, S
AU  - Buscaglia S
FAU - Tosca, M
AU  - Tosca M
FAU - Canonica, G W
AU  - Canonica GW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Spain
TA  - J Investig Allergol Clin Immunol
JT  - Journal of investigational allergology & clinical immunology
JID - 9107858
RN  - 0 (Ophthalmic Solutions)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Conjunctivitis, Allergic/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ophthalmic Solutions
MH  - Safety
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - J Investig Allergol Clin Immunol. 1992 Jan-Feb;2(1):15-8.

PMID- 6779148
OWN - NLM
STAT- MEDLINE
DCOM- 19810327
LR  - 20131121
IS  - 0341-3098 (Print)
IS  - 0341-3098 (Linking)
VI  - 122
IP  - 49
DP  - 1980 Dec 5
TI  - [Persantin and aspirin in coronary heart disease. The persantin-aspirin 
      reinfarction study group (PARIS)].
PG  - 1761-71
AB  - In the Persantine-Aspirin Reinfarction Study (PARIS) trial 2026 persons who had 
      recovered from myocardial infarction (MI) were randomized into three groups: 
      Persantine plus Aspirin (PR/A) (n = 810); aspirin alone (ASA) (n = 810); placebo 
      (PLBO) (n = 406). The average length of follow-up study was 41 months. Results 
      for the three specified primary end points were: total mortality 16% lower in 
      PR/A and 18% lower in ASA compared with PLBO; coronary mortality 24% and 21% 
      lower; incidence of nonfatal MI plus fatal coronary disease 25% and 24% lower. 
      These differences were not statistically significant by the study criterion (Z 
      greater than or equal to 2.6). By life-table analysis, the rates of coronary 
      mortality and coronary incidence were about 50% lower in the PR/A group than in 
      the PLBO group from 8--24 months, and for coronary incidence all Z values were 
      greater than or equal to 2.6; ASA rates were about 30% lower than PLBO rates, and 
      for coronary incidence, Z values were greater than or equal to 2.6 at two points. 
      For these end points, from 8--20 months, PR/A rates were about 30% lower than ASA 
      rates, but all Z values were < 2.0. PR/A and ASA patients entering within 6 
      months of last MI showed the largest percentage reductions in mortality; only the 
      difference between PR/A and PLBO groups for 3-year coronary mortality yielded a Z 
      value of 2.6.
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Persantin und Azetylsalizylsäure bei koronarer Herzkrankheit.
PL  - Germany
TA  - MMW Munch Med Wochenschr
JT  - MMW, Munchener medizinische Wochenschrift
JID - 7801805
RN  - 0 (Placebos)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/*prevention & control
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Recurrence
MH  - Statistics as Topic
EDAT- 1980/12/05 00:00
MHDA- 1980/12/05 00:01
CRDT- 1980/12/05 00:00
PHST- 1980/12/05 00:00 [pubmed]
PHST- 1980/12/05 00:01 [medline]
PHST- 1980/12/05 00:00 [entrez]
PST - ppublish
SO  - MMW Munch Med Wochenschr. 1980 Dec 5;122(49):1761-71.

PMID- 16317809
OWN - NLM
STAT- MEDLINE
DCOM- 20060131
LR  - 20220316
IS  - 1740-7745 (Print)
IS  - 1740-7745 (Linking)
VI  - 2
IP  - 5
DP  - 2005
TI  - Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access 
      Stenosis Trial.
PG  - 400-12
AB  - BACKGROUND: Surgically created arteriovenous (AV) grafts are the most common type 
      of hemodialysis vascular access in the United States, but fail frequently due to 
      the development of venous stenosis. The Dialysis Access Consortium (DAC) Aggrenox 
      Prevention of Access Stenosis Trial tests the hypothesis that Aggrenox 
      (containing dipyridamole and aspirin) can prevent stenosis and prolong survival 
      of arteriovenous grafts. METHODS: This is a multicenter, randomized, 
      double-blind, placebo-controlled trial that will enroll 1056 subjects over four 
      years with one-half year follow-up. Subjects undergoing placement of a new AV 
      graft for hemodialysis are randomized to treatment with Aggrenox or placebo 
      immediately following access surgery. The primary outcome is primary unassisted 
      patency defined as the time from access placement until thrombosis or an access 
      procedure carried out to maintain or restore patency. The major secondary outcome 
      is cumulative access patency. Monthly access flow monitoring is incorporated in 
      the study design to enhance detection of a hemodynamically significant access 
      stenosis before it leads to thrombosis. RESULTS: This paper describes the key 
      issues in trial design, broadly including: 1) ethical issues surrounding the 
      study of a clinical procedure that, although common, is no longer the clinical 
      intervention of choice; 2) acceptable risk (bleeding) from the primary 
      intervention; 3) inclusion of subjects already receiving a portion of the study 
      intervention; 4) inclusion of subjects with incident rather than prevalent 
      qualifying clinical conditions; 5) timing of the study intervention to balance 
      safety and efficacy concerns; and 6) the selection of primary and secondary study 
      endpoints. CONCLUSIONS: This is the first, large, multicenter trial evaluating a 
      pharmacologic approach to prevent AV graft stenosis and failure, an important and 
      costly problem in this patient population. Numerous design issues were addressed 
      in implementing the trial and these will form a roadmap for future trials in this 
      area.
FAU - Dixon, Bradley S
AU  - Dixon BS
AD  - Nephrology Division, Veterans Affairs Medical Center and University of Iowa 
      School of Medicine, Iowa City 52242-1081, USA. bradley-dixon@uiowa.edu
FAU - Beck, Gerald J
AU  - Beck GJ
FAU - Dember, Laura M
AU  - Dember LM
FAU - Depner, Thomas A
AU  - Depner TA
FAU - Gassman, Jennifer J
AU  - Gassman JJ
FAU - Greene, Tom
AU  - Greene T
FAU - Himmelfarb, Jonathan
AU  - Himmelfarb J
FAU - Hunsicker, Lawrence G
AU  - Hunsicker LG
FAU - Kaufman, James S
AU  - Kaufman JS
FAU - Lawson, Jeffrey H
AU  - Lawson JH
FAU - Meyers, Catherine M
AU  - Meyers CM
FAU - Middleton, John P
AU  - Middleton JP
FAU - Radeva, Milena
AU  - Radeva M
FAU - Schwab, Steve J
AU  - Schwab SJ
FAU - Whiting, James F
AU  - Whiting JF
FAU - Feldman, Harold I
AU  - Feldman HI
CN  - DAC Study Group
LA  - eng
GR  - U01DK058981/DK/NIDDK NIH HHS/United States
GR  - U01 DK058986/DK/NIDDK NIH HHS/United States
GR  - U01DK058978/DK/NIDDK NIH HHS/United States
GR  - U01DK058985/DK/NIDDK NIH HHS/United States
GR  - U01DK058986/DK/NIDDK NIH HHS/United States
GR  - U01DK058966/DK/NIDDK NIH HHS/United States
GR  - U01DK058982/DK/NIDDK NIH HHS/United States
GR  - U01DK058973/DK/NIDDK NIH HHS/United States
GR  - U01DK058968/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Clin Trials
JT  - Clinical trials (London, England)
JID - 101197451
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - *Arteriovenous Shunt, Surgical
MH  - Aspirin/pharmacology/therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Delayed-Action Preparations/therapeutic use
MH  - Dipyridamole/pharmacology/therapeutic use
MH  - Drug Combinations
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - *Randomized Controlled Trials as Topic
MH  - *Renal Dialysis
MH  - Research Design
MH  - Sample Size
MH  - Vascular Patency/drug effects
EDAT- 2005/12/02 09:00
MHDA- 2006/02/01 09:00
CRDT- 2005/12/02 09:00
PHST- 2005/12/02 09:00 [pubmed]
PHST- 2006/02/01 09:00 [medline]
PHST- 2005/12/02 09:00 [entrez]
AID - 10.1191/1740774505cn110oa [doi]
PST - ppublish
SO  - Clin Trials. 2005;2(5):400-12. doi: 10.1191/1740774505cn110oa.

PMID- 11259548
OWN - NLM
STAT- MEDLINE
DCOM- 20010503
LR  - 20181130
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 297
IP  - 1
DP  - 2001 Apr
TI  - Effects of diaspirin cross-linked hemoglobin (DCLHb) during and post-CPR in 
      swine.
PG  - 224-9
AB  - The purpose of the study was to test the hypothesis that diaspirin cross-linked 
      hemoglobin (DCLHb) can produce improved resuscitation during cardiac arrest. 
      DCLHb, a derivative of human hemoglobin, has previously been demonstrated to 
      produce a vasopressor response that is associated with increased blood flow to 
      vital organs. In addition, it is an oxygen carrier. These effects may be 
      beneficial to extreme low flow states, such as that during cardiac arrest and 
      cardiopulmonary resuscitation (CPR). Experimental cardiac arrest and CPR were 
      carried out in 32 anesthetized immature pigs. In each animal, ventricular 
      fibrillation was induced for 5 min, followed by 10 min of standard CPR with a 
      pneumatic device and room air ventilation. High (15 ml/kg) and low (5 ml/kg) 
      doses of DCLHb or equivalent volume of normal saline were infused at the 
      beginning of CPR in a random and blind manner. Cardiac output, organ blood flow, 
      aortic pressure, coronary perfusion pressure, blood gases, and lactate 
      concentrations were obtained before and during CPR. Following the 10-min CPR, the 
      animals were defibrillated and the return of spontaneous circulation (ROSC) 
      determined. DCLHb treatment achieved 75% ROSC compared with 25% in the saline 
      group (p < 0.05). In addition, a better (p < 0.05) myocardial O(2) delivery, 
      venous blood O(2) content, and myocardial and cerebral perfusion pressure were 
      observed in the DCLHb group. DCLHb treatment during cardiac arrest and CPR 
      significantly improves ROSC. This is most likely related to its improvement in 
      coronary perfusion and myocardial oxygen delivery.
FAU - Chow, M S
AU  - Chow MS
AD  - The Chinese University of Hong Kong, School of Pharmacy, Faculty of Medicine, 
      Shatin, Hong Kong, China. msschow@cuhk.edu.hk
FAU - Fan, C
AU  - Fan C
FAU - Tran, H
AU  - Tran H
FAU - Zhao, H
AU  - Zhao H
FAU - Zhou, L
AU  - Zhou L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Blood Pressure
MH  - Blood Substitutes/*pharmacology
MH  - *Cardiopulmonary Resuscitation
MH  - Female
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Oxygen/blood
MH  - Swine
EDAT- 2001/03/22 10:00
MHDA- 2001/05/05 10:01
CRDT- 2001/03/22 10:00
PHST- 2001/03/22 10:00 [pubmed]
PHST- 2001/05/05 10:01 [medline]
PHST- 2001/03/22 10:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2001 Apr;297(1):224-9.

PMID- 30665790
OWN - NLM
STAT- MEDLINE
DCOM- 20190226
LR  - 20190226
IS  - 2213-0276 (Electronic)
IS  - 0755-4982 (Linking)
VI  - 48
IP  - 1 Pt 1
DP  - 2019 Jan
TI  - [Aspirin and preeclampsia].
PG  - 34-45
LID - S0755-4982(18)30480-9 [pii]
LID - 10.1016/j.lpm.2018.11.022 [doi]
AB  - Indications for aspirin during pregnancy are a matter of debate and there is a 
      recent trend to an extended prescription and an overuse of aspirin in pregnancy. 
      Aspirin is efficient in secondary prevention of preeclampsia essentially in 
      patients with a personal history of preeclampsia. The effect of aspirin on 
      platelet aggregation and on the TXA2/PGI2 balance is dose-dependent. The optimum 
      dosage, from 75mg/day to 150mg/day, needs to be determined. Fetal safety data at 
      150mg/day are still limited. The efficacy of aspirin seems to be subject to a 
      chronobiological effect. It is recommended to prescribe an evening or bedtime 
      intake. Aspirin, in primary prevention of preeclampsia, given to high-risk 
      patients identified in the first trimester by screening tests, seems to reduce 
      the occurrence of early-onset preeclampsia. Nevertheless, there are insufficient 
      data for the implementation of such screening procedures in practice.
CI  - Copyright © 2018 Elsevier Masson SAS. All rights reserved.
FAU - Atallah, Anthony
AU  - Atallah A
AD  - Groupement hospitalier Est, centre hospitalier universitaire, département de 
      gynécologie-obstétrique, maternité de l'hôpital Femme-Mère-Enfant, hospices 
      civils de Lyon, 59, boulevard Pinel, 69100 Bron, France; Université 
      Claude-Bernard Lyon1, Lyon, France. Electronic address: 
      anthony.atallah@chu-lyon.fr.
FAU - Lecarpentier, Edouard
AU  - Lecarpentier E
AD  - Centre hospitalier intercommunal de Créteil, centre hospitalier universitaire, 
      université Paris Est Créteil, département de gynécologie-obstétrique, maternité 
      de l'hôpital intercommunal de Créteil, 40, avenue de Verdun, 94000 Créteil, 
      France.
FAU - Goffinet, François
AU  - Goffinet F
AD  - Assistance publique-Hôpital de Paris, centre hospitalier universitaire Cochin 
      Broca Hôtel-Dieu, groupe hospitalier universitaire Ouest, département de 
      gynécologie-obstétrique, maternité de Port-Royal, 53, avenue de l'Observatoire, 
      75014 Paris, France; PRES Sorbonne Paris Cité, université Paris Descartes, Paris, 
      France; Fondation PremUP, Paris, France; DHU Risques et grossesse, Paris, France.
FAU - Gaucherand, Pascal
AU  - Gaucherand P
AD  - Groupement hospitalier Est, centre hospitalier universitaire, département de 
      gynécologie-obstétrique, maternité de l'hôpital Femme-Mère-Enfant, hospices 
      civils de Lyon, 59, boulevard Pinel, 69100 Bron, France; Université 
      Claude-Bernard Lyon1, Lyon, France.
FAU - Doret-Dion, Muriel
AU  - Doret-Dion M
AD  - Groupement hospitalier Est, centre hospitalier universitaire, département de 
      gynécologie-obstétrique, maternité de l'hôpital Femme-Mère-Enfant, hospices 
      civils de Lyon, 59, boulevard Pinel, 69100 Bron, France; Université 
      Claude-Bernard Lyon1, Lyon, France.
FAU - Tsatsaris, Vassilis
AU  - Tsatsaris V
AD  - Assistance publique-Hôpital de Paris, centre hospitalier universitaire Cochin 
      Broca Hôtel-Dieu, groupe hospitalier universitaire Ouest, département de 
      gynécologie-obstétrique, maternité de Port-Royal, 53, avenue de l'Observatoire, 
      75014 Paris, France; PRES Sorbonne Paris Cité, université Paris Descartes, Paris, 
      France; Fondation PremUP, Paris, France; DHU Risques et grossesse, Paris, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Aspirine et prééclampsie.
DEP - 20190118
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prostaglandin Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use
MH  - Chronobiology Phenomena
MH  - Contraindications, Drug
MH  - Cyclooxygenase Inhibitors/administration & dosage/adverse 
      effects/pharmacokinetics/therapeutic use
MH  - Drug Utilization
MH  - Early Diagnosis
MH  - Female
MH  - Fetal Diseases/chemically induced
MH  - France/epidemiology
MH  - Humans
MH  - Mass Screening
MH  - Meta-Analysis as Topic
MH  - Placenta/metabolism
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/pharmacokinetics/*therapeutic use
MH  - Pre-Eclampsia/diagnosis/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications/chemically induced
MH  - Pregnancy Trimester, First
MH  - Primary Prevention
MH  - Prostaglandin Antagonists/administration & dosage/adverse 
      effects/pharmacokinetics/therapeutic use
MH  - Risk Factors
MH  - Secondary Prevention
EDAT- 2019/01/23 06:00
MHDA- 2019/02/27 06:00
CRDT- 2019/01/23 06:00
PHST- 2018/04/30 00:00 [received]
PHST- 2018/08/02 00:00 [revised]
PHST- 2018/11/27 00:00 [accepted]
PHST- 2019/01/23 06:00 [pubmed]
PHST- 2019/02/27 06:00 [medline]
PHST- 2019/01/23 06:00 [entrez]
AID - S0755-4982(18)30480-9 [pii]
AID - 10.1016/j.lpm.2018.11.022 [doi]
PST - ppublish
SO  - Presse Med. 2019 Jan;48(1 Pt 1):34-45. doi: 10.1016/j.lpm.2018.11.022. Epub 2019 
      Jan 18.

PMID- 20869297
OWN - NLM
STAT- MEDLINE
DCOM- 20110228
LR  - 20131121
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 77
IP  - 5
DP  - 2010 Dec
TI  - Spectroscopic studies of the interaction of aspirin and its important metabolite, 
      salicylate ion, with DNA, A·T and G·C rich sequences.
PG  - 1077-83
LID - 10.1016/j.saa.2010.08.078 [doi]
AB  - Among different biological effects of acetylsalicylic acid (ASA), its anticancer 
      property is controversial. Since ASA hydrolyzes rapidly to salicylic acid (SA), 
      especially in the blood, interaction of both ASA and SA (as the small molecules) 
      with ctDNA, oligo(dA·dT)15 and oligo(dG·dC)15, as a possible mechanism of their 
      action, is investigated here. The results show that the rate of ASA hydrolysis in 
      the absence and presence of ctDNA is similar. The spectrophotometric results 
      indicate that both ASA and SA cooperatively bind to ctDNA. The binding constants 
      (K) are (1.7±0.7)×10(3) M(-1) and (6.7±0.2)×10(3) M(-1) for ASA and SA, 
      respectively. Both ligands quench the fluorescence emission of ethidium bromide 
      (Et)-ctDNA complex. The Scatchard plots indicate the non-displacement based 
      quenching (non-intercalative binding). The circular dichroism (CD) spectra of 
      ASA- or SA-ctDsNA complexes show the minor distortion of ctDNA structure, with no 
      characteristic peaks for intercalation of ligands. Tm of ctDNA is decreased up to 
      3°C upon ASA binding. The CD results also indicate more distortions on 
      oligo(dG·dC)15 structure due to the binding of both ASA and SA in comparison with 
      oligo(dA·dT)15. All data indicate the more affinity for SA binding with DNA minor 
      groove in comparison with ASA which has more hydrophobic character.
CI  - Copyright © 2010 Elsevier B.V. All rights reserved.
FAU - Bathaie, S Z
AU  - Bathaie SZ
AD  - Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares 
      University, P.O. Box: 14115-111, Tehran, Iran. z.batha2000@yahoo.com
FAU - Nikfarjam, L
AU  - Nikfarjam L
FAU - Rahmanpour, R
AU  - Rahmanpour R
FAU - Moosavi-Movahedi, A A
AU  - Moosavi-Movahedi AA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 0 (Salicylates)
RN  - 9007-49-2 (DNA)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/*metabolism/pharmacology
MH  - Base Composition/drug effects/*physiology
MH  - Base Sequence
MH  - Circular Dichroism/methods
MH  - DNA/chemistry/drug effects/*metabolism
MH  - Drug Evaluation, Preclinical
MH  - Drug Interactions
MH  - Models, Biological
MH  - Nucleic Acid Conformation
MH  - Salicylates/*chemistry/*metabolism
MH  - Spectrometry, Fluorescence/methods
MH  - Spectrophotometry, Ultraviolet/methods
MH  - Spectrum Analysis/methods
EDAT- 2010/09/28 06:00
MHDA- 2011/03/01 06:00
CRDT- 2010/09/28 06:00
PHST- 2010/05/28 00:00 [received]
PHST- 2010/08/01 00:00 [revised]
PHST- 2010/08/26 00:00 [accepted]
PHST- 2010/09/28 06:00 [entrez]
PHST- 2010/09/28 06:00 [pubmed]
PHST- 2011/03/01 06:00 [medline]
AID - S1386-1425(10)00468-3 [pii]
AID - 10.1016/j.saa.2010.08.078 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2010 Dec;77(5):1077-83. doi: 
      10.1016/j.saa.2010.08.078.

PMID- 3958916
OWN - NLM
STAT- MEDLINE
DCOM- 19860425
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 75
IP  - 1
DP  - 1986 Jan
TI  - Stability of aspirin in solid mixtures.
PG  - 97-101
AB  - It has been shown that the degradation of aspirin in mixtures may be monitored by 
      thermal analytical techniques. The methodology employed differential scanning 
      calorimetry and thermal gravimetric analysis by standard techniques providing 
      simple and rapid analysis for screening the stability of aspirin in mixtures. The 
      degradation was found to depend on the nature of the additive but, in particular, 
      the presence of acidic or basic groups within its structure.
FAU - Ager, D J
AU  - Ager DJ
FAU - Alexander, K S
AU  - Alexander KS
FAU - Bhatti, A S
AU  - Bhatti AS
FAU - Blackburn, J S
AU  - Blackburn JS
FAU - Dollimore, D
AU  - Dollimore D
FAU - Koogan, T S
AU  - Koogan TS
FAU - Mooseman, K A
AU  - Mooseman KA
FAU - Muhvic, G M
AU  - Muhvic GM
FAU - Sims, B
AU  - Sims B
FAU - Webb, V J
AU  - Webb VJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Indicators and Reagents)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Calorimetry, Differential Scanning
MH  - Chromatography, Gas
MH  - Drug Stability
MH  - Indicators and Reagents
MH  - Magnetic Resonance Spectroscopy
MH  - Tablets
MH  - Temperature
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - S0022-3549(15)46977-1 [pii]
AID - 10.1002/jps.2600750124 [doi]
PST - ppublish
SO  - J Pharm Sci. 1986 Jan;75(1):97-101. doi: 10.1002/jps.2600750124.

PMID- 11165987
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20220311
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 110
IP  - 1A
DP  - 2001 Jan 8
TI  - Nonsteroidal anti-inflammatory drug prescribing: past, present, and future.
PG  - 4S-7S
AB  - Nonsteroidal anti-inflammatory drugs, including aspirin, are now among the most 
      widely prescribed medications in the world. They have a long and fascinating 
      history, with the use of aspirin derived from willow bark stretching back into 
      the Assyrian culture. In the twenty-first century we are faced with both the 
      challenge of balancing the benefits and side effects of these drugs and the 
      exciting prospect of new, safer agents with comparable efficacy.
FAU - Jones, R
AU  - Jones R
AD  - Guy's, King's & St. Thomas' School of Medicine, London, United Kingdom.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*history/therapeutic use
MH  - Aspirin/*history/therapeutic use
MH  - Drug Prescriptions/history/statistics & numerical data
MH  - Europe
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, Ancient
MH  - History, Medieval
MH  - Humans
RF  - 10
EDAT- 2001/02/13 11:00
MHDA- 2001/04/03 10:01
CRDT- 2001/02/13 11:00
PHST- 2001/02/13 11:00 [pubmed]
PHST- 2001/04/03 10:01 [medline]
PHST- 2001/02/13 11:00 [entrez]
AID - S0002934300006276 [pii]
AID - 10.1016/s0002-9343(00)00627-6 [doi]
PST - ppublish
SO  - Am J Med. 2001 Jan 8;110(1A):4S-7S. doi: 10.1016/s0002-9343(00)00627-6.

PMID- 10976713
OWN - NLM
STAT- MEDLINE
DCOM- 20010116
LR  - 20131121
IS  - 1386-0291 (Print)
IS  - 1386-0291 (Linking)
VI  - 22
IP  - 3
DP  - 2000
TI  - Effect of naftidrofuryl on platelet aggregation in plasma from aspirin treated 
      patients: an in vitro study.
PG  - 197-204
AB  - This study concerns an in vitro evaluation of the effect of naftidrofuryl on 
      platelet aggregation in plasma of 15 diabetic patients, who were being treated 
      with aspirin, and who were suffering from chronic arterial disease of the lower 
      limbs. Platelet aggregation, induced either spontaneously or by aggregating 
      agents, was measured in platelet-rich plasma (PRP). The results show that 
      serotonin (5-HT)- and adenosine 5'-diphosphate (ADP)-induced platelet aggregation 
      significantly decreased after addition of naftidrofuryl. Decreases were achieved 
      with naftidrofuryl at a low dose (0.06 microM) and became more marked with 
      naftidrofuryl at higher concentrations. In contrast, naftidrofuryl did not appear 
      to modify routinely spontaneous platelet aggregation. These results show an in 
      vitro antiaggregating effect of naftidrofuryl on platelets of aspirinized 
      patients. However, the clinical interest of a such coadministration of 
      naftidrofuryl and aspirin in patients, has still to be confirmed in a double 
      blind randomized trial.
FAU - Le Dévéhat, C
AU  - Le Dévéhat C
AD  - Diabetology, Endocrinology and Nutrition Department, Centre Hospitalier, Nevers, 
      France. ledevehat@ifrance.com
FAU - Khodabandehlou, T
AU  - Khodabandehlou T
FAU - Mosnier, M
AU  - Mosnier M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - 42H8PQ0NMJ (Nafronyl)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Diabetic Angiopathies/*drug therapy
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nafronyl/*pharmacology
MH  - Peripheral Vascular Diseases/*drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Vasodilator Agents/*pharmacology
EDAT- 2000/09/08 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/08 11:00
PHST- 2000/09/08 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/08 11:00 [entrez]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 2000;22(3):197-204.

PMID- 1600651
OWN - NLM
STAT- MEDLINE
DCOM- 19920716
LR  - 20161123
IS  - 0009-921X (Print)
IS  - 0009-921X (Linking)
IP  - 279
DP  - 1992 Jun
TI  - Short-term treatment with nonsteroidal antiinflammatory medications to prevent 
      heterotopic bone formation after total hip arthroplasty. A preliminary report.
PG  - 157-62
AB  - The effect of short-term postoperative treatment with nonsteroidal 
      antiinflammatory medication to prevent the formation of heterotopic ossification 
      (HO) after total hip arthroplasty (THA) was studied in two groups of patients. 
      Group A included 46 noncemented THAs in 40 men. Eight patients (13 hips) received 
      prophylaxis with 25 mg of indomethacin three times daily for 14 days, and 32 
      patients (33 hips) received prophylaxis of 650 mg of aspirin twice daily for six 
      weeks. Six to 12 months after surgery, only one hip (aspirin treated) developed 
      HO, this being Grade I. In group B, 17 hips in 17 patients with cemented THA 
      received prophylaxis of 25 mg of indomethacin three times daily. Of these, 12 
      patients were given indomethacin from one to nine days. One year after surgery, 
      five hips had no HO and seven hips showed a Grade I or Grade II lesion. The 
      remaining five patients in Group B received indomethacin from 19 to 26 days; one 
      developed HO. This study demonstrated that treatment with either 650 mg of 
      aspirin twice daily for six weeks or 25 mg of indomethacin three times daily for 
      the first 14 postoperative days is sufficient to prevent the formation of severe 
      HO after THA.
FAU - Kjaersgaard-Andersen, P
AU  - Kjaersgaard-Andersen P
AD  - Orthopaedic Hospital, University of Aarhus, Denmark.
FAU - Ritter, M A
AU  - Ritter MA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Hip Prosthesis
MH  - Humans
MH  - Indomethacin/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Ossification, Heterotopic/diagnostic imaging/*prevention & control
MH  - Postoperative Complications/prevention & control
MH  - Radiography
EDAT- 1992/06/01 00:00
MHDA- 1992/06/01 00:01
CRDT- 1992/06/01 00:00
PHST- 1992/06/01 00:00 [pubmed]
PHST- 1992/06/01 00:01 [medline]
PHST- 1992/06/01 00:00 [entrez]
PST - ppublish
SO  - Clin Orthop Relat Res. 1992 Jun;(279):157-62.

PMID- 3341280
OWN - NLM
STAT- MEDLINE
DCOM- 19880311
LR  - 20190510
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 89
IP  - 2
DP  - 1988 Feb
TI  - A rapid assay for platelet thromboxane production and its use in assessing prior 
      aspirin ingestion.
PG  - 216-21
AB  - In the laboratory evaluation of platelet disorders, there are a number of 
      situations in which determining the capacity of platelets to synthesize 
      thromboxane is of diagnostic value. An assay for thromboxane production is 
      required for the diagnosis of cyclooxygenase and thromboxane synthetase defects 
      and is useful in detecting prior aspirin ingestion. The authors describe an assay 
      for platelet thromboxane production that is simple, rapid, inexpensive, and 
      suitable for routine use in the clinical coagulation laboratory. It is based on 
      platelet synthesis of 14C-thromboxane from 14C-arachidonate. 14C-thromboxane is 
      isolated by thin-layer chromatography and its radioactivity quantitated by 
      scintillation counting. The results are expressed as the thromboxane index: 
      14C-arachidonate converted to thromboxane/platelet count. The assay is linear 
      with respect to platelet concentration and substrate concentration and is 
      independent of recovery. Using this assay, the authors demonstrated that platelet 
      thromboxane production, expressed as thromboxane index (mean +/- standard 
      deviation) was completely inhibited 12-16 hours after ingestion of a single 
      aspirin dose of 650 mg (0.27 +/- 0.14), 325 mg (0.29 +/- 0.18), or 163 mg (0.13 
      +/- 0.13), with partial inhibition by 81 mg (0.41 +/- 0.46) or 41 mg (1.41 +/- 
      0.75) (n = 3 for each dose). Thromboxane index for normal controls was 2.41 +/- 
      0.77 (n = 25). The authors also determined the time for recovery of thromboxane 
      synthetic capacity to normal levels in four subjects followed longitudinally 
      after ingesting a single 650-mg dose of aspirin. Platelets from three of the four 
      subjects recovered normal thromboxane synthetic capacity by the fifth day after 
      aspirin ingestion, consistent with platelet half-life in the circulation. Thus, 
      the authors have developed a rapid, inexpensive assay for assessing the function 
      of cyclooxygenase and thromboxane synthetase in platelets, which can be 
      especially useful as a screening test to detect ingestion of aspirin before 
      performance of expensive and labor-intensive platelet function studies.
FAU - Connor, A M
AU  - Connor AM
AD  - Department of Pathology and Laboratory Medicine, Hospital of the University of 
      Pennsylvania, Philadelphia 19104.
FAU - Laposata, M
AU  - Laposata M
LA  - eng
GR  - 1 RO1 AM37454-01/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Thromboxanes/antagonists & inhibitors/*biosynthesis
MH  - Time Factors
EDAT- 1988/02/01 00:00
MHDA- 1988/02/01 00:01
CRDT- 1988/02/01 00:00
PHST- 1988/02/01 00:00 [pubmed]
PHST- 1988/02/01 00:01 [medline]
PHST- 1988/02/01 00:00 [entrez]
AID - 10.1093/ajcp/89.2.216 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1988 Feb;89(2):216-21. doi: 10.1093/ajcp/89.2.216.

PMID- 2723963
OWN - NLM
STAT- MEDLINE
DCOM- 19890626
LR  - 20131121
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 6
IP  - 2
DP  - 1989 Apr-Jun
TI  - Evaluation of compressibility of pentaestergum coated aspirin microcapsules.
PG  - 199-203
AB  - We have earlier reported the usefulness of the pentaerythritol rosin ester 
      (pentaestergum) as a coating material, its dissolution kinetics and in vivo 
      release studies in dogs. The present communication deals with the compressibility 
      of the pentaestergum-coated aspirin microcapsules. The microcapsules were 
      prepared by the pan-coating method described earlier. These were compressed into 
      the tablets using a single punch machine. The tablets were evaluated for 
      hardness, friability loss, disintegration time and dissolution studies. The 
      results showed that there were significant differences in the release 
      characteristics from the microcapsules and the compressed tablets. The effect of 
      5 per cent starch as a disintegrating agent in the tablet formulation was also 
      studied. The results showed that the tablets can be a suitable dosage form for 
      pentaestergum-coated microcapsules to give a delayed drug release.
FAU - Pathak, Y V
AU  - Pathak YV
AD  - College of Pharmacy, Manipal, India.
FAU - Dorle, A K
AU  - Dorle AK
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Capsules)
RN  - 0 (Propylene Glycols)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
RN  - SU420W1S6N (pentaerythritol)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Capsules
MH  - Hydrogen-Ion Concentration
MH  - Propylene Glycols
MH  - Tablets, Enteric-Coated
EDAT- 1989/04/01 00:00
MHDA- 1989/04/01 00:01
CRDT- 1989/04/01 00:00
PHST- 1989/04/01 00:00 [pubmed]
PHST- 1989/04/01 00:01 [medline]
PHST- 1989/04/01 00:00 [entrez]
AID - 10.3109/02652048909098021 [doi]
PST - ppublish
SO  - J Microencapsul. 1989 Apr-Jun;6(2):199-203. doi: 10.3109/02652048909098021.

PMID- 7160424
OWN - NLM
STAT- MEDLINE
DCOM- 19830415
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 23
IP  - 6
DP  - 1982
TI  - Plasma levels of aspirin following effervescent and enteric coated tablets, and 
      their effect on platelet function.
PG  - 545-51
AB  - Single doses of effervescent tablets (1200 mg) and enteric coated (EC) tablets 
      (1300 mg and 650 mg) of acetylsalicylic acid (aspirin, ASA) were given to healthy 
      volunteers in random order. Plasma ASA and salicylic acid (SA) levels were 
      measured and concurrent in vitro measurements of the volunteers' platelet 
      aggregation were carried out. The effervescent preparation resulted in peak ASA 
      concentrations of 17-40 mg/l, achieved 20 to 30 min after a 1200 mg dose, whereas 
      peak ASA levels of 0.01-0.37 mg/l were observed 4-6 h after a 650 mg dose of the 
      EC preparation. With all the aggregating agents that were added to the test 
      system maximum inhibition of platelet aggregation (about 50% of pre dose levels) 
      was seen 1.0 h after the effervescent ASA dose, and persisted to at least 24 h, 
      but with the EC preparation not until 24 h, at which time the degree of 
      inhibition was also about 50% of pre-dose levels. A 1.0 g dose of sodium 
      salicylate had no effect on in vitro platelet function. It was concluded that 
      mean plasma levels of ASA of less than 0.25 mg/l are sufficient to depress 
      aggregation by approximately 50%. A low dose of ASA taken daily either as 
      effervescent ASA or EC ASA, significantly inhibits platelet aggregation and so 
      may reduce the risk of ischaemic episodes in susceptible patients.
FAU - Ross-Lee, L M
AU  - Ross-Lee LM
FAU - Elms, M J
AU  - Elms MJ
FAU - Cham, B E
AU  - Cham BE
FAU - Bochner, F
AU  - Bochner F
FAU - Bunce, I H
AU  - Bunce IH
FAU - Eadie, M J
AU  - Eadie MJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*blood/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Sodium Salicylate/administration & dosage/blood
MH  - Tablets, Enteric-Coated
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1007/BF00637504 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1982;23(6):545-51. doi: 10.1007/BF00637504.

PMID- 8706118
OWN - NLM
STAT- MEDLINE
DCOM- 19960912
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 15
IP  - 6
DP  - 1995 Dec
TI  - Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison 
      with acetylsalicylic acid and placebo.
PG  - 531-5
AB  - A double-blind, threefold crossover, double-dummy trial was performed, 
      investigating the efficacy of 200 mg ibuprofen compared with 500 mg 
      acetylsalicylic acid and placebo in patients who usually treated their headaches 
      with over-the-counter drugs. Ninety-five patients suffering from mild to moderate 
      migraine or episodic tension-type headache were included. Seventy-seven patients 
      entered the intention-to-treat analysis and 65 completed all three treatments. 
      For the main response criterion, a minimum 50% decrease of headache intensity on 
      a visual analogue scale at 1 h after treatment, ibuprofen was significantly 
      superior to acetylsalicylic acid and placebo. This was true for migraine attacks 
      and tension-type headache episodes. Towards the end of the observation period 
      (150 min), the differences between ibuprofen and acetylsalicylic acid were no 
      longer significant. In conclusion, ibuprofen was at least equivalent to 
      acetylsalicylic acid and superior to placebo.
FAU - Nebe, J
AU  - Nebe J
AD  - Department of Neurology, University of Essen, Germany.
FAU - Heier, M
AU  - Heier M
FAU - Diener, H C
AU  - Diener HC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Case-Control Studies
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Ibuprofen/administration & dosage/*therapeutic use
MH  - Male
MH  - Placebos
MH  - *Self Medication
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
AID - 10.1046/j.1468-2982.1995.1506531.x [doi]
PST - ppublish
SO  - Cephalalgia. 1995 Dec;15(6):531-5. doi: 10.1046/j.1468-2982.1995.1506531.x.

PMID- 22579989
OWN - NLM
STAT- MEDLINE
DCOM- 20121119
LR  - 20131121
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 433
IP  - 1-2
DP  - 2012 Aug 20
TI  - Distribution of esterase activity in porcine ear skin, and the effects of 
      freezing and heat separation.
PG  - 10-5
LID - 10.1016/j.ijpharm.2012.04.079 [doi]
AB  - Porcine ear skin is widely used to study skin permeation and absorption of ester 
      compounds, whose permeation and absorption profiles may be directly influenced by 
      in situ skin esterase activity. Importantly, esterase distribution and activity 
      in porcine ear skin following common protocols of skin handling and storage have 
      not been characterised. Thus, we have compared the distribution and hydrolytic 
      activity of esterases in freshly excised, frozen, heated and explanted porcine 
      ear skin. Using an esterase staining kit, esterase activity was found to be 
      localised in the stratum corneum and viable epidermis. Under frozen storage and a 
      common heating protocol of epidermal sheet separation, esterase staining in the 
      skin visibly diminished. This was confirmed by a quantitative assay using HPLC to 
      monitor the hydrolysis of aspirin, in freshly excised, frozen or heated porcine 
      ear skin. Compared to vehicle-only control, the rate of aspirin hydrolysis was 
      approximately three-fold higher in the presence of freshly excised skin, but no 
      different in the presence of frozen or heated skin. Therefore, frozen and 
      heat-separated porcine ear skin should not be used to study the permeation of 
      ester-containing permeants, in particular co-drugs and pro-drugs, whose 
      hydrolysis or degradation can be modulated by skin esterases.
CI  - Copyright © 2012 Elsevier B.V. All rights reserved.
FAU - Lau, Wing Man
AU  - Lau WM
AD  - School of Pharmacy, University of Reading, Whiteknights, PO Box 226, Reading RG6 
      6AP, UK. w.lau@reading.ac.uk
FAU - Ng, Keng Wooi
AU  - Ng KW
FAU - Sakenyte, Kristina
AU  - Sakenyte K
FAU - Heard, Charles M
AU  - Heard CM
LA  - eng
PT  - Journal Article
DEP - 20120508
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - EC 3.1.- (Esterases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry/*pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Esterases/*metabolism
MH  - Freezing
MH  - Hot Temperature
MH  - Hydrolysis
MH  - Permeability
MH  - Skin/enzymology/*metabolism
MH  - *Skin Absorption
MH  - Swine
MH  - Tissue Distribution
EDAT- 2012/05/15 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/05/15 06:00
PHST- 2012/02/21 00:00 [received]
PHST- 2012/04/18 00:00 [revised]
PHST- 2012/04/21 00:00 [accepted]
PHST- 2012/05/15 06:00 [entrez]
PHST- 2012/05/15 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S0378-5173(12)00455-3 [pii]
AID - 10.1016/j.ijpharm.2012.04.079 [doi]
PST - ppublish
SO  - Int J Pharm. 2012 Aug 20;433(1-2):10-5. doi: 10.1016/j.ijpharm.2012.04.079. Epub 
      2012 May 8.

PMID- 7466399
OWN - NLM
STAT- MEDLINE
DCOM- 19810424
LR  - 20190618
IS  - 0036-8075 (Print)
IS  - 0036-8075 (Linking)
VI  - 211
IP  - 4489
DP  - 1981 Mar 27
TI  - Aspirin prevention of cholesterol gallstone formation in prairie dogs.
PG  - 1429-31
AB  - When prairie dogs (Cynomys ludovicianus) are fed a diet containing cholesterol, a 
      marked increase in gallbladder mucin secretion parallels the evolution of 
      cholesterol supersaturated bile. Gelation of mucin precedes the precipitation of 
      cholesterol liquid and solid crystals and the development of gallstones. Aspirin 
      given to prairie dogs inhibited mucin hypersecretion and gel accumulation and 
      prevented gallstone formation without influencing the cholesterol content of 
      supersaturated bile. This suggests that gallbladder mucin is a nucleation matrix 
      for cholesterol gallstones.
FAU - Lee, S P
AU  - Lee SP
FAU - Carey, M C
AU  - Carey MC
FAU - LaMont, J T
AU  - LaMont JT
LA  - eng
GR  - 5 FO5 TWO2663-02/TW/FIC NIH HHS/United States
GR  - AM 18559/AM/NIADDK NIH HHS/United States
GR  - AM 21892/AM/NIADDK NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (Cholesterol, Dietary)
RN  - 0 (Lipids)
RN  - 0 (Mucins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Bile/analysis
MH  - Cholelithiasis/metabolism/*prevention & control
MH  - Cholesterol, Dietary/metabolism
MH  - Crystallization
MH  - Culture Techniques
MH  - Gallbladder/metabolism
MH  - Lipids/analysis
MH  - Mucins/*metabolism
MH  - Sciuridae
MH  - Secretory Rate/drug effects
EDAT- 1981/03/27 00:00
MHDA- 1981/03/27 00:01
CRDT- 1981/03/27 00:00
PHST- 1981/03/27 00:00 [pubmed]
PHST- 1981/03/27 00:01 [medline]
PHST- 1981/03/27 00:00 [entrez]
AID - 10.1126/science.7466399 [doi]
PST - ppublish
SO  - Science. 1981 Mar 27;211(4489):1429-31. doi: 10.1126/science.7466399.

PMID- 27424342
OWN - NLM
STAT- MEDLINE
DCOM- 20160726
LR  - 20160718
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 12
IP  - 520
DP  - 2016 May 25
TI  - [Dual antiplatelet therapy for treatment and secondary prevention of coronary 
      artery disease: indications, modalities and duration].
PG  - 1022-6, 1028-34
AB  - The choice and optimal duration of dualantiplatelet therapy (DAPT) for the 
      treatment of coronary artery disease (CAD) represent a challenging clinical 
      dilemma. Antiplatelet treatment strategies are determined by the clinical 
      setting, patient comorbidities and management strategy. While aspirin remains the 
      cornerstone for secondary prevention of CAD, DAPT significantly reduces recurrent 
      ischemic adverse events at the expense of an increased risk of major bleeding 
      complications. A tailored approach based on individual ischemic and hemorrhagic 
      risk assessment is currently recommended. This review aims to provide a 
      contemporary overview on the current body of evidence concerning DAPT for 
      treatment and secondary prevention of CAD with practical emphasis on current 
      indications, choice, combination and optimal duration of antiplatelet therapy.
FAU - Degrauwe, Sophie
AU  - Degrauwe S
FAU - Iglesias, Juan F
AU  - Iglesias JF
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Double antiagrégation plaquettaire pour le traitement et la prévention secondaire 
      de la maladie coronarienne. Indications, modalités et durées de traitement.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy/prevention & control
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Risk Assessment/methods
MH  - Secondary Prevention/methods
MH  - Time Factors
EDAT- 2016/07/19 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/07/19 06:00
PHST- 2016/07/19 06:00 [entrez]
PHST- 2016/07/19 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
PST - ppublish
SO  - Rev Med Suisse. 2016 May 25;12(520):1022-6, 1028-34.

PMID- 2534667
OWN - NLM
STAT- MEDLINE
DCOM- 19900713
LR  - 20131121
IS  - 0032-3756 (Print)
IS  - 0032-3756 (Linking)
VI  - 44
IP  - 28-29
DP  - 1989 Jul 10-17
TI  - [Aspirin tolerance in individuals with aspirin-induced urticaria-edematous 
      lesions].
PG  - 667-9
AB  - The study involved 22 individuals with aspirin-produced urticaria-edematous skin 
      lesions. Hypersensitivity to aspirin was established with anamnesis showing such 
      lesions on aspirin intake and oral test with aspirin. Threshold, provocative dose 
      of aspirin was determined in all patients at the beginning of the study. 
      Moreover, threshold provocative indomethacin dose was additionally determined in 
      12 patients. Tolerance to aspirin was produced by the oral administration of 
      aspirin in increasing doses upto total dose 600 mg at a 24-hour intervals. Twelve 
      patients were given 25 mg of indomethacin after 24 hours, and 50 mg of this drug 
      after 48 hours. The patients tolerated indomethacin well during aspirin tolerance 
      stage. The authors suggest that both urticaria-edematous and bronchial type of 
      aspirin hypersensitivity are of the same pathogenetic origin.
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
FAU - Rozniecki, J
AU  - Rozniecki J
FAU - Szmidt, M
AU  - Szmidt M
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Tolerancja na aspiryne u osób z poaspirynowymi zmianami pokrzywkowo-obrzekowymi.
PL  - Poland
TA  - Pol Tyg Lek
JT  - Polski tygodnik lekarski (Warsaw, Poland : 1960)
JID - 9705468
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Desensitization, Immunologic
MH  - Drug Eruptions/*etiology
MH  - Edema/*chemically induced
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiratory Hypersensitivity/etiology
MH  - Urticaria/*chemically induced
EDAT- 1989/07/10 00:00
MHDA- 1989/07/10 00:01
CRDT- 1989/07/10 00:00
PHST- 1989/07/10 00:00 [pubmed]
PHST- 1989/07/10 00:01 [medline]
PHST- 1989/07/10 00:00 [entrez]
PST - ppublish
SO  - Pol Tyg Lek. 1989 Jul 10-17;44(28-29):667-9.

PMID- 3927764
OWN - NLM
STAT- MEDLINE
DCOM- 19850904
LR  - 20190703
IS  - 0003-2409 (Print)
IS  - 0003-2409 (Linking)
VI  - 40
IP  - 6
DP  - 1985 Jun
TI  - Parenteral aspirin for pain relief in day-case dental anaesthesia. A randomised 
      double blind placebo controlled trial.
PG  - 576-8
AB  - Forty patients undergoing day-case anaesthesia for surgical extraction of third 
      molar teeth received either lysine acetylsalicylate 1.8 g in 10 ml of saline 
      intravenously or a placebo injection of 10 ml of saline intravenously just prior 
      to induction of anaesthesia. Lysine acetylsalicylate was associated with a 
      significantly more satisfactory postoperative recovery overall. However, there 
      was no significant difference in mean pain scores between the two treatment 
      groups at 1, 6, 12 or 24 hours following administration. Both treatment groups 
      self administered additional oral analgesics to the same extent during the first 
      24 hours following surgery.
FAU - Foster, J M
AU  - Foster JM
FAU - Cashman, J N
AU  - Cashman JN
FAU - Jones, R M
AU  - Jones RM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Anaesthesia
JT  - Anaesthesia
JID - 0370524
RN  - 0 (Analgesics)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Ambulatory Surgical Procedures
MH  - Analgesics/*administration & dosage
MH  - *Anesthesia, Dental
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Random Allocation
MH  - Tooth Extraction
EDAT- 1985/06/01 00:00
MHDA- 1985/06/01 00:01
CRDT- 1985/06/01 00:00
PHST- 1985/06/01 00:00 [pubmed]
PHST- 1985/06/01 00:01 [medline]
PHST- 1985/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2044.1985.tb10901.x [doi]
PST - ppublish
SO  - Anaesthesia. 1985 Jun;40(6):576-8. doi: 10.1111/j.1365-2044.1985.tb10901.x.

PMID- 30346860
OWN - NLM
STAT- MEDLINE
DCOM- 20200127
LR  - 20200127
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 30
IP  - 7
DP  - 2019
TI  - Aspirin intake in the morning is associated with suboptimal platelet inhibition, 
      as measured by serum Thromboxane B(2,) during infarct-prone early-morning hours.
PG  - 871-877
LID - 10.1080/09537104.2018.1528347 [doi]
AB  - Aspirin is traditionally taken once daily in the morning and considered to be 
      effective throughout the 24h interval. Cardiovascular events occur most 
      frequently in the early morning, suggesting that these hours are critical in 
      terms of adequate platelet inhibition. This study therefore assed platelet 
      function in the early morning-8.00 AM-in healthy volunteers, during a once-daily 
      (OD) 80 mg morning in comparison with an OD evening regimen and a twice-daily 
      (BID) 40 mg regimen. It was an open-label randomized cross-over study, comprising 
      12 healthy subjects. Subjects were allocated to three sequential dosage regimens: 
      80 mg OD at 8.00 AM, 80mg OD at 8.00 PM, and 40 mg BID at 8.00 AM and PM. 
      Platelet function 12 and 24 hours after aspirin intake was measured by means of 
      serum thromboxane B(2) (sTxB(2)) levels, the collagen/epinephrine closure time 
      (Platelet Function Analyzer(PFA)-200(®)) and the Aspirin Reaction Units (ARU, 
      VerifyNow(®)). The results demonstrated that early morning sTxB(2) concentrations 
      were 5843pg in the morning regimen, 2877pg in the evening OD regimen, and 3343pg 
      in the BID regimen (morning- vs evening regimen p = < 0.01; morning- vs BID 
      regimen p = < 0.01). Early morning PFA-closure time (p = 0.12)) as well as 
      VerifyNow ARU (p = 0.17) mean values were similar for all three regimens. In 
      conclusion, the OD-morning regimen seems to acquire the lowest level of platelet 
      inhibition during the critical early morning window. Switching to an OD-evening 
      or BID intake seems prudent, although further research on clinical cardiovascular 
      outcome in patients with stable cardiovascular disease is needed.
FAU - Racca, Cati
AU  - Racca C
AD  - Department of Internal Medicine, Amsterdam University Medical Center, VU 
      University , Amsterdam , The Netherlands.
FAU - van Diemen, Jeske Joanna Katarina
AU  - van Diemen JJK
AD  - Department of Internal Medicine, Amsterdam University Medical Center, VU 
      University , Amsterdam , The Netherlands.
FAU - Fuijkschot, Wessel Willem
AU  - Fuijkschot WW
AD  - Department of Internal Medicine, Amsterdam University Medical Center, VU 
      University , Amsterdam , The Netherlands.
FAU - Spit, Karlinde
AU  - Spit K
AD  - Department of Internal Medicine, Amsterdam University Medical Center, VU 
      University , Amsterdam , The Netherlands.
FAU - Bonten, Tobias Nicolaas
AU  - Bonten TN
AD  - Department of Public Health & Primary Care, Leiden University Medical Center , 
      Leiden , The Netherlands.
AD  - Department of Clinical Epidemiology, Leiden University Medical Center , Leiden , 
      The Netherlands.
FAU - Numans, Mattijs Everard
AU  - Numans ME
AUID- ORCID: 0000-0002-0368-5426
AD  - Department of Public Health & Primary Care, Leiden University Medical Center , 
      Leiden , The Netherlands.
FAU - van der Bom, Johanna Gerarda
AU  - van der Bom JG
AD  - Department of Clinical Epidemiology, Leiden University Medical Center , Leiden , 
      The Netherlands.
AD  - JJ van Rood Center for Clinical Transfusion Research, Sanquin Research , Leiden , 
      The Netherlands.
FAU - Smulders, Yvo Michiel
AU  - Smulders YM
AD  - Department of Internal Medicine, Amsterdam University Medical Center, VU 
      University , Amsterdam , The Netherlands.
FAU - Thijs, Abel
AU  - Thijs A
AD  - Department of Internal Medicine, Amsterdam University Medical Center, VU 
      University , Amsterdam , The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20181022
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*blood/*drug therapy
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Thromboxane B2/*blood
MH  - Time Factors
MH  - Young Adult
OTO - NOTNLM
OT  - Cross-over trial
OT  - aspirin
OT  - chronotherapy
OT  - circadian rhythm
OT  - platelet aggregation
EDAT- 2018/10/23 06:00
MHDA- 2020/01/28 06:00
CRDT- 2018/10/23 06:00
PHST- 2018/10/23 06:00 [pubmed]
PHST- 2020/01/28 06:00 [medline]
PHST- 2018/10/23 06:00 [entrez]
AID - 10.1080/09537104.2018.1528347 [doi]
PST - ppublish
SO  - Platelets. 2019;30(7):871-877. doi: 10.1080/09537104.2018.1528347. Epub 2018 Oct 
      22.

PMID- 1082620
OWN - NLM
STAT- MEDLINE
DCOM- 19760429
LR  - 20191028
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - 15
IP  - 1
DP  - 1976 Feb
TI  - Occult gastrointestinal bleeding due to aspirin: comparison of two compounds.
PG  - 31-4
AB  - Occult gastrointestinal bleeding as measured by the faecal 51Cr-labelled red-cell 
      loss was compared in eight healthy volunteers while on therapeutic doses of 
      soluble aspirin and a new slow-release formulation of aspirin (Deskoval). While 
      both preparations led to increased faecal blood loss, this was significantly less 
      during administration of Deskoval than when soluble aspirin was taken.
FAU - Rossouw, J E
AU  - Rossouw JE
FAU - Clarke, M
AU  - Clarke M
FAU - Davis, M
AU  - Davis M
FAU - Williams, R
AU  - Williams R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Chromium Radioisotopes
MH  - Erythrocytes/metabolism
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Melena/diagnosis
MH  - *Occult Blood
MH  - Tablets, Enteric-Coated
EDAT- 1976/02/01 00:00
MHDA- 1976/02/01 00:01
CRDT- 1976/02/01 00:00
PHST- 1976/02/01 00:00 [pubmed]
PHST- 1976/02/01 00:01 [medline]
PHST- 1976/02/01 00:00 [entrez]
AID - 10.1093/rheumatology/15.1.31 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1976 Feb;15(1):31-4. doi: 10.1093/rheumatology/15.1.31.

PMID- 1257500
OWN - NLM
STAT- MEDLINE
DCOM- 19760602
LR  - 20190824
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 11
IP  - 1
DP  - 1976 Jan
TI  - Aspirin and exercise-induced asthma.
PG  - 71-6
AB  - In four subjects with exercise-induced asthma, aspirin and placebo were 
      administered prior to exercise in a double blind study. Pulmonary function tests 
      did not reveal any difference between the response after aspirin or placebo. We 
      conclude that in these four subjects aspirin did not prevent the 
      bronchoconstrictor response. This might suggest that prostaglandins have no 
      significant role in exercise-induced asthma.
FAU - Taveira da Silva, A M
AU  - Taveira da Silva AM
FAU - Hamosh, P
AU  - Hamosh P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Placebos)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Airway Resistance/drug effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Asthma/*drug therapy/etiology
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Maximal Expiratory Flow-Volume Curves
MH  - Physical Exertion
MH  - Placebos
MH  - Prostaglandins/metabolism
MH  - Vital Capacity
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 0090-6980(76)90174-X [pii]
AID - 10.1016/0090-6980(76)90174-x [doi]
PST - ppublish
SO  - Prostaglandins. 1976 Jan;11(1):71-6. doi: 10.1016/0090-6980(76)90174-x.

PMID- 25250815
OWN - NLM
STAT- MEDLINE
DCOM- 20150623
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 9
DP  - 2014
TI  - Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer 
      in older patients.
PG  - e107866
LID - 10.1371/journal.pone.0107866 [doi]
LID - e107866
AB  - BACKGROUND & AIMS: Recent observational studies showed that post-operative 
      aspirin use reduces cancer relapse and death in the earliest stages of colorectal 
      cancer. We sought to evaluate the cost-effectiveness of aspirin as an adjuvant 
      therapy in Stage I and II colorectal cancer patients aged 65 years and older. 
      METHODS: Two five-state Markov models were constructed separately for Stage I and 
      II colorectal cancer using TreeAge Pro 2014. Two hypothetical cohorts of 10,000 
      individuals at a starting age of 65 years and with colorectal cancer in remission 
      were put through the models separately. Cost-effectiveness of aspirin was 
      evaluated against no treatment (Stage I and II) and capecitabine (Stage II) over 
      a 20-year period from the United States societal perspective. Extensive one-way 
      sensitivity analyses and multivariable Probabilistic Sensitivity Analyses (PSA) 
      were performed. RESULTS: In the base case analyses, aspirin was cheaper and more 
      effective compared to other comparators in both stages. Sensitivity analyses 
      showed that no treatment and capecitabine (Stage II only) can be cost-effective 
      alternatives if the utility of taking aspirin is below 0.909, aspirin's annual 
      fatal adverse event probability exceeds 0.57%, aspirin's relative risk of disease 
      progression is 0.997 or more, or when capecitabine's relative risk of disease 
      progression is less than 0.228. Probabilistic Sensitivity Analyses (PSA) further 
      showed that aspirin could be cost-effective 50% to 80% of the time when the 
      willingness-to-pay threshold was varied from USD 20,000 to USD 100,000. 
      CONCLUSION: Even with a modest treatment benefit, aspirin is likely to be 
      cost-effective in Stage I and II colorectal cancer, thus suggesting a potential 
      unique role in secondary prevention in this group of patients.
FAU - Soon, Swee Sung
AU  - Soon SS
AD  - Department of Pharmacy, National University of Singapore, Singapore, Singapore.
FAU - Chia, Whay-Kuang
AU  - Chia WK
AD  - Department of Medical Oncology, National Cancer Centre Singapore, Singapore, 
      Singapore.
FAU - Chan, Mun-ling Sarah
AU  - Chan ML
AD  - Department of Pharmacy, National University of Singapore, Singapore, Singapore.
FAU - Ho, Gwo Fuang
AU  - Ho GF
AD  - Department of Radiation Oncology, University of Malaya Medical Centre, Kuala 
      Lumpur, Malaysia.
FAU - Jian, Xiao
AU  - Jian X
AD  - Department of Medical Oncology, Sixth Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Deng, Yan Hong
AU  - Deng YH
AD  - Department of Medical Oncology, Sixth Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Tan, Chuen-Seng
AU  - Tan CS
AD  - Saw Swee Hock School of Public Health, National University of Singapore, 
      Singapore, Singapore.
FAU - Sharma, Atul
AU  - Sharma A
AD  - Department of Oncology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Segelov, Eva
AU  - Segelov E
AD  - National Health and Medical Research Council Clinical Trials Centre, University 
      of Sydney, Sydney, Australia.
FAU - Mehta, Shaesta
AU  - Mehta S
AD  - Department of Digestive Diseases and Nutrition, Tata Memorial Hospital, Mumbai, 
      India.
FAU - Ali, Raghib
AU  - Ali R
AD  - Nuffield Department of Population Health, University of Oxford, Oxford, United 
      Kingdom.
FAU - Toh, Han-Chong
AU  - Toh HC
AD  - Department of Medical Oncology, National Cancer Centre Singapore, Singapore, 
      Singapore.
FAU - Wee, Hwee-Lin
AU  - Wee HL
AD  - Department of Pharmacy, National University of Singapore, Singapore, Singapore.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140924
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - R16CO5Y76E (Aspirin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/economics/therapeutic use
MH  - Antimetabolites, Antineoplastic/economics/therapeutic use
MH  - Aspirin/*economics/*therapeutic use
MH  - Capecitabine
MH  - Chemotherapy, Adjuvant/methods
MH  - Colorectal Neoplasms/*drug therapy/pathology
MH  - Cost-Benefit Analysis
MH  - Deoxycytidine/analogs & derivatives/economics/therapeutic use
MH  - Fluorouracil/analogs & derivatives/economics/therapeutic use
MH  - Humans
MH  - *Markov Chains
MH  - Models, Economic
MH  - Neoplasm Recurrence, Local
MH  - Neoplasm Staging
MH  - Outcome Assessment, Health Care/economics/statistics & numerical data
MH  - Quality-Adjusted Life Years
MH  - Remission Induction
MH  - Reproducibility of Results
MH  - Secondary Prevention/methods
PMC - PMC4176715
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/09/25 06:00
MHDA- 2015/06/24 06:00
CRDT- 2014/09/25 06:00
PHST- 2014/02/01 00:00 [received]
PHST- 2014/08/19 00:00 [accepted]
PHST- 2014/09/25 06:00 [entrez]
PHST- 2014/09/25 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - PONE-D-14-04893 [pii]
AID - 10.1371/journal.pone.0107866 [doi]
PST - epublish
SO  - PLoS One. 2014 Sep 24;9(9):e107866. doi: 10.1371/journal.pone.0107866. 
      eCollection 2014.

PMID- 34350898
OWN - NLM
STAT- MEDLINE
DCOM- 20220126
LR  - 20220126
IS  - 1423-0313 (Electronic)
IS  - 0031-7012 (Linking)
VI  - 106
IP  - 11-12
DP  - 2021
TI  - Aspirin I.V. Loading during Elective Percutaneous Coronary Intervention.
PG  - 682-686
LID - 10.1159/000517994 [doi]
AB  - Additional loading dose of acetylsalicylic acid (ASA) during percutaneous 
      coronary interventions (PCIs) despite permanent oral ASA medication is frequently 
      applicated. The impact on platelet reactivity and clinical events is not known. 
      In this pilot study, we aimed to analyze high on-treatment platelet reactivity 
      (HTPR) to aspirin in patients undergoing elective PCI. Platelet reactivity was 
      measured using light-transmission aggregometry in 100 patients on permanent 
      low-dose ASA medication undergoing elective PCI. Platelet reactivity measured by 
      arachidonic acid-induced maximum of aggregation (MoA) in patients with versus 
      without additional peri-procedural ASA loading (500 mg i.v.) was compared. HTPR 
      was defined as MoA >20% for ASA. Major adverse cerebro- and cardiovascular events 
      (MACCEs) and bleeding events were evaluated during hospital course. HTPR rate was 
      similar in both groups (HTPR to ASA: loading vs. control 6% vs. 16%, odds ratio 
      [OR] = 0.33, 95% confidence interval [CI] 0.08-1.35, p = 0.12). In-hospital 
      MACCEs were not different between groups (MACCE: loading vs. control: 0 vs. 0 
      patient, OR = 1.32, 95% CI 0.03-67.95, p = 0.89). Thrombolysis in myocardial 
      infarction minimal bleedings were numerically higher in patients without ASA 
      loading dose. In this pharmacodynamic pilot study, additional ASA loading did not 
      reduce HTPR to ASA. Furthermore, ASA loading did not increase in-hospital MACCE 
      and bleeding complications.
CI  - © 2021 S. Karger AG, Basel.
FAU - Naguib, David
AU  - Naguib D
AD  - Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital 
      Düsseldorf, Düsseldorf, Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Department of Cardiology, 
      Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine 
      University Düsseldorf, Düsseldorf, Germany.
FAU - Helten, Carolin
AU  - Helten C
AD  - Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital 
      Düsseldorf, Düsseldorf, Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Department of Cardiology, 
      Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine 
      University Düsseldorf, Düsseldorf, Germany.
FAU - Zako, Saif
AU  - Zako S
AD  - Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital 
      Düsseldorf, Düsseldorf, Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Department of Cardiology, 
      Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine 
      University Düsseldorf, Düsseldorf, Germany.
FAU - Mourikis, Philipp
AU  - Mourikis P
AD  - Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital 
      Düsseldorf, Düsseldorf, Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Department of Cardiology, 
      Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine 
      University Düsseldorf, Düsseldorf, Germany.
FAU - M'Pembele, René
AU  - M'Pembele R
AD  - Department of Anesthesiology, University Hospital Düsseldorf, Düsseldorf, 
      Germany.
FAU - Trojovsky, Kajetan
AU  - Trojovsky K
AD  - Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital 
      Düsseldorf, Düsseldorf, Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Department of Cardiology, 
      Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine 
      University Düsseldorf, Düsseldorf, Germany.
FAU - Ahlbrecht, Samantha
AU  - Ahlbrecht S
AD  - Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital 
      Düsseldorf, Düsseldorf, Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Department of Cardiology, 
      Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine 
      University Düsseldorf, Düsseldorf, Germany.
FAU - Zikeli, Dorothee
AU  - Zikeli D
AD  - Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital 
      Düsseldorf, Düsseldorf, Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Department of Cardiology, 
      Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine 
      University Düsseldorf, Düsseldorf, Germany.
FAU - Zeus, Tobias
AU  - Zeus T
AD  - Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital 
      Düsseldorf, Düsseldorf, Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Department of Cardiology, 
      Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine 
      University Düsseldorf, Düsseldorf, Germany.
FAU - Kelm, Malte
AU  - Kelm M
AD  - Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital 
      Düsseldorf, Düsseldorf, Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Department of Cardiology, 
      Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine 
      University Düsseldorf, Düsseldorf, Germany.
FAU - Dannenberg, Lisa
AU  - Dannenberg L
AD  - Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital 
      Düsseldorf, Düsseldorf, Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Department of Cardiology, 
      Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine 
      University Düsseldorf, Düsseldorf, Germany.
FAU - Polzin, Amin
AU  - Polzin A
AD  - Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital 
      Düsseldorf, Düsseldorf, Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Department of Cardiology, 
      Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine 
      University Düsseldorf, Düsseldorf, Germany.
LA  - eng
PT  - News
PT  - Observational Study
DEP - 20210730
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Intravenous
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*methods
MH  - Pilot Projects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Prospective Studies
MH  - Thrombosis/prevention & control
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Aspirin
OT  - Elective percutaneous coronary intervention
OT  - High on-treatment platelet reactivity
OT  - Percutaneous coronary intervention
EDAT- 2021/08/06 06:00
MHDA- 2022/01/27 06:00
CRDT- 2021/08/05 08:45
PHST- 2021/03/13 00:00 [received]
PHST- 2021/06/14 00:00 [accepted]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2021/08/05 08:45 [entrez]
AID - 000517994 [pii]
AID - 10.1159/000517994 [doi]
PST - ppublish
SO  - Pharmacology. 2021;106(11-12):682-686. doi: 10.1159/000517994. Epub 2021 Jul 30.

PMID- 19342858
OWN - NLM
STAT- MEDLINE
DCOM- 20090806
LR  - 20221207
IS  - 1421-9867 (Electronic)
IS  - 0012-2823 (Linking)
VI  - 79
IP  - 3
DP  - 2009
TI  - A questionnaire-based survey on the prescription of non-steroidal 
      anti-inflammatory drugs by physicians in East Asian countries in 2007.
PG  - 177-85
LID - 10.1159/000211713 [doi]
AB  - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin are widely 
      used clinically but increase the risk of gastrointestinal (GI) complications. 
      AIM: To examine the current prescription of NSAIDs and comedication to prevent GI 
      complications from NSAIDs within East Asia by means of a questionnaire survey. 
      METHODS: Representative members of the Committee of the International 
      Gastrointestinal Consensus Symposium provided a questionnaire to physicians in 6 
      East Asian countries. RESULTS: A total of 1,568 physicians participated in this 
      survey. Most physicians prescribed nonselective NSAIDs, cyclooxygenase-2 
      inhibitors (COXIBs) or aspirin for more than 5 patients per week in all 
      countries, with the exception of the prescription of COXIBs in Japan. Of the 
      nonselective NSAIDs, the drug most frequently prescribed as a first choice was 
      loxoprofen (34%), which was mainly prescribed in Japan, followed by diclofenac 
      (30%). The frequency of prescription of comedication with nonselective NSAIDs was 
      higher compared with that for selective COXIBs or aspirin. Physicians in the 
      northern region (China, Japan and Korea) preferred mucoprotective drugs for 
      comedication with NSAIDs or aspirin, while those in southern region (Indonesia, 
      Philippines and Thailand) frequently used proton-pump inhibitors. CONCLUSION: 
      Among East Asian countries, there are both similarities and differences in the 
      prescription of NSAIDs and of comedication to prevent GI complications.
FAU - Arakawa, Tetsuo
AU  - Arakawa T
AD  - Department of Gastroenterology, Osaka City University Graduate School of 
      Medicine, Abenoku, Osaka, Japan. arakawat@med.osaka-cu.ac.jp
FAU - Fujiwara, Yasuhiro
AU  - Fujiwara Y
FAU - Sollano, Jose D
AU  - Sollano JD
FAU - Zhu, Qi
AU  - Zhu Q
FAU - Kachintorn, Udom
AU  - Kachintorn U
FAU - Rani, Abdul Aziz
AU  - Rani AA
FAU - Hahm, Ki-Baik
AU  - Hahm KB
FAU - Takahashi, Shin-ichi
AU  - Takahashi S
FAU - Joh, Takashi
AU  - Joh T
FAU - Kinoshita, Yoshikazu
AU  - Kinoshita Y
FAU - Matsumoto, Takayuki
AU  - Matsumoto T
FAU - Naito, Yuji
AU  - Naito Y
FAU - Takeuchi, Koji
AU  - Takeuchi K
FAU - Yamagami, Hirokazu
AU  - Yamagami H
FAU - Agustanti, Nenny
AU  - Agustanti N
FAU - Xiong, Huifang
AU  - Xiong H
FAU - Chen, Xi
AU  - Chen X
FAU - Jang, Eun Jung
AU  - Jang EJ
FAU - Furuta, Kenji
AU  - Furuta K
FAU - Terano, Akira
AU  - Terano A
CN  - IGICS study group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090403
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Asia, Eastern
MH  - Female
MH  - Humans
MH  - Male
MH  - *Practice Patterns, Physicians'
MH  - Surveys and Questionnaires
EDAT- 2009/04/04 09:00
MHDA- 2009/08/07 09:00
CRDT- 2009/04/04 09:00
PHST- 2008/12/02 00:00 [received]
PHST- 2009/02/26 00:00 [accepted]
PHST- 2009/04/04 09:00 [entrez]
PHST- 2009/04/04 09:00 [pubmed]
PHST- 2009/08/07 09:00 [medline]
AID - 000211713 [pii]
AID - 10.1159/000211713 [doi]
PST - ppublish
SO  - Digestion. 2009;79(3):177-85. doi: 10.1159/000211713. Epub 2009 Apr 3.

PMID- 1799906
OWN - NLM
STAT- MEDLINE
DCOM- 19920423
LR  - 20190510
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 25
IP  - 9
DP  - 1991 Sep
TI  - Prevention by DV-7028, a selective 5-HT2 receptor antagonist, of the formation of 
      coronary thrombi in dogs.
PG  - 727-30
AB  - STUDY OBJECTIVE: The aim was to determine the role of 5-HT derived from activated 
      platelets in the formation of intracoronary thrombi in dogs. DESIGN: Canine 
      coronary thrombi were produced by inserting a small catheter filled with collagen 
      powder into the endothelial-injured partially occluded left anterior descending 
      coronary artery. The effects of intravenous DV-7028, a selective 5-HT2 receptor 
      antagonist (bolus of 0.1 mg.kg-1, followed by 0.3 mg.kg-1.h-1 by infusion), and 
      intravenous aspirin (1 mg.kg-1, followed by 3 mg.kg-1.h-1) in this experimental 
      thrombus model were examined. SUBJECTS: 43 dogs of either sex were used. In 
      experiment A, DV-7028 (n = 12) or saline (n = 11) was given. In experiment B, 
      aspirin (n = 10) or saline (n = 10) was given. MEASUREMENTS AND MAIN RESULTS: 
      DV-7028 significantly reduced the formation of coronary thrombi by 51% and 
      attenuated the decrease in coronary blood flow without affecting systemic blood 
      pressure and heart rate. There was a significant relationship between the 
      thrombus weight and the decrease in coronary blood flow (p less than 0.005). 
      Aspirin failed to prevent the formation of coronary thrombi. CONCLUSION: The 
      results suggest that 5-HT is involved in the platelet thrombosis and that 
      inhibitory effect of DV-7028, a 5-HT2 receptor antagonist, on coronary thrombus 
      formation was superior to that of aspirin.
FAU - Morishima, Y
AU  - Morishima Y
AD  - Research Institute, Daiichi Pharmaceutical Co Ltd, Tokyo, Japan.
FAU - Tanaka, T
AU  - Tanaka T
FAU - Watanabe, K
AU  - Watanabe K
FAU - Igarashi, T
AU  - Igarashi T
FAU - Yasuoka, M
AU  - Yasuoka M
FAU - Shibano, T
AU  - Shibano T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Piperidines)
RN  - 0 (Serotonin Antagonists)
RN  - 0 (Triazines)
RN  - 133364-63-3 (DV 7028)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Coronary Thrombosis/*prevention & control
MH  - Disease Models, Animal
MH  - Dogs
MH  - Drug Administration Schedule
MH  - Piperidines/*administration & dosage/therapeutic use
MH  - *Serotonin Antagonists
MH  - Triazines/*administration & dosage/therapeutic use
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
AID - 10.1093/cvr/25.9.727 [doi]
PST - ppublish
SO  - Cardiovasc Res. 1991 Sep;25(9):727-30. doi: 10.1093/cvr/25.9.727.

PMID- 16260580
OWN - NLM
STAT- MEDLINE
DCOM- 20060413
LR  - 20171116
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 316
IP  - 3
DP  - 2006 Mar
TI  - The effect of NCX4016 [2-acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester] on 
      the consequences of ischemia and reperfusion in the streptozotocin diabetic rat.
PG  - 1107-14
AB  - The aim of this study was to assess the effect of chronic administration of 
      NCX4016 [2 acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester], a nitric 
      oxide-releasing aspirin derivative on the consequences of coronary artery 
      occlusion in streptozotocin-diabetic rats. Rats were made diabetic by injection 
      of streptozotocin (60 mg kg(-1)) and received insulin (2.5 U kg(-1) s.c.) daily 
      for 4 weeks. Animals received vehicle (1 ml kg(-1) polyethylene glycol), aspirin 
      (65.2 mg kg(-1)), NCX4016 (60 mg kg(-1)), or (iv) NCX4016 (120 mg kg(-1)) orally, 
      once daily for the last 5 days before coronary artery occlusion (CAO). One hour 
      after the last dose, pentobarbital-anesthetized rats were subjected to CAO for 30 
      min followed by 120-min reperfusion. Neither drug significantly modified initial 
      hemodynamics or plasma glucose levels compared with vehicle treatment in either 
      nondiabetic or diabetic rats. Neither drug modified the total ventricular 
      premature beat (VPB) count in normal animals, although NCX4016, but not aspirin, 
      reduced the total VPB count and the incidence of ventricular tachycardia in 
      diabetic rats. In nondiabetic animals, both aspirin and NCX4016 reduced infarct 
      size. However, in diabetic rats, infarct size was reduced only by the larger dose 
      of NCX4016 (120 mg kg(-1)) but not by aspirin or the lower dose of NCX4016. These 
      results demonstrate that the cardioprotective effects of NCX4016 are reduced in 
      the presence of diabetes compared with the effects seen in nondiabetic animals. 
      In summary, the present study confirms the protective effect of NCX4016 against 
      ischemia-reperfusion injury in the normal rat heart and demonstrates for the 
      first time its protective effect in the heart of streptozotocin-diabetic rats.
FAU - Burke, S G
AU  - Burke SG
AD  - Department of Physiology and Pharmacology, Strathclyde Institute for Biomedical 
      Sciences, University of Strathclyde, Glasgow, United Kingdom.
FAU - Wainwright, C L
AU  - Wainwright CL
FAU - Vojnovic, I
AU  - Vojnovic I
FAU - Warner, T
AU  - Warner T
FAU - Watson, D G
AU  - Watson DG
FAU - Furman, B L
AU  - Furman BL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051031
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 37H9VM9WZL (Calcimycin)
RN  - 5W494URQ81 (Streptozocin)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Calcimycin/pharmacology
MH  - Diabetes Mellitus, Experimental/*physiopathology
MH  - Heart Rate/drug effects
MH  - Male
MH  - Myocardial Ischemia/*drug therapy
MH  - Myocardial Reperfusion Injury/*prevention & control
MH  - Nitric Oxide/physiology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Streptozocin
EDAT- 2005/11/02 09:00
MHDA- 2006/04/14 09:00
CRDT- 2005/11/02 09:00
PHST- 2005/11/02 09:00 [pubmed]
PHST- 2006/04/14 09:00 [medline]
PHST- 2005/11/02 09:00 [entrez]
AID - jpet.105.096339 [pii]
AID - 10.1124/jpet.105.096339 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2006 Mar;316(3):1107-14. doi: 10.1124/jpet.105.096339. Epub 
      2005 Oct 31.

PMID- 8238182
OWN - NLM
STAT- MEDLINE
DCOM- 19931215
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 169
IP  - 5
DP  - 1993 Nov
TI  - Are pill counts valid measures of compliance in clinical obstetric trials?
PG  - 1181-2
AB  - We compared pill counts with a biochemical measure of compliance in 283 women who 
      participated in a randomized double-blind trial that evaluated the efficacy of 
      low-dose aspirin in the prevention of preeclampsia. Subjects whose pill counts 
      indicated a usage > 100% were less compliant than women with lower pill counts.
FAU - DuBard, M B
AU  - DuBard MB
AD  - Department of Obstetrics and Gynecology, University of Alabama at Birmingham 
      35233-7333.
FAU - Goldenberg, R L
AU  - Goldenberg RL
FAU - Copper, R L
AU  - Copper RL
FAU - Hauth, J C
AU  - Hauth JC
LA  - eng
GR  - 1 R01 HD24496-01/HD/NICHD NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - *Patient Compliance
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Thromboxane B2/blood
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
AID - 0002-9378(93)90278-Q [pii]
AID - 10.1016/0002-9378(93)90278-q [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1993 Nov;169(5):1181-2. doi: 10.1016/0002-9378(93)90278-q.

PMID- 31900955
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 1097-458X (Electronic)
IS  - 0749-1581 (Linking)
VI  - 58
IP  - 11
DP  - 2020 Nov
TI  - Identifying aspirin polymorphs from combined DFT-based crystal structure 
      prediction and solid-state NMR.
PG  - 1018-1025
LID - 10.1002/mrc.4987 [doi]
AB  - A combined experimental and computational approach was used to distinguish 
      between different polymorphs of the pharmaceutical drug aspirin. This method 
      involves the use of ab initio random structure searching (AIRSS), a density 
      functional theory (DFT)-based crystal structure prediction method for the 
      high-accuracy prediction of polymorphic structures, with DFT calculations of 
      nuclear magnetic resonance (NMR) parameters and solid-state NMR experiments at 
      natural abundance. AIRSS was used to predict the crystal structures of form-I and 
      form-II of aspirin. The root-mean-square deviation between experimental and 
      calculated (1) H chemical shifts was used to identify form-I as the polymorph 
      present in the experimental sample, the selection being successful despite the 
      large similarities between the molecular environments in the crystals of the two 
      polymorphs.
CI  - © 2020 The Authors. Magnetic Resonance in Chemistry published by John Wiley & 
      Sons Ltd.
FAU - Mathew, Renny
AU  - Mathew R
AD  - Division of Science, New York University Abu Dhabi, Abu Dhabi, UAE.
FAU - Uchman, Karolina A
AU  - Uchman KA
AD  - Division of Science, New York University Abu Dhabi, Abu Dhabi, UAE.
FAU - Gkoura, Lydia
AU  - Gkoura L
AUID- ORCID: 0000-0001-5298-6498
AD  - Division of Science, New York University Abu Dhabi, Abu Dhabi, UAE.
FAU - Pickard, Chris J
AU  - Pickard CJ
AD  - Department of Materials Science and Metallurgy, University of Cambridge, 
      Cambridge, UK.
AD  - Advanced Institute for Materials Research, Tohoku University, Sendai, Japan.
FAU - Baias, Maria
AU  - Baias M
AUID- ORCID: 0000-0002-4152-405X
AD  - Division of Science, New York University Abu Dhabi, Abu Dhabi, UAE.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200121
PL  - England
TA  - Magn Reson Chem
JT  - Magnetic resonance in chemistry : MRC
JID - 9882600
RN  - 0 (Protons)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Crystallography, X-Ray
MH  - *Density Functional Theory
MH  - Magnetic Resonance Spectroscopy
MH  - Models, Molecular
MH  - Protons
OTO - NOTNLM
OT  - 1H NMR
OT  - NMR
OT  - NMR crystallography
OT  - ab initio random structure searching
OT  - crystal structure prediction
OT  - organic molecular crystals
OT  - pharmaceuticals
OT  - polymorphism
OT  - small molecules
EDAT- 2020/01/05 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/01/05 06:00
PHST- 2019/10/01 00:00 [received]
PHST- 2019/12/17 00:00 [revised]
PHST- 2020/01/02 00:00 [accepted]
PHST- 2020/01/05 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
PHST- 2020/01/05 06:00 [entrez]
AID - 10.1002/mrc.4987 [doi]
PST - ppublish
SO  - Magn Reson Chem. 2020 Nov;58(11):1018-1025. doi: 10.1002/mrc.4987. Epub 2020 Jan 
      21.

PMID- 2313226
OWN - NLM
STAT- MEDLINE
DCOM- 19900420
LR  - 20190903
IS  - 0954-6820 (Print)
IS  - 0954-6820 (Linking)
VI  - 227
IP  - 3
DP  - 1990 Mar
TI  - Low dose acetylsalicylic acid and thromboxane release at the site of plug 
      formation in vivo in elderly patients with cardiovascular disease.
PG  - 189-93
AB  - Thromboxane B2 (TXB2) levels in bleeding time blood and in serum were measured in 
      13 elderly patients with cardiovascular disease, seven of whom were receiving 
      continuous treatment with low dose acetylsalicylic acid (ASA, 125 mg every second 
      day--250 mg daily) for prevention of stroke. Blood sampling was performed openly, 
      but assays of TXB2 were performed by a blinded investigator. In patients treated 
      with ASA, median serum TXB2-levels were 4% and TXB2-levels in bleeding-time blood 
      were less than 16% of the corresponding levels in patients without ASA (P less 
      than 0.01). The results show that in elderly atherosclerotic patients very low 
      doses of ASA substantially suppress TXB2 formation, not only in serum but also at 
      the site of local haemostasis. The extent of suppression is comparable to that 
      previously reported from young healthy subjects.
FAU - Thorngren, M
AU  - Thorngren M
AD  - Department of Community Health Sciences, University Hospital, Lund, Sweden.
FAU - Eckert, B
AU  - Eckert B
FAU - Vinge, E
AU  - Vinge E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Bleeding Time
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Thromboxane B2/*metabolism
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
AID - 10.1111/j.1365-2796.1990.tb00141.x [doi]
PST - ppublish
SO  - J Intern Med. 1990 Mar;227(3):189-93. doi: 10.1111/j.1365-2796.1990.tb00141.x.

PMID- 27197430
OWN - NLM
STAT- MEDLINE
DCOM- 20160608
LR  - 20160520
IS  - 0033-2240 (Print)
IS  - 0033-2240 (Linking)
VI  - 73
IP  - 2
DP  - 2016
TI  - [Induced sputum supernatant prostaglandin E2 during oral aspirin challenge of 
      asthmatic patients with and without aspirin hypersensitivity and healthy 
      controls--pilot study].
PG  - 93-6
AB  - The aim of this pilot study was to evaluate changes in the concentration of 
      prostaglandin E2 (PGE2) in induced sputum supernatant in 3 groups: sub- jects 
      with NSAID-exacerbated respira- tory disease (NERD), aspirin tolerant asthma 
      (ATA) and healthy controls (HC), before and after oral aspirin chal- lenge test. 
      The study was conducted in the years 2014-2015 at the Clinical Department of the 
      Pulmonology Clinic at the University Hospital in Cracow. 43 patients were 
      enrolled in the study (NERD - n = 15, ATA - n = 15 and HC - n = 13). All of them 
      underwent a placebo-controlled oral aspirin challenge. Sputum was induced 24 
      hours before the challenge and immediately after the test. Induced sputum was 
      processed in order to obtain cystospin slides to depict inflammatory cell 
      patterns and supernatants, in which PGE2 was measured. The concentration of PGE2 
      was determined using mass spectrometry coupled with gas chromatography (gas 
      chromatography/mass spectrometry - GC/MS). After aspirin challenge, the 
      concentration of PGE2 in induced sputum supernatant decreased in both asthmatics 
      hypersensitive to aspirin (p = 0.01) and those who tolerated aspirin well (p = 
      0.17). The change in the healthy control group was not statistically significant. 
      These results support the cyclooxygenase theory of PGE2 inhibition by aspirin. 
      However, the mechanism of bronchoconstriction after aspirin administration alone 
      in patients with NSAID-exacerbated respiratory disease remains unclear.
FAU - Ignacak, Maria
AU  - Ignacak M
FAU - Celejewska-Wójcik, Natalia
AU  - Celejewska-Wójcik N
FAU - Wójcik, Krzysztof
AU  - Wójcik K
FAU - Sałapa, Kinga
AU  - Sałapa K
FAU - Konduracka, Ewa
AU  - Konduracka E
FAU - Sanak, Marek
AU  - Sanak M
FAU - Tyrak, Katarzyna
AU  - Tyrak K
FAU - Sładek, Krzysztof
AU  - Sładek K
FAU - Musiał, Jacek
AU  - Musiał J
FAU - Mastalerz, Lucyna
AU  - Mastalerz L
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Wpływ dawki prowokacyjnej aspiryny na poziom prostaglandyny E2 w plwocinie 
      indukowanej u chorych na astmę z i bez nadwrażliwości na aspirynę oraz u osób 
      zdrowych--badanie pilotażowe.
PL  - Poland
TA  - Przegl Lek
JT  - Przeglad lekarski
JID - 19840720R
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Asthma, Aspirin-Induced/*metabolism
MH  - Dinoprostone/*analysis
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Sputum/chemistry/*drug effects
MH  - Young Adult
EDAT- 2016/05/21 06:00
MHDA- 2016/06/09 06:00
CRDT- 2016/05/21 06:00
PHST- 2016/05/21 06:00 [entrez]
PHST- 2016/05/21 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
PST - ppublish
SO  - Przegl Lek. 2016;73(2):93-6.

PMID- 37108226
OWN - NLM
STAT- MEDLINE
DCOM- 20230501
LR  - 20230501
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 8
DP  - 2023 Apr 11
TI  - Molecular Ultrasound Imaging Depicts the Modulation of Tumor Angiogenesis by 
      Acetylsalicylic Acid.
LID - 10.3390/ijms24087060 [doi]
LID - 7060
AB  - Acetylsalicylic acid (ASA) is a well-established drug for heart attack and stroke 
      prophylaxis. Furthermore, numerous studies have reported an anti-carcinogenic 
      effect, but its exact mechanism is still unknown. Here, we applied 
      VEGFR-2-targeted molecular ultrasound to explore a potential inhibitory effect of 
      ASA on tumor angiogenesis in vivo. Daily ASA or placebo therapy was performed in 
      a 4T1 tumor mouse model. During therapy, ultrasound scans were performed using 
      nonspecific microbubbles (CEUS) to determine the relative intratumoral blood 
      volume (rBV) and VEGFR-2-targeted microbubbles to assess angiogenesis. Finally, 
      vessel density and VEGFR-2 expression were assessed histologically. CEUS 
      indicated a decreasing rBV in both groups over time. VEGFR-2 expression increased 
      in both groups up to Day 7. Towards Day 11, the binding of VEGFR-2-specific 
      microbubbles further increased in controls, but significantly (p = 0.0015) 
      decreased under ASA therapy (2.24 ± 0.46 au vs. 0.54 ± 0.55 au). 
      Immunofluorescence showed a tendency towards lower vessel density under ASA and 
      confirmed the result of molecular ultrasound. Molecular US demonstrated an 
      inhibitory effect of ASA on VEGFR-2 expression accompanied by a tendency towards 
      lower vessel density. Thus, this study suggests the inhibition of angiogenesis 
      via VEGFR-2 downregulation as one of the anti-tumor effects of ASA.
FAU - Mueller-Diesing, Flurin
AU  - Mueller-Diesing F
AD  - Institute for Experimental Molecular Imaging, Helmholtz Institute for Biomedical 
      Engineering, RWTH Aachen University, Forckenbeckstrasse 55, 52074 Aachen, 
      Germany.
FAU - Lederle, Wiltrud
AU  - Lederle W
AD  - Institute for Experimental Molecular Imaging, Helmholtz Institute for Biomedical 
      Engineering, RWTH Aachen University, Forckenbeckstrasse 55, 52074 Aachen, 
      Germany.
FAU - Rix, Anne
AU  - Rix A
AD  - Institute for Experimental Molecular Imaging, Helmholtz Institute for Biomedical 
      Engineering, RWTH Aachen University, Forckenbeckstrasse 55, 52074 Aachen, 
      Germany.
FAU - Koletnik, Susanne
AU  - Koletnik S
AD  - Institute for Experimental Molecular Imaging, Helmholtz Institute for Biomedical 
      Engineering, RWTH Aachen University, Forckenbeckstrasse 55, 52074 Aachen, 
      Germany.
FAU - Doleschel, Dennis
AU  - Doleschel D
AD  - Institute for Experimental Molecular Imaging, Helmholtz Institute for Biomedical 
      Engineering, RWTH Aachen University, Forckenbeckstrasse 55, 52074 Aachen, 
      Germany.
FAU - Snelting, Maximilian
AU  - Snelting M
AD  - Institute for Experimental Molecular Imaging, Helmholtz Institute for Biomedical 
      Engineering, RWTH Aachen University, Forckenbeckstrasse 55, 52074 Aachen, 
      Germany.
FAU - Gremse, Felix
AU  - Gremse F
AD  - Institute for Experimental Molecular Imaging, Helmholtz Institute for Biomedical 
      Engineering, RWTH Aachen University, Forckenbeckstrasse 55, 52074 Aachen, 
      Germany.
FAU - Kiessling, Fabian
AU  - Kiessling F
AUID- ORCID: 0000-0002-7341-0399
AD  - Institute for Experimental Molecular Imaging, Helmholtz Institute for Biomedical 
      Engineering, RWTH Aachen University, Forckenbeckstrasse 55, 52074 Aachen, 
      Germany.
LA  - eng
GR  - GRK2375 (331065168)/Deutsche Forschungsgemeinschaft/
PT  - Journal Article
DEP - 20230411
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - R16CO5Y76E (Aspirin)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Vascular Endothelial Growth Factor Receptor-2/metabolism
MH  - *Neoplasms
MH  - Neovascularization, Pathologic/diagnostic imaging/drug therapy
MH  - Ultrasonography
PMC - PMC10139153
OTO - NOTNLM
OT  - CEUS
OT  - COX inhibitor
OT  - VEGFR-2
OT  - acetylsalicylic acid
OT  - breast cancer
OT  - molecular ultrasound
COIS- F.K. is Co-founder and Co-owner of the Sono-MAc company, and F.G. is Founder and 
      Owner of Gremse-IT. F.K. collaborates with FUJIFILM-VisualSonics and is an 
      Advisor of the company.
EDAT- 2023/04/28 06:41
MHDA- 2023/05/01 06:42
CRDT- 2023/04/28 01:26
PHST- 2023/02/28 00:00 [received]
PHST- 2023/03/30 00:00 [revised]
PHST- 2023/04/07 00:00 [accepted]
PHST- 2023/05/01 06:42 [medline]
PHST- 2023/04/28 06:41 [pubmed]
PHST- 2023/04/28 01:26 [entrez]
AID - ijms24087060 [pii]
AID - ijms-24-07060 [pii]
AID - 10.3390/ijms24087060 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Apr 11;24(8):7060. doi: 10.3390/ijms24087060.

PMID- 35805887
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20221207
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 13
DP  - 2022 Jun 21
TI  - D,L-Lysine-Acetylsalicylate + Glycine (LASAG) Reduces SARS-CoV-2 Replication and 
      Shows an Additive Effect with Remdesivir.
LID - 10.3390/ijms23136880 [doi]
LID - 6880
AB  - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the 
      coronavirus disease-19 (COVID-19) is still challenging healthcare systems and 
      societies worldwide. While vaccines are available, therapeutic strategies are 
      developing and need to be adapted to each patient. Many clinical approaches focus 
      on the repurposing of approved therapeutics against other diseases. However, the 
      efficacy of these compounds on viral infection or even harmful secondary effects 
      in the context of SARS-CoV-2 infection are sparsely investigated. Similarly, 
      adverse effects of commonly used therapeutics against lifestyle diseases have not 
      been studied in detail. Using mono cell culture systems and a more complex chip 
      model, we investigated the effects of the acetylsalicylic acid (ASA) salt 
      D,L-lysine-acetylsalicylate + glycine (LASAG) on SARS-CoV-2 infection in vitro. 
      ASA is commonly known as Aspirin(®) and is one of the most frequently used 
      medications worldwide. Our data indicate an inhibitory effect of LASAG on 
      SARS-CoV-2 replication and SARS-CoV-2-induced expression of pro-inflammatory 
      cytokines and coagulation factors. Remarkably, our data point to an additive 
      effect of the combination of LASAG and the antiviral acting drug remdesivir on 
      SARS-CoV-2 replication in vitro.
FAU - Jungwirth, Johannes
AU  - Jungwirth J
AD  - Section of Experimental Virology, Institute of Medical Microbiology, Center for 
      Molecular Biomedicine (CMB), Jena University Hospital, Hans-Knoell-Str. 2, 
      D-07745 Jena, Germany.
FAU - Häring, Clio
AU  - Häring C
AD  - Section of Experimental Virology, Institute of Medical Microbiology, Center for 
      Molecular Biomedicine (CMB), Jena University Hospital, Hans-Knoell-Str. 2, 
      D-07745 Jena, Germany.
FAU - König, Sarah
AU  - König S
AD  - Section of Experimental Virology, Institute of Medical Microbiology, Center for 
      Molecular Biomedicine (CMB), Jena University Hospital, Hans-Knoell-Str. 2, 
      D-07745 Jena, Germany.
FAU - Giebeler, Liane
AU  - Giebeler L
AD  - Section of Experimental Virology, Institute of Medical Microbiology, Center for 
      Molecular Biomedicine (CMB), Jena University Hospital, Hans-Knoell-Str. 2, 
      D-07745 Jena, Germany.
FAU - Doshi, Heena
AU  - Doshi H
AD  - Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), Jena 
      University Hospital, Hans-Knoell-Str. 2, D-07745 Jena, Germany.
FAU - Brandt, Christian
AU  - Brandt C
AUID- ORCID: 0000-0002-7199-3957
AD  - Institute for Infectious Diseases and Infection Control, Jena University 
      Hospital, Am Klinikum 1, D-07747 Jena, Germany.
FAU - Deinhardt-Emmer, Stefanie
AU  - Deinhardt-Emmer S
AUID- ORCID: 0000-0003-4495-4052
AD  - Institute of Medical Microbiology, Jena University Hospital, Am Klinikum 1, 
      D-07747 Jena, Germany.
FAU - Löffler, Bettina
AU  - Löffler B
AD  - Institute of Medical Microbiology, Jena University Hospital, Am Klinikum 1, 
      D-07747 Jena, Germany.
FAU - Ehrhardt, Christina
AU  - Ehrhardt C
AUID- ORCID: 0000-0002-8879-6087
AD  - Section of Experimental Virology, Institute of Medical Microbiology, Center for 
      Molecular Biomedicine (CMB), Jena University Hospital, Hans-Knoell-Str. 2, 
      D-07745 Jena, Germany.
LA  - eng
GR  - 01KI20168/Bundesministerium für Bildung und Forschung-BMBF (Federal Ministry of 
      Education and Research)/
PT  - Journal Article
DEP - 20220621
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antiviral Agents)
RN  - 3QKI37EEHE (remdesivir)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - K3Z4F929H6 (Lysine)
RN  - OF5P57N2ZX (Alanine)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Adenosine Monophosphate/analogs & derivatives
MH  - Alanine/analogs & derivatives
MH  - Antiviral Agents/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Glycine/pharmacology/therapeutic use
MH  - Humans
MH  - Lysine
MH  - *SARS-CoV-2
MH  - *COVID-19 Drug Treatment
PMC - PMC9266999
OTO - NOTNLM
OT  - COVID-19
OT  - LASAG
OT  - SARS-CoV-2
OT  - chip model
OT  - pro-inflammation
OT  - remdesivir
COIS- The authors declare no conflict of interest.
EDAT- 2022/07/10 06:00
MHDA- 2022/07/14 06:00
CRDT- 2022/07/09 01:10
PHST- 2022/06/09 00:00 [received]
PHST- 2022/06/15 00:00 [accepted]
PHST- 2022/07/09 01:10 [entrez]
PHST- 2022/07/10 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
AID - ijms23136880 [pii]
AID - ijms-23-06880 [pii]
AID - 10.3390/ijms23136880 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Jun 21;23(13):6880. doi: 10.3390/ijms23136880.

PMID- 9000223
OWN - NLM
STAT- MEDLINE
DCOM- 19970325
LR  - 20190830
IS  - 0097-0549 (Print)
IS  - 0097-0549 (Linking)
VI  - 26
IP  - 5
DP  - 1996 Sep-Dec
TI  - Influence of aspirin on the contingent negative wave in healthy subjects.
PG  - 489-91
AB  - A study was made of the alterations of the parameters of the slow brain 
      potential, the contingent negative wave, under the influence of aspirin in 
      healthy individuals, using the double blind method. The early and late wave of 
      the CNW were investigated. A statistically significant decrease in the early CN 
      wave was obtained after the ingestion of aspirin, and an increase in the late 
      wave after the ingestion of aspirin and placebo. A central effect of aspirin, 
      affecting the noradrenergic and dopaminergic brain systems, is hypothesized to 
      explain the changes described.
FAU - Vein, A M
AU  - Vein AM
AD  - Department of Nervous Diseases, Faculty of Advanced Postdiploma Education, I. M. 
      Sechenov Moscow Medical Academy.
FAU - Voznesenskaya, T G
AU  - Voznesenskaya TG
FAU - Danilov, A B
AU  - Danilov AB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosci Behav Physiol
JT  - Neuroscience and behavioral physiology
JID - 0330471
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/*pharmacology
MH  - Brain/*drug effects
MH  - *Electroencephalography
MH  - Humans
MH  - Reference Values
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - 10.1007/BF02359412 [doi]
PST - ppublish
SO  - Neurosci Behav Physiol. 1996 Sep-Dec;26(5):489-91. doi: 10.1007/BF02359412.

PMID- 10705557
OWN - NLM
STAT- MEDLINE
DCOM- 20000411
LR  - 20190905
IS  - 0045-6535 (Print)
IS  - 0045-6535 (Linking)
VI  - 40
IP  - 7
DP  - 2000 Apr
TI  - Environmental risk assessment of human pharmaceuticals in Denmark after normal 
      therapeutic use.
PG  - 783-93
AB  - An environmental risk assessment is presented for the 25 most used 
      pharmaceuticals in the primary health sector in Denmark. Predicted environmental 
      concentrations (PECs) for the aquatic environment were calculated using 
      conservative assumptions and all PECs exceeded 1 ng/l. Measured concentrations 
      were in general within a factor of 2-5 of PECs and ranged from approximately 0.5 
      ng/l to 3 micrograms/l for nine of the pharmaceuticals reported in literature. 
      The calculation of predicted no-effect concentration (PNEC) based on aquatic 
      ecotoxicity data was possible for six of the pharmaceuticals. PEC/PNEC ratio 
      exceeded one for ibuprofen, acetylsalicylic acid, and paracetamol. For estrogens 
      the PEC/PNEC ratio approached one when non-standard test was used. The ratio was 
      below one for estrogens (standard test), diazepam and digoxin. For the 
      terrestrial compartment, toxicity data were not available, and no assessment was 
      carried out. Comparisons of predicted concentrations of furosemide, ibuprofen, 
      oxytetracycline and ciprofloxacin in sludge based on either preliminary 
      experimental sludge-water partition coefficients (Kd), octanol-water coefficients 
      (Kow) or acid-base constants (pKa) revealed large variations.
FAU - Stuer-Lauridsen, F
AU  - Stuer-Lauridsen F
AD  - COWI Consulting Engineers and Planners, Lyngby, Denmark. fsl@cowi.dk
FAU - Birkved, M
AU  - Birkved M
FAU - Hansen, L P
AU  - Hansen LP
FAU - Lützhøft, H C
AU  - Lützhøft HC
FAU - Halling-Sørensen, B
AU  - Halling-Sørensen B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Sewage)
RN  - 0 (Water Pollutants, Chemical)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/analysis/therapeutic use/toxicity
MH  - Aspirin/analysis/therapeutic use/toxicity
MH  - Biodegradation, Environmental
MH  - Denmark
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - *Pharmaceutical Preparations/analysis/metabolism
MH  - *Risk Assessment
MH  - Sewage/chemistry
MH  - Water Pollutants, Chemical/analysis/metabolism/*toxicity
EDAT- 2000/03/08 09:00
MHDA- 2000/04/15 09:00
CRDT- 2000/03/08 09:00
PHST- 2000/03/08 09:00 [pubmed]
PHST- 2000/04/15 09:00 [medline]
PHST- 2000/03/08 09:00 [entrez]
AID - S0045653599004531 [pii]
AID - 10.1016/s0045-6535(99)00453-1 [doi]
PST - ppublish
SO  - Chemosphere. 2000 Apr;40(7):783-93. doi: 10.1016/s0045-6535(99)00453-1.

PMID- 6681968
OWN - NLM
STAT- MEDLINE
DCOM- 19830421
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 33
IP  - 1
DP  - 1983
TI  - Comparative gastric irritation by two buffered acetylsalicylic acid formulations 
      and acetylsalicylic acid. A gastric potential difference analysis.
PG  - 158-60
AB  - In a single dose clinical investigation two buffered acetylsalicylic acid 
      formulations (Ascriptin and Ascriptin A/D) were shown to be significantly less 
      irritating to the human gastric mucosa than acetylsalicylic acid, and no more 
      irritating than a pharmacologically inert placebo. The measurements were taken 
      using a minimally invasive method for recording transmural gastric potential 
      difference changes versus time.
FAU - Bruhn, R
AU  - Bruhn R
FAU - Ganote, D P
AU  - Ganote DP
FAU - Lücker, P W
AU  - Lücker PW
FAU - Vance, J
AU  - Vance J
FAU - Procaccini, R L
AU  - Procaccini RL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Buffers)
RN  - 0 (Irritants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Buffers
MH  - Female
MH  - Gastric Mucosa/drug effects
MH  - Humans
MH  - *Irritants
MH  - Male
MH  - Membrane Potentials/drug effects
MH  - Stomach Diseases/*chemically induced
MH  - Time Factors
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1983;33(1):158-60.

PMID- 20501864
OWN - NLM
STAT- MEDLINE
DCOM- 20110110
LR  - 20131121
IS  - 1555-824X (Electronic)
IS  - 1062-8606 (Linking)
VI  - 25
IP  - 5
DP  - 2010 Sep-Oct
TI  - Advancing aspirin utilization: a review of clinical and systems-based 
      interventions.
PG  - 351-8
LID - 10.1177/1062860610366032 [doi]
AB  - Underuse of clinical preventive services (CPS) such as low-dose aspirin therapy 
      leads to tens of thousands of preventable deaths per year. The authors examined 
      the current literature related to delivery of CPS and then provided the results 
      to a preventive medicine expert panel who identified best practices to improve 
      aspirin counseling and use. An exploratory literature search was conducted in 
      PubMed using keywords associated with preventive health interventions. The review 
      included articles published between January 2000 and March 2009. More than 200 
      articles were identified for review, and 35 met inclusion criteria. Interventions 
      that increased patient-provider contact and physician interactive educational 
      programs were most likely to improve delivery of CPS. The expert panel 
      recommended a prevention systems cascade of reinforcing strategies and tools to 
      maximize appropriate aspirin use. This model emphasizes important 
      interrelationships of clinical practice settings and how they affect aspirin use.
FAU - Parkinson, Michael D
AU  - Parkinson MD
AD  - American College of Preventive Medicine, Pittsburgh, PA, USA.
FAU - Ahluwalia, Jaspal S
AU  - Ahluwalia JS
FAU - Shih, David C
AU  - Shih DC
FAU - Barry, Michael A
AU  - Barry MA
FAU - Schechter, Clyde B
AU  - Schechter CB
CN  - ACPM Aspirin Expert Panel
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20100525
PL  - Netherlands
TA  - Am J Med Qual
JT  - American journal of medical quality : the official journal of the American 
      College of Medical Quality
JID - 9300756
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Primary Prevention
EDAT- 2010/05/27 06:00
MHDA- 2011/01/11 06:00
CRDT- 2010/05/27 06:00
PHST- 2010/05/27 06:00 [entrez]
PHST- 2010/05/27 06:00 [pubmed]
PHST- 2011/01/11 06:00 [medline]
AID - 1062860610366032 [pii]
AID - 10.1177/1062860610366032 [doi]
PST - ppublish
SO  - Am J Med Qual. 2010 Sep-Oct;25(5):351-8. doi: 10.1177/1062860610366032. Epub 2010 
      May 25.

PMID- 19630490
OWN - NLM
STAT- MEDLINE
DCOM- 20100303
LR  - 20181201
IS  - 1369-6998 (Print)
IS  - 1369-6998 (Linking)
VI  - 12
IP  - 2
DP  - 2009 Jun
TI  - Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of 
      dual oral antiplatelet therapy.
PG  - 141-53
LID - 10.3111/13696990903123813 [doi]
AB  - OBJECTIVE: Cost-effectiveness analyses of new treatments for cardiovascular 
      disease frequently require input parameters whose values are known with 
      uncertainty due to limited data. The objective of this paper is to examine the 
      extent to which published sensitivity analyses addressing this uncertainty adhere 
      to Health Technology Assessment (HTA) guidelines. RESEARCH DESIGN AND METHODS: A 
      systematic review of published cost-effectiveness analyses was performed for an 
      example drug treatment scenario, dual oral antiplatelet therapy compared with 
      aspirin alone following acute coronary syndromes and/or percutaneous coronary 
      intervention. The following medical literature databases were searched for 
      articles published from January 1997 to June 2007: PubMed, Cochrane 
      Collaboration, EMBASE and the Health Economic Evaluation Database (HEED). 
      Evidence tables were created to show the sensitivity of the cost-effectiveness 
      estimates to changes in the input parameter values, as well as the data sources 
      used for the reference-case and sensitivity analysis input parameter values. The 
      extent to which the sensitivity analyses adhered to HTA guidelines were also 
      examined. RESULTS: Cost-effectiveness ratios were most sensitive to changes in 
      the efficacy of dual antiplatelet therapy and reference-case model assumptions 
      about costs beyond the trial period. Although alternative values tested in the 
      sensitivity analysis for some input parameters were based on observed ranges or 
      distributions, alternative values tested for many other input parameters were 
      assumed without justification. CONCLUSIONS: Sensitivity analyses in the 
      cost-effectiveness studies of dual oral antiplatelet therapy were not fully 
      adherent with HTA guidelines. In particular, long-term costs and benefits were 
      not always included in the sensitivity estimates, the impact of differential 
      effects on death and myocardial infarction was not explored, and justification 
      for the alternative parameter values tested was not always provided.
FAU - Mauskopf, Josephine A
AU  - Mauskopf JA
AD  - RTI Health Solutions, Research Triangle Park, NC 27709-2194, USA. 
      jmauskopf@rti.org
FAU - Boye, Kristina S
AU  - Boye KS
FAU - Schmitt, Claude
AU  - Schmitt C
FAU - McCollam, Patrick
AU  - McCollam P
FAU - Birt, Julie
AU  - Birt J
FAU - Juniper, Melissa D
AU  - Juniper MD
FAU - Bakhai, Ameet
AU  - Bakhai A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/economics/therapeutic use
MH  - Cost-Benefit Analysis
MH  - *Guideline Adherence
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*economics/therapeutic 
      use
MH  - Sensitivity and Specificity
RF  - 34
EDAT- 2009/07/28 09:00
MHDA- 2010/03/04 06:00
CRDT- 2009/07/28 09:00
PHST- 2009/07/28 09:00 [entrez]
PHST- 2009/07/28 09:00 [pubmed]
PHST- 2010/03/04 06:00 [medline]
AID - 10.3111/13696990903123813 [doi]
PST - ppublish
SO  - J Med Econ. 2009 Jun;12(2):141-53. doi: 10.3111/13696990903123813.

PMID- 1206501
OWN - NLM
STAT- MEDLINE
DCOM- 19760401
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 64
IP  - 12
DP  - 1975 Dec
TI  - Stability of aspirin in liquid and semisolid bases V: polyglycerol esters.
PG  - 2018-20
AB  - The stability of aspirin in decaglycerol tetraoleate, decaglycerol octaoleate, 
      and decaglycerol decaoleate was studied at 4, 26, and 45 degrees. Degradation of 
      aspirin in these polyglycerol esters was temperature dependent. Aspirin 
      demonstrated the greatest stability in decaglycerol octaoleate and the lowest 
      stability in decaglycerol tetraoleate at all temperatures studied. The hydroxyl 
      value and the viscosity of the polyglycerol ester appeared to influence the 
      stability of aspirin.
FAU - Whitworth, C W
AU  - Whitworth CW
FAU - Asker, A F
AU  - Asker AF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Pharmaceutical Vehicles)
RN  - 0 (Polymers)
RN  - PDC6A3C0OX (Glycerol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Drug Stability
MH  - Glycerol
MH  - Pharmaceutical Vehicles
MH  - Polymers
MH  - Solubility
MH  - Temperature
EDAT- 1975/12/01 00:00
MHDA- 1975/12/01 00:01
CRDT- 1975/12/01 00:00
PHST- 1975/12/01 00:00 [pubmed]
PHST- 1975/12/01 00:01 [medline]
PHST- 1975/12/01 00:00 [entrez]
AID - S0022-3549(15)40564-7 [pii]
AID - 10.1002/jps.2600641230 [doi]
PST - ppublish
SO  - J Pharm Sci. 1975 Dec;64(12):2018-20. doi: 10.1002/jps.2600641230.

PMID- 2082489
OWN - NLM
STAT- MEDLINE
DCOM- 19910509
LR  - 20191029
IS  - 0896-0569 (Print)
IS  - 0896-0569 (Linking)
VI  - 12
DP  - 1990
TI  - Secondary prevention of myocardial infarction in the first European Stroke 
      Prevention Study.
PG  - 59-63
AB  - The first European Stroke Prevention Study (ESPS 1) showed that a statistically 
      significant degree of secondary ischemic lesions could be prevented by combined 
      therapy with aspirin (330 mg) and dipyridamole (75 mg) t.i.d. The risk of both 
      central and myocardial secondary ischemic lesions was reduced by more than 30%. 
      Similar results were seen after both transient ischemic attacks and stroke, and 
      in both men and women.
FAU - Lowenthal, A
AU  - Lowenthal A
AD  - Algemeen Ziekenhuis Middelheim, Antwerp, Belgium.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Thromb Res Suppl
JT  - Thrombosis research. Supplement
JID - 8309239
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Europe
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1016/0049-3848(90)90440-n [doi]
PST - ppublish
SO  - Thromb Res Suppl. 1990;12:59-63. doi: 10.1016/0049-3848(90)90440-n.

PMID- 11134820
OWN - NLM
STAT- MEDLINE
DCOM- 20010301
LR  - 20190816
IS  - 0301-2115 (Print)
IS  - 0301-2115 (Linking)
VI  - 94
IP  - 1
DP  - 2001 Jan
TI  - Prevention of pre-eclampsia: status and perspectives 2000.
PG  - 13-22
AB  - Because pre-eclampsia is a relatively common complication of pregnancy and forms 
      a major cause of maternal, fetal, and neonatal morbidity and mortality, attempts 
      at prevention are justified, but hampered by the fact that as yet no reliable and 
      acceptable screening tests for women at risk are available. Analysis of the many 
      interventions advocated to prevent or delay the onset of pre-eclampsia reveals 
      that dietary calcium supplementation and prophylactic low-dose aspirin treatment 
      have shown promise of efficacy in small randomized, placebo-controlled trials, 
      but the results of large, multicenter trials are generally disappointing. The 
      disappointing results obtained in large, multicenter trials may in part be 
      explained by the lack of strict criteria for inclusion, late initiation of 
      treatment, use of ill-defined end points, different timing of aspirin ingestion, 
      and low patient compliance. Recent evidence that supplementation with vitamins C 
      and E could prevent pre-eclampsia awaits confirmation. Future clinical trials on 
      prevention of pre-eclampsia should be based on results of basic research.
FAU - Wallenburg, H C
AU  - Wallenburg HC
AD  - Department of Obstetrics and Gynecology, Erasmus University Rotterdam, Rotterdam, 
      The Netherlands. hcswallenburg@hotmail.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Antioxidants)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Antioxidants
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Calcium/administration & dosage/therapeutic use
MH  - Diet
MH  - Female
MH  - Humans
MH  - Life Style
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
RF  - 87
EDAT- 2001/01/03 11:00
MHDA- 2001/03/07 10:01
CRDT- 2001/01/03 11:00
PHST- 2001/01/03 11:00 [pubmed]
PHST- 2001/03/07 10:01 [medline]
PHST- 2001/01/03 11:00 [entrez]
AID - S0301211500003031 [pii]
AID - 10.1016/s0301-2115(00)00303-1 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2001 Jan;94(1):13-22. doi: 
      10.1016/s0301-2115(00)00303-1.

PMID- 781231
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 2
DP  - 1976
TI  - Comparison of benefit-to-risk ratios of aspirin and fenoprofen: controlled 
      multicentre study in rheumatoid arthritis.
PG  - 49-60
AB  - The benefit-to-risk ratios of fenoprofen (2.4 gm/day) and aspirin (3.9 gm/day) 
      were compared in a randomized, double-blind, 26-week parallel study involving 216 
      patients. Criteria for inclusion, exclusion, subjective, and objective 
      evaluations were based on the PMA-FDA Nonsteroidal Anti-Inflammatory Drug 
      Clinical Testing Guidelines. Thirty-four of 109 aspirin-treated patients and 23 
      of 107 patients on fenoprofen dropped out of the study. Both fenoprofen and 
      aspirin brought about improvement in most efficacy parameters measured, but 
      fenoprofen was superior to aspirin (p less than 0.05) in reduction of swollen 
      joints, grip strength, activity index, and patients' preference of medication. 
      The number and frequency of complaints and the incidence of abnormal SGOT levels, 
      were greater with aspirin than with fenoprofen. The study suggests that 
      fenoprofen has a better benefit-to-risk ratio than aspirin, when given in equally 
      effective doses.
FAU - Sigler, J W
AU  - Sigler JW
FAU - Ridolfo, A S
AU  - Ridolfo AS
FAU - Bluhm, G B
AU  - Bluhm GB
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Fenoprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenylpropionates/*therapeutic use
MH  - Time Factors
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1976;2:49-60.

PMID- 12669898
OWN - NLM
STAT- MEDLINE
DCOM- 20030505
LR  - 20131121
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 90
IP  - 3
DP  - 2003 Mar
TI  - Early effects of aspirin desensitization treatment in asthmatic patients with 
      aspirin-exacerbated respiratory disease.
PG  - 338-41
AB  - BACKGROUND: Aspirin (ASA)-exacerbated respiratory disease (AERD) is characterized 
      by aggressive inflammation of the respiratory tract and often requires topical 
      and/or systemic corticosteroids to maintain partial control of this disease. 
      Previous studies have revealed that ASA desensitization and subsequent treatment 
      with ASA is associated with clinical improvement in AERD. OBJECTIVE: The aim of 
      the present study was to determine the effect of daily ASA treatment for the 
      first 4 weeks after ASA desensitization. METHODS: Thirty-eight patients underwent 
      ASA oral challenge followed by ASA desensitization and daily ASA therapy. Changes 
      in nasal and asthma symptoms, combined with changes in oral prednisone, were 
      recorded daily during 4 weeks before and after desensitization. Severity of 
      symptoms ranged from a scale of 1 to 5 (1 = asymptomatic and 5 = most severe 
      symptoms). For statistical analyses the sum of nasal symptoms and asthma symptoms 
      was calculated. Olfactory scores were also analyzed. RESULTS: Nasal and asthma 
      symptom scores, as well as olfactory scores, improved significantly (P < 0.0001). 
      For the 15 patients taking prednisone, their mean doses decreased from 10.7 to 
      5.9 mg daily (P = 0.0003). CONCLUSIONS: Our study suggests that ASA 
      desensitization treatment is effective during the first 4 weeks of daily 
      treatment with ASA.
FAU - Berges-Gimeno, M Pilar
AU  - Berges-Gimeno MP
AD  - The Scripps Research Institute, La Jolla, California 92037, USA.
FAU - Simon, Ronald A
AU  - Simon RA
FAU - Stevenson, Donald D
AU  - Stevenson DD
LA  - eng
GR  - M01RR00833/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Glucocorticoids)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects/*therapeutic use
MH  - Asthma/*complications/diagnosis
MH  - Female
MH  - Glucocorticoids/administration & dosage/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prednisone/administration & dosage/therapeutic use
MH  - Respiratory Tract Diseases/complications/diagnosis/*drug therapy
MH  - Time Factors
EDAT- 2003/04/03 05:00
MHDA- 2003/05/06 05:00
CRDT- 2003/04/03 05:00
PHST- 2003/04/03 05:00 [pubmed]
PHST- 2003/05/06 05:00 [medline]
PHST- 2003/04/03 05:00 [entrez]
AID - S1081-1206(10)61803-0 [pii]
AID - 10.1016/S1081-1206(10)61803-0 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2003 Mar;90(3):338-41. doi: 
      10.1016/S1081-1206(10)61803-0.

PMID- 19836506
OWN - NLM
STAT- MEDLINE
DCOM- 20100120
LR  - 20131121
IS  - 1873-3573 (Electronic)
IS  - 0039-9140 (Linking)
VI  - 80
IP  - 2
DP  - 2009 Dec 15
TI  - Nir-chemical imaging study of acetylsalicylic acid in commercial tablets.
PG  - 473-8
LID - 10.1016/j.talanta.2009.07.008 [doi]
AB  - Near Infrared Chemical Imaging (NIR-CI) is demonstrating an increasing interest 
      in pharmaceutical research since it meets the challenging analytical needs of 
      pharmaceutical quality and may serve as a versatile adjunct to conventional NIR 
      spectroscopy in many fields. The direct analysis of samples by using 
      hyperspectral imaging techniques, which provide a NIR spectrum in each pixel of 
      the image, generates a big amount of information from one sample. Focusing the 
      interest in pharmaceutical research, several chemometric algorithms are 
      demonstrating their usefulness extracting the relevant information (i.e. 
      quantitative determination of the component in one sample) in tablets with only 
      one sample and without damaging it. In this work, a quantitative method to 
      analyze different commercial Acetylsalicylic acid tablets is proposed by using 
      Multivariate Curve Resolution-Alternating Least Squares (MCR-ALS) method to the 
      hyperspectral image and without any previous calibration model. For this purpose, 
      a large concentration range of active pharmaceutical ingredient (ASA, 
      Acetylsalicylic acid in this work), between 82% and 12%, was covered depending on 
      the manufacturer. MCR-ALS allowed obtaining a concentration maps for 
      acetylsalicylic acid and therefore, consequent analysis of the ASA distribution 
      in the tablet was developed by using the histograms of the distribution of 
      concentration. Results certified the good distribution of ASA despite the 
      different origins of the tablets. Moreover, the obtained values of concentration 
      showed a very good concordance with the nominal value of ASA. As a matter of 
      fact, the quality of the results demonstrated the useful of encompassing NIR-CI 
      techniques with MCR-ALS and, consequently, the well development on the production 
      of Acetylsalicylic acid tablets.
FAU - Cruz, Jordi
AU  - Cruz J
AD  - Unidad de Química Analítica, Departamento de Química, Facultad de Ciencias, 
      Universitat Autónoma de Barcelona, Barcelona, España, Spain.
FAU - Bautista, Manel
AU  - Bautista M
FAU - Amigo, José Manuel
AU  - Amigo JM
FAU - Blanco, Marcel
AU  - Blanco M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090710
PL  - Netherlands
TA  - Talanta
JT  - Talanta
JID - 2984816R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/analysis
MH  - Aspirin/*analysis/chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - Least-Squares Analysis
MH  - Multivariate Analysis
MH  - Reproducibility of Results
MH  - Spectroscopy, Near-Infrared/*methods
MH  - Tablets
MH  - Technology, Pharmaceutical/*methods
EDAT- 2009/10/20 06:00
MHDA- 2010/01/21 06:00
CRDT- 2009/10/20 06:00
PHST- 2009/03/24 00:00 [received]
PHST- 2009/06/30 00:00 [revised]
PHST- 2009/07/02 00:00 [accepted]
PHST- 2009/10/20 06:00 [entrez]
PHST- 2009/10/20 06:00 [pubmed]
PHST- 2010/01/21 06:00 [medline]
AID - S0039-9140(09)00568-2 [pii]
AID - 10.1016/j.talanta.2009.07.008 [doi]
PST - ppublish
SO  - Talanta. 2009 Dec 15;80(2):473-8. doi: 10.1016/j.talanta.2009.07.008. Epub 2009 
      Jul 10.

PMID- 7700969
OWN - NLM
STAT- MEDLINE
DCOM- 19950502
LR  - 20191210
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 50
IP  - 2
DP  - 1995 Feb
TI  - Effect of dissolution profile and (-)-alpha-bisabolol on the gastrotoxicity of 
      acetylsalicylic acid.
PG  - 141-3
AB  - The effect of particle size and (-)-alpha-bisabolol on the gastric toxicity 
      produced by acetylsalicylic acid (AAS) was studied in rats. AAS crystals of size 
      0.5-0.4, 0.2-0.05 mm and AAS pellets were administered orally (dose 200 mg/kg) to 
      rats. The effect of particle size on gastric toxicity was not significant (P < 
      0.05). Small AAS crystals (0.2-0.05 mm) were granulated with ethanol to produce 
      pellets (0.5-0.4 mm). The resultant pellets were less ulcerogenic than AAS 
      crystals (P < 0.05). The pelletization process improves the wetting process of 
      AAS crystals and for this reason produces a faster dissolution profile of AAS. 
      When (-)-alpha-bisabolol, a natural essential oil obtained from camomile oil, was 
      administered orally (dose 0.8-80 mg/kg) with AAS (dose 200 mg/kg), a significant 
      (P < 0.05) protective effect was found. Some possible mechanisms of protection 
      are suggested for (-)-alpha-bisabolol.
FAU - Torrado, S
AU  - Torrado S
AD  - Department of Pharmaceutical Technology, Faculty of Pharmacy, Complutense 
      University and Hospital La Paz, Madrid, Spain.
FAU - Torrado, S
AU  - Torrado S
FAU - Agis, A
AU  - Agis A
FAU - Jimenez, M E
AU  - Jimenez ME
FAU - Cadórniga, R
AU  - Cadórniga R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Monocyclic Sesquiterpenes)
RN  - 0 (Sesquiterpenes)
RN  - 24WE03BX2T (bisabolol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*chemistry/*toxicity
MH  - Chemistry, Pharmaceutical
MH  - Gastric Mucosa/pathology
MH  - Male
MH  - Monocyclic Sesquiterpenes
MH  - Necrosis/chemically induced/pathology
MH  - Particle Size
MH  - Rats
MH  - Rats, Wistar
MH  - Sesquiterpenes/*pharmacology
MH  - Solubility
MH  - Stomach Ulcer/*chemically induced/pathology
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1995 Feb;50(2):141-3.

PMID- 712586
OWN - NLM
STAT- MEDLINE
DCOM- 19790124
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 67
IP  - 11
DP  - 1978 Nov
TI  - Influence of food and fluid ingestion on aspirin bioavailability.
PG  - 1533-5
AB  - The influence of test meals and accompanying fluid volume on aspirin 
      bioavailability from commercial tablets was determined following single oral 
      doses to healthy male volunteers. Plasma aspirin and salicylate levels were 
      determined simultaneously using a GLC end-point. Area analysis indicated that 
      approximately 5--8% of absorbed drug entered the systemic circulation as 
      unchanged aspirin in nonfasted subjects compared to 16--18% in fasted 
      individuals. Food tended to reduce the appearance rate of aspirin into the 
      circulation, resulting in lower and somewhat more sustained levels than with 
      fasting. Plasma salicylate levels were not influenced markedly by the various 
      treatments, although levels were higher in fasted than in nonfasted subjects 
      during the 1st hr after dosing. After this time, fat pretreatment tended to 
      produce higher levels than other treatments.
FAU - Koch, P A
AU  - Koch PA
FAU - Schultz, C A
AU  - Schultz CA
FAU - Wills, R J
AU  - Wills RJ
FAU - Hallquist, S L
AU  - Hallquist SL
FAU - Welling, P G
AU  - Welling PG
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*metabolism
MH  - Biological Availability
MH  - Drinking
MH  - Eating
MH  - *Food
MH  - Humans
MH  - Male
MH  - Models, Biological
MH  - Salicylates/blood
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
AID - S0022-3549(15)42318-4 [pii]
AID - 10.1002/jps.2600671110 [doi]
PST - ppublish
SO  - J Pharm Sci. 1978 Nov;67(11):1533-5. doi: 10.1002/jps.2600671110.

PMID- 18223512
OWN - NLM
STAT- MEDLINE
DCOM- 20080328
LR  - 20181201
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 100
IP  - 12
DP  - 2007 Dec
TI  - [Platelet response to aspirin and clopidogrel. Biochemical evaluation, clinical 
      impact, and pharmacological modulation].
PG  - 992-1002
AB  - In the vasculature, platelets contribute to thrombotic and inflammatory 
      responses, key processes in atherothrombosis. During percutaneous coronary 
      interventions, several studies have emphasized the deleterious impact of enhanced 
      platelet aggregation on early clinical outcome. However, despite the significant 
      interest of determining platelet responsiveness appears worth, the clinically 
      accurate and practical platelet function assay is still not widespread available. 
      Furthermore, standardized definitions of platelet "low-responders" are still 
      lacking. Up to now, light transmission platelet aggregometry remains the 
      "gold-standard". Platelets "points of care" assays might overcome the limitations 
      of conventional optical platelet aggregation but need further validation in 
      clinical settings. The most recent ACC/AHA guideline endorses a strategy of 
      platelet monitoring in the highest risk patients (IIb C). In "low-responders" 
      patients, clopidogrel dose escalation was demonstrated to improve platelet 
      responsiveness. Others potential pharmacological solutions could include the 
      switch for another thienopyridine. Indeed, prasugrel a P2Y12 receptor inhibitor 
      was demonstrated to provide higher levels of inhibition of ADP-induced platelet 
      aggregation.
FAU - Morel, O
AU  - Morel O
AD  - Hôpital de Hautepierre, fédération de cardiologie des hôpitaux universitaires de 
      Strasbourg. Oliver.Morel@chru-strasbourg.fr
FAU - Ohlmann, P
AU  - Ohlmann P
FAU - Bareiss, P
AU  - Bareiss P
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Réponse plaquettaire à l'aspirine et au clopidogrel. Evaluation biologique, 
      impact clinique, modulation pharmacologique.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cardiovascular Diseases/metabolism
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Flow Cytometry
MH  - Humans
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests/methods
MH  - Thrombosis/metabolism
MH  - Ticlopidine/*analogs & derivatives/pharmacology
RF  - 59
EDAT- 2008/01/29 09:00
MHDA- 2008/03/29 09:00
CRDT- 2008/01/29 09:00
PHST- 2008/01/29 09:00 [pubmed]
PHST- 2008/03/29 09:00 [medline]
PHST- 2008/01/29 09:00 [entrez]
AID - MDOI-AMCV-12-2007-100-12-0003-9683-101019-200705530 [pii]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 2007 Dec;100(12):992-1002.

PMID- 17623031
OWN - NLM
STAT- MEDLINE
DCOM- 20080103
LR  - 20131121
IS  - 1567-1356 (Print)
IS  - 1567-1356 (Linking)
VI  - 7
IP  - 8
DP  - 2007 Dec
TI  - Oxylipin studies expose aspirin as antifungal.
PG  - 1207-17
AB  - The presence of aspirin-sensitive 3-hydroxy fatty acids (i.e. 3-OH oxylipins) in 
      yeasts was first reported in the early 1990s. Since then, these oxidized fatty 
      acids have been found to be widely distributed in yeasts. 3-OH oxylipins may: (1) 
      have potent biological activity in mammalian cells; (2) act as antifungals; and 
      (3) assist during forced spore release from enclosed sexual cells (asci). A link 
      between 3-OH oxylipin production, mitochondria and aspirin sensitivity exists. 
      Research suggests that: (1) 3-OH oxylipins in some yeasts are probably also 
      produced by mitochondria through incomplete beta-oxidation; (2) aspirin inhibits 
      mitochondrial beta-oxidation and 3-OH oxylipin production; (3) yeast sexual 
      stages, which are probably more dependent on mitochondrial activity, are also 
      characterized by higher 3-OH oxylipin levels as compared to asexual stages; (4) 
      yeast sexual developmental stages as well as cell adherence/flocculation are more 
      sensitive to aspirin than corresponding asexual growth stages; and (5) 
      mitochondrion-dependent asexual yeast cells with a strict aerobic metabolism are 
      more sensitive to aspirin than those that can also produce energy through an 
      alternative anaerobic glycolytic fermentative pathway in which mitochondria are 
      not involved. This review interprets a wide network of studies that reveal 
      aspirin to be a novel antifungal.
FAU - Kock, Johan L F
AU  - Kock JL
AD  - Department of Microbial, Biochemical and Food Biotechnology, University of the 
      Free State, Bloemfontein, South Africa. Kockjl.sci@mail.uovs.ac.za
FAU - Sebolai, Olihile M
AU  - Sebolai OM
FAU - Pohl, Carolina H
AU  - Pohl CH
FAU - van Wyk, Pieter W J
AU  - van Wyk PW
FAU - Lodolo, Elizabeth J
AU  - Lodolo EJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20070709
PL  - England
TA  - FEMS Yeast Res
JT  - FEMS yeast research
JID - 101085384
RN  - 0 (Antifungal Agents)
RN  - 0 (Oxylipins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antifungal Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Fungi/*drug effects
MH  - Oxylipins/*antagonists & inhibitors
RF  - 86
EDAT- 2007/07/12 09:00
MHDA- 2008/01/04 09:00
CRDT- 2007/07/12 09:00
PHST- 2007/07/12 09:00 [pubmed]
PHST- 2008/01/04 09:00 [medline]
PHST- 2007/07/12 09:00 [entrez]
AID - FYR273 [pii]
AID - 10.1111/j.1567-1364.2007.00273.x [doi]
PST - ppublish
SO  - FEMS Yeast Res. 2007 Dec;7(8):1207-17. doi: 10.1111/j.1567-1364.2007.00273.x. 
      Epub 2007 Jul 9.

PMID- 5797782
OWN - NLM
STAT- MEDLINE
DCOM- 19690909
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 3
IP  - 5667
DP  - 1969 Aug 16
TI  - Inhibition by aspirin of release of antiheparin activity from human platelets.
PG  - 394-6
AB  - Both in vitro and in vivo, aspirin inhibited the adenosine diphosphate and 
      collagen-induced release of platelet factor 4 (antiheparin factor). The release 
      induced by adrenaline and thrombin was not affected. The in-vivo effect in normal 
      persons lasted for at least three days. Platelet uptake of acetyl-(14)C-aspirin 
      was significantly greater than that of carboxyl-(14)C-aspirin.
FAU - Youssef, A H
AU  - Youssef AH
FAU - Barkhan, P
AU  - Barkhan P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Adenine Nucleotides)
RN  - 0 (Blood Coagulation Factors)
RN  - 0 (Carbon Isotopes)
RN  - 9007-34-5 (Collagen)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenine Nucleotides
MH  - Aspirin/metabolism/*pharmacology
MH  - Blood Coagulation Factors/*metabolism
MH  - Blood Coagulation Tests
MH  - Blood Platelets/*drug effects/metabolism
MH  - *Calcium
MH  - Carbon Isotopes
MH  - Collagen
MH  - Epinephrine
MH  - Humans
MH  - In Vitro Techniques
MH  - Thrombin
PMC - PMC1984151
EDAT- 1969/08/16 00:00
MHDA- 1969/08/16 00:01
CRDT- 1969/08/16 00:00
PHST- 1969/08/16 00:00 [pubmed]
PHST- 1969/08/16 00:01 [medline]
PHST- 1969/08/16 00:00 [entrez]
AID - 10.1136/bmj.3.5667.394 [doi]
PST - ppublish
SO  - Br Med J. 1969 Aug 16;3(5667):394-6. doi: 10.1136/bmj.3.5667.394.

PMID- 37272503
OWN - NLM
STAT- MEDLINE
DCOM- 20230606
LR  - 20230809
IS  - 1473-5687 (Electronic)
IS  - 0954-691X (Linking)
VI  - 35
IP  - 7
DP  - 2023 Jul 1
TI  - Does use of long-term aspirin impact outcomes in patients with acute 
      pancreatitis?
PG  - 721-727
LID - 10.1097/MEG.0000000000002578 [doi]
AB  - INTRODUCTION: Although the effect of rectal indomethacin in post-endoscopic 
      retrograde cholangiopancreatography pancreatitis is well established, the effect 
      of aspirin on acute pancreatitis (AP) is not well studied. We investigate the 
      effect of aspirin on AP. METHODS: We collected data from the National Inpatient 
      Sample database from 2016 to 2020, to identify adult patients with acute 
      pancreatitis. Patients were stratified into 2 groups, based on the presence of 
      aspirin use. The primary outcome was mortality, while other outcomes were sepsis, 
      shock, acute kidney injury (AKI), ICU admission, deep venous thrombosis (DVT), 
      pulmonary embolism (PE), portal vein thrombosis (PVT), pseudocyst and ileus. 
      RESULTS: A total of 2.09 million patients met the inclusion criteria, of which 
      197 170 (9.41%) had long-term aspirin use. The majority of the patients with 
      aspirin use were aged >65 years, male, White and had Medicare insurance. There 
      was a higher incidence of biliary pancreatitis while rates of alcohol-induced 
      pancreatitis were lower in patients with aspirin use. There was a lower incidence 
      of mortality, sepsis, shock, PE, DVT, PVT and pseudocyst in patients with aspirin 
      use. There was no difference in the incidence of ileus, while the incidence of 
      AKI was higher. After adjusting for confounding factors, patients with aspirin 
      use had a 23.6% lower risk of mortality. DISCUSSION: Our results reveal a 
      significant finding of aspirin's protective effect on AP in the US population. 
      Our study is the largest study revealing an association between aspirin and AP. 
      Further studies assessing the role of aspirin use in AP are warranted.
CI  - Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Chaudhry, Hunza
AU  - Chaudhry H
AD  - Department of Internal Medicine, University of California, San Francisco-Fresno, 
      California.
FAU - Sohal, Aalam
AU  - Sohal A
AD  - Department of Hepatology, Liver Institute Northwest, Seattle, Washington.
FAU - Dukovic, Dino
AU  - Dukovic D
AD  - Department of Medicine, Ross University School of Medicine, Florida.
FAU - Kohli, Isha
AU  - Kohli I
AD  - Department of Public Health, Graduate Program in Public Health, Icahn School of 
      Medicine, Mount Sinai, New York, New York, USA.
FAU - Sharma, Raghav
AU  - Sharma R
AD  - Department of Medicine, Punjab Institute of Medical Sciences.
FAU - Singla, Piyush
AU  - Singla P
AD  - Department of Medicine, Dayanand Medical College and Hospital, India.
FAU - Prajapati, Devang
AU  - Prajapati D
AD  - Department of Gastroenterology and Hepatology, University of California, San 
      Francisco-Fresno, California, USA.
FAU - Yang, Juliana
AU  - Yang J
AD  - Department of Gastroenterology and Hepatology, University of California, San 
      Francisco-Fresno, California, USA.
LA  - eng
PT  - Journal Article
DEP - 20230531
PL  - England
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Male
MH  - Aged
MH  - United States/epidemiology
MH  - *Pancreatitis/etiology
MH  - Aspirin/adverse effects
MH  - Risk Factors
MH  - Acute Disease
MH  - Medicare
MH  - *Venous Thrombosis/epidemiology/prevention & control/chemically induced
MH  - *Cysts
MH  - *Acute Kidney Injury/complications
MH  - Incidence
MH  - Retrospective Studies
EDAT- 2023/06/05 13:04
MHDA- 2023/06/06 06:42
CRDT- 2023/06/05 06:53
PHST- 2023/06/06 06:42 [medline]
PHST- 2023/06/05 13:04 [pubmed]
PHST- 2023/06/05 06:53 [entrez]
AID - 00042737-202307000-00004 [pii]
AID - 10.1097/MEG.0000000000002578 [doi]
PST - ppublish
SO  - Eur J Gastroenterol Hepatol. 2023 Jul 1;35(7):721-727. doi: 
      10.1097/MEG.0000000000002578. Epub 2023 May 31.

PMID- 1298987
OWN - NLM
STAT- MEDLINE
DCOM- 19930507
LR  - 20161123
IS  - 0125-1562 (Print)
IS  - 0125-1562 (Linking)
VI  - 23 Suppl 2
DP  - 1992
TI  - Hypoxemia in thalassemia.
PG  - 22-4
AB  - Data are reviewed describing hypoxemia, a newly identified feature in 
      thalassemia. Evidence indicates platelet aggregation in the pulmonary circulation 
      as being a key factor leading to hypoxemia and cor-pulmonale with right heart 
      failure.
FAU - Fucharoen, S
AU  - Fucharoen S
AD  - Thalassemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, 
      Bangkok, Thailand.
FAU - Winichagoon, P
AU  - Winichagoon P
FAU - Siritanaratkul, N
AU  - Siritanaratkul N
FAU - Sonakul, D
AU  - Sonakul D
FAU - Chantaraksri, U
AU  - Chantaraksri U
FAU - Bunyaratvej, A
AU  - Bunyaratvej A
FAU - Piankijagum, A
AU  - Piankijagum A
FAU - Wasi, P
AU  - Wasi P
LA  - eng
GR  - HL 34408/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Thailand
TA  - Southeast Asian J Trop Med Public Health
JT  - The Southeast Asian journal of tropical medicine and public health
JID - 0266303
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Blood Gas Analysis
MH  - Dipyridamole/administration & dosage/pharmacology/therapeutic use
MH  - Follow-Up Studies
MH  - Heart Failure/etiology
MH  - Humans
MH  - Hypoxia/blood/drug therapy/*etiology
MH  - *Platelet Aggregation
MH  - Pulmonary Circulation
MH  - Pulmonary Heart Disease/etiology
MH  - Splenectomy
MH  - Thalassemia/*complications/surgery
RF  - 20
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Southeast Asian J Trop Med Public Health. 1992;23 Suppl 2:22-4.

PMID- 6793927
OWN - NLM
STAT- MEDLINE
DCOM- 19811222
LR  - 20161123
IS  - 0375-9393 (Print)
IS  - 0375-9393 (Linking)
VI  - 47
IP  - 5
DP  - 1981 May
TI  - [Comparison between extradural morphine and lysine acetylsalicylate in the 
      treatment of postoperative pain].
PG  - 253-64
AB  - We have compared the analgesic properties in post-operative pain using Morphine 
      (3 mg) injected in the extradural space and I.V. Lysine acetil salicilate (ASL) 
      (1.8 g). Extradural morphine is much more effective in eliminating pain and in 
      prolonging the analgesia. Insignificant the side effect for both treatments. The 
      authors underline the possibility of dependence with extradural morphine 
      especially in those cases when morphine is repeated more than 2-3 times.
FAU - Rucci, F S
AU  - Rucci FS
FAU - Munno, M T
AU  - Munno MT
FAU - Spaziani, S
AU  - Spaziani S
FAU - Cardamone, M
AU  - Cardamone M
LA  - ita
PT  - Comparative Study
PT  - Journal Article
TT  - Confronto tra morfina extradurale e acetilsalicilato di lisina (ASL) nel 
      trattamento del dolore post-operatorio.
PL  - Italy
TA  - Minerva Anestesiol
JT  - Minerva anestesiologica
JID - 0375272
RN  - 76I7G6D29C (Morphine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Dura Mater
MH  - Female
MH  - Humans
MH  - Injections
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Morphine/*administration & dosage/therapeutic use
MH  - Pain, Postoperative/*drug therapy
EDAT- 1981/05/01 00:00
MHDA- 1981/05/01 00:01
CRDT- 1981/05/01 00:00
PHST- 1981/05/01 00:00 [pubmed]
PHST- 1981/05/01 00:01 [medline]
PHST- 1981/05/01 00:00 [entrez]
PST - ppublish
SO  - Minerva Anestesiol. 1981 May;47(5):253-64.

PMID- 7243039
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Broncaspin in the therapy of pediatric diseases of the respiratory tract].
PG  - 435-42
AB  - A paediatric suspension of Broncaspin was administered to 32 children aged 2-12 
      yr hospitalised for acute respiratory infection of the respiratory apparatus or 
      hyperpirexia with no evident location. The drug was given as the sole treatment 
      in 9 cases, whereas combination with antibacterial drugs proved indispensable in 
      the other 23 cases. The satisfactory results obtained, together with its 
      excellent tolerability, show that the new preparation is active, and is capable 
      of rapidly eliminating the symptoms, so that the general clinical picture is both 
      evidently and persistently improved.
FAU - Saldi, M
AU  - Saldi M
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Il Broncaspin nella terapia delle malattie pediatriche dell'apparato 
      respiratorio.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Anti-Bacterial Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Age Factors
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Bronchitis/drug therapy
MH  - Bronchopneumonia/drug therapy
MH  - Child
MH  - Child, Preschool
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fever/drug therapy
MH  - Humans
MH  - Male
MH  - Pharyngitis/drug therapy
MH  - Pleurisy/drug therapy
MH  - Respiratory Tract Diseases/*drug therapy
MH  - Rhinitis/drug therapy
MH  - Tonsillitis/drug therapy
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):435-42.

PMID- 23464577
OWN - NLM
STAT- MEDLINE
DCOM- 20131022
LR  - 20151119
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 68
IP  - 5
DP  - 2013
TI  - Low-dose aspirin desensitization in individuals with aspirin-exacerbated 
      respiratory disease.
PG  - 659-65
LID - 10.1111/all.12131 [doi]
AB  - BACKGROUND: Nasal polyposis frequently occurs within the clinical picture of 
      aspirin-exacerbated respiratory disease (AERD). A derailed arachidonic acid 
      metabolism is regarded to be part of the pathophysiology of AERD, and aspirin 
      desensitization is the only causal therapeutic option, so far. The optimal 
      maintenance dose of aspirin desensitization to prevent nasal polyp recurrence on 
      the one hand and to minimize aspirin-related side-effects, on the other hand, is 
      still a matter of debate. The aim of this trial was to investigate the efficacy 
      and safety of a low-dose aspirin desensitization protocol. METHODS: After sinus 
      surgery, 70 individuals with AERD were randomly allocated to a prospective 
      double-blind placebo-controlled aspirin desensitization protocol with a 
      maintenance dose of 100 mg daily. The primary outcome was polyp relapse after 
      36 months. Nasal endoscopy status, quality of life, and patients' symptom score 
      as well as aspirin-related side-effects were monitored. RESULTS: Due to the high 
      dropout rate, only 31 individuals were evaluated. After 36 months, nasal polyp 
      relapse was less frequent (P = 0.0785) and the polyposis score was lower 
      (P = 0.0702) in the therapy group. Quality of life obviously improved 
      (P = 0.0324), clinical complaints (P = 0.0083) were significantly reduced, and no 
      severe aspirin-related side-effects were observed. CONCLUSION: Aspirin 
      desensitization with a maintenance dose of 100 mg daily has a positive impact on 
      nasal polyp relapse and seems to be a safe and suitable therapy to improve 
      clinical complaints and the quality of life of individuals with AERD.
CI  - © 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.
FAU - Fruth, K
AU  - Fruth K
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, University Medical 
      Center of the Johannes Gutenberg University Mainz, 55101 Mainz, Germany. 
      kai.fruth@unimedizin-mainz.de
FAU - Pogorzelski, B
AU  - Pogorzelski B
FAU - Schmidtmann, I
AU  - Schmidtmann I
FAU - Springer, J
AU  - Springer J
FAU - Fennan, N
AU  - Fennan N
FAU - Fraessdorf, N
AU  - Fraessdorf N
FAU - Boessert, A
AU  - Boessert A
FAU - Schaefer, D
AU  - Schaefer D
FAU - Gosepath, J
AU  - Gosepath J
FAU - Mann, W J
AU  - Mann WJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130307
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/*therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Quality of Life
MH  - Recurrence
MH  - Respiratory Hypersensitivity/*therapy
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2013/03/08 06:00
MHDA- 2013/10/23 06:00
CRDT- 2013/03/08 06:00
PHST- 2013/01/10 00:00 [accepted]
PHST- 2013/03/08 06:00 [entrez]
PHST- 2013/03/08 06:00 [pubmed]
PHST- 2013/10/23 06:00 [medline]
AID - 10.1111/all.12131 [doi]
PST - ppublish
SO  - Allergy. 2013;68(5):659-65. doi: 10.1111/all.12131. Epub 2013 Mar 7.

PMID- 6105528
OWN - NLM
STAT- MEDLINE
DCOM- 19801027
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8191
DP  - 1980 Aug 23
TI  - Reappraisal of the effects of aspirin on the stomach.
PG  - 410-3
AB  - In a survey of the published evidence linking aspirin ingestion to gastric 
      mucosal damage an attempt has been made to assess the role of aspirin in the 
      pathogenesis of acute and chronic gastric haemorrhage and peptic ulceration. It 
      seems that aspirin ingestion rarely causes clinically significant gastric damage 
      in normal subjects and then usually only with large or frequent doses. Even in 
      these rare instances the specific role of aspirin remains uncertain.
FAU - Rees, W D
AU  - Rees WD
FAU - Turnberg, L A
AU  - Turnberg LA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Gastric Mucosa/drug effects
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Peptic Ulcer/chemically induced
MH  - Risk
MH  - Stomach/*drug effects
MH  - Time Factors
EDAT- 1980/08/23 00:00
MHDA- 1980/08/23 00:01
CRDT- 1980/08/23 00:00
PHST- 1980/08/23 00:00 [pubmed]
PHST- 1980/08/23 00:01 [medline]
PHST- 1980/08/23 00:00 [entrez]
AID - S0140-6736(80)90452-3 [pii]
AID - 10.1016/s0140-6736(80)90452-3 [doi]
PST - ppublish
SO  - Lancet. 1980 Aug 23;2(8191):410-3. doi: 10.1016/s0140-6736(80)90452-3.

PMID- 121613
OWN - NLM
STAT- MEDLINE
DCOM- 19801021
LR  - 20191027
IS  - 0161-4630 (Print)
IS  - 0161-4630 (Linking)
VI  - 3
IP  - 6
DP  - 1979 Dec
TI  - Interference by sulfinpyrazone and salicylate of aspirin inhibition of platelet 
      cyclooxygenase activity.
PG  - 327-32
AB  - The irreversible effect of acetylsalicylic acid on platelet cyclooxygenase 
      activity is inhibited by salicylate and by sulfinpyrazone. Since acetylsalicylate 
      is rapidly hydrolysed in plasma to salicylate which has a relatively prolonged 
      half life in plasma, it is possible that persistant elevation of plasma 
      salicylate may interfere with the efficacy of subsequent doses of aspirin. 
      Sulfinpyrazone is sometimes used in combination with aspirin, and could interfere 
      with the efficacy of aspirin on platelets. This theoretical possibility would be 
      more likely to occur at lower doses of aspirin.
FAU - Ali, M
AU  - Ali M
FAU - McDonald, J W
AU  - McDonald JW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins Med
JT  - Prostaglandins and medicine
JID - 7810330
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Salicylates)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/*antagonists & inhibitors/pharmacology
MH  - Blood Platelets/enzymology
MH  - Cyclooxygenase Inhibitors
MH  - Humans
MH  - Prostaglandin-Endoperoxide Synthases/*blood
MH  - Salicylates/*pharmacology
MH  - Sulfinpyrazone/*pharmacology
EDAT- 1979/12/01 00:00
MHDA- 1979/12/01 00:01
CRDT- 1979/12/01 00:00
PHST- 1979/12/01 00:00 [pubmed]
PHST- 1979/12/01 00:01 [medline]
PHST- 1979/12/01 00:00 [entrez]
AID - 10.1016/0161-4630(79)90025-9 [doi]
PST - ppublish
SO  - Prostaglandins Med. 1979 Dec;3(6):327-32. doi: 10.1016/0161-4630(79)90025-9.

PMID- 26085469
OWN - NLM
STAT- MEDLINE
DCOM- 20160527
LR  - 20181113
IS  - 2095-0225 (Electronic)
IS  - 2095-0217 (Linking)
VI  - 9
IP  - 3
DP  - 2015 Sep
TI  - Severe hepatoxicity caused by aspirin overdose: a case report.
PG  - 388-91
LID - 10.1007/s11684-015-0398-7 [doi]
AB  - We report here the rare case of a 61-year-old man with multiple organ dysfunction 
      caused by an aspirin overdose (4 g orally). The patient presented with a fever 
      that reached 39.2 °C, a peptic ulcer, and massive upper gastrointestinal 
      bleeding. His blood test results were as follows: white blood cell count, 1.8 × 
      10(9)/L; absolute lymphocytes, 0.4 × 10(9)/L; absolute neutrophils, 1.2 × 
      10(9)/L; and electrolyte disturbances. A computed tomography (CT) scan showed 
      evidence of bilateral inferior pulmonary infection and acute pancreatitis. Thick 
      dark bile with visible floccule was drawn via a percutaneous transhepatic 
      cholangiodrainage (PTCD). Klebsiella pneumoniae was detected in microbiological 
      bile tests. Two years later, the patient died of chronic liver failure.
FAU - Cao, Zhuping
AU  - Cao Z
AD  - Department of Nursing, School of Medicine, Shihezi University, Shihezi, 832002, 
      China.
FAU - Liu, Shiqi
AU  - Liu S
FAU - Niu, Jianhua
AU  - Niu J
FAU - Wei, Bing
AU  - Wei B
FAU - Xu, Jie
AU  - Xu J
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20150617
PL  - China
TA  - Front Med
JT  - Frontiers of medicine
JID - 101549428
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*toxicity
MH  - Chemical and Drug Induced Liver Injury/*diagnosis
MH  - Drug Overdose/*complications
MH  - Humans
MH  - Liver Failure/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Tomography, X-Ray Computed
EDAT- 2015/06/19 06:00
MHDA- 2016/05/28 06:00
CRDT- 2015/06/19 06:00
PHST- 2014/07/30 00:00 [received]
PHST- 2015/04/16 00:00 [accepted]
PHST- 2015/06/19 06:00 [entrez]
PHST- 2015/06/19 06:00 [pubmed]
PHST- 2016/05/28 06:00 [medline]
AID - 10.1007/s11684-015-0398-7 [doi]
PST - ppublish
SO  - Front Med. 2015 Sep;9(3):388-91. doi: 10.1007/s11684-015-0398-7. Epub 2015 Jun 
      17.

PMID- 7506176
OWN - NLM
STAT- MEDLINE
DCOM- 19940204
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 46 Suppl 1
DP  - 1993
TI  - Double-blind evaluation of nimesulide vs lysine-aspirin in the treatment of 
      paediatric acute respiratory tract infections.
PG  - 219-21
AB  - 70 children aged 4 to 12 years with acute infection and inflammation of the 
      respiratory tract (laryngitis, tracheitis, bronchitis, pneumonia) were enrolled 
      in a double-blind investigation and randomised to treatment with nimesulide (50mg 
      granules twice daily) or lysine-aspirin (360mg granules twice daily) for 5 days. 
      The drugs were similarly effective in reducing cough, asthenia and dyspnoea, 
      although nimesulide-treated patients experienced fewer gastrointestinal adverse 
      events. These results confirm the efficacy of nimesulide in the treatment of 
      respiratory inflammation and provide preliminary evidence of its value in 
      children.
FAU - Barberi, I
AU  - Barberi I
AD  - Istituto di Pediatria Medica Preventiva e Sociale, Università di Messina, Italy.
FAU - Macchia, A
AU  - Macchia A
FAU - Spata, N
AU  - Spata N
FAU - Scaricabarozzi, I
AU  - Scaricabarozzi I
FAU - Nava, M L
AU  - Nava ML
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Sulfonamides)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - V4TKW1454M (nimesulide)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acute Disease
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Respiratory Tract Infections/*drug therapy
MH  - Sulfonamides/*therapeutic use
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.2165/00003495-199300461-00056 [doi]
PST - ppublish
SO  - Drugs. 1993;46 Suppl 1:219-21. doi: 10.2165/00003495-199300461-00056.

PMID- 16330241
OWN - NLM
STAT- MEDLINE
DCOM- 20070112
LR  - 20191210
IS  - 1386-1425 (Print)
IS  - 1386-1425 (Linking)
VI  - 65
IP  - 1
DP  - 2006 Sep
TI  - Radial basis function neural networks in non-destructive determination of 
      compound aspirin tablets on NIR spectroscopy.
PG  - 79-83
AB  - The application of the second most popular artificial neural networks (ANNs), 
      namely, the radial basis function (RBF) networks, has been developed for 
      quantitative analysis of drugs during the last decade. In this paper, the two 
      components (aspirin and phenacetin) were simultaneously determined in compound 
      aspirin tablets by using near-infrared (NIR) spectroscopy and RBF networks. The 
      total database was randomly divided into a training set (50) and a testing set 
      (17). Different preprocessing methods (standard normal variate (SNV), 
      multiplicative scatter correction (MSC), first-derivative and second-derivative) 
      were applied to two sets of NIR spectra of compound aspirin tablets with 
      different concentrations of two active components and compared each other. After 
      that, the performance of RBF learning algorithm adopted the nearest neighbor 
      clustering algorithm (NNCA) and the criterion for selection used a 
      cross-validation technique. Results show that using RBF networks to 
      quantificationally analyze tablets is reliable, and the best RBF model was 
      obtained by first-derivative spectra.
FAU - Dou, Ying
AU  - Dou Y
AD  - College of Chemistry, Jilin University, 2519 Jiefang Avenue, Changchun 130021, 
      China.
FAU - Mi, Hong
AU  - Mi H
FAU - Zhao, Lingzhi
AU  - Zhao L
FAU - Ren, Yuqiu
AU  - Ren Y
FAU - Ren, Yulin
AU  - Ren Y
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20051205
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Calibration
MH  - Computer Simulation
MH  - *Neural Networks, Computer
MH  - Spectroscopy, Near-Infrared/*methods
MH  - Tablets/chemistry
EDAT- 2005/12/07 09:00
MHDA- 2007/01/16 09:00
CRDT- 2005/12/07 09:00
PHST- 2005/06/09 00:00 [received]
PHST- 2005/09/22 00:00 [accepted]
PHST- 2005/12/07 09:00 [pubmed]
PHST- 2007/01/16 09:00 [medline]
PHST- 2005/12/07 09:00 [entrez]
AID - S1386-1425(05)00530-5 [pii]
AID - 10.1016/j.saa.2005.09.031 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2006 Sep;65(1):79-83. doi: 
      10.1016/j.saa.2005.09.031. Epub 2005 Dec 5.

PMID- 432254
OWN - NLM
STAT- MEDLINE
DCOM- 19790626
LR  - 20131121
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 34
IP  - 1
DP  - 1979 Jan
TI  - Stability of acetylsalicylic acid in divided powders in the presence of 
      aminophenazone.
PG  - 33-6
AB  - The combination of acetylsalicylic acid with aminophenazone, often prescribed in 
      divided powders, is considered to be incompatible. High performance liquid 
      chromatography was applied to determine the content of salicylic acid which is 
      the main known product from the decomposition of acetylsalicylic acid. The 
      analysis of model samples containing a 1:1 (by weight) mixture of acetylsalicylic 
      acid and aminophenazone, after having been stored under usual conditions in 
      starch capsules, showed that the decomposition of acetylsalicylic acid into 
      salicylic acid did not exceed 0.8% even after ten weeks.
FAU - Subert, J
AU  - Subert J
FAU - Slais, K
AU  - Slais K
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Powders)
RN  - 01704YP3MO (Aminopyrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aminopyrine/*analysis
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid
MH  - Drug Stability
MH  - Powders
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1979 Jan;34(1):33-6.

PMID- 2347518
OWN - NLM
STAT- MEDLINE
DCOM- 19900709
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 20
IP  - 2
DP  - 1990
TI  - Aspirin at very ultra low dosage in healthy volunteers: effects on bleeding time, 
      platelet aggregation and coagulation.
PG  - 99-105
AB  - Aspirin at very ultra low dosage was tested in healthy volunteers (n = 20) in a 
      randomized, double-blind and placebo-controlled trial. The results showed a 
      bleeding time reduction (p less than 0.05) in volunteers having previously 
      ingested aspirin. Platelet aggregation on platelet-rich plasma was not 
      statistically modified after aspirin ingestion. Thrombin clotting time was always 
      higher (p less than 0.05) in the treated group.
FAU - Doutremepuich, C
AU  - Doutremepuich C
AD  - Laboratoire d'hématologie, CJF INSERM 88/13, Bordeaux, France.
FAU - de Sèze, O
AU  - de Sèze O
FAU - Le Roy, D
AU  - Le Roy D
FAU - Lalanne, M C
AU  - Lalanne MC
FAU - Anne, M C
AU  - Anne MC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation/*drug effects
MH  - Collagen/pharmacology
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Random Allocation
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1159/000216114 [doi]
PST - ppublish
SO  - Haemostasis. 1990;20(2):99-105. doi: 10.1159/000216114.

PMID- 21625173
OWN - NLM
STAT- MEDLINE
DCOM- 20111121
LR  - 20211203
IS  - 1661-6758 (Electronic)
IS  - 1661-6499 (Print)
IS  - 1661-6499 (Linking)
VI  - 4
IP  - 2
DP  - 2011
TI  - Determinants of aspirin metabolism in healthy men and women: effects of dietary 
      inducers of UDP-glucuronosyltransferases.
PG  - 110-8
LID - 10.1159/000327782 [doi]
AB  - BACKGROUND/AIMS: Interindividual variation in aspirin (ASA) metabolism is 
      attributed to concomitant use of drugs or alcohol, urine pH, ethnicity, sex, and 
      genetic variants in UDP-glucuronosyltransferases (UGT). Little is known about the 
      effects of diet. METHODS: We evaluated cross-sectionally whether urinary 
      excretion of ASA and its metabolites [salicylic acid (SA), salicyluric acid (SUA) 
      phenolic glucuronide (SUAPG), salicylic acid acyl glucuronide (SAAG) and 
      salicylic acid phenolic glucuronide (SAPG)] differed by UGT1A6 genotype and 
      dietary factors shown to induce UGT. Following oral treatment with 650 mg ASA, 
      urine was collected over 8 h in 264 men and 264 women (21-45 years old). RESULTS: 
      There were statistically significant differences in metabolites excreted between 
      sexes and ethnicities. Men excreted more SUA; women more ASA (p = 0.03), SA, SAAG 
      and SAPG (p ≤ 0.001 for all). Compared to Caucasians, Asians excreted more ASA, 
      SA and SAAG, and less SUA and SUAPG (p ≤ 0.03 for all); African-Americans 
      excreted more SAAG and SAPG and less SUA (p ≤ 0.04). There was no effect of 
      UGT1A6 genotypes. Increased ASA and decreased SUAPG excretion was observed with 
      increased servings of vegetables (p = 0.008), specifically crucifers (p = 0.05). 
      CONCLUSION: Diet may influence the pharmacokinetics of ASA, but effects may be 
      through modulation of glycine conjugation rather than glucuronidation.
CI  - Copyright © 2011 S. Karger AG, Basel.
FAU - Navarro, Sandi L
AU  - Navarro SL
AD  - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Wash., 
      USA.
FAU - Saracino, Misty R
AU  - Saracino MR
FAU - Makar, Karen W
AU  - Makar KW
FAU - Thomas, Sushma S
AU  - Thomas SS
FAU - Li, Lin
AU  - Li L
FAU - Zheng, Yingye
AU  - Zheng Y
FAU - Levy, Lisa
AU  - Levy L
FAU - Schwarz, Yvonne
AU  - Schwarz Y
FAU - Bigler, Jeannette
AU  - Bigler J
FAU - Potter, John D
AU  - Potter JD
FAU - Lampe, Johanna W
AU  - Lampe JW
LA  - eng
GR  - R01 CA092288/CA/NCI NIH HHS/United States
GR  - R25 CA094880/CA/NCI NIH HHS/United States
GR  - R01 CA94954/CA/NCI NIH HHS/United States
GR  - R01 CA92288/CA/NCI NIH HHS/United States
GR  - R01 CA094954/CA/NCI NIH HHS/United States
GR  - R25 CA94880/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20110528
PL  - Switzerland
TA  - J Nutrigenet Nutrigenomics
JT  - Journal of nutrigenetics and nutrigenomics
JID - 101299758
RN  - 0 (Glucuronides)
RN  - EC 2.4.1.- (UDP-glucuronosyltransferase, UGT1A6)
RN  - EC 2.4.1.17 (Glucuronosyltransferase)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*metabolism/pharmacokinetics
MH  - Cross-Sectional Studies
MH  - *Diet
MH  - Enzyme Induction
MH  - Ethnicity
MH  - Female
MH  - Genetic Association Studies
MH  - Glucuronides/metabolism
MH  - Glucuronosyltransferase/*biosynthesis/genetics
MH  - Glycine/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nutrigenomics
MH  - Sex Characteristics
MH  - Young Adult
PMC - PMC3121547
EDAT- 2011/06/01 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/06/01 06:00
PHST- 2010/11/25 00:00 [received]
PHST- 2011/03/21 00:00 [accepted]
PHST- 2011/06/01 06:00 [entrez]
PHST- 2011/06/01 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 000327782 [pii]
AID - jnn0004-0110 [pii]
AID - 10.1159/000327782 [doi]
PST - ppublish
SO  - J Nutrigenet Nutrigenomics. 2011;4(2):110-8. doi: 10.1159/000327782. Epub 2011 
      May 28.

PMID- 11128825
OWN - NLM
STAT- MEDLINE
DCOM- 20010208
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 20
IP  - 7
DP  - 2000 Sep
TI  - Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a 
      multicentre, randomized, double-blind, single-dose, placebo-controlled parallel 
      group study.
PG  - 663-7
AB  - In this multicentre, randomized, double-blind, single-dose study a total of 374 
      patients generally suffering from migraine attacks suitable for treatment with 
      non-prescription drugs, received either oral acetylsalicylic acid effervescent 
      1000 mg (ASAE) or effervescent placebo for the treatment of an acute migraine 
      attack. Of the 343 patients fulfilling the criteria for efficacy analysis 169 
      patients took acetylsalicylic acid and 174 placebo. Response rates (reduction of 
      headache severity from severe or moderate to mild or no pain at 2 h after 
      administration) were 55.0% for acetylsalicylic acid and 36.8% for placebo (P < 
      0.001). Twenty-nine percent of patients in the active treatment group were 
      pain-free after 2 h compared with 16.7% in the placebo group (P = 0.007). No 
      headache recurred within 24 h post-dose in 84.6% of patients in the active group 
      and in 85.1% of patients in the placebo group. Effervescent placebo reduced 
      nausea and vomiting to the same degree as the active drug. Adverse events of 
      acetylsalicylic acid (8.3%) were generally mild or moderate and comparable to 
      those of placebo (2.9%). This study shows that oral ASAE is safe and effective 
      for the treatment of acute migraine attacks.
FAU - Lange, R
AU  - Lange R
AD  - Bayer AG, BG Consumer Care, Medical Department, Leverkusen, Germany. 
      ralph.lange.rl@bayer-ag.de
FAU - Schwarz, J A
AU  - Schwarz JA
FAU - Hohn, M
AU  - Hohn M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy/physiopathology
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2000/12/29 11:00
MHDA- 2001/03/03 10:01
CRDT- 2000/12/29 11:00
PHST- 2000/12/29 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2000/12/29 11:00 [entrez]
AID - 10.1111/j.1468-2982.2000.00101.x [doi]
PST - ppublish
SO  - Cephalalgia. 2000 Sep;20(7):663-7. doi: 10.1111/j.1468-2982.2000.00101.x.

PMID- 27423939
OWN - NLM
STAT- MEDLINE
DCOM- 20171012
LR  - 20220408
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Linking)
VI  - 18
IP  - 8
DP  - 2016 Aug
TI  - The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with 
      Coronary Artery Disease.
PG  - 81
LID - 10.1007/s11886-016-0749-2 [doi]
AB  - Coronary artery disease (CAD) is the underlying cause of death in one out of 
      seven deaths in the USA. Aspirin therapy has been proven to decrease mortality 
      and major adverse cardiovascular events in patients with CAD. Despite a plethora 
      of studies showing the benefit of aspirin in secondary prevention of 
      cardiovascular events, debate remains regarding the optimal dose due to 
      relatively small studies that had disparate results when comparing patients 
      taking different aspirin dosages. More recently, aspirin dosing has been 
      thoroughly studied in the CAD population with concomitant therapy (such as P2Y12 
      inhibitors); however, patients in these studies were not randomized to aspirin 
      dose. No randomized controlled trial has directly measured aspirin dosages in a 
      population of patients with established coronary artery disease. In 2015, the 
      Patient-Centered Outcomes Research Institute (PCORI) developed a network, called 
      PCORnet, that includes patient-powered research networks (PPRN) and clinical data 
      research networks (CDRN). The main objective of PCORnet is to conduct widely 
      generalizable observational studies and clinical trials (including large, 
      pragmatic clinical trials) at a low cost. The first clinical trial, called 
      Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term 
      Effectiveness (ADAPTABLE), will randomly assign 20,000 subjects with established 
      coronary heart disease to either low dose (81 mg) or high dose (325 mg) and 
      should be able to finally answer which dosage of aspirin is best for patients 
      with established cardiovascular disease.
FAU - Johnston, Abigail
AU  - Johnston A
AD  - Duke Clinical Research Institute, Duke University School of Medicine, PO Box 
      17969, Durham, NC, 27715, USA.
AD  - Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
FAU - Jones, W Schuyler
AU  - Jones WS
AD  - Duke Clinical Research Institute, Duke University School of Medicine, PO Box 
      17969, Durham, NC, 27715, USA.
AD  - Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
FAU - Hernandez, Adrian F
AU  - Hernandez AF
AD  - Duke Clinical Research Institute, Duke University School of Medicine, PO Box 
      17969, Durham, NC, 27715, USA. adrian.hernandez@duke.edu.
AD  - Department of Medicine, Duke University School of Medicine, Durham, NC, USA. 
      adrian.hernandez@duke.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Artery Disease/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Secondary Prevention/*methods
OTO - NOTNLM
OT  - Aspirin
OT  - Coronary artery disease
OT  - Myocardial infarction
OT  - Secondary prevention
EDAT- 2016/07/18 06:00
MHDA- 2017/10/13 06:00
CRDT- 2016/07/18 06:00
PHST- 2016/07/18 06:00 [entrez]
PHST- 2016/07/18 06:00 [pubmed]
PHST- 2017/10/13 06:00 [medline]
AID - 10.1007/s11886-016-0749-2 [pii]
AID - 10.1007/s11886-016-0749-2 [doi]
PST - ppublish
SO  - Curr Cardiol Rep. 2016 Aug;18(8):81. doi: 10.1007/s11886-016-0749-2.

PMID- 21959824
OWN - NLM
STAT- MEDLINE
DCOM- 20120302
LR  - 20161125
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 24
IP  - 4
DP  - 2011 Oct
TI  - Fabrication of potential macromolecular prodrugs of aspirin and diclofenac with 
      dextran.
PG  - 575-81
AB  - Aspirin and diclofenac conjugates with dextran were synthesized as potential 
      macromolecular prodrugs under homogeneous reaction conditions by using 
      4-methyl-benzenesulfonyl chloride as an acylating agent in the presence of 
      triethylamine as a base. Highly pure conjugates with good yields were synthesized 
      by this acylation method. All of the products were found soluble in aqueous 
      medium as well as in dimethylsulfoxide and N,N-dimethylacetamide. The UV/Vis 
      spectrophotometry has indicated the incorporation of drugs in conjugates and 
      extent of substitution of drug onto dextran polymer. Covalent attachment of the 
      drug onto the drug carrier polymer (dextran) was verified by (1)H NMR and Fourier 
      transform infrared (FTIR) spectroscopic analysis. The prodrugs were analysed by 
      powder X-ray diffraction (XRD) measurements. Phase changes were noticed by powder 
      XRD for all macromolecular prodrugs indicating the change of state of matter 
      towards more crystallinity. Therefore, fabricated macromolecular prodrugs are 
      potential candidates to show better pharmacokinetic profile. All of the products 
      were thoroughly characterized by using different spectroscopic techniques.
FAU - Hussain, Muhammad Ajaz
AU  - Hussain MA
AD  - Department of Chemistry, University of Sargodha, Sargodha, Pakistan. 
      majaz172@yahoo.com
FAU - Hassan, Zahid
AU  - Hassan Z
FAU - Haseeb, Muhammad Tahir
AU  - Haseeb MT
FAU - Iqbal, Mohammad Saeed
AU  - Iqbal MS
FAU - Sher, Muhammad
AU  - Sher M
FAU - Tahir, Muhammad Nawaz
AU  - Tahir MN
FAU - Tremel, Wolfgung
AU  - Tremel W
FAU - Bashir, Sajid
AU  - Bashir S
FAU - Ahmad, Riaz
AU  - Ahmad R
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - 0 (Dextrans)
RN  - 0 (Prodrugs)
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/chemistry
MH  - Dextrans/*chemistry
MH  - Diclofenac/*administration & dosage/chemistry
MH  - Esterification
MH  - Magnetic Resonance Spectroscopy
MH  - Molecular Structure
MH  - Powder Diffraction
MH  - Prodrugs/*chemical synthesis/chemistry
MH  - Spectrophotometry, Ultraviolet
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Thermogravimetry
EDAT- 2011/10/01 06:00
MHDA- 2012/03/03 06:00
CRDT- 2011/10/01 06:00
PHST- 2011/10/01 06:00 [entrez]
PHST- 2011/10/01 06:00 [pubmed]
PHST- 2012/03/03 06:00 [medline]
PST - ppublish
SO  - Pak J Pharm Sci. 2011 Oct;24(4):575-81.

PMID- 8665721
OWN - NLM
STAT- MEDLINE
DCOM- 19960806
LR  - 20190909
IS  - 0307-7772 (Print)
IS  - 0307-7772 (Linking)
VI  - 20
IP  - 6
DP  - 1995 Dec
TI  - Intranasal lysine aspirin in recurrent nasal polyposis.
PG  - 561-3
AB  - Twenty patients with recurrent nasal polyposis but without any history of aspirin 
      sensitivity were given 2000 micrograms of intranasal lysine aspirin to one 
      nostril and saline to the other once a week for periods of up to 15 months. Two 
      patients had increased nasal obstruction following the initial test doses of 
      lysine aspirin and were excluded from the trial proper. In the remainder 
      symptomatic polyp recurrence was delayed compared with the previous experience 
      while on intranasal steroids, with eight patients remaining symptom free at 15 
      months compared with an expected number of three (P = < 0.05, chi 2 test). Polyp 
      recurrence was bilateral but there was a tendency for the lysine aspirin treated 
      side to have less polyp tissue as assessed by nasendoscopy and by acoustic 
      rhinometry.
FAU - Scadding, G K
AU  - Scadding GK
AD  - Royal National Throat, Nose and Ear Hospital NHS Trust, London, UK.
FAU - Hassab, M
AU  - Hassab M
FAU - Darby, Y C
AU  - Darby YC
FAU - Lund, V J
AU  - Lund VJ
FAU - Freedman, A
AU  - Freedman A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Clin Otolaryngol Allied Sci
JT  - Clinical otolaryngology and allied sciences
JID - 7701793
RN  - 0 (Drug Combinations)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Intranasal
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drug Combinations
MH  - Humans
MH  - Lysine/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/*drug therapy/surgery
MH  - Recurrence
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
AID - 10.1111/j.1365-2273.1995.tb01603.x [doi]
PST - ppublish
SO  - Clin Otolaryngol Allied Sci. 1995 Dec;20(6):561-3. doi: 
      10.1111/j.1365-2273.1995.tb01603.x.

PMID- 33081590
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20210830
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Linking)
VI  - 30
IP  - 1
DP  - 2021 Jan
TI  - Prevention of recurrent miscarriage in women with antiphospholipid syndrome: A 
      systematic review and network meta-analysis.
PG  - 70-79
LID - 10.1177/0961203320967097 [doi]
AB  - OBJECTIVES: To compare and rank currently available pharmacological interventions 
      for the prevention of recurrent miscarriage (RM) in women with antiphospholipid 
      syndrome (APS). METHODS: A search was performed using PubMed, Embase, the 
      Cochrane Central Register of Controlled Trials, Web of Science, CNKI, 
      ClinicalTrials.gov, and the UK National Research Register on December 15, 2019. 
      Studies comparing any types of active interventions with placebo/inactive control 
      or another active intervention for the prevention of RM in patients with APS were 
      considered for inclusion. The primary outcomes were efficacy (measured by live 
      birth rate) and acceptability (measured by all-cause discontinuation); secondary 
      outcomes were birthweight, preterm birth, preeclampsia, and intrauterine growth 
      retardation. The protocol of this study was registered with Open Science 
      Framework (DOI: 10.17605/OSF.IO/B9T4E). RESULTS: In total, 54 randomized 
      controlled trials (RCTs) comprising 4,957 participants were included. 
      Low-molecular-weight heparin (LMWH) alone, aspirin plus LMWH or unfractionated 
      heparin (UFH), aspirin plus LMWH plus intravenous immunoglobulin (IVIG), aspirin 
      plus LMWH plus IVIG plus prednisone were found to be effective pharmacological 
      interventions for increasing live birth rate (ORs ranging between 2.88 to 11.24). 
      In terms of acceptability, no significant difference was found between 
      treatments. In terms of adverse perinatal outcomes, aspirin alone was associated 
      with a higher risk of preterm birth than aspirin plus LMWH (OR 3.92, 95% CI 1.16 
      to 16.44) and with lower birthweight than LMWH (SMD -808.76, 95% CI -1596.54 to 
      -5.07). CONCLUSIONS: Our findings support the use of low-dose aspirin plus 
      heparin as the first-line treatment for prevention of RM in women with APS, and 
      support the efficacy of hydroxychloroquine, IVIG, and prednisone when added to 
      current treatment regimens. More large-scale, high-quality RCTs are needed to 
      confirm these findings, and new pharmacological options should be further 
      evaluated.
FAU - Yang, Ziyi
AU  - Yang Z
AUID- ORCID: 0000-0002-4138-5598
AD  - The First Clinical College of Chongqing Medical University, Chongqing, China.
FAU - Shen, Xiangli
AU  - Shen X
AD  - Department of Obstetrics, Chengdu Jinjiang Maternity and Child Health Hospital, 
      Chengdu, China.
FAU - Zhou, Chuqing
AU  - Zhou C
AD  - The First Clinical College of Chongqing Medical University, Chongqing, China.
FAU - Wang, Min
AU  - Wang M
AD  - North Sichuan Medical College, Nanchong, China.
FAU - Liu, Yi
AU  - Liu Y
AD  - Department of Obstetrics, Chengdu Jinjiang Maternity and Child Health Hospital, 
      Chengdu, China.
FAU - Zhou, Lin
AU  - Zhou L
AD  - Department of Obstetrics, Chengdu Jinjiang Maternity and Child Health Hospital, 
      Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201020
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*prevention & control
MH  - Antiphospholipid Syndrome/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Live Birth
MH  - Pregnancy
MH  - Premature Birth/chemically induced
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Antiphospholipid syndrome
OT  - network meta-analysis
OT  - pregnancy
OT  - recurrent miscarriage
OT  - systematic review
EDAT- 2020/10/22 06:00
MHDA- 2021/08/31 06:00
CRDT- 2020/10/21 05:36
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
PHST- 2020/10/21 05:36 [entrez]
AID - 10.1177/0961203320967097 [doi]
PST - ppublish
SO  - Lupus. 2021 Jan;30(1):70-79. doi: 10.1177/0961203320967097. Epub 2020 Oct 20.

PMID- 729734
OWN - NLM
STAT- MEDLINE
DCOM- 19790313
LR  - 20191210
IS  - 0014-4754 (Print)
IS  - 0014-4754 (Linking)
VI  - 34
IP  - 12
DP  - 1978 Dec 15
TI  - Autophagy in mouse hepatocytes induced by lysine acetylsalicylate.
PG  - 1618-9
AB  - I.v. administration of lysine acetylsalicylate inces autophagy in mouse liver 
      cells. Single and multiple membrane-bounded vacuoles were found. The latter seems 
      to be an unusual morphological form of the sequestration process. These findings 
      could express a transitory sublethal liver cell injury induced by the drug.
FAU - Aguas, A P
AU  - Aguas AP
FAU - Soares, J O
AU  - Soares JO
FAU - Nunes, J F
AU  - Nunes JF
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Experientia
JT  - Experientia
JID - 0376547
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Autophagy/*drug effects
MH  - Female
MH  - Liver/*drug effects/ultrastructure
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Mice
MH  - Phagocytosis/*drug effects
MH  - Vacuoles/drug effects
EDAT- 1978/12/15 00:00
MHDA- 1978/12/15 00:01
CRDT- 1978/12/15 00:00
PHST- 1978/12/15 00:00 [pubmed]
PHST- 1978/12/15 00:01 [medline]
PHST- 1978/12/15 00:00 [entrez]
AID - 10.1007/BF02034711 [doi]
PST - ppublish
SO  - Experientia. 1978 Dec 15;34(12):1618-9. doi: 10.1007/BF02034711.

PMID- 25046207
OWN - NLM
STAT- MEDLINE
DCOM- 20151207
LR  - 20140827
IS  - 1944-8252 (Electronic)
IS  - 1944-8244 (Linking)
VI  - 6
IP  - 16
DP  - 2014 Aug 27
TI  - Synthesis of aspirin-loaded polymer-silica composites and their release 
      characteristics.
PG  - 14369-76
LID - 10.1021/am5036384 [doi]
AB  - This study describes a novel approach to the synthesis of polymer-drug-silica 
      nanocomposites via encapsulation/isolation of drug molecules, introduced into the 
      polymer matrix by the silica gel. For the first time, tetraethoxysilane (TEOS) 
      gelation in the vapor phase of the acidic catalyst is presented as an efficient 
      method to enter the silica gel nanoparticles into the polymer-aspirin conjugate. 
      The conducted studies reveal that the internal structure of the polymer carrier 
      is significantly reorganized after the embedding of aspirin molecules and the 
      silica gel. The total porosity of the polymer-drug-silica nanocomposites and the 
      molecular structure of the silica gel embedded in the system strongly depend on 
      the conditions of the silica source transformation. Additionally, the release of 
      the drug was fine-tuned by adapting the conditions of hydrolysis and condensation 
      of the silica gel precursor. Finally, to prove the usefulness of the proposed 
      synthesis, the controlled release of aspirin from the polymer-drug-silica 
      nanocomposites is demonstrated.
FAU - Kierys, Agnieszka
AU  - Kierys A
AD  - Department of Adsorption, Faculty of Chemistry, Maria Curie-Sklodowska University 
      , M. Curie-Sklodowska Sq. 3, 20-031 Lublin, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140730
PL  - United States
TA  - ACS Appl Mater Interfaces
JT  - ACS applied materials & interfaces
JID - 101504991
RN  - 0 (Polymers)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Nanocomposites/*chemistry
MH  - Polymers/*chemistry
MH  - Silicon Dioxide/*chemistry
EDAT- 2014/07/22 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/07/22 06:00
PHST- 2014/07/22 06:00 [entrez]
PHST- 2014/07/22 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1021/am5036384 [doi]
PST - ppublish
SO  - ACS Appl Mater Interfaces. 2014 Aug 27;6(16):14369-76. doi: 10.1021/am5036384. 
      Epub 2014 Jul 30.

PMID- 15133250
OWN - NLM
STAT- MEDLINE
DCOM- 20050203
LR  - 20190719
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 27
IP  - 5
DP  - 2004 May
TI  - Pharmacokinetics and metabolic rates of acetyl salicylic acid and its metabolites 
      in an Otomi ethnic group of Mexico.
PG  - 706-9
AB  - The objective of this study was to determine pharmacokinetic differences of 
      acetyl salicylic acid (ASA) and its metabolites: gentisic acid (GA), salicylic 
      acid (SA) and salicyluric acid (SUA) between Otomies and Mesticians healthy 
      subjects. Design. Ten Otomies and 10 Mesticians were included. After a single 
      dose of aspirin given orally (15 mg/kg), blood and urine samples were collected 
      at different times. Results. Pharmacokinetic parameters of salicylates showed 
      significant differences, except distribution volume of SA, and elimination 
      half-life of SUA. Metabolic rates of ASA showed significant differences for all 
      rates between both groups. On the other hand, percentages of dose excreted were 
      more reduced for SA and SUA for the Otomies than for the Mesticians. Conclusion. 
      Results reflect differences in the hydrolysis way i.e. from ASA to SA and 
      aromatic hydroxylation i.e. from SA to GA, which were slower in Otomies subjects, 
      showing a possible pharmacokinetic differences about the capabilities of ASA 
      biotransformation as a consequence of ethnic differences.
FAU - Lares-Asseff, Ismael
AU  - Lares-Asseff I
AD  - Interdisciplinary Centre of Investigation for the Regional Integral Development, 
      National Politechnic Institute, México.
FAU - Juárez-Olguín, Hugo
AU  - Juárez-Olguín H
FAU - Flores-Pérez, Janett
AU  - Flores-Pérez J
FAU - Guillé-Pérez, Adrian
AU  - Guillé-Pérez A
FAU - Vargas, Arturo
AU  - Vargas A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/metabolism/*pharmacokinetics
MH  - Female
MH  - Humans
MH  - *Indians, North American
MH  - Male
MH  - Metabolic Clearance Rate/physiology
MH  - Mexico/ethnology
MH  - Statistics, Nonparametric
EDAT- 2004/05/11 05:00
MHDA- 2005/02/04 09:00
CRDT- 2004/05/11 05:00
PHST- 2004/05/11 05:00 [pubmed]
PHST- 2005/02/04 09:00 [medline]
PHST- 2004/05/11 05:00 [entrez]
AID - 10.1248/bpb.27.706 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2004 May;27(5):706-9. doi: 10.1248/bpb.27.706.

PMID- 3236215
OWN - NLM
STAT- MEDLINE
DCOM- 19890511
LR  - 20190912
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 11
IP  - 8
DP  - 1988 Aug
TI  - Gastric emptying rates of drug preparations. II. Effects of size and density of 
      enteric-coated drug preparations and food on gastric emptying rates in humans.
PG  - 571-5
AB  - Enteric-coated granules with different densities and tablets of different sizes 
      were prepared in order to study the effect of these physical properties of dosage 
      forms on the gastric emptying rates in humans. The effect of food on the gastric 
      emptying rate was also studied. Aspirin contained in an enteric-coated product as 
      a marker drug was used to determine the gastric emptying rate by measuring 
      salicylates excreted into the urine. The larger the size of the dosage form, the 
      larger were the values of parameters for estimating the gastric emptying rate 
      such as tlag, tmax and the mean absorption time. There was a significant 
      correlation between the gastric emptying rates and sizes of dosage forms. On the 
      other hand, no effects of density of enteric-coated granules on the gastric 
      emptying rate were observed. The gastric emptying of dosage forms of various 
      sizes or densities tested were prolonged by food. However, the gastric emptying 
      rate of granules was less affected by food than that of tablets.
FAU - Kaniwa, N
AU  - Kaniwa N
AD  - Drugs Division, National Institute of Hygienic Sciences, Tokyo, Japan.
FAU - Aoyagi, N
AU  - Aoyagi N
FAU - Ogata, H
AU  - Ogata H
FAU - Ejima, A
AU  - Ejima A
FAU - Motoyama, H
AU  - Motoyama H
FAU - Yasumi, H
AU  - Yasumi H
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Dosage Forms)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - Biological Availability
MH  - *Dosage Forms
MH  - *Eating
MH  - *Gastric Emptying
MH  - Humans
MH  - Intestinal Absorption
MH  - Metabolic Clearance Rate
MH  - Particle Size
MH  - Specific Gravity
MH  - Tablets, Enteric-Coated
MH  - Time Factors
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
AID - 10.1248/bpb1978.11.571 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1988 Aug;11(8):571-5. doi: 10.1248/bpb1978.11.571.

PMID- 19127088
OWN - NLM
STAT- MEDLINE
DCOM- 20090227
LR  - 20131121
IS  - 1424-8840 (Electronic)
IS  - 1424-8832 (Linking)
VI  - 36
IP  - 2
DP  - 2008
TI  - Variation in platelet function testing has a major influence on detection of 
      aspirin resistance in healthy subjects.
PG  - 84-90
LID - 10.1159/000173727 [doi]
AB  - INTRODUCTION: An increased demand for monitoring aspirin treatment by platelet 
      function tests has been observed, but data on the biological variation of these 
      tests are insufficient. The aim of this study was to assess the biological 
      variation of optical platelet aggregometry and closure time in healthy subjects 
      without aspirin and after aspirin ingestion. SUBJECTS AND METHODS: In 20 healthy 
      subjects, blood was sampled 4 times: on 2 consecutive mornings a day after 
      aspirin ingestion (100 mg/daily) and on 2 consecutive days of no treatment. In 
      all samples, arachidonic acid-, ADP- and collagen-induced optical platelet 
      aggregation was measured, and closure times were determined by 
      collagen/epinephrine (CEPI) and collagen/ADP (CADP) cartridges in a platelet 
      function analyzer-100. RESULTS: Aspirin significantly reduced arachidonic acid- 
      and ADP-induced platelet aggregation and significantly prolonged CEPI closure 
      time, but had no significant effect on collagen-induced platelet aggregation and 
      CADP closure time. Aspirin increased both within- and between-subject 
      coefficients of variation. Arachidonic acid-induced platelet aggregation was the 
      most sensitive to aspirin and no aspirin-resistant subjects were detected on 
      either day after aspirin. According to ADP-induced platelet aggregation or CEPI 
      closure time, 25 and 30% of healthy subjects, respectively, changed from aspirin 
      resistant to aspirin responsive or vice versa from one day to another. There was 
      no agreement between platelet function tests in determining aspirin resistance. 
      CONCLUSIONS: A significant variation in optical platelet aggregometry and closure 
      time exists and is presumed to have a major effect on determination of aspirin 
      resistance.
CI  - Copyright 2009 S. Karger AG, Basel.
FAU - Bozic-Mijovski, Mojca
AU  - Bozic-Mijovski M
AD  - Department of Vascular Diseases, University Medical Centre, Ljubljana, Slovenia. 
      mojca.bozic@kclj.si
FAU - Rakusa, Matej
AU  - Rakusa M
FAU - Stegnar, Mojca
AU  - Stegnar M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090105
PL  - Switzerland
TA  - Pathophysiol Haemost Thromb
JT  - Pathophysiology of haemostasis and thrombosis
JID - 101142710
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Bleeding Time
MH  - Diagnostic Errors
MH  - Drug Monitoring
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Nephelometry and Turbidimetry
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Function Tests/*standards
MH  - Reproducibility of Results
EDAT- 2009/01/08 09:00
MHDA- 2009/02/28 09:00
CRDT- 2009/01/08 09:00
PHST- 2008/08/11 00:00 [received]
PHST- 2008/10/06 00:00 [accepted]
PHST- 2009/01/08 09:00 [entrez]
PHST- 2009/01/08 09:00 [pubmed]
PHST- 2009/02/28 09:00 [medline]
AID - 000173727 [pii]
AID - 10.1159/000173727 [doi]
PST - ppublish
SO  - Pathophysiol Haemost Thromb. 2008;36(2):84-90. doi: 10.1159/000173727. Epub 2009 
      Jan 5.

PMID- 23591584
OWN - NLM
STAT- MEDLINE
DCOM- 20151023
LR  - 20130610
IS  - 1308-0032 (Electronic)
IS  - 1302-8723 (Linking)
VI  - 13
IP  - 4
DP  - 2013 Jun
TI  - Aspirin resistance: Where are we now?
PG  - 370-3
LID - 10.5152/akd.2013.107 [doi]
AB  - Aspirin is an effective antiplatelet drug for preventing thrombo-embolic vascular 
      events. However, clinical and laboratory evidence demonstrates diminished or no 
      response to aspirin in some patients that is called aspirin resistance. This 
      situation has been reported to be independently associated with an increased risk 
      of adverse cardiovascular events. The exact mechanism of aspirin resistance has 
      not been established yet. The clinical, pharmacological and genetic factors may 
      be associated with aspirin resistance. However, there is not currently 
      standardized test to the diagnosis and no proven effective treatment of aspirin 
      resistance. This article summarizes aspirin resistance, discussing its 
      definition, clinical outcomes, laboratory tests, possible causes and therapeutic 
      approaches.
FAU - Abacı, Okay
AU  - Abacı O
AD  - Department of Cardiology, Cardiology Institute of Istanbul University, 
      İstanbul-Turkey.
FAU - Kılıçkesmez, Kadriye Orta
AU  - Kılıçkesmez KO
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130411
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 2013/04/18 06:00
MHDA- 2015/10/24 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/18 06:00 [entrez]
PHST- 2013/04/18 06:00 [pubmed]
PHST- 2015/10/24 06:00 [medline]
AID - 10.5152/akd.2013.107 [doi]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2013 Jun;13(4):370-3. doi: 10.5152/akd.2013.107. Epub 2013 
      Apr 11.

PMID- 18160363
OWN - NLM
STAT- MEDLINE
DCOM- 20080221
LR  - 20131121
IS  - 1308-0032 (Electronic)
IS  - 1302-8723 (Linking)
VI  - 7 Suppl 2
DP  - 2007 Dec
TI  - [A current problem in atherothrombotic diseases--aspirin resistance: definition, 
      mechanisms, determination with laboratory tests and clinical implications].
PG  - 20-6
AB  - Aspirin (acetylsalicylic acid) is a powerful antiplatelet agent used in 
      prevention of atherothrombotic vascular events. However, antiplatelet effect of 
      aspirin is not uniform and some patients could not benefit from aspirin. These 
      patients are clinically called as aspirin resistant or aspirin non-responders. 
      Aspirin resistance could be determined by: bleeding time, optical aggregometry, 
      PFA-100 (Platelet Function Analyzer), Ultegra-RPFA (Rapid Platelet Function 
      Assay), activated aggregation time, whole blood aggregometry, platelet aggregate 
      ratio, flow cytometry, measurements of platelet surface proteins and blood or 
      urine thromboxane B2 levels. Mechanisms of aspirin resistance have not been 
      elucidated yet. There is evidence that aspirin resistance increases clinical 
      cardiovascular events. Adequate additional therapies may reduce atherothrombotic 
      risks and major cardiovascular events rate in aspirin resistant subjects. 
      However, we need further studies to decrease major cardiovascular events risk in 
      aspirin resistant subjects and to optimize antiplatelet therapy.
FAU - Pamukçu, Burak
AU  - Pamukçu B
AD  - Istanbul Universitesi, Istanbul Tip Fakültesi, Kardiyoloji Anabilim Dali, 
      Istanbul, Türkiye. burakpamukcu@ttnet.net.tr
FAU - Oflaz, Hüseyin
AU  - Oflaz H
FAU - Nişanci, Yilmaz
AU  - Nişanci Y
LA  - tur
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aterotrombotik hastaliklarda güncel bir sorun--aspirin direnci: tanimi, oluşum 
      mekanizmalari, laboratuvar yöntemleri ile belirlenmesi ve klinik sonuçlari.
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Platelets/drug effects
MH  - Coronary Thrombosis/*prevention & control
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Platelet Function Tests
RF  - 50
EDAT- 2008/02/09 09:00
MHDA- 2008/02/22 09:00
CRDT- 2008/02/09 09:00
PHST- 2008/02/09 09:00 [pubmed]
PHST- 2008/02/22 09:00 [medline]
PHST- 2008/02/09 09:00 [entrez]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2007 Dec;7 Suppl 2:20-6.

PMID- 28416068
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20191219
IS  - 1603-6824 (Electronic)
IS  - 0041-5782 (Linking)
VI  - 179
IP  - 14
DP  - 2017 Apr 3
TI  - [Treatment with low-dose acetylsalicylic acid can reduce risk of pre-eclampsia in 
      high-risk pregnant women].
LID - V07160511 [pii]
AB  - Pre-eclampsia is a major contributor to perinatal morbidity and mortality. Large 
      studies of high-risk pregnant women have shown reduced risk of developing 
      pre-eclampsia when they are treated with low-dose acetylsalicylic acid in early 
      pregnancy. Treatment is also effective in preventing intrauterine growth 
      restriction, preterm birth and perinatal death. No major side effects, including 
      risk of malformations or miscarriage, are reported. It is important that general 
      practitioners are aware of women who have an increased risk of developing 
      pre-eclampsia, so that treatment with 100 mg of acetylsalicylic acid can be 
      started early in pregnancy.
FAU - Käehne, Line Vedel
AU  - Käehne LV
AD  - line_gd@hotmail.com.
FAU - Rørbye, Christina
AU  - Rørbye C
LA  - dan
PT  - Journal Article
PT  - Review
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Early Medical Intervention
MH  - Female
MH  - Fetal Growth Retardation/prevention & control
MH  - Humans
MH  - Infant, Newborn
MH  - Perinatal Death/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Premature Birth/prevention & control
MH  - Risk Factors
EDAT- 2017/04/19 06:00
MHDA- 2018/12/12 06:00
CRDT- 2017/04/19 06:00
PHST- 2017/04/19 06:00 [entrez]
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
AID - V07160511 [pii]
PST - ppublish
SO  - Ugeskr Laeger. 2017 Apr 3;179(14):V07160511.

PMID- 1153942
OWN - NLM
STAT- MEDLINE
DCOM- 19751106
LR  - 20181203
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 10
IP  - 5
DP  - 1975
TI  - Distribution of intravenous sodium acetylsalicylate in the unanaesthetized rat on 
      stimulation and inhibition of gastric secretion.
PG  - 465-9
AB  - Sodium carboxyl-14C acetylsalicylate was injected intravenously into fasted rats 
      in which gastric secretion was either inhibited by atropine or stimulated by 
      histamine. After one hour blood samples and specimens from the glandular portion 
      of the gastric mucosa, muscle, liver, and kidney were taken. The 14C activity in 
      the blood and specimens was determined by liquid scintillation counting after 
      combustion. The drug concentration was lowest in muscle and gastric mucosa, 
      intermediate in the liver, and highest in the kidney, where it equalled that in 
      the blood. The concentrations were proportional to the amount of drug injected in 
      all the examined tissues. There was no difference between rats given histamine 
      and those given atropine. The secretory state of the gastric mucosa thus did not 
      affect the concentration of the drug in this tissue when acetylsalicylate was 
      given intravenously.
FAU - Frenning, B
AU  - Frenning B
FAU - Flemström, G
AU  - Flemström G
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 7C0697DR9I (Atropine)
RN  - 820484N8I3 (Histamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/blood/*metabolism
MH  - Atropine/pharmacology
MH  - Gastric Juice/*metabolism
MH  - Gastric Mucosa/metabolism
MH  - Histamine/pharmacology
MH  - Injections, Intravenous
MH  - Kidney/metabolism
MH  - Liver/metabolism
MH  - Male
MH  - Muscles/metabolism
MH  - Rats
MH  - Secretory Rate/drug effects
MH  - Stimulation, Chemical
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol. 1975;10(5):465-9.

PMID- 21093073
OWN - NLM
STAT- MEDLINE
DCOM- 20120925
LR  - 20151119
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 156
IP  - 1
DP  - 2012 Apr 5
TI  - Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects 
      treated with low dose aspirin: the UGLA survey.
PG  - 69-75
LID - 10.1016/j.ijcard.2010.10.027 [doi]
AB  - BACKGROUND: Upper Gastrointestinal Symtoms (UGS) is a reason for discontinuation 
      in patients treated by Low Dose Aspirin (LDA). The nationwide UGLA survey was 
      designed to evaluate the prevalence and the pattern of UGS in patients on LDA, to 
      assess the independent correlates of UGS and finally to determine their impact on 
      treatment compliance. METHODS: The UGLA survey was carried out on a 
      representative sample of 10,000 subjects aged 50 or over. Prevalence and clinical 
      impact of UGS related to LDA was appraised by standardised multi-choice 
      questions. RESULTS: A total of 8106 propositus (8106/10,000) accepted to 
      participate in the survey. Among them, 986 (12.2%) were treated with LDA. The 
      prevalence of UGS was 15.4% in subjects on chronic LDA (152/986), 70% being 
      gastroesophageal reflux (GER) (heartburn and/or regurgitation). UGS was reported 
      to occur at least once a week in 60% of propositus (91/152) and daily life was 
      reported to be moderately and severely impaired in 53% (81/152) and 20% (30/152) 
      of them, respectively. UGS impacted compliance to treatment in 12% of propositus 
      with UGS. A prior history of dyspeptic symptoms was predictive of LDA-related UGS 
      (OR: 17.60; CI 95%: 11.52-26.88) whereas neither, gender nor aspirin dosage 
      (ranging from 75 and 325 mg) predicted the occurrence of UGS. CONCLUSIONS: 
      Fifteen percent of patients treated with LDA suffered UGS, mostly GER symptoms 
      which had a negative impact on daily life in 3 out of 4 patients and on treatment 
      compliance in 1 out of 8 patients.
CI  - Copyright Â© 2010 Elsevier Ireland Ltd. All rights reserved.
FAU - Cayla, Guillaume
AU  - Cayla G
AD  - Institut de Cardiologie, Pitié-Salpêtrière Hospital, Paris, France.
FAU - Collet, Jean-Philippe
AU  - Collet JP
FAU - Silvain, Johanne
AU  - Silvain J
FAU - Thiefin, Gérard
AU  - Thiefin G
FAU - Woimant, France
AU  - Woimant F
FAU - Montalescot, Gilles
AU  - Montalescot G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101118
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced/*epidemiology
MH  - *Health Surveys
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2010/11/26 06:00
MHDA- 2012/09/26 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/02/24 00:00 [received]
PHST- 2010/08/05 00:00 [revised]
PHST- 2010/10/23 00:00 [accepted]
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2012/09/26 06:00 [medline]
AID - S0167-5273(10)00875-2 [pii]
AID - 10.1016/j.ijcard.2010.10.027 [doi]
PST - ppublish
SO  - Int J Cardiol. 2012 Apr 5;156(1):69-75. doi: 10.1016/j.ijcard.2010.10.027. Epub 
      2010 Nov 18.

PMID- 36541862
OWN - NLM
STAT- MEDLINE
DCOM- 20230127
LR  - 20230814
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Linking)
VI  - 30
IP  - 2
DP  - 2023 Feb 1
TI  - Aspirin for primary prevention of cardiovascular disease in women.
PG  - 215-217
LID - 10.1097/GME.0000000000002114 [doi]
AB  - Aspirin use for primary prevention of cardiovascular disease is controversial. 
      Low-dose aspirin may be considered for primary prevention in women on an 
      individualized basis for those aged 40 to 59 years with a 10-year cardiovascular 
      risk of 10% or more and without increased bleeding risk. Low-dose aspirin for 
      primary prevention is not advised for low-risk women or women aged 60 years or 
      older.
CI  - Copyright © 2022 by The North American Menopause Society.
FAU - Lau, Emily S
AU  - Lau ES
AD  - From Massachusetts General Hospital, Harvard Medical School, Boston, 
      Massachusetts.
LA  - eng
GR  - K23 HL159243/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20221219
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Risk
MH  - Primary Prevention
EDAT- 2022/12/22 06:00
MHDA- 2023/01/28 06:00
CRDT- 2022/12/21 09:43
PHST- 2022/12/22 06:00 [pubmed]
PHST- 2023/01/28 06:00 [medline]
PHST- 2022/12/21 09:43 [entrez]
AID - 00042192-202302000-00016 [pii]
AID - 10.1097/GME.0000000000002114 [doi]
PST - ppublish
SO  - Menopause. 2023 Feb 1;30(2):215-217. doi: 10.1097/GME.0000000000002114. Epub 2022 
      Dec 19.

PMID- 11402787
OWN - NLM
STAT- MEDLINE
DCOM- 20010705
LR  - 20131121
IS  - 1088-6222 (Print)
IS  - 1088-6222 (Linking)
VI  - 94
IP  - 6
DP  - 2001 Jun
TI  - Aspirin in cardiovascular disease.
PG  - 208-10
AB  - The historic genesis of aspirin as a therapeutic agent is discussed. The use of 
      aspirin as a primary and secondary chemo-preventive agent is reviewed. Those who 
      introduced aspirin in the late 19th century would be surprised by the uses of 
      aspirin today. It is anticipated that existing and further studies on the use of 
      aspirin as a primary preventive agent will establish its utility and a more 
      precise niche for it as a chemo-preventive agent. Reports indicate that it may be 
      useful as a chemo-preventive agent in the prevention and possibly in the 
      treatment of cancer of the colon and other malignancies. This plebeian drug, 
      aspirin, has earned a position, some would say an egalitarian position, along 
      with thrombolysis and primary coronary angioplasty in the emergency treatment of 
      AMI. There are those who would add an intravenous beta blocker and an ACE 
      inhibitor to this regimen. The laborious history of aspirin should again remind 
      clinicians that they should continue to heed the admonition of Alexander Pope 
      when he asserted, "Be not the first by whom the new is tried nor yet the last to 
      lay the old aside."
FAU - Sexton, R C Jr
AU  - Sexton RC Jr
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Tenn Med
JT  - Tennessee medicine : journal of the Tennessee Medical Association
JID - 9609310
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/*prevention & control
MH  - Humans
MH  - Myocardial Infarction/drug therapy
MH  - Primary Prevention
MH  - Stroke/drug therapy
RF  - 9
EDAT- 2001/06/14 10:00
MHDA- 2001/07/06 10:01
CRDT- 2001/06/14 10:00
PHST- 2001/06/14 10:00 [pubmed]
PHST- 2001/07/06 10:01 [medline]
PHST- 2001/06/14 10:00 [entrez]
PST - ppublish
SO  - Tenn Med. 2001 Jun;94(6):208-10.

PMID- 12623974
OWN - NLM
STAT- MEDLINE
DCOM- 20030414
LR  - 20220408
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
VI  - 41
IP  - 3 Pt 2
DP  - 2003 Mar
TI  - Administration time-dependent influence of aspirin on blood pressure in pregnant 
      women.
PG  - 651-6
AB  - This study prospectively investigates the potential influence of low-dose aspirin 
      on blood pressure in pregnant women who were at a higher risk of developing 
      preeclampsia than that of the general obstetric population and who received 
      aspirin at different times of the day according to their rest-activity cycle. A 
      double-blind, randomized, controlled trial was conducted in 341 pregnant women 
      (181 primipara) randomly assigned to 1 of 6 possible groups according to 
      treatment (either placebo or aspirin, 100 mg/day, starting at 12 to 16 weeks of 
      gestation) and the time of treatment: on awakening (time 1), 8 hours after 
      awakening (time 2), or before bedtime (time 3). Blood pressure was automatically 
      monitored for 48 consecutive hours every 4 weeks from the day of recruitment 
      until delivery, as well as at puerperium. There was no effect of aspirin on blood 
      pressure at time 1 (compared with placebo). A blood pressure reduction was highly 
      statistically significant when aspirin was given at time 2 and, to a greater 
      extent, at time 3 (mean reductions of 9.7/6.5 mm Hg in 24-hour mean for 
      systolic/diastolic blood pressure at the time of delivery as compared with 
      placebo given at bedtime). Differences in blood pressure among women receiving 
      aspirin at different circadian times disappeared at puerperium (P>0.096). Results 
      indicate a highly significant effect of aspirin on blood pressure that is 
      markedly dependent on the time of aspirin administration with respect to the 
      rest-activity cycle. Timed use of aspirin at low dose effectively contributes to 
      blood pressure control in women at high risk for preeclampsia.
FAU - Hermida, Ramón C
AU  - Hermida RC
AD  - Bioengineering Laboratory, University of Vigo, Spain. rhermida@tsc.uvigo.es
FAU - Ayala, Diana E
AU  - Ayala DE
FAU - Iglesias, Manuel
AU  - Iglesias M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20021209
PL  - United States
TA  - Hypertension
JT  - Hypertension (Dallas, Tex. : 1979)
JID - 7906255
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Blood Pressure Monitoring, Ambulatory
MH  - Circadian Rhythm
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Placebos/administration & dosage
MH  - Postpartum Period
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Time Factors
EDAT- 2003/03/08 04:00
MHDA- 2003/04/15 05:00
CRDT- 2003/03/08 04:00
PHST- 2003/03/08 04:00 [pubmed]
PHST- 2003/04/15 05:00 [medline]
PHST- 2003/03/08 04:00 [entrez]
AID - 01.HYP.0000047876.63997.EE [pii]
AID - 10.1161/01.HYP.0000047876.63997.EE [doi]
PST - ppublish
SO  - Hypertension. 2003 Mar;41(3 Pt 2):651-6. doi: 10.1161/01.HYP.0000047876.63997.EE. 
      Epub 2002 Dec 9.

PMID- 14519047
OWN - NLM
STAT- MEDLINE
DCOM- 20040226
LR  - 20131121
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 37
IP  - 10
DP  - 2003 Oct
TI  - Aspirin and warfarin versus aspirin monotherapy after myocardial infarction.
PG  - 1502-5
AB  - OBJECTIVE: To review data concerning combined aspirin/warfarin versus aspirin 
      alone for secondary prevention after myocardial infarction (MI). DATA SOURCES: 
      Literature was accessed through MEDLINE (1966-September 2002). Search terms 
      included aspirin, warfarin, secondary prevention, and myocardial infarction. DATA 
      SYNTHESIS: Despite use of low-dose aspirin after an MI, risk of subsequent death 
      and ischemic events remains high, making strategies for secondary prevention 
      imperative. Relevant, large, long-term studies focusing on dual aspirin/warfarin 
      versus aspirin alone in post-MI patients were evaluated. CONCLUSIONS: Aspirin 
      75-325 mg/d should remain first-line therapy for secondary prevention after MI. 
      Combining aspirin 75-81 mg with warfarin to maintain the international normalized 
      ratio at 2.0-2.5 may provide added benefit, but should be considered only for 
      patients at high risk for thromboembolic events.
FAU - Jeddy, Azzah S
AU  - Jeddy AS
AD  - St. Louis College of Pharmacy, St. Louis, MO, USA.
FAU - Gleason, Brenda L
AU  - Gleason BL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects/pharmacokinetics
MH  - Drug Interactions
MH  - *Drug Therapy, Combination
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Warfarin/administration & dosage/*adverse effects/pharmacokinetics
RF  - 15
EDAT- 2003/10/02 05:00
MHDA- 2004/02/27 05:00
CRDT- 2003/10/02 05:00
PHST- 2003/10/02 05:00 [pubmed]
PHST- 2004/02/27 05:00 [medline]
PHST- 2003/10/02 05:00 [entrez]
AID - 10.1345/aph.1C474 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2003 Oct;37(10):1502-5. doi: 10.1345/aph.1C474.

PMID- 22462627
OWN - NLM
STAT- MEDLINE
DCOM- 20120926
LR  - 20211021
IS  - 1179-1969 (Electronic)
IS  - 1170-229X (Linking)
VI  - 29
IP  - 4
DP  - 2012 Apr 1
TI  - Aspirin for primary prevention of cardiovascular events in the elderly: current 
      status and future directions.
PG  - 251-8
LID - 10.2165/11599030-000000000-00000 [doi]
AB  - The role of aspirin in the secondary prevention of occlusive cardiovascular 
      events has now been well established. Given this, aspirin in primary prevention 
      has been the focus of several large trials and subsequent meta-analyses over the 
      past 3 decades, and yet the issue remains controversial. Recent studies in 
      populations with high baseline risk - such as diabetics and those with 
      asymptomatic peripheral arterial disease - have not found the expected benefits 
      of aspirin on cardiovascular endpoints, which contrasts with earlier studies that 
      reported a reduced relative risk for outcomes such as myocardial infarction and 
      ischaemic stroke, but not for mortality. Furthermore, in healthy populations, the 
      absolute risk reduction conferred by aspirin is small and needs to be balanced 
      against the risk of a major haemorrhage. Older adults have a higher risk for 
      cardiovascular events and therefore might represent the group in which aspirin 
      for primary prevention could deliver the greatest absolute benefit, yet at the 
      same time, the elderly bear an increased vulnerability to major haemorrhage, 
      including haemorrhagic stroke. It is also not known whether older adults 
      experience the same risk reduction from aspirin as middle-aged individuals. The 
      current evidence base does not sufficiently clarify whether aspirin for primary 
      prevention confers a meaningful net benefit in the elderly.
FAU - Ward, Stephanie A
AU  - Ward SA
AD  - Monash Ageing Research Centre (MONARC), The Kingston Centre, Cheltenham, VIC, 
      Australia. Stephanie.ward@monash.edu
FAU - Demos, Lisa
AU  - Demos L
FAU - Workman, Barbara
AU  - Workman B
FAU - McNeil, John J
AU  - McNeil JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Randomized Controlled Trials as Topic
EDAT- 2012/04/03 06:00
MHDA- 2012/09/27 06:00
CRDT- 2012/04/03 06:00
PHST- 2012/04/03 06:00 [entrez]
PHST- 2012/04/03 06:00 [pubmed]
PHST- 2012/09/27 06:00 [medline]
AID - 1 [pii]
AID - 10.2165/11599030-000000000-00000 [doi]
PST - ppublish
SO  - Drugs Aging. 2012 Apr 1;29(4):251-8. doi: 10.2165/11599030-000000000-00000.

PMID- 1091965
OWN - NLM
STAT- MEDLINE
DCOM- 19750707
LR  - 20151119
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 10
IP  - 2
DP  - 1975
TI  - Acetylsalicylic acid and gastrointestinal bleeding measurement of blood loss 
      using a modified radioactive chromium method.
PG  - 155-60
AB  - A comparative study of the gastrointestinal blood loss during intake of a new 
      buffered acetylsalicylic acid (ASA) preparation and plain ASA tablets has been 
      performed. A modified radioactive chromium method was used. The 51Cr activity was 
      considerably less than that used in previous methods, and no feces homogenization 
      was necessary. The study was performed in 18 volunteers using a randomized 
      crossover design. A significant reduction in gastrointestinal bleeding was 
      registered during ingestion of the buffered ASA in comparison with the plain ASA 
      tablets.
FAU - Arvidsson, B
AU  - Arvidsson B
FAU - Magnusson, B
AU  - Magnusson B
FAU - Sölvell
AU  - Sölvell
FAU - Magnusson, A
AU  - Magnusson A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Buffers)
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Buffers
MH  - *Chromium Radioisotopes
MH  - Clinical Trials as Topic
MH  - Feces/analysis
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tablets
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol. 1975;10(2):155-60.

PMID- 6692345
OWN - NLM
STAT- MEDLINE
DCOM- 19840321
LR  - 20190720
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 21
IP  - 3
DP  - 1984 Jan
TI  - Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced 
      epithelial proliferation in the urinary bladder and forestomach of the rat.
PG  - 269-75
AB  - The co-administration of aspirin with 
      N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a 
      reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction 
      of forestomach tumors. An autoradiographic study was performed on male F-344 rats 
      fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to 
      evaluate the effect of aspirin on the increased cell proliferation induced by 
      FANFT in the forestomach and bladder. FANFT-induced cell proliferation in the 
      bladder was significantly suppressed by aspirin co-administration after 4 weeks 
      but not after 12 weeks. In the forestomach, and also in the liver, aspirin did 
      not affect the FANFT-induced increase in labeling index. The present results are 
      consistent with the carcinogenicity experiment suggesting that different 
      mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, 
      and that aspirin's effect on FANFT in the forestomach is not due to an irritant 
      effect associated with increased cell proliferation. Also, there appears to be an 
      adaptation by the rats to the chronic ingestion of aspirin.
FAU - Hasegawa, R
AU  - Hasegawa R
FAU - St John, M
AU  - St John M
FAU - Murasaki, G
AU  - Murasaki G
FAU - Fukushima, S
AU  - Fukushima S
FAU - Cohen, S M
AU  - Cohen SM
LA  - eng
GR  - CA28015/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Carcinogens)
RN  - 0 (Thiazoles)
RN  - 7N99PZG62O (FANFT)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - *Carcinogens
MH  - Cell Division/drug effects
MH  - Epithelium/pathology
MH  - FANFT/*toxicity
MH  - Male
MH  - Rats
MH  - Rats, Inbred F344
MH  - Stomach Neoplasms/*chemically induced
MH  - Thiazoles/*toxicity
MH  - Urinary Bladder Neoplasms/*chemically induced
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 0304-3835(84)90005-3 [pii]
AID - 10.1016/0304-3835(84)90005-3 [doi]
PST - ppublish
SO  - Cancer Lett. 1984 Jan;21(3):269-75. doi: 10.1016/0304-3835(84)90005-3.

PMID- 2749611
OWN - NLM
STAT- MEDLINE
DCOM- 19890817
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 54
IP  - 3
DP  - 1989 May 1
TI  - Prevention of the formation of arterial thrombi using different antiplatelet 
      drugs: experimental study in dogs.
PG  - 187-95
AB  - We have induced the formation of arterial thrombosis in dogs by means of an 
      intima lesion produced by continuous current. The platelets were labeled with 
      111-In-oxine. Groups of 7 mongrel dogs received treatment for 7 days prior to the 
      trial: Group I, control; Group II, 5 mg/kg body weight/day acetylsalicylic acid; 
      Group III, 20 mg/kg body wt/day acetylsalicylic acid; Group IV, 15 mg/kg body 
      wt/day triflusal + 5 mg/kg body wt/day dipyridamole; Group V, 15 mg/kg body 
      wt/day triflusal; and Group VI, 5 mg/kg body wt/day acetylsalicylic acid + 5 
      mg/kg body wt/day dipyridamole. The only effective treatment for arterial 
      thrombosis prevention was that employed in Group II (p less than 0.05).
FAU - Escudero-Vela, M C
AU  - Escudero-Vela MC
AD  - Servicio de Cirugía Experimental, Clínica Puerta de Hierro, Madrid, Spain.
FAU - Alvarez, L
AU  - Alvarez L
FAU - Rodríguez, V
AU  - Rodríguez V
FAU - del Moral, J H
AU  - del Moral JH
FAU - Millán, I
AU  - Millán I
FAU - Castillo-Olivares, J L
AU  - Castillo-Olivares JL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Indium Radioisotopes)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 1Z0YFI05OO (triflusal)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Dogs
MH  - Indium Radioisotopes
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Salicylates/therapeutic use
MH  - Scintillation Counting
MH  - Thrombosis/*prevention & control
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
AID - 10.1016/0049-3848(89)90226-0 [doi]
PST - ppublish
SO  - Thromb Res. 1989 May 1;54(3):187-95. doi: 10.1016/0049-3848(89)90226-0.

PMID- 6378232
OWN - NLM
STAT- MEDLINE
DCOM- 19840913
LR  - 20220330
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 17
IP  - 6
DP  - 1984 Jun
TI  - Low-dose acetylsalicylic acid (100 mg/day) after aortocoronary bypass surgery: a 
      placebo-controlled trial.
PG  - 703-11
AB  - The effect of low-dose acetylsalicylic acid (100 mg/day) upon bypass patency-rate 
      and clinical course after aortocoronary bypass surgery was investigated in a 
      randomized, placebo-controlled clinical trial. Sixty patients with 143 distal 
      anastomoses of bypasses were randomized, 46 underwent repeat angiography after 4 
      months. Using the intention to treat-strategy, treatment was superior to placebo 
      as judged by bypass patency rate and occurrence of cardiovascular complications 
      or death. Counting the six drop-outs as failures, only nine of the 31 patients of 
      the placebo group, but 16 of the 29 patients of the treatment group were 
      considered successes (P less than 0.04). Eighteen patients in the placebo group 
      and eight patients of the treatment group received beta-adrenoceptor blockers 
      postoperatively, suggesting again a favourable effect of the treatment. Adverse 
      drug reactions were very rare and minor. Supported by pathophysiological insights 
      and positive trends in similar trials, the positive result justifies the 
      recommendation of prescribing 100 mg of acetylsalicylic acid once daily to all 
      patients without contraindications after aortocoronary bypass surgery. The 
      positive result of this trial warrants further clinical trials of low-dose 
      acetylsalicylic acid for other indications in arterial diseases.
FAU - Meister, W
AU  - Meister W
FAU - von Schacky, C
AU  - von Schacky C
FAU - Weber, M
AU  - Weber M
FAU - Lorenz, R
AU  - Lorenz R
FAU - Kotzur, J
AU  - Kotzur J
FAU - Reichart, B
AU  - Reichart B
FAU - Theisen, K
AU  - Theisen K
FAU - Weber, P C
AU  - Weber PC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - *Coronary Artery Bypass
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Placebos
MH  - Postoperative Care
MH  - Random Allocation
PMC - PMC1463415
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1984.tb02407.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1984 Jun;17(6):703-11. doi: 
      10.1111/j.1365-2125.1984.tb02407.x.

PMID- 19136474
OWN - NLM
STAT- MEDLINE
DCOM- 20090410
LR  - 20211020
IS  - 1460-2180 (Electronic)
IS  - 0143-3334 (Print)
IS  - 0143-3334 (Linking)
VI  - 30
IP  - 3
DP  - 2009 Mar
TI  - Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of 
      human cancer cell lines more potently than aspirin: a redox-dependent effect.
PG  - 512-9
LID - 10.1093/carcin/bgp015 [doi]
AB  - Aspirin is chemopreventive against colon and probably other cancers, but this 
      effect is relatively weak and its chronic administration to humans is associated 
      with significant side effects. Because of these limitations, extensive effort has 
      been exerted to improve the pharmacological properties of aspirin. We have 
      determined the anticancer activity and mechanisms of action of the novel para 
      positional isomer of phosphoaspirin [P-ASA; MDC-43; 
      4-((diethoxyphosphoryloxy)methyl)phenyl 2-acetoxybenzoate]. P-ASA inhibited the 
      growth of 10 human cancer cell lines originating from colon, lung, liver, 
      pancreas and breast, at least 18- to 144-fold more potently than conventional 
      aspirin. P-ASA achieved this effect by modulating cell kinetics; compared with 
      controls, P-ASA reduced cell proliferation by up to 68%, increased apoptosis 
      5.5-fold and blocked cell cycle progression in the G(2)/M phase. P-ASA increased 
      intracellular levels of reactive oxygen species (ROS), depleted glutathione 
      levels and modulated cell signaling predominantly through the mitogen-activated 
      protein kinase (p38 and c-jun N-terminal kinase), cyclooxygenase (COX) and 
      nuclear factor-kappa B pathways. P-ASA targeted the mitochondria, increasing 
      mitochondrial superoxide anion levels; this effect on ROS led to collapsed 
      mitochondrial membrane potential and triggered the intrinsic apoptotic pathway. 
      The antioxidant N-acetyl cysteine abrogated the cell growth inhibitory and 
      signaling effects of P-ASA, underscoring the centrality of ROS in its mechanism 
      of action. Our results, establishing P-ASA as a potent inhibitor of the growth of 
      several human cancer cell lines, suggest that it may possess broad anticancer 
      properties. We conclude that the novel P-ASA is a promising anticancer agent, 
      which merits further evaluation.
FAU - Zhao, Wenping
AU  - Zhao W
AD  - Department of Medicine, Division of Cancer Prevention, Stony Brook University, 
      Stony Brook, NY 11794-5200, USA.
FAU - Mackenzie, Gerardo G
AU  - Mackenzie GG
FAU - Murray, Onika T
AU  - Murray OT
FAU - Zhang, Zhiquan
AU  - Zhang Z
FAU - Rigas, Basil
AU  - Rigas B
LA  - eng
GR  - R01 CA092423/CA/NCI NIH HHS/United States
GR  - R01 CA101019/CA/NCI NIH HHS/United States
GR  - 2R01 CA92423/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20090109
PL  - England
TA  - Carcinogenesis
JT  - Carcinogenesis
JID - 8008055
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Organophosphates)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (phosphoaspirin)
RN  - R16CO5Y76E (Aspirin)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/pharmacology
MH  - Antineoplastic Agents/*pharmacology
MH  - Antioxidants/pharmacology
MH  - Apoptosis/drug effects/physiology
MH  - Aspirin/*analogs & derivatives/chemistry/*pharmacology
MH  - Cell Cycle/*drug effects/physiology
MH  - Cell Death/*drug effects/physiology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Humans
MH  - Isomerism
MH  - Membrane Potential, Mitochondrial/drug effects/physiology
MH  - Organophosphates/chemistry/*pharmacology
MH  - Oxidation-Reduction
MH  - Reactive Oxygen Species/*metabolism
MH  - Signal Transduction/drug effects/physiology
PMC - PMC2650796
EDAT- 2009/01/13 09:00
MHDA- 2009/04/11 09:00
CRDT- 2009/01/13 09:00
PHST- 2009/01/13 09:00 [entrez]
PHST- 2009/01/13 09:00 [pubmed]
PHST- 2009/04/11 09:00 [medline]
AID - bgp015 [pii]
AID - 10.1093/carcin/bgp015 [doi]
PST - ppublish
SO  - Carcinogenesis. 2009 Mar;30(3):512-9. doi: 10.1093/carcin/bgp015. Epub 2009 Jan 
      9.

PMID- 22847393
OWN - NLM
STAT- MEDLINE
DCOM- 20130426
LR  - 20211021
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 35
IP  - 12
DP  - 2012 Dec
TI  - Relationship between endothelial functions and acetylsalicylic acid resistance in 
      newly diagnosed hypertensive patients.
PG  - 755-63
LID - 10.1002/clc.22042 [doi]
AB  - BACKGROUND: We aimed to investigate the effects and dose dependency of aspirin on 
      endothelial functions and prevalence of aspirin resistance in newly diagnosed 
      hypertensive patients without previous drug therapy and development of cardiac 
      complications. HYPOTHESIS: Acetylsalicyclic acid improves endothelial function. 
      METHODS: Fifty-eight hypertensive patients and 61 healthy subjects in the control 
      group were included in the study. Endothelial functions of the patient and 
      control groups were evaluated with brachial artery examination. Patient and 
      control groups were divided into 2 groups. A total of 100 mg and 300 mg of 
      aspirin were given to the separate groups for 1 week. After 1 week, endothelial 
      functions were reevaluated and aspirin resistance examined with a platelet 
      function analyzer (PFA-100; Dade Behring, Marbourg, Germany). RESULTS: Baseline 
      flow-mediated dilatation (FMD) change percent in hypertensive patients was 9.8%, 
      and it was significantly lower than in the control group (12%) (P < 0.001). 
      Frequency of acetylsalicylic acid (ASA) resistance was 20% and 26% in control and 
      hypertensive patient groups, respectively (P = not significant). ASA resistance 
      was 28% and 24% in 100 mg and 300 mg in hypertensive patients, respectively (P = 
      not significant). FMD change percent increased both in the control and 
      hypertensive groups after ASA treatment from 12.4% to 13.3% and 9.8 % to 11.9 %, 
      respectively. FMD percentage change was significantly increased in hypertensive 
      patients irrespective of ASA resistance (P = 0.02, for ASA resistance [+]; P < 
      0.012, for ASA resistance [-]). CONCLUSIONS: Endothelial functions were impaired 
      more in hypertensive patients compared to the control group. Endothelial 
      functions were improved with all ASA doses in hypertensive patients irrespective 
      of ASA resistance.
CI  - © 2012 Wiley Periodicals, Inc.
FAU - Sahin, Tayfun
AU  - Sahin T
AD  - Department of Cardiology, Medical Faculty of Kocaeli University, Kocaeli, Turkey. 
      tayfunsa@yahoo.com
FAU - Celikyurt, Umut
AU  - Celikyurt U
FAU - Geyik, Bilal
AU  - Geyik B
FAU - Oner, Gökhan
AU  - Oner G
FAU - Kilic, Teoman
AU  - Kilic T
FAU - Bildirici, Ulas
AU  - Bildirici U
FAU - Kozdag, Guliz
AU  - Kozdag G
FAU - Ural, Dilek
AU  - Ural D
LA  - eng
PT  - Journal Article
DEP - 20120727
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Drug Resistance
MH  - Echocardiography
MH  - Endothelium, Vascular/diagnostic imaging/*drug effects/physiology
MH  - Female
MH  - Humans
MH  - Hypertension/*physiopathology
MH  - Male
MH  - Observer Variation
PMC - PMC6652709
EDAT- 2012/08/01 06:00
MHDA- 2013/04/27 06:00
CRDT- 2012/08/01 06:00
PHST- 2012/04/18 00:00 [received]
PHST- 2012/06/23 00:00 [accepted]
PHST- 2012/08/01 06:00 [entrez]
PHST- 2012/08/01 06:00 [pubmed]
PHST- 2013/04/27 06:00 [medline]
AID - CLC22042 [pii]
AID - 10.1002/clc.22042 [doi]
PST - ppublish
SO  - Clin Cardiol. 2012 Dec;35(12):755-63. doi: 10.1002/clc.22042. Epub 2012 Jul 27.

PMID- 1501071
OWN - NLM
STAT- MEDLINE
DCOM- 19920917
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 81
IP  - 4
DP  - 1992 Apr
TI  - Absorption of acetylsalicylic acid from the rat nasal cavity.
PG  - 348-9
AB  - The fate of salicylate in the plasma of rats was followed after nasal, 
      intravenous, and oral administration of 2.0-mg doses of aspirin. Aspirin was well 
      absorbed following nasal administration of a neutralized, nonirritating solution 
      containing triethanolamine. The rate of absorption was slower than that of other 
      nasally administered drugs, such as propranolol or progesterone. The 
      bioavailability of aspirin following nasal administration was 100%, whereas the 
      oral bioavailability was only 58.8% at the dose studied.
FAU - Hussain, A A
AU  - Hussain AA
AD  - College of Pharmacy, University of Kentucky, Lexington 40536-0082.
FAU - Iseki, K
AU  - Iseki K
FAU - Kagoshima, M
AU  - Kagoshima M
FAU - Dittert, L W
AU  - Dittert LW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Animals
MH  - Aspirin/blood/*pharmacokinetics
MH  - Biological Availability
MH  - Drug Stability
MH  - Male
MH  - Nasal Cavity/*metabolism
MH  - Nasal Mucosa/metabolism
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Time Factors
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
AID - S0022-3549(15)48815-X [pii]
AID - 10.1002/jps.2600810411 [doi]
PST - ppublish
SO  - J Pharm Sci. 1992 Apr;81(4):348-9. doi: 10.1002/jps.2600810411.

PMID- 1269980
OWN - NLM
STAT- MEDLINE
DCOM- 19760802
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 17
IP  - 1
DP  - 1976 Jan
TI  - Effects of aspirin on gastric prostaglandin E (PGE) and acid output in normal 
      subjects.
PG  - 54-7
AB  - Aspirin administration to normal subjects resulted in a reduction in gastric 
      prostaglandin E (PGE) output. Both PGE concentration and gastric juice volume 
      were decreased. Gastric acid output also decreased, although the difference was 
      not statistically significant. An increased sensitivity of the PGE system to 
      inhibition by aspirin at 11 p.m., midnight, and 1am was observed.
FAU - Child, C
AU  - Child C
FAU - Jubiz, W
AU  - Jubiz W
FAU - Moore, J G
AU  - Moore JG
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Prostaglandins E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Circadian Rhythm/drug effects
MH  - Gastric Acidity Determination
MH  - Gastric Juice/analysis/*metabolism
MH  - Humans
MH  - Male
MH  - Prostaglandins E/analysis/*metabolism
MH  - Stomach/drug effects
PMC - PMC1411058
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1136/gut.17.1.54 [doi]
PST - ppublish
SO  - Gut. 1976 Jan;17(1):54-7. doi: 10.1136/gut.17.1.54.

PMID- 14727884
OWN - NLM
STAT- MEDLINE
DCOM- 20040223
LR  - 20181113
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 2
IP  - 2
DP  - 2001 Jun 9
TI  - Multispectral imaging of tablets in blister packaging.
PG  - E9
AB  - This experiment tested the hypothesis that using near-infrared (IR) imaging 
      spectrometry on tablets through blister packs permits the identification and 
      composition of multiple individual tablets to be determined simultaneously. 
      Aspirin was selected for this study because its breakdown mechanism is well 
      understood. Near-IR cameras were used to collect thousands of spectra 
      simultaneously from a field of packaged aspirin tablets. Tablets were selected by 
      a principal component analysis selection algorithm. Graphs of the columns of the 
      transformation matrix showed that salicylic acid and acetylsalicylic acid in the 
      samples were modeled by the principal components. The bootstrap error-adjusted 
      single-sample technique chemometric-imaging algorithm was used to draw 
      probability-density contour plots that revealed tablet composition. Choice of 
      color was used to represent constituent identity, whereas intensity represented 
      concentration. The percentage of usable pixels in the indium antimonide (InSb) 
      array was 99.9%. The SEP was 0.06% of the tablet mass for both water uptake and 
      salicylic acid production. The number of tablets that a typical near-IR camera 
      can currently analyze simultaneously was also estimated to be approximately 1300.
FAU - Malik, I
AU  - Malik I
AD  - Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky 
      Medical Center, Lexington, KY 40536-0082, USA.
FAU - Poonacha, M
AU  - Poonacha M
FAU - Moses, J
AU  - Moses J
FAU - Lodder, R A
AU  - Lodder RA
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20010609
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - *Drug Packaging
MH  - Drug Stability
MH  - Spectroscopy, Near-Infrared/*methods
MH  - Tablets
PMC - PMC2750475
EDAT- 2004/01/20 05:00
MHDA- 2004/02/24 05:00
CRDT- 2004/01/20 05:00
PHST- 2004/01/20 05:00 [pubmed]
PHST- 2004/02/24 05:00 [medline]
PHST- 2004/01/20 05:00 [entrez]
AID - 2238 [pii]
AID - 10.1208/pt020209 [doi]
PST - epublish
SO  - AAPS PharmSciTech. 2001 Jun 9;2(2):E9. doi: 10.1208/pt020209.

PMID- 8533923
OWN - NLM
STAT- MEDLINE
DCOM- 19960126
LR  - 20190628
IS  - 0003-3022 (Print)
IS  - 0003-3022 (Linking)
VI  - 83
IP  - 6
DP  - 1995 Dec
TI  - Diaspirin cross-linked hemoglobin does not increase brain oxygen consumption 
      during hypothermic cardiopulmonary bypass in rabbits.
PG  - 1302-11
AB  - BACKGROUND: Decreased erythrocyte deformability due to cardiopulmonary bypass 
      (CPB) and/or hypothermia, may result in brain capillary beds that have decreased 
      erythrocyte transit, resulting in a generalized impairment of brain oxygenation 
      during CPB. Because brain capillary plasma flow continues even when erythrocyte 
      flow is absent, the authors' hypothesized augmentation of plasma oxygen content 
      with a non-erythrocyte-associated oxygen transport molecule would increase brain 
      oxygen uptake during hypothermic CPB. METHODS: Anesthetized New Zealand white 
      rabbits, maintained on CPB at 27 degrees C, were randomized to one of three 
      groups. In group 1 (n = 13), plasma oxygen content was increased by 
      administration of alpha-alpha diaspirin cross-linked hemoglobin. In this group, 
      pretreatment with 0.5 mg/kg verapamil was necessary to prevent hypertension. In 
      group 2 (n = 13), alpha-alpha diaspirin cross-linked hemoglobin was not 
      administered, but verapamil was given as before (control). In group 3 (n = 13), 
      neither alpha-alpha diaspirin cross-linked hemoglobin nor verapamil was 
      administered (control). At 60 min of CPB, cerebral blood flow (microspheres) and 
      cerebral metabolic rate for oxygen (Fick) were determined. RESULTS: Systemic 
      physiologic variables did not differ among groups. Although total arterial oxygen 
      content was equivalent in all groups (approximately 12.1 ml O2/dl), the 
      alpha-alpha diaspirin cross-linked hemoglobin group had a much greater proportion 
      of the total arterial oxygen content present in a non-erythrocyte-associated 
      form, 29 +/- 5% versus 6 +/- 2% and 5 +/- 3%, in groups 2 and 3, respectively. 
      Nevertheless, neither cerebral blood flow (approximately 34 ml.100g-1.min-1) nor 
      cerebral metabolic rate for oxygen (approximately 1.2 ml O2.100g-1.min-1) 
      differed among groups. CONCLUSIONS: Because oxygen was equally available to the 
      brain in all groups, independent of whether oxygen was associated with 
      erythrocytes or not, it was concluded that erythrocyte/capillary interactions do 
      not limit oxygen transfer from blood to brain during moderately hypothermic CPB. 
      The hypertensive response to alpha-alpha diaspirin cross-linked hemoglobin during 
      CPB is probably a result of nitric oxide scavenging.
FAU - Hindman, B J
AU  - Hindman BJ
AD  - Department of Anesthesia, University of Iowa, College of Medicine, Iowa City, 
      USA.
FAU - Dexter, F
AU  - Dexter F
FAU - Cutkomp, J
AU  - Cutkomp J
FAU - Smith, T
AU  - Smith T
LA  - eng
GR  - 1RO1 HL47159/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Anesthesiology
JT  - Anesthesiology
JID - 1300217
RN  - 0 (Blood Substitutes)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 578-19-8 (succinyldisalicylic acid)
RN  - CJ0O37KU29 (Verapamil)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/chemistry
MH  - *Blood Substitutes
MH  - Brain/*blood supply
MH  - Calcium Channel Blockers/pharmacology
MH  - *Cardiopulmonary Bypass
MH  - Cell-Free System
MH  - Cerebrovascular Circulation
MH  - Cold Temperature
MH  - Cross-Linking Reagents
MH  - Hemoglobins/*administration & dosage/*chemistry
MH  - Hypothermia, Induced
MH  - Models, Biological
MH  - Oxygen Consumption
MH  - Rabbits
MH  - Verapamil/pharmacology
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
AID - 10.1097/00000542-199512000-00021 [doi]
PST - ppublish
SO  - Anesthesiology. 1995 Dec;83(6):1302-11. doi: 10.1097/00000542-199512000-00021.

PMID- 8094440
OWN - NLM
STAT- MEDLINE
DCOM- 19930316
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 45
IP  - 1
DP  - 1993 Jan
TI  - Oral sustained-release drug delivery systems using polycarbonate microspheres 
      capable of floating on the gastric fluid.
PG  - 21-4
AB  - Polycarbonate microspheres loaded with aspirin, griseofulvin and p-nitroaniline 
      were prepared by a solvent evaporation technique. High drug loading (> 50%) was 
      achieved by this process. Drug-loaded microspheres were found to float on 
      simulated gastric fluid and intestinal fluid. Drug-release studies were carried 
      out in these fluids at 37 degrees C. Increasing the drug to polymer ratio in the 
      microspheres increased both their mean particle size and the release rate of the 
      drugs. It was concluded that sustained delivery of drugs could be effected using 
      this matrix.
FAU - Thanoo, B C
AU  - Thanoo BC
AD  - Polymer Chemistry Division, Sree Chitra Tirunal Institute for Medical Sciences 
      and Technology, Trivandrum, India.
FAU - Sunny, M C
AU  - Sunny MC
FAU - Jayakrishnan, A
AU  - Jayakrishnan A
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Aniline Compounds)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Polycarboxylate Cement)
RN  - 1MRQ0QZG7G (4-nitroaniline)
RN  - 25766-59-0 (polycarbonate)
RN  - 32HRV3E3D5 (Griseofulvin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aniline Compounds/administration & dosage/chemistry
MH  - Aspirin/administration & dosage/chemistry
MH  - Body Fluids/*chemistry
MH  - *Delayed-Action Preparations
MH  - Griseofulvin/administration & dosage/chemistry
MH  - Microscopy, Electron, Scanning
MH  - *Microspheres
MH  - Particle Size
MH  - Polycarboxylate Cement/*analysis
MH  - Stomach/*chemistry
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1993.tb03672.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1993 Jan;45(1):21-4. doi: 10.1111/j.2042-7158.1993.tb03672.x.

PMID- 12712729
OWN - NLM
STAT- MEDLINE
DCOM- 20030623
LR  - 20131121
IS  - 1000-8020 (Print)
IS  - 1000-8020 (Linking)
VI  - 28
IP  - 3
DP  - 1999 May 30
TI  - [Antagonism of folic acid on the toxicity of aspirin in yolk sac of rats].
PG  - 181-2
AB  - The antagonistic effects of folic acid to aspirin on the development of rat yolk 
      sac and embryos were studied during early organogenesis by using whole embryo 
      culture technique and electron microscopy. The results showed that when treated 
      with aspirin, the diameter of yolk sac and the body length of embryo were much 
      shorter, the frequencies of abnormal embryos were significantly higher, and the 
      yolk sac became thinner than those without treatment. The number of blood islands 
      and capillaries decreased, the differentiation and development of blood vessel 
      were retarded in the treated group. Ultrastructure observation also showed that 
      the numbers of microvilli and capillaries were greatly decreased, and the 
      structure and the numbers of lysosomes, endoplasmic reticula and ribosomes 
      significantly changed in the treated group. When aspirin was added with high 
      folic acid serum, the toxicity on yolk sac decreased or disappeared. The results 
      suggested that the protection of yolk sac would be related to the antagonism of 
      folic acid to aspirin.
FAU - Wang, X
AU  - Wang X
AD  - Shandong Institute of Industrial Hygiene and Occupational Disease, Jinan 250062, 
      China.
FAU - Han, M
AU  - Han M
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Wei Sheng Yan Jiu
JT  - Wei sheng yan jiu = Journal of hygiene research
JID - 9426367
RN  - 0 (Teratogens)
RN  - 935E97BOY8 (Folic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*antagonists & inhibitors/*toxicity
MH  - Embryonic and Fetal Development/drug effects
MH  - Female
MH  - Folic Acid/*pharmacology
MH  - Male
MH  - Pregnancy
MH  - Rats
MH  - Rats, Wistar
MH  - Teratogens/*toxicity
MH  - Yolk Sac/drug effects
EDAT- 2003/04/26 05:00
MHDA- 2003/06/24 05:00
CRDT- 2003/04/26 05:00
PHST- 2003/04/26 05:00 [pubmed]
PHST- 2003/06/24 05:00 [medline]
PHST- 2003/04/26 05:00 [entrez]
PST - ppublish
SO  - Wei Sheng Yan Jiu. 1999 May 30;28(3):181-2.

PMID- 20473591
OWN - NLM
STAT- MEDLINE
DCOM- 20110613
LR  - 20211020
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Linking)
VI  - 12
IP  - 4
DP  - 2010 Jul
TI  - Aspirin for acute coronary syndromes: have we learned the correct dose yet?
PG  - 344-7
LID - 10.1007/s11886-010-0120-y [doi]
AB  - Despite its universal use, the optimal dose of aspirin from an efficacy and 
      safety perspective remains unclear. There are wide variations in international 
      practice and a lack of consensus as to the most appropriate dose of aspirin in 
      patients with acute coronary syndromes (ACS), mainly because of the wide range of 
      doses evaluated in early randomized trials of aspirin versus placebo. Comparisons 
      of aspirin dose have been based on observational studies or indirect comparisons 
      from meta-analysis of antiplatelet trials. These studies have suggested that 
      aspirin, in doses>or=300 mg, is similar to aspirin doses 75-100 mg/d for 
      prevention of major vascular events, but that higher doses increase the risk of 
      major bleeding complications. Recently, the CURRENT-OASIS study, a randomized 
      head-to-head comparison of higher-dose (>or=300 mg/d) versus low-dose aspirin 
      (75-81 mg/d) for 1 month in over 25,000 patients with ACS referred for an early 
      invasive strategy demonstrated similar outcomes between higher- and low-dose 
      aspirin for efficacy, with no difference in the risk of major bleeding 
      complications. Results from this mega-trial suggest that low-dose or higher-dose 
      aspirin is a reasonable option in ACS patients undergoing an early invasive 
      strategy.
FAU - Bainey, Kevin R
AU  - Bainey KR
AD  - Hamilton Health Sciences, David Braley Cardiac Vascular and Stroke Institute, 
      C3-11A, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada. 
      kbainey@ualberta.ca
FAU - Mehta, Shamir R
AU  - Mehta SR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/drug therapy/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Risk Factors
MH  - Risk Reduction Behavior
MH  - Secondary Prevention
RF  - 17
EDAT- 2010/05/18 06:00
MHDA- 2011/06/15 06:00
CRDT- 2010/05/18 06:00
PHST- 2010/05/18 06:00 [entrez]
PHST- 2010/05/18 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
AID - 10.1007/s11886-010-0120-y [doi]
PST - ppublish
SO  - Curr Cardiol Rep. 2010 Jul;12(4):344-7. doi: 10.1007/s11886-010-0120-y.

PMID- 16735832
OWN - NLM
STAT- MEDLINE
DCOM- 20060907
LR  - 20131121
IS  - 1040-872X (Print)
IS  - 1040-872X (Linking)
VI  - 18
IP  - 3
DP  - 2006 Jun
TI  - Is there a benefit of low-dose aspirin in assisted reproduction?
PG  - 313-8
AB  - PURPOSE OF REVIEW: Assisted reproduction is an effective treatment for infertile 
      women but, despite advances in ovarian stimulation and laboratory techniques, 
      overall pregnancy rates are still relatively low suggesting that methods to 
      improve implantation are required. One strategy is to increase the blood flow to 
      the uterus with low-dose aspirin. The objective of this review is to determine if 
      low-dose aspirin improves clinical pregnancy rates when administered to infertile 
      women undergoing treatment with assisted reproduction. RECENT FINDINGS: A 
      retrospective review was unable to demonstrate improved pregnancy rates when 
      low-dose aspirin was compared with no treatment. Such studies, however, have 
      limited value in clinical decision-making because of poor methodological quality. 
      A recent high-quality randomized, placebo-controlled trial of low-dose aspirin 
      was also unable to demonstrate any benefit, a finding supported by a 
      meta-analysis of 10 trials that collectively had sufficient power to detect a 
      clinically relevant improvement in clinical pregnancy rate. Evidence also exists 
      that low-dose aspirin is potentially harmful, because of increased bleeding 
      problems, miscarriage and congenital anomalies. SUMMARY: Given the lack of 
      efficacy and the potential for harmful effects to both the patient and her 
      offspring, low-dose aspirin should not be administered to infertile women 
      undergoing treatment with assisted reproduction.
FAU - Daya, Salim
AU  - Daya S
AD  - ISIS Regional Fertility Centre, Mississauga, Ontario, Canada. dayas@mcmaster.ca
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Obstet Gynecol
JT  - Current opinion in obstetrics & gynecology
JID - 9007264
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Pregnancy
MH  - Reproductive Techniques, Assisted
MH  - Research Design
MH  - Uterus/*blood supply/drug effects
RF  - 20
EDAT- 2006/06/01 09:00
MHDA- 2006/09/08 09:00
CRDT- 2006/06/01 09:00
PHST- 2006/06/01 09:00 [pubmed]
PHST- 2006/09/08 09:00 [medline]
PHST- 2006/06/01 09:00 [entrez]
AID - 00001703-200606000-00012 [pii]
AID - 10.1097/01.gco.0000193013.19147.9a [doi]
PST - ppublish
SO  - Curr Opin Obstet Gynecol. 2006 Jun;18(3):313-8. doi: 
      10.1097/01.gco.0000193013.19147.9a.

PMID- 2224948
OWN - NLM
STAT- MEDLINE
DCOM- 19901204
LR  - 20131121
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 12
IP  - 4
DP  - 1990 Jul-Aug
TI  - Nicardipine in the prevention of cerebral infarction.
PG  - 344-51
AB  - Two hundred and sixty-four patients were included in an open, randomized, 
      multicenter trial, with the aim of determining whether nicardipine can be useful 
      in the prevention of cerebral infarction. The patients had experienced one or 
      more transient ischemic attacks, reversible ischemic neurologic defect, or stroke 
      with minor permanent neurological deficit in the 12 months before enrolling in 
      the study. Each patient was randomly assigned to received 250 mg of aspirin once 
      daily plus 20 mg of nicardipine thrice daily (n = 170) or 250 mg of aspirin once 
      daily (n = 94) for 12 months. During the 12-month treatment period, 12% of the 
      aspirin-plus-nicardipine group and 19% of the aspirin-only group experienced an 
      ischemic cerebrovascular event; at six months, the cumulative incidence of events 
      was significantly lower in the aspirin-plus-nicardipine group than in the 
      aspirin-only group. One patient in each group died of a recurrent stroke. 
      Aspirin-related side effects were dyspepsia (reported by four patients), 
      heartburn (by seven), nausea and vomiting (by four), and melena (by five); 
      nicardipine-related side effects were transient hypotension (by two), headache 
      (by four), ankle edema (by three), and constipation (by four). Results indicate 
      that the addition of nicardipine to antiplatelet treatment may safely prevent the 
      recurrence of ischemic cerebrovascular events.
FAU - Martí Massó, J F
AU  - Martí Massó JF
AD  - Department of Neurosciences, País Vasco University, San Sebastian, Spain.
FAU - Lozano, R
AU  - Lozano R
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - CZ5312222S (Nicardipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Brain Ischemia/drug therapy
MH  - Cerebral Infarction/*prevention & control
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nicardipine/adverse effects/*therapeutic use
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1990 Jul-Aug;12(4):344-51.

PMID- 1403491
OWN - NLM
STAT- MEDLINE
DCOM- 19921103
LR  - 20161123
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 9
IP  - 4
DP  - 1992 Oct-Dec
TI  - Poly(4-vinylpyridine)-coated liposomes: stability studies and release of 
      acetylsalicylic acid.
PG  - 437-48
AB  - Liposomes of dimyristoylphosphatidylcholine (DMPC) and dicetylphosphate (DCP) 
      reacted with 4-vinylpyridine (4-VP) to form a salt and, subsequently, 
      autopolymerized for form poly(4-vinylpyridine) (poly(4-VP))-coated liposomes. The 
      conditions for optimization of polymer coating have been determined; also, the 
      effects of polymer coating on liposome stability, the encapsulation of ASA and 
      its release kinetics have been measured. The coating efficiency was maximum at a 
      DMPC:DCP 1:1 mole ratio, at pH 4.0 in acetate buffer, and a polymerization time 
      of 40 min. The polymer-coated liposomes were stable in 2 mM sodium cholate and 4 
      per cent isopropanol solutions, as determined from turbidity measurements, versus 
      a 20-25% decrease in stability of uncoated liposomes. The encapsulation 
      efficiency of ASA reached a maximum of 9 per cent at DMPC:DCP 1:1 mole ratio. The 
      release of ASA at 37 degrees C, pH 7.0 was characterized by an initial fast 
      release (85 and 63 per cent in 20 min from uncoated and polymer-coated liposomes, 
      respectively) followed by a slow, constant release rate up to 140 min. Thus, 
      autopolymerization of a polymerizable monomer at liposome surfaces represents a 
      potentially feasible stabilization approach for liposomes exposed to sodium 
      cholate solutions with greater retention of solute than uncoated liposomes.
FAU - Dong, C
AU  - Dong C
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Canada.
FAU - Rogers, J A
AU  - Rogers JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Liposomes)
RN  - 0 (Polymers)
RN  - 0 (Pyridines)
RN  - I56G67XM8D (4-vinylpyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/chemistry
MH  - Drug Stability
MH  - Liposomes/administration & dosage
MH  - Polymers/administration & dosage
MH  - Pyridines/*administration & dosage
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 10.3109/02652049209040482 [doi]
PST - ppublish
SO  - J Microencapsul. 1992 Oct-Dec;9(4):437-48. doi: 10.3109/02652049209040482.

PMID- 25362110
OWN - NLM
STAT- MEDLINE
DCOM- 20150914
LR  - 20220321
IS  - 1477-0377 (Electronic)
IS  - 1358-863X (Linking)
VI  - 19
IP  - 6
DP  - 2014 Dec
TI  - Beneficial effects of low-dose aspirin on aortic stiffness in hypertensive 
      patients.
PG  - 452-7
LID - 10.1177/1358863X14556695 [doi]
AB  - While treatment with low-dose aspirin has been established as a therapeutic tool 
      for secondary prevention, the role of aspirin on primary prevention remains 
      controversial. Aortic stiffness and wave reflections are independent predictors 
      of cardiovascular events. The aim of the present study was to investigate the 
      effect of low-dose aspirin on aortic stiffness and wave reflections in 
      hypertensive patients. We studied 30 patients with grade I hypertension. Fifteen 
      patients were treated with 160 mg of aspirin and 15 patients with placebo. Aortic 
      stiffness and wave reflections were assessed by measuring carotid-femoral pulse 
      wave velocity (PWV) and heart rate-adjusted augmentation index (AIx75), 
      respectively. All measurements were conducted at baseline and 2 weeks after 
      treatment. In the aspirin group, there was a significant reduction in PWV 
      compared to the placebo group (from 8.9±1.5 to 8.5±1.6 m/s for the aspirin group 
      vs from 8.6±1.4 to 8.7±1.6 m/s for the placebo group, net change: -0.5 m/s; 
      p=0.02). AIx75 showed a marginal decrease (from 28.0±5.4 to 26.2±5.0% for the 
      aspirin group vs from 31.2±9.7 to 30.6±9.2% for the placebo group, net change: 
      -1.2%; p=0.06). In conclusion, a 2-week course of aspirin administration has a 
      favorable effect on aortic stiffness and, to a lesser extent, on wave reflections 
      in hypertensive patients. Whether the reduction in arterial stiffness is 
      translated to fewer cardiovascular events needs to be confirmed by future 
      prospective studies.
CI  - © The Author(s) 2014.
FAU - Pietri, Panagiota
AU  - Pietri P
AD  - Peripheral Vessels and Hypertension Unit, 1 Cardiology Department, Athens Medical 
      School, Hippokration Hospital, Athens, Greece.
FAU - Vlachopoulos, Charalambos
AU  - Vlachopoulos C
AD  - Peripheral Vessels and Hypertension Unit, 1 Cardiology Department, Athens Medical 
      School, Hippokration Hospital, Athens, Greece cvlachop@otenet.gr.
FAU - Terentes-Printzios, Dimitris
AU  - Terentes-Printzios D
AD  - Peripheral Vessels and Hypertension Unit, 1 Cardiology Department, Athens Medical 
      School, Hippokration Hospital, Athens, Greece.
FAU - Xaplanteris, Panagiotis
AU  - Xaplanteris P
AD  - Peripheral Vessels and Hypertension Unit, 1 Cardiology Department, Athens Medical 
      School, Hippokration Hospital, Athens, Greece.
FAU - Aznaouridis, Konstantinos
AU  - Aznaouridis K
AD  - Peripheral Vessels and Hypertension Unit, 1 Cardiology Department, Athens Medical 
      School, Hippokration Hospital, Athens, Greece.
FAU - Petrocheilou, Katerina
AU  - Petrocheilou K
AD  - Peripheral Vessels and Hypertension Unit, 1 Cardiology Department, Athens Medical 
      School, Hippokration Hospital, Athens, Greece.
FAU - Stefanadis, Christodoulos
AU  - Stefanadis C
AD  - Peripheral Vessels and Hypertension Unit, 1 Cardiology Department, Athens Medical 
      School, Hippokration Hospital, Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141031
PL  - England
TA  - Vasc Med
JT  - Vascular medicine (London, England)
JID - 9610930
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aorta/drug effects
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Female
MH  - Heart Rate/physiology
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Pulse Wave Analysis
MH  - Treatment Outcome
MH  - Vascular Stiffness/*drug effects
OTO - NOTNLM
OT  - aortic stiffness
OT  - aspirin
OT  - hypertension
OT  - wave reflections
EDAT- 2014/11/02 06:00
MHDA- 2015/09/15 06:00
CRDT- 2014/11/02 06:00
PHST- 2014/11/02 06:00 [entrez]
PHST- 2014/11/02 06:00 [pubmed]
PHST- 2015/09/15 06:00 [medline]
AID - 1358863X14556695 [pii]
AID - 10.1177/1358863X14556695 [doi]
PST - ppublish
SO  - Vasc Med. 2014 Dec;19(6):452-7. doi: 10.1177/1358863X14556695. Epub 2014 Oct 31.

PMID- 34539583
OWN - NLM
STAT- MEDLINE
DCOM- 20220216
LR  - 20220216
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 12
DP  - 2021
TI  - Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the 
      Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis.
PG  - 741374
LID - 10.3389/fendo.2021.741374 [doi]
LID - 741374
AB  - PURPOSE: A meta-analysis was conducted to assess the benefits and risks of 
      aspirin for the primary prevention of cardiovascular disease and all-cause 
      mortality events in adults with diabetes. METHODS: An extensive and systematic 
      search was conducted in MEDLINE (via PubMed), Cinahl (via Ebsco), Scopus, and Web 
      of Sciences from 1988 to December 2020. A detailed literature search was 
      conducted using aspirin, cardiovascular disease (CVD), diabetes, and efficacy to 
      identify trials of patients with diabetes who received aspirin for primary 
      prevention of CVD. Demographic details with the primary outcome of events and 
      bleeding outcomes were analyzed. The Cochrane Collaboration's risk of bias tool 
      was used to assess the methodological quality of the included studies. 
      Random-effects meta-analysis was used to calculate the pooled odds ratio for 
      outcomes of cardiovascular events, death, and adverse events. FINDINGS: A total 
      of 8 studies were included with 32,024 patients with diabetes; 16,001 allocated 
      to aspirin, and 16,023 allocated to the control group. There was no difference 
      between aspirin and control groups with respect to all-cause mortality, 
      cardiovascular mortality, or bleeding events. However, MACE was significantly 
      lower in the aspirin group. IMPLICATIONS: Although aspirin has no significant 
      risk on primary endpoints of cardiovascular events and bleeding outcomes in 
      patients with diabetes compared to control, major adverse cardiovascular events 
      (MACE) were significantly lower in the aspirin group. Further research on the use 
      of aspirin alone or in combination with other antiplatelet drugs is required in 
      patients with diabetes to supplement currently available research. SYSTEMATIC 
      REVIEW REGISTRATION: identifier [XU#/IRB/2020/1005].
CI  - Copyright © 2021 Ma, Gu, Niu, Li and Wang.
FAU - Ma, Hua
AU  - Ma H
AD  - Deparment of Vasculocardiology, Xianyang Central Hospital, Xianyang, China.
FAU - Gu, Qing
AU  - Gu Q
AD  - Deparment of Vasculocardiology, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences, Beijing, China.
FAU - Niu, Huining
AU  - Niu H
AD  - Department of Hematology, Xianyang Central Hospital, Xianyang, China.
FAU - Li, Xiaohua
AU  - Li X
AD  - Deparment of Vasculocardiology, Xianyang Central Hospital, Xianyang, China.
FAU - Wang, Rong
AU  - Wang R
AD  - Department of General Surgery, The Second People's Hospital, Kunshan, Suzhou, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210901
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Diabetes Complications/*prevention & control
MH  - Diabetic Angiopathies/*prevention & control
MH  - Diabetic Cardiomyopathies/*prevention & control
MH  - Hemorrhage
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/*therapeutic use
PMC - PMC8440957
OTO - NOTNLM
OT  - MACE
OT  - aspirin
OT  - cardiovascular diseases
OT  - diabetes
OT  - mortality rate
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/21 06:00
MHDA- 2022/02/17 06:00
CRDT- 2021/09/20 06:02
PHST- 2021/07/14 00:00 [received]
PHST- 2021/08/16 00:00 [accepted]
PHST- 2021/09/20 06:02 [entrez]
PHST- 2021/09/21 06:00 [pubmed]
PHST- 2022/02/17 06:00 [medline]
AID - 10.3389/fendo.2021.741374 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2021 Sep 1;12:741374. doi: 
      10.3389/fendo.2021.741374. eCollection 2021.

PMID- 34937670
OWN - NLM
STAT- MEDLINE
DCOM- 20220426
LR  - 20220523
IS  - 1873-2607 (Electronic)
IS  - 0749-3797 (Linking)
VI  - 62
IP  - 5
DP  - 2022 May
TI  - Cardiovascular Disease Preventive Services Among Smaller Primary Care Practices.
PG  - e285-e295
LID - S0749-3797(21)00568-7 [pii]
LID - 10.1016/j.amepre.2021.10.011 [doi]
AB  - INTRODUCTION: Cardiovascular disease preventive services (aspirin use, blood 
      pressure control, and smoking-cessation support) are crucial to controlling 
      cardiovascular diseases. This study draws from 1,248 small-to-medium-sized 
      primary care practices participating in the EvidenceNOW Initiative from 2015-2016 
      across 12 states to provide practice-level aspirin use, blood pressure control, 
      and smoking-cessation support estimates; report the percentage of practices that 
      meet Million Hearts targets; and identify the practice characteristics associated 
      with better performance. METHODS: This cross-sectional study utilized linear 
      regression modeling (analyzed in 2020-2021) to examine the association of aspirin 
      use, blood pressure control, and smoking-cessation support performance with 
      practice characteristics that included structural attributes (e.g., size, 
      ownership, rurality), practice capacity and contextual characteristics, health 
      information technology, and patient panel demographics. RESULTS: On average, 
      practice performance on aspirin use, blood pressure control, and 
      smoking-cessation support quality measures was 64% for aspirin, 63% for blood 
      pressure, and 62% for smoking-cessation support. The 2012 Million Hearts goal of 
      achieving the rates of 70% was achieved by 52% (aspirin), 32% (blood pressure), 
      and 54% (smoking) of practices. Practice characteristics associated with aspirin 
      use, blood pressure control, and smoking-cessation support performance included 
      ownership (hospital/health system-owned practices had 11% higher aspirin 
      performance than clinician-owned practices [p=0.001]), rurality (rural practices 
      had lower performance than urban practices in all aspirin use, blood pressure 
      control, and smoking-cessation support quality metrics [difference in 
      aspirin=11.1%, p=0.001; blood pressure=4.2%, p=0.022; smoking=14.4%, p=0.009]), 
      and disruptions (practices that experienced >1 major disruption showed lower 
      aspirin performance [-7.1%, p<0.001]). CONCLUSIONS: Achieving the Million Hearts 
      targets may be assisted by collecting and reporting practice-level performance, 
      which can promote change at the practice level and identify areas where 
      additional support is needed to achieve initiative goals.
CI  - Copyright © 2021 American Journal of Preventive Medicine. Published by Elsevier 
      Inc. All rights reserved.
FAU - Marino, Miguel
AU  - Marino M
AD  - Department of Family Medicine, Oregon Health & Science University, Portland, 
      Oregon; School of Public Health, Oregon Health & Science University, Portland, 
      Oregon. Electronic address: marinom@ohsu.edu.
FAU - Solberg, Leif
AU  - Solberg L
AD  - HealthPartners Institute, Minneapolis, Minnesota.
FAU - Springer, Rachel
AU  - Springer R
AD  - Department of Family Medicine, Oregon Health & Science University, Portland, 
      Oregon.
FAU - McConnell, K John
AU  - McConnell KJ
AD  - Center for Health Systems Effectiveness, Oregon Health & Science University, 
      Portland, Oregon; Department of Emergency Medicine, School of Medicine, Oregon 
      Health & Science University, Portland, Oregon.
FAU - Lindner, Stephan
AU  - Lindner S
AD  - Center for Health Systems Effectiveness, Oregon Health & Science University, 
      Portland, Oregon.
FAU - Ward, Rikki
AU  - Ward R
AD  - Department of Epidemiology, Human Genetics, and Environmental Sciences, UTHealth 
      School of Public Health, Dallas, Texas.
FAU - Edwards, Samuel T
AU  - Edwards ST
AD  - Department of Family Medicine, Oregon Health & Science University, Portland, 
      Oregon.
FAU - Stange, Kurt C
AU  - Stange KC
AD  - Center for Community Health Integration, Case Western Reserve University, 
      Cleveland, Ohio.
FAU - Cohen, Deborah J
AU  - Cohen DJ
AD  - Department of Family Medicine, Oregon Health & Science University, Portland, 
      Oregon; Department of Medical Informatics and Clinical Epidemiology, Oregon 
      Health & Science University, Portland, Oregon.
FAU - Balasubramanian, Bijal A
AU  - Balasubramanian BA
AD  - Department of Epidemiology, Human Genetics, and Environmental Sciences, UTHealth 
      School of Public Health, Dallas, Texas.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20211220
PL  - Netherlands
TA  - Am J Prev Med
JT  - American journal of preventive medicine
JID - 8704773
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Primary Health Care
MH  - Quality Improvement
EDAT- 2021/12/24 06:00
MHDA- 2022/04/27 06:00
CRDT- 2021/12/23 05:31
PHST- 2021/05/25 00:00 [received]
PHST- 2021/10/14 00:00 [revised]
PHST- 2021/10/17 00:00 [accepted]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2022/04/27 06:00 [medline]
PHST- 2021/12/23 05:31 [entrez]
AID - S0749-3797(21)00568-7 [pii]
AID - 10.1016/j.amepre.2021.10.011 [doi]
PST - ppublish
SO  - Am J Prev Med. 2022 May;62(5):e285-e295. doi: 10.1016/j.amepre.2021.10.011. Epub 
      2021 Dec 20.

PMID- 8354011
OWN - NLM
STAT- MEDLINE
DCOM- 19930923
LR  - 20170112
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 11 Suppl 9
DP  - 1993 May-Jun
TI  - Relevance of the pharmacokinetics of non-steroidal anti-inflammatory drugs 
      (NSAIDs) in children.
PG  - S57-8
AB  - The pharmacokinetics of the NSAIDs is relevant to therapy in different ways: 
      absorption, protein binding and distribution, metabolism and elimination. The 
      pharmacokinetics of a drug is most relevant to therapy when plasma concentrations 
      of the drug are related to efficacy and/or to side effects. The kinetic 
      parameters then allow one to calculate the optimal dose regimen, i.e. the one 
      maintaining plasma concentrations within the therapeutic range. The 
      pharmacokinetic characteristics of the different NSAIDs relevant to therapy in 
      children are reviewed.
FAU - Pons, G
AU  - Pons G
AD  - Department of Perinatal and Pediatric Pharmacology, Hôpital Saint-Vincent de 
      Paul, Paris, France.
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Absorption
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics/*therapeutic use
MH  - Aspirin/adverse effects/pharmacokinetics/therapeutic use
MH  - Child, Preschool
MH  - Humans
MH  - Ibuprofen/adverse effects/pharmacokinetics/therapeutic use
MH  - Stereoisomerism
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Rheumatol. 1993 May-Jun;11 Suppl 9:S57-8.

PMID- 30400937
OWN - NLM
STAT- MEDLINE
DCOM- 20190408
LR  - 20190408
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 19
IP  - 1
DP  - 2018 Nov 6
TI  - Low-dose aspirin in the prevention of pre-eclampsia in China (APPEC study): 
      protocol for a multicentre randomized controlled trial.
PG  - 608
LID - 10.1186/s13063-018-2970-3 [doi]
LID - 608
AB  - BACKGROUND: Low-dose aspirin (LDA) has been proposed as a safe and inexpensive 
      prophylactic agent. Studies in European/Western populations have shown promising 
      results indicating that LDA can reduce the occurrence of pre-eclampsia (PE) in 
      women with identifiable risk factors. However, few controlled trials, 
      particularly large randomized controlled trials, have been performed in Asian 
      populations. The aim of this project is to evaluate the effect of LDA for PE 
      prevention on high-risk pregnant women in China, where PE is highly prevalent and 
      the LDA supply status is commonly suboptimal. METHODS/DESIGN: An open-label, 
      multicentre randomized controlled trial is being conducted at 13 tertiary 
      hospitals in 11 provinces in China. A total of 1000 eligible women with high-risk 
      factors for developing PE according to their medical histories are being 
      randomized into two groups: a control group (n = 500) and an intervention group 
      (n = 500). Women with high-risk factors, such as a history of PE, chronic 
      hypertension, type 1 or 2 diabetes, advanced maternal age, obesity, family 
      history of PE or nulliparity are eligible. The control group is advised to 
      undergo routine examinations, whereas the intervention group undergoes the 
      routine examinations and receives LDA. LDA (100 mg/d) should be prescribed at 
      night, initiating from early pregnancy (12-20 weeks of gestation) and lasting 
      until 34 weeks of gestation. Demographic data and clinical endpoint outcomes, as 
      well as biological samples (e.g., maternal blood, cord blood, amniotic fluid and 
      placental samples), will be collected. The primary outcome is the occurrence of 
      PE, and the secondary outcomes include maternal and neonatal outcomes and 
      maternal biomarker levels. DISCUSSION: This is the first and largest multicentre 
      randomized controlled trial to assess the effect of LDA in preventing PE in a 
      Chinese population. The results will potentially influence the prenatal care 
      recommendations in China regarding intervention with LDA for PE. TRIAL 
      REGISTRATION: ClinicalTrials.gov, NCT02797249 . Registered on 7 June 2016.
FAU - Lin, Li
AU  - Lin L
AD  - Department of Obstetrics and Gynaecology, Peking University First Hospital, No. 1 
      Xi'anmen Street, Xicheng District, Beijing, 100034, China.
AD  - Beijing Key Laboratory of Maternal Foetal Medicine of Gestational Diabetes 
      Mellitus, Beijing, 100034, China.
FAU - Zhu, Yuchun
AU  - Zhu Y
AD  - Department of Obstetrics and Gynaecology, Peking University First Hospital, No. 1 
      Xi'anmen Street, Xicheng District, Beijing, 100034, China.
AD  - Beijing Key Laboratory of Maternal Foetal Medicine of Gestational Diabetes 
      Mellitus, Beijing, 100034, China.
FAU - Li, Boya
AU  - Li B
AD  - Department of Obstetrics and Gynaecology, Peking University First Hospital, No. 1 
      Xi'anmen Street, Xicheng District, Beijing, 100034, China.
AD  - Beijing Key Laboratory of Maternal Foetal Medicine of Gestational Diabetes 
      Mellitus, Beijing, 100034, China.
FAU - Yang, Huixia
AU  - Yang H
AD  - Department of Obstetrics and Gynaecology, Peking University First Hospital, No. 1 
      Xi'anmen Street, Xicheng District, Beijing, 100034, China. 
      yanghuixia@bjmu.edu.cn.
AD  - Beijing Key Laboratory of Maternal Foetal Medicine of Gestational Diabetes 
      Mellitus, Beijing, 100034, China. yanghuixia@bjmu.edu.cn.
CN  - APPEC Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT02797249
GR  - 81490745/Major Program of the National Natural Science Foundation of China/
GR  - 2015CB943300/State Key Development Program for Basic Research of China/
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20181106
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Data Collection
MH  - Data Interpretation, Statistical
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - *Randomized Controlled Trials as Topic
PMC - PMC6218975
OTO - NOTNLM
OT  - China
OT  - Low-dose aspirin
OT  - Pre-eclampsia
OT  - Pregnancy
OT  - Prevention
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This study was reviewed and approved 
      by the Ethics Committee of the Peking University First Hospital (reference number 
      2016 [1109]). Verbal and written information regarding informed consent will be 
      presented to the caregivers and/or patients. Any modifications to the protocol 
      that may affect the conduct of the study will be presented to the committee. The 
      trial was registered with ClinicaTrials.gov (NCT02797249) prior to the inclusion 
      of the first patient. All important changes to the protocol will be implemented 
      in the trial registration. All participants will provide written informed 
      content, and the ethics committee has approved the procedures. The full protocol 
      will be available freely owing to the open access nature of the publication. The 
      findings of this RCT will be submitted to a peer-reviewed journal. Abstracts will 
      be submitted to relevant national and international conferences. The standards 
      delineated in the guidelines of the Consolidated Standards of Reporting Trials 
      will be followed in this RCT. All investigators will have access to the final 
      trial dataset. We plan to communicate the trial results to the participants, 
      healthcare professionals, policy makers, the funding agencies, the public and 
      other relevant groups via conferences, publications and/or other data-sharing 
      arrangements. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The 
      authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer 
      Nature remains neutral with regard to jurisdictional claims in published maps and 
      institutional affiliations.
FIR - Li, Xiaotian
IR  - Li X
FIR - Zhao, Yangyu
IR  - Zhao Y
FIR - Chen, Dunjin
IR  - Chen D
FIR - Qi, Hongbo
IR  - Qi H
FIR - Zhang, Weishe
IR  - Zhang W
FIR - Ding, Hongjuan
IR  - Ding H
FIR - Zhang, Meihua
IR  - Zhang M
FIR - Zhao, Xianlan
IR  - Zhao X
FIR - Cui, Shihong
IR  - Cui S
FIR - Mi, Yang
IR  - Mi Y
FIR - Sun, Xiaotong
IR  - Sun X
FIR - Ma, Yuyan
IR  - Ma Y
EDAT- 2018/11/08 06:00
MHDA- 2019/04/09 06:00
CRDT- 2018/11/08 06:00
PHST- 2018/05/20 00:00 [received]
PHST- 2018/10/08 00:00 [accepted]
PHST- 2018/11/08 06:00 [entrez]
PHST- 2018/11/08 06:00 [pubmed]
PHST- 2019/04/09 06:00 [medline]
AID - 10.1186/s13063-018-2970-3 [pii]
AID - 2970 [pii]
AID - 10.1186/s13063-018-2970-3 [doi]
PST - epublish
SO  - Trials. 2018 Nov 6;19(1):608. doi: 10.1186/s13063-018-2970-3.

PMID- 35732963
OWN - NLM
STAT- MEDLINE
DCOM- 20220812
LR  - 20230424
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 78
IP  - 9
DP  - 2022 Sep
TI  - Does aspirin have an effect on risk of death in patients with COVID-19? A 
      meta-analysis.
PG  - 1403-1420
LID - 10.1007/s00228-022-03356-5 [doi]
AB  - PURPOSE: The coronavirus disease 2019 (COVID-19) pandemic has shown unprecedented 
      impact world-wide since the eruption in late 2019. Importantly, emerging reports 
      suggest an increased risk of thromboembolism development in patients with 
      COVID-19. Meanwhile, it is found that aspirin reduced mortality in critically ill 
      patients with non-COVID-19 acute respiratory distress syndrome. Therefore, a 
      meta-analysis was performed to investigate the effects of aspirin on COVID-19 
      mortality. METHODS: A systematic literature search was conducted in 10 electronic 
      databases and 4 registries. Random effects models were used to calculate pooled 
      relative risks (RRs) with 95% confidence intervals (Cis) to estimate the effect 
      of aspirin on COVID-19 mortality. Relevant subgroup analyses and sensitivity 
      analyses were also performed. RESULTS: The results showed that aspirin use was 
      associated with a reduction in COVID-19 mortality (adjusted RR 0.69; 95% CI 
      0.50-0.95; P < 0.001). Subgroup analysis found that the low-dose group was 
      associated with a reduced COVID-19 mortality (adjusted RR 0.64; 95% CI 0.48-0.85; 
      P < 0.01). Aspirin use was associated with reduced COVID-19 mortality in Europe 
      and America (crude RR 0.71; 95% CI 0.52-0.98; P = 0.04), and results from cohort 
      studies suggested that aspirin use was a protective factor for COVID-19 mortality 
      (adjusted RR 0.73; 95% CI 0.52-0.99; P = 0.04). Meanwhile, aspirin use was not 
      associated with bleeding risk (crude RR 1.22; 95% CI 0.80-1.87; P = 0.96). 
      CONCLUSIONS: This meta-analysis found that aspirin use was associated with a 
      reduction in mortality in patients with COVID-19 and not with an increased risk 
      of bleeding.
CI  - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Ma, Shaodi
AU  - Ma S
AD  - Department of Epidemiology and Health Statistics, School of Public, Health Anhui 
      Medical University, No. 81 Meishan Road, 230032, Anhui, People's Republic of 
      China.
FAU - Su, Wanying
AU  - Su W
AD  - Department of Epidemiology and Health Statistics, School of Public, Health Anhui 
      Medical University, No. 81 Meishan Road, 230032, Anhui, People's Republic of 
      China.
FAU - Sun, Chenyu
AU  - Sun C
AD  - AMITA Health Saint Joseph Hospital Chicago, 2900 N. Lake Shore Drive, Chicago, 
      IL, 60657, USA.
FAU - Lowe, Scott
AU  - Lowe S
AD  - College of Osteopathic Medicine, Kansas City University, 1750 Independence Ave, 
      Kansas City, MO, 64106, USA.
FAU - Zhou, Zhen
AU  - Zhou Z
AD  - Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool 
      Street, Hobart, TAS, 7000, Australia.
FAU - Liu, Haixia
AU  - Liu H
AD  - Department of Epidemiology and Health Statistics, School of Public, Health Anhui 
      Medical University, No. 81 Meishan Road, 230032, Anhui, People's Republic of 
      China.
FAU - Qu, Guangbo
AU  - Qu G
AD  - Department of Epidemiology and Health Statistics, School of Public, Health Anhui 
      Medical University, No. 81 Meishan Road, 230032, Anhui, People's Republic of 
      China.
FAU - Xia, Weihang
AU  - Xia W
AD  - Department of Epidemiology and Health Statistics, School of Public, Health Anhui 
      Medical University, No. 81 Meishan Road, 230032, Anhui, People's Republic of 
      China.
FAU - Xie, Peng
AU  - Xie P
AD  - Department of Epidemiology and Health Statistics, School of Public, Health Anhui 
      Medical University, No. 81 Meishan Road, 230032, Anhui, People's Republic of 
      China.
FAU - Wu, Birong
AU  - Wu B
AD  - Department of Epidemiology and Health Statistics, School of Public, Health Anhui 
      Medical University, No. 81 Meishan Road, 230032, Anhui, People's Republic of 
      China.
FAU - Gao, Juan
AU  - Gao J
AD  - Department of Epidemiology and Health Statistics, School of Public, Health Anhui 
      Medical University, No. 81 Meishan Road, 230032, Anhui, People's Republic of 
      China.
FAU - Feng, Linya
AU  - Feng L
AD  - Department of Epidemiology and Health Statistics, School of Public, Health Anhui 
      Medical University, No. 81 Meishan Road, 230032, Anhui, People's Republic of 
      China.
FAU - Sun, Yehuan
AU  - Sun Y
AUID- ORCID: 0000-0002-8651-8059
AD  - Department of Epidemiology and Health Statistics, School of Public, Health Anhui 
      Medical University, No. 81 Meishan Road, 230032, Anhui, People's Republic of 
      China. yhsun_ahmu_edu@yeah.net.
AD  - Chaohu Hospital, Anhui Medical University, No. 64 Chaohubei Road, Anhui, 238000, 
      China. yhsun_ahmu_edu@yeah.net.
AD  - Center for Evidence-Based Practice, Anhui Medical University, No. 81 Meishan 
      Road, Anhui, 230032, China. yhsun_ahmu_edu@yeah.net.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220622
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur J Intern Med. 2023 Apr;110:101-103. PMID: 36464550
MH  - *Aspirin/therapeutic use
MH  - Critical Illness
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Pandemics
MH  - *COVID-19 Drug Treatment
PMC - PMC9217117
OTO - NOTNLM
OT  - Aspirin
OT  - Bleed
OT  - COVID-19
OT  - Meta-analysis
OT  - Mortality
COIS- The authors declare no competing interests.
EDAT- 2022/06/23 06:00
MHDA- 2022/08/13 06:00
CRDT- 2022/06/22 23:32
PHST- 2022/03/14 00:00 [received]
PHST- 2022/06/14 00:00 [accepted]
PHST- 2022/06/23 06:00 [pubmed]
PHST- 2022/08/13 06:00 [medline]
PHST- 2022/06/22 23:32 [entrez]
AID - 10.1007/s00228-022-03356-5 [pii]
AID - 3356 [pii]
AID - 10.1007/s00228-022-03356-5 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2022 Sep;78(9):1403-1420. doi: 10.1007/s00228-022-03356-5. 
      Epub 2022 Jun 22.

PMID- 656556
OWN - NLM
STAT- MEDLINE
DCOM- 19780814
LR  - 20131121
IS  - 0306-042X (Print)
IS  - 0306-042X (Linking)
VI  - 5
IP  - 5
DP  - 1978 May
TI  - Profiles in altered metabolism. II.--Accumulation of homogentisic acid in serum 
      and urine following acetylsalicylic acid ingestion.
PG  - 331-3
AB  - Homogentisic acid elevations have been found in urine and serum of patients on 
      long term heavy salicylate therapy and those acutely intoxicated with 
      acetylsalicylic acid. Loading of two normal volunteers with single oral 
      acetylsalicylate doses produced transient elevations in urinary homogentisic acid 
      excretion. These findings suggest that heavy salicylate use results in the 
      partial inhibition of homogentisic acid oxidase in vivo.
FAU - Montgomery, J A
AU  - Montgomery JA
FAU - Mamer, O A
AU  - Mamer OA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biomed Mass Spectrom
JT  - Biomedical mass spectrometry
JID - 0430246
RN  - NP8UE6VF08 (Homogentisic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*metabolism/poisoning
MH  - Homogentisic Acid/blood/*metabolism/urine
MH  - Humans
MH  - Mass Spectrometry
EDAT- 1978/05/01 00:00
MHDA- 1978/05/01 00:01
CRDT- 1978/05/01 00:00
PHST- 1978/05/01 00:00 [pubmed]
PHST- 1978/05/01 00:01 [medline]
PHST- 1978/05/01 00:00 [entrez]
AID - 10.1002/bms.1200050503 [doi]
PST - ppublish
SO  - Biomed Mass Spectrom. 1978 May;5(5):331-3. doi: 10.1002/bms.1200050503.

PMID- 22609818
OWN - NLM
STAT- MEDLINE
DCOM- 20140617
LR  - 20221207
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 19
IP  - 5
DP  - 2013 Sep
TI  - Genetic polymorphisms of HO-1 and COX-1 are associated with aspirin resistance 
      defined by light transmittance aggregation in Chinese Han patients.
PG  - 513-21
LID - 10.1177/1076029612444002 [doi]
AB  - BACKGROUND: Cyclooxygenase 1 (COX-1), COX-2, and HO-1 are involved in the process 
      of aspirin's effect. The genetic susceptibility of these enzymes to aspirin 
      resistance (AR) is unclear. METHODS: A total of 431 patients took aspirin. Using 
      arachidonic acid-induced light transmittance aggregation combined with adenosine 
      diphosphate-induced light transmittance aggregation, 36 participants served for 
      AR, 164 participants for semi-AR, and 231 participants for aspirin sensitivity 
      (AS). The AR with 9 single-nucleotide polymorphism in COX-1, COX-2, and HO-1 
      genes was investigated. RESULTS: COX-1 rs1330344 (-1676A>G) is associated with 
      AR. G-Allele carriers significantly increased the risk of AR. For patients with 
      AS as control, P is .02 (odds ratio [OR] = 1.77, confidence interval [CI]: 
      1.07-2.92). For patients with semi-AR as control, P is .05. HO-1 rs2071746 
      (-413A>T) is associated with AR. T-Allele carriers significantly increased the 
      risk of AR. For patients with AS as control, P is .04 (OR = 1.70, CI: 1.02-2.79). 
      For patients with semi-AR as control, P is .05 (OR = 1.68, CI: 1.00-2.80). 
      CONCLUSION: rs2071746 in HO-1 gene, rs1330344 in COX-1 gene contribute to AR.
FAU - Li, Xiao-li
AU  - Li XL
AD  - 1First Department of Geriatric Cardiology of South Building, Chinese People's 
      Liberation Army General Hospital, Beijing, China.
FAU - Cao, Jian
AU  - Cao J
FAU - Fan, Li
AU  - Fan L
FAU - Wang, Qiang
AU  - Wang Q
FAU - Ye, Ling
AU  - Ye L
FAU - Cui, Chun-Ping
AU  - Cui CP
FAU - Wang, Ya-Zhen
AU  - Wang YZ
FAU - Liu, Lin
AU  - Liu L
FAU - Li, Bin
AU  - Li B
FAU - Wu, Ruo-Jun
AU  - Wu RJ
FAU - Zhou, Feng-chun
AU  - Zhou FC
FAU - Zhang, Jun-hong
AU  - Zhang JH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120519
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.14.18 (HMOX1 protein, human)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Asian People
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/chemistry/cytology/drug effects
MH  - Cyclooxygenase 1/*genetics
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Drug Resistance
MH  - Female
MH  - Heme Oxygenase-1/*genetics
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Polymorphism, Single Nucleotide
MH  - Scattering, Radiation
OTO - NOTNLM
OT  - aspirin resistance
OT  - cyclooxygenase-1 (COX-1)
OT  - hemoxygenase-1 (HO-1)
OT  - platelet aggregation
OT  - single-nucleotide polymorphism (SNP)
EDAT- 2012/05/23 06:00
MHDA- 2014/06/18 06:00
CRDT- 2012/05/22 06:00
PHST- 2012/05/22 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2014/06/18 06:00 [medline]
AID - 1076029612444002 [pii]
AID - 10.1177/1076029612444002 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2013 Sep;19(5):513-21. doi: 10.1177/1076029612444002. 
      Epub 2012 May 19.

PMID- 35429915
OWN - NLM
STAT- MEDLINE
DCOM- 20220505
LR  - 20220505
IS  - 1879-1514 (Electronic)
IS  - 0166-445X (Linking)
VI  - 247
DP  - 2022 Jun
TI  - Aspirin inhibits stem cell proliferation during freshwater Dugesia japonica 
      regeneration by STAT3/SOX2/OCT4 signaling pathway.
PG  - 106158
LID - S0166-445X(22)00084-4 [pii]
LID - 10.1016/j.aquatox.2022.106158 [doi]
AB  - As a widely used drug in clinical practice, aspirin has a large number of 
      residual drugs and metabolites discharged into the environment during the 
      pharmaceutical process or after taking the drug. Aspirin content and its 
      metabolite, salicylic acid, have been reported and detected in several river 
      water samples and municipal wastewaters. However, little is known about the 
      toxicity mechanisms of this drug in aquatic invertebrates. In this study, we 
      examine the toxic effect and investigate the toxicity mechanism of aspirin in 
      planarian, which own the excellent regeneration and sensitive toxicity detection 
      ability. Planarian is treated with 0.7 mM aspirin for 6 h, 48 h, 3 d and 5 d, and 
      the mRNA and protein expression levels of the stem cells markers, in parallel 
      with the target genes of the signaling pathway are analyzed by RT-qPCR, 
      whole-mount immunofluorescence, and Western blot. The results show that aspirin 
      strongly inhibits stem cell proliferation and causes retarded blastemas growth in 
      planarians. Furthermore, the mRNA and protein expression levels of stem cells 
      markers and the target genes dramatically decrease after the aspirin treatment. 
      Meanwhile, the expression level of apoptotic cells also shows a downward trend. 
      Their significant and coincident downregulations after the aspirin treatment 
      suggest that aspirin regulates planarian regeneration via STAT3/SOX2/OCT4 
      signaling pathway. Our work reveals the toxicological effect and the mechanism of 
      aspirin to the planarian, and provides basic data for therapeutic applications of 
      aspirin in regeneration and warns about the ecological damage of aspirin abuse.
CI  - Copyright © 2022. Published by Elsevier B.V.
FAU - Liang, Ang
AU  - Liang A
AD  - College of Life Science, Henan Normal University, Xinxiang, 453007 Henan, China; 
      School of Nursing, Xinxiang Medical University, Xinxiang, 453003 Henan, China.
FAU - Wu, Fan
AU  - Wu F
AD  - College of Life Science, Henan Normal University, Xinxiang, 453007 Henan, China.
FAU - Li, Chaojie
AU  - Li C
AD  - College of Life Science, Henan Normal University, Xinxiang, 453007 Henan, China.
FAU - Yu, Yiyang
AU  - Yu Y
AD  - University of California, San Diego, La Jolla, CA, United States.
FAU - Dong, Zimei
AU  - Dong Z
AD  - College of Life Science, Henan Normal University, Xinxiang, 453007 Henan, China. 
      Electronic address: dzmhjx@163.com.
FAU - Chen, Guangwen
AU  - Chen G
AD  - College of Life Science, Henan Normal University, Xinxiang, 453007 Henan, China. 
      Electronic address: chengw0183@sina.com.
FAU - Yu, Fei
AU  - Yu F
AD  - College of Life Science, Henan Normal University, Xinxiang, 453007 Henan, China.
FAU - Yuwen, Yanqing
AU  - Yuwen Y
AD  - College of Life Science, Henan Normal University, Xinxiang, 453007 Henan, China.
FAU - Liu, Dezeng
AU  - Liu D
AD  - College of Life Science, Henan Normal University, Xinxiang, 453007 Henan, China.
LA  - eng
PT  - Journal Article
DEP - 20220410
PL  - Netherlands
TA  - Aquat Toxicol
JT  - Aquatic toxicology (Amsterdam, Netherlands)
JID - 8500246
RN  - 0 (RNA, Messenger)
RN  - 0 (Water Pollutants, Chemical)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/metabolism/toxicity
MH  - Cell Proliferation
MH  - Fresh Water
MH  - *Planarians/genetics
MH  - RNA, Messenger/genetics/metabolism
MH  - Signal Transduction
MH  - *Water Pollutants, Chemical/toxicity
OTO - NOTNLM
OT  - Aspirin
OT  - Planarian
OT  - Proliferation
OT  - Regeneration
OT  - Stem cell
EDAT- 2022/04/17 06:00
MHDA- 2022/05/06 06:00
CRDT- 2022/04/16 20:15
PHST- 2022/01/10 00:00 [received]
PHST- 2022/04/02 00:00 [revised]
PHST- 2022/04/05 00:00 [accepted]
PHST- 2022/04/17 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2022/04/16 20:15 [entrez]
AID - S0166-445X(22)00084-4 [pii]
AID - 10.1016/j.aquatox.2022.106158 [doi]
PST - ppublish
SO  - Aquat Toxicol. 2022 Jun;247:106158. doi: 10.1016/j.aquatox.2022.106158. Epub 2022 
      Apr 10.

PMID- 3613624
OWN - NLM
STAT- MEDLINE
DCOM- 19870828
LR  - 20131121
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 94
IP  - 2
DP  - 1987 Aug
TI  - Low-dose aspirin protects against lipid accumulation in primate vein bypass 
      grafts.
PG  - 251-5
AB  - Platelet inhibition with high-dose aspirin combined with dipyridamole reduces 
      lipid accumulation and improves early patency of coronary artery bypass grafts. 
      However, recent evidence suggests that platelet inhibition can be achieved with 
      substantially lower aspirin doses than have been conventionally prescribed. To 
      evaluate whether low-dose aspirin protects against lipid accumulation in bypass 
      grafts, we studied 15 stump-tailed macaque monkeys in which autologous cephalic 
      veins were grafted into the femoral arteries. A control group received no 
      treatment, a second group was treated with a low, single daily dose of aspirin 
      (12 mg), and a third group was given a higher dosage of aspirin (80 mg/day) 
      combined with dipyridamole (50 mg/day) divided into two daily doses. A special 
      diet was fed that resulted in plasma cholesterol levels (224 +/- 50 mg/dl, mean 
      +/- standard deviation) and plasma lipoprotein distributions that mimic the 
      profile in humans. Cholesterol concentration in grafts removed 3 months after 
      insertion was 0.47 +/- 0.12 mg/100 mg tissue in the control group; it was reduced 
      to 0.23 +/- 0.04 mg/100 mg (p less than 0.001) by low-dose aspirin and to 0.17 
      +/- 0.05 mg/100 mg (p less than 0.001) by combined aspirin and dipyridamole 
      therapy. Graft apolipoprotein B concentration was 66 +/- 19 micrograms/100 mg in 
      control group; it was reduced to 40 +/- 8 micrograms/100 mg (p less than 0.05) by 
      low-dose aspirin and to 23 +/- 7 micrograms/100 mg (p less than 0.001) with the 
      combination treatment. There were no differences between groups in either 
      cholesterol concentration (0.09 +/- 0.02 mg/100 mg) or apolipoprotein B 
      concentration (10 +/- 3 micrograms/100 mg) in normal ungrafted vein. Platelet 
      function tests demonstrated platelet aggregation in all control monkeys, in none 
      of the combined therapy group, and in two of five monkeys receiving low-dose 
      aspirin. This study indicates that low-dose aspirin is protective against graft 
      lipid accumulation in monkeys. The mechanism of this antilipid effect and its 
      relation to any antithrombotic effect remain to be elucidated.
FAU - Boerboom, L E
AU  - Boerboom LE
FAU - Olinger, G N
AU  - Olinger GN
FAU - Kissebah, A H
AU  - Kissebah AH
FAU - Montgomery, R R
AU  - Montgomery RR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Apolipoproteins B)
RN  - 0 (Lipids)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apolipoproteins B/metabolism
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/drug effects
MH  - Cholesterol/metabolism
MH  - Drug Administration Schedule
MH  - *Lipid Metabolism
MH  - Lipids/blood
MH  - Macaca fascicularis
MH  - Veins/metabolism/*transplantation
EDAT- 1987/08/01 00:00
MHDA- 1987/08/01 00:01
CRDT- 1987/08/01 00:00
PHST- 1987/08/01 00:00 [pubmed]
PHST- 1987/08/01 00:01 [medline]
PHST- 1987/08/01 00:00 [entrez]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1987 Aug;94(2):251-5.

PMID- 7320849
OWN - NLM
STAT- MEDLINE
DCOM- 19820313
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 12
DP  - 1981 Dec
TI  - Relative bioavailability of aspirin gum.
PG  - 1341-3
AB  - The bioavailability of aspirin gum relative to unbuffered aspirin tablets was 
      determined in six normal volunteers. Twenty-four hours following the 
      administration of two aspirin tablets, 91.2 +/- 1.7% (SE) of the 648-mg dose was 
      recovered in the urine. The relative bioavailability of aspirin gum was 69.5 +/- 
      3.4% (SE), based on cumulative 4-hr urinary excretion of total salicylate after 
      the chewing of three gum tablets for 15 min. The chewed gum was analyzed for 
      total salicylate and contained an average of 37.8% of the administered dose. When 
      added to the cumulative amount of total salicylate excreted in the urine at 24 hr 
      after dosing, the salicylate contained in the chewed gum accounted for 
      essentially 100% of the dose administered. Chewing aspirin gum for up to 30 min 
      did not significantly (p greater than 0.05) reduce the amount of salicylate 
      entrapped in the gum base when compared to chewing times of 5, 10, and 15 min. 
      Based on the results of this study, four pieces of aspirin gum would be needed to 
      provide the same amount of salicylate to the general circulation as two 324-mg 
      aspirin tablets.
FAU - Woodford, D W
AU  - Woodford DW
FAU - Lesko, L J
AU  - Lesko LJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Chewing Gum)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/metabolism
MH  - Biological Availability
MH  - Chewing Gum
MH  - Humans
MH  - Male
MH  - Salicylates/urine
MH  - Time Factors
EDAT- 1981/12/01 00:00
MHDA- 1981/12/01 00:01
CRDT- 1981/12/01 00:00
PHST- 1981/12/01 00:00 [pubmed]
PHST- 1981/12/01 00:01 [medline]
PHST- 1981/12/01 00:00 [entrez]
AID - S0022-3549(15)43980-2 [pii]
AID - 10.1002/jps.2600701213 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Dec;70(12):1341-3. doi: 10.1002/jps.2600701213.

PMID- 34118111
OWN - NLM
STAT- MEDLINE
DCOM- 20211022
LR  - 20221005
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 75
IP  - 11
DP  - 2021 Nov
TI  - Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis.
PG  - e14515
LID - 10.1111/ijcp.14515 [doi]
LID - e14515
AB  - COVID-19 infection, affecting every one of us from the last year. Emerging 
      reports have indicated thromboembolism in serious cases of COVID-19. The aspirin 
      is useful to reduce mortality of serious patients with acute respiratory distress 
      syndrome without COVID-19. Thus, we have conducted a metanalysis to find out the 
      role of aspirin in the mortality of COVID-19 patients using RevMan 5. A total of 
      10 studies containing 56 696 COVID-19 patients were found appropriate for 
      quantitative analysis. The quality of articles was assessed using 
      Newcastle-Ottawa scale. The fixed-effect model was used to calculate the odds 
      ratio with 95% confidence interval (CI). The odd ratio was found to be 0.70 
      [0.63, 0.77] which indicates a lesser likelihood of having death in COVID-19 
      patients in aspirin group as compared with non-aspirin group. However, no effect 
      0.00 [-0.04, 0.04] was observed after the exclusion of outliers. Thus, further 
      clinical evidence is required to make valid conclusion.
CI  - © 2021 John Wiley & Sons Ltd.
FAU - Srivastava, Ritika
AU  - Srivastava R
AD  - Department of Pharmacology and Clinical Research, Delhi Institute of 
      Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and 
      Research University (DPSRU), New Delhi, India.
FAU - Kumar, Anoop
AU  - Kumar A
AUID- ORCID: 0000-0002-7806-9986
AD  - Department of Pharmacology and Clinical Research, Delhi Institute of 
      Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and 
      Research University (DPSRU), New Delhi, India.
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Delhi 
      Pharmaceutical Sciences & Research University (DPSRU), New Delhi, India.
LA  - eng
PT  - Meta-Analysis
DEP - 20210628
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *COVID-19
MH  - Humans
MH  - *Respiratory Distress Syndrome
MH  - SARS-CoV-2
PMC - PMC8420464
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/06/13 06:00
MHDA- 2022/10/06 06:00
CRDT- 2021/06/12 12:16
PHST- 2021/05/11 00:00 [received]
PHST- 2021/06/06 00:00 [accepted]
PHST- 2021/06/13 06:00 [pubmed]
PHST- 2022/10/06 06:00 [medline]
PHST- 2021/06/12 12:16 [entrez]
AID - IJCP14515 [pii]
AID - 10.1111/ijcp.14515 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2021 Nov;75(11):e14515. doi: 10.1111/ijcp.14515. Epub 2021 Jun 
      28.

PMID- 31403606
OWN - NLM
STAT- MEDLINE
DCOM- 20200323
LR  - 20210108
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 134
IP  - 3
DP  - 2019 Sep
TI  - Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness 
      Analysis.
PG  - 537-544
LID - 10.1097/AOG.0000000000003413 [doi]
AB  - OBJECTIVE: To evaluate the cost effectiveness of various preeclampsia screening 
      and aspirin prophylaxis strategies, including a strategy based on biomarker and 
      ultrasound measures. METHODS: We designed a decision analysis to compare 
      preeclampsia-related costs and effects of four strategies for aspirin use in 
      pregnancy initiated before 16 weeks of gestation to prevent preeclampsia. The 
      four strategies were: 1) no aspirin use, 2) biomarker and ultrasound 
      measure-predicated use, 3) use based on the U.S. Preventive Services Task Force 
      guidelines, and 4) universal aspirin use. Our outcomes were preeclampsia-related 
      costs and number of cases per 100,000 pregnant women. Using a threshold of 
      $90,843 per case of preeclampsia, one-way, two-way, and Monte-Carlo sensitivity 
      analyses incorporating varying probabilities of risk reduction due to aspirin 
      use, aspirin-related side effects, and costs were performed to identify ranges at 
      which costs and risks of aspirin-related complications shifted the preferred 
      strategy. RESULTS: Compared with universal aspirin administration, the use of 
      U.S. Preventive Services Task Force guidelines is associated with $8,011,725 
      higher health care costs and 346 additional cases of preeclampsia per 100,000 
      pregnant women; biomarker and ultrasound screening is associated with an 
      additional $19,216,551 and 308 additional cases. Similarly, no aspirin use is 
      associated with an increased cost of $18,750,381 and 762 additional cases. Thus, 
      universal aspirin use dominated all three other strategies. In a Monte Carlo 
      simulation of 10,000 pregnant women, universal aspirin was the preferred strategy 
      in 91% of simulations. The U.S. Preventive Task Force screen was preferred in 
      8.5% of simulations, and biomarker and ultrasound screening and no aspirin were 
      preferred in 0% and 0.5% of simulations, respectively. CONCLUSION: Over a broad 
      range of assumptions, universal aspirin administration is associated with fewer 
      cases of preeclampsia and fewer costs relative to no aspirin administration and 
      aspirin administration based on serum and ultrasound measures or clinical risk 
      factors.
FAU - Mallampati, Divya
AU  - Mallampati D
AD  - Department of Obstetrics and Gynecology, Feinberg School of Medicine, 
      Northwestern University, Chicago, Illinois; and Department of Obstetrics and 
      Gynecology, Alpert Medical School, Brown University, Providence, Rhode Island.
FAU - Grobman, William
AU  - Grobman W
FAU - Rouse, Dwight J
AU  - Rouse DJ
FAU - Werner, Erika F
AU  - Werner EF
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Obstet Gynecol. 2020 Jan;135(1):217. PMID: 31856104
CIN - Obstet Gynecol. 2020 Jan;135(1):217-218. PMID: 31856105
MH  - Adult
MH  - Aspirin/*economics/therapeutic use
MH  - Biomarkers/analysis
MH  - Cost-Benefit Analysis
MH  - Decision Support Techniques
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*economics/therapeutic use
MH  - Pre-Eclampsia/*economics/*prevention & control
MH  - Pregnancy
MH  - Prenatal Diagnosis/*economics
MH  - Risk Factors
EDAT- 2019/08/14 06:00
MHDA- 2020/03/24 06:00
CRDT- 2019/08/13 06:00
PHST- 2019/08/14 06:00 [pubmed]
PHST- 2020/03/24 06:00 [medline]
PHST- 2019/08/13 06:00 [entrez]
AID - 00006250-201909000-00015 [pii]
AID - 10.1097/AOG.0000000000003413 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2019 Sep;134(3):537-544. doi: 10.1097/AOG.0000000000003413.

PMID- 19128908
OWN - NLM
STAT- MEDLINE
DCOM- 20090424
LR  - 20181201
IS  - 0398-0499 (Print)
IS  - 0398-0499 (Linking)
VI  - 34
IP  - 1
DP  - 2009 Feb
TI  - [Resistance to platelet antiaggregants: the cardiologist's point of view].
PG  - 26-33
LID - 10.1016/j.jmv.2008.11.005 [doi]
AB  - The concept of resistance to aspirin and clopidogrel, initially described in the 
      laboratory, has currently been reinforced with recent epidemiological clinical 
      data. One of the elements of particular importance for the cardiologist is the 
      possible participation of this resistance in the process of coronary stent 
      thrombosis, a problem which appeared to be solved early in the 1990s with the 
      introduction of thienopyridines. This complication has however become 
      preoccupying again, particularly when occurring late, notably since the 
      widespread use of biologically active coronary endoprostheses. Nevertheless, the 
      debate continues concerning the usefulness of the biological definition of this 
      concept since we still do not have correctly standardized coherent biological 
      tools that can be used in the clinical setting to detect "resistant" patients. 
      Since there is no real therapeutic strategy which should be applied in the event 
      of resistance, there still is little interest in developing screening methods. 
      But the cardiology community can learn from this concept. We should revisit the 
      principles of revascularization within the framework of the rules of good 
      clinical practice, without speculating about the possible therapeutic finality 
      which might develop should such and such a phenomenon occur.
FAU - Metz, D
AU  - Metz D
AD  - EA 3801, laboratoire d'hématologie biologique, service de cardiologie, centre 
      hospitalier universitaire Robert-Debré, rue du Pr-Kochman, 51092 Reims, France. 
      dmetz@chu-reims.fr
FAU - Hézard, N
AU  - Hézard N
FAU - Duval, S
AU  - Duval S
FAU - Tassan-Mangina, S
AU  - Tassan-Mangina S
FAU - Deschildre, A
AU  - Deschildre A
FAU - Brasselet, C
AU  - Brasselet C
FAU - Nguyen, P
AU  - Nguyen P
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Résistance aux antiagrégants plaquettaires : le point de vue du cardiologue.
DEP - 20090106
PL  - France
TA  - J Mal Vasc
JT  - Journal des maladies vasculaires
JID - 7707965
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cardiology/methods
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Stents
MH  - Ticlopidine/analogs & derivatives/pharmacology
RF  - 37
EDAT- 2009/01/09 09:00
MHDA- 2009/04/25 09:00
CRDT- 2009/01/09 09:00
PHST- 2008/11/06 00:00 [received]
PHST- 2008/11/19 00:00 [accepted]
PHST- 2009/01/09 09:00 [entrez]
PHST- 2009/01/09 09:00 [pubmed]
PHST- 2009/04/25 09:00 [medline]
AID - S0398-0499(08)00412-5 [pii]
AID - 10.1016/j.jmv.2008.11.005 [doi]
PST - ppublish
SO  - J Mal Vasc. 2009 Feb;34(1):26-33. doi: 10.1016/j.jmv.2008.11.005. Epub 2009 Jan 
      6.

PMID- 6371535
OWN - NLM
STAT- MEDLINE
DCOM- 19840618
LR  - 20151119
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 310
IP  - 22
DP  - 1984 May 31
TI  - Membranoproliferative glomerulonephritis. A prospective clinical trial of 
      platelet-inhibitor therapy.
PG  - 1421-6
AB  - Forty patients with Type I membranoproliferative glomerulonephritis were treated 
      for one year with dipyridamole, 225 mg per day, and aspirin, 975 mg per day, in a 
      prospective, randomized, double-blind, placebo-controlled study. At the base 
      line, the half-life of 51Cr-labeled platelets was reduced in 12 of 17 patients. 
      The platelet half-life became longer and renal function stabilized in the treated 
      group, as compared with the placebo group, suggesting a relation between platelet 
      consumption and the glomerulopathy. The glomerular filtration rate, determined by 
      iothalamate clearance, was better maintained in the treated group (average 
      decrease, 1.3 ml per minute per 1.73 m2 of body-surface area per 12 months) than 
      in the placebo group (average decrease, 19.6). Fewer patients in the treated 
      group than in the placebo group had progression to end-stage renal disease (3 of 
      21 after 62 months as compared with 9 of 19 after 33 months). The data suggest 
      that dipyridamole and aspirin slowed the deterioration of renal function and the 
      development of end-stage renal disease.
FAU - Donadio, J V Jr
AU  - Donadio JV Jr
FAU - Anderson, C F
AU  - Anderson CF
FAU - Mitchell, J C 3rd
AU  - Mitchell JC 3rd
FAU - Holley, K E
AU  - Holley KE
FAU - Ilstrup, D M
AU  - Ilstrup DM
FAU - Fuster, V
AU  - Fuster V
FAU - Chesebro, J H
AU  - Chesebro JH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Chromium Radioisotopes)
RN  - 16CHD79MIX (Iothalamic Acid)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Cell Survival/drug effects
MH  - Child
MH  - Chromium Radioisotopes
MH  - Clinical Trials as Topic
MH  - Dipyridamole/administration & dosage/pharmacology/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glomerulonephritis/*drug therapy
MH  - Half-Life
MH  - Humans
MH  - Iothalamic Acid
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Random Allocation
EDAT- 1984/05/31 00:00
MHDA- 2001/03/28 10:01
CRDT- 1984/05/31 00:00
PHST- 1984/05/31 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1984/05/31 00:00 [entrez]
AID - 10.1056/NEJM198405313102203 [doi]
PST - ppublish
SO  - N Engl J Med. 1984 May 31;310(22):1421-6. doi: 10.1056/NEJM198405313102203.

PMID- 30017552
OWN - NLM
STAT- MEDLINE
DCOM- 20180924
LR  - 20210503
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 392
IP  - 10145
DP  - 2018 Aug 4
TI  - Effects of aspirin on risks of vascular events and cancer according to bodyweight 
      and dose: analysis of individual patient data from randomised trials.
PG  - 387-399
LID - S0140-6736(18)31133-4 [pii]
LID - 10.1016/S0140-6736(18)31133-4 [doi]
AB  - BACKGROUND: A one-dose-fits-all approach to use of aspirin has yielded only 
      modest benefits in long-term prevention of cardiovascular events, possibly due to 
      underdosing in patients of large body size and excess dosing in patients of small 
      body size, which might also affect other outcomes. METHODS: Using individual 
      patient data, we analysed the modifying effects of bodyweight (10 kg bands) and 
      height (10 cm bands) on the effects of low doses (≤100 mg) and higher doses 
      (300-325 mg or ≥500 mg) of aspirin in randomised trials of aspirin in primary 
      prevention of cardiovascular events. We stratified the findings by age, sex, and 
      vascular risk factors, and validated them in trials of aspirin in secondary 
      prevention of stroke. Additionally, we assessed whether any weight or height 
      dependence was evident for the effect of aspirin on 20-year risk of colorectal 
      cancer or any in-trial cancer. RESULTS: Among ten eligible trials of aspirin in 
      primary prevention (including 117 279 participants), bodyweight varied four-fold 
      and trial median weight ranged from 60·0 kg to 81·2 kg (p<0·0001). The ability of 
      75-100 mg aspirin to reduce cardiovascular events decreased with increasing 
      weight (p(interaction)=0·0072), with benefit seen in people weighing 50-69 kg 
      (hazard ratio [HR] 0·75 [95% CI 0·65-0·85]) but not in those weighing 70 kg or 
      more (0·95 [0·86-1·04]; 1·09 [0·93-1·29] for vascular death). Furthermore, the 
      case fatality of a first cardiovascular event was increased by low-dose aspirin 
      in people weighing 70 kg or more (odds ratio 1·33 [95% CI 1·08-1·64], p=0·0082). 
      Higher doses of aspirin (≥325 mg) had the opposite interaction with bodyweight 
      (difference p(interaction)=0·0013), reducing cardiovascular events only at higher 
      weight (p(interaction)=0·017). Findings were similar in men and women, in people 
      with diabetes, in trials of aspirin in secondary prevention, and in relation to 
      height (p(interaction)=0·0025 for cardiovascular events). Aspirin-mediated 
      reductions in long-term risk of colorectal cancer were also weight dependent 
      (p(interaction)=0·038). Stratification by body size also revealed harms due to 
      excess dosing: risk of sudden death was increased by aspirin in people at low 
      weight for dose (p(interaction)=0·0018) and risk of all-cause death was increased 
      in people weighing less than 50 kg who were receiving 75-100 mg aspirin (HR 1·52 
      [95% CI 1·04-2·21], p=0·031). In participants aged 70 years or older, the 3-year 
      risk of cancer was also increased by aspirin (1·20 [1·03-1·47], p=0·02), 
      particularly in those weighing less than 70 kg (1·31 [1·07-1·61], p=0·009) and 
      consequently in women (1·44 [1·11-1·87], p=0·0069). INTERPRETATION: Low doses of 
      aspirin (75-100 mg) were only effective in preventing vascular events in patients 
      weighing less than 70 kg, and had no benefit in the 80% of men and nearly 50% of 
      all women weighing 70 kg or more. By contrast, higher doses of aspirin were only 
      effective in patients weighing 70 kg or more. Given that aspirin's effects on 
      other outcomes, including cancer, also showed interactions with body size, a 
      one-dose-fits-all approach to aspirin is unlikely to be optimal, and a more 
      tailored strategy is required. FUNDING: Wellcome Trust and National Institute for 
      Health Research Oxford Biomedical Research Centre.
CI  - Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access 
      article under the CC-BY 4.0 license. Published by Elsevier Ltd.. All rights 
      reserved.
FAU - Rothwell, Peter M
AU  - Rothwell PM
AD  - Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical 
      Neuroscience, University of Oxford, Oxford, UK. Electronic address: 
      peter.rothwell@clneuro.ox.ac.uk.
FAU - Cook, Nancy R
AU  - Cook NR
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
FAU - Gaziano, J Michael
AU  - Gaziano JM
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Price, Jacqueline F
AU  - Price JF
AD  - Usher Institute of Population Health Sciences and Informatics, University of 
      Edinburgh, Edinburgh, UK.
FAU - Belch, Jill F F
AU  - Belch JFF
AD  - Institute of Cardiovascular Research, Vascular and Inflammatory Diseases Research 
      Unit, University Division of Medicine and Therapeutics, Ninewells Hospital and 
      Medical School, Dundee, UK.
FAU - Roncaglioni, Maria Carla
AU  - Roncaglioni MC
AD  - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
FAU - Morimoto, Takeshi
AU  - Morimoto T
AD  - Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, 
      Japan.
FAU - Mehta, Ziyah
AU  - Mehta Z
AD  - Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical 
      Neuroscience, University of Oxford, Oxford, UK.
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180717
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2018 Aug 4;392(10145):361-362. PMID: 30017553
CIN - Nat Rev Cardiol. 2018 Sep;15(9):501. PMID: 30065259
CIN - Am J Nurs. 2018 Oct;118(10):69-70. PMID: 30260890
CIN - Ann Intern Med. 2018 Nov 20;169(10):JC57. PMID: 30452564
CIN - Ned Tijdschr Geneeskd. 2018 Nov 21;162:. PMID: 30500120
CIN - Internist (Berl). 2019 Feb;60(2):209-216. PMID: 30645666
CIN - Natl Med J India. 2019 Mar-Apr;32(2):97-99. PMID: 31939407
MH  - Age Factors
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Body Height
MH  - *Body Weight
MH  - Cardiovascular Diseases/epidemiology/mortality/*prevention & control
MH  - Colorectal Neoplasms/*epidemiology/prevention & control
MH  - Death, Sudden/epidemiology/prevention & control
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Proportional Hazards Models
MH  - Randomized Controlled Trials as Topic/statistics & numerical data
MH  - Risk Factors
MH  - Sex Factors
MH  - Stroke/prevention & control
PMC - PMC6083400
EDAT- 2018/07/19 06:00
MHDA- 2018/09/25 06:00
CRDT- 2018/07/19 06:00
PHST- 2018/04/27 00:00 [received]
PHST- 2018/05/11 00:00 [revised]
PHST- 2018/05/15 00:00 [accepted]
PHST- 2018/07/19 06:00 [pubmed]
PHST- 2018/09/25 06:00 [medline]
PHST- 2018/07/19 06:00 [entrez]
AID - S0140-6736(18)31133-4 [pii]
AID - 10.1016/S0140-6736(18)31133-4 [doi]
PST - ppublish
SO  - Lancet. 2018 Aug 4;392(10145):387-399. doi: 10.1016/S0140-6736(18)31133-4. Epub 
      2018 Jul 17.

PMID- 16444957
OWN - NLM
STAT- MEDLINE
DCOM- 20060314
LR  - 20131121
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 46
IP  - 4
DP  - 2005 Apr
TI  - [Significance of the stool occult blood test in patients with thrombotic disease 
      under treatment with low dose aspirin].
PG  - 254-60
AB  - We encountered lower gastrointestinal bleeding in 16 patients taking a low dose 
      of aspirin and examined the effect of low aspirin dose on the stool occult blood 
      test in 49 thrombotic patients (mean: 76.7 +/- 9.6 years old) including 39 with 
      cerebral infarction, 8 with ischemic heart disease and 2 with atrial 
      fibrillation. The mean aspirin dosage was 81 mg/day over a period of 6-288 weeks 
      (mean: 86.4 +/- 66.9 weeks). Positive occult blood test was seen in 16/49 
      (32.7%). Severe lower gastrointestinal bleeding was observed in one case (2%) 
      with colon diverticulosis. Aspirin dosage per patient was significantly higher 
      (p<0.01) in the occult blood test positive group (60.1 +/- 47.2 g) than in the 
      occult blood test negative group (42.6 +/- 32.8 g). The positive ratio of occult 
      blood test was significantly higher (p<0.01) in the aspirin and antithrombotic 
      drugs-taking group (8/5; positive/negative) than in the aspirin-taking group 
      (8/28; p/n), whereas it was not significant between the aspirin taking-group and 
      aspirin not taking-group. The odds ratio between aspirin and antithrombotic drugs 
      (warfarin, beraprost, cilostazol or ticlopidine)-taking group and the 
      aspirin-taking group was 3.47 (p<0.05). A low dose of aspirin was associated with 
      a positive occult blood test. Aspirin should be carefully administered when 
      patient has a diverticle or is taking other antithrombotic drugs.
FAU - Hayashi, Shigeru
AU  - Hayashi S
AD  - Thrombosis Chemical Institute.
FAU - Wakizaka, Akira
AU  - Wakizaka A
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/*diagnosis/epidemiology
MH  - Humans
MH  - Male
MH  - *Occult Blood
MH  - Thrombosis/*drug therapy
EDAT- 2006/02/01 09:00
MHDA- 2006/03/15 09:00
CRDT- 2006/02/01 09:00
PHST- 2006/02/01 09:00 [pubmed]
PHST- 2006/03/15 09:00 [medline]
PHST- 2006/02/01 09:00 [entrez]
PST - ppublish
SO  - Rinsho Ketsueki. 2005 Apr;46(4):254-60.

PMID- 7386801
OWN - NLM
STAT- MEDLINE
DCOM- 19800815
LR  - 20190821
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 35
IP  - 2
DP  - 1980 Mar
TI  - Sodium salicylate and aspirin disease.
PG  - 155-6
AB  - Patients with "aspirin disease" are often offered a diet devoid not only of food 
      colorants and food preservatives but also of salicylic acid. In patients reacting 
      with bronchial asthma after aspirin ingestion administration of large amounts of 
      sodium salicylate did not elicit any reaction. It is therefore concluded that a 
      less strict diet without exclusion of salicylate-containing food can be 
      recommended.
FAU - Dahl, R
AU  - Dahl R
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Aspirin/*adverse effects/immunology
MH  - Bronchial Spasm/chemically induced
MH  - Diet
MH  - Drug Hypersensitivity/*etiology
MH  - Humans
MH  - Peak Expiratory Flow Rate
MH  - *Sodium Salicylate/administration & dosage
EDAT- 1980/03/01 00:00
MHDA- 1980/03/01 00:01
CRDT- 1980/03/01 00:00
PHST- 1980/03/01 00:00 [pubmed]
PHST- 1980/03/01 00:01 [medline]
PHST- 1980/03/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1980.tb01731.x [doi]
PST - ppublish
SO  - Allergy. 1980 Mar;35(2):155-6. doi: 10.1111/j.1398-9995.1980.tb01731.x.

PMID- 20666569
OWN - NLM
STAT- MEDLINE
DCOM- 20110106
LR  - 20140730
IS  - 1175-3277 (Print)
IS  - 1175-3277 (Linking)
VI  - 10
IP  - 5
DP  - 2010
TI  - The impact of upper gastrointestinal symptoms on nonadherence to, and 
      discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular 
      risk.
PG  - 281-8
LID - 10.2165/11584410-000000000-00000 [doi]
AB  - BACKGROUND: While low-dose acetylsalicylic acid (ASA [aspirin]; 75-325 mg) is a 
      mainstay of cardiovascular (CV) protection in patients at high risk of CV events, 
      such protection may be compromised due to poor adherence (or discontinuation) 
      resulting from gastrointestinal (GI) adverse events. To date, however, the link 
      between GI adverse events and nonadherence to, and discontinuation of, low-dose 
      ASA is not well established in the literature. OBJECTIVE: The aim of this study 
      was to characterize the real-world impact of upper GI symptoms on low-dose ASA 
      nonadherence and discontinuation in patients with CV risk taking low-dose ASA for 
      CV protection. STUDY DESIGN: Multicenter, observational, noninterventional study. 
      SETTING: Primary-care, cardiology, and practice group centers in the US, Canada, 
      and France. PATIENTS: Subjects aged ≥18 years at risk of, or with confirmed, CV 
      disease, and who had been prescribed or recommended low-dose ASA (75-325 mg 
      daily) by a physician. MAIN OUTCOME MEASURE: Adherence to low-dose ASA was 
      assessed using 3 months of data prospectively collected using an electronic diary 
      (completed at least three times/day). Adherence was defined as low-dose ASA 
      intake of ≥75% over the 3-month eDiary phase. Discontinuation was defined as no 
      reported low-dose ASA intake for ≥7 continuous days. The odds of daily adherence 
      were calculated using a mixed-model analysis for repeated measures, and a 
      Cox-proportional hazard model was used to assess the association between upper GI 
      symptoms and time to discontinuation of low-dose ASA. RESULTS: Overall, 340 
      patients (mean age 50 years; 59% women) participated in the analysis. Most 
      patients (75%) were low-dose ASA naïve at inclusion, and had not experienced 
      upper GI symptoms within the previous 14 days. Among these patients, the onset of 
      upper GI symptoms was rapid; symptoms were reported by 19% of patients on the 
      first day of the study, rising to 46% of patients at the end of the first week. 
      Over the 3-month study period, 18% of patients were nonadherent to low-dose ASA 
      treatment. The occurrence of upper GI symptoms negatively affected low-dose ASA 
      adherence, in both the overall patient population (odds ratio [OR] = 0.84; 95% CI 
      0.70, 1.0) and among patients who were low-dose ASA naïve at baseline (OR = 0.76; 
      95% CI 0.57, 1.0). A total of 13% of patients discontinued low-dose ASA therapy. 
      For the overall cohort and for the low-dose ASA-naïve patients at baseline, more 
      than three episodes of upper GI symptoms during the previous week was associated 
      with an increased risk of low-dose ASA discontinuation compared with no episodes 
      of upper GI symptoms during the previous week (hazard ratio [HR] = 2.60; 95% CI 
      1.00, 6.80, and HR = 7.52; 95% CI 2.57, 22.04, respectively). CONCLUSIONS: Upper 
      GI symptoms can lead to nonadherence to, and discontinuation of, low-dose ASA 
      CV-protective therapy. Patients who initiate low-dose ASA may experience an early 
      onset of upper GI symptoms. ( TRIAL REGISTRATION NUMBER: NCT00681759 
      [ClinicalTrials.gov Identifier]; AstraZeneca study code: D961FC00004).
FAU - Pratt, Stephen
AU  - Pratt S
AD  - West Coast Research, San Ramon, CA, USA. spratt@westcoastresearch.com
FAU - Thompson, Vincent J
AU  - Thompson VJ
FAU - Elkin, Eric P
AU  - Elkin EP
FAU - Næsdal, Jørgen
AU  - Næsdal J
FAU - Sörstadius, Elisabeth
AU  - Sörstadius E
LA  - eng
SI  - ClinicalTrials.gov/NCT00681759
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Humans
MH  - Male
MH  - *Medication Adherence
MH  - Middle Aged
EDAT- 2010/07/30 06:00
MHDA- 2011/01/07 06:00
CRDT- 2010/07/30 06:00
PHST- 2010/07/30 06:00 [entrez]
PHST- 2010/07/30 06:00 [pubmed]
PHST- 2011/01/07 06:00 [medline]
AID - 10.2165/11584410-000000000-00000 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2010;10(5):281-8. doi: 10.2165/11584410-000000000-00000.

PMID- 11145135
OWN - NLM
STAT- MEDLINE
DCOM- 20010419
LR  - 20190706
IS  - 0009-2363 (Print)
IS  - 0009-2363 (Linking)
VI  - 48
IP  - 12
DP  - 2000 Dec
TI  - Development of spherical crystals of acetylsalicylic acid for direct 
      tablet-making.
PG  - 1877-81
AB  - The production of spherical crystals has recently gained great attention due to 
      the fact that the crystal habit (form, surface, size, etc.) can be modified 
      during the crystallization process. Spherical crystals of ASA were developed by 
      non-typical and typical spherical crystallization techniques. The non-typical 
      spherical crystallization process (conventional stirred tank method) resulted in 
      few monocrystals and non-spherical crystal agglomerates. The typical spherical 
      crystallization process was carried out by the three solvent-system 
      (ethanol-water-carbon tetrachloride). The products were qualified by 
      morphological study, NIR investigation, salicylic acid content, dissolution rate, 
      studies on flowability, compactibility, cohesivity and tablettability. The 
      results demonstrate that only typical spherical crystallization can be 
      recommended for the production of spherical crystals of ASA. Only product made by 
      this technique shows excellent flow properties and favourable compactibility, 
      cohesiveness and tablettability values.
FAU - Göczõ, H
AU  - Göczõ H
AD  - University of Szeged, Faculty of Pharmacy, Pharmaceutical Technology Department, 
      Hungary.
FAU - Szabó-Révész, P
AU  - Szabó-Révész P
FAU - Farkas, B
AU  - Farkas B
FAU - Hasznos-Nezdei, M
AU  - Hasznos-Nezdei M
FAU - Serwanis, S F
AU  - Serwanis SF
FAU - Pintye-Hódi, A K
AU  - Pintye-Hódi AK
FAU - Kása, P Jr
AU  - Kása P Jr
FAU - Erõs, I
AU  - Erõs I
FAU - Antal, I
AU  - Antal I
FAU - Marto, S
AU  - Marto S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - 0 (Solvents)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Particle Size
MH  - Solvents/chemistry
MH  - *Tablets/chemistry
EDAT- 2001/01/06 11:00
MHDA- 2001/04/21 10:01
CRDT- 2001/01/06 11:00
PHST- 2001/01/06 11:00 [pubmed]
PHST- 2001/04/21 10:01 [medline]
PHST- 2001/01/06 11:00 [entrez]
AID - 10.1248/cpb.48.1877 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 2000 Dec;48(12):1877-81. doi: 10.1248/cpb.48.1877.

PMID- 9893756
OWN - NLM
STAT- MEDLINE
DCOM- 19990129
LR  - 20190512
IS  - 1460-2725 (Print)
IS  - 1460-2393 (Linking)
VI  - 91
IP  - 8
DP  - 1998 Aug
TI  - Aspirin: benefit and risk in thromboprophylaxis.
PG  - 523-38
AB  - Aspirin is often perceived either as a harmless panacea or as a useless poison 
      which causes endless, needless trouble. We have carefully reviewed the literature 
      on all aspects of aspirin and find that neither view is justified. Regular use of 
      even low-dose aspirin (150 mg/day or less) may lead to clinically-important 
      adverse events, particularly haemorrhage. The risk of such an event is 
      considerably outweighed by the benefit for patients with a significant risk of a 
      thromboembolic event. For individuals without a clear risk of thrombosis or 
      thromboembolism, the balance is more even: indiscriminate aspirin-taking is to be 
      discouraged.
FAU - Dickinson, J P
AU  - Dickinson JP
AD  - Division of Medicine, General Infirmary, Leeds, UK.
FAU - Prentice, C R
AU  - Prentice CR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - QJM
JT  - QJM : monthly journal of the Association of Physicians
JID - 9438285
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Loss, Surgical
MH  - Case-Control Studies
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Thromboembolism/*prevention & control
RF  - 125
EDAT- 1999/01/20 00:00
MHDA- 1999/01/20 00:01
CRDT- 1999/01/20 00:00
PHST- 1999/01/20 00:00 [pubmed]
PHST- 1999/01/20 00:01 [medline]
PHST- 1999/01/20 00:00 [entrez]
AID - 10.1093/qjmed/91.8.523 [doi]
PST - ppublish
SO  - QJM. 1998 Aug;91(8):523-38. doi: 10.1093/qjmed/91.8.523.

PMID- 1627709
OWN - NLM
STAT- MEDLINE
DCOM- 19920819
LR  - 20191028
IS  - 1035-7319 (Print)
IS  - 1035-7319 (Linking)
VI  - 16
IP  - 1
DP  - 1992 Mar
TI  - Aspirin use in children: heeding the warning?
PG  - 35-7
AB  - In 1986, the Australian Government issued warnings about the use of aspirin for 
      children and adolescents after the link had been established between aspirin use 
      and Reye's syndrome in America. This study questioned a representative community 
      sample of parents in Newcastle, New South Wales, about their awareness of this 
      caution, and their recent aspirin use for children under 18 years. While 65% of 
      women and 47% of men reported that they were aware of the Government 
      recommendations, only 8% of women and 9% of men reported obtaining this 
      information from the printed warning on the medicine container or packet. Despite 
      awareness of the warnings, almost one third of parents reported administering 
      aspirin to their children. When it is necessary to caution patients about the use 
      of over-the-counter medications, it is not sufficient to use package labelling as 
      the main site of information.
FAU - Hancock, L
AU  - Hancock L
AD  - University of Newcastle, Faculty of Medicine, NSW.
FAU - Henry, D A
AU  - Henry DA
FAU - Sanson-Fisher, R W
AU  - Sanson-Fisher RW
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust J Public Health
JT  - Australian journal of public health
JID - 9105166
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Australia
MH  - Child
MH  - Child, Preschool
MH  - *Drug Labeling
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Parents
MH  - Reye Syndrome/*chemically induced
EDAT- 1992/03/01 00:00
MHDA- 1992/03/01 00:01
CRDT- 1992/03/01 00:00
PHST- 1992/03/01 00:00 [pubmed]
PHST- 1992/03/01 00:01 [medline]
PHST- 1992/03/01 00:00 [entrez]
AID - 10.1111/j.1753-6405.1992.tb00022.x [doi]
PST - ppublish
SO  - Aust J Public Health. 1992 Mar;16(1):35-7. doi: 
      10.1111/j.1753-6405.1992.tb00022.x.

PMID- 19544525
OWN - NLM
STAT- MEDLINE
DCOM- 20100209
LR  - 20131121
IS  - 1520-6017 (Electronic)
IS  - 0022-3549 (Linking)
VI  - 98
IP  - 12
DP  - 2009 Dec
TI  - An examination of binding motifs associated with inter-particle interactions 
      between facetted nano-crystals of acetylsalicylic acid and ascorbic acid through 
      the application of molecular grid-based search methods.
PG  - 4589-602
LID - 10.1002/jps.21758 [doi]
AB  - Grid-based intermolecular search methods using atom-atom force fields are used to 
      assess the structural nature of potential crystal-crystal interfacial binding 
      associated with the examination of representative pharmaceutical formulation 
      components, viz acetylsalicylic acid (aspirin) and ascorbic acid (vitamin C). 
      Molecular models of nano-sized molecular clusters for these two compounds, shaped 
      in accordance with an attachment energy model of the respective particle 
      morphologies, are constructed and used together with a grid-based search method 
      to model the likely inter-particle interactions. The most-stable, mutual 
      alignments of the respective nano-clusters based on their interaction energies 
      are identified in the expectation that these are indicative of the most likely 
      inter-particle binding configurations. The stable inter-particle binding 
      configurations identified reveal that the number of interfacial hydrogen bonds 
      formed between the binding particles is, potentially, an important factor in 
      terms of the stability of inter-particle cohesion. All preferred inter-particle 
      alignments are found to involve either the (1 0 0) or the (1 1 0) face of aspirin 
      crystals interacting with a number of the growth forms of ascorbic acid. Four 
      main types of interfacial hydrogen bonds are found to be associated with 
      inter-particle binding and involve acceptor-donor interactions between hydroxyl, 
      carbonyl, ester and lactone acceptor groups and hydroxyl donor groups. This 
      hydrogen bonding network is found to be consistent with the surface chemistry of 
      the interacting habit faces with, in general, the number of hydrogen bonds 
      increasing for the more stable alignments. The likely usefulness of this approach 
      for predicting solid-state formulation properties is reviewed.
CI  - 2009 Wiley-Liss, Inc. and the American Pharmacists Association
FAU - Hammond, R B
AU  - Hammond RB
AD  - Institute of Particle Science and Engineering, School of Process, Environmental 
      and Materials Engineering, University of Leeds, Leeds LS2 9JT, UK.
FAU - Jeck, S
AU  - Jeck S
FAU - Ma, C Y
AU  - Ma CY
FAU - Pencheva, K
AU  - Pencheva K
FAU - Roberts, K J
AU  - Roberts KJ
FAU - Auffret, T
AU  - Auffret T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/*chemistry
MH  - Aspirin/*chemistry
MH  - Hydrogen Bonding
MH  - Models, Chemical
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Nanoparticles
EDAT- 2009/06/23 09:00
MHDA- 2010/02/10 06:00
CRDT- 2009/06/23 09:00
PHST- 2009/06/23 09:00 [entrez]
PHST- 2009/06/23 09:00 [pubmed]
PHST- 2010/02/10 06:00 [medline]
AID - S0022-3549(16)33182-3 [pii]
AID - 10.1002/jps.21758 [doi]
PST - ppublish
SO  - J Pharm Sci. 2009 Dec;98(12):4589-602. doi: 10.1002/jps.21758.

PMID- 16081182
OWN - NLM
STAT- MEDLINE
DCOM- 20051214
LR  - 20161124
IS  - 0168-3659 (Print)
IS  - 0168-3659 (Linking)
VI  - 107
IP  - 2
DP  - 2005 Oct 3
TI  - Finite element analysis of the release of slowly dissolving drugs from 
      cylindrical matrix systems.
PG  - 320-9
AB  - Drug release from matrix systems of cylindrical shape is analyzed in detail by 
      using the finite element method. The model used combines the Noyes-Whitney and 
      diffusion equations, and thus takes the effects of a finite dissolution rate into 
      account. The model is valid for all drug solubilities and dissolution rates, and 
      allows accurate predictions of the drug release to be made. Anisotropic drug 
      transport that may result from the manufacturing process is properly accounted 
      for. Model calculations show that a finite dissolution rate may affect the 
      release profile significantly, producing an initial delay. The equivalence 
      between anisotropic release and isotropic release from a matrix with different 
      dimensions is demonstrated. Comparisons are made with the predictions of a 
      recently proposed pseudo-steady state (PSS) analysis of drug release from 
      cylindrical matrices [Y. Zhou, J. S. Chu, T. Zhou, X. Y. Wu, Modeling of 
      dispersed-drug release from two-dimensional matrix tablets, Biomaterials 26 
      (2005) 945-952]. This comparison reveals that important discrepancies exist 
      between the numerical and analytical results, which are attributed to the 
      simplifying assumption made in the PSS analysis that the region containing solid 
      drug remains cylindrical in shape throughout the release process. The proposed 
      model is shown to describe experimental release data well.
FAU - Frenning, Göran
AU  - Frenning G
AD  - Department of Pharmacy, Uppsala University, Uppsala Biomedical Center, P. O. Box 
      580, SE-751 23 Uppsala, Sweden. Goran.Frenning@farmaci.uu.se
FAU - Brohede, Ulrika
AU  - Brohede U
FAU - Strømme, Maria
AU  - Strømme M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Drug Carriers)
RN  - 0 (Tablets)
RN  - 7Z8S9VYZ4B (ethyl cellulose)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Anisotropy
MH  - Aspirin/administration & dosage/chemistry
MH  - Cellulose/analogs & derivatives
MH  - Chemistry, Pharmaceutical/*statistics & numerical data
MH  - Diffusion
MH  - Drug Carriers
MH  - *Finite Element Analysis
MH  - Models, Statistical
MH  - Solubility
MH  - Tablets
EDAT- 2005/08/06 09:00
MHDA- 2005/12/15 09:00
CRDT- 2005/08/06 09:00
PHST- 2005/01/21 00:00 [received]
PHST- 2005/05/17 00:00 [revised]
PHST- 2005/06/30 00:00 [accepted]
PHST- 2005/08/06 09:00 [pubmed]
PHST- 2005/12/15 09:00 [medline]
PHST- 2005/08/06 09:00 [entrez]
AID - S0168-3659(05)00301-9 [pii]
AID - 10.1016/j.jconrel.2005.06.016 [doi]
PST - ppublish
SO  - J Control Release. 2005 Oct 3;107(2):320-9. doi: 10.1016/j.jconrel.2005.06.016.

PMID- 10766315
OWN - NLM
STAT- MEDLINE
DCOM- 20000614
LR  - 20190814
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 35
IP  - 3
DP  - 2000 Mar
TI  - Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in 
      man.
PG  - 242-6
AB  - BACKGROUND: Experimental studies have shown that omeprazole and other 
      anti-inflammatory agents compromise the therapeutic activity of nonsteroidal 
      anti-inflammatory drugs and aspirin in rats. It is not known whether this effect 
      will occur in humans. Our aim was to determine whether omeprazole affects the 
      antiplatelet effects of low-dose aspirin in humans. METHODS: Platelet 
      lumiaggregation, skin bleeding time, plasma levels of aspirin and salicylic acid, 
      and serum gastrin levels were determined in 14 healthy men before and after the 
      ingestion of 125 mg aspirin with or without previous treatment with 20 mg/day of 
      omeprazole for 4 days before testing. RESULTS: Omeprazole increased serum gastrin 
      levels from 64 (median; range, 52-91) pg/ml to 80.5 (median; range, 56-455) pg/ml 
      (P < 0.05) but did not significantly affect the plasma concentration of aspirin 
      or salicylic acid. Aspirin increased skin bleeding time in all subjects, and the 
      increase was similar with and without previous omeprazole treatment. Aspirin 
      inhibited platelet aggregation in response to both collagen and arachidonic acid 
      regardless of omeprazole treatment. CONCLUSION: A single dose of 20 mg omeprazole 
      daily does not interfere with the biologic activity of 125 mg aspirin on 
      platelets in humans.
FAU - Iñarrea, P
AU  - Iñarrea P
AD  - Services of Gastroenterology, Hematology, and Biochemistry, University Hospital, 
      Zaragoza, Spain.
FAU - Esteva, F
AU  - Esteva F
FAU - Cornudella, R
AU  - Cornudella R
FAU - Lanas, A
AU  - Lanas A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Ulcer Agents/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Drug Interactions
MH  - Humans
MH  - Male
MH  - Omeprazole/*pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Time Factors
EDAT- 2000/04/15 09:00
MHDA- 2000/06/17 09:00
CRDT- 2000/04/15 09:00
PHST- 2000/04/15 09:00 [pubmed]
PHST- 2000/06/17 09:00 [medline]
PHST- 2000/04/15 09:00 [entrez]
AID - 10.1080/003655200750024083 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2000 Mar;35(3):242-6. doi: 10.1080/003655200750024083.

PMID- 3103169
OWN - NLM
STAT- MEDLINE
DCOM- 19870420
LR  - 20190824
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 32
IP  - 5
DP  - 1986 Nov
TI  - Effects of 1 gram oral or intravenous aspirin on urinary excretion of thromboxane 
      B2 and 6-keto-PGF1 alpha in healthy subjects.
PG  - 691-701
AB  - Aspirin inhibits cyclo-oxygenase, thus preventing prostanoids formation. After 
      oral administration aspirin is hydrolysed to inactive salicylate partly within 
      the gastrointestinal tract, partly during first pass in the liver, partly in the 
      circulation by plasma esterases. Intravenous aspirin, in contrast, mainly 
      undergoes plasma esterase-catalysed deacetylation. Six healthy male subjects were 
      given 1 g aspirin orally and intravenously two weeks apart according to a 
      cross-over randomized design. Whereas serum TxB2 generation reflecting platelet 
      cyclo-oxygenase activity was suppressed by aspirin by both routes, urinary 
      excretion of TxB2 and 6-keto-PGF1 alpha was not affected by oral aspirin, but was 
      partially though significantly reduced by the i.v. drug. Drug disposition seems 
      therefore to be essential in determining the "biochemical selectivity" of aspirin 
      as related to platelet and renal prostanoids generation.
FAU - Bucchi, F
AU  - Bucchi F
FAU - Bodzenta, A
AU  - Bodzenta A
FAU - de Gaetano, G
AU  - de Gaetano G
FAU - Cerletti, C
AU  - Cerletti C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - EC 3.1.- (Esterases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/*urine
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*administration & dosage/metabolism/pharmacology
MH  - Biotransformation
MH  - Blood Platelets/enzymology
MH  - Cyclooxygenase Inhibitors
MH  - Esterases/blood
MH  - Humans
MH  - Injections, Intravenous
MH  - Kidney/drug effects/metabolism
MH  - Male
MH  - Thromboxane B2/*urine
EDAT- 1986/11/01 00:00
MHDA- 1986/11/01 00:01
CRDT- 1986/11/01 00:00
PHST- 1986/11/01 00:00 [pubmed]
PHST- 1986/11/01 00:01 [medline]
PHST- 1986/11/01 00:00 [entrez]
AID - 0090-6980(86)90191-7 [pii]
AID - 10.1016/0090-6980(86)90191-7 [doi]
PST - ppublish
SO  - Prostaglandins. 1986 Nov;32(5):691-701. doi: 10.1016/0090-6980(86)90191-7.

PMID- 1151713
OWN - NLM
STAT- MEDLINE
DCOM- 19751106
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 64
IP  - 8
DP  - 1975 Aug
TI  - Differentiating nonaqueous titration of aspirin, acetaminophen, and salicylamide 
      mixtures.
PG  - 1386-8
AB  - Mixtures containing aspirin, acetaminophen, and salicylamide were assayed 
      potentiometrically by nonaqueous titration. The difference in pKa values for 
      these weak acids was sufficient to permit successful differentiation. The titrant 
      was tetrabutylammonium hydroxide, and the titration solvent was 
      dimethylformamide. The procedure was applied to commercial dosage forms.
FAU - Rhodes, H J
AU  - Rhodes HJ
FAU - DeNardo, J J
AU  - DeNardo JJ
FAU - Bode, D W
AU  - Bode DW
FAU - Blake, M I
AU  - Blake MI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Drug Combinations)
RN  - 0 (Salicylamides)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Aspirin/*analysis
MH  - Drug Combinations
MH  - Electrodes
MH  - Methods
MH  - Salicylamides/*analysis
MH  - Tablets/analysis
EDAT- 1975/08/01 00:00
MHDA- 1975/08/01 00:01
CRDT- 1975/08/01 00:00
PHST- 1975/08/01 00:00 [pubmed]
PHST- 1975/08/01 00:01 [medline]
PHST- 1975/08/01 00:00 [entrez]
AID - S0022-3549(15)40317-X [pii]
AID - 10.1002/jps.2600640828 [doi]
PST - ppublish
SO  - J Pharm Sci. 1975 Aug;64(8):1386-8. doi: 10.1002/jps.2600640828.

PMID- 3588140
OWN - NLM
STAT- MEDLINE
DCOM- 19870707
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 79
IP  - 6
DP  - 1987 Jun
TI  - National patterns of aspirin use and Reye syndrome reporting, United States, 1980 
      to 1985.
PG  - 858-63
AB  - The number of cases of Reye syndrome reported annually to the Centers for Disease 
      Control declined markedly between 1980 and 1985. In this article, we present 
      pharmaceutical marketing research data that suggest sharp decreases in the use 
      and purchase of children's aspirin between 1980 and 1985. These trends appear to 
      correspond to the decrease in reporting of Reye syndrome cases. Additionally, 
      analysis of physician mentions of aspiring and acetaminophen for treating flu and 
      chickenpox showed statistically significant trends toward decreasing 
      recommendations for the use of aspirin and significant trends toward increasing 
      recommendations for use of acetaminophen. Trends in wholesale purchases of 
      aspirin and acetaminophen by drug stores from 1979 through 1985 demonstrated a 
      significant decline for the 81-mg children's aspirin tablet and an increase in 
      purchases of children's acetaminophen products. Many factors may influence 
      physician and parents' choice of analgesic/antipyretic medication, including 
      information about Reye syndrome. Data suggest that a continuing decline in the 
      use of aspirin for children may be accompanied by a continuing decline in the 
      reported number of Reye syndrome cases.
FAU - Arrowsmith, J B
AU  - Arrowsmith JB
FAU - Kennedy, D L
AU  - Kennedy DL
FAU - Kuritsky, J N
AU  - Kuritsky JN
FAU - Faich, G A
AU  - Faich GA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Adult
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Child
MH  - Drug Utilization/trends
MH  - Humans
MH  - Middle Aged
MH  - Reye Syndrome/chemically induced/*epidemiology
MH  - United States
EDAT- 1987/06/01 00:00
MHDA- 1987/06/01 00:01
CRDT- 1987/06/01 00:00
PHST- 1987/06/01 00:00 [pubmed]
PHST- 1987/06/01 00:01 [medline]
PHST- 1987/06/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1987 Jun;79(6):858-63.

PMID- 2222866
OWN - NLM
STAT- MEDLINE
DCOM- 19901206
LR  - 20181113
IS  - 0114-5916 (Print)
IS  - 0114-5916 (Linking)
VI  - 5
IP  - 5
DP  - 1990 Sep-Oct
TI  - Adverse reactions and interactions with aspirin. Considerations in the treatment 
      of the elderly patient.
PG  - 317-27
AB  - Aspirin (acetylsalicylic acid) is probably the most frequently used medication, 
      and its use is generally uneventful. However, aspirin is also noted for numerous 
      side effects and drug interactions that can complicate the course of therapy. The 
      elderly, especially those with complicated medical histories, are more prone to 
      the adverse effects of salicylates and may develop gastrointestinal tract 
      bleeding, renal insufficiency, asthma and CNS toxicity. In the clinical 
      situation, important drug interactions can occur with concurrent use of 
      anticoagulants, sulphonylureas, diuretics, methotrexate and antacids. In long 
      term aspirin therapy, enteric-coated or nonacetylated forms of aspirin are 
      associated with fewer side effects and may be better tolerated. Monitoring of 
      therapy (especially in the higher risk patient), with frequent assessments of the 
      clinical state and measurements of serum creatinine, electrolytes and salicylate 
      concentrations, may diminish the likelihood of toxicity.
FAU - Karsh, J
AU  - Karsh J
AD  - Division of Rheumatology, Ottawa General Hospital, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aging/*physiology
MH  - Aspirin/*adverse effects
MH  - Drug Interactions
MH  - Humans
RF  - 74
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
AID - 10.2165/00002018-199005050-00002 [doi]
PST - ppublish
SO  - Drug Saf. 1990 Sep-Oct;5(5):317-27. doi: 10.2165/00002018-199005050-00002.

PMID- 4074576
OWN - NLM
STAT- MEDLINE
DCOM- 19860217
LR  - 20131121
IS  - 0006-8969 (Print)
IS  - 0006-8969 (Linking)
VI  - 37
IP  - 10
DP  - 1985 Oct
TI  - [Anti-platelet therapy in ischemic cerebrovascular disorder--clinical and 
      hematological study].
PG  - 985-90
AB  - Anti-platelet therapy (Aspirin 250 mg/every other day approximately 1000 mg/day + 
      Dipyridamole 150 mg/day) was performed on 51 patients with ischemic 
      cerebrovascular disorders (ICVD). Among these patients, 41 cases showed no 
      recurrence of ICVD attack, whereas the remaining 10 cases had re-attacks. These 2 
      groups were compared from the viewpoint of various risk factors and other 
      clinical findings: e.g. CT scan and angiographic appearance. But there was no 
      statistically significant difference between them. Platelet aggregability and 
      platelet survival time were examined in twenty-eight patients out of cases. We 
      used a simple nonradioisotope technic for the determination of platelet survival 
      time. Platelet survival time was shortened in 22 of 28 (79%) patients. On the 
      other hand, platelet aggregability was found to have no definite tendency. In 9 
      of 10 cases, platelet survival time was revealed to be prolonged several months 
      after administration of anti-platelet drugs. There was no re-attack in 7 of these 
      9 patients. Some reports also showed that platelet survival time was shortened in 
      various thromboembolism and recovered by anti-platelet drugs. Measurement of 
      platelet survival time is thought to be an important method as to the indication 
      and the monitoring of anti-platelet therapy.
FAU - Yoshii, K
AU  - Yoshii K
FAU - Seki, Y
AU  - Seki Y
FAU - Aiba, T
AU  - Aiba T
FAU - Tsukada, T
AU  - Tsukada T
FAU - Shiozawa, R
AU  - Shiozawa R
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - No To Shinkei
JT  - No to shinkei = Brain and nerve
JID - 0413550
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*physiology
MH  - Cell Survival
MH  - Cerebrovascular Disorders/blood/*drug therapy
MH  - Dipyridamole/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
EDAT- 1985/10/01 00:00
MHDA- 1985/10/01 00:01
CRDT- 1985/10/01 00:00
PHST- 1985/10/01 00:00 [pubmed]
PHST- 1985/10/01 00:01 [medline]
PHST- 1985/10/01 00:00 [entrez]
PST - ppublish
SO  - No To Shinkei. 1985 Oct;37(10):985-90.

PMID- 32910441
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20210707
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 80
IP  - 14
DP  - 2020 Sep
TI  - Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD.
PG  - 1465-1475
LID - 10.1007/s40265-020-01397-7 [doi]
AB  - Secondary cardiovascular (CV) prevention in patients with vascular disease [e.g. 
      coronary (CAD) and peripheral (PAD) artery disease] is crucial and typically 
      involves antiplatelet therapy with aspirin; however, managing residual ischaemic 
      and bleeding risks in CV disease (CVD) remains a challenge. Combining the oral 
      anticoagulant rivaroxaban (Xarelto(®)) with aspirin targets both the platelet and 
      thrombotic processes of atherosclerosis, a common pathophysiological process 
      associated with CVD. In the global COMPASS trial (n > 27,000), rivaroxaban 2.5 mg 
      twice daily plus aspirin 100 mg once daily (vs aspirin alone) significantly 
      reduced the risk of the primary composite major adverse CV event (MACE) outcome 
      (i.e. myocardial infarction, stroke or CV death) in adults with stable CAD and/or 
      PAD and, in those with PAD, significantly reduced the risk of the composite major 
      adverse limb event (MALE) outcome. Rivaroxaban + aspirin treatment was generally 
      well tolerated; however, the risk of the composite major bleeding outcome, but 
      not intracranial or fatal bleeding, was significantly higher with 
      rivaroxaban + aspirin than aspirin. The increased risk for the composite major 
      bleeding outcome did not negate the composite net clinical benefits of 
      rivaroxaban + aspirin for secondary CV prevention, with rivaroxaban + aspirin 
      especially beneficial in those with a greater CV risk at baseline. Ongoing 
      clinical experience is required to fully define the role of rivaroxaban + aspirin 
      in secondary CV prevention. In the meantime, dual therapy with 
      rivaroxaban + aspirin is an important emerging option for secondary CV prevention 
      of atherothrombotic events in adults with CAD or symptomatic PAD who are at high 
      risk of ischaemic events.
FAU - Scott, Lesley J
AU  - Scott LJ
AD  - Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
      demail@springer.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anticoagulants)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Rivaroxaban/administration & dosage/*therapeutic use
MH  - Secondary Prevention
EDAT- 2020/09/11 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/09/10 12:28
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/09/10 12:28 [entrez]
AID - 10.1007/s40265-020-01397-7 [pii]
AID - 10.1007/s40265-020-01397-7 [doi]
PST - ppublish
SO  - Drugs. 2020 Sep;80(14):1465-1475. doi: 10.1007/s40265-020-01397-7.

PMID- 2389117
OWN - NLM
STAT- MEDLINE
DCOM- 19900921
LR  - 20191022
IS  - 0284-4311 (Print)
IS  - 0284-4311 (Linking)
VI  - 24
IP  - 1
DP  - 1990
TI  - Low dose ASA (4 mg/kg) peroperatively does not prevent in vivo platelet 
      accumulation at microarterial anastomotic sites. An experimental study in the 
      rabbit.
PG  - 21-6
AB  - Twenty microarterial end-to-end anastomoses were performed on the central 
      arteries of the ears in 12 rabbits divided into two groups: Group A (10 
      anastomoses) served as control and Group B (10 anastomoses) was treated with 4 mg 
      ASA per kg b.w. given as a single intraaortical dose 5 min prior to infusion of 
      32P-labelled platelets. Two hours later blood-flow was reestablished after 
      end-to-end anastomoses. Anastomotic bleeding-times, qualitative and quantitative 
      differences in platelet accumulation and patency were registered. In addition, 
      platelet aggregability and thromboxane production were studied in 3 rabbits. The 
      bleeding-times (median and quartiles) in group A were 3(+0)-2 min and in group B 
      3(+2)-0 min. In vivo accumulation of 32P-labelled platelets was somewhat 
      increased initially (p less than 0.05) in the ASA group. Poor patency was 
      registered in two vessels, one in each group, all other vessels having good 
      patency. Aspirin peroperatively in low doses (4 mg/kg) did not markedly affect 
      bleeding-times or patency rates in microarterial anastomoses, but platelet 
      accumulation in vivo was initially increased. The radioactivity values decreased 
      with time in all aspirin cases but only in 50% of the control group vessels, 
      suggesting efficient platelet disaggregation/fibrinolysis. This might favour the 
      view that PGI2 production in the endothelium recovers more rapidly than the 
      pro-aggregatory mechanisms affected by ASA. ASA-treatment led to almost complete 
      inhibition of thromboxane production for at least four hours, but, despite this, 
      a moderate decrease in platelet aggregability occurred only when collagen was 
      used as stimulant.
FAU - Wieslander, J B
AU  - Wieslander JB
AD  - Department of Plastic and Reconstructive Surgery, Malmö General Hospital, Sweden.
FAU - Dougan, P
AU  - Dougan P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Plast Reconstr Surg Hand Surg
JT  - Scandinavian journal of plastic and reconstructive surgery and hand surgery
JID - 8707869
RN  - 0 (Phosphorus Radioisotopes)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anastomosis, Surgical
MH  - Animals
MH  - Arteries/*surgery
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Ear/blood supply
MH  - Phosphorus Radioisotopes
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
MH  - Rats
MH  - Thromboxanes/metabolism
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.3109/02844319009004515 [doi]
PST - ppublish
SO  - Scand J Plast Reconstr Surg Hand Surg. 1990;24(1):21-6. doi: 
      10.3109/02844319009004515.

PMID- 7353465
OWN - NLM
STAT- MEDLINE
DCOM- 19800425
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 25
IP  - 2
DP  - 1980 Feb
TI  - Acute effect of systemic aspirin on gastric mucosa in man.
PG  - 97-9
AB  - Aspirin was administered intravenously to study its effect upon gastric mucosa at 
      high blood levels in the therapeutic range for rheumatic diseases. Five healthy 
      volunteers were studied twice each with intravenous aspirin (3 g over 2 hr) and 
      isotonic saline infusion as control. In one study, gastric potential difference 
      was measured; in the other, coded gastric biopsies were taken sequentially prior 
      to infusion, and at the end of infusion. Duplicate biopsies were taken for light 
      and scanning electron microscopy. Mean potential difference at the end of the 
      intravenous aspirin infusions was -47.7 +/- 1.4 mV, compared with saline, -51.1 
      +/- 2.5 mV (P greater than 0.05). The percentage of cells damaged after 2 hr 
      intravenous infusion of aspirin (3.2 +/- 0.4%) was not significantly different 
      from that after intravenous saline (2.6 +/- 0.3%). In contrast to oral aspirin, 
      acute administration of aspirin parenterally does not produce detectable 
      histological damage in man, nor does it significantly alter gastric mucosal 
      potential difference. We conclude that high blood levels of circulating 
      salicylate do not acutely damage gastric mucosa. Thus, histologic gastric mucosal 
      damage produced acutely after single oral doses of aspirin are due to its 
      topical, rather than systemic, action.
FAU - Ivey, K J
AU  - Ivey KJ
FAU - Paone, D B
AU  - Paone DB
FAU - Krause, W J
AU  - Krause WJ
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Gastric Mucosa/drug effects/*pathology/ultrastructure
MH  - Humans
MH  - Infusions, Parenteral
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
AID - 10.1007/BF01308304 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1980 Feb;25(2):97-9. doi: 10.1007/BF01308304.

PMID- 25795564
OWN - NLM
STAT- MEDLINE
DCOM- 20160119
LR  - 20150429
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 135
IP  - 5
DP  - 2015 May
TI  - Comparative efficacy and safety of anticoagulants and aspirin for extended 
      treatment of venous thromboembolism: A network meta-analysis.
PG  - 888-96
LID - S0049-3848(15)00104-8 [pii]
LID - 10.1016/j.thromres.2015.02.032 [doi]
AB  - OBJECTIVE: To systematically review the literature and to quantitatively evaluate 
      the efficacy and safety of extended pharmacologic treatment of venous 
      thromboembolism (VTE) through network meta-analysis (NMA). METHODS: A systematic 
      literature search (MEDLINE, Embase, Cochrane CENTRAL, through September 2014) and 
      searching of reference lists of included studies and relevant reviews was 
      conducted to identify randomized controlled trials of patients who completed 
      initial anticoagulant treatment for VTE and then randomized for the extension 
      study; compared extension of anticoagulant treatment to placebo or active 
      control; and reported at least one outcome of interest (VTE or a composite of 
      major bleeding or clinically relevant non-major bleeding). A random-effects 
      Frequentist approach to NMA was used to calculate relative risks with 95% 
      confidence intervals. RESULTS: Ten trials (n=11,079) were included. Risk of bias 
      (assessed with the Cochrane tool) was low in most domains assessed across the 
      included trials. Apixaban (2.5mg and 5mg), dabigatran, rivaroxaban, idraparinux 
      and vitamin K antagonists (VKA) each significantly reduced the risk of VTE 
      recurrence compared to placebo, ranging from a 73% reduction with idraparinux to 
      86% with VKAs. With exception of idraparinux, all active therapies significantly 
      reduced VTE recurrence risk versus aspirin, ranging from a 73% reduction with 
      either apixaban 2.5mg or rivaroxaban to 80% with VKAs. Apixaban and aspirin were 
      the only therapies that did not increase composite bleeding risk significantly 
      compared to placebo. All active therapies except aspirin increased risk of 
      composite bleeding by 2 to 4-fold compared to apixaban 2.5mg, with no difference 
      found between the two apixaban doses. CONCLUSION: Extended treatment of VTE is a 
      reasonable approach to provide continued protection from VTE recurrence although 
      bleeding risk is variable across therapeutic options. Our results indicate that 
      apixaban, dabigatran, rivaroxaban, idraparinux and VKAs all reduced VTE 
      recurrence when compared to placebo. Apixaban appears to have a more favorable 
      safety profile compared to other therapies.
CI  - Copyright © 2015 Elsevier Ltd. All rights reserved.
FAU - Sobieraj, Diana M
AU  - Sobieraj DM
AD  - University of Connecticut School of Pharmacy, Department of Pharmacy Practice, 69 
      North Eagleville Rd Unit 3092, Storrs, CT 06269, USA. Electronic address: 
      Diana.sobieraj@hhchealth.org.
FAU - Coleman, Craig I
AU  - Coleman CI
AD  - University of Connecticut School of Pharmacy, Department of Pharmacy Practice, 69 
      North Eagleville Rd Unit 3092, Storrs, CT 06269, USA. Electronic address: 
      craig.coleman@hhchealth.org.
FAU - Pasupuleti, Vinay
AU  - Pasupuleti V
AD  - Case Cardiovascular Research Institute, Department of Medicine, Case Western 
      Reserve University School of Medicine, Cleveland, OH, USA. Electronic address: 
      lepiscean@gmail.com.
FAU - Deshpande, Abhishek
AU  - Deshpande A
AD  - Medicine Institute Center for Value Based Care Research, Cleveland Clinic, 
      Cleveland, OH, USA. Electronic address: abhishekdp@gmail.com.
FAU - Kaw, Roop
AU  - Kaw R
AD  - Department of Hospital Medicine & Outcomes Research, Anesthesiology, Cleveland 
      Clinic, Cleveland, OH, USA. Electronic address: kawr@ccf.org.
FAU - Hernandez, Adrian V
AU  - Hernandez AV
AD  - Medical School, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, Peru, 
      Health Outcomes and Clinical Epidemiology Section, Dept. of Quantitative Health 
      Sciences, Lerner, Research Institute, Cleveland Clinic, Cleveland, OH, USA. 
      Electronic address: adrianhernandezdiaz@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20150304
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/administration & dosage/*adverse 
      effects/classification/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Research Design
MH  - Treatment Outcome
MH  - Venous Thromboembolism/*drug therapy
OTO - NOTNLM
OT  - Anticoagulant
OT  - Antiplatelet
OT  - Deep vein thrombosis
OT  - Pulmonary embolism
OT  - Venous thromboembolism
EDAT- 2015/03/22 06:00
MHDA- 2016/01/20 06:00
CRDT- 2015/03/22 06:00
PHST- 2014/12/15 00:00 [received]
PHST- 2015/02/06 00:00 [revised]
PHST- 2015/02/24 00:00 [accepted]
PHST- 2015/03/22 06:00 [entrez]
PHST- 2015/03/22 06:00 [pubmed]
PHST- 2016/01/20 06:00 [medline]
AID - S0049-3848(15)00104-8 [pii]
AID - 10.1016/j.thromres.2015.02.032 [doi]
PST - ppublish
SO  - Thromb Res. 2015 May;135(5):888-96. doi: 10.1016/j.thromres.2015.02.032. Epub 
      2015 Mar 4.

PMID- 31788685
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20210111
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 77
IP  - 2
DP  - 2020 Jan 8
TI  - Aspirin rechallenge in an adult patient previously diagnosed with Reye syndrome.
PG  - 123-127
LID - 10.1093/ajhp/zxz276 [doi]
AB  - PURPOSE: Aspirin has been the cornerstone of antiplatelet therapy in patients 
      with acute coronary syndromes and is well accepted and recommended by several 
      major healthcare organizations. A combination of aspirin and a P2Y12 inhibitor, 
      commonly known as dual antiplatelet therapy, is recommended in patients with 
      coronary stent implantation to reduce the risk of stent thrombosis and ischemic 
      events. SUMMARY: We recently cared for an adult male who presented with an acute 
      coronary syndrome who had a history of Reye syndrome during childhood. During 
      this admission, he was rechallenged with low-dose aspirin for the first time 
      since his diagnosis of Reye syndrome as a child after aspirin therapy. There have 
      been various case reports in children and adults who have been rechallenged with 
      aspirin within days to weeks after the initial diagnosis of Reye syndrome. These 
      reports show mixed results in children and adults regarding the return of Reye 
      syndrome upon aspirin rechallenge shortly after initial aspirin exposure. 
      CONCLUSION: This, to our knowledge, appears to be the first report of a low-dose 
      aspirin rechallenge 30 years later in life in an adult patient with a history of 
      Reye syndrome while receiving aspirin therapy during childhood.
CI  - © American Society of Health-System Pharmacists 2019. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Magrum, BrookeAnne G
AU  - Magrum BG
AD  - Department of Pharmacy, The Ohio State University Wexner Medical Center, 
      Columbus, OH.
FAU - Pickworth, Kerry K
AU  - Pickworth KK
AD  - Department of Pharmacy, The Ohio State University Wexner Medical Center, 
      Columbus, OH.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Rev Chilena Infectol. 2020 Nov;37(5):615-616. PMID: 33399813
MH  - Acute Coronary Syndrome/complications/*drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Reye Syndrome/*complications
MH  - Survivors
OTO - NOTNLM
OT  - acute coronary syndrome
OT  - antiplatelet
OT  - cardiology
OT  - liver
EDAT- 2019/12/04 06:00
MHDA- 2020/09/29 06:00
CRDT- 2019/12/03 06:00
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2019/12/03 06:00 [entrez]
AID - 5648981 [pii]
AID - 10.1093/ajhp/zxz276 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2020 Jan 8;77(2):123-127. doi: 10.1093/ajhp/zxz276.

PMID- 8064590
OWN - NLM
STAT- MEDLINE
DCOM- 19940922
LR  - 20170214
IS  - 0885-3282 (Print)
IS  - 0885-3282 (Linking)
VI  - 8
IP  - 4
DP  - 1994 Apr
TI  - Effect of controlled local acetylsalicylic acid release on in vitro platelet 
      adhesion to vascular grafts.
PG  - 361-84
AB  - Thrombosis is the most serious acute problem for small diameter arterial bypass 
      grafts. In this research, small diameter expanded polytetrafluoroethylene 
      (e-PTFE) vascular grafts were coated with acetylsalicylic acid (ASA) loaded poly 
      (d,l-lactide) (PLA) by a solvent casting method. The feasibility and efficacy of 
      this approach were evaluated by ASA release studies and platelet adhesion tests. 
      First, the ASA release kinetics were evaluated from the ASA/PLA coated vascular 
      grafts in an in vitro steady flow loop model. ASA release was measured by a 
      spectrophotometric technique. Finally, the efficacy of local ASA release to 
      reduce in vitro canine platelet adhesion to grafts was determined with 
      epifluorescent video microscopy and quantitative image analysis. The steady state 
      release rates from the 5%, 10%, and 15% ASA/PLA coated grafts were 13.2 x 10(-5), 
      32.0 x 10(-5), and 41.5 x 10(-5) micrograms/cm2.sec, respectively. Platelet 
      adhesion to 10% and 15% ASA/PLA coated grafts was reduced with respect to the 
      control and 5% grafts for 10 days. Platelet adhesion to 5% ASA/PLA coated grafts 
      was reduced with respect to controls at 2 and 10 days, but not initially.
FAU - Hall, J D
AU  - Hall JD
AD  - Department of Biomedical Engineering, University of Akron, OH 44325-0302.
FAU - Rittgers, S E
AU  - Rittgers SE
FAU - Schmidt, S P
AU  - Schmidt SP
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Biomater Appl
JT  - Journal of biomaterials applications
JID - 8813912
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Lactates)
RN  - 0 (Polyesters)
RN  - 0 (Polymers)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 459TN2L5F5 (poly(lactide))
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - *Blood Vessel Prosthesis
MH  - Delayed-Action Preparations
MH  - Dogs
MH  - Hemorheology
MH  - Lactates/chemistry
MH  - *Lactic Acid
MH  - Microscopy, Electron, Scanning
MH  - Microscopy, Fluorescence
MH  - Models, Cardiovascular
MH  - Platelet Adhesiveness/*drug effects
MH  - Polyesters
MH  - Polymers/chemistry
MH  - Polytetrafluoroethylene/*chemistry
MH  - Porosity
MH  - Surface Properties
MH  - Thrombosis/prevention & control
MH  - Video Recording
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
AID - 10.1177/088532829400800404 [doi]
PST - ppublish
SO  - J Biomater Appl. 1994 Apr;8(4):361-84. doi: 10.1177/088532829400800404.

PMID- 1243042
OWN - NLM
STAT- MEDLINE
DCOM- 19760209
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 25
IP  - 10
DP  - 1975 Oct
TI  - Sexual differences in the metabolism of salicylates.
PG  - 1581-2
AB  - During 6 h the plasma level of salicylates was followed after oral administration 
      of aspirin. The plasma levels of salicylic acid were significantly lower in bull 
      than in heifer calves during the whole observation period. The toxicity of the 
      drug was higher in female animals.
FAU - Sechserová, M
AU  - Sechserová M
FAU - Sechser, T
AU  - Sechser T
FAU - Rasková, H
AU  - Rasková H
FAU - Jecná, J
AU  - Jecná J
FAU - Elis, J
AU  - Elis J
FAU - Vanecek, J
AU  - Vanecek J
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*metabolism/toxicity
MH  - Cattle
MH  - Female
MH  - Lethal Dose 50
MH  - Male
MH  - Mice
MH  - Salicylates/*blood
MH  - Sex Factors
MH  - Time Factors
EDAT- 1975/10/01 00:00
MHDA- 1975/10/01 00:01
CRDT- 1975/10/01 00:00
PHST- 1975/10/01 00:00 [pubmed]
PHST- 1975/10/01 00:01 [medline]
PHST- 1975/10/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1975 Oct;25(10):1581-2.

PMID- 28230634
OWN - NLM
STAT- MEDLINE
DCOM- 20180606
LR  - 20180606
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 28
IP  - 6
DP  - 2017 Sep
TI  - Platelet dysfunction in critically ill patients.
PG  - 475-478
LID - 10.1097/MBC.0000000000000625 [doi]
AB  - : Thrombelastography Platelet Mapping (TEG-PM) allows for measurement of maximal 
      potential clot strength (MA) and strength from stimulation of arachidonic acid 
      (MA-AA) and adenosine disphosphate (MA-ADP) receptors. This study was conducted 
      to assess degree of platelet dysfunction in critically ill adult patients. A 
      retrospective study of critically ill, adult, nontrauma patients in a 
      medical/surgical ICU was conducted from August 2013 to September 2014. All 
      patients who underwent TEG-PM were enrolled. Patients with intracerebral 
      hemorrhage, following cardiac surgery, or without an APACHE II score were 
      excluded. Patients were divided into those with and without aspirin use. 
      Demographics, APACHE II score, and laboratory results were abstracted. Student t 
      test was used to test significance. A total of 79 patients were enrolled (61% 
      male). Average age and APACHE II score were 61 ± 16 years and 18 ± 9, 
      respectively. Factor-associated coagulation measures and MA were normal in all 
      groups but MA-AA and MA-ADP were significantly reduced irrespective of 
      anticoagulant use. Compared to the nonanticoagulated cohort, MA-AA was 
      significantly reduced in those on aspirin. There was no difference in mortality 
      or length of stay in any cohort. Inhibition of the AA and ADP pathways is common 
      in critically ill patients. Clinical correlation with propensity for bleeding and 
      need for transfusion requires further assessment.
FAU - Hase, Travis
AU  - Hase T
AD  - aCenter for Trauma and Critical Care, Department of Surgery bDepartment of 
      Pathology, The George Washington University, Washington, DC, USA.
FAU - Sirajuddin, Sarah
AU  - Sirajuddin S
FAU - Maluso, Patrick
AU  - Maluso P
FAU - Bangalore, Raksha
AU  - Bangalore R
FAU - DePalma, Louis
AU  - DePalma L
FAU - Sarani, Babak
AU  - Sarani B
LA  - eng
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/metabolism
MH  - Aged
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelet Disorders/*physiopathology
MH  - *Critical Illness
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Function Tests
MH  - Retrospective Studies
MH  - Thrombelastography
EDAT- 2017/02/24 06:00
MHDA- 2018/06/07 06:00
CRDT- 2017/02/24 06:00
PHST- 2017/02/24 06:00 [pubmed]
PHST- 2018/06/07 06:00 [medline]
PHST- 2017/02/24 06:00 [entrez]
AID - 10.1097/MBC.0000000000000625 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2017 Sep;28(6):475-478. doi: 
      10.1097/MBC.0000000000000625.

PMID- 30401649
OWN - NLM
STAT- MEDLINE
DCOM- 20190404
LR  - 20190404
IS  - 1879-0003 (Electronic)
IS  - 0141-8130 (Linking)
VI  - 122
DP  - 2019 Feb 1
TI  - Aspirin in retrieving the inactivated catalase to active form: Displacement of 
      one inhibitor with a protective agent.
PG  - 306-311
LID - S0141-8130(18)34210-7 [pii]
LID - 10.1016/j.ijbiomac.2018.10.183 [doi]
AB  - Aspirin as a potential drug is able to bind to different targets and also could 
      affect on the binding process of other ligands. In the present work, aspirin was 
      considered as a protective agent to retrieve the inactivated catalase by 
      farnesiferol C (FC) through displacement manner. The catalytic assessment 
      revealed that aspirin is able to remarkably retrieve the activity of FC-catalase 
      from 4.2 ± 0.2% to 98 ± 0.1% compare to the control sample. Furthermore, 
      displacement study and CD spectroscopy indicated that aspirin could reduce the 
      stability of FC-catalase complex. Based on the obtained data, it is shown that 
      the binding of aspirin to catalase led to decrease the affinity of catalase to 
      the inhibitor. The releasing analysis of FC from the complex showed that the 
      dissociation constant (K(d)) of FC-catalase was increased, considerably from 
      8.9 ± 0.2 μM to 256 ± 01 μM in the presence of aspirin at 298 K. Also, molecular 
      simulation proved the instability of FC-catalase following the binding of aspirin 
      to the complex.
CI  - Copyright © 2018. Published by Elsevier B.V.
FAU - Panahi, Yunes
AU  - Panahi Y
AD  - Pharmacotherapy Department, Baqiyatallah University of Medical Sciences, Tehran, 
      Iran.
FAU - Yekta, Reza
AU  - Yekta R
AD  - Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, 
      Iran.
FAU - Dehghan, Gholamreza
AU  - Dehghan G
AD  - Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, 
      Iran. Electronic address: gdehghan@tabrizu.ac.ir.
FAU - Rashtbari, Samaneh
AU  - Rashtbari S
AD  - Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, 
      Iran.
FAU - Baradaran, Behzad
AU  - Baradaran B
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Jafari, Nematollah Jonaidi
AU  - Jafari NJ
AD  - Research Centers of Molecular Biology, Baqiyatallah University of Medical 
      Sciences, Tehran, Iran.
FAU - Moosavi-Movahedi, Ali A
AU  - Moosavi-Movahedi AA
AD  - Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran; 
      Center of Excellence in Biothermodynamics, University of Tehran, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20181027
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
RN  - 0 (Enzyme Inhibitors)
RN  - EC 1.11.1.6 (Catalase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/metabolism/*pharmacology
MH  - Binding, Competitive
MH  - Biocatalysis/drug effects
MH  - Catalase/*antagonists & inhibitors/chemistry/*metabolism
MH  - Cattle
MH  - Enzyme Activation/drug effects
MH  - Enzyme Inhibitors/metabolism/*pharmacology
MH  - Molecular Docking Simulation
MH  - Protein Conformation
OTO - NOTNLM
OT  - Aspirin
OT  - Catalase
OT  - Inhibitor
OT  - Molecular simulation
EDAT- 2018/11/08 06:00
MHDA- 2019/04/05 06:00
CRDT- 2018/11/08 06:00
PHST- 2018/08/12 00:00 [received]
PHST- 2018/09/23 00:00 [revised]
PHST- 2018/10/26 00:00 [accepted]
PHST- 2018/11/08 06:00 [pubmed]
PHST- 2019/04/05 06:00 [medline]
PHST- 2018/11/08 06:00 [entrez]
AID - S0141-8130(18)34210-7 [pii]
AID - 10.1016/j.ijbiomac.2018.10.183 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2019 Feb 1;122:306-311. doi: 10.1016/j.ijbiomac.2018.10.183. 
      Epub 2018 Oct 27.

PMID- 8794989
OWN - NLM
STAT- MEDLINE
DCOM- 19961220
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 48
IP  - 4
DP  - 1996 Apr
TI  - Prediction of in-vivo blood level with controlled-release dosage forms. Effect of 
      the gastrointestinal tract time.
PG  - 390-4
AB  - The process of in-vivo drug transfer is very complex in the case of oral dosage 
      forms with controlled release. A numerical model taking all the known facts into 
      account, including the release of the drug controlled by diffusion through the 
      dosage form along the gastrointestinal tract, the kinetics of absorption in the 
      blood compartment and the kinetics of elimination was constructed. Various 
      parameters intervene in an important manner for a given drug: the size of the 
      dosage form which is associated with the rate of release of the drug, and the 
      dose frequency in multidosing. Some emphasis is placed upon the gastrointestinal 
      tract time which appears to be the main and first parameter to be considered in 
      preparing a dosage form.
FAU - Ouriemchi, I M
AU  - Ouriemchi IM
AD  - Faculty of Sciences, University of Saint-Etienne, France.
FAU - Vergnaud, J M
AU  - Vergnaud JM
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Delayed-Action Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics, Non-Narcotic/administration & dosage/pharmacokinetics
MH  - Aspirin/administration & dosage/blood/pharmacokinetics
MH  - Body Fluids/metabolism
MH  - *Delayed-Action Preparations
MH  - Diffusion
MH  - Gastrointestinal Transit/*physiology
MH  - Models, Biological
MH  - *Pharmacokinetics
MH  - Solubility
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1996.tb05939.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1996 Apr;48(4):390-4. doi: 10.1111/j.2042-7158.1996.tb05939.x.

PMID- 1154559
OWN - NLM
STAT- MEDLINE
DCOM- 19751101
LR  - 20131121
IS  - 0340-2592 (Print)
IS  - 0340-2592 (Linking)
VI  - 14
IP  - 3
DP  - 1975 May
TI  - [Inhibition of platelet aggregation under estrogen-treatment in patients with 
      carcinoma of the prostate (author's transl)].
PG  - 132-6
AB  - In patients with carcinoma of the prostate treated with estrogens platelet 
      aggregation is increased. Patients with increased platelet aggregation have a 
      high incidence of cardio-vascular and thrombo-embolic diseases. Platelet 
      aggregation was measured by the platelet-aggregation test (PAT). Platelet 
      aggregation was inhibited by administration of acetyl-salicylic acid (ASS) 2 
      times 500 mg daily. An aggregation inhibiting effect was found in all 38 
      patients. To reduce the cardio-vascular complications of estrogens in treating 
      carcinoma of the prostate acetyl-salicylic acid as an adjunct therapy is 
      recommended. A long-term study has been started.
FAU - Eisen, M
AU  - Eisen M
FAU - Napp, H E
AU  - Napp HE
FAU - Vock, R
AU  - Vock R
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Thrombocyten-Aggregationshemmung bei Oestrogen-behandelten 
      Prostata-Carcinom-Patienten.
PL  - Germany
TA  - Urologe A
JT  - Der Urologe. Ausg. A
JID - 1304110
RN  - 0 (Estrogens)
RN  - 731DCA35BT (Diethylstilbestrol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Blood Coagulation Disorders/prevention & control
MH  - Blood Platelets/*drug effects
MH  - Diethylstilbestrol/administration & dosage
MH  - Estrogens/adverse effects/*pharmacology/therapeutic use
MH  - Humans
MH  - Male
MH  - *Platelet Adhesiveness
MH  - *Platelet Aggregation
MH  - Prostatic Neoplasms/*drug therapy
MH  - Thrombosis/prevention & control
EDAT- 1975/05/01 00:00
MHDA- 1975/05/01 00:01
CRDT- 1975/05/01 00:00
PHST- 1975/05/01 00:00 [pubmed]
PHST- 1975/05/01 00:01 [medline]
PHST- 1975/05/01 00:00 [entrez]
PST - ppublish
SO  - Urologe A. 1975 May;14(3):132-6.

PMID- 12630979
OWN - NLM
STAT- MEDLINE
DCOM- 20030721
LR  - 20190513
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 55
IP  - 3
DP  - 2003 Mar
TI  - Aspirin for the prevention of cardiovascular disease: calculating benefit and 
      harm in the individual patient.
PG  - 282-7
AB  - AIMS: To estimate the absolute reduction in the risk of cardiovascular events and 
      absolute increase in gastrointestinal haemorrhage associated with aspirin for 
      individuals with different baseline risks. METHODS: Calculation of absolute 
      treatment effects from estimates of: (i) baseline risks for cardiovascular event 
      and gastrointestinal haemorrhage; and (ii) relative risks of these events with 
      treatment. Baseline cardiovascular risks were derived from existing risk scores, 
      and baseline risk of gastrointestinal haemorrhage from an observational cohort 
      study. Changes in relative risks were obtained from clinical trial data. The 
      effects of aspirin treatment were calculated in examples of two individuals with 
      very different baseline risks. RESULTS: Treatment of a healthy 74-year-old man 
      (blood pressure 144/88 mm Hg and no history of gastrointestinal disorder) would 
      reduce his annual risk of a cardiovascular event from 2% to 1.74% (absolute risk 
      reduction 0.26%, number needed to treat 385), but increase the gastrointestinal 
      haemorrhage risk from 0.3% to 0.51% (absolute risk increase 0.21%, number needed 
      to harm 476). In a 66-year-old obese man, following a transient ischaemic attack, 
      and with a history of hospital treatment for a peptic ulcer, the annual risk of a 
      cardiovascular event would be reduced from 5% to 4.35% (absolute risk reduction 
      0.65%, number needed to treat 153), but the risk of gastrointestinal haemorrhage 
      would increase from 1.08% to 1.83% (absolute risk increase 0.75%, number needed 
      to harm 133). CONCLUSIONS: Estimating benefit and harm by taking into account the 
      baseline risks in each individual allows patients and doctors to judge for 
      themselves the magnitude of the trade-offs involved in taking aspirin.
FAU - Loke, Yoon Kong
AU  - Loke YK
AD  - Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, 
      Oxford OX2 6HE. yoon.loke@clinpharm.ox.ac.uk
FAU - Bell, Alastair
AU  - Bell A
FAU - Derry, Sheena
AU  - Derry S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Evidence-Based Medicine
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
PMC - PMC1884222
EDAT- 2003/03/13 04:00
MHDA- 2003/07/23 05:00
CRDT- 2003/03/13 04:00
PHST- 2003/03/13 04:00 [pubmed]
PHST- 2003/07/23 05:00 [medline]
PHST- 2003/03/13 04:00 [entrez]
AID - 1774 [pii]
AID - 10.1046/j.1365-2125.2003.01774.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2003 Mar;55(3):282-7. doi: 10.1046/j.1365-2125.2003.01774.x.

PMID- 6970559
OWN - NLM
STAT- MEDLINE
DCOM- 19810413
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 141
IP  - 3 Spec No
DP  - 1981 Feb 23
TI  - Effects of aspirin and acetaminophen in gastrointestinal hemorrhage. Results from 
      the Boston Collaborative Drug Surveillance Program.
PG  - 316-21
AB  - All patients observed in this analysis of the Boston Collaborative Drug 
      Surveillance Program data had no known disease predisposing them to 
      gastrointestinal (GI) bleeding. Major GI bleeding occurred in hospitalized 
      patients recently exposed to ethacrynic acid (5/111; 4.5%), heparin sodium 
      (7/575; 1.2%), corticosteroids (7/1,484; 0.5%), aspirin (6/2,081; 0.3%), and 
      warfarin sodium (1/423; 0.2%); combinations of two or more of these drugs also 
      resulted in substantial incidences of bleeding. The rates for minor GI bleeding 
      in hospitalized patients varied from 8.3% for heparin to 1.6% for aspirin. In 
      outpatients admitted because of serious GI bleeding, 14/88 (16%) had a history of 
      heavy, regular aspirin use compared with 1,015/14,813 (6.9%) control subjects 
      admitted for other reasons (relative risk, 2.1). No association between light 
      regular use of aspirin and GI bleeding was noted. No association between the use 
      of acetaminophen and GI bleeding was noted in any of the patients studied.
FAU - Jick, H
AU  - Jick H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*adverse effects
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outpatients
MH  - Sex Factors
EDAT- 1981/02/23 00:00
MHDA- 1981/02/23 00:01
CRDT- 1981/02/23 00:00
PHST- 1981/02/23 00:00 [pubmed]
PHST- 1981/02/23 00:01 [medline]
PHST- 1981/02/23 00:00 [entrez]
AID - 10.1001/archinte.141.3.316 [doi]
PST - ppublish
SO  - Arch Intern Med. 1981 Feb 23;141(3 Spec No):316-21. doi: 
      10.1001/archinte.141.3.316.

PMID- 2384905
OWN - NLM
STAT- MEDLINE
DCOM- 19900914
LR  - 20190918
IS  - 0140-7783 (Print)
IS  - 0140-7783 (Linking)
VI  - 13
IP  - 2
DP  - 1990 Jun
TI  - Gastric retention of enteric-coated aspirin tablets in beagle dogs.
PG  - 148-53
AB  - Administration of acetylsalicylic acid (ASA) in the dog may cause gastric mucosal 
      damage. Enteric-coated tablets protect the canine stomach during oral ASA 
      medication. A therapeutic plasma salicylate concentration can be attained using 
      enteric-coated ASA tablets at a dose rate of 25 mg/kg body wt, administered every 
      8 h. Six beagle dogs were given enteric-coated ASA tablets (500 mg) orally, in a 
      5-day cross-over experiment on two different feeding regimens: i.e. feeding once 
      daily (Group I) or 8 hourly (Group II). Results demonstrate that feeding regimen 
      strongly influences the plasma salicylate concentration pattern. Subtherapeutic 
      mean plasma salicylate concentrations were found in both groups. In Group II the 
      standard deviation (SD) of the mean plasma salicylate concentration was larger 
      than that of Group I. The minimal plasma salicylate concentration never reached 
      detectable levels in Group II. In both groups large numbers of tablets were 
      vomited. Gastric evacuation of the ASA tablets is comparable to indigestible 
      solid particles; their removal was dependent on the interdigestive gastric 
      motility. It is concluded that large enteric-coated ASA tablets are not suitable 
      for therapeutic use in small dogs.
FAU - Nap, R C
AU  - Nap RC
AD  - Department of Clinical Sciences of Companion Animals, Utrecht University, The 
      Netherlands.
FAU - Breen, D J
AU  - Breen DJ
FAU - Lam, T J
AU  - Lam TJ
FAU - De Bruyne, J J
AU  - De Bruyne JJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects/pharmacokinetics
MH  - Dogs/*metabolism
MH  - Female
MH  - *Food
MH  - Gastric Mucosa/*metabolism
MH  - Male
MH  - Salicylates/blood
MH  - Stomach/drug effects
MH  - Tablets, Enteric-Coated
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2885.1990.tb00762.x [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 1990 Jun;13(2):148-53. doi: 
      10.1111/j.1365-2885.1990.tb00762.x.

PMID- 27027712
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181202
IS  - 1943-5681 (Electronic)
IS  - 0002-9645 (Linking)
VI  - 77
IP  - 2
DP  - 2016 Feb
TI  - In vitro and in vivo assessment of platelet function in healthy dogs during 
      administration of a low-dose aspirin regimen.
PG  - 174-85
LID - 10.2460/ajvr.77.2.174 [doi]
AB  - OBJECTIVE: To assess the in vitro and in vivo platelet function of healthy dogs 
      during administration of a low-dose aspirin regimen. ANIMALS: 16 dogs. 
      PROCEDURES: Dogs received aspirin (1 mg/kg, PO, q 24 h) for 7 days. Blood and 
      urine samples were collected before (day 1; baseline) and on days 3 and 7 of the 
      low-dose aspirin regimen. Platelet function was evaluated by use of turbidimetric 
      and conventional impedance aggregometry, multiple-electrode impedance 
      aggregometry, a platelet function analyzer (PFA), and determination of urine 
      11-dehydro-thromboxane B2 concentration. Turbidimetric aggregometry results were 
      compared with the results obtained by the other 4 methods. Fourteen days after 
      cessation of aspirin, platelet-rich plasma was incubated with acetylsalicylic 
      acid and platelet function was assessed by turbidimetric aggregometry to 
      determine whether this technique could accurately identify dogs that responded to 
      the low-dose aspirin regimen. RESULTS: Of the 16 dogs, 13 had turbidimetric and 
      conventional impedance aggregometry results that were decreased by > 25% from 
      baseline on days 3 and 7, and 4 and 7 dogs had PFA closure times > 300 seconds on 
      days 3 and 7, respectively. The median urine 11-dehydro-thromboxane B2 
      concentration-to-creatinine concentration ratio decreased by 49% between days 1 
      and 7. Turbidimetric aggregometry results were correlated with conventional 
      impedance aggregometry results. There was poor agreement between the 
      turbidimetric aggregometry and PFA results. The multiple-electrode impedance 
      aggregometry protocol failed to reliably detect aspirin-induced platelet 
      dysfunction. In vitro incubation of platelet-rich plasma with acetylsalicylic 
      acid followed by turbidimetric aggregometry did not predict whether dogs 
      responded to the low-dose aspirin regimen. CONCLUSIONS AND CLINICAL RELEVANCE: 
      Results indicated that the response to a low-dose aspirin regimen varied among 
      healthy dogs.
FAU - Haines, Jillian M
AU  - Haines JM
FAU - Thomason, John M
AU  - Thomason JM
FAU - Seage, Eileen C
AU  - Seage EC
FAU - Wills, Robert W
AU  - Wills RW
FAU - Bulla, Camilo
AU  - Bulla C
FAU - Lunsford, Kari V
AU  - Lunsford KV
FAU - Mackin, Andrew J
AU  - Mackin AJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Dogs/*blood
MH  - Dose-Response Relationship, Drug
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
EDAT- 2016/03/31 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/03/31 06:00
PHST- 2016/03/31 06:00 [entrez]
PHST- 2016/03/31 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.2460/ajvr.77.2.174 [doi]
PST - ppublish
SO  - Am J Vet Res. 2016 Feb;77(2):174-85. doi: 10.2460/ajvr.77.2.174.

PMID- 16181981
OWN - NLM
STAT- MEDLINE
DCOM- 20051228
LR  - 20131121
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 116
IP  - 6
DP  - 2005
TI  - Effect of increasing doses of aspirin on platelet function as measured by PFA-100 
      in patients with diabetes.
PG  - 465-70
AB  - INTRODUCTION: Platelets of diabetic patients have been reported to be less 
      sensitive to aspirin. The aim of this study is to compare a medium (300 mg) and 
      low (100 mg) dose of aspirin on platelet function in diabetic patients. METHODS: 
      We have included one hundred and two patients with type 2 diabetes mellitus. 
      Platelet function was measured as closure time (CT) with the Platelet Function 
      Analyzer (PFA)-100 before the administration of aspirin. Initially the patients 
      were given 100 mg aspirin once daily for seven days, and then the measurements 
      were repeated. If the CT exceeded the upper limit of 300 s, the study was 
      terminated. If not, the patients continued the aspirin therapy with a dose of 300 
      mg daily for another seven days, and the CTs were measured again. RESULTS: After 
      taking 100 mg aspirin, the CT significantly increased from 126+/-29 s to 256+/-66 
      s (p<0.001). In 68 of 102 (67%) patients, the CT increased to 300 s. In the 
      remaining 34 patients, the baseline CT was 113+/-29, and increased to 170+/-45 s 
      after 100 mg aspirin (p<0.001). In these patients, there was a further increase 
      in the CT from 170+/-45 to 229+/-75 s following 300 mg aspirin (p<0.001). On 
      average, the CT was increased by 60% and 39% following ingestion of 100 and 300 
      mg aspirin, respectively. CT>300 s were obtained in 15 (44%) of 34 patients after 
      300 mg aspirin. CONCLUSIONS: Although, a daily dose of 100 mg aspirin effectively 
      inhibited platelet function in a majority of diabetics, a considerable proportion 
      of patients showed a greater platelet inhibition with the use of 300 mg aspirin. 
      The PFA-100 closure time may be used to separate those patients who require a 
      higher dose of aspirin to achieve desired antiplatelet effect.
FAU - Abaci, Adnan
AU  - Abaci A
AD  - Department of Cardiology, Gazi University School of Medicine, Ankara 06550, 
      Turkey. abaci@gazi.edu.tr
FAU - Yilmaz, Yucel
AU  - Yilmaz Y
FAU - Caliskan, Mustafa
AU  - Caliskan M
FAU - Bayram, Fahri
AU  - Bayram F
FAU - Cetin, Mustafa
AU  - Cetin M
FAU - Unal, Ali
AU  - Unal A
FAU - Cetin, Servet
AU  - Cetin S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Coagulation Tests/instrumentation/*methods
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Time Factors
EDAT- 2005/09/27 09:00
MHDA- 2005/12/29 09:00
CRDT- 2005/09/27 09:00
PHST- 2004/10/18 00:00 [received]
PHST- 2005/02/07 00:00 [revised]
PHST- 2005/02/07 00:00 [accepted]
PHST- 2005/09/27 09:00 [pubmed]
PHST- 2005/12/29 09:00 [medline]
PHST- 2005/09/27 09:00 [entrez]
AID - S0049-3848(05)00072-1 [pii]
AID - 10.1016/j.thromres.2005.02.005 [doi]
PST - ppublish
SO  - Thromb Res. 2005;116(6):465-70. doi: 10.1016/j.thromres.2005.02.005.

PMID- 26881711
OWN - NLM
STAT- MEDLINE
DCOM- 20170208
LR  - 20190907
IS  - 1873-4294 (Electronic)
IS  - 1568-0266 (Linking)
VI  - 16
IP  - 19
DP  - 2016
TI  - Repurposing Drugs for Cancer Prevention.
PG  - 2169-78
AB  - Development of agents for cancer prevention has been particularly challenging for 
      two main reasons. One is the inherent difficulty in identifying targets for the 
      heterogeneous group of processes that lead to invasive cancer arising at 
      different target organ sites, while the other is the need for safe, tolerable 
      interventions that can be given for lengthy periods of time. The rapidly 
      increasing understanding of the molecular pathogenesis of cancer is providing new 
      opportunities for early intervention, prior to the development of invasive 
      disease. Furthermore, there is an ever-increasing number of approved drugs with 
      many different mechanisms of action. The appeal of using drugs with well 
      described mechanisms of action and safety profiles has led to renewed interest in 
      repurposing such agents for cancer prevention. Here we review the rationale and 
      evidence of effectiveness of three agents that are the current focus of much 
      interest in the field of cancer prevention - aspirin, metformin, and 
      pioglitazone.
FAU - Lee, Daniel K
AU  - Lee DK
FAU - Szabo, Eva
AU  - Szabo E
AD  - Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer 
      Prevention, National Cancer Institute, National Institutes of Health, 9609 
      Medical Center Drive, Room 5E-102, Bethesda, MD 20892, USA. szaboe@mail.nih.gov.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Top Med Chem
JT  - Current topics in medicinal chemistry
JID - 101119673
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Thiazolidinediones)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Anticarcinogenic Agents/chemistry/*pharmacology
MH  - Aspirin/chemistry/pharmacology
MH  - Drug Repositioning/*methods
MH  - Humans
MH  - Metformin/chemistry/pharmacology
MH  - Neoplasms/*prevention & control
MH  - Pioglitazone
MH  - Thiazolidinediones/chemistry/pharmacology
EDAT- 2016/02/18 06:00
MHDA- 2017/02/09 06:00
CRDT- 2016/02/17 06:00
PHST- 2015/08/04 00:00 [received]
PHST- 2015/10/07 00:00 [revised]
PHST- 2015/11/25 00:00 [accepted]
PHST- 2016/02/17 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
AID - CTMC-EPUB-73749 [pii]
AID - 10.2174/1568026616666160216154946 [doi]
PST - ppublish
SO  - Curr Top Med Chem. 2016;16(19):2169-78. doi: 10.2174/1568026616666160216154946.

PMID- 24720117
OWN - NLM
STAT- MEDLINE
DCOM- 20140501
LR  - 20140411
IS  - 0033-2240 (Print)
IS  - 0033-2240 (Linking)
VI  - 70
IP  - 12
DP  - 2013
TI  - [Desensitization in drug hypersensitivity].
PG  - 1008-10
AB  - Drug hypersensitivity can occur with almost any drug and may range widely in 
      clinical severity from mild pruritus, acute urticaria or angioedema to 
      life-threatening anaphylaxis. Affected patients usually avoid the suspected drug 
      in the future, but in selected cases the particular drug is essential for optimal 
      therapy due to unavailable or ineffective alternative therapy. Under these 
      circumstances, desensitization may be performed. Desensitization protocols have 
      been developed and are used for antibiotics, sulfonamides, non-steroidal 
      antiinflammatory drugs, insulins, biologic agents, and many others. 
      Desensitization procedure is based on the induction of a temporary state of 
      tolerance of a substance responsible for a hypersensitivity reaction. Gradually 
      increasing doses of the drug are administered to the patient over several hours 
      to a few days, until the total cumulative therapeutic dose is achieved and 
      tolerated. Hypersensitivity to acetylsalicylic acid is a common indication to 
      desensitization in a daily practice. A few protocols for this drug have been 
      described. Recently, 7 patients hypersensitive to acetylsalicylic acid have been 
      desensitized in our department due to cardiologic and rheumatologic reasons. In 
      this group, desensitization procedures were performed successfully and the 
      patients could continue pharmacotherapy with aspirin.
FAU - Piotrowicz-Wójcik, Katarzyna
AU  - Piotrowicz-Wójcik K
FAU - Porebski, Grzegorz
AU  - Porebski G
FAU - Czarnobilska, Ewa
AU  - Czarnobilska E
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Desensytyzacja w nadwrazliwości na leki.
PL  - Poland
TA  - Przegl Lek
JT  - Przeglad lekarski
JID - 19840720R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Desensitization, Immunologic/*methods
MH  - Drug Administration Schedule
MH  - Drug Hypersensitivity/drug therapy/*immunology/*prevention & control
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Immune Tolerance
MH  - Male
MH  - Middle Aged
EDAT- 2013/01/01 00:00
MHDA- 2014/05/03 06:00
CRDT- 2014/04/12 06:00
PHST- 2014/04/12 06:00 [entrez]
PHST- 2013/01/01 00:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
PST - ppublish
SO  - Przegl Lek. 2013;70(12):1008-10.

PMID- 26456910
OWN - NLM
STAT- MEDLINE
DCOM- 20161227
LR  - 20161230
IS  - 1879-3649 (Electronic)
IS  - 1537-1891 (Linking)
VI  - 80
DP  - 2016 May
TI  - Acetylsalicylic acid desensitization in patients with coronary artery disease: A 
      comprehensive overview of currently available protocols.
PG  - 43-9
LID - S1537-1891(15)00216-5 [pii]
LID - 10.1016/j.vph.2015.09.005 [doi]
AB  - BACKGROUND: Acetylsalicylic acid (ASA) represents the basis of pharmacological 
      therapy for cardiovascular prevention. However, several patients are excluded 
      from the benefits of ASA for hypersensitivity problems, and controversies still 
      exist on their management. The aim of present study was to evaluate the safety 
      and efficacy of ASA desensitization protocols in patients requiring dual 
      antiplatelet therapy for coronary artery disease. METHODS: Literature archives 
      and main scientific sessions' abstracts were scanned for studies describing 
      desensitization protocols for patients with ASA hypersensitivity. Primary 
      endpoint was the tolerance of ASA maintenance therapy (protocol success). 
      Secondary endpoints were: 1) the occurrence of hypersensitivity symptoms during 
      the protocol, 2) the rate of ASA discontinuation at follow-up; 3) recurrent 
      cardiovascular ischemic events. RESULTS: We finally selected 14 studies out of 
      335 initially screened citation, reporting complete data on protocol 
      desensitization strategies, with a total of 256 patients. Among them 213 (83.2%) 
      underwent an oral desensitization protocol, while 43 received endovenous ASA. The 
      protocol was successfully completed in 238 out of 256 patients (92.9%), who were 
      subsequently kept on chronic daily therapy with ASA. The weighted success 
      proportion was wP [95%CI] = 93[89.8–96.1]%. Hypersensivity symptoms occurred 
      during the desensitization protocol in 29 patients, with a pooled events rate of 
      11.3[7.5–15.2]%. All adverse reactions were safely faced with pharmacological 
      interventions. In 11 of these patients, slowing the protocol or restarting 
      another ASA challenge could successfully achieve the tolerance. The rate of ASA 
      discontinuation and major cardiovascular events was extremely low (6.1 and 2.3% 
      respectively). CONCLUSIONS: Aspirin desensitization protocols represent a safe 
      and effective option for the management of patients with a cardiovascular 
      indication to ASA and history of allergy to ASA. Future randomized trials are 
      certainly needed to confirm present findings and provide indications for the 
      optimization of these protocols.
FAU - Verdoia, Monica
AU  - Verdoia M
AD  - Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della 
      Carità", Eastern Piedmont University, Novara, Italy.
FAU - Barbieri, Lucia
AU  - Barbieri L
AD  - Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della 
      Carità", Eastern Piedmont University, Novara, Italy.
FAU - Schaffer, Alon
AU  - Schaffer A
AD  - Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della 
      Carità", Eastern Piedmont University, Novara, Italy.
FAU - Nardin, Matteo
AU  - Nardin M
AD  - Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della 
      Carità", Eastern Piedmont University, Novara, Italy.
FAU - Suryapranata, Harry
AU  - Suryapranata H
AD  - Department of Cardiology, UMC St Radboud, Nijmegen, The Netherlands.
FAU - De Luca, Giuseppe
AU  - De Luca G
AD  - Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della 
      Carità", Eastern Piedmont University, Novara, Italy. Electronic address: 
      giuseppe.deluca@maggioreosp.novara.it.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20151009
PL  - United States
TA  - Vascul Pharmacol
JT  - Vascular pharmacology
JID - 101130615
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects/immunology/therapeutic use
MH  - Coronary Artery Disease/blood/*drug therapy/prevention & control
MH  - Drug Hypersensitivity/epidemiology/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/immunology/therapeutic use
MH  - Secondary Prevention/*methods
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Coronary artery disease
OT  - Desensitization protocol
OT  - Hypersensitivity
EDAT- 2015/10/13 06:00
MHDA- 2016/12/28 06:00
CRDT- 2015/10/13 06:00
PHST- 2015/07/08 00:00 [received]
PHST- 2015/09/08 00:00 [revised]
PHST- 2015/09/23 00:00 [accepted]
PHST- 2015/10/13 06:00 [entrez]
PHST- 2015/10/13 06:00 [pubmed]
PHST- 2016/12/28 06:00 [medline]
AID - S1537-1891(15)00216-5 [pii]
AID - 10.1016/j.vph.2015.09.005 [doi]
PST - ppublish
SO  - Vascul Pharmacol. 2016 May;80:43-9. doi: 10.1016/j.vph.2015.09.005. Epub 2015 Oct 
      9.

PMID- 6711770
OWN - NLM
STAT- MEDLINE
DCOM- 19840524
LR  - 20190821
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 39
IP  - 3
DP  - 1984 Apr
TI  - Aspirin tolerance induced in aspirin-sensitive asthmatics.
PG  - 171-8
AB  - Twenty-nine patients with asthma and aspirin-sensitivity were studied in an 
      attempt to induce tolerance to aspirin (ASA). Starting with the smallest ASA 
      doses eliciting bronchial obstruction (threshold doses) we doubled the doses on 
      subsequent days and finally achieved good tolerance of 600 mg ASA per day in 27 
      patients. It was more difficult to achieve tolerance in patients with low 
      ASA-thresholds than in patients with high ones. Daily ASA administration led to 
      prolongation of the refractory state but when the intervals between consecutive 
      doses were increased, aspirin hypersensitivity recurred. The pause sufficient for 
      a recurrence of sensitivity to ASA was measured in 16 patients and ranged from 24 
      h to 9 days. Twelve patients challenged with indomethacin after 
      ASA-desensitisation showed good drug tolerance.
FAU - Kowalski, M L
AU  - Kowalski ML
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
FAU - Rozniecki, J
AU  - Rozniecki J
FAU - Szmidt, M
AU  - Szmidt M
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/*chemically induced
MH  - Cross Reactions
MH  - Dose-Response Relationship, Drug
MH  - Dose-Response Relationship, Immunologic
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Immunization
MH  - Indomethacin/immunology
MH  - Male
MH  - Time Factors
EDAT- 1984/04/01 00:00
MHDA- 1984/04/01 00:01
CRDT- 1984/04/01 00:00
PHST- 1984/04/01 00:00 [pubmed]
PHST- 1984/04/01 00:01 [medline]
PHST- 1984/04/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1984.tb02621.x [doi]
PST - ppublish
SO  - Allergy. 1984 Apr;39(3):171-8. doi: 10.1111/j.1398-9995.1984.tb02621.x.

PMID- 6793921
OWN - NLM
STAT- MEDLINE
DCOM- 19811222
LR  - 20161123
IS  - 0375-9393 (Print)
IS  - 0375-9393 (Linking)
VI  - 47
IP  - 5
DP  - 1981 May
TI  - [Treatment of postoperative pain with non-narcotic drugs; evaluation of lysine 
      acetylsalicylate in high doses. Double-blind controlled study].
PG  - 215-20
AB  - Further work on the treatment of postoperative pain with non-narcotic analgesics 
      involving an investigation of the effect of twice the customary dose of lysine 
      acetylsalicylate in a double-blind trial versus meperidine is reported. In 
      addition to subjective and objective pain, the parameters included blood 
      pressure, pulse rate, breathing rate, sweating, pupil diameter, nausea, vomiting, 
      somnolence, hiccuping feeling of cold, erythema, dizziness, and nasograstric 
      sound intolerance. Application of Wilcoxon's non-parametric tests and the 
      chi-square test showed that the drug was as good as or better than meperidine 
      with regard to pain, and performed very well overall with respect to the other 
      parameters. The conclusion is drawn that its administration in high doses is 
      justified in many patients subjected to general surgery.
FAU - Pagni, E
AU  - Pagni E
FAU - Poggiali, C
AU  - Poggiali C
FAU - Piazza, M
AU  - Piazza M
FAU - Mancini, A
AU  - Mancini A
FAU - Sassu, B
AU  - Sassu B
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
TT  - Trattamento del dolore post-operatorio con farmaci non narcotici: valutazione 
      dell'acetilsalicilato di lisina ad alto dosaggio. Studio controllato a doppio 
      cieco.
PL  - Italy
TA  - Minerva Anestesiol
JT  - Minerva anestesiologica
JID - 0375272
RN  - 9E338QE28F (Meperidine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Abdomen/surgery
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Meperidine/administration & dosage/*therapeutic use
MH  - Pain, Postoperative/*drug therapy
EDAT- 1981/05/01 00:00
MHDA- 1981/05/01 00:01
CRDT- 1981/05/01 00:00
PHST- 1981/05/01 00:00 [pubmed]
PHST- 1981/05/01 00:01 [medline]
PHST- 1981/05/01 00:00 [entrez]
PST - ppublish
SO  - Minerva Anestesiol. 1981 May;47(5):215-20.

PMID- 8481398
OWN - NLM
STAT- MEDLINE
DCOM- 19930603
LR  - 20190610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1181
IP  - 2
DP  - 1993 Apr 30
TI  - Reaction of aspirin with cysteinyl residues of lens gamma-crystallins: a 
      mechanism for the proposed anti-cataract effect of aspirin.
PG  - 103-10
AB  - Incubation of lens crystallins with aspirin inhibits the development of opacities 
      caused by cyanate. Cyanate-induced opacities are thought to be due to 
      carbamylation of the lysyl residues which causes a decrease in the protein charge 
      and subsequent conformational changes that permit disulfide bonding. Because 
      aspirin can also react with lysyl residues, it has been proposed that the aspirin 
      inhibition of cataractogenesis is due to acetylation of the lysyl residues which 
      would block their reaction with cyanate. However, acetylation of lysyl residues 
      also lowers the protein charge and would be expected to effect changes in protein 
      conformation similar to those caused by carbamylation. Therefore, acetylation of 
      the lysyl residues is not a satisfactory explanation for the inhibitory effect of 
      aspirin on lens opacification. Our investigations of the reactions of cyanate and 
      aspirin with bovine gamma II-crystallins show that the cysteinyl residues are 
      also carbamylated and acetylated at pH 7.4. At this pH, the carbamylation at the 
      cysteinyl residues is reversible, leading to regeneration of the thiol group and 
      disulfide bonding. In contrast, the acetylation at cysteinyl residues is stable 
      at pH 7.4 and can prevent disulfide bonding. This difference in stability 
      explains how cyanate promotes, and aspirin inhibits, cataractogenesis.
FAU - Qin, W
AU  - Qin W
AD  - Department of Medicinal Chemistry and Pharmacognosy, Purdue University, West 
      Lafayette, IN 47907.
FAU - Smith, J B
AU  - Smith JB
FAU - Smith, D L
AU  - Smith DL
LA  - eng
GR  - EY R01 7609/EY/NEI NIH HHS/United States
GR  - GM R01 40384/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Crystallins)
RN  - 0 (Cyanates)
RN  - 0 (Peptide Fragments)
RN  - EC 3.4.23.1 (Pepsin A)
RN  - G9C31TWN5M (potassium cyanate)
RN  - K848JZ4886 (Cysteine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Amino Acid Sequence
MH  - Animals
MH  - Aspirin/metabolism/*pharmacology
MH  - Cataract/*prevention & control
MH  - Cattle
MH  - Crystallins/*metabolism
MH  - Cyanates/pharmacology
MH  - Cysteine/*metabolism
MH  - Lens, Crystalline/*drug effects/metabolism
MH  - Molecular Sequence Data
MH  - Pepsin A
MH  - Peptide Fragments/chemistry
EDAT- 1993/04/30 00:00
MHDA- 1993/04/30 00:01
CRDT- 1993/04/30 00:00
PHST- 1993/04/30 00:00 [pubmed]
PHST- 1993/04/30 00:01 [medline]
PHST- 1993/04/30 00:00 [entrez]
AID - 0925-4439(93)90098-L [pii]
AID - 10.1016/0925-4439(93)90098-l [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 1993 Apr 30;1181(2):103-10. doi: 
      10.1016/0925-4439(93)90098-l.

PMID- 19306941
OWN - NLM
STAT- MEDLINE
DCOM- 20090826
LR  - 20131121
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
VI  - 7
IP  - 7
DP  - 2009 Jul
TI  - Proton pump inhibitors for gastroduodenal damage related to nonsteroidal 
      anti-inflammatory drugs or aspirin: twelve important questions for clinical 
      practice.
PG  - 725-35
LID - 10.1016/j.cgh.2009.03.015 [doi]
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin are among the most 
      commonly used medications worldwide. Their use is associated with significant 
      gastroduodenal adverse effects, including dyspepsia, bleeding, ulcer formation, 
      and perforation. Given their long-term use by millions of patients, there is a 
      substantial impact at the population level of these complications. In this 
      evidence-based review, we have endeavored to answer 12 commonly encountered 
      questions in clinical practice that deal with the following: extent of the 
      problem of NSAID/aspirin-induced gastroduodenal damage and its impact on public 
      health; role of proton pump inhibitors (PPIs) in the primary prevention, healing, 
      and secondary prevention of NSAID/aspirin-induced gastroduodenal ulceration as 
      assessed by using endoscopic end points; role of PPIs in the prevention of 
      adverse clinical outcomes related to NSAID/aspirin use; whether PPIs are 
      effective in NSAID-induced dyspepsia; comparison of PPI co-therapy with selective 
      cyclooxygenase-2 inhibitors for risk reduction of adverse clinical outcomes; role 
      of PPIs in preventing rebleeding from aspirin +/- clopidogrel therapy in 
      high-risk patients; identifying high-risk patients who can benefit from PPI 
      co-therapy; the role of other gastroprotective agents for prevention of 
      NSAID/aspirin-induced gastroduodenal damage; and the cost-effectiveness of and 
      limitations to the use of PPIs for prevention of gastroduodenal damage related to 
      the use of NSAIDs or aspirin. We then summarized our recommendations on the use 
      of PPIs for the clinical management of patients using NSAIDs or aspirin.
FAU - Arora, Gaurav
AU  - Arora G
AD  - Division of Gastroenterology and Hepatology, Stanford University School of 
      Medicine, Stanford, California 94305-5187, USA.
FAU - Singh, Gurkirpal
AU  - Singh G
FAU - Triadafilopoulos, George
AU  - Triadafilopoulos G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20090321
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal 
      of the American Gastroenterological Association
JID - 101160775
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Clin Gastroenterol Hepatol. 2010 Apr;8(4):395; author reply 395-6. PMID: 19833229
MH  - Anti-Inflammatory Agents/*adverse effects/toxicity
MH  - Aspirin/adverse effects/toxicity
MH  - Humans
MH  - Peptic Ulcer/*chemically induced/*drug therapy
MH  - Proton Pump Inhibitors/*therapeutic use
RF  - 107
EDAT- 2009/03/25 09:00
MHDA- 2009/08/27 09:00
CRDT- 2009/03/25 09:00
PHST- 2008/08/20 00:00 [received]
PHST- 2009/03/06 00:00 [revised]
PHST- 2009/03/11 00:00 [accepted]
PHST- 2009/03/25 09:00 [entrez]
PHST- 2009/03/25 09:00 [pubmed]
PHST- 2009/08/27 09:00 [medline]
AID - S1542-3565(09)00230-4 [pii]
AID - 10.1016/j.cgh.2009.03.015 [doi]
PST - ppublish
SO  - Clin Gastroenterol Hepatol. 2009 Jul;7(7):725-35. doi: 10.1016/j.cgh.2009.03.015. 
      Epub 2009 Mar 21.

PMID- 10824632
OWN - NLM
STAT- MEDLINE
DCOM- 20000613
LR  - 20131121
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 67
IP  - 5
DP  - 2000 May
TI  - Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart 
      failure.
PG  - 530-7
AB  - BACKGROUND: There is some evidence that aspirin may be harmful to patients with 
      congestive heart failure treated with angiotensin-converting enzyme (ACE) 
      inhibitors, but there has never been any direct examination of the vascular 
      effects of aspirin in these patients. We sought to determine whether there is an 
      arachidonic acid-dependent vasodilator pathway in resistance arteries in humans, 
      whether it is affected by congestive heart failure, and whether it is inhibited 
      by low-dose aspirin. METHODS: A locally active dose of arachidonic acid was 
      infused into the nondominant brachial artery while forearm blood flow was 
      measured by venous occlusion plethysmography in 10 healthy subjects in a control 
      group and 15 patients with congestive heart failure treated with ACE inhibitor. 
      Patients with congestive heart failure were studied after administration of 0 mg, 
      75 mg, and 300 mg aspirin for 14 days. RESULTS: Arachidonic acid produced 
      progressive and incremental vasodilation (up to 64%). There was no significant 
      difference between patients and healthy control subjects studied after 
      administration of 0 mg aspirin. In patients, however, administration of 75 mg and 
      300 mg aspirin inhibited mean vasodilation by 55% and 59%, respectively. 
      CONCLUSIONS: There is an arachidonic acid-dependent vasodilator pathway in 
      humans. This pathway is not significantly affected by congestive heart failure. 
      It is significantly inhibited by even low-dose aspirin therapy. These results 
      imply that even the very lowest dose of aspirin in common use for 
      cardioprotection has potentially detrimental vasoconstrictor effects.
FAU - Davie, A P
AU  - Davie AP
AD  - Medical Research Council Clinical Research Initiative in Heart Failure, 
      University of Glasgow, Scotland.
FAU - Love, M P
AU  - Love MP
FAU - McMurray, J J
AU  - McMurray JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arachidonic Acid
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Brachial Artery/drug effects
MH  - Case-Control Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Heart Failure/*physiopathology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Plethysmography
MH  - Vasodilation/*drug effects
EDAT- 2000/05/29 09:00
MHDA- 2000/06/17 09:00
CRDT- 2000/05/29 09:00
PHST- 2000/05/29 09:00 [pubmed]
PHST- 2000/06/17 09:00 [medline]
PHST- 2000/05/29 09:00 [entrez]
AID - S0009-9236(00)11009-4 [pii]
AID - 10.1067/mcp.2000.106290 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2000 May;67(5):530-7. doi: 10.1067/mcp.2000.106290.

PMID- 30667501
OWN - NLM
STAT- MEDLINE
DCOM- 20190219
LR  - 20220408
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 321
IP  - 3
DP  - 2019 Jan 22
TI  - Association of Aspirin Use for Primary Prevention With Cardiovascular Events and 
      Bleeding Events: A Systematic Review and Meta-analysis.
PG  - 277-287
LID - 10.1001/jama.2018.20578 [doi]
AB  - IMPORTANCE: The role for aspirin in cardiovascular primary prevention remains 
      controversial, with potential benefits limited by an increased bleeding risk. 
      OBJECTIVE: To assess the association of aspirin use for primary prevention with 
      cardiovascular events and bleeding. DATA SOURCES: PubMed and Embase were searched 
      on Cochrane Library Central Register of Controlled Trials from the earliest 
      available date through November 1, 2018. STUDY SELECTION: Randomized clinical 
      trials enrolling at least 1000 participants with no known cardiovascular disease 
      and a follow-up of at least 12 months were included. Included studies compared 
      aspirin use with no aspirin (placebo or no treatment). DATA EXTRACTION AND 
      SYNTHESIS: Data were screened and extracted independently by both investigators. 
      Bayesian and frequentist meta-analyses were performed. MAIN OUTCOMES AND 
      MEASURES: The primary cardiovascular outcome was a composite of cardiovascular 
      mortality, nonfatal myocardial infarction, and nonfatal stroke. The primary 
      bleeding outcome was any major bleeding (defined by the individual studies). 
      RESULTS: A total of 13 trials randomizing 164 225 participants with 1 050 511 
      participant-years of follow-up were included. The median age of trial 
      participants was 62 years (range, 53-74), 77 501 (47%) were men, 30 361 (19%) had 
      diabetes, and the median baseline risk of the primary cardiovascular outcome was 
      9.2% (range, 2.6%-15.9%). Aspirin use was associated with significant reductions 
      in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 
      participant-years with aspirin and 61.4 per 10 000 participant-years with no 
      aspirin) (hazard ratio [HR], 0.89 [95% credible interval, 0.84-0.95]; absolute 
      risk reduction, 0.38% [95% CI, 0.20%-0.55%]; number needed to treat, 265). 
      Aspirin use was associated with an increased risk of major bleeding events 
      compared with no aspirin (23.1 per 10 000 participant-years with aspirin and 16.4 
      per 10 000 participant-years with no aspirin) (HR, 1.43 [95% credible interval, 
      1.30-1.56]; absolute risk increase, 0.47% [95% CI, 0.34%-0.62%]; number needed to 
      harm, 210). CONCLUSIONS AND RELEVANCE: The use of aspirin in individuals without 
      cardiovascular disease was associated with a lower risk of cardiovascular events 
      and an increased risk of major bleeding. This information may inform discussions 
      with patients about aspirin for primary prevention of cardiovascular events and 
      bleeding.
FAU - Zheng, Sean L
AU  - Zheng SL
AD  - Faculty of Medicine, Imperial College London, London, United Kingdom.
AD  - Department of Cardiology, King's College Hospital NHS Foundation Trust, Denmark 
      Hill, London, United Kingdom.
AD  - Faculty of Life Sciences and Medicine, King's College London, London, United 
      Kingdom.
FAU - Roddick, Alistair J
AU  - Roddick AJ
AD  - Faculty of Life Sciences and Medicine, King's College London, London, United 
      Kingdom.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2019 Jan 22;321(3):253-255. PMID: 30667488
CIN - Ann Intern Med. 2019 May 21;170(10):JC53. PMID: 31108515
EIN - JAMA. 2019 Jun 11;321(22):2245. PMID: 31184719
CIN - JAMA. 2019 Jun 11;321(22):2243-2244. PMID: 31184732
CIN - JAMA. 2019 Jun 11;321(22):2244. PMID: 31184734
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Complications/prevention & control
MH  - Diabetes Mellitus/drug therapy
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - *Primary Prevention
MH  - Risk
PMC - PMC6439678
COIS- Conflict of Interest Disclosures: The authors have no conflicts of interest to 
      disclose.
EDAT- 2019/01/23 06:00
MHDA- 2019/03/21 06:00
CRDT- 2019/01/23 06:00
PHST- 2019/01/23 06:00 [entrez]
PHST- 2019/01/23 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
AID - 2721178 [pii]
AID - joi180151 [pii]
AID - 10.1001/jama.2018.20578 [doi]
PST - ppublish
SO  - JAMA. 2019 Jan 22;321(3):277-287. doi: 10.1001/jama.2018.20578.

PMID- 9399638
OWN - NLM
STAT- MEDLINE
DCOM- 19971229
LR  - 20190701
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 61
IP  - 24
DP  - 1997
TI  - Aspalatone, a new antiplatelet agent, attenuates the neurotoxicity induced by 
      kainic acid in the rat.
PG  - PL 373-81
AB  - The antioxidant efficacy of aspalatone (APT; acetyl salicylic acid maltol ester), 
      a new antiplatelet agent, has been characterized in vivo as well as in vitro, and 
      several observations indicated that the antioxidant could prevent the 
      neuroexcitation caused by oxidative stress. In this report, the effect of APT was 
      evaluated on kainic acid (KA)-induced neurotoxicity, since the neurotoxicity 
      induced by KA is, at least in part, mediated via the formation of free radicals. 
      The results showed that pretreatments with APT or maltol (MAL) significantly 
      attenuated seizure activity, oxidative stress (lipid peroxidation and protein 
      oxidation) and the loss of hippocampal neurons induced by KA. On the other hand, 
      the pretreatments with aspirin (ASP), ASP together with MAL or vitamin E failed 
      to protect against the toxicity produced by KA suggesting that the mechanism of 
      action for APT on the KA-induced neurotoxicity is different from that of ASP. 
      These finding raise the possibility that salicylmaltol, a metabolite of APT, 
      plays a role in preventing the neurotoxicity evoked by KA. Therefore, our results 
      suggest that an APT-related antioxidant mechanism, which is linked to the MAL 
      moiety, is involved in the neuroprotective effect against KA.
FAU - Kim, H C
AU  - Kim HC
AD  - Department of Pharmacy, College of Pharmacy, Kangwon National University, 
      Chunchon, Korea.
FAU - Choi, D Y
AU  - Choi DY
FAU - Jhoo, W K
AU  - Jhoo WK
FAU - Lee, D W
AU  - Lee DW
FAU - Koo, C H
AU  - Koo CH
FAU - Kim, C
AU  - Kim C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A233M007P0 (aspalatone)
RN  - R16CO5Y76E (Aspirin)
RN  - SIV03811UC (Kainic Acid)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Brain/drug effects/pathology
MH  - Kainic Acid/*toxicity
MH  - Lipid Peroxidation/drug effects
MH  - Male
MH  - Neuroprotective Agents/*pharmacology
MH  - Oxidative Stress
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1997/01/01 00:00
MHDA- 1997/12/17 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/12/17 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - S0024-3205(97)00963-6 [pii]
AID - 10.1016/s0024-3205(97)00963-6 [doi]
PST - ppublish
SO  - Life Sci. 1997;61(24):PL 373-81. doi: 10.1016/s0024-3205(97)00963-6.

PMID- 10092935
OWN - NLM
STAT- MEDLINE
DCOM- 19990601
LR  - 20191103
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 27
IP  - 2
DP  - 1999 Mar
TI  - Comparison of resuscitation with diaspirin crosslinked hemoglobin (DCLHb) vs 
      fresh blood in a rat burn shock model.
PG  - 135-52
AB  - Diaspirin crosslinked hemoglobin (DCLHb; Baxter Healthcare Corp, Deerfield, IL) 
      is hemoglobin-based oxygen carrier which, in our laboratory, improved hemodynamic 
      parameters in a rat burn shock model. Our objective was to compare the effects on 
      hemodynamic parameters and metabolic acidosis of resuscitation with different 
      doses of fresh blood (FB) vs DCLHb. Male Wistar rats (200 to 250 g), surgically 
      prepared for an acute study, were randomly assigned to one of five treatment 
      groups. (n = 8): I. SHAM (not burned, not resuscitated), II. DCLHb 2 ml/kg/% 
      Total Body Surface Area (TBSA) burn and 2 ml/kg/% TBSA burn of Lactated Ringers 
      (LR), III. DCLHb 1 ml/kg/% TBSA burn and 1 ml/kg/% TBSA burn of LR IV. FB 2 
      ml/kg/% TBSA burn and 2 ml/kg/% TBSA burn of LR V. FB 1 ml/kg/% TBSA burn and 1 
      ml/kg/% TBSA burn of LR After placement of indwelling catheters, the following 
      baseline hemodynamic values were obtained mean arterial pressure (MAP), cardiac 
      output (CO), stroke volume (SV), systemic vascular resistance (SVR) and base 
      excess (BE). The animals were immediately intravenously resuscitated after 
      receiving a 30% scald burn and were followed for 6 hours. Resuscitation was based 
      on the Parkland formula. Blood was obtained from donor male Wistar rats. The 
      animals were euthanized at 6 hours. MAP remained within normal range in all 
      groups. The SVR, CO, SV and BE were normalized earlier in the LR-DCLHb groups 
      when compared to the LR-FB groups (p < 0.05). Early resuscitation with DCLHb is 
      superior to FB in improving hemodynamics in this model. There appears to be a 
      direct relationship between dose and effect with the use of DCLHb. DCLHb could be 
      useful in decreasing resuscitation fluid requirements in acute burns without 
      compromising general tissue perfusion.
FAU - Soltero, R G
AU  - Soltero RG
AD  - Department of Surgery, University of California San Diego Medical Center 92103, 
      USA.
FAU - Hansbrough, J F
AU  - Hansbrough JF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - *Blood Transfusion
MH  - Burns/*therapy
MH  - Hemodynamics
MH  - Hemoglobins/*therapeutic use
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - *Resuscitation
MH  - Shock/*therapy
EDAT- 1999/03/27 00:00
MHDA- 1999/03/27 00:01
CRDT- 1999/03/27 00:00
PHST- 1999/03/27 00:00 [pubmed]
PHST- 1999/03/27 00:01 [medline]
PHST- 1999/03/27 00:00 [entrez]
AID - 10.3109/10731199909117688 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1999 Mar;27(2):135-52. doi: 
      10.3109/10731199909117688.

PMID- 3379588
OWN - NLM
STAT- MEDLINE
DCOM- 19880727
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 77
IP  - 4
DP  - 1988 Apr
TI  - Decomposition of aspirin in the solid state in the presence of limited amounts of 
      moisture II: Kinetics and salting-in of aspirin in aqueous acetic acid solutions.
PG  - 314-7
AB  - The solubility of aspirin in saturated solutions of salicylic acid (and vice 
      versa) was studied in 0 to 16 M aqueous solutions of acetic acid. The 
      solubilities, when expressed in molarity, go through a maximum at an acetic acid 
      concentration of approximately 12 M. The temperature dependence of the 
      solubilities is such that the logarithm of the solubility is linear in reciprocal 
      absolute temperature. The calculated enthalpies are of the order of 11 kcal/mol. 
      The kinetics of aspirin decomposition was also studied at the different acetic 
      acid concentrations, and it was found that the second-order hydrolysis rate 
      constant is fairly independent of acetic acid concentration. Aspirin 
      decomposition follows an Arrhenius equation and has an activation energy of 18 
      kcal/mol.
FAU - Carstensen, J T
AU  - Carstensen JT
AD  - University of Wisconsin School of Pharmacy, Madison 53706.
FAU - Attarchi, F
AU  - Attarchi F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Acetates)
RN  - 0 (Solutions)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates
MH  - Aspirin/*analysis
MH  - Chemistry, Pharmaceutical
MH  - Drug Stability
MH  - Kinetics
MH  - Solubility
MH  - Solutions
MH  - Temperature
EDAT- 1988/04/01 00:00
MHDA- 1988/04/01 00:01
CRDT- 1988/04/01 00:00
PHST- 1988/04/01 00:00 [pubmed]
PHST- 1988/04/01 00:01 [medline]
PHST- 1988/04/01 00:00 [entrez]
AID - S0022-3549(15)47666-X [pii]
AID - 10.1002/jps.2600770406 [doi]
PST - ppublish
SO  - J Pharm Sci. 1988 Apr;77(4):314-7. doi: 10.1002/jps.2600770406.

PMID- 26088608
OWN - NLM
STAT- MEDLINE
DCOM- 20160216
LR  - 20181203
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 4
DP  - 2015 Jun 19
TI  - Investigating the effectiveness of different aspirin dosing regimens and the 
      timing of aspirin intake in primary and secondary prevention of cardiovascular 
      disease: protocol for a systematic review.
PG  - 88
LID - 10.1186/s13643-015-0078-3 [doi]
LID - 88
AB  - BACKGROUND: Once-daily low-dose aspirin is routinely used for the prevention of 
      secondary events in cardiovascular disease (CVD). The routine use of aspirin in 
      primary prevention of CVD is less clear due to a finer balance between benefits 
      and harms. In addition, the variability in benefit achievable from the 
      prescription of aspirin has led to a growing interest in considering whether 
      there are more effective aspirin regimens than once-daily dosing or whether 
      effectiveness is influenced by the time of day aspirin is taken (chronotherapy). 
      The proposed systematic review will evaluate the evidence on the effects of 
      different aspirin regimens used in terms of number of doses (e.g. split or 
      alternate dosing) or dosing time of aspirin (e.g. morning versus evening) in 
      primary and secondary prevention of CVD. METHODS/DESIGN: Standard systematic 
      review methodology will be employed for study identification, selection and data 
      extraction. Electronic databases will be searched incorporating terms relating to 
      population and the intervention. No date or language limitations will apply. 
      Systematic reviews and controlled studies comparing different aspirin regimens-in 
      terms of frequency or timing-for primary and/or secondary prevention of CVD will 
      be included. No restrictions on outcome will apply. Quality assessment will be 
      appropriate for each study design. The data will be tabulated and narratively 
      synthesised. Meta-analysis may be undertaken where clinical and methodological 
      homogeneity exists. DISCUSSION: There are a number of published and ongoing 
      primary studies that investigate the cardiovascular protective effect of 
      different aspirin regimens. However, no systematic review to date has attempted 
      to review the evidence pertaining to aspirin dosing regimens differing in 
      frequency and/or in timing. The proposed systematic review will cover both the 
      above questions and could potentially be beneficial for reconsidering the current 
      practice of managing patients with aspirin in primary care. SYSTEMATIC REVIEW 
      REGISTRATION: PROSPERO CRD42014010596.
FAU - Bem, Danai
AU  - Bem D
AD  - Public Health, Epidemiology and Biostatistics, School of Health and Population 
      Sciences, College of Medical and Dental Sciences, University of Birmingham, 
      Edgbaston, Birmingham, B15 2TT, UK. d.bem@bham.ac.uk.
FAU - Dretzke, Janine
AU  - Dretzke J
AD  - Public Health, Epidemiology and Biostatistics, School of Health and Population 
      Sciences, College of Medical and Dental Sciences, University of Birmingham, 
      Edgbaston, Birmingham, B15 2TT, UK. j.dretzke@bham.ac.uk.
AD  - NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth 
      Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, UK. j.dretzke@bham.ac.uk.
FAU - Stevens, Simon
AU  - Stevens S
AD  - Public Health, Epidemiology and Biostatistics, School of Health and Population 
      Sciences, College of Medical and Dental Sciences, University of Birmingham, 
      Edgbaston, Birmingham, B15 2TT, UK. s.stevens@bham.ac.uk.
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
AD  - Montreal Heart Institute, Research Centre, 5000 rue Bélanger, Montréal, QC, H1T 
      1C8, Canada. marie.lordkipanidze@umontreal.ca.
AD  - Faculté de pharmacie, Université de Montreal, C.P. 6128, Succ. Centre-ville, 
      Montreal, QC, H3C 3J7, Canada. marie.lordkipanidze@umontreal.ca.
FAU - Hodgkinson, James
AU  - Hodgkinson J
AD  - Primary Care Clinical Sciences, School of Health and Population Sciences, College 
      of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, 
      B15 2TT, UK. j.a.hodgkinson@bham.ac.uk.
FAU - Bayliss, Sue
AU  - Bayliss S
AD  - Public Health, Epidemiology and Biostatistics, School of Health and Population 
      Sciences, College of Medical and Dental Sciences, University of Birmingham, 
      Edgbaston, Birmingham, B15 2TT, UK. s.bayliss@bham.ac.uk.
FAU - Moore, David
AU  - Moore D
AD  - Public Health, Epidemiology and Biostatistics, School of Health and Population 
      Sciences, College of Medical and Dental Sciences, University of Birmingham, 
      Edgbaston, Birmingham, B15 2TT, UK. d.j.moore@bham.ac.uk.
FAU - Fitzmaurice, David
AU  - Fitzmaurice D
AD  - Primary Care Clinical Sciences, School of Health and Population Sciences, College 
      of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, 
      B15 2TT, UK. d.a.fitzmaurice@bham.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150619
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - *Clinical Protocols
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Primary Prevention/*methods
MH  - *Research Design
MH  - Secondary Prevention/*methods
MH  - Systematic Reviews as Topic
PMC - PMC4475616
EDAT- 2015/06/20 06:00
MHDA- 2016/02/18 06:00
CRDT- 2015/06/20 06:00
PHST- 2015/04/02 00:00 [received]
PHST- 2015/06/11 00:00 [accepted]
PHST- 2015/06/20 06:00 [entrez]
PHST- 2015/06/20 06:00 [pubmed]
PHST- 2016/02/18 06:00 [medline]
AID - 10.1186/s13643-015-0078-3 [pii]
AID - 78 [pii]
AID - 10.1186/s13643-015-0078-3 [doi]
PST - epublish
SO  - Syst Rev. 2015 Jun 19;4:88. doi: 10.1186/s13643-015-0078-3.

PMID- 1682734
OWN - NLM
STAT- MEDLINE
DCOM- 19911224
LR  - 20220321
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 338
IP  - 8779
DP  - 1991 Nov 30
TI  - Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis 
      after cerebrovascular ischaemic events. The SALT Collaborative Group.
PG  - 1345-9
AB  - The efficacy of aspirin in daily doses of 300 mg and more as secondary 
      prophylaxis after cerebrovascular events is well established. Since much lower 
      doses of aspirin can inhibit platelet function, and carry a lower risk of adverse 
      effects, the Swedish Aspirin Low-dose Trial (SALT) was set up to study the 
      efficacy of 75 mg aspirin daily in prevention of stroke and death after transient 
      ischaemic attack (TIA) or minor stroke. 1360 patients entered the study 1-4 
      months after the qualifying event: 676 were randomly assigned to aspirin 
      treatment and 684 to placebo treatment. The median duration of follow-up was 32 
      months. Compared with the placebo group, the aspirin group showed a reduction of 
      18% in the risk of primary outcome events (stroke or death; relative risk 0.82, 
      95% confidence interval 0.67-0.99; log-rank analysis p = 0.02), and reductions of 
      16-20% in the risks of secondary outcome events (stroke; stroke or two or more 
      TIAs within a week of each other necessitating a change of treatment; or 
      myocardial infarction). Adverse drug effects were reported by 147 aspirin-treated 
      and 123 placebo-treated patients Gastrointestinal side-effects were only slightly 
      more common in the aspirin-treated patients, but that group had a significant 
      excess of bleeding episodes (p = 0.04). Thus, we have found that a low dose (75 
      mg/day) of aspirin significantly reduces the risk of stroke or death in patients 
      with cerebrovascular ischaemic events.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 1992 Feb 8;339(8789):377. PMID: 1346461
CIN - Lancet. 1992 Feb 8;339(8789):377. PMID: 1346462
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Chi-Square Distribution
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Sweden
MH  - Treatment Outcome
EDAT- 1991/11/30 00:00
MHDA- 1991/11/30 00:01
CRDT- 1991/11/30 00:00
PHST- 1991/11/30 00:00 [pubmed]
PHST- 1991/11/30 00:01 [medline]
PHST- 1991/11/30 00:00 [entrez]
AID - 0140-6736(91)92233-R [pii]
PST - ppublish
SO  - Lancet. 1991 Nov 30;338(8779):1345-9.

PMID- 7138604
OWN - NLM
STAT- MEDLINE
DCOM- 19821221
LR  - 20190718
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 25
IP  - 11
DP  - 1982 Nov
TI  - Aspirin aggravates the degeneration of canine joint cartilage caused by 
      immobilization.
PG  - 1333-42
AB  - The effect of aspirin on the degeneration of knee cartilage caused by 
      immobilization was examined. If dogs were fed aspirin daily (serum salicylate = 
      20-25 mg/dl) for 6 weeks while one hind limb was immobilized in a cast, the 
      decreases in uronic acid content and net proteoglycan synthesis in cartilage from 
      the immobilized knee were significantly greater than the decreases in cartilage 
      from immobilized knees of dogs that had not received aspirin (P less than 0.01). 
      Furthermore, neither aspirin administration nor immobilization alone affected the 
      extractability of proteoglycans from the cartilage. However, in organ cultures of 
      cartilage from the immobilized knee of dogs fed aspirin, the proportion of the 
      total 35S-proteoglycans present in the culture medium was nearly twice that from 
      cultures of cartilage of the contralateral knee. Also, more than twice as many of 
      the total tissue proteoglycans (uronic acid) were extractable with 0.4 M 
      guanidinium chloride, a nondissociating solvent (P less than 0.01). Regardless of 
      whether the dogs received aspirin, the in vitro interaction of proteoglycans with 
      hyaluronic acid from cartilage of the immobilized knee was diminished, apparently 
      due to an abnormality in the hyaluronate-binding region of the core protein. 
      Although these results indicate that aspirin had an adverse effect in vivo on 
      articular cartilage of immobilized joint, aspirin administration did not preclude 
      reversal of all of the above changes if the dog was allowed to walk about in a 
      pen for 3 weeks after cast removal. If, however, the dog was run daily on a 
      treadmill for 3 weeks after cast removal, the decrease in uronic acid content in 
      cartilage from the immobilized knee persisted and was more profound if the animal 
      had received aspirin than if it had not (P less than 0.01).
FAU - Palmoski, M J
AU  - Palmoski MJ
FAU - Brandt, K D
AU  - Brandt KD
LA  - eng
GR  - AM 20582/AM/NIADDK NIH HHS/United States
GR  - AM 27075/AM/NIADDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Proteoglycans)
RN  - 0 (Uronic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*pharmacology
MH  - Body Water/metabolism
MH  - Cartilage, Articular/*drug effects
MH  - Dogs
MH  - *Immobilization
MH  - Knee Joint
MH  - Physical Exertion
MH  - Proteoglycans/biosynthesis/metabolism
MH  - Uronic Acids/metabolism
OID - NASA: 83048464
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
AID - 10.1002/art.1780251109 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1982 Nov;25(11):1333-42. doi: 10.1002/art.1780251109.

PMID- 3777289
OWN - NLM
STAT- MEDLINE
DCOM- 19861211
LR  - 20190514
IS  - 0090-0036 (Print)
IS  - 1541-0048 (Electronic)
IS  - 0090-0036 (Linking)
VI  - 76
IP  - 12
DP  - 1986 Dec
TI  - A survey of aspirin use and Reye's syndrome awareness among parents.
PG  - 1422-4
AB  - A national telephone survey of 1,155 parents of children 19 years of age and 
      younger solicited patterns of medication use during episodes of childhood flu and 
      chicken pox. During the previous two years, 6 per cent of the parents whose 
      children had chicken pox and 16 per cent of parents whose children had flu 
      administered aspirin. Approximately 12 per cent of the total sample said they 
      would give their child aspirin if their child were to get the flu or chicken pox 
      today. About half (53 per cent) were aware of the contraindication against 
      aspirin use and 40 per cent could spontaneously recall the name Reye's Syndrome 
      (RS). When measured by a recognition test, 84 per cent of the sample said they 
      had heard of RS. People who continued to believe that aspirin was an appropriate 
      medication were more likely to have treated older children. The RS 
      contraindication for aspirin should be emphasized for teenagers in future public 
      informational programs.
FAU - Morris, L A
AU  - Morris LA
FAU - Klimberg, R
AU  - Klimberg R
LA  - eng
GR  - 223-85-6010/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Public Health
JT  - American journal of public health
JID - 1254074
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/therapeutic use
MH  - *Attitude to Health
MH  - Chickenpox/drug therapy
MH  - Data Collection
MH  - Female
MH  - Humans
MH  - Income
MH  - Influenza, Human/drug therapy
MH  - Male
MH  - Reye Syndrome/*chemically induced
MH  - Texas
PMC - PMC1646993
EDAT- 1986/12/01 00:00
MHDA- 1986/12/01 00:01
CRDT- 1986/12/01 00:00
PHST- 1986/12/01 00:00 [pubmed]
PHST- 1986/12/01 00:01 [medline]
PHST- 1986/12/01 00:00 [entrez]
AID - 10.2105/ajph.76.12.1422 [doi]
PST - ppublish
SO  - Am J Public Health. 1986 Dec;76(12):1422-4. doi: 10.2105/ajph.76.12.1422.

PMID- 755033
OWN - NLM
STAT- MEDLINE
DCOM- 19791128
LR  - 20190819
IS  - 0020-9996 (Print)
IS  - 0020-9996 (Linking)
VI  - 13
IP  - 6
DP  - 1978 Nov-Dec
TI  - Aspirin effect on canine iopanoate transport maximun.
PG  - 541-3
AB  - Iopanoate saturation kinetics were measured in four dogs both drug free and 
      following six days of low dose aspirin ingestion. Each animal acted as its own 
      control. In post aspirin ingestion studies there was s significant (P less than 
      .001) decrease in the apparent Vmax of iopanoate. The volume of distribution 
      showed no significant change, and gallbladder visualization showed no significant 
      change despite the decrease in Vmax. Although aspirin pretreatment decreases the 
      control Vmax by 50%, its mechanism and significance in the clinical setting will 
      require further study.
FAU - Nelson, J A
AU  - Nelson JA
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Invest Radiol
JT  - Investigative radiology
JID - 0045377
RN  - FE9794P71J (Iopanoic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/blood/*pharmacology
MH  - *Cholecystography
MH  - Dogs
MH  - Drug Interactions
MH  - Iopanoic Acid/administration & dosage/*metabolism
MH  - Kinetics
MH  - Male
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
AID - 10.1097/00004424-197811000-00011 [doi]
PST - ppublish
SO  - Invest Radiol. 1978 Nov-Dec;13(6):541-3. doi: 10.1097/00004424-197811000-00011.

PMID- 7381740
OWN - NLM
STAT- MEDLINE
DCOM- 19800828
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 69
IP  - 5
DP  - 1980 May
TI  - Aspirin--a national survey II: Determination of salicylic acid in bulk aspirin 
      and aspirin formulations by high-pressure liquid chromatography using a 
      fluorescence detector.
PG  - 548-50
AB  - A quantitative high-pressure liquid chromatographic method, using a 
      reversed-phase column coupled to a fluorescence detector, was developed to 
      determine salicylic acid in bulk aspirin and plain and buffered aspirin tablets. 
      The aspirin was dissolved, filtered, and injected into the chromatograph; the 
      fluorescence of the salicylic acid was measured at approximately 425 nm. 
      Excipients and impurities did not interfere, and recoveries of 100% were 
      obtained. The method was used to analyze 84 aspirin samples.
FAU - Kirchhoefer, R D
AU  - Kirchhoefer RD
FAU - Juhl, W E
AU  - Juhl WE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Fluorometry
MH  - Salicylates/*analysis
MH  - Tablets
EDAT- 1980/05/01 00:00
MHDA- 1980/05/01 00:01
CRDT- 1980/05/01 00:00
PHST- 1980/05/01 00:00 [pubmed]
PHST- 1980/05/01 00:01 [medline]
PHST- 1980/05/01 00:00 [entrez]
AID - S0022-3549(15)43192-2 [pii]
AID - 10.1002/jps.2600690518 [doi]
PST - ppublish
SO  - J Pharm Sci. 1980 May;69(5):548-50. doi: 10.1002/jps.2600690518.

PMID- 9083630
OWN - NLM
STAT- MEDLINE
DCOM- 19970605
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 25
IP  - 1-2
DP  - 1997 Jan-Mar
TI  - Effect of subarachnoid administration of alpha-alpha diaspirin crosslinked 
      hemoglobin on cerebral blood flow in rats.
PG  - 95-104
AB  - As extravasated red blood cells have been implicated in the pathogenesis of 
      perfusion deficits after subarachnoid hemorrhage, alpha-alpha diaspirin 
      crosslinked hemoglobin (DCLHb) might have a detrimental effect on cerebral 
      perfusion after subarachnoid hemorrhage. We evaluated the effect of subarachnoid 
      administration of DCLHb on cerebral blood flow (CBF). Rats were randomized to 
      receive one of the following solutions into the cisterna magna: Control-0.3 ml of 
      mock cerebrospinal fluid; Blood-0.3 ml of autologous blood; DCLHb-0.3 ml of 10% 
      DCLHb. After 20-min, the area of cerebral hypoperfusion was determined (CBF < 40 
      ml.100g-1.min-1). The area of hypoperfusion (% area of a coronal brain section, 
      mean +/- SD) was greater in the Blood group (58 +/- 16) than the DCLHb (16 +/- 7) 
      and Control (5 +/- 5) groups (p < 0.05), and was greater in the DCLHb group than 
      the Control group (p < 0.05). These data support a hypothesis that extravasation 
      of blood from the intravascular to the subarachnoid space induces cerebral 
      hypoperfusion. Moreover, the data support the hypothesis that although 
      extravasated molecular hemoglobin decreases CBF, the adverse effect is not as 
      severe as a similar volume of blood.
FAU - Cole, D J
AU  - Cole DJ
AD  - Department of Anesthesiology-School of Medicine, Loma Linda University, 
      California 92354, USA.
FAU - McKay, L
AU  - McKay L
FAU - Jacobsen, W K
AU  - Jacobsen WK
FAU - Drummond, J C
AU  - Drummond JC
FAU - Patel, P M
AU  - Patel PM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Blood Substitutes/chemistry/*pharmacology
MH  - Cerebrovascular Circulation/drug effects/*physiology
MH  - Cross-Linking Reagents/chemistry/*pharmacology
MH  - Extravasation of Diagnostic and Therapeutic Materials
MH  - Hemoglobins/chemistry/*pharmacology
MH  - Humans
MH  - Injections
MH  - Male
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Subarachnoid Space
MH  - Vasoconstriction/drug effects/physiology
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.3109/10731199709118901 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1997 Jan-Mar;25(1-2):95-104. doi: 
      10.3109/10731199709118901.

PMID- 3986089
OWN - NLM
STAT- MEDLINE
DCOM- 19850620
LR  - 20190511
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 19
IP  - 3
DP  - 1985 Mar
TI  - Pharmacokinetic interaction of acetylsalicylic acid and dipyridamole.
PG  - 379-83
AB  - It is often recommended that acetylsalicylic acid (ASA) and dipyridamole should 
      be given together in order to obtain secondary prophylaxis against certain 
      ischaemic diseases. Therefore, the possible pharmacokinetic interactions between 
      these agents were assessed following single-dose exposures in 14 healthy 
      volunteers. The plasma concentrations of ASA, salicylic acid (SA) and 
      dipyridamole were measured by selective h.p.l.c. techniques. It was found that, 
      while dipyridamole kinetics were unaffected by concurrent ASA, concurrent 
      dipyridamole significantly enhanced the peak concentration (24%) and AUC (27%) of 
      ASA. Thus, co-administered dipyridamole might influence the anti-platelet effect 
      of ASA.
FAU - Nitelius, E
AU  - Nitelius E
FAU - Melander, A
AU  - Melander A
FAU - Wåhlin-Boll, E
AU  - Wåhlin-Boll E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*blood
MH  - Dipyridamole/administration & dosage/*blood
MH  - Drug Interactions
MH  - Humans
MH  - Kinetics
MH  - Male
PMC - PMC1463725
EDAT- 1985/03/01 00:00
MHDA- 1985/03/01 00:01
CRDT- 1985/03/01 00:00
PHST- 1985/03/01 00:00 [pubmed]
PHST- 1985/03/01 00:01 [medline]
PHST- 1985/03/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1985.tb02657.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1985 Mar;19(3):379-83. doi: 
      10.1111/j.1365-2125.1985.tb02657.x.

PMID- 7017492
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Preliminary study of guacetisal in chronic bronchitis].
PG  - 409-16
AB  - A single-blind, between-patients trial was run on two randomly formed groups of 
      15 hospitalised male patients with chronic obstructive bronchitis, carefully 
      selected to rule out excessive interference on the part of other pathologies or 
      lund complications, in which 3 tablespoonfuls a day Broncaspin suspension were 
      compared with the same dose of a recognised commercial preparation composed by 
      sodium thymosulphonate, ammonium acetate, codeine, and tincture of datura. The 
      clinical and instrumental data showed that Broncaspin had greater therapeutic 
      activity. The local and general tolerability of the two preparations was 
      uneceptionable.
FAU - Marvulli, G
AU  - Marvulli G
FAU - Partipilo, N
AU  - Partipilo N
LA  - ita
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Studio preliminare del guacetisal nella bronchite cronica.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Aged
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Bronchitis/*drug therapy
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Cough/drug therapy
MH  - Dyspnea/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiration/drug effects
MH  - Spirometry
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):409-16.

PMID- 1246989
OWN - NLM
STAT- MEDLINE
DCOM- 19760311
LR  - 20190509
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 65
IP  - 1
DP  - 1976 Jan
TI  - Bleeding times, platelet adhesion, and aspirin.
PG  - 69-72
AB  - The effects of aspirin on well-standardized commercially produced platelet 
      adhesiveness devices and template bleeding times were simultaneously studied in 
      19 normal volunteers. As expected, there was significant prolongation of the 
      bleeding time after aspirin, but there was no change in platelet adhesion. Reason 
      for the different effects of aspirin on the two tests are discussed. In addition, 
      the normal range of platelet adhesion was further defined utilizing commercially 
      prepared glass-bead columns.
FAU - Bick, R L
AU  - Bick RL
FAU - Adams, T
AU  - Adams T
FAU - Schmalhorst, W R
AU  - Schmalhorst WR
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Adhesiveness/*drug effects
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1093/ajcp/65.1.69 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1976 Jan;65(1):69-72. doi: 10.1093/ajcp/65.1.69.

PMID- 18318719
OWN - NLM
STAT- MEDLINE
DCOM- 20080708
LR  - 20220311
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Linking)
VI  - 34
IP  - 6
DP  - 2008 Jun
TI  - Effect of aspirin and heparin on random skin flap survival in rats.
PG  - 785-90; discussion 790
LID - 10.1111/j.1524-4725.2008.34147.x [doi]
AB  - BACKGROUND: Aspirin and heparin are commonly given to patients undergoing 
      microvascular procedures to increase flap survival and patency, yet there is 
      scant information concerning the effect these flaps have on nonmicrovascular 
      flaps. OBJECTIVE: The objective was to obtain baseline values concerning the 
      effect of aspirin and heparin on the viability of standardized flap tissues. 
      METHODS AND MATERIALS: One hundred rats were divided into five groups receiving 
      high-dose aspirin, low-dose aspirin, high-dose aspirin in combination with 
      heparin, and heparin alone and the final group were controls. The viability of 
      the tissue was measured at 1 week by fluorescein fluorescence. RESULTS: There was 
      significant improvement in flap survival in the high-dose aspirin and high-dose 
      aspirin combination groups. CONCLUSIONS: It appears that high-dose aspirin 
      increases survival of ischemic flap tissue irrespective of the presence of 
      microvascular anastomosis and may be of clinical benefit in all flap surgery. The 
      authors have indicated no significant interest with commercial supporters.
FAU - Shalom, Avshalom
AU  - Shalom A
AD  - Department of Plastic Surgery, Assaf Harofeh Medical Center, Zerifin, Israel. 
      fredricag@asaf.health.gov.il
FAU - Friedman, Tal
AU  - Friedman T
FAU - Westreich, Melvyn
AU  - Westreich M
LA  - eng
PT  - Journal Article
DEP - 20080303
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Anticoagulants/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Heparin/administration & dosage/*pharmacology
MH  - Lysine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Surgical Flaps/*pathology
MH  - Suture Techniques
MH  - Tissue Survival/*drug effects
EDAT- 2008/03/06 09:00
MHDA- 2008/07/09 09:00
CRDT- 2008/03/06 09:00
PHST- 2008/03/06 09:00 [pubmed]
PHST- 2008/07/09 09:00 [medline]
PHST- 2008/03/06 09:00 [entrez]
AID - DSU34147 [pii]
AID - 10.1111/j.1524-4725.2008.34147.x [doi]
PST - ppublish
SO  - Dermatol Surg. 2008 Jun;34(6):785-90; discussion 790. doi: 
      10.1111/j.1524-4725.2008.34147.x. Epub 2008 Mar 3.

PMID- 7354423
OWN - NLM
STAT- MEDLINE
DCOM- 19800417
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 69
IP  - 1
DP  - 1980 Jan
TI  - High-pressure liquid chromatographic determination of salicylic acid in aspirin 
      powder and pharmaceutical dosage forms.
PG  - 113-5
AB  - A sensitive, simple, and rapid method for the quantitation of salicylic acid in 
      aspirin powders and its dosage forms was developed. The method is based on 
      reversed-phase high-pressure liquid chromatography using a mobile phase 
      containing 20% methanol in aqueous phosphate buffer of pH 2.3. Other common 
      ingredients present with aspirin such as acetaminophen, caffeine, codeine 
      phosphate, phenacetin, and salicylamide do not interfere. Salicylic acid 
      quantities as low as 0.1 microgram can be assayed with a relative standard 
      deviation of +/- 2.3%. Sensitivity can be increased by using lower sensitivity 
      settings. The method was tried on numerous commercial products and an old aspirin 
      powder. The results generally were excellent, except that all of the aspirin and 
      salicylic acid could not be extracted from suppositories. The old aspirin powder 
      failed the USP limit test for salicylic acid. The powder apparently absorbed 
      moisture and contained salicylamide as an impurity.
FAU - Das Gupta, V
AU  - Das Gupta V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Dosage Forms)
RN  - 0 (Powders)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid
MH  - Dosage Forms
MH  - Powders
MH  - Salicylates/*analysis
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - S0022-3549(15)43018-7 [pii]
AID - 10.1002/jps.2600690137 [doi]
PST - ppublish
SO  - J Pharm Sci. 1980 Jan;69(1):113-5. doi: 10.1002/jps.2600690137.

PMID- 28238314
OWN - NLM
STAT- MEDLINE
DCOM- 20171011
LR  - 20220321
IS  - 2468-7189 (Electronic)
IS  - 2468-7189 (Linking)
VI  - 45
IP  - 1
DP  - 2017 Jan
TI  - [Obstetrical APS: Is there a place for additional treatment to aspirin-heparin 
      combination?].
PG  - 37-42
LID - S2468-7189(16)30010-1 [pii]
LID - 10.1016/j.gofs.2016.12.010 [doi]
AB  - Obstetrical APS is defined by thrombosis and/or obstetrical morbidity associated 
      with persistent antiphospholipid antibodies. The aspirin and low molecular 
      weighted heparin combination dramatically improved obstetrical outcome in APS 
      patients. Several factors could be associated with obstetrical prognosis, as 
      previous history of thrombosis, associated SLE, the presence of lupus 
      anticoagulant and triple positivity of antiphospholipid antibodies. Obstetrical 
      APS with isolated recurrent miscarriages is mostly associated with isolated 
      anticardiolipids antibodies and have better obstetrical outcome. The pregnancy 
      loss despite aspirin and heparin combination define the refractory obstetrical 
      APS, and the prevalence could be estimated to 20-39%. Several other treatments 
      have been used in small and open labeled studies, as steroids, intravenous 
      immunoglobulins, plasma exchanges and hydroxychloroquine to improve the 
      obstetrical outcome. Some other drugs as eculizumab and statins could also have 
      physiopathological rational, but studies are necessary to define the place of 
      these various drugs.
CI  - Copyright © 2016 Elsevier Masson SAS. All rights reserved.
FAU - Mekinian, A
AU  - Mekinian A
AD  - AP-HP, hôpital Saint-Antoine, service de médecine interne et l'inflammation-(DHU 
      i2B), université Paris 06, 184, rue Faubourg-Saint-Antoine, 75012 Paris, France. 
      Electronic address: arsene.mekinian@aphp.fr.
FAU - Kayem, G
AU  - Kayem G
AD  - AP-HP, hôpital Trousseau, service d'obstétrique, université de Paris 06, 75012 
      Paris, France.
FAU - Cohen, J
AU  - Cohen J
AD  - AP-HP, hôpital Tenon, service d'obstétrique et de procréation médicalement 
      assistée, université Paris 06, UMRS-938, 75020 Paris, France.
FAU - Carbillon, L
AU  - Carbillon L
AD  - AP-HP, hôpital Jean-Verdier, service d'obstétrique, université Paris 13, 93300 
      Bondy, France.
FAU - Abisror, N
AU  - Abisror N
AD  - AP-HP, hôpital Saint-Antoine, service de médecine interne et l'inflammation-(DHU 
      i2B), université Paris 06, 184, rue Faubourg-Saint-Antoine, 75012 Paris, France.
FAU - Josselin-Mahr, L
AU  - Josselin-Mahr L
AD  - AP-HP, hôpital Saint-Antoine, service de médecine interne et l'inflammation-(DHU 
      i2B), université Paris 06, 184, rue Faubourg-Saint-Antoine, 75012 Paris, France.
FAU - Bornes, M
AU  - Bornes M
AD  - AP-HP, hôpital Bichat, auto-immunité et hypersensibilité, université Paris 7, 
      Paris, France.
FAU - Fain, O
AU  - Fain O
AD  - AP-HP, hôpital Saint-Antoine, service de médecine interne et l'inflammation-(DHU 
      i2B), université Paris 06, 184, rue Faubourg-Saint-Antoine, 75012 Paris, France.
LA  - fre
PT  - Journal Article
TT  - Le syndrome des antiphospholipides obstétrical : quelle est la place d’un 
      traitement complémentaire à la combinaison aspirine et héparine ?
DEP - 20170131
PL  - France
TA  - Gynecol Obstet Fertil Senol
JT  - Gynecologie, obstetrique, fertilite & senologie
JID - 101693805
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/immunology
MH  - Antiphospholipid Syndrome/complications/*drug therapy
MH  - Aspirin/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy/*immunology
MH  - Pregnancy Outcome
OTO - NOTNLM
OT  - Associated immunomodulation
OT  - Obstetrical APS
OT  - Refractory
OT  - Réfractaire
OT  - SAPL obstétrical
OT  - Traitement
OT  - Traitements immunomodulateurs
OT  - Treatment
EDAT- 2017/02/28 06:00
MHDA- 2017/10/12 06:00
CRDT- 2017/02/28 06:00
PHST- 2016/09/06 00:00 [received]
PHST- 2016/11/14 00:00 [accepted]
PHST- 2017/02/28 06:00 [entrez]
PHST- 2017/02/28 06:00 [pubmed]
PHST- 2017/10/12 06:00 [medline]
AID - S2468-7189(16)30010-1 [pii]
AID - 10.1016/j.gofs.2016.12.010 [doi]
PST - ppublish
SO  - Gynecol Obstet Fertil Senol. 2017 Jan;45(1):37-42. doi: 
      10.1016/j.gofs.2016.12.010. Epub 2017 Jan 31.

PMID- 6422821
OWN - NLM
STAT- MEDLINE
DCOM- 19840327
LR  - 20131121
IS  - 0003-410X (Print)
IS  - 0003-410X (Linking)
VI  - 135
IP  - 1
DP  - 1984
TI  - [Respiratory manifestations and intolerance to aspirin and non-steroidal 
      anti-inflammatory agents].
PG  - 21-5
AB  - This pathology is not due to the drug but revealed or aggravated by it. The most 
      commonly implicated drugs are the anti-inflammatory group, especially aspirin. 
      However, the list of drugs liable to induce intolerance continues to grow. The 
      clinical manifestations are mainly observed in middle age and may regress. Drug 
      intolerance can be demonstrated by provocative tests; it can be limited by 
      methods of drug tolerance. The most commonly pathogenic mechanisms are: 
      -inflammatory mechanisms (role of kinin), -disturbance of the metabolism of 
      arachidonic acid, prostaglandin blockage, stimulation of leukotrienes. This 
      expanding pathogenic entity is independent though similar in many aspects to the 
      immediate forms of allergy, so explaining its importance in the general field of 
      pseudo-allergy.
FAU - Grilliat, J P
AU  - Grilliat JP
FAU - Moneret-Vautrin, D A
AU  - Moneret-Vautrin DA
FAU - You, B
AU  - You B
FAU - Reynier, A
AU  - Reynier A
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Manifestations respiratoires et intolérance à l'aspirine et aux 
      anti-inflammatoires non stéroïdiens.
PL  - France
TA  - Ann Med Interne (Paris)
JT  - Annales de medecine interne
JID - 0171744
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Prostaglandins)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/*adverse effects
MH  - Arachidonic Acid
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/adverse effects
MH  - Bradykinin/physiology
MH  - Bronchial Provocation Tests
MH  - Drug Hypersensitivity/*physiopathology
MH  - Humans
MH  - Middle Aged
MH  - Prostaglandins/physiology
MH  - Respiratory Tract Diseases/*chemically induced
MH  - Skin Tests
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Ann Med Interne (Paris). 1984;135(1):21-5.

PMID- 35679244
OWN - NLM
STAT- MEDLINE
DCOM- 20220613
LR  - 20220716
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 6
DP  - 2022
TI  - Improved implementation of aspirin in pregnancy among Dutch gynecologists: 
      Surveys in 2016 and 2021.
PG  - e0268673
LID - 10.1371/journal.pone.0268673 [doi]
LID - e0268673
AB  - OBJECTIVE: To evaluate the implementation of low-dose aspirin in pregnancy for 
      the prevention of utero-placental complications among gynecologists in the 
      Netherlands between 2016 and 2021. In this timeframe, a national guideline about 
      aspirin in pregnancy was introduced by the Dutch Society of Obstetrics and 
      Gynecology. MATERIALS AND METHODS: A national online survey among Dutch 
      gynecologists and residents was performed. An online questionnaire was 
      distributed among the members of the Dutch Society of Obstetrics and Gynecology 
      in April 2016 and April 2021. Main outcome measure was the proportion of 
      gynecologists indicating prescription of aspirin in pregnancy for high and 
      moderate risk indications. RESULTS: In 2016, 133 respondents completed the 
      survey, and in 2021 231. For all indications mentioned in the guideline there was 
      an increase in prescribing aspirin in 2021 in comparison to 2016. More 
      specifically, the percentage of gynecologists prescribing aspirin for a history 
      of preeclampsia before 34 weeks, between 34 and 37 weeks and at term increased 
      from respectively 94% to 100%, 39% to 98%, and 15% to 97%. Consultant 
      obstetricians and respondents working in an university hospital did not more 
      often indicate the prescription of aspirin for tertiary care indications in 2021. 
      Future use of a prediction model was suggested in the narrative comments. 
      CONCLUSION: Implementation of aspirin in pregnancy among Dutch gynecologists 
      substantially improved after a five year timeframe in which the national 
      guideline on aspirin during pregnancy was introduced and trials confirming the 
      effect of aspirin were published.
FAU - Bij de Weg, Jeske Milou
AU  - Bij de Weg JM
AUID- ORCID: 0000-0002-9275-8825
AD  - Amsterdam UMC location Vrije Universiteit Amsterdam, Obstetrics and Gynecology, 
      Amsterdam, Netherlands.
AD  - Amsterdam Reproduction and Development Research Institute, Pregnancy and Birth, 
      Amsterdam, Netherlands.
FAU - Visser, Laura
AU  - Visser L
AD  - Amsterdam UMC location Vrije Universiteit Amsterdam, Obstetrics and Gynecology, 
      Amsterdam, Netherlands.
AD  - Amsterdam Reproduction and Development Research Institute, Pregnancy and Birth, 
      Amsterdam, Netherlands.
FAU - Oudijk, Martijn Alexander
AU  - Oudijk MA
AD  - Amsterdam UMC location Vrije Universiteit Amsterdam, Obstetrics and Gynecology, 
      Amsterdam, Netherlands.
AD  - Amsterdam Reproduction and Development Research Institute, Pregnancy and Birth, 
      Amsterdam, Netherlands.
FAU - de Vries, Johanna Inge Petra
AU  - de Vries JIP
AD  - Amsterdam UMC location Vrije Universiteit Amsterdam, Obstetrics and Gynecology, 
      Amsterdam, Netherlands.
AD  - Amsterdam Reproduction and Development Research Institute, Pregnancy and Birth, 
      Amsterdam, Netherlands.
FAU - de Groot, Christianne Johanna Maria
AU  - de Groot CJM
AD  - Amsterdam UMC location Vrije Universiteit Amsterdam, Obstetrics and Gynecology, 
      Amsterdam, Netherlands.
AD  - Amsterdam Reproduction and Development Research Institute, Pregnancy and Birth, 
      Amsterdam, Netherlands.
FAU - de Boer, Marjon Alina
AU  - de Boer MA
AD  - Amsterdam UMC location Vrije Universiteit Amsterdam, Obstetrics and Gynecology, 
      Amsterdam, Netherlands.
AD  - Amsterdam Reproduction and Development Research Institute, Pregnancy and Birth, 
      Amsterdam, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20220609
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - *Gynecology
MH  - Humans
MH  - *Obstetrics
MH  - Placenta
MH  - Pregnancy
MH  - Surveys and Questionnaires
PMC - PMC9182337
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/06/10 06:00
MHDA- 2022/06/14 06:00
CRDT- 2022/06/09 13:33
PHST- 2022/02/07 00:00 [received]
PHST- 2022/05/05 00:00 [accepted]
PHST- 2022/06/09 13:33 [entrez]
PHST- 2022/06/10 06:00 [pubmed]
PHST- 2022/06/14 06:00 [medline]
AID - PONE-D-22-03768 [pii]
AID - 10.1371/journal.pone.0268673 [doi]
PST - epublish
SO  - PLoS One. 2022 Jun 9;17(6):e0268673. doi: 10.1371/journal.pone.0268673. 
      eCollection 2022.

PMID- 398994
OWN - NLM
STAT- MEDLINE
DCOM- 19801021
LR  - 20191028
IS  - 0161-4630 (Print)
IS  - 0161-4630 (Linking)
VI  - 3
IP  - 6
DP  - 1979 Dec
TI  - Shortening of the bleeding time in thrombocytopenic rabbits after exposure of 
      jugular vein to high aspirin concentration.
PG  - 333-42
AB  - Aspirin, in doses which inhibit platelet thromboxane A2 production, prolongs the 
      bleeding time but this effect on the bleeding time is lost when doses of aspirin 
      which also inhibit vessel wall prostaglandin I2 (PGI2) production are used. PGI2 
      is both a potent inhibitor of platelet aggregation and a powerful vasodilator. We 
      have investigated the contribution of the vascular effect of PGI2 on hemostasis 
      by studying the effect of high concentrations of aspirin on the jugular vein 
      bleeding time in severely thrombocytopenic rabbits and on the loss of 
      non-platelet-containing fluid from standard puncture wounds in aspirin-treated 
      veins perfused under constant pressure. After aspirin treatment, the bleeding 
      time was significantly shortened in both normal and thrombocytopenic rabbits. 
      This effect was associated with a decreased production of PGI2-like material by 
      the vessel wall and a reduction in the volume of fluid lost from the standard 
      puncture wound in the jugular vein. The effect of aspirin on the bleeding time 
      and on PGI2 production was relatively short-lived and the bleeding time returned 
      to normal within 2-3 hours. These observations indicate that PGI2 can influence 
      hemostasis by mechanisms independent of platelet aggregation.
FAU - Buchanan, M R
AU  - Buchanan MR
FAU - Blajchman, M A
AU  - Blajchman MA
FAU - Dejana, E
AU  - Dejana E
FAU - Mustard, J F
AU  - Mustard JF
FAU - Senyi, A F
AU  - Senyi AF
FAU - Hirsh, J
AU  - Hirsh J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins Med
JT  - Prostaglandins and medicine
JID - 7810330
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Epoprostenol/biosynthesis
MH  - Female
MH  - Jugular Veins/drug effects/metabolism
MH  - Male
MH  - Rabbits
MH  - Thrombocytopenia/*blood
EDAT- 1979/12/01 00:00
MHDA- 1979/12/01 00:01
CRDT- 1979/12/01 00:00
PHST- 1979/12/01 00:00 [pubmed]
PHST- 1979/12/01 00:01 [medline]
PHST- 1979/12/01 00:00 [entrez]
AID - 10.1016/0161-4630(79)90026-0 [doi]
PST - ppublish
SO  - Prostaglandins Med. 1979 Dec;3(6):333-42. doi: 10.1016/0161-4630(79)90026-0.

PMID- 20856266
OWN - NLM
STAT- MEDLINE
DCOM- 20110128
LR  - 20211020
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Print)
IS  - 1759-5029 (Linking)
VI  - 6
IP  - 11
DP  - 2010 Nov
TI  - Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.
PG  - 619-28
LID - 10.1038/nrendo.2010.169 [doi]
AB  - Aspirin is effective for the prevention of cardiovascular events in patients with 
      a history of vascular disease, as so-called secondary prevention. In general 
      populations with no history of previous myocardial infarction or stroke, aspirin 
      also seems useful for primary prevention of cardiovascular events, although the 
      absolute benefits are smaller than those seen in patients with previous 
      cardiovascular disease. Patients with diabetes mellitus are at an increased risk 
      of cardiovascular events, but new trials have raised questions about the benefit 
      of aspirin for primary prevention in patients with this disorder. This Review 
      comprehensively examines the basic pharmacology of aspirin and provides an 
      overview of the randomized, controlled trials of aspirin therapy that have 
      included patients with diabetes mellitus. On the basis of currently available 
      evidence from primary prevention trials, aspirin is estimated to reduce the 
      relative risk of myocardial infarction and stroke by about 10% in patients with 
      diabetes mellitus; however, aspirin also increases the risk of gastrointestinal 
      bleeding. As such, low-dose aspirin therapy (75-162 mg) is reasonable for 
      patients with diabetes mellitus and a 10-year risk of cardiovascular events >10%. 
      Results from upcoming large trials will help clarify the effects of aspirin with 
      greater precision, including whether the benefits differ between men and women.
FAU - Pignone, Michael
AU  - Pignone M
AD  - Department of Medicine, University of North Carolina, 5039 Old Clinic Building, 
      CB7110, Chapel Hill, NC 27599-7110, USA. michael_pignone@med.unc.edu
FAU - Williams, Craig D
AU  - Williams CD
LA  - eng
GR  - K05 CA129166/CA/NCI NIH HHS/United States
GR  - K05 CA129166-04/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20100921
PL  - England
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Complications/*prevention & control
MH  - Drug Resistance
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology/prevention & control
MH  - Practice Guidelines as Topic
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Stroke/epidemiology/prevention & control
PMC - PMC3145323
MID - NIHMS307267
EDAT- 2010/09/22 06:00
MHDA- 2011/02/01 06:00
CRDT- 2010/09/22 06:00
PHST- 2010/09/22 06:00 [entrez]
PHST- 2010/09/22 06:00 [pubmed]
PHST- 2011/02/01 06:00 [medline]
AID - nrendo.2010.169 [pii]
AID - 10.1038/nrendo.2010.169 [doi]
PST - ppublish
SO  - Nat Rev Endocrinol. 2010 Nov;6(11):619-28. doi: 10.1038/nrendo.2010.169. Epub 
      2010 Sep 21.

PMID- 2404046
OWN - NLM
STAT- MEDLINE
DCOM- 19900209
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 15
IP  - 1
DP  - 1990 Jan
TI  - Implications of preoperative administration of aspirin in patients undergoing 
      coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study 
      on Antiplatelet Therapy.
PG  - 15-20
AB  - The perioperative consequences of preoperative aspirin administration were 
      assessed in a large prospective cooperative study of 772 patients undergoing 
      coronary artery bypass grafting. The 772 patients were randomized to receive 
      either aspirin (325 mg once a day), aspirin (325 mg three times a day), aspirin 
      plus dipyridamole (325 and 75 mg together three times a day) (aspirin group), 
      sulfinpyrazone (267 mg three times a day) or placebo (nonaspirin group). The 
      therapy, except in the aspirin group, was started 48 h before the operation. In 
      all aspirin subgroups, one 325 mg aspirin dose was given 12 h before surgery and 
      maintained thereafter according to the assigned regimen. Patients in the aspirin 
      group had significantly more postoperative bleeding and received more packed 
      blood cells and blood products than did patients in the nonaspirin group. 
      Although total operative duration and cardiopulmonary bypass duration were not 
      different, the interval between completion of cardiopulmonary bypass and wound 
      closure was significantly longer (p = 0.035) in the aspirin group. Thirty-one 
      (6.6%) of 471 patients in the aspirin group and 5 (1.7%) of 301 patients in the 
      nonaspirin group also required reoperation for control of postoperative bleeding 
      (p = 0.002). The site of bleeding found at reoperation was not different between 
      the two groups. There was no difference in operative mortality rates, incidence 
      of other bleeding complications or occurrence of other post-operative 
      complications between the two groups. Thus, antiplatelet regimens involving 
      preoperative initiation of aspirin therapy, which has been shown to improve graft 
      patency, increase the risk of abnormal postoperative bleeding and the need for 
      reoperation.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Sethi, G K
AU  - Sethi GK
AD  - Division of Cardiothoracic Surgery, Department of Veterans Affairs Medical 
      Center, Tucson, Arizona 85723.
FAU - Copeland, J G
AU  - Copeland JG
FAU - Goldman, S
AU  - Goldman S
FAU - Moritz, T
AU  - Moritz T
FAU - Zadina, K
AU  - Zadina K
FAU - Henderson, W G
AU  - Henderson WG
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
CIN - J Am Coll Cardiol. 1990 Jan;15(1):21-2. PMID: 2295734
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Transfusion
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/therapeutic use
MH  - Double-Blind Method
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Premedication
MH  - Randomized Controlled Trials as Topic
MH  - Reoperation
MH  - Sulfinpyrazone/therapeutic use
MH  - Vascular Patency/drug effects
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 0735-1097(90)90168-O [pii]
AID - 10.1016/0735-1097(90)90168-o [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1990 Jan;15(1):15-20. doi: 10.1016/0735-1097(90)90168-o.

PMID- 17512048
OWN - NLM
STAT- MEDLINE
DCOM- 20070614
LR  - 20220330
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 369
IP  - 9575
DP  - 2007 May 26
TI  - Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of 
      individual patient data.
PG  - 1791-1798
LID - S0140-6736(07)60712-0 [pii]
LID - 10.1016/S0140-6736(07)60712-0 [doi]
AB  - BACKGROUND: Pre-eclampsia is a major cause of mortality and morbidity during 
      pregnancy and childbirth. Antiplatelet agents, especially low-dose aspirin, might 
      prevent or delay pre-eclampsia, and thereby improve outcome. Our aim was to 
      assess the use of antiplatelet agents for the primary prevention of 
      pre-eclampsia, and to explore which women are likely to benefit most. METHODS: We 
      did a meta-analysis of individual patient data from 32,217 women, and their 
      32,819 babies, recruited to 31 randomised trials of pre-eclampsia primary 
      prevention. FINDINGS: For women assigned to receive antiplatelet agents rather 
      than control, the relative risk of developing pre-eclampsia was 0.90 (95% CI 
      0.84-0.97), of delivering before 34 weeks was 0.90 (0.83-0.98), and of having a 
      pregnancy with a serious adverse outcome was 0.90 (0.85-0.96). Antiplatelet 
      agents had no significant effect on the risk of death of the fetus or baby, 
      having a small for gestational age infant, or bleeding events for either the 
      women or their babies. No particular subgroup of women was substantially more or 
      less likely to benefit from antiplatelet agents than any other. INTERPRETATION: 
      Antiplatelet agents during pregnancy are associated with moderate but consistent 
      reductions in the relative risk of pre-eclampsia, of birth before 34 weeks' 
      gestation, and of having a pregnancy with a serious adverse outcome.
FAU - Askie, Lisa M
AU  - Askie LM
AD  - Centre for Perinatal Health Services Research, University of Sydney, Sydney, 
      Australia; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; 
      UK Cochrane Centre, Oxford, UK. Electronic address: laskie@ctc.usyd.edu.au.
FAU - Duley, Lelia
AU  - Duley L
AD  - Nuffield Department of Medicine, University of Oxford, Oxford, UK.
FAU - Henderson-Smart, David J
AU  - Henderson-Smart DJ
AD  - Centre for Perinatal Health Services Research, University of Sydney, Sydney, 
      Australia.
FAU - Stewart, Lesley A
AU  - Stewart LA
AD  - Centre for Reviews and Dissemination, University of York, UK.
CN  - PARIS Collaborative Group
LA  - eng
GR  - G116/98/MRC_/Medical Research Council/United Kingdom
GR  - MC_U122861323/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2007 May 26;369(9575):1765-6. PMID: 17512047
CIN - Lancet. 2007 Nov 17;370(9600):1685; author reply 1685-6. PMID: 18022031
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Pre-Eclampsia/physiopathology/*prevention & control
MH  - Pregnancy
MH  - *Pregnancy Outcome
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
RF  - 59
EDAT- 2007/05/22 09:00
MHDA- 2007/06/15 09:00
CRDT- 2007/05/22 09:00
PHST- 2007/05/22 09:00 [pubmed]
PHST- 2007/06/15 09:00 [medline]
PHST- 2007/05/22 09:00 [entrez]
AID - S0140-6736(07)60712-0 [pii]
AID - 10.1016/S0140-6736(07)60712-0 [doi]
PST - ppublish
SO  - Lancet. 2007 May 26;369(9575):1791-1798. doi: 10.1016/S0140-6736(07)60712-0.

PMID- 37373019
OWN - NLM
STAT- MEDLINE
DCOM- 20230629
LR  - 20230701
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 12
DP  - 2023 Jun 7
TI  - Acetylsalicylic Acid Supplementation Affects the Neurochemical Phenotyping of 
      Porcine Duodenal Neurons.
LID - 10.3390/ijms24129871 [doi]
LID - 9871
AB  - Aspirin (ASA) is a popular nonsteroidal anti-inflammatory drug (NSAID), which 
      exerts its therapeutic properties through the inhibition of cyclooxygenase (COX) 
      isoform 2 (COX-2), while the inhibition of COX-1 by ASA results in the formation 
      of gastrointestinal side effects. Due to the fact that the enteric nervous system 
      (ENS) is involved in the regulation of digestive functions both in physiological 
      and pathological states, the aim of this study was to determine the influence of 
      ASA on the neurochemical profile of enteric neurons in the porcine duodenum. Our 
      research, conducted using the double immunofluorescence technique, proved an 
      increase in the expression of selected enteric neurotransmitters in the duodenum 
      as a result of ASA treatment. The mechanisms of the visualized changes are not 
      entirely clear but are probably related to the enteric adaptation to inflammatory 
      conditions resulting from aspirin supplementation. A detailed understanding of 
      the role of the ENS in the development of drug-induced inflammation will 
      contribute to the establishment of new strategies for the treatment of 
      NSAID-induced lesions.
FAU - Brzozowska, Marta
AU  - Brzozowska M
AUID- ORCID: 0000-0002-7233-4187
AD  - Department of Clinical Physiology, Faculty of Veterinary Medicine, University of 
      Warmia and Mazury in Olsztyn, Oczapowskiego Str. 13, 10-718 Olsztyn, Poland.
FAU - Całka, Jarosław
AU  - Całka J
AD  - Department of Clinical Physiology, Faculty of Veterinary Medicine, University of 
      Warmia and Mazury in Olsztyn, Oczapowskiego Str. 13, 10-718 Olsztyn, Poland.
LA  - eng
GR  - 2018/29/N/NZ4/00348/National Science Center/
PT  - Journal Article
DEP - 20230607
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
SB  - IM
MH  - Swine
MH  - Animals
MH  - *Aspirin/pharmacology/metabolism
MH  - *Enteric Nervous System/metabolism
MH  - Neurons/metabolism
MH  - Duodenum
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/metabolism
MH  - Dietary Supplements
PMC - PMC10298401
OTO - NOTNLM
OT  - ENS
OT  - acetylsalicylic acid
OT  - duodenum
OT  - peripheral nervous system
OT  - pig
COIS- The authors declare no conflict of interest.
EDAT- 2023/06/28 06:42
MHDA- 2023/06/29 06:43
CRDT- 2023/06/28 01:16
PHST- 2023/04/22 00:00 [received]
PHST- 2023/06/03 00:00 [revised]
PHST- 2023/06/04 00:00 [accepted]
PHST- 2023/06/29 06:43 [medline]
PHST- 2023/06/28 06:42 [pubmed]
PHST- 2023/06/28 01:16 [entrez]
AID - ijms24129871 [pii]
AID - ijms-24-09871 [pii]
AID - 10.3390/ijms24129871 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Jun 7;24(12):9871. doi: 10.3390/ijms24129871.

PMID- 3975255
OWN - NLM
STAT- MEDLINE
DCOM- 19850404
LR  - 20180214
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 30
IP  - 1
DP  - 1985
TI  - Minimization of gastric damage with enteric-coated aspirin granules compared to 
      buffered aspirin.
PG  - 40-4
AB  - This study involved a randomized parallel groups comparison of the effects of 
      aspirin formulated as enteric-coated granules (25 subjects) or as buffered 
      tablets (26 subjects) with that of a lactose placebo (5 subjects), on the gastric 
      and duodenal mucosa, as determined by endoscopic examination 2 h after a fasting 
      single 975-mg dose. A grading scale of 0 (no damage) to 4 (severe damage) was 
      used. The granule formulation produced a statistically significant (p less than 
      0.05) lower severity (mean 0.40 +/- 0.58 vs. 3.00 +/- 0.94) and incidence (36% of 
      subjects vs. 100%) of gastric lesions than the buffered aspirin formulation. None 
      of the lesions produced by the granule formulation or the placebo was considered 
      clinically significant by the blinded endoscopist, whereas 17 subjects on the 
      buffered formulation (65%) had clinically meaningful stomach damage. The 
      incidence of duodenal lesions was minimal and comparable for the two 
      formulations.
FAU - Anslow, J A
AU  - Anslow JA
FAU - Balm, T K
AU  - Balm TK
FAU - Hooper, J W
AU  - Hooper JW
FAU - Szego, P
AU  - Szego P
FAU - Wagner, G S
AU  - Wagner GS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Buffers)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Buffers
MH  - Female
MH  - Gastric Mucosa/pathology
MH  - Gastrointestinal Diseases/*chemically induced/pathology
MH  - Humans
MH  - Intestinal Mucosa/pathology
MH  - Male
MH  - Tablets, Enteric-Coated
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1159/000138048 [doi]
PST - ppublish
SO  - Pharmacology. 1985;30(1):40-4. doi: 10.1159/000138048.

PMID- 11342207
OWN - NLM
STAT- MEDLINE
DCOM- 20011025
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 101
IP  - 2
DP  - 2001 Jan 15
TI  - Characterization of whole blood aggregation with a new type of aggregometer by a 
      screen filtration pressure method.
PG  - 65-72
AB  - A new type of platelet aggregometer of whole blood, based on the screen 
      filtration pressure method, has been developed and characterized. It measures 
      resistance of flow of whole blood samples through a screen of microsieve with 
      30-microm(2) openings and provides pressure rate as an index of platelet 
      aggregation. On optical microscopic observation, platelet aggregates, but not 
      fibrin fibers, were found to be trapped on microsieves, and the pressure rate and 
      protein amounts on microsieves are correlated. The aggregometer showed good 
      reproducibility for investigations performed on different days. The time course 
      of pressure rates indicated a bell curve change, where the pressure rate was very 
      low immediately after blood collection and gradually increased up to 60 min 
      thereafter. Use of the aggregometer was able to confirm that orally administered 
      aspirin inhibits ADP- and collagen-induced whole blood aggregation as well as 
      platelet aggregation. The results suggest that this platelet aggregometer might 
      be useful in research and clinical diagnosis of thrombotic diseases.
FAU - Ozeki, Y
AU  - Ozeki Y
AD  - 1st Institute of New Drug Research, Otsuka Pharmaceutical Co., Ltd., 463-10 
      Kagasuno, Kawauchi-cho, 771-0192, Tokushima, Japan. y_ozeki@research.otsuka.co.jp
FAU - Sudo, T
AU  - Sudo T
FAU - Toga, K
AU  - Toga K
FAU - Nagamura, Y
AU  - Nagamura Y
FAU - Ito, H
AU  - Ito H
FAU - Ogawa, T
AU  - Ogawa T
FAU - Kimura, Y
AU  - Kimura Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Collagen/pharmacology
MH  - Equipment Design
MH  - Filtration/methods
MH  - Humans
MH  - *Platelet Aggregation/drug effects
MH  - Platelet Function Tests/*instrumentation
MH  - Pressure
MH  - Reproducibility of Results
EDAT- 2001/05/09 10:00
MHDA- 2001/10/26 10:01
CRDT- 2001/05/09 10:00
PHST- 2001/05/09 10:00 [pubmed]
PHST- 2001/10/26 10:01 [medline]
PHST- 2001/05/09 10:00 [entrez]
AID - S0049-3848(00)00377-7 [pii]
AID - 10.1016/s0049-3848(00)00377-7 [doi]
PST - ppublish
SO  - Thromb Res. 2001 Jan 15;101(2):65-72. doi: 10.1016/s0049-3848(00)00377-7.

PMID- 8519621
OWN - NLM
STAT- MEDLINE
DCOM- 19960124
LR  - 20190914
IS  - 1040-8711 (Print)
IS  - 1040-8711 (Linking)
VI  - 7
IP  - 5
DP  - 1995 Sep
TI  - Kawasaki syndrome.
PG  - 455-8
AB  - Although a general consensus on the etiology of Kawasaki syndrome has not been 
      reached, increasing evidence suggests that this illness represents a response to 
      a superantigen. This conclusion is based on the observations of the immunologic 
      changes that characterize the acute stages of illness as well as on the 
      demonstrated association with toxin-producing bacteria in the pharynx and 
      gastrointestinal tract. Therapy with intravenous gamma globulin and high-dose 
      aspirin remains the standard of care for acute disease. Long-term follow-up of 
      increasing numbers of children has confirmed that few properly treated children 
      are at risk for the development of coronary artery abnormalities due to this 
      illness.
FAU - Meissner, H C
AU  - Meissner HC
AD  - Department of Pediatrics, Floating Hospital for Children, New England Medical 
      Center, Boston, MA 02111-1526, USA.
FAU - Leung, D Y
AU  - Leung DY
LA  - eng
GR  - AR-41256/AR/NIAMS NIH HHS/United States
GR  - HL-36577/HL/NHLBI NIH HHS/United States
GR  - HL-37620/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Curr Opin Rheumatol
JT  - Current opinion in rheumatology
JID - 9000851
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunotherapy
MH  - Mucocutaneous Lymph Node Syndrome/*etiology/immunology/*therapy
RF  - 26
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
AID - 10.1097/00002281-199509000-00016 [doi]
PST - ppublish
SO  - Curr Opin Rheumatol. 1995 Sep;7(5):455-8. doi: 10.1097/00002281-199509000-00016.

PMID- 21387691
OWN - NLM
STAT- MEDLINE
DCOM- 20110517
LR  - 20181201
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 69
IP  - 2
DP  - 2011 Feb
TI  - [Strategy to manage low dose aspirin-induced gastrointestinal injury].
PG  - 369-75
AB  - Low dose aspirin, as an anti-platelet medication, has been increasingly 
      prescribed to elderly patients for primary and secondary prevention of cardio- 
      and cerebro-vascular events. Nonetheless, aspirin's effectiveness in such disease 
      prevention is limited by the risk of upper and lower gastrointestinal (GI) 
      complications such as ulceration, hemorrhage and perforation. Aspirin 
      administration is associated with 2-fold increase in the GI risk in middle-aged 
      users without prior history of peptic ulcer and without concomitant medications. 
      However, such GI risk increases dramatically in patients with a prior history of 
      peptic ulcer disease, advanced age, and concomitant use of NSAIDs, 
      corticosteroids, clopidogrel, or anticoagulants. Mechanisms of aspirin-induced GI 
      injury are believed to be through local effects within the GI mucosa that cause 
      topical injury and through systemic inhibition of cyclo-oxygenase (COX) resulting 
      in depletion of mucosal protective prostaglandins. Herein, we focus on the 
      strategy to manage aspirin-induced peptic ulcerations and their complications, 
      based on the scientific evidence.
FAU - Hiraishi, Hideyuki
AU  - Hiraishi H
AD  - Department of Gastroenterology, Dokkyo Medical University.
FAU - Maeda, Mitsunori
AU  - Maeda M
FAU - Sasai, Takako
AU  - Sasai T
FAU - Kanke, Kazunari
AU  - Kanke K
FAU - Shimada, Tadahito
AU  - Shimada T
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prostaglandins)
RN  - 0 (Proton Pump Inhibitors)
RN  - 5QZO15J2Z8 (Famotidine)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - KG60484QX9 (Omeprazole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Ulcer Agents/administration & dosage
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Cerebrovascular Disorders/prevention & control
MH  - Clopidogrel
MH  - Famotidine/administration & dosage
MH  - Gastric Mucosa/drug effects/enzymology/metabolism
MH  - Humans
MH  - Omeprazole/administration & dosage
MH  - Peptic Ulcer/*chemically induced/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Prostaglandins/metabolism
MH  - Proton Pump Inhibitors/administration & dosage
MH  - Ticlopidine/administration & dosage/analogs & derivatives
EDAT- 2011/03/11 06:00
MHDA- 2011/05/18 06:00
CRDT- 2011/03/11 06:00
PHST- 2011/03/11 06:00 [entrez]
PHST- 2011/03/11 06:00 [pubmed]
PHST- 2011/05/18 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2011 Feb;69(2):369-75.

PMID- 1922220
OWN - NLM
STAT- MEDLINE
DCOM- 19911105
LR  - 20220321
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 325
IP  - 18
DP  - 1991 Oct 31
TI  - A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a 
      transient ischemic attack or minor ischemic stroke.
PG  - 1261-6
AB  - BACKGROUND: Aspirin is known to improve the outcome of patients who have had a 
      cerebral transient ischemic attack, but the optimal dose of aspirin remains 
      uncertain. Experimental evidence indicates that 30 mg of aspirin daily alters 
      platelet aggregation more favorably than the 300-mg dose currently used in 
      patients after transient ischemic attack or minor ischemic stroke. METHODS: We 
      assessed the effects of two doses of a water-soluble preparation of 
      acetylsalicylic acid, or aspirin (30 mg vs. 283 mg a day), on the occurrence of 
      death from all vascular causes, nonfatal stroke, or nonfatal myocardial 
      infarction in a double-blind, randomized, controlled clinical trial in patients 
      who had had a transient ischemic attack or minor stroke. A total of 3131 patients 
      participated in the study. The mean follow-up was 2.6 years. RESULTS: In the 
      group assigned to receive 30 mg of aspirin, the frequency of death from vascular 
      causes, nonfatal stroke, or nonfatal myocardial infarction was 228 of 1555 (14.7 
      percent), as compared with 240 of 1576 (15.2 percent) in the group assigned to 
      receive 283 mg. The age- and sex-adjusted hazard ratio for the group receiving 
      the lower dose was 0.91 (95 percent confidence interval, 0.76 to 1.09). There 
      were slightly fewer major bleeding complications in the 30-mg group than in the 
      283-mg group (40 vs. 53), and significantly fewer reports of minor bleeding (49 
      vs. 84). Fewer patients receiving 30 mg of aspirin reported gastrointestinal 
      symptoms (164 vs. 179) and other adverse effects (73 vs. 90). CONCLUSIONS: Our 
      data indicate that 30 mg of aspirin daily is no less effective in the prevention 
      of vascular events than a 283-mg dose in patients with a transient ischemic 
      attack or minor stroke, and has fewer adverse effects.
CN  - Dutch TIA Trial Study Group
FAU - van Gijn, Jan
AU  - van Gijn J
FAU - Algra, Ale
AU  - Algra A
FAU - Kappelle, Jaap
AU  - Kappelle J
FAU - Koudstaal, Peter J
AU  - Koudstaal PJ
FAU - van Latum, Anet
AU  - van Latum A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 1992 May 7;326(19):1288-9. PMID: 1343814
CIN - N Engl J Med. 1992 May 7;326(19):1288; author reply 1289. PMID: 1560807
CIN - N Engl J Med. 1991 Oct 31;325(18):1303-4. PMID: 1922226
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cerebrovascular Disorders/*complications
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/*complications
MH  - Male
MH  - Middle Aged
MH  - Vascular Diseases/*mortality
EDAT- 1991/10/31 00:00
MHDA- 1991/10/31 00:01
CRDT- 1991/10/31 00:00
PHST- 1991/10/31 00:00 [pubmed]
PHST- 1991/10/31 00:01 [medline]
PHST- 1991/10/31 00:00 [entrez]
AID - 10.1056/NEJM199110313251801 [doi]
PST - ppublish
SO  - N Engl J Med. 1991 Oct 31;325(18):1261-6. doi: 10.1056/NEJM199110313251801.

PMID- 15953947
OWN - NLM
STAT- MEDLINE
DCOM- 20060302
LR  - 20191109
IS  - 0034-9887 (Print)
IS  - 0034-9887 (Linking)
VI  - 133
IP  - 4
DP  - 2005 Apr
TI  - [Frequency and characteristics of aspirin resistance in Chilean cardiovascular 
      patients].
PG  - 409-17
AB  - BACKGROUND: Studies performed in Anglo-Saxon countries show that 5% of patients 
      are resistant to the antiplatelet effects of aspirin. AIM: To assess the 
      prevalence of aspirin resistance in a sample of Chilean cardiovascular patients 
      and its association with clinical and laboratory characteristics. PATIENTS AND 
      METHODS: Ninety nine patients (30 women, 63+/-10 years) treated for stable 
      cardiovascular diseases with aspirin 100-325 mg/day were studied. Clinical and 
      basic coagulation variables were assessed. Platelet aggregation was studied with 
      platelet rich plasma using three different agonists in an optical aggregometer. 
      Aspirin resistance was defined as an aggregation 20% with arachidonic acid and an 
      aggregation 70% with ADP or collagen. RESULTS: Eleven patients (11.11%, 95% CI= 
      4.95-17.27%) complied with both criteria and were classified as aspirin 
      resistant. Current smoking was more common in aspirin resistant patients (63.6 vs 
      29.6%, p=0.039). CONCLUSIONS: Aspirin resistance was found in a significant 
      proportion of cardiovascular patients and was more common among current smokers.
FAU - Dussaillant N, Gastón
AU  - Dussaillant N G
AD  - Sección de Hematología, Hospital Clínico de la Universidad de Chile, Av. Santos 
      Dumont 999, Independencia, Santiago, Chile. gdussailant@redclinicauchile.cl
FAU - Zapata M, Mario
AU  - Zapata M M
FAU - Fardella B, Patricia
AU  - Fardella B P
FAU - Conte L, Guillermo
AU  - Conte L G
FAU - Cuneo V, Marianela
AU  - Cuneo V M
LA  - spa
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Frecuencia y características de la resistencia a aspirina en pacientes 
      cardiovasculares chilenos.
DEP - 20050608
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cardiovascular Diseases/*drug therapy
MH  - Chile
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Smoking/adverse effects
EDAT- 2005/06/15 09:00
MHDA- 2006/03/03 09:00
CRDT- 2005/06/15 09:00
PHST- 2005/06/15 09:00 [pubmed]
PHST- 2006/03/03 09:00 [medline]
PHST- 2005/06/15 09:00 [entrez]
AID - S0034-98872005000400003 [pii]
AID - 10.4067/s0034-98872005000400003 [doi]
PST - ppublish
SO  - Rev Med Chil. 2005 Apr;133(4):409-17. doi: 10.4067/s0034-98872005000400003. Epub 
      2005 Jun 8.

PMID- 7149413
OWN - NLM
STAT- MEDLINE
DCOM- 19830119
LR  - 20131121
IS  - 0002-9645 (Print)
IS  - 0002-9645 (Linking)
VI  - 43
IP  - 9
DP  - 1982 Sep
TI  - Effect of aspirin on collateral blood flow after experimental thrombosis of the 
      feline aorta.
PG  - 1647-50
AB  - In 11 cats, the caudal aorta was occluded with a thrombus to inhibit opening of 
      collateral vessels to the hindlimbs. Five cats were not treated, and 6 cats were 
      given aspirin (650 mg, orally) 1 hour before aortic occlusion. Before the aortas 
      were occluded, platelet counts were measured in the 11 cats, and platelet 
      aggregation by adenosine diphosphate was assessed in 4 cats scheduled for aspirin 
      treatment. Cats were maintained for 3 hours after surgery, and the tests were 
      repeated. In addition, serum salicylate concentrations were determined for all 
      aspirin-treated cats. Collateral circulation was assessed as the time necessary 
      for contrast media to appear in the iliac arteries caudal to the thrombus during 
      aortography. Platelet counts were significantly (P less than or equal to 0.05) 
      reduced in nontreated cats, but not in the aspirin-treated cats. Serum salicylate 
      concentrations indicated that aspirin had reached therapeutic blood 
      concentrations. Inhibition of adenosine diphosphate-induced platelet aggregation 
      was observed in all postthrombosis aspirin-treated cats. Contrast media did not 
      appear in the iliac arteries of nontreated cats until 7.5 +/- 0.5 s after 
      injection. In all aspirin-treated cats, contrast media appeared in the iliac 
      arteries within 2.3 +/- 0.3 s after injection. Platelet thromboxane A2 may be the 
      factor promoting collateral inhibition after aortic thrombosis in cats.
FAU - Schaub, R G
AU  - Schaub RG
FAU - Gates, K A
AU  - Gates KA
FAU - Roberts, R E
AU  - Roberts RE
LA  - eng
GR  - RR09012/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aortic Diseases/drug therapy/physiopathology/*veterinary
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cat Diseases/*drug therapy/physiopathology
MH  - Cats
MH  - Collateral Circulation/*drug effects
MH  - Hindlimb/blood supply
MH  - Platelet Aggregation/drug effects
MH  - Thrombosis/drug therapy/physiopathology/*veterinary
EDAT- 1982/09/01 00:00
MHDA- 1982/09/01 00:01
CRDT- 1982/09/01 00:00
PHST- 1982/09/01 00:00 [pubmed]
PHST- 1982/09/01 00:01 [medline]
PHST- 1982/09/01 00:00 [entrez]
PST - ppublish
SO  - Am J Vet Res. 1982 Sep;43(9):1647-50.

PMID- 31542891
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20210110
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
VI  - 14
IP  - 8
DP  - 2019 Nov
TI  - Aspirin in primary prevention: the triumph of clinical judgement over complex 
      equations.
PG  - 1217-1231
LID - 10.1007/s11739-019-02191-4 [doi]
AB  - Aspirin, in 2017, has celebrated its 120th birthday. The efficacy and safety of 
      low-dose aspirin in secondary prevention of cardiovascular disease is well 
      supported by many studies, instead in primary prevention it remains 
      controversial, especially in the aftermath of the publication in 2018 of three 
      novel primary prevention randomized clinical trials, showing that the benefit of 
      low-dose aspirin, although additive to that of statin, is counterbalanced by an 
      excess of (mainly gastrointestinal) bleeding events. The signal for a net benefit 
      seems to be even more controversial in the elderly starting aspirin after the age 
      of 70 years. While international guidelines have promptly downgraded their 
      recommendations to more conservative indications, the practicing clinician is 
      called to make the effort to individualize the treatment, after careful 
      evaluation of the haemorrhagic risk vis-a-vis the risk to develop, in the 
      mid-term and long-term follow-up, major cardiovascular events or cancer. This is 
      a particularly complex task, given the different immediate and long-term impact 
      of diverse outcomes on health, the dynamic nature over time of the benefit/risk 
      balance, prompting periodic re-assessments of its indication, and the 
      interindividual variability in aspirin response. The chemopreventive properties 
      of aspirin, anticipated by a large body of epidemiological and mechanistic 
      evidence, are awaiting their final confirmation by the long-term follow-up of the 
      latest trials specifically designed to assess this endpoint, with the expectation 
      to subvert the delicate benefit/risk balance of aspirin in primary prevention. 
      This review is intended to provide an interpretation of past and current evidence 
      to guide clinical decision making on the contemporary patient.
FAU - Santilli, Francesca
AU  - Santilli F
AUID- ORCID: 0000-0002-4593-905X
AD  - Department of Medicine and Aging, and Center of Aging Science and Translational 
      Medicine (CESI-Met), "G. D'Annunzio" University Foundation School of Medicine, 
      Via Luigi Polacchi, 66013, Chieti, Italy. francesca.santilli@unich.it.
FAU - Simeone, Paola
AU  - Simeone P
AD  - Department of Medicine and Aging, and Center of Aging Science and Translational 
      Medicine (CESI-Met), "G. D'Annunzio" University Foundation School of Medicine, 
      Via Luigi Polacchi, 66013, Chieti, Italy.
LA  - eng
GR  - COD WF GR 2011-02350450/Italian Ministry of Health/International
PT  - Journal Article
PT  - Review
DEP - 20190921
PL  - Italy
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*standards/therapeutic use
MH  - Cardiovascular Diseases/drug therapy/prevention & control
MH  - Clinical Competence/standards/statistics & numerical data
MH  - Humans
MH  - Platelet Aggregation Inhibitors/standards/therapeutic use
MH  - Primary Prevention/methods
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirin responsiveness
OT  - Cancer
OT  - Clinical trials
OT  - Primary prevention
EDAT- 2019/09/23 06:00
MHDA- 2020/05/06 06:00
CRDT- 2019/09/23 06:00
PHST- 2019/06/22 00:00 [received]
PHST- 2019/09/04 00:00 [accepted]
PHST- 2019/09/23 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
PHST- 2019/09/23 06:00 [entrez]
AID - 10.1007/s11739-019-02191-4 [pii]
AID - 10.1007/s11739-019-02191-4 [doi]
PST - ppublish
SO  - Intern Emerg Med. 2019 Nov;14(8):1217-1231. doi: 10.1007/s11739-019-02191-4. Epub 
      2019 Sep 21.

PMID- 35882144
OWN - NLM
STAT- MEDLINE
DCOM- 20220810
LR  - 20220810
IS  - 2772-9508 (Electronic)
IS  - 2772-9508 (Linking)
VI  - 139
DP  - 2022 Aug
TI  - Blood-brain barrier penetrating carbon dots with intrinsic anti-inflammatory and 
      drug-loading properties.
PG  - 212995
LID - S2772-9508(22)00272-2 [pii]
LID - 10.1016/j.bioadv.2022.212995 [doi]
AB  - The blood-brain barrier (BBB) is the major obstacle limiting the reach of 
      therapeutic drugs into the brain. Herein, an aspirin-based anti-inflammatory 
      replenisher (aspCD) was fabricated by carbonizing aspirin to deliver drugs into 
      the brain visually. The as-prepared aspCD combined the BBB-penetrating and 
      anti-inflammatory effects of aspirin with the fluorescent and drug-loading 
      properties of carbon dots (CDs), thereby delivering therapeutic drugs into the 
      brain and acting as imaging agent as well as anti-inflammatory replenisher. In 
      vivo experiments of mice and zebrafish revealed that fluorescence aspCD could 
      effectively penetrate BBB. In vitro and in vivo inflammatory models demonstrated 
      that aspCD could be regarded as an excellent anti-inflammatory replenisher. In 
      addition, as a functional carrier, aspCD was proved to be capable of loading 
      drugs with different polarity. In summary, carbonization of active precursors 
      (therapeutic drugs) into CDs could be a promising strategy to achieve the loading 
      and visualization of drugs as well as the retainment of their biological 
      activities.
CI  - Copyright © 2022 Elsevier B.V. All rights reserved.
FAU - Zhang, Xianming
AU  - Zhang X
AD  - College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China; 
      Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing 
      400016, PR China.
FAU - Yu, Qinghua
AU  - Yu Q
AD  - College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China; 
      Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, 
      Chongqing 400016, PR China.
FAU - Zhou, Ping
AU  - Zhou P
AD  - College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China; 
      Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, 
      Chongqing 400016, PR China.
FAU - Yang, Shiyu
AU  - Yang S
AD  - College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China; 
      Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, 
      Chongqing 400016, PR China.
FAU - Xia, Jiashan
AU  - Xia J
AD  - College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China; 
      Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, 
      Chongqing 400016, PR China.
FAU - Deng, Tao
AU  - Deng T
AD  - College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China; 
      Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing 
      400016, PR China; Chongqing Pharmacodynamic Evaluation Engineering Technology 
      Research Center, Chongqing 400016, PR China. Electronic address: 
      190444@cqmu.edu.cn.
FAU - Yu, Chao
AU  - Yu C
AD  - College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China; 
      Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing 
      400016, PR China; Chongqing Pharmacodynamic Evaluation Engineering Technology 
      Research Center, Chongqing 400016, PR China. Electronic address: 
      yuchao@cqmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220622
PL  - Netherlands
TA  - Biomater Adv
JT  - Biomaterials advances
JID - 9918383886206676
RN  - 0 (Anti-Inflammatory Agents)
RN  - 7440-44-0 (Carbon)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Aspirin/pharmacology
MH  - *Blood-Brain Barrier
MH  - *Carbon/pharmacology
MH  - Zebrafish
OTO - NOTNLM
OT  - Anti-inflammatory replenisher
OT  - Bioimaging
OT  - Blood-brain barrier
OT  - Carbon dots
OT  - Visualized drug carrier
EDAT- 2022/07/27 06:00
MHDA- 2022/08/11 06:00
CRDT- 2022/07/26 18:18
PHST- 2022/03/24 00:00 [received]
PHST- 2022/06/08 00:00 [revised]
PHST- 2022/06/17 00:00 [accepted]
PHST- 2022/07/27 06:00 [pubmed]
PHST- 2022/08/11 06:00 [medline]
PHST- 2022/07/26 18:18 [entrez]
AID - S2772-9508(22)00272-2 [pii]
AID - 10.1016/j.bioadv.2022.212995 [doi]
PST - ppublish
SO  - Biomater Adv. 2022 Aug;139:212995. doi: 10.1016/j.bioadv.2022.212995. Epub 2022 
      Jun 22.

PMID- 31604350
OWN - NLM
STAT- MEDLINE
DCOM- 20211104
LR  - 20211104
IS  - 1098-8785 (Electronic)
IS  - 0735-1631 (Linking)
VI  - 38
IP  - 4
DP  - 2021 Mar
TI  - The Impact of the New Hypertension Guidelines to Low-Dose Aspirin Prophylaxis 
      Eligibility for the Prevention of Preeclampsia: A Cost-Benefit Analysis.
PG  - 363-369
LID - 10.1055/s-0039-1697588 [doi]
AB  - OBJECTIVE: American College of Cardiology and American Heart Association 
      (ACC/AHA) published new guidelines which lower the cut-off for hypertension. We 
      sought to evaluate the impact of these guidelines to cost and benefit of various 
      low-dose aspirin prophylaxis approaches. STUDY DESIGN: Decision tree analysis was 
      created using R software to evaluate four approaches to aspirin prophylaxis in 
      the United States: no aspirin, United States Preventive Service Task Force 
      (USPSTF) with Seventh Report of the Joint National Committee on Prevention, 
      Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) hypertension 
      guidelines, USPSTF with ACC/AHA hypertension guidelines, as well as universal 
      aspirin prophylaxis. This model was executed to simulate a hypothetical cohort of 
      4 million pregnant women in the United States. RESULTS: The new guidelines would 
      expand the aspirin eligibility by 8% (76,953 women) in the USPSTF guidelines. 
      Even with this increased eligibility, the USPSTF guidelines continue to be the 
      approach with the most cost savings ($386.5 million) when compared with universal 
      aspirin and no aspirin prophylaxis. The new hypertension guidelines are projected 
      to increase the cost savings of the USPSTF approach by $9.4 million. CONCLUSION: 
      Despite the small change in aspirin prophylaxis, using ACC/AHA definition of 
      hypertension still results in an annual cost-saving of $9.4 million in the United 
      States when compared with JNC7.
CI  - Thieme. All rights reserved.
FAU - Putra, Manesha
AU  - Putra M
AD  - Department of Reproductive Biology, MetroHealth Medical Center, Cleveland, Ohio.
AD  - Department of Reproductive Biology, University Hospitals Cleveland Medical 
      Center, Cleveland, Ohio.
AD  - Department of Reproductive Biology, Case Western Reserve University, Cleveland, 
      Ohio.
FAU - Balasooriya, Madagedara Maduka
AU  - Balasooriya MM
AD  - Department of Industrials and System Engineering, Wayne State University, 
      Detroit, Michigan.
FAU - Boscia, Alexander L
AU  - Boscia AL
AD  - Department of Reproductive Biology, Case Western Reserve University, Cleveland, 
      Ohio.
FAU - Dalkiran, Evrim
AU  - Dalkiran E
AD  - Department of Industrials and System Engineering, Wayne State University, 
      Detroit, Michigan.
FAU - Sokol, Robert J
AU  - Sokol RJ
AD  - Department of Obstetrics and Gynecology, Wayne State University, Detroit, 
      Michigan.
LA  - eng
PT  - Journal Article
DEP - 20191011
PL  - United States
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - American Heart Association
MH  - Aspirin/*administration & dosage/economics
MH  - Blood Pressure
MH  - *Cost-Benefit Analysis
MH  - Eligibility Determination/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Hypertension/diagnosis
MH  - *Practice Guidelines as Topic
MH  - Pre-Eclampsia/economics/*prevention & control
MH  - Pregnancy
MH  - Risk Factors
MH  - United States
COIS- None declared.
EDAT- 2019/10/12 06:00
MHDA- 2021/11/05 06:00
CRDT- 2019/10/12 06:00
PHST- 2019/10/12 06:00 [pubmed]
PHST- 2021/11/05 06:00 [medline]
PHST- 2019/10/12 06:00 [entrez]
AID - 10.1055/s-0039-1697588 [doi]
PST - ppublish
SO  - Am J Perinatol. 2021 Mar;38(4):363-369. doi: 10.1055/s-0039-1697588. Epub 2019 
      Oct 11.

PMID- 33706985
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 144 Suppl 1
DP  - 2021 Apr 1
TI  - Aspirin for Primary Prevention of Cardiovascular Disease in the 21(st) Century: A 
      Review of the Evidence.
PG  - S15-S22
LID - S0002-9149(20)31349-7 [pii]
LID - 10.1016/j.amjcard.2020.12.022 [doi]
AB  - Aspirin (ASA) is the most commonly prescribed antiplatelet agent. Although the 
      evidence for efficacy of aspirin for secondary prevention of ischemic events in 
      patients with established cardiovascular disease is strong, its role in primary 
      prevention has been subject of controversies over the past decades. In fact, 
      historical trials have shown only modest benefit in terms of reduction of 
      ischemic events, mostly myocardial infarction and to a lesser extent stroke, and 
      only at the expense of an increased risk of bleeding. These observations have led 
      to divergent recommendations from professional societies on the use of ASA for 
      primary prevention of cardiovascular disease manifestations. However, recent 
      results from three trials of primary prevention have shown either no benefit or 
      modest benefit on combined ischemic end points, without any impact on hard 
      cardiovascular events such as myocardial infarction or stroke, accompanied by an 
      increased risk of bleeding. Overall, this translated into neutral net benefit or 
      even harm with the use of aspirin in patients with no overt cardiovascular 
      disease. These results have accordingly led to a downgrade in the current 
      recommendations on the use of ASA for primary prevention. This article provides 
      an overview on the current evidence on the use of aspirin for primary prevention 
      of cardiovascular disease.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - Division of Cardiology, University of Florida College of Medicine, Jacksonville, 
      Florida. Electronic address: dominick.angiolillo@jax.ufl.edu.
FAU - Capodanno, Davide
AU  - Capodanno D
AD  - Division of Cardiology, A.O.U. "Policlinico-Vittorio Emanuele," University of 
      Catania, Catania, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Primary Prevention
COIS- Conflict of Interest Dr. Angiolillo declares that he has received consulting fees 
      or honoraria from Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, 
      Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, 
      Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The 
      Medicines Company and has received payments for participation in review 
      activities from CeloNova and St Jude Medical. D.J.A. also declares that his 
      institution has received research grants from Amgen, AstraZeneca, Bayer, 
      Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, 
      Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey 
      Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. Dr. 
      Capodanno declares that he has received consulting and speaker's fee from 
      AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, outside the present 
      work. The authors of this Supplement gratefully acknowledge the financial support 
      of educational grant funding from AstraZeneca Pharmaceuticals.
EDAT- 2021/03/13 06:00
MHDA- 2021/04/10 06:00
CRDT- 2021/03/12 06:01
PHST- 2020/11/21 00:00 [received]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2021/03/12 06:01 [entrez]
PHST- 2021/03/13 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - S0002-9149(20)31349-7 [pii]
AID - 10.1016/j.amjcard.2020.12.022 [doi]
PST - ppublish
SO  - Am J Cardiol. 2021 Apr 1;144 Suppl 1:S15-S22. doi: 10.1016/j.amjcard.2020.12.022.

PMID- 17488967
OWN - NLM
STAT- MEDLINE
DCOM- 20070515
LR  - 20220316
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 297
IP  - 18
DP  - 2007 May 9
TI  - Aspirin dose for the prevention of cardiovascular disease: a systematic review.
PG  - 2018-24
AB  - CONTEXT: More than 50 million US adults take aspirin regularly for long-term 
      prevention of cardiovascular disease, typically either 81 mg/d or 325 mg/d. 
      Controversy remains regarding the most appropriate long-term daily dose. 
      OBJECTIVE: To review the mechanism of action of aspirin and the clinical 
      literature for relationships among aspirin dosage, efficacy, and safety. EVIDENCE 
      ACQUISITION: A systematic review of the English-language literature was 
      undertaken using MEDLINE and EMBASE (searched through February 2007) and the 
      search term aspirin or acetylsalicylic acid and dose. The search was limited to 
      clinical trials and was extended by a review of bibliographies of pertinent 
      reports of original data and review articles. Published prospective studies using 
      different aspirin dosages in the setting of cardiovascular disease were included. 
      EVIDENCE SYNTHESIS: Although pharmacodynamic data demonstrate that long-term 
      aspirin dosages as low as 30 mg/d are adequate to fully inhibit platelet 
      thromboxane production, dosages as high as 1300 mg/d are approved for use. In the 
      United States, 81 mg/d of aspirin is prescribed most commonly (60%), followed by 
      325 mg/d (35%). The available evidence, predominantly from secondary-prevention 
      observational studies, supports that dosages greater than 75 to 81 mg/d do not 
      enhance efficacy, whereas larger dosages are associated with an increased 
      incidence of bleeding events, primarily related to gastrointestinal tract 
      toxicity. CONCLUSIONS: Currently available clinical data do not support the 
      routine, long-term use of aspirin dosages greater than 75 to 81 mg/d in the 
      setting of cardiovascular disease prevention. Higher dosages, which may be 
      commonly prescribed, do not better prevent events but are associated with 
      increased risks of gastrointestinal bleeding.
FAU - Campbell, Charles L
AU  - Campbell CL
AD  - Gill Heart Institute, University of Kentucky, Lexington, USA. clcampbell@uky.edu
FAU - Smyth, Susan
AU  - Smyth S
FAU - Montalescot, Gilles
AU  - Montalescot G
FAU - Steinhubl, Steven R
AU  - Steinhubl SR
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2007 Aug 8;298(6):625; author reply 625-6. PMID: 17684181
CIN - JAMA. 2007 Aug 8;298(6):625; author reply 625-6. PMID: 17684182
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
RF  - 61
EDAT- 2007/05/10 09:00
MHDA- 2007/05/16 09:00
CRDT- 2007/05/10 09:00
PHST- 2007/05/10 09:00 [pubmed]
PHST- 2007/05/16 09:00 [medline]
PHST- 2007/05/10 09:00 [entrez]
AID - 297/18/2018 [pii]
AID - 10.1001/jama.297.18.2018 [doi]
PST - ppublish
SO  - JAMA. 2007 May 9;297(18):2018-24. doi: 10.1001/jama.297.18.2018.

PMID- 34609920
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20220202
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 27
DP  - 2021 Jan-Dec
TI  - The Pre- and Postoperative Prevalence and Risk Factors of ASA Nonresponse in 
      Vascular Surgery.
PG  - 10760296211044723
LID - 10.1177/10760296211044723 [doi]
LID - 10760296211044723
AB  - BACKGROUND: An antiplatelet therapy with acetylsalicylic acid (ASA) is prescribed 
      in the prevention of cardiovascular events, but around 24% of ASA takers are 
      resistant to the treatment. AIM: In this prospective, observational cohort study, 
      we aimed to identify the prevalence and risk factors of ASA nonresponse in 
      patients who underwent vascular surgery. METHODS: The study was conducted in the 
      University hospital in Frankfurt am Main. In total, 70 patients were pre-treated 
      with 100 mg of ASA per day and underwent either elective carotid 
      thromboendarterectomy, femoral thromboendarterectomy or endovascular aneurysm 
      repair of the abdominal aorta. The platelet function was measured on the first 
      preoperative and the second or fourth postoperative day with the multiple 
      electrode aggregometry by in-vitro stimulation with arachidonic acid (ASPItest) 
      and thrombin receptor activating peptide 6 (TRAPtest). The primary end point was 
      the in-vitro induced platelet aggregation in the ASPItest. If the ASPItest 
      amounted ≥400 AU × min, the patients were categorized as ASA nonresponders. 
      RESULTS: The total prevalence of ASA nonresponse in our study was 20% 
      preoperatively and 35.7% postoperatively (p = 0.005). As significant predictors 
      for ASA nonresponse, we demonstrated the area under the aggregation curve in the 
      TRAPtest preoperatively (p = 0.04) and postoperatively (p = 0.02), and the two 
      comorbidities arterial hypertension (P < .001; rho 0.44) and diabetes mellitus 
      (p = 0.04; rho 0.39), which are already well known to be associated with ASA 
      nonresponse. CONCLUSION: In conclusion, data of the study indicate a high 
      incidence of perioperative, laboratory ASA nonresponse in patients undergoing 
      vascular surgery.
FAU - Kazimi, Alia Uzra
AU  - Kazimi AU
AUID- ORCID: 0000-0001-9083-5914
AD  - Sana Klinikum Offenbach, Medical Clinic I, 9206Internal Intensive Care Medicine 
      and General Medicine, Offenbach, Germany.
FAU - Weber, Christian Friedrich
AU  - Weber CF
AD  - 39482Asklepios Klinik Wandsbek, Intensive Care Medicine and Emergency Medicine, 
      Hamburg, Germany.
FAU - Keese, Michael
AU  - Keese M
AD  - University Hospital Mannheim, Mannheim, Germany.
FAU - Miesbach, Wolfgang
AU  - Miesbach W
AD  - Hemophilia Centre, 14984University Hospital Frankfurt, Medical Clinic II, 
      Institute of Transfusion Medicine and Immunhematology, Frankfurt, Germany.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Postoperative Period
MH  - Preoperative Period
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Factors
MH  - Vascular Surgical Procedures/*methods
PMC - PMC8642110
OTO - NOTNLM
OT  - ASA nonresponse
OT  - Multiplate Analyzer
OT  - platelet aggregation
OT  - vascular surgery
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2021/10/06 06:00
MHDA- 2022/02/03 06:00
CRDT- 2021/10/05 17:14
PHST- 2021/10/05 17:14 [entrez]
PHST- 2021/10/06 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
AID - 10.1177_10760296211044723 [pii]
AID - 10.1177/10760296211044723 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211044723. doi: 
      10.1177/10760296211044723.

PMID- 21477559
OWN - NLM
STAT- MEDLINE
DCOM- 20110712
LR  - 20170214
IS  - 1203-4754 (Print)
IS  - 1203-4754 (Linking)
VI  - 15
IP  - 2
DP  - 2011 Mar-Apr
TI  - Effect of aspirin pre- and postburn on survival of experimental intermediate 
      burns in rats.
PG  - 111-4
AB  - BACKGROUND: Burns are a major health care problem. Early treatment increases 
      survival of intermediate burn zones, thus decreasing morbidity, mortality, 
      surgery, and hospitalization. Previously, aspirin was shown to improve burn 
      perfusion and increase failing flap survival. OBJECTIVE: Owing to similarities 
      between failing flaps and intermediate burn zones, we conducted this study to 
      evaluate the effect of aspirin on intermediate burn zone survival. METHODS: An 
      intermediate burn was created in 30 rats randomly divided into three experimental 
      groups: pre- and postburn aspirin groups and a control group. Final burn survival 
      was evaluated on day 7. RESULTS: No statistical difference was observed between 
      the test and control groups. Both aspirin regimens failed to improve intermediate 
      burn survival. CONCLUSION: Presumably, administration of aspirin could not 
      prevent the noxious tissue events of burn injury that cause cell death. Possibly, 
      different dosages or modes of administering aspirin could have a beneficial 
      effect on burn wound survival.
FAU - Hadad, Eran
AU  - Hadad E
AD  - Department of Plastic Sugery, Assaf Harofeh Medical Center, Zerifin, Israel.
FAU - Westreich, Melvyn
AU  - Westreich M
FAU - Friedman, Tal
AU  - Friedman T
FAU - Shalom, Avshalom
AU  - Shalom A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cutan Med Surg
JT  - Journal of cutaneous medicine and surgery
JID - 9614685
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Burns/*physiopathology
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Skin/*injuries
MH  - Tissue Survival/*drug effects
EDAT- 2011/04/12 06:00
MHDA- 2011/07/13 06:00
CRDT- 2011/04/12 06:00
PHST- 2011/04/12 06:00 [entrez]
PHST- 2011/04/12 06:00 [pubmed]
PHST- 2011/07/13 06:00 [medline]
AID - 10.2310/7750.2011.10016 [doi]
PST - ppublish
SO  - J Cutan Med Surg. 2011 Mar-Apr;15(2):111-4. doi: 10.2310/7750.2011.10016.

PMID- 6863578
OWN - NLM
STAT- MEDLINE
DCOM- 19830811
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 23
IP  - 4
DP  - 1983 Apr
TI  - Effects of oxaprozin alone or in combination with aspirin on hemostasis and 
      plasma protein binding.
PG  - 139-46
AB  - Oxaprozin, a new nonsteroidal antiinflammatory agent, was studied alone and in 
      combination with aspirin for its effects on hemostasis and protein binding in 10 
      healthy adults. When both oxaprozin and aspirin were given separately for seven 
      days and in combination for five days, both drugs prolonged bleeding time and 
      inhibited collagen- and epinephrine-induced platelet aggregation to a similar 
      degree. The effects of the combination of oxaprozin and aspirin were not 
      additive. The data from the protein binding study showed that oxaprozin was more 
      than 99 per cent bound to plasma proteins. Aspirin displaced oxaprozin from its 
      binding sites. As a result, the rate of plasma clearance of oxaprozin 
      significantly increased from 20 to 26 ml/min/kg (P less than 0.05), and the 
      plasma half-life decreased from 45 to 40 hours. Platelet count and the humoral 
      clotting mechanism were not affected by either drug alone or in combination. 
      There was no clinical evidence of bleeding. One subject who received oxaprozin 
      for 12 days and, in addition, aspirin for the last five days developed a rash 
      that subsided after both drugs were discontinued; one subject treated with 
      aspirin experienced tinnitus. These data suggest that oxaprozin, like aspirin and 
      other nonsteroidal antiinflammatory drugs, should be used with caution when 
      administered to patients who have suffered trauma, who undergo surgery, or who 
      have known defects in hemostasis.
FAU - Kahn, S B
AU  - Kahn SB
FAU - Hubsher, J A
AU  - Hubsher JA
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Blood Proteins)
RN  - 0 (Propionates)
RN  - 9007-34-5 (Collagen)
RN  - MHJ80W9LRB (Oxaprozin)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/metabolism/*pharmacology
MH  - Bleeding Time
MH  - Blood Proteins/*metabolism
MH  - Collagen/pharmacology
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Oxaprozin
MH  - Platelet Aggregation/drug effects
MH  - Propionates/administration & dosage/metabolism/*pharmacology
MH  - Protein Binding
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1983.tb02717.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1983 Apr;23(4):139-46. doi: 10.1002/j.1552-4604.1983.tb02717.x.

PMID- 23324504
OWN - NLM
STAT- MEDLINE
DCOM- 20130708
LR  - 20220317
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 47
IP  - 1
DP  - 2013 Jan
TI  - Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery 
      patients: a comparison of the AAOS and ACCP guidelines with review of the 
      evidence.
PG  - 63-74
LID - 10.1345/aph.1R331 [doi]
AB  - BACKGROUND: The American Academy of Orthopaedic Surgeons (AAOS) and the American 
      College of Chest Physicians (ACCP) have both developed evidence-based guidelines 
      to prevent venous thromboembolism (VTE) in high-risk orthopedic surgery patients. 
      Recent changes to these documents have brought them into agreement as to the 
      inclusion of aspirin as an appropriate option for VTE prophylaxis in this patient 
      population. OBJECTIVE: To evaluate the appropriateness of aspirin to prevent VTE 
      in high-risk orthopedic surgery patients. DATA SOURCES: Guidelines published by 
      the AAOS in 2011 and the ACCP in 2012 were compared regarding their 
      recommendations on the use of aspirin for the prevention of VTE. A literature 
      search was also conducted to identify clinical trials that evaluated the use of 
      aspirin for the prevention of VTE in this patient population. Search terms 
      included the MeSH terms venous thromboembolism; venous thrombosis; pulmonary 
      embolism; aspirin; arthroplasty, replacement, knee; arthroplasty, replacement, 
      hip; and hip fractures/surgery. STUDY SELECTION AND DATA EXTRACTION: Any study 
      that evaluated aspirin, even in combination with another method of prophylaxis 
      (such as pneumatic compression devices), and had been published during or after 
      1985 was included. DATA SYNTHESIS: Randomized controlled trials, meta-analyses, 
      and other large pooled and retrospective reviews have failed to consistently 
      arrive at similar conclusions regarding the efficacy and safety of aspirin as an 
      option for VTE prophylaxis in patients undergoing total knee arthroplasty (TKA), 
      total hip arthroplasty (THA), or hip fracture surgery (HFS). Disagreements in the 
      appropriateness of surrogate markers for safety and efficacy have resulted in 
      differing recommendations from the ACCP and AAOS. The primary argument lies in 
      the appropriateness of deep vein thrombosis as a surrogate marker for more 
      serious outcomes such as pulmonary emboli. CONCLUSIONS: Recent changes to both 
      the ACCP and AAOS guidelines are in agreement for those who choose to use aspirin 
      for chemoprophylaxis of VTE. Current surgical care improvement project measures 
      do not include aspirin as an appropriate sole option for the prevention of VTE, 
      but in patients undergoing elective TKA or who have a contraindication to 
      pharmacologic prophylaxis and undergo a THA or HFS, aspirin in conjunction with 
      compression devices as part of a multimodal approach would meet these measures. 
      Data do not support the hypothesis that aspirin is less likely to cause adverse 
      bleeding events than more potent anticoagulants.
FAU - Stewart, David W
AU  - Stewart DW
AD  - Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, 
      TN, USA. stewardw@etsu.edu
FAU - Freshour, Jessica E
AU  - Freshour JE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20130116
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Orthopedic Procedures/*methods
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - *Practice Guidelines as Topic
MH  - Risk Factors
MH  - Societies, Medical
MH  - United States
MH  - Venous Thromboembolism/etiology/*prevention & control
EDAT- 2013/01/18 06:00
MHDA- 2013/07/09 06:00
CRDT- 2013/01/18 06:00
PHST- 2013/01/18 06:00 [entrez]
PHST- 2013/01/18 06:00 [pubmed]
PHST- 2013/07/09 06:00 [medline]
AID - aph.1R331 [pii]
AID - 10.1345/aph.1R331 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2013 Jan;47(1):63-74. doi: 10.1345/aph.1R331. Epub 2013 Jan 16.

PMID- 8509520
OWN - NLM
STAT- MEDLINE
DCOM- 19930715
LR  - 20190905
IS  - 0148-0812 (Print)
IS  - 0148-0812 (Linking)
VI  - 19
IP  - 6
DP  - 1993 Jun
TI  - Management of patients taking anticoagulants and platelet inhibitors prior to 
      dermatologic surgery.
PG  - 578-81
AB  - BACKGROUND: The use of anticoagulants and platelet inhibitors can increase the 
      risk of intraoperative and postoperative hemorrhagic complications in cutaneous 
      surgery. Currently there are no general guidelines and no consensus among 
      dermatologic surgeons on how to manage patients taking these medicines. 
      OBJECTIVE: To address many of the issues involved in the management of these 
      patients. CONCLUSION: General recommendations are made for managing patients 
      taking anticoagulants and platelet inhibitors prior to dermatologic surgery.
FAU - Goldsmith, S M
AU  - Goldsmith SM
AD  - Department of Dermatology, Bowman Gray School of Medicine, Wake Forest 
      University, Winston-Salem, NC 27157-1071.
FAU - Leshin, B
AU  - Leshin B
FAU - Owen, J
AU  - Owen J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Dermatol Surg Oncol
JT  - The Journal of dermatologic surgery and oncology
JID - 7707501
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*adverse effects/pharmacology
MH  - Aspirin/*adverse effects/pharmacology
MH  - Blood Loss, Surgical/*prevention & control
MH  - Clinical Protocols
MH  - Humans
MH  - *Patient Care Planning
MH  - Postoperative Complications/*prevention & control
MH  - Risk Factors
MH  - Skin Diseases/*surgery
RF  - 9
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - 10.1111/j.1524-4725.1993.tb00392.x [doi]
PST - ppublish
SO  - J Dermatol Surg Oncol. 1993 Jun;19(6):578-81. doi: 
      10.1111/j.1524-4725.1993.tb00392.x.

PMID- 7971242
OWN - NLM
STAT- MEDLINE
DCOM- 19941129
LR  - 20131121
VI  - 36
IP  - 3
DP  - 1994 Jun
TI  - Antiplatelet therapy in the prevention of ischaemic stroke.
PG  - 213-28
AB  - Prevention of stroke is a crucial health care issue, as stroke is the third cause 
      of death and the first cause of major disability in developed countries. The 
      established role of platelet aggregation in TIA or minor and major ischaemic 
      stroke has provided the rationale for many randomized trials of antiplatelet 
      agents (aspirin, sulfinpyrazone, dipyridamole alone or in combination with 
      aspirin, suloctidil, ticlopidine). The recent Antiplatelet Trialists' 
      Collaboration (APT) meta-analysis (1994) based on 142 trials involving 100,000 
      vascular patients confirmed the data of the previous overview (1988). Aspirin, 
      the only drug evaluated for primary prevention of ischaemic events, is not 
      indicated for safety reasons in subjects at low risk of occlusive disease. 
      Compared to control, antiplatelet therapy, notably aspirin which is by far the 
      most widely used agent in trials, provides a 27% risk reduction of stroke, 
      myocardial infarction or vascular death in patients suffering from ischaemic 
      vascular events and a 22% risk reduction of these outcomes in patients having 
      experienced a prior TIA/stroke. Aspirin (around 325 mg/day) and ticlopidine (500 
      mg/day) are currently the reference drugs for secondary prevention in 
      cerebrovascular patients. The long term efficacy of ticlopidine, a specific 
      antiaggregating agent, has been evaluated in two North American trials involving 
      more than 4,000 patients. TASS showed ticlopidine to be significantly more 
      effective in reducing the incidence of fatal or nonfatal stroke and death than 
      aspirin in patients with TIA or minor stroke. The relative risk reductions over 
      aspirin, the first year of greatest risk, were 41% for stroke and death and 46% 
      for fatal or nonfatal stroke. CATS showed that ticlopidine compared with placebo 
      induces a significant 30% relative risk reduction of stroke, myocardial 
      infarction and vascular death over three years in patients who had suffered a 
      recent thromboembolic stroke. The above results elicit two important issues: the 
      optimal dose of aspirin and its tolerability compared to ticlopidine. The three 
      controlled trials (UK-TIA, SALT, Dutch TIA) which have compared high (> or = 1 
      g/day) and low dose aspirin (< or = 300 mg/day) or various low doses of aspirin 
      did not give a definite answer on the efficacy of low or very low (30 or 75 
      mg/day) doses of aspirin for reducing the risk of vascular outcomes in patients 
      with stroke precursors. Even with low doses of aspirin there was still a risk of 
      severe gastrointestinal bleeding, although minor side effects were less 
      frequent.(ABSTRACT TRUNCATED AT 400 WORDS)
FAU - Verry, M
AU  - Verry M
AD  - Sanofi Pharma, Gentilly, France.
FAU - Panak, E
AU  - Panak E
FAU - Cazenave, J P
AU  - Cazenave JP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Nouv Rev Fr Hematol (1978)
JT  - Nouvelle revue francaise d'hematologie
JID - 7909092
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Brain Ischemia/*prevention & control
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/adverse effects/therapeutic use
RF  - 34
EDAT- 1994/06/01 00:00
MHDA- 1994/06/01 00:01
CRDT- 1994/06/01 00:00
PHST- 1994/06/01 00:00 [pubmed]
PHST- 1994/06/01 00:01 [medline]
PHST- 1994/06/01 00:00 [entrez]
PST - ppublish
SO  - Nouv Rev Fr Hematol (1978). 1994 Jun;36(3):213-28.

PMID- 331504
OWN - NLM
STAT- MEDLINE
DCOM- 19771031
LR  - 20140912
IS  - 0256-9574 (Print)
VI  - 52
IP  - 5
DP  - 1977 Jul 23
TI  - Clinical trial of tolmetin and aspirin in the treatment of rheumatoid arthritis.
PG  - 167-9
AB  - A double-blind crossover, within-patient trial was conducted, to compare the 
      efficacy of tolmetin (Tolectin; Ethnor) with that of aspirin in the treatment of 
      rheumatoid arthritis. Tolmetin significantly improved morning stiffness (P less 
      than 0.01), while aspirin was superior in reducing the number of painful joints 
      (P less than 0.001) and the articular index (P less than 0.01). Tolmetin, in 
      marked contrast to aspirin, was well tolerated, producing virtually no 
      side-effects. An elevation of the alkaline phosphatase was noted in 4 patients on 
      tolmetin therapy. When used after aspirin, tolmetin had a significantly adverse 
      effect on the erythrocyte sedimentation rate (P less than 0.05). The results of 
      this study indicate that tolmetin is a useful addition to the therapeutic agents 
      for the treatment of rheumatoid arthritis, because of its ability to reduce 
      morning stiffness and its lack of side-effects.
FAU - Klemp, P
AU  - Klemp P
FAU - Meyers, O L
AU  - Meyers OL
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - 0 (Pyrroles)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pyrroles/*therapeutic use
MH  - Tolmetin/adverse effects/*therapeutic use
EDAT- 1977/07/23 00:00
MHDA- 1977/07/23 00:01
CRDT- 1977/07/23 00:00
PHST- 1977/07/23 00:00 [pubmed]
PHST- 1977/07/23 00:01 [medline]
PHST- 1977/07/23 00:00 [entrez]
PST - ppublish
SO  - S Afr Med J. 1977 Jul 23;52(5):167-9.

PMID- 14738916
OWN - NLM
STAT- MEDLINE
DCOM- 20040929
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 34
IP  - 1
DP  - 2004 Jan 27
TI  - N-way PLS applied to simultaneous spectrophotometric determination of 
      acetylsalicylic acid, paracetamol and caffeine.
PG  - 27-34
AB  - In this work, a simple and rapid analytical procedure was proposed for 
      simultaneous determination of acetylsalicylic acid (ASA), paracetamol (PRC, also 
      known as acetaminophen) and caffeine (CAF) in pharmaceutical formulations based 
      on multivariate calibration and UV spectrophotometric measurements (210-300 nm). 
      The calibration set was constructed with nine solutions in the concentration 
      ranges from 10.0 to 15.0 microg x ml(-1) for ASA and PRC and from 2.0 to 6.0 
      microg x ml(-1) for CAF, according to an experimental design. The procedure was 
      repeated at four different pH values: 2.0, 3.0, 4.0 and 5.0. Partial least 
      squares (PLS) models were built at each pH and used to determinate a set of 
      synthetic mixtures. The best model was obtained at pH 5.0. An N-way PLS model was 
      applied to a three-way array constructed using all the pH data sets and enabled 
      better results. This calibration model provided root mean squares errors of 
      prediction (RMSEP) from 11.5 to 35% lower than those obtained with PLS at pH 5.0, 
      depending on the analyte. The results achieved for the determination of these 
      drugs in commercial tablets were in agreement to the values specified by the 
      manufactures and the recovery was between 94.7 and 104.5%.
FAU - Sena, Marcelo M
AU  - Sena MM
AD  - Departamento de Química Analítica, Instituto de Química, Universidade Estadual de 
      Campinas, PO Box 6154, CEP 13083-862, Campinas SP, Brazil.
FAU - Poppi, Ronei J
AU  - Poppi RJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis/chemistry
MH  - Aspirin/*analysis/chemistry
MH  - Caffeine/*analysis/chemistry
MH  - Calibration
MH  - Least-Squares Analysis
MH  - Spectrophotometry, Ultraviolet/methods/standards
EDAT- 2004/01/24 05:00
MHDA- 2004/09/30 05:00
CRDT- 2004/01/24 05:00
PHST- 2004/01/24 05:00 [pubmed]
PHST- 2004/09/30 05:00 [medline]
PHST- 2004/01/24 05:00 [entrez]
AID - S0731708503004849 [pii]
AID - 10.1016/j.japna.2003.08.011 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2004 Jan 27;34(1):27-34. doi: 10.1016/j.japna.2003.08.011.

PMID- 10362704
OWN - NLM
STAT- MEDLINE
DCOM- 19990722
LR  - 20181218
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 276
IP  - 6
DP  - 1999 Jun
TI  - Plasma volume expansion with solutions of hemoglobin, albumin, and Ringer lactate 
      in sheep.
PG  - H2194-203
LID - 10.1152/ajpheart.1999.276.6.H2194 [doi]
AB  - We have measured plasma volume expansion (Evans blue and hematocrit changes) and 
      hemodynamic responses in conscious hemorrhaged and normovolemic splenectomized 
      sheep after a 30-min infusion of either 20 ml/kg of diaspirin cross-linked 
      hemoglobin (DCLHb), 20 ml/kg of human albumin (Alb), or 60 ml/kg of a solution of 
      Ringer lactate (RL). All regimens expanded blood volume and increased blood 
      pressure and cardiac output after hemorrhage. However, only 15 +/- 3% of the 
      infused volume of RL was evident as intravascular expansion 10-min postinfusion, 
      compared with 67 +/- 16% and 139 +/- 139% for Alb and DCLHb, respectively. DCLHb 
      infusions were associated with higher blood pressures and lower cardiac outputs 
      compared with RL and Alb infusions, but the increased oxygen content of blood 
      with DCLHb resulted in systemic delivery of oxygen similar to that of the other 
      infusions. These differences in hemodynamics and vascular volume continued for 6 
      h, and at 24 h vascular volume and all hemodynamics were similar in all three 
      groups. The better volume expansion with DCLHb may be due to greater mobilization 
      of endogenous interstitial protein or reduced transcapillary loss as total 
      intravascular endogenous plasma protein increased after infusion of DCLHb, 
      whereas there was an apparent loss of endogenous intravascular protein after 
      infusions of Alb and RL. Vasoconstriction by DCLHb is one mechanism that could 
      lower blood-to-tissue transport of fluid and protein. In addition to its 
      oxygen-carrying capacity and vasoactivity, DCLHb is associated with volume 
      expansion properties out of proportion to its colloid osmotic pressure.
FAU - Fischer, S R
AU  - Fischer SR
AD  - Department of Anesthesiology, University of Texas Medical Branch and Shriners 
      Burns Hospital, Galveston, Texas 77555, USA.
FAU - Burnet, M
AU  - Burnet M
FAU - Traber, D L
AU  - Traber DL
FAU - Prough, D S
AU  - Prough DS
FAU - Kramer, G C
AU  - Kramer GC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Hemoglobins)
RN  - 0 (Isotonic Solutions)
RN  - 0 (Plasma Substitutes)
RN  - 0 (Ringer's Lactate)
RN  - 0 (Serum Albumin)
RN  - 0 (Solutions)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Female
MH  - Hemoglobins/*pharmacology
MH  - Hemorrhage/physiopathology
MH  - Isotonic Solutions/*pharmacology
MH  - Plasma Substitutes/*pharmacology
MH  - Plasma Volume/*drug effects
MH  - Reference Values
MH  - Ringer's Lactate
MH  - Serum Albumin/*pharmacology
MH  - Sheep
MH  - Solutions
MH  - Splenectomy
EDAT- 1999/06/11 00:00
MHDA- 1999/06/11 00:01
CRDT- 1999/06/11 00:00
PHST- 1999/06/11 00:00 [pubmed]
PHST- 1999/06/11 00:01 [medline]
PHST- 1999/06/11 00:00 [entrez]
AID - 10.1152/ajpheart.1999.276.6.H2194 [doi]
PST - ppublish
SO  - Am J Physiol. 1999 Jun;276(6):H2194-203. doi: 10.1152/ajpheart.1999.276.6.H2194.

PMID- 32991066
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 11
IP  - 11
DP  - 2020 Nov
TI  - Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell 
      stemness.
PG  - 3117-3125
LID - 10.1111/1759-7714.13619 [doi]
AB  - BACKGROUND: Lung cancer is the leading cause of cancer death and is commonly 
      treated by cisplatin. Although cisplatin treatment may initially be successful, 
      its effectiveness usually reduces significantly in disease-recurrent patients. 
      Aspirin, a nonselective COX inhibitor, has been shown to help reverse the status 
      of cisplatin sensitivity in recurrent human ovarian cancer cells. This study 
      aimed to explore the effect of aspirin on cisplatin resistance through the 
      perspective of cancer cell stemness. METHODS: We used clustering analysis to 
      predict the H460 cisplatin resistance from the GSE21656 dataset. The increased 
      lung cancer cell stemness may contribute to enhanced tolerance. In this study, we 
      used aspirin, a nonselective COX inhibitor, with cisplatin for several hours in 
      cells and days in vivo, and studied the inhibition against human 
      cisplatin-resistant H460 cells. H460 cisplatin-sensitive and H460 
      cisplatin-resistant cells were treated with 16 μM aspirin or/and 0.3 μg/mL 
      cisplatin for 72 hours. RESULTS: H460 cisplatin-resistant cells showed stronger 
      resistance, stemness, and invasiveness than H460 cisplatin-sensitive, and 
      cisplatin significantly reduced the survival of cisplatin-sensitive cells, while 
      cisplatin with aspirin dramatically reduced the surviving fractions of 
      cisplatin-resistant cells. CONCLUSIONS: This study revealed that stemness is a 
      latent inhibitor of the resistance of lung cancer cisplatin-resistant cells and 
      might be effectively inhibited by aspirin.
CI  - © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Zhao, Maoyuan
AU  - Zhao M
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Beijing, China.
AD  - Department of VIP Medical Services, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Beijing, China.
FAU - Wang, Ting
AU  - Wang T
AD  - State Key Laboratory of Molecular Oncology, National Cancer Center/National 
      Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical 
      Sciences & Peking Union Medical College, Beijing, China.
FAU - Hui, Zhouguang
AU  - Hui Z
AUID- ORCID: 0000-0002-7189-4692
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Beijing, China.
AD  - Department of VIP Medical Services, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - Q20Q21Q62J (Cisplatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cell Line, Tumor
MH  - Cisplatin/pharmacology/*therapeutic use
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
PMC - PMC7605995
OTO - NOTNLM
OT  - Aspirin
OT  - cisplatin
OT  - lung cancer
OT  - stemness
EDAT- 2020/09/30 06:00
MHDA- 2021/08/07 06:00
CRDT- 2020/09/29 12:40
PHST- 2020/04/24 00:00 [received]
PHST- 2020/07/26 00:00 [revised]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
PHST- 2020/09/29 12:40 [entrez]
AID - TCA13619 [pii]
AID - 10.1111/1759-7714.13619 [doi]
PST - ppublish
SO  - Thorac Cancer. 2020 Nov;11(11):3117-3125. doi: 10.1111/1759-7714.13619. Epub 2020 
      Sep 29.

PMID- 21804241
OWN - NLM
STAT- MEDLINE
DCOM- 20111201
LR  - 20190706
IS  - 1347-5223 (Electronic)
IS  - 0009-2363 (Linking)
VI  - 59
IP  - 8
DP  - 2011
TI  - Oral administration of Bis(aspirinato)zinc(II) complex ameliorates hyperglycemia 
      and metabolic syndrome-like disorders in spontaneously diabetic KK-A(y) mice: 
      structure-activity relationship on zinc-salicylate complexes.
PG  - 972-7
AB  - In recent years, the number of patients suffering from diseases, such as cancer, 
      apoplexy, osteoporosis, hypertension, and type 2 diabetes mellitus is increasing 
      worldwide. Type 2 diabetes, a lifestyle-related disease, is recognized as a 
      serious disease. Various types of pharmaceutics for diabetes have been used. 
      Since the relationship between diabetes and biometals such as vanadium, copper, 
      and zinc ions has been recognized for many years, we have been developing the 
      anti-diabetic metal complexes as new candidates. We found that several zinc(II) 
      (Zn) complexes exhibit glucose-lowering activity for treating type 2 diabetes. 
      High doses of salicylates have been known to reverse hyperglycemia and 
      hyperinsulinemia in type 2 diabetic patients. These findings strongly suggest 
      that the combined use of Zn and salicylates achieves the synergism in treating 
      type 2 diabetes. Because aspirin, acetyl salicylic acid, has a chelating ability, 
      we used it as a ligand to Zn. Several Zn-salicylate complexes were prepared and 
      their biological activities were examined in this study. The complexes with an 
      electron-withdrawing group in the ligand exhibited higher in vitro 
      insulinomimetic activity than those of Zn complexes with an electron-donating 
      group in the ligand. When bis(aspirinato)Zn (Zn(asp)₂) complex was orally 
      administered on KK-A(y) mice with hereditary type 2 diabetes, the diabetic state 
      was improved. In addition, this complex exhibited normalizing effects on serum 
      adiponectin level and high blood pressure in metabolic syndrome. In conclusion, 
      Zn(asp)₂ complex is newly proposed as a potent anti-diabetic and anti-metabolic 
      syndrome agent.
FAU - Yoshikawa, Yutaka
AU  - Yoshikawa Y
AD  - Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical 
      University, Japan. yutaka@mb.kyoto-phu.ac.jp
FAU - Adachi, Yusuke
AU  - Adachi Y
FAU - Yasui, Hiroyuki
AU  - Yasui H
FAU - Hattori, Masakazu
AU  - Hattori M
FAU - Sakurai, Hiromu
AU  - Sakurai H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - 0 (Adiponectin)
RN  - 0 (Coordination Complexes)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Leptin)
RN  - 0 (bis(aspirinato)zinc(II))
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adiponectin/blood
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & 
      derivatives/chemistry/pharmacokinetics/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Coordination Complexes/administration & 
      dosage/chemistry/pharmacokinetics/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Hyperglycemia/*drug therapy
MH  - Hypoglycemic Agents/administration & 
      dosage/chemistry/pharmacokinetics/*therapeutic use
MH  - Insulin Resistance
MH  - Leptin/metabolism
MH  - Male
MH  - Metabolic Syndrome/*drug therapy
MH  - Mice
MH  - Structure-Activity Relationship
EDAT- 2011/08/02 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/08/02 06:00
PHST- 2011/08/02 06:00 [entrez]
PHST- 2011/08/02 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - JST.JSTAGE/cpb/59.972 [pii]
AID - 10.1248/cpb.59.972 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 2011;59(8):972-7. doi: 10.1248/cpb.59.972.

PMID- 15961818
OWN - NLM
STAT- MEDLINE
DCOM- 20050711
LR  - 20181113
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Print)
IS  - 0959-8138 (Linking)
VI  - 330
IP  - 7505
DP  - 2005 Jun 18
TI  - Aspirin for everyone older than 50? For.
PG  - 1440-1
AB  - Current population screening for vascular disease is neither efficient nor 
      effective. Peter Elwood and colleagues believe we should have a public 
      information strategy highlighting the benefits (and risks) of aspirin for older 
      people, but Colin Baigent argues that the evidence of benefit is not yet strong 
      enough
FAU - Elwood, Peter
AU  - Elwood P
AD  - Welsh Aspirin Group, Department of Epidemiology, Statistics and Public Health, 
      Cardiff University, Llandough Hospital, Penarth CF64 2XW. pelwood@doctors.org.uk 
      <pelwood@doctors.org.uk>
FAU - Morgan, Gareth
AU  - Morgan G
FAU - Brown, Ginevra
AU  - Brown G
FAU - Pickering, Janet
AU  - Pickering J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 2005 Jun 18;330(7505):1442-3. PMID: 15961819
CIN - BMJ. 2005 Jul 16;331(7509):160; author reply 161. PMID: 16020863
CIN - BMJ. 2005 Jul 16;331(7509):161; author reply 161. PMID: 16020866
CIN - BMJ. 2005 Jul 16;331(7509):161; author reply 161. PMID: 16020867
CIN - BMJ. 2005 Jul 16;331(7509):161; author reply 161. PMID: 16020868
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Infarction/*pathology
MH  - Risk Factors
PMC - PMC558385
EDAT- 2005/06/18 09:00
MHDA- 2005/07/12 09:00
CRDT- 2005/06/18 09:00
PHST- 2005/06/18 09:00 [pubmed]
PHST- 2005/07/12 09:00 [medline]
PHST- 2005/06/18 09:00 [entrez]
AID - 330/7505/1440 [pii]
AID - 03301440 [pii]
AID - 10.1136/bmj.330.7505.1440 [doi]
PST - ppublish
SO  - BMJ. 2005 Jun 18;330(7505):1440-1. doi: 10.1136/bmj.330.7505.1440.

PMID- 24472400
OWN - NLM
STAT- MEDLINE
DCOM- 20140527
LR  - 20220330
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 52
IP  - 3
DP  - 2014 Mar
TI  - Difference in risk of gastrointestinal complications between users of 
      enteric-coated and buffered low-dose aspirin.
PG  - 181-91
LID - 10.5414/CP201997 [doi]
AB  - OBJECTIVE: Difference in the risk of gastrointestinal (GI) complications between 
      users of enteric-coated and buffered low-dose aspirin (LDA) is unclear. The 
      purpose of the study is to examine the difference in risk of GI damage between 
      enteric-coated and buffered LDA products. METHODS: A large and chronologically 
      organized receipt database constructed by a database vendor was utilized. 
      Prescription and event sequence symmetry analysis was used to identify the risk 
      of LDA-induced GI complications over the period from January 2005 to July 2011. 
      LDA use in combination with H2-receptor antagonists (H2RAs) and proton pump 
      inhibitors (PPIs) was examined by prescription sequence symmetry analysis. 
      Likewise, symmetry analysis was undertaken to evaluate the association between 
      the diagnosis of GI disease and the prescription of LDA products. RESULTS: In 
      July 2011, enteric-coated LDA users were more frequently co-administered PPIs 
      than buffered LDA users (25.4% vs. 14.4%). Prescription sequence symmetry 
      analysis of acid inhibitor use found no significant associations with 
      enteric-coated LDA use and buffered LDA use. The event sequence symmetry analysis 
      of ulcer, gastritis and duodenitis, and melena found significant associations 
      with entericcoated LDA use, with adjusted sequence ratios (ASRs) of 1.58 (1.23 - 
      2.06), 1.30 (1.03 - 1.65), and 14.38 (2.19 - 607.95), respectively, at the 
      6-month interval. At the 12-month interval, analysis of ulcers and melena found 
      significant associations for enteric-coated LDA users, with ASRs of 1.39 (1.13 - 
      1.73) and 20.83 (3.33 - 863.25), respectively. CONCLUSIONS: Our findings do not 
      support that there is no difference in the risk of GI complications between 
      enteric-coated LDA and buffered LDA, but rather may imply that the risk of GI 
      complications associated with enteric-coated LDA is higher than that with 
      buffered LDA.
FAU - Takada, Mitsutaka
AU  - Takada M
FAU - Fujimoto, Mai
AU  - Fujimoto M
FAU - Hosomi, Kouichi
AU  - Hosomi K
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Buffers)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Buffers
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*chemically induced
MH  - Risk
MH  - Tablets, Enteric-Coated
EDAT- 2014/01/30 06:00
MHDA- 2014/05/28 06:00
CRDT- 2014/01/30 06:00
PHST- 2014/02/18 00:00 [accepted]
PHST- 2014/01/30 06:00 [entrez]
PHST- 2014/01/30 06:00 [pubmed]
PHST- 2014/05/28 06:00 [medline]
AID - 11211 [pii]
AID - 10.5414/CP201997 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2014 Mar;52(3):181-91. doi: 10.5414/CP201997.

PMID- 8132248
OWN - NLM
STAT- MEDLINE
DCOM- 19940418
LR  - 20131121
IS  - 0019-5499 (Print)
IS  - 0019-5499 (Linking)
VI  - 38
IP  - 1
DP  - 1994 Jan
TI  - Effect of variable low doses of aspirin on platelet functions.
PG  - 56-60
AB  - The effect of chronic administration of variable low doses of Aspirin was studied 
      on platelet adhesiveness, platelet count, bleeding time and clotting time to find 
      out as to how low the dose of aspirin needs to be in order to have an effective 
      antiplatelet effect in patients who require such therapy. A statistically 
      significant reduction in the platelet adhesiveness was observed in all the 
      groups, but the best effect was exhibited by 50 mgm of aspirin dose. Bleeding 
      time was also increased in all the groups but statistically significant 
      difference was observed with 50, 75 and 100 mgm doses. There was no change in 
      platelet count and clotting time.
FAU - Bose, S
AU  - Bose S
AD  - Department of Physiology, M.G.M. Medical College, Indore.
FAU - Roohi, F
AU  - Roohi F
FAU - Shiralkar, M
AU  - Shiralkar M
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Physiol Pharmacol
JT  - Indian journal of physiology and pharmacology
JID - 0374707
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects
MH  - Coronary Thrombosis/prevention & control
MH  - Female
MH  - Humans
MH  - Intracranial Embolism and Thrombosis/prevention & control
MH  - Male
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Function Tests
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Physiol Pharmacol. 1994 Jan;38(1):56-60.

PMID- 1864205
OWN - NLM
STAT- MEDLINE
DCOM- 19910906
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 36
IP  - 8
DP  - 1991 Aug
TI  - One gram of aspirin per day does not reduce risk of hospitalization for gallstone 
      disease.
PG  - 1110-5
AB  - Data from 4524 patients in a randomized, controlled trial of aspirin were 
      analyzed to determine if aspirin reduced the risk for hospitalization for 
      gallstone disease. Aspirin at a dose of 1000 mg/day did not reduce the risk of 
      hospitalization for gallstones. Hospitalization rates for gallstone disease were 
      consistent with national rates, and the data confirmed previous associations of 
      gallstone disease with age, elevated serum triglycerides, obesity, and female 
      gender.
FAU - Kurata, J H
AU  - Kurata JH
AD  - Department of Family Medicine, San Bernardino County Medical Center, California.
FAU - Marks, J
AU  - Marks J
FAU - Abbey, D
AU  - Abbey D
LA  - eng
GR  - AM 17328/AM/NIADDK NIH HHS/United States
GR  - AM 37080/AM/NIADDK NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cholelithiasis/*epidemiology/prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - Risk Factors
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
AID - 10.1007/BF01297455 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1991 Aug;36(8):1110-5. doi: 10.1007/BF01297455.

PMID- 29720629
OWN - NLM
STAT- MEDLINE
DCOM- 20190304
LR  - 20190304
IS  - 2155-384X (Electronic)
IS  - 2155-384X (Linking)
VI  - 9
IP  - 5
DP  - 2018 May 2
TI  - Aspirin: the miracle drug?
PG  - 153
LID - 10.1038/s41424-018-0009-4 [doi]
LID - 153
AB  - Aspirin use is associated with reduction of esophageal adenocarcinoma but it is 
      not known if it does so by preventing the development of Barrett's esophagus or 
      by reducing neoplastic progression in patients with Barrett's esophagus. There is 
      sparse literature to support the former assumption especially in women. This 
      study by Jovani et al. based on Nurses' Health Study reports 27% lower risk of 
      Barrett's esophagus among women using aspirin. The protective effect seems to 
      increase with higher frequency and longer duration of aspirin use. This study 
      provides evidence for lower prevalence of Barrett's esophagus in female aspirin 
      users.
FAU - Thota, Prashanthi N
AU  - Thota PN
AD  - Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, 
      USA. thotap@ccf.org.
LA  - eng
GR  - U54 CA163060/CA/NCI NIH HHS/United States
PT  - Editorial
DEP - 20180502
PL  - United States
TA  - Clin Transl Gastroenterol
JT  - Clinical and translational gastroenterology
JID - 101532142
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Barrett Esophagus/*prevention & control
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Risk Assessment
PMC - PMC5932067
COIS- Guarantor of the article: Prashanthi N. Thota Specific author contributions: 
      Drafting the manuscript and approval of final draft: Prashanthi N. Thota 
      Financial support: None Potential competing interests: None
EDAT- 2018/05/04 06:00
MHDA- 2019/03/05 06:00
CRDT- 2018/05/04 06:00
PHST- 2018/01/14 00:00 [received]
PHST- 2018/01/31 00:00 [accepted]
PHST- 2018/05/04 06:00 [entrez]
PHST- 2018/05/04 06:00 [pubmed]
PHST- 2019/03/05 06:00 [medline]
AID - 10.1038/s41424-018-0009-4 [pii]
AID - 9 [pii]
AID - 10.1038/s41424-018-0009-4 [doi]
PST - epublish
SO  - Clin Transl Gastroenterol. 2018 May 2;9(5):153. doi: 10.1038/s41424-018-0009-4.

PMID- 8519040
OWN - NLM
STAT- MEDLINE
DCOM- 19930726
LR  - 20131121
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 15
IP  - 2
DP  - 1993 Mar-Apr
TI  - Endoscopic comparison of three aspirin preparations and placebo.
PG  - 314-20
AB  - Eighty of 84 volunteers aged 22 to 70 years successfully completed a 3-month, 
      single-blind endoscopic study in which they received single-dose placebo or 325 
      mg/day of enteric-coated aspirin (ECA), buffered aspirin (BA), or plain aspirin 
      (ASA). Upper endoscopy was performed at the beginning of the study and after 4, 
      8, and 12 weeks. The gastric and duodenal mucosa was scored endoscopically using 
      a system adapted from Lanza et al. Enteric-coated aspirin and placebo were not 
      statistically different from one another in the gastric damage produced, but both 
      were significantly different from ASA and BA. Significant damage to the gastric 
      mucosa was seen with ASA and BA, with no significant difference between them. 
      Analysis of duodenal mucosa injury revealed that BA, ECA, ASA, and placebo were 
      not significantly different from one another. In addition, a statistical 
      relationship between age and injury could not be proven.
FAU - Petroski, D
AU  - Petroski D
AD  - Rancocas Hospital, Willingboro, New Jersey.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Buffers)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Buffers
MH  - Endoscopy
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Intestinal Mucosa/*drug effects
MH  - Male
MH  - Middle Aged
MH  - Single-Blind Method
MH  - Tablets, Enteric-Coated
EDAT- 1993/03/01 00:00
MHDA- 1993/03/01 00:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 1993/03/01 00:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1993 Mar-Apr;15(2):314-20.

PMID- 696734
OWN - NLM
STAT- MEDLINE
DCOM- 19781129
LR  - 20131121
IS  - 0002-9289 (Print)
IS  - 0002-9289 (Linking)
VI  - 35
IP  - 10
DP  - 1978 Oct
TI  - Cross-reactivity between aspirin and ibuprofen in an asthmatic--a case report.
PG  - 1245-8
AB  - A case of an adverse reaction occurring in a 53-year-old, aspirin-sensitive 
      asthmatic male with nasal polyps following administration of a 400-mg ibuprofen 
      tablet is reported. Symptoms of the adverse reaction included an urticarial rash, 
      labored breathing, laryngeal edema and tightness of the chest. Treatment 
      consisted of isoproterenol inhalant (self-administered), subcutaneous epinephrine 
      0.25 mg, intramuscular diphenhydramine hydrochloride 50 mg and intravenous 
      hydrocortisone 250 mg. The pathogenesis of the patient's adverse reaction and the 
      possible fole of aspirin, of other analgesics and of tartrazine in its 
      development are discussed. The adverse reaction was not mediated immunologically 
      but rather resulted from the prostaglandin synthetase (PGS)-inhibitor activity 
      shared by aspirin, ibuprofen and other analgesics. Selection of an analgesic for 
      an aspirin-sensitive patient should be based on the analgesic's PGS-inhibitor 
      activity.
FAU - Merritt, G J
AU  - Merritt GJ
FAU - Selle, R I Jr
AU  - Selle RI Jr
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Hosp Pharm
JT  - American journal of hospital pharmacy
JID - 0370474
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/*adverse effects/immunology
MH  - *Asthma
MH  - Cross Reactions
MH  - Drug Hypersensitivity/*etiology/immunology
MH  - Humans
MH  - Ibuprofen/*adverse effects/immunology
MH  - Male
MH  - Middle Aged
EDAT- 1978/10/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1978/10/01 00:00
PHST- 1978/10/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1978/10/01 00:00 [entrez]
PST - ppublish
SO  - Am J Hosp Pharm. 1978 Oct;35(10):1245-8.

PMID- 4009911
OWN - NLM
STAT- MEDLINE
DCOM- 19850822
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 254
IP  - 6
DP  - 1985 Aug 9
TI  - Probable efficacy of high-dose salicylates in reducing coronary involvement in 
      Kawasaki disease.
PG  - 767-9
AB  - The efficacy of high-dose salicylates in reducing the coronary artery involvement 
      of Kawasaki disease was compared in 36 children who received acetylsalicylic 
      acid, 80 to 180 mg/kg/day, and in 18 who did not receive high-dose salicylates 
      during the febrile phase of the disease and whose fever was controlled mainly 
      with acetaminophen. The two groups were comparable with respect to age and body 
      weight. In the acetylsalicylic acid-treated group, the dose was adjusted to meet 
      the therapeutic serum concentration range (greater than or equal to 20 mg/dL). 
      There were significantly more cases of coronary involvement in the nontreated 
      group (50%) than in the salicylate-treated group (16.6%) and of coronary 
      aneurysms (39% vs 3%). During the febrile phase of the disease, salicylate serum 
      concentrations achieved with a given dose were on the average twofold lower than 
      during the nonfebrile phase, owing to impaired absorption of acetylsalicylic 
      acid. It is suggested that despite the difficulty in achieving therapeutic serum 
      concentrations of salicylate during the febrile phase of Kawasaki disease with a 
      dose as high as 100 mg/kg/day, this dose is potentially capable of preventing the 
      associated coronary disease.
FAU - Koren, G
AU  - Koren G
FAU - Rose, V
AU  - Rose V
FAU - Lavi, S
AU  - Lavi S
FAU - Rowe, R
AU  - Rowe R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aneurysm/etiology/prevention & control
MH  - Aspirin/*administration & dosage/blood/therapeutic use
MH  - Child, Preschool
MH  - Coronary Disease/etiology/*prevention & control
MH  - Drug Administration Schedule
MH  - Echocardiography
MH  - Female
MH  - Fever/drug therapy/etiology
MH  - Humans
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/complications/*drug therapy
EDAT- 1985/08/09 00:00
MHDA- 1985/08/09 00:01
CRDT- 1985/08/09 00:00
PHST- 1985/08/09 00:00 [pubmed]
PHST- 1985/08/09 00:01 [medline]
PHST- 1985/08/09 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1985 Aug 9;254(6):767-9.

PMID- 36829052
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230731
IS  - 1745-7254 (Electronic)
IS  - 1671-4083 (Print)
IS  - 1671-4083 (Linking)
VI  - 44
IP  - 8
DP  - 2023 Aug
TI  - Aspirin triggers ferroptosis in hepatocellular carcinoma cells through 
      restricting NF-κB p65-activated SLC7A11 transcription.
PG  - 1712-1724
LID - 10.1038/s41401-023-01062-1 [doi]
AB  - A number of studies have shown that aspirin, as commonly prescribed drug, 
      prevents the development of hepatocellular carcinoma (HCC). Ferroptosis as a 
      dynamic tumor suppressor plays a vital role in hepatocarcinogenesis. In this 
      study we investigated whether aspirin affected ferroptosis in liver cancer cells. 
      RNA-seq analysis revealed that aspirin up-regulated 4 ferroptosis-related drivers 
      and down-regulated 5 ferroptosis-related suppressors in aspirin-treated HepG2 
      cells. Treatment with aspirin (4 mM) induced remarkable ferroptosis in HepG2 and 
      Huh7 cells, which was enhanced by the ferroptosis inducer erastin (10 μM). We 
      demonstrated that NF-κB p65 restricted ferroptosis in HepG2 and Huh7 cells 
      through directly binding to the core region of SLC7A11 promoter and activating 
      the transcription of ferroptosis inhibitor SLC7A11, whereas aspirin induced 
      ferroptosis through inhibiting NF-κB p65-activated SLC7A11 transcription. 
      Overexpression of p65 rescued HepG2 and Huh7 cells from aspirin-induced 
      ferroptosis. HCC patients with high expression levels of SLC7A11 and p65 
      presented lower survival rate. Functionally, NF-κB p65 blocked the 
      aspirin-induced ferroptosis in vitro and in vivo, which was attenuated by 
      erastin. We conclude that aspirin triggers ferroptosis by restricting 
      NF-κB-activated SLC7A11 transcription to suppress the growth of HCC. These 
      results provide a new insight into the mechanism by which aspirin regulates 
      ferroptosis in hepatocarcinogenesis. A combination of aspirin and ferroptosis 
      inducer may provide a potential strategy for the treatment of HCC in clinic.
CI  - © 2023. The Author(s), under exclusive licence to Shanghai Institute of Materia 
      Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.
FAU - Wang, Yu-Fei
AU  - Wang YF
AD  - Department of Gastrointestinal Cancer Biology, Tianjin Cancer Institute, Liver 
      Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National 
      Clinical Research Center for Cancer, Tianjin, 300060, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
FAU - Feng, Jin-Yan
AU  - Feng JY
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
AD  - Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer 
      Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 
      300060, China.
FAU - Zhao, Li-Na
AU  - Zhao LN
AD  - Department of Gastrointestinal Cancer Biology, Tianjin Cancer Institute, Liver 
      Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National 
      Clinical Research Center for Cancer, Tianjin, 300060, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
FAU - Zhao, Man
AU  - Zhao M
AD  - Department of Cancer Research, College of Life Sciences, Nankai University, 
      Tianjin, 300071, China.
FAU - Wei, Xian-Fu
AU  - Wei XF
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
AD  - Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer 
      Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 
      300060, China.
FAU - Geng, Yu
AU  - Geng Y
AD  - Department of Cancer Research, College of Life Sciences, Nankai University, 
      Tianjin, 300071, China.
FAU - Yuan, Hong-Feng
AU  - Yuan HF
AD  - Department of Gastrointestinal Cancer Biology, Tianjin Cancer Institute, Liver 
      Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National 
      Clinical Research Center for Cancer, Tianjin, 300060, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
FAU - Hou, Chun-Yu
AU  - Hou CY
AD  - Department of Gastrointestinal Cancer Biology, Tianjin Cancer Institute, Liver 
      Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National 
      Clinical Research Center for Cancer, Tianjin, 300060, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
FAU - Zhang, Hui-Hui
AU  - Zhang HH
AD  - Department of Gastrointestinal Cancer Biology, Tianjin Cancer Institute, Liver 
      Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National 
      Clinical Research Center for Cancer, Tianjin, 300060, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
FAU - Wang, Guo-Wen
AU  - Wang GW
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China. 
      wangguowen@tmu.edu.cn.
AD  - Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer 
      Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 
      300060, China. wangguowen@tmu.edu.cn.
FAU - Yang, Guang
AU  - Yang G
AD  - Department of Gastrointestinal Cancer Biology, Tianjin Cancer Institute, Liver 
      Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National 
      Clinical Research Center for Cancer, Tianjin, 300060, China. 
      yangguang@tjmuch.com.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China. 
      yangguang@tjmuch.com.
FAU - Zhang, Xiao-Dong
AU  - Zhang XD
AD  - Department of Gastrointestinal Cancer Biology, Tianjin Cancer Institute, Liver 
      Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National 
      Clinical Research Center for Cancer, Tianjin, 300060, China. 
      zhangxiaodong@tjmuch.com.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China. 
      zhangxiaodong@tjmuch.com.
LA  - eng
PT  - Journal Article
DEP - 20230224
PL  - United States
TA  - Acta Pharmacol Sin
JT  - Acta pharmacologica Sinica
JID - 100956087
RN  - 0 (NF-kappa B)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (SLC7A11 protein, human)
RN  - 0 (Amino Acid Transport System y+)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/pathology
MH  - NF-kappa B/metabolism
MH  - *Liver Neoplasms/pathology
MH  - *Ferroptosis
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Amino Acid Transport System y+/genetics
PMC - PMC10374658
OTO - NOTNLM
OT  - NF-κB
OT  - PDTC
OT  - SLC7A11
OT  - aspirin
OT  - erastin
OT  - ferroptosis
OT  - ferrostatin-1
OT  - hepatocellular carcinoma
COIS- The authors declare no competing interests.
EDAT- 2023/02/25 06:00
MHDA- 2023/07/31 11:42
PMCR- 2024/08/01
CRDT- 2023/02/24 23:33
PHST- 2023/01/09 00:00 [received]
PHST- 2023/02/06 00:00 [accepted]
PHST- 2024/08/01 00:00 [pmc-release]
PHST- 2023/07/31 11:42 [medline]
PHST- 2023/02/25 06:00 [pubmed]
PHST- 2023/02/24 23:33 [entrez]
AID - 10.1038/s41401-023-01062-1 [pii]
AID - 1062 [pii]
AID - 10.1038/s41401-023-01062-1 [doi]
PST - ppublish
SO  - Acta Pharmacol Sin. 2023 Aug;44(8):1712-1724. doi: 10.1038/s41401-023-01062-1. 
      Epub 2023 Feb 24.

PMID- 24292635
OWN - NLM
STAT- MEDLINE
DCOM- 20140820
LR  - 20140507
IS  - 0340-1022 (Print)
IS  - 0340-1022 (Linking)
VI  - 345
DP  - 2014
TI  - Accurate and robust molecular crystal modeling using fragment-based electronic 
      structure methods.
PG  - 59-93
LID - 10.1007/128_2013_502 [doi]
AB  - Accurately modeling molecular crystal polymorphism requires careful treatment of 
      diverse intra- and intermolecular interactions which can be difficult to achieve 
      without the use of high-level ab initio electronic structure techniques. 
      Fragment-based methods like the hybrid many-body interaction QM/MM technique 
      enable the application of accurate electronic structure models to chemically 
      interesting molecular crystals. The theoretical underpinnings of this approach 
      and the practical requirements for the QM and MM contributions are discussed. 
      Benchmark results and representative applications to aspirin and oxalyl 
      dihydrazide crystals are presented.
FAU - Beran, Gregory J O
AU  - Beran GJ
AD  - Department of Chemistry, University of California, Riverside, CA, 92521, USA, 
      gregory.beran@ucr.edu.
FAU - Wen, Shuhao
AU  - Wen S
FAU - Nanda, Kaushik
AU  - Nanda K
FAU - Huang, Yuanhang
AU  - Huang Y
FAU - Heit, Yonaton
AU  - Heit Y
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - Germany
TA  - Top Curr Chem
JT  - Topics in current chemistry
JID - 0432204
RN  - 0 (Hydrazines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Crystallization
MH  - Crystallography, X-Ray
MH  - *Electrons
MH  - Hydrazines/chemistry
MH  - *Models, Molecular
MH  - Quantum Theory
MH  - Thermodynamics
EDAT- 2013/12/03 06:00
MHDA- 2014/08/21 06:00
CRDT- 2013/12/03 06:00
PHST- 2013/12/03 06:00 [entrez]
PHST- 2013/12/03 06:00 [pubmed]
PHST- 2014/08/21 06:00 [medline]
AID - 10.1007/128_2013_502 [doi]
PST - ppublish
SO  - Top Curr Chem. 2014;345:59-93. doi: 10.1007/128_2013_502.

PMID- 7398829
OWN - NLM
STAT- MEDLINE
DCOM- 19801027
LR  - 20200304
IS  - 0014-4819 (Print)
IS  - 0014-4819 (Linking)
VI  - 39
IP  - 4
DP  - 1980
TI  - Aspirin analgesia evaluated by event-related potentials in man: possible central 
      action in brain.
PG  - 359-64
AB  - The mechanism of aspirin analgesia is still unclear, but it is generally assumed 
      that aspirin exerts its analgesic effect mainly on peripheral nociceptors. In 
      this study, we demonstrate possible brain effects of 975 mg aspirin in man. When 
      brain electrical potentials evoked by painful electrical tooth shocks were 
      examined, aspirin was observed to significantly reduce the amplitude of the late 
      waveform components, but it did not affect the earlier components. Since our 
      earlier findings suggest that early waveform components reflect the energy 
      transmission and the late components manifest the brain activities in an 
      individual's perception of painful information, we postulate that aspirin may act 
      centrally in pain processing.
FAU - Chen, A C
AU  - Chen AC
FAU - Chapman, C R
AU  - Chapman CR
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Exp Brain Res
JT  - Experimental brain research
JID - 0043312
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Analgesia
MH  - Aspirin/*physiology
MH  - Brain/*physiology
MH  - Electric Stimulation
MH  - Evoked Potentials/drug effects
MH  - Humans
MH  - Male
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1007/BF00239300 [doi]
PST - ppublish
SO  - Exp Brain Res. 1980;39(4):359-64. doi: 10.1007/BF00239300.

PMID- 15153656
OWN - NLM
STAT- MEDLINE
DCOM- 20050106
LR  - 20190911
IS  - 1347-8613 (Print)
IS  - 1347-8613 (Linking)
VI  - 95
IP  - 1
DP  - 2004 May
TI  - Mechanism of action by which aspirin alleviates detrusor hyperactivity in rats.
PG  - 101-7
AB  - We examined the effect of aspirin on urodynamic parameters in normal and 
      cyclophosphamide-induced cystitic rats and compared them in rats with or without 
      sensory denervation. Cystometry was performed under urethane anesthesia; and 
      volume threshold for micturition (VT), micturition frequency (MF), micturition 
      pressure (MP), and micturition volume (MV) were determined. Cystitis was induced 
      by pretreatment with cyclophosphamide and sensory denervation was performed by 
      pretreating animals with a large dose of capsaicin. PGE(2) and 6-keto-PGF(1alpha) 
      contents in the bladder were determined by ELISA. Sensory intact, cystitic rats 
      showed decrement of VT and increment of MF. Aspirin increased VT and decreased MF 
      in the cystitic condition. Both PGE(2) and 6-keto-PGF(1alpha) contents in the 
      bladder were significantly increased in cystitic rats, but such increases were 
      completely inhibited by aspirin. In sensory denervated rats, aspirin showed a 
      marginal tendency of increment of VT. Cystitic rats showed overflow micturition 
      in the sensory denervated condition, but VT was the same as that of normal rats. 
      Furthermore, following capsaicin pretreatment, aspirin had no effect on the 
      cystometrogram in cystitic rats. From these findings, it is concluded that 
      suppression of sensory C-fiber via inhibition of PGs synthesis in the bladder is 
      involved in the pharmacological action of aspirin in the detrusor hyperactivity.
FAU - Tsukimi, Yasuhiro
AU  - Tsukimi Y
AD  - TRA Urology, Laboratory-4, Research Center Kyoto, Bayer Yakuhin Ltd., Soraku-gun, 
      Kyoto, Japan. Tsukimi_Yasuhiro@takeda.co.jp
FAU - Mizuyachi, Kaori
AU  - Mizuyachi K
FAU - Matsumoto, Hiroko
AU  - Matsumoto H
FAU - Sato, Masako
AU  - Sato M
FAU - Ng, Betty
AU  - Ng B
FAU - Tajimi, Masaomi
AU  - Tajimi M
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacol Sci
JT  - Journal of pharmacological sciences
JID - 101167001
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cystitis/*drug therapy/physiopathology
MH  - Female
MH  - In Vitro Techniques
MH  - Muscle Hypertonia/*drug therapy/physiopathology
MH  - Nerve Fibers, Unmyelinated/drug effects/physiology
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2004/05/22 05:00
MHDA- 2005/01/07 09:00
CRDT- 2004/05/22 05:00
PHST- 2004/05/22 05:00 [pubmed]
PHST- 2005/01/07 09:00 [medline]
PHST- 2004/05/22 05:00 [entrez]
AID - 10.1254/jphs.95.101 [doi]
PST - ppublish
SO  - J Pharmacol Sci. 2004 May;95(1):101-7. doi: 10.1254/jphs.95.101.

PMID- 25514511
OWN - NLM
STAT- MEDLINE
DCOM- 20160224
LR  - 20181113
IS  - 1520-5126 (Electronic)
IS  - 0002-7863 (Print)
IS  - 0002-7863 (Linking)
VI  - 137
IP  - 1
DP  - 2015 Jan 14
TI  - Mechanistic insights into a classic wonder drug--aspirin.
PG  - 70-3
LID - 10.1021/ja5112964 [doi]
AB  - Aspirin, one of the oldest and most common anti-inflammatory agents, has recently 
      been shown to reduce cancer risks. The principal pharmacological effects of 
      aspirin are known to arise from its covalent modification of cyclooxygenase-2 
      (COX-2) through acetylation of Ser530, but the detailed mechanism of its 
      biochemical action and specificity remains to be elucidated. In this work, we 
      have filled this gap by employing a state-of-the-art computational approach, 
      Born-Oppenheimer molecular dynamics simulations with ab initio quantum 
      mechanical/molecular mechanical potential and umbrella sampling. Our studies have 
      characterized a substrate-assisted inhibition mechanism for aspirin acetylating 
      COX: it proceeds in two successive stages with a metastable tetrahedral 
      intermediate, in which the carboxyl group of aspirin serves as the general base. 
      The computational results confirmed that aspirin would be 10-100 times more 
      potent against COX-1 than against COX-2, and revealed that this inhibition 
      specificity between the two COX isoforms can be attributed mainly to the 
      difference in kinetics rate of the covalent inhibition reaction, not the 
      aspirin-binding step. The structural origin of this differential inhibition of 
      the COX enzymes by aspirin has also been elucidated.
FAU - Lei, Jinping
AU  - Lei J
AD  - Institute of Theoretical and Computational Chemistry, Laboratory of Mesoscopic 
      Chemistry, School of Chemistry and Chemical Engineering, Nanjing University , 
      Nanjing 210093, China.
FAU - Zhou, Yanzi
AU  - Zhou Y
FAU - Xie, Daiqian
AU  - Xie D
FAU - Zhang, Yingkai
AU  - Zhang Y
LA  - eng
GR  - R01 GM079223/GM/NIGMS NIH HHS/United States
GR  - R01-GM079223/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20141222
PL  - United States
TA  - J Am Chem Soc
JT  - Journal of the American Chemical Society
JID - 7503056
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation/drug effects
MH  - Aspirin/chemistry/*pharmacology
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Cyclooxygenase Inhibitors/chemistry/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Models, Molecular
MH  - Molecular Dynamics Simulation
MH  - Molecular Structure
MH  - Quantum Theory
MH  - Structure-Activity Relationship
PMC - PMC4309031
EDAT- 2014/12/17 06:00
MHDA- 2016/02/26 06:00
CRDT- 2014/12/17 06:00
PHST- 2014/12/17 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
AID - 10.1021/ja5112964 [doi]
PST - ppublish
SO  - J Am Chem Soc. 2015 Jan 14;137(1):70-3. doi: 10.1021/ja5112964. Epub 2014 Dec 22.

PMID- 3787562
OWN - NLM
STAT- MEDLINE
DCOM- 19870102
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 44
IP  - 1
DP  - 1986 Oct 1
TI  - Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall 
      interactions.
PG  - 65-74
AB  - The effect of in vitro aspirin treatment and alpha adrenergic receptor 
      stimulation on the interaction of platelets with the subendothelium was studied 
      using citrated human blood obtained from normal control donors. Reconstituted 
      blood following drug treatment was circulated through a chamber which housed 
      everted segments of deendothelialized rabbit aorta. The wall shear rate was 800 
      sec-1. Surface coverage of platelets were morphometrically evaluated. Aspirin 
      treatment significantly reduced platelet thrombi on exposed subendothelium. 
      However, platelet spreading was increased. There was no significant difference in 
      the total percent coverage of platelets in the vascular surface between the 
      aspirin treated group and normal controls. Epinephrine exposure of aspirin 
      treated platelets completely reversed the effect of alterations induced in 
      platelet behavior by aspirin. Epinephrine exposed aspirin treated platelets had 
      as many platelet thrombi on exposed subendothelium as normal control platelets. 
      In addition, epinephrine treatment decreased the spreading of aspirin treated 
      platelets on the vascular surface. Results of the present study and our earlier 
      findings suggest that the epinephrine induced membrane modulation may be a major 
      mechanism for protecting the hemostatic role of platelets after their function is 
      compromised in vivo and in vitro. The failure of aspirin to offer significant 
      protection in many clinical trials may be due to the presence of a salvage 
      pathway in platelets provided by the mechanism of membrane modulation.
FAU - Rao, G H
AU  - Rao GH
FAU - Escolar, G
AU  - Escolar G
FAU - White, J G
AU  - White JG
LA  - eng
GR  - CA-21737/CA/NCI NIH HHS/United States
GR  - GM-22167/GM/NIGMS NIH HHS/United States
GR  - HL-11880/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Aspirin/antagonists & inhibitors/*pharmacology
MH  - Blood Platelet Disorders/chemically induced
MH  - Blood Platelets/*drug effects/physiology
MH  - Blood Vessels/*physiology
MH  - Drug Interactions
MH  - Epinephrine/*pharmacology
MH  - Humans
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Thrombosis/etiology
EDAT- 1986/10/01 00:00
MHDA- 1986/10/01 00:01
CRDT- 1986/10/01 00:00
PHST- 1986/10/01 00:00 [pubmed]
PHST- 1986/10/01 00:01 [medline]
PHST- 1986/10/01 00:00 [entrez]
AID - 0049-3848(86)90181-7 [pii]
AID - 10.1016/0049-3848(86)90181-7 [doi]
PST - ppublish
SO  - Thromb Res. 1986 Oct 1;44(1):65-74. doi: 10.1016/0049-3848(86)90181-7.

PMID- 24625848
OWN - NLM
STAT- MEDLINE
DCOM- 20140522
LR  - 20140314
IS  - 1827-6806 (Print)
IS  - 1827-6806 (Linking)
VI  - 15
IP  - 2
DP  - 2014 Feb
TI  - [Upstream administration of oral antiplatelet agents in patients with 
      ST-elevation myocardial infarction undergoing primary percutaneous coronary 
      intervention].
PG  - 90-8
LID - 10.1714/1424.15778 [doi]
AB  - Current guidelines for the management of patients with ST-elevation myocardial 
      infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) 
      recommend the administration of dual antiplatelet therapy with aspirin and an ADP 
      receptor blocker "as early as possible" before angiography (upstream), though 
      this suggestion is not based on the results of randomized clinical trials 
      designed to investigate pre-hospital rather than in-hospital drug administration. 
      The present review analyzed randomized clinical trials, registries and 
      observational studies that assessed clopidogrel, prasugrel and ticagrelor 
      administration in STEMI patients undergoing primary PCI to evaluate if their 
      upstream use may be justified in clinical practice. A significant difference 
      favoring early clopidogrel administration has been demonstrated in observational 
      studies. No evidence is available for prasugrel and ticagrelor; however, the 
      initial delay of their antiplatelet effect in STEMI patients could support an 
      upstream strategy to obtain complete platelet inhibition in the first hours after 
      PCI and prevent major adverse events (e.g., stent thrombosis) despite an 
      increased risk of major bleeding, particularly in case of urgent bypass surgery. 
      Data from specifically designed randomized clinical trials are warranted to 
      establish whether early administration of prasugrel and ticagrelor may favor 
      reperfusion and improve clinical outcome with an acceptable risk-benefit ratio.
FAU - Ferlini, Marco
AU  - Ferlini M
FAU - Mafrici, Antonio
AU  - Mafrici A
FAU - Marzegalli, Maurizio
AU  - Marzegalli M
FAU - Piccaluga, Emanuela
AU  - Piccaluga E
FAU - Sponzilli, Carlo
AU  - Sponzilli C
FAU - Bramucci, Ezio
AU  - Bramucci E
FAU - Visconti, Luigi Oltrona
AU  - Visconti LO
LA  - ita
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Utilizzo upstream degli antiaggreganti piastrinici orali nei pazienti con infarto 
      miocardico acuto con sopraslivellamento del tratto ST trattati con angioplastica 
      primaria.
PL  - Italy
TA  - G Ital Cardiol (Rome)
JT  - Giornale italiano di cardiologia (2006)
JID - 101263411
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Coronary Angiography
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/physiopathology/*therapy
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Practice Guidelines as Topic
EDAT- 2014/03/15 06:00
MHDA- 2014/05/23 06:00
CRDT- 2014/03/15 06:00
PHST- 2014/03/15 06:00 [entrez]
PHST- 2014/03/15 06:00 [pubmed]
PHST- 2014/05/23 06:00 [medline]
AID - 10.1714/1424.15778 [doi]
PST - ppublish
SO  - G Ital Cardiol (Rome). 2014 Feb;15(2):90-8. doi: 10.1714/1424.15778.

PMID- 32896390
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20211203
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Print)
IS  - 0015-0282 (Linking)
VI  - 114
IP  - 6
DP  - 2020 Dec
TI  - Low-dose aspirin in reproductive health: effects on menstrual cycle 
      characteristics.
PG  - 1263-1270
LID - S0015-0282(20)30594-X [pii]
LID - 10.1016/j.fertnstert.2020.06.022 [doi]
AB  - OBJECTIVE: To estimate the effect of daily 81 mg low-dose aspirin (LDA) on 
      menstrual cycle length and hormone profiles. DESIGN: Secondary analysis of a 
      trial evaluating the effect of daily LDA or placebo on live birth among women 
      with one or two previous pregnancy losses. SETTING: University medical centers. 
      PATIENT(S): A total of 915 regularly menstruating women who had at least one 
      menstrual cycle (3,190 total cycles) in which pregnancy did not occur. 
      INTERVENTION(S): Randomized allocation to LDA versus placebo. MAIN OUTCOME 
      MEASURE(S): Menstrual cycle length and follicular and luteal phases were 
      measured. Urinary pregnanediol glucuronide, follicle-stimulating hormone, 
      luteinizing hormone, and estrone-3-glucuronide were assessed up to six times 
      during the first two cycles. Generalized estimating equations estimated relative 
      risk of short (<25th percentile: <27 days) and long (>75th percentile: ≥32 days) 
      versus normal cycle length. Linear mixed models estimated mean hormone level 
      differences with weights used to account for multiple cycles contributed per 
      participant. RESULT(S): There were no significant differences in total menstrual 
      cycle, follicular phase, or luteal phase length between LDA and placebo groups. 
      LDA posed no greater risk of having a short versus normal-length or long versus 
      normal-length follicular phase, or having a short versus normal-length or long 
      versus normal-length luteal phase. There were no significant differences in 
      hormone levels across the menstrual cycle between the LDA and placebo groups. 
      CONCLUSION(S): Daily LDA use did not result in any changes to menstrual cycle, 
      follicular phase, or luteal phase length or hormone levels across the menstrual 
      cycle compared with placebo. CLINICAL TRIAL REGISTRATION NUMBER: NCT00467363.
CI  - Published by Elsevier Inc.
FAU - Evans, M Blake
AU  - Evans MB
AD  - Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver 
      National Institute of Child Health and Human Development, National Institutes of 
      Health, Bethesda, Maryland.
FAU - Nobles, Carrie J
AU  - Nobles CJ
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, Maryland.
FAU - Kim, Keewan
AU  - Kim K
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, Maryland.
FAU - Hill, Micah J
AU  - Hill MJ
AD  - Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver 
      National Institute of Child Health and Human Development, National Institutes of 
      Health, Bethesda, Maryland.
FAU - DeCherney, Alan H
AU  - DeCherney AH
AD  - Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver 
      National Institute of Child Health and Human Development, National Institutes of 
      Health, Bethesda, Maryland.
FAU - Silver, Robert M
AU  - Silver RM
AD  - Department of Obstetrics and Gynecology, University of Utah School of Medicine, 
      Salt Lake City, Utah.
FAU - Mumford, Sunni L
AU  - Mumford SL
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, Maryland.
FAU - Sjaarda, Lindsey A
AU  - Sjaarda LA
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, Maryland.
FAU - Perkins, Neil J
AU  - Perkins NJ
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, Maryland.
FAU - Schisterman, Enrique F
AU  - Schisterman EF
AD  - Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver 
      National Institute of Child Health and Human Development, National Institutes of 
      Health, Bethesda, Maryland. Electronic address: schistee@mail.nih.gov.
LA  - eng
SI  - ClinicalTrials.gov/NCT00467363
GR  - Z01 HD008795/ImNIH/Intramural NIH HHS/United States
GR  - ZIA HD008795/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Intramural
DEP - 20200904
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - 0 (Biomarkers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Fertil Steril. 2020 Dec;114(6):1177-1178. PMID: 32907743
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Biomarkers/urine
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Menstrual Cycle/*drug effects/urine
MH  - *Reproductive Health
MH  - Time Factors
MH  - United States
MH  - Young Adult
PMC - PMC7722096
MID - NIHMS1604872
OTO - NOTNLM
OT  - Low dose aspirin
OT  - menstrual cycle hormones
OT  - menstrual cycle length
EDAT- 2020/09/09 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/09/08 08:47
PHST- 2020/02/21 00:00 [received]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/09/08 08:47 [entrez]
AID - S0015-0282(20)30594-X [pii]
AID - 10.1016/j.fertnstert.2020.06.022 [doi]
PST - ppublish
SO  - Fertil Steril. 2020 Dec;114(6):1263-1270. doi: 10.1016/j.fertnstert.2020.06.022. 
      Epub 2020 Sep 4.

PMID- 2272812
OWN - NLM
STAT- MEDLINE
DCOM- 19910226
LR  - 20190828
IS  - 0017-8748 (Print)
IS  - 0017-8748 (Linking)
VI  - 30
IP  - 10
DP  - 1990 Oct
TI  - Acetylsalicylic acid vs. metoprolol in migraine prophylaxis--a double-blind 
      cross-over study.
PG  - 639-41
AB  - In a double blind cross-over study, 28 patients, 5 male and 23 female, aged 31 
      +/- 14 years, after a run-in period of 8 weeks, were treated for 3 months with 
      acetylsalicylic acid and for another 3 months with metoprolol, both in a 
      prophylactic mode. Attack frequency was reduced significantly with both 
      therapeutic regimens (ASA p less than 0.001, metoprolol p less than 0.00005). 
      Reduction of attacks below 50% was seen with metoprolol in 14 cases, and with ASA 
      in three cases. Even though ASA was of statistically significant efficacy in 
      migraine prophylaxis, it clearly is not the drug of first choice in migraine 
      prophylaxis.
FAU - Grotemeyer, K H
AU  - Grotemeyer KH
AD  - Department of Neurology, University of Münster, FRG.
FAU - Scharafinski, H W
AU  - Scharafinski HW
FAU - Schlake, H P
AU  - Schlake HP
FAU - Husstedt, I W
AU  - Husstedt IW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - GEB06NHM23 (Metoprolol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Metoprolol/adverse effects/*therapeutic use
MH  - Migraine Disorders/*prevention & control
MH  - Recurrence
EDAT- 1990/10/01 00:00
MHDA- 1990/10/01 00:01
CRDT- 1990/10/01 00:00
PHST- 1990/10/01 00:00 [pubmed]
PHST- 1990/10/01 00:01 [medline]
PHST- 1990/10/01 00:00 [entrez]
AID - 10.1111/j.1526-4610.1990.hed3010639.x [doi]
PST - ppublish
SO  - Headache. 1990 Oct;30(10):639-41. doi: 10.1111/j.1526-4610.1990.hed3010639.x.

PMID- 6793924
OWN - NLM
STAT- MEDLINE
DCOM- 19811222
LR  - 20161123
IS  - 0375-9393 (Print)
IS  - 0375-9393 (Linking)
VI  - 47
IP  - 5
DP  - 1981 May
TI  - [Postoperative analgesia with lysine salicylate and pentazocine].
PG  - 237-40
AB  - The analgesic effect of two doses (1.8 and 3.6 g) of acetylsalicylate of lysine 
      and two doses (30 and 60 mg) of pentazocine was studied after random 
      administration to 40 patients who had undergone cholecystectomy. The experimental 
      pattern was a four-point bio-assay and pain intensity was assessed on a 0 to 100 
      algesimetric scale by the patients themselves upon administration of the 
      analgesic and after 30, 60 and 120 minutes. The analgesic of acetylsalicylate of 
      lysine proved dose-dependent with a power ratio with respect to pentazocine of 
      between 43 and 65.
FAU - Launo, C
AU  - Launo C
FAU - Molinino, M
AU  - Molinino M
FAU - Bassi, C
AU  - Bassi C
FAU - Carbone, M
AU  - Carbone M
FAU - Novielli, N
AU  - Novielli N
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Analgesia post-operatoria con acetilsalicilato di lisina e pentazocina.
PL  - Italy
TA  - Minerva Anestesiol
JT  - Minerva anestesiologica
JID - 0375272
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - RP4A60D26L (Pentazocine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Cholecystectomy
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Pentazocine/*therapeutic use
EDAT- 1981/05/01 00:00
MHDA- 1981/05/01 00:01
CRDT- 1981/05/01 00:00
PHST- 1981/05/01 00:00 [pubmed]
PHST- 1981/05/01 00:01 [medline]
PHST- 1981/05/01 00:00 [entrez]
PST - ppublish
SO  - Minerva Anestesiol. 1981 May;47(5):237-40.

PMID- 18575872
OWN - NLM
STAT- MEDLINE
DCOM- 20090220
LR  - 20211020
IS  - 1433-0350 (Electronic)
IS  - 0256-7040 (Linking)
VI  - 24
IP  - 12
DP  - 2008 Dec
TI  - Subgaleal hematoma in a child with Sturge-Weber syndrome: to prevent stroke-like 
      episodes, is treatment with aspirin advisable?
PG  - 1479-81
LID - 10.1007/s00381-008-0662-0 [doi]
AB  - CASE REPORT: A subgaleal hematoma (SGH) occurred in a young patient with 
      Sturge-Weber syndrome (SWS) who was treated with aspirin after a mild head 
      trauma. MATERIALS AND METHODS: A 4-year-old child with SWS, who was chronically 
      treated with aspirin at an antiplatelet dosage of 3 mg/kg per day, presented with 
      extensive SGH and significant anemia after a mild head trauma. RESULTS AND 
      CONCLUSION: It is conceivable that the minor head trauma and chronic use of 
      aspirin caused the SGH. Based on this event, the chronic use of aspirin in young 
      patients with SWS, as suggested to prevent stroke-like episodes, is disputable.
FAU - Greco, Filippo
AU  - Greco F
AD  - Department of Pediatrics, University of Catania, Via S. Sofia 78, 95123, Catania, 
      Italy. coicoico@hotmail.com
FAU - Fiumara, Agata
AU  - Fiumara A
FAU - Sorge, Giovanni
AU  - Sorge G
FAU - Pavone, Lorenzo
AU  - Pavone L
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20080625
PL  - Germany
TA  - Childs Nerv Syst
JT  - Child's nervous system : ChNS : official journal of the International Society for 
      Pediatric Neurosurgery
JID - 8503227
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Child, Preschool
MH  - Craniocerebral Trauma/complications
MH  - Hematoma/*diagnosis/etiology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/therapeutic use
MH  - *Scalp
MH  - Stroke/etiology/prevention & control
MH  - Sturge-Weber Syndrome/complications/*drug therapy
MH  - Tomography Scanners, X-Ray Computed
EDAT- 2008/06/26 09:00
MHDA- 2009/02/21 09:00
CRDT- 2008/06/26 09:00
PHST- 2008/04/22 00:00 [received]
PHST- 2008/06/26 09:00 [pubmed]
PHST- 2009/02/21 09:00 [medline]
PHST- 2008/06/26 09:00 [entrez]
AID - 10.1007/s00381-008-0662-0 [doi]
PST - ppublish
SO  - Childs Nerv Syst. 2008 Dec;24(12):1479-81. doi: 10.1007/s00381-008-0662-0. Epub 
      2008 Jun 25.

PMID- 30561620
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20201210
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 40
IP  - 7
DP  - 2019 Feb 14
TI  - Efficacy and safety of aspirin for primary prevention of cardiovascular events: a 
      meta-analysis and trial sequential analysis of randomized controlled trials.
PG  - 607-617
LID - 10.1093/eurheartj/ehy813 [doi]
AB  - AIMS: The role of aspirin in the primary prevention setting is continuously 
      evolving. Recent randomized trials have challenged the role of aspirin in the 
      primary prevention setting. METHODS AND RESULTS: Electronic databases were 
      searched for randomized trials that compared aspirin vs. placebo (or control) in 
      subjects without established atherosclerotic disease. The primary efficacy 
      outcome was all-cause mortality, while the primary safety outcome was major 
      bleeding. Summary estimates were reported using a DerSimonian and Laird random 
      effects model. A total of 11 trials with 157 248 subjects were included. At a 
      mean follow-up of 6.6 years, aspirin was not associated with a lower incidence of 
      all-cause mortality [risk ratio (RR) 0.98, 95% confidence interval (CI) 
      0.93-1.02; P = 0.30]; however, aspirin was associated with an increased incidence 
      of major bleeding (RR 1.47, 95% CI 1.31-1.65; P < 0.0001) and intracranial 
      haemorrhage (RR 1.33, 95% CI 1.13-1.58; P = 0.001). A similar effect on all-cause 
      mortality and major bleeding was demonstrated in diabetic and high cardiovascular 
      risk patients (i.e. 10-year risk >7.5%). Aspirin was associated with a lower 
      incidence of myocardial infarction (RR 0.82, 95% CI 0.71-0.94; P = 0.006); 
      however, this outcome was characterized by considerable heterogeneity (I2 = 67%), 
      and this effect was no longer evident upon limiting the analysis to the more 
      recent trials. Trial sequential analysis confirmed the lack of benefit of aspirin 
      for all-cause mortality up to a relative risk reduction of 5%. CONCLUSION: Among 
      adults without established cardiovascular disease, aspirin was not associated 
      with a reduction in the incidence of all-cause mortality; however, it was 
      associated with an increased incidence of major bleeding. The routine use of 
      aspirin for primary prevention needs to be reconsidered.
CI  - Published by Oxford University Press on behalf of the European Society of 
      Cardiology 2018.
FAU - Mahmoud, Ahmed N
AU  - Mahmoud AN
AD  - Division of Cardiovascular Medicine, Department of Medicine, University of 
      Florida, 1600 SW Archer Road, Gainesville, FL, USA.
FAU - Gad, Mohamed M
AU  - Gad MM
AD  - Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland 
      Clinic, 9500 Euclid Ave, Cleveland, OH, USA.
FAU - Elgendy, Akram Y
AU  - Elgendy AY
AD  - Division of Cardiovascular Medicine, Department of Medicine, University of 
      Florida, 1600 SW Archer Road, Gainesville, FL, USA.
FAU - Elgendy, Islam Y
AU  - Elgendy IY
AD  - Division of Cardiovascular Medicine, Department of Medicine, University of 
      Florida, 1600 SW Archer Road, Gainesville, FL, USA.
FAU - Bavry, Anthony A
AU  - Bavry AA
AD  - Division of Cardiovascular Medicine, Department of Medicine, University of 
      Florida, 1600 SW Archer Road, Gainesville, FL, USA.
AD  - North Florida/South Georgia Veterans Health System, Malcom Randall Veterans 
      Administration Medical Center, Medical Service, Cardiology Section (111D), 1601 
      SW Archer Road, Gainesville, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2019 Feb 14;40(7):618-620. PMID: 30590516
CIN - Eur Heart J. 2019 Sep 7;40(34):2924-2925. PMID: 31005974
CIN - Eur Heart J. 2019 Sep 7;40(34):2922-2923. PMID: 31005987
CIN - Eur Heart J Qual Care Clin Outcomes. 2020 Apr 1;6(2):175-176. PMID: 31553436
CIN - J Fam Pract. 2020 Nov;69(9):461-462. PMID: 33176342
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular
OT  - Meta-analysis
OT  - Mortality
OT  - Prevention
EDAT- 2018/12/19 06:00
MHDA- 2020/09/12 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/09/28 00:00 [received]
PHST- 2018/10/13 00:00 [revised]
PHST- 2018/11/14 00:00 [accepted]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2018/12/19 06:00 [entrez]
AID - 5250614 [pii]
AID - 10.1093/eurheartj/ehy813 [doi]
PST - ppublish
SO  - Eur Heart J. 2019 Feb 14;40(7):607-617. doi: 10.1093/eurheartj/ehy813.

PMID- 17186390
OWN - NLM
STAT- MEDLINE
DCOM- 20070516
LR  - 20181113
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 23
IP  - 3
DP  - 2007 Jun
TI  - A review of aspirin resistance; definition, possible mechanisms, detection with 
      platelet function tests, and its clinical outcomes.
PG  - 213-22
AB  - Aspirin (acetylsalicylic acid) is one of the main therapeutics in prevention of 
      thrombo-embolic vascular events. Its efficiency is proved in the prevention of 
      cardiovascular events. However, antiplatelet effect of aspirin is not absolute in 
      all patients and some patients experience thrombo-embolic events despite aspirin. 
      These patients are clinically called as aspirin resistant or aspirin 
      non-responders. Globally, a lot of people are affected by aspirin resistance 
      according to the high prevalence of athero-thrombotic vascular diseases. A 
      prevalence of 5.5-45% in patients with various cardiovascular disease by 
      different laboratory methods has been reported for aspirin resistance. Clinical 
      outcome of aspirin resistance has been demonstrated in patients with different 
      vascular diseases. Detection of platelet function in patients treated with 
      aspirin may be necessary in the prediction of clinical outcome. Point of care 
      methods, which have correlated results with the standard light transmittance 
      aggregometry may be appropriate choices in the detection of platelets' response 
      to antiplatelet therapy. Adequate additional therapies may reduce 
      atherothrombotic risks and major cardiovascular events rate in aspirin resistant 
      subjects. None of the current researches advised the cessation of aspirin 
      therapy. There is need to investigate the efficacy of additional adenosine 
      diphosphate receptor antagonists or newer antiplatelet agents in aspirin 
      resistant subjects. The intent of this paper is to review the literature 
      discussing possible mechanisms, determination techniques, and clinical effects of 
      aspirin resistance.
FAU - Pamukcu, Burak
AU  - Pamukcu B
AD  - Department of Cardiology, Istanbul University, Hasan Halife Mahallesi Oksuzler 
      Sokak No: 9 K:2 D: 4 Fatih, Istanbul 34080, Turkey. bpamukcu@istanbul.edu.tr
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20061222
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Function Tests
MH  - Treatment Outcome
RF  - 76
EDAT- 2006/12/23 09:00
MHDA- 2007/05/17 09:00
CRDT- 2006/12/23 09:00
PHST- 2006/09/29 00:00 [received]
PHST- 2006/11/07 00:00 [accepted]
PHST- 2006/12/23 09:00 [pubmed]
PHST- 2007/05/17 09:00 [medline]
PHST- 2006/12/23 09:00 [entrez]
AID - 10.1007/s11239-006-9043-2 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2007 Jun;23(3):213-22. doi: 10.1007/s11239-006-9043-2. 
      Epub 2006 Dec 22.

PMID- 16198840
OWN - NLM
STAT- MEDLINE
DCOM- 20051222
LR  - 20131121
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 46
IP  - 7
DP  - 2005 Oct 4
TI  - Platelet response to low-dose enteric-coated aspirin in patients with stable 
      cardiovascular disease.
PG  - 1258-63
AB  - OBJECTIVES: We investigated whether use of low-dose enteric-coated (EC) aspirin 
      for secondary prevention of cardiovascular events has sufficient bioavailability 
      to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. 
      BACKGROUND: Aspirin reduces cardiovascular morbidity and mortality in patients 
      with pre-existing vascular disease; however, there is variability in the way 
      individuals respond. Persistent normal platelet function despite therapy, 
      referred to as "aspirin resistance," is associated with an increased risk of 
      major cardiovascular events. METHODS: We studied 131 stable cardiovascular 
      patients between March and September 2002 who were taking 75 mg EC aspirin. Serum 
      thromboxane (TX) B2 levels were assayed as a measure of COX activity. Mean 
      arachidonic acid (AA)-induced platelet aggregation > or =20% was deemed evidence 
      of persistent platelet activity and an incomplete aspirin response. RESULTS: 
      Patients of median age 63 years (61% men) were enrolled. Forty-four percent of 
      patients had elevated serum TX B2 levels (>2.2 ng/ml). Arachidonic acid-induced 
      platelet aggregation occurred more frequently in these patients (21% vs. 3%; p = 
      0.004). In all cases addition of exogenous aspirin during the assay abolished 
      platelet aggregation. Patient weight and age were significant independent 
      predictors of an incomplete response to EC aspirin (p = 0.025 and p < 0.001, 
      respectively). These patients were also more likely to have a history of 
      myocardial infarction (MI) (p = 0.038). CONCLUSIONS: Many patients who are 
      prescribed low-dose EC aspirin for secondary prevention of cardiovascular events 
      have persistent uninhibited platelet COX activity. Younger and heavier patients 
      and those with a previous MI are most likely to have an inadequate response to 
      treatment.
FAU - Maree, Andrew O
AU  - Maree AO
AD  - Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, 
      Dublin, Ireland.
FAU - Curtin, Ronan J
AU  - Curtin RJ
FAU - Dooley, Michelle
AU  - Dooley M
FAU - Conroy, Ronan M
AU  - Conroy RM
FAU - Crean, Peter
AU  - Crean P
FAU - Cox, Dermot
AU  - Cox D
FAU - Fitzgerald, Desmond J
AU  - Fitzgerald DJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/chemistry/*drug effects/*physiology
MH  - Cardiovascular Diseases/*blood/*prevention & control
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Tablets, Enteric-Coated
MH  - Thromboxane B2/blood
EDAT- 2005/10/04 09:00
MHDA- 2005/12/24 09:00
CRDT- 2005/10/04 09:00
PHST- 2005/02/11 00:00 [received]
PHST- 2005/06/07 00:00 [revised]
PHST- 2005/06/13 00:00 [accepted]
PHST- 2005/10/04 09:00 [pubmed]
PHST- 2005/12/24 09:00 [medline]
PHST- 2005/10/04 09:00 [entrez]
AID - S0735-1097(05)01652-9 [pii]
AID - 10.1016/j.jacc.2005.06.058 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2005 Oct 4;46(7):1258-63. doi: 10.1016/j.jacc.2005.06.058.

PMID- 1686333
OWN - NLM
STAT- MEDLINE
DCOM- 19920323
LR  - 20171116
IS  - 0037-5675 (Print)
IS  - 0037-5675 (Linking)
VI  - 32
IP  - 5
DP  - 1991 Oct
TI  - Early management of myocardial infraction: a report from the Waikato Hospital, 
      New Zealand.
PG  - 373-5
AB  - A retrospective review was made of the early management of 50 consecutive 
      patients admitted with an acute myocardial infarction to assess the potential 
      suitability and actual application of thrombolysis, intravenous beta-blockade and 
      aspirin therapy. Thrombolysis was indicated for 15 patients (30%), of whom 14 
      actually did receive intravenous streptokinase. Thus, 93.3% of all eligible 
      patients received thrombolysis. The main contraindication to thrombolysis was a 
      presentation more than six hours from onset of symptoms in 26 patients (52%). 
      Intravenous beta-blockade was indicated for 17 patients (34%), six patients were 
      actually treated resulting in a therapeutic coverage of 35.3%. Heart failure in 
      21 patients (42%) was the main contraindication. Aspirin was indicated for 48 
      patients (96%). However, only 14 were treated giving a therapeutic coverage of 
      29.2%. A large majority of our patients with an acute myocardial infarction were 
      eligible to receive aspirin which has been a neglected therapeutic modality.
FAU - Ong, H T
AU  - Ong HT
AD  - Department of Cardiology, Walkato Hospital, Hamilton, New Zealand.
FAU - Friedlander, D H
AU  - Friedlander DH
LA  - eng
PT  - Journal Article
PL  - India
TA  - Singapore Med J
JT  - Singapore medical journal
JID - 0404516
RN  - 0 (Adrenergic beta-Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adrenergic beta-Antagonists/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Contraindications
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Myocardial Infarction/*drug therapy
MH  - New Zealand
MH  - *Thrombolytic Therapy
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
PST - ppublish
SO  - Singapore Med J. 1991 Oct;32(5):373-5.

PMID- 35121011
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220407
IS  - 1872-9754 (Electronic)
IS  - 0197-0186 (Linking)
VI  - 154
DP  - 2022 Mar
TI  - The effect of clopidogrel and aspirin on the severity of traumatic brain injury 
      in a rat model.
PG  - 105301
LID - S0197-0186(22)00026-2 [pii]
LID - 10.1016/j.neuint.2022.105301 [doi]
AB  - Traumatic Brain Injury (TBI) is one of the leading causes of death and disability 
      worldwide. Aspirin (ASA) and clopidogrel (CLOP) are antiplatelet agents that 
      inhibit platelet aggregation. They are implicated in worsening the intracerebral 
      haemorrhage (ICH) risk post-TBI. However, antiplatelet drugs may also exert a 
      neuroprotective effect post-injury. We determined the impact of ASA and CLOP 
      treatment, alone or in combination, on ICH and brain damage in an experimental 
      rat TBI model. We assessed changes in platelet aggregation and measured serum 
      thromboxane by enzyme immune assay. We also explored a panel of brain damage and 
      apoptosis biomarkers by immunoblotting. Rats were treated with ASA and/or CLOP 
      for 48 h prior to TBI and sacrificed 48 h post-injury. In rats treated with 
      antiplatelet agents prior to TBI, platelet aggregation was completely inhibited, 
      and serum thromboxane was significantly decreased, compared to the TBI group 
      without treatment. TBI increases UCHL-1 and GFAP, but decreases hexokinase 
      expression compared to the non-injured controls. All groups treated with 
      antiplatelet drugs prior to TBI had decreased UCH-L1 and GFAP serum levels 
      compared to the TBI untreated group. Furthermore, the ASA and CLOP single 
      treatments increased the hexokinase serum levels. We confirmed that αII-spectrin 
      cleavage increased post-TBI, with the highest cleavage detected in CLOP-treated 
      rats. Aspirin and/or CLOP treatment prior to TBI is a double-edged sword that 
      exerts a dual effect post-injury. On one hand, ASA and CLOP single treatments 
      increase the post-TBI ICH risk, with a further detrimental effect from the 
      ASA + CLOP treatment. On the other hand, ASA and/or CLOP treatments are 
      neuroprotective and result in a favourable profile of TBI injury markers. The ICH 
      risk and the neuroprotection benefits from antiplatelet therapy should be weighed 
      against each other to ameliorate the management of TBI patients.
CI  - Copyright © 2022 Elsevier Ltd. All rights reserved.
FAU - Kobeissy, Firas
AU  - Kobeissy F
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon. Electronic address: firasko@gmail.com.
FAU - Mallah, Khalil
AU  - Mallah K
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon; Department of Microbiology and Immunology, 
      Medical University of South Carolina, 173 Ashley Avenue, BSB 204, MSC 504, 
      Charleston, SC, 29425, USA.
FAU - Zibara, Kazem
AU  - Zibara K
AD  - ER045, Laboratory of Stem Cells, DSST, PRASE, Lebanese University, Beirut, 
      Lebanon; Department of Biology, Faculty of Sciences-I, Lebanese University, 
      Beirut, Lebanon.
FAU - Dakroub, Fatima
AU  - Dakroub F
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon; Molecular Biology and Cancer Immunology 
      Laboratory, Faculty of Sciences-I, Lebanese University, Beirut, Lebanon.
FAU - Dalloul, Zeinab
AU  - Dalloul Z
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon.
FAU - Nasser, Mohammad
AU  - Nasser M
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon; Molecular Biology and Cancer Immunology 
      Laboratory, Faculty of Sciences-I, Lebanese University, Beirut, Lebanon.
FAU - Nasrallah, Leila
AU  - Nasrallah L
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon.
FAU - Mallah, Zahraa
AU  - Mallah Z
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon; Molecular Biology and Cancer Immunology 
      Laboratory, Faculty of Sciences-I, Lebanese University, Beirut, Lebanon.
FAU - El-Achkar, Ghewa A
AU  - El-Achkar GA
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon.
FAU - Ramadan, Naify
AU  - Ramadan N
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon.
FAU - Mohamed, Wael
AU  - Mohamed W
AD  - Clinical Pharmacology Department, Menoufia Medical School, Menoufia University, 
      AlMinufya, Egypt; Basic Medical Science Department, Kulliyyah of Medicine, 
      International Islamic University Malaysia, Kuantan, Pahang, Malaysia.
FAU - Mondello, Stefania
AU  - Mondello S
AD  - Department of Neurosciences, University of Messina, Messina, Italy.
FAU - Darwish, Hala
AU  - Darwish H
AD  - Nehme and Therese Tohme Multiple Sclerosis Center, Faculty of Medicine, American 
      University of Beirut Medical Center, Lebanon; Hariri School of Nursing, American 
      University of Beirut, Lebanon.
FAU - Hamade, Eva
AU  - Hamade E
AD  - Molecular Biology and Cancer Immunology Laboratory, Faculty of Sciences-I, 
      Lebanese University, Beirut, Lebanon; Department of Biochemistry, Faculty of 
      Sciences-I, Lebanese University, Beirut, Lebanon. Electronic address: 
      eva.hamade@ul.edu.lb.
FAU - Habib, Aida
AU  - Habib A
AD  - Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar 
      University, Doha, Qatar. Electronic address: aida.habib@qu.edu.qa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220202
PL  - England
TA  - Neurochem Int
JT  - Neurochemistry international
JID - 8006959
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Brain Injuries/drug therapy
MH  - *Brain Injuries, Traumatic/drug therapy
MH  - Clopidogrel/pharmacology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Rats
OTO - NOTNLM
OT  - Aspirin
OT  - Clopidogrel
OT  - Controlled cortical impact
OT  - Intracerebral haemorrhage
OT  - Neuroprotection
OT  - Traumatic brain injury
EDAT- 2022/02/06 06:00
MHDA- 2022/04/08 06:00
CRDT- 2022/02/05 05:37
PHST- 2021/10/10 00:00 [received]
PHST- 2022/01/07 00:00 [revised]
PHST- 2022/01/31 00:00 [accepted]
PHST- 2022/02/06 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
PHST- 2022/02/05 05:37 [entrez]
AID - S0197-0186(22)00026-2 [pii]
AID - 10.1016/j.neuint.2022.105301 [doi]
PST - ppublish
SO  - Neurochem Int. 2022 Mar;154:105301. doi: 10.1016/j.neuint.2022.105301. Epub 2022 
      Feb 2.

PMID- 16527427
OWN - NLM
STAT- MEDLINE
DCOM- 20060823
LR  - 20131121
IS  - 0306-9877 (Print)
IS  - 0306-9877 (Linking)
VI  - 67
IP  - 2
DP  - 2006
TI  - Therapeutic potentials of aspirin in glaucomatous optic neuropathy.
PG  - 375-7
AB  - Glaucoma is a common blinding disease worldwide. Although traditionally 
      considered as a disease of elevated intraocular pressure, it is now clear that 
      glaucoma is primarily a distinctive optic neuropathy with many proposed 
      pathogenic mechanisms. Impaired blood flow resulting in ischemia has been 
      proposed to be involved in the retinal ganglion cell loss seen in glaucoma. 
      Aspirin might improve optic nerve head perfusion by stabilizing microcirculatory 
      flow. Evidence also indicates that apoptosis may be the final common pathway for 
      ganglion cell death in glaucoma. Aspirin has been shown to exhibit 
      neuroprotective properties. Prostaglandins play an important role in the 
      regulation of intraocular pressure. Aspirin is well known to inhibit 
      cyclooxygenase mediated prostaglandin synthesis. The NSAID-inhibition of PGs 
      synthesis up-regulates the concentration prostaglandin receptors in 
      retinovascular tissues. Based on the body of evidence implicating ocular blood 
      flow disturbances, apoptotic cell death, and also the role of prostaglandins in 
      the pathogenesis of glaucoma we hypothesize that aspirin could be potentially 
      useful drugs in the treatment of glaucoma. Hypothetical pathophysiologic 
      mechanisms explaining potential beneficial effects of aspirin on glaucomatous 
      optic neuropathy include: increasing optic nerve blood flow, preventing retinal 
      ganglion cell death through neuroprotective mechanisms, and upregulating 
      prostaglandin receptors.
FAU - Attarzadeh, Abbas
AU  - Attarzadeh A
AD  - Ophthalmology Department, Khalili Hospital, Shiraz, Iran.
FAU - Hosseini, Hamid
AU  - Hosseini H
FAU - Nowroozizadeh, Sarah
AU  - Nowroozizadeh S
LA  - eng
PT  - Journal Article
DEP - 20060309
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Glaucoma/*drug therapy
MH  - Humans
MH  - Neuroprotective Agents/pharmacology/*therapeutic use
MH  - Optic Nerve/*blood supply/drug effects
MH  - Optic Nerve Diseases/*drug therapy
MH  - Prostaglandins/pharmacology/therapeutic use
MH  - Regional Blood Flow/drug effects
EDAT- 2006/03/11 09:00
MHDA- 2006/08/24 09:00
CRDT- 2006/03/11 09:00
PHST- 2006/01/06 00:00 [received]
PHST- 2006/01/10 00:00 [revised]
PHST- 2006/01/11 00:00 [accepted]
PHST- 2006/03/11 09:00 [pubmed]
PHST- 2006/08/24 09:00 [medline]
PHST- 2006/03/11 09:00 [entrez]
AID - S0306-9877(06)00094-6 [pii]
AID - 10.1016/j.mehy.2006.01.033 [doi]
PST - ppublish
SO  - Med Hypotheses. 2006;67(2):375-7. doi: 10.1016/j.mehy.2006.01.033. Epub 2006 Mar 
      9.

PMID- 18541683
OWN - NLM
STAT- MEDLINE
DCOM- 20080724
LR  - 20190101
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 65
IP  - 12
DP  - 2008 Jun 15
TI  - Dual antiplatelet therapy with clopidogrel and aspirin.
PG  - 1134-43
LID - 10.2146/ajhp060662 [doi]
AB  - PURPOSE: Dual antiplatelet therapy with clopidogrel and aspirin is reviewed. 
      SUMMARY: Several studies have evaluated the effectiveness of clopidogrel, 
      aspirin, or the combination of these agents in a variety of patient populations. 
      The results of these studies have helped determine the role of clopidogrel and 
      aspirin in evidence-based medicine. Investigators in the Clopidogrel for High 
      Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance trial 
      concluded that patients with multiple atherothrombotic risk factors who have 
      stable cardiovascular disease (CVD) or no history of CVD or documented vascular 
      disease should not receive combination clopidogrel and aspirin due to an increase 
      in death. Patients with established vascular disease being treated with 
      clopidogrel and aspirin may benefit from the combination through a reduction in 
      the rate of myocardial infarction, stroke, or death from cardiovascular causes. 
      The combination should not be used longer than one year since the benefits past 
      one year have not been established by clinical trials, though consideration for 
      longer treatment may be warranted in patients with stent implantation. One of the 
      inherent risks associated with using clopidogrel and aspirin is the risk for 
      increased bleeding. If a patient is started on combination therapy, it is 
      imperative to monitor for signs and symptoms of bleeding. CONCLUSION: Dual 
      antiplatelet therapy with clopidogrel and aspirin should be used in certain 
      patients, such as those with any type of acute coronary syndrome or stent 
      implantation, if there are no contraindications to combined therapy. The risk of 
      bleeding should be considered in patients receiving the combination.
FAU - Sullivan, Joshua
AU  - Sullivan J
AD  - Veterans Affairs Medical Center, Memphis, TN 38104, USA. j007ws99@aol.com
FAU - Amarshi, Naseem
AU  - Amarshi N
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases
MH  - Clopidogrel
MH  - Contraindications
MH  - Coronary Artery Bypass
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - *Polypharmacy
MH  - Ticlopidine/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
RF  - 42
EDAT- 2008/06/11 09:00
MHDA- 2008/07/25 09:00
CRDT- 2008/06/11 09:00
PHST- 2008/06/11 09:00 [pubmed]
PHST- 2008/07/25 09:00 [medline]
PHST- 2008/06/11 09:00 [entrez]
AID - 65/12/1134 [pii]
AID - 10.2146/ajhp060662 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2008 Jun 15;65(12):1134-43. doi: 10.2146/ajhp060662.

PMID- 29513994
OWN - NLM
STAT- MEDLINE
DCOM- 20181127
LR  - 20181127
IS  - 1549-9626 (Electronic)
IS  - 1549-9618 (Linking)
VI  - 14
IP  - 4
DP  - 2018 Apr 10
TI  - Evaluation of General and Tailor Made Force Fields via X-ray Thermal Diffuse 
      Scattering Using Molecular Dynamics and Monte Carlo Simulations of Crystalline 
      Aspirin.
PG  - 2165-2179
LID - 10.1021/acs.jctc.7b01073 [doi]
AB  - We have performed a comparison of the experimental thermal diffuse scattering 
      (TDS) from crystalline Aspirin (form I) to that calculated from molecular 
      dynamics (MD) simulations based on a variety of general force fields and a 
      tailor-made force field (TMFF). A comparison is also made with Monte Carlo (MC) 
      simulations which use a "harmonic network" approach to describe the 
      intermolecular interactions. These comparisons were based on the hypothesis that 
      TDS could be a useful experimental data in validation of such simulation 
      parameter sets, especially when calculations of dynamical properties (e.g., 
      thermodynamic free energies) from molecular crystals are concerned. Currently 
      such a validation of force field parameters against experimental data is often 
      limited to calculation of specific physical properties, e.g., absolute lattice 
      energies usually at 0 K or heat capacity measurements. TDS harvested from 
      in-house or synchrotron experiments comprises highly detailed structural 
      information representative of the dynamical motions of the crystal lattice. Thus, 
      TDS is a well-suited experimental data-driven means of cross validating 
      theoretical approaches targeted at understanding dynamical properties of 
      crystals. We found from the results of our investigation that the TMFF and 
      COMPASS (from the commercial software "Materials Studio") parameter sets gave the 
      best agreement with experiment. From our homologous MC simulation analysis we are 
      able to show that force constants associated with the molecular torsion angles 
      are likely to be a strong contributing factor for the apparent reason why these 
      aforementioned force fields performed better.
FAU - Chan, Eric J
AU  - Chan EJ
AUID- ORCID: 0000-0003-1105-2773
AD  - Drug Product Science and Technology , Bristol Myers Squibb , New Brunswick , New 
      Jersey 08901 , United States.
FAU - Neumann, Marcus A
AU  - Neumann MA
AD  - Avant-garde Materials Simulation, Deutshland GmbH , Merzhauserstr 177 , D-79100 
      Freiburg im Breisgau , Germany.
LA  - eng
PT  - Journal Article
DEP - 20180328
PL  - United States
TA  - J Chem Theory Comput
JT  - Journal of chemical theory and computation
JID - 101232704
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - *Molecular Dynamics Simulation
MH  - *Monte Carlo Method
EDAT- 2018/03/08 06:00
MHDA- 2018/11/28 06:00
CRDT- 2018/03/08 06:00
PHST- 2018/03/08 06:00 [pubmed]
PHST- 2018/11/28 06:00 [medline]
PHST- 2018/03/08 06:00 [entrez]
AID - 10.1021/acs.jctc.7b01073 [doi]
PST - ppublish
SO  - J Chem Theory Comput. 2018 Apr 10;14(4):2165-2179. doi: 10.1021/acs.jctc.7b01073. 
      Epub 2018 Mar 28.

PMID- 15366727
OWN - NLM
STAT- MEDLINE
DCOM- 20041005
LR  - 20131121
IS  - 0028-2162 (Print)
IS  - 0028-2162 (Linking)
VI  - 148
IP  - 31
DP  - 2004 Jul 31
TI  - [Periorbital swelling caused by carbasalate calcium].
PG  - 1550-4
AB  - A 61-year-old man presented with visual problems due to a marked two-sided 
      periorbital swelling that had started three years earlier. There was no obvious 
      underlying cause and he had persistent rhinoconjunctival symptoms. At the time 
      the swelling started he was already suffering from xanthelasmata palpebrarum and 
      chronic obstructive pulmonary disease. He had been taking simvastatin and 
      salmeterol-fluticason for a year and carbasalate calcium for two years. There was 
      marked periorbital swelling accompanied by xanthelasmata palpebrarum and slight 
      chemosis and erythema of the eyelids. After exclusion of other potential causes 
      for the swelling, acenocoumarol was prescribed in place of carbasalate calcium. 
      This resulted in a quick recovery from the swelling and rhinoconjunctival 
      symptoms. Provocation with acetyl salicylic acid led to renewed swelling of both 
      eyelids. Periorbital angio-oedema, a relatively uncommonly reported side effect 
      of acetyl salicylic acid and its derivates, can occur even after previous 
      long-term medication use.
FAU - Vodegel, R M
AU  - Vodegel RM
AD  - Academisch Ziekenhuis, afd. Dermatologie, Postbus 30.001, 9700 RB Groningen.
FAU - Kardaun, S H
AU  - Kardaun SH
LA  - dut
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Periorbitale zwelling bij gebruik van carbasalaatcalcium.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 8W8T17847W (Urea)
RN  - N667F17JP1 (carbaspirin calcium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects/*analogs & derivatives
MH  - Diagnosis, Differential
MH  - Edema/*chemically induced/diagnosis/pathology
MH  - Eyelid Diseases/*chemically induced/diagnosis/pathology
MH  - Eyelids/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Urea/administration & dosage/*adverse effects/*analogs & derivatives
MH  - Visual Fields
EDAT- 2004/09/16 05:00
MHDA- 2004/10/06 09:00
CRDT- 2004/09/16 05:00
PHST- 2004/09/16 05:00 [pubmed]
PHST- 2004/10/06 09:00 [medline]
PHST- 2004/09/16 05:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2004 Jul 31;148(31):1550-4.

PMID- 3116508
OWN - NLM
STAT- MEDLINE
DCOM- 19871029
LR  - 20161123
IS  - 0391-5387 (Print)
IS  - 0391-5387 (Linking)
VI  - 9
IP  - 2
DP  - 1987 Mar-Apr
TI  - [Lysine acetyl salicylate. Clinical contribution and preliminary data].
PG  - 179-82
AB  - In the general study of antipyretic products for children prone to febrile 
      convulsions, the authors describe the results obtained administering, the rectal 
      route, three different doses of lysine acetylsalicylate (20-30-40 mg/kg/b.w.) to 
      53 children with fever. The lower dose was often inadequate in these patients, 
      who need a quick reduction of body temperature below 38 degrees C. The two higher 
      doses were useful both in clinical and in statistical terms, without relevant 
      differences between groups. A statistically significant inverse correlation 
      between blood levels of salicylates and temperature was also shown. No 
      undesirable side effects were observed. The authors conclude that ASL, by rectal 
      route, has to be considered a drug of choice for this indication.
FAU - Franzoni, E
AU  - Franzoni E
AD  - Clinical Pediatrica I, Università di Bologna, Italia.
FAU - Callivà, R
AU  - Callivà R
FAU - Donati, C
AU  - Donati C
LA  - ita
PT  - Journal Article
TT  - L'acetilsalicilato di lisina per via rettale. Contributo clinico e dati 
      preliminary.
PL  - Italy
TA  - Pediatr Med Chir
JT  - La Pediatria medica e chirurgica : Medical and surgical pediatrics
JID - 8100625
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Rectal
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Body Temperature
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Fever/*drug therapy
MH  - Humans
MH  - Infant
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Time Factors
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
PST - ppublish
SO  - Pediatr Med Chir. 1987 Mar-Apr;9(2):179-82.

PMID- 33386798
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210521
IS  - 1875-8622 (Electronic)
IS  - 1386-0291 (Linking)
VI  - 77
IP  - 4
DP  - 2021
TI  - Anti-thrombotic and anti-inflammatory activity of sulodexide compared to aspirin 
      in the rat model.
PG  - 435-442
LID - 10.3233/CH-201043 [doi]
AB  - BACKGROUND: Although the number of vascular surgeries performed is increasing, 
      the incidence of complications associated with this surgery has not improved and 
      re-operations are frequently required. Thrombosis in a vessel is the most 
      hazardous postoperative complication. OBJECTIVE: The aim of this study was to 
      evaluate the anti-thrombotic and anti-inflammatory effects of sulodexide compared 
      to aspirin in a rat model. METHODS: We divided the animals into three groups 
      (sham (saline), aspirin, and sulodexide). The abdominal aorta was surgically 
      opened and closed, primarily with 8/0 Prolene sutures. Postoperatively, saline, 
      aspirin, or sulodexide was administered by oral gavage for 14 days to the rats. 
      The degree of neovascularization, thrombus, calcification, inflammatory 
      infiltrates, and fibrosis were analyzed histopathologically by hematoxylin and 
      eosin staining. RESULTS: There was no significant difference in the incidence of 
      postoperative thrombogenesis, but less calcification and inflammatory infiltrates 
      were observed in the sulodexide group compared to the aspirin group. 
      Histopathologic score revealed less infiltration of inflammatory cells and mild 
      calcification for the sulodexide group (0.17±0.41 and 1.33±0.52, respectively) 
      compared to the aspirin group (0.67±0.52 and 1.67±0.52, respectively) at days 14. 
      CONCLUSIONS: This study offers the possibility that sulodexide could be used as 
      an aspirin substitute for the postoperative management of vascular patients, with 
      low gastrointestinal discomfort. In addition, it may also offer reduced 
      postoperative calcification and inflammation.
FAU - Sohn, Sung-Hwa
AU  - Sohn SH
AD  - Department of Thoracic & Cardiovascular Surgery, Korea University Ansan Hospital, 
      Korea University College of Medicine, Ansan, Korea.
FAU - Kim, Tae Sik
AU  - Kim TS
AD  - Department of Thoracic & Cardiovascular Surgery, Korea University Ansan Hospital, 
      Korea University College of Medicine, Ansan, Korea.
FAU - Kim, Ji-Won
AU  - Kim JW
AD  - Department of Thoracic & Cardiovascular Surgery, Korea University Ansan Hospital, 
      Korea University College of Medicine, Ansan, Korea.
FAU - Yoo, Sung Mook
AU  - Yoo SM
AD  - Department of Thoracic & Cardiovascular Surgery, Korea University Ansan Hospital, 
      Korea University College of Medicine, Ansan, Korea.
FAU - Jo, Won-Min
AU  - Jo WM
AD  - Department of Thoracic & Cardiovascular Surgery, Korea University Ansan Hospital, 
      Korea University College of Medicine, Ansan, Korea.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anticoagulants)
RN  - 0 (Glycosaminoglycans)
RN  - 75HGV0062C (glucuronyl glucosamine glycan sulfate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Glycosaminoglycans/pharmacology/*therapeutic use
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thrombosis/*drug therapy
OTO - NOTNLM
OT  - Sulodexide
OT  - aspirin
OT  - calcification
OT  - inflammation
OT  - thrombogenesis
EDAT- 2021/01/03 06:00
MHDA- 2021/05/22 06:00
CRDT- 2021/01/02 12:06
PHST- 2021/01/03 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
PHST- 2021/01/02 12:06 [entrez]
AID - CH201043 [pii]
AID - 10.3233/CH-201043 [doi]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 2021;77(4):435-442. doi: 10.3233/CH-201043.

PMID- 34380322
OWN - NLM
STAT- MEDLINE
DCOM- 20211229
LR  - 20211229
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 144
IP  - 14
DP  - 2021 Oct 5
TI  - Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease 
      Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
PG  - 1104-1116
LID - 10.1161/CIRCULATIONAHA.121.054835 [doi]
AB  - BACKGROUND: Patients with peripheral artery disease requiring lower extremity 
      revascularization (LER) are at high risk of adverse limb and cardiovascular 
      events. The VOYAGER PAD trial (Vascular Outcomes Study of ASA [Acetylsalicylic 
      Acid] Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization 
      for PAD) demonstrated that rivaroxaban significantly reduced this risk. The 
      efficacy and safety of rivaroxaban has not been described in patients who 
      underwent surgical LER. METHODS: The VOYAGER PAD trial randomized patients with 
      peripheral artery disease after surgical and endovascular LER to rivaroxaban 2.5 
      mg twice daily plus aspirin or matching placebo plus aspirin and followed for a 
      median of 28 months. The primary end point was a composite of acute limb 
      ischemia, major vascular amputation, myocardial infarction, ischemic stroke, or 
      cardiovascular death. The principal safety outcome was Thrombolysis in Myocardial 
      Infarction major bleeding. International Society on Thrombosis and Haemostasis 
      bleeding was a secondary safety outcome. All efficacy and safety outcomes were 
      adjudicated by a blinded independent committee. RESULTS: Of the 6564 randomized, 
      2185 (33%) underwent surgical LER and 4379 (67%) endovascular. Compared with 
      placebo, rivaroxaban reduced the primary end point consistently regardless of LER 
      method (P-interaction, 0.43). After surgical LER, the primary efficacy outcome 
      occurred in 199 (18.4%) patients in the rivaroxaban group and 242 (22.0%) 
      patients in the placebo group with a cumulative incidence at 3 years of 19.7% and 
      23.9%, respectively (hazard ratio, 0.81 [95% CI, 0.67-0.98]; P=0.026). In the 
      overall trial, Thrombolysis in Myocardial Infarction major bleeding and 
      International Society on Thrombosis and Haemostasis major bleeding were increased 
      with rivaroxaban. There was no heterogeneity for Thrombolysis in Myocardial 
      Infarction major bleeding (P-interaction, 0.17) or International Society on 
      Thrombosis and Haemostasis major bleeding (P-interaction, 0.73) on the basis of 
      the LER approach. After surgical LER, the principal safety outcome occurred in 11 
      (1.0%) patients in the rivaroxaban group and 13 (1.2%) patients in the placebo 
      group; 3-year cumulative incidence was 1.3% and 1.4%, respectively (hazard ratio, 
      0.88 [95% CI, 0.39-1.95]; P=0.75) Among surgical patients, the composite of fatal 
      bleeding or intracranial hemorrhage (P=0.95) and postprocedural bleeding 
      requiring intervention (P=0.93) was not significantly increased. CONCLUSIONS: The 
      efficacy of rivaroxaban is associated with a benefit in patients who underwent 
      surgical LER. Although bleeding was increased with rivaroxaban plus aspirin, the 
      incidence was low, with no significant increase in fatal bleeding, intracranial 
      hemorrhage, or postprocedural bleeds requiring intervention. Registration: URL: 
      http://www.clinicaltrials.gov; Unique Identifier: NCT02504216.
FAU - Debus, E Sebastian
AU  - Debus ES
AUID- ORCID: 0000-0002-5664-6439
AD  - Department of Vascular Medicine, Vascular Surgery-Angiology-Endovascular Therapy, 
      University of Hamburg-Eppendorf, Hamburg, Germany (E.S.D.).
FAU - Nehler, Mark R
AU  - Nehler MR
AD  - CPC Clinical Research, Aurora, CO (M.R.N., N.G., W.H.C., T.B., N.J., C.N.H., 
      W.R.H., M.P.B.).
AD  - Division of Vascular Surgery, Department of Surgery (M.R.N., N.G.), Department of 
      Medicine, University of Colorado School of Medicine, Aurora.
FAU - Govsyeyev, Nicholas
AU  - Govsyeyev N
AUID- ORCID: 0000-0001-9410-4094
AD  - CPC Clinical Research, Aurora, CO (M.R.N., N.G., W.H.C., T.B., N.J., C.N.H., 
      W.R.H., M.P.B.).
AD  - Division of Vascular Surgery, Department of Surgery (M.R.N., N.G.), Department of 
      Medicine, University of Colorado School of Medicine, Aurora.
FAU - Bauersachs, Rupert M
AU  - Bauersachs RM
AD  - Department of Vascular Medicine, Klinikum Darmstadt, Darmstadt, and Center for 
      Thrombosis and Hemostasis, University of Mainz, Germany (R.M.B.).
FAU - Anand, Sonia S
AU  - Anand SS
AD  - Population Health Research Institute, Hamilton Health Sciences and McMaster 
      University, Ontario, Canada (S.S.A.).
FAU - Patel, Manesh R
AU  - Patel MR
AUID- ORCID: 0000-0002-2393-0855
AD  - Duke Clinical Research Institute, Division of Cardiology, Duke University, 
      Durham, NC (M.R.P.).
FAU - Fanelli, Fabrizio
AU  - Fanelli F
AUID- ORCID: 0000-0002-5273-0609
AD  - Vascular and Interventional Radiology Department, Careggi University Hospital, 
      University of Florence, Italy (F.F.).
FAU - Capell, Warren H
AU  - Capell WH
AD  - CPC Clinical Research, Aurora, CO (M.R.N., N.G., W.H.C., T.B., N.J., C.N.H., 
      W.R.H., M.P.B.).
AD  - Division of Endocrinology (W.H.C.), Department of Medicine, University of 
      Colorado School of Medicine, Aurora.
FAU - Brackin, Taylor
AU  - Brackin T
AD  - CPC Clinical Research, Aurora, CO (M.R.N., N.G., W.H.C., T.B., N.J., C.N.H., 
      W.R.H., M.P.B.).
FAU - Hinterreiter, Franz
AU  - Hinterreiter F
AD  - Department for Vascular Surgery Krankenhaus Barmherzige Brüder Linz, Austria 
      (F.H.).
FAU - Krievins, Dainis
AU  - Krievins D
AD  - Pauls Stradins University Hospital, University of Latvia, Riga (D.K.).
FAU - Nault, Patrice
AU  - Nault P
AD  - Vascular and Endovascular Surgery, McGill University Montreal, Quebec, Canada 
      (P.N.).
FAU - Piffaretti, Gabriele
AU  - Piffaretti G
AUID- ORCID: 0000-0002-9906-4658
AD  - Vascular Surgery, Department of Medicine and Surgery, University of Insubria 
      School of Medicine, Varese, Italy (G.P.).
FAU - Svetlikov, Alexei
AU  - Svetlikov A
AD  - The I.I. Mechnikov North-Western State Medical University, Department of 
      Cardiovascular Surgery, St. Petersburg, Russia (A.S.).
FAU - Jaeger, Nicole
AU  - Jaeger N
AD  - CPC Clinical Research, Aurora, CO (M.R.N., N.G., W.H.C., T.B., N.J., C.N.H., 
      W.R.H., M.P.B.).
FAU - Hess, Connie N
AU  - Hess CN
AD  - CPC Clinical Research, Aurora, CO (M.R.N., N.G., W.H.C., T.B., N.J., C.N.H., 
      W.R.H., M.P.B.).
AD  - Division of Cardiology (C.N.H., W.R.H., M.P.B.), Department of Medicine, 
      University of Colorado School of Medicine, Aurora.
FAU - Sillesen, Henrik H
AU  - Sillesen HH
AD  - Department of Vascular Surgery, Rigshospitalet, Institute of Clinical Medicine, 
      University of Copenhagen, Denmark (H.H.S.).
FAU - Conte, Michael
AU  - Conte M
AD  - Division of Vascular and Endovascular Surgery, University of California, San 
      Francisco (M.C.).
FAU - Mills, Joseph
AU  - Mills J
AUID- ORCID: 0000-0002-4955-4384
AD  - Division of Vascular Surgery and Endovascular Therapy, Baylor College of 
      Medicine, Houston, TX (J.M.).
FAU - Muehlhofer, Eva
AU  - Muehlhofer E
AD  - Bayer, Wuppertal, Germany (E.M.).
FAU - Haskell, Lloyd P
AU  - Haskell LP
AD  - Janssen Research and Development, Raritan, NJ (L.P.H.).
FAU - Berkowitz, Scott D
AU  - Berkowitz SD
AD  - Thrombosis Group Head, Clinical Development, Bayer US, Whippany, NJ (S.D.B.).
FAU - Hiatt, William R
AU  - Hiatt WR
AD  - CPC Clinical Research, Aurora, CO (M.R.N., N.G., W.H.C., T.B., N.J., C.N.H., 
      W.R.H., M.P.B.).
AD  - Division of Cardiology (C.N.H., W.R.H., M.P.B.), Department of Medicine, 
      University of Colorado School of Medicine, Aurora.
FAU - Bonaca, Marc P
AU  - Bonaca MP
AD  - CPC Clinical Research, Aurora, CO (M.R.N., N.G., W.H.C., T.B., N.J., C.N.H., 
      W.R.H., M.P.B.).
AD  - Division of Cardiology (C.N.H., W.R.H., M.P.B.), Department of Medicine, 
      University of Colorado School of Medicine, Aurora.
LA  - eng
SI  - ClinicalTrials.gov/NCT02504216
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20210812
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 2021 Oct 5;144(14):1117-1119. PMID: 34606303
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peripheral Arterial Disease/*drug therapy/*surgery
MH  - Rivaroxaban/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - lower extremity revascularization
OT  - major adverse cardiovascular events (MACE)
OT  - major adverse limb events (MALE)
OT  - peripheral artery disease
OT  - revascularization
OT  - rivaroxaban
EDAT- 2021/08/13 06:00
MHDA- 2021/12/30 06:00
CRDT- 2021/08/12 05:26
PHST- 2021/08/13 06:00 [pubmed]
PHST- 2021/12/30 06:00 [medline]
PHST- 2021/08/12 05:26 [entrez]
AID - 10.1161/CIRCULATIONAHA.121.054835 [doi]
PST - ppublish
SO  - Circulation. 2021 Oct 5;144(14):1104-1116. doi: 
      10.1161/CIRCULATIONAHA.121.054835. Epub 2021 Aug 12.

PMID- 308334
OWN - NLM
STAT- MEDLINE
DCOM- 19781027
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 89
IP  - 3
DP  - 1978 Sep
TI  - Aspirin- and coumadin-related bleeding after coronary- artery bypass graft 
      surgery.
PG  - 325-8
AB  - We studied 100 consecutive patients to evaluate the potential effect of platelet 
      active and antithrombotic agents prescribed preoperatively on bleeding 
      complications after coronary-artery bypass graft surgery. Preoperative hemostatic 
      values were normal in all patients. Mean mediastinal blood loss was significantly 
      greater in 13 patients taking aspirin (892 +/- 91 ml) and six patients taking 
      Coumadin (warfarin sodium) (858 +/- 168 ml) within 7 days of surgery than in 64 
      control subjects (439 +/- 28, P less than 0.001). Less marked but similar 
      differences (P less than 0.05) were noted with other agents inhibiting platelet 
      function. However, in nine patients given heparin, mean mediastinal blood loss 
      (436 +/- 61 ml) was no different from that of control subjects. The degree of 
      mediastinal blood loss did not correlate with age, sex, mean total operative 
      time, bypass time, or number of vessels diseased or bypassed. In addition, 
      patients taking aspirin or Coumadin required prolonged chest tube drainage 
      compared to those in heparin or control groups (34 +/- 4 versus 20 +/- 1 h) (P 
      less than 0.001).
FAU - Torosian, M
AU  - Torosian M
FAU - Michelson, E L
AU  - Michelson EL
FAU - Morganroth, J
AU  - Morganroth J
FAU - MacVaugh, H 3rd
AU  - MacVaugh H 3rd
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*etiology
MH  - Preoperative Care
MH  - Warfarin/*adverse effects/therapeutic use
EDAT- 1978/09/01 00:00
MHDA- 1978/09/01 00:01
CRDT- 1978/09/01 00:00
PHST- 1978/09/01 00:00 [pubmed]
PHST- 1978/09/01 00:01 [medline]
PHST- 1978/09/01 00:00 [entrez]
AID - 10.7326/0003-4819-89-3-325 [doi]
PST - ppublish
SO  - Ann Intern Med. 1978 Sep;89(3):325-8. doi: 10.7326/0003-4819-89-3-325.

PMID- 9356662
OWN - NLM
STAT- MEDLINE
DCOM- 19971230
LR  - 20131121
IS  - 1023-2028 (Print)
IS  - 1023-2028 (Linking)
VI  - 34
DP  - 1997
TI  - Platelet aggregation in response to collagen and thrombin reliably detects the 
      ingestion of low-dose aspirin.
PG  - 105-9
AB  - The exposure of blood donors to aspirin is not reliably excluded by 
      pharmacokinetic measurements due to the irreversible effects of aspirin which 
      persist even after elimination of aspirin and its metabolites from plasma. Tests 
      of platelet functions do overcome this deficit, but are usually limited by 
      substantial inter-individual variability of parameters of platelet function. We 
      have evaluated platelet aggregation ex vivo in 20 aspirin-treated (100 mg single 
      oral dose/day) patients in comparison with a control group of 20 aspirin-free 
      donors. The results demonstrate a significant reduction in the collagen(2.5 
      micrograms/ml)-induced platelet aggregation by aspirin treatment, whereas 
      thrombin(50 mumol/l TRAP-6)-induced platelet aggregation was not affected at all. 
      Assessment of collagen-induced platelet aggregation relative to platelet 
      responses of the same subject elicited either by thrombin or by a combination of 
      collagen and thrombin does substantially improve the reliability of functional 
      assays of aspirin.
FAU - Müller, T H
AU  - Müller TH
AD  - Institut Oldenburg, DRK-Blutspendedienst Niedersachsen, Germany.
FAU - Schmidt, S
AU  - Schmidt S
FAU - Schunter, F
AU  - Schunter F
FAU - Reil, G H
AU  - Reil GH
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Beitr Infusionsther Transfusionsmed
JT  - Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to 
      infusion therapy and transfusion medicine
JID - 9442459
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9007-34-5 (Collagen)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/*administration & dosage/adverse effects/pharmacokinetics
MH  - Collagen/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Metabolic Clearance Rate/physiology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/pharmacokinetics
MH  - Predictive Value of Tests
MH  - Thrombin/*pharmacology
EDAT- 1997/01/01 00:00
MHDA- 1997/11/14 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/11/14 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Beitr Infusionsther Transfusionsmed. 1997;34:105-9.

PMID- 489767
OWN - NLM
STAT- MEDLINE
DCOM- 19791218
LR  - 20190823
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 19
IP  - 8-9 Pt 1
DP  - 1979 Aug-Sep
TI  - An analgesic comparison study of indoprofen versus aspirin and placebo in 
      surgical pain.
PG  - 487-92
AB  - Single oral doses of 100 and 200 mg indoprofen were compared with 600 mg aspirin 
      and placebo in a double-blind, completely randomized study of hospitalized 
      patients with postoperative, post-fracture, or musculoskeletal pain. The patients 
      evaluated their pain for 5 hours after administration of the study drug. Each of 
      the three active treatments performed significantly better than placebo. The 
      200-mg dose level of indoprofen demonstrated the greatest analgesic activity 
      based on pain intensity and pain relief scores and on the patients' global 
      evaluations. The analgesic activity of 100 mg indoprofen fell between that of 200 
      mg indoprofen and 600 mg aspirin and was not significantly different from either.
FAU - Okun, R
AU  - Okun R
FAU - Green, J W
AU  - Green JW
FAU - Shackleford, R W
AU  - Shackleford RW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Phenylpropionates)
RN  - 0 (Placebos)
RN  - CPE46ZU14N (Indoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Indoprofen/adverse effects/*therapeutic use
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - Placebos
MH  - Time Factors
EDAT- 1979/08/01 00:00
MHDA- 1979/08/01 00:01
CRDT- 1979/08/01 00:00
PHST- 1979/08/01 00:00 [pubmed]
PHST- 1979/08/01 00:01 [medline]
PHST- 1979/08/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1979.tb02511.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1979 Aug-Sep;19(8-9 Pt 1):487-92. doi: 
      10.1002/j.1552-4604.1979.tb02511.x.

PMID- 1169743
OWN - NLM
STAT- MEDLINE
DCOM- 19750820
LR  - 20180216
IS  - 0301-1569 (Print)
IS  - 0301-1569 (Linking)
VI  - 37
IP  - 1
DP  - 1975
TI  - Aspirin ototoxicity in the guinea pig.
PG  - 27-34
AB  - Aspirin ototoxicity has been studied on guinea pigs by shiver-audiometry and 
      histological investigation of the cochlear duct. One dose of 350 mg/kg has 
      provoked, after 7 h, a mean hearing loss of 18-24 dB at 0.25-8 kHz, followed by 
      complete recovery in 3 days. The difference between the administration of 50 
      mg/kg/day and 350 mg/kg/day consists of a wide extension of the frequencies 
      involved, and in about 10 dB a greater hearing loss. In both cases, no 
      appreciable recovery of hearing was observed after 22 days (the histological 
      investigations were negative). The biochemical pathogenesis of aspirin 
      ototoxicity is discussed and periodical audiometric controls before and during 
      salicylate treatment are recommended.
FAU - Crifò, S
AU  - Crifò S
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - ORL J Otorhinolaryngol Relat Spec
JT  - ORL; journal for oto-rhino-laryngology and its related specialties
JID - 0334721
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*toxicity
MH  - Audiometry
MH  - Deafness/etiology
MH  - Differential Threshold
MH  - Dose-Response Relationship, Drug
MH  - Ear, Inner/*drug effects
MH  - Guinea Pigs
MH  - Hearing/*drug effects
MH  - Reflex/drug effects
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 10.1159/000275201 [doi]
PST - ppublish
SO  - ORL J Otorhinolaryngol Relat Spec. 1975;37(1):27-34. doi: 10.1159/000275201.

PMID- 31153866
OWN - NLM
STAT- MEDLINE
DCOM- 20200316
LR  - 20200316
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 132
IP  - 11
DP  - 2019 Nov
TI  - A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases 
      in the Context of Contemporary Preventive Strategies.
PG  - 1295-1304.e3
LID - S0002-9343(19)30448-6 [pii]
LID - 10.1016/j.amjmed.2019.05.015 [doi]
AB  - BACKGROUND: The role of aspirin for primary prevention of cardiovascular diseases 
      remains controversial, particularly in the context of contemporary aggressive 
      preventive strategies. METHODS: Relevant randomized clinical trials were 
      included, and risk ratios (RRs) were calculated using random-effects models. 
      Additional moderator analyses were performed to compare the pooled treatment 
      effects from recent trials (those reported after the guidelines of the National 
      Cholesterol Education Program Third Adult Treatment Panel were published in 2001; 
      thus, conducted on the background of contemporary preventive strategies) to the 
      results of older trials. RESULTS: Data from 14 randomized controlled trials 
      involving 164,751 patients were included. Aspirin use decreased myocardial 
      infarction risk by 16% compared with placebo (RR 0.84; 95% confidence interval 
      [CI], 0.75-0.94); however, in the moderator analyses, aspirin was not associated 
      with a decreased risk of myocardial infarction in recent trials, but was in older 
      trials (P-interaction = .02). Overall, aspirin use significantly increased the 
      occurrence of major bleeding (RR 1.49; 95% CI, 1.32-1.69) and hemorrhagic stroke 
      (RR 1.25; 95% CI, 1.01-1.54). In moderator analyses, the risk of major bleeding 
      (P-interaction = .12) or hemorrhagic stroke (P-interaction = .44) with aspirin 
      was not significantly different between the older and new trials. Differences 
      between aspirin and placebo in the risks for all-cause stroke, cardiac death, and 
      all-cause mortality were not found. CONCLUSIONS: In the context of contemporary 
      primary prevention guidelines, the effect of aspirin on myocardial infarction 
      risk was significantly attenuated, whereas its major bleeding and hemorrhagic 
      stroke complications were retained. Therefore, in contemporary practice, routine 
      use of aspirin for the primary prevention of cardiovascular events may have a net 
      harmful effect.
CI  - Published by Elsevier Inc.
FAU - Shah, Rahman
AU  - Shah R
AD  - Division of Cardiovascular Medicine, University of Tennessee, Memphis; Gulf Coast 
      Medical Center, Panama City, FL. Electronic address: shahcardiology@yahoo.com.
FAU - Khan, Babar
AU  - Khan B
AD  - Division of Cardiovascular Medicine, University of Tennessee, Memphis.
FAU - Latham, Samuel B
AU  - Latham SB
AD  - Division of Cardiovascular Medicine, University of Tennessee, Memphis.
FAU - Khan, Sajjad A
AU  - Khan SA
AD  - Department of Medicine, Aga Khan University, Karachi, Pakistan.
FAU - Rao, Sunil V
AU  - Rao SV
AD  - Duke Clinical Research Institute, Durham, NC.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20190531
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2019 Nov 19;171(10):JC55. PMID: 31739338
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Intracranial Hemorrhages/chemically induced
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - *Primary Prevention
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular diseases
OT  - Primary prevention
EDAT- 2019/06/04 06:00
MHDA- 2020/03/17 06:00
CRDT- 2019/06/03 06:00
PHST- 2019/03/31 00:00 [received]
PHST- 2019/05/09 00:00 [revised]
PHST- 2019/05/09 00:00 [accepted]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2020/03/17 06:00 [medline]
PHST- 2019/06/03 06:00 [entrez]
AID - S0002-9343(19)30448-6 [pii]
AID - 10.1016/j.amjmed.2019.05.015 [doi]
PST - ppublish
SO  - Am J Med. 2019 Nov;132(11):1295-1304.e3. doi: 10.1016/j.amjmed.2019.05.015. Epub 
      2019 May 31.

PMID- 8484511
OWN - NLM
STAT- MEDLINE
DCOM- 19930603
LR  - 20190704
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 76
IP  - 5
DP  - 1993 May
TI  - Intrathecal acetylsalicylic acid and indomethacin are not analgesic for a 
      supramaximal stimulus.
PG  - 1079-82
AB  - Intrathecal acetylsalicylic acid and indomethacin are analgesic for painful 
      stimuli, and this has been demonstrated when the noxious stimuli are applied to 
      normal and inflamed tissue. This study determined whether these drugs would alter 
      the response to a supramaximal stimulus, e.g., tail-clamp. Rabbits were 
      anesthetized with halothane and after arterial and venous cannulation, an 
      intrathecal catheter was placed via a lumbar laminectomy. The minimum alveolar 
      anesthetic concentration was then determined. Groups 1 (n = 8) and 2 (n = 6) 
      received 0.5 mg/kg acetylsalicylic acid intrathecally and Group 3 (n = 7) 0.5 
      mg/kg indomethacin intrathecally. Group 4 (n = 8) did not undergo a laminectomy 
      and received acetylsalicylic acid 25 mg/kg intraperitoneally. In addition, in 
      Groups 2-4, before the surgical procedures, carrageenin 1 mg was injected into 
      the tail to evoke an inflammatory response. Approximately 20 min after injection 
      of the study drugs, minimum alveolar anesthetic concentration was determined 
      again. In Groups 1-4, control minimum alveolar anesthetic concentration was 1.2 
      +/- 0.2%, 1.4 +/- 0.3%, 1.2 +/- 0.2%, and 1.5 +/- 0.1%, respectively; there was 
      no statistically significant change in any group after injection of the study 
      drugs. There were no temperature, hematocrit, or arterial blood pressure 
      differences between groups or after injection of the study drugs. In this model 
      intrathecal acetylsalicylic acid and indomethacin do not provide analgesia for a 
      supramaximal stimulus.
FAU - Antognini, J F
AU  - Antognini JF
AD  - Department of Anesthesiology, University of California-Davis 95616.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Indomethacin/administration & dosage/*therapeutic use
MH  - Injections, Spinal
MH  - Pain/*drug therapy
MH  - Rabbits
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
AID - 10.1213/00000539-199305000-00029 [doi]
PST - ppublish
SO  - Anesth Analg. 1993 May;76(5):1079-82. doi: 10.1213/00000539-199305000-00029.

PMID- 3355152
OWN - NLM
STAT- MEDLINE
DCOM- 19880427
LR  - 20190628
IS  - 0003-9861 (Print)
IS  - 0003-9861 (Linking)
VI  - 261
IP  - 2
DP  - 1988 Mar
TI  - Effects of crosslinking on the thermal stability of hemoglobins. II. The 
      stabilization of met-, cyanomet-, and carbonmonoxyhemoglobins A and S with 
      bis(3,5-dibromosalicyl) fumarate.
PG  - 283-90
AB  - Hemoglobins A and S were crosslinked between Lys 82 beta 1 and Lys 82 beta 2 
      using bis (3,5-dibromosalicyl) fumarate (J. A. Walder et al. (1979) Biochemistry 
      18, 4265). Thermal denaturation experiments were used to compare the stabilities 
      of the met, cyanomet, and carbonmonoxy forms of these crosslinked hemoglobins to 
      the corresponding uncrosslinked proteins. Uncrosslinked carbonmonoxy- and 
      cyanomethemoglobins had transition temperatures about 11 degrees C higher than 
      the corresponding met samples. The increase in denaturation temperature (Tm) due 
      to crosslinking was 15 degrees C for the methemoglobins, 10 degrees C for the 
      cyanomethemoglobins, and 4 degrees C for the carbonmonoxy ones. There was no 
      significant difference in stability between the met and carbonmonoxy crosslinked 
      proteins. In order of increasing stability the samples were: met Hb S less than 
      met Hb A less than CO Hb S less than CO Hb A = CN-met Hb A less than met XL-Hb S 
      = CO XL-Hb S less than met XL-Hb A = CO XL-Hb A less than CN-met XL-Hb A. The 
      slight decrease in the stability of Hb S (beta 6 Glu----Val) compared to Hb A can 
      be explained by the replacement of an external ionic group by a hydrophobic 
      residue in Hb S. In mixtures of crosslinked and normal Hb A, the Tm of the 
      uncrosslinked material was slightly increased by the presence of the more stable 
      crosslinked hemoglobin. The effects of both crosslinking and cyanide or carbon 
      monoxide binding can be explained by Le Chatelier's principle since both would 
      favor the native form of the protein.
FAU - Yang, T
AU  - Yang T
AD  - Department of Chemistry, Loyola University of Chicago, Illinois 60626.
FAU - Olsen, K W
AU  - Olsen KW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Biochem Biophys
JT  - Archives of biochemistry and biophysics
JID - 0372430
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobin, Sickle)
RN  - 0 (carboxyhemoglobin, sickle)
RN  - 0 (cyanomethemoglobin)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 9008-37-1 (Methemoglobin)
RN  - 9061-29-4 (Carboxyhemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Carboxyhemoglobin/analysis
MH  - *Cross-Linking Reagents
MH  - Electrophoresis
MH  - Hemoglobin, Sickle/analysis
MH  - Methemoglobin/*analogs & derivatives/*analysis
MH  - Protein Binding
MH  - Protein Denaturation
MH  - Temperature
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
AID - 0003-9861(88)90343-8 [pii]
AID - 10.1016/0003-9861(88)90343-8 [doi]
PST - ppublish
SO  - Arch Biochem Biophys. 1988 Mar;261(2):283-90. doi: 10.1016/0003-9861(88)90343-8.

PMID- 3970225
OWN - NLM
STAT- MEDLINE
DCOM- 19850315
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 248
IP  - 2 Pt 2
DP  - 1985 Feb
TI  - Effect of high doses of aspirin on pulmonary hemodynamics and lung water.
PG  - H225-31
AB  - The purpose of this study was to determine if aspirin, in doses that elevate 
      plasma salicylate concentrations to values reported in patients with 
      salicylate-induced pulmonary edema, produce pulmonary vasoconstriction in a 
      canine, isolated perfused left lower lung lobe (LLL) preparation. In 10 LLL's, 
      aspirin (avg 97.8 mg/dl plasma) caused LLL arterial pressure to rise from 9.1 +/- 
      0.3 to 23.0 +/- 1.8 (SE) Torr. In contrast, no vascular pressure changes were 
      observed in placebo-treated control LLL's. Sodium meclofenamate and indomethacin, 
      structurally dissimilar cyclooxygenase inhibitors, elicited similar responses to 
      aspirin, suggesting that a mechanism involving products of prostaglandin 
      cyclooxygenase was involved in producing the vasoconstriction. The 
      double-occlusion technique was used to localize the sites of the 
      vasoconstriction. The results suggested that all three drugs caused both lobar 
      arterial and venous tone to increase. Although high doses of aspirin produced 
      pulmonary vasoconstriction in the isolated, perfused LLL, the aspirin-treated 
      LLL's gained less weight and extravascular water than the control lobes.
FAU - Maron, M B
AU  - Maron MB
LA  - eng
GR  - HL-31070/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 48I5LU4ZWD (Meclofenamic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Pressure/drug effects
MH  - Blood Volume/drug effects
MH  - Body Water/*metabolism
MH  - Dogs
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Indomethacin/pharmacology
MH  - Lung/*metabolism
MH  - Male
MH  - Meclofenamic Acid/pharmacology
MH  - Pulmonary Circulation/*drug effects
EDAT- 1985/02/01 00:00
MHDA- 1985/02/01 00:01
CRDT- 1985/02/01 00:00
PHST- 1985/02/01 00:00 [pubmed]
PHST- 1985/02/01 00:01 [medline]
PHST- 1985/02/01 00:00 [entrez]
AID - 10.1152/ajpheart.1985.248.2.H225 [doi]
PST - ppublish
SO  - Am J Physiol. 1985 Feb;248(2 Pt 2):H225-31. doi: 
      10.1152/ajpheart.1985.248.2.H225.

PMID- 29995772
OWN - NLM
STAT- MEDLINE
DCOM- 20180718
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 28
DP  - 2018 Jul
TI  - Association between use of aspirin or non-aspirin non-steroidal anti-inflammatory 
      drugs and erectile dysfunction: A systematic review.
PG  - e11367
LID - 10.1097/MD.0000000000011367 [doi]
LID - e11367
AB  - OBJECTIVE: There are various etiologies of erectile dysfunction (ED), including 
      endothelial dysfunction, atherosclerosis, and chronic inflammation. Aspirin has a 
      protective role against endothelial dysfunction and atherosclerosis, whease all 
      non-steroidal anti-inflammatory drugs (NSAIDs) are known for their 
      anti-inflammatory properties. However, association between the use of aspirin or 
      non-aspirin NSAIDs and ED is controversial. Therefore, we reviewed this 
      relationship. METHODS: We systematically reviewed the pathophysiology of ED, 
      physiological effect of prostaglandins, pharmacological action of NSAIDs, and 
      clinical and basic research studies that evaluated the effect of aspirin or 
      non-aspirin NSAIDs on ED. RESULTS: The research studies that assessed association 
      between aspirin or non-aspirin NSAIDs are limited, and only 12 articles have been 
      published. One clinical and three basic studies have claimed that aspirin or 
      non-aspirin NSAIDs are beneficial for ED by preserving nitric oxide synthase 
      impairment or penile blood hypercoagulability. One basic and two clinical studies 
      considered them as risk factors because they interfered with prostaglandin 
      production. By contrast, four clinical studies showed irrelevant results after 
      controlling various medical indications. In addition, the mechanical effect of 
      aspirin or non-aspirin NSAIDs on the nitric oxide pathway is still controversial. 
      CONCLUSIONS: The available research studies revealed that association between 
      aspirin or non-aspirin NSAIDs and ED is controversial. Considering the high 
      frequency of drug use, further clinical and basic investigations should be 
      conducted to clarify their exact relationship.
FAU - Li, Tao
AU  - Li T
AD  - The Andrology Laboratory Department of Urology, West China Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
FAU - Wu, Changjing
AU  - Wu C
FAU - Fu, Fudong
AU  - Fu F
FAU - Qin, Feng
AU  - Qin F
FAU - Wei, Qiang
AU  - Wei Q
FAU - Yuan, Jiuhong
AU  - Yuan J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology/*therapeutic 
      use
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Erectile Dysfunction/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Nitric Oxide/physiology
MH  - Penis/blood supply
MH  - Prostaglandin Antagonists
MH  - Prostaglandins/physiology
MH  - Risk Factors
PMC - PMC6076183
COIS- The authors report no conflicts of interest.
EDAT- 2018/07/12 06:00
MHDA- 2018/07/19 06:00
CRDT- 2018/07/12 06:00
PHST- 2018/07/12 06:00 [entrez]
PHST- 2018/07/12 06:00 [pubmed]
PHST- 2018/07/19 06:00 [medline]
AID - 00005792-201807130-00023 [pii]
AID - MD-D-17-08257 [pii]
AID - 10.1097/MD.0000000000011367 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jul;97(28):e11367. doi: 10.1097/MD.0000000000011367.

PMID- 7994378
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Diaspirin crosslinked hemoglobin: evaluation of effects on the microcirculation 
      of striated muscle.
PG  - 587-92
AB  - Hemoglobin-based oxygen carriers such as diaspirin-crosslinked hemoglobin (DCLHb) 
      have been proposed for blood substitution due to their plasma expansion and 
      oxygen transport capacity. This study investigates the effects of DCLHb on the 
      microcirculation of striated muscle after moderate topload infusion and 
      isovolemic exchange transfusion in awake hamsters. The skinfold chamber model in 
      hamsters and intravital fluorescence microscopy were used for analysis of vessel 
      diameter, red blood cell velocity (RBCV), leukocyte sticking to the microvascular 
      endothelium, and macromolecular leakage in striated skin muscle. In each animal, 
      arteriolar and postcapillary vessel segments were chosen and sequentially 
      recorded on videotape (baseline). Animals were subjected to either topload 
      infusion (10% of blood volume) or isovolemic exchange transfusion (hct 30%) of 
      DCLHb followed by measurements at 10, 30, and 60 min thereafter. In vivo 
      visualization of plasma and leukocytes was performed using FITC-dextran 150,000 
      and rhodamine 6G, respectively. No significant changes of vessel diameter and 
      RBCV were observed after topload infusion or isovolemic exchange transfusion with 
      DCLHb, either in postcapillary venules or in arterioles when compared with 
      baseline values. Leukocyte sticking and macromolecular leakage were not found 
      enhanced after administration of DCLHb. We conclude that the introduction of 
      DCLHb-bound oxygen into the tissue does neither stimulate leukocyte adhesion nor 
      impair endothelial integrity.
FAU - Nolte, D
AU  - Nolte D
AD  - Institute for Surgical Research, Klinikum Grosshadern University of Munich, 
      Germany.
FAU - Botzlar, A
AU  - Botzlar A
FAU - Hecht, R
AU  - Hecht R
FAU - Csapó, C
AU  - Csapó C
FAU - Menger, M D
AU  - Menger MD
FAU - Messmer, K
AU  - Messmer K
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Blood Substitutes/administration & dosage/*pharmacology
MH  - Cricetinae
MH  - Exchange Transfusion, Whole Blood
MH  - Hemoglobins/administration & dosage/*pharmacology
MH  - Infusions, Intravenous
MH  - Mesocricetus
MH  - Microcirculation/drug effects
MH  - Muscle, Skeletal/*blood supply/*drug effects
MH  - Skin/blood supply/drug effects
MH  - Vasoconstriction/drug effects
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117887 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):587-92. doi: 
      10.3109/10731199409117887.

PMID- 20451957
OWN - NLM
STAT- MEDLINE
DCOM- 20110203
LR  - 20131121
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 126
IP  - 4
DP  - 2010 Oct
TI  - Reduced platelet response to aspirin in patients with coronary artery disease and 
      type 2 diabetes mellitus.
PG  - e318-22
LID - 10.1016/j.thromres.2010.03.013 [doi]
AB  - INTRODUCTION: Diabetes mellitus is complicated by accelerated atherosclerosis, 
      resulting in an increased risk of coronary artery disease (CAD) and thrombosis. 
      Despite the proven benefits of aspirin, previous studies indicate a reduced 
      cardiovascular protection from aspirin in diabetic patients. We aimed to 
      investigate whether diabetes mellitus influenced the platelet response to aspirin 
      in patients with CAD. MATERIALS AND METHODS: Platelet aggregation and activation 
      were evaluated during aspirin treatment in 85 diabetic and 92 non-diabetic 
      patients with CAD. Adherence to aspirin was carefully controlled. All patients 
      had CAD verified by coronary angiography and were taking 75 mg non-enteric coated 
      aspirin daily. RESULTS: Diabetic patients showed significantly higher levels of 
      platelet aggregation compared to non-diabetic patients evaluated by VerifyNow® 
      Aspirin (p=0.03) and Multiplate® aggregometry using arachidonic acid (AA) 0.5 mM 
      (p=0.005) and 1.0 mM (p=0.009). In addition, platelet activation determined by 
      soluble P-selectin was significantly higher in diabetics compared to 
      non-diabetics (p=0.005). The higher AA-induced aggregation was associated with 
      higher levels of HbA(1c). Compliance was confirmed by low levels of serum 
      thromboxane B(2) (below 7.2 ng/mL). Diabetics had significantly higher levels of 
      serum thromboxane B(2) (p<0.0001). CONCLUSIONS: Diabetic patients with CAD had 
      significantly higher levels of both platelet aggregation and activation compared 
      to non-diabetic patients with CAD despite treatment with the same dosage of 
      aspirin. These findings may partly explain the reduced cardiovascular protection 
      from aspirin in diabetic patients.
CI  - Copyright © 2010 Elsevier Ltd. All rights reserved.
FAU - Mortensen, S B
AU  - Mortensen SB
AD  - Department of Cardiology, Aarhus University Hospital Skejby, Denmark. 
      sosbm@dadlnet.dk
FAU - Larsen, S B
AU  - Larsen SB
FAU - Grove, E L
AU  - Grove EL
FAU - Kristensen, S D
AU  - Kristensen SD
FAU - Hvas, A-M
AU  - Hvas AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100507
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Thromb Res. 2011 Aug;128(2):196-9. PMID: 21543109
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Coronary Artery Disease/*complications/*drug therapy
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
EDAT- 2010/05/11 06:00
MHDA- 2011/02/04 06:00
CRDT- 2010/05/11 06:00
PHST- 2010/01/26 00:00 [received]
PHST- 2010/03/11 00:00 [revised]
PHST- 2010/03/27 00:00 [accepted]
PHST- 2010/05/11 06:00 [entrez]
PHST- 2010/05/11 06:00 [pubmed]
PHST- 2011/02/04 06:00 [medline]
AID - S0049-3848(10)00202-1 [pii]
AID - 10.1016/j.thromres.2010.03.013 [doi]
PST - ppublish
SO  - Thromb Res. 2010 Oct;126(4):e318-22. doi: 10.1016/j.thromres.2010.03.013. Epub 
      2010 May 7.

PMID- 12555346
OWN - NLM
STAT- MEDLINE
DCOM- 20030623
LR  - 20131121
IS  - 0003-3928 (Print)
IS  - 0003-3928 (Linking)
VI  - 49
IP  - 6
DP  - 2000 Sep
TI  - [Staphylococcus epidermidis infective endocarditis after mitral surgery, 
      successfully treated with aspirin and antibiotics: a case report].
PG  - 347-50
AB  - We report a case of infectious endocarditis from Staphylococcus epidermidis that 
      occurred early after mitral valve repair (one month), suggested by fever of 38.5 
      degrees C and valvular vegetations of less than 10 mm on the mitral valve. In the 
      absence of standard recommendations (medical or surgical) in treating patients 
      with infectious endocarditis occurring after mitral valve repair, and in the 
      absence of complications, a medical regimen was chosen associating aspirin 
      (anti-aggregant dosages) with antibiotics. The benefit of aspirin in endocarditis 
      has been demonstrated in experimental studies with regards to valvular 
      vegetations and embolic risk but remains to be studied in human clinical trials. 
      With the association of aspirin (100 mg/d) and triple antibiotic therapy 
      (rifampicin 1200 mg/d, vancomycin 2 g/d, gentamycin 180 mg/d), the clinical 
      status improved with complete regression of vegetations in less than 24 days and 
      the absence of recurrence at one-year follow-up.
FAU - Meimoun, P
AU  - Meimoun P
AD  - Département de chirurgie cardiovasculaire, hôpital Broussais, 96, rue Didot, 
      75674 Paris, France.
FAU - Mainardi, J L
AU  - Mainardi JL
FAU - Berrebi, A
AU  - Berrebi A
FAU - Marino, J P
AU  - Marino JP
FAU - Waldmann, T
AU  - Waldmann T
FAU - Carpentier, A
AU  - Carpentier A
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Endocardite infectieuse à Staphylococcus epidermidis après plastie mitrale, 
      traitée avec succès par aspirine et antibiotiques: à propos d'un cas.
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Endocarditis, Bacterial/*drug therapy/etiology
MH  - Female
MH  - Humans
MH  - Mitral Valve/*surgery
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/*drug therapy/etiology
MH  - Remission Induction
MH  - Staphylococcal Infections/*drug therapy/etiology
EDAT- 2003/01/31 04:00
MHDA- 2003/06/24 05:00
CRDT- 2003/01/31 04:00
PHST- 2003/01/31 04:00 [pubmed]
PHST- 2003/06/24 05:00 [medline]
PHST- 2003/01/31 04:00 [entrez]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 2000 Sep;49(6):347-50.

PMID- 7646574
OWN - NLM
STAT- MEDLINE
DCOM- 19950915
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 45
IP  - 6
DP  - 1995 Jun
TI  - [Protective effect of omeprazole against low-dose acetylsalicylic acid. 
      Endoscopic controlled double-blind study in healthy subjects].
PG  - 701-3
AB  - Protective Effects of Omeprazole against Low-dose Acetylsalicylic Acid/An 
      endoscopic controlled double-blind study in healthy volunteers. In a randomized 
      double-blind parallel study the gastroduodenal tolerability of 300 mg 
      acetylsalicylic acid (CAS 50-78-2, ASA) daily (8 p.m.) has been evaluated in the 
      presence of 20 mg and 40 mg omeprazole (CAS 73590-58-6) daily (8 p.m.) or placebo 
      in 36 healthy volunteers using upper GI-endoscopy. The treatment periods lasted 
      14 days. Endoscopic controls were performed at entry and repeated at day 14. At 
      entry the mean endoscopic score averaged 0.9 +/- 0.08 in the ASA/placebo (n = 
      12), the ASA/omeprazole 20 mg (n = 12) and the ASA/omeprazole 40 mg group (n = 
      12). The median values were 1.0. In the placebo experiments 300 mg ASA daily 
      induced marked gastroduodenal lesions at day 14 (12.4 +/- 1.7). The median value 
      was 10.0. Concomitant administration of 20 mg omeprazole daily afforded 
      significant protection against 300 mg ASA daily on day 14 (2.9 +/- 0.9) (p < 
      0.0005 vs. ASA/placebo). 300 mg ASA + 40 mg omeprazole daily reduced the damaging 
      score to 1.8 +/- 0.5 (p < 0.00002 vs. ASA/placebo). The median values in the 
      ASA/omeprazole 20 mg and in the ASA/omeprazole 40 mg group were 1.0. The 
      difference in the damaging score between ASA/omeprazole 20 mg and ASA/omeprazole 
      40 mg after 14 days did not reach statistical significance. Our data suggest that 
      coadministration of 20 mg omeprazole daily reduces almost completely 
      gastroduodenal lesions evoked by 300 mg ASA.
FAU - Simon, B
AU  - Simon B
AD  - Kreiskrankenhaus Schwetzingen.
FAU - Elsner, H
AU  - Elsner H
FAU - Müller, P
AU  - Müller P
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Schutzwirkung von Omeprazol gegenüber niedrig dosierter Acetylsalicylsäure. 
      Endoskopisch kontrollierte Doppelblindstudie an gesunden Probanden.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/*antagonists & inhibitors
MH  - Double-Blind Method
MH  - Endoscopy, Gastrointestinal
MH  - Humans
MH  - Male
MH  - Omeprazole/*pharmacology
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1995 Jun;45(6):701-3.

PMID- 6344620
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 74
IP  - 6A
DP  - 1983 Jun 14
TI  - Aspirin in the treatment of juvenile arthritis.
PG  - 10-5
AB  - Aspirin can be more closely controlled than other nonsteroidal anti-inflammatory 
      drugs because serum salicylate levels can be measured. Dosages of 80 to 100 mg/kg 
      per day usually lead to the desired serum salicylate levels of 20 to 25 mg/dl. 
      Gastric irritation, the most frequent cause for cessation of aspirin therapy, is 
      significantly reduced by the use of enteric-coated aspirin. At the onset of 
      aspirin therapy in children, there is frequently moderate elevation of SGOT and 
      SGPT liver enzyme levels. With continued treatment these levels usually fall into 
      the range of mild elevations. Although these children with arthritis often take 
      high doses of aspirin for years, Reye's syndrome is virtually never seen.
FAU - Baum, J
AU  - Baum J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Salicylates)
RN  - 0 (Serum Albumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Chemical and Drug Induced Liver Injury
MH  - Child
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Liver Diseases/enzymology
MH  - Protein Binding
MH  - Salicylates/administration & dosage/blood
MH  - Serum Albumin/metabolism
RF  - 20
EDAT- 1983/06/14 00:00
MHDA- 1983/06/14 00:01
CRDT- 1983/06/14 00:00
PHST- 1983/06/14 00:00 [pubmed]
PHST- 1983/06/14 00:01 [medline]
PHST- 1983/06/14 00:00 [entrez]
AID - 0002-9343(83)90523-5 [pii]
AID - 10.1016/0002-9343(83)90523-5 [doi]
PST - ppublish
SO  - Am J Med. 1983 Jun 14;74(6A):10-5. doi: 10.1016/0002-9343(83)90523-5.

PMID- 8212707
OWN - NLM
STAT- MEDLINE
DCOM- 19931123
LR  - 20131121
IS  - 0043-5325 (Print)
IS  - 0043-5325 (Linking)
VI  - 105
IP  - 17
DP  - 1993
TI  - [Low dose acetylsalicylic acid in secondary prevention of stroke].
PG  - 485-7
AB  - Acetylsalicylic acid (ASA) as secondary prophylaxis after ischaemic 
      cerebrovascular events is well established and its efficacy unquestioned since 
      over 15 years. According to the results of two European studies a dose of 100 mg 
      per day is sufficient to reduce the incidence of further stroke, myocardial 
      infarction, and death due to cardiovascular causes. This satisfactory response to 
      low-dose ASA applies to patients with transient ischaemic attacks, reversible 
      ischaemic events, and minor strokes. In cases with severe cardiac disease, 
      however, a high dosage of ASA or anticoagulation therapy may be necessary to 
      prevent further vascular events.
FAU - Deecke, L
AU  - Deecke L
AD  - Neurologische Universitätsklinik, Wien.
FAU - Zeiler, K
AU  - Zeiler K
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Niedrig dosierte Acetylsalizylsäure (ASS) in der Sekundärprophylaxe des 
      Schlaganfalls.
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy
MH  - Long-Term Care
MH  - Randomized Controlled Trials as Topic
RF  - 20
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Wien Klin Wochenschr. 1993;105(17):485-7.

PMID- 16951898
OWN - NLM
STAT- MEDLINE
DCOM- 20060922
LR  - 20220129
IS  - 1537-744X (Electronic)
IS  - 2356-6140 (Print)
IS  - 1537-744X (Linking)
VI  - 6
DP  - 2006 Aug 31
TI  - New perspectives on aspirin and the endogenous control of acute inflammatory 
      resolution.
PG  - 1048-65
AB  - Aspirin is unique among the nonsteroidal anti-inflammatory drugs in that it has 
      both anti-inflammatory as well as cardio-protective properties. The 
      cardio-protective properties arise form its judicious inhibition of 
      platelet-derived thromboxane A2 over prostacyclin, while its anti-inflammatory 
      effects of aspirin stem from its well-established inhibition of prostaglandin 
      (PG) synthesis within inflamed tissues. Thus aspirin and the other NSAIDs have 
      popularised the notion of inhibiting PG biosynthesis as a common 
      anti-inflammatory strategy based on the erroneous premise that all eicosanoids 
      are generally detrimental to inflammation. However, our fascination with aspirin 
      has shown a more affable side to lipid mediators based on our increasing interest 
      in the endogenous control of acute inflammation and in factors that mediate its 
      resolution. Epi-lipoxins (epi-LXs), for instance, are produced from aspirin's 
      acetylation of inducible cyclooxygenase 2 (COX-2) and together with Resolvins 
      represent an increasingly important family of immuno-regulatory and potentially 
      cardio-protective lipid mediators. Aspirin is beginning to teach us what nature 
      knew all along--that not all lipid mediators are bad. It seems that while some 
      eicosanoids are pathogenic in a variety of diseases, others are unarguable 
      protective. In this review we will re-count aspirin's colorful history, discuss 
      its traditional mode of action and the controversies associated therewith, as 
      well as highlight some of the new pathways in inflammation and the cardiovascular 
      systems that aspirin has recently revealed.
FAU - Morris, Thea
AU  - Morris T
AD  - Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, 5 
      University Street, University College London, London WC1E 6JJ, UK.
FAU - Stables, Melanie
AU  - Stables M
FAU - Gilroy, Derek W
AU  - Gilroy DW
LA  - eng
GR  - G0500017/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20060831
PL  - United States
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (HSH2 protein, mouse)
RN  - 0 (Lipoxins)
RN  - 0 (Receptors, Aryl Hydrocarbon)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - EC 1.13.11.12 (Lipoxygenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/physiology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Docosahexaenoic Acids/metabolism
MH  - Eicosapentaenoic Acid/analogs & derivatives/physiology
MH  - Endothelial Cells/physiology
MH  - Fatty Acids, Omega-3/physiology
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Leukocytes/physiology
MH  - Lipoxins/physiology
MH  - Lipoxygenase/metabolism
MH  - Models, Biological
MH  - Nitric Oxide/physiology
MH  - Receptors, Aryl Hydrocarbon/physiology
MH  - Signal Transduction
PMC - PMC5944180
EDAT- 2006/09/05 09:00
MHDA- 2006/09/23 09:00
CRDT- 2006/09/05 09:00
PHST- 2006/09/05 09:00 [pubmed]
PHST- 2006/09/23 09:00 [medline]
PHST- 2006/09/05 09:00 [entrez]
AID - 324218 [pii]
AID - 10.1100/tsw.2006.192 [doi]
PST - epublish
SO  - ScientificWorldJournal. 2006 Aug 31;6:1048-65. doi: 10.1100/tsw.2006.192.

PMID- 3880861
OWN - NLM
STAT- MEDLINE
DCOM- 19850201
LR  - 20131121
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 142
IP  - 1
DP  - 1985 Jan 7
TI  - Aspirin and other platelet-aggregation inhibiting drugs.
PG  - 41-7
AB  - The biochemistry of platelets is surprisingly complex, and offers the opportunity 
      for numerous platelet-aggregation inhibiting ("antiplatelet") drugs to interfere 
      with different aspects of their metabolism and function. Thus, aspirin inhibits 
      platelet aggregation by irreversibly inactivating cyclo-oxygenase, a key enzyme 
      in platelet prostaglandin metabolism, while the other nonsteroidal 
      anti-inflammatory drugs and sulphinpyrazone cause reversible and dose-dependent 
      inhibition of the same enzyme. Dipyridamole can inhibit both platelet adhesion 
      and aggregation by raising the platelet cyclic AMP level through 
      phosphodiesterase inhibition. The use of aspirin, sulphinpyrazone, and 
      dipyridamole as antithrombotic agents has now been extensively evaluated. In 
      general, treatment with these drugs has been more likely to prevent arterial than 
      venous thromboembolism, and aspirin or the combination of aspirin and 
      dipyridamole has been more effective in this respect than has sulphinpyrazone. 
      Recent evidence strongly suggests that aspirin reduces the risk of non-fatal 
      myocardial infarction in patients with unstable angina, and that the 
      administration of aspirin in combination with dipyridamole significantly improves 
      graft patency after aortocoronary bypass. Aspirin also appears to reduce the 
      likelihood of stroke or death in men with transient cerebral ischaemic attacks.
FAU - Gallus, A S
AU  - Gallus AS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/metabolism/*pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/physiology
MH  - Coronary Artery Bypass
MH  - Coronary Disease/drug therapy/physiopathology
MH  - Dipyridamole/metabolism/pharmacology/therapeutic use
MH  - Female
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy
MH  - Kinetics
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Sulfinpyrazone/metabolism/pharmacology/therapeutic use
MH  - Thrombophlebitis/drug therapy
RF  - 71
EDAT- 1985/01/07 00:00
MHDA- 1985/01/07 00:01
CRDT- 1985/01/07 00:00
PHST- 1985/01/07 00:00 [pubmed]
PHST- 1985/01/07 00:01 [medline]
PHST- 1985/01/07 00:00 [entrez]
PST - ppublish
SO  - Med J Aust. 1985 Jan 7;142(1):41-7.

PMID- 21240348
OWN - NLM
STAT- MEDLINE
DCOM- 20110520
LR  - 20190813
IS  - 1573-8221 (Electronic)
IS  - 0007-4888 (Linking)
VI  - 150
IP  - 3
DP  - 2011 Jan
TI  - Pharmacological correction of the negative effects of acetylsalicylic acid on the 
      energy production system.
PG  - 336-9
AB  - Experiments of outbred rats with modeled xenobiotic load with acetylsalicylic 
      acid (250 mg/kg for 7 days) revealed inhibition of mitochondrial respiration rate 
      in states of rest and active phosphorylation, inhibition of succinate-dependent 
      oxidation pathway, and a decrease in energization of organelles in the heart. For 
      correction of the observed changes in energy production, succinic acid was 
      preventively administered in a dose of 50 mg/kg for 7 days, which abolished the 
      negative metabolic shifts in myocardial mitochondria. Comparison of 
      pharmacokinetics of acetylsalicylic acid and acetylsalicylic acid against the 
      background of succinate treatment performed on rabbits revealed complete 
      coincidence of the studied parameters, which attests to the possibility of 
      prevention of mitochondrial dysregulations with this Krebs cycle intermediate.
FAU - Bryushinina, O S
AU  - Bryushinina OS
AD  - Laboratory of Physiology, Molecular and Clinical Pharmacology, Department of 
      Clinical Pharmacology, Institute of Pharmacology, Siberian Division of the 
      Russian Academy of Medical Sciences, Tomsk, Russia.
FAU - Gurto, R V
AU  - Gurto RV
FAU - Slepichev, V A
AU  - Slepichev VA
FAU - Stykon, G A
AU  - Stykon GA
FAU - Zyuz'kova, Yu G
AU  - Zyuz'kova YG
FAU - Yanovskaya, E A
AU  - Yanovskaya EA
FAU - Udut, V V
AU  - Udut VV
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bull Exp Biol Med
JT  - Bulletin of experimental biology and medicine
JID - 0372557
RN  - AB6MNQ6J6L (Succinic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Area Under Curve
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Cell Respiration/*drug effects
MH  - Energy Metabolism/*drug effects/physiology
MH  - Heart/*physiology
MH  - Mitochondria/*drug effects
MH  - Polarography
MH  - Rabbits
MH  - Rats
MH  - Succinic Acid/*pharmacology
EDAT- 2011/01/18 06:00
MHDA- 2011/05/21 06:00
CRDT- 2011/01/18 06:00
PHST- 2011/01/18 06:00 [entrez]
PHST- 2011/01/18 06:00 [pubmed]
PHST- 2011/05/21 06:00 [medline]
AID - 10.1007/s10517-011-1136-z [doi]
PST - ppublish
SO  - Bull Exp Biol Med. 2011 Jan;150(3):336-9. doi: 10.1007/s10517-011-1136-z.

PMID- 16952012
OWN - NLM
STAT- MEDLINE
DCOM- 20070307
LR  - 20181113
IS  - 1053-0509 (Print)
IS  - 1053-0509 (Linking)
VI  - 16
IP  - 5
DP  - 2006 Sep
TI  - Simultaneous determination of acetylsalicylic acid and caffeine in pharmaceutical 
      formulation by first derivative synchronous fluorimetric method.
PG  - 713-21
AB  - A sensitive, rapid, and specific assay has been developed for the simultaneous 
      determination of acetylsalicylic acid and caffeine in commercial tablets based on 
      their natural fluorescence. The mixture of these drugs was resolved by first 
      derivative synchronous fluorimetric technique using two scans. At Deltalambda=106 
      nm, using first derivative synchronous scanning, only acetylsalicylic acid yields 
      a detectable signal at 316 nm (peak to zero method) which is unaffected by 
      caffeine. At Deltalambda=30 nm, the signal of caffeine at 288 nm (peak to zero 
      method) is not affected by acetylsalicylic acid. The range of application is 
      between 0.021 and 41.62 microg ml(-1) (correlation coefficient, R=0.9995) for 
      acetylsalicylic acid and between 0.4486 and 44.86 microg ml(-1) (correlation 
      coefficient, R=0.99786) for caffeine. The recovery range of 98.40-102% for 
      acetylsalicylic acid and 90-100.5% for caffeine from their synthetic mixture was 
      reported. Overall recovery of both compounds about 97-99% for acetylsalicylic 
      acid and 97-98% for caffeine was obtained from real sample analysis. The 
      detection limits are 0.0013 microg ml(-1) and 0.0306 microg ml(-1) for 
      acetylsalicylic acid and caffeine, respectively. The relative standard deviation 
      (n=10) for 20 microg ml(-1) of acetylsalicylic acid is 2.75% and for 2.2 microg 
      ml(-1)of caffeine is 1.7%.
FAU - Karim, Mohammad Mainul
AU  - Karim MM
AD  - Department of Chemistry, Kyungpook National University, Taegu 702-701, Republic 
      of Korea.
FAU - Jeon, Chi Wan
AU  - Jeon CW
FAU - Lee, Hyun Sook
AU  - Lee HS
FAU - Alam, Seikh Mafiz
AU  - Alam SM
FAU - Lee, Sang Hak
AU  - Lee SH
FAU - Choi, Jong Ha
AU  - Choi JH
FAU - Jin, Seung Oh
AU  - Jin SO
FAU - Das, Ajoy Kumar
AU  - Das AK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060902
PL  - Netherlands
TA  - J Fluoresc
JT  - Journal of fluorescence
JID - 9201341
RN  - 0 (Drug Combinations)
RN  - 0 (Surface-Active Agents)
RN  - 0 (Tablets)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*analysis
MH  - Caffeine/administration & dosage/*analysis
MH  - Drug Combinations
MH  - Hydrogen-Ion Concentration
MH  - Spectrometry, Fluorescence/*methods/statistics & numerical data
MH  - Surface-Active Agents
MH  - Tablets
EDAT- 2006/09/05 09:00
MHDA- 2007/03/08 09:00
CRDT- 2006/09/05 09:00
PHST- 2006/05/30 00:00 [received]
PHST- 2006/08/01 00:00 [accepted]
PHST- 2006/09/05 09:00 [pubmed]
PHST- 2007/03/08 09:00 [medline]
PHST- 2006/09/05 09:00 [entrez]
AID - 10.1007/s10895-006-0115-7 [doi]
PST - ppublish
SO  - J Fluoresc. 2006 Sep;16(5):713-21. doi: 10.1007/s10895-006-0115-7. Epub 2006 Sep 
      2.

PMID- 30448498
OWN - NLM
STAT- MEDLINE
DCOM- 20190426
LR  - 20190426
IS  - 1879-0003 (Electronic)
IS  - 0141-8130 (Linking)
VI  - 124
DP  - 2019 Mar 1
TI  - Effect of lignin on the release rate of acetylsalicylic acid tablets.
PG  - 354-359
LID - S0141-8130(18)33217-3 [pii]
LID - 10.1016/j.ijbiomac.2018.11.136 [doi]
AB  - The main focus of this paper is on the improvement of formulations utilising 
      non-conventional bio-based excipients to improve tablet release rates. Two 
      different formulations were considered. The first formulation contains Alcell 
      lignin, lactose monohydrate and microcrystalline cellulose as excipients and 
      acetylsalicylic acid (aspirin) as active pharmaceutical ingredient (API). The 
      second formulation contains lactose monohydrate and microcrystalline cellulose as 
      excipients and aspirin as API. The prepared formulations were roller compacted 
      followed by milling, sieving, and tableting. The tablets were then characterised 
      in terms of dissolution rate in order to compare the release rates. Results 
      indicated that tablets containing Alcell lignin have quicker release, faster 
      disintegration times and higher tablet hardness for all samples with differing 
      process parameters. Higher API dissolution has been attributed to the amorphous 
      structure of lignin and its interaction with aspirin, which increases dissolution 
      of the API.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Pishnamazi, Mahboubeh
AU  - Pishnamazi M
AD  - Department of Chemical Sciences, Bernal Institute, Synthesis and Solid State 
      Pharmaceutical Centre (SSPC), University of Limerick, Limerick, Ireland.
FAU - Iqbal, Javed
AU  - Iqbal J
AD  - Department of Chemical Sciences, Bernal Institute, Synthesis and Solid State 
      Pharmaceutical Centre (SSPC), University of Limerick, Limerick, Ireland.
FAU - Shirazian, Saeed
AU  - Shirazian S
AD  - Department of Chemical Sciences, Bernal Institute, Synthesis and Solid State 
      Pharmaceutical Centre (SSPC), University of Limerick, Limerick, Ireland.
FAU - Walker, Gavin M
AU  - Walker GM
AD  - Department of Chemical Sciences, Bernal Institute, Synthesis and Solid State 
      Pharmaceutical Centre (SSPC), University of Limerick, Limerick, Ireland.
FAU - Collins, Maurice N
AU  - Collins MN
AD  - Stokes Laboratories, Bernal Institute, University of Limerick, Limerick, Ireland; 
      Health Research Institute, University of Limerick, Limerick, Ireland. Electronic 
      address: maurice.collins@ul.ie.
LA  - eng
PT  - Journal Article
DEP - 20181115
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
RN  - 0 (Tablets)
RN  - 9004-34-6 (Cellulose)
RN  - 9005-53-2 (Lignin)
RN  - J2B2A4N98G (Lactose)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/therapeutic use
MH  - Cellulose/chemistry
MH  - Chemistry, Pharmaceutical
MH  - *Drug Compounding
MH  - Drug Liberation
MH  - Hardness
MH  - Humans
MH  - Lactose/chemistry
MH  - Lignin/*chemistry/therapeutic use
MH  - Solubility/drug effects
MH  - Tablets/chemistry/therapeutic use
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Drug dissolution
OT  - Drug release
OT  - Dry granulation
OT  - Hydrolysation
OT  - Lignin
OT  - Roll compaction
EDAT- 2018/11/19 06:00
MHDA- 2019/04/27 06:00
CRDT- 2018/11/19 06:00
PHST- 2018/06/27 00:00 [received]
PHST- 2018/11/05 00:00 [revised]
PHST- 2018/11/14 00:00 [accepted]
PHST- 2018/11/19 06:00 [pubmed]
PHST- 2019/04/27 06:00 [medline]
PHST- 2018/11/19 06:00 [entrez]
AID - S0141-8130(18)33217-3 [pii]
AID - 10.1016/j.ijbiomac.2018.11.136 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2019 Mar 1;124:354-359. doi: 10.1016/j.ijbiomac.2018.11.136. 
      Epub 2018 Nov 15.

PMID- 22770476
OWN - NLM
STAT- MEDLINE
DCOM- 20130418
LR  - 20151119
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 60
IP  - 3
DP  - 2012 Sep
TI  - Impact of low-dose aspirin on coronary artery spasm as assessed by intracoronary 
      acetylcholine provocation test in Korean patients.
PG  - 187-91
LID - S0914-5087(12)00058-5 [pii]
LID - 10.1016/j.jjcc.2012.02.007 [doi]
AB  - High-dose aspirin has been reported to aggravate coronary artery spasm (CAS). 
      However, it is unknown whether low-dose aspirin (LDA; 100 mg) has deleterious 
      impact on CAS. We assessed the impact of LDA on CAS induced by intracoronary 
      acetylcholine (ACh) provocation test. A total of 2789 consecutive patients 
      without significant coronary artery disease who underwent ACh test between 
      November 2004 and March 2010 were enrolled. The patients were divided into two 
      groups: the aspirin group taking LDA before ACh test (n=221) and the no aspirin 
      group not taking aspirin (n=2568). At baseline, the prevalence of old age, 
      diabetes mellitus, hypertension, and hyperlipidemia were higher in the aspirin 
      group. During the ACh test, the incidence of significant CAS, ischemic chest 
      pain, as well as severe and multivessel spasm was higher in the aspirin group. 
      The response rate to lower ACh dose was higher in the aspirin group. Multivariate 
      analysis showed that the previous use of LDA was an independent predictor of CAS 
      (adjusted odds ratio, 1.6, 95% confidence interval, 1.0-2.3; p=0.031). However, 
      it is likely that the association of LDA and CAS that we have observed is not 
      causal but may be hypothesis generating due to significant baseline differences. 
      Further, male gender, old age, lipid-lowering drugs, baseline spasm, and 
      myocardial bridge were independent predictors of CAS. LDA was more frequently 
      associated with CAS and ischemic symptoms, as well as severe and multivessel 
      spasm, suggesting the patients who have received LDA would require more intensive 
      medical therapies and close follow up.
CI  - Copyright © 2012 Japanese College of Cardiology. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Park, Ji Young
AU  - Park JY
AD  - Cardiovascular Center, Korea University Guro Hospital, Cardiology Department, 
      Eulji University, Seoul, Republic of Korea.
FAU - Rha, Seung-Woon
AU  - Rha SW
FAU - Poddar, Kanhaiya L
AU  - Poddar KL
FAU - Ramasamy, Sureshkumar
AU  - Ramasamy S
FAU - Chen, Kang-Yin
AU  - Chen KY
FAU - Li, Yong-Jian
AU  - Li YJ
FAU - Choi, Byoung Geol
AU  - Choi BG
FAU - Ryu, Sung Kee
AU  - Ryu SK
FAU - Choi, Jae Woong
AU  - Choi JW
FAU - Park, Sang Hyun
AU  - Park SH
FAU - Park, Songree
AU  - Park S
FAU - Elnagar, Amro
AU  - Elnagar A
FAU - Im, Sung Il
AU  - Im SI
FAU - Kim, Sun Won
AU  - Kim SW
FAU - Na, Jin Oh
AU  - Na JO
FAU - Choi, Cheol Ung
AU  - Choi CU
FAU - Lim, Hong Euy
AU  - Lim HE
FAU - Kim, Jin Won
AU  - Kim JW
FAU - Kim, Eung Ju
AU  - Kim EJ
FAU - Han, Seong Woo
AU  - Han SW
FAU - Park, Chang Gyu
AU  - Park CG
FAU - Seo, Hong Seog
AU  - Seo HS
FAU - Oh, Dong Joo
AU  - Oh DJ
LA  - eng
PT  - Journal Article
DEP - 20120705
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acetylcholine
MH  - Age Factors
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Coronary Angiography
MH  - Coronary Vasospasm/*chemically induced
MH  - Diabetes Complications
MH  - Female
MH  - Humans
MH  - Hyperlipidemias/complications
MH  - Hypertension/complications
MH  - Male
MH  - Middle Aged
MH  - Sex Factors
EDAT- 2012/07/10 06:00
MHDA- 2013/04/20 06:00
CRDT- 2012/07/10 06:00
PHST- 2011/10/27 00:00 [received]
PHST- 2012/02/14 00:00 [revised]
PHST- 2012/02/16 00:00 [accepted]
PHST- 2012/07/10 06:00 [entrez]
PHST- 2012/07/10 06:00 [pubmed]
PHST- 2013/04/20 06:00 [medline]
AID - S0914-5087(12)00058-5 [pii]
AID - 10.1016/j.jjcc.2012.02.007 [doi]
PST - ppublish
SO  - J Cardiol. 2012 Sep;60(3):187-91. doi: 10.1016/j.jjcc.2012.02.007. Epub 2012 Jul 
      5.

PMID- 314279
OWN - NLM
STAT- MEDLINE
DCOM- 19791024
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 139
IP  - 9
DP  - 1979 Sep
TI  - Possible hazard of timed-release aspirin in a patient with pancreatic 
      insufficiency.
PG  - 1054-5
AB  - An episode of severe small intestinal hemorrhage occurred in a cystic fibrosis 
      patient having pancreatic insufficiency and receiving timed-release aspirin 
      therapy for disabling hypertrophic pulmonary osteoarthropathy. The increased 
      acidity of small intestinal contents due to decreased bicarbonate secretion 
      observed in patients with pancreatic insufficiency may alter the luminal 
      environment and result in mucosal erosions and/or ulcerations in association with 
      the presence of aspirin. Thus, physicians should be aware of the possibility that 
      timed-release aspirin causes small intestinal hemorrhage in such patients.
FAU - Hubbard, V S
AU  - Hubbard VS
FAU - Davis, P B
AU  - Davis PB
FAU - di Sant'Agnese, P A
AU  - di Sant'Agnese PA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Delayed-Action Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cystic Fibrosis/*complications
MH  - Delayed-Action Preparations
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Intestine, Small/drug effects
MH  - Male
MH  - Osteoarthropathy, Secondary Hypertrophic/drug therapy/etiology
EDAT- 1979/09/01 00:00
MHDA- 1979/09/01 00:01
CRDT- 1979/09/01 00:00
PHST- 1979/09/01 00:00 [pubmed]
PHST- 1979/09/01 00:01 [medline]
PHST- 1979/09/01 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1979 Sep;139(9):1054-5.

PMID- 31645164
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 31
IP  - 6
DP  - 2020 Aug 17
TI  - Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without 
      increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery 
      disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study.
PG  - 788-794
LID - 10.1080/09537104.2019.1680825 [doi]
AB  - Patients treated with ticagrelor and aspirin usually suffer from bleeding events, 
      especially mild bleeding which is one of the main factors reducing patients' 
      adherence to ticagrelor. The objective of this study is to investigate the 
      efficacy and safety of ticagrelor combined with a lower dose of aspirin (50 mg) 
      than that recommended by guidelines (75-100 mg). In this study, we prospectively 
      enrolled 1220 patients who take ticagrelor in the hospital. After excluding the 
      patients who did not take ticagrelor after discharge or lost to follow-up, the 
      remaining 1066 patients were divided into two aspirin dose groups: 75-100 mg (n = 
      744) and 50 mg (n = 322). The rates of major adverse cardiovascular events 
      (MACEs), bleeding events and ticagrelor adherence were compared between the two 
      groups. MACEs risk was not significantly different between the two groups (OR = 
      0.563, 95% CI: 0.244-1.300, P = .179). However, 50 mg aspirin was associated with 
      a lower risk of any Bleeding Academic Research Consortium (BARC) bleeding events 
      (OR = 0.605, 95% CI: 0.399-0.713, P = .001), also lower BARC bleeding events (OR 
      = 0.639, 95% CI: 0.468-0.872, P = .005). Moreover, lower-dose aspirin was 
      associated with a lower rate of ticagrelor withdrawal (OR = 0.459, 95% CI: 
      0.279-0.754, P = .002), mainly because of the decrease in ticagrelor withdrawal 
      due to bleeding (OR = 0.378, 95% CI: 0.156-0.916, P = .031). After propensity 
      score matching (PSM), a total of 317 patients in each group were matched. The 
      MACEs composite was not significantly different between the two matched groups 
      and 50 mg aspirin was associated with a lower risk of bleeding events and low 
      ticagrelor withdrawal before and after multivariate adjustment. In conclusion, 
      among patients who took ticagrelor (90 mg twice daily), 50 mg aspirin daily is 
      associated with a lower rate of bleeding events and ticagrelor withdrawal but 
      does not increase the MACE risk compared with 75-100 mg aspirin daily.
FAU - Li, Jiannan
AU  - Li J
AD  - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences , 
      Beijing, China.
FAU - Sheng, Zhaoxue
AU  - Sheng Z
AD  - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences , 
      Beijing, China.
FAU - Tan, Yu
AU  - Tan Y
AD  - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences , 
      Beijing, China.
FAU - Liu, Chen
AU  - Liu C
AD  - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences , 
      Beijing, China.
FAU - Zhou, Peng
AU  - Zhou P
AD  - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences , 
      Beijing, China.
FAU - Zhou, Jinying
AU  - Zhou J
AD  - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences , 
      Beijing, China.
FAU - Chen, Runzhen
AU  - Chen R
AD  - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences , 
      Beijing, China.
FAU - Chen, Yi
AU  - Chen Y
AD  - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences , 
      Beijing, China.
FAU - Song, Li
AU  - Song L
AD  - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences , 
      Beijing, China.
FAU - Zhao, Hanjun
AU  - Zhao H
AD  - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences , 
      Beijing, China.
FAU - Yan, Hongbing
AU  - Yan H
AD  - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences , 
      Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20191023
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy
MH  - Female
MH  - Hemorrhage/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Prospective Studies
MH  - Ticagrelor/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - bleeding events
OT  - major adverse cardiovascular events
OT  - ticagrelor
EDAT- 2019/10/28 06:00
MHDA- 2021/05/29 06:00
CRDT- 2019/10/25 06:00
PHST- 2019/10/28 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
PHST- 2019/10/25 06:00 [entrez]
AID - 10.1080/09537104.2019.1680825 [doi]
PST - ppublish
SO  - Platelets. 2020 Aug 17;31(6):788-794. doi: 10.1080/09537104.2019.1680825. Epub 
      2019 Oct 23.

PMID- 34633837
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20220614
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 174
IP  - 10
DP  - 2021 Oct
TI  - Would You Recommend Aspirin to This Patient for Primary Prevention of 
      Atherosclerotic Cardiovascular Disease? : Grand Rounds Discussion From Beth 
      Israel Deaconess Medical Center.
PG  - 1439-1446
LID - 10.7326/M21-2596 [doi]
AB  - Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death 
      in the United States. Reducing ASCVD risk through primary prevention strategies 
      has been shown to be effective; however, the role of aspirin in primary 
      prevention remains unclear. The decision to recommend aspirin has been limited by 
      the difficulty clinicians and patients face when trying to balance benefits and 
      harms. In 2016, the U.S. Preventive Services Task Force addressed this issue by 
      determining the risk level at which prophylactic aspirin generally becomes more 
      favorable, recommending aspirin above a risk cut point (>10% estimated ASCVD 
      risk). In 2019, the American College of Cardiology and the American Heart 
      Association issued a guideline on the primary prevention of CVD that recommends 
      low-dose aspirin might be considered for the primary prevention of ASCVD among 
      select adults aged 40 to 70 years who are at higher ASCVD risk but not at 
      increased risk for bleeding. Here, 2 experts discuss how to apply this guideline 
      in general and to a patient in particular while answering the following 
      questions: How do you assess ASCVD risk, and what is the role, if any, of the 
      coronary artery calcium score?; At what risk threshold of benefits and harms 
      would you recommend aspirin or not?; and How do you help a patient come to a 
      decision about starting or stopping aspirin therapy?
FAU - Burns, Risa B
AU  - Burns RB
AD  - Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, 
      Massachusetts (R.B.B., Z.K.).
FAU - Pignone, Michael
AU  - Pignone M
AD  - Dell Medical School, The University of Texas at Austin, Austin, Texas (M.P.).
FAU - Michos, Erin D
AU  - Michos ED
AUID- ORCID: 0000-0002-5547-5084
AD  - Johns Hopkins University School of Medicine, Baltimore, Maryland (E.D.M.).
FAU - Kanjee, Zahir
AU  - Kanjee Z
AUID- ORCID: 0000-0001-9287-4503
AD  - Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, 
      Massachusetts (R.B.B., Z.K.).
LA  - eng
PT  - Clinical Conference
PT  - Journal Article
DEP - 20211012
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atherosclerosis/*prevention & control
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention/*methods
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2021/10/12 06:00
MHDA- 2021/11/09 06:00
CRDT- 2021/10/11 17:10
PHST- 2021/10/12 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
PHST- 2021/10/11 17:10 [entrez]
AID - 10.7326/M21-2596 [doi]
PST - ppublish
SO  - Ann Intern Med. 2021 Oct;174(10):1439-1446. doi: 10.7326/M21-2596. Epub 2021 Oct 
      12.

PMID- 6348718
OWN - NLM
STAT- MEDLINE
DCOM- 19830909
LR  - 20131121
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - Spec No
DP  - 1983 May
TI  - Piroxicam in osteoarthritis: a controlled long-term study.
PG  - 32-40
AB  - This six-month double-blind, parallel-design study compared the efficacy and 
      safety of piroxicam 20 mg and 40 mg with that of 12 tablets of aspirin in 29 
      patients with osteoarthritis and demonstrated that both piroxicam doses were 
      superior to aspirin in the treatment of osteoarthritis with respect to 
      physicians' opinion of improvement and ease of movement. The safety of piroxicam 
      20 mg and aspirin were comparable, with gastrointestinal side effects being the 
      most prevalent adverse effect. Patients receiving piroxicam are continuing in a 
      five-year efficacy and safety study.
FAU - Zizic, T M
AU  - Zizic TM
FAU - Stevens, M B
AU  - Stevens MB
FAU - Sutton, J D
AU  - Sutton JD
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Thiazines)
RN  - 13T4O6VMAM (Piroxicam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Piroxicam
MH  - Thiazines/adverse effects/*therapeutic use
EDAT- 1983/05/01 00:00
MHDA- 1983/05/01 00:01
CRDT- 1983/05/01 00:00
PHST- 1983/05/01 00:00 [pubmed]
PHST- 1983/05/01 00:01 [medline]
PHST- 1983/05/01 00:00 [entrez]
PST - ppublish
SO  - Postgrad Med. 1983 May;Spec No:32-40.

PMID- 479385
OWN - NLM
STAT- MEDLINE
DCOM- 19791128
LR  - 20190823
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 19
IP  - 7
DP  - 1979 Jul
TI  - The clinical analgesic efficacy of oral nefopam hydrochloride.
PG  - 395-402
AB  - The analgesic efficacy of 60 and 120 mg nefopam hydrochloride was compared to 650 
      mg aspirin and placebo in a double-blind single-dose study. Oral doses were 
      administered to 120 patients suffering from acute postsurgical or fracture pain. 
      All active medications demonstrated analgesic activity in comparison to placebo. 
      Patients on 120 mg nefopam obtained the greatest degree of analgesia. Side 
      effects were minor and did not interfere with the course of therapy. The 
      incidence of side effects (sweating, nausea, and lightheadedness) was greater on 
      120 mg nefopam than on 650 mg aspirin).
FAU - Wang, R I
AU  - Wang RI
FAU - Waite, E M
AU  - Waite EM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Oxazocines)
RN  - 0 (Placebos)
RN  - 4UP8060B7J (Nefopam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Nefopam/adverse effects/*therapeutic use
MH  - Oxazocines/*therapeutic use
MH  - Pain/*drug therapy
MH  - Placebos
MH  - Time Factors
EDAT- 1979/07/01 00:00
MHDA- 1979/07/01 00:01
CRDT- 1979/07/01 00:00
PHST- 1979/07/01 00:00 [pubmed]
PHST- 1979/07/01 00:01 [medline]
PHST- 1979/07/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1979.tb02498.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1979 Jul;19(7):395-402. doi: 
      10.1002/j.1552-4604.1979.tb02498.x.

PMID- 4031819
OWN - NLM
STAT- MEDLINE
DCOM- 19851007
LR  - 20131121
IS  - 0022-1198 (Print)
IS  - 0022-1198 (Linking)
VI  - 30
IP  - 3
DP  - 1985 Jul
TI  - Fatal in utero salicylism.
PG  - 942-4
AB  - An aspirin overdose by an eight-month primigravida proved to be the mechanism of 
      death for the fetus. Clinical progress of the mother and postmortem 
      concentrations of salicylate in the fetus are listed exhibiting the fetal 
      survival time of about 18 to 20 h post ingestion by the mother.
FAU - Rejent, T A
AU  - Rejent TA
FAU - Baik, S
AU  - Baik S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Forensic Sci
JT  - Journal of forensic sciences
JID - 0375370
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/blood/*poisoning
MH  - Female
MH  - Fetal Death/*chemically induced
MH  - Gestational Age
MH  - Humans
MH  - *Maternal-Fetal Exchange
MH  - Pregnancy
MH  - Suicide, Attempted/*legislation & jurisprudence
EDAT- 1985/07/01 00:00
MHDA- 1985/07/01 00:01
CRDT- 1985/07/01 00:00
PHST- 1985/07/01 00:00 [pubmed]
PHST- 1985/07/01 00:01 [medline]
PHST- 1985/07/01 00:00 [entrez]
PST - ppublish
SO  - J Forensic Sci. 1985 Jul;30(3):942-4.

PMID- 3149152
OWN - NLM
STAT- MEDLINE
DCOM- 19890503
LR  - 20170214
IS  - 0363-5465 (Print)
IS  - 0363-5465 (Linking)
VI  - 16
IP  - 6
DP  - 1988 Nov-Dec
TI  - Comparison of diclofenac sodium and aspirin in the treatment of acute sports 
      injuries.
PG  - 656-9
AB  - A randomized, double-blind, parallel-group clinical trial compared diclofenac 
      sodium (Voltaren, Ciba-Geigy Summit, NJ) with aspirin for the treatment of acute 
      sprains and/or strains of the knee or ankle. One hundred thirty-nine patients 
      were admitted to the study. Patients received either 150 mg (75 mg twice daily) 
      of diclofenac (N = 69) or 3.6 g (1.2 g three times daily) of aspirin (N = 70) for 
      3 to 10 days. Forty-seven diclofenac patients and 49 aspirin patients, mean age 
      for both groups 25 years, were evaluated to determine the efficacy of each 
      treatment. Both groups experienced significant (P less than 0.001) improvements 
      for all efficacy variables measured. Treating sprains and strains with diclofenac 
      rather than with aspirin allowed an earlier return to activity. Of those patients 
      who achieved playing fitness, those in the diclofenac group resumed athletic 
      activities in a mean of 4.7 days, compared with a mean of 5.9 days for patients 
      in the aspirin group. Although the overall multivariate F was nonsignificant (P = 
      0.19), the univariate F for days required to resume playing fitness was 
      significantly (P = 0.025) shorter in the diclofenac group. While the 
      nonsignificant multivariate result suggests that the significance may be due to 
      chance, it is also possible that there was a trend toward earlier resumption of 
      activities with diclofenac treatment compared to aspirin, but an insufficient 
      sample size to demonstrate the trend statistically. Since others have reported 
      such a trend without the greater controls of a multivariate analysis, this area 
      warrants further research.
FAU - Duncan, J J
AU  - Duncan JJ
FAU - Farr, J E
AU  - Farr JE
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Sports Med
JT  - The American journal of sports medicine
JID - 7609541
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Ankle Injuries
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Athletic Injuries/*drug therapy
MH  - Clinical Trials as Topic
MH  - Diclofenac/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Knee Injuries/drug therapy
MH  - Male
MH  - Middle Aged
EDAT- 1988/11/01 00:00
MHDA- 1988/11/01 00:01
CRDT- 1988/11/01 00:00
PHST- 1988/11/01 00:00 [pubmed]
PHST- 1988/11/01 00:01 [medline]
PHST- 1988/11/01 00:00 [entrez]
AID - 10.1177/036354658801600618 [doi]
PST - ppublish
SO  - Am J Sports Med. 1988 Nov-Dec;16(6):656-9. doi: 10.1177/036354658801600618.

PMID- 6579709
OWN - NLM
STAT- MEDLINE
DCOM- 19831220
LR  - 20191031
IS  - 0896-0569 (Print)
IS  - 0896-0569 (Linking)
VI  - 4
DP  - 1983
TI  - Relevance to redesigning aspirin therapeutic regimens.
PG  - 163-70
AB  - The quantitative relationship between the plasma aspirin (ASA) concentrations and 
      the various responses have not been established in man. Nevertheless, available 
      information would suggest that the pharmacodynamic Emax model adequately 
      describes both the inhibition of TxB2 production by ASA and the competitive role 
      of salicylic acid (SA) in the reaction. Available pharmacokinetic data can be 
      used to predict plasma ASA and SA levels following different ASA dosing regimen. 
      Such information can be useful in designing prospective studies and managing 
      patients who receive ASA.
FAU - Thiessen, J J
AU  - Thiessen JJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res Suppl
JT  - Thrombosis research. Supplement
JID - 8309239
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/blood
MH  - Drug Administration Schedule
MH  - Humans
MH  - Kinetics
MH  - Models, Biological
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1016/0049-3848(83)90372-9 [doi]
PST - ppublish
SO  - Thromb Res Suppl. 1983;4:163-70. doi: 10.1016/0049-3848(83)90372-9.

PMID- 305723
OWN - NLM
STAT- MEDLINE
DCOM- 19780517
LR  - 20190716
IS  - 0002-9629 (Print)
IS  - 0002-9629 (Linking)
VI  - 274
IP  - 3
DP  - 1977 Nov-Dec
TI  - Acute toxicity of aspirin in hospitalized medical patients.
PG  - 271-9
AB  - Among 2,391 recipients of plain aspirin tablets, 121 (5.1%) were reported to have 
      adverse reactions. Minor gastrointestinal disturbances, particularly heartburn 
      and nausea, were most common (2.1%). Central nervous system effects were second 
      (1.2%). Among these, tinnitus was reported most often (0.8%); deafness occurred 
      in eight patients (0.3%). Gastrointestinal bleeding, the third major category of 
      adverse reactions, occurred in 1.0% of recipients; it was not considered serious 
      in any of the patients with reactions judged "definitely" or "probably" related 
      to aspirin. The frequency of all adverse reactions increased as the unit dose, 
      daily dose and total dose became larger. Deafness occurred only at high doses. 
      Reactions were more common in females.
FAU - Miller, R R
AU  - Miller RR
FAU - Jick, H
AU  - Jick H
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Deafness/chemically induced
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Sex Factors
MH  - Tinnitus/chemically induced
EDAT- 1977/11/01 00:00
MHDA- 1977/11/01 00:01
CRDT- 1977/11/01 00:00
PHST- 1977/11/01 00:00 [pubmed]
PHST- 1977/11/01 00:01 [medline]
PHST- 1977/11/01 00:00 [entrez]
AID - 10.1097/00000441-197711000-00005 [doi]
PST - ppublish
SO  - Am J Med Sci. 1977 Nov-Dec;274(3):271-9. doi: 10.1097/00000441-197711000-00005.

PMID- 9366162
OWN - NLM
STAT- MEDLINE
DCOM- 19980120
LR  - 20131121
IS  - 0301-1542 (Print)
IS  - 0301-1542 (Linking)
VI  - 35
IP  - 8
DP  - 1997 Aug
TI  - [Acute eosinophilic pneumonia associated with aspirin].
PG  - 873-7
AB  - A 21-year-old man was admitted to our hospital with acute progressive dyspnea and 
      a high fever. He had started smoking 6 weeks before admission. A chest radiograph 
      showed diffuse infiltrates with Kerley B lines and bilateral pleural effusions. 
      There was no evidence of infection. His condition improved rapidly and without 
      medication. On admission the concentrations of interleukin-5 in bronchoalveolar 
      lavage fluid and in blood were high, but they were normal one week later. Acute 
      eosinophilic pneumonia was diagnosed. A positive result of a lymphocyte 
      stimulation test indicated that the development of symptoms was closely 
      associated with ingestion of aspirin. We know of no previous report of acute 
      eosinophilic pneumonia associated with aspirin.
FAU - Uchida, K
AU  - Uchida K
AD  - Department of Respirology, Inada-Nobovito Hospital.
FAU - Sekiguchi, S
AU  - Sekiguchi S
FAU - Matsuda, K
AU  - Matsuda K
FAU - Kurihara, Y
AU  - Kurihara Y
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Kyobu Shikkan Gakkai Zasshi
JT  - Nihon Kyobu Shikkan Gakkai zasshi
JID - 7505737
RN  - 0 (Interleukin-5)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aspirin/*adverse effects/immunology
MH  - Bronchoalveolar Lavage Fluid/chemistry
MH  - Humans
MH  - Interleukin-5/metabolism
MH  - Lymphocyte Activation
MH  - Male
MH  - Pulmonary Eosinophilia/*chemically induced
EDAT- 1997/08/01 00:00
MHDA- 1997/11/20 00:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 1997/11/20 00:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
PST - ppublish
SO  - Nihon Kyobu Shikkan Gakkai Zasshi. 1997 Aug;35(8):873-7.

PMID- 30219678
OWN - NLM
STAT- MEDLINE
DCOM- 20190314
LR  - 20190314
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 108
DP  - 2018 Dec
TI  - Metabolism of liver CYP450 and ultrastructural changes after long-term 
      administration of aspirin and ibuprofen.
PG  - 208-215
LID - S0753-3322(18)34044-7 [pii]
LID - 10.1016/j.biopha.2018.08.162 [doi]
AB  - Worldwide, aspirin and ibuprofen are the most commonly used non-steroidal 
      anti-inflammatory drugs (NSAIDs). Some adverse reactions, including 
      gastrointestinal reactions, have been concerned extensively. Nevertheless, the 
      mechanism of liver injury remains unclear. In the present study, we focused on 
      the metabolism of liver cytochrome P450 (CYP450) and ultrastructural morphology 
      of liver cells. A total of thirty rats were divided into three groups of 10. Rats 
      in the aspirin and ibuprofen groups were given enteric-coated aspirin (15 mg/kg) 
      and ibuprofen (15 mg/kg), respectively by gavage for four weeks. The body weights 
      were recorded every two days. Liver function and metabolic capacity of CYP450 
      were studied on days 14 and 28. We then conducted ultrastructural examinations. 
      Body weights in the Ibuprofen group were lower than those of the Control group, 
      and ALT and AST levels were significantly higher (P < 0.05). There were no 
      significant differences in terms of body weight, ALT or AST between the Aspirin 
      and Control groups. The metabolic capacity of CYP450 was evaluated using five 
      probe drugs, phenacetin, tolbutamide, metoprolol, midazolam, and bupropion. We 
      found that ibuprofen and aspirin induced metabolism of the probe drugs. Moreover, 
      according to the pharmacokinetic data, the Control, Aspirin and Ibuprofen groups 
      could be discriminated accurately. Ultrastructural examination showed that the 
      number of mitochondria was increased in both the Ibuprofen and Aspirin groups. 
      Long-term administration of enteric-coated aspirin and ibuprofen induced the 
      metabolic activity of the CYP450 enzyme. Aspirin had better tolerability than did 
      ibuprofen, as reflected by pharmacokinetic data of probe drug metabolism.
CI  - Copyright © 2018. Published by Elsevier Masson SAS.
FAU - Wen, Congcong
AU  - Wen C
AD  - Laboratory Animal Center, Wenzhou Medical University, Wenzhou 325035, China.
FAU - Zhuang, Zaishou
AU  - Zhuang Z
AD  - Department of Intensive Care Unit, Cangnan People's Hospital, Wenzhou 325000, 
      China.
FAU - Song, Huanchun
AU  - Song H
AD  - Department of Pharmacy, Jinhua Municipal Central Hospital, Jinhua, China.
FAU - Tong, Shuhua
AU  - Tong S
AD  - Department of Pharmacy, Jinhua Municipal Central Hospital, Jinhua, China.
FAU - Wang, Xianchuan
AU  - Wang X
AD  - Laboratory Animal Center, Wenzhou Medical University, Wenzhou 325035, China.
FAU - Lin, Yijing
AU  - Lin Y
AD  - Laboratory Animal Center, Wenzhou Medical University, Wenzhou 325035, China.
FAU - Zhan, Haichao
AU  - Zhan H
AD  - Department of Pharmacy, Jinhua Municipal Central Hospital, Jinhua, China.
FAU - Chen, Zhibin
AU  - Chen Z
AD  - Department of Nephrology, The Affiliated Yueqing Hospital of Wenzhou Medical 
      University, Yueqing, China. Electronic address: czb-888@163.com.
FAU - Hu, Lufeng
AU  - Hu L
AD  - Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou 325000, China. Electronic address: hulufeng79@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20180913
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Body Weight/drug effects
MH  - Cytochrome P-450 Enzyme System/*metabolism
MH  - Discriminant Analysis
MH  - Ibuprofen/administration & dosage/pharmacokinetics/*pharmacology
MH  - Liver/drug effects/*enzymology/*ultrastructure
MH  - Male
MH  - Rats, Sprague-Dawley
OTO - NOTNLM
OT  - Aspirin
OT  - CYP450
OT  - Ibuprofen
OT  - Liver
OT  - Rat
EDAT- 2018/09/17 06:00
MHDA- 2019/03/15 06:00
CRDT- 2018/09/17 06:00
PHST- 2018/06/14 00:00 [received]
PHST- 2018/08/20 00:00 [revised]
PHST- 2018/08/31 00:00 [accepted]
PHST- 2018/09/17 06:00 [pubmed]
PHST- 2019/03/15 06:00 [medline]
PHST- 2018/09/17 06:00 [entrez]
AID - S0753-3322(18)34044-7 [pii]
AID - 10.1016/j.biopha.2018.08.162 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2018 Dec;108:208-215. doi: 10.1016/j.biopha.2018.08.162. 
      Epub 2018 Sep 13.

PMID- 313449
OWN - NLM
STAT- MEDLINE
DCOM- 19790917
LR  - 20190709
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 22
IP  - 6
DP  - 1979 Jun
TI  - Glycerides as prodrugs. 1. Synthesis and antiinflammatory activity of 
      1,3-bis(alkanoyl)-2-(O-acetylsalicyloyl)glycerides (aspirin triglycerides).
PG  - 683-7
AB  - A series of 1,3-bis(alkanoyl)-2-(O-acetylsalicyloyl)glycerides (aspirin 
      triglycerides) having aspirin at the 2 position of glycerol and fatty acids at 
      the 1 and 3 positions was prepared. The compounds were administered orally and 
      tested for efficacy in the rat paw edema test, and the stomachs were examined for 
      the presence of lesions. The results showed that the members of this series in 
      which the fatty acids are of intermediate chain length (C4-C12) do not cause 
      gastric lesions and have essentially all the systemic activity associated with 
      aspirin.
FAU - Paris, G Y
AU  - Paris GY
FAU - Garmaise, D L
AU  - Garmaise DL
FAU - Cimon, D G
AU  - Cimon DG
FAU - Swett, L
AU  - Swett L
FAU - Carter, G W
AU  - Carter GW
FAU - Young, P
AU  - Young P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - 0 (Triglycerides)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*chemical synthesis
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis
MH  - Aspirin/*analogs & derivatives/chemical synthesis/pharmacology
MH  - Carrageenan
MH  - Dose-Response Relationship, Drug
MH  - Edema/chemically induced/physiopathology
MH  - Male
MH  - Rats
MH  - Salicylates/blood
MH  - Stomach Ulcer/chemically induced
MH  - Structure-Activity Relationship
MH  - Time Factors
MH  - Triglycerides/*chemical synthesis/pharmacology
EDAT- 1979/06/01 00:00
MHDA- 1979/06/01 00:01
CRDT- 1979/06/01 00:00
PHST- 1979/06/01 00:00 [pubmed]
PHST- 1979/06/01 00:01 [medline]
PHST- 1979/06/01 00:00 [entrez]
AID - 10.1021/jm00192a014 [doi]
PST - ppublish
SO  - J Med Chem. 1979 Jun;22(6):683-7. doi: 10.1021/jm00192a014.

PMID- 8321817
OWN - NLM
STAT- MEDLINE
DCOM- 19930803
LR  - 20200313
IS  - 0032-5791 (Print)
IS  - 0032-5791 (Linking)
VI  - 72
IP  - 6
DP  - 1993 Jun
TI  - Response of layer breeders to dietary acetylsalicylic acid. 3. Effects on 
      fertility and hatchability of embryos exposed to control and elevated incubation 
      temperatures.
PG  - 1100-8
AB  - Because acetylsalicylic acid (ASA, aspirin) is a common antipyretic drug, there 
      has been considerable research on the effects of ASA on mammalian embryonic 
      development. However, very limited research has been conducted on the effects of 
      ASA on avian development and hatchability. The present study investigated the 
      effect of dietary ASA on fertility and hatchability and whether embryos of 
      breeder hens fed ASA, as compared with embryos of hens fed a control diet, would 
      survive elevated temperatures during incubation. White Leghorn layer breeders 
      were fed 0, .025, .050, .100, .200, and .400% ASA for the first 13 mo of egg 
      production. When averaged over 13 mo, hens fed .40% dietary ASA demonstrated a 
      decline in fertility (P < .03), hatchability of fertile eggs (P < .04), and 
      hatchability of eggs set (P < .02). Chicks from hens fed .10% ASA weighed more 
      than chicks from hens receiving 0, .025, .20, or .40% ASA (P < .01). When embryos 
      were incubated at elevated temperatures of 42.8 or 43.3 C for 5.5 to 12 h on Day 
      16 of incubation, hatchability declined. Also, ASA fed to layer breeders did not 
      improve hatchability of embryos exposed to elevated incubation temperatures when 
      compared with embryos exposed to a control incubation temperature (37.2 C). 
      During Month 9 of production, chicks from hens fed .05 and .10% ASA and exposed 
      to an elevated temperature of 42.8 C for 9 h on Day 16 of incubation weighed more 
      than similarly heat-stressed chicks of hens fed 0, .20, or .40% ASA (temperature 
      by diet interaction, P < .03).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - McDaniel, C D
AU  - McDaniel CD
AD  - Department of Animal Sciences, Purdue University, West Lafayette, Indiana 47907.
FAU - Balog, J M
AU  - Balog JM
FAU - Freed, M
AU  - Freed M
FAU - Elkin, R G
AU  - Elkin RG
FAU - Wellenreiter, R H
AU  - Wellenreiter RH
FAU - Kuczek, T
AU  - Kuczek T
FAU - Hester, P Y
AU  - Hester PY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Poult Sci
JT  - Poultry science
JID - 0401150
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chick Embryo
MH  - Chickens/*physiology
MH  - Diet
MH  - Embryonic and Fetal Development/drug effects
MH  - Female
MH  - Fertility/*drug effects
MH  - Hot Temperature/adverse effects
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - S0032-5791(19)45095-5 [pii]
AID - 10.3382/ps.0721100 [doi]
PST - ppublish
SO  - Poult Sci. 1993 Jun;72(6):1100-8. doi: 10.3382/ps.0721100.

PMID- 29316620
OWN - NLM
STAT- MEDLINE
DCOM- 20180726
LR  - 20191023
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 19
IP  - 1
DP  - 2018 Jan 6
TI  - Could Aspirin and Diets High in Fiber Act Synergistically to Reduce the Risk of 
      Colon Cancer in Humans?
LID - 10.3390/ijms19010166 [doi]
LID - 166
AB  - Early inhibition of inflammation suppresses the carcinogenic process. Aspirin is 
      the most commonly used non-steroid anti-inflammatory drugs (NSAIDs), and it 
      irreversibly inhibits cyclooxygenase-1 and -2 (COX1, COX2). Multiple randomized 
      clinical trials have demonstrated that aspirin offers substantial protection from 
      colon cancer mortality. The lower aspirin doses causing only minimal 
      gastrointestinal disturbance, ideal for long-term use, can achieve only partial 
      and transitory inhibition of COX2. Aspirin's principal metabolite, salicylic 
      acid, is also found in fruits and vegetables that inhibit COX2. Other 
      phytochemicals such as curcumin, resveratrol, and anthocyanins also inhibit COX2. 
      Such dietary components are good candidates for combination with aspirin because 
      they have little or no toxicity. However, obstacles to using phytochemicals for 
      chemoprevention, including bioavailability and translational potential, must be 
      resolved. The bell/U-shaped dose-response curves seen with vitamin D and 
      resveratrol might apply to other phytochemicals, shedding doubt on 'more is 
      better'. Solutions include: (1) using special delivery systems (e.g., 
      nanoparticles) to retain phytochemicals; (2) developing robust pharmacodynamic 
      biomarkers to determine efficacy in humans; and (3) selecting pharmacokinetic 
      doses relevant to humans when performing preclinical experiments. The combination 
      of aspirin and phytochemicals is an attractive low-cost and low-toxicity approach 
      to colon cancer prevention that warrants testing, particularly in high-risk 
      individuals.
FAU - Pan, Pan
AU  - Pan P
AD  - Division of Hematology and Oncology, Department of Medicine, Medical College of 
      Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA. ppan@mcw.edu.
FAU - Huang, Yi-Wen
AU  - Huang YW
AD  - Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, 
      WI 53226, USA. ywhuang@mcw.edu.
FAU - Oshima, Kiyoko
AU  - Oshima K
AD  - Department of Pathology, John Hopkins University, Baltimore, MD 21218, USA. 
      koshima3@jhmi.edu.
FAU - Yearsley, Martha
AU  - Yearsley M
AD  - Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA. 
      martha.yearsley@osumc.edu.
FAU - Zhang, Jianying
AU  - Zhang J
AD  - Center for Biostatistics, The Ohio State University, Columbus, Ohio 43210, USA. 
      jianying.zhang@osumc.edu.
FAU - Yu, Jianhua
AU  - Yu J
AD  - Division of Hematology, Department of Internal Medicine, College of Medicine, 
      Comprehensive Cancer Center and The James Cancer Hospital, The Ohio State 
      University, Columbus, OH 43210, USA. Jianhua.yu@osumc.edu.
FAU - Arnold, Mark
AU  - Arnold M
AD  - Department of Surgery, The Ohio State University, Columbus, OH 43210, USA. 
      arnold.16@osu.edu.
FAU - Wang, Li-Shu
AU  - Wang LS
AD  - Division of Hematology and Oncology, Department of Medicine, Medical College of 
      Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA. liswang@mcw.edu.
LA  - eng
GR  - R01 AI129582/AI/NIAID NIH HHS/United States
GR  - R01 NS106170/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20180106
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Dietary Fiber)
RN  - 0 (Phytochemicals)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Chemoprevention
MH  - Clinical Trials as Topic
MH  - Colonic Neoplasms/pathology/*prevention & control
MH  - Dietary Fiber/*therapeutic use
MH  - Drug Synergism
MH  - Humans
MH  - Phytochemicals/chemistry/therapeutic use
MH  - Prostaglandin-Endoperoxide Synthases/chemistry/metabolism
PMC - PMC5796115
OTO - NOTNLM
OT  - aspirin
OT  - bell/U-shaped
OT  - cancer prevention
OT  - cyclooxygenase 2
OT  - fruits and vegetables
OT  - human clinical trials
OT  - phytochemicals
OT  - salicylic acid
OT  - synergy
COIS- The authors declare no conflict of interest.
EDAT- 2018/01/11 06:00
MHDA- 2018/07/27 06:00
CRDT- 2018/01/11 06:00
PHST- 2017/12/11 00:00 [received]
PHST- 2017/12/30 00:00 [revised]
PHST- 2018/01/04 00:00 [accepted]
PHST- 2018/01/11 06:00 [entrez]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2018/07/27 06:00 [medline]
AID - ijms19010166 [pii]
AID - ijms-19-00166 [pii]
AID - 10.3390/ijms19010166 [doi]
PST - epublish
SO  - Int J Mol Sci. 2018 Jan 6;19(1):166. doi: 10.3390/ijms19010166.

PMID- 7050710
OWN - NLM
STAT- MEDLINE
DCOM- 19821012
LR  - 20170403
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 307
IP  - 12
DP  - 1982 Sep 16
TI  - A controlled comparison of aspirin and oral anticoagulants in prevention of death 
      after myocardial infarction.
PG  - 701-8
AB  - Although neither aspirin nor oral anticoagulants have been conclusively shown to 
      reduce mortality in patients surviving myocardial infarction, both have been 
      widely used for that purpose. In the present clinical trial we compared the 
      effects of aspirin (0.5 g given three times a day) and oral-anticoagulant 
      therapy. Of 6908 patients considered for entry, 1303 were randomized to 
      anticoagulant (652) or aspirin (651) an average of 11.4 days after the onset of 
      myocardial infarction and were followed for 6 to 59 months (mean, 29 months). 
      There were 65 deaths in the anticoagulant group and 72 in the aspirin group. The 
      number of patients with reinfarctions was higher in the aspirin group (33 vs. 
      20). None of these differences were statistically significant. Almost twice as 
      many patients were withdrawn from therapy in the aspirin group. There were 54 per 
      cent more patients with gastrointestinal events in the aspirin group and four 
      times more patients with episodes of severe bleeding in the anticoagulant group. 
      We conclude that aspirin in the dosage used in probably not different from oral 
      anticoagulants in affecting mortality and morbidity after a myocardial 
      infarction. However, this study does not consider the effectiveness of either 
      agent in comparison to no antithrombotic therapy -- an issue that remains 
      unsettled.
CN  - E.P.S.I.M. Research Group
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Death, Sudden
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/*mortality
MH  - Random Allocation
MH  - Recurrence
EDAT- 1982/09/16 00:00
MHDA- 1982/09/16 00:01
CRDT- 1982/09/16 00:00
PHST- 1982/09/16 00:00 [pubmed]
PHST- 1982/09/16 00:01 [medline]
PHST- 1982/09/16 00:00 [entrez]
AID - 10.1056/NEJM198209163071201 [doi]
PST - ppublish
SO  - N Engl J Med. 1982 Sep 16;307(12):701-8. doi: 10.1056/NEJM198209163071201.

PMID- 25466903
OWN - NLM
STAT- MEDLINE
DCOM- 20150811
LR  - 20210109
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 3
DP  - 2014 Dec 3
TI  - Methodological issues and recommendations for systematic reviews of prognostic 
      studies: an example from cardiovascular disease.
PG  - 140
LID - 10.1186/2046-4053-3-140 [doi]
LID - 140
AB  - BACKGROUND: Prognostic factors are associated with the risk of future health 
      outcomes in individuals with a particular health condition. The prognostic 
      ability of such factors is increasingly being assessed in both primary research 
      and systematic reviews. Systematic review methodology in this area is continuing 
      to evolve, reflected in variable approaches to key methodological aspects. The 
      aim of this article was to (i) explore and compare the methodology of systematic 
      reviews of prognostic factors undertaken for the same clinical question, (ii) to 
      discuss implications for review findings, and (iii) to present recommendations on 
      what might be considered to be 'good practice' approaches. METHODS: The sample 
      was comprised of eight systematic reviews addressing the same clinical question, 
      namely whether 'aspirin resistance' (a potential prognostic factor) has 
      prognostic utility relative to future vascular events in patients on aspirin 
      therapy for secondary prevention. A detailed comparison of methods around study 
      identification, study selection, quality assessment, approaches to analysis, and 
      reporting of findings was undertaken and the implications discussed. These were 
      summarised into key considerations that may be transferable to future systematic 
      reviews of prognostic factors. RESULTS: Across systematic reviews addressing the 
      same clinical question, there were considerable differences in the numbers of 
      studies identified and overlap between included studies, which could only 
      partially be explained by different study eligibility criteria. Incomplete 
      reporting and differences in terminology within primary studies hampered study 
      identification and selection process across reviews. Quality assessment was 
      highly variable and only one systematic review considered a checklist for studies 
      of prognostic questions. There was inconsistency between reviews in approaches 
      towards analysis, synthesis, addressing heterogeneity and reporting of results. 
      CONCLUSIONS: Different methodological approaches may ultimately affect the 
      findings and interpretation of systematic reviews of prognostic research, with 
      implications for clinical decision-making.
FAU - Dretzke, Janine
AU  - Dretzke J
AD  - School of Health and Population Sciences, University of Birmingham, Edgbaston, 
      Birmingham B15 2TT, UK. j.dretzke@bham.ac.uk.
FAU - Ensor, Joie
AU  - Ensor J
FAU - Bayliss, Sue
AU  - Bayliss S
FAU - Hodgkinson, James
AU  - Hodgkinson J
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
FAU - Riley, Richard D
AU  - Riley RD
FAU - Fitzmaurice, David
AU  - Fitzmaurice D
FAU - Moore, David
AU  - Moore D
LA  - eng
GR  - 10/36/02/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20141203
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Drug Resistance
MH  - Humans
MH  - *Prognosis
MH  - *Review Literature as Topic
PMC - PMC4265412
EDAT- 2014/12/04 06:00
MHDA- 2015/08/12 06:00
CRDT- 2014/12/04 06:00
PHST- 2014/08/12 00:00 [received]
PHST- 2014/11/13 00:00 [accepted]
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2015/08/12 06:00 [medline]
AID - 2046-4053-3-140 [pii]
AID - 307 [pii]
AID - 10.1186/2046-4053-3-140 [doi]
PST - epublish
SO  - Syst Rev. 2014 Dec 3;3:140. doi: 10.1186/2046-4053-3-140.

PMID- 1762060
OWN - NLM
STAT- MEDLINE
DCOM- 19920207
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 259
IP  - 3
DP  - 1991 Dec
TI  - Presystemic acetylation of platelets by aspirin: reduction in rate of drug 
      delivery to improve biochemical selectivity for thromboxane A2.
PG  - 1043-9
AB  - The utility of aspirin in the treatment of vascular occlusive disease has been 
      ascribed to its blockade of platelet thromboxane A2 (TxA2), a potent inhibitor of 
      vascular smooth muscle contraction and platelet aggregation. Coincident with the 
      inhibition of TxA2 by aspirin at currently used dose regimens is a decrease in 
      formation of prostacyclin (PGI2), an eicosanoid with opposing effects to TxA2 in 
      vivo. The coincident inhibition of PGI2 could potentially limit the therapeutic 
      efficacy of aspirin. This study addressed the issue as to whether a reduction in 
      the rate of drug delivery could enhance the biochemical selectivity of aspirin 
      toward inhibition of TxA2. Intubation studies were performed in parallel groups 
      of healthy volunteers in which a 50-mg aspirin dose was administered as either a 
      bolus or a 5 or 10 mg/hr infusion via a nasogastric tube. A control group 
      received buffer solution. Systemic plasma levels of aspirin, major urinary 
      metabolites of TxA2 and PGI2 and serum thromboxane B2 levels ex vivo were 
      evaluated. Relative to the group receiving bolus aspirin, the slower rates of 
      aspirin delivery increased the effective selectivity of the administered aspirin 
      for TxA2. To investigate further this apparent selectivity, controlled release 
      (CR) dose forms of aspirin were prepared and evaluated in a preliminary 
      dose-ranging study in healthy subjects. The doses studied were 50 and 75 mg CR 
      and a 75-mg aspirin solution. The CR aspirin dose forms decreased the maximal 
      plasma concentration of aspirin relative to a bolus dose. The pharmacodynamic 
      effects of the CR formulations were assessed via measurement of ex vivo serum 
      thromboxane B2 formation.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - FitzGerald, G A
AU  - FitzGerald GA
AD  - Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee.
FAU - Lupinetti, M
AU  - Lupinetti M
FAU - Charman, S A
AU  - Charman SA
FAU - Charman, W N
AU  - Charman WN
LA  - eng
GR  - GM07569/GM/NIGMS NIH HHS/United States
GR  - HL 30400/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Delayed-Action Preparations)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/blood/pharmacokinetics/*pharmacology
MH  - Blood Platelets/drug effects/*metabolism
MH  - Delayed-Action Preparations
MH  - Dose-Response Relationship, Drug
MH  - Drug Delivery Systems/methods
MH  - Duodenum/metabolism
MH  - Humans
MH  - Intestinal Absorption
MH  - Liver/metabolism
MH  - Male
MH  - Thromboxane A2/*biosynthesis
MH  - Thromboxane B2/blood
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1991 Dec;259(3):1043-9.

PMID- 12387809
OWN - NLM
STAT- MEDLINE
DCOM- 20030211
LR  - 20131121
IS  - 1521-6942 (Print)
IS  - 1521-6942 (Linking)
VI  - 16
IP  - 3
DP  - 2002 Jul
TI  - Controversies in the management of Kawasaki disease.
PG  - 427-42
AB  - While there is a generally accepted standard approach to the management of 
      Kawasaki disease (KD) in North America, controversy still exists regarding 
      certain aspects of treatment. Do all patients require treatment with intravenous 
      immunoglobulin (IVIG)? What is the appropriate dose of aspirin (ASA) during the 
      acute phase of the disease? Is there a role for corticosteroids in those who fail 
      IVIG? How should patients with atypical, incomplete or late presentations of KD 
      be managed? What is the appropriate long-term management and follow-up, 
      particularly for those without coronary artery abnormalities (CAA)? Is there a 
      role for surgical intervention, particularly transplantation? These questions, 
      among others, are explored with reference to the pertinent literature.IVIG has 
      been well studied and shown to be efficacious in a number of studies and in two 
      meta-analyses, with clear evidence to support the use of 2g/kg in a single dose. 
      The appropriate dose of ASA during the acute phase is less clear but, 
      increasingly, data suggest that lower doses of ASA are adequate and perhaps more 
      appropriate. Corticosteroids appear to have a role in those who have failed IVIG 
      but this requires further study before being embraced as accepted treatment. The 
      management of less typical presentations of KD remains controversial, with 
      inadequate data to direct us, although there is a general trend towards treating 
      such patients with IVIG. Careful follow-up of all patients is recommended and, 
      while there are guidelines for this, there is no clear consensus on the most 
      appropriate monitoring investigations for those with and without CAA. There is an 
      expanding role for transplantation, with clearly defined indications for this 
      intervention.
FAU - Lang, Bianca
AU  - Lang B
AD  - Division of Rheumatology, IWK Health Centre, 5850 University Ave, Halifax, Nova 
      Scotia Canada.
FAU - Duffy, Ciaran M
AU  - Duffy CM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Rheumatol
JT  - Best practice & research. Clinical rheumatology
JID - 101121149
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Child
MH  - Dose-Response Relationship, Drug
MH  - Follow-Up Studies
MH  - Glucocorticoids/therapeutic use
MH  - Heart Transplantation
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Mucocutaneous Lymph Node Syndrome/*therapy
RF  - 65
EDAT- 2002/10/22 04:00
MHDA- 2003/02/13 04:00
CRDT- 2002/10/22 04:00
PHST- 2002/10/22 04:00 [pubmed]
PHST- 2003/02/13 04:00 [medline]
PHST- 2002/10/22 04:00 [entrez]
AID - S152169420290238X [pii]
PST - ppublish
SO  - Best Pract Res Clin Rheumatol. 2002 Jul;16(3):427-42.

PMID- 30336320
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1879-1298 (Electronic)
IS  - 0045-6535 (Linking)
VI  - 215
DP  - 2019 Jan
TI  - Statistical optimization of preparing marine macroalgae derived activated 
      carbon/iron oxide magnetic composites for sequestering acetylsalicylic acid from 
      aqueous media using response surface methodologys.
PG  - 432-443
LID - S0045-6535(18)31924-6 [pii]
LID - 10.1016/j.chemosphere.2018.10.069 [doi]
AB  - This study focuses on the optimization of synthetic conditions for preparing 
      marine macroalgae-derived activated carbon/iron oxide magnetic composites 
      (AC/Fe-MC) and its feasibility for the removal of acetylsalicylic acid from 
      aqueous media. Response surface methodology coupled with a 3(k) Box-Behnken 
      design was applied to determine the optimal conditions (independent variables: 
      impregnation ratio, activation temperature, and activation time) towards two 
      response variables (production yield and adsorption capacity). According to the 
      analysis of variance and numerical desirability function approaches, the optimal 
      conditions were impregnation ratio of 2.62:1, activation temperature of 727 °C, 
      and activation time of 129 min. Physicochemical properties of the prepared 
      composite revealed that AC/Fe-MC possesses a porous structure and 
      superparamagnetic property, which substantially contributed to the effective 
      adsorption capacity and separation from the solution using an external magnetic 
      field. Adsorption kinetics and equilibrium studies delineated that the 
      pseudo-second-order and Sips isotherm models represent the adsorption behavior of 
      AC/Fe-MC accurately. The maximum adsorption capacity of AC/Fe-MC was found to be 
      around 127 mg/g at 10 °C, as fitted by Sips isotherm model, which is higher than 
      that of other adsorbents reported in the literature. Intraparticle diffusion and 
      Boyd models suggested that the adsorption process was mainly controlled by film 
      diffusion mechanism. Lastly, thermodynamic and isosteric heat of adsorption 
      analyses demonstrated that the adsorption process was controlled by physisorption 
      and exothermic mechanisms.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Jung, Kyung-Won
AU  - Jung KW
AD  - Center for Water Resources Cycle Research, Korea Institute of Science and 
      Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, Republic of Korea.
FAU - Choi, Brian Hyun
AU  - Choi BH
AD  - Center for Water Resources Cycle Research, Korea Institute of Science and 
      Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, Republic of Korea; 
      Division of Energy and Environmental Engineering, KIST School, Korea University 
      of Science and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, 
      Republic of Korea.
FAU - Song, Kyung Guen
AU  - Song KG
AD  - Center for Water Resources Cycle Research, Korea Institute of Science and 
      Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, Republic of Korea; 
      Division of Energy and Environmental Engineering, KIST School, Korea University 
      of Science and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, 
      Republic of Korea.
FAU - Choi, Jae-Woo
AU  - Choi JW
AD  - Center for Water Resources Cycle Research, Korea Institute of Science and 
      Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, Republic of Korea; 
      Division of Energy and Environmental Engineering, KIST School, Korea University 
      of Science and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul, 02792, 
      Republic of Korea. Electronic address: plead36@kist.re.kr.
LA  - eng
PT  - Journal Article
DEP - 20181012
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - 0 (Water Pollutants, Chemical)
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Aspirin/analysis/*isolation & purification
MH  - Charcoal/chemistry
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Magnetics
MH  - Porosity
MH  - Seaweed/*chemistry
MH  - Thermodynamics
MH  - Water Pollutants, Chemical/analysis/*isolation & purification
MH  - Water Purification/methods
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Adsorption
OT  - Magnetic composites
OT  - Response surface methodology
OT  - Superparamagnetic
EDAT- 2018/10/20 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/10/19 06:00
PHST- 2018/06/26 00:00 [received]
PHST- 2018/10/10 00:00 [revised]
PHST- 2018/10/11 00:00 [accepted]
PHST- 2018/10/20 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/10/19 06:00 [entrez]
AID - S0045-6535(18)31924-6 [pii]
AID - 10.1016/j.chemosphere.2018.10.069 [doi]
PST - ppublish
SO  - Chemosphere. 2019 Jan;215:432-443. doi: 10.1016/j.chemosphere.2018.10.069. Epub 
      2018 Oct 12.

PMID- 26803084
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20160124
IS  - 0888-5109 (Print)
IS  - 0888-5109 (Linking)
VI  - 31
IP  - 1
DP  - 2016 Jan
TI  - Aspirin Use for the Primary Prevention of Cardiovascular Disease in the Elderly.
PG  - 24-32
LID - 10.4140/TCP.n.2016.24 [doi]
AB  - OBJECTIVE: This article aims to use the available evidence assessing aspirin for 
      primary prevention of cardiovascular (CV) events in the elderly to determine its 
      appropriate use. DATA SOURCES: A literature search of clinical trials and 
      meta-analyses was conducted using MEDLINE and PubMed with the search terms 
      aspirin, bleeding, CV events, elderly, geriatrics, hemorrhage, myocardial 
      infarction (MI), primary prevention, and stroke. STUDY SELECTION/DATA EXTRACTION: 
      Twelve hundred fourteen (1,214) articles were initially found, and 55 were 
      reviewed. These articles assessed the use of aspirin for primary prevention of CV 
      events. Only trials comparing aspirin with placebo, a non-antiplatelet, or a 
      non-anticoagulant were included in this review. Of the articles reviewed, 10 met 
      the stated criteria. DATA SYNTHESIS: It is well documented that the risk of CV 
      events increases as patients age. Primary prevention of these events with aspirin 
      may be beneficial in some patients. Currently, a specific recommendation for the 
      use of aspirin for primary prevention in the geriatric population is not 
      available. This paper reviews the available evidence for primary prevention of CV 
      disease. This population is under-represented in the literature, making it 
      challenging to apply the study findings. CONCLUSION: Aspirin may be considered 
      for the primary prevention of CV events in the elderly population. Because of the 
      lack of data in patients 80 years of age and older, it is difficult to make a 
      decision on the initiation of aspirin therapy in this population. Additional 
      research is necessary to better balance the risk versus benefit of this treatment 
      option.
FAU - Sarbacker, G Blair
AU  - Sarbacker GB
AD  - Feik School of Pharmacy, University of the Incarnate Word, San Antonio, Texas, 
      USA.
FAU - Lusk, Kathleen A
AU  - Lusk KA
FAU - Flieller, Lauren A
AU  - Flieller LA
FAU - Van Liew, Jeffrey R
AU  - Van Liew JR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant 
      Pharmacists
JID - 9013983
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Primary Prevention
EDAT- 2016/01/24 06:00
MHDA- 2016/08/30 06:00
CRDT- 2016/01/24 06:00
PHST- 2016/01/24 06:00 [entrez]
PHST- 2016/01/24 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - 10.4140/TCP.n.2016.24 [doi]
PST - ppublish
SO  - Consult Pharm. 2016 Jan;31(1):24-32. doi: 10.4140/TCP.n.2016.24.

PMID- 17208597
OWN - NLM
STAT- MEDLINE
DCOM- 20070313
LR  - 20131121
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 119
IP  - 1
DP  - 2007 Jan
TI  - Selection of aspirin dosages for aspirin desensitization treatment in patients 
      with aspirin-exacerbated respiratory disease.
PG  - 157-64
AB  - BACKGROUND: Aspirin desensitization followed by daily aspirin therapy is 
      effective add-on treatment for patients with aspirin-exacerbated respiratory 
      disease. Prior studies used 650 mg of aspirin twice daily, but studies at lower 
      dosages were inconclusive. OBJECTIVE: We sought to determine the optimal daily 
      dosage of aspirin treatment. METHODS: We studied 137 patients who had undergone 
      successful aspirin desensitization and randomized them into 2 groups, 650 mg 
      twice daily versus 325 mg twice daily. After 1 month, patients either increased 
      or decreased their dosage based on their symptom control and continued that 
      dosage for the remainder of the year. RESULTS: Patients taking either 650 mg 
      twice daily or 325 mg twice daily showed significant improvements in number of 
      sinus infections, sinus operations, and hospitalizations for asthma (all P < 
      .0001). Anosmia, nasal/sinus symptoms, and asthma symptoms also improved in both 
      groups (all P < .03). Systemic corticosteroid dosages decreased by 3- and 4-fold 
      in the 325 mg twice daily and 650 mg twice daily groups, respectively. Of the 137 
      patients, 32 had adverse effects from or discontinued aspirin therapy: 14 (44%) 
      of 32 from the group randomized to taking 650 mg twice daily and 18 (56%) of 32 
      from the group randomized to 325 mg twice daily. The most common adverse effect 
      was dyspepsia. CONCLUSION: Both dosages were efficacious, and side effects 
      occurred in both groups at similar frequencies. Some patients initially taking 
      325 mg twice daily required an increase to 650 mg twice daily for optimal symptom 
      control. CLINICAL IMPLICATIONS: We recommend that patients begin daily aspirin 
      therapy with 650 mg twice daily and subsequently decrease to the lowest effective 
      dosage (usually 325 mg twice daily).
FAU - Lee, Jennifer Y
AU  - Lee JY
AD  - Division of Allergy, Asthma and Immunology, Scripps Clinic, La Jolla, CA 92037, 
      USA.
FAU - Simon, Ronald A
AU  - Simon RA
FAU - Stevenson, Donald D
AU  - Stevenson DD
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20061113
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/immunology
MH  - Aspirin/*administration & dosage/adverse effects/immunology
MH  - *Desensitization, Immunologic
MH  - Humans
MH  - Respiratory Tract Diseases/chemically induced/*therapy
MH  - Treatment Outcome
EDAT- 2007/01/09 09:00
MHDA- 2007/03/14 09:00
CRDT- 2007/01/09 09:00
PHST- 2006/06/14 00:00 [received]
PHST- 2006/09/05 00:00 [revised]
PHST- 2006/09/08 00:00 [accepted]
PHST- 2007/01/09 09:00 [pubmed]
PHST- 2007/03/14 09:00 [medline]
PHST- 2007/01/09 09:00 [entrez]
AID - S0091-6749(06)01911-7 [pii]
AID - 10.1016/j.jaci.2006.09.011 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2007 Jan;119(1):157-64. doi: 10.1016/j.jaci.2006.09.011. 
      Epub 2006 Nov 13.

PMID- 7948633
OWN - NLM
STAT- MEDLINE
DCOM- 19941221
LR  - 20151119
IS  - 0067-8856 (Print)
IS  - 0067-8856 (Linking)
VI  - 30
DP  - 1994
TI  - A ceramic system for continuous release of acetylsalicylic acid.
PG  - 175-80
AB  - This investigation was conducted to study the release of acetylsalicylic acid 
      (ASA) from a beta-Tricalcium Phosphate (TCP) resorbable ceramic matrix (RCM) in 
      Tris-HCl (pH 7.4, 0.5M) at 37 degrees C. Initial compression load studies were 
      conducted for 12 hours. Compression load and dose-response studies were conducted 
      for a total duration of seven days. Mixtures of 150 mg acetylsalicylic acid 
      (Aspirin) and 500 mg TCP were compressed at loads of 2000, 3000, or 4000 lbs. 
      Ceramics with 75, 150, 225, 300, or 375 mg of ASA were mixed with 500 mg TCP and 
      compressed at 3000 lbs. Aliquots of Tris-HCl, taken at two hour intervals for the 
      first 12 hours, and daily thereafter, were assayed spectrophotometrically for ASA 
      at 245 nm. Differences in the amounts of ASA released by RCMs compressed at the 
      three loads were not significant. Release of ASA from RCMs was linear only if the 
      ceramic/ASA ratio was close to 6.67:1. Results of this investigation suggest that 
      resorbable TCP ceramics can be used for continuous delivery of ASA for seven 
      days.
FAU - Moldovan, K M
AU  - Moldovan KM
AD  - University of Dayton, OH 45469-2320.
FAU - Bajpai, P K
AU  - Bajpai PK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biomed Sci Instrum
JT  - Biomedical sciences instrumentation
JID - 0140524
RN  - 0 (Calcium Phosphates)
RN  - 0 (Drug Implants)
RN  - 0 (alpha-tricalcium phosphate)
RN  - 0 (tetracalcium phosphate)
RN  - 701EKV9RMN (calcium phosphate, monobasic, anhydrous)
RN  - 97Z1WI3NDX (calcium phosphate)
RN  - L11K75P92J (calcium phosphate, dibasic, anhydrous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - *Calcium Phosphates
MH  - *Ceramics
MH  - Drug Implants
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Biomed Sci Instrum. 1994;30:175-80.

PMID- 31820360
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
VI  - 52
IP  - 2
DP  - 2020 Feb
TI  - Is there a cardiovascular protective effect of aspirin in chronic kidney disease 
      patients? A systematic review and meta-analysis.
PG  - 315-324
LID - 10.1007/s11255-019-02350-8 [doi]
AB  - PURPOSE: To perform a systematic review and meta-analysis to evaluate the 
      cardiovascular prevention effect of aspirin among patients with chronic kidney 
      disease (CKD). METHODS: A comprehensive literature search was conducted in 
      Embase, PubMed, and Cochrane library (up to March 2019) without language 
      limitations. Randomized control trials (RCT) and observational studies that met 
      the inclusion and exclusion criteria were included. Two reviewers independently 
      extracted data, and evaluated study quality using modified Jadad score for RCTs 
      and Newcastle-Ottawa Scale for observational study. A meta-analysis was conducted 
      in the Stata 15.0 software using the DerSimonian and Laird random-effects model. 
      RESULTS: 1768 references were identified from literature searching. Four RCTs and 
      four cohort studies that reported the cardiovascular prevention outcome of 
      aspirin in CKD patients (38,341 participants) were included in this review. The 
      pooled data revealed that aspirin had no significant prevention effect on 
      cardiovascular events among CKD patients (RR = 0.96, 95% CI, 0.59-1.13). There 
      was also no significant reduction in cardiovascular mortality and all-cause 
      mortality. Although we found no significant increased risk in major bleeding 
      events, there was a statistically significant increased risk of minor bleeding 
      events (RR = 2.57, 95% CI, 1.60-4.13) and renal events (RR = 1.30, 95% CI, 
      1.02-1.65) for aspirin use. CONCLUSION: Our review indicated that aspirin use in 
      CKD patients had no prevention effect on cardiovascular events and no 
      statistically significant reduction in risk of cardiovascular or all-cause 
      mortality, with a significant increased risk of minor bleeding and renal events.
FAU - Qu, Bo
AU  - Qu B
AD  - No. 1 Department of Nephrology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, No. 37 Shierqiao Road, Chengdu, Sichuan Province, People's 
      Republic of China.
FAU - He, Yuhua
AU  - He Y
AD  - No. 1 Department of Nephrology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, No. 37 Shierqiao Road, Chengdu, Sichuan Province, People's 
      Republic of China.
FAU - Wu, Lihua
AU  - Wu L
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, People's Republic of China.
FAU - Lu, Hongmei
AU  - Lu H
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, People's Republic of China.
FAU - Wu, Haili
AU  - Wu H
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, People's Republic of China.
FAU - Li, Mingquan
AU  - Li M
AD  - No. 1 Department of Nephrology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, No. 37 Shierqiao Road, Chengdu, Sichuan Province, People's 
      Republic of China. 838127560@qq.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20191209
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/etiology/mortality/*prevention & control
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Renal Insufficiency, Chronic/*complications
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular event
OT  - Chronic kidney disease
OT  - Meta-analysis
OT  - Prevention
EDAT- 2019/12/11 06:00
MHDA- 2020/12/15 06:00
CRDT- 2019/12/11 06:00
PHST- 2019/07/06 00:00 [received]
PHST- 2019/11/24 00:00 [accepted]
PHST- 2019/12/11 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2019/12/11 06:00 [entrez]
AID - 10.1007/s11255-019-02350-8 [pii]
AID - 10.1007/s11255-019-02350-8 [doi]
PST - ppublish
SO  - Int Urol Nephrol. 2020 Feb;52(2):315-324. doi: 10.1007/s11255-019-02350-8. Epub 
      2019 Dec 9.

PMID- 33964863
OWN - NLM
STAT- MEDLINE
DCOM- 20211224
LR  - 20211224
IS  - 1875-5305 (Electronic)
IS  - 0929-8665 (Linking)
VI  - 28
IP  - 9
DP  - 2021
TI  - Multidrug Resistance Protein 4 (MRP4/ABCC4): A Suspected Efflux Transporter for 
      Human's Platelet Activation.
PG  - 983-995
LID - 10.2174/0929866528666210505120659 [doi]
AB  - The main role of platelets is to contribute to hemostasis. However, under 
      pathophysiological conditions, platelet activation may lead to thrombotic events 
      of cardiovascular diseases. Thus, anti-thrombotic treatment is important in 
      patients with cardiovascular disease. This review focuses on a platelet receptor, 
      a transmembrane protein, the Multidrug Resistance Protein 4, MRP4, which 
      contributes to platelet activation, by extruding endogenous molecules responsible 
      for their activation and accumulation. The regulation of the intracellular 
      concentration levels of these molecules by MRP4 turned to make the protein 
      suspicious and at the same time an interesting regulatory factor of platelet 
      normal function. Especially, the possible role of MRP4 in the excretion of 
      xenobiotic and antiplatelet drugs such as aspirin is discussed, thus imparting 
      platelet aspirin tolerance and correlating the protein with the ineffectiveness 
      of aspirin antiplatelet therapy. Based on the above, this review finally 
      underlines that the development of a highly selective and targeted strategy for 
      platelet MRP4 inhibition will also lead to inhibition of platelet activation and 
      accumulation.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Angelis, Ioannis
AU  - Angelis I
AD  - Department of Chemistry, Faculty of Organic Chemistry & Biochemistry, University 
      of Ioannina, Ioannina, Greece.
FAU - Moussis, Vassilios
AU  - Moussis V
AD  - Department of Chemistry, Faculty of Organic Chemistry & Biochemistry, University 
      of Ioannina, Ioannina, Greece.
FAU - Tsoukatos, Demokritos C
AU  - Tsoukatos DC
AD  - Department of Chemistry, Faculty of Organic Chemistry & Biochemistry, University 
      of Ioannina, Ioannina, Greece.
FAU - Tsikaris, Vassilios
AU  - Tsikaris V
AD  - Department of Chemistry, Faculty of Organic Chemistry & Biochemistry, University 
      of Ioannina, Ioannina, Greece.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Protein Pept Lett
JT  - Protein and peptide letters
JID - 9441434
RN  - 0 (ABCC4 protein, human)
RN  - 0 (Multidrug Resistance-Associated Proteins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacokinetics/therapeutic use
MH  - Blood Platelets/*metabolism
MH  - Humans
MH  - Multidrug Resistance-Associated Proteins/*metabolism
MH  - Platelet Activation/*drug effects
MH  - *Platelet Aggregation Inhibitors/pharmacokinetics/therapeutic use
OTO - NOTNLM
OT  - MRP4/ABCC4
OT  - Multidrug Resistance (MDR).
OT  - antiplatelet target
OT  - aspirin
OT  - cAMP-compartmentalization
OT  - platelet
EDAT- 2021/05/10 06:00
MHDA- 2021/12/25 06:00
CRDT- 2021/05/09 20:18
PHST- 2020/12/18 00:00 [received]
PHST- 2021/03/10 00:00 [revised]
PHST- 2021/03/16 00:00 [accepted]
PHST- 2021/05/10 06:00 [pubmed]
PHST- 2021/12/25 06:00 [medline]
PHST- 2021/05/09 20:18 [entrez]
AID - PPL-EPUB-115564 [pii]
AID - 10.2174/0929866528666210505120659 [doi]
PST - ppublish
SO  - Protein Pept Lett. 2021;28(9):983-995. doi: 10.2174/0929866528666210505120659.

PMID- 10926135
OWN - NLM
STAT- MEDLINE
DCOM- 20001128
LR  - 20190915
IS  - 1058-2916 (Print)
IS  - 1058-2916 (Linking)
VI  - 46
IP  - 4
DP  - 2000 Jul-Aug
TI  - Hemoglobin substitute and cardiopulmonary bypass.
PG  - 403-8
AB  - The effects of diaspirin crosslinked hemoglobin (DCLHb, Baxter Health Care Corp., 
      Round Lake, IL) on oxygen exchange in the setting of cardiopulmonary bypass (CPB) 
      are unknown. Six calves (71.2 +/- 1.3 kg) were connected to CPB by jugular venous 
      and carotid arterial cannulation for 5 hours. Each 1 hour period included 45 min 
      of partial CPB (mean flow rate of 50 ml/kg per min) followed by 15 min without 
      CPB, at the end of which 500 ml of blood were substituted for with either 500 ml 
      of hydroxyethyl starch (Haes; n = 3) or 500 ml of DCLHb (n = 3). A total of 2 
      liters of blood was, thus, exchanged (28 ml/kg of blood substitute). Values are 
      expressed as mean +/- 1 SD. Analysis of variance for repeated measurements was 
      used. The cardiac output (CO) values at 1 h, 3 h, and 5 h were in the Haes group: 
      5.7 +/- 2, 6.7 +/- 2.5, and 7.7 +/- 2.5L/min, and in the DCLHb group: 5.7 +/- 
      0.6, 4 +/- 1, and 4.7 +/- 1.2 L/min, respectively. The arteriovenous oxygen 
      content difference (Ca-Cvo2) values at 1 h, 3 h, and 5 h were in the Haes group: 
      4.6 +/- 1, 3.3 +/- 1.5, and 3.5 +/- 1.5 ml/dl, and in the DCLHb group: 4.9 +/- 
      0.6, 7.4 +/- 0.7, and 6.6 +/- 0.6 ml/dl, respectively. The oxygen consumption 
      (Vo2) values at 1 h, 3 h, and 5 h were in the Haes group: 244 +/- 29, 198 +/- 58, 
      and 249 +/- 42 ml/min, and in the DCLHb group: 273 +/- 28, 296 +/- 75, and 306 
      +/- 65 ml/min, respectively. CO and Ca-Cvo2 showed a significant difference (p < 
      0.01), whereas Vo2 did not (p = 0.52). In the DCLHb group of this CPB animal 
      model, the cardiac output is lower and the arteriovenous oxygen content 
      difference higher than in the Haes group, allowing for preserved oxygen 
      consumption.
FAU - Mueller, X M
AU  - Mueller XM
AD  - Clinic for Cardiovascular Surgery, Centre Hospitalier Universitaire Vaudois, 
      Lausanne, Switzerland.
FAU - Tevaearai, H T
AU  - Tevaearai HT
FAU - Jegger, D
AU  - Jegger D
FAU - Mallabiabarrena, I
AU  - Mallabiabarrena I
FAU - Gardaz, J P
AU  - Gardaz JP
FAU - von Segesser, L K
AU  - von Segesser LK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - ASAIO J
JT  - ASAIO journal (American Society for Artificial Internal Organs : 1992)
JID - 9204109
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Substitutes/*pharmacology
MH  - *Cardiopulmonary Bypass
MH  - Cattle
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/*pharmacology
MH  - Oxygen/blood
EDAT- 2000/08/05 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/05 11:00
PHST- 2000/08/05 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/05 11:00 [entrez]
AID - 10.1097/00002480-200007000-00006 [doi]
PST - ppublish
SO  - ASAIO J. 2000 Jul-Aug;46(4):403-8. doi: 10.1097/00002480-200007000-00006.

PMID- 10915412
OWN - NLM
STAT- MEDLINE
DCOM- 20000607
LR  - 20181130
IS  - 1049-023X (Print)
IS  - 1049-023X (Linking)
VI  - 14
IP  - 4
DP  - 1999 Oct-Dec
TI  - A safety assessment of diaspirin cross-linked hemoglobin (DCLHb) in the treatment 
      of hemorrhagic, hypovolemic shock.
PG  - 251-64
AB  - OBJECTIVE: To determine the safety and possible efficacy of diaspirin 
      cross-linked hemoglobin (DCLHb) in the treatment of patients in Class II-IV 
      hemorrhagic, hypovolemic shock. DESIGN: Multicenter, randomized, normal 
      saline-controlled, dose-escalation study. SETTING: Eleven hospitals in the U.S. 
      and Belgium. SUBJECTS: One hundred and thirty-nine (139) hospitalized patients 
      with Class II-IV hemorrhagic, hypovolemic shock within the previous 4 hours who 
      still were requiring therapy for shock. INTERVENTIONS: Beginning with the lowest 
      dose, patients were randomized to receive 50, 100, or 200 mL of either 10% DCLHb 
      or normal saline infused intravenously over 15 minutes. Following infusion of 
      either treatment, further fluid resuscitation could be given, as necessary, to 
      maintain perfusion. Vital signs, laboratory assessments, blood and fluid 
      administration, complications, and adverse events were recorded at various times 
      from the end of infusion through 72 hours after infusion. RESULTS: A total of 29 
      (13 DCLHb- and 16 saline-treated) patients died during the study period. Adverse 
      events were experienced by 61% of patients in the DCLHb group and 53% of patients 
      in the saline group; serious adverse events occurred in 28% of DCLHb-treated 
      patients and 30% of saline-treated patients. The incidence of prospectively 
      defined, clinical complications, including renal insufficiency and renal failure, 
      was similar between the treatment groups except for the occurrence of 
      dysrhythmias/conduction disorders, which occurred significantly more frequently 
      in the saline-treated patients than the DCLHb-treated patients (p = 0.041). At 
      the highest dose level (200 mL), statistically significant between-group 
      differences were observed with greater increases in serum amylase, LDH, the 
      isoenzymes LD1,2,4 and 5, and CK-MB in the DCLHb group compared to the control 
      group; none were of clinical significance. The volume of blood administered did 
      not differ between the groups. Overall 24- and 72-hour survival rates were 
      similar between treatment groups, although the hospital discharge rate was 
      slightly higher in the DCLHb-treated patients (80%) compared with the 
      saline-treated patients (74%). CONCLUSION: Administration of 50 to 200 mL of 
      DCLHb to patients in hemorrhagic, hypovolemic shock was not associated with 
      evidence of end organ toxicity or significant adverse events. Further studies 
      involving larger doses and, perhaps, earlier administration of DCLHb are 
      warranted.
FAU - Przybelski, R J
AU  - Przybelski RJ
AD  - Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, 
      USA.
FAU - Daily, E K
AU  - Daily EK
FAU - Micheels, J
AU  - Micheels J
FAU - Sloan, E
AU  - Sloan E
FAU - Mols, P
AU  - Mols P
FAU - Corne, L
AU  - Corne L
FAU - Koenigsberg, M D
AU  - Koenigsberg MD
FAU - Bickell, W H
AU  - Bickell WH
FAU - Thompson, D R
AU  - Thompson DR
FAU - Harviel, J D
AU  - Harviel JD
FAU - Cohn, S M
AU  - Cohn SM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prehosp Disaster Med
JT  - Prehospital and disaster medicine
JID - 8918173
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Hemoglobins/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Shock, Hemorrhagic/*therapy
EDAT- 2000/08/01 00:00
MHDA- 2000/08/01 00:01
CRDT- 2000/08/01 00:00
PHST- 2000/08/01 00:00 [pubmed]
PHST- 2000/08/01 00:01 [medline]
PHST- 2000/08/01 00:00 [entrez]
PST - ppublish
SO  - Prehosp Disaster Med. 1999 Oct-Dec;14(4):251-64.

PMID- 1109706
OWN - NLM
STAT- MEDLINE
DCOM- 19750411
LR  - 20190902
IS  - 0008-2856 (Print)
IS  - 0008-2856 (Linking)
VI  - 22
IP  - 1
DP  - 1975 Jan
TI  - Use of aspirin in haemorrhagic shock.
PG  - 50-60
AB  - Haemorrhagic shock was induced in two similar groups of dogs for two hours. One 
      group received aspirin before shock and the other group served as a control. When 
      blood was retransfused the PVR which was markedly elevated during shock returned 
      to pre-shock value in the aspirin group but was elevated 100 per cent in the 
      control group, despite correction of a cidosis. Aspirin reduces collagen-induced 
      platelet aggregation and thereby inhibits the formation of platelet micro-emboli 
      without affecting the coagulationfactors. This effect of aspirin is thought to be 
      responsible for the lowering of the elevated PVR to pre-shock values in the 
      aspirin group following retransfusion. Because of the metabolic acidosis 
      associated with the shock state, concurrent administration of sodium bicarbonate 
      is recommended when transfusing shocked patients with blood. A clinical trial of 
      aspirin in early treatment of shocked patients as well as for prophylaxis in high 
      risk situations is justified.
FAU - Famewo, C E
AU  - Famewo CE
FAU - Noble, W H
AU  - Noble WH
FAU - Garvey, M B
AU  - Garvey MB
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Anaesth Soc J
JT  - Canadian Anaesthetists' Society journal
JID - 0371163
RN  - 0 (Bicarbonates)
RN  - 0 (Blood Coagulation Factors)
RN  - 142M471B3J (Carbon Dioxide)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/pharmacology/*therapeutic use
MH  - Bicarbonates/pharmacology
MH  - Blood Coagulation Factors/analysis
MH  - Blood Pressure/drug effects
MH  - Carbon Dioxide/blood
MH  - Cardiac Output/drug effects
MH  - Central Venous Pressure
MH  - Dogs
MH  - Oxygen/blood
MH  - Platelet Adhesiveness/drug effects
MH  - Prothrombin Time
MH  - Pulmonary Artery/drug effects
MH  - Respiratory Dead Space
MH  - Shock, Hemorrhagic/*drug therapy
MH  - Vascular Resistance/drug effects
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 10.1007/BF03004818 [doi]
PST - ppublish
SO  - Can Anaesth Soc J. 1975 Jan;22(1):50-60. doi: 10.1007/BF03004818.

PMID- 6815744
OWN - NLM
STAT- MEDLINE
DCOM- 19830107
LR  - 20131121
IS  - 0034-5288 (Print)
IS  - 0034-5288 (Linking)
VI  - 33
IP  - 2
DP  - 1982 Sep
TI  - Effect of administering two prostaglandin synthetase inhibitors (indomethacin and 
      aspirin) on egg production in the domestic fowl (Gallus domesticus).
PG  - 216-20
AB  - The injection of 50 mg/kg bodyweight of a prostaglandin synthetase inhibitor 
      (indomethacin) brought about a delayed oviposition time in birds of three breeds 
      of layers, whereas the injection of 5 mg indomethacin had no effect. The daily 
      ingestion of up to 400 mg aspirin or up to 10 mg indomethacin for three weeks, or 
      750 mg aspirin or 200 mg indomethacin for two weeks had no effect on egg 
      production, oviposition time, egg-shell water conductance, oviducal prostaglandin 
      synthetase activity or bird behaviour. Prostaglandin synthetase activity was 
      demonstrable in both control and treated birds only in the tubular glands of the 
      shell gland. These observations suggest that prostaglandins play a minor role in 
      normal reproductive activity in the female domestic fowl.
FAU - Gilbert, A B
AU  - Gilbert AB
FAU - Mitchell, G G
AU  - Mitchell GG
FAU - Davidson, M F
AU  - Davidson MF
FAU - Laughlin, K F
AU  - Laughlin KF
FAU - Hughes, B O
AU  - Hughes BO
LA  - eng
PT  - Journal Article
PL  - England
TA  - Res Vet Sci
JT  - Research in veterinary science
JID - 0401300
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chickens/*physiology
MH  - Female
MH  - Indomethacin/administration & dosage/*pharmacology
MH  - Injections, Intramuscular/veterinary
MH  - Oviducts/enzymology
MH  - Oviposition/*drug effects
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
EDAT- 1982/09/01 00:00
MHDA- 1982/09/01 00:01
CRDT- 1982/09/01 00:00
PHST- 1982/09/01 00:00 [pubmed]
PHST- 1982/09/01 00:01 [medline]
PHST- 1982/09/01 00:00 [entrez]
PST - ppublish
SO  - Res Vet Sci. 1982 Sep;33(2):216-20.

PMID- 6393800
OWN - NLM
STAT- MEDLINE
DCOM- 19850215
LR  - 20190825
IS  - 0145-6008 (Print)
IS  - 0145-6008 (Linking)
VI  - 8
IP  - 6
DP  - 1984 Nov-Dec
TI  - Aspirin reduces alcohol-induced prenatal mortality and malformations in mice.
PG  - 513-5
AB  - Oral alcohol administration (5.8 g/kg) on gestation day 10 resulted in an 
      increase in both prenatal mortality and birth defects as well as decreased fetal 
      weight in C57BL/6J mice. Aspirin pretreatment (150 mg/kg subcutaneously) 
      significantly reduced the number of malformed pups and prevented the increase in 
      prenatal mortality produced by alcohol. The mechanism of action remains to be 
      elucidated.
FAU - Randall, C L
AU  - Randall CL
FAU - Anton, R F
AU  - Anton RF
LA  - eng
GR  - AA04574/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Alcohol Clin Exp Res
JT  - Alcoholism, clinical and experimental research
JID - 7707242
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced/*prevention & control
MH  - Alcoholic Intoxication/complications
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Ethanol/*antagonists & inhibitors
MH  - Female
MH  - Fetal Death/*chemically induced/prevention & control
MH  - Humans
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Pregnancy
MH  - Pregnancy Complications
EDAT- 1984/11/01 00:00
MHDA- 1984/11/01 00:01
CRDT- 1984/11/01 00:00
PHST- 1984/11/01 00:00 [pubmed]
PHST- 1984/11/01 00:01 [medline]
PHST- 1984/11/01 00:00 [entrez]
AID - 10.1111/j.1530-0277.1984.tb05719.x [doi]
PST - ppublish
SO  - Alcohol Clin Exp Res. 1984 Nov-Dec;8(6):513-5. doi: 
      10.1111/j.1530-0277.1984.tb05719.x.

PMID- 7469620
OWN - NLM
STAT- MEDLINE
DCOM- 19810413
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 141
IP  - 3 Spec No
DP  - 1981 Feb 23
TI  - Comparative pharmacokinetics of aspirin and acetaminophen.
PG  - 279-81
AB  - Aspirin is extensively hydrolyzed to salicylic acid during absorption after oral 
      administration. This hydrolysis is completed systemically. Salicylic acid, an 
      effective analgesic, antipyretic, and anti-inflammatory agent, is eliminated by 
      renal excretion and by metabolic conversion to conjugates with glycine and 
      glucuronic acid, respectively, and to gentisic acid. Two of these metabolic 
      processes are easily saturable, causing systemic clearance of salicylate to 
      decrease with increasing dose. Acetaminophen metabolism during absorption is 
      minor, and the drug is eliminated primarily by conjugation with glucuronic acid 
      and with sulfate to pharmacologically inactive products. These processes become 
      saturated only in the supertherapeutic dose range, thereby causing an increase in 
      the fraction in the dose converted to a minor but potentially hepatotoxic 
      metabolite. In the usual therapeutic dose range, acetaminophen is much more 
      rapidly eliminated from the body than is salicylic acid.
FAU - Levy, G
AU  - Levy G
LA  - eng
GR  - GM 19568/GM/NIGMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Blood Proteins)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/*metabolism
MH  - Aspirin/administration & dosage/*metabolism
MH  - Blood Proteins/metabolism
MH  - Drug Administration Schedule
MH  - Half-Life
MH  - Humans
MH  - Intestinal Absorption
MH  - Kinetics
MH  - Protein Binding
EDAT- 1981/02/23 00:00
MHDA- 1981/02/23 00:01
CRDT- 1981/02/23 00:00
PHST- 1981/02/23 00:00 [pubmed]
PHST- 1981/02/23 00:01 [medline]
PHST- 1981/02/23 00:00 [entrez]
AID - 10.1001/archinte.141.3.279 [doi]
PST - ppublish
SO  - Arch Intern Med. 1981 Feb 23;141(3 Spec No):279-81. doi: 
      10.1001/archinte.141.3.279.

PMID- 1150400
OWN - NLM
STAT- MEDLINE
DCOM- 19751030
LR  - 20131121
IS  - 0020-9988 (Print)
IS  - 0020-9988 (Linking)
VI  - 14
IP  - 8
DP  - 1975 Aug
TI  - Systemic aspirin and indomethacin do not prevent the response of the monkey eye 
      to trauma.
PG  - 604-6
AB  - The stability of the blood-aqueous barrier of the monkey eye was challenged by 
      three different methods: anterior chamber paracentesis, intravitreal shigella 
      endotoxin, and subconjunctival arachidonic acid. Systemic aspirin and 
      indomethacin were ineffective in stabilizing the blood-aqueous barrier in all 
      three of these systems.
FAU - Kass, M A
AU  - Kass MA
FAU - Neufeld, A H
AU  - Neufeld AH
FAU - Sears, M L
AU  - Sears ML
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Invest Ophthalmol
JT  - Investigative ophthalmology
JID - 0374730
RN  - 0 (Arachidonic Acids)
RN  - 0 (Endotoxins)
RN  - 0 (Eye Proteins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - *Aqueous Humor/analysis
MH  - Arachidonic Acids
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Endotoxins
MH  - Eye Injuries/*physiopathology
MH  - Eye Proteins/*metabolism
MH  - Indomethacin/*therapeutic use
MH  - *Intraocular Pressure/drug effects
MH  - Macaca mulatta
MH  - Punctures
MH  - Shigella
MH  - Uveitis/prevention & control
EDAT- 1975/08/01 00:00
MHDA- 1975/08/01 00:01
CRDT- 1975/08/01 00:00
PHST- 1975/08/01 00:00 [pubmed]
PHST- 1975/08/01 00:01 [medline]
PHST- 1975/08/01 00:00 [entrez]
PST - ppublish
SO  - Invest Ophthalmol. 1975 Aug;14(8):604-6.

PMID- 22533300
OWN - NLM
STAT- MEDLINE
DCOM- 20121023
LR  - 20161125
IS  - 1520-6882 (Electronic)
IS  - 0003-2700 (Linking)
VI  - 84
IP  - 11
DP  - 2012 Jun 5
TI  - Effect of particle properties of powders on the generation and transmission of 
      Raman scattering.
PG  - 4665-70
LID - 10.1021/ac203446g [doi]
AB  - Transmission Raman measurements of a 1 mm thick sulfur-containing disk were made 
      at different positions as it was moved through 4 mm of aspirin (150-212 μm) or 
      microcrystalline cellulose (Avicel) of different size ranges (<38, 53-106, and 
      150-212 μm). The transmission Raman intensity of the sulfur interlayer at 218 
      cm(-1) was lower when the disk was placed at the top or bottom of the powder bed, 
      compared to positions within the bed and the difference between the sulfur 
      intensity at the outer and inner positions increased with Avicel particle size. 
      Also, the positional intensity difference was smaller for needle-shaped aspirin 
      than for granular Avicel of the same size. The attenuation coefficients for the 
      propagation of the exciting laser and transmitted Raman photons through the 
      individual powders were the same but decreased as the particle size of Avicel 
      increased; also, the attenuation coefficients for propagation through 150-212 μm 
      aspirin were almost half of those through similar sized Avicel particles. The 
      study has demonstrated that particulate size and type affect transmitted Raman 
      intensities and, consequently, such factors need to be considered in the analysis 
      of powders, especially if particle properties vary between the samples.
FAU - Townshend, Nichola
AU  - Townshend N
AD  - WestCHEM, Department of Pure and Applied Chemistry and CPACT, University of 
      Strathclyde, 295 Cathedral Street, Glasgow, G1 1XL, UK.
FAU - Nordon, Alison
AU  - Nordon A
FAU - Littlejohn, David
AU  - Littlejohn D
FAU - Andrews, John
AU  - Andrews J
FAU - Dallin, Paul
AU  - Dallin P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120509
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
RN  - 0 (Capsules)
RN  - 0 (Excipients)
RN  - 0 (Powders)
RN  - 0 (Tablets)
RN  - 9004-34-6 (Cellulose)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/chemistry
MH  - Capsules/analysis/chemistry
MH  - Cellulose/*analysis/chemistry
MH  - Excipients/chemistry
MH  - Lasers
MH  - Particle Size
MH  - *Photons
MH  - Powders/*analysis/chemistry
MH  - Spectrum Analysis, Raman/methods
MH  - Tablets/*analysis/chemistry
EDAT- 2012/04/27 06:00
MHDA- 2012/10/24 06:00
CRDT- 2012/04/27 06:00
PHST- 2012/04/27 06:00 [entrez]
PHST- 2012/04/27 06:00 [pubmed]
PHST- 2012/10/24 06:00 [medline]
AID - 10.1021/ac203446g [doi]
PST - ppublish
SO  - Anal Chem. 2012 Jun 5;84(11):4665-70. doi: 10.1021/ac203446g. Epub 2012 May 9.

PMID- 25984731
OWN - NLM
STAT- MEDLINE
DCOM- 20160208
LR  - 20210109
IS  - 2046-4924 (Electronic)
IS  - 1366-5278 (Print)
IS  - 1366-5278 (Linking)
VI  - 19
IP  - 37
DP  - 2015 May
TI  - The prognostic utility of tests of platelet function for the detection of 
      'aspirin resistance' in patients with established cardiovascular or 
      cerebrovascular disease: a systematic review and economic evaluation.
PG  - 1-366
LID - 10.3310/hta19370 [doi]
AB  - BACKGROUND: The use of aspirin is well established for secondary prevention of 
      cardiovascular disease. However, a proportion of patients suffer repeat 
      cardiovascular events despite being prescribed aspirin treatment. It is uncertain 
      whether or not this is due to an inherent inability of aspirin to sufficiently 
      modify platelet activity. This report aims to investigate whether or not 
      insufficient platelet function inhibition by aspirin ('aspirin resistance'), as 
      defined using platelet function tests (PFTs), is linked to the occurrence of 
      adverse clinical outcomes, and further, whether or not patients at risk of future 
      adverse clinical events can be identified through PFTs. OBJECTIVES: To review 
      systematically the clinical effectiveness and cost-effectiveness evidence 
      regarding the association between PFT designation of 'aspirin resistance' and the 
      risk of adverse clinical outcome(s) in patients prescribed aspirin therapy. To 
      undertake exploratory model-based cost-effectiveness analysis on the use of PFTs. 
      DATA SOURCES: Bibliographic databases (e.g. MEDLINE from inception and EMBASE 
      from 1980), conference proceedings and ongoing trial registries up to April 2012. 
      METHODS: Standard systematic review methods were used for identifying clinical 
      and cost studies. A risk-of-bias assessment tool was adapted from checklists for 
      prognostic and diagnostic studies. (Un)adjusted odds and hazard ratios for the 
      association between 'aspirin resistance', for different PFTs, and clinical 
      outcomes are presented; however, heterogeneity between studies precluded pooling 
      of results. A speculative economic model of a PFT and change of therapy strategy 
      was developed. RESULTS: One hundred and eight relevant studies using a variety of 
      PFTs, 58 in patients on aspirin monotherapy, were analysed in detail. Results 
      indicated that some PFTs may have some prognostic utility, i.e. a trend for more 
      clinical events to be associated with groups classified as 'aspirin resistant'. 
      Methodological and clinical heterogeneity prevented a quantitative summary of 
      prognostic effect. Study-level effect sizes were generally small and absolute 
      outcome risk was not substantially different between 'aspirin resistant' and 
      'aspirin sensitive' designations. No studies on the cost-effectiveness of PFTs 
      for 'aspirin resistance' were identified. Based on assumptions of PFTs being able 
      to accurately identify patients at high risk of clinical events and such patients 
      benefiting from treatment modification, the economic model found that a 
      test-treat strategy was likely to be cost-effective. However, neither assumption 
      is currently evidence based. LIMITATIONS: Poor or incomplete reporting of studies 
      suggests a potentially large volume of inaccessible data. Analyses were confined 
      to studies on patients prescribed aspirin as sole antiplatelet therapy at the 
      time of PFT. Clinical and methodological heterogeneity across studies precluded 
      meta-analysis. Given the lack of robust data the economic modelling was 
      speculative. CONCLUSIONS: Although evidence indicates that some PFTs may have 
      some prognostic value, methodological and clinical heterogeneity between studies 
      and different approaches to analyses create confusion and inconsistency in 
      prognostic results, and prevented a quantitative summary of their prognostic 
      effect. Protocol-driven and adequately powered primary studies are needed, using 
      standardised methods of measurements to evaluate the prognostic ability of each 
      test in the same population(s), and ideally presenting individual patient data. 
      For any PFT to inform individual risk prediction, it will likely need to be 
      considered in combination with other prognostic factors, within a prognostic 
      model. STUDY REGISTRATION: This study is registered as PROSPERO 
      2012:CRD42012002151. FUNDING: The National Institute for Health Research Health 
      Technology Assessment programme.
FAU - Dretzke, Janine
AU  - Dretzke J
AD  - Public Health, Epidemiology and Biostatistics, School of Health and Population 
      Sciences, University of Birmingham, Birmingham, UK.
FAU - Riley, Richard D
AU  - Riley RD
AD  - Research Institute of Primary Care and Health Sciences, Keele University, 
      Staffordshire, UK.
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
AD  - Faculté de Pharmacie, Université de Montréal, Montreal, QC, Canada.
FAU - Jowett, Susan
AU  - Jowett S
AD  - Health Economics, School of Health and Population Sciences, University of 
      Birmingham, Birmingham, UK.
FAU - O'Donnell, Jennifer
AU  - O'Donnell J
AD  - Primary Care Clinical Sciences, School of Health and Population Sciences, 
      University of Birmingham, Birmingham, UK.
FAU - Ensor, Joie
AU  - Ensor J
AD  - Research Institute of Primary Care and Health Sciences, Keele University, 
      Staffordshire, UK.
FAU - Moloney, Eoin
AU  - Moloney E
AD  - Institute of Health and Society, Newcastle University, Newcastle, UK.
FAU - Price, Malcolm
AU  - Price M
AD  - Public Health, Epidemiology and Biostatistics, School of Health and Population 
      Sciences, University of Birmingham, Birmingham, UK.
FAU - Raichand, Smriti
AU  - Raichand S
AD  - Public Health, Epidemiology and Biostatistics, School of Health and Population 
      Sciences, University of Birmingham, Birmingham, UK.
FAU - Hodgkinson, James
AU  - Hodgkinson J
AD  - Primary Care Clinical Sciences, School of Health and Population Sciences, 
      University of Birmingham, Birmingham, UK.
FAU - Bayliss, Susan
AU  - Bayliss S
AD  - Public Health, Epidemiology and Biostatistics, School of Health and Population 
      Sciences, University of Birmingham, Birmingham, UK.
FAU - Fitzmaurice, David
AU  - Fitzmaurice D
AD  - Primary Care Clinical Sciences, School of Health and Population Sciences, 
      University of Birmingham, Birmingham, UK.
FAU - Moore, David
AU  - Moore D
AD  - Public Health, Epidemiology and Biostatistics, School of Health and Population 
      Sciences, University of Birmingham, Birmingham, UK.
LA  - eng
GR  - 10/36/02/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Health Technol Assess
JT  - Health technology assessment (Winchester, England)
JID - 9706284
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cerebrovascular Disorders/*drug therapy
MH  - Cost-Benefit Analysis
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests/*economics/*instrumentation
MH  - Prognosis
MH  - Risk Factors
MH  - Technology Assessment, Biomedical
MH  - Thrombosis/prevention & control
PMC - PMC4781102
EDAT- 2015/05/20 06:00
MHDA- 2016/02/09 06:00
CRDT- 2015/05/19 06:00
PHST- 2015/05/19 06:00 [entrez]
PHST- 2015/05/20 06:00 [pubmed]
PHST- 2016/02/09 06:00 [medline]
AID - 10.3310/hta19370 [doi]
PST - ppublish
SO  - Health Technol Assess. 2015 May;19(37):1-366. doi: 10.3310/hta19370.

PMID- 10933569
OWN - NLM
STAT- MEDLINE
DCOM- 20001130
LR  - 20190513
IS  - 0895-7061 (Print)
IS  - 0895-7061 (Linking)
VI  - 13
IP  - 7
DP  - 2000 Jul
TI  - Intermediate but not low doses of aspirin can suppress angiotensin-converting 
      enzyme inhibitor-induced cough.
PG  - 776-82
AB  - This self-matched control study aimed to compare the efficiency of two different 
      regimens of active treatment: aspirin in low (100 mg daily) versus intermediate 
      (500 mg daily) doses in abolishing angiotensin-converting enzyme inhibitor 
      (ACEI)-induced cough. A dry bothersome cough is the most common adverse class 
      effect of all angiotensin-converting enzyme inhibitors. Prostaglandins (PG) have 
      been pinpointed as playing a leading role in the genesis of ACEI-associated 
      cough. The role of different doses of the most commonly used PG 
      inhibitor-aspirin-in ACEI cough modification was not yet elucidated. Of 350 
      consecutive ACEI-treated patients, we identified 34 (9.7%) nonsmoking 
      ACEI-related coughers. Patients with lung disease, nonsteroidal anti-inflammatory 
      drug (NSAID) treatment, and those who did not agree to participate in the study 
      were excluded. In the remaining 14 ACEI coughers (eight men, six women; mean age, 
      63 +/- 11 years), the treatment was discontinued; the dry cough completely 
      disappeared, but returned in all patients within 1 week after ACEI 
      reintroduction. At the end of the rechallenge period, patients started a low dose 
      of aspirin for 1 week, switching thereafter to the intermediate dose of aspirin 
      for an additional week. On each visit the cough severity (CS, 0-4) and frequency 
      (CF, 0-10) scores were registered. Low doses of aspirin were ineffective in 
      suppressing ACEI-induced cough, whereas intermediate doses completely abolished 
      cough in five patients and reduced coughing in all but one patient; CS and CF 
      decreased, respectively, from 2.5 +/- 1.0 to 0.9 +/- 1.1, P < .002 and from 6.6 
      +/- 2.4 to 2.4 +/- 1.1, P < .0002. Overall, intermediate doses of aspirin 
      beneficially modified cough scores in 13 (93%) patients, enabling nine (64%) to 
      continue ACEI treatment. Aspirin did not influence blood pressure control either 
      in hypertensives or in postinfarction patients. We conclude that intermediate but 
      not low doses of aspirin probably can suppress ACEI-induced cough. These findings 
      propose a new alternative therapeutic approach for patients with ACEI-related 
      cough, especially those in whom ACEI treatment seems to be essential.
FAU - Tenenbaum, A
AU  - Tenenbaum A
AD  - Cardiac Rehabilitation Institute and the Department of Internal Medicine D, the 
      Chaim Sheba Medical Center, Tel-Hashomer, Israel. zfisman@post.tau.ac.il
FAU - Grossman, E
AU  - Grossman E
FAU - Shemesh, J
AU  - Shemesh J
FAU - Fisman, E Z
AU  - Fisman EZ
FAU - Nosrati, I
AU  - Nosrati I
FAU - Motro, M
AU  - Motro M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Hypertens
JT  - American journal of hypertension
JID - 8803676
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Cough/*chemically induced/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2000/08/10 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/10 11:00
PHST- 2000/08/10 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/10 11:00 [entrez]
AID - S0895-7061(00)00268-5 [pii]
AID - 10.1016/s0895-7061(00)00268-5 [doi]
PST - ppublish
SO  - Am J Hypertens. 2000 Jul;13(7):776-82. doi: 10.1016/s0895-7061(00)00268-5.

PMID- 27153119
OWN - NLM
STAT- MEDLINE
DCOM- 20170717
LR  - 20190219
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 5
DP  - 2016
TI  - Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and 
      Meta-Analysis.
PG  - e0154897
LID - 10.1371/journal.pone.0154897 [doi]
LID - e0154897
AB  - OBJECTIVES: To assess the effectiveness and safety of Chinese herbal medicine 
      (CHM) for the treatment of aspirin resistance (AR). METHODS: A comprehensive 
      research of seven electronic databases was performed for comparative studies 
      evaluating CHM for AR. Two authors independently extracted data and assessed the 
      methodological quality of the included trials using the Cochrane risk of bias 
      tool. Data wasere synthesized by using RevMan 5.3 software. (PROSPERO 
      Registration #CRD42015020182). RESULTS: 18 randomized controlled trials (RCTs) 
      involving 1,460 patients were included. 15 RCTs reported significant difference 
      in the reduction of platelet aggregation rate (PAR) induced by adenosine 
      diphosphate (ADP) (P<0.05), and 11 reported significant effect of CHM plus 
      aspirin to reduce PAR induced by arachidonic acid (AA) (P<0.05) compared with 
      aspirin 100mg/d treatment. The pooling data of 3 RCTs showed the thromboxane B2 
      (TXB2) in patients with CHM plus aspirin versus aspirin were significantly 
      reduced (Random Effect model (RE), Standard Deviation (SD) = -95.93, 95% 
      Confidential Interval (CI)[-118.25,-73.61], P<0.00001). Subgroup analysis showed 
      that TXB2 (Fixed Effect model (FE), SD = -89.23, 95%CI[-121.96,-56.49], 
      P<0.00001) had significant difference in Tongxinluo capsule plus aspirin versus 
      aspirin. 2 RCTs reported the clinical effective rate, and the meta-analysis 
      result showed a significant difference in intervention and control group (FE, 
      Relative Risk (RR) = 1.67, 95%CI[1.15, 2.42], P = 0.007<0.05). In 4 trials, CHM 
      plus aspirin had better effects of reducing the reoccurrence of cerebral 
      infarction than aspirin (FE, RR = 0.24, 95%CI [0.11, 0.49], P<0.0001). And one 
      trial showed that CHM plus aspirin could decrease the National Institutes of 
      Health Stroke Scale (NHISS) score (P<0.05) and increase the Barthel Index (BI) 
      score (P<0.05). 4 trials stated that there were no adverse effects occurred in 
      intervention group, and analysis showed significant difference of CHM or CHM plus 
      aspirin in reducing the occurrence of adverse events (FE, RR = 0.22, 95%CI[0.13, 
      0.39], P<0.00001). 5 trials claimed that the CHM monotherapy and CHM adjunctive 
      therapy for AR did not add the risk of bleeding (FE, RR = 0.50, 95%CI[0.20, 
      1.22], P = 0.13>0.05). CONCLUSIONS: CHM may be effective and safe as an 
      alternative and collaborative therapy for AR. However, the current evidence and 
      potential promising findings should be interpreted with caution due to poor and 
      varying methodological quality of included studies and the heterogeneity of 
      interventions. Thus, further exploration of this strategy with adequately powered 
      RCTs is warranted.
FAU - Chen, Hanyu
AU  - Chen H
AD  - First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 
      China.
AD  - Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese 
      Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, 
      Nanjing, China.
FAU - Shen, Zhengjie
AU  - Shen Z
AD  - First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 
      China.
AD  - Translational Medicine Center of Nanjing University of Chinese Medicine, Key 
      Laboratory of Famous Doctor's Proved Recipe Evaluation and Transformation of 
      State Administration of Traditional Chinese Medicine, Nanjing, China.
FAU - Chen, Jiandong
AU  - Chen J
AD  - Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese 
      Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, 
      Nanjing, China.
FAU - Zhang, Haowen
AU  - Zhang H
AD  - First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 
      China.
AD  - Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese 
      Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, 
      Nanjing, China.
FAU - Chen, Xiaohu
AU  - Chen X
AD  - Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese 
      Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, 
      Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160506
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Drugs, Chinese Herbal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Drug Resistance
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Observer Variation
PMC - PMC4859478
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2016/05/07 06:00
MHDA- 2017/07/18 06:00
CRDT- 2016/05/07 06:00
PHST- 2015/08/25 00:00 [received]
PHST- 2016/04/20 00:00 [accepted]
PHST- 2016/05/07 06:00 [entrez]
PHST- 2016/05/07 06:00 [pubmed]
PHST- 2017/07/18 06:00 [medline]
AID - PONE-D-15-37404 [pii]
AID - 10.1371/journal.pone.0154897 [doi]
PST - epublish
SO  - PLoS One. 2016 May 6;11(5):e0154897. doi: 10.1371/journal.pone.0154897. 
      eCollection 2016.

PMID- 23345599
OWN - NLM
STAT- MEDLINE
DCOM- 20140219
LR  - 20211021
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Print)
IS  - 0003-4967 (Linking)
VI  - 73
IP  - 2
DP  - 2014 Feb
TI  - Low-dose aspirin use and recurrent gout attacks.
PG  - 385-90
LID - 10.1136/annrheumdis-2012-202589 [doi]
AB  - OBJECTIVE: To examine the association between cardioprotective use of low-dose 
      aspirin and the risk of recurrent gout attacks among gout patients. METHODS: We 
      conducted an online case-crossover study of individuals with gout over 1 year. 
      The following information was obtained during gout attacks: the onset dates, 
      symptoms and signs, medications, and exposure to potential risk factors, 
      including daily aspirin use and dosage, during the 2-day hazard period prior to 
      the gout attacks. The same exposure information was also obtained over 2-day 
      control periods. RESULTS: Of the 724 participants analysed, 40.5% took aspirin 
      ≤325 mg/day during either a hazard or a control period. Compared with no aspirin 
      use, the adjusted OR of gout attacks increased by 81% (OR=1.81, 95% CI 1.30 to 
      2.51) for ≤325 mg/day of aspirin use on two consecutive days. The corresponding 
      ORs were stronger with lower doses (eg, OR=1.91 for ≤100 mg, 95% CI 1.32 to 
      2.85). These associations persisted across subgroups by sex, age, body mass index 
      categories and renal insufficiency status. Concomitant use of allopurinol 
      nullified the detrimental effect of aspirin. CONCLUSIONS: Our findings suggest 
      that the use of low-dose aspirin on two consecutive days is associated with an 
      increased risk of recurrent gout attacks. Recommended serum urate monitoring with 
      concomitant use and dose adjustment of a urate-lowering therapy among patients 
      with gout may be especially important to help avoid the risk of gout attacks 
      associated with low-dose aspirin.
FAU - Zhang, Yuqing
AU  - Zhang Y
AD  - Clinical Epidemiology Research and Training Unit, Department of Medicine, Boston 
      University School of Medicine, , Boston, Massachusetts, USA.
FAU - Neogi, Tuhina
AU  - Neogi T
FAU - Chen, Clara
AU  - Chen C
FAU - Chaisson, Christine
AU  - Chaisson C
FAU - Hunter, David J
AU  - Hunter DJ
FAU - Choi, Hyon
AU  - Choi H
LA  - eng
GR  - K23 AR055127/AR/NIAMS NIH HHS/United States
GR  - P30 AG013846/AG/NIA NIH HHS/United States
GR  - P60 AR047785/AR/NIAMS NIH HHS/United States
GR  - P60-AR047785/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130123
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Cardiotonic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Cardiotonic Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Gout/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Risk Assessment/methods
MH  - Socioeconomic Factors
MH  - Young Adult
PMC - PMC3902644
MID - NIHMS544954
OTO - NOTNLM
OT  - Epidemiology
OT  - Gout
OT  - Treatment
COIS- Competing interests None.
EDAT- 2013/01/25 06:00
MHDA- 2014/02/20 06:00
CRDT- 2013/01/25 06:00
PHST- 2013/01/25 06:00 [entrez]
PHST- 2013/01/25 06:00 [pubmed]
PHST- 2014/02/20 06:00 [medline]
AID - annrheumdis-2012-202589 [pii]
AID - 10.1136/annrheumdis-2012-202589 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 2014 Feb;73(2):385-90. doi: 10.1136/annrheumdis-2012-202589. Epub 
      2013 Jan 23.

PMID- 2685532
OWN - NLM
STAT- MEDLINE
DCOM- 19891228
LR  - 20131121
IS  - 0723-5003 (Print)
IS  - 0723-5003 (Linking)
VI  - 84
IP  - 10
DP  - 1989 Oct 15
TI  - [Stomach tolerance of acetylsalicylic acid by addition of calcium carbonate. A 
      study of a 2-treatment/3-period cross-over design].
PG  - 474-8, 511
AB  - 18 male volunteers (age 24 +/- 4 years; Broca index 0.94 +/- 0.08; mean +/- SD) 
      underwent six upper endoscopies (three control and three test investigations) in 
      a single blind two treatments-crossover designed study which evaluated the effect 
      of buffering on aspirin-induced (one single oral dose of 0.5 g aspirin to fasted 
      subjects) gastroduodenal mucosal injury. All subjects had a normal endoscopy 
      prior to applications of 0.5 g plain aspirin (group A; swallowed) or 0.5 g 
      aspirin + 0.3 g calcium carbonate (group B; chewed before swallowing). The 
      sequence groups were A-B-B (n = 9) or B-A-A (n = 9). In advance fo the performed 
      tests a washout period of six days was chosen. Endoscopies were performed two 
      hours after ingestion of the respective tablets. The appearance of corpus, 
      antrum, and duodenum was scored. Biopsies were taken for histological 
      examinations. 15 volunteers experienced no gastrointestinal side effects. Three 
      complained short-lasting gastric burning (two of group A, one of group B). In 
      both treatment groups no significant lesions of the duodenum were found. 
      Buffering significantly (p less than 0.0005) reduced mucosal injuries which 
      occurred mainly as submucosal hemorrhage but without histological alterations of 
      the mucosal architecture after aspirin ingestion. These findings suggest that 
      oral administration of calcium carbonate buffered, chewable aspirin tablets is 
      less harmful to the gastric mucosa than plain aspirin.
FAU - Göke, B
AU  - Göke B
FAU - Schmitz-Moormann, P
AU  - Schmitz-Moormann P
FAU - Boehme, K
AU  - Boehme K
FAU - Lange, K
AU  - Lange K
FAU - Arnold, R
AU  - Arnold R
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Magenverträglichkeit von Acetylsalicylsäure bei Zusatz von Calciumcarbonat. Eine 
      Studie im Zwei-Behandlungen-/Drei-Perioden-Cross-over-Design.
PL  - Germany
TA  - Med Klin (Munich)
JT  - Medizinische Klinik (Munich, Germany : 1983)
JID - 8303501
RN  - H0G9379FGK (Calcium Carbonate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*toxicity
MH  - Calcium Carbonate/*administration & dosage
MH  - Gastric Mucosa/*drug effects
MH  - *Gastroscopy
MH  - Humans
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
EDAT- 1989/10/15 00:00
MHDA- 2000/03/22 09:00
CRDT- 1989/10/15 00:00
PHST- 1989/10/15 00:00 [pubmed]
PHST- 2000/03/22 09:00 [medline]
PHST- 1989/10/15 00:00 [entrez]
PST - ppublish
SO  - Med Klin (Munich). 1989 Oct 15;84(10):474-8, 511.

PMID- 27139040
OWN - NLM
STAT- MEDLINE
DCOM- 20171019
LR  - 20171121
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 13
IP  - 6
DP  - 2016 Jun 6
TI  - Toward Biopredictive Dissolution for Enteric Coated Dosage Forms.
PG  - 1927-36
LID - 10.1021/acs.molpharmaceut.6b00077 [doi]
AB  - The aim of this work was to develop a phosphate buffer based dissolution method 
      for enteric-coated formulations with improved biopredictivity for fasted 
      conditions. Two commercially available enteric-coated aspirin products were used 
      as model formulations (Aspirin Protect 300 mg, and Walgreens Aspirin 325 mg). The 
      disintegration performance of these products in a physiological 8 mM pH 6.5 
      bicarbonate buffer (representing the conditions in the proximal small intestine) 
      was used as a standard to optimize the employed phosphate buffer molarity. To 
      account for the fact that a pH and buffer molarity gradient exists along the 
      small intestine, the introduction of such a gradient was proposed for products 
      with prolonged lag times (when it leads to a release lower than 75% in the first 
      hour post acid stage) in the proposed buffer. This would allow the method also to 
      predict the performance of later-disintegrating products. Dissolution performance 
      using the accordingly developed method was compared to that observed when using 
      two well-established dissolution methods: the United States Pharmacopeia (USP) 
      method and blank fasted state simulated intestinal fluid (FaSSIF). The resulting 
      dissolution profiles were convoluted using GastroPlus software to obtain 
      predicted pharmacokinetic profiles. A pharmacokinetic study on healthy human 
      volunteers was performed to evaluate the predictions made by the different 
      dissolution setups. The novel method provided the best prediction, by a 
      relatively wide margin, for the difference between the lag times of the two 
      tested formulations, indicating its being able to predict the post gastric 
      emptying onset of drug release with reasonable accuracy. Both the new and the 
      blank FaSSIF methods showed potential for establishing in vitro-in vivo 
      correlation (IVIVC) concerning the prediction of Cmax and AUC0-24 (prediction 
      errors not more than 20%). However, these predictions are strongly affected by 
      the highly variable first pass metabolism necessitating the evaluation of an 
      absorption rate metric that is more independent of the first-pass effect. The 
      Cmax/AUC0-24 ratio was selected for this purpose. Regarding this metric's 
      predictions, the new method provided very good prediction of the two products' 
      performances relative to each other (only 1.05% prediction error in this regard), 
      while its predictions for the individual products' values in absolute terms were 
      borderline, narrowly missing the regulatory 20% prediction error limits (21.51% 
      for Aspirin Protect and 22.58% for Walgreens Aspirin). The blank FaSSIF-based 
      method provided good Cmax/AUC0-24 ratio prediction, in absolute terms, for 
      Aspirin Protect (9.05% prediction error), but its prediction for Walgreens 
      Aspirin (33.97% prediction error) was overwhelmingly poor. Thus it gave 
      practically the same average but much higher maximum prediction errors compared 
      to the new method, and it was strongly overdiscriminating as for predicting their 
      performances relative to one another. The USP method, despite not being 
      overdiscriminating, provided poor predictions of the individual products' 
      Cmax/AUC0-24 ratios. This indicates that, overall, the new method is of improved 
      biopredictivity compared to established methods.
FAU - Al-Gousous, J
AU  - Al-Gousous J
AD  - Institute of Pharmacy and Biochemistry, Johannes Gutenberg University Mainz , 
      Staudinger Weg 5, 55099 Mainz, Germany.
FAU - Amidon, G L
AU  - Amidon GL
AD  - Department of Pharmaceutical Sciences, University of Michigan , Ann Arbor, 
      Michigan 48109, United States.
FAU - Langguth, P
AU  - Langguth P
AD  - Institute of Pharmacy and Biochemistry, Johannes Gutenberg University Mainz , 
      Staudinger Weg 5, 55099 Mainz, Germany.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160510
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 0 (Bicarbonates)
RN  - 0 (Buffers)
RN  - 0 (Coated Materials, Biocompatible)
RN  - 0 (Dosage Forms)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Area Under Curve
MH  - Aspirin/*chemistry/*metabolism
MH  - Bicarbonates/chemistry
MH  - Biological Availability
MH  - Buffers
MH  - Chemistry, Pharmaceutical/methods
MH  - Coated Materials, Biocompatible/*chemistry
MH  - Dosage Forms
MH  - Drug Liberation/physiology
MH  - Gastric Emptying/physiology
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Intestine, Small/metabolism
MH  - Kinetics
MH  - Solubility
OTO - NOTNLM
OT  - IVIVC
OT  - aspirin
OT  - biopredictive dissolution
OT  - enteric coating
OT  - pharmacokinetics
EDAT- 2016/05/04 06:00
MHDA- 2017/10/20 06:00
CRDT- 2016/05/04 06:00
PHST- 2016/05/04 06:00 [entrez]
PHST- 2016/05/04 06:00 [pubmed]
PHST- 2017/10/20 06:00 [medline]
AID - 10.1021/acs.molpharmaceut.6b00077 [doi]
PST - ppublish
SO  - Mol Pharm. 2016 Jun 6;13(6):1927-36. doi: 10.1021/acs.molpharmaceut.6b00077. Epub 
      2016 May 10.

PMID- 9669495
OWN - NLM
STAT- MEDLINE
DCOM- 19980914
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 349
IP  - 1
DP  - 1998 May 15
TI  - Aspirin induces short-chain free fatty acid accumulation in rats.
PG  - 49-52
AB  - Aspirin is used for the prophylaxis of infarction. A low dose of aspirin is 
      effective for the prophylaxis of myocardial infarction, whereas a higher dose is 
      necessary for that of stroke. Salicylic acid, the in vivo metabolite of aspirin, 
      inhibits the beta-oxidation of short-chain fatty acids. Accordingly, drinking 
      water containing 400, 800, or 1200 mg/l aspirin was given to each of eight rats 
      for 30 days to determine the serum short-chain fatty acid levels. Analysis of 
      variance and a post-hoc Fisher's protected least significant differences test 
      revealed significantly increased levels (P < 0.05) of monocarboxylic acids, 
      n-hexanoate, n-octanoate, n-decanoate, n-dodecanoate, and dicarboxylic acids, 
      adipate (C6,) and suberate (C8): 78.7 +/- 36.2, 61.1 +/- 30.6, 215 +/- 151, 47.5 
      +/- 24.0, 3.64 +/- 2.09 and 1.71 +/- 1.45 micromol/l in the 800 mg/l aspirin 
      group compared to 23.8 +/- 12.3, 20.1 +/- 9.0, 24.3 +/- 12.1, 6.3 +/- 5.6, 0.56 
      +/- 0.50 and 0.44 +/- 0.25 micromol/l in the control group, respectively. These 
      levels were also increased in the 400 or 1200 mg/l aspirin groups but less so. 
      These findings may help us to understand the aspirin toxicity in Reye's syndrome.
FAU - Yoshida, Y
AU  - Yoshida Y
AD  - School of Allied Medical Sciences, Kagoshima University, Sakuragaoka, Japan. 
      yoshiday@health.nop.kagoshima-u.ac.jp
FAU - Wang, S
AU  - Wang S
FAU - Osame, M
AU  - Osame M
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Fatty Acids, Volatile)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics, Non-Narcotic/administration & dosage/*pharmacology/toxicity
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology/toxicity
MH  - Dose-Response Relationship, Drug
MH  - Fatty Acids, Volatile/*blood
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/toxicity
MH  - Rats
MH  - Rats, Wistar
EDAT- 1998/07/21 00:00
MHDA- 1998/07/21 00:01
CRDT- 1998/07/21 00:00
PHST- 1998/07/21 00:00 [pubmed]
PHST- 1998/07/21 00:01 [medline]
PHST- 1998/07/21 00:00 [entrez]
AID - S0014-2999(98)00168-X [pii]
AID - 10.1016/s0014-2999(98)00168-x [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1998 May 15;349(1):49-52. doi: 10.1016/s0014-2999(98)00168-x.

PMID- 3386327
OWN - NLM
STAT- MEDLINE
DCOM- 19880804
LR  - 20131121
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 10
IP  - 3
DP  - 1988 Mar
TI  - Effects of administration route on pharmacokinetics of aspirin in the rabbit.
PG  - 171-5
AB  - The absorption of aspirin used in the form of lysine acetylsalicylate was studied 
      in the rabbit. Each animal received the drug by three routes: intravenous, 
      gastric and duodenal. Plasma concentrations of acetylsalicylic acid (ASA) and 
      salicylic acid (SA) were compared. ASA plasma concentrations obtained after 
      gastric or duodenal administration were low compared to those after intravenous 
      injection. Concentrations were 2 to 5 times higher after gastric than duodenal 
      administration. SA plasma concentrations were lower at the beginning of the 
      experiment for gastric than for duodenal administration; after 90 min the 
      concentrations were similar. A better absorption of aspirin (as lysine 
      acetylsalicylate) after administration occurred in the stomach than in the 
      duodenum, but the amount of ASA which reached the central compartment was quite 
      poor.
FAU - Kergueris, M F
AU  - Kergueris MF
AD  - Department of Pharmacology, U.E.R. of Medicine, Nantes, France.
FAU - Bourin, M
AU  - Bourin M
FAU - Larousse, C
AU  - Larousse C
FAU - Lasserre, M P
AU  - Lasserre MP
FAU - Ortega, A
AU  - Ortega A
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Infusions, Parenteral
MH  - Injections, Intravenous
MH  - Male
MH  - Rabbits
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 1988 Mar;10(3):171-5.

PMID- 934566
OWN - NLM
STAT- MEDLINE
DCOM- 19760901
LR  - 20131121
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 48
IP  - 1
DP  - 1976 Jul
TI  - Effect of aspirin on bleeding time during elective abortion.
PG  - 108-10
AB  - The template bleeding time, indicative of a predictable measure of potential 
      blood loss due to altered platelet function, is unaffected by pregnancy or by the 
      first stage of labor. Two tablets of aspirin (650 mg), but not sodium salicylate 
      or acetaminophen, significantly prolongs the template bleeding time for at least 
      26 hours after consumption in patients undergoing first or second trimester 
      induced abortion. Patients anticipating induced pregnancy interruption should 
      refrain from any aspirin consumption for at least 26 hours prior to abortion.
FAU - Waltman, R
AU  - Waltman R
FAU - Tricomi, V
AU  - Tricomi V
FAU - Tavakoli, F M
AU  - Tavakoli FM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - *Abortion, Induced
MH  - Acetaminophen/pharmacology
MH  - Adolescent
MH  - Adult
MH  - Aspirin/adverse effects/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Disorders/*chemically induced
MH  - Blood Platelets/drug effects
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Pregnancy Trimester, Second
MH  - Pregnancy Trimester, Third
MH  - Sodium Salicylate/pharmacology
EDAT- 1976/07/01 00:00
MHDA- 1976/07/01 00:01
CRDT- 1976/07/01 00:00
PHST- 1976/07/01 00:00 [pubmed]
PHST- 1976/07/01 00:01 [medline]
PHST- 1976/07/01 00:00 [entrez]
PST - ppublish
SO  - Obstet Gynecol. 1976 Jul;48(1):108-10.

PMID- 8154176
OWN - NLM
STAT- MEDLINE
DCOM- 19940512
LR  - 20131121
IS  - 0301-1526 (Print)
IS  - 0301-1526 (Linking)
VI  - 23
IP  - 1
DP  - 1994
TI  - Acetylsalicylic acid--reocclusion--prophylaxis after angioplasty (ARPA-study). A 
      randomized double-blind trial of two different dosages of ASA in patients with 
      peripheral occlusive arterial disease.
PG  - 57-65
AB  - We report on a randomized controlled clinical trial in patients with peripheral 
      occlusive arterial disease who have been successfully treated with angioplasty. 
      The efficacy and the rate of side effects of two doses of ASA (300 mg vs. 1000 mg 
      daily) have been compared during a treatment period of 6 months after 
      angioplasty. It was planned to include a total of 600 patients in the trial. A 
      predefined interim analysis of 200 patients which was performed after the actual 
      inclusion of 218 patients showed identical reocclusions rates and a very similar 
      frequency of side effects in both treatment groups. The study was then terminated 
      since it was not expected that further continuation would lead to a relevant 
      difference between the two treatment groups concerning efficacy or side effects. 
      Patients already included in the trial at the interim evaluation were included in 
      the final analysis, leading to a total number of 223 patients. Finally 112 
      patients had been randomized to receive a daily dose of 300 mg ASA and 111 
      patients to receive 1000 mg ASA. Reocclusions occurred in 18 patients (16%) on 
      300 mg of ASA/day and in 20 patients (18%) receiving 1000 mg ASA/day. The study 
      was interrupted because of side effects in 27 patients (24%) in the 300 mg/day 
      group and in 27 patients (24%) in the 1000 mg/day group. Mostly subjective 
      gastric complaints were the cause of interruption in 17 patients (15%) in the 300 
      mg group and in 21 patients (19%) receiving the higher dose regimen. So the 
      reocclusion rate was identical in both dosage-groups.(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Weichert, W
AU  - Weichert W
AD  - Department of Internal Medicine, J.W. Goethe-University, Frankfurt/Main.
FAU - Meents, H
AU  - Meents H
FAU - Abt, K
AU  - Abt K
FAU - Lieb, H
AU  - Lieb H
FAU - Hach, W
AU  - Hach W
FAU - Krzywanek, H J
AU  - Krzywanek HJ
FAU - Breddin, H K
AU  - Breddin HK
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Vasa
JT  - VASA. Zeitschrift fur Gefasskrankheiten
JID - 0317051
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon
MH  - Arterial Occlusive Diseases/*therapy
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Combined Modality Therapy
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Recurrence
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Vasa. 1994;23(1):57-65.

PMID- 22473097
OWN - NLM
STAT- MEDLINE
DCOM- 20120920
LR  - 20220409
IS  - 1759-4782 (Electronic)
IS  - 1759-4774 (Linking)
VI  - 9
IP  - 5
DP  - 2012 Apr 3
TI  - The role of aspirin in cancer prevention.
PG  - 259-67
LID - 10.1038/nrclinonc.2011.199 [doi]
AB  - Clinical guidelines for prophylactic aspirin use currently only consider the 
      cardiovascular benefits of aspirin, weighed against the potential harm from 
      aspirin-induced bleeding. Daily aspirin use has been convincingly shown to reduce 
      the risk of colorectal cancer and recurrence of adenomatous polyps, but in 
      average-risk populations, these benefits alone do not outweigh harms from 
      aspirin-induced bleeding. Recently published secondary analyses of cardiovascular 
      trials provide the first randomized evidence that daily aspirin use may also 
      reduce the incidence of all cancers combined, even at low doses (75-100 mg 
      daily). This Review considers the general mechanism of action that defines 
      aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) as a class, the 
      specific advantages of aspirin over other NSAIDs for prophylactic use, the 
      current evidence concerning the main health outcomes affected by aspirin use, and 
      the hypothesis that inhibition of platelet activation may mediate both the 
      cardioprotective and cancer-preventive effects of low-dose aspirin. It also 
      considers how even a 10% reduction in overall cancer incidence beginning during 
      the first 10 years of treatment could tip the balance of benefits and risks 
      favourably in average-risk populations.
FAU - Thun, Michael J
AU  - Thun MJ
AD  - Epidemiology Research Program, American Cancer Society, 250 Williams Street, 
      Atlanta, GA 30303-1002, USA. michael.thun@ cancer.org
FAU - Jacobs, Eric J
AU  - Jacobs EJ
FAU - Patrono, Carlo
AU  - Patrono C
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120403
PL  - England
TA  - Nat Rev Clin Oncol
JT  - Nature reviews. Clinical oncology
JID - 101500077
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Neoplasms/*prevention & control
EDAT- 2012/04/05 06:00
MHDA- 2012/09/21 06:00
CRDT- 2012/04/05 06:00
PHST- 2012/04/05 06:00 [entrez]
PHST- 2012/04/05 06:00 [pubmed]
PHST- 2012/09/21 06:00 [medline]
AID - nrclinonc.2011.199 [pii]
AID - 10.1038/nrclinonc.2011.199 [doi]
PST - epublish
SO  - Nat Rev Clin Oncol. 2012 Apr 3;9(5):259-67. doi: 10.1038/nrclinonc.2011.199.

PMID- 26415442
OWN - NLM
STAT- MEDLINE
DCOM- 20151007
LR  - 20181202
IS  - 1000-0593 (Print)
IS  - 1000-0593 (Linking)
VI  - 35
IP  - 5
DP  - 2015 May
TI  - [Fast Discrimination of Drugs by Improved Projection Algorithm Based on Raman 
      Spectroscopy].
PG  - 1271-5
AB  - The projection algorithm used in mixture analysis to determine whether there is 
      unknown disturbance existing in grey system can not accurately identify different 
      samples and similar samples at the same time when it is used in the 
      identification of drugs, because of the insufficient criteria. In the present 
      study, one of its criteria for whether the size of measurement error of testing 
      sample is at a limited level is improved for whether the size and distribution of 
      measurement error is equal and similar between testing sample and standard 
      sample. By testing 6 kinds of normal drugs (including BAYER Aspirin 
      Enteric-coated Tablets, TYLENOL Acetaminophen Sustained Release Tablets, BAYER 
      Compound Paracetamol Tablets(II), HUAZHONG Compound Vitamin C, HUAZHONG Vitamin B 
      and MADINGLIN Demperidone Tablets) and 3 kinds of similar drugs of aspirin 
      (including BAYER Aspirin Enteric-coated Tablets, Shanghai SINE Aspirin 
      Enteric-coated Tablets and Bamyl Aspirin Effervescent Tablets), it was found that 
      the un-improved projection algorithm directly used in discrimination of drugs 
      shows poor performance with many problems existing, however, the improved 
      projection algorithm can discriminate different drugs and similar drugs with 
      accuracy up to 100%. The improved projection algorithm can be a universal, 
      accurate and reliable automated pharmaceutical identification algorithm and can 
      provide a reference for the study on identification of substance.
FAU - Jia, Nan-nan
AU  - Jia NN
FAU - Ji, Jiang
AU  - Ji J
FAU - Gao, Peng-fei
AU  - Gao PF
FAU - Ruan, Bin
AU  - Ruan B
FAU - Tao, Zhen-qiang
AU  - Tao ZQ
FAU - Li, Long-tan
AU  - Li LT
FAU - Li, Xiao
AU  - Li X
FAU - Guo, Han-ming
AU  - Guo HM
LA  - chi
PT  - Journal Article
PL  - China
TA  - Guang Pu Xue Yu Guang Pu Fen Xi
JT  - Guang pu xue yu guang pu fen xi = Guang pu
JID - 9424805
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/analysis
MH  - *Algorithms
MH  - Aspirin/analysis
MH  - Chemistry, Pharmaceutical/*methods
MH  - *Spectrum Analysis, Raman
MH  - Tablets
EDAT- 2015/09/30 06:00
MHDA- 2015/10/08 06:00
CRDT- 2015/09/30 06:00
PHST- 2015/09/30 06:00 [entrez]
PHST- 2015/09/30 06:00 [pubmed]
PHST- 2015/10/08 06:00 [medline]
PST - ppublish
SO  - Guang Pu Xue Yu Guang Pu Fen Xi. 2015 May;35(5):1271-5.

PMID- 3881574
OWN - NLM
STAT- MEDLINE
DCOM- 19850228
LR  - 20190814
IS  - 0278-2391 (Print)
IS  - 0278-2391 (Linking)
VI  - 43
IP  - 2
DP  - 1985 Feb
TI  - Comparison of the analgesic efficacy of flurbiprofen and aspirin for postsurgical 
      dental pain.
PG  - 106-9
AB  - The analgesic efficacy of flurbiprofen 25 mg and 50 mg compared with aspirin 650 
      mg and placebo (lactose) was evaluated. Subjects were 164 dental outpatients 
      undergoing the surgical removal of impacted teeth. Each subject received a single 
      dose of study medication and was evaluated hourly for six hours. Aspirin was 
      superior to placebo in all measures of analgesic efficacy, and both dosages of 
      flurbiprofen were superior to aspirin.
FAU - Mardirossian, G
AU  - Mardirossian G
FAU - Cooper, S A
AU  - Cooper SA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Oral Maxillofac Surg
JT  - Journal of oral and maxillofacial surgery : official journal of the American 
      Association of Oral and Maxillofacial Surgeons
JID - 8206428
RN  - 0 (Placebos)
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Flurbiprofen/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
MH  - Propionates/*therapeutic use
MH  - Time Factors
MH  - Tooth Extraction
EDAT- 1985/02/01 00:00
MHDA- 1985/02/01 00:01
CRDT- 1985/02/01 00:00
PHST- 1985/02/01 00:00 [pubmed]
PHST- 1985/02/01 00:01 [medline]
PHST- 1985/02/01 00:00 [entrez]
AID - 0278-2391(85)90056-4 [pii]
AID - 10.1016/0278-2391(85)90056-4 [doi]
PST - ppublish
SO  - J Oral Maxillofac Surg. 1985 Feb;43(2):106-9. doi: 10.1016/0278-2391(85)90056-4.

PMID- 6115201
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8244
DP  - 1981 Aug 29
TI  - Failure of aspirin to prevent incorporation of indium-111 labelled platelets into 
      cardiac thrombi in man.
PG  - 440-3
AB  - The in vitro and in vivo behaviour of platelets was studied in eleven patients 
      with left ventricular aneurysms and mural thrombi. Five patients were on aspirin 
      300-2400 mg/day; the remaining six patients were controls. In vitro function was 
      tested by the aggregation response of platelets to adenosine diphosphate (ADP) 
      and collagen. In vivo function was assessed by the incorporation of 
      indium-111-labelled platelets into cardiac thrombi as measured by scintigraphy. 
      Platelets from patients on aspirin, whether tested before or after labelling, 
      aggregated less with collagen than did those of controls (18 vs 52%; p less than 
      0.01 before labelling, 13 vs 49%; p less than 0.02 after labelling). Second wave 
      aggregation, induced by ADP, was impaired in patients on aspirin. In all patients 
      scintigraphy showed that the autologous labelled platelets were incorporated into 
      ventricular thrombi. Thus, although in vitro the platelets from patients on 
      aspirin aggregated subnormally, in vivo they took part in thrombosis.
FAU - Ezekowitz, M D
AU  - Ezekowitz MD
FAU - Cox, A C
AU  - Cox AC
FAU - Smith, E O
AU  - Smith EO
FAU - Taylor, F B
AU  - Taylor FB
LA  - eng
GR  - 2 PO1 HC 17812-06/HC/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Radioisotopes)
RN  - 045A6V3VFX (Indium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/diagnostic imaging/*drug effects/metabolism
MH  - Heart Aneurysm/complications
MH  - Heart Diseases/*prevention & control
MH  - Heart Ventricles
MH  - Humans
MH  - Indium
MH  - Platelet Aggregation/drug effects
MH  - Radioisotopes
MH  - Radionuclide Imaging
MH  - Thrombosis/*prevention & control
EDAT- 1981/08/29 00:00
MHDA- 1981/08/29 00:01
CRDT- 1981/08/29 00:00
PHST- 1981/08/29 00:00 [pubmed]
PHST- 1981/08/29 00:01 [medline]
PHST- 1981/08/29 00:00 [entrez]
AID - S0140-6736(81)90775-3 [pii]
AID - 10.1016/s0140-6736(81)90775-3 [doi]
PST - ppublish
SO  - Lancet. 1981 Aug 29;2(8244):440-3. doi: 10.1016/s0140-6736(81)90775-3.

PMID- 35699872
OWN - NLM
STAT- MEDLINE
DCOM- 20221101
LR  - 20221224
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 54
IP  - 4
DP  - 2022 Nov
TI  - A survey of internists' recommendations for aspirin in older adults and barriers 
      to evidence-based use.
PG  - 639-646
LID - 10.1007/s11239-022-02669-7 [doi]
AB  - Recent trials suggest that aspirin for primary prevention may do more harm than 
      good for some, including adults over 70 years of age. We sought to assess how 
      primary care providers (PCPs) use aspirin for the primary prevention in older 
      patients and to identify barriers to use according to recent guidelines, which 
      recommend against routine use in patients over age 70. We surveyed PCPs about 
      whether they would recommend aspirin in clinical vignettes of a 75-year-old 
      patient with a 10-year atherosclerotic cardiovascular disease risk of 25%. We 
      also queried perceived difficulty following guideline recommendations, as well as 
      perceived barriers and facilitators. We obtained responses from 372 PCPs (47.9% 
      response). In the patient vignette, 45.4% of clinicians recommended aspirin use, 
      which did not vary by whether the patient was using aspirin initially (p = 0.21); 
      41.7% believed aspirin was beneficial. Perceived barriers to guideline-based 
      aspirin use included concern about patients being upset (41.6%), possible 
      malpractice claims (25.0%), and not having a strategy for discussing aspirin use 
      (24.5%). The estimated adjusted probability of rating the guideline as "hard to 
      follow" was higher in clinicians who believed aspirin was beneficial (29.4% vs. 
      8.0%; p < 0.001) and who worried the patient would be upset if told to stop 
      aspirin (26.7% vs. 12.5%; p = 0.001). Internists vary considerably in their 
      recommendations for aspirin use for primary prevention in older patients. A high 
      proportion of PCPs continue to believe aspirin is beneficial in this setting. 
      These results can inform de-implementation efforts to optimize evidence-based 
      aspirin use.
CI  - © 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Schaefer, Jordan K
AU  - Schaefer JK
AUID- ORCID: 0000-0002-7166-386X
AD  - Department of Internal Medicine, Division of Hematology/Oncology, University of 
      Michigan, C366 Med Inn Building, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, 
      USA. jschaef@med.umich.edu.
FAU - Barnes, Geoffrey D
AU  - Barnes GD
AD  - Department of Internal Medicine, Division of Cardiovascular Medicine, University 
      of Michigan, Ann Arbor, MI, USA.
FAU - Sussman, Jeremy B
AU  - Sussman JB
AD  - Department of Internal Medicine, Division of General Medicine, University of 
      Michigan, Ann Arbor, MI, USA.
AD  - Veterans Affairs Ann Arbor Center for Clinical Management Research, Ann Arbor, 
      MI, USA.
FAU - Saini, Sameer D
AU  - Saini SD
AD  - Veterans Affairs Ann Arbor Center for Clinical Management Research, Ann Arbor, 
      MI, USA.
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      University of Michigan, Ann Arbor, MI, USA.
FAU - Caverly, Tanner J
AU  - Caverly TJ
AD  - Veterans Affairs Ann Arbor Center for Clinical Management Research, Ann Arbor, 
      MI, USA.
AD  - Department of Learning Health Sciences, University of Michigan, Ann Arbor, MI, 
      USA.
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      University of Michigan, Ann Arbor, MI, USA.
FAU - Read, Susan
AU  - Read S
AD  - Research Center, American College of Physicians, Philadelphia, PA, USA.
FAU - Zikmund-Fisher, Brian J
AU  - Zikmund-Fisher BJ
AD  - Department of Internal Medicine, Division of General Medicine, University of 
      Michigan, Ann Arbor, MI, USA.
AD  - Department of Health Behavior and Health Education, School of Public Health, 
      University of Michigan, Ann Arbor, MI, USA.
AD  - Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann 
      Arbor, MI, USA.
FAU - Kurlander, Jacob E
AU  - Kurlander JE
AD  - Veterans Affairs Ann Arbor Center for Clinical Management Research, Ann Arbor, 
      MI, USA.
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      University of Michigan, Ann Arbor, MI, USA.
LA  - eng
GR  - K23DK118179/DK/NIDDK NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
DEP - 20220614
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aspirin/therapeutic use
MH  - Attitude of Health Personnel
MH  - *Physicians
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Primary prevention
OT  - Surveys and questionnaires
EDAT- 2022/06/15 06:00
MHDA- 2022/11/02 06:00
CRDT- 2022/06/14 11:19
PHST- 2022/05/20 00:00 [accepted]
PHST- 2022/06/15 06:00 [pubmed]
PHST- 2022/11/02 06:00 [medline]
PHST- 2022/06/14 11:19 [entrez]
AID - 10.1007/s11239-022-02669-7 [pii]
AID - 10.1007/s11239-022-02669-7 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2022 Nov;54(4):639-646. doi: 10.1007/s11239-022-02669-7. 
      Epub 2022 Jun 14.

PMID- 16316223
OWN - NLM
STAT- MEDLINE
DCOM- 20060216
LR  - 20131121
IS  - 0002-7863 (Print)
IS  - 0002-7863 (Linking)
VI  - 127
IP  - 48
DP  - 2005 Dec 7
TI  - The predictably elusive form II of aspirin.
PG  - 16802-3
AB  - The elusive form II of aspirin has been obtained during co-crystallization 
      experiments with levetiracetam or acetamide, and it has been characterized by IR, 
      DSC, HPLC, and single-crystal X-ray diffraction.
FAU - Vishweshwar, Peddy
AU  - Vishweshwar P
AD  - Department of Chemistry, University of South Florida, Tampa, 33620, USA.
FAU - McMahon, Jennifer A
AU  - McMahon JA
FAU - Oliveira, Mark
AU  - Oliveira M
FAU - Peterson, Matthew L
AU  - Peterson ML
FAU - Zaworotko, Michael J
AU  - Zaworotko MJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Chem Soc
JT  - Journal of the American Chemical Society
JID - 7503056
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Models, Molecular
MH  - X-Ray Diffraction
EDAT- 2005/12/01 09:00
MHDA- 2006/02/17 09:00
CRDT- 2005/12/01 09:00
PHST- 2005/12/01 09:00 [pubmed]
PHST- 2006/02/17 09:00 [medline]
PHST- 2005/12/01 09:00 [entrez]
AID - 10.1021/ja056455b [doi]
PST - ppublish
SO  - J Am Chem Soc. 2005 Dec 7;127(48):16802-3. doi: 10.1021/ja056455b.

PMID- 2122535
OWN - NLM
STAT- MEDLINE
DCOM- 19901212
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 59
IP  - 2
DP  - 1990 Jul 15
TI  - Effects on cyclo-oxygenase of low and high dose aspirin.
PG  - 227-35
AB  - The study was undertaken to develop clinically applicable methods to detect the 
      influence of low dose treatment with acetylsalicylic acid (ASA) on the platelet 
      function. The cyclooxygenase activity of the platelets was measured by 
      determination of the metabolite 12-HHT after challenge with arachidonic acid. Two 
      healthy subjects received 600 mg ASA in a single dose. Two hours after intake the 
      salicylate concentration level in plasma was 600 nmol/ml, with a 90 per cent 
      reduction after 24 hours. The platelet cyclooxygenase activity (12-HHT) was 
      completely and irreversibly inhibited within two hours after ASA intake. Five 
      subjects received 75 mg ASA for eight consecutive days. The salicylate 
      concentrations two hours after the intake of the first and last tablet were 
      within 65 and 71 nmol/ml plasma, indicating that no accumulation of salicylate 
      occurred during the treatment period. The decrease in cyclooxygenase activity 
      during low dose treatment varied in the different subjects between 60 and 90 per 
      cent. The rate of recovery of cyclooxygenase activity after termination of the 
      low dose ASA treatment was faster than after the large single dose.
FAU - Beving, H
AU  - Beving H
AD  - Department of Experimental Surgery, Karolinska Hospital, Stockholm, Sweden.
FAU - Eksborg, S
AU  - Eksborg S
FAU - Nordlander, R
AU  - Nordlander R
FAU - Olsson, P
AU  - Olsson P
FAU - Olsson, U
AU  - Olsson U
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 50683-78-8 (12-hydroxy-5,8,10-heptadecatrienoic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Blood Platelets/drug effects/enzymology
MH  - *Cyclooxygenase Inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Fatty Acids, Unsaturated/blood
MH  - Hematologic Tests
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1990/07/15 00:00
MHDA- 1990/07/15 00:01
CRDT- 1990/07/15 00:00
PHST- 1990/07/15 00:00 [pubmed]
PHST- 1990/07/15 00:01 [medline]
PHST- 1990/07/15 00:00 [entrez]
AID - 10.1016/0049-3848(90)90126-w [doi]
PST - ppublish
SO  - Thromb Res. 1990 Jul 15;59(2):227-35. doi: 10.1016/0049-3848(90)90126-w.

PMID- 6737250
OWN - NLM
STAT- MEDLINE
DCOM- 19840801
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 73
IP  - 5
DP  - 1984 May
TI  - Disintegrating force as a new formulation parameter.
PG  - 701-5
AB  - Some coated aspirin tablet formulations were evaluated by relating their 
      properties to disintegrating force development patterns. The treatment of 
      disintegrating force-time curves was effected using the Weibull distribution as 
      proposed for dissolution. Such parameters as the maximum disintegrating force 
      developed, the time needed to reach 63.2% maximum disintegrating force (tau d) 
      the shape parameter, the lag time, and the input value were used for evaluating 
      the formulas examined. It was concluded that the input values, the integrating 
      force development rate at tau d, can be employed as a new formulation parameter 
      since, when correlated with the crushing strength, it allows an overall 
      evaluation of the formula examined.
FAU - Colombo, P
AU  - Colombo P
FAU - Conte, U
AU  - Conte U
FAU - Caramella, C
AU  - Caramella C
FAU - Geddo, M
AU  - Geddo M
FAU - La Manna, A
AU  - La Manna A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - *Drug Compounding
MH  - Excipients
MH  - Pressure
MH  - Solubility
MH  - *Tablets
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
AID - S0022-3549(15)46110-6 [pii]
AID - 10.1002/jps.2600730531 [doi]
PST - ppublish
SO  - J Pharm Sci. 1984 May;73(5):701-5. doi: 10.1002/jps.2600730531.

PMID- 12481162
OWN - NLM
STAT- MEDLINE
DCOM- 20030428
LR  - 20171101
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 66
IP  - 3
DP  - 2002
TI  - Nitric oxide releasing aspirin protects the gastric mucosa against stress and 
      promotes healing of stress-induced gastric mucosal damage: role of heat shock 
      protein 70.
PG  - 160-72
AB  - BACKGROUND/AIM: Nitric oxide (NO) releasing nonsteroidal anti-inflammatory drugs 
      do not cause gastric mucosal damage, despite inhibition of the cyclooxygenase 
      activity to a similar extent as conventional nonsteroidal anti-inflammatory drugs 
      that induce such damage. We compared the effects of native aspirin (ASA) with 
      those of NO-releasing ASA (NO-ASA) on the development and healing of acute 
      gastric lesions induced by water immersion and restraint stress (WRS) and the 
      mucosal expression of heat shock protein 70 (HSP70). METHODS: Wistar rats 
      received: (1). vehicle; (2). ASA (40 mg/kg i.g), and (3). NO-ASA (2.5-40 mg/kg 
      i.g.), followed 0.5 h later by 3.5 h of WRS with or without glyceryl trinitrate, 
      the donor of NO, and carboxy-PTIO, a NO scavenger. Healing of WRS lesions was 
      assessed 0-24 h after termination of WRS. Number of gastric lesions, gastric 
      mucosal blood flow (GBF), malondialdehyde (MDA) content, and RT-PCR expression of 
      HSP70 mRNA were determined. RESULTS: WRS caused typical bleeding erosions that 
      were aggravated by aspirin and this was accompanied by a fall in the GBF and a 
      significant rise in the mucosal MDA concentrations. In contrast, NO-ASA, which 
      raised significantly the luminal content of NO(x), reduced number of WRS lesions 
      and mucosal MDA levels while increasing significantly the GBF. These protective 
      and hyperemic effects of NO-ASA against WRS lesions were mimicked by addition of 
      glyceryl trinitrate to native ASA and significantly attenuated by carboxy-PTIO 
      added to NO-ASA. HSP70 mRNA was significantly upregulated by WRS, and this was 
      significantly attenuated by ASA, but not by NO-ASA. NO-ASA decreased 
      significantly the MDA content and induced overexpression of HSP70 mRNA during 
      healing of WRS lesions. CONCLUSION: NO-ASA exhibits mucosal protective and 
      healing effects against WRS-induced gastric lesions due to the release of NO, 
      which induces gastric hyperemia, and the attenuation of lipid peroxidation and 
      counteracts the inhibition of HSP70 expression induced by native ASA.
CI  - Copyright 2002 S. Karger AG, Basel
FAU - Konturek, Peter C
AU  - Konturek PC
AD  - First Department of Medicine I, University Erlangen-Nürnberg, Erlangen, Germany. 
      pkonturek@aol.com
FAU - Brzozowski, Thomas
AU  - Brzozowski T
FAU - Ptak, Agata
AU  - Ptak A
FAU - Kania, Joanna
AU  - Kania J
FAU - Kwiecień, Sławomir
AU  - Kwiecień S
FAU - Hahn, Eckhart G
AU  - Hahn EG
FAU - Konturek, Stanisław J
AU  - Konturek SJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (HSP70 Heat-Shock Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Gastric Mucosa/*drug effects
MH  - HSP70 Heat-Shock Proteins/biosynthesis/*physiology
MH  - Lipid Peroxidation
MH  - RNA, Messenger/genetics
MH  - Rats
MH  - Rats, Wistar
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Stress, Physiological/*physiopathology
EDAT- 2002/12/14 04:00
MHDA- 2003/04/29 05:00
CRDT- 2002/12/14 04:00
PHST- 2002/12/14 04:00 [pubmed]
PHST- 2003/04/29 05:00 [medline]
PHST- 2002/12/14 04:00 [entrez]
AID - 66762 [pii]
AID - 10.1159/000066762 [doi]
PST - ppublish
SO  - Digestion. 2002;66(3):160-72. doi: 10.1159/000066762.

PMID- 25660719
OWN - NLM
STAT- MEDLINE
DCOM- 20151117
LR  - 20150302
IS  - 1873-376X (Electronic)
IS  - 1570-0232 (Linking)
VI  - 985
DP  - 2015 Mar 15
TI  - Determination of acetylsalicylic acid and its major metabolites in bovine urine 
      using ultra performance liquid chromatography.
PG  - 85-90
LID - S1570-0232(15)00059-8 [pii]
LID - 10.1016/j.jchromb.2015.01.026 [doi]
AB  - A new method based on ultra high performance liquid chromatography (UPLC) with 
      photometric and fluorometric detection for the determination of acetylsalicylic 
      acid and its main metabolites, namely gentisic, salicylic and salicyluric acids, 
      in bovine urine samples is reported. Photometric detection was used for 
      acetylsalicylic acid determination, whereas the native fluorescence of the 
      metabolites was monitored using fluorometric detection. The separation was 
      performed under isocratic conditions, using acetonitrile-phosphate solution 
      (3.5mM, pH 3.5) (26:74, v/v) as the mobile phase. The retention times of the four 
      compounds were lower than 2min, which are shorter than those achieved using 
      conventional HPLC. Under the optimum separation conditions, the dynamic ranges 
      and detection limits (ngmL(-1)) were: 0.2-2500, 0.09 for gentisic acid; 0.2-2500, 
      0.08 for salicylic acid and 2.5-15,000, 1.1 for salicyluric acid, using 
      fluorescence detection, and 10-25,000, 2.2 for acetylsalicylic acid, using UV 
      detection. Intra-day and inter-day precision data were assessed at two levels of 
      concentration of each analyte using both detection systems. The selectivity of 
      the method was checked by assaying different drugs of veterinary use showing that 
      most of them did not interfere with the determination of the analytes. The method 
      has been applied to the analysis of bovine urine samples, which only required a 
      simple clean up step of the samples prior to injection in the UPLC system. A 
      recovery study was performed, which provided values in the range of 80-100%. This 
      fact proves the practical usefulness of this method as an ultrafast analytical 
      tool for the therapeutic control of acetylsalicylic acid administration in bovine 
      animals intended for food production.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Castillo-García, M L
AU  - Castillo-García ML
AD  - Analytical Chemistry Department, Institute of Fine Chemistry and Nanochemistry, 
      Campus of Rabanales, Annex to Marie Curie Building, University of Córdoba, 14071 
      Córdoba, Spain. Electronic address: q32cagam@uco.es.
FAU - Aguilar-Caballos, M P
AU  - Aguilar-Caballos MP
AD  - Analytical Chemistry Department, Institute of Fine Chemistry and Nanochemistry, 
      Campus of Rabanales, Annex to Marie Curie Building, University of Córdoba, 14071 
      Córdoba, Spain. Electronic address: qalagcam@uco.es.
FAU - Gómez-Hens, A
AU  - Gómez-Hens A
AD  - Analytical Chemistry Department, Institute of Fine Chemistry and Nanochemistry, 
      Campus of Rabanales, Annex to Marie Curie Building, University of Córdoba, 14071 
      Córdoba, Spain. Electronic address: qalgohea@uco.es.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150125
PL  - Netherlands
TA  - J Chromatogr B Analyt Technol Biomed Life Sci
JT  - Journal of chromatography. B, Analytical technologies in the biomedical and life 
      sciences
JID - 101139554
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*metabolism/*urine
MH  - Cattle
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Limit of Detection
MH  - Linear Models
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Bovine urine samples
OT  - Major metabolites
OT  - Photometric and fluorometric detection
OT  - Ultraperformance liquid chromatography
EDAT- 2015/02/11 06:00
MHDA- 2015/11/18 06:00
CRDT- 2015/02/10 06:00
PHST- 2014/09/19 00:00 [received]
PHST- 2014/12/22 00:00 [revised]
PHST- 2015/01/19 00:00 [accepted]
PHST- 2015/02/10 06:00 [entrez]
PHST- 2015/02/11 06:00 [pubmed]
PHST- 2015/11/18 06:00 [medline]
AID - S1570-0232(15)00059-8 [pii]
AID - 10.1016/j.jchromb.2015.01.026 [doi]
PST - ppublish
SO  - J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Mar 15;985:85-90. doi: 
      10.1016/j.jchromb.2015.01.026. Epub 2015 Jan 25.

PMID- 25144449
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 8
DP  - 2014
TI  - Safety of low-dose aspirin in endovascular treatment for intracranial 
      atherosclerotic stenosis.
PG  - e105252
LID - 10.1371/journal.pone.0105252 [doi]
LID - e105252
AB  - OBJECTIVES: To evaluate the safety of low-dose aspirin plus clopidogrel versus 
      high-dose aspirin plus clopidogrel in prevention of vascular risk within 90 days 
      of duration of dual antiplatelet therapy in patients treated with intracranial 
      endovascular treatment. METHODS: From January 2012 to December 2013, this 
      prospective and observational study enrolled 370 patients with symptomatic 
      intracranial atherosclerotic stenosis of ≥70% with poor collateral undergoing 
      intracranial endovascular treatment. Antiplatelet therapy consists of aspirin, at 
      a low-dose of 100 mg or high-dose of 300 mg daily; clopidogrel, at a dose of 75 
      mg daily for 5 days before endovascular treatment. The dual antiplatelet therapy 
      continued for 90 days after intervention. The study endpoints include acute 
      thrombosis, subacute thrombosis, stroke or death within 90 days after 
      intervention. RESULTS: Two hundred and seventy three patients received low-dose 
      aspirin plus clopidogrel and 97 patients received high-dose aspirin plus 
      clopidogrel before intracranial endovascular treatment. Within 90 days after 
      intervention, there were 4 patients (1.5%) with acute thrombosis, 5 patients 
      (1.8%) with subacute thrombosis, 17 patients (6.2%) with stroke, and 2 death 
      (0.7%) in low-dose aspirin group, compared with no patient (0%) with acute 
      thrombosis, 2 patient (2.1%) with subacute thrombosis, 6 patients (6.2%) with 
      stroke, and 2 death (2.1%) in high-dose aspirin group, and there were no 
      significant difference in all study endpoints between two groups. CONCLUSION: 
      Low-dose aspirin plus clopidogrel is comparative in safety with high-dose aspirin 
      plus clopidogrel within 90 days of duration of dual antiplatelet therapy in 
      patients treated with intracranial endovascular treatment.
FAU - Ma, Ning
AU  - Ma N
AD  - Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Xu, Ziqi
AU  - Xu Z
AD  - Department of Neurology, the First Affiliated Hospital of College of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Mo, Dapeng
AU  - Mo D
AD  - Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Gao, Feng
AU  - Gao F
AD  - Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Gao, Kun
AU  - Gao K
AD  - Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Sun, Xuan
AU  - Sun X
AD  - Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Xu, Xiaotong
AU  - Xu X
AD  - Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Liu, Lian
AU  - Liu L
AD  - Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Song, Ligang
AU  - Song L
AD  - Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Wang, Tiejun
AU  - Wang T
AD  - Department of Neurology, the Daxing District Hospital of Beijing, Beijing, China.
FAU - Zhao, Xingquan
AU  - Zhao X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wang, Yilong
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Miao, Zhongrong
AU  - Miao Z
AD  - Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140821
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Constriction, Pathologic/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Prospective Studies
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
PMC - PMC4140744
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/08/22 06:00
MHDA- 2015/05/12 06:00
CRDT- 2014/08/22 06:00
PHST- 2013/12/17 00:00 [received]
PHST- 2014/07/22 00:00 [accepted]
PHST- 2014/08/22 06:00 [entrez]
PHST- 2014/08/22 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - PONE-D-13-52175 [pii]
AID - 10.1371/journal.pone.0105252 [doi]
PST - epublish
SO  - PLoS One. 2014 Aug 21;9(8):e105252. doi: 10.1371/journal.pone.0105252. 
      eCollection 2014.

PMID- 21544823
OWN - NLM
STAT- MEDLINE
DCOM- 20111027
LR  - 20131121
IS  - 1520-6017 (Electronic)
IS  - 0022-3549 (Linking)
VI  - 100
IP  - 9
DP  - 2011 Sep
TI  - A randomized, quadruple crossover single-blind study on immediate action of 
      chewed and unchewed low-dose acetylsalicylic acid tablets in healthy volunteers.
PG  - 3884-91
LID - 10.1002/jps.22602 [doi]
AB  - In the initial treatment of acute myocardial infarction, it is important to 
      administer oral low-dose acetylsalicylic acid (ASA) within 10 min of arrival at 
      the hospital. However, ASA is supplied as an enteric-coated tablet or buffered 
      tablet to prevent gastric irritation. Although current guidelines recommended 
      that patients should chew their initial dose of ASA, there is little evidence as 
      to whether this is efficacious. Therefore, we aimed to make a direct comparison 
      of the pharmacokinetics and pharmacodynamics of ASA after ingestion of intact and 
      chewed nonenteric-coated buffered ASA tablet (NBA) and enteric-coated ASA tablet 
      (ECA) in a quadruple crossover study in healthy volunteers. Chewing ECA 
      accelerated t(max) of ASA absorption, which became equivalent to that after 
      ingestion of intact or chewed NBA. A significant decrease in serum thromboxane 
      B(2) was observed 20 min after ingestion of chewed ECA, or intact or chewed NBA, 
      and inhibition of platelet aggregation was also observed within 20 min. Thus, 
      chewing of the ECA appears to result in a similar timing of ASA action to that in 
      the case of chewed or unchewed NBA.
CI  - Copyright © 2011 Wiley-Liss, Inc.
FAU - Sai, Yoshimichi
AU  - Sai Y
AD  - Department of Hospital Pharmacy, Kanazawa University, Kanazawa 920-8641, Japan. 
      sai-ys@staff.kanazawa-u.ac.jp
FAU - Kusaka, Akiyo
AU  - Kusaka A
FAU - Imanishi, Kaori
AU  - Imanishi K
FAU - Matsumoto, Manami
AU  - Matsumoto M
FAU - Takahashi, Rie
AU  - Takahashi R
FAU - Sugimoto, Natsumi
AU  - Sugimoto N
FAU - Sugama, Junko
AU  - Sugama J
FAU - Anada, Takako
AU  - Anada T
FAU - Asakura, Hidesaku
AU  - Asakura H
FAU - Miyamoto, Ken-ichi
AU  - Miyamoto K
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110504
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Tablets)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Cross-Over Studies
MH  - Humans
MH  - *Mastication
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Reference Values
MH  - Single-Blind Method
MH  - *Tablets
MH  - Thromboxane A2/blood
EDAT- 2011/05/06 06:00
MHDA- 2011/10/28 06:00
CRDT- 2011/05/06 06:00
PHST- 2011/02/24 00:00 [received]
PHST- 2011/04/13 00:00 [revised]
PHST- 2011/04/18 00:00 [accepted]
PHST- 2011/05/06 06:00 [entrez]
PHST- 2011/05/06 06:00 [pubmed]
PHST- 2011/10/28 06:00 [medline]
AID - S0022-3549(15)31954-7 [pii]
AID - 10.1002/jps.22602 [doi]
PST - ppublish
SO  - J Pharm Sci. 2011 Sep;100(9):3884-91. doi: 10.1002/jps.22602. Epub 2011 May 4.

PMID- 786007
OWN - NLM
STAT- MEDLINE
DCOM- 19761101
LR  - 20200304
IS  - 0002-9211 (Print)
IS  - 0002-9211 (Linking)
VI  - 21
IP  - 9
DP  - 1976 Sep
TI  - Aspirin-induced hepatic dysfunction in a patient with adult rheumatoid arthritis.
PG  - 815-20
AB  - A patient with classical rheumatoid arthritis receiving high doses of aspirin 
      developed significant elevation of serum glutamic oxaloacetic transaminase. This 
      patient had recently been on phenylbutazone and an initial liver biopsy, at the 
      time of elevation of the transaminase revealed nonspecific mild fatty 
      infiltration of the liver compatible with the pathology seen with rheumatoid 
      disease. Because of the severity and activity of her rheumatoid arthritis, and 
      thus the need to know whether aspirin was the etiologic factor in liver 
      dysfunction, the patient was challenged with aspirin. SGOT elevation occurred 
      after a 4-6 day lag period, which promptly remitted when salicylates were 
      discontinued. A liver biopsy at this time revealed evidence for degeneration, 
      regeneration, and mild focal mononuclear infiltration. Although previous reports 
      note salicylate-related hepatocellular dysfunction in patients with systemic 
      lupus erythematosus and juvenile rheumatoid arthritis, these data clearly 
      demonstrate the relationship of ASA to liver dysfunction in a patient with adult 
      onset rheumatoid arthritis. This histologic picture as well as the clinical 
      course of this patient's hepatic abnormality suggest a toxic rather than 
      hypersensitivity etiology for this syndrome.
FAU - Saltzman, D A
AU  - Saltzman DA
FAU - Gall, E P
AU  - Gall EP
FAU - Robinson, S F
AU  - Robinson SF
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am J Dig Dis
JT  - The American journal of digestive diseases
JID - 0404011
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspartate Aminotransferases/*blood
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Biopsy
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Liver/*drug effects/pathology
MH  - Middle Aged
EDAT- 1976/09/01 00:00
MHDA- 1976/09/01 00:01
CRDT- 1976/09/01 00:00
PHST- 1976/09/01 00:00 [pubmed]
PHST- 1976/09/01 00:01 [medline]
PHST- 1976/09/01 00:00 [entrez]
AID - 10.1007/BF01073038 [doi]
PST - ppublish
SO  - Am J Dig Dis. 1976 Sep;21(9):815-20. doi: 10.1007/BF01073038.

PMID- 17971198
OWN - NLM
STAT- MEDLINE
DCOM- 20080307
LR  - 20211020
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 5
DP  - 2007 Oct 30
TI  - Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel 
      nitric oxide-releasing aspirin, in colon cancer cell lines.
PG  - 52
AB  - BACKGROUND: Despite numerous studies aimed at verifying the antitumor activity of 
      nitric oxide-releasing nonsteroidal antiflammatory drugs (NO-NSAIDs), little is 
      known about the molecular targets responsible for their antineoplastic 
      properties. In the present study, we investigated the mechanisms underlying the 
      cytotoxicity of NCX 4040, a novel NO-aspirin with promising antineoplastic 
      action, in in vitro human colon cancer models. METHODS: The effect on tumor 
      growth was evaluated in four human colon cancer cell lines (LoVo, LRWZ, WiDr and 
      LoVo Dx) by sulforhodamine B assay, oxidative stress by immunohistochemistry, 
      apoptosis by laddering assay, mitochondrial membrane potential (DeltaPsim) by 
      flow cytometry, and apoptosis- and chemoresistance-related markers by 
      western-blot and real-time method, respectively. Prostaglandin E2 levels were 
      determined by ELISA. RESULTS: NCX 4040 produced a higher cytotoxic effect in all 
      the cell lines than that produced by other NO donors tested. In particular, in 
      LoVo and LRWZ cells, NCX 4040 induced a cytocidal effect and apoptosis through 
      p53 and NAG-1 expression, an early DeltaPsim collapse, and a sequential release 
      of cytoplasmatic cytochrome c and caspase -9 and -3 active forms. 
      8-hydroxyguanine lesions, indicative of oxidative stress, were also observed. 
      Conversely, in WiDr line, the drug caused a cytocidal effect, albeit not through 
      apoptosis, and a concomitant increase in COX-2 activity. In LoVo Dx line, 
      characterized by high levels drug resistance and DNA repair-related markers, only 
      a cytostatic effect was observed, again in concomitance with the increase in 
      COX-2 enzyme activity. CONCLUSION: This study highlights the multiplicity of 
      mechanisms involved in sensitivity or resistance to NCX 4040 and could provide 
      useful indications for tailored therapy by identifying potentially 
      drug-responsive tumors.
FAU - Tesei, Anna
AU  - Tesei A
AD  - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, 
      Italy. anna.tesei@ausl.fo.it
FAU - Rosetti, Marco
AU  - Rosetti M
FAU - Ulivi, Paola
AU  - Ulivi P
FAU - Fabbri, Francesco
AU  - Fabbri F
FAU - Medri, Laura
AU  - Medri L
FAU - Vannini, Ivan
AU  - Vannini I
FAU - Bolla, Manlio
AU  - Bolla M
FAU - Amadori, Dino
AU  - Amadori D
FAU - Zoli, Wainer
AU  - Zoli W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071030
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (NCX 4040)
RN  - 0 (Nitro Compounds)
RN  - 169D1260KM (Nitroprusside)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Apoptosis/*drug effects
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Cell Line, Tumor
MH  - Colonic Neoplasms/*pathology
MH  - Humans
MH  - Membrane Potentials/drug effects
MH  - Mitochondrial Membranes/drug effects/physiology
MH  - Molecular Conformation
MH  - Nitric Oxide/metabolism
MH  - Nitro Compounds/chemistry/*pharmacology
MH  - Nitroprusside/pharmacology
PMC - PMC2174440
EDAT- 2007/11/01 09:00
MHDA- 2008/03/08 09:00
CRDT- 2007/11/01 09:00
PHST- 2007/10/02 00:00 [received]
PHST- 2007/10/30 00:00 [accepted]
PHST- 2007/11/01 09:00 [pubmed]
PHST- 2008/03/08 09:00 [medline]
PHST- 2007/11/01 09:00 [entrez]
AID - 1479-5876-5-52 [pii]
AID - 10.1186/1479-5876-5-52 [doi]
PST - epublish
SO  - J Transl Med. 2007 Oct 30;5:52. doi: 10.1186/1479-5876-5-52.

PMID- 30391545
OWN - NLM
STAT- MEDLINE
DCOM- 20190506
LR  - 20190506
IS  - 1879-3649 (Electronic)
IS  - 1537-1891 (Linking)
VI  - 113
DP  - 2019 Feb
TI  - The first 3500 years of aspirin history from its roots - A concise summary.
PG  - 1-8
LID - S1537-1891(18)30354-9 [pii]
LID - 10.1016/j.vph.2018.10.008 [doi]
AB  - Aspirin is currently the most widely used drug worldwide, and has been clearly 
      one of the most important pharmacological achievements of the twentieth century. 
      Historians of medicine have traced its birth in 1897, but the fascinating history 
      of aspirin actually dates back >3500 years, when willow bark was used as a 
      painkiller and antipyretic by Sumerians and Egyptians, and then by great 
      physicians from ancient Greece and Rome. The modern history of aspirin 
      precursors, salicylates, began in 1763 with Reverend Stone - who first described 
      their antipyretic effects - and continued in the 19th century with many 
      researchers involved in their extraction and chemical synthesis. Bayer chemist 
      Felix Hoffmann synthesized aspirin in 1897, and 70 years later the pharmacologist 
      John Vane elucidated its mechanism of action in inhibiting prostaglandin 
      production. Originally used as an antipyretic and anti-inflammatory drug, aspirin 
      then became, for its antiplatelet properties, a milestone in preventing 
      cardiovascular and cerebrovascular diseases. The aspirin story continues today 
      with the growing evidence of its chemopreventive effect against colorectal and 
      other types of cancer, now awaiting the results of ongoing primary prevention 
      trials in this setting. This concise review revisits the history of aspirin with 
      a focus on its most remote origins.
CI  - Copyright © 2018 Elsevier Inc. All rights reserved.
FAU - Montinari, Maria Rosa
AU  - Montinari MR
AD  - Department of Biological and Environmental Science and Technology, University of 
      Salento, Lecce, Italy. Electronic address: mariarosa.montinari@unisalento.it.
FAU - Minelli, Sergio
AU  - Minelli S
AD  - ASL Lecce, D.S.S. n. 52, Lecce, Italy.
FAU - De Caterina, Raffaele
AU  - De Caterina R
AD  - Cardiology, University of Pisa, Pisa, Italy. Electronic address: 
      rdecater@unich.it.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Portrait
PT  - Review
DEP - 20181102
PL  - United States
TA  - Vascul Pharmacol
JT  - Vascular pharmacology
JID - 101130615
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antipyretics)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis/*history/isolation & 
      purification/therapeutic use
MH  - Antipyretics/chemical synthesis/*history/isolation & purification/therapeutic use
MH  - Aspirin/chemical synthesis/*history/isolation & purification/therapeutic use
MH  - Cardiovascular Agents/chemical synthesis/*history/isolation & 
      purification/therapeutic use
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - History, Ancient
MH  - Humans
MH  - Plant Bark
MH  - Plant Leaves
MH  - Platelet Aggregation Inhibitors/chemical synthesis/*history/isolation & 
      purification/therapeutic use
MH  - *Salix/chemistry
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Antiplatelet agents
OT  - Aspirin
OT  - Cardiovascular disease
OT  - History of medicine
EDAT- 2018/11/06 06:00
MHDA- 2019/05/07 06:00
CRDT- 2018/11/05 06:00
PHST- 2018/09/08 00:00 [received]
PHST- 2018/10/19 00:00 [revised]
PHST- 2018/10/25 00:00 [accepted]
PHST- 2018/11/06 06:00 [pubmed]
PHST- 2019/05/07 06:00 [medline]
PHST- 2018/11/05 06:00 [entrez]
AID - S1537-1891(18)30354-9 [pii]
AID - 10.1016/j.vph.2018.10.008 [doi]
PST - ppublish
SO  - Vascul Pharmacol. 2019 Feb;113:1-8. doi: 10.1016/j.vph.2018.10.008. Epub 2018 Nov 
      2.

PMID- 34142960
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20220311
IS  - 2146-3131 (Electronic)
IS  - 2146-3123 (Print)
IS  - 2146-3123 (Linking)
VI  - 38
IP  - 3
DP  - 2021 May
TI  - Inappropriate Use of Aspirin in Real-Life Cardiology Practice: Results from the 
      Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, 
      Observational Study (ASSOS) Study.
PG  - 183-189
LID - 10.5152/balkanmedj.2021.21143 [doi]
AB  - BACKGROUND: Indications and appropriateness of aspirin use have not been well 
      investigated in Turkey. AIMS: To investigate the prescription patterns and 
      appropriateness of aspirin in a real-world clinical setting. STUDY DESIGN: 
      Cross-sectional study. METHODS: The Appropriateness of Aspirin Use in Medical 
      Outpatients: A Multicenter, Observational Study (ASSOS) is a cross-sectional and 
      multicenter study that included 5007 consecutive patients aged 18 or over who 
      presented to 30 different cardiology outpatient clinics from 14 cities throughout 
      Turkey. Only patients using aspirin (80-325 mg) were included. The study 
      population was divided into 2 groups regarding the use of aspirin: primary 
      prevention (PP) group and secondary prevention (SP) group. The indication of 
      aspirin use was evaluated following the 2016 European Society of Cardiology (ESC) 
      and the 2016 United States Preventative Services Task Force (USPTF) guidelines in 
      the PP group. RESULTS: A total of 5007 patients (mean age 62.15 ± 11.05, 39% 
      female) were enrolled. The PP group included 1132 (22.6%) patients, and the SP 
      group included 3875 (77.4%) patients. Of the 1132 patients, inappropriate use of 
      aspirin was determined in 100% of the patients according to the ESC guidelines, 
      and 71% of the patients according to the USPTF guidelines. Multivariate logistic 
      regression analysis showed age OR: 0.98 CI (0.97-0.99) P = .037, smoking OR: 0.60 
      CI (0.44-0.82) P = .001, heart failure OR: 2.11 CI (1.14-3.92) P = .017, 
      hypertension OR: 0.51 CI (0.36-0.74) P < .001, diabetes mellitus OR: 0.34 CI 
      (0.25-0.47) P < .001, oral anticoagulant use OR: 3.01 CI (1.10-8.25) P = .032, 
      and female sex OR: 2.73 CI (1.96-3.80) P < .001 were independent predictors of 
      inappropriate aspirin use in PP patients. CONCLUSION: Although there are 
      considerable differences between the USPTF and the ESC guidelines with respect to 
      recommendations for aspirin use in PP, inappropriate use of aspirin in Turkey is 
      frequent in real-world practice for both guidelines. Besides, heart failure, oral 
      anticoagulant use, and the female sex of the patients were independent predictors 
      of inappropriate use of aspirin.
FAU - Çelik, Oğuzhan
AU  - Çelik O
AD  - Department of Cardiology, Muğla Sıtkı Koçman University School of Medicine, 
      Muğla, Turkey.
FAU - Çil, Cem
AU  - Çil C
AD  - Department of Cardiology, Muğla Sıtkı Koçman University School of Medicine, 
      Muğla, Turkey.
FAU - Başaran, Özcan
AU  - Başaran Ö
AD  - Department of Cardiology, Muğla Sıtkı Koçman University School of Medicine, 
      Muğla, Turkey.
FAU - Demirci, Erkan
AU  - Demirci E
AD  - Clinic of Cardiology, Kayseri City Hospital, Kayseri, Turkey.
FAU - Tanık, Veysel Ozan
AU  - Tanık VO
AD  - Department of Cardiology, Ankara Dışkapı Yıldırım Beyazıt Training and Research 
      Hospital, Ankara, Turkey.
FAU - Altuntaş, Emine
AU  - Altuntaş E
AD  - Department of Cardiology, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and 
      Research Hospital, İstanbul, Turkey.
FAU - Memiç Sancar, Kadriye
AU  - Memiç Sancar K
AD  - Department of Cardiology, Mehmet Akif Ersoy Training and Research Hospital, 
      İstanbul, Turkey.
FAU - Örsçelik, Özcan
AU  - Örsçelik Ö
AD  - Department of Cardiology, Mersin University School of Medicine, Mersin, Turkey.
FAU - Yetim, Mücahit
AU  - Yetim M
AD  - Department of Cardiology, Hitit University Çorum Erol Olçok Training and Research 
      Hospital, Çorum, Turkey.
FAU - Bekar, Lütfü
AU  - Bekar L
AD  - Department of Cardiology, Hitit University Çorum Erol Olçok Training and Research 
      Hospital, Çorum, Turkey.
FAU - Karaarslan, Osman
AU  - Karaarslan O
AD  - Department of Cardiology, Hitit University Çorum Erol Olçok Training and Research 
      Hospital, Çorum, Turkey.
FAU - Özlek, Bülent
AU  - Özlek B
AD  - Department of Cardiology, Muğla Sıtkı Koçman University School of Medicine, 
      Muğla, Turkey.
FAU - Özlek, Eda
AU  - Özlek E
AD  - Department of Cardiology, Muğla Sıtkı Koçman University School of Medicine, 
      Muğla, Turkey.
FAU - Gökçek, Aysel
AU  - Gökçek A
AD  - Department of Cardiology, Muğla Sıtkı Koçman University School of Medicine, 
      Muğla, Turkey.
FAU - Doğan, Tolga
AU  - Doğan T
AD  - Department of Cardiology, University of Health Sciences, Bursa Yüksek İhtisas 
      Training and Research Hospital, Bursa, Turkey.
FAU - Resulzade, Mubariz Murat
AU  - Resulzade MM
AD  - Clinic of Cardiology, Private Hospitalpark Darıca Hospital, Kocaeli, Turkey.
FAU - Kaya, Çağlar
AU  - Kaya Ç
AD  - Department of Cardiology, Trakya University School of Medicine, Edirne, Turkey.
FAU - Küçük, Emrah
AU  - Küçük E
AD  - Clinic of Cardiology, Kızıltepe State Hospital, Mardin, Turkey.
FAU - Kırış, Tuncay
AU  - Kırış T
AD  - Department of Cardiology, İzmir Katip Çelebi University, Atatürk Training and 
      Research Hospital, İzmir, Turkey.
FAU - Demirtaş, Abdullah Orhan
AU  - Demirtaş AO
AD  - Clinic of Cardiology, Adana City Hospital, Adana, Turkey.
FAU - Civan, Murat
AU  - Civan M
AD  - Department of Cardiology, Bahçelievler Vital Private Hospital, İstanbul, Turkey.
FAU - Asoğlu, Ramazan
AU  - Asoğlu R
AD  - Department of Cardiology, Adıyaman University School of Medicine, Adıyaman, 
      Turkey.
FAU - Doğan, Volkan
AU  - Doğan V
AD  - Department of Cardiology, Muğla Sıtkı Koçman University School of Medicine, 
      Muğla, Turkey.
FAU - Biteker, Murat
AU  - Biteker M
AD  - Department of Cardiology, Muğla Sıtkı Koçman University School of Medicine, 
      Muğla, Turkey.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - Turkey
TA  - Balkan Med J
JT  - Balkan medical journal
JID - 101571817
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/standards/*therapeutic use
MH  - Body Mass Index
MH  - Cardiology/methods/*standards/statistics & numerical data
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Inappropriate Prescribing/*statistics & numerical data
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Outpatients/*statistics & numerical data
MH  - Turkey
PMC - PMC8880923
COIS- Conflict of Interest: The authors have no conflicts of interest to declare.
EDAT- 2021/06/19 06:00
MHDA- 2022/03/12 06:00
CRDT- 2021/06/18 12:17
PHST- 2021/06/18 12:17 [entrez]
PHST- 2021/06/19 06:00 [pubmed]
PHST- 2022/03/12 06:00 [medline]
AID - bmj-38-3-183 [pii]
AID - 10.5152/balkanmedj.2021.21143 [doi]
PST - ppublish
SO  - Balkan Med J. 2021 May;38(3):183-189. doi: 10.5152/balkanmedj.2021.21143.

PMID- 7552725
OWN - NLM
STAT- MEDLINE
DCOM- 19951101
LR  - 20191023
IS  - 1072-8368 (Print)
IS  - 1072-8368 (Linking)
VI  - 2
IP  - 8
DP  - 1995 Aug
TI  - The structural basis of aspirin activity inferred from the crystal structure of 
      inactivated prostaglandin H2 synthase.
PG  - 637-43
AB  - Aspirin exerts its anti-inflammatory effects through selective acetylation of 
      serine 530 on prostaglandin H2 synthase (PGHS). Here we present the 3.4 A 
      resolution X-ray crystal structure of PGHS isoform-1 inactivated by the potent 
      aspirin analogue 2-bromoacetoxy-benzoic acid. Acetylation by this analogue 
      abolishes cyclooxygenase activity by steric blockage of the active-site channel 
      and not through a large conformational change. We observe two rotameric states of 
      the acetyl-serine side chain which block the channel to different extents, a 
      result which may explain the dissimilar effects of aspirin on the two PGHS 
      isoforms. We also observe the product salicylic acid binding at a site consistent 
      with its antagonistic effect on aspirin activity.
FAU - Loll, P J
AU  - Loll PJ
AD  - Department of Biochemistry and Molecular Biology, University of Chicago, Illinois 
      60637, USA.
FAU - Picot, D
AU  - Picot D
FAU - Garavito, R M
AU  - Garavito RM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nat Struct Biol
JT  - Nature structural biology
JID - 9421566
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 452VLY9402 (Serine)
RN  - 77382-69-5 (bromoaspirin)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Nat Struct Biol. 1995 Aug;2(8):605-6. PMID: 7552717
MH  - Acetylation
MH  - Amino Acid Sequence
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*pharmacology
MH  - Aspirin/analogs & derivatives/*chemistry/*pharmacology
MH  - Binding Sites
MH  - Crystallography, X-Ray
MH  - Cyclooxygenase Inhibitors/*chemistry/*pharmacology
MH  - Isoenzymes/chemistry/metabolism
MH  - Kinetics
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Prostaglandin-Endoperoxide Synthases/*chemistry/*metabolism
MH  - *Protein Conformation
MH  - Protein Structure, Secondary
MH  - Serine
MH  - Sheep
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
AID - 10.1038/nsb0895-637 [doi]
PST - ppublish
SO  - Nat Struct Biol. 1995 Aug;2(8):637-43. doi: 10.1038/nsb0895-637.

PMID- 2704111
OWN - NLM
STAT- MEDLINE
DCOM- 19890519
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 261
IP  - 17
DP  - 1989 May 5
TI  - New epidemiologic evidence confirming that bias does not explain the 
      aspirin/Reye's syndrome association.
PG  - 2517-24
AB  - To determine the validity of the aspirin/Reye's syndrome association, we 
      developed an epidemiologic investigation to assess the effects of five potential 
      sources of bias. A case-control study incorporated procedures to avoid temporal 
      precedence and susceptibility bias. These included classifying cases as having 
      monophasic or biphasic patterns of illness and matching for severity of symptoms 
      at zero-time. To evaluate the effect of a potential recall bias, an 
      "alternate-condition" control group was enrolled. A medical record review study 
      was conducted to assess the potential for diagnostic bias, and a blanket 
      surveillance of all hospitals in a region was conducted to evaluate reporting 
      bias. Twenty-four case subjects and 48 matched controls were enrolled. 
      Eight-eight percent of case subjects and only 17% of controls had received 
      aspirin prior to the onset of Reye's syndrome (matched odds ratio, 35; 95% 
      confidence interval, 4.2 to 288). Further analyses demonstrated that the 
      association could not be attributed to the five potential sources of bias.
FAU - Forsyth, B W
AU  - Forsyth BW
AD  - Department of Pediatrics, Yale University School of Medicine, New Haven, Conn 
      06510.
FAU - Horwitz, R I
AU  - Horwitz RI
FAU - Acampora, D
AU  - Acampora D
FAU - Shapiro, E D
AU  - Shapiro ED
FAU - Viscoli, C M
AU  - Viscoli CM
FAU - Feinstein, A R
AU  - Feinstein AR
FAU - Henner, R
AU  - Henner R
FAU - Holabird, N B
AU  - Holabird NB
FAU - Jones, B A
AU  - Jones BA
FAU - Karabelas, A D
AU  - Karabelas AD
AU  - et al.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Data Collection
MH  - *Epidemiologic Methods
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Population Surveillance
MH  - Research Design
MH  - Reye Syndrome/*chemically induced
MH  - Time Factors
EDAT- 1989/05/05 00:00
MHDA- 1989/05/05 00:01
CRDT- 1989/05/05 00:00
PHST- 1989/05/05 00:00 [pubmed]
PHST- 1989/05/05 00:01 [medline]
PHST- 1989/05/05 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1989 May 5;261(17):2517-24.

PMID- 19667530
OWN - NLM
STAT- MEDLINE
DCOM- 20160422
LR  - 20181201
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 108
IP  - 4 Suppl
DP  - 2000 Sep 15
TI  - Dose selection and dosing interval determination for LTRA use in asthma.
PG  - 12-21
LID - 10.3810/pgm.09.15.2000.suppl7.40 [doi]
AB  - The dose and dosing interval for leukotriene receptor antagonists montelukast and 
      zafirlukast in adult asthmatic patients were determined by bronchoprovocation 
      with exercise or leukotriene D4 inhalation. Subsequent dose-ranging studies 
      confirmed that once-daily ingestion of a 10-mg dose of montelukast was effective 
      and safe; higher doses did not improve efficacy or increase the risk of adverse 
      effects. In contrast, zafirlukast doses that exceeded the approved dose of 20 mg 
      ingested twice daily during fasting improved efficacy but increased the risk of 
      elevated liver enzymes. Pharmacokinetic studies showed that montelukast 
      bioavailability is not affected by food and did not interact with other drugs. 
      Zafirlukast inhibited warfarin metabolism while food intake and concurrent 
      therapy with theophylline or aspirin decreased zafirlukast levels. 
      Pharmacokinetic and subsequent efficacy or safety studies revealed that a 5-mg 
      and a 4-mg chewable tablet of montelukast ingested once daily were effective in 
      and well tolerated by patients in the 6- to 14-year and 2- to 5-year age-groups, 
      respectively. Both pediatric montelukast doses produced the same magnitude of 
      tissue exposure as did the 10-mg adult dose. The Food and Drug Administration 
      approved a 10-mg film-coated tablet of zafirlukast for children 7 to 11 years of 
      age. It must be administered twice daily fasting.
FAU - Hendeles, L
AU  - Hendeles L
AD  - Department of Pharmacy Practice, University of Florida, Gainesville, FL 
      32610-0486, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Leukotriene Antagonists)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Asthma
MH  - Humans
MH  - *Leukotriene Antagonists
MH  - Tablets
EDAT- 2000/09/01 00:00
MHDA- 2016/04/23 06:00
CRDT- 2009/08/12 09:00
PHST- 2009/08/12 09:00 [entrez]
PHST- 2000/09/01 00:00 [pubmed]
PHST- 2016/04/23 06:00 [medline]
AID - 10.3810/pgm.09.15.2000.suppl7.40 [doi]
PST - ppublish
SO  - Postgrad Med. 2000 Sep 15;108(4 Suppl):12-21. doi: 
      10.3810/pgm.09.15.2000.suppl7.40.

PMID- 30506894
OWN - NLM
STAT- MEDLINE
DCOM- 20200129
LR  - 20200129
IS  - 1469-1809 (Electronic)
IS  - 0003-4800 (Linking)
VI  - 83
IP  - 3
DP  - 2019 May
TI  - Association between TNF-α polymorphisms and the risk of upper gastrointestinal 
      bleeding induced by aspirin in patients with coronary heart disease.
PG  - 124-133
LID - 10.1111/ahg.12295 [doi]
AB  - OBJECTIVE: To investigate the correlation of tumor necrosis factor α (TNF-α) 
      polymorphisms with upper gastrointestinal bleeding (UGIB) induced by 
      enteric-coated aspirin in coronary heart disease (CHD) patients. METHODS: In 
      total, 154 CHD patients taking enteric-coated aspirin were enrolled in this 
      study. Patients were divided into the UGIB group (n = 57) and non-UGIB group 
      (n = 97) based on the presence or absence of signs of UGIB, respectively. TNF-α 
      polymorphism (-857C > T, -863C > A, and -1031T > C) genotyping was performed 
      using polymerase chain reaction (PCR) amplification with sequence-specific 
      primers (PCR-SSP). RESULTS: Patients who had the CC genotype and C allele of 
      -1031T > C exhibited a significantly increase risk of UGIB after receiving 
      enteric-coated aspirin (CC vs. TT: odds (OR) (95% confidence interval (CI)): 
      7.568 (1.527-37.49), P = 0.005; C vs. T: OR (95% CI): 1.852 (1.036-3.312), 
      P = 0.036). Patients who had CA and CA + AA genotypes and the A allele of 
      -863C > A also exhibited an increased risk of aspirin-induced UGIB (CA vs. CC: OR 
      (95% CI): 2.415 (1.143-5.101), P = 0.019: CA + AA vs. CC: OR (95% CI): 2.218 
      (1.123-4.381), P = 0.021; A vs. C: OR (95% CI): 1.788 (1.039-3.078), P = 0.035). 
      However, the TNF-α -857 C > T polymorphism was unrelated to the induction of UGIB 
      by enteric-coated aspirin in CHD patients (P > 0.05). In addition, the haplotypes 
      of CCC (-1031T > C, -863C > A, and -857C > T) markedly reduced the risk of 
      aspirin-induced UGIB in CHD patients. CONCLUSION: TNF-α -863A and -1031C 
      increased the risk of UGIB induction by enteric-coated aspirin in CHD patients, 
      whereas TNF-α -857C > T was not correlated with the UGIB risk.
CI  - © 2018 John Wiley & Sons Ltd/University College London.
FAU - Wang, Tai-Ping
AU  - Wang TP
AUID- ORCID: 0000-0001-6996-6119
AD  - Department of Gastroenterology, Rizhao People's Hospital of Shandong Province, 
      Rizhao, 276800, China.
LA  - eng
PT  - Journal Article
DEP - 20181202
PL  - England
TA  - Ann Hum Genet
JT  - Annals of human genetics
JID - 0416661
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Alleles
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Genotype
MH  - Haplotypes
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tumor Necrosis Factor-alpha/*genetics
OTO - NOTNLM
OT  - TNF-α
OT  - aspirin
OT  - coronary heart disease
OT  - polymorphism
OT  - upper gastrointestinal bleeding
EDAT- 2018/12/07 06:00
MHDA- 2020/01/30 06:00
CRDT- 2018/12/04 06:00
PHST- 2018/05/25 00:00 [received]
PHST- 2018/10/25 00:00 [revised]
PHST- 2018/10/28 00:00 [accepted]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2020/01/30 06:00 [medline]
PHST- 2018/12/04 06:00 [entrez]
AID - 10.1111/ahg.12295 [doi]
PST - ppublish
SO  - Ann Hum Genet. 2019 May;83(3):124-133. doi: 10.1111/ahg.12295. Epub 2018 Dec 2.

PMID- 8787334
OWN - NLM
STAT- MEDLINE
DCOM- 19960923
LR  - 20131121
IS  - 0003-3928 (Print)
IS  - 0003-3928 (Linking)
VI  - 44
IP  - 10
DP  - 1995 Dec
TI  - [Treatments of ischemic cardiopathies (IC) and modalities of prescription of 
      aspirin in the three French MONICA centers in 1990].
PG  - 578-86
AB  - In 1990, the three French MONICA centres recorded comparable frequencies of 
      myocardial infarction admitted and not admitted to hospital. However, the 
      mortality on the 28th day revealed an excess hospital mortality in Lille compared 
      to Strasbourg and Toulouse (p < 0.001). Toulouse infarct patients were younger. 
      The emergency management of coronary patients subsequently admitted to hospital 
      also differed (16.7% patients in Lille vs 40% in Strasbourg and 24.3% in 
      Toulouse) (p < 0.01). In Lille, 41.6% of patients had known coronary heart 
      disease vs 30.4% in Toulouse and 38.4% in Strasbourg (p < 0.05). These three 
      characteristics influenced the mortality. During admission, considerable 
      differences were observed in the therapeutic strategies in the 3 centres: in 
      Toulouse, angioplasty was predominant (51.4%) together with prescription of 
      calcium channel blockers (65.5%) and aspirin (82.5%). In Lille, there were a high 
      prescription (20.3%) of antiplatelets other than aspirin during the acute phase 
      compared to Toulouse (0.6%) and Strasbourg (7.3%). In Strasbourg, the 
      cardiologists of the department rarely used angioplasty during the acute phase, 
      but were the leading prescribers of beta-blockers. Fibrinolysis was performed in 
      4 out of 10 patients in the three centres. Aspirin was used in more than 7 out of 
      10 patients during the acute phase in all MONICA centres, but at a variable 
      dosage: doses greater than or equal to 250 mg per day were prescribed in Toulouse 
      (97.6%) and Strasbourg 82.8%), while, in Lille, only one out of 2 patients 
      received this dosage (50.6%).
FAU - Cambou, J P
AU  - Cambou JP
AD  - INSERM U326, CHU Purpan, TOULOUSE.
FAU - Amouyel, P
AU  - Amouyel P
FAU - Arveiler, D
AU  - Arveiler D
FAU - Bingham, A
AU  - Bingham A
FAU - Ruidavets, J B
AU  - Ruidavets JB
FAU - Montayé, M
AU  - Montayé M
FAU - Haas, B
AU  - Haas B
FAU - Ferrières, J
AU  - Ferrières J
FAU - Lablache Combier, B
AU  - Lablache Combier B
FAU - Richard, J L
AU  - Richard JL
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
TT  - Les thérapeutiques des cardiopathies ischémiques (CI) et modalités de 
      prescription de l'aspirine dans les trois centres MONICA Français en 1990.
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anticoagulants)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Adult
MH  - Angioplasty, Balloon, Coronary/methods
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Calcium Channel Blockers/*therapeutic use
MH  - Coronary Artery Bypass/methods
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Female
MH  - France
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/*therapy
MH  - Pilot Projects
MH  - Postoperative Care
MH  - World Health Organization
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 1995 Dec;44(10):578-86.

PMID- 34806161
OWN - NLM
STAT- MEDLINE
DCOM- 20220315
LR  - 20220531
IS  - 1479-828X (Electronic)
IS  - 0004-8666 (Linking)
VI  - 62
IP  - 1
DP  - 2022 Feb
TI  - Aspirin for the prevention of pre-eclampsia in women with pre-existing diabetes: 
      Systematic review.
PG  - 12-21
LID - 10.1111/ajo.13460 [doi]
AB  - BACKGROUND: There is a lack of evidence for pre-eclampsia prophylaxis with 
      aspirin in women with pre-existing diabetes mellitus (DM). AIMS: To examine the 
      evidence for aspirin in pre-eclampsia prophylaxis in women with pre-existing DM. 
      MATERIAL AND METHODS: An electronic search using Ovid MEDLINE, Embase, 
      CinicalTrials.gov and the Cochrane CENTRAL register of controlled trials through 
      to February 2021 was performed. Reference lists of identified studies, previous 
      review articles, clinical practice guidelines and government reports were 
      manually searched. Randomised controlled trials (RCTs) of aspirin vs placebo for 
      pre-eclampsia prophylaxis were included. Articles were manually reviewed to 
      determine if cohorts included women with DM. The systematic review was performed 
      following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
      statement. Data from included trials were extracted independently by two authors 
      who also independently assessed risk of bias as per the Cochrane Handbook 
      criteria version 5.1.0. Data were analysed using Rev-Man 5.4. RESULTS: Forty RCTs 
      were identified, of which 11 included a confirmed subset of women with DM; 
      however, data were insufficient for meta-analysis. Meta-analysis of 930 women 
      with DM, from individual patient data included in a systematic review and 
      unpublished data from one of the 11 RCTs, showed a non-significant difference in 
      the outcome of pre-eclampsia in participants treated with aspirin compared to 
      placebo (odds ratio 0.58; 95% CI 0.20-1.71; P = 0.33). CONCLUSIONS: Pre-eclampsia 
      risk reduction with aspirin prophylaxis in women with pre-existing DM may be 
      similar to women without pre-existing DM. However, randomised data within this 
      meta-analysis were insufficient, warranting the need for further studies within 
      this high-risk group of women.
CI  - © 2021 The Royal Australian and New Zealand College of Obstetricians and 
      Gynaecologists.
FAU - Zen, Monica
AU  - Zen M
AUID- ORCID: 0000-0002-6441-9818
AD  - Westmead Institute for Maternal & Fetal Medicine, Westmead Hospital, Sydney, New 
      South Wales, Australia.
AD  - Westmead Clinical School, Faculty of Medicine and Health, Westmead Hospital, The 
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Haider, Rabbia
AU  - Haider R
AD  - Department of Endocrinology, Nepean Hospital, Sydney, New South Wales, Australia.
FAU - Simmons, David
AU  - Simmons D
AUID- ORCID: 0000-0003-0560-0761
AD  - Macarthur Clinical School, Western Sydney University, Sydney, New South Wales, 
      Australia.
FAU - Peek, Michael
AU  - Peek M
AD  - ANU Medical School, The Australian National University, Canberra, Australian 
      Capital Territory, Australia.
FAU - Nolan, Christopher J
AU  - Nolan CJ
AD  - ANU Medical School, The Australian National University, Canberra, Australian 
      Capital Territory, Australia.
FAU - Padmanabhan, Suja
AU  - Padmanabhan S
AD  - Westmead Clinical School, Faculty of Medicine and Health, Westmead Hospital, The 
      University of Sydney, Sydney, New South Wales, Australia.
AD  - Department of Diabetes & Endocrinology, Westmead Hospital, Sydney, New South 
      Wales, Australia.
FAU - Jesudason, Shilpa
AU  - Jesudason S
AD  - Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South 
      Australia, Australia.
FAU - Alahakoon, Thushari I
AU  - Alahakoon TI
AD  - Westmead Institute for Maternal & Fetal Medicine, Westmead Hospital, Sydney, New 
      South Wales, Australia.
AD  - Westmead Clinical School, Faculty of Medicine and Health, Westmead Hospital, The 
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Cheung, Ngai Wah
AU  - Cheung NW
AUID- ORCID: 0000-0001-6323-8006
AD  - Westmead Clinical School, Faculty of Medicine and Health, Westmead Hospital, The 
      University of Sydney, Sydney, New South Wales, Australia.
AD  - Department of Diabetes & Endocrinology, Westmead Hospital, Sydney, New South 
      Wales, Australia.
FAU - Lee, Vincent W
AU  - Lee VW
AD  - Westmead Clinical School, Faculty of Medicine and Health, Westmead Hospital, The 
      University of Sydney, Sydney, New South Wales, Australia.
AD  - Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South 
      Australia, Australia.
AD  - Department of Renal Medicine, Westmead Hospital, Sydney, New South Wales, 
      Australia.
LA  - eng
GR  - Postgraduate Scholarship/National Health and Medical Research Council/
PT  - Journal Article
PT  - Systematic Review
DEP - 20211121
PL  - Australia
TA  - Aust N Z J Obstet Gynaecol
JT  - The Australian & New Zealand journal of obstetrics & gynaecology
JID - 0001027
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Diabetes Mellitus
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - aspirin
OT  - diabetes mellitus
OT  - pre-eclampsia
OT  - prevention
EDAT- 2021/11/23 06:00
MHDA- 2022/03/16 06:00
CRDT- 2021/11/22 07:08
PHST- 2021/10/12 00:00 [revised]
PHST- 2021/08/18 00:00 [received]
PHST- 2021/11/03 00:00 [accepted]
PHST- 2021/11/23 06:00 [pubmed]
PHST- 2022/03/16 06:00 [medline]
PHST- 2021/11/22 07:08 [entrez]
AID - 10.1111/ajo.13460 [doi]
PST - ppublish
SO  - Aust N Z J Obstet Gynaecol. 2022 Feb;62(1):12-21. doi: 10.1111/ajo.13460. Epub 
      2021 Nov 21.

PMID- 6230778
OWN - NLM
STAT- MEDLINE
DCOM- 19840425
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 15
IP  - 2
DP  - 1984 Mar-Apr
TI  - Study of platelet activation in migraine: control by low doses of aspirin.
PG  - 271-5
AB  - Although platelet activation is known to occur during migraine attacks, the 
      cause-effect relationship remains to be determined. This problem was approached 
      by studying the possible occurrence of platelet activation in vivo in 
      headache-free periods of subjects affected by common or classic migraine and, 
      subsequently, by verifying the possibility of its pharmacological control through 
      administration of a classic anti-aggregation drug such as aspirin (ASA). The 
      plasma levels of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4), 
      indices of the occurrence of platelet activation in vivo, were therefore first 
      assayed in both groups of migraine sufferers in the absence of therapy and then 
      during the administration of aspirin (50 mg/daily). In the group of 15 patients 
      affected by classic migraine, basal plasma levels of beta-TG and PF4 were 
      significantly higher than control subjects. On the other hand, only beta-TG 
      plasma levels were significantly higher in the group of 18 patients affected by 
      common migraine. Patients suffering from classic migraine showed a high incidence 
      of platelet activation (greater than 90%) in comparison with common migraine 
      patients (approximately 33%). This suggests that platelet activation occurs in 
      vivo in migrainous patients also during headache-free periods. Administration of 
      aspirin to the patients affected by common and classic migraine caused a decrease 
      in plasma beta-TG and PF4 concentration. Consequently, pharmacological treatment 
      with aspirin in adequate dose may prove to be helpful in diminishing the vascular 
      side-effects known to occur in migraine sufferers.
FAU - D'Andrea, G
AU  - D'Andrea G
FAU - Toldo, M
AU  - Toldo M
FAU - Cananzi, A
AU  - Cananzi A
FAU - Ferro-Milone, F
AU  - Ferro-Milone F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (beta-Thromboglobulin)
RN  - 37270-94-3 (Platelet Factor 4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Factor 4/analysis
MH  - beta-Thromboglobulin/analysis
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
AID - 10.1161/01.str.15.2.271 [doi]
PST - ppublish
SO  - Stroke. 1984 Mar-Apr;15(2):271-5. doi: 10.1161/01.str.15.2.271.

PMID- 10543308
OWN - NLM
STAT- MEDLINE
DCOM- 19991202
LR  - 20191103
IS  - 0910-8327 (Print)
IS  - 0910-8327 (Linking)
VI  - 14
IP  - 1
DP  - 1999
TI  - Effects of diaspirin crosslinked hemoglobin infusion in treadmill-exercised 
      swine.
PG  - 1-8
AB  - The hemodynamic and metabolic effects of diaspirin crosslinked hemoglobin (DCLHb) 
      were investigated using graded treadmill exercise in swine (n = 5/group). Swine 
      received DCLHb (10% solution, 5 ml/kg) or oncotically-matched human serum albumin 
      (HSA, 5ml/kg). Baseline metabolic and hemodynamic data were similar. In both 
      groups exercise increased hemodynamic parameters. Exercise increased heart rate 
      (HR) from 139 +/- 12 to 293 +/- 28 bpm with DCLHb and from 136 +/- 13 to 314 +/- 
      13 bpm with HSA. Exercise increased cardiac output (CO) from 5.7 +/- 0.75 to 15.6 
      +/- 2.01/min in the DCLHb group and from 5.3 +/- 0.48 to 15.7 +/- 0.881/min in 
      the HSA group. However, CO returned to baseline faster with DCLHb upon stopping 
      exercise. The DCLHb-treated group demonstrated a significantly higher oxygen 
      extraction during exercise (12.04 +/- 0.38 vs 9.48 +/- 0.99 ml O2/100 ml blood) 
      and a lower oxygen delivery throughout recovery (74.6 +/- 6.6 vs 102.2 +/- 7.21 
      O2/min), indicating enhanced oxygen delivery during exercise in the treatment 
      group. DCLHb infusion did not impair metabolic or hemodynamic functions. These 
      data indicate that DCLHb may increase oxygen delivery to working tissue more 
      efficiently than HSA during treadmill exercise in swine.
FAU - Crago, M S
AU  - Crago MS
AD  - Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
FAU - West, S D
AU  - West SD
FAU - McKenzie, J E
AU  - McKenzie JE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - Heart Vessels
JT  - Heart and vessels
JID - 8511258
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Blood Gas Analysis
MH  - Blood Substitutes/administration & dosage/*pharmacology
MH  - Energy Metabolism/*drug effects
MH  - Exercise Test
MH  - Female
MH  - Hemodynamics/*drug effects
MH  - Hemoglobins/administration & dosage/*pharmacology
MH  - Hydrogen-Ion Concentration
MH  - Infusions, Intravenous
MH  - Male
MH  - Oxygen Consumption/drug effects
MH  - *Physical Conditioning, Animal
MH  - Swine/*physiology
EDAT- 1999/10/30 00:00
MHDA- 1999/10/30 00:01
CRDT- 1999/10/30 00:00
PHST- 1999/10/30 00:00 [pubmed]
PHST- 1999/10/30 00:01 [medline]
PHST- 1999/10/30 00:00 [entrez]
AID - 10.1007/BF02481737 [doi]
PST - ppublish
SO  - Heart Vessels. 1999;14(1):1-8. doi: 10.1007/BF02481737.

PMID- 1376787
OWN - NLM
STAT- MEDLINE
DCOM- 19920721
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 19
IP  - 2
DP  - 1992 Feb
TI  - Residual platelet function under acetylsalicylic acid and the risk of restenosis 
      after coronary angioplasty.
PG  - 190-3
AB  - Restenosis after percutaneous transluminal coronary angioplasty (PTCA) was shown 
      not to be preventable by antiplatelet therapy; residual platelet function under 
      treatment with platelet inhibitors could be one cause of this. Therefore, in a 
      prospective investigation, residual platelet function was assessed in 98 patients 
      treated with acetylsalicylic acid (ASA) on three occasions during the first 3 
      months after successful PTCA. Control cardiac catheterization was obtained in 75 
      of these patients (77%) with 82 dilated stenoses 173 +/- 117 days after PTCA. 
      Restenosis, defined as diameter stenosis greater than or equal to 50% at control 
      angiography, occurred in 41% of the dilated vessels, and 43% of patients 
      experienced restenosis in at least one vessel. The in vitro platelet aggregatory 
      response to either ADP (0.5, 1, and 10 microM) or collagen (1 and 5 mg/L) as 
      aggregating agents did not differ between patients with and without restenosis. 
      In addition, neither the collagen-stimulated in vitro synthesis of thromboxane 
      nor the basal or prostaglandin E1-stimulated concentrations of cyclic AMP in 
      platelet-rich plasma (PRP) was different in the two groups. There was no 
      significant correlation between any of the parameters of platelet function 
      assessed and the change in coronary luminal diameter observed between immediately 
      after PTCA and control coronary angiography. The mean dose of ASA ingested during 
      follow-up was also not a determinant of the occurrence of restenosis. Thus, 
      residual platelet function under treatment with ASA as measured in vitro in this 
      study, did not influence the occurrence of restenosis after successful PTCA.
FAU - Terres, W
AU  - Terres W
AD  - Department of Cardiology, Eppendorf University Hospital, Hamburg, Germany.
FAU - Hamm, C W
AU  - Hamm CW
FAU - Ruchelka, A
AU  - Ruchelka A
FAU - Weilepp, A
AU  - Weilepp A
FAU - Kupper, W
AU  - Kupper W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 54397-85-2 (Thromboxane B2)
RN  - E0399OZS9N (Cyclic AMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Coronary Disease/blood/*therapy
MH  - Cyclic AMP/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Recurrence
MH  - Thromboxane B2/analysis/biosynthesis
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
AID - 10.1097/00005344-199202000-00006 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1992 Feb;19(2):190-3. doi: 
      10.1097/00005344-199202000-00006.

PMID- 2675430
OWN - NLM
STAT- MEDLINE
DCOM- 19891018
LR  - 20131121
IS  - 0041-5782 (Print)
IS  - 0041-5782 (Linking)
VI  - 151
IP  - 25
DP  - 1989 Jun 19
TI  - [Acetylsalicylic acid in the treatment of arterial thromboembolic diseases. 1. 
      Pharmacologic aspects].
PG  - 1597-9
AB  - The possible antithrombotic potential of acetyl salicylic acid (ASA) has been 
      established in recent years and the preparation has been employed extensively in 
      ischaemic cardiac disease and cerebrovascular conditions. The inhibiting effect 
      of ASA on platelet function by means of blocking of cyclo-oxygenase is mentioned 
      and, similarly, the presumed role in thrombosis development and atherogenesis is 
      mentioned. ASA's pharmacokinetics are illustrated with emphasis on optimal 
      anti-thrombotic ASA dosage, in particular, in relation to the effects of the 
      preparation on the thromboxan A2 (TxA2)/prostacyclin (PGI2)-ratio. This is 
      probably best achieved by means of low oral dosage in the form of 
      sustained-release ASA formulation where the inhibition of platelet function 
      probably occurs mainly in the presystemic circulation. It is concluded that a 
      daily dosage of 80-100 mg ASA ensures effective and rapid inhibition of TxA2 
      production. Administration of 30-50 mg ASA daily results in a corresponding 
      blockage of TxA2 production but not until after treatment for three to four days.
FAU - Husted, S E
AU  - Husted SE
FAU - Nielsen, H K
AU  - Nielsen HK
FAU - Krusell, L R
AU  - Krusell LR
FAU - Faergeman, O
AU  - Faergeman O
LA  - dan
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Acetylsalicylsyrebehandling ved arterielle trombo-emboliske sygdomme. 1. 
      Farmakologiske aspekter.
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacokinetics/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Fibrinolytic Agents/pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Thromboembolism/*drug therapy
RF  - 23
EDAT- 1989/06/19 00:00
MHDA- 1989/06/19 00:01
CRDT- 1989/06/19 00:00
PHST- 1989/06/19 00:00 [pubmed]
PHST- 1989/06/19 00:01 [medline]
PHST- 1989/06/19 00:00 [entrez]
PST - ppublish
SO  - Ugeskr Laeger. 1989 Jun 19;151(25):1597-9.

PMID- 749194
OWN - NLM
STAT- MEDLINE
DCOM- 19790611
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 108
IP  - 49
DP  - 1978 Dec 9
TI  - [Effect of anti-inflammatory agents on chemotaxis of human neutrophils studied in 
      vitro].
PG  - 1969-70
AB  - Using a modified Boyden chamber the effect of three antiinflammatory drugs on the 
      chemotaxis of human neutrophils has been tested in vitro. Gold salt produced a 
      reduction of both neutrophil migration and the ability of plasma to attract this 
      cell. Betamethasone decreased chemotaxis by an action on the cell itself but not 
      on the plasma. Aspirin had no effect on this function. These data suggest that 
      antiinflammatory drugs act through different mechanisms and that the reduction of 
      neutrophil chemotaxis may contribute to the antiinflammatory action of gold 
      salts.
FAU - Pécoud, A
AU  - Pécoud A
FAU - Leimgruber, A
AU  - Leimgruber A
FAU - Frei, P C
AU  - Frei PC
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Effet de substances anti-inflammatoires sur le chimiotactisme des poly-nucléaires 
      humains étudié in vitro.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Propanols)
RN  - 7440-57-5 (Gold)
RN  - 96F264O9SV (1-Propanol)
RN  - 9842X06Q6M (Betamethasone)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 1-Propanol/pharmacology
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Betamethasone/pharmacology
MH  - Chemotaxis, Leukocyte/*drug effects
MH  - Gold/pharmacology
MH  - Humans
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Neutrophils/drug effects
MH  - Propanols
EDAT- 1978/12/09 00:00
MHDA- 1978/12/09 00:01
CRDT- 1978/12/09 00:00
PHST- 1978/12/09 00:00 [pubmed]
PHST- 1978/12/09 00:01 [medline]
PHST- 1978/12/09 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1978 Dec 9;108(49):1969-70.

PMID- 24857471
OWN - NLM
STAT- MEDLINE
DCOM- 20150119
LR  - 20181202
IS  - 1873-0191 (Electronic)
IS  - 0928-4931 (Linking)
VI  - 40
DP  - 2014 Jul 1
TI  - Synthesis of magnetic FexOy@silica-pillared clay (SPC) composites via a novel 
      sol-gel route for controlled drug release and targeting.
PG  - 102-8
LID - S0928-4931(14)00166-0 [pii]
LID - 10.1016/j.msec.2014.03.040 [doi]
AB  - Novel magnetic silica-pillared clay (SPC) materials with an ordered interlayered 
      mesopore structure were synthesized via a two-step method including gallery 
      molecular self-assembly and sol-gel magnetic functionalization, resulting in the 
      formation of FexOy@SPC composites. Small-angle XRD, TEM and N2 
      adsorption-desorption isotherms results show that these composites conserved a 
      regular layered and ordered mesoporous structure after the formation of FexOy 
      nanoparticles. Wide-angle XRD and XPS analyses confirmed that the FexOy generated 
      in these mesoporous silica-pillared clay hosts is mainly composed of γ-Fe2O3. 
      Magnetic measurements reveal that these composites with different γ-Fe2O3 loading 
      amounts possess super-paramagnetic properties at 300K, and the saturation 
      magnetization increases with increasing Fe ratio loaded. Compared to the pure 
      SPC, the in vitro drug release rate of the FexOy@SPC composites was enhanced due 
      to the fact that the intensities of the SiOH bands on the pore surface of SPC 
      decrease after the generation of FexOy. However, under an external magnetic field 
      of 0.15T, the drug release rate of the FexOy@SPC composites decreases 
      dramatically owing to the aggregation of the magnetic FexOy@SPC particles 
      triggered by non-contact magnetic force. The obtained FexOy@SPC composites imply 
      the possibility of application in magnetic drug targeting.
CI  - Copyright © 2014 Elsevier B.V. All rights reserved.
FAU - Mao, Huihui
AU  - Mao H
AD  - Jiangsu Key Laboratory of Advanced Catalytic Materials and Technology, Changzhou 
      University, Changzhou, Jiangsu Province 213164, PR China; State Key Laboratory of 
      Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 
      100029, PR China. Electronic address: maohuihui_beijing@126.com.
FAU - Liu, Xiaoting
AU  - Liu X
AD  - Jiangsu Key Laboratory of Advanced Catalytic Materials and Technology, Changzhou 
      University, Changzhou, Jiangsu Province 213164, PR China.
FAU - Yang, Jihe
AU  - Yang J
AD  - Jiangsu Key Laboratory of Advanced Catalytic Materials and Technology, Changzhou 
      University, Changzhou, Jiangsu Province 213164, PR China. Electronic address: 
      yangjihe@cczu.edu.cn.
FAU - Li, Baoshan
AU  - Li B
AD  - State Key Laboratory of Chemical Resource Engineering, Beijing University of 
      Chemical Technology, Beijing 100029, PR China.
FAU - Yao, Chao
AU  - Yao C
AD  - Jiangsu Key Laboratory of Advanced Catalytic Materials and Technology, Changzhou 
      University, Changzhou, Jiangsu Province 213164, PR China.
FAU - Kong, Yong
AU  - Kong Y
AD  - Jiangsu Key Laboratory of Advanced Catalytic Materials and Technology, Changzhou 
      University, Changzhou, Jiangsu Province 213164, PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140326
PL  - Netherlands
TA  - Mater Sci Eng C Mater Biol Appl
JT  - Materials science & engineering. C, Materials for biological applications
JID - 101484109
RN  - 0 (Aluminum Silicates)
RN  - 0 (Drug Carriers)
RN  - 0 (Ferric Compounds)
RN  - 0 (Gels)
RN  - 1K09F3G675 (ferric oxide)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - R16CO5Y76E (Aspirin)
RN  - T1FAD4SS2M (Clay)
SB  - IM
MH  - Aluminum Silicates/*chemistry
MH  - Aspirin/*chemistry/metabolism
MH  - Clay
MH  - Drug Carriers/*chemistry
MH  - Ferric Compounds/*chemistry
MH  - Gels/*chemistry
MH  - *Magnetics
MH  - Metal Nanoparticles/chemistry
MH  - Silicon Dioxide/*chemistry
OTO - NOTNLM
OT  - Drug release
OT  - Magnetic functionalization
OT  - Silica-pillared clay
OT  - Sol–gel
EDAT- 2014/05/27 06:00
MHDA- 2015/01/20 06:00
CRDT- 2014/05/27 06:00
PHST- 2013/10/12 00:00 [received]
PHST- 2014/03/18 00:00 [accepted]
PHST- 2014/05/27 06:00 [entrez]
PHST- 2014/05/27 06:00 [pubmed]
PHST- 2015/01/20 06:00 [medline]
AID - S0928-4931(14)00166-0 [pii]
AID - 10.1016/j.msec.2014.03.040 [doi]
PST - ppublish
SO  - Mater Sci Eng C Mater Biol Appl. 2014 Jul 1;40:102-8. doi: 
      10.1016/j.msec.2014.03.040. Epub 2014 Mar 26.

PMID- 6863205
OWN - NLM
STAT- MEDLINE
DCOM- 19830817
LR  - 20190920
IS  - 0277-0903 (Print)
IS  - 0277-0903 (Linking)
VI  - 20 Suppl 1
DP  - 1983
TI  - Desensitization of aspirin-sensitive asthmatics: a therapeutic alternative?
PG  - 31-8
AB  - To identify and characterize aspirin sensitivity, over 500 oral aspirin 
      challenges have been performed in patients since 1970. Protocols were developed, 
      and an aspirin desensitization process was created as an extension of the 
      challenge protocol. Without exception, desensitization has been achieved in 66 of 
      66 consecutive aspirin-sensitive asthmatics. There is also cross-desensitization 
      with nonsteroidal anti-inflammatory drugs (NSAIDs) in the limited number of 
      patients studied. After desensitization with either aspirin or NSAIDs, an 
      interruption of continuous therapy is followed by a reappearance of sensitivity. 
      Patients must be cautioned about this and the possibility of a severe reaction 
      should aspirin be reintroduced after aspirin avoidance for 2-5 days.
FAU - Stevenson, D D
AU  - Stevenson DD
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Asthma
JT  - The Journal of asthma : official journal of the Association for the Care of 
      Asthma
JID - 8106454
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/immunology
MH  - Aspirin/adverse effects/*immunology
MH  - Asthma/chemically induced/*immunology
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity
MH  - Humans
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.3109/02770908309078050 [doi]
PST - ppublish
SO  - J Asthma. 1983;20 Suppl 1:31-8. doi: 10.3109/02770908309078050.

PMID- 35796692
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20220929
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 71
IP  - 10
DP  - 2022 Oct 1
TI  - Topical Aspirin Administration Improves Cutaneous Wound Healing in Diabetic Mice 
      Through a Phenotypic Switch of Wound Macrophages Toward an Anti-inflammatory and 
      Proresolutive Profile Characterized by LXA4 Release.
PG  - 2181-2196
LID - 10.2337/db20-1245 [doi]
AB  - Patients with diabetes present a persistent inflammatory process, leading to 
      impaired wound healing. Since nonhealing diabetic wound management shows limited 
      results, the introduction of advanced therapies targeting and correcting the 
      inflammatory status of macrophages in chronic wounds could be an effective 
      therapeutic strategy to stop the sustained inflammation and to return to a 
      healing state. In an excisional skin injury in a diet-induced diabetic murine 
      model, we demonstrate that topical administration of low-dose aspirin (36 
      μg/wound/day) improves cutaneous wound healing by increasing wound closure 
      through the promotion of the inflammation resolution program of macrophages. This 
      treatment increased efferocytosis of wound macrophages from aspirin-treated 
      diabetic mice compared with untreated diabetic mice. We also show that aspirin 
      treatment of high-fat-fed mice oriented the phenotype of wound macrophages toward 
      an anti-inflammatory and proresolutive profile characterized by a decrease of 
      LTB4 production. The use of diabetic mice deficient for 5-LOX or 12/15-LOX 
      demonstrated that these two enzymes of acid arachidonic metabolism are essential 
      for the beneficial effect of aspirin on wound healing. Thus, aspirin treatment 
      modified the balance between pro- and anti-inflammatory eicosanoids by promoting 
      the synthesis of proresolving LXA4 through 5-LOX, LTA4, 12/15-LOX signaling. In 
      conclusion, the restoration of an anti-inflammatory and proresolutive phenotype 
      of wound macrophages by the topical administration of low-dose aspirin represents 
      a promising therapeutic approach in chronic wounds.
CI  - © 2022 by the American Diabetes Association.
FAU - Dardenne, Christophe
AU  - Dardenne C
AD  - UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le 
      Développement, Université Paul Sabatier, Toulouse, France.
FAU - Salon, Marie
AU  - Salon M
AD  - UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le 
      Développement, Université Paul Sabatier, Toulouse, France.
AD  - RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, Université 
      Paul Sabatier, Toulouse, France.
FAU - Authier, Hélène
AU  - Authier H
AD  - UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le 
      Développement, Université Paul Sabatier, Toulouse, France.
AD  - RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, Université 
      Paul Sabatier, Toulouse, France.
FAU - Meunier, Etienne
AU  - Meunier E
AD  - UMR 5089, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France.
FAU - AlaEddine, Mohamad
AU  - AlaEddine M
AD  - UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le 
      Développement, Université Paul Sabatier, Toulouse, France.
FAU - Bernad, José
AU  - Bernad J
AD  - UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le 
      Développement, Université Paul Sabatier, Toulouse, France.
FAU - Bouschbacher, Marielle
AU  - Bouschbacher M
AD  - URGO Group, Chenôve, France.
FAU - Lefèvre, Lise
AU  - Lefèvre L
AD  - UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le 
      Développement, Université Paul Sabatier, Toulouse, France.
AD  - RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, Université 
      Paul Sabatier, Toulouse, France.
FAU - Pipy, Bernard
AU  - Pipy B
AD  - UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le 
      Développement, Université Paul Sabatier, Toulouse, France.
FAU - Coste, Agnès
AU  - Coste A
AUID- ORCID: 0000-0001-7781-3323
AD  - UMR 152 PHARMA-DEV, Université de Toulouse, and Institut de Recherche pour le 
      Développement, Université Paul Sabatier, Toulouse, France.
AD  - RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, Université 
      Paul Sabatier, Toulouse, France.
LA  - eng
SI  - figshare/10.2337/figshare.20234823
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Leukotriene A4)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - 1HGW4DR56D (Leukotriene B4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Aspirin/metabolism/pharmacology/therapeutic use
MH  - *Diabetes Mellitus, Experimental/metabolism
MH  - Inflammation/drug therapy/metabolism
MH  - Leukotriene A4/metabolism/pharmacology
MH  - Leukotriene B4/metabolism
MH  - Lipoxins
MH  - Macrophages/metabolism
MH  - Mice
MH  - Phenotype
MH  - Skin/metabolism
MH  - Wound Healing
EDAT- 2022/07/08 06:00
MHDA- 2022/09/24 06:00
CRDT- 2022/07/07 10:33
PHST- 2020/12/10 00:00 [received]
PHST- 2022/06/29 00:00 [accepted]
PHST- 2022/07/08 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/07/07 10:33 [entrez]
AID - 147206 [pii]
AID - 10.2337/db20-1245 [doi]
PST - ppublish
SO  - Diabetes. 2022 Oct 1;71(10):2181-2196. doi: 10.2337/db20-1245.

PMID- 955326
OWN - NLM
STAT- MEDLINE
DCOM- 19761020
LR  - 20180216
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 14
IP  - 1
DP  - 1976
TI  - Effects of acetylsalicylic acid (ASA), ASA plus L-glutamine and L-glutamine on 
      healing of chronic gastric ulcer in the rat.
PG  - 85-8
AB  - A chronic gastric ulcer model was produced in rats by the subserosal injection of 
      20% acetic acid solution (0.015 ml) in order to examine whether (1) 
      acetylsalicylic acid (ASA) irritates the chronic gastric ulcer in active or 
      healed or diminished stage, (2) L-glutamine, given together with ASA, inhibits 
      the adverse effect of ASA. Oral ASA 200 mg/kg/day, given in two divided doses for 
      10 consecutive days, apparently delayed the healing of the gastric ulcer and 
      irritated the healed ulcer to reulcerate. L-Glutamine, 1,500 mg/kg/day, which was 
      given together with ASA in two divided doses, markedly protected the gastric 
      ulcer both in active and healed stages from the deleterious activity of ASA.
FAU - Okabe, S
AU  - Okabe S
FAU - Takeuchi, K
AU  - Takeuchi K
FAU - Honda, K
AU  - Honda K
FAU - Takagi, K
AU  - Takagi K
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0RH81L854J (Glutamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/antagonists & inhibitors/*toxicity
MH  - Chronic Disease
MH  - Drug Evaluation, Preclinical
MH  - Glutamine/*therapeutic use
MH  - Male
MH  - Rats
MH  - Recurrence
MH  - Stomach Ulcer/chemically induced/*drug therapy
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1159/000197802 [doi]
PST - ppublish
SO  - Digestion. 1976;14(1):85-8. doi: 10.1159/000197802.

PMID- 28265622
OWN - NLM
STAT- MEDLINE
DCOM- 20180220
LR  - 20180220
IS  - 1463-9084 (Electronic)
IS  - 1463-9076 (Linking)
VI  - 19
IP  - 11
DP  - 2017 Mar 15
TI  - Ab initio study of aspirin adsorption on single-walled carbon and carbon nitride 
      nanotubes.
PG  - 8076-8081
LID - 10.1039/c6cp08122c [doi]
AB  - Using density functional theory, we investigate the adsorption properties of 
      acetylsalicylic acid (aspirin) on the outer surfaces of a (10,0) carbon nanotube 
      (CNT) and a (8,0) triazine-based graphitic carbon nitride nanotube (CNNT). The 
      adsorption energies for the CNNT and CNT are 0.67 and 0.51 eV, respectively, and 
      hence, the aspirin molecule binds more strongly to the CNNT. The stronger 
      adsorption energy for the binding to the CNNT is ascribed to the high reactivity 
      of its nitrogen atoms with high electron affinity. The CNNT exhibits local 
      electric dipole moments that cause strong charge redistribution in the adsorbed 
      aspirin molecule. The influence of an external electric field on the adsorption 
      of aspirin on the nanotubes is explored by examining modifications in their 
      electronic band structures, partial densities of states, and charge 
      distributions. An electric field applied along a particular direction is found to 
      induce molecular states of aspirin that lie within the in-gap region of the CNNT. 
      This implies that the CNNT can be potentially utilized for the detection of 
      aspirin.
FAU - Lee, Yongju
AU  - Lee Y
AD  - Department of Physics and Research Institute for Basic Sciences, Kyung Hee 
      University, Seoul, 02447, Korea. ykkwon@khu.ac.kr.
FAU - Kwon, Dae-Gyeon
AU  - Kwon DG
AD  - Department of Physics and Research Institute for Basic Sciences, Kyung Hee 
      University, Seoul, 02447, Korea. ykkwon@khu.ac.kr.
FAU - Kim, Gunn
AU  - Kim G
AUID- ORCID: 0000-0002-6016-1813
AD  - Department of Physics & Astronomy and Graphene Research Institute, Sejong 
      University, Seoul, 05006, Korea. gunnkim@sejong.ac.kr.
FAU - Kwon, Young-Kyun
AU  - Kwon YK
AD  - Department of Physics and Research Institute for Basic Sciences, Kyung Hee 
      University, Seoul, 02447, Korea. ykkwon@khu.ac.kr.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Phys Chem Chem Phys
JT  - Physical chemistry chemical physics : PCCP
JID - 100888160
RN  - 0 (Nanotubes, Carbon)
RN  - 0 (Nitriles)
RN  - 0 (Triazines)
RN  - 534Q0F66RK (cyanogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Aspirin/*chemistry
MH  - Nanotubes, Carbon/*chemistry
MH  - Nitriles/*chemistry
MH  - Quantum Theory
MH  - Triazines/chemistry
EDAT- 2017/03/08 06:00
MHDA- 2018/02/21 06:00
CRDT- 2017/03/08 06:00
PHST- 2017/03/08 06:00 [pubmed]
PHST- 2018/02/21 06:00 [medline]
PHST- 2017/03/08 06:00 [entrez]
AID - 10.1039/c6cp08122c [doi]
PST - ppublish
SO  - Phys Chem Chem Phys. 2017 Mar 15;19(11):8076-8081. doi: 10.1039/c6cp08122c.

PMID- 28106908
OWN - NLM
STAT- MEDLINE
DCOM- 20170807
LR  - 20180209
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 177
IP  - 5
DP  - 2017 Jun
TI  - The aspirin story - from willow to wonder drug.
PG  - 674-683
LID - 10.1111/bjh.14520 [doi]
AB  - The story of the discovery of aspirin stretches back more than 3500 years to when 
      bark from the willow tree was used as a pain reliever and antipyretic. It 
      involves an Oxfordshire clergyman, scientists at a German dye manufacturer, a 
      Nobel Prize-winning discovery and a series of pivotal clinical trials. Aspirin is 
      now the most commonly used drug in the world. Its role in preventing 
      cardiovascular and cerebrovascular disease has been revolutionary and one of the 
      biggest pharmaceutical success stories of the last century.
CI  - © 2017 John Wiley & Sons Ltd.
FAU - Desborough, Michael J R
AU  - Desborough MJR
AUID- ORCID: 0000-0002-1951-5616
AD  - NHS Blood and Transplant, John Radcliffe Hospital, Oxford, UK.
AD  - Oxford Clinical Research in Transfusion Medicine, Nuffield Division of Clinical 
      Laboratory Sciences, University of Oxford, Oxford, UK.
FAU - Keeling, David M
AU  - Keeling DM
AUID- ORCID: 0000-0001-6779-6566
AD  - Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford, UK.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20170120
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antipyretics)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/history/pharmacology/*therapeutic use
MH  - Antipyretics/history/pharmacology/*therapeutic use
MH  - Aspirin/history/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/history/prevention & control
MH  - Drug Discovery/history
MH  - Forecasting
MH  - Hematologic Diseases/history/prevention & control
MH  - Hemorrhage/chemically induced/history
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - History, Ancient
MH  - Plant Bark
MH  - Platelet Aggregation Inhibitors/history/pharmacology/*therapeutic use
MH  - *Salix
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - antiplatelet agent
OT  - aspirin
OT  - history
OT  - willow
EDAT- 2017/01/21 06:00
MHDA- 2017/08/08 06:00
CRDT- 2017/01/21 06:00
PHST- 2017/01/21 06:00 [pubmed]
PHST- 2017/08/08 06:00 [medline]
PHST- 2017/01/21 06:00 [entrez]
AID - 10.1111/bjh.14520 [doi]
PST - ppublish
SO  - Br J Haematol. 2017 Jun;177(5):674-683. doi: 10.1111/bjh.14520. Epub 2017 Jan 20.

PMID- 9416734
OWN - NLM
STAT- MEDLINE
DCOM- 19980115
LR  - 20190628
IS  - 0003-3022 (Print)
IS  - 0003-3022 (Linking)
VI  - 87
IP  - 6
DP  - 1997 Dec
TI  - Experimental subarachnoid hemorrhage in rats: effect of intravenous alpha-alpha 
      diaspirin crosslinked hemoglobin on hypoperfusion and neuronal death.
PG  - 1486-93
AB  - BACKGROUND: Hemodilution with diaspirin crosslinked hemoglobin (DCLHb) 
      ameliorates occlusive cerebral ischemia. However, subarachnoid hemoglobin has 
      been implicated as a cause of cerebral hypoperfusion. The effect of intravenous 
      DCLHb on cerebral perfusion and neuronal death after experimental subarachnoid 
      hemorrhage was evaluated. METHODS: Rats (n = 48) were anesthetized with 
      isoflurane and subarachnoid hemorrhage was induced by injecting 0.3 ml of 
      autologous blood into the cistema magna. Each animal received one of the 
      following regimens: Control, no hematocrit manipulation; DCLHb, hematocrit 
      concentration decreased to 30% with DCLHb; or Alb, hematocrit concentration 
      decreased to 30% with human serum albumin. The experiments had two parts, A and 
      B. In part A, after 20 min, cerebral blood flow (CBF) was assessed with 
      14C-iodoantipyrine autoradiography. In part B, after 96 h, in separate animals, 
      the number of dead neurons was determined in predetermined coronal sections by 
      hematoxylin and eosin staining. RESULTS: Cerebral blood flow was greater for the 
      DCLHb group than for the control group; and CBF was greater for the Alb group 
      than the other two groups (P < 0.05). In one section, CBF was 45.5 +/- 10.9 ml x 
      100 g(-1) x min(-1) (mean +/- SD) for the control group, 95.3 +/- 16.6 ml x 100 
      g(-1) x min(-1) for the DCLHb group, and 138.1 +/- 18.7 ml x 100 g(-1) x min(-1) 
      for the Alb group. The number of dead neurons was less in the Alb group (611 +/- 
      84) than in the control group (1,097 +/- 211), and was less in the DCLHb group 
      (305 +/- 38) than in the other two groups (P < 0.05). CONCLUSIONS: These data 
      support a hypothesis that hemodilution decreases hypoperfusion and neuronal death 
      after subarachnoid hemorrhage. The data do not support the notion that 
      intravascular molecular hemoglobin has an adverse effect on brain injury after 
      subarachnoid hemorrhage.
FAU - Cole, D J
AU  - Cole DJ
AD  - Department of Anesthesiology, Loma Linda University, California 92354, USA. 
      djcole@ccmail.llu.edu
FAU - Nary, J C
AU  - Nary JC
FAU - Reynolds, L W
AU  - Reynolds LW
FAU - Patel, P M
AU  - Patel PM
FAU - Drummond, J C
AU  - Drummond JC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesthesiology
JT  - Anesthesiology
JID - 1300217
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Brain/blood supply/*drug effects/pathology
MH  - Cell Death/drug effects
MH  - Cerebrovascular Circulation/*drug effects
MH  - Exchange Transfusion, Whole Blood
MH  - Hemodilution
MH  - Hemoglobins/*pharmacology/therapeutic use
MH  - Male
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Subarachnoid Hemorrhage/physiopathology/*therapy
MH  - Vasoconstriction/drug effects
EDAT- 1998/01/07 00:00
MHDA- 1998/01/07 00:01
CRDT- 1998/01/07 00:00
PHST- 1998/01/07 00:00 [pubmed]
PHST- 1998/01/07 00:01 [medline]
PHST- 1998/01/07 00:00 [entrez]
AID - 10.1097/00000542-199712000-00028 [doi]
PST - ppublish
SO  - Anesthesiology. 1997 Dec;87(6):1486-93. doi: 10.1097/00000542-199712000-00028.

PMID- 35717628
OWN - NLM
STAT- MEDLINE
DCOM- 20230119
LR  - 20230207
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 1
DP  - 2023 Jan
TI  - Low-dose aspirin use and colorectal cancer survival in 32,195 patients-A national 
      cohort study.
PG  - 315-324
LID - 10.1002/cam4.4859 [doi]
AB  - BACKGROUND: Results from previous studies indicate that use of aspirin may 
      improve colorectal cancer (CRC) survival. The aim of this study was to assess 
      whether use of aspirin influences overall survival or CRC-specific survival in an 
      unselected cohort of patients diagnosed with CRC. METHODS: The study was 
      performed using the Colorectal Cancer Data Base Sweden (CRCBaSe), a mega-linkage 
      originating from the Swedish Colorectal Cancer Register, with additional linkages 
      to other national health care registers. All patients diagnosed with primary CRC 
      stage I-III treated with curative surgery, aged 18-85 years at diagnosis, from 
      2007 through 2016 were identified. Information on low-dose aspirin use was 
      extracted from the Swedish Prescribed Drug Register. Exposure was defined as 
      dispensed prescription for at least 6 months. Aspirin exposure was analyzed at 
      the time of surgery (yes/no) and as a time-varying exposure during follow-up. 
      Follow-up was restricted to a maximum 6 years, to model 5-year survival. Cox 
      regression models were fitted to estimate hazard ratios (HRs) with 95% confidence 
      intervals (CIs). Adjustments were performed for sex, age, year of diagnosis, 
      Charlson comorbidity index, hypertension, and ASA score as potential confounders. 
      RESULTS: A total of 32,195 patients diagnosed with CRC were included. 6764 (21%) 
      were exposed to aspirin at the time of CRC surgery. The median time of follow-up 
      was 4.2 years. Aspirin use at the time of surgery was not associated with 
      all-cause (adjusted HR = 1.03, 95% CI: 0.97-1.08) nor CRC-specific mortality 
      (adjusted HR = 0.99, 95% CI: 0.91-1.07). Aspirin use during follow-up was 
      associated with increased all-cause (adjusted HR = 1.09, 95% CI: 1.04-1.15) but 
      not CRC-specific mortality (adjusted HR = 0.98, 95% CI: 0.91-1.06). A 
      CRC-specific effect associated with aspirin was noted from approximately 3 years 
      following surgery. CONCLUSIONS: In this large nation-wide cohort study there was 
      no convincing association between aspirin use after CRC and OS or CRC-specific 
      survival.
CI  - © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Shahrivar, Mehrnoosh
AU  - Shahrivar M
AUID- ORCID: 0000-0003-1994-0361
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Weibull, Caroline E
AU  - Weibull CE
AUID- ORCID: 0000-0001-8231-8183
AD  - Department of Medicine Solna, Clinical Epidemiology Division, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Ekström Smedby, Karin
AU  - Ekström Smedby K
AD  - Department of Medicine Solna, Clinical Epidemiology Division, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Glimelius, Bengt
AU  - Glimelius B
AD  - Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 
      Sweden.
FAU - Syk, Ingvar
AU  - Syk I
AD  - Department of Surgery, Skåne University Hospital, Malmö, Sweden.
FAU - Matthiessen, Peter
AU  - Matthiessen P
AD  - Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, 
      Sweden.
FAU - Nordenvall, Caroline
AU  - Nordenvall C
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 
      Sweden.
AD  - Department of Pelvic Cancer, GI oncology and colorectal surgery unit, Karolinska 
      University Hospital, Stockholm, Sweden.
FAU - Martling, Anna
AU  - Martling A
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 
      Sweden.
AD  - Department of Pelvic Cancer, GI oncology and colorectal surgery unit, Karolinska 
      University Hospital, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220619
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Cohort Studies
MH  - *Colorectal Neoplasms
MH  - Aspirin/therapeutic use
MH  - *Hypertension
MH  - *Digestive System Surgical Procedures
PMC - PMC9844641
OTO - NOTNLM
OT  - aspirin
OT  - colorectal cancer
OT  - pharmacoepidemiology
OT  - survival
COIS- CEW is part of a research collaboration between Karolinska Institutet and Janssen 
      Pharmaceutica NV for which Karolinska Institutet has received/receives grant 
      support. The remaining authors have no disclosures or potential conflict of 
      interest.
EDAT- 2022/06/20 06:00
MHDA- 2023/01/20 06:00
CRDT- 2022/06/19 10:25
PHST- 2022/04/28 00:00 [revised]
PHST- 2021/10/15 00:00 [received]
PHST- 2022/05/17 00:00 [accepted]
PHST- 2022/06/20 06:00 [pubmed]
PHST- 2023/01/20 06:00 [medline]
PHST- 2022/06/19 10:25 [entrez]
AID - CAM44859 [pii]
AID - 10.1002/cam4.4859 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Jan;12(1):315-324. doi: 10.1002/cam4.4859. Epub 2022 Jun 19.

PMID- 22493984
OWN - NLM
STAT- MEDLINE
DCOM- 20130521
LR  - 20191027
IS  - 1875-5453 (Electronic)
IS  - 1389-2002 (Linking)
VI  - 13
IP  - 9
DP  - 2012 Nov
TI  - Aspirin as a chemoprevention agent for colorectal cancer.
PG  - 1313-22
AB  - Colorectal cancer (CRC) is one of the leading causes of mortality in the western 
      world. It is widely accepted that neoplasms such as colonic polyps are precursors 
      to CRC formation; with the polyp-adenoma-carcinoma sequences well described in 
      medical literature [1, 2]. It has been shown that Aspirin and other non-steroid 
      anti-inflammatory drugs (NSAID) have a negative effect on polyp and cancer 
      formation. This review aims to describe some of the mechanism behind the 
      chemoprotective properties of aspirin; COX 2 inhibition, regulation of 
      proliferation and apoptosis and effects on the immune system and also the current 
      evidence that supports its use as a chemoprevention agent against CRC. We will 
      also aim to explore the side effects with the use of aspirin and the pitfalls of 
      using aspirin routinely for primary prophylaxis against CRC.
FAU - Lee, Chun Seng
AU  - Lee CS
AD  - Department of Clinical Medicine, Trinity Centre for Health sciences, Adelaide and 
      Meath, Hospital, Dublin, Ireland. chunseng75@yahoo.co.uk
FAU - McNamara, Deirdre
AU  - McNamara D
FAU - O'Morain, Colm A
AU  - O'Morain CA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Drug Metab
JT  - Current drug metabolism
JID - 100960533
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/economics/pharmacology/*therapeutic use
MH  - Anticarcinogenic Agents/economics/pharmacology/*therapeutic use
MH  - Aspirin/economics/pharmacology/*therapeutic use
MH  - Colorectal Neoplasms/economics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Humans
EDAT- 2012/04/13 06:00
MHDA- 2013/05/23 06:00
CRDT- 2012/04/13 06:00
PHST- 2011/06/01 00:00 [received]
PHST- 2011/08/01 00:00 [revised]
PHST- 2011/09/15 00:00 [accepted]
PHST- 2012/04/13 06:00 [entrez]
PHST- 2012/04/13 06:00 [pubmed]
PHST- 2013/05/23 06:00 [medline]
AID - CDM-EPUB-20120410-001 [pii]
AID - 10.2174/138920012803341384 [doi]
PST - ppublish
SO  - Curr Drug Metab. 2012 Nov;13(9):1313-22. doi: 10.2174/138920012803341384.

PMID- 8242294
OWN - NLM
STAT- MEDLINE
DCOM- 19940106
LR  - 20190705
IS  - 0007-1323 (Print)
IS  - 0007-1323 (Linking)
VI  - 80
IP  - 10
DP  - 1993 Oct
TI  - Low-dose aspirin fails to inhibit increased platelet reactivity in patients with 
      peripheral vascular disease.
PG  - 1266-8
AB  - A study was performed to evaluate the effect of low-dose aspirin (75 mg/day) on 
      platelet reactivity in patients with peripheral vascular disease. Platelet 
      function was measured in 31 patients with advanced peripheral vascular disease 
      requiring surgery. Shear-induced haemostasis and collagen-induced thrombus 
      formation were used as indicators of platelet reactivity. They were measured in 
      non-anticoagulated fresh whole blood samples ex vivo using a haemostatometer. 
      Results were compared with those from 30 age- and sex-matched controls. 
      Shear-induced haemostasis and collagen-induced thrombus formation were also 
      measured in 18 of the 31 patients before the start of aspirin administration 
      (before operation) and 1 week after surgery. Patients with advanced peripheral 
      vascular disease were found to have increased platelet reactivity with a 
      mean(s.e.m.) shear-induced haemostasis index of 1977(180) mmHg s compared with a 
      control value of 3161(234) mmHg s (P < 0.001) and a mean(s.e.m.) collagen-induced 
      thrombus formation index of 3980(460) mmHg s compared with a control value of 
      5350(420) mmHg s (P = 0.02). Perioperative low-dose aspirin failed to inhibit 
      platelet function in patients with peripheral vascular disease.
FAU - Walters, T K
AU  - Walters TK
AD  - Professorial Surgical Unit, St Bartholomew's Hospital, London, UK.
FAU - Mitchell, D C
AU  - Mitchell DC
FAU - Wood, R F
AU  - Wood RF
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Platelets/drug effects
MH  - Collagen/pharmacology
MH  - Drug Administration Schedule
MH  - Female
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/*blood/surgery
MH  - Platelet Activation/*drug effects
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
AID - 10.1002/bjs.1800801014 [doi]
PST - ppublish
SO  - Br J Surg. 1993 Oct;80(10):1266-8. doi: 10.1002/bjs.1800801014.

PMID- 1601897
OWN - NLM
STAT- MEDLINE
DCOM- 19920716
LR  - 20210210
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 267
IP  - 17
DP  - 1992 Jun 15
TI  - Prostaglandin endoperoxide synthase. The aspirin acetylation region.
PG  - 12387-92
AB  - Aspirin selectively acetylates Ser-530 of prostaglandin endoperoxide (PGH) 
      synthase-1. This causes inactivation of the cyclooxygenase activity of the 
      enzyme, but does not appreciably affect its peroxidase activity. Although the 
      aspirin-acetylated enzyme is inactive, we found that PGH synthase-1 in which 
      Ser-530 had been replaced with an alanine was catalytically active; accordingly, 
      we proposed that aspirin inhibits cyclooxygenase activity by placing a larger 
      than normal side chain at position 530 thereby interfering with arachidonate 
      binding (DeWitt, D.L., El-Harith, E. A., Kraemer, S. A., Andrews, M. J., Yao, E. 
      F., Armstrong, R. L., and Smith, W. L. (1990) J. Biol. Chem. 265, 5192-5198). As 
      a further test of this hypothesis we have used site-directed mutagenesis and 
      transient expression in cos-1 cells to prepare and characterize five additional 
      substitutions of Ser-530. Consistent with our proposal, the presence of amino 
      acids with bulky side chains at position 530 inhibited cyclooxygenase activity 
      and decreased the apparent affinity of the enzyme for arachidonate. In related 
      work, we characterized a series of mutant PGH synthases-1 having substitutions at 
      residues adjoining Ser-530, including Phe-529, Leu-531, Lys-532, and Gly-533, in 
      order to evaluate the contributions of each residue to cyclooxygenase catalysis. 
      The most significant conclusion of this part of the study is that residues 
      529-533 all are important for the peroxidase activity as well as the 
      cyclooxygenase activity of PGH synthase-1. Phe-529, in particular, was found to 
      be critical for PGH synthase-1 structure and catalysis; some substitutions at 
      this position led to the production of proteins lacking about 100 amino acids 
      from their COOH termini.
FAU - Shimokawa, T
AU  - Shimokawa T
AD  - Department of Biochemistry, Michigan State University, East Lansing 48824.
FAU - Smith, W L
AU  - Smith WL
LA  - eng
GR  - DK42509/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 3.4.21.4 (Trypsin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Amino Acid Sequence
MH  - Aspirin/*metabolism/pharmacology
MH  - Base Sequence
MH  - Blotting, Western
MH  - Cell Line
MH  - Cyclooxygenase Inhibitors/*metabolism
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Molecular Sequence Data
MH  - Mutation
MH  - Trypsin/metabolism
EDAT- 1992/06/15 00:00
MHDA- 1992/06/15 00:01
CRDT- 1992/06/15 00:00
PHST- 1992/06/15 00:00 [pubmed]
PHST- 1992/06/15 00:01 [medline]
PHST- 1992/06/15 00:00 [entrez]
AID - S0021-9258(19)49852-9 [pii]
PST - ppublish
SO  - J Biol Chem. 1992 Jun 15;267(17):12387-92.

PMID- 30779982
OWN - NLM
STAT- MEDLINE
DCOM- 20190806
LR  - 20190918
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 131
DP  - 2019 Apr 1
TI  - A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing 
      molsidomine moiety.
PG  - 159-166
LID - S0928-0987(19)30073-9 [pii]
LID - 10.1016/j.ejps.2019.02.020 [doi]
AB  - Ischemic heart conditions are among the main causes of sudden cardiac death 
      worldwide. One of the strategies for avoiding myocardial infarction is the 
      low-dose, prophylactic use of acetylsalicylic acid (ASA), an inhibitor of 
      platelet aggregation. To avoid the gastrointestinal damage, ASA prodrugs bearing 
      nitric oxide (NO)-donating moiety covalently conjugated to ASA have been 
      synthesized and evaluated extensively worldwide. Herein the synthesis of a new 
      hybrid ASA ester covalently attached to the NO donor linsidomine, an active 
      metabolite of molsidomine (MOL) is reported. Cell viability assay and hemolysis 
      tests were performed in H9c2 cells and rat erythrocytes, respectively. Our new 
      compound, the ERJ-500 not affected negatively the viability of living cells in 
      the concentration range of 100 nM to 100 μM. Using the ex vivo Langendorff method 
      on hearts originated from female rats, compound ERJ-500 displayed a 
      dose-dependent, outwashable vasodilative effect in coronary arteries. 
      Vasodilation was observed on isolated working heart model as well, with elevated 
      stroke volume in hearts treated with ERJ-500. Furthermore, a decreased infarct 
      size was also noticed in ERJ-500 treated hearts after ischemia/reperfusion. Based 
      on these observations it can be expected that our new hybrid ASA may contribute 
      to new pharmacological tool in the therapy of ischemic heart conditions and 
      associated syndromes.
CI  - Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Szőke, Kitti
AU  - Szőke K
AD  - Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, 
      Debrecen, Hungary.
FAU - Czompa, Attila
AU  - Czompa A
AD  - Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, 
      Debrecen, Hungary.
FAU - Lekli, István
AU  - Lekli I
AD  - Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, 
      Debrecen, Hungary.
FAU - Szabados-Fürjesi, Péter
AU  - Szabados-Fürjesi P
AD  - Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, 
      Debrecen, Hungary; Department of Bioanalytical Chemistry, Faculty of Pharmacy, 
      University of Debrecen, Debrecen, Hungary.
FAU - Herczeg, Mihály
AU  - Herczeg M
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of 
      Debrecen, Debrecen, Hungary.
FAU - Csávás, Magdolna
AU  - Csávás M
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of 
      Debrecen, Debrecen, Hungary.
FAU - Borbás, Anikó
AU  - Borbás A
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of 
      Debrecen, Debrecen, Hungary.
FAU - Herczegh, Pál
AU  - Herczegh P
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of 
      Debrecen, Debrecen, Hungary. Electronic address: Herczegh.pal@pharm.unideb.hu.
FAU - Tósaki, Árpád
AU  - Tósaki Á
AD  - Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, 
      Debrecen, Hungary. Electronic address: tosaki.arpad@pharm.unideb.hu.
LA  - eng
PT  - Journal Article
DEP - 20190216
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (ERJ-500)
RN  - 0 (Vasodilator Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - D46583G77X (Molsidomine)
RN  - R16CO5Y76E (Aspirin)
MH  - Animals
MH  - Aspirin/*administration & dosage/*analogs & derivatives/pharmacology
MH  - Cell Line
MH  - Coronary Circulation/drug effects
MH  - Erythrocytes/drug effects
MH  - Female
MH  - Heart/*drug effects/physiology
MH  - Heart Rate/drug effects
MH  - Hemolysis/drug effects
MH  - Molsidomine/*administration & dosage
MH  - Nitric Oxide/*administration & dosage
MH  - Rats, Sprague-Dawley
MH  - Vasodilation/drug effects
MH  - Vasodilator Agents/*administration & dosage
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Coronary flow
OT  - Isolated heart
OT  - Molsidomine
OT  - Nitrogen oxide liberation
OT  - Vasoactivity
EDAT- 2019/02/20 06:00
MHDA- 2019/08/07 06:00
CRDT- 2019/02/20 06:00
PHST- 2018/02/22 00:00 [received]
PHST- 2019/02/13 00:00 [revised]
PHST- 2019/02/14 00:00 [accepted]
PHST- 2019/02/20 06:00 [pubmed]
PHST- 2019/08/07 06:00 [medline]
PHST- 2019/02/20 06:00 [entrez]
AID - S0928-0987(19)30073-9 [pii]
AID - 10.1016/j.ejps.2019.02.020 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2019 Apr 1;131:159-166. doi: 10.1016/j.ejps.2019.02.020. Epub 
      2019 Feb 16.

PMID- 34021
OWN - NLM
STAT- MEDLINE
DCOM- 19790523
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 68
IP  - 3
DP  - 1979 Mar
TI  - Kinetics and mechanism of hydrolysis of 
      1-(2'-acetoxybenzoyl)-2-deoxy-alpha-D-glucopyranose, a novel aspirin prodrug.
PG  - 299-301
AB  - The formation rate of aspirin from the prodrug was determined as a function of 
      the pH, temperature, and dielectric constant of the solvent 
      spectrophotometrically and was confirmed by high-pressure liquid chromatography. 
      Aspirin formation was first order with respect to the prodrug and zero order with 
      respect to the hydroxide-ion concentrations. The hydrolysis rate was independent 
      of buffer concentration but very sensitive to the dielectric constant of the 
      solvents. The half-life for the formation of aspirin at 37 degrees was 7 min. The 
      activation energy for the hydrolysis was 23.7 kcal/mole. The results suggest that 
      the hydrolysis of the prodrug to aspirin proceeds by an SN1-type mechanism.
FAU - Hussain, A
AU  - Hussain A
FAU - Truelove, J
AU  - Truelove J
FAU - Kostenbauder, H
AU  - Kostenbauder H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Deoxy Sugars)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives
MH  - Chemical Phenomena
MH  - Chemistry
MH  - *Deoxy Sugars
MH  - Electrochemistry
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - Kinetics
MH  - Temperature
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
AID - S0022-3549(15)42545-6 [pii]
AID - 10.1002/jps.2600680311 [doi]
PST - ppublish
SO  - J Pharm Sci. 1979 Mar;68(3):299-301. doi: 10.1002/jps.2600680311.

PMID- 11388690
OWN - NLM
STAT- MEDLINE
DCOM- 20010621
LR  - 20220317
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 68
IP  - 12
DP  - 2001 Feb 9
TI  - Modulation of diaspirin crosslinked hemoglobin induced systemic and regional 
      hemodynamic response by ethanol in normal rats.
PG  - 1383-94
AB  - DCLHb, a hemoglobin based oxygen carrier, has been extensively studied for the 
      treatment of hemorrhagic shock in both animal models and humans. Numerous 
      accidents resulting in trauma are due to ethanol intoxication, in particular 
      cases of car accidents. Therefore, trauma patients might be intoxicated with 
      drugs of abuse like ethanol. Ethanol has significant effects on the 
      cardiovascular system including peripheral vasodilation and decreased myocardial 
      contractility. Such effects are likely to alter the cardiovascular actions of 
      DCLHb, a resuscitative agent. Hence, this study investigated the effect of 
      ethanol on the cardiovascular actions of DCLHb. Urethane anesthetized male 
      Sprague-Dawley rats were divided into following groups (i) Saline + DCLHb (400 
      mg/kg) (n = 9), (ii) Ethanol (1 g/kg) + DCLHb (400 mg/kg) (n = 9), and (iii) 
      Ethanol (4 g/kg) + DCLHb (400 mg/kg) (n = 8). Cardiovascular parameters were 
      determined using a radioactive microsphere technique. DCLHb when administered to 
      saline treated rats produced an increase in MAP, TPR, decreased renal and hepatic 
      blood flow and increased blood flow to the skin and mesentery & pancreas. A high 
      dose of ethanol (4 g/kg) significantly attenuated the DCLHb induced pressor 
      response (p < 0.05) and increase in TPR (p < 0.05). Cardiac output was severely 
      reduced by DCLHb in rats treated with high dose ethanol as compared to saline. No 
      changes in TPR and cardiac output were observed in the low dose ethanol (1 g/kg) 
      group. DCLHb reduced blood flow to the heart and mesentery & pancreas in rats 
      treated with high dose ethanol. DCLHb caused a decrease in musculo-skeletal 
      vascular resistance in rats treated with high dose ethanol. This decrease in 
      vascular resistance in the musculo-skeletal system appears to be contributing to 
      a decrease in TPR. It is concluded that ethanol in higher doses significantly 
      alters the hemodynamic effects of DCLHb and may interfere with the resuscitative 
      effects of DCLHb.
FAU - Palaparthy, R
AU  - Palaparthy R
AD  - Department of Pharmaceutics and Pharmacodynamics, The University of Illinois at 
      Chicago, 60612, USA.
FAU - Saini, B K
AU  - Saini BK
FAU - Gulati, A
AU  - Gulati A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 3K9958V90M (Ethanol)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Blood Substitutes/*pharmacology
MH  - Cross-Linking Reagents/*pharmacology
MH  - Drug Interactions
MH  - Ethanol/*pharmacology
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/*drug effects
MH  - Time Factors
EDAT- 2001/06/05 10:00
MHDA- 2001/06/22 10:01
CRDT- 2001/06/05 10:00
PHST- 2001/06/05 10:00 [pubmed]
PHST- 2001/06/22 10:01 [medline]
PHST- 2001/06/05 10:00 [entrez]
AID - S0024320500010407 [pii]
AID - 10.1016/s0024-3205(00)01040-7 [doi]
PST - ppublish
SO  - Life Sci. 2001 Feb 9;68(12):1383-94. doi: 10.1016/s0024-3205(00)01040-7.

PMID- 7980147
OWN - NLM
STAT- MEDLINE
DCOM- 19941128
LR  - 20131121
IS  - 0300-8495 (Print)
IS  - 0300-8495 (Linking)
VI  - 23
IP  - 8
DP  - 1994 Aug
TI  - Anticoagulation and the GP patient.
PG  - 1476-81
AB  - The use of anticoagulant drugs requires a knowledge of the essential elements of 
      their pharmacology and mechanisms of action. This article illustrates the marked 
      differences for the drugs warfarin, heparin and aspirin.
FAU - Lloyd, J V
AU  - Lloyd JV
AD  - Transfusion/Haemostasis Unit, Institute of Medical and Veterinary Science, 
      Adelaide, South Australia.
FAU - Rodgers, S E
AU  - Rodgers SE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Aust Fam Physician
JT  - Australian family physician
JID - 0326701
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Blood Coagulation/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Overdose/prevention & control
MH  - Family Practice
MH  - Hemostasis, Surgical/*methods
MH  - *Heparin/pharmacology/therapeutic use
MH  - Humans
MH  - Preoperative Care
MH  - Tooth Extraction
MH  - *Warfarin/pharmacology/therapeutic use
RF  - 10
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
PST - ppublish
SO  - Aust Fam Physician. 1994 Aug;23(8):1476-81.

PMID- 31263057
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20200909
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 28
IP  - 7
DP  - 2019 Jul
TI  - Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a 
      Randomized Clinical Trial.
PG  - 1262-1265
LID - 10.1158/1055-9965.EPI-19-0205 [doi]
AB  - BACKGROUND: Visceral adiposity is a risk factor for colorectal adenomas, and 
      aspirin is an established chemopreventive agent. Evidence from clinical trials 
      suggests the effectiveness of aspirin at preventing cardiovascular disease and 
      cancer may require higher doses for higher body weight. METHODS: Body mass index, 
      body surface area, fat-free mass, and fat mass were calculated from baseline 
      height and weight in 1,121 participants of the Aspirin/Folate Polyp Prevention 
      Study, a double-blind, placebo-controlled, 3 × 2 factorial randomized clinical 
      trial of low-dose (81 mg/day) or high-dose (325 mg/day) aspirin and/or 1 mg/day 
      folic acid to prevent metachronous colorectal adenomas. Participants were treated 
      during a surveillance colonoscopy interval of approximately 3 years. Risk ratios 
      (RR) with 95% confidence intervals (CI) for any colorectal neoplasia and 
      high-risk adenoma (HRA, advanced or ≥3 adenomas) were estimated from log-linear 
      regression. RESULTS: We did not find evidence to suggest aspirin dose-response 
      differed by body composition measurements, including weight alone. Among those 
      weighing ≥ 80 kg, treatment effects for low-dose aspirin (RR for colorectal 
      neoplasia, 0.75; 95% CI, 0.60-0.94; RR for HRA, 0.52; 95% CI, 0.31-0.86) and 
      high-dose aspirin (RR for colorectal neoplasia, 0.88; 95% CI, 0.72-1.08; RR for 
      HRA, 0.68; 95% CI, 0.43-1.09) were not meaningfully different than for those 
      weighing 70-79 kg or <70 kg. CONCLUSIONS: Measurements of body composition 
      calculated from height and weight did not modify aspirin treatment effects for 
      colorectal adenoma prevention. IMPACT: Aspirin dosing strategies accounting for 
      body weight suggested in previous trials of colorectal cancer may not apply to 
      adenomas.
CI  - ©2019 American Association for Cancer Research.
FAU - Passarelli, Michael N
AU  - Passarelli MN
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New 
      Hampshire. michael.n.passarelli@dartmouth.edu.
FAU - Barry, Elizabeth L
AU  - Barry EL
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New 
      Hampshire.
FAU - Rees, Judy R
AU  - Rees JR
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New 
      Hampshire.
FAU - Mott, Leila A
AU  - Mott LA
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New 
      Hampshire.
FAU - Ahnen, Dennis J
AU  - Ahnen DJ
AUID- ORCID: 0000-0003-1783-1129
AD  - Department of Medicine, University of Colorado School of Medicine, Aurora, 
      Colorado.
AD  - Gastroenterology of the Rockies, Denver, Colorado.
FAU - Baron, John A
AU  - Baron JA
AUID- ORCID: 0000-0003-3461-1056
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New 
      Hampshire.
AD  - Department of Medicine, University of North Carolina School of Medicine, Chapel 
      Hill, North Carolina.
AD  - Department of Epidemiology, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill, North Carolina.
LA  - eng
SI  - ClinicalTrials.gov/NCT00272324
GR  - P20 GM104416/GM/NIGMS NIH HHS/United States
GR  - R01 CA059005/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/drug therapy/*prevention & control
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Body Composition
MH  - Colorectal Neoplasms/drug therapy/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
PMC - PMC6608598
MID - NIHMS1527690
COIS- Disclosure of Potential Conflicts of Interest Together with the Trustees of 
      Dartmouth College, J. A. Baron holds a use patent, not licensed, for the 
      chemopreventive use of aspirin for colorectal cancer.
EDAT- 2019/07/03 06:00
MHDA- 2020/09/10 06:00
CRDT- 2019/07/03 06:00
PHST- 2019/02/19 00:00 [received]
PHST- 2019/04/10 00:00 [revised]
PHST- 2019/04/16 00:00 [accepted]
PHST- 2019/07/03 06:00 [entrez]
PHST- 2019/07/03 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
AID - 28/7/1262 [pii]
AID - 10.1158/1055-9965.EPI-19-0205 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1262-1265. doi: 
      10.1158/1055-9965.EPI-19-0205.

PMID- 21807238
OWN - NLM
STAT- MEDLINE
DCOM- 20111215
LR  - 20171116
IS  - 1873-3573 (Electronic)
IS  - 0039-9140 (Linking)
VI  - 85
IP  - 3
DP  - 2011 Sep 15
TI  - Acetylsalicylic acid electrochemical sensor based on PATP-AuNPs modified 
      molecularly imprinted polymer film.
PG  - 1672-9
LID - 10.1016/j.talanta.2011.06.067 [doi]
AB  - A novel electrochemical sensor based on molecularly imprinted polymer film has 
      been developed for aspirin detection. The sensitive film was prepared by 
      co-polymerization of p-aminothiophenol (p-ATP) and HAuCl(4) on the Au electrode 
      surface. First, p-ATP was self-assembled on the Au electrode surface by the 
      formation of Au-S bonds. Then, the acetylsalicylic acid (ASA) template was 
      assembled onto the monolayer of p-ATP through the hydrogen-bonding interaction 
      between amino group (p-ATP) and oxygen (ASA). Finally, a conductive hybrid 
      membrane was fabricated at the surface of Au electrode by the co-polymerization 
      in the mixing solution containing additional p-ATP, HAuCl(4) and ASA template. 
      Meanwhile, the ASA was spontaneously imprinted into the poly-aminothiophenol gold 
      nanoparticles (PATP-AuNPs) complex film. The amount of imprinted sites at the 
      PATP-AuNPs film significantly increases due to the additional replenishment of 
      ASA templates. With the significant increasing of imprinted sites and doped gold 
      nanoparticles, the sensitivity of the molecular imprinted polymer (MIP) electrode 
      gradually increased. The molecularly imprinted sensor was characterized by 
      electrochemical impedance spectroscopy (EIS), differential pulse voltammetry 
      (DPV), and cyclic voltammetry (CV). The linear relationships between current and 
      logarithmic concentration were obtained in the range from 1 nmol L(-1) to 0.1 
      μmol L(-1) and 0.7 μmol L(-1) to 0.1 mmol L(-1). The detection limit of 0.3 nmol 
      L(-1) was achieved. This molecularly imprinted sensor for the determination of 
      ASA has high sensitivity, good selectivity and reproducibility, with the testing 
      in some biological fluids also has good selectivity and recovery.
CI  - Crown Copyright © 2011. Published by Elsevier B.V. All rights reserved.
FAU - Wang, Zhihua
AU  - Wang Z
AD  - Key Laboratory of Bioelectrochemistry & Environmental Analysis of Gansu Province, 
      College of Chemistry & Chemical Engineering, Northwest Normal University, 
      Lanzhou, China.
FAU - Li, Hui
AU  - Li H
FAU - Chen, Jing
AU  - Chen J
FAU - Xue, Zhonghua
AU  - Xue Z
FAU - Wu, Bowan
AU  - Wu B
FAU - Lu, Xiaoquan
AU  - Lu X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110702
PL  - Netherlands
TA  - Talanta
JT  - Talanta
JID - 2984816R
RN  - 0 (Aniline Compounds)
RN  - 0 (Chlorides)
RN  - 0 (Gold Compounds)
RN  - 0 (Polymers)
RN  - 0 (Sulfhydryl Compounds)
RN  - 7440-57-5 (Gold)
RN  - 8H372EGX3V (gold tetrachloride, acid)
RN  - 8X56V0K20X (4-aminothiophenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aniline Compounds/chemistry
MH  - Aspirin/*blood/chemistry/*urine
MH  - Biosensing Techniques/instrumentation/*methods
MH  - Chlorides/chemistry
MH  - Electrochemical Techniques/instrumentation/*methods
MH  - Electrodes
MH  - Gold/chemistry
MH  - Gold Compounds/chemistry
MH  - Humans
MH  - Microscopy, Electron, Scanning
MH  - Molecular Imprinting
MH  - Molecular Structure
MH  - Polymers/*chemistry
MH  - Reproducibility of Results
MH  - Saliva/chemistry
MH  - Sulfhydryl Compounds/chemistry
EDAT- 2011/08/03 06:00
MHDA- 2011/12/16 06:00
CRDT- 2011/08/03 06:00
PHST- 2011/04/02 00:00 [received]
PHST- 2011/06/27 00:00 [revised]
PHST- 2011/06/27 00:00 [accepted]
PHST- 2011/08/03 06:00 [entrez]
PHST- 2011/08/03 06:00 [pubmed]
PHST- 2011/12/16 06:00 [medline]
AID - S0039-9140(11)00566-2 [pii]
AID - 10.1016/j.talanta.2011.06.067 [doi]
PST - ppublish
SO  - Talanta. 2011 Sep 15;85(3):1672-9. doi: 10.1016/j.talanta.2011.06.067. Epub 2011 
      Jul 2.

PMID- 17609236
OWN - NLM
STAT- MEDLINE
DCOM- 20070810
LR  - 20201209
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 41
IP  - 7
DP  - 2007 Jul
TI  - Management options for patients with aspirin and nonsteroidal antiinflammatory 
      drug sensitivity.
PG  - 1191-200
AB  - OBJECTIVE: To evaluate and provide management strategies for patients with 
      aspirin or nonselective nonsteroidal antiinflammatory drug (NSAID) sensitivity. 
      DATA SOURCES: Literature retrieval was accessed through MEDLINE (1966-March 2007) 
      using the terms acetaminophen, aspirin, antiinflammatory agents nonsteroidal, 
      urticaria, angioedema, asthma, leukotriene antagonists, desensitization, and 
      tacrolimus. Article references retrieved were hand-searched for other relevant 
      articles. STUDY SELECTION AND DATA EXTRACTION: All studies published in English 
      were evaluated. Studies, review articles, and commentaries on aspirin-induced 
      asthma and aspirin- or NSAID-induced urticaria/angioedema were included in the 
      review. DATA SYNTHESIS: Aspirin sensitivity is most often manifested as 
      respiratory reactions (eg, bronchospasm, profuse rhinorrhea, conjunctival 
      injection) or urticaria/angioedema. The primary mechanism is believed to be 
      inhibition of the cyclooxygenase 1 (COX-1) enzyme; as such, patients with aspirin 
      sensitivity often display cross-reactions to nonselective NSAIDs that inhibit the 
      COX-1 enzyme. Management strategies include avoidance of aspirin and 
      cross-reacting nonselective NSAIDs. However, desensitization to aspirin is a 
      viable option for patients with aspirin-induced respiratory reactions, especially 
      for those who require aspirin for thromboembolic prophylaxis. Aspirin 
      desensitization is maintained indefinitely with a daily aspirin dose. There is 
      limited evidence of the use of leukotriene modifiers in preventing 
      aspirin-induced asthma. COX-2 selective NSAIDs, especially in patients with 
      aspirin-induced asthma, have not been found to cross-react. However, 
      approximately 4% of patients with a history of aspirin-induced skin reactions may 
      experience a cutaneous reaction following a challenge to a COX-2 selective NSAID. 
      Since acetaminophen is a weak inhibitor of the COX-1 enzyme, patients with 
      aspirin-induced asthma should not take more than 1000 mg of acetaminophen in a 
      single dose. CONCLUSIONS: Management of patients with aspirin/NSAID sensitivity 
      includes avoidance of aspirin/nonselective NSAIDs, use of COX-2 selective NSAIDs, 
      acetaminophen in doses less than 1000 mg, and desensitization. The role of 
      leukotriene modifiers requires further study before they can be recommended for 
      patients.
FAU - Knowles, Sandra R
AU  - Knowles SR
AD  - Sunnybrook Health Sciences Centre, Department of Pharmacy and Drug Safety Clinic, 
      Toronto, ON, Canada. sandra.knowles@sunnybrook.ca
FAU - Drucker, Aaron M
AU  - Drucker AM
FAU - Weber, Elizabeth A
AU  - Weber EA
FAU - Shear, Neil H
AU  - Shear NH
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20070703
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Disease Management
MH  - Drug Hypersensitivity
MH  - Humans
MH  - Respiratory Distress Syndrome/chemically induced/enzymology/prevention & control
RF  - 92
EDAT- 2007/07/05 09:00
MHDA- 2007/08/11 09:00
CRDT- 2007/07/05 09:00
PHST- 2007/07/05 09:00 [pubmed]
PHST- 2007/08/11 09:00 [medline]
PHST- 2007/07/05 09:00 [entrez]
AID - aph.1K023 [pii]
AID - 10.1345/aph.1K023 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2007 Jul;41(7):1191-200. doi: 10.1345/aph.1K023. Epub 2007 Jul 
      3.

PMID- 27064410
OWN - NLM
STAT- MEDLINE
DCOM- 20170427
LR  - 20220408
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 164
IP  - 12
DP  - 2016 Jun 21
TI  - Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic 
      Evidence Review for the U.S. Preventive Services Task Force.
PG  - 804-13
LID - 10.7326/M15-2113 [doi]
AB  - BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death in the 
      United States. PURPOSE: To update a systematic review about the benefits of 
      aspirin for the primary prevention of cardiovascular events in adults aged 40 
      years or older and to evaluate effect modification in subpopulations. DATA 
      SOURCES: MEDLINE, PubMed, Cochrane Central Register of Controlled Trials (January 
      2008 to January 2015), and Cochrane Database of Systematic Reviews. STUDY 
      SELECTION: Two investigators independently reviewed 3396 abstracts and 65 
      articles according to prespecified criteria. All included trials evaluated 
      aspirin for the primary prevention of cardiovascular events. DATA EXTRACTION: Two 
      investigators assessed study quality; data were abstracted by 1 reviewer and 
      checked by a second. DATA SYNTHESIS: Two good-quality and 9 fair-quality 
      randomized, controlled trials were identified. In analyses of all doses, aspirin 
      reduced the risk for nonfatal myocardial infarction (MI) (relative risk [RR], 
      0.78 [95% CI, 0.71 to 0.87]) but not nonfatal stroke; aspirin showed little or no 
      benefit for all-cause or cardiovascular mortality. Benefits began within the 
      first 5 years. Older adults achieved greater relative MI reduction, but no other 
      effect modifications were found in analyzed subpopulations. In trials with 
      aspirin doses of 100 mg or less per day, the reduction in nonfatal MI benefit 
      persisted (absolute risk reduction, 0.15 to 1.43 events per 1000 person-years) 
      and a 14% reduction in nonfatal stroke benefit was noted, but no benefit was 
      found for all-cause mortality (RR, 0.95 [CI, 0.89 to 1.01]) or cardiovascular 
      mortality (RR, 0.97 [CI, 0.85 to 1.10]). LIMITATION: Evidence for aspirin in 
      primary prevention is heterogeneous and limited by rare events and few credible 
      subgroup analyses. CONCLUSION: The beneficial effect of aspirin for the primary 
      prevention of CVD is modest and occurs at doses of 100 mg or less per day. Older 
      adults seem to achieve a greater relative MI benefit. PRIMARY FUNDING SOURCE: 
      Agency for Healthcare Research and Quality.
FAU - Guirguis-Blake, Janelle M
AU  - Guirguis-Blake JM
FAU - Evans, Corinne V
AU  - Evans CV
FAU - Senger, Caitlyn A
AU  - Senger CA
FAU - O'Connor, Elizabeth A
AU  - O'Connor EA
FAU - Whitlock, Evelyn P
AU  - Whitlock EP
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20160412
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Cause of Death
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Humans
MH  - *Primary Prevention
MH  - Risk Factors
EDAT- 2016/04/12 06:00
MHDA- 2017/04/28 06:00
CRDT- 2016/04/12 06:00
PHST- 2016/04/12 06:00 [entrez]
PHST- 2016/04/12 06:00 [pubmed]
PHST- 2017/04/28 06:00 [medline]
AID - 2513176 [pii]
AID - 10.7326/M15-2113 [doi]
PST - ppublish
SO  - Ann Intern Med. 2016 Jun 21;164(12):804-13. doi: 10.7326/M15-2113. Epub 2016 Apr 
      12.

PMID- 17200429
OWN - NLM
STAT- MEDLINE
DCOM- 20070323
LR  - 20131121
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 41
IP  - 1
DP  - 2007 Jan
TI  - Rapid desensitization protocols for patients with cardiovascular disease and 
      aspirin hypersensitivity in an era of dual antiplatelet therapy.
PG  - 61-7
AB  - OBJECTIVE: To review the available protocols for rapid desensitization of 
      patients with aspirin hypersensitivity and apply the data for use in patients 
      with cardiovascular disease who would benefit from the dual antiplatelet therapy. 
      DATA SOURCES: A literature search was conducted via MEDLINE from 1966 to December 
      2006. Main search terms included: aspirin sensitivity, aspirin allergy, aspirin 
      desensitization, aspirin-induced asthma, aspirin therapy, and aspirin intolerance 
      syndrome. STUDY SELECTION AND DATA EXTRACTION: Articles describing rapid aspirin 
      desensitization protocols were selected for review. Literature pertaining to 
      aspirin hypersensitivity, drug desensitization, and the use of aspirin and dual 
      antiplatelet therapy was also examined. Three rapid desensitization protocols 
      were identified and evaluated. DATA SYNTHESIS: While landmark studies 
      demonstrated that dual antiplatelet therapy with aspirin and clopidogrel 
      significantly reduces mortality and morbidity in acute coronary syndromes and 
      coronary stenting, patients with aspirin hypersensitivity are frequently managed 
      with clopidogrel alone with no supporting data. Approximately 10% of the 
      population experiences hypersensitivity to aspirin, which can manifest as asthma 
      exacerbations, rhinorrhea, angioedema, urticaria, and anaphylaxis. The 
      hypersensitivity reaction is mediated through aspirin-directed antibodies or by 
      excessive leukotriene production. The desensitization process involved depletion 
      of these mediators, as well as down-regulation of leukotriene receptors. Two 
      groups of investigators developed rapid protocols to desensitize patients with 
      aspirin hypersensitivity safely and effectively. The rapid protocol developed by 
      Wong provides benefits over other protocols with its low starting dose and 
      completion in less than 3 hours, low incidence of adverse effects, and high 
      success rate in aspirin desensitization. CONCLUSIONS: The Wong protocol is an 
      attractive option for the rapid desensitization of patients requiring dual 
      antiplatelet therapy with aspirin and clopidogrel in the perimyocardial 
      infarction period.
FAU - Page, Nathaniel A
AU  - Page NA
AD  - School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, 
      NY 14260, USA.
FAU - Schroeder, Walter S
AU  - Schroeder WS
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20070102
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*drug therapy/immunology
MH  - *Clinical Protocols
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/immunology/*prevention & control
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
RF  - 28
EDAT- 2007/01/04 09:00
MHDA- 2007/03/24 09:00
CRDT- 2007/01/04 09:00
PHST- 2007/01/04 09:00 [pubmed]
PHST- 2007/03/24 09:00 [medline]
PHST- 2007/01/04 09:00 [entrez]
AID - aph.1H437 [pii]
AID - 10.1345/aph.1H437 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2007 Jan;41(1):61-7. doi: 10.1345/aph.1H437. Epub 2007 Jan 2.

PMID- 2957675
OWN - NLM
STAT- MEDLINE
DCOM- 19871022
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 16
IP  - 30
DP  - 1987 Sep 19
TI  - [Chronic refractory pain in cancer patients. Value of the spinal injection of 
      lysine acetylsalicylate. 60 cases].
PG  - 1465-8
AB  - Several animal studies have demonstrated that pain is modulated by spinal 
      mechanisms involving prostaglandins and that acetylsalicylic acid (ASA) 
      administered intrathecally has an analgesic effect. We report our experience of 
      this treatment in 60 patients with proven and advanced cancer. An isobaric 
      solution of lysine acetylsalicylate was administered by lumbar puncture in doses 
      ranging from 120 to 720 mg of ASA. The results were evaluated using the habitual 
      criteria: scoring system, behaviour, consumption of analgesic drugs. In this 
      trial the method proved astonishingly effective (78% of the cases). Analgesia was 
      strong, almost immediate and without influence on motricity. No thermic or 
      neurovegetative changes were noted. The effect of one injection lasted from 3 
      weeks to 1 month on average; it was reproduced and often more prolonged after a 
      repeat injection. Pain associated with bone metastases seems to constitute the 
      best indication, notably in breast and lung cancer and in myeloma. Visceral 
      (pancreas) or neural pain requires higher doses to respond. Failures (22%) were 
      due to such factors as insufficient dosage at the very beginning of our 
      experience or severe depressive syndrome. The perineal and sphincteral pain of 
      rectal cancer often resists treatment. This simple, inexpensive and very 
      effective method with no other complication than a frequent tendency to fatigue 
      should rank among other analgesic measures in cancer. The lack of respiratory 
      depression is a major advantage over catheter spinal opiate analgesia. We 
      consider that its main indications are pain associated with osteolytic metastases 
      of adenocarcinomas, and myelomas. Owing to the absence of formal toxicological 
      data, its use must be limited to cancer pain and to patients with a life 
      expectancy of less than 2 years.
FAU - Pellerin, M
AU  - Pellerin M
FAU - Hardy, F
AU  - Hardy F
FAU - Abergel, A
AU  - Abergel A
FAU - Boule, D
AU  - Boule D
FAU - Palacci, J H
AU  - Palacci JH
FAU - Babinet, P
AU  - Babinet P
FAU - Wingtin, L N
AU  - Wingtin LN
FAU - Glowinski, J
AU  - Glowinski J
FAU - Amiot, J F
AU  - Amiot JF
FAU - Mechali, D
AU  - Mechali D
AU  - et al.
LA  - fre
PT  - Journal Article
TT  - Douleur chronique rebelle des cancéreux. Intérêt de l'injection intrarachidienne 
      d'acétylsalicylate de lysine. Soixante observations.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Analgesics)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analgesics/*administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - Injections, Spinal
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*physiopathology
MH  - Pain/*drug therapy
EDAT- 1987/09/19 00:00
MHDA- 1987/09/19 00:01
CRDT- 1987/09/19 00:00
PHST- 1987/09/19 00:00 [pubmed]
PHST- 1987/09/19 00:01 [medline]
PHST- 1987/09/19 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1987 Sep 19;16(30):1465-8.

PMID- 304434
OWN - NLM
STAT- MEDLINE
DCOM- 19780310
LR  - 20190827
IS  - 0015-5691 (Print)
IS  - 0015-5691 (Linking)
VI  - 73
IP  - 7
DP  - 1977 Oct
TI  - [Studies on absorption and metabolism of drugs in febrile animals. (III). 
      Antipyretic effect of acetylsalicyclic acid and aminopyrine and their plasma 
      concentrations in febrile rabbits induced with lipopolysaccharide (author's 
      transl)].
PG  - 829-36
AB  - The present investigation was an attempt to clarify the mechanism of combined 
      effect of acetylsalicylic acid (ASA) and aminopyrine (AMI) in febrile rabbits as 
      induced by lipopolysaccharide (LPS). In addition, the possible synergic effect of 
      both agents was studied in relation to the plasma concentration. In febrile 
      rabbits, the plasma concentration of ASA (500 mg/kg, p.o.) was a higher level 
      than in the control, but the concentration of salicylic acid (SA), the metabolite 
      of ASA, was similar to that in the control. The plasma concentration of AMI (100 
      mg/kg, p.o.) in febrile rabbits was lower than in the control. A dose-dependent 
      antipyretic effect was seen in the successive doses from 125 to 500 mg/kg of ASA, 
      and a similar tendency was also observed in AMI from 25 to 100 mg/kg. To observe 
      the synergic effect of ASA and AMI, we prepared the following three combinations: 
      I (ASA/AMI; 125 plus 75 mg/kg), II (ASA/AMI; 250 plus 50 mg/kg) and III (ASA/AMI; 
      375 plus 25 mg/kg). Plasma concentrations of ASA, SA and AMI were measured after 
      oral administration of the preparations and these concentrations were lower than 
      in the separate administration of ASA ans AMI. The antipyretic effect of the 
      three preparations was weaker than the expected value, respectively.
FAU - Itami, T
AU  - Itami T
FAU - Kanoh, S
AU  - Kanoh S
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Yakurigaku Zasshi
JT  - Nihon yakurigaku zasshi. Folia pharmacologica Japonica
JID - 0420550
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 0 (Lipopolysaccharides)
RN  - 01704YP3MO (Aminopyrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aminopyrine/administration & dosage/*blood/pharmacology
MH  - Animals
MH  - *Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/administration & dosage/*blood/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Fever/chemically induced/*metabolism
MH  - Lipopolysaccharides
MH  - Male
MH  - Rabbits
EDAT- 1977/10/01 00:00
MHDA- 1977/10/01 00:01
CRDT- 1977/10/01 00:00
PHST- 1977/10/01 00:00 [pubmed]
PHST- 1977/10/01 00:01 [medline]
PHST- 1977/10/01 00:00 [entrez]
AID - 10.1254/fpj.73.829 [doi]
PST - ppublish
SO  - Nihon Yakurigaku Zasshi. 1977 Oct;73(7):829-36. doi: 10.1254/fpj.73.829.

PMID- 20095114
OWN - NLM
STAT- MEDLINE
DCOM- 20100304
LR  - 20131121
IS  - 0012-7183 (Print)
IS  - 0012-7183 (Linking)
VI  - 125
IP  - 22
DP  - 2009
TI  - [Why does acetylsalicylic acid have so many effects and applications?].
PG  - 2433-9
AB  - The history of acetylsalicylic acid (ASA, aspirin), extending over a period of 
      more than 100 years, is among other things a story of the possibilities of 
      medical research to identify and develop new indications for use based on 
      observations that are often unexpected and accidental. Acetylsalicylic acid is an 
      anti-inflammatory agent, but currently its main indication for use is the 
      prevention of circulatory disorders via inhibition of thrombocyte function. The 
      major activities and adverse effects of acetylsalicylic acid are based on 
      inhibition of the function of the cyclooxygenase enzyme, although it possesses 
      other mechanisms of action as well.
FAU - Pelkonen, Olavi
AU  - Pelkonen O
AD  - Oulun yliopisto, bioläaketieteen laitos, farmakologian ja toksikologian yksikkö.
LA  - fin
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Miksi asetyylisalisyylihapolla on niin monia vaikutuksia ja käyttökohteita?
PL  - Finland
TA  - Duodecim
JT  - Duodecim; laaketieteellinen aikakauskirja
JID - 0373207
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Humans
RF  - 20
EDAT- 2010/01/26 06:00
MHDA- 2010/03/05 06:00
CRDT- 2010/01/26 06:00
PHST- 2010/01/26 06:00 [entrez]
PHST- 2010/01/26 06:00 [pubmed]
PHST- 2010/03/05 06:00 [medline]
PST - ppublish
SO  - Duodecim. 2009;125(22):2433-9.

PMID- 8202629
OWN - NLM
STAT- MEDLINE
DCOM- 19940707
LR  - 20131121
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 83
IP  - 2
DP  - 1994 Feb
TI  - Correlation between bleeding time and antithrombotic effect of 
      platelet-suppressive agents in rat experimental model.
PG  - 157-63
AB  - To examine whether the dosage of a platelet-suppressive agent at which an 
      antithrombotic effect is adequate and bleeding tendency is not increased can be 
      found, the antithrombotic effects, antiplatelet effects and bleeding times of 
      ticlopidine and aspirin were investigated in the rat experimental thrombus 
      formation model. Thrombus formation was determined by measuring the change in wet 
      weight of a silk thread placed in a carotid arteriovenous shunt. Ticlopidine 
      inhibited thrombus formation and platelet aggregation at rather low doses (50-100 
      mg/kg) without prolonging bleeding time. However, aspirin did not inhibit 
      thrombus formation at even the highest examined dose (200 mg/kg), while bleeding 
      time was prolonged at even the lowest dose (50 mg/kg). These results suggest that 
      a dosage of antithrombotic agent that does not increase bleeding tendency can be 
      easily established using ticlopidine, although it is relatively difficult using 
      aspirin.
FAU - Suehiro, A
AU  - Suehiro A
AD  - Second Department of Internal Medicine, Hyogo College of Medicine, Japan.
FAU - Oura, Y
AU  - Oura Y
FAU - Ueda, M
AU  - Ueda M
FAU - Kakishita, E
AU  - Kakishita E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - *Bleeding Time
MH  - Carotid Artery Thrombosis/*prevention & control
MH  - Disease Models, Animal
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Ticlopidine/*pharmacology/therapeutic use
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1994 Feb;83(2):157-63.

PMID- 12911657
OWN - NLM
STAT- MEDLINE
DCOM- 20040213
LR  - 20220321
IS  - 0815-9319 (Print)
IS  - 0815-9319 (Linking)
VI  - 18
IP  - 9
DP  - 2003 Sep
TI  - Effect of Helicobacter pylori infection and low-dose aspirin use on iron stores 
      in the elderly.
PG  - 1024-8
AB  - BACKGROUND AND AIMS: Helicobacter pylori infection has been associated with lower 
      ferritin levels in some adult populations, but subsets of potentially higher risk 
      subjects, such as the elderly have not been examined. The aim of the present 
      study was to determine the impact of H. pylori infection and low-dose aspirin use 
      on iron stores in a well elderly population. METHODS: Consecutive subjects aged 
      65 years or older attending day care facilities were studied. Each subject was 
      assisted in completing a medical questionnaire. Serum ferritin, hemoglobin, mean 
      corpuscular volumes (MCV) and IgG antibodies (ELISA) against H. pylori were 
      measured. RESULTS: In 220 subjects (age 75 +/- 8 years), 42% were H. pylori 
      seropositive (male 41%, female 44%). The median (IQR) ferritin level (ug/L) was 
      higher in men 149 (89-280) than women 94 (54-161), p < 0.002. The ferritin levels 
      were not different in H. pylori positive males 151 (105-283) compared with H. 
      pylori negative males 145 (72-249), or H. pylori positive females 93 (60-142) 
      compared with H. pylori negative females 97 (45-149). This relationship was not 
      altered when controlled for non-steroidal anti-inflammatory agents (NSAID) use 
      (9% of subjects), alcohol or dietary iron intake. Low-dose aspirin use was common 
      (28%), but did not have an independent impact on iron stores: male users 181 
      (95-248), non-users 145 (86-284); female users 92 (43-162), non-users 95 
      (62-163). However, in female aspirin users, H. pylori infection was associated 
      with significantly lower ferritin levels: 65 (43-112) compared with uninfected 
      subjects 103 (41-180), p < 0.04. CONCLUSIONS: In this well elderly population, 
      the combination of H. pylori infection and low-dose aspirin use was associated 
      with significantly lower serum ferritin concentrations in females. This 
      difference supports the observation that H. pylori, even in asymptomatic 
      subjects, may be a stressor of iron stores.
FAU - Kaffes, Arthur
AU  - Kaffes A
AD  - Gastroenterology Department, Concord Hospital, The University of Sydney, Sydney 
      2139, Australia.
FAU - Cullen, John
AU  - Cullen J
FAU - Mitchell, Hazel
AU  - Mitchell H
FAU - Katelaris, Peter H
AU  - Katelaris PH
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Fibrinolytic Agents)
RN  - E1UOL152H7 (Iron)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/pharmacology
MH  - *Helicobacter Infections/*metabolism
MH  - *Helicobacter pylori
MH  - Humans
MH  - Iron/*metabolism
MH  - Male
EDAT- 2003/08/13 05:00
MHDA- 2004/02/14 05:00
CRDT- 2003/08/13 05:00
PHST- 2003/08/13 05:00 [pubmed]
PHST- 2004/02/14 05:00 [medline]
PHST- 2003/08/13 05:00 [entrez]
AID - 3089 [pii]
AID - 10.1046/j.1440-1746.2003.03089.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2003 Sep;18(9):1024-8. doi: 
      10.1046/j.1440-1746.2003.03089.x.

PMID- 10445563
OWN - NLM
STAT- MEDLINE
DCOM- 19990823
LR  - 20220316
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 94
IP  - 8
DP  - 1999 Aug
TI  - Spontaneous intramural hematoma of the esophagus.
PG  - 2282-4
AB  - Spontaneous intramural hematoma of the esophagus (SIHE) is a rare condition, 
      usually presenting with severe acute chest pain. Vomiting, dysphagia, 
      odynophagia, and hematemesis may appear later. We herein report a case of this 
      disease in a patient treated with low doses of aspirin, and review the literature 
      for possible etiologies for this condition. In addition, we compare the utility 
      of the various diagnostic modalities in this uncommon condition.
FAU - Hiller, N
AU  - Hiller N
AD  - Department of Radiology, Shaare Zedek Medical Center, Jerusalem, Israel.
FAU - Zagal, I
AU  - Zagal I
FAU - Hadas-Halpern, I
AU  - Hadas-Halpern I
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects
MH  - *Diagnostic Imaging
MH  - Esophageal Diseases/*diagnosis/etiology
MH  - Female
MH  - Gastrointestinal Hemorrhage/*diagnosis/etiology
MH  - Hematoma/*diagnosis/etiology
MH  - Humans
MH  - Risk Factors
EDAT- 1999/08/13 00:00
MHDA- 1999/08/13 00:01
CRDT- 1999/08/13 00:00
PHST- 1999/08/13 00:00 [pubmed]
PHST- 1999/08/13 00:01 [medline]
PHST- 1999/08/13 00:00 [entrez]
AID - S0002927099003706 [pii]
AID - 10.1111/j.1572-0241.1999.01314.x [doi]
PST - ppublish
SO  - Am J Gastroenterol. 1999 Aug;94(8):2282-4. doi: 10.1111/j.1572-0241.1999.01314.x.

PMID- 6882881
OWN - NLM
STAT- MEDLINE
DCOM- 19831008
LR  - 20191023
IS  - 0142-2782 (Print)
IS  - 0142-2782 (Linking)
VI  - 4
IP  - 2
DP  - 1983 Apr-Jun
TI  - Urinary pH and plasma levels of salicylate after administration of different 
      buffered acetylsalicylic acid formulations.
PG  - 137-43
AB  - In a controlled cross-over study comprising eight healthy subjects of 
      effervescent acetylsalicylic acid (ASA) and an experimental ASA formulation were 
      compared with unbuffered ASA and placebo concerning effects on the urinary pH 
      within a dosage interval after 2 days' medication with 3 g ASA daily. The effects 
      on the urinary pH were related to the morning plasma salicylate concentrations 
      observed. Both the buffered formulations significantly increased the median pH of 
      the period studied compared to unbuffered ASA, the effervescent by 1.5 units and 
      the experimental by 0.6 units. Unbuffered ASA significantly decreased the median 
      pH compared to placebo. Those subjects with the most acidic urine during placebo 
      treatment showed the most pronounced pH elevations due to effervescent ASA. The 
      plasma salicylate concentration was significantly lower with the effervescent 
      formulation compared with unbuffered ASA, but there was no statistical difference 
      between the experimental tablet and unbuffered ASA. The variable effects on the 
      urinary pH and the plasma salicylate concentrations induced by the two buffered 
      preparations are explained by the different absorbabilities of the buffering 
      agents included. The results presented are consistent with recommendations not to 
      use bicarbonate-containing ASA formulations continuously when high plasma levels 
      are desirable.
FAU - Bogentoft, C
AU  - Bogentoft C
FAU - Dahl, G
AU  - Dahl G
FAU - Magnusson, A
AU  - Magnusson A
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Biopharm Drug Dispos
JT  - Biopharmaceutics & drug disposition
JID - 7911226
RN  - 0 (Buffers)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*metabolism
MH  - Buffers
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Middle Aged
MH  - Salicylates/*blood
MH  - Urine
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 10.1002/bdd.2510040205 [doi]
PST - ppublish
SO  - Biopharm Drug Dispos. 1983 Apr-Jun;4(2):137-43. doi: 10.1002/bdd.2510040205.

PMID- 8808776
OWN - NLM
STAT- MEDLINE
DCOM- 19970124
LR  - 20131121
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 13
IP  - 4
DP  - 1996 Jul-Aug
TI  - Combined dipyridamole and aspirin pellet formulation for improved oral drug 
      delivery. Part 1: Development pharmaceutics.
PG  - 385-94
AB  - The dissolution profile of various weight fractions of dipyridamole: 
      hydropropylmethylcellulose acetate succinate (HPMC-AS) and dipyridamole: 
      hydroxypropylmethylcellulose phthalate co-precipitates lead to the choice of 1:2 
      dipyridamole: HPMC-AS as the controlled-release component. It was deposited to 
      form two-third of the total dose as an inner layer on inert sucrose cores by air 
      suspension coating for release mainly in the small intestine. Further examination 
      of this material by IR spectroscopy, differential scanning calorimetry and X-ray 
      diffraction indicated some free drug, preferentially soluble under gastric pH 
      conditions. One-third of the total dose was applied by pan coating as an outer 
      layer of micronized dipyridamole around the inner enteric co-precipitate layer. 
      Aspirin-loaded cores were prepared also by pan coating for use in the final 
      product, which contained both anti-platelet drugs.
FAU - Deasy, P B
AU  - Deasy PB
AD  - Department of Pharmaceutics, Trinity College, University of Dublin, Ireland.
FAU - Murtagh, P W
AU  - Murtagh PW
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Suspensions)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/chemistry
MH  - Calorimetry, Differential Scanning
MH  - Dipyridamole/*administration & dosage/chemistry
MH  - Drug Combinations
MH  - Drug Compounding/methods
MH  - Hydrogen-Ion Concentration
MH  - Microscopy, Electron, Scanning
MH  - Platelet Aggregation Inhibitors/*administration & dosage/chemistry
MH  - Solubility
MH  - Spectrophotometry, Infrared
MH  - Suspensions
MH  - X-Ray Diffraction
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
AID - 10.3109/02652049609026025 [doi]
PST - ppublish
SO  - J Microencapsul. 1996 Jul-Aug;13(4):385-94. doi: 10.3109/02652049609026025.

PMID- 31706067
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20200505
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 184
DP  - 2019 Dec
TI  - Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the 
      vascular dose and dual pathway inhibition.
PG  - 44-49
LID - S0049-3848(19)30442-6 [pii]
LID - 10.1016/j.thromres.2019.09.033 [doi]
AB  - This review provides the rationale for dual pathway inhibition with the 
      combination of low-dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin 
      generation and aspirin (100 mg once daily) to reduce platelet activation. Such 
      therapy has been licensed for secondary prevention in patients with coronary or 
      peripheral artery disease.
CI  - Copyright © 2019 Elsevier Ltd. All rights reserved.
FAU - Ramacciotti, Eduardo
AU  - Ramacciotti E
AD  - Hospital e Maternidade Dr. Christovão da Gama, Grupo Leforte, Santo André, SP, 
      Brazil; Vascular Surgery, Santa Casa School of Medicine Hospital, SP, Brazil; 
      Hemostasis & Thrombosis Research Laboratories, Loyola University Medical Center, 
      Maywood, IL, USA. Electronic address: eduardoramacciotti@gmail.com.
FAU - Weitz, Jeffrey I
AU  - Weitz JI
AD  - Thrombosis and Atherosclerosis Research Institute and McMaster University, 
      Hamilton, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Review
DEP - 20191023
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Factor Xa Inhibitors/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Activation
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Prospective Studies
MH  - Rivaroxaban/pharmacology/*therapeutic use
EDAT- 2019/11/11 06:00
MHDA- 2020/05/06 06:00
CRDT- 2019/11/10 06:00
PHST- 2019/03/26 00:00 [received]
PHST- 2019/08/24 00:00 [revised]
PHST- 2019/09/24 00:00 [accepted]
PHST- 2019/11/11 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
PHST- 2019/11/10 06:00 [entrez]
AID - S0049-3848(19)30442-6 [pii]
AID - 10.1016/j.thromres.2019.09.033 [doi]
PST - ppublish
SO  - Thromb Res. 2019 Dec;184:44-49. doi: 10.1016/j.thromres.2019.09.033. Epub 2019 
      Oct 23.

PMID- 408631
OWN - NLM
STAT- MEDLINE
DCOM- 19771028
LR  - 20131121
IS  - 0341-3098 (Print)
IS  - 0341-3098 (Linking)
VI  - 119
IP  - 28
DP  - 1977 Jul 15
TI  - [The effect of Aspisol on platelet function after vascular surgery (author's 
      transl)].
PG  - 961-4
AB  - We found increased aggregation of thrombocytes in more than two thirds of the 
      patients with vascular processes referred to us for vascular reconstruction. But 
      even in patients with normal preoperative thrombocyte aggregation (control 
      group), the aggregaiton is increased in three quarters of the cases 
      portoperatively. Therefore in all vascular operations we have changed over to a 
      therapy for the inhibition of thrombocyte aggregation according to the following 
      scheme: intravenous injection of 2 ampoules Aspisol on the evening before the 
      operation, 2 ampoules Aspisol in the morning and evening of the day of the 
      operation and 1 ampoule Aspisol in the morning and evening on the 1st, 2nd and 
      3rd day after the operation, overlapping with 1 Colfarit tablet given orally 3 
      times a day from the 2nd day after the operation.
FAU - Schricker, K T
AU  - Schricker KT
FAU - Raithel, D
AU  - Raithel D
FAU - Juchelka, L
AU  - Juchelka L
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Einfluss von Aspisol auf die Plättchenfunktion bei gefsschirurgischen Eingriffen.
PL  - Germany
TA  - MMW Munch Med Wochenschr
JT  - MMW, Munchener medizinische Wochenschrift
JID - 7801805
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Coagulation Disorders/blood/drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Postoperative Complications/prevention & control
MH  - Thromboembolism/prevention & control
MH  - Vascular Diseases/blood
MH  - *Vascular Surgical Procedures
EDAT- 1977/07/15 00:00
MHDA- 1977/07/15 00:01
CRDT- 1977/07/15 00:00
PHST- 1977/07/15 00:00 [pubmed]
PHST- 1977/07/15 00:01 [medline]
PHST- 1977/07/15 00:00 [entrez]
PST - ppublish
SO  - MMW Munch Med Wochenschr. 1977 Jul 15;119(28):961-4.

PMID- 7674387
OWN - NLM
STAT- MEDLINE
DCOM- 19951019
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 39
IP  - 2
DP  - 1995 Aug
TI  - Diaspirin cross-linked hemoglobin resuscitation of hemorrhage: comparison of a 
      blood substitute with hypertonic saline and isotonic saline.
PG  - 210-6; discussion 216-7
AB  - Resuscitation with tiny volumes of hypertonic solutions rapidly restores tissue 
      perfusion while minimizing edema after hemorrhage and tissue trauma. METHODS: We 
      compared an O2-carrying fluid, Diaspirin Cross-Linked Hemoglobin (DCLHb), to 7.5% 
      NS/Dextran-70 (HTS) or 0.9% saline (NS) in a trauma (celiotomy) hemorrhage model. 
      Anesthetized rats (n = 10/group) underwent a tracheotomy, placement of jugular 
      vein and carotid artery catheters, and placement of an abdominal aortic flow 
      probe. Rats were hemorrhaged (20 mL/kg) from t = 0-15 minutes, and were given NS 
      (group I), 60 mL/kg, HTS (group II), 4 mL/kg, or DCLHb (group III), 4 mL/kg, from 
      t = 15-30 minutes. Sampling mandated removal of an additional 10 mL/kg of blood 
      during the 2-hour experiment. RESULTS: Mean arterial pressure was restored after 
      hemorrhage in all groups. Oxygen delivery, which diminished dramatically after 
      hemorrhage, was less than baseline in all groups after resuscitation. Oxygen 
      consumption was restored in all groups after a sharp decrease during hemorrhage. 
      Base deficit increased in the all groups but was greatest after normal saline or 
      hypertonic saline resuscitation (t = 120 minutes; I = 12 +/- 0.4*, II = 13 +/- 
      0.5* c, III = 10 +/- 0.1*; * = p < 0.05 versus baseline value within group for 
      groups I, II, and III; c = p < 0.05 group versus DCLHb (group II), by ANOVA). 
      CONCLUSION: DCLHb restored mean arterial pressure and ameliorated the development 
      of flow-dependent oxygen consumption. Base deficit, a reflection of systemic 
      oxygen debt, was minimized with this blood substitute. DCLHb may represent a 
      superior small volume resuscitative fluid after trauma and hemorrhage.
FAU - Cohn, S M
AU  - Cohn SM
AD  - Section of Trauma and Surgical Critical Care, Yale School of Medicine, New Haven, 
      Connecticut.
FAU - Farrell, T J
AU  - Farrell TJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Hemoglobins)
RN  - 0 (Isotonic Solutions)
RN  - 0 (Saline Solution, Hypertonic)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Hemodynamics
MH  - Hemoglobins/*therapeutic use
MH  - Hemorrhage/*therapy
MH  - Isotonic Solutions
MH  - Male
MH  - Oxygen Consumption/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Resuscitation/*methods
MH  - Saline Solution, Hypertonic/*therapeutic use
MH  - Sodium Chloride/*therapeutic use
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
AID - 10.1097/00005373-199508000-00005 [doi]
PST - ppublish
SO  - J Trauma. 1995 Aug;39(2):210-6; discussion 216-7. doi: 
      10.1097/00005373-199508000-00005.

PMID- 2797631
OWN - NLM
STAT- MEDLINE
DCOM- 19891031
LR  - 20220408
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 74
IP  - 4
DP  - 1989 Oct
TI  - Low-dose aspirin in pregnancy.
PG  - 551-7
AB  - In a prospective study, we evaluated the effects of low-dose aspirin on maternal 
      and neonatal plasma 6-keto-prostaglandin (PG) F1 alpha concentration, platelet 
      aggregation, platelet thromboxane production, and neonatal transitional 
      circulation. Forty women, at a mean (+/- SD) of 37 +/- 2 weeks' gestation, were 
      randomized to receive (N = 10 each) placebo or 20, 60, or 80 mg of aspirin per 
      day until delivery. Maternal serum 6-keto-PGF1 alpha levels were not affected by 
      these doses of aspirin, whereas thromboxane B2 generated during clotting of 
      maternal blood was decreased significantly by 60 and 80 mg of aspirin by 1 week 
      of therapy. Maternal platelet thromboxane B2 production in response to adenosine 
      diphosphate or collagen was reduced 98% by the 80-mg dose after 1 week of aspirin 
      therapy. The 60-mg dose reduced maternal platelet thromboxane B2 production in 
      response to adenosine diphosphate (50% decrease) or collagen (60% decrease) after 
      1 week of treatment, a nonsignificant difference. After 2 weeks of treatment with 
      60 mg of aspirin, platelet thromboxane B2 production induced by both collagen and 
      adenosine diphosphate was inhibited significantly (P less than .01). Neonatal 
      serum levels of 6-keto-PGF1 alpha and thromboxane B2 were not affected by any 
      doses of aspirin. Further, neonatal platelet aggregation in response to platelet 
      stimulation by collagen and adenosine diphosphate was not inhibited. All neonates 
      had echocardiographic evidence of a patent ductus arteriosus, and noninvasive 
      estimates of pulmonary arterial pressure were similar among the groups of 
      infants.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Sibai, B M
AU  - Sibai BM
AD  - Department of Obstetrics and Gynecology, University of Tennessee, Memphis.
FAU - Mirro, R
AU  - Mirro R
FAU - Chesney, C M
AU  - Chesney CM
FAU - Leffler, C
AU  - Leffler C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 54397-85-2 (Thromboxane B2)
RN  - F5TD010360 (Alprostadil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alprostadil/metabolism
MH  - Apgar Score
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Blood Platelets/drug effects/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Ductus Arteriosus, Patent/drug therapy
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Maternal-Fetal Exchange
MH  - Platelet Aggregation/drug effects
MH  - Pregnancy/*blood
MH  - Pregnancy Trimester, Third
MH  - Prospective Studies
MH  - Thromboxane B2/*biosynthesis
EDAT- 1989/10/01 00:00
MHDA- 1989/10/01 00:01
CRDT- 1989/10/01 00:00
PHST- 1989/10/01 00:00 [pubmed]
PHST- 1989/10/01 00:01 [medline]
PHST- 1989/10/01 00:00 [entrez]
AID - 0029-7844(89)90090-2 [pii]
PST - ppublish
SO  - Obstet Gynecol. 1989 Oct;74(4):551-7.

PMID- 3826813
OWN - NLM
STAT- MEDLINE
DCOM- 19870417
LR  - 20190717
IS  - 0196-0644 (Print)
IS  - 0196-0644 (Linking)
VI  - 16
IP  - 4
DP  - 1987 Apr
TI  - Delayed absorption following enteric-coated aspirin overdose.
PG  - 434-6
AB  - We present the case of a patient with an enteric-coated salicylate overdose, in 
      which absorption was delayed significantly despite active treatment. The 
      patient's serum salicylate level one hour and three hours after ingestion, as 
      well as the initial gastric lavage, was 0. The serum salicylate level reached a 
      peak of 35.8 mg% 24 hours after ingestion. The Done nomogram is of no benefit in 
      the initial assessment of sustained release salicylate overdoses.
FAU - Wortzman, D J
AU  - Wortzman DJ
FAU - Grunfeld, A
AU  - Grunfeld A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*poisoning
MH  - Emergencies
MH  - Humans
MH  - Intestinal Absorption/*drug effects
MH  - Male
MH  - Tablets, Enteric-Coated/*adverse effects
MH  - Time Factors
EDAT- 1987/04/01 00:00
MHDA- 1987/04/01 00:01
CRDT- 1987/04/01 00:00
PHST- 1987/04/01 00:00 [pubmed]
PHST- 1987/04/01 00:01 [medline]
PHST- 1987/04/01 00:00 [entrez]
AID - S0196-0644(87)80366-9 [pii]
AID - 10.1016/s0196-0644(87)80366-9 [doi]
PST - ppublish
SO  - Ann Emerg Med. 1987 Apr;16(4):434-6. doi: 10.1016/s0196-0644(87)80366-9.

PMID- 12184966
OWN - NLM
STAT- MEDLINE
DCOM- 20020906
LR  - 20181130
IS  - 0094-3509 (Print)
IS  - 0094-3509 (Linking)
VI  - 51
IP  - 8
DP  - 2002 Aug
TI  - Aspirin prophylaxis in patients at low risk for cardiovascular disease: a 
      systematic review of all-cause mortality.
PG  - 700-4
AB  - OBJECTIVE: We investigated whether aspirin reduces all-cause mortality in 
      low-risk patients. STUDY DESIGN: We systematically reviewed studies of aspirin 
      for primary prevention to measure total mortality. We included all clinical 
      trials, cohort studies, and case control studies that assessed primary 
      prevention, included low-risk subjects, and measured total mortality. The quality 
      of studies was evaluated with a standard scale. DATA SOURCES: MEDLINE, the 
      Cochrane Library, and the Internet were systematically searched for studies with 
      the key terms primary, prevention, aspirin, myocardial infarction, stroke, and 
      mortality. Reference lists of identified trials and reviews also were examined. 
      POPULATION: Active members in the Indiana Academy of Family Physicians 2000-2001 
      membership database (N = 1328). OUTCOMES MEASURED: Primary outcomes were 
      myocardial infarction, stroke, and mortality. RESULTS: Three primary prevention 
      studies met our criteria. Two clinical trials, the United States Physicians 
      Health Study and British Doctors Study, demonstrated no significant decrease in 
      mortality in the aspirin group alone or when results from the 2 studies were 
      combined. The United States Physicians Health Study showed a lower rate of 
      myocardial infarction (odds ratio [OR], 0.58; 95% confidence interval [CI], 
      0.47-0.71). In the Nurses Health Study, a cohort study, taking aspirin at any 
      dose was associated with higher rates of myocardial infarction (OR, 2.34; CI, 
      1.92-2.86), stroke (OR, 1.84; CI, 1.39-2.44), and all-cause mortality (OR, 1.83; 
      CI, 1.57-2.14). CONCLUSIONS: There is currently no evidence to recommend for or 
      against the use of aspirin to decrease mortality in low-risk individuals.
FAU - Boltri, John M
AU  - Boltri JM
AD  - Dept of Family Medicine, Mercer University School of Medicine, 3780 Eisenhower 
      Parkway, Macon, GA 31206, USA. boltri.john@mccg.org
FAU - Akerson, Mark R
AU  - Akerson MR
FAU - Vogel, Robert L
AU  - Vogel RL
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/*mortality
MH  - Humans
MH  - Risk Assessment
RF  - 32
EDAT- 2002/08/20 10:00
MHDA- 2002/09/07 10:01
CRDT- 2002/08/20 10:00
PHST- 2002/08/20 10:00 [pubmed]
PHST- 2002/09/07 10:01 [medline]
PHST- 2002/08/20 10:00 [entrez]
AID - jfp_0802_00700 [pii]
PST - ppublish
SO  - J Fam Pract. 2002 Aug;51(8):700-4.

PMID- 9092411
OWN - NLM
STAT- MEDLINE
DCOM- 19970410
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 89
IP  - 11 Suppl
DP  - 1996 Nov
TI  - [Antiplatelet agents (inhibitors of platelet function) orally administered. Bases 
      for their practical use in coronary artery disease].
PG  - 1507-13
AB  - Long-term antithrombotic therapy, administered orally, is necessary in all 
      patients with symptomatic coronary artery disease; the most commonly used drugs 
      are those which inhibit platelet aggregation. Aspirin and ticlopidine do not act 
      on the same point of platelet function. They have the common property of 
      inhibiting platelet function irreversibly and of partially inhibiting platelet 
      aggregation. Flurbiprofenee acts like aspirin on thromboxane synthesis but the 
      effect is reversible in 24 hours. The full effect of ticlopidine is only observed 
      after several days' administration. The association of aspirin and ticlopidine is 
      used over short periods after implantation of a stent. The dosage of ticlopidine 
      is 2 tablets per day; that of aspirin is not well established (100 to 330 mg per 
      day in a single dose). Special galenic forms are marketed for this indication in 
      France. Biological monitoring (white cell count) is required with ticlopidine. It 
      has not been shown to be of value to investigate the parameters of primary 
      haemostasis (bleeding time, platelet function--tests of platelet aggregation). 
      However, under certain circumstances, the advice of a haematologist may be 
      useful, especially before an invasive procedure.
FAU - Lecompte, T
AU  - Lecompte T
AD  - Unité d'hémostase, hématologie biologique, CHU de Nancy, hôpitaux de Brabois, 
      Vandoeuvre.
FAU - de Maistre, E
AU  - de Maistre E
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Médicaments antiplaquettaires (inhibiteurs) administrés per os. Bases pour 
      l'utilisation pratique en pathologie coronaire.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/pharmacology/therapeutic use
MH  - Coronary Disease/*drug therapy/mortality/surgery
MH  - Dipyridamole/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Monitoring
MH  - Drug Therapy, Combination
MH  - Drug Tolerance
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
RF  - 26
EDAT- 1996/11/01 00:00
MHDA- 1996/11/01 00:01
CRDT- 1996/11/01 00:00
PHST- 1996/11/01 00:00 [pubmed]
PHST- 1996/11/01 00:01 [medline]
PHST- 1996/11/01 00:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 1996 Nov;89(11 Suppl):1507-13.

PMID- 15171956
OWN - NLM
STAT- MEDLINE
DCOM- 20050202
LR  - 20131121
IS  - 1521-6926 (Print)
IS  - 1521-6926 (Linking)
VI  - 17
IP  - 1
DP  - 2004 Mar
TI  - First-generation agents: aspirin, heparin and coumarins.
PG  - 23-53
AB  - Aspirin, heparin and the coumarins are the classical anti-thrombotic agents. They 
      represent the platform upon which newer drugs holding the promise of greater 
      efficacy and less toxicity are being developed. Even as such newer drugs arrive 
      into clinical practice, the older agents remain remarkable for their decades-long 
      pre-eminence. All derive from natural sources, and none from a search for 
      therapeutic anti-thrombotic agents; they have saved countless lives but also 
      served as essential probes into basic mechanisms of thrombosis. Testament to 
      their clinical importance is that these agents are the only drugs profiled on a 
      regular basis in special scientific statements by the American Heart 
      Association/American College of Cardiology and by the American College of Chest 
      Physicians. This chapter reviews their biology, uses and limitations.
FAU - Mueller, Richard L
AU  - Mueller RL
AD  - nycitydoc@aol.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Haematol
JT  - Best practice & research. Clinical haematology
JID - 101120659
RN  - 0 (Coumarins)
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/complications/drug therapy/prevention & control
MH  - Coumarins/adverse effects/pharmacology/therapeutic use
MH  - Fibrinolytic Agents/adverse effects/*pharmacology/therapeutic use
MH  - Heparin/adverse effects/pharmacology/therapeutic use
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Treatment Outcome
RF  - 141
EDAT- 2004/06/03 05:00
MHDA- 2005/02/03 09:00
CRDT- 2004/06/03 05:00
PHST- 2004/06/03 05:00 [pubmed]
PHST- 2005/02/03 09:00 [medline]
PHST- 2004/06/03 05:00 [entrez]
AID - S1521692604000064 [pii]
AID - 10.1016/j.beha.2004.03.003 [doi]
PST - ppublish
SO  - Best Pract Res Clin Haematol. 2004 Mar;17(1):23-53. doi: 
      10.1016/j.beha.2004.03.003.

PMID- 34242462
OWN - NLM
STAT- MEDLINE
DCOM- 20211103
LR  - 20220902
IS  - 1521-3773 (Electronic)
IS  - 1433-7851 (Print)
IS  - 1433-7851 (Linking)
VI  - 60
IP  - 36
DP  - 2021 Sep 1
TI  - Mechanically Triggered Hybridization Chain Reaction.
PG  - 19974-19981
LID - 10.1002/anie.202107660 [doi]
AB  - Cells transmit piconewton forces to receptors to mediate processes such as 
      migration and immune recognition. A major challenge in quantifying such forces is 
      the sparsity of cell mechanical events. Accordingly, molecular tension is 
      typically quantified with high resolution fluorescence microscopy, which hinders 
      widespread adoption and application. Here, we report a mechanically triggered 
      hybridization chain reaction (mechano-HCR) that allows chemical amplification of 
      mechanical events. The amplification is triggered when a cell receptor 
      mechanically denatures a duplex revealing a cryptic initiator to activate the HCR 
      reaction in situ. Importantly, mechano-HCR enables direct readout of pN forces 
      using a plate reader. We leverage this capability and measured mechano-IC(50) for 
      aspirin, Y-27632, and eptifibatide. Given that cell mechanical phenotypes are of 
      clinical importance, mechano-HCR may offer a convenient route for drug discovery, 
      personalized medicine, and disease diagnosis.
CI  - © 2021 Wiley-VCH GmbH.
FAU - Duan, Yuxin
AU  - Duan Y
AD  - Department of Chemistry, Emory University, Atlanta, GA, 30322, USA.
FAU - Glazier, Roxanne
AU  - Glazier R
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology and Emory University, Atlanta, GA, 30322, USA.
FAU - Bazrafshan, Alisina
AU  - Bazrafshan A
AD  - Department of Chemistry, Emory University, Atlanta, GA, 30322, USA.
FAU - Hu, Yuesong
AU  - Hu Y
AD  - Department of Chemistry, Emory University, Atlanta, GA, 30322, USA.
FAU - Rashid, Sk Aysha
AU  - Rashid SA
AD  - Department of Chemistry, Emory University, Atlanta, GA, 30322, USA.
FAU - Petrich, Brian G
AU  - Petrich BG
AD  - Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA.
FAU - Ke, Yonggang
AU  - Ke Y
AUID- ORCID: 0000-0003-1673-2153
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology and Emory University, Atlanta, GA, 30322, USA.
FAU - Salaita, Khalid
AU  - Salaita K
AUID- ORCID: 0000-0003-4138-3477
AD  - Department of Chemistry, Emory University, Atlanta, GA, 30322, USA.
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology and Emory University, Atlanta, GA, 30322, USA.
LA  - eng
GR  - DMR-1905947/National Science Foundation/
GR  - R01 HL142866/HL/NHLBI NIH HHS/United States
GR  - U01 AA029345/AA/NIAAA NIH HHS/United States
GR  - DMR-1654485/National Science Foundation/
GR  - R01 GM124472/GM/NIGMS NIH HHS/United States
GR  - R01 GM131099/GM/NIGMS NIH HHS/United States
GR  - DMR 1905947/National Science Foundation/
GR  - R01 GM097399/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20210729
PL  - Germany
TA  - Angew Chem Int Ed Engl
JT  - Angewandte Chemie (International ed. in English)
JID - 0370543
RN  - NA8320J834 (Eptifibatide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Eptifibatide/*chemistry
MH  - Humans
MH  - Nucleic Acid Hybridization
PMC - PMC8390435
MID - NIHMS1723596
OTO - NOTNLM
OT  - biosensors
OT  - cellular receptor tension
OT  - drug screening
OT  - hybridization chain reaction
OT  - nanotechnology
EDAT- 2021/07/10 06:00
MHDA- 2021/11/04 06:00
CRDT- 2021/07/09 17:32
PHST- 2021/06/08 00:00 [received]
PHST- 2021/07/10 06:00 [pubmed]
PHST- 2021/11/04 06:00 [medline]
PHST- 2021/07/09 17:32 [entrez]
AID - 10.1002/anie.202107660 [doi]
PST - ppublish
SO  - Angew Chem Int Ed Engl. 2021 Sep 1;60(36):19974-19981. doi: 
      10.1002/anie.202107660. Epub 2021 Jul 29.

PMID- 2618718
OWN - NLM
STAT- MEDLINE
DCOM- 19900301
LR  - 20131121
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 24
IP  - 9
DP  - 1989
TI  - [Determination of three components in aspirin compound tablets by use of UV-PLS 
      method].
PG  - 684-9
AB  - The optimum experimental condition for simultaneous UV-spectrophotometric 
      determination of the contents of aspirin, phenacetin and caffeine in aspirin 
      compound tablets (APC) and the basic principle and application of partial least 
      squares method(PLS) in simultaneous multicomponent determination have been 
      studied. Confidence intervals of the three components are 100.1 +/- 0.23% 
      (aspirin), 100.0 +/- 0.25% (phenacetin) and 100.1 +/- 0.33% (caffeine) 
      (confidence 95%). No information has ever been available in the literature for 
      the application of PLS in pharmaceutical analysis. Compared with other 
      traditional computing methods, PLS is a more perfect multicomponent determination 
      method. It is especially applicable to analyzing samples in batches. It is faster 
      and produces more accurate and reliable results. PLS provides a new method for 
      in-line UV-visible spectrophotometric automation.
FAU - Luo, G A
AU  - Luo GA
FAU - Lan, Q T
AU  - Lan QT
FAU - Wang, Z P
AU  - Wang ZP
FAU - Zhou, G H
AU  - Zhou GH
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Drug Combinations
MH  - Phenacetin/*analysis
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Yao Xue Xue Bao. 1989;24(9):684-9.

PMID- 1095794
OWN - NLM
STAT- MEDLINE
DCOM- 19751003
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 233
IP  - 4
DP  - 1975 Jul 28
TI  - Ibuprofen or aspirin in rheumatoid arthritis therapy.
PG  - 336-40
AB  - Ibuprofen is a nonsteroidal drug with analgesic, antipyretic, and 
      anti-inflammatory properties that was recently introduced for use in 
      antiarthritis therapy in the United States. In a year-long double-blind 
      multiclinic trial in 885 patients with rheumatoid arthritis, ibuprofen was at 
      least as satisfactory as aspirin, considering both efficacy and tolerance. In the 
      majority of patients, daily doses ranged from 800 to 1,600 mg of ibuprofen and 3 
      to 6 gm of aspirin. The drugs did not differ greatly in providing relief from 
      arthritis symptoms, but ibuprofen was definitely better tolerated, especially in 
      regard to gastrointestinal complaints. Seven percent of the ibuprofen group 
      dropped out of the study because of adverse reactions, as compared with 16% of 
      the aspirin group; 17% of the ibuprofen group and 31% of the aspirin group had 
      gastrointestinal symptoms.
FAU - Blechman, W J
AU  - Blechman WJ
FAU - Schmid, F R
AU  - Schmid FR
FAU - April, P A
AU  - April PA
FAU - Wilson, C H Jr
AU  - Wilson CH Jr
FAU - Brooks, C D
AU  - Brooks CD
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Propionates)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aged
MH  - Alkaline Phosphatase/blood
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Central Nervous System/drug effects
MH  - Clinical Trials as Topic
MH  - Digestive System/drug effects
MH  - Ear/drug effects
MH  - Female
MH  - Humans
MH  - Ibuprofen/administration & dosage/adverse effects/*therapeutic use
MH  - Informed Consent
MH  - Male
MH  - Middle Aged
MH  - Propionates/*therapeutic use
MH  - Skin/drug effects
EDAT- 1975/08/07 19:15
MHDA- 2001/03/28 10:01
CRDT- 1975/08/07 19:15
PHST- 1975/08/07 19:15 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1975/08/07 19:15 [entrez]
PST - ppublish
SO  - JAMA. 1975 Jul 28;233(4):336-40.

PMID- 1482811
OWN - NLM
STAT- MEDLINE
DCOM- 19930212
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 26
IP  - 12
DP  - 1992 Dec
TI  - Aspirin for the prevention of vascular death in women.
PG  - 1530-4
AB  - OBJECTIVE: To review current information relevant to the use of aspirin for 
      preventing vascular death in women, and to provide recommendations based on this 
      information. DATA SOURCES: References from pertinent articles are identified 
      throughout the text. DATA SYNTHESIS: Based on current information, low-dose 
      aspirin is not recommended as primary prevention for cardiovascular death in 
      women; efforts are better focused at promoting risk-factor reduction. Low-dose 
      aspirin is recommended for reducing further cardiovascular morbidity and 
      mortality in women with known cardiovascular disease. Women presenting with 
      unstable angina or myocardial infarction should receive aspirin 325 mg as soon as 
      the diagnosis is confirmed, and this dosage should be continued on a chronic 
      basis. Women who have experienced transient ischemic attacks or ischemic stroke 
      should receive aspirin 1000 mg/d, with a subsequent dosage reduction to 325 mg/d 
      in patients who do not tolerate the higher dose. CONCLUSIONS: Current 
      recommendations are based on the results of studies that involved few women. 
      Further investigation of antiplatelet agents for primary and secondary prevention 
      of vascular death in women is needed.
FAU - McAnally, L E
AU  - McAnally LE
AD  - College of Pharmacy, Department of Pharmacy Practice, University of Oklahoma, 
      Health Sciences Center, Oklahoma City 73190.
FAU - Corn, C R
AU  - Corn CR
FAU - Hamilton, S F
AU  - Hamilton SF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/drug therapy/mortality
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/drug therapy/mortality/*prevention & control
MH  - Cerebrovascular Disorders/drug therapy/mortality/*prevention & control
MH  - Female
MH  - Humans
MH  - Risk Factors
RF  - 26
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
AID - 10.1177/106002809202601210 [doi]
PST - ppublish
SO  - Ann Pharmacother. 1992 Dec;26(12):1530-4. doi: 10.1177/106002809202601210.

PMID- 31006118
OWN - NLM
STAT- MEDLINE
DCOM- 20200528
LR  - 20200528
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 36
IP  - 9
DP  - 2019 Sep
TI  - Differential vascular effects of aspirin in people with Type 2 diabetes without 
      cardiovascular disease and matched controls without diabetes.
PG  - 1141-1148
LID - 10.1111/dme.13978 [doi]
AB  - AIM: We investigated whether the effect of low-dose aspirin on 
      endothelium-dependent vasodilation and arterial stiffness in people with Type 2 
      diabetes is different from a matched control group. We examined acute and chronic 
      effects, and effects over the 24h dosing interval. METHODS: In an open-label 
      parallel group intervention study, we included 21 participants with Type 2 
      diabetes and 21 age- and sex-matched controls. Endothelium-dependent vasodilation 
      was assessed as the reactive hyperaemia index (lnRHI) measured by peripheral 
      arterial tonometry (EndoPAT(®) ). Arterial stiffness was assessed as pulse wave 
      velocity (PWV) measured by applanation tonometry (SphygmoCor(®) ). Measurements 
      were performed prior to aspirin intake and 1h after aspirin administration (75 
      mg). Participants were then treated for 6 days, and measurements were repeated at 
      24 h and 1 h after aspirin intake. RESULTS: Baseline lnRHI did not differ between 
      groups. The controls had an immediate increase in lnRHI after the first aspirin 
      tablet. This was not observed in participants with diabetes (difference between 
      groups; P < 0.05). After 1 week, both groups demonstrated increased lnRHI 
      compared with baseline (P < 0.01). In participants with diabetes, lnRHI was 
      significantly lower 24 h after aspirin administration compared with 1 h after 
      administration (P < 0.05). This difference was not observed in controls 
      (P = 0.84, difference between groups; P = 0.12). The effect on PWV did not differ 
      between groups. CONCLUSION: Aspirin had a reduced immediate effect on 
      endothelium-dependent vasodilation in participants with diabetes. Both groups had 
      improved endothelial function after 1 week of treatment. Further, the effect of 
      aspirin on endothelial function may be declining during a 24 h dosing interval in 
      people with Type 2 diabetes. (Clinical Trial Registry No: 2016-000515-32).
CI  - © 2019 Diabetes UK.
FAU - Vernstrøm, L
AU  - Vernstrøm L
AUID- ORCID: 0000-0003-2875-435X
AD  - Department of Endocrinology and Internal Medicine, Aarhus, Denmark.
FAU - Laugesen, E
AU  - Laugesen E
AD  - Department of Endocrinology and Internal Medicine, Aarhus, Denmark.
FAU - Grove, E L
AU  - Grove EL
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
AD  - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
FAU - Baier, J M
AU  - Baier JM
AD  - Department of Endocrinology and Internal Medicine, Aarhus, Denmark.
FAU - Gullaksen, S
AU  - Gullaksen S
AD  - Department of Endocrinology and Internal Medicine, Aarhus, Denmark.
FAU - Hvas, A-M
AU  - Hvas AM
AD  - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
AD  - Department of Clinical Biochemistry, Thrombosis & Haemostasis Research Unit, 
      Aarhus University Hospital, Aarhus, Denmark.
FAU - Poulsen, P L
AU  - Poulsen PL
AD  - Department of Endocrinology and Internal Medicine, Aarhus, Denmark.
FAU - Funck, K L
AU  - Funck KL
AUID- ORCID: 0000-0003-0213-5550
AD  - Department of Endocrinology and Internal Medicine, Aarhus, Denmark.
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190511
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cardiovascular System/*drug effects/physiopathology
MH  - Diabetes Mellitus, Type 2/drug therapy/*physiopathology
MH  - Endothelium, Vascular/*drug effects/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Matched-Pair Analysis
MH  - Middle Aged
MH  - Pulse Wave Analysis
MH  - Vascular Stiffness/drug effects
MH  - Vasodilation/drug effects
EDAT- 2019/04/22 06:00
MHDA- 2020/05/29 06:00
CRDT- 2019/04/22 06:00
PHST- 2019/04/18 00:00 [accepted]
PHST- 2019/04/22 06:00 [pubmed]
PHST- 2020/05/29 06:00 [medline]
PHST- 2019/04/22 06:00 [entrez]
AID - 10.1111/dme.13978 [doi]
PST - ppublish
SO  - Diabet Med. 2019 Sep;36(9):1141-1148. doi: 10.1111/dme.13978. Epub 2019 May 11.

PMID- 7149171
OWN - NLM
STAT- MEDLINE
DCOM- 19830119
LR  - 20151119
IS  - 0192-8562 (Print)
IS  - 0192-8562 (Linking)
VI  - 4
IP  - 3
DP  - 1982 Fall
TI  - Inhibitors of sickling.
PG  - 320-7
AB  - A number of agents that prevent sickling in vitro have been discovered during the 
      past decade. In general, such agents act directly on the hemoglobin S tetramer to 
      inhibit gelation or alter oxygen affinity. Most currently recognized agents lack 
      specificity for hemoglobin and modify other cellular constituents. Synthesis of 
      reagents such as the bifunctional aspirin derivative, bis (3,5-dibromosalicyl) 
      fumarate, with increased specificity for hemoglobin, represents a rational 
      approach to the design of new therapeutic agents for sickle cell anemia. Membrane 
      active agents such as cetiedil inhibit sickling in vitro but have not yet been 
      shown to be effective in vivo. Reduction in the intracellular concentration of 
      hemoglobin S apparently may reduce the frequency of painful crises but is 
      difficult to achieve with current techniques. Although no antisickling therapy 
      can yet be described as both safe and effective, the outlook for the future seems 
      promising because of the large number of agents under active investigation.
FAU - Mentzer, W C Jr
AU  - Mentzer WC Jr
LA  - eng
GR  - HL 20985/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Pediatr Hematol Oncol
JT  - The American journal of pediatric hematology/oncology
JID - 7908071
RN  - 0 (Antisickling Agents)
RN  - 0 (Azepines)
RN  - 0 (Benzopyrans)
RN  - 0 (Cyanates)
RN  - 0 (Hemoglobin, Sickle)
RN  - 0 (Hormones)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 58821-97-9 (3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-6-butyric acid)
RN  - 621RT200TO (cetiedil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antisickling Agents/*pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Azepines/pharmacology
MH  - Benzopyrans/pharmacology
MH  - Cyanates/pharmacology
MH  - Erythrocyte Aging/drug effects
MH  - Erythrocytes, Abnormal/drug effects
MH  - Hemoglobin, Sickle
MH  - Hormones/pharmacology
MH  - Humans
MH  - In Vitro Techniques
EDAT- 1982/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - Am J Pediatr Hematol Oncol. 1982 Fall;4(3):320-7.

PMID- 27343573
OWN - NLM
STAT- MEDLINE
DCOM- 20180126
LR  - 20181211
IS  - 1873-3573 (Electronic)
IS  - 0039-9140 (Linking)
VI  - 158
DP  - 2016 Sep 1
TI  - Graphene/Nafion composite film modified glassy carbon electrode for simultaneous 
      determination of paracetamol, aspirin and caffeine in pharmaceutical 
      formulations.
PG  - 21-29
LID - S0039-9140(16)30372-1 [pii]
LID - 10.1016/j.talanta.2016.05.046 [doi]
AB  - A graphene-Nafion composite film was fabricated on the glassy carbon electrode 
      (GR-NF/GCE), and used for simultaneous determination of paracetamol (PAR), 
      aspirin (ASA) and caffeine (CAF). The electrochemical behaviors of PAR, ASA and 
      CAF were investigated by cyclic voltammetry and square-wave adsorptive anodic 
      stripping voltammetry. By using stripping one for simultaneous determination of 
      PAR, ASA and CAF, their electrochemical oxidation peaks appeared at +0.64, 1.04 
      and 1.44V, and good linear current responses were obtained with the detection 
      limits of 18ngmL(-1) (1.2×10(-9)M), 11.7ngmL(-1) (6.5×10(-8)M) and 7.3ngmL(-1) 
      (3.8×10(-8)M), respectively. Finally, the proposed electrochemical sensor was 
      successfully applied for quantifying PAR, ASA and CAF in commercial tablet 
      formulations.
CI  - Copyright © 2016 Elsevier B.V. All rights reserved.
FAU - Yiğit, Aydın
AU  - Yiğit A
AD  - Yüzüncü Yıl University, Faculty of Pharmacy, Department of Analytical Chemistry, 
      65080 Van, Turkey.
FAU - Yardım, Yavuz
AU  - Yardım Y
AD  - Yüzüncü Yıl University, Faculty of Pharmacy, Department of Analytical Chemistry, 
      65080 Van, Turkey. Electronic address: yavuzyardim2002@yahoo.com.
FAU - Çelebi, Metin
AU  - Çelebi M
AD  - Yüzüncü Yıl University, Faculty of Science, Department of Inorganic Chemistry, 
      65080 Van, Turkey.
FAU - Levent, Abdulkadir
AU  - Levent A
AD  - Batman University, Health Services Vocational College, 72100 Batman, Turkey.
FAU - Şentürk, Zühre
AU  - Şentürk Z
AD  - Yüzüncü Yıl University, Faculty of Science, Department of Analytical Chemistry, 
      65080 Van, Turkey. Electronic address: zuhresenturk@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20160516
PL  - Netherlands
TA  - Talanta
JT  - Talanta
JID - 2984816R
RN  - 0 (Fluorocarbon Polymers)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 39464-59-0 (perfluorosulfonic acid)
RN  - 3G6A5W338E (Caffeine)
RN  - 7440-44-0 (Carbon)
RN  - 7782-42-5 (Graphite)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis/chemistry
MH  - Aspirin/*analysis/chemistry
MH  - Caffeine/*analysis/chemistry
MH  - Carbon/chemistry
MH  - Electrochemical Techniques
MH  - Electrodes
MH  - Fluorocarbon Polymers/*chemistry
MH  - Graphite/*chemistry
MH  - Reproducibility of Results
MH  - Tablets
OTO - NOTNLM
OT  - Aspirin
OT  - Caffeine
OT  - Graphene-Nafion composite film modified glassy carbon electrode
OT  - Paracetamol
OT  - Pharmaceutical formulation
EDAT- 2016/06/28 06:00
MHDA- 2018/01/27 06:00
CRDT- 2016/06/26 06:00
PHST- 2016/03/06 00:00 [received]
PHST- 2016/05/11 00:00 [revised]
PHST- 2016/05/14 00:00 [accepted]
PHST- 2016/06/26 06:00 [entrez]
PHST- 2016/06/28 06:00 [pubmed]
PHST- 2018/01/27 06:00 [medline]
AID - S0039-9140(16)30372-1 [pii]
AID - 10.1016/j.talanta.2016.05.046 [doi]
PST - ppublish
SO  - Talanta. 2016 Sep 1;158:21-29. doi: 10.1016/j.talanta.2016.05.046. Epub 2016 May 
      16.

PMID- 33181650
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 46
DP  - 2020 Nov 13
TI  - Efficacy and safety of low dose aspirin and magnesium sulfate in the treatment of 
      pregnancy induced hypertension: A protocol for systematic review and 
      meta-analysis.
PG  - e22801
LID - 10.1097/MD.0000000000022801 [doi]
LID - e22801
AB  - BACKGROUND: Magnesium sulfate combined with low-dose aspirin can significantly 
      reduce adverse reactions and effectively lower blood pressure in patients with 
      pregnancy induced hypertension, but the overall efficacy and safety of the 
      combination of drugs are not clear. The purpose of this study was to evaluate the 
      efficacy and safety of magnesium sulfate combined with low-dose aspirin in the 
      treatment of pregnancy induced hypertension. METHODS: Randomized controlled 
      trials focusing on the administration of magnesium sulfate combined with low-dose 
      aspirin for pregnancy induced hypertension were searched from PubMed, EMbase, 
      Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), 
      WanFang, and the Chongqing VIP Chinese Science and Technology Periodical 
      Database. Two researchers independently screened titles, abstracts, and full 
      texts, and extracted relevant data. The RevMan 5.3 software and Stata 14 software 
      were used for statistical analysis. RESULTS: The effect and safety of magnesium 
      sulfate combined with low-dose aspirin in the treatment of pregnancy induced 
      hypertension were assessed by summarizing the related randomized controlled 
      trials. CONCLUSION: This article provides theoretical support for the clinical 
      application of magnesium sulfate combined with low-dose aspirin in the treatment 
      of pregnancy induced hypertension. OSF REGISTRATION NUMBER: DOI 
      10.17605/OSF.IO/SZFGB.
FAU - He, Guolin
AU  - He G
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children, 
      Ministry of Education, West China Second University Hospital, Sichuan University.
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital, 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Chen, Yihong
AU  - Chen Y
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children, 
      Ministry of Education, West China Second University Hospital, Sichuan University.
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital, 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Chen, Meng
AU  - Chen M
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children, 
      Ministry of Education, West China Second University Hospital, Sichuan University.
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital, 
      Sichuan University, Chengdu, Sichuan, China.
FAU - He, Guoqian
AU  - He G
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children, 
      Ministry of Education, West China Second University Hospital, Sichuan University.
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital, 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Liu, Xinghui
AU  - Liu X
AUID- ORCID: 0000-0002-2838-4224
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children, 
      Ministry of Education, West China Second University Hospital, Sichuan University.
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital, 
      Sichuan University, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 7487-88-9 (Magnesium Sulfate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - *Clinical Protocols
MH  - Female
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/*drug therapy
MH  - Magnesium Sulfate/*administration & dosage/therapeutic use
MH  - Meta-Analysis as Topic
MH  - Pregnancy
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7668468
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/11/13 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/11/12 20:17
PHST- 2020/11/12 20:17 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
AID - 00005792-202011130-00018 [pii]
AID - MD-D-20-09253 [pii]
AID - 10.1097/MD.0000000000022801 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 13;99(46):e22801. doi: 
      10.1097/MD.0000000000022801.

PMID- 22226416
OWN - NLM
STAT- MEDLINE
DCOM- 20120928
LR  - 20191210
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 61
DP  - 2012 Mar 5
TI  - Development and validation of a liquid chromatographic method for purity control 
      of clopidogrel-acetylsalicylic acid in combined oral dosage forms.
PG  - 271-6
LID - 10.1016/j.jpba.2011.12.019 [doi]
AB  - A reversed phase liquid chromatographic method with UV detection for the 
      simultaneous determination of clopidogrel and acetylsalicylic acid and their 
      related substances in combined oral formulations was developed and validated. 
      Good separation was achieved on a Luna C18 column (150 mm × 4.6 mm, 3 μm) using 
      gradient elution at a flow rate of 1 mL/min and a column temperature of 35 °C. UV 
      detection was performed at 220 nm. The validation was performed according to the 
      ICH guidelines. The method proved to be specific, sensitive (LOQ=0.975 μg/mL and 
      0.0384 μg/mL for clopidogrel and acetylsalicylic acid, respectively), linear in 
      the concentration range from LOQ to 325 μg/mL for clopidogrel and from LOQ to 650 
      μg/mL for acetylsalicylic acid, precise (RSD values for intermediate precision 
      <1%) and accurate with mean recovery values of 100.7% and 100.2% for clopidogrel 
      and acetylsalicylic acid, respectively. Moreover, the solution stability and 
      method robustness were examined. The method gives satisfactory separation of 
      impurities of clopidogrel and acetylsalicylic acid and so it is suitable for 
      quantification of the related substances as well as for the assay of the actives.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Kahsay, Getu
AU  - Kahsay G
AD  - Katholieke Universiteit Leuven, Faculteit Farmaceutische Wetenschappen, 
      Laboratorium voor Farmaceutische Analyse, O&N2, Herestraat 49, PB 923, B-3000 
      Leuven, Belgium.
FAU - Van Schepdael, Ann
AU  - Van Schepdael A
FAU - Adams, Erwin
AU  - Adams E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20111223
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Dosage Forms)
RN  - 0 (Drug Combinations)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*analysis/chemistry
MH  - Chromatography, Liquid/methods/standards
MH  - Chromatography, Reverse-Phase/*methods/standards
MH  - Clopidogrel
MH  - Dosage Forms
MH  - Drug Combinations
MH  - *Drug Contamination
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/analysis/chemistry
EDAT- 2012/01/10 06:00
MHDA- 2012/09/29 06:00
CRDT- 2012/01/10 06:00
PHST- 2011/11/05 00:00 [received]
PHST- 2011/12/14 00:00 [revised]
PHST- 2011/12/14 00:00 [accepted]
PHST- 2012/01/10 06:00 [entrez]
PHST- 2012/01/10 06:00 [pubmed]
PHST- 2012/09/29 06:00 [medline]
AID - S0731-7085(11)00726-6 [pii]
AID - 10.1016/j.jpba.2011.12.019 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2012 Mar 5;61:271-6. doi: 10.1016/j.jpba.2011.12.019. Epub 
      2011 Dec 23.

PMID- 24739129
OWN - NLM
STAT- MEDLINE
DCOM- 20140623
LR  - 20140417
IS  - 1764-1489 (Print)
IS  - 1764-1489 (Linking)
VI  - 46
IP  - 2
DP  - 2014 Mar
TI  - Exercise-induced anaphylaxis in a cardiopathic patient on chronic aspirin 
      therapy.
PG  - 95-6
AB  - We report the case of a 73 year old man on chronic aspirin therapy who went in 
      anaphylactic shock during his daily farm chores following a meal rich in wheat 
      products. The serum specific IgE assay (ImmunoCAP) showed strong positive 
      specific IgE responses to ω-5 gliadin. A two-year period avoiding wheat meals 3 
      hours prior to exercise, resulted in a lack of further anaphylaxis; this results 
      aided us in making the diagnosis.
FAU - Micucci, C
AU  - Micucci C
AD  - UOC di Broncopneumologia - Servizio di Allergologia, Ospedale "Carlo Urbani", 
      Jesi (Ancona) Italy. corrado.micucci@tin.it.
FAU - Amico, D
AU  - Amico D
AD  - UOC di Broncopneumologia - Ospedale "Carlo Urbani", Jesi (Ancona) Italy. 
      donatellaamico@libero.it.
FAU - Braconi, M
AU  - Braconi M
AD  - UOC di Broncopneumologia - Ospedale "Carlo Urbani", Jesi (Ancona) Italy.
FAU - Pareo, C
AU  - Pareo C
AD  - UOC di Broncopneumologia - Ospedale "Carlo Urbani", Jesi (Ancona) Italy.
FAU - Cimarelli, M E
AU  - Cimarelli ME
AD  - UOC di Broncopneumologia - Ospedale "Carlo Urbani", Jesi (Ancona) Italy.
FAU - Subiaco, S
AU  - Subiaco S
AD  - UOC di Broncopneumologia - Ospedale "Carlo Urbani", Jesi (Ancona) Italy.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Italy
TA  - Eur Ann Allergy Clin Immunol
JT  - European annals of allergy and clinical immunology
JID - 101466614
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anaphylaxis/*etiology
MH  - Aspirin/administration & dosage/*adverse effects
MH  - *Exercise
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Male
MH  - Wheat Hypersensitivity/*complications
EDAT- 2014/04/18 06:00
MHDA- 2014/06/24 06:00
CRDT- 2014/04/18 06:00
PHST- 2014/04/18 06:00 [entrez]
PHST- 2014/04/18 06:00 [pubmed]
PHST- 2014/06/24 06:00 [medline]
PST - ppublish
SO  - Eur Ann Allergy Clin Immunol. 2014 Mar;46(2):95-6.

PMID- 828848
OWN - NLM
STAT- MEDLINE
DCOM- 19770512
LR  - 20190704
IS  - 0003-9950 (Print)
IS  - 0003-9950 (Linking)
VI  - 93
IP  - 9
DP  - 1975 Sep
TI  - Ibuprofen and visual function. Prospective evaluation.
PG  - 781-2
AB  - Eye evaluations before and after 24 weeks of treatment with either ibuprofen 
      (Motrin) or aspirin did not show eye toxicity with either drug in a double-blind 
      study of 78 patients with osteoarthritis. The possibility of eye complications 
      resulting from ibuprofen therapy suggested in two earlier reports has not been 
      confirmed in clinical usage in other countries or in clinical trials in the 
      United States.
FAU - Melluish, J W
AU  - Melluish JW
FAU - Brooks, C D
AU  - Brooks CD
FAU - Ruoff, G
AU  - Ruoff G
FAU - Cross, C J
AU  - Cross CJ
FAU - Sanborn, E C
AU  - Sanborn EC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Arch Ophthalmol
JT  - Archives of ophthalmology (Chicago, Ill. : 1960)
JID - 7706534
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Ibuprofen/adverse effects/*pharmacology/therapeutic use
MH  - Long-Term Care
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/drug therapy
MH  - Phenylpropionates/*pharmacology
MH  - Vision, Ocular/*drug effects
EDAT- 1975/09/01 00:00
MHDA- 1975/09/01 00:01
CRDT- 1975/09/01 00:00
PHST- 1975/09/01 00:00 [pubmed]
PHST- 1975/09/01 00:01 [medline]
PHST- 1975/09/01 00:00 [entrez]
AID - 10.1001/archopht.1975.01010020675003 [doi]
PST - ppublish
SO  - Arch Ophthalmol. 1975 Sep;93(9):781-2. doi: 10.1001/archopht.1975.01010020675003.

PMID- 24132773
OWN - NLM
STAT- MEDLINE
DCOM- 20150112
LR  - 20211021
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
VI  - 34
IP  - 1
DP  - 2014 Jan
TI  - Pharmacodynamics and pharmacokinetics of a novel, low-dose, soft-gel capsule of 
      acetylsalicylic acid in comparison with an oral solution after single-dose 
      administration to healthy volunteers: a phase I, two-way crossover study.
PG  - 19-25
LID - 10.1007/s40261-013-0145-2 [doi]
AB  - BACKGROUND: Low-dose acetylsalicylic acid (ASA; aspirin) is well-established as a 
      platelet anti-aggregating agent for the secondary prevention of cardiovascular 
      events. OBJECTIVES: The objective of this study was to investigate the 
      non-inferiority of a novel ASA 75 mg soft-gel capsule formulation compared with a 
      marketed powder for oral solution in terms of reduction in serum thromboxane B2 
      (TXB2), a surrogate for platelet aggregation. Pharmacokinetics and tolerability 
      of the products were also investigated. METHODS: In this randomised, two-way 
      crossover study, 46 male and female healthy subjects received a single dose of 
      the investigational products in two periods separated by a 14-day washout. Serum 
      TXB2 and plasma ASA were determined up to 24 h post-dose. Maximum percentage of 
      TXB2 inhibition (I max) and area under the inhibition-time curve (AUICt) were 
      calculated. Non-inferiority was assumed if the lower limits of the 95 % 
      confidence intervals (CIs) for the two pharmacodynamic parameters were above 85 
      %. RESULTS: The 95 % CI lower limits were 95.35 % for I max and 86.12 % for 
      AUICt, i.e. within the pre-specified delta. Time to achieve I max did not differ 
      between treatments (p = 0.88). The two formulations were bioequivalent as regards 
      the extent of ASA exposure (area under the plasma concentration-time curve from 
      zero to time t [AUCt] 90 % CIs 96.67-113.37); a delayed ASA absorption (later 
      time to reach maximum plasma concentration [t max], lower maximum plasma 
      concentration [C max]) was observed for the test product. No treatment-related 
      adverse events were reported. CONCLUSIONS: In healthy subjects, the 75 mg 
      soft-gel capsules were not inferior to the oral solution in terms of serum TXB2 
      inhibition, indicating that the novel formulation could be an effective 
      alternative in the secondary prevention of cardiovascular events.
FAU - Loprete, Luca
AU  - Loprete L
AD  - CROSS Research S.A., via F.A. Giorgioli 14, 6864, Arzo, Switzerland, 
      luca.loprete@croalliance.com.
FAU - Leuratti, Chiara
AU  - Leuratti C
FAU - Scarsi, Claudia
AU  - Scarsi C
FAU - Radicioni, Milko
AU  - Radicioni M
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Capsules)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Solutions)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects/*pharmacokinetics/pharmacology
MH  - Capsules
MH  - Cross-Over Studies
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/pharmacokinetics/pharmacology
MH  - Solutions
MH  - Therapeutic Equivalency
MH  - Thromboxane B2/antagonists & inhibitors/blood
MH  - Young Adult
EDAT- 2013/10/18 06:00
MHDA- 2015/01/13 06:00
CRDT- 2013/10/18 06:00
PHST- 2013/10/18 06:00 [entrez]
PHST- 2013/10/18 06:00 [pubmed]
PHST- 2015/01/13 06:00 [medline]
AID - 10.1007/s40261-013-0145-2 [doi]
PST - ppublish
SO  - Clin Drug Investig. 2014 Jan;34(1):19-25. doi: 10.1007/s40261-013-0145-2.

PMID- 7923312
OWN - NLM
STAT- MEDLINE
DCOM- 19941123
LR  - 20131121
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 16
IP  - 3
DP  - 1994 May-Jun
TI  - Comparison of single-dose ibuprofen lysine, acetylsalicylic acid, and placebo for 
      moderate-to-severe postoperative dental pain.
PG  - 458-65
AB  - In a single-dose, double-blind, parallel-group, single-site study, ibuprofen 
      lysine 200 mg (IBL 200) was compared with acetylsalicylic acid 500 mg (ASA 500) 
      and placebo in 183 patients with moderate-to-severe postoperative dental pain. 
      The relative onset of analgesic response, duration and degree of analgesia, and 
      safety were assessed over a 6-hour postdose period. Analgesic efficacy was 
      assessed by patient self-rating of pain intensity, pain relief, time to 
      meaningful pain relief, global evaluation, and requirement for additional 
      analgesic medication; both IBL 200 and ASA 500 were significantly more effective 
      than placebo. IBL 200 also had a significantly faster onset of action, greater 
      peak and overall analgesic effect, and longer duration of analgesia than ASA 500. 
      All treatments were generally well tolerated.
FAU - Nelson, S L
AU  - Nelson SL
AD  - Rivers Center Research Corporation, Columbia, Maryland.
FAU - Brahim, J S
AU  - Brahim JS
FAU - Korn, S H
AU  - Korn SH
FAU - Greene, S S
AU  - Greene SS
FAU - Suchower, L J
AU  - Suchower LJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Ibuprofen/*adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Pain, Postoperative/*drug therapy
MH  - *Tooth Extraction
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1994 May-Jun;16(3):458-65.

PMID- 27765537
OWN - NLM
STAT- MEDLINE
DCOM- 20170707
LR  - 20221207
IS  - 1879-3649 (Electronic)
IS  - 1537-1891 (Linking)
VI  - 87
DP  - 2016 Dec
TI  - Aspirin, stroke and drug-drug interactions.
PG  - 14-22
LID - S1537-1891(16)30269-5 [pii]
LID - 10.1016/j.vph.2016.10.006 [doi]
AB  - Low-dose aspirin, alone or in combination, is recommended for the secondary 
      prevention of acute non-cardioembolic ischemic stroke and transient ischemic 
      attack, starting soon after the acute event. Clinically-relevant drug-drug 
      interactions (DDIs) are a major concern of regulatory agencies and practicing 
      physicians. Drug's pharmacodynamics and/or pharmacokinetics account for 
      clinically-relevant DDIs that modify efficacy and/or safety of one or more of the 
      co-administered drugs. Some non-steroidal anti-inflammatory drugs interact with 
      aspirin pharmacodynamics by competing on the drug target, i.e. the platelet's 
      cyclooxygenase-1 protein. Although the molecular mechanism(s) of this DDI and its 
      effect on the degree of platelet inhibition in vitro and ex vivo are well 
      unraveled, nevertheless, the extent to which this DDI impacts on long-term 
      antithrombotic efficacy of aspirin in secondary prevention remains unclear. 
      Aspirin pharmacokinetics does not involve critical cytochrome P450 enzymes nor 
      efflux transporters, therefore clinically-relevant DDIs competing on 
      pharmacokinetic pathways seem unlikely. The co-administration of antiplatelet 
      drugs with serotonin storage reuptake inhibitors can create a synergistic effect 
      with antiplatelet agents on platelet inhibition. Low-dose aspirin, alone or in 
      combination with other antiplatelet agents, remains a cornerstone in treating 
      cerebrovascular disorders. The relatively straightforward pharmacokinetics of 
      aspirin limits DDIs, giving it a unique advantage over most antiplatelet drugs.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Russo, Nicholas W
AU  - Russo NW
AD  - Institute of Pharmacology, Catholic University School of Medicine, Rome, Italy.
FAU - Petrucci, Giovanna
AU  - Petrucci G
AD  - Institute of Pharmacology, Catholic University School of Medicine, Rome, Italy.
FAU - Rocca, Bianca
AU  - Rocca B
AD  - Institute of Pharmacology, Catholic University School of Medicine, Rome, Italy. 
      Electronic address: b.rocca@tiscali.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20161017
PL  - United States
TA  - Vascul Pharmacol
JT  - Vascular pharmacology
JID - 101130615
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/*administration & dosage/pharmacokinetics/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Synergism
MH  - Humans
MH  - Ischemic Attack, Transient/prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & 
      dosage/pharmacokinetics/pharmacology
MH  - Selective Serotonin Reuptake Inhibitors/pharmacology
MH  - Stroke/*prevention & control
OTO - NOTNLM
OT  - Aspirin
OT  - Cyclooxygenase-1
OT  - Drug-drug interaction
OT  - Non-steroidal anti-inflammatory drugs
OT  - Serotonin storage reuptake inhibitors
EDAT- 2016/10/23 06:00
MHDA- 2017/07/08 06:00
CRDT- 2016/10/23 06:00
PHST- 2016/09/14 00:00 [received]
PHST- 2016/10/06 00:00 [revised]
PHST- 2016/10/14 00:00 [accepted]
PHST- 2016/10/23 06:00 [pubmed]
PHST- 2017/07/08 06:00 [medline]
PHST- 2016/10/23 06:00 [entrez]
AID - S1537-1891(16)30269-5 [pii]
AID - 10.1016/j.vph.2016.10.006 [doi]
PST - ppublish
SO  - Vascul Pharmacol. 2016 Dec;87:14-22. doi: 10.1016/j.vph.2016.10.006. Epub 2016 
      Oct 17.

PMID- 27322160
OWN - NLM
STAT- MEDLINE
DCOM- 20170210
LR  - 20170210
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 12
IP  - 9
DP  - 2016 Sep
TI  - Drug-disease interactions: narrative review of aspirin in gastric ulcer.
PG  - 1081-7
LID - 10.1080/17425255.2016.1201064 [doi]
AB  - INTRODUCTION: Drug-disease interactions include the impact of a drug and a 
      particular disease condition on each other. However, the current practice in 
      addressing drug-disease interaction is unbalanced and mostly limited to how the 
      drug worsens the disease or health condition. AREAS COVERED: Aspirin and gastric 
      ulcer interaction are used as an example to illustrate this concept, especially 
      the narration of how disease affects drug efficacy. The number of molecules that 
      make up 100 mg of aspirin is identified with a view to discuss the 
      pharmacokinetics, especially in terms of absorption and distribution. Using 
      hypothetical scenarios, the pharmacodynamics in co-morbidities that could involve 
      gastric ulcer and aspirin are also discussed. EXPERT OPINION: There seems to be 
      oversight in definition and description of drug-disease interaction, which is 
      often limited to 'how drug exacerbates disease'. The implication of this limited 
      definition is that the discussions, research and teaching of the topic either 
      lacks information, or are not clear on 'how disease affects drug efficacy'. For 
      example, gastric ulcer has the potential to enhance absorption, bioavailability 
      and therapeutic effects of aspirin, but this is rarely discussed in preference to 
      the probability of gastro-intestinal bleeding side-effect.
FAU - Nwose, Ezekiel Uba
AU  - Nwose EU
AD  - a Faculty of Science , Charles Sturt University , Orange , NSW , Australia.
FAU - Yee, Kwang Choon
AU  - Yee KC
AD  - b School of Psychological and Clinical Science , Charles Darwin University , 
      Darwin , Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160627
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects/pharmacokinetics
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/pharmacokinetics
MH  - Research Design
MH  - Stomach Ulcer/chemically induced/*complications/pathology
MH  - Tissue Distribution
OTO - NOTNLM
OT  - Anti-inflammatory drugs
OT  - antiplatelet function
OT  - co-morbidities
OT  - drug-disease interactions
OT  - gastric ulcer
OT  - pharmacodynamics and pharmacokinetics
EDAT- 2016/06/21 06:00
MHDA- 2017/02/12 06:00
CRDT- 2016/06/21 06:00
PHST- 2016/06/21 06:00 [entrez]
PHST- 2016/06/21 06:00 [pubmed]
PHST- 2017/02/12 06:00 [medline]
AID - 10.1080/17425255.2016.1201064 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2016 Sep;12(9):1081-7. doi: 
      10.1080/17425255.2016.1201064. Epub 2016 Jun 27.

PMID- 19954823
OWN - NLM
STAT- MEDLINE
DCOM- 20100702
LR  - 20131121
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 125
IP  - 4
DP  - 2010 Apr
TI  - The risk of false results in the assessment of platelet function in the absence 
      of antiplatelet medication: comparison of the PFA-100, multiplate electrical 
      impedance aggregometry and verify now assays.
PG  - e132-7
LID - 10.1016/j.thromres.2009.11.005 [doi]
AB  - OBJECTIVES: Evaluation of aspirin (ASA) responsiveness with platelet function 
      tests varies by the choice of blood mixture and functional test and cut off 
      values for defining the the treatment used. Addition to that we also aimed to 
      determine agreement between three tests and to research whether there is any 
      necessity to measure baseline platelet activity. METHODS: The study group 
      comprised of 52 patients with multiple risk factors receiving primary prophylaxis 
      of ASA (100 mg/day). For each patient inhibition of platelet aggregation with 
      aspirin was determined using three different whole blood tests: Multiplate 
      electrical impedance aggregometry, Verify Now Aspirin, and collagen-epinephrine 
      closure time PFA-100. Platelet aggregation was assessed with multiplate 
      electrical impedance aggregometry,and was defined as the area under curve 
      (AUC,AUxmin). Maximal 6,4 microM collagen-induced AUC were used to quantify 
      platelet aggregation due to ASA. The ASA response was defined as >30 % reduction 
      in basal platelet aggregation with multiplate electrical impedance aggregometry. 
      Collagen induced platelet aggregation at the Verify Now Aspirin assay quantitated 
      the ASA-induced platelet inhibition as aspirin reaction units (ARU). According to 
      manufacturer insert ARU>550 indicates aspirin resistance. ASA platelet function 
      studies were assessed twice at baseline (pre-aspirin), and after 7 
      day(post-aspirin) were performed. RESULTS: After ASA intake none of the patients 
      was found aspirin resistant with PFA-100. (CEPI-CT (129+/-36 vs 289+/-18 ). None 
      of the patients was found aspirin resistant with PFA-100. As>30 % reduction in 
      basal platelet aggregation with multiplate electrical impedance aggregometry is 
      selected all of the patients have been stratified as responders.(COL TEST 
      688+/-230 vs 169+/-131 AU) None of the patients with Verify Now Aspirin found 
      resistance to ASA(594+/-62 vs 446+/-43).Prior to ASA intake 15 of all patients 
      with VN(501+/-16) and 2 of all patients with multiplate electrical impedance 
      aggregometry (223+/-40 AUC )aggregation levels below the cut off label before 
      ingestion of ASA.None of the patients was above the cut off label with PFA -100 
      (129+/-36). CONCLUSIONS: Verify Now ASA assay, multiplate electrical impedance 
      aggregometry and PFA-100 seem to be reliable tests in reflecting ASA effect on 
      platelets. Cut off labels for the defining the responsiveness given by 
      manufacturer may show significant interindividual variability with Verify Now ASA 
      assay and multiplate electrical impedance aggregometry, and these test may show 
      platelet inhibition despite the absence of ASA intake. Consideration of the 
      pretreatment values may eliminate the risk of overestimation in the assessment of 
      platelet inhibition by ASA.
CI  - (c) 2009 Elsevier Ltd. All rights reserved.
FAU - Can, Mehmet Mustafa
AU  - Can MM
AD  - Department of Cardiology, Koşuyolu Heart & Research Hospital, Istanbul, Turkey. 
      mehmetmustafacan@yahoo.com
FAU - Tanboğa, Ibrahim Halil
AU  - Tanboğa IH
FAU - Türkyilmaz, Erdem
AU  - Türkyilmaz E
FAU - Karabay, Can Yucel
AU  - Karabay CY
FAU - Akgun, Taylan
AU  - Akgun T
FAU - Koca, Fatih
AU  - Koca F
FAU - Tokgoz, Hacer Ceren
AU  - Tokgoz HC
FAU - Keles, Nursen
AU  - Keles N
FAU - Ozkan, Alper
AU  - Ozkan A
FAU - Bezgin, Tahir
AU  - Bezgin T
FAU - Ozveren, Olcay
AU  - Ozveren O
FAU - Sonmez, Kenan
AU  - Sonmez K
FAU - Sağlam, Mustafa
AU  - Sağlam M
FAU - Ozdemir, Nihal
AU  - Ozdemir N
FAU - Kaymaz, Cihangir
AU  - Kaymaz C
LA  - eng
PT  - Journal Article
DEP - 20091201
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Biological Assay/instrumentation
MH  - Blood Platelets/drug effects/*physiology
MH  - Clinical Laboratory Techniques/instrumentation
MH  - Collagen/pharmacology
MH  - Electric Impedance
MH  - Epinephrine/pharmacology
MH  - Hemostasis/drug effects/physiology
MH  - Humans
MH  - Platelet Aggregation/drug effects/*physiology
MH  - Platelet Count/instrumentation
MH  - Platelet Function Tests/*instrumentation/*methods
MH  - Risk
MH  - Risk Factors
EDAT- 2009/12/04 06:00
MHDA- 2010/07/03 06:00
CRDT- 2009/12/04 06:00
PHST- 2009/09/16 00:00 [received]
PHST- 2009/10/22 00:00 [revised]
PHST- 2009/11/06 00:00 [accepted]
PHST- 2009/12/04 06:00 [entrez]
PHST- 2009/12/04 06:00 [pubmed]
PHST- 2010/07/03 06:00 [medline]
AID - S0049-3848(09)00506-4 [pii]
AID - 10.1016/j.thromres.2009.11.005 [doi]
PST - ppublish
SO  - Thromb Res. 2010 Apr;125(4):e132-7. doi: 10.1016/j.thromres.2009.11.005. Epub 
      2009 Dec 1.

PMID- 671238
OWN - NLM
STAT- MEDLINE
DCOM- 19780925
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 67
IP  - 8
DP  - 1978 Aug
TI  - Determination of salicylic acid and aspirin in multicomponent tablets by liquid 
      chromatography on a nonionic resin.
PG  - 1066-9
AB  - Aspirin and free salicylic acid were determined in combinations containing 
      caffeine, phenacetin, salicylamide, and acetaminophen by liquid chromatography on 
      poly(methyl methacrylate) resin. Precision and accuracy were +/- 2% for salicylic 
      acid, the latter at levels corresponding to 0.02% of the aspirin content.
FAU - Baum, R G
AU  - Baum RG
FAU - Cantwell, F F
AU  - Cantwell FF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Drug Combinations)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, Liquid
MH  - Drug Combinations
MH  - Methods
MH  - Salicylates/*analysis
MH  - Tablets/analysis
EDAT- 1978/08/01 00:00
MHDA- 1978/08/01 00:01
CRDT- 1978/08/01 00:00
PHST- 1978/08/01 00:00 [pubmed]
PHST- 1978/08/01 00:01 [medline]
PHST- 1978/08/01 00:00 [entrez]
AID - S0022-3549(15)42184-7 [pii]
AID - 10.1002/jps.2600670811 [doi]
PST - ppublish
SO  - J Pharm Sci. 1978 Aug;67(8):1066-9. doi: 10.1002/jps.2600670811.

PMID- 19427478
OWN - NLM
STAT- MEDLINE
DCOM- 20090807
LR  - 20131121
IS  - 1873-4324 (Electronic)
IS  - 0003-2670 (Linking)
VI  - 642
IP  - 1-2
DP  - 2009 May 29
TI  - Simultaneous determination of acetylsalicylic acid, paracetamol and caffeine 
      using solid-phase molecular fluorescence and parallel factor analysis.
PG  - 212-6
LID - 10.1016/j.aca.2008.10.067 [doi]
AB  - This paper describes the determination of acetylsalicylic acid (ASA), paracetamol 
      and caffeine in pharmaceutical formulations using solid-phase molecular 
      fluorescence and second order multivariate calibration. This methodology is 
      applicable even in the presence of unknown interferences and with spectral 
      overlap of the components in the mixture. Parallel factor analysis (PARAFAC) was 
      used for model development, whose effectiveness was demonstrated by analysis of 
      variance (ANOVA). Errors below 10% were obtained for all compounds using an 
      external validation set. Benefits of the new procedures not included in the 
      reference methods such as low cost, no need of sample preparation, simple and 
      fast analysis using fluorescence spectrometer and no generation of waste, make 
      this method very attractive, allowing for the simultaneous determination of 
      compounds with good reproducibility and accuracy.
FAU - Alves, Julio Cesar L
AU  - Alves JC
AD  - Institute of Chemistry, University of Campinas, P.O. Box 6154, 13083-970 
      Campinas, SP, Brazil.
FAU - Poppi, Ronei J
AU  - Poppi RJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081105
PL  - Netherlands
TA  - Anal Chim Acta
JT  - Analytica chimica acta
JID - 0370534
RN  - 0 (Pharmaceutical Preparations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis/chemistry
MH  - Analysis of Variance
MH  - Aspirin/*analysis/chemistry
MH  - Caffeine/*analysis/chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - Pharmaceutical Preparations/analysis
MH  - Reproducibility of Results
MH  - Spectrometry, Fluorescence/*methods
EDAT- 2009/05/12 09:00
MHDA- 2009/08/08 09:00
CRDT- 2009/05/12 09:00
PHST- 2008/08/08 00:00 [received]
PHST- 2008/10/23 00:00 [revised]
PHST- 2008/10/24 00:00 [accepted]
PHST- 2009/05/12 09:00 [entrez]
PHST- 2009/05/12 09:00 [pubmed]
PHST- 2009/08/08 09:00 [medline]
AID - S0003-2670(08)01870-9 [pii]
AID - 10.1016/j.aca.2008.10.067 [doi]
PST - ppublish
SO  - Anal Chim Acta. 2009 May 29;642(1-2):212-6. doi: 10.1016/j.aca.2008.10.067. Epub 
      2008 Nov 5.

PMID- 6721262
OWN - NLM
STAT- MEDLINE
DCOM- 19840607
LR  - 20131121
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 52
IP  - 5
DP  - 1984 May
TI  - Decreased sensitivity to tartrazine after aspirin desensitization in an asthmatic 
      patient intolerant to both aspirin and tartrazine.
PG  - 368-70
AB  - An aspirin- and tartrazine-sensitive asthmatic patient underwent a 
      desensitization to the adverse effects of aspirin by oral aspirin challenges. 
      After a month of daily aspirin ingestion, the patient's reactivity to tartrazine, 
      tested by oral challenge, was observed to the blunted. This report suggests that 
      desensitization to the adverse effects of aspirin might protect the patient 
      against the adverse effects of tartrazine.
FAU - Michel, O
AU  - Michel O
FAU - Naeije, N
AU  - Naeije N
FAU - Bracamonte, M
AU  - Bracamonte M
FAU - Duchateau, J
AU  - Duchateau J
FAU - Sergysels, R
AU  - Sergysels R
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - 0 (Azo Compounds)
RN  - I753WB2F1M (Tartrazine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/*immunology
MH  - Azo Compounds/*adverse effects
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/*etiology
MH  - Female
MH  - Humans
MH  - Respiratory Function Tests
MH  - Tartrazine/*adverse effects/immunology
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1984 May;52(5):368-70.

PMID- 2372267
OWN - NLM
STAT- MEDLINE
DCOM- 19900821
LR  - 20190824
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 20
IP  - 3
DP  - 1990 Jun
TI  - Aspirin concurrently administered with ranitidine does not delay healing of 
      duodenal ulcer.
PG  - 201-3
AB  - Sixty-nine patients with endoscopically diagnosed duodenal ulcer were randomised 
      to either Group I or Group II. Group I patients (n = 35) received tablet 
      ranitidine 150 mg twice daily along with tablet aspirin 600 mg three times a day 
      while Group II patients received only tablet ranitidine 150 mg twice daily. Eight 
      patients (four in each group) dropped out of the trial but were included in the 
      final analysis as failure of treatment. At the end of four weeks 51.4% ulcers 
      healed in Group I compared to 58.8% in Group II. The difference between the two 
      groups was not significant. There was also no statistical difference in the time 
      required for relief of pain, number of patients relieved of pain and the 
      complication rate. It is concluded that aspirin concurrently administered with 
      ranitidine is safe and does not delay the healing of uncomplicated duodenal 
      ulcers.
FAU - Misra, S P
AU  - Misra SP
AD  - Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India.
FAU - Kumar, N
AU  - Kumar N
FAU - Anand, B S
AU  - Anand BS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 884KT10YB7 (Ranitidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Aust N Z J Med. 1991 Feb;21(1):80. PMID: 1867709
CIN - Aust N Z J Med. 1991 Feb;21(1):80-1. PMID: 2036084
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Therapy, Combination
MH  - Duodenal Ulcer/drug therapy/*pathology
MH  - Duodenoscopy
MH  - Female
MH  - Humans
MH  - Male
MH  - Ranitidine/*administration & dosage
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
AID - 10.1111/j.1445-5994.1990.tb01018.x [doi]
PST - ppublish
SO  - Aust N Z J Med. 1990 Jun;20(3):201-3. doi: 10.1111/j.1445-5994.1990.tb01018.x.

PMID- 35142767
OWN - NLM
STAT- MEDLINE
DCOM- 20220311
LR  - 20220311
IS  - 2042-650X (Electronic)
IS  - 2042-6496 (Linking)
VI  - 13
IP  - 4
DP  - 2022 Feb 21
TI  - Combined royal jelly 10-hydroxydecanoic acid and aspirin has a synergistic effect 
      against memory deficit and neuroinflammation.
PG  - 2336-2353
LID - 10.1039/d1fo02397g [doi]
AB  - Alzheimer's disease (AD), the most common form of neurodegenerative dementia 
      among the older population, is associated with acute or chronic inflammation. As 
      a nonsteroidal anti-inflammatory drug, aspirin has recently been widely studied 
      in the prevention and treatment of neurodegenerative diseases. However, there is 
      a controversy about the efficacy as well as the adverse effects of aspirin. 
      10-Hydroxydecanoic acid (10-HDAA) is a characteristic fatty acid found in the 
      honey bee product royal jelly. In this study, we found that 10-HDAA attenuated 
      the activation of the NF-κB pathway, then targeted Ptgs-1/2, the well-known 
      target of aspirin. Hence, combined therapy of 10-HDAA and aspirin was conducted. 
      In vitro assays suggested that this combinatory group alleviated LPS-induced 
      inflammation in BV-2 cells, as assessed by the downregulation of nitric oxide, 
      COX-2, and IL-6 compared to 10-HDAA or aspirin treatment alone. In vivo assays 
      showed that the combined treatment synergistically inhibited the overactivation 
      of glial cells and decreased the levels of pro-inflammatory mediators. Moreover, 
      10-HDAA alleviated the adverse effects of aspirin on gastrointestinal injuries 
      and microbiota dysbiosis. The Morris water maze test indicated that neither 
      10-HDAA nor aspirin effectively improved LPS-induced memory dysfunction, but the 
      combined therapy showed synergistic effects. Altogether, our findings support 
      10-HDAA and aspirin combinatory therapy as the basis for future therapeutics for 
      AD and other neuroinflammation-related diseases with minimal adverse effects.
FAU - You, Mengmeng
AU  - You M
AUID- ORCID: 0000-0002-7152-6523
AD  - College of Animal Sciences, Zhejiang University, Hangzhou, China. 
      flhu@zju.edu.cn.
AD  - School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, 
      China.
AD  - College of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Wang, Kangli
AU  - Wang K
AUID- ORCID: 0000-0002-6987-2558
AD  - College of Animal Sciences, Zhejiang University, Hangzhou, China. 
      flhu@zju.edu.cn.
FAU - Pan, Yongming
AU  - Pan Y
AD  - Experimental Animal Research Center, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Tao, Lingchen
AU  - Tao L
AD  - College of Animal Sciences, Zhejiang University, Hangzhou, China. 
      flhu@zju.edu.cn.
FAU - Ma, Quanxin
AU  - Ma Q
AD  - College of Animal Sciences, Zhejiang University, Hangzhou, China. 
      flhu@zju.edu.cn.
FAU - Zhang, Guozhi
AU  - Zhang G
AD  - College of Animal Sciences, Zhejiang University, Hangzhou, China. 
      flhu@zju.edu.cn.
FAU - Hu, Fuliang
AU  - Hu F
AD  - College of Animal Sciences, Zhejiang University, Hangzhou, China. 
      flhu@zju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220221
PL  - England
TA  - Food Funct
JT  - Food & function
JID - 101549033
RN  - 0 (10-hydroxydecanoic acid)
RN  - 0 (Decanoic Acids)
RN  - 0 (Fatty Acids)
RN  - 0 (Neuroprotective Agents)
RN  - L497I37F0C (royal jelly)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/chemistry/*pharmacology
MH  - Astrocytes/drug effects
MH  - Bees
MH  - Decanoic Acids/administration & dosage/chemistry/*pharmacology
MH  - Disease Models, Animal
MH  - Drug Synergism
MH  - Fatty Acids
MH  - Functional Food
MH  - Male
MH  - Maze Learning/drug effects
MH  - Memory Disorders/*prevention & control
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neuroinflammatory Diseases/*prevention & control
MH  - Neuroprotective Agents/administration & dosage/chemistry/*pharmacology
MH  - Random Allocation
EDAT- 2022/02/11 06:00
MHDA- 2022/03/12 06:00
CRDT- 2022/02/10 12:14
PHST- 2022/02/11 06:00 [pubmed]
PHST- 2022/03/12 06:00 [medline]
PHST- 2022/02/10 12:14 [entrez]
AID - 10.1039/d1fo02397g [doi]
PST - epublish
SO  - Food Funct. 2022 Feb 21;13(4):2336-2353. doi: 10.1039/d1fo02397g.

PMID- 14565783
OWN - NLM
STAT- MEDLINE
DCOM- 20040401
LR  - 20181113
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 20
IP  - 12
DP  - 2003
TI  - Rationale for a trial of low-dose aspirin for the primary prevention of major 
      adverse cardiovascular events and vascular dementia in the elderly: Aspirin in 
      Reducing Events in the Elderly (ASPREE).
PG  - 897-903
AB  - Low-dose aspirin (acetylsalicylic acid) therapy has been shown to reduce the risk 
      of vascular events and there is increasing evidence of its potential to reduce 
      the rate of cognitive decline in the elderly. Adverse effects including 
      gastrointestinal and intracranial haemorrhage may offset these benefits. The 
      balance of risks versus benefits of aspirin for the primary prevention of 
      cardiovascular disease and vascular dementia has not been established in the 
      elderly. There is clearly a need to conduct a study in family practice to 
      investigate whether routine use of low-dose aspirin for the primary prevention of 
      cardiovascular disease and vascular dementia in the elderly is beneficial or 
      harmful. Aspirin in reducing events in the elderly (ASPREE) is a 
      placebo-controlled trial of low-dose aspirin for the primary prevention of major 
      adverse cardiovascular events and vascular dementia. It will follow 15,000 
      subjects aged 70 years or more for an average of 5 years. This sample size has a 
      power of 87% to detect a 15% reduction in primary events in the aspirin group, 
      with an anticipated combined primary event rate of 20 per 1000 patient years.
FAU - Nelson, Mark
AU  - Nelson M
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Alfred 
      Hospital, Prahan, Victoria, Australia. mark.nelson@med.monash.edu.au
FAU - Reid, Christopher
AU  - Reid C
FAU - Beilin, Lawrence
AU  - Beilin L
FAU - Donnan, Geoffrey
AU  - Donnan G
FAU - Johnston, Colin
AU  - Johnston C
FAU - Krum, Henry
AU  - Krum H
FAU - Storey, Elsdon
AU  - Storey E
FAU - Tonkin, Andrew
AU  - Tonkin A
FAU - McNeil, John
AU  - McNeil J
CN  - Aspirin in Reducing Events in the Elderly (ASPREE) Study Group,
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Dementia, Vascular/mortality/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
EDAT- 2003/10/21 05:00
MHDA- 2004/04/02 05:00
CRDT- 2003/10/21 05:00
PHST- 2003/10/21 05:00 [pubmed]
PHST- 2004/04/02 05:00 [medline]
PHST- 2003/10/21 05:00 [entrez]
AID - 20124 [pii]
AID - 10.2165/00002512-200320120-00004 [doi]
PST - ppublish
SO  - Drugs Aging. 2003;20(12):897-903. doi: 10.2165/00002512-200320120-00004.

PMID- 7635350
OWN - NLM
STAT- MEDLINE
DCOM- 19950914
LR  - 20190825
IS  - 0891-5849 (Print)
IS  - 0891-5849 (Linking)
VI  - 19
IP  - 1
DP  - 1995 Jul
TI  - Diaspirin crosslinked hemoglobin (DCLHb): absence of increased free radical 
      generation following administration in a rabbit model of renal ischemia and 
      reperfusion.
PG  - 1-9
AB  - In control rabbits, a renal ischemia of 60 min followed by 10 min of reperfusion 
      resulted in an enhanced free radical production in cortical tissue, as assessed 
      by a significant decrease of free glutathione (42%), protein-bound GSH (17%), and 
      vitamin E (49%). In contrast, catalase or glutathione peroxidase activities were 
      not affected by these experimental conditions. Free radical production in this 
      model was also measured directly using electron spin resonance (ESR) spectroscopy 
      associated with a PBN (alpha-phenyl N-tert-butyl-nitrone) spin trap agent in the 
      venous blood arising from the ischemic kidney. The signal consisted of a triplet 
      of doublets. In contrast, no signal could be detected in control blood samples 
      taken prior to inducing ischemia. The burst of free radical production occurred 
      in the early phase after restoration of flow in the kidneys rendered ischemic, as 
      evidenced by a signal of weak intensity which generally appeared within the third 
      minute after reperfusion and progressively increased to form a well-defined 
      asymmetric signal following 10 min of reperfusion. The precise nature of free 
      radicals trapped by the PBN agent remains, however, to be elucidated, but 
      analysis of the coupling constants (aN = 14.5-15 G; a beta H = 2.5-3 G) and 
      asymmetry of the central doublets suggests that the ESR signal may arise from a 
      nitorxy-radical adduct resulting from the spin trapping by PBN of both oxygen- or 
      carbon-centered radicals of lipid origin. As evidenced by both direct and 
      indirect measurements, exchange of rabbit blood immediately after inducing renal 
      ischemia with 30 ml/kg of Diaspirin Crosslinked Hemoglobin (7.5 g/dl in lactated 
      electrolyte) or human serum albumin (7.5 g/dl in lactated electrolyte) did not 
      exacerbate free radical production mediated by an ischemia reperfusion 
      phenomenon, a typical situation found in a resuscitation setting.
FAU - Pincemail, J
AU  - Pincemail J
AD  - Centre Interdisciplinaire de la Biochimie de l'Oxygène, University of Liège, 
      Belgium.
FAU - Detry, O
AU  - Detry O
FAU - Philippart, C
AU  - Philippart C
FAU - Defraigne, J O
AU  - Defraigne JO
FAU - Franssen, C
AU  - Franssen C
FAU - Burhop, K
AU  - Burhop K
FAU - Deby, C
AU  - Deby C
FAU - Meurisse, M
AU  - Meurisse M
FAU - Lamy, M
AU  - Lamy M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Free Radic Biol Med
JT  - Free radical biology & medicine
JID - 8709159
RN  - 0 (Cyclic N-Oxides)
RN  - 0 (Free Radicals)
RN  - 0 (Hemoglobins)
RN  - 0 (Nitrogen Oxides)
RN  - 0 (Spin Labels)
RN  - 1406-18-4 (Vitamin E)
RN  - 3I91332OPG (phenyl-N-tert-butylnitrone)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Cyclic N-Oxides
MH  - Disease Models, Animal
MH  - Electron Spin Resonance Spectroscopy
MH  - Free Radicals
MH  - Glutathione/metabolism
MH  - Hemoglobins/administration & dosage/*pharmacology
MH  - Ischemia/*metabolism
MH  - Kidney/*blood supply
MH  - Kidney Cortex/metabolism
MH  - Nitrogen Oxides
MH  - Rabbits
MH  - *Reperfusion
MH  - Spin Labels
MH  - Vitamin E/metabolism
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
AID - 089158499400219A [pii]
AID - 10.1016/0891-5849(94)00219-a [doi]
PST - ppublish
SO  - Free Radic Biol Med. 1995 Jul;19(1):1-9. doi: 10.1016/0891-5849(94)00219-a.

PMID- 8328716
OWN - NLM
STAT- MEDLINE
DCOM- 19930812
LR  - 20161123
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 71
IP  - 1
DP  - 1993 Jul
TI  - Dosimeter inhalation test with lysine acetylsalicylate for the detection of 
      aspirin-induced asthma.
PG  - 61-5
AB  - Inhalation challenge with lysine acetylsalicylate (L-ASA) is often used to 
      diagnose aspirin-induced asthma. The aim of this study was to evaluate the 
      specificity and safety of performing L-ASA inhalation challenge with a dosimeter. 
      Twenty-four subjects entered the study: ten ASA-sensitive asthmatic patients, 
      seven non-ASA-sensitive asthmatic patients, and seven normal control subjects. 
      The investigation was performed on two consecutive days. On day 1 a dosimeter 
      inhalation test with methacholine was performed to establish the provocation dose 
      (PD20). On day 2, patients underwent the L-ASA inhalation test, whereby 
      increasing doses of L-ASA (from 1 to 32 mg cumulative dose) were inhaled using a 
      dosimeter and a dose response curve was constructed. In subjects negative to the 
      top dose, an additional oral dose of 500 mg of aspirin was administered to 
      exclude aspirin sensitivity not revealed with the inhaled drug. The ten 
      ASA-sensitive asthmatic patients developed early reactions within 30 minutes of 
      PD20 administration. Recovery time from induced bronchoconstriction varied from 
      two to three hours to six hours or longer resulting in an "early prolonged 
      reaction." The response was limited to airways. No clear late reactions were 
      observed. There was no correlation between PD20 with methacholine and PD20 with 
      L-ASA. The L-ASA challenge was negative in the seven non-ASA-sensitive asthmatic 
      patients and in the seven normal control subjects. In conclusion the dosimeter 
      method is sensitive, specific, and safe for the detection of aspirin-induced 
      asthma.
FAU - Melillo, G
AU  - Melillo G
AD  - Foundation Clinica del Lavoro, Division of Pharmacology, Campoli, Italy.
FAU - Padovano, A
AU  - Padovano A
FAU - Cocco, G
AU  - Cocco G
FAU - Masi, C
AU  - Masi C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/administration & dosage/*adverse effects/*analogs & derivatives
MH  - Asthma/*chemically induced/*diagnosis
MH  - Bronchi/drug effects/physiology
MH  - Bronchial Provocation Tests/*methods
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Time Factors
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1993 Jul;71(1):61-5.

PMID- 3393733
OWN - NLM
STAT- MEDLINE
DCOM- 19880818
LR  - 20131121
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 60
IP  - 2
DP  - 1988 May
TI  - Antiinflammatory activities of copper-aspirinate and aspirin in adjuvant 
      arthritic rats.
PG  - 257-60
AB  - The antiinflammatory activities of copper aspirinate and aspirin were determined 
      in adjuvant arthritic rats following oral administration for twenty-one days. 
      Results clearly indicated that copper aspirinate acts as a mixed 
      agonist/antagonist showing agonist action at lower doses and antagonist action at 
      higher doses.
FAU - Kishore, V
AU  - Kishore V
AD  - College of Pharmacy, Xavier University of Louisiana, New Orleans 70125.
LA  - eng
GR  - S06RR08008/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Arthritis/*drug therapy
MH  - Arthritis, Experimental/*drug therapy
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Body Weight
MH  - Edema/prevention & control
MH  - Foot
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1988 May;60(2):257-60.

PMID- 21054811
OWN - NLM
STAT- MEDLINE
DCOM- 20111209
LR  - 20181201
IS  - 1751-553X (Electronic)
IS  - 1751-5521 (Linking)
VI  - 33
IP  - 1
DP  - 2011 Feb
TI  - Resistance to aspirin and clopidogrel therapy.
PG  - 1-18
LID - 10.1111/j.1751-553X.2010.01268.x [doi]
AB  - INTRODUCTION: Despite increasing evidence on the roles of aspirin and clopidogrel 
      in decreasing morbidity and mortality from cardiovascular disease, resistance to 
      therapy remains an emerging clinical entity. The aim of this review was to 
      revisit current knowledge of the mechanisms, laboratory evaluation, clinical 
      impact and management of resistance to aspirin and clopidogrel therapy. METHODS: 
      Potentially relevant studies were identified from an electronic search of MEDLINE 
      and PubMed databases. There were no language or publication year restrictions. 
      References in published articles were also reviewed. RESULTS: Several definitions 
      for resistance have been set, and various laboratory testing modalities are 
      available. The pathophysiological mechanisms remain poorly understood; yet, 
      several extrinsic, intrinsic and genetic factors are described. The clinical 
      implications of this phenomenon are alarming and warrant concern. Management is 
      currently limited to dosing alteration and introduction of other antiplatelet 
      agents. CONCLUSION: Data from ongoing and future studies are awaited to better 
      understand this entity and to highlight the most appropriate treatment 
      strategies.
CI  - © 2010 Blackwell Publishing Ltd.
FAU - Musallam, K M
AU  - Musallam KM
AD  - Department of Internal Medicine, American University of Beirut Medical Center, 
      Riad El Solh 1107-2020, Beirut, Lebanon.
FAU - Charafeddine, K
AU  - Charafeddine K
FAU - Bitar, A
AU  - Bitar A
FAU - Khoury, M
AU  - Khoury M
FAU - Assaad, S
AU  - Assaad S
FAU - Beresian, J
AU  - Beresian J
FAU - Alam, S
AU  - Alam S
FAU - Taher, A T
AU  - Taher AT
LA  - eng
PT  - Journal Article
DEP - 20101103
PL  - England
TA  - Int J Lab Hematol
JT  - International journal of laboratory hematology
JID - 101300213
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clopidogrel
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2010/11/09 06:00
MHDA- 2011/12/14 06:00
CRDT- 2010/11/09 06:00
PHST- 2010/11/09 06:00 [entrez]
PHST- 2010/11/09 06:00 [pubmed]
PHST- 2011/12/14 06:00 [medline]
AID - 10.1111/j.1751-553X.2010.01268.x [doi]
PST - ppublish
SO  - Int J Lab Hematol. 2011 Feb;33(1):1-18. doi: 10.1111/j.1751-553X.2010.01268.x. 
      Epub 2010 Nov 3.

PMID- 30790162
OWN - NLM
STAT- MEDLINE
DCOM- 20190722
LR  - 20200225
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 47
IP  - 3
DP  - 2019 Apr
TI  - Increased exercise-related platelet activation assessed by impedance aggregometry 
      in diabetic patients despite aspirin therapy.
PG  - 396-402
LID - 10.1007/s11239-019-01825-w [doi]
AB  - Aspirin is widely used for the prevention of thromboembolic diseases, but 
      inhibition of platelet aggregation (PA) is not uniform. Additionally, aspirin has 
      been shown to be ineffective in blunting PA in response to exercise in patients 
      with coronary artery disease (CAD). Limited data exists about platelet function 
      following acute exercise in diabetics taking aspirin. In our study, we aimed to 
      investigate PA before and after exercise stress test in type-2 diabetic patients 
      taking aspirin. Forty-three patients with type-2 diabetes mellitus (DM) and 36 
      subjects (age- and sex-matched) as control group were included prospectively. All 
      participants were under aspirin (100 mg/day) therapy for at least 1 week. The 
      measures of PA were assessed by impedance aggregometry using arachidonic acid as 
      an agonist (ASPI test). Blood samplings were undertaken before and immediately 
      after treadmill exercise test. At rest, diabetic and control groups had 
      comparable pre-exercise PA (22.97 ± 14.57 versus 22.11 ± 12.71 AU min, p = NS, 
      respectively). After treadmill exercise, both groups showed significantly higher 
      absolute increase (9.02 ± 13.08 and 3.66 ± 5.87 AU min, p < 0.01, p < 0.01, 
      respectively) and percent (%) increase (45.67 ± 49.34 and 24.04 ± 46.59 AU min, 
      p < 0.01, p = 0.01, respectively) in PA. Both absolute increase (p < 0.05) and % 
      increase (p < 0.05) in PA were significantly higher in DM group compared to the 
      control group. Multiple regression analysis revealed that high-sensitive 
      C-reactive protein (p = 0.014) was independent predictor of absolute increase PA. 
      Our study showed that aspirin has limited effect in inhibiting exercise-induced 
      PA, even in the absence of documented CAD. The increase in PA following exercise 
      was significantly greater in patients with DM compared with controls.
FAU - Çakır, Hakan
AU  - Çakır H
AUID- ORCID: 0000-0002-9741-5426
AD  - Department of Cardiology, Bursa Yuksek İhtisas Training and Research Hospital, 
      Health Sciences University, Bursa, Turkey. dr.hcakir@gmail.com.
FAU - Kaymaz, Cihangir
AU  - Kaymaz C
AD  - Department of Cardiology, Kartal Koşuyolu Cardiovascular Research and Training 
      Hospital, Health Sciences University, Istanbul, Turkey.
FAU - Tanboga, İbrahim Halil
AU  - Tanboga İH
AD  - Department of Cardiology, Ataturk University Medical School, Erzurum, Turkey.
FAU - Çakır, Hilal
AU  - Çakır H
AD  - Department of Internal Medicine, Kelkit State Hospital, Gümüşhane, Turkey.
FAU - Tokgöz, Hacer Ceren
AU  - Tokgöz HC
AD  - Department of Cardiology, Kartal Koşuyolu Cardiovascular Research and Training 
      Hospital, Health Sciences University, Istanbul, Turkey.
FAU - Hakgör, Aykun
AU  - Hakgör A
AD  - Department of Cardiology, Kartal Koşuyolu Cardiovascular Research and Training 
      Hospital, Health Sciences University, Istanbul, Turkey.
FAU - Akbal, Özgür Yaşar
AU  - Akbal ÖY
AD  - Department of Cardiology, Kartal Koşuyolu Cardiovascular Research and Training 
      Hospital, Health Sciences University, Istanbul, Turkey.
FAU - Er, Fahri
AU  - Er F
AD  - Department of Cardiology, Bursa Yuksek İhtisas Training and Research Hospital, 
      Health Sciences University, Bursa, Turkey.
FAU - Topal, Dursun
AU  - Topal D
AD  - Department of Cardiology, Bursa Yuksek İhtisas Training and Research Hospital, 
      Health Sciences University, Bursa, Turkey.
FAU - Mutluer, Ferit Onur
AU  - Mutluer FO
AD  - Department of Cardiology, Medicine School, Koc University, Istanbul, Turkey.
FAU - Demir, Mehmet
AU  - Demir M
AD  - Department of Cardiology, Bursa Yuksek İhtisas Training and Research Hospital, 
      Health Sciences University, Bursa, Turkey.
FAU - Tenekecioglu, Erhan
AU  - Tenekecioglu E
AD  - Department of Cardiology, Bursa Yuksek İhtisas Training and Research Hospital, 
      Health Sciences University, Bursa, Turkey.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Specimen Collection
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy
MH  - Electric Impedance
MH  - *Exercise
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Prospective Studies
OTO - NOTNLM
OT  - Aspirin
OT  - Diabetes
OT  - Exercise
OT  - Platelet aggregation
EDAT- 2019/02/23 06:00
MHDA- 2019/07/23 06:00
CRDT- 2019/02/22 06:00
PHST- 2019/02/23 06:00 [pubmed]
PHST- 2019/07/23 06:00 [medline]
PHST- 2019/02/22 06:00 [entrez]
AID - 10.1007/s11239-019-01825-w [pii]
AID - 10.1007/s11239-019-01825-w [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2019 Apr;47(3):396-402. doi: 10.1007/s11239-019-01825-w.

PMID- 26265434
OWN - NLM
STAT- MEDLINE
DCOM- 20170208
LR  - 20170811
IS  - 1873-376X (Electronic)
IS  - 1570-0232 (Linking)
VI  - 1026
DP  - 2016 Jul 15
TI  - A metabolomics strategy to explore urinary biomarkers and metabolic pathways for 
      assessment of interaction between Danhong injection and low-dose aspirin during 
      their synergistic treatment.
PG  - 168-175
LID - S1570-0232(15)30112-4 [pii]
LID - 10.1016/j.jchromb.2015.07.045 [doi]
AB  - The drug combination of Danhong injection (DHI) and low-dose aspirin (ASA) was 
      frequently applied for the treatment of cardiovascular and cerebrovascular 
      diseases. Due to the drug interactions, a lot of potential benefits and risks 
      might exist side by side in the course of combination therapy. However, there had 
      been no studies of interaction between DHI and ASA. Metabolomics was a powerful 
      tool to explore endogenous biomarkers and metabolic pathways. In present study, 
      metabolic profiling with ultra-high-performance liquid chromatography coupled to 
      quadrupole time of flight mass spectrometry (UHPLC-QTOF/MS) coupled with 
      multivariate statistical analysis was performed to provide insight into 
      understanding the interaction between DHI and low-dose ASA. Eleven potential 
      biomarkers of three types were identified and seven metabolic pathways were 
      constructed. The results showed that the interaction between DHI and low-dose ASA 
      during synergistic treatment indeed affected some key endogenous biomarkers and 
      metabolic pathways, which could not happen when DHI or low-dose ASA was used 
      alone. The quality and quantity of endogenous metabolite were both influenced by 
      interaction between DHI and low-dose ASA. In details, the amount of flavin 
      mononucleotide, L-2, 4-diaminobutyric acid (DABA) and 4-aminohippuric acid were 
      significantly increased. On the contrary, the amount of 3-methyluridine, 4, 
      6-dihydroxyquinoline, cortolone-3-glucuronide, and serotonin were significantly 
      decreased. Furthermore, O-phosphotyrosine, 3-methyl-2-butenal, indoxyl sulfate 
      and dolichyl diphosphate were disappeared in urine. As to metabolic pathways, 
      riboflavin metabolism, pentose and glucuronate interconversions, and tryptophan 
      metabolism were all significantly influenced. The emerging alterations of 
      biomarkers and metabolic pathways were associated with a lot of drugs and 
      diseases based on literature researches, which might influence the 
      co-administration of other drugs or the treatments of relevant diseases. Our 
      paper presented some hints to uncover the mechanism of interaction between DHI 
      and low-dose ASA, which would provide some references for application of DHI and 
      low-dose ASA combination.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Li, Jianping
AU  - Li J
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China.
FAU - Guo, Jianming
AU  - Guo J
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China. Electronic address: 
      njuguo@njucm.edu.cn.
FAU - Shang, Erxin
AU  - Shang E
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China.
FAU - Zhu, Zhenhua
AU  - Zhu Z
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China.
FAU - Zhu, Kevin Yue
AU  - Zhu KY
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China.
FAU - Li, Shujiao
AU  - Li S
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China.
FAU - Zhao, Buchang
AU  - Zhao B
AD  - Buchang Pharma, Xi'an 710000, China.
FAU - Jia, Lifu
AU  - Jia L
AD  - Buchang Pharma, Xi'an 710000, China.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Buchang Pharma, Xi'an 710000, China.
FAU - Tang, Zhishu
AU  - Tang Z
AD  - Shanxi University of Chinese Medicine, Xianyang 712000, China.
FAU - Duan, Jinao
AU  - Duan J
AD  - Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative 
      Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 
      University of Chinese Medicine, Nanjing 210023, China. Electronic address: 
      dja@njucm.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20150726
PL  - Netherlands
TA  - J Chromatogr B Analyt Technol Biomed Life Sci
JT  - Journal of chromatography. B, Analytical technologies in the biomedical and life 
      sciences
JID - 101139554
RN  - 0 (Biomarkers)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (danhong)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biomarkers/*urine
MH  - Drug Synergism
MH  - Drugs, Chinese Herbal/administration & dosage/*pharmacology
MH  - Male
MH  - *Metabolomics
MH  - Quality Control
MH  - Rats
MH  - Rats, Sprague-Dawley
OTO - NOTNLM
OT  - Aspirin
OT  - Danhong injection
OT  - Drug combination
OT  - Interaction
OT  - Metabolomics
EDAT- 2015/08/13 06:00
MHDA- 2017/02/09 06:00
CRDT- 2015/08/13 06:00
PHST- 2015/04/30 00:00 [received]
PHST- 2015/06/26 00:00 [revised]
PHST- 2015/07/22 00:00 [accepted]
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
AID - S1570-0232(15)30112-4 [pii]
AID - 10.1016/j.jchromb.2015.07.045 [doi]
PST - ppublish
SO  - J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jul 15;1026:168-175. doi: 
      10.1016/j.jchromb.2015.07.045. Epub 2015 Jul 26.

PMID- 15810326
OWN - NLM
STAT- MEDLINE
DCOM- 20100521
LR  - 20181201
IS  - 1000-0593 (Print)
IS  - 1000-0593 (Linking)
VI  - 18
IP  - 1
DP  - 1998 Feb
TI  - [Cetyltrimethylammonium bromide fluorescence enhancement of aspirin].
PG  - 27-9
AB  - The fluorescence intensities of aspirin with cetyltrimethylammonium bromide 
      enhanced by micellar solutions have been examined. It is found that fluorescence 
      enhancement depend on the concentration of CTAB and pH of solution.
FAU - Zha, J
AU  - Zha J
AD  - Department of Pharmacy, Medical University of Hebei, Shijiazhuang.
FAU - Wang, Y
AU  - Wang Y
FAU - Ji, Y
AU  - Ji Y
FAU - Wang, W
AU  - Wang W
LA  - chi
PT  - Journal Article
PL  - China
TA  - Guang Pu Xue Yu Guang Pu Fen Xi
JT  - Guang pu xue yu guang pu fen xi = Guang pu
JID - 9424805
RN  - 0 (Cetrimonium Compounds)
RN  - 0 (Micelles)
RN  - R16CO5Y76E (Aspirin)
RN  - Z7FF1XKL7A (Cetrimonium)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Cetrimonium
MH  - Cetrimonium Compounds/*chemistry
MH  - Fluorescence
MH  - Hydrogen-Ion Concentration
MH  - Micelles
MH  - Spectrometry, Fluorescence
EDAT- 2005/04/07 09:00
MHDA- 2010/05/22 06:00
CRDT- 2005/04/07 09:00
PHST- 2005/04/07 09:00 [pubmed]
PHST- 2010/05/22 06:00 [medline]
PHST- 2005/04/07 09:00 [entrez]
PST - ppublish
SO  - Guang Pu Xue Yu Guang Pu Fen Xi. 1998 Feb;18(1):27-9.

PMID- 22246632
OWN - NLM
STAT- MEDLINE
DCOM- 20120629
LR  - 20131121
IS  - 1520-6017 (Electronic)
IS  - 0022-3549 (Linking)
VI  - 101
IP  - 4
DP  - 2012 Apr
TI  - Decoupling the effects of surface chemistry and humidity on solid-state 
      hydrolysis of aspirin in the presence of dicalcium phosphate dihydrate.
PG  - 1496-507
LID - 10.1002/jps.23038 [doi]
AB  - Atomic force microscopy (AFM) cantilevers were functionalized with particles of 
      dicalcium phosphate dihydrate (DCP), and AFM, in force-displacement mode, was 
      used to bring these probes into contact with aspirin (100) and (001) surfaces in 
      order to investigate the effect of aspirin surface chemistry on the interaction 
      between the two materials as a function of relative humidity (RH). The force of 
      adhesion measurements showed a strong dependence on RH for the interactions 
      between DCP and the aspirin (100) surface, with stronger interactions occurring 
      at higher humudities. Relatively much weaker interactions were measured between 
      DCP and the aspirin (001) surface under all RH conditions. Topographic imaging 
      showed that contact between DCP and the aspirin (100) surface at high RH led to 
      localised development of etch pits and, in some cases, growth normal to the 
      surface. The methodology allows for the creation of a localised solid-solid 
      interface between pharmaceutically relevant materials, providing a means of 
      studying solid-state excipient-active ingredient decomposition reactions.
CI  - Copyright © 2012 Wiley Periodicals, Inc.
FAU - Cassidy, Andrew M
AU  - Cassidy AM
AD  - Department of Chemistry, University of Cambridge, Cambridge, UK.
FAU - Gardner, Catherine E
AU  - Gardner CE
FAU - Auffret, Tony
AU  - Auffret T
FAU - Aldous, Barry
AU  - Aldous B
FAU - Jones, William
AU  - Jones W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120113
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Calcium Phosphates)
RN  - O7TSZ97GEP (calcium phosphate, dibasic, dihydrate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Calcium Phosphates/*chemistry
MH  - Drug Stability
MH  - Humidity
MH  - Hydrolysis
MH  - Microscopy, Atomic Force
MH  - Surface Properties
EDAT- 2012/01/17 06:00
MHDA- 2012/06/30 06:00
CRDT- 2012/01/17 06:00
PHST- 2011/08/01 00:00 [received]
PHST- 2011/11/16 00:00 [revised]
PHST- 2011/12/13 00:00 [accepted]
PHST- 2012/01/17 06:00 [entrez]
PHST- 2012/01/17 06:00 [pubmed]
PHST- 2012/06/30 06:00 [medline]
AID - S0022-3549(15)31644-0 [pii]
AID - 10.1002/jps.23038 [doi]
PST - ppublish
SO  - J Pharm Sci. 2012 Apr;101(4):1496-507. doi: 10.1002/jps.23038. Epub 2012 Jan 13.

PMID- 37098090
OWN - NLM
STAT- MEDLINE
DCOM- 20230427
LR  - 20230427
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 18
IP  - 4
DP  - 2023
TI  - Aspirin modulates production of pro-inflammatory and pro-resolving mediators in 
      endothelial cells.
PG  - e0283163
LID - 10.1371/journal.pone.0283163 [doi]
LID - e0283163
AB  - Endothelial cells synthesize biochemical signals to coordinate a response to 
      insults, resolve inflammation and restore barrier integrity. Vascular cells 
      release a variety of vasoactive bioactive lipid metabolites during the 
      inflammatory response and produce pro-resolving mediators (e.g., Lipoxin A4, 
      LXA4) in cooperation with leukocytes and platelets to bring a halt to 
      inflammation. Aspirin, used in a variety of cardiovascular and pro-thrombotic 
      disorders (e.g., atherosclerosis, angina, preeclampsia), potently inhibits 
      proinflammatory eicosanoid formation. Moreover, aspirin stimulates the synthesis 
      of pro-resolving lipid mediators (SPM), so-called Aspirin-Triggered Lipoxins 
      (ATL). We demonstrate that cytokines stimulated a time- and dose-dependent 
      increase in PGI2 (6-ketoPGF1α) and PGE2 formation that is blocked by aspirin. 
      Eicosanoid production was caused by cytokine-induced expression of 
      cyclooxygenase-2 (COX-2). We also detected increased production of pro-resolving 
      LXA4 in cytokine-stimulated endothelial cells. The R-enantiomer of LXA4, 
      15-epi-LXA4, was enhanced by aspirin, but only in the presence of cytokine 
      challenge, indicating dependence on COX-2 expression. In contrast to previous 
      reports, we detected arachidonate 5-lipoxygenase (ALOX5) mRNA expression and its 
      cognate protein (5-lipoxygenase, 5-LOX), suggesting that endothelial cells 
      possess the enzymatic machinery necessary to synthesize both pro-inflammatory and 
      pro-resolving lipid mediators independent of added leukocytes or platelets. 
      Finally, we observed that, endothelial cells produced LTB4 in the absence of 
      leukocytes. These results indicate that endothelial cells produce both 
      pro-inflammatory and pro-resolving lipid mediators in the absence of other cell 
      types and aspirin exerts pleiotropic actions influencing both COX and LOX 
      pathways.
CI  - Copyright: © 2023 Rood et al. This is an open access article distributed under 
      the terms of the Creative Commons Attribution License, which permits unrestricted 
      use, distribution, and reproduction in any medium, provided the original author 
      and source are credited.
FAU - Rood, Kara M
AU  - Rood KM
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      College of Medicine and Wexner Medical Center, The Ohio State University, 
      Columbus, Ohio, United States of America.
FAU - Patel, Niharika
AU  - Patel N
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Laboratory of Perinatal Research, College of Medicine and Wexner Medical Center, 
      The Ohio State University, Columbus, Ohio, United States of America.
FAU - DeVengencie, Ivana M
AU  - DeVengencie IM
AUID- ORCID: 0000-0002-3215-849X
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Laboratory of Perinatal Research, College of Medicine and Wexner Medical Center, 
      The Ohio State University, Columbus, Ohio, United States of America.
FAU - Quinn, John P
AU  - Quinn JP
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Laboratory of Perinatal Research, College of Medicine and Wexner Medical Center, 
      The Ohio State University, Columbus, Ohio, United States of America.
FAU - Gowdy, Kymberly M
AU  - Gowdy KM
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal 
      Medicine, College of Medicine and Wexner Medical Center, Columbus, Ohio, United 
      States of America.
AD  - Dorothy Davis Heart and Lung Institute, College of Medicine and Wexner Medical 
      Center, The Ohio State University, Columbus, Ohio, United States of America.
FAU - Costantine, Maged M
AU  - Costantine MM
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      College of Medicine and Wexner Medical Center, The Ohio State University, 
      Columbus, Ohio, United States of America.
FAU - Kniss, Douglas A
AU  - Kniss DA
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      College of Medicine and Wexner Medical Center, The Ohio State University, 
      Columbus, Ohio, United States of America.
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Laboratory of Perinatal Research, College of Medicine and Wexner Medical Center, 
      The Ohio State University, Columbus, Ohio, United States of America.
AD  - Department of Biomedical Engineering, College of Engineering, Fontana Labs, The 
      Ohio State University, Columbus, Ohio, United States of America.
AD  - Infectious Disease Institute, The Ohio State University, Columbus, Ohio, United 
      States of America.
LA  - eng
GR  - UL1 TR002733/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20230425
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - 0 (Lipoxins)
RN  - 0 (Eicosanoids)
RN  - 0 (Cytokines)
SB  - IM
MH  - Humans
MH  - *Aspirin/pharmacology/metabolism
MH  - Cyclooxygenase 2/genetics/metabolism
MH  - Endothelial Cells/metabolism
MH  - *Lipoxins/pharmacology
MH  - Inflammation/metabolism
MH  - Eicosanoids/metabolism
MH  - Cytokines/metabolism
PMC - PMC10128936
COIS- The authors have declared that no competing interests exist.
EDAT- 2023/04/25 18:42
MHDA- 2023/04/27 06:42
CRDT- 2023/04/25 13:44
PHST- 2022/06/03 00:00 [received]
PHST- 2023/03/02 00:00 [accepted]
PHST- 2023/04/27 06:42 [medline]
PHST- 2023/04/25 18:42 [pubmed]
PHST- 2023/04/25 13:44 [entrez]
AID - PONE-D-22-15963 [pii]
AID - 10.1371/journal.pone.0283163 [doi]
PST - epublish
SO  - PLoS One. 2023 Apr 25;18(4):e0283163. doi: 10.1371/journal.pone.0283163. 
      eCollection 2023.

PMID- 7381739
OWN - NLM
STAT- MEDLINE
DCOM- 19800828
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 69
IP  - 5
DP  - 1980 May
TI  - Aspirin--a national survey I: Semiautomated determination of aspirin in bulk and 
      tablet formulations and salicyclic acid in tablet formulations.
PG  - 544-8
AB  - A semiautomated assay to determine aspirin (acetylsalicylic acid) in aspirin 
      tablets, powdered tablet composites, and pure drug substances is presented. The 
      sample was dissolved in alcoholic buffer, diluted, and extracted with chloroform. 
      The absorbance of the chloroform solution was read at 280 nm. Results obtained by 
      the USP XIX and semiautomated methods are compared. The proposed method is 
      accurate and precise, and common excipients do not interfere. Recoveries of 100% 
      were obtained. A semiautomated assay for salicylic acid in aspirin tablets also 
      is presented. The sample was dissolved in alcoholic buffer, ferric nitrate was 
      added, and the absorbance of the resulting purple color was read at 532 nm. The 
      method is suitable as a rapid screening procedure for testing the salicylic acid 
      content of aspirin products. Results obtained by the USP XIX and semiautomated 
      methods are compared, and the accuracy and precision of the proposed method are 
      given. One hundred seventy tablet samples and 34 bulk drug substances were 
      analyzed for aspirin and salicylic acid content. Approximately 5% of the tablet 
      samples failed to meet the USP XIX limits for aspirin content, and 10% failed to 
      meet the limits for salicylic acid.
FAU - Juhl, W E
AU  - Juhl WE
FAU - Kirchhoefer, R D
AU  - Kirchhoefer RD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Autoanalysis/*methods
MH  - Colorimetry
MH  - Hydrolysis
MH  - Salicylates/*analysis
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets
EDAT- 1980/05/01 00:00
MHDA- 1980/05/01 00:01
CRDT- 1980/05/01 00:00
PHST- 1980/05/01 00:00 [pubmed]
PHST- 1980/05/01 00:01 [medline]
PHST- 1980/05/01 00:00 [entrez]
AID - S0022-3549(15)43193-4 [pii]
AID - 10.1002/jps.2600690517 [doi]
PST - ppublish
SO  - J Pharm Sci. 1980 May;69(5):544-8. doi: 10.1002/jps.2600690517.

PMID- 2385209
OWN - NLM
STAT- MEDLINE
DCOM- 19900920
LR  - 20131121
IS  - 0723-5003 (Print)
IS  - 0723-5003 (Linking)
VI  - 85
IP  - 7
DP  - 1990 Jul 15
TI  - [Gastrointestinal tolerance of 30 mg versus 300 mg acetylsalicylic acid daily. An 
      endoscopically controlled double-blind study of healthy subjects].
PG  - 429-31
AB  - Acetylsalicylic acid (ASS) is increasingly used in the prevention of 
      cardiovascular diseases. In recent years daily ASS-doses (100 to 300 mg) have 
      been given for this indication. Studies with still lower ASS-doses (f. i. 30 mg 
      daily) are the focus of ongoing clinical trials. In a randomized double-blind 
      study we have evaluated the gastroduodenal tolerability of 30 mg ASS and 300 mg 
      ASS daily in 20 healthy volunteers using upper GI-endoscopy. Both ASS-dosages 
      have been taken for a period of four weeks. Endoscopic controls were performed at 
      entry and repeated after seven, 14 and 28 days of treatment. 30 mg ASS daily did 
      not induce significant gastroduodenal damages during the whole treatment period 
      in contrast to 300 mg ASS daily (p less than 0.05). The lesions score under 300 
      mg ASS on day 7 and 28 was almost identical. Our data suggest that extremely low 
      doses of ASS are almost harmless to the human gastroduodenal mucosa. No adaptive 
      phenomena occur during a 28 days treatment with 300 mg ASS daily.
FAU - Müller, P
AU  - Müller P
AD  - Medizinische Universitätsklinik Heidelberg, Gastroenterologische Abteilung.
FAU - Dammann, H G
AU  - Dammann HG
FAU - Marinis, E
AU  - Marinis E
FAU - Simon, B
AU  - Simon B
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Gastroduodenale Verträglichkeit von 30 mg versus 300 mg Acetylsalicylsäure 
      täglich. Eine endoskopisch kontrollierte Doppelblindstudie an gesunden Probanden.
PL  - Germany
TA  - Med Klin (Munich)
JT  - Medizinische Klinik (Munich, Germany : 1983)
JID - 8303501
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Duodenum/*drug effects
MH  - Endoscopy
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Intestinal Mucosa/drug effects
MH  - Male
MH  - Random Allocation
EDAT- 1990/07/15 00:00
MHDA- 2000/03/22 09:00
CRDT- 1990/07/15 00:00
PHST- 1990/07/15 00:00 [pubmed]
PHST- 2000/03/22 09:00 [medline]
PHST- 1990/07/15 00:00 [entrez]
PST - ppublish
SO  - Med Klin (Munich). 1990 Jul 15;85(7):429-31.

PMID- 3768378
OWN - NLM
STAT- MEDLINE
DCOM- 19861210
LR  - 20190609
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 874
IP  - 1
DP  - 1986 Nov 7
TI  - Bovine hemoglobin as a potential source of hemoglobin-based oxygen carriers: 
      crosslinking with bis(2,3-dibromosalycyl)fumarate.
PG  - 76-81
AB  - Reaction in anaerobic conditions of bovine hemoglobin with 
      bis(2,3-dibromosalycyl)fumarate resulted in new derivatives with P50 in excess of 
      40 mmHg, as determined at 37 degrees C in 0.15 M Cl- at pH 7.4. Although the 
      chromatographic preparations indicated some heterogeneity of the reacted 
      material, the proteins obtained were homogeneous with regard to sedimentation 
      velocity, which showed the presence of only nondissociable tetrameric species. 
      SDS gel electrophoresis showed the presence of a new band with a mobility 
      corresponding approximately to a molecular mass of 32 kDa, indicating the 
      presence of covalent intramolecular crosslinks between subunit pairs. 
      Chromatographic analyses indicated that both alpha and beta chains were 
      chemically modified. The retention times in rats of the crosslinked hemoglobin 
      was 10-times longer than that of untreated hemoglobin.
FAU - Fronticelli, C
AU  - Fronticelli C
FAU - Sato, T
AU  - Sato T
FAU - Orth, C
AU  - Orth C
FAU - Bucci, E
AU  - Bucci E
LA  - eng
GR  - GM-32084/GM/NIGMS NIH HHS/United States
GR  - HL-13164/HL/NHLBI NIH HHS/United States
GR  - HL-33629/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 106044-07-9 (bis(2,3-dibromosalicyl)fumarate)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cattle
MH  - Cross-Linking Reagents/*pharmacology
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Hemoglobins/analysis/*metabolism
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Oxygen/*metabolism
MH  - Protein Conformation
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1986/11/07 00:00
MHDA- 1986/11/07 00:01
CRDT- 1986/11/07 00:00
PHST- 1986/11/07 00:00 [pubmed]
PHST- 1986/11/07 00:01 [medline]
PHST- 1986/11/07 00:00 [entrez]
AID - 0167-4838(86)90104-4 [pii]
AID - 10.1016/0167-4838(86)90104-4 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 1986 Nov 7;874(1):76-81. doi: 10.1016/0167-4838(86)90104-4.

PMID- 32755957
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20220204
IS  - 1751-875X (Electronic)
IS  - 1751-8741 (Print)
IS  - 1751-8741 (Linking)
VI  - 14
IP  - 6
DP  - 2020 Aug
TI  - Chitosan nanoparticles loaded with aspirin and 5-fluororacil enable synergistic 
      antitumour activity through the modulation of NF-κB/COX-2 signalling pathway.
PG  - 479-484
LID - 10.1049/iet-nbt.2020.0002 [doi]
AB  - Based on the enhancement of synergistic antitumour activity to treat cancer and 
      the correlation between inflammation and carcinogenesis, the authors designed 
      chitosan nanoparticles for co-delivery of 5-fluororacil (5-Fu: an as anti-cancer 
      drug) and aspirin (a non-steroidal anti-inflammatory drug) and induced 
      synergistic antitumour activity through the modulation of the nuclear factor 
      kappa B (NF-κB)/cyclooxygenase-2 (COX-2) signalling pathways. The results showed 
      that aspirin at non-cytotoxic concentrations synergistically sensitised 
      hepatocellular carcinoma cells to 5-Fu in vitro. It demonstrated that aspirin 
      inhibited NF-κB activation and suppressed NF-κB regulated COX-2 expression and 
      prostaglandin E2 (PGE2) synthesis. Furthermore, the proposed results clearly 
      indicated that the combination of 5-Fu and aspirin by chitosan nanoparticles 
      enhanced the intracellular concentration of drugs and exerted synergistic growth 
      inhibition and apoptosis induction on hepatocellular carcinoma cells by 
      suppressing NF-κB activation and inhibition of expression of COX-2.
FAU - Wang, Peng
AU  - Wang P
AD  - Department of General Surgery, The First Affiliated Hospital of Jinzhou Medical 
      University, Jinzhou 121000, People's Republic of China.
FAU - Shen, Yaping
AU  - Shen Y
AD  - School of Pharmacy, Jinzhou Medical University, Jinzhou 121000, People's Republic 
      of China.
FAU - Zhao, Liang
AU  - Zhao L
AD  - School of Pharmacy, Jinzhou Medical University, Jinzhou 121000, People's Republic 
      of China. liangzhao79@163.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - IET Nanobiotechnol
JT  - IET nanobiotechnology
JID - 101303205
RN  - 0 (Antineoplastic Agents)
RN  - 0 (NF-kappa B)
RN  - 9012-76-4 (Chitosan)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - *Antineoplastic Agents/chemistry/pharmacokinetics/pharmacology
MH  - *Aspirin/chemistry/pharmacokinetics/pharmacology
MH  - Chitosan/*chemistry
MH  - Cyclooxygenase 2/metabolism
MH  - Drug Synergism
MH  - *Fluorouracil/chemistry/pharmacokinetics/pharmacology
MH  - Hep G2 Cells
MH  - Humans
MH  - NF-kappa B/metabolism
MH  - Nanoparticles/*chemistry
MH  - Signal Transduction/drug effects
PMC - PMC8676317
EDAT- 2020/08/07 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - NBT2BF00715 [pii]
AID - 10.1049/iet-nbt.2020.0002 [doi]
PST - ppublish
SO  - IET Nanobiotechnol. 2020 Aug;14(6):479-484. doi: 10.1049/iet-nbt.2020.0002.

PMID- 572448
OWN - NLM
STAT- MEDLINE
DCOM- 19790925
LR  - 20131121
IS  - 0300-8630 (Print)
IS  - 0300-8630 (Linking)
VI  - 191
IP  - 3
DP  - 1979 May
TI  - [The effect of acetylsalicylic acid on some parameters of peripheral circulation 
      in children (author's transl)].
PG  - 301-4
AB  - Acetylsalicylic acid in a single dose of 10 mg/kg orally affected the skin 
      temperature of the hand of febrile and afebrile children. In the afebrile group 
      the rise of skin temperature after 1 hour (p less than 0,05) and 2 hours (p less 
      than 0.01) was not accompanied by significant change of the sublingual or axillar 
      temperature. In the febrile group the rise of the skin temperature of the 3rd 
      finger after 1 hour (p less than 0,001) and 2 hours (p less than 0.001) was 
      accompanied by a significant decrease of the sublingual and axillar temperature 
      and by a decrease of pulse rate. The changes were more pronounced after 1 hour 
      after administration of the drug. Similarly, the acetylsalicylic acid enhanced 
      the relative blood flow through the skin of the finger of hand.
FAU - Buchanec, J
AU  - Buchanec J
FAU - Visnovský, P
AU  - Visnovský P
FAU - Buchancová, J
AU  - Buchancová J
FAU - Cervenáková, E
AU  - Cervenáková E
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Der Einfluss von Azetylsalizylsäure auf einige Kennziffern der peripheren 
      Zirkulation bei Kindern.
PL  - Germany
TA  - Klin Padiatr
JT  - Klinische Padiatrie
JID - 0326144
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Circulation/*drug effects
MH  - Body Temperature/drug effects
MH  - Child
MH  - Child, Preschool
MH  - Fever
MH  - Fingers/blood supply
MH  - Humans
MH  - Pulse/drug effects
MH  - Regional Blood Flow/drug effects
MH  - Skin Temperature/drug effects
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
PST - ppublish
SO  - Klin Padiatr. 1979 May;191(3):301-4.

PMID- 2588164
OWN - NLM
STAT- MEDLINE
DCOM- 19891229
LR  - 20151119
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 61
IP  - 8
DP  - 1989
TI  - [The late results of aspirin treatment in patients with aspirin-induced bronchial 
      asthma].
PG  - 41-3
AB  - The paper treats long-term results of aspirin treatment of patients with 
      aspirin-induced bronchial asthma. The data obtained indicate that in this 
      patients' group, the beneficial effect of aspirin treatment is also preserved 
      after its withdrawal at any rate within up to one year. The authors have every 
      reason to believe that such a treatment is unlikely to be applied for life.
FAU - Chuchalin, A G
AU  - Chuchalin AG
FAU - Priputenova, Z V
AU  - Priputenova ZV
FAU - Sulakvelidze, I V
AU  - Sulakvelidze IV
LA  - rus
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Otdalennye rezul'taty lecheniia aspirinom bol'nykh aspirinovoĭ bronkhial'noĭ 
      astmoĭ.
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/*drug therapy
MH  - Desensitization, Immunologic/methods
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Ter Arkh. 1989;61(8):41-3.

PMID- 8605
OWN - NLM
STAT- MEDLINE
DCOM- 19761101
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 28
IP  - 7
DP  - 1976 Jul
TI  - Colorimetric analysis of immunogenic impurities in acetylsalicylic acid.
PG  - 544-7
AB  - A rapid and convenient colorimetric method is described for the quantitative 
      determination of the immunogenic impurities in acetylsalicylic acid, 
      acetylsalicylsalicylic acid and acetylsalicylic anhydride. The method involves 
      initial aminolysis of the compounds by ammonia to give salicylamide and 
      subsequent coupling of this with 4-amino-phenazone in the presence of an 
      oxidizing agent. In conjunction with a previously described method for analysis 
      of the anhydride the method allows a specific determination of 
      acetylsalicylsalicylic acid in concentrations down to 0-005%. Applying the 
      methods to 15 different commercial acetylsalicylic acid samples and formulations, 
      acetylsalicylic anhydride and acetylsalicylsalicylic acid were found to be 
      present in amounts ranging from 0-001 to 0-024% and from 0-006 to 0-58% (w/w), 
      respectively.
FAU - Bungaard, H
AU  - Bungaard H
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Anhydrides)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anhydrides/analysis
MH  - Aspirin/*analysis
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Colorimetry
MH  - Drug Contamination
MH  - Methods
MH  - Tablets/analysis
MH  - Time Factors
EDAT- 1976/07/01 00:00
MHDA- 1976/07/01 00:01
CRDT- 1976/07/01 00:00
PHST- 1976/07/01 00:00 [pubmed]
PHST- 1976/07/01 00:01 [medline]
PHST- 1976/07/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1976.tb02791.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1976 Jul;28(7):544-7. doi: 10.1111/j.2042-7158.1976.tb02791.x.

PMID- 7844233
OWN - NLM
STAT- MEDLINE
DCOM- 19950307
LR  - 20220419
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 9
IP  - 10
DP  - 1994 Oct
TI  - The benefits of low-dose aspirin therapy in women with impaired uterine perfusion 
      during assisted conception.
PG  - 1954-7
AB  - The objective of this long-running study was to determine whether the addition of 
      low-dose aspirin to a standard hormone replacement therapy (HRT) protocol 
      improved uterine perfusion during assisted conception. A total of 99 women 
      scheduled for frozen embryo replacement were studied. Endometrial preparation was 
      with a standard buserelin/HRT protocol. Uterine perfusion was assessed by Doppler 
      ultrasound and classified as impaired or normal. In their first attempts, those 
      with impaired perfusion (group I, n = 37) received low doses of aspirin [150 mg 
      (n = 26) or 300 mg daily (n = 11)], starting from day 13 of HRT. Women with 
      normal perfusion (group II) did not receive aspirin. In subsequent attempts, 
      those from group I were arbitrarily allocated to start aspirin on day 1 or day 13 
      of HRT, and 10 women from group II were arbitrarily selected to receive aspirin 
      from day 1 of HRT. In group I, the cancellation (46 versus 36%) and pregnancy 
      rates (15 versus 25%) in those who received 150 or 300 mg aspirin daily were 
      similar. In those with cancelled first attempts, good perfusion was achieved in 
      82 versus 20% (P < 0.02) of subsequent attempts using aspirin from day 1 versus 
      day 13 of HRT. Higher pregnancy rates (47 versus 17%) were achieved in those 
      taking aspirin from day 1 of HRT. In group II, pregnancy rates were not 
      statistically different in those who did or did not receive aspirin during their 
      subsequent attempts (10 versus 35%). The addition of low-dose aspirin to a 
      standard HRT protocol in women with impaired uterine perfusion is associated with 
      improved blood flow and satisfactory pregnancy rates.
FAU - Wada, I
AU  - Wada I
AD  - Bourn Hall Clinic, Cambridge, UK.
FAU - Hsu, C C
AU  - Hsu CC
FAU - Williams, G
AU  - Williams G
FAU - Macnamee, M C
AU  - Macnamee MC
FAU - Brinsden, P R
AU  - Brinsden PR
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 61489-71-2 (Menotropins)
RN  - 9002-68-0 (Follicle Stimulating Hormone)
RN  - PXW8U3YXDV (Buserelin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Flow Velocity
MH  - Buserelin/therapeutic use
MH  - Cryopreservation
MH  - Female
MH  - *Fertilization in Vitro
MH  - Follicle Stimulating Hormone/therapeutic use
MH  - Humans
MH  - Menotropins/therapeutic use
MH  - Pregnancy
MH  - Uterus/*blood supply
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.humrep.a138366 [doi]
PST - ppublish
SO  - Hum Reprod. 1994 Oct;9(10):1954-7. doi: 10.1093/oxfordjournals.humrep.a138366.

PMID- 6104131
OWN - NLM
STAT- MEDLINE
DCOM- 19800825
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 8182
DP  - 1980 Jun 21
TI  - Reduction by aspirin of intestinal fluid-loss in acute childhood gastroenteritis.
PG  - 1329-30
AB  - Soluble aspirin was given by mouth in therapeutic doses in a double-blind trial 
      to malnourished infants and young children with gastroenteritis and dehydration. 
      Faecal fluid-losses were reduced and weight-grain was enhanced in the group given 
      aspirin. These effects were statistically significant when compared with those 
      obtained with a placebo preparation and in a group of patients given supportive 
      therapy but no specific drug treatment. The results suggest that aspirin may be 
      useful in reducing intestinal fluid-loss in childhood gastroenteritis. Before the 
      widespread use of aspirin can be recommended, its effects in patients not under 
      hospital supervision must be determined.
FAU - Burke, V
AU  - Burke V
FAU - Gracey, M
AU  - Gracey M
FAU - Suharyono
AU  - Suharyono
FAU - Sunoto
AU  - Sunoto
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Bacterial Infections
MH  - Body Weight/drug effects
MH  - Clinical Trials as Topic
MH  - Dehydration/*prevention & control
MH  - Diarrhea, Infantile/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Gastroenteritis/*drug therapy/etiology
MH  - Humans
MH  - Infant
MH  - Intestinal Secretions/drug effects
MH  - Male
MH  - Secretory Rate/drug effects
OID - PIP: 803195
OID - POP: 00083414
OAB - A double-blind clinical trial to test the hypothesis that soluble buffered 
      aspirin may control fluid loss in the presence of a range of microorganisms 
      commonly found in upper intestinal secretions of malnourished children with 
      diarrhea was performed on malnourished Indonesian children with acute diarrhea. 
      Soluble aspirin was given by mouth. Fecal fluid losses were reduced and weight 
      gain was enhanced in the aspirin group but not in the placebo (aspirin was given 
      in therapeutic doses of 25 mg/kg/day). The stool volume decrease was 
      statistically significant in the aspirin group (P .05).
OABL- eng
OTO - PIP
OT  - Age Factors
OT  - Biology
OT  - Demographic Factors
OT  - *Diarrhea
OT  - Diseases
OT  - *Double-blind Studies
OT  - *Fluid Balance
OT  - Homeostasis
OT  - *Infant
OT  - *Malnutrition
OT  - Nutrition Disorders
OT  - *Oral Rehydration
OT  - Physiology
OT  - Population
OT  - Population Characteristics
OT  - Research Methodology
OT  - Studies
OT  - Treatment
OT  - Youth
GN  - PIP: TJ: LANCET.
EDAT- 1980/06/21 00:00
MHDA- 1980/06/21 00:01
CRDT- 1980/06/21 00:00
PHST- 1980/06/21 00:00 [pubmed]
PHST- 1980/06/21 00:01 [medline]
PHST- 1980/06/21 00:00 [entrez]
AID - S0140-6736(80)91786-9 [pii]
AID - 10.1016/s0140-6736(80)91786-9 [doi]
PST - ppublish
SO  - Lancet. 1980 Jun 21;1(8182):1329-30. doi: 10.1016/s0140-6736(80)91786-9.

PMID- 3266912
OWN - NLM
STAT- MEDLINE
DCOM- 19890713
LR  - 20181113
IS  - 0003-3006 (Print)
IS  - 0003-3006 (Linking)
VI  - 35
IP  - 5
DP  - 1988 Sep-Oct
TI  - Evaluation of low-intensity transcutaneous electrical nerve stimulation in 
      combination with aspirin for reduction of controlled thermal sensation.
PG  - 195-8
AB  - Reductions in cutaneous thermal sensation produced by placebo, aspirin, 
      transcutaneous electrical nerve stimulation, and transcutaneous electrical nerve 
      stimulation plus aspirin were compared in 60 normal volunteers. The combination 
      of transcutaneous electrical nerve stimulation plus aspirin produced a 
      statistically significant reduction as compared with placebo. The results suggest 
      this treatment combination may provide levels of analgesia useful for completion 
      of minor dental procedures.
FAU - Kajander, K C
AU  - Kajander KC
LA  - eng
GR  - DEO7014/DE/NIDCR NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Anesth Prog
JT  - Anesthesia progress
JID - 0043533
RN  - R16CO5Y76E (Aspirin)
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Combined Modality Therapy
MH  - *Electric Stimulation Therapy
MH  - Female
MH  - Hot Temperature
MH  - Humans
MH  - Male
MH  - *Transcutaneous Electric Nerve Stimulation
PMC - PMC2167860
EDAT- 1988/09/01 00:00
MHDA- 1988/09/01 00:01
CRDT- 1988/09/01 00:00
PHST- 1988/09/01 00:00 [pubmed]
PHST- 1988/09/01 00:01 [medline]
PHST- 1988/09/01 00:00 [entrez]
PST - ppublish
SO  - Anesth Prog. 1988 Sep-Oct;35(5):195-8.

PMID- 7381126
OWN - NLM
STAT- MEDLINE
DCOM- 19800828
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 66
IP  - 1
DP  - 1980 Jul
TI  - Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin 
      challenges.
PG  - 82-8
AB  - Two aspirin-sensitive asthmatic patients underwent oral aspirin challenges for 
      investigative purposes. Folowoing the expected respiratory reaction to aspirin, 
      the patients became refractory to the further adverse effects of aspirin. 
      Additionally they began taking 325 mg aspirin per day, and after 6 and 8 mo 
      aspirin dosage was increased to 650 mg per day. We have noted an improvement in 
      their rhinitis and asthma during this open drug trial. Furthermore, maintenance 
      systemic corticosteroids have been reduced in one patient and discontinued in the 
      other without a decline in lung function values. If these intitial observations 
      are found in a larger number of aspirin-sensitive asthmatic patients, changes in 
      our understanding of the pathogenesis of rhinosinusitis-asthma-aspirin syndrome 
      would follow, and treatment for such asthmatic patients might be improved.
FAU - Stevenson, D D
AU  - Stevenson DD
FAU - Simon, R A
AU  - Simon RA
FAU - Mathison, D A
AU  - Mathison DA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Adrenal Cortex Hormones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/drug therapy
MH  - Desensitization, Immunologic
MH  - Drug Tolerance
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Time Factors
EDAT- 1980/07/01 00:00
MHDA- 1980/07/01 00:01
CRDT- 1980/07/01 00:00
PHST- 1980/07/01 00:00 [pubmed]
PHST- 1980/07/01 00:01 [medline]
PHST- 1980/07/01 00:00 [entrez]
AID - 0091-6749(80)90143-8 [pii]
AID - 10.1016/0091-6749(80)90143-8 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1980 Jul;66(1):82-8. doi: 10.1016/0091-6749(80)90143-8.

PMID- 29857271
OWN - NLM
STAT- MEDLINE
DCOM- 20190709
LR  - 20190709
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 167
DP  - 2018 Jul
TI  - Effects of clopidogrel with or without aspirin on the generation of extracellular 
      vesicles in the microcirculation and in venous blood: A randomized placebo 
      controlled trial.
PG  - 149-155
LID - S0049-3848(18)30362-1 [pii]
LID - 10.1016/j.thromres.2018.05.021 [doi]
AB  - BACKGROUND: Dual-antiplatelet therapy (DAPT) is a standard strategy in acute 
      coronary heart disease; however, it confers a considerable bleeding risk. 
      Single-antiplatelet therapy (SAPT) inhibits haemostatic system activation ex vivo 
      to a similar extent as DAPT. Extracellular vesicles (EV) are procoagulant and 
      contribute to haemostatic system activation. We aimed to investigate the effect 
      of DAPT compared with SAPT on EV. METHODS: In a randomized, double-blind, 
      placebo-controlled trial, 44 healthy volunteers received DAPT 
      (clopidogrel + aspirin) or SAPT (clopidogrel + placebo) for 7 days. Blood was 
      obtained from a standardized microvascular injury and through venipuncture at 
      baseline (BL) and at 2 h, 24 h, and 8 days after treatment initiation. The 
      number, origin, and surface expression of EV were assessed using flow cytometry. 
      Data are given as median (quartiles). Non-parametric tests were used to evaluate 
      the short-term (BL vs 2 h) and long-term differences (2 h to 8 days), as well as 
      the differences between treatment groups. RESULTS: There was no difference either 
      in the short-term effects on the number (×10(3) mL(-1)) of EV in microvascular 
      blood between DAPT [BL: 1433 (653; 3184) vs 2 h: 862 (545; 2026), p = 0.39] and 
      SAPT [(BL: 614 (552; 1402) vs 2 h: 1079 (781; 1538), p = 0.75)] or in the 
      long-term effects. DAPT and SAPT did not exhibit differential short-term effects 
      on the number and proportion (36% and 27% vs 55% and 36%) of platelet-derived EV. 
      DAPT and SAPT resulted in a significant short-term increase in phosphatidylserine 
      expression in microvascular blood. The effects of DAPT and SAPT on EV in venous 
      blood were similar to those in microvascular blood. CONCLUSION: DAPT and SAPT 
      have comparable effects on the amount, origin, and surface characteristics of EV.
CI  - Copyright © 2018. Published by Elsevier Ltd.
FAU - Traby, L
AU  - Traby L
AD  - Department of Medicine I, Division of Hematology and Hemostasis and Division of 
      Infectious Diseases and Tropical Medicine, Medical University of Vienna, 
      Waehringer Guertel 18-20, 1090 Vienna, Austria. Electronic address: 
      ludwig.traby@meduniwien.ac.at.
FAU - Kaider, A
AU  - Kaider A
AD  - Center for Medical Statistics, Informatics and Intelligent Systems, Section for 
      Clinical Biometrics, Medical University of Vienna, Waehringer Guertel 18-20, 1090 
      Vienna, Austria. Electronic address: alexandra.kaider@meduniwien.ac.at.
FAU - Kollars, M
AU  - Kollars M
AD  - Department of Medicine I, Division of Hematology and Hemostasis, Medical 
      University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Electronic 
      address: marietta.kollars@meduniwien.ac.at.
FAU - Eichinger, S
AU  - Eichinger S
AD  - Department of Medicine I, Division of Hematology and Hemostasis, Medical 
      University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Electronic 
      address: sabine.eichinger@meduniwien.ac.at.
FAU - Wolzt, M
AU  - Wolzt M
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Waehringer 
      Guertel 18-20, 1090 Vienna, Austria. Electronic address: 
      michael.wolzt@meduniwien.ac.at.
FAU - Kyrle, P A
AU  - Kyrle PA
AD  - Department of Medicine I, Division of Hematology and Hemostasis, Medical 
      University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Electronic 
      address: paul.kyrle@meduniwien.ac.at.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20180517
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Clopidogrel/pharmacology/*therapeutic use
MH  - Extracellular Vesicles/*drug effects
MH  - Healthy Volunteers
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Microcirculation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Coronary heart disease
OT  - Dual-antiplatelet therapy
OT  - Extracellular vesicles
OT  - P2Y12 inhibitors
EDAT- 2018/06/02 06:00
MHDA- 2019/07/10 06:00
CRDT- 2018/06/02 06:00
PHST- 2018/01/12 00:00 [received]
PHST- 2018/05/12 00:00 [revised]
PHST- 2018/05/16 00:00 [accepted]
PHST- 2018/06/02 06:00 [pubmed]
PHST- 2019/07/10 06:00 [medline]
PHST- 2018/06/02 06:00 [entrez]
AID - S0049-3848(18)30362-1 [pii]
AID - 10.1016/j.thromres.2018.05.021 [doi]
PST - ppublish
SO  - Thromb Res. 2018 Jul;167:149-155. doi: 10.1016/j.thromres.2018.05.021. Epub 2018 
      May 17.

PMID- 20690297
OWN - NLM
STAT- MEDLINE
DCOM- 20100824
LR  - 20131121
IS  - 1172-6164 (Print)
IS  - 1172-6156 (Linking)
VI  - 2
IP  - 2
DP  - 2010 Jun
TI  - Aspirin for primary prevention: yes or no?
PG  - 92-9
AB  - AIM: To assess benefit versus harm of aspirin for cardiovascular disease (CVD) 
      primary prevention by age group, gender and risk category and to interpret these 
      results in light of current New Zealand CVD risk assessment and management 
      guidelines. METHODS: Rates of benefit (avoided vascular events) and harm 
      (additional major extracranial bleeds) for each gender and age group were 
      calculated from data from the six randomised controlled trials included in the 
      Anti-Thrombotic Trialists' (ATT) Collaboration meta-analysis. These rates were 
      applied to CVD risk categories to calculate the net benefit or net harm likely to 
      occur from the use of aspirin in primary prevention of CVD as monotherapy and 
      when added to lipid and blood pressure-loweringtherapies. RESULTS: Benefits of 
      aspirin monotherapy outweigh the harms for both men and women aged up to 80 years 
      with calculated five-year CVD risk >15% in primary prevention. Harm may outweigh 
      benefit for primary prevention for those over 80 years. For men 70-79 years the 
      benefit of aspirin in primary prevention is marginal when added to lipid and 
      blood pressure-lowering therapies. DISCUSSION: The recent ATT Collaboration 
      meta-analysis has raised doubts about the relative safety of aspirin in primary 
      prevention of CVD. However, modelling by risk category and age group suggests 
      that current guidelines are justified in recommending aspirin for primary 
      prevention of CVD in those with five-year CVD risk > or = 15% up to the age of 80 
      years. For men 70-79, consider lipid and blood pressure-lowering therapies first 
      then reassess whether aspirin adds additional net benefit.
FAU - Selak, Vanessa
AU  - Selak V
AD  - Clinical Trials Research Unit, School of Population Health, The University of 
      Auckland, Auckland, New Zealand. v.selak@ctru.auckland.ac.nz
FAU - Elley, C Raina
AU  - Elley CR
FAU - Wells, Sue
AU  - Wells S
FAU - Rodgers, Anthony
AU  - Rodgers A
FAU - Sharpe, Norman
AU  - Sharpe N
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Prim Health Care
JT  - Journal of primary health care
JID - 101524060
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Prim Health Care. 2013;5(2):174. PMID: 23894771
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Family Practice
MH  - Female
MH  - Humans
MH  - Hypolipidemic Agents/therapeutic use
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Primary Prevention/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
EDAT- 2010/08/10 06:00
MHDA- 2010/08/25 06:00
CRDT- 2010/08/10 06:00
PHST- 2010/08/10 06:00 [entrez]
PHST- 2010/08/10 06:00 [pubmed]
PHST- 2010/08/25 06:00 [medline]
PST - ppublish
SO  - J Prim Health Care. 2010 Jun;2(2):92-9.

PMID- 21193940
OWN - NLM
STAT- MEDLINE
DCOM- 20120221
LR  - 20211020
IS  - 0948-5023 (Electronic)
IS  - 0948-5023 (Linking)
VI  - 17
IP  - 10
DP  - 2011 Oct
TI  - The role of hydrogen bonds in an aqueous solution of acetylsalicylic acid: a 
      molecular dynamics simulation study.
PG  - 2485-90
LID - 10.1007/s00894-010-0930-2 [doi]
AB  - This work focuses on the role of the dynamic hydrogen bonds (HB) formed in an 
      aqueous solution of aspirin using molecular dynamics simulation. The statistics 
      reveal the existence of internal HB that inhibit the rotational movements of the 
      acetyl and the carboxylic acid groups, forcing the molecule to adopt a closed 
      conformer structure in water, and playing an important role in stabilizing this 
      conformation.
FAU - Donnamaria, Maria Cristina
AU  - Donnamaria MC
AD  - Instituto de Fisica de Líquidos y Sistemas Biológicos 
      (IFLYSIB)-CONICET-UNLP-CICPBA, CICPBA, C.C. 565, B1900BTE La Plata, Argentina. 
      donna@iflysib.unlp.edu.ar
FAU - de Xammar Oro, Juan Roberto
AU  - de Xammar Oro JR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101231
PL  - Germany
TA  - J Mol Model
JT  - Journal of molecular modeling
JID - 9806569
RN  - 0 (Solutions)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Hydrogen Bonding
MH  - *Molecular Dynamics Simulation
MH  - Solutions
MH  - Vacuum
MH  - Water
EDAT- 2011/01/05 06:00
MHDA- 2012/02/22 06:00
CRDT- 2011/01/04 06:00
PHST- 2010/04/05 00:00 [received]
PHST- 2010/12/06 00:00 [accepted]
PHST- 2011/01/04 06:00 [entrez]
PHST- 2011/01/05 06:00 [pubmed]
PHST- 2012/02/22 06:00 [medline]
AID - 10.1007/s00894-010-0930-2 [doi]
PST - ppublish
SO  - J Mol Model. 2011 Oct;17(10):2485-90. doi: 10.1007/s00894-010-0930-2. Epub 2010 
      Dec 31.

PMID- 7942322
OWN - NLM
STAT- MEDLINE
DCOM- 19941103
LR  - 20190825
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 41
IP  - 3-4
DP  - 1994 May
TI  - Role of aspirin in modulating myocardial ischemic reperfusion injury.
PG  - 151-5
AB  - The role of low-dose aspirin (3 mg/kg, i.v.) in attenuating ischemic reperfusion 
      injury was studied in a canine model. Regional ischemia for 40 min was produced 
      by temporary occlusion of the left anterior descending coronary artery and 
      thereafter reperfusion instituted for 3 h. Mean arterial pressure (MAP), heart 
      rate (HR), left ventricular end diastolic pressure (LVEDP), positive (+) LV 
      dP/dtmax and negative (-) LV dP/dtmax were monitored along with myocardial 
      adenosine triphosphate (ATP), creatine phosphate (CP), glycogen and lactate. 
      Following reperfusion, there was a significant fall in (i) MAP, (ii) (+) LV 
      dP/dtmax and (iii) (-) LV dP/dtmax. LVEDP was corrected after about 2 h of 
      reperfusion. Replenishment of only myocardial CP occurred, without any change in 
      ATP and glycogen, although lactate accumulation was corrected. Aspirin 
      administered 15 min before reperfusion (post-treatment) caused normalisation of 
      LVEDP within 15 min and prevented any deterioration in (-) LV dP/dtmax, although 
      it had no effect on MAP and (+) LV dP/dtmax. After 3 h of reperfusion 
      (post-treatment), myocardial ATP, CP, glycogen and lactate contents became 
      normal. The number of premature ventricular complexes was significantly reduced 
      after aspirin treatment. The present study indicates that low-dose aspirin 
      post-treatment can ameliorate at least some of the deleterious consequences of 
      reperfusion injury of the myocardium.
FAU - Seth, S D
AU  - Seth SD
AD  - Department of Pharmacology, All India Institute of Medical Sciences, Ansari 
      Nagar, New Delhi.
FAU - Maulik, M
AU  - Maulik M
FAU - Manchanda, S C
AU  - Manchanda SC
FAU - Maulik, S K
AU  - Maulik SK
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Lactates)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - 9005-79-2 (Glycogen)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Triphosphate/metabolism
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Creatinine/metabolism
MH  - Disease Models, Animal
MH  - Dogs
MH  - Glycogen/metabolism
MH  - Heart Rate/drug effects
MH  - Injections, Intravenous
MH  - Lactates/metabolism
MH  - Lactic Acid
MH  - Myocardial Ischemia/*drug therapy/mortality
MH  - Myocardial Reperfusion Injury/*drug therapy
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
AID - 10.1007/BF02001909 [doi]
PST - ppublish
SO  - Agents Actions. 1994 May;41(3-4):151-5. doi: 10.1007/BF02001909.

PMID- 36939950
OWN - NLM
STAT- MEDLINE
DCOM- 20230721
LR  - 20230721
IS  - 2211-3436 (Electronic)
IS  - 2211-3428 (Linking)
VI  - 46
IP  - 4
DP  - 2023 Aug
TI  - Dipyridamole enhances the anti-cancer ability of aspirin against colorectal 
      cancer by inducing apoptosis in an unfolded protein response-dependent manner.
PG  - 953-967
LID - 10.1007/s13402-023-00789-7 [doi]
AB  - PURPOSE: Available evidence indicates that dipyridamole enhances the 
      anti-thrombotic effects of aspirin for the prevention of secondary strokes. 
      Aspirin is a well-known non-steroid anti-inflammatory drug. This 
      anti-inflammatory property has turned aspirin into a potential drug for 
      inflammation-related cancers such as colorectal cancer (CRC). Here, we aimed to 
      explore whether the anti-cancer effect of aspirin against CRC could be improved 
      by combined administration with dipyridamole. METHODS: Population-based clinical 
      data analysis was conducted to assess a possible therapeutic effect of combined 
      dipyridamole and aspirin treatment in inhibiting CRC compared with either 
      monotherapy. This therapeutic effect was further verified in different CRC mouse 
      models, i.e. an orthotopic xenograft mouse model, an AOM/DSS mouse model, 
      an Apc(min/+) mouse model and a patient derived xenograft (PDX) mouse model. The 
      in vitro effects of the drugs on CRC cells were tested using CCK8 and flow 
      cytometry assays. RNA-Seq, Western blotting, qRT-PCR and flow cytometry were used 
      to identify the underlying molecular mechanisms. RESULTS: We found that 
      dipyridamole combined with aspirin had a better inhibitory effect on CRC than 
      either monotherapy alone. The enhanced anti-cancer effect of the combined use of 
      dipyridamole with aspirin was found to rely on the induction of an overwhelmed 
      endoplasmic reticulum (ER) stress and subsequent pro-apoptotic unfolded protein 
      response (UPR), which was different from the anti-platelet effect. CONCLUSIONS: 
      Our data indicate that the anti-cancer effect of aspirin against CRC may be 
      enhanced by combined administration with dipyridamole. In case further clinical 
      studies confirm our findings, these may be repurposed as adjuvant agents.
CI  - © 2023. Springer Nature Switzerland AG.
FAU - Huang, Shan
AU  - Huang S
AD  - State Key Laboratory of Oncogenes and Related Genes, Ren Ji Hospital, School of 
      Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, P.R. China.
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 
      P.R. China.
FAU - Zhang, Nai-Qi
AU  - Zhang NQ
AD  - Center for Primary Health Care Research, Lund University/Region Skåne, Lund, 
      Sweden.
FAU - Xu, Chun-Jie
AU  - Xu CJ
AD  - Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, 
      Shanghai Jiao Tong University, Shanghai, P.R. China.
FAU - Huang, Wu-Qing
AU  - Huang WQ
AD  - School of Public Health, Fujian Medical University, Fuzhou City, P.R. China.
FAU - Li, Dong-Xue
AU  - Li DX
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 
      P.R. China.
FAU - Li, Jun
AU  - Li J
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 
      P.R. China.
FAU - Yao, Lin-Li
AU  - Yao LL
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 
      P.R. China.
FAU - Sundquist, Kristina
AU  - Sundquist K
AD  - Center for Primary Health Care Research, Lund University/Region Skåne, Lund, 
      Sweden.
AD  - Department of Family Medicine and Community Health, Department of Population 
      Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, 
      USA.
FAU - Sundquist, Jan
AU  - Sundquist J
AD  - Center for Primary Health Care Research, Lund University/Region Skåne, Lund, 
      Sweden.
AD  - Department of Family Medicine and Community Health, Department of Population 
      Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, 
      USA.
FAU - Jiang, Shu-Heng
AU  - Jiang SH
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 
      P.R. China.
FAU - Xing, Xin
AU  - Xing X
AD  - Shanghai Fengxian District Central Hospital, No. 6600, Nanfeng Road, Shanghai, 
      201499, China.
FAU - Hu, Li-Peng
AU  - Hu LP
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 
      P.R. China. lphu@shsci.org.
FAU - Zhang, Zhi-Gang
AU  - Zhang ZG
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 
      P.R. China. zzhang@shsci.org.
FAU - Ji, Jianguang
AU  - Ji J
AD  - Center for Primary Health Care Research, Lund University/Region Skåne, Lund, 
      Sweden. Jianguang.ji@med.lu.se.
FAU - Zhang, Xue-Li
AU  - Zhang XL
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 
      P.R. China. xlzhang@shsci.org.
LA  - eng
GR  - 82073023/the National Natural Science Foundation of China/
GR  - 81902370/the National Natural Science Foundation of China/
GR  - 82103357/the National Natural Science Foundation of China/
GR  - 92168111/the National Natural Science Foundation of China/
GR  - SHSMU-ZDCX20210802/Innovative research team of high-level local universities in 
      Shanghai/
GR  - 21ZR1461300/the National Natural Science Foundation of Shanghai/
GR  - 22ZR1460000/the National Natural Science Foundation of Shanghai/
GR  - 21YF1445200/Shanghai Sailing Program/
GR  - 20181708/the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine 
      Grant Support/
GR  - 19XD1403400/Program of Shanghai Academic/Technology Research Leader/
GR  - YG2021ZD08/Medicine and Engineering Interdisciplinary Research Fund of Shanghai 
      Jiao Tong University/
GR  - 2021-01187/the Swedish Research Council/
GR  - 202040092/Shanghai Municipal Health Commission/
PT  - Journal Article
DEP - 20230320
PL  - Netherlands
TA  - Cell Oncol (Dordr)
JT  - Cellular oncology (Dordrecht)
JID - 101552938
RN  - R16CO5Y76E (Aspirin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 0 (Anti-Inflammatory Agents)
SB  - IM
MH  - Humans
MH  - Animals
MH  - Mice
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Dipyridamole/pharmacology/therapeutic use
MH  - *Colorectal Neoplasms/drug therapy/metabolism
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Unfolded Protein Response
MH  - Apoptosis
OTO - NOTNLM
OT  - Anti-cancer drug
OT  - Colorectal cancer
OT  - Drug combination
OT  - ER stress
OT  - Pro-apoptotic UPR
EDAT- 2023/03/21 06:00
MHDA- 2023/07/21 06:44
CRDT- 2023/03/20 12:21
PHST- 2023/02/21 00:00 [accepted]
PHST- 2023/07/21 06:44 [medline]
PHST- 2023/03/21 06:00 [pubmed]
PHST- 2023/03/20 12:21 [entrez]
AID - 10.1007/s13402-023-00789-7 [pii]
AID - 10.1007/s13402-023-00789-7 [doi]
PST - ppublish
SO  - Cell Oncol (Dordr). 2023 Aug;46(4):953-967. doi: 10.1007/s13402-023-00789-7. Epub 
      2023 Mar 20.

PMID- 24350940
OWN - NLM
STAT- MEDLINE
DCOM- 20151106
LR  - 20181202
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 12
DP  - 2013 Dec
TI  - [Present and future of pharmaco-arteriothromboprophylaxis in clinical practice. 
      Guidelines of Angiology Section of Slovak Medical Chamber].
PG  - 1081-7
AB  - Antiplatelet therapy by acetylsalicylic acid (aspirin) provided pivotal advances 
      in the prevention and treatment of organovascular (cardiovascular, 
      cerebrovascular, extremitovascular, renovascular, genitovascular, 
      mesenteriovascular, bronchopulmovascular, oculovascular, otovascular and other) 
      arterial ischemic diseases. Currently available antiplatelet drugs have some 
      limitations which might be overcomed by improved dosing regimens, use of 
      combination of agents affecting different platelet functions and, in particular, 
      by the new antiplatelet drugs (new arterial antithrombotics) with distinct 
      pharmacodynamic properties offering new advantages, including faster onset of 
      action, greater potency, and reversibility of effects. Document (Guidelines) of 
      the Angiology Section of the Slovak Medical Chamber (AS SMS, 2013).
FAU - Gavornik, P
AU  - Gavornik P
FAU - Dukát, A
AU  - Dukát A
FAU - Gašpar, L
AU  - Gašpar L
CN  - Angiology Section of Slovak Medical Chamber
LA  - cze
PT  - Comparative Study
PT  - Journal Article
PT  - Practice Guideline
PT  - Review
TT  - Súčasnosť a budúcnosť farmako-artériotromboprofylaxie v klinickej praxi. 
      Odporúčania Angiologickej sekcie Slovenskej lekárskej komory.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - 0 (Drugs, Investigational)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Czech Republic
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Drugs, Investigational/adverse effects/therapeutic use
MH  - Forecasting
MH  - Humans
MH  - Ischemia/drug therapy
MH  - Platelet Activation
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Platelet Function Tests
MH  - Thrombosis/drug therapy
MH  - Vascular Diseases
EDAT- 2013/12/20 06:00
MHDA- 2015/11/07 06:00
CRDT- 2013/12/20 06:00
PHST- 2013/12/20 06:00 [entrez]
PHST- 2013/12/20 06:00 [pubmed]
PHST- 2015/11/07 06:00 [medline]
AID - 46943 [pii]
PST - ppublish
SO  - Vnitr Lek. 2013 Dec;59(12):1081-7.

PMID- 3382069
OWN - NLM
STAT- MEDLINE
DCOM- 19880728
LR  - 20190717
IS  - 0196-0644 (Print)
IS  - 0196-0644 (Linking)
VI  - 17
IP  - 7
DP  - 1988 Jul
TI  - Effect of whole-bowel irrigation on the antidotal efficacy of oral activated 
      charcoal.
PG  - 681-3
AB  - Whole-bowel irrigation was studied in three volunteer subjects and compared with 
      oral activated charcoal as a gastrointestinal decontamination procedure for acute 
      drug overdose. The volunteer subjects were given 650 mg aspirin and were assigned 
      randomly to the following treatment groups: 24-hour urine collection only; 
      immediate whole-bowel irrigation with a polyethylene glycol solution; 50 g oral 
      activated charcoal followed by whole-bowel irrigation; and oral activated 
      charcoal alone. The cumulative 24-hour urinary salicylate excretion was measured 
      in each trial. Catharsis was achieved rapidly with whole-bowel irrigation. Oral 
      activated charcoal without catharsis was most effective in decreasing aspirin 
      absorption (P = .011). These results do not support the routine use of a 
      cathartic in combination with oral activated charcoal.
FAU - Rosenberg, P J
AU  - Rosenberg PJ
AD  - Emergency Department, Sunnybrook Medical Centre, University of Toronto, Ontario, 
      Canada.
FAU - Livingstone, D J
AU  - Livingstone DJ
FAU - McLellan, B A
AU  - McLellan BA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
RN  - 16291-96-6 (Charcoal)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacokinetics
MH  - Charcoal/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - *Intestines
MH  - Poisoning/*therapy
MH  - Polyethylene Glycols
MH  - *Therapeutic Irrigation
EDAT- 1988/07/01 00:00
MHDA- 1988/07/01 00:01
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 1988/07/01 00:01 [medline]
PHST- 1988/07/01 00:00 [entrez]
AID - S0196-0644(88)80610-3 [pii]
AID - 10.1016/s0196-0644(88)80610-3 [doi]
PST - ppublish
SO  - Ann Emerg Med. 1988 Jul;17(7):681-3. doi: 10.1016/s0196-0644(88)80610-3.

PMID- 25670517
OWN - NLM
STAT- MEDLINE
DCOM- 20150408
LR  - 20150211
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 97
IP  - 2
DP  - 2015 Feb
TI  - Inhibition of antiplatelet effects of aspirin by nonopioid analgesics.
PG  - 131-4
LID - 10.1002/cpt.21 [doi]
AB  - In patients undergoing coronary bypass grafting, we noticed that low-dose aspirin 
      failed to inhibit platelet aggregation, potentially elevating the risk of 
      thrombotic bypass occlusion. This "high on-treatment platelet reactivity" was 
      reproducible in vitro and could be transferred with patient plasma or urine to 
      aspirin-sensitive donor platelets, suggesting a drug/drug interaction. Loss of 
      aspirin efficacy was associated with analgesia by dipyrone (metamizol) and 
      initiated further study of the interaction between aspirin and other nonopioid 
      analgesics.
CI  - © 2014 American Society for Clinical Pharmacology and Therapeutics.
FAU - Hohlfeld, T
AU  - Hohlfeld T
AD  - Institut für Pharmakologie und Klinische Pharmakologie, 
      Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
FAU - Schrör, K
AU  - Schrör K
LA  - eng
PT  - Journal Article
DEP - 20141215
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Analgesics, Non-Narcotic)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics, Non-Narcotic/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Drug Interactions
MH  - Humans
MH  - Platelet Aggregation/*drug effects
EDAT- 2015/02/12 06:00
MHDA- 2015/04/09 06:00
CRDT- 2015/02/12 06:00
PHST- 2014/08/19 00:00 [received]
PHST- 2014/09/30 00:00 [accepted]
PHST- 2015/02/12 06:00 [entrez]
PHST- 2015/02/12 06:00 [pubmed]
PHST- 2015/04/09 06:00 [medline]
AID - 10.1002/cpt.21 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2015 Feb;97(2):131-4. doi: 10.1002/cpt.21. Epub 2014 Dec 15.

PMID- 2188536
OWN - NLM
STAT- MEDLINE
DCOM- 19900626
LR  - 20190717
IS  - 0196-0644 (Print)
IS  - 0196-0644 (Linking)
VI  - 19
IP  - 6
DP  - 1990 Jun
TI  - Contribution of sorbitol combined with activated charcoal in prevention of 
      salicylate absorption.
PG  - 654-6
AB  - The use of cathartics and activated charcoal in treating toxic ingestions has 
      become a standard treatment modality. Sorbitol has been shown to be the most 
      rapidly acting cathartic, but its therapeutic significance has been debated. 
      Using a previously described aspirin overdose model, ten healthy volunteers 
      participated in a crossover design study that investigated the effect of 
      activated charcoal alone versus that of activated charcoal and sorbitol in 
      preventing salicylate absorption. In phase 1 of the study, subjects consumed 2.5 
      g aspirin followed by 25 g activated charcoal one hour later. Urine was collected 
      for 48 hours and analyzed for quantitative salicylate metabolites. Phase 2 was 
      identical except that 1.5 g/kg sorbitol was consumed with the activated charcoal. 
      The mean amount of aspirin absorbed without the use of sorbitol was 1.26 +/- 0.15 
      g, whereas the mean absorption was 0.912 +/- 0.18 g with the addition of 
      sorbitol. This is a 28% decrease in absorption of salicylates attributable to the 
      use of sorbitol. The difference is significant at P less than .05 by the paired 
      Student's t test. This study demonstrates that the addition of sorbitol 
      significantly decreases drug absorption in a simulated drug overdose model. 
      Effects on absorption in actual overdose situations and on patient outcome should 
      be the subjects of further study.
FAU - Keller, R E
AU  - Keller RE
AD  - Department of Emergency Medicine, Geisinger Medical Center, Danville, 
      Pennsylvania 17822.
FAU - Schwab, R A
AU  - Schwab RA
FAU - Krenzelok, E P
AU  - Krenzelok EP
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
RN  - 16291-96-6 (Charcoal)
RN  - 506T60A25R (Sorbitol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacokinetics/*poisoning/urine
MH  - Biological Availability
MH  - Charcoal/administration & dosage/pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination/standards
MH  - Female
MH  - Gastrointestinal Transit/drug effects
MH  - Humans
MH  - Male
MH  - Sorbitol/administration & dosage/pharmacology/*therapeutic use
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
AID - S0196-0644(05)82470-9 [pii]
AID - 10.1016/s0196-0644(05)82470-9 [doi]
PST - ppublish
SO  - Ann Emerg Med. 1990 Jun;19(6):654-6. doi: 10.1016/s0196-0644(05)82470-9.

PMID- 8366176
OWN - NLM
STAT- MEDLINE
DCOM- 19931004
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 33
IP  - 6
DP  - 1993 Jun
TI  - Pharmacokinetics of cyclosporine and steady-state aspirin during 
      coadministration.
PG  - 513-21
AB  - Anecdotal reports from clinical trials assessing the use of cyclosporine in the 
      treatment of rheumatoid arthritis suggest an association between enhanced renal 
      impairment and combined use of cyclosporine with nonsteroidal anti-inflammatory 
      drugs. To explore possible pharmacokinetic contributions to this phenomenon, a 
      randomized, two-period crossover investigation was performed in 24 healthy 
      volunteers in which a single oral dose of 300 mg cyclosporine was administered 
      alone and on day 10 of multiple oral dosing of aspirin 960 mg three times daily. 
      Serial blood samples were obtained over 48 hours after each cyclosporine dose and 
      over a steady-state dosing interval for aspirin on day 9 (aspirin alone) and day 
      10 (coadministration of cyclosporine and aspirin). Cyclosporine whole blood 
      concentrations were determined by a specific monoclonal radioimmunoassay and 
      plasma concentrations of acetylsalicylic acid and metabolites by high-performance 
      liquid chromatography. Lack of a pharmacokinetic interaction was conclusively 
      demonstrated for the rate and extent of cyclosporine and acetylsalicylic acid 
      absorption and for the rate and extent of salicylic acid formation after a single 
      dose of cyclosporine was coadministered during steady-state aspirin dosing. If a 
      clear association between enhanced renal impairment and the combined use of 
      cyclosporine and aspirin is substantiated, the underlying mechanism appears to be 
      pharmacodynamic rather than pharmacokinetic.
FAU - Kovarik, J M
AU  - Kovarik JM
AD  - Department of Human Pharmacology, Sandoz Pharma, Ltd., Basle, Switzerland.
FAU - Mueller, E A
AU  - Mueller EA
FAU - Gaber, M
AU  - Gaber M
FAU - Johnston, A
AU  - Johnston A
FAU - Jähnchen, E
AU  - Jähnchen E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Cyclosporine/administration & dosage/*pharmacokinetics
MH  - Drug Interactions
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Metabolic Clearance Rate
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1993.tb04697.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1993 Jun;33(6):513-21. doi: 10.1002/j.1552-4604.1993.tb04697.x.

PMID- 11139802
OWN - NLM
STAT- MEDLINE
DCOM- 20010607
LR  - 20191104
IS  - 1523-3782 (Print)
IS  - 1523-3782 (Linking)
VI  - 3
IP  - 1
DP  - 2001 Jan
TI  - Anticoagulation and heart failure.
PG  - 72-7
AB  - There are no clear data regarding whether to use warfarin, aspirin, or no therapy 
      in patients with left ventricular systolic dysfunction. Aspirin use is widespread 
      in patients with vascular disease but it can decrease renal blood flow in low 
      output states. Warfarin may be used in patients with advancing heart failure due 
      to the perceived risk of in situ thromboembolism. However, we know that ejection 
      fraction and symptom class do not always match and that the regulation of 
      warfarin dosing is more difficult in worsening heart failure. Drug use must be 
      individualized, based on knowledge of underlying heart failure etiology, 
      functional class, drug side effects, and renal function. We await ongoing studies 
      to elucidate the differential effects of these drugs on global outcome as well as 
      on the mechanisms by which they achieve their results.
FAU - Graham, S P
AU  - Graham SP
AD  - Buffalo General Hospital, Department of Medicine, Division of Cardiology, 100 
      High Street, Buffalo, NY 14203, USA. Dbrennan@KaleidaHealth.org
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Heart Failure/*complications/drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thromboembolism/*etiology/*prevention & control
MH  - Ventricular Dysfunction, Left/*drug therapy
MH  - Warfarin/therapeutic use
RF  - 31
EDAT- 2001/01/05 11:00
MHDA- 2001/06/08 10:01
CRDT- 2001/01/05 11:00
PHST- 2001/01/05 11:00 [pubmed]
PHST- 2001/06/08 10:01 [medline]
PHST- 2001/01/05 11:00 [entrez]
AID - 10.1007/s11886-001-0013-1 [doi]
PST - ppublish
SO  - Curr Cardiol Rep. 2001 Jan;3(1):72-7. doi: 10.1007/s11886-001-0013-1.

PMID- 29129512
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20180105
IS  - 1768-3254 (Electronic)
IS  - 0223-5234 (Linking)
VI  - 143
DP  - 2018 Jan 1
TI  - Thieno[2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting 
      platelet activation, aggregation and showing synergy with aspirin.
PG  - 1997-2004
LID - S0223-5234(17)30907-8 [pii]
LID - 10.1016/j.ejmech.2017.11.014 [doi]
AB  - Drugs which inhibit platelet function are commonly used to prevent blood clot 
      formation in patients with Acute Coronary Syndromes (ACS) or those at risk of 
      stroke. The thieno[3,2-c]pyridine class of therapeutic agents, of which 
      clopidogrel is the most commonly used, target the P2Y(12) receptor, and are often 
      used in combination with acetylsalicylic acid (ASA). Six thieno[2,3-b]pyridine 
      were assessed for in vitro anti-platelet activity; all derivatives showed effects 
      on both platelet activation and aggregation, and showed synergy with ASA. Some 
      compounds demonstrated greater activity when compared to clopidogrel. These 
      compounds, therefore, represent potential novel P2Y(12) inhibitors for improved 
      treatment for patients.
CI  - Copyright © 2017 Elsevier Masson SAS. All rights reserved.
FAU - Binsaleh, Naif K
AU  - Binsaleh NK
AD  - School of Healthcare Science, Manchester Metropolitan University, Manchester M1 
      5GD, UK.
FAU - Wigley, Catherine A
AU  - Wigley CA
AD  - School of Healthcare Science, Manchester Metropolitan University, Manchester M1 
      5GD, UK.
FAU - Whitehead, Kathryn A
AU  - Whitehead KA
AD  - School of Healthcare Science, Manchester Metropolitan University, Manchester M1 
      5GD, UK.
FAU - van Rensburg, Michelle
AU  - van Rensburg M
AD  - School of Chemical Sciences, The University of Auckland, New Zealand.
FAU - Reynisson, Johannes
AU  - Reynisson J
AD  - School of Chemical Sciences, The University of Auckland, New Zealand.
FAU - Pilkington, Lisa I
AU  - Pilkington LI
AD  - School of Chemical Sciences, The University of Auckland, New Zealand.
FAU - Barker, David
AU  - Barker D
AD  - School of Chemical Sciences, The University of Auckland, New Zealand. Electronic 
      address: d.barker@auckland.ac.nz.
FAU - Jones, Sarah
AU  - Jones S
AD  - School of Healthcare Science, Manchester Metropolitan University, Manchester M1 
      5GD, UK.
FAU - Dempsey-Hibbert, Nina C
AU  - Dempsey-Hibbert NC
AD  - School of Healthcare Science, Manchester Metropolitan University, Manchester M1 
      5GD, UK. Electronic address: n.dempsey-hibbert@mmu.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20171107
PL  - France
TA  - Eur J Med Chem
JT  - European journal of medicinal chemistry
JID - 0420510
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thieno(2,3-b)pyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/chemistry/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Molecular Structure
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/chemical synthesis/chemistry/*pharmacology
MH  - Pyridines/chemical synthesis/chemistry/*pharmacology
MH  - Structure-Activity Relationship
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Clopidogrel
OT  - Platelets
OT  - Thienopyridine
OT  - Thrombosis
EDAT- 2017/11/14 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/11/14 06:00
PHST- 2017/10/07 00:00 [received]
PHST- 2017/10/19 00:00 [revised]
PHST- 2017/11/04 00:00 [accepted]
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
PHST- 2017/11/14 06:00 [entrez]
AID - S0223-5234(17)30907-8 [pii]
AID - 10.1016/j.ejmech.2017.11.014 [doi]
PST - ppublish
SO  - Eur J Med Chem. 2018 Jan 1;143:1997-2004. doi: 10.1016/j.ejmech.2017.11.014. Epub 
      2017 Nov 7.

PMID- 19605947
OWN - NLM
STAT- MEDLINE
DCOM- 20091130
LR  - 20200106
IS  - 1734-1140 (Print)
IS  - 1734-1140 (Linking)
VI  - 61
IP  - 3
DP  - 2009 May-Jun
TI  - Structure, stability, and antiplatelet activity of O-acyl derivatives of 
      salicylic acid and lipophilic esters of acetylsalicylate.
PG  - 476-89
AB  - The anti-thrombotic activity of acetylsalicylic acid (ASA) has been shown to be 
      due to specific irreversible acetylation of blood platelet cyclooxygenase. The 
      aim of our study was to investigate the associations between the antiplatelet 
      activities of derivatives of both ASA and salicylic acid (SA), as well as the 
      structure, stability, and molecular properties of these compounds. Homologous 
      series of O-acyl derivatives of salicylic acid (propionyl-, butyrylsalicylic 
      acids, PSA, BSA) and lipophilic dodecyl (C12)-, hexadecyl (C16)-, and cholesteryl 
      acetylsalicylates were synthesized and tested for structure-activity 
      relationships. The molecular properties (heat of formation, molecular surface 
      area, dipole moment) of ASA and SA derivatives obtained by theoretical 
      calculations changed with the increasing length of the acyl or alkyl residue. The 
      inhibition of whole blood platelet aggregation and the reduction in thromboxane 
      (TX) generation by O-acyl derivatives were concentration-dependent and decreased 
      along with increasing the length of acyl hain. These effects correlated with the 
      extent of platelet reactivity and P-selectin expression inhibition in 
      collagen-activated platelets. In contrast to ASA and O-acyl derivatives of SA, 
      none of the lipophilic ASA derivatives had a significant inhibitory effect on 
      platelet aggregation. In conclusion, all SA and ASA derivatives studied under in 
      vitro conditions showed much lower antiplatelet activities than ASA itself, 
      despite their higher affinity to plasma proteins or membrane components and their 
      equivalent ability to acetylate protein free amino groups.We suggest the 
      significance of the carboxylic group, dipole moment, geometry, and size of these 
      pharmaceuticals in their ability to bind to the active site of cyclooxygenase and 
      their antiplatelet efficacy.
FAU - Zavodnik, Ilya B
AU  - Zavodnik IB
AD  - Department of Bioregulators, Institute of Pharmacology and Biochemistry, National 
      Academy of Sciences, Grodno, Belarus.
FAU - Lapshina, Elena
AU  - Lapshina E
FAU - Sudnikovich, Elena
AU  - Sudnikovich E
FAU - Boncler, Magdalena
AU  - Boncler M
FAU - Luzak, Bogusława
AU  - Luzak B
FAU - Rózalski, Marcin
AU  - Rózalski M
FAU - Helińska, Magdalena
AU  - Helińska M
FAU - Watała, Cezary
AU  - Watała C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Esters)
RN  - 0 (P-Selectin)
RN  - 0 (Thromboxanes)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Drug Stability
MH  - Esters/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Molecular Structure
MH  - P-Selectin/antagonists & inhibitors
MH  - Platelet Aggregation/*drug effects
MH  - Protein Binding
MH  - Salicylic Acid/*chemistry/pharmacology
MH  - Structure-Activity Relationship
MH  - Thromboxanes/biosynthesis
EDAT- 2009/07/17 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/07/17 09:00
PHST- 2008/09/29 00:00 [received]
PHST- 2009/04/28 00:00 [revised]
PHST- 2009/07/17 09:00 [entrez]
PHST- 2009/07/17 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S1734-1140(09)70089-1 [pii]
AID - 10.1016/s1734-1140(09)70089-1 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2009 May-Jun;61(3):476-89. doi: 10.1016/s1734-1140(09)70089-1.

PMID- 6372841
OWN - NLM
STAT- MEDLINE
DCOM- 19840709
LR  - 20190511
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 17
IP  - 4
DP  - 1984 Apr
TI  - The effects of acetylsalicylic acid on swelling, pain and other events after 
      surgery.
PG  - 379-84
AB  - In a double-blind crossover study acetylsalicylic acid (ASA) in low (2 g daily) 
      or high (4 g daily) dosage was tested against placebo in two groups of 20 
      patients who each underwent identical oral surgical procedures on two separate 
      occasions. Medication started 3 h post-operatively and continued for 3 days. ASA 
      in low dosage tended to increase the postoperative swelling, which on day 3 and 6 
      averaged 109 and 133% respectively of that with placebo (P greater than 0.05). In 
      contrast, ASA in high dosage tended to reduce the swelling, which on day 3 and 6 
      averaged 85 and 90% respectively of that with placebo (P greater than 0.05). 
      Comparison of the two groups receiving ASA in low or high dosage revealed a 
      significant difference in their effect on swelling; day 3, P = 0.05. Pain was 
      significantly reduced with ASA, but there appeared to be no greater analgesic 
      effect with 4 g ASA daily than with 2 g ASA daily. There was, however, a 
      substantial increase in the number of patients who reported tinnitus after taking 
      4 g ASA daily. Subjective postoperative bleeding scores were significantly 
      increased with 2 g ASA daily, but not with 4 g ASA daily. None of the dosages of 
      ASA appeared to reduce the swelling as efficiently, give better pain relief, or 
      as high preference scores as previously obtained in studies when paracetamol and 
      short term glucocorticoid administration were tested against placebo in this 
      model.
FAU - Skjelbred, P
AU  - Skjelbred P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Body Temperature/drug effects
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Edema/*drug therapy/etiology
MH  - Female
MH  - Hematoma/epidemiology
MH  - Hemorrhage/epidemiology
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Postoperative Complications/*drug therapy
MH  - Random Allocation
MH  - Time Factors
MH  - Tooth Extraction
MH  - Wound Healing/drug effects
PMC - PMC1463410
EDAT- 1984/04/01 00:00
MHDA- 1984/04/01 00:01
CRDT- 1984/04/01 00:00
PHST- 1984/04/01 00:00 [pubmed]
PHST- 1984/04/01 00:01 [medline]
PHST- 1984/04/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1984.tb02361.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1984 Apr;17(4):379-84. doi: 
      10.1111/j.1365-2125.1984.tb02361.x.

PMID- 3514494
OWN - NLM
STAT- MEDLINE
DCOM- 19860507
LR  - 20131121
IS  - 0251-1649 (Print)
IS  - 0251-1649 (Linking)
VI  - 6
IP  - 1
DP  - 1986
TI  - Treatment of claudication with dipyridamole and aspirin.
PG  - 59-60
AB  - The effects of dipyridamole in association with acetylsalicylic acid were 
      compared with the effects of acetylsalicylic acid alone in patients with 
      peripheral vascular disease. The following parameters were studied in each 
      patient: symptoms-free interval on the treadmill, ankle-arm arterial pressure 
      gradient, oscillographic index, venous occlusion plethysmography and any untoward 
      reactions. Changes were observed in the pain-free interval (p less than 0.005), 
      and in the venous occlusion plethysmography (p less than 0.001) in the patients 
      treated with the two drugs in association.
FAU - Libretti, A
AU  - Libretti A
FAU - Catalano, M
AU  - Catalano M
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Int J Clin Pharmacol Res
JT  - International journal of clinical pharmacology research
JID - 8110183
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Intermittent Claudication/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Res. 1986;6(1):59-60.

PMID- 26234512
OWN - NLM
STAT- MEDLINE
DCOM- 20160621
LR  - 20190923
IS  - 1875-5402 (Electronic)
IS  - 1386-2073 (Linking)
VI  - 18
IP  - 8
DP  - 2015
TI  - Chemometrics-assisted Spectrofluorimetric Determination of Two Co-administered 
      Drugs of Major Interaction, Methotrexate and Aspirin, in Human Urine Following 
      Acid-induced Hydrolysis.
PG  - 723-34
AB  - Methotrexate (MTX) is widely used to treat rheumatoid arthritis (RA), mostly 
      along with non-steroidal anti-inflammatory drugs (NSAIDs), the most common of 
      which is aspirin or acetyl salicylic acid (ASA). Since NSAIDs impair MTX 
      clearance and increase its toxicity, it was necessary to develop a simple and 
      reliable method for the monitoring of MTX levels in urine samples, when 
      coadministered with ASA. The method was based on the spectrofluorimetric 
      measurement of the acid-induced hydrolysis product of MTX, 
      4-amino-4-deoxy-10-methylpteroic acid (AMP), along with the strongly fluorescent 
      salicylic acid (SA), a product of acid-induced hydrolysis of aspirin and its 
      metabolites in urine. The overlapping emission spectra were resolved using the 
      derivative method (D method). In addition, the corresponding derivative emission 
      spectra were convoluted using discrete Fourier functions, 8-points sin xi 
      polynomials, (D/FF method) for better elimination of interferences. Validation of 
      the developed methods was carried out according to the ICH guidelines. Moreover, 
      the data obtained using derivative and convoluted derivative spectra were treated 
      using the non-parametric Theil's method (NP), compared with the least-squares 
      parametric regression method (LSP). The results treated with Theil's method were 
      more accurate and precise compared with LSP since the former is less affected by 
      the outliers. This work offers the potential of both derivative and convolution 
      using discrete Fourier functions in addition to the effectiveness of using the NP 
      regression analysis of data. The high sensitivity obtained by the proposed 
      methods was promising for measuring low concentration levels of the two drugs in 
      urine samples. These methods were efficiently used to measure the drugs in human 
      urine samples following their co-administration.
FAU - Maher, Hadir M
AU  - Maher HM
AD  - Department of Pharmaceutical Chemistry, King Saud University, Riyadh 11495, P.O. 
      Box 22452, Saudi Arabia. hadirrona@yahoo.com.
FAU - Ragab, Marwa A A
AU  - Ragab MA
FAU - El-Kimary, Eman I
AU  - El-Kimary EI
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Comb Chem High Throughput Screen
JT  - Combinatorial chemistry & high throughput screening
JID - 9810948
RN  - R16CO5Y76E (Aspirin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Aspirin/*pharmacology/urine
MH  - Computational Biology
MH  - *Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hydrolysis
MH  - Methotrexate/*pharmacology/urine
MH  - Spectrometry, Fluorescence
MH  - Urinalysis/*methods
EDAT- 2015/08/04 06:00
MHDA- 2016/06/22 06:00
CRDT- 2015/08/04 06:00
PHST- 2015/01/24 00:00 [received]
PHST- 2015/04/23 00:00 [revised]
PHST- 2015/07/28 00:00 [accepted]
PHST- 2015/08/04 06:00 [entrez]
PHST- 2015/08/04 06:00 [pubmed]
PHST- 2016/06/22 06:00 [medline]
AID - CCHTS-EPUB-69280 [pii]
AID - 10.2174/1386207318666150803140749 [doi]
PST - ppublish
SO  - Comb Chem High Throughput Screen. 2015;18(8):723-34. doi: 
      10.2174/1386207318666150803140749.

PMID- 25174598
OWN - NLM
STAT- MEDLINE
DCOM- 20141104
LR  - 20220408
IS  - 1827-6806 (Print)
IS  - 1827-6806 (Linking)
VI  - 15
IP  - 7-8
DP  - 2014 Jul-Aug
TI  - [Italian intersocietary consensus document on aspirin therapy in primary 
      cardiovascular prevention].
PG  - 442-51
LID - 10.1714/1596.17424 [doi]
AB  - The indications for the use of aspirin in primary cardiovascular prevention 
      continue to be a source of intense debate, with major international guidelines 
      providing conflicting advices. This document, written by delegates of the main 
      Italian scientific societies dealing with cardiovascular prevention and modeled 
      on a similar document by the European Society of Cardiology Working Group on 
      Thrombosis, reviews the evidence in favor and against the use of aspirin therapy 
      in primary prevention based on data cumulated so far, including recent data 
      linking aspirin with cancer protection. While awaiting the results of several 
      ongoing studies, this document argues for a pragmatic approach to the use of 
      low-dose aspirin in primary cardiovascular prevention, and suggests its use in 
      patients at high cardiovascular risk, defined as ≥2 major cardiovascular events 
      (death, myocardial infarction, or stroke) projected per 100 person-years, who are 
      not at increased risk of bleeding.
FAU - Volpe, Massimo
AU  - Volpe M
FAU - Abrignani, Maurizio Giuseppe
AU  - Abrignani MG
FAU - Borghi, Claudio
AU  - Borghi C
FAU - Coccheri, Sergio
AU  - Coccheri S
FAU - Gresele, Paolo
AU  - Gresele P
FAU - Patti, Giuseppe
AU  - Patti G
FAU - Trimarco, Bruno
AU  - Trimarco B
FAU - De Caterina, Raffaele
AU  - De Caterina R
LA  - ita
PT  - Consensus Development Conference
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - La terapia con aspirina nella prevenzione cardiovascolare primaria. Documento di 
      consenso intersocietario italiano.
PL  - Italy
TA  - G Ital Cardiol (Rome)
JT  - Giornale italiano di cardiologia (2006)
JID - 101263411
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Italy
MH  - Meta-Analysis as Topic
MH  - *Primary Prevention/methods
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2014/09/02 06:00
MHDA- 2014/11/05 06:00
CRDT- 2014/09/02 06:00
PHST- 2014/09/02 06:00 [entrez]
PHST- 2014/09/02 06:00 [pubmed]
PHST- 2014/11/05 06:00 [medline]
AID - 10.1714/1596.17424 [doi]
PST - ppublish
SO  - G Ital Cardiol (Rome). 2014 Jul-Aug;15(7-8):442-51. doi: 10.1714/1596.17424.

PMID- 18316013
OWN - NLM
STAT- MEDLINE
DCOM- 20080910
LR  - 20131121
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 62
IP  - 6
DP  - 2007 Nov-Dec
TI  - [Prescription of aspirin in recent acute painful disorders: results of a survey 
      among French general practitioners].
PG  - 477-81
LID - 10.2515/therapie:2007075 [doi]
AB  - AIMS: To analyse recent acute painful conditions for which general practitioners 
      (GPs) would prescribe aspirin. METHODS: Prospective observational study 
      investigating GPs' prescription of aspirin to adult patients with acute pain of < 
      or =5 days of duration. Pain intensity was graded on a 100 mm visual analogue 
      scale (VAS) prior to and at the 48th hour of aspirin therapy. RESULTS: 4765 
      patients (53.9% males), aged 42.6 +/- 14.7 years, with recent acute pain (2.2 +/- 
      1.2 days) were enrolled. Aspirin was prescribed at a mean daily dose of 3g, for 
      musculoskeletal pain (40.8%), headaches and/or migraine (30.7%), ENT pain (23.2%) 
      or dental pain (9.5%), some patients having complained of different types of 
      pain. Pain relief was assessable in 3793 patients (79.6%). In this population, 
      pain intensity was reduced by 65% within 48 hours, from 63.5 +/- 16.7 mm to 22.2 
      +/- 17.1 mm on the VAS. The rate of responders (decrease > or =75 % on VAS) was 
      39.6%; however it varied markedly across the different painful disorders. 
      CONCLUSION: Our survey suggests that GPs may prescribe aspirin for acute pain 
      states similar to those for which they prescribe over-the-counter non aspirin non 
      steroidal anti-inflammatory drugs.
FAU - Bannwarth, Bernard
AU  - Bannwarth B
AD  - Service de Rhumatologie, CHU de Bordeaux, Groupe Hospitalier Pellegrin, Bordeaux, 
      France. bernard.bannwarth@u-bordeau2.fr
FAU - Allaert, François-André
AU  - Allaert FA
FAU - Dubreuil, Christian
AU  - Dubreuil C
FAU - Allain, Hervé
AU  - Allain H
FAU - Azerad, Jean
AU  - Azerad J
FAU - Becq, Jean-Philippe
AU  - Becq JP
FAU - Trèves, Richard
AU  - Trèves R
FAU - Valade, Dominique
AU  - Valade D
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Prescription d'aspirine dans les douleurs aiguës récentes: résultats d'une 
      enquête en médecine générale.
DEP - 20080304
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Utilization
MH  - Family Practice
MH  - Female
MH  - France/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain/*drug therapy/epidemiology
MH  - Pain Measurement
MH  - Prospective Studies
EDAT- 2008/03/05 09:00
MHDA- 2008/09/11 09:00
CRDT- 2008/03/05 09:00
PHST- 2008/03/05 09:00 [pubmed]
PHST- 2008/09/11 09:00 [medline]
PHST- 2008/03/05 09:00 [entrez]
AID - th071665 [pii]
AID - 10.2515/therapie:2007075 [doi]
PST - ppublish
SO  - Therapie. 2007 Nov-Dec;62(6):477-81. doi: 10.2515/therapie:2007075. Epub 2008 Mar 
      4.

PMID- 341228
OWN - NLM
STAT- MEDLINE
DCOM- 19780329
LR  - 20190823
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 14
IP  - 6
DP  - 1977
TI  - Prostacyclin-like activity in rat vascular tissues. Fast, long-lasting inhibition 
      by treatment with lysine acetylsalicylate.
PG  - 1117-24
AB  - Both arterial and venous tissues obtained from normal rats released prostacyclin 
      (PGI2)-like activity, as marked by its potent inhibitory effect on platelet 
      aggregation. Intraperitoneal or intravenous administration of a single dose of a 
      soluble lysine salt of acetylsalicyclic acid (L-ASA, 1-400 mg/kg) resulted in 
      abolition or substantial reduction of prostacyclin-like activity released from 
      rat vasculature. The inhibitory effect of L-ASA was evident one minute after its 
      i.v. administration to the animals, persisted for at least 24 hours and was still 
      detectable (in venous tissues only) 168 hours later. Venous tissues were 
      inhibited by doses of L-ASA as low as 1 mg/kg, whereas arterial tissues were not 
      inhibited by doses of LA-ASA lower than 10 mg/kg. This difference may possibly be 
      related to the lower prostacyclin-like activity shown by rat venous tissues 
      compared to arterial ones. It is suggested that L-ASA or part of its molecule may 
      bind to and inhibit cyclo-oxygenase in the blood vessel wall in a manner similar 
      to the acetylation of platelt cyclo-oxygenase.
FAU - Villa, S
AU  - Villa S
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Prostaglandins)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Vessels/*metabolism
MH  - Epoprostenol/*metabolism
MH  - Injections, Intraperitoneal
MH  - Injections, Intravenous
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandins/*metabolism
MH  - Rats
MH  - Time Factors
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 0090-6980(77)90289-1 [pii]
AID - 10.1016/0090-6980(77)90289-1 [doi]
PST - ppublish
SO  - Prostaglandins. 1977;14(6):1117-24. doi: 10.1016/0090-6980(77)90289-1.

PMID- 31344573
OWN - NLM
STAT- MEDLINE
DCOM- 20200210
LR  - 20200210
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 224
DP  - 2020 Jan 5
TI  - Advanced approaches for the treatment and amplification of weak spectral signals 
      produced by critical concentrations in white multicomponent systems.
PG  - 117339
LID - S1386-1425(19)30729-2 [pii]
LID - 10.1016/j.saa.2019.117339 [doi]
AB  - An analytical investigation was carried out to study the treatment and 
      amplification of the spectral signals produced by critical concentrations with 
      high accuracy and precision using two advanced approaches. The 
      factorized-spectrum approach was applied through two novel methods which were: 
      absorptivity centering technique via both: factorized zero order absorption 
      spectrum (ACT-FSD(0)(ΔA)) and factorized ratio spectrum (ACT-FSR(ΔP)). The 
      proposed methods were found to be linear in the ranges of (15-100 μg/mL) and 
      (3-40 μg/mL) for ASP and MTO, respectively. Those methods were compared to the 
      methods following the geometrical standard addition approach: ratio H-point 
      standard addition method (RHPSAM) and geometrical induced amplitude modulation 
      (GIAM). The approaches were applied for the determination of the minor component 
      metoclopramide in its mixture with the major component aspirin in the 
      challengeable ratio of (1,90) respectively in a white multicomponent system. The 
      results obtained from the proposed approaches were statistically compared with 
      each other. The methods were validated according to ICH guidelines where the 
      results were found to be within the acceptable limits. The methods were found to 
      be accurate and reliable for the determination of metoclopramide critical 
      concentration besides aspirin concentration. The results of single factor ANOVA 
      analysis indicated that there is no significant difference among the developed 
      methods. These methods provided simple resolution of this binary combination from 
      synthetic mixtures and pharmaceutical preparation and can be conveniently adopted 
      for routine quality control analysis.
CI  - Copyright © 2019 Elsevier B.V. All rights reserved.
FAU - Lotfy, Hayam M
AU  - Lotfy HM
AD  - Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr-El 
      Aini Street, 11562 Cairo, Egypt; Pharmaceutical Chemistry Department, Faculty of 
      Pharmaceutical Sciences & Pharmaceutical Industries, Future University in Egypt, 
      12311, Cairo, Egypt.
FAU - Saleh, Sarah S
AU  - Saleh SS
AD  - Analytical Chemistry Department, Faculty of Pharmacy, October University for 
      Modern Sciences and Arts (MSA), 11787 6(th) October, Egypt. Electronic address: 
      drsarahsalah@gmail.com.
FAU - El-Maraghy, Christine M
AU  - El-Maraghy CM
AD  - Analytical Chemistry Department, Faculty of Pharmacy, October University for 
      Modern Sciences and Arts (MSA), 11787 6(th) October, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20190708
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 0 (Pharmaceutical Preparations)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis/chemistry
MH  - Linear Models
MH  - Metoclopramide/analysis/chemistry
MH  - Models, Chemical
MH  - Models, Statistical
MH  - Pharmaceutical Preparations/*analysis/chemistry
MH  - Reproducibility of Results
MH  - *Signal Processing, Computer-Assisted
MH  - Spectrophotometry/*methods
OTO - NOTNLM
OT  - Amplitude modulation
OT  - Aspirin
OT  - Factorized
OT  - H-point
OT  - Metoclopramide
EDAT- 2019/07/26 06:00
MHDA- 2020/02/11 06:00
CRDT- 2019/07/26 06:00
PHST- 2019/05/26 00:00 [received]
PHST- 2019/07/04 00:00 [revised]
PHST- 2019/07/04 00:00 [accepted]
PHST- 2019/07/26 06:00 [pubmed]
PHST- 2020/02/11 06:00 [medline]
PHST- 2019/07/26 06:00 [entrez]
AID - S1386-1425(19)30729-2 [pii]
AID - 10.1016/j.saa.2019.117339 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2020 Jan 5;224:117339. doi: 
      10.1016/j.saa.2019.117339. Epub 2019 Jul 8.

PMID- 3798362
OWN - NLM
STAT- MEDLINE
DCOM- 19870219
LR  - 20131121
IS  - 0040-3709 (Print)
IS  - 0040-3709 (Linking)
VI  - 34
IP  - 3
DP  - 1986 Dec
TI  - Teratogenic effects on the CD-1 mouse embryo exposed to concurrent doses of 
      ethanol and aspirin.
PG  - 249-61
AB  - Human fetal alcohol syndrome characteristics have been seen in the mouse fetus by 
      several investigators who dosed the dam with only one or two doses of alcohol. 
      The purpose of this study was to determine if the fetal effects of acute doses of 
      alcohol (ethanol) are altered by aspirin. CD-1 mice were given two IP doses of a 
      25% v/v solution of 95% ethanol/saline (2.5 hours apart) and intubated with 250 
      mg/kg aspirin. The treatment regimen, begun at 8 days, 4 hours gestation, 
      consisted of either aspirin pretreatment 1 hour before or posttreatment 1 hour 
      after the ethanol. Control animals were treated similarly and included vehicle 
      only, ethanol/vehicle, and aspirin/vehicle groups. One group was untreated. On 
      gestational day 18, the dams were killed and the uterine horns were examined for 
      live, dead, and resorbed fetuses. The live were weighed and examined for external 
      malformations and either skeletal or visceral abnormalities. With the litter as 
      the unit of analysis, no significant difference was found in the number of dead 
      and resorbed among groups. There was a significant difference (P less than .01) 
      in average fetal weight in the aspirin-pretreated group. When the total number of 
      fetuses affected was considered, the aspirin pretreatment group showed 
      significantly (P less than .05) more external and visceral malformations. The 
      skeletal examination revealed a significant (P less than .05) difference in 
      anomalies plus delayed ossification in both groups treated with the 
      aspirin/ethanol combination. No significant differences were seen in any category 
      in the groups receiving aspirin alone or ethanol alone. These results indicate an 
      additive effect of aspirin and ethanol on the developing CD-1 mouse fetus.
FAU - Guy, J F
AU  - Guy JF
FAU - Sucheston, M E
AU  - Sucheston ME
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Teratology
JT  - Teratology
JID - 0153257
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abnormalities, Drug-Induced/pathology
MH  - Animals
MH  - Aspirin/administration & dosage/*toxicity
MH  - Bone and Bones/abnormalities
MH  - Drug Interactions
MH  - Ethanol/administration & dosage/blood/*toxicity
MH  - Female
MH  - Maternal-Fetal Exchange
MH  - Mice
MH  - Pregnancy
EDAT- 1986/12/01 00:00
MHDA- 1986/12/01 00:01
CRDT- 1986/12/01 00:00
PHST- 1986/12/01 00:00 [pubmed]
PHST- 1986/12/01 00:01 [medline]
PHST- 1986/12/01 00:00 [entrez]
AID - 10.1002/tera.1420340304 [doi]
PST - ppublish
SO  - Teratology. 1986 Dec;34(3):249-61. doi: 10.1002/tera.1420340304.

PMID- 23889241
OWN - NLM
STAT- MEDLINE
DCOM- 20140306
LR  - 20211021
IS  - 1365-2222 (Electronic)
IS  - 0954-7894 (Print)
IS  - 0954-7894 (Linking)
VI  - 43
IP  - 8
DP  - 2013 Aug
TI  - Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated 
      respiratory disease: asthma and rhinitis.
PG  - 874-80
LID - 10.1111/cea.12110 [doi]
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease is under-diagnosed and 
      therefore effective and inexpensive therapy with aspirin desensitization is 
      rarely performed. METHODS: We present an audit of 150 patients with difficult to 
      treat nasal polyposis, 132 of whom also had asthma, 131 of whom underwent 
      challenge with the only soluble form of aspirin, lysine aspirin (LAS), to confirm 
      or exclude the diagnosis of aspirin-exacerbated respiratory disease (AERD). 
      RESULTS: One hundred patients proved positive on nasal challenge, 31 who were 
      negative went onto oral LAS challenge and a further 14 gave positive results, 
      leaving 17 who were negative to a dose equivalent to over 375 mg of aspirin. 
      Nineteen were not challenged because of contraindications. With the exception of 
      one patient who developed facial angioedema and two patients with > 20% drop in 
      FEV1 (following nasal plus oral challenge) no other severe adverse events 
      occurred. No hospitalization was required for these three patients. Nasal 
      inspiratory peak flow monitoring was less sensitive to obstruction caused by 
      aspirin than was acoustic rhinometry - which should be employed when aspirin 
      challenge is an outpatient procedure. CONCLUSIONS: Provided patients are 
      carefully chosen and monitored LAS challenge is suitable for ENT day case 
      practice where respiratory physician help with asthma is available and should 
      reduce the under-diagnosis of this condition.
CI  - © 2013 Blackwell Publishing Ltd.
FAU - Miller, B
AU  - Miller B
AD  - Imperial College, London, UK.
FAU - Mirakian, R
AU  - Mirakian R
FAU - Gane, S
AU  - Gane S
FAU - Larco, J
AU  - Larco J
FAU - Sannah, A A
AU  - Sannah AA
FAU - Darby, Y
AU  - Darby Y
FAU - Scadding, G
AU  - Scadding G
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/*analogs & derivatives
MH  - Asthma, Aspirin-Induced/*diagnosis
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Nasal Provocation Tests
MH  - Reproducibility of Results
MH  - Rhinitis/*chemically induced/*diagnosis
PMC - PMC4204273
OTO - NOTNLM
OT  - aspirin
OT  - aspirin-exacerbated respiratory disease
OT  - asthma
OT  - diagnosis
OT  - nasal polyps
EDAT- 2013/07/31 06:00
MHDA- 2014/03/07 06:00
CRDT- 2013/07/30 06:00
PHST- 2012/01/17 00:00 [received]
PHST- 2013/02/08 00:00 [revised]
PHST- 2013/02/12 00:00 [accepted]
PHST- 2013/07/30 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2014/03/07 06:00 [medline]
AID - 10.1111/cea.12110 [doi]
PST - ppublish
SO  - Clin Exp Allergy. 2013 Aug;43(8):874-80. doi: 10.1111/cea.12110.

PMID- 35902612
OWN - NLM
STAT- MEDLINE
DCOM- 20220801
LR  - 20221011
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Jul 28
TI  - Staphylococcus aureus increases platelet reactivity in patients with infective 
      endocarditis.
PG  - 12933
LID - 10.1038/s41598-022-16681-7 [doi]
LID - 12933
AB  - Thromboembolism is frequent in infective endocarditis (IE). However, the optimal 
      antithrombotic regimen in IE is unknown. Staphylococcus aureus (SA) is the 
      leading cause of IE. First studies emphasize increased platelet reactivity by SA. 
      In this pilot study, we hypothesized that platelet reactivity is increased in 
      patients with SA- IE, which could be abrogated by antiplatelet medication. We 
      conducted a prospective, observatory, single-center cohort study in 114 patients 
      with IE, with four cohorts: (1) SA coagulase positive IE without aspirin (ASA) 
      medication, (2) coagulase negative IE without ASA, (3) SA coagulase positive IE 
      with ASA, (4) coagulase negative IE with ASA. Platelet function was measured by 
      Multiplate electrode aggregometry, blood clotting by ROTEM thromboelastometry. 
      Bleeding events were assessed according to TIMI classification. In ASA-naïve 
      patients, aggregation with ADP was increased with coag. pos. IE (coagulase 
      negative: 39.47 ± 4.13 AUC vs. coagulase positive: 59.46 ± 8.19 AUC, p = 0.0219). 
      This was abrogated with ASA medication (coagulase negative: 42.4 ± 4.67 AUC vs. 
      coagulase positive: 45.11 ± 6.063 AUC p = 0.7824). Aspirin did not increase 
      bleeding in SA positive patients. However, in SA negative patients with aspirin, 
      red blood cell transfusions were enhanced. SA coagulase positive IE is associated 
      with increased platelet reactivity. This could be abrogated by aspirin without 
      increased bleeding risk. The results of this pilot study suggest that ASA might 
      be beneficial in SA coagulase positive IE. This needs to be confirmed in clinical 
      trials.
CI  - © 2022. The Author(s).
FAU - Polzin, Amin
AU  - Polzin A
AD  - Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, 
      Germany. amin.polzin@med.uni-duesseldorf.de.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Düsseldorf, Germany. 
      amin.polzin@med.uni-duesseldorf.de.
FAU - Dannenberg, Lisa
AU  - Dannenberg L
AD  - Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, 
      Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Düsseldorf, Germany.
FAU - M'Pembele, René
AU  - M'Pembele R
AD  - Department of Anesthesiology, Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Mourikis, Philipp
AU  - Mourikis P
AD  - Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, 
      Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Düsseldorf, Germany.
FAU - Naguib, David
AU  - Naguib D
AD  - Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, 
      Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Düsseldorf, Germany.
FAU - Zako, Saif
AU  - Zako S
AD  - Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, 
      Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Düsseldorf, Germany.
FAU - Helten, Carolin
AU  - Helten C
AD  - Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, 
      Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Düsseldorf, Germany.
FAU - Petzold, Tobias
AU  - Petzold T
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Levkau, Bodo
AU  - Levkau B
AD  - Institute of Molecular Medicine III, Heinrich Heine University, Düsseldorf, 
      Germany.
FAU - Hohlfeld, Thomas
AU  - Hohlfeld T
AD  - Institute of Pharmacology and Clinical Pharmacology, Heinrich Heine University, 
      Düsseldorf, Germany.
FAU - Barth, Mareike
AU  - Barth M
AD  - Department of Cardiovascular Surgery, Medical Faculty, Heinrich-Heine-University, 
      Düsseldorf, Germany.
FAU - Zeus, Tobias
AU  - Zeus T
AD  - Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, 
      Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Düsseldorf, Germany.
FAU - Sixt, Stephan
AU  - Sixt S
AD  - Department of Anesthesiology, Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Huhn, Ragnar
AU  - Huhn R
AD  - Department of Anesthesiology, Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Akhyari, Payam
AU  - Akhyari P
AD  - Department of Cardiovascular Surgery, Medical Faculty, Heinrich-Heine-University, 
      Düsseldorf, Germany.
FAU - Lichtenberg, Artur
AU  - Lichtenberg A
AD  - Department of Cardiovascular Surgery, Medical Faculty, Heinrich-Heine-University, 
      Düsseldorf, Germany.
FAU - Kelm, Malte
AU  - Kelm M
AD  - Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, 
      Germany.
AD  - Cardiovascular Research Institute Düsseldorf (CARID), Düsseldorf, Germany.
FAU - Hoffmann, Till
AU  - Hoffmann T
AD  - Transfusion Medicine and Clinical Hemostaseology, Heinrich Heine University 
      Medical Center Düsseldorf, Düsseldorf, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220728
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Coagulase)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Coagulase
MH  - Cohort Studies
MH  - *Endocarditis, Bacterial/drug therapy
MH  - Humans
MH  - Pilot Projects
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prospective Studies
MH  - *Staphylococcal Infections/complications/drug therapy
MH  - Staphylococcus aureus
PMC - PMC9334290
COIS- The authors declare no competing interests.
EDAT- 2022/07/29 06:00
MHDA- 2022/08/02 06:00
CRDT- 2022/07/28 23:30
PHST- 2022/03/30 00:00 [received]
PHST- 2022/07/13 00:00 [accepted]
PHST- 2022/07/28 23:30 [entrez]
PHST- 2022/07/29 06:00 [pubmed]
PHST- 2022/08/02 06:00 [medline]
AID - 10.1038/s41598-022-16681-7 [pii]
AID - 16681 [pii]
AID - 10.1038/s41598-022-16681-7 [doi]
PST - epublish
SO  - Sci Rep. 2022 Jul 28;12(1):12933. doi: 10.1038/s41598-022-16681-7.

PMID- 28947724
OWN - NLM
STAT- MEDLINE
DCOM- 20180702
LR  - 20181023
IS  - 1308-4488 (Electronic)
IS  - 1016-5169 (Linking)
VI  - 45
IP  - Suppl 4
DP  - 2017 Sep
TI  - [After the GEMINI-ACS-1 trial].
PG  - 8-9
LID - 10.5543/tkda.2017.52358 [doi]
AB  - The GEMINI-ACS-1 trial has recently been published. It was designed to test 
      whether low dose rivaroxaban as an antithrombotic agent is as safe as aspirin in 
      patients with acute coronary syndromes (ACS). The trial is important to set light 
      to future of ACS management.
FAU - Yılmaz, Mehmet Birhan
AU  - Yılmaz MB
AD  - Department of Cardiology, Cumhuriyet University Faculty of Medicine, Sivas, 
      Turkey. mehmet.birhan.yilmaz@tkd.org.tr.
LA  - tur
PT  - Clinical Trial
PT  - Journal Article
TT  - GEMINI-ACS-1 çalışmasının ardından.
PL  - Turkey
TA  - Turk Kardiyol Dern Ars
JT  - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
JID - 9426239
RN  - 0 (Anticoagulants)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*complications
MH  - *Anticoagulants/administration & dosage/adverse effects/therapeutic use
MH  - *Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Humans
MH  - *Rivaroxaban/administration & dosage/adverse effects/therapeutic use
MH  - Thrombosis/complications/drug therapy/prevention & control
EDAT- 2017/09/28 06:00
MHDA- 2018/07/03 06:00
CRDT- 2017/09/27 06:00
PHST- 2017/09/27 06:00 [entrez]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2018/07/03 06:00 [medline]
AID - 10.5543/tkda.2017.52358 [doi]
PST - ppublish
SO  - Turk Kardiyol Dern Ars. 2017 Sep;45(Suppl 4):8-9. doi: 10.5543/tkda.2017.52358.

PMID- 36316768
OWN - NLM
STAT- MEDLINE
DCOM- 20221102
LR  - 20221104
IS  - 1471-2490 (Electronic)
IS  - 1471-2490 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Oct 31
TI  - The targets of aspirin in bladder cancer: bioinformatics analysis.
PG  - 168
LID - 10.1186/s12894-022-01119-z [doi]
LID - 168
AB  - BACKGROUND: The anti-carcinogenic properties of aspirin have been observed in 
      some solid tumors. However, the molecular mechanism of therapeutic effects of 
      aspirin on bladder cancer is still indistinct. We introduced a bioinformatics 
      analysis approach, to explore the targets of aspirin in bladder cancer (BC). 
      METHODS: To find out the potential targets of aspirin in BC, we analyzed direct 
      protein targets (DPTs) of aspirin in Drug Bank 5.0. The protein-protein 
      interaction (PPI) network and signaling pathway of aspirin DPTs were then 
      analyzed subsequently. A detailed analysis of the KEGG (Kyoto Encyclopedia of 
      Genes and Genomes) pathway has shown that aspirin is linked to BC. We identified 
      overexpressed genes in BC comparing with normal samples by Oncomine and genes 
      that interlinked with aspirin target genes in BC by STRING. RESULTS: Firstly, we 
      explored 16 direct protein targets (DPT) of aspirin. We analyzed the 
      protein-protein interaction (PPI) network and signaling pathways of aspirin DPT. 
      We found that aspirin is closely associated with a variety of cancers, including 
      BC. Then, we classified mutations in 3 aspirin DPTs (CCND1, MYC and TP53) in BC 
      using the cBio Portal database. In addition, we extracted the top 50 
      overexpressed genes in bladder cancer by Oncomine and predicted the genes 
      associated with the 3 aspirin DPTs (CCND1, MYC and TP53) in BC by STRING. 
      Finally, 5 exact genes were identified as potential therapeutic targets of 
      aspirin in bladder cancer. CONCLUSION: The analysis of relevant databases will 
      improve our mechanistic understanding of the role of aspirin in bladder cancer. 
      This will guide the direction of our next drug-disease interaction studies.
CI  - © 2022. The Author(s).
FAU - Li, Xiao
AU  - Li X
AD  - Department of Thoracic Oncology, Lin Fen Central Hospital, 041000, Lin Fen, 
      China.
FAU - Tai, Yanghao
AU  - Tai Y
AD  - Shanxi Medical University, 030000, Taiyuan, China.
FAU - Liu, Shuying
AU  - Liu S
AD  - Department of Thoracic Oncology, Lin Fen Central Hospital, 041000, Lin Fen, 
      China.
FAU - Gao, Yating
AU  - Gao Y
AD  - Department of Thoracic Oncology, Lin Fen Central Hospital, 041000, Lin Fen, 
      China.
FAU - Zhang, Kaining
AU  - Zhang K
AD  - Department of Thoracic Oncology, Lin Fen Central Hospital, 041000, Lin Fen, 
      China.
FAU - Yin, Jierong
AU  - Yin J
AD  - Department of Thoracic Oncology, Lin Fen Central Hospital, 041000, Lin Fen, 
      China.
FAU - Zhang, Huijuan
AU  - Zhang H
AD  - Department of Thoracic Oncology, Lin Fen Central Hospital, 041000, Lin Fen, 
      China.
FAU - Wang, Xia
AU  - Wang X
AD  - Department of Thoracic Oncology, Lin Fen Central Hospital, 041000, Lin Fen, 
      China.
FAU - Li, Xiaofei
AU  - Li X
AD  - Department of Thoracic Oncology, Lin Fen Central Hospital, 041000, Lin Fen, 
      China.
FAU - Zhang, Dongfeng
AU  - Zhang D
AD  - Department of Thoracic Oncology, Lin Fen Central Hospital, 041000, Lin Fen, 
      China. zdongfeng2022@163.com.
FAU - Zhang, Dong-Feng
AU  - Zhang DF
AD  - Department of Thoracic Oncology, Lin Fen Central Hospital, 041000, Lin Fen, 
      China. zdongfeng2022@163.com.
LA  - eng
PT  - Journal Article
DEP - 20221031
PL  - England
TA  - BMC Urol
JT  - BMC urology
JID - 100968571
RN  - R16CO5Y76E (Aspirin)
RN  - 1208-20-4 (diphenylthiosulfinate)
SB  - IM
MH  - Humans
MH  - *Computational Biology
MH  - *Urinary Bladder Neoplasms/drug therapy/genetics/metabolism
MH  - Aspirin/pharmacology/therapeutic use
MH  - Protein Interaction Maps/genetics
PMC - PMC9620658
OTO - NOTNLM
OT  - Aspirin
OT  - Bladder cancer
OT  - Comprehensive bioinformatics analysis
OT  - Target gene
COIS- The authors have no relevant financial or non-financial interests to disclose.
EDAT- 2022/11/02 06:00
MHDA- 2022/11/03 06:00
CRDT- 2022/11/01 00:52
PHST- 2022/03/31 00:00 [received]
PHST- 2022/10/10 00:00 [accepted]
PHST- 2022/11/01 00:52 [entrez]
PHST- 2022/11/02 06:00 [pubmed]
PHST- 2022/11/03 06:00 [medline]
AID - 10.1186/s12894-022-01119-z [pii]
AID - 1119 [pii]
AID - 10.1186/s12894-022-01119-z [doi]
PST - epublish
SO  - BMC Urol. 2022 Oct 31;22(1):168. doi: 10.1186/s12894-022-01119-z.

PMID- 34606309
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 174
IP  - 10
DP  - 2021 Oct
TI  - In ASCVD, 81 mg and 325 mg of aspirin did not differ for CV or bleeding events.
PG  - JC118
LID - 10.7326/ACPJ202110190-118 [doi]
AB  - Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing 
      in cardiovascular disease. N Engl J Med. 2021;384:1981-90. 33999548.
FAU - McCarthy, Lucas
AU  - McCarthy L
AD  - Virginia Mason Medical Center, Seattle, Washington, USA (L.M.).
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20211005
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - N Engl J Med. 2021 May 27;384(21):1981-1990. PMID: 33999548
MH  - *Aspirin/adverse effects
MH  - *Cardiovascular Diseases
MH  - Hemorrhage/chemically induced
MH  - Humans
EDAT- 2021/10/05 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/10/04 17:16
PHST- 2021/10/05 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/10/04 17:16 [entrez]
AID - 10.7326/ACPJ202110190-118 [doi]
PST - ppublish
SO  - Ann Intern Med. 2021 Oct;174(10):JC118. doi: 10.7326/ACPJ202110190-118. Epub 2021 
      Oct 5.

PMID- 17493983
OWN - NLM
STAT- MEDLINE
DCOM- 20070522
LR  - 20181113
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Print)
IS  - 0959-8138 (Linking)
VI  - 334
IP  - 7601
DP  - 2007 May 12
TI  - Aspirin and cognitive function.
PG  - 961-2
AB  - Benefit has not yet been shown, but may be due to difficulties in selecting the 
      right outcome measure
FAU - Whalley, Lawrence J
AU  - Whalley LJ
FAU - Mowat, Donald H R
AU  - Mowat DH
LA  - eng
PT  - Comment
PT  - Editorial
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Nootropic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - BMJ. 2007 May 12;334(7601):987. PMID: 17468120
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cognition Disorders/*prevention & control
MH  - Humans
MH  - Nootropic Agents/*therapeutic use
PMC - PMC1867914
COIS- Competing interests: None declared.
EDAT- 2007/05/12 09:00
MHDA- 2007/05/23 09:00
CRDT- 2007/05/12 09:00
PHST- 2007/05/12 09:00 [pubmed]
PHST- 2007/05/23 09:00 [medline]
PHST- 2007/05/12 09:00 [entrez]
AID - 334/7601/961 [pii]
AID - whal467803 [pii]
AID - 10.1136/bmj.39204.473252.80 [doi]
PST - ppublish
SO  - BMJ. 2007 May 12;334(7601):961-2. doi: 10.1136/bmj.39204.473252.80.

PMID- 11062772
OWN - NLM
STAT- MEDLINE
DCOM- 20001116
LR  - 20131121
IS  - 1565-1088 (Print)
VI  - 2
IP  - 9
DP  - 2000 Sep
TI  - Non-steroidal anti-inflammatory drugs and selective apoptotic anti-neoplastic 
      drugs in the prevention of colorectal cancer: the role of super aspirins.
PG  - 695-702
AB  - There is increasing evidence to suggest that aspirin and other non-steroidal 
      anti-inflammatory drugs reduce the risk of colorectal cancer. This observation is 
      supported by animal studies that show fewer tumors per animal and fewer animals 
      with tumors after administration of several different NSAIDs. Intervention data 
      in familial adenomatous polyposis have established that the effect is exerted on 
      the process of human colonic adenoma formation. Supportive evidence in sporadic 
      colorectal neoplasia, derived from 22 of 24 studies (both case-control and 
      cohort), found a reduced risk in men and women for cancers of the colon and the 
      rectum and for both aspirin and the other NSAIDs. Earlier detection of lesions as 
      a result of drug-induced bleeding does not seem to account for these findings. 
      Although the molecular mechanism responsible for the chemopreventive action of 
      this class of drugs is not yet completely understood, the protection may affect 
      several pathways including both cell cycle arrest and induction of apoptosis. In 
      the third millennium the question is not if but how. Based on the consistency of 
      epidemiological, clinical and experimental data, the association between regular 
      long-term aspirin or NSAIDs intake and a decreased death rate from colorectal 
      cancer is sound and there is no need for further placebo trials. At the same 
      time, despite this consistency there is no clear data on the dose, duration or 
      frequency of use for cancer-preventive activity.
FAU - Strul, H
AU  - Strul H
AD  - Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Israel.
FAU - Arber, N
AU  - Arber N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Israel
TA  - Isr Med Assoc J
JT  - The Israel Medical Association journal : IMAJ
JID - 100930740
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - EC 1.11.1.- (Peroxidases)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenomatous Polyposis Coli/pathology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Apoptosis/*drug effects
MH  - Aspirin/*therapeutic use
MH  - Chemoprevention
MH  - Colorectal Neoplasms/*prevention & control
MH  - Cyclooxygenase 2
MH  - Humans
MH  - Isoenzymes/antagonists & inhibitors
MH  - Membrane Proteins
MH  - Peroxidases/antagonists & inhibitors
MH  - Prostaglandin-Endoperoxide Synthases
RF  - 40
EDAT- 2000/11/04 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/04 11:00
PHST- 2000/11/04 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/04 11:00 [entrez]
PST - ppublish
SO  - Isr Med Assoc J. 2000 Sep;2(9):695-702.

PMID- 18001624
OWN - NLM
STAT- MEDLINE
DCOM- 20080314
LR  - 20211020
IS  - 1523-3804 (Print)
IS  - 1523-3804 (Linking)
VI  - 9
IP  - 5
DP  - 2007 Nov
TI  - Clopidogrel and risk for acute coronary events.
PG  - 401-8
AB  - Clopidogrel bisulfate is a potent adenosine diphosphate receptor blocker that 
      irreversibly inhibits platelet aggregation by preventing the activation of the 
      glycoprotein IIb/IIIa pathway. This helps to prevent thrombus formation and 
      resultant ischemic or thrombotic complications. Clopidogrel was proven to be 
      superior to aspirin in the treatment of atherothrombotic diseases. Clopidogrel 
      plus aspirin, known as dual antiplatelet therapy, is highly effective in patients 
      with acute coronary syndromes or undergoing percutaneous coronary intervention. 
      There is no apparent benefit of dual antiplatelet therapy in primary prevention. 
      In this article, we review the benefits of clopidogrel as an antiplatelet agent 
      and its role in the management of acute coronary syndromes and following 
      percutaneous coronary intervention.
FAU - Mood, Girish R
AU  - Mood GR
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Desk 
      F25, Cleveland, OH 44195, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/pharmacokinetics/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Clopidogrel
MH  - Coronary Restenosis/prevention & control
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/adverse effects/*analogs & 
      derivatives/pharmacokinetics/pharmacology/therapeutic use
RF  - 50
EDAT- 2007/11/16 09:00
MHDA- 2008/03/15 09:00
CRDT- 2007/11/16 09:00
PHST- 2007/11/16 09:00 [pubmed]
PHST- 2008/03/15 09:00 [medline]
PHST- 2007/11/16 09:00 [entrez]
AID - 10.1007/s11883-007-0052-1 [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2007 Nov;9(5):401-8. doi: 10.1007/s11883-007-0052-1.

PMID- 29335863
OWN - NLM
STAT- MEDLINE
DCOM- 20190913
LR  - 20211204
IS  - 1672-0415 (Print)
IS  - 1672-0415 (Linking)
VI  - 25
IP  - 5
DP  - 2019 May
TI  - Integrative Medicine on Optimizing Clopidogrel and Aspirin Therapy.
PG  - 395-400
LID - 10.1007/s11655-017-2551-4 [doi]
AB  - This article reviews the available published data on optimizing clopidogrel and 
      aspirin therapy using translational and integrative medicine. Translational and 
      evidence-based medical studies show that the CYP2C19 gene mutation (CYP2C19*2 and 
      CYP2C19*3) could affect > 50% of the Chinese population, and that this mutation 
      is closely associated with clopidogrel resistance and an increased risk of major 
      adverse cardiovascular events, particularly stent thrombosis in patients 
      following percutaneous coronary intervention (PCI). Adjusted-dose warfarin and 
      aspirin reduce stroke in patients with atrial fibrillation (AF), and warfarin is 
      substantially more efficacious than aspirin. However, a poor compliance is a big 
      problem in warfarin use especially in China. The genetic variants of vitamin K 
      expoxide reductase might account for the universally lower warfarin dosage used 
      in Chinese population. The available evidence indicates that the integrating 
      mainstream treatments (e.g., clopidogrel, CYP2C19 genotyping) and non-mainstream 
      medicines [e.g., Chinese medicines, Naoxintong Capsule (, NXT)] to treat CYP2C19 
      gene mutation patients following PCI can be effective. Aspirin combined NXT and 
      the adjusted-dose warfarin was equally effective in elderly patients with 
      non-valvular AF in prevention of ischemic stroke.
FAU - Chen, Hui
AU  - Chen H
AD  - Department of Internal Medicine, Fujian Provincial Cardiovascular Disease 
      Institute, the Shengli Clinical Medical College of Fujian Medical University, 
      Fuzhou, 350001, China. chenhuiwyd@sina.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180115
PL  - China
TA  - Chin J Integr Med
JT  - Chinese journal of integrative medicine
JID - 101181180
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel/*therapeutic use
MH  - Humans
MH  - *Integrative Medicine
MH  - Translational Research, Biomedical
OTO - NOTNLM
OT  - Chinese medicine
OT  - aspirin
OT  - clopidogrel
OT  - integrative medicine
OT  - optimizing therapy
EDAT- 2018/01/18 06:00
MHDA- 2019/09/14 06:00
CRDT- 2018/01/17 06:00
PHST- 2015/04/23 00:00 [accepted]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2019/09/14 06:00 [medline]
PHST- 2018/01/17 06:00 [entrez]
AID - 10.1007/s11655-017-2551-4 [pii]
AID - 10.1007/s11655-017-2551-4 [doi]
PST - ppublish
SO  - Chin J Integr Med. 2019 May;25(5):395-400. doi: 10.1007/s11655-017-2551-4. Epub 
      2018 Jan 15.

PMID- 17904211
OWN - NLM
STAT- MEDLINE
DCOM- 20080605
LR  - 20131121
IS  - 0091-7435 (Print)
IS  - 0091-7435 (Linking)
VI  - 46
IP  - 2
DP  - 2008 Feb
TI  - Aspirin use for the primary prevention of coronary heart disease: a 
      population-based study in Switzerland.
PG  - 137-44
AB  - OBJECTIVE: To determine the patterns of aspirin use for the primary prevention of 
      coronary heart disease (CHD). Aspirin for primary prevention has a more favorable 
      risk/benefit profile among adults with high CHD risk than among low-risk adults. 
      METHOD: We studied 5725 adults aged 35-75 without cardiovascular disease in a 
      population-based study in Switzerland in 2003-2006. We examined regular aspirin 
      use for cardiovascular prevention according to 10-year CHD risk and other 
      cardiovascular risk factors. RESULTS: One hundred seventy-four participants used 
      aspirin. Aspirin use increased with 10-year CHD risk, from 2.6% in persons with 
      risk <6% (low risk) to 9% in those with risk 6-20% (intermediate risk, p=0.001), 
      but no adults with risk >or=20% used aspirin. Participants with cardiovascular 
      risk factors were more likely to use aspirin. However, 1.9% adults with risk <6% 
      and no diabetes used aspirin. Using a population perspective, a more appropriate 
      aspirin use would reduce up to 2,348/24,310 CHD deaths expected over 10 years in 
      Switzerland, and avoid about 700 gastrointestinal bleedings and hemorrhagic 
      strokes among those not eligible. CONCLUSION: Individuals at intermediate CHD 
      risk and diabetics are more likely to take aspirin, but there are significant 
      opportunities for improvement. The underuse of aspirin for those at risk coexists 
      with an overuse among those at low risk.
FAU - Rodondi, Nicolas
AU  - Rodondi N
AD  - Department of Ambulatory Care and Community Medicine, University of Lausanne, 
      Bugnon 44, 1011 Lausanne, Switzerland. Nicolas.Rodondi@hospvd.ch
FAU - Cornuz, Jacques
AU  - Cornuz J
FAU - Marques-Vidal, Pedro
AU  - Marques-Vidal P
FAU - Butler, Javed
AU  - Butler J
FAU - Hayoz, Daniel
AU  - Hayoz D
FAU - Pécoud, Alain
AU  - Pécoud A
FAU - Paccaud, Fred
AU  - Paccaud F
FAU - Waeber, Gérard
AU  - Waeber G
FAU - Vollenweider, Peter
AU  - Vollenweider P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070823
PL  - United States
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Disease/drug therapy/*prevention & control
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Primary Prevention/*methods
MH  - Switzerland
EDAT- 2007/10/02 09:00
MHDA- 2008/06/06 09:00
CRDT- 2007/10/02 09:00
PHST- 2007/05/08 00:00 [received]
PHST- 2007/08/07 00:00 [revised]
PHST- 2007/08/14 00:00 [accepted]
PHST- 2007/10/02 09:00 [pubmed]
PHST- 2008/06/06 09:00 [medline]
PHST- 2007/10/02 09:00 [entrez]
AID - S0091-7435(07)00370-2 [pii]
AID - 10.1016/j.ypmed.2007.08.006 [doi]
PST - ppublish
SO  - Prev Med. 2008 Feb;46(2):137-44. doi: 10.1016/j.ypmed.2007.08.006. Epub 2007 Aug 
      23.

PMID- 34715602
OWN - NLM
STAT- MEDLINE
DCOM- 20220211
LR  - 20220211
IS  - 1873-2534 (Electronic)
IS  - 0165-2427 (Linking)
VI  - 242
DP  - 2021 Dec
TI  - Pharmacokinetics, pharmacodynamics and safety evaluation of 
      5,5'-methylenebis(2-acetoxybenzoic acid) in dogs following intravenous 
      administration.
PG  - 110339
LID - S0165-2427(21)00157-4 [pii]
LID - 10.1016/j.vetimm.2021.110339 [doi]
AB  - Complement-mediated intravascular hemolysis occurs in canine immune-mediated 
      hemolytic anemia (IMHA). Complement inhibitors might enhance treatment of this 
      disease. Dimers of acetylsalicylic acid such as 
      5,5'-methylenebis(2-acetoxybenzoic acid) (DAS) have been reported to inhibit 
      complement. This study aimed to characterize the pharmacokinetics and safety 
      profile of a single 3 mg/kg IV dose of DAS in 6 healthy mixed-breed dogs. Serum 
      concentrations of DAS and its primary metabolites were measured by liquid 
      chromatography-tandem mass spectrometry at baseline and at 5, 10 and 30 min, and 
      1, 2, 4, 6, 8, 12, 18 and 24 h post-administration. Additional blood samples were 
      collected 7 and 14 days after drug administration. Complete blood counts, serum 
      chemistry panels, C-reactive protein measurements, coagulation testing and 
      cytokine analyses were used for safety monitoring. Following IV administration of 
      3 mg/kg DAS, the estimated mean maximum plasma concentration was 54,709 ng/mL. 
      Pharmacokinetic modeling suggested that DAS was eliminated with a half-life value 
      of 8.1 h, equivalent to a clearance of 6.93 L/hr kg and a volume of distribution 
      of 56 mL/kg. Plasma concentrations of the metabolites were measured rapidly 
      (within 15-60 min for M1 and M2 respectively). Overall, the relative exposure to 
      M1 and M2 suggest significant biotransformation of DAS occurred, but DAS was the 
      most abundant circulating species. No adverse clinical reactions were noted 
      following DAS administration and safety studies suggested DAS caused no 
      inflammatory response or coagulation disturbance. Further clinical evaluation of 
      DAS is warranted.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Goggs, Robert
AU  - Goggs R
AD  - Department of Clinical Sciences, Ithaca, NY, 14853, United States. Electronic 
      address: r.goggs@cornell.edu.
FAU - Kannampuzha-Francis, Jasmine
AU  - Kannampuzha-Francis J
AD  - Department of Population Medicine, Cornell University College of Veterinary 
      Medicine, Ithaca, NY, 14853, United States.
FAU - Campbell, Christopher J
AU  - Campbell CJ
AD  - Aurin Biotech Inc., 555 Burrard St Floor 2, Vancouver, BC, V7X 1M8, Canada.
FAU - Moreau, Jean-Pierre
AU  - Moreau JP
AD  - Aurin Biotech Inc., 555 Burrard St Floor 2, Vancouver, BC, V7X 1M8, Canada.
FAU - Behling-Kelly, Erica
AU  - Behling-Kelly E
AD  - Department of Population Medicine, Cornell University College of Veterinary 
      Medicine, Ithaca, NY, 14853, United States.
LA  - eng
PT  - Journal Article
DEP - 20211014
PL  - Netherlands
TA  - Vet Immunol Immunopathol
JT  - Veterinary immunology and immunopathology
JID - 8002006
RN  - 0 (5,5'-methylenebis(2-acetoxybenzoic acid))
RN  - 0 (Benzhydryl Compounds)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacokinetics
MH  - Benzhydryl Compounds/*pharmacokinetics
MH  - Chromatography, Liquid/veterinary
MH  - Dogs
MH  - Infusions, Intravenous/veterinary
MH  - Kinetics
OTO - NOTNLM
OT  - Canine
OT  - Complement
OT  - DAS
OT  - Hemolytic anemia
OT  - Inhibitor
OT  - Membrane attack complex
EDAT- 2021/10/30 06:00
MHDA- 2022/02/12 06:00
CRDT- 2021/10/29 20:30
PHST- 2021/05/17 00:00 [received]
PHST- 2021/10/07 00:00 [revised]
PHST- 2021/10/12 00:00 [accepted]
PHST- 2021/10/30 06:00 [pubmed]
PHST- 2022/02/12 06:00 [medline]
PHST- 2021/10/29 20:30 [entrez]
AID - S0165-2427(21)00157-4 [pii]
AID - 10.1016/j.vetimm.2021.110339 [doi]
PST - ppublish
SO  - Vet Immunol Immunopathol. 2021 Dec;242:110339. doi: 10.1016/j.vetimm.2021.110339. 
      Epub 2021 Oct 14.

PMID- 11589255
OWN - NLM
STAT- MEDLINE
DCOM- 20020123
LR  - 20190921
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 23
IP  - 9
DP  - 2001 Sep
TI  - Analysis of trials evaluating combinations of acetylsalicylic acid and 
      dipyridamole in the secondary prevention of stroke.
PG  - 1391-408
AB  - BACKGROUND: Stroke is one of the leading causes of morbidity and mortality in the 
      United States. Patients who suffer a cerebrovascular event are at high risk of a 
      recurrence, and secondary prevention is crucial to reducing the burden of 
      cerebrovascular disease. Acetylsalicylic acid (ASA, aspirin) is an established 
      method of stroke prophylaxis. OBJECTIVE: This review investigates whether the 
      addition of dipyridamole to ASA further reduces the risk of stroke recurrence. 
      METHODS: To identify clinical trials of the use of combinations of ASA and 
      dipyridamole in the prevention of recurrent stroke in patients who have suffered 
      a first stroke or transient ischemic attack, the English-language literature was 
      searched from 1966 through May 2001 using the MEDLINE, International 
      Pharmaceutical Abstracts, EMBASE, and BIOSIS databases. The search terms used 
      were dipyridamole, aspirin, acetylsalicylic acid, ischemic stroke, and 
      cerebrovascular disorders. CONCLUSIONS: Of the 5 published studies, 3 earlier 
      studies detected no differences in outcome when dipyridamole was added to ASA 
      therapy for stroke prophylaxis. Two more recent trials found that the addition of 
      dipyridamole to ASA therapy provided further reduction in the risk of secondary 
      cerebrovascular events compared with placebo and with ASA alone. Further studies 
      are needed to confirm long-term benefit.
FAU - Redman, A R
AU  - Redman AR
AD  - Department of Pharmacy Practice, Mercer University Southern School of Pharmacy, 
      Atlanta, Georgia 30341, USA. Redman_ar@mercer.edu
FAU - Ryan, G J
AU  - Ryan GJ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Treatment Outcome
RF  - 31
EDAT- 2001/10/09 10:00
MHDA- 2002/01/24 10:01
CRDT- 2001/10/09 10:00
PHST- 2001/10/09 10:00 [pubmed]
PHST- 2002/01/24 10:01 [medline]
PHST- 2001/10/09 10:00 [entrez]
AID - S0149-2918(01)80115-6 [pii]
AID - 10.1016/s0149-2918(01)80115-6 [doi]
PST - ppublish
SO  - Clin Ther. 2001 Sep;23(9):1391-408. doi: 10.1016/s0149-2918(01)80115-6.

PMID- 20815284
OWN - NLM
STAT- MEDLINE
DCOM- 20130124
LR  - 20161018
IS  - 1003-5370 (Print)
IS  - 1003-5370 (Linking)
VI  - 30
IP  - 6
DP  - 2010 Jun
TI  - [Progress of research on aspirin resistance and its related course of integrative 
      medical research].
PG  - 645-8
AB  - Aspirin is the most classic anti-platelet drug, plays its important role in 
      preventing and treating cardio- and cerebro-vascular diseases for its excellent 
      potency ratio; however, there exists individual difference in its anti-platelet 
      effect, aspirin resistance (AR) presented in about 25%-40% of patients, which 
      seriously influences the intervention effect of aspirin. So AR has become a 
      clinical problem that attached more attention. In this paper, the authors put 
      forward a new thinking for clinical studying and inventing new effective Chinese 
      drugs on AR by means of screen out AR suffered from cardio/cerebro-vascular 
      patients long-term received aspirin; find their gene difference sites from MtSNP 
      to establish a foundation for AR predication and reasonable strategy formation; 
      meantime, through platelet intervention in vitro adopting uniform design 
      optimization method to explore the best compatibility and matching relationship 
      of anti-platelet Chinese medicine for AR prevention and treatment, so as to fully 
      display the multi-target intervening effects of Chinese drug-therapy.
FAU - Lu, Xiao-Yan
AU  - Lu XY
AD  - National Integrative Medicine Center for Cardiovascular Diseases, China-Japan 
      Friendship Hospital, Beijing. deerxiaoyan@126.com
FAU - Xu, Hao
AU  - Xu H
FAU - Chen, Ke-Ji
AU  - Chen KJ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Xi Yi Jie He Za Zhi
JT  - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese 
      journal of integrated traditional and Western medicine
JID - 9211576
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - *Drug Resistance
MH  - Humans
MH  - Integrative Medicine/*methods
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Research Design
EDAT- 2010/09/08 06:00
MHDA- 2013/01/25 06:00
CRDT- 2010/09/07 06:00
PHST- 2010/09/07 06:00 [entrez]
PHST- 2010/09/08 06:00 [pubmed]
PHST- 2013/01/25 06:00 [medline]
PST - ppublish
SO  - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010 Jun;30(6):645-8.

PMID- 6836459
OWN - NLM
STAT- MEDLINE
DCOM- 19830505
LR  - 20131121
IS  - 0039-6087 (Print)
IS  - 0039-6087 (Linking)
VI  - 156
IP  - 4
DP  - 1983 Apr
TI  - Aspirin usage and perioperative blood loss in patients undergoing unexpected 
      operations.
PG  - 439-42
AB  - The effect of aspirin on perioperative blood loss was studied in 52 patients 
      undergoing unplanned operation. Twenty-two of 52 patients were found to have 
      taken aspirin prior to operation. Five others were suspected of having taken 
      aspirin or some aspirin-like drug prior to operation. All patients who remembered 
      taking aspirin preoperatively had significantly decreased platelet thromboxane B2 
      levels caused by aspirin inhibition of platelet arachidonic acid metabolism. 
      Eight of 22 patients who took aspirin had abnormal template bleeding times. No 
      significant increase occurred in the perioperative blood loss of patients who had 
      taken aspirin. Neither the aspirin induced decrease in thromboxane B2 levels nor 
      the increase in template bleeding times was associated with an increased 
      perioperative blood loss. We concluded that aspirin is commonly used prior to 
      unplanned operations but that preoperative aspirin usage does not result in 
      increased perioperative blood loss in patients with normal platelet counts and 
      with normal coagulation factors. These results suggest that there is no need to 
      delay operation in this group of patients because of recent aspirin ingestion.
FAU - Ferraris, V A
AU  - Ferraris VA
FAU - Swanson, E
AU  - Swanson E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Surg Gynecol Obstet
JT  - Surgery, gynecology & obstetrics
JID - 0101370
RN  - 0 (Arachidonic Acids)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/adverse effects/*pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation/drug effects
MH  - Blood Platelets/drug effects
MH  - Hemorrhage/*etiology
MH  - Humans
MH  - *Intraoperative Period
MH  - *Surgical Procedures, Operative
MH  - Thromboxane B2/blood
MH  - Time Factors
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
PST - ppublish
SO  - Surg Gynecol Obstet. 1983 Apr;156(4):439-42.

PMID- 3511824
OWN - NLM
STAT- MEDLINE
DCOM- 19860317
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 104
IP  - 3
DP  - 1986 Mar
TI  - Aspirin and the stomach.
PG  - 390-8
AB  - Aspirin often causes acute gastric mucosal damage that can be seen endoscopically 
      or assessed indirectly (for example, by measuring increased gastrointestinal 
      blood loss). The occurrence of most adverse effects is apparently related to the 
      dose administered. This dose-response effect, evident in both endoscopic and 
      microbleeding studies done after acute or short-term aspirin administration, is 
      also associated with the risk of developing chronic gastric ulcer. The occurrence 
      of gastric adaptation, or lessening injury with continued treatment, obscures the 
      interpretation of results from studies of acute administration. Moreover, 
      evidence of dose-response effects has frequently been ignored when lists of 
      complications and side effects are compiled. The absence of symptoms does not 
      correlate with acute or chronic mucosal damage and appears to have no predictive 
      value. Endoscopic studies linking the extent and degree of acute mucosal injury 
      to various nonsteroidal anti-inflammatory drugs have little or no value in 
      predicting the frequency or severity of chronic gastric ulcer or gastrointestinal 
      bleeding.
FAU - Graham, D Y
AU  - Graham DY
FAU - Smith, J L
AU  - Smith JL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Buffers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adaptation, Physiological
MH  - Anemia/chemically induced
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects/metabolism
MH  - Buffers
MH  - Chronic Disease
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Gastroscopy
MH  - Humans
MH  - Intestinal Absorption
MH  - Membrane Potentials/drug effects
MH  - Stomach Diseases/*chemically induced
MH  - Stomach Ulcer/chemically induced
RF  - 98
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
AID - 10.7326/0003-4819-104-3-390 [doi]
PST - ppublish
SO  - Ann Intern Med. 1986 Mar;104(3):390-8. doi: 10.7326/0003-4819-104-3-390.

PMID- 332184
OWN - NLM
STAT- MEDLINE
DCOM- 19771014
LR  - 20190717
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 20
IP  - 6
DP  - 1977 Jul-Aug
TI  - Aspirin and delayed type hypersensitivity.
PG  - 1174-8
AB  - The effects of aspirin on delayed hypersensitivity were assessed in 40 healthy 
      subjects who were randomly assigned to two equal groups. In a double-blind 
      format, the individuals in one group were placed on 4 gm aspirin daily for 5 
      days, and individuals in the other group were given placebo. Lymphocyte 
      proliferation was measured before and 72 hours after the initiation of drug, by 
      using three mitogens and four antigens. The percentages of T and B lymphocytes 
      were likewise measured before and during therapy. The subjects were skin tested 
      with the same four antigens 72 hours after the initiation of drug, and the skin 
      tests were read 48 hours later. No significant differences between the two groups 
      were detected when skin tests, lymphocyte proliferation, and percentage of T 
      lymphocytes were compared.
FAU - Duncan, M W
AU  - Duncan MW
FAU - Person, D A
AU  - Person DA
FAU - Rich, R R
AU  - Rich RR
FAU - Sharp, J T
AU  - Sharp JT
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Antigens)
RN  - 0 (Antigens, Fungal)
RN  - 0 (Lectins)
RN  - 0 (Mitogens)
RN  - 0 (Placebos)
RN  - 11028-71-0 (Concanavalin A)
RN  - EC 3.- (Streptodornase and Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antigens
MH  - Antigens, Fungal
MH  - Aspirin/immunology/*pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Concanavalin A/pharmacology
MH  - Depression, Chemical
MH  - Female
MH  - Humans
MH  - *Hypersensitivity, Delayed/immunology
MH  - Immunity, Cellular/drug effects
MH  - Lectins/pharmacology
MH  - Lymphocyte Activation/drug effects
MH  - Male
MH  - Mitogens/pharmacology
MH  - Placebos
MH  - Skin Tests
MH  - Streptodornase and Streptokinase/immunology
MH  - Trichophyton/immunology
EDAT- 1977/07/01 00:00
MHDA- 1977/07/01 00:01
CRDT- 1977/07/01 00:00
PHST- 1977/07/01 00:00 [pubmed]
PHST- 1977/07/01 00:01 [medline]
PHST- 1977/07/01 00:00 [entrez]
AID - 10.1002/art.1780200603 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1977 Jul-Aug;20(6):1174-8. doi: 10.1002/art.1780200603.

PMID- 20334544
OWN - NLM
STAT- MEDLINE
DCOM- 20100910
LR  - 20131121
IS  - 1520-5762 (Electronic)
IS  - 0363-9045 (Linking)
VI  - 36
IP  - 7
DP  - 2010 Jul
TI  - Nondestructive prediction of the drug content of an aspirin suppository by 
      near-infrared spectroscopy.
PG  - 839-44
LID - 10.3109/03639040903532053 [doi]
AB  - BACKGROUND: A suppository dosage form has a rapid effect on therapeutics, because 
      it dissolves in the rectum, is absorbed in the bloodstream, and passes the 
      hepatic metabolism. However, the dosage form is unstable, because a suppository 
      is made in a semisolid form, and so it is not easy to mix the bulk drug powder in 
      the base. AIM: This article describes a nondestructive method of determining the 
      drug content of suppositories using near-infrared spectrometry (NIR) combined 
      with chemometrics. METHOD: Suppositories (aspirin content: 1.8, 2.7, 4.5, 7.3, 
      and 9.1%, w/w) were produced by mixing an aspirin bulk powder with hard fat at 50 
      degrees C and pouring the melt mixture into a plastic mold (2.25 mL). NIR spectra 
      of 12 calibration and 12 validation sample sets were recorded 5 times. A total of 
      60 spectral data were used as a calibration set to establish a calibration model 
      to predict drug content with a partial least-squares (PLS) regression analysis. 
      NIR data of the suppository samples were divided into two wave number ranges, 
      4000-12500 cm(-1) (LR), and 5900-6300 cm(-1) (SR). Calibration models for the 
      aspirin content of the suppositories were calculated based on LR and SR ranges of 
      second-derivative NIR spectra using PLS. RESULTS: The models for LR and SR 
      consisted of five and one principal components (PC), respectively. The plots of 
      predicted values against actual values gave a straight line with regression 
      coefficient constants of 0.9531 and 0.9749, respectively. The mean bias and mean 
      accuracy of the calibration models were calculated based on the SR of variation 
      data sets, and were lower than those of LR, respectively. CONCLUSION: Limiting 
      the wave number of spectral data sets is useful to help understand the 
      calibration model because of noise cancellation and to measure objective 
      functions.
FAU - Otsuka, Eri
AU  - Otsuka E
AD  - Research Institute of Pharmaceutical Science, Faculty of Pharmacy, Musashino 
      University, Shinmachi, Nishi-Tokyo, Japan. motsuka@musashino-u.ac.jp
FAU - Abe, Hiroyuki
AU  - Abe H
FAU - Aburada, Masaki
AU  - Aburada M
FAU - Otsuka, Makoto
AU  - Otsuka M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Carriers)
RN  - 0 (Suppositories)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/analysis
MH  - Aspirin/*administration & dosage/*analysis
MH  - Drug Carriers
MH  - Drug Compounding
MH  - Drug Design
MH  - Molecular Weight
MH  - Regression Analysis
MH  - Spectroscopy, Near-Infrared
MH  - Suppositories/*chemistry
EDAT- 2010/03/26 06:00
MHDA- 2010/09/11 06:00
CRDT- 2010/03/26 06:00
PHST- 2010/03/26 06:00 [entrez]
PHST- 2010/03/26 06:00 [pubmed]
PHST- 2010/09/11 06:00 [medline]
AID - 10.3109/03639040903532053 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 2010 Jul;36(7):839-44. doi: 10.3109/03639040903532053.

PMID- 17622200
OWN - NLM
STAT- MEDLINE
DCOM- 20071211
LR  - 20131121
IS  - 0392-9590 (Print)
IS  - 0392-9590 (Linking)
VI  - 26
IP  - 3
DP  - 2007 Sep
TI  - The effectiveness of antiplatelet treatment with aspirin in polymorbid patients.
PG  - 206-12
AB  - AIM: The ineffectiveness of antiplatelet treatment with aspirin is a widely 
      discussed problem today. It is usually described with individual diseases. In old 
      age, the patient is polymorbid and uses numerous treatments. This work enquires 
      into how polymorbidity and polymedication can have an influence on the 
      anti-aggregation effect of aspirin. METHODS: A group of 508 patients, who used 
      100 mg aspirin daily, was examined. Clinical and laboratory tests were carried 
      out on all, and pharmacotherapy analysis was conducted. Selected, concurrently 
      used medicines were divided into 12 groups. Levels of 11-dehydrothromboxane B2 
      (11-dTxB2) in the first morning urine sample were examined in all cases. RESULTS: 
      Of the 508 patients, 233 patients (46%) showed insufficient suppression of 
      urinary thromboxanes. In the resistant group, a statistically significant 
      negative correlation was found with a higher concentration of C-reactive protein 
      and smoking, from co-morbidity with atrial fibrillation and ischemic cerebral 
      stroke in the case history. The risk of ineffective anti-aggregation therapy is 
      increased 1.8 times by smoking and 1.6 times by ischemic cerebral stroke. Every 
      increase in C-reactive protein by one unit increases the ineffectiveness of 
      anti-aggregation therapy by 1.3 times. From the field of pharmacotherapy, a 
      significant positive statistical effect on treatment with statins and nitrates 
      occurred, and a negative effect with digoxin. The possible effectiveness and 
      ineffectiveness of anti-aggregation treatment were not, in this study, influenced 
      to a statistically significant degree by the presence of ischemic coronary 
      disease, ischemic diseases of the lower limbs, arterial hypertension, diabetes 
      and heart failure. CONCLUSION: Anti-aggregation treatment with aspirin in doses 
      of 100 mg per day is, for a major part of polymorbid patients, insufficient. The 
      risk of ineffectiveness of the treatment is increased by smoking, increased 
      levels of C-reactive protein, and from comorbidities of atrial fibrillation and 
      ischemic cerebral stroke. From the point of view of concurrently used medicines, 
      the risk is increased by treatment with digoxin and on the other hand, reduced by 
      treatment with statins and nitrates.
FAU - Paluch, Z
AU  - Paluch Z
AD  - Department of Medicine I, Thomayer's Hospital, Prague, Czech Republic.
FAU - Jedlicková, V
AU  - Jedlicková V
FAU - Skibova, J
AU  - Skibova J
FAU - Adamek, T
AU  - Adamek T
FAU - Alusík, S
AU  - Alusík S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Italy
TA  - Int Angiol
JT  - International angiology : a journal of the International Union of Angiology
JID - 8402693
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/blood/*drug therapy/physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Treatment Outcome
EDAT- 2007/07/12 09:00
MHDA- 2007/12/12 09:00
CRDT- 2007/07/12 09:00
PHST- 2007/07/12 09:00 [pubmed]
PHST- 2007/12/12 09:00 [medline]
PHST- 2007/07/12 09:00 [entrez]
PST - ppublish
SO  - Int Angiol. 2007 Sep;26(3):206-12.

PMID- 24848762
OWN - NLM
STAT- MEDLINE
DCOM- 20150605
LR  - 20211021
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 15
IP  - 5
DP  - 2014 Oct
TI  - Functionality of disintegrants and their mixtures in enabling fast disintegration 
      of tablets by a quality by design approach.
PG  - 1093-104
LID - 10.1208/s12249-014-0137-4 [doi]
AB  - Investigation of the effect of disintegrants on the disintegration time and 
      hardness of rapidly disintegrating tablets (RDTs) was carried out using a quality 
      by design (QbD) paradigm. Ascorbic acid, aspirin, and ibuprofen, which have 
      different water solubilities, were chosen as the drug models. Disintegration time 
      and hardness of RDTs were determined and modeled by executing combined optimal 
      design. The generated models were validated and used for further analysis. Sodium 
      starch glycolate, croscarmellose sodium, and crospovidone were found to lengthen 
      disintegration time when utilized at high concentrations. Sodium starch glycolate 
      and crospovidone worked synergistically in aspirin RDTs to decrease 
      disintegration time. Sodium starch glycolate-crospovidone mixtures, as well as 
      croscarmellose sodium-crospovidone mixtures, also decreased disintegration time 
      in ibuprofen RDTs at high compression pressures as compared to the disintegrants 
      used alone. The use of sodium starch glycolate in RDTs with highly water soluble 
      active ingredients like ascorbic acid slowed disintegration, while 
      microcrystalline cellulose and crospovidone drew water into the tablet rapidly 
      and quickened disintegration. Graphical optimization analysis demonstrated that 
      the RDTs with desired disintegration times and hardness can be formulated with a 
      larger area of design space by combining disintegrants at difference compression 
      pressures. QbD was an efficient and effective paradigm in understanding 
      formulation and process parameters and building quality in to RDT formulated 
      systems.
FAU - Desai, Parind Mahendrakumar
AU  - Desai PM
AD  - GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, 
      National University of Singapore, 18 Science Drive 4, Singapore, 117543, 
      Singapore.
FAU - Er, Patrick Xuan Hua
AU  - Er PX
FAU - Liew, Celine Valeria
AU  - Liew CV
FAU - Heng, Paul Wan Sia
AU  - Heng PW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140522
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/administration & dosage/chemistry
MH  - Aspirin/administration & dosage/chemistry
MH  - Chemistry, Pharmaceutical/*methods
MH  - *Drug Design
MH  - Drug Liberation
MH  - Excipients/chemistry
MH  - Hardness Tests
MH  - Particle Size
MH  - Reproducibility of Results
MH  - Solubility
MH  - Tablets/*chemistry
PMC - PMC4179650
EDAT- 2014/05/23 06:00
MHDA- 2015/06/06 06:00
CRDT- 2014/05/23 06:00
PHST- 2014/01/09 00:00 [received]
PHST- 2014/04/24 00:00 [accepted]
PHST- 2014/05/23 06:00 [entrez]
PHST- 2014/05/23 06:00 [pubmed]
PHST- 2015/06/06 06:00 [medline]
AID - 137 [pii]
AID - 10.1208/s12249-014-0137-4 [doi]
PST - ppublish
SO  - AAPS PharmSciTech. 2014 Oct;15(5):1093-104. doi: 10.1208/s12249-014-0137-4. Epub 
      2014 May 22.

PMID- 18539156
OWN - NLM
STAT- MEDLINE
DCOM- 20081003
LR  - 20131121
IS  - 0891-5849 (Print)
IS  - 0891-5849 (Linking)
VI  - 45
IP  - 5
DP  - 2008 Sep 1
TI  - Effects of (-)-epigallocatechin gallate on the redox reactions of human 
      hemoglobin.
PG  - 659-66
LID - 10.1016/j.freeradbiomed.2008.05.010 [doi]
AB  - The toxicity of acellular hemoglobin (Hb)-based therapeutics has been attributed 
      in part to the uncontrolled oxidative reactions. A variety of antioxidant 
      strategies to ameliorate potential oxidative damage in vivo have been suggested. 
      We have examined the effects of (-)-epigallocatechin gallate (EGCG), a green tea 
      polyphenol compound widely regarded as a chain-breaking antioxidant, on the 
      oxidative stability of diaspirin crosslinked Hb (DBBF) and its cytotoxic ferryl 
      intermediate. DBBF (ferrous) was rapidly oxidized to the ferric form in the 
      presence of EGCG relative to the normal spontaneous oxidation of this Hb. The 
      fast elimination of ferrous Hb is probably due to the ability of EGCG to produce 
      hydrogen peroxide (H2O2) as these reactions were almost completely reversed by 
      the addition of catalase and superoxide dismutase to the reaction medium. EGCG, 
      however, effectively reduced ferryl back to ferric Hb in a biphasic kinetic 
      reaction at physiological pH. At acidic pH where the autoreduction of protonated 
      ferryl Hb is enhanced, a monophasic reduction process of the ferryl heme is 
      achieved. A balance between pro and antioxidant properties of EGCG should be 
      taken into account if EGCG is used in combination therapy with redox active 
      acellular Hbs.
FAU - Jia, Yiping
AU  - Jia Y
AD  - Laboratory of Biochemistry and Vascular Biology, Division of Hematology, Center 
      for Biologics Evaluation and Research, Food and Drug Administration, National 
      Institutes of Health Campus, Bethesda, MD 20892, USA. yiping.jia@fda.hhs.gov
FAU - Alayash, Abdu I
AU  - Alayash AI
LA  - eng
PT  - Journal Article
DEP - 20080524
PL  - United States
TA  - Free Radic Biol Med
JT  - Free radical biology & medicine
JID - 8709159
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 578-19-8 (succinyldisalicylic acid)
RN  - 8R1V1STN48 (Catechin)
RN  - BQM438CTEL (epigallocatechin gallate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/chemistry
MH  - Catechin/*analogs & derivatives/pharmacology
MH  - Cross-Linking Reagents/chemistry
MH  - Hemoglobins/chemistry/*metabolism
MH  - Humans
MH  - Oxidation-Reduction/drug effects
EDAT- 2008/06/10 09:00
MHDA- 2008/10/04 09:00
CRDT- 2008/06/10 09:00
PHST- 2008/01/15 00:00 [received]
PHST- 2008/04/21 00:00 [revised]
PHST- 2008/05/15 00:00 [accepted]
PHST- 2008/06/10 09:00 [pubmed]
PHST- 2008/10/04 09:00 [medline]
PHST- 2008/06/10 09:00 [entrez]
AID - S0891-5849(08)00301-8 [pii]
AID - 10.1016/j.freeradbiomed.2008.05.010 [doi]
PST - ppublish
SO  - Free Radic Biol Med. 2008 Sep 1;45(5):659-66. doi: 
      10.1016/j.freeradbiomed.2008.05.010. Epub 2008 May 24.

PMID- 1780714
OWN - NLM
STAT- MEDLINE
DCOM- 19920312
LR  - 20191021
IS  - 0284-4311 (Print)
IS  - 0284-4311 (Linking)
VI  - 25
IP  - 3
DP  - 1991
TI  - Effect of low and ultra low oral doses of acetylsalicylic acid in microvascular 
      surgery. An experimental study in the rabbit.
PG  - 203-11
AB  - About 10 h after administering acetylsalicylic acid (ASA) orally in doses of 4 mg 
      and 20 micrograms/kg b.w., the central arteries of rabbit ears were subjected to 
      severe vascular trauma (arteriotomy/intimectomy). Bleeding times from the trauma 
      regions at reperfusion were measured and the activities from accumulating 
      32P-labelled homologous platelets recorded until 2 h after reperfusion when 
      patencies were determined. In other studies, the effects of ASA on ex vivo 
      platelet aggregation (aggregometry), thromboxane production, euglobulin clot 
      lysis time and bleeding time following arterial puncture were investigated. 
      Relative to controls, the following parameters were changed: patency was 
      increased, as were the bleeding times following arterial puncture and thromboxane 
      production was reduced. The median values of platelet accumulation were lower, 
      but the changes were not statistically significant. Aggregometry showed decreased 
      rates of platelet aggregability following treatment with ASA 4 mg/kg.
FAU - Salemark, L
AU  - Salemark L
AD  - Department of Plastic and Reconstructive Surgery, Malmö General Hospital, Sweden.
FAU - Wieslander, J B
AU  - Wieslander JB
FAU - Dougan, P
AU  - Dougan P
FAU - Arnljots, B
AU  - Arnljots B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Plast Reconstr Surg Hand Surg
JT  - Scandinavian journal of plastic and reconstructive surgery and hand surgery
JID - 8707869
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Ear, External/blood supply
MH  - Female
MH  - Male
MH  - Microscopy, Electron, Scanning
MH  - Platelet Function Tests
MH  - Postoperative Complications/*prevention & control
MH  - *Premedication
MH  - Rabbits
MH  - Thrombosis/*prevention & control
MH  - Vascular Patency/drug effects
MH  - Vascular Surgical Procedures
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.3109/02844319109020620 [doi]
PST - ppublish
SO  - Scand J Plast Reconstr Surg Hand Surg. 1991;25(3):203-11. doi: 
      10.3109/02844319109020620.

PMID- 7017483
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Controlled clinical study of the treatment of chronic bronchitis with 
      guacetisal].
PG  - 339-46
AB  - Controlled clinical research has been carried out on the activity and tolerance 
      of a new active principle, guacetisal (Broncaspin) obtained from the 
      esterification of acetylsalicylic acid with guaiacol, in the treatment of chronic 
      bronchitis. The drug's therapeutic response was evaluated with respect to that of 
      bromexine. Guacetisal was generally well tolerated. It had no unwanted 
      side-effects on the main haematochemical parameters or on the function of organs 
      and systems. It was found to have considerable therapeutic effectiveness, at 
      times even superior to that of the control drug, with respect to general 
      symptomatology and at respiratory system level. It produced early, lasting 
      reduction in temperature, heart frequency, dyspnoea, duration of expirium and in 
      the intensity and number of coughing attacks. It also led to an appreciable 
      improvement in thoracic objectivity and the X-ray picture. Variations in 
      respiratory functional parameters were of considerable interest and from these it 
      is concluded that guacetisal exerts its polyvalent activity to a proportionately 
      higher extent in the bronchial districts more seriously involved in the 
      inflammatory process, inducing an elective improvement in bronchial permeability, 
      a reduction in total pulmonary resistances--with consequent tendency for 
      ventilation-perfusion relations to normalise--as well as an improvement in gas 
      exchanges and patient oxygenation.
FAU - Caltagirone, S
AU  - Caltagirone S
FAU - Vagliasindi, M
AU  - Vagliasindi M
FAU - Palermo, F
AU  - Palermo F
FAU - Di Maria, G U
AU  - Di Maria GU
FAU - Crimi, N
AU  - Crimi N
FAU - Cusmano, F
AU  - Cusmano F
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Studio clinico controllato sul trattamento della bronchite cronica con 
      guacetisal.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - Q1J152VB1P (Bromhexine)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Bromhexine/*therapeutic use
MH  - Bronchitis/*drug therapy
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Cough/drug therapy
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiration/drug effects
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):339-46.

PMID- 14504184
OWN - NLM
STAT- MEDLINE
DCOM- 20031103
LR  - 20131121
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 108
IP  - 14
DP  - 2003 Oct 7
TI  - Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and 
      low-dose aspirin.
PG  - 1673-5
AB  - BACKGROUND: This study was aimed at verifying whether activation of platelets 
      might represent a source of interleukin (IL)-1beta levels in 
      hypercholesterolemia. To this purpose, we compared the effects of a short-term 
      treatment with simvastatin or low-dose aspirin on circulating levels of this 
      cytokine. METHODS AND RESULTS: Fifty patients with hypercholesterolemia were 
      randomly allocated to receive an 8-week therapeutic course of simvastatin 20 mg 
      daily (n=25) or aspirin 100 mg daily (n=25). Baseline soluble (s) P-selectin 
      directly correlated with IL-1beta (P<0.0001) and C-reactive protein (CRP) 
      (P<0.05) but not with von Willebrand factor, total cholesterol, or LDL 
      cholesterol levels. Furthermore, sP-selectin (P<0.02) and IL-1beta (P<0.0001) 
      levels were independently related to CRP by multiple regression analysis. Both 
      drugs were associated with comparable, significant reductions in IL-1beta and 
      sP-selectin. Simvastatin, but not aspirin treatment, significantly lowered CRP 
      levels (P<0.05). The change in IL-1beta levels correlated with the change in 
      sP-selectin in patients randomized to either simvastatin (Rho, 0.42; P<0.05) or 
      aspirin (Rho, 0.42; P<0.05). In contrast, the simvastatin-induced change in 
      IL-1beta did not correlate with the change in CRP levels. CONCLUSIONS: This study 
      suggests that platelets might contribute to IL-1beta production in 
      hypercholesterolemia, thus providing an additional link between inflammation and 
      the prothrombotic state in this setting.
FAU - Ferroni, Patrizia
AU  - Ferroni P
AD  - Department of Experimental Medicine & Pathology, University of Rome, La Sapienza, 
      Italy.
FAU - Martini, Francesca
AU  - Martini F
FAU - Cardarello, Cristiano M
AU  - Cardarello CM
FAU - Gazzaniga, Pier Paolo
AU  - Gazzaniga PP
FAU - Davi, Giovanni
AU  - Davi G
FAU - Basili, Stefania
AU  - Basili S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20030922
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Interleukin-1)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - AGG2FN16EV (Simvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Hypercholesterolemia/*blood/diagnosis/drug therapy
MH  - Interleukin-1/*blood
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/therapeutic 
      use
MH  - Simvastatin/*pharmacology/therapeutic use
EDAT- 2003/09/25 05:00
MHDA- 2003/11/05 05:00
CRDT- 2003/09/25 05:00
PHST- 2003/09/25 05:00 [pubmed]
PHST- 2003/11/05 05:00 [medline]
PHST- 2003/09/25 05:00 [entrez]
AID - 01.CIR.0000094732.02060.27 [pii]
AID - 10.1161/01.CIR.0000094732.02060.27 [doi]
PST - ppublish
SO  - Circulation. 2003 Oct 7;108(14):1673-5. doi: 10.1161/01.CIR.0000094732.02060.27. 
      Epub 2003 Sep 22.

PMID- 3743627
OWN - NLM
STAT- MEDLINE
DCOM- 19861008
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 30
IP  - 4
DP  - 1986
TI  - Comparative efficacy of soluble aspirin and aspirin tablets in postoperative 
      dental pain.
PG  - 495-8
AB  - The efficacy of single doses (1.2 g) of soluble aspirin and aspirin tablets was 
      determined in a randomised, placebo-controlled, double-blind, parallel study in 
      90 patients (45 females) with postoperative pain after removal of impacted lower 
      third molars. Also investigated was the relationship between plasma aspirin 
      esterase activity and overall pain scores after both aspirin preparations. 
      Patients reported significantly less pain (p less than 0.001) after treatment 
      with aspirin than after treatment with placebo. However, patients receiving 
      soluble aspirin reported both an earlier onset and a longer duration of pain 
      relief than those who received aspirin tablets. A significant correlation was 
      observed between plasma aspirin esterase activity and overall pain scores after 
      both soluble aspirin (r = 0.57, p less than 0.01) and aspirin tablets (r = 0.51, 
      p less than 0.02). It is concluded that soluble aspirin is the preferred aspirin 
      formulation for treating postoperative pain after third molar surgery and that 
      plasma aspirin esterase activity is determinant of a patient's analgesic response 
      to aspirin in postoperative dental pain.
FAU - Seymour, R A
AU  - Seymour RA
FAU - Williams, F M
AU  - Williams FM
FAU - Luyk, N M
AU  - Luyk NM
FAU - Boyle, M A
AU  - Boyle MA
FAU - Whitfield, P M
AU  - Whitfield PM
FAU - Nicholson, E
AU  - Nicholson E
FAU - Booth, P W
AU  - Booth PW
FAU - Rawlins, M D
AU  - Rawlins MD
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Solutions)
RN  - 0 (Tablets)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.- (acetylsalicylic acid hydrolase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Carboxylic Ester Hydrolases/*blood
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/*drug therapy/enzymology
MH  - Random Allocation
MH  - Solutions
MH  - Tablets
MH  - Tooth Extraction
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1007/BF00607968 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1986;30(4):495-8. doi: 10.1007/BF00607968.

PMID- 7486364
OWN - NLM
STAT- MEDLINE
DCOM- 19951214
LR  - 20190717
IS  - 0196-0644 (Print)
IS  - 0196-0644 (Linking)
VI  - 26
IP  - 5
DP  - 1995 Nov
TI  - Effect of multiple-dose activated charcoal on the clearance of high-dose 
      intravenous aspirin in a porcine model.
PG  - 569-74
AB  - STUDY OBJECTIVE: To study the effect of multiple-dose activated charcoal (MDAC) 
      on salicylate clearance in pigs given high-dose i.v. aspirin. DESIGN: In a 
      crossover design, six fasted pigs received 300 mg/kg i.v. aspirin followed by no 
      treatment or MDAC (1 g/kg hourly for 6 doses by gastrostomy). Serum salicylate 
      samples were obtained every 30 minutes for 6 hours. RESULTS: The mean peak 
      salicylate concentrations were 47.4 +/- 6.2 mg/dL and 48.4 +/- 3.9 mg/dL (P = 
      .74), and the areas under the time-serum salicylate concentration curve over 6 
      hours were 171,000 +/- 24,000 mg.minute/L and 188,000 +/- 18,000 mg.minute/L for 
      the control and treatment arms, respectively (P = .22). This study had a 90% 
      power to detect a 30% difference between arms. CONCLUSION: MDAC does not enhance 
      the clearance of salicylate after administration of high-dose i.v. aspirin.
FAU - Johnson, D
AU  - Johnson D
AD  - Division of Clinical Pharmacology, Hospital for Sick Children, University of 
      Toronto, Ontario.
FAU - Eppler, J
AU  - Eppler J
FAU - Giesbrecht, E
AU  - Giesbrecht E
FAU - Verjee, Z
AU  - Verjee Z
FAU - Rais, A
AU  - Rais A
FAU - Wiggins, T
AU  - Wiggins T
FAU - Fraga, C
AU  - Fraga C
FAU - Ito, S
AU  - Ito S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
RN  - 0 (Antidotes)
RN  - 0 (Salicylates)
RN  - 16291-96-6 (Charcoal)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Emerg Med. 1996 May;27(5):672-3. PMID: 8629794
MH  - Animals
MH  - Antidotes/*therapeutic use
MH  - Aspirin/blood/pharmacokinetics/*poisoning
MH  - Charcoal/*therapeutic use
MH  - Cross-Over Studies
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Metabolic Clearance Rate
MH  - Poisoning/drug therapy
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Swine
MH  - Time Factors
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - S0196-0644(95)70006-4 [pii]
AID - 10.1016/s0196-0644(95)70006-4 [doi]
PST - ppublish
SO  - Ann Emerg Med. 1995 Nov;26(5):569-74. doi: 10.1016/s0196-0644(95)70006-4.

PMID- 28322829
OWN - NLM
STAT- MEDLINE
DCOM- 20171108
LR  - 20171108
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 805
DP  - 2017 Jun 15
TI  - AT-RvD1 modulates the activation of bronchial epithelial cells induced by 
      lipopolysaccharide and Dermatophagoides pteronyssinus.
PG  - 46-50
LID - S0014-2999(17)30199-1 [pii]
LID - 10.1016/j.ejphar.2017.03.029 [doi]
AB  - Bronchial epithelial cells are essential to airways homeostasis; however, they 
      are also involved in exacerbation of airway inflammatory responses of patients 
      with conditions such as asthma. Dermatophagoides pteronyssinus (Dp), the most 
      important allergen, and lipopolysaccharide (LPS), both of which are present in 
      house dust mites (HDM), can activate immune and structural cells (such as 
      bronchial epithelial cells) and modulate the airway inflammation in asthma 
      patients. Resolvin D1 (RvD1) and its epimer aspirin-triggered-resolvin D1 
      (AT-RvD1) are lipid mediators that are produced during the resolution of 
      inflammation and demonstrate anti-inflammatory and pro-resolution effects in 
      several experimental models including experimental models of allergic airway 
      inflammation. Here, we evaluated the effects of AT-RvD1 (10(-12)-10(-10) M) on 
      human bronchial epithelial cells (BEAS-2B) stimulated with LPS (2μg/ml) or Dp 
      (10μg/ml). After 24h, the C-C motif chemokine ligand 2 (CCL-2) production was 
      increased in cells that had been stimulated with LPS and Dp compared to the 
      control. However, AT-RvD1 (10(-11) and 10(-10) M) significantly reduced the 
      concentration of CCL-2 in a manner that was dependent on the N-formyl peptide 
      receptor 2 (FPR2/ALX) and nuclear factor kappa B (NF-κB) pathways in cells 
      stimulated with LPS or Dp compared to controls. In addition, AT-RvD1 reduced the 
      phosphorylation of signal transducer and activator of transcription (STAT)6 and 
      STAT1 in cells stimulated with Dp and LPS, respectively. In conclusion, AT-RvD1 
      demonstrated significant anti-inflammatory effects in bronchial epithelial cells 
      that were stimulated with LPS or Dp, which provides new perspectives for 
      therapeutic strategies to control inflammatory airway diseases.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - de Oliveira, Jhony Robison
AU  - de Oliveira JR
AD  - Institute of Health Sciences, Department of Clinical Medicine, Laboratory of 
      Experimental Immunopharmacology, Federal University of Triangulo Mineiro, 
      Uberaba, MG 38025-350, Brazil.
FAU - da Silva, Paulo Roberto
AU  - da Silva PR
AD  - Institute of Health Sciences, Department of Clinical Medicine, Laboratory of 
      Experimental Immunopharmacology, Federal University of Triangulo Mineiro, 
      Uberaba, MG 38025-350, Brazil.
FAU - Rogério, Alexandre de Paula
AU  - Rogério AP
AD  - Institute of Health Sciences, Department of Clinical Medicine, Laboratory of 
      Experimental Immunopharmacology, Federal University of Triangulo Mineiro, 
      Uberaba, MG 38025-350, Brazil. Electronic address: alexandre.rogerio@uftm.edu.br.
LA  - eng
PT  - Journal Article
DEP - 20170318
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Lipopolysaccharides)
RN  - 0 (resolvin D1)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry/*pharmacology
MH  - Bronchi/*cytology
MH  - Cell Line
MH  - Dermatophagoides pteronyssinus/*physiology
MH  - Docosahexaenoic Acids/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Epithelial Cells/*cytology/*drug effects
MH  - Humans
MH  - Lipopolysaccharides/*pharmacology
MH  - Stereoisomerism
OTO - NOTNLM
OT  - AT-RvD1
OT  - Bronchial Epithelial Cells
OT  - Dermatophagoides pteronyssinus
OT  - FPR2/ALX receptor
OT  - Lipopolysaccharide
EDAT- 2017/03/23 06:00
MHDA- 2017/11/09 06:00
CRDT- 2017/03/22 06:00
PHST- 2016/12/14 00:00 [received]
PHST- 2017/03/11 00:00 [revised]
PHST- 2017/03/15 00:00 [accepted]
PHST- 2017/03/23 06:00 [pubmed]
PHST- 2017/11/09 06:00 [medline]
PHST- 2017/03/22 06:00 [entrez]
AID - S0014-2999(17)30199-1 [pii]
AID - 10.1016/j.ejphar.2017.03.029 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2017 Jun 15;805:46-50. doi: 10.1016/j.ejphar.2017.03.029. Epub 
      2017 Mar 18.

PMID- 35162965
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220308
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 3
DP  - 2022 Jan 18
TI  - The Importance of Platelets Response during Antiplatelet Treatment after Ischemic 
      Stroke-Between Benefit and Risk: A Systematic Review.
LID - 10.3390/ijms23031043 [doi]
LID - 1043
AB  - Ischemic stroke is a disease related to abnormal blood flow that leads to brain 
      dysfunction. The early and late phases of the disease are distinguished. A 
      distinction is made between the early and late stages of the disease, and the 
      best effect in treating an ischemic stroke is usually achieved within the first 
      hours after the onset of symptoms. This review looked at studies platelet 
      activity monitoring studies to determine the risks and benefits of various 
      approaches including antiplatelet therapy. A study was conducted on recently 
      published literature based on PRISMA. This review includes 32 research articles 
      directly addressing the importance of monitoring platelet function during 
      antiplatelet therapy (dual or monotherapy) after ischemic stroke. In patients 
      with transient ischemic attack or ischemic stroke, antiplatelet therapy can 
      reduce the risk of stroke by 11-15%, assuming that patients respond well. 
      Secondary prevention results are dependent on platelet reactivity, meaning that 
      patients do not respond equally to antiplatelet therapy. It is very important 
      that aspirin-resistant patients can benefit from the use of dual antiplatelet 
      therapy. The individualized approach to secondary stroke prevention is to 
      administer the most appropriate drug at the correct dose and apply the optimal 
      therapeutic procedure to the individual patient.
FAU - Sikora, Joanna
AU  - Sikora J
AUID- ORCID: 0000-0003-1095-3844
AD  - Research and Education Unit for Experimental Biotechnology, Department of 
      Transplantology and General Surgery, Faculty of Medicine, Collegium Medicum in 
      Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland.
FAU - Karczmarska-Wódzka, Aleksandra
AU  - Karczmarska-Wódzka A
AUID- ORCID: 0000-0003-4077-6412
AD  - Research and Education Unit for Experimental Biotechnology, Department of 
      Transplantology and General Surgery, Faculty of Medicine, Collegium Medicum in 
      Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland.
FAU - Bugieda, Joanna
AU  - Bugieda J
AUID- ORCID: 0000-0001-5008-1943
AD  - Research and Education Unit for Experimental Biotechnology, Department of 
      Transplantology and General Surgery, Faculty of Medicine, Collegium Medicum in 
      Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland.
FAU - Sobczak, Przemysław
AU  - Sobczak P
AD  - Department of Laboratory Medicine, Collegium Medicum in Bydgoszcz, Nicolaus 
      Copernicus University in Toruń, 85-094 Bydgoszcz, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20220118
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ischemic Stroke/blood/*drug therapy
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
PMC - PMC8835275
OTO - NOTNLM
OT  - antiplatelet drugs
OT  - ischemic stroke
OT  - monitoring of platelet function
OT  - personalized treatment
COIS- The authors declare no conflict of interest.
EDAT- 2022/02/16 06:00
MHDA- 2022/03/09 06:00
CRDT- 2022/02/15 01:15
PHST- 2021/12/07 00:00 [received]
PHST- 2022/01/11 00:00 [revised]
PHST- 2022/01/13 00:00 [accepted]
PHST- 2022/02/15 01:15 [entrez]
PHST- 2022/02/16 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
AID - ijms23031043 [pii]
AID - ijms-23-01043 [pii]
AID - 10.3390/ijms23031043 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Jan 18;23(3):1043. doi: 10.3390/ijms23031043.

PMID- 30998747
OWN - NLM
STAT- MEDLINE
DCOM- 20191216
LR  - 20200309
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 4
DP  - 2019
TI  - Effect of preconception low dose aspirin on pregnancy and live birth according to 
      socioeconomic status: A secondary analysis of a randomized clinical trial.
PG  - e0200533
LID - 10.1371/journal.pone.0200533 [doi]
LID - e0200533
AB  - Low socioeconomic status (SES) is associated with adverse pregnancy outcomes and 
      infertility. Low-dose aspirin (LDA) was shown to improve livebirth rates in 
      certain subsets of women, and therefore, may impact pregnancy rates 
      differentially by SES status. Therefore, the aim of the current study was to 
      examine whether daily preconception-initiated LDA affects rates of pregnancy, 
      livebirth, and pregnancy loss differently across strata of socioeconomic status 
      (SES). This is a secondary analysis of The Effects of Aspirin in Gestation and 
      Reproduction (EAGeR) Trial, a multisite, block- randomized, placebo-controlled 
      trial conducted at four U.S. medical centers (n = 1,228, 2007-2012). Women 
      attempting spontaneous conception with a history of pregnancy loss were randomly 
      allocated preconception to 81mg of aspirin + 400mcg of folic acid (n = 615) or 
      placebo + 400mcg of folic acid (n = 613). Study medication was administered for 
      six menstrual cycles or until 36 weeks' gestation if pregnancy was achieved. For 
      this analysis, women were stratified by SES, which included income (low, mid, 
      high) and a combined grouping of education and income (low-low, low-high, 
      high-low, high-high). Log binomial models with robust variance estimated risks of 
      pregnancy, livebirth, and pregnancy loss for LDA versus placebo. LDA increased 
      pregnancy and livebirth rates (RR 1.23, 95% CI: 1.03, 1.45) in the high-income, 
      but not mid- or low-income groups. LDA increased pregnancy rates in both the low 
      education-low income group (RR 1.22, 95% CI: 1.02, 1.46) and the high 
      education-high income group (RR 1.23, 95%CI: 1.06, 1.42), with no effect observed 
      in mid-SES groupings. LDA, a low-cost and widely available treatment, may be 
      particularly beneficial to women at the highest and lowest ends of the 
      socioeconomic spectrum, though underlying mechanisms of this disparity are 
      unclear. Confirming these findings and identifying factors which may modulate the 
      effectiveness of LDA will ultimately facilitate personalized clinical care and 
      improvements in population-level reproductive health. Trial registration number: 
      ClinicalTrials.gov, NCT00467363.
FAU - Agrawala, Shilpi
AU  - Agrawala S
AD  - University of Texas Southwestern Medical Center, Dallas, TX, United States of 
      America.
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD, United States of America.
FAU - Sjaarda, Lindsey A
AU  - Sjaarda LA
AUID- ORCID: 0000-0003-0539-8110
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD, United States of America.
FAU - Omosigho, Ukpebo R
AU  - Omosigho UR
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD, United States of America.
FAU - Perkins, Neil J
AU  - Perkins NJ
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD, United States of America.
FAU - Silver, Robert M
AU  - Silver RM
AD  - Department of Obstetrics and Gynecology, University of Utah and Intermountain 
      Healthcare, Salt Lake City, UT, United States of America.
FAU - Mumford, Sunni L
AU  - Mumford SL
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD, United States of America.
FAU - Connell, Matthew T
AU  - Connell MT
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD, United States of America.
AD  - Program of Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National 
      Institute of Child Health and Human Development, National Institutes of Health, 
      Bethesda, MD, United States of America.
FAU - Naimi, Ashley I
AU  - Naimi AI
AD  - Department of Epidemiology, University of Pittsburgh Graduate School of Public 
      Health, Pittsburgh, PA, United States of America.
FAU - Halvorson, Lisa M
AU  - Halvorson LM
AD  - Gynecologic Health and Disease Branch, Division of Extramural Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD, United States of America.
FAU - Schisterman, Enrique F
AU  - Schisterman EF
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD, United States of America.
LA  - eng
SI  - ClinicalTrials.gov/NCT00467363
GR  - R01 HD093602/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190418
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Aspirin/administration & dosage/economics
MH  - Female
MH  - Humans
MH  - Live Birth/*economics
MH  - Preconception Care/*economics
MH  - Pregnancy
MH  - *Pregnancy Rate
MH  - Socioeconomic Factors
PMC - PMC6472730
COIS- Study funding/competing interest(s): Eunice Kennedy Shriver National Institute of 
      Child Health and Human Development (Contract Nos. HHSN267200603423, 
      HHSN267200603424, HHSN267200603426); NIH Medical Research Scholars Program; Doris 
      Duke Charitable Foundation (Grant #2014194). The authors have no competing 
      interests to report. Trial registration number: ClinicalTrials.gov, NCT00467363.
EDAT- 2019/04/19 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/04/19 06:00
PHST- 2017/09/19 00:00 [received]
PHST- 2018/06/25 00:00 [accepted]
PHST- 2019/04/19 06:00 [entrez]
PHST- 2019/04/19 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
AID - PONE-D-17-33258 [pii]
AID - 10.1371/journal.pone.0200533 [doi]
PST - epublish
SO  - PLoS One. 2019 Apr 18;14(4):e0200533. doi: 10.1371/journal.pone.0200533. 
      eCollection 2019.

PMID- 315734
OWN - NLM
STAT- MEDLINE
DCOM- 19800128
LR  - 20190911
IS  - 0065-6100 (Print)
IS  - 0065-6100 (Linking)
VI  - 210
IP  - 3
DP  - 1979 May 7
TI  - [Inhibition of secondary increase of intraocular pressure following 
      cyclokryocoagulation (author's transl)].
PG  - 225-8
AB  - Prostaglandin mediated transient increase in intraocular pressure following 
      cryokoagulation of the ciliary body in rabbits was completely inhibited by 
      preoperative administration of Aspisol (D, L-Lysin-mono-(acetylsalicylat)). To 
      avoid additional increase in intraocular pressure in patients chosen for 
      cyclocryotherapy, pretreatment with Aspisol could prove to be effective.
FAU - Haddad, R
AU  - Haddad R
FAU - Grabner, G
AU  - Grabner G
FAU - Braun, F
AU  - Braun F
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Die Blockade sekundärer Drucksteigerungen nach Cyclokryocoagulation.
PL  - Germany
TA  - Albrecht Von Graefes Arch Klin Exp Ophthalmol
JT  - Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 
      Albrecht von Graefe's archive for clinical and experimental ophthalmology
JID - 0044637
RN  - 0 (Prostaglandins)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Ciliary Body/metabolism
MH  - Cold Temperature
MH  - Depression, Chemical
MH  - Female
MH  - Intraocular Pressure/*drug effects
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
MH  - Prostaglandins/*biosynthesis
MH  - Rabbits
EDAT- 1979/05/07 00:00
MHDA- 1979/05/07 00:01
CRDT- 1979/05/07 00:00
PHST- 1979/05/07 00:00 [pubmed]
PHST- 1979/05/07 00:01 [medline]
PHST- 1979/05/07 00:00 [entrez]
AID - 10.1007/BF00414574 [doi]
PST - ppublish
SO  - Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1979 May 7;210(3):225-8. doi: 
      10.1007/BF00414574.

PMID- 10347783
OWN - NLM
STAT- MEDLINE
DCOM- 19990909
LR  - 20190516
IS  - 0100-879X (Print)
IS  - 0100-879X (Linking)
VI  - 32
IP  - 3
DP  - 1999 Mar
TI  - Sex-dependent differences in the activities of acetylsalicylic acid-esterases in 
      mouse kidneys.
PG  - 275-8
AB  - Acetylsalicylic acid (ASA), the most used drug worldwide, is hydrolyzed to 
      salicylic acid and acetate by esterases present in tissues of several species 
      including humans. Sex differences in drug metabolism by rodent liver are 
      documented in the literature. In this paper we report a difference in the 
      activities of the esterases (ASA-esterase I and II) in the kidneys of male and 
      female mice. In this species there is no difference between males and females in 
      liver ASA-esterases (ASA-esterase I: males 38.5 +/- 7.9 (N = 5) and females 31.6 
      +/- 7.6 (N = 5) nmol of salicylic acid formed min-1 mg protein-1, P > 0.05; 
      ASA-esterase II: males 77.3 +/- 17.4 (N = 5) and females 61.4 +/- 15.1 (N = 5) 
      nmol of salicylic acid formed min-1 mg protein-1, P > 0.05). However, in the 
      kidneys males presented a much higher enzyme activity than females (ASA-esterase 
      I: males 25.2 +/- 6.3 (N = 5) and females 6.8 +/- 0.6 (N = 5) nmol of salicylic 
      acid formed min-1 mg protein-1, P < 0.0002; ASA-esterase II: males 79.8 +/- 10.1 
      (N = 5) and females 13.0 +/- 1.1 (N = 5) nmol of salicylic acid formed min-1 mg 
      protein-1, P < 0.0001). The difference between sexes observed in mouse kidneys 
      could serve as a model to study the molecular basis of this sex difference and 
      also to determine the possible involvement of pituitary and gonadal hormones in 
      this difference in ASA-esterase activities since these hormones control the sex 
      differences in rodent liver enzyme activity.
FAU - Benedito, M A
AU  - Benedito MA
AD  - Departamento de Psicobiologia, Escola Paulista de Medicina, Universidade Federal 
      de São Paulo, Brasil.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Brazil
TA  - Braz J Med Biol Res
JT  - Brazilian journal of medical and biological research = Revista brasileira de 
      pesquisas medicas e biologicas
JID - 8112917
RN  - 0 (Fatty Acids)
RN  - EC 3.1.- (Esterases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*metabolism/pharmacology
MH  - Esterases/*metabolism
MH  - Fatty Acids/metabolism
MH  - Female
MH  - Kidney/drug effects/*enzymology
MH  - Liver/drug effects/enzymology
MH  - Male
MH  - Mice
MH  - Sex Characteristics
MH  - *Sex Differentiation
EDAT- 1999/05/29 00:00
MHDA- 1999/05/29 00:01
CRDT- 1999/05/29 00:00
PHST- 1999/05/29 00:00 [pubmed]
PHST- 1999/05/29 00:01 [medline]
PHST- 1999/05/29 00:00 [entrez]
AID - 10.1590/s0100-879x1999000300004 [doi]
PST - ppublish
SO  - Braz J Med Biol Res. 1999 Mar;32(3):275-8. doi: 10.1590/s0100-879x1999000300004.

PMID- 7718584
OWN - NLM
STAT- MEDLINE
DCOM- 19950523
LR  - 20190613
IS  - 0006-2960 (Print)
IS  - 0006-2960 (Linking)
VI  - 34
IP  - 14
DP  - 1995 Apr 11
TI  - Oxygen equilibrium properties of nickel(II)-iron(II) hybrid hemoglobins 
      cross-linked between 82 beta 1 and 82 beta 2 lysyl residues by 
      bis(3,5-dibromosalicyl)fumarate: determination of the first two-step microscopic 
      Adair constants for human hemoglobin.
PG  - 4773-80
AB  - We have previously reported that cross-linked asymmetric Ni(II)-Fe(II) hybrid 
      hemoglobin, XL[alpha (Fe) beta (Fe)][alpha (Ni) beta (Ni)], in which the alpha 1 
      beta 1 dimer containing ferrous protoporphyrin IX and the adjacent alpha 2 beta 2 
      dimer containing nickel(II) protoporphyrin IX were cross-linked between Lys-82 
      beta 1 and Lys-82 beta 2 by reaction with bis(3,5-dibromosalicyl)fumarate, 
      represents an adequate model for determination of the alpha 1 beta 1 oxygenation 
      properties of native hemoglobin [Shibayama, N., Imai, K., Morimoto, H., & Saigo, 
      S. (1993) Biochemistry 32, 8792-8798]. To extend the approach using cross-linked 
      Ni(II)-Fe(II) hybrids to all possible pathways for initial-half oxygenation of 
      hemoglobin, we have prepared three other types of cross-linked Ni(II)-Fe(II) 
      hybrids, carrying nickel(II) protoporphyrin IX in two subunits and ferrous 
      protoporphyrin IX in the other two subunits, and have determined the two-step 
      oxygen equilibrium curves of the ferrous subunits within these cross-linked 
      hybrids. For the first step of oxygenation, the alpha subunit shows about 3-fold 
      higher affinity than the beta subunit at all pH values examined, indicative of a 
      significant functional heterogeneity of the subunits in deoxyhemoglobin. For the 
      second step of oxygenation, the cooperativity represented by the Hill coefficient 
      (nmax) increases in the order of beta 1 beta 2 (nmax = 1.36), alpha 1 beta 1 
      (nmax = 1.41), alpha 1 beta 2 (nmax = 1.64), and alpha 1 alpha 2 (nmax = 1.72) at 
      pH 7.4 in the presence of 0.1 M Cl- at 25 degrees C.(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Shibayama, N
AU  - Shibayama N
AD  - Department of Physics, Jichi Medical School, Tochigi, Japan.
FAU - Imai, K
AU  - Imai K
FAU - Morimoto, H
AU  - Morimoto H
FAU - Saigo, S
AU  - Saigo S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (nickel-iron hybrid hemoglobin)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 7OV03QG267 (Nickel)
RN  - E1UOL152H7 (Iron)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemistry
MH  - Cross-Linking Reagents/chemistry
MH  - Hemoglobins/*chemistry
MH  - Humans
MH  - Iron/*chemistry
MH  - Lysine/chemistry
MH  - Nickel/*chemistry
MH  - Oxygen/*chemistry
MH  - Protein Multimerization
EDAT- 1995/04/11 00:00
MHDA- 1995/04/11 00:01
CRDT- 1995/04/11 00:00
PHST- 1995/04/11 00:00 [pubmed]
PHST- 1995/04/11 00:01 [medline]
PHST- 1995/04/11 00:00 [entrez]
AID - 10.1021/bi00014a035 [doi]
PST - ppublish
SO  - Biochemistry. 1995 Apr 11;34(14):4773-80. doi: 10.1021/bi00014a035.

PMID- 35751401
OWN - NLM
STAT- MEDLINE
DCOM- 20220907
LR  - 20220907
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 48
IP  - 9
DP  - 2022 Sep
TI  - Low-dose aspirin for prevention of preeclampsia: Implementation of the NICE 
      guideline in Thailand.
PG  - 2345-2352
LID - 10.1111/jog.15343 [doi]
AB  - AIM: To evaluate the effectiveness of a preeclampsia (PE) screening program using 
      the National Institute for Health and Care Excellence (NICE) guideline in 
      pregnant Thai women. METHODS: A total of 2552 pregnancies received antenatal care 
      and were delivered at Songklanagarind Hospital between November 2016 and April 
      2020. PE screening with the NICE guideline was used to identify mothers at risk. 
      In cases of positive screening results, a daily dose of 81 mg aspirin was 
      prescribed. Pregnancy outcomes were compared with 2783 participants who had 
      maternity care before the implementation of the screening program. The 
      effectiveness of aspirin prophylaxis following the NICE guideline was assessed by 
      a logistic regression model to compare the risk of PE development between before 
      and after guidance. RESULTS: The screening positive rate by NICE was 8.3%. Of 
      these, 77.36% of the participants received aspirin prophylaxis according to the 
      NICE recommendation. After the implementation of the PE screening program, the 
      incidence of PE slightly decreased (from 4.31% to 3.72%, p = 0.274). The chance 
      of PE in pregnancies who had high-risk factors was reduced after using low-dose 
      aspirin prophylaxis, even though the difference was not statistically 
      significant. CONCLUSIONS: Screening with the NICE guidelines followed by 
      prescription of low-dose aspirin (81 mg/day) was probably not an effective 
      strategy for the prevention of PE in our population. Combining biophysical and 
      biochemical markers to identify pregnant women who subsequently develop PE, 
      concurrently with an increased dose of aspirin prophylaxis, may provide a better 
      outcome in clinical practice.
CI  - © 2022 Japan Society of Obstetrics and Gynecology.
FAU - Suksai, Manaphat
AU  - Suksai M
AUID- ORCID: 0000-0003-4441-4988
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla 
      University, Songkhla, Thailand.
FAU - Geater, Alan
AU  - Geater A
AD  - Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla, 
      Thailand.
FAU - Suntharasaj, Thitima
AU  - Suntharasaj T
AUID- ORCID: 0000-0001-7343-5425
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla 
      University, Songkhla, Thailand.
FAU - Suwanrath, Chitkasaem
AU  - Suwanrath C
AUID- ORCID: 0000-0001-8634-2359
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla 
      University, Songkhla, Thailand.
FAU - Charernjiratragul, Kla
AU  - Charernjiratragul K
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla 
      University, Songkhla, Thailand.
FAU - Khwankaew, Noppasin
AU  - Khwankaew N
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla 
      University, Songkhla, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20220624
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Maternal Health Services
MH  - *Pre-Eclampsia/diagnosis
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Thailand
OTO - NOTNLM
OT  - NICE guideline
OT  - Thai
OT  - aspirin
OT  - preeclampsia
OT  - prevention
EDAT- 2022/06/26 06:00
MHDA- 2022/09/08 06:00
CRDT- 2022/06/25 02:32
PHST- 2022/06/03 00:00 [revised]
PHST- 2022/02/14 00:00 [received]
PHST- 2022/06/14 00:00 [accepted]
PHST- 2022/06/26 06:00 [pubmed]
PHST- 2022/09/08 06:00 [medline]
PHST- 2022/06/25 02:32 [entrez]
AID - 10.1111/jog.15343 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2022 Sep;48(9):2345-2352. doi: 10.1111/jog.15343. Epub 
      2022 Jun 24.

PMID- 1149460
OWN - NLM
STAT- MEDLINE
DCOM- 19751106
LR  - 20131121
IS  - 0010-8650 (Print)
IS  - 0010-8650 (Linking)
VI  - 17
IP  - 1
DP  - 1975
TI  - The effect of some antithrombotic drugs on experimental arterial thrombosis.
PG  - 66-74
AB  - The model of arterial thrombosis in rats used in this study is especially 
      suitable for testing the preventive effect of antithrombotic drugs. An oral 
      anticoagulant was ineffective in this model. Heparin, streptokinase, 
      acetylsalicylic acid and dipyridamole were only moderately effective whereas 
      highest effectiveness was attained by combining heparin with acetylsalicylic 
      acid.
FAU - Hladovec, J
AU  - Hladovec J
LA  - eng
PT  - Journal Article
PL  - Czech Republic
TA  - Cor Vasa
JT  - Cor et vasa
JID - 0372614
RN  - 0 (Anticoagulants)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Anticoagulants/*therapeutic use
MH  - *Arteries
MH  - Aspirin/pharmacology/therapeutic use
MH  - Dipyridamole/pharmacology
MH  - Drug Synergism
MH  - Fibrinolysis/drug effects
MH  - Heparin/pharmacology/therapeutic use
MH  - Models, Biological
MH  - Prothrombin Time
MH  - Rats
MH  - Streptokinase/therapeutic use
MH  - Thrombosis/*drug therapy
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
PST - ppublish
SO  - Cor Vasa. 1975;17(1):66-74.

PMID- 21355319
OWN - NLM
STAT- MEDLINE
DCOM- 20130926
LR  - 20131121
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 44
IP  - 11
DP  - 2009 Nov
TI  - [Advances in the study of nitric oxide-donating drugs].
PG  - 1200-10
AB  - Nitric oxide (NO) as a messenger and/or effector plays important roles in vivo. 
      The decreased availability of NO or dysfunction in NO signaling has often been 
      implicated in the development and progression of diseases, and design and 
      research of NO-donating drugs has become one of the important strategies in drug 
      discovery. In connection with authors' scientific practice, this article reviews 
      the recent advances in the research of NO-donating drugs.
FAU - Zhang, Yi-hua
AU  - Zhang YH
AD  - Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China. 
      zyhtgd@sohu.com
FAU - Peng, Si-xun
AU  - Peng SX
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Azo Compounds)
RN  - 0 (N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 
      4-(nitrooxy)butyl ester)
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (O(2)-(2,4-dinitrophenyl) 
      1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate)
RN  - 0 (Piperazines)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Aspirin/analogs & derivatives/pharmacology/therapeutic use
MH  - Azo Compounds/pharmacology
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cell Line, Tumor
MH  - Drug Design
MH  - Humans
MH  - Neoplasms/drug therapy/pathology
MH  - Nitrates/pharmacology/therapeutic use
MH  - Nitric Oxide/*metabolism
MH  - Nitric Oxide Donors/*pharmacology/therapeutic use
MH  - Piperazines/pharmacology
MH  - Signal Transduction/drug effects
EDAT- 2009/11/01 00:00
MHDA- 2013/09/27 06:00
CRDT- 2011/03/02 06:00
PHST- 2011/03/02 06:00 [entrez]
PHST- 2009/11/01 00:00 [pubmed]
PHST- 2013/09/27 06:00 [medline]
PST - ppublish
SO  - Yao Xue Xue Bao. 2009 Nov;44(11):1200-10.

PMID- 968799
OWN - NLM
STAT- MEDLINE
DCOM- 19761201
LR  - 20190503
IS  - 0040-6376 (Print)
IS  - 1468-3296 (Electronic)
IS  - 0040-6376 (Linking)
VI  - 31
IP  - 4
DP  - 1976 Aug
TI  - Complement components and IgE in patients with asthma and aspirin idiosyncrasy.
PG  - 425-7
AB  - Levels of circulating IgE, total haemolytic complement, and components C4 and C3 
      were measured in 16 asthmatics with aspirin idiosyncrasy and in control subjects. 
      IgE levels were mostly within normal limits. No differences were found between 
      the complement profiles-in particular the C4 levels-in the two groups. As low 
      levels of C4 have been found in patients with intrinsic asthma, these results 
      would suggest a fundamental difference between asthmatics with aspirin 
      idiosyncrasy and others with intrinsic asthma.
FAU - Delaney, J C
AU  - Delaney JC
FAU - Kay, A B
AU  - Kay AB
LA  - eng
PT  - Journal Article
PL  - England
TA  - Thorax
JT  - Thorax
JID - 0417353
RN  - 0 (Complement C3)
RN  - 0 (Complement C4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/*immunology
MH  - Complement C3/analysis
MH  - Complement C4/analysis
MH  - Drug Hypersensitivity/*immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/*analysis
MH  - Male
PMC - PMC470453
EDAT- 1976/08/01 00:00
MHDA- 1976/08/01 00:01
CRDT- 1976/08/01 00:00
PHST- 1976/08/01 00:00 [pubmed]
PHST- 1976/08/01 00:01 [medline]
PHST- 1976/08/01 00:00 [entrez]
AID - 10.1136/thx.31.4.425 [doi]
PST - ppublish
SO  - Thorax. 1976 Aug;31(4):425-7. doi: 10.1136/thx.31.4.425.

PMID- 26230053
OWN - NLM
STAT- MEDLINE
DCOM- 20160913
LR  - 20220330
IS  - 1099-0801 (Electronic)
IS  - 0269-3879 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Mar
TI  - Simultaneous quantitation of acetylsalicylic acid and clopidogrel along with 
      their metabolites in human plasma using liquid chromatography tandem mass 
      spectrometry.
PG  - 466-73
LID - 10.1002/bmc.3573 [doi]
AB  - The interest in therapeutic drug monitoring has increased over the last few 
      years. Inter- and intra-patient variability in pharmacokinetics, plasma 
      concentration related toxicity and success of therapy have stressed the need of 
      frequent therapeutic drug monitoring of the drugs. A sensitive, selective and 
      rapid liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) 
      method was developed for the simultaneous quantification of acetylsalicylic acid 
      (aspirin), salicylic acid, clopidogrel and carboxylic acid metabolite of 
      clopidogrel in human plasma. The chromatographic separations were achieved on 
      Waters Symmetry Shield(TM) C18 column (150 × 4.6 mm, 5 µm) using 3.5 mm ammonium 
      acetate (pH 3.5)-acetonitrile (10:90, v/v) as mobile phase at a flow rate of 
      0.75 mL/min. The present method was successfully applied for therapeutic drug 
      monitoring of aspirin and clopidogrel in 67 patients with coronary artery 
      disease.
CI  - Copyright © 2015 John Wiley & Sons, Ltd.
FAU - Chhonker, Yashpal S
AU  - Chhonker YS
AD  - Pharmacokinetics and Metabolism Division, CSIR - Central Drug Research Institute, 
      Lucknow, 226031, India.
AD  - Academy of Scientific and Innovative Research, Anusandhan Bhawan, Rafi Marg, New 
      Delhi, 110 001, India.
FAU - Pandey, Chandra P
AU  - Pandey CP
AD  - Pharmacology Division, CSIR - Central Drug Research Institute, Lucknow, 226031, 
      India.
AD  - Department of Cardiology, King George's Medical University, Lucknow, 226001, 
      India.
FAU - Chandasana, Hardik
AU  - Chandasana H
AD  - Pharmacokinetics and Metabolism Division, CSIR - Central Drug Research Institute, 
      Lucknow, 226031, India.
AD  - Academy of Scientific and Innovative Research, Anusandhan Bhawan, Rafi Marg, New 
      Delhi, 110 001, India.
FAU - Laxman, Tulsankar Sachin
AU  - Laxman TS
AD  - Pharmacokinetics and Metabolism Division, CSIR - Central Drug Research Institute, 
      Lucknow, 226031, India.
AD  - Academy of Scientific and Innovative Research, Anusandhan Bhawan, Rafi Marg, New 
      Delhi, 110 001, India.
FAU - Prasad, Yarra Durga
AU  - Prasad YD
AD  - Pharmacokinetics and Metabolism Division, CSIR - Central Drug Research Institute, 
      Lucknow, 226031, India.
AD  - Academy of Scientific and Innovative Research, Anusandhan Bhawan, Rafi Marg, New 
      Delhi, 110 001, India.
FAU - Narain, V S
AU  - Narain VS
AD  - Department of Cardiology, King George's Medical University, Lucknow, 226001, 
      India.
FAU - Dikshit, Madhu
AU  - Dikshit M
AD  - Pharmacology Division, CSIR - Central Drug Research Institute, Lucknow, 226031, 
      India.
FAU - Bhatta, Rabi S
AU  - Bhatta RS
AD  - Pharmacokinetics and Metabolism Division, CSIR - Central Drug Research Institute, 
      Lucknow, 226031, India.
AD  - Academy of Scientific and Innovative Research, Anusandhan Bhawan, Rafi Marg, New 
      Delhi, 110 001, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150918
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*blood/chemistry/metabolism
MH  - Chromatography, Liquid/*methods
MH  - Clopidogrel
MH  - Drug Monitoring
MH  - Drug Stability
MH  - Humans
MH  - Limit of Detection
MH  - Reproducibility of Results
MH  - Tandem Mass Spectrometry/*methods
MH  - Ticlopidine/*analogs & derivatives/blood/chemistry/metabolism
OTO - NOTNLM
OT  - LC-MS/MS
OT  - acetylsalicylic acid
OT  - clopidogrel
OT  - pharmacokinetics
OT  - therapeutic drug monitoring
EDAT- 2015/08/01 06:00
MHDA- 2016/09/14 06:00
CRDT- 2015/08/01 06:00
PHST- 2015/04/05 00:00 [received]
PHST- 2015/07/14 00:00 [revised]
PHST- 2015/07/23 00:00 [accepted]
PHST- 2015/08/01 06:00 [entrez]
PHST- 2015/08/01 06:00 [pubmed]
PHST- 2016/09/14 06:00 [medline]
AID - 10.1002/bmc.3573 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2016 Mar;30(3):466-73. doi: 10.1002/bmc.3573. Epub 2015 Sep 
      18.

PMID- 36063559
OWN - NLM
STAT- MEDLINE
DCOM- 20220922
LR  - 20221019
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 175
IP  - 9
DP  - 2022 Sep
TI  - USPSTF recommends aspirin to prevent CVD in adults 40 to 59 y as an individual 
      decision; not recommended for adults ≥60 y.
PG  - JC98
LID - 10.7326/J22-0064 [doi]
AB  - Davidson KW, Barry MJ, Mangione CM, et al. Aspirin use to prevent cardiovascular 
      disease: US Preventive Services Task Force recommendation statement. JAMA. 
      2022;327:1577-84. 35471505.
FAU - Nudy, Matthew
AU  - Nudy M
AD  - Penn State Hershey Medical Center, Hershey, Pennsylvania, USA (M.N., J.L.C.).
FAU - Cooper, Jennifer L
AU  - Cooper JL
AD  - Penn State Hershey Medical Center, Hershey, Pennsylvania, USA (M.N., J.L.C.).
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20220906
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - JAMA. 2022 Apr 26;327(16):1577-1584. PMID: 35471505
MH  - Adult
MH  - Advisory Committees
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - Preventive Health Services
MH  - Risk Assessment
EDAT- 2022/09/06 06:00
MHDA- 2022/09/23 06:00
CRDT- 2022/09/05 17:02
PHST- 2022/09/06 06:00 [pubmed]
PHST- 2022/09/23 06:00 [medline]
PHST- 2022/09/05 17:02 [entrez]
AID - 10.7326/J22-0064 [doi]
PST - ppublish
SO  - Ann Intern Med. 2022 Sep;175(9):JC98. doi: 10.7326/J22-0064. Epub 2022 Sep 6.

PMID- 36550905
OWN - NLM
STAT- MEDLINE
DCOM- 20221226
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 50
DP  - 2022 Dec 16
TI  - To study the mechanism of panax notoginseng in the treatment of aspirin 
      resistance in the secondary prevention of stroke based on TLR4/MyD88/NF-κB 
      signaling pathway: A study protocol.
PG  - e31919
LID - 10.1097/MD.0000000000031919 [doi]
LID - e31919
AB  - INTRODUCTION: Aspirin, as an typical antiplatelet therapy for secondary stroke 
      prevention, have been proved that can significantly reduce incidence and 
      recurrence of cerebrovascular ischemic events. However, due to drugs biological 
      characteristics, aspirin resistance (AR) often occurs in clinical practice, which 
      significantly influence secondary prevention in stroke patients. The growing 
      evidence of activating blood and removing stasis herbs medicine (Sanqi) for AR is 
      promising. However, the efficacy and mechanism of Panax notoginseng (Sanqi) for 
      AR in secondary stroke prevention has not been confirmed. METHODS/DESIGN: This is 
      a prospective 2-center, assessor and statistician blinded, randomized, controlled 
      trial. We will allocate 106 subjects aged between 45 and 65 years old, diagnosed 
      with aspirin semi-resistance after stroke to 2 groups randomly in a ratio of 1:1. 
      Patients in the experimental group will be treated with conventional treatments 
      plus Panax notoginseng (Sanqi) while the others in the control group will be 
      treated with only conventional treatments. All will be given different 
      medications for 30 days. Patients will be measured with the platelet aggregation 
      rate and serum TLR4, MyD88, NF-κB, COX-2, IL-6, CRP, TXB2 level for clinical 
      efficacy and mechanisms at baseline and the 14th, 30th day of treatment. Baseline 
      characteristics of patients will be summarized by groups and compared with 
      Chi-square for categorical variables, and Student's independent t test or 
      nonparametric Mann-Whitney U test for the continuous variables. Primary and 
      secondary outcomes will be analyzed with 2-way repeated measures Anova, and Post 
      Hoc test. CONCLUSION: The present study aims to investigate short-term add-on 
      efficacy and mechanism of Panax notoginseng (Sanqi) for aspirin resistance in 
      secondary stroke prevention via TLR4/MyD88/NF-κB signaling pathway. With this, we 
      expect to find out an appropriate partial substitute of aspirin for aspirin 
      resistance individuals. TRIAL REGISTRATION: The trial was registered on Chinese 
      Clinical Trial Registry (http://www.chictr.org.cn/index.aspx) with the ID 
      ChiCTR2100045773 at April 24, 2021.
CI  - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wang, Hui
AU  - Wang H
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, China.
AD  - Geriatric Department, Xi'an Hospital of Traditional Chinese Medicine (Xi'an 
      Affiliated Hospital of Shaanxi Provincial Hospital of Chinese Medicine), Xi'an, 
      China.
AD  - Shanxi Provincial Hospital of Chinese Medicine (Shaanxi Academy of Traditional 
      Chinese Medicine), Xian, China.
FAU - Yuan, Jie
AU  - Yuan J
AD  - Department of Encephalopathy, Shaanxi Hospital Province of Traditional Chinese 
      Medicine, Xian, China.
AD  - School of Basic Medical Sciences, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Shaanxi University of Traditional Chinese Medicine, Shaanxi Province, Xianyang, 
      China.
FAU - Chen, Jie
AU  - Chen J
AUID- ORCID: 0000-0002-5160-3763
AD  - Department of Encephalopathy, Shaanxi Hospital Province of Traditional Chinese 
      Medicine, Xian, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (NF-kappa B)
RN  - 0 (Myeloid Differentiation Factor 88)
RN  - 0 (Toll-Like Receptor 4)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (TLR4 protein, human)
SB  - IM
MH  - Humans
MH  - Middle Aged
MH  - Aged
MH  - NF-kappa B
MH  - *Panax notoginseng
MH  - Myeloid Differentiation Factor 88
MH  - Toll-Like Receptor 4
MH  - Secondary Prevention
MH  - Prospective Studies
MH  - *Stroke/complications
MH  - Aspirin/pharmacology/therapeutic use
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Signal Transduction
MH  - Randomized Controlled Trials as Topic
PMC - PMC9771212
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/27 06:00
CRDT- 2022/12/23 01:07
PHST- 2022/12/23 01:07 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/27 06:00 [medline]
AID - 00005792-202212160-00113 [pii]
AID - 10.1097/MD.0000000000031919 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Dec 16;101(50):e31919. doi: 
      10.1097/MD.0000000000031919.

PMID- 7438383
OWN - NLM
STAT- MEDLINE
DCOM- 19810226
LR  - 20131121
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 62
IP  - 6 Pt 2
DP  - 1980 Dec
TI  - The aspirin myocardial infarction study: final results. The Aspirin Myocardial 
      Infarction Study research group.
PG  - V79-84
AB  - The Aspirin Myocardial Infarction Study (AMIS) was a multicenter, randomized, 
      double-blind, placebo-controlled trial of 1.0 g of aspirin daily in men and women 
      who had had a documented myocardial infarction. In the trial 4524 persons, ages 
      30-69 years, were recruited; 2267 were randomized to aspirin and 2257 to placebo. 
      The major end point, total mortality, was 10.8% in the aspirin group and 9.7% in 
      the placebo group. There was a nonsignificant trend indicating a lower incidence 
      of nonfatal myocardial infarction in the aspirin group (6.3%) compared with the 
      placebo group (8.1%). Symptoms suggestive of gastrointestinal irritation appeared 
      in 23.7% of the aspirin group and in 14.9% of the placebo group. Based on these 
      findings, routine use of aspirin after myocardial infarction is not recommended.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Diseases/diagnosis
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*drug therapy/mortality
MH  - Patient Compliance
MH  - Placebos
MH  - Ulcer/diagnosis
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
PST - ppublish
SO  - Circulation. 1980 Dec;62(6 Pt 2):V79-84.

PMID- 310771
OWN - NLM
STAT- MEDLINE
DCOM- 19790425
LR  - 20190623
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 53
IP  - 1
DP  - 1978 Dec 15
TI  - Central and peripheral antialgesic action of aspirin-like drugs.
PG  - 39-48
AB  - The peripheral and central effects of some non-steroid anti-inflammatory drugs, 
      aspirin, indomethacin, paracetamol and phenacetin were studied by comparing their 
      intraplantar and intracerebroventricular effects on hyperalgesia induced by 
      carrageenin injected into the rat paw. Hyperalgesia was measured by a 
      modification of the Randall-Selitto test. The agents tested had antialgesic 
      effects when given by any route. Their intraventricular administration enhanced 
      the antialgesic effect of anti-inflammatory drugs administered into the paw. 
      Previous treatment of one paw with carrageenin reduced the oedema caused by a 
      second injection of carrageenin in the contralateral paw. In contrast, it had no 
      effect on the intensity of hyperalgesia but shortened the time necessary for it 
      to reach a plateau. Administration of a prostaglandin antagonist (SC-19220) in 
      the cerebral ventricles, in the rat paw or in both sites, significantly inhibited 
      the hyperalgesia evoked by carrageenin. The maximal hyperalgesic effect of 
      intraplantar injections of prostaglandin E2 could be further enhanced by its 
      cerebroventricular administration. It was suggested that carrageenin hyperalgesia 
      has a peripheral and a central component and that the cyclo-oxygenase inhibitors 
      used may exert an antialgesic effect by preventing the hyperalgesia induced by a 
      peripheral and/or central release of prostaglandins.
FAU - Ferreira, S H
AU  - Ferreira SH
FAU - Lorenzetti, B B
AU  - Lorenzetti BB
FAU - Corrêa, F M
AU  - Corrêa FM
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandins E)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesics
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Carrageenan/pharmacology
MH  - Drug Interactions
MH  - Edema/chemically induced/physiopathology
MH  - Injections, Intraperitoneal
MH  - Injections, Intraventricular
MH  - Male
MH  - Pressure
MH  - Prostaglandins E/pharmacology
MH  - Rats
MH  - Time Factors
EDAT- 1978/12/15 00:00
MHDA- 1978/12/15 00:01
CRDT- 1978/12/15 00:00
PHST- 1978/12/15 00:00 [pubmed]
PHST- 1978/12/15 00:01 [medline]
PHST- 1978/12/15 00:00 [entrez]
AID - 0014-2999(78)90265-0 [pii]
AID - 10.1016/0014-2999(78)90265-0 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1978 Dec 15;53(1):39-48. doi: 10.1016/0014-2999(78)90265-0.

PMID- 23121403
OWN - NLM
STAT- MEDLINE
DCOM- 20121205
LR  - 20220409
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 367
IP  - 21
DP  - 2012 Nov 22
TI  - Low-dose aspirin for preventing recurrent venous thromboembolism.
PG  - 1979-87
LID - 10.1056/NEJMoa1210384 [doi]
AB  - BACKGROUND: Patients who have had a first episode of unprovoked venous 
      thromboembolism have a high risk of recurrence after anticoagulants are 
      discontinued. Aspirin may be effective in preventing a recurrence of venous 
      thromboembolism. METHODS: We randomly assigned 822 patients who had completed 
      initial anticoagulant therapy after a first episode of unprovoked venous 
      thromboembolism to receive aspirin, at a dose of 100 mg daily, or placebo for up 
      to 4 years. The primary outcome was a recurrence of venous thromboembolism. 
      RESULTS: During a median follow-up period of 37.2 months, venous thromboembolism 
      recurred in 73 of 411 patients assigned to placebo and in 57 of 411 assigned to 
      aspirin (a rate of 6.5% per year vs. 4.8% per year; hazard ratio with aspirin, 
      0.74; 95% confidence interval [CI], 0.52 to 1.05; P=0.09). Aspirin reduced the 
      rate of the two prespecified secondary composite outcomes: the rate of venous 
      thromboembolism, myocardial infarction, stroke, or cardiovascular death was 
      reduced by 34% (a rate of 8.0% per year with placebo vs. 5.2% per year with 
      aspirin; hazard ratio with aspirin, 0.66; 95% CI, 0.48 to 0.92; P=0.01), and the 
      rate of venous thromboembolism, myocardial infarction, stroke, major bleeding, or 
      death from any cause was reduced by 33% (hazard ratio, 0.67; 95% CI, 0.49 to 
      0.91; P=0.01). There was no significant between-group difference in the rates of 
      major or clinically relevant nonmajor bleeding episodes (rate of 0.6% per year 
      with placebo vs. 1.1% per year with aspirin, P=0.22) or serious adverse events. 
      CONCLUSIONS: In this study, aspirin, as compared with placebo, did not 
      significantly reduce the rate of recurrence of venous thromboembolism but 
      resulted in a significant reduction in the rate of major vascular events, with 
      improved net clinical benefit. These results substantiate earlier evidence of a 
      therapeutic benefit of aspirin when it is given to patients after initial 
      anticoagulant therapy for a first episode of unprovoked venous thromboembolism. 
      (Funded by National Health and Medical Research Council [Australia] and others; 
      Australian New Zealand Clinical Trials Registry number, ACTRN12605000004662.).
FAU - Brighton, Timothy A
AU  - Brighton TA
AD  - Department of Haematology, South Eastern Area Laboratory Services (SEALS), Prince 
      of Wales Hospital, Sydney, Australia. aspire@ctc.usyd.edu.au
FAU - Eikelboom, John W
AU  - Eikelboom JW
FAU - Mann, Kristy
AU  - Mann K
FAU - Mister, Rebecca
AU  - Mister R
FAU - Gallus, Alexander
AU  - Gallus A
FAU - Ockelford, Paul
AU  - Ockelford P
FAU - Gibbs, Harry
AU  - Gibbs H
FAU - Hague, Wendy
AU  - Hague W
FAU - Xavier, Denis
AU  - Xavier D
FAU - Diaz, Rafael
AU  - Diaz R
FAU - Kirby, Adrienne
AU  - Kirby A
FAU - Simes, John
AU  - Simes J
CN  - ASPIRE Investigators
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20121104
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2012 Nov 22;367(21):2039-41. PMID: 23121404
CIN - Nat Rev Cardiol. 2013 Jan;10(1):4. PMID: 23165071
CIN - N Engl J Med. 2013 Feb 21;368(8):773. PMID: 23425172
CIN - N Engl J Med. 2013 Feb 21;368(8):772. PMID: 23425173
CIN - N Engl J Med. 2013 Feb 21;368(8):772-3. PMID: 23425174
CIN - Dtsch Med Wochenschr. 2013 Feb;138(6):244. PMID: 23479792
CIN - Ann Intern Med. 2013 Mar 19;158(6):JC2. PMID: 23552619
CIN - Rev Clin Esp (Barc). 2013 May;213(4):212. PMID: 23814790
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Risk
MH  - Secondary Prevention
MH  - Venous Thromboembolism/epidemiology/*prevention & control
FIR - Brighton, T
IR  - Brighton T
FIR - Eikelboom, J
IR  - Eikelboom J
FIR - Hague, W
IR  - Hague W
FIR - Kirby, A
IR  - Kirby A
FIR - Mister, R
IR  - Mister R
FIR - Simes, J
IR  - Simes J
FIR - Gallus, A
IR  - Gallus A
FIR - Ockelford, P
IR  - Ockelford P
FIR - Baker, R
IR  - Baker R
FIR - Gibbs, H
IR  - Gibbs H
FIR - Coughlin, P
IR  - Coughlin P
FIR - Xavier, D
IR  - Xavier D
FIR - Diaz, R
IR  - Diaz R
FIR - Agnelli, G
IR  - Agnelli G
FIR - Gibbs, H
IR  - Gibbs H
FIR - Karplus, T
IR  - Karplus T
FIR - Fletcher, J
IR  - Fletcher J
FIR - van Rij, A
IR  - van Rij A
FIR - Rogers, Anthony
IR  - Rogers A
FIR - Hayward, C
IR  - Hayward C
FIR - Young, Graham
IR  - Young G
FIR - Crispin, P
IR  - Crispin P
FIR - Slade, J
IR  - Slade J
FIR - Ward, C
IR  - Ward C
FIR - Tadayon, N
IR  - Tadayon N
FIR - Koutts, J
IR  - Koutts J
FIR - Fisher, L
IR  - Fisher L
FIR - Brighton, T
IR  - Brighton T
FIR - McCardie, K
IR  - McCardie K
FIR - Bianchi, A
IR  - Bianchi A
FIR - Trinh, J
IR  - Trinh J
FIR - Joseph, J
IR  - Joseph J
FIR - Plenge, P
IR  - Plenge P
FIR - Chong, B
IR  - Chong B
FIR - Davidson, S
IR  - Davidson S
FIR - Waites, J
IR  - Waites J
FIR - Cahill, P
IR  - Cahill P
FIR - Tiley, C
IR  - Tiley C
FIR - Lacey, M
IR  - Lacey M
FIR - Jackson, D
IR  - Jackson D
FIR - Boys, J
IR  - Boys J
FIR - Seldon, M
IR  - Seldon M
FIR - Gambrill, M
IR  - Gambrill M
FIR - Nandurkar, H
IR  - Nandurkar H
FIR - Worland, H
IR  - Worland H
FIR - Salem, H
IR  - Salem H
FIR - Gollogly, C
IR  - Gollogly C
FIR - Campbell, P
IR  - Campbell P
FIR - Marshall, I
IR  - Marshall I
FIR - Hamilton, K
IR  - Hamilton K
FIR - Goss, C
IR  - Goss C
FIR - Salem, H
IR  - Salem H
FIR - Poulton, L
IR  - Poulton L
FIR - Jackson, M
IR  - Jackson M
FIR - de Man, T
IR  - de Man T
FIR - Gan, E
IR  - Gan E
FIR - Cummins, A
IR  - Cummins A
FIR - Leyden, M
IR  - Leyden M
FIR - Sturtz, C
IR  - Sturtz C
FIR - Kubler, P
IR  - Kubler P
FIR - Sansome, X
IR  - Sansome X
FIR - McCann, A
IR  - McCann A
FIR - Downey, C
IR  - Downey C
FIR - Carroll, P
IR  - Carroll P
FIR - Duroux, M
IR  - Duroux M
FIR - Hamwood, S
IR  - Hamwood S
FIR - Styles, G
IR  - Styles G
FIR - Buckmaster, N
IR  - Buckmaster N
FIR - Schmidt, T
IR  - Schmidt T
FIR - Colquhoun, D
IR  - Colquhoun D
FIR - Jardim, A
IR  - Jardim A
FIR - Gallus, A
IR  - Gallus A
FIR - Osmond, J
IR  - Osmond J
FIR - Jeffries, W
IR  - Jeffries W
FIR - Trezona, B
IR  - Trezona B
FIR - McRae, S
IR  - McRae S
FIR - King, D
IR  - King D
FIR - Baker, R
IR  - Baker R
FIR - Courtley, K
IR  - Courtley K
FIR - Kimber, R
IR  - Kimber R
FIR - Oliver, L
IR  - Oliver L
FIR - MacDonald, A
IR  - MacDonald A
FIR - Shepherd, J
IR  - Shepherd J
FIR - Ockelford, P
IR  - Ockelford P
FIR - Hulton, M
IR  - Hulton M
FIR - Royle, G
IR  - Royle G
FIR - Haycock, L
IR  - Haycock L
FIR - Simpson, D
IR  - Simpson D
FIR - Yap, K
IR  - Yap K
FIR - Baker, B
IR  - Baker B
FIR - McQuilkin, H
IR  - McQuilkin H
FIR - Carter, J
IR  - Carter J
FIR - Body, J
IR  - Body J
FIR - Heng, L Lai
IR  - Heng LL
FIR - Tan, M
IR  - Tan M
FIR - Tay, J Chin
IR  - Tay JC
FIR - Zou, J
IR  - Zou J
FIR - Pandharpurkar, H Kumar
IR  - Pandharpurkar HK
FIR - G, Remya
IR  - G R
FIR - Stephen, E
IR  - Stephen E
FIR - Benjamin, A
IR  - Benjamin A
FIR - Desai, S C
IR  - Desai SC
FIR - Singh, R
IR  - Singh R
FIR - Suresh, K R
IR  - Suresh KR
FIR - R, Girija K
IR  - R GK
FIR - Natarajan, S
IR  - Natarajan S
FIR - Goel, D
IR  - Goel D
FIR - Gupta, R
IR  - Gupta R
FIR - Mishra, B S
IR  - Mishra BS
FIR - Sidhu, G
IR  - Sidhu G
FIR - Sidhu, R Singh
IR  - Sidhu RS
FIR - Parakh, R
IR  - Parakh R
FIR - Sharma, R
IR  - Sharma R
FIR - Joshi, S
IR  - Joshi S
FIR - Mahajan, M
IR  - Mahajan M
FIR - Grover, T
IR  - Grover T
FIR - Sharma, K
IR  - Sharma K
FIR - Patel, P
IR  - Patel P
FIR - Kothurkar, A
IR  - Kothurkar A
FIR - Ranade, P
IR  - Ranade P
FIR - Fedele, J L
IR  - Fedele JL
FIR - Cristófaro, A C
IR  - Cristófaro AC
FIR - Gelersztein, E
IR  - Gelersztein E
FIR - Gelersztein, M
IR  - Gelersztein M
FIR - Sánchez, A S
IR  - Sánchez AS
FIR - Bowen, L C
IR  - Bowen LC
FIR - Durán, R O García
IR  - Durán RO
FIR - Cámpora, F
IR  - Cámpora F
FIR - Ferro, H Héctor
IR  - Ferro HH
FIR - Casais, M V
IR  - Casais MV
FIR - Mister, R
IR  - Mister R
FIR - Kirby, A
IR  - Kirby A
FIR - Mann, K
IR  - Mann K
FIR - Van Holst Pellekaan, C
IR  - Van Holst Pellekaan C
FIR - Chinchen, S
IR  - Chinchen S
FIR - Lucas, A
IR  - Lucas A
FIR - Hague, W
IR  - Hague W
FIR - Simes, J
IR  - Simes J
FIR - Xavier, D
IR  - Xavier D
FIR - Pais, P
IR  - Pais P
FIR - Sigamani, A
IR  - Sigamani A
FIR - Mathur, N
IR  - Mathur N
FIR - M, Anupama
IR  - M A
FIR - B, Deepthi K
IR  - B DK
FIR - Diaz, R
IR  - Diaz R
FIR - Chacon, C
IR  - Chacon C
FIR - Rucci, R
IR  - Rucci R
EDAT- 2012/11/06 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/11/06 06:00
PHST- 2012/11/06 06:00 [entrez]
PHST- 2012/11/06 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.1056/NEJMoa1210384 [doi]
PST - ppublish
SO  - N Engl J Med. 2012 Nov 22;367(21):1979-87. doi: 10.1056/NEJMoa1210384. Epub 2012 
      Nov 4.

PMID- 6389847
OWN - NLM
STAT- MEDLINE
DCOM- 19850110
LR  - 20190908
IS  - 0022-3921 (Print)
IS  - 0022-3921 (Linking)
VI  - 31
IP  - 3
DP  - 1984 Aug
TI  - The effects of aspirin-containing serum in the continuous culture of Plasmodium 
      falciparum.
PG  - 381-4
AB  - In vitro culture of Plasmodium falciparum-infected human erythrocytes (RBC) has 
      permitted systematic study of human host-parasite relations. In this study the 
      effect of aspirin in the culture system was examined by using serum from blood of 
      fasting, healthy male volunteers, before and after the ingestion of aspirin. The 
      addition of aspirin-containing serum disturbed parasite growth and development: 
      0-1/2 dilutions of treated/control sera inhibited parasite development, with 
      nuclear pyknosis, pyknotic extracellular parasites (trophozoites) in the media, 
      decreased numbers and sizes of "rings" (early trophozoites), and an increased 
      number of later trophozoites and schizonts. Paradoxically, while the 
      incorporation of [3H]isoleucine into protein was not affected by the 
      aspirin-containing sera, the incorporation [3H]hypoxanthine was significantly 
      changed and did not correlate with morphological evidence of cytotoxicity. Thus, 
      the so-called "incorporation" of a radioactive tracer is not a fully reliable 
      index of parasite growth in the presence of certain compounds. The findings 
      underscore the importance, in this culture system which employs human serum, of 
      avoiding serum from donors who have recently ingested aspirin.
FAU - Whaun, J M
AU  - Whaun JM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Protozool
JT  - The Journal of protozoology
JID - 2985197R
RN  - 0 (Culture Media)
RN  - 0 (Hypoxanthines)
RN  - 04Y7590D77 (Isoleucine)
RN  - 2TN51YD919 (Hypoxanthine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*pharmacology
MH  - Blood
MH  - Culture Media
MH  - Erythrocytes/*parasitology
MH  - Host-Parasite Interactions
MH  - Humans
MH  - Hypoxanthine
MH  - Hypoxanthines/metabolism
MH  - Isoleucine/metabolism
MH  - Male
MH  - Plasmodium falciparum/drug effects/*growth & development
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 10.1111/j.1550-7408.1984.tb02983.x [doi]
PST - ppublish
SO  - J Protozool. 1984 Aug;31(3):381-4. doi: 10.1111/j.1550-7408.1984.tb02983.x.

PMID- 1676731
OWN - NLM
STAT- MEDLINE
DCOM- 19910815
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 43
IP  - 4
DP  - 1991 Apr
TI  - Effects of compaction variables on porosity and material tensile strength of 
      convex-faced aspirin tablets.
PG  - 219-25
AB  - The porosity and tensile strength of convex-faced aspirin tablets formed under a 
      compaction pressure in the range 40-320 MPa and at punch velocities in the range 
      0.008 to 500 mm s-1 have been determined. The material tensile strength, sigma f, 
      was calculated from the observed fracture load, Ps, using the equation of Pitt et 
      al (1988): sigma f = 10 Ps/pi D2(2.84 t/D - 0.126 t/W + 3.15 W/D + 0.01)-1 where 
      D is the tablet diameter, t is the overall tablet thickness and W is the central 
      cylinder thickness. Tablets formed at lower compaction pressures had a higher 
      porosity and lower tensile strength than those formed at higher compaction 
      pressures. Tablets of face curvature ratio (D/R) in the range 0.25-0.67 and a 
      normalized cylinder length (W/D) of 0.2 had the optimum tensile strength. (R is 
      the radius of curvature of the tablet face.) Tablets formed at high compaction 
      rates were significantly weaker than those formed at lower compaction rates.
FAU - Pitt, K G
AU  - Pitt KG
AD  - School of Pharmacy, University of London, UK.
FAU - Newton, J M
AU  - Newton JM
FAU - Stanley, P
AU  - Stanley P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Drug Compounding
MH  - Regression Analysis
MH  - *Tablets
MH  - Tensile Strength
EDAT- 1991/04/01 00:00
MHDA- 1991/04/01 00:01
CRDT- 1991/04/01 00:00
PHST- 1991/04/01 00:00 [pubmed]
PHST- 1991/04/01 00:01 [medline]
PHST- 1991/04/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1991.tb06672.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1991 Apr;43(4):219-25. doi: 
      10.1111/j.2042-7158.1991.tb06672.x.

PMID- 3740630
OWN - NLM
STAT- MEDLINE
DCOM- 19860916
LR  - 20131121
IS  - 0002-9645 (Print)
IS  - 0002-9645 (Linking)
VI  - 47
IP  - 7
DP  - 1986 Jul
TI  - Serum salicylate concentrations and endoscopic evaluation of the gastric mucosa 
      in dogs after oral administration of aspirin-containing products.
PG  - 1586-9
AB  - The serum salicylate concentration produced by oral administration of plain 
      aspirin and several aspirin-containing products given at 8-hour intervals for 7 
      treatments was measured in 36 laboratory-conditioned adult dogs. The dogs were 
      randomly allotted to 6 groups of 6 dogs each: group 1 was given plain aspirin at 
      a dosage of 25 mg/kg of body weight: group 2 was given plain aspirin at a dosage 
      of 10 mg/kg; group 3 was given buffered aspirin at a dosage of 25 mg/kg; group 4 
      was given enteric-coated aspirin at a dosage of 25 mg/kg; group 5 was given 
      buffered aspirin at a dosage of 25 mg/kg; and, group 6 was given a placebo. Serum 
      salicylate concentration was measured at 2-hour intervals for the first 8 hours, 
      and then at 8-hour intervals for the next 40 hours. Following the last dosing, 
      serum salicylate concentration was measured at 2-hour intervals until 56 hours; 
      the final 2 samples were measured at 64 and 72 hours. The effect of aspirin on 
      the gastric mucosa was studied in 12 dogs, 3 each randomly selected from groups 
      1, 3, 4, and 5. The gastric mucosa of each dog was examined with a fiberoptic 
      gastroscope 3 days before the beginning of treatment; lesions were not seen. The 
      drugs were administered as described and the gastric mucosa of each dog was 
      reexamined at 72 hours. Administration of the aspirin-containing products at 
      8-hour intervals resulted in sustained therapeutic serum salicylate 
      concentrations (greater than 5 mg/dl) in all dogs, except those of group 2. The 
      greatest fluctuation in serum salicylate concentration was found in dogs of group 
      4. Gastric lesions were seen only in the 3 dogs of group 1.(ABSTRACT TRUNCATED AT 
      250 WORDS)
FAU - Lipowitz, A J
AU  - Lipowitz AJ
FAU - Boulay, J P
AU  - Boulay JP
FAU - Klausner, J S
AU  - Klausner JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dogs
MH  - Female
MH  - Gastric Mucosa/cytology/*drug effects
MH  - Kinetics
MH  - Male
MH  - Salicylates/*blood
MH  - Time Factors
EDAT- 1986/07/01 00:00
MHDA- 1986/07/01 00:01
CRDT- 1986/07/01 00:00
PHST- 1986/07/01 00:00 [pubmed]
PHST- 1986/07/01 00:01 [medline]
PHST- 1986/07/01 00:00 [entrez]
PST - ppublish
SO  - Am J Vet Res. 1986 Jul;47(7):1586-9.

PMID- 3940363
OWN - NLM
STAT- MEDLINE
DCOM- 19860123
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 77
IP  - 1
DP  - 1986 Jan
TI  - Decreasing trends in Reye syndrome and aspirin use in Michigan, 1979 to 1984.
PG  - 93-8
AB  - The incidence of Reye syndrome has been decreasing in Michigan, perhaps as a 
      result of decreased aspirin use among children. To evaluate possible changes in 
      the frequency of aspirin use, 199 families in Tecumseh, MI, with children younger 
      than 18 years of age were interviewed by telephone in February 1981 and again in 
      February 1983. Based on the reported use of medications for colds or influenza 
      between 1981 and 1983, fewer parents gave aspirin (56% v 25%), but acetaminophen 
      use did not change (59% v 55%). Younger parents and parents who had heard of the 
      association between aspirin and Reye syndrome were more likely to stop giving 
      aspirin. More parents chose to use either no medication or medications containing 
      neither aspirin nor acetaminophen (6% v 32%) for the treatment of colds or 
      influenza. Approximately 90% of parents who chose not to give aspirin for fever 
      also gave medications for colds or influenza that did not contain aspirin. These 
      results suggest that fewer children are receiving aspirin during illnesses that 
      may precede Reye syndrome. The associated decrease in the incidence of Reye 
      syndrome tends to support the hypothesis that the use of aspirin increases the 
      risk for the development of Reye syndrome.
FAU - Remington, P L
AU  - Remington PL
FAU - Rowley, D
AU  - Rowley D
FAU - McGee, H
AU  - McGee H
FAU - Hall, W N
AU  - Hall WN
FAU - Monto, A S
AU  - Monto AS
LA  - eng
GR  - AI 62514/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Common Cold/drug therapy
MH  - Fever/drug therapy
MH  - Humans
MH  - Michigan
MH  - Reye Syndrome/chemically induced/*epidemiology
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1986 Jan;77(1):93-8.

PMID- 6712756
OWN - NLM
STAT- MEDLINE
DCOM- 19840511
LR  - 20190718
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 27
IP  - 4
DP  - 1984 Apr
TI  - The relative roles of hydrolases of the erythrocyte and other tissues in 
      controlling aspirin survival in vivo.
PG  - 422-6
AB  - The rate of aspirin (acetylsalicylic acid, ASA) deacetylation to salicylate in 
      vivo determines the availability of the intact molecule for therapeutically 
      important transacetylation reactions. Experiments were carried out to assess the 
      relative contribution of a previously isolated human erythrocyte ASA esterase to 
      the overall hydrolysis rate in vivo, as opposed to similar enzymes in other 
      tissues. In vitro, the rates of ASA hydrolysis were relatively slow in plasma 
      from humans and dogs. The hydrolysis rates were significantly greater in whole 
      blood in dogs, rabbits, and humans. In human and canine whole blood, the rate of 
      hydrolysis correlated positively with hematocrit. In vivo studies with dogs 
      showed that ASA decay rates conform to a 2-compartment model. After reduction of 
      hematocrit by a mean of 49% in 4 dogs without previous splenectomy, the 
      "availability" of ASA increased. In 4 dogs with previous splenectomy, this 
      measurement was increased even more after comparable hematocrit reduction. In 2 
      dogs that underwent a sub-total hepatectomy, ASA availability increased by only 
      35% and 12.8%, respectively. These results suggest a significant role for the 
      erythrocyte esterase in vivo in the dog and possibly in humans.
FAU - Costello, P B
AU  - Costello PB
FAU - Caruana, J A
AU  - Caruana JA
FAU - Green, F A
AU  - Green FA
LA  - eng
GR  - HL 24009/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - EC 3.- (Hydrolases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*blood/metabolism
MH  - Dogs
MH  - Erythrocytes/*enzymology
MH  - Hepatectomy
MH  - Humans
MH  - Hydrolases/blood
MH  - Hydrolysis
MH  - Kinetics
MH  - Metabolic Clearance Rate
MH  - Rabbits
MH  - Splenectomy
EDAT- 1984/04/01 00:00
MHDA- 1984/04/01 00:01
CRDT- 1984/04/01 00:00
PHST- 1984/04/01 00:00 [pubmed]
PHST- 1984/04/01 00:01 [medline]
PHST- 1984/04/01 00:00 [entrez]
AID - 10.1002/art.1780270409 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1984 Apr;27(4):422-6. doi: 10.1002/art.1780270409.

PMID- 59932
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20150423
IS  - 1011-6206 (Print)
IS  - 1011-6206 (Linking)
VI  - 13
IP  - 2
DP  - 1976 Apr-Jun
TI  - Experimental studies on drug sensitization. II. Production of antiacetylsalicylyl 
      antibodies and their detection by passive hemagglutination.
PG  - 135-40
AB  - Antiacetylsalicylyl antibodies were produced in rabbits and guinea-pigs by 
      innoculation of acetylsalicylic acid incorporated in Freund adjuvant. These 
      antibodies were readily detected by a passive hemagglutination test using rabbit 
      erythrocytes incubated with acetylsalicylic acid at alkaline pH. Acetylsalicylyl 
      conjugates with human gammaglobulin, bovine gammaglobulin and rabbit 
      gammaglobulin were also prepared by incubating the proteins with acetylsalicylic 
      acid at alkaline pH. In parallel experiments, salicylic acid did not induce 
      formation of specific antibodies capable of reacting with acetylsalicylic or 
      salicylic acid-treated erythrocytes.
FAU - Cîrstea, M
AU  - Cîrstea M
FAU - Suhaciu, G
AU  - Suhaciu G
LA  - eng
PT  - Journal Article
PL  - Romania
TA  - Physiologie
JT  - Physiologie (Bucarest)
JID - 7510964
RN  - 0 (Antibodies)
RN  - 0 (gamma-Globulins)
RN  - 9007-81-2 (Freund's Adjuvant)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antibodies/analysis
MH  - Antibody Formation
MH  - Antibody Specificity
MH  - Aspirin/adverse effects/*immunology
MH  - Drug Hypersensitivity/*diagnosis/immunology
MH  - Freund's Adjuvant/pharmacology
MH  - Guinea Pigs
MH  - Hemagglutination Tests
MH  - Rabbits
MH  - gamma-Globulins/pharmacology
EDAT- 1976/04/01 00:00
MHDA- 1976/04/01 00:01
CRDT- 1976/04/01 00:00
PHST- 1976/04/01 00:00 [pubmed]
PHST- 1976/04/01 00:01 [medline]
PHST- 1976/04/01 00:00 [entrez]
PST - ppublish
SO  - Physiologie. 1976 Apr-Jun;13(2):135-40.

PMID- 26859324
OWN - NLM
STAT- MEDLINE
DCOM- 20160720
LR  - 20181113
IS  - 1520-4995 (Electronic)
IS  - 0006-2960 (Print)
IS  - 0006-2960 (Linking)
VI  - 55
IP  - 8
DP  - 2016 Mar 1
TI  - Crystal Structure of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the 
      Formation of Products with Reversed Stereochemistry.
PG  - 1226-38
LID - 10.1021/acs.biochem.5b01378 [doi]
AB  - Aspirin and other nonsteroidal anti-inflammatory drugs target the cyclooxygenase 
      enzymes (COX-1 and COX-2) to block the formation of prostaglandins. Aspirin is 
      unique in that it covalently modifies each enzyme by acetylating Ser-530 within 
      the cyclooxygenase active site. Acetylation of COX-1 leads to complete loss of 
      activity, while acetylation of COX-2 results in the generation of the 
      monooxygenated product 15(R)-hydroxyeicosatetraenoic acid (15R-HETE). Ser-530 has 
      also been shown to influence the stereochemistry for the addition of oxygen to 
      the prostaglandin product. We determined the crystal structures of S530T murine 
      (mu) COX-2, aspirin-acetylated human (hu) COX-2, and huCOX-2 in complex with 
      salicylate to 1.9, 2.0, and 2.4 Å, respectively. The structures reveal that (1) 
      the acetylated Ser-530 completely blocks access to the hydrophobic groove, (2) 
      the observed binding pose of salicylate is reflective of the enzyme-inhibitor 
      complex prior to acetylation, and (3) the observed Thr-530 rotamer in the S530T 
      muCOX-2 crystal structure does not impede access to the hydrophobic groove. On 
      the basis of these structural observations, along with functional analysis of the 
      S530T/G533V double mutant, we propose a working hypothesis for the generation of 
      15R-HETE by aspirin-acetylated COX-2. We also observe differential acetylation of 
      COX-2 purified in various detergent systems and nanodiscs, indicating that 
      detergent and lipid binding within the membrane-binding domain of the enzyme 
      alters the rate of the acetylation reaction in vitro.
FAU - Lucido, Michael J
AU  - Lucido MJ
AD  - Department of Structural Biology, The State University of New York at Buffalo and 
      Hauptman-Woodward Medical Research Institute , Buffalo, New York 14203, United 
      States.
FAU - Orlando, Benjamin J
AU  - Orlando BJ
AD  - Department of Structural Biology, The State University of New York at Buffalo and 
      Hauptman-Woodward Medical Research Institute , Buffalo, New York 14203, United 
      States.
FAU - Vecchio, Alex J
AU  - Vecchio AJ
AD  - Department of Structural Biology, The State University of New York at Buffalo and 
      Hauptman-Woodward Medical Research Institute , Buffalo, New York 14203, United 
      States.
FAU - Malkowski, Michael G
AU  - Malkowski MG
AD  - Department of Structural Biology, The State University of New York at Buffalo and 
      Hauptman-Woodward Medical Research Institute , Buffalo, New York 14203, United 
      States.
LA  - eng
GR  - R01 GM077176/GM/NIGMS NIH HHS/United States
GR  - P41 GM103485/GM/NIGMS NIH HHS/United States
GR  - P41 RR001646/RR/NCRR NIH HHS/United States
GR  - DMR0225180/GM/NIGMS NIH HHS/United States
GR  - R01 GM115386/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160219
PL  - United States
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation/*drug effects
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry/pharmacology
MH  - Aspirin/*chemistry/pharmacology
MH  - Crystallography, X-Ray
MH  - Cyclooxygenase 2/*chemistry/metabolism
MH  - Humans
MH  - Mice
MH  - Molecular Docking Simulation
MH  - Protein Conformation
PMC - PMC4775376
MID - NIHMS761856
EDAT- 2016/02/10 06:00
MHDA- 2016/07/21 06:00
PMCR- 2017/03/01
CRDT- 2016/02/10 06:00
PHST- 2017/03/01 00:00 [pmc-release]
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/07/21 06:00 [medline]
AID - 10.1021/acs.biochem.5b01378 [doi]
PST - ppublish
SO  - Biochemistry. 2016 Mar 1;55(8):1226-38. doi: 10.1021/acs.biochem.5b01378. Epub 
      2016 Feb 19.

PMID- 1597302
OWN - NLM
STAT- MEDLINE
DCOM- 19920709
LR  - 20131121
IS  - 0367-6102 (Print)
IS  - 0367-6102 (Linking)
VI  - 67
IP  - 2
DP  - 1992 Mar
TI  - [Effect of intravenous injection of aspirin on the cochlea].
PG  - 216-33
AB  - It is not yet well understood how aspirin acts on the auditory system. This study 
      was aimed at elucidating the effects of aspirin on the cochlear hair cells and 
      cochlear nerve of guinea pigs by recording (1) spontaneous activity of cochlear 
      nerve fibers, (2) compound action potentials (CAPs) evoked by electrical pulses 
      applied to the cochlea through the round window membrane, (3) acoustically evoked 
      action potentials (APs) through the round window membrane and (4) acoustic 
      emissions (sound pressure near the tympanic membrane) evoked by electrical pulses 
      applied to the cochlea. The following results were obtained. (1) After guinea 
      pigs were given aspirin (200 mg/kg) intravenously, a transient reduction in 
      spontaneous activity of cochlear nerve fibers and elevation over the subsequent 
      10-20 minutes were observed in three of four fibers recorded for more than 30 
      minutes. The mean spontaneous discharge rate in 102 fibers after aspirin 
      administration (200 mg/kg) was not significantly higher than the control values 
      from 30 to 120 minutes after aspirin administration, while the rate in 112 fibers 
      after aspirin administration (400 mg/kg) was significantly higher. (2) After 
      injecting of 100 mg/kg, 200 mg/kg and 400 mg/kg of aspirin, the amplitude of 
      electrically evoked CAPs decreased significantly, while their latency increased 
      significantly only after injection of 400 mg/kg of aspirin. (3) Changes in the 
      amplitude of acoustically evoked APs and electrically evoked CAPs were compared 
      before and after intravenous injections of 400 mg/kg of aspirin. The AP 
      suppression ratio at low sound intensity was significantly greater than that of 
      CAPs at low and high current levels. (4) After injection of 400 mg/kg of aspirin, 
      the waves of electrically evoked acoustic emissions and their peaks in the 
      frequency analysis disappeared either reversibly or irreversibly. The observed 
      changes in spontaneous activity of cochlear nerve fibers in response to aspirin 
      administration to guinea pigs may represent a tinnitus-like phenomenon. The 
      detection of electrically evoked CAPs suggests that aspirin acts on the cochlear 
      nerve and causes a decrease in its excitability, and the discovery of 
      acoustically evoked APs and electrically evoked acoustic emissions is interpreted 
      as indicating that aspirin acts not only on the cochlear nerve but also on 
      cochlear hair cells.
FAU - Kumagai, M
AU  - Kumagai M
AD  - Department of Otolaryngology, Hokkaido University School of Medicine, Sapporo, 
      Japan.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Hokkaido Igaku Zasshi
JT  - [Hokkaido igaku zasshi] The Hokkaido journal of medical science
JID - 17410290R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acoustic Stimulation
MH  - Action Potentials/drug effects
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cochlea/*drug effects/physiology
MH  - Cochlear Nerve/drug effects/physiology
MH  - Electric Stimulation
MH  - Guinea Pigs
MH  - Hair Cells, Auditory/drug effects
MH  - Injections, Intravenous
MH  - Reaction Time/drug effects
EDAT- 1992/03/01 00:00
MHDA- 1992/03/01 00:01
CRDT- 1992/03/01 00:00
PHST- 1992/03/01 00:00 [pubmed]
PHST- 1992/03/01 00:01 [medline]
PHST- 1992/03/01 00:00 [entrez]
PST - ppublish
SO  - Hokkaido Igaku Zasshi. 1992 Mar;67(2):216-33.

PMID- 14710213
OWN - NLM
STAT- MEDLINE
DCOM- 20040224
LR  - 20220309
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 90
IP  - 1
DP  - 2004 Jan 12
TI  - Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic 
      review and meta-analysis.
PG  - 93-9
AB  - Animal and laboratory studies suggest that regular use of nonsteroidal 
      anti-inflammatory drugs (NSAIDs) may reduce prostate cancer risk. To assess this 
      association, we conducted a systematic review and meta-analysis of observational 
      studies published before January 2003. We derived summary odds ratios (ORs) using 
      both fixed and random effects models and performed subgroup analyses to explore 
      the possible sources of heterogeneity between combined studies. We identified 12 
      reports (five retrospective and seven prospective studies). Most studies of 
      aspirin use reported inverse associations, but only two were statistically 
      significant. The summary OR for the association between aspirin use and prostate 
      cancer was 0.9 (95% confidence interval: 0.82-0.99; test of homogeneity P=0.32), 
      and varied from 1.0 for retrospective studies to 0.85 for prospective studies. 
      Studies that measured exposure to a mixture of NSAIDs were less consistent. These 
      results indicate an inverse association between aspirin use and prostate cancer 
      risk. The current epidemiological evidence and, in particular, the strong and 
      consistent laboratory evidence underline the need for additional epidemiological 
      studies to confirm the direction and magnitude of the association.
FAU - Mahmud, S
AU  - Mahmud S
AD  - Department of Oncology, McGill University, Gerald Bronfman Centre, 546 Pine 
      Avenue West, Montreal, Quebec, Canada. Salaheddin.mahmud@mcgill.ca
FAU - Franco, E
AU  - Franco E
FAU - Aprikian, A
AU  - Aprikian A
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/*therapeutic use
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Case-Control Studies
MH  - Chemoprevention
MH  - Epidemiologic Studies
MH  - Humans
MH  - Male
MH  - Odds Ratio
MH  - Prostatic Neoplasms/*prevention & control
MH  - Retrospective Studies
PMC - PMC2395299
EDAT- 2004/01/08 05:00
MHDA- 2004/02/26 05:00
CRDT- 2004/01/08 05:00
PHST- 2004/01/08 05:00 [pubmed]
PHST- 2004/02/26 05:00 [medline]
PHST- 2004/01/08 05:00 [entrez]
AID - 6601416 [pii]
AID - 10.1038/sj.bjc.6601416 [doi]
PST - ppublish
SO  - Br J Cancer. 2004 Jan 12;90(1):93-9. doi: 10.1038/sj.bjc.6601416.

PMID- 3337412
OWN - NLM
STAT- MEDLINE
DCOM- 19880209
LR  - 20190717
IS  - 0196-0644 (Print)
IS  - 0196-0644 (Linking)
VI  - 17
IP  - 1
DP  - 1988 Jan
TI  - Evaluation of the effects of multiple-dose activated charcoal on the absorption 
      of orally administered salicylate in a simulated toxic ingestion model.
PG  - 34-7
AB  - The effects of multiple-dose activated charcoal administration on the absorption 
      of orally administered salicylate were evaluated in a simulated overdose model. 
      Thirteen adult volunteers were each given 24 81-mg aspirin tablets during a 
      control phase, and during three randomized treatment periods the volunteers 
      received 50 g activated charcoal for one, two, or three doses (separated by four 
      hours). The control phase and treatment periods were separated by a one-week 
      interval. Urine was collected for 48 hours to determine percent total salicylate 
      excretion. Ten subjects completed all four phases of the study. Mean +/- SD 
      percent recovery of salicylate from urine was: control, 91.0 +/- 6.12; one-dose 
      charcoal, 68.3 +/- 12.46; two-dose charcoal, 65.9 +/- 13.48; and three-dose 
      charcoal, 49.2 +/- 12.48. Each charcoal treatment significantly lowered the 
      absorption of aspirin as compared with the control (P less than .01). There was 
      no significant difference between one-dose and two-dose charcoal regimens. There 
      was a statistically significant decrease in salicylate absorption with the 
      three-dose charcoal regimen as compared to one-dose and two-dose regimens (P less 
      than .01). We conclude that activated charcoal is effective in inhibiting 
      absorption of orally administered salicylate, in a small-dose aspirin ingestion 
      model, with a three-dose multiple charcoal regimen being superior to either 
      single-dose or two-dose regimens.
FAU - Barone, J A
AU  - Barone JA
AD  - College of Pharmacy, Rutgers State University, Piscataway, New Jersey 08855-0789.
FAU - Raia, J J
AU  - Raia JJ
FAU - Huang, Y C
AU  - Huang YC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*poisoning/urine
MH  - Charcoal/*administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Models, Biological
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.1016/s0196-0644(88)80500-6 [doi]
PST - ppublish
SO  - Ann Emerg Med. 1988 Jan;17(1):34-7. doi: 10.1016/s0196-0644(88)80500-6.

PMID- 2303582
OWN - NLM
STAT- MEDLINE
DCOM- 19900320
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 30
IP  - 1
DP  - 1990 Jan
TI  - Clinical pharmacology of predisintegrated ibuprofen 800 mg tablets: an endoscopic 
      and pharmacokinetic study.
PG  - 57-63
AB  - Thirty-five healthy adults were randomized to receive either: (1) ibuprofen 800 
      mg tablets; (2) ibuprofen 800 mg aqueous suspension; (3) ibuprofen 800 mg orange 
      juice suspension; or (3) 325 mg aspirin tablets. All treatments were tid for 7 
      days. Pharmacokinetic sampling was conducted on days 1, 4 and 8. 
      Gastroduodenoscopy was performed on days 1 and 8. Side effects and safety 
      laboratory tests were monitored throughout the study. On day 8 the aspirin group 
      showed significantly more gastric irritation than all of the ibuprofen groups (P 
      less than .005). Both ibuprofen suspension groups showed more gastric irritation 
      than the ibuprofen tablet group (P less than .1). The duodenal scores did not 
      differ among the treatment groups. The aspirin group experienced a higher rate of 
      tinnitus and abdominal pain. The rate and extent of absorption of the ibuprofen 
      suspensions were significantly less than that of the tablets. These data suggest 
      that the taking of ibuprofen as an extemporaneous suspension is therapeutically 
      inferior to ibuprofen tablets and therefore should be discouraged.
FAU - Friedman, H
AU  - Friedman H
AD  - Clinical Pharmacology Unit, Upjohn Company, Kalamazoo, Michigan 49001.
FAU - Seckman, C
AU  - Seckman C
FAU - Lanza, F
AU  - Lanza F
FAU - Royer, G
AU  - Royer G
FAU - Perry, K
AU  - Perry K
FAU - Francom, S
AU  - Francom S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Tablets)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/pharmacokinetics
MH  - Beverages
MH  - Chromatography, High Pressure Liquid
MH  - Citrus
MH  - Duodenoscopy
MH  - Female
MH  - Gastric Mucosa/drug effects
MH  - Gastroscopy
MH  - Humans
MH  - Ibuprofen/administration & dosage/adverse effects/*pharmacokinetics
MH  - Intestinal Mucosa/drug effects
MH  - Male
MH  - Middle Aged
MH  - Tablets
MH  - Water
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1990.tb03439.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1990 Jan;30(1):57-63. doi: 10.1002/j.1552-4604.1990.tb03439.x.

PMID- 1233206
OWN - NLM
STAT- MEDLINE
DCOM- 19761201
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 8
IP  - 2
DP  - 1975 Feb 28
TI  - The effect of buffered aspirin on plasma indomethacin.
PG  - 107-13
AB  - Plasma indomethacin levels have been compared in 10 subjects following 100 mg of 
      indomethacin from two different formulations, with similar disintegration and 
      dissolution profiles. In four of these ten subjects plasma indomethacin levels 
      were estimated after pretreatment with, and concurrent administration of, a 
      buffered aspirin. The percentage of protein binding of indomethacin in the 
      presence of salicylate was also estimated. No significant differences between 
      peak plasma indomethacin levels with or without buffered aspirin were detected, 
      but the rate of indomethacin absorption as shown by plasma levels, was 
      significantly increased by pretreatment with and concurrent administration of, 
      buffered aspirin. This was associated with a marked increase in side effects.
FAU - Garnham, J C
AU  - Garnham JC
FAU - Raymond, K
AU  - Raymond K
FAU - Shotton, E
AU  - Shotton E
FAU - Turner, P
AU  - Turner P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Blood Proteins)
RN  - 0 (Buffers)
RN  - 0 (Capsules)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biological Availability
MH  - Blood Proteins/metabolism
MH  - Buffers
MH  - Capsules
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Indomethacin/administration & dosage/adverse effects/*blood
MH  - Male
MH  - Protein Binding
MH  - Solubility
MH  - Tablets
MH  - Time Factors
EDAT- 1975/02/28 00:00
MHDA- 1975/02/28 00:01
CRDT- 1975/02/28 00:00
PHST- 1975/02/28 00:00 [pubmed]
PHST- 1975/02/28 00:01 [medline]
PHST- 1975/02/28 00:00 [entrez]
AID - 10.1007/BF00561558 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1975 Feb 28;8(2):107-13. doi: 10.1007/BF00561558.

PMID- 11980730
OWN - NLM
STAT- MEDLINE
DCOM- 20021010
LR  - 20190513
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 17
IP  - 5
DP  - 2002 May
TI  - Aspirin dilemma. Remodelling the hypothesis from a fertility perspective.
PG  - 1146-8
AB  - Many clinical trials in obstetrics have failed to demonstrate improved outcomes 
      with low-dose aspirin. This is not entirely surprising as prescribing aspirin for 
      compromised tissue perfusion without insight into underlying pathology inevitably 
      leads to suboptimal outcomes. We argue that a mismatch between the aspirin dose 
      and the underlying pathology of altered tissue perfusion is the key factor to 
      this failure. Based on this groundwork, we address the question of how best to 
      optimize the dose of aspirin for use in fertility management, by providing 
      examples from the assisted conception and recurrent miscarriage settings.
FAU - Ozturk, O
AU  - Ozturk O
AD  - Department of Obstetrics and Gynaecology, University of Aberdeen, UK. 
      ozkanozturk@tesco.net
FAU - Greaves, M
AU  - Greaves M
FAU - Templeton, A
AU  - Templeton A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/drug therapy
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cyclooxygenase Inhibitors/*administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Fertility/*drug effects
MH  - Humans
RF  - 41
EDAT- 2002/05/01 10:00
MHDA- 2002/10/11 04:00
CRDT- 2002/05/01 10:00
PHST- 2002/05/01 10:00 [pubmed]
PHST- 2002/10/11 04:00 [medline]
PHST- 2002/05/01 10:00 [entrez]
AID - 10.1093/humrep/17.5.1146 [doi]
PST - ppublish
SO  - Hum Reprod. 2002 May;17(5):1146-8. doi: 10.1093/humrep/17.5.1146.

PMID- 9540188
OWN - NLM
STAT- MEDLINE
DCOM- 19980519
LR  - 20131121
IS  - 0340-2592 (Print)
IS  - 0340-2592 (Linking)
VI  - 37
IP  - 1
DP  - 1998 Jan
TI  - [Does treatment with thrombocyte aggregation inhibitors modify kidney 
      transplantation surgery?].
PG  - 75-8
AB  - The influence of aspirin treatment on haemostasis is still under debate. There 
      are doubts in emergency operations, especially in transplant patients, concerning 
      dosage and change in medication. Our results are based on an analysis of the 
      therapeutic approaches in German transplantation centres. The question of 
      transplant suitability, dosage and haemostatic effects are discussed with respect 
      to the literature. Some 92.11% of the transplantation centres perform the 
      operation even though the patient has been treated with aspirin. In these cases 
      an increased bleeding tendency is tolerated and observed in 34.2% of the centres. 
      An increased mortality has not been reported. Most of the transplantation centres 
      accept a dosage of 100 mg aspirin daily. Only 7.89% of the transplantation 
      centres refuse to operate on aspirin-treated patients. Correctly indicated 
      aspirin treatment (for cardiac arrhythmia, embolism, or thrombosis, for example) 
      does not contraindicate renal transplantation (daily dosage up to 100 mg). In 
      elective surgery, however, a preoperative change in medication is recommended, 
      e.g., the heparin instead of aspirin.
FAU - Werner, W
AU  - Werner W
AD  - Klinik und Poliklinik für Urologie, Friedrich-Schiller-Universität Jena.
FAU - Klemm, A
AU  - Klemm A
FAU - Wunderlich, H
AU  - Wunderlich H
FAU - Schubert, J
AU  - Schubert J
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Beeinflusst die Einnahme von Thrombozytenaggregationshemmern die Durchführung 
      einer Nierentransplantation?
PL  - Germany
TA  - Urologe A
JT  - Der Urologe. Ausg. A
JID - 1304110
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Urologe A. 1998 Jan;37(1):102. PMID: 9599183
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Loss, Surgical/*physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Hemostasis, Surgical
MH  - Humans
MH  - Kidney Transplantation/*physiology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk Factors
RF  - 19
EDAT- 1998/04/16 00:00
MHDA- 1998/04/16 00:01
CRDT- 1998/04/16 00:00
PHST- 1998/04/16 00:00 [pubmed]
PHST- 1998/04/16 00:01 [medline]
PHST- 1998/04/16 00:00 [entrez]
PST - ppublish
SO  - Urologe A. 1998 Jan;37(1):75-8.

PMID- 29633739
OWN - NLM
STAT- MEDLINE
DCOM- 20191028
LR  - 20200306
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Print)
IS  - 0392-4203 (Linking)
VI  - 89
IP  - 1
DP  - 2018 Feb 27
TI  - Aspirin for thromboprophylaxis in major orthopedic surgery: old drug, new tricks?
PG  - 31-33
LID - 10.23750/abm.v89i1.7121 [doi]
AB  - Major orthopedic surgery, mainly entailing hip fracture surgery, hip and knee 
      arthroplasty, is associated with significant morbidity and mortality, which are 
      especially attributable to the high risk of postoperative VTE. Such a 
      considerable risk is mainly due to a procoagulant state sustained by several 
      important mechanisms, including massive release of procoagulants from tissue and 
      bone damage, blood vessel injury, reduced venous emptying, perioperative 
      immobilization and cement polymerization, among others. The risk of VTE during 
      and after major orthopedic surgery approximates 50-80% in patients with no 
      thromboprophylaxis, and persists for up 3 to 6 months after surgery. The 
      anticoagulant or antithrombotic armamentarium entails several anticoagulants such 
      as heparin, coumarins, fondaparinux, and the recently developed DOACs inhibiting 
      either activated factor Xa (i.e., rivaroxaban, apixaban, edoxaban) or thrombin 
      (i.e., dabigatran), as well as aspirin, i.e., the oldest antiplatelet drug to be 
      ever discovered and used in clinical practice. The current guidelines are not in 
      complete agreement regarding the choice of the ideal thromboprophylaxis, since 
      some consider aspirin, and some discourage it. Recent evidence seems to support 
      the use of aspirin in selected situations and in selected protocols. Therefore, 
      we believe that consideration should be made about increasing the use of this old 
      but still effective drug for perioperative prophylaxis of VTE, especially in 
      patients for whom the administration of DOACs may be challenging.
FAU - Lippi, Giuseppeli
AU  - Lippi G
AD  - University of Verona, Italy. giuseppe.lippi@univr.it.
FAU - Cervellin, Gianfranco
AU  - Cervellin G
AD  - University Hospital of Parma, Italy. gcervellin@ao.pr.it.
LA  - eng
PT  - Journal Article
DEP - 20180227
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/classification/therapeutic use
MH  - Arthroplasty, Replacement, Knee
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Contraindications, Drug
MH  - Drug Evaluation
MH  - Humans
MH  - *Orthopedic Procedures
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Postoperative Complications/epidemiology/etiology/*prevention & control
MH  - Premedication
MH  - Retrospective Studies
MH  - Thrombophilia/*drug therapy
MH  - Venous Thromboembolism/epidemiology/etiology/*prevention & control
PMC - PMC6357605
EDAT- 2018/04/11 06:00
MHDA- 2019/10/29 06:00
CRDT- 2018/04/11 06:00
PHST- 2018/02/22 00:00 [received]
PHST- 2018/02/26 00:00 [accepted]
PHST- 2018/04/11 06:00 [entrez]
PHST- 2018/04/11 06:00 [pubmed]
PHST- 2019/10/29 06:00 [medline]
AID - ACTA-89-31 [pii]
AID - 10.23750/abm.v89i1.7121 [doi]
PST - epublish
SO  - Acta Biomed. 2018 Feb 27;89(1):31-33. doi: 10.23750/abm.v89i1.7121.

PMID- 6145780
OWN - NLM
STAT- MEDLINE
DCOM- 19840817
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 36
IP  - 5
DP  - 1984 May
TI  - Absorption of acetylsalicylic acid from enteric-coated tablets in relation to 
      gastric emptying and in-vivo disintegration.
PG  - 350-1
AB  - The absorption of acetylsalicylic (ASA) acid from enteric coated tablets was 
      studied in relation to gastric emptying and in-vivo disintegration. ASA tablets 
      labelled with 51Cr were given to six healthy subjects under fasting and 
      non-fasting conditions. The position and disintegration of the 51Cr-labelled 
      tablets was followed by external radiation measurement and the amount of 
      salicylic acid in blood and urine was analysed. The absorption of ASA from the 
      studied enteric coated tablets was usually correlated with gastric emptying and 
      in-vivo disintegration. However in some cases the absorption can be delayed 
      between 10-20 h even if gastric emptying and disintegration of the tablet have 
      occurred.
FAU - Bogentoft, C
AU  - Bogentoft C
FAU - Alpsten, M
AU  - Alpsten M
FAU - Ekenved, G
AU  - Ekenved G
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*metabolism
MH  - *Gastric Emptying
MH  - Humans
MH  - *Intestinal Absorption
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Solubility
MH  - Tablets, Enteric-Coated
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1984.tb04394.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1984 May;36(5):350-1. doi: 10.1111/j.2042-7158.1984.tb04394.x.

PMID- 6793920
OWN - NLM
STAT- MEDLINE
DCOM- 19811222
LR  - 20161123
IS  - 0375-9393 (Print)
IS  - 0375-9393 (Linking)
VI  - 47
IP  - 5
DP  - 1981 May
TI  - [Double-blind study of lysine acetylsalicylate in the control of postoperative 
      pain of somatic origin].
PG  - 205-14
AB  - In 61 patients submitted to subdural anesthesia for orthopedic operations, 
      postoperative somatic pain was treated by double-blind iv injection of lysine 
      acetylsalicylate 1.8 g or placebo randomly. Patients with persistent pain 
      received methadone 10 mg im. No placebo response was obtained; LAS had similar 
      but shorter effects than methadone. No significant side effect was observed.
FAU - Frova, G
AU  - Frova G
FAU - Geraci, P
AU  - Geraci P
FAU - Giurati, G
AU  - Giurati G
FAU - Pagani, I
AU  - Pagani I
FAU - Ronchi, G
AU  - Ronchi G
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Studio in doppio cieco dell'acetilsalicilato di lisina nel controllo del dolore 
      post-operatorio di origine somatica.
PL  - Italy
TA  - Minerva Anestesiol
JT  - Minerva anestesiologica
JID - 0375272
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - UC6VBE7V1Z (Methadone)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Bone and Bones/surgery
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Methadone/*therapeutic use
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
EDAT- 1981/05/01 00:00
MHDA- 1981/05/01 00:01
CRDT- 1981/05/01 00:00
PHST- 1981/05/01 00:00 [pubmed]
PHST- 1981/05/01 00:01 [medline]
PHST- 1981/05/01 00:00 [entrez]
PST - ppublish
SO  - Minerva Anestesiol. 1981 May;47(5):205-14.

PMID- 1096521
OWN - NLM
STAT- MEDLINE
DCOM- 19751010
LR  - 20190819
IS  - 0001-6470 (Print)
IS  - 0001-6470 (Linking)
VI  - 46
IP  - 2
DP  - 1975 May
TI  - Acetylsalicylic acid in a trial to diminish thromboembolic complications after 
      elective hip surgery.
PG  - 246-55
AB  - Fifty-one patients were investigated concerning thromboembolic complications in 
      the operated leg after elective surgery of the hip. Suspicion of clinical deep 
      venous thrombosis (DVT) arose in 11 patients, i.e. 21 per cent. Thirty-five 
      patients were investigated with phlebography. The incidence of DVT among those 
      patients was 15 cases, i.e. 43 per cent. It is concluded that acetylsalicylic 
      acid, a drug which inhibits the platelet release reaction and thereby blocks the 
      platelet aggregation, given orally in a dose of 2 gram per day from the first 
      postoperative day, is not effective in diminishing the incidence of postoperative 
      deep venous thrombosis.
FAU - Soreff, J
AU  - Soreff J
FAU - Johnsson, H
AU  - Johnsson H
FAU - Diener, L
AU  - Diener L
FAU - Göransson, L
AU  - Göransson L
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Acta Orthop Scand
JT  - Acta orthopaedica Scandinavica
JID - 0370352
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Hip/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/surgery
MH  - Placebos
MH  - Postoperative Complications/*drug therapy
MH  - Thrombophlebitis/*drug therapy
MH  - Time Factors
EDAT- 1975/05/01 00:00
MHDA- 1975/05/01 00:01
CRDT- 1975/05/01 00:00
PHST- 1975/05/01 00:00 [pubmed]
PHST- 1975/05/01 00:01 [medline]
PHST- 1975/05/01 00:00 [entrez]
AID - 10.3109/17453677508989215 [doi]
PST - ppublish
SO  - Acta Orthop Scand. 1975 May;46(2):246-55. doi: 10.3109/17453677508989215.

PMID- 33176342
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20210226
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Print)
IS  - 0094-3509 (Linking)
VI  - 69
IP  - 9
DP  - 2020 Nov
TI  - PURL:Rethinking daily aspirin for primary prevention.
PG  - 461-462
AB  - An updated meta-analysis of newer RCTs seems to settle the matter as to whether 
      to use aspirin in individuals with no known history of atherosclerotic CVD.
FAU - Poplawski, Michael
AU  - Poplawski M
AD  - Dwight D. Eisenhower Army Medical Center, Fort Gordon, GA, USA.
FAU - Nelson, Nicole K
AU  - Nelson NK
AD  - Dwight D. Eisenhower Army Medical Center, Fort Gordon, GA, USA.
FAU - Earwood, J Scott
AU  - Earwood JS
AD  - Dwight D. Eisenhower Army Medical Center, Fort Gordon, GA, USA.
LA  - eng
GR  - UL1 RR024999/RR/NCRR NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Eur Heart J. 2019 Feb 14;40(7):607-617. PMID: 30561620
MH  - *Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Safety
PMC - PMC7891365
EDAT- 2020/11/12 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/11 20:11
PHST- 2020/11/11 20:11 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - jfp_6909f [pii]
AID - 10.12788/jfp.0092 [doi]
PST - ppublish
SO  - J Fam Pract. 2020 Nov;69(9):461-462. doi: 10.12788/jfp.0092.

PMID- 3370916
OWN - NLM
STAT- MEDLINE
DCOM- 19880708
LR  - 20190820
IS  - 0143-5221 (Print)
IS  - 0143-5221 (Linking)
VI  - 74
IP  - 5
DP  - 1988 May
TI  - Inhibition of platelet aggregation and thromboxane production by low 
      concentrations of aspirin in vitro.
PG  - 491-7
AB  - 1. The aspirin concentrations previously reported to inhibit platelet aggregation 
      in vitro (40-500 mumol/l) are much greater than those required in vivo in man (5 
      mumol/l). 2. Human platelet-rich plasma was incubated with buffer or various 
      aspirin concentrations at 37 degrees C for up to 4.5 h. Platelet aggregation and 
      thromboxane generation were measured in response to collagen (0.4-6.3 
      micrograms/ml) and adenosine 5'-pyrophosphate (0.5-4 mumol/l). 3. The 
      concentration of aspirin needed to inhibit platelet aggregation in response to a 
      critical concentration of aggregating agent (lowest concentration to cause 
      greater than 50% aggregation) was lower than that required for higher 
      concentrations of aggregating agent. 4. With more prolonged incubation times with 
      aspirin, lower concentrations of aspirin inhibited platelet aggregation. 5. 
      Inhibition of platelet aggregation and thromboxane formation by 10 mumol/l 
      aspirin was maximal by 90 min. There was progressive inhibition by 3 mumol/l 
      aspirin during incubation for 270 min. By the end of this time there was also 
      significant inhibition by 1 mumol/l aspirin. 6. The apparent discrepancy between 
      inhibitory aspirin concentrations in vivo and those observed in vitro in previous 
      studies appears to have been resolved by extending the incubation time of 
      platelets with low aspirin concentrations, thus mimicking the conditions in vivo.
FAU - Sils, D
AU  - Sils D
AD  - Department of Clinical and Experimental Pharmacology, University of Adelaide, 
      Australia.
FAU - Rodgers, S E
AU  - Rodgers SE
FAU - Lloyd, J V
AU  - Lloyd JV
FAU - Wilson, K M
AU  - Wilson KM
FAU - Siebert, D M
AU  - Siebert DM
FAU - Bochner, F
AU  - Bochner F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 0 (Thromboxanes)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Collagen/antagonists & inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxanes/*biosynthesis
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
AID - 10.1042/cs0740491 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 1988 May;74(5):491-7. doi: 10.1042/cs0740491.

PMID- 309511
OWN - NLM
STAT- MEDLINE
DCOM- 19790115
LR  - 20181113
IS  - 0027-9684 (Print)
IS  - 0027-9684 (Linking)
VI  - 70
IP  - 10
DP  - 1978 Oct
TI  - Aspirin and gastrointestinal bleeding.
PG  - 761-2
AB  - There is no other over-the-counter (OTC) drug having the widespread use of 
      aspirin. Evoking the well-established analgesic, antipyretic, and 
      anti-inflammatory activities with an amazingly low degree of toxicity, its use 
      has increased in this country to the astounding figure of more than 20 tons 
      daily. The observation that comparatively small daily doses of aspirin may serve 
      as a means of preventing certain types of cardiovascular disasters may lead to 
      even more widespread use of the drug. The most frequent untoward side effect of 
      aspirin is gastric discomfort with or without microbleeding. The amount of 
      bleeding is usually quite small but owing to the long interest of the author in 
      buffered aspirin, it is prudent to determine whether or not this action of 
      aspirin is serious.
FAU - Krantz, J C
AU  - Krantz JC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Natl Med Assoc
JT  - Journal of the National Medical Association
JID - 7503090
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
PMC - PMC2537102
EDAT- 1978/10/01 00:00
MHDA- 1978/10/01 00:01
CRDT- 1978/10/01 00:00
PHST- 1978/10/01 00:00 [pubmed]
PHST- 1978/10/01 00:01 [medline]
PHST- 1978/10/01 00:00 [entrez]
PST - ppublish
SO  - J Natl Med Assoc. 1978 Oct;70(10):761-2.

PMID- 8980919
OWN - NLM
STAT- MEDLINE
DCOM- 19970401
LR  - 20181113
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 21
IP  - 3
DP  - 1996 Jul-Sep
TI  - Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human 
      volunteers.
PG  - 223-6
AB  - The influence of Tamarindus indica L. fruit extract incorporated in a traditional 
      meal on the bioavailability of aspirin tablets 600 mg dose was studied in 6 
      healthy volunteers. There was a statistically significant increase in the plasma 
      levels of aspirin and salicylic acid, respectively, when the meal containing 
      Tamarindus indica fruit extract was administered with the aspirin tablets than 
      when taken under fasting state or with the meal without the fruit extract. The 
      Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 
      +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 
      0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively. There was 
      no change in the tmax (0.50 +/- 0.17 h) but there was a decrease in the kel from 
      0.633 +/- 0.22 to 0.463 +/- 0.29 (P < 0.05). Similarly, the Cmax, AUC0-6h and kel 
      for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 
      0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 
      +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively. The tmax decreased from 2.0 
      +/- 0.18 h to 1.0 +/- 0.08 h (P < 0.05) and t1/2 from 0.25 +/- 0.21 h to 0.184 
      +/- 0.11 h (P < 0.05). The study has indicated that Tamarindus indica L. fruit 
      extract significantly increased the bioavailability of aspirin.
FAU - Mustapha, A
AU  - Mustapha A
AD  - Department of Pharmaceutical and Medicinal Chemistry, Ahmadu Bello University, 
      Zaria.
FAU - Yakasai, I A
AU  - Yakasai IA
FAU - Aguye, I A
AU  - Aguye IA
LA  - eng
PT  - Journal Article
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (Plant Extracts)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/metabolism/*pharmacokinetics
MH  - Biological Availability
MH  - Diet
MH  - Drug Interactions
MH  - Fasting
MH  - Humans
MH  - Male
MH  - Plant Extracts/pharmacology
MH  - *Plants, Medicinal
MH  - Salicylates/blood/pharmacokinetics
MH  - Salicylic Acid
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
AID - 10.1007/BF03189717 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 1996 Jul-Sep;21(3):223-6. doi: 
      10.1007/BF03189717.

PMID- 9532649
OWN - NLM
STAT- MEDLINE
DCOM- 19980513
LR  - 20131121
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 70
IP  - 1
DP  - 1998
TI  - [Ascolong: a new buccal dosage form of acetylsalicylic acid to be used and 
      antiaggregant].
PG  - 32-7
AB  - AIM: Study of the tolerance and pharmacodynamic and pharmacokinetic 
      characteristics of ascolong, a new buccal dosage form of aspirin containing a 
      very low dose of acetylsalicylic acid (ASA): 12.5 mg. MATERIALS AND METHODS: The 
      study was carried out in 43 healthy men (assessment of the drug tolerance) and 19 
      male patients with coronary disease or cerebrovascular disorders. In 10 patients 
      the antiaggregant efficacy of ascolong administered once or regularly (for 2 
      weeks) in a dose of 12.5 mg was compared with placebo, in 9 patients a random 
      cross study of 2-week courses of ascolong and Russian aspirin tablets in a dose 
      of 100 mg was carried out. Platelet aggregation was assessed on days 1 and 14 of 
      each course before and 2, 4, and 24 h after the drug intake. RESULTS: Ascolong 
      containing a very low dose of ASA exerts a reliable antiaggregant effect after a 
      single and regular intake, although this effect is less manifest than after 
      aspirin tablets. Profiles of ASA concentrations in the blood were studied. 
      Transbuccal entry of ASA in systemic circulation decelerated its metabolism into 
      a less active metabolite, salicylic acid, due to which fact the ASA microdose had 
      an expressed antiaggregant effect. The drug was sufficiently well tolerated. 
      CONCLUSION: The new buccal film form of aspirin containing a very low dose of ASA 
      possesses a good antiaggregant effect and is promising in subjects with 
      contraindications to oral intake of aspirin.
FAU - Kokurina, E V
AU  - Kokurina EV
FAU - Suslina, Z A
AU  - Suslina ZA
FAU - Khromov, G L
AU  - Khromov GL
FAU - Davydo, A B
AU  - Davydo AB
FAU - Metelitsa, V I
AU  - Metelitsa VI
FAU - Ionova, V G
AU  - Ionova VG
FAU - Tanashian, M M
AU  - Tanashian MM
FAU - Demina, E G
AU  - Demina EG
FAU - Bochkareva, E V
AU  - Bochkareva EV
FAU - Belolipetskaia, V G
AU  - Belolipetskaia VG
FAU - Deev, A D
AU  - Deev AD
FAU - Kucheriaeva, N G
AU  - Kucheriaeva NG
FAU - Zidra, S I
AU  - Zidra SI
FAU - Gorin, N N
AU  - Gorin NN
FAU - Rumiantsev, D O
AU  - Rumiantsev DO
LA  - rus
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Aksolong: novaia bukkal'naia forma atsetilsalitsilovoĭ kisloty dlia primeneniia v 
      kachestve antiagreganta.
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Dosage Forms)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Buccal
MH  - Aspirin/*administration & dosage/pharmacokinetics/therapeutic use
MH  - Cerebrovascular Disorders/drug therapy/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Coronary Disease/drug therapy/metabolism
MH  - Cross-Over Studies
MH  - Dosage Forms
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & 
      dosage/pharmacokinetics/therapeutic use
MH  - Safety
MH  - Treatment Outcome
EDAT- 1998/04/09 00:00
MHDA- 1998/04/09 00:01
CRDT- 1998/04/09 00:00
PHST- 1998/04/09 00:00 [pubmed]
PHST- 1998/04/09 00:01 [medline]
PHST- 1998/04/09 00:00 [entrez]
PST - ppublish
SO  - Ter Arkh. 1998;70(1):32-7.

PMID- 21654128
OWN - NLM
STAT- MEDLINE
DCOM- 20120105
LR  - 20151221
IS  - 0972-2823 (Electronic)
IS  - 0022-3859 (Linking)
VI  - 57
IP  - 2
DP  - 2011 Apr-Jun
TI  - A meta-analysis of low-dose aspirin for prevention of preeclampsia.
PG  - 91-5
LID - 10.4103/0022-3859.81858 [doi]
AB  - BACKGROUND: Low-dose aspirin (LDA) is widely used for prevention of preeclampsia. 
      However, conflicting results have been obtained from various studies. AIM: The 
      aim of our study was to evaluate the effect of LDA in prevention of preeclampsia 
      in high-risk and low-risk women. MATERIALS AND METHODS: A total of 19 randomized 
      control trials were identified using PUBMED search engine and Cochrane Clinical 
      Trial register. The study population was divided into high-risk and low-risk 
      groups. The effect measured was incidence of preeclampsia in women taking either 
      LDA or placebo where the relative risk (RR) and the 95% confidence interval (CI) 
      were calculated for both groups. RESULTS: A total of 28237 women were studied, 
      out of which 16550 were in the low-risk group while 11687 were in the high-risk 
      group. The overall incidence of preeclampsia was 7.4%. With the aspirin group it 
      was 6.9% while in the placebo group it was 7.8%. In the high-risk group there was 
      21% reduction in the risk of preeclampsia associated with the use of aspirin (RR 
      0.79, 95% CI 0.65-0.97). However, LDA is not effective in reducing the risk in 
      low-risk population (RR 0.86, 95% CI 0.64-1.17). CONCLUSION: LDA has a small 
      effect in the prevention of preeclampsia in women considered to be at high risk 
      for the disease. However, it is not effective in reducing the risk in the 
      low-risk group.
FAU - Trivedi, N A
AU  - Trivedi NA
AD  - Department of Pharmacology, Medical College, Baroda, Gujarat, India. 
      natrivedi@yahoo.com
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - India
TA  - J Postgrad Med
JT  - Journal of postgraduate medicine
JID - 2985196R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Postgrad Med. 2011 Apr-Jun;57(2):89-90. PMID: 21654127
CIN - J Postgrad Med. 2011 Oct-Dec;57(4):350. PMID: 22120871
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Risk
EDAT- 2011/06/10 06:00
MHDA- 2012/01/06 06:00
CRDT- 2011/06/10 06:00
PHST- 2011/06/10 06:00 [entrez]
PHST- 2011/06/10 06:00 [pubmed]
PHST- 2012/01/06 06:00 [medline]
AID - jpgm_2011_57_2_91_81858 [pii]
AID - 10.4103/0022-3859.81858 [doi]
PST - ppublish
SO  - J Postgrad Med. 2011 Apr-Jun;57(2):91-5. doi: 10.4103/0022-3859.81858.

PMID- 4024217
OWN - NLM
STAT- MEDLINE
DCOM- 19850919
LR  - 20190903
IS  - 0163-4356 (Print)
IS  - 0163-4356 (Linking)
VI  - 7
IP  - 2
DP  - 1985
TI  - A sensitive liquid chromatographic assay for plasma aspirin and salicylate 
      concentrations after low doses of aspirin.
PG  - 216-21
AB  - An original, highly sensitive and specific high performance liquid 
      chromatographic method has been developed for the measurement of aspirin and 
      salicylate in plasma. Minimum concentrations of 10 micrograms/L (aspirin) and 0.5 
      mg/L (salicylate) can be measured using 1 ml of plasma. After collection, plasma 
      is first treated with physostigmine sulfate to inhibit enzymatic hydrolysis of 
      aspirin to salicylate. Maximal recovery is achieved using an acid extraction into 
      anhydrous diethyl ether with a subsequent drying-down step in an iced water bath. 
      Aspirin and salicylate are separated by elution with a mixture of methanol, 
      1-butanol, orthophosphoric acid, and water on a reversed-phase octadecyl silane 
      column at 47 degrees C and detected at 234 nm by ultraviolet absorption. 
      Quantitation is achieved using the peak height ratio of aspirin and salicylate to 
      internal standard (m-anisic acid). The assay has been used for the study of 
      simultaneous aspirin and salicylate pharmacokinetics after a single oral dose of 
      100 mg soluble glycinated aspirin for platelet antiaggregatory therapy in six 
      subjects, one of whom was also studied after receiving a 600 mg dose.
FAU - Brandon, R A
AU  - Brandon RA
FAU - Eadie, M J
AU  - Eadie MJ
FAU - Smith, M T
AU  - Smith MT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ther Drug Monit
JT  - Therapeutic drug monitoring
JID - 7909660
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*blood
MH  - Chromatography, Liquid
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Salicylates/*blood
MH  - Salicylic Acid
MH  - Spectrophotometry, Ultraviolet
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1097/00007691-198506000-00014 [doi]
PST - ppublish
SO  - Ther Drug Monit. 1985;7(2):216-21. doi: 10.1097/00007691-198506000-00014.

PMID- 15944844
OWN - NLM
STAT- MEDLINE
DCOM- 20051004
LR  - 20131121
IS  - 0940-5429 (Print)
IS  - 0940-5429 (Linking)
VI  - 42
IP  - 2
DP  - 2005 Jun
TI  - Prevalence of aspirin resistance in patients with type 2 diabetes.
PG  - 99-103
AB  - Aspirin resistance has been recognised to occur in patients with cardiovascular 
      disease and is associated with poor clinical prognosis. The purpose of the 
      present study was to evaluate the prevalence of aspirin resistance in 172 
      patients with diabetes mellitus type 2 (DM-2). Platelet function of 172 
      consecutive patients with type 2 diabetes on chronic aspirin therapy was 
      evaluated. The effect of aspirin was assessed using the platelet function 
      analyser (PFA-100) system, reporting platelet-dependent thrombus formation as the 
      time required to close a small aperture in a biologically active membrane. 
      Resistance to aspirin was defined as a normal collagen/epinephrine-induced 
      closure time (82-165 s). Aspirin responders were defined when closure time was > 
      or =300 s. Thirty-seven (21.5%) of the type 2 diabetic patients were found to be 
      resistant to chronic aspirin therapy, 29 (16.9%) were semi-responders and 106 
      (61.6%) were responders. Univariate analysis revealed that aspirin non-responders 
      were significantly younger (p<0.05) compared to aspirin responders. A significant 
      number of type 2 diabetic patients are resistant to aspirin therapy. Aspirin 
      resistance can be evaluated by point-of-care testing and should be recognised in 
      diabetic patients that are treated for primary or secondary prevention.
FAU - Fateh-Moghadam, S
AU  - Fateh-Moghadam S
AD  - Medizinische Klinik mit Schwerpunkt Kardiologie, Universitätsmedizin 
      Charité-Campus Virchow, Humboldt-Universität zu Berlin und Freie Universität 
      Berlin, Germany.
FAU - Plöckinger, U
AU  - Plöckinger U
FAU - Cabeza, N
AU  - Cabeza N
FAU - Htun, P
AU  - Htun P
FAU - Reuter, T
AU  - Reuter T
FAU - Ersel, S
AU  - Ersel S
FAU - Gawaz, M
AU  - Gawaz M
FAU - Dietz, R
AU  - Dietz R
FAU - Bocksch, W
AU  - Bocksch W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/physiology
MH  - Cardiovascular Diseases/prevention & control
MH  - Diabetes Mellitus, Type 2/*physiopathology
MH  - Diabetic Angiopathies/prevention & control
MH  - Drug Resistance/*physiology
MH  - Female
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Prevalence
MH  - Smoking
EDAT- 2005/06/10 09:00
MHDA- 2005/10/05 09:00
CRDT- 2005/06/10 09:00
PHST- 2004/04/26 00:00 [received]
PHST- 2005/03/21 00:00 [accepted]
PHST- 2005/06/10 09:00 [pubmed]
PHST- 2005/10/05 09:00 [medline]
PHST- 2005/06/10 09:00 [entrez]
AID - 10.1007/s00592-005-0186-y [doi]
PST - ppublish
SO  - Acta Diabetol. 2005 Jun;42(2):99-103. doi: 10.1007/s00592-005-0186-y.

PMID- 8012625
OWN - NLM
STAT- MEDLINE
DCOM- 19940727
LR  - 20191023
IS  - 1063-3987 (Print)
IS  - 1063-3987 (Linking)
VI  - 3
IP  - 4
DP  - 1994 Apr
TI  - Primary prevention of coronary heart disease in women. Should asymptomatic women 
      50 years of age take aspirin regularly?
PG  - 361-4
AB  - Based on the results of the Physician's Health Study, the US Preventive Services 
      Task Force currently recommends low doses of aspirin on alternate days for men 
      over age 50 years to prevent first myocardial infarction. Although there are no 
      clinical trials involving women, three female cohort studies of aspirin and 
      prevention of myocardial infarction have been published with conflicting results. 
      We conducted a critical review of the three female cohort studies. Although a 
      general recommendation for asymptomatic women to take aspirin to prevent 
      myocardial infarction is not currently indicated, the best available data suggest 
      a beneficial effect, particularly in women at high risk of coronary artery 
      disease. The clinician should therefore consider aspirin use in each patient 
      individually.
FAU - Woods, S E
AU  - Woods SE
AD  - Department of Family Medicine, University of North Carolina at Chapel Hill.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Arch Fam Med
JT  - Archives of family medicine
JID - 9300357
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/*prevention & control
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Women's Health
RF  - 20
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
AID - 10.1001/archfami.3.4.361 [doi]
PST - ppublish
SO  - Arch Fam Med. 1994 Apr;3(4):361-4. doi: 10.1001/archfami.3.4.361.

PMID- 19568178
OWN - NLM
STAT- MEDLINE
DCOM- 20091202
LR  - 20131121
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 54
IP  - 2
DP  - 2009 Aug
TI  - Do proton pump inhibitors attenuate the effect of aspirin on platelet 
      aggregation? A randomized crossover study.
PG  - 163-8
LID - 10.1097/FJC.0b013e3181af6d9c [doi]
AB  - It is common practice to coadminister proton pump inhibitors with aspirin to 
      diminish the risk of upper gastrointestinal bleeding. This is the first study 
      that investigated the potential impact of a proton pump inhibitor on aspirin 
      effects on platelet aggregation. Twenty-four hypertensive subjects eligible for 
      treatment with low-dose enteric-coated aspirin (LDECA) for primary prevention of 
      cardiovascular disease were randomized to receive 100 mg LDECA or 100 mg LDECA 
      plus 30 mg lansoprazole for 4 weeks. Then, participants were crossed over to the 
      alternative regimen for another 4 weeks. Salicylic, gastrin, and pepsinogen I 
      blood level counting were used to ensure adherence to treatment. Platelet 
      aggregation was evaluated by light transmittance aggregometry and PFA100. The 
      LDECA administration reduced arachidonic acid (P < 0.001), collagen (P < 0.01), 
      and epinephrine (P < 0.001) tests. These changes paralleled an increase in 
      collagen/epinephrine duration (P < 0.001) but not in collagen/adenosine 
      diphosphate duration and platelet count. No significant difference was found in 
      any of these platelets' function tests with LDECA alone versus LDECA plus 
      lansoprazole. A significant increase in salicylic levels was observed in patients 
      on LDECA as well as in those on LDECA plus lansoprazole, whereas gastrin and 
      pepsinogen I levels were increased only when lansoprazole was added. These data 
      suggest that the concomitant use of the lansoprazole at 30-mg daily does not 
      influence the long-term effect of LDECA on platelet aggregation. Furthermore, 
      they might imply that an interaction of LDECA with other proton pump inhibitors 
      on platelet aggregation is unlikely.
FAU - Adamopoulos, Adam B
AU  - Adamopoulos AB
AD  - 3rd Department of Medicine, University of Athens, Sotiria Hospital, Athens 11527, 
      Greece.
FAU - Sakizlis, George N
AU  - Sakizlis GN
FAU - Nasothimiou, Efthimia G
AU  - Nasothimiou EG
FAU - Anastasopoulou, Ioanna
AU  - Anastasopoulou I
FAU - Anastasakou, Eugenia
AU  - Anastasakou E
FAU - Kotsi, Paraskevi
AU  - Kotsi P
FAU - Karafoulidou, Anastasia
AU  - Karafoulidou A
FAU - Stergiou, George S
AU  - Stergiou GS
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/pharmacology
MH  - Adult
MH  - Aged
MH  - Anti-Ulcer Agents/pharmacology
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Cardiovascular Diseases/prevention & control
MH  - Cross-Over Studies
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Hypertension/complications/drug therapy
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*pharmacology
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/*pharmacology
EDAT- 2009/07/02 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/07/02 09:00
PHST- 2009/07/02 09:00 [entrez]
PHST- 2009/07/02 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 10.1097/FJC.0b013e3181af6d9c [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2009 Aug;54(2):163-8. doi: 10.1097/FJC.0b013e3181af6d9c.

PMID- 6470575
OWN - NLM
STAT- MEDLINE
DCOM- 19840926
LR  - 20190724
IS  - 0022-2151 (Print)
IS  - 0022-2151 (Linking)
VI  - 98
IP  - 8
DP  - 1984 Aug
TI  - Salicylates and post-tonsillectomy haemorrhage.
PG  - 803-5
AB  - A prospective study of 712 patients who had tonsillectomy by guillotine or 
      dissection suggests that salicylates used as post-tonsillectomy analgesia 
      increase the post-operative haemorrhage rate. Paracetamol used as post-operative 
      analgesia was shown to be related to a significantly reduced haemorrhage rate. 
      Guillotine tonsillectomy was not shown to have any adverse effect on the 
      haemorrhage rate.
FAU - Carrick, D G
AU  - Carrick DG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Laryngol Otol
JT  - The Journal of laryngology and otology
JID - 8706896
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Hemorrhage/*etiology
MH  - Humans
MH  - Pain, Postoperative/drug therapy
MH  - Postoperative Complications/etiology
MH  - Prospective Studies
MH  - Tonsillectomy/*methods
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 10.1017/s0022215100147486 [doi]
PST - ppublish
SO  - J Laryngol Otol. 1984 Aug;98(8):803-5. doi: 10.1017/s0022215100147486.

PMID- 32163488
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20200622
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 3
DP  - 2020
TI  - Effects of intestinal flora on the pharmacokinetics and pharmacodynamics of 
      aspirin in high-altitude hypoxia.
PG  - e0230197
LID - 10.1371/journal.pone.0230197 [doi]
LID - e0230197
AB  - Since hypobaric hypoxia significantly affects metabolic characteristics of 
      intestinal flora, which plays an important role in the biotransformation of 
      aspirin, high altitudes may influence the pharmacokinetics and therapeutic 
      effects of aspirin in the intestines. In the present study, to test alterations 
      of intestinal microbiota at high altitude comparing to that at low altitude, we 
      analyzed rat feces from plain group and high-altitude group by 16S rRNA analysis. 
      To detect concentrations of aspirin and salicylic acid, we established a reliable 
      liquid chromatography tandem mass spectrometry method to measure aspirin and 
      salicylic acid concentrations in fecal suspensions and plasma. Our study found 
      that the plateau hypoxic environment caused a significant increase in Bacteroides 
      in rat feces, while Corynebacterium, Prevotella, and Coprococcus were declined. 
      In addition, compared with the plain group, the metabolic activity of fecal 
      suspensions from the plateau group on aspirin was significantly reduced. More 
      importantly, these changes in the intestinal microbiota led to increasing 
      absorption of aspirin in the rats after rapidly ascent to the plateau, and a 
      reduction in the pharmacodynamic index TXB2, which would possibly result in 
      bleeding. In conclusion, our research provides new ideas for changes in plateau 
      pharmacokinetics, and then guide the corresponding reduction in aspirin dose for 
      the population quickly entering the plateau.
FAU - Sun, Yuemei
AU  - Sun Y
AUID- ORCID: 0000-0002-1629-7529
AD  - Key Laboratory for Prevention and Remediation of Plateau Environmental Damage, 
      The 940th Hospital of Joint Logistics Support Force of Chinese People's 
      Liberation Army, Lanzhou, China.
FAU - Zhang, Juanhong
AU  - Zhang J
AD  - Key Laboratory for Prevention and Remediation of Plateau Environmental Damage, 
      The 940th Hospital of Joint Logistics Support Force of Chinese People's 
      Liberation Army, Lanzhou, China.
FAU - Zhao, Anpeng
AU  - Zhao A
AD  - Key Laboratory for Prevention and Remediation of Plateau Environmental Damage, 
      The 940th Hospital of Joint Logistics Support Force of Chinese People's 
      Liberation Army, Lanzhou, China.
FAU - Li, Wenbin
AU  - Li W
AD  - Key Laboratory for Prevention and Remediation of Plateau Environmental Damage, 
      The 940th Hospital of Joint Logistics Support Force of Chinese People's 
      Liberation Army, Lanzhou, China.
FAU - Feng, Qiangsheng
AU  - Feng Q
AD  - Key Laboratory for Prevention and Remediation of Plateau Environmental Damage, 
      The 940th Hospital of Joint Logistics Support Force of Chinese People's 
      Liberation Army, Lanzhou, China.
FAU - Wang, Rong
AU  - Wang R
AD  - Key Laboratory for Prevention and Remediation of Plateau Environmental Damage, 
      The 940th Hospital of Joint Logistics Support Force of Chinese People's 
      Liberation Army, Lanzhou, China.
AD  - School of Pharmacy, Lanzhou University, Lanzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200312
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (RNA, Ribosomal, 16S)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Altitude
MH  - Altitude Sickness/microbiology
MH  - Animals
MH  - Aspirin/*pharmacokinetics/*pharmacology
MH  - Feces/microbiology
MH  - Gastrointestinal Microbiome/*drug effects
MH  - Hypoxia/*drug therapy/microbiology
MH  - RNA, Ribosomal, 16S/genetics
MH  - Rats
MH  - Rats, Wistar
PMC - PMC7067402
COIS- The authors declared that there are not any potential conflicts of interest.
EDAT- 2020/03/13 06:00
MHDA- 2020/06/23 06:00
CRDT- 2020/03/13 06:00
PHST- 2019/09/29 00:00 [received]
PHST- 2020/02/24 00:00 [accepted]
PHST- 2020/03/13 06:00 [entrez]
PHST- 2020/03/13 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
AID - PONE-D-19-24208 [pii]
AID - 10.1371/journal.pone.0230197 [doi]
PST - epublish
SO  - PLoS One. 2020 Mar 12;15(3):e0230197. doi: 10.1371/journal.pone.0230197. 
      eCollection 2020.

PMID- 16310244
OWN - NLM
STAT- MEDLINE
DCOM- 20060622
LR  - 20131121
IS  - 0047-6374 (Print)
IS  - 0047-6374 (Linking)
VI  - 127
IP  - 3
DP  - 2006 Mar
TI  - Effect of short-term, low dose aspirin supplementation on the activation of 
      pro-inflammatory NF-kappaB in aged rats.
PG  - 223-30
AB  - The basis of our recently proposed "molecular inflammation theory of aging" is 
      that activated inflammatory transcription factors, including versatile NF-kappaB, 
      occur widespread in the organism during aging. NF-kappaB plays a key role in 
      pro-inflammatory gene expression, such as cyclooxygenase (COX). Aspirin is one of 
      the most commonly used non-steroidal anti-inflammatory drugs because of its 
      ability to inhibit COX activity. Thus, in the present study, we investigated the 
      effect of short-term, low dose aspirin intake on the modulation of 
      pro-inflammatory NF-kappaB activation in old rats. To conduct the study, 
      24-month-old Fischer 344 rats were supplemented with low dose aspirin (0.015%) 
      for 10 days. Biochemical analyses showed suppressed reactive species (RS) and 
      COX-2 activity. The data also showed that NF-kappaB activation and its associated 
      gene expressions, such as COX-2, iNOS, VCAM-1 and ICAM-1, were all suppressed by 
      the low dose aspirin supplementation through the inhibition of phosphorylation 
      and degradation of IkappaBalpha via the NIK/IKK pathway. Our molecular 
      exploration further revealed that aspirin's suppressive action of NF-kappaB was 
      mediated by its ability to inhibit the nuclear translocation of cytosolic 
      thioredoxin and redox factor-1. These findings showed for the first time that in 
      aged rat short-term low dose dietary aspirin feeding modulates the molecular 
      signal transduction involved in the inflammatory process.
FAU - Jung, Kyung Jin
AU  - Jung KJ
AD  - Department of Pharmacy, College of Pharmacy, Aging Tissue Bank, Pusan National 
      University, Gumjung-gu, Busan 609 735, Republic of Korea.
FAU - Kim, Ji Young
AU  - Kim JY
FAU - Zou, Yani
AU  - Zou Y
FAU - Kim, You Jung
AU  - Kim YJ
FAU - Yu, Byung Pal
AU  - Yu BP
FAU - Chung, Hae Young
AU  - Chung HY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051123
PL  - Ireland
TA  - Mech Ageing Dev
JT  - Mechanisms of ageing and development
JID - 0347227
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (NF-kappa B)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aging/*drug effects/metabolism/pathology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Gene Expression Regulation/*drug effects
MH  - Inflammation/metabolism/pathology
MH  - Male
MH  - NF-kappa B/*metabolism
MH  - Rats
MH  - Rats, Inbred F344
MH  - Signal Transduction/*drug effects
MH  - Time Factors
EDAT- 2005/11/29 09:00
MHDA- 2006/06/23 09:00
CRDT- 2005/11/29 09:00
PHST- 2005/09/30 00:00 [accepted]
PHST- 2005/11/29 09:00 [pubmed]
PHST- 2006/06/23 09:00 [medline]
PHST- 2005/11/29 09:00 [entrez]
AID - S0047-6374(05)00247-2 [pii]
AID - 10.1016/j.mad.2005.09.029 [doi]
PST - ppublish
SO  - Mech Ageing Dev. 2006 Mar;127(3):223-30. doi: 10.1016/j.mad.2005.09.029. Epub 
      2005 Nov 23.

PMID- 28177735
OWN - NLM
STAT- MEDLINE
DCOM- 20180216
LR  - 20180216
IS  - 1715-5320 (Electronic)
IS  - 1715-5312 (Linking)
VI  - 42
IP  - 5
DP  - 2017 May
TI  - Protective effects of essential oil of Citrus limon against aspirin-induced 
      toxicity in IEC-6 cells.
PG  - 479-486
LID - 10.1139/apnm-2016-0515 [doi]
AB  - Aspirin, one of the widely used nonsteroidal anti-inflammatory drugs, is the most 
      highly consumed pharmaceutical product in the world. However, it has several side 
      effects in cells. This study was designed to investigate the antioxidative 
      activity and cytoprotective effects of essential oil of Citrus limon (EOC) 
      extracted from leaves against aspirin-induced damages in the rat small intestine 
      epithelial cells (IEC-6). Biochemical indicators were used to assess cytotoxicity 
      and oxidative damages caused by aspirin treatment on IEC-6. Our results showed 
      that the chemical characterization of EOC identified 25 compounds representing 
      98.19% of the total oil. The major compounds from this oil were z-citral 
      (53.21%), neryl acetate (13.06%), geranyl acetate (10.33%), and limonene (4.23%). 
      Aspirin induced a decrease in cell viability as well as an increase in superoxide 
      dismutase (SOD) and catalase (CAT) activities. Contrariwise, the co-exposure of 
      cells to aspirin and EOC alleviated every above syndrome by an increase in cell 
      survival and decrease in SOD and CAT activities. In conclusion, the essential oil 
      of C. limon has a potent cytoprotective effect against aspirin-induced toxicity 
      in IEC-6 cells.
FAU - Bouzenna, Hafsia
AU  - Bouzenna H
AD  - a Physiology Department-EA1274, Faculty of Medicine and Health Sciences, 
      University of Western Brittany, 22 Avenue Camille Desmoulins, CS 93837, 29238 
      Brest Cedex 3, France.
AD  - b Laboratory of Environmental Physiopathology, Valorization of Bioactive 
      Molecules and Mathematical Modeling, Faculty of Sciences Sfax, Road Soukra km 
      3.5, PB no 171-3000, Sfax-Tunisia.
AD  - c Laboratory of Animal Eco Physiology, Faculty of Sciences of Gafsa, 2112, 
      Tunisia.
FAU - Hfaiedh, Najla
AU  - Hfaiedh N
AD  - b Laboratory of Environmental Physiopathology, Valorization of Bioactive 
      Molecules and Mathematical Modeling, Faculty of Sciences Sfax, Road Soukra km 
      3.5, PB no 171-3000, Sfax-Tunisia.
AD  - c Laboratory of Animal Eco Physiology, Faculty of Sciences of Gafsa, 2112, 
      Tunisia.
FAU - Giroux-Metges, Marie-Agnès
AU  - Giroux-Metges MA
AD  - a Physiology Department-EA1274, Faculty of Medicine and Health Sciences, 
      University of Western Brittany, 22 Avenue Camille Desmoulins, CS 93837, 29238 
      Brest Cedex 3, France.
FAU - Elfeki, Abdelfattah
AU  - Elfeki A
AD  - b Laboratory of Environmental Physiopathology, Valorization of Bioactive 
      Molecules and Mathematical Modeling, Faculty of Sciences Sfax, Road Soukra km 
      3.5, PB no 171-3000, Sfax-Tunisia.
FAU - Talarmin, Hélène
AU  - Talarmin H
AD  - a Physiology Department-EA1274, Faculty of Medicine and Health Sciences, 
      University of Western Brittany, 22 Avenue Camille Desmoulins, CS 93837, 29238 
      Brest Cedex 3, France.
LA  - eng
PT  - Journal Article
DEP - 20161215
PL  - Canada
TA  - Appl Physiol Nutr Metab
JT  - Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition 
      et metabolisme
JID - 101264333
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Free Radical Scavengers)
RN  - 0 (Oils, Volatile)
RN  - 0 (Picrates)
RN  - 0 (Protective Agents)
RN  - DFD3H4VGDH (1,1-diphenyl-2-picrylhydrazyl)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/toxicity
MH  - Aspirin/*toxicity
MH  - Biphenyl Compounds/toxicity
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Citrus/*chemistry
MH  - Epithelial Cells/*drug effects
MH  - Free Radical Scavengers
MH  - Intestinal Mucosa/*cytology
MH  - Oils, Volatile/chemistry/*pharmacology
MH  - Picrates/toxicity
MH  - Protective Agents/chemistry/pharmacology
MH  - Rats
OTO - NOTNLM
OT  - Citrus limon
OT  - activités antioxydantes
OT  - antioxidant activities
OT  - aspirin
OT  - aspirine
OT  - cytotoxicity
OT  - cytotoxicité
OT  - essential oil
OT  - huile essentielle
EDAT- 2017/02/09 06:00
MHDA- 2018/02/17 06:00
CRDT- 2017/02/09 06:00
PHST- 2017/02/09 06:00 [pubmed]
PHST- 2018/02/17 06:00 [medline]
PHST- 2017/02/09 06:00 [entrez]
AID - 10.1139/apnm-2016-0515 [doi]
PST - ppublish
SO  - Appl Physiol Nutr Metab. 2017 May;42(5):479-486. doi: 10.1139/apnm-2016-0515. 
      Epub 2016 Dec 15.

PMID- 1829277
OWN - NLM
STAT- MEDLINE
DCOM- 19910729
LR  - 20141120
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 65
IP  - 4
DP  - 1991 Apr 8
TI  - Stimulation of plasmin activity by aspirin.
PG  - 389-93
AB  - This study demonstrates an enhancing effect of aspirin on the amidolytic activity 
      of plasmin. The stimulation of plasmin by aspirin was concentration-dependent and 
      was attained at aspirin concentrations above 2 x 10(-4) M. Aspirin produced a 
      small, reproducible and statistically significant stimulation of the chromogenic 
      activity of plasmin upon H-D-Valyl-L-Leucyl-L-Lysine-p-nitroanilide (S-2251) or 
      pyro-Glu-Gly-Arg-p-nitroanilide (S-2444). Kinetic analysis demonstrated a slight 
      decrease in the affinity of plasmin for substrate S-2251 in the presence of 
      aspirin, reflected by a change of the Km from 3.2 x 10(-4) M to 3.8 x 10(-4) M, 
      and an increase of the Vm. The reciprocal Lineweaver-Burk curve indicated an 
      uncompetitive type of stimulation. The stimulatory effect of aspirin was 
      abolished by the lysine analogue 6-aminohexanoic acid (AHA) but not by the 
      alpha-amino acid glutamic acid. The effect of AHA suggests a specific involvement 
      of lysine binding sites (LBS) on plasmin in the interaction of the enzyme with 
      aspirin. Transient acidification of plasmin abolished its response to aspirin, to 
      AHA and to their combination. The addition of aspirin to diluted human control or 
      pregnancy plasma in vitro stimulated the plasma-mediated cleavage of the 
      chromogenic substrate S-2251. In contrast to its effect on plasmin, aspirin 
      failed to change the activity of tissue-type or urokinase-type plasminogen 
      activators. It is conceivable that in addition to the antithrombotic effect of 
      aspirin ascribed to its interaction with the platelets, aspirin also directly 
      stimulates plasmin activity.
FAU - Milwidsky, A
AU  - Milwidsky A
AD  - Department of Obstetrics, Hadassah University Hospital, Mount Scopus, Jerusalem, 
      Israel.
FAU - Finci-Yeheskel, Z
AU  - Finci-Yeheskel Z
FAU - Mayer, M
AU  - Mayer M
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Chromogenic Compounds)
RN  - 0 (Oligopeptides)
RN  - 63589-93-5 (valyl-leucyl-lysine 4-nitroanilide)
RN  - 74661-31-7 (5-oxo-prolyl-glycyl-arginine-4-nitroanilide)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - EC 3.4.21.7 (Fibrinolysin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chromogenic Compounds
MH  - Dose-Response Relationship, Drug
MH  - Fibrinolysin/*metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Molecular Sequence Data
MH  - Oligopeptides/chemistry/metabolism
MH  - Plasminogen Activators/metabolism
EDAT- 1991/04/08 00:00
MHDA- 1991/04/08 00:01
CRDT- 1991/04/08 00:00
PHST- 1991/04/08 00:00 [pubmed]
PHST- 1991/04/08 00:01 [medline]
PHST- 1991/04/08 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1991 Apr 8;65(4):389-93.

PMID- 8471398
OWN - NLM
STAT- MEDLINE
DCOM- 19930514
LR  - 20220408
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 35
IP  - 3
DP  - 1993 Mar
TI  - The gastrointestinal toxicity of aspirin: an overview of randomised controlled 
      trials.
PG  - 219-26
AB  - The proven benefit of aspirin in the secondary prevention of cardiovascular 
      disease and its possible value in primary prevention must be weighted against its 
      potential hazards. This paper is an overview of the gastrointestinal toxicity of 
      aspirin, its most serious complication after intracerebral haemorrhage. 
      Information on toxicity has been drawn only from randomised trials, thus avoiding 
      the potential biases of observational studies. All randomised placebo controlled 
      trials listed in the Anti-platelet Trialists Collaboration where a direct 
      aspirin-placebo comparison was possible were included. Twenty-one trials were 
      included, all but one of secondary prevention. There were over 75,000 person 
      years of aspirin exposure. The pooled odds ratios for categories of 
      gastrointestinal bleeding (e.g. haematemesis, melaena) were between 1.5-2.0; 
      fatal bleeds were very rare. The risk of peptic ulcers was 1.3 and of upper 
      gastrointestinal symptoms 1.7. These risks were lower than those found in 
      observational studies. Attributable disease rates are also presented. For 
      haematemesis for example they varied from 0.2-1.0 per 1000 person years. Toxicity 
      was dose related. Aspirin does have significant gastrointestinal toxicity, 
      although this is rarely fatal. More recent work has demonstrated the efficacy of 
      low doses of aspirin (75 mg daily) but there is limited information yet available 
      on its toxicity.
FAU - Roderick, P J
AU  - Roderick PJ
AD  - MRC Epidemiology and Medical Care Unit, Northwick Park Hospital, Harrow, 
      Middlesex.
FAU - Wilkes, H C
AU  - Wilkes HC
FAU - Meade, T W
AU  - Meade TW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Digestive System/*drug effects
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/chemically induced
MH  - Randomized Controlled Trials as Topic
MH  - Thrombosis/prevention & control
PMC - PMC1381566
EDAT- 1993/03/01 00:00
MHDA- 1993/03/01 00:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 1993/03/01 00:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1993.tb05689.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1993 Mar;35(3):219-26. doi: 
      10.1111/j.1365-2125.1993.tb05689.x.

PMID- 16799203
OWN - NLM
STAT- MEDLINE
DCOM- 20061031
LR  - 20131121
IS  - 1064-3745 (Print)
IS  - 1064-3745 (Linking)
VI  - 341
DP  - 2006
TI  - Cell-cell interaction in the transcellular biosynthesis of novel omega-3-derived 
      lipid mediators.
PG  - 227-50
AB  - Omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) 
      and docosa-hexaenoic acid (DHA) display beneficial actions in human diseases. The 
      molecular basis for these actions remains of interest. We recently identified 
      novel mediators generated from omega-3 PUFA during cell-cell interactions that 
      displayed potent anti-inflammatory and proresolving actions. Compounds derived 
      from EPA are designated resolvins of the E series (RvE1), and those 
      biosynthesized from DHA are denoted resolvins of the D series (RvD) and 
      docosatriene, such as protectin D1 (PD1), which belongs to the family of 
      protectins. In addition, treatment using aspirin initiates a related epimeric 
      series by triggering endogenous formation of the 17R-RvD series, denoted as 
      aspirin-triggered (AT)-RvDs. These compounds possess potent anti-inflammatory 
      actions in vivo that essentially are equivalent to their counterpart generated 
      without aspirin, namely the 17S-RvDs. In this chapter, we provide an overview and 
      detail protocols of the biosynthesis and bioactions of these newly uncovered 
      pathways and products that include three distinct series: 18R-resolvins of the E 
      series derived from EPA (i.e., RvE1); 17R-resolvins of the D series from DHA 
      (AT-RvD1 through RvD4); and 17S-resolvins of the D series from DHA (RvD1 through 
      RvD4).
FAU - Chiang, Nan
AU  - Chiang N
AD  - Department of Anesthesiology, Perioperative, and Pain Medicine, Center for 
      Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital, 
      Harvard Medical School, Boston, MA, USA.
FAU - Serhan, Charles N
AU  - Serhan CN
LA  - eng
GR  - GM38675/GM/NIGMS NIH HHS/United States
GR  - P01-DE13499/DE/NIDCR NIH HHS/United States
GR  - P50-DE016191/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism/pharmacology/therapeutic use
MH  - Aspirin/*metabolism/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Docosahexaenoic Acids/analysis/*metabolism
MH  - Eicosapentaenoic Acid/analysis/*metabolism
MH  - Humans
MH  - Inflammation/drug therapy/metabolism
RF  - 53
EDAT- 2006/06/27 09:00
MHDA- 2006/11/01 09:00
CRDT- 2006/06/27 09:00
PHST- 2006/06/27 09:00 [pubmed]
PHST- 2006/11/01 09:00 [medline]
PHST- 2006/06/27 09:00 [entrez]
AID - 1-59745-113-4:227 [pii]
AID - 10.1385/1-59745-113-4:227 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2006;341:227-50. doi: 10.1385/1-59745-113-4:227.

PMID- 12388216
OWN - NLM
STAT- MEDLINE
DCOM- 20030117
LR  - 20200930
IS  - 0363-6135 (Print)
IS  - 0363-6135 (Linking)
VI  - 284
IP  - 1
DP  - 2003 Jan
TI  - Sodium selenite reduces hemoglobin-induced venular leakage in the rat mesentery.
PG  - H81-91
AB  - Modified Hbs are being developed as "blood substitutes," but intravascular 
      injection of diaspirin cross-linked Hb (DBBF-Hb) can produce venular leakage. Hb 
      toxicity may arise from reactive oxygen species, so the antioxidant sodium 
      selenite (Na(2)SeO(3)) was used in an attempt to reduce leak formation. In 
      anesthetized Sprague-Dawley rats, one-half of which received 2 x 10(-6) g/ml 
      Na(2)SeO(3) in their drinking water for 3 wk, the mesenteric microvasculature was 
      perfused with 2 mg/ml DBBF-Hb (N = 8) for 10 min. Controls (N = 7) received 
      saline. This was followed by perfusion with FITC-albumin for 3 min, fixation, and 
      microscopic examination. In rats given DBBF-Hb, Na(2)SeO(3) significantly reduced 
      leak number, leak area, and mast cell degranulation. Venular leakage was also 
      reduced in rats that only received Na(2)SeO(3) locally during DBBF-Hb perfusion. 
      However, Na(2)SeO(3) did not affect animals receiving cyanomet-DBBF-Hb instead of 
      DBBF-Hb and significantly increased leak number and mast cell degranulation in 
      animals receiving saline. In vitro, Na(2)SeO(3) reduced the oxidation rate of 
      DBBF-Hb while in the presence of oxidants. These results suggest that Na(2)SeO(3) 
      reduces DBBF-Hb-induced microvascular leakage partly by retarding the oxidation 
      of its heme iron.
FAU - Baldwin, Ann L
AU  - Baldwin AL
AD  - Department of Physiology, College of Medicine, University of Arizona, Tucson 
      85724-5051, USA. abaldwin@u.arizona.edu
FAU - Wiley, Elizabeth B
AU  - Wiley EB
FAU - Summers, Amber G
AU  - Summers AG
FAU - Alayash, Abdu I
AU  - Alayash AI
LA  - eng
GR  - HL-53047/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20020926
PL  - United States
TA  - Am J Physiol Heart Circ Physiol
JT  - American journal of physiology. Heart and circulatory physiology
JID - 100901228
RN  - 0 (Hemoglobins)
RN  - 0 (diaspirin-cross-linked cyanomethemoglobin)
RN  - 9008-37-1 (Methemoglobin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - HIW548RQ3W (Sodium Selenite)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/metabolism/pharmacology
MH  - Capillary Permeability/*drug effects
MH  - Cell Degranulation/physiology
MH  - Hemoglobins/metabolism/*pharmacology
MH  - Male
MH  - Mast Cells/physiology
MH  - Methemoglobin/analogs & derivatives/pharmacology
MH  - Oxidation-Reduction/drug effects
MH  - Oxygen/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sodium Selenite/*pharmacology
MH  - Splanchnic Circulation/*drug effects
MH  - Venules/*drug effects
EDAT- 2002/10/22 04:00
MHDA- 2003/01/18 04:00
CRDT- 2002/10/22 04:00
PHST- 2002/10/22 04:00 [pubmed]
PHST- 2003/01/18 04:00 [medline]
PHST- 2002/10/22 04:00 [entrez]
AID - 00562.2002 [pii]
AID - 10.1152/ajpheart.00562.2002 [doi]
PST - ppublish
SO  - Am J Physiol Heart Circ Physiol. 2003 Jan;284(1):H81-91. doi: 
      10.1152/ajpheart.00562.2002. Epub 2002 Sep 26.

PMID- 32655007
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 13
IP  - 10
DP  - 2020 Oct
TI  - Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations 
      with Adenoma Risk.
PG  - 863-876
LID - 10.1158/1940-6207.CAPR-20-0014 [doi]
AB  - Although substantial evidence supports aspirin's efficacy in colorectal cancer 
      chemoprevention, key molecular mechanisms are uncertain. An untargeted 
      metabolomics approach with high-resolution mass spectrometry was used to 
      elucidate metabolic effects of aspirin treatment in human colon tissue. We 
      measured 10,269 metabolic features in normal mucosal biopsies collected at 
      colonoscopy after approximately 3 years of randomized treatment with placebo, 81 
      or 325 mg/day aspirin from 325 participants in the Aspirin/Folate Polyp 
      Prevention Study. Linear regression was used to identify aspirin-associated 
      metabolic features and network analysis was used to identify pathways and predict 
      metabolite identities. Poisson regression was used to examine metabolic features 
      associations with colorectal adenoma risk. We detected 471 aspirin-associated 
      metabolic features. Aside from the carnitine shuttle, aspirin-associated 
      metabolic pathways were largely distinct for 81 mg aspirin (e.g., pyrimidine 
      metabolism) and 325 mg (e.g., arachidonic acid metabolism). Among 
      aspirin-associated metabolic features, we discovered three that were associated 
      with adenoma risk and could contribute to the chemopreventive effect of aspirin 
      treatment, and which have also previously been associated with colorectal cancer: 
      creatinine, glycerol 3-phosphate, and linoleate. The last two of these are in the 
      glycerophospholipid metabolism pathway, which was associated with 81 mg aspirin 
      treatment and provides precursors for the synthesis of eicosanoids from 
      arachidonic acid upstream of cyclooxygenase inhibition by aspirin. Conversely, 
      carnitine shuttle metabolites were increased with aspirin treatment and 
      associated with increased adenoma risk. Thus, our untargeted metabolomics 
      approach has identified novel metabolites and pathways that may underlie the 
      effects of aspirin during early colorectal carcinogenesis.
CI  - ©2020 American Association for Cancer Research.
FAU - Barry, Elizabeth L
AU  - Barry EL
AUID- ORCID: 0000-0001-9637-3036
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New 
      Hampshire. Elizabeth.L.Barry@dartmouth.edu.
FAU - Fedirko, Veronika
AU  - Fedirko V
AUID- ORCID: 0000-0002-7805-9913
AD  - Department of Epidemiology, Rollins School of Public Health, Emory University and 
      Winship Cancer Institute, Atlanta, Georgia.
FAU - Uppal, Karan
AU  - Uppal K
AD  - Department of Medicine, Emory University, Atlanta, Georgia.
FAU - Ma, Chunyu
AU  - Ma C
AD  - Department of Medicine, Emory University, Atlanta, Georgia.
FAU - Liu, Ken
AU  - Liu K
AD  - Department of Medicine, Emory University, Atlanta, Georgia.
FAU - Mott, Leila A
AU  - Mott LA
AUID- ORCID: 0000-0001-8972-7692
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New 
      Hampshire.
FAU - Peacock, Janet L
AU  - Peacock JL
AUID- ORCID: 0000-0002-0310-2518
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New 
      Hampshire.
AD  - School of Population Health and Environmental Sciences, King's College, London, 
      UK.
FAU - Passarelli, Michael N
AU  - Passarelli MN
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New 
      Hampshire.
FAU - Baron, John A
AU  - Baron JA
AUID- ORCID: 0000-0003-3461-1056
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New 
      Hampshire.
AD  - Department of Medicine, University of North Carolina at Chapel Hill, School of 
      Medicine, Chapel Hill, North Carolina.
FAU - Jones, Dean P
AU  - Jones DP
AD  - Department of Medicine, Emory University, Atlanta, Georgia.
LA  - eng
GR  - T32 GM008602/GM/NIGMS NIH HHS/United States
GR  - P30 CA023108/CA/NCI NIH HHS/United States
GR  - R01 CA059005/CA/NCI NIH HHS/United States
GR  - R01 CA188038/CA/NCI NIH HHS/United States
GR  - P20 GM104416/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200712
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/drug therapy/metabolism/*pathology
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Colon/drug effects/*metabolism
MH  - Colorectal Neoplasms/drug therapy/metabolism/*pathology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolome/*drug effects
MH  - Middle Aged
PMC - PMC7541578
MID - NIHMS1611576
COIS- Potential Conflict of Interest Disclosures: Together with the Trustees of 
      Dartmouth College, John A. Baron holds a use patent, not currently licensed, for 
      the chemopreventive use of aspirin for colorectal cancer. The other authors had 
      no disclosures.
EDAT- 2020/07/14 06:00
MHDA- 2021/10/05 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/01/06 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - 1940-6207.CAPR-20-0014 [pii]
AID - 10.1158/1940-6207.CAPR-20-0014 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2020 Oct;13(10):863-876. doi: 
      10.1158/1940-6207.CAPR-20-0014. Epub 2020 Jul 12.

PMID- 32142233
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20210615
IS  - 0038-3317 (Print)
IS  - 0038-3317 (Linking)
VI  - 73
IP  - 3
DP  - 2020 Mar
TI  - Aspirin in Primary and Secondary Prevention of Cardiovascular Disease.
PG  - 130-135
AB  - Aspirin is one of the most widely used drugs for the treatment of cardiovascular 
      disease. While its use in patients with known cardiovascular disease has been 
      supported with trials which have included mortality benefit, the utility of 
      aspirin therapy in patients without established cardiovascular disease has been 
      less clear. Early trials appeared to demonstrate benefit with the use of aspirin, 
      but trials after 2000 did not consistently substantiate using aspirin for primary 
      prevention of cardiovascular disease. Despite the lack of robust supportive 
      evidence, aspirin was recommended and used extensively for primary prevention in 
      patients at higher risk for cardiovascular events. More recently in 2018, results 
      of three randomized, controlled trials: ARRIVE, ASCEND, ASPREE demonstrated 
      modest to no benefit in preventing cardiovascular events and mortality with 
      aspirin use for primary prevention. These trials also demonstrated an increased 
      risk of bleeding in these patients who were on aspirin for primary prevention.
CI  - Copyright© South Dakota State Medical Association.
FAU - Gowda, Smitha Narayana
AU  - Gowda SN
AD  - University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.
FAU - Bell, Matthew
AU  - Bell M
AD  - University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.
FAU - Jahraus, Matthew
AU  - Jahraus M
AD  - Department of Internal Medicine, University of South Dakota Sanford School of 
      Medicine, Sioux Falls, South Dakota.
FAU - Fanciullo, Joseph
AU  - Fanciullo J
AD  - Internal Medicine Residency Program, University of South Dakota Sanford School of 
      Medicine, Sioux Falls, South Dakota.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - S D Med
JT  - South Dakota medicine : the journal of the South Dakota State Medical Association
JID - 101265265
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Hemorrhage
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - Primary Prevention
MH  - Secondary Prevention
EDAT- 2020/03/07 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/03/07 06:00
PHST- 2020/03/07 06:00 [entrez]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PST - ppublish
SO  - S D Med. 2020 Mar;73(3):130-135.

PMID- 12699722
OWN - NLM
STAT- MEDLINE
DCOM- 20040112
LR  - 20190823
IS  - 0306-9877 (Print)
IS  - 0306-9877 (Linking)
VI  - 60
IP  - 6
DP  - 2003 Jun
TI  - A quantitative illustration of the public health potential of aspirin.
PG  - 900-2
AB  - Aspirin is showing potential in reducing the risk of several diseases of public 
      health importance. These include cardiovascular disease, cancer and Alzheimer's 
      disease. In this paper, a fictional scenario is considered in which 50 year old 
      individuals are encouraged to take aspirin. Using crude assumptions and simple 
      calculations, a Kaplan-Meier survival curve of aspirin users is presented. The 
      main finding of this exercise is the possibility that the long-term use of low 
      dose aspirin may double the chances of individuals living a healthy life into 
      their 90's. Further research is needed.
FAU - Morgan, Gareth
AU  - Morgan G
AD  - Department of Public Health, Iechyd Morgannwg Health Authority, Swansea, Wales, 
      UK. gareth.morgan@morgannwg-ha.wales.nhs.uk
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*mortality/*prevention & control
MH  - Female
MH  - Finland/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/drug therapy/*mortality/*prevention & control
MH  - Risk Assessment/*methods
MH  - Survival
MH  - *Survival Analysis
MH  - United Kingdom/epidemiology
EDAT- 2003/04/18 05:00
MHDA- 2004/01/13 05:00
CRDT- 2003/04/18 05:00
PHST- 2003/04/18 05:00 [pubmed]
PHST- 2004/01/13 05:00 [medline]
PHST- 2003/04/18 05:00 [entrez]
AID - S0306987703000744 [pii]
AID - 10.1016/s0306-9877(03)00074-4 [doi]
PST - ppublish
SO  - Med Hypotheses. 2003 Jun;60(6):900-2. doi: 10.1016/s0306-9877(03)00074-4.

PMID- 3668817
OWN - NLM
STAT- MEDLINE
DCOM- 19871207
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 76
IP  - 7
DP  - 1987 Jul
TI  - Determination of aspirin by pre-column transacetylation reaction of 3-aminophenol 
      and reversed-phase high-performance liquid chromatography: simultaneous 
      determination of aspirin, acetaminophen, and caffeine.
PG  - 551-3
AB  - The accuracy of the measurement of aspirin by high-performance liquid 
      chromatography (HPLC) is reduced by its hydrolysis into salicylic and acetic 
      acids during sample preparation. The ready and quantitative transacetylation of 
      3-aminophenol by aspirin, giving 3-hydroxyacetanilide (which is stable), has been 
      utilized as a pre-column reaction for the determination of aspirin either alone 
      or in the presence of acetaminophen and caffeine by reversed-phase HPLC.
FAU - Verma, K K
AU  - Verma KK
AD  - Department of Chemistry, Rani Durgavati University, Jabalpur, India.
FAU - Sanghi, S K
AU  - Sanghi SK
FAU - Jain, A
AU  - Jain A
FAU - Gupta, D
AU  - Gupta D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Aminophenols)
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/*analysis
MH  - Acetylation
MH  - Aminophenols
MH  - Aspirin/administration & dosage/*analysis
MH  - Caffeine/administration & dosage/*analysis
MH  - Chromatography, High Pressure Liquid/methods
MH  - Drug Combinations
EDAT- 1987/07/01 00:00
MHDA- 1987/07/01 00:01
CRDT- 1987/07/01 00:00
PHST- 1987/07/01 00:00 [pubmed]
PHST- 1987/07/01 00:01 [medline]
PHST- 1987/07/01 00:00 [entrez]
AID - S0022-3549(15)47459-3 [pii]
AID - 10.1002/jps.2600760713 [doi]
PST - ppublish
SO  - J Pharm Sci. 1987 Jul;76(7):551-3. doi: 10.1002/jps.2600760713.

PMID- 6841285
OWN - NLM
STAT- MEDLINE
DCOM- 19830623
LR  - 20190821
IS  - 0378-5955 (Print)
IS  - 0378-5955 (Linking)
VI  - 9
IP  - 3
DP  - 1983 Mar
TI  - Aspirin can potentiate the temporary hearing loss induced by intense sounds.
PG  - 295-316
AB  - Aspirin is known to produce a reversible loss of hearing that can be as great as 
      40 dB, depending upon the dose and the individual subject. Here we show that 
      aspirin-induced losses exacerbate the temporary hearing loss induced by exposure 
      to intense sound. EXPOSUREs that ordinarily produce about 14 dB of temporary 
      threshold shift (TTS) will produce about 18-27 dB of TTS if the listener has been 
      taking 3.9 g of aspirin for the past two days or more. A lesser dose or a shorter 
      duration of use produces a smaller, or no, increment in temporary hearing loss. 
      This greater TTS, and an apparent prolongation of recovery from exposure, make 
      chronic aspirin use ill-advised for people routinely exposed to intense sounds. 
      EXPOSURE: 2500 Hz, 10 min, varying intensity. TTS frequency: 3550 Hz. 
      Psychophysical method: 2IFC, adaptive.
FAU - McFadden, D
AU  - McFadden D
FAU - Plattsmier, H S
AU  - Plattsmier HS
LA  - eng
GR  - NS 15895/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Hear Res
JT  - Hearing research
JID - 7900445
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Auditory Fatigue/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Hearing Loss/chemically induced
MH  - Humans
MH  - Male
MH  - Noise/*adverse effects
MH  - Time Factors
EDAT- 1983/03/01 00:00
MHDA- 1983/03/01 00:01
CRDT- 1983/03/01 00:00
PHST- 1983/03/01 00:00 [pubmed]
PHST- 1983/03/01 00:01 [medline]
PHST- 1983/03/01 00:00 [entrez]
AID - 0378-5955(83)90033-3 [pii]
AID - 10.1016/0378-5955(83)90033-3 [doi]
PST - ppublish
SO  - Hear Res. 1983 Mar;9(3):295-316. doi: 10.1016/0378-5955(83)90033-3.

PMID- 24073925
OWN - NLM
STAT- MEDLINE
DCOM- 20140607
LR  - 20131101
IS  - 1520-5207 (Electronic)
IS  - 1520-5207 (Linking)
VI  - 117
IP  - 43
DP  - 2013 Oct 31
TI  - Motion and interaction of aspirin crystals at aqueous-air interfaces.
PG  - 13572-7
LID - 10.1021/jp405364c [doi]
AB  - Small-molecule amphiphiles such as aspirin have unique properties arising from a 
      combination of an aromatic hydrophobic part and a hydrophilic part. We show that 
      crystals of aspirin are capable of generating convective flows at the air-aqueous 
      interface from both Marangoni effects (through weak surface activity) and 
      capillarity (surface deformations). The flow-driven motion of millimeter-sized 
      crystals was found to depend on the presence of other ions in solution as well as 
      the distance and orientation of the crystals. The interactions lead to the 
      formation of groups of two or more crystals that also underwent motion. The 
      convective flows created by small amphiphile crystals might be exploited in the 
      dynamic self-organization of particles at interfaces.
FAU - Bánsági, Tamás Jr
AU  - Bánsági T Jr
AD  - School of Chemistry, University of Leeds , Woodhouse Lane, Leeds LS2 9JT, United 
      Kingdom.
FAU - Wrobel, Magdalena M
AU  - Wrobel MM
FAU - Scott, Stephen K
AU  - Scott SK
FAU - Taylor, Annette F
AU  - Taylor AF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131017
PL  - United States
TA  - J Phys Chem B
JT  - The journal of physical chemistry. B
JID - 101157530
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Air
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Motion
MH  - Particle Size
MH  - Surface Properties
MH  - Water/chemistry
EDAT- 2013/10/01 06:00
MHDA- 2014/06/08 06:00
CRDT- 2013/10/01 06:00
PHST- 2013/10/01 06:00 [entrez]
PHST- 2013/10/01 06:00 [pubmed]
PHST- 2014/06/08 06:00 [medline]
AID - 10.1021/jp405364c [doi]
PST - ppublish
SO  - J Phys Chem B. 2013 Oct 31;117(43):13572-7. doi: 10.1021/jp405364c. Epub 2013 Oct 
      17.

PMID- 11280684
OWN - NLM
STAT- MEDLINE
DCOM- 20010802
LR  - 20191104
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 29
IP  - 1
DP  - 2001 Jan
TI  - Direct measurements of hemoglobin interactions with liposomes using EPR 
      spectroscopy.
PG  - 5-18
AB  - Electron paramagnetic resonance (EPR) spectroscopy was used to compare the rates 
      of autoxidation at 37 degrees C of acellular and liposome-encapsulated hemoglobin 
      (LEH) crosslinked between alpha chains with bis (3,5-dibromosalicyl) fumarate 
      (alphaalphaHb). This method avoids the difficulties inherent in using 
      conventional ultraviolet-visible (UV-vis) spectroscopy caused by the high 
      turbidity of liposome suspensions. Rate constants of 0.039/h and 0.065/h were 
      obtained for the alphaalphaHb and LEH samples, respectively. Similar oxidation 
      measurements with alphaalphaHb using UV-vis spectroscopy gave a rate constant 
      comparable to that obtained with EPR spectroscopy. Indirect measurement of the 
      oxidation kinetics of LEH utilizing extraction of alphaalphaHb with chloroform 
      from partially oxidized LEH samples was unreliable because the amount of 
      extractable hemoglobin was inversely proportional to the degree of oxidation. EPR 
      measurements showed a shift in the g value and substantial enhancement in the 
      intensity of the bis-histidine low-spin B complex for the encapsulated 
      hemoglobin, indicating a perturbation of this low-spin complex. We suggest that 
      lipid-associated perturbations are responsible for the enhancement of the 
      oxidation observed with the LEH samples compared to the unencapsulated material.
FAU - Abugo, O O
AU  - Abugo OO
AD  - Blood Research Detachment, Walter Reed Army Institute of Research, Silver Spring, 
      Maryland 20910, USA.
FAU - Balagopalakrishna, C
AU  - Balagopalakrishna C
FAU - Rifkind, J M
AU  - Rifkind JM
FAU - Rudolph, A S
AU  - Rudolph AS
FAU - Hess, J R
AU  - Hess JR
FAU - Macdonald, V W
AU  - Macdonald VW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Liposomes)
RN  - 0 (hemoglobin XL99alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Blood Substitutes/chemistry/*metabolism
MH  - Drug Interactions
MH  - Electron Spin Resonance Spectroscopy
MH  - Hemoglobins/pharmacology
MH  - Humans
MH  - Kinetics
MH  - Liposomes
MH  - Oxidation-Reduction
MH  - Protein Binding
MH  - Spectrophotometry, Ultraviolet
EDAT- 2001/03/31 10:00
MHDA- 2001/08/03 10:01
CRDT- 2001/03/31 10:00
PHST- 2001/03/31 10:00 [pubmed]
PHST- 2001/08/03 10:01 [medline]
PHST- 2001/03/31 10:00 [entrez]
AID - 10.1081/bio-100001252 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 2001 Jan;29(1):5-18. doi: 
      10.1081/bio-100001252.

PMID- 428733
OWN - NLM
STAT- MEDLINE
DCOM- 19790626
LR  - 20180216
IS  - 0304-324X (Print)
IS  - 0304-324X (Linking)
VI  - 25
IP  - 1
DP  - 1979
TI  - Pharmacokinetics of salicylates in elderly.
PG  - 49-55
AB  - In order to study changes in the pharmacokinetics of salicylates in old people, 
      we used two groups of inpatients without hepatic or renal impairment: the first 
      comprised 15 patients more than 65 years old, mean age 77 years; the second, 7 
      patients of mean age 21 years. Each patient was given 1 g of acetylsalicylic acid 
      orally in the morning while fasting. Blood samples were subsequently taken after 
      30, 60 and 90 min and 2, 3, 4, 6, 8, 10, and 24 h. Fluorimetric assay results 
      were analyzed kinetically with a mathematical model corresponding to a single 
      diffusion compartment model. The results showed only a slight increase in the 
      absorption half-time in old subjects, and a marked increase in elimination 
      half-time (3.71 and 2.38 h in old and young subjects, respectively; t = 2.33: p 
      less than 0.05) and in the volume of distribution (5.51 and 3.83 liters 
      respectively; t = 3.20: p less than 0.1). On the other hand, bioavailability 
      varied little, as did metabolic clearance. This study confirms that intestinal 
      absorption of this drug is not much impaired in old people, while hepatic and/or 
      renal elimination functions are changed. This finding agrees with results found 
      for aminopyrine, antipyrine, and digoxin.
FAU - Cuny, G
AU  - Cuny G
FAU - Royer, R J
AU  - Royer RJ
FAU - Mur, J M
AU  - Mur JM
FAU - Serot, J M
AU  - Serot JM
FAU - Faure, G
AU  - Faure G
FAU - Netter, P
AU  - Netter P
FAU - Maillard, A
AU  - Maillard A
FAU - Penin, F
AU  - Penin F
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Gerontology
JT  - Gerontology
JID - 7601655
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*metabolism
MH  - Half-Life
MH  - Humans
MH  - Kinetics
MH  - Salicylates/blood
MH  - Spectrometry, Fluorescence
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1159/000212320 [doi]
PST - ppublish
SO  - Gerontology. 1979;25(1):49-55. doi: 10.1159/000212320.

PMID- 25187029
OWN - NLM
STAT- MEDLINE
DCOM- 20150512
LR  - 20211021
IS  - 1573-7438 (Electronic)
IS  - 0049-4747 (Linking)
VI  - 46
IP  - 8
DP  - 2014 Dec
TI  - Egg production response of laying chickens to feather clipping, cool water and 
      aspirin during hot weather conditions.
PG  - 1523-6
LID - 10.1007/s11250-014-0666-6 [doi]
AB  - An 8-week trial was conducted between March and May (hot-dry season) to determine 
      effects of water temperature, feather clipping and aspirin on egg production of 
      chickens. The treatments tested were hens given ordinary drinking water 
      (control), cool water (100 g ice block per L) and aspirin (0.3 mg per L of 
      ordinary water) and hens whose feathers were clipped (about two thirds of body 
      feathers clipped). At 32 weeks of age, 120 Lohmann brown layer chickens of 
      similar live weights were randomly divided into 12 groups of ten hens each and 
      assigned to the treatments in triplicate using a completely randomized design. 
      Feed and water were given ad libitum. Data included feed intake, water 
      consumption, hen-day egg production and egg weight. Ambient house temperature, 
      hen's cloacal temperature and water temperature were monitored daily during the 
      experimental period. Mean daily ambient temperature increased from 28.4 to 35.0 
      °C during the study period with consequent increase in cloacal temperatures 
      (40.31 to 41.18 °C) of hens, ordinary drinking water and cool water. None of the 
      treatments had any significant (P > 0.05) effects on feed intake and water 
      consumption of the birds. Hens given cool water produced more (P < 0.05) eggs and 
      better (P < 0.05) feed efficiency than hens assigned to other treatments. Mean 
      egg weight of each treatment was similar (P > 0.05). It is concluded that the 
      provision of cool water in a hot-dry climate had a beneficial effect on egg 
      laying performance of chickens.
FAU - Dei, Herbert Kwabla
AU  - Dei HK
AD  - Department of Animal Science, Faculty of Agriculture, University for Development 
      Studies, P.O. Box TL 1882, Tamale, Ghana, hkdei@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20140904
PL  - United States
TA  - Trop Anim Health Prod
JT  - Tropical animal health and production
JID - 1277355
RN  - 0 (Antipyretics)
RN  - 0 (Drinking Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animal Husbandry
MH  - Animals
MH  - Antipyretics/administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Body Weight
MH  - Chickens/*physiology
MH  - *Climate
MH  - Drinking Behavior
MH  - *Drinking Water
MH  - *Feathers
MH  - Female
MH  - Oviposition/physiology
MH  - *Temperature
EDAT- 2014/09/05 06:00
MHDA- 2015/05/13 06:00
CRDT- 2014/09/05 06:00
PHST- 2014/05/16 00:00 [received]
PHST- 2014/08/19 00:00 [accepted]
PHST- 2014/09/05 06:00 [entrez]
PHST- 2014/09/05 06:00 [pubmed]
PHST- 2015/05/13 06:00 [medline]
AID - 10.1007/s11250-014-0666-6 [doi]
PST - ppublish
SO  - Trop Anim Health Prod. 2014 Dec;46(8):1523-6. doi: 10.1007/s11250-014-0666-6. 
      Epub 2014 Sep 4.

PMID- 15686355
OWN - NLM
STAT- MEDLINE
DCOM- 20050322
LR  - 20131121
IS  - 0002-7863 (Print)
IS  - 0002-7863 (Linking)
VI  - 127
IP  - 5
DP  - 2005 Feb 9
TI  - Face-integrated Fukui function: understanding wettability anisotropy of molecular 
      crystals from density functional theory.
PG  - 1364-5
AB  - Wettability is one of the anisotropic surface properties of molecular crystals 
      that exhibit the structural variance of chemical moieties on various growth 
      faces. The divergence in liquid-solid interactions at different faces is thought 
      to be related to the inherent responding capacity or sensitivity of a solid 
      surface to the perturbation in electronic structures and atomic positions as a 
      result of the contact by a liquid. Since the Fukui function, according to density 
      functional theory (DFT), is a local function for describing such sensitivity to 
      the structural perturbation and is directly related to local softness, it has 
      been proposed and tested to use an integrated Fukui function over a 
      crystallographic plane for describing the anisotropy of solid-liquid 
      interactions. It is found that the contact angle of a polar solvent, such as 
      water, on a crystal surface shows an intimate connection to the integrated Fukui 
      functions of the surface, illustrating an extension of Pearson's HSAB (hard and 
      soft acids and bases) to crystal systems. The concept of face-integrated Fukui 
      function and the approach to apply the HSAB with the DFT-based concepts may 
      provide a powerful means for describing anisotropic properties, including 
      wettability of organic crystals.
FAU - Li, Tonglei
AU  - Li T
AD  - Department of Pharmaceutical Sciences, University of Kentucky, 907 Rose Street, 
      Lexington, KY 40536-0082, USA. tonglei@uky.edu
FAU - Liu, Shubin
AU  - Liu S
FAU - Feng, Shaoxin
AU  - Feng S
FAU - Aubrey, Clare E
AU  - Aubrey CE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Am Chem Soc
JT  - Journal of the American Chemical Society
JID - 7503056
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anisotropy
MH  - Aspirin/*chemistry
MH  - Chemistry, Pharmaceutical
MH  - Crystallization
MH  - Models, Molecular
MH  - Thermodynamics
MH  - *Wettability
EDAT- 2005/02/03 09:00
MHDA- 2005/03/23 09:00
CRDT- 2005/02/03 09:00
PHST- 2005/02/03 09:00 [pubmed]
PHST- 2005/03/23 09:00 [medline]
PHST- 2005/02/03 09:00 [entrez]
AID - 10.1021/ja0476009 [doi]
PST - ppublish
SO  - J Am Chem Soc. 2005 Feb 9;127(5):1364-5. doi: 10.1021/ja0476009.

PMID- 34000418
OWN - NLM
STAT- MEDLINE
DCOM- 20210819
LR  - 20221031
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Print)
IS  - 1201-9712 (Linking)
VI  - 108
DP  - 2021 Jul
TI  - Active prescription of low-dose aspirin during or prior to hospitalization and 
      mortality in COVID-19: A systematic review and meta-analysis of adjusted effect 
      estimates.
PG  - 6-12
LID - S1201-9712(21)00417-3 [pii]
LID - 10.1016/j.ijid.2021.05.016 [doi]
AB  - BACKGROUND: This study aimed to investigate whether the active prescription of 
      low-dose aspirin during or prior to hospitalization affects mortality in patients 
      with coronavirus disease 2019 (COVID-19). Aspirin is often prescribed for 
      secondary prevention in patients with cardiovascular disease and other 
      comorbidities that might increase mortality, and may therefore falsely 
      demonstrate increased mortality. To reduce bias, only studies that performed an 
      adjusted analysis were included in this review. METHODS: A systematic literature 
      search of PubMed, Scopus, Embase and Clinicaltrials.gov was performed, from 
      inception until 16 April 2021. The exposure was active prescription of low-dose 
      aspirin during or prior to hospitalization. The primary outcome was mortality. 
      The pooled adjusted effect estimate was reported as relative risk (RR). RESULTS: 
      Six eligible studies were included in this meta-analysis, comprising 13,993 
      patients. The studies had low-to-moderate risk of bias based on the 
      Newcastle-Ottawa Scale. The meta-analysis indicated that the use of low-dose 
      aspirin was independently associated with reduced mortality {RR 0.46 [95% 
      confidence interval (CI) 0.35-0.61], P < 0.001; I(2) = 36.2%}. Subgroup analysis 
      on in-hospital low-dose aspirin administration also showed a significant 
      reduction in mortality [RR 0.39 (95% CI 0.16-0.96), P < 0.001; I(2) = 47.0%]. 
      CONCLUSION: Use of low-dose aspirin is independently associated with reduced 
      mortality in patients with COVID-19, with low certainty of evidence.
CI  - Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Martha, Januar Wibawa
AU  - Martha JW
AD  - Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas 
      Padjadjaran, Rumah Sakit Umum Pusat Hasan Sadikin, Bandung, Indonesia. Electronic 
      address: jwmartha@gmail.com.
FAU - Pranata, Raymond
AU  - Pranata R
AD  - Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas 
      Padjadjaran, Rumah Sakit Umum Pusat Hasan Sadikin, Bandung, Indonesia; Faculty of 
      Medicine, Universitas Pelita Harapan, Tangerang, Indonesia. Electronic address: 
      raymond_pranata@hotmail.com.
FAU - Lim, Michael Anthonius
AU  - Lim MA
AD  - Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia. Electronic 
      address: lim.michael.a@gmail.com.
FAU - Wibowo, Arief
AU  - Wibowo A
AD  - Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas 
      Padjadjaran, Rumah Sakit Umum Pusat Hasan Sadikin, Bandung, Indonesia. Electronic 
      address: ariefwibowo.doc@gmail.com.
FAU - Akbar, Mohammad Rizki
AU  - Akbar MR
AD  - Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas 
      Padjadjaran, Rumah Sakit Umum Pusat Hasan Sadikin, Bandung, Indonesia. Electronic 
      address: m.r.akbar@unpad.ac.id.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210515
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the 
      International Society for Infectious Diseases
JID - 9610933
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *COVID-19
MH  - Hospitalization
MH  - Humans
MH  - Prescriptions
MH  - SARS-CoV-2
PMC - PMC8123385
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Aspirin
OT  - Coronavirus
OT  - Outcome
OT  - Thrombosis
EDAT- 2021/05/18 06:00
MHDA- 2021/08/20 06:00
CRDT- 2021/05/17 20:20
PHST- 2021/04/19 00:00 [received]
PHST- 2021/05/06 00:00 [revised]
PHST- 2021/05/10 00:00 [accepted]
PHST- 2021/05/18 06:00 [pubmed]
PHST- 2021/08/20 06:00 [medline]
PHST- 2021/05/17 20:20 [entrez]
AID - S1201-9712(21)00417-3 [pii]
AID - 10.1016/j.ijid.2021.05.016 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2021 Jul;108:6-12. doi: 10.1016/j.ijid.2021.05.016. Epub 2021 
      May 15.

PMID- 23876721
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20131121
IS  - 1943-3530 (Electronic)
IS  - 0003-7028 (Linking)
VI  - 67
IP  - 8
DP  - 2013 Aug
TI  - Sensitivity-enhanced transmission Raman spectroscopy.
PG  - 829-40
LID - 10.1366/13-07115 [doi]
AB  - Transmission Raman sensitivity for a representative commercial pharmaceutical 
      tablet was increased by a factor of 40 using optics that returned lost laser and 
      Raman photons to the tablet surface. A new achromatic one-way mirror is 
      introduced that uses the spatial coherence of laser light to nondestructively 
      force laser photons through the reflective tablet coating. Transmission Raman 
      mapping and spatially offset Raman spectroscopy (SORS) mapping were developed and 
      used to better understand the sensitivity-enhancement technology. Fundamental 
      limitations of the sensitivity-enhancement approach are described and used to 
      guide the design of the optics. The sensitivity-enhancement optics are compatible 
      with commercial transmission Raman instruments.
FAU - Pelletier, Michael J
AU  - Pelletier MJ
AD  - Pfizer Worldwide Research and Development, Analytical Technology, Pharmaceutical 
      Sciences, 445 Eastern Point Road, Groton, CT 06340, USA. 
      michael.pelletier@pfizer.com
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Appl Spectrosc
JT  - Applied spectroscopy
JID - 0372406
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 0 (acetaminophen, aspirin, caffeine drug combination)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis/chemistry
MH  - Aspirin/*analysis/chemistry
MH  - Caffeine/*analysis/chemistry
MH  - Chemistry, Pharmaceutical/*methods
MH  - Drug Combinations
MH  - Drug Industry/*methods
MH  - Humans
MH  - Image Enhancement/*methods
MH  - Spectrum Analysis, Raman/*methods
MH  - Surface Properties
MH  - Tablets/analysis
EDAT- 2013/07/24 06:00
MHDA- 2013/10/18 06:00
CRDT- 2013/07/24 06:00
PHST- 2013/07/24 06:00 [entrez]
PHST- 2013/07/24 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - 10.1366/13-07115 [doi]
PST - ppublish
SO  - Appl Spectrosc. 2013 Aug;67(8):829-40. doi: 10.1366/13-07115.

PMID- 2022014
OWN - NLM
STAT- MEDLINE
DCOM- 19910606
LR  - 20220408
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 83
IP  - 5
DP  - 1991 May
TI  - Immediate postoperative aspirin improves vein graft patency early and late after 
      coronary artery bypass graft surgery. A placebo-controlled, randomized study.
PG  - 1526-33
AB  - BACKGROUND: The efficacy of aspirin for prevention of thrombotic graft occlusion 
      after coronary artery bypass grafting (CABG) depends both on the dosage and time 
      window of administration. Early and late graft patency were therefore assessed in 
      a prospective, double-blind, randomized, placebo-controlled trial of aspirin, 324 
      mg daily, given within 1 hour of CABG. METHODS AND RESULTS: Angiographic graft 
      patency was determined at 1 week (231 patients) and 1 year (219 patients) after 
      CABG. The early vein graft occlusion rate was 1.6% on aspirin and 6.2% on placebo 
      (p = 0.004), and late graft occlusion rate was 5.8% on continued aspirin and 
      11.6% on placebo (p = 0.01). New graft occlusion between 1 week and 1 year was 
      less common in patients on aspirin than on placebo (4.3% versus 7.4%, p = 0.013). 
      The protective effect of aspirin against occlusion persisted in most subgroups of 
      graft type, graft flow, diameter of recipient artery, location of grafted artery, 
      and endarterectomy. Mean chest tube blood loss for the first 24 hours was 571 ml 
      for the aspirin group and 563 ml for the placebo group. Red cell transfusion 
      requirements were 902 ml in the aspirin group and 934 ml in the placebo group (p 
      = NS). The reoperation rate was 4.8% in the aspirin group and 1% in the placebo 
      group (p = 0.1). CONCLUSIONS: Immediate postoperative administration of aspirin 
      (324 mg) improves early graft patency and, with continued usage, protects against 
      further occlusion up to 1 year after CABG. Postoperative blood loss was similar 
      in the two groups; however, aspirin was associated with a nonsignificant higher 
      rate of reoperation.
FAU - Gavaghan, T P
AU  - Gavaghan TP
AD  - Department of Cardiology and Cardiothoracic Surgery, St. Vincent's Hospital, 
      Sydney, New South Wales, Australia.
FAU - Gebski, V
AU  - Gebski V
FAU - Baron, D W
AU  - Baron DW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiography/adverse effects
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Transfusion
MH  - *Coronary Artery Bypass
MH  - Graft Occlusion, Vascular/diagnostic imaging/epidemiology
MH  - Hemorrhage/etiology/therapy
MH  - Humans
MH  - Patient Compliance
MH  - Placebos
MH  - *Postoperative Care
MH  - Postoperative Complications
MH  - Reoperation
MH  - Vascular Patency/*drug effects
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
AID - 10.1161/01.cir.83.5.1526 [doi]
PST - ppublish
SO  - Circulation. 1991 May;83(5):1526-33. doi: 10.1161/01.cir.83.5.1526.

PMID- 11516901
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 26
IP  - 4
DP  - 2001 Nov
TI  - Nitrosylhemoglobin, an unequivocal index of nitric oxide release from 
      nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy.
PG  - 509-18
AB  - Electron spin resonance (ESR) spectroscopy was applied for the unequivocal 
      detection/quantitation of nitric oxide (NO) as nitrosylhemoglobin (HbFe(II)NO) 
      released from nitroaspirin, benzoic acid,2-(acetyloxy)-3-[(nitrooxy)methyl]phenyl 
      ester (NCX-4016; NO-ASA), the lead of a new class of nonsteroidal 
      anti-inflammatory drugs. In both in vitro and in vivo experiments, the 
      paramagnetic complex was detected at 100 K in the venous blood of the rat 
      (microwave power, 20 mW) and characterized by a three-line hyperfine structure 
      with coupling constants (A(x) and A(z)) of 17 G at g(x)=2.066 and g(z)=2.009. The 
      kinetics of NO release from the drug were first determined in vitro by incubating 
      rat blood with 1 mM NO-ASA and confirmed by the two-line hyperfine structure 
      obtained with the labeled compound ((15)N-NO-ASA). In in vivo studies, the 
      hematic levels of HbFe(II)NO were determined after oral (p.o.) and 
      intraperitoneal (i.p.) administration of the drug (100 and 200 mg kg(-1)). In 
      p.o. treated animals, the complex was detectable at 1 h post-dosing and its 
      formation was maximal at 4-6 h, where the antithrombotic activity peaks. In i.p. 
      treated animals, HbFe(II)NO complex peaks at the second hour to decline 
      thereafter: in these animals, the ESR technique was applied to also detect 
      nitrosylmyoglobin as an index of NO diffusion/compartmentalization in myocardial 
      tissue. The results of this study emphasize the great potentiality of ESR 
      spectroscopy for the study of the release, the metabolic fate and distribution of 
      NO from nitrovasodilators.
FAU - Carini, M
AU  - Carini M
AD  - Istituto Chimico Farmaceutico e Tossicologico, Università degli studi di Milano, 
      Viale Abruzzi 42, 20131 Milan, Italy. marina.carini@unimi.it
FAU - Aldini, G
AU  - Aldini G
FAU - Stefani, R
AU  - Stefani R
FAU - Orioli, M
AU  - Orioli M
FAU - Facino, R M
AU  - Facino RM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hemoglobins)
RN  - 0 (nitrosyl hemoglobin)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism
MH  - Aspirin/administration & dosage/*analogs & derivatives/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Electron Spin Resonance Spectroscopy
MH  - Hemoglobins/*metabolism
MH  - Injections, Intraperitoneal
MH  - Male
MH  - Nitric Oxide/metabolism/*pharmacokinetics
MH  - Rats
MH  - Rats, Wistar
EDAT- 2001/08/23 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/08/23 10:00
PHST- 2001/08/23 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/08/23 10:00 [entrez]
AID - S0731-7085(01)00478-2 [pii]
AID - 10.1016/s0731-7085(01)00478-2 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2001 Nov;26(4):509-18. doi: 10.1016/s0731-7085(01)00478-2.

PMID- 1501078
OWN - NLM
STAT- MEDLINE
DCOM- 19920917
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 81
IP  - 4
DP  - 1992 Apr
TI  - Influence of in vitro test conditions on release of aspirin from commercial 
      tablets.
PG  - 386-91
AB  - The influence of in vitro test conditions on the release of aspirin from 
      commercial tablets was assessed with a USP rotating-basket dissolution apparatus. 
      Three types of aspirin tablets were evaluated: plain, buffered, and 
      microencapsulated. The variables investigated were stirring speed, pH, and volume 
      and temperature of the dissolution medium. Plain tablets gave the best 
      dissolution profiles under all experimental conditions, except at pH 3. 
      Microencapsulated tablets showed sustained release. For all three types of 
      tablets, faster dissolution was observed at pH 4.5 compared with that in 
      artificial gastric juices. Increasing the stirring rate increased the dissolution 
      rate, an effect most pronounced for plain tablets. Very similar dissolution 
      curves were obtained when the dissolution test was conducted in 500 and 900 mL of 
      dissolution media regardless of the pH of the media. No significant difference in 
      dissolution profiles was observed when the effect of temperature was 
      investigated. The dissolution data were evaluated on the basis of theoretical 
      dissolution equations and by linear transformation of dissolution curves. Highly 
      significant linear correlation coefficients revealed that the cube root equation 
      could be used to describe drug release in artificial gastric juices, regardless 
      of tablet type. When pH 4.5 buffer solution was used as the dissolution medium, 
      different kinetic models were applicable.
FAU - Nikolić, L
AU  - Nikolić L
AD  - Department of Pharmaceutical Technology, Faculty of Pharmacy, Belgrade, 
      Yugoslavia.
FAU - Djurić, Z
AU  - Djurić Z
FAU - Jovanović, M
AU  - Jovanović M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Chemistry, Pharmaceutical/*methods
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Solubility
MH  - Tablets/chemistry
MH  - Temperature
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
AID - S0022-3549(15)48797-0 [pii]
AID - 10.1002/jps.2600810420 [doi]
PST - ppublish
SO  - J Pharm Sci. 1992 Apr;81(4):386-91. doi: 10.1002/jps.2600810420.

PMID- 36565510
OWN - NLM
STAT- MEDLINE
DCOM- 20230207
LR  - 20230426
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 190
DP  - 2023 Mar 1
TI  - Temporal Trends in Low-Dose Aspirin Use (from the CoLaus|PsyCoLaus Study).
PG  - 61-66
LID - S0002-9149(22)01230-9 [pii]
LID - 10.1016/j.amjcard.2022.11.037 [doi]
AB  - Although established in secondary prevention, the use of low-dose aspirin for 
      primary cardiovascular prevention remains uncertain. We assessed the temporal 
      trend of low-dose aspirin use in people at primary and secondary prevention over 
      14 years. We used data from the population-based CoLaus|PsyCoLaus study. A 
      baseline survey was conducted from 2003 to 2006, involving 6,733 participants. 
      The first and second follow-up investigations were performed from 2009 to 2012 
      and 2014 to 2017, respectively. Low-dose aspirin use was defined as ≤300 mg/daily 
      oral administration or administration of an anticoagulant for similar 
      indications. For primary prevention analysis, 6,555, 4,695, and 3,893 
      participants were included in the analysis at baseline, first and second 
      follow-ups, respectively. Overall, low-dose aspirin use doubled between baseline 
      (4.1%) and second follow-up (8.1%). Appropriate use of low-dose aspirin rose from 
      32% at baseline to 64% at the second follow-up for primary prevention. In 
      secondary prevention, 71.8%, 75.9%, and 71.7% of participants were taking 
      low-dose aspirin at baseline, first, and second follow-up, respectively. On the 
      basis of a population-based cohort, the appropriateness of low-dose aspirin use 
      increased over a 10-year follow-up in primary prevention, but its inappropriate 
      use still concerned 44% of subjects. In secondary prevention, a quarter of 
      individuals were not taking low-dose aspirin which remained stable over the 
      analyzed period.
CI  - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Drai, Elodie
AU  - Drai E
AD  - Faculty of Biology and Medicine.
FAU - Marques-Vidal, Pedro
AU  - Marques-Vidal P
AD  - Department of Medicine, Internal Medicine, Lausanne University Hospital.
FAU - Bochud, Murielle
AU  - Bochud M
AD  - Faculty of Biology and Medicine; Center for Primary Care and Public Health 
      (Unisanté), University of Lausanne, Lausanne, Switzerland.
FAU - Vaucher, Julien
AU  - Vaucher J
AD  - Faculty of Biology and Medicine; Department of Medicine, Internal Medicine, 
      Lausanne University Hospital. Electronic address: Julien.Vaucher@chuv.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221222
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Humans
MH  - *Cardiovascular Diseases/epidemiology/prevention & control/drug therapy
MH  - Aspirin/therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - Primary Prevention
COIS- Disclosures The authors have no conflicts of interest to declare.
EDAT- 2022/12/25 06:00
MHDA- 2023/02/08 06:00
CRDT- 2022/12/24 18:08
PHST- 2022/06/28 00:00 [received]
PHST- 2022/10/08 00:00 [revised]
PHST- 2022/11/19 00:00 [accepted]
PHST- 2022/12/25 06:00 [pubmed]
PHST- 2023/02/08 06:00 [medline]
PHST- 2022/12/24 18:08 [entrez]
AID - S0002-9149(22)01230-9 [pii]
AID - 10.1016/j.amjcard.2022.11.037 [doi]
PST - ppublish
SO  - Am J Cardiol. 2023 Mar 1;190:61-66. doi: 10.1016/j.amjcard.2022.11.037. Epub 2022 
      Dec 22.

PMID- 8149942
OWN - NLM
STAT- MEDLINE
DCOM- 19940510
LR  - 20181113
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 18
IP  - 3
DP  - 1993 Jul-Sep
TI  - Comparative bioequivalence study of different brands of acetyl salicylic acid in 
      human volunteers.
PG  - 251-3
AB  - A double blind cross over randomized study was conducted in 7 normal healthy 
      volunteers. Single dose (700 mg) of buffered aspirin or aspirin with calcium 
      carbonate or aspirin with caffeine was administered orally, at least 3 days 
      apart. Blood samples were drawn at different time intervals after administration 
      of drug for estimation of salicylate levels. The values of different 
      pharmacokinetic parameters (AUC0-infinity, Cmax and tmax) did not show any 
      significant difference, suggesting that these three brands of aspirin are 
      biologically equivalent.
FAU - Valecha, N
AU  - Valecha N
AD  - Department of Pharmacology, Maulana Azad Medical College, New Delhi, India.
FAU - Gupta, U
AU  - Gupta U
FAU - Mehta, V L
AU  - Mehta VL
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (Salicylates)
RN  - 3G6A5W338E (Caffeine)
RN  - H0G9379FGK (Calcium Carbonate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/classification/*pharmacokinetics
MH  - Caffeine
MH  - Calcium Carbonate
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Therapeutic Equivalency
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
AID - 10.1007/BF03188804 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 1993 Jul-Sep;18(3):251-3. doi: 
      10.1007/BF03188804.

PMID- 31904094
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20210711
IS  - 1460-2180 (Electronic)
IS  - 0143-3334 (Print)
IS  - 0143-3334 (Linking)
VI  - 41
IP  - 6
DP  - 2020 Jul 10
TI  - A comprehensive in vivo and mathematic modeling-based kinetic characterization 
      for aspirin-induced chemoprevention in colorectal cancer.
PG  - 751-760
LID - 10.1093/carcin/bgz195 [doi]
AB  - Accumulating evidence suggests that aspirin has anti-tumorigenic properties in 
      colorectal cancer (CRC). Herein, we undertook a comprehensive and systematic 
      series of in vivo animal experiments followed by 3D-mathematical modeling to 
      determine the kinetics of aspirin's anti-cancer effects on CRC growth. In this 
      study, CRC xenografts were generated using four CRC cell lines with and without 
      PIK3CA mutations and microsatellite instability, and the animals were 
      administered with various aspirin doses (0, 15, 50, and 100 mg/kg) for 2 weeks. 
      Cell proliferation, apoptosis and protein expression were evaluated, followed by 
      3D-mathematical modeling analysis to estimate cellular division and death rates 
      and their impact on aspirin-mediated changes on tumor growth. We observed that 
      aspirin resulted in a dose-dependent decrease in the cell division rate, and a 
      concomitant increase in the cell death rates in xenografts from all cell lines. 
      Aspirin significantly inhibited cell proliferation as measured by Ki67 staining 
      (P < 0.05-0.01). The negative effect of aspirin on the rate of tumor cell 
      proliferation was more significant in xenograft tumors derived from PIK3CA mutant 
      versus wild-type cells. A computational model of 3D-tumor growth suggests that 
      the growth inhibitory effect of aspirin on the tumor growth kinetics is due to a 
      reduction of tumor colony formation, and that this effect is sufficiently strong 
      to be an important contributor to the reduction of CRC incidence in 
      aspirin-treated patients. In conclusion, we provide a detailed kinetics of 
      aspirin-mediated inhibition of tumor cell proliferation, which support the 
      epidemiological data for the observed protective effect of aspirin in CRC 
      patients.
CI  - © The Author(s) 2020. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Shimura, Tadanobu
AU  - Shimura T
AD  - Center for Gastrointestinal Research, Center from Translational Genomics and 
      Oncology, Baylor Scott and White Research Institute and Charles A. Sammons Cancer 
      Center, Baylor University Medical Center, Dallas, TX, USA.
FAU - Toden, Shusuke
AU  - Toden S
AD  - Center for Gastrointestinal Research, Center from Translational Genomics and 
      Oncology, Baylor Scott and White Research Institute and Charles A. Sammons Cancer 
      Center, Baylor University Medical Center, Dallas, TX, USA.
FAU - Komarova, Natalia L
AU  - Komarova NL
AD  - Department of Mathematics, University of California, Irvine, CA, USA.
FAU - Boland, Crichard
AU  - Boland C
AD  - Center for Gastrointestinal Research, Center from Translational Genomics and 
      Oncology, Baylor Scott and White Research Institute and Charles A. Sammons Cancer 
      Center, Baylor University Medical Center, Dallas, TX, USA.
FAU - Wodarz, Dominik
AU  - Wodarz D
AD  - Department of Population Health and Disease Prevention Program in Public Health 
      Susan and Henry Samueli College of Health Sciences and Department of Mathematics, 
      University of California, Irvine, CA, USA.
FAU - Goel, Ajay
AU  - Goel A
AD  - Center for Gastrointestinal Research, Center from Translational Genomics and 
      Oncology, Baylor Scott and White Research Institute and Charles A. Sammons Cancer 
      Center, Baylor University Medical Center, Dallas, TX, USA.
AD  - Department of Molecular Diagnostics and Experimental Therapeutics, Beckman 
      Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
LA  - eng
GR  - R01 CA072851/CA/NCI NIH HHS/United States
GR  - R01 CA184792/CA/NCI NIH HHS/United States
GR  - R01 CA202797/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Carcinogenesis
JT  - Carcinogenesis
JID - 8008055
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Apoptosis
MH  - Aspirin/*pharmacology
MH  - *Cell Proliferation
MH  - Colorectal Neoplasms/metabolism/pathology/*prevention & control
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - *Models, Theoretical
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
PMC - PMC7351132
EDAT- 2020/01/07 06:00
MHDA- 2020/10/28 06:00
CRDT- 2020/01/07 06:00
PHST- 2019/09/14 00:00 [received]
PHST- 2019/10/22 00:00 [revised]
PHST- 2020/01/07 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
PHST- 2020/01/07 06:00 [entrez]
AID - 5696845 [pii]
AID - bgz195 [pii]
AID - 10.1093/carcin/bgz195 [doi]
PST - ppublish
SO  - Carcinogenesis. 2020 Jul 10;41(6):751-760. doi: 10.1093/carcin/bgz195.

PMID- 5315501
OWN - NLM
STAT- MEDLINE
DCOM- 19711216
LR  - 20181113
IS  - 0008-1264 (Print)
IS  - 0008-1264 (Linking)
VI  - 115
IP  - 4
DP  - 1971 Oct
TI  - Aspirin-induced prolongation of the ivy bleeding time. Its diagnostic usefulness.
PG  - 10-3
AB  - Ivy bleeding time values before and two hours after ingestion of 600 mg of 
      aspirin (aspirin tolerance test) were studied in normal persons, in patients with 
      a disorder of primary hemostasis and in patients with various coagulation factor 
      deficiencies. Aspirin produced a significant prolongation of the bleeding time in 
      patients with von Willebrand's disease, uremia, and primary platelet disease, and 
      in two patients with Factor XI deficiency. Dextropropoxyphene hydrochloride 
      caused no prolongation of the bleeding time in normal persons.
FAU - Sahud, M A
AU  - Sahud MA
FAU - Cohen, R J
AU  - Cohen RJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Calif Med
JT  - California medicine
JID - 0410260
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Disorders
MH  - Blood Platelet Disorders
MH  - Humans
MH  - Time Factors
MH  - Uremia
MH  - von Willebrand Diseases
PMC - PMC1517969
EDAT- 1971/10/01 00:00
MHDA- 1971/10/01 00:01
CRDT- 1971/10/01 00:00
PHST- 1971/10/01 00:00 [pubmed]
PHST- 1971/10/01 00:01 [medline]
PHST- 1971/10/01 00:00 [entrez]
PST - ppublish
SO  - Calif Med. 1971 Oct;115(4):10-3.

PMID- 17257477
OWN - NLM
STAT- MEDLINE
DCOM- 20070403
LR  - 20220330
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 23
IP  - 1
DP  - 2007 Jan
TI  - Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and 
      treatment.
PG  - 163-73
AB  - BACKGROUND: Low-dose aspirin (75-325 mg/day) is widely used for the prevention of 
      cardiovascular disease. However, due to its action on cyclo-oxygenase (COX), 
      aspirin is associated with upper gastrointestinal (GI) side effects including 
      ulcers and bleeding. SCOPE: This was a comprehensive review of the literature 
      available on the side effects associated with low-dose aspirin, together with the 
      available treatment and prevention options, which was based on the authors' 
      expertise in the field and a supplementary PubMed search limited to papers 
      published in English during the last 10 years, up to November 2006. FINDINGS: 
      Although the risk of upper GI side effects is smaller with low-dose aspirin 
      compared with non-selective, non-steroidal anti-inflammatory drugs (NSAIDs), it 
      is nevertheless a substantial healthcare issue. Factors associated with an 
      increased risk of upper GI complications during low-dose aspirin therapy include 
      aspirin dose, history of ulcer or upper GI bleeding, age > 70 years, concomitant 
      use of NSAIDs (including COX-2-selective NSAIDs), and Helicobacter pylori 
      infection. Co-administration of a gastroprotective agent such as proton pump 
      inhibitors (PPIs) may be useful for alleviating the upper GI side effects 
      associated with use of low-dose aspirin. Eradication of H. pylori also appears to 
      reduce the risk of these side effects, especially in those at high risk. The use 
      of other antiplatelet agents such as clopidogrel does not seem to provide a safer 
      alternative to low-dose aspirin in at-risk patients. CONCLUSIONS: Prophylactic 
      low-dose aspirin therapy is associated with an increased risk of developing upper 
      GI side effects. Administration of a PPI seems the most effective therapy for the 
      prevention and/or relief of such side effects in at-risk patients. H. pylori 
      eradication therapy further reduces the risk of upper GI bleeding in these 
      patients.
FAU - Lanas, Angel
AU  - Lanas A
AD  - Service of Gastroenterology, Instituto Aragones de Ciencias de la Salud, 
      University Hospital, Zaragoza, Spain. alanas@unizar.es <alanas@unizar.es>
FAU - Scheiman, James
AU  - Scheiman J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Ulcer Agents/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Gastrointestinal Diseases/*chemically induced/epidemiology/prevention & control
MH  - Helicobacter Infections/complications/epidemiology/prevention & control
MH  - Helicobacter pylori
MH  - Humans
MH  - Proton Pump Inhibitors
MH  - Risk Factors
MH  - Upper Gastrointestinal Tract/*drug effects
RF  - 88
EDAT- 2007/01/30 09:00
MHDA- 2007/04/04 09:00
CRDT- 2007/01/30 09:00
PHST- 2007/01/30 09:00 [pubmed]
PHST- 2007/04/04 09:00 [medline]
PHST- 2007/01/30 09:00 [entrez]
AID - 10.1185/030079907X162656 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2007 Jan;23(1):163-73. doi: 10.1185/030079907X162656.

PMID- 20229592
OWN - NLM
STAT- MEDLINE
DCOM- 20100524
LR  - 20131121
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 85
IP  - 5
DP  - 2010 May
TI  - Laboratory evaluation of aspirin responsiveness.
PG  - 358-60
LID - 10.1002/ajh.21674 [doi]
AB  - Aspirin is the most commonly used antiplatelet medication. Laboratory monitoring 
      of aspirin response has recently become a topic of interest due to potential 
      impacts on patient management and clinical outcomes. This article summarizes 
      available laboratory testing of aspirin response with focus on technical issues, 
      limitations, and current opinion on the utility of routine patient testing.
CI  - (c) 2010 Wiley-Liss, Inc.
FAU - Smock, Kristi J
AU  - Smock KJ
AD  - Department of Pathology, University of Utah Health Sciences Center and ARUP 
      Laboratories, Salt Lake City, Utah, USA. kristi.smock@aruplab.com
FAU - Rodgers, George M
AU  - Rodgers GM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Function Tests/*methods
MH  - Thromboxane B2/blood/urine
EDAT- 2010/03/17 06:00
MHDA- 2010/05/25 06:00
CRDT- 2010/03/16 06:00
PHST- 2010/03/16 06:00 [entrez]
PHST- 2010/03/17 06:00 [pubmed]
PHST- 2010/05/25 06:00 [medline]
AID - 10.1002/ajh.21674 [doi]
PST - ppublish
SO  - Am J Hematol. 2010 May;85(5):358-60. doi: 10.1002/ajh.21674.

PMID- 9423294
OWN - NLM
STAT- MEDLINE
DCOM- 19980226
LR  - 20131121
IS  - 0001-6659 (Print)
IS  - 0001-6659 (Linking)
VI  - 67
IP  - 6
DP  - 1997 Nov
TI  - The influence of Eudragit type on the dissolution rate of acetylsalicylic acid 
      from matrix tablets.
PG  - 229-34
AB  - The effect of four Eudragits used as matrix substances on the physical 
      characteristics of tablets and on the dissolution rate of acetylsalicylic acid 
      has been investigated. The concentration of matrix substance necessary for 
      achieving the appropriate effect of sustained release of acetylsalicylic acid 
      (ASA) depends on the type of Eudragit used. For tablets prepared using Eudragit 
      RS-100, Eudragit L-100-55 and Eudragit S-100, the acceptable dissolution rate of 
      ASA was obtained with only 3% of polymer. In the case of Eudragit RL-100, to 
      obtain the same effect, 10% of polymer was required. The dissolution data were 
      evaluated on the basis of theoretical dissolution equations and by linear 
      transformation of dissolution curves. The following mathematical models were 
      employed: zero order equation, first order kinetics, Hixon-Crowell's cube root 
      kinetics and diffusion model. The results indicated that the fitness of the 
      kinetic model was dependent on the type of Eudragit used.
FAU - Jovanović, M
AU  - Jovanović M
AD  - Faculty of Pharmacy, Belgrade University, Yugoslavia.
FAU - Jovicić, G
AU  - Jovicić G
FAU - Djurić, Z
AU  - Djurić Z
FAU - Agbaba, D
AU  - Agbaba D
FAU - Karljiković-Rajić, K
AU  - Karljiković-Rajić K
FAU - Nikolić, L
AU  - Nikolić L
FAU - Radovanović, J
AU  - Radovanović J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Hungary
TA  - Acta Pharm Hung
JT  - Acta pharmaceutica Hungarica
JID - 0414322
RN  - 0 (Acrylic Resins)
RN  - 0 (Gels)
RN  - 0 (Polymethacrylic Acids)
RN  - 0 (Tablets)
RN  - 25086-15-1 (methylmethacrylate-methacrylic acid copolymer)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acrylic Resins
MH  - Aspirin/*chemistry
MH  - Gels
MH  - Polymethacrylic Acids
MH  - Solubility
MH  - Tablets
EDAT- 1998/01/10 00:00
MHDA- 1998/01/10 00:01
CRDT- 1998/01/10 00:00
PHST- 1998/01/10 00:00 [pubmed]
PHST- 1998/01/10 00:01 [medline]
PHST- 1998/01/10 00:00 [entrez]
PST - ppublish
SO  - Acta Pharm Hung. 1997 Nov;67(6):229-34.

PMID- 23681842
OWN - NLM
STAT- MEDLINE
DCOM- 20140620
LR  - 20211021
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Print)
IS  - 0884-8734 (Linking)
VI  - 28
IP  - 11
DP  - 2013 Nov
TI  - Effect of including cancer mortality on the cost-effectiveness of aspirin for 
      primary prevention in men.
PG  - 1483-91
LID - 10.1007/s11606-013-2465-6 [doi]
AB  - BACKGROUND: Recent data suggest that aspirin may be effective for reducing cancer 
      mortality. OBJECTIVE: To examine whether including a cancer mortality-reducing 
      effect influences which men would benefit from aspirin for primary prevention. 
      DESIGN: We modified our existing Markov model that examines the effects of 
      aspirin among middle-aged men with no previous history of cardiovascular disease 
      or diabetes. For our base case scenario of 45-year-old men, we examined costs and 
      life-years for men taking aspirin for 10 years compared with men who were not 
      taking aspirin over those 10 years; after 10 years, we equalized treatment and 
      followed the cohort until death. We compared our results depending on whether or 
      not we included a 22 % relative reduction in cancer mortality, based on a recent 
      meta-analysis. We discounted costs and benefits at 3 % and employed a third party 
      payer perspective. MAIN MEASURE: Cost per quality-adjusted life year (QALY) 
      gained. KEY RESULTS: When no effect on cancer mortality was included, aspirin had 
      a cost per QALY gained of $22,492 at 5 % 10-year coronary heart disease (CHD) 
      risk; at 2.5 % risk or below, no treatment was favored. When we included a 
      reduction in cancer mortality, aspirin became cost-effective for men at 2.5 % 
      risk as well (cost per QALY, $43,342). Results were somewhat sensitive to utility 
      of taking aspirin daily; risk of death after myocardial infarction; and effects 
      of aspirin on stroke, myocardial infarction, and sudden death. However, aspirin 
      remained cost-saving or cost-effective (< $50,000 per QALY) in probabilistic 
      analyses (59 % with no cancer effect included; 96 % with cancer effect) for men 
      at 5 % risk. CONCLUSIONS: Including an effect of aspirin on cancer mortality 
      influences the threshold for prescribing aspirin for primary prevention in men. 
      If such an effect is real, many middle-aged men at low cardiovascular risk would 
      become candidates for regular aspirin use.
FAU - Pignone, Michael
AU  - Pignone M
AD  - Cecil Sheps Center for Health Services Research, University of North Carolina, 
      Chapel Hill, NC, USA, pignone@med.unc.edu.
FAU - Earnshaw, Stephanie
AU  - Earnshaw S
FAU - McDade, Cheryl
AU  - McDade C
FAU - Pletcher, Mark J
AU  - Pletcher MJ
LA  - eng
GR  - K05 CA129166/CA/NCI NIH HHS/United States
GR  - R21 HL112256/HL/NHLBI NIH HHS/United States
GR  - K05CA129166/CA/NCI NIH HHS/United States
GR  - R21HL112256-01/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130517
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*economics
MH  - Cost-Benefit Analysis/economics/methods
MH  - Humans
MH  - Male
MH  - *Markov Chains
MH  - Middle Aged
MH  - Neoplasms/*economics/*mortality
MH  - Primary Prevention/*economics/methods
MH  - Treatment Outcome
PMC - PMC3797356
EDAT- 2013/05/18 06:00
MHDA- 2014/06/21 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/10/31 00:00 [received]
PHST- 2013/04/10 00:00 [accepted]
PHST- 2013/01/01 00:00 [revised]
PHST- 2013/05/18 06:00 [entrez]
PHST- 2013/05/18 06:00 [pubmed]
PHST- 2014/06/21 06:00 [medline]
AID - 2465 [pii]
AID - 10.1007/s11606-013-2465-6 [doi]
PST - ppublish
SO  - J Gen Intern Med. 2013 Nov;28(11):1483-91. doi: 10.1007/s11606-013-2465-6. Epub 
      2013 May 17.

PMID- 2569513
OWN - NLM
STAT- MEDLINE
DCOM- 19890921
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 41
IP  - 5
DP  - 1989 May
TI  - The material tensile strength of convex-faced aspirin tablets.
PG  - 289-92
AB  - The material tensile strength of a range of convex-faced tablets, compacted under 
      controlled conditions at pressures of 40 and 320 MPa from a size fraction of 
      acetylsalicylic acid, has been assessed. The calculation of the tensile strength 
      sigma 1, from observed fracture loads obtained in diametral compression testing, 
      is based on the equation derived by Pitt et al (1988), namely: (formula; see 
      text) where P is the fracture load, D is the tablet diameter, t is the overall 
      tablet thickness and W is the central cylinder thickness. The strength of a 
      tablet of a given shape compacted at 320 MPa was between two and four times 
      greater than that of a similar tablet compacted at 40 MPa. For the thicker 
      tablets (W/D greater than or equal to 0.2) the material tensile strength was 
      practically independent of shape. For the thinner tablets (W/D = 0.1) the 
      material tensile strength varied considerably with face-curvature, showing a 
      maximum for each of the two compaction pressures at a D/R value of 0.67.
FAU - Pitt, K G
AU  - Pitt KG
AD  - School of Pharmacy, University of London, Brunswick Square, UK.
FAU - Newton, J M
AU  - Newton JM
FAU - Richardson, R
AU  - Richardson R
FAU - Stanley, P
AU  - Stanley P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Chemistry, Pharmaceutical
MH  - Drug Compounding
MH  - Pressure
MH  - Tablets
MH  - Tensile Strength
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1989.tb06458.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1989 May;41(5):289-92. doi: 
      10.1111/j.2042-7158.1989.tb06458.x.

PMID- 36480147
OWN - NLM
STAT- MEDLINE
DCOM- 20230315
LR  - 20230315
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 55
IP  - 2
DP  - 2023 Feb
TI  - Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet 
      responsiveness in patients with ST-segment elevation myocardial infarction: the 
      ECCLIPSE-STEMI trial.
PG  - 203-210
LID - 10.1007/s11239-022-02737-y [doi]
AB  - Prasugrel and ticagrelor, new P2Y12-ADP receptor antagonists, are associated with 
      greater pharmacodynamic inhibition and reduction of cardiovascular events in 
      patients with an acute coronary syndrome. However, evidence is lacked about the 
      effects of achieving faster and stronger cyclooxygenase inhibition with 
      intravenous lysine acetylsalicylate (LA) compared to oral aspirin. Recently, we 
      demonstrated in healthy volunteers that the administration of intravenous LA 
      resulted in a significantly reduction of platelet reactivity compared to oral 
      aspirin. Loading dose of LA achieves platelet inhibition faster, and with less 
      variability than aspirin. However, there are no data of this issue in patients 
      with an ST-segment elevation myocardial infarction (STEMI). This is a 
      prospective, randomized, multicenter, open platelet function study conducted in 
      STEMI patients. Subjects were randomly assigned to receive a loading dose (LD) of 
      intravenous LA 450 mg plus oral ticagrelor 180 mg, or LD of aspirin 300 mg plus 
      ticagrelor 180 mg orally. Platelet function was evaluated at baseline, 30 min, 
      1 h, 4 h and 24 h using multiple electrode aggregometry and 
      vasodilator-stimulated phosphoprotein phosphorylation (VASP). The primary 
      endpoint of the study is the inhibition of platelet aggregation (IPA) after 
      arachidonic acid (AA) 0.5 mM at 30 min. Secondary endpoints were the IPA at 1, 4, 
      and 24 h after AA, and non-AA pathways through the sequence (ADP and TRAP). A 
      total of 32 STEMI patients were randomized (16 LA, 16 aspirin). The inhibition of 
      platelet aggregation after AA 0.5 mM at 30 min was greater in subjects treated 
      with LA compared with aspirin: 166 vs. 412 respectively (p = 0.001). This 
      differential effect was observed at 1 h (p = 0.01), but not at 4 and 24 h. 
      Subjects treated with LA presented less variability and faster inhibition of 
      platelet aggregation wit AA compared with aspirin. The administration of 
      intravenous LA resulted in a significantly reduction of platelet reactivity 
      compared to oral aspirin on ticagrelor inhibited platelets in patients with 
      STEMI. Loading dose of LA achieves an earlier platelet inhibition, and with less 
      variability than aspirin.Trial Registration: Unique identifier: NCT02929888; URL: 
      http://www.clinicaltrials.gov.
CI  - © 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Vivas, David
AU  - Vivas D
AD  - Cardiovascular Institute, San Carlos University Hospital, Profesor Martin Lagos 
      S/N. 28040, Madrid, Spain. dvivas@secardiologia.es.
FAU - Jiménez, José Julio
AU  - Jiménez JJ
AD  - SUMMA 112 Emergency Medical Service, Madrid, Spain.
FAU - Martín-Asenjo, Roberto
AU  - Martín-Asenjo R
AD  - Cardiology Unit, 12 Octubre University Hospital, Madrid, Spain.
FAU - Bernardo, Esther
AU  - Bernardo E
AD  - Cardiovascular Institute, San Carlos University Hospital, Profesor Martin Lagos 
      S/N. 28040, Madrid, Spain.
FAU - Ortega-Pozzi, María Aranzazu
AU  - Ortega-Pozzi MA
AD  - Cardiovascular Institute, San Carlos University Hospital, Profesor Martin Lagos 
      S/N. 28040, Madrid, Spain.
FAU - Gómez-Polo, Juan Carlos
AU  - Gómez-Polo JC
AD  - Cardiovascular Institute, San Carlos University Hospital, Profesor Martin Lagos 
      S/N. 28040, Madrid, Spain.
FAU - Moreno, Guillermo
AU  - Moreno G
AD  - Cardiology Unit, 12 Octubre University Hospital, Madrid, Spain.
FAU - Vilacosta, Isidre
AU  - Vilacosta I
AD  - Cardiovascular Institute, San Carlos University Hospital, Profesor Martin Lagos 
      S/N. 28040, Madrid, Spain.
FAU - Pérez-Villacastín, Julián
AU  - Pérez-Villacastín J
AD  - Cardiovascular Institute, San Carlos University Hospital, Profesor Martin Lagos 
      S/N. 28040, Madrid, Spain.
FAU - Fernández-Ortiz, Antonio
AU  - Fernández-Ortiz A
AD  - Cardiovascular Institute, San Carlos University Hospital, Profesor Martin Lagos 
      S/N. 28040, Madrid, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT02929888
GR  - PI16/00191/Instituto de Salud Carlos III/
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20221208
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - GLH0314RVC (Ticagrelor)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
SB  - IM
MH  - Humans
MH  - Ticagrelor
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - *ST Elevation Myocardial Infarction/therapy
MH  - Prospective Studies
MH  - Aspirin/therapeutic use/pharmacology
MH  - Blood Platelets
MH  - Prasugrel Hydrochloride/therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
MH  - Treatment Outcome
MH  - *Percutaneous Coronary Intervention/adverse effects
PMC - PMC9735024
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Aspirin
OT  - Lysine acetylsalicylate
OT  - Platelets
COIS- The authors declare that there is no conflict of interest in this manuscript.
EDAT- 2022/12/09 06:00
MHDA- 2023/03/16 06:00
CRDT- 2022/12/08 14:46
PHST- 2022/11/20 00:00 [accepted]
PHST- 2022/12/09 06:00 [pubmed]
PHST- 2023/03/16 06:00 [medline]
PHST- 2022/12/08 14:46 [entrez]
AID - 10.1007/s11239-022-02737-y [pii]
AID - 2737 [pii]
AID - 10.1007/s11239-022-02737-y [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2023 Feb;55(2):203-210. doi: 10.1007/s11239-022-02737-y. 
      Epub 2022 Dec 8.

PMID- 9433378
OWN - NLM
STAT- MEDLINE
DCOM- 19980204
LR  - 20190921
IS  - 0939-5555 (Print)
IS  - 0939-5555 (Linking)
VI  - 75
IP  - 5-6
DP  - 1997 Nov-Dec
TI  - Excessive prolongation of the bleeding time by aspirin in essential 
      thrombocythemia is related to a decrease of large von Willebrand factor multimers 
      in plasma.
PG  - 215-20
AB  - Patients with essential thrombocythemia (ET), who frequently have bleeding 
      complications, may manifest an excessive prolongation of the bleeding time (BT) 
      after ingestion of aspirin (ASA). The reason for this excessive prolongation of 
      the BT is unknown, but it is attributed to qualitative platelet defects. Since 
      patients with ET may also have acquired abnormalities of plasma and platelet von 
      Willebrand factor (vWF), we questioned whether the excessive prolongation of the 
      BT by ASA was related to changes in either plasma or platelet vWF. To that end, 
      we studied BT and plasma and platelet vWF in ten ET patients, ten patients with 
      reactive thrombocytosis (RT), and ten normal individuals, both before and after 
      administration of 500 mg ASA for 7 days. In a second study, the effect of DDAVP 
      infusion on plasma vWF in relation to the BT was studied in ten normal 
      individuals and ten ET patients after treatment with 100 mg ASA for 3 days. In 
      the first study, treatment with ASA resulted in a significant prolongation of the 
      BT in normal subjects, RT patients, and ET patients. However, in five ET patients 
      an excessive (> 2 SD) prolongation of the BT by ASA was observed. Although ASA 
      induced no direct changes in either plasma or platelet vWF levels in either 
      normal subjects, RT patients, or ET patients, all five ET patients who showed an 
      excessive prolongation of the BT by ASA had significantly decreased levels of 
      large vWF multimers in plasma. In the second study, infusion with DDAVP resulted 
      in a significant increase in plasma large vWF multimers, paralleled by a 
      normalization of (excessively) prolonged BT. Our data suggest that in ET 
      inhibition of platelet function by ASA in the presence of concurrently decreased 
      levels of large vWF multimers in plasma may have provoked the excessive BT 
      prolongation.
FAU - van Genderen, P J
AU  - van Genderen PJ
AD  - Department of Hematology, University Hospital Dijkzigt, Rotterdam, The 
      Netherlands.
FAU - van Vliet, H H
AU  - van Vliet HH
FAU - Prins, F J
AU  - Prins FJ
FAU - van de Moesdijk, D
AU  - van de Moesdijk D
FAU - van Strik, R
AU  - van Strik R
FAU - Zijlstra, F J
AU  - Zijlstra FJ
FAU - Budde, U
AU  - Budde U
FAU - Michiels, J J
AU  - Michiels JJ
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (von Willebrand Factor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Bleeding Time
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Thrombocytosis/blood/*drug therapy
MH  - von Willebrand Factor/*analysis
EDAT- 1998/01/20 00:00
MHDA- 1998/01/20 00:01
CRDT- 1998/01/20 00:00
PHST- 1998/01/20 00:00 [pubmed]
PHST- 1998/01/20 00:01 [medline]
PHST- 1998/01/20 00:00 [entrez]
AID - 10.1007/s002770050345 [doi]
PST - ppublish
SO  - Ann Hematol. 1997 Nov-Dec;75(5-6):215-20. doi: 10.1007/s002770050345.

PMID- 333079
OWN - NLM
STAT- MEDLINE
DCOM- 19771130
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 91
IP  - 5
DP  - 1977 Nov
TI  - Comparison of tolmetin sodium and aspirin in the treatment of juvenile rheumatoid 
      arthritis.
PG  - 799-804
AB  - The Pediatric Rheumatology Collaborative Study Group was established in 1973 to 
      undertake systematic trials of new drugs in the treatment of juvenile rheumatoid 
      arthritis. The first drug evaluated was tolmetin (1-methyl-5-p-toluoylpyrrole-2 
      acetic acid), a new nonsteroid anti-inflammatory agent. A four-week open trial 
      with 30 patients and a subsequent 12-week double-blind trial against aspirin with 
      107 patients were conducted. Tolmetin and aspirin had equal anti-inflammatory and 
      analgesic effects in the treatment of JRA. Elevations of transaminase values 
      attributed to aspirin were not found with tolmetin. Adverse effects accompanying 
      administration of tolmetin did not appear to be of major clinical significance.
FAU - Levinson, J E
AU  - Levinson JE
FAU - Baum, J
AU  - Baum J
FAU - Brewer, E Jr
AU  - Brewer E Jr
FAU - Fink, C
AU  - Fink C
FAU - Hanson, V
AU  - Hanson V
FAU - Schaller, J
AU  - Schaller J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 0 (Pyrroles)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Pyrroles/*therapeutic use
MH  - Tolmetin/adverse effects/*therapeutic use
EDAT- 1977/11/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1977/11/01 00:00
PHST- 1977/11/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1977/11/01 00:00 [entrez]
AID - S0022-3476(77)81045-7 [pii]
AID - 10.1016/s0022-3476(77)81045-7 [doi]
PST - ppublish
SO  - J Pediatr. 1977 Nov;91(5):799-804. doi: 10.1016/s0022-3476(77)81045-7.

PMID- 8371226
OWN - NLM
STAT- MEDLINE
DCOM- 19931008
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 20
IP  - 7
DP  - 1993 Jul
TI  - Postpartum cerebral infarction associated with aspirin withdrawal in the 
      antiphospholipid antibody syndrome.
PG  - 1229-32
AB  - We observed 2 cases of antiphospholipid syndrome complicated with hemiparesis 
      appearing after delivery. During pregnancy, both women were systematically 
      treated with aspirin (100 mg/day) in addition to prednisone in the second case. 
      Cerebral infarction appeared a few hours after delivery and 8 days after 
      discontinuation of aspirin. The close temporal relationship between 
      discontinuation of aspirin and stroke occurring in early postpartum period 
      suggests a causal link. If aspirin must be stopped for obstetrical reasons, we 
      think that efficient anticoagulation should be started even if the presence of 
      the antiphospholipid antibodies has been priorly asymptomatic.
FAU - Lê Thi Huong, D
AU  - Lê Thi Huong D
AD  - Department of Internal Medicine, Groupe Hospitalier Pitié-Salpêtrière, Paris.
FAU - Wechsler, B
AU  - Wechsler B
FAU - Edelman, P
AU  - Edelman P
FAU - Fournié, A
AU  - Fournié A
FAU - Le Tallec, Y
AU  - Le Tallec Y
FAU - Piette, J C
AU  - Piette JC
FAU - Godeau, P
AU  - Godeau P
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antiphospholipid Syndrome/*complications/*drug therapy
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cerebral Infarction/*etiology/prevention & control
MH  - Female
MH  - Hemiplegia/etiology
MH  - Humans
MH  - Postpartum Period
MH  - Puerperal Disorders/*etiology/prevention & control
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1993 Jul;20(7):1229-32.

PMID- 1863573
OWN - NLM
STAT- MEDLINE
DCOM- 19910911
LR  - 20190918
IS  - 0920-5063 (Print)
IS  - 0920-5063 (Linking)
VI  - 2
IP  - 1
DP  - 1991
TI  - Study on antithrombogenicity of poly[beta-(acetylsalicylyloxy)ethyl methacrylate] 
      relative to poly(hydroxyethyl methacrylate).
PG  - 1-13
AB  - The antithrombogenicity of a polymer made of aspirin bound to hydroxyethyl 
      methacrylate (HEMA), abbreviated as ASA-polymer, was compared with that of 
      poly(hydroxyethyl methacrylate) (PHEMA). Platelet from platelet rich plasma (PRP) 
      incubated with ASA-polymer surface exhibited noticeable decreases in adhesion and 
      aggregation as compared to platelets incubated with PHEMA. Low molecular weight 
      components other than aspirin, which may be released from ASA-polymer during the 
      incubation with PRP, or contact with ASA-polymer causing denaturation of 
      platelets without morphological changes could be responsible for the decrease of 
      adhesion and aggregation. Both PRP and PPP exposed to ASA-polymer-coated surfaces 
      exhibited a much smaller partial thromboplastin time (PTT) than if exposed to 
      PHEMA-coated surfaces; the PTT of ASA-polymer was similar to that of glass 
      exposed plasma. With respect to the in vivo antithrombogenicity, the ASA-polymer 
      surface led to thrombus formation. This may be due to the partial hydrolysis of 
      the acetyl groups resulting in the formation of a negatively charged surface 
      which in turn accelerates the coagulation cascade despite its inhibitory effects 
      on platelet adhesion and aggregation. On the other hand, neointima formed around 
      a thrombus layer on PHEMA-coated sutures after 14 days.
FAU - Sato, H
AU  - Sato H
AD  - Research Center for Medical Polymers and Biomaterials, Kyoto University, Japan.
FAU - Kojima, J
AU  - Kojima J
FAU - Nakajima, A
AU  - Nakajima A
FAU - Morita, T
AU  - Morita T
FAU - Noishiki, Y
AU  - Noishiki Y
FAU - Gu, Z W
AU  - Gu ZW
FAU - Li, F M
AU  - Li FM
FAU - Feng, X D
AU  - Feng XD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Biomater Sci Polym Ed
JT  - Journal of biomaterials science. Polymer edition
JID - 9007393
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polymethacrylic Acids)
RN  - 25249-16-5 (Polyhydroxyethyl Methacrylate)
RN  - 80044-26-4 (poly(beta-(acetylsalicylyloxy)ethylmethacrylate))
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Delayed-Action Preparations
MH  - Dogs
MH  - *Fibrinolytic Agents
MH  - In Vitro Techniques
MH  - Molecular Structure
MH  - Platelet Adhesiveness/drug effects
MH  - *Platelet Aggregation Inhibitors
MH  - Polyhydroxyethyl Methacrylate/*pharmacology
MH  - Polymethacrylic Acids/*pharmacology
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1163/156856291x00016 [doi]
PST - ppublish
SO  - J Biomater Sci Polym Ed. 1991;2(1):1-13. doi: 10.1163/156856291x00016.

PMID- 1589237
OWN - NLM
STAT- MEDLINE
DCOM- 19920625
LR  - 20210112
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 48
IP  - 2
DP  - 1992 Feb
TI  - Acetylsalicylic acid activates antinociceptive brain-stem reflex activity in 
      headache patients and in healthy subjects.
PG  - 187-195
LID - 10.1016/0304-3959(92)90058-J [doi]
AB  - The exteroceptive suppression (ES) of electrical activity in the temporal muscle 
      is an inhibitory antinociceptive brain-stem reflex. We investigated whether 
      aspirin can significantly modulate latencies or durations of the early (ES1) and 
      late (ES2) exteroceptive suppression periods of electrical activity in the 
      temporal muscle. Participating in the randomized double-blind crossover study 
      were 20 patients with migraine without aura, 20 patients with tension-type 
      headache, and 20 healthy subjects. ES1 and ES2 elicited by an electrical stimulus 
      of 20 mA lasting 0.2 msec were recorded during maximal voluntary contraction of 
      the mastication muscles before and 30 min after medication. In a randomized and 
      double-blind fashion half of the subjects were given 1200 mg of aspirin in the 
      form of an effervescent solution and the other half were given an identically 
      tasting solution without aspirin. One week later the experiment was repeated with 
      the substances exchanged in crossover fashion. The administration of placebo as 
      well as aspirin caused a highly significant increase in ES1 duration (P less than 
      or equal to 0.001). While aspirin caused a highly significant increase in ES2 
      duration (P less than or equal to 0.001) the taking of placebo showed no 
      significant effect on ES2 duration. In giving aspirin as opposed to the placebo, 
      there was a significant interaction between groups and drug effect on the latency 
      of ES1; whereas in migraine patients and in patients with tension-type headache 
      the latency of ES1 was reduced by administration of aspirin, it was increased in 
      healthy subjects (P less than or equal to 0.05). Neither aspirin nor placebo 
      significantly varied the ES2 latency.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Göbel, Hartmut
AU  - Göbel H
AD  - Department of Neurology, Christian-Albrechts University, KielGermany.
FAU - Ernst, Meike
AU  - Ernst M
FAU - Jeschke, Jörg
AU  - Jeschke J
FAU - Keil, Rainer
AU  - Keil R
FAU - Weigle, Lars
AU  - Weigle L
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Brain Stem/*drug effects
MH  - Electromyography
MH  - Female
MH  - Headache/drug therapy/*physiopathology
MH  - Humans
MH  - Male
MH  - Nociceptors/*drug effects
MH  - Reaction Time
MH  - Reflex/*drug effects
MH  - Temporal Muscle/physiopathology
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
AID - 00006396-199202000-00014 [pii]
AID - 10.1016/0304-3959(92)90058-J [doi]
PST - ppublish
SO  - Pain. 1992 Feb;48(2):187-195. doi: 10.1016/0304-3959(92)90058-J.

PMID- 15351052
OWN - NLM
STAT- MEDLINE
DCOM- 20050209
LR  - 20131121
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 36
IP  - 1
DP  - 2004 Sep 21
TI  - Comparison of fluorimetric, voltammetric and biosensor methods for the 
      determination of total antioxidant capacity of drug products containing 
      acetylsalicylic acid.
PG  - 91-9
AB  - Antioxidant capacity of several drug specialities containing as mean component 
      acetylsalicylic acid were experimentally evaluated using an enzymatic electrode, 
      recently developed by the present authors, based on superoxide dismutase (SOD) 
      enzyme. The precision of this method of analysis was found to be good (for drug 
      samples RSD < or = 5%). The results were also compared with those ones by a 
      traditional spectrofluorimetric method and by two other methods, respectively, 
      based on cyclic and pulsed voltammetry, recently trialled by the present authors.
FAU - Campanella, L
AU  - Campanella L
AD  - Department of Chemistry, University of Rome La Sapienza, Piazzale Aldo Moro, 5 
      00185 Rome, Italy.
FAU - Bonanni, A
AU  - Bonanni A
FAU - Bellantoni, D
AU  - Bellantoni D
FAU - Favero, G
AU  - Favero G
FAU - Tomassetti, M
AU  - Tomassetti M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Antioxidants)
RN  - 0 (Pharmaceutical Preparations)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - EC 1.17.3.2 (Xanthine Oxidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - J Pharm Biomed Anal. 2005 Apr 29;37(5):1185
MH  - Antioxidants/*analysis/standards
MH  - Aspirin/*analysis/standards
MH  - Biosensing Techniques
MH  - Electrochemistry
MH  - Pharmaceutical Preparations/*analysis/standards
MH  - Sensitivity and Specificity
MH  - Spectrometry, Fluorescence
MH  - Superoxide Dismutase/chemistry
MH  - Technology, Pharmaceutical/instrumentation/*methods
MH  - Xanthine Oxidase/chemistry
EDAT- 2004/09/08 05:00
MHDA- 2005/02/11 09:00
CRDT- 2004/09/08 05:00
PHST- 2004/05/04 00:00 [received]
PHST- 2004/06/03 00:00 [accepted]
PHST- 2004/09/08 05:00 [pubmed]
PHST- 2005/02/11 09:00 [medline]
PHST- 2004/09/08 05:00 [entrez]
AID - S0731708504002535 [pii]
AID - 10.1016/j.jpba.2004.06.002 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2004 Sep 21;36(1):91-9. doi: 10.1016/j.jpba.2004.06.002.

PMID- 11229224
OWN - NLM
STAT- MEDLINE
DCOM- 20010419
LR  - 20131121
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 46
IP  - 11
DP  - 1998 Nov
TI  - Combining aspirin with angiotensin converting enzyme inhibitors in heart failure: 
      how safe is it?
PG  - 953-6
AB  - The above discussion on the interaction of aspirin and ACE inhibitors seems to 
      suggest that aspirin in high doses may have adverse interaction with ACE 
      inhibitors in patients with heart failure but the data obtained is not sufficient 
      or conclusive to recommended omission of aspirin in patients with heart failure. 
      This raises a query in the mind of the physician whether to use a combination or 
      not? The role of aspirin in the early period after myocardial infarction is well 
      established so is the role of ACE inhibitors. Hence in patients with myocardial 
      infarction and preserved left ventricular function it would not be wrong to 
      administer combination of ACE inhibitors and aspirin. Albeit at a lower dose. In 
      patients with large myocardial infarction or heart failure, warfarin may be an 
      option but still needs to be documented in large trials. As suggested long term 
      use of aspirin after infarction is still ambiguous and may be harmful in patients 
      with heart failure with its anticedent side effects. But long term benefits of 
      ACE inhibitors in heart failure are well documented. Hence if a choice has to be 
      made whether to discontinue either of the two drugs it would be preferable to 
      stop the aspirin. To answer the issue of use of aspirin in patients with heart 
      failure it would be essential to conduct a double blind randomized trial 
      comparing known anti-thrombotic treatment, aspirin and anti-coagulants on 
      mortality in patients with heart failure, especially caused by coronary artery 
      disease. Such a trial is underway at the present and till the results are 
      available it should be left to clinical judgement of the physician whether to 
      administer aspirin in patients with heart failure after weighing the benefits 
      versus risk.
FAU - Mehta, H
AU  - Mehta H
AD  - Dept. of Cardiology, Sir JJ Group of Hospitals, Mumbai.
FAU - Mahajan, A
AU  - Mahajan A
FAU - Bansal, N
AU  - Bansal N
FAU - Vaidya, S
AU  - Vaidya S
FAU - Pathak, L
AU  - Pathak L
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Therapy, Combination
MH  - Heart Failure/*drug therapy/mortality
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Survival Analysis
RF  - 39
EDAT- 2001/03/07 10:00
MHDA- 2001/04/21 10:01
CRDT- 2001/03/07 10:00
PHST- 2001/03/07 10:00 [pubmed]
PHST- 2001/04/21 10:01 [medline]
PHST- 2001/03/07 10:00 [entrez]
PST - ppublish
SO  - J Assoc Physicians India. 1998 Nov;46(11):953-6.

PMID- 10885481
OWN - NLM
STAT- MEDLINE
DCOM- 20010201
LR  - 20190910
IS  - 0162-0134 (Print)
IS  - 0162-0134 (Linking)
VI  - 80
IP  - 1-2
DP  - 2000 May 30
TI  - Synthesis, characterization and bioactivity of a new VO2+/aspirin complex.
PG  - 169-71
AB  - A new VO2+ complex with salicylic acid acetate (Aspirin) of formula 
      C18H18Cl2O12V2 was synthesized and characterized. Its biological effects upon 
      cell proliferation, differentiation and promotion of tyrosine protein 
      phosphorylation have been tested in two lines of osteoblast-like cells in 
      culture.
FAU - Etcheverry, S B
AU  - Etcheverry SB
AD  - Cátedra de Bioquímica Patológica, Facultad de Ciencias Exactas, Universidad 
      Nacional de La Plata, Argentina. etcheverry@nahuel.biol.unlp.edu.ar
FAU - Williams, P A
AU  - Williams PA
FAU - Barrio, D A
AU  - Barrio DA
FAU - Sálice, V C
AU  - Sálice VC
FAU - Ferrer, E G
AU  - Ferrer EG
FAU - Cortizo, A M
AU  - Cortizo AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Inorg Biochem
JT  - Journal of inorganic biochemistry
JID - 7905788
RN  - 21820-51-9 (Phosphotyrosine)
RN  - 3WHH0066W5 (Vanadates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*chemical synthesis/pharmacology
MH  - Blotting, Western
MH  - Bone and Bones/metabolism
MH  - Cell Differentiation/drug effects
MH  - Cell Division/drug effects
MH  - Cells, Cultured
MH  - Humans
MH  - Osteoblasts/drug effects
MH  - Phosphorylation
MH  - Phosphotyrosine/metabolism
MH  - Spectrophotometry, Infrared
MH  - Vanadates/*chemical synthesis/pharmacology
EDAT- 2000/07/08 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/07/08 11:00
PHST- 2000/07/08 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/07/08 11:00 [entrez]
AID - S0162-0134(00)00026-X [pii]
AID - 10.1016/s0162-0134(00)00026-x [doi]
PST - ppublish
SO  - J Inorg Biochem. 2000 May 30;80(1-2):169-71. doi: 10.1016/s0162-0134(00)00026-x.

PMID- 2009936
OWN - NLM
STAT- MEDLINE
DCOM- 19910503
LR  - 20190629
IS  - 0014-4754 (Print)
IS  - 0014-4754 (Linking)
VI  - 47
IP  - 3
DP  - 1991 Mar 15
TI  - Aspirin-like drugs may block pain independently of prostaglandin synthesis 
      inhibition.
PG  - 257-61
AB  - Using flurbiprofen, a chiral anti-inflammatory and analgesic 2-arylpropionic acid 
      derivative, the enantiomers of which are not converted to each other (less than 
      5%) in rats or man, we obtained evidence that prostaglandin synthesis inhibition 
      is primarily mediating the anti-inflammatory activity but prostaglandin synthesis 
      independent mechanisms contribute to the analgesic effects. Thus, the S-form 
      inhibited prostaglandin synthesis, inflammation and nociception in rats. The 
      R-form had much less effect on prostaglandin synthesis and did not affect 
      inflammation. It did, however, block nociception in rats almost as potently as 
      the S-form. S-flurbiprofen, in contrast to the R-form, was clearly ulcerogenic in 
      the gastrointestinal mucosa. These results indicate additional molecular 
      mechanisms of analgesia and suggest the use of R-arylpropionic acids as 
      analgesics.
FAU - Brune, K
AU  - Brune K
AD  - Department of Pharmacology and Toxicology, University of Erlangen-Nürnberg, 
      Federal Republic of Germany.
FAU - Beck, W S
AU  - Beck WS
FAU - Geisslinger, G
AU  - Geisslinger G
FAU - Menzel-Soglowek, S
AU  - Menzel-Soglowek S
FAU - Peskar, B M
AU  - Peskar BM
FAU - Peskar, B A
AU  - Peskar BA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Experientia
JT  - Experientia
JID - 0376547
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Digestive System/drug effects
MH  - Flurbiprofen/adverse effects/chemistry/pharmacology/therapeutic use
MH  - Male
MH  - Pain/*drug therapy
MH  - Prostaglandin Antagonists/*therapeutic use
MH  - Prostaglandins/*biosynthesis
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stereoisomerism
EDAT- 1991/03/15 00:00
MHDA- 1991/03/15 00:01
CRDT- 1991/03/15 00:00
PHST- 1991/03/15 00:00 [pubmed]
PHST- 1991/03/15 00:01 [medline]
PHST- 1991/03/15 00:00 [entrez]
AID - 10.1007/BF01958153 [doi]
PST - ppublish
SO  - Experientia. 1991 Mar 15;47(3):257-61. doi: 10.1007/BF01958153.

PMID- 6511062
OWN - NLM
STAT- MEDLINE
DCOM- 19850204
LR  - 20131121
IS  - 0019-5499 (Print)
IS  - 0019-5499 (Linking)
VI  - 28
IP  - 2
DP  - 1984 Apr-Jun
TI  - Status of platelet functions in volunteers of various blood groups: effect of 
      aspirin.
PG  - 137-40
AB  - Platelet functions (platelet aggregation and adhesiveness) were studied in 
      volunteers of different blood groups. The platelet aggregation time was found to 
      be significantly (P less than 0.01) more in blood group O as compared A, B and AB 
      blood groups. Similarly, platelet adhesive index was higher in A, B and AB blood 
      groups when compared to that of blood group O. The administration of a single 
      dose of aspirin (4 mg/kg, po) increased the platelet aggregation time and reduced 
      the platelet adhesive index in all the blood groups.
FAU - Sudhir, S
AU  - Sudhir S
FAU - Gupta, L C
AU  - Gupta LC
FAU - Singh, J
AU  - Singh J
FAU - Garg, K N
AU  - Garg KN
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Physiol Pharmacol
JT  - Indian journal of physiology and pharmacology
JID - 0374707
RN  - 0 (Blood Group Antigens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - *Blood Group Antigens
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/*drug effects
EDAT- 1984/04/01 00:00
MHDA- 1984/04/01 00:01
CRDT- 1984/04/01 00:00
PHST- 1984/04/01 00:00 [pubmed]
PHST- 1984/04/01 00:01 [medline]
PHST- 1984/04/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Physiol Pharmacol. 1984 Apr-Jun;28(2):137-40.

PMID- 7420289
OWN - NLM
STAT- MEDLINE
DCOM- 19801218
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 69
IP  - 10
DP  - 1980 Oct
TI  - Simultaneous determination of aspirin and salicylic acid in bulk aspirin and in 
      plain, buffered, and enteric-coated tablets by high-pressure liquid 
      chromatography with UV and fluorescence detectors.
PG  - 1188-91
AB  - A quantitative high-pressure liquid chromatographic method that uses a 
      reversed-phase column coupled to UV and fluorescence detectors was developed to 
      determine aspirin and salicylic acid in bulk aspirin and in plain, buffered, and 
      enteric-coated tablets. The aspirin was dissolved, filtered, and injected into 
      the chromatograph. The UV absorbance of aspirin was determined at 254 nm, and the 
      fluorescence of salicylic acid was measured at 425 nm. Excipients and impurities 
      did not interfere. Recoveries of 100% were obtained for aspirin and salicylic 
      acid from simulated tablet formulations. Results obtained by the USP XIX 
      procedure and the proposed method were compared. The coefficient of variation for 
      the aspirin analysis was 0.59%; for salicylic acid, it was 1.69%. The rate of 
      hydrolysis of aspirin to salicylic acid in the solvents used was < 0.05%/hr.
FAU - Kirchhoefer, R D
AU  - Kirchhoefer RD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid
MH  - Salicylates/*analysis
MH  - Spectrometry, Fluorescence
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets
MH  - Tablets, Enteric-Coated
EDAT- 1980/10/01 00:00
MHDA- 1980/10/01 00:01
CRDT- 1980/10/01 00:00
PHST- 1980/10/01 00:00 [pubmed]
PHST- 1980/10/01 00:01 [medline]
PHST- 1980/10/01 00:00 [entrez]
AID - S0022-3549(15)43402-1 [pii]
AID - 10.1002/jps.2600691018 [doi]
PST - ppublish
SO  - J Pharm Sci. 1980 Oct;69(10):1188-91. doi: 10.1002/jps.2600691018.

PMID- 18635333
OWN - NLM
STAT- MEDLINE
DCOM- 20090226
LR  - 20131121
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 48
IP  - 3
DP  - 2008 Nov 4
TI  - Polypill for the treatment of cardiovascular diseases part 2. LC-MS/TOF 
      characterization of interaction/degradation products of atenolol/lisinopril and 
      aspirin, and mechanisms of formation thereof.
PG  - 619-28
LID - 10.1016/j.jpba.2008.06.003 [doi]
AB  - A polypill for cardiovascular diseases (CVD) is under development. It is proposed 
      to contain a combination of antithrombotic agent (aspirin), low-dose blood 
      pressure lowering agents, i.e., angiotensin-converting enzyme inhibitor 
      (lisinopril), one among a beta-blocker (atenolol) or diuretic 
      (hydrochlorothiazide), and a statin (simvastatin/atorvastatin/pravatsatin, etc.). 
      Due to the presence of multiple drugs in the same formulation, there is a strong 
      likelihood of interaction among the drugs and/or their products. In a previous 
      study, we observed formation of a number of interaction/degradation products from 
      atenolol and lisinopril in the presence of aspirin. Accordingly, the purpose of 
      this study was to characterize the resolved products using high resolution mass 
      spectrometric and fragmentation analyses using a LC-MS/TOF system. Initially, 
      studies were carried out on the drugs (atenolol, lisinopril and aspirin) to 
      establish their complete fragmentation pattern. These studies were then extended 
      to degraded samples to postulate the structures of interaction/degradation 
      products. The characterized structures were justified through mechanistic 
      explanations.
FAU - Kumar, Vijay
AU  - Kumar V
AD  - Department of Pharmaceutical Analysis, National Institute of Pharmaceutical 
      Education and Research (NIPER), Sector 67, S.A.S. Nagar 160062, Punjab, India.
FAU - Malik, Satish
AU  - Malik S
FAU - Singh, Saranjit
AU  - Singh S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080611
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 50VV3VW0TI (Atenolol)
RN  - E7199S1YWR (Lisinopril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/analysis
MH  - Angiotensin-Converting Enzyme Inhibitors/analysis
MH  - Aspirin/analysis/chemistry
MH  - Atenolol/analysis/chemistry
MH  - Cardiovascular Agents/*analysis/chemistry
MH  - Chromatography, Liquid/*methods
MH  - *Drug Combinations
MH  - Drug Interactions
MH  - Lisinopril/analysis/chemistry
MH  - Mass Spectrometry/*methods
MH  - Molecular Structure
MH  - Molecular Weight
MH  - Platelet Aggregation Inhibitors/analysis
EDAT- 2008/07/19 09:00
MHDA- 2009/02/27 09:00
CRDT- 2008/07/19 09:00
PHST- 2008/03/31 00:00 [received]
PHST- 2008/06/03 00:00 [revised]
PHST- 2008/06/04 00:00 [accepted]
PHST- 2008/07/19 09:00 [pubmed]
PHST- 2009/02/27 09:00 [medline]
PHST- 2008/07/19 09:00 [entrez]
AID - S0731-7085(08)00348-8 [pii]
AID - 10.1016/j.jpba.2008.06.003 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2008 Nov 4;48(3):619-28. doi: 10.1016/j.jpba.2008.06.003. 
      Epub 2008 Jun 11.

PMID- 29145278
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20220321
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 46
DP  - 2017 Nov
TI  - Safety of continuing aspirin therapy during spinal surgery: A systematic review 
      and meta-analysis.
PG  - e8603
LID - 10.1097/MD.0000000000008603 [doi]
LID - e8603
AB  - BACKGROUND: Questions whether to continue or discontinue aspirin administration 
      in the perioperative period of spinal surgery has not been systematically 
      evaluated. OBJECTIVE: The present systematic review is carried out to assess the 
      impact of continuing aspirin administration on the bleeding and cardiovascular 
      events in perispinal surgery period. METHODS: Studies were retrieved through 
      MEDLINE, EMBASE, and Springer Link Databases (search terms, aspirin, continue or 
      discontinue, and spinal fusion), bibliographies of the articles retrieved, and 
      the authors' reference files. We included studies that enrolled patients who 
      underwent spinal surgery who were anticoagulated with aspirin alone and that 
      reported bleeding or cardiovascular events as an outcome. Study quality was 
      assessed using a validated form. 95% confidence interval (95% CI) was pooled to 
      give summary estimates of bleeding and cardiovascular risk. RESULTS: We 
      identified 4 studies assessing bleeding risk associated with aspirin continuation 
      or cardiovascular risk with aspirin discontinuation during spinal surgery. The 
      continuation of aspirin will not increase the risk of blood loss during the 
      spinal surgery (95% CI, -111.72 to -0.59; P = .05). Also, there was no observed 
      increase in the operative time (95% CI, -33.29 to -3.89; P = .01) and 
      postoperative blood transfusion (95% CI, 0.00-0.27; P = .05). But as for the 
      cardiovascular risk without aspirin continuation and mean hospital length of stay 
      with aspirin continuation, we did not get enough samples to make an accurate 
      decision about their relations with aspirin. CONCLUSION: Patients undergoing 
      spinal surgery with continued aspirin administration do not have an increased 
      risk for bleeding. In addition, there is no observed increase in the operation 
      time and postoperative blood transfusion.
FAU - Zhang, Chenggui
AU  - Zhang C
AD  - aDepartment of Spine, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan, Shandong Province bAnatomical Institute of Minimally Invasive 
      Surgery, Southern Medical University, Guangzhou, China.
FAU - Wang, Guodong
AU  - Wang G
FAU - Liu, Xiaoyang
AU  - Liu X
FAU - Li, Yang
AU  - Li Y
FAU - Sun, Jianmin
AU  - Sun J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Loss, Surgical
MH  - Blood Transfusion/statistics & numerical data
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Hemorrhage/chemically induced
MH  - Risk Factors
MH  - Spine/*surgery
PMC - PMC5704823
COIS- There is no interest of conflict among the authors.
EDAT- 2017/11/18 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/18 06:00
PHST- 2017/11/18 06:00 [entrez]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 00005792-201711170-00042 [pii]
AID - MD-D-17-05692 [pii]
AID - 10.1097/MD.0000000000008603 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Nov;96(46):e8603. doi: 10.1097/MD.0000000000008603.

PMID- 12098767
OWN - NLM
STAT- MEDLINE
DCOM- 20020827
LR  - 20211203
IS  - 0582-9879 (Print)
IS  - 0582-9879 (Linking)
VI  - 34
IP  - 4
DP  - 2002 Jul
TI  - PEG and DBBF modified porcine hemoglobin and their oxygen-carrying capacity.
PG  - 452-6
AB  - Modifications of proteins with polyethylene glycol (PEG) have been proven to 
      enlarge molecule size of proteins, to prolong their retention time in the 
      circulation as well as blunt immune or allergic reactions. Hemoglobin 
      cross-linked with small molecular modifiers turns out to be more stable and to 
      have better oxygen carrying capacity. In the present study, four derivatives of 
      PEG with different activation groups, and several PEGs with different molecular 
      weights were covalently bound to porcine hemoglobin (pHb). PEG-pHbs exhibited a 
      variety of differences in their properties depending on the molecular weights of 
      the used PEGs, the amounts of bound PEGs and the presence or absence of 
      allosteric cofactors. The optimal modification conditions for bis (3, 
      5-dibromosalicyl) fumarate (DBBF) as well as the physical features and oxygen 
      carrying capacity of DBBF-modified pHb were evaluated. Furthermore, both PEG and 
      DBBF were used simultaneously to modify pHb. The results indicate that the pHbs 
      modified with PEG and DBBF have more stable tetrameric conformations with a 
      molecular weight of 107 kD. Their oxygen half-saturation pressure (P(50)) is 
      around 3.33 kPa which approximates the physiological P(50) of human red blood 
      cells.
FAU - Hong, Min
AU  - Hong M
AD  - Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological 
      Sciences, the Chinese Academy of Sciences, Shanghai 200031, China. 
      zhongyi@sunm.shcnc.ac.cn
FAU - Cai, Jin
AU  - Cai J
FAU - Meng, Wen-Fang
AU  - Meng WF
FAU - Li, Shi-Yun
AU  - Li SY
FAU - Yuan, Zhong-Yi
AU  - Yuan ZY
LA  - eng
PT  - Journal Article
PL  - China
TA  - Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)
JT  - Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica
JID - 20730160R
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (PHB protein, human)
RN  - 0 (Prohibitins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*chemistry
MH  - Cross-Linking Reagents/chemistry
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Hemoglobins/chemistry/*metabolism
MH  - Oxygen/*blood
MH  - Polyethylene Glycols/*chemistry
MH  - Prohibitins
MH  - Swine
EDAT- 2002/07/06 10:00
MHDA- 2002/08/28 10:01
CRDT- 2002/07/06 10:00
PHST- 2002/07/06 10:00 [pubmed]
PHST- 2002/08/28 10:01 [medline]
PHST- 2002/07/06 10:00 [entrez]
PST - ppublish
SO  - Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002 Jul;34(4):452-6.

PMID- 1019292
OWN - NLM
STAT- MEDLINE
DCOM- 19770415
LR  - 20131121
IS  - 0033-4979 (Print)
IS  - 0033-4979 (Linking)
VI  - 12
IP  - 1
DP  - 1976 Mar
TI  - [A new standardized method for determination of the bleeding time].
PG  - 79-83
AB  - The standardized bleeding time is considered a valuable measure of the platelet 
      role in haemostasis. It is particularly useful for the evaluation of drugs that 
      affect platelet functions. Measurements of the bleeding time were performed using 
      a new system which was designed following the instructions of Mielke and 
      co-workers with some variations of the described method. The standardized 
      bleeding time proved to be a high reproducible and sensitive technique.
FAU - Rubegni, M
AU  - Rubegni M
FAU - De Mauro, G
AU  - De Mauro G
FAU - Provvedi, D
AU  - Provvedi D
FAU - Bandinelli, C
AU  - Bandinelli C
FAU - Bellini, P G
AU  - Bellini PG
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Un nuovo metodo standardizzato per la determinazione del tempo di sanguinamento.
PL  - Italy
TA  - Quad Sclavo Diagn
JT  - Quaderni Sclavo di diagnostica clinica e di laboratorio
JID - 0040616
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Coagulation Tests/*methods
MH  - Blood Platelets/physiology
EDAT- 1976/03/01 00:00
MHDA- 1976/03/01 00:01
CRDT- 1976/03/01 00:00
PHST- 1976/03/01 00:00 [pubmed]
PHST- 1976/03/01 00:01 [medline]
PHST- 1976/03/01 00:00 [entrez]
PST - ppublish
SO  - Quad Sclavo Diagn. 1976 Mar;12(1):79-83.

PMID- 2214644
OWN - NLM
STAT- MEDLINE
DCOM- 19901119
LR  - 20131121
IS  - 0023-2149 (Print)
IS  - 0023-2149 (Linking)
VI  - 68
IP  - 6
DP  - 1990 Jun
TI  - [Bronchoconstrictive and bronchodilating effects of acetylsalicylic acid in 
      patients with bronchial asthma].
PG  - 74-7
AB  - An aspirin test has been performed in 100 asthma patients. The response of the 
      bronchi appeared contradictory: aspirin asthma on the one hand, and 
      bronchodilatation on the other occurred in 31 and 28 patients, respectively; 41 
      patients appeared nonresponders. Maximum effect of the drug was noted in the 
      small bronchi. Desensitization to aspirin and hemosorption reduced asthma 
      patients sensitivity to nonsteroid antiinflammatory drugs.
FAU - Treskunov, V K
AU  - Treskunov VK
FAU - Didkovskiĭ, N A
AU  - Didkovskiĭ NA
FAU - Zakharzhevskaia, T V
AU  - Zakharzhevskaia TV
FAU - Evseev, N G
AU  - Evseev NG
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Bronkhokonstriktornoe i bronkhodilatiruiushchee deĭstvie atsetil- salitsilovoĭ 
      kisloty u bol'nykh bronkhial'noĭ astmoĭ.
PL  - Russia (Federation)
TA  - Klin Med (Mosk)
JT  - Klinicheskaia meditsina
JID - 2985204R
RN  - 0 (Bronchoconstrictor Agents)
RN  - 0 (Bronchodilator Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Asthma/*drug therapy
MH  - Bronchi/*drug effects/immunology
MH  - Bronchial Spasm/*chemically induced
MH  - Bronchoconstrictor Agents/*therapeutic use
MH  - Bronchodilator Agents
MH  - Drug Hypersensitivity/*complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
PST - ppublish
SO  - Klin Med (Mosk). 1990 Jun;68(6):74-7.

PMID- 27374042
OWN - NLM
STAT- MEDLINE
DCOM- 20181025
LR  - 20190107
IS  - 1122-0643 (Print)
IS  - 1122-0643 (Linking)
VI  - 84
IP  - 1-2
DP  - 2016 Jun 22
TI  - Aspirin use for primary prevention in elderly patients.
PG  - 728
LID - 10.4081/monaldi.2015.728 [doi]
AB  - The net clinical benefit of aspirin in primary prevention is uncertain as the 
      reduction in occlusive events needs to be balanced against the increase in 
      gastro-intestinal and cerebral bleedings. The meta-analysis of ATT (Anti 
      Thrombotic Trialists) Collaboration in 2009 showed that aspirin therapy in 
      primary prevention was associated with 12% reduction in cardio-vascular events, 
      due mainly to a reduction in non-fatal myocardial infarction (0.18% vs 0.23% per 
      year, p<0.0001). However, the benefit in term of coronary events was almost 
      balanced by the increase in major bleedings. The balance between potential 
      benefit and harm of aspirin differs in each person and appears to be favorable in 
      subjects at higher cardio-vascular risk. Older people have increased risk of 
      hemorrhage as well as increased risk of heart attack and stroke. As a 
      consequence, it is important consider both likelihoods of benefits as well as 
      harm within the lifespan and functioning of the person. The older people who most 
      likely benefit from aspirin in primary prevention are those at higher 
      cardio-vascular risk, with preserved functional abilities, low comorbidity, low 
      risk of bleeding and a prolonged life expectancy.
FAU - Terrosu, Pierfranco
AU  - Terrosu P
AD  - Ospedale Civile SS. Annunziata. pterrosu@hotmail.com.
LA  - eng
LA  - ita
PT  - Journal Article
PT  - Review
DEP - 20160622
PL  - Italy
TA  - Monaldi Arch Chest Dis
JT  - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
JID - 9307314
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention/*methods
MH  - Stroke/prevention & control
EDAT- 2016/07/05 06:00
MHDA- 2018/10/26 06:00
CRDT- 2016/07/05 06:00
PHST- 2016/05/24 00:00 [received]
PHST- 2016/05/24 00:00 [accepted]
PHST- 2016/07/05 06:00 [entrez]
PHST- 2016/07/05 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
AID - 10.4081/monaldi.2015.728 [doi]
PST - epublish
SO  - Monaldi Arch Chest Dis. 2016 Jun 22;84(1-2):728. doi: 10.4081/monaldi.2015.728.

PMID- 15043117
OWN - NLM
STAT- MEDLINE
DCOM- 20040505
LR  - 20190605
IS  - 0009-921X (Print)
IS  - 0009-921X (Linking)
IP  - 418
DP  - 2004 Jan
TI  - Aspirin therapy and bleeding during proximal femoral fracture surgery.
PG  - 205-8
AB  - To assess the effect of daily low-dose aspirin therapy on perioperative bleeding 
      of patients operated on for proximal femoral fracture, we did a prospective 
      case-control study. During 14 months, we followed up 104 patients, 39 of whom 
      were taking aspirin before the injury. The bleeding was estimated by the number 
      of blood units needed perioperatively, the change in hemoglobin values, and 
      followup on complications and drain volume. The aspirin-treated group received an 
      average of 0.5 units of blood more than the control group, postoperatively. This 
      finding was statistically significant. The groups did not differ significantly in 
      any other bleeding parameter. No major bleeding occurred in the patients. It is 
      safe to do surgery for a proximal femoral fracture in patients who are taking 
      aspirin.
FAU - Anekstein, Yoram
AU  - Anekstein Y
AD  - Department of Orthopaedic Surgery, Assaf-Harofe Medical Center, Zerifin, Israel. 
      nuritan@internet-zahav.net
FAU - Tamir, Eran
AU  - Tamir E
FAU - Halperin, Nahum
AU  - Halperin N
FAU - Mirovsky, Yigal
AU  - Mirovsky Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - *Blood Loss, Surgical
MH  - Case-Control Studies
MH  - Femoral Fractures/*surgery
MH  - Humans
MH  - Intraoperative Complications/*chemically induced
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Prospective Studies
EDAT- 2004/03/27 05:00
MHDA- 2004/05/07 05:00
CRDT- 2004/03/27 05:00
PHST- 2004/03/27 05:00 [pubmed]
PHST- 2004/05/07 05:00 [medline]
PHST- 2004/03/27 05:00 [entrez]
AID - 10.1097/00003086-200401000-00034 [doi]
PST - ppublish
SO  - Clin Orthop Relat Res. 2004 Jan;(418):205-8. doi: 
      10.1097/00003086-200401000-00034.

PMID- 1532629
OWN - NLM
STAT- MEDLINE
DCOM- 19920506
LR  - 20131121
IS  - 0733-8619 (Print)
IS  - 0733-8619 (Linking)
VI  - 10
IP  - 1
DP  - 1992 Feb
TI  - Aspirin: dose and indications in modern stroke prevention.
PG  - 193-207; discussion 208
AB  - Until recently, a gap existed between the rapidly advancing knowledge about the 
      pharmacology of aspirin and the management of patients who are threatened by 
      stroke. In doses as low as 20 to 40 mg per day, aspirin can completely suppress 
      the production of the aggregant agent thromboxane A2. The clinical evidence, 
      however, which shows a reduction of 20% to 25% in the incidence of vascular 
      death, stroke, or myocardial infarction, is based on trials with 300 to 1300 mg 
      of aspirin per day. The clinicians are catching up now that recent trials have 
      demonstrated similar effects with 30 or 75 mg of aspirin per day, and with fewer 
      side effects. The hope that the protective effects of these low doses would be 
      even greater, thanks to the sparing of the prostaglandin synthesis in endothelial 
      tissue, has not yet materialized.
FAU - van Gijn, J
AU  - van Gijn J
AD  - University Department of Neurology, University Hospital, Utrecht, The 
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Neurol Clin
JT  - Neurologic clinics
JID - 8219232
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cerebrovascular Disorders/etiology/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Ischemic Attack, Transient/etiology/prevention & control
MH  - Meta-Analysis as Topic
MH  - Platelet Aggregation/drug effects
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
PST - ppublish
SO  - Neurol Clin. 1992 Feb;10(1):193-207; discussion 208.

PMID- 3529884
OWN - NLM
STAT- MEDLINE
DCOM- 19860926
LR  - 20190824
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 18
IP  - 3-4
DP  - 1986 Jun
TI  - A study to determine the clinical relevance of the pharmacokinetic interaction 
      between aspirin and diclofenac.
PG  - 447-9
AB  - Interaction studies in the rat and healthy human volunteers have shown that 
      protein binding of diclofenac is reduced by the addition of salicylic acid 
      causing an increased free drug level of diclofenac. The diclofenac area under 
      curve (AUC) is also reduced by approximately one-third in the presence of 
      salicylate. We have performed a crossover comparison of soluble aspirin, 
      diclofenac and the two drugs in combination in patients with rheumatoid arthritis 
      to determine whether this had clinical relevance. 36 patients entered the study. 
      There was a high dropout rate on aspirin alone but analysis of completors (22 
      patients) showed diclofenac either alone or in combination to be superior to 
      aspirin alone on two of the five clinical parameters measured. There was no 
      significant difference between disclofenac and aspirin + diclofenac. We thus 
      found no clinical manifestations of the pharmacokinetic interaction.
FAU - Bird, H A
AU  - Bird HA
FAU - Hill, J
AU  - Hill J
FAU - Leatham, P
AU  - Leatham P
FAU - Wright, V
AU  - Wright V
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Diclofenac/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1986/06/01 00:00
MHDA- 1986/06/01 00:01
CRDT- 1986/06/01 00:00
PHST- 1986/06/01 00:00 [pubmed]
PHST- 1986/06/01 00:01 [medline]
PHST- 1986/06/01 00:00 [entrez]
AID - 10.1007/BF01965010 [doi]
PST - ppublish
SO  - Agents Actions. 1986 Jun;18(3-4):447-9. doi: 10.1007/BF01965010.

PMID- 16285234
OWN - NLM
STAT- MEDLINE
DCOM- 20051213
LR  - 20131121
IS  - 1764-1489 (Print)
IS  - 1764-1489 (Linking)
VI  - 37
IP  - 7
DP  - 2005 Sep
TI  - Aspirin and non steroidal anti-inflammatory drugs hypersensitivity review 
      (2002-2004).
PG  - 279-82
AB  - According to physician, Aspirin and NSAIDS hypersensitivity are causing three 
      major problems: how to make the diagnosis? Which treatment are to he given to 
      these patients? What kind of anti-inflammatory drugs are to be prescribed? For 
      these last three years, several articles regarding these matters were being 
      published.
FAU - Touraine, F
AU  - Touraine F
AD  - Service de Pathologie Respiratoire et d'Allergologie, CHU Limoges.
FAU - Moldovan, D
AU  - Moldovan D
FAU - Touraine, P
AU  - Touraine P
FAU - Chenot, P
AU  - Chenot P
FAU - Bonnaud, F
AU  - Bonnaud F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Eur Ann Allergy Clin Immunol
JT  - European annals of allergy and clinical immunology
JID - 101466614
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/immunology
MH  - Aspirin/*adverse effects/immunology
MH  - Drug Hypersensitivity/*diagnosis/physiopathology
MH  - Humans
RF  - 27
EDAT- 2005/11/16 09:00
MHDA- 2005/12/15 09:00
CRDT- 2005/11/16 09:00
PHST- 2005/11/16 09:00 [pubmed]
PHST- 2005/12/15 09:00 [medline]
PHST- 2005/11/16 09:00 [entrez]
PST - ppublish
SO  - Eur Ann Allergy Clin Immunol. 2005 Sep;37(7):279-82.

PMID- 1953991
OWN - NLM
STAT- MEDLINE
DCOM- 19911230
LR  - 20131121
IS  - 0006-5250 (Print)
IS  - 0006-5250 (Linking)
VI  - 28
IP  - 5
DP  - 1991 Sep
TI  - [Pharmacokinetic interactions between alcohol and acetylsalicylic acid].
PG  - 273-8
AB  - Twelve healthy test subjects ingested 0.75 g alcohol/kg body weight in 500 ml 
      carbon dioxide-free mineral water and 1,000 mg powdered acetylsalicylic acid (on 
      average, 13.1 mg/kg body weight) on an empty stomach at 9 a.m. to test the 
      interaction between alcohol and acetylsalicylic acid. Whereas acetylsalicylic 
      acid does not have any effect on the kinetics of alcohol, alcohol effects the 
      metabolism of acetylsalicylic acid. However, an additional restriction of 
      psychophysical performance was not observed.
FAU - Locher, K B
AU  - Locher KB
AD  - Institut für Gerichtliche Medizin, Universität Tübingen.
FAU - Mallach, H J
AU  - Mallach HJ
FAU - Moosmayer, A
AU  - Moosmayer A
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Pharmakokinetische Wechselwirkungen zwischen Alkohol und Acetylsalicylsäure.
PL  - Germany
TA  - Blutalkohol
JT  - Blutalkohol
JID - 0372531
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alcohol Drinking/*blood/psychology
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Ethanol/*pharmacokinetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolic Clearance Rate/physiology
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
PST - ppublish
SO  - Blutalkohol. 1991 Sep;28(5):273-8.

PMID- 1461292
OWN - NLM
STAT- MEDLINE
DCOM- 19930112
LR  - 20151119
IS  - 0028-2162 (Print)
IS  - 0028-2162 (Linking)
VI  - 136
IP  - 46
DP  - 1992 Nov 14
TI  - [How much information is retained by participants in clinical trials?].
PG  - 2272-6
AB  - OBJECTIVE: To assess which information participants of the Dutch TIA trial could 
      remember from the informed consent procedure. DESIGN: Descriptive investigation. 
      SETTING: The University Hospital Utrecht and the University Medical Centre 
      Amsterdam. METHODS: One hundred of the 308 patients from 2 of the 63 
      participating clinical centres (the University Hospital Utrecht and the 
      University Medical Centre Amsterdam), were selected at random for telephone 
      interviews. Nineteen were not interviewed, most of them because they did not have 
      access to a telephone. By a weighted score based on the replies the influence of 
      some baseline variables was explored. The information sheet that patients had 
      received was analysed with the readability tests of Flesh and Fry. RESULTS: 
      Eighty-six percent of all patients were aware of the correct diagnosis. The name 
      and action of the trial drug Ascal (a brand of acetylsalicylic acid) were 
      retained better than those of atenolol. The nature of the disease and therapy 
      were better known than the design of the trial. Of the baseline variables 
      explored only the level of education was significantly related to what patients 
      remembered about the trial. The readability of the information sheet required 
      more education than was intended. CONCLUSION: Although we did not study a random 
      sample the conclusion seems warranted that the level of information was not 
      optimal in this trial.
FAU - Oddens, B J
AU  - Oddens BJ
AD  - Rijksuniversiteit, vakgroep Neurologie, Utrecht.
FAU - Algra, A
AU  - Algra A
FAU - van Gijn, J
AU  - van Gijn J
LA  - dut
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Hoe goed zijn deelnemers aan een klinisch onderzoek geïnformeerd?
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - *Informed Consent
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Mental Recall
MH  - Middle Aged
MH  - Surveys and Questionnaires
EDAT- 1992/11/14 00:00
MHDA- 1992/11/14 00:01
CRDT- 1992/11/14 00:00
PHST- 1992/11/14 00:00 [pubmed]
PHST- 1992/11/14 00:01 [medline]
PHST- 1992/11/14 00:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 1992 Nov 14;136(46):2272-6.

PMID- 3313023
OWN - NLM
STAT- MEDLINE
DCOM- 19871214
LR  - 20140728
IS  - 0026-9298 (Print)
IS  - 0026-9298 (Linking)
VI  - 135
IP  - 9
DP  - 1987 Sep
TI  - [Prevention of migraine with flunarizine and acetylsalicylic acid. A double-blind 
      study].
PG  - 646-9
AB  - 30 children between 7 and 17 years suffering from at least 2 attacks/month of 
      common or classical migraine since more than 1 year were studied. After clinical 
      exclusion of symptomatic headache 4 weeks were documented by means of a migraine 
      diary. Prophylaxis with Calcium entry blocker Flunarizine (Sibelium) or 
      Thromboxane A inhibitor Acetylsalicylic acid (ASS) was carried out in a double 
      blind design for 3 months. Medication was given as one dosage in the evening: 2-5 
      mg/kg KG ASS or 5-10 mg Flunarizine. Documented attack frequency and duration 
      were controlled at monthly physical examinations. Final results showed no 
      differences in significant reduction of attack frequency or symptoms between both 
      different therapeutic principals. 72.4% (ASS 73.3%; Flunarizine 71.4%) of 
      patients were attack-free or had at least a 50% reduction. Migraine frequency of 
      initially 7-8 was reduced to 1-2 attacks/month. Duration remained constant in 
      both groups (1-3 h). Side effects were slight body weight gain or abdominal pain 
      after intake, prophylaxis had not to be interrupted therefore. Longtime prognosis 
      is not yet possible because the time of observation is too short so far. 
      CONCLUSION: Both substances are definitely useful and have few side effects in 
      childhood migraine. If the response to one is insufficient the other substance 
      should be tried.
FAU - Pothmann, R
AU  - Pothmann R
AD  - Kinderklinik, Wuppertal.
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Migräneprophylaxe mit Flunarizin und Azetylsalizylsäure. Eine Doppelblindstudie.
PL  - Germany
TA  - Monatsschr Kinderheilkd
JT  - Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur 
      Kinderheilkunde
JID - 8206462
RN  - R16CO5Y76E (Aspirin)
RN  - R7PLA2DM0J (Flunarizine)
SB  - IM
MH  - Adolescent
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Flunarizine/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Migraine Disorders/*prevention & control
EDAT- 1987/09/01 00:00
MHDA- 1987/09/01 00:01
CRDT- 1987/09/01 00:00
PHST- 1987/09/01 00:00 [pubmed]
PHST- 1987/09/01 00:01 [medline]
PHST- 1987/09/01 00:00 [entrez]
PST - ppublish
SO  - Monatsschr Kinderheilkd. 1987 Sep;135(9):646-9.

PMID- 34495376
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220401
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Print)
IS  - 0012-186X (Linking)
VI  - 64
IP  - 12
DP  - 2021 Dec
TI  - Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes 
      and high cardiovascular risk: a randomised trial to assess effects on endothelial 
      function, platelet activation and vascular biomarkers.
PG  - 2701-2712
LID - 10.1007/s00125-021-05562-9 [doi]
AB  - AIMS/HYPOTHESIS: Individuals with type 2 diabetes mellitus and subclinical 
      inflammation have stimulated coagulation, activated platelets and endothelial 
      dysfunction. Recent studies with the direct factor Xa inhibitor rivaroxaban in 
      combination with low-dose aspirin demonstrated a significant reduction of major 
      cardiovascular events, especially in individuals with type 2 diabetes and proven 
      cardiovascular disease. Therefore, we asked the question of whether treatment 
      with rivaroxaban could influence endothelial function, arterial stiffness and 
      platelet activation. METHODS: We conducted a multi-centre, prospective, 
      randomised, open-label trial in 179 participants with type 2 diabetes (duration 
      2-20 years), subclinical inflammation (high-sensitivity C-reactive protein 
      2-10 mg/l) and at least two traits of the metabolic syndrome to compare the 
      effects of the direct factor Xa inhibitor rivaroxaban (5 mg twice daily) vs 
      aspirin (100 mg every day) on endothelial function (assessed by forearm occlusion 
      plethysmography), skin blood flow (assessed by laser-Doppler fluxmetry), arterial 
      stiffness (assessed by pulse wave velocity) and serum biomarkers of endothelial 
      function and inflammation. Furthermore, we investigated phosphorylation of 
      vasodilator-stimulated phosphoprotein (VASP) in platelets, the concentration of 
      platelet-derived microparticles (PMPs) and the effects of isolated PMPs on HUVEC 
      proliferation in vitro. RESULTS: Rivaroxaban treatment for 20 weeks (n = 89) 
      resulted in a significant improvement of post-ischaemic forearm blood flow 
      (3.6 ± 4.7 vs 1.0 ± 5.2 ml/100 ml, p = 0.004), a numerically increased skin blood 
      flow and reduced soluble P-Selectin plasma level vs aspirin. We did not find 
      significant differences of arterial stiffness or further biomarkers. Neither 
      rivaroxaban nor aspirin influenced VASP phosphorylation of platelets. The number 
      of PMPs increased significantly with both rivaroxaban (365.2 ± 372.1 vs 
      237.4 ± 157.1 μl(-1), p = 0.005) and aspirin (266.0 ± 212.7 vs 
      201.7 ± 162.7 μl(-1), p = 0.021). PMPs of rivaroxaban-treated participants 
      stimulated HUVEC proliferation in vitro compared with aspirin. Rivaroxaban was 
      associated with a higher number of bleeding events. CONCLUSIONS/INTERPRETATION: 
      Our findings indicate that the direct factor Xa inhibitor rivaroxaban improved 
      endothelial function in participants with type 2 diabetes and subclinical 
      inflammation but also increased the risk of bleeding. TRIAL REGISTRATION: 
      ClinicalTrials.gov NCT02164578. FUNDING: The study was supported by a research 
      grant from Bayer Vital AG, Germany.
CI  - © 2021. The Author(s).
FAU - Pistrosch, Frank
AU  - Pistrosch F
AUID- ORCID: 0000-0001-8866-321X
AD  - Medical Clinic III, Universitätsklinikum 'Carl Gustav Carus', Dresden, Germany. 
      frank.pistrosch@uniklinikum-dresden.de.
FAU - Matschke, Jan B
AU  - Matschke JB
AD  - Medical Clinic III, Universitätsklinikum 'Carl Gustav Carus', Dresden, Germany.
FAU - Schipp, Dorothea
AU  - Schipp D
AD  - Independent Statistician, Rosenthal-Bielatal, Germany.
FAU - Schipp, Bernhard
AU  - Schipp B
AD  - Faculty of Business and Economics, Department of Quantitative Methods, 
      TU-Dresden, Dresden, Germany.
FAU - Henkel, Elena
AU  - Henkel E
AD  - GWT TU-Dresden GmbH, Dresden, Germany.
FAU - Weigmann, Ingo
AU  - Weigmann I
AD  - Medical Clinic III, Universitätsklinikum 'Carl Gustav Carus', Dresden, Germany.
FAU - Sradnick, Jan
AU  - Sradnick J
AD  - Medical Clinic III, Universitätsklinikum 'Carl Gustav Carus', Dresden, Germany.
FAU - Bornstein, Stefan R
AU  - Bornstein SR
AD  - Medical Clinic III, Universitätsklinikum 'Carl Gustav Carus', Dresden, Germany.
FAU - Birkenfeld, Andreas L
AU  - Birkenfeld AL
AD  - Internal Medicine IV, Universitätsklinikum Tuebingen, Tuebingen, Germany.
AD  - Institute of Diabetes Research and Metabolic Diseases of the Helmholtz Centre 
      Munich, Tuebingen, Germany.
FAU - Hanefeld, Markolf
AU  - Hanefeld M
AD  - Medical Clinic III, Universitätsklinikum 'Carl Gustav Carus', Dresden, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT02164578
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20210908
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Biomarkers
MH  - *Cardiovascular Diseases/drug therapy
MH  - *Cell-Derived Microparticles
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Activation
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Prospective Studies
MH  - Pulse Wave Analysis
MH  - Risk Factors
MH  - Rivaroxaban/pharmacology/therapeutic use
PMC - PMC8563606
EDAT- 2021/09/09 06:00
MHDA- 2022/04/01 06:00
CRDT- 2021/09/08 12:26
PHST- 2020/12/25 00:00 [received]
PHST- 2021/06/22 00:00 [accepted]
PHST- 2021/09/09 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2021/09/08 12:26 [entrez]
AID - 10.1007/s00125-021-05562-9 [pii]
AID - 5562 [pii]
AID - 10.1007/s00125-021-05562-9 [doi]
PST - ppublish
SO  - Diabetologia. 2021 Dec;64(12):2701-2712. doi: 10.1007/s00125-021-05562-9. Epub 
      2021 Sep 8.

PMID- 11727363
OWN - NLM
STAT- MEDLINE
DCOM- 20020419
LR  - 20191105
IS  - 0951-3590 (Print)
IS  - 0951-3590 (Linking)
VI  - 15
IP  - 5
DP  - 2001 Oct
TI  - Hypertension in menopausal women--a special case, for special treatment?
PG  - 397-405
AB  - After the menopause the consequences of hypertension in women change. Their risks 
      of myocardial infarction and stroke rise steeply, a rise that has been blamed in 
      part on the loss of estrogen and the onset of menopausal metabolic syndrome, with 
      endothelial dysfunction, hyperlipidemia, insulin resistance and derangement in 
      coagulation. Hypertensive menopausal women have not had optimum treatment. They 
      have poorer prognoses than men of the same age. Their antihypertensive management 
      therefore merits special attention. Hormone replacement, aspirin prophylaxis and 
      lipid-lowering drugs have their place. The antihypertensive drug chosen should 
      not worsen the metabolic syndrome: angiotensin-II converting enzyme (ACE) 
      inhibitors are therefore among the first-line drugs. Few drugs have been 
      specifically aimed at menopausal hypertension and these are reviewed here.
FAU - Pines, A
AU  - Pines A
AD  - Department of Medicine T, Ichilov Hospital, 6 Weizman Street, Tel-Aviv 64239, 
      Israel.
FAU - Fisman, E Z
AU  - Fisman EZ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Gynecol Endocrinol
JT  - Gynecological endocrinology : the official journal of the International Society 
      of Gynecological Endocrinology
JID - 8807913
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/pharmacology/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Female
MH  - *Hormone Replacement Therapy
MH  - Humans
MH  - Hypertension/*drug therapy/pathology
MH  - Postmenopause/drug effects/*physiology
RF  - 45
EDAT- 2001/12/01 10:00
MHDA- 2002/04/20 10:01
CRDT- 2001/12/01 10:00
PHST- 2001/12/01 10:00 [pubmed]
PHST- 2002/04/20 10:01 [medline]
PHST- 2001/12/01 10:00 [entrez]
AID - 10.1080/gye.15.5.397.405 [doi]
PST - ppublish
SO  - Gynecol Endocrinol. 2001 Oct;15(5):397-405. doi: 10.1080/gye.15.5.397.405.

PMID- 7093110
OWN - NLM
STAT- MEDLINE
DCOM- 19820924
LR  - 20190512
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 13
IP  - 6
DP  - 1982 Jun
TI  - Efficacy and pharmacokinetics of aspirin in post-operative dental pain.
PG  - 807-10
AB  - 1 Soluble aspirin, 600 mg and 1200 mg, and placebo were compared in a 
      double-blind, cross-over study in 12 patients with post-operative pain following 
      removal of impacted lower third molars. 2 Significant analgesia after 600 mg 
      aspirin occurred only at 45 min after administration, whereas significant 
      analgesia after 1200 mg aspirin occurred from 45 to 240 min. The 1200 mg dose 
      produced greater analgesia than the 600 mg dose and is to be recommended in 
      clinical practice. 3 Plasma concentrations of salicylate and acetylsalicylate 
      were measured after both doses. A significant correlation (rs = 0.876, P less 
      than 0.01) was observed between analgesia and plasma salicylate concentration 
      after 1200 mg aspirin.
FAU - Seymour, R A
AU  - Seymour RA
FAU - Rawlins, M D
AU  - Rawlins MD
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*therapeutic use
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Tooth Extraction
PMC - PMC1402030
EDAT- 1982/06/01 00:00
MHDA- 1982/06/01 00:01
CRDT- 1982/06/01 00:00
PHST- 1982/06/01 00:00 [pubmed]
PHST- 1982/06/01 00:01 [medline]
PHST- 1982/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1982.tb01870.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1982 Jun;13(6):807-10. doi: 
      10.1111/j.1365-2125.1982.tb01870.x.

PMID- 6431562
OWN - NLM
STAT- MEDLINE
DCOM- 19840912
LR  - 20161123
IS  - 0034-9402 (Print)
IS  - 0034-9402 (Linking)
VI  - 40
IP  - 1
DP  - 1984 Mar
TI  - [Possible mechanism of action of a water-soluble tissue extract on arterial 
      pressure in the rat].
PG  - 37-42
AB  - A double hypo-hypertension effect is seen when a hydrosoluble splenic extract at 
      pH 5 is injected to rats intravenously. The hypotensive effect may be caused by 
      local vasodilating agents, such as histamine. The hypertensive one does not 
      appear in adrenoprive animals or in rats treated with inhibitors of prostaglandin 
      synthesis which suggests that the mechanism for this effect is complex.
FAU - de Gandarias, J M
AU  - de Gandarias JM
FAU - Iribar, M C
AU  - Iribar MC
FAU - Casis, L
AU  - Casis L
FAU - Múgica, J
AU  - Múgica J
LA  - spa
PT  - Journal Article
TT  - Aportaciones al posible mecanismo de acción de un extracto tisular hidrosoluble 
      sobre la presión arterial en rata.
PL  - Spain
TA  - Rev Esp Fisiol
JT  - Revista espanola de fisiologia
JID - 0404475
RN  - 0 (Tissue Extracts)
RN  - 059QF0KO0R (Water)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adrenalectomy
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Blood Pressure/*drug effects
MH  - Cattle
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Solubility
MH  - Spleen/*physiology
MH  - Tissue Extracts/*pharmacology
MH  - Water
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
PST - ppublish
SO  - Rev Esp Fisiol. 1984 Mar;40(1):37-42.

PMID- 16087788
OWN - NLM
STAT- MEDLINE
DCOM- 20051215
LR  - 20160726
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
VI  - 46
IP  - 4
DP  - 2005 Oct
TI  - Differing administration time-dependent effects of aspirin on blood pressure in 
      dipper and non-dipper hypertensives.
PG  - 1060-8
AB  - Aspirin is a potent antioxidative agent that reduces vascular production of 
      superoxide, prevents angiotensin II-induced hypertension, and induces NO release. 
      Low-dose aspirin administered at bedtime, but not on awakening, has also been 
      shown to reduce blood pressure, possibly enhancing the nocturnal trough in NO 
      production. Because endothelium-dependent vasodilation is blunted through a 
      decrease in NO release in non-dipper compared with dipper patients, we compared 
      the administration time-dependent influence of aspirin on ambulatory blood 
      pressure in dipper and non-dipper hypertensive subjects. We studied 257 patients 
      with mild hypertension (98 men and 159 women), 44.6+/-12.5 years of age, randomly 
      assigned to receive 100 mg per day of aspirin either on awakening or at bedtime. 
      Ambulatory blood pressure was measured for 48 hours at baseline and after 3 
      months of intervention. Blood pressure was slightly elevated after aspirin on 
      awakening (increase of 1.5/1.0 mm Hg in the 24-hour mean of systolic/diastolic 
      blood pressure; P<0.028). A highly significant blood pressure reduction was 
      observed in patients who received aspirin at bedtime (decrease of 7.2/4.9 mm Hg 
      in systolic/diastolic blood pressure; P<0.001). The reduction in nocturnal blood 
      pressure mean was double in non-dippers (11.0/7.1 mm Hg) compared with dippers 
      (5.5/3.3 mm Hg; P<0.001). This prospective trial corroborates the significant 
      administration time-dependent effect of low-dose aspirin on blood pressure, 
      mainly in non-dipper hypertensive patients. The timed administration of low-dose 
      aspirin could thus provide a valuable approach, beyond prevention of 
      cardiovascular disease, in the blood pressure control of patients with mild 
      hypertension.
FAU - Hermida, Ramón C
AU  - Hermida RC
AD  - Bioengineering Laboratory, University of Vigo, Campus Universitario, Spain. 
      rhermida@tsc.uvigo.es
FAU - Ayala, Diana E
AU  - Ayala DE
FAU - Calvo, Carlos
AU  - Calvo C
FAU - López, José E
AU  - López JE
FAU - Mojón, Artemio
AU  - Mojón A
FAU - Rodríguez, Marta
AU  - Rodríguez M
FAU - Fernández, José R
AU  - Fernández JR
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20050808
PL  - United States
TA  - Hypertension
JT  - Hypertension (Dallas, Tex. : 1979)
JID - 7906255
RN  - 0 (Antioxidants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antioxidants/*administration & dosage/*therapeutic use
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Blood Pressure Monitoring, Ambulatory
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Hypertension/diagnosis/*physiopathology
MH  - Male
MH  - Middle Aged
EDAT- 2005/08/10 09:00
MHDA- 2005/12/16 09:00
CRDT- 2005/08/10 09:00
PHST- 2005/08/10 09:00 [pubmed]
PHST- 2005/12/16 09:00 [medline]
PHST- 2005/08/10 09:00 [entrez]
AID - 01.HYP.0000172623.36098.4e [pii]
AID - 10.1161/01.HYP.0000172623.36098.4e [doi]
PST - ppublish
SO  - Hypertension. 2005 Oct;46(4):1060-8. doi: 10.1161/01.HYP.0000172623.36098.4e. 
      Epub 2005 Aug 8.

PMID- 31601291
OWN - NLM
STAT- MEDLINE
DCOM- 20191107
LR  - 20211008
IS  - 2639-9636 (Print)
IS  - 2639-9636 (Linking)
VI  - 34
IP  - 9
DP  - 2019 Oct 1
TI  - Aspirin Use for Primary Prevention of Cardiovascular Disease in Older Patients: A 
      Review of Clinical Guidelines and Updated Evidence.
PG  - 580-594
LID - 10.4140/TCP.n.2019.580 [doi]
AB  - OBJECTIVE: To provide an up-to-date review of current guidelines, previous 
      trials, and new trials regarding aspirin use in primary prevention of 
      cardiovascular (CV) disease in the elderly population. DATA SOURCES: A PubMed 
      search of articles published through April 2019 was performed using a combination 
      of the following words: aspirin, bleeding, cardiovascular, elderly, hemorrhage, 
      myocardial infarction, primary prevention, stroke. STUDY SELECTION/DATA 
      EXTRACTION: Relevant randomized controlled trials, meta-analyses, and guidelines 
      were assessed for the use of aspirin in primary prevention of CV disease in older 
      patients. References from the above literature were also evaluated. Articles were 
      selected for inclusion based on relevance to the topic, detailed methods, and 
      complete results. DATA SYNTHESIS: The role of aspirin for primary prevention of 
      CV disease in older adults is not well defined. As a result, the guideline 
      recommendations for the use of aspirin in this setting are inconsistent. In 2018, 
      the ARRIVE, ASCEND, and ASPREE studies were published. These studies tried to 
      address some of the inconsistencies regarding the use of aspirin in primary 
      prevention of CV disease. This article reviews the current recommendations along 
      with previous and recent studies for aspirin use for primary prevention in older 
      adults. CONCLUSION: The role of aspirin for primary prevention of CV disease in 
      older adults should be individualized based on patient's risk factors, including 
      risk of CV disease and likelihood of bleeding. Updated evidence provides more 
      guidance regarding which patient populations will benefit from therapy.
FAU - Lewis, Jelena
AU  - Lewis J
FAU - Bethishou, Laressa
AU  - Bethishou L
FAU - Tsu, Laura V
AU  - Tsu LV
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Sr Care Pharm
JT  - The Senior care pharmacist
JID - 101737969
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Hemorrhage
MH  - Humans
MH  - Primary Prevention
MH  - Risk Factors
EDAT- 2019/10/12 06:00
MHDA- 2019/11/08 06:00
CRDT- 2019/10/12 06:00
PHST- 2019/10/12 06:00 [entrez]
PHST- 2019/10/12 06:00 [pubmed]
PHST- 2019/11/08 06:00 [medline]
AID - 10.4140/TCP.n.2019.580 [doi]
PST - ppublish
SO  - Sr Care Pharm. 2019 Oct 1;34(9):580-594. doi: 10.4140/TCP.n.2019.580.

PMID- 3984974
OWN - NLM
STAT- MEDLINE
DCOM- 19850521
LR  - 20190716
IS  - 0002-922X (Print)
IS  - 0002-922X (Linking)
VI  - 139
IP  - 5
DP  - 1985 May
TI  - Antipyretic use among children during the 1983 influenza season.
PG  - 486-8
AB  - We conducted a telephone survey in Houston in March 1983 to assess the level of 
      aspirin use among children during the influenza season. We completed interviews 
      of 200 households with 346 children aged 12 years or younger. Fifty-two percent 
      of the 346 children experienced at least one acute illness in the preceding three 
      months. Fever was measured with a thermometer in 114 ill children, 103 of whom 
      had at least one measured temperature of 37.7 degrees C or greater. Fourteen 
      percent of these 103 children received aspirin only, 61% received acetaminophen 
      only, and 20% received both. Among a subgroup of 44 children with temperatures of 
      at least 39.4 degrees C, 11% received aspirin only, 59% received acetaminophen 
      only, and 27% received both. Only 60% of the 200 parents interviewed had heard of 
      Reye's syndrome. Forty-two percent knew of the association between Reye's 
      syndrome and aspirin use. The survey suggests that acetaminophen has replaced 
      aspirin as the major antipyretic used by children in Houston. If the decline in 
      aspirin use in Houston is representative of the population in the United States, 
      and if aspirin is causally related to Reye's syndrome, the incidence of Reye's 
      syndrome may decline.
FAU - Taylor, J P
AU  - Taylor JP
FAU - Gustafson, T L
AU  - Gustafson TL
FAU - Johnson, C C
AU  - Johnson CC
FAU - Brandenburg, N
AU  - Brandenburg N
FAU - Glezen, W P
AU  - Glezen WP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Dis Child
JT  - American journal of diseases of children (1960)
JID - 0370471
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chickenpox/drug therapy
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Fever/*drug therapy
MH  - Health Surveys
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiratory Tract Diseases/drug therapy
MH  - Reye Syndrome/chemically induced
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
AID - 10.1001/archpedi.1985.02140070060034 [doi]
PST - ppublish
SO  - Am J Dis Child. 1985 May;139(5):486-8. doi: 10.1001/archpedi.1985.02140070060034.

PMID- 3259918
OWN - NLM
STAT- MEDLINE
DCOM- 19880728
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 33
IP  - 7
DP  - 1988 Jul
TI  - Intragastric accumulation of Evan's blue as a method for assessing 
      aspirin-induced acute gastric mucosal injury in humans.
PG  - 769-73
AB  - Aspirin administration results in gastric mucosal damage. Although the 
      pathogenesis of these lesions remains unclear, in animals it appears that 
      increased vascular permeability precedes development of grossly visible lesions. 
      We examined the effect of aspirin administration on gastric vascular permeability 
      in eight healthy subjects. We used gastric accumulation of Evan's blue dye (which 
      is bound to albumin) as a marker of vascular integrity and assessed gastric 
      accumulation of Evan's blue, blood, and DNA during serial 10-min washes. Both 
      bleeding and Evan's blue in the gastric washings increased with time after 
      administration of aspirin in an acid solution (P less than 0.01). Evan's blue 
      increased from a median value of 8 micrograms/10 min to 24.5 micrograms/10 min 
      period after 60 min of aspirin administration. By 20 min after aspirin 
      administration, the accumulation of Evan's blue in the gastric wash was 
      significantly greater than the initial aspirin period (P less than 0.05). Blood 
      loss increased from 147 to 650 micrograms Hgb/10-min period. The increase in 
      bleeding rate did not become significant until 40 min after the first aspirin 
      dose. Our study showed that aspirin-induced gastric mucosal damage can be 
      detected by assessing accumulation of Evan's blue in the gastric contents after 
      aspirin administration. Studies in which various doses of aspirin or other agents 
      are administered will be required to confirm whether the increased vascular 
      permeability actually precedes bleeding in man. Measurement of Evan's blue dye in 
      the gastric contents appears to provide a qualitative (and possibly quantitative) 
      and sensitive early index of gastric mucosal injury.
FAU - Woods, K L
AU  - Woods KL
AD  - Digestive Disease Section, Veterans Administration Medical Center, Houston, Texas 
      77211.
FAU - Smith, J L
AU  - Smith JL
FAU - Graham, D Y
AU  - Graham DY
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Azo Compounds)
RN  - 45PG892GO1 (Evans Blue)
RN  - 9007-49-2 (DNA)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacokinetics/*toxicity
MH  - *Azo Compounds
MH  - Capillary Permeability/drug effects
MH  - DNA/analysis
MH  - *Evans Blue
MH  - Female
MH  - Gastric Juice/analysis
MH  - Gastric Mucosa/*drug effects
MH  - Gastrointestinal Contents/analysis
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
EDAT- 1988/07/01 00:00
MHDA- 1988/07/01 00:01
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 1988/07/01 00:01 [medline]
PHST- 1988/07/01 00:00 [entrez]
AID - 10.1007/BF01550961 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1988 Jul;33(7):769-73. doi: 10.1007/BF01550961.

PMID- 35180553
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220603
IS  - 1532-3072 (Electronic)
IS  - 0040-8166 (Linking)
VI  - 76
DP  - 2022 Jun
TI  - Aspirin effect on bone remodeling and skeletal regeneration: Review article.
PG  - 101753
LID - S0040-8166(22)00025-8 [pii]
LID - 10.1016/j.tice.2022.101753 [doi]
AB  - Bone tissues are one of the most complex tissues in the body that regenerate and 
      repair themselves spontaneously under the right physiological conditions. Within 
      the limitations of treating bone defects, mimicking tissue engineering through 
      the recruitment of scaffolds, cell sources and growth factors, is strongly 
      recommended. Aspirin is one of the non-steroidal anti-inflammatory drugs (NSAIDs) 
      and has been used in clinical studies for many years due to its anti-coagulant 
      effect. On the other hand, aspirin and other NSAIDs activate cytokines and some 
      mediators in osteoclasts, osteoblasts and their progenitor cells in a defect 
      area, thereby promoting bone regeneration. It also stimulates angiogenesis by 
      increasing migration of endothelial cells and the newly developed vessels are of 
      emergency in bone fracture repair. This review covers the role of aspirin in bone 
      tissue engineering and also, highlights its chemical reactions, mechanisms, 
      dosages, anti-microbial and angiogenesis activities.
CI  - Copyright © 2022. Published by Elsevier Ltd.
FAU - Fattahi, Roya
AU  - Fattahi R
AD  - Department of Tissue engineering and Applied Cell Sciences, School of Advanced 
      Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Mohebichamkhorami, Fariba
AU  - Mohebichamkhorami F
AD  - Department of Tissue engineering and Applied Cell Sciences, School of Advanced 
      Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Khani, Mohammad Mehdi
AU  - Khani MM
AD  - Department of Tissue engineering and Applied Cell Sciences, School of Advanced 
      Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran; Medical Nanotechnology and Tissue Engineering Research Center, Shahid 
      Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Soleimani, Masoud
AU  - Soleimani M
AD  - Department of Tissue engineering and Applied Cell Sciences, School of Advanced 
      Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran; Medical Nanotechnology and Tissue Engineering Research Center, Shahid 
      Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: 
      soleimani.masoud@gmail.com.
FAU - Hosseinzadeh, Simzar
AU  - Hosseinzadeh S
AD  - Department of Tissue engineering and Applied Cell Sciences, School of Advanced 
      Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran; Medical Nanotechnology and Tissue Engineering Research Center, Shahid 
      Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: 
      S.hosseinzadeh@sbmu.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220207
PL  - Scotland
TA  - Tissue Cell
JT  - Tissue & cell
JID - 0214745
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - *Aspirin/pharmacology
MH  - Bone Remodeling
MH  - *Endothelial Cells
MH  - Osteogenesis
MH  - Tissue Engineering
MH  - Tissue Scaffolds
OTO - NOTNLM
OT  - Angiogenesis
OT  - Antimicrobial activity
OT  - Aspirin
OT  - Bone tissue
OT  - Tissue engineering
EDAT- 2022/02/19 06:00
MHDA- 2022/06/07 06:00
CRDT- 2022/02/18 20:12
PHST- 2021/10/24 00:00 [received]
PHST- 2022/01/21 00:00 [revised]
PHST- 2022/02/06 00:00 [accepted]
PHST- 2022/02/19 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
PHST- 2022/02/18 20:12 [entrez]
AID - S0040-8166(22)00025-8 [pii]
AID - 10.1016/j.tice.2022.101753 [doi]
PST - ppublish
SO  - Tissue Cell. 2022 Jun;76:101753. doi: 10.1016/j.tice.2022.101753. Epub 2022 Feb 
      7.

PMID- 28363584
OWN - NLM
STAT- MEDLINE
DCOM- 20170615
LR  - 20220311
IS  - 1535-6280 (Electronic)
IS  - 0146-2806 (Linking)
VI  - 42
IP  - 5
DP  - 2017 May
TI  - Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: 
      Consequences and Prevention.
PG  - 146-164
LID - S0146-2806(17)30016-6 [pii]
LID - 10.1016/j.cpcardiol.2017.01.006 [doi]
AB  - Antiplatelet therapy represents a fundamental part of preventive management for 
      patients who are at risk of a secondary cardiovascular disease (CVD) event. In 
      most cases, the antiplatelet regimen is based on low-dose aspirin, a drug that is 
      highly effective in reducing the incidence of CVD events, but is associated with 
      a substantial risk of gastrointestinal (GI) toxicity. The dyspeptic symptoms, 
      which can result from aspirin administration, and which may occur with or without 
      associated ulceration and bleeding, may lead patients to discontinue therapy, 
      thus increasing their CVD risk. For patients in whom aspirin is indicated and who 
      are deemed to be at increased risk of upper GI events, concomitant therapy with a 
      proton pump inhibitor (PPI) is currently recommended. These agents are highly 
      effective in reducing the upper GI lesions associated with aspirin therapy and 
      have been associated with increased aspirin adherence. However, widespread 
      under-prescribing of PPIs and potential noncompliance with their use means that 
      substantial numbers of patients are at unnecessary risk of upper GI toxicity 
      and-if aspirin therapy is discontinued-CVD events. Provision of aspirin and an 
      immediate-release PPI as a coordinated-delivery combination tablet has been shown 
      to both reduce the risk of gastric ulcer formation and improve patient 
      compliance. This strategy, which may ultimately reduce the incidence of CVD 
      outcomes because of the associated reduction in GI symptoms and the potential for 
      greater patient adherence to aspirin, warrants further investigation under both 
      randomized controlled conditions (explanatory trials), and in real-life settings 
      (pragmatic trials).
CI  - Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Lavie, Carl J
AU  - Lavie CJ
FAU - Howden, Colin W
AU  - Howden CW
FAU - Scheiman, James
AU  - Scheiman J
FAU - Tursi, James
AU  - Tursi J
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170201
PL  - Netherlands
TA  - Curr Probl Cardiol
JT  - Current problems in cardiology
JID - 7701802
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Gastrointestinal Diseases/*chemically induced/epidemiology
MH  - Gastrointestinal Tract/*drug effects
MH  - Global Health
MH  - Humans
MH  - Incidence
MH  - Intestinal Mucosa/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Risk Factors
MH  - Time Factors
EDAT- 2017/04/02 06:00
MHDA- 2017/06/16 06:00
CRDT- 2017/04/02 06:00
PHST- 2017/04/02 06:00 [entrez]
PHST- 2017/04/02 06:00 [pubmed]
PHST- 2017/06/16 06:00 [medline]
AID - S0146-2806(17)30016-6 [pii]
AID - 10.1016/j.cpcardiol.2017.01.006 [doi]
PST - ppublish
SO  - Curr Probl Cardiol. 2017 May;42(5):146-164. doi: 10.1016/j.cpcardiol.2017.01.006. 
      Epub 2017 Feb 1.

PMID- 20076848
OWN - NLM
STAT- MEDLINE
DCOM- 20100824
LR  - 20131121
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 103
IP  - 3
DP  - 2010 Mar
TI  - Effect of two doses of aspirin on thromboxane biosynthesis and platelet function 
      in patients undergoing coronary surgery.
PG  - 516-24
LID - 10.1160/TH09-07-0470 [doi]
AB  - Early post-operative aspirin improves survival in patients undergoing coronary 
      artery bypass graft (CABG). However, most patients do not benefit of aspirin 
      after CABG, still remaining at risk of thrombotic events due to insufficient 
      platelet inhibition, specifically via the thromboxane (TX) pathway. We evaluated 
      the effect of two aspirin doses (100 or 325 mg daily, enteric coated 
      formulations) on platelet function and TX biosynthesis in patients after CABG and 
      assessed whether the incidence of residual platelet reactivity could be reduced 
      by the higher dose. Fifty-six patients undergoing CABG were randomly assigned to 
      100 or 325 mg aspirin daily for five days in a prospective single-centre study. 
      Treatment effect was assessed by measuring either platelet function 
      (light-transmission aggregometry and point-of-care PFA-100(R)) or TX biosynthesis 
      in collagen-stimulated platelets, serum, urine, and in lipopolysaccharide 
      (LPS)-cultured whole blood (WB). An insufficient TX inhibition was observed with 
      100 mg aspirin but not with the higher dose. The different effect of the two 
      doses was, however, highlighted by either TX (platelet- or serum-derived) or by 
      PFA-100(R) but not by the other assays. In conclusion, early after CABG, the 
      incidence of residual platelet activity was lower in patients who received 325 mg 
      aspirin. Moreover, evidence was provided that different methods yield different 
      results in the detection of aspirin resistance, rendering them not 
      interchangeable.
FAU - Brambilla, Marta
AU  - Brambilla M
AD  - Centro Cardiologico Monzino, IRCCS, Via Parea, 4, 20138 Milano, Italy.
FAU - Parolari, Alessandro
AU  - Parolari A
FAU - Camera, Marina
AU  - Camera M
FAU - Colli, Susanna
AU  - Colli S
FAU - Eligini, Sonia
AU  - Eligini S
FAU - Centenaro, Chiara
AU  - Centenaro C
FAU - Anselmo, Achille
AU  - Anselmo A
FAU - Alamanni, Francesco
AU  - Alamanni F
FAU - Tremoli, Elena
AU  - Tremoli E
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100113
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/drug effects/physiology
MH  - Coronary Artery Bypass/*methods
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Platelet Function Tests
MH  - Thromboxanes/*biosynthesis
MH  - Treatment Outcome
EDAT- 2010/01/16 06:00
MHDA- 2010/08/25 06:00
CRDT- 2010/01/16 06:00
PHST- 2009/07/21 00:00 [received]
PHST- 2009/11/02 00:00 [accepted]
PHST- 2010/01/16 06:00 [entrez]
PHST- 2010/01/16 06:00 [pubmed]
PHST- 2010/08/25 06:00 [medline]
AID - 09-07-0470 [pii]
AID - 10.1160/TH09-07-0470 [doi]
PST - ppublish
SO  - Thromb Haemost. 2010 Mar;103(3):516-24. doi: 10.1160/TH09-07-0470. Epub 2010 Jan 
      13.

PMID- 34224271
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20210831
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 174
IP  - 7
DP  - 2021 Jul
TI  - In healthy older adults, daily aspirin increased cancer mortality.
PG  - JC74
LID - 10.7326/ACPJ202107200-074 [doi]
AB  - McNeil JJ, Gibbs P, Orchard SG, et al. Effect of aspirin on cancer incidence and 
      mortality in older adults. J Natl Cancer Inst. 2021;113:258-65. 32778876.
FAU - Agarwal, Arnav
AU  - Agarwal A
AD  - University of Toronto, Toronto, Ontario, Canada (A.A.).
FAU - Holbrook, Anne M
AU  - Holbrook AM
AD  - McMaster University, Hamilton, Ontario, Canada (A.M.H.).
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20210706
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - J Natl Cancer Inst. 2021 Mar 1;113(3):258-265. PMID: 32778876
MH  - Aged
MH  - *Aspirin/adverse effects
MH  - Humans
MH  - Incidence
MH  - *Neoplasms
EDAT- 2021/07/06 06:00
MHDA- 2021/09/01 06:00
CRDT- 2021/07/05 17:07
PHST- 2021/07/06 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2021/07/05 17:07 [entrez]
AID - 10.7326/ACPJ202107200-074 [doi]
PST - ppublish
SO  - Ann Intern Med. 2021 Jul;174(7):JC74. doi: 10.7326/ACPJ202107200-074. Epub 2021 
      Jul 6.

PMID- 12357134
OWN - NLM
STAT- MEDLINE
DCOM- 20030305
LR  - 20191025
IS  - 0268-4705 (Print)
IS  - 0268-4705 (Linking)
VI  - 17
IP  - 5
DP  - 2002 Sep
TI  - Aspirin in the prophylaxis of coronary artery disease.
PG  - 552-8
AB  - Aspirin has been used for more than 100 years, but its mechanisms of action have 
      only been understood in the past 20 years. Aspirin interferes with arachidonic 
      acid metabolism in platelets and endothelial cells and thereby reduces 
      thromboxane A2 and prostacyclin. It also has other mechanisms of action, 
      including anti-inflammatory roles, protection from oxidative stress, enhancement 
      of fibrinolysis, and suppression of plasma coagulation and platelet-dependent 
      inhibition of thrombin generation. It has been used for primary and secondary 
      prevention of myocardial ischemia, and for primary and secondary prevention of 
      cerebrovascular ischemia. We review the 5 pivotal studies relating to primary 
      prevention for cardiovascular risk and the many studies relating to secondary 
      prevention of myocardial ischemia. We also review the utility of aspirin in 
      primary prevention of myocardial infarction and stroke. We conclude that aspirin 
      is one of the most potent drugs ever discovered and that its effects extend well 
      beyond those of cycloxoxygenase enzyme inhibition. Aspirin treatment does not 
      preclude control of underlying and comorbid conditions such as diabetes mellitus, 
      hypertension, and dyslipidemia. For most patients, a daily dose of 325 mg is 
      optimal. Patients must understand the potential for gastrointestinal upset and 
      hemorrhagic complications. The utility of aspirin is greater in coronary artery 
      disease prevention than in cerebrovascular prevention.
FAU - Mehta, Paulette
AU  - Mehta P
AD  - University of Arkansas for Medical Sciences and Central Arkansas Veterans 
      Healthcare System, Little Rock, 72205, USA. MehtaPaulette@uams.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Brain Ischemia/prevention & control
MH  - Coronary Disease/physiopathology/*prevention & control
MH  - Dipyridamole/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Myocardial Ischemia/prevention & control
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Risk Factors
MH  - Stroke/prevention & control
RF  - 93
EDAT- 2002/10/03 04:00
MHDA- 2003/03/06 04:00
CRDT- 2002/10/03 04:00
PHST- 2002/10/03 04:00 [pubmed]
PHST- 2003/03/06 04:00 [medline]
PHST- 2002/10/03 04:00 [entrez]
AID - 10.1097/00001573-200209000-00017 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2002 Sep;17(5):552-8. doi: 10.1097/00001573-200209000-00017.

PMID- 2720715
OWN - NLM
STAT- MEDLINE
DCOM- 19890626
LR  - 20131121
IS  - 0393-1978 (Print)
IS  - 0393-1978 (Linking)
VI  - 34
IP  - 1
DP  - 1989 Jan
TI  - [Antiplatelet effects of combined therapy with ticlopidine and low doses of 
      aspirin on patients with ischemic cardiopathy].
PG  - 69-71
AB  - The aim of study was to evaluate the effects on platelet function, in 8 patients 
      with ischemic heart disease, of the following treatments administered 
      consecutively: ticlopidine in a daily dose of 500 mg (10 days); aspirin in a 
      daily dose of 50 mg (10 days); ticlopidine plus ASA, at the same dosages, for the 
      last 10 days. Only ticlopidine plus ASA significantly inhibited EC 50 of ADP, 
      collagen and arachidonate. Platelet activation and platelet sensitivity to 
      prostacyclin was affected by ticlopidine and ticlopidine plus ASA but not by ASA 
      alone. We conclude that in our ischemic heart disease patients the association of 
      ticlopidine and low dose aspirin seems superior to each drug alone in inhibiting 
      platelet activity.
FAU - Davì, G
AU  - Davì G
FAU - Catalano, I
AU  - Catalano I
FAU - Spatola, A
AU  - Spatola A
FAU - Alaimo, P
AU  - Alaimo P
FAU - Notarbartolo, A
AU  - Notarbartolo A
FAU - Cerbone, A M
AU  - Cerbone AM
FAU - Strano, A
AU  - Strano A
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Effetti antipiastrinici della terapia combinata ticlopidina più basse dosi di 
      aspirina in pazienti con cardiopatia ischemica.
PL  - Italy
TA  - Cardiologia
JT  - Cardiologia (Rome, Italy)
JID - 8506637
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/physiopathology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - *Platelet Aggregation Inhibitors
MH  - Ticlopidine/administration & dosage/*pharmacology
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Cardiologia. 1989 Jan;34(1):69-71.

PMID- 7804312
OWN - NLM
STAT- MEDLINE
DCOM- 19950202
LR  - 20170214
IS  - 0961-2033 (Print)
IS  - 0961-2033 (Linking)
VI  - 3
IP  - 4
DP  - 1994 Aug
TI  - Role of IL-3 in the antiphospholipid syndrome.
PG  - 259-61
AB  - Antiphospholipid syndrome (APLS) is characterized by recurrent thromboembolic 
      phenomena, thrombocytopenia and fetal loss. We describe various methods of 
      induction of experimental APLS. These models were employed to study a variety of 
      therapeutic agents including low dose aspirin, low molecular weight heparin, IVIG 
      and thromboxane receptor antagonist. Because interleukin-3 (IL-3) is a 
      multilineage cytokine affecting also megakaryocytes, is regarded as a 'good' 
      cytokine in various stages of pregnancy and as low levels of IL-3 were recorded 
      in APLS, it was logical to employ IL-3 as a therapy for APLS. Indeed, this 
      treatment completely abrogated all the manifestations of experimental APLS. 
      Furthermore, it was found that low dose aspirin most probably affect positively 
      APLS via inducing an increased production of IL-3 by monocytes.
FAU - Shoenfeld, Y
AU  - Shoenfeld Y
AD  - Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel.
FAU - Fishman, P
AU  - Fishman P
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Interleukin-3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antiphospholipid Syndrome/*etiology
MH  - Aspirin/pharmacology
MH  - Humans
MH  - Interleukin-3/*physiology
RF  - 26
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
AID - 10.1177/096120339400300410 [doi]
PST - ppublish
SO  - Lupus. 1994 Aug;3(4):259-61. doi: 10.1177/096120339400300410.

PMID- 2231997
OWN - NLM
STAT- MEDLINE
DCOM- 19901210
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 264
IP  - 18
DP  - 1990 Nov 14
TI  - Aspirin increases blood alcohol concentrations in humans after ingestion of 
      ethanol.
PG  - 2406-8
AB  - Gastric first-pass metabolism of ethanol is an important determinant of blood 
      alcohol concentrations. We studied five healthy volunteers after ingestion of 
      ethanol (0.3 g/kg of body weight) and found that blood alcohol concentrations in 
      the fed state (ie, 1 hour after a standard breakfast) were significantly higher 
      when the subjects received 1 g of aspirin 1 hour before ingestion of ethanol than 
      without the drug. In vitro, aspirin clearly decreased the activity of gastric 
      alcohol dehydrogenase in human subjects and in rat models, but not that of 
      hepatic alcohol dehydrogenase in rats. Furthermore, blood alcohol concentrations 
      in rats were unaffected by ingestion of aspirin when ethanol was infused 
      intravenously. Thus, aspirin may increase the bioavailability of ingested ethanol 
      in humans, possibly by reducing ethanol oxidation by gastric alcohol 
      dehydrogenase.
FAU - Roine, R
AU  - Roine R
AD  - Section of Liver Diseases and Nutrition and the Alcohol Research and Treatment 
      Center, Bronx Veterans Administration Medical Center, NY 10468.
FAU - Gentry, R T
AU  - Gentry RT
FAU - Hernández-Munõz, R
AU  - Hernández-Munõz R
FAU - Baraona, E
AU  - Baraona E
FAU - Lieber, C S
AU  - Lieber CS
LA  - eng
GR  - AA 03508/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 3K9958V90M (Ethanol)
RN  - EC 1.1.1.1 (Alcohol Dehydrogenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Alcohol Dehydrogenase/metabolism
MH  - Alcohol Drinking
MH  - Animals
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Ethanol/administration & dosage/*blood
MH  - Gastric Mucosa/drug effects/enzymology
MH  - Humans
MH  - Male
EDAT- 1990/11/14 00:00
MHDA- 1990/11/14 00:01
CRDT- 1990/11/14 00:00
PHST- 1990/11/14 00:00 [pubmed]
PHST- 1990/11/14 00:01 [medline]
PHST- 1990/11/14 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1990 Nov 14;264(18):2406-8.

PMID- 23289172
OWN - NLM
STAT- MEDLINE
DCOM- 20130125
LR  - 20181202
IS  - 0019-1442 (Print)
IS  - 0019-1442 (Linking)
VI  - 65
IP  - 11-12
DP  - 2012 Nov 30
TI  - Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. 
      Part I: Concept of resistance.
PG  - 377-85
AB  - Aspirin and clopidogrel are well established as antiplatelet medication in the 
      treatment of atherothrombotic vascular disease. However, despite treatment, a 
      substantial number of patients experience recurrent ischemic episodes, referred 
      to as aspirin or clopidogrel treatment failure. Various laboratory techniques are 
      available with which to evaluate the effectiveness of antiplatelet drugs. 
      Interestingly, the agreement between the results of the different tests may be 
      poor. The term aspirin or clopidogrel resistance denotes those conditions in 
      which an inadequate inhibitory efficacy of the given antiplatelet agent is 
      detected by an in vitro assay of platelet function. It has been estimated that on 
      average some 30% of patients treated with aspirin, and 20% on clopidogrel, do not 
      achieve an appropriate level of efficacy as concerns platelet activity.
FAU - Vadász, Dávid
AU  - Vadász D
AD  - University of Szeged, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, 
      Neurology Department, Szeged.
FAU - Sztriha, László K
AU  - Sztriha LK
FAU - Sas, Katalin
AU  - Sas K
FAU - Vecsei, László
AU  - Vecsei L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Hungary
TA  - Ideggyogy Sz
JT  - Ideggyogyaszati szemle
JID - 17510500R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Treatment Outcome
EDAT- 2013/01/08 06:00
MHDA- 2013/01/26 06:00
CRDT- 2013/01/08 06:00
PHST- 2013/01/08 06:00 [entrez]
PHST- 2013/01/08 06:00 [pubmed]
PHST- 2013/01/26 06:00 [medline]
PST - ppublish
SO  - Ideggyogy Sz. 2012 Nov 30;65(11-12):377-85.

PMID- 14503120
OWN - NLM
STAT- MEDLINE
DCOM- 20040106
LR  - 20141010
IS  - 0544-0440 (Print)
IS  - 0544-0440 (Linking)
VI  - 17
IP  - 2
DP  - 2003 Jun
TI  - The patient on low dose aspirin: a concern for the anesthesiologist?
PG  - 177-92
AB  - Low dose aspirin administration has been generally accepted as prophylactic 
      therapy for myocardial infarction and cerebrovascular disease. It is also used 
      generally to prevent embolic phenomenon, as for example in pregnant patients. 
      Thus, anesthesiologists are often confronted with patients receiving aspirin for 
      whom neuraxial anesthesia may be the preferred technique. Much controversy has 
      arisen in the literature as to whether the possible complications of 
      anticoagulation outweigh the benefits of regional techniques. The 
      anesthesiologist must be able to provide patients with a rational and current 
      approach to the selection of an appropriate anesthetic technique.
FAU - Frost, Elizabeth A
AU  - Frost EA
AD  - Mount Sinai Medical Center, New York, N.Y., USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Lebanon
TA  - Middle East J Anaesthesiol
JT  - Middle East journal of anaesthesiology
JID - 8604187
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anesthesia/*methods
MH  - Aspirin/*adverse effects
MH  - Hematoma/etiology
MH  - Hemostasis
MH  - Humans
RF  - 44
EDAT- 2003/09/25 05:00
MHDA- 2004/01/07 05:00
CRDT- 2003/09/25 05:00
PHST- 2003/09/25 05:00 [pubmed]
PHST- 2004/01/07 05:00 [medline]
PHST- 2003/09/25 05:00 [entrez]
PST - ppublish
SO  - Middle East J Anaesthesiol. 2003 Jun;17(2):177-92.

PMID- 11858523
OWN - NLM
STAT- MEDLINE
DCOM- 20020820
LR  - 20190922
IS  - 0363-9045 (Print)
IS  - 0363-9045 (Linking)
VI  - 28
IP  - 1
DP  - 2002 Jan
TI  - Polydisperse powder mixtures: effect of particle size and shape on mixture 
      stability.
PG  - 41-8
AB  - The effect of the shape and size of the components on the stability of mixtures 
      was evaluated in binary mixtures of drug and carrier. Aspirin was used as model 
      drug; spray-dried lactose and microcrystalline cellulose were used as carriers. 
      The coefficient of variation (CV) of the drug in the mixture at various time 
      intervals during mixing was used as a measure of homogeneity. The stability of 
      mixtures was assessed under conditions that were conducive to segregation-in this 
      case, prolonged mixing. The pattern of change in CV with time was analyzed in 
      terms of convective, shear, and diffusive mixing stages. The variation resulting 
      from a change in the shape of the carriers was smaller than that resulting from 
      size differences. The segregation rate constant, calculated on the assumption of 
      a first-order mixing process, was found to be larger in mixtures having 
      components of different shape than in mixtures having components of similar 
      shape. In mixtures of micronized drug and carrier, the pattern of change in the 
      CV of drug with mixing time was attributed to the distribution of agglomerates of 
      micronized drug during convective mixing, followed by shearing of agglomerates 
      and, finally, the distribution of the primary particles during diffusive mixing. 
      Mixtures of non-cohesive powders of similar size and shape behaved like random 
      mixtures of non-interacting components.
FAU - Swaminathan, Vidya
AU  - Swaminathan V
AD  - Department of Industrial and Physical Pharmacy, Purdue University, West 
      Lafayette, IN 47907, USA.
FAU - Kildsig, Dane O
AU  - Kildsig DO
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - 0 (Drug Carriers)
RN  - 0 (Powders)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Drug Carriers/chemistry
MH  - Drug Compounding
MH  - Drug Stability
MH  - Particle Size
MH  - Powders/*chemistry
MH  - Surface Properties
EDAT- 2002/02/23 10:00
MHDA- 2002/08/21 10:01
CRDT- 2002/02/23 10:00
PHST- 2002/02/23 10:00 [pubmed]
PHST- 2002/08/21 10:01 [medline]
PHST- 2002/02/23 10:00 [entrez]
AID - 10.1081/ddc-120001484 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 2002 Jan;28(1):41-8. doi: 10.1081/ddc-120001484.

PMID- 12118084
OWN - NLM
STAT- MEDLINE
DCOM- 20020808
LR  - 20230216
IS  - 0023-6837 (Print)
IS  - 0023-6837 (Linking)
VI  - 82
IP  - 7
DP  - 2002 Jul
TI  - Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation 
      and promoting apoptosis.
PG  - 825-32
AB  - Endothelial dysfunction, defined as a deficit in the bioavailability of nitric 
      oxide (NO), occurs as sequelae of many vascular diseases; however, the utility of 
      supplementing NO to obviate the extent of disease is understudied. Here, we 
      examined if prolonged treatment with an NO-releasing form of aspirin (NO-ASA) can 
      influence neointimal remodeling of femoral arteries of hypercholesterolemic ApoE 
      (-/-) mice. Treatment of ApoE (-/-) mice with NO-ASA, but not aspirin (ASA), 
      improved neointimal remodeling post-injury. NO-ASA treatment increased lumen 
      diameters and reduced intimal-to-medial ratios of injured femoral arteries 
      compared with ASA- or vehicle-treated mice. The reduction in lumen diameter in 
      NO-ASA-treated mice was associated with a marked reduction in CD45-positive 
      inflammatory cells and an increased number of TUNEL-positive cells. Thus, NO-ASA, 
      by virtue of releasing NO, can reduce vascular inflammation and promote apoptosis 
      during vascular remodeling associated with neointimal thickening.
FAU - Yu, Jun
AU  - Yu J
AD  - Department of Pharmacology and Program in Vascular Cell Signaling and 
      Therapeutics,Boyer Center for Molecular Medicine, Yale University School of 
      Medicine, New Haven, Connecticut 06536, USA.
FAU - Rudic, Radu Daniel
AU  - Rudic RD
FAU - Sessa, William C
AU  - Sessa WC
LA  - eng
GR  - HL61371/HL/NHLBI NIH HHS/United States
GR  - HL64793/HL/NHLBI NIH HHS/United States
GR  - R01 HL57665/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Lab Invest
JT  - Laboratory investigation; a journal of technical methods and pathology
JID - 0376617
RN  - 0 (Apolipoproteins E)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apolipoproteins E/deficiency
MH  - Apoptosis/*drug effects
MH  - Aspirin/*analogs & derivatives/pharmacology/*therapeutic use
MH  - Cholesterol/*blood
MH  - Disease Models, Animal
MH  - Femoral Artery/drug effects/*pathology
MH  - Humans
MH  - Inflammation/*prevention & control
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Muscle, Smooth, Vascular/drug effects/*pathology
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2002/07/16 10:00
MHDA- 2002/08/09 10:01
CRDT- 2002/07/16 10:00
PHST- 2002/07/16 10:00 [pubmed]
PHST- 2002/08/09 10:01 [medline]
PHST- 2002/07/16 10:00 [entrez]
AID - S0023-6837(22)03034-3 [pii]
AID - 10.1097/01.lab.0000018828.61722.bd [doi]
PST - ppublish
SO  - Lab Invest. 2002 Jul;82(7):825-32. doi: 10.1097/01.lab.0000018828.61722.bd.

PMID- 8739461
OWN - NLM
STAT- MEDLINE
DCOM- 19970311
LR  - 20220408
IS  - 1046-7408 (Print)
IS  - 1046-7408 (Linking)
VI  - 35
IP  - 4
DP  - 1996 Apr
TI  - A clinical trial for the treatment of antiphospholipid antibody-associated 
      recurrent pregnancy loss with lower dose heparin and aspirin.
PG  - 402-7
AB  - This study was conducted to determine if lower dose heparin (LD Heparin) combined 
      with aspirin is as efficacious as higher dose heparin (HD Heparin) for the 
      treatment of the antiphospholipid antibody syndrome in women seeking pregnancy. 
      The method of the study was a prospective, single center trial including 50 
      patients who were consecutively assigned to treatment. Each patient had at least 
      three consecutive, spontaneous pregnancy losses, positive antiphospholipid 
      antibodies on two occasions, and a complete evaluation. Data were compared using 
      Fisher's exact test. Viable infants were delivered from 20/25 (80%) women treated 
      with higher dose heparin vs. 19/25 (76%) of women treated with lower dose 
      heparin. There were no significant differences between groups with respect to 
      gestational age at the time of delivery (37.2 +/- 3.4 versus 37.7 +/- 1.6 weeks), 
      maternal complications, or fetal complications. A lower dose of heparin plus 
      aspirin was as effective as higher dose heparin for the treatment of 
      antiphospholipid antibody-associated recurrent pregnancy loss.
FAU - Kutteh, W H
AU  - Kutteh WH
AD  - Department of Obstetrics and Gynecology, University of Texas Southwestern Medical 
      Center at Dallas 75235-9032, USA.
FAU - Ermel, L D
AU  - Ermel LD
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/diagnostic imaging/*drug therapy/*immunology
MH  - Adult
MH  - Antibodies, Antiphospholipid/*blood
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Dose-Response Relationship, Immunologic
MH  - Drug Administration Schedule
MH  - Female
MH  - Heparin/administration & dosage/adverse effects/*pharmacology
MH  - Humans
MH  - Pregnancy
MH  - Syndrome
MH  - Ultrasonography
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
AID - 10.1111/j.1600-0897.1996.tb00501.x [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 1996 Apr;35(4):402-7. doi: 
      10.1111/j.1600-0897.1996.tb00501.x.

PMID- 8055101
OWN - NLM
STAT- MEDLINE
DCOM- 19940912
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 1
DP  - 1994
TI  - Characterization of the hemodynamic response to intravenous diaspirin crosslinked 
      hemoglobin solution in rats.
PG  - 91-107
AB  - Diaspirin crosslinked hemoglobin solution (DCLHB) has potential for clinical use 
      as an oxygen-carrying solution because of its excellent oxygen transport 
      properties and biochemical stability. The present study characterizes the effects 
      of intravenous infusions of 0.625-40 mL/kg (62.5-4000 mg/kg) DCLHb on mean blood 
      pressure (MAP) and heart rate (HR) in conscious rats. DCLHb at all doses tested 
      except 62.5 mg/kg was associated with an immediate increase in MAP (25-30% above 
      baseline) that peaked between 20-30 minutes after infusion and returned to 
      baseline within 120-300 minutes in a dose-dependent manner. Maximum MAP achieved 
      was in the range of 129 +/- 7 to 140 +/- 7 mm Hg and there was no statistically 
      significant difference in the response between doses. HR responded in a 
      reciprocal manner to changes in MAP. Volume- and oncotic-matched infusions of LR 
      and albumin did not alter MAP or HR. Slow infusion (0.34 mL/min) of DCLHb 
      appeared to blunt the magnitude of the pressor response when compared to bolus 
      injection (< 10 sec). DCLHb administration is associated with a pressor response 
      that is not due to volume load, oncotic pressure, or rate of infusion, suggesting 
      that it is intrinsic to the modified hemoglobin molecule and pharmacologic in 
      nature.
FAU - Malcolm, D S
AU  - Malcolm DS
AD  - Department of Surgery, Uniformed Services University of the Health Sciences, 
      Bethesda, Maryland.
FAU - Hamilton, I N Jr
AU  - Hamilton IN Jr
FAU - Schultz, S C
AU  - Schultz SC
FAU - Cole, F
AU  - Cole F
FAU - Burhop, K
AU  - Burhop K
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Hemoglobins)
RN  - 0 (Solutions)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Pressure/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Heart Rate/*drug effects
MH  - Hemoglobins/*pharmacology
MH  - Infusions, Intra-Arterial
MH  - Infusions, Intravenous
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Solutions
MH  - Temperature
EDAT- 1994/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117402 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(1):91-107. doi: 
      10.3109/10731199409117402.

PMID- 1403345
OWN - NLM
STAT- MEDLINE
DCOM- 19921113
LR  - 20190509
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 6
IP  - 5
DP  - 1992
TI  - Evaluation of the clinical utility of platelet aggregation studies in the 
      long-term follow-up of patients with atherosclerotic vascular disease.
PG  - 257-63
AB  - The present study was designed to evaluate the usefulness of laboratory 
      monitoring of antiplatelet therapy by means of a multiparametric evaluation of in 
      vitro platelet aggregation tests in the attempt to individually optimize a given 
      therapeutic regimen. The presence of a condition of hyperaggregability was shown 
      in approximately 80% of patients with different forms of atherosclerotic vascular 
      disease not undergoing any therapeutic regimen with antiplatelet agents. 
      Conversely, a significant decrease in platelet activity was observed in patients 
      undergoing different therapies based on acetylsalicylic acid (ASA), ticlopidine, 
      or indobufen. The similar antiaggregatory effect of low-dose vs. high-dose ASA 
      therapies was also shown. Dipyridamole alone showed no antiaggregatory effect, 
      which, in turn, was reached only by the addition of ASA. Nevertheless, the 
      association of ASA plus dipyridamole did not show any stronger antiplatelet 
      effect than ASA alone. The evaluation of in vitro platelet activity in a group of 
      patients treated with picotamide failed to show any significant change in 
      comparison with the untreated group, probably due to the short half-life of 
      picotamide in man and/or to its capability of reversibly antagonizing the action 
      of thromboxane at receptor level. The evaluation of a long-term follow-up of 90 
      patients treated with different antiplatelet agents supports the idea that a 
      multiparametric analysis of in vitro platelet aggregation may provide valuable 
      help in monitoring and optimizing a given therapeutic regimen.
FAU - Ferroni, P
AU  - Ferroni P
AD  - Department of Experimental Medicine, University of Rome La Sapienza, Italy.
FAU - Gazzaniga, P P
AU  - Gazzaniga PP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arteriosclerosis/*blood/drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - *Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Time Factors
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1002/jcla.1860060503 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 1992;6(5):257-63. doi: 10.1002/jcla.1860060503.

PMID- 28062260
OWN - NLM
STAT- MEDLINE
DCOM- 20170526
LR  - 20170526
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 99
DP  - 2017 Mar 1
TI  - Effect of differential surface anisotropy on performance of two plate shaped 
      crystals of aspirin form I.
PG  - 318-327
LID - S0928-0987(16)30575-9 [pii]
LID - 10.1016/j.ejps.2016.12.034 [doi]
AB  - Differential surface anisotropy of different crystals of the same API can have a 
      significant impact on their pharmaceutical performance. The present work 
      investigated the impact of differential surface anisotropy of two plate-shaped 
      crystals of aspirin (form I) on their hygroscopicity, stability and compaction 
      behavior. These crystals differed in their predominant facets (100) and (001) and 
      were coded as AE-100 & E-001. (100) facets exposed polar carbonyl groups which 
      provided hydrophilicity to the facets. In contrast, (001) facets possessed 
      hydrophobicity as they exposed non-polar aryl and methyl groups. Both the samples 
      showed different degradation behavior, at various stability conditions (i.e. 
      40°C/75%RH, 30°C/90%RH and 30°C/60%RH) and different time intervals. Polar groups 
      of aspirin have been reported to be prone to hydrolysis due to which AE-100 was 
      less stable than E-001. Dynamic vapor sorption (DVS) analysis at different 
      simulated stability conditions also supported this observation, wherein AE-100 
      showed higher moisture sorption than E-001. Both the samples having similar 
      particle size, shape, surface area and hardness value, showed differences in 
      their compactibility. However, milling narrowed down the predominance of facets 
      and both the milled samples showed similar stability and compaction behavior. 
      This study was also supported by surface free energy determination, molecular 
      modeling and face indexation of unmilled and milled samples.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - Jain, Tanshu
AU  - Jain T
AD  - Department of Pharmaceutics, National Institute of Pharmaceutical Education and 
      Research (NIPER), Sector-67, S. A. S Nagar, Mohali, Punjab, India.
FAU - Sheokand, Sneha
AU  - Sheokand S
AD  - Department of Pharmaceutics, National Institute of Pharmaceutical Education and 
      Research (NIPER), Sector-67, S. A. S Nagar, Mohali, Punjab, India.
FAU - Modi, Sameer R
AU  - Modi SR
AD  - Department of Pharmaceutics, National Institute of Pharmaceutical Education and 
      Research (NIPER), Sector-67, S. A. S Nagar, Mohali, Punjab, India.
FAU - Ugale, Bharat
AU  - Ugale B
AD  - Department of Chemistry, Indian Institute of Technology (IIT), Ropar, Punjab, 
      India.
FAU - Yadav, Ram Naresh
AU  - Yadav RN
AD  - Department of Mechanical Engineering, Indian Institute of Technology (IIT), 
      Ropar, Punjab, India.
FAU - Kumar, Navin
AU  - Kumar N
AD  - Department of Mechanical Engineering, Indian Institute of Technology (IIT), 
      Ropar, Punjab, India.
FAU - Nagaraja, C M
AU  - Nagaraja CM
AD  - Department of Chemistry, Indian Institute of Technology (IIT), Ropar, Punjab, 
      India.
FAU - Bansal, Arvind K
AU  - Bansal AK
AD  - Department of Pharmaceutics, National Institute of Pharmaceutical Education and 
      Research (NIPER), Sector-67, S. A. S Nagar, Mohali, Punjab, India. Electronic 
      address: akbansal@niper.ac.in.
LA  - eng
PT  - Journal Article
DEP - 20170103
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anisotropy
MH  - Aspirin/*chemistry
MH  - Crystallization/methods
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Particle Size
MH  - Surface Properties
MH  - Technology, Pharmaceutical/methods
MH  - Wettability
OTO - NOTNLM
OT  - Compactibility
OT  - Facet
OT  - Milling
OT  - Sorption
OT  - Stability
OT  - Surface anisotropy
OT  - Wettability
EDAT- 2017/01/08 06:00
MHDA- 2017/05/27 06:00
CRDT- 2017/01/08 06:00
PHST- 2016/11/21 00:00 [received]
PHST- 2016/12/14 00:00 [revised]
PHST- 2016/12/30 00:00 [accepted]
PHST- 2017/01/08 06:00 [pubmed]
PHST- 2017/05/27 06:00 [medline]
PHST- 2017/01/08 06:00 [entrez]
AID - S0928-0987(16)30575-9 [pii]
AID - 10.1016/j.ejps.2016.12.034 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2017 Mar 1;99:318-327. doi: 10.1016/j.ejps.2016.12.034. Epub 
      2017 Jan 3.

PMID- 8158499
OWN - NLM
STAT- MEDLINE
DCOM- 19940513
LR  - 20220321
IS  - 0022-3484 (Print)
IS  - 0022-3484 (Linking)
VI  - 29
IP  - 2
DP  - 1994 Mar
TI  - Inhibitory effect of aspirin on root resorption induced by mechanical injury of 
      the soft periodontal tissues in rats.
PG  - 113-7
AB  - The purpose of the present study was to study histologically and histometrically 
      the inhibitory effect of aspirin on root resorption induced by mechanical injury 
      of the periodontal soft tissues in rats. Resorption lacuna in the root surface of 
      the molar in animals given both mechanical injury and aspirin administration 
      contained fewer odontoclasts and was smaller in length and area than that in 
      animals given only mechanical injury. The result of the present investigation 
      indicated that the administration of aspirin might suppress root resorption 
      induced by mechanical injury of the periodontal soft tissues.
FAU - Kameyama, Y
AU  - Kameyama Y
AD  - Department of Pathology, School of Dentistry, Aichi-Gakuin University, Nagoya, 
      Japan.
FAU - Nakane, S
AU  - Nakane S
FAU - Maeda, H
AU  - Maeda H
FAU - Fujita, K
AU  - Fujita K
FAU - Takesue, M
AU  - Takesue M
FAU - Sato, E
AU  - Sato E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Periodontal Res
JT  - Journal of periodontal research
JID - 0055107
RN  - 0 (Prostaglandin Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Gingiva/*injuries
MH  - Male
MH  - Osteoclasts/drug effects/metabolism
MH  - Periodontal Ligament/*injuries
MH  - Prostaglandin Antagonists/pharmacology/*therapeutic use
MH  - Rats
MH  - Rats, Wistar
MH  - Root Resorption/etiology/*prevention & control
MH  - Wounds, Penetrating/complications
EDAT- 1994/03/01 00:00
MHDA- 1994/03/01 00:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 1994/03/01 00:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
AID - 10.1111/j.1600-0765.1994.tb01099.x [doi]
PST - ppublish
SO  - J Periodontal Res. 1994 Mar;29(2):113-7. doi: 10.1111/j.1600-0765.1994.tb01099.x.

PMID- 7386800
OWN - NLM
STAT- MEDLINE
DCOM- 19800815
LR  - 20190821
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 35
IP  - 2
DP  - 1980 Mar
TI  - Aspirin intolerance and recurrent urticaria in normal adults and children. 
      Epidemiology and review.
PG  - 149-54
AB  - The frequency of aspirin intolerance by history in 2,592 normal individuals was 
      0.3%. Although the frequency of aspirin intolerance was similar in adults and 
      children, the bronchospastic type predominated in adults, and only the urticarial 
      type was found in normal children. The frequency of recurrent urticaria, 
      regardless of etiology, was significantly greater in adults than in children 
      (3.8% vs. 0.3, P less than 0.001). In adults the frequency of aspirin intolerance 
      was over 20 times greater in individuals with recurrent urticaria than in normal 
      individuals (6.5% vs. 0.3%, P less than 0.001).
FAU - Settipane, R A
AU  - Settipane RA
FAU - Constantine, H P
AU  - Constantine HP
FAU - Settipane, G A
AU  - Settipane GA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aspirin/*adverse effects/immunology
MH  - Bronchial Spasm/*chemically induced/etiology
MH  - Child
MH  - Child, Preschool
MH  - Drug Hypersensitivity/*etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Urticaria/*chemically induced/etiology
EDAT- 1980/03/01 00:00
MHDA- 1980/03/01 00:01
CRDT- 1980/03/01 00:00
PHST- 1980/03/01 00:00 [pubmed]
PHST- 1980/03/01 00:01 [medline]
PHST- 1980/03/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1980.tb01730.x [doi]
PST - ppublish
SO  - Allergy. 1980 Mar;35(2):149-54. doi: 10.1111/j.1398-9995.1980.tb01730.x.

PMID- 7304632
OWN - NLM
STAT- MEDLINE
DCOM- 19820120
LR  - 20131121
IS  - 0002-9289 (Print)
IS  - 0002-9289 (Linking)
VI  - 38
IP  - 11
DP  - 1981 Nov
TI  - Comparative bioavailability of sustained-release and uncoated aspirin tablets.
PG  - 1754-6
AB  - Plasma salicylate concentrations during multiple-dose administration of an 
      uncoated and a sustained-release aspirin preparation were compared. Eight healthy 
      adult subjects were given aspirin 2.6 g/day as sustained-release and uncoated 
      tablets in two and four divided doses, respectively, for five-day periods in a 
      crossover design. Treatment regimens were compared on the basis of five plasma 
      salicylate concentrations measured during the fourth and fifth days of drug 
      administration. Although there was considerable intersubject variation, no 
      significant differences in salicylate concentrations (p less than or equal to 
      0.05) were found between treatments at any sampling time using the Wilcoxon 
      signed-rank test or analysis of variance. Sustained-release aspirin preparations 
      are capable of producing plasma salicylate concentrations comparable with those 
      produced by uncoated aspirin tablets administered more frequently.
FAU - Karahalios, W J
AU  - Karahalios WJ
FAU - Sawyer, W T
AU  - Sawyer WT
FAU - Rittase, R A
AU  - Rittase RA
FAU - Maynard, S A
AU  - Maynard SA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Hosp Pharm
JT  - American journal of hospital pharmacy
JID - 0370474
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/blood
MH  - Biological Availability
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Salicylates/blood
MH  - Tablets
MH  - Time Factors
EDAT- 1981/11/01 00:00
MHDA- 1981/11/01 00:01
CRDT- 1981/11/01 00:00
PHST- 1981/11/01 00:00 [pubmed]
PHST- 1981/11/01 00:01 [medline]
PHST- 1981/11/01 00:00 [entrez]
PST - ppublish
SO  - Am J Hosp Pharm. 1981 Nov;38(11):1754-6.

PMID- 2459887
OWN - NLM
STAT- MEDLINE
DCOM- 19881114
LR  - 20131121
IS  - 0001-5555 (Print)
IS  - 0001-5555 (Linking)
VI  - 68
IP  - 4
DP  - 1988
TI  - Skin blood flow in necrobiosis lipoidica during treatment with low-dose 
      acetylsalicylic acid.
PG  - 364-5
AB  - Skin blood flow was measured by the laser Doppler technique in lesional and 
      clinically normal skin of 10 diabetic patients with necrobiosis lipoidica during 
      and after treatment with 40 mg acetylsalicylic acid (ASA) daily. The measurements 
      showed that the blood flow during ASA treatment was significantly decreased in 
      the central lesional skin without changes in the peripheral part of the lesions 
      and normal skin. In view of these findings we suggest that low-dose ASA may not 
      be the best treatment for necrobiosis lipoidica.
FAU - Beck, H I
AU  - Beck HI
AD  - Department of Dermatology and Venerology, Marselisborg Hospital, Arhus, Denmark.
FAU - Bjerring, P
AU  - Bjerring P
LA  - eng
PT  - Journal Article
PL  - Sweden
TA  - Acta Derm Venereol
JT  - Acta dermato-venereologica
JID - 0370310
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Necrobiosis Lipoidica/drug therapy/*physiopathology
MH  - Regional Blood Flow/drug effects
MH  - Skin/*blood supply
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Derm Venereol. 1988;68(4):364-5.

PMID- 4070347
OWN - NLM
STAT- MEDLINE
DCOM- 19860116
LR  - 20141120
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 40
IP  - 9
DP  - 1985 Sep
TI  - Availability studies on acetylsalicylic acid, salicylamide and phenacetin at 
      different pH values.
PG  - 639-41
AB  - The optimum partitioning rate of acetylsalicylic acid has been attained at pH = 4 
      and minimum partitioning rate was found to be at pH = 8. The maximum partitioning 
      rate of salicylamide was observed at pH = 5 and the smallest one was found at pH 
      = 6 or 8. At pH = 3 a maximum amount of phenacetin was found in the aqueous 
      phase, while at pH = 6 a maximum amount was found in the octanolic layer. The 
      maximum partitioning rate was found at pH = 6 and lowest one was observed at pH = 
      3. The gastrointestinal absorption of acetylsalicylic acid, salicylamide and 
      phenacetin was significantly increased, as reflected by the urinary excretion 
      data in presence of solid buffer components at pH values of 4,5 and 6 
      respectively.
FAU - el-Sourady, H A
AU  - el-Sourady HA
FAU - Habib, F S
AU  - Habib FS
FAU - Mohamed, S I
AU  - Mohamed SI
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Salicylamides)
RN  - EM8BM710ZC (salicylamide)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*analysis/urine
MH  - Biological Availability
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Phenacetin/*analysis/urine
MH  - Salicylamides/*analysis/urine
MH  - Solubility
MH  - Time Factors
EDAT- 1985/09/01 00:00
MHDA- 1985/09/01 00:01
CRDT- 1985/09/01 00:00
PHST- 1985/09/01 00:00 [pubmed]
PHST- 1985/09/01 00:01 [medline]
PHST- 1985/09/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1985 Sep;40(9):639-41.

PMID- 27079719
OWN - NLM
STAT- MEDLINE
DCOM- 20171024
LR  - 20180131
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 52
IP  - 3
DP  - 2016 Apr 12
TI  - Influence of Low-Dose Aspirin on Cerebral Amyloid Angiopathy in Mice.
PG  - 1037-45
LID - 10.3233/JAD-160013 [doi]
AB  - Accumulation of amyloid-β peptide (Aβ) in the brain is one of the most important 
      features of Alzheimer's dementia (AD). Cerebral amyloid angiopathy (CAA) is 
      characterized by Aβ accumulation in the walls of cerebral arteries and 
      capillaries, and is present in over 90% of patients with AD. Several novel agents 
      for AD/CAA developed around the amyloid hypothesis have shown positive signs in 
      animal studies but have failed in clinical trials due to adverse events and/or 
      lack of efficiency. As CAA is presumably caused by a failure in Aβ clearance, 
      drugs that promote Aβ clearance may hold promise in the treatment of CAA and 
      possibly AD. With this in mind, cilostazol, an anti-platelet drug with 
      vasodilating action, has been found to promote Aβ clearance along perivascular 
      drainage pathway, reduce Aβ accumulation in the brain, and restore memory 
      impairment in Tg-SwDI mice, an animal model of CAA. We therefore tested whether 
      the most common anti-platelet agent, aspirin, also reduced Aβ and rescued 
      cognitive impairment in Tg-SwDI mice, and also whether aspirin affected 
      hemorrhagic complications that can occur in Tg-SwDI mice. Mice aged 4 months were 
      assigned into vehicle-treated and low-dose aspirin-treated groups. Low-dose 
      aspirin for 8 months did not increase hemorrhagic lesions, nor increase resting 
      cerebral blood flow or cerebral vascular reserve in response to hypercapnia or 
      acetylcholine. Subsequently, aspirin did not restore cognitive dysfunction. These 
      results suggest that low-dose aspirin does not have a direct influence on 
      cerebrovascular Aβ metabolism nor aggravate hemorrhagic complications in CAA.
FAU - Hattori, Yorito
AU  - Hattori Y
AD  - Department of Stroke and Cerebrovascular Diseases, National Cerebral and 
      Cardiovascular Center, Suita, Osaka, Japan.
FAU - Maki, Takakuni
AU  - Maki T
AD  - Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, 
      Kyoto, Japan.
FAU - Saito, Satoshi
AU  - Saito S
AD  - Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, 
      Kyoto, Japan.
AD  - Department of Regenerative Medicine, National Cerebral and Cardiovascular Center, 
      Suita, Osaka, Japan.
FAU - Yamamoto, Yumi
AU  - Yamamoto Y
AD  - Department of Regenerative Medicine, National Cerebral and Cardiovascular Center, 
      Suita, Osaka, Japan.
FAU - Nagatsuka, Kazuyuki
AU  - Nagatsuka K
AD  - Department of Stroke and Cerebrovascular Diseases, National Cerebral and 
      Cardiovascular Center, Suita, Osaka, Japan.
FAU - Ihara, Masafumi
AU  - Ihara M
AD  - Department of Stroke and Cerebrovascular Diseases, National Cerebral and 
      Cardiovascular Center, Suita, Osaka, Japan.
AD  - Department of Regenerative Medicine, National Cerebral and Cardiovascular Center, 
      Suita, Osaka, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - 0 (Amyloid beta-Peptides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Amyloid beta-Peptides/antagonists & inhibitors
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Brain/drug effects/metabolism
MH  - Cerebral Amyloid Angiopathy/*drug therapy
MH  - Cerebrovascular Circulation/drug effects
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
OTO - NOTNLM
OT  - Alzheimer’s dementia
OT  - amyloid β
OT  - aspirin
OT  - cerebral amyloid angiopathy
EDAT- 2016/04/16 06:00
MHDA- 2017/10/25 06:00
CRDT- 2016/04/16 06:00
PHST- 2016/04/16 06:00 [entrez]
PHST- 2016/04/16 06:00 [pubmed]
PHST- 2017/10/25 06:00 [medline]
AID - JAD160013 [pii]
AID - 10.3233/JAD-160013 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2016 Apr 12;52(3):1037-45. doi: 10.3233/JAD-160013.

PMID- 7353335
OWN - NLM
STAT- MEDLINE
DCOM- 19800417
LR  - 20190512
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 27
IP  - 2
DP  - 1980 Feb
TI  - Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects.
PG  - 170-8
AB  - In vitro studies have shown that phenytoin (DPH) is displaced from plasma protein 
      binding sites by some drugs. These results have been extrapolated to suggest 
      that, in vivo, this may cause a rise in the free concentration, leading to a 
      greater pharmacologic effect. We examined the effects of aspirin on the levels 
      and kinetics of total serum DPH and free drug as represented by salivary 
      concentrations in 7 healthy subjects. Aspirin induced a decrease (mean, 27.4 +/- 
      3.7%) in total serum DPH concentration but no corresponding change in salivary 
      concentration. During continued aspirin administration, no change was observed in 
      elimination half-life (t 1/2 beta) of total serum DPH but there was a trend 
      toward reduced t 1/2 beta in saliva. The ratio of saliva to total serum DPH 
      concentration also increased during this period. These results suggest that 
      displacement of DPH from plasma protein binding sites does not result in an 
      increase in free concentration and thus increased pharmacologic activity, but any 
      previous relationship between total serum concentration and therapeutic effect 
      will no longer hold, as a greater proportion of the total concentration will be 
      in the free form and therapeutically active.
FAU - Paxton, J W
AU  - Paxton JW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 6158TKW0C5 (Phenytoin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Phenytoin/*analysis/blood/metabolism/pharmacology
MH  - Protein Binding
MH  - Saliva/*analysis
MH  - Time Factors
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
AID - 0009-9236(80)90092-2 [pii]
AID - 10.1038/clpt.1980.26 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1980 Feb;27(2):170-8. doi: 10.1038/clpt.1980.26.

PMID- 7279987
OWN - NLM
STAT- MEDLINE
DCOM- 19811118
LR  - 20131121
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 36
IP  - 6
DP  - 1981 Jun
TI  - The construction and uses of factorial designs in the preparation of solid dosage 
      forms. Part 1: Effervescent acetylsalicylic acid tablets.
PG  - 417-20
AB  - The construction and application of a fractional factorial design of the type N = 
      2(5-2) for the preparation of effervescent acetylsalicylic acid tablets by a new 
      technique was demonstrated. This method involved direct compression of the tablet 
      ingredients, dipping the tablets in a volatile mixed solvent system and 
      subsequent removal of the solvent. With the help of a derived regression 
      equation, the factors considered most likely to have a beneficial effect on 
      tablet hardness were: the compression force, the percent of acetylsalicylic acid 
      content/tablet, the particle size of tablet ingredients and the solvent ratio. 
      The time of dipping was found to have an insignificant effect on tablet hardness. 
      By following the path of the steepest ascent, effervescent acetylsalicylic acid 
      tablets of remarkable hardness, friability and dissolution time were obtained. 
      The optimum conditions for preparing these tablets were determined.
FAU - El-Banna, H M
AU  - El-Banna HM
FAU - Minina, S A
AU  - Minina SA
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Solvents)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Drug Compounding
MH  - Solvents
MH  - Surface Properties
MH  - Tablets
EDAT- 1981/06/01 00:00
MHDA- 1981/06/01 00:01
CRDT- 1981/06/01 00:00
PHST- 1981/06/01 00:00 [pubmed]
PHST- 1981/06/01 00:01 [medline]
PHST- 1981/06/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1981 Jun;36(6):417-20.

PMID- 2873217
OWN - NLM
STAT- MEDLINE
DCOM- 19860821
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 38
IP  - 6
DP  - 1986 Jun
TI  - Mechanical properties of some pigmented and unpigmented aqueous-based film 
      coating formulations applied to aspirin tablets.
PG  - 414-9
AB  - The Brinell hardness and Young's modulus of pigmented and unpigmented films of 
      hydroxypropyl methylcellulose alone, and in combination with either polyethylene 
      glycol 400 (plasticizer) or polyvinyl alcohol, which were applied to aspirin 
      tablets, have been measured. Generally hardness and modulus data showed similar 
      trends. The hardness and modulus of hydroxypropyl methylcellulose fell in the 
      presence of polyethylene glycol 400 as a result of its plasticizing action. On 
      the other hand, the hardness and modulus of the film former rose slightly when 
      polyvinyl alcohol was initially incorporated, probably due to the crystalline 
      phase of the additive, and then decreased when the level of the additive was 
      further raised. Hardness and modulus were higher in films pigmented with talc 
      than in those containing titanium dioxide because of the plate-like shape of talc 
      and its greater interaction with the polymer systems. Some correlation was found 
      between the Young's moduli of the applied films and those of the corresponding 
      free films, with the moduli of the latter two 2-5 times greater. Ageing at 37 
      degrees C and 75% r.h. was found to cause a decrease in the mechanical properties 
      of the unplasticized film coating systems probably as a result of decreased 
      molecular order and enhanced polymer chain mobility.
FAU - Okhamafe, A O
AU  - Okhamafe AO
FAU - York, P
AU  - York P
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Excipients)
RN  - 0 (Plasticizers)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Drug Stability
MH  - Drug Storage
MH  - Excipients
MH  - Hardness
MH  - Pigmentation
MH  - Plasticizers
MH  - Tablets, Enteric-Coated
MH  - Tensile Strength
MH  - Time Factors
EDAT- 1986/06/01 00:00
MHDA- 1986/06/01 00:01
CRDT- 1986/06/01 00:00
PHST- 1986/06/01 00:00 [pubmed]
PHST- 1986/06/01 00:01 [medline]
PHST- 1986/06/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1986.tb04603.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1986 Jun;38(6):414-9. doi: 10.1111/j.2042-7158.1986.tb04603.x.

PMID- 8540946
OWN - NLM
STAT- MEDLINE
DCOM- 19960213
LR  - 20131121
IS  - 0735-1631 (Print)
IS  - 0735-1631 (Linking)
VI  - 12
IP  - 5
DP  - 1995 Sep
TI  - Effects of low-dose aspirin therapy on plasma levels of polyunsaturated fatty 
      acids: a preliminary investigation.
PG  - 371-4
AB  - Polyunsaturated fatty acids play an important yet poorly understood role in 
      pregnancy complications. We are interested in the effects of aspirin therapy on 
      the metabolism of these compounds. To determine the effects of low-dose aspirin 
      on plasma levels of polyunsaturated fatty acid precursors, we assayed linoleic, 
      linolenic, arachidonic, eicosapentaenoic, and docosahexaenoic acids using 
      high-performance liquid chromatography. Seventeen pregnant women being treated 
      with aspirin therapy (81 mg/day) were evaluated between 9 and 37 weeks' 
      gestation. Blood was drawn before initiation of aspirin therapy and after 3 or 4 
      days, and again after 3 or 4 weeks of therapy. We found no significant change in 
      the plasma levels of fatty acids during aspirin therapy at either 3 or 4 days or 
      3 or 4 weeks compared with baseline. In this group of women with preexisting 
      disease, low-dose aspirin does not appear to change the plasma levels of 
      polyunsaturated fatty acid precursors of eicosanoids. Data on pregnant women 
      without hypertensive disorders is needed to help in understanding the role and 
      physiology of these important compounds.
FAU - McCoy, M C
AU  - McCoy MC
AD  - Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, 
      North Carolina, USA.
FAU - Wang, Y
AU  - Wang Y
FAU - Coffman, T M
AU  - Coffman TM
FAU - Killam, A P
AU  - Killam AP
FAU - Kay, H H
AU  - Kay HH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
RN  - 0 (Fatty Acids, Unsaturated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Fatty Acids, Unsaturated/*blood
MH  - Female
MH  - Humans
MH  - Hypertension/blood
MH  - Pilot Projects
MH  - Pre-Eclampsia/blood
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*blood
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
AID - 10.1055/s-2007-994499 [doi]
PST - ppublish
SO  - Am J Perinatol. 1995 Sep;12(5):371-4. doi: 10.1055/s-2007-994499.

PMID- 6491946
OWN - NLM
STAT- MEDLINE
DCOM- 19841123
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 73
IP  - 9
DP  - 1984 Sep
TI  - Kinetics of aspirin absorption following oral administration of six aqueous 
      solutions with different buffer capacities.
PG  - 1258-61
AB  - Fifteen volunteers each received two of six aspirin solutions in a balanced 
      incomplete block design. The solutions contained 0, 3, 6, 10, 16, and 34 mEq of 
      sodium bicarbonate-citric acid buffer and 650 mg of aspirin. Plasma aspirin 
      levels were measured in blood samples collected frequently during the first 2.5 
      h, and the accumulation of aspirin, salicylic acid, and salicyluric acid were 
      measured over 2 and 24 h. The most rapid absorption rates occurred with solutions 
      which contained small quantities of the antacid buffer. The 3- and 6-mEq antacid 
      buffers had mean maximal aspirin concentrations of 17.3 and 17.8 micrograms/mL, 
      respectively. In the absence of the buffering agent, the 650 mg of aspirin failed 
      to dissolve completely and gave a mean maximal plasma concentration of 13.4 
      micrograms/mL. With 34 mEq of a buffering agent, a delay in the onset of 
      absorption occurred and the presystemic hydrolysis increased. This was probably 
      because more aspirin was emptied into and absorbed from the small intestine with 
      higher concentrations of the buffering agent.
FAU - Mason, W D
AU  - Mason WD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Buffers)
RN  - 0 (Solutions)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*metabolism
MH  - Buffers
MH  - Humans
MH  - *Intestinal Absorption
MH  - Kinetics
MH  - Solutions
MH  - Tablets
EDAT- 1984/09/01 00:00
MHDA- 1984/09/01 00:01
CRDT- 1984/09/01 00:00
PHST- 1984/09/01 00:00 [pubmed]
PHST- 1984/09/01 00:01 [medline]
PHST- 1984/09/01 00:00 [entrez]
AID - S0022-3549(15)46295-1 [pii]
AID - 10.1002/jps.2600730917 [doi]
PST - ppublish
SO  - J Pharm Sci. 1984 Sep;73(9):1258-61. doi: 10.1002/jps.2600730917.

PMID- 22893199
OWN - NLM
STAT- MEDLINE
DCOM- 20121108
LR  - 20220409
IS  - 0080-0015 (Print)
IS  - 0080-0015 (Linking)
VI  - 191
DP  - 2013
TI  - Mode of action of aspirin as a chemopreventive agent.
PG  - 39-65
LID - 10.1007/978-3-642-30331-9_3 [doi]
AB  - Aspirin taken for several years at doses of at least 75 mg daily reduced 
      long-term incidence and mortality due to colorectal cancer. The finding of 
      aspirin benefit at low-doses given once daily, used for cardioprevention, locates 
      the antiplatelet effect of aspirin at the center of its antitumor efficacy. In 
      fact, at low-doses, aspirin acts mainly by an irreversible inactivation of 
      platelet cyclooxygenase (COX)-1 in the presystemic circulation, which translates 
      into a long-lasting inhibition of platelet function. Given the short half-life of 
      aspirin in the human circulation(approximately 20 min) and the capacity of 
      nucleated cells to resynthesize the acetylated COX-isozyme(s), it seems unlikely 
      that a nucleated cell could be the target of aspirin chemoprevention. These 
      findings convincingly suggest that colorectal cancer and atherothrombosis may 
      share a common mechanism of disease, i.e. platelet activation in response to 
      epithelial(in tumorigenesis) and endothelial(in tumorigenesis and 
      atherothrombosis) injury. Activated platelets may also enhance the metastatic 
      potential of cancer cells (through a direct interaction and/or the release of 
      soluble mediators or exosomes) at least in part by inducing the overexpression of 
      COX-2. COX-independent mechanisms of aspirin, such as the inhibition of NF-kB 
      signaling and Wnt/β-catenin signaling and the acetylation of extra-COX proteins, 
      have been suggested to play a role in its chemopreventive effects. However, their 
      relevance remains to be demonstrated in vivo at clinical doses.
FAU - Dovizio, Melania
AU  - Dovizio M
AD  - Department of Neuroscience and Imaging, G. d'Annunzio University, School of 
      Medicine, Via dei Vestini 31, Chieti, Italy.
FAU - Bruno, Annalisa
AU  - Bruno A
FAU - Tacconelli, Stefania
AU  - Tacconelli S
FAU - Patrignani, Paola
AU  - Patrignani P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Germany
TA  - Recent Results Cancer Res
JT  - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans 
      les recherches sur le cancer
JID - 0044671
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticarcinogenic Agents/*pharmacology
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Blood Platelets/physiology
MH  - Colorectal Neoplasms/*prevention & control
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Humans
MH  - Prostaglandin-Endoperoxide Synthases/physiology
EDAT- 2012/08/16 06:00
MHDA- 2012/11/09 06:00
CRDT- 2012/08/16 06:00
PHST- 2012/08/16 06:00 [entrez]
PHST- 2012/08/16 06:00 [pubmed]
PHST- 2012/11/09 06:00 [medline]
AID - 10.1007/978-3-642-30331-9_3 [doi]
PST - ppublish
SO  - Recent Results Cancer Res. 2013;191:39-65. doi: 10.1007/978-3-642-30331-9_3.

PMID- 11225462
OWN - NLM
STAT- MEDLINE
DCOM- 20010503
LR  - 20190921
IS  - 0009-4722 (Print)
IS  - 0009-4722 (Linking)
VI  - 72
IP  - 1
DP  - 2001 Jan
TI  - [Abdominal hemorrhage in multiple intrahepatic aneurysms].
PG  - 82-5
AB  - A 17-year-old male patient presented with diffuse abdominal pain, acute drop in 
      hemoglobin and free subhepatic fluid. The patient was transferred to our unit for 
      investigation of presumed spontaneous hepatic bleeding. Questioning revealed 
      daily medication of 2 g acetylsalicylic acid because of influenzal infection. At 
      exploratory laparoscopy 1.8 l hematoma was removed; the origin of bleeding could 
      not be identified. The liver surface appeared macroscopically unremarkable, with 
      the exception of an aneurysmal dilatation of the cystic artery that was 
      considered as possible bleeding cause. Postoperative angiography confirmed the 
      presence of multiple aneurysmal dialatations of both left and right hepatic 
      arteries. Extensive investigations did not show any further aneurysms or vascular 
      abnormalities in any other part of the body. There was no evidence of a 
      preexistent systemic vasculitis or primary collagen disease.
FAU - Husmann, I
AU  - Husmann I
AD  - Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Charité Campus 
      Virchow Klinikum, Humboldt Universität zu Berlin.
FAU - Hierholzer, J
AU  - Hierholzer J
FAU - Langrehr, J M
AU  - Langrehr JM
LA  - ger
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Abdominelle Blutung bei multiplen intrahepatischen Aneurysmen.
PL  - Germany
TA  - Chirurg
JT  - Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
JID - 16140410R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aneurysm/chemically induced/*complications/diagnosis
MH  - Aspirin/administration & dosage/adverse effects
MH  - Diagnosis, Differential
MH  - Diagnostic Imaging
MH  - Hemoperitoneum/etiology/*surgery
MH  - *Hepatic Artery
MH  - Humans
MH  - Laparoscopy
MH  - Male
EDAT- 2001/02/28 10:00
MHDA- 2001/05/05 10:01
CRDT- 2001/02/28 10:00
PHST- 2001/02/28 10:00 [pubmed]
PHST- 2001/05/05 10:01 [medline]
PHST- 2001/02/28 10:00 [entrez]
AID - 10.1007/s001040051272 [doi]
PST - ppublish
SO  - Chirurg. 2001 Jan;72(1):82-5. doi: 10.1007/s001040051272.

PMID- 6793922
OWN - NLM
STAT- MEDLINE
DCOM- 19811222
LR  - 20161123
IS  - 0375-9393 (Print)
IS  - 0375-9393 (Linking)
VI  - 47
IP  - 5
DP  - 1981 May
TI  - [Lysine acetylsalicylate in the control of postoperative pain in surgery of the 
      upper abdomen].
PG  - 221-8
AB  - To evaluate the action of lysine acetylsalicylate in controlling post-operative 
      pain a controlled double blind clinical trial was carried out in thirty patients 
      subjected to surgical procedures on the upper gastrointestinal tract. The results 
      or the trial support analgesic properties of the drug in the postoperative period 
      and the absence of relevant untoward effects. The low toxicity and the absence of 
      the side effects typical to narcotic analgesics suggest to study the analgesic 
      effects of ASL with higher dosage schedules or different administrations in order 
      to increase the analgesic potency of the drug in the post-operative period.
FAU - Andreoni, A
AU  - Andreoni A
FAU - Cristofori, G B
AU  - Cristofori GB
FAU - Fochi, C
AU  - Fochi C
FAU - Sganzerla, E
AU  - Sganzerla E
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
TT  - L'acetilsalicilato di lisina nel controllo del dolore post-operatorio nella 
      chirurgia dell'addome alto.
PL  - Italy
TA  - Minerva Anestesiol
JT  - Minerva anestesiologica
JID - 0375272
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - RP4A60D26L (Pentazocine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Abdomen/surgery
MH  - Adult
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Pentazocine/*therapeutic use
MH  - Random Allocation
EDAT- 1981/05/01 00:00
MHDA- 1981/05/01 00:01
CRDT- 1981/05/01 00:00
PHST- 1981/05/01 00:00 [pubmed]
PHST- 1981/05/01 00:01 [medline]
PHST- 1981/05/01 00:00 [entrez]
PST - ppublish
SO  - Minerva Anestesiol. 1981 May;47(5):221-8.

PMID- 31005060
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20200616
IS  - 1476-4245 (Electronic)
IS  - 1475-4916 (Linking)
VI  - 108
IP  - 3
DP  - 2019 Aug
TI  - Effects of Ultra-Low-Dose Aspirin in Thrombosis and Haemorrhage.
PG  - 158-168
LID - 10.1055/s-0038-1677495 [doi]
AB  - BACKGROUND: Aspirin is the oldest and possibly the most widely used 
      pharmacologically active substance still used in allopathic medicine. Its effect 
      on fever and inflammation has paved the way to its anti-thrombotic effect. 
      Dilutions of aspirin have been tested for many years in the University of 
      Bordeaux, in humans as well as in animal models. METHODS: This article is a 
      review of the totality of articles published by the Laboratory of Hematology of 
      the Faculty of Pharmacy of the University of Bordeaux, reporting different doses 
      and dilutions of aspirin, different kinds of inhibitors, transgenic mice and 
      animal models of disease such as portal hypertension and cirrhosis. RESULTS: 
      Homeopathic dilutions of aspirin, notably 15 cH, have shown a pro-thrombotic 
      effect in humans and in in-vivo animal studies. Longitudinal studies in rats have 
      also shown an initial anti-thrombotic effect followed by a pro-thrombotic effect 
      of aspirin several days after a single high-dose administration. This 
      pro-thrombotic effect seems to act by inhibiting the cyclooxygenase (COX)-2 
      pathway in studies performed with COX selective inhibitors and in knock-out mice 
      without COX-1 or COX-2. This effect may explain the thrombo-embolic complications 
      described after aspirin withdrawal for the purposes of surgery or after 
      non-compliance with anti-platelet therapy, and it may be beneficial in 
      normalising primary haemostasis and decreasing haemorrhage in animal models of 
      portal hypertension and cirrhosis. CONCLUSIONS: Aspirin 15 cH acts through the 
      inhibition of the COX-2 pathway producing a clear pro-thrombotic effect. Further 
      studies should clarify if the pro-thrombotic effect of aspirin withdrawal and the 
      effect of aspirin 15 cH are related, as secondary effects of the same drug. 
      Clarifying this last outcome may be of great significance to public health.
CI  - The Faculty of Homeopathy.
FAU - Eizayaga, Francisco Xavier
AU  - Eizayaga FX
AD  - Departamento de Homeopatía, Universidad Maimónides, Buenos Aires, Argentina.
FAU - Belon, Philippe
AU  - Belon P
AD  - Centre de Recherche et de Documentation Thérapeutique, Lyon, France.
FAU - Desplat, Vanessa
AU  - Desplat V
AD  - Laboratoire d'Hématologie, UFR des Sciences Pharmaceutiques, Université de 
      Bordeaux, Bordeaux, France.
FAU - Aguejouf, Omar
AU  - Aguejouf O
AD  - Laboratoire d'Hématologie, UFR des Sciences Pharmaceutiques, Université de 
      Bordeaux, Bordeaux, France.
FAU - Doutremepuich, Christian
AU  - Doutremepuich C
AD  - Laboratoire d'Hématologie, UFR des Sciences Pharmaceutiques, Université de 
      Bordeaux, Bordeaux, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190420
PL  - Germany
TA  - Homeopathy
JT  - Homeopathy : the journal of the Faculty of Homeopathy
JID - 101140517
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cyclooxygenase 2 Inhibitors/pharmacology/therapeutic use
MH  - Disease Models, Animal
MH  - Hemorrhage/*drug therapy
MH  - Homeopathy/standards/statistics & numerical data
MH  - Humans
MH  - Mice
MH  - Rats
MH  - Thrombosis/*drug therapy
COIS- None declared.
EDAT- 2019/04/21 06:00
MHDA- 2020/06/17 06:00
CRDT- 2019/04/21 06:00
PHST- 2019/04/21 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2019/04/21 06:00 [entrez]
AID - 10.1055/s-0038-1677495 [doi]
PST - ppublish
SO  - Homeopathy. 2019 Aug;108(3):158-168. doi: 10.1055/s-0038-1677495. Epub 2019 Apr 
      20.

PMID- 19321250
OWN - NLM
STAT- MEDLINE
DCOM- 20090714
LR  - 20131121
IS  - 1873-4200 (Electronic)
IS  - 0301-4622 (Linking)
VI  - 142
IP  - 1-3
DP  - 2009 Jun
TI  - Effect of acetylsalicylic acid on the current-voltage characteristics of planar 
      lipid membranes.
PG  - 27-33
LID - 10.1016/j.bpc.2009.03.003 [doi]
AB  - Monitoring of influence of acetylsalicylic acid (ASA) on lipid bilayer 
      conductance may contribute to better understanding of molecular mechanisms 
      underlying passage of ASA into cells. This paper presents effects of increasing 
      sweeping potential on stability of egg yolk phosphatidylcholine planar bilayer 
      lipid membranes (BLM) without or with cholesterol incubated in the presence of 
      ASA. We demonstrated that current flow through bilayer membranes generated 
      fluctuating pores in their structure. Presence of cholesterol in the membrane 
      caused an increase in the value of the breakdown potential, thus confirming that 
      cholesterol had a stabilizing effect on BLM. Otherwise, ASA significantly reduced 
      these values regardless of cholesterol concentration. Overall, by destabilizing 
      the lipid bilayer, ASA contributed to the formation of metastable single pores, 
      which facilitated ASA diffusion through a bilayer. Our data point out that ASA 
      transport across the lipid bilayer takes place predominantly via the process of 
      passive diffusion. In conclusion, the effects of ASA on lipid bilayer stability 
      may contribute to drug transport through membrane lipid bilayers.
FAU - Watala, Cezary
AU  - Watala C
AD  - Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, 
      113 Zeromski str., 90-549 Lodz, Poland. cwatala@csk.umed.lodz.pl
FAU - Drapeza, Aleksandr
AU  - Drapeza A
FAU - Loban, Valery
AU  - Loban V
FAU - Asztemborska, Monika
AU  - Asztemborska M
FAU - Shcharbin, Dzmitry
AU  - Shcharbin D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090312
PL  - Netherlands
TA  - Biophys Chem
JT  - Biophysical chemistry
JID - 0403171
RN  - 0 (Lipid Bilayers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - *Electric Conductivity
MH  - Electrochemistry
MH  - Hydrogen-Ion Concentration
MH  - Lipid Bilayers/*chemistry
EDAT- 2009/03/27 09:00
MHDA- 2009/07/15 09:00
CRDT- 2009/03/27 09:00
PHST- 2008/12/16 00:00 [received]
PHST- 2009/02/27 00:00 [revised]
PHST- 2009/03/01 00:00 [accepted]
PHST- 2009/03/27 09:00 [entrez]
PHST- 2009/03/27 09:00 [pubmed]
PHST- 2009/07/15 09:00 [medline]
AID - S0301-4622(09)00050-7 [pii]
AID - 10.1016/j.bpc.2009.03.003 [doi]
PST - ppublish
SO  - Biophys Chem. 2009 Jun;142(1-3):27-33. doi: 10.1016/j.bpc.2009.03.003. Epub 2009 
      Mar 12.

PMID- 8897279
OWN - NLM
STAT- MEDLINE
DCOM- 19970226
LR  - 20131121
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 85
IP  - 10
DP  - 1996 Oct
TI  - Hydrolysis of aspirin studied by spectrophotometric and fluorometric 
      variable-temperature kinetics.
PG  - 1105-8
AB  - Pseudo-first-order rate constants for the hydrolysis of acetylsalicylic acid as a 
      function of temperature have been obtained by variable-temperature kinetic 
      experiments. A method, based on a generalization of non-isothermal analysis, has 
      been used that takes advantage of the capabilities of modern data collection and 
      processing systems. Both spectrophotometric and, for the first time under 
      non-isothermal conditions, fluorometric measurements have been carried out. The 
      results obtained are identical to those obtained under the same conditions but 
      using traditional constant-temperature kinetic runs. This provides the 
      possibility of reducing the amounts of time and chemicals usually spent in 
      collecting kinetic data in mechanistic studies in solution by an order of 
      magnitude.
FAU - Alibrandi, G
AU  - Alibrandi G
AD  - Dipartimento di Chimica Inorganica, Analitica e Struttura Molecolare, Università 
      di Messina, Italy.
FAU - Micali, N
AU  - Micali N
FAU - Trusso, S
AU  - Trusso S
FAU - Villari, A
AU  - Villari A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Fluorometry/methods
MH  - Hydrolysis
MH  - Spectrophotometry, Ultraviolet/methods
MH  - Temperature
EDAT- 1996/10/01 00:00
MHDA- 2000/07/19 11:00
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 2000/07/19 11:00 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - S0022-3549(15)50163-9 [pii]
AID - 10.1021/js950506t [doi]
PST - ppublish
SO  - J Pharm Sci. 1996 Oct;85(10):1105-8. doi: 10.1021/js950506t.

PMID- 29614147
OWN - NLM
STAT- MEDLINE
DCOM- 20190613
LR  - 20190613
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 67
IP  - 4
DP  - 2018 Apr
TI  - Clinical Inquiries: What are the benefits and risks of daily low-dose aspirin for 
      primary prevention of CV events?
PG  - 247-248
AB  - One nonfatal myocardial infarction (MI) will be avoided for every 126 to 138 
      adults who take daily aspirin for 10 years (strength of recommendation [SOR]: A, 
      systematic reviews and meta-analyses of multiple randomized controlled trials 
      [RCTs]). Taking low-dose aspirin for primary prevention shows no clear mortality 
      benefit. A benefit for primary prevention of stroke is less certain. Although no 
      evidence establishes increased risk of hemorrhagic stroke from daily low-dose 
      aspirin, one gastrointestinal hemorrhage will occur for every 72 to 357 adults 
      who take aspirin for longer than 10 years (SOR: A, systematic reviews and 
      meta-analyses of multiple RCTs and cohort studies).
FAU - Mutter, Justin
AU  - Mutter J
AD  - University of Virginia School of Medicine, Charlottesville, USA.
FAU - Grandy, Rebecca
AU  - Grandy R
AD  - Mountain Area Health Education Center, Asheville, NC, and Eshelman School of 
      Pharmacy, University of North Carolina-Chapel Hill, Asheville, USA.
FAU - Hulkower, Stephen
AU  - Hulkower S
AD  - Mountain Area Health Education Center, Asheville, NC, USA.
FAU - Stigleman, Sue
AU  - Stigleman S
AD  - Mountain Area Health Education Center, Asheville, NC, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/*therapeutic use
MH  - Primary Prevention/*methods
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2018/04/04 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/04/04 06:00
PHST- 2018/04/04 06:00 [entrez]
PHST- 2018/04/04 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
AID - jfp_6703f [pii]
PST - ppublish
SO  - J Fam Pract. 2018 Apr;67(4):247-248.

PMID- 14680441
OWN - NLM
STAT- MEDLINE
DCOM- 20040407
LR  - 20190917
IS  - 1465-6566 (Print)
IS  - 1465-6566 (Linking)
VI  - 5
IP  - 1
DP  - 2004 Jan
TI  - Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
PG  - 117-23
AB  - Stroke is the third leading cause of death in the US with recurrent events a high 
      likelihood in those who survive an initial event. The long-term goal of therapy 
      is to prevent the recurrence of stroke and other atherosclerotic events. Aspirin 
      has been the first-line agent for stroke prevention for a long time. As new 
      antiplatelet agents have been introduced, their role in the secondary prevention 
      of stroke remains to be defined. In particular, the role of the combination of 
      aspirin and modified-release dipyridamole (Aggrenox, Boehringer Ingelheim Corp.), 
      the newest product, in the secondary prevention of stroke, remains unknown. The 
      purpose of this manuscript is to review the evidence of these antiplatelet agents 
      in the secondary prevention of stroke and arrive at a conclusion specifically 
      regarding the role of Aggrenox. Clinical studies which examined stroke as a 
      single primary outcome or as one event in a combined primary outcome will be 
      reviewed.
FAU - Redman, Andrea R
AU  - Redman AR
AD  - Department of Clinical and Administrative Sciences, Mercer University Southern 
      School of Pharmacy, 3001 Mercer University Drive, Atlanta, GA 30341, USA. 
      Redman_ar@mercer.edu
FAU - Ryan, Gina J
AU  - Ryan GJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/economics/*therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Delayed-Action Preparations
MH  - Dipyridamole/economics/*therapeutic use
MH  - Drug Combinations
MH  - Humans
MH  - Platelet Aggregation Inhibitors/economics/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Secondary Prevention
MH  - Stroke/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
RF  - 33
EDAT- 2003/12/19 05:00
MHDA- 2004/04/08 05:00
CRDT- 2003/12/19 05:00
PHST- 2003/12/19 05:00 [pubmed]
PHST- 2004/04/08 05:00 [medline]
PHST- 2003/12/19 05:00 [entrez]
AID - 10.1517/14656566.5.1.117 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2004 Jan;5(1):117-23. doi: 10.1517/14656566.5.1.117.

PMID- 6510466
OWN - NLM
STAT- MEDLINE
DCOM- 19850205
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 27
IP  - 3
DP  - 1984
TI  - Platelet aggregation and plasma levels of acetylsalicylic acid in stroke patients 
      on long-term treatment with an enteric-coated aspirin formulation.
PG  - 363-5
AB  - Enteric-coated formulations of acetylsalicylic acid (ASA) should be advantageous 
      in prophylaxis after stroke because they cause fewer gastrointestinal side 
      effects. However, the absorption of unchanged ASA and the effectiveness of these 
      formulations have been questioned, which prompted the present investigation. 
      Fourteen elderly stroke patients on long-term medication with enteric-coated ASA 
      1.5 g daily and four patients on placebo were studied. When tested with 
      arachidonic acid platelet aggregation was completely inhibited in all ASA 
      subjects whereas it was normal in the controls. Plasma samples, drawn every 1/2 h 
      for 6 h after tablet intake, were analyzed by HPLC. The presence of ASA was short 
      lasting with a mean peak concentration of 55 mumol/l reached after 2-3.5 h. 
      Salicylic acid (SA) appeared later, having a mean peak value of 591 mumol/l after 
      2.5-6 h. Thus, absorption of ASA as well as inhibition of platelet aggregation 
      were confirmed during long-term medication with enteric-coated ASA.
FAU - Britton, M
AU  - Britton M
FAU - Melander, A
AU  - Melander A
FAU - Svensson, J
AU  - Svensson J
FAU - Wåhlin-Boll, E
AU  - Wåhlin-Boll E
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*blood
MH  - Cerebrovascular Disorders/*blood/drug therapy
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Tablets, Enteric-Coated
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1007/BF00542177 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1984;27(3):363-5. doi: 10.1007/BF00542177.

PMID- 3104934
OWN - NLM
STAT- MEDLINE
DCOM- 19870501
LR  - 20131121
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 41
IP  - 11
DP  - 1986 Nov
TI  - Investigation of dressings designed for treatment of alveolitis sicca dolorosa 
      ("dry socket"). Part 3: Influence of mannitol and sorbitol on properties of 
      tablets and dressings comprising acetylsalicylic acid, mefenamic acid and aseptin 
      P.
PG  - 782-3
AB  - In the dressings for dry tooth sockets, mannitol and sorbitol as solid 
      hydrophilizers have been applied. Increase of concentrations of these 
      hydrophilizers in the tablets results in dressings with increased swelling 
      ability and pharmaceutical availability but decreased viscosity and resistance to 
      washing out. These properties of the dressings are also influenced by medicinal 
      substances present. The dressing fills the tooth socket within several min, 
      removes pain and remain there for 24-48 h.
FAU - Grabowska-Bochenek, J
AU  - Grabowska-Bochenek J
FAU - Kubis, A
AU  - Kubis A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Organic Chemicals)
RN  - 0 (Tablets)
RN  - 367589PJ2C (Mefenamic Acid)
RN  - 3OWL53L36A (Mannitol)
RN  - 506T60A25R (Sorbitol)
RN  - 94187-87-8 (aseptin P)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Infective Agents/*administration & dosage/metabolism/therapeutic use
MH  - Aspirin/*administration & dosage/metabolism/therapeutic use
MH  - Bandages
MH  - Biological Availability
MH  - Dry Socket/*drug therapy
MH  - Mannitol/analysis
MH  - Mefenamic Acid/*administration & dosage/metabolism/therapeutic use
MH  - Organic Chemicals
MH  - Sorbitol/analysis
MH  - Tablets
EDAT- 1986/11/01 00:00
MHDA- 1986/11/01 00:01
CRDT- 1986/11/01 00:00
PHST- 1986/11/01 00:00 [pubmed]
PHST- 1986/11/01 00:01 [medline]
PHST- 1986/11/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1986 Nov;41(11):782-3.

PMID- 18449473
OWN - NLM
STAT- MEDLINE
DCOM- 20100301
LR  - 20211020
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 27
IP  - 4
DP  - 2009 May
TI  - Aspirin is insufficient in inhibition of platelet aggregation and thromboxane 
      formation early after coronary artery bypass surgery.
PG  - 394-9
LID - 10.1007/s11239-008-0225-y [doi]
AB  - BACKGROUND: Aspirin administered early after coronary artery bypass grafting 
      surgery (CABG) improves graft patency and patients survival. However, the 
      antiplatelet effect of aspirin seems to be variable and aspirin resistance is 
      currently still being discussed. The aim of the study was to assess aspirin 
      efficacy in the early postoperative period. METHODS: Forty patients undergoing 
      elective CABG surgery (20 in on-pump and 20 in off-pump) were enrolled in the 
      study. Functional and biochemical responses to aspirin were evaluated by 
      arachidonic acid (ARA)-induced platelet aggregation and urine 11-dehydro 
      Thromboxane B2 metabolite excretion. Samples were collected before surgery 
      (baseline; > or =7 days after aspirin withdrawal) and on days 1, 2 and 5 after 
      surgery. RESULTS: Median baseline ARA aggregability was 55%. On day 1, platelet 
      aggregability decreased (12%, P < 0.001). On day 2, despite the aspirin 
      administration, platelet aggregability exceeded the values from day 1 (38%, P < 
      0.001). Only on day 5, sufficient inhibition of platelet aggregation was achieved 
      (8%, P < 0.001). Median preoperative urine concentration of 11-dehydroTxB2 was 
      106 ng/mmol of creatinine. On day 1, the concentration decreased only slightly 
      and insignificantly (97 ng/ml, P = NS), similarly as on day 2 (86 ng/ml, P = NS). 
      Only on day 5, significant decrease in concentration of thromboxane metabolite 
      was achieved compared to preoperative values (46 ng/ml, P = 0.001). CONCLUSION: 
      Aspirin did not sufficiently inhibit platelet aggregation and thromboxane 
      formation in the early postoperative period. Thus, antiplatelet treatment 
      strategy should be intensified or modified in patients early after bypass 
      surgery.
FAU - Bednar, Frantisek
AU  - Bednar F
AD  - Cardiocenter, Department of Cardiac Surgery, 3rd Medical School, Charles 
      University and University Hospital Kralovske Vinohrady, Srobarova 50, 100 34 
      Prague, Czech Republic. fandabednar@email.cz
FAU - Osmancik, Pavel
AU  - Osmancik P
FAU - Hlavicka, Jan
AU  - Hlavicka J
FAU - Jedlickova, Vera
AU  - Jedlickova V
FAU - Paluch, Zoltan
AU  - Paluch Z
FAU - Vanek, Tomas
AU  - Vanek T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080501
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/blood/drug therapy/surgery
MH  - Coronary Artery Bypass/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Prospective Studies
MH  - Thromboxanes/*blood
EDAT- 2008/05/02 09:00
MHDA- 2010/03/02 06:00
CRDT- 2008/05/02 09:00
PHST- 2007/12/19 00:00 [received]
PHST- 2008/04/21 00:00 [accepted]
PHST- 2008/05/02 09:00 [pubmed]
PHST- 2010/03/02 06:00 [medline]
PHST- 2008/05/02 09:00 [entrez]
AID - 10.1007/s11239-008-0225-y [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2009 May;27(4):394-9. doi: 10.1007/s11239-008-0225-y. Epub 
      2008 May 1.

PMID- 2809856
OWN - NLM
STAT- MEDLINE
DCOM- 19891211
LR  - 20131121
IS  - 0030-6207 (Print)
IS  - 0030-6207 (Linking)
VI  - 39
IP  - 8-9
DP  - 1989 Aug-Sep
TI  - Effects of highly concentrated omega-3 polyunsaturated fatty acids and 
      acetylsalicylic acid, alone and combined, on bleeding time and serum lipid 
      profile.
PG  - 97-101
AB  - Twenty-two patients with stable coronary heart disease were randomly assigned to 
      either of two groups. Group I (n = 11) was given acetylsalicylic acid (ASA) 300 
      mg daily for 1 week, whereafter a daily supplement of 3,4 g eicosapentaenoic acid 
      (EPA) and docosahexaenoic acid (DHA) as a highly concentrated ethylester, 
      formulation ("K-85", Norsk Hydro) was added for another 4 weeks. Group II (n = 
      11) was given 3,4 g daily of EPA and DHA for 4 weeks, after which ASA 300 mg 
      daily was added for another week. Determination of serum fatty acids confirmed 
      satisfying absorption of EPA and DHA. A significant increase of the Ivy bleeding 
      time was registered following administration of both "K-85" (240 to 270 sec, 
      median values) and ASA (270 to 360 sec, median values) alone. A slighter increase 
      was noted by a combination of the two principles. A reduction in serum 
      triglycerides of 17% was noted after "K-85" (median values, both groups). Serum 
      total cholesterol decreased after "K-85" administration in group I, but not so in 
      group II. HDL-cholesterol remained unchanged. Serum lipids remained unaffected by 
      ASA. During administration of "K-85" no adverse effects or bleeding episodes were 
      seen.
FAU - Eritsland, J
AU  - Eritsland J
FAU - Arnesen, H
AU  - Arnesen H
FAU - Smith, P
AU  - Smith P
FAU - Seljeflot, I
AU  - Seljeflot I
FAU - Dahl, K
AU  - Dahl K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Norway
TA  - J Oslo City Hosp
JT  - Journal of the Oslo city hospitals
JID - 7908151
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Triglycerides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Bleeding Time
MH  - Blood Platelets/drug effects
MH  - Coronary Disease/blood/*drug therapy
MH  - Fatty Acids, Unsaturated/*pharmacology/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Triglycerides/blood
EDAT- 1989/08/01 00:00
MHDA- 1989/08/01 00:01
CRDT- 1989/08/01 00:00
PHST- 1989/08/01 00:00 [pubmed]
PHST- 1989/08/01 00:01 [medline]
PHST- 1989/08/01 00:00 [entrez]
PST - ppublish
SO  - J Oslo City Hosp. 1989 Aug-Sep;39(8-9):97-101.

PMID- 20446806
OWN - NLM
STAT- MEDLINE
DCOM- 20110103
LR  - 20131121
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 21
IP  - 6
DP  - 2010
TI  - Aspirin can stimulate luminol-enhanced chemiluminescence of activated platelets.
PG  - 486-9
LID - 10.3109/09537101003777947 [doi]
AB  - A preliminary investigation was conducted into the influence of aspirin on the 
      luminol-enhanced chemiluminescence of platelets stimulated with 
      platelet-activating factor (PAF). Ten coronary artery disease patients and six 
      volunteers without coronary artery disease were included in the study. All the 
      patients received aspirin (daily dose, 100 mg) for at least 10 days before in 
      vitro experiments. Luminol-enhanced luminescence of platelet-rich plasma samples 
      mixed with a PAF solution was measured. After stimulation of platelets with PAF, 
      we did not find a luminol-enhanced chemiluminescent response either in the 
      non-coronary artery disease volunteers or in eight out of the 10 coronary artery 
      disease patients examined. However, in samples from two patients where platelets 
      were stimulated with PAF reactive oxygen species were formed. This ability was 
      expressed as an intensive luminol-enhanced luminescence of activated platelets. 
      Such a reaction was observed against the background of the administration of 
      aspirin. The addition of aspirin to a test tube considerably enhanced the 
      intensity of chemiluminescence. In one case, the cancellation of aspirin was 
      accompanied by diminution of the intensity of luminol-enhanced chemiluminescence 
      of platelets. The clinical significance of this phenomenon is unknown.
FAU - Gabbasov, Zufar
AU  - Gabbasov Z
AD  - Institute of Experimental Cardiology, Cardiology Research Center, Moscow, Russia. 
      gabbasov@cardio.ru
FAU - Ivanova, Oksana
AU  - Ivanova O
FAU - Kogan-Yasny, Victor
AU  - Kogan-Yasny V
FAU - Vasilieva, Elena
AU  - Vasilieva E
LA  - eng
PT  - Journal Article
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Reactive Oxygen Species)
RN  - 5EXP385Q4F (Luminol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/chemistry
MH  - Blood Platelets/chemistry/*drug effects
MH  - Coronary Artery Disease/blood
MH  - Female
MH  - Humans
MH  - Luminescent Measurements/methods
MH  - Luminol/*chemistry
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Reactive Oxygen Species/metabolism
EDAT- 2010/05/08 06:00
MHDA- 2011/01/05 06:00
CRDT- 2010/05/08 06:00
PHST- 2010/05/08 06:00 [entrez]
PHST- 2010/05/08 06:00 [pubmed]
PHST- 2011/01/05 06:00 [medline]
AID - 10.3109/09537101003777947 [doi]
PST - ppublish
SO  - Platelets. 2010;21(6):486-9. doi: 10.3109/09537101003777947.

PMID- 16044106
OWN - NLM
STAT- MEDLINE
DCOM- 20060425
LR  - 20190906
IS  - 0163-4356 (Print)
IS  - 0163-4356 (Linking)
VI  - 27
IP  - 4
DP  - 2005 Aug
TI  - Resistance to aspirin in patients after coronary artery bypass grafting is 
      transient: impact on the monitoring of aspirin antiplatelet therapy.
PG  - 484-90
AB  - The aim of the present study was to assess the responsiveness of blood platelets 
      to aspirin in patients following coronary artery bypass grafting (CABG) surgery. 
      Aspirin was administered following CABG in 24 operated patients (aged 63.2 +/- 
      6.3 years). Platelet function was monitored on the 10th postoperative day (A) and 
      1 month after CABG (B) with the use of whole-blood aggregometry (WBEA) and 
      PFA-100 closure time (PFA-100 CTCEPI). Normal platelet response to aspirin was 
      defined by 3 criteria: the complete inhibition of WBEA induced by arachidonic 
      acid (0.5 mmol/L), partial inhibition of collagen (1 microg/mL)-induced 
      aggregation (WBEA < 14 Omega), and prolongation of PFA-100 CTCEPI (>150 seconds) 
      ("good responders"). Depending on whether 0, 1, 2, or 3 of these 3 criteria were 
      fulfilled, patients were classified as "nonresponders," "weak responders," 
      "incomplete responders," or "good responders," respectively. On the 10th 
      postoperative day, there were 3 good responders, 6 incomplete responders, 11 weak 
      responders, and 4 nonresponders among 24 patients. In contrast, 1 month after 
      CABG within the same group of 24 patients there were 18 good responders, 5 
      incomplete responders, and 1 weak responder. Using a new methodology to assess 
      impaired platelet responsiveness to aspirin ex vivo, we describe here the 
      transient nature of "aspirin resistance" following CABG. These results indicate 
      the necessity for the prolonged monitoring of the antiplatelet effectiveness of 
      aspirin in the postoperative period after CABG.
FAU - Golański, Jacek
AU  - Golański J
AD  - Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, 
      Lodz, Poland.
FAU - Chłopicki, Stefan
AU  - Chłopicki S
FAU - Golański, Ryszard
AU  - Golański R
FAU - Gresner, Peter
AU  - Gresner P
FAU - Iwaszkiewicz, Alicja
AU  - Iwaszkiewicz A
FAU - Watala, Cezary
AU  - Watala C
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ther Drug Monit
JT  - Therapeutic drug monitoring
JID - 7909660
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Biomarkers/blood
MH  - Blood Platelets/drug effects/physiology
MH  - Coronary Artery Bypass/*methods
MH  - Drug Monitoring/methods
MH  - *Drug Resistance
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Postoperative Period
MH  - Time Factors
EDAT- 2005/07/27 09:00
MHDA- 2006/04/28 09:00
CRDT- 2005/07/27 09:00
PHST- 2005/07/27 09:00 [pubmed]
PHST- 2006/04/28 09:00 [medline]
PHST- 2005/07/27 09:00 [entrez]
AID - 00007691-200508000-00014 [pii]
AID - 10.1097/01.ftd.0000158084.84071.41 [doi]
PST - ppublish
SO  - Ther Drug Monit. 2005 Aug;27(4):484-90. doi: 10.1097/01.ftd.0000158084.84071.41.

PMID- 11441320
OWN - NLM
STAT- MEDLINE
DCOM- 20011025
LR  - 20191105
IS  - 1075-2765 (Print)
IS  - 1075-2765 (Linking)
VI  - 8
IP  - 4
DP  - 2001 Jul-Aug
TI  - Age-related differences in the use of cardiac medications in patients with 
      coronary artery disease.
PG  - 225-9
AB  - BACKGROUND: Benefits of aspirin and beta-blocker use in patients with coronary 
      artery disease and angiotensin-converting enzyme (ACE) inhibitors in those with 
      left ventricular systolic dysfunction are well documented in all age groups. 
      OBJECTIVE: To investigate whether aspirin, beta-blockers, and ACE inhibitors are 
      equally used in geriatric (> or =65 years) versus younger (<65 years) patients 
      with coronary artery disease. SETTING: University-affiliated major academic 
      hospital. METHODS: Records of 402 patients with coronary artery disease were 
      analyzed for use of aspirin, beta-blockers, and ACE inhibitors. One hundred 
      thirty patients with contraindications to use of these agents were excluded. 
      RESULTS: Of 272 study patients, 85% were using aspirin and 71% beta-blockers. 
      Among the patients with left ventricular systolic dysfunction, 79% were using ACE 
      inhibitors. One hundred forty-seven patients were of geriatric age, whereas 125 
      were of younger age. No significant difference in the use of aspirin (82% versus 
      89%, P = 0.10), beta-blockers (71% versus 70%, P = 0.85), or ACE inhibitors (86% 
      versus 69%, P = 0.13) was found between geriatric and younger patients. This lack 
      of difference in use of cardiac medications between geriatric and younger 
      patients persisted on gender-based subgroup analysis. On decade-of-age-based 
      analysis, aspirin use was not equally distributed among all the decades of age (P 
      < 0.005), but beta-blocker use was. CONCLUSION: Results of this study demonstrate 
      equal use of aspirin, beta-blockers, and ACE inhibitors in geriatric versus 
      younger patients with coronary artery disease. Aspirin use was not equally 
      distributed among all the decades of age.
FAU - Mehta, R N
AU  - Mehta RN
AD  - Division of Geriatric Medicine, Long Island College Hospital, Brooklyn, NY, USA.
FAU - Khan, I A
AU  - Khan IA
FAU - Mehta, N J
AU  - Mehta NJ
FAU - Ryschon, K L
AU  - Ryschon KL
FAU - Vasavada, B C
AU  - Vasavada BC
FAU - Sacchi, T J
AU  - Sacchi TJ
FAU - Mendoza, C
AU  - Mendoza C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Coronary Disease/*drug therapy/epidemiology
MH  - Cross-Sectional Studies
MH  - Drug Utilization/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
EDAT- 2001/07/07 10:00
MHDA- 2001/10/26 10:01
CRDT- 2001/07/07 10:00
PHST- 2001/07/07 10:00 [pubmed]
PHST- 2001/10/26 10:01 [medline]
PHST- 2001/07/07 10:00 [entrez]
AID - 10.1097/00045391-200107000-00003 [doi]
PST - ppublish
SO  - Am J Ther. 2001 Jul-Aug;8(4):225-9. doi: 10.1097/00045391-200107000-00003.

PMID- 6480998
OWN - NLM
STAT- MEDLINE
DCOM- 19841109
LR  - 20190515
IS  - 0001-4966 (Print)
IS  - 0001-4966 (Linking)
VI  - 76
IP  - 2
DP  - 1984 Aug
TI  - Aspirin abolishes spontaneous oto-acoustic emissions.
PG  - 443-8
AB  - Spontaneous oto-acoustic emissions (OAEs) were measured prior to, during, and 
      following administration of aspirin. The dose schedule was three 325-mg tablets 
      every 6 h for a total of 16 doses (3.75 days). In every subject studied, all 
      spontaneous OAEs gradually diminished and then disappeared during the drug 
      regimen. Emissions that were initially small disappeared within 14-20 h of 
      beginning the drug regimen (3-4 doses), while initially large emissions took 
      40-70 h (7-12 doses) to disappear completely. In contrast, the initial size of an 
      emission appeared unrelated to the time required for it to recover to full 
      strength once drug administration ceased. The recovery process was highly 
      idiosyncratic, with the emissions of some subjects returning to full strength 
      within 24 h, while for other subjects, full recovery required several days. In 
      two subjects having multiple emissions in the same ear, the relative sizes of the 
      different emissions often changed greatly during the disappearance and recovery 
      phases. When small frequency shifts appeared for these subjects, they 
      appeared--and were in the same direction--for each of the multiple emissions. In 
      a related experiment, the spontaneous emission was unchanged in one subject who 
      took a drug that inhibits the intracellular entry of calcium ions (verapamil).
FAU - McFadden, D
AU  - McFadden D
FAU - Plattsmier, H S
AU  - Plattsmier HS
LA  - eng
GR  - NS 15895/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Acoust Soc Am
JT  - The Journal of the Acoustical Society of America
JID - 7503051
RN  - CJ0O37KU29 (Verapamil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cochlea/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - Verapamil/pharmacology
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 10.1121/1.391585 [doi]
PST - ppublish
SO  - J Acoust Soc Am. 1984 Aug;76(2):443-8. doi: 10.1121/1.391585.

PMID- 3592141
OWN - NLM
STAT- MEDLINE
DCOM- 19870716
LR  - 20190820
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 42
IP  - 3
DP  - 1987 Apr
TI  - Tolerance to acetylsalicylic acid (ASA) induced in ASA-sensitive asthmatics does 
      not depend on initial adverse reaction.
PG  - 182-5
AB  - A state of tolerance to aspirin (ASA) was induced in 10 aspirin-sensitive 
      patients by daily administration of incremental doses of ASA. No adverse 
      reactions were reported. The initial dose (from 5 to 60 mg) was gradually 
      increased each day up to 300 mg and then doubled. 50 mg indomethacin given the 
      day after administration of 600 mg ASA did not elicit any symptom of intolerance. 
      The authors discuss a possible mechanism of tolerance to aspirin in ASA-sensitive 
      asthmatics after ASA administration, suggesting that it might be connected either 
      with inhibition of the lipooxygenetic pathway of arachidonic acid metabolism or 
      with blockade of the cyclooxygenase supplementary binding site by salicylic acid, 
      a product of acetylsalicylic acid hydrolysis. This would prevent aspirin from 
      binding with the catalytic cyclooxygenase site.
FAU - Szmidt, M
AU  - Szmidt M
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
FAU - Kowalski, M L
AU  - Kowalski ML
FAU - Rozniecki, J
AU  - Rozniecki J
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*immunology
MH  - Asthma/*immunology
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/*immunology
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Indomethacin/immunology
MH  - Male
MH  - Middle Aged
EDAT- 1987/04/01 00:00
MHDA- 1987/04/01 00:01
CRDT- 1987/04/01 00:00
PHST- 1987/04/01 00:00 [pubmed]
PHST- 1987/04/01 00:01 [medline]
PHST- 1987/04/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1987.tb02197.x [doi]
PST - ppublish
SO  - Allergy. 1987 Apr;42(3):182-5. doi: 10.1111/j.1398-9995.1987.tb02197.x.

PMID- 22148001
OWN - NLM
STAT- MEDLINE
DCOM- 20120510
LR  - 20211021
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Print)
IS  - 1011-8934 (Linking)
VI  - 26
IP  - 12
DP  - 2011 Dec
TI  - Little impact of antiplatelet agents on venous thromboembolism after hip fracture 
      surgery.
PG  - 1625-9
LID - 10.3346/jkms.2011.26.12.1625 [doi]
AB  - Since the late 1980s, low dose aspirin has been used to prevent stroke and 
      ischemic heart disease. However, prophylactic effect of antiplatelets against 
      venous thromboembolism (VTE), in patients who undergo hip fracture surgery (HFS) 
      is controversial. Our purpose was to determine the incidence of symptomatic VTE 
      after HFS and to evaluate whether antiplatelets reduce the development of 
      symptomatic VTE following HFS. We retrospectively reviewed 858 HFS in 824 
      consecutive patients which were performed from May 2003 to April 2010 at an East 
      Asian institute. We compared the incidence of symptomatic VTE in antiplatelet 
      users and non-users using multivariate logistic regression analyses. Overall 
      incidences of symptomatic pulmonary embolism including fatal pulmonary embolism, 
      and symptomatic deep vein thrombosis in this study were 2.4% (21/858), and 3.5% 
      (30/858), respectively. The incidence of symptomatic VTE was 4.8% (12/250) in 
      antiplatelet users and 4.3% (26/608) in non-users (P = 0.718). It is suggested 
      that antiplatelet agents are not effective in prevention of symptomatic VTE after 
      HFS.
FAU - Ji, Hyung-Min
AU  - Ji HM
AD  - Department of Orthopaedic Surgery, Ajou University School of Medicine, Suwon, 
      Korea.
FAU - Lee, Young-Kyun
AU  - Lee YK
FAU - Ha, Yong-Chan
AU  - Ha YC
FAU - Kim, Ki-Choul
AU  - Kim KC
FAU - Koo, Kyung-Hoi
AU  - Koo KH
LA  - eng
PT  - Journal Article
DEP - 20111129
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Female
MH  - Hip Fractures/complications/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/drug therapy/*epidemiology/*prevention & control
MH  - Regression Analysis
MH  - Venous Thromboembolism/complications/*epidemiology/*prevention & control
PMC - PMC3230024
OTO - NOTNLM
OT  - Antiplatelet Agents
OT  - Hip Fractures
OT  - Incidence
OT  - Pulmonary Embolism
OT  - Venous Thromboembolism
OT  - Venous Thrombosis
EDAT- 2011/12/08 06:00
MHDA- 2012/05/11 06:00
CRDT- 2011/12/08 06:00
PHST- 2011/07/09 00:00 [received]
PHST- 2011/10/31 00:00 [accepted]
PHST- 2011/12/08 06:00 [entrez]
PHST- 2011/12/08 06:00 [pubmed]
PHST- 2012/05/11 06:00 [medline]
AID - 10.3346/jkms.2011.26.12.1625 [doi]
PST - ppublish
SO  - J Korean Med Sci. 2011 Dec;26(12):1625-9. doi: 10.3346/jkms.2011.26.12.1625. Epub 
      2011 Nov 29.

PMID- 2998640
OWN - NLM
STAT- MEDLINE
DCOM- 19860116
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 72
IP  - 6
DP  - 1985 Dec
TI  - Pharmacology of platelet inhibition in humans: implications of the 
      salicylate-aspirin interaction.
PG  - 1185-93
AB  - The current dispute over the effects of "low" vs "high" doses of aspirin should 
      take into consideration the pharmacokinetics of this drug. In fact, different 
      pharmaceutical formulations of aspirin may deliver little or no aspirin to the 
      systemic blood. This was the case, for instance, in healthy volunteers taking 320 
      mg of compressed aspirin or 800 mg of enteric-coated aspirin. In all instances 
      thromboxane B2 generation in serum was fully inhibited. Platelet cyclooxygenase 
      might therefore be effectively acetylated by exposure to aspirin in the portal 
      circulation, whereas vascular cyclooxygenase could be spared. Thus aspirin 
      formulations ensuring complete first-pass deacetylation should be sought rather 
      than "low" or "high" doses of unspecified aspirin formulations. Regardless of the 
      type and dose of aspirin administered, salicylate is formed and accumulates in 
      the circulation. It may antagonize the effects of aspirin on cyclooxygenase, at 
      least in acute conditions. As an example, after administration of 1 g of 
      salicylate to healthy volunteers, when plasma levels of the drug were about 75 
      micrograms/ml, the effect of 40 mg iv aspirin (given 40 min later) on platelet 
      cyclooxygenase and aggregation was significantly diminished. In contrast, in 
      patients undergoing saphenectomy, the same dose of salicylate (1 g) gave plasma 
      drug levels of about 25 micrograms/ml; salicylate was unable to prevent the 
      inhibitory effect on platelets of 40 mg iv aspirin (given 1 hr later) but did act 
      on vascular prostacyclin. Thus the combination of salicylate with aspirin at an 
      appropriate dose and blood level ratio may result in almost complete dissociation 
      of the drug's effect on platelets and vessels in man.(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - de Gaetano, G
AU  - de Gaetano G
FAU - Cerletti, C
AU  - Cerletti C
FAU - Dejana, E
AU  - Dejana E
FAU - Latini, R
AU  - Latini R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Salicylates)
RN  - 11062-77-4 (Superoxides)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Aspirin/administration & dosage/metabolism/*pharmacology
MH  - Blood Platelets/*drug effects/enzymology
MH  - Blood Vessels/enzymology
MH  - Cyclooxygenase Inhibitors
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Leukocytes/drug effects/metabolism
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Salicylates/*pharmacology
MH  - Salicylic Acid
MH  - Superoxides/metabolism
MH  - Thrombosis/prevention & control
RF  - 60
EDAT- 1985/12/01 00:00
MHDA- 1985/12/01 00:01
CRDT- 1985/12/01 00:00
PHST- 1985/12/01 00:00 [pubmed]
PHST- 1985/12/01 00:01 [medline]
PHST- 1985/12/01 00:00 [entrez]
AID - 10.1161/01.cir.72.6.1185 [doi]
PST - ppublish
SO  - Circulation. 1985 Dec;72(6):1185-93. doi: 10.1161/01.cir.72.6.1185.

PMID- 115978
OWN - NLM
STAT- MEDLINE
DCOM- 19800119
LR  - 20191027
IS  - 0300-9777 (Print)
IS  - 0300-9777 (Linking)
VI  - 8
IP  - 4
DP  - 1979 Aug
TI  - The effect on bone repair of aspirin cones placed in extraction sockets in dogs: 
      a histopathologic study.
PG  - 198-206
AB  - Four canines of eight 2-year-old dogs were extracted surgically, a mucoperiosteal 
      flap being raised. A standardized pair of the post-extraction cavities were 
      filled with three aspirin cones, the other pair being used as controls. The flaps 
      were sutured with surgical gut. The dogs were killed at intervals of 2, 4, 6 and 
      8 weeks; bone blocks including the cavities were resected and decalcified for 
      histologic examination; serial sections were stained with hematoxylin and 
      eosisin. Microscopic observation on 2 week samples showed an inflammatory 
      response with granulation tissue in both experimental and control cavities with 
      delayed bone apposition in cavities filled with aspirin cones. The 4, 6 and 8 
      week samples did not show any major difference between the experimental and 
      control cavities. We observed a decrease in infiltrating of cells followed in 
      both by a similarly increasing amount of fibrous tissue and bone remodeling. 
      These results were due perhaps to the details of the experimental method as the 
      suture allowed aspirin to stay in the cavities for only a short time (2--3 days), 
      as occurs in clinical practice.
FAU - Baratieri, A
AU  - Baratieri A
FAU - Deli, R
AU  - Deli R
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - J Oral Pathol
JT  - Journal of oral pathology
JID - 0342050
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/toxicity
MH  - Cuspid/*surgery
MH  - Dogs
MH  - Mandible/drug effects/*pathology
MH  - Maxilla/drug effects/*pathology
MH  - Suture Techniques
MH  - Time Factors
MH  - *Tooth Extraction
MH  - Wound Healing/*drug effects
EDAT- 1979/08/01 00:00
MHDA- 1979/08/01 00:01
CRDT- 1979/08/01 00:00
PHST- 1979/08/01 00:00 [pubmed]
PHST- 1979/08/01 00:01 [medline]
PHST- 1979/08/01 00:00 [entrez]
AID - 10.1111/j.1600-0714.1979.tb01886.x [doi]
PST - ppublish
SO  - J Oral Pathol. 1979 Aug;8(4):198-206. doi: 10.1111/j.1600-0714.1979.tb01886.x.

PMID- 941924
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20161123
IS  - 0002-9289 (Print)
IS  - 0002-9289 (Linking)
VI  - 33
IP  - 7
DP  - 1976 Jul
TI  - Activated charcoal-carboxymethylcellulose gel formulation as an antidotal agent 
      for orally ingested aspirin.
PG  - 717-9
AB  - The in vivo effect on aspirin absorption of a potentially more palatable form of 
      activated charcoal was compared to that of a simple aqueous slurry of activated 
      charcoal. The experimental formulation consisted of 20.0 g of activated charcoal, 
      2.25 g of carboxymethylcellulose (CMC) and 42.8 ml of water; it was tested with 
      and without chocolate syrup as a flavoring agent added just prior to 
      administration. Six subjects were treated in crossover fashion following an 
      aspirin dose of 972 mg. Total urinary excretion of salicylate was measured over 
      48 hours. Although all three treatments appeared to be effective in reducing the 
      rate and extent of aspirin absorption, the slurry was significantly more 
      effective in reducing the total amount absorbed than the charcoal-CMC gel with 
      chocolate syrup. The slight difference in effectiveness between the gel 
      formulation with and without the chocolate syrup was not significant.
FAU - Mathur, L K
AU  - Mathur LK
FAU - Jaffe, J M
AU  - Jaffe JM
FAU - Colaizzi, J L
AU  - Colaizzi JL
FAU - Moriarty, R W
AU  - Moriarty RW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Hosp Pharm
JT  - American journal of hospital pharmacy
JID - 0370474
RN  - 0 (Antidotes)
RN  - 0 (Drug Combinations)
RN  - 0 (Gels)
RN  - 16291-96-6 (Charcoal)
RN  - 9004-67-5 (Methylcellulose)
RN  - K679OBS311 (Carboxymethylcellulose Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Antidotes/*pharmacology
MH  - Aspirin/*metabolism/urine
MH  - Carboxymethylcellulose Sodium/*pharmacology
MH  - Charcoal/pharmacology
MH  - Depression, Chemical
MH  - Drug Combinations
MH  - Gels
MH  - Humans
MH  - Intestinal Absorption/drug effects
MH  - Male
MH  - Methylcellulose/*analogs & derivatives
MH  - Time Factors
EDAT- 1976/07/01 00:00
MHDA- 1976/07/01 00:01
CRDT- 1976/07/01 00:00
PHST- 1976/07/01 00:00 [pubmed]
PHST- 1976/07/01 00:01 [medline]
PHST- 1976/07/01 00:00 [entrez]
PST - ppublish
SO  - Am J Hosp Pharm. 1976 Jul;33(7):717-9.

PMID- 3146859
OWN - NLM
STAT- MEDLINE
DCOM- 19890317
LR  - 20131121
IS  - 0303-8173 (Print)
IS  - 0303-8173 (Linking)
VI  - 15
IP  - 3
DP  - 1988
TI  - [Changes in stomach and duodenal mucosa caused by acetylsalicylic acid therapy].
PG  - 80-2
AB  - The ulcerogenic effect of acetylsalicylic acid on the gastric and duodenal mucosa 
      is well known. In a retrospective survey we analysed 1203 gastroscopic 
      investigations from 1980 to 1986. Of these patients 47 were under therapy with 
      acetylsalicylic acid for at least 4 weeks and 39 of them (82.9%) showed 
      pathologic changes of the gastric and duodenal mucosa. The residual 1156 patients 
      received no therapy; among these only 426 patients (36.8%) showed pathologic 
      changes of the gastric and duodenal mucosa. The significant difference in the 
      incidence of peptic lesions of the gastroduodenal mucosa between the two patient 
      groups confirms the existence of an ulcerogenic side effect of acetylsalicylic 
      acid.
FAU - Prochazka, E
AU  - Prochazka E
AD  - I. Universitätsklinik für Gastroenterologie und Hepatologie Wien.
FAU - Pötzi, R
AU  - Pötzi R
FAU - Ehringer, H
AU  - Ehringer H
FAU - Gangl, A
AU  - Gangl A
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Veränderungen der Magen- und Duodenalschleimhaut unter 
      Azetylsalizylsäuretherapie.
PL  - Austria
TA  - Acta Med Austriaca
JT  - Acta medica Austriaca
JID - 7501997
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Acta Med Austriaca 1988;15(5):129
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Duodenal Ulcer/chemically induced
MH  - Duodenum/*drug effects
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Intestinal Mucosa/*drug effects
MH  - Long-Term Care
MH  - Male
MH  - Middle Aged
MH  - Stomach Ulcer/chemically induced
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Med Austriaca. 1988;15(3):80-2.

PMID- 4074414
OWN - NLM
STAT- MEDLINE
DCOM- 19860117
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 35
IP  - 10
DP  - 1985
TI  - Comparison of the concentration-effect relationship of a local antiinflammatory 
      agent and oral acetylsalicylic acid: the value of local application.
PG  - 1550-2
AB  - Using a pharmacological model, the comparison between acetylsalicylic acid (ASA), 
      administered orally, and a solution combining two salicylate derivatives (ethyl 
      5-methoxy-salicylate and 3-phenyl-propyl-salicylate), applied locally, 
      demonstrated the value of the local application. Indeed, the pharmacological 
      activity was highly significant and directly related to the tissue concentration 
      of salicyl ions, which was higher after local application of the solution than 
      after oral administration of ASA. The local solution also resulted in a lower 
      plasma concentration of salicylate ions, allowing high plasma salicylate 
      concentrations to be avoided.
FAU - Poisson, M
AU  - Poisson M
FAU - Ralambosoa, C
AU  - Ralambosoa C
FAU - Blehaut, H
AU  - Blehaut H
FAU - Astoin, J
AU  - Astoin J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Irritants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - *Anti-Inflammatory Agents
MH  - Aspirin/blood/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Edema/prevention & control
MH  - Irritants/antagonists & inhibitors
MH  - Male
MH  - Organ Size/drug effects
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1985;35(10):1550-2.

PMID- 1002084
OWN - NLM
STAT- MEDLINE
DCOM- 19770224
LR  - 20131121
IS  - 0015-8178 (Print)
IS  - 0015-8178 (Linking)
VI  - 94
IP  - 31
DP  - 1976 Nov 4
TI  - [Thrombosis, embolism and aggregation inhibitors in surgery].
PG  - 1791-8
AB  - The frequency in letal pulmonary embolism at the I. Chirurgische Univ.-Klinik and 
      the Unfallchirurgie I, Vienna, and experimental and clinical studies of the 
      protective effect of aggregation inhibitors are reported. Significant difference 
      of extent in experimentally induced venous thrombosis was found in animal groups 
      with and without preventive treatment. Two double-blind trials with 
      acetylsalicylic acid and placebo brought significant differences in the frequency 
      of letal pulmonary embolism in patients with hip fracture and a lower rate of 
      immediate post-operative vascular reobstruction due to high peripher vascular 
      resistance in patients undergoing vascular surgery.
FAU - Zekert, F
AU  - Zekert F
LA  - ger
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Thrombosen, Embolien und Aggregationshemmer in der Chirurgie.
PL  - Germany
TA  - Fortschr Med
JT  - Fortschritte der Medizin
JID - 2984763R
RN  - 0 (Anticoagulants)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Dipyridamole/pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Postoperative Complications/*prevention & control
MH  - Pulmonary Embolism/*prevention & control
MH  - Sex Factors
MH  - Thrombophlebitis/*prevention & control
EDAT- 1976/11/04 00:00
MHDA- 1976/11/04 00:01
CRDT- 1976/11/04 00:00
PHST- 1976/11/04 00:00 [pubmed]
PHST- 1976/11/04 00:01 [medline]
PHST- 1976/11/04 00:00 [entrez]
PST - ppublish
SO  - Fortschr Med. 1976 Nov 4;94(31):1791-8.

PMID- 9342481
OWN - NLM
STAT- MEDLINE
DCOM- 19971114
LR  - 20200923
IS  - 0390-6663 (Print)
IS  - 0390-6663 (Linking)
VI  - 24
IP  - 2
DP  - 1997
TI  - Pregnancy in a patient with essential thrombocytosis.
PG  - 114-5
AB  - An insurgent case of pregnancy in a patient in whom essential thrombocytosis was 
      diagnosed five years earlier is described. Pregnancy was confirmed and therapy 
      with platelet aggregation inhibitor was introduced. The pregnancy reached full 
      term notwithstanding a positive result of the "Triple Test" during the 15th week 
      of gestation. A histology exam of the placenta revealed an ischemic lesion. We 
      retain that platelet aggregation inhibitor therapy remains an important aid in 
      eliminating the risk of thrombosis determined by the presence of two conditions 
      that are predisposed to these risks, such as pregnancy and essential 
      thrombocytosis.
FAU - Rossi, G
AU  - Rossi G
AD  - Department of Infectious Diseases, Ospedale S. Maria Sopra i Ponti, Arezzo, 
      Italy.
FAU - Appiano, G
AU  - Appiano G
FAU - Lapini, L
AU  - Lapini L
FAU - Caremani, M
AU  - Caremani M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Singapore
TA  - Clin Exp Obstet Gynecol
JT  - Clinical and experimental obstetrics & gynecology
JID - 7802110
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Female
MH  - Humans
MH  - Ischemia/etiology
MH  - Placenta/blood supply
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Pregnancy
MH  - *Pregnancy Complications, Hematologic
MH  - *Pregnancy Outcome
MH  - *Thrombocytosis/complications/drug therapy/pathology
EDAT- 1997/01/01 00:00
MHDA- 1997/10/29 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/10/29 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Obstet Gynecol. 1997;24(2):114-5.

PMID- 19918728
OWN - NLM
STAT- MEDLINE
DCOM- 20100119
LR  - 20131121
IS  - 1661-8157 (Print)
IS  - 1661-8157 (Linking)
VI  - 98
IP  - 23
DP  - 2009 Nov 18
TI  - [Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic 
      options].
PG  - 1361-5; quiz 1363, 1365
LID - 10.1024/1661-8157.98.23.1361 [doi]
AB  - Chronic rhinosinusitis is often associated with bronchial asthma. If it's joined 
      by intolerance to analgetics we call it Morbus Widal or Samters Trias. Especially 
      chronic rhinosinusitis is often difficult to treat in these patients. Mostly the 
      patients suffer a lot from nasal symptoms. This article presents the clinical 
      aspects with a special focus on the therapy with acetylsalicylacid (ASA). The 
      substance is used to induce a tolerance against ASA or other NSAID 
      (desensitization or "adaptive desactivation") with the purpose to improve the 
      symptoms in the upper airways sustainable. As addition we present a retrospective 
      study generated out of data of our own patients.
FAU - Jung, H
AU  - Jung H
AD  - Hochgebirgsklinik Davos, Davos Wolfgang. harald.jung@hgk.ch
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Die chronische Rhinosinusitis bei Morbus Widal: Krankheitsbild und 
      Therapiemöglichkeiten.
PL  - Switzerland
TA  - Praxis (Bern 1994)
JT  - Praxis
JID - 101468093
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Leukotriene Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/immunology
MH  - Asthma/*chemically induced/drug therapy
MH  - Chronic Disease
MH  - Desensitization, Immunologic
MH  - *Drug Hypersensitivity/diagnosis/therapy
MH  - Humans
MH  - Leukotriene Antagonists/therapeutic use
MH  - Recurrence
MH  - *Rhinitis/diagnosis/therapy
MH  - *Sinusitis/diagnosis/therapy
MH  - Time Factors
RF  - 10
EDAT- 2009/11/18 06:00
MHDA- 2010/01/20 06:00
CRDT- 2009/11/18 06:00
PHST- 2009/11/18 06:00 [entrez]
PHST- 2009/11/18 06:00 [pubmed]
PHST- 2010/01/20 06:00 [medline]
AID - 10.1024/1661-8157.98.23.1361 [doi]
PST - ppublish
SO  - Praxis (Bern 1994). 2009 Nov 18;98(23):1361-5; quiz 1363, 1365. doi: 
      10.1024/1661-8157.98.23.1361.

PMID- 7994373
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Enhanced oxidation of bis(3,5-dibromosalicyl) fumarate alpha-alpha cross linked 
      hemoglobin by free radicals generated by xanthine/xanthine oxidase.
PG  - 517-24
AB  - The xanthine/xanthine oxidase reaction produces reproducible amounts of 
      oxygen-derived free radicals that oxidize human oxyhemoglobin (Hb). We monitored 
      the kinetics of the oxidation of stripped Hb (sHb), purified HbA0 and alpha-alpha 
      cross-linked Hb (HbXL99 alpha) at [Hb] in the 5 to 150 microM (heme) range. For 
      increasing [Hb], the oxidation halftime (t1/2) increased for all Hbs, but t1/2 
      was always less for HbXL99 alpha than for HbA0 and sHb. Such feature was 
      attributed to the lower affinity for O2 of HbXL99 alpha and may represent a 
      serious problem for use of this Hb as blood substitute.
FAU - Samaja, M
AU  - Samaja M
AD  - Department of Biomedical Science and Technology, University of Milano, Italy.
FAU - Motterlini, R
AU  - Motterlini R
FAU - Rovida, E
AU  - Rovida E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Free Radicals)
RN  - 0 (Hemoglobins)
RN  - 0 (Oxyhemoglobins)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Xanthines)
RN  - 0 (hemoglobin XL99alpha)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 1AVZ07U9S7 (Xanthine)
RN  - 54651-57-9 (hemoglobin A(0))
RN  - 9034-51-9 (Hemoglobin A)
RN  - EC 1.17.3.2 (Xanthine Oxidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemistry/metabolism
MH  - Cross-Linking Reagents
MH  - Free Radicals
MH  - Half-Life
MH  - Hemoglobin A/chemistry/metabolism
MH  - Hemoglobins/chemistry/*metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Oxidation-Reduction
MH  - Oxyhemoglobins/chemistry/metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Xanthine
MH  - Xanthine Oxidase/metabolism
MH  - Xanthines/metabolism
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117879 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):517-24. doi: 
      10.3109/10731199409117879.

PMID- 157516
OWN - NLM
STAT- MEDLINE
DCOM- 19791024
LR  - 20180216
IS  - 0025-7931 (Print)
IS  - 0025-7931 (Linking)
VI  - 37
IP  - 4
DP  - 1979
TI  - Effects of verapamil and aspirin on experimental chronic hypoxic pulmonary 
      hypertension and right ventricular hypertrophy in rats.
PG  - 192-6
AB  - Rats made hypoxic by confinement in hypoxic cages for 4 weeks developed pulmonary 
      hypertension and right ventricular hypertrophy. Treatment with Verapamil or 
      aspirin reduced both chronic hypoxic pulmonary hypertension and the hypertrophy 
      of the right ventricle. The antihypertensive effect of Verapamil is explained by 
      the involvement of the transmembrane calcium flux in pulmonary vascular smooth 
      muscle in the hypoxic vasoconstrictory response. Part of the antihypertensive 
      effect of inhibition of prostaglandin synthesis is attributed to a decrease in 
      packed cell volume produced in hypoxic, aspirin treated rats.
FAU - Kentera, D
AU  - Kentera D
FAU - Susić, D
AU  - Susić D
FAU - Zdravković, M
AU  - Zdravković M
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Respiration
JT  - Respiration; international review of thoracic diseases
JID - 0137356
RN  - 0 (Prostaglandins)
RN  - CJ0O37KU29 (Verapamil)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Biological Transport
MH  - Calcium/*metabolism
MH  - Cardiomegaly/*drug therapy
MH  - Chronic Disease
MH  - Female
MH  - Haplorhini
MH  - Hypertension, Pulmonary/*drug therapy
MH  - Prostaglandins/*biosynthesis
MH  - Rats
MH  - Verapamil/*pharmacology/therapeutic use
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1159/000194026 [doi]
PST - ppublish
SO  - Respiration. 1979;37(4):192-6. doi: 10.1159/000194026.

PMID- 1826129
OWN - NLM
STAT- MEDLINE
DCOM- 19910501
LR  - 20131121
IS  - 0022-1198 (Print)
IS  - 0022-1198 (Linking)
VI  - 36
IP  - 1
DP  - 1991 Jan
TI  - Hmong folk remedies: limited acetylation of opium by aspirin and acetaminophen.
PG  - 280-7
AB  - The traditional folk medicine of the Hmong and other Southeast Asian refugees has 
      accompanied them during their immigration in this country over the past two 
      decades. In two recent cases involving Hmong defendants, unknown solids, 
      resembling charcoal in consistency and purported to be "backache remedies," were 
      analyzed and found to be complex mixtures of aspirin, acetaminophen, caffeine and 
      partly acetylated opium. In particular, significant amounts of 
      acetylacetaminophen, 3-O-acetylmorphine, 6-O-acetylcodeine, 6-O-acetylmorphine, 
      and heroin were identified by gas chromatography/mass spectrometry. Heating 
      approximately equal weights of solid opium, aspirin, and acetaminophen at 130 
      degrees C for several hours produced a mixture of compounds showing a similar 
      acetylation pattern.
FAU - Smith, R M
AU  - Smith RM
AD  - Wisconsin Department of Justice Crime Laboratory, Madison.
FAU - Nelsen, L A
AU  - Nelsen LA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Forensic Sci
JT  - Journal of forensic sciences
JID - 0375370
RN  - 362O9ITL9D (Acetaminophen)
RN  - 8008-60-4 (Opium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/analysis/*metabolism
MH  - Acetylation
MH  - Aged
MH  - Asia, Southeastern
MH  - Aspirin/analysis/*metabolism
MH  - Back Pain/*drug therapy
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry
MH  - Hot Temperature
MH  - Humans
MH  - *Medicine, Traditional
MH  - Opium/analysis/*metabolism
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
PST - ppublish
SO  - J Forensic Sci. 1991 Jan;36(1):280-7.

PMID- 2625097
OWN - NLM
STAT- MEDLINE
DCOM- 19900409
LR  - 20190903
IS  - 0012-4486 (Print)
IS  - 0012-4486 (Linking)
VI  - 72
IP  - 3-4
DP  - 1989 Aug
TI  - Anticoagulant therapy and cataract surgery.
PG  - 367-73
AB  - A questionnaire was sent round to the 200 members of the Netherlands Intraocular 
      Implant Club (NIOIC), in which they were asked about the policy followed in 1988 
      with regard to anticoagulant therapy (ACT) and the use of aspirin before and 
      after cataract surgery. Ninety-nine formulas were returned, of which ninety-two 
      were suitable for analysis. It appeared that 62% of the eye surgeons stopped ACT, 
      whereas only 33% stopped the use of aspirin. After stopping ACT nine, in some 
      cases serious, systemic complications arose. The continuation of ACT led to 3 
      ocular complications. It would appear that continuation of ACT and the use of 
      aspirin is to be recommended.
FAU - Moll, A C
AU  - Moll AC
AD  - Department of Ophthalmology, Erasmus University, Rotterdam, The Netherlands.
FAU - van Rij, G
AU  - van Rij G
FAU - van der Loos, T L
AU  - van der Loos TL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Doc Ophthalmol
JT  - Documenta ophthalmologica. Advances in ophthalmology
JID - 0370667
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cataract Extraction/*adverse effects
MH  - Hemorrhage/etiology/prevention & control
MH  - Humans
MH  - Postoperative Care
MH  - Preoperative Care
MH  - Surveys and Questionnaires
MH  - Vascular Diseases/drug therapy/etiology
EDAT- 1989/08/01 00:00
MHDA- 1989/08/01 00:01
CRDT- 1989/08/01 00:00
PHST- 1989/08/01 00:00 [pubmed]
PHST- 1989/08/01 00:01 [medline]
PHST- 1989/08/01 00:00 [entrez]
AID - 10.1007/BF00153505 [doi]
PST - ppublish
SO  - Doc Ophthalmol. 1989 Aug;72(3-4):367-73. doi: 10.1007/BF00153505.

PMID- 7351346
OWN - NLM
STAT- MEDLINE
DCOM- 19800324
LR  - 20190816
IS  - 0020-5915 (Print)
IS  - 0020-5915 (Linking)
VI  - 61
IP  - 2
DP  - 1980
TI  - Effect of aspirin on complement in vivo.
PG  - 145-9
AB  - Following ingestion of aspirin (1 g) complement consumption could be demonstrated 
      in 18/20 healthy volunteers. A slight to moderate decrease of whole complement 
      activity (CH50) and of the components C1, C4 and C2 was found. In addition, 
      reduced levels of the C1 inactivator (C1 IA) were measured in 19/20 probands. The 
      drop in C titers and C1 IA was only detectable within a short period of time and 
      30 min after ingestion of the drug the titers were usually returning to normal. 
      In view of these findings, the possible role of complement in adverse reactions 
      to aspirin is discussed.
FAU - Voigtländer, V
AU  - Voigtländer V
FAU - Hänsch, G M
AU  - Hänsch GM
FAU - Rother, U
AU  - Rother U
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Int Arch Allergy Appl Immunol
JT  - International archives of allergy and applied immunology
JID - 0404561
RN  - 0 (Complement C1)
RN  - 0 (Complement C1 Inactivator Proteins)
RN  - 0 (Complement C2)
RN  - 0 (Complement C4)
RN  - 9007-36-7 (Complement System Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*pharmacology
MH  - Complement Activation/*drug effects
MH  - Complement C1/metabolism
MH  - Complement C1 Inactivator Proteins/metabolism
MH  - Complement C2/metabolism
MH  - Complement C4/metabolism
MH  - Complement System Proteins/*metabolism
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Time Factors
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1159/000232427 [doi]
PST - ppublish
SO  - Int Arch Allergy Appl Immunol. 1980;61(2):145-9. doi: 10.1159/000232427.

PMID- 15658875
OWN - NLM
STAT- MEDLINE
DCOM- 20050304
LR  - 20131121
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 48
IP  - 2
DP  - 2005 Jan 27
TI  - Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: 
      studies on the mode of drug action.
PG  - 622-9
AB  - Cobalt-alkyne complexes are drugs with remarkable cytotoxicity. From the 
      complexes tested up to now we selected the aspirin derivative 
      [2-acetoxy-(2-propynyl)benzoate]hexacarbonyldicobalt (Co-ASS) as the lead 
      compound. To get more insight into the mode of action, we systematically modified 
      the alkyne ligand and determined the cytotoxic properties of the resulting cobalt 
      complexes. Further investigations were performed on the drug lipophilicity, the 
      cellular uptake into MCF-7 and MDA-MB 231 breast cancer cells, the DNA-binding 
      efficacy, and the nuclear drug content. The ability to inhibit glutathione 
      reductase and cyclooxygenase (COX) enzymes, the binding to the estrogen receptor, 
      and the induction of apoptotic processes were examined for selected compounds. 
      Interestingly, the most antitumor active compounds were potent COX inhibitors 
      (COX-1 and COX-2). The presented results indicate that cobalt-alkyne complexes of 
      the Co-ASS type, represent a new class of organometallic cytostatics with a mode 
      of drug action in which COX inhibition probably plays a major role.
FAU - Ott, Ingo
AU  - Ott I
AD  - Institute of Pharmacy, Free University of Berlin, Königin Luise Str. 2+4, 14195 
      Berlin, Germany.
FAU - Schmidt, Kathrin
AU  - Schmidt K
FAU - Kircher, Brigitte
AU  - Kircher B
FAU - Schumacher, Petra
AU  - Schumacher P
FAU - Wiglenda, Thomas
AU  - Wiglenda T
FAU - Gust, Ronald
AU  - Gust R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Alkynes)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Membrane Proteins)
RN  - 0 (Organometallic Compounds)
RN  - 3G0H8C9362 (Cobalt)
RN  - 9007-49-2 (DNA)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alkynes/chemical synthesis/chemistry/*pharmacology
MH  - Antineoplastic Agents/chemical synthesis/chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*analogs & derivatives/chemical synthesis/chemistry/*pharmacology
MH  - Cell Line, Tumor
MH  - Cell Nucleus/metabolism
MH  - *Cobalt
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/chemical synthesis/chemistry/pharmacology
MH  - DNA/chemistry
MH  - Drug Screening Assays, Antitumor
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Membrane Proteins
MH  - Organometallic Compounds/chemical synthesis/chemistry/*pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
EDAT- 2005/01/22 09:00
MHDA- 2005/03/05 09:00
CRDT- 2005/01/22 09:00
PHST- 2005/01/22 09:00 [pubmed]
PHST- 2005/03/05 09:00 [medline]
PHST- 2005/01/22 09:00 [entrez]
AID - 10.1021/jm049326z [doi]
PST - ppublish
SO  - J Med Chem. 2005 Jan 27;48(2):622-9. doi: 10.1021/jm049326z.

PMID- 23765256
OWN - NLM
STAT- MEDLINE
DCOM- 20131203
LR  - 20211021
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 58
IP  - 10
DP  - 2013 Oct
TI  - The role of food for the formation and prevention of gastrointestinal lesions 
      induced by aspirin in cats.
PG  - 2840-9
LID - 10.1007/s10620-013-2725-7 [doi]
AB  - BACKGROUND/AIMS: The effects of feeding conditions (fasted or fed) and dietary 
      fiber (DF) in the diet on gastrointestinal (GI) damage induced by aspirin (ASA) 
      were examined in cats. METHODS: Plain ASA (P-ASA, 20 mg/kg) or one enteric-coated 
      ASA tablet (EC-ASA, containing 100 mg ASA) was administered p.o. once daily for 3 
      or 7 days just after morning meal, 3 h after the evening meal, or in the morning 
      without a morning meal (fasted). Several types of diet, dry food (DRY, DF: 2.8 
      %), canned food (CAN, DF: 0.4 %), and diets with added cellulose or pectin were 
      provided twice daily. RESULTS: P-ASA or EC-ASA administered just after feeding of 
      DRY caused marked lesions in the GI tract, although EC-ASA did not produce any 
      lesions in the stomach. GI damage was markedly decreased when ASA was 
      administered 3 h after the evening meal. The induction of lesions by EC-ASA was 
      markedly decreased in cats that ate CAN, but lesions were induced in cats fed CAN 
      with added cellulose (6 %). The addition of pectin (6 %) to the DRY markedly 
      decreased the induction of lesions by EC-ASA. CONCLUSIONS: The results indicate 
      that the induction of GI lesions by ASA was highly dependent on the feeding 
      conditions and DF. To minimize the induction of GI damage, it would be better to 
      take ASA 3 h after the evening meal, or after consuming diets that contain low 
      amounts of insoluble DF and high amounts of soluble DF.
FAU - Satoh, Hiroshi
AU  - Satoh H
AD  - Division of Pathological Sciences, Department of Pharmacology and Experimental 
      Therapeutics, Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto, 
      607-8414, Japan, h_satoh@mb.kyoto-phu.ac.jp.
FAU - Amagase, Kikuko
AU  - Amagase K
FAU - Takeuchi, Koji
AU  - Takeuchi K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20130614
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Dietary Fiber)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 0E43V0BB57 (Misoprostol)
RN  - 80061L1WGD (Cimetidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects/pharmacology
MH  - Cats
MH  - Cimetidine/therapeutic use
MH  - *Diet
MH  - Dietary Fiber/pharmacology
MH  - Disease Models, Animal
MH  - Eating/*physiology
MH  - Female
MH  - Intestines/drug effects/pathology
MH  - Male
MH  - Misoprostol/therapeutic use
MH  - Peptic Ulcer/*chemically induced/physiopathology/*prevention & control
MH  - Stomach/drug effects/pathology
MH  - Tablets, Enteric-Coated
EDAT- 2013/06/15 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/06/15 06:00
PHST- 2013/03/16 00:00 [received]
PHST- 2013/05/15 00:00 [accepted]
PHST- 2013/06/15 06:00 [entrez]
PHST- 2013/06/15 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 10.1007/s10620-013-2725-7 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2013 Oct;58(10):2840-9. doi: 10.1007/s10620-013-2725-7. Epub 2013 
      Jun 14.

PMID- 34935556
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20220913
IS  - 1460-2202 (Electronic)
IS  - 0271-3683 (Linking)
VI  - 47
IP  - 4
DP  - 2022 Apr
TI  - An Evaluation of the Inhibition Effects of Cell Migration of Aspirin Soaking 
      360°Square-Edge Intraocular Lens in an in Vitro Lens Capsule Model.
PG  - 565-572
LID - 10.1080/02713683.2021.2012201 [doi]
AB  - PURPOSE: This study performs to evaluate the Hydrophobic and Hydrosmart 
      360°square-edge intraocular lens drug delivery of Aspirin using an in vitro lens 
      capsular model. METHODS: Cell counting kit-8 assay was used to calculate 50% 
      inhibiting concentration values in both SRA01/04 and HLE-B3 cells. Hoechst 
      staining and transwell assay were used to detect cell proliferation and cell 
      migration. The in vitro lens capsule model was established mainly with a special 
      transwell-col and cell climbing sheet, in which an intraocular lens and the 
      TGF-β2 were added. The ultraviolet spectrophotometer was used to measure the drug 
      concentrations released in vitro. Cell-exclusion zone assay was used to detect 
      the cell migration in the in vitro capsular model. RESULTS: It shows that cell 
      morphology and distribution of SRA01/04 in the in vitro lens capsular model were 
      closer to those in vivo. The results revealed that there could be significant 
      inhibiting effects on cell migration of the hydrosmart intraocular lens with a 
      sustained drug release in vitro in 7 days, while the hydrophobic intraocular lens 
      drug delivery of Aspirin was mainly performed only from day 1 to day 3. 
      CONCLUSIONS: Results showed the developed hydrosmart intraocular lens could 
      release Aspirin continuously in vitro to inhibit the cell migration of lens 
      epithelial cells.
FAU - Feiyue, Lian
AU  - Feiyue L
AD  - Department of Ophthalmology, The Fourth Affiliated Hospital of China Medical 
      University, Shenyang, China.
FAU - Yang, Li
AU  - Yang L
AD  - Department of Ophthalmology, The Fourth Affiliated Hospital of China Medical 
      University, Shenyang, China.
FAU - Zhao, Jiangyue
AU  - Zhao J
AD  - Department of Ophthalmology, The Fourth Affiliated Hospital of China Medical 
      University, Shenyang, China.
FAU - Yu, Qin
AU  - Yu Q
AD  - Department of Ophthalmology, The Fourth Affiliated Hospital of China Medical 
      University, Shenyang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211222
PL  - England
TA  - Curr Eye Res
JT  - Current eye research
JID - 8104312
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - *Capsule Opacification/prevention & control
MH  - Cell Movement
MH  - Epithelial Cells
MH  - Humans
MH  - *Lens Capsule, Crystalline
MH  - *Lens, Crystalline
MH  - *Lenses, Intraocular
OTO - NOTNLM
OT  - Aspirin
OT  - Posterior capsule opacification
OT  - cell migration
OT  - in vitro capsular model
OT  - intraocular lens
EDAT- 2021/12/23 06:00
MHDA- 2022/06/03 06:00
CRDT- 2021/12/22 12:29
PHST- 2021/12/23 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
PHST- 2021/12/22 12:29 [entrez]
AID - 10.1080/02713683.2021.2012201 [doi]
PST - ppublish
SO  - Curr Eye Res. 2022 Apr;47(4):565-572. doi: 10.1080/02713683.2021.2012201. Epub 
      2021 Dec 22.

PMID- 15961819
OWN - NLM
STAT- MEDLINE
DCOM- 20050711
LR  - 20181113
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Print)
IS  - 0959-8138 (Linking)
VI  - 330
IP  - 7505
DP  - 2005 Jun 18
TI  - Aspirin for everyone older than 50? Against.
PG  - 1442-3
AB  - Current population screening for vascular disease is neither efficient nor 
      effective. Peter Elwood and colleagues believe we should have a public 
      information strategy highlighting the benefits (and risks) of aspirin for older 
      people, but Colin Baigent argues that the evidence of benefit is not yet strong 
      enough
FAU - Baigent, Colin
AU  - Baigent C
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe 
      Infirmary, Oxford OX2 6HE. colin.baigent@ctsu.ox.ac.uk
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - BMJ. 2005 Jun 18;330(7505):1440-1. PMID: 15961818
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Infarction/*pathology
MH  - Risk Factors
PMC - PMC558386
EDAT- 2005/06/18 09:00
MHDA- 2005/07/12 09:00
CRDT- 2005/06/18 09:00
PHST- 2005/06/18 09:00 [pubmed]
PHST- 2005/07/12 09:00 [medline]
PHST- 2005/06/18 09:00 [entrez]
AID - 330/7505/1442 [pii]
AID - 03301442 [pii]
AID - 10.1136/bmj.330.7505.1442 [doi]
PST - ppublish
SO  - BMJ. 2005 Jun 18;330(7505):1442-3. doi: 10.1136/bmj.330.7505.1442.

PMID- 31525775
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20200615
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 171
IP  - 8
DP  - 2019 Oct 15
TI  - Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From 
      Aspirin for Primary Prevention: A Benefit-Harm Analysis.
PG  - 529-539
LID - 10.7326/M19-1132 [doi]
AB  - BACKGROUND: Whether the benefits of aspirin for the primary prevention of 
      cardiovascular disease (CVD) outweigh its bleeding harms in some patients is 
      unclear. OBJECTIVE: To identify persons without CVD for whom aspirin would 
      probably result in a net benefit. DESIGN: Individualized benefit-harm analysis 
      based on sex-specific risk scores and estimates of the proportional effect of 
      aspirin on CVD and major bleeding from a 2019 meta-analysis. SETTING: New Zealand 
      primary care. PARTICIPANTS: 245 028 persons (43.6% women) aged 30 to 79 years 
      without established CVD who had their CVD risk assessed between 2012 and 2016. 
      MEASUREMENTS: The net effect of aspirin was calculated for each participant by 
      subtracting the number of CVD events likely to be prevented (CVD risk 
      score × proportional effect of aspirin on CVD risk) from the number of major 
      bleeds likely to be caused (major bleed risk score × proportional effect of 
      aspirin on major bleeding risk) over 5 years. RESULTS: 2.5% of women and 12.1% of 
      men were likely to have a net benefit from aspirin treatment for 5 years if 1 CVD 
      event was assumed to be equivalent in severity to 1 major bleed, increasing to 
      21.4% of women and 40.7% of men if 1 CVD event was assumed to be equivalent to 2 
      major bleeds. Net benefit subgroups had higher baseline CVD risk, higher levels 
      of most established CVD risk factors, and lower levels of bleeding-specific risk 
      factors than net harm subgroups. LIMITATIONS: Risk scores and effect estimates 
      were uncertain. Effects of aspirin on cancer outcomes were not considered. 
      Applicability to non-New Zealand populations was not assessed. CONCLUSION: For 
      some persons without CVD, aspirin is likely to result in net benefit. PRIMARY 
      FUNDING SOURCE: Health Research Council of New Zealand.
FAU - Selak, Vanessa
AU  - Selak V
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., Y.C., S.W.).
FAU - Jackson, Rod
AU  - Jackson R
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., Y.C., S.W.).
FAU - Poppe, Katrina
AU  - Poppe K
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., Y.C., S.W.).
FAU - Wu, Billy
AU  - Wu B
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., Y.C., S.W.).
FAU - Harwood, Matire
AU  - Harwood M
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., Y.C., S.W.).
FAU - Grey, Corina
AU  - Grey C
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., Y.C., S.W.).
FAU - Pylypchuk, Romana
AU  - Pylypchuk R
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., Y.C., S.W.).
FAU - Mehta, Suneela
AU  - Mehta S
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., Y.C., S.W.).
FAU - Choi, Yeun-Hyang
AU  - Choi YH
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., Y.C., S.W.).
FAU - Kerr, Andrew
AU  - Kerr A
AD  - University of Auckland and Middlemore Hospital, Auckland, New Zealand (A.K.).
FAU - Wells, Sue
AU  - Wells S
AD  - University of Auckland, Auckland, New Zealand (V.S., R.J., K.P., B.W., M.H., 
      C.G., R.P., S.M., Y.C., S.W.).
LA  - eng
PT  - Journal Article
DEP - 20190917
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2019 Oct 15;171(8):583-584. PMID: 31525772
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Precision Medicine/methods
MH  - Primary Prevention/*methods
MH  - Proportional Hazards Models
MH  - Risk Assessment
EDAT- 2019/09/17 06:00
MHDA- 2020/06/17 06:00
CRDT- 2019/09/17 06:00
PHST- 2019/09/17 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2019/09/17 06:00 [entrez]
AID - 2751452 [pii]
AID - 10.7326/M19-1132 [doi]
PST - ppublish
SO  - Ann Intern Med. 2019 Oct 15;171(8):529-539. doi: 10.7326/M19-1132. Epub 2019 Sep 
      17.

PMID- 12766359
OWN - NLM
STAT- MEDLINE
DCOM- 20030717
LR  - 20171101
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 16
IP  - 1
DP  - 2003
TI  - The antiplatelet aggregation effects of aspirin suppositories.
PG  - 31-5
AB  - To confirm that aspirin suppositories are an effective treatment for acute 
      ischemic stroke, we examined the suppressive effects of 200-mg aspirin 
      suppositories on platelet aggregation. Aspirin suppositories suppressed platelet 
      aggregation induced by ADP or collagen, and the suppression continued for 24 h. 
      There was no significant difference in suppression of platelet aggregation 
      between aspirin administered by suppository and orally given aspirin. These 
      results suggest that aspirin suppositories are a useful treatment for acute 
      ischemic stroke.
CI  - Copyright 2003 S. Karger AG, Basel
FAU - Nakayasu, Hiroyuki
AU  - Nakayasu H
AD  - Department of Neurology, Institute of Neurological Sciences, Faculty of Medicine, 
      Tottori University, Yonago, Japan.
FAU - Maeda, Masanobu
AU  - Maeda M
FAU - Soda, Takao
AU  - Soda T
FAU - Iijima, Kenji
AU  - Iijima K
FAU - Ishimoto, Manabu
AU  - Ishimoto M
FAU - Ieiri, Ichiro
AU  - Ieiri I
FAU - Tabuchi, Fumie
AU  - Tabuchi F
FAU - Otsubo, Kenji
AU  - Otsubo K
FAU - Nakashima, Kenji
AU  - Nakashima K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Suppositories)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/antagonists & inhibitors/pharmacology
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacokinetics/*therapeutic use
MH  - Collagen/antagonists & inhibitors/pharmacology
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & 
      dosage/pharmacokinetics/*therapeutic use
MH  - Sex Characteristics
MH  - Suppositories
EDAT- 2003/05/27 05:00
MHDA- 2003/07/18 05:00
CRDT- 2003/05/27 05:00
PHST- 2002/02/20 00:00 [received]
PHST- 2002/07/30 00:00 [accepted]
PHST- 2003/05/27 05:00 [pubmed]
PHST- 2003/07/18 05:00 [medline]
PHST- 2003/05/27 05:00 [entrez]
AID - 70112 [pii]
AID - 10.1159/000070112 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2003;16(1):31-5. doi: 10.1159/000070112.

PMID- 9825650
OWN - NLM
STAT- MEDLINE
DCOM- 19990120
LR  - 20131121
IS  - 1426-9686 (Print)
IS  - 1426-9686 (Linking)
VI  - 4
IP  - 23
DP  - 1998 May
TI  - [Urticaria (angioedema type sensitivity) caused by aspirin].
PG  - 233-7
AB  - The paper deals with urticaria/angioedema type of sensitivity to aspirin and 
      other nonsteroidal antiinflammatory drugs. The clinical, alergological studies 
      and usefulness of the available diagnostic methods are presented. The 
      pathomechanism of bronchospastic and urticarial type of sensitivity to aspirin is 
      also discussed.
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
AD  - Klinika Pneumonologii i Alergologii IMW Akademii Medycznej w Lodzi.
LA  - pol
PT  - Editorial
PT  - English Abstract
PT  - Review
TT  - Pokrzywkowo-obrzekowa postać nadwrazliwości na kwas acetylosalicylowy.
PL  - Poland
TA  - Pol Merkur Lekarski
JT  - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
JID - 9705469
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Urticaria/*chemically induced
RF  - 54
EDAT- 1998/11/24 00:00
MHDA- 1998/11/24 00:01
CRDT- 1998/11/24 00:00
PHST- 1998/11/24 00:00 [pubmed]
PHST- 1998/11/24 00:01 [medline]
PHST- 1998/11/24 00:00 [entrez]
PST - ppublish
SO  - Pol Merkur Lekarski. 1998 May;4(23):233-7.

PMID- 773495
OWN - NLM
STAT- MEDLINE
DCOM- 19760802
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 1
IP  - 6016
DP  - 1976 Apr 24
TI  - Prevention of postoperative deep vein thrombosis with dipyridamole and aspirin.
PG  - 992-4
AB  - One hundred and sixty patients have been studied in a controlled trial of two 
      drugs which have been in combination to prevent postoperative-deep-vein 
      thrombosis. Both the drugs, dipyridamole (Persantin) and aspirin, were given by 
      mouth from the evening before operation and for seven days after operation. The 
      radioactive fibrinogen test was used to diagnose thrombosis. Of the 85 patients 
      in the control group 24 developed thrombosis (28%). Twelve out of 85 patients 
      (14%) in the test group were found to have thrombosis. Similar significant 
      differences in incidence were found in the various subgroups.
FAU - Renney, J T
AU  - Renney JT
FAU - O'Sullivan, E F
AU  - O'Sullivan EF
FAU - Burke, P F
AU  - Burke PF
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation
MH  - Postoperative Complications/*prevention & control
MH  - Radionuclide Imaging
MH  - Thrombophlebitis/diagnosis/*prevention & control
PMC - PMC1639649
EDAT- 1976/04/24 00:00
MHDA- 1976/04/24 00:01
CRDT- 1976/04/24 00:00
PHST- 1976/04/24 00:00 [pubmed]
PHST- 1976/04/24 00:01 [medline]
PHST- 1976/04/24 00:00 [entrez]
AID - 10.1136/bmj.1.6016.992 [doi]
PST - ppublish
SO  - Br Med J. 1976 Apr 24;1(6016):992-4. doi: 10.1136/bmj.1.6016.992.

PMID- 25099258
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20211021
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 78
IP  - 2
DP  - 2014 Aug
TI  - Increased platelet expression of glycoprotein IIIa following aspirin treatment in 
      aspirin-resistant but not aspirin-sensitive subjects.
PG  - 320-8
LID - 10.1111/bcp.12335 [doi]
AB  - AIMS: Aspirin is widely used as an anti-platelet agent for cardiovascular 
      prophylaxis. Despite aspirin treatment, many patients experience recurrent 
      thrombotic events, and aspirin resistance may contribute to this. We examined the 
      prevalence of aspirin resistance in a healthy population, and investigated 
      whether the platelet proteome differed in aspirin-resistant subjects. METHODS: 
      Ninety-three healthy subjects received aspirin 300 mg daily for 28 days. Before 
      and at the end of treatment, urine was taken to determine 11-dehydrothromboxane 
      B2 , and blood was taken to measure arachidonic acid (AA)-induced aggregation of 
      platelet-rich plasma and to interrogate the platelet proteome by mass 
      spectrometric analysis with further confirmation of findings using Western 
      blotting. RESULTS: In two of the 93 subjects, neither AA-induced aggregation nor 
      urinary 11-dehydrothromboxane B2 was effectively suppressed by aspirin, despite 
      measurable plasma salicylate concentrations, suggesting the presence of true 
      aspirin resistance. Despite no detectable differences in the platelet proteome at 
      baseline, following aspirin a marked increase was seen in platelet glycoprotein 
      IIIa expression in the aspirin-resistant but not aspirin-sensitive subjects. An 
      increase in platelet glycoprotein IIIa expression with aspirin resistance was 
      confirmed in a separate cohort of 17 patients with stable coronary artery disease 
      on long term aspirin treatment, four of whom exhibited aspirin resistance. 
      CONCLUSIONS: In a healthy population, true aspirin resistance is uncommon but 
      exists. Resistance is associated with an increase in platelet glycoprotein IIIa 
      expression in response to aspirin. These data shed new light on the mechanism of 
      aspirin resistance, and provide the potential to identify aspirin-resistant 
      subjects using a novel biomarker.
CI  - © 2014 The British Pharmacological Society.
FAU - Floyd, Christopher N
AU  - Floyd CN
AD  - Department of Clinical Pharmacology, Cardiovascular Division, British Heart 
      Foundation Centre of Research Excellence, King's College London, London, UK.
FAU - Goodman, Timothy
AU  - Goodman T
FAU - Becker, Silke
AU  - Becker S
FAU - Chen, Nan
AU  - Chen N
FAU - Mustafa, Agnesa
AU  - Mustafa A
FAU - Schofield, Emma
AU  - Schofield E
FAU - Campbell, James
AU  - Campbell J
FAU - Ward, Malcolm
AU  - Ward M
FAU - Sharma, Pankaj
AU  - Sharma P
FAU - Ferro, Albert
AU  - Ferro A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Integrin beta3)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/blood/*pharmacology/urine
MH  - Blood Platelets/cytology/*drug effects/metabolism
MH  - Cohort Studies
MH  - Coronary Artery Disease/blood/drug therapy
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Integrin beta3/*biosynthesis
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane B2/analogs & derivatives/urine
PMC - PMC4137824
OTO - NOTNLM
OT  - aspirin resistance
OT  - glycoprotein IIIa
OT  - platelets
OT  - proteomics
EDAT- 2014/08/08 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/08/08 06:00
PHST- 2013/12/09 00:00 [received]
PHST- 2014/01/18 00:00 [accepted]
PHST- 2014/08/08 06:00 [entrez]
PHST- 2014/08/08 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - 10.1111/bcp.12335 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2014 Aug;78(2):320-8. doi: 10.1111/bcp.12335.

PMID- 3416553
OWN - NLM
STAT- MEDLINE
DCOM- 19881021
LR  - 20190510
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 44
IP  - 3
DP  - 1988 Sep
TI  - Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.
PG  - 320-5
AB  - Platelet aggregation in vivo occurs through the combined effects of many 
      agonists. Aspirin inhibits platelet aggregation but its antiaggregate effects can 
      be overcome by the synergistic action of sodium arachidonate (AA) plus platelet 
      activating factor (PAF). We tested the effect of a calcium entry-blocking agent, 
      diltiazem, on AA-PAF-induced platelet aggregation in platelet-rich plasma from 
      seven healthy volunteers. The studies were done before and after aspirin (100 
      mg/day) administration for 7 to 10 days. Stimulation of platelet was done in 
      vitro by AA, PAF, or both. Before aspirin treatment, diltiazem (2 micrograms/ml) 
      added in vitro to the platelet-rich plasma inhibited platelet aggregation induced 
      by AA (0.75 mmol/L) by 50%. When PAF was used the inhibition of aggregation was 
      obtained at a lower concentration of diltiazem (0.4 to 1 microgram/ml). After 
      aspirin treatment, AA-induced aggregation was inhibited, and PAF alone (30 
      nmol/L) produced a first-wave aggregation followed by complete disaggregation. 
      When AA and PAF were added together a full aggregation of postaspirin treatment 
      platelets was obtained. Diltiazem added in vitro at the clinically attainable 
      concentration of 0.1 microgram/ml produced a complete inhibition of this AA-PAF 
      synergism on platelet aggregation. These results suggest that administration of a 
      combination of low-dose aspirin and diltiazem may be of greater benefit than 
      aspirin alone for prophylaxis of cardiovascular diseases where platelets are 
      involved in the pathogenesis.
FAU - Altman, R
AU  - Altman R
AD  - Centro de Estudios Medicos y Bioquimicos, Buenos Aires, Argentina.
FAU - Scazziota, A
AU  - Scazziota A
FAU - Dujovne, C
AU  - Dujovne C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Arachidonic Acids)
RN  - 0 (Platelet Activating Factor)
RN  - EE92BBP03H (Diltiazem)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Diltiazem/administration & dosage/*pharmacology
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Activating Factor/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Time Factors
EDAT- 1988/09/01 00:00
MHDA- 1988/09/01 00:01
CRDT- 1988/09/01 00:00
PHST- 1988/09/01 00:00 [pubmed]
PHST- 1988/09/01 00:01 [medline]
PHST- 1988/09/01 00:00 [entrez]
AID - 0009-9236(88)90453-5 [pii]
AID - 10.1038/clpt.1988.157 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1988 Sep;44(3):320-5. doi: 10.1038/clpt.1988.157.

PMID- 19683923
OWN - NLM
STAT- MEDLINE
DCOM- 20091123
LR  - 20220311
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 19
IP  - 18
DP  - 2009 Sep 15
TI  - NO-NSAIDs: Gastric-sparing nitric oxide-releasable prodrugs of non-steroidal 
      anti-inflammatory drugs.
PG  - 5297-301
LID - 10.1016/j.bmcl.2009.07.142 [doi]
AB  - Recently, a new class of nitric-oxide-releasing non-steroidal anti-inflammatory 
      drugs (NO-NSAIDs) is being studied as 'Safe NSAIDs' because of their 
      gastric-sparing properties. As an extension of our novel disulfide linker 
      technology, we have designed, synthesized and evaluated novel NO-releasing NSAID 
      prodrugs such as NO-Aspirin (1b-d) and NO-Diclofenac (2b-c). Although the 
      amide-containing derivative 1d did not show any bioavailability, the remaining 
      compounds have shown fair to excellent pharmacokinetic, anti-inflammatory and 
      gastric-sparing properties. Among them, however, the NO-Diclofenac (2b) has shown 
      the most promising pharmacokinetic, anti-inflammatory and NO-releasing properties 
      and protected rats from NSAID-induced gastric damage which could be attributable 
      to the beneficial effects of NO released from these prodrugs.
FAU - Nemmani, Kumar V S
AU  - Nemmani KV
AD  - Pharmacology Department, Piramal Life Sciences Limited, Nirlon Complex, Goregaon 
      East, Mumbai 400 063, India.
FAU - Mali, Sunil V
AU  - Mali SV
FAU - Borhade, Namdev
AU  - Borhade N
FAU - Pathan, Asif R
AU  - Pathan AR
FAU - Karwa, Manoj
AU  - Karwa M
FAU - Pamidiboina, Venu
AU  - Pamidiboina V
FAU - Senthilkumar, S P
AU  - Senthilkumar SP
FAU - Gund, Machhindra
AU  - Gund M
FAU - Jain, Arun K
AU  - Jain AK
FAU - Mangu, Naveen K
AU  - Mangu NK
FAU - Dubash, Nauzer P
AU  - Dubash NP
FAU - Desai, Dattatraya C
AU  - Desai DC
FAU - Sharma, Somesh
AU  - Sharma S
FAU - Satyam, Apparao
AU  - Satyam A
LA  - eng
PT  - Journal Article
DEP - 20090803
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prodrugs)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*pharmacology
MH  - Aspirin/chemistry/*pharmacology
MH  - Diclofenac/chemistry/*pharmacology
MH  - Nitric Oxide/*metabolism
MH  - Prodrugs/chemistry/*pharmacology
MH  - Rats
MH  - Stomach/*drug effects
EDAT- 2009/08/18 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/08/18 09:00
PHST- 2009/06/03 00:00 [received]
PHST- 2009/07/29 00:00 [revised]
PHST- 2009/07/30 00:00 [accepted]
PHST- 2009/08/18 09:00 [entrez]
PHST- 2009/08/18 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S0960-894X(09)01118-4 [pii]
AID - 10.1016/j.bmcl.2009.07.142 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2009 Sep 15;19(18):5297-301. doi: 
      10.1016/j.bmcl.2009.07.142. Epub 2009 Aug 3.

PMID- 24669568
OWN - NLM
STAT- MEDLINE
DCOM- 20151027
LR  - 20191112
IS  - 0354-950X (Print)
IS  - 0354-950X (Linking)
VI  - 60
IP  - 1
DP  - 2013
TI  - [Aspirin withdrawal in high risk cardiac patients before the operation of total 
      colectomy with resection of ileum--case report].
PG  - 83-6
AB  - Coronary artery disease is one of the risk factors for myocardial infarction and 
      it is present in 40% of patients who are undergoing noncardiac surgery. Despite 
      evidence of the benefit of the antiplatelet therapy in patients at risk of 
      cardiac complications, aspirin treatment is often discontinued before surgery due 
      to the risk of perioperative bleeding. In many studies and meta-analysis it is 
      shown that aspirin withdrawal in perioperative period was associated with 
      three-fold higher risk of major adverse cardiac events. Perioperative 
      continuation of aspirin increase the rate of bleeding by 1.5, but it doesn't 
      increase the level of the severity of bleeding complications. In perioperative 
      periode aspirin is discontinued only if it is estimated that the bleeding risk is 
      higher than the risk of thrombosis. In the paper authors present a case report of 
      patient who developed a perioperative myocardial in-farction as a consequence of 
      aspirin withdrawal before total colectomy.
FAU - Ivosević, Tjasa B
AU  - Ivosević TB
FAU - Kalezić, Nevena K
AU  - Kalezić NK
FAU - Barović, Svetlana
AU  - Barović S
FAU - Palibrk, Ivan G
AU  - Palibrk IG
FAU - Karapandzić, Vesna M
AU  - Karapandzić VM
FAU - Marković, Dejan Z
AU  - Marković DZ
FAU - Ivanović, Branislava A
AU  - Ivanović BA
LA  - srp
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Serbia
TA  - Acta Chir Iugosl
JT  - Acta chirurgica Iugoslavica
JID - 0372631
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Colectomy
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*etiology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Hemorrhage/*prevention & control
MH  - Preoperative Care
MH  - *Withholding Treatment
EDAT- 2013/01/01 00:00
MHDA- 2015/10/28 06:00
CRDT- 2014/03/28 06:00
PHST- 2014/03/28 06:00 [entrez]
PHST- 2013/01/01 00:00 [pubmed]
PHST- 2015/10/28 06:00 [medline]
AID - 10.2298/aci1301083i [doi]
PST - ppublish
SO  - Acta Chir Iugosl. 2013;60(1):83-6. doi: 10.2298/aci1301083i.

PMID- 36745891
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20230301
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 176
IP  - 2
DP  - 2023 Feb
TI  - In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced 
      disease progression or death at 45 d.
PG  - JC17
LID - 10.7326/J22-0118 [doi]
AB  - Eikelboom JW, Jolly SS, Belley-Cote EP, et al. Colchicine and aspirin in 
      community patients with COVID-19 (ACT): an open-label, factorial, randomised, 
      controlled trial. Lancet Respir Med. 2022;10:1160-8. 36228639.
FAU - Schectman, Joel M
AU  - Schectman JM
AD  - University of Virginia Health System, Charlottesville, Virginia, USA (J.M.S.).
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20230207
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
CON - Lancet Respir Med. 2022 Dec;10(12):1160-1168. PMID: 36228639
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - Colchicine/therapeutic use
MH  - *COVID-19
MH  - Disease Progression
MH  - Outpatients
MH  - Treatment Outcome
EDAT- 2023/02/07 06:00
MHDA- 2023/02/25 06:00
CRDT- 2023/02/06 17:02
PHST- 2023/02/07 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2023/02/06 17:02 [entrez]
AID - 10.7326/J22-0118 [doi]
PST - ppublish
SO  - Ann Intern Med. 2023 Feb;176(2):JC17. doi: 10.7326/J22-0118. Epub 2023 Feb 7.

PMID- 14760328
OWN - NLM
STAT- MEDLINE
DCOM- 20040326
LR  - 20220316
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 147
IP  - 2
DP  - 2004 Feb
TI  - Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?
PG  - 293-300
AB  - BACKGROUND: A lack of aspirin effect on platelets after a myocardial infarction 
      (MI) is associated with poor health outcome. This lack of effect may be due to 
      biological resistance to aspirin or due to nonadherence (the patient is not 
      taking the aspirin, hence it has no effect). Determining which of these factors 
      predicts poor outcome would inform potential intervention strategies. METHODS: 
      Aspirin effect on platelets was assessed in a cohort of MI survivors who were 
      divided into three groups: group A ("adherent"), patients whose platelets were 
      affected by aspirin; group B ("nonadherent"), patients whose platelets showed no 
      aspirin effect and who admitted in an interview that they were not taking their 
      medications; and group C (potentially biologically resistant to aspirin), 
      patients whose platelets showed no aspirin effect but maintained that they were 
      taking their aspirin. Two health outcome measures (death, reinfarction, or 
      rehospitalization for unstable angina; or admission for any cardiovascular 
      causes) were assessed 12 months after enrollment. RESULTS: Seventy-three patients 
      were enrolled and classified into groups A ("adherent," 52 patients), B 
      ("nonadherent," 12 patients), and C ("potentially aspirin resistant," 9 
      patients). Adverse events and readmission were more common in the nonadherent 
      group (B)-42% and 67%, respectively, when compared with the adherent group (A)-6% 
      and 11%, and with the potentially biologically resistant group (C)-11% and 11%. 
      CONCLUSIONS: Nonadherence is a significant mediator of poor outcome. It is 
      important to evaluate whether or not patients are taking their medications in 
      clinical settings and in studies that evaluate the effect of prescribed 
      medications.
FAU - Cotter, Gad
AU  - Cotter G
AD  - Clinical Pharmacological Research Unit, The Cardiology Institute, Zerifin, 
      Israel.
FAU - Shemesh, Eyal
AU  - Shemesh E
FAU - Zehavi, Miriam
AU  - Zehavi M
FAU - Dinur, Irit
AU  - Dinur I
FAU - Rudnick, Abraham
AU  - Rudnick A
FAU - Milo, Olga
AU  - Milo O
FAU - Vered, Zvi
AU  - Vered Z
FAU - Krakover, Rikardo
AU  - Krakover R
FAU - Kaluski, Edo
AU  - Kaluski E
FAU - Kornberg, Abraham
AU  - Kornberg A
LA  - eng
GR  - MH63755/MH/NIMH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Blood Platelets/*drug effects/metabolism
MH  - Cardiovascular Diseases/prevention & control
MH  - Cohort Studies
MH  - Disease-Free Survival
MH  - Drug Resistance
MH  - Follow-Up Studies
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - Patient Compliance
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Risk Factors
MH  - Thromboxane B2/*biosynthesis/blood
MH  - *Treatment Refusal
EDAT- 2004/02/05 05:00
MHDA- 2004/03/27 05:00
CRDT- 2004/02/05 05:00
PHST- 2004/02/05 05:00 [pubmed]
PHST- 2004/03/27 05:00 [medline]
PHST- 2004/02/05 05:00 [entrez]
AID - S0002870303005842 [pii]
AID - 10.1016/j.ahj.2003.07.011 [doi]
PST - ppublish
SO  - Am Heart J. 2004 Feb;147(2):293-300. doi: 10.1016/j.ahj.2003.07.011.

PMID- 4005105
OWN - NLM
STAT- MEDLINE
DCOM- 19850731
LR  - 20190511
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 19
IP  - 5
DP  - 1985 May
TI  - The effects of age and sex on the disposition of acetylsalicylic acid and its 
      metabolites.
PG  - 675-84
AB  - The disposition of a low dose (600 mg) of acetylsalicylic acid (ASA) and its 
      metabolites (salicylate, salicyluric acid and salicyl glucuronides) was studied 
      in 25 male and female patients of different ages. Plasma levels of ASA and 
      salicylate were found to be significantly higher in the females (young and 
      elderly), whereas plasma levels of salicyluric acid were found to be 
      significantly higher in the elderly (male and female) groups. The higher plasma 
      levels of ASA and salicylate in the females appear to be due to an intrinsically 
      lower metabolic activity in that sex, while the lower clearance of salicyluric 
      acid leads to the accumulation of that compound in the aged. No age and sex 
      effects were found to influence the volumes of distribution of ASA, salicylate 
      and salicyluric acid.
FAU - Ho, P C
AU  - Ho PC
FAU - Triggs, E J
AU  - Triggs EJ
FAU - Bourne, D W
AU  - Bourne DW
FAU - Heazlewood, V J
AU  - Heazlewood VJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aspirin/blood/*metabolism/urine
MH  - Biotransformation
MH  - Female
MH  - Hippurates/blood
MH  - Humans
MH  - Male
MH  - Models, Biological
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Sex Factors
PMC - PMC1463851
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1985.tb02695.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1985 May;19(5):675-84. doi: 
      10.1111/j.1365-2125.1985.tb02695.x.

PMID- 6857147
OWN - NLM
STAT- MEDLINE
DCOM- 19830708
LR  - 20190909
IS  - 0036-553X (Print)
IS  - 0036-553X (Linking)
VI  - 30
IP  - 4
DP  - 1983 Apr
TI  - An assessment of the sensitivity of 3 bleeding time techniques.
PG  - 311-6
AB  - The sensitivity of 3 bleeding time techniques to an aspirin-induced defect of 
      platelet function has been assessed in 35 normal volunteers. A carefully 
      standardised Ivy technique was compared with 2 commercial devices for a template 
      bleeding time, the Simplate II and the Thrombolette. The standardised Ivy and the 
      Simplate II were found to have a similar sensitivity; the Thrombolette tended to 
      be less sensitive but the difference was not significant.
FAU - Bain, B
AU  - Bain B
FAU - Forster, T
AU  - Forster T
FAU - Baker, A
AU  - Baker A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Denmark
TA  - Scand J Haematol
JT  - Scandinavian journal of haematology
JID - 0404507
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - *Bleeding Time
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - *Platelet Function Tests
MH  - Reference Values
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1983.tb01498.x [doi]
PST - ppublish
SO  - Scand J Haematol. 1983 Apr;30(4):311-6. doi: 10.1111/j.1600-0609.1983.tb01498.x.

PMID- 1829118
OWN - NLM
STAT- MEDLINE
DCOM- 19910730
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 266
IP  - 2
DP  - 1991 Jul 10
TI  - A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced 
      hypertensive disease.
PG  - 260-4
AB  - BACKGROUND: --Pregnancy-induced hypertension (PIH), defined as either isolated 
      hypertension after the 20th week of gestation or hypertension with proteinuria 
      (preeclampsia), occurs in 5% to 15% of pregnancies and is associated with 
      maternal and neonatal morbidity. Previous clinical trials with small numbers of 
      patients have suggested that aspirin in doses of 60 to 150 mg/d during the second 
      and third trimesters reduces the risk of PIH and improves maternal and neonatal 
      outcomes. OBJECTIVE: --We performed a meta-analysis of the six published 
      controlled trials to estimate more precisely (1) the magnitude of protection of 
      aspirin from PIH; (2) the effect of aspirin on severe low-birth-weight infants, 
      cesarean section, and perinatal mortality; and (3) the risk of adverse effects. 
      METHODS: --We critically and independently evaluated study methods, assigned a 
      quality score to each trial, and abstracted quantitative outcomes data. For each 
      outcome, both relative risk (RR) and the number needed to be treated were 
      calculated. RESULTS: --Among 394 subjects from six trials, the RR of PIH among 
      women who took aspirin was 0.35 (95% confidence interval [CI], 0.22 to 0.55) and 
      the number needed to be treated was 4.4, meaning that between four and five 
      high-risk women would need to be treated with aspirin to prevent one case of PIH. 
      Aspirin reduced the risk of severe low birth weight among newborns by 44% (RR = 
      0.56; 95% CI, 0.36 to 0.88) and reduced the risk of cesarean section by 66% 
      overall (RR = 0.34; 95% CI, 0.25 to 0.48), although the specific indications for 
      cesarean section were generally not described. There was no effect on fetal and 
      neonatal death (RR = 0.88; 95% CI, 0.32 to 2.46), and there were no maternal or 
      neonatal adverse effects associated with taking aspirin. CONCLUSION: --This 
      meta-analysis suggests that low-dose aspirin reduces the risks of PIH and severe 
      low birth weight, with no observed risk of maternal or neonatal adverse effects.
FAU - Imperiale, T F
AU  - Imperiale TF
AD  - Department of Medicine, Case Western Reserve University School of Medicine, 
      Cleveland, Ohio.
FAU - Petrulis, A S
AU  - Petrulis AS
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 1991 Dec 11;266(22):3126-8. PMID: 1835503
CIN - JAMA. 1991 Dec 11;266(22):3128-9. PMID: 1956095
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cesarean Section/statistics & numerical data
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Hypertension/*prevention & control
MH  - Infant, Low Birth Weight
MH  - Infant, Newborn
MH  - Meta-Analysis as Topic
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*prevention & control
MH  - Pregnancy Outcome
EDAT- 1991/07/10 00:00
MHDA- 1991/07/10 00:01
CRDT- 1991/07/10 00:00
PHST- 1991/07/10 00:00 [pubmed]
PHST- 1991/07/10 00:01 [medline]
PHST- 1991/07/10 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1991 Jul 10;266(2):260-4.

PMID- 7679439
OWN - NLM
STAT- MEDLINE
DCOM- 19930315
LR  - 20190913
IS  - 0890-5339 (Print)
IS  - 0890-5339 (Linking)
VI  - 7
IP  - 1
DP  - 1993
TI  - Clinical efficacy of aspirin and dextran for thromboprophylaxis in geriatric hip 
      fracture patients.
PG  - 1-5
AB  - The clinical efficacy of thromboprophylaxis with aspirin and dextran 40 was 
      compared in a prospective review of 530 geriatric hip fracture patients treated 
      surgically. All patients were also treated with early mobilization with weight 
      bearing as tolerated and above-knee elastic stockings. In addition to clinical 
      efficacy in preventing thromboembolic complications [deep vein thrombosis (DVT), 
      pulmonary embolism (PE)], safety and cost-effectiveness were also assessed. The 
      overall incidence of clinical thromboembolic disease was 2.8% (DVT = 0.4%, PE = 
      2.4%). The incidence of DVT (0.5%) and PE (2.6%) in the aspirin group was 
      essentially the same as the incidence of DVT (0.3%) and PE (2.4%) in the dextran 
      group. The inhospital mortality rate (aspirin 4.6%, dextran 3.8%), wound drainage 
      (aspirin 1.5%, dextran 0.9%), deep wound infection (aspirin 0.5%, dextran 0.3%), 
      gastrointestinal bleeding (aspirin 2.1%, dextran 1.5%), and congestive heart 
      failure (aspirin 2.6%, dextran 1.8%) did not differ significantly between the two 
      groups. The intraoperative transfusion rate was similar in both groups (aspirin 
      .65 units, dextran .55 units). However, postoperatively, the transfusion rate was 
      significantly higher in the dextran group (aspirin .26 units, dextran .41 units, 
      p < .05). The treatment of thromboembolic complications was the same for each 
      group and therefore represents similar treatment costs. However, the cost of 
      prophylaxis with dextran was $309 per patient and with aspirin was $1.79 per 
      patient. Our findings suggest that, based on clinical diagnostic criteria, 
      aspirin and dextran are equally effective thromboembolic prophylactic agents in 
      geriatric hip fracture patients. The safety, cost, and ease of administration of 
      aspirin may make its use more desirable.
FAU - Feldman, D S
AU  - Feldman DS
AD  - Department of Orthopedic Surgery, Hospital for Joint Diseases, New York, New 
      York.
FAU - Zuckerman, J D
AU  - Zuckerman JD
FAU - Walters, I
AU  - Walters I
FAU - Sakales, S R
AU  - Sakales SR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Orthop Trauma
JT  - Journal of orthopaedic trauma
JID - 8807705
RN  - 0 (Dextrans)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Dextrans/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - *Hip Fractures/complications
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Pulmonary Embolism/etiology/*prevention & control
MH  - Thrombolytic Therapy/adverse effects/*methods
MH  - Thrombophlebitis/etiology/*prevention & control
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1097/00005131-199302000-00001 [doi]
PST - ppublish
SO  - J Orthop Trauma. 1993;7(1):1-5. doi: 10.1097/00005131-199302000-00001.

PMID- 36949715
OWN - NLM
STAT- MEDLINE
DCOM- 20230324
LR  - 20230829
IS  - 1672-173X (Print)
IS  - 1672-173X (Linking)
VI  - 54
IP  - 2
DP  - 2023 Mar
TI  - [Important Considerations of Low-Dose Aspirin in the Prevention of Preeclampsia].
PG  - 450-454
LID - 10.12182/20230360207 [doi]
AB  - Low-dose prophylactic aspirin is widely recommended for pregnant women for the 
      prevention of preeclampsia (PE). Although the efficacy of aspirin in preventing 
      PE has been evaluated in many studies, due to the differences in dosage, 
      initiation time, and screening methods for the identification of women at high 
      risk of PE and the lack of a uniform opinion on the medication regimen of 
      aspirin, currently in China there is no consensus on the standardized treatment 
      scheme of aspirin for the prevention of PE in clinical guidelines. Herein, we 
      reviewed the current available evidence and the recommendations of clinical 
      guidelines concerning the controversies about aspirin dosage as well as the 
      timing of starting and stopping aspirin, so as to provide further guidance for 
      clinical practice. Based on the existing research findings on and clinical 
      practice of using aspirin for PE prevention, we suggested that PE risk screening 
      should be conducted at 11-13(+6) weeks of gestation. In addition, the recommended 
      dose for prophylactic use of aspirin for pregnant women at high risk of PE is 150 
      mg/d, and the recommended minimum effective dose is 100 mg/d. Pregnant women at 
      high risk of PE should start taking low-dose aspirin orally before 16 weeks of 
      pregnancy. Week 36 of gestation is considered the window of opportunity for 
      discontinuation of low-dose aspirin.
CI  - Copyright© by Editorial Board of Journal of Sichuan University (Medical 
      Sciences).
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou 510080, China.
FAU - Shen, Li-Xia
AU  - Shen LX
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou 510080, China.
AD  - Department of Obstetrics and Gynecology, Chinese University of Hong Kong, Hong 
      Kong 999077, China.
FAU - Wang, Zi-Lian
AU  - Wang ZL
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou 510080, China.
FAU - Liona, C Poon
AU  - Liona CP
AD  - Department of Obstetrics and Gynecology, Chinese University of Hong Kong, Hong 
      Kong 999077, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - China
TA  - Sichuan Da Xue Xue Bao Yi Xue Ban
JT  - Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical 
      science edition
JID - 101162609
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Pregnancy
MH  - Humans
MH  - *Pre-Eclampsia/prevention & control/diagnosis
MH  - Aspirin/therapeutic use
MH  - China
PMC - PMC10409147
OTO - NOTNLM
OT  - Aspirin
OT  - Low-dose prophylaxis
OT  - Preeclampsia
COIS- 利益冲突　所有作者均声明不存在利益冲突
EDAT- 2023/03/24 06:00
MHDA- 2023/03/25 06:00
CRDT- 2023/03/23 02:03
PHST- 2023/03/23 02:03 [entrez]
PHST- 2023/03/24 06:00 [pubmed]
PHST- 2023/03/25 06:00 [medline]
AID - scdxxbyxb-54-2-450 [pii]
AID - 10.12182/20230360207 [doi]
PST - ppublish
SO  - Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 Mar;54(2):450-454. doi: 
      10.12182/20230360207.

PMID- 15738456
OWN - NLM
STAT- MEDLINE
DCOM- 20050309
LR  - 20220317
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 142
IP  - 5
DP  - 2005 Mar 1
TI  - Narrative review: aspirin resistance and its clinical implications.
PG  - 370-80
AB  - Aspirin is currently the most cost-effective drug for the secondary prevention of 
      cardiovascular disease, but treatment failures are relatively common. Several 
      factors have been linked to these recurrent vascular events in patients 
      prescribed aspirin, including smoking, drug interactions, nonadherence, comorbid 
      conditions, and aspirin resistance. The term aspirin resistance has been used to 
      describe not only an absence of the expected pharmacologic effects of aspirin on 
      platelets but also poor clinical outcomes, such as recurrent vascular events, in 
      patients treated with aspirin. Aspirin resistance is perhaps more precisely 
      understood as the phenomenon of measurable, persisting platelet activation that 
      occurs in patients prescribed a therapeutic dose of aspirin and may underlie an 
      unknown proportion of aspirin treatment failures. Key challenges for future 
      research are to standardize a definition of aspirin resistance and to compare 
      whether different measures of platelet activation, either alone or in 
      combination, independently predict cardiovascular events. These challenges must 
      be met before researchers conduct studies to assess the clinical utility of 
      testing on patient outcomes and cost-effective prescribing.
FAU - Sanderson, Simon
AU  - Sanderson S
AD  - University of Cambridge, Addenbrooke's Hospital, and Institute of Public Health, 
      Cambridge, United Kingdom. simon.sanderson@srl.cam.ac.uk
FAU - Emery, Jon
AU  - Emery J
FAU - Baglin, Trevor
AU  - Baglin T
FAU - Kinmonth, Ann-Louise
AU  - Kinmonth AL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Secondary Prevention
RF  - 68
EDAT- 2005/03/02 09:00
MHDA- 2005/03/10 09:00
CRDT- 2005/03/02 09:00
PHST- 2005/03/02 09:00 [pubmed]
PHST- 2005/03/10 09:00 [medline]
PHST- 2005/03/02 09:00 [entrez]
AID - 142/5/370 [pii]
AID - 10.7326/0003-4819-142-5-200503010-00012 [doi]
PST - ppublish
SO  - Ann Intern Med. 2005 Mar 1;142(5):370-80. doi: 
      10.7326/0003-4819-142-5-200503010-00012.

PMID- 21078235
OWN - NLM
STAT- MEDLINE
DCOM- 20101221
LR  - 20191111
IS  - 1476-0320 (Print)
IS  - 1475-9985 (Linking)
VI  - 18
IP  - 2
DP  - 2010
TI  - Automated processing of electronic medical records is a reliable method of 
      determining aspirin use in populations at risk for cardiovascular events.
PG  - 125-33
AB  - BACKGROUND: Low-dose aspirin reduces cardiovascular risk; however, monitoring 
      over-the-counter medication use relies on the time-consuming and costly manual 
      review of medical records. Our objective is to validate natural language 
      processing (NLP) of the electronic medical record (EMR) for extracting medication 
      exposure and contraindication information. METHODS: The text of EMRs for 499 
      patients with type 2 diabetes was searched using NLP for evidence of aspirin use 
      and its contraindications. The results were compared to a standardised manual 
      records review. RESULTS: Of the 499 patients, 351 (70%) were using aspirin and 
      148 (30%) were not, according to manual review. NLP correctly identified 346 of 
      the 351 aspirin-positive and 134 of the 148 aspirin-negative patients, indicating 
      a sensitivity of 99% (95% CI 97-100) and specificity of 91% (95% CI 88-97). Of 
      the 148 aspirin-negative patients, 66 (45%) had contraindications and 82 (55%) 
      did not, according to manual review. NLP search for contraindications correctly 
      identified 61 of the 66 patients with contraindications and 58 of the 82 patients 
      without, yielding a sensitivity of 92% (95% CI 84-97) and a specificity of 71% 
      (95% CI 60-80). CONCLUSIONS: NLP of the EMR is accurate in ascertaining 
      documented aspirin use and could potentially be used for epidemiological research 
      as a source of cardiovascular risk factor information.
FAU - Pakhomov, Serguei Vs
AU  - Pakhomov SV
AD  - Department of Pharmaceutical Care and Health Systems, University of Minnesota, 
      Minnesota, USA.
FAU - Shah, Nilay D
AU  - Shah ND
FAU - Hanson, Penny
AU  - Hanson P
FAU - Balasubramaniam, Saranya C
AU  - Balasubramaniam SC
FAU - Smith, Steven A
AU  - Smith SA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Inform Prim Care
JT  - Informatics in primary care
JID - 101150138
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Drug Utilization
MH  - Humans
MH  - Medical Records Systems, Computerized/*statistics & numerical data
MH  - Medication Adherence
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
EDAT- 2010/11/17 06:00
MHDA- 2010/12/22 06:00
CRDT- 2010/11/17 06:00
PHST- 2010/11/17 06:00 [entrez]
PHST- 2010/11/17 06:00 [pubmed]
PHST- 2010/12/22 06:00 [medline]
AID - 762 [pii]
AID - 10.14236/jhi.v18i2.762 [doi]
PST - ppublish
SO  - Inform Prim Care. 2010;18(2):125-33. doi: 10.14236/jhi.v18i2.762.

PMID- 11310519
OWN - NLM
STAT- MEDLINE
DCOM- 20010816
LR  - 20190915
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 21
IP  - 4
DP  - 2001 Apr
TI  - Antithrombotic drugs for secondary stroke prophylaxis.
PG  - 452-63
AB  - Stroke is the third most common cause of adult mortality in the United States. 
      Antithrombotic agents form the mainstay of stroke prevention. Aspirin produces a 
      modest reduction in the risk of second stroke and is widely recommended for 
      initial therapy. The thienopyridines ticlopidine and clopidogrel are alternatives 
      for secondary prevention in patients who do not respond to or cannot take 
      aspirin. They are no more effective than aspirin and have been associated with 
      thrombotic thrombocytopenic purpura. The combination of aspirin and 
      extended-release dipyridamole has several mechanisms of action and an additive 
      effect on reducing stroke risk compared with either agent alone. A 2-fold 
      increase in risk reduction and favorable safety profile suggest that the 
      combination can serve as first-line prophylaxis against a second stroke.
FAU - Pettigrew, L C
AU  - Pettigrew LC
AD  - Sanders-Brown Center on Aging, Department of Neurology, University of Kentucky 
      College of Medicine, Lexington 40536-0230, USA. cpettigrew@aging.coa.uky.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Fibrinolytic Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Pharmacotherapy. 2001 Aug;21(8):1020; author reply 1021-2. PMID: 11718493
CIN - Pharmacotherapy. 2001 Aug;21(8):1021; author reply 1021-2. PMID: 11718494
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Stroke/economics/*prevention & control
MH  - Structure-Activity Relationship
RF  - 63
EDAT- 2001/04/20 10:00
MHDA- 2001/08/17 10:01
CRDT- 2001/04/20 10:00
PHST- 2001/04/20 10:00 [pubmed]
PHST- 2001/08/17 10:01 [medline]
PHST- 2001/04/20 10:00 [entrez]
AID - 10.1592/phco.21.5.452.34498 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2001 Apr;21(4):452-63. doi: 10.1592/phco.21.5.452.34498.

PMID- 6794308
OWN - NLM
STAT- MEDLINE
DCOM- 19811215
LR  - 20220408
IS  - 0001-5792 (Print)
IS  - 0001-5792 (Linking)
VI  - 66
IP  - 2
DP  - 1981
TI  - Therapeutic effect of aspirin in sickle cell anaemia.
PG  - 102-7
AB  - This work was carried out to demonstrate the possibility of beneficial 
      therapeutic effects of aspirin in sickle cell anaemia patients. Two groups of 50 
      patients each, with haemoglobin genotype SS were studied, one group receiving 
      soluble aspirin daily for 6 weeks, while the other was used as a control. There 
      was evidence of increase in oxygen affinity, in haemoglobin levels, and in the 
      life span of RBC, probably due to acetylation of HbS.
FAU - Osamo, N O
AU  - Osamo NO
FAU - Photiades, D P
AU  - Photiades DP
FAU - Famodu, A A
AU  - Famodu AA
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anemia, Sickle Cell/*drug therapy
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Child
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Erythrocyte Aging/drug effects
MH  - Female
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Male
MH  - Nigeria
MH  - Oxygen/blood
MH  - Partial Pressure
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1159/000207105 [doi]
PST - ppublish
SO  - Acta Haematol. 1981;66(2):102-7. doi: 10.1159/000207105.

PMID- 6799989
OWN - NLM
STAT- MEDLINE
DCOM- 19820412
LR  - 20190825
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 22
IP  - 5
DP  - 1981 Nov
TI  - Rapid return of cyclo-oxygenase active platelets in dogs after a single oral dose 
      of aspirin.
PG  - 761-72
AB  - A single dose of oral aspirin in human subjects inhibits the aggregation response 
      of platelets to arachidonate and other agents for approximately one week after 
      ingestion. In the present study we have evaluated the rate at which 
      cyclo-oxygenase active platelets return to the circulation in humans and dogs and 
      compared the response curves obtained to improvements in cyclo-oxygenase activity 
      produced by the aspirin platelets. After a single dose of aspirin, dog platelet 
      function was compromised for several days. Normal responses to arachidonate and 
      other aggregating agents were restored six days after aspirin, and the pattern of 
      recovery was the same for dogs and human subjects. However, cyclo-oxygenase 
      active platelets returned to the circulation in dogs more rapidly than in humans 
      and chemical competence was restored in both species well before correction of 
      the defective response to aggregating agents. The delay of 1-3 days before return 
      of significant numbers of cyclo-oxygenase active platelets most likely reflects 
      acetylation of bone marrow megakaryocytes by the drug. More rapid return of 
      chemically competent cells in dogs than humans probably relates to the more rapid 
      turnover and shorter life span of canine platelets. The basis for the discrepancy 
      in return of chemical integrity compared to functional activity after aspirin in 
      vivo compared to simultaneous correction of chemistry and function when 10% 
      normal platelets are added to aspirin platelets in vitro remains unresolved.
FAU - Rao, G H
AU  - Rao GH
FAU - Johnson, G J
AU  - Johnson GJ
FAU - Reddy, R K
AU  - Reddy RK
FAU - White, J G
AU  - White JG
LA  - eng
GR  - AM-06317/AM/NIADDK NIH HHS/United States
GR  - HL-06314/HL/NHLBI NIH HHS/United States
GR  - HL-11880/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Arachidonic Acids)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects/enzymology
MH  - Dogs
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandin-Endoperoxide Synthases/*blood
MH  - Time Factors
EDAT- 1981/11/01 00:00
MHDA- 1981/11/01 00:01
CRDT- 1981/11/01 00:00
PHST- 1981/11/01 00:00 [pubmed]
PHST- 1981/11/01 00:01 [medline]
PHST- 1981/11/01 00:00 [entrez]
AID - 0090-6980(81)90215-X [pii]
AID - 10.1016/0090-6980(81)90215-x [doi]
PST - ppublish
SO  - Prostaglandins. 1981 Nov;22(5):761-72. doi: 10.1016/0090-6980(81)90215-x.

PMID- 6796445
OWN - NLM
STAT- MEDLINE
DCOM- 19820225
LR  - 20190515
IS  - 0012-1797 (Print)
IS  - 0012-1797 (Linking)
VI  - 30
IP  - 12
DP  - 1981 Dec
TI  - Colchicine and insulin secretion in man.
PG  - 1008-12
AB  - The present study is aimed at investigating the effect of acute and chronic 
      colchicine administration on insulin secretion in humans. Acute insulin response 
      to glucose (0.33 g/kg) was significantly decreased by colchicine (3 mg i.v.). In 
      fact, this response (mean change 2-10 min insulin) was 44 +/- 8 microunits/ml 
      before and 32 +/- 6 microunits/ml after colchicine administration (P less than 
      0.01). As a consequence of this, glucose disappearance rates were reduced (P less 
      than 0.05). Infusion of lysine acetylsalicylate (LAS), an inhibitor of endogenous 
      PG synthesis, completely reversed the inhibitory effect of colchicine upon 
      insulin secretion and also augmented acute insulin response to glucose (response 
      before colchicine + LAS = 45 +/- 8 microunits/ml; response after colchicine + LAS 
      = 51 +/- 9 microunits/ml, P less than 0.05). This effect was associated with an 
      increase in glucose disappearance rates (P less than 0.05). The 10-day treatment 
      with colchicine (2 mg daily) caused a significant suppression of insulin 
      secretion induced by oral glucose (100 g) and significantly increased the plasma 
      glucose concentrations following the test (P less than 0.05). These findings 
      demonstrate that (1) both acute and chronic colchicine administration inhibit 
      glucose-induced insulin secretion and deteriorate glucose tolerance in humans, 
      and (2) LAS completely reverses these negative effects of colchicine. An 
      increased synthesis of endogenous PGE, which are known to inhibit insulin 
      secretion in humans, might account for the inhibiting effect of colchicine on 
      insulin secretion.
FAU - Giugliano, D
AU  - Giugliano D
FAU - Cerciello, T
AU  - Cerciello T
FAU - Passariello, N
AU  - Passariello N
FAU - Torella, R
AU  - Torella R
FAU - Saccà, L
AU  - Saccà L
FAU - Sgambato, S
AU  - Sgambato S
FAU - D'Onofrio, F
AU  - D'Onofrio F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 0 (Insulin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - *Colchicine/administration & dosage
MH  - Drug Interactions
MH  - Female
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Insulin/*metabolism
MH  - Insulin Secretion
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Middle Aged
EDAT- 1981/12/01 00:00
MHDA- 1981/12/01 00:01
CRDT- 1981/12/01 00:00
PHST- 1981/12/01 00:00 [pubmed]
PHST- 1981/12/01 00:01 [medline]
PHST- 1981/12/01 00:00 [entrez]
AID - 10.2337/diab.30.12.1008 [doi]
PST - ppublish
SO  - Diabetes. 1981 Dec;30(12):1008-12. doi: 10.2337/diab.30.12.1008.

PMID- 9103279
OWN - NLM
STAT- MEDLINE
DCOM- 19970513
LR  - 20190720
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 114
IP  - 1-2
DP  - 1997 Mar 19
TI  - Acetylsalicylate and salicylates in foods.
PG  - 163-4
AB  - Acetylsalicylic acid is effective in the prevention of cardiovascular disease. It 
      was suggested that fruits and vegetables provide unknown amounts of 
      acetylsalicylic acid. We could not find any acetylsalicylic acid in 30 foods 
      using HPLC with fluorescence detection (detection limits: 0.02 mg/kg for fresh, 
      and 0.2 mg/kg for dried products). We showed that urinary excretion of 
      salicylates is a valid indicator for intake, and found a median salicylate 
      excretion of 10 micromol (1.4 mg) in 24 h urine of 17 volunteers eating a variety 
      of diets. Our data suggest that the content of (acetyl)salicylic acid of diets 
      may be too low to affect disease risk.
FAU - Janssen, P L
AU  - Janssen PL
AD  - Department of Human Nutrition, Agricultural University, Wageningen, The 
      Netherlands. karin.janssen@et3.voed.wau.nl
FAU - Katan, M B
AU  - Katan MB
FAU - van Staveren, W A
AU  - van Staveren WA
FAU - Hollman, P C
AU  - Hollman PC
FAU - Venema, D P
AU  - Venema DP
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/pharmacology/*urine
MH  - Chromatography, High Pressure Liquid
MH  - Cross-Over Studies
MH  - *Food Analysis
MH  - Fruit/chemistry
MH  - Humans
MH  - Magnoliopsida/chemistry
MH  - Salicylates/*analysis/pharmacology/*urine
MH  - Spices/analysis
MH  - Vegetables/chemistry
EDAT- 1997/03/19 00:00
MHDA- 1997/03/19 00:01
CRDT- 1997/03/19 00:00
PHST- 1997/03/19 00:00 [pubmed]
PHST- 1997/03/19 00:01 [medline]
PHST- 1997/03/19 00:00 [entrez]
AID - S0304-3835(97)04650-8 [pii]
AID - 10.1016/s0304-3835(97)04650-8 [doi]
PST - ppublish
SO  - Cancer Lett. 1997 Mar 19;114(1-2):163-4. doi: 10.1016/s0304-3835(97)04650-8.

PMID- 1067733
OWN - NLM
STAT- MEDLINE
DCOM- 19761201
LR  - 20190907
IS  - 0001-6357 (Print)
IS  - 0001-6357 (Linking)
VI  - 34
IP  - 3
DP  - 1976
TI  - Salicylates in saliva.
PG  - 155-61
AB  - The possible excretion of acetylsalicylic acid and salicylic acid into human 
      whole-mouth saliva was studied after the ingestion of 1.0 g of acetylsalicylic 
      acid in gelatine capsules. In addition, the oral clearance of both salicylates 
      was determined after a sham intake of acetylsalicylic acid in solution. No 
      acetylsalicylic acid was excreted in saliva. The maximum concentration of 1.2 
      mug/ml of the metabolite, salicylic acid, was excreted after 3 hours. 
      Considerable concentrations of both salicylates were retained from 2 to 3 hours 
      in the mouth after the sham intake of the drug in solution. During the retention 
      period, part of the acetylsalicylic acid was hydrolyzed to salicylic acid. In 
      vitro, at low concentration levels about 50% of salicylic acid was bound to 
      salivary proteins. The degree of binding was dependent on the drug concentration. 
      The reason for the absence of excreted acetylsalicylic acid from the saliva was 
      evidently its hydrolysis in the body. Protein binding in the oral cavity may 
      explain the slow clearance of locally applied salicylates. Retention of 
      salicylates in the mouth after the use of drug solutions or effervescent 
      preparations should be considered in, e.g. evaluations of local analgesic effects 
      or bleeding disorders.
FAU - Pohto, P
AU  - Pohto P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Odontol Scand
JT  - Acta odontologica Scandinavica
JID - 0370344
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/analysis/*metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Protein Binding
MH  - Salicylates/administration & dosage/*metabolism
MH  - *Saliva/analysis
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.3109/00016357609002563 [doi]
PST - ppublish
SO  - Acta Odontol Scand. 1976;34(3):155-61. doi: 10.3109/00016357609002563.

PMID- 2029014
OWN - NLM
STAT- MEDLINE
DCOM- 19910613
LR  - 20170908
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 90
IP  - 5
DP  - 1991 May
TI  - Effects of acetylsalicylic acid on renal function in patients with chronic heart 
      failure.
PG  - 571-5
AB  - PURPOSE: We conducted a double-blind, placebo-controlled trial to determine 
      whether the administration of acetylsalicylic acid has adverse effects on renal 
      function in patients with moderate chronic congestive heart failure with and 
      without stimulation of the renin system. PATIENTS AND METHODS: Forty patients 
      were randomly assigned to one of the following four groups: Group 1, low sodium 
      diet and placebo; Group 2, low sodium diet and acetylsalicylic acid; Group 3, 
      normal sodium diet and placebo; or Group 4, normal sodium diet and 
      acetylsalicylic acid. Patients were studied over 8 days. After Day 5, patients in 
      Groups 2 and 4 received acetylsalicylic acid (500 mg three times a day). The low 
      sodium diet consisted of 13.6 mmol of sodium per day and the normal sodium diet 
      consisted of 136 mmol of sodium per day. RESULTS: The low sodium diet resulted in 
      a highly significant increase in the plasma renin (2p = 0.0001), aldosterone (2p 
      = 0.0006), and urinary prostaglandin E2 (2p = 0.01) concentrations and the renal 
      potassium excretion (2p = 0.0009), whereas renal sodium excretion was 
      significantly reduced (2p = 0.0001). Severe sodium depletion led to a reduction 
      of the glomerular filtration rate (2p = 0.007), which was independent from 
      cyclooxygenase inhibition. In patients on the low sodium diet, acetylsalicylic 
      acid reduced the elevated urinary prostaglandin E2 levels to normal values 
      without changing the renal sodium excretion rate. In patients with a normal 
      sodium intake, acetylsalicylic acid significantly reduced the renal sodium 
      excretion rate by 29% (2p = 0.04). CONCLUSION: We conclude that severe sodium 
      depletion has adverse effects on kidney function in patients with heart failure 
      due to a reduction in the glomerular filtration rate. Administration of 
      acetylsalicylic acid in doses that reduce the synthesis of renal prostaglandin E2 
      significantly reduces renal sodium excretion.
FAU - Riegger, G A
AU  - Riegger GA
AD  - Medizinische Universitätsklinik, Würzburg, Federal Republic of Germany.
FAU - Kahles, H W
AU  - Kahles HW
FAU - Elsner, D
AU  - Elsner D
FAU - Kromer, E P
AU  - Kromer EP
FAU - Kochsiek, K
AU  - Kochsiek K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Prostaglandins E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Combined Modality Therapy
MH  - Diet, Sodium-Restricted/*standards
MH  - Double-Blind Method
MH  - Glomerular Filtration Rate/drug effects/physiology
MH  - Heart Failure/diet therapy/*drug therapy/physiopathology
MH  - Humans
MH  - Kidney/*drug effects/physiology
MH  - Middle Aged
MH  - Prostaglandins E/biosynthesis
MH  - Renin-Angiotensin System/*drug effects/physiology
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
AID - 0002-9343(91)90631-7 [pii]
PST - ppublish
SO  - Am J Med. 1991 May;90(5):571-5.

PMID- 9136963
OWN - NLM
STAT- MEDLINE
DCOM- 19970619
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 97
IP  - 1
DP  - 1997 Apr
TI  - Prevention and treatment of thrombotic complications in essential 
      thrombocythaemia: efficacy and safety of aspirin.
PG  - 179-84
AB  - The efficacy and safety of aspirin in the prevention and treatment of thrombosis 
      in essential thrombocythaemia (ET) was retrospectively analysed in a cohort of 68 
      ET patients. 41 patients presented with thrombosis, five patients with bleeding: 
      two patients had a paradoxical combination of bleeding and thrombosis at 
      presentation. At presentation, patients with bleeding had significantly higher 
      platelet and leucocyte counts than patients with thrombosis. During long-term 
      follow-up the incidence of thrombosis was significantly reduced in patients 
      receiving aspirin, either as monotherapy or in combination with cytoreduction. 
      However, treatment with aspirin (500 mg/d) was associated with an increase in 
      (minor) bleeding complications. In patients receiving aspirin, bleeding occurred 
      particularly at platelet counts exceeding 1000 x 10(9)/l. The overall 5- and 
      10-years survival probability was 93% and 84% respectively, indicating that life 
      expectancy in ET is close to normal. Although our data need confirmation in 
      prospective clinical trials, they suggest that aspirin, particularly in lower 
      doses (100 mg/d), may be a safe antithrombotic agent in ET with an acceptable 
      risk for bleeding, if applied to patients with a platelet count <1000 x 10(9)/l 
      and/or absence of a bleeding history.
FAU - van Genderen, P J
AU  - van Genderen PJ
AD  - Department of Haematology, University Hospital Dijkzigt, The Netherlands.
FAU - Mulder, P G
AU  - Mulder PG
FAU - Waleboer, M
AU  - Waleboer M
FAU - van de Moesdijk, D
AU  - van de Moesdijk D
FAU - Michiels, J J
AU  - Michiels JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Analysis
MH  - Thrombocytopenia/*complications
MH  - Thrombosis/*prevention & control
MH  - Treatment Outcome
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - 10.1046/j.1365-2141.1997.d01-2127.x [doi]
PST - ppublish
SO  - Br J Haematol. 1997 Apr;97(1):179-84. doi: 10.1046/j.1365-2141.1997.d01-2127.x.

PMID- 36036856
OWN - NLM
STAT- MEDLINE
DCOM- 20221013
LR  - 20221014
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 54
IP  - 3
DP  - 2022 Oct
TI  - Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin 
      complex liquid formulation and low dose enteric-coated aspirin: results from a 
      prospective, randomized, crossover study.
PG  - 373-381
LID - 10.1007/s11239-022-02687-5 [doi]
AB  - Low dose enteric-coated aspirin (EC-ASA) is routinely used for secondary 
      cardiovascular event prevention. However, absorption of EC tablets is poor, which 
      can result in subtherapeutic antiplatelet effects. Phospholipid-aspirin liquid 
      filled capsules (PL-ASA) are a novel FDA-approved immediate-release formulation 
      designed to reduce gastrointestinal (GI) injury by limiting direct contact with 
      the stomach lining. We compared the pharmacokinetic (PK) and pharmacodynamic (PD) 
      profiles of PL-ASA versus EC-ASA at a low dose. This randomized, open-label, 
      crossover study assessed PK and PD following a single 81-mg dose of PL-ASA versus 
      EC-ASA under fasting conditions in 36 volunteers without cardiovascular disease 
      between 18 and 75 years of age. Volunteers were randomly assigned 1:1 to either 
      PL-ASA then EC-ASA or vice versa with a minimum 14-day washout. Assessments 
      included PK parameters for acetylsalicylic acid and salicylic acid, platelet 
      aggregation in response to arachidonic acid (AA), and serum thromboxane B2 
      (TxB(2)) assessments over 24 h. PL-ASA was rapidly absorbed. PL-ASA reached 
      T(max) 3 h earlier (1.01 vs. 4.00 h, p < 0.0001), with almost double the C(max) 
      (720 vs. 368 ng/mL, p < 0.0001) and overall 44% higher exposure of 
      acetylsalicylic acid (AUC(0-t): 601 vs. 416 h*ng/mL, p = 0.0013) compared with 
      EC-ASA. Within 1 h of dosing, PL-ASA achieved significantly lower residual 
      platelet aggregation, which persisted for the full 24 h (median AA-LTA was 47% 
      with PL-ASA vs. 80.5% with EC-ASA; p = 0.0022 at hour-24). Treatment with PL-ASA 
      also resulted in significantly lower serum TxB(2) concentrations at each time 
      point compared with EC-ASA (all p-values < 0.05). PL-ASA resulted in faster and 
      more complete aspirin absorption paralleled by more prompt and potent platelet 
      inhibition compared with EC-ASA after a single 81 mg dose. PL-ASA represents an 
      attractive novel aspirin formulation for the secondary prevention of 
      cardiovascular events.Clinical Trial Registration ClinicalTrials.gov identifier: 
      NCT04811625.
CI  - © 2022. The Author(s).
FAU - Franchi, Francesco
AU  - Franchi F
AD  - Division of Cardiology, University of Florida College of Medicine - Jacksonville, 
      655 West 8th Street, Jacksonville, FL, 32209, USA.
FAU - Schneider, David J
AU  - Schneider DJ
AD  - Department of Medicine, Cardiovascular Research Institute, The University of 
      Vermont, Burlington, VT, USA.
FAU - Prats, Jayne
AU  - Prats J
AD  - Elysis LLC, Carlisle, MA, USA.
FAU - Fan, Weihong
AU  - Fan W
AD  - PLx Pharma, Inc., Sparta, NJ, USA.
FAU - Rollini, Fabiana
AU  - Rollini F
AD  - Division of Cardiology, University of Florida College of Medicine - Jacksonville, 
      655 West 8th Street, Jacksonville, FL, 32209, USA.
FAU - Been, Latonya
AU  - Been L
AD  - Division of Cardiology, University of Florida College of Medicine - Jacksonville, 
      655 West 8th Street, Jacksonville, FL, 32209, USA.
FAU - Taatjes-Sommer, Heidi S
AU  - Taatjes-Sommer HS
AD  - Department of Medicine, Cardiovascular Research Institute, The University of 
      Vermont, Burlington, VT, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Deliargyris, Efthymios N
AU  - Deliargyris EN
AD  - Science and Strategy Consulting Group, Basking Ridge, NJ, USA.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AUID- ORCID: 0000-0001-8451-2131
AD  - Division of Cardiology, University of Florida College of Medicine - Jacksonville, 
      655 West 8th Street, Jacksonville, FL, 32209, USA. 
      dominick.angiolillo@jax.ufl.edu.
LA  - eng
SI  - ClinicalTrials.gov/NCT04811625
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220829
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Capsules)
RN  - 0 (Phospholipids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid
MH  - *Aspirin/pharmacokinetics/pharmacology
MH  - Capsules
MH  - Cross-Over Studies
MH  - Humans
MH  - Phospholipids
MH  - *Platelet Aggregation Inhibitors/pharmacokinetics/pharmacology
MH  - Prospective Studies
MH  - Salicylic Acid
MH  - Tablets
MH  - Thromboxane B2
PMC - PMC9421621
OTO - NOTNLM
OT  - Aspirin
OT  - PL-ASA
OT  - Pharmacodynamic
OT  - Pharmacokinetic
OT  - Platelet
COIS- Dr Franchi declares that he has received payment as an individual for consulting 
      or honoraria from AstraZeneca, Bayer and Sanofi, and institutional payments for 
      grants from PLx Pharma, and The Scott R. MacKenzie Foundation. Dr Schneider 
      reports grant support from PLx Pharma, Inc. Dr Prats is a consultant to PLx 
      Pharma, Inc, and a member of the Scientific Advisory Board. Ms Fan: is an 
      employee of PLx Pharma, Inc. DLB: Dr. Deepak L. Bhatt discloses the following 
      relationships—Advisory Board: Bayer, Boehringer Ingelheim, Cardax, CellProthera, 
      Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, 
      Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx 
      Pharma, Regado Biosciences, Stasys; Board of Directors: AngioWave (stock 
      options), Boston VA Research Institute, DRS.LINQ (stock options), Society of 
      Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart 
      Association Quality Oversight Committee; Data Monitoring Committees: Acesion 
      Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical 
      Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, 
      funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), 
      Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego 
      Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, 
      Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; 
      for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health 
      Research Institute; Rutgers University (for the NIH-funded MINT Trial); 
      Honoraria: American College of Cardiology (Senior Associate Editor, Clinical 
      Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold 
      and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel 
      litigation), Baim Institute for Clinical Research (formerly Harvard Clinical 
      Research Institute; RE-DUAL PCI clinical trial steering committee funded by 
      Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), 
      Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical 
      and Surgical Knowledge Translation Research Group (clinical trial steering 
      committees), Cowen and Company, Duke Clinical Research Institute (clinical trial 
      steering committees, including for the PRONOUNCE trial, funded by Ferring 
      Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), 
      Journal of the American College of Cardiology (Guest Editor; Associate Editor), 
      K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD 
      (CME steering committees), MJH Life Sciences, Oakstone CME, Piper Sandler, 
      Population Health Research Institute (for the COMPASS operations committee, 
      publications committee, steering committee, and USA national co-leader, funded by 
      Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s 
      Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), 
      WebMD (CME steering committees), Wiley (steering committee); Other: Clinical 
      Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA 
      CART Research and Publications Committee (Chair); Research Funding: Abbott, 
      Acesion Pharma, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, 
      Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, 
      CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday 
      Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, 
      HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, 
      Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, 
      Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, 
      Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio; Royalties: 
      Elsevier (Editor, Braunwald’s Heart Disease); Site Co-Investigator: Abbott, 
      Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), 
      Philips, Svelte; Trustee: American College of Cardiology; Unfunded Research: 
      FlowCo, Takeda. Dr. Deliargyris is a member of the PLx Pharma Scientific Advisory 
      Board. Dr. Angiolillo declares that he has received consulting fees or honoraria 
      from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, 
      Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, 
      Merck, PhaseBio, PLx Pharma, Pfizer, and Sanofi. D.J.A. also declares that his 
      institution has received research grants from Amgen, AstraZeneca, Bayer, 
      Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, 
      Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey 
      Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. The other 
      authors have no relevant disclosures.
EDAT- 2022/08/30 06:00
MHDA- 2022/10/14 06:00
CRDT- 2022/08/29 11:14
PHST- 2022/07/16 00:00 [accepted]
PHST- 2022/08/30 06:00 [pubmed]
PHST- 2022/10/14 06:00 [medline]
PHST- 2022/08/29 11:14 [entrez]
AID - 10.1007/s11239-022-02687-5 [pii]
AID - 2687 [pii]
AID - 10.1007/s11239-022-02687-5 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2022 Oct;54(3):373-381. doi: 10.1007/s11239-022-02687-5. 
      Epub 2022 Aug 29.

PMID- 1432636
OWN - NLM
STAT- MEDLINE
DCOM- 19921210
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 81
IP  - 9
DP  - 1992 Sep
TI  - Simultaneous spectrophotometric determination in solid phase of aspirin and its 
      impurity salicylic acid in pharmaceutical formulations.
PG  - 895-8
AB  - We report the simultaneous determination of aspirin and its hydrolysis product, 
      salicylic acid, in solid phase by fluorescence spectrophotometry. Aspirin is 
      often the most labile component in a combination-type analgesic compound. 
      Therefore, its stability is often the initial concern in any 
      formulation-screening program. Preliminary screening of a large number of 
      potential formulations can be arduous, because most current methods of analysis 
      generally consist of several steps: extractions or column separations followed by 
      UV, colorimetric, or gas-liquid chromatographic assays. The method proposed here 
      is quite suited to large numbers of assays because it is not time consuming, it 
      is straightforward, and it is not subject to interference from the substances 
      present in the pharmaceutical formulations. In addition, the method is 
      nondestructive, not dependent on the sampling procedure, and, above all, quite 
      sensitive.
FAU - Villari, A
AU  - Villari A
AD  - Dipartimento Farmaco-Chimico, Università di Messina, Italy.
FAU - Micali, N
AU  - Micali N
FAU - Fresta, M
AU  - Fresta M
FAU - Puglisi, G
AU  - Puglisi G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Drug Contamination
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Spectrophotometry
EDAT- 1992/09/01 00:00
MHDA- 1992/09/01 00:01
CRDT- 1992/09/01 00:00
PHST- 1992/09/01 00:00 [pubmed]
PHST- 1992/09/01 00:01 [medline]
PHST- 1992/09/01 00:00 [entrez]
AID - S0022-3549(15)48937-3 [pii]
AID - 10.1002/jps.2600810911 [doi]
PST - ppublish
SO  - J Pharm Sci. 1992 Sep;81(9):895-8. doi: 10.1002/jps.2600810911.

PMID- 33749312
OWN - NLM
STAT- MEDLINE
DCOM- 20211026
LR  - 20220421
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 27
DP  - 2021 Jan-Dec
TI  - Efficacy of Monitoring Platelet Function by an Automated PL-12 Analyzer During 
      the Treatment of Acute Cerebral Infarction With Antiplatelet Medicine.
PG  - 10760296211001119
LID - 10.1177/10760296211001119 [doi]
LID - 10760296211001119
AB  - All participants were administered with oral aspirin (100 mg/d) for 7 days. Blood 
      samples were then collected and platelet function evaluated by an automated PL-12 
      analyzer, TEG, and the platelet count drop method. We found that platelet counts 
      determined by the traditional platelet drop method were significantly lower in 
      the PL-12 sensitive group and significantly higher in the PL-12 insensitive group 
      (P < 0.05). Furthermore, MAR measured by PL-12 was positively correlated with the 
      MA values determined by TEG and the platelet drop method (r = 0.322, r = 0.036, 
      respectively, P < 0.05), More importantly, the PL-12 analyzer showed the largest 
      AUC (0.748) with a sensitivity of 87.4% and a specificity of 57.4%, indicating 
      PL-12 analyzer using in platelet aggregation evaluation of ACI patients more 
      credibly and accuracy. Additionally, genetic analysis showed that the polymorphic 
      of A-allele in the PEAR1 (rs12041331) gene was significantly increased in the 
      PL-12 sensitive group rather than in the PL-12 insensitive group (P < 0.05), 
      suggesting the predictive value of PL-12 analyzer for the prognosis of ACI 
      patients was superior to the other methods tested herein. Our analyses 
      demonstrate that PL-12 analysis offer a new superior technology for monitoring 
      antiplatelet drug efficacy and for clinical prognosis of ACI patients, which has 
      the advantages of simplicity, speed, and automation in platelet aggregation 
      measurement.
FAU - Yue, Cen
AU  - Yue C
AD  - Department of Neurology, The First Affiliated Hospital of Xiamen University, 
      Xiamen, Fujian, China.
FAU - Lin, Zhiwei
AU  - Lin Z
AD  - Department of Neurology, The First Hospital of Putian City, Putian, Fujian, 
      China.
FAU - Lu, Congxia
AU  - Lu C
AD  - Department of Neurology, The First Affiliated Hospital of Xiamen University, 
      Xiamen, Fujian, China.
FAU - Chen, Hanshui
AU  - Chen H
AUID- ORCID: 0000-0002-1257-5480
AD  - Department of Neurology, The First Affiliated Hospital of Xiamen University, 
      Xiamen, Fujian, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cerebral Infarction/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests/*methods
MH  - Thrombelastography/*methods
PMC - PMC7989109
OTO - NOTNLM
OT  - PL-12 analyzer
OT  - acute cerebral infarction
OT  - aspirin
OT  - thrombelastography
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2021/03/23 06:00
MHDA- 2021/10/27 06:00
CRDT- 2021/03/22 12:23
PHST- 2021/03/22 12:23 [entrez]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/10/27 06:00 [medline]
AID - 10.1177_10760296211001119 [pii]
AID - 10.1177/10760296211001119 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211001119. doi: 
      10.1177/10760296211001119.

PMID- 35416770
OWN - NLM
STAT- MEDLINE
DCOM- 20220415
LR  - 20220913
IS  - 2050-084X (Electronic)
IS  - 2050-084X (Linking)
VI  - 11
DP  - 2022 Apr 13
TI  - Aspirin's effect on kinetic parameters of cells contributes to its role in 
      reducing incidence of advanced colorectal adenomas, shown by a multiscale 
      computational study.
LID - 10.7554/eLife.71953 [doi]
LID - e71953
AB  - Aspirin intake has been shown to lead to significant protection against 
      colorectal cancer, for example with an up to twofold reduction in colorectal 
      adenoma incidence rates at higher doses. The mechanisms contributing to 
      protection are not yet fully understood. While aspirin is an anti-inflammatory 
      drug and can thus influence the tumor microenvironment, in vitro and in vivo 
      experiments have recently shown that aspirin can also have a direct effect on 
      cellular kinetics and fitness. It reduces the rate of tumor cell division and 
      increases the rate of cell death. The question arises whether such changes in 
      cellular fitness are sufficient to significantly contribute to the 
      epidemiologically observed protection. To investigate this, we constructed a 
      class of mathematical models of in vivo evolution of advanced adenomas, 
      parameterized it with available estimates, and calculated population level 
      incidence. Fitting the predictions to age incidence data revealed that only a 
      model that included colonic crypt competition can account for the observed 
      age-incidence curve. This model was then used to predict modified incidence 
      patterns if cellular kinetics were altered as a result of aspirin treatment. We 
      found that changes in cellular fitness that were within the experimentally 
      observed ranges could reduce advanced adenoma incidence by a sufficient amount to 
      account for age incidence data in aspirin-treated patient cohorts. While the 
      mechanisms that contribute to the protective effect of aspirin are likely complex 
      and multi-factorial, our study demonstrates that direct aspirin-induced changes 
      of tumor cell fitness can significantly contribute to epidemiologically observed 
      reduced incidence patterns.
CI  - © 2022, Wang et al.
FAU - Wang, Yifan
AU  - Wang Y
AUID- ORCID: 0000-0003-3292-4972
AD  - Department of Mathematics, University of California Irvine, Irvine, United 
      States.
FAU - Boland, C Richard
AU  - Boland CR
AUID- ORCID: 0000-0002-8120-5088
AD  - Department of Medicine, University of California San Diego School of Medicine, 
      San Diego, United States.
FAU - Goel, Ajay
AU  - Goel A
AUID- ORCID: 0000-0003-1396-6341
AD  - Department of Molecular Diagnostics and Experimental Therapeutics, Beckman 
      Research Institute of City of Hope Comprehensive Cancer Center, Duarte, United 
      States.
FAU - Wodarz, Dominik
AU  - Wodarz D
AUID- ORCID: 0000-0002-8017-3707
AD  - Department of Mathematics, University of California Irvine, Irvine, United 
      States.
AD  - Department of Population Health and Disease Prevention, University of California 
      Irvine, Irvine, United States.
FAU - Komarova, Natalia L
AU  - Komarova NL
AUID- ORCID: 0000-0003-4876-0343
AD  - Department of Mathematics, University of California Irvine, Irvine, United 
      States.
LA  - eng
SI  - Dryad/10.7280/D1M11M
GR  - U01 CA187956/CA/NCI NIH HHS/United States
GR  - U54 CA217378/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20220413
PL  - England
TA  - Elife
JT  - eLife
JID - 101579614
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Adenoma/epidemiology/prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/pharmacology
MH  - *Colorectal Neoplasms/drug therapy/epidemiology/prevention & control
MH  - Humans
MH  - Incidence
MH  - Kinetics
MH  - Tumor Microenvironment
PMC - PMC9007589
OTO - NOTNLM
OT  - advanced adenoma
OT  - aspirin
OT  - cancer biology
OT  - colon cancer
OT  - computational biology
OT  - human
OT  - mathematical modeling
OT  - systems biology
COIS- YW, CB, AG, DW, NK No competing interests declared
EDAT- 2022/04/14 06:00
MHDA- 2022/04/16 06:00
CRDT- 2022/04/13 12:13
PHST- 2021/07/05 00:00 [received]
PHST- 2022/03/15 00:00 [accepted]
PHST- 2022/04/13 12:13 [entrez]
PHST- 2022/04/14 06:00 [pubmed]
PHST- 2022/04/16 06:00 [medline]
AID - 71953 [pii]
AID - 10.7554/eLife.71953 [doi]
PST - epublish
SO  - Elife. 2022 Apr 13;11:e71953. doi: 10.7554/eLife.71953.

PMID- 21548636
OWN - NLM
STAT- MEDLINE
DCOM- 20110923
LR  - 20131121
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 8
IP  - 3
DP  - 2011 Jun 6
TI  - Unintended water mediated cocrystal formation in carbamazepine and aspirin 
      tablets.
PG  - 982-9
LID - 10.1021/mp200043u [doi]
AB  - The water of crystallization released during dehydration of dibasic calcium 
      phosphate dihydrate (DCPD) mediated the cocrystal formation between carbamazepine 
      (CBZ) and nicotinamide (NMA) in intact tablets. The dehydration of DCPD, the 
      disappearance of the reactants (CBZ and NMA) and the appearance of the product 
      (CBZ-NMA cocrystal) were simultaneously monitored by quantitative powder X-ray 
      diffractometry. In a second model system, the water of crystallization released 
      by the dehydration of DCPD caused the chemical decomposition of aspirin. 
      Salicylic acid, one of the decomposition products, reacted with CBZ to form 
      CBZ-salicylic acid cocrystal in tablets. This is the first report of cocrystal 
      formation in intact tablets, demonstrating water mediated noncovalent synthesis 
      in a multicomponent matrix. While the potential implications of such 
      transformations, on both the mechanical and biopharmaceutical properties, can be 
      profound, their characterization, using conventional solution based analytical 
      techniques, can be challenging.
FAU - Arora, Kapildev K
AU  - Arora KK
AD  - Department of Pharmaceutics, University of Minnesota , Minneapolis, Minnesota 
      55455, USA.
FAU - Tayade, Nitin G
AU  - Tayade NG
FAU - Suryanarayanan, Raj
AU  - Suryanarayanan R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20110516
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 0 (Tablets)
RN  - 059QF0KO0R (Water)
RN  - 33CM23913M (Carbamazepine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Carbamazepine/*chemistry
MH  - Crystallization
MH  - Tablets/*chemistry
MH  - Water/*chemistry
EDAT- 2011/05/10 06:00
MHDA- 2011/09/29 06:00
CRDT- 2011/05/10 06:00
PHST- 2011/05/10 06:00 [entrez]
PHST- 2011/05/10 06:00 [pubmed]
PHST- 2011/09/29 06:00 [medline]
AID - 10.1021/mp200043u [doi]
PST - ppublish
SO  - Mol Pharm. 2011 Jun 6;8(3):982-9. doi: 10.1021/mp200043u. Epub 2011 May 16.

PMID- 3450629
OWN - NLM
STAT- MEDLINE
DCOM- 19880706
LR  - 20131121
IS  - 0019-5499 (Print)
IS  - 0019-5499 (Linking)
VI  - 31
IP  - 4
DP  - 1987 Oct-Dec
TI  - Acute effect of ethanol administration on platelet function.
PG  - 240-4
AB  - The acute effect of single dose of ethanol (1.5 g kg) and aspirin (10 mg/kg) 
      alone and in combination, on platelet aggregation time and platelet adhesiveness 
      were studied in rabbits. There was a significant and comparable increase in 
      aggregation time both by aspirin and ethanol. Similarly platelet adhesiveness was 
      decreased by both the agents.
FAU - Sudhir, S
AU  - Sudhir S
AD  - Department of Pharmacology and Blood Bank, Medical College, Haryana.
FAU - Gupta, L C
AU  - Gupta LC
FAU - Singh, J
AU  - Singh J
FAU - Budhiraja, R D
AU  - Budhiraja RD
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Physiol Pharmacol
JT  - Indian journal of physiology and pharmacology
JID - 0374707
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Ethanol/*pharmacology
MH  - Female
MH  - Male
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
EDAT- 1987/10/01 00:00
MHDA- 1987/10/01 00:01
CRDT- 1987/10/01 00:00
PHST- 1987/10/01 00:00 [pubmed]
PHST- 1987/10/01 00:01 [medline]
PHST- 1987/10/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Physiol Pharmacol. 1987 Oct-Dec;31(4):240-4.

PMID- 33706986
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 144 Suppl 1
DP  - 2021 Apr 1
TI  - Overview of Aspirin and Platelet Biology.
PG  - S2-S9
LID - S0002-9149(20)31345-X [pii]
LID - 10.1016/j.amjcard.2020.12.018 [doi]
AB  - Aspirin (ASA) has historically been one of the most important drugs in cardiology 
      and has long been the cornerstone of antiplatelet therapy. Although its role in 
      acute coronary syndrome remains undisputed, emerging data suggest that 
      reappraisal of the efficacy of long-term ASA in some primary and secondary 
      prevention may be warranted. The aim of this review is to place these new results 
      in the context of previous evidence on aspirin by appraising the current body of 
      evidence on its use of for cardiovascular diseases. This overview first 
      summarizes the history of the discovery of aspirin, as well as its pharmacology 
      and the concept of ASA resistance. We subsequently recapitulate the evidence of 
      ASA on primary prevention and secondary prevention starting from the classical 
      studies in order to serve as an introductory background to the examination of the 
      most recent clinical trials that will be performed in the rest of the articles of 
      this Supplement. Although the benefit of ASA in acute coronary syndrome remains 
      incontrovertible, emerging evidence challenge the universal need for primary 
      prevention, or for lifelong treatment in secondary prevention or all adults with 
      stable coronary disease who are at highest risk for ASA-induced bleeding. The 
      role of aspirin is quickly changing in recent times and this review provides a 
      review for the clinician about the current role of this drug in cardiovascular 
      care.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Santos-Gallego, Carlos G
AU  - Santos-Gallego CG
AD  - AtheroThrombosis Research Unit. Icahn School of Medicine at Mount Sinai Mount 
      Sinai Heart. Mount Sinai Hospital, New York, New York.
FAU - Badimon, Juan
AU  - Badimon J
AD  - AtheroThrombosis Research Unit. Icahn School of Medicine at Mount Sinai Mount 
      Sinai Heart. Mount Sinai Hospital, New York, New York. Electronic address: 
      Juan.badimon@mssm.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 2021/03/13 06:00
MHDA- 2021/04/10 06:00
CRDT- 2021/03/12 06:01
PHST- 2020/11/22 00:00 [received]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2021/03/12 06:01 [entrez]
PHST- 2021/03/13 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - S0002-9149(20)31345-X [pii]
AID - 10.1016/j.amjcard.2020.12.018 [doi]
PST - ppublish
SO  - Am J Cardiol. 2021 Apr 1;144 Suppl 1:S2-S9. doi: 10.1016/j.amjcard.2020.12.018.

PMID- 3410591
OWN - NLM
STAT- MEDLINE
DCOM- 19880929
LR  - 20131121
IS  - 0174-4879 (Print)
IS  - 0174-4879 (Linking)
VI  - 26
IP  - 2
DP  - 1988 Feb
TI  - The absorption of acetylsalicylic acid from an enteric-coated formulation and the 
      inhibition of thromboxane formation.
PG  - 88-92
AB  - To compare conventional (CT) and enteric-coated (ECT) tablets of acetylsalicylic 
      acid (ASA) six healthy adult subjects ingested one 0.5-g tablet of these 
      formulations daily for fifteen days in a cross-over study. Significant amount of 
      ASA was detected in peripheral blood of every subject after the ingestion of CT 
      or ECT. The rate of absorption of ASA was faster and its peak plasma 
      concentration was higher after the ingestion of CT. The formation of thromboxane 
      B2 (TXB2) decreased during blood clotting concomitantly with the absorption of 
      ASA from both formulations. The formation of TXB2 was equally and completely 
      inhibited by CT and ECT as it decreased to 1% of the control value one day after 
      the first dose. During treatment with a single daily dose of 0.5 g of CT or ECT, 
      the serum level of TXB2 remained at this low level and returned to the control 
      level gradually in two weeks after the last dose. The present study indicates 
      that significant amount of unchanged ASA is absorbed also from ECT and that the 
      formation of TXB2 is equally and completely inhibited with a 0.5-g daily dose of 
      both formulations.
FAU - Anttila, M
AU  - Anttila M
AD  - Research Center, Farmos Group Ltd., Turku, Finland.
FAU - Kahela, P
AU  - Kahela P
FAU - Uotila, P
AU  - Uotila P
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther Toxicol
JT  - International journal of clinical pharmacology, therapy, and toxicology
JID - 8003415
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics/pharmacology
MH  - Depression, Chemical
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Tablets
MH  - Tablets, Enteric-Coated
MH  - Thromboxane B2/blood
MH  - Thromboxanes/*biosynthesis
EDAT- 1988/02/01 00:00
MHDA- 1988/02/01 00:01
CRDT- 1988/02/01 00:00
PHST- 1988/02/01 00:00 [pubmed]
PHST- 1988/02/01 00:01 [medline]
PHST- 1988/02/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther Toxicol. 1988 Feb;26(2):88-92.

PMID- 21311841
OWN - NLM
STAT- MEDLINE
DCOM- 20111207
LR  - 20211020
IS  - 1475-1534 (Electronic)
IS  - 1471-4418 (Print)
IS  - 1471-4418 (Linking)
VI  - 20
IP  - 2
DP  - 2011 Jun
TI  - Recognising the risk of aspirin-sensitive respiratory disease in a patient with 
      asthma who has previously tolerated aspirin.
PG  - 214-7
LID - 10.4104/pcrj.2011.00001 [doi]
AB  - Asthma is a common chronic condition composed of numerous different phenotypes. 
      One clinically relevant phenotype is that of aspirin-sensitive respiratory 
      disease (ASRD) which is more frequently seen in patients with difficult asthma. 
      Reliance on a history of previous reaction to non-steroidal anti-inflammatory 
      drugs (NSAIDs) in order to diagnose ASRD may give false reassurance. We describe 
      the case of a 58-year old man with late onset asthma who was suspected to have 
      ASRD on the basis of associated clinical features despite having taken aspirin 
      safely in the past. The diagnosis of ASRD was subsequently confirmed by an 
      inadvertent aspirin challenge which led to a serious adverse asthma outcome.
FAU - Abayaratne, Damita
AU  - Abayaratne D
AD  - Foundation Year 2 (FY2) Doctor, Department of Respiratory Medicine, Southampton 
      General Hospital, Southampton, UK.
FAU - Kurukulaaratchy, Ramesh J
AU  - Kurukulaaratchy RJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Prim Care Respir J
JT  - Primary care respiratory journal : journal of the General Practice Airways Group
JID - 101121543
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Asthma/*drug therapy
MH  - Drug Hypersensitivity/*diagnosis
MH  - *Drug Tolerance
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiratory Tract Diseases/*chemically induced/diagnosis
PMC - PMC6549812
COIS- There were no conflicts of interest for the authors during the preparation of 
      this manuscript
EDAT- 2011/02/12 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/02/12 06:00
PHST- 2011/02/12 06:00 [entrez]
PHST- 2011/02/12 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - pcrj-2009-12-0098-R1 [pii]
AID - 10.4104/pcrj.2011.00001 [doi]
PST - ppublish
SO  - Prim Care Respir J. 2011 Jun;20(2):214-7. doi: 10.4104/pcrj.2011.00001.

PMID- 1526087
OWN - NLM
STAT- MEDLINE
DCOM- 19921022
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 52
IP  - 3
DP  - 1992 Sep
TI  - The efficacy of locally applied aspirin and acetaminophen in postoperative pain 
      after third molar surgery.
PG  - 292-6
AB  - This study evaluated the efficacy of and investigated the site of action of 
      aspirin and acetaminophen placed directly into tooth sockets after bilateral 
      third molar surgery under local anaesthesia. On completion of surgery, 12 
      patients received in random, blind order either a suspension of aspirin in a 
      methyl cellulose gel (100 mg/ml) in their tooth sockets and an oral placebo or 
      the methyl cellulose alone in their sockets and an oral dose of aspirin (50 mg). 
      The remaining 12 patients were treated in the same fashion with use 
      acetaminophen. Patients were asked to record their pain, at intervals, over an 
      8-hour period on a 10 cm visual analog scale. Significantly less pain (p less 
      than 0.05) was recorded throughout the 8-hour investigation period after both 
      locally placed drugs than after placebo. There was no adverse effect on healing. 
      The peripheral activity of aspirin is confirmed, and our findings suggest that 
      acetaminophen has a significant peripheral effect in mediating its analgesic 
      properties in postoperative pain after third molar surgery.
FAU - Moore, U J
AU  - Moore UJ
AD  - Department of Oral Surgery, University of Newcastle upon Tyne, England.
FAU - Seymour, R A
AU  - Seymour RA
FAU - Rawlins, M D
AU  - Rawlins MD
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Gels)
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/*therapeutic use
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Gels
MH  - Humans
MH  - Molar, Third/*surgery
MH  - Pain Measurement
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
EDAT- 1992/09/01 00:00
MHDA- 1992/09/01 00:01
CRDT- 1992/09/01 00:00
PHST- 1992/09/01 00:00 [pubmed]
PHST- 1992/09/01 00:01 [medline]
PHST- 1992/09/01 00:00 [entrez]
AID - 10.1038/clpt.1992.144 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1992 Sep;52(3):292-6. doi: 10.1038/clpt.1992.144.

PMID- 3987774
OWN - NLM
STAT- MEDLINE
DCOM- 19850603
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 27
IP  - 6
DP  - 1985
TI  - Plasma salicylate levels and platelet function after acute and chronic 
      administration of slow-release acetylsalicylic acid (Monobeltin).
PG  - 683-7
AB  - The relationships between the antiplatelet effects and the pharmacokinetics of a 
      slow release formulation of acetylsalicylic acid (ASA) have been investigated. 
      After acute intake of 750 mg ASA in a slow-release formulation (Monobeltin), a 
      slow increase in plasma ASA was paralleled by a gradual decrease in certain 
      platelet functions. During chronic medication (750 mg twice daily), ASA was 
      present in plasma at all times accompanied by full inhibition of platelet 
      aggregation. For chronic antiplatelet therapy, this slow release formulation of 
      ASA appears to be very effective, unless rapid inhibition of platelet function 
      must be achieved.
FAU - Rehders, K
AU  - Rehders K
FAU - Simrock, R
AU  - Simrock R
FAU - Spahn, H
AU  - Spahn H
FAU - Mutschler, E
AU  - Mutschler E
FAU - Breddin, H K
AU  - Breddin HK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Delayed-Action Preparations
MH  - Hippurates/blood
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Salicylates/*blood
MH  - Salicylic Acid
MH  - Time Factors
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1007/BF00547049 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1985;27(6):683-7. doi: 10.1007/BF00547049.

PMID- 37178937
OWN - NLM
STAT- MEDLINE
DCOM- 20230605
LR  - 20230605
IS  - 1879-1298 (Electronic)
IS  - 0045-6535 (Linking)
VI  - 333
DP  - 2023 Aug
TI  - Ecotoxicological impacts of environmentally relevant concentrations of aspirin in 
      the liver of Labeo rohita: Biochemical and histopathological investigation.
PG  - 138921
LID - S0045-6535(23)01188-8 [pii]
LID - 10.1016/j.chemosphere.2023.138921 [doi]
AB  - Aspirin is one of the emerging pharmaceutical contaminants in the aquatic 
      environment and thus it could impart toxicity to non-target organisms including 
      fish. The present study aims to investigate the biochemical and histopathological 
      alterations in the liver of the fish, Labeo rohita exposed to environmentally 
      relevant concentrations of aspirin (1, 10, and 100 μg/L) for 7, 14, 21, and 28 
      days. The biochemical investigation revealed a significant (p < 0.05) decrease in 
      the activity of antioxidant enzymes such as catalase, glutathione peroxidase, 
      glutathione reductase; and reduced glutathione content in a concentration and 
      duration dependent manner. Further, the decrease in the activity of superoxide 
      dismutase was in a dose dependent manner. The activity of 
      glutathione-s-transferase, however, increased significantly (p < 0.05) in a dose 
      dependent manner. The lipid peroxidation and total nitrate content showed a 
      significant (p < 0.05) increase in a dose and duration dependent manner. The 
      metabolic enzymes such as acid phosphatase, alkaline phosphatase, and lactate 
      dehydrogenase showed a significant (p < 0.05) increase in all three exposure 
      concentrations and durations. The histopathological alterations in the liver such 
      as vacuolization, hypertrophy of the hepatocytes, nuclear degenerative changes, 
      and bile stagnosis increased in a dose and duration dependent manner. Hence, the 
      present study concludes aspirin has a toxic impact on fish, which is evidenced by 
      its profound effect on biochemical parameters and histopathological analysis. 
      These can be employed as potential indicators of pharmaceutical toxicity in the 
      field of environmental biomonitoring.
CI  - Copyright © 2023 Elsevier Ltd. All rights reserved.
FAU - Gayen, Tuhina
AU  - Gayen T
AD  - Fish Physiology Laboratory, Zoology Section, Mahila Mahavidyalaya, Banaras Hindu 
      University, Varanasi, 221 005, India.
FAU - Tripathi, Anchal
AU  - Tripathi A
AD  - Fish Physiology Laboratory, Zoology Section, Mahila Mahavidyalaya, Banaras Hindu 
      University, Varanasi, 221 005, India.
FAU - Kumari, Usha
AU  - Kumari U
AD  - Fish Physiology Laboratory, Zoology Section, Mahila Mahavidyalaya, Banaras Hindu 
      University, Varanasi, 221 005, India. Electronic address: usha.kumari1@bhu.ac.in.
FAU - Mittal, Swati
AU  - Mittal S
AD  - Skin Physiology Laboratory, Department of Zoology, Institute of Science, Banaras 
      Hindu University, Varanasi, 221 005, India.
FAU - Mittal, Ajay Kumar
AU  - Mittal AK
AD  - Department of Zoology, Banaras Hindu University, 9, Mani Nagar, Kandawa, Varanasi 
      - 221106, India.
LA  - eng
PT  - Journal Article
DEP - 20230511
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Antioxidants)
RN  - EC 1.11.1.6 (Catalase)
RN  - GAN16C9B8O (Glutathione)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Animals
MH  - *Oxidative Stress
MH  - Aspirin/toxicity/metabolism
MH  - Antioxidants/metabolism
MH  - *Cyprinidae/metabolism
MH  - Catalase/metabolism
MH  - Liver/metabolism
MH  - Glutathione/metabolism
MH  - Lipid Peroxidation
MH  - Superoxide Dismutase/metabolism
MH  - Pharmaceutical Preparations/metabolism
OTO - NOTNLM
OT  - Aspirin
OT  - Fish
OT  - Histopathology
OT  - Liver
OT  - Oxidative stress
COIS- Declaration of competing interest The authors declare the following financial 
      interests/personal relationships which may be considered as potential competing 
      interests: Tuhina Gayen reports financial support was provided by Council of 
      Scientific and Industrial Research Human Resource Development Group.
EDAT- 2023/05/14 01:07
MHDA- 2023/06/05 06:42
CRDT- 2023/05/13 19:28
PHST- 2022/12/23 00:00 [received]
PHST- 2023/05/03 00:00 [revised]
PHST- 2023/05/10 00:00 [accepted]
PHST- 2023/06/05 06:42 [medline]
PHST- 2023/05/14 01:07 [pubmed]
PHST- 2023/05/13 19:28 [entrez]
AID - S0045-6535(23)01188-8 [pii]
AID - 10.1016/j.chemosphere.2023.138921 [doi]
PST - ppublish
SO  - Chemosphere. 2023 Aug;333:138921. doi: 10.1016/j.chemosphere.2023.138921. Epub 
      2023 May 11.

PMID- 7059243
OWN - NLM
STAT- MEDLINE
DCOM- 19820420
LR  - 20190514
IS  - 0003-4932 (Print)
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 195
IP  - 3
DP  - 1982 Mar
TI  - Antiplatelet therapy reduces aortic intimal hyperplasia distal to small diameter 
      vascular prostheses (PTFE) in nonhuman primates.
PG  - 328-39
AB  - While the use of prosthetic grafts in small diameter arterial reconstruction is 
      required when suitable autogenous graft material is unavailable, late occlusion 
      of prosthetic grafts caused by proliferative lesions has been described. This 
      study evaluated the suitability of 3-mm (ID) microporous polytetrafluoroethylene 
      (PTFE) Gore-Tex grafts inserted in the abdominal aorta of eight nonhuman primates 
      (Macaca fascicularis), and the effects of prolonged antiplatelet treatment on 
      both graft patency and the development of intimal hyperplasia in the adjacent 
      vasculature. Four monkeys received antiplatelet medication consisting of aspirin 
      (163 mg twice daily) and dipyridamole (25 mg twice daily). When killed at four 
      months following graft insertion, all four grafts in the antiplatelet medicated 
      group were patent, while in the control group, only two of four grafts were 
      patent. Histologic examination and quantitative photogravitometric evaluation of 
      the degree of luminal narrowing were performed on all grafts and the adjacent 
      vasculature. These studies revealed that while all graft and aortic segments 
      showed varying amounts of intimal thickening, occlusions in the control animals 
      were related to intimal hyperplasia in the host aorta at the site of the distal 
      anastomosis. Intimal hyperplasia in all aortic segments examined distal to the 
      graft was significantly reduced by antiplatelet therapy. Electronmicroscopy 
      showed that smooth muscle cells were the predominant cells of the intimal 
      thickening of the aorta (intimal hyperplasia), and that proliferation of these 
      cells did not extend into the graft itself. The predominant cell population of 
      the intimal thickening of the graft were of the myofibroblast type (neointimal 
      hyperplasis). The luminal surface of the graft was lined with cells that had some 
      but not all of the characteristics of mature endothelial cells. In vitro studies 
      confirmed global interference with platelet function and arachidonic acid 
      metabolism in medicated animals. Medication inhibited platelet cyclo-oxygenase 
      without affecting platelet lipoxygenase, thromboxane synthetase, or 
      prostacyclin-like activity in undisturbed arteries. This study shows that severe 
      intimal hyperplasia develops rapidly in the recipient vessel adjacent to small 
      diameter Gore-Tex grafts, and that the severity of the response is reduced by 
      antiplatelet agents. Histologic examination revealed that the intimal thickening 
      in the graft and the adjacent aortic segments were composed of cells that were 
      not morphologically identical, suggesting two separate aetiologies and the 
      possible need to use different approaches in their prevention.
FAU - Hagen, P O
AU  - Hagen PO
FAU - Wang, Z G
AU  - Wang ZG
FAU - Mikat, E M
AU  - Mikat EM
FAU - Hackel, D B
AU  - Hackel DB
LA  - eng
GR  - HL05875/HL/NHLBI NIH HHS/United States
GR  - HL15448/HL/NHLBI NIH HHS/United States
GR  - HL17636/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta, Abdominal/pathology
MH  - Aortic Diseases/*pathology/prevention & control
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Blood Vessel Prosthesis/*standards
MH  - Dipyridamole/pharmacology/*therapeutic use
MH  - Hyperplasia/prevention & control
MH  - In Vitro Techniques
MH  - Macaca fascicularis
MH  - Male
MH  - Polytetrafluoroethylene
PMC - PMC1352640
EDAT- 1982/03/01 00:00
MHDA- 1982/03/01 00:01
CRDT- 1982/03/01 00:00
PHST- 1982/03/01 00:00 [pubmed]
PHST- 1982/03/01 00:01 [medline]
PHST- 1982/03/01 00:00 [entrez]
AID - 10.1097/00000658-198203000-00014 [doi]
PST - ppublish
SO  - Ann Surg. 1982 Mar;195(3):328-39. doi: 10.1097/00000658-198203000-00014.

PMID- 17264714
OWN - NLM
STAT- MEDLINE
DCOM- 20070312
LR  - 20190628
IS  - 0003-3022 (Print)
IS  - 0003-3022 (Linking)
VI  - 106
IP  - 2
DP  - 2007 Feb
TI  - Effects of dexibuprofen on platelet function in humans: comparison with low-dose 
      aspirin.
PG  - 218-25
AB  - BACKGROUND: The aim of the current study is to evaluate the antiplatelet effect 
      of dexibuprofen in healthy volunteers in comparison with low-dose aspirin. 
      METHODS: Healthy volunteers (n = 12) were treated in a crossover manner with 100 
      mg daily aspirin or with 800 mg daily dexibuprofen. Blood samples were obtained 
      within 24 h; 3, 7, and 14 days after repeated doses; and 24 h after the last 
      dose. In each sample, the authors measured platelet aggregation, thromboxane B2, 
      6-keto-prostaglandin F1alpha, and nitric oxide. RESULTS: The antiplatelet effect 
      of dexibuprofen (maximal inhibition of aggregation was 48-55% for adenosine 
      diphosphate and 90-95% for collagen and arachidonic acid) was equal to the effect 
      of aspirin. The main difference between the two drugs was in the degree of 
      recovery of platelet function. The effect of aspirin persisted for 24 h after the 
      last dose (remaining inhibition 50%, respect to the pretreatment value), whereas 
      platelet aggregation had returned to baseline pretreatment values within 24 h 
      after dexibuprofen was stopped. CONCLUSIONS: Both aspirin and dexibuprofen 
      inhibited platelet function with a similar intensity, but dexibuprofen exerted a 
      reversible effect for 24 h after the last dose.
FAU - González-Correa, José Antonio
AU  - González-Correa JA
AD  - Department of Pharmacology and Therapeutics, School of Medicine, University of 
      Malaga, Spain.
FAU - Arrebola, María Monsalud
AU  - Arrebola MM
FAU - Martín-Salido, Eva
AU  - Martín-Salido E
FAU - Muñoz-Marín, Javier
AU  - Muñoz-Marín J
FAU - de la Cuesta, Felipe Sánchez
AU  - de la Cuesta FS
FAU - De La Cruz, José Pedro
AU  - De La Cruz JP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesthesiology
JT  - Anesthesiology
JID - 1300217
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
CIN - Anesthesiology. 2007 Feb;106(2):205-6. PMID: 17264710
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cross-Over Studies
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Female
MH  - Humans
MH  - Ibuprofen/*pharmacology
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Stereoisomerism
EDAT- 2007/02/01 09:00
MHDA- 2007/03/14 09:00
CRDT- 2007/02/01 09:00
PHST- 2007/02/01 09:00 [pubmed]
PHST- 2007/03/14 09:00 [medline]
PHST- 2007/02/01 09:00 [entrez]
AID - 00000542-200702000-00008 [pii]
AID - 10.1097/00000542-200702000-00008 [doi]
PST - ppublish
SO  - Anesthesiology. 2007 Feb;106(2):218-25. doi: 10.1097/00000542-200702000-00008.

PMID- 35434898
OWN - NLM
STAT- MEDLINE
DCOM- 20221021
LR  - 20221104
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 11
IP  - 20
DP  - 2022 Oct
TI  - Implementing subtype-specific pre-clinical models of breast cancer to study 
      pre-treatment aspirin effects.
PG  - 3820-3836
LID - 10.1002/cam4.4756 [doi]
AB  - BACKGORUND: Prior data suggest pre-diagnostic aspirin use impacts breast tumour 
      biology and patient outcome. Here, we employed faithful surgical resection models 
      of HER2+ and triple-negative breast cancer (TNBC), to study outcome and response 
      mechanisms across breast cancer subtypes. METHOD: NOD/SCID mice were implanted 
      with HER2+ MDA-MB-231/LN/2-4/H2N, trastuzumab-resistant HER2+ HCC1954 or a TNBC 
      patient-derived xenograft (PDX). A daily low-dose aspirin regimen commenced until 
      primary tumours reached ~250 mm(3) and subsequently resected. 
      MDA-MB-231/LN/2-4/H2N mice were monitored for metastasis utilising imaging. To 
      interrogate the survival benefit of pre-treatment aspirin, 3 weeks 
      post-resection, HCC1954/TNBC animals received standard-of-care (SOC) chemotherapy 
      for 6 weeks. Primary tumour response to aspirin was interrogated using 
      immunohistochemistry. RESULTS: Aspirin delayed time to metastasis in 
      MDA-MB-231/LN/2-4/H2N xenografts and decreased growth of HER2(+) /TNBC primary 
      tumours. Lymphangiogenic factors and lymph vessels number were decreased in 
      HER2(+) tumours. However, no survival benefit was seen in aspirin pre-treated 
      animals (HCC1954/TNBC) that further received adjuvant SOC, compared with animals 
      treated with SOC alone. In an effort to study mechanisms responsible for the 
      observed reduction in lymphangiogenesis in HER2(+) BC we utilised an in vitro 
      co-culture system of HCC1954 tumour cells and mesenchymal stromal cells (MSC). 
      Aspirin abrogated the secretion of VEGF-C in MSCs and also decreased the 
      lymph/angiogenic potential of the MSCs and HCC1954 by tubule formation assay. 
      Furthermore, aspirin decreased the secretion of uPA in HCC1954 cells potentially 
      diminishing its metastatic capability. CONCLUSION: Our data employing clinically 
      relevant models demonstrate that aspirin alters breast tumour biology. However, 
      aspirin may not represent a robust chemo-preventative agent in the HER2(+) or 
      TNBC setting.
CI  - © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Miller, Ian S
AU  - Miller IS
AUID- ORCID: 0000-0003-2118-6345
AD  - Department of Physiology and Medical Physics, Royal College of Surgeons in 
      Ireland, St Stephens Green, Dublin, Ireland.
AD  - National Preclinical Imaging Centre, Royal College of Surgeons in Ireland, St 
      Stephens Green, Dublin, Ireland.
FAU - Khan, Sonja
AU  - Khan S
AD  - Discipline of Surgery, The Lambe Institute for Translational Research, National 
      University of Ireland Galway, Galway, Ireland.
FAU - Shiels, Liam P
AU  - Shiels LP
AD  - Department of Physiology and Medical Physics, Royal College of Surgeons in 
      Ireland, St Stephens Green, Dublin, Ireland.
FAU - Das, Sudipto
AU  - Das S
AD  - School of Pharmacy and Biomedical Sciences, Royal College of Surgeons in Ireland, 
      St Stepehen's Green, Dublin, Ireland.
FAU - O' Farrell, Alice C
AU  - O' Farrell AC
AD  - Department of Physiology and Medical Physics, Royal College of Surgeons in 
      Ireland, St Stephens Green, Dublin, Ireland.
FAU - Connor, Kate
AU  - Connor K
AD  - Department of Physiology and Medical Physics, Royal College of Surgeons in 
      Ireland, St Stephens Green, Dublin, Ireland.
FAU - Lafferty, Adam
AU  - Lafferty A
AD  - Department of Physiology and Medical Physics, Royal College of Surgeons in 
      Ireland, St Stephens Green, Dublin, Ireland.
FAU - Moran, Bruce
AU  - Moran B
AD  - UCD School of Bimolecular and Biomedical Science, University College Dublin, 
      Dublin, Ireland.
FAU - Isella, Claudio
AU  - Isella C
AD  - Institute for Cancer Research and Treatment, University of Turin, Turin, Italy.
FAU - Loadman, Paul
AU  - Loadman P
AD  - School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.
FAU - Conroy, Emer
AU  - Conroy E
AD  - UCD School of Bimolecular and Biomedical Science, University College Dublin, 
      Dublin, Ireland.
FAU - Cohrs, Susan
AU  - Cohrs S
AD  - Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, 
      Switzerland.
FAU - Schibli, Roger
AU  - Schibli R
AD  - Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, 
      Switzerland.
FAU - Kerbel, Robert S
AU  - Kerbel RS
AD  - Sunnybrook Research Institute, University of Toronto, Ontario, Canada.
FAU - Gallagher, William M
AU  - Gallagher WM
AD  - UCD School of Bimolecular and Biomedical Science, University College Dublin, 
      Dublin, Ireland.
FAU - Marangoni, Elisabetta
AU  - Marangoni E
AD  - Translational Research Department, Institute Curie, PSL Research University, 
      Paris, France.
FAU - Bennett, Kathleen
AU  - Bennett K
AD  - Division of Population Health Science, Royal College of Surgeons in Ireland, 
      Dublin, Ireland.
FAU - O' Connor, Darran P
AU  - O' Connor DP
AD  - School of Pharmacy and Biomedical Sciences, Royal College of Surgeons in Ireland, 
      St Stepehen's Green, Dublin, Ireland.
FAU - Dwyer, Róisín M
AU  - Dwyer RM
AUID- ORCID: 0000-0002-5854-0339
AD  - Discipline of Surgery, The Lambe Institute for Translational Research, National 
      University of Ireland Galway, Galway, Ireland.
FAU - Byrne, Annette T
AU  - Byrne AT
AD  - Department of Physiology and Medical Physics, Royal College of Surgeons in 
      Ireland, St Stephens Green, Dublin, Ireland.
AD  - National Preclinical Imaging Centre, Royal College of Surgeons in Ireland, St 
      Stephens Green, Dublin, Ireland.
AD  - UCD School of Bimolecular and Biomedical Science, University College Dublin, 
      Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220417
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - 0 (Vascular Endothelial Growth Factor C)
RN  - R16CO5Y76E (Aspirin)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Humans
MH  - Animals
MH  - Mice
MH  - Female
MH  - Receptor, ErbB-2
MH  - *Triple Negative Breast Neoplasms/pathology
MH  - Vascular Endothelial Growth Factor C
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Mice, SCID
MH  - Mice, Inbred NOD
MH  - Trastuzumab/therapeutic use
MH  - *Breast Neoplasms/pathology
PMC - PMC9582689
OTO - NOTNLM
OT  - aspirin
OT  - breast cancer
OT  - cancer prevention lymphangiogenesis
OT  - mouse model
COIS- All other authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2022/04/19 06:00
MHDA- 2022/10/22 06:00
CRDT- 2022/04/18 06:44
PHST- 2022/03/31 00:00 [revised]
PHST- 2021/07/02 00:00 [received]
PHST- 2022/04/07 00:00 [accepted]
PHST- 2022/04/19 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
PHST- 2022/04/18 06:44 [entrez]
AID - CAM44756 [pii]
AID - 10.1002/cam4.4756 [doi]
PST - ppublish
SO  - Cancer Med. 2022 Oct;11(20):3820-3836. doi: 10.1002/cam4.4756. Epub 2022 Apr 17.

PMID- 29138036
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 218
IP  - 3
DP  - 2018 Mar
TI  - Aspirin for the prevention of preterm and term preeclampsia: systematic review 
      and metaanalysis.
PG  - 287-293.e1
LID - S0002-9378(17)32326-8 [pii]
LID - 10.1016/j.ajog.2017.11.561 [doi]
AB  - OBJECTIVE DATA: Metaanalyses of randomized controlled trials have reported 
      contradictory results about the effect of aspirin in the prevention of 
      preeclampsia, both in terms of the gestational age at the onset of treatment and 
      the dose of the drug. The controversy may be resolved by a metaanalysis that 
      includes several recently published trials and particularly the large Combined 
      Multimarker Screening and Randomized Patient Treatment with Aspirin for 
      Evidence-based Preeclampsia Prevention trial and by examination of whether there 
      is a difference of the effect of aspirin on preterm vs term preeclampsia. STUDY: 
      We performed a systematic review and metaanalysis that evaluated the prophylactic 
      effect of aspirin during pregnancy. STUDY APPRAISAL AND SYNTHESIS METHODS: We 
      completed a literature search through PubMed, Cinhal, Embase, Web of Science, and 
      Cochrane library from 1985 to June 2017. Relative risks with random effect were 
      calculated with their 95% confidence intervals. RESULTS: Sixteen trials that 
      included 18,907 participants provided data for preterm and term preeclampsia. 
      Eight of the included studies were evaluated as being of good quality, and the 
      other 8 studies were deemed to be of poor or uncertain quality. There was high 
      heterogeneity within studies (I(2) >50%) for preterm and term preeclampsia, but 
      no heterogeneity was found in the subgroup of preterm preeclampsia when the onset 
      of treatment was ≤16 weeks of gestation and the daily dose of aspirin was ≥100 mg 
      (I(2)=0%). Administration of aspirin was associated with reduction in the risk of 
      preterm preeclampsia (relative risk, 0.62; 95% confidence interval, 0.45-0.87), 
      but there was no significant effect on term preeclampsia (relative risk, 0.92; 
      95% confidence interval, 0.70-1.21). The reduction in preterm preeclampsia was 
      confined to the subgroup in which aspirin was initiated at ≤16 weeks of gestation 
      and at a daily dose of ≥100 mg (relative risk, 0.33; 95% confidence interval, 
      0.19-0.57). This effect was also observed in the high-quality studies. The 
      reduction in preterm preeclampsia that was observed in the largest trial 
      (Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for 
      Evidence-based Preeclampsia Prevention; n=1620; relative risk, 0.38; 95% 
      confidence interval, 0.20-0.72) was similar to that in the 5 smaller trials in 
      which aspirin was initiated at ≤16 weeks of gestation and at a daily dose of ≥100 
      mg (n=639; relative risk, 0.22; 95% confidence interval, 0.07-0.66). CONCLUSION: 
      Aspirin reduces the risk of preterm preeclampsia, but not term preeclampsia, and 
      only when it is initiated at ≤16 weeks of gestation and at a daily dose of ≥100 
      mg.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Roberge, Stephanie
AU  - Roberge S
AD  - Harris Birthright Research Centre of Fetal Medicine, Fetal Medicine Research 
      Institute, King's College Hospital, London, United Kingdom. Electronic address: 
      Stephanie.g.roberge@gmail.com.
FAU - Bujold, Emmanuel
AU  - Bujold E
AD  - Department of Obstetrics and Gynecology & Department of Social and Preventive 
      Medicine, Faculty of Medecine, Université Laval, Quebec City, Quebec, Canada.
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
AD  - Harris Birthright Research Centre of Fetal Medicine, Fetal Medicine Research 
      Institute, King's College Hospital, London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20171111
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Obstet Gynecol. 2018 Dec;219(6):633-634. PMID: 30144402
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Female
MH  - *Gestational Age
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - aspirin
OT  - metaanalysis
OT  - preeclampsia
EDAT- 2017/11/16 06:00
MHDA- 2018/12/12 06:00
CRDT- 2017/11/16 06:00
PHST- 2017/08/15 00:00 [received]
PHST- 2017/09/29 00:00 [revised]
PHST- 2017/11/07 00:00 [accepted]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2017/11/16 06:00 [entrez]
AID - S0002-9378(17)32326-8 [pii]
AID - 10.1016/j.ajog.2017.11.561 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2018 Mar;218(3):287-293.e1. doi: 10.1016/j.ajog.2017.11.561. 
      Epub 2017 Nov 11.

PMID- 27907854
OWN - NLM
STAT- MEDLINE
DCOM- 20170523
LR  - 20171208
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 134
DP  - 2017 Feb 5
TI  - Raman spectroscopy and capillary zone electrophoresis for the analysis of 
      degradation processes in commercial effervescent tablets containing 
      acetylsalicylic acid and ascorbic acid.
PG  - 122-129
LID - S0731-7085(16)31103-7 [pii]
LID - 10.1016/j.jpba.2016.11.020 [doi]
AB  - In order to ensure the stability of pharmaceutical products appropriate 
      manufacturing and storage conditions are required. In general, the degradation of 
      active pharmaceutical ingredients (APIs) and subsequent formation of degradation 
      products affect the pharmaceutical quality. Thus, a fast and effective detection 
      and characterization of these substances is mandatory. Here, the applicability of 
      Raman spectroscopy and CZE for the characterization of the degradation of 
      effervescent tablets containing acetylsalicylic acid (ASA) and ascorbic acid (AA) 
      was evaluated. Therefore, a degradation study was performed analyzing tablets 
      from two different manufacturers at varying conditions (relative humidity (RH) 
      33%, 52% and 75% at 30°C). Raman spectroscopy combined with principal component 
      analysis could be successfully applied for the fast and easy discrimination of 
      non-degraded and degraded effervescent tablets after a storage period of 
      approximately 24h (RH 52%). Nevertheless, a clear identification or 
      quantification of APIs and degradation products within the analyzed tablets was 
      not possible, i.a. due to missing reference materials. CZE-UV enabled the 
      quantification of the APIs (ASA, AA) and related degradation products (salicylic 
      acid (SA); semi-quantitative also mono- and diacetylated AA) within the complex 
      tablet mixtures. The higher the RH, the faster the degradation of ASA and AA as 
      well as the formation of the degradation products. Mono- and diacetylated AA are 
      major primary degradation products of AA for the applied effervescent tablets. A 
      significant degradation of the APIs was detected earlier by CZE (6-12h, RH 52%) 
      than by Raman spectroscopy. Summarized, Raman spectroscopy is well-suited as 
      quick test to detect degradation of these tablets and CZE can be utilized for 
      further detailed characterization and quantification of specific APIs and related 
      degradation products.
CI  - Copyright © 2016 Elsevier B.V. All rights reserved.
FAU - Neuberger, Sabine
AU  - Neuberger S
AD  - Aalen University, Aalen, Germany.
FAU - Jooß, Kevin
AU  - Jooß K
AD  - Aalen University, Aalen, Germany.
FAU - Flottmann, Dirk
AU  - Flottmann D
AD  - Aalen University, Aalen, Germany.
FAU - Scriba, Gerhard
AU  - Scriba G
AD  - Department of Pharmaceutical Chemistry, University of Jena, Germany.
FAU - Neusüß, Christian
AU  - Neusüß C
AD  - Aalen University, Aalen, Germany. Electronic address: 
      Christian.Neusuess@hs-aalen.de.
LA  - eng
PT  - Journal Article
DEP - 20161115
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/*analysis/chemistry
MH  - Aspirin/*analysis/chemistry
MH  - Electrophoresis, Capillary/methods/standards
MH  - Excipients/analysis/chemistry
MH  - Spectrum Analysis, Raman/*methods/standards
MH  - Tablets
OTO - NOTNLM
OT  - Acetylated ascorbic acid
OT  - Characterization of pharmaceuticals
OT  - Degradation of effervescent tablets
OT  - Multivariate statistical analysis
OT  - Pharmaceutical product quality
EDAT- 2016/12/03 06:00
MHDA- 2017/05/24 06:00
CRDT- 2016/12/02 06:00
PHST- 2016/08/11 00:00 [received]
PHST- 2016/11/05 00:00 [revised]
PHST- 2016/11/09 00:00 [accepted]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2017/05/24 06:00 [medline]
PHST- 2016/12/02 06:00 [entrez]
AID - S0731-7085(16)31103-7 [pii]
AID - 10.1016/j.jpba.2016.11.020 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2017 Feb 5;134:122-129. doi: 10.1016/j.jpba.2016.11.020. 
      Epub 2016 Nov 15.

PMID- 8076917
OWN - NLM
STAT- MEDLINE
DCOM- 19941005
LR  - 20131121
IS  - 0270-9139 (Print)
IS  - 0270-9139 (Linking)
VI  - 20
IP  - 3
DP  - 1994 Sep
TI  - Acetylsalicylic acid in the prevention of early stenosis and occlusion of 
      transjugular intrahepatic portal-systemic stent shunts: a controlled study.
PG  - 592-7
AB  - Stenosis or occlusion of the transjugular intrahepatic portal-systemic stent 
      shunt may be initiated by aggregation and activation of thrombocytes on the 
      surface of the metallic stent material. To find effective prevention of this 
      event, we conducted a controlled trial administering acetylsalicylic acid for 3 
      mo. Forty-four patients (8 women and 36 men) with portal hypertension were 
      included in this study. The patients were randomized into a group receiving 100 
      mg acetylsalicylic acid/day (n = 21) or into a control group (n = 23). Treatment 
      was started immediately after transjugular intrahepatic portal-systemic stent 
      shunt. Three months after transjugular intrahepatic portal-systemic stent shunt, 
      15 patients in the acetylsalicylic acid group and 19 patients in the control 
      group underwent clinical reevaluation, gastroscopy and recatheterization with 
      determination of the portal-systemic pressure gradient. No variceal bleeding 
      occurred in any patients. In four patients in the acetylsalicylic acid group, 
      erosive gastritis was observed in gastroscopy in contrast to only one patient in 
      the control group. Complete patency of the stent was noted in 10 of 15 patients 
      in the acetylsalicylic acid group and in 14 of 19 patients in the control group. 
      Transjugular intrahepatic portal-systemic stent shunt restenosis associated with 
      a significant increase of the portal-systemic gradient occurred in five patients 
      in the acetylsalicylic acid group, which required redilation in all and 
      additional stent placement for expansion of the stented tract in two patients. In 
      the control group, redilation was necessary in five patients with additional 
      stent extension in two patients.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Theilmann, L
AU  - Theilmann L
AD  - Department of Internal Medicine, University of Heidelberg, Germany.
FAU - Sauer, P
AU  - Sauer P
FAU - Roeren, T
AU  - Roeren T
FAU - Otto, G
AU  - Otto G
FAU - Arnold, J C
AU  - Arnold JC
FAU - Noeldge, G
AU  - Noeldge G
FAU - Richter, G
AU  - Richter G
FAU - Stiehl, A
AU  - Stiehl A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Constriction, Pathologic/prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Liver/surgery
MH  - Liver Transplantation
MH  - Male
MH  - Middle Aged
MH  - Portasystemic Shunt, Surgical/*methods
MH  - Postoperative Complications/prevention & control
MH  - Recurrence
MH  - Reoperation
MH  - Stents
MH  - Vascular Patency
EDAT- 1994/09/01 00:00
MHDA- 1994/09/01 00:01
CRDT- 1994/09/01 00:00
PHST- 1994/09/01 00:00 [pubmed]
PHST- 1994/09/01 00:01 [medline]
PHST- 1994/09/01 00:00 [entrez]
AID - 0270-9139(94)90092-2 [pii]
PST - ppublish
SO  - Hepatology. 1994 Sep;20(3):592-7.

PMID- 8294191
OWN - NLM
STAT- MEDLINE
DCOM- 19940303
LR  - 20190830
IS  - 0017-8748 (Print)
IS  - 0017-8748 (Linking)
VI  - 33
IP  - 10
DP  - 1993 Nov-Dec
TI  - Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the 
      dorsal horn of the upper cervical spinal cord in the cat.
PG  - 541-4
AB  - Acetylsalicylic acid (ASA) is one of the most commonly used substances in the 
      treatment of headache and other pain syndromes. It is only recently that its 
      efficacy in the treatment of acute attacks and in the prophylaxis of migraine has 
      been proven in clinical trials. Various peripheral and central mechanisms have 
      been proposed for the analgesic effects of acetylsalicylic acid and its mode of 
      action in migraine. The possible actions of acetylsalicylic acid in migraine 
      include local analgesic effects, changes in cerebral serotonin turnover, 
      modulation of antinociceptive neurons in the hypothalamus and inhibition of the 
      release of algogenic peptides during neurogenic inflammation. In this study 
      trigeminal somatosensory evoked potentials and single unit activity of central 
      trigeminal neurons in the dorsolateral C2 spinal cord were monitored during 
      electrical stimulation of the superior sagittal sinus in the cat. Intravenous 
      administration of the soluble acetylsalicylic salt (acetylsalicylic lysinate, 30 
      mg/kg) reduced the peak-to-peak amplitudes of somatosensory evoked potentials 
      from 219 +/- 11 mV by 18% after 45 minutes and by 26% after 60 minutes. Naloxone 
      injection (0.5 mg/kg and 1.5 mg/kg) did not reverse the inhibition caused by ASA. 
      The probability of trigeminal cell tiring was reduced in 63% percent of the 
      monitored single units. The effect was not mediated through naloxone-sensitive 
      opioid receptors and was independent from ASA-induced peripheral blockade of 
      neuropeptides during neurogenic inflammation. The non-steroidal anti-inflammatory 
      agent ketorolac (0.4 mg/kg, IVI) a new cyclooxygenase inhibitor, also reduced the 
      somatosensory evoked potentials by 30% following the same time course.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Kaube, H
AU  - Kaube H
AD  - Department of Neurology, Prince Henry Hospital, Sydney, NSW, Australia.
FAU - Hoskin, K L
AU  - Hoskin KL
FAU - Goadsby, P J
AU  - Goadsby PJ
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cats
MH  - Electric Stimulation
MH  - Evoked Potentials, Somatosensory/drug effects/physiology
MH  - Female
MH  - Injections, Intravenous
MH  - Time Factors
MH  - Trigeminal Nucleus, Spinal/*drug effects/physiology
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
AID - 10.1111/j.1526-4610.1993.hed3310541.x [doi]
PST - ppublish
SO  - Headache. 1993 Nov-Dec;33(10):541-4. doi: 10.1111/j.1526-4610.1993.hed3310541.x.

PMID- 16955294
OWN - NLM
STAT- MEDLINE
DCOM- 20081231
LR  - 20181201
IS  - 0932-433X (Print)
IS  - 0932-433X (Linking)
VI  - 21
IP  - 1
DP  - 2007 Feb
TI  - [Acetylsalicylic acid in self-medication of migraine. A pharmacy-based 
      observational study].
PG  - 49-54, 56
AB  - BACKGROUND: The aim of the study was to investigate the efficacy and tolerability 
      of acetylsalicylic acid in the treatment of acute migraine attacks by 
      self-medication under daily life conditions when bought in a pharmacy and also 
      the ability of patients to self-diagnose correctly. METHODS: A total of 296 
      patients were recruited from 156 pharmacies and recorded up to 3 migraine 
      attacks. Following an advisory discussion the pharmacists gave a questionnaire to 
      persons who had purchased acetylsalicylic acid (Aspirin Migraine) in the pharmacy 
      to treat migraine. A total of 578 questionnaires containing 36 questions about 
      demographic details, headache phenotype, medical history, efficacy over 2 h and 
      tolerability of the preparation were analyzed. RESULTS: The IHS criteria (1988) 
      for migraine were identified correctly by 92.7% of the patients. In 66.3% of the 
      attacks, the intensity of the headache was reported as severe. In 60% of the 
      documented attacks, a decrease from severe or moderate to mild or no headache was 
      recorded after medication, and freedom from headache was achieved in 35.8%. The 
      effect was reproducible over 3 migraine attacks. Nausea, photophobia and 
      phonophobia were reduced by 71-86% compared to the baseline level. Side-effects 
      were reported twice as often by the participants in response to closed questions 
      than to open questions (16.6 vs. 8.3%). CONCLUSION: A high percentage of migraine 
      patients are capable of diagnosing their condition themselves when they seek 
      advice in a pharmacy. The data on efficacy confirm the results from controlled 
      clinical studies. The same parameters as those used in controlled clinical 
      studies can also be recorded in pharmacy-based observational studies, therefore, 
      the safety and tolerability of the medication can be recorded under real 
      conditions.
FAU - Göbel, H
AU  - Göbel H
AD  - Neurologisch-verhaltensmedizinische Schmerzklinik, Kiel, Deutschland. 
      hg@schmerzklinik.de
FAU - Gessner, U
AU  - Gessner U
FAU - Petersen-Braun, M
AU  - Petersen-Braun M
FAU - Weingärtner, U
AU  - Weingärtner U
LA  - ger
PT  - Journal Article
TT  - Acetylsalicylsäure bei der Selbstmedikation von Migränekopfschmerzen. Eine 
      apothekenbasierte Analyse.
PL  - Germany
TA  - Schmerz
JT  - Schmerz (Berlin, Germany)
JID - 8906258
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Community Pharmacy Services/statistics & numerical data
MH  - Drug Utilization/statistics & numerical data
MH  - Female
MH  - Germany
MH  - Health Surveys
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/diagnosis/*drug therapy
MH  - Pain Measurement
MH  - Self Medication/*statistics & numerical data
MH  - Treatment Outcome
EDAT- 2006/09/07 09:00
MHDA- 2009/01/01 09:00
CRDT- 2006/09/07 09:00
PHST- 2006/09/07 09:00 [pubmed]
PHST- 2009/01/01 09:00 [medline]
PHST- 2006/09/07 09:00 [entrez]
AID - 10.1007/s00482-006-0499-y [doi]
PST - ppublish
SO  - Schmerz. 2007 Feb;21(1):49-54, 56. doi: 10.1007/s00482-006-0499-y.

PMID- 8710671
OWN - NLM
STAT- MEDLINE
DCOM- 19960909
LR  - 20131121
IS  - 0954-7762 (Print)
IS  - 0954-7762 (Linking)
VI  - 92
IP  - 8
DP  - 1996 Feb 21-27
TI  - Measurement of aspirin and paracetamol metabolites.
PG  - 40-1
AB  - Clinical laboratories are frequently asked to measure the concentration of drugs 
      in blood and urine. Of the many thousands of drugs prescribed, however, the 
      measurement of only a relatively small number provides useful clinical 
      information. There are three main reasons for measuring drugs: to test patient 
      compliance, to ensure that dosage is high enough to have therapeutic effect but 
      sufficiently low to avoid toxicity and, finally, to identify drugs taken during 
      deliberate or accidental overdose. This article is concerned with the last of 
      these.
FAU - Higgins, C
AU  - Higgins C
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nurs Times
JT  - Nursing times
JID - 0423236
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
MH  - Acetaminophen/*metabolism/poisoning
MH  - Aspirin/*metabolism/poisoning
MH  - Biotransformation
MH  - Drug Monitoring
MH  - Humans
MH  - Poisoning/blood/*diagnosis/nursing
EDAT- 1996/02/21 00:00
MHDA- 1996/02/21 00:01
CRDT- 1996/02/21 00:00
PHST- 1996/02/21 00:00 [pubmed]
PHST- 1996/02/21 00:01 [medline]
PHST- 1996/02/21 00:00 [entrez]
PST - ppublish
SO  - Nurs Times. 1996 Feb 21-27;92(8):40-1.

PMID- 3938537
OWN - NLM
STAT- MEDLINE
DCOM- 19860506
LR  - 20161123
IS  - 0301-0244 (Print)
IS  - 0301-0244 (Linking)
VI  - 37
IP  - 6
DP  - 1985 Nov-Dec
TI  - Differences between the effect of prazosin and lysine-acetylsalicylate on some 
      thermoregulatory parameters in nonfeverish rabbits.
PG  - 875-82
AB  - Thermoregulatory responses to prazosin and lysine-acetylsalicylate (LAS) were 
      investigated in afebrile rabbits at different ambient temperatures, i.e. at 5, 21 
      and 28 degrees C. In cold as well as in heat prazosin significantly inhibited the 
      metabolic rate. This effect was accompanied by falls in rectal temperatures, 
      particularly at the ambient temperature of 5 degrees C. Increases in ear skin 
      temperatures became visible only when this drug was used in rabbits maintained in 
      the thermoneutral environment. On the other hand LAS in all tested conditions 
      indicated a marked metabolic activity associated with an intensified respiratory 
      heat loss. As a consequence, the rabbits responded with slight increases in body 
      temperature. The possible mode of thermoregulatory activity of prazosin is being 
      considered in confrontation with that of LAS.
FAU - Matuszek, M
AU  - Matuszek M
FAU - Szreder, Z
AU  - Szreder Z
FAU - Korolkiewicz, Z
AU  - Korolkiewicz Z
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Pol J Pharmacol Pharm
JT  - Polish journal of pharmacology and pharmacy
JID - 0366561
RN  - 142M471B3J (Carbon Dioxide)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - XM03YJ541D (Prazosin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Body Temperature Regulation/*drug effects
MH  - Carbon Dioxide/metabolism
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
MH  - Oxygen Consumption/drug effects
MH  - Prazosin/*pharmacology
MH  - Rabbits
MH  - Respiration/drug effects
MH  - Skin Temperature/drug effects
EDAT- 1985/11/01 00:00
MHDA- 1985/11/01 00:01
CRDT- 1985/11/01 00:00
PHST- 1985/11/01 00:00 [pubmed]
PHST- 1985/11/01 00:01 [medline]
PHST- 1985/11/01 00:00 [entrez]
PST - ppublish
SO  - Pol J Pharmacol Pharm. 1985 Nov-Dec;37(6):875-82.

PMID- 6859836
OWN - NLM
STAT- MEDLINE
DCOM- 19830708
LR  - 20210526
IS  - 0066-4804 (Print)
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Linking)
VI  - 23
IP  - 4
DP  - 1983 Apr
TI  - Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 
      infection after treatment with aspirin or amantadine.
PG  - 577-82
AB  - During an outbreak of influenza A/Brazil/78 H1N1 infection, 47 volunteers with 
      clinical and virological influenza of less than 2 days duration were treated in a 
      randomized double-blind fashion for 5 days with 100 or 200 mg of amantadine daily 
      or with 3.25 g of aspirin daily. The aspirin treatment group defervesced more 
      rapidly (10.3 h versus 21.5 h and 23.6 h; P less than 0.01), but by the second 
      daily follow-up visit, both groups of amantadine recipients exhibited greater 
      symptomatic improvement. Bothersome side effects resulted in discontinuation of 
      therapy by 35% of the aspirin treatment group but only 3% of the amantadine 
      treatment group (P less than 0.05). Individuals who present to a physician during 
      an influenza A epidemic with characteristic symptoms will experience symptomatic 
      benefit from amantadine treatment, with negligible toxicity.
FAU - Younkin, S W
AU  - Younkin SW
FAU - Betts, R F
AU  - Betts RF
FAU - Roth, F K
AU  - Roth FK
FAU - Douglas, R G Jr
AU  - Douglas RG Jr
LA  - eng
GR  - A107169/PHS HHS/United States
GR  - N01 AI 02653/AI/NIAID NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - BF4C9Z1J53 (Amantadine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Amantadine/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Female
MH  - Fever/*drug therapy
MH  - Humans
MH  - Influenza A Virus, H1N1 Subtype
MH  - Influenza A virus/isolation & purification
MH  - Influenza, Human/*drug therapy
MH  - Male
PMC - PMC184704
EDAT- 1983/04/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 10.1128/AAC.23.4.577 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 1983 Apr;23(4):577-82. doi: 10.1128/AAC.23.4.577.

PMID- 1111740
OWN - NLM
STAT- MEDLINE
DCOM- 19750505
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 1
IP  - 5951
DP  - 1975 Jan 25
TI  - Role of taurocholic acid in production of gastric mucosal damage after ingestion 
      of aspirin.
PG  - 183-5
AB  - The possibility that aspirin-induced gastric mucosal damage may occur more 
      readily in the presence of bile has been studied in man using measurement of 
      transmucosal electrical potential difference as a marker of disruption of the 
      gastric mucosal barrier. After the introduction of acetylsalicylic acid (600 mg) 
      in suspension to seven subjects the mean electrical potential difference (plus or 
      minus S.E. of mean) fell significantly from -33-3 plus or minus 2-0 mV to - 17-1 
      plus or minus 2-1 mV, and after the introduction of taurocholic acid (5 mmol/1) 
      to seven other subjects the electrical potential difference fell significantly 
      from -38-1 plus or minus 3-0 mV to-19-1 plus or minus 3-4 mV, the mean duration 
      of these changes being 14-4 and 17-5 minutes respectively. When a combination of 
      acetylsalicylic acid and taurocholic acid was introduced to eight subjects the 
      mean electrical potential difference also fell significantly from -38-6 plus or 
      minus 1-8 mV to -17-9 plus or minus 1-8 mV, but mean duration of this change (27 
      minutes) was significantly longer than that found after acetylsalicylic acid or 
      taurocholic acid alone. These results indicate that the ingestion of aspirin, 
      together with coincidental reflux of bile from duodenum, may be a factor in the 
      pathogenesis of aspirin-induced gastric mucosal damage.
FAU - Cochran, K M
AU  - Cochran KM
FAU - Mackenzie, J F
AU  - Mackenzie JF
FAU - Russell, R I
AU  - Russell RI
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 5E090O0G3Z (Taurocholic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/pharmacology
MH  - Bile/metabolism
MH  - Drug Synergism
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Membrane Potentials/drug effects
MH  - Stomach Diseases/chemically induced
MH  - Taurocholic Acid/*pharmacology/physiology
PMC - PMC1672147
EDAT- 1975/01/25 00:00
MHDA- 1975/01/25 00:01
CRDT- 1975/01/25 00:00
PHST- 1975/01/25 00:00 [pubmed]
PHST- 1975/01/25 00:01 [medline]
PHST- 1975/01/25 00:00 [entrez]
AID - 10.1136/bmj.1.5951.183 [doi]
PST - ppublish
SO  - Br Med J. 1975 Jan 25;1(5951):183-5. doi: 10.1136/bmj.1.5951.183.

PMID- 2773529
OWN - NLM
STAT- MEDLINE
DCOM- 19891012
LR  - 20131121
IS  - 0044-2771 (Print)
IS  - 0044-2771 (Linking)
VI  - 27
IP  - 6
DP  - 1989 Jun
TI  - [The effect of acetylsalicylic acid on gastric transmural potential difference in 
      healthy children and in children with inflammatory diseases].
PG  - 317-20
AB  - The transmural potential difference (tpd) of the gastric mucosa was investigated 
      in relation to age and sex of the patients. The administration of acetylsalicylic 
      acid in healthy children causes no significant decrease in gastric potential 
      difference. In children with acute of chronic inflammatory diseases (elevated 
      blood sedimentation velocity) the tpd was found to be increased compared with 
      normal controls. After local ASA application a temporary, significant decrease of 
      the tpd to normal values could be observed.
FAU - König, A
AU  - König A
AD  - Klinik für Kindermedizin, Ernst-Moritz-Arndt-Universität Greifswald.
FAU - Jährig, K
AU  - Jährig K
FAU - Nikolaides, N
AU  - Nikolaides N
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Der Einfluss von Azetylsalizylsäure (ASS) auf die gastrale transmurale 
      Potentialdifferenz (tPD) bei gesunden Kindern und Kindern mit entzündlichen 
      Erkrankungen.
PL  - Germany
TA  - Z Gastroenterol
JT  - Zeitschrift fur Gastroenterologie
JID - 0033370
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Blood Sedimentation
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Gastric Juice/drug effects
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Male
MH  - Membrane Potentials/drug effects
MH  - Risk Factors
MH  - Water-Electrolyte Balance/drug effects
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
PST - ppublish
SO  - Z Gastroenterol. 1989 Jun;27(6):317-20.

PMID- 3079688
OWN - NLM
STAT- MEDLINE
DCOM- 19860205
LR  - 20190706
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 14
IP  - 1
DP  - 1986 Jan
TI  - Endotoxin protection against oxygen toxicity and its reversal by acetylsalicylic 
      acid.
PG  - 32-3
AB  - This study investigated the involvement of substances derived from arachidonic 
      acid in the mechanism of endotoxin's protective action against pulmonary oxygen 
      toxicity. Eighty-three percent of rats treated with a small dose of endotoxin (1 
      mg/kg) survived exposure to over 95% oxygen for 7 days. In contrast, all control 
      rats exposed to the same oxygen concentration died within 3 days. When the 
      endotoxin-treated rats were also treated with the soluble lysine salt of 
      acetylsalicylic acid (100 mg/kg), 7-day survival decreased to 25%. This suggests 
      that prostaglandin metabolism may play an important role in the protective action 
      of endotoxin during hyperoxia.
FAU - Klein, J
AU  - Klein J
FAU - Trouwborst, A
AU  - Trouwborst A
FAU - Salt, P J
AU  - Salt PJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Endotoxins)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Endotoxins/antagonists & inhibitors/*therapeutic use
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
MH  - Oxygen/*poisoning
MH  - Rats
MH  - Rats, Inbred Strains
MH  - *Salmonella typhimurium
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1097/00003246-198601000-00008 [doi]
PST - ppublish
SO  - Crit Care Med. 1986 Jan;14(1):32-3. doi: 10.1097/00003246-198601000-00008.

PMID- 4024050
OWN - NLM
STAT- MEDLINE
DCOM- 19850916
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 38
IP  - 6
DP  - 1985 Jun 15
TI  - Interactions between sodium salicylate and acetyl salicylic acid evaluated using 
      ADP induced platelet aggregation and bleeding time.
PG  - 687-93
AB  - 1 g acetyl salicylic acid orally significantly enhanced the initial rate of 
      platelet aggregation induced by 1 mumol/l and 2.5 mumol/l ADP. Sodium salicylate 
      was without effects on the platelet aggregation and specifically it did not 
      prevent acetylsalicylic acid from inhibiting the secondary aggregation. Sodium 
      salicylate was without effect on the bleeding time and did not inhibit the 
      prolongation induced by acetyl salicylic acid. Our study does not lend support to 
      the concept of an important interaction in vivo between acetyl salicylic acid and 
      its first metabolite salicylate in man.
FAU - Ring, T
AU  - Ring T
FAU - Dyerberg, J
AU  - Dyerberg J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Fibrinolytic Agents)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/antagonists & inhibitors/*pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation/drug effects
MH  - Drug Interactions
MH  - Fibrinolytic Agents/pharmacology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Sodium Salicylate/*pharmacology
EDAT- 1985/06/15 00:00
MHDA- 1985/06/15 00:01
CRDT- 1985/06/15 00:00
PHST- 1985/06/15 00:00 [pubmed]
PHST- 1985/06/15 00:01 [medline]
PHST- 1985/06/15 00:00 [entrez]
AID - 10.1016/0049-3848(85)90212-9 [doi]
PST - ppublish
SO  - Thromb Res. 1985 Jun 15;38(6):687-93. doi: 10.1016/0049-3848(85)90212-9.

PMID- 2647321
OWN - NLM
STAT- MEDLINE
DCOM- 19890502
LR  - 20180215
IS  - 0257-2753 (Print)
IS  - 0257-2753 (Linking)
VI  - 7
IP  - 1
DP  - 1989
TI  - Aspirin and gastroduodenal injury.
PG  - 28-38
AB  - Aspirin almost invariably causes acute mucosal injury to the stomach or duodenum 
      as evidenced by erosions seen endoscopically, extensive surface cell disruption 
      on histology, reduced mucosal potential difference and increased gastric 
      bleeding. This injury is usually minor and transient, and not associated with 
      symptoms. However, in the elderly recent aspirin intake may be associated with 
      bleeding peptic ulcer, and along with other NSAIDs, may be causal in a third of 
      cases. Regular chronic aspirin intake may also be associated with gastric 
      ulceration. Such ulceration, however, although seemingly capable of healing 
      despite continued aspirin or other NSAID use, may take longer to do so. Although 
      aspirin and other NSAIDs have a strong connection with gastroduodenal problems 
      the risk in an individual needs to be balanced by the likelihood of such events. 
      Given their widespread use, the serious side effects of these drugs occur in only 
      a small proportion of users. This, however, does not mitigate against careful 
      prescription.
FAU - Prichard, P J
AU  - Prichard PJ
AD  - Department of Medicine, Flinders Medical Centre, Adelaide, Australia.
FAU - Hawkey, C J
AU  - Hawkey CJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Dig Dis
JT  - Digestive diseases (Basel, Switzerland)
JID - 8701186
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Duodenum/*drug effects
MH  - Humans
MH  - Stomach/*drug effects
RF  - 76
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1159/000171204 [doi]
PST - ppublish
SO  - Dig Dis. 1989;7(1):28-38. doi: 10.1159/000171204.

PMID- 22095955
OWN - NLM
STAT- MEDLINE
DCOM- 20120417
LR  - 20131121
IS  - 1860-7187 (Electronic)
IS  - 1860-7179 (Linking)
VI  - 7
IP  - 1
DP  - 2012 Jan 2
TI  - Aspirin analogues as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, 
      nitric oxide release, molecular modeling, and biological evaluation as 
      anti-inflammatory agents.
PG  - 144-50
LID - 10.1002/cmdc.201100460 [doi]
AB  - Analogues of aspirin were synthesized through an efficient one-step reaction in 
      which the carboxyl group was replaced by an ethyl ester, and/or the acetoxy group 
      was replaced by an N-substituted sulfonamide (SO(2)NHOR(2):R(2) =H, Me, CH(2)Ph) 
      pharmacophore. These analogues were designed for evaluation as dual 
      cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) inhibitors. In vitro 
      COX-1/COX-2 isozyme inhibition studies identified compounds 11 (CO(2) H, 
      SO(2)NHOH), 12 (CO(2)H, SO(2)NHOCH(2)Ph), and 16 (CO(2)Et, SO(2)NHOH) as highly 
      potent and selective COX-2 inhibitors (IC(50) range: 0.07-0.7 μM), which 
      exhibited appreciable in vivo anti-inflammatory activity (ED(50) range: 23.1-31.4 
      mg kg(-1)). Moreover, compounds 11 (IC(50) =0.2 μM) and 16 (IC(50) =0.3 μM), with 
      a sulfohydroxamic acid (SO(2)NHOH) moiety showed potent 5-LOX inhibitory 
      activity. Furthermore, the SO(2)NHOH moiety present in compounds 11 and 16 was 
      found to be a good nitric oxide (NO) donor upon incubation in phosphate buffer at 
      pH 7.4. Molecular docking studies in the active binding site of COX-2 and 5-LOX 
      provided complementary theoretical support for the experimental biological 
      structure-activity data acquired.
CI  - Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Kaur, Jatinder
AU  - Kaur J
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, 
      AB, Canada.
FAU - Bhardwaj, Atul
AU  - Bhardwaj A
FAU - Huang, Zhangjian
AU  - Huang Z
FAU - Knaus, Edward E
AU  - Knaus EE
LA  - eng
GR  - MOP-14712/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111118
PL  - Germany
TA  - ChemMedChem
JT  - ChemMedChem
JID - 101259013
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/chemical synthesis/*chemistry/pharmacology/*therapeutic 
      use
MH  - Aspirin/*analogs & derivatives/chemical synthesis/pharmacology/*therapeutic use
MH  - Cyclooxygenase 2 Inhibitors/chemical 
      synthesis/*chemistry/pharmacology/*therapeutic use
MH  - Edema/chemically induced/drug therapy
MH  - Humans
MH  - Lipoxygenase Inhibitors/chemical synthesis/*chemistry/pharmacology/*therapeutic 
      use
MH  - Male
MH  - Models, Molecular
MH  - Nitric Oxide/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2011/11/19 06:00
MHDA- 2012/04/18 06:00
CRDT- 2011/11/19 06:00
PHST- 2011/10/04 00:00 [received]
PHST- 2011/11/19 06:00 [entrez]
PHST- 2011/11/19 06:00 [pubmed]
PHST- 2012/04/18 06:00 [medline]
AID - 10.1002/cmdc.201100460 [doi]
PST - ppublish
SO  - ChemMedChem. 2012 Jan 2;7(1):144-50. doi: 10.1002/cmdc.201100460. Epub 2011 Nov 
      18.

PMID- 26842876
OWN - NLM
STAT- MEDLINE
DCOM- 20170329
LR  - 20170330
IS  - 1538-7445 (Electronic)
IS  - 0008-5472 (Linking)
VI  - 76
IP  - 7
DP  - 2016 Apr 1
TI  - Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by 
      Disrupting an NFκB-IL6 Signaling Axis Responsible for the Generation of Cancer 
      Stem Cells.
PG  - 2000-12
LID - 10.1158/0008-5472.CAN-15-1360 [doi]
AB  - Acquired chemoresistance has curtailed cancer survival since the dawn of 
      chemotherapy. Accumulating evidence suggests a major role for cancer stem cells 
      (CSC) in chemoresistance, although their involvement in acquired resistance is 
      still unknown. The use of aspirin has been associated with reduced cancer risk 
      and recurrence, suggesting that the anti-inflammatory drug may exert effects on 
      CSCs. In this study, we investigated the contribution of CSCs to acquired 
      chemoresistance of breast cancer and the avenues for reversing such effects with 
      aspirin. We observed that the residual risk of recurrence was higher in breast 
      cancer patients who had acquired chemoresistance. Treatment of preexisting CSCs 
      with a genotoxic drug combination (5-fluorouracil, doxorubicin, and 
      cyclophosphamide) generated an NFκB-IL6-dependent inflammatory environment that 
      imparted stemness to nonstem cancer cells, induced multidrug resistance, and 
      enhanced the migration potential of CSCs. Treatment with aspirin prior to 
      chemotherapy suppressed the acquisition of chemoresistance by perturbing the 
      nuclear translocation of NFκB in preexisting CSCs. Therefore, disruptions to the 
      NFκB-IL6 feedback loop prevented CSC induction and sensitized preexisting CSCs to 
      chemotherapy. Collectively, our findings suggest that combining aspirin and 
      conventional chemotherapy may offer a new treatment strategy to improve 
      recurrence-free survival of breast cancer patients. Cancer Res; 76(7); 2000-12. 
      ©2016 AACR.
CI  - ©2016 American Association for Cancer Research.
FAU - Saha, Shilpi
AU  - Saha S
AD  - Division of Molecular Medicine, Bose Institute, Kolkata, West Bengal, India.
FAU - Mukherjee, Shravanti
AU  - Mukherjee S
AD  - Division of Molecular Medicine, Bose Institute, Kolkata, West Bengal, India.
FAU - Khan, Poulami
AU  - Khan P
AD  - Division of Molecular Medicine, Bose Institute, Kolkata, West Bengal, India.
FAU - Kajal, Kirti
AU  - Kajal K
AD  - Division of Molecular Medicine, Bose Institute, Kolkata, West Bengal, India.
FAU - Mazumdar, Minakshi
AU  - Mazumdar M
AD  - Division of Molecular Medicine, Bose Institute, Kolkata, West Bengal, India.
FAU - Manna, Argha
AU  - Manna A
AD  - Division of Molecular Medicine, Bose Institute, Kolkata, West Bengal, India.
FAU - Mukherjee, Sanhita
AU  - Mukherjee S
AD  - Department of Physiology, Bankura Sammilani Medical College, Kenduadihi, Bankura, 
      West Bengal, India.
FAU - De, Sunanda
AU  - De S
AD  - Department of Surgery, Seth Sukhlal Karnani Memorial Hospital, Kolkata, West 
      Bengal, India.
FAU - Jana, Debarshi
AU  - Jana D
AD  - Department of Surgery, Seth Sukhlal Karnani Memorial Hospital, Kolkata, West 
      Bengal, India.
FAU - Sarkar, Diptendra K
AU  - Sarkar DK
AD  - Department of Surgery, Seth Sukhlal Karnani Memorial Hospital, Kolkata, West 
      Bengal, India.
FAU - Das, Tanya
AU  - Das T
AD  - Division of Molecular Medicine, Bose Institute, Kolkata, West Bengal, India. 
      tanya@jcbose.ac.in.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160203
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Interleukin-6)
RN  - 0 (NF-kappa B)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism/*pharmacology
MH  - Breast Neoplasms/drug therapy
MH  - Cell Line, Tumor
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Interleukin-6/*metabolism
MH  - Microscopy, Confocal
MH  - NF-kappa B/*metabolism
MH  - Neoplastic Stem Cells/drug effects
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Transfection
EDAT- 2016/02/05 06:00
MHDA- 2017/03/31 06:00
CRDT- 2016/02/05 06:00
PHST- 2015/05/27 00:00 [received]
PHST- 2015/12/28 00:00 [accepted]
PHST- 2016/02/05 06:00 [entrez]
PHST- 2016/02/05 06:00 [pubmed]
PHST- 2017/03/31 06:00 [medline]
AID - 0008-5472.CAN-15-1360 [pii]
AID - 10.1158/0008-5472.CAN-15-1360 [doi]
PST - ppublish
SO  - Cancer Res. 2016 Apr 1;76(7):2000-12. doi: 10.1158/0008-5472.CAN-15-1360. Epub 
      2016 Feb 3.

PMID- 724761
OWN - NLM
STAT- MEDLINE
DCOM- 19790221
LR  - 20161123
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 33
IP  - 7
DP  - 1978 Jul
TI  - Physico-chemical analysis of systems with a main component acetylsalicylic acid 
      in ethanol-water mixtures, part 2: on the existence of potassium and lithium 
      hydrogen acetylsalicylates.
PG  - 441-2
AB  - The systems acetylsalicylic acid -- potassium acetylsalicylate -- 50 wt. % 
      ethanol -- water mixture and acetylsalicylic acid -- lithium acetylsalicylate -- 
      95 wt. % ethanol -- water mixture have been investigated at 15,0 degrees C. The 
      solubility diagrams of the systems and the distribution of the components between 
      the liquid and the crystal phases have been determined. It was established that 
      the solutions of both systems yield hydrogen acetylsalicylates. Their 
      crystallization fields were determined in the solubility diagrams. The hydrogen 
      acetylsalicylates obtained were isolated as preparations under the conditions of 
      the systems and were analyzed by chemical analysis, X-ray diffraction analysis 
      and IR spectroscopy. These analyses are evidence of their definite 
      composition--C9H8O4 . C9H7O4K and C9H8O4 . C9H7O4Li.
FAU - Trendafelov, D
AU  - Trendafelov D
FAU - Ivanov, D S
AU  - Ivanov DS
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 3K9958V90M (Ethanol)
RN  - 9FN79X2M3F (Lithium)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Ethanol
MH  - Lithium
MH  - Potassium
MH  - Solubility
MH  - Thermodynamics
MH  - X-Ray Diffraction
EDAT- 1978/07/01 00:00
MHDA- 1978/07/01 00:01
CRDT- 1978/07/01 00:00
PHST- 1978/07/01 00:00 [pubmed]
PHST- 1978/07/01 00:01 [medline]
PHST- 1978/07/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1978 Jul;33(7):441-2.

PMID- 7994379
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Regional circulatory and systemic hemodynamic effects of diaspirin cross-linked 
      hemoglobin in the rat.
PG  - 593-602
AB  - Diaspirin cross-linked hemoglobin (DCLHb) (Baxter Healthcare Corporation) is a 
      promising resuscitative fluid. The effect of DCLHb (400 mg/kg, i.v.), on regional 
      circulation and systemic hemodynamics was studied in male Sprague-Dawley rats 
      using a radioactive microsphere technique. Systemic hemodynamics, distribution of 
      cardiac output, regional blood flow and vascular resistance were determined 
      before (baseline) and 15, 30 and 60 min after the administration of DCLHb. 
      Infusion of an equal volume of saline did not produce any significant change in 
      systemic hemodynamics or regional circulation. DCLHb produced an increase (79%) 
      in the mean blood pressure which lasted for more than 60 min. Heart rate, cardiac 
      output and stroke volume were not significantly affected, while total peripheral 
      resistance was increased after the administration of DCLHb. DCLHb produced 
      significant increases in blood flow to the heart, gastrointestinal tract (GIT), 
      portal system and skin. The blood flow to the kidney, brain and musculoskeletal 
      system was not significantly affected by DCLHb. The vascular resistance was not 
      altered in the heart, brain, GIT, portal system, kidney or skin, but there was a 
      marked increase in the vascular resistance in the musculoskeletal system. There 
      was a significant increase in the percentage of cardiac output to visceral organs 
      like heart, GIT and portal system, while a marked decrease in the percent cardiac 
      output to musculoskeletal system was observed with DCLHb. It is concluded that 
      the blood flow to most of the organs is either increased or is not affected by 
      DCLHb.
FAU - Sharma, A C
AU  - Sharma AC
AD  - Department of Pharmacodynamics (m/c 865), University of Illinois at Chicago 
      60612-7231.
FAU - Rebello, S
AU  - Rebello S
FAU - Gulati, A
AU  - Gulati A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Substitutes/*pharmacology
MH  - Cardiac Output/drug effects
MH  - Hemodynamics/*drug effects
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/drug effects
MH  - Vascular Resistance/drug effects
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117888 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):593-602. doi: 
      10.3109/10731199409117888.

PMID- 21480598
OWN - NLM
STAT- MEDLINE
DCOM- 20110811
LR  - 20131121
IS  - 1520-5827 (Electronic)
IS  - 0743-7463 (Linking)
VI  - 27
IP  - 9
DP  - 2011 May 3
TI  - Surface design for controlled crystallization: the role of surface chemistry and 
      nanoscale pores in heterogeneous nucleation.
PG  - 5324-34
LID - 10.1021/la104351k [doi]
AB  - Current industrial practice for control of primary nucleation (nucleation from a 
      system without pre-existing crystalline matter) during crystallization from 
      solution involves control of supersaturation generation, impurity levels, and 
      solvent composition. Nucleation behavior remains largely unpredictable, however, 
      due to the presence of container surfaces, dust, dirt, and other impurities that 
      can provide heterogeneous nucleation sites, thus making the control and scale-up 
      of processes that depend on primary nucleation difficult. To develop a basis for 
      the rational design of surfaces to control nucleation during crystallization from 
      solution, we studied the role of surface chemistry and morphology of various 
      polymeric substrates on heterogeneous nucleation using aspirin as a model 
      compound. Nucleation induction time statistics were utilized to investigate and 
      quantify systematically the effectiveness of polymer substrates in inducing 
      nucleation. The nucleation induction time study revealed that 
      poly(4-acryloylmorpholine) and poly(2-carboxyethyl acrylate), each cross-linked 
      by divinylbenzene, significantly lowered the nucleation induction time of aspirin 
      while the other polymers were essentially inactive. In addition, we found the 
      presence of nanoscopic pores on certain polymer surfaces led to 
      order-of-magnitude faster aspirin nucleation rates when compared with surfaces 
      without pores. We studied the preferred orientation of aspirin crystals on 
      polymer films and found the nucleation-active polymer surfaces preferentially 
      nucleated the polar facets of aspirin, guided by hydrogen bonds. A model based on 
      interfacial free energies was also developed which predicted the same trend of 
      polymer surface nucleation activities as indicated by the nucleation induction 
      times.
FAU - Diao, Ying
AU  - Diao Y
AD  - Department of Chemical Engineering, Massachusetts Institute of Technology, 
      E19-502B, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139-4307, United 
      States.
FAU - Myerson, Allan S
AU  - Myerson AS
FAU - Hatton, T Alan
AU  - Hatton TA
FAU - Trout, Bernhardt L
AU  - Trout BL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110411
PL  - United States
TA  - Langmuir
JT  - Langmuir : the ACS journal of surfaces and colloids
JID - 9882736
RN  - 0 (Polymers)
RN  - 0 (Solvents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Crystallization/*methods
MH  - *Nanopores
MH  - Polymers/chemistry
MH  - Solvents/chemistry
MH  - Surface Properties
MH  - Thermodynamics
MH  - Time Factors
EDAT- 2011/04/13 06:00
MHDA- 2011/08/13 06:00
CRDT- 2011/04/13 06:00
PHST- 2011/04/13 06:00 [entrez]
PHST- 2011/04/13 06:00 [pubmed]
PHST- 2011/08/13 06:00 [medline]
AID - 10.1021/la104351k [doi]
PST - ppublish
SO  - Langmuir. 2011 May 3;27(9):5324-34. doi: 10.1021/la104351k. Epub 2011 Apr 11.

PMID- 16649722
OWN - NLM
STAT- MEDLINE
DCOM- 20060905
LR  - 20211020
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 29
IP  - 4
DP  - 2006 Apr
TI  - Aspirin resistance, an emerging, often overlooked, factor in the management of 
      patients with coronary artery disease.
PG  - 144-8
AB  - Aspirin is the most widely used medication in patients with cardiovascular 
      disease. It has had a greater effect on patients with cardiovascular disease than 
      any other drug. With the importance of aspirin now known for decades, it is 
      recently becoming clearer that some patients do not derive as great a benefit 
      from this "wonder drug" secondary to their resistance to its effects. Aspirin 
      resistance, its prevalence, its identification, and how to overcome or avert it 
      with other medications then becomes a central topic of discussion as important, 
      if not more so, than the importance of aspirin itself as a cornerstone in the 
      treatment of patients with cardiovascular disease. This review explores the 
      current understanding of the mechanism of aspirin resistance with regard to its 
      prevalence and the magnitude of its clinical significance. It also examines the 
      therapeutic implications of a diagnosis of aspirin resistance.
FAU - Makaryus, Amgad N
AU  - Makaryus AN
AD  - Division of Cardiology, North Shore University Hospital, Manhasset, New York 
      11030, USA. amakaryu@nshs.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Clin Cardiol. 2006 Aug;29(8):334; author reply 334. PMID: 16933571
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*prevention & control
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
PMC - PMC6654371
EDAT- 2006/05/03 09:00
MHDA- 2006/09/06 09:00
CRDT- 2006/05/03 09:00
PHST- 2006/05/03 09:00 [pubmed]
PHST- 2006/09/06 09:00 [medline]
PHST- 2006/05/03 09:00 [entrez]
AID - CLC4960290404 [pii]
AID - 10.1002/clc.4960290404 [doi]
PST - ppublish
SO  - Clin Cardiol. 2006 Apr;29(4):144-8. doi: 10.1002/clc.4960290404.

PMID- 345993
OWN - NLM
STAT- MEDLINE
DCOM- 19780517
LR  - 20200304
IS  - 0003-9128 (Print)
IS  - 0003-9128 (Linking)
VI  - 225
IP  - 1
DP  - 1978 Feb 22
TI  - Indomethacin in the treatment of primary dysmenorrhoea.
PG  - 1-5
AB  - The efficacy of indomethacin, a prostaglandin synthetase inhibitor, in severe 
      dysmenorrhoea was established in a double-blind crossover study using aspirin and 
      placebo as the control drugs. Forty-seven female undergraduates were treated 
      twice with each of the three substances during six consecutive menstrual cycles. 
      Good or moderate relief was achieved in 71% of the cycles treated with 
      indomethacin, in 40% of those treated with aspirin and in 21% of those treated 
      with the placebo. Dizziness and drowsiness were cited by 14 patients (30%) as 
      side-effects of indomethacin, none of these patients discontinued the therapy 
      because all obtained good or moderate relief from dysmenorrhoea. Indomethacin 
      proved to be a valuable agent, and significantly better than aspirin in the 
      treatment of dysmenorrhoea. It allowed many dysmenorrhoeic women to carry out 
      their normal activities and work during the menstrual period.
FAU - Kajanoja, P
AU  - Kajanoja P
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Arch Gynakol
JT  - Archiv fur Gynakologie
JID - 0372655
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Dysmenorrhea/*drug therapy
MH  - Female
MH  - Humans
MH  - Indomethacin/administration & dosage/adverse effects/*therapeutic use
MH  - Placebos
MH  - Time Factors
EDAT- 1978/02/22 00:00
MHDA- 1978/02/22 00:01
CRDT- 1978/02/22 00:00
PHST- 1978/02/22 00:00 [pubmed]
PHST- 1978/02/22 00:01 [medline]
PHST- 1978/02/22 00:00 [entrez]
AID - 10.1007/BF00672828 [doi]
PST - ppublish
SO  - Arch Gynakol. 1978 Feb 22;225(1):1-5. doi: 10.1007/BF00672828.

PMID- 17698681
OWN - NLM
STAT- MEDLINE
DCOM- 20071002
LR  - 20181201
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 167
IP  - 15
DP  - 2007 Aug 13-27
TI  - Association of laboratory-defined aspirin resistance with a higher risk of 
      recurrent cardiovascular events: a systematic review and meta-analysis.
PG  - 1593-9
AB  - BACKGROUND: The risk of recurrence of cardiovascular events among patients using 
      aspirin (acetylsalicylic acid) for secondary prevention of such events remains 
      high. Persistent platelet reactivity despite aspirin therapy, a 
      laboratory-defined phenomenon called aspirin resistance (hereinafter, laboratory 
      aspirin resistance), might explain this in part, but its actual contribution to 
      the risk remains unclear. The objective of this study was to systematically 
      review all available evidence on whether laboratory aspirin resistance is related 
      to a higher risk of cardiovascular recurrent events. METHODS: Using a predefined 
      search strategy, we searched electronic databases. To be included in our 
      analysis, articles had to report on patients who used aspirin for secondary 
      cardiovascular prevention, had to contain a clear description of a method to 
      establish the effects of aspirin on platelet reactivity, and had to report 
      recurrence rates of cardiovascular events. Odds ratios of cardiovascular outcome 
      of eligible studies were pooled in a random-effects model. RESULTS: We included 
      15 full-text articles and 1 meeting abstract. Fifteen of these studies revealed 
      an adverse association between laboratory aspirin resistance and occurrence of 
      cardiovascular events. The pooled odds ratio of all cardiovascular outcomes was 
      3.8 (95% confidence interval, 2.3-6.1) for laboratory aspirin resistance. 
      CONCLUSION: This systematic review and meta-analysis shows that patients 
      biochemically identified as having laboratory aspirin resistance are more likely 
      to also have "clinical resistance" to aspirin because they exhibit significantly 
      higher risks of recurrent cardiovascular events compared with patients who are 
      identified as (laboratory) aspirin sensitive.
FAU - Snoep, Jaapjan D
AU  - Snoep JD
AD  - Department of General Internal Medicine and Endocrinology, Leiden University 
      Medical Center, C-09-P, PO Box 9600, 2300 RC Leiden, the Netherlands. 
      j.d.snoep@lumc.nl
FAU - Hovens, Marcel M C
AU  - Hovens MM
FAU - Eikenboom, Jeroen C J
AU  - Eikenboom JC
FAU - van der Bom, Johanna G
AU  - van der Bom JG
FAU - Huisman, Menno V
AU  - Huisman MV
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Intern Med. 2008 Mar 10;168(5):549-50. PMID: 18332305
CIN - Arch Intern Med. 2008 Mar 10;168(5):550; author reply 550. PMID: 18332307
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Recurrence
MH  - Risk Factors
RF  - 38
EDAT- 2007/08/19 09:00
MHDA- 2007/10/03 09:00
CRDT- 2007/08/19 09:00
PHST- 2007/08/19 09:00 [pubmed]
PHST- 2007/10/03 09:00 [medline]
PHST- 2007/08/19 09:00 [entrez]
AID - 167/15/1593 [pii]
AID - 10.1001/archinte.167.15.1593 [doi]
PST - ppublish
SO  - Arch Intern Med. 2007 Aug 13-27;167(15):1593-9. doi: 
      10.1001/archinte.167.15.1593.

PMID- 1872484
OWN - NLM
STAT- MEDLINE
DCOM- 19910919
LR  - 20190820
IS  - 0003-2654 (Print)
IS  - 0003-2654 (Linking)
VI  - 116
IP  - 4
DP  - 1991 Apr
TI  - Simultaneous determination of acetylsalicylic and salicylic acids in human serum 
      and aspirin formulations by second-derivative synchronous fluorescence 
      spectrometry.
PG  - 373-8
AB  - A second-derivative synchronous scanning spectrofluorimetric method for the 
      simultaneous determination of acetylsalicylic acid (ASA) and salicylic acid (SA) 
      is described. The method is based on the native fluorescence of both acids in a 
      1% acetic acid-chloroform solution. Both ASA and SA can be determined within the 
      concentration ranges 0.2-70 and 0.03-10 micrograms ml-1, respectively. The effect 
      of each acid on the signal of the other has been studied in detail. Empirical 
      equations have been used to overcome this effect, thus allowing the accurate 
      determination of both acids in binary mixtures, without a separation step. The 
      method has been applied to the determination of ASA and SA in blood serum and to 
      the determination of SA impurities in aspirin formulations. Recoveries from sera 
      spiked with both ASA (2.5-50 micrograms ml-1) and SA (100-160 micrograms ml-1) 
      varied from 99.5 to 106.7% (mean = 102.6%) and from 93.0 to 98.0% (mean = 95.8%), 
      respectively. Recoveries of SA from spiked aspirin solutions (0.25-1.5 mg g-1 of 
      aspirin) varied from 98.0 to 102.0% (mean = 100.3%).
FAU - Konstantianos, D G
AU  - Konstantianos DG
AD  - Department of Chemistry, University of Athens, Greece.
FAU - Ioannou, P C
AU  - Ioannou PC
FAU - Efstathiou, C E
AU  - Efstathiou CE
LA  - eng
PT  - Journal Article
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis/*blood
MH  - Humans
MH  - Salicylates/analysis/*blood
MH  - Salicylic Acid
MH  - Spectrometry, Fluorescence/*methods
EDAT- 1991/04/01 00:00
MHDA- 1991/04/01 00:01
CRDT- 1991/04/01 00:00
PHST- 1991/04/01 00:00 [pubmed]
PHST- 1991/04/01 00:01 [medline]
PHST- 1991/04/01 00:00 [entrez]
AID - 10.1039/an9911600373 [doi]
PST - ppublish
SO  - Analyst. 1991 Apr;116(4):373-8. doi: 10.1039/an9911600373.

PMID- 8477113
OWN - NLM
STAT- MEDLINE
DCOM- 19930521
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 27
IP  - 4
DP  - 1993 Apr
TI  - Single-dose effect of enteric-coated aspirin on platelet function and thromboxane 
      generation in middle-aged men.
PG  - 405-10
AB  - OBJECTIVE: To evaluate the effect of a single dose of enteric-coated aspirin 
      (ECA) in three different dosages on platelet function and thromboxane generation 
      in middle-aged men. DESIGN AND METHODS: In a nonblind, nonplacebo-controlled, 
      crossover study, a single dose of ECA (50, 250, or 1000 mg) was given in a tablet 
      form to a group of healthy, middle-aged men. Ten subjects, aged 50-67 years, 
      volunteered to participate in this study. Platelet functions including bleeding 
      time, platelet aggregation, adenine nucleotides, beta-thromboglobulin, platelet 
      factor 4, thromboxane generation, and aspirin measurement were determined. 
      RESULTS: Before ECA ingestion, the intracellular adenine nucleotides (adenosine 
      triphosphate, adenosine diphosphate) were decreased, and both 
      beta-thromboglobulin and platelet factor 4 were increased. These observations 
      suggested that platelets were activated in vivo in middle-aged men. These 
      findings returned to normal within 8 hours after the ingestion of ECA, and 
      maintained normal for at least two days. Bleeding time was significantly 
      prolonged at 8 and 24 hours compared with that before ingestion of ECA 1000 mg (p 
      < 0.05). The generation of platelet thromboxane was maximally inhibited by 
      approximately 40 percent in the samples 8 hours after ECA ingestion. Abnormal 
      values of adenine nucleotides, beta-thromboglobulin, and platelet factor 4 
      returned to normal within 8 hours. Arachidonic acid-induced platelet aggregation 
      was inhibited compared with that before treatment (p < 0.01) and the inhibitory 
      effect was maintained for at least three days. Adenosine diphosphate- and 
      epinephrine-induced aggregations were less inhibited than those induced by 
      arachidonic acid. Inhibitory effects of ECA on platelet aggregation were dose 
      dependent. CONCLUSIONS: Our study indicates that platelets are activated in 
      middle-aged men and that a single dose of ECA 50 mg is safe and can inhibit 
      thromboxane synthesis and platelet aggregation. These results suggest that a 
      daily dose of ECA 50 mg may be useful for blocking platelet activation and 
      preventing thrombosis.
FAU - Mohri, H
AU  - Mohri H
AD  - First Department of Internal Medicine, Yokohama City University School of 
      Medicine, Japan.
FAU - Ohkubo, T
AU  - Ohkubo T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/blood
MH  - Tablets, Enteric-Coated
MH  - Thromboxane B2/*biosynthesis/blood
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
AID - 10.1177/106002809302700401 [doi]
PST - ppublish
SO  - Ann Pharmacother. 1993 Apr;27(4):405-10. doi: 10.1177/106002809302700401.

PMID- 33608434
OWN - NLM
STAT- MEDLINE
DCOM- 20220401
LR  - 20220531
IS  - 2047-9956 (Print)
IS  - 2047-9964 (Electronic)
IS  - 2047-9956 (Linking)
VI  - 28
IP  - 2
DP  - 2021 Mar
TI  - Adjusting the dose in paediatric care: dispersing four different aspirin tablets 
      and taking a proportion.
PG  - 76-82
LID - 10.1136/ejhpharm-2019-001903 [doi]
AB  - OBJECTIVES: When caring for children in a hospital setting, tablets are often 
      manipulated at the ward to obtain the right dose. One example is manipulation of 
      tablets containing the slightly water-soluble substance aspirin, used in 
      paediatric care as an antiplatelet agent. The evidence base, however, for 
      choosing certain tablet formulations and manipulation methods over others for 
      extraction of proportions is lacking. The aim of this study was to investigate 
      the effect of tablet formulation and manipulation technique on the dose accuracy 
      and precision attained when dispersing different commercially available aspirin 
      tablets and extracting a small proportion suitable for children. METHODS: The 
      manipulation methods investigated simulated those observed in the paediatric 
      clinic. Four tablet formulations-one chewable, one conventional and two 
      dispersible-were dispersed in 10 mL water in a medicine measure. On (1) passive 
      dispersion, (2) mixing by stirring with the syringe, or (3) stirring and pumping 
      the dispersion in and out of the syringe, respectively, proportions (1 mL or 2 
      mL) were extracted and the doses recovered were determined using a validated 
      UHPLC (ultra high-pressure liquid chromatography) method. RESULTS: Fractions from 
      the four different dispersed aspirin tablet formulations varied from 99% to 3% of 
      that intended with the lowest degree of mixing, and from 96% to 34% of that 
      intended with the highest degree of mixing. Only the dispersible tablets gave 
      average doses within 20% of the intended dose. CONCLUSIONS: Fraction extraction 
      from dispersed aspirin tablets only gave doses within 20% of intended for the 
      dispersible tablets, and then only for some of the manipulation methods: 'passive 
      dispersion' for the 75 mg dispersible tablet and 'stirring and pumping' for the 
      300 mg dispersible tablet. The tablets not intended for dispersion gave 
      unsatisfactory results, outside 20%, regardless of manipulation method. The 
      findings underline the importance of considering both tablet formulation and dose 
      extraction technique when manipulations are required.
CI  - © European Association of Hospital Pharmacists 2021. Re-use permitted under CC 
      BY-NC. No commercial re-use. Published by BMJ.
FAU - Brustugun, Jørgen
AU  - Brustugun J
AD  - Oslo Hospital Pharmacy, Hospital Pharmacies Enterprise, South Eastern Norway, 
      Oslo, Norway jorgen.brustugun@sykehusapotekene.no.
FAU - Notaker, Nikolai
AU  - Notaker N
AD  - Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University 
      of Oslo, Oslo, Norway.
FAU - Paetz, Lasse Holtan
AU  - Paetz LH
AD  - Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University 
      of Oslo, Oslo, Norway.
FAU - Tho, Ingunn
AU  - Tho I
AUID- ORCID: 0000-0003-4241-4183
AD  - School of Pharmacy, University of Oslo, Oslo, Norway.
FAU - Bjerknes, Kathrin
AU  - Bjerknes K
AD  - Hospital Pharmacy Enterprises Norway, Lørenskog, Norway.
LA  - eng
PT  - Journal Article
DEP - 20190611
PL  - England
TA  - Eur J Hosp Pharm
JT  - European journal of hospital pharmacy : science and practice
JID - 101578294
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage
MH  - Child
MH  - Chromatography, High Pressure Liquid
MH  - Humans
MH  - *Pediatrics
MH  - Tablets
PMC - PMC7907695
OTO - NOTNLM
OT  - clinical pharmacy
OT  - dispensing forms
OT  - drug administration (others)
OT  - drug formulation
OT  - paediatrics
OT  - pharmaceutical excipients
COIS- Competing interests: None declared.
EDAT- 2021/02/21 06:00
MHDA- 2022/04/02 06:00
CRDT- 2021/02/20 05:31
PHST- 2019/02/18 00:00 [received]
PHST- 2019/05/06 00:00 [revised]
PHST- 2019/05/08 00:00 [accepted]
PHST- 2021/02/20 05:31 [entrez]
PHST- 2021/02/21 06:00 [pubmed]
PHST- 2022/04/02 06:00 [medline]
AID - ejhpharm-2019-001903 [pii]
AID - 10.1136/ejhpharm-2019-001903 [doi]
PST - ppublish
SO  - Eur J Hosp Pharm. 2021 Mar;28(2):76-82. doi: 10.1136/ejhpharm-2019-001903. Epub 
      2019 Jun 11.

PMID- 17239674
OWN - NLM
STAT- MEDLINE
DCOM- 20070320
LR  - 20220419
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 153
IP  - 2
DP  - 2007 Feb
TI  - Prevalence of persistent platelet reactivity despite use of aspirin: a systematic 
      review.
PG  - 175-81
AB  - BACKGROUND: The absolute risk of recurrences among patients using aspirin for 
      prevention of cardiovascular events remains high. Persistent platelet reactivity 
      despite aspirin therapy might explain this in part. Reported prevalences of this 
      so-called aspirin resistance vary widely, between 0% and 57%. OBJECTIVES: The aim 
      of the study was to systematically review all available evidence on prevalence of 
      aspirin resistance and to study determinants of reported prevalence. METHODS: 
      Using a predefined search strategy, we searched electronic databases MEDLINE, 
      EMBASE, CENTRAL, and Web of Science. To be included in our analysis, articles had 
      to contain a laboratory definition of aspirin resistance, use aspirin as 
      secondary prevention, and report associated prevalence. RESULTS: We included 34 
      full-text articles and 8 meeting abstracts. The mean prevalence of aspirin 
      resistance was 24% (95% CI 20%-28%). After adjustment for differences in 
      definition, used dosage, and population, a statistically significant higher 
      prevalence was found in studies with aspirin dosage < or =100 mg compared with > 
      or =300 mg (36% [95% CI 28%-43%] vs 19% [95% CI 11%-26%], P < .0001). Studies 
      measuring platelet aggregation using light aggregometry with arachidonic acid as 
      an agonist had a pooled unadjusted prevalence of 6% (95% CI 0%-12%). In studies 
      using point-of-care platelet function-analyzing devices, the unadjusted 
      prevalence was significantly higher, at 26% (95% CI 21%-31%). CONCLUSIONS: 
      Prevalences widely differ between studies reporting on aspirin resistance. Both 
      aspirin dosage and the method of defining aspirin resistance strongly influence 
      estimated prevalence, which explains found heterogeneity among studies. On 
      average, it appears that about 1 in 4 individuals may express biochemically 
      defined aspirin resistance.
FAU - Hovens, Marcel M C
AU  - Hovens MM
AD  - Department of General Internal Medicine and Endocrinology, Leiden University 
      Medical Center, Leiden, The Netherlands. m.m.c.hovens@lumc.nl
FAU - Snoep, Jaapjan D
AU  - Snoep JD
FAU - Eikenboom, Jeroen C J
AU  - Eikenboom JC
FAU - van der Bom, Johanna G
AU  - van der Bom JG
FAU - Mertens, Bart J A
AU  - Mertens BJ
FAU - Huisman, Menno V
AU  - Huisman MV
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prevalence
RF  - 67
EDAT- 2007/01/24 09:00
MHDA- 2007/03/21 09:00
CRDT- 2007/01/24 09:00
PHST- 2006/06/08 00:00 [received]
PHST- 2006/10/28 00:00 [accepted]
PHST- 2007/01/24 09:00 [pubmed]
PHST- 2007/03/21 09:00 [medline]
PHST- 2007/01/24 09:00 [entrez]
AID - S0002-8703(06)01018-0 [pii]
AID - 10.1016/j.ahj.2006.10.040 [doi]
PST - ppublish
SO  - Am Heart J. 2007 Feb;153(2):175-81. doi: 10.1016/j.ahj.2006.10.040.

PMID- 19049433
OWN - NLM
STAT- MEDLINE
DCOM- 20090122
LR  - 20171116
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 51
IP  - 24
DP  - 2008 Dec 25
TI  - Discovery of a "true" aspirin prodrug.
PG  - 7991-9
LID - 10.1021/jm801094c [doi]
AB  - Aspirin prodrugs formed by derivatization at the benzoic acid group are very 
      difficult to obtain because the promoiety accelerates the rate of hydrolysis by 
      plasma esterases at the neighboring acetyl group, generating salicylic acid 
      derivatives. By tracing the hydrolysis pattern of the aspirin prodrug 
      isosorbide-2,5-diaspirinate (ISDA) in human plasma solution, we were able to 
      identify a metabolite, isosorbide-2-aspirinate-5-salicylate, that undergoes 
      almost complete conversion to aspirin by human plasma butyrylcholinesterase, 
      making it the most successful aspirin prodrug discovered to date.
FAU - Moriarty, Louise M
AU  - Moriarty LM
AD  - School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin 2, 
      Ireland.
FAU - Lally, Maeve N
AU  - Lally MN
FAU - Carolan, Ciaran G
AU  - Carolan CG
FAU - Jones, Michael
AU  - Jones M
FAU - Clancy, John M
AU  - Clancy JM
FAU - Gilmer, John F
AU  - Gilmer JF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Esters)
RN  - 0 (Prodrugs)
RN  - 0 (isosorbide-2,5-diaspirinate)
RN  - EC 3.1.1.8 (Butyrylcholinesterase)
RN  - R16CO5Y76E (Aspirin)
RN  - WXR179L51S (Isosorbide)
SB  - IM
MH  - Aspirin/*analogs & derivatives/*chemical synthesis/pharmacokinetics
MH  - Butyrylcholinesterase/blood
MH  - Chemistry, Pharmaceutical/*methods
MH  - Drug Design
MH  - Drug Evaluation, Preclinical
MH  - Esters/chemistry
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - Isosorbide/*analogs & derivatives/chemical synthesis/chemistry/pharmacokinetics
MH  - Kinetics
MH  - Models, Chemical
MH  - Prodrugs/*chemical synthesis/pharmacokinetics
MH  - Temperature
MH  - Time Factors
EDAT- 2008/12/04 09:00
MHDA- 2009/01/23 09:00
CRDT- 2008/12/04 09:00
PHST- 2008/12/04 09:00 [pubmed]
PHST- 2009/01/23 09:00 [medline]
PHST- 2008/12/04 09:00 [entrez]
AID - 10.1021/jm801094c [pii]
AID - 10.1021/jm801094c [doi]
PST - ppublish
SO  - J Med Chem. 2008 Dec 25;51(24):7991-9. doi: 10.1021/jm801094c.

PMID- 8746055
OWN - NLM
STAT- MEDLINE
DCOM- 19961003
LR  - 20161123
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 19
IP  - 11
DP  - 1995 Nov
TI  - [Liver cirrhosis and granulomatous hepatitis after prolonged ingestion of lysine 
      acetylsalicylate].
PG  - 944-7
AB  - We report the case of a 75-year-old woman who was hospitalized for serum 
      aminotransferase elevation. She had taken 1 g/d of salicylate therapy (Aspegic 
      1000) for 5 years, clorazepate for 10 years, naftidrofuryl for 8 months and 
      quinapril for 3 months. Liver histology showed cirrhosis and granulomatous 
      hepatitis. Discontinuation of salicylate therapy resulted in normalization of 
      liver tests, although other drug administration was pursued. This observation 
      suggests that salicylate therapy can induce cirrhosis.
FAU - D'Abrigeon, G
AU  - D'Abrigeon G
AD  - Service d'Hépato-Gastroentérologie, Institut des Maladies de l'Appareil Digestif, 
      Montpellier.
FAU - Blanc, P
AU  - Blanc P
FAU - Durand, L
AU  - Durand L
FAU - Larrey, D
AU  - Larrey D
FAU - Michel, H
AU  - Michel H
LA  - fre
PT  - Case Reports
PT  - Journal Article
TT  - Cirrhose et hépatite granulomateuse après la prise prolongée d'acétylsalicylate 
      de lysine.
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - 0 (Analgesics)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aged
MH  - Analgesics/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/*analogs & derivatives/therapeutic use
MH  - Chemical and Drug Induced Liver Injury/*etiology/pathology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Liver Cirrhosis/*chemically induced/pathology
MH  - Lysine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Rheumatic Diseases/drug therapy
MH  - Time Factors
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
PST - ppublish
SO  - Gastroenterol Clin Biol. 1995 Nov;19(11):944-7.

PMID- 1397856
OWN - NLM
STAT- MEDLINE
DCOM- 19921103
LR  - 20161123
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 16
IP  - 4
DP  - 1992
TI  - [Severe hepatitis with encephalopathy induced by acetylsalicylic acid in a case 
      of lupus erythematosus disseminatus].
PG  - 359-61
AB  - The observation of a 62 year-old woman who had been suffering from arthritis for 
      several years and in whom treatment with high doses of acetylsalicylic acid 
      resulted in severe acute hepatitis is reported. Clinical and serological findings 
      led to the diagnosis of systemic lupus erythematosus complicated by acute drug 
      induced hepatitis.
FAU - De Leeuw, P
AU  - De Leeuw P
AD  - Service de Gastroentérologie, Cliniques Universitaires St-Luc, Bruxelles, 
      Belgique.
FAU - Lefebvre, C
AU  - Lefebvre C
FAU - Tomasi, J P
AU  - Tomasi JP
FAU - Rahier, J
AU  - Rahier J
FAU - Geubel, A
AU  - Geubel A
LA  - fre
PT  - Case Reports
PT  - Journal Article
TT  - Hépatite grave avec encéphalopathie imputable à l'acide acétylsalicylique dans un 
      cas de lupus érythémateux disséminé.
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Chemical and Drug Induced Liver Injury/drug therapy/*etiology/pathology
MH  - Female
MH  - Hepatic Encephalopathy/*chemically induced/drug therapy/pathology
MH  - Humans
MH  - Lupus Erythematosus, Systemic/*drug therapy
MH  - Middle Aged
MH  - Prednisolone/therapeutic use
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Gastroenterol Clin Biol. 1992;16(4):359-61.

PMID- 36973090
OWN - NLM
STAT- MEDLINE
DCOM- 20230516
LR  - 20230518
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 45
IP  - 4
DP  - 2023 Apr
TI  - Aspirin Therapy and 28-Day Mortality in ICU Patients: A Retrospective 
      Observational Study From Two Large Databases.
PG  - 316-332
LID - S0149-2918(23)00066-8 [pii]
LID - 10.1016/j.clinthera.2023.02.005 [doi]
AB  - PURPOSE: Aspirin is widely used in patients in the intensive care unit (ICU); 
      nonetheless, its effects on these patients remain controversial. This 
      retrospective analysis of data from clinical practice investigated the effects of 
      aspirin on 28-day mortality in ICU patients. METHODS: This retrospective study 
      included data from patients in the Medical Information Mart for Intensive Care 
      (MIMIC)-III database and the eICU-Collaborative Research Database (CRD). Patients 
      aged 18 to 90 years and admitted to the ICU were eligible and were assigned to 
      one of two groups according to whether they were given aspirin during their ICU 
      stay. Multiple imputation was used for patients with >10% missing data. 
      Multivariate Cox models and propensity score analysis were used to estimate the 
      association of aspirin treatment with 28-day mortality among patients admitted to 
      the ICU. FINDINGS: In total, 146,191 patients were enrolled in this study, and 
      27,424 (18.8%) used aspirin. Aspirin treatment in ICU patients, especially in 
      nonseptic patients, was associated with a lower 28-day all-cause mortality on 
      multivariate Cox analysis (eICU-CRD, hazard ratio [HR] = 0.81, [95% CI, 
      0.75-0.87]; MIMIC-III, HR = 0.72 [95% CI, 0.68-0.76]). Aspirin treatment was 
      associated with lower 28-day all-cause mortality after propensity score matching 
      (eICU-CRD, HR = 0.80 [95% CI, 0.72-0.88]; MIMIC-III, HR = 0.80 [95% CI, 
      0.76-0.85]). However, on subgroup analysis, aspirin therapy was not associated 
      with a lower 28-day mortality in patients without systemic inflammatory response 
      syndrome (SIRS) symptoms or with sepsis in either database. IMPLICATIONS: Aspirin 
      treatment during the ICU stay was associated with a significantly reduced 28-day 
      all-cause mortality, particularly in patients with SIRS symptoms but without 
      sepsis. In patients with sepsis and with/without SIRS symptoms, beneficial 
      effects were not clear, or more careful patient selection is required.
CI  - Copyright © 2023. Published by Elsevier Inc.
FAU - Wang, Luhao
AU  - Wang L
AD  - Department of Critical Care Medicine, Sun Yat-Sen University First Affiliated 
      Hospital, Guangzhou, People's Republic of China. Electronic address: 
      wanglh36@mail.sysu.edu.cn.
FAU - Li, Bin
AU  - Li B
AD  - Clinical Trials Unit, Sun Yat-Sen University First Affiliated Hospital, 
      Guangzhou, People's Republic of China.
FAU - Zuo, Lingyun
AU  - Zuo L
AD  - Department of Critical Care Medicine, Sun Yat-Sen University First Affiliated 
      Hospital, Guangzhou, People's Republic of China.
FAU - Pei, Fei
AU  - Pei F
AD  - Department of Critical Care Medicine, Sun Yat-Sen University First Affiliated 
      Hospital, Guangzhou, People's Republic of China.
FAU - Nie, Yao
AU  - Nie Y
AD  - Department of Critical Care Medicine, Sun Yat-Sen University First Affiliated 
      Hospital, Guangzhou, People's Republic of China.
FAU - Liu, Yongjun
AU  - Liu Y
AD  - Department of Critical Care Medicine, Sun Yat-Sen University First Affiliated 
      Hospital, Guangzhou, People's Republic of China.
FAU - Liu, Zimeng
AU  - Liu Z
AD  - Department of Critical Care Medicine, Sun Yat-Sen University First Affiliated 
      Hospital, Guangzhou, People's Republic of China.
FAU - Wu, Jianfeng
AU  - Wu J
AD  - Department of Critical Care Medicine, Sun Yat-Sen University First Affiliated 
      Hospital, Guangzhou, People's Republic of China. Electronic address: 
      wujianf@mail.sysu.edu.cn.
FAU - Guan, Xiangdong
AU  - Guan X
AD  - Department of Critical Care Medicine, Sun Yat-Sen University First Affiliated 
      Hospital, Guangzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20230325
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Retrospective Studies
MH  - *Critical Care
MH  - *Sepsis
MH  - Systemic Inflammatory Response Syndrome
MH  - Intensive Care Units
MH  - Aspirin/therapeutic use
OTO - NOTNLM
OT  - anti-inflammation
OT  - aspirin
OT  - big data
OT  - critical care
COIS- Declaration of Interest This study was an analysis of data from a third-party 
      anonymized publicly available database with preexisting institutional review 
      board approval. The use of the MIMIC-III and eICU-CRD was approved by the CITI 
      Program (record ID 35925919). The authors have indicated that they have no 
      conflicts of interest with regard to the content of this article.
EDAT- 2023/03/28 06:00
MHDA- 2023/05/16 06:42
CRDT- 2023/03/27 21:58
PHST- 2022/12/05 00:00 [received]
PHST- 2023/01/31 00:00 [revised]
PHST- 2023/02/14 00:00 [accepted]
PHST- 2023/05/16 06:42 [medline]
PHST- 2023/03/28 06:00 [pubmed]
PHST- 2023/03/27 21:58 [entrez]
AID - S0149-2918(23)00066-8 [pii]
AID - 10.1016/j.clinthera.2023.02.005 [doi]
PST - ppublish
SO  - Clin Ther. 2023 Apr;45(4):316-332. doi: 10.1016/j.clinthera.2023.02.005. Epub 
      2023 Mar 25.

PMID- 21088658
OWN - NLM
STAT- MEDLINE
DCOM- 20110121
LR  - 20191111
IS  - 1947-6094 (Print)
IS  - 1947-6108 (Linking)
VI  - 6
IP  - 4
DP  - 2010 Nov-2011 Jan
TI  - Aspirin for primary prevention of cardiovascular disease in women.
PG  - 37-42
LID - 1947-6108-6-4-37 [pii]
AB  - Cardiovascular disease (CVD) accounts for 34% of overall mortality in the United 
      States or an average of 1 death every 38 seconds. While the majority of these 
      events are related to coronary heart disease (CHD), stroke accounts for a 
      sizeable burden of CVD among postmenopausal women. Before 75 years of age, a 
      higher proportion of CVD events due to CHD occur in men than in women, as opposed 
      to a higher proportion of events due to stroke occurring in women. Sex-based 
      disparities in medical care are well documented, and under-treatment of women 
      with aspirin for secondary prevention of CVD is a blatant example of the quality 
      chasm described in the Institute of Medicine report "between the care we have and 
      the care we could have". However, while aspirin appears to be of substantial net 
      benefit in secondary prevention, the balance of its beneficial effects and 
      bleeding hazards in primary prevention remains less certain, especially in women. 
      The current review examines the evidence and provides recommendations for the use 
      of aspirin for primary prevention of CVD in women.
FAU - Jneid, Hani
AU  - Jneid H
AD  - Baylor College of Medicine and Michael E. DeBakey VA Medical Center, Houston, 
      Texas, USA.
LA  - eng
PT  - Journal Article
PT  - Portrait
PT  - Review
PL  - United States
TA  - Methodist Debakey Cardiovasc J
JT  - Methodist DeBakey cardiovascular journal
JID - 101508600
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Evidence-Based Medicine
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Middle Aged
MH  - Practice Guidelines as Topic
MH  - *Preventive Health Services
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
MH  - *Women's Health Services
EDAT- 2010/11/20 06:00
MHDA- 2011/01/22 06:00
CRDT- 2010/11/20 06:00
PHST- 2010/11/20 06:00 [entrez]
PHST- 2010/11/20 06:00 [pubmed]
PHST- 2011/01/22 06:00 [medline]
AID - 1947-6108-6-4-37 [pii]
AID - 10.14797/mdcj-6-4-37 [doi]
PST - ppublish
SO  - Methodist Debakey Cardiovasc J. 2010 Nov-2011 Jan;6(4):37-42. doi: 
      10.14797/mdcj-6-4-37.

PMID- 320671
OWN - NLM
STAT- MEDLINE
DCOM- 19770415
LR  - 20190702
IS  - 0038-4348 (Print)
IS  - 0038-4348 (Linking)
VI  - 70
IP  - 1
DP  - 1977 Jan
TI  - Ibuprofen in osteoarthritis.
PG  - 49-52
AB  - In a double-blind, multiclinic study, 437 patients with osteoarthritis were 
      treated sequentially with ibuprofen, 1,800 mg/day, and placebo, or with aspirin, 
      3,600 mg/day, and placebo. Each treatment was given for four weeks. Considering 
      relief of pain, ability to function, and general well-being, the patients 
      preferred drug to placebo, usually by a statistically significant margin. 
      Combined results showed no significant differences between ibuprofen and aspirin. 
      Patients' evaluations of exercise-related pain, ability to perform a selected 
      activity, and total discomfort and disability, and physicians' evaluations of 
      discomfort and disability, all favored drug over placebo, and the differences 
      were significant for a number of endpoints. The results indicated ibuprofen, 
      1,800 mg/day, offers about the same antiarthritic benefit as aspirin, 3,600 
      mg/day. Both drugs are superior to placebo. The incidence of gastrointestinal 
      complaints with ibuprofen was similar to that with placebo and significantly 
      lower than that with aspirin.
FAU - Giansiracusa, J E
AU  - Giansiracusa JE
FAU - Donaldson, M S
AU  - Donaldson MS
FAU - Koonce, M L
AU  - Koonce ML
FAU - Lefton, T E
AU  - Lefton TE
FAU - Ruoff, G E
AU  - Ruoff GE
FAU - Brooks, C D
AU  - Brooks CD
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - 0 (Phenylpropionates)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Activities of Daily Living
MH  - Aspirin/adverse effects/therapeutic use
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Clinical Trials as Topic
MH  - Dextropropoxyphene/therapeutic use
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Ibuprofen/*therapeutic use
MH  - Osteoarthritis/*drug therapy
MH  - Pain/drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - Placebos
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1097/00007611-197701000-00022 [doi]
PST - ppublish
SO  - South Med J. 1977 Jan;70(1):49-52. doi: 10.1097/00007611-197701000-00022.

PMID- 6782797
OWN - NLM
STAT- MEDLINE
DCOM- 19810521
LR  - 20180216
IS  - 0001-5792 (Print)
IS  - 0001-5792 (Linking)
VI  - 64
IP  - 6
DP  - 1980
TI  - Chronic myeloproliferative disorders: a quantitative assessment of platelet 
      ultrastructure.
PG  - 319
AB  - In patients with chronic myeloproliferative disorders (MPD) and impaired in vitro 
      platelet aggregation, a quantitative assessment of platelet ultrastructure showed 
      reduced numbers of alpha granules and excessive dilation of the open canalicular 
      systems. After 10 days of aspirin therapy, some abnormalities were significantly 
      reduced. The implications of this finding are discussed.
FAU - Boughton, B J
AU  - Boughton BJ
FAU - Jerrome, D W
AU  - Jerrome DW
FAU - Rychetnik, M
AU  - Rychetnik M
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/*ultrastructure
MH  - Chronic Disease
MH  - Cytoplasmic Granules/drug effects/ultrastructure
MH  - Humans
MH  - Myeloproliferative Disorders/*blood/drug therapy
MH  - Platelet Aggregation
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1159/000207311 [doi]
PST - ppublish
SO  - Acta Haematol. 1980;64(6):319. doi: 10.1159/000207311.

PMID- 23256098
OWN - NLM
STAT- MEDLINE
DCOM- 20130909
LR  - 20211021
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Print)
IS  - 0094-3509 (Linking)
VI  - 61
IP  - 11
DP  - 2012 Nov
TI  - PURLs: a safer way to prevent VTE recurrence.
PG  - 673-4
AB  - Rather than extend oral anticoagulation therapy for patients at high risk for 
      recurrence of venous thromboembolism, advise them to take an aspirin a day.
FAU - Kaiseruddin, Altaf
AU  - Kaiseruddin A
AD  - The University of Chicago, IL, USA.
FAU - Oyola, Sonia
AU  - Oyola S
FAU - Rao, Goutham
AU  - Rao G
LA  - eng
GR  - UL1 RR024999/RR/NCRR NIH HHS/United States
GR  - UL1RR024999/RR/NCRR NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - N Engl J Med. 2012 May 24;366(21):1959-67. PMID: 22621626
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Venous Thromboembolism/*prevention & control
PMC - PMC3601812
EDAT- 2012/12/21 06:00
MHDA- 2013/09/10 06:00
CRDT- 2012/12/21 06:00
PHST- 2012/12/21 06:00 [entrez]
PHST- 2012/12/21 06:00 [pubmed]
PHST- 2013/09/10 06:00 [medline]
AID - jfp_6111g [pii]
AID - jfp_6111n [pii]
PST - ppublish
SO  - J Fam Pract. 2012 Nov;61(11):673-4.

PMID- 14617340
OWN - NLM
STAT- MEDLINE
DCOM- 20040727
LR  - 20191108
IS  - 0958-7578 (Print)
IS  - 0958-7578 (Linking)
VI  - 13
IP  - 5
DP  - 2003 Oct
TI  - Effect of haemodilution with diaspirin cross-linked haemoglobin on the oxygen 
      reserve in a rodent model of surgical blood loss.
PG  - 293-301
AB  - The efficacy of pre-operative haemodilution is limited by the reduction in 
      haemoglobin concentration. Acellular haemoglobin-based oxygen carriers provide an 
      alternative to colloid as a haemodiluent, potentially extending the safe limits 
      of this procedure. The aim of this investigation was to determine whether 
      haemodilution with a cross-linked haemoglobin solution, diaspirin cross-linked 
      haemoglobin solution (DCLHb), would enhance the oxygen reserve compared to 
      pentastarch. Sprague Dawley rats were placed in a metabolic box to directly 
      measure systemic oxygen consumption (VO2). Rats were randomized to be 
      haemodiluted to a cellular haemoglobin of 80 g L(-1) with either DCLHb or 
      pentastarch. Oxygen reserve was assessed during isovolemic haemorrhage by 
      determining the critical oxygen delivery (DO2crit) and haemoglobin concentration 
      at the point of oxygen supply dependency (OSD). Following haemodilution and for 
      the duration of the experiment, cardiac index (CI) was significantly lower and 
      systemic vascular resistance was significantly higher in the DCLHb than the 
      pentastarch group. The DO2crit (3.2 +/- 0.4 mL minAg(-1) and 3.4 +/- 0.5 mL 
      minAg(-1), DCLHb versus pentastarch) and cellular haemoglobin concentration (51 
      +/- 9 g L(-1) and 48 +/- 9 g L(-1)), at which rats entered OSD were similar in 
      both groups. Total haemoglobin concentration (cellular and plasma DCLHb) and 
      arterial oxygen content were significantly higher in the DCLHb group (total 
      haemoglobin, 66 +/- 8 g L(-1) and arterial content, 9.2 +/- 1.4 mL dL(-1)) 
      compared to the pentastarch group (total haemoglobin, 48 +/- 9 g L(-1) and 
      arterial content, 7.3 +/- 1.4 mL dL(-1)). Oxygen extraction ratios increased from 
      baseline levels to 0.53 +/- 0.07 and 0.56 +/- 0.1, for the DCLHb and pentastarch 
      groups, respectively, and were not significantly different. The increase in 
      arterial oxygen content from DCLHb in plasma was offset by the decrease in CI 
      observed in this group. Plasma DCLHb did not extend the limits of haemodilution 
      beyond the capacity of the cellular haemoglobin concentration.
FAU - d'Almeida, M S
AU  - d'Almeida MS
AD  - University of Manitoba, Winnipeg, Manitoba, Ontario, Canada.
FAU - White, M
AU  - White M
FAU - Martin, C M
AU  - Martin CM
FAU - Sibbald, W J
AU  - Sibbald WJ
FAU - Chin-Yee, I H
AU  - Chin-Yee IH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Transfus Med
JT  - Transfusion medicine (Oxford, England)
JID - 9301182
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Hydroxyethyl Starch Derivatives)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology/therapeutic use
MH  - *Blood Loss, Surgical
MH  - Blood Substitutes/pharmacology/therapeutic use
MH  - Hematologic Tests
MH  - Hemodilution/*methods/standards
MH  - Hemoglobins/*pharmacology/physiology/therapeutic use
MH  - Hydroxyethyl Starch Derivatives/pharmacology/therapeutic use
MH  - Models, Animal
MH  - Oxygen/*blood
MH  - Oxygen Consumption
MH  - Preoperative Care
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2003/11/18 05:00
MHDA- 2004/07/28 05:00
CRDT- 2003/11/18 05:00
PHST- 2003/11/18 05:00 [pubmed]
PHST- 2004/07/28 05:00 [medline]
PHST- 2003/11/18 05:00 [entrez]
AID - 456 [pii]
AID - 10.1046/j.1365-3148.2003.00456.x [doi]
PST - ppublish
SO  - Transfus Med. 2003 Oct;13(5):293-301. doi: 10.1046/j.1365-3148.2003.00456.x.

PMID- 9689880
OWN - NLM
STAT- MEDLINE
DCOM- 19980827
LR  - 20151119
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 53
IP  - 5
DP  - 1998 May
TI  - [An acetylsalicylic acid-dypiridamole combination (Asasantine) in the prevention 
      of the recurrence of cerebrovascular accidents (a cost-effectiveness analysis)].
PG  - 265-9
AB  - On the basis of the results of the European stroke Prevention Study (ESPS 2) 
      obtained on 6,602 patients, we used a Markov model to perform a 
      cost-effectiveness analysis of a combination of a low-dose of acetylsalicylic 
      acid (ASA) (25 mg b.i.d.) and sustained-release dipyridamole (DP) (200 mg b.i.d.) 
      versus a low-dose of acetylsalicylic acid alone in the prevention of recurrent 
      stroke in Belgium. The perspective was that of the Social Security. Total costs 
      per patient over 5 years amounted to 1,317,718 FB for placebo, 1,312,015 FB for 
      ASA and 1,326,526 FB for ASA-DP, with respectively 3.16, 3.25 and 3.33 
      stroke-free life years (SFLY). For 1,000 patients followed over 5 years, the 
      number of SFLYs gained by ASA-DP is 170 when compared to placebo and 100 when 
      compared to ASA. As compared to placebo, ASA is a dominant strategy and the 
      combination AAS-DP has a cost-effectiveness ratio of 50,569 FB per SFLY gained. 
      The cost-effectiveness ratio of ASA-DP vs. ASA was 176,963 FB per SFLY gained and 
      was not substantially modified in sensitivity analyses. The favourable 
      cost-effectiveness ratio for ASA-DP is mainly explained by the reduction of costs 
      associated with the acute treatment of stroke.
FAU - Kurz, X
AU  - Kurz X
AD  - Laboratoire de Pharmacologie, Université de Liège.
FAU - Annemans, L
AU  - Annemans L
FAU - Dresse, A
AU  - Dresse A
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Association AAS-dypiridamole (Asasantine) dans la prévention des récidives d'AVC 
      (analyse coût-efficacité).
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/economics/*therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Belgium
MH  - Cerebrovascular Disorders/economics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Costs and Cost Analysis
MH  - Delayed-Action Preparations
MH  - Dipyridamole/administration & dosage/economics/*therapeutic use
MH  - Disease-Free Survival
MH  - Drug Combinations
MH  - Drug Costs
MH  - Economics, Pharmaceutical
MH  - Follow-Up Studies
MH  - Humans
MH  - Markov Chains
MH  - Placebos
MH  - Platelet Aggregation Inhibitors/administration & dosage/economics/*therapeutic 
      use
MH  - Recurrence
MH  - Sensitivity and Specificity
MH  - Social Security/economics
EDAT- 1998/08/05 00:00
MHDA- 1998/08/05 00:01
CRDT- 1998/08/05 00:00
PHST- 1998/08/05 00:00 [pubmed]
PHST- 1998/08/05 00:01 [medline]
PHST- 1998/08/05 00:00 [entrez]
PST - ppublish
SO  - Rev Med Liege. 1998 May;53(5):265-9.

PMID- 17296886
OWN - NLM
STAT- MEDLINE
DCOM- 20070316
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 167
IP  - 3
DP  - 2007 Feb 12
TI  - Aspirin for the primary prevention of cardiovascular disease in women: a 
      cost-utility analysis.
PG  - 290-5
AB  - BACKGROUND: The cost-effectiveness of aspirin for primary prevention of 
      cardiovascular events in women is unclear. We sought to perform a cost-utility 
      analysis to address this issue. METHODS: We developed a Markov model, based on 
      published literature, to compare aspirin prevention with no therapy. We used the 
      perspective of a third-party payer and a lifetime time horizon. Our main outcome 
      measure was cost per quality-adjusted life-year (QALY) gained. Our base case 
      analysis considered 65-year-old women with a 7.5% 10-year risk of coronary heart 
      disease events and a 2.8% risk of stroke. RESULTS: Aspirin use cost $13 300 per 
      additional QALY gained in the base case. Results were sensitive to age, 
      cardiovascular disease risk, relative risk reductions with aspirin for ischemic 
      strokes and myocardial infarction, excess risk of hemorrhagic stroke and 
      gastrointestinal bleeding, and the disutility of taking medication. Probabilistic 
      sensitivity analysis for 65-year-old women at moderate cardiovascular disease 
      risk found a 27% chance that aspirin produces fewer QALYs than no treatment, a 
      35% chance that the cost-utility ratio was less than $50 000 per QALY gained, and 
      a 37% probability that it was greater than $50 000 per QALY gained. CONCLUSIONS: 
      Aspirin use appears to have a favorable cost-utility ratio for older women with 
      moderate cardiovascular risk, but firm conclusions about its effects are limited 
      by the imprecision of available evidence, which comes mainly from 1 trial. 
      Aspirin is indicated for women at higher risk for stroke but should not be 
      prescribed for low-risk women, including most younger women.
FAU - Pignone, Michael
AU  - Pignone M
AD  - Department of Medicine, Division of General Medicine, University of North 
      Carolina, 5039 Old Clinic Building, Chapel Hill, NC 27599, USA. 
      pignone@med.unc.edu
FAU - Earnshaw, Stephanie
AU  - Earnshaw S
FAU - Pletcher, Mark J
AU  - Pletcher MJ
FAU - Tice, Jeffrey A
AU  - Tice JA
LA  - eng
GR  - 1P30 CD 000138-01/CD/ODCDC CDC HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 2007 Jul-Aug;147(1):24. PMID: 17608389
MH  - Aged
MH  - Aspirin/*economics/*therapeutic use
MH  - Cardiovascular Diseases/*economics/etiology/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Drug Costs
MH  - Female
MH  - Fibrinolytic Agents/*economics/*therapeutic use
MH  - Humans
MH  - Markov Chains
MH  - Middle Aged
MH  - Quality-Adjusted Life Years
MH  - Risk Assessment
EDAT- 2007/02/14 09:00
MHDA- 2007/03/17 09:00
CRDT- 2007/02/14 09:00
PHST- 2007/02/14 09:00 [pubmed]
PHST- 2007/03/17 09:00 [medline]
PHST- 2007/02/14 09:00 [entrez]
AID - 167/3/290 [pii]
AID - 10.1001/archinte.167.3.290 [doi]
PST - ppublish
SO  - Arch Intern Med. 2007 Feb 12;167(3):290-5. doi: 10.1001/archinte.167.3.290.

PMID- 8303656
OWN - NLM
STAT- MEDLINE
DCOM- 19940307
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 72
IP  - 3
DP  - 1993 Nov 1
TI  - Aspirin fails to inhibit platelet aggregation in sheep.
PG  - 175-82
AB  - This is the first report in which aspirin (ASA) has failed to inhibit aggregation 
      of mammalian platelets. Preincubation of citrated sheep platelet rich plasma with 
      a final concentration of 500 microM ASA for 3 minutes at 37 degrees C did not 
      inhibit aggregation induced by either arachidonic acid (AA; 1.6 mM), ADP (2.5 
      microM), collagen (5.6 micrograms/ml) or thrombin (0.04U). Instead, ASA 
      potentiated the aggregation response produced by these agents except AA. Platelet 
      aggregation that was reversible with ADP became irreversible after adding ASA. 
      The inhibitory properties of ASA was confirmed with human platelets, challenged 
      with AA, ADP, adrenalin and collagen. These findings suggest that sheep platelets 
      have an ASA resistant cyclo oxygenase and may be able to aggregate by a pathway 
      that is independent of arachidonic acid.
FAU - Spanos, H G
AU  - Spanos HG
AD  - Department of Physiology, University of New England, Armidale N.S.W., Australia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Sheep
MH  - Species Specificity
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
AID - 0049-3848(93)90184-P [pii]
AID - 10.1016/0049-3848(93)90184-p [doi]
PST - ppublish
SO  - Thromb Res. 1993 Nov 1;72(3):175-82. doi: 10.1016/0049-3848(93)90184-p.

PMID- 6411101
OWN - NLM
STAT- MEDLINE
DCOM- 19831021
LR  - 20161123
IS  - 0037-8771 (Print)
IS  - 0037-8771 (Linking)
VI  - 59
IP  - 5
DP  - 1983 May 30
TI  - [Responses of isolated hepatic artery segments to barium in the presence of a 
      flavonoid (4-methylesculetin), indomethacin and acetylsalicylate].
PG  - 674-8
AB  - The aim of this work is to study the mechanism by which 4-methylesculetin (4-Me) 
      inhibits the Ba++ induced contraction in smooth muscle. The effect of 4-Me, alone 
      or associated with ascorbic acid, on basal tone and Ba++ induced contraction of 
      isolated hepatic artery strips have been studied. Experiments have been carried 
      out in the presence of lysine acetylsalicylate (LAS) and indomethacin (IN), 
      specific inhibitors of prostaglandin-synthetase. Both LAS and IN suppressed the 
      depressive effect of 4-Me on the Ba++ dependent contraction. Therefore, it seems 
      reasonable to conclude that the 4-Me influence could be mediated by 
      prostaglandins release smooth muscle.
FAU - Bettini, V
AU  - Bettini V
FAU - Gamba, G
AU  - Gamba G
FAU - Legrenzi, E
AU  - Legrenzi E
FAU - Mayellaro, F
AU  - Mayellaro F
FAU - Santoni, G
AU  - Santoni G
LA  - ita
PT  - Journal Article
TT  - Risposte di segmenti di arteria epatica isolata al bario in presenza di un 
      flavonoide (4-metilesculetolo) ed indometacina ed acetil-salicilato.
PL  - Italy
TA  - Boll Soc Ital Biol Sper
JT  - Bollettino della Societa italiana di biologia sperimentale
JID - 7506962
RN  - 0 (Umbelliferones)
RN  - 24GP945V5T (Barium)
RN  - K3Z4F929H6 (Lysine)
RN  - KLF1HS0SXJ (Scopoletin)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Barium/*pharmacology
MH  - Hepatic Artery/*drug effects
MH  - Indomethacin/*pharmacology
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Muscle Contraction/drug effects
MH  - Scopoletin/*pharmacology
MH  - Sheep
MH  - Umbelliferones/*pharmacology
EDAT- 1983/05/30 00:00
MHDA- 1983/05/30 00:01
CRDT- 1983/05/30 00:00
PHST- 1983/05/30 00:00 [pubmed]
PHST- 1983/05/30 00:01 [medline]
PHST- 1983/05/30 00:00 [entrez]
PST - ppublish
SO  - Boll Soc Ital Biol Sper. 1983 May 30;59(5):674-8.

PMID- 6990941
OWN - NLM
STAT- MEDLINE
DCOM- 19800825
LR  - 20131121
IS  - 0539-6115 (Print)
IS  - 0539-6115 (Linking)
VI  - 37
IP  - 2
DP  - 1980 Mar-Apr
TI  - [Evaluation of nephropathies in children with rheumatoid arthritis and prolonged 
      therapy with salicylates].
PG  - 333-43
AB  - The study included 18 school-age and adolescent patients with juvenile rheumatoid 
      arthritis who had consumed from 351 to 6393 gm. (average 2813 gm.) as total dose 
      for the control of their disease. All of them underwent a complete physical 
      examination, general laboratory tests and as specific tests of renal function; 
      urinalysis, urine culture, endogenous creatinine clearance, Addis count (red and 
      white cells), sodium and potassium urinary excretion, urinary acidity capacity, 
      administration of ammonium chloride and capacity of urinary concentration 
      following water restriction. Normal results in practically all parameters led to 
      conclude that a clear evidence of nephropathy due to salicylic acid consumption, 
      was not found in any of the patients studied.
FAU - Salazar, A C
AU  - Salazar AC
FAU - López, E
AU  - López E
FAU - Vargas, R
AU  - Vargas R
LA  - spa
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Valoración de nefropatía en niños con artritis reumatoide y terapia prolongada 
      con salicilatos.
PL  - Mexico
TA  - Bol Med Hosp Infant Mex
JT  - Boletin medico del Hospital Infantil de Mexico
JID - 0414106
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Kidney Diseases/chemically induced/*diagnosis
MH  - Kidney Function Tests
MH  - Male
MH  - Placebos
EDAT- 1980/03/01 00:00
MHDA- 1980/03/01 00:01
CRDT- 1980/03/01 00:00
PHST- 1980/03/01 00:00 [pubmed]
PHST- 1980/03/01 00:01 [medline]
PHST- 1980/03/01 00:00 [entrez]
PST - ppublish
SO  - Bol Med Hosp Infant Mex. 1980 Mar-Apr;37(2):333-43.

PMID- 579108
OWN - NLM
STAT- MEDLINE
DCOM- 19771229
LR  - 20221014
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 27
IP  - 10
DP  - 1977
TI  - Antithrombotic effects of some flavonoids alone and combined with acetylsalicylic 
      acid.
PG  - 1989-92
AB  - In the rat, a selection of two experimental models of "prethrombotic states", one 
      of venostatic thrombosis and one of arterial thrombosis was used to compare the 
      antithrombotic of three flavonoid preparations: O,-(beta-hydroxyethyl)-rutosides 
      (HR), an association of trihydroxyethylrutoside and coumarin (troxerutin) and 
      7-mono-hydroxyethylrutoside (7-Mono-HR), as well as acetylsalicylic acid (ASA). 
      The flavonoids were very effective "protectors" on the prethrombotic models, but 
      only ASA was active on the model of arterial thrombosis. No compound showed a 
      clear protection on the venostatic model if direct activation by kaolin was used. 
      However, if an indirect activation by vessel wall stimulation was used, 7-Mono-HR 
      possessed a marked protective effect. The most favourable results were obtained 
      with an association of 7-Mono-HR and ASA, which could be considered for 
      investigation in clinical thrombosis prophylaxis.
FAU - Hladovec, J
AU  - Hladovec J
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Flavonoids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Vessels/pathology
MH  - Drug Therapy, Combination
MH  - Endothelium/drug effects
MH  - Flavonoids/administration & dosage/*therapeutic use
MH  - Platelet Adhesiveness/drug effects
MH  - Rats
MH  - Regional Blood Flow/drug effects
MH  - Thrombosis/*drug therapy
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1977;27(10):1989-92.

PMID- 19884005
OWN - NLM
STAT- MEDLINE
DCOM- 20100209
LR  - 20131121
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 19
IP  - 24
DP  - 2009 Dec 15
TI  - Synthesis and biological evaluation of salicylic acid and 
      N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a 
      N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: dual inhibitors of 
      cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
PG  - 6855-61
LID - 10.1016/j.bmcl.2009.10.083 [doi]
AB  - A novel class of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide 
      regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore 
      attached to its C-4 or C-5 position was designed for evaluation as 
      anti-inflammatory (AI) agents. Replacement of the 2,4-difluorophenyl ring in 
      diflunisal by the N-difluoromethyl-1,2-dihydropyrid-2-one moiety provided 
      compounds showing dual selective cyclooxygenase-2 (COX-2)/5-lipoxygenase (5-LOX) 
      inhibitory activities. AI structure-activity studies showed that the C-4 (14a) 
      and C-5 (14b) salicylate regioisomers were 1.4- and 1.6-fold more potent than 
      aspirin, and the C-5 N-acetyl-2-carboxybenzenesulfonamide regioisomer (22b) was 
      1.3- and 2.8-fold more potent than ibuprofen and aspirin, respectively. In vivo 
      ulcer index (UI) studies showed that the 4- and 
      5-(N-difluoromethyl-1,2-dihydropyrid-2-one-4-yl)salicylic acids (14a and 14b) 
      were completely non-ulcerogenic since no gastric lesions were present (UI=0) 
      relative to aspirin (UI=57) at an equivalent mumol/kg oral dose. The 
      N-difluoromethyl-1,2-dihydropyridin-2-one moiety provides a novel 5-LOX 
      pharmacophore for the design of cyclic hydroxamic mimetics for exploitation in 
      the development of dual COX-2/5-LOX inhibitory AI drugs.
FAU - Chowdhury, Morshed A
AU  - Chowdhury MA
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Alta, Canada T6G 2N8.
FAU - Abdellatif, Khaled R A
AU  - Abdellatif KR
FAU - Dong, Ying
AU  - Dong Y
FAU - Das, Dipankar
AU  - Das D
FAU - Yu, Gang
AU  - Yu G
FAU - Velázquez, Carlos A
AU  - Velázquez CA
FAU - Suresh, Mavanur R
AU  - Suresh MR
FAU - Knaus, Edward E
AU  - Knaus EE
LA  - eng
GR  - MOP-14712/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091023
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (2-(N-difluoromethyl-1,2-dihydropyridin-2-one))
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 0 (N-acetyl-2-carboxymethylbenzenesulfonamide)
RN  - 0 (Pyridones)
RN  - 0 (Salicylates)
RN  - 0 (Sulfonamides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/chemical synthesis/chemistry/pharmacology
MH  - Cyclooxygenase 2 Inhibitors/chemical synthesis/*chemistry/pharmacology
MH  - Humans
MH  - Isomerism
MH  - Lipoxygenase Inhibitors/chemical synthesis/*chemistry/pharmacology
MH  - Pyridones/chemical synthesis/*chemistry/pharmacology
MH  - Salicylates/chemical synthesis/*chemistry/pharmacology
MH  - Sulfonamides/chemical synthesis/*chemistry/pharmacology
EDAT- 2009/11/04 06:00
MHDA- 2010/02/10 06:00
CRDT- 2009/11/04 06:00
PHST- 2009/09/25 00:00 [received]
PHST- 2009/10/16 00:00 [revised]
PHST- 2009/10/20 00:00 [accepted]
PHST- 2009/11/04 06:00 [entrez]
PHST- 2009/11/04 06:00 [pubmed]
PHST- 2010/02/10 06:00 [medline]
AID - S0960-894X(09)01494-2 [pii]
AID - 10.1016/j.bmcl.2009.10.083 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2009 Dec 15;19(24):6855-61. doi: 
      10.1016/j.bmcl.2009.10.083. Epub 2009 Oct 23.

PMID- 16460136
OWN - NLM
STAT- MEDLINE
DCOM- 20060504
LR  - 20181113
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 24
IP  - 2
DP  - 2006
TI  - A multi-country economic evaluation of low-dose aspirin in the primary prevention 
      of cardiovascular disease.
PG  - 155-69
AB  - BACKGROUND: Low-dose aspirin (acetylsalicylic acid) is standard care in patients 
      with a history of cardiovascular disease (CVD). The use of low-dose aspirin in 
      primary prevention is not yet fully established, although meta-analyses and US 
      and European guidelines support its use in people at increased risk of CVD. The 
      primary objective of this study was to assess the economic consequences of the 
      use of low-dose aspirin in the primary prevention of CVD in four European 
      countries (UK, Germany, Spain and Italy). METHODS: Based on results (benefits and 
      harms) reported in meta-analyses, a state-transition model was developed to 
      predict the cost effectiveness of low-dose aspirin in the primary prevention of 
      CVD. The model consists of five health states: no history of CVD, history of 
      stroke, history of myocardial infarction (MI), history of stroke and MI, and 
      death. A 10-year time horizon and 1-year cycles were used. Secondary prevention 
      data were derived from the aspirin arm of the CAPRIE (Clopidogrel versus Aspirin 
      in Patients at Risk of Ischaemic Events) study. Direct costs from the public 
      healthcare payer's perspective were used (euro, 2003 values). Effects were 
      expressed in life-years (LY) and QALYs gained. Quality weights were obtained from 
      published data.Country-specific discounting was applied on effects and costs 
      (3.5% for the UK, 5% for Germany and 3% for Spain and Italy). Univariate 
      sensitivity analysis and Monte Carlo simulation were performed to assess 
      uncertainty in the results. RESULTS: For patients with an annual risk of coronary 
      heart disease (CHD) of 1.5%, the model resulted in 10-year savings with low-dose 
      aspirin of on average euro 201 (95% CI 81, 331), euro 281 (95% CI 141, 422), euro 
      797 (95% CI 301, 1331) and euro 427 (95% CI 122, 731) per patient in the UK, 
      Germany, Spain and Italy, respectively. Average total cost was almost 3- to 
      4-fold higher in Spain and Italy than in the UK and Germany. Savings 
      (non-significant) start in the first year of treatment in all countries. 
      Sensitivity analyses on cost of complications, utility, discounting, stroke rate 
      and gastrointestinal bleeding rate showed the robustness of the results. From an 
      annual risk of CHD of 0.236% for the UK, 0.324% for Germany, 0.244% for Spain and 
      0.560% for Italy, low-dose aspirin was cost saving compared with placebo. Monte 
      Carlo analysis showed aspirin dominance in about 97% of cases for the three 
      studied annual risks of CHD (0.6%, 1.0% and 1.5%) in the UK, Germany and Spain. 
      In Italy, aspirin dominance in > 95% of cases was seen at annual risks of 1% and 
      1.5%. CONCLUSIONS: Administering low-dose aspirin to patients with an annual risk 
      of CHD of > or = 1% appears to be significantly cost saving from the healthcare 
      payer's perspective in all countries analysed. Sensitivity analyses (CHD risk and 
      bleedings) suggested the results were robust.
FAU - Lamotte, Mark
AU  - Lamotte M
AD  - Health Economics and Disease Management, Brussels, Belgium. 
      MLamotte@be.imshealth.com
FAU - Annemans, Lieven
AU  - Annemans L
FAU - Evers, Thomas
AU  - Evers T
FAU - Kubin, Maria
AU  - Kubin M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
MH  - Anti-Inflammatory Agents, Non-Steroidal/*economics/therapeutic use
MH  - Aspirin/*economics/therapeutic use
MH  - Cardiovascular Diseases/economics/mortality/*prevention & control
MH  - *Cost-Benefit Analysis
MH  - Economics, Pharmaceutical/*statistics & numerical data
MH  - Europe
MH  - Humans
MH  - Markov Chains
MH  - Meta-Analysis as Topic
MH  - Risk Factors
EDAT- 2006/02/08 09:00
MHDA- 2006/05/05 09:00
CRDT- 2006/02/08 09:00
PHST- 2006/02/08 09:00 [pubmed]
PHST- 2006/05/05 09:00 [medline]
PHST- 2006/02/08 09:00 [entrez]
AID - 2425 [pii]
AID - 10.2165/00019053-200624020-00005 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2006;24(2):155-69. doi: 10.2165/00019053-200624020-00005.

PMID- 2365516
OWN - NLM
STAT- MEDLINE
DCOM- 19900813
LR  - 20190816
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 27
IP  - 2
DP  - 1990 May
TI  - Human equivalent doses of platelet inhibitors and experimental atherosclerosis.
PG  - 275-6
AB  - The effects of aspirin, dipyridamole and sulfinpyrazone on the development of 
      atherosclerotic lesions in the aorta were studied in cholesterol-fed rabbits. 
      Aspirin and sulfinpyrazone prevented the development of atherosclerosis, whereas 
      dipyridamole-treated animals developed advanced atherosclerotic lesions. As all 
      the three drugs inhibit platelet function, some non-platelet effects are probably 
      responsible for the differences in results. It is felt that dipyridamole should 
      be avoided in hypercholesterolemic individuals.
FAU - Mittal, S R
AU  - Mittal SR
AD  - Department of Medicine (Cardiology), J.L.N. Medical College and Hospital, Ajmer 
      (Rajasthan), India.
FAU - Mathur, A K
AU  - Mathur AK
FAU - Tandon, R
AU  - Tandon R
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Animals
MH  - Aorta/drug effects
MH  - Arteriosclerosis/*prevention & control
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Dipyridamole/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Rabbits
MH  - Sulfinpyrazone/administration & dosage/*pharmacology
EDAT- 1990/05/01 00:00
MHDA- 1990/05/01 00:01
CRDT- 1990/05/01 00:00
PHST- 1990/05/01 00:00 [pubmed]
PHST- 1990/05/01 00:01 [medline]
PHST- 1990/05/01 00:00 [entrez]
AID - 0167-5273(90)90171-Z [pii]
AID - 10.1016/0167-5273(90)90171-z [doi]
PST - ppublish
SO  - Int J Cardiol. 1990 May;27(2):275-6. doi: 10.1016/0167-5273(90)90171-z.

PMID- 375850
OWN - NLM
STAT- MEDLINE
DCOM- 19790728
LR  - 20190503
IS  - 0003-4967 (Print)
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 38
IP  - 2
DP  - 1979 Apr
TI  - Naproxen in juvenile chronic polyarthritis.
PG  - 152-4
AB  - Naproxen at 10 mg per kg body weight was compared with aspirin at 80 mg per kg 
      body weight in children suffering from juvenile chronic polyarthritis. It was 
      found to be as effective as aspirin, with certainly no more and possibly fewer 
      gastrointestinal side effects. A long-term tolerance study up to 12 months 
      confirmed that naproxed was a satisfactory nonsteroidal anti-inflammatory drug in 
      the management of various types of juvenile chronic arthritis.
FAU - Moran, H
AU  - Moran H
FAU - Hanna, D B
AU  - Hanna DB
FAU - Ansell, B M
AU  - Ansell BM
FAU - Hall, M
AU  - Hall M
FAU - Engler, C
AU  - Engler C
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Arthritis/*drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Naproxen/adverse effects/*therapeutic use
MH  - Random Allocation
MH  - Time Factors
PMC - PMC1000341
EDAT- 1979/04/01 00:00
MHDA- 1979/04/01 00:01
CRDT- 1979/04/01 00:00
PHST- 1979/04/01 00:00 [pubmed]
PHST- 1979/04/01 00:01 [medline]
PHST- 1979/04/01 00:00 [entrez]
AID - 10.1136/ard.38.2.152 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 1979 Apr;38(2):152-4. doi: 10.1136/ard.38.2.152.

PMID- 31583045
OWN - NLM
STAT- MEDLINE
DCOM- 20200320
LR  - 20200320
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2019
DP  - 2019
TI  - Aspirin Eugenol Ester Reduces H(2)O(2)-Induced Oxidative Stress of HUVECs via 
      Mitochondria-Lysosome Axis.
PG  - 8098135
LID - 10.1155/2019/8098135 [doi]
LID - 8098135
AB  - The oxidative stress of vessel endothelium is a major risk factor of 
      cardiovascular disorders. Antioxidative stress drugs are widely used in 
      cardiovascular therapy. Aspirin eugenol ester (AEE) is a new pharmaceutical 
      compound synthesized by esterification reaction of aspirin with eugenols and 
      possesses antioxidative activity. The present study was designed to investigate 
      the mechanism how AEE protects human umbilical vein endothelial cells (HUVECs) 
      from H(2)O(2)-induced oxidative stress. H(2)O(2) was given to the HUVECs with or 
      without AEE pretreatment. Changes in the oxidative stress-related factors, 
      including those related to the mitochondria-lysosome axis, were determined with 
      Western blotting, cellular immunofluorescence, and enzyme activity test. The 
      results showed that, in the HUVECs, 300 μM H(2)O(2) treatment significantly 
      increased the apoptosis rate, MDA concentration, reactive oxygen species (ROS) 
      production, mitochondrial membrane potential, expression of Bax and mature 
      cathepsin D (CTSD), and activity of CTSD and Caspase3 (Cas3) but decreased the 
      expression of Bcl2 and lysosomal membrane stability, while in the HUVECs 
      pretreated with AEE, the above changes caused by either the stimulatory or the 
      inhibitory effect of H(2)O(2) on the relevant factors were significantly reduced. 
      AEE pretreatment significantly enhanced the activity of cellular superoxide 
      dismutase and glutathione peroxidase in the HUVECs. Our findings suggest that AEE 
      effectively reduced H(2)O(2)-induced oxidative stress in the HUVECs via 
      mitochondria-lysosome axis.
CI  - Copyright © 2019 Mei-Zhou Huang et al.
FAU - Huang, Mei-Zhou
AU  - Huang MZ
AUID- ORCID: 0000-0003-2538-0217
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China.
FAU - Yang, Ya-Jun
AU  - Yang YJ
AUID- ORCID: 0000-0001-9651-8549
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China.
FAU - Liu, Xi-Wang
AU  - Liu XW
AUID- ORCID: 0000-0002-1623-0308
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China.
FAU - Qin, Zhe
AU  - Qin Z
AUID- ORCID: 0000-0001-5417-5285
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China.
FAU - Li, Jian-Yong
AU  - Li JY
AUID- ORCID: 0000-0003-3317-0666
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China.
LA  - eng
PT  - Journal Article
DEP - 20190909
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Eugenol/*analogs & derivatives/pharmacology/therapeutic use
MH  - Human Umbilical Vein Endothelial Cells/*drug effects
MH  - Humans
MH  - Hydrogen Peroxide/*adverse effects
MH  - Lysosomes/*metabolism
MH  - Mitochondria/*metabolism
MH  - Oxidative Stress/*drug effects
PMC - PMC6754946
COIS- The authors declare no conflict of interest.
EDAT- 2019/10/05 06:00
MHDA- 2020/03/21 06:00
CRDT- 2019/10/05 06:00
PHST- 2018/10/14 00:00 [received]
PHST- 2019/03/12 00:00 [revised]
PHST- 2019/04/07 00:00 [accepted]
PHST- 2019/10/05 06:00 [entrez]
PHST- 2019/10/05 06:00 [pubmed]
PHST- 2020/03/21 06:00 [medline]
AID - 10.1155/2019/8098135 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2019 Sep 9;2019:8098135. doi: 10.1155/2019/8098135. 
      eCollection 2019.

PMID- 29065836
OWN - NLM
STAT- MEDLINE
DCOM- 20190812
LR  - 20190812
IS  - 1875-6220 (Electronic)
IS  - 1570-1638 (Linking)
VI  - 15
IP  - 4
DP  - 2018
TI  - Stability Indicating Liquid Chromatographic Method for Simultaneous Determination 
      of Aspirin and Omeprazole.
PG  - 351-360
LID - 10.2174/1570163814666171023144105 [doi]
AB  - BACKGROUND: Aspirin combination is prescribed for its thrombolytic activity where 
      gastric ulceration is the major side effect of aspirin which can be prevented by 
      combining it with proton pump inhibitor omeprazole. Present study describes 
      development of analytical method for the estimation of aspirin and omeprazole in 
      combination. OBJECTIVE: The aim of the present study was to develop and validate 
      chromatographic method for simultaneous analysis of aspirin and omeprazole. 
      METHODS: Isocratic, reversed phase stability indicating liquid chromatographic 
      method was developed for the simultaneous determination of Aspirin and Omeprazole 
      in combination. The separation was achieved on a Thermo Scientific Hypersil ODS 
      (250 x 4.6 mm, 5 µm) column, kept at ambient temperature, using acetonitrile: 
      methanol: 0.05 M phosphate buffer (40:5:55; pH 4 adjusted with 0.1% tri ethyl 
      amine) as a mobile phase at a flow rate of 1 mL/min and UV detection was 
      performed at 225 nm. RESULTS: The retention time was found to be 3.9 min for 
      aspirin and 5.3 min for omeprazole. The method was observed to be linear in the 
      range of 2 - 80 µg/mL for aspirin and 1 - 40 µg/mL for omeprazole, respectively. 
      The proposed method was validated as per ICH guidelines Q2 (R1). The developed 
      RP- HPLC method was successfully applied for the simultaneous estimation of 
      aspirin and omeprazole in the presence of degradation products of both the drugs. 
      CONCLUSION: The present study describes liquid chromatographic method for the 
      estimation of aspirin and omeprzole in combination. The method can be used for 
      the analysis of stability samples and routine quality control samples.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Patel, Vandana B
AU  - Patel VB
AD  - Babaria Institute of Pharmacy, Vadodara - Mumbai National Highway 8, Varnama, 
      Vadodara- 391240, Gujarat, India.
FAU - Patel, Aishwarya D
AU  - Patel AD
AD  - Babaria Institute of Pharmacy, Vadodara - Mumbai National Highway 8, Varnama, 
      Vadodara- 391240, Gujarat, India.
FAU - Shah, Dimal A
AU  - Shah DA
AD  - Babaria Institute of Pharmacy, Vadodara - Mumbai National Highway 8, Varnama, 
      Vadodara- 391240, Gujarat, India.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Drug Discov Technol
JT  - Current drug discovery technologies
JID - 101157212
RN  - 0 (Drug Combinations)
RN  - 0 (Fibrinolytic Agents)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects/*analysis/chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - Chromatography, High Pressure Liquid/methods
MH  - Drug Combinations
MH  - Drug Compounding/*standards
MH  - Drug Stability
MH  - Feasibility Studies
MH  - Fibrinolytic Agents/adverse effects/*analysis/chemistry
MH  - Humans
MH  - Omeprazole/*analysis/chemistry
MH  - Quality Control
MH  - Stomach Ulcer/chemically induced/prevention & control
MH  - Thrombosis/drug therapy
OTO - NOTNLM
OT  - Aspirin
OT  - LC (liquid chromatography)
OT  - Omeprazole
OT  - gastic ulteration
OT  - stability indicating method
OT  - validation.
EDAT- 2017/10/27 06:00
MHDA- 2019/08/14 06:00
CRDT- 2017/10/26 06:00
PHST- 2017/07/26 00:00 [received]
PHST- 2017/09/14 00:00 [revised]
PHST- 2017/10/17 00:00 [accepted]
PHST- 2017/10/27 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2017/10/26 06:00 [entrez]
AID - CDDT-EPUB-86470 [pii]
AID - 10.2174/1570163814666171023144105 [doi]
PST - ppublish
SO  - Curr Drug Discov Technol. 2018;15(4):351-360. doi: 
      10.2174/1570163814666171023144105.

PMID- 24510919
OWN - NLM
STAT- MEDLINE
DCOM- 20150702
LR  - 20141111
IS  - 1945-239X (Electronic)
IS  - 0021-9665 (Linking)
VI  - 52
IP  - 10
DP  - 2014 Nov-Dec
TI  - Derivative spectrophotometric and liquid chromatographic methods for the 
      simultaneous determination of metoclopramide hydrochloride and aspirin in 
      pharmaceuticals.
PG  - 1224-32
LID - 10.1093/chromsci/bmt202 [doi]
AB  - Two simple analytical methods were developed and validated for the analysis of a 
      binary mixture of metoclopramide (MET) and aspirin (ASP). The first method 
      depends on measuring the first derivative amplitudes at 257 nm for MET and at 310 
      nm for ASP, respectively. The calibration graphs were linear in the range of 
      0.25-20.0 µg/mL for MET and 10.0-200.0 µg/mL for ASP. For the second method, good 
      chromatographic separation was achieved using Promosil C18 column (250 × 4.6 mm 
      i.d., 5 µm particle size). Mobile phase consisting of methanol and 0.02 M 
      phosphate buffer in the ratio of 60:40 (v/v) at pH 4.0 was pumped at a flow rate 
      of 1 mL/min with UV detection at 260 nm. Indapamide was used as an internal 
      standard. The method showed good linearity over the concentration ranges of 
      0.20-10.0 and 10.0-200.0 μg/mL with limits of detection of 0.06, 1.81 μg/mL and 
      limits of quantification of 0.17, 5.46 μg/mL for MET and ASP, respectively. The 
      results of the proposed methods were statistically compared with those obtained 
      by the official United States Pharmacopeia method revealing non-significant 
      differences in the performance of the methods regarding accuracy and precision. 
      The suggested methods were successfully applied for the simultaneous analysis of 
      the studied drugs in their co-formulated tablets as well as in their single 
      dosage forms.
CI  - © The Author [2014]. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Belal, Fathalla F
AU  - Belal FF
AD  - Faculty of Pharmacy, Department of Analytical Chemistry, University of Mansoura, 
      35516 Mansoura, Egypt.
FAU - Sharaf El-Din, Mohie K
AU  - Sharaf El-Din MK
AD  - Faculty of Pharmacy, Department of Analytical Chemistry, University of Mansoura, 
      35516 Mansoura, Egypt.
FAU - Tolba, Manar M
AU  - Tolba MM
AD  - Faculty of Pharmacy, Department of Analytical Chemistry, University of Mansoura, 
      35516 Mansoura, Egypt.
FAU - Elmansi, Heba
AU  - Elmansi H
AD  - Faculty of Pharmacy, Department of Analytical Chemistry, University of Mansoura, 
      35516 Mansoura, Egypt dr_heba85@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20140207
PL  - United States
TA  - J Chromatogr Sci
JT  - Journal of chromatographic science
JID - 0173225
RN  - 0 (Tablets)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/chemistry
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Hydrogen-Ion Concentration
MH  - Limit of Detection
MH  - Linear Models
MH  - Metoclopramide/*analysis/chemistry
MH  - Reproducibility of Results
MH  - Spectrum Analysis/*methods
MH  - Tablets/chemistry
EDAT- 2014/02/11 06:00
MHDA- 2015/07/03 06:00
CRDT- 2014/02/11 06:00
PHST- 2014/02/11 06:00 [entrez]
PHST- 2014/02/11 06:00 [pubmed]
PHST- 2015/07/03 06:00 [medline]
AID - bmt202 [pii]
AID - 10.1093/chromsci/bmt202 [doi]
PST - ppublish
SO  - J Chromatogr Sci. 2014 Nov-Dec;52(10):1224-32. doi: 10.1093/chromsci/bmt202. Epub 
      2014 Feb 7.

PMID- 24093222
OWN - NLM
STAT- MEDLINE
DCOM- 20140902
LR  - 20211021
IS  - 1477-7827 (Electronic)
IS  - 1477-7827 (Linking)
VI  - 11
DP  - 2013 Oct 5
TI  - A retrospective study on IVF/ICSI outcome in patients with anti-nuclear 
      antibodies: the effects of prednisone plus low-dose aspirin adjuvant treatment.
PG  - 98
LID - 10.1186/1477-7827-11-98 [doi]
AB  - BACKGROUND: Anti-nuclear antibodies (ANA) are suspected of having relevance to 
      adverse reproductive events. METHODS: This study aims to investigate the 
      potential effect of ANA on IVF/ICSI outcome and the therapeutic role of 
      prednisone plus low-dose aspirin (P + A) adjuvant treatment in ANA + patients. 
      The first IVF/ICSI cycles without P + A of sixty-six ANA + women were enrolled as 
      the ANA + group, and the 233 first IVF/ICSI cycles of matched ANA- women served 
      as the ANA- group. The ANA + group was divided into the Titre < =1:320 subgroup 
      and the Titre > 1:320 subgroup. Twenty-one ANA + women with adverse outcomes in 
      their first cycles (ANA + cycles without P + A) received P + A adjuvant treatment 
      for three months before the second IVF/ICSI cycle (ANA + cycles with P + A). The 
      clinical characteristics and the IVF/ICSI outcomes were compared, respectively, 
      between 1) the ANA + group and the ANA- group, 2) the Titre < =1:320 subgroup and 
      the Titre > 1:320 subgroup, and 3) the ANA + cycles without P + A and the ANA + 
      cycles with P + A. RESULTS: No significant differences were observed between each 
      of the two-group pairs in the clinical characteristics. The ANA + group exhibited 
      significantly lower MII oocytes rate, normal fertilisation, pregnancy and 
      implantation rates, as well as remarkably higher abnormal fertilisation and early 
      miscarriage rates. The Titre < =1:320 subgroup's IVF/ICSI outcomes were as poor 
      as those of the Titre > 1:320 subgroup. After the P + A adjuvant treatment, the 
      number of two pro-nuclei, perfect embryos and available embryos, and the 
      implantation rate increased significantly. CONCLUSIONS: These observations 
      suggest that ANA could exert a detrimental effect on IVF/ICSI outcome that might 
      not be titre-dependent, and P + A adjuvant treatment could be useful for ANA + 
      patients. This hypothesis should be verified in further prospective randomised 
      studies.
FAU - Zhu, Qing
AU  - Zhu Q
AD  - Centre for Reproductive Medicine, Department of Obstetrics and Gynecology, Anhui 
      Provincial Hospital affiliated with Anhui Medical University, Hefei, Anhui 
      230000, China. shengzhizhongxin@126.com.
FAU - Wu, Li
AU  - Wu L
FAU - Xu, Bo
AU  - Xu B
FAU - Hu, Mei-Hong
AU  - Hu MH
FAU - Tong, Xian-Hong
AU  - Tong XH
FAU - Ji, Jing-Juan
AU  - Ji JJ
FAU - Liu, Yu-Sheng
AU  - Liu YS
LA  - eng
PT  - Journal Article
DEP - 20131005
PL  - England
TA  - Reprod Biol Endocrinol
JT  - Reproductive biology and endocrinology : RB&E
JID - 101153627
RN  - 0 (Antibodies, Antinuclear)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Abortion, Spontaneous
MH  - Adult
MH  - Antibodies, Antinuclear/*blood
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - *Fertilization in Vitro
MH  - Humans
MH  - Prednisone/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Retrospective Studies
PMC - PMC3852712
EDAT- 2013/10/08 06:00
MHDA- 2014/09/03 06:00
CRDT- 2013/10/08 06:00
PHST- 2013/06/21 00:00 [received]
PHST- 2013/10/03 00:00 [accepted]
PHST- 2013/10/08 06:00 [entrez]
PHST- 2013/10/08 06:00 [pubmed]
PHST- 2014/09/03 06:00 [medline]
AID - 1477-7827-11-98 [pii]
AID - 10.1186/1477-7827-11-98 [doi]
PST - epublish
SO  - Reprod Biol Endocrinol. 2013 Oct 5;11:98. doi: 10.1186/1477-7827-11-98.

PMID- 3884806
OWN - NLM
STAT- MEDLINE
DCOM- 19850430
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 12
IP  - 1
DP  - 1985 Feb
TI  - A double blind comparison of piroxicam and enteric coated ASA in rheumatoid 
      arthritis. A Cooperative Multicenter Canadian trial.
PG  - 68-77
AB  - A double blind study compared piroxicam, 20 mg OD to enteric coated 
      acetylsalicylic acid (EC ASA), 3.9-5.2 g daily in divided doses, in 145 patients 
      with rheumatoid arthritis (RA). Both drugs improved the signs and symptoms of RA. 
      Patients showed significantly better compliance with a once daily dosage regimen. 
      Gastrointestinal side effect profiles were similar. The EC ASA group showed a 
      higher frequency of tinnitis and more dropouts, while there were more skin 
      reactions in the piroxicam group. Decreased hemoglobin and hematocrit values were 
      more prevalent in the piroxicam group. Piroxicam proved to be an effective 
      alternative therapy to EC ASA.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Hemoglobins)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 0 (Thiazines)
RN  - 13T4O6VMAM (Piroxicam)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alkaline Phosphatase/metabolism
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Aspirin/administration & dosage/adverse effects/blood/*therapeutic use
MH  - Blood Urea Nitrogen
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Hematocrit
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Piroxicam
MH  - Self Concept
MH  - Tablets, Enteric-Coated
MH  - Thiazines/administration & dosage/adverse effects/blood/*therapeutic use
EDAT- 1985/02/01 00:00
MHDA- 1985/02/01 00:01
CRDT- 1985/02/01 00:00
PHST- 1985/02/01 00:00 [pubmed]
PHST- 1985/02/01 00:01 [medline]
PHST- 1985/02/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1985 Feb;12(1):68-77.

PMID- 2883278
OWN - NLM
STAT- MEDLINE
DCOM- 19870610
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 39
IP  - 3
DP  - 1987 Mar
TI  - The angle of internal flow as an indicator of filling and drug release properties 
      of capsule formulations.
PG  - 164-8
AB  - The cohesiveness of size fractions of acetylsalicylic acid and lactose alone and 
      in various combinations has been determined by estimation of the rate of decrease 
      in volume as a function of tamping under standard conditions. The cohesiveness 
      was quantified in terms of empirically derived characteristic, the angle of 
      internal flow phi. The value of phi was found to decrease with the particle size 
      of acetylsalicylic acid, but not lactose, and was found to be dependent on the 
      relative proportion and particle sizes of acetylsalicylic acid and lactose when 
      blends of powder were studied. The value of the time for 50% of the drug content 
      to be released from a hard gelatin capsule in an in-vitro dissolution test, T50, 
      was found to decrease with decreasing values of omega for capsules containing 
      acetylsalicylic acid alone. For capsules containing powder blends there was no 
      consistent relationship between the value of T50 and phi.
FAU - Newton, J M
AU  - Newton JM
FAU - Bader, F
AU  - Bader F
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Capsules)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - *Capsules
MH  - *Drug Compounding
MH  - In Vitro Techniques
MH  - Lactose
MH  - Mathematics
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1987.tb06242.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1987 Mar;39(3):164-8. doi: 10.1111/j.2042-7158.1987.tb06242.x.

PMID- 23639712
OWN - NLM
STAT- MEDLINE
DCOM- 20131118
LR  - 20131121
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 33
IP  - 2
DP  - 2013 May
TI  - Aspirin-exacerbated cutaneous disease.
PG  - 251-62
LID - S0889-8561(12)00115-4 [pii]
LID - 10.1016/j.iac.2012.10.004 [doi]
AB  - It has been recognized that a high proportion of chronic urticaria patients 
      experience symptom aggravation when exposed to aspirin and NSAIDs. This clinical 
      picture is known as Aspirin-exacerbated cutaneous disease. The pathogenesis of 
      these exacerbations is related to the inhibition of cyclooxygenase-1 leading to a 
      decreased synthesis of PGE2 and an increased cysteinyl leukotriene production in 
      the skin and subcutaneous tissues. Patient management comprises the treatment of 
      the underlying cutaneous disease with nonsedating antihistamines and other 
      medications, avoidance of COX-1 inhibitors, and the use of alternative NSAIDs 
      that do not inhibit COX-1 for the relief of pain, inflammation and fever.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Sánchez-Borges, Mario
AU  - Sánchez-Borges M
AD  - Department of Allergy and Clinical Immunology, Centro Médico-Docente La Trinidad, 
      Carretera La Trinidad-El Hatillo, Caracas, Venezuela. sanchezbmario@gmail.com
FAU - Caballero-Fonseca, Fernan
AU  - Caballero-Fonseca F
FAU - Capriles-Hulett, Arnaldo
AU  - Capriles-Hulett A
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20121031
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology
MH  - Aspirin/*adverse effects/pharmacology
MH  - Drug Hypersensitivity/diagnosis/drug therapy/etiology
MH  - Humans
MH  - Skin Diseases/diagnosis/drug therapy/*etiology
EDAT- 2013/05/04 06:00
MHDA- 2013/11/19 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/05/04 06:00 [entrez]
PHST- 2013/05/04 06:00 [pubmed]
PHST- 2013/11/19 06:00 [medline]
AID - S0889-8561(12)00115-4 [pii]
AID - 10.1016/j.iac.2012.10.004 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2013 May;33(2):251-62. doi: 
      10.1016/j.iac.2012.10.004. Epub 2012 Oct 31.

PMID- 29122278
OWN - NLM
STAT- MEDLINE
DCOM- 20171218
LR  - 20220330
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 121
IP  - 1
DP  - 2018 Jan 1
TI  - Meta-Analysis of Aspirin Versus Dual Antiplatelet Therapy Following Coronary 
      Artery Bypass Grafting.
PG  - 32-40
LID - S0002-9149(17)31594-1 [pii]
LID - 10.1016/j.amjcard.2017.09.022 [doi]
AB  - Although aspirin monotherapy is considered the standard of care after coronary 
      artery bypass grafting (CABG), more recent evidence has suggested a benefit with 
      dual antiplatelet therapy (DAPT) after CABG. We performed a meta-analysis of 
      observational studies and randomized controlled trials comparing outcomes of 
      aspirin monotherapy with DAPT in patients after CABG. Subgroup analyses were 
      conducted according to surgical technique (i.e., on vs off pump) and clinical 
      presentation (acute coronary syndrome vs no acute coronary syndrome). Random 
      effects overall risk ratios (RR) were calculated using the DerSimonian and Laird 
      model. Eight randomized control trials and 9 observational studies with a total 
      of 11,135 patients were included. At a mean follow-up of 23 months, major adverse 
      cardiac events (10.3% vs 12.1%, RR 0.84, confidence interval [CI] 0.71 to 0.99), 
      all-cause mortality (5.7% vs 7.0%, RR 0.67, CI 0.48 to 0.94), and graft occlusion 
      (11.3% vs 14.2%, RR 0.79, CI 0.63 to 0.98) were less with DAPT than with aspirin 
      monotherapy. There was no difference in myocardial infarction, stroke, or major 
      bleeding between the 2 groups. In conclusion, DAPT appears to be associated with 
      a reduction in graft occlusion, major adverse cardiac events, and all-cause 
      mortality, without significantly increasing major bleeding compared with aspirin 
      monotherapy in patients undergoing CABG.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Agarwal, Nayan
AU  - Agarwal N
AD  - Department of Medicine, University of Florida, Gainesville, Florida.
FAU - Mahmoud, Ahmed N
AU  - Mahmoud AN
AD  - Department of Medicine, University of Florida, Gainesville, Florida.
FAU - Patel, Nimesh Kirit
AU  - Patel NK
AD  - Department of Medicine, Virginia Commonwealth University Health System, Richmond, 
      Virginia.
FAU - Jain, Ankur
AU  - Jain A
AD  - Department of Medicine, University of Florida, Gainesville, Florida.
FAU - Garg, Jalaj
AU  - Garg J
AD  - Department of Medicine, Lehigh Valley, Allentown, Pennsylvania.
FAU - Mojadidi, Mohammad Khalid
AU  - Mojadidi MK
AD  - Department of Medicine, University of Florida, Gainesville, Florida.
FAU - Agrawal, Sahil
AU  - Agrawal S
AD  - Department of Medicine, St Lukes University Health Network, Bethlehem, 
      Pennsylvania.
FAU - Qamar, Arman
AU  - Qamar A
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
FAU - Golwala, Harsh
AU  - Golwala H
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
FAU - Gupta, Tanush
AU  - Gupta T
AD  - Department of Medicine, Montefiore Medical Centre, Albert Einstein College of 
      Medicine, Bronx, New York.
FAU - Bhatia, Nirmanmoh
AU  - Bhatia N
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville, 
      Tennessee.
FAU - Anderson, R David
AU  - Anderson RD
AD  - Department of Medicine, University of Florida, Gainesville, Florida.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 
      Electronic address: dlbhattmd@post.harvard.edu.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20171026
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Care
EDAT- 2017/11/11 06:00
MHDA- 2017/12/19 06:00
CRDT- 2017/11/11 06:00
PHST- 2017/08/20 00:00 [received]
PHST- 2017/09/18 00:00 [revised]
PHST- 2017/09/19 00:00 [accepted]
PHST- 2017/11/11 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
PHST- 2017/11/11 06:00 [entrez]
AID - S0002-9149(17)31594-1 [pii]
AID - 10.1016/j.amjcard.2017.09.022 [doi]
PST - ppublish
SO  - Am J Cardiol. 2018 Jan 1;121(1):32-40. doi: 10.1016/j.amjcard.2017.09.022. Epub 
      2017 Oct 26.

PMID- 6342354
OWN - NLM
STAT- MEDLINE
DCOM- 19830623
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 51
IP  - 9
DP  - 1983 May 15
TI  - Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic 
      heart valve replacement: danger of aspirin compared with dipyridamole.
PG  - 1537-41
AB  - Despite the use of oral anticoagulation in patients with prosthetic heart valves, 
      persistent thromboembolism over time warrants a search for improved methods of 
      prevention. Thus, patients receiving 1 or more mechanical prosthetic heart valves 
      were randomized to therapy with warfarin plus dipyridamole (400 mg/day) or 
      warfarin plus aspirin (500 mg/day) on the basis of location and type of valve and 
      surgeon, and followed up with a concurrent, nonrandomized control group taking 
      warfarin alone. In 534 patients followed up 1,319 patient-years, excessive 
      bleeding (necessitating blood transfusion or hospitalization) was noted in the 
      warfarin plus aspirin group (23 of 170 [14%], or 6.0/100 patient-years) compared 
      with warfarin plus dipyridamole (7 of 181 [4%], or 1.6/100 patient-years, p less 
      than 0.001), or warfarin alone (9 of 183 [5%], or 1.8/100 patient-years, p less 
      than 0.001). A trend was evident toward a reduction in thromboembolism in the 
      warfarin plus dipyridamole group (2 of 181 [1%], or 0.5/100 patient-years) as 
      compared with warfarin plus aspirin (7 of 170 [4%], or 1.8/100 patient-years), or 
      warfarin alone (6 of 183 [4%], or 1.2/100 patient-years). Adequacy of 
      anticoagulation (based on 12,720 prothrombin time determinations) was similar in 
      all 3 groups with 65% of prothrombin times in the therapeutic range (1.5 less 
      than or equal to prothrombin time/control less than or equal to 2.5), 30% too 
      low, and 5% too high. Warfarin plus aspirin therapy resulted in excessive 
      bleeding and is contraindicated. Longer follow-up study is needed to determine 
      whether further separation of the incidence of thromboembolism can be detected.
FAU - Chesebro, J H
AU  - Chesebro JH
FAU - Fuster, V
AU  - Fuster V
FAU - Elveback, L R
AU  - Elveback LR
FAU - McGoon, D C
AU  - McGoon DC
FAU - Pluth, J R
AU  - Pluth JR
FAU - Puga, F J
AU  - Puga FJ
FAU - Wallace, R B
AU  - Wallace RB
FAU - Danielson, G K
AU  - Danielson GK
FAU - Orszulak, T A
AU  - Orszulak TA
FAU - Piehler, J M
AU  - Piehler JM
FAU - Schaff, H V
AU  - Schaff HV
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Heart Valve Prosthesis/*adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Random Allocation
MH  - Thromboembolism/etiology/*prevention & control
MH  - Warfarin/*therapeutic use
EDAT- 1983/05/15 00:00
MHDA- 1983/05/15 00:01
CRDT- 1983/05/15 00:00
PHST- 1983/05/15 00:00 [pubmed]
PHST- 1983/05/15 00:01 [medline]
PHST- 1983/05/15 00:00 [entrez]
AID - 0002-9149(83)90673-2 [pii]
AID - 10.1016/0002-9149(83)90673-2 [doi]
PST - ppublish
SO  - Am J Cardiol. 1983 May 15;51(9):1537-41. doi: 10.1016/0002-9149(83)90673-2.

PMID- 29266502
OWN - NLM
STAT- MEDLINE
DCOM- 20190417
LR  - 20190417
IS  - 1469-0705 (Electronic)
IS  - 0960-7692 (Linking)
VI  - 52
IP  - 6
DP  - 2018 Dec
TI  - Maternal blood-pressure trends throughout pregnancy and development of 
      pre-eclampsia in women receiving first-trimester aspirin prophylaxis.
PG  - 728-733
LID - 10.1002/uog.18992 [doi]
AB  - OBJECTIVES: To study women who initiated aspirin in the first trimester for high 
      risk of pre-eclampsia, and compare blood-pressure trends throughout pregnancy 
      between those with normal outcome and those who subsequently developed 
      pre-eclampsia. METHODS: Women were enrolled into a prospective observational 
      study at 9-14 weeks' gestation. This was a secondary analysis of those who 
      started daily doses of 81 mg of aspirin before 16 weeks for increased risk of 
      pre-eclampsia based on maternal history and bilateral uterine artery notching. 
      Enrollment characteristics and blood-pressure measurements throughout gestation 
      were compared between women who did and those who did not develop pre-eclampsia. 
      RESULTS: Of the 237 women who initiated first-trimester aspirin prophylaxis, 29 
      (12.2%) developed pre-eclampsia. A total of 2881 serial blood-pressure 
      measurements obtained between 4 and 41 weeks' gestation (747 in the first 
      trimester, 1008 in the second and 1126 in the third) showed that women with 
      pre-eclampsia started pregnancy with higher blood pressure and maintained this 
      trend despite taking aspirin (mean arterial blood pressure in women with 
      pre-eclampsia = (0.13 × gestational age (weeks)) + 93.63, vs (0.11 × gestational 
      age (weeks)) + 82.61 in those without; P < 0.005). First-trimester diastolic and 
      second-trimester systolic blood pressure were independent risk factors for 
      pre-eclampsia (β = 1.087 and 1.050, respectively; r(2)  = 0.24, P < 0.0001). When 
      average first-trimester diastolic blood pressure was >74 mmHg, the odds ratio for 
      pre-eclampsia was 6.5 (95% CI, 2.8-15.1; P < 0.001) and that for pre-eclampsia 
      before 34 weeks was 14.6 (95% CI, 1.72-123.5; P = 0.004). If, in addition, 
      average second-trimester systolic blood pressure was >125 mmHg, the odds ratio 
      for pre-eclampsia was 9.4 (95% CI, 4.1-22.4; P < 0.001) and that for early-onset 
      disease was 34.6 (95% CI, 4.1-296.4; P = 0.004). CONCLUSION: In women treated 
      with prophylactic aspirin from the first trimester, those who develop 
      pre-eclampsia have significantly and sustained higher blood pressure from the 
      onset of pregnancy compared with those who do not develop pre-eclampsia. This 
      raises the possibility that mildly elevated blood pressure predisposes women to 
      abnormal placentation, which then acts synergistically with elevated blood 
      pressure to predispose such women to pre-eclampsia to a degree that is 
      incompletely mitigated by aspirin. Copyright © 2017 ISUOG. Published by John 
      Wiley & Sons Ltd.
CI  - Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
FAU - Baschat, A A
AU  - Baschat AA
AUID- ORCID: 0000-0003-1927-2084
AD  - Center for Fetal Therapy, Department of Gynecology & Obstetrics, Johns Hopkins 
      School of Medicine, Baltimore, MD, USA.
FAU - Dewberry, D
AU  - Dewberry D
AD  - Center for Fetal Therapy, Department of Gynecology & Obstetrics, Johns Hopkins 
      School of Medicine, Baltimore, MD, USA.
FAU - Seravalli, V
AU  - Seravalli V
AUID- ORCID: 0000-0001-8706-3925
AD  - Center for Fetal Therapy, Department of Gynecology & Obstetrics, Johns Hopkins 
      School of Medicine, Baltimore, MD, USA.
FAU - Miller, J L
AU  - Miller JL
AUID- ORCID: 0000-0003-0189-8265
AD  - Center for Fetal Therapy, Department of Gynecology & Obstetrics, Johns Hopkins 
      School of Medicine, Baltimore, MD, USA.
FAU - Block-Abraham, D
AU  - Block-Abraham D
AD  - Center for Fetal Therapy, Department of Gynecology & Obstetrics, Johns Hopkins 
      School of Medicine, Baltimore, MD, USA.
FAU - Blitzer, M G
AU  - Blitzer MG
AD  - Department of Pediatrics, University of Maryland School of Medicine, Baltimore, 
      MD, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20181109
PL  - England
TA  - Ultrasound Obstet Gynecol
JT  - Ultrasound in obstetrics & gynecology : the official journal of the International 
      Society of Ultrasound in Obstetrics and Gynecology
JID - 9108340
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Pressure Determination/trends
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Maternal Age
MH  - Middle Aged
MH  - Pre-Eclampsia/*epidemiology/prevention & control
MH  - Pre-Exposure Prophylaxis
MH  - Pregnancy
MH  - Prospective Studies
MH  - Risk Factors
MH  - Young Adult
OTO - NOTNLM
OT  - aspirin
OT  - blood pressure
OT  - first-trimester screening
OT  - pre-eclampsia
EDAT- 2017/12/22 06:00
MHDA- 2019/04/18 06:00
CRDT- 2017/12/22 06:00
PHST- 2017/07/08 00:00 [received]
PHST- 2017/10/14 00:00 [revised]
PHST- 2017/12/08 00:00 [accepted]
PHST- 2017/12/22 06:00 [pubmed]
PHST- 2019/04/18 06:00 [medline]
PHST- 2017/12/22 06:00 [entrez]
AID - 10.1002/uog.18992 [doi]
PST - ppublish
SO  - Ultrasound Obstet Gynecol. 2018 Dec;52(6):728-733. doi: 10.1002/uog.18992. Epub 
      2018 Nov 9.

PMID- 27032934
OWN - NLM
STAT- MEDLINE
DCOM- 20170120
LR  - 20170120
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 17
IP  - 3
DP  - 2016 Jun
TI  - Finding New Tricks for Old Drugs: Tumoricidal Activity of Non-Traditional 
      Antitumor Drugs.
PG  - 539-52
LID - 10.1208/s12249-016-0518-y [doi]
AB  - Chemotherapy, a traditional method, plays an important role in tumor therapy. 
      Currently, common clinical antitumor drugs have several defects like poor 
      efficacy, side effects, etc. Furthermore, developing new antitumor drugs takes a 
      long time and requires many resources. Recent studies have found that oldies are 
      newbies for the oncologist, such as flavonoid, metformin, aspirin, etc. These 
      non-traditional antitumor drugs (NTADs) are widely used in management of 
      non-cancer diseases, which gained FDA approval for treatment of patients. 
      Increasingly, studies about antitumor action of NTADs have attracted many 
      researchers' interests. A giant amount of studies showed a decrease in cancer 
      incidence in NTAD-treated patients. Several reports outlined a direct inhibitory 
      effect of NTADs on cancer cell growth and antitumoral actions. This review 
      summarized the research progress on antitumor effects of ten NTADs. Retrospective 
      and meta-analyses of trials also showed that these NTADs had preventive effects 
      against cancer in vitro and in vivo. These drugs represent a promising option for 
      cancer treatment, which have clear benefits including clinical safety, obvious 
      curative effect, and saving medical and health resources. Judged from previous 
      reports, future studies will yield valuable data about the profitable effects of 
      these drugs. With a better understanding of its mechanisms of antitumor activity, 
      NTADs may become available for combination with chemotherapy or targeted therapy 
      in clinic.
FAU - Zhang, Fangrong
AU  - Zhang F
AD  - State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China 
      Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China.
FAU - Li, Min
AU  - Li M
AD  - State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China 
      Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China.
FAU - Wang, Junling
AU  - Wang J
AD  - Department of Analytical Chemistry, China Pharmaceutical University, Nanjing, 
      210009, China.
FAU - Liang, Xi
AU  - Liang X
AD  - State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China 
      Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China.
FAU - Su, Yujie
AU  - Su Y
AD  - State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China 
      Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China.
FAU - Wang, Wei
AU  - Wang W
AD  - State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China 
      Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China. 
      wangcpu209@cpu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160331
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Flavonoids)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*chemistry/*therapeutic use
MH  - Aspirin/chemistry/therapeutic use
MH  - Clinical Trials as Topic/methods
MH  - Flavonoids/chemistry/therapeutic use
MH  - Humans
MH  - Metformin/chemistry/therapeutic use
MH  - Neoplasms/*drug therapy/metabolism
MH  - Retrospective Studies
OTO - NOTNLM
OT  - chemotherapy
OT  - non-traditional anticarcinogen
OT  - pharmacological action
OT  - tumoricidal activity
EDAT- 2016/04/02 06:00
MHDA- 2017/01/21 06:00
CRDT- 2016/04/02 06:00
PHST- 2015/12/22 00:00 [received]
PHST- 2016/03/20 00:00 [accepted]
PHST- 2016/04/02 06:00 [entrez]
PHST- 2016/04/02 06:00 [pubmed]
PHST- 2017/01/21 06:00 [medline]
AID - 10.1208/s12249-016-0518-y [pii]
AID - 10.1208/s12249-016-0518-y [doi]
PST - ppublish
SO  - AAPS PharmSciTech. 2016 Jun;17(3):539-52. doi: 10.1208/s12249-016-0518-y. Epub 
      2016 Mar 31.

PMID- 32959950
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
VI  - 43
IP  - 1
DP  - 2021 Jan
TI  - Aspirin use predicts prolonged survival in patients with oropharyngeal cancer: 
      Nationwide Veterans Affairs database study.
PG  - 247-254
LID - 10.1002/hed.26481 [doi]
AB  - BACKGROUND: Single-institution studies suggest that aspirin reduces the risk of 
      death in head and neck cancer. The aim of this study was to investigate the 
      effect of aspirin use on overall survival (OS) in veterans with oropharyngeal 
      cancer (OPC). METHODS: A total of 23 083 veterans with OPC were identified 
      between 2005 and 2018 from the Veterans Health Administration Corporate Data 
      Warehouse. Records were queried for clinical-demographic data, aspirin 
      prescriptions, and outcomes. Three-year OS was estimated. A Cox model was used to 
      estimate hazard ratios (HR) for aspirin use. RESULTS: Among the 23 083 identified 
      veterans, 17 206 veterans met inclusion criteria. 21.8% used aspirin. Three-year 
      OS was prolonged for aspirin users (66%) compared to nonaspirin users (54%; 
      P < .001). Adjusted HR for death for nonaspirin users was 1.75 (95% confidence 
      interval (CI) [1.60-1.91]). The average treatment effect of aspirin on survival 
      using inverse probability weighting was 10% (95% CI [0.08-0.11]). CONCLUSION: 
      Aspirin use following OPC diagnosis was independently associated with improved 
      3-year OS among veterans nationwide.
CI  - © 2020 Wiley Periodicals LLC.
FAU - Clark, Christine M
AU  - Clark CM
AUID- ORCID: 0000-0003-2255-4816
AD  - Department of Otolaryngology - Head and Neck Surgery, MedStar Georgetown 
      University Hospital, Washington, DC, USA.
FAU - Newark, Annemarie C
AU  - Newark AC
AD  - Georgetown University School of Medicine, Washington, DC, USA.
FAU - Fokar, Ali
AU  - Fokar A
AD  - Department of Surgery, Washington DC Veterans Affairs Medical Center, Washington, 
      DC, USA.
FAU - Maxwell, Jessica H
AU  - Maxwell JH
AD  - Department of Otolaryngology - Head and Neck Surgery, MedStar Georgetown 
      University Hospital, Washington, DC, USA.
AD  - Department of Surgery, Washington DC Veterans Affairs Medical Center, Washington, 
      DC, USA.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Head and Neck Neoplasms
MH  - Humans
MH  - *Oropharyngeal Neoplasms/therapy
MH  - Proportional Hazards Models
MH  - *Veterans
OTO - NOTNLM
OT  - aspirin
OT  - oropharyngeal cancer
OT  - squamous cell carcinoma
OT  - survival
OT  - veterans
EDAT- 2020/09/23 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/22 08:42
PHST- 2020/06/09 00:00 [received]
PHST- 2020/08/06 00:00 [revised]
PHST- 2020/09/11 00:00 [accepted]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/22 08:42 [entrez]
AID - 10.1002/hed.26481 [doi]
PST - ppublish
SO  - Head Neck. 2021 Jan;43(1):247-254. doi: 10.1002/hed.26481. Epub 2020 Sep 22.

PMID- 29557194
OWN - NLM
STAT- MEDLINE
DCOM- 20180921
LR  - 20180921
IS  - 1466-1799 (Electronic)
IS  - 0007-1668 (Linking)
VI  - 59
IP  - 3
DP  - 2018 Jun
TI  - Inhibition of heat stress-related apoptosis of chicken myocardial cells through 
      inducing Hsp90 expression by aspirin administration in vivo.
PG  - 308-317
LID - 10.1080/00071668.2018.1454585 [doi]
AB  - 1. This experiment investigated the anti-apoptosis effects and the mechanism of 
      aspirin action in the heat shock response of chicken myocardial cells in vivo, 
      via changes in the heat stress (HS) protein Hsp90 and the rate of apoptosis. 
      Broiler chickens were administered aspirin (1 mg/kg body weight) 2 h before 
      exposure to HS, and then exposed to 40 ± 1°C for 0, 1, 2, 3, 5, 7, 10, 15 and 
      24 h. 2. The induction and consumption of the HS factor heat shock factor 
      (HSF)-1, and reductions of HSF-2 and HSF-3 induced by HS led to a delay in Hsp90 
      expression. HSF-1, 2 and 3 regulation of hsp90 expression in turn inhibited the 
      synthesis and activation of protein kinase β (Akt), which resulted in a 
      significant increase in caspase-3 at 2 and 10 h, caspase-9 from 1 to 7 h (except 
      at 5 h), and the heat-stressed apoptosis of the myocardial cells. 3. 
      Administration of aspirin changed the expression patterns of HSF-1, 2 and 3 such 
      that the expression of Hsp90 protein was significantly upregulated (by 2.3-4.1 
      times compared with that of the non-treated cells). The resultant increase in Akt 
      expression and activation, compared with the HS group, inhibited caspase-3 and 
      caspase-9 activities and reduced the myocardial cells apoptosis rate (by 
      2.14-2.56 times). 4. Aspirin administration could inhibit heat-stressed apoptosis 
      of myocardial cells in vivo and may be closely associated with its promotion of 
      HS response of chicken hearts, especially Hsp90 expression.
FAU - Zhang, X
AU  - Zhang X
AD  - a College of Veterinary Medicine, Nanjing Agricultural University , Nanjing , 
      China.
FAU - Zhang, M
AU  - Zhang M
AD  - b College of Animal Science and Technology , Jinling Institute of Technology , 
      Nanjing , China.
FAU - Su, Y
AU  - Su Y
AD  - a College of Veterinary Medicine, Nanjing Agricultural University , Nanjing , 
      China.
FAU - Wang, Z
AU  - Wang Z
AD  - a College of Veterinary Medicine, Nanjing Agricultural University , Nanjing , 
      China.
FAU - Zhao, Q
AU  - Zhao Q
AD  - a College of Veterinary Medicine, Nanjing Agricultural University , Nanjing , 
      China.
FAU - Zhu, H
AU  - Zhu H
AD  - a College of Veterinary Medicine, Nanjing Agricultural University , Nanjing , 
      China.
FAU - Qian, Z
AU  - Qian Z
AD  - a College of Veterinary Medicine, Nanjing Agricultural University , Nanjing , 
      China.
FAU - Xu, J
AU  - Xu J
AD  - a College of Veterinary Medicine, Nanjing Agricultural University , Nanjing , 
      China.
FAU - Tang, S
AU  - Tang S
AD  - a College of Veterinary Medicine, Nanjing Agricultural University , Nanjing , 
      China.
FAU - Wu, D
AU  - Wu D
AD  - a College of Veterinary Medicine, Nanjing Agricultural University , Nanjing , 
      China.
FAU - Lin, Y
AU  - Lin Y
AD  - a College of Veterinary Medicine, Nanjing Agricultural University , Nanjing , 
      China.
FAU - Kemper, N
AU  - Kemper N
AD  - c Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour , 
      University of Veterinary Medicine Hannover , Hannover , Germany.
FAU - Hartung, J
AU  - Hartung J
AD  - c Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour , 
      University of Veterinary Medicine Hannover , Hannover , Germany.
FAU - Bao, E
AU  - Bao E
AD  - a College of Veterinary Medicine, Nanjing Agricultural University , Nanjing , 
      China.
LA  - eng
PT  - Journal Article
DEP - 20180411
PL  - England
TA  - Br Poult Sci
JT  - British poultry science
JID - 15740290R
RN  - 0 (Antipyretics)
RN  - 0 (HSP90 Heat-Shock Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antipyretics/administration & dosage/*pharmacology
MH  - Apoptosis/*physiology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chickens/*physiology
MH  - HSP90 Heat-Shock Proteins/*metabolism
MH  - Heat-Shock Response/*physiology
MH  - Myocytes, Cardiac/*drug effects/physiology
MH  - Time Factors
OTO - NOTNLM
OT  - Aspirin administration
OT  - Hsp90 expression
OT  - chicken myocardial cells
OT  - heat stress
OT  - inhibition of apoptosis
EDAT- 2018/03/21 06:00
MHDA- 2018/09/22 06:00
CRDT- 2018/03/21 06:00
PHST- 2018/03/21 06:00 [pubmed]
PHST- 2018/09/22 06:00 [medline]
PHST- 2018/03/21 06:00 [entrez]
AID - 10.1080/00071668.2018.1454585 [doi]
PST - ppublish
SO  - Br Poult Sci. 2018 Jun;59(3):308-317. doi: 10.1080/00071668.2018.1454585. Epub 
      2018 Apr 11.

PMID- 25047282
OWN - NLM
STAT- MEDLINE
DCOM- 20150804
LR  - 20141208
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 24
IP  - 1
DP  - 2015 Jan
TI  - Hydrogen sulfide inhibits human platelet aggregation in vitro in part by 
      interfering gap junction channels: effects of ACS14, a hydrogen sulfide-releasing 
      aspirin.
PG  - 77-85
LID - S1443-9506(14)00515-0 [pii]
LID - 10.1016/j.hlc.2014.05.019 [doi]
AB  - BACKGROUND: Hydrogen sulfide (H2S), as a newly identified gaseous mediator, has 
      been widely investigated in various systems. However, the effect of H2S on 
      cardiovascular system haemostasis, including platelet aggregation and the precise 
      mechanisms remain unclear. Therefore, the present study was aimed to examine the 
      inhibitory effect of H2S on human platelet aggregation in vitro and its relevance 
      to gap junction channels. METHODS AND RESULTS: The antiaggregatory property of 
      H2S-releasing aspirin derivative (ACS14) was compared with its mother compound, 
      aspirin. In comparison to an equimolar dose of aspirin, ACS14 not only exerted a 
      more potent inhibitory effect on platelet aggregation induced by ADP or thrombin, 
      but also significantly inhibited αIIbβ3 integrin activation and P-selectin 
      expression. Similarly, NaHS (100μM), a conventional H2S donor significantly 
      inhibited platelet aggregation as well as αIIbβ3 integrin activation and 
      P-selectin expression induced by ADP or thrombin. Furthermore, pretreatment with 
      rotigaptide, a gap junction modifier abolished the inhibitory properties of ACS14 
      or NaHS on platelet aggregation, suggesting that suppression of platelet 
      aggregation by H2S is, at least in part, gap junction channel-dependent. 
      CONCLUSIONS: H2S may inhibit human platelet aggregation at least in part by 
      depressing gap junction intercellular communication and H2S released from ACS14 
      may contribute to its additional anti-platelet effect in vitro in comparison to 
      aspirin.
CI  - Copyright © 2014 Australian and New Zealand Society of Cardiac and Thoracic 
      Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). 
      Published by Elsevier B.V. All rights reserved.
FAU - Gao, Lin
AU  - Gao L
AD  - Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai JiaoTong 
      University School of Medicine, Shanghai, China.
FAU - Cheng, Chun
AU  - Cheng C
AD  - Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai JiaoTong 
      University School of Medicine, Shanghai, China.
FAU - Sparatore, Anna
AU  - Sparatore A
AD  - Dipartimento di Scienze Farmaceutiche "Pietro Pratesi", Università degli Studi di 
      Milano, Milano, Italy.
FAU - Zhang, Huili
AU  - Zhang H
AD  - Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai JiaoTong 
      University School of Medicine, Shanghai, China. Electronic address: 
      huili.zhang815@gmail.com.
FAU - Wang, Changqian
AU  - Wang C
AD  - Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai JiaoTong 
      University School of Medicine, Shanghai, China. Electronic address: 
      changqianwang@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140624
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
RN  - 0 (2-acetyloxybenzoic acid 4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl ester)
RN  - 0 (Disulfides)
RN  - 0 (Gasotransmitters)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Adult
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Platelets/*metabolism
MH  - Disulfides/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gap Junctions/*metabolism
MH  - Gasotransmitters/*pharmacology
MH  - Humans
MH  - Hydrogen Sulfide/*pharmacology
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
OTO - NOTNLM
OT  - ACS14
OT  - Aspirin
OT  - Gap junction
OT  - Hydrogen sulfide
OT  - Platelet aggregation
EDAT- 2014/07/23 06:00
MHDA- 2015/08/05 06:00
CRDT- 2014/07/23 06:00
PHST- 2014/03/02 00:00 [received]
PHST- 2014/05/24 00:00 [revised]
PHST- 2014/05/27 00:00 [accepted]
PHST- 2014/07/23 06:00 [entrez]
PHST- 2014/07/23 06:00 [pubmed]
PHST- 2015/08/05 06:00 [medline]
AID - S1443-9506(14)00515-0 [pii]
AID - 10.1016/j.hlc.2014.05.019 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2015 Jan;24(1):77-85. doi: 10.1016/j.hlc.2014.05.019. Epub 2014 
      Jun 24.

PMID- 23352527
OWN - NLM
STAT- MEDLINE
DCOM- 20130402
LR  - 20181202
IS  - 1534-4436 (Electronic)
IS  - 1081-1206 (Linking)
VI  - 110
IP  - 2
DP  - 2013 Feb
TI  - Characterization of aspirin allergies in patients with coronary artery disease.
PG  - 92-5
LID - S1081-1206(12)00938-6 [pii]
LID - 10.1016/j.anai.2012.11.013 [doi]
AB  - BACKGROUND: Aspirin prevents coronary thrombosis and is used extensively in 
      cardiovascular prophylaxis. However, patients with a prior history of an aspirin 
      "reaction" are routinely denied this medication. OBJECTIVE: To characterize the 
      clinical presentation of a cohort of patients with coronary artery disease (CAD) 
      and aspirin reactions. METHODS: Between 2009 and 2012, using a retrospective 
      computer analysis, information was collected on all patients within a county-wide 
      health care system presenting with CAD and a prior history of aspirin reactions. 
      RESULTS: Of 9,565 patients with CAD, a prior history of aspirin reactions was 
      recorded in 142 patients. Of these 142 patients, 30 (21%) had histories 
      compatible with cutaneous and/or respiratory reactions. The other patients 
      described adverse effects to aspirin, mostly gastrointestinal intolerance and 
      bleeding. Aspirin-induced anaphylaxis was recorded in patients but may have been 
      misdiagnosed, describing instead respiratory hypersensitivity reactions. Of the 
      142 patients, only 34 (24%) were receiving daily cardiovascular prophylaxis with 
      aspirin. Of 108 patients not receiving aspirin, 25 (17.6%) were prescribed 
      clopidogrel. CONCLUSION: Histories of aspirin reactions in patients with CAD are 
      uncommon, occurring in only 1.5% of our study population. The 21% of patients 
      with histories compatible with aspirin hypersensitivities can be challenged and, 
      if the results are positive, successfully desensitized. Moreover, almost all 
      patients with gastric intolerance to aspirin can be treated with aspirin and a 
      proton pump inhibitor. However, both approaches, which result in restoration of 
      cardiovascular prophylaxis, were seriously underused in our study population.
CI  - Copyright © 2013 American College of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Feng, Charles H
AU  - Feng CH
AD  - Department of Internal Medicine, Scripps Green Hospital, La Jolla, California, 
      USA. cfeng622@gmail.com
FAU - White, Andrew A
AU  - White AA
FAU - Stevenson, Donald D
AU  - Stevenson DD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/immunology/therapeutic use
MH  - California/epidemiology
MH  - Cardiovascular Diseases/drug therapy/epidemiology/prevention & control
MH  - Clopidogrel
MH  - Coronary Artery Disease/epidemiology/*immunology
MH  - Drug Hypersensitivity/epidemiology/*immunology
MH  - Female
MH  - Humans
MH  - Male
MH  - Retrospective Studies
MH  - Ticlopidine/analogs & derivatives/therapeutic use
EDAT- 2013/01/29 06:00
MHDA- 2013/04/03 06:00
CRDT- 2013/01/29 06:00
PHST- 2012/09/19 00:00 [received]
PHST- 2012/11/11 00:00 [revised]
PHST- 2012/11/17 00:00 [accepted]
PHST- 2013/01/29 06:00 [entrez]
PHST- 2013/01/29 06:00 [pubmed]
PHST- 2013/04/03 06:00 [medline]
AID - S1081-1206(12)00938-6 [pii]
AID - 10.1016/j.anai.2012.11.013 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2013 Feb;110(2):92-5. doi: 
      10.1016/j.anai.2012.11.013.

PMID- 32780215
OWN - NLM
STAT- MEDLINE
DCOM- 20211026
LR  - 20211026
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 21
IP  - 2
DP  - 2021 Mar
TI  - Toward Brief Dual Antiplatelet Therapy and P2Y12 Inhibitors for Monotherapy After 
      PCI.
PG  - 153-163
LID - 10.1007/s40256-020-00430-0 [doi]
AB  - The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous 
      coronary intervention remains a controversial topic. The European Society of 
      Cardiology and the American College of Cardiology/American Heart Association 
      recommend at least 6 and 12 months of DAPT after PCI in patients with stable 
      coronary artery disease or acute coronary syndrome, respectively. Although 
      prolonging DAPT duration reduces ischemic events, it is associated with higher 
      rates of bleeding and possible fatal outcomes. The DAPT score can be an important 
      tool to identify patients who may still benefit from prolonged therapy. 
      Nevertheless, several recent randomized controlled trials showed that shortening 
      DAPT duration from 12 to 1-3 months reduces bleeding rates without significantly 
      increasing ischemic event rates. These trials also suggested replacing 
      acetylsalicylic acid (aspirin) with P2Y12 inhibitors after short-term DAPT. We 
      review and compare past and present studies regarding DAPT and analyze the 
      evidence favoring a short DAPT duration and the long-term single antiplatelet 
      agent of choice.
FAU - Ayoub, Ali
AU  - Ayoub A
AUID- ORCID: 0000-0002-6508-5397
AD  - Tulane University Heart and Vascular Institute, 1415 Tulane Ave, New Orleans, LA, 
      70112, USA. Aayoub1@tulane.edu.
FAU - Ayinapudi, Karnika
AU  - Ayinapudi K
AUID- ORCID: 0000-0001-8623-7452
AD  - Tulane University Heart and Vascular Institute, 1415 Tulane Ave, New Orleans, LA, 
      70112, USA.
FAU - Al-Ogaili, Ahmed
AU  - Al-Ogaili A
AUID- ORCID: 0000-0002-1481-8044
AD  - Department of Cardiology, John H. Stroger, Jr. Hospital of Cook County, Chicago, 
      IL, USA.
FAU - Panhwar, Muhammad Siyab
AU  - Panhwar MS
AUID- ORCID: 0000-0002-8338-7524
AD  - Tulane University Heart and Vascular Institute, 1415 Tulane Ave, New Orleans, LA, 
      70112, USA.
FAU - Dakkak, Wael
AU  - Dakkak W
AD  - Department of Medicine, Southern Illinois University, Springfield, IL, USA.
FAU - LeJemtel, Thierry
AU  - LeJemtel T
AUID- ORCID: 0000-0003-3315-6880
AD  - Tulane University Heart and Vascular Institute, 1415 Tulane Ave, New Orleans, LA, 
      70112, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Administration Schedule
MH  - Dual Anti-Platelet Therapy/adverse effects/*methods
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stents/adverse effects
EDAT- 2020/08/12 06:00
MHDA- 2021/10/27 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/10/27 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - 10.1007/s40256-020-00430-0 [pii]
AID - 10.1007/s40256-020-00430-0 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2021 Mar;21(2):153-163. doi: 10.1007/s40256-020-00430-0.

PMID- 1993037
OWN - NLM
STAT- MEDLINE
DCOM- 19910308
LR  - 20190704
IS  - 0003-9950 (Print)
IS  - 0003-9950 (Linking)
VI  - 109
IP  - 2
DP  - 1991 Feb
TI  - Low-dose aspirin and risks of cataract in a randomized trial of US physicians.
PG  - 252-5
AB  - Observational studies have raised the question of a possible benefit of aspirin 
      on the development of cataract. The Physicians' Health Study, a randomized 
      double-masked placebo-controlled trial among 22,071 male physicians, aged 40 to 
      84 years, provided the opportunity to collect information about whether low-dose 
      aspirin therapy (325 mg on alternate days) affects the development or extraction 
      of cataract. There were 173 age-related cataracts among those physicians assigned 
      to aspirin therapy and 180 among those given placebo (relative risk, 0.95; 95% 
      confidence interval, 0.74 to 1.22). Cataract extractions were less frequent in 
      the aspirin than in the placebo group, but this difference was not statistically 
      significant (relative risk, 0.80; 95% confidence interval, 0.56 to 1.15). Among 
      younger men (aged 40 to 59 years), the relative risks were 0.62 (95% confidence 
      interval, 0.40 to 0.94) for cataract development and 0.67 (95% confidence 
      interval, 0.38 to 1.31) for cataract extraction. These randomized trial data tend 
      to exclude any large benefit of aspirin. While the overall findings concerning 
      cataract development seem to be null, the data on extraction of age-related 
      cataract, while not statistically significant, cannot exclude a possible small to 
      moderate benefit of alternate-day aspirin therapy on the extraction of 
      age-related cataract.
FAU - Seddon, J M
AU  - Seddon JM
AD  - Epidemiology Unit, Massachusetts Eye and Ear Infirmary, Boston.
FAU - Christen, W G
AU  - Christen WG
FAU - Manson, J E
AU  - Manson JE
FAU - Buring, J E
AU  - Buring JE
FAU - Sperduto, R D
AU  - Sperduto RD
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA 40360/CA/NCI NIH HHS/United States
GR  - EY 06633/EY/NEI NIH HHS/United States
GR  - HL 34595/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Ophthalmol
JT  - Archives of ophthalmology (Chicago, Ill. : 1960)
JID - 7706534
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Ophthalmol. 1991 Oct;109(10):1344-5. PMID: 1929911
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cataract/epidemiology/*prevention & control
MH  - Cataract Extraction
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physicians
MH  - Placebos
MH  - Risk Factors
MH  - United States/epidemiology
EDAT- 1991/02/01 00:00
MHDA- 1991/02/01 00:01
CRDT- 1991/02/01 00:00
PHST- 1991/02/01 00:00 [pubmed]
PHST- 1991/02/01 00:01 [medline]
PHST- 1991/02/01 00:00 [entrez]
AID - 10.1001/archopht.1991.01080020098052 [doi]
PST - ppublish
SO  - Arch Ophthalmol. 1991 Feb;109(2):252-5. doi: 
      10.1001/archopht.1991.01080020098052.

PMID- 34979192
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220407
IS  - 1872-9711 (Electronic)
IS  - 0161-813X (Linking)
VI  - 89
DP  - 2022 Mar
TI  - Aspirin ameliorates the cognition impairment in mice following benzo[a]pyrene 
      treatment via down-regulating BDNF IV methylation.
PG  - 20-30
LID - S0161-813X(21)00170-4 [pii]
LID - 10.1016/j.neuro.2021.12.008 [doi]
AB  - Benzo[a]pyrene (B[a]P) is neurotoxic, however, the mechanisms remain unclear and 
      there is no effective prevention. Available evidence suggests a role of DNA 
      methylation in B[a]P-induced neurotoxicity. This study investigated the 
      brain-derived neurotrophic factor (BDNF) IV methylation in the development of and 
      aspirin intervention against B[a]P's neurotoxicity in mice and HT22 cells. Mice 
      were intraperitoneally treated with solvent or B[a]P (0.5, 2, and 10 mg/kg b.w.) 
      for 60 days. An intervention group was treated simultaneously with B[a]P (10 
      mg/kg, i.p.) and aspirin (10 mg/kg, daily water-drinking). The treated mice 
      showed a dose-dependent cognitive and behavioral impairment, and cerebral cell 
      apoptosis, which were alleviated by aspirin co-treatment. Following B[a]P 
      treatment, DNA methyltransferase (DNMTs) and BDNF IV hypermethylation were 
      increased in the cerebral cortex of mice compared to controls, while significant 
      decreases were found in BDNF IV and BDNF mRNA, and BDNF protein levels. Aspirin 
      co-treatment rescued DNMTs activation and BDNF IV hypermethylation, and mitigated 
      the recession in BDNF mRNA and protein induced by B[a]P treatment. Similar 
      results were shown in HT22 cells. These findings reveal a critical role of BDNF 
      IV methylation in the neurotoxicity of B[a]P, and demonstrate a promising 
      prevention of aspirin against B[a]P-induced cognitive impairment via inhibiting 
      BDNF IV hypermethylation.
CI  - Copyright © 2021. Published by Elsevier B.V.
FAU - Li, Yangyang
AU  - Li Y
AD  - Department of Environmental Health, School of Public Health, Shanxi Medical 
      University, Taiyuan, 030001, Shanxi, China.
FAU - Cao, Jingjing
AU  - Cao J
AD  - Department of Environmental Health, School of Public Health, Shanxi Medical 
      University, Taiyuan, 030001, Shanxi, China.
FAU - Hao, Zhongsuo
AU  - Hao Z
AD  - Department of Environmental Health, School of Public Health, Shanxi Medical 
      University, Taiyuan, 030001, Shanxi, China.
FAU - Liu, Aixiang
AU  - Liu A
AD  - Department of Environmental Health, School of Public Health, Shanxi Medical 
      University, Taiyuan, 030001, Shanxi, China.
FAU - Li, Xin
AU  - Li X
AD  - Center of Disease Control and Prevention, Taiyuan Iron and Steel Company, 
      Taiyuan, 030003, Shanxi, China.
FAU - Li, Huan
AU  - Li H
AD  - Department of Environmental Health, School of Public Health, Shanxi Medical 
      University, Taiyuan, 030001, Shanxi, China.
FAU - Xia, Na
AU  - Xia N
AD  - Department of Environmental Health, School of Public Health, Shanxi Medical 
      University, Taiyuan, 030001, Shanxi, China.
FAU - Wang, Zemin
AU  - Wang Z
AD  - Laboratory of Investigative Toxicology and Pathology, Department of Environmental 
      Health, Indiana University School of Public Health, 1025 E 7th St, Bloomington, 
      IN, 47405, USA.
FAU - Zhang, Zhihong
AU  - Zhang Z
AD  - Department of Environmental Health, School of Public Health, Shanxi Medical 
      University, Taiyuan, 030001, Shanxi, China.
FAU - Bai, Jianying
AU  - Bai J
AD  - Department of Environmental Health, School of Public Health, Shanxi Medical 
      University, Taiyuan, 030001, Shanxi, China.
FAU - Zhang, Hongmei
AU  - Zhang H
AD  - Department of Environmental Health, School of Public Health, Shanxi Medical 
      University, Taiyuan, 030001, Shanxi, China; Key Laboratory of Cellular Physiology 
      (Shanxi Medical University), Ministry of Education, Taiyuan, 030001, Shanxi, 
      China; Key Laboratory of Cellular Physiology, Shanxi Province, Taiyuan, 030001, 
      Shanxi, China; Department of Physiology, Shanxi Medical University, Taiyuan, 
      030001, Shanxi, China. Electronic address: hm.zhang@sxmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211231
PL  - Netherlands
TA  - Neurotoxicology
JT  - Neurotoxicology
JID - 7905589
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 3417WMA06D (Benzo(a)pyrene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/metabolism/pharmacology
MH  - Benzo(a)pyrene/metabolism/toxicity
MH  - *Brain-Derived Neurotrophic Factor/metabolism
MH  - Cognition
MH  - *Cognitive Dysfunction/metabolism
MH  - DNA Methylation
MH  - Hippocampus
MH  - Mice
OTO - NOTNLM
OT  - Aspirin
OT  - Benzo[a]pyrene
OT  - Brain-derived neurotrophic factor
OT  - Cognitive impairment
OT  - DNA methylation
EDAT- 2022/01/04 06:00
MHDA- 2022/04/08 06:00
CRDT- 2022/01/03 20:13
PHST- 2021/10/03 00:00 [received]
PHST- 2021/12/14 00:00 [revised]
PHST- 2021/12/29 00:00 [accepted]
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
PHST- 2022/01/03 20:13 [entrez]
AID - S0161-813X(21)00170-4 [pii]
AID - 10.1016/j.neuro.2021.12.008 [doi]
PST - ppublish
SO  - Neurotoxicology. 2022 Mar;89:20-30. doi: 10.1016/j.neuro.2021.12.008. Epub 2021 
      Dec 31.

PMID- 24384107
OWN - NLM
STAT- MEDLINE
DCOM- 20140224
LR  - 20181202
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 127
IP  - 1
DP  - 2014 Jan
TI  - Prevalence of high on-treatment platelet reactivity in diabetic patients treated 
      with aspirin.
PG  - 95.e1-9
LID - S0002-9343(13)00843-7 [pii]
LID - 10.1016/j.amjmed.2013.09.019 [doi]
AB  - BACKGROUND: Randomized controlled trials have shown that ≤ 100 mg aspirin daily 
      is not effective for primary prevention of cardiovascular events in diabetes; 
      however, clinical and pharmacologic evidence suggests these patients need >100 mg 
      for adequate antiplatelet activity. Although high on-treatment platelet 
      reactivity (HTPR) could explain the lack of benefit, prevalence of HTPR in 
      diabetes is not known. This systematic review examined the relationship between 
      daily aspirin dose and prevalence of HTPR in patients with diabetes. METHODS: 
      Three electronic databases were searched until May 2013 using 
      database-appropriate terms for aspirin, resistance, and diabetes. Studies were 
      included if prevalence of HTPR was reported according to daily dose and diabetes 
      status. Patients were stratified by daily aspirin dose and the weighted mean 
      prevalence across studies was calculated. Where appropriate, pooled relative 
      risks (RR) were calculated using a random-effects model. RESULTS: Data were 
      available from 31 studies that enrolled 2147 diabetic patients. Overall, 
      prevalence of HTPR was 21.9% (95% confidence interval [CI], 15.2%-28.5%) in 
      diabetic patients and 15.8% (95% CI, 11.4%-20.3%) in nondiabetic patients (pooled 
      RR 1.36; 95% CI, 1.08-1.71; I(2) 56%). Prevalence appeared to be dose related, 
      with 398 (23.6%) of 1689 diabetic patients using ≤ 100 mg daily having HTPR 
      compared with 64 (12.3%) of 518 diabetic patients using 101-325 mg daily (pooled 
      RR 1.70; 95% CI, 1.07-2.72; I(2) 0%). CONCLUSIONS: Although these observations 
      should be verified in a clinical trial, the possibility that 1 in 4 patients have 
      HTPR with doses commonly used in diabetes could have significant implications on 
      overall effectiveness of aspirin.
CI  - Copyright © 2014 Elsevier Inc. All rights reserved.
FAU - Simpson, Scot H
AU  - Simpson SH
AD  - Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Canada. Electronic address: scot@ualberta.ca.
FAU - Abdelmoneim, Ahmed S
AU  - Abdelmoneim AS
AD  - Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Canada.
FAU - Omran, Dima
AU  - Omran D
AD  - Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Canada.
FAU - Featherstone, Travis R
AU  - Featherstone TR
AD  - Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20131008
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Complications/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Humans
MH  - Medical Records Systems, Computerized
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Prevalence
MH  - Primary Prevention/*methods
OTO - NOTNLM
OT  - Aspirin
OT  - Diabetes
OT  - Drug resistance
OT  - Systematic review
EDAT- 2014/01/05 06:00
MHDA- 2014/02/25 06:00
CRDT- 2014/01/04 06:00
PHST- 2013/07/03 00:00 [received]
PHST- 2013/09/20 00:00 [revised]
PHST- 2013/09/23 00:00 [accepted]
PHST- 2014/01/04 06:00 [entrez]
PHST- 2014/01/05 06:00 [pubmed]
PHST- 2014/02/25 06:00 [medline]
AID - S0002-9343(13)00843-7 [pii]
AID - 10.1016/j.amjmed.2013.09.019 [doi]
PST - ppublish
SO  - Am J Med. 2014 Jan;127(1):95.e1-9. doi: 10.1016/j.amjmed.2013.09.019. Epub 2013 
      Oct 8.

PMID- 6144975
OWN - NLM
STAT- MEDLINE
DCOM- 19840716
LR  - 20220330
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 8389
DP  - 1984 Jun 9
TI  - Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects 
      on platelet aggregation and thromboxane formation.
PG  - 1261-4
AB  - Prevention of aortocoronary bypass occlusion by aspirin (ASA, 1 X 100 mg per day) 
      was studied in a prospective double-blind trial of 83 patients. 60 (72%) were 
      randomly allocated to ASA or placebo starting 24 h after operation. 90% of grafts 
      in the ASA group and 68% in the placebo group were patent at four months. At 
      least one anastomosis was occluded in 62% of the patients on placebo and in 27% 
      of those on aspirin. Ventricular arrhythmias increased after surgery in more 
      patients on placebo (12/18) than in patients on ASA (5/17). Platelet thromboxane 
      formation on collagen tested before operation was significantly higher in 
      patients in whom bypass occlusion developed (occlusion: 40 +/- 19, no occlusion: 
      25 +/- 13 ng/ml). A 100 mg dose of ASA per day effectively blocked platelet 
      thromboxane formation and thromboxane-supported aggregation on collagen and was 
      safe in the postoperative phase. No side effects were reported throughout the 
      trial. The reduced toxicity with full efficacy favours a low and infrequent 
      dosage of aspirin.
FAU - Lorenz, R L
AU  - Lorenz RL
FAU - Schacky, C V
AU  - Schacky CV
FAU - Weber, M
AU  - Weber M
FAU - Meister, W
AU  - Meister W
FAU - Kotzur, J
AU  - Kotzur J
FAU - Reichardt, B
AU  - Reichardt B
FAU - Theisen, K
AU  - Theisen K
FAU - Weber, P C
AU  - Weber PC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/metabolism
MH  - Clinical Trials as Topic
MH  - *Coronary Artery Bypass
MH  - Double-Blind Method
MH  - Female
MH  - Graft Survival
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Prospective Studies
MH  - Random Allocation
MH  - Thromboxanes/*biosynthesis
EDAT- 1984/06/09 00:00
MHDA- 1984/06/09 00:01
CRDT- 1984/06/09 00:00
PHST- 1984/06/09 00:00 [pubmed]
PHST- 1984/06/09 00:01 [medline]
PHST- 1984/06/09 00:00 [entrez]
AID - S0140-6736(84)92446-2 [pii]
AID - 10.1016/s0140-6736(84)92446-2 [doi]
PST - ppublish
SO  - Lancet. 1984 Jun 9;1(8389):1261-4. doi: 10.1016/s0140-6736(84)92446-2.

PMID- 21985823
OWN - NLM
STAT- MEDLINE
DCOM- 20120207
LR  - 20211020
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 134
IP  - 3
DP  - 2011 Sep
TI  - Antiarthritic activity of majoon suranjan (a polyherbal Unani formulation) in 
      rat.
PG  - 384-8
AB  - BACKGROUND & OBJECTIVES: Majoon Suranjan (MS) is a polyherbal formulation used in 
      Unani system of medicine for the treatment of rheumatoid arthritis (RA). The 
      present study evaluates the antiarthritic efficacy of this formulation in three 
      different experimental models. METHODS: The anti-inflammatory activity of MS (in 
      doses of 450, 900 and 1800 mg/kg body wt) was evaluated using the turpentine oil 
      induced paw oedema model and the antiarthritic efficacy was evaluated using the 
      formaldehyde and complete Freund's adjuvant (CFA) induced arthritis models. 
      Aspirin (100 mg/kg body wt) was used as the standard drug in all the models. In 
      order to assess the safety of the test drug, oral acute and 28 day toxicity 
      studies were also carried out. RESULTS: MS produced a dose dependent protective 
      effect in all the experimental models. Its antiarthritic efficacy was comparable 
      to aspirin in formaldehyde induced arthritis and was superior to aspirin in 
      turpentine oil induced paw oedema and CFA induced arthritis. MS also inhibited 
      the delayed increase in joint diameter as seen in control and aspirin treated 
      animals in CFA induced arthritis. Oral LD 50 of MS was found to be >5000 mg/kg in 
      rats. Chronic administration did not produce any significant physiological 
      changes in the tested animals. INTERPRETATION & CONCLUSIONS: Results of the 
      present study suggest that the antiarthritic activity of MS was due to the 
      interplay between its anti-inflammatory and disease modifying activities, thus 
      supporting its use in traditional medicine for the treatment of RA.
FAU - Singh, Surender
AU  - Singh S
AD  - Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 
      India. surenderaiims@gmail.com
FAU - Nair, Vinod
AU  - Nair V
FAU - Gupta, Y K
AU  - Gupta YK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (Plant Extracts)
RN  - 1HG84L3525 (Formaldehyde)
RN  - R16CO5Y76E (Aspirin)
RN  - XJ6RUH0O4G (Turpentine)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Arthritis, Experimental/*drug therapy
MH  - Aspirin/administration & dosage/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Formaldehyde
MH  - Male
MH  - *Medicine, Unani
MH  - Phytotherapy/*methods
MH  - Plant Extracts/*pharmacology/toxicity
MH  - Rats
MH  - Rats, Wistar
MH  - Toxicity Tests
MH  - Turpentine
PMC - PMC3193721
COIS- Conflict of Interest: None to declare.
EDAT- 2011/10/12 06:00
MHDA- 2012/02/09 06:00
CRDT- 2011/10/12 06:00
PHST- 2011/10/12 06:00 [entrez]
PHST- 2011/10/12 06:00 [pubmed]
PHST- 2012/02/09 06:00 [medline]
AID - IndianJMedRes_2011_134_3_384_85585 [pii]
AID - IJMR-134-384 [pii]
PST - ppublish
SO  - Indian J Med Res. 2011 Sep;134(3):384-8.

PMID- 14752603
OWN - NLM
STAT- MEDLINE
DCOM- 20040608
LR  - 20181113
VI  - 15
IP  - 1
DP  - 2004 Jan-Feb
TI  - Gauze packing for aspirin-induced hemorrhage in vaginal hysterectomy.
PG  - 59-60
AB  - Intra-abdominal packing has been used to control massive hemorrhage in many 
      difficult situations. Gynecologists are finding it increasingly useful in 
      controlling persistent hemorrhage in a variety of situations. Recently we found 
      it necessary to use packing for persistent brisk bleeding during 'vaginal 
      hysterectomy' in a patient on aspirin therapy for heart disease. We could find no 
      similar report in the literature and now describe our experience.
FAU - Ramsewak, Samuel
AU  - Ramsewak S
AD  - Department of Obstetrics and Gynaecology, Medical Associates Hospital, University 
      of the West Indies, Cor. Albert & Abercromby Streets, Trinidad, West Indies.
FAU - Sohan, Karen
AU  - Sohan K
FAU - Ramdass, Michael J
AU  - Ramdass MJ
FAU - Naraynsingh, Vijay
AU  - Naraynsingh V
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20040109
PL  - England
TA  - Int Urogynecol J Pelvic Floor Dysfunct
JT  - International urogynecology journal and pelvic floor dysfunction
JID - 9514583
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - *Bandages
MH  - Female
MH  - Humans
MH  - Hysterectomy/*adverse effects
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Postoperative Hemorrhage/*therapy
MH  - Uterine Hemorrhage/etiology/*therapy
MH  - Vagina
EDAT- 2004/01/31 05:00
MHDA- 2004/06/21 10:00
CRDT- 2004/01/31 05:00
PHST- 2003/06/18 00:00 [received]
PHST- 2003/11/19 00:00 [accepted]
PHST- 2004/01/31 05:00 [pubmed]
PHST- 2004/06/21 10:00 [medline]
PHST- 2004/01/31 05:00 [entrez]
AID - 10.1007/s00192-003-1116-6 [doi]
PST - ppublish
SO  - Int Urogynecol J Pelvic Floor Dysfunct. 2004 Jan-Feb;15(1):59-60. doi: 
      10.1007/s00192-003-1116-6. Epub 2004 Jan 9.

PMID- 29913174
OWN - NLM
STAT- MEDLINE
DCOM- 20190812
LR  - 20190812
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 219
IP  - 4
DP  - 2018 Oct
TI  - Low-dose aspirin is associated with reduced spontaneous preterm birth in 
      nulliparous women.
PG  - 399.e1-399.e6
LID - S0002-9378(18)30498-8 [pii]
LID - 10.1016/j.ajog.2018.06.011 [doi]
AB  - BACKGROUND: Preterm birth is one of the leading causes of perinatal morbidity and 
      mortality. Clinical data suggest that low-dose aspirin may decrease the rate of 
      overall preterm birth, but investigators have speculated that this is likely due 
      to a decrease in medically indicated preterm birth through its effect on the 
      incidence of preeclampsia and other placental disease. We hypothesized that 
      low-dose aspirin may also have an impact on the mechanism of spontaneous preterm 
      labor. OBJECTIVE: Our objective was to determine whether low-dose aspirin reduces 
      the rate of spontaneous preterm birth in nulliparous women without medical 
      comorbidities. STUDY DESIGN: This is a secondary analysis of a randomized, 
      placebo-controlled trial of low-dose aspirin for the prevention of preeclampsia 
      in healthy, low-risk, nulliparous women. Low-risk women were defined by the 
      absence of hypertension, renal disease, diabetes, other endocrine disorders, 
      seizures, heart disease, or collagen vascular disease. Our study was limited to 
      singleton, nonanomalous gestations. Women were eligible if they had prior 
      pregnancy terminations but not prior spontaneous pregnancy loss <20 weeks. 
      Current pregnancies that resulted in a loss or termination <20 weeks or 
      antepartum stillbirth or had missing follow-up data were excluded. The treatment 
      intervention was 60 mg of aspirin, initiated at 13-25 weeks' gestation or 
      matching placebo. The primary outcome was spontaneous preterm birth <34 weeks' 
      gestation. Secondary outcomes included spontaneous preterm birth <37 weeks and 
      overall preterm birth <37 and <34 weeks. Baseline demographics and primary and 
      secondary outcomes were compared between treatment groups. A logistic regression 
      model was used to adjust for confounders related to spontaneous preterm birth. 
      RESULTS: Of 2543 included women, 1262 (49.6%) received low-dose aspirin and 1281 
      (50.4%) placebo. Baseline characteristics were similar between groups, except for 
      marital status. The rate of spontaneous preterm birth <34 weeks was 1.03% (n = 
      13) and 2.34% (n = 30) in the low-dose aspirin and placebo group, respectively 
      (odds ratio, 0.43, 95% confidence interval, 0.26-0.84). Additionally, the rate of 
      spontaneous preterm birth <37 weeks was 6.58% (n = 83) in the low-dose aspirin 
      group and 7.03% (n = 90) in the placebo group (odds ratio, 0.97, 95% confidence 
      interval, 0.71-1.33), and the rate of overall preterm birth <37 weeks was 7.84% 
      (n = 99) in the low-dose aspirin group and 8.2% (n = 105) in the placebo group 
      (odds ratio, 0.97, 95% confidence interval, 0.72-1.31). After adjustment for 
      variables that were clinically relevant or statistically significant, including 
      body mass index, race, tobacco use, marital status, and education level, there 
      was a significant reduction in spontaneous preterm birth <34 weeks in the 
      low-dose aspirin group (adjusted odds ratio, 0.46, 95% confidence interval, 
      0.23-0.89). The rates of overall preterm birth <34 and <37 weeks and spontaneous 
      preterm birth <37 weeks were similar in women who received low-dose aspirin 
      compared with placebo. CONCLUSION: Low-dose aspirin is associated with a 
      substantial decrease in spontaneous preterm birth <34 weeks in healthy 
      nulliparous women without comorbidities. These findings suggest a new therapeutic 
      option for preterm birth prevention that requires further study.
CI  - Copyright © 2018. Published by Elsevier Inc.
FAU - Andrikopoulou, Maria
AU  - Andrikopoulou M
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Columbia University Medical Center, New York, NY.
FAU - Purisch, Stephanie E
AU  - Purisch SE
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Columbia University Medical Center, New York, NY.
FAU - Handal-Orefice, Roxane
AU  - Handal-Orefice R
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Columbia University Medical Center, New York, NY.
FAU - Gyamfi-Bannerman, Cynthia
AU  - Gyamfi-Bannerman C
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Columbia University Medical Center, New York, NY. Electronic address: 
      cg2231@cumc.columbia.edu.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20180618
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
CIN - Evid Based Nurs. 2019 Jul;22(3):82-83. PMID: 31147347
MH  - Administration, Oral
MH  - Adolescent
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Parity
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pre-Eclampsia/*drug therapy
MH  - Pregnancy
MH  - Premature Birth/*prevention & control
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - low-dose aspirin
OT  - nulliparous
OT  - placental disease
OT  - platelet aggregation
OT  - preeclampsia
OT  - preterm birth
OT  - spontaneous preterm birth
OT  - uteroplacental ischemia
EDAT- 2018/06/19 06:00
MHDA- 2019/08/14 06:00
CRDT- 2018/06/19 06:00
PHST- 2018/03/01 00:00 [received]
PHST- 2018/06/03 00:00 [revised]
PHST- 2018/06/09 00:00 [accepted]
PHST- 2018/06/19 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2018/06/19 06:00 [entrez]
AID - S0002-9378(18)30498-8 [pii]
AID - 10.1016/j.ajog.2018.06.011 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2018 Oct;219(4):399.e1-399.e6. doi: 
      10.1016/j.ajog.2018.06.011. Epub 2018 Jun 18.

PMID- 781501
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20131121
IS  - 0025-8458 (Print)
IS  - 0025-8458 (Linking)
VI  - 71
IP  - 30
DP  - 1976 Jul 23
TI  - [Gastric tolerance of different preparations of acetylsalicylic acid in 
      postoperative prevention of thrombo-embolism (author's transl)].
PG  - 1235-8
AB  - The necessity for thrombosis-prophylaxis is indisputable. The evaluation of our 
      patients over a period of 2 years revealed results compatible with other authors. 
      Due to its thrombocyte desaggregating action, acetyl-salicylic acid was found to 
      have a definite effect on the thrombophilia by inhibiting the thrombocyte 
      adhesiveness in a beginning thrombosis. It was shown that acetylsalicylic acid in 
      combination with glycocoll is apparently superior to microencapsulated acetylic 
      acid in terms of gastric tolerance. In a small number of patients the therapeutic 
      efficiency was investigated and according to the platelets agglutination test, 
      verified. Further investigations are planned in a major series of patients where 
      acetylsalicylic acid with glycocoll was administered in respect to the treatment 
      of rheumatic fever.
FAU - Knote, G
AU  - Knote G
FAU - Vielsäcker, H
AU  - Vielsäcker H
FAU - Mappes, G
AU  - Mappes G
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Verträglichkeit verschiedener Acetylsalicylsäurepräparate in der 
      Thromboseprophylaxe.
PL  - Germany
TA  - Med Klin
JT  - Medizinische Klinik
JID - 0376637
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Aspirin/*adverse effects/pharmacology
MH  - Biological Availability
MH  - Clinical Trials as Topic
MH  - Delayed-Action Preparations
MH  - Drug Combinations
MH  - Drug Compounding
MH  - Drug Tolerance
MH  - Gastric Mucosa/drug effects
MH  - Glycine/therapeutic use
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Postoperative Care
MH  - Retrospective Studies
MH  - Thromboembolism/*prevention & control
EDAT- 1976/07/23 00:00
MHDA- 2000/03/22 09:00
CRDT- 1976/07/23 00:00
PHST- 1976/07/23 00:00 [pubmed]
PHST- 2000/03/22 09:00 [medline]
PHST- 1976/07/23 00:00 [entrez]
PST - ppublish
SO  - Med Klin. 1976 Jul 23;71(30):1235-8.

PMID- 1133721
OWN - NLM
STAT- MEDLINE
DCOM- 19750905
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 64
IP  - 6
DP  - 1975 Jun
TI  - Automated high-pressure liquid chromatographic analysis of aspirin, phenacetin, 
      and caffeine.
PG  - 1029-33
AB  - An automated high-pressure liquid chromatographic (HPLC) method for the 
      separation and determination of aspirin, phenacetin, and caffeine in 
      pharmaceutical dosage forms is descreibed. Separation of these compounds for 
      quantitation is achieved on a controlled pore glass support, utilizing a mixture 
      of acetic acid and chloroform as the mobile phase. The method is specific, 
      accurate, and simple and provides for the quantitation of each chromatogram in a 
      continuous fashion every 7 min. HPLC separation of other analgesics was studied 
      on a spherical siliceous support. The feasibility of determining free salicylic 
      acid in analgesics also was established.
FAU - Ascione, P P
AU  - Ascione PP
FAU - Chrekian, G P
AU  - Chrekian GP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Autoanalysis/instrumentation
MH  - Caffeine/*analysis
MH  - Chromatography/methods
MH  - Phenacetin/*analysis
EDAT- 1975/06/01 00:00
MHDA- 1975/06/01 00:01
CRDT- 1975/06/01 00:00
PHST- 1975/06/01 00:00 [pubmed]
PHST- 1975/06/01 00:01 [medline]
PHST- 1975/06/01 00:00 [entrez]
AID - S0022-3549(15)40257-6 [pii]
AID - 10.1002/jps.2600640633 [doi]
PST - ppublish
SO  - J Pharm Sci. 1975 Jun;64(6):1029-33. doi: 10.1002/jps.2600640633.

PMID- 10952521
OWN - NLM
STAT- MEDLINE
DCOM- 20001107
LR  - 20190717
IS  - 0003-2700 (Print)
IS  - 0003-2700 (Linking)
VI  - 72
IP  - 15
DP  - 2000 Aug 1
TI  - Surface characterization of aspirin crystal planes by dynamic chemical force 
      microscopy.
PG  - 3419-22
AB  - Tapping mode (TM) atomic force microscopy (AFM) has been applied in a novel 
      fashion to characterize and distinguish the (001) and (100) surfaces of 
      individual aspirin crystals. The surface characterization was achieved by 
      amplitude-phase, distance (a-p,d) measurements employing gold-coated AFM probes 
      functionalized with self-assembled monolayers (SAM). Experiments using model 
      probes coated with -CH3 and -COOH terminated SAMs have been performed on the two 
      aspirin crystal planes (001) and (100). Results indicate that the hydrophobic 
      -CH3 terminated AFM probes had a greater degree of interaction with the crystal 
      plane (001), whereas the -COOH terminated AFM probes had a larger interaction 
      with the crystal plane (100). Interpretation of these data, based upon the 
      chemistries of the probes, correlates with current understanding of the crystal 
      surface chemistry derived from X-ray diffraction data and dissolution rate 
      studies.
FAU - Danesh, A
AU  - Danesh A
AD  - Laboratory of Biophysics and Surface Analysis, School of Pharmaceutical Sciences, 
      University of Nottingham, UK.
FAU - Davies, M C
AU  - Davies MC
FAU - Hinder, S J
AU  - Hinder SJ
FAU - Roberts, C J
AU  - Roberts CJ
FAU - Tendler, S J
AU  - Tendler SJ
FAU - Williams, P M
AU  - Williams PM
FAU - Wilkins, M J
AU  - Wilkins MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Microscopy, Atomic Force/methods
MH  - Molecular Structure
EDAT- 2000/08/22 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/22 11:00
PHST- 2000/08/22 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/22 11:00 [entrez]
AID - 10.1021/ac991498u [doi]
PST - ppublish
SO  - Anal Chem. 2000 Aug 1;72(15):3419-22. doi: 10.1021/ac991498u.

PMID- 163931
OWN - NLM
STAT- MEDLINE
DCOM- 19750527
LR  - 20181203
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 231
IP  - 12
DP  - 1975 Mar 24
TI  - Increased virus shedding with aspirin treatment of rhinovirus infection.
PG  - 1248-51
AB  - In two double-blind trials, volunteers challenged with rhinovirus were treated 
      with aspirin or placebo. Aspirin treatment did not alter the rates of infection 
      or illness but was associated with a moderate reduction in the frequency or 
      severity of some symptoms. The overall benefit in rhinovirus infection was not 
      statistically significant. Aspirin treatment appeared to cause a highly 
      significant increase in the rate of virus shedding in treated subjects. The 
      increase in virus shedding must be considered an adverse event that could 
      influence the course of the disease in the individual and increase the likelihood 
      of the spread of the infection to contacts.
FAU - Stanley, E D
AU  - Stanley ED
FAU - Jackson, G G
AU  - Jackson GG
FAU - Panusarn, C
AU  - Panusarn C
FAU - Rubenis, M
AU  - Rubenis M
FAU - Dirda, V
AU  - Dirda V
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Antibodies, Viral)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Antibodies, Viral/analysis
MH  - Aspirin/*adverse effects/pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Common Cold/drug therapy/*microbiology/transmission
MH  - Guinea Pigs/immunology
MH  - Humans
MH  - Informed Consent
MH  - Nasal Mucosa/metabolism
MH  - Neutralization Tests
MH  - Placebos
MH  - Rhinovirus/drug effects/immunology/*isolation & purification
MH  - Time Factors
MH  - Virus Replication
EDAT- 1975/03/24 00:00
MHDA- 1975/03/24 00:01
CRDT- 1975/03/24 00:00
PHST- 1975/03/24 00:00 [pubmed]
PHST- 1975/03/24 00:01 [medline]
PHST- 1975/03/24 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1975 Mar 24;231(12):1248-51.

PMID- 2376250
OWN - NLM
STAT- MEDLINE
DCOM- 19900904
LR  - 20131121
IS  - 0903-1936 (Print)
IS  - 0903-1936 (Linking)
VI  - 3
IP  - 5
DP  - 1990 May
TI  - Comparison of bronchial and per oral provocation with aspirin in 
      aspirin-sensitive asthmatics.
PG  - 527-34
AB  - Oral challenge with acetylsalicylic acid was compared with inhalation of Lysine 
      acetylsalicylic acid (L-ASA) as a means to diagnose aspirin-idiosyncrasy in the 
      airways. On the basis of history and/or clinical findings (asthma, rhinorrhea, 
      nasal polyposis) 22 consecutive patients were challenged by both routes. Ten of 
      these developed significant bronchoconstriction (greater than or equal to 20% 
      drop in forced expiratory volume in one second (FEV1)) during either challenge, 
      with the same absolute sensitivity for both tests (9/10). During the bronchial 
      provocations, the reactions developed more promptly (20 min vs 1 h after 
      provocation dose) and were limited to the airways. In contrast, the reactions 
      evoked by the oral provocations were often more pronounced, longer lasting and 
      occurrence of generalized symptoms was more common. Accordingly, the oral tests 
      required more extensive drug treatment for reversal, whereas the bronchial 
      provocations always were reversed by inhalation of bronchodilators. The bronchial 
      method thus resulted in considerably shorter test sessions (4 h vs 8 h). The 
      specificity of the bronchial test was indicated by the observation that a control 
      group of 19 asthmatics with comparable severity of disease failed to 
      bronchoconstrict in response to L-ASA. In conclusion, we have found the bronchial 
      provocation method to be easy to interpret and to control, even in severely 
      asthmatic patients. Consequently, bronchial provocation with L-ASA appears 
      particularly useful in the out-patient office or for research on airway responses 
      to ASA in ASA-sensitive asthmatics.
FAU - Dahlén, B
AU  - Dahlén B
AD  - Dept of Thoracic Medicine, Karolinska Institutet, Stockholm, Sweden.
FAU - Zetterström, O
AU  - Zetterström O
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Inhalation
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/diagnosis
MH  - Bronchial Provocation Tests
MH  - Drug Hypersensitivity/*diagnosis
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Time Factors
EDAT- 1990/05/01 00:00
MHDA- 1990/05/01 00:01
CRDT- 1990/05/01 00:00
PHST- 1990/05/01 00:00 [pubmed]
PHST- 1990/05/01 00:01 [medline]
PHST- 1990/05/01 00:00 [entrez]
PST - ppublish
SO  - Eur Respir J. 1990 May;3(5):527-34.

PMID- 28387027
OWN - NLM
STAT- MEDLINE
DCOM- 20180720
LR  - 20180720
IS  - 1365-2885 (Electronic)
IS  - 0140-7783 (Linking)
VI  - 40
IP  - 6
DP  - 2017 Dec
TI  - Establishment of reference ranges and evaluation of in vitro 
      concentration-dependent platelet inhibition by acetylsalicylic acid for multiple 
      electrode impedance aggregometry in healthy dogs.
PG  - 618-628
LID - 10.1111/jvp.12405 [doi]
AB  - Acetylsalicylic acid (ASA, aspirin) is an antiplatelet medication used for 
      prevention of thromboembolism. Effects of ASA appear to vary widely between dogs, 
      but the underlying mechanisms are not understood. The Multiplate analyzer is a 
      newer form of whole-blood impedance aggregometry recently validated for use in 
      healthy dogs. A method utilizing this instrument to measure ASA effects on 
      platelet function has not been established. The goals of this study were to 
      establish reference ranges for the Multiplate in healthy dogs and secondly, to 
      develop a technique to determine the in vitro concentration of ASA needed to 
      cause 50% inhibition of platelet aggregation (IC50). Reference ranges established 
      from 40 dogs at multiple test times for three agonists were consistent with 
      previously published values. In vitro IC50 values were calculated using the 
      sigmoid E(max) model in 20 healthy dogs on two occasions to determine individual 
      repeatability. Calculated in vitro IC50 demonstrated four ASA response groups: 
      responder (n = 16), poor responder (n = 1), variable responder (n = 2), and 
      nonresponder (n = 1). Multiplate within-assay variability was  <10% for area 
      under the curve (AUC), and between-assay baseline AUC variability was  <15%. The 
      described technique allowed for determination of an in vitro IC50 for ASA in dogs 
      using a multiple electrode impedance aggregometer.
CI  - © 2017 John Wiley & Sons Ltd.
FAU - Haines, J M
AU  - Haines JM
AUID- ORCID: 0000-0002-8066-838X
AD  - Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical 
      Sciences, College of Veterinary Medicine, Washington State University, Pullman, 
      WA, USA.
FAU - Lee, P M
AU  - Lee PM
AUID- ORCID: 0000-0001-6003-0496
AD  - Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical 
      Sciences, College of Veterinary Medicine, Washington State University, Pullman, 
      WA, USA.
FAU - Hegedus, R M
AU  - Hegedus RM
AD  - Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical 
      Sciences, College of Veterinary Medicine, Washington State University, Pullman, 
      WA, USA.
FAU - Hwang, J K
AU  - Hwang JK
AD  - Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical 
      Sciences, College of Veterinary Medicine, Washington State University, Pullman, 
      WA, USA.
FAU - Court, M H
AU  - Court MH
AD  - Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical 
      Sciences, College of Veterinary Medicine, Washington State University, Pullman, 
      WA, USA.
LA  - eng
PT  - Journal Article
DEP - 20170406
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Electric Impedance
MH  - Female
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Reference Values
EDAT- 2017/04/08 06:00
MHDA- 2018/07/22 06:00
CRDT- 2017/04/08 06:00
PHST- 2016/09/15 00:00 [received]
PHST- 2017/02/23 00:00 [accepted]
PHST- 2017/04/08 06:00 [pubmed]
PHST- 2018/07/22 06:00 [medline]
PHST- 2017/04/08 06:00 [entrez]
AID - 10.1111/jvp.12405 [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 2017 Dec;40(6):618-628. doi: 10.1111/jvp.12405. Epub 2017 
      Apr 6.

PMID- 8223068
OWN - NLM
STAT- MEDLINE
DCOM- 19931202
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 38
IP  - 11
DP  - 1993 Nov
TI  - Anorectal stenosis in patients with prolonged use of suppositories containing 
      paracetamol and acetylsalicylic acid.
PG  - 1970-7
AB  - We report five cases in which anorectal stenosis was associated with chronic 
      administration of suppositories containing paracetamol and acetylsalicylic acid. 
      All patients were females taking suppositories for chronic migraine. Patients 
      experienced anal pain, tenesmus, fecal incontinence, and, in two cases, 
      intestinal obstruction. Lesions were characterized by a severe circular narrowing 
      of the distal rectum with superficial ulcerations. Radiographs demonstrated the 
      presence of sinus-tract-like formations in the diseased segment and thickening of 
      the rectal wall. Histologic examination showed signs of chronic inflammation with 
      deep ulcerations associated with obliteration of the lamina propria by a 
      fibromuscular proliferation, as was described in the solitary ulcer syndrome of 
      the rectum. Rectal administration of suppositories was discontinued in all the 
      patients. Two patients were improved by anorectal dilatation, but the remaining 
      three required a left proctocolectomy with subsequent coloanal anastomosis. The 
      use of such suppositories must be restricted.
FAU - Van Gossum, A
AU  - Van Gossum A
AD  - Medico-surgical Department of Gastroenterology, Hôpital Erasme, Brussels, 
      Belgium.
FAU - Zalcman, M
AU  - Zalcman M
FAU - Adler, M
AU  - Adler M
FAU - Peny, M O
AU  - Peny MO
FAU - Houben, J J
AU  - Houben JJ
FAU - Cremer, M
AU  - Cremer M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Drug Combinations)
RN  - 0 (Suppositories)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/*adverse effects/therapeutic use
MH  - Administration, Rectal
MH  - Adult
MH  - Anus Diseases/*chemically induced/diagnosis
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Constriction, Pathologic/chemically induced/diagnosis
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Migraine Disorders/drug therapy
MH  - Rectal Diseases/*chemically induced/diagnosis
MH  - Suppositories
MH  - Time Factors
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
AID - 10.1007/BF01297071 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1993 Nov;38(11):1970-7. doi: 10.1007/BF01297071.

PMID- 3110654
OWN - NLM
STAT- MEDLINE
DCOM- 19870730
LR  - 20161123
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 78
IP  - 12
DP  - 1987 Jun 30
TI  - [Comparative clinical study of tiaprofenic acid and lysine acetylsalicylate in 
      aged osteoarthrosis patients].
PG  - 865-70
AB  - Thirty elderly patients (mean age 74) with osteoarthritis effecting various 
      joints were treated with an oral suspension of either tiaprofenic acid (TA) (600 
      mg per diem b.i.d.) or lysine acetyl salicylate (1800 mg per diem b.i.d.) for 3-6 
      months in an open randomized experimental study. The parameters of efficacy 
      assessed were pain at rest and under load, stiffness, ability to perform a 
      pre-selected daily exercise and joint movements hampered by the disease. Blood 
      flow, liver and kidney function and side effects were examined on a monthly 
      basis. The tiaprofenic acid proved more effective in reducing pain and aiding 
      functional recovery and was also better tolerated, especially at gastrointestinal 
      level. Nine patients under lysine acetyl salicylate and 2 under tiaprofenic acid 
      were forced to suspend treatment due to pyrosis, epigastralgia ed dyspepsia.
FAU - Viara, M
AU  - Viara M
FAU - Amato, A M
AU  - Amato AM
FAU - Menicanti, V
AU  - Menicanti V
FAU - Longatti, S
AU  - Longatti S
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Studio clinico di confronto tra acido tiaprofenico e acetilsalicilato di lisina 
      in pazienti anziani osteoartrosici.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Analgesics)
RN  - 0 (Propionates)
RN  - 1LS1T6R34C (tiaprofenic acid)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Analgesics/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Bone Diseases/*drug therapy
MH  - Female
MH  - Humans
MH  - Joint Diseases/*drug therapy
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Propionates/administration & dosage/*therapeutic use
MH  - Random Allocation
EDAT- 1987/06/30 00:00
MHDA- 1987/06/30 00:01
CRDT- 1987/06/30 00:00
PHST- 1987/06/30 00:00 [pubmed]
PHST- 1987/06/30 00:01 [medline]
PHST- 1987/06/30 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1987 Jun 30;78(12):865-70.

PMID- 23081668
OWN - NLM
STAT- MEDLINE
DCOM- 20130926
LR  - 20131121
IS  - 1099-0801 (Electronic)
IS  - 0269-3879 (Linking)
VI  - 27
IP  - 5
DP  - 2013 May
TI  - Low dose aspirin estimation: an application to a human pharmacokinetic study.
PG  - 589-98
LID - 10.1002/bmc.2832 [doi]
AB  - Low dose to very high dose aspirin is used to prevent heart attack. We have 
      developed and validated a sensitive and robust method that could detect low 
      levels of aspirin and salicylic acid in plasma and also a novel sample collection 
      procedure to carry out sample preparation at room temperature. The total run time 
      was 3.00 min; the developed method was validated in human plasma with a lower 
      limit of quantitation of 0.99 ng/mL for aspirin and 2.01 ng/mL for salicylic 
      acid. A linear response function was established for the range of concentrations 
      0.99-756.20 ng/mL (r > 0.998) for aspirin and 2.01-2486.86 ng/mL for salicylic 
      acid. The intra- and inter-day precision values for aspirin and salicylic acid 
      met the acceptance as per FDA guidelines. The developed assay method was applied 
      to an oral pharmacokinetic study in humans.
CI  - Copyright © 2012 John Wiley & Sons, Ltd.
FAU - Vijaya Bharathi, D
AU  - Vijaya Bharathi D
AD  - Bioanalytical Department, Integrated Product Development, Dr Reddy's Laboratories 
      Ltd, Bachupalli, Hyderabad-500 072, India. vijayabd@drreddys.com
FAU - Hotha, Kishore Kumar
AU  - Hotha KK
FAU - Kolagatla, Pandu Ranga Reddy
AU  - Kolagatla PR
FAU - Venkateswarlu, V
AU  - Venkateswarlu V
LA  - eng
PT  - Journal Article
DEP - 20121018
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/*administration & dosage/blood/*pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Dose-Response Relationship, Drug
MH  - Drug Stability
MH  - Humans
MH  - Limit of Detection
MH  - Male
MH  - Reproducibility of Results
MH  - Salicylic Acid/blood/pharmacokinetics
MH  - Tandem Mass Spectrometry
EDAT- 2012/10/20 06:00
MHDA- 2013/09/27 06:00
CRDT- 2012/10/20 06:00
PHST- 2012/08/28 00:00 [received]
PHST- 2012/09/19 00:00 [accepted]
PHST- 2012/10/20 06:00 [entrez]
PHST- 2012/10/20 06:00 [pubmed]
PHST- 2013/09/27 06:00 [medline]
AID - 10.1002/bmc.2832 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2013 May;27(5):589-98. doi: 10.1002/bmc.2832. Epub 2012 Oct 
      18.

PMID- 4808815
OWN - NLM
STAT- MEDLINE
DCOM- 19740214
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 1
IP  - 5896
DP  - 1974 Jan 5
TI  - Effect of several drugs on gastric potential difference in man.
PG  - 19-21
AB  - Measurement of gastric mucosal potential difference was used to study the effect 
      on the gastric mucosal barrier in six volunteer subjects of several drugs known 
      to provoke ulcers. Potential differences were also recorded in nine patients with 
      rheumatoid arthritis being treated with long-term aspirin and five patients on 
      long-term prednisone. Unbuffered aspirin and ethanol "broke" the barrier as shown 
      by a rapid fall in potential difference. The effects of aspirin were dose 
      related, with 600 mg causing a greater reduction than 300 mg. The effects of 
      aspirin and ethanol given together were additive and caused the greatest fall in 
      potential difference. Sodium acetylsalicylate did not alter the normal potential 
      difference. Indomethacin, phenylbutazone, and prednisone all failed to cause any 
      change in potential difference. The patients on long-term aspirin and prednisone 
      had readings within the normal range and responded the same as normal subjects to 
      an acute challenge. These studies show that aspirin and ethanol will damage the 
      gastric mucosal barrier but that indomethacin, phenylbutazone, and prednisone do 
      not.
FAU - Murray, H S
AU  - Murray HS
FAU - Strottman, M P
AU  - Strottman MP
FAU - Cooke, A R
AU  - Cooke AR
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Drug Combinations)
RN  - 3K9958V90M (Ethanol)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/drug therapy/physiopathology
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Drug Combinations
MH  - Drug Synergism
MH  - Ethanol/pharmacology
MH  - Female
MH  - Gastric Mucosa/drug effects/physiopathology
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Male
MH  - Membrane Potentials/*drug effects
MH  - Phenylbutazone/pharmacology
MH  - Prednisone/administration & dosage/pharmacology/therapeutic use
PMC - PMC1632844
EDAT- 1974/01/05 00:00
MHDA- 1974/01/05 00:01
CRDT- 1974/01/05 00:00
PHST- 1974/01/05 00:00 [pubmed]
PHST- 1974/01/05 00:01 [medline]
PHST- 1974/01/05 00:00 [entrez]
AID - 10.1136/bmj.1.5896.19 [doi]
PST - ppublish
SO  - Br Med J. 1974 Jan 5;1(5896):19-21. doi: 10.1136/bmj.1.5896.19.

PMID- 23345
OWN - NLM
STAT- MEDLINE
DCOM- 19780321
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 6
IP  - 5
DP  - 1977
TI  - Ditazole activity and its interaction with urokinase on experimental thrombosis.
PG  - 310-7
AB  - The effect of ditazole, a new antiaggregant oxazole derivative as well as its 
      possible interaction with urokinase on the formation of electrically induced 
      thrombus, was assayed in rabbits. The activity of ditazole in reducing thrombus 
      weight was comparable to that of aspirin. In the ditazole- or aspirin-treated 
      animals, the microscopical examination of the thrombus showed a reduction in the 
      fibrin component, and well-isolated platelets not undergoing a viscous 
      metamorphosis were present. Urokinase, administered in combination with these 
      antiaggregant drugs, did not induce a further reduction in thrombus weight. 
      However, this additional treatment did induce clearly visible lytic areas and 
      histological modifications as observed with the antiaggregant drugs. These data 
      suggest that the antiplatelet drug ditazole may be an effective antithrombotic 
      agent in man and could facilitate the penetration of urokinase into the thrombus.
FAU - Caprino, L
AU  - Caprino L
FAU - Borrelli, F
AU  - Borrelli F
FAU - Falchetti, R
AU  - Falchetti R
FAU - Cafiero, C
AU  - Cafiero C
FAU - Gandolfo, G M
AU  - Gandolfo GM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Oxazoles)
RN  - EC 3.4.- (Endopeptidases)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Carotid Arteries/pathology
MH  - Drug Evaluation, Preclinical
MH  - Drug Interactions
MH  - Endopeptidases/*metabolism
MH  - Male
MH  - Oxazoles/pharmacology/*therapeutic use
MH  - Rabbits
MH  - Thrombosis/*drug therapy
MH  - Urokinase-Type Plasminogen Activator/*metabolism/pharmacology
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1159/000214196 [doi]
PST - ppublish
SO  - Haemostasis. 1977;6(5):310-7. doi: 10.1159/000214196.

PMID- 324036
OWN - NLM
STAT- MEDLINE
DCOM- 19770630
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 8
IP  - 3
DP  - 1977 May-Jun
TI  - Controlled trial of aspirin in cerebral ischemia.
PG  - 301-14
AB  - Adouble-blind trial of aspirin for the treatment of cerebral ischemia was begun 
      in 1972 and continued for 37 months. This was accomplished despite difficulties 
      in controlling a long-term study of a drug which has widespread availability and 
      consumption. The study design, criteria for selection of patients, follow-up 
      surveillance, and methods of data analysis are presented. We report only subjects 
      without carotid surgery before randomization. Patients (178) who had carotid 
      transient ischemic attacks (TIAs) were randomly allocated to aspirin or placebo 
      and followed to determine the incidence of subsequent TIAs,death, cerebral 
      infarction or retinal infarction. Analysis of the first six months of follow-up 
      revealed a statistically significant differential in favar of aspirin when death 
      or cerebral or retinal infarction and the occurrence of TIAs were grouped and 
      considered together as end points. Significance in favor of aspirin treatment was 
      mainly revealed in patients with a history of multiple TIAs and was most evident 
      in those individuals having carotid lesions appropriate to the TIA symptoms. It 
      cannot be inferred from this study that aspirin prevents stroke because when end 
      points were restriced to death or cerebral or retinal infarction, there was no 
      statistically significant differential between the aspirin and placebo 
      treatments.
FAU - Fields, W S
AU  - Fields WS
FAU - Lemak, N A
AU  - Lemak NA
FAU - Frankowski, R F
AU  - Frankowski RF
FAU - Hardy, R J
AU  - Hardy RJ
LA  - eng
PT  - Case Reports
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blindness/prevention & control
MH  - Cerebrovascular Disorders/mortality/prevention & control
MH  - Clinical Trials as Topic
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/mortality/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Platelet Aggregation/drug effects
EDAT- 1977/05/01 00:00
MHDA- 1977/05/01 00:01
CRDT- 1977/05/01 00:00
PHST- 1977/05/01 00:00 [pubmed]
PHST- 1977/05/01 00:01 [medline]
PHST- 1977/05/01 00:00 [entrez]
AID - 10.1161/01.str.8.3.301 [doi]
PST - ppublish
SO  - Stroke. 1977 May-Jun;8(3):301-14. doi: 10.1161/01.str.8.3.301.

PMID- 32243964
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 581
DP  - 2020 May 15
TI  - End-to-end continuous manufacturing of conventional compressed tablets: From flow 
      synthesis to tableting through integrated crystallization and filtration.
PG  - 119297
LID - S0378-5173(20)30281-7 [pii]
LID - 10.1016/j.ijpharm.2020.119297 [doi]
AB  - An end-to-end continuous pharmaceutical manufacturing process was developed for 
      the production of conventional direct compressed tablets on a proof-of-concept 
      level for the first time. The output reaction mixture of the flow synthesis of 
      acetylsalicylic acid was crystallized continuously in a mixed suspension mixed 
      product removal crystallizer. The crystallizer was directly connected to a 
      continuous filtration carousel device, thus the crystallization, filtration and 
      drying of acetylsalicylic acid (ASA) was carried out in an integrated 2-step 
      process. Steady state was reached during longer operations and the interaction of 
      process parameters was evaluated in a series of experiments. The filtered 
      crystals were ready for further processing in a following continuous blending and 
      tableting experiment due to the good flowability of the material. The ASA 
      collected during the crystallization-filtration experiments was fed into a 
      continuous twin-screw blender along with microcrystalline cellulose as tableting 
      excipient. After continuous blending Near-Infrared spectroscopy was applied to 
      in-line analyze the drug content of the powder mixture. A belt conveyor carried 
      the mixture towards an eccentric lab-scale tablet press, which continuously 
      produced 500 mg ASA-loaded compressed tablets of 100 mg dose strength. Thus, 
      starting from raw materials, the final drug product was obtained by continuous 
      manufacturing steps with appropriate quality.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Domokos, András
AU  - Domokos A
AD  - Budapest University of Technology and Economics, Organic Chemistry and Technology 
      Department, H-1111 Budapest, Hungary; Davidson School of Chemical Engineering, 
      Purdue University, West Lafayette, IN 47907, United States.
FAU - Nagy, Brigitta
AU  - Nagy B
AD  - Budapest University of Technology and Economics, Organic Chemistry and Technology 
      Department, H-1111 Budapest, Hungary; Davidson School of Chemical Engineering, 
      Purdue University, West Lafayette, IN 47907, United States.
FAU - Gyürkés, Martin
AU  - Gyürkés M
AD  - Budapest University of Technology and Economics, Organic Chemistry and Technology 
      Department, H-1111 Budapest, Hungary.
FAU - Farkas, Attila
AU  - Farkas A
AD  - Budapest University of Technology and Economics, Organic Chemistry and Technology 
      Department, H-1111 Budapest, Hungary.
FAU - Tacsi, Kornélia
AU  - Tacsi K
AD  - Budapest University of Technology and Economics, Organic Chemistry and Technology 
      Department, H-1111 Budapest, Hungary.
FAU - Pataki, Hajnalka
AU  - Pataki H
AD  - Budapest University of Technology and Economics, Organic Chemistry and Technology 
      Department, H-1111 Budapest, Hungary.
FAU - Liu, Yiqing Claire
AU  - Liu YC
AD  - Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN 
      47907, United States.
FAU - Balogh, Attila
AU  - Balogh A
AD  - Budapest University of Technology and Economics, Organic Chemistry and Technology 
      Department, H-1111 Budapest, Hungary.
FAU - Firth, Paul
AU  - Firth P
AD  - Alconbury Weston Ltd. (AWL), Stoke-on-Trent, Staffordshire ST4 3PE, United 
      Kingdom.
FAU - Szilágyi, Botond
AU  - Szilágyi B
AD  - Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN 
      47907, United States.
FAU - Marosi, György
AU  - Marosi G
AD  - Budapest University of Technology and Economics, Organic Chemistry and Technology 
      Department, H-1111 Budapest, Hungary.
FAU - Nagy, Zoltán K
AU  - Nagy ZK
AD  - Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN 
      47907, United States; Department of Chemical Engineering, Loughborough 
      University, Loughborough, LE11 3TU, United Kingdom. Electronic address: 
      zknagy@purdue.edu.
FAU - Nagy, Zsombor Kristóf
AU  - Nagy ZK
AD  - Budapest University of Technology and Economics, Organic Chemistry and Technology 
      Department, H-1111 Budapest, Hungary. Electronic address: zsknagy@oct.bme.hu.
LA  - eng
PT  - Journal Article
DEP - 20200331
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Tablets)
RN  - 9004-34-6 (Cellulose)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis/*chemical synthesis
MH  - Cellulose/analysis/chemical synthesis
MH  - Chemistry, Pharmaceutical/*methods
MH  - *Compressive Strength
MH  - Crystallization/*methods
MH  - Filtration/methods
MH  - Spectroscopy, Near-Infrared/methods
MH  - Tablets
OTO - NOTNLM
OT  - Blending
OT  - Continuous manufacturing
OT  - Crystallization
OT  - End-to-end
OT  - Filtration
OT  - Integration
OT  - Tableting
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/04/04 06:00
MHDA- 2021/01/29 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/03/02 00:00 [received]
PHST- 2020/03/28 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - S0378-5173(20)30281-7 [pii]
AID - 10.1016/j.ijpharm.2020.119297 [doi]
PST - ppublish
SO  - Int J Pharm. 2020 May 15;581:119297. doi: 10.1016/j.ijpharm.2020.119297. Epub 
      2020 Mar 31.

PMID- 8923964
OWN - NLM
STAT- MEDLINE
DCOM- 19970303
LR  - 20131121
IS  - 0003-2697 (Print)
IS  - 0003-2697 (Linking)
VI  - 242
IP  - 1
DP  - 1996 Nov 1
TI  - Mapping cross-linking sites in modified proteins with mass spectrometry: an 
      application to cross-linked hemoglobins.
PG  - 55-63
AB  - The combined use of trypsin digestion and peptide mass mapping by matrix-assisted 
      laser desorption/ionization mass spectrometry (MALDI-MS) is reported here as an 
      effective and rapid means for identifying the cross-linking sites in human oxy 
      hemoglobin A (HbA) cross-linked with either bis(3,5-dibromosalicyl)-succinate or 
      -glutarate. MALDI-MS analysis of a nondigested sample of oxy HbA modified with 
      bis(3,5-dibromosalicyl)-glutarate showed that cross-linking only occurred between 
      the beta 1- and beta 2-protomers and not between alpha 1- and alpha 2- or alpha- 
      and beta-protomers, along with a modification reaction on an un-cross-linked 
      beta-chain. Results of the MALDI tryptic peptide mass maps of cross-linked 
      hemoglobins showed several cross-linked peptides having masses consistent with: 
      beta Val67-Lys95-XL-beta Val67-Lys95, beta Val67-Lys95-XL-beta Val67-Arg104, beta 
      Val67-Arg104-XL-beta Val67-Arg104, where XL represents the succinyl or glutaryl 
      bridging span moiety. Each of these peptides contains Lys82, the targeted residue 
      for these reagents, substantiating the cross-linking sites at beta 1Lys82-beta 
      2Lys82. This approach in general will enable rapid identification of the 
      cross-linking sites in engineered proteins or intracellularly recombinant 
      cross-linked proteins when the mass of the cross-linker and the protein primary 
      structure are known.
FAU - Yang, T
AU  - Yang T
AD  - Department of Chemistry, University of Wisconsin-Eau Claire 54702, USA. 
      yangt@uwec.edu
FAU - Horejsh, D R
AU  - Horejsh DR
FAU - Mahan, K J
AU  - Mahan KJ
FAU - Zaluzec, E J
AU  - Zaluzec EJ
FAU - Watson, T J
AU  - Watson TJ
FAU - Gage, D A
AU  - Gage DA
LA  - eng
GR  - RR00480/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Anal Biochem
JT  - Analytical biochemistry
JID - 0370535
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Oxyhemoglobins)
RN  - 0 (Peptides)
RN  - 71337-52-5 (bis(3,5-dibromosalicyl)succinate)
RN  - 75848-75-8 (bis(3,5-dibromosalicyl)glutarate)
RN  - 9034-51-9 (Hemoglobin A)
RN  - EC 3.4.21.4 (Trypsin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Aspirin/analogs & derivatives/chemistry
MH  - Binding Sites
MH  - Cross-Linking Reagents/*chemistry
MH  - Hemoglobin A/*chemistry
MH  - Humans
MH  - Molecular Sequence Data
MH  - Oxyhemoglobins/analysis/*chemistry
MH  - Peptides/analysis/*chemistry
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
MH  - Trypsin
EDAT- 1996/11/01 00:00
MHDA- 1996/11/01 00:01
CRDT- 1996/11/01 00:00
PHST- 1996/11/01 00:00 [pubmed]
PHST- 1996/11/01 00:01 [medline]
PHST- 1996/11/01 00:00 [entrez]
AID - S0003-2697(96)90427-3 [pii]
AID - 10.1006/abio.1996.0427 [doi]
PST - ppublish
SO  - Anal Biochem. 1996 Nov 1;242(1):55-63. doi: 10.1006/abio.1996.0427.

PMID- 29985750
OWN - NLM
STAT- MEDLINE
DCOM- 20181219
LR  - 20181219
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 29
IP  - 8
DP  - 2018 Dec
TI  - Aspirin, platelet inhibition and cancer prevention.
PG  - 779-785
LID - 10.1080/09537104.2018.1492105 [doi]
AB  - Several lines of evidence are consistent with the hypothesis that activated 
      platelets contribute to colorectal tumorigenesis and metastatization through 
      direct cell-cell interactions and the release of different lipid and protein 
      mediators, and microvesicles. This review examines the clinical pharmacology of 
      low-dose aspirin as a basis for discussing the mechanisms underlying the 
      contribution of platelets to neoplastic transformation and progression of cancer 
      via the development of metastases.
FAU - Patrignani, Paola
AU  - Patrignani P
AD  - a Department of Neuroscience, Imaging and Clinical Sciences, Section of 
      Cardiovascular and Pharmacological Sciences, and CeSI-MeT (Centro Scienze dell' 
      Invecchiamento e Medicina Traslazionale) , "G. d'Annunzio" University , Chieti , 
      Italy.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - b Department of Pharmacology , Catholic University School of Medicine , Rome , 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180709
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Neoplasms/metabolism/pathology/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - colorectal cancer
OT  - cyclooxygenases
OT  - platelet activation
OT  - prostaglandin E2
OT  - thromboxane A2
EDAT- 2018/07/10 06:00
MHDA- 2018/12/20 06:00
CRDT- 2018/07/10 06:00
PHST- 2018/07/10 06:00 [pubmed]
PHST- 2018/12/20 06:00 [medline]
PHST- 2018/07/10 06:00 [entrez]
AID - 10.1080/09537104.2018.1492105 [doi]
PST - ppublish
SO  - Platelets. 2018 Dec;29(8):779-785. doi: 10.1080/09537104.2018.1492105. Epub 2018 
      Jul 9.

PMID- 22740110
OWN - NLM
STAT- MEDLINE
DCOM- 20130522
LR  - 20220330
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 35
IP  - 11
DP  - 2012 Nov
TI  - Aspirin resistance: current status and role of tailored therapy.
PG  - 673-81
LID - 10.1002/clc.22031 [doi]
AB  - Aspirin is integral in the primary and secondary prevention of coronary artery 
      disease and acute coronary syndrome. Given the high clinical importance of 
      aspirin in the management of coronary artery disease, much attention has been 
      directed towards the concept of "aspirin resistance." Unfortunately, the term 
      aspirin resistance is ill-defined in the literature, leading to a large variance 
      in the reported prevalence of this phenomenon. In this review, the current 
      understanding of aspirin resistance is discussed. Commonly used functional and 
      diagnostic tests of platelet function, including their strengths and weakness, 
      are reviewed. We next discuss several proposed mechanisms of aspirin resistance 
      and special high-risk groups at risk for aspirin treatment failure. We then 
      discuss optimal dosing and diagnostic strategies for those populations at risk 
      for aspirin resistance with a focus on tailored aspirin therapy for high-risk 
      groups. Finally, future topics of interest in the field of aspirin resistance are 
      considered.
CI  - © 2012 Wiley Periodicals, Inc.
FAU - Grinstein, Jonathan
AU  - Grinstein J
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA. 
      jgrinstein@partners.org
FAU - Cannon, Christopher P
AU  - Cannon CP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120627
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Platelets/*drug effects/metabolism
MH  - Coronary Artery Disease/blood/*drug therapy
MH  - Drug Resistance
MH  - Humans
MH  - Patient Selection
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Platelet Function Tests
MH  - Predictive Value of Tests
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Failure
PMC - PMC6652698
EDAT- 2012/06/29 06:00
MHDA- 2013/05/23 06:00
CRDT- 2012/06/29 06:00
PHST- 2012/02/04 00:00 [received]
PHST- 2012/05/16 00:00 [revised]
PHST- 2012/06/29 06:00 [entrez]
PHST- 2012/06/29 06:00 [pubmed]
PHST- 2013/05/23 06:00 [medline]
AID - CLC22031 [pii]
AID - 10.1002/clc.22031 [doi]
PST - ppublish
SO  - Clin Cardiol. 2012 Nov;35(11):673-81. doi: 10.1002/clc.22031. Epub 2012 Jun 27.

PMID- 8193274
OWN - NLM
STAT- MEDLINE
DCOM- 19940630
LR  - 20141120
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 7
IP  - 6A
DP  - 1993 Nov-Dec
TI  - Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral 
      vascular disease.
PG  - 543-8
AB  - Platelet aggregation in whole blood (WB) was assessed in healthy subjects and in 
      patients with peripheral vascular disease (PVD) using a WB-free platelet counting 
      (WB-FPC) method. Aggregation induced by stirring and platelet agonists was 
      significantly enhanced in PVD patients. WB-FPC aggregation induced by 5-HT was 
      diminished significantly by incubation with naftidrofuryl (NAF) in WB of PVD 
      patients. In contrast, aspirin (acetylsalicylic acid; ASA), added in vitro, did 
      not significantly affect 5-HT or stirring-induced WB-PFC aggregation in PVD 
      patients. Furthermore, 5-HT-induced WB-FPC was inhibited by NAF in blood 
      collected from PVD patients that were taking low dose aspirin. These findings 
      suggest that NAF may be of benefit to patients with hyperaggregable platelets and 
      elevated plasma 5-HT concentrations, factors thought to predispose to thrombotic 
      complications.
FAU - Barradas, M A
AU  - Barradas MA
AD  - Department of Chemical Pathology and Human Metabolism, Royal Free Hospital School 
      of Medicine (University of London), U.K.
FAU - Stansby, G
AU  - Stansby G
FAU - Hamilton, G
AU  - Hamilton G
FAU - Mikhailidis, D P
AU  - Mikhailidis DP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - 333DO1RDJY (Serotonin)
RN  - 42H8PQ0NMJ (Nafronyl)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Nafronyl/*pharmacology
MH  - Peripheral Vascular Diseases/*blood/drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Reference Values
MH  - Serotonin/pharmacology
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PST - ppublish
SO  - In Vivo. 1993 Nov-Dec;7(6A):543-8.

PMID- 18700638
OWN - NLM
STAT- MEDLINE
DCOM- 20080922
LR  - 20131121
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 56
DP  - 2008 May
TI  - Variability in platelet response to a single daily dose of 150 mg enteric coated 
      aspirin in a high risk population.
PG  - 321-4
AB  - PURPOSE: Previous studies have reported inadequate anti-platelet effect in 
      0.4-35% of patients taking aspirin. Such studies have arbitrarily defined the 
      terms "semi-responders", "non-responders" or "resistant" to variable doses of 
      aspirin on the basis of absolute values derived from different ex-vivo platelet 
      aggregation (PA) methods. Our objective was to define response to 150-mg dose of 
      aspirin in terms of normally distributed values using an ex-vivo measure of PA in 
      a population at high risk for vascular events. METHODS: We prospectively studied 
      high risk patients with either established coronary artery disease (CAD) or 
      stroke or transient ischemic attack (TIA) or peripheral vascular disease or with 
      multiple atherothrombotic risk factors like diabetes plus one of the following-- 
      hypertension, increased total cholesterol, cigarette smoking, micro-albuminuria, 
      low-high density lipoprotein (HDL), family history of CAD and receiving single 
      150 mg dose of aspirin daily. PA was assessed by chronolog lumi-aggregometer 
      (490-2D) using arachidonic acid (AA) reagent. RESULTS: 130 patients were studied. 
      The response of subjects to aspirin followed a normal, bell shaped distribution 
      curve with a mean and standard deviation (S.D.) of 13.1 +/- 4.4%. 3.1% patients 
      had PA values more than 2 S.D. of the mean, hence termed as hypo-responders to 
      aspirin while another 3.1% patients had PA values less than 2 S.D. of the mean, 
      hence termed as hyper-responders to aspirin. CONCLUSION: There is minimal 
      inter-individual variability in the response to aspirin when tested with AA as 
      the reagent. The response to aspirin follows a normal Gaussian distribution. The 
      prevalence of hypo-responders to aspirin in high risk population is only 3.1%. 
      This is the first study to document "hypo" and "hyper-responders" to single daily 
      dose of 150 mg aspirin. The clinical relevance of these findings remains to be 
      determined.
FAU - Mardikar, H
AU  - Mardikar H
AD  - Spandan Heart Institute and Research Center, Nagpur, India.
FAU - Deo, D
AU  - Deo D
FAU - Deshpande, N
AU  - Deshpande N
FAU - Mardikar, Manjusha
AU  - Mardikar M
FAU - Ghosh, A
AU  - Ghosh A
FAU - Munot, Khushboo
AU  - Munot K
FAU - Steinhubl, S
AU  - Steinhubl S
FAU - Mukherjee, D
AU  - Mukherjee D
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Assoc Physicians India. 2008 May;56:317-9. PMID: 18700637
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects/pharmacokinetics
MH  - Bleeding Time/statistics & numerical data
MH  - Cardiovascular Diseases/*prevention & control
MH  - *Developing Countries
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - India
MH  - Male
MH  - Middle Aged
MH  - Normal Distribution
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/pharmacokinetics
MH  - Prospective Studies
MH  - Risk Factors
MH  - Tablets, Enteric-Coated
EDAT- 2008/08/15 09:00
MHDA- 2008/09/23 09:00
CRDT- 2008/08/15 09:00
PHST- 2008/08/15 09:00 [pubmed]
PHST- 2008/09/23 09:00 [medline]
PHST- 2008/08/15 09:00 [entrez]
PST - ppublish
SO  - J Assoc Physicians India. 2008 May;56:321-4.

PMID- 24573704
OWN - NLM
STAT- MEDLINE
DCOM- 20150929
LR  - 20220409
IS  - 1554-6179 (Electronic)
IS  - 1539-4182 (Print)
IS  - 1539-4182 (Linking)
VI  - 12
IP  - 3-4
DP  - 2014 Dec
TI  - The role of aspirin in the prevention of cardiovascular disease.
PG  - 147-54
LID - 10.3121/cmr.2013.1197 [doi]
AB  - Aspirin therapy is well-accepted as an agent for the secondary prevention of 
      cardiovascular events and current guidelines also define a role for aspirin in 
      primary prevention. In this review, we describe the seminal trials of aspirin use 
      in the context of current guidelines, discuss factors that may influence the 
      effectiveness of aspirin therapy for cardiovascular disease prevention, and 
      briefly examine patterns of use. The body of evidence supports a role for aspirin 
      in both secondary and primary prevention of cardiovascular events in selected 
      population groups, but practice patterns may be suboptimal. As a simple and 
      inexpensive prophylactic measure for cardiovascular disease, aspirin use should 
      be carefully considered in all at-risk adult patients, and further measures, 
      including patient education, are necessary to ensure its proper use.
CI  - © 2013 Marshfield Clinic.
FAU - Ittaman, Sunitha V
AU  - Ittaman SV
AD  - Department of Internal Medicine, Marshfield Clinic, Marshfield, WI USA.
FAU - VanWormer, Jeffrey J
AU  - VanWormer JJ
AD  - Epidemiology Research Center, Marshfield Clinic Research Foundation, Marshfield, 
      WI USA.
FAU - Rezkalla, Shereif H
AU  - Rezkalla SH
AD  - Department of Cardiology, Marshfield Clinic, Marshfield, WI USA 
      rezkalla.shereif@marshfieldclinic.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140226
PL  - United States
TA  - Clin Med Res
JT  - Clinical medicine & research
JID - 101175887
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Primary Prevention
MH  - Secondary Prevention
PMC - PMC4317158
OTO - NOTNLM
OT  - Aspirin/history/therapeutic use
OT  - Cardiovascular diseases/drug therapy
OT  - Coronary artery disease
OT  - Non-steroidal anti-inflammatory agents
EDAT- 2014/02/28 06:00
MHDA- 2015/09/30 06:00
CRDT- 2014/02/28 06:00
PHST- 2014/02/28 06:00 [entrez]
PHST- 2014/02/28 06:00 [pubmed]
PHST- 2015/09/30 06:00 [medline]
AID - cmr.2013.1197 [pii]
AID - 0120147 [pii]
AID - 10.3121/cmr.2013.1197 [doi]
PST - ppublish
SO  - Clin Med Res. 2014 Dec;12(3-4):147-54. doi: 10.3121/cmr.2013.1197. Epub 2014 Feb 
      26.

PMID- 26345154
OWN - NLM
STAT- MEDLINE
DCOM- 20160524
LR  - 20181113
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Print)
IS  - 1176-6344 (Linking)
VI  - 11
DP  - 2015
TI  - Are the current recommendations for the use of aspirin in primary prevention of 
      cardiovascular disease applicable in low-income countries?
PG  - 503-6
LID - 10.2147/VHRM.S87398 [doi]
AB  - Although evidence has accumulated that long-term aspirin therapy is beneficial in 
      secondary prevention of cardiovascular disease (CVD), a lot of controversies 
      persist regarding the benefit of aspirin use in primary prevention of CVD. In 
      low-income countries (LIC) specifically, the decision to prescribe aspirin for 
      primary CVD prevention is more problematic, as there is a dearth of evidence in 
      this regard. Aspirin has been shown to have relative beneficial effects in 
      preventing a first myocardial infarction, but not stroke. However, as stroke is 
      the prevailing CVD in many LIC, especially in Africa, the benefit of aspirin in 
      these settings is therefore questionable. Indeed, there is no published trial 
      that has evaluated the benefits and risks of continuous aspirin therapy in 
      populations of LIC. Furthermore, though cardiovascular risk assessment is crucial 
      in decision-making for the use of aspirin in primary prevention of CVD, there are 
      no risk assessment tools that have been validated in African populations. Studies 
      are urgently warranted, to determine the usefulness of aspirin in primary 
      prevention of CVD in low-income settings where the drug is highly available and 
      affordable, as CVD is becoming the leading cause of deaths in LIC.
FAU - Noubiap, Jean Jacques N
AU  - Noubiap JJ
AD  - Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape 
      Town, South Africa ; Medical Diagnostic Center, Yaoundé, Cameroon.
FAU - Nansseu, Jobert Richie N
AU  - Nansseu JR
AD  - Sickle Cell Disease Unit, Mother and Child Centre, Chantal BIYA Foundation, 
      Yaoundé, Cameroon ; Department of Public Health, Faculty of Medicine and 
      Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon.
LA  - eng
PT  - Journal Article
DEP - 20150825
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Africa/epidemiology
MH  - Aspirin/adverse effects/economics/*therapeutic use
MH  - Cardiovascular Agents/adverse effects/economics/*therapeutic use
MH  - Cardiovascular Diseases/economics/epidemiology/*prevention & control
MH  - Cost-Benefit Analysis
MH  - *Developing Countries/economics
MH  - Drug Costs
MH  - Health Services Accessibility
MH  - Healthcare Disparities
MH  - Humans
MH  - *Poverty/economics
MH  - *Practice Guidelines as Topic/standards
MH  - Primary Prevention/economics/*methods/standards
MH  - Risk Assessment
MH  - Risk Factors
PMC - PMC4556041
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular disease
OT  - low-income countries
OT  - primary prevention
EDAT- 2015/09/09 06:00
MHDA- 2016/05/25 06:00
CRDT- 2015/09/09 06:00
PHST- 2015/09/09 06:00 [entrez]
PHST- 2015/09/09 06:00 [pubmed]
PHST- 2016/05/25 06:00 [medline]
AID - vhrm-11-503 [pii]
AID - 10.2147/VHRM.S87398 [doi]
PST - epublish
SO  - Vasc Health Risk Manag. 2015 Aug 25;11:503-6. doi: 10.2147/VHRM.S87398. 
      eCollection 2015.

PMID- 10102949
OWN - NLM
STAT- MEDLINE
DCOM- 19990414
LR  - 20190831
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 13
IP  - 2
DP  - 1999 Feb
TI  - Protection of human gastric mucosa against aspirin-enteric coating or dose 
      reduction?
PG  - 187-93
AB  - BACKGROUND: Aspirin is widely used for cardiovascular prophylaxis. AIM: To 
      compare the effectiveness of two widely-used strategies-dose reduction and 
      enteric coating-for the minimization of gastric mucosal injury or toxicity. 
      METHODS: Twelve healthy volunteers were studied. On four separate occasions each 
      received, under blinded conditions, five daily doses of plain aspirin 300 mg, 
      plain aspirin 75 mg, enteric-coated aspirin 300 mg or placebo. Ex vivo 
      prostaglandin E2 synthesis was stimulated by the vortex mixing of gastric mucosal 
      biopsies in Tris saline and measured by radioimmunoassay. Mucosal injury was 
      quantified both by counting erosions and with a visual analogue scale. RESULTS: 
      All three preparations reduced prostaglandin E2 synthesis by day five, by 
      (median) 84% for plain aspirin 300 mg, by 80% for enteric coated aspirin 300 mg 
      and by 63% for plain aspirin 75 mg. There was little mucosal injury prior to the 
      start of each dose and period and no significant change with placebo. Plain 
      aspirin caused a dose-dependent mucosal injury, with two (median, IQR 0-7) 
      gastric erosions after five days of plain aspirin 75 mg, and 18 (2-26) after five 
      days of plain aspirin 300 mg. With enteric-coated aspirin 300 mg there were 0 
      (0-1) gastric erosions (P = 0.003 compared to plain aspirin 300 mg P = 0.11, 
      compared to plain aspirin 75 mg). CONCLUSION: Enteric coated aspirin reduces 
      acute gastric mucosal injury to placebo levels, despite its inhibition of 
      prostaglandin synthesis. Enteric coating is an appropriate strategy for the 
      prevention of gastric mucosal damage induced by low-dose aspirin, which warrants 
      systematic clinical evaluation.
FAU - Cole, A T
AU  - Cole AT
AD  - Division of Gastroenterology, University Hospital, Nottingham, UK.
FAU - Hudson, N
AU  - Hudson N
FAU - Liew, L C
AU  - Liew LC
FAU - Murray, F E
AU  - Murray FE
FAU - Hawkey, C J
AU  - Hawkey CJ
FAU - Heptinstall, S
AU  - Heptinstall S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Tablets, Enteric-Coated)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dinoprostone/biosynthesis
MH  - Female
MH  - Gastric Mucosa/*drug effects/metabolism/pathology
MH  - Humans
MH  - Male
MH  - Tablets, Enteric-Coated
EDAT- 1999/04/02 00:00
MHDA- 1999/04/02 00:01
CRDT- 1999/04/02 00:00
PHST- 1999/04/02 00:00 [pubmed]
PHST- 1999/04/02 00:01 [medline]
PHST- 1999/04/02 00:00 [entrez]
AID - 10.1046/j.1365-2036.1999.00470.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 1999 Feb;13(2):187-93. doi: 
      10.1046/j.1365-2036.1999.00470.x.

PMID- 32725931
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1439-0272 (Electronic)
IS  - 0303-4569 (Linking)
VI  - 52
IP  - 10
DP  - 2020 Nov
TI  - Aspirin decreases human sperm motility and vitality, chelates seminal calcium, 
      but insignificantly reduces seminal nitric oxide production.
PG  - e13776
LID - 10.1111/and.13776 [doi]
AB  - Lately, there is a systematic research consensus that reveals adverse effects of 
      aspirin on semen quality characteristics; however, such consensus is lacking 
      further confirmation by human studies. Therefore, here, we asked whether sperm 
      motility and vitality are affected in the presence of aspirin at 0.1 and 1 mM in 
      the ejaculated semen, and whether such effect may be due to an alteration in 
      seminal calcium ions or seminal nitric oxide production. Forty-three semen 
      samples from different normozoospermic men were recruited in this study. Sperm 
      motility was measured by Makler counting chamber, and sperm vitality was measured 
      by Eosin test. Calcium chelating effect of aspirin and seminal nitric oxide 
      production was measured spectrophotometrically. Aspirin at both tested 
      concentrations significantly (p < .05) reduced progressive grade-a motility and 
      vitality of spermatozoa. Additionally, aspirin was found to have significant 
      ability (p < .05) to bind seminal calcium ions, but insignificantly reduced the 
      amount of seminal nitric oxide. In conclusion, sperm motility and vitality were 
      reduced in the presence of aspirin at 0.1 and 1 mM in semen. Such reduction may 
      be attributable to the ability of aspirin to chelate seminal calcium ions, but 
      not to an alteration in the amount of nitric oxide produced.
CI  - © 2020 Blackwell Verlag GmbH.
FAU - Banihani, Saleem A
AU  - Banihani SA
AUID- ORCID: 0000-0002-6830-6247
AD  - Department of Medical Laboratory Sciences, Jordan University of Science and 
      Technology, Irbid, Jordan.
FAU - Shatnawi, Reema M
AU  - Shatnawi RM
AD  - Department of Medical Laboratory Sciences, Jordan University of Science and 
      Technology, Irbid, Jordan.
LA  - eng
GR  - 20200066/Jordan University of Science and Technology/
PT  - Journal Article
DEP - 20200729
PL  - Germany
TA  - Andrologia
JT  - Andrologia
JID - 0423506
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Aspirin/pharmacology
MH  - *Calcium
MH  - Humans
MH  - Male
MH  - *Nitric Oxide
MH  - Semen
MH  - Semen Analysis
MH  - Sperm Motility
MH  - Spermatozoa
OTO - NOTNLM
OT  - aspirin
OT  - calcium ions
OT  - nitric oxide
OT  - sperm motility
OT  - sperm vitality
EDAT- 2020/07/30 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/07/04 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - 10.1111/and.13776 [doi]
PST - ppublish
SO  - Andrologia. 2020 Nov;52(10):e13776. doi: 10.1111/and.13776. Epub 2020 Jul 29.

PMID- 35906540
OWN - NLM
STAT- MEDLINE
DCOM- 20220802
LR  - 20220804
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Jul 29
TI  - The preventive effect of low-dose aspirin in a PPAR-γ antagonist treated mouse 
      model of preeclampsia.
PG  - 606
LID - 10.1186/s12884-022-04901-x [doi]
LID - 606
AB  - BACKGROUND: Preeclampsia (PE) is one of the leading causes of maternal and 
      perinatal mortality and morbidity. Low-dose aspirin (LDA) is the most widely used 
      drug to prevent PE, but the recommended dose of LDA varies according to different 
      guidelines. Peroxisome proliferator-activated receptor (PPAR)-γ is involved in 
      the formation of the placenta during pregnancy and is expressed in women with 
      severe PE. In the present study, Our purpose was to investigate whether aspirin 
      intervention in preeclampsia was related to PPAR-γ. METHODS: We administered 
      pregnant mice with PPAR-γ-specific antagonist(T0070907) 2 mg/kg/d at 
      8.5-12.5 days of pregnancy. Mice treated with T0070907 developed key features of 
      preeclampsia. Two doses of LDA (10 mg/kg/d and 20 mg/kg/d) were administered to 
      the mice with a PE phenotype for intervention. RESULTS: LDA effectively decreased 
      the increase in blood pressure in mice caused by T0070907 and decreased urinary 
      protein levels and the urinary protein/creatinine ratio. LDA also inhibited the 
      overexpression of endoglin and IL-β treated by T0070907. In addition, LDA 
      evidently increased the placental weight and alleviates the degree of placental 
      lesions of placenta and kidney. LDA alleviated the inhibition of PPAR-γ mRNA 
      expression. The beneficial effect of 20 mg LDA was significantly better than that 
      of 10 mg. CONCLUSIONS: (1) LDA has a preventive effect against PE treated by 
      PPAR-γ antagonist. (2) The preventive effect of LDA against PE is dose-dependent.
CI  - © 2022. The Author(s).
FAU - Guo, Yongbing
AU  - Guo Y
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, No. 8 
      Sishku Street, Xicheng District, Beijing, 100034, PR China.
FAU - Zhu, Yuchun
AU  - Zhu Y
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, No. 8 
      Sishku Street, Xicheng District, Beijing, 100034, PR China.
FAU - Sun, Yu
AU  - Sun Y
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, No. 8 
      Sishku Street, Xicheng District, Beijing, 100034, PR China. sunyu2491@163.com.
FAU - Yang, Huixia
AU  - Yang H
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, No. 8 
      Sishku Street, Xicheng District, Beijing, 100034, PR China.
LA  - eng
GR  - 81701466/National natural science foundation of China"The mechanism of low dose 
      asprin regulating soluble endoglin expression to prevent preeclampsia"/
GR  - (2017YFC1001404/National Key R&D Program of China"Research on prevention and 
      control of reproductive health and major birth defects: regulation of human 
      embryo implantation and related mechanisms of major pregnancy diseases"/
GR  - 81490745/Major projects of the national natural science foundation of 
      China"Sample library constrution and plasma biomarker investigation on recurrent 
      spontaneous abortion and preeclampsia"/
PT  - Journal Article
DEP - 20220729
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
RN  - 0 (PPAR gamma)
RN  - 0 (Pparg protein, mouse)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Disease Models, Animal
MH  - Female
MH  - Mice
MH  - PPAR gamma/antagonists & inhibitors/metabolism/pharmacology
MH  - Placenta/pathology
MH  - *Pre-Eclampsia/drug therapy/metabolism/prevention & control
MH  - Pregnancy
PMC - PMC9338524
OTO - NOTNLM
OT  - Dose-dependent
OT  - Low-dose aspirin
OT  - Peroxisome proliferator-activated receptor-γ
OT  - Preeclampsia
COIS- The authors declare that they have no competing interests.
EDAT- 2022/07/30 06:00
MHDA- 2022/08/03 06:00
CRDT- 2022/07/29 23:40
PHST- 2021/09/04 00:00 [received]
PHST- 2022/07/08 00:00 [accepted]
PHST- 2022/07/29 23:40 [entrez]
PHST- 2022/07/30 06:00 [pubmed]
PHST- 2022/08/03 06:00 [medline]
AID - 10.1186/s12884-022-04901-x [pii]
AID - 4901 [pii]
AID - 10.1186/s12884-022-04901-x [doi]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2022 Jul 29;22(1):606. doi: 10.1186/s12884-022-04901-x.

PMID- 27807890
OWN - NLM
STAT- MEDLINE
DCOM- 20170918
LR  - 20171116
IS  - 1469-0705 (Electronic)
IS  - 0960-7692 (Linking)
VI  - 49
IP  - 4
DP  - 2017 Apr
TI  - Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery 
      Doppler at 11-14 weeks: a randomized controlled study.
PG  - 435-441
LID - 10.1002/uog.17351 [doi]
AB  - OBJECTIVE: Defective trophoblastic invasion is a key feature in many cases of 
      pre-eclampsia (PE). Uterine artery (UtA) Doppler is a validated non-invasive 
      proxy for trophoblastic invasion. The aim of this study was to explore whether 
      low-dose aspirin, administered from the first trimester, improves trophoblastic 
      invasion, evaluated by UtA Doppler during the second and third trimesters in 
      women defined as high risk by abnormal first-trimester UtA Doppler. METHODS: This 
      randomized Phase-II study had a triple-blind, parallel-arm, controlled design. 
      Singleton pregnancies with abnormal mean UtA Doppler at 11-14 weeks and absence 
      of other major risk factors for PE received 150 mg extended-release aspirin or 
      identical-appearing placebo tablets from study inclusion to 28 weeks. Main 
      outcome measure was UtA pulsatility index (PI) at 28 weeks' gestation. Secondary 
      outcomes included frequency of development of PE and growth 
      restriction/small-for-gestational age (SGA). RESULTS: A total of 155 women 
      completed the follow-up and were analyzed. No difference in mean UtA-PI was found 
      between women in the aspirin and placebo groups at 28 weeks (mean UtA-PI Z-score 
      (mean ± SD), 0.99 ± 1.48 vs 0.85 ± 1.25; P = 0.52). Seven women developed PE: 
      four (5%) in the aspirin group and three (4%) in the placebo group. There was a 
      trend toward lower incidence of SGA in the aspirin group (8.8% vs 17.3%; 
      P = 0.11). CONCLUSION: In women with defective trophoblastic invasion, as 
      reflected by abnormal UtA Doppler, low-dose aspirin started in the first 
      trimester does not have a significant effect on UtA impedance as pregnancy 
      progresses; however, the study was underpowered to detect potential small effects 
      . Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.
CI  - Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.
FAU - Scazzocchio, E
AU  - Scazzocchio E
AD  - Obstetrics, Gynecology and Reproductive Medicine Department, Quirón Dexeus 
      University Hospital, Barcelona, Spain.
FAU - Oros, D
AU  - Oros D
AD  - Obstetrics Department, Hospital Clínico Lozano Blesa, University of Zaragoza and 
      Instituto de Investigación Sanitaria de Aragón (ISS-Aragón), Zaragoza, Spain.
FAU - Diaz, D
AU  - Diaz D
AD  - BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital 
      Clínic and Hospital Sant Joan de Deu), IDIBAPS, University of Barcelona and 
      Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain.
FAU - Ramirez, J C
AU  - Ramirez JC
AD  - BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital 
      Clínic and Hospital Sant Joan de Deu), IDIBAPS, University of Barcelona and 
      Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain.
FAU - Ricart, M
AU  - Ricart M
AD  - Obstetrics, Gynecology and Reproductive Medicine Department, Quirón Dexeus 
      University Hospital, Barcelona, Spain.
FAU - Meler, E
AU  - Meler E
AD  - Obstetrics, Gynecology and Reproductive Medicine Department, Quirón Dexeus 
      University Hospital, Barcelona, Spain.
FAU - González de Agüero, R
AU  - González de Agüero R
AD  - Obstetrics Department, Hospital Clínico Lozano Blesa, University of Zaragoza and 
      Instituto de Investigación Sanitaria de Aragón (ISS-Aragón), Zaragoza, Spain.
FAU - Gratacos, E
AU  - Gratacos E
AD  - BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital 
      Clínic and Hospital Sant Joan de Deu), IDIBAPS, University of Barcelona and 
      Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain.
FAU - Figueras, F
AU  - Figueras F
AD  - BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital 
      Clínic and Hospital Sant Joan de Deu), IDIBAPS, University of Barcelona and 
      Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Ultrasound Obstet Gynecol
JT  - Ultrasound in obstetrics & gynecology : the official journal of the International 
      Society of Ultrasound in Obstetrics and Gynecology
JID - 9108340
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ultrasound Obstet Gynecol. 2017 Apr;49(4):433. PMID: 28374437
CIN - Ultrasound Obstet Gynecol. 2017 May;49(5):664-665. PMID: 28471025
CIN - Ultrasound Obstet Gynecol. 2017 May;49(5):665. PMID: 28471031
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Cell Movement
MH  - Female
MH  - Humans
MH  - Infant, Small for Gestational Age
MH  - Pre-Eclampsia/*epidemiology
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Pregnancy Trimester, Second
MH  - Treatment Outcome
MH  - Trophoblasts/*drug effects
MH  - Ultrasonography, Doppler
MH  - Ultrasonography, Prenatal
MH  - Uterine Artery/*abnormalities/diagnostic imaging
OTO - NOTNLM
OT  - aspirin
OT  - first-trimester screening
OT  - pre-eclampsia
OT  - prevention
OT  - uterine artery Doppler
EDAT- 2016/11/04 06:00
MHDA- 2017/09/19 06:00
CRDT- 2016/11/04 06:00
PHST- 2016/07/02 00:00 [received]
PHST- 2016/10/25 00:00 [revised]
PHST- 2016/10/28 00:00 [accepted]
PHST- 2016/11/04 06:00 [pubmed]
PHST- 2017/09/19 06:00 [medline]
PHST- 2016/11/04 06:00 [entrez]
AID - 10.1002/uog.17351 [doi]
PST - ppublish
SO  - Ultrasound Obstet Gynecol. 2017 Apr;49(4):435-441. doi: 10.1002/uog.17351.

PMID- 16931440
OWN - NLM
STAT- MEDLINE
DCOM- 20061012
LR  - 20191110
IS  - 0148-0545 (Print)
IS  - 0148-0545 (Linking)
VI  - 29
IP  - 4
DP  - 2006
TI  - Effect of cotreatment of aspirin metabolites on mitomycin C-induced genotoxicity 
      using the somatic mutation and recombination test in Drosophila melanogaster.
PG  - 379-96
AB  - In our previous reports, aspirin, an antipyretic analgesic, suppressed the 
      genotoxicity of mitomycin C (MMC) in a somatic mutation and recombination test 
      (SMART) in Drosophila melanogaster. In order to reveal the mechanism of the 
      anti-genotoxicity of aspirin, we evaluated the suppressing ability of each 
      aspirin metabolite, such as salicylic acid (SA), salicyluric acid (SUA), gentisic 
      acid (GA), gentisuric acid (GUA), and 2,3-dihydroxybenzoic acid (DHBA), in SMART 
      in Drosophila melanogaster using the cotreatment protocol in this report. SUA, 
      GA, GUA, and DHBA reduced the number of the three types of spot induced by MMC 
      without decrease of survival. These aspirin metabolites decreased the 
      genotoxicity frequency of MMC for total spots in a dose-dependent manner. 
      Furthermore, each metabolite decreased the genotoxicity frequency of MMC by 
      approximately 80% at a dose of 40 mg/bottle, respectively. It is suggested that 
      these metabolites are the main substances of anti-genotoxicity in the aspirin 
      metabolic pathway.
FAU - Niikawa, Miki
AU  - Niikawa M
AD  - Department of Hygienics, Gifu Pharmaceutical University, Gifu, Japan. 
      niikawam@tim.hi-ho.ne.jp
FAU - Nakamura, Takeshi
AU  - Nakamura T
FAU - Nagase, Hisamitsu
AU  - Nagase H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Drug Chem Toxicol
JT  - Drug and chemical toxicology
JID - 7801723
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antimutagenic Agents)
RN  - 0 (Mutagens)
RN  - 50SG953SK6 (Mitomycin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Anti-Inflammatory Agents, Non-Steroidal/metabolism/pharmacology
MH  - Antimutagenic Agents/metabolism/*pharmacology
MH  - *Aspirin/analogs & derivatives/metabolism/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drosophila melanogaster/drug effects/genetics
MH  - Drug Antagonism
MH  - Drug Therapy, Combination
MH  - Female
MH  - Male
MH  - Mitomycin/*toxicity
MH  - Mutagens/*toxicity
MH  - Mutation/*drug effects
MH  - Recombination, Genetic/*drug effects
EDAT- 2006/08/26 09:00
MHDA- 2006/10/13 09:00
CRDT- 2006/08/26 09:00
PHST- 2006/08/26 09:00 [pubmed]
PHST- 2006/10/13 09:00 [medline]
PHST- 2006/08/26 09:00 [entrez]
AID - G781716V11820073 [pii]
AID - 10.1080/01480540600820528 [doi]
PST - ppublish
SO  - Drug Chem Toxicol. 2006;29(4):379-96. doi: 10.1080/01480540600820528.

PMID- 29512816
OWN - NLM
STAT- MEDLINE
DCOM- 20180724
LR  - 20180724
IS  - 0017-0011 (Print)
IS  - 0017-0011 (Linking)
VI  - 89
IP  - 2
DP  - 2018
TI  - The practical use of acetylsalicylic acid in the era of the ASPRE trial. Update 
      and literature review.
PG  - 107-111
LID - 10.5603/GP.a2018.0018 [doi]
AB  - It is now well established that acetylsalicylic acid - one of the most widely 
      prescribed drugs today - has brought a new era in maternal-fetal medicine. The 
      History of medicine mentions several antecedents. Extracts made from willow 
      contained in clay tablets are reported in both ancient Sumer and Egypt. In 400 
      BC, Hippocrates referred to the use of salicylic tea to reduce fevers. In the 
      1950s, acetylsalicylic acid entered the Guinness Book of Records as the highest 
      selling painkiller. There is little doubt that acetylsalicylic acid - one of the 
      first drugs to enter common usage - remains one of the most researched drugs in 
      the world.
FAU - Kosinski, Przemyslaw
AU  - Kosinski P
AD  - 1st Department of Obstetrics and Gynecology, Medical University of Warsaw,, Plac 
      Starynkiewicza 1/3, 02-015 Warszawa, Poland. pkosinski@wum.edu.pl.
FAU - Sarzynska-Nowacka, Urszula
AU  - Sarzynska-Nowacka U
FAU - Fiolna, Magdalena
AU  - Fiolna M
FAU - Wielgos, Miroslaw
AU  - Wielgos M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Poland
TA  - Ginekol Pol
JT  - Ginekologia polska
JID - 0374641
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy, High-Risk
MH  - Randomized Controlled Trials as Topic
EDAT- 2018/03/08 06:00
MHDA- 2018/07/25 06:00
CRDT- 2018/03/08 06:00
PHST- 2017/11/23 00:00 [received]
PHST- 2018/01/14 00:00 [accepted]
PHST- 2018/03/08 06:00 [entrez]
PHST- 2018/03/08 06:00 [pubmed]
PHST- 2018/07/25 06:00 [medline]
AID - VM/OJS/J/56157 [pii]
AID - 10.5603/GP.a2018.0018 [doi]
PST - ppublish
SO  - Ginekol Pol. 2018;89(2):107-111. doi: 10.5603/GP.a2018.0018.

PMID- 1175340
OWN - NLM
STAT- MEDLINE
DCOM- 19751218
LR  - 20191210
IS  - 0301-0538 (Print)
IS  - 0301-0538 (Linking)
VI  - 49
IP  - 3
DP  - 1975 Sep
TI  - Effect of lysine acetylsalicylate on biliary lipid secretion in dogs.
PG  - 253-6
AB  - 1. The influence of lysine acetylsalicylate on bile flow, erythritol clearance 
      and bile salt, phospholipid and cholesterol secretion in bile was studied in 
      unanaesthetized dogs fitted with a Thomas duodenal cannula. 2. Lysine 
      acetylsalicylate induced a marked increase in bile flow and a parallel increase 
      in erythritol clearance although the bile salt secretion remained unchanged; this 
      suggests that the compound stimulated the formation of the canalicular 
      (hepatocytic) bile salt-independent fraction of bile flow. 3. Lysine 
      acetylsalicylate induced a significant decrease in biliary phospholipid and 
      cholesterol secretion and the cholesterol saturation of bile was significantly 
      reduced. 4. It is postulated that the decrease in phospholipid and cholesterol 
      secretion resulted from the dilution of intracanalicular bile salts. This effect 
      of lysine acetylsalicylate, and possibly of other bile salt-independent 
      choleretics, may be of value in the treatment of cholesterol gallstones in man.
FAU - Erlinger, S
AU  - Erlinger S
FAU - Bienfait, D
AU  - Bienfait D
FAU - Poupon, R
AU  - Poupon R
FAU - Dumont, M
AU  - Dumont M
FAU - Duval, M
AU  - Duval M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Sci Mol Med
JT  - Clinical science and molecular medicine
JID - 0367540
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Phospholipids)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - RA96B954X6 (Erythritol)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Bile/*metabolism
MH  - Bile Acids and Salts/*metabolism
MH  - Cholesterol/*metabolism
MH  - Dogs
MH  - Erythritol/metabolism
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Phospholipids/*metabolism
EDAT- 1975/09/01 00:00
MHDA- 1975/09/01 00:01
CRDT- 1975/09/01 00:00
PHST- 1975/09/01 00:00 [pubmed]
PHST- 1975/09/01 00:01 [medline]
PHST- 1975/09/01 00:00 [entrez]
AID - 10.1042/cs0490253 [doi]
PST - ppublish
SO  - Clin Sci Mol Med. 1975 Sep;49(3):253-6. doi: 10.1042/cs0490253.

PMID- 35857202
OWN - NLM
STAT- MEDLINE
DCOM- 20220817
LR  - 20221013
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Print)
IS  - 1523-3782 (Linking)
VI  - 24
IP  - 9
DP  - 2022 Sep
TI  - Aspirin for Primary Prevention of Cardiovascular Diseases: "WALTZ" with the 
      Evidence.
PG  - 1139-1147
LID - 10.1007/s11886-022-01740-2 [doi]
AB  - PURPOSE OF REVIEW: In this review article, a detailed analysis of the current 
      literature is provided, along with a "glimpse" into what the future holds for 
      aspirin in the context of primary prevention. RECENT FINDINGS: The role of 
      aspirin in primary prevention of cardiovascular diseases (CVD) has been 
      extensively evaluated; however, the results provided over the years have been 
      controversial. Identification of individual subgroups who may benefit from 
      aspirin administration at an acceptable risk of bleeding complications is of 
      paramount importance. Additionally, questions emerge at everyday clinical 
      practice regarding the optimal use of aspirin in different phenotypes of patients 
      due to age, sex, obesity status, frailty and diabetes mellitus. Until further 
      data become available, the effective management of the well-established CV risk 
      factors constitutes the milestone in the primary prevention of CVD. Moreover, 
      based on the available evidence, the beneficial addition of aspirin in the modern 
      era of lifestyle and pharmacological interventions for primary CVD prevention 
      remains largely undetermined and further research is needed.
CI  - © 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Dimitriadis, Kyriakos
AU  - Dimitriadis K
AD  - First Department of Cardiology, Medical School, National and Kapodistrian 
      University of Athens, Hippokration Hospital, 114 Vassilissis Sofias Ave 11527, 
      Athens, Greece.
FAU - Lazarou, Emilia
AU  - Lazarou E
AD  - First Department of Cardiology, Medical School, National and Kapodistrian 
      University of Athens, Hippokration Hospital, 114 Vassilissis Sofias Ave 11527, 
      Athens, Greece.
FAU - Tsioufis, Panagiotis
AU  - Tsioufis P
AD  - First Department of Cardiology, Medical School, National and Kapodistrian 
      University of Athens, Hippokration Hospital, 114 Vassilissis Sofias Ave 11527, 
      Athens, Greece.
FAU - Soulaidopoulos, Stergios
AU  - Soulaidopoulos S
AD  - First Department of Cardiology, Medical School, National and Kapodistrian 
      University of Athens, Hippokration Hospital, 114 Vassilissis Sofias Ave 11527, 
      Athens, Greece.
FAU - Tsioufis, Konstantinos
AU  - Tsioufis K
AD  - First Department of Cardiology, Medical School, National and Kapodistrian 
      University of Athens, Hippokration Hospital, 114 Vassilissis Sofias Ave 11527, 
      Athens, Greece. ktsioufis@hippocratio.gr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220720
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/drug therapy
MH  - *Diabetes Mellitus
MH  - Humans
MH  - Primary Prevention/methods
MH  - Risk Factors
PMC - PMC9297059
OTO - NOTNLM
OT  - Aspirin
OT  - Bleeding risk
OT  - Primary cardiovascular disease prevention
COIS- The authors declare that they have no conflict of interest.
EDAT- 2022/07/21 06:00
MHDA- 2022/08/18 06:00
CRDT- 2022/07/20 11:21
PHST- 2022/06/13 00:00 [accepted]
PHST- 2022/07/21 06:00 [pubmed]
PHST- 2022/08/18 06:00 [medline]
PHST- 2022/07/20 11:21 [entrez]
AID - 10.1007/s11886-022-01740-2 [pii]
AID - 1740 [pii]
AID - 10.1007/s11886-022-01740-2 [doi]
PST - ppublish
SO  - Curr Cardiol Rep. 2022 Sep;24(9):1139-1147. doi: 10.1007/s11886-022-01740-2. Epub 
      2022 Jul 20.

PMID- 31912772
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 1872-213X (Print)
IS  - 2212-4055 (Electronic)
IS  - 1872-213X (Linking)
VI  - 14
IP  - 1
DP  - 2020
TI  - Anti-Inflammatory and Gastroprotective Properties of Aspirin - Entrapped Solid 
      Lipid Microparticles.
PG  - 78-88
LID - 10.2174/1872213X14666200108101548 [doi]
AB  - BACKGROUND: Aspirin is a nonsteroidal anti-inflammatory drug that is very 
      effective in the treatment of inflammation and other health conditions, however, 
      it causes gastric irritation. Recently, researchers have developed patents 
      (US9757529, 2019) of inhalable aspirin for rapid absorption and circumvention of 
      gastric irritation. OBJECTIVE: The aim of this work was to formulate 
      aspirin-loaded lipid based formulation in order to enhance oral bioavailability 
      and inhibit gastric irritation. METHODS: This solid lipid microparticles loaded 
      with aspirin (SLM) was formulated by a modified cold homogenization-solvent 
      evaporation method. In vitro studies such as in vitro drug release, particle 
      size, Encapsulation Efficiency (EE), micromeritic properties and loading capacity 
      were carried out. Pharmacodynamics studies such as anti-inflammatory and 
      ulcerative properties of the SLM were also carried out in Wistar rats. RESULTS: 
      The results showed that aspirin entrapped SLM exhibited the highest EE of 72% and 
      particle size range of 7.60 + 0.141µm to 20.25 + 0.070µm. Formulations had about 
      55% drug release at 6h in simulated intestinal fluid pH 6.8. The formulations had 
      good flowability that could facilitate filling into hard gelatin capsule shells. 
      The SLM exhibited 100% gastroprotection against aspirin-induced ulcers (p < 
      0.05). The percentage of anti-inflammatory activities also showed that 
      aspirin-entrapped SLM had 78% oedema inhibition at 7h, while the reference had 
      68% inhibition at 7h. CONCLUSION: Aspirin-entrapped SLM showed good 
      sustained-release properties, enhanced antiinflammatory properties and total 
      gastric protection from aspirin-induced ulcers and could be used as once-daily 
      oral aspirin.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Chime, Salome A
AU  - Chime SA
AD  - Department of Pharmaceutical Technology and Industrial Pharmacy, University of 
      Nigeria, Nsukka 410001, Nigeria.
FAU - Akpa, Paul A
AU  - Akpa PA
AD  - Department of Pharmaceutics, University of Nigeria, Nsukka 410001, Nigeria.
FAU - Ugwuanyi, Cosmas C
AU  - Ugwuanyi CC
AD  - Department of Pharmaceutical Technology and Industrial Pharmacy, University of 
      Nigeria, Nsukka 410001, Nigeria.
FAU - Attama, Anthony A
AU  - Attama AA
AD  - Department of Pharmaceutics, University of Nigeria, Nsukka 410001, Nigeria.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Recent Pat Inflamm Allergy Drug Discov
JT  - Recent patents on inflammation & allergy drug discovery
JID - 101309297
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Carriers)
RN  - 0 (Lipids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & 
      dosage/pharmacokinetics/pharmacology
MH  - Aspirin/*administration & dosage/pharmacokinetics/pharmacology
MH  - Biological Availability
MH  - Chemistry, Pharmaceutical
MH  - Drug Carriers/*chemistry
MH  - Drug Liberation
MH  - Female
MH  - Lipids/*chemistry
MH  - Male
MH  - Microspheres
MH  - Particle Size
MH  - Patents as Topic
MH  - Rats
MH  - Rats, Wistar
MH  - Stomach Ulcer/prevention & control
PMC - PMC7516335
OTO - NOTNLM
OT  - Anti-inflammatory
OT  - aspirin
OT  - drug delivery
OT  - gastroprotection
OT  - kinetics of release
OT  - lipids
OT  - micromerics
OT  - ulcers.gugu.
EDAT- 2020/01/09 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/01/09 06:00
PHST- 2019/08/06 00:00 [received]
PHST- 2019/11/18 00:00 [revised]
PHST- 2019/12/12 00:00 [accepted]
PHST- 2020/01/09 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/01/09 06:00 [entrez]
AID - IAD-EPUB-103545 [pii]
AID - IAD-14-78 [pii]
AID - 10.2174/1872213X14666200108101548 [doi]
PST - ppublish
SO  - Recent Pat Inflamm Allergy Drug Discov. 2020;14(1):78-88. doi: 
      10.2174/1872213X14666200108101548.

PMID- 8502115
OWN - NLM
STAT- MEDLINE
DCOM- 19930701
LR  - 20190701
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 52
IP  - 21
DP  - 1993
TI  - In vitro glycation and acetylation (by aspirin) of rat crystallins.
PG  - 1699-707
AB  - In vitro studies with rat lens crystallins were conducted to explore the 
      mechanism by which aspirin (ASA-acetylsalicylic acid) could inhibit 
      cataractogenesis. The purpose of the present study is to show whether 
      gamma-crystallin is the primary target for glycation by glucose and acetylation 
      by ASA. Lens soluble fractions from one and seven month old Sprague-Dawley rats 
      were incubated with 5 mM [14C]glucose with and without 10 mM ASA. alpha, beta, 
      and gamma-crystallins were separated by molecular sieve HPLC and specific 
      activities of each crystallin determined. In vitro acetylation was also studied 
      by measuring protein bound [14C]acetyl groups after incubation with [14C]acetyl 
      ASA. There was 2 to 4-fold faster glycation of gamma-crystallin than all other 
      crystallins from 1-month-old rats and ASA inhibited glycation of gamma-crystallin 
      four times more than that of alpha and beta-crystallins, thus showing 
      preferential glycation of gamma-crystallin and its selective inhibition by ASA. 
      [14C]acetyl incorporation showed increased acetylation of gamma-crystallin in one 
      month old rats, whereas in older lenses acetylation of other crystallins 
      predominated. Treatment with 10 mM ASA showed 35% decrease in free -NH2 groups 
      but protein thiols remained unchanged.
FAU - Cherian, M
AU  - Cherian M
AD  - Dept. of Biochemistry & Molecular Biology, Medical College of Georgia, Augusta 
      30912.
FAU - Abraham, E C
AU  - Abraham EC
LA  - eng
GR  - EY 07394/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Amines)
RN  - 0 (Carbon Radioisotopes)
RN  - 0 (Crystallins)
RN  - 0 (Sulfhydryl Compounds)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation/drug effects
MH  - Amines/analysis
MH  - Animals
MH  - Aspirin/metabolism/*pharmacology
MH  - Carbon Radioisotopes
MH  - Chromatography, High Pressure Liquid
MH  - Crystallins/*drug effects/metabolism
MH  - Glucose/metabolism/pharmacology
MH  - Glycosylation/drug effects
MH  - In Vitro Techniques
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sulfhydryl Compounds/analysis
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 0024-3205(93)90478-L [pii]
AID - 10.1016/0024-3205(93)90478-l [doi]
PST - ppublish
SO  - Life Sci. 1993;52(21):1699-707. doi: 10.1016/0024-3205(93)90478-l.

PMID- 15345513
OWN - NLM
STAT- MEDLINE
DCOM- 20050531
LR  - 20171116
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
VI  - 24
IP  - 11
DP  - 2004 Nov
TI  - Nitric oxide-releasing aspirin derivative, NCX 4016, promotes reparative 
      angiogenesis and prevents apoptosis and oxidative stress in a mouse model of 
      peripheral ischemia.
PG  - 2082-7
AB  - BACKGROUND: Recently, nitric oxide (NO) donors have been developed that mimic the 
      physiological intracellular release of NO. We evaluated whether one of these new 
      compounds, consisting of aspirin coupled to an NO-releasing moiety (NCX 4016), 
      would protect limbs from supervening arterial occlusion. METHODS AND RESULTS: 
      Mice were assigned to receive regular chow or chow containing NCX 4016 or aspirin 
      (both at 300 mumol/kg body weight, daily) throughout the 3-week experimental 
      period. One week after randomization, they underwent surgical excision of the 
      left femoral artery. Limb blood flow recovery (laser Doppler flowmetry) was 
      accelerated by NCX 4016 as compared with aspirin or vehicle (P<0.05). In 
      controls, histological analysis revealed a 35% increase in the capillary density 
      of ischemic muscles compared with contralateral ones, indicative of spontaneous 
      angiogenesis. Neovascularization was enhanced by NCX 4016 (91%; P<0.05 versus 
      vehicle), but not by aspirin (51%; P=NS versus vehicle). Furthermore, NCX 4016 
      reduced endothelial cell (EC) apoptosis (4.3+/-1.0 versus 8.7+/-2.0 in aspirin 
      and 12.6+/-3.3 ECs/1000 cap in vehicle; P<0.05 for either comparison) as well as 
      caspase-3 mRNA levels in ischemic muscles ([caspase-3/GAPDH]*100 = 0.09+/-0.04 
      versus 2.30+/-0.44 in aspirin and 2.30+/-0.32 in vehicle; P<0.01 for either 
      comparison). Nitrite levels and the ratio of reduced to oxidized glutathione were 
      selectively increased in ischemic muscles by NCX 4016. Vascular endothelial 
      growth factor-A expression was reduced by aspirin, with this effect being blunted 
      by NCX 4016. CONCLUSIONS: Pretreatment with the new oral NO-releasing aspirin 
      derivative stimulates reparative angiogenesis and prevents apoptosis and 
      oxidative stress, thereby alleviating the consequences of supervening arterial 
      occlusion.
FAU - Emanueli, Costanza
AU  - Emanueli C
AD  - Molecular and Cellular Medicine, National Institute of Biostructures and 
      Biosystems, Alghero, Italy.
FAU - Van Linthout, Sophie
AU  - Van Linthout S
FAU - Salis, Maria Bonaria
AU  - Salis MB
FAU - Monopoli, Angela
AU  - Monopoli A
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Ongini, Ennio
AU  - Ongini E
FAU - Madeddu, Paolo
AU  - Madeddu P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20040902
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 0 (Nitrites)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects/physiology
MH  - Aspirin/*analogs & derivatives/antagonists & inhibitors/*metabolism/*pharmacology
MH  - *Disease Models, Animal
MH  - Down-Regulation/physiology
MH  - Gene Expression Regulation/drug effects
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Muscle, Skeletal/blood supply/chemistry/drug effects/pathology
MH  - Neovascularization, Physiologic/*drug effects
MH  - Nitric Oxide/*metabolism
MH  - Nitrites/blood
MH  - Oxidative Stress/*drug effects/physiology
MH  - Reperfusion Injury/blood/*metabolism/pathology
MH  - Vascular Endothelial Growth Factor A/genetics
EDAT- 2004/09/04 05:00
MHDA- 2005/06/01 09:00
CRDT- 2004/09/04 05:00
PHST- 2004/09/04 05:00 [pubmed]
PHST- 2005/06/01 09:00 [medline]
PHST- 2004/09/04 05:00 [entrez]
AID - 01.ATV.0000144030.39087.3b [pii]
AID - 10.1161/01.ATV.0000144030.39087.3b [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2082-7. doi: 
      10.1161/01.ATV.0000144030.39087.3b. Epub 2004 Sep 2.

PMID- 14671677
OWN - NLM
STAT- MEDLINE
DCOM- 20040621
LR  - 20191210
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 25
IP  - 8
DP  - 2003 Oct
TI  - Evaluation of antiepileptic activity of aspirin in combination with newer 
      antiepileptic lamotrigine in mice.
PG  - 607-10
AB  - Neurotransmitters such as GABA, glutamate and prostaglandins mediate synaptic 
      transmission and their modulation may play a role in the generation of seizures. 
      Numerous studies implicate prostaglandins as potential modulators of seizure 
      activity. This study was designed to assess the antiepileptic activity of aspirin 
      and to investigate the potentiation of its activity in combination with a 
      subconvulsive dose of lamotrigine. Graded doses of aspirin and lamotrigine were 
      used in pentylenetetrazole (PTZ) and maximal electroshock (MES) seizure models in 
      mice. To study the interaction of aspirin and lamotrigine, ED(25) doses of 
      aspirin (250 mg/kg) and lamotrigine (1.5 mg/kg) were used in the two seizure 
      models. Aspirin dose-dependently decreased the incidence of seizures in the 
      PTZ-model mice but did not show any effect in MES-model mice. ED(25) doses of 
      aspirin and lamotrigine showed 100% protection of the PTZ seizure model. Aspirin 
      alone in doses of 400 and 800 mg/kg and in combination decreased mortality in the 
      PTZ model. Aspirin showed a significant anticonvulsant effect in PTZ seizure 
      mode. Potentiation of the anticonvulsant effect of lamotrigine with aspirin was 
      shown in the PTZ model, indicating that prostaglandins could play an important 
      role in this seizure model.
CI  - (c) 2003 Prous Science. All rights reserved.
FAU - Tandon, M
AU  - Tandon M
AD  - Department of Pharmacology, Postgraduate Institute of Medical Education & 
      Research, Chandigarh-160012, India.
FAU - Anuradha, K
AU  - Anuradha K
FAU - Pandhi, P
AU  - Pandhi P
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - 0 (Anticonvulsants)
RN  - 0 (Drug Combinations)
RN  - 0 (Triazines)
RN  - R16CO5Y76E (Aspirin)
RN  - U3H27498KS (Lamotrigine)
RN  - WM5Z385K7T (Pentylenetetrazole)
SB  - IM
MH  - Animals
MH  - Anticonvulsants/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Aspirin/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - *Drug Combinations
MH  - Drug Evaluation, Preclinical/*methods
MH  - Drug Synergism
MH  - Electroshock/methods
MH  - Injections, Intraperitoneal
MH  - Lamotrigine
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Pentylenetetrazole
MH  - Seizures/chemically induced/mortality/*prevention & control
MH  - Triazines
EDAT- 2003/12/13 05:00
MHDA- 2004/06/23 05:00
CRDT- 2003/12/13 05:00
PHST- 2003/12/13 05:00 [pubmed]
PHST- 2004/06/23 05:00 [medline]
PHST- 2003/12/13 05:00 [entrez]
AID - 778080 [pii]
AID - 10.1358/mf.2003.25.8.778080 [doi]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 2003 Oct;25(8):607-10. doi: 
      10.1358/mf.2003.25.8.778080.

PMID- 28464540
OWN - NLM
STAT- MEDLINE
DCOM- 20180501
LR  - 20180501
IS  - 1868-6982 (Electronic)
IS  - 1868-6974 (Linking)
VI  - 24
IP  - 7
DP  - 2017 Jul
TI  - Safety and feasibility of liver resection with continued antiplatelet therapy 
      using aspirin.
PG  - 375-381
LID - 10.1002/jhbp.461 [doi]
AB  - BACKGROUND: Aspirin is widely used for the secondary prevention of ischemic 
      stroke and cardiovascular disease. Perioperative aspirin may decrease thrombotic 
      morbidity, but may also increase hemorrhagic morbidity. In particular, liver 
      resection carries risks of bleeding, leading to higher risks of hemorrhagic 
      morbidity. Our institution has continued aspirin therapy perioperatively in 
      patients undergoing liver resection. This study examined the safety and 
      feasibility of liver resection while continuing aspirin. METHODS: We 
      retrospectively evaluated 378 patients who underwent liver resection between 
      January 2010 and January 2016. Patients were grouped according to preoperative 
      aspirin prescription: patients with aspirin therapy (aspirin users, n = 31); and 
      patients without use of aspirin (aspirin non-users, n = 347). RESULTS: Aspirin 
      users were significantly older (P < 0.001), with a higher proportion of males (P 
      < 0.001) and higher frequencies of hypertension (P  = 0.004) and diabetes 
      mellitus (P < 0.001). No significant differences were observed in intraoperative 
      parameters. Although the frequency of major morbidity tended to be higher among 
      aspirin users than among aspirin non-users, no significant difference was 
      identified. No postoperative hemorrhage was seen among aspirin users. 
      CONCLUSIONS: Liver resection can be safely performed while continuing aspirin 
      therapy without increasing hemorrhagic morbidity. Our results suggest that 
      interruption of aspirin therapy is unnecessary for patients undergoing liver 
      resection.
CI  - © 2017 Japanese Society of Hepato-Biliary-Pancreatic Surgery.
FAU - Monden, Kazuteru
AU  - Monden K
AD  - Department of Gastroenterological Surgery, Fukuyama City Hospital, Fukuyama, 
      Hiroshima, Japan.
FAU - Sadamori, Hiroshi
AU  - Sadamori H
AD  - Department of Gastroenterological Surgery, Fukuyama City Hospital, Fukuyama, 
      Hiroshima, Japan.
FAU - Hioki, Masayoshi
AU  - Hioki M
AD  - Department of Gastroenterological Surgery, Fukuyama City Hospital, Fukuyama, 
      Hiroshima, Japan.
FAU - Ohno, Satoshi
AU  - Ohno S
AD  - Department of Gastroenterological Surgery, Fukuyama City Hospital, Fukuyama, 
      Hiroshima, Japan.
FAU - Saneto, Hiromi
AU  - Saneto H
AD  - Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Hiroshima, 
      Japan.
FAU - Ueki, Toru
AU  - Ueki T
AD  - Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Hiroshima, 
      Japan.
FAU - Yabushita, Kazuhisa
AU  - Yabushita K
AD  - Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Hiroshima, 
      Japan.
FAU - Ono, Kazumi
AU  - Ono K
AD  - Department of Anesthesiology and Oncological Pain Medicine, Fukuyama City 
      Hospital, Fukuyama, Hiroshima, Japan.
FAU - Sakaguchi, Kousaku
AU  - Sakaguchi K
AD  - Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Hiroshima, 
      Japan.
FAU - Takakura, Norihisa
AU  - Takakura N
AD  - Department of Gastroenterological Surgery, Fukuyama City Hospital, Fukuyama, 
      Hiroshima, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170605
PL  - Japan
TA  - J Hepatobiliary Pancreat Sci
JT  - Journal of hepato-biliary-pancreatic sciences
JID - 101528587
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/therapeutic use
MH  - *Blood Loss, Surgical
MH  - Cardiovascular Diseases/prevention & control
MH  - Feasibility Studies
MH  - Female
MH  - *Hepatectomy
MH  - Humans
MH  - Liver/*drug effects/surgery
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Postoperative Hemorrhage/*etiology
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiplatelet treatment
OT  - Aspirin
OT  - Bleeding complication
OT  - Liver resection
OT  - Preoperative
EDAT- 2017/05/04 06:00
MHDA- 2018/05/02 06:00
CRDT- 2017/05/03 06:00
PHST- 2017/05/04 06:00 [pubmed]
PHST- 2018/05/02 06:00 [medline]
PHST- 2017/05/03 06:00 [entrez]
AID - 10.1002/jhbp.461 [doi]
PST - ppublish
SO  - J Hepatobiliary Pancreat Sci. 2017 Jul;24(7):375-381. doi: 10.1002/jhbp.461. Epub 
      2017 Jun 5.

PMID- 32661222
OWN - NLM
STAT- MEDLINE
DCOM- 20210415
LR  - 20210713
IS  - 2041-4889 (Electronic)
VI  - 11
IP  - 7
DP  - 2020 Jul 13
TI  - Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome 
      docetaxel and vinorelbine resistance in triple-negative breast cancer.
PG  - 530
LID - 10.1038/s41419-020-2719-2 [doi]
LID - 530
AB  - The use of aspirin has been associated with reduced breast cancer risk, but it is 
      litter known if aspirin overcomes chemoresistance in triple-negative breast 
      cancer (TNBC). Herein, we demonstrated that changes in the expression of 
      Yes-associated protein (YAP) and β-catenin might be a promising predictive 
      biomarker for neoadjuvant chemotherapy sensitivity in TNBC patients. Inhibition 
      of YAP or β-catenin enhanced the cytotoxicity of the anti-microtubule agents 
      docetaxel and vinorelbine against drug-resistant TNBC cells as well as the 
      sensitivity of these cells to the agents in vitro and in vivo. Interestingly, 
      aspirin not only significantly inhibited the growth of TNBC cells, but also 
      attenuated YAP and β-catenin expression by upregulating the E3 ubiquitin ligase 
      β-TrCP to abolished docetaxel and vinorelbine resistance. The combination of 
      aspirin and docetaxel or vinorelbine remarkably inhibited the growth of 
      drug-resistant TNBC cells in vitro and in vivo. Moreover, TNBC patients with high 
      YAP and/or β-catenin expression had a higher risk of relapse or mortality than 
      patients with low YAP and/or β-catenin expression. Collectively, our study 
      discovered a novel role of aspirin based on its anticancer effect, and put 
      forward some possible mechanisms of chemoresistance in TNBC. The combined use of 
      aspirin and anti-microtubule drugs presented several promising therapeutic 
      approaches for TNBC treatment.
FAU - Ma, Ji
AU  - Ma J
AD  - Department of Medical Oncology and Laboratory of Molecular Targeted Therapy in 
      Oncology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan 
      University, No. 37, Guoxue Lane, 610041, Chengdu, Sichuan, China.
FAU - Fan, Zhenhai
AU  - Fan Z
AD  - Key Laboratory of Cell Engineering of Guizhou, The Affiliated Hospital of Zunyi 
      Medical College, No. 149, Dalian Road, 573003, Zunyi, Guizhou, China.
FAU - Tang, Qiulin
AU  - Tang Q
AD  - Department of Medical Oncology and Laboratory of Molecular Targeted Therapy in 
      Oncology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan 
      University, No. 37, Guoxue Lane, 610041, Chengdu, Sichuan, China.
FAU - Xia, Hongwei
AU  - Xia H
AD  - Department of Medical Oncology and Laboratory of Molecular Targeted Therapy in 
      Oncology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan 
      University, No. 37, Guoxue Lane, 610041, Chengdu, Sichuan, China. 
      hw.xia@scu.edu.cn.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Department of Oncology, The General Hospital of Western Theater Command, No. 270, 
      Tianhui Road, 610041, Chengdu, Sichuan Province, PR China. zhangtao269@126.com.
FAU - Bi, Feng
AU  - Bi F
AD  - Department of Medical Oncology and Laboratory of Molecular Targeted Therapy in 
      Oncology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan 
      University, No. 37, Guoxue Lane, 610041, Chengdu, Sichuan, China. 
      bifeng@scu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200713
PL  - England
TA  - Cell Death Dis
JT  - Cell death & disease
JID - 101524092
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Transcription Factors)
RN  - 0 (YY1AP1 protein, human)
RN  - 0 (beta Catenin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cell Cycle Proteins/*metabolism
MH  - Disease Models, Animal
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Transcription Factors/*metabolism
MH  - Triple Negative Breast Neoplasms/*drug therapy/*genetics
MH  - beta Catenin/metabolism
PMC - PMC7359325
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/07/15 06:00
MHDA- 2021/04/16 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/04/16 06:00 [medline]
AID - 10.1038/s41419-020-2719-2 [pii]
AID - 2719 [pii]
AID - 10.1038/s41419-020-2719-2 [doi]
PST - epublish
SO  - Cell Death Dis. 2020 Jul 13;11(7):530. doi: 10.1038/s41419-020-2719-2.

PMID- 11918835
OWN - NLM
STAT- MEDLINE
DCOM- 20020627
LR  - 20131121
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 13
IP  - 1
DP  - 2002 Feb
TI  - Towards a definition of aspirin resistance: a typological approach.
PG  - 37-40
AB  - 'Aspirin resistance' is a poorly defined term to describe the inability of 
      aspirin to protect individuals from thrombotic complications and there are 
      conflicting reports on incidence rates and clinical relevance of this phenomenon. 
      Using collagen (1 microg/ml)-induced platelet aggregation and thromboxane 
      formation (measured as thromboxane B(2)) in citrated platelet-rich plasma, this 
      study demonstrates that aspirin resistance can be classified into three distinct 
      types. In aspirin responders, both, collagen-induced platelet aggregation and 
      thromboxane formation was completely (>95%) inhibited by oral aspirin treatment 
      (100 mg/day). In type I resistance (pharmacokinetic type), oral treatment with 
      aspirin was ineffective but addition of aspirin (100 microM) in vitro resulted in 
      a complete inhibition of collagen-induced platelet aggregation and thromboxane 
      formation. In type II resistance (pharmacodynamic type), neither oral treatment 
      with aspirin nor addition of aspirin in vitro inhibited collagen-induced platelet 
      aggregation and thromboxane formation. In type III resistance 
      (pseudo-resistance), platelet aggregation was induced by a low concentration of 
      collagen (1 microg/ml) despite of a complete inhibition of thromboxane formation 
      by oral aspirin treatment. This typology of aspirin resistance should help to 
      clarify the mechanisms, the actual rate, and the possible clinical consequences 
      of this phenomenon.
FAU - Weber, Artur-Aron
AU  - Weber AA
AD  - Institut für Pharmakologie und Klinische Pharmakologie, 
      Heinrich-Heine-Universität, Düsseldorf, Germany.
FAU - Przytulski, Boris
AU  - Przytulski B
FAU - Schanz, Andrea
AU  - Schanz A
FAU - Hohlfeld, Thomas
AU  - Hohlfeld T
FAU - Schrör, Karsten
AU  - Schrör K
LA  - eng
PT  - Journal Article
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/*physiology
MH  - Cardiovascular Diseases/drug therapy
MH  - Cerebrovascular Disorders/drug therapy
MH  - Drug Resistance/*physiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Reference Values
MH  - Thromboxanes/blood
EDAT- 2002/03/29 10:00
MHDA- 2002/06/28 10:01
CRDT- 2002/03/29 10:00
PHST- 2002/03/29 10:00 [pubmed]
PHST- 2002/06/28 10:01 [medline]
PHST- 2002/03/29 10:00 [entrez]
AID - 10.1080/09537100120104890 [doi]
PST - ppublish
SO  - Platelets. 2002 Feb;13(1):37-40. doi: 10.1080/09537100120104890.

PMID- 2688043
OWN - NLM
STAT- MEDLINE
DCOM- 19900116
LR  - 20131121
IS  - 0035-2640 (Print)
IS  - 0035-2640 (Linking)
VI  - 39
IP  - 25
DP  - 1989 Nov 1
TI  - [Platelet antiaggregants and coronary pathology].
PG  - 2228-33
AB  - Platelet inhibitors have widely been studied in various clinical situations 
      resulting from atherosclerosis of the coronary arteries. At present, aspirin is 
      virtually the only drug that has proved to be effective in all cases where the 
      risk of coronary thrombosis was very high. Administered in daily doses of 160 to 
      1,500 mg, acetylsalicylic acid reduces the frequency of coronary thrombosis and 
      its consequence, myocardial infarction, in the following clinical situations: 
      year following myocardial infarction, acute phase of myocardial infarction, 
      unstable angina, year following aorto-coronary bypass, days following dilatation 
      of the coronary arteries. Acetylsalicylic acid has been compared with heparin and 
      anti-vitamin K agents in four trial: whatever the model studied, no difference 
      was found in the effectiveness of the two treatments tested. Aspirin ha recently 
      been reported as preventing myocardial infarction in healthy subjects. The 
      practical value of this finding is questionable. The various effects of aspirin 
      have been ascribed to the fact that it interrupts a cascade of events ranging 
      from rupture of atherosclerosis plaques to arterial thrombosis.
FAU - Castaigne, A
AU  - Castaigne A
FAU - Duval-Moulin, A M
AU  - Duval-Moulin AM
FAU - Dutoit, C
AU  - Dutoit C
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Antiagrégants plaquettaires et pathologie coronaire.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
RN  - R16CO5Y76E (Aspirin)
MH  - Angina, Unstable/drug therapy
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Coronary Disease/physiopathology/*prevention & control
MH  - Humans
MH  - Myocardial Infarction/complications/prevention & control
MH  - Recurrence
RF  - 22
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
PST - ppublish
SO  - Rev Prat. 1989 Nov 1;39(25):2228-33.

PMID- 21453696
OWN - NLM
STAT- MEDLINE
DCOM- 20110909
LR  - 20220408
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 659
IP  - 2-3
DP  - 2011 Jun 1
TI  - Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease.
PG  - 289-95
LID - 10.1016/j.ejphar.2011.03.016 [doi]
AB  - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic 
      liver injury; however its therapeutic strategy has not been established yet. 
      Nitro-aspirin (NO-aspirin) is a new molecule in which aspirin and a NO-donating 
      group are covalently linked. This study investigated the potential protective 
      effect of NO-aspirin on NAFLD. Experimental rats were assigned into 4 groups. 
      Group 1 was fed with normal diet and served as normal control group. Group 2 was 
      fed with 2% cholesterol diet and received vehicle as positive control NAFLD 
      group. Group 3 was fed with 2% cholesterol diet plus NO-aspirin (100 mg/kg/day). 
      Group 4 was fed with 2% cholesterol diet plus aspirin (55 mg/kg/day). Rats were 
      treated for 8 weeks. The results showed that NO-aspirin (but not aspirin) 
      prevented the development of NAFLD as evidenced by significant reduction in liver 
      weight/body weight ratio (liver index) and histopathologic changes. The 
      protective effect of NO-aspirin is accompanied with significant decrease in 
      triglycerides, malondialdehyde (MDA), and nitric oxide (NO) in hepatic tissue. 
      Semi-quantitative immunohistochemical studies showed significant decrease in 
      expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) 
      in hepatic tissue. In conclusion, NO-aspirin inhibited multiple pathways involved 
      in the pathogenesis of NAFLD indicating that it might serve as a new therapeutic 
      strategy.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Ibrahim, Mohamed
AU  - Ibrahim M
AD  - Department of Pharmacology, Faculty of Medicine, Minia University, Egypt. 
      mabdellah69@yahoo.com
FAU - Farghaly, Entesar
AU  - Farghaly E
FAU - Gomaa, Wafaey
AU  - Gomaa W
FAU - Kelleni, Mina
AU  - Kelleni M
FAU - Abdelrahman, Aly Mohamed
AU  - Abdelrahman AM
LA  - eng
PT  - Journal Article
DEP - 20110329
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Triglycerides)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alanine Transaminase/metabolism
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Cyclooxygenase 2/metabolism
MH  - Fatty Liver/*drug therapy/enzymology/metabolism/pathology
MH  - Gene Expression Regulation, Enzymologic/drug effects
MH  - Liver/drug effects/enzymology/metabolism/pathology
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Synthase Type II/metabolism
MH  - Non-alcoholic Fatty Liver Disease
MH  - Rats
MH  - Rats, Wistar
MH  - Triglycerides/metabolism
EDAT- 2011/04/02 06:00
MHDA- 2011/09/10 06:00
CRDT- 2011/04/02 06:00
PHST- 2010/07/30 00:00 [received]
PHST- 2011/02/17 00:00 [revised]
PHST- 2011/03/09 00:00 [accepted]
PHST- 2011/04/02 06:00 [entrez]
PHST- 2011/04/02 06:00 [pubmed]
PHST- 2011/09/10 06:00 [medline]
AID - S0014-2999(11)00287-1 [pii]
AID - 10.1016/j.ejphar.2011.03.016 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2011 Jun 1;659(2-3):289-95. doi: 10.1016/j.ejphar.2011.03.016. 
      Epub 2011 Mar 29.

PMID- 36233049
OWN - NLM
STAT- MEDLINE
DCOM- 20221017
LR  - 20221019
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 19
DP  - 2022 Oct 4
TI  - From Solution Studies of Pharmaceuticals (Aspirin and Related Compounds) to the 
      Thermodynamics of Aspirin-β-Cyclodextrin Interaction in water and 
      N,N-Dimethylformamide.
LID - 10.3390/ijms231911750 [doi]
LID - 11750
AB  - The solution behavior of pharmaceuticals (acetylsalicylic acid, 4-acetoxybenzoic 
      acid and 5-acetylsalicylic acid) in water and N,N-Dimethylformamide (DMF) at 
      298.15 K were investigated through solubility, conductance and calorimetric 
      measurements. Taking into account the formation of ion pairs of these 
      pharmaceuticals in water, the solution Gibbs energies of the dissociated 
      electrolytes in this solvent were calculated. Thus, the solution thermodynamics 
      of these compounds in water are reported using enthalpy data obtained by 
      calorimetry. These pharmaceuticals undergo solvation when exposed to a saturated 
      atmosphere of DMF. As the composition of the solid is not the same as that in 
      solution, the Gibbs energy of the solutions of these compounds could not be 
      obtained; only enthalpy data are reported. The thermodynamics of the interaction 
      of acetylsalicylic acid (aspirin) with β-cyclodextrin in water and DMF is fully 
      discussed, emphasizing the two different processes that take place in water at 
      the two different pHs. In all cases, the favorable Gibbs energies for these 
      processes are entropically controlled, mainly resulting from the higher 
      dehydration/desolvation that the receptor undergoes upon interaction with the 
      guest.
FAU - Danil de Namor, Angela F
AU  - Danil de Namor AF
AD  - Laboratory of Thermochemistry, Department of Chemistry, University of Surrey, 
      Guildford, Surrey GU2 7XH, UK.
FAU - Cambanis, Alexandros
AU  - Cambanis A
AD  - Laboratory of Thermochemistry, Department of Chemistry, University of Surrey, 
      Guildford, Surrey GU2 7XH, UK.
FAU - Al Hakawati, Nawal
AU  - Al Hakawati N
AD  - Department of Biological Sciences, Faculty of Science, Beirut Arab University, 
      Tripoli P.O. Box 11-5020, Lebanon.
FAU - Khalife, Rasha
AU  - Khalife R
AD  - School of Chemical, Biological and Environmental Engineering, Oregon State 
      University, 116 Johnson Hall 105 SW 26th Sr, Corvallis, OR 97331, USA.
LA  - eng
PT  - Journal Article
DEP - 20221004
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Solvents)
RN  - 0 (beta-Cyclodextrins)
RN  - 059QF0KO0R (Water)
RN  - 8696NH0Y2X (Dimethylformamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Dimethylformamide
MH  - Pharmaceutical Preparations
MH  - Solubility
MH  - Solvents/chemistry
MH  - Thermodynamics
MH  - *Water/chemistry
MH  - *beta-Cyclodextrins
PMC - PMC9569790
OTO - NOTNLM
OT  - aspirin
OT  - thermodynamic parameters
OT  - β-cyclodextrin
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/15 06:00
MHDA- 2022/10/18 06:00
CRDT- 2022/10/14 02:12
PHST- 2022/08/13 00:00 [received]
PHST- 2022/09/15 00:00 [revised]
PHST- 2022/10/01 00:00 [accepted]
PHST- 2022/10/14 02:12 [entrez]
PHST- 2022/10/15 06:00 [pubmed]
PHST- 2022/10/18 06:00 [medline]
AID - ijms231911750 [pii]
AID - ijms-23-11750 [pii]
AID - 10.3390/ijms231911750 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Oct 4;23(19):11750. doi: 10.3390/ijms231911750.

PMID- 16927187
OWN - NLM
STAT- MEDLINE
DCOM- 20061214
LR  - 20181113
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 23
IP  - 10
DP  - 2006 Oct
TI  - Empirically augmented density functional theory for predicting lattice energies 
      of aspirin, acetaminophen polymorphs, and ibuprofen homochiral and racemic 
      crystals.
PG  - 2326-32
AB  - PURPOSE: Lattice energies of drug crystals are closely associated with many 
      important physicochemical properties including polymorphism of the crystals. 
      Current quantum mechanical methods that can be applied to calculate the lattice 
      energy of most drug crystals are not capable of fully considering the van der 
      Waals interaction energy, a dominant component in the lattice energy. Herein, we 
      report the results of using empirically augmented quantum mechanical methods for 
      predicting the lattice energies of selected drug crystals. METHODS: Long-range 
      van der Waals energies were evaluated by atom-atom pairwise C ( 6 ) R (-6 ) 
      functions that were damped at short interatomic distance where interatomic 
      interactions could be better evaluated by density functional theory (DFT). The 
      atomic C ( 6 ) coefficients were taken from literature, and three damping 
      functions were tested. For the quantum mechanical calculations, different basis 
      sets were tested with aspirin as the model system. Basis set superposition error 
      (BSSE) was considered. In addition to aspirin, acetaminophen Form I and Form II, 
      and s(+)- and (+/-)-ibuprofen were calculated and the results were compared to 
      experimental values. Experimentally determined single crystal structures were 
      optimized prior to both empirical and DFT energy calculations. RESULTS: Lattice 
      energies calculated by the empirically augmented quantum mechanical methods are 
      in very good agreement with experimental values, suggesting the approach is 
      acceptable. The results also indicate that the long-range van der Waals or 
      dispersion energy is a significant part of the lattice energy, which cannot be 
      accurately estimated by the DFT methods alone. CONCLUSIONS: Due to the empirical 
      nature for estimating the dispersion energy, choosing the right empirical 
      parameters is crucial. The methods and parameters tested seem to be able to 
      produce reliable values of lattice energies of the drug crystals.
FAU - Li, Tonglei
AU  - Li T
AD  - Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536, USA. 
      tonglei@uky.edu
FAU - Feng, Shaoxin
AU  - Feng S
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20060823
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/*chemistry
MH  - Algorithms
MH  - Aspirin/*chemistry
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Crystallization
MH  - Ibuprofen/*chemistry
EDAT- 2006/08/24 09:00
MHDA- 2006/12/15 09:00
CRDT- 2006/08/24 09:00
PHST- 2006/01/05 00:00 [received]
PHST- 2006/03/08 00:00 [accepted]
PHST- 2006/08/24 09:00 [pubmed]
PHST- 2006/12/15 09:00 [medline]
PHST- 2006/08/24 09:00 [entrez]
AID - 10.1007/s11095-006-9006-5 [doi]
PST - ppublish
SO  - Pharm Res. 2006 Oct;23(10):2326-32. doi: 10.1007/s11095-006-9006-5. Epub 2006 Aug 
      23.

PMID- 8272297
OWN - NLM
STAT- MEDLINE
DCOM- 19940128
LR  - 20131121
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 83
IP  - 1
DP  - 1994 Jan
TI  - Increased platelet volume and aggregation precede the onset of preeclampsia.
PG  - 146-9
AB  - OBJECTIVE: To determine whether changes in platelet aggregation, numbers, or mean 
      volume precede the onset of preeclampsia in patients given anti-platelet therapy. 
      METHODS: Changes in platelet aggregation, numbers, and volumes were followed 
      longitudinally in 17 women who had previously lost 44 of 56 pregnancies and were 
      thus considered to be at risk of preeclampsia. The subjects were treated with 
      low-dose aspirin. Mean platelet volume, platelet numbers, and platelet 
      aggregation were monitored every 2-4 weeks during pregnancy. RESULTS: All eight 
      subjects who developed preeclampsia delivered growth-retarded infants before 
      term. All showed increased platelet aggregation in vitro, accompanied by 
      increased platelet volumes (by at least 0.8 fL) and decreased platelet numbers 
      (by at least 60 x 10(9)/L) in five subjects, increased volumes alone in one, and 
      decreased numbers alone in one. The increases in platelet aggregation and volumes 
      predated the development of preeclampsia by 2-5 weeks. Nine subjects had 
      pregnancies that progressed normally to term (beyond 37 weeks), with the delivery 
      of eight normal and one growth-retarded infant; platelet aggregation, numbers, 
      and volumes did not change to the same extent as in the subjects who developed 
      preeclampsia. CONCLUSION: Increased mean platelet volume and increased platelet 
      aggregation compared to the individual patient's first-trimester data were 
      detected 2-5 weeks before the development of all cases of preeclampsia. In 
      contrast, normal pregnancies did not show significant changes in mean platelet 
      volume or platelet aggregation.
FAU - Hutt, R
AU  - Hutt R
AD  - Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.
FAU - Ogunniyi, S O
AU  - Ogunniyi SO
FAU - Sullivan, M H
AU  - Sullivan MH
FAU - Elder, M G
AU  - Elder MG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Count/*drug effects
MH  - Pre-Eclampsia/*blood/prevention & control
MH  - Pregnancy
MH  - Risk Factors
MH  - Time Factors
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Obstet Gynecol. 1994 Jan;83(1):146-9.

PMID- 2761587
OWN - NLM
STAT- MEDLINE
DCOM- 19890921
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 321
IP  - 8
DP  - 1989 Aug 24
TI  - A randomized trial comparing ticlopidine hydrochloride with aspirin for the 
      prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study 
      Group.
PG  - 501-7
AB  - We report the results of the Ticlopidine Aspirin Stroke Study, a blinded trial at 
      56 North American centers that compared the effects of ticlopidine hydrochloride 
      (500 mg daily) with those of aspirin (1300 mg daily) on the risk of stroke or 
      death. The medications were randomly assigned to 3069 patients with recent 
      transient or mild persistent focal cerebral or retinal ischemia. Follow-up lasted 
      for two to six years. The three-year event rate for nonfatal stroke or death from 
      any cause was 17 percent for ticlopidine and 19 percent for aspirin--a 12 percent 
      risk reduction (95 percent confidence interval, -2 to 26 percent) with 
      ticlopidine (P = 0.048 for cumulative Kaplan-Meier estimates). The rates of fatal 
      and nonfatal stroke at three years were 10 percent for ticlopidine and 13 percent 
      for aspirin--a 21 percent risk reduction (95 percent confidence interval, 4 to 38 
      percent) with ticlopidine (P = 0.024 for cumulative Kaplan-Meier estimates). 
      Ticlopidine was more effective than aspirin in both sexes. The adverse effects of 
      aspirin included diarrhea (10 percent), rash (5.5 percent), peptic ulceration (3 
      percent), gastritis (2 percent), and gastrointestinal bleeding (1 percent). With 
      ticlopidine, diarrhea (20 percent), skin rash (14 percent), and severe but 
      reversible neutropenia (less than 1 percent) were noted. The mean increase in 
      total cholesterol level was 9 percent with ticlopidine and 2 percent with aspirin 
      (P less than 0.01). The ratios of high-density lipoprotein and low-density 
      lipoprotein to total cholesterol were similar in both treatment groups. We 
      conclude that ticlopidine was somewhat more effective than aspirin in preventing 
      strokes in this population, although the risks of side effects were greater.
FAU - Hass, W K
AU  - Hass WK
AD  - New York University Medical Center, Department of Neurology, NY 10016.
FAU - Easton, J D
AU  - Easton JD
FAU - Adams, H P Jr
AU  - Adams HP Jr
FAU - Pryse-Phillips, W
AU  - Pryse-Phillips W
FAU - Molony, B A
AU  - Molony BA
FAU - Anderson, S
AU  - Anderson S
FAU - Kamm, B
AU  - Kamm B
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 1990 Feb 8;322(6):404-5. PMID: 2300095
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/mortality/*prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/complications
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
MH  - Retina/blood supply
MH  - Ticlopidine/administration & dosage/adverse effects/*therapeutic use
EDAT- 1989/08/24 00:00
MHDA- 2001/03/28 10:01
CRDT- 1989/08/24 00:00
PHST- 1989/08/24 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1989/08/24 00:00 [entrez]
AID - 10.1056/NEJM198908243210804 [doi]
PST - ppublish
SO  - N Engl J Med. 1989 Aug 24;321(8):501-7. doi: 10.1056/NEJM198908243210804.

PMID- 3921141
OWN - NLM
STAT- MEDLINE
DCOM- 19850607
LR  - 20190501
IS  - 0267-0623 (Print)
IS  - 0267-0623 (Linking)
VI  - 290
IP  - 6476
DP  - 1985 Apr 20
TI  - Effect of aspirin on nasal resistance to airflow.
PG  - 1171-3
AB  - The effect of aspirin on nasal resistance to airflow was investigated by 
      rhinomanometry in 25 healthy subjects before and after ingestion of aspirin or 
      vitamin C in a double blind crossover trial. Aspirin caused a significant 
      increase in nasal resistance compared with vitamin C. The effect of aspirin may 
      be due to its inhibition of the synthesis of prostaglandins.
FAU - Jones, A S
AU  - Jones AS
FAU - Lancer, J M
AU  - Lancer JM
FAU - Moir, A A
AU  - Moir AA
FAU - Stevens, J C
AU  - Stevens JC
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br Med J (Clin Res Ed)
JT  - British medical journal (Clinical research ed.)
JID - 8302911
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Airway Resistance/*drug effects
MH  - Aspirin/*pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Nasal Cavity/*drug effects
PMC - PMC1418864
EDAT- 1985/04/20 00:00
MHDA- 1985/04/20 00:01
CRDT- 1985/04/20 00:00
PHST- 1985/04/20 00:00 [pubmed]
PHST- 1985/04/20 00:01 [medline]
PHST- 1985/04/20 00:00 [entrez]
AID - 10.1136/bmj.290.6476.1171 [doi]
PST - ppublish
SO  - Br Med J (Clin Res Ed). 1985 Apr 20;290(6476):1171-3. doi: 
      10.1136/bmj.290.6476.1171.

PMID- 22231610
OWN - NLM
STAT- MEDLINE
DCOM- 20120404
LR  - 20220129
IS  - 1538-3679 (Electronic)
IS  - 0003-9926 (Linking)
VI  - 172
IP  - 3
DP  - 2012 Feb 13
TI  - Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of 
      randomized controlled trials.
PG  - 209-16
LID - 10.1001/archinternmed.2011.628 [doi]
AB  - BACKGROUND: The net benefit of aspirin in prevention of CVD and nonvascular 
      events remains unclear. Our objective was to assess the impact (and safety) of 
      aspirin on vascular and nonvascular outcomes in primary prevention. DATA SOURCES: 
      MEDLINE, Cochrane Library of Clinical Trials (up to June 2011) and unpublished 
      trial data from investigators. STUDY SELECTION: Nine randomized 
      placebo-controlled trials with at least 1000 participants each, reporting on 
      cardiovascular disease (CVD), nonvascular outcomes, or death were included. DATA 
      EXTRACTION: Three authors abstracted data. Study-specific odds ratios (ORs) were 
      combined using random-effects meta-analysis. Risks vs benefits were evaluated by 
      comparing CVD risk reductions with increases in bleeding. RESULTS: During a mean 
      (SD) follow-up of 6.0 (2.1) years involving over 100, 000 participants, aspirin 
      treatment reduced total CVD events by 10% (OR, 0.90; 95% CI, 0.85-0.96; number 
      needed to treat, 120), driven primarily by reduction in nonfatal MI (OR, 0.80; 
      95% CI, 0.67-0.96; number needed to treat, 162). There was no significant 
      reduction in CVD death (OR, 0.99; 95% CI, 0.85-1.15) or cancer mortality (OR, 
      0.93; 95% CI, 0.84-1.03), and there was increased risk of nontrivial bleeding 
      events (OR, 1.31; 95% CI, 1.14-1.50; number needed to harm, 73). Significant 
      heterogeneity was observed for coronary heart disease and bleeding outcomes, 
      which could not be accounted for by major demographic or participant 
      characteristics. CONCLUSIONS: Despite important reductions in nonfatal MI, 
      aspirin prophylaxis in people without prior CVD does not lead to reductions in 
      either cardiovascular death or cancer mortality. Because the benefits are further 
      offset by clinically important bleeding events, routine use of aspirin for 
      primary prevention is not warranted and treatment decisions need to be considered 
      on a case-by-case basis.
FAU - Seshasai, Sreenivasa Rao Kondapally
AU  - Seshasai SR
AD  - St George's University of London, London, England. rkondapa@sgul.ac.uk
FAU - Wijesuriya, Shanelle
AU  - Wijesuriya S
FAU - Sivakumaran, Rupa
AU  - Sivakumaran R
FAU - Nethercott, Sarah
AU  - Nethercott S
FAU - Erqou, Sebhat
AU  - Erqou S
FAU - Sattar, Naveed
AU  - Sattar N
FAU - Ray, Kausik K
AU  - Ray KK
LA  - eng
GR  - G9534799/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20120109
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Intern Med. 2012 Feb 13;172(3):217-8. PMID: 22231608
CIN - Ann Intern Med. 2012 Jun 19;156(12):JC6-3. PMID: 22711104
CIN - Evid Based Med. 2013 Apr;18(2):e14. PMID: 22851620
CIN - J Clin Epidemiol. 2013 Jul;66(7):803-5. PMID: 23523548
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Primary Prevention
MH  - *Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2012/01/11 06:00
MHDA- 2012/04/05 06:00
CRDT- 2012/01/11 06:00
PHST- 2012/01/11 06:00 [entrez]
PHST- 2012/01/11 06:00 [pubmed]
PHST- 2012/04/05 06:00 [medline]
AID - archinternmed.2011.628 [pii]
AID - 10.1001/archinternmed.2011.628 [doi]
PST - ppublish
SO  - Arch Intern Med. 2012 Feb 13;172(3):209-16. doi: 10.1001/archinternmed.2011.628. 
      Epub 2012 Jan 9.

PMID- 19821574
OWN - NLM
STAT- MEDLINE
DCOM- 20091215
LR  - 20171116
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 52
IP  - 21
DP  - 2009 Nov 12
TI  - Isosorbide-based aspirin prodrugs: integration of nitric oxide releasing groups.
PG  - 6588-98
LID - 10.1021/jm900561s [doi]
AB  - Aspirin prodrugs and related nitric oxide releasing compounds hold significant 
      therapeutic promise, but they are hard to design because aspirin esterification 
      renders its acetate group very susceptible to plasma esterase mediated 
      hydrolysis. Isosorbide-2-aspirinate-5-salicylate is a true aspirin prodrug in 
      human blood because it can be effectively hydrolyzed to aspirin upon interaction 
      with plasma BuChE. We show that the identity of the remote 5-ester dictates 
      whether aspirin is among the products of plasma-mediated hydrolysis. By observing 
      the requirements for aspirin release from an initial panel of isosorbide-based 
      esters, we were able to introduce nitroxymethyl groups at the 5-position while 
      maintaining ability to release aspirin. Several of these compounds are potent 
      inhibitors of platelet aggregation. The design of these compounds will allow 
      better exploration of cross-talk between COX inhibition and nitric oxide release 
      and potentially lead to the development of selective COX-1 acetylating drugs 
      without gastric toxicity.
FAU - Jones, Michael
AU  - Jones M
AD  - School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin 2, 
      Ireland.
FAU - Inkielewicz, Iwona
AU  - Inkielewicz I
FAU - Medina, Carlos
AU  - Medina C
FAU - Santos-Martinez, Maria Jose
AU  - Santos-Martinez MJ
FAU - Radomski, Anna
AU  - Radomski A
FAU - Radomski, Marek W
AU  - Radomski MW
FAU - Lally, Maeve N
AU  - Lally MN
FAU - Moriarty, Louise M
AU  - Moriarty LM
FAU - Gaynor, Joanne
AU  - Gaynor J
FAU - Carolan, Ciaran G
AU  - Carolan CG
FAU - Khan, Denise
AU  - Khan D
FAU - O'Byrne, Paul
AU  - O'Byrne P
FAU - Harmon, Shona
AU  - Harmon S
FAU - Holland, Valerie
AU  - Holland V
FAU - Clancy, John M
AU  - Clancy JM
FAU - Gilmer, John F
AU  - Gilmer JF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Esters)
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prodrugs)
RN  - 0 (isosorbide-2-aspirinate-5-(2-nitroxymethyl)benzoate)
RN  - 0 (isosorbide-2-aspirinate-5-(3-nitrooxymethyl)benzoate)
RN  - EC 3.1.1.8 (Butyrylcholinesterase)
RN  - R16CO5Y76E (Aspirin)
RN  - WXR179L51S (Isosorbide)
SB  - IM
MH  - Aspirin/*analogs & derivatives/blood/*chemical synthesis/pharmacology
MH  - Butyrylcholinesterase/blood
MH  - Esters
MH  - Humans
MH  - Hydrolysis
MH  - In Vitro Techniques
MH  - Isosorbide/*analogs & derivatives/*chemical synthesis/pharmacology
MH  - Models, Molecular
MH  - Nitrates/*chemical synthesis/pharmacology
MH  - Nitric Oxide Donors/blood/*chemical synthesis/pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/blood/*chemical synthesis/pharmacology
MH  - Prodrugs/*chemical synthesis/pharmacology
MH  - Structure-Activity Relationship
EDAT- 2009/10/14 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/10/14 06:00
PHST- 2009/10/14 06:00 [entrez]
PHST- 2009/10/14 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 10.1021/jm900561s [doi]
PST - ppublish
SO  - J Med Chem. 2009 Nov 12;52(21):6588-98. doi: 10.1021/jm900561s.

PMID- 311303
OWN - NLM
STAT- MEDLINE
DCOM- 19790516
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 7
IP  - 1
DP  - 1979
TI  - Diflunisal, a new-acting analgesic and prostaglandin inhibitor: effect of 
      concomitant acetylsalicylic acid therapy on ototoxicity and on disposition of 
      both drugs.
PG  - 61-8
AB  - Intermittent and concomitant acetylsalicylic acid (ASA) therapy was superimposed 
      onto a 21-day regimen with diflunisal 250 mg b.i.d. Low doses of ASA (600 mg 
      single dose or 300 mg q.i.d.) did not influence signficantly diflunisal blood 
      levels whereas a 600 mg q.i.d. dosing caused a small significant drop, especially 
      at trough level. This drop is not expected to be clinically significant. No 
      ototoxicity could be demonstrated with any treatment of diflunisal though four of 
      fourteen subjects reported mild tinnitus during concomitant therapy at the higher 
      doses of ASA. Diflunisal at 375 mg b.i.d. failed to alter the metabolism of a 
      single dose of labelled ASA (600 mg) as judged by plasma levels, urinary 
      excretion and plasma binding. Daily urinary excretion of prostaglandins E1 and E2 
      major metabolite was decreased by about 70% by diflunisal.
FAU - Schulz, P
AU  - Schulz P
FAU - Perrier, C V
AU  - Perrier CV
FAU - Ferber-Perret, F
AU  - Ferber-Perret F
FAU - VandenHeuvel, W J
AU  - VandenHeuvel WJ
FAU - Steelman, S L
AU  - Steelman SL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandins E)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/metabolism/*pharmacology
MH  - Aspirin/adverse effects/metabolism/*pharmacology
MH  - Drug Interactions
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Male
MH  - Prostaglandins E/biosynthesis
MH  - Salicylates/metabolism/*pharmacology
MH  - Tinnitus/chemically induced
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1177/030006057900700110 [doi]
PST - ppublish
SO  - J Int Med Res. 1979;7(1):61-8. doi: 10.1177/030006057900700110.

PMID- 20509453
OWN - NLM
STAT- MEDLINE
DCOM- 20100820
LR  - 20131121
IS  - 0084-9588 (Print)
IS  - 0084-9588 (Linking)
VI  - 37
DP  - 2009
TI  - [From willow bark to acetylsalicylic acid].
PG  - 79-98
AB  - Acetylsalicylic acid is one of the most widely used drugs in the world. Its 
      ancestry the salicylates, including salicin and salicylic acid, are found in the 
      bark and leaves of the willow and poplar trees. The ancient Sumerians and 
      Egyptians, as well as Hippocrates, Celsus, Pliny the Elder, Dioscorides and Galen 
      used these natural products as remedies for pain, fever and inflammation. In the 
      Middle Ages these remedies were used for fever and rheumatism by Hildegard of 
      Bingen and Henrik Harpestreng. The first "clinical trial" was reported by Edward 
      Stone in 1763 with a successful treatment of malarial fever with the willow bark. 
      In 1876 the antirheumatic effect of salicin was described by T. MacLagan, and 
      that of salicylic acid by S. Stricker and L. Riess. Acetylsalicylic acid was 
      synthesized by Charles Gerhardt in 1853 and in 1897 by Felix Hoffmann in the 
      Bayer Company. The beneficial effect of acetylsalicylic acid (Aspirin) on pain 
      and rheumatic fever was recognized by K. Witthauer and J. Wohlgemuth, and the 
      mechanism of action was explained in 1971 by John Vane. Today the antithrombotic 
      effect of acetylsalicylic acid and new aspects of ongoing research demonstrates a 
      still living drug.
FAU - Norn, Svend
AU  - Norn S
AD  - Farmakologisk Afdeling, H. Lundbeck & Co. ksnorn@post.cybercity.dk
FAU - Permin, Henrik
AU  - Permin H
FAU - Kruse, Poul R
AU  - Kruse PR
FAU - Kruse, Edith
AU  - Kruse E
LA  - dan
PT  - English Abstract
PT  - Historical Article
PT  - Journal Article
TT  - Fra pilebark til acetylsalicylsyre.
PL  - Denmark
TA  - Dan Medicinhist Arbog
JT  - Dansk medicinhistorisk arbog
JID - 0434570
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biological Products)
RN  - 0 (Plant Extracts)
RN  - R16CO5Y76E (Aspirin)
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/*history/therapeutic use
MH  - Biological Products/history/therapeutic use
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, Ancient
MH  - History, Medieval
MH  - Humans
MH  - Pain/drug therapy
MH  - Plant Extracts/*history/therapeutic use
MH  - Rheumatic Fever/drug therapy
EDAT- 2009/01/01 00:00
MHDA- 2010/08/21 06:00
CRDT- 2010/06/01 06:00
PHST- 2010/06/01 06:00 [entrez]
PHST- 2009/01/01 00:00 [pubmed]
PHST- 2010/08/21 06:00 [medline]
PST - ppublish
SO  - Dan Medicinhist Arbog. 2009;37:79-98.

PMID- 30266114
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1681-7168 (Electronic)
IS  - 1022-386X (Linking)
VI  - 28
IP  - 10
DP  - 2018 Oct
TI  - Histological Effects of Nigella Sativa on Aspirin-Induced Nephrotoxicity in 
      Albino Rats.
PG  - 735-738
AB  - OBJECTIVE: To determine the histological effects of Nigella sativa on kidneys 
      against aspirin-induced nephrotoxicity in albino rats. STUDY DESIGN: An 
      experimental study. PLACE AND DURATION OF STUDY: Anatomy Department, University 
      of Health Sciences, Lahore, from January 2014 to December 2015. METHODOLOGY: 
      Thirty-two rats were equally divided into four groups A, B, C and D of eight 
      animals each. Group A (control) was provided with single oral dose of 10 mg/100 
      gm body weight of 1% methyl cellulose. Group B (experimental group) and C (self 
      recovery group) were provided with single oral dose of 1000 mg/kg aspirin. Group 
      D was provided with 250 mg/kg ethanolic extract of Nigella sativa followed by 
      1000 mg/kg aspirin by oral gavage, after that only extract of Nigella sativa was 
      given for seven days. Animals of groups A, C and D were sacrificed on the 8th day 
      of experiment and that of group B on the second day of experiment. Kidneys were 
      excised and fixed in 10% formalin solution. Hematoxylin, eosin and periodic acid 
      Schiff's reagents were used to stain the kidney tissues. Histological slides were 
      prepared to study proximal convoluted tubules. RESULTS: Histological parameters 
      were normal in control group A. Significant impairment was present in group B. 
      There was no self-recovery in group C. Significant improvement was present in all 
      the parameters of group D. CONCLUSION: Nigella sativa has protective effect on 
      aspirin-induced nephrotoxicity in rats.
FAU - Asif, Sania
AU  - Asif S
AD  - Department of Anatomy, King Edward Medical University, Lahore, Pakistan.
FAU - Mudassir, Sitwat
AU  - Mudassir S
AD  - Department of Anatomy, University College of Medicine and Dentistry (UCMD), 
      Lahore, Pakistan.
FAU - Toor, Rabia Sajjad
AU  - Toor RS
AD  - Department of Anatomy, Sahara Medical College, Mureedkey Road, Narowal, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Coll Physicians Surg Pak
JT  - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
JID - 9606447
RN  - 0 (Plant Extracts)
RN  - 0 (Protective Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*toxicity
MH  - Cytoprotection
MH  - Humans
MH  - Kidney/*drug effects
MH  - Kidney Diseases/*chemically induced
MH  - Male
MH  - Nigella sativa/*chemistry
MH  - *Phytotherapy
MH  - Plant Extracts/*pharmacology
MH  - Protective Agents/chemistry/*pharmacology
MH  - Rats
MH  - Rats, Wistar
EDAT- 2018/09/30 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/09/30 06:00
PHST- 2017/12/07 00:00 [received]
PHST- 2018/06/22 00:00 [accepted]
PHST- 2018/09/30 06:00 [entrez]
PHST- 2018/09/30 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
AID - 040579197 [pii]
PST - ppublish
SO  - J Coll Physicians Surg Pak. 2018 Oct;28(10):735-738.

PMID- 20978715
OWN - NLM
STAT- MEDLINE
DCOM- 20110518
LR  - 20220311
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 105
IP  - 1
DP  - 2011 Jan
TI  - Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and 
      oxidised low-density lipoproteins in patients after ischaemic stroke. The 
      AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy.
PG  - 81-7
LID - 10.1160/TH10-05-0316 [doi]
AB  - Plasma endothelial nitric oxide synthase (eNOS), and oxidised low-density 
      lipoproteins (oxLDL) are established biomarkers of atherosclerosis. We defined 
      the time course and magnitude of changes of plasma eNOS and oxLDL after Aggrenox 
      or aspirin in post-stroke patients. Baseline pretreatment eNOS levels were 
      significantly diminished (110 ± 66pg /ml vs. 374 ± 88 pg/ml, p=0.0001), while 
      oxLDL was twice higher (58 ± 9 mg/l vs. 23 ± 7 mg/l, p=0.004) in post-stroke 
      survivors when compared to controls. Both Aggrenox and aspirin similarly 
      increased plasma eNOS activity. However, oxLDL levels were static after aspirin, 
      but inhibited late after Aggrenox. In the small randomised study, both aspirin 
      and Aggrenox produced fast and sustained recovery of plasma eNOS levels, while 
      only therapy with Aggrenox was associated with oxLDL inhibition late in the 
      trial.
FAU - Serebruany, Victor
AU  - Serebruany V
AD  - Johns Hopkins University, Baltimore, Maryland, 21204, USA. heartdrug@aol.com
FAU - Sani, Yanti
AU  - Sani Y
FAU - Eisert, Christian
AU  - Eisert C
FAU - Schevchuck, Alex
AU  - Schevchuck A
FAU - Fong, Alan
AU  - Fong A
FAU - Hanley, Dan
AU  - Hanley D
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20101026
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Biomarkers)
RN  - 0 (Drug Combinations)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (oxidized low density lipoprotein)
RN  - 64ALC7F90C (Dipyridamole)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Atherosclerosis/diagnosis
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Dipyridamole/administration & dosage/pharmacokinetics/*pharmacology
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Lipoproteins, LDL/antagonists & inhibitors/*drug effects
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide Synthase Type III/blood/*drug effects
MH  - Pharmacokinetics
MH  - Platelet Aggregation Inhibitors
MH  - Stroke/*blood
EDAT- 2010/10/28 06:00
MHDA- 2011/05/19 06:00
CRDT- 2010/10/28 06:00
PHST- 2010/05/24 00:00 [received]
PHST- 2010/09/08 00:00 [accepted]
PHST- 2010/10/28 06:00 [entrez]
PHST- 2010/10/28 06:00 [pubmed]
PHST- 2011/05/19 06:00 [medline]
AID - 10-05-0316 [pii]
AID - 10.1160/TH10-05-0316 [doi]
PST - ppublish
SO  - Thromb Haemost. 2011 Jan;105(1):81-7. doi: 10.1160/TH10-05-0316. Epub 2010 Oct 
      26.

PMID- 11675854
OWN - NLM
STAT- MEDLINE
DCOM- 20020305
LR  - 20181130
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 35
IP  - 10
DP  - 2001 Oct
TI  - Antiplatelet agents for secondary prevention of ischemic stroke.
PG  - 1241-7
AB  - OBJECTIVE: To review and summarize the efficacy, mechanisms of action, and cost 
      of the options available when choosing antiplatelet agents for secondary stroke 
      prevention. DATA SOURCES: This article is based on a review of the literature 
      found with MEDLINE, CINAHL, and Cochrane Reviews (1980-June 2000) and abstracts 
      from relevant international scientific meetings. We searched for the terms 
      aspirin, ticlopidine, dipyridamole, antiplatelet, and clopidogrel. STUDY 
      SELECTION: English-language articles, both reviews and original studies, were 
      evaluated, and all information considered relevant was included in this review. 
      In addition, guidelines from the American Heart Association are included. DATA 
      SYNTHESIS: Aspirin is a relatively inexpensive and effective agent for secondary 
      stroke prevention, and lower doses of aspirin appear as effective as higher 
      doses. Ticlopidine has been used alone or in combination with aspirin, but 
      serious adverse effects have limited its use. Clopidogrel has emerged as a safe 
      and effective alternative to ticlopidine and lacks some of the serious adverse 
      effects associated with ticlopicine, but is not superior to aspirin in secondary 
      stroke prevention. Unlike previous studies, one recent trial showed that 
      dipyridamole in combination with aspirin is superior to aspirin alone. 
      CONCLUSIONS: Antiplatelet therapy is a key component of secondary prevention 
      strategies in ischemic stroke. While aspirin has been the cornerstone in the 
      management of stroke, other classes of antiplatelet drugs present new 
      opportunities to optimize antiplatelet therapy.
FAU - Majid, A
AU  - Majid A
AD  - Department of Neurology, University of Pennsylvania School of Medicine, 
      Philadelphia, USA. arshadmajid@hotmail.com
FAU - Delanty, N
AU  - Delanty N
FAU - Kantor, J
AU  - Kantor J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Dipyridamole/administration & dosage/adverse effects/therapeutic use
MH  - Humans
MH  - Myocardial Ischemia/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/*prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
RF  - 53
EDAT- 2001/10/26 10:00
MHDA- 2002/03/07 10:01
CRDT- 2001/10/26 10:00
PHST- 2001/10/26 10:00 [pubmed]
PHST- 2002/03/07 10:01 [medline]
PHST- 2001/10/26 10:00 [entrez]
AID - 10.1345/aph.10381 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2001 Oct;35(10):1241-7. doi: 10.1345/aph.10381.

PMID- 9354198
OWN - NLM
STAT- MEDLINE
DCOM- 19971218
LR  - 20190831
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 11
IP  - 5
DP  - 1997 Oct
TI  - Effect of omeprazole on the bioavailability of unmodified and 
      phospholipid-complexed aspirin in rats.
PG  - 899-906
AB  - BACKGROUND: Treatment and prevention of non-steroidal anti-inflammatory 
      drug-induced gastropathy involve the concurrent use of antisecretory drugs. 
      Recently, we have shown that the ability of these drugs to increase the 
      intragastric pH to values > > pKa of NSAIDs compromises their therapeutic 
      activity. In the present study, we evaluated the potential of omeprazole to 
      interfere with the bioavailability of aspirin administered to rats either alone 
      or complexed with the zwitterionic phospholipid, dipalmitoylphosphatidylcholine 
      (DPPC). METHODS: Aspirin or aspirin/DPPC was administered intragastrically to 
      rats pre-dosed with either saline or omeprazole. Concentrations of aspirin and 
      salicylic acid in the blood and the gastric mucosa were assessed by HPLC and the 
      6-keto-PGF1 alpha gastric mucosal concentration by radioimmunoassay. RESULTS: 
      Gastric absorption of aspirin and its relative bioavailability were reduced by an 
      antisecretory dose of omeprazole; its inhibitory effect on gastric prostaglandin 
      synthesis was consequently attenuated. However, these effects could be partly 
      overcome if aspirin was administered as a complex with DPPC. CONCLUSIONS: These 
      observations suggest that: (i) DPPC increases the lipid solubility and gastric 
      permeability of NSAIDs; and (ii) neutralization of the gastric pH results in a 
      shift of aspirin absorption toward the intestine where it could be degraded to 
      salicylic acid.
FAU - Giraud, M N
AU  - Giraud MN
AD  - Department of Integrative Biology, Pharmacology and Physiology, University of 
      Texas-Houston Medical School, Houston 77030, USA.
FAU - Sanduja, S K
AU  - Sanduja SK
FAU - Felder, T B
AU  - Felder TB
FAU - Illich, P A
AU  - Illich PA
FAU - Dial, E J
AU  - Dial EJ
FAU - Lichtenberger, L M
AU  - Lichtenberger LM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Carriers)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 2644-64-6 (1,2-Dipalmitoylphosphatidylcholine)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *1,2-Dipalmitoylphosphatidylcholine/chemistry
MH  - 6-Ketoprostaglandin F1 alpha/metabolism
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics
MH  - Aspirin/blood/chemistry/*pharmacokinetics
MH  - Biological Availability
MH  - Drug Carriers
MH  - Enzyme Inhibitors/*pharmacology
MH  - Gastric Mucosa/metabolism
MH  - Male
MH  - Neutralization Tests
MH  - Omeprazole/*pharmacology
MH  - *Proton Pump Inhibitors
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1997/11/14 00:00
MHDA- 1997/11/14 00:01
CRDT- 1997/11/14 00:00
PHST- 1997/11/14 00:00 [pubmed]
PHST- 1997/11/14 00:01 [medline]
PHST- 1997/11/14 00:00 [entrez]
AID - 10.1046/j.1365-2036.1997.00216.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 1997 Oct;11(5):899-906. doi: 
      10.1046/j.1365-2036.1997.00216.x.

PMID- 18759979
OWN - NLM
STAT- MEDLINE
DCOM- 20081118
LR  - 20211020
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 6
DP  - 2008 Aug 29
TI  - 'Aspirin resistance' or treatment non-compliance: which is to blame for 
      cardiovascular complications?
PG  - 47
LID - 10.1186/1479-5876-6-47 [doi]
AB  - Aspirin is one of the 'cornerstone' drugs in our current management of 
      cardiovascular disorders. However, despite the prescription of aspirin recurrent 
      vascular events still occur in 10-20% of patients. These, data together with the 
      observations of diminished antiaggregatory response to aspirin in some subjects 
      have provided the basis of the current debate on the existence of so-called 
      "aspirin resistance". Unfortunately, many of the tests employed to define 
      'aspirin resistance' lack sufficient sensitivity, specificity, and 
      reproducibility. The prevalence of 'aspirin resistance' as defined by each test 
      varies widely, and furthermore, the value of a single point estimate measure of 
      aspirin resistance is questionable. The rate of 'aspirin resistance' is law if 
      patients observed to ingest aspirin, with large proportion of patients to be 
      pseudo-'aspirin resistant', due to non-compliance. What are the implications for 
      clinical practice? Possible non-adherence to aspirin prescription should also be 
      carefully considered before changing to higher aspirin doses, other antiplatelet 
      drugs (e.g. clopidogrel) or even combination antiplatelet drug therapy. Given the 
      multifactorial nature of atherothrombotic disease, it is not surprising that only 
      about 25% of all cardiovascular complications can usually be prevented by any 
      single medication. We would advocate against routine testing of platelet 
      sensitivity to aspirin (as an attempt to look for 'aspirin resistance') but 
      rather, to highlight the importance of clinicians and public attention to the 
      problem of treatment non-compliance.
FAU - Shantsila, Eduard
AU  - Shantsila E
FAU - Lip, Gregory Y H
AU  - Lip GY
LA  - eng
PT  - Comment
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080829
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - J Transl Med. 2008;6:46. PMID: 18759978
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/*complications/*drug therapy/physiopathology
MH  - Drug Resistance
MH  - Humans
MH  - Myocardial Infarction/complications/drug therapy/physiopathology
MH  - Platelet Aggregation
MH  - *Treatment Refusal
PMC - PMC2535592
EDAT- 2008/09/02 09:00
MHDA- 2008/11/19 09:00
CRDT- 2008/09/02 09:00
PHST- 2008/07/11 00:00 [received]
PHST- 2008/08/29 00:00 [accepted]
PHST- 2008/09/02 09:00 [pubmed]
PHST- 2008/11/19 09:00 [medline]
PHST- 2008/09/02 09:00 [entrez]
AID - 1479-5876-6-47 [pii]
AID - 10.1186/1479-5876-6-47 [doi]
PST - epublish
SO  - J Transl Med. 2008 Aug 29;6:47. doi: 10.1186/1479-5876-6-47.

PMID- 15868987
OWN - NLM
STAT- MEDLINE
DCOM- 20050609
LR  - 20131121
IS  - 0028-2162 (Print)
IS  - 0028-2162 (Linking)
VI  - 149
IP  - 16
DP  - 2005 Apr 16
TI  - [Primary prevention of cardiovascular disease with acetylsalicylic acid: in 
      high-risk patients].
PG  - 853-4
AB  - In the recently published placebo-controlled 'Women's health study', use of 
      acetylsalicylic acid 100 mg daily in healthy women older than 45 years protected 
      against having a stroke. In men, higher doses of acetylsalicylic acid protects 
      against myocardial infarction. However, risk reduction using acetylsalicylic acid 
      is only clinically relevant if the absolute risk of cardiovascular disease is 
      high. Countering vascular-risk factors reduces the chance of cardiovascular 
      complications much more than the use of acetylsalicylic acid and therefore should 
      be pursued without any reservation.
FAU - Kappelle, L J
AU  - Kappelle LJ
AD  - Universitair Medisch Centrum Utrecht, afd. Neurologie, huispostnummer G03.228, 
      Postbus 85.500, 3508 GA Utrecht. l.kappelle@neuro.azu.nl
LA  - dut
PT  - English Abstract
PT  - Journal Article
TT  - Primaire preventie van hart--en vaatziekten met acetylsalicylzuur: bij 
      hoogrisicopatiënten.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Sex Factors
EDAT- 2005/05/05 09:00
MHDA- 2005/06/10 09:00
CRDT- 2005/05/05 09:00
PHST- 2005/05/05 09:00 [pubmed]
PHST- 2005/06/10 09:00 [medline]
PHST- 2005/05/05 09:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2005 Apr 16;149(16):853-4.

PMID- 11460511
OWN - NLM
STAT- MEDLINE
DCOM- 20010802
LR  - 20190616
IS  - 0077-8923 (Print)
IS  - 0077-8923 (Linking)
VI  - 936
DP  - 2001
TI  - Modified clotting properties of fibrinogen in the presence of acetylsalicylic 
      acid in a purified system.
PG  - 531-5
AB  - To assess how treatment with acetylsalicylic acid (ASA) alters the fibrin network 
      structure, clotting was initiated in purified fibrinogen incubated with ASA by 
      adding thrombin. Clotting time and maximum absorbance of the fibrin aggregation 
      curve were used to demonstrate the potential of fibrin generation. The results 
      showed that the clotting properties of fibrinogen decreased and that the affinity 
      of plasminogen to fibrin or thrombin inhibition by antithrombin increased if 
      plasminogen or antithrombin, respectively, were present in the reaction system. 
      The effect of ASA varied in a dose dependent manner. It was concluded that ASA 
      may directly or indirectly confer positive or negative effects on the stability 
      of the fibrin clot and that the balance between these effects may be regulated by 
      the ASA dose.
FAU - He, S
AU  - He S
AD  - Coagulation Research, Department of Surgical Sciences, Karolinska Institutet, 
      Stockholm, Sweden. he_shu@yahoo.com
FAU - Blombäck, M
AU  - Blombäck M
FAU - Yoo, G
AU  - Yoo G
FAU - Sinha, R
AU  - Sinha R
FAU - Henschen-Edman, A H
AU  - Henschen-Edman AH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Fibrinogen/*physiology
MH  - Humans
EDAT- 2001/07/20 10:00
MHDA- 2001/08/03 10:01
CRDT- 2001/07/20 10:00
PHST- 2001/07/20 10:00 [pubmed]
PHST- 2001/08/03 10:01 [medline]
PHST- 2001/07/20 10:00 [entrez]
AID - 10.1111/j.1749-6632.2001.tb03540.x [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2001;936:531-5. doi: 10.1111/j.1749-6632.2001.tb03540.x.

PMID- 22716465
OWN - NLM
STAT- MEDLINE
DCOM- 20131227
LR  - 20120621
IS  - 1097-9867 (Electronic)
IS  - 1083-7450 (Linking)
VI  - 15
IP  - 3
DP  - 2010 Jun
TI  - Preparation and investigation of acetyl salicylic acid-caffeine complex for 
      rectal administration.
PG  - 249-57
LID - 10.3109/10837450903127350 [doi]
AB  - An acetyl salicylic acid-caffeine complex was prepared and evaluated for the 
      potential use in rectal administration. The results revealed the formation of a 
      complex between acetyl salicylic acid and caffeine in a 1:1 molar ratio by a 
      charge transfer mechanism. The effects of acetyl salicylic acid and complex on 
      the rectal tissues showed destruction in the mucosal epithelium in case of acetyl 
      salicylic acid; however, no change in the rectal tissues was noticed upon the 
      administration of the complex. The effect of suppository bases on the release of 
      the complex was studied using Witepsol H15 as fatty base and polyethylene glycols 
      (PEG) 1000 and 4000 as a water soluble suppository base. The release profiles of 
      acetyl salicylic acid and the complex were faster from PEG than from that of 
      Witepsol H15. The percent release for the complex and acetyl salicylic acid from 
      PEG base were 45.8, and 34.9%, respectively. However, it was 8.7 and 7.8%, 
      respectively, from Witepsol H15 fatty base. The release kinetic was found to 
      follow the non-Fickian diffusion model for complex from the suppository bases. It 
      was concluded that acetyl salicylic acid caffeine complex can be used safely for 
      rectal administration.
FAU - Fouad, Ehab A
AU  - Fouad EA
AD  - Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 
      Saudi Arabia.
FAU - El-Badry, Mahmoud
AU  - El-Badry M
FAU - Alanazi, Fars K
AU  - Alanazi FK
FAU - Arafah, Maha M
AU  - Arafah MM
FAU - Al-Ashban, Riyadh
AU  - Al-Ashban R
FAU - Alsarra, Ibrahim A
AU  - Alsarra IA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharm Dev Technol
JT  - Pharmaceutical development and technology
JID - 9610932
RN  - 0 (Suppositories)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Rectal
MH  - Animals
MH  - Aspirin/*administration & dosage/*chemical synthesis/pharmacokinetics
MH  - Caffeine/*administration & dosage/*chemical synthesis/pharmacokinetics
MH  - Chemistry, Pharmaceutical/*methods
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Rectum/drug effects/metabolism
MH  - Suppositories
EDAT- 2010/05/01 00:00
MHDA- 2013/12/29 06:00
CRDT- 2012/06/22 06:00
PHST- 2012/06/22 06:00 [entrez]
PHST- 2010/05/01 00:00 [pubmed]
PHST- 2013/12/29 06:00 [medline]
AID - 10.3109/10837450903127350 [doi]
PST - ppublish
SO  - Pharm Dev Technol. 2010 Jun;15(3):249-57. doi: 10.3109/10837450903127350.

PMID- 8279257
OWN - NLM
STAT- MEDLINE
DCOM- 19940210
LR  - 20190814
IS  - 0001-5172 (Print)
IS  - 0001-5172 (Linking)
VI  - 37
IP  - 8
DP  - 1993 Nov
TI  - Intrathecal injection of lysine acetylsalicylic acid in the rat: a 
      neurotoxicological study.
PG  - 799-805
AB  - Lysine acetylsalicylic acid has been reported to induce analgesic effects in 
      humans after intrathecal (i.t.) injection. Before conducting further studies in 
      humans with this drug, it is important to evaluate potential toxicological 
      effects on the spinal cord in animals. In the present study the effects of 
      chronic intrathecal administration of provocative doses of lysine acetylsalicylic 
      acid (L-ASA) on the rat spinal cord were evaluated using light and electron 
      microscopy and a quantitative morphometric method. We also investigated the 
      effects of single doses of the drug on the spinal cord blood flow (SCBF) using 
      the laser-Doppler flowmetry technique. No histopathological changes or 
      differences in number or density of neuronal cells could be seen after chronic 
      administration of L-ASA as compared to controls. The SCBF decreased immediately 
      after i.t. injection of a large dose (4 mg) of L-ASA and returned to predrug 
      levels within 10 min. At the end of the experiment metabolic acidosis was 
      detected, indicating a systemic effect of acetylsalicylic acid. It is concluded 
      that no neurotoxic effects on the spinal cord were seen after chronic i.t. 
      injection of L-ASA. From a neurotoxicological point of view, our findings do not 
      contraindicate the spinal use of L-ASA in humans.
FAU - Svensson, B A
AU  - Svensson BA
AD  - Department of Anatomy, Uppsala University, Sweden.
FAU - Karlsten, R
AU  - Karlsten R
FAU - Kristensen, J D
AU  - Kristensen JD
FAU - Sottile, A
AU  - Sottile A
FAU - Bennett, A
AU  - Bennett A
FAU - Gordh, T Jr
AU  - Gordh T Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Acta Anaesthesiol Scand
JT  - Acta anaesthesiologica Scandinavica
JID - 0370270
RN  - 0 (Analgesics)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Analgesics/*administration & dosage/toxicity
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/toxicity
MH  - Injections, Spinal
MH  - Lysine/administration & dosage/*analogs & derivatives/toxicity
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Spinal Cord/blood supply/*drug effects
EDAT- 1993/11/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
AID - 10.1111/j.1399-6576.1993.tb03812.x [doi]
PST - ppublish
SO  - Acta Anaesthesiol Scand. 1993 Nov;37(8):799-805. doi: 
      10.1111/j.1399-6576.1993.tb03812.x.

PMID- 19897665
OWN - NLM
STAT- MEDLINE
DCOM- 20091117
LR  - 20220311
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Print)
IS  - 0959-8138 (Linking)
VI  - 339
DP  - 2009 Nov 6
TI  - Aspirin for primary prevention of cardiovascular events in people with diabetes: 
      meta-analysis of randomised controlled trials.
PG  - b4531
LID - bmj.b4531 [pii]
LID - 10.1136/bmj.b4531 [doi]
LID - b4531
AB  - OBJECTIVE: To evaluate the benefits and harms of low dose aspirin in people with 
      diabetes and no cardiovascular disease. DESIGN: Meta-analysis of randomised 
      controlled trials. DATA SOURCES: Medline (1966-November 2008), the Cochrane 
      central register of controlled trials (Cochrane Library 2008;issue 4), and 
      reference lists of retrieved articles. Review methods Randomised trials of 
      aspirin compared with placebo or no aspirin in people with diabetes and no 
      pre-existing cardiovascular disease were eligible for inclusion. Data on major 
      cardiovascular events (death from cardiovascular causes, non-fatal myocardial 
      infarction, non-fatal stroke, and all cause mortality) were extracted and pooled 
      with a random effect model. Results are reported as relative risks with 95% 
      confidence intervals. RESULTS: Of 157 studies in the literature searches, six 
      were eligible (10 117 participants). When aspirin was compared with placebo there 
      was no statistically significant reduction in the risk of major cardiovascular 
      events (five studies, 9584 participants; relative risk 0.90, 95% confidence 
      interval 0.81 to 1.00), cardiovascular mortality (four studies, n=8557, 0.94; 
      0.72 to 1.23), or all cause mortality (four studies, n=8557; 0.93, 0.82 to 1.05). 
      Significant heterogeneity was found in the analysis for myocardial infarction 
      (I(2)=62.2%; P=0.02) and stroke (I(2)=52.5%; P=0.08). Aspirin significantly 
      reduced the risk of myocardial infarction in men (0.57, 0.34 to 0.94) but not in 
      women (1.08, 0.71 to 1.65; P for interaction=0.056). Evidence relating to harms 
      was inconsistent. CONCLUSIONS: A clear benefit of aspirin in the primary 
      prevention of major cardiovascular events in people with diabetes remains 
      unproved. Sex may be an important effect modifier. Toxicity is to be explored 
      further.
FAU - De Berardis, Giorgia
AU  - De Berardis G
AD  - Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, 
      Via Nazionale 8/a, 66030 S. Maria Imbaro, Italy.
FAU - Sacco, Michele
AU  - Sacco M
FAU - Strippoli, Giovanni F M
AU  - Strippoli GF
FAU - Pellegrini, Fabio
AU  - Pellegrini F
FAU - Graziano, Giusi
AU  - Graziano G
FAU - Tognoni, Gianni
AU  - Tognoni G
FAU - Nicolucci, Antonio
AU  - Nicolucci A
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20091106
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - BMJ. 2010;340:c374
CIN - BMJ. 2009;339:b4596. PMID: 19897667
CIN - BMJ. 2009;339:b5588. PMID: 20032069
CIN - Ann Intern Med. 2010 Apr 20;152(8):JC4-10. PMID: 20404367
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Agents/*administration & dosage/adverse effects
MH  - Diabetic Angiopathies/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Primary Prevention
MH  - Prognosis
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
PMC - PMC2774388
COIS- Competing interests: None declared.
EDAT- 2009/11/10 06:00
MHDA- 2009/11/18 06:00
CRDT- 2009/11/10 06:00
PHST- 2009/11/10 06:00 [entrez]
PHST- 2009/11/10 06:00 [pubmed]
PHST- 2009/11/18 06:00 [medline]
AID - bmj.b4531 [pii]
AID - berg679159 [pii]
AID - 10.1136/bmj.b4531 [doi]
PST - epublish
SO  - BMJ. 2009 Nov 6;339:b4531. doi: 10.1136/bmj.b4531.

PMID- 35121597
OWN - NLM
STAT- MEDLINE
DCOM- 20220322
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 12
IP  - 2
DP  - 2022 Feb 4
TI  - Safety and effectiveness of low-dose aspirin for the prevention of 
      gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: 
      a population-based cohort study.
PG  - e050510
LID - 10.1136/bmjopen-2021-050510 [doi]
LID - e050510
AB  - OBJECTIVE: To assess the association between low-dose aspirin and the incidence 
      of colorectal cancer (CRC), gastric cancer (GC), oesophageal cancer (EC) and 
      gastrointestinal bleeding (GIB) in adults without established atherosclerotic 
      cardiovascular disease. DESIGN: Cohort study with propensity score matching of 
      new-users of aspirin to non-users. SETTING: Clinical Data Analysis and Reporting 
      System database, Hong Kong. PARTICIPANTS: Adults ≥40 years with a prescription 
      start date of either low-dose aspirin (75-300 mg/daily) or paracetamol 
      (non-aspirin users) between 1 January 2004 to 31 December 2008 without a history 
      of atherosclerotic cardiovascular disease. MAIN OUTCOME MEASURES: The primary 
      outcome was the first diagnosis of gastrointestinal cancer (either CRC, GC or EC) 
      and the secondary outcome was GIB. Individuals were followed from index date of 
      prescription until the earliest occurrence of an outcome of interest, an incident 
      diagnosis of any type of cancer besides the outcome, death or until 31 December 
      2017. A competing risk survival analysis was used to estimate HRs and 95% CIs 
      with death as the competing risk. RESULTS: After matching, 49 679 aspirin and 
      non-aspirin users were included. The median (IQR) follow-up was 10.0 (6.4) years. 
      HRs for low-dose aspirin compared with non-aspirin users were 0.83 for CRC 
      (95% CI, 0.76 to 0.91), 0.77 for GC (95% CI, 0.65 to 0.92) and 0.88 for EC (95% 
      CI, 0.67 to 1.16). Patients prescribed low-dose aspirin had an increased risk of 
      GIB (HR 1.15, 95% CI, 1.11 to 1.20), except for patients prescribed proton pump 
      inhibitors or histamine H2-receptor antagonists (HR 1.03, 95% CI, 0.96 to 1.10). 
      CONCLUSION: In this cohort study of Chinese adults, patients prescribed low-dose 
      aspirin had reduced risks of CRC and GC and an increased risk of GIB. Among the 
      subgroup of patients prescribed gastroprotective agents at baseline, however, the 
      association with GIB was attenuated.
CI  - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Shami, Jessica J P
AU  - Shami JJP
AUID- ORCID: 0000-0002-1084-1829
AD  - Centre for Safe Medication Practice and Research, Department of Pharmacology and 
      Pharmacy, The University of Hong Kong, Hong Kong SAR, China.
FAU - Zhao, Jiaxi
AU  - Zhao J
AD  - Centre for Safe Medication Practice and Research, Department of Pharmacology and 
      Pharmacy, The University of Hong Kong, Hong Kong SAR, China.
AD  - Digital and Data Innovation, AstraZeneca Global R&D (China) Co., Ltd, Shanghai, 
      China.
FAU - Pathadka, Swathi
AU  - Pathadka S
AD  - Centre for Safe Medication Practice and Research, Department of Pharmacology and 
      Pharmacy, The University of Hong Kong, Hong Kong SAR, China.
FAU - Wan, Eric Yuk Fai
AU  - Wan EYF
AUID- ORCID: 0000-0002-6275-1147
AD  - Centre for Safe Medication Practice and Research, Department of Pharmacology and 
      Pharmacy, The University of Hong Kong, Hong Kong SAR, China.
AD  - Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology 
      Park, Hong Kong SAR, China.
AD  - Department of Family Medicine and Primary Care, University of Hong Kong, Hong 
      Kong.
FAU - Blais, Joseph Edgar
AU  - Blais JE
AUID- ORCID: 0000-0001-7895-198X
AD  - Centre for Safe Medication Practice and Research, Department of Pharmacology and 
      Pharmacy, The University of Hong Kong, Hong Kong SAR, China.
FAU - Vora, Pareen
AU  - Vora P
AD  - Epidemiology, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany.
FAU - Soriano-Gabarró, Montse
AU  - Soriano-Gabarró M
AD  - Epidemiology, Bayer Pharma AG, Berlin, Germany.
FAU - Cheung, Ka Shing
AU  - Cheung KS
AD  - Department of Medicine, University of Hong Kong, Hong Kong.
FAU - Leung, W K
AU  - Leung WK
AD  - Department of Medicine, University of Hong Kong, Hong Kong.
FAU - Wong, Ian C K
AU  - Wong ICK
AD  - Centre for Safe Medication Practice and Research, Department of Pharmacology and 
      Pharmacy, The University of Hong Kong, Hong Kong SAR, China.
AD  - Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology 
      Park, Hong Kong SAR, China.
AD  - Centre for Medicines Optimisation Research and Education, University College 
      London Hospitals NHS Foundation Trust, London, UK.
FAU - Chan, Esther W
AU  - Chan EW
AD  - Centre for Safe Medication Practice and Research, Department of Pharmacology and 
      Pharmacy, The University of Hong Kong, Hong Kong SAR, China ewchan@hku.hk.
AD  - Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology 
      Park, Hong Kong SAR, China.
AD  - Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 
      China.
AD  - Shenzhen Institute of Research and Innovation, The University of Hong Kong, 
      Shenzhen, China.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220204
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases
MH  - Cohort Studies
MH  - Gastrointestinal Hemorrhage/chemically induced/epidemiology
MH  - *Gastrointestinal Neoplasms/epidemiology/prevention & control
MH  - Hong Kong
MH  - Humans
PMC - PMC8819826
OTO - NOTNLM
OT  - epidemiology
OT  - gastroenterology
OT  - gastrointestinal tumours
OT  - preventive medicine
OT  - primary care
COIS- Competing interests: EWC has received honorarium from the Hospital Authority and 
      research funding from The Hong Kong Research Grants Council, The Research Fund 
      Secretariat of the Food and Health Bureau, Narcotics Division of the Security 
      Bureau of HKSAR, Hong Kong; National Natural Science Fund of China, China; 
      Wellcome Trust, UK; Bristol Myers Squibb, Pfizer and Takeda, for work unrelated 
      to this study. ICKW has received research funding outside the submitted work from 
      the Hong Kong Research Grants Council and the Hong Kong Health and Medical 
      Research Fund, National Institute for Health Research in the UK, European 
      Commission, Amgen, Bayer, Bristol Myers Squibb, GSK and Janssen. PV and MS-G are 
      employees of Bayer AG.
EDAT- 2022/02/06 06:00
MHDA- 2022/03/23 06:00
CRDT- 2022/02/05 05:47
PHST- 2022/02/05 05:47 [entrez]
PHST- 2022/02/06 06:00 [pubmed]
PHST- 2022/03/23 06:00 [medline]
AID - bmjopen-2021-050510 [pii]
AID - 10.1136/bmjopen-2021-050510 [doi]
PST - epublish
SO  - BMJ Open. 2022 Feb 4;12(2):e050510. doi: 10.1136/bmjopen-2021-050510.

PMID- 20429671
OWN - NLM
STAT- MEDLINE
DCOM- 20100824
LR  - 20131121
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 11
IP  - 9
DP  - 2010 Jun
TI  - Role of aspirin in the primary prevention of cardiovascular disease in diabetes 
      mellitus: a meta-analysis.
PG  - 1459-66
LID - 10.1517/14656561003792538 [doi]
AB  - OBJECTIVE: To evaluate the benefits of aspirin in people with diabetes mellitus 
      for the primary prevention of cardiovascular disease. RESEARCH DESIGN/METHODS: We 
      searched MEDLINE and Cochrane database for randomized, controlled trials of 
      aspirin in people with diabetes and no cardiovascular disease. Relative risks 
      were determined using random-effects meta-analysis. MAIN OUTCOME MEASURES: Risk 
      reduction of aspirin compared with control groups for major cardiovascular 
      events. RESULTS: Six trials consisting of 7374 patients with diabetes showed no 
      benefits of aspirin compared with non-aspirin users with regard to overall 
      mortality, risk reduction (relative risk (RR) = 0.96, 95% CI 0.78 - 1.18, p = 
      0.71), major cardiovascular events (RR = 0.90, 95% CI 0.78 - 1.05, p = 0.17) and 
      myocardial infarction (RR = 0.95, 95% CI 0.76 - 1.18, p = 0.63). Risk of major 
      bleeding in the aspirin compared with the non-aspirin group was not significant 
      (RR = 2.49, 95% CI 0.70 - 8.84, p = 0.16). CONCLUSIONS: Aspirin therapy did not 
      reduce the risk of cardiovascular events. Existing trials were limited by small 
      patient numbers and low cardiovascular event rates. The use of aspirin cannot be 
      routinely recommended for primary prevention of cardiovascular events in 
      diabetes.
FAU - Younis, Naveed
AU  - Younis N
AD  - University Hospital South Manchester, Wythenshawe Hospital, Department of 
      Diabetes & Endocrinology, Southmoor Road, Manchester M23 9LT, UK. 
      naveed.younis@uhsm.nhs.uk
FAU - Williams, Steven
AU  - Williams S
FAU - Ammori, Basil
AU  - Ammori B
FAU - Soran, Handrean
AU  - Soran H
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/complications/*prevention & control
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Humans
MH  - Primary Prevention
EDAT- 2010/05/01 06:00
MHDA- 2010/08/25 06:00
CRDT- 2010/05/01 06:00
PHST- 2010/05/01 06:00 [entrez]
PHST- 2010/05/01 06:00 [pubmed]
PHST- 2010/08/25 06:00 [medline]
AID - 10.1517/14656561003792538 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2010 Jun;11(9):1459-66. doi: 10.1517/14656561003792538.

PMID- 1151665
OWN - NLM
STAT- MEDLINE
DCOM- 19751030
LR  - 20171204
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 64
IP  - 5
DP  - 1975 May
TI  - Influence of particle size on rectal absorption of aspirin.
PG  - 875-80
AB  - The rectal absorption of aspirin from theobroma oil suppositories was studied in 
      seven human subjects using urinary excretion measurements. The effect of particle 
      size on the excretion rate and cumulative amount of total salicylate excreted was 
      demonstrated by the administration of a 600-mg dose as powdered aspirin and as 
      aspirin disks having 0.023 as much surface as powdered aspirin. In vitro 
      dissolution profiles of aspirin from the suppositories were studied. By the NF 
      XIII Method II, the time required for 50% of the aspirin to dissolve from the 
      suppository was 50 and 100 min for the powdered aspirin and the aspirin disks, 
      respectively. In the bioavailability study, the diffusion equilibrium was 
      attained at approximately 4-5 and 9-10 hr after the rectal administration of 
      powdered aspirin and aspirin disks, respectively. No correlation was found 
      between bioavailability and the dissolution profiles as determined by the USP 
      XVIII dissolution method.
FAU - Parrott, E L
AU  - Parrott EL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Oils)
RN  - 0 (Salicylates)
RN  - 0 (Suppositories)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*metabolism
MH  - Biological Availability
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Middle Aged
MH  - Oils
MH  - Particle Size
MH  - Rectum/metabolism
MH  - Salicylates/urine
MH  - Solubility
MH  - Suppositories
MH  - Time Factors
EDAT- 1975/05/01 00:00
MHDA- 1975/05/01 00:01
CRDT- 1975/05/01 00:00
PHST- 1975/05/01 00:00 [pubmed]
PHST- 1975/05/01 00:01 [medline]
PHST- 1975/05/01 00:00 [entrez]
AID - S0022-3549(15)40173-X [pii]
PST - ppublish
SO  - J Pharm Sci. 1975 May;64(5):875-80.

PMID- 33706989
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 144 Suppl 1
DP  - 2021 Apr 1
TI  - The Future of Aspirin Therapy in Cardiovascular Disease.
PG  - S40-S47
LID - S0002-9149(20)31346-1 [pii]
LID - 10.1016/j.amjcard.2020.12.019 [doi]
AB  - Much has been written about the demise of aspirin (ASA) but reports of its death 
      are premature. The drug remains one of the most widely prescribed by physicians 
      worldwide. It is cheap, familiar, and effective for a variety of uses, including 
      in patients with acute or prior myocardial infarction, ischemic stroke, 
      peripheral artery disease, and percutaneous or surgical revascularization 
      procedures, as well as for use for pain and fever relief. Beyond physician 
      prescription or recommendation, over the counter use of ASA is common, including 
      for primary cardiovascular prevention, though this decision really should involve 
      a discussion of risks and benefits with a physician. ASA is an essential member 
      of the duo that makes up dual antiplatelet therapy (a P2Y(12) inhibitor plus ASA) 
      and also dual pathway inhibition (vascular dose rivaroxaban plus ASA), and data 
      for both approaches are growing. Furthermore, research is ongoing as to the 
      optimal dosing frequency (once vs twice daily), potentially safer 
      gastrointestinal delivery, and possibly more effective formulations in terms of 
      platelet inhibition. One goal of ASA research is to try to reduce bleeding 
      complications that are a risk with all anti-thrombotic therapies. Although its 
      exact roles will continue to evolve, the future for ASA remains bright.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 
      Electronic address: dlbhattmd@post.harvard.edu.
FAU - Pollack, Charles V Jr
AU  - Pollack CV Jr
AD  - University of Mississippi Medical Center, Jackson, Mississippi.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Assessment
EDAT- 2021/03/13 06:00
MHDA- 2021/04/10 06:00
CRDT- 2021/03/12 06:01
PHST- 2020/11/21 00:00 [received]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2021/03/12 06:01 [entrez]
PHST- 2021/03/13 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - S0002-9149(20)31346-1 [pii]
AID - 10.1016/j.amjcard.2020.12.019 [doi]
PST - ppublish
SO  - Am J Cardiol. 2021 Apr 1;144 Suppl 1:S40-S47. doi: 10.1016/j.amjcard.2020.12.019.

PMID- 24417442
OWN - NLM
STAT- MEDLINE
DCOM- 20150226
LR  - 20140522
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 11
IP  - 2
DP  - 2014 Feb 3
TI  - Structural diversity of solid dispersions of acetylsalicylic acid as seen by 
      solid-state NMR.
PG  - 516-30
LID - 10.1021/mp400495h [doi]
AB  - Solid dispersions of active pharmaceutical ingredients are of increasing interest 
      due to their versatile use. In the present study polyvinylpyrrolidone (PVP), 
      poly[N-(2-hydroxypropyl)-metacrylamide] (pHPMA), poly(2-ethyl-2-oxazoline) 
      (PEOx), and polyethylene glycol (PEG), each in three Mw, were used to demonstrate 
      structural diversity of solid dispersions. Acetylsalicylic acid (ASA) was used as 
      a model drug. Four distinct types of the solid dispersions of ASA were created 
      using a freeze-drying method: (i) crystalline solid dispersions containing 
      nanocrystalline ASA in a crystalline PEG matrix; (ii) amorphous glass suspensions 
      with large ASA crystallites embedded in amorphous pHPMA; (iii) solid solutions 
      with molecularly dispersed ASA in rigid amorphous PVP; and (iv) nanoheterogeneous 
      solid solutions/suspensions containing nanosized ASA clusters dispersed in a 
      semiflexible matrix of PEOx. The obtained structural data confirmed that the type 
      of solid dispersion can be primarily controlled by the chemical constitutions of 
      the applied polymers, while the molecular weight of the polymers had no 
      detectable impact. The molecular structure of the prepared dispersions was 
      characterized using solid-state NMR, wide-angle X-ray scattering (WAXS), and 
      differential scanning calorimetry (DSC). By applying various (1)H-(13)C and 
      (1)H-(1)H correlation experiments combined with T1((1)H) and T1ρ((1)H) relaxation 
      data, the extent of the molecular mixing was determined over a wide range of 
      distances, from intimate intermolecular contacts (0.1-0.5 nm) up to the 
      phase-separated nanodomains reaching ca. 500 nm. Hydrogen-bond interactions 
      between ASA and polymers were probed by the analysis of (13)C and (15)N CP/MAS 
      NMR spectra combined with the measurements of (1)H-(15)N dipolar profiles. 
      Overall potentialities and limitations of individual experimental techniques were 
      thoroughly evaluated.
FAU - Policianova, Olivia
AU  - Policianova O
AD  - Institute of Macromolecular Chemistry , Academy of Sciences of the Czech 
      Republic, Heyrovského nám. 2, 162 06 Praha 6, Czech Republic.
FAU - Brus, Jiri
AU  - Brus J
FAU - Hruby, Martin
AU  - Hruby M
FAU - Urbanova, Martina
AU  - Urbanova M
FAU - Zhigunov, Alexander
AU  - Zhigunov A
FAU - Kredatusova, Jana
AU  - Kredatusova J
FAU - Kobera, Libor
AU  - Kobera L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140117
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 0 (Suspensions)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Calorimetry, Differential Scanning
MH  - *Magnetic Resonance Spectroscopy
MH  - Molecular Structure
MH  - Suspensions/*chemistry
EDAT- 2014/01/15 06:00
MHDA- 2015/02/27 06:00
CRDT- 2014/01/15 06:00
PHST- 2014/01/15 06:00 [entrez]
PHST- 2014/01/15 06:00 [pubmed]
PHST- 2015/02/27 06:00 [medline]
AID - 10.1021/mp400495h [doi]
PST - ppublish
SO  - Mol Pharm. 2014 Feb 3;11(2):516-30. doi: 10.1021/mp400495h. Epub 2014 Jan 17.

PMID- 26282158
OWN - NLM
STAT- MEDLINE
DCOM- 20160831
LR  - 20151110
IS  - 2213-2201 (Electronic)
VI  - 3
IP  - 6
DP  - 2015 Nov-Dec
TI  - An Hourly Dose-Escalation Desensitization Protocol for Aspirin-Exacerbated 
      Respiratory Disease.
PG  - 926-31.e1
LID - S2213-2198(15)00317-7 [pii]
LID - 10.1016/j.jaip.2015.06.013 [doi]
AB  - BACKGROUND: Aspirin desensitization followed by maintenance therapy effectively 
      improves symptom control in patients with aspirin exacerbated respiratory disease 
      (AERD). The majority of current desensitization protocols use 3-hour dosing 
      intervals and often require 2 to 3 days to complete. OBJECTIVE: We evaluated 
      hourly dose escalations in a subset of patients with chronic rhinosinusitis, 
      nasal polyps, and asthma who historically reacted to aspirin within 1 hour or 
      were avoiding aspirin with the goal of developing a safe and efficient 
      desensitization protocol. METHODS: Fifty-seven aspirin desensitizations were 
      performed under the hourly protocol. All patients had refractory nasal polyposis 
      as an indication for aspirin desensitization. The clinical characteristics of 
      each subject were analyzed in relation to aspects of his or her reactions during 
      the procedure. RESULTS: Ninety-eight percent of study patients were successfully 
      treated under the hourly protocol, including those with a history of severe 
      reactions and intubation. None required further medication than is available in 
      an outpatient allergy clinic. A total of 96% of reactors recorded a bronchial or 
      naso-ocular reaction within 1 hour of the preceding dose. Of the total patients 
      on this protocol, 40% were able to complete the procedure in a single day, and 
      60% within 2 days. CONCLUSION: Patients with AERD who have a history of symptoms 
      less than 1 hour after aspirin exposure can be safely desensitized with a 1-hour 
      dose-escalation protocol that can often be completed in a single day.
CI  - Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Chen, Justin R
AU  - Chen JR
AD  - Division of Allergy and Immunology, Department of Internal Medicine, the 
      University of Texas Southwestern Medical Center, Dallas, Tex.
FAU - Buchmiller, Brett L
AU  - Buchmiller BL
AD  - Division of Allergy and Immunology, Department of Internal Medicine, the 
      University of Texas Southwestern Medical Center, Dallas, Tex.
FAU - Khan, David A
AU  - Khan DA
AD  - Division of Allergy and Immunology, Department of Internal Medicine, the 
      University of Texas Southwestern Medical Center, Dallas, Tex. Electronic address: 
      dave.khan@utsouthwestern.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150815
PL  - United States
TA  - J Allergy Clin Immunol Pract
JT  - The journal of allergy and clinical immunology. In practice
JID - 101597220
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Allergy Clin Immunol Pract. 2015 Nov-Dec;3(6):932-3. PMID: 26553618
MH  - Administration, Oral
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/immunology
MH  - Aspirin/*administration & dosage/*adverse effects/immunology
MH  - Desensitization, Immunologic/*methods
MH  - Dose-Response Relationship, Immunologic
MH  - Drug Hypersensitivity/immunology/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiration Disorders/*chemically induced/immunology
OTO - NOTNLM
OT  - Aspirin desensitization
OT  - Aspirin-exacerbated respiratory disease
OT  - Asthma
OT  - Chronic rhinosinusitis
OT  - Nasal polyps
EDAT- 2015/08/19 06:00
MHDA- 2016/09/01 06:00
CRDT- 2015/08/19 06:00
PHST- 2015/02/24 00:00 [received]
PHST- 2015/06/06 00:00 [revised]
PHST- 2015/06/10 00:00 [accepted]
PHST- 2015/08/19 06:00 [entrez]
PHST- 2015/08/19 06:00 [pubmed]
PHST- 2016/09/01 06:00 [medline]
AID - S2213-2198(15)00317-7 [pii]
AID - 10.1016/j.jaip.2015.06.013 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol Pract. 2015 Nov-Dec;3(6):926-31.e1. doi: 
      10.1016/j.jaip.2015.06.013. Epub 2015 Aug 15.

PMID- 6107722
OWN - NLM
STAT- MEDLINE
DCOM- 19810129
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8204
DP  - 1980 Nov 22
TI  - Clinical trials of intra-articular aspirin in rheumatoid arthritis.
PG  - 1099-102
AB  - The effect of the intra-articular injection of acetylsalicylic acid in patients 
      with rheumatoid arthritis was compared with that of hydrocortisone acetate and 
      with that of saline in blind, controlled, clinical trials. All three preparations 
      were effective in relieving pain and improving the range of motion, and no 
      significant differences were demonstrated. The results suggest a need for the 
      re-appraisal of the value of intra-articular administration of synthetic 
      corticosteroids.
FAU - Rylance, H J
AU  - Rylance HJ
FAU - Chalmers, T M
AU  - Chalmers TM
FAU - Elton, R A
AU  - Elton RA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hydrocortisone/therapeutic use
MH  - Injections, Intra-Articular
MH  - Male
MH  - Pain/drug therapy
EDAT- 1980/11/22 00:00
MHDA- 1980/11/22 00:01
CRDT- 1980/11/22 00:00
PHST- 1980/11/22 00:00 [pubmed]
PHST- 1980/11/22 00:01 [medline]
PHST- 1980/11/22 00:00 [entrez]
AID - S0140-6736(80)92539-8 [pii]
AID - 10.1016/s0140-6736(80)92539-8 [doi]
PST - ppublish
SO  - Lancet. 1980 Nov 22;2(8204):1099-102. doi: 10.1016/s0140-6736(80)92539-8.

PMID- 32568481
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20220415
IS  - 2448-5667 (Electronic)
IS  - 0443-5117 (Linking)
VI  - 57
IP  - 5
DP  - 2019 Sep 2
TI  - [Acetylsalicylic acid in prevention of pre-eclampsia].
PG  - 270-276
LID - http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/2448/3711 
      [pii]
AB  - BACKGROUND: Pre-eclampsia (PE) is an important cause of morbidity and mortality 
      in our country. OBJECTIVE: Evaluate if the administration of acetylsalicylic acid 
      (ASA) at a low dose reduces its presence. METHODS: Comparative, cohort study. 
      Pregnant women with risk factors for PE: Primigravidae, PE antecedent and twin 
      pregnancy were included. Primigravidae and multigested with previous vascular 
      pathology weren't included. Group 1: 150, 11 excluded, 80 mg ASA from week 20 at 
      the end of pregnancy. Group 2: 150, without ASA. The presence of PE or 
      gestational hypertension (HG) was monitored. General data and clinical controls 
      were taken. Chi square and relative risk (RR) were calculated. RESULTS: Group 1: 
      n = 139, 26 ± 5.6 years, 9% PE. Group 2: n = 150, 25.5 ± 5.6 years, PE 20% (p = 
      0.01), RR 0.47 (95% CI 0.19 - 0.87) (p = 0.01), attributable risk -0.11 
      equivalent to an absolute reduction of 11% for PE in group 1. CONCLUSIONS: 
      Pregnant women with risk factor for PE who received ASA diminished the risk of 
      developing PE in 50%.
FAU - Godínez, Víctor
AU  - Godínez V
AD  - Instituto Mexicano del Seguro Social, Unidad Médica de Alta Especialidad Hospital 
      de Gíneco-Pediatría No. 48, División de Ginecología y Obstetricia. León, 
      Guanajuato, México.
FAU - Godínez-Vázquez, Víctor Junior
AU  - Godínez-Vázquez VJ
FAU - Godínez-Vázquez, Paulina Del Rocío
AU  - Godínez-Vázquez PDR
FAU - Sosa-Bustamante, Gloria Patricia
AU  - Sosa-Bustamante GP
FAU - Díaz de León-Morales, Luz Verónica
AU  - Díaz de León-Morales LV
LA  - spa
PT  - Comparative Study
TT  - Prevención de la preeclampsia con ácido acetilsalicílico.
DEP - 20190902
PL  - Mexico
TA  - Rev Med Inst Mex Seguro Soc
JT  - Revista medica del Instituto Mexicano del Seguro Social
JID - 101243727
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Pre-Eclampsia
OT  - Pregnancy
EDAT- 2020/06/23 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/01/27 00:00 [received]
PHST- 2020/02/05 00:00 [accepted]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/2448/3711 
      [pii]
PST - epublish
SO  - Rev Med Inst Mex Seguro Soc. 2019 Sep 2;57(5):270-276.

PMID- 26548565
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1366-5928 (Electronic)
IS  - 0049-8254 (Linking)
VI  - 46
IP  - 6
DP  - 2016
TI  - Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in 
      beagle dogs.
PG  - 530-41
LID - 10.3109/00498254.2015.1096979 [doi]
AB  - 1. Warfarin and aspirin are widely used in a wide spectrum of thromboembolic and 
      atherothrombotic diseases. Despite the potential efficacy of warfarin-aspirin 
      therapy, the safety and side effect of combined therapy remains unclear. 2. The 
      aim of this study was to investigate the pharmacokinetic and pharmacodynamic 
      interactions between warfarin and aspirin in beagles after single and multiple 
      doses. 3. Coadministration of aspirin had no significant effects on the area 
      under the plasma concentration time curve (AUC(0-t)) and maximum plasma 
      concentration (Cmax) of R- and S-warfarin after a single dose of warfarin, but 
      significantly increase the AUC(0-t) and Cmax and dramatically decrease the 
      clearance (CL) of R- and S-warfarin after multiple dose of warfarin. Accordingly, 
      there was a slight increase in the AUEC(0-t) and Emax of activated partial 
      thromboplastin time (aPTT), prothrombin time (PT) and international normalized 
      ratio (INR) after multiple dose of warfarin. 4. Coadministration of warfarin had 
      no markedly effects on the AUC(0-t) and Cmax of aspirin and its metabolite 
      salicylic acid after single or multiple dose of aspirin. Meanwhile, the AUEC(0-t) 
      and Emax of inhibition of platelet aggregation (IPA) were not significantly 
      affected by warfarin. 5. Our animal study indicated that coadministration of 
      aspirin with warfarin can cause significant pharmacokinetic and pharmacodynamic 
      drug-drug interactions in beagles. However, more studies are urgently needed to 
      assess related information of warfarin-aspirin drug interactions in healthy 
      volunteers or patients.
FAU - Shen, Chenlin
AU  - Shen C
AD  - a Department of Basic and Clinical Pharmacology , School of Pharmacy, Anhui 
      Medical University , Hefei , Anhui , China .
AD  - b Institute for Liver Diseases of Anhui Medical University (AMU), Anhui Key 
      Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical 
      University , Hefei , Anhui , China .
FAU - Huang, Xiaohui
AU  - Huang X
AD  - a Department of Basic and Clinical Pharmacology , School of Pharmacy, Anhui 
      Medical University , Hefei , Anhui , China .
FAU - Li, Jun
AU  - Li J
AD  - b Institute for Liver Diseases of Anhui Medical University (AMU), Anhui Key 
      Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical 
      University , Hefei , Anhui , China .
FAU - Zhang, Ping
AU  - Zhang P
AD  - a Department of Basic and Clinical Pharmacology , School of Pharmacy, Anhui 
      Medical University , Hefei , Anhui , China .
FAU - Li, Lin
AU  - Li L
AD  - a Department of Basic and Clinical Pharmacology , School of Pharmacy, Anhui 
      Medical University , Hefei , Anhui , China .
FAU - Zhang, Wei
AU  - Zhang W
AD  - a Department of Basic and Clinical Pharmacology , School of Pharmacy, Anhui 
      Medical University , Hefei , Anhui , China .
FAU - Hu, Tingting
AU  - Hu T
AD  - b Institute for Liver Diseases of Anhui Medical University (AMU), Anhui Key 
      Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical 
      University , Hefei , Anhui , China .
FAU - Pappoe, Faustina
AU  - Pappoe F
AD  - c Department of Parasitology , Provincial Laboratory of Microbiology & 
      Parasitology and the Key Laboratory of Zoonoses Anhui, Anhui Medical University , 
      Hefei , Anhui , China .
FAU - Huang, Jihan
AU  - Huang J
AD  - d Center for Drug Clinical Research, Shanghai University of Chinese Medicine , 
      Shanghai , China , and.
FAU - Tang, Haiqin
AU  - Tang H
AD  - e Department of Cardiology , the First Affiliated Hospital of Anhui Medical 
      University , Hefei , Anhui , China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151107
PL  - England
TA  - Xenobiotica
JT  - Xenobiotica; the fate of foreign compounds in biological systems
JID - 1306665
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics/*pharmacology
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - International Normalized Ratio
MH  - Male
MH  - Partial Thromboplastin Time
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Prothrombin Time
MH  - Reference Standards
MH  - Salicylic Acid/blood
MH  - Warfarin/administration & dosage/blood/*pharmacokinetics/*pharmacology
OTO - NOTNLM
OT  - Aspirin
OT  - R- and S-warfarin
OT  - drug–drug interaction
OT  - pharmacodynamics
OT  - pharmacokinetic
OT  - salicylic acid
EDAT- 2015/11/10 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/11/10 06:00
PHST- 2015/11/10 06:00 [entrez]
PHST- 2015/11/10 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.3109/00498254.2015.1096979 [doi]
PST - ppublish
SO  - Xenobiotica. 2016;46(6):530-41. doi: 10.3109/00498254.2015.1096979. Epub 2015 Nov 
      7.

PMID- 21962274
OWN - NLM
STAT- MEDLINE
DCOM- 20120126
LR  - 20131121
IS  - 1943-5681 (Electronic)
IS  - 0002-9645 (Linking)
VI  - 72
IP  - 10
DP  - 2011 Oct
TI  - Independent and combined effects of prednisone and acetylsalicylic acid on 
      thromboelastography variables in healthy dogs.
PG  - 1325-32
LID - 10.2460/ajvr.72.10.1325 [doi]
AB  - OBJECTIVE: To describe the effects of prednisone and acetylsalicylic acid (ASA) 
      on results of thromboelastography in healthy dogs. ANIMALS: 16 male mixed-breed 
      dogs. PROCEDURES: Dogs were randomly assigned to 3 treatment groups (4 
      dogs/group) that received prednisone (median dose, 2.07 mg/kg), ASA (median dose, 
      0.51 mg/kg), or both drugs, PO, every 24 hours from days 0 through 6. Another 
      group received no treatment (control dogs; n = 4). Thromboelastography variables 
      (reaction time, clotting time, α-angle, maximum amplitude [MA], global clot 
      strength, coagulation index, and percentage of clot lysis at 60 minutes [CL(60)]) 
      were evaluated in blood samples collected (prior to drug administration in 
      treated dogs) on days 0 (baseline), 2, 4, and 6. RESULTS: Administration of ASA 
      alone did not alter TEG variables. For treatment effect, mean global clot 
      strength was increased in the prednisone and drug combination groups, compared 
      with values for control dogs; MA was also increased in the prednisone and drug 
      combination groups, compared with that of controls. For treatment-by-time effect, 
      median CL(60) was increased in the prednisone group on day 6, compared with 
      baseline value in the same dogs and with median CL(60) of the control group on 
      day 6. Median CL(60) was also increased in the drug combination group on day 6, 
      compared with the baseline value and with that of the control group on day 6. 
      CONCLUSIONS AND CLINICAL RELEVANCE: Prednisone administered at approximately 2 
      mg/kg/d, PO, for 7 days with or without concurrently administered ASA increased 
      clot strength and decreased clot lysis in healthy dogs.
FAU - Flint, Sarah K
AU  - Flint SK
AD  - Guardian Veterinary Centre, 5620 99th St NW, Edmonton, AB T6E 1V2, Canada. 
      sarah.flint@guardianvetcentre.com
FAU - Abrams-Ogg, Anthony C G
AU  - Abrams-Ogg AC
FAU - Kruth, Stephen A
AU  - Kruth SA
FAU - Bersenas, Alexa M
AU  - Bersenas AM
FAU - Wood, R Darren
AU  - Wood RD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Dogs
MH  - Drug Combinations
MH  - Male
MH  - Prednisone/*pharmacology
MH  - Reaction Time/drug effects
MH  - Thrombelastography/*drug effects/*veterinary
MH  - Time Factors
EDAT- 2011/10/04 06:00
MHDA- 2012/01/27 06:00
CRDT- 2011/10/04 06:00
PHST- 2011/10/04 06:00 [entrez]
PHST- 2011/10/04 06:00 [pubmed]
PHST- 2012/01/27 06:00 [medline]
AID - 10.2460/ajvr.72.10.1325 [doi]
PST - ppublish
SO  - Am J Vet Res. 2011 Oct;72(10):1325-32. doi: 10.2460/ajvr.72.10.1325.

PMID- 1981223
OWN - NLM
STAT- MEDLINE
DCOM- 19910401
LR  - 20161013
IS  - 0929-6646 (Print)
IS  - 0929-6646 (Linking)
VI  - 89
IP  - 8
DP  - 1990 Aug
TI  - Secondary prevention of ischemic stroke with low dose acetylsalicylic acid.
PG  - 635-44
AB  - In order to evaluate the efficacy of low dose acetylsalicylic acid (ASA) for the 
      secondary prevention of ischemic stroke, this cooperative multicenter clinical 
      trial was conducted on a non-blind basis. Patients having a first transient 
      ischemic attack (TIA), reversible ischemic neurological deficit (RIND) or 
      completed ischemic stroke were eligible for this trial. A total of 590 patients 
      including 47 cases of TIA, 23 cases of RIND and 520 cases of completed stroke 
      entered this study. These patients were allocated by the time of admission to one 
      of the following 5 trial regimens: (1) vasodilators having no known inhibitory 
      effect on platelet function (control group), (2) dipyridamole (DP) 50 mg 3 times 
      a day (DP group), (3) ASA 300 mg once a day (ASA 300 mg group), (4) ASA 300 mg 
      once in combination with DP 50 mg 3 times a day (ASADP group), and (5) ASA 100 mg 
      once a day (ASA1 group). No difference in effect between the control and DP 
      groups was observed, nor between the ASA 300 mg and ASADP groups. Therefore, we 
      combined the control and DP groups to make a non-ASA group, and joined the ASA 
      300 mg and ASADP groups to make an ASA3 group. The differences in the cumulative 
      event-free rate appeared to be significant between the non-ASA group and the ASA3 
      group and also between the non-ASA group and the ASA1 group. But the frequency 
      distribution of age, territory of stroke, diabetes mellitus, cardiac disease, 
      hematological disease and hyperuricemia were significantly different among these 
      3 study groups. We thus included these covariates in the Cox's proportional 
      hazard model to control their possible confounding effects.(ABSTRACT TRUNCATED AT 
      250 WORDS)
FAU - Lee, T K
AU  - Lee TK
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei, 
      R.O.C.
FAU - Lien, I N
AU  - Lien IN
FAU - Ryu, S J
AU  - Ryu SJ
FAU - Lee, K Y
AU  - Lee KY
FAU - Hu, H H
AU  - Hu HH
FAU - Tchen, P H
AU  - Tchen PH
FAU - Chen, C J
AU  - Chen CJ
FAU - Wu, S C
AU  - Wu SC
FAU - Chen, Y C
AU  - Chen YC
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Singapore
TA  - J Formos Med Assoc
JT  - Journal of the Formosan Medical Association = Taiwan yi zhi
JID - 9214933
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Brain Ischemia/*prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Prognosis
MH  - Recurrence
EDAT- 1990/08/01 00:00
MHDA- 1990/08/01 00:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 1990/08/01 00:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
PST - ppublish
SO  - J Formos Med Assoc. 1990 Aug;89(8):635-44.

PMID- 20828891
OWN - NLM
STAT- MEDLINE
DCOM- 20110203
LR  - 20131121
IS  - 1768-3254 (Electronic)
IS  - 0223-5234 (Linking)
VI  - 45
IP  - 11
DP  - 2010 Nov
TI  - [Cyclopentadienyl]metalcarbonyl complexes of acetylsalicylic acid as 
      neo-anticancer agents.
PG  - 5157-63
LID - 10.1016/j.ejmech.2010.08.028 [doi]
AB  - [(Prop-2-ynyl)-2-acetoxybenzoate]dicobalthexacarbonyl (Co-ASS), a derivative of 
      the nonsteroidal anti-inflammatory drug aspirin(®) (ASS), demonstrated high 
      cytotoxic potential against various tumor cells. The [acetylene]Co(2)(CO)(6) 
      cluster strongly increased the biological effects compared to aspirin(®). In this 
      study we evaluated the use of [cyclopentadienyl]metalcarbonyl as cytotoxic moiety 
      with a broader series of metals: molybdenum, manganese, cobalt and rhodium. All 
      compounds were tested for cytotoxicity against breast (MCF-7, MDA-MB-231) and 
      colon cancer (HT-29) cell lines. Their COX-1 and COX-2 inhibitory effects were 
      evaluated at isolated isoenzymes. Additionally, the influence on the level of the 
      major COX metabolite prostaglandin E(2) (PGE(2)) was quantified in MDA-MB-231 
      breast cancer cells. Whereas the pure ligands or ASS did not show any cytotoxic 
      effect, all metal complexes inhibited the tumor cell growth. The inhibitory 
      effects at COX-1 and COX-2 enzymes were low. Only the Prop-Cp-ASS-Rh complex (10 
      μM) caused an important inhibition of COX-1 by 60% and COX-2 by 30%. ASS showed 
      at the same concentration only a marginal repression of COX-1 activity (30%) and 
      no effect on COX-2.
CI  - Copyright © 2010 Elsevier Masson SAS. All rights reserved.
FAU - Rubner, Gerhard
AU  - Rubner G
AD  - Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Str. 2 + 4, 14195 
      Berlin, Germany.
FAU - Bensdorf, Kerstin
AU  - Bensdorf K
FAU - Wellner, Anja
AU  - Wellner A
FAU - Bergemann, Silke
AU  - Bergemann S
FAU - Ott, Ingo
AU  - Ott I
FAU - Gust, Ronald
AU  - Gust R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100818
PL  - France
TA  - Eur J Med Chem
JT  - European journal of medicinal chemistry
JID - 0420510
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Cyclopentanes)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*chemistry/pharmacology
MH  - Aspirin/*chemistry/pharmacology
MH  - Cell Line, Tumor
MH  - Cyclooxygenase 1/drug effects
MH  - Cyclooxygenase 2/drug effects
MH  - Cyclooxygenase Inhibitors/chemistry/pharmacology
MH  - Cyclopentanes/*chemistry
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Magnetic Resonance Spectroscopy
MH  - Spectrometry, Mass, Electrospray Ionization
MH  - Structure-Activity Relationship
EDAT- 2010/09/11 06:00
MHDA- 2011/02/04 06:00
CRDT- 2010/09/11 06:00
PHST- 2010/05/14 00:00 [received]
PHST- 2010/07/30 00:00 [revised]
PHST- 2010/08/10 00:00 [accepted]
PHST- 2010/09/11 06:00 [entrez]
PHST- 2010/09/11 06:00 [pubmed]
PHST- 2011/02/04 06:00 [medline]
AID - S0223-5234(10)00606-9 [pii]
AID - 10.1016/j.ejmech.2010.08.028 [doi]
PST - ppublish
SO  - Eur J Med Chem. 2010 Nov;45(11):5157-63. doi: 10.1016/j.ejmech.2010.08.028. Epub 
      2010 Aug 18.

PMID- 25098174
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20140814
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 7
IP  - 5
DP  - 2014 Sep
TI  - Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump 
      inhibitors and aspirin.
PG  - 645-53
LID - 10.1586/17512433.2014.945428 [doi]
AB  - The efficacy of aspirin in primary and secondary prevention of cardiovascular 
      diseases has been convincingly demonstrated. Gastrointestinal (GI) adverse 
      effects with aspirin may lead to poor adherence and/or discontinuation of 
      treatment. Proton pump inhibitors (PPIs) have been used for more than 20 years as 
      the first choice for treating peptic ulcers and their bleeding complications, 
      gastroesophageal reflux disease, non-steroidal anti-inflammatory drug-induced GI 
      lesions and dyspepsia. Adherence becomes a major concern when aspirin is 
      co-prescribed with PPIs to prevent GI adverse effects. Combining aspirin and PPIs 
      into one tablet is an effective approach to address aspirin-related GI adverse 
      effects and increase adherence to aspirin therapy for the prevention of 
      cardiovascular diseases.
FAU - Gesheff, Martin G
AU  - Gesheff MG
AD  - Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, 2401 W. 
      Belvedere Ave, Baltimore, MD 21215, USA.
FAU - Franzese, Christopher J
AU  - Franzese CJ
FAU - Bliden, Kevin P
AU  - Bliden KP
FAU - Contino, Chase J
AU  - Contino CJ
FAU - Rafeedheen, Rahil
AU  - Rafeedheen R
FAU - Tantry, Udaya S
AU  - Tantry US
FAU - Gurbel, Paul A
AU  - Gurbel PA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140807
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects/pharmacokinetics
MH  - Cardiovascular Diseases/prevention & control
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Medication Adherence
MH  - *Models, Biological
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/pharmacokinetics
MH  - Proton Pump Inhibitors/*administration & dosage/adverse 
      effects/pharmacokinetics/therapeutic use
OTO - NOTNLM
OT  - PA32540
OT  - PA8140
OT  - antiplatelet therapy
OT  - aspirin
OT  - combination tablets
OT  - proton pump inhibitor
EDAT- 2014/08/08 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/08/08 06:00
PHST- 2014/08/08 06:00 [entrez]
PHST- 2014/08/08 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - 10.1586/17512433.2014.945428 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2014 Sep;7(5):645-53. doi: 
      10.1586/17512433.2014.945428. Epub 2014 Aug 7.

PMID- 432801
OWN - NLM
STAT- MEDLINE
DCOM- 19790629
LR  - 20131121
IS  - 0039-6060 (Print)
IS  - 0039-6060 (Linking)
VI  - 85
IP  - 4
DP  - 1979 Apr
TI  - Platelet aggregation inhibition in human umbilical vein grafts and negatively 
      charged bovine heterografts.
PG  - 395-9
AB  - Glutaraldehye-tanned human umbilical vein grafts (4 mm) and negatively charged 
      bovine heterografts (4 mm) were placed as bypasses in the femoral arteries of 20 
      dogs randomized into 10 treated with aspirin and dipyridamole and 10 were not 
      treated. Autogenous vein grafts were placed as controls. Platelet aggregation 
      inhibition by aspirin and dipyridamole significantly improved the patency of 
      human umbilical vein grafts from 10% to 60%. It had no effect on patencies of 
      autogenous veins (100%) or on negatively charged bovine heterografts (0% 
      patency). Inherent graft properties continue to play an important and sometimes 
      overriding role in long-term graft patency in small vessel bypasses. Neointimal 
      fibrous hyperplasia at both proximal and distal anastomoses again was shown to be 
      intimately associated with late graft occlusions.
FAU - Feins, R H
AU  - Feins RH
FAU - Roedersheimer, R
AU  - Roedersheimer R
FAU - Green, R M
AU  - Green RM
FAU - DeWeese, J A
AU  - DeWeese JA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cattle
MH  - Dipyridamole/administration & dosage/*pharmacology
MH  - Dogs
MH  - Femoral Artery/surgery
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Transplantation, Autologous
MH  - Transplantation, Heterologous
MH  - Umbilical Veins/*transplantation
EDAT- 1979/04/01 00:00
MHDA- 1979/04/01 00:01
CRDT- 1979/04/01 00:00
PHST- 1979/04/01 00:00 [pubmed]
PHST- 1979/04/01 00:01 [medline]
PHST- 1979/04/01 00:00 [entrez]
AID - 0039-6060(79)90008-4 [pii]
PST - ppublish
SO  - Surgery. 1979 Apr;85(4):395-9.

PMID- 59014
OWN - NLM
STAT- MEDLINE
DCOM- 19760823
LR  - 20190610
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 7974
DP  - 1976 Jun 26
TI  - Aspirin and congenital malformations.
PG  - 1373-5
AB  - In a cohort of 50 282 gravidas and their offspring in the U.S.A., malformation 
      rates were similar in the children of 35 418 women not exposed to aspirin, 9736 
      with intermediate exposure, and 5128 women heavily exposed during the first four 
      lunar months of pregnancy. After controlling a wide range of potential 
      confounding factors using multi-variate analysis, the observed and expected 
      numbers for a variety of malformation categories were similar in all three 
      comparison groups. The data suggest that aspirin is not teratogenic.
FAU - Slone, D
AU  - Slone D
FAU - Siskind, V
AU  - Siskind V
FAU - Heinonen, O P
AU  - Heinonen OP
FAU - Monson, R R
AU  - Monson RR
FAU - Kaufman, D W
AU  - Kaufman DW
FAU - Shapiro, S
AU  - Shapiro S
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced/*etiology
MH  - Abnormalities, Multiple/chemically induced
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Birth Weight/drug effects
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Newborn, Diseases/mortality
MH  - Maternal-Fetal Exchange
MH  - Pregnancy
MH  - Smoking/complications
MH  - Time Factors
OID - PIP: 017834
OID - POP: 00127246
OTO - PIP
OT  - Americas
OT  - *Analgesia
OT  - Cardiovascular Effects
OT  - Central Nervous System Effects
OT  - *Cohort Analysis
OT  - *Congenital Abnormalities
OT  - Data Analysis
OT  - Developed Countries
OT  - Diseases
OT  - *Drugs
OT  - Gastrointestinal Effects
OT  - *Incidence
OT  - Measurement
OT  - *Multivariate Analysis
OT  - Neonatal Diseases And Abnormalities
OT  - North America
OT  - Northern America
OT  - *Prospective Studies
OT  - Research Methodology
OT  - Statistical Studies
OT  - Studies
OT  - Treatment
OT  - United States
OT  - Urogenital Effects
GN  - PIP: TJ: LANCET.
EDAT- 1976/06/26 00:00
MHDA- 1976/06/26 00:01
CRDT- 1976/06/26 00:00
PHST- 1976/06/26 00:00 [pubmed]
PHST- 1976/06/26 00:01 [medline]
PHST- 1976/06/26 00:00 [entrez]
AID - S0140-6736(76)93025-7 [pii]
AID - 10.1016/s0140-6736(76)93025-7 [doi]
PST - ppublish
SO  - Lancet. 1976 Jun 26;1(7974):1373-5. doi: 10.1016/s0140-6736(76)93025-7.

PMID- 23422285
OWN - NLM
STAT- MEDLINE
DCOM- 20140217
LR  - 20140529
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 131
IP  - 4
DP  - 2013 Apr
TI  - New direct and indirect methods for the detection of cyclooxygenase 1 acetylation 
      by aspirin; the lack of aspirin resistance among healthy individuals.
PG  - 320-4
LID - S0049-3848(13)00038-8 [pii]
LID - 10.1016/j.thromres.2013.01.033 [doi]
AB  - BACKGROUND: Aspirin is widely used in the prevention of acute atherothrombotic 
      complications. It acetylates Ser529 residue in cyclooxygenase-1 (COX-1) and 
      prevents thromboxane A2 (TXA2) formation from arachidonic acid (AA) in platelets. 
      Laboratory methods used for the detection of aspirin effect provide inconsistent 
      results. METHODS: Two new methods were developed for the direct and indirect 
      detection of COX-1 acetylation by aspirin in 108 healthy volunteers treated daily 
      with 100mg enteric-coated aspirin for 7days. Monoclonal antibodies were raised 
      against acetylated and non-acetylated nonapeptides corresponding to the amino 
      acid sequence of human COX-1 525-533 residues. Using Western blotting technique 
      the antibodies clearly distinguished between acetylated and non-acetylated COX-1 
      in platelet lysate. The second method measures AA-induced TXB2 production of 
      platelets in diluted platelet rich plasma. RESULTS: No acetylated COX-1 was 
      detected in platelets before aspirin treatment. At the same time antibodies 
      raised against non-acetylated peptide gave intense reaction with COX-1 on the 
      Western blot. In contrast, after 7days of aspirin treatment, with a single 
      exception, only acetylated COX-1 could be detected in the platelet lysate. The 
      non-responding volunteer showed full response to aspirin after controlled drug 
      intake. In parallel experiments aspirin treatment for 7days practically 
      completely inhibited AA-induced TXB2 production by platelets. CONCLUSIONS: 
      Chemical ("true") aspirin resistance, if it exists, must be a rarity among 
      healthy individuals. The new methods could be used for detecting the acetylation 
      of COX-1 by aspirin in patients on preventive aspirin therapy and for evaluating 
      methods routinely used for such purpose.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Kovács, Emese G
AU  - Kovács EG
AD  - Clinical Research Center, University of Debrecen, Medical and Health Science 
      Center, Debrecen, Hungary.
FAU - Katona, Eva
AU  - Katona E
FAU - Bereczky, Zsuzsanna
AU  - Bereczky Z
FAU - Homoródi, Nóra
AU  - Homoródi N
FAU - Balogh, László
AU  - Balogh L
FAU - Tóth, Eszter
AU  - Tóth E
FAU - Péterfy, Hajna
AU  - Péterfy H
FAU - Kiss, Róbert G
AU  - Kiss RG
FAU - Edes, István
AU  - Edes I
FAU - Muszbek, László
AU  - Muszbek L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130217
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Thromb Res. 2014 May;133(5):697-8. PMID: 24315499
MH  - Acetylation/drug effects
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects/*enzymology
MH  - Cyclooxygenase 1/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology
MH  - Young Adult
EDAT- 2013/02/21 06:00
MHDA- 2014/02/18 06:00
CRDT- 2013/02/21 06:00
PHST- 2012/10/30 00:00 [received]
PHST- 2013/01/24 00:00 [revised]
PHST- 2013/01/26 00:00 [accepted]
PHST- 2013/02/21 06:00 [entrez]
PHST- 2013/02/21 06:00 [pubmed]
PHST- 2014/02/18 06:00 [medline]
AID - S0049-3848(13)00038-8 [pii]
AID - 10.1016/j.thromres.2013.01.033 [doi]
PST - ppublish
SO  - Thromb Res. 2013 Apr;131(4):320-4. doi: 10.1016/j.thromres.2013.01.033. Epub 2013 
      Feb 17.

PMID- 25087045
OWN - NLM
STAT- MEDLINE
DCOM- 20140919
LR  - 20220129
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 8
DP  - 2014 Aug 3
TI  - Aspirin as adjunctive treatment for giant cell arteritis.
PG  - CD010453
LID - 10.1002/14651858.CD010453.pub2 [doi]
AB  - BACKGROUND: Giant cell arteritis (GCA) is a common inflammatory condition that 
      affects medium and large-sized arteries and can cause sudden, permanent 
      blindness. At present there is no alternative to early treatment with high-dose 
      corticosteroids as the recommended standard management. Corticosteroid-induced 
      side effects can develop and further disease-related ischaemic complications can 
      still occur. Alternative and adjunctive therapies are sought. Aspirin has been 
      shown to have effects on the immune-mediated inflammation in GCA, hence it may 
      reduce damage caused in the arterial wall. OBJECTIVES: To assess the safety and 
      effectiveness of low-dose aspirin, as an adjunctive, in the treatment of giant 
      cell arteritis (GCA). SEARCH METHODS: We searched CENTRAL (which contains the 
      Cochrane Eyes and Vision Group Trials Register) (2013, Issue 12), Ovid MEDLINE, 
      Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid 
      OLDMEDLINE (January 1946 to January 2014), EMBASE (January 1980 to January 2014), 
      Latin American and Caribbean Health Sciences Literature Database (LILACS) 
      (January 1982 to January 2014), the metaRegister of Controlled Trials (mRCT) 
      (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov), the 
      World Health Organization (WHO) International Clinical Trials Registry Platform 
      (ICTRP) (www.who.int/ictrp/search/en) and the US Food and Drugs Administration 
      (FDA) web site (www.fda.gov). We did not use any date or language restrictions in 
      the electronic searches for trials. We last searched the electronic databases on 
      24 January 2014. SELECTION CRITERIA: We planned to include only randomised 
      controlled trials (RCTs) comparing outcomes of GCA with and without concurrent 
      adjunctive use of low-dose aspirin. DATA COLLECTION AND ANALYSIS: Two authors 
      independently assessed the search results for trials identified by the electronic 
      searches. No trials met our inclusion criteria, therefore we undertook no 
      assessment of risk of bias or meta-analysis. MAIN RESULTS: We found no RCTs that 
      met the inclusion criteria. AUTHORS' CONCLUSIONS: There is currently no evidence 
      from RCTs to determine the safety and efficacy of low-dose aspirin as an 
      adjunctive treatment in GCA. Clinicians who are considering the use of low-dose 
      aspirin as an adjunctive treatment in GCA must also recognise the established 
      haemorraghic risks associated with aspirin, especially in the context of 
      concurrent treatment with corticosteroids. There is a clear need for 
      effectiveness trials to guide the management of this life-threatening condition.
FAU - Mollan, Susan P
AU  - Mollan SP
AD  - Ophthalmology Department, University Hospitals Birmingham NHS Trust, Queen 
      Elizabeth Hospital, Birmingham, UK.
FAU - Sharrack, Noor
AU  - Sharrack N
FAU - Burdon, Mike A
AU  - Burdon MA
FAU - Denniston, Alastair K
AU  - Denniston AK
LA  - eng
GR  - G0600416/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20140803
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Chemotherapy, Adjuvant/methods
MH  - Giant Cell Arteritis/*drug therapy
MH  - Humans
EDAT- 2014/08/05 06:00
MHDA- 2014/09/23 06:00
CRDT- 2014/08/04 06:00
PHST- 2014/08/04 06:00 [entrez]
PHST- 2014/08/05 06:00 [pubmed]
PHST- 2014/09/23 06:00 [medline]
AID - 10.1002/14651858.CD010453.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2014 Aug 3;(8):CD010453. doi: 
      10.1002/14651858.CD010453.pub2.

PMID- 12494116
OWN - NLM
STAT- MEDLINE
DCOM- 20031106
LR  - 20181130
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 42
IP  - 7
DP  - 2002
TI  - [Interaction of angiotensin converting enzyme inhibitors with nonsteroidal 
      antiinflammatory drugs].
PG  - 68-75
AB  - Analysis of results of randomized controlled studies revealed pronounced 
      attenuation of vasodilating, natriuretic, and cardioprotective effects of 
      angiotensin converting enzyme inhibitors (ACEI) by concomitant use with of 
      indomethacin and aspirin in patients with hypertension, chronic heart failure, 
      and acute myocardial infarction. In some studies beneficial effects of ACEI were 
      shown to be weakened by concomitant use with of other nonsteroidal 
      antiinflammatory drugs, including selective inhibitors of cyclooxygenase-2.
FAU - Preobrazhenskiĭ, D V
AU  - Preobrazhenskiĭ DV
FAU - Sidorenko, B A
AU  - Sidorenko BA
FAU - Batyraliev, T A
AU  - Batyraliev TA
FAU - Malysheva, N V
AU  - Malysheva NV
FAU - Tsurko, V V
AU  - Tsurko VV
LA  - rus
PT  - Lecture
TT  - Vzaimodeĭstvie ingibitorov angiotenzinprevrashchaiushchego fermenta s 
      nesteroidnymi protivovospalitel'nymi sredstvami.
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*metabolism/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/*therapeutic use
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Drug Synergism
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Indomethacin/*pharmacology/*therapeutic use
MH  - Randomized Controlled Trials as Topic
EDAT- 2002/12/21 04:00
MHDA- 2003/11/07 05:00
CRDT- 2002/12/21 04:00
PHST- 2002/12/21 04:00 [pubmed]
PHST- 2003/11/07 05:00 [medline]
PHST- 2002/12/21 04:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 2002;42(7):68-75.

PMID- 14748818
OWN - NLM
STAT- MEDLINE
DCOM- 20040416
LR  - 20190513
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 57
IP  - 2
DP  - 2004 Feb
TI  - Cardiovascular prophylaxis with aspirin: costs of supply and management of upper 
      gastrointestinal and renal toxicity.
PG  - 188-98
AB  - AIMS: To determine the cost to the NHS of prescribed low-dose aspirin. METHODS: 
      This was a population based observational cohort study. Patients from Tayside 
      Scotland (17 244 new users of dispensed aspirin each with 10 matched comparators) 
      were included. A pragmatic analysis totalled costs from the start to end of the 
      study and compared these with a matched cohort of aspirin nonusers to estimate 
      excess costs. Fastidious analyses were done of subjects with no prior history of 
      upper gastrointestinal (UGI) or renal disease where the cost that occurred during 
      aspirin exposure, the 30 days following aspirin exposure and subsequent 
      nonexposure was calculated adjusting for risk factors in each period. RESULTS: 
      Subjects took aspirin for only 1.18 of the 2.53 years follow-up (47% compliance). 
      Aspirin use cost an additional 49.86 UK pounds per year (pragmatic analysis) made 
      up of 1.96 UK pounds for aspirin tablets (4%), 5.49 UK pounds for dispensing 
      costs (11%), 24.60 UK pounds for UGI complications (49%) and 17.81 UK pounds for 
      renal complications (36%). The costs for managing complications were 
      substantially lower in the fastidious analysis (2.66 UK pounds for UGI 
      complications and 2.92 UK pounds for renal complications). Assuming that the 
      antiplatelet trial meta-analysis is an accurate assessment of the benefits of 
      aspirin, the costs of preventing one vascular event lay between 62 500 UK pounds 
      (primary prevention, pragmatic analysis) and 867 UK pounds (secondary prevention, 
      fastidious analysis). These costs may be underestimates due to the low compliance 
      observed. CONCLUSIONS: Compliance with aspirin was poor. Serious adverse events 
      were uncommon but despite this aspirin cost the NHS between 6 and 25 times the 
      cost of aspirin tablets due to dispensing costs and the cost of managing adverse 
      effects.
FAU - Morant, S V
AU  - Morant SV
AD  - Medicines Monitoring Unit (MEMO), Department of Medicine & Therapeutics, 
      University of Dundee, Ninewells Hospital & Medical School, Dundee DD1 9SY, 
      Scotland, UK.
FAU - McMahon, A D
AU  - McMahon AD
FAU - Cleland, J G F
AU  - Cleland JG
FAU - Davey, P G
AU  - Davey PG
FAU - MacDonald, T M
AU  - MacDonald TM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Kidney Injury/*chemically induced/economics
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*economics
MH  - Cohort Studies
MH  - Cost of Illness
MH  - Cost-Benefit Analysis
MH  - Drug Costs
MH  - Gastrointestinal Diseases/*chemically induced/economics
MH  - Hospitalization/economics
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*economics
MH  - Renal Dialysis/economics
MH  - Risk Factors
PMC - PMC1884435
EDAT- 2004/01/30 05:00
MHDA- 2004/04/17 05:00
CRDT- 2004/01/30 05:00
PHST- 2004/01/30 05:00 [pubmed]
PHST- 2004/04/17 05:00 [medline]
PHST- 2004/01/30 05:00 [entrez]
AID - 1979 [pii]
AID - 10.1046/j.1365-2125.2003.01979.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2004 Feb;57(2):188-98. doi: 
      10.1046/j.1365-2125.2003.01979.x.

PMID- 21863903
OWN - NLM
STAT- MEDLINE
DCOM- 20120110
LR  - 20131121
IS  - 1520-5126 (Electronic)
IS  - 0002-7863 (Linking)
VI  - 133
IP  - 37
DP  - 2011 Sep 21
TI  - Sonofragmentation of molecular crystals.
PG  - 14530-3
LID - 10.1021/ja205867f [doi]
AB  - Possible mechanisms for the breakage of molecular crystals under high-intensity 
      ultrasound were investigated using acetylsalicylic acid (aspirin) crystals as a 
      model compound for active pharmaceutical ingredients. Surprisingly, kinetics 
      experiments ruled out particle-particle collisions as a viable mechanism for 
      sonofragmentation. Two other possible mechanisms (particle-horn and particle-wall 
      collisions) were dismissed on the basis of decoupling experiments. Direct 
      particle-shock wave interactions are therefore indicated as the primary mechanism 
      of sonofragmentation of molecular crystals.
FAU - Zeiger, Brad W
AU  - Zeiger BW
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 South 
      Mathews Avenue, Urbana, Illinois 61801, USA.
FAU - Suslick, Kenneth S
AU  - Suslick KS
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20110825
PL  - United States
TA  - J Am Chem Soc
JT  - Journal of the American Chemical Society
JID - 7503056
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Kinetics
MH  - Particle Size
MH  - Ultrasonics/*methods
EDAT- 2011/08/26 06:00
MHDA- 2012/01/11 06:00
CRDT- 2011/08/26 06:00
PHST- 2011/08/26 06:00 [entrez]
PHST- 2011/08/26 06:00 [pubmed]
PHST- 2012/01/11 06:00 [medline]
AID - 10.1021/ja205867f [doi]
PST - ppublish
SO  - J Am Chem Soc. 2011 Sep 21;133(37):14530-3. doi: 10.1021/ja205867f. Epub 2011 Aug 
      25.

PMID- 23659069
OWN - NLM
STAT- MEDLINE
DCOM- 20130618
LR  - 20131121
IS  - 0023-2149 (Print)
IS  - 0023-2149 (Linking)
VI  - 91
IP  - 1
DP  - 2013
TI  - [Potential utility of optic aggregometry for identification of patients with 
      coronary heart disease resistant to acetylsalicylic acid].
PG  - 37-41
AB  - We estimated potential of optic aggregometry for the identification of patients 
      with coronary heart disease in 271 patients with coronary heart disease (CHD) and 
      230 ones with FC 2-3 angina of effort. Duration of the study was 24 months. 
      Platelet aggregation in patients given anti-aggregation therapy with 
      acetylsalicylic acid (ASA) was assessed with a Biola laser aggregometer (Russia) 
      from changes in transmissivity in the presence of aggregation agonists. Optic 
      aggregometry permitted to distinguish the forms of CHD producing increased risk 
      of atherothrombotic complications in patients with enhanced platelet functional 
      activity resistant to ASA. The prevalence of ACA resistance was estimated at 10% 
      and did not depend on the form of CHD. It was 11.3 and 9.95% in patients with 
      stable angina and acute coronary syndrome respectively. Resistance to ACA was an 
      independent predictor of atherothrombotic complications in patients with 
      different forms of CHD (OR = 8.25; 95% CI 5.77-11.82; p = 0.05).
FAU - Puchin'ian, N F
AU  - Puchin'ian NF
FAU - Furman, N V
AU  - Furman NV
FAU - Dovgalevskiĭ, Ia P
AU  - Dovgalevskiĭ IaP
LA  - rus
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Klin Med (Mosk)
JT  - Klinicheskaia meditsina
JID - 2985204R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - *Angina Pectoris/blood/drug therapy
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - *Coronary Disease/blood/drug therapy
MH  - Drug Resistance/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Predictive Value of Tests
MH  - Severity of Illness Index
MH  - Time Factors
EDAT- 2013/05/11 06:00
MHDA- 2013/06/19 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/05/11 06:00 [entrez]
PHST- 2013/05/11 06:00 [pubmed]
PHST- 2013/06/19 06:00 [medline]
PST - ppublish
SO  - Klin Med (Mosk). 2013;91(1):37-41.

PMID- 3229444
OWN - NLM
STAT- MEDLINE
DCOM- 19890418
LR  - 20191029
IS  - 0232-7384 (Print)
IS  - 0232-7384 (Linking)
VI  - 92
IP  - 1
DP  - 1988 Sep
TI  - Insulin receptors and glucose homeostasis in type 2 diabetics influenced by 
      acetyl-salicylic acid treatment.
PG  - 119-22
AB  - The effect of acetyl-salicylic acid administration on insulin receptors on the 
      erythrocytes and the changes of glucose homeostasis examined by hyperglycaemic 
      clamps were evaluated in 8 Type 2 diabetics. Significantly increased number of 
      insulin receptors and decreased insulin affinity constants were found in 
      diabetics after the acetyl-salicylic acid treatment (p less than 0.02). 
      Significantly decreased tissue sensitivity to insulin and metabolic clearance 
      rate of insulin (p less than 0.02) were observed in Type 2 diabetics after the 
      acetyl-salicylic acid treatment. We conclude that acetyl-salicylic acid may 
      impair glucose homeostasis due to interference with insulin action in peripheral 
      tissues.
FAU - Skrha, J
AU  - Skrha J
AD  - Department of Internal Medicine, Faculty of Medicine, Charles University, 
      Prague/Czechoslovakia.
FAU - Hilgertová, J
AU  - Hilgertová J
FAU - Svacina, S
AU  - Svacina S
FAU - Srámková, J
AU  - Srámková J
FAU - Páv, J
AU  - Páv J
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Exp Clin Endocrinol
JT  - Experimental and clinical endocrinology
JID - 8302802
RN  - EC 2.7.10.1 (Receptor, Insulin)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Diabetes Mellitus, Type 2/drug therapy/*metabolism
MH  - Glucose/*metabolism
MH  - Homeostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Receptor, Insulin/*metabolism
EDAT- 1988/09/01 00:00
MHDA- 1988/09/01 00:01
CRDT- 1988/09/01 00:00
PHST- 1988/09/01 00:00 [pubmed]
PHST- 1988/09/01 00:01 [medline]
PHST- 1988/09/01 00:00 [entrez]
AID - 10.1055/s-0029-1210791 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol. 1988 Sep;92(1):119-22. doi: 10.1055/s-0029-1210791.

PMID- 3715816
OWN - NLM
STAT- MEDLINE
DCOM- 19860703
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 42
IP  - 4
DP  - 1986 May 15
TI  - Increasing platelet aggregability after venepuncture is platelet, not plasma 
      derived.
PG  - 539-48
AB  - The time course of ADP induced aggregation of human platelets was determined in 
      aliquots of stored platelet rich plasma 3.5, 10, 30 and 100 minutes after 
      venepuncture. The maximal rate of aggregation was found to increase throughout 
      this entire period, even though pH (7.4), CO2 (7 volume per cent) and temperature 
      (35 degrees C) of the samples were kept constant. The mean acceleration (+/- SEM) 
      between 3.5 and 100 minutes was 41.7 +/- 6.9 per cent (n = 67) at an 
      ADP-concentration of 1 mumol/l and 18.3 +/- 6.2 per cent (n = 23) at 2 mumol/l 
      ADP. The effect did not result from changes of any platelet regulatory factors 
      putatively present alone in the plasma. Acceleration of aggregability was only 
      found when the platelets themselves underwent storage, but not when freshly 
      prepared plasma was given to prestored platelets. The change in aggregability was 
      not diminished after inhibition of platelet cyclooxygenase by oral administration 
      of acetylsalicylic acid.
FAU - Terres, W
AU  - Terres W
FAU - Becker, B F
AU  - Becker BF
FAU - Kratzer, M A
AU  - Kratzer MA
FAU - Gerlach, E
AU  - Gerlach E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 463-79-6 (Carbonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacology
MH  - Blood Platelets/*physiology
MH  - *Bloodletting
MH  - Carbonic Acid/pharmacology
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Middle Aged
MH  - Plasma/*physiology
MH  - *Platelet Aggregation/drug effects
MH  - Temperature
MH  - Time Factors
EDAT- 1986/05/15 00:00
MHDA- 1986/05/15 00:01
CRDT- 1986/05/15 00:00
PHST- 1986/05/15 00:00 [pubmed]
PHST- 1986/05/15 00:01 [medline]
PHST- 1986/05/15 00:00 [entrez]
AID - 10.1016/0049-3848(86)90217-3 [doi]
PST - ppublish
SO  - Thromb Res. 1986 May 15;42(4):539-48. doi: 10.1016/0049-3848(86)90217-3.

PMID- 6628518
OWN - NLM
STAT- MEDLINE
DCOM- 19831220
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 25
IP  - 3
DP  - 1983
TI  - Effect of acetylsalicylic acid on plasma thromboxane B2 and platelet aggregation 
      in man.
PG  - 313-7
AB  - The effect of acetylsalicylic acid (ASA) on plasma thromboxane A2 (TXA2) and 
      platelet aggregation was studied in 12 healthy, non-smoking, male students, in a 
      double-blind, cross-over study, after single doses and 14-days on ASA 50, 100, 
      250 and 1000 mg/day. Platelet production of TXA2 was assessed by measuring the 
      thromboxane B2 (TXB2) content of clotted venous blood by RIA. Platelet 
      aggregation induced by ADP and adrenaline was studied by the method of Born. All 
      doses of ASA completely suppressed the production of TXB2 within 3 h, with the 
      exception of the 50 mg dose, which effected only 61% suppression (p less than 
      0.001). After administration for 14 days the suppression was complete, even 
      including the lowest dose. At that time ASA had blocked the secondary phase of 
      adrenaline- and ADP-induced platelet aggregation. It is concluded that the 
      maximal antithromboxane and antiaggregatory effects, which last for at least 24 
      h, can be achieved by continuous daily administration of ASA 50 mg.
FAU - Nuotto, E
AU  - Nuotto E
FAU - Gordin, A
AU  - Gordin A
FAU - Paasonen, M K
AU  - Paasonen MK
FAU - Metsä-Ketelä, T
AU  - Metsä-Ketelä T
FAU - Lamminsivu, U
AU  - Lamminsivu U
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Thromboembolism/prevention & control
MH  - Thromboxane B2/*blood
MH  - Thromboxanes/*blood
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1007/BF01037940 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1983;25(3):313-7. doi: 10.1007/BF01037940.

PMID- 12769697
OWN - NLM
STAT- MEDLINE
DCOM- 20040217
LR  - 20190916
IS  - 1389-5575 (Print)
IS  - 1389-5575 (Linking)
VI  - 3
IP  - 5
DP  - 2003 Aug
TI  - The medicinal chemistry implications of the anticancer effects of aspirin and 
      other NSAIDs.
PG  - 461-70
AB  - The regular intake of aspirin and other non-steroidal anti-inflammatory drugs 
      (NSAIDs) has been associated with decreased incidence of certain types of cancer 
      particularly those with an inflammatory component. The protective effects of 
      these drugs in colorectal cancer are particularly marked, with a 40-50% reduction 
      in risk. Research in this area has focussed on understanding and optimising these 
      cytoprotective effects. NSAIDs are believed to operate by inhibiting COX-2, an 
      enzyme that appears to be involved in a number of cancer promoting processes. 
      This hypothesis is consistent with the observation that the COX-2 selective 
      inhibitors dramatically decrease tumour formation in human and animal studies. 
      Surprisingly aspirin, which is selective for COX-1 over COX-2, and sulindac, 
      which is an equipotent inhibitor of the COX isoenzymes, appear to have a similar 
      anticancer profile to the COX-2 selective NSAIDs. A number of mechanisms have 
      been proposed to explain the anomalous effects of aspirin. The first of these 
      relates to the unique mode of action of aspirin, which acetylates the COX-2 
      enzyme and generates the cancer-suppressing 15R-hydroxyeicosatetraenoic acid at 
      the site of a potential tumour. The alternative rationale relates to the 
      metabolism of aspirin to salicylic acid, which has a cyclooxygenase independent 
      anti-inflammatory mechanism, preventing the inflammatory response at the gene 
      transcription level. A new generation of drugs could evolve from approaches to 
      improving the therapeutic index of aspirin or by modifications to known therapies 
      such as sulindac and celecoxib.
FAU - Gardiner, P S
AU  - Gardiner PS
AD  - Department of Pharmaceutical Chemistry, School of Pharmacy, Trinity College, 
      Dublin, Ireland. gardinps@tcd.ie
FAU - Gilmer, J F
AU  - Gilmer JF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Mini Rev Med Chem
JT  - Mini reviews in medicinal chemistry
JID - 101094212
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - 0 (NF-kappa B)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/pharmacology/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/chemistry/pharmacology/*therapeutic use
MH  - Cyclooxygenase 2
MH  - Gastrointestinal Neoplasms/*drug therapy/enzymology/pathology/*prevention & 
      control
MH  - Humans
MH  - Isoenzymes/antagonists & inhibitors/metabolism
MH  - Membrane Proteins
MH  - NF-kappa B/metabolism
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
RF  - 132
EDAT- 2003/05/29 05:00
MHDA- 2004/02/18 05:00
CRDT- 2003/05/29 05:00
PHST- 2003/05/29 05:00 [pubmed]
PHST- 2004/02/18 05:00 [medline]
PHST- 2003/05/29 05:00 [entrez]
AID - 10.2174/1389557033488033 [doi]
PST - ppublish
SO  - Mini Rev Med Chem. 2003 Aug;3(5):461-70. doi: 10.2174/1389557033488033.

PMID- 10719942
OWN - NLM
STAT- MEDLINE
DCOM- 20000328
LR  - 20190628
IS  - 0003-3022 (Print)
IS  - 0003-3022 (Linking)
VI  - 92
IP  - 3
DP  - 2000 Mar
TI  - Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative 
      to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial 
      Collaborative Group.
PG  - 646-56
AB  - BACKGROUND: Risks associated with transfusion of allogeneic blood have prompted 
      development of methods to avoid or reduce blood transfusions. New oxygen-carrying 
      compounds such as diaspirin cross-linked hemoglobin (DCLHb) could enable more 
      patients to avoid allogeneic blood transfusion. METHODS: The efficacy, safety, 
      hemodynamic effects, and plasma persistence of DCLHb were investigated in a 
      randomized, active-control, single-blind, multicenter study in post-cardiac 
      bypass surgery patients. Of 1,956 screened patients, 209 were determined to 
      require a blood transfusion and met the inclusion criteria during the 24-h 
      post-cardiac bypass period. These patients were randomized to receive up to three 
      250-ml infusions of DCLHb (n = 104) or three units of packed erythrocytes (pRBCs; 
      n = 105). Further transfusions of pRBCs or whole blood were permitted, if 
      indicated. Primary efficacy end points were the avoidance of blood transfusion 
      through hospital discharge or 7 days postsurgery, whichever came first, and a 
      reduction in the number of units of pRBCs transfused during this same time 
      period. Various laboratory, physiologic, and hemodynamic parameters were 
      monitored to define the safety and pharmacologic effect of DCLHb in this patient 
      population. RESULTS: During the period from the end of cardiopulmonary bypass 
      surgery through postoperative day 7 or hospital discharge, 20 of 104 (19%) DCLHb 
      recipients did not receive a transfusion of pRBCs compared with 100% of control 
      patients (P < 0.05). The overall number of pRBCs administered during the 7-day 
      postoperative period was not significantly different. Mortality was similar 
      between the DCLHb (6 of 104 patients) and the control (8 of 105 patients) groups. 
      Hypertension, jaundice/hyperbilirubinemia, increased serum glutamic oxalo-acetic 
      transaminase, abnormal urine, and hematuria were reported more frequently in the 
      DCLHb group, and there was one case of renal failure in each group. The 
      hemodynamic effects of DCLHb included a consistent and slightly greater increase 
      in systemic and pulmonary vascular resistance with associated increases in 
      systemic and pulmonary arterial pressures compared with pRBC. Cardiac output 
      values decreased more in the DCLHb group patients after the first administration 
      than the control group patients. At 24 h postinfusion, the plasma hemoglobin 
      level was less than one half the maximal level for any amount of DCLHb infused. 
      CONCLUSIONS: Administration of DCLHb allowed a significant number (19%) of 
      cardiac surgery patients to avoid exposure to erythrocytes postoperatively.
FAU - Lamy, M L
AU  - Lamy ML
AD  - Department of Anesthesia and Intensive Care Medicine of the University of Liège, 
      Centre Hospitalier Universitaire, Belgium. mlamy@chu.ulg.ac.be
FAU - Daily, E K
AU  - Daily EK
FAU - Brichant, J F
AU  - Brichant JF
FAU - Larbuisson, R P
AU  - Larbuisson RP
FAU - Demeyere, R H
AU  - Demeyere RH
FAU - Vandermeersch, E A
AU  - Vandermeersch EA
FAU - Lehot, J J
AU  - Lehot JJ
FAU - Parsloe, M R
AU  - Parsloe MR
FAU - Berridge, J C
AU  - Berridge JC
FAU - Sinclair, C J
AU  - Sinclair CJ
FAU - Baron, J F
AU  - Baron JF
FAU - Przybelski, R J
AU  - Przybelski RJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesthesiology
JT  - Anesthesiology
JID - 1300217
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Isotonic Solutions)
RN  - 8026-10-6 (Ringer's Solution)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Anesthesiology. 2000 Mar;92(3):637-8. PMID: 10719938
CIN - Anesthesiology. 2000 Mar;92(3):639-41. PMID: 10719939
MH  - Aged
MH  - Aspirin/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use
MH  - Blood Substitutes/pharmacokinetics/*therapeutic use
MH  - *Blood Transfusion
MH  - *Cardiac Surgical Procedures
MH  - Female
MH  - Hematocrit
MH  - Hemodynamics/drug effects/physiology
MH  - Hemoglobins/adverse effects/pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Isotonic Solutions
MH  - Male
MH  - Middle Aged
MH  - Myocardium/enzymology
MH  - Reticulocyte Count
MH  - Ringer's Solution
MH  - Single-Blind Method
EDAT- 2000/03/17 09:00
MHDA- 2000/04/01 09:00
CRDT- 2000/03/17 09:00
PHST- 2000/03/17 09:00 [pubmed]
PHST- 2000/04/01 09:00 [medline]
PHST- 2000/03/17 09:00 [entrez]
AID - 10.1097/00000542-200003000-00007 [doi]
PST - ppublish
SO  - Anesthesiology. 2000 Mar;92(3):646-56. doi: 10.1097/00000542-200003000-00007.

PMID- 10643705
OWN - NLM
STAT- MEDLINE
DCOM- 20000203
LR  - 20220331
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 43
IP  - 1
DP  - 2000 Jan
TI  - The effect of mini-dose aspirin on renal function and uric acid handling in 
      elderly patients.
PG  - 103-8
AB  - OBJECTIVE: Aspirin is known to have a bimodal effect on the renal handling of 
      uric acid (UA). High dosages (>3 gm/day) are uricosuric, while low dosages (1-2 
      gm/day) cause UA retention. Although very-low-dose (mini-dose) aspirin is used 
      increasingly as a platelet aggregation inhibitor, no studies have been published 
      on whether aspirin's renal effects occur at dosages of <0.5 gm/day. The aim of 
      the present study was to evaluate the effects of commonly used mini-dosages of 
      aspirin on renal function and UA handling in elderly patients. METHODS: The study 
      included 49 elderly inpatients (age 61-94). Patients were excluded if they had 
      renal failure, hyperuricemia, gout, or a history of bleeding, or if they were 
      receiving anticoagulants, aspirin, or nonsteroidal antiinflammatory drugs. 
      Previous medications and diet were kept unchanged. Aspirin was administered as 
      follows: 75 mg/day (week 1), 150 mg/day (week 2), 325 mg/day (week 3), and 0 
      mg/day (week 4). Baseline and weekly samples of blood and urine were evaluated 
      for UA, creatinine, blood urea nitrogen, creatinine clearance, UA excretion, UA 
      clearance, and plasma levels of aspirin. RESULTS: At the lowest dosage, aspirin 
      caused a 15% decrease in the rate of UA excretion (P = 0.045 by t-test), which 
      was associated with a slight but significant increase in serum levels of UA (P = 
      0.009). These effects on UA levels were gradually reduced with increasing dosages 
      of aspirin (multivariate analysis of variance with repeated measures showed no 
      statistically significant difference in the rate of UA excretion between weeks 
      1-3 and week 0 [baseline], but the difference in serum UA levels for the same 
      comparison was statistically significant [P = 0.038]). Generally, creatinine and 
      UA clearance rates paralleled each other during aspirin treatment. However, 1 
      week after aspirin was discontinued, creatinine clearance remained decreased 
      while UA clearance returned to baseline. Plasma aspirin concentrations were low 
      and variable. However, patients with above-median aspirin levels had 
      significantly greater changes in serum creatinine levels, urinary UA excretion 
      rates, and UA clearance rates following the first week of aspirin treatment. 
      Hypoalbuminemia and concomitant treatment with diuretics enhanced the effects of 
      aspirin on renal function and UA retention. CONCLUSION: Mini-dose aspirin, even 
      at a dosage of 75 mg/day, caused significant changes in renal function and UA 
      handling within 1 week in a group of elderly inpatients, mainly in those with 
      preexisting hypoalbuminemia. Given the widespread (and often unmonitored) use of 
      mini-dose aspirin, especially among the elderly, these findings call for 
      clinician alertness as well as for further studies to clarify the mechanisms 
      underlying these phenomena.
FAU - Caspi, D
AU  - Caspi D
AD  - Tel Aviv University, Israel.
FAU - Lubart, E
AU  - Lubart E
FAU - Graff, E
AU  - Graff E
FAU - Habot, B
AU  - Habot B
FAU - Yaron, M
AU  - Yaron M
FAU - Segal, R
AU  - Segal R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Diuretics)
RN  - 0 (Serum Albumin)
RN  - 268B43MJ25 (Uric Acid)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/blood
MH  - Aspirin/*administration & dosage/blood
MH  - Blood Urea Nitrogen
MH  - Creatinine/blood/urine
MH  - Diuretics/administration & dosage
MH  - Female
MH  - Furosemide/administration & dosage
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Kidney/*drug effects/physiology
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Serum Albumin
MH  - Uric Acid/*blood/urine
EDAT- 2000/01/22 00:00
MHDA- 2000/01/22 00:01
CRDT- 2000/01/22 00:00
PHST- 2000/01/22 00:00 [pubmed]
PHST- 2000/01/22 00:01 [medline]
PHST- 2000/01/22 00:00 [entrez]
AID - 10.1002/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C [doi]
PST - ppublish
SO  - Arthritis Rheum. 2000 Jan;43(1):103-8. doi: 
      10.1002/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C.

PMID- 12844223
OWN - NLM
STAT- MEDLINE
DCOM- 20040312
LR  - 20131121
IS  - 0932-0067 (Print)
IS  - 0932-0067 (Linking)
VI  - 268
IP  - 3
DP  - 2003 Aug
TI  - Pregnancy in essential thrombocythemia during aspirin treatment.
PG  - 209-10
AB  - INTRODUCTION: Essential thrombocythemia is a rare disease of unknown origin 
      characterized by abnormal increase in the platelet count. CASE REPORT: We report 
      a case diagnosed in a woman who had had an early miscarriage in her first 
      pregnancy, a voluntary abortion because a fetal chromosomal aberration in the 
      second pregnancy and at last a third normal pregnancy. Treatment with low-dose 
      aspirin (100 mg/day) and the use of low molecular weight heparin in the last 
      three weeks of gestation appears to improve the obstetric outcome.
FAU - Ruggeri, Zaira
AU  - Ruggeri Z
AD  - Dipartimento di Scienze Ginecologiche, Ostetriche e Medicina della Riproduzione, 
      Università di Messina, Messina, Italy.
FAU - Cannata, Maria L
AU  - Cannata ML
FAU - Stella, Narciso Carlo
AU  - Stella NC
FAU - Corrado, Francesco
AU  - Corrado F
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20030703
PL  - Germany
TA  - Arch Gynecol Obstet
JT  - Archives of gynecology and obstetrics
JID - 8710213
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cesarean Section
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Parity
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*drug therapy
MH  - Thrombocythemia, Essential/*drug therapy
EDAT- 2003/07/05 05:00
MHDA- 2004/03/16 05:00
CRDT- 2003/07/05 05:00
PHST- 2003/03/06 00:00 [received]
PHST- 2003/04/11 00:00 [accepted]
PHST- 2003/07/05 05:00 [pubmed]
PHST- 2004/03/16 05:00 [medline]
PHST- 2003/07/05 05:00 [entrez]
AID - 10.1007/s00404-003-0520-y [doi]
PST - ppublish
SO  - Arch Gynecol Obstet. 2003 Aug;268(3):209-10. doi: 10.1007/s00404-003-0520-y. Epub 
      2003 Jul 3.

PMID- 11430095
OWN - NLM
STAT- MEDLINE
DCOM- 20010802
LR  - 20190710
IS  - 0022-3263 (Print)
IS  - 0022-3263 (Linking)
VI  - 66
IP  - 3
DP  - 2001 Feb 9
TI  - Aspirin. An ab initio quantum-mechanical study of conformational preferences and 
      of neighboring group interactions.
PG  - 771-9
AB  - The potential energy surface of acetylsalicylic acid, aspirin, has been explored 
      at the RHF/6-31G* and B3LYP/6-31G* levels, and single-point calculations were 
      performed at levels up to B3LYP/6-311G**//B3LYP/6-31G*. All conformational 
      isomers have been located, the thermochemical functions have been computed, and 
      relative energies and free enthalpies were determined. The conformational space 
      of aspirin is spanned by three internal coordinates, and these are the carboxylic 
      acid C-O conformation (s-trans preferred by about 7 kcal/mol), the C-COOH 
      conformation (Z preferred unless there are H-bonding opportunities), and the 
      ester C-O conformation (s-trans preferred by about 4 kcal/mol). There are nine 
      aspirin isomers since one of the conformers realizes hydrogen-bonding structure 
      isomerism as well. Neighboring group interactions are discussed with reference to 
      the intrinsic properties of benzoic acid and phenyl acetate. The intrinsic 
      conformational preference energies for benzoic acid and phenyl acetate are not 
      additive. The acid s-trans preference energies differ by as much as 9 kcal/mol 
      depending on the Ph-COOH and ester conformations. Similarly, the E-preference 
      energies about the Ph-COOH bond vary by as much as 6 kcal/mol depending on the 
      ester conformation. The structural discussion suggests an overall ortho repulsion 
      between the functional groups in all aspirin isomers including the 
      intramolecularly hydrogen-bonded isomers. The isodesmic reaction between the most 
      stable conformers of benzoic acid and phenyl acetate to form aspirin and benzene 
      is found to be endothermic by 2.7 kcal/mol and provides compelling evidence for 
      and a quantitative measure of ortho repulsion. The ortho repulsion of 2.7 
      kcal/mol is a lower limit, and the ortho repulsion can increase to as much as 6 
      kcal/mol in some aspirin isomers.
FAU - Glaser, R
AU  - Glaser R
AD  - Department of Chemistry, University of Missouri-Columbia, Columbia, Missouri 
      65211, USA. glaserr@missouri.edu
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Org Chem
JT  - The Journal of organic chemistry
JID - 2985193R
RN  - 0 (Acetates)
RN  - 8SKN0B0MIM (Benzoic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/chemistry
MH  - Aspirin/*chemistry
MH  - Benzoic Acid/chemistry
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Quantum Theory
MH  - Thermodynamics
EDAT- 2001/06/30 10:00
MHDA- 2001/08/03 10:01
CRDT- 2001/06/30 10:00
PHST- 2001/06/30 10:00 [pubmed]
PHST- 2001/08/03 10:01 [medline]
PHST- 2001/06/30 10:00 [entrez]
AID - 10.1021/jo001241s [doi]
PST - ppublish
SO  - J Org Chem. 2001 Feb 9;66(3):771-9. doi: 10.1021/jo001241s.

PMID- 6135771
OWN - NLM
STAT- MEDLINE
DCOM- 19830923
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 35
IP  - 6
DP  - 1983 Jun
TI  - The influence of pH of dissolution fluid and particle size of drug on the 
      in-vitro release of drug from hard gelatin capsules.
PG  - 345-9
AB  - The influence of pH of the dissolution fluid on the in-vitro release of 
      acetylsalicylic acid from hard gelatin capsules has been studied for a series of 
      particle size fractions of the drug. Generally, the time required for 50% of the 
      drug content of the capsule to appear in solution during a dissolution test, T50, 
      increased as the pH increased from 1.2 to 2.0; thereafter the value of T50 
      decreased as the pH increased from 3 to 7. These changes were found to be related 
      to the apparent solubility of the drug. The extent of the changes was found to be 
      further dependent on the particle size of the drug. For capsules filled with 
      particle size fractions of 2.5 and 5.5 microns median diameter, the changes were 
      small. Larger changes were observed with particles of median diameters of 45, 
      100, 220 and 330 microns while the largest changes (greater than two-fold) were 
      obtained with particles of median diameter 130 and 430 microns. The type of 
      kinetics that could be used to express the release rates was found to be particle 
      size-dependent. For particles of 45 microns and larger, the release rate followed 
      an apparent zero order process while an apparent first order process represented 
      the release for the two smallest particle size fractions.
FAU - Muhammad, N A
AU  - Muhammad NA
FAU - Newton, J M
AU  - Newton JM
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Capsules)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - *Capsules
MH  - Drug Compounding
MH  - Hydrogen-Ion Concentration
MH  - Particle Size
MH  - *Solubility
EDAT- 1983/06/01 00:00
MHDA- 1983/06/01 00:01
CRDT- 1983/06/01 00:00
PHST- 1983/06/01 00:00 [pubmed]
PHST- 1983/06/01 00:01 [medline]
PHST- 1983/06/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1983.tb02954.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1983 Jun;35(6):345-9. doi: 10.1111/j.2042-7158.1983.tb02954.x.

PMID- 1080631
OWN - NLM
STAT- MEDLINE
DCOM- 19751204
LR  - 20190823
IS  - 0002-9211 (Print)
IS  - 0002-9211 (Linking)
VI  - 20
IP  - 9
DP  - 1975 Sep
TI  - Parenteral aspirin produces and enhances gastric mucosal lesions and bleeding in 
      rats.
PG  - 847-52
AB  - The effect of parenteral sodium acetylsalicylate (Na ASA) on the development of 
      gastric mucosal lesions and bleeding was studied in control rats and in rats 
      subjected to cold-restraint stress. Although both doses of Na ASA studied, 15 and 
      60 mg/kg intraperitoneally, alone resulted in lesion formation, only with the 
      larger dose did this reach the level of statistical significance. However both 
      doses of Na ASA alone significantly increased blood loss as measured by a 
      decrease in hematocrit value. The administration of Na ASA 15 MG/kg 
      intraperitoneally to animals subjected to cold-restraint significantly increased 
      blood loss, but not lesion formation, while the larger dose of Na ASA 
      significantly increased both parameters. Thus parenteral aspirin not only can 
      cause gastric mucosal damage and bleeding, but it can enhance lesion formation 
      and blood loss produced by cold-restraint. Two mechanisms may be involved: a 
      smaller dose of Na ASA significantly affecting hemostasis but a larger dose being 
      required for gastric mucosal damage.
FAU - Meeroff, J C
AU  - Meeroff JC
FAU - Paulsen, G
AU  - Paulsen G
FAU - Guth, P H
AU  - Guth PH
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Dig Dis
JT  - The American journal of digestive diseases
JID - 0404011
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*toxicity
MH  - Cold Temperature/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/*drug effects
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Injections, Intraperitoneal
MH  - Male
MH  - Rats
MH  - Stress, Physiological/etiology
EDAT- 1975/09/01 00:00
MHDA- 1975/09/01 00:01
CRDT- 1975/09/01 00:00
PHST- 1975/09/01 00:00 [pubmed]
PHST- 1975/09/01 00:01 [medline]
PHST- 1975/09/01 00:00 [entrez]
AID - 10.1007/BF01070953 [doi]
PST - ppublish
SO  - Am J Dig Dis. 1975 Sep;20(9):847-52. doi: 10.1007/BF01070953.

PMID- 20173160
OWN - NLM
STAT- MEDLINE
DCOM- 20100323
LR  - 20220331
IS  - 1546-3141 (Electronic)
IS  - 0361-803X (Linking)
VI  - 194
IP  - 3
DP  - 2010 Mar
TI  - Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin.
PG  - 784-9
LID - 10.2214/AJR.08.2122 [doi]
AB  - OBJECTIVE: The objective of our study was to report the incidence of bleeding 
      after imaging-guided percutaneous core biopsy at a single center using a 
      standardized technique. MATERIALS AND METHODS: We performed a retrospective 
      review of percutaneous core biopsies performed at our institution from January 
      2002 through February 2008. Data were collected at the time of biopsy, and 
      clinical information was obtained 24 hours and 3 months after the biopsy. The 
      specific information that was collected included the results of coagulation 
      studies, aspirin use, the organ biopsied, the size of the biopsy needle, and the 
      number of needle passes. Bleeding complications were defined using the Common 
      Terminology Criteria for Adverse Events (CTCAE, version 3.0) established by the 
      National Cancer Institute. RESULTS: Among the 15,181 percutaneous core biopsies 
      performed during the study period, 70 hemorrhages (0.5%) that were CTCAE grade 3 
      or greater were identified within 3 months of biopsy. The incidence of bleeding 
      in patients taking aspirin within 10 days before biopsy was 0.6% (18/3,195), 
      which was not statistically different compared with the incidence of bleeding in 
      those not taking aspirin (52/11,986, 0.4%; p = 0.34). The incidence of bleeding 
      after liver biopsy was 0.5%; kidney biopsy, 0.7%; lung biopsy, 0.2%; pancreas 
      biopsy, 1.0%; and other biopsy, 0.2%. There were significant associations between 
      major bleeding and serum platelet count and international normalized ratio (p < 
      0.001), although the association between major bleeding and the size of the 
      biopsy needle was not significant (p = 0.97). CONCLUSION: The overall incidence 
      of major bleeding after imaging-guided percutaneous core needle biopsy is low. 
      Recent aspirin therapy does not appear to significantly increase the risk of such 
      bleeding complications.
FAU - Atwell, Thomas D
AU  - Atwell TD
AD  - Department of Radiology, Mayo Clinic, 200 1st St., SW, Rochester, MN 55905, USA.
FAU - Smith, Ryan L
AU  - Smith RL
FAU - Hesley, Gina K
AU  - Hesley GK
FAU - Callstrom, Matthew R
AU  - Callstrom MR
FAU - Schleck, Cathy D
AU  - Schleck CD
FAU - Harmsen, W Scott
AU  - Harmsen WS
FAU - Charboneau, J William
AU  - Charboneau JW
FAU - Welch, Timothy J
AU  - Welch TJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AJR Am J Roentgenol
JT  - AJR. American journal of roentgenology
JID - 7708173
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Biopsy/*adverse effects
MH  - Female
MH  - Hemorrhage/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Logistic Models
MH  - Male
MH  - Radiography, Interventional
MH  - Retrospective Studies
MH  - Ultrasonography, Interventional
EDAT- 2010/02/23 06:00
MHDA- 2010/03/24 06:00
CRDT- 2010/02/23 06:00
PHST- 2010/02/23 06:00 [entrez]
PHST- 2010/02/23 06:00 [pubmed]
PHST- 2010/03/24 06:00 [medline]
AID - 194/3/784 [pii]
AID - 10.2214/AJR.08.2122 [doi]
PST - ppublish
SO  - AJR Am J Roentgenol. 2010 Mar;194(3):784-9. doi: 10.2214/AJR.08.2122.

PMID- 17852773
OWN - NLM
STAT- MEDLINE
DCOM- 20080811
LR  - 20220410
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 19
IP  - 2
DP  - 2008 Mar
TI  - Hypersensitivity of platelets to adenosine diphosphate in patients with stable 
      cardiovascular disease predicts major adverse events despite antiplatelet 
      therapy.
PG  - 104-10
AB  - Enhanced platelet activity correlates with early markers of myocardial damage in 
      patients with cardiovascular disease. However, the extent to which enhanced 
      platelet function signals subsequent adverse clinical outcomes in patients with 
      cardiovascular disease is unknown. Blood from patients with stable cardiovascular 
      disease receiving aspirin (325 mg/day) as the only antiplatelet therapy was 
      tested for closure time (CT) with the Dade PFA-100 Platelet Function Analyzer 
      system collagen/adenosine diphosphate (ADP) [CADP] cartridge and platelet 
      aggregometry using 10 microM ADP. This study intentionally focused on those 
      patients defined as aspirin sensitive by previously established criteria of 
      arachidonic acid- and ADP-induced platelet aggregometry, and separately by 
      collagen/epinephrine (CEPI) CT using the PFA-100. Follow up averaged 22 months 
      for the adverse clinical events of death, myocardial infarction or 
      cerebrovascular accident. For aspirin sensitivity determined by aggregometry, 
      patients with CADP CT < 90 seconds (125/296 = 42.2%) had a composite endpoint 
      rate of 19.2% (24/125), while those with CADP CT 90 seconds (171/296 = 57.8%) had 
      an endpoint rate of 5.3% (9/171). Patients with CADP CT <90 seconds had a 
      relative risk (RR) of 3.65 (95% CI.: 1.76-7.57) for recurrent events and 6.56 
      (95% CI.: 1.93-22.35) for death compared to patients with CADP CT 90s. Nearly 
      identical results were obtained when patients were categorized as aspirin 
      sensitive by CEPI CT. Platelet aggregometry with 10 microM ADP yielded no 
      significant RR for the selected outcomes. Platelet function testing using the 
      PFA-100 system appears to identify a subgroup of stable cardiovascular disease 
      patients with increased risk of major adverse events that is associated with 
      hypersensitivity to ADP, regardless of apparently effective aspirin therapy.
FAU - Christie, Douglas J
AU  - Christie DJ
AD  - Dade Behring Inc., Newark, DE 19702, USA. doug_christie@dadebehring.com
FAU - Kottke-Marchant, Kandice
AU  - Kottke-Marchant K
FAU - Gorman, Robert T
AU  - Gorman RT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/*pharmacology/physiology
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/*physiology
MH  - Cardiovascular Diseases/blood/*drug therapy
MH  - Collagen
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Platelet Function Tests/methods
EDAT- 2007/09/14 09:00
MHDA- 2008/08/12 09:00
CRDT- 2007/09/14 09:00
PHST- 2007/09/14 09:00 [pubmed]
PHST- 2008/08/12 09:00 [medline]
PHST- 2007/09/14 09:00 [entrez]
AID - 780862415 [pii]
AID - 10.1080/09537100701504095 [doi]
PST - ppublish
SO  - Platelets. 2008 Mar;19(2):104-10. doi: 10.1080/09537100701504095.

PMID- 30109026
OWN - NLM
STAT- MEDLINE
DCOM- 20191001
LR  - 20200511
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 7
DP  - 2018
TI  - Challenges in the use of atomistic simulations to predict solubilities of 
      drug-like molecules.
PG  - 686
LID - 10.12688/f1000research.14960.2 [doi]
LID - 686
AB  - Background: Solubility is a physical property of high importance to the 
      pharmaceutical industry, the prediction of which for potential drugs has so far 
      been a hard task. We attempted to predict the solubility of acetylsalicylic acid 
      (ASA) by estimating the absolute chemical potentials of its most stable polymorph 
      and of solutions with different concentrations of the drug molecule. 
      Methods: Chemical potentials were estimated from all-atom molecular dynamics 
      simulations.  We used the Einstein molecule method (EMM) to predict the absolute 
      chemical potential of the solid and solvation free energy calculations to predict 
      the excess chemical potentials of the liquid-phase systems. Results: Reliable 
      estimations of the chemical potentials for the solid and for a single ASA 
      molecule using the EMM required an extremely large number of intermediate states 
      for the free energy calculations, meaning that the calculations were extremely 
      demanding computationally. Despite the computational cost, however, the computed 
      value did not agree well with the experimental value, potentially due to 
      limitations with the underlying energy model. Perhaps better values could be 
      obtained with a better energy model; however, it seems likely computational cost 
      may remain a limiting factor for use of this particular approach to solubility 
      estimation.    Conclusions: Solubility prediction of drug-like solids remains 
      computationally challenging, and it appears that both the underlying energy model 
      and the computational approach applied may need improvement before the approach 
      is suitable for routine use.
FAU - Duarte Ramos Matos, Guilherme
AU  - Duarte Ramos Matos G
AD  - Department of Chemistry, University of California, Irvine, Irvine, California, 
      USA.
FAU - Mobley, David L
AU  - Mobley DL
AD  - Department of Chemistry, University of California, Irvine, Irvine, California, 
      USA.
AD  - Departments of Pharmaceutical Sciences and Chemistry, University of California, 
      Irvine, Irvine, California, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20180531
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
RN  - 0 (Pharmaceutical Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - *Computer Simulation
MH  - *Models, Chemical
MH  - Pharmaceutical Preparations/*chemistry
MH  - *Solubility
MH  - Thermodynamics
PMC - PMC6069752
OTO - NOTNLM
OT  - chemical potentials
OT  - free energy calculations
OT  - molecular crystals
OT  - solubility
OT  - solvation
COIS- Competing interests: D.L.M. is a member of the Scientific Advisory Board for 
      OpenEye Scientific Software.
EDAT- 2019/01/16 06:00
MHDA- 2019/10/02 06:00
CRDT- 2019/01/16 06:00
PHST- 2018/12/06 00:00 [accepted]
PHST- 2019/01/16 06:00 [entrez]
PHST- 2019/01/16 06:00 [pubmed]
PHST- 2019/10/02 06:00 [medline]
AID - 10.12688/f1000research.14960.2 [doi]
PST - epublish
SO  - F1000Res. 2018 May 31;7:686. doi: 10.12688/f1000research.14960.2. eCollection 
      2018.

PMID- 22882748
OWN - NLM
STAT- MEDLINE
DCOM- 20130610
LR  - 20141120
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 38
IP  - 1
DP  - 2013 Feb
TI  - Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of 
      aspirin.
PG  - 12-5
LID - 10.1111/j.1365-2710.2012.01373.x [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: It has been reported that ibuprofen interferes with 
      the antiplatelet effect of low-dose aspirin. This interaction is ascribed to 
      steric hindrance at the active site of cyclooxygenase-1 by ibuprofen, when 
      aspirin is administered after ibuprofen. However, whether other non-steroidal 
      anti-inflammatory drugs (NSAIDs) interact with aspirin similarly is not well 
      defined. The aim of this study was to assess the influence of nine NSAIDs on the 
      antiplatelet effect of aspirin. METHODS: We investigated the antiplatelet effect 
      of NSAIDs using steady-state plasma concentration reported after usual doses. We 
      studied the in vitro antiplatelet effect of NSAID alone, aspirin alone, aspirin 
      before NSAID addition and aspirin after NSAID addition to platelet-rich plasma. 
      The rates of platelet aggregation induced by collagen were determined. The final 
      concentration of aspirin used was the 50% effective concentration (EC(50)) 
      previously estimated in vitro. RESULTS AND DISCUSSION: Ibuprofen and mefenamic 
      acid interfere with the antiplatelet effect of aspirin when added before the 
      latter. The rate of platelet aggregation was reduced by 48·1% and 22·7%, 
      respectively. The other NSAIDs tested did not significantly affect the aspirin 
      antiplatelet effect when exposure was prior to aspirin. None of the nine NSAIDs 
      altered the aspirin effect if administration followed that of aspirin. WHAT IS 
      NEW AND CONCLUSION: Naproxen and flurbiprofen have significant antiplatelet 
      effects at plasma concentrations seen with usual doses. Our in vitro model 
      suggests that the antiplatelet effect of aspirin is significantly diminished when 
      taken after, but not before, ibuprofen or mefenamic acid. None of the other 
      NSAIDs tested had any effect irrespective of the timing of dosing.
CI  - © 2012 Blackwell Publishing Ltd.
FAU - Yokoyama, H
AU  - Yokoyama H
AD  - School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, 
      Japan.
FAU - Ito, N
AU  - Ito N
FAU - Soeda, S
AU  - Soeda S
FAU - Ozaki, M
AU  - Ozaki M
FAU - Suzuki, Y
AU  - Suzuki Y
FAU - Watanabe, M
AU  - Watanabe M
FAU - Kashiwakura, E
AU  - Kashiwakura E
FAU - Kawada, T
AU  - Kawada T
FAU - Ikeda, N
AU  - Ikeda N
FAU - Tokuoka, K
AU  - Tokuoka K
FAU - Kitagawa, Y
AU  - Kitagawa Y
FAU - Yamada, Y
AU  - Yamada Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20120806
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Collagen/administration & dosage
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Time Factors
EDAT- 2012/08/14 06:00
MHDA- 2013/06/12 06:00
CRDT- 2012/08/14 06:00
PHST- 2012/08/14 06:00 [entrez]
PHST- 2012/08/14 06:00 [pubmed]
PHST- 2013/06/12 06:00 [medline]
AID - 10.1111/j.1365-2710.2012.01373.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2013 Feb;38(1):12-5. doi: 10.1111/j.1365-2710.2012.01373.x. 
      Epub 2012 Aug 6.

PMID- 15877994
OWN - NLM
STAT- MEDLINE
DCOM- 20050623
LR  - 20220321
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 95
IP  - 10
DP  - 2005 May 15
TI  - Analysis of risk of bleeding complications after different doses of aspirin in 
      192,036 patients enrolled in 31 randomized controlled trials.
PG  - 1218-22
AB  - We sought to compare the risk of hemorrhage due to the low (<100 mg), moderate 
      (100 to 200 mg), and high (>200 mg) doses of aspirin (acetylsalicylic acid [ASA]) 
      in 192,036 patients enrolled in 31 clinical trials. Despite substantial 
      differences in the reporting patterns of bleeding complications, low-dose ASA was 
      associated with the lowest risk, and moderate doses caused a relatively high 
      hemorrhagic event rate, especially with regard to minor, gastrointestinal, and 
      total bleeding, and stroke. These findings should be considered when using 
      combination antiplatelets, anticoagulant therapy, or both, with ASA, especially 
      with the daily dose of >100 mg.
FAU - Serebruany, Victor L
AU  - Serebruany VL
AD  - HeartDrug Research Laboratories, Towson, Maryland, USA. Heartdrug@aol.com 
      <Heartdrug@aol.com>
FAU - Steinhubl, Steven R
AU  - Steinhubl SR
FAU - Berger, Peter B
AU  - Berger PB
FAU - Malinin, Alex I
AU  - Malinin AI
FAU - Baggish, Jeffrey S
AU  - Baggish JS
FAU - Bhatt, Deepak L
AU  - Bhatt DL
FAU - Topol, Eric J
AU  - Topol EJ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Cardiol. 2005 Oct 1;96(7):1035-6. PMID: 16188542
CIN - Am J Cardiol. 2005 Nov 15;96(10):1467. PMID: 16275203
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Thromboembolism/*prevention & control
EDAT- 2005/05/10 09:00
MHDA- 2005/06/24 09:00
CRDT- 2005/05/10 09:00
PHST- 2004/10/19 00:00 [received]
PHST- 2005/01/05 00:00 [revised]
PHST- 2005/01/04 00:00 [accepted]
PHST- 2005/05/10 09:00 [pubmed]
PHST- 2005/06/24 09:00 [medline]
PHST- 2005/05/10 09:00 [entrez]
AID - S0002-9149(05)00294-8 [pii]
AID - 10.1016/j.amjcard.2005.01.049 [doi]
PST - ppublish
SO  - Am J Cardiol. 2005 May 15;95(10):1218-22. doi: 10.1016/j.amjcard.2005.01.049.

PMID- 724339
OWN - NLM
STAT- MEDLINE
DCOM- 19790226
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 62
IP  - 5 Pt 2 Suppl
DP  - 1978 Nov
TI  - Clinical pharmacokinetics of aspirin.
PG  - 867-72
AB  - Aspirin is very rapidly absorbed from the gastrointestinal tract when 
      administered as a solution, and somewhat more slowly when administered in 
      tablets. It is rapidly hydrolyzed in the body to salicylic acid; the plasma 
      concentration of the latter must be maintained within a relatively narrow range 
      to obtain an adequate anti-inflammatory effect and to minimize systemic adverse 
      effects. The two major pathways of salicylate elimination, i.e., formation of 
      salicyluric acid and salicyl phenolic glucuronide, become saturated at relatively 
      low body levels of the drug. Consequently, steady-state ("plateau") salicylate 
      levels increase more than proportionately with increasing daily dose, and the 
      time required to reach steady state increases with increasing daily dose. The 
      renal clearance of salicylic acid increases markedly with increasing urine pH; 
      antacids capable of increasing urine pH can therefore cause a pronounced lowering 
      of steady-state salicylate concentrations under clinical conditions. There are 
      pronounced intersubject differences in salicylate elimination kinetics; dosage 
      must be individualized on the basis of plasma concentration and clinical 
      response. The drug is readily transferred across the placenta and is only slowly 
      eliminated by the newborn infant. The drug is also transferred from mother to 
      nursing infant through the breast milk.
FAU - Levy, G
AU  - Levy G
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Aspirin/administration & dosage/*metabolism
MH  - Biotransformation
MH  - Child
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Intestinal Absorption
MH  - Kinetics
MH  - Male
MH  - Maternal-Fetal Exchange
MH  - Pregnancy
MH  - Salicylates/blood
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1978 Nov;62(5 Pt 2 Suppl):867-72.

PMID- 17426365
OWN - NLM
STAT- MEDLINE
DCOM- 20071005
LR  - 20220716
IS  - 1080-0549 (Print)
IS  - 1080-0549 (Linking)
VI  - 32
IP  - 1
DP  - 2007 Feb
TI  - Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity.
PG  - 97-110
AB  - Acetylsalicylic acid (ASA) or aspirin and nonsteroidal anti-inflammatory drug 
      (NSAID) sensitivities encompass a diverse group of both pharmacological and 
      hypersensitivity reactions. Conventionally, hypersensitivities include 
      aspirin-exacerbated respiratory disease (AERD), ASA-induced urticaria, and 
      anaphylaxis. With an increasing prevalence of coronary artery disease in an aging 
      population, aspirin continues to play a significant role in cardiac prophylaxis 
      in a large patient population. Invariably, the clinician will encounter patients 
      with clear indications for aspirin therapy but a history of aspirin sensitivity. 
      Although protocols have been established for aspirin challenge and 
      desensitization, it is not always an efficacious or safe procedure. This article 
      reviews the different classifications of ASA/NSAIDs hypersensitivities to better 
      guide the clinician in dealing with this patient population. History of 
      crossrelativities between multiple NSAIDs implies a non-IgE-mediated process. 
      Similarly, a history of monosensitivity to one NSAID implies an IgE-mediated 
      process, although specific antibodies are often elusive. Despite the name, AERD 
      can potentially be exacerbated by all cyclooxygenase (COX) inhibitors based on 
      dose-dependent inhibition of COX-1. Aspirin desensitization can be achieved to 
      improve both upper and lower respiratory symptoms for most patient with AERD. 
      Aspirin desensitization can usually be achieved for those in need of the 
      antiplatelet effects of aspirin, with the exception of those with aspirin-induced 
      urticaria and baseline chronic urticaria. However, desensitization should only be 
      attempted in those with stable coronary artery disease because the process of 
      desensitization carries the inherent risk of anaphylaxis/anaphylactoid reaction, 
      which may further increase cardiac demand and bring about ischemic injury. 
      Therefore, desensitization is reserved until coronary artery disease is 
      stabilized.
FAU - Kong, James S W
AU  - Kong JS
AD  - Division of Rheumatology, Allergy, and Clinical Immunology, Department of 
      Internal Medicine, University of California at Davis, Davis, CA, USA.
FAU - Teuber, Suzanne S
AU  - Teuber SS
FAU - Gershwin, M Eric
AU  - Gershwin ME
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology
MH  - Aspirin/*adverse effects/pharmacology
MH  - Drug Hypersensitivity/*immunology/*pathology
MH  - Humans
MH  - Urticaria/chemically induced/pathology
RF  - 62
EDAT- 2007/04/12 09:00
MHDA- 2007/10/06 09:00
CRDT- 2007/04/12 09:00
PHST- 1999/11/30 00:00 [received]
PHST- 1999/11/30 00:00 [revised]
PHST- 1999/11/30 00:00 [accepted]
PHST- 2007/04/12 09:00 [pubmed]
PHST- 2007/10/06 09:00 [medline]
PHST- 2007/04/12 09:00 [entrez]
AID - CRIAI:32:1:97 [pii]
AID - 10.1007/BF02686086 [doi]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2007 Feb;32(1):97-110. doi: 10.1007/BF02686086.

PMID- 33849034
OWN - NLM
STAT- MEDLINE
DCOM- 20220329
LR  - 20220329
IS  - 1423-0151 (Electronic)
IS  - 1011-7571 (Print)
IS  - 1011-7571 (Linking)
VI  - 30
IP  - 5
DP  - 2021
TI  - Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: 
      Current Evidence and Dilemmas.
PG  - 412-421
LID - 10.1159/000516471 [doi]
AB  - Thrombotic diseases like ischemic stroke are common complications of essential 
      thrombocythemia (ET) due to abnormal megakaryopoiesis and platelet dysfunction. 
      Ischemic stroke in ET can occur as a result of both cerebral arterial and venous 
      thrombosis. Management of ET is aimed at preventing vascular complications 
      including thrombosis. Acute management of ischemic stroke in ET is the same as 
      that in the general population without myeloproliferative disorders. However, an 
      ET patient with ischemic stroke is at high risk for rethrombosis and is therefore 
      additionally managed with cytoreductive therapy and antithrombotic agents. Given 
      abnormal platelet production in ET, there is suboptimal suppression of platelets 
      with the standard recommended dose of aspirin for cardiovascular (CV) prevention. 
      Hence, for optimal CV protection in ET, low-dose aspirin is recommended twice 
      daily in an arterial thrombotic disease like atherothrombotic ischemic stroke in 
      presence of the following risk factors: age >60 years, Janus kinase2 V617F gene 
      mutation, and presence of CV risk factors. In the presence of the same risk 
      factors, concurrent antiplatelet and anticoagulant therapy is suggested for 
      venous thrombosis. However, increased risk of bleeding with dual antithrombotic 
      agents poses a significant challenge in their use in cerebral venous 
      thromboembolism or atrial fibrillation in presence of the above-mentioned risk 
      factors. We discuss these dilemmas regarding antithrombotic management in 
      ischemic stroke in ET in this case-based review of literature in the light of 
      current evidence.
CI  - © 2021 The Author(s) Published by S. Karger AG, Basel.
FAU - Das, Shubhabrata
AU  - Das S
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Deb, Anasua
AU  - Deb A
AD  - Department of Internal Medicine, Texas Tech University Health Sciences Center, 
      Lubbock, Texas, USA.
FAU - Pal, Tanmoy
AU  - Pal T
AD  - Department of Neurology, Neotia Getwel Healthcare Centre, Siliguri, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210413
PL  - Switzerland
TA  - Med Princ Pract
JT  - Medical principles and practice : international journal of the Kuwait University, 
      Health Science Centre
JID - 8901334
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Fibrinolytic Agents/*administration & dosage/therapeutic use
MH  - Humans
MH  - *Ischemic Stroke
MH  - Middle Aged
MH  - Thrombocythemia, Essential/complications/*drug therapy
PMC - PMC8562054
OTO - NOTNLM
OT  - Antithrombotic management
OT  - Essential thrombocythemia
OT  - Ischemic stroke
OT  - Low-dose aspirin
COIS- The authors have no conflicts of interest to declare.
EDAT- 2021/04/14 06:00
MHDA- 2022/03/30 06:00
CRDT- 2021/04/13 20:31
PHST- 2020/06/06 00:00 [received]
PHST- 2021/04/10 00:00 [accepted]
PHST- 2021/04/14 06:00 [pubmed]
PHST- 2022/03/30 06:00 [medline]
PHST- 2021/04/13 20:31 [entrez]
AID - 000516471 [pii]
AID - mpp-0030-0412 [pii]
AID - 10.1159/000516471 [doi]
PST - ppublish
SO  - Med Princ Pract. 2021;30(5):412-421. doi: 10.1159/000516471. Epub 2021 Apr 13.

PMID- 32080811
OWN - NLM
STAT- MEDLINE
DCOM- 20210120
LR  - 20210120
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 49
IP  - 3
DP  - 2020 Apr
TI  - Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical 
      lipid aspirin complex formulation.
PG  - 337-343
LID - 10.1007/s11239-020-02051-5 [doi]
AB  - Dyspeptic symptoms are common with aspirin and clinicians frequently recommend 
      that it be taken with food to reduce these side effects. However, food can 
      interfere with absorption, especially with enteric-coated aspirin formulations. 
      We evaluated whether food interferes with the bioavailability of a new, 
      pharmaceutical lipid-aspirin complex (PL-ASA) liquid-filled capsule formulation. 
      In this randomized, open label, crossover study, 20 healthy volunteers fasted 
      for ≥ 10 h and then randomized as either "fasted", receiving 650 mg of PL-ASA, or 
      as "fed", with a standard high-fat meal and 650 mg of PL-ASA 30 min later. After 
      a washout of 7 days, participants crossed over to the other arm. The primary 
      outcome was comparison of PK parameters of the stable aspirin metabolite 
      salicylic acid (SA) between fasted and fed states. Mean age of participants was 
      36.8 years and 55% were male. The ratios for the fed to fasted states of the 
      primary SA PK parameters of AUC(0-t) and AUC(0-∞) were 88.7% and 88.8% 
      respectively, with 90% confidence intervals between 80 and 125%, which is 
      consistent with FDA bioequivalence guidance. Mean peak SA concentration was about 
      22% lower and occurred about 1.5 h later in the fed state. Food had a modest 
      effect on peak SA levels and the time required to reach them after PL-ASA 
      administration, but did not impact the extent of exposure (AUC) compared with 
      intake in a fasted state. These data demonstrate that PL-ASA may be 
      co-administered with food without significant impact on aspirin 
      bioavailability.Clinical Trial Registration:http://www.clinicaltrials.gov Unique 
      Identifier: NCT01244100.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AUID- ORCID: 0000-0001-8451-2131
AD  - Division of Cardiology, University of Florida College of Medicine, Jacksonville, 
      655 West 8th Street, Jacksonville, FL, 32209, USA. 
      dominick.angiolillo@jax.ufl.edu.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, 
      Boston, MA, USA.
FAU - Lanza, Frank
AU  - Lanza F
AD  - Houston Institute for Clinical Research, Houston, TX, USA.
FAU - Deliargyris, Efthymios N
AU  - Deliargyris EN
AD  - PLx Pharma, Sparta, NJ, USA.
FAU - Prats, Jayne
AU  - Prats J
AD  - Elysis LLC, Carlisle, MA, USA.
FAU - Fan, Weihong
AU  - Fan W
AD  - PLx Pharma, Sparta, NJ, USA.
FAU - Marathi, Upendra
AU  - Marathi U
AD  - , 7 Hills Pharma, Houston, TX, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01244100
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Lipids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - *Aspirin/administration & dosage/pharmacokinetics
MH  - Biological Availability
MH  - Cross-Over Studies
MH  - Fasting/*blood
MH  - Female
MH  - Food-Drug Interactions
MH  - Humans
MH  - *Lipids/administration & dosage/pharmacokinetics
MH  - Male
PMC - PMC7145786
OTO - NOTNLM
OT  - Aspirin
OT  - Bioavailability
OT  - Fasted
OT  - Fed
OT  - Pharmacokinetic
OT  - Platelet
COIS- Dr Angiolillo declares that he has received consulting fees or honoraria from 
      Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, 
      Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, 
      Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company and has 
      received payments for participation in review activities from CeloNova and St 
      Jude Medical. D.J.A. also declares that his institution has received research 
      grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, 
      Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical 
      Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions. Dr. 
      Deepak L. Bhatt discloses the following relationships—Advisory Board: Cardax, 
      Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, 
      PhaseBio, Regado Biosciences; Board of Directors: Boston VA Research Institute, 
      Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart 
      Association Quality Oversight Committee; Data Monitoring Committees: Baim 
      Institute for Clinical Research (formerly Harvard Clinical Research Institute, 
      for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic 
      (including for the ExCEED trial, funded by Edwards), Duke Clinical Research 
      Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, 
      funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: 
      American College of Cardiology (Senior Associate Editor, Clinical Trials and 
      News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for 
      Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI 
      clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II 
      executive committee funded by CSL Behring), Belvoir Publications (Editor in 
      Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial 
      steering committees), HMP Global (Editor in Chief, Journal of Invasive 
      Cardiology), Journal of the American College of Cardiology (Guest Editor; 
      Associate Editor), Medtelligence/ReachMD (CME steering committees), Population 
      Health Research Institute (for the COMPASS operations committee, publications 
      committee, steering committee, and USA national co-leader, funded by Bayer), 
      Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), 
      Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering 
      committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry 
      Steering Committee (Chair), VA CART Research and Publications Committee (Chair); 
      Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer 
      Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Ferring 
      Pharmaceuticals, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, 
      Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The 
      Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A 
      Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston 
      Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of 
      Cardiology; Unfunded Research: FlowCo, Fractyl, Merck, Novo Nordisk, PLx Pharma, 
      Takeda. Dr. Deliargyris, Ms. Fan are employees of PLx Pharma. Dr. Prats is a 
      consultant to PLx Pharma. Dr. Marathi was an employee of PLx Pharma at the time 
      of the study, and is an investor, option holder, and a co-inventor of the PL-ASA 
      delivery technology. No other conflicts related to the current study are 
      reported.
EDAT- 2020/02/23 06:00
MHDA- 2021/01/21 06:00
CRDT- 2020/02/22 06:00
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2021/01/21 06:00 [medline]
PHST- 2020/02/22 06:00 [entrez]
AID - 10.1007/s11239-020-02051-5 [pii]
AID - 2051 [pii]
AID - 10.1007/s11239-020-02051-5 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2020 Apr;49(3):337-343. doi: 10.1007/s11239-020-02051-5.

PMID- 9521569
OWN - NLM
STAT- MEDLINE
DCOM- 19980513
LR  - 20190831
IS  - 1387-2273 (Print)
IS  - 1387-2273 (Linking)
VI  - 705
IP  - 2
DP  - 1998 Feb 13
TI  - Determination of acetylsalicylic acid and salicylic acid in skin and plasma by 
      high-performance liquid chromatography.
PG  - 309-15
AB  - This study describes a HPLC method to determine the concentrations of 
      acetylsalicylic acid (ASA) and salicylic acid (SA) in human stratum corneum and 
      in plasma. The stratum corneum layers for ASA/SA analysis were removed from three 
      patients with postherpetic hyperalgesia treated with topical and oral aspirin. 
      Blood samples were also collected from the same patients. Tape strippings were 
      placed in acetonitrile and sonicated for 15 min. After centrifuging, aliquots of 
      the supernatant were injected into the chromatograph. ASA and SA from plasma 
      samples were extracted on Isolute C8 columns. Due to interfering peaks in the 
      tape samples, HPLC conditions were slightly different for tape and plasma 
      samples. ASA and SA were separated on a LiChrospher 100 RP-18 column at 1 ml/min 
      using a water-phosphate buffer (pH 2.5)-acetonitrile mobile phase (35:40:25, 
      v/v/v). A linear response to quantities of ASA from 0.1 to 100 microg/cm2 and of 
      SA from 0.1 to 5 microg/cm2 in tape and to quantities of ASA 0.1 to 2 microg/ml 
      and 1 to 50 microg/ml was obtained and the recovery from tape and plasma samples 
      was over 98%. The method is sensitive (0.1 microg/cm2) and specific enough to 
      allow the determination of the drugs in the skin not only after topical but also 
      after oral administration. A good sensitivity was also obtained in plasma (0.1 
      microg/ml) allowing study of the kinetics of ASA and SA in plasma after oral 
      administration. Concentrations of ASA after topical administration were 100-200 
      times higher than after oral administration. Plasma levels of ASA and SA after 
      oral administration were similar to those previously found. No ASA or SA were 
      detected in plasma after topical ASA administration.
FAU - Pirola, R
AU  - Pirola R
AD  - Department of Pharmacology, Institute of Neurosurgery, University of Milan, 
      Italy.
FAU - Bareggi, S R
AU  - Bareggi SR
FAU - De Benedittis, G
AU  - De Benedittis G
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Chromatogr B Biomed Sci Appl
JT  - Journal of chromatography. B, Biomedical sciences and applications
JID - 9714109
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Administration, Topical
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/*analysis/*blood
MH  - Chromatography, High Pressure Liquid/methods
MH  - Epidermis/chemistry
MH  - Humans
MH  - Reference Values
MH  - Reproducibility of Results
MH  - Salicylates/*analysis/*blood
MH  - Salicylic Acid
MH  - Sensitivity and Specificity
MH  - Skin/*chemistry
EDAT- 1998/04/01 00:00
MHDA- 1998/04/01 00:01
CRDT- 1998/04/01 00:00
PHST- 1998/04/01 00:00 [pubmed]
PHST- 1998/04/01 00:01 [medline]
PHST- 1998/04/01 00:00 [entrez]
AID - 10.1016/s0378-4347(97)00539-2 [doi]
PST - ppublish
SO  - J Chromatogr B Biomed Sci Appl. 1998 Feb 13;705(2):309-15. doi: 
      10.1016/s0378-4347(97)00539-2.

PMID- 9172913
OWN - NLM
STAT- MEDLINE
DCOM- 19970530
LR  - 20131121
IS  - 0210-0010 (Print)
IS  - 0210-0010 (Linking)
VI  - 25
IP  - 140
DP  - 1997 Apr
TI  - [Secondary prevention of ischemic strokes: effect of dosage of aspirin].
PG  - 541-4
AB  - INTRODUCTION AND OBJECTIVE: The value of acetylsalicylic acid (ASS) in the 
      secondary prevention of ischemic stroke is well established. However, the optimum 
      dose of AAS for stroke-threatened patients remains unsettled. This paper reviews 
      the pattern of adverse reactions to AAS and their relationship to the dosage of 
      ASS evaluated. METHOD: All the clinical trials in which AAS was used as the sole 
      antiaggregant in the secondary prevention of ischemic stroke were reviewed. The 
      crude odds ratio for the different adverse reactions was calculated using three 
      sub tests: AAS versus placebo; AAS < 330 mg/d versus AAS > 330 mg/d; and each 
      dosage level versus a placebo. RESULTS: There is an increased risk associated 
      with the use of AAS as compared to a placebo with respect to gastrointestinal 
      bleeding (OR 2.3, IC 95% (1.6-4.1)), peptic ulcer (10.1 (2.5-85.2)), 
      intracerebral hemorrhage (2.2 (1.3-4)) and other hemorrhagic phenomena (2.6 
      (2-3.3)). CONCLUSIONS: There seems to be a direct relationship between the dosage 
      of AAS and the frequency with which adverse reactions occur, except in the case 
      of intracerebral hemorrhage. In the latter case there was no relationship with 
      the dose given (0.8 (0.5-1.4)).
FAU - Alvarez-Sabín, J
AU  - Alvarez-Sabín J
AD  - Servicio de Neurología, Hospital General i Universitari Vall d'Hebron, Barcelona, 
      España.
FAU - Calvo, G
AU  - Calvo G
FAU - Morros, R
AU  - Morros R
LA  - spa
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Prevención secundaria del ictus isquémico. Efecto de la dosis en el perfil de la 
      aspirina.
PL  - Spain
TA  - Rev Neurol
JT  - Revista de neurologia
JID - 7706841
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects/*therapeutic use
MH  - Brain Ischemia/*drug therapy/etiology/*prevention & control
MH  - Cerebral Hemorrhage/complications/drug therapy
MH  - *Dose-Response Relationship, Drug
MH  - Humans
MH  - Placebos
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/*therapeutic use
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
PST - ppublish
SO  - Rev Neurol. 1997 Apr;25(140):541-4.

PMID- 24773275
OWN - NLM
STAT- MEDLINE
DCOM- 20150102
LR  - 20181202
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 13
IP  - 6
DP  - 2014 Jun
TI  - Does aspirin increase the risk of age-related macular degeneration?
PG  - 691-3
LID - 10.1517/14740338.2014.914169 [doi]
AB  - This commentary on the review by Christen and Chew discusses the controversy 
      surrounding aspirin use and its association with age-related macular degeneration 
      (AMD). We address the strength of evidence between low-dose aspirin use and AMD 
      and also discuss the risks and benefits of aspirin use in primary versus 
      secondary prevention of cardiovascular diseases in these cases. We also highlight 
      an ongoing randomized controlled trial in this area.
FAU - Chong, Elaine W
AU  - Chong EW
AD  - University of Melbourne, Royal Victorian Eye and Ear Hospital, Centre for Eye 
      Research Australia (CERA) , 32 Gisbourne Street, East Melbourne, Victoria 3002 , 
      Australia +61 3 9929 8968 ; +61 399298379 ; elainechongwt@alumni.unimelb.edu.au.
FAU - Guymer, Robyn H
AU  - Guymer RH
FAU - Robman, Liubov D
AU  - Robman LD
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20140429
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Expert Opin Drug Saf. 2014 Apr;13(4):421-9. PMID: 24547895
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Macular Degeneration/*chemically induced/*etiology
OTO - NOTNLM
OT  - age-related macular degeneration
OT  - aspirin
OT  - epidemiology
OT  - randomized controlled trial
EDAT- 2014/04/30 06:00
MHDA- 2015/01/03 06:00
CRDT- 2014/04/30 06:00
PHST- 2014/04/30 06:00 [entrez]
PHST- 2014/04/30 06:00 [pubmed]
PHST- 2015/01/03 06:00 [medline]
AID - 10.1517/14740338.2014.914169 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2014 Jun;13(6):691-3. doi: 10.1517/14740338.2014.914169. 
      Epub 2014 Apr 29.

PMID- 20692369
OWN - NLM
STAT- MEDLINE
DCOM- 20110131
LR  - 20131121
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
VI  - 8
IP  - 11
DP  - 2010 Nov
TI  - Undisclosed use of nonsteroidal anti-inflammatory drugs may underlie small-bowel 
      injury observed by capsule endoscopy.
PG  - 992-5
LID - 10.1016/j.cgh.2010.07.011 [doi]
AB  - BACKGROUND & AIMS: Findings from capsule endoscopies (CEs) of patients with 
      enteropathy from nonsteroidal anti-inflammatory drugs (NSAIDs) may be 
      indistinguishable from those with Crohn's disease, making medication history 
      crucial to image interpretation. Undeclared NSAID use has been proposed to cause 
      unexplained peptic ulcers; we investigated whether it is also an issue among 
      patients referred for small-bowel CE. METHODS: We collected demographic data, 
      indications for CE, and medication history prospectively. A salicylate spot test 
      and gas chromatography-mass spectrometry were performed for NSAID metabolites in 
      urine samples of patients undergoing routine CE. Videos were analyzed by a 
      gastroenterologist who was blinded to the urinalysis results. RESULTS: 
      Seventy-six patients (52 women; mean age, 50 y) underwent CE for suspected 
      small-bowel pathology. Urinalysis was positive in 13.6% of patients (salicylates, 
      n = 3; ibuprofen, n = 6; and ibuprofen and diclofenac, n = 1) although only 1 of 
      these patients declared use of an NSAID (aspirin). Although 2 patients had normal 
      CE results, 80% had positive results, including the presence of erosions (n = 5), 
      ulceration (n = 2), and ulcers with early stricturing (n = 1, diagnosed with 
      Crohn's disease). A patient with small-bowel ulceration underwent surgery and was 
      found to have NSAID-associated enteropathy, based on histologic analysis. 
      CONCLUSIONS: Of patients who undergo CE, 13.6% took NSAIDs or aspirin, but most 
      did not declare using these medications. Small-bowel inflammation was common in 
      this cohort and could be mistaken for Crohn's disease. Patients should be 
      questioned about use of over-the-counter medications, and routine urinalysis for 
      NSAID metabolites may be helpful before interpretation of CE findings.
CI  - Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
FAU - Sidhu, Reena
AU  - Sidhu R
AD  - Gastroenterology and Liver Unit, Royal Hallamshire Hospital, Sheffield Teaching 
      Hospitals National Health Service Trust, Sheffield, United Kingdom.
FAU - Brunt, Lorraine K
AU  - Brunt LK
FAU - Morley, Stephen R
AU  - Morley SR
FAU - Sanders, David S
AU  - Sanders DS
FAU - McAlindon, Mark E
AU  - McAlindon ME
LA  - eng
PT  - Journal Article
DEP - 20100806
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal 
      of the American Gastroenterological Association
JID - 101160775
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*adverse effects/analysis
MH  - Aspirin/adverse effects/analysis
MH  - Capsule Endoscopy/*methods
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry
MH  - Gastrointestinal Diseases/*chemically induced/*diagnosis
MH  - Humans
MH  - Intestinal Mucosa/pathology
MH  - Intestine, Small/*pathology
MH  - Male
MH  - Middle Aged
MH  - Urine/chemistry
EDAT- 2010/08/10 06:00
MHDA- 2011/02/01 06:00
CRDT- 2010/08/10 06:00
PHST- 2010/05/12 00:00 [received]
PHST- 2010/07/09 00:00 [revised]
PHST- 2010/07/18 00:00 [accepted]
PHST- 2010/08/10 06:00 [entrez]
PHST- 2010/08/10 06:00 [pubmed]
PHST- 2011/02/01 06:00 [medline]
AID - S1542-3565(10)00734-2 [pii]
AID - 10.1016/j.cgh.2010.07.011 [doi]
PST - ppublish
SO  - Clin Gastroenterol Hepatol. 2010 Nov;8(11):992-5. doi: 10.1016/j.cgh.2010.07.011. 
      Epub 2010 Aug 6.

PMID- 27981529
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180318
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 20
IP  - 23
DP  - 2016 Dec
TI  - Effect of regular oral intake of aspirin during pregnancy on pregnancy outcome of 
      high-risk pregnancy-induced hypertension syndrome patients.
PG  - 5013-5016
LID - 11871 [pii]
AB  - OBJECTIVE: The aim of this study is to analyze the effect of 100 mg/d regular 
      oral intake of aspirin during pregnancy on high-risk pregnancy-induced 
      hypertension syndrome patients. PATIENTS AND METHODS: We consecutively selected 
      98 cases high-risk pregnancy-induced hypertension syndrome patients. After 
      obtaining the informed consent of the patients, we randomly divided the patients 
      into aspirin group (50 cases) and placebo group (48 cases). The oral intake of 
      aspirin lasted from the final diagnosis of pregnancy to antepartum time, and was 
      taken before sleep. The bleeding index was closely detected and we stop taking 
      aspirin when necessary. RESULTS: The comparison of clinical outcome showed that 
      the incidents of pregnancy-induced hypertension syndrome, pre-eclampsia and 
      eclampsia of aspirin group were significantly lower than that of the placebo 
      group (p<0.05). Comparing the complications of fetus perinatal period, the 
      difference was not statistically significant (p>0.05). CONCLUSIONS: 100 mg/d 
      regular oral intake of aspirin during pregnancy is safe, effective and worthy of 
      generalization to high-risk pregnancy-induced hypertension syndrome patients.
FAU - Liu, F-M
AU  - Liu FM
AD  - Department of Obstetrics and Gynecology, Jinan Central Hospital, Shandong 
      University, Jinan, Shandong, China. cefsyalxxid62@163.com.
FAU - Zhao, M
AU  - Zhao M
FAU - Wang, M
AU  - Wang M
FAU - Yang, H-L
AU  - Yang HL
FAU - Li, L
AU  - Li L
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hypertension/drug therapy
MH  - *Hypertension, Pregnancy-Induced
MH  - Pre-Eclampsia
MH  - Pregnancy
MH  - *Pregnancy Outcome
EDAT- 2016/12/17 06:00
MHDA- 2017/06/22 06:00
CRDT- 2016/12/17 06:00
PHST- 2016/12/17 06:00 [entrez]
PHST- 2016/12/17 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - 11871 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2016 Dec;20(23):5013-5016.

PMID- 32750421
OWN - NLM
STAT- MEDLINE
DCOM- 20210526
LR  - 20210526
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 154
DP  - 2020 Nov 1
TI  - Effect of the molecular mobility of water adsorbed by disintegrants on 
      storage-induced hydrolytic degradation of acetylsalicylic acid incorporated into 
      tablets under humid conditions.
PG  - 105502
LID - S0928-0987(20)30291-8 [pii]
LID - 10.1016/j.ejps.2020.105502 [doi]
AB  - The purpose of this study was to investigate the effect of molecular mobility of 
      water adsorbed by disintegrants on the hydrolytic degradation of active 
      pharmaceutical ingredients (APIs). Fourteen different disintegrants were tested. 
      First, powdered disintegrants were stored at conditions of 40 °C/75% relative 
      humidity ("humid conditions") and their T(2) relaxation times were measured by 
      time-domain nuclear magnetic resonance for examination of the molecular mobility 
      of water adsorbed by the disintegrant. From the observed T(2) values, the water 
      molecular mobility was fully characterized. In particular, the molecular mobility 
      of water adsorbed by crospovidones was much higher than the molecular mobility of 
      water adsorbed by the other test disintegrants because of longer T(2) values. The 
      next study examined the hydrolytic degradation of acetylsalicylic acid (ASA), a 
      model moisture-sensitive API, stored under humid conditions. Physical mixtures of 
      ASA and disintegrants or their model tablets were used as test samples, and they 
      were stored for 7 d. The disintegrants contained in the samples clearly affected 
      the ASA degradation: the most significant ASA degradation was observed for the 
      crospovidone-containing samples. Finally, we analyzed the effect of the molecular 
      mobility of water adsorbed by disintegrants on the ASA degradation by the least 
      absolute shrinkage and selection operator (Lasso) regression techniques. As in 
      the T(2) experiment, various properties of disintegrants (i.e., water content, 
      pH, and water activity) were used in this experiment as the explanatory 
      variables. From the Lasso analysis, we successfully showed that the higher 
      molecular mobility of water adsorbed by disintegrants significantly enhanced ASA 
      degradation. These findings provide profound insights into the chemical stability 
      of moisture-sensitive APIs in tablets.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Ougi, Kousuke
AU  - Ougi K
AD  - Laboratory of Pharmaceutical Technology, School of Pharmacy and Pharmaceutical 
      Sciences, University of Toyama, Sugitani 2630. Toyama, Toyama, 930-0194, Japan.
FAU - Okada, Kotaro
AU  - Okada K
AD  - Laboratory of Pharmaceutical Technology, School of Pharmacy and Pharmaceutical 
      Sciences, University of Toyama, Sugitani 2630. Toyama, Toyama, 930-0194, Japan.
FAU - Leong, Kok Hoong
AU  - Leong KH
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of 
      Malaya, 50603 Kuala Lumpur, Malaysia.
FAU - Hayashi, Yoshihiro
AU  - Hayashi Y
AD  - Nichi-Iko Pharmaceutical Co., Ltd., Formulation Development Department, 205-1 
      Shimoumezawa, Namerikawa, Toyama, 936-0857, Japan.
FAU - Kumada, Shungo
AU  - Kumada S
AD  - Nichi-Iko Pharmaceutical Co., Ltd., Formulation Development Department, 205-1 
      Shimoumezawa, Namerikawa, Toyama, 936-0857, Japan.
FAU - Onuki, Yoshinori
AU  - Onuki Y
AD  - Laboratory of Pharmaceutical Technology, School of Pharmacy and Pharmaceutical 
      Sciences, University of Toyama, Sugitani 2630. Toyama, Toyama, 930-0194, Japan. 
      Electronic address: onuki@pha.u-toyama.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20200801
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Excipients)
RN  - 0 (Powders)
RN  - 0 (Tablets)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/chemistry
MH  - Excipients
MH  - Powders
MH  - Solubility
MH  - Tablets
MH  - Water
OTO - NOTNLM
OT  - Disintegrant
OT  - Hydrolytic degradation
OT  - T(2) relaxation time
OT  - Tablet
OT  - Time-domain nuclear magnetic resonance
OT  - Water adsorption
OT  - Water molecular mobility
COIS- Declaration of Competing Interest The authors declare that they have no financial 
      or competing interests concerning this manuscript. The Laboratory of 
      Pharmaceutical Technology, University of Toyama, is an endowed department 
      supported by an unrestricted grant from Nichi-Iko Pharmaceutical Co. Ltd. 
      (Toyama, Japan).
EDAT- 2020/08/05 06:00
MHDA- 2021/05/27 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/07/10 00:00 [revised]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/05/27 06:00 [medline]
PHST- 2020/08/05 06:00 [entrez]
AID - S0928-0987(20)30291-8 [pii]
AID - 10.1016/j.ejps.2020.105502 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2020 Nov 1;154:105502. doi: 10.1016/j.ejps.2020.105502. Epub 
      2020 Aug 1.

PMID- 10722063
OWN - NLM
STAT- MEDLINE
DCOM- 20000418
LR  - 20190720
IS  - 0021-9673 (Print)
IS  - 0021-9673 (Linking)
VI  - 870
IP  - 1-2
DP  - 2000 Feb 18
TI  - Validation of the removal of acetylsalicylic acid. Recovery and determination of 
      residues on various surfaces by high performance liquid chromatographic.
PG  - 69-75
AB  - The validation of a procedure to clean glass, vinyl and stainless steel surfaces 
      that have been exposed to acetylsalicylic acid during its manufacture is 
      described. The cleaning procedure using two cotton swabs moistened with the 
      mobile phase was validated using a wipe-test and a high-performance liquid 
      chromatography (HPLC) method developed to determine low quantities of the acid. 
      The HPLC method involves an octadecylsilane column at 55 degrees C, a mixture of 
      water-acetonitrile-orthophosphoric acid (779:220:1, v/v) as mobile phase and 
      detection at 226 nm. Recoveries of 86%, 90% and 94% were obtained from vinyl, 
      glass and stainless steel plates respectively. The validation gave acceptable 
      levels of sensitivity, recovery, precision and linearity.
FAU - Nozal, M J
AU  - Nozal MJ
AD  - Department of Analytical Chemistry, Faculty of Sciences, University of 
      Valladolid, Spain.
FAU - Bernal, J L
AU  - Bernal JL
FAU - Toribio, L
AU  - Toribio L
FAU - Jiménez, J J
AU  - Jiménez JJ
FAU - Martín, M T
AU  - Martín MT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Chromatogr A
JT  - Journal of chromatography. A
JID - 9318488
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
EDAT- 2000/03/18 09:00
MHDA- 2000/04/25 09:00
CRDT- 2000/03/18 09:00
PHST- 2000/03/18 09:00 [pubmed]
PHST- 2000/04/25 09:00 [medline]
PHST- 2000/03/18 09:00 [entrez]
AID - S0021-9673(99)01134-6 [pii]
AID - 10.1016/s0021-9673(99)01134-6 [doi]
PST - ppublish
SO  - J Chromatogr A. 2000 Feb 18;870(1-2):69-75. doi: 10.1016/s0021-9673(99)01134-6.

PMID- 5470057
OWN - NLM
STAT- MEDLINE
DCOM- 19701201
LR  - 20190503
IS  - 0007-0769 (Print)
IS  - 0007-0769 (Linking)
VI  - 32
IP  - 5
DP  - 1970 Sep
TI  - Giant peaked upright T waves in cerebrovascular accident.
PG  - 717-9
AB  - Tall upright T waves, with a maximal T/QRS ratio (in lead V4) of 1.32, appeared 
      in a 52-year-old patient after a cerebral haemorrhage which was confirmed at 
      necropsy. Hyperkalaemia during life and endocardial or myocardial damage were not 
      found.
FAU - Runge, P J
AU  - Runge PJ
FAU - Bousvaros, G
AU  - Bousvaros G
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Heart J
JT  - British heart journal
JID - 0370634
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/blood
MH  - Autopsy
MH  - Blood Pressure
MH  - Cerebral Hemorrhage/*physiopathology
MH  - *Electrocardiography
MH  - Humans
MH  - Hyperkalemia
MH  - Male
MH  - Middle Aged
MH  - Myocardium/pathology
MH  - Pulse
PMC - PMC487400
EDAT- 1970/09/01 00:00
MHDA- 1970/09/01 00:01
CRDT- 1970/09/01 00:00
PHST- 1970/09/01 00:00 [pubmed]
PHST- 1970/09/01 00:01 [medline]
PHST- 1970/09/01 00:00 [entrez]
AID - 10.1136/hrt.32.5.717 [doi]
PST - ppublish
SO  - Br Heart J. 1970 Sep;32(5):717-9. doi: 10.1136/hrt.32.5.717.

PMID- 6411052
OWN - NLM
STAT- MEDLINE
DCOM- 19830920
LR  - 20191031
IS  - 0276-5047 (Print)
IS  - 0276-5047 (Linking)
VI  - 3
IP  - 4
DP  - 1983 Jul-Aug
TI  - Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by 
      aspirin.
PG  - 383-8
AB  - Previous investigations have shown that ibuprofen inhibits the second wave of 
      platelet aggregation and blocks the conversion of 14C-arachidonic acid to 
      thromboxane. However, the influence of the drug on platelet function and 
      cyclooxygenase is transitory, lasting only 24 hours. The present study has taken 
      advantage of the short-lived influence of ibuprofen to study its interaction with 
      the long-term effects of aspirin. As expected, both aspirin and ibuprofen 
      suppressed platelet cyclooxygenase activity and function, but addition of aspirin 
      to ibuprofen-treated platelets did not increase the degree of inhibition in 
      vitro. Platelet function and prostaglandin synthesis recovered completely 26 
      hours following ingestion of ibuprofen, but remained compromised 26 hours after 
      taking aspirin. When 650 mg of aspirin was administered after ibuprofen, platelet 
      function and cyclooxygenase activity recovered as completely at 26 hours as did 
      platelets which had been exposed to ibuprofen alone. Thus, prior exposure to 
      ibuprofen in vivo completely protected cyclooxygenase from the irreversible 
      effects of aspirin. Our findings indicate that ibuprofen-like indomethacin and 
      other nonsteroidal antiinflammatory drugs react with the heme group of 
      cyclooxygenase to prevent arachidonic acid conversion. Since ibuprofen completely 
      blocks the effects of aspirin in platelets in vitro and in vivo, aspirin's 
      primary influence on inhibition of cyclooxygenase must also be through action on 
      the heme portion of the enzyme, rather than acetylation of the protein.
FAU - Rao, G H
AU  - Rao GH
FAU - Johnson, G G
AU  - Johnson GG
FAU - Reddy, K R
AU  - Reddy KR
FAU - White, J G
AU  - White JG
LA  - eng
GR  - HL-11880/HL/NHLBI NIH HHS/United States
GR  - HL-16833/HL/NHLBI NIH HHS/United States
GR  - HL-20695/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arteriosclerosis
JT  - Arteriosclerosis (Dallas, Tex.)
JID - 8401388
RN  - 0 (Arachidonic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 42VZT0U6YR (Heme)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/*enzymology
MH  - Cyclooxygenase Inhibitors
MH  - Dogs
MH  - Heme/metabolism
MH  - Humans
MH  - Ibuprofen/*pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandin-Endoperoxide Synthases/*blood
MH  - Thromboxane B2/biosynthesis
MH  - Time Factors
EDAT- 1983/07/01 00:00
MHDA- 1983/07/01 00:01
CRDT- 1983/07/01 00:00
PHST- 1983/07/01 00:00 [pubmed]
PHST- 1983/07/01 00:01 [medline]
PHST- 1983/07/01 00:00 [entrez]
AID - 10.1161/01.atv.3.4.383 [doi]
PST - ppublish
SO  - Arteriosclerosis. 1983 Jul-Aug;3(4):383-8. doi: 10.1161/01.atv.3.4.383.

PMID- 24057863
OWN - NLM
STAT- MEDLINE
DCOM- 20140623
LR  - 20181202
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 18
IP  - 6
DP  - 2013 Nov
TI  - Cardiovascular pharmacology core reviews: aspirin.
PG  - 505-13
LID - 10.1177/1074248413503043 [doi]
AB  - Acetylsalicylic acid, or aspirin, is perhaps the most well-studied drug in human 
      history, but controversy persists regarding both optimal dose and its use in the 
      primary prevention of atherothrombotic events. This article reviews the 
      following: the effect of aspirin upon the cyclooxygenase pathway; clinical trials 
      of aspirin for both secondary and primary prevention; prospective and 
      retrospective studies of aspirin dose; the potential interaction between aspirin 
      and ticagrelor; and the concept of aspirin resistance. It concludes with a review 
      of major society guidelines regarding aspirin and offers a perspective on the 
      evidence-based use of aspirin in clinical practice.
FAU - Gaglia, Michael A Jr
AU  - Gaglia MA Jr
AD  - 1Division of Cardiovascular Medicine, Keck School of Medicine, University of 
      Southern California, Los Angeles, CA, USA.
FAU - Clavijo, Leonardo
AU  - Clavijo L
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130919
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine/analogs & derivatives/pharmacology
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Resistance
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Primary Prevention/methods
MH  - Secondary Prevention/methods
MH  - Ticagrelor
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular diseases
OT  - drug resistance
OT  - primary prevention
OT  - secondary prevention
EDAT- 2013/09/24 06:00
MHDA- 2014/06/24 06:00
CRDT- 2013/09/24 06:00
PHST- 2013/09/24 06:00 [entrez]
PHST- 2013/09/24 06:00 [pubmed]
PHST- 2014/06/24 06:00 [medline]
AID - 1074248413503043 [pii]
AID - 10.1177/1074248413503043 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):505-13. doi: 
      10.1177/1074248413503043. Epub 2013 Sep 19.

PMID- 24507089
OWN - NLM
STAT- MEDLINE
DCOM- 20140929
LR  - 20220316
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 14
DP  - 2014 Feb 7
TI  - Aspirin use and knowledge in the community: a population- and health facility 
      based survey for measuring local health system performance.
PG  - 16
LID - 10.1186/1471-2261-14-16 [doi]
AB  - BACKGROUND: Little is known about the relationship between cardiovascular risk, 
      disease and actual use of aspirin in the community. METHODS: The Measuring 
      Disparities in Chronic Conditions (MDCC) study is a community and health 
      facility-based survey designed to track disparities in the delivery of health 
      interventions for common chronic diseases. MDCC includes a survey instrument 
      designed to collect detailed information about aspirin use. In King County, WA 
      between 2011 and 2012, we surveyed 4633 white, African American, or Hispanic 
      adults (45% home address-based sample, 55% health facility sample). We examined 
      self-reported counseling on, frequency of use and risks of aspirin for all 
      respondents. For a subgroup free of CAD or cerebral infarction that underwent 
      physical examination, we measured 10-year coronary heart disease risk and blood 
      salicylate concentration. RESULTS: Two in five respondents reported using aspirin 
      routinely while one in five with a history of CAD or cerebral infarction and 
      without contraindication did not report routine use of aspirin. Women with these 
      conditions used less aspirin than men (65.0% vs. 76.5%) and reported more health 
      problems that would make aspirin unsafe (29.4% vs. 21.2%). In a subgroup 
      undergoing phlebotomy a third of respondents with low cardiovascular risk used 
      aspirin routinely and only 4.6% of all aspirin users had no detectable salicylate 
      in their blood. CONCLUSIONS: In this large urban county where health care 
      delivery should be of high quality, there is insufficient aspirin use among those 
      with high cardiovascular risk or disease and routine aspirin use by many at low 
      risk. Further efforts are needed to promote shared-decision making between 
      patients and clinicians as well as inform the public about appropriate use of 
      routine aspirin to reduce the burden of atherosclerotic vascular disease.
FAU - Roth, Gregory A
AU  - Roth GA
AD  - Department of Medicine, Division of Cardiology, University of Washington, 
      Seattle, WA, USA. rothg@uw.edu.
FAU - Gillespie, Catherine W
AU  - Gillespie CW
FAU - Mokdad, Ali A
AU  - Mokdad AA
FAU - Shen, Danny D
AU  - Shen DD
FAU - Fleming, David W
AU  - Fleming DW
FAU - Stergachis, Andy
AU  - Stergachis A
FAU - Murray, Christopher J L
AU  - Murray CJ
FAU - Mokdad, Ali H
AU  - Mokdad AH
LA  - eng
PT  - Journal Article
DEP - 20140207
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/blood/*therapeutic use
MH  - Cardiovascular Agents/adverse effects/blood/*therapeutic use
MH  - Cardiovascular Diseases/blood/epidemiology/*prevention & control
MH  - *Community Health Services
MH  - Comorbidity
MH  - *Delivery of Health Care
MH  - Female
MH  - Health Behavior
MH  - Health Care Surveys
MH  - *Health Facilities
MH  - *Health Knowledge, Attitudes, Practice
MH  - Healthcare Disparities
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Quality Indicators, Health Care
MH  - Risk Assessment
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - *Urban Health Services
MH  - Washington/epidemiology
PMC - PMC3922250
EDAT- 2014/02/11 06:00
MHDA- 2014/09/30 06:00
CRDT- 2014/02/11 06:00
PHST- 2013/09/04 00:00 [received]
PHST- 2014/01/29 00:00 [accepted]
PHST- 2014/02/11 06:00 [entrez]
PHST- 2014/02/11 06:00 [pubmed]
PHST- 2014/09/30 06:00 [medline]
AID - 1471-2261-14-16 [pii]
AID - 10.1186/1471-2261-14-16 [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2014 Feb 7;14:16. doi: 10.1186/1471-2261-14-16.

PMID- 1340383
OWN - NLM
STAT- MEDLINE
DCOM- 19931206
LR  - 20160815
IS  - 0104-4230 (Print)
IS  - 0104-4230 (Linking)
VI  - 38
IP  - 4
DP  - 1992 Oct-Dec
TI  - [Primary erythromelalgia].
PG  - 228-30
AB  - Erythromelalgia is a rare disease characterized by intense erythema, burning pain 
      and increased temperature in the distal of the extremities. Primary forms and 
      secondary forms have been described, most commonly with essential thrombocythemia 
      and policythemia vera. The authors describe a fifteen year old patient with 
      primary erythromelalgia and discuss the pathogenic, clinical and therapeutic 
      features of this disease.
FAU - Pereira, I A
AU  - Pereira IA
AD  - Disciplina de Reumatologia do Hospital das Clínicas da Faculdade de Medicina da 
      Universidade de São Paulo.
FAU - Pereira, R M
AU  - Pereira RM
FAU - Borba, E F
AU  - Borba EF
FAU - Gonçalves, C R
AU  - Gonçalves CR
FAU - Yoshinari, N H
AU  - Yoshinari NH
FAU - Cossermelli, W
AU  - Cossermelli W
LA  - por
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Eritromelalgia primária.
PL  - Brazil
TA  - Rev Assoc Med Bras (1992)
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/therapeutic use
MH  - Erythromelalgia/*diagnosis/drug therapy
MH  - Humans
MH  - Male
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
PST - ppublish
SO  - Rev Assoc Med Bras (1992). 1992 Oct-Dec;38(4):228-30.

PMID- 1665284
OWN - NLM
STAT- MEDLINE
DCOM- 19920402
LR  - 20191021
VI  - 52
DP  - 1991
TI  - Antinociceptive activity of intracerebroventricular lysine acetylsalicylate: an 
      experimental study.
PG  - 5-6
AB  - We investigated the antinociceptive activity of Lysine Acetylsalicylate (LAS) 
      after intracerebroventricular (icv) injection in experimental animals. The effect 
      on tonic pain was studied by means of the Formalin test on 140 male Swiss mice. 
      In a first group of animals icv LAS was injected at different doses (0.25-0.5-1 
      mg in saline solution 5 microliters). A second group received icv morphine 1 
      microgram in 5 microliters saline, and finally a third control group received icv 
      5 microliters saline. The effect of the compounds on the Formalin test was 
      evaluated under blind conditions. Icv LAS had no effect on the nociceptive 
      behaviour at doses of 0.25 and 0.5 mg, while a reduction of the licking time was 
      evident after the injection of 1 mg of the drug. The time course and the degree 
      of the analgesic effect of icv LAS was investigated and compared to the effect of 
      icv morphine.
FAU - Meglio, M
AU  - Meglio M
AD  - Istituto di Neurochirurgia, Università Cattolica, Roma, Italy.
FAU - Cioni, B
AU  - Cioni B
FAU - Moles, A
AU  - Moles A
FAU - Puca, A
AU  - Puca A
FAU - Visocchi, M
AU  - Visocchi M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Austria
TA  - Acta Neurochir Suppl (Wien)
JT  - Acta neurochirurgica. Supplementum
JID - 0140560
RN  - 0 (Analgesics)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Brain/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Hindlimb/innervation
MH  - Injections, Intraventricular
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
MH  - Mice
MH  - Nociceptors/*drug effects
MH  - Synaptic Transmission/drug effects
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1007/978-3-7091-9160-6_2 [doi]
PST - ppublish
SO  - Acta Neurochir Suppl (Wien). 1991;52:5-6. doi: 10.1007/978-3-7091-9160-6_2.

PMID- 6752878
OWN - NLM
STAT- MEDLINE
DCOM- 19821218
LR  - 20151119
IS  - 0301-1518 (Print)
IS  - 0301-1518 (Linking)
VI  - 11
IP  - 33
DP  - 1982 Aug 28
TI  - [Comparative therapeutic activity of pirprofen and acetylsalicylic acid in 
      rheumatoid arthritis. A 12-month controlled multicenter study].
PG  - 2517-21
AB  - This double-blind cooperative study comparing pirprofen and acetylsalicylic acid 
      (ASA) in the treatment of rheumatoid arthritis was conducted in 12 centres and 
      involved 342 patients distributed throughout the United States. The patients were 
      randomized to either pirprofen 200 mg four times a day or ASA 900 mg four times a 
      day. The drugs were administered for 52 weeks. Nine standard clinical criteria 
      were used for assessment of the therapeutic results by the investigators and by 
      the patients themselves. Fifty-five % of the total patient population reported 
      that they were highly satisfied with pirprofen, as against 47% with ASA. The 
      investigators preferred pirprofen in 51% of the cases and ASA in 38% (p less than 
      0.05). Side effects (tinnitus, gastrointestinal disorders) were more frequent in 
      the ASA group than in the pirprofen group. During the 52-week treatment-period, 
      biological alterations were only observed in two patients (1 on pirprofen, 1 on 
      ASA).
FAU - Roth, H
AU  - Roth H
FAU - Levasseur, Y J
AU  - Levasseur YJ
FAU - Ryan, R
AU  - Ryan R
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Activité thérapeutique comparée du pirprofène et de l'acide acétylsalicylique 
      dans le traitement de la polyarthrite rhumatoïde. Etude multicentrique contrôlée 
      sur douze mois.
PL  - France
TA  - Nouv Presse Med
JT  - La Nouvelle presse medicale
JID - 0312552
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - T7KN291890 (pirprofen)
SB  - IM
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Phenylpropionates/adverse effects/*therapeutic use
EDAT- 1982/08/28 00:00
MHDA- 1982/08/28 00:01
CRDT- 1982/08/28 00:00
PHST- 1982/08/28 00:00 [pubmed]
PHST- 1982/08/28 00:01 [medline]
PHST- 1982/08/28 00:00 [entrez]
PST - ppublish
SO  - Nouv Presse Med. 1982 Aug 28;11(33):2517-21.

PMID- 12552715
OWN - NLM
STAT- MEDLINE
DCOM- 20040224
LR  - 20141120
IS  - 1001-5515 (Print)
IS  - 1001-5515 (Linking)
VI  - 16
IP  - 4
DP  - 1999 Dec
TI  - [Studies on degradation of poly-(propyl,3-hydroxypropyl)-DL-asparamide and 
      release of conjugate linking aspirin in vivo and in vitro].
PG  - 423-8
AB  - Two polyasparamide derivants having different hydrophilicities were selected to 
      be degraded in vivo and in vitro. The results demonstrate that the degradation 
      process of polyasparamide is enzymatic hydrolysis. Materials with different 
      hydrophobicities are different in degradation rate and the same material has 
      different metabolic rates in the planting position, kidney and liver. The release 
      results of two polymeric drugs indicate that protease is of advantage to release 
      of drug, and hydrophobicity of material is also an advantage to the release.
FAU - Zhou, T
AU  - Zhou T
AD  - Department of Food Science and Engineering, Ningbo University, Ningbo 315211.
FAU - Wang, B
AU  - Wang B
FAU - Tang, G
AU  - Tang G
FAU - Chen, Q
AU  - Chen Q
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
JT  - Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = 
      Shengwu yixue gongchengxue zazhi
JID - 9426398
RN  - 0 (Drug Carriers)
RN  - 0 (Peptides)
RN  - 0 (poly(3-hydroxypropyl-propyl)asparamide)
RN  - 30KYC7MIAI (Aspartic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspartic Acid/*analogs & derivatives/chemistry/*pharmacokinetics
MH  - Aspirin/chemistry/*pharmacokinetics
MH  - Drug Carriers
MH  - Female
MH  - In Vitro Techniques
MH  - Mice
MH  - Peptides/chemistry/*pharmacokinetics
MH  - Rabbits
EDAT- 2003/01/30 04:00
MHDA- 2004/02/26 05:00
CRDT- 2003/01/30 04:00
PHST- 2003/01/30 04:00 [pubmed]
PHST- 2004/02/26 05:00 [medline]
PHST- 2003/01/30 04:00 [entrez]
PST - ppublish
SO  - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 1999 Dec;16(4):423-8.

PMID- 23636924
OWN - NLM
STAT- MEDLINE
DCOM- 20140114
LR  - 20130502
IS  - 1939-2869 (Electronic)
IS  - 0891-1150 (Linking)
VI  - 80
IP  - 5
DP  - 2013 May
TI  - Aspirin: its risks, benefits, and optimal use in preventing cardiovascular 
      events.
PG  - 318-26
LID - 10.3949/ccjm.80a.12146 [doi]
AB  - Aspirin has a well-established role in preventing adverse events in patients with 
      known cardiovascular disease. However, its benefit in patients without a history 
      of cardiovascular disease is not as clear, particularly in people with diabetes, 
      in women, and in the elderly. Recent studies have provided insight into the risks 
      of aspirin use, particularly bleeding, compared with its benefits in these 
      subgroups.
FAU - Park, Ki
AU  - Park K
AD  - Division of Cardiovascular Medicine, University of Florida, Gainesville, FL 
      32610, USA.
FAU - Bavry, Anthony A
AU  - Bavry AA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cleve Clin J Med
JT  - Cleveland Clinic journal of medicine
JID - 8703441
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Cleve Clin J Med. 2013 Jul;80(7):435
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Primary Prevention/*methods
EDAT- 2013/05/03 06:00
MHDA- 2014/01/15 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/05/03 06:00 [entrez]
PHST- 2013/05/03 06:00 [pubmed]
PHST- 2014/01/15 06:00 [medline]
AID - 80/5/318 [pii]
AID - 10.3949/ccjm.80a.12146 [doi]
PST - ppublish
SO  - Cleve Clin J Med. 2013 May;80(5):318-26. doi: 10.3949/ccjm.80a.12146.

PMID- 3632441
OWN - NLM
STAT- MEDLINE
DCOM- 19871005
LR  - 20190704
IS  - 0003-9950 (Print)
IS  - 0003-9950 (Linking)
VI  - 105
IP  - 9
DP  - 1987 Sep
TI  - Lack of evidence for aspirin use and prevention of cataracts.
PG  - 1229-31
AB  - A population-based cross-sectional survey of 838 men aged 30 years and over was 
      conducted to examine the effect of aspirin, and other potential risk factors, on 
      the prevalence of cataracts. Lens opacities were graded on clinical examination 
      for location (cortical, nuclear, and posterior or subcapsular) and severity. The 
      results do not support the claim that large doses of aspirin, or frequent use of 
      aspirin, protects against or retards the growth of lens opacities.
FAU - West, S K
AU  - West SK
FAU - Muñoz, B E
AU  - Muñoz BE
FAU - Newland, H S
AU  - Newland HS
FAU - Emmett, E A
AU  - Emmett EA
FAU - Taylor, H R
AU  - Taylor HR
LA  - eng
GR  - EY04547/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Ophthalmol
JT  - Archives of ophthalmology (Chicago, Ill. : 1960)
JID - 7706534
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aspirin/*therapeutic use
MH  - Cataract/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - Regression Analysis
EDAT- 1987/09/01 00:00
MHDA- 1987/09/01 00:01
CRDT- 1987/09/01 00:00
PHST- 1987/09/01 00:00 [pubmed]
PHST- 1987/09/01 00:01 [medline]
PHST- 1987/09/01 00:00 [entrez]
AID - 10.1001/archopht.1987.01060090087034 [doi]
PST - ppublish
SO  - Arch Ophthalmol. 1987 Sep;105(9):1229-31. doi: 
      10.1001/archopht.1987.01060090087034.

PMID- 758857
OWN - NLM
STAT- MEDLINE
DCOM- 19790226
LR  - 20190514
IS  - 0003-4932 (Print)
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 189
IP  - 1
DP  - 1979 Jan
TI  - Effects of aspirin and dextran on patency of bovine heterografts in the venous 
      system.
PG  - 116-9
AB  - The effect of short-term treatment with aspirin or dextran on the patency of 
      bovine heterografts in the venous system was investigated. Animals treated 
      preoperatively and for three days postoperatively with either aspirin (600 mgm 
      BID) or low molecular weight dextran (500 cc/day) had statistically significant 
      increased graft patency as compared to controls during the treatment interval. 
      Significance was lost, however, after cessation of therapy. These results suggest 
      that either aspirin or low molecular weight dextran would be useful adjuvants to 
      venous reconstruction. If used in the venous system, bovine heterografts might be 
      expected to yield better short term patency with adjuvant therapy employing 
      either dextran or aspirin.
FAU - Ricotta, J J
AU  - Ricotta JJ
FAU - Collins, G J
AU  - Collins GJ
FAU - Rich, N M
AU  - Rich NM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 0 (Dextrans)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cattle
MH  - Dextrans/administration & dosage/*therapeutic use
MH  - Dogs
MH  - Drug Evaluation, Preclinical
MH  - Female
MH  - Femoral Vein/*surgery
MH  - Follow-Up Studies
MH  - Male
MH  - Thrombophlebitis/*prevention & control
MH  - *Transplantation, Heterologous
MH  - Veins/*transplantation
PMC - PMC1396933
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1097/00000658-197901000-00022 [doi]
PST - ppublish
SO  - Ann Surg. 1979 Jan;189(1):116-9. doi: 10.1097/00000658-197901000-00022.

PMID- 8714450
OWN - NLM
STAT- MEDLINE
DCOM- 19961122
LR  - 20131121
IS  - 0213-4853 (Print)
IS  - 0213-4853 (Linking)
VI  - 10 Suppl 2
DP  - 1995 Dec
TI  - [Antithrombotic treatment in acute ischemia stroke].
PG  - 48-54
AB  - Antithrombotic drugs (especially heparin and aspirin) are widely used to treat 
      patients during the acute phase of ischemic stroke, yet there is no evidence of 
      any beneficial effect on the course of the disease. Although these drugs can 
      reduce the risk of such complications as deep venous thrombosis and, possibly, 
      the number of recurrences of stroke, they can also give rise to systemic or 
      cerebral hemorrhage. Given the uncertainty about the efficacy and safety of 
      antithrombotic drugs, and specifically about the risk/benefit ratio, large 
      clinical trials are needed to determine the indications for their use in the 
      management of acute ischemic stroke. We stress the importance, because of its 
      magnitude, of the International Stroke Trial (IST), the results of which will be 
      available in 1996.
FAU - Díez-Tejedor, E
AU  - Díez-Tejedor E
AD  - Servicio de Neurología, Hospital Universitario La Paz, Universidad Autónoma, 
      Madrid.
FAU - Alonso de Leciñana, M
AU  - Alonso de Leciñana M
FAU - Counsell, C
AU  - Counsell C
FAU - Sandercock, P
AU  - Sandercock P
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Tratamiento antitrómbico en la fase aguda de la isquemia cerebral.
PL  - Spain
TA  - Neurologia
JT  - Neurologia (Barcelona, Spain)
JID - 9005460
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
RF  - 42
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
PST - ppublish
SO  - Neurologia. 1995 Dec;10 Suppl 2:48-54.

PMID- 11741515
OWN - NLM
STAT- MEDLINE
DCOM- 20030523
LR  - 20131121
IS  - 1671-4083 (Print)
IS  - 1671-4083 (Linking)
VI  - 22
IP  - 2
DP  - 2001 Feb
TI  - Effect of copper aspirinate on contraction of isolated rabbit aortic strips.
PG  - 121-4
AB  - AIM: To investigate the effect of copper aspirinate on contraction of vascular 
      smooth muscle. METHODS: Isolated rabbit aortic strips, including intact 
      endothelium strips and endothelial cell-denuded aortic strips, were suspended in 
      modified Krebs'solution to determine effects of copper aspirinate on the 
      contraction induced by norepinephrine (NE), KCl, and CaCl2, while CuSO4, aspirin, 
      and vehicle were used as controls. RESULTS: Copper aspirinate possessed 
      antagonistic effect on contraction of rabbit aortic strips induced by NE with an 
      IC50 value of 31 nmol/L, while CuSO4 had much l ess antagonistic effect with an 
      IC50 value of 0.29 micromol/L, and aspirin did not work in the same preparation. 
      No effect of copper aspirinate were found on the contraction induced by KCl and 
      CaCl2. Effects on endothelial cell denuded aortic strips were similar to those in 
      the normal aortic strips. CONCLUSION: Copper aspirinate possessed different 
      effects from aspirin and CuSO4 on vascular smooth muscles. It inhibited 
      contraction induced by NE with an activity stronger than CuSO4 at the same Cu2+ 
      concentration, this action might be due to blockade of the receptor-operated Ca2+ 
      channels, and it might not be linked to the endothelium.
FAU - Yang, W M
AU  - Yang WM
AD  - Yunnan Pharmacological Laboratories of Natural Products, Kunming Medical College, 
      Kunming 650031, China. YWM2000@yahoo.com
FAU - Shen, Z Q
AU  - Shen ZQ
FAU - Chen, Z H
AU  - Chen ZH
FAU - Li, L
AU  - Li L
FAU - Peng, F
AU  - Peng F
FAU - Liu, W P
AU  - Liu WP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Acta Pharmacol Sin
JT  - Acta pharmacologica Sinica
JID - 100956087
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - 660YQ98I10 (Potassium Chloride)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Animals
MH  - Aorta/drug effects
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Female
MH  - Male
MH  - Muscle Contraction/*drug effects
MH  - Muscle, Smooth, Vascular/*drug effects
MH  - Norepinephrine/antagonists & inhibitors
MH  - Potassium Chloride/antagonists & inhibitors
MH  - Rabbits
EDAT- 2001/12/14 10:00
MHDA- 2003/05/24 05:00
CRDT- 2001/12/14 10:00
PHST- 2001/12/14 10:00 [pubmed]
PHST- 2003/05/24 05:00 [medline]
PHST- 2001/12/14 10:00 [entrez]
PST - ppublish
SO  - Acta Pharmacol Sin. 2001 Feb;22(2):121-4.

PMID- 6382343
OWN - NLM
STAT- MEDLINE
DCOM- 19841024
LR  - 20191031
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 15
IP  - 1
DP  - 1984 Jul
TI  - Effects of aspirin dosage and time of administration on arterial prostacyclin 
      production and platelet aggregation in rats.
PG  - 91-102
AB  - Previously we reported that electrically-induced carotid artery thrombosis in 
      anesthetized rats was prevented by 3.3 or 10 mg/kg aspirin (ASA) given i.v. 10 
      min before injury but not by 1.7, 20 or 100 mg/kg and protection was lost by 
      delaying injury to 20 min (Haemostasis 13:42, 1983). Here, collagen-induced 
      platelet aggregation and arterial prostacyclin-generating activity, measured by 
      RIA for 6 keto-PGF1 alpha and by human platelet aggregation bioassay, were 
      studied ex vivo after i.v. ASA to anesthetized rats. In all cases where platelet 
      aggregation was inhibited less than 50%, no protection had been observed (1.7 
      mg/kg at 10 min, 3.3 at 20 min, 20 at 10 min). In the two cases where protection 
      had been observed, platelet aggregation was inhibited by about 75% or more and in 
      one, prostacyclin activity was about 50% of normal (3.3 mg/kg at 10 min). Thus in 
      five of six dose-time combinations tested, antithrombotic protection could be 
      explained by a requirement for about 50% of normal prostacyclin activity and 
      about 75% of inhibition of collagen aggregation. Aberrant findings are discussed 
      in the light of knowledge of salicylate/aspirin competition for cyclooxygenase.
FAU - Philp, R B
AU  - Philp RB
FAU - Paul, M L
AU  - Paul ML
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 9007-34-5 (Collagen)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteries/*drug effects/metabolism
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biological Assay
MH  - Collagen/pharmacology
MH  - Drug Administration Schedule
MH  - Epoprostenol/*biosynthesis
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Radioimmunoassay
MH  - Rats
MH  - Thrombosis/prevention & control
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
AID - 10.1016/0262-1746(84)90059-3 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1984 Jul;15(1):91-102. doi: 
      10.1016/0262-1746(84)90059-3.

PMID- 14711910
OWN - NLM
STAT- MEDLINE
DCOM- 20040116
LR  - 20220330
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 350
IP  - 2
DP  - 2004 Jan 8
TI  - Efficacy and safety of low-dose aspirin in polycythemia vera.
PG  - 114-24
AB  - BACKGROUND: The use of aspirin for the prevention of thrombotic complications in 
      polycythemia vera is controversial. METHODS: We enrolled 518 patients with 
      polycythemia vera, no clear indication for aspirin treatment, and no 
      contraindication to such treatment in a double-blind, placebo-controlled, 
      randomized trial to assess the safety and efficacy of prophylaxis with low-dose 
      aspirin (100 mg daily). The two primary end points were the cumulative rate of 
      nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular 
      causes and the cumulative rate of nonfatal myocardial infarction, nonfatal 
      stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular 
      causes. The mean duration of follow-up was about three years. RESULTS: Treatment 
      with aspirin, as compared with placebo, reduced the risk of the combined end 
      point of nonfatal myocardial infarction, nonfatal stroke, or death from 
      cardiovascular causes (relative risk, 0.41; 95 percent confidence interval, 0.15 
      to 1.15; P=0.09) and the risk of the combined end point of nonfatal myocardial 
      infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or 
      death from cardiovascular causes (relative risk, 0.40; 95 percent confidence 
      interval, 0.18 to 0.91; P=0.03). Overall mortality and cardiovascular mortality 
      were not reduced significantly. The incidence of major bleeding episodes was not 
      significantly increased in the aspirin group (relative risk, 1.62; 95 percent 
      confidence interval, 0.27 to 9.71). CONCLUSIONS: Low-dose aspirin can safely 
      prevent thrombotic complications in patients with polycythemia vera who have no 
      contraindications to such treatment.
CI  - Copyright 2004 Massachusetts Medical Society
FAU - Landolfi, Raffaele
AU  - Landolfi R
AD  - Catholic University School of Medicine, Rome, Italy. rlandolfi@rm.unicatt.it
FAU - Marchioli, Roberto
AU  - Marchioli R
FAU - Kutti, Jack
AU  - Kutti J
FAU - Gisslinger, Heinz
AU  - Gisslinger H
FAU - Tognoni, Gianni
AU  - Tognoni G
FAU - Patrono, Carlo
AU  - Patrono C
FAU - Barbui, Tiziano
AU  - Barbui T
CN  - European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2004 Jan 8;350(2):99-101. PMID: 14711906
CIN - N Engl J Med. 2004 Apr 15;350(16):1683-5; author reply 1683-5. PMID: 15084704
CIN - N Engl J Med. 2004 Apr 15;350(16):1683-5; author reply 1683-5. PMID: 15088322
CIN - N Engl J Med. 2004 Apr 15;350(16):1683-5; author reply 1683-5. PMID: 15088323
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/epidemiology/mortality
MH  - Disease-Free Survival
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Polycythemia Vera/*complications/drug therapy
MH  - Risk Factors
MH  - Thrombosis/etiology/*prevention & control
EDAT- 2004/01/09 05:00
MHDA- 2004/01/17 05:00
CRDT- 2004/01/09 05:00
PHST- 2004/01/09 05:00 [pubmed]
PHST- 2004/01/17 05:00 [medline]
PHST- 2004/01/09 05:00 [entrez]
AID - 350/2/114 [pii]
AID - 10.1056/NEJMoa035572 [doi]
PST - ppublish
SO  - N Engl J Med. 2004 Jan 8;350(2):114-24. doi: 10.1056/NEJMoa035572.

PMID- 33075272
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20201222
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 173
IP  - 8
DP  - 2020 Oct 20
TI  - Treatment effect of aspirin for primary prevention does not differ according to 
      baseline ASCVD risk.
PG  - JC39
LID - 10.7326/ACPJ202010200-039 [doi]
AB  - Nudy M, Cooper J, Ghahramani M, et al. Aspirin for primary atherosclerotic 
      cardiovascular disease prevention as baseline risk increases: a meta-regression 
      analysis. Am J Med. 2020;133:1056-64. 32445718.
FAU - Haley, Sean P
AU  - Haley SP
AD  - Medical University of South Carolina, Charleston, South Carolina, USA (S.P.H., 
      A.C.).
FAU - Chessman, Alexander
AU  - Chessman A
AD  - Medical University of South Carolina, Charleston, South Carolina, USA (S.P.H., 
      A.C.).
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Am J Med. 2020 Sep;133(9):1056-1064. PMID: 32445718
MH  - Aspirin/therapeutic use
MH  - *Atherosclerosis/prevention & control
MH  - *Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - Primary Prevention
MH  - Regression Analysis
EDAT- 2020/10/20 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/10/19 20:08
PHST- 2020/10/19 20:08 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
AID - 10.7326/ACPJ202010200-039 [doi]
PST - ppublish
SO  - Ann Intern Med. 2020 Oct 20;173(8):JC39. doi: 10.7326/ACPJ202010200-039.

PMID- 26009747
OWN - NLM
STAT- MEDLINE
DCOM- 20150723
LR  - 20181202
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Print)
IS  - 0094-3509 (Linking)
VI  - 64
IP  - 5
DP  - 2015 May
TI  - Another good reason to recommend low-dose aspirin.
PG  - 301-3
AB  - Evidence shows that daily low-dose aspirin during pregnancy can safely lower the 
      risk of preeclampsia and other adverse outcomes.
FAU - Oyola, Sonia
AU  - Oyola S
AD  - University of Chicago, Department of Family Medicine, IL, USA.
FAU - Kirley, Katherine
AU  - Kirley K
AD  - University of Chicago, Department of Family Medicine, IL, USA.
LA  - eng
GR  - UL1 RR024999/RR/NCRR NIH HHS/United States
GR  - UL1RR024999/RR/NCRR NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Ann Intern Med. 2014 May 20;160(10):695-703. PMID: 24711050
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*drug therapy
MH  - Pregnancy
PMC - PMC4443891
EDAT- 2015/05/27 06:00
MHDA- 2015/07/24 06:00
CRDT- 2015/05/27 06:00
PHST- 2015/05/27 06:00 [entrez]
PHST- 2015/05/27 06:00 [pubmed]
PHST- 2015/07/24 06:00 [medline]
AID - jfp_6405o [pii]
AID - jfp_6405l [pii]
PST - ppublish
SO  - J Fam Pract. 2015 May;64(5):301-3.

PMID- 7495235
OWN - NLM
STAT- MEDLINE
DCOM- 19960111
LR  - 20180510
IS  - 0002-9165 (Print)
IS  - 0002-9165 (Linking)
VI  - 62
IP  - 6 Suppl
DP  - 1995 Dec
TI  - Vitamin E plus aspirin compared with aspirin alone in patients with transient 
      ischemic attacks.
PG  - 1381S-1384S
LID - 10.1093/ajcn/62.6.1381S [doi]
AB  - One hundred patients with transient ischemic attacks, minor strokes, or residual 
      ischemic neurologic deficits were enrolled in a double-blind, randomized study 
      comparing the effects of aspirin plus vitamin E [0.4 g (400 IU)/d; n = 52] with 
      aspirin alone (325 mg; n = 48). The patients received study medication for 2 y or 
      until they reached a termination point. Preliminary results show a significant 
      reduction in the incidence of ischemic events in patients in the vitamin E plus 
      aspirin group compared with patients taking only aspirin. There was no 
      significant difference in the incidence of hemorrhagic stroke although both 
      patients who developed it were taking vitamin E. Platelet adhesion was also 
      measured in a randomized subgroup of both study populations by using collagen III 
      as the adhesive surface. There was a highly significant reduction in platelet 
      adhesiveness in patients who were taking vitamin E plus aspirin compared with 
      those taking aspirin only. Measurement of alpha-tocopherol concentrations 
      confirmed compliance of the patients with the medication schedule, showing a near 
      doubling of serum concentrations of alpha-tocopherol. We concluded that the 
      combination of vitamin E and a platelet antiaggregating agent (eg, aspirin) 
      significantly enhances the efficacy of the preventive treatment regimen in 
      patients with transient ischemic attacks and other ischemic cerebrovascular 
      problems.
FAU - Steiner, M
AU  - Steiner M
AD  - Division of Hematology/Oncology, Memorial Hospital of Rhode Island, Pawtucket, 
      USA.
FAU - Glantz, M
AU  - Glantz M
FAU - Lekos, A
AU  - Lekos A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Vitamin E/*administration & dosage/blood
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
AID - 10.1093/ajcn/62.6.1381S [doi]
PST - ppublish
SO  - Am J Clin Nutr. 1995 Dec;62(6 Suppl):1381S-1384S. doi: 10.1093/ajcn/62.6.1381S.

PMID- 27889668
OWN - NLM
STAT- MEDLINE
DCOM- 20170523
LR  - 20171208
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 134
DP  - 2017 Feb 5
TI  - Drug-protein binding of Danhong injection and the potential influence of drug 
      combination with aspirin: Insight by ultrafiltration LC-MS and molecular 
      modeling.
PG  - 100-107
LID - S0731-7085(16)30503-9 [pii]
LID - 10.1016/j.jpba.2016.11.028 [doi]
AB  - Danhong injection (DHI) is a widely used Chinese medicine injection (CMI) for the 
      clinical treatment of cardiovascular and cerebrovascular diseases. In this study, 
      a simple and efficient in vitro method based on ultrafiltration LC-MS and 
      molecular modeling has been developed to study the human serum albumin (HSA) 
      binding of the compounds in DHI. Seven major components including protocatechuic 
      aldehyde, p-coumaric acid, salvianolic acid D, rosmarinic acid, salvianolic acid 
      E, lithospermic acid and salvianolic acid B were identified as HSA ligands and 
      their binding degrees in the proposed non-saturated model were 26.17, 37.69, 
      99.77, 91.78, 96.91, 99.42 and 98.10%, respectively. Considering the drug-HSA 
      binding property of the compounds in DHI may change during drug combination 
      therapy, competitive binding assay was carried out to evaluate the influence of 
      aspirin on the DHI-HSA binding. Experimental results revealed that the 
      salvianolic acids in DHI had stronger binding ability to HSA than sodium 
      salicylate. To further verify the results above, molecular modeling and probe 
      displacement assay were conducted to investigate the optimum binding site and 
      binding affinity of the ligands on HSA. Our findings suggested that the 
      established method could be a powerful tool to study the drug-HSA binding 
      property of CMIs.
CI  - Copyright © 2016 Elsevier B.V. All rights reserved.
FAU - Zhu, Junfeng
AU  - Zhu J
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR 
      China.
FAU - Yi, Xiaojiao
AU  - Yi X
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR 
      China.
FAU - Huang, Peng
AU  - Huang P
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR 
      China.
FAU - Chen, Shuqing
AU  - Chen S
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR 
      China.
FAU - Wu, Yongjiang
AU  - Wu Y
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR 
      China. Electronic address: yjwu@zju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20161118
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Serum Albumin)
RN  - 0 (danhong)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/*metabolism
MH  - Chromatography, Liquid/methods
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/*analysis/*metabolism
MH  - Humans
MH  - Mass Spectrometry/methods
MH  - Models, Molecular
MH  - Protein Binding/physiology
MH  - Serum Albumin/analysis/metabolism
MH  - Tandem Mass Spectrometry/*methods
MH  - Ultrafiltration/methods
OTO - NOTNLM
OT  - Aspirin
OT  - Danhong injection
OT  - Drug-protein binding
OT  - Human serum albumin
OT  - Molecular modeling
OT  - Ultrafiltration LC–MS
EDAT- 2016/11/28 06:00
MHDA- 2017/05/24 06:00
CRDT- 2016/11/28 06:00
PHST- 2016/09/02 00:00 [received]
PHST- 2016/11/03 00:00 [revised]
PHST- 2016/11/05 00:00 [accepted]
PHST- 2016/11/28 06:00 [pubmed]
PHST- 2017/05/24 06:00 [medline]
PHST- 2016/11/28 06:00 [entrez]
AID - S0731-7085(16)30503-9 [pii]
AID - 10.1016/j.jpba.2016.11.028 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2017 Feb 5;134:100-107. doi: 10.1016/j.jpba.2016.11.028. 
      Epub 2016 Nov 18.

PMID- 15671997
OWN - NLM
STAT- MEDLINE
DCOM- 20050303
LR  - 20220331
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 192
IP  - 1
DP  - 2005 Jan
TI  - Heparin and aspirin attenuate placental apoptosis in vitro: implications for 
      early pregnancy failure.
PG  - 23-30
AB  - OBJECTIVE: Live birth rates are increased by treatment with heparin and aspirin 
      in cases of poor pregnancy outcome such as antiphospholipid syndrome. Both drugs 
      may attenuate miscarriage by inhibiting aberrant coagulation or by modulating 
      trophoblast apoptosis. Here we assessed their roles in trophoblast apoptosis in 
      vitro. STUDY DESIGN: BeWo cells and placental villi were cultured in sera from 
      women with successful or failing in vitro fertilization, with and without heparin 
      or aspirin. Apoptosis was assessed by using DNA laddering, cytokeratin 18 
      neoepitope formation, Bcl-2, and caspase 7 expression. RESULTS: In BeWo cells, 
      sera from in vitro fertilization failure increased trophoblast apoptosis, whereas 
      heparin and aspirin reversed these effects. In villous trophoblast, heparin 
      increased Bcl-2 and cytokeratin 18 protein expression. Heparin and aspirin 
      inhibited DNA laddering. CONCLUSION: Heparin and aspirin modulate trophoblast 
      apoptosis suggesting a direct impact on trophoblast biology, thus providing an 
      additional mechanism to explain the clinical benefits of heparin and aspirin on 
      recurrent pregnancy loss.
FAU - Bose, Patrick
AU  - Bose P
AD  - Department of Anatomy II, University Hospital RWTH, Aachen, Germany.
FAU - Black, Simon
AU  - Black S
FAU - Kadyrov, Mamed
AU  - Kadyrov M
FAU - Weissenborn, Ute
AU  - Weissenborn U
FAU - Neulen, Joseph
AU  - Neulen J
FAU - Regan, Lesley
AU  - Regan L
FAU - Huppertz, Berthold
AU  - Huppertz B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/pathology/prevention & control
MH  - Anticoagulants/administration & dosage/*pharmacology/therapeutic use
MH  - Apoptosis
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Cell Line/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fertilization in Vitro
MH  - Heparin/administration & dosage/*pharmacology/therapeutic use
MH  - Humans
MH  - Placenta/*drug effects
MH  - Placenta Diseases/pathology/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/pathology/*prevention & control
MH  - Trophoblasts/drug effects
EDAT- 2005/01/27 09:00
MHDA- 2005/03/04 09:00
CRDT- 2005/01/27 09:00
PHST- 2005/01/27 09:00 [pubmed]
PHST- 2005/03/04 09:00 [medline]
PHST- 2005/01/27 09:00 [entrez]
AID - S000293780401049X [pii]
AID - 10.1016/j.ajog.2004.09.029 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2005 Jan;192(1):23-30. doi: 10.1016/j.ajog.2004.09.029.

PMID- 11779889
OWN - NLM
STAT- MEDLINE
DCOM- 20020201
LR  - 20221207
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 33
IP  - 1
DP  - 2002 Jan
TI  - Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke 
      patients.
PG  - 57-60
AB  - BACKGROUND AND PURPOSE: The aim of the study was to evaluate the relationship 
      between daily aspirin use and urinary excretion of a stable thromboxane 
      metabolite, 11-dehydrothromboxane B(2) (11-DTB2), in African American stroke 
      patients. METHODS: Subjects were a subgroup of those screened for the African 
      American Antiplatelet Stroke Prevention Study. Subjects were within 4 months of 
      noncardioembolic ischemic stroke and were not being treated with anticoagulants. 
      Antithrombotic therapy at the time of urine collection varied according to the 
      practice patterns of various attending physicians who treated the patients during 
      their acute strokes. 11-DTB2 was measured by enzyme immunoassay in random urine 
      samples 1 to 4 months after the stroke. RESULTS: Eighty-seven of 92 patients 
      enrolled were able to give a urine sample at the time of enrollment. There were 
      51 men and 36 women aged 36 to 87 (mean 62) years. On the basis of antithrombotic 
      treatment before the sample collection, we divided patients into 4 groups: (1) 16 
      patients treated with no aspirin (no antithrombotic drugs [n=4] or ticlopidine 
      [n=12]), (2) 21 patients treated with 81 to 325 mg aspirin per day (81 mg/d 
      [n=2], 325 mg/d [n=19]), (3) 20 patients treated with 650 mg aspirin per day, and 
      (4) 30 patients treated with 975 to 1300 mg aspirin per day (975 mg/d [n=2] and 
      1300 mg/d [n=28]). In patients taking daily aspirin at any dose, the median 
      urinary 11-DTB2 was 783 pg/mg creatinine compared with 1386 pg/mg creatinine in 
      patients not taking daily aspirin (P=0.01 by Wilcoxon rank sum test). In 
      multivariate regression analysis, aspirin use remained significantly associated 
      with lower urinary 11-DTB2 (P=0.008). There was no dose-response effect between 
      the 3 aspirin dose groups and urinary 11-DTB2 (P=0.70). CONCLUSIONS: In African 
      American stroke patients, aspirin use is associated with significantly lower 
      urinary 11-DTB2 independent of other vascular factors, and there does not appear 
      to be a dose-response effect for aspirin doses of 325 to 1300 mg daily. The 
      clinical significance of these finding remains to be determined.
FAU - Bruno, Askiel
AU  - Bruno A
AD  - Indiana University School of Medicine, Indianapolis, IN 46202-5111, USA. 
      abruno@iupui.edu
FAU - McConnell, Joseph P
AU  - McConnell JP
FAU - Mansbach, Harry H 3rd
AU  - Mansbach HH 3rd
FAU - Cohen, Stanley N
AU  - Cohen SN
FAU - Tietjen, Gretchen E
AU  - Tietjen GE
FAU - Bang, Nils U
AU  - Bang NU
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Fibrinolytic Agents)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - *Black People
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*pharmacology/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Stroke/*ethnology/prevention & control/*urine
MH  - Thromboxane B2/*analogs & derivatives/*urine
EDAT- 2002/01/10 10:00
MHDA- 2002/02/02 10:01
CRDT- 2002/01/10 10:00
PHST- 2002/01/10 10:00 [pubmed]
PHST- 2002/02/02 10:01 [medline]
PHST- 2002/01/10 10:00 [entrez]
AID - 10.1161/hs0102.102010 [doi]
PST - ppublish
SO  - Stroke. 2002 Jan;33(1):57-60. doi: 10.1161/hs0102.102010.

PMID- 1166983
OWN - NLM
STAT- MEDLINE
DCOM- 19751211
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 83
IP  - 4
DP  - 1975 Oct
TI  - Aspirin and lymphocyte transformation.
PG  - 509-11
AB  - Twelve healthy subjects were placed on aspirin in a dosage of 600 mg five times 
      daily for 14 days. The capability of their lymphocytes in culture to incorporate 
      3H-thymidine in response to phytohemagglutinin and allogeneic lymphocytes 
      (one-way mixed lymphocyte culture) was measured before and after the course of 
      aspirin. The results were compared with those obtained simultaneously from 
      non-aspirin-treated control subjects. Statistical analysis showed no significant 
      differences between lymphocyte response in the pretreatment and posttreatment 
      periods or between aspirin-treated and non-aspirin-treated subjects. In contrast 
      to previous reports of lymphocyte suppression resulting from addition of aspirin 
      directly to lymphocyte culture and from orally administered aspirin, we conclude 
      that comparable dose ranges in vivo do not suppress lymphocyte responsiveness to 
      either phytohemagglutinin or allogeneic lymphocytes, at least within a 2-week 
      period of treatment.
FAU - Smith, M J
AU  - Smith MJ
FAU - Hoth, M
AU  - Hoth M
FAU - Davis, K
AU  - Davis K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Lectins)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Female
MH  - Humans
MH  - Lectins/metabolism/pharmacology
MH  - Lymphocyte Activation/*drug effects
MH  - Lymphocytes/metabolism
MH  - Male
MH  - Salicylates/blood
MH  - Time Factors
EDAT- 1975/10/01 00:00
MHDA- 1975/10/01 00:01
CRDT- 1975/10/01 00:00
PHST- 1975/10/01 00:00 [pubmed]
PHST- 1975/10/01 00:01 [medline]
PHST- 1975/10/01 00:00 [entrez]
AID - 10.7326/0003-4819-83-4-509 [doi]
PST - ppublish
SO  - Ann Intern Med. 1975 Oct;83(4):509-11. doi: 10.7326/0003-4819-83-4-509.

PMID- 3621780
OWN - NLM
STAT- MEDLINE
DCOM- 19871022
LR  - 20220330
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 42
IP  - 3
DP  - 1987 Sep
TI  - The consent form as a possible cause of side effects.
PG  - 250-3
AB  - In a multicenter trial of aspirin or sulfinpyrazone in the treatment of unstable 
      angina, we examined the possible importance to the outcome of mentioning 
      potential side effects in the consent form. Inclusion, in two of the three 
      centers, of a statement outlining possible gastrointestinal side effects resulted 
      in a sixfold increase (P less than 0.001) in the number of subjects in these 
      centers withdrawing from the study because of subjective, minor gastrointestinal 
      symptoms. Major gastrointestinal complications such as peptic ulcer or bleeding 
      as diagnosed by study physicians were similar in the three centers. Furthermore, 
      no patient discontinued therapy because of subjective, nongastrointestinal side 
      effects. Post hoc analysis suggests that the inclusion of gastrointestinal side 
      effects in the consent form may have increased the likelihood of patients 
      attributing gastrointestinal symptoms to drug therapy, leading to subsequent 
      withdrawal from the study.
FAU - Myers, M G
AU  - Myers MG
FAU - Cairns, J A
AU  - Cairns JA
FAU - Singer, J
AU  - Singer J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Angina Pectoris/*drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - *Clinical Trials as Topic
MH  - Digestive System/drug effects
MH  - Humans
MH  - *Informed Consent
MH  - Placebos
MH  - Sulfinpyrazone/*adverse effects/therapeutic use
MH  - Surveys and Questionnaires
EDAT- 1987/09/01 00:00
MHDA- 1987/09/01 00:01
CRDT- 1987/09/01 00:00
PHST- 1987/09/01 00:00 [pubmed]
PHST- 1987/09/01 00:01 [medline]
PHST- 1987/09/01 00:00 [entrez]
AID - 0009-9236(87)90143-3 [pii]
AID - 10.1038/clpt.1987.142 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1987 Sep;42(3):250-3. doi: 10.1038/clpt.1987.142.

PMID- 15013918
OWN - NLM
STAT- MEDLINE
DCOM- 20040521
LR  - 20220331
IS  - 1465-6566 (Print)
IS  - 1465-6566 (Linking)
VI  - 5
IP  - 3
DP  - 2004 Mar
TI  - Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, 
      safety, costs and cost-effectiveness.
PG  - 493-503
AB  - Atherothrombotic coronary artery disease is the single most common cause of death 
      worldwide and a growing public health problem. Platelets play a central role in 
      the pathogenesis of atherothrombosis and are therefore commonly targeted by one 
      or more antiplatelet drugs as part of primary and secondary atherothrombosis 
      prevention strategies. Aspirin reduces the risk of serious vascular events 
      (myocardial infarction, stroke or cardiovascular death) by approximately 20% in a 
      broad range of high-risk patients and remains the first-line antiplatelet drug 
      because of its relative safety, low cost and cost-effectiveness. Compared with 
      aspirin alone, clopidogrel reduces the risk of serious vascular events by 
      approximately 10% and the combination of aspirin and clopidogrel reduces the risk 
      by approximately 20% in patients with non-ST-segment elevation acute coronary 
      syndrome. Clopidogrel has a similar safety profile to aspirin but clopidogrel 
      tablets are substantially more expensive. However, the incremental 
      cost-effectiveness ratio of clopidogrel compared with aspirin is favourable, 
      particularly in high-risk patients and is intermediate compared with a range of 
      other effective therapeutic strategies for the treatment of coronary heart 
      disease. Clopidogrel should be considered as a replacement for aspirin in 
      patients who are allergic to aspirin, cannot tolerate aspirin, have experienced a 
      recurrent atherothrombotic vascular event whilst taking aspirin and are at very 
      high absolute risk of a serious vascular event (e.g., > 20%/year). The 
      combination of clopidogrel and aspirin should be considered in patients with 
      non-ST-segment elevation acute coronary syndrome or undergoing percutaneous 
      coronary intervention.
FAU - Ho, Wai Khoon
AU  - Ho WK
AD  - Department of Haematology, Royal Perth Hospital, Perth, Australia.
FAU - Hankey, Graeme J
AU  - Hankey GJ
FAU - Eikelboom, John W
AU  - Eikelboom JW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/economics/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Coronary Disease/diagnosis/*economics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/economics/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/economics/*therapeutic use
MH  - Treatment Outcome
RF  - 56
EDAT- 2004/03/12 05:00
MHDA- 2004/05/22 05:00
CRDT- 2004/03/12 05:00
PHST- 2004/03/12 05:00 [pubmed]
PHST- 2004/05/22 05:00 [medline]
PHST- 2004/03/12 05:00 [entrez]
AID - 10.1517/14656566.5.3.493 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2004 Mar;5(3):493-503. doi: 10.1517/14656566.5.3.493.

PMID- 10345257
OWN - NLM
STAT- MEDLINE
DCOM- 19990316
LR  - 20151119
IS  - 1099-8128 (Print)
IS  - 1099-8128 (Linking)
VI  - 1
IP  - 1
DP  - 1998 Aug-Sep
TI  - Does professional advice influence aspirin use to prevent heart disease in an HMO 
      population?
PG  - 26-32
AB  - OBJECTIVE: Aspirin use seems to reduce coronary artery disease events in some 
      groups of patients. Factors associated with use of aspirin to prevent heart 
      disease in an HMO population were examined. DESIGN: A population-based survey. 
      SETTING: A large HMO in the midwestern United States. PARTICIPANTS: 8000 health 
      plan members 40 years of age and older. MAIN OUTCOME MEASURES: The survey 
      assessed use of aspirin, professional advice to use aspirin, and coronary heart 
      disease risk factors and status. The sample was stratified by whether members had 
      none, one, or more than one of the following chronic conditions: diabetes, 
      hypertension, lipid disorder, or heart disease. The mailed survey had a corrected 
      response rate of 82.4%. RESULTS: Overall, 38% of respondents reported using 
      aspirin at least three times a week to prevent heart disease. Aspirin use did not 
      vary in owned versus contracted clinics. Aspirin use was 71.3% in patients with 
      and 27.7% in patients without diagnosed coronary heart disease (P < 0.001). In 
      logistic regression models, professional advice to take aspirin was strongly 
      associated with self-reported use of aspirin (odds ratio, 13.86) (P < 0.001) 
      after adjustment for age, sex, level of education, and chronic disease status. 
      CONCLUSIONS: Aspirin is widely used by HMO members with coronary artery disease 
      to prevent subsequent coronary artery disease events. Professional advice to use 
      aspirin seems to be strongly related to aspirin use.
FAU - O'Connor, P J
AU  - O'Connor PJ
AD  - Health Partners Research Foundation, St. Paul, MN, USA.
FAU - Pronk, N P
AU  - Pronk NP
FAU - Tan, A W
AU  - Tan AW
FAU - Rush, W A
AU  - Rush WA
FAU - Gray, R J
AU  - Gray RJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Eff Clin Pract
JT  - Effective clinical practice : ECP
JID - 9815774
RN  - R16CO5Y76E (Aspirin)
MH  - Adult
MH  - Aged
MH  - Aspirin/economics/*therapeutic use
MH  - Diabetes Complications
MH  - Drug Costs
MH  - Female
MH  - Health Care Surveys
MH  - Health Maintenance Organizations/*statistics & numerical data
MH  - Heart Diseases/complications/*prevention & control
MH  - Humans
MH  - Hyperlipidemias/complications
MH  - Hypertension/complications
MH  - Male
MH  - Middle Aged
MH  - Midwestern United States
MH  - *Patient Compliance
MH  - Surveys and Questionnaires
EDAT- 1999/05/27 00:00
MHDA- 1999/05/27 00:01
CRDT- 1999/05/27 00:00
PHST- 1999/05/27 00:00 [pubmed]
PHST- 1999/05/27 00:01 [medline]
PHST- 1999/05/27 00:00 [entrez]
PST - ppublish
SO  - Eff Clin Pract. 1998 Aug-Sep;1(1):26-32.

PMID- 11053009
OWN - NLM
STAT- MEDLINE
DCOM- 20001130
LR  - 20171213
IS  - 0193-1857 (Print)
IS  - 0193-1857 (Linking)
VI  - 279
IP  - 5
DP  - 2000 Nov
TI  - Time course inhibition of gastric and platelet COX activity by acetylsalicylic 
      acid in humans.
PG  - G1113-20
AB  - Aspirin causes peptic ulcers predominately by reducing gastric mucosal 
      cyclooxygenase (COX) activity and prostaglandin synthesis. Because aspirin 
      circulates for only a few hours, we hypothesized that aspirin's inhibitory effect 
      on gastric COX activity must be prolonged. We performed a placebo-controlled 
      experiment in healthy humans to determine the duration of inhibition of aspirin 
      on gastric mucosal COX activity (PGE(2) and PGF(2alpha) synthesis rates). 
      Recovery of gastric COX activity after stopping aspirin was slow and linear. 
      Seventy-two hours after 325-mg aspirin, gastric COX activity was still reduced by 
      57% (P < 0.001). Duration of inhibition of gastric COX activity was estimated to 
      be 7-8 days after 325-mg aspirin and 5 days after 81-mg aspirin. Recovery of 
      gastric prostaglandin synthesis after 325-mg but not after 81-mg aspirin occurred 
      at slower rates in subjects with Helicobacter pylori-associated gastritis than in 
      those with normal histology. In conclusion, aspirin inhibits gastric COX activity 
      for much longer than predicted from its pharmacokinetic profile, explaining why 
      aspirin at widely spaced intervals is ulcerogenic.
FAU - Feldman, M
AU  - Feldman M
AD  - Medical Service, Dallas Department of Veterans Affairs Medical Center, and 
      Department of Internal Medicine, University of Texas Southwestern Medical School, 
      Dallas, Texas 75216, USA. mark.feldman@med.va.gov
FAU - Shewmake, K
AU  - Shewmake K
FAU - Cryer, B
AU  - Cryer B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Am J Physiol Gastrointest Liver Physiol
JT  - American journal of physiology. Gastrointestinal and liver physiology
JID - 100901227
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - B7IN85G1HY (Dinoprost)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Platelets/*enzymology
MH  - Cyclooxygenase Inhibitors/administration & dosage/*adverse effects
MH  - Dinoprost/biosynthesis
MH  - Dinoprostone/biosynthesis
MH  - Female
MH  - Gastric Mucosa/*enzymology/microbiology
MH  - Gastritis/metabolism/microbiology
MH  - Helicobacter Infections/metabolism
MH  - Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - Regression Analysis
MH  - Stomach Ulcer/chemically induced/metabolism/microbiology
MH  - Thromboxane A2/blood
MH  - Time Factors
EDAT- 2000/10/29 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/29 11:00
PHST- 2000/10/29 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/29 11:00 [entrez]
AID - 10.1152/ajpgi.2000.279.5.G1113 [doi]
PST - ppublish
SO  - Am J Physiol Gastrointest Liver Physiol. 2000 Nov;279(5):G1113-20. doi: 
      10.1152/ajpgi.2000.279.5.G1113.

PMID- 35147105
OWN - NLM
STAT- MEDLINE
DCOM- 20220223
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 6
DP  - 2022 Feb 11
TI  - Evaluation of efficacy and safety of rivaroxaban combined with aspirin in 
      patients with chronic coronary artery disease: A protocol for systematic review 
      and meta-analysis.
PG  - e28779
LID - 10.1097/MD.0000000000028779 [doi]
LID - e28779
AB  - BACKGROUND: Coronary artery disease (CAD) is among the main causes of morbidities 
      and mortalities globally. It is also considered to be an outcome of acute 
      thrombotic events which entail activating platelets as well as coagulation 
      proteins. In particular, rivaroxaban along with aspirin have been considered to 
      reduce thrombotic events. However, they are yet to be evaluated by combining with 
      or putting them against each other in patients experiencing CAD. This study 
      intends to carry out an evaluation of whether combining rivaroxaben with aspirin 
      will be effective and safe in treating patients experiencing chronic CAD. METHODS 
      AND ANALYSIS: We intend to search information from the following databases: 
      MEDLINE, EMBASE, Web of Science, Cochrane library, WanFang, and China National 
      Knowledge Infrastructure. In the search, we intend to regard randomized control 
      trials written in either English or Chinese and only those published until 
      December 2021, as well as only those that have assessed the effectiveness and 
      safety of combining rivaroxaban and aspirin in treating patients suffering from 
      chronic CAD. We intend to accompany the study identification with searching or 
      relevant reference lists as well as citations. We will also contact respective 
      authors to provide additional information or data were needful. From the search, 
      we will collate all citations identified and remove all duplicates. Similarly, 2 
      independent authors will screen all the titles and abstracts and assess them 
      against the inclusion criteria for the study. Only selected studies will be 
      included for critical appraisal, extraction of data, and synthesis. We will then 
      conduct statistical analyses by utilizing a random-effect model. ETHICS AND 
      DISSEMINATION: This study does not require ethical approval as the findings will 
      be published in a peer-review journal. REGISTRATION NUMBER: 
      10.17605/OSF.IO/WBGE4.
CI  - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wang, Han
AU  - Wang H
AD  - Department of Cardiology, General Hospital of the Yangtze River Shipping, Wuhan, 
      Hubei, China.
FAU - Li, Xiuqi
AU  - Li X
AD  - Department of Cardiology, General Hospital of the Yangtze River Shipping, Wuhan, 
      Hubei, China.
FAU - Wu, Xingan
AU  - Wu X
AD  - Department of Cardiology, General Hospital of the Yangtze River Shipping, Wuhan, 
      Hubei, China.
FAU - Wu, Huiting
AU  - Wu H
AD  - Department of Cardiology, General Hospital of the Yangtze River Shipping, Wuhan, 
      Hubei, China.
FAU - Xie, Gang
AU  - Xie G
AD  - Department of Cardiology, General Hospital of the Yangtze River Shipping, Wuhan, 
      Hubei, China.
FAU - Wang, Hui
AU  - Wang H
AUID- ORCID: 0000-0002-6457-4180
AD  - Department of Cardiology, Caidian District People's Hospital, Union Jiangbei 
      Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China.
LA  - eng
GR  - WX19Q19/Wuhan Health and Family Planning Commission Project/
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Coronary Artery Disease/*drug therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Myocardial Ischemia
MH  - Research Design
MH  - Rivaroxaban/*adverse effects/therapeutic use
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC8830853
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2022/02/12 06:00
MHDA- 2022/02/24 06:00
CRDT- 2022/02/11 08:46
PHST- 2022/01/13 00:00 [received]
PHST- 2022/01/20 00:00 [accepted]
PHST- 2022/02/11 08:46 [entrez]
PHST- 2022/02/12 06:00 [pubmed]
PHST- 2022/02/24 06:00 [medline]
AID - 00005792-202202110-00022 [pii]
AID - MD-D-22-00313 [pii]
AID - 10.1097/MD.0000000000028779 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Feb 11;101(6):e28779. doi: 
      10.1097/MD.0000000000028779.

PMID- 2223121
OWN - NLM
STAT- MEDLINE
DCOM- 19901211
LR  - 20190510
IS  - 1010-7940 (Print)
IS  - 1010-7940 (Linking)
VI  - 4
IP  - 8
DP  - 1990
TI  - The effects of low, medium and high dose aspirin on intimal proliferation in 
      autologous vein grafts used for arterial reconstruction.
PG  - 441-4
AB  - Bilateral femoral vein grafts were implanted in 47 adult mongrel dogs to 
      determine the effects of aspirin on intimal hyperplasia. The animals were fed a 
      commercially-prepared 2% cholesterol diet before and for 6 weeks following 
      operation. Twelve animals served as the controls while the remaining animals were 
      divided into three groups receiving low, medium, and high dose aspirin. Eleven 
      animals received 75 mg of aspirin daily, 11 animals were fed 225 mg of aspirin 
      daily and the remaining 13 animals received 650 mg of aspirin daily. A 
      coagulation profile was carried out before operation and at 2, 4 and 6 weeks 
      following operation. The grafts were harvested at 6 weeks and intimal thickness 
      was measured with a Zeiss computerized interactive image-analyzing system. The 
      prothrombin time, partial thromboplastin time, and platelet count were unchanged 
      in all animals. The bleeding time was prolonged in animals receiving aspirin (P 
      less than 0.02). Intimal thickness measured 4 +/- 0.2 microns before implantation 
      and increased at 6 weeks to 39 +/- 5 microns in the control group. Aspirin failed 
      to reduce intimal hyperplasia. Intimal thickness measured 37 +/- 2 microns in 
      those animals receiving 75 mg of aspirin daily, 35 +/- 3 microns after a daily 
      dose of 225 mg of aspirin and 51 +/- 4 microns in the high dose group receiving 
      650 mg of aspirin daily. Our data indicates that aspirin fails to reduce intimal 
      proliferation in canine vein grafts which suggests that alternative or combined 
      drug therapy may be necessary to reduce the incidence of late graft failure.
FAU - Landymore, R W
AU  - Landymore RW
AD  - Department of Surgery, Dalhousie University, Halifax, N.S., Canada.
FAU - MacAulay, M A
AU  - MacAulay MA
FAU - Manku, M S
AU  - Manku MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European 
      Association for Cardio-thoracic Surgery
JID - 8804069
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteries/*drug effects/transplantation
MH  - Aspirin/*pharmacology
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Surgery, Plastic/*methods
MH  - Transplantation, Autologous
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1016/1010-7940(90)90075-b [doi]
PST - ppublish
SO  - Eur J Cardiothorac Surg. 1990;4(8):441-4. doi: 10.1016/1010-7940(90)90075-b.

PMID- 7813591
OWN - NLM
STAT- MEDLINE
DCOM- 19950208
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 262
IP  - 3
DP  - 1994 Sep 12
TI  - Fibroblast growth-promoting activity in proliferative vitreoretinopathy: 
      antagonism by acetylsalicylic acid.
PG  - 261-9
AB  - Proliferative vitreoretinopathy is a severe reactive process which leads to the 
      formation of cellular membranes on the surface of the retina and in the vitreous. 
      We determined the fibroblast growth-promoting activity of intraocular fluid from 
      patients suffering from proliferative vitreoretinopathy, retinal detachment or 
      cataract and further evaluated the effect of acetylsalicylic acid on 
      growth-stimulated fibroblasts. The results demonstrated a significant enhancement 
      of growth-promoting activity of intraocular fluid in proliferative 
      vitreoretinopathy as compared to that of control samples. We showed that the 
      augmented growth-promoting activity of intraocular fluid in proliferative 
      vitreoretinopathy was significantly antagonized by inhibition of cyclooxygenase 
      with acetylsalicylic acid (ID50 approximately 5 microM). In contrast, no 
      significant effect was seen in corresponding control experiments. The findings 
      suggest that metabolites of the cyclooxygenase pathway are involved in the 
      regulation of enhanced intraocular fluid-induced fibroblast proliferation in 
      proliferative vitreoretinopathy and that acetylsalicylic acid might be useful as 
      an antiproliferative agent in intraocular fibrogenesis.
FAU - Kähler, C M
AU  - Kähler CM
AD  - Department of Internal Medicine, Faculty of Medicine, University of Innsbruck, 
      Austria.
FAU - Kieselbach, G F
AU  - Kieselbach GF
FAU - Reinisch, N
AU  - Reinisch N
FAU - Troger, J
AU  - Troger J
FAU - Göttinger, W
AU  - Göttinger W
FAU - Wiedermann, C J
AU  - Wiedermann CJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Cataract/metabolism
MH  - Cell Division/drug effects
MH  - Cells, Cultured
MH  - Colorimetry
MH  - Female
MH  - Fibroblasts/cytology/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retina/*drug effects/pathology
MH  - Retinal Detachment/metabolism
MH  - Skin/cytology
MH  - Vitreoretinopathy, Proliferative/*drug therapy/metabolism
MH  - Vitreous Body/*drug effects/metabolism/pathology
EDAT- 1994/09/12 00:00
MHDA- 1994/09/12 00:01
CRDT- 1994/09/12 00:00
PHST- 1994/09/12 00:00 [pubmed]
PHST- 1994/09/12 00:01 [medline]
PHST- 1994/09/12 00:00 [entrez]
AID - 0014-2999(94)90740-4 [pii]
AID - 10.1016/0014-2999(94)90740-4 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1994 Sep 12;262(3):261-9. doi: 10.1016/0014-2999(94)90740-4.

PMID- 2353031
OWN - NLM
STAT- MEDLINE
DCOM- 19900716
LR  - 20190912
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 39
IP  - 4
DP  - 1990 Apr
TI  - Equivalent inhibition of in vivo platelet function by low dose and high dose 
      aspirin treatment.
PG  - 319-21
AB  - In vitro platelet function was inhibited in healthy volunteers by two different 
      doses of aspirin, as confirmed by measurement of maximum serum production of 
      thromboxane B2 (TXB2) by platelets. 75 mg aspirin did not fully inhibit serum 
      TXB2 production after 24 hours, whereas 300 mg aspirin did. Inhibition of 
      platelet function in vitro was maintained by both 75 mg/day aspirin or 300 
      mg/alternate day aspirin. In contrast, in vivo production of TXB2, measured as 
      urinary levels of the 11-keto-TXB2 metabolite, was inhibited similarly by both 
      doses of aspirin throughout the study. These findings suggest that 75 mg/day 
      aspirin may be sufficient adequately to inhibit platelet aggregation in vivo.
FAU - Sullivan, M H
AU  - Sullivan MH
AD  - Institute of Obstetrics and Gynaecology, Royal Postgraduate Medical School, 
      Hammersmith Hospital, London, UK.
FAU - Zosmer, A
AU  - Zosmer A
FAU - Gleeson, R P
AU  - Gleeson RP
FAU - Elder, M G
AU  - Elder MG
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 54397-85-2 (Thromboxane B2)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Creatinine/urine
MH  - Humans
MH  - Thromboxane B2/*blood/urine
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
AID - 10.1016/0952-3278(90)90012-a [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 1990 Apr;39(4):319-21. doi: 
      10.1016/0952-3278(90)90012-a.

PMID- 6322341
OWN - NLM
STAT- MEDLINE
DCOM- 19840413
LR  - 20131121
VI  - 60
IP  - 8
DP  - 1984 Feb 16
TI  - [Controlled study of the analgesic efficacy of 2 drugs: tiapride versus aspirin].
PG  - 565-7
AB  - Analgesic effect of aspirin 500 mg IM or IV and tiapride 300 mg IM or IV was 
      compared in a double blind controlled study. Twenty-four patients with active 
      cancer were each given both drugs successively, over 48 hours. No difference was 
      demonstrated in analgesic effects of tiapride (14/24: 58%) and aspirin (11/24: 
      46%), or in toxicity which was minor for both drugs.
FAU - Clavel, M
AU  - Clavel M
FAU - Pommatau, E
AU  - Pommatau E
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Etude contrôlée de l'efficacité antalgique de deux médicaments: tiapride versus 
      aspirine.
PL  - France
TA  - Sem Hop
JT  - La semaine des hopitaux : organe fonde par l'Association d'enseignement medical 
      des hopitaux de Paris
JID - 9410059
RN  - 0 (Benzamides)
RN  - R16CO5Y76E (Aspirin)
RN  - V824N2T753 (Tiapamil Hydrochloride)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Benzamides/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Injections
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/physiopathology
MH  - Pain/*drug therapy/etiology
MH  - Tiapamil Hydrochloride/administration & dosage/adverse effects/*therapeutic use
EDAT- 1984/02/16 00:00
MHDA- 1984/02/16 00:01
CRDT- 1984/02/16 00:00
PHST- 1984/02/16 00:00 [pubmed]
PHST- 1984/02/16 00:01 [medline]
PHST- 1984/02/16 00:00 [entrez]
PST - ppublish
SO  - Sem Hop. 1984 Feb 16;60(8):565-7.

PMID- 32443379
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20200616
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 20
DP  - 2020 May
TI  - An investigation into the impact of enteric coated of aspirin in patients with 
      newly diagnosed ischemic stroke (ECASIS).
PG  - e20307
LID - 10.1097/MD.0000000000020307 [doi]
LID - e20307
AB  - INTRODUCTION: Uncertainty remains regarding the impact of enteric-coated (EC) 
      aspirin as it relates to the reduction of cardiovascular risk. We hypothesize 
      that EC formulation based on a previous report may blunt aspirin response as 
      evidenced by reduced Thromboxane A2 (TXA 2) levels in diabetic patients. Thus, it 
      was imperative to ascertain and validate the effect of the EC formulation of 
      Aspirin on the Thromboxane B2 (TXB2) level. METHODS/DESIGN: An open-label 
      consecutive randomized interventional controlled trial. Patients with newly 
      diagnosed ischemic stroke who are just about to start Aspirin were assessed for 
      eligibility and inclusion in our trial. Consecutive patients (admitted to the 
      stroke unit of Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar) 
      will be randomized to receive either EC aspirin or plain Aspirin. They will be 
      required to continue taking them throughout the study (3 days). Demographics and 
      laboratory records of the study participants will be abstracted from online 
      records. Further study variables will be obtained manually in designated case 
      record forms (CRF). The primary outcomes are the incidence of aspirin 
      non-responders (level of residual serum TXB2 associated with elevated thrombotic 
      risk (<99.0% inhibition or TXB2 >3.1 ng/mL) within 72 h after three daily aspirin 
      doses). Whereas secondary outcomes are the incidence of GIT bleeding of various 
      preparations of Aspirin. The study was approved by MRC and IRB of Hamad Medical 
      Corporation (MRC number: 01-18-156). DISCUSSION: This trial will determine 
      potential differences in the efficacy of EC Aspirin and plain Aspirin on the 
      Thromboxane B2 level. Additionally, it will ascertain the tolerability and safety 
      of both formulations of Aspirin in patients with newly diagnosed ischemic stroke. 
      These results will either support the current notion of no difference between the 
      two formulations. However, if a difference is found, this will invite for future 
      trials exploring clinical outcomes occurrence between various formulations. 
      CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov NCT04330872 registered on April 
      2, 2020.
FAU - Elshafei, Mohamed Nabil
AU  - Elshafei MN
AD  - Clinical Pharmacy Department.
FAU - Imam, Yahia
AU  - Imam Y
AD  - Neurology Department, Hamad General Hospital, Hamad Medical Corporation.
AD  - Weill Cornell Medicine-Qatar.
FAU - Mohamed, Mouhand F H
AU  - Mohamed MFH
AD  - Internal Medicine Department, Hamad General Hospital.
FAU - AlSaud, Arwa Ebrahim
AU  - AlSaud AE
AD  - Internal Medicine Department, Hamad General Hospital.
FAU - Ahmed, Mohamed Sayed
AU  - Ahmed MS
AD  - Neurology Department, Hamad General Hospital, Hamad Medical Corporation.
FAU - Obeidat, Khaldun
AU  - Obeidat K
AD  - Internal Medicine Department, Hamad General Hospital.
FAU - Saeid, Razan
AU  - Saeid R
AD  - Internal Medicine Department, Hamad General Hospital.
FAU - Ali, Mohamed
AU  - Ali M
AD  - Internal Medicine Department, Hamad General Hospital.
FAU - Abdallah, Ibtihal M
AU  - Abdallah IM
AD  - Clinical Pharmacy Department.
FAU - Parray, Aeijaz Sultan
AU  - Parray AS
AD  - Interim-Lab, Hamad Medical City, Hamad Medical Corporation.
FAU - Danjuma, Mohammed Ibn-Masoud
AU  - Danjuma MI
AD  - Internal Medicine Department, Hamad General Hospital.
AD  - Qatar University, College of Medicine, Doha, Qatar.
LA  - eng
SI  - ClinicalTrials.gov/NCT04330872
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Brain Ischemia/*drug therapy
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Single-Blind Method
MH  - Socioeconomic Factors
MH  - Stroke/*drug therapy
MH  - Tablets, Enteric-Coated
MH  - Thromboxane B2/blood
MH  - Young Adult
PMC - PMC7254488
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/05/24 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - 00005792-202005150-00095 [pii]
AID - MD-D-20-03118 [pii]
AID - 10.1097/MD.0000000000020307 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(20):e20307. doi: 10.1097/MD.0000000000020307.

PMID- 1860197
OWN - NLM
STAT- MEDLINE
DCOM- 19910830
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 84
IP  - 2
DP  - 1991 Aug
TI  - Starting aspirin therapy after operation. Effects on early graft patency. 
      Department of Veterans Affairs Cooperative Study Group.
PG  - 520-6
AB  - BACKGROUND: Although aspirin therapy started before operation improves vein graft 
      patency after coronary artery bypass grafting, it also causes bleeding. The 
      objective of this prospective, centrally directed, randomized, double-blind, 
      placebo-controlled trial was to compare the effects of aspirin therapy started 
      before operation with aspirin started 6 hours after operation on early (7-10-day) 
      graft patency. METHODS AND RESULTS: Patients were randomized to receive either 
      aspirin 325 mg or placebo the night before surgery; after operation, all patients 
      received aspirin 325 mg daily, with the first dose administered through the 
      nasogastric tube 6 hours after operation. Angiography was performed in 72% of the 
      analyzed patients an average of 8 days after operation, and the primary end point 
      was saphenous vein graft patency in 351 patients. Internal mammary artery graft 
      patency was also assessed in 246 patients because many individuals received both 
      internal mammary artery and vein grafts. In the patients given preoperative 
      aspirin, the vein graft occlusion rate was 7.4 +/- 1.3% compared with 7.8 +/- 
      1.5% in those who received preoperative placebo (p = 0.871). In the subgroup of 
      patients receiving Y grafts, 0.0% of the grafts were occluded in the preoperative 
      aspirin group compared with 7.0 +/- 3.6% in the preoperative placebo group (p = 
      0.066). The internal mammary artery occlusion rate was 0.0% (0 of 131) in the 
      aspirin group compared with 2.4 +/- 1.4% (three of 125) in the placebo group (p = 
      0.081). Patients in the aspirin group received more transfusions than those in 
      the placebo group (median, 900 versus 725 ml, p = 0.006). The reoperation rate 
      for bleeding in the aspirin group was 6.3% compared with 2.4% in the placebo 
      group (p = 0.036). Median chest tube drainage within the first 6 hours after 
      operation was 500 ml in the aspirin group compared with 448 ml in the placebo 
      group (p = 0.011). CONCLUSIONS: Thus, preoperative aspirin is associated with 
      increased bleeding complications and offers no additional benefit in early vein 
      graft patency compared with starting aspirin therapy 6 hours after operation. 
      There was a trend, although not significant, toward improved early patency for Y 
      grafts and internal mammary artery grafts with preoperative aspirin.
FAU - Goldman, S
AU  - Goldman S
AD  - Department of Veterans Affairs Medical Center, Tucson, AZ 85723.
FAU - Copeland, J
AU  - Copeland J
FAU - Moritz, T
AU  - Moritz T
FAU - Henderson, W
AU  - Henderson W
FAU - Zadina, K
AU  - Zadina K
FAU - Ovitt, T
AU  - Ovitt T
FAU - Kern, K B
AU  - Kern KB
FAU - Sethi, G
AU  - Sethi G
FAU - Sharma, G V
AU  - Sharma GV
FAU - Khuri, S
AU  - Khuri S
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 1992 Apr;85(4):1637. PMID: 1555306
MH  - Aged
MH  - Angiography/adverse effects
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - *Coronary Artery Bypass/methods
MH  - Double-Blind Method
MH  - Humans
MH  - Mammary Arteries/physiopathology/transplantation
MH  - Middle Aged
MH  - *Postoperative Care
MH  - Preoperative Care
MH  - Prospective Studies
MH  - *Vascular Patency
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
AID - 10.1161/01.cir.84.2.520 [doi]
PST - ppublish
SO  - Circulation. 1991 Aug;84(2):520-6. doi: 10.1161/01.cir.84.2.520.

PMID- 3531373
OWN - NLM
STAT- MEDLINE
DCOM- 19861030
LR  - 20190724
IS  - 0022-2151 (Print)
IS  - 0022-2151 (Linking)
VI  - 100
IP  - 9
DP  - 1986 Sep
TI  - Syrup formulations for post-tonsillectomy analgesia: a double-blind study 
      comparing ibuprofen, aspirin and placebo.
PG  - 1055-60
AB  - Post-tonsillectomy analgesia from ibuprofen, aspirin and placebo is compared in a 
      double-blind study. The results are reported showing ibuprofen to have greater 
      therapeutic benefit than placebo whereas aspirin did not. Methods of providing 
      pain relief after tonsillectomy and the relative clinical merits of ibuprofen and 
      aspirin are discussed.
FAU - Parker, D A
AU  - Parker DA
FAU - Gibbin, K P
AU  - Gibbin KP
FAU - Noyelle, R M
AU  - Noyelle RM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Laryngol Otol
JT  - The Journal of laryngology and otology
JID - 8706896
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Ibuprofen/administration & dosage/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Time Factors
MH  - *Tonsillectomy
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
AID - 10.1017/s0022215100100568 [doi]
PST - ppublish
SO  - J Laryngol Otol. 1986 Sep;100(9):1055-60. doi: 10.1017/s0022215100100568.

PMID- 6408055
OWN - NLM
STAT- MEDLINE
DCOM- 19830817
LR  - 20190919
IS  - 0277-0903 (Print)
IS  - 0277-0903 (Linking)
VI  - 20 Suppl 1
DP  - 1983
TI  - Anti-cyclo-oxygenase agents and asthma.
PG  - 23-9
AB  - Aspirin inhibits cyclo-oxygenase by an irreversible time-dependent process of 
      inactivation; this mechanism appears to be responsible for precipitation of 
      asthmatic attacks in about 5%-10% of adult asthmatic patients. Besides aspirin, 
      all other cyclo-oxygenase inhibitors induce bronchoconstriction in sensitive 
      patients, while nonsteroidal anti-inflammatory drugs without anti-cyclo-oxygenase 
      activity can be taken by the same patients with impunity. While aspirin-sensitive 
      patients should avoid the potential for adverse reactions, there are rare reports 
      of bronchodilation following ingestion of aspirin and aspirinlike drugs.
FAU - Szczeklik, A
AU  - Szczeklik A
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Asthma
JT  - The Journal of asthma : official journal of the Association for the Care of 
      Asthma
JID - 8106454
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandin Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/adverse effects/*pharmacology
MH  - Asthma/chemically induced/*metabolism
MH  - Bronchi/*drug effects
MH  - *Cyclooxygenase Inhibitors
MH  - Drug Hypersensitivity
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostaglandin Antagonists
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.3109/02770908309078049 [doi]
PST - ppublish
SO  - J Asthma. 1983;20 Suppl 1:23-9. doi: 10.3109/02770908309078049.

PMID- 17697141
OWN - NLM
STAT- MEDLINE
DCOM- 20071226
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 5
IP  - 11
DP  - 2007 Nov
TI  - Persistent platelet activation in patients with type 2 diabetes treated with low 
      doses of aspirin.
PG  - 2197-203
AB  - BACKGROUND: The percentage of diabetic patients who do not benefit from the 
      protective effect of aspirin is larger than in other populations at 
      cardiovascular risk. OBJECTIVE: We compared the ability of aspirin to suppress 
      TxA2 and platelet activation in vivo, in type-2 diabetics vs. high-risk 
      non-diabetic patients. METHODS: Urinary 11-dehydro-TXB2, plasma sCD40 L, and 
      sP-selectin were measured, together with indices of low-grade inflammation, 
      glycemic control, and lipid profile, in 82 patients with type-2 diabetes and 39 
      without diabetes, treated with low doses of aspirin. RESULTS: Urinary 
      11-dehydro-TxB2, plasma sCD40L and sP-selectin were significantly higher in 
      diabetics than in controls: [38.9 (27.8-63.3) vs. 28.5 (22.5-43.9) ng mmol(-1) of 
      creatinine, P = 0.02], [1.06 (0.42-3.06) vs. 0.35 (0.22-0.95) ng mL(-1); P = 
      0.0001], [37.0 (16.8-85.6) vs. 20.0 (11.2-35.6) ng mL(-1), P = 0.0001], 
      respectively. The proportion of individuals with diabetes increased across 
      quartiles of 11-dehydro-TxB2, sCD40L, and sP-selectin, with the highest quartiles 
      of 11-dehydro-TxB2, sCD40L and sP-selectin, including 66%, 93.3%, and 93.3% of 
      individuals with diabetes. Markers of platelet activation positively correlated 
      with indices of glycemic control but not with markers of low-grade inflammation. 
      CONCLUSIONS: Platelet dysfunction associated with insufficient glycemic control, 
      may mediate persistent platelet activation under aspirin treatment.
FAU - Evangelista, V
AU  - Evangelista V
AD  - Department of Translational Pharmacology, Consorzio Mario Negri Sud, Santa Maria 
      Imbaro, Chieti, Italy. evangelista@negrisud.it
FAU - de Berardis, G
AU  - de Berardis G
FAU - Totani, L
AU  - Totani L
FAU - Avanzini, F
AU  - Avanzini F
FAU - Giorda, C B
AU  - Giorda CB
FAU - Brero, L
AU  - Brero L
FAU - Levantesi, G
AU  - Levantesi G
FAU - Marelli, G
AU  - Marelli G
FAU - Pupillo, M
AU  - Pupillo M
FAU - Iacuitti, G
AU  - Iacuitti G
FAU - Pozzoli, G
AU  - Pozzoli G
FAU - di Summa, P
AU  - di Summa P
FAU - Nada, E
AU  - Nada E
FAU - de Simone, G
AU  - de Simone G
FAU - Dell'Elba, G
AU  - Dell'Elba G
FAU - Amore, C
AU  - Amore C
FAU - Manarini, S
AU  - Manarini S
FAU - Pecce, R
AU  - Pecce R
FAU - Maione, A
AU  - Maione A
FAU - Tognoni, G
AU  - Tognoni G
FAU - Nicolucci, A
AU  - Nicolucci A
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070807
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Biomarkers/blood
MH  - Blood Glucose
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy
MH  - Glycemic Index
MH  - Humans
MH  - Inflammation
MH  - *Platelet Activation/drug effects
MH  - Thromboxane A2/antagonists & inhibitors
EDAT- 2007/08/19 09:00
MHDA- 2007/12/27 09:00
CRDT- 2007/08/19 09:00
PHST- 2007/08/19 09:00 [pubmed]
PHST- 2007/12/27 09:00 [medline]
PHST- 2007/08/19 09:00 [entrez]
AID - S1538-7836(22)08100-4 [pii]
AID - 10.1111/j.1538-7836.2007.02728.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2007 Nov;5(11):2197-203. doi: 10.1111/j.1538-7836.2007.02728.x. 
      Epub 2007 Aug 7.

PMID- 910028
OWN - NLM
STAT- MEDLINE
DCOM- 19771130
LR  - 20131121
IS  - 0033-4979 (Print)
IS  - 0033-4979 (Linking)
VI  - 13
IP  - 1
DP  - 1977 Mar
TI  - [Behaviour of "haemorrhage times" in hypocolinesterasic subjects after 
      administration of acetil-salicylic acid (author's transl)].
PG  - 1-7
AB  - The competitive action of acetil-salicylic acid with respect to colinesterasi is 
      demonstrated. The A. proposes a routine dose of this enzyme in the preparation 
      for surgery with a high haemorrhage risk, such as tonsillectomy.
FAU - Schirru, P L
AU  - Schirru PL
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Comportamento del tempo di emorragia dopo somministrazione di acido 
      acetil-salicilico in pazienti ipocolinesterasici.
PL  - Italy
TA  - Quad Sclavo Diagn
JT  - Quaderni Sclavo di diagnostica clinica e di laboratorio
JID - 0040616
RN  - EC 3.1.1.8 (Cholinesterases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Cholinesterases/administration & dosage/*deficiency
MH  - Hemorrhage/*prevention & control
MH  - Hepatitis/enzymology
MH  - Humans
MH  - Liver Cirrhosis/enzymology
MH  - Preoperative Care
EDAT- 1977/03/01 00:00
MHDA- 1977/03/01 00:01
CRDT- 1977/03/01 00:00
PHST- 1977/03/01 00:00 [pubmed]
PHST- 1977/03/01 00:01 [medline]
PHST- 1977/03/01 00:00 [entrez]
PST - ppublish
SO  - Quad Sclavo Diagn. 1977 Mar;13(1):1-7.

PMID- 3873372
OWN - NLM
STAT- MEDLINE
DCOM- 19850626
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 88
IP  - 6
DP  - 1985 Jun
TI  - Effects of aspirin and an aspirin-acetaminophen combination on the gastric mucosa 
      in normal subjects. A double-blind endoscopic study.
PG  - 1922-5
AB  - Coadministration or preadministration of acetaminophen with aspirin affords 
      partial protection against aspirin-induced gastric mucosal injury in animals. 
      Recently, it was reported that preadministration of acetaminophen in humans 
      yielded similar protection. That study used pylorus occlusion, intravenous 
      atropine, and exogenous acid, and thus may not have mimicked the usual clinical 
      situation. We studied a clinical regimen, in 7 normal volunteers. We 
      coadministered acetaminophen (1.95 or 2.6 g/day) and aspirin (in a 1:1 ratio) and 
      used gastroscopy to evaluate if there was gastric mucosal protection. Aspirin 
      alone was used as a positive control. We found the expected significant increase 
      in mucosal damage associated with increasing aspirin dose (p less than 0.05) 
      comparing the lowest and highest aspirin doses (1.95 g vs. 3.9 g) after 7 days of 
      continuous therapy. There was no difference in the degree of mucosal injury when 
      receiving the same dose of aspirin (p = 0.38) whether or not acetaminophen was 
      administered in a dose equal to that of aspirin. Thus, in a more normal clinical 
      situation, we were unable to confirm the findings from the pylorus-occluded 
      model, i.e., we failed to identify either a beneficial effect, or a trend, for 
      protection from gross mucosal damage by the coadministration of acetaminophen and 
      aspirin in equal dosages.
FAU - Graham, D Y
AU  - Graham DY
FAU - Smith, J L
AU  - Smith JL
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/*pharmacology
MH  - Adult
MH  - Aspirin/adverse effects/*pharmacology
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Combinations
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - *Gastroscopy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
EDAT- 1985/06/01 00:00
MHDA- 1985/06/01 00:01
CRDT- 1985/06/01 00:00
PHST- 1985/06/01 00:00 [pubmed]
PHST- 1985/06/01 00:01 [medline]
PHST- 1985/06/01 00:00 [entrez]
AID - S0016508585001718 [pii]
AID - 10.1016/0016-5085(85)90020-4 [doi]
PST - ppublish
SO  - Gastroenterology. 1985 Jun;88(6):1922-5. doi: 10.1016/0016-5085(85)90020-4.

PMID- 23121257
OWN - NLM
STAT- MEDLINE
DCOM- 20130418
LR  - 20131121
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 37
IP  - 6
DP  - 2012 Dec
TI  - Resistance to low-dose aspirin therapy among patients with acute coronary 
      syndrome in relation to associated risk factors.
PG  - 630-6
LID - 10.1111/j.1365-2710.2009.01083.x [doi]
AB  - BACKGROUND: A substantial proportion of patients have recurrence of vascular 
      events despite daily intake of low-dose aspirin therapy. Therefore, different 
      patients may require different aspirin dosages to achieve complete inhibition of 
      platelet function. OBJECTIVE: The aim of this work was to measure the response to 
      low-dose aspirin therapy (150 mg/day) among patients with unstable angina or 
      non-ST-segment elevation myocardial infarction and to find out whether titrating 
      aspirin dosage to 300 mg/day, would provide a better therapeutic response in the 
      resistant cases. Moreover, we also aimed to study any association between aspirin 
      non-responsiveness and atherothrombotic risk factors. METHODS: The antiplatelet 
      effect of 150 mg/day aspirin was studied prospectively in 50 consecutive patients 
      with unstable angina or non-ST-segment elevation myocardial infarction. Platelet 
      aggregation was measured using optical platelet aggregometry and serum 
      thromboxane B(2) level. Aspirin resistance was defined as collagen (1 μg/mL) and 
      adenosine diphosphate (ADP) (5 μmol/L)-induced platelet aggregation of ≥ 40% when 
      compared with control values. Twenty healthy age- and sex-matched individuals 
      were taken as a control group. All patients were subjected to complete medical 
      history (risk factors, medications), thorough clinical examination, ECG, coronary 
      angiography and laboratory investigations including: complete haemogram, 
      coagulation, kidney, liver and lipid profiles, fasting blood glucose and glycated 
      haemoglobin (HbA(1C) ). RESULTS: Eleven of 50 patients (22%) were found to be 
      aspirin resistant. A highly significant difference was found between the mean 
      values of ADP, collagen-induced platelet aggregation percentage and thromboxane 
      B(2) level after aspirin 150 mg/day when compared with the corresponding mean 
      values after aspirin 300 mg/day among the resistant patients (66 ± 7.01%, 62 ± 
      4.34% and 620 ± 64.58 pg/mL, respectively, vs. 26.87 ± 2.85%, 16.5 ± 3.8% and 77 
      ± 11.3 pg/mL) indicating enhanced response to aspirin after escalating the dose. 
      The presence of atherothrombotic risk factors (hypertension, smoking, family 
      history of ischaemic heart disease and previous MI) were not statistically 
      different between aspirin-resistant and aspirin-sensitive patients. However, 
      there was a highly significant difference between the aspirin sensitive and the 
      resistant patients regarding the other risk factors (diabetes mellitus and 
      dyslipidaemia) (P < 0.01). CONCLUSION: There is inter-individual variability in 
      response to the antiplatelet effect of standard doses of aspirin (150, 300 
      mg/day). The response to aspirin 300 mg/day is enhanced in resistant patients 
      when compared to 150 mg/day. There was a significant association between aspirin 
      resistance and atherothrombotic risk factors (diabetes, hyperlipidaemia and 
      obesity).
CI  - © 2009 Blackwell Publishing Ltd.
FAU - Salama, M M
AU  - Salama MM
AD  - Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt. 
      miramiramira_5@yahoo.com
FAU - Morad, A-R Mohamed
AU  - Morad AR
FAU - Saleh, M A
AU  - Saleh MA
FAU - Sabri, N A
AU  - Sabri NA
FAU - Zaki, M M
AU  - Zaki MM
FAU - ElSafady, L A
AU  - ElSafady LA
LA  - eng
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20090812
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/physiopathology
MH  - Adenosine Diphosphate/metabolism
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Collagen/administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/therapeutic 
      use
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Risk Factors
MH  - Thromboxane B2/blood
EDAT- 2012/11/06 06:00
MHDA- 2013/04/20 06:00
CRDT- 2012/11/06 06:00
PHST- 2012/11/06 06:00 [entrez]
PHST- 2012/11/06 06:00 [pubmed]
PHST- 2013/04/20 06:00 [medline]
AID - 10.1111/j.1365-2710.2009.01083.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2012 Dec;37(6):630-6. doi: 10.1111/j.1365-2710.2009.01083.x. 
      Epub 2009 Aug 12.

PMID- 1407882
OWN - NLM
STAT- MEDLINE
DCOM- 19921026
LR  - 20131121
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 80
IP  - 4
DP  - 1992 Oct
TI  - Outcome of treated pregnancies in women with antiphospholipid syndrome: an update 
      of the Utah experience.
PG  - 614-20
AB  - OBJECTIVE: To determine the outcome of treated pregnancies in women with 
      well-characterized antiphospholipid syndrome. METHODS: We reviewed 82 consecutive 
      pregnancies in 54 women with antiphospholipid syndrome who were treated during 
      pregnancy with the following: 1) prednisone and low-dose aspirin; 2) heparin and 
      low-dose aspirin; 3) prednisone, heparin, and low-dose aspirin; or 4) other 
      combinations of these medications or immunoglobulin. RESULTS: The overall 
      neonatal survival rate was 73%, excluding spontaneous abortions, but treatment 
      failures (fetal and neonatal deaths) occurred in all treatment groups. Patients 
      with successful treated pregnancies had fewer previous fetal deaths than those 
      with unsuccessful treated pregnancies. There were no significant differences in 
      outcome among the four treatment groups. Preeclampsia and fetal distress occurred 
      in half of all pregnancies, and fetal growth impairment occurred in nearly 
      one-third. Preterm delivery due to maternal or fetal indications was required in 
      37% of the pregnancies. Four pregnancies were also complicated by postpartum 
      thrombosis during treatment. CONCLUSIONS: Pregnancy in women with 
      antiphospholipid syndrome appears to be improved by treatment, but fetal loss may 
      occur despite treatment. Preeclampsia, fetal distress, fetal growth impairment, 
      and premature delivery are common. Because of the clinically significant risk of 
      thrombotic episodes, thrombosis prophylaxis should be considered in these 
      patients.
FAU - Branch, D W
AU  - Branch DW
AD  - Department of Obstetrics and Gynecology, University of Utah School of Medicine, 
      Salt Lake City.
FAU - Silver, R M
AU  - Silver RM
FAU - Blackwell, J L
AU  - Blackwell JL
FAU - Reading, J C
AU  - Reading JC
FAU - Scott, J R
AU  - Scott JR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Antiphospholipid Syndrome/*drug therapy/epidemiology
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Prednisone/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy/epidemiology
MH  - *Pregnancy Outcome
MH  - Treatment Outcome
MH  - Utah
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
PST - ppublish
SO  - Obstet Gynecol. 1992 Oct;80(4):614-20.

PMID- 27156005
OWN - NLM
STAT- MEDLINE
DCOM- 20180205
LR  - 20181113
IS  - 1939-1676 (Electronic)
IS  - 0891-6640 (Print)
IS  - 0891-6640 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Jul
TI  - The Effects of Cyclosporine and Aspirin on Platelet Function in Normal Dogs.
PG  - 1022-30
LID - 10.1111/jvim.13960 [doi]
AB  - BACKGROUND: Cyclosporine increases thromboxane synthesis in dogs, potentially 
      increasing the thrombogenic properties of platelets. HYPOTHESIS/OBJECTIVES: Our 
      hypothesis was that the concurrent administration of low-dose aspirin and 
      cyclosporine would inhibit cyclosporine-associated thromboxane synthesis without 
      altering the antiplatelet effects of aspirin. The objective was to determine the 
      effects of cyclosporine and aspirin on primary hemostasis. ANIMALS: Seven healthy 
      dogs. METHODS: A randomized, crossover study utilized turbidimetric aggregometry 
      and a platelet function analyzer to evaluate platelet function during the 
      administration of low-dose aspirin (1 mg/kg PO q24h), high-dose aspirin (10 mg/kg 
      PO q12h), cyclosporine (10 mg/kg PO q12h), and combined low-dose aspirin and 
      cyclosporine. The urine 11-dehydro-thromboxane-B2 (11-dTXB2 )-to-creatinine ratio 
      also was determined. RESULTS: On days 3 and 7 of administration, there was no 
      difference in the aggregometry amplitude or the platelet function analyzer 
      closure time between the low-dose aspirin group and the combined low-dose aspirin 
      and cyclosporine group. On day 7, there was a significant difference in amplitude 
      and closure time between the cyclosporine group and the combined low-dose aspirin 
      and cyclosporine group. High-dose aspirin consistently inhibited platelet 
      function. On both days, there was a significant difference in the urinary 
      11-dTXB2 -to-creatinine ratio between the cyclosporine group and the combined 
      low-dose aspirin and cyclosporine group. There was no difference in the urinary 
      11-dTXB2 -to-creatinine ratio among the low-dose aspirin, high-dose aspirin, and 
      combined low-dose aspirin and cyclosporine groups. CONCLUSIONS AND CLINICAL 
      IMPORTANCE: Low-dose aspirin inhibits cyclosporine-induced thromboxane synthesis, 
      and concurrent use of these medications does not alter the antiplatelet effects 
      of aspirin.
CI  - Copyright © 2016 The Authors. Journal of Veterinary Internal Medicine published 
      by Wiley Periodicals, Inc. on behalf of the American College of Veterinary 
      Internal Medicine.
FAU - Thomason, J
AU  - Thomason J
AD  - Department of Clinical Sciences, College of Veterinary Medicine, Mississippi 
      State University, MS, 39762-6100.
FAU - Archer, T
AU  - Archer T
AD  - Department of Clinical Sciences, College of Veterinary Medicine, Mississippi 
      State University, MS, 39762-6100.
FAU - Wills, R
AU  - Wills R
AD  - Department of Pathobiology and Population Medicine, College of Veterinary 
      Medicine, Mississippi State University, MS, 39762-6100.
FAU - Press, S
AU  - Press S
AD  - Department of Clinical Sciences, College of Veterinary Medicine, Mississippi 
      State University, MS, 39762-6100.
FAU - Mackin, A
AU  - Mackin A
AD  - Department of Clinical Sciences, College of Veterinary Medicine, Mississippi 
      State University, MS, 39762-6100.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160507
PL  - United States
TA  - J Vet Intern Med
JT  - Journal of veterinary internal medicine
JID - 8708660
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cross-Over Studies
MH  - Cyclosporine/*pharmacology
MH  - Dogs/*blood
MH  - Immunosuppressive Agents/pharmacology
MH  - Nephelometry and Turbidimetry
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology
PMC - PMC5084737
OTO - NOTNLM
OT  - Canine
OT  - Immune-mediated hemolytic anemia
OT  - Immunosuppression
OT  - Thromboxane
EDAT- 2016/05/09 06:00
MHDA- 2018/02/06 06:00
CRDT- 2016/05/09 06:00
PHST- 2015/12/17 00:00 [received]
PHST- 2016/03/22 00:00 [revised]
PHST- 2016/04/14 00:00 [accepted]
PHST- 2016/05/09 06:00 [entrez]
PHST- 2016/05/09 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
AID - JVIM13960 [pii]
AID - 10.1111/jvim.13960 [doi]
PST - ppublish
SO  - J Vet Intern Med. 2016 Jul;30(4):1022-30. doi: 10.1111/jvim.13960. Epub 2016 May 
      7.

PMID- 10961474
OWN - NLM
STAT- MEDLINE
DCOM- 20010126
LR  - 20220331
IS  - 0036-5599 (Print)
IS  - 0036-5599 (Linking)
VI  - 34
IP  - 3
DP  - 2000 Jun
TI  - The effect of low-dose acetylsalicylic acid on bleeding after transurethral 
      prostatectomy--a prospective, randomized, double-blind, placebo-controlled study.
PG  - 194-8
AB  - OBJECTIVE: An increase in the loss of blood after ingestion of acetylsalicylic 
      acid (ASA) has been reported after several types of surgery, but randomized 
      placebo-controlled studies have exclusively been performed after coronary artery 
      bypass surgery. The reported effects of ASA on bleeding after transurethral 
      prostatectomy (TURP) have been conflicting. We have studied the effect of low 
      doses of ASA (150 mg) on bleeding after TURP in a prospective, randomized, 
      double-blind, placebo-controlled trial. PATIENTS AND METHODS: Patients were 
      randomized to receive either 150 mg ASA (n = 26) or placebo (n = 27) 10 days 
      before surgery. The weight of resected tissue, operation time and blood loss, 
      transfusion requirements and complications were recorded. RESULTS: There was no 
      significant difference in the median operative blood loss between the groups (p = 
      0.528), but postoperatively the blood loss in the ASA group (median 284; 
      quartiles 196-660 ml) was significantly higher than in the placebo group (median 
      144; quartiles 75-379 ml), (p = 0.011). No significant difference was observed 
      between the groups regarding the amount of resected tissue (p = 0.209) or the 
      operating time (p = 0.297). In both groups the operative blood loss was 
      significantly related to the amount of resected tissue (p < 0.005) and the 
      operating time (p < 0.005). No significant difference in transfusion requirements 
      (p = 0.280), time to catheter removal (p = 0.455) and hospital stay (p = 0.820) 
      were observed between the groups. CONCLUSION: Long-term low-dose ASA therapy is 
      associated with a significant increase in the postoperative blood loss after 
      TURP, and although no significant difference in transfusion requirements was 
      observed more units of blood were used in the ASA group. We advise that ASA 
      therapy should be withdrawn 10 days before TURP.
FAU - Nielsen, J D
AU  - Nielsen JD
AD  - Department of Surgery, Ribe County Hospital in Esbjerg, Denmark.
FAU - Holm-Nielsen, A
AU  - Holm-Nielsen A
FAU - Jespersen, J
AU  - Jespersen J
FAU - Vinther, C C
AU  - Vinther CC
FAU - Settgast, I W
AU  - Settgast IW
FAU - Gram, J
AU  - Gram J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Urol Nephrol
JT  - Scandinavian journal of urology and nephrology
JID - 0114501
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Blood Loss, Surgical
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Postoperative Period
MH  - Prospective Studies
MH  - Prostate/surgery
MH  - *Transurethral Resection of Prostate
EDAT- 2000/08/29 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/29 11:00
PHST- 2000/08/29 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/29 11:00 [entrez]
AID - 10.1080/003655900750016580 [doi]
PST - ppublish
SO  - Scand J Urol Nephrol. 2000 Jun;34(3):194-8. doi: 10.1080/003655900750016580.

PMID- 16981479
OWN - NLM
STAT- MEDLINE
DCOM- 20061031
LR  - 20220318
IS  - 1044-9167 (Print)
IS  - 1044-9167 (Linking)
VI  - 18
IP  - 9
DP  - 2006 Sep
TI  - EKG at triage slashes door-to-aspirin time.
PG  - 101-2
AB  - Giving all chest pain patients an electrocardiogram (EKG) in triage can 
      significantly improve treatment times and quality of care and it eliminates the 
      need to prioritize patients and takes undue pressure off the nurses, ED managers 
      say. Triage delays in chest pain evaluation are eliminated by giving all patients 
      the same treatment. Time to first aspirin at one hospital was slashed from 67 
      minutes to eight minutes. Asking nurses to differentiate patients on the basis of 
      an interview and a set of vitals is unrealistic, managers say.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - ED Manag
JT  - ED management : the monthly update on emergency department management
JID - 9425690
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*therapeutic use
MH  - California
MH  - Diagnosis, Differential
MH  - *Electrocardiography
MH  - Emergency Service, Hospital
MH  - Humans
MH  - Organizational Case Studies
MH  - Time Factors
MH  - *Triage
EDAT- 2006/09/20 09:00
MHDA- 2006/11/01 09:00
CRDT- 2006/09/20 09:00
PHST- 2006/09/20 09:00 [pubmed]
PHST- 2006/11/01 09:00 [medline]
PHST- 2006/09/20 09:00 [entrez]
PST - ppublish
SO  - ED Manag. 2006 Sep;18(9):101-2.

PMID- 8150610
OWN - NLM
STAT- MEDLINE
DCOM- 19940512
LR  - 20190920
IS  - 0017-8470 (Print)
IS  - 0017-8470 (Linking)
VI  - 45
IP  - 1
DP  - 1994 Jan
TI  - [Catamnestic studies of patients with chronic urticaria and aspirin intolerance 
      ].
PG  - 12-4
AB  - Of a total of 131 patients suffering from chronic urticaria, 15 were cautiously 
      re-exposed to ASA after an initial provocative exposure during an urticaria test 
      programme 2-11 years before. Only 1 of these patients, who had undergone the 
      initial provocative test 7 years earlier, reacted at the same intensity; 1 other 
      patient reacted with much less intense symptoms 4 years after the original test. 
      Among 3 other patients, who merely reacted to ASA intake with urticarial 
      eruptions and did not suffer from chronic urticaria, only 1 presented 4 years 
      after the initial exposure with oedema of the skin and itching. The tolerance 
      threshold was markedly higher. These results suggest that the sensitivity to 
      intolerance-inducing agents is reduced relatively quickly and may subside 
      completely in most cases.
FAU - Paul, E
AU  - Paul E
AD  - Hautklinik, Klinikum Nürnberg.
FAU - Geipel, M
AU  - Geipel M
FAU - Möller, R
AU  - Möller R
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Katamnestische Untersuchungen an Patienten mit chronischer Urtikaria und 
      ASS-Intoleranz.
PL  - Germany
TA  - Hautarzt
JT  - Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
JID - 0372755
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anaphylaxis/chemically induced/diagnosis
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Eruptions/*diagnosis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Urticaria/*chemically induced/diagnosis
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1007/pl00013248 [doi]
PST - ppublish
SO  - Hautarzt. 1994 Jan;45(1):12-4. doi: 10.1007/pl00013248.

PMID- 22513905
OWN - NLM
STAT- MEDLINE
DCOM- 20120723
LR  - 20221219
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 2012
IP  - 4
DP  - 2012 Apr 18
TI  - Single dose oral aspirin for acute postoperative pain in adults.
PG  - CD002067
LID - 10.1002/14651858.CD002067.pub2 [doi]
LID - CD002067
AB  - BACKGROUND: This review is an update of a previously published review in the 
      Cochrane Database of Systematic Reviews on 'Single dose oral aspirin for acute 
      pain'. Aspirin has been known for many years to be an effective analgesic for 
      many different pain conditions. Although its use as an analgesic is now limited 
      in developed countries, it is widely available, inexpensive, and remains commonly 
      used throughout the world. OBJECTIVES: To assess the analgesic efficacy and 
      associated adverse events of single dose oral aspirin in acute postoperative 
      pain. SEARCH METHODS: For the earlier review, we identified randomised trials by 
      searching CENTRAL (The Cochrane Library) (1998, Issue 1), MEDLINE (1966 to March 
      1998), EMBASE (1980 to January 1998), and the Oxford Pain Relief Database (1950 
      to 1994). We updated searches of CENTRAL, MEDLINE, and EMBASE to January 2012. 
      SELECTION CRITERIA: Single oral dose, randomised, double-blind, 
      placebo-controlled trials of aspirin for relief of established moderate to severe 
      postoperative pain in adults. DATA COLLECTION AND ANALYSIS: We assessed studies 
      for methodological quality and two review authors extracted the data 
      independently. We used summed total pain relief (TOTPAR) over four to six hours 
      to calculate the number of participants achieving at least 50% pain relief. We 
      used these derived results to calculate, with 95% confidence intervals, the 
      relative benefit compared to placebo, and the number needed to treat (NNT) for 
      one participant to experience at least 50% pain relief over four to six hours. We 
      sought numbers of participants using rescue medication over specified time 
      periods, and time to use of rescue medication, as additional measures of 
      efficacy. We collected information on adverse events and withdrawals. MAIN 
      RESULTS: We included 68 studies in which aspirin was used at doses from 300 mg to 
      1200 mg, but the vast majority of participants received either 600/650 mg (2409 
      participants, 64 studies) or 990/1000 mg (380 participants, eight studies). There 
      was only one new study.Studies were overwhelmingly of adequate or good 
      methodological quality. NNTs for at least 50% pain relief over four to six hours 
      were 4.2 (3.9 to 4.8), 3.8 (3.0 to 5.1), and 2.7 (2.0 to 3.8) for 600/650 mg, 
      900/1000 mg, and 1200 mg respectively, compared with placebo. Type of pain model 
      had no significant impact on the results. Lower doses were not significantly 
      different from placebo. These results do not differ from those of the earlier 
      review.Fewer participants required rescue medication with aspirin than with 
      placebo over four to eight hours postdose, but by 12 hours there was no 
      difference. The number of participants experiencing adverse events was not 
      significantly different from placebo for 600/650 mg aspirin, but for 900/1000 mg 
      the number needed to treat to harm was 7.5 (4.8 to 17). The most commonly 
      reported events were dizziness, drowsiness, gastric irritation, nausea, and 
      vomiting, nearly all of which were of mild to moderate severity. AUTHORS' 
      CONCLUSIONS: Aspirin is an effective analgesic for acute pain of moderate to 
      severe intensity. High doses are more effective, but are associated with 
      increased adverse events, including drowsiness and gastric irritation. The pain 
      relief achieved with aspirin was very similar milligram for milligram to that 
      seen with paracetamol. There was no change to the conclusions in this update.
FAU - Derry, Sheena
AU  - Derry S
AD  - Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield 
      Division of Anaesthetics), University of Oxford, Churchill Hospital, Oxford, 
      Oxfordshire, UK, OX3 7LE.
FAU - Moore, R Andrew
AU  - Moore RA
LA  - eng
GR  - Biotechnology and Biological Sciences Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20120418
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Analgesics, Non-Narcotic)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2000;(2):CD002067. PMID: 10796855
MH  - Acute Disease
MH  - Administration, Oral
MH  - Adult
MH  - Analgesics, Non-Narcotic/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Humans
MH  - Pain, Postoperative/*drug therapy
PMC - PMC6485902
COIS- RAM has consulted for various pharmaceutical companies and received lecture fees 
      from pharmaceutical companies related to analgesics and other healthcare 
      interventions. RAM and SD have received research support from charities, 
      government and industry sources at various times. Support for this review came 
      from Oxford Pain Research Funds.
EDAT- 2012/04/20 06:00
MHDA- 2012/07/24 06:00
CRDT- 2012/04/20 06:00
PHST- 2012/04/20 06:00 [entrez]
PHST- 2012/04/20 06:00 [pubmed]
PHST- 2012/07/24 06:00 [medline]
AID - CD002067.pub2 [pii]
AID - 10.1002/14651858.CD002067.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD002067. doi: 
      10.1002/14651858.CD002067.pub2.

PMID- 16454741
OWN - NLM
STAT- MEDLINE
DCOM- 20060222
LR  - 20220309
IS  - 1381-6128 (Print)
IS  - 1381-6128 (Linking)
VI  - 12
IP  - 2
DP  - 2006
TI  - Aspirin resistance: definitions, mechanisms, prevalence, and clinical 
      significance.
PG  - 251-8
AB  - Aspirin is the most commonly used therapeutic agent in prevention of vascular 
      ischemic events. Aspirin exerts its antithrombotic effect primarily by 
      interfering with the biosynthesis of thromboxane A2 (TXA2) and inhibition of TXA2 
      -dependent platelet aggregation. A meta-analysis of secondary prevention trials 
      indicated that aspirin reduced major cardiovascular or cerebral events by 25%. 
      This led to the widespread use of aspirin for prevention of cardiovascular 
      events. However, it appears that aspirin antiplatelet effect is not uniform in 
      all patients and previous studies estimated that 8-45% of the population were 
      aspirin resistant. Furthermore, (i) the optimal dosage of aspirin for complete 
      inhibition of platelet aggregation by physiological agonists (i.e arachidonic 
      acid) is subject to great interindividual variability, (ii) the tests to detect 
      aspirin resistance in vitro are subject to debate and (iii) the mechanisms by 
      which some patients are resistant to aspirin in vitro remain to be determined. 
      Despite these unresolved questions, recent clinical studies provide the reliable 
      evidence that aspirin resistance correlates with confirmed clinical 
      unresponsiveness, highlighting the clinical interest of determining the aspirin 
      inhibitory effects on patients' platelets. In conclusion, discovery of aspirin 
      resistance in individuals might be important in order to devise better 
      anti-platelet strategies and improve our ability to prevent acute thrombotic 
      complication.
FAU - Macchi, L
AU  - Macchi L
AD  - Laboratoire d'Hématologie et des maladies du sang, CHU de Poitiers, Hôpital La 
      Milétrie, 86 021 Poitiers, France. l.macchi@chu-poitiers.fr
FAU - Sorel, N
AU  - Sorel N
FAU - Christiaens, L
AU  - Christiaens L
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Coronary Disease/epidemiology/prevention & control
MH  - Drug Resistance
MH  - Heart Failure/epidemiology/prevention & control
MH  - Humans
MH  - Ischemia/epidemiology/*prevention & control
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Stroke/epidemiology/prevention & control
RF  - 77
EDAT- 2006/02/04 09:00
MHDA- 2006/02/24 09:00
CRDT- 2006/02/04 09:00
PHST- 2006/02/04 09:00 [pubmed]
PHST- 2006/02/24 09:00 [medline]
PHST- 2006/02/04 09:00 [entrez]
AID - 10.2174/138161206775193064 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2006;12(2):251-8. doi: 10.2174/138161206775193064.

PMID- 18202035
OWN - NLM
STAT- MEDLINE
DCOM- 20080211
LR  - 20211020
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Print)
IS  - 0959-8138 (Linking)
VI  - 336
IP  - 7637
DP  - 2008 Jan 26
TI  - Aspirin resistance in cardiovascular disease.
PG  - 166-7
LID - 10.1136/bmj.39405.635498.80 [doi]
AB  - Carries a worse prognosis, but may be indicative of pre-existing higher risk
FAU - Biondi-Zoccai, Giuseppe
AU  - Biondi-Zoccai G
FAU - Lotrionte, Marzia
AU  - Lotrionte M
LA  - eng
PT  - Comment
PT  - Editorial
DEP - 20080117
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - BMJ. 2008 Jan 26;336(7637):195-8. PMID: 18202034
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - *Drug Resistance
MH  - Humans
MH  - Prognosis
MH  - Risk Factors
PMC - PMC2213790
COIS- Competing interests:GB-Z has received lecture fees from Bristol-Myers Squibb.
EDAT- 2008/01/19 09:00
MHDA- 2008/02/12 09:00
CRDT- 2008/01/19 09:00
PHST- 2008/01/19 09:00 [pubmed]
PHST- 2008/02/12 09:00 [medline]
PHST- 2008/01/19 09:00 [entrez]
AID - bmj.39405.635498.80 [pii]
AID - biog1511 [pii]
AID - 10.1136/bmj.39405.635498.80 [doi]
PST - ppublish
SO  - BMJ. 2008 Jan 26;336(7637):166-7. doi: 10.1136/bmj.39405.635498.80. Epub 2008 Jan 
      17.

PMID- 15870140
OWN - NLM
STAT- MEDLINE
DCOM- 20060302
LR  - 20131121
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 39
IP  - 6
DP  - 2005 Jun
TI  - Impact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of 
      aspirin.
PG  - 1073-9
AB  - OBJECTIVE: To examine the evidence of a pharmacodynamic interaction between 
      aspirin and nonsteroidal antiinflammatory drugs (NSAIDs); specifically, to 
      determine whether a deleterious relationship exists with respect to the 
      cardioprotective effects of aspirin. DATA SOURCES: Primary articles were 
      identified by a MEDLINE search (1966-May 2004). Search terms included aspirin, 
      nonsteroidal antiinflammatory drug, drug interaction, mortality, myocardial 
      infarction, and stroke. STUDY SELECTION AND DATA EXTRACTION: All prospective and 
      retrospective studies conducted in human subjects and investigating the potential 
      interaction between aspirin and NSAIDs were included. DATA SYNTHESIS: Several 
      controlled pharmacodynamic studies indicate that the sustained inhibition of 
      cyclooxygenase activity by aspirin is blunted in the presence of some NSAIDs. 
      While these data are fairly consistent, they are limited in that they rely on 
      surrogate markers and not clinical outcomes. Observational studies have shown 
      conflicting results regarding the effect of combination NSAID and aspirin therapy 
      on mortality risk and incidence of myocardial infarction. CONCLUSIONS: 
      Pharmacodynamic data indicating an interaction between aspirin and NSAIDs have 
      not translated to a consistent clinical effect in observational studies. In the 
      absence of a randomized, controlled, clinical outcomes study, there is 
      insufficient evidence to dictate a change in therapy.
FAU - Corman, Shelby L
AU  - Corman SL
AD  - Department of Pharmacy and Therapeutics, School of Pharmacy, University of 
      Pittsburgh, Pittsburgh, PA 15213-2500, USA. cormansl@upmc.edu
FAU - Fedutes, Bethany A
AU  - Fedutes BA
FAU - Ansani, Nicole T
AU  - Ansani NT
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20050503
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/mortality
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Drug Interactions
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Survival Rate
MH  - Treatment Outcome
RF  - 21
EDAT- 2005/05/05 09:00
MHDA- 2006/03/03 09:00
CRDT- 2005/05/05 09:00
PHST- 2005/05/05 09:00 [pubmed]
PHST- 2006/03/03 09:00 [medline]
PHST- 2005/05/05 09:00 [entrez]
AID - aph.1E514 [pii]
AID - 10.1345/aph.1E514 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2005 Jun;39(6):1073-9. doi: 10.1345/aph.1E514. Epub 2005 May 3.

PMID- 16829171
OWN - NLM
STAT- MEDLINE
DCOM- 20070307
LR  - 20131121
IS  - 1386-1425 (Print)
IS  - 1386-1425 (Linking)
VI  - 66
IP  - 2
DP  - 2007 Feb
TI  - Hydrogen bonding effects on infrared and Raman spectra of drug molecules.
PG  - 213-24
AB  - Infrared and Raman spectra of three drug molecules, aspirin, caffeine and 
      ibuprofen, in gas phase and in aqueous solution have been simulated using hybrid 
      density functional theory. The long range solvent effect is modelled by the 
      polarizable continuum model, while the short range hydrogen bonding effects are 
      taken care of by the super-molecular approach with explicit inclusion of water 
      molecules. The calculated spectra are found to compare well with available 
      experimental results. The agreement obtained make grounds for proposing 
      theoretical modeling as a tool for characterizing changes in the bonding 
      environments of drug molecules in terms of particular variations in their IR and 
      Raman spectra.
FAU - Bondesson, Laban
AU  - Bondesson L
AD  - Theoretical Chemistry, Royal Institute of Technology, SCFAB, SE-106 91 Stockholm, 
      Sweden.
FAU - Mikkelsen, Kurt V
AU  - Mikkelsen KV
FAU - Luo, Yi
AU  - Luo Y
FAU - Garberg, Per
AU  - Garberg P
FAU - Agren, Hans
AU  - Agren H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060710
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Caffeine/*chemistry
MH  - Hydrogen Bonding
MH  - Ibuprofen/*chemistry
MH  - *Models, Molecular
MH  - Molecular Structure
MH  - *Spectrum Analysis, Raman
EDAT- 2006/07/11 09:00
MHDA- 2007/03/08 09:00
CRDT- 2006/07/11 09:00
PHST- 2005/09/06 00:00 [received]
PHST- 2006/01/27 00:00 [revised]
PHST- 2006/02/23 00:00 [accepted]
PHST- 2006/07/11 09:00 [pubmed]
PHST- 2007/03/08 09:00 [medline]
PHST- 2006/07/11 09:00 [entrez]
AID - S1386-1425(06)00138-7 [pii]
AID - 10.1016/j.saa.2006.02.045 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2007 Feb;66(2):213-24. doi: 
      10.1016/j.saa.2006.02.045. Epub 2006 Jul 10.

PMID- 33316184
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20210823
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 173
IP  - 12
DP  - 2020 Dec 15
TI  - Stopping aspirin 1 to 3 mo after PCI reduces bleeding without increasing MACE vs. 
      continued DAPT.
PG  - JC64
LID - 10.7326/ACPJ202012150-064 [doi]
AB  - O'Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin 
      discontinuation on a background of a P2Y12 inhibitor in patients after 
      percutaneous coronary intervention: a systematic review and meta-analysis. 
      Circulation. 2020;142:538-45. 32551860.
FAU - Kesarwani, Manoj
AU  - Kesarwani M
AD  - University of California, Davis, School of Medicine, Sacramento, California, USA 
      (M.K.).
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Circulation. 2020 Aug 11;142(6):538-545. PMID: 32551860
MH  - Aspirin/therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - *Platelet Aggregation Inhibitors/adverse effects
EDAT- 2020/12/15 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/12/14 20:08
PHST- 2020/12/14 20:08 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - 10.7326/ACPJ202012150-064 [doi]
PST - ppublish
SO  - Ann Intern Med. 2020 Dec 15;173(12):JC64. doi: 10.7326/ACPJ202012150-064.

PMID- 25701248
OWN - NLM
STAT- MEDLINE
DCOM- 20160321
LR  - 20181202
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Linking)
VI  - 26
IP  - 4
DP  - 2015 Apr
TI  - Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis 
      are associated with improved breast cancer survival: a meta-analysis.
PG  - 589-600
LID - 10.1007/s10552-015-0539-y [doi]
AB  - PURPOSE: The association between nonsteroidal anti-inflammatory drugs (NSAIDs) 
      and breast cancer survival is still controversial. The aim of our meta-analysis 
      was to assess the survival benefit of NSAIDs. METHODS: A literature search was 
      conducted in PubMed and EMBASE (to September 2014). A meta-analysis was performed 
      with hazard ratios (HRs) and 95% confidence intervals (CIs) as the effect 
      measures. Subgroup analyses were based on time of NSAID use (before and after 
      diagnosis), medication type (aspirin and other nonaspirin NSAIDs), and study 
      design (cohort and case-control studies). RESULTS: There were 16 eligible 
      studies. Use of NSAIDs after diagnosis was significantly inversely associated 
      with relapse/metastasis (HR 0.69, 95% CI 0.59-0.80) and tended toward potentially 
      protective effects on all-cause mortality, although significance was not reached 
      (HR 0.79, 95% CI 0.61-1.02). In cohort studies, the association between 
      post-diagnostic use of NSAIDs and breast cancer survival was stronger with 
      reduced heterogeneity (breast-cancer-specific mortality: HR 0.65, 95% CI 
      0.48-0.89, I(2) = 65.3%; all-cause mortality: HR 0.73, 95% CI 0.57-0.92, I(2) = 
      83.2%; relapse/metastasis: HR 0.73, 95% CI 0.61-0.86, I(2) = 48.3%). Aspirin use 
      after diagnosis was significantly associated with breast-cancer-specific 
      mortality (HR 0.69, 95% CI 0.50-0.96) and relapse/metastasis (HR 0.75, 95% CI 
      0.56-1.00), and tended toward a protective effect on all-cause mortality, 
      although significance was not reached (HR 0.79, 95% CI 0.60-1.03). Including 
      cohort studies only, we obtained similar results and post-diagnostic use of 
      aspirin was significantly associated with all-cause mortality (HR 0.72, 95% CI 
      0.56-0.93). CONCLUSIONS: NSAIDs and aspirin after but not before diagnosis were 
      associated with improved breast cancer survival, including breast-cancer-specific 
      mortality, all-cause mortality, and relapse/metastasis.
FAU - Huang, Xuan-zhang
AU  - Huang XZ
AD  - Department of Surgical Oncology and General Surgery, First Hospital of China 
      Medical University, 155 North Nanjing Street, Heping District, Shenyang City, 
      110001, People's Republic of China.
FAU - Gao, Peng
AU  - Gao P
FAU - Sun, Jing-xu
AU  - Sun JX
FAU - Song, Yong-xi
AU  - Song YX
FAU - Tsai, Cheng-che
AU  - Tsai CC
FAU - Liu, Jing
AU  - Liu J
FAU - Chen, Xiao-wan
AU  - Chen XW
FAU - Chen, Ping
AU  - Chen P
FAU - Xu, Hui-mian
AU  - Xu HM
FAU - Wang, Zhen-ning
AU  - Wang ZN
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20150221
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Breast Neoplasms/diagnosis/*mortality
MH  - Female
MH  - Humans
MH  - Neoplasm Recurrence, Local
EDAT- 2015/02/24 06:00
MHDA- 2016/03/22 06:00
CRDT- 2015/02/22 06:00
PHST- 2014/12/11 00:00 [received]
PHST- 2015/02/13 00:00 [accepted]
PHST- 2015/02/22 06:00 [entrez]
PHST- 2015/02/24 06:00 [pubmed]
PHST- 2016/03/22 06:00 [medline]
AID - 10.1007/s10552-015-0539-y [doi]
PST - ppublish
SO  - Cancer Causes Control. 2015 Apr;26(4):589-600. doi: 10.1007/s10552-015-0539-y. 
      Epub 2015 Feb 21.

PMID- 6744359
OWN - NLM
STAT- MEDLINE
DCOM- 19840918
LR  - 20190511
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 18
IP  - 7
DP  - 1984 Jul
TI  - Activation of platelets by autogenous vein grafts is not prevented by 
      acetylsalicylic acid and dipyridamole.
PG  - 391-6
AB  - We have shown previously that experimental autogenous vein grafts activate 
      platelets for up to four months following operation. In the present study, 
      animals were treated with middle dose ASA (10 mg X kg-1 X 24 h-1) plus 
      dipyridamole (8 mg X kg-1 X 24 h-1) and followed for 8 months. Despite this 
      treatment, platelets were activated by the vein graft for up to four months after 
      operation but not after this time. Similarly, treatment with low dose ASA (0.5 mg 
      X kg-1 X 24 h-1) plus dipyridamole (8 mg X kg-1 X 25 h-1), high dose ASA (40 mg X 
      kg-1 X 24 h-1) plus dipyridamole (8 mg X kg-1 X 24 h-1), or dipyridamole alone (8 
      mg X kg-1 X 24 h-1), did not prevent the vein graft-induced activation of 
      platelets. Full inhibition of platelet arachidonic acid metabolism was 
      demonstrated in the high dose ASA plus dipyridamole group. These results suggest 
      that the interaction between the vessel wall and platelet is not inhibited by ASA 
      plus dipyridamole. Platelets have first to be activated before causing intimal 
      hyperplasia. Since aspirin and dipyridamole did not prevent activation of 
      platelets by the graft, this drug combination is unlikely to prevent the 
      development of intimal hyperplasia in the graft wall.
FAU - Gershlick, A H
AU  - Gershlick AH
FAU - Syndercombe-Court, Y D
AU  - Syndercombe-Court YD
FAU - Murday, A J
AU  - Murday AJ
FAU - Lewis, C T
AU  - Lewis CT
FAU - Mills, P G
AU  - Mills PG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Arachidonic Acids)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Animals
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dipyridamole/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Jugular Veins/*transplantation
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
MH  - Time Factors
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
AID - 10.1093/cvr/18.7.391 [doi]
PST - ppublish
SO  - Cardiovasc Res. 1984 Jul;18(7):391-6. doi: 10.1093/cvr/18.7.391.

PMID- 31653347
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20200706
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 521
IP  - 1
DP  - 2020 Jan 1
TI  - Identification of glycated and acetylated lysine residues in human 
      α2-antiplasmin.
PG  - 19-23
LID - S0006-291X(19)31889-3 [pii]
LID - 10.1016/j.bbrc.2019.09.144 [doi]
AB  - BACKGROUND: The post-translational protein modification via lysine residues can 
      significantly alter its function. α2-antiplasmin, a key inhibitor of 
      fibrinolysis, contains 19 lysine residues. AIM: We sought to identify sites of 
      glycation and acetylation in human α2-antiplasmin and test whether the 
      competition might occur on the lysine residues of α2-antiplasmin. METHODS: We 
      analyzed human α2-antiplasmin (1) untreated; (2) incubated with increasing 
      concentrations of β-d-glucose (0, 5, 10, 50 mM); (3) incubated with 1.6 mM 
      acetylsalicylic acid (ASA) and (4) incubated with 1.6 mM ASA and 50 mM 
      β-d-glucose, using the ultraperformance liquid chromatography system coupled to 
      mass spectrometer. RESULTS: Eleven glycation sites and 10 acetylation sites were 
      found in α2-antiplasmin. Incubation with β-d-glucose was associated with 
      glycation of 4 (K-418, K-427, K-434, K-441) out of 6 lysine residues, known to be 
      important for mediating the interaction with plasmin. Glycation and acetylation 
      overlapped at 9 sites in samples incubated with β-d-glucose or ASA. Incubation 
      with concomitant ASA and β-d-glucose was associated with the decreased 
      acetylation at all sites overlapping with glycation sites. At K-182 and K-448, 
      decreased acetylation was associated with increased glycation when compared with 
      α2-antiplasmin incubated with 50 mM β-d-glucose alone. Although K-24 located in 
      the proximity of the α2-antiplasmin cleavage site, was found to be only 
      acetylated, incubation with ASA and 50 mM β-d-glucose was associated the absence 
      of acetylation at that site. CONCLUSION: Human α2-antiplasmin is glycated and 
      acetylated at several sites, with the possible competition between acetylation 
      and glycation at K-182 and K-448. Our finding suggests possibly relevant 
      alterations to α2-antiplasmin function at high glycemia and during aspirin use.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Bryk, Agata Hanna
AU  - Bryk AH
AD  - Institute of Cardiology, Jagiellonian University Medical College, Cracow, Poland; 
      John Paul II Hospital, Cracow, Poland. Electronic address: agata.bryk@uj.edu.pl.
FAU - Cysewski, Dominik
AU  - Cysewski D
AD  - Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, 
      Poland.
FAU - Dadlez, Michał
AU  - Dadlez M
AD  - Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, 
      Poland.
FAU - Undas, Anetta
AU  - Undas A
AD  - Institute of Cardiology, Jagiellonian University Medical College, Cracow, Poland; 
      John Paul II Hospital, Cracow, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191023
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (alpha-2-Antiplasmin)
RN  - IY9XDZ35W2 (Glucose)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/chemistry/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Glucose/chemistry/metabolism
MH  - Glycosylation
MH  - Humans
MH  - Lysine/*metabolism
MH  - Mass Spectrometry
MH  - alpha-2-Antiplasmin/*chemistry/*metabolism
OTO - NOTNLM
OT  - Acetylation
OT  - Acetylsalicylic acid
OT  - Glycation
OT  - Mass-spectrometry
OT  - α2-antiplasmin
EDAT- 2019/10/28 06:00
MHDA- 2020/07/07 06:00
CRDT- 2019/10/27 06:00
PHST- 2019/09/27 00:00 [received]
PHST- 2019/09/30 00:00 [accepted]
PHST- 2019/10/28 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PHST- 2019/10/27 06:00 [entrez]
AID - S0006-291X(19)31889-3 [pii]
AID - 10.1016/j.bbrc.2019.09.144 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2020 Jan 1;521(1):19-23. doi: 
      10.1016/j.bbrc.2019.09.144. Epub 2019 Oct 23.

PMID- 2563096
OWN - NLM
STAT- MEDLINE
DCOM- 19890223
LR  - 20220408
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 8631
DP  - 1989 Jan 28
TI  - Placebo-controlled, randomised trial of warfarin and aspirin for prevention of 
      thromboembolic complications in chronic atrial fibrillation. The Copenhagen 
      AFASAK study.
PG  - 175-9
AB  - From November, 1985, to June, 1988, 1007 outpatients with chronic non-rheumatic 
      atrial fibrillation (AF) entered a randomised trial; 335 received anticoagulation 
      with warfarin openly, and in a double-blind study 336 received aspirin 75 mg once 
      daily and 336 placebo. Each patient was followed up for 2 years or until 
      termination of the trial. The primary endpoint was a thromboembolic complication 
      (stroke, transient cerebral ischaemic attack, or embolic complications to the 
      viscera and extremities). The secondary endpoint was death. The incidence of 
      thromboembolic complications and vascular mortality were significantly lower in 
      the warfarin group than in the aspirin and placebo groups, which did not differ 
      significantly. 5 patients on warfarin had thromboembolic complications compared 
      with 20 patients on aspirin and 21 on placebo. 21 patients on warfarin were 
      withdrawn because of non-fatal bleeding complications compared with 2 on aspirin 
      and none on placebo. Thus, anticoagulation therapy with warfarin can be 
      recommended to prevent thromboembolic complications in patients with chronic 
      non-rheumatic AF.
FAU - Petersen, P
AU  - Petersen P
AD  - Department of Neurology, University Hospital, Copenhagen, Denmark.
FAU - Boysen, G
AU  - Boysen G
FAU - Godtfredsen, J
AU  - Godtfredsen J
FAU - Andersen, E D
AU  - Andersen ED
FAU - Andersen, B
AU  - Andersen B
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Denmark
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
MH  - Thromboembolism/etiology/*prevention & control
MH  - Warfarin/administration & dosage/adverse effects/*therapeutic use
EDAT- 1989/01/28 00:00
MHDA- 1989/01/28 00:01
CRDT- 1989/01/28 00:00
PHST- 1989/01/28 00:00 [pubmed]
PHST- 1989/01/28 00:01 [medline]
PHST- 1989/01/28 00:00 [entrez]
AID - S0140-6736(89)91200-2 [pii]
AID - 10.1016/s0140-6736(89)91200-2 [doi]
PST - ppublish
SO  - Lancet. 1989 Jan 28;1(8631):175-9. doi: 10.1016/s0140-6736(89)91200-2.

PMID- 20674823
OWN - NLM
STAT- MEDLINE
DCOM- 20101103
LR  - 20131121
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 105
IP  - 2
DP  - 2010 Aug
TI  - Use of intranasal ketorolac and modified oral aspirin challenge for 
      desensitization of aspirin-exacerbated respiratory disease.
PG  - 130-5
LID - 10.1016/j.anai.2010.05.020 [doi]
AB  - BACKGROUND: Intranasal ketorolac challenges can induce respiratory reactions in 
      patients with aspirin-exacerbated respiratory disease (AERD). OBJECTIVE: To 
      determine whether intranasal ketorolac challenges might be used for aspirin 
      desensitization. METHODS: One hundred patients with suspected AERD who were 
      referred to Scripps Clinic from May 1, 2007 to December 31, 2009 were challenged 
      with 4 increasing doses of ketorolac intranasally at 30-minute intervals. 
      Symptoms, objective changes in the results of their nasal examination, peak nasal 
      inspiratory flow rates, and forced expiratory volume in 1 second (FEV(1)) values 
      were recorded. After nasal ketorolac dosing, patients were given oral aspirin as 
      part of the challenge and desensitization. A control group consisted of 100 
      patients who had previously undergone our standard oral aspirin challenges and 
      desensitization. Both groups were consecutively enrolled and had similar clinical 
      characteristics. RESULTS: Compared with the standard oral aspirin challenge and 
      desensitization, intranasal ketorolac and modified aspirin challenge 
      significantly attenuated the mean percentage decrease in FEV(1) values (8.5% vs 
      13.4%; P = .01) and decreased the percentage of extrapulmonary reactions (23% vs 
      45%; P = .002), particularly laryngospasm (7% vs19%; P = .02) and 
      gastrointestinal reactions (12% vs 33%; P = .001). This new protocol was 
      significantly shorter, lasting an average of 1.9 vs 2.6 days (P = <.001). In 
      fact, 83% of the patients completed the new protocol in less than 48 hours 
      compared with only 20% in the oral challenge control group (P < .001). 
      CONCLUSIONS: Intranasal ketorolac challenge and desensitization followed by rapid 
      oral aspirin challenges is effective, safe, and less time-consuming than our 
      standard oral aspirin desensitization protocol.
CI  - Copyright 2010 American College of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Lee, Rachel U
AU  - Lee RU
AD  - Division of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, California 
      92130, USA.
FAU - White, Andrew A
AU  - White AA
FAU - Ding, Ding
AU  - Ding D
FAU - Dursun, Adile Berna
AU  - Dursun AB
FAU - Woessner, Katharine M
AU  - Woessner KM
FAU - Simon, Ronald A
AU  - Simon RA
FAU - Stevenson, Donald D
AU  - Stevenson DD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20100701
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 4EVE5946BQ (Ketorolac Tromethamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Intranasal
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects/analogs & derivatives
MH  - Asthma, Aspirin-Induced/*etiology/immunology/physiopathology/*therapy
MH  - Clinical Protocols
MH  - *Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Ketorolac Tromethamine/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Respiratory Function Tests
EDAT- 2010/08/03 06:00
MHDA- 2010/11/04 06:00
CRDT- 2010/08/03 06:00
PHST- 2010/03/03 00:00 [received]
PHST- 2010/05/24 00:00 [revised]
PHST- 2010/05/25 00:00 [accepted]
PHST- 2010/08/03 06:00 [entrez]
PHST- 2010/08/03 06:00 [pubmed]
PHST- 2010/11/04 06:00 [medline]
AID - S1081-1206(10)00554-5 [pii]
AID - 10.1016/j.anai.2010.05.020 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2010 Aug;105(2):130-5. doi: 
      10.1016/j.anai.2010.05.020. Epub 2010 Jul 1.

PMID- 9272238
OWN - NLM
STAT- MEDLINE
DCOM- 19971009
LR  - 20181212
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 47
IP  - 7
DP  - 1997 Jul
TI  - Salicylate levels in rat stomach tissues after administration of aspalatone and 
      acetylsalicylic acid in relation to their ulcerogenicity.
PG  - 826-8
AB  - To study the mechanism for the low ulcerogenicity of the antithrombotic agent 
      aspalatone ([3-[2-methyl-4-pyronyl)]-2-acetyloxybenzoate, CAS 147249-33-0), the 
      metabolism and disposition of aspalatone were compared with those of 
      acetylsalicylic acid (ASA) in the gut wall in relation to the salicylate level in 
      the stomach tissues following oral administration in pyrolus-ligated rats. Both 
      aspalatone and ASA were essentially stable in gastric juice and were absorbed in 
      stomach unchanged. In glandular portion of the stomach, salicylate level found at 
      10 min post-dose in aspalatone (80 mg/kg)-and in ASA (50 mg/kg)-treated group was 
      67 +/- 43 nmol/g tissue and 2000 +/- 250 nmol/g tissue, respectively. In 
      non-glandular (rumen) tissue, salicylate was not detected in the aspalatone 
      group, whereas it reached a concentration of up to 1100 +/- 130 nmol/g tissue in 
      the ASA group. As a result of the relative stability of the ester bond connecting 
      the salicylic acid and maltol groups towards hydrolysis in the stomach and 
      entrapment of ASA due to ion trapping, a lower salicylate level was observed in 
      the stomach after oral aspalatone administration, and this may, at least in part, 
      be the underlying mechanism for the low ulcerogenicity of aspalatone.
FAU - Suh, D Y
AU  - Suh DY
AD  - Natural Products Research Institute, Seoul National University, Korea.
FAU - Kang, Y H
AU  - Kang YH
FAU - Han, B H
AU  - Han BH
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - A233M007P0 (aspalatone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacokinetics/toxicity
MH  - Gastric Mucosa/*metabolism
MH  - Male
MH  - Platelet Aggregation Inhibitors/*pharmacokinetics/*toxicity
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Salicylates/*metabolism
MH  - Stomach Ulcer/*chemically induced/pathology
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1997 Jul;47(7):826-8.

PMID- 16005201
OWN - NLM
STAT- MEDLINE
DCOM- 20060120
LR  - 20131121
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 73
IP  - 3-4
DP  - 2005 Sep-Oct
TI  - Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of 
      endogenous anti-inflammation and resolution.
PG  - 141-62
AB  - Lipoxins (LXs) or the lipoxygenase interaction products are generated from 
      arachidonic acid via sequential actions of lipoxygenases and subsequent reactions 
      to give specific trihydroxytetraene-containing eicosanoids. These unique 
      structures are formed during cell-cell interactions and appear to act at both 
      temporal and spatially distinct sites from other eicosanoids produced during the 
      course of inflammatory responses and to stimulate natural resolution. Lipoxin A4 
      (LXA4) and lipoxin B4 (LXB4) are positional isomers that each possesses potent 
      cellular and in vivo actions. These LX structures are conserved across species. 
      The results of numerous studies reviewed in this work now confirm that they are 
      the first recognized eicosanoid chemical mediators that display both potent 
      anti-inflammatory and pro-resolving actions in vivo in disease models that 
      include rabbit, rat, and mouse systems. LXs act at specific GPCRs as agonists to 
      regulate cellular responses of interest in inflammation and resolution. Aspirin 
      has a direct impact in the LX circuit by triggering the biosynthesis of 
      endogenous epimers of LX, termed the aspirin-triggered 15-epi-LX, that share the 
      potent anti-inflammatory actions of LX. Stable analogs of LXA4, LXB4, and 
      aspirin-triggered lipoxin were prepared, and several of these display potent 
      actions in vitro and in vivo. The results reviewed herein implicate a role of LX 
      and their analogs in many common human diseases including airway inflammation, 
      asthma, arthritis, cardiovascular disorders, gastrointestinal disease, 
      periodontal disease, kidney diseases and graft-vs.-host disease, as well as 
      others where uncontrolled inflammation plays a key role in disease pathogenesis. 
      Hence, the LX pathways and mechanisms reviewed to date in this work provide a 
      basis for new approaches to treatment of many common human diseases that involve 
      inflammation.
FAU - Serhan, Charles N
AU  - Serhan CN
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesia, Perioperative and Pain Medicine, Brigham and Women's Hospital and 
      Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. 
      cnserhan@zeus.bwh.harvard.edu
LA  - eng
GR  - GM38765/GM/NIGMS NIH HHS/United States
GR  - P50-DE016191/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - 92950-25-9 (lipoxin B4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Humans
MH  - Inflammation/drug therapy/*physiopathology
MH  - Lipoxins/antagonists & inhibitors/biosynthesis/*physiology/therapeutic use
MH  - Signal Transduction
RF  - 194
EDAT- 2005/07/12 09:00
MHDA- 2006/01/21 09:00
CRDT- 2005/07/12 09:00
PHST- 2005/07/12 09:00 [pubmed]
PHST- 2006/01/21 09:00 [medline]
PHST- 2005/07/12 09:00 [entrez]
AID - S0952-3278(05)00080-3 [pii]
AID - 10.1016/j.plefa.2005.05.002 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):141-62. doi: 
      10.1016/j.plefa.2005.05.002.

PMID- 35060092
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220606
IS  - 1179-1926 (Electronic)
IS  - 0312-5963 (Print)
IS  - 0312-5963 (Linking)
VI  - 61
IP  - 4
DP  - 2022 Apr
TI  - Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin 
      Formulation.
PG  - 465-479
LID - 10.1007/s40262-021-01090-2 [doi]
AB  - Aspirin is one of the most widely used medicines. Although aspirin is commonly 
      utilized for the treatment of several medical conditions, its broadest uptake is 
      for the prevention of recurrent ischemic events in patients with atherosclerotic 
      disease. Its mechanism of action of inhibiting platelet activation via blockade 
      of thromboxane A(2) production is unique and is not covered by any other 
      antiplatelet agents. While plain, uncoated, immediate-release aspirin is used in 
      acute settings to help assure rapid absorption, enteric-coated aspirin 
      formulations dominate current chronic use, particularly in North America, 
      including for secondary prevention of cardiovascular events. The unmet needs with 
      current aspirin formulations include a high risk of gastrointestinal (GI) adverse 
      events with plain aspirin, which enteric-coated formulations are not able to 
      overcome, and subject to erratic absorption leading to reduced drug 
      bioavailability. These observations underscore the need for aspirin formulations 
      with a more favorable safety and efficacy profile. Phospholipid-aspirin complex 
      (PL-ASA) is a novel formulation designed to address these needs. It is associated 
      with reduced local acute GI injury compared with plain aspirin, and predictable 
      absorption resulting in more reliable platelet inhibition compared with 
      enteric-coated tablets. This review explores the rationale and pharmacologic 
      profile of PL-ASA intended to address the unmet needs for aspirin therapy.
CI  - © 2022. The Author(s).
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AUID- ORCID: 0000-0001-8451-2131
AD  - Division of Cardiology, University of Florida College of Medicine, 655 West 8th 
      street, Jacksonville, FL, 32209, USA. dominick.angiolillo@jax.ufl.edu.
FAU - Prats, Jayne
AU  - Prats J
AUID- ORCID: 0000-0003-2146-9820
AD  - Elysis LLC, Carlisle, MA, USA.
FAU - Deliargyris, Efthymios N
AU  - Deliargyris EN
AD  - Science and Strategy Consulting Group, Basking Ridge, NJ, USA.
FAU - Schneider, David J
AU  - Schneider DJ
AD  - Cardiovascular Division Department of Medicine and Cardiovascular Research 
      Institute, University of Vermont Burlington, Burlington, VT, USA.
FAU - Scheiman, James
AU  - Scheiman J
AD  - iDivision of Gastroenterology and Hepatology, University of Virginia, 
      Charlottesville, VA, USA.
FAU - Kimmelstiel, Carey
AU  - Kimmelstiel C
AD  - Division of Cardiology, Tufts Medical Center Boston, Boston, MA, USA.
FAU - Steg, Ph Gabriel
AU  - Steg PG
AD  - Université de Paris, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, 
      INSERM-U1148, Paris, France.
FAU - Alberts, Mark
AU  - Alberts M
AD  - Department of Neurology, Hartford Hospital, Hartford, CT, USA.
FAU - Rosengart, Todd
AU  - Rosengart T
AD  - Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, 
      TX, USA.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at 
      Mount Sinai, New York, NY, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AUID- ORCID: 0000-0002-1278-6245
AD  - Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 
      Boston, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220120
PL  - Switzerland
TA  - Clin Pharmacokinet
JT  - Clinical pharmacokinetics
JID - 7606849
RN  - 0 (Phospholipids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacology
MH  - Blood Platelets
MH  - Humans
MH  - *Phospholipids
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Tablets, Enteric-Coated
PMC - PMC8773391
COIS- Dr. Angiolillo is a member of the PLx Pharma Scientific Advisory Board has 
      received payment as an individual for: a) Consulting fee or honorarium from 
      Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, 
      Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, 
      Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; b) 
      Participation in review activities from CeloNova and St. Jude Medical; c) 
      Institutional payments for grants from Amgen, AstraZeneca, Bayer, Biosensors, 
      CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli-Lilly, Gilead, Idorsia, 
      Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal 
      Guard Solutions and the Scott R. MacKenzie Foundation. Dr. Prats is a consultant 
      to PLxPharma, manufacturer of PL-ASA (Vazalore) Dr. Deliargyris is a member of 
      the PLx Pharma Scientific Advisory Board, no other relevant conflicts. Dr. 
      Schneider has received grant funding from Plx Pharma. Dr. Scheiman is a member of 
      the PLx Pharma Scientific Advisory Board and consultant, Tremeau Pharmaceuticals. 
      Dr. Kimmelstiel is a member of the PLx Pharma Scientific Advisory Board, no other 
      relevant conflicts. Dr. Steg is a member of the PLx Pharma Scientific Advisory 
      Board. He reports research grants from Amarin, Bayer, Sanofi, and Servier; 
      clinical trial conduct (Steering committee, CEC, DSMB) with Amarin, AstraZeneca, 
      Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Idorsia, Novartis, Pfizer, 
      Sanofi, Servier; consulting or speaking activity for Amgen, BMS/Myokardia, 
      Novo-Nordisk, Regeneron ; and is a Senior Associate Editor at Circulation. Dr. 
      Alberts is a member of the PLx Pharma Scientific Advisory Board, no other 
      relevant conflicts. Dr. Rosengart is a member of the PLx Pharma Scientific 
      Advisory Board, no other relevant conflicts. Dr. Mehran reports institutional 
      research grants from Abbott, Abiomed, Applied Therapeutics, Arena, AstraZeneca, 
      Bayer, Biosensors, Boston Scientific, Bristol-Myers Squibb, CardiaWave, 
      CellAegis, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Insel Gruppe AG, 
      Medtronic, Novartis Pharmaceuticals, OrbusNeich, Philips, Transverse Medical, 
      Zoll; personal fees from ACC, Boston Scientific, California Institute for 
      Regenerative Medicine (CIRM), Cine-Med Research, Janssen, WebMD, SCAI; consulting 
      fees paid to the institution from Abbott, Abiomed, AM-Pharma, Alleviant Medical, 
      Bayer, Beth Israel Deaconess, CardiaWave, CeloNova, Chiesi, CSL Behring, Concept 
      Medical, DSI, Duke University, Idorsia Pharmaceuticals, Medtronic, Novartis, 
      Philips; Equity <1% in Applied Therapeutics, Elixir Medical, STEL, CONTROLRAD 
      (spouse); Scientific Advisory Board for AMA, Biosensors (spouse); Faculty CRF (no 
      fee). Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: 
      Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, 
      Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, 
      PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research 
      Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural 
      Chair, American Heart Association Quality Oversight Committee; Data Monitoring 
      Committees: Baim Institute for Clinical Research (formerly Harvard Clinical 
      Research Institute, for the PORTICO trial, funded by St. Jude Medical, now 
      Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), 
      Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo 
      Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi 
      Sankyo), Population Health Research Institute; Honoraria: American College of 
      Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, 
      ACC Accreditation Oversight Committee), Baim Institute for Clinical Research 
      (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial 
      steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee 
      funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart 
      Letter), Canadian Medical and Surgical Knowledge Translation Research Group 
      (clinical trial steering committees), Duke Clinical Research Institute (clinical 
      trial steering committees, including for the PRONOUNCE trial, funded by Ferring 
      Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), 
      Journal of the American College of Cardiology (Guest Editor; Associate Editor), 
      K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD 
      (CME steering committees), MJH Life Sciences, Population Health Research 
      Institute (for the COMPASS operations committee, publications committee, steering 
      committee, and USA national co-leader, funded by Bayer), Slack Publications 
      (Chief Medical Editor, Cardiology Today’s Intervention), Society of 
      Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering 
      committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry 
      Steering Committee (Chair), VA CART Research and Publications Committee (Chair); 
      Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer 
      Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, 
      CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, 
      Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, 
      Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, 
      PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, The Medicines Company, 
      89Bio; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to 
      Braunwald’s Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston 
      Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte; Trustee: 
      American College of Cardiology; Unfunded Research: FlowCo, Merck, Takeda.
EDAT- 2022/01/22 06:00
MHDA- 2022/04/06 06:00
CRDT- 2022/01/21 06:38
PHST- 2021/11/01 00:00 [accepted]
PHST- 2022/01/22 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
PHST- 2022/01/21 06:38 [entrez]
AID - 10.1007/s40262-021-01090-2 [pii]
AID - 1090 [pii]
AID - 10.1007/s40262-021-01090-2 [doi]
PST - ppublish
SO  - Clin Pharmacokinet. 2022 Apr;61(4):465-479. doi: 10.1007/s40262-021-01090-2. Epub 
      2022 Jan 20.

PMID- 24022207
OWN - NLM
STAT- MEDLINE
DCOM- 20140711
LR  - 20211021
IS  - 1179-2027 (Electronic)
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 31
IP  - 11
DP  - 2013 Nov
TI  - Antiplatelet therapy in patients undergoing percutaneous coronary intervention: 
      economic considerations.
PG  - 959-70
AB  - Percutaneous coronary intervention (PCI) is one of the most common medical 
      procedures performed for treatment of coronary artery disease. Antiplatelet 
      medications as adjunctive therapy for PCI are used routinely, with indications 
      for specific agents or their combinations varying depending on the clinical 
      scenario. While the cost-effectiveness of well-established agents has been 
      extensively studied, newer drugs have not been evaluated as thoroughly. In 
      addition, the clinical application of some antiplatelet drugs has recently 
      changed, thus making older studies of cost effectiveness less applicable to the 
      current landscape of clinical practice. This article reviews cost-effectiveness 
      considerations of antiplatelet therapies in the treatment of coronary artery 
      disease in patients undergoing PCI. Aspirin, P2Y12 inhibitors including 
      clopidogrel and the newer agents prasugrel and ticagrelor, as well as 
      glycoprotein (GP) IIb/IIIa inhibitors, are discussed. Overall, the use of dual 
      antiplatelet therapy with aspirin and a P2Y12 inhibitor in patients undergoing 
      PCI improves ischaemic outcomes and appears to be cost effective. The few 
      available studies suggest that the recently approved medications prasugrel and 
      ticagrelor are cost-effective alternatives to clopidogrel. However, no direct 
      comparison between these two newer agents is available. The indications for GP 
      IIb/IIIa inhibitors have changed in the current PCI era, and there is a paucity 
      of cost-effectiveness data for their use in contemporary care.
FAU - Weintraub, William S
AU  - Weintraub WS
FAU - Mandel, Leonid
AU  - Mandel L
FAU - Weiss, Sandra A
AU  - Weiss SA
LA  - eng
GR  - R01 NR010786/NR/NINR NIH HHS/United States
GR  - R34 DA031063/DA/NIDA NIH HHS/United States
GR  - R01 DA011611/DA/NIDA NIH HHS/United States
GR  - M01 RR000039/RR/NCRR NIH HHS/United States
GR  - R01 HD037874/HD/NICHD NIH HHS/United States
GR  - U54 GM104941/GM/NIGMS NIH HHS/United States
GR  - R01 HD036797/HD/NICHD NIH HHS/United States
GR  - R01 HD038582/HD/NICHD NIH HHS/United States
GR  - U19 HD035470/HD/NICHD NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/administration & dosage/economics/therapeutic use
MH  - Coronary Artery Disease/economics/*surgery
MH  - Cost-Benefit Analysis
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Percutaneous Coronary Intervention/economics/*methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/economics/*therapeutic 
      use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Treatment Outcome
PMC - PMC4816975
MID - NIHMS523516
COIS- WW has no present conflicts of interest. He has had previous grant funding and 
      consulting from Sanofi-Aventis, AstraZeneca, Lilly and Daiichi-Sankyo. LM and SW 
      report no conflicts of interest.
EDAT- 2013/09/12 06:00
MHDA- 2014/07/12 06:00
CRDT- 2013/09/12 06:00
PHST- 2013/09/12 06:00 [entrez]
PHST- 2013/09/12 06:00 [pubmed]
PHST- 2014/07/12 06:00 [medline]
AID - 10.1007/s40273-013-0088-8 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2013 Nov;31(11):959-70. doi: 10.1007/s40273-013-0088-8.

PMID- 34460000
OWN - NLM
STAT- MEDLINE
DCOM- 20220126
LR  - 20220218
IS  - 1573-4838 (Electronic)
IS  - 0957-4530 (Print)
IS  - 0957-4530 (Linking)
VI  - 32
IP  - 9
DP  - 2021 Aug 30
TI  - Preparation and preliminary quality evaluation of aspirin/L-glutamate compound 
      pellets.
PG  - 116
LID - 10.1007/s10856-021-06594-8 [doi]
LID - 116
AB  - L-glutamate is an important component of protein. It can prevent gastrointestinal 
      damage caused by NSAIDs. We constructed two-phase enteric-coated granules of 
      aspirin and L-glutamate compound by extrusion spheronization method and fluidized 
      bed coating. The subliminal effective dose of L-glutamate is 100 mg/kg tested by 
      model of gastric ulcer of rats induced by aspirin and drug administration. 
      HPLC-UV and UV-Vis methods were adopted to determine content and cumulative 
      release of aspirin and L-glutamate as quality analysis method indexes. The 
      prescription and process optimization were carried out with yield, sphericity and 
      dissolution. The two-phase compound granules have good sphericity of 0.93 ± 0.05 
      (aspirin pellets) and 0.94 ± 0.02 (L-glutamate pellets), content of salicylic 
      acid (0.24 ± 0.03)%, dissolution of aspirin (2.36 ± 0.11)%. Quality evaluation 
      and preliminary stability meet the commercial requirements. The stored 
      environment of compound preparation should be sealed in a cool and dark place.
CI  - © 2021. The Author(s).
FAU - Xu, Mengchang
AU  - Xu M
AD  - Academician Workstation, Changsha Medical University, Changsha, 410219, China.
FAU - Liu, Fenglin
AU  - Liu F
AD  - Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 
      410013, China.
FAU - Zhou, Wenhu
AU  - Zhou W
AD  - Academician Workstation, Changsha Medical University, Changsha, 410219, China. 
      zhouwenhu@csu.edu.cn.
AD  - Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 
      410013, China. zhouwenhu@csu.edu.cn.
FAU - He, Binsheng
AU  - He B
AD  - Academician Workstation, Changsha Medical University, Changsha, 410219, China.
FAU - Tan, Songwen
AU  - Tan S
AD  - Academician Workstation, Changsha Medical University, Changsha, 410219, China. 
      stan0309@uni.sydney.edu.au.
AD  - Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 
      410013, China. stan0309@uni.sydney.edu.au.
LA  - eng
GR  - No.2016TP1029/Key Laboratory Breeding Base of Hu'nan Oriented Fundamental and 
      Applied Research of Innovative Pharmaceutics/
PT  - Journal Article
DEP - 20210830
PL  - United States
TA  - J Mater Sci Mater Med
JT  - Journal of materials science. Materials in medicine
JID - 9013087
RN  - 0 (Tablets, Enteric-Coated)
RN  - 3KX376GY7L (Glutamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Aspirin/administration & dosage/chemical synthesis/pharmacology
MH  - Chemistry, Pharmaceutical/methods/standards
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - *Drug Compounding/methods/standards
MH  - Drug Evaluation, Preclinical/methods/standards
MH  - Gastric Mucosa/drug effects
MH  - Gastrointestinal Tract/drug effects
MH  - *Glutamic Acid/administration & dosage/chemical synthesis/pharmacology
MH  - Quality Control
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Stomach Ulcer/drug therapy/pathology
MH  - Tablets, Enteric-Coated
PMC - PMC8405465
COIS- The authors declare no competing interests.
EDAT- 2021/08/31 06:00
MHDA- 2022/01/27 06:00
CRDT- 2021/08/30 12:29
PHST- 2020/10/21 00:00 [received]
PHST- 2021/08/16 00:00 [accepted]
PHST- 2021/08/30 12:29 [entrez]
PHST- 2021/08/31 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
AID - 10.1007/s10856-021-06594-8 [pii]
AID - 6594 [pii]
AID - 10.1007/s10856-021-06594-8 [doi]
PST - epublish
SO  - J Mater Sci Mater Med. 2021 Aug 30;32(9):116. doi: 10.1007/s10856-021-06594-8.

PMID- 21191260
OWN - NLM
STAT- MEDLINE
DCOM- 20110204
LR  - 20131121
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
VI  - 341
IP  - 1
DP  - 2011 Jan
TI  - Low-dose aspirin for primary prevention of cardiovascular events in patients with 
      diabetes: a meta-analysis.
PG  - 1-9
LID - 10.1097/MAJ.0b013e3181f1fba8 [doi]
AB  - INTRODUCTION: The use of low-dose aspirin for primary prevention of 
      cardiovascular events in patients with diabetes is recommended by existing 
      guidelines, but definitive evidence supporting its efficacy is lacking. The 
      authors undertook a meta-analysis of published trials to determine the effect of 
      low-dose aspirin for primary prevention of cardiovascular events in patients with 
      diabetes. METHODS: Randomized controlled trials comparing low-dose aspirin versus 
      placebo or no treatment in patients with diabetes (either exclusively or as a 
      subgroup) with no previous history of cardiovascular disease were identified 
      through MEDLINE and EMBASE databases. RESULTS: Seven randomized controlled trials 
      met the inclusion criteria. Two studies included exclusively patients with 
      diabetes, whereas the remaining 5 studies included patients with diabetes as a 
      subgroup. Two studies were excluded because they did not provide 
      diabetes-specific data. Overall, aspirin was associated with a nonsignificant 
      reduction in the hazard rate of the composite endpoint of major cardiovascular 
      events compared with control (hazard ratio = 0.89, 95% confidence interval: 
      0.70-1.13, P = 0.33). Similarly, there was a nonsignificant reduction in the 
      hazard rate of the individual endpoints of myocardial infarction, stroke, 
      cardiovascular and all-cause mortality. The risk of major bleeding increased 
      nonsignificantly with aspirin compared with control (relative risk = 3.02, 95% 
      confidence interval: 0.48-18.86, P = 0.24). DISCUSSION: The role of low-dose 
      aspirin for primary prevention of cardiovascular events in patients with diabetes 
      remains unproven, and its routine use cannot be justified at present. More trials 
      are needed to definitively address this issue.
FAU - Stavrakis, Stavros
AU  - Stavrakis S
AD  - Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma 
      City, 73104, USA.
FAU - Stoner, Julie A
AU  - Stoner JA
FAU - Azar, Madona
AU  - Azar M
FAU - Wayangankar, Siddharth
AU  - Wayangankar S
FAU - Thadani, Udho
AU  - Thadani U
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Complications/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/mortality/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Primary Prevention/*methods
MH  - Stroke/mortality/prevention & control
EDAT- 2010/12/31 06:00
MHDA- 2011/02/05 06:00
CRDT- 2010/12/31 06:00
PHST- 2010/12/31 06:00 [entrez]
PHST- 2010/12/31 06:00 [pubmed]
PHST- 2011/02/05 06:00 [medline]
AID - S0002-9629(15)31392-6 [pii]
AID - 10.1097/MAJ.0b013e3181f1fba8 [doi]
PST - ppublish
SO  - Am J Med Sci. 2011 Jan;341(1):1-9. doi: 10.1097/MAJ.0b013e3181f1fba8.

PMID- 12927657
OWN - NLM
STAT- MEDLINE
DCOM- 20040130
LR  - 20190906
IS  - 0376-8716 (Print)
IS  - 0376-8716 (Linking)
VI  - 71
IP  - 2
DP  - 2003 Aug 20
TI  - Aspirin or amiloride for cerebral perfusion defects in cocaine dependence.
PG  - 187-94
AB  - Cocaine dependent (CD) patients have regional cerebral blood flow (rCBF) deficits 
      that may be related to occlusion of blood vessels by vasoconstriction and 
      abnormal platelet aggregation. This study determined whether aspirin, which 
      reverses platelet aggregation, or amiloride, a vasodilator, significantly 
      reversed this rCBF hypoperfusion. This 1-month randomized trial compared clusters 
      of voxels with significant hypoperfusion in recently abstinent CD patients after 
      aspirin (325 mg daily), amiloride (10 mg daily) or placebo treatment. Forty-nine 
      primary CD patients and 18 non-drug abusing controls were compared using single 
      photon emission computed tomography (SPECT) neuroimaging with 
      99mTc-hexamethyl-propyleneamine-oxime and statistical parametric mapping (SPM). 
      Platelet aggregation to adenosine diphosphate (ADP) was examined after treatment 
      to determine whether rCBF improvement was related to decreased platelet 
      aggregation. Following treatment, areas of hypoperfusion were improved with 
      amiloride, unchanged with aspirin, and worsened with placebo in comparison to 
      baseline levels. Platelet aggregation after ADP showed no significant change 
      during the month, but reduced rCBF significantly improved after 1-month treatment 
      with amiloride compared with placebo and cocaine abstinence alone.
FAU - Kosten, Thomas R
AU  - Kosten TR
AD  - Department of Psychiatry, 151D, Yale University School of Medicine, VA 
      Connecticut Healthcare System, 950 Campbell Avenue Bldg., Room 41, West Haven, CT 
      06516, USA. thomas.kosten@yale.edu
FAU - Gottschalk, P Christopher
AU  - Gottschalk PC
FAU - Tucker, Karen
AU  - Tucker K
FAU - Rinder, Christine S
AU  - Rinder CS
FAU - Dey, Holly M
AU  - Dey HM
FAU - Rinder, Henry M
AU  - Rinder HM
LA  - eng
GR  - DA00167/DA/NIDA NIH HHS/United States
GR  - DA12762/DA/NIDA NIH HHS/United States
GR  - HL47193/HL/NHLBI NIH HHS/United States
GR  - HL61223/HL/NHLBI NIH HHS/United States
GR  - K05-DA0454/DA/NIDA NIH HHS/United States
GR  - P50-DA04060/DA/NIDA NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Ireland
TA  - Drug Alcohol Depend
JT  - Drug and alcohol dependence
JID - 7513587
RN  - 7DZO8EB0Z3 (Amiloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Amiloride/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cerebrovascular Circulation/*drug effects/physiology
MH  - Chi-Square Distribution
MH  - Cocaine-Related Disorders/diagnostic imaging/*drug therapy/physiopathology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Tomography, Emission-Computed, Single-Photon/methods
EDAT- 2003/08/21 05:00
MHDA- 2004/01/31 05:00
CRDT- 2003/08/21 05:00
PHST- 2003/08/21 05:00 [pubmed]
PHST- 2004/01/31 05:00 [medline]
PHST- 2003/08/21 05:00 [entrez]
AID - S0376871603001327 [pii]
AID - 10.1016/s0376-8716(03)00132-7 [doi]
PST - ppublish
SO  - Drug Alcohol Depend. 2003 Aug 20;71(2):187-94. doi: 
      10.1016/s0376-8716(03)00132-7.

PMID- 12945285
OWN - NLM
STAT- MEDLINE
DCOM- 20040317
LR  - 20131121
IS  - 1000-0593 (Print)
IS  - 1000-0593 (Linking)
VI  - 21
IP  - 4
DP  - 2001 Aug
TI  - [Simultaneous determination of aspirin, phenacetin and caffeine in compound APC 
      by derivative ratio UV adsorption spectrum method].
PG  - 534-7
AB  - The principle of derivative spectrum is described, which is based on the 
      simultaneous use of the first derivative of ratio spectra and measurements of 
      zero-crossing wavelengths. The method can be used to analyze one of three 
      components in ternary mixture and eliminate the interference of others. This 
      method is used to determine the ternary mixture of aspirin, phenacetin and 
      caffeine in APC simultaneous with satisfactory results. The regression 
      coefficient is higher than 0.9992, the relative standard derivatives (RSD) is 
      less than 3.2%, the recovery is between 93.3%-106.3%.
FAU - Wei, Y
AU  - Wei Y
AD  - Department of Chemistry, Northwest University, 710069 Xi'an.
FAU - Wang, D
AU  - Wang D
FAU - Yan, H
AU  - Yan H
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Guang Pu Xue Yu Guang Pu Fen Xi
JT  - Guang pu xue yu guang pu fen xi = Guang pu
JID - 9424805
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Drug Combinations
MH  - Phenacetin/*analysis
MH  - Spectrophotometry, Ultraviolet/methods
MH  - Tablets
EDAT- 2003/08/30 05:00
MHDA- 2004/03/18 05:00
CRDT- 2003/08/30 05:00
PHST- 2003/08/30 05:00 [pubmed]
PHST- 2004/03/18 05:00 [medline]
PHST- 2003/08/30 05:00 [entrez]
PST - ppublish
SO  - Guang Pu Xue Yu Guang Pu Fen Xi. 2001 Aug;21(4):534-7.

PMID- 6517905
OWN - NLM
STAT- MEDLINE
DCOM- 19850205
LR  - 20151119
IS  - 0232-766X (Print)
IS  - 0232-766X (Linking)
VI  - 43
IP  - 8-9
DP  - 1984
TI  - Impaired red blood cell deformability after oral administration of aspirin in 
      man.
PG  - S395-8
AB  - The effect of aspirin on red blood cell (RBC) deformability was studied in nine 
      healthy male volunteers. They received 1.5 g aspirin daily in divided doses for 
      three days and RBC deformability was measured before and two hours after the last 
      dose of aspirin. Measurements were repeated seven and fourteen days after the 
      last dose in five of the nine subjects. Red blood cell deformability was 
      significantly (P less than 0.01) decreased 2 hours after aspirin and the effect 
      persisted for seven days through by fourteen days after aspirin values had 
      returned to pre-aspirin control levels. Direct incubations of RBC's with aspirin 
      (300 mg/ml) in vitro had no effect on RBC deformability. These findings are 
      consistent with a role of endogenous epoprostenol (prostacyclin) in regulating 
      RBC deformability in vivo.
FAU - Kovacs, I B
AU  - Kovacs IB
FAU - O'Grady, J
AU  - O'Grady J
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Biomed Biochim Acta
JT  - Biomedica biochimica acta
JID - 8304435
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - *Aspirin/administration & dosage
MH  - Erythrocyte Deformability/*drug effects
MH  - Humans
MH  - Male
MH  - Reference Values
MH  - Time Factors
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Biomed Biochim Acta. 1984;43(8-9):S395-8.

PMID- 427005
OWN - NLM
STAT- MEDLINE
DCOM- 19790611
LR  - 20190509
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 7
IP  - 3
DP  - 1979 Mar
TI  - Effect of a single oral dose of aspirin on the platelet aggregation response to 
      arachidonic acid.
PG  - 283-6
AB  - 1 The platelet aggregation response to arachidonic acid ex vivo was measured in 
      six volunteers daily before and for 10 days after a single oral dose of 600 mg 
      aspirin. 2 Arachidonic acid induced aggregation of platelets from all subjects 
      before aspirin and aggregation occurred after an interval which varied inversely 
      with the concentration of arachidonic acid. No aggregation occurred for 4 days 
      after aspirin; a reduced response, compared with pre-aspirin values, was obtained 
      on the 5th, 6th and 8th day. The values on days 7, 9 and 10 were not consistently 
      different from the pre-aspirin values. In 6 subjects 24 h after aspirin ingestion 
      the addition of 10--25% v/v normal platelets restored the aggregation response. 3 
      It is concluded that aspirin has an effect on the platelet precursors in the 
      marrow in addition to its effect on circulating platelets.
FAU - Bye, A
AU  - Bye A
FAU - Lewis, Y
AU  - Lewis Y
FAU - O'Grady, J
AU  - O'Grady J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Arachidonic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acids/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Time Factors
PMC - PMC1429489
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1979.tb00933.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1979 Mar;7(3):283-6. doi: 
      10.1111/j.1365-2125.1979.tb00933.x.

PMID- 21995892
OWN - NLM
STAT- MEDLINE
DCOM- 20120507
LR  - 20171116
IS  - 1873-2682 (Electronic)
IS  - 1011-1344 (Linking)
VI  - 105
IP  - 3
DP  - 2011 Dec 2
TI  - Interaction of aspirin and vitamin C with bovine serum albumin.
PG  - 198-202
LID - 10.1016/j.jphotobiol.2011.09.002 [doi]
AB  - Vitamin C (L-ascorbic acid) has a major biological role as a natural antioxidant. 
      Aspirin belongs to the nonsteroidal anti-inflammatory drugs and functions as an 
      antioxidant via its ability to scavenge-OH radicals. Bovine serum albumin (BSA) 
      is the major soluble protein constituent of the circulatory system and has many 
      physiological functions including transport of a variety of compounds. In this 
      report, the competitive binding of vitamin C and aspirin to bovine serum albumin 
      has been studied using constant protein concentration and various drug 
      concentrations at pH 7.2. FTIR and UV-Vis spectroscopic methods were used to 
      analyze vitamin C and aspirin binding modes, the binding constants and the 
      effects of drug complexation on BSA stability and conformation. Spectroscopic 
      evidence showed that vitamin C and aspirin bind BSA via hydrophilic interactions 
      (polypeptide and amine polar groups) with overall binding constants of K(vitamin 
      C-BSA)=1.57×10(4)M(-1) and K(aspirin-BSA)=1.15×10(4)M(-1); assuming that there is 
      one drug molecule per protein. The BSA secondary structure was altered with major 
      decrease of α-helix from 64% (free protein) to 57% (BSA-vitamin C) and 54% 
      (BSA-aspirin) and β-sheet from 15% (free protein) to 6-7% upon drug complexation, 
      inducing a partial protein destabilization.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Nafisi, Shohreh
AU  - Nafisi S
AD  - Department of Chemistry, Islamic Azad University, Central Tehran Branch, Tehran, 
      Iran. drsnafisi@yahoo.com
FAU - Bagheri Sadeghi, Golshan
AU  - Bagheri Sadeghi G
FAU - PanahYab, Ataollah
AU  - PanahYab A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110922
PL  - Switzerland
TA  - J Photochem Photobiol B
JT  - Journal of photochemistry and photobiology. B, Biology
JID - 8804966
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 27432CM55Q (Serum Albumin, Bovine)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism/pharmacology
MH  - Antioxidants/chemistry/*metabolism/pharmacology
MH  - Ascorbic Acid/chemistry/*metabolism/pharmacology
MH  - Aspirin/chemistry/*metabolism/pharmacology
MH  - Cattle
MH  - Dose-Response Relationship, Drug
MH  - Protein Binding
MH  - Protein Conformation/drug effects
MH  - Protein Stability/drug effects
MH  - Serum Albumin, Bovine/chemistry/*metabolism
MH  - Spectroscopy, Fourier Transform Infrared
EDAT- 2011/10/15 06:00
MHDA- 2012/05/09 06:00
CRDT- 2011/10/15 06:00
PHST- 2011/07/04 00:00 [received]
PHST- 2011/08/16 00:00 [revised]
PHST- 2011/09/14 00:00 [accepted]
PHST- 2011/10/15 06:00 [entrez]
PHST- 2011/10/15 06:00 [pubmed]
PHST- 2012/05/09 06:00 [medline]
AID - S1011-1344(11)00200-4 [pii]
AID - 10.1016/j.jphotobiol.2011.09.002 [doi]
PST - ppublish
SO  - J Photochem Photobiol B. 2011 Dec 2;105(3):198-202. doi: 
      10.1016/j.jphotobiol.2011.09.002. Epub 2011 Sep 22.

PMID- 1832517
OWN - NLM
STAT- MEDLINE
DCOM- 19911016
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 91
IP  - 3
DP  - 1991 Sep
TI  - Stroke prevention in women: role of aspirin versus ticlopidine.
PG  - 288-92
AB  - Stroke is the third leading cause of death in North America. Most studies 
      indicate that women are just as likely as men to have an initial stroke but less 
      likely to have a recurrent stroke. Aspirin and ticlopidine are two antiplatelet 
      drugs that reduce the risk of recurrent stroke by 25% to 30%. In some stroke 
      prevention trials, aspirin has been shown to be more effective for men than for 
      women. In contrast, major stroke prevention trials using ticlopidine have 
      demonstrated equal benefit in women and in men. The overall incidence of adverse 
      effects seen with ticlopidine is not significantly different from that observed 
      with aspirin. There are now two effective agents useful in stroke prevention in 
      both men and women.
FAU - Hershey, L A
AU  - Hershey LA
AD  - Department of Neurology, State University of New York, Buffalo.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/epidemiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Recurrence
MH  - Sex Factors
MH  - Ticlopidine/adverse effects/*therapeutic use
MH  - United States/epidemiology
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
AID - 0002-9343(91)90130-P [pii]
AID - 10.1016/0002-9343(91)90130-p [doi]
PST - ppublish
SO  - Am J Med. 1991 Sep;91(3):288-92. doi: 10.1016/0002-9343(91)90130-p.

PMID- 9082488
OWN - NLM
STAT- MEDLINE
DCOM- 19970403
LR  - 20131121
IS  - 0300-8932 (Print)
IS  - 0300-8932 (Linking)
VI  - 49
IP  - 11
DP  - 1996 Nov
TI  - [Should individuals without evidence of coronary disease and with risk factors 
      receive continuous treatment with aspirin? Arguments in favor].
PG  - 793-800
AB  - There is general agreement on the efficacy of aspirin treatment in patients with 
      coronary heart disease, but the indications of aspirin in individuals without 
      coronary heart disease are debated. This paper analyses data from the main 
      studies which investigated the usefulness of aspirin in the primary prevention of 
      coronary heart disease. Particular attention is paid to the risks and benefits of 
      aspirin treatment in different clinically relevant subgroups of patients. It is 
      concluded that, according to available information, the use of aspirin must be 
      integrated in a global strategy for the primary prevention of coronary heart 
      disease and should be probable recommended in males older than 50 years old 
      presenting a higher risk of coronary heart disease (due to the number and 
      intensity of risk factors) and low risk of adverse effects.
FAU - Calvo, F
AU  - Calvo F
AD  - Servicio de Cardiología, Hospital General Universitario Vall d'Hebron, Barcelona.
FAU - Barrabés, J A
AU  - Barrabés JA
FAU - García-Dorado, D
AU  - García-Dorado D
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Deben recibir tratamento continuado con aspirina los individuos sin evidencia de 
      enfermedad coronaria y con factores de riesgo? Argumentos a favor.
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/*administration & dosage/economics
MH  - Cost-Benefit Analysis
MH  - Diabetes Complications
MH  - Female
MH  - Humans
MH  - Hypercholesterolemia/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/etiology/*prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Smoking/adverse effects
MH  - Thrombosis/complications
EDAT- 1996/11/01 00:00
MHDA- 1996/11/01 00:01
CRDT- 1996/11/01 00:00
PHST- 1996/11/01 00:00 [pubmed]
PHST- 1996/11/01 00:01 [medline]
PHST- 1996/11/01 00:00 [entrez]
PST - ppublish
SO  - Rev Esp Cardiol. 1996 Nov;49(11):793-800.

PMID- 3531311
OWN - NLM
STAT- MEDLINE
DCOM- 19861118
LR  - 20190817
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 8
IP  - 3 Pt 2
DP  - 1986 Jun
TI  - Reduction of aspirin-induced gastroduodenal mucosal damage with ranitidine.
PG  - 377-80
AB  - A randomized, double-blind, placebo-controlled study was conducted to determine 
      if concomitant administration of ranitidine, an H2-receptor antagonist, could 
      reduce the gastroduodenal mucosal damage associated with short-term (3 day) 
      aspirin therapy. Nineteen subjects received ranitidine 150 mg b.i.d. plus aspirin 
      650 mg q.i.d., and 21 received placebo b.i.d. plus aspirin 650 mg q.i.d. for 3 
      days. Gastric injury and duodenal injury were assessed separately on the basis of 
      pre- and posttreatment endoscopic examinations. The ranitidine/aspirin group had 
      significantly less mucosal damage in the stomach (p less than or equal to 0.01) 
      and duodenum (p less than 0.05) than the placebo/aspirin group. There was no 
      significant difference in mean serum salicylate levels between treatment groups 
      after 3 days of aspirin consumption, indicating that the protective effect was 
      achieved without compromising salicylate absorption.
FAU - Berkowitz, J M
AU  - Berkowitz JM
FAU - Adler, S N
AU  - Adler SN
FAU - Sharp, J T
AU  - Sharp JT
FAU - Warner, C W
AU  - Warner CW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 884KT10YB7 (Ranitidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*toxicity
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Gastric Mucosa/*drug effects
MH  - Gastroscopy
MH  - Humans
MH  - Intestinal Mucosa/*drug effects
MH  - Male
MH  - Random Allocation
MH  - Ranitidine/administration & dosage/*therapeutic use
MH  - Time Factors
EDAT- 1986/06/01 00:00
MHDA- 1986/06/01 00:01
CRDT- 1986/06/01 00:00
PHST- 1986/06/01 00:00 [pubmed]
PHST- 1986/06/01 00:01 [medline]
PHST- 1986/06/01 00:00 [entrez]
AID - 10.1097/00004836-198606002-00009 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 1986 Jun;8(3 Pt 2):377-80. doi: 
      10.1097/00004836-198606002-00009.

PMID- 21284360
OWN - NLM
STAT- MEDLINE
DCOM- 20110311
LR  - 20131121
IS  - 1167-7422 (Print)
IS  - 1167-7422 (Linking)
VI  - 19
IP  - 110
DP  - 2010 Nov
TI  - Aspirin and primary cardiovascular prevention. Uncertain balance between benefits 
      and risks.
PG  - 258-61
AB  - Most individuals with no pre-existing cardiovascular disease have a low risk of 
      experiencing arterial thrombosis. Using the standard Prescrire methodology, we 
      reviewed the literature on the risk-benefit balance of aspirin in the primary 
      prevention of cardiovascular events. In the general population, a meta-analysis 
      in 95 456 persons suggests that aspirin has no effect on either total or 
      cardiovascular mortality. Aspirin may slightly reduce the risk of stroke in women 
      and myocardial infarction in men, but it increases the risk of bleeding. It is 
      unclear whether the benefits outweigh the risks. Aspirin does not reduce 
      mortality in the elderly. in one trial, aspirin reduced the risk of ischaemic 
      stroke and myocardial infarction in women aged 65 and over. However, the risk of 
      cerebral haemorrhage associated with aspirin increases with age. Therefore, the 
      risk-benefit balance of aspirin in primary cardiovascular prevention in the 
      elderly is uncertain. Aspirin is more beneficial in patients with cardiovascular 
      risk factors, but the bleeding risk is sometimes higher too. In clinical trials, 
      aspirin did not reduce either total or cardiovascular mortality in hypertensive 
      or diabetic patients. In contrast, it reduced the risk of myocardial infarction 
      in hypertensive patients and diabetic men. Aspirin did not prevent cardiovascular 
      events in smokers, and has not been assessed in patients with 
      hypercholesterolaemia. In practice, the risks outweigh the benefits when aspirin 
      is used to prevent a first thrombotic event in people at low risk. When the 
      cardiovascular risk is higher than in the general population, for example in 
      patients with risk factors, the weak preventive effects of aspirin on myocardial 
      infarction and ischaemic stroke may outweigh the small extra risk of bleeding. 
      The possible value of aspirin for cardiovascular prevention should be discussed 
      with each individual patient. In general, it is preferable to recommend measures 
      with a proven impact on mortality, such as dietary changes, smoking cessation, or 
      drug therapy for patients with risk factors.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Prescrire Int
JT  - Prescrire international
JID - 9439295
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
EDAT- 2011/02/03 06:00
MHDA- 2011/03/12 06:00
CRDT- 2011/02/03 06:00
PHST- 2011/02/03 06:00 [entrez]
PHST- 2011/02/03 06:00 [pubmed]
PHST- 2011/03/12 06:00 [medline]
PST - ppublish
SO  - Prescrire Int. 2010 Nov;19(110):258-61.

PMID- 23883603
OWN - NLM
STAT- MEDLINE
DCOM- 20131018
LR  - 20230807
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 34
IP  - 4
DP  - 2013 Jul-Aug
TI  - The clinical dilemma of "silent desensitization" in aspirin-exacerbated 
      respiratory disease.
PG  - 378-382
LID - 10.2500/aap.2013.34.3670 [doi]
AB  - Aspirin desensitization is a treatment option for patients with 
      aspirin-exacerbated respiratory disease (AERD). Some patients with an excellent 
      history of aspirin or nonsteroidal anti-inflammatory drug (NSAID) reactions have 
      negative aspirin challenges/desensitization. This study discusses the clinical 
      entity of silent desensitization in AERD and the dilemma that this presents to 
      the practicing allergist/immunologist. We discuss a series of patients with a 
      strong history of NSAID reactions who initially underwent a negative 
      challenge/silent desensitization. These patients were subsequently proven to have 
      AERD after a second positive aspirin challenge. Silent desensitization is an 
      uncommon but important outcome to recognize in AERD. Clinicians performing 
      aspirin desensitization should understand that this can occur and consider a 
      second confirmatory aspirin challenge in some patients.
FAU - White, Andrew A
AU  - White AA
AD  - Division of Allergy, Asthma and Immunology, Scripps Clinic, La Jolla California, 
      USA.
FAU - Bosso, John V
AU  - Bosso JV
FAU - Stevenson, Donald D
AU  - Stevenson DD
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - *Aspirin/adverse effects/therapeutic use
MH  - Child
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiratory Tract Diseases/chemically induced/drug therapy
MH  - Young Adult
EDAT- 2013/07/26 06:00
MHDA- 2013/10/19 06:00
CRDT- 2013/07/26 06:00
PHST- 2013/07/26 06:00 [entrez]
PHST- 2013/07/26 06:00 [pubmed]
PHST- 2013/10/19 06:00 [medline]
AID - 10.2500/aap.2013.34.3670 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2013 Jul-Aug;34(4):378-382. doi: 10.2500/aap.2013.34.3670.

PMID- 1931061
OWN - NLM
STAT- MEDLINE
DCOM- 19911220
LR  - 20190912
IS  - 0952-8180 (Print)
IS  - 0952-8180 (Linking)
VI  - 3
IP  - 5
DP  - 1991 Sep-Oct
TI  - A comparison of thromboelastogram and template bleeding time in the evaluation of 
      platelet function after aspirin ingestion.
PG  - 377-81
AB  - STUDY OBJECTIVE: To compare template bleeding time (TBT) with thromboelastography 
      (TEG) in human subjects after aspirin ingestion. DESIGN: Healthy volunteers were 
      given a single 650 mg dose of aspirin or a dose of 650 mg of aspirin on three 
      successive days. TBT and TEG studies were performed prior to aspirin ingestion 
      and 4, 24, 72, and 168 hours after ingestion. SETTING: Inpatient operating room 
      support area at the UCLA Center for Health Sciences. VOLUNTEERS: Residents and 
      nurses who were in good general health, had not taken aspirin for 2 weeks, had 
      normal platelet counts, and had no evidence of bleeding or coagulation disorders. 
      INTERVENTION: TBT and TEG studies were performed prior to and after the ingestion 
      of aspirin. MEASUREMENTS AND MAIN RESULTS: TBT studies were significantly 
      prolonged at 4, 24, and 72 hours compared with controls. Maximum bleeding time 
      prolongation occurred 24 hours after aspirin ingestion. Bleeding time returned to 
      control values by the end of 168 hours (1 week). No TEG parameter was 
      significantly changed by aspirin ingestion. CONCLUSION: TEG results may not 
      identify patients who have an increased bleeding time as a result of aspirin 
      ingestion.
FAU - Trentalange, M J
AU  - Trentalange MJ
AD  - Department of Anesthesiology, UCLA School of Medicine 90024-1778.
FAU - Walts, L F
AU  - Walts LF
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Clin Anesth
JT  - Journal of clinical anesthesia
JID - 8812166
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - *Bleeding Time
MH  - Blood Platelets/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Thrombelastography
MH  - Time Factors
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
AID - 0952-8180(91)90179-Q [pii]
AID - 10.1016/0952-8180(91)90179-q [doi]
PST - ppublish
SO  - J Clin Anesth. 1991 Sep-Oct;3(5):377-81. doi: 10.1016/0952-8180(91)90179-q.

PMID- 6956985
OWN - NLM
STAT- MEDLINE
DCOM- 19821203
LR  - 20190702
IS  - 0038-4348 (Print)
IS  - 0038-4348 (Linking)
VI  - 75
IP  - 10
DP  - 1982 Oct
TI  - Analgesics and asthma.
PG  - 1239-44
AB  - Aspirin and many other analgesics may be hazardous for some patients with asthma. 
      These patients, numbering approximately 10% to 15% of all asthmatics, have a 
      clinical course that has been well characterized. The diagnosis is usually made 
      from the history, but sometimes it requires analgesic challenge tests. The 
      pathogenesis remains controversial. It appears that the analgesics responsible 
      for the syndrome inhibit prostaglandin synthesis, and this action in turn causes 
      the release of potent bronchoconstrictors such as SRS-A, histamine, or kinins. 
      Usually, recognition of the syndrome and careful avoidance of prostaglandin 
      synthesis inhibitors in affected patients are the two steps needed for effective 
      management. Persistent symptoms, however, may require aminophylline, 
      corticosteroids, and disodium cromoglycate as well. Recent developments may allow 
      these patients to use substituted aspirin analogues or even aspirin itself under 
      certain conditions. Further investigation of the prostaglandins may promote a 
      better understanding of asthma.
FAU - Margolis, M
AU  - Margolis M
FAU - Mohan, K K
AU  - Mohan KK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - 0 (Analgesics)
RN  - 0 (Prostaglandins)
RN  - 0 (Prostaglandins E)
RN  - 0 (Prostaglandins F)
RN  - 0 (SRS-A)
RN  - B7IN85G1HY (Dinoprost)
RN  - F5TD010360 (Alprostadil)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Alprostadil
MH  - Analgesics/*adverse effects
MH  - Aspirin/*adverse effects/analogs & derivatives/physiology
MH  - Asthma/*chemically induced/complications/physiopathology
MH  - Dinoprost
MH  - Dinoprostone
MH  - Drug Hypersensitivity/*etiology
MH  - Humans
MH  - Prostaglandins/*physiology
MH  - Prostaglandins E/physiology
MH  - Prostaglandins F/physiology
MH  - SRS-A/physiology
EDAT- 1982/10/01 00:00
MHDA- 1982/10/01 00:01
CRDT- 1982/10/01 00:00
PHST- 1982/10/01 00:00 [pubmed]
PHST- 1982/10/01 00:01 [medline]
PHST- 1982/10/01 00:00 [entrez]
AID - 10.1097/00007611-198210000-00021 [doi]
PST - ppublish
SO  - South Med J. 1982 Oct;75(10):1239-44. doi: 10.1097/00007611-198210000-00021.

PMID- 3436909
OWN - NLM
STAT- MEDLINE
DCOM- 19880325
LR  - 20131121
IS  - 0004-5756 (Print)
IS  - 0004-5756 (Linking)
VI  - 70
IP  - 6
DP  - 1987 Nov-Dec
TI  - Determination of aspirin and salicylic acid by reverse-phase liquid 
      chromatography.
PG  - 964-6
AB  - Buffered solid dosage forms containing aspirin, magnesium hydroxide, and aluminum 
      hydroxide are blended with acidic ethanol to extract the aspirin and salicylic 
      acid rapidly. The resulting preparation is then immediately injected onto a 4.6 
      mm x 3 cm 5 micron reverse-phase column. Aspirin and free salicylic acid are 
      determined simultaneously. The run time is less than 2 min. The total time from 
      the initiation of sample extraction to completion of the separation is less than 
      5 min.
FAU - Heidemann, D R
AU  - Heidemann DR
AD  - Sandoz Consumer Health Care Group (Sandoz Pharmaceuticals Corp.), Analytical 
      Research Department, Lincoln, NE 68501-3288.
FAU - Schulenberg, E S
AU  - Schulenberg ES
FAU - Smith, W H
AU  - Smith WH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Assoc Off Anal Chem
JT  - Journal - Association of Official Analytical Chemists
JID - 7505559
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, Liquid
MH  - Hydrolysis
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets
EDAT- 1987/11/01 00:00
MHDA- 1987/11/01 00:01
CRDT- 1987/11/01 00:00
PHST- 1987/11/01 00:00 [pubmed]
PHST- 1987/11/01 00:01 [medline]
PHST- 1987/11/01 00:00 [entrez]
PST - ppublish
SO  - J Assoc Off Anal Chem. 1987 Nov-Dec;70(6):964-6.

PMID- 24861258
OWN - NLM
STAT- MEDLINE
DCOM- 20150417
LR  - 20140716
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 175
IP  - 2
DP  - 2014 Aug 1
TI  - 24-hour antiplatelet effect of aspirin in patients with previous definite stent 
      thrombosis.
PG  - 274-9
LID - S0167-5273(14)00996-6 [pii]
LID - 10.1016/j.ijcard.2014.05.013 [doi]
AB  - OBJECTIVE: Once-daily aspirin is standard treatment, but recent studies point 
      towards increased platelet function at the end of the dosing interval. Stent 
      thrombosis (ST) has been linked with reduced antiplatelet effect of aspirin, so 
      we investigated if platelet inhibition by aspirin declines through 24 h in 
      patients with previous definite ST. Furthermore, we explored whether increased 
      levels of immature platelets and thrombopoietin are associated with a 
      particularly rapid recovery of platelet function. METHODS: This case-control 
      study included 50 patients with previous definite ST matched with 100 patients 
      with stable coronary artery disease and 50 healthy volunteers. All participants 
      were on aspirin 75 mg/day mono antiplatelet therapy. Platelet aggregation was 
      measured 1 and 24 h after aspirin intake using platelet aggregometry (Multiplate® 
      Analyzer). Cyclooxygenase-1 activity, platelet activation, immature platelets, 
      and thrombopoietin were measured. RESULTS: Platelet aggregation increased by 
      109±150 (arachidonic acid) and 47±155 (collagen) aggregation units per minute 
      from 1 to 24 h after aspirin intake (p-values <0.0001) with corresponding 
      increases in thromboxane B2 (5.6±5.1 ng/ml, p<0.0001) and soluble P-selectin 
      (6.2±15.5 ng/ml, p<0.0001). Platelet aggregation increased equally in all groups, 
      but patients with previous ST displayed the highest levels of platelet 
      aggregation at 24 h (p-values≤0.05) and the highest levels of immature platelets 
      (p<0.01) and thrombopoietin (p<0.0001). CONCLUSIONS: Platelet inhibition declined 
      significantly during the 24-hour dosing interval in aspirin-treated patients with 
      previous definite ST or stable coronary artery disease and in healthy 
      individuals. Increased levels of immature platelets and thrombopoietin were 
      observed in patients with previous definite ST.
CI  - Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
FAU - Würtz, Morten
AU  - Würtz M
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Hvas, Anne-Mette
AU  - Hvas AM
AD  - Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
FAU - Jensen, Lisette O
AU  - Jensen LO
AD  - Department of Cardiology, Odense University Hospital, Odense, Denmark.
FAU - Kaltoft, Anne K
AU  - Kaltoft AK
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Tilsted, Hans H
AU  - Tilsted HH
AD  - Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
FAU - Kristensen, Steen D
AU  - Kristensen SD
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Grove, Erik L
AU  - Grove EL
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. Electronic 
      address: erikgrove@dadlnet.dk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140516
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/blood/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects/physiology
MH  - Case-Control Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/blood/pharmacology/*therapeutic use
MH  - Stents/*adverse effects
MH  - Thrombosis/blood/diagnosis/*prevention & control
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Platelet aggregation
OT  - Platelet function test
OT  - Platelet turnover
OT  - Stent thrombosis
EDAT- 2014/05/28 06:00
MHDA- 2015/04/18 06:00
CRDT- 2014/05/28 06:00
PHST- 2013/10/08 00:00 [received]
PHST- 2014/03/19 00:00 [revised]
PHST- 2014/05/11 00:00 [accepted]
PHST- 2014/05/28 06:00 [entrez]
PHST- 2014/05/28 06:00 [pubmed]
PHST- 2015/04/18 06:00 [medline]
AID - S0167-5273(14)00996-6 [pii]
AID - 10.1016/j.ijcard.2014.05.013 [doi]
PST - ppublish
SO  - Int J Cardiol. 2014 Aug 1;175(2):274-9. doi: 10.1016/j.ijcard.2014.05.013. Epub 
      2014 May 16.

PMID- 1438512
OWN - NLM
STAT- MEDLINE
DCOM- 19921211
LR  - 20131121
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 47
IP  - 8
DP  - 1992 Aug
TI  - Bioavailability of two formulations of acetylsalicylic acid gums.
PG  - 607-9
AB  - Bioavailability studies have been performed with ten healthy volunteers on 
      different dosage forms of acetylsalicylic acid (ASA) in order to assess the 
      bioavailability of two different ASA gums compared with commercial ASA tablets. 
      The results of this study show that ASA is more readily absorbed and eliminated 
      after administration of gum formulations than after administration of tablets, 
      but the bioavailability obtained from the gums was lower than that observed from 
      the tablets.
FAU - Bousquet, E
AU  - Bousquet E
AD  - Istituto di Chimica Farmaceutica e Tossicologia, Facoltà di Farmacia, Università 
      di Catania, Italy.
FAU - Tirendi, S
AU  - Tirendi S
FAU - Bonina, F P
AU  - Bonina FP
FAU - Montenegro, L
AU  - Montenegro L
FAU - Bianchi, A
AU  - Bianchi A
FAU - Ciampini, N
AU  - Ciampini N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Chewing Gum)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Biological Availability
MH  - Chewing Gum
MH  - Humans
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1992 Aug;47(8):607-9.

PMID- 665123
OWN - NLM
STAT- MEDLINE
DCOM- 19780901
LR  - 20181130
IS  - 0300-970X (Print)
IS  - 0300-970X (Linking)
VI  - 25
IP  - 3
DP  - 1978 Jun
TI  - Failure of lysine-acetylsalicylate and phenylbutazone to affect gastrin secretion 
      in healthy adults.
PG  - 219-21
AB  - The effect of acute parenteral and chronic oral administration of 
      lysine-acetylsalicylate and phenylbutazone on fasting and meal-stimulated serum 
      gastrin levels was investigated in healthy volunteers. No significant changes in 
      gastrin secretion were induced by any treatment. The results confirm and extend 
      previous observations suggesting that the ulcerogenic properties of salicylates 
      and phenylbutazone are not related to increased gastrin secretion.
FAU - Caldara, R
AU  - Caldara R
FAU - Cutarelli, G
AU  - Cutarelli G
FAU - Ferrari, C
AU  - Ferrari C
FAU - Romussi, M
AU  - Romussi M
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Acta Hepatogastroenterol (Stuttg)
JT  - Acta hepato-gastroenterologica
JID - 0340734
RN  - 0 (Gastrins)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Gastrins/*metabolism
MH  - Humans
MH  - Infusions, Parenteral
MH  - Lysine/administration & dosage/*pharmacology
MH  - Phenylbutazone/administration & dosage/*pharmacology
EDAT- 1978/06/01 00:00
MHDA- 1978/06/01 00:01
CRDT- 1978/06/01 00:00
PHST- 1978/06/01 00:00 [pubmed]
PHST- 1978/06/01 00:01 [medline]
PHST- 1978/06/01 00:00 [entrez]
PST - ppublish
SO  - Acta Hepatogastroenterol (Stuttg). 1978 Jun;25(3):219-21.

PMID- 12383337
OWN - NLM
STAT- MEDLINE
DCOM- 20030610
LR  - 20191106
IS  - 0958-7578 (Print)
IS  - 0958-7578 (Linking)
VI  - 12
IP  - 5
DP  - 2002 Oct
TI  - Effect of diaspirin cross-linked haemoglobin (DCLHb) on mean arterial pressure 
      during cardiopulmonary bypass in swine.
PG  - 311-6
AB  - Diaspirin cross-linked haemoglobin (DCLHb) is a haemoglobin-based oxygen carrier 
      which had been proposed as a resuscitative solution to replace red cell 
      transfusion in many clinical situations. The present study was designed to 
      evaluate the effect of different volumes of DCLHb 10% (1, 5 and 10 mL kg-1) on 
      the cardiovascular system during cardiopulmonary bypass (CPB), and to determine 
      the effect of DCLHb (18 mL kg-1) when added directly to the CPB prime in 
      anaesthetized swine. DCLHb, when used as a priming solution, induced a 
      significant increase (around 20%) in mean arterial pressure (MAP), which 
      persisted during the entire period of CPB (P < 0.05) as compared with controls. 
      Administration of increasing doses of DCLHb during the time course of CPB 
      resulted in a progressive increase in MAP (P < 0.05), suggesting a linear 
      dose-response relationship. Nicardipine, a calcium channel blocker, returned MAP 
      to baseline. Finally, weaning of CPB was easier in animals that received DCLHb, 
      thereby suggesting a potential protective effect of free haemoglobin in this 
      particular clinical situation.
FAU - Ferrera, R
AU  - Ferrera R
AD  - INSERM EMI-U 0226, Laboratoire de Physiologie, Lyon, France. 
      ferrera@lyon151.inserm.fr
FAU - Hadour, G
AU  - Hadour G
FAU - Chiari, P
AU  - Chiari P
FAU - Montagna, P
AU  - Montagna P
FAU - Jegaden, O
AU  - Jegaden O
FAU - Burhop, K
AU  - Burhop K
FAU - Lehot, J J
AU  - Lehot JJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Transfus Med
JT  - Transfusion medicine (Oxford, England)
JID - 9301182
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - CZ5312222S (Nicardipine)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteries/physiology
MH  - Aspirin/administration & dosage/*analogs & derivatives/*pharmacology
MH  - Blood Gas Analysis
MH  - Blood Pressure/*drug effects
MH  - Blood Substitutes/administration & dosage/*pharmacology
MH  - Cardiopulmonary Bypass/*methods
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical
MH  - Hemoglobins/administration & dosage/*pharmacology
MH  - Nicardipine/administration & dosage/pharmacology
MH  - Perioperative Care
MH  - Swine
EDAT- 2002/10/18 04:00
MHDA- 2003/06/11 05:00
CRDT- 2002/10/18 04:00
PHST- 2002/10/18 04:00 [pubmed]
PHST- 2003/06/11 05:00 [medline]
PHST- 2002/10/18 04:00 [entrez]
AID - 391 [pii]
AID - 10.1046/j.1365-3148.2002.00391.x [doi]
PST - ppublish
SO  - Transfus Med. 2002 Oct;12(5):311-6. doi: 10.1046/j.1365-3148.2002.00391.x.

PMID- 6470964
OWN - NLM
STAT- MEDLINE
DCOM- 19841012
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 73
IP  - 7
DP  - 1984 Jul
TI  - Hypolipidemic activity of 
      tetrakis-mu-(trimethylamine-boranecarboxylato)-bis(trimethylamin e- 
      carboxyborane)-dicopper(II) in rodents and its effect on lipid metabolism.
PG  - 973-7
AB  - A binuclear copper(II) complex was shown to have potent hypolipidemic activity in 
      rats and mice at low doses, i.e., 2.5-10 mg/kg/d. The agent moderately lowered 
      liver ATP-dependent citrate lyase, acetyl CoA synthetase, and phosphatidate 
      phosphohydrolase activities in vivo. The appetite of the animal was reduced by 
      drug treatment, and orally administered cholesterol absorption from the intestine 
      was markedly lowered. Higher lipid levels were found in the chyme and the feces, 
      indicating accelerated excretion of lipids by the drug, probably via the biliary 
      route. Organs, e.g., liver and small intestine, as well as serum lipoprotein 
      levels, demonstrated lower lipid content after drug administration. Thus, this 
      chemical class of agents may have potential as a hypolipidemic agent in humans.
FAU - Hall, I H
AU  - Hall IH
FAU - Williams, W L Jr
AU  - Williams WL Jr
FAU - Gilbert, C J
AU  - Gilbert CJ
FAU - McPhail, A T
AU  - McPhail AT
FAU - Spielvogel, B F
AU  - Spielvogel BF
LA  - eng
GR  - 1 RO1 HL25680/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Lipoproteins)
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - 789U1901C5 (Copper)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemical synthesis/pharmacology
MH  - Bile/metabolism
MH  - Cholesterol/metabolism
MH  - Copper/metabolism
MH  - Feces/analysis
MH  - Hypolipidemic Agents/chemical synthesis/*pharmacology
MH  - Intestinal Absorption
MH  - Intestine, Small/metabolism
MH  - *Lipid Metabolism
MH  - Lipoproteins/blood
MH  - Liver/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Organ Size/drug effects
MH  - Rats
EDAT- 1984/07/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
AID - S0022-3549(15)46220-3 [pii]
AID - 10.1002/jps.2600730728 [doi]
PST - ppublish
SO  - J Pharm Sci. 1984 Jul;73(7):973-7. doi: 10.1002/jps.2600730728.

PMID- 16488805
OWN - NLM
STAT- MEDLINE
DCOM- 20060302
LR  - 20150616
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 367
IP  - 9510
DP  - 2006 Feb 18
TI  - Aspirin resistance.
PG  - 606-17
AB  - Aspirin resistance is the inability of aspirin to reduce platelet production of 
      thromboxane A2 and thereby platelet activation and aggregation. Increasing 
      degrees of aspirin resistance may correlate independently with increasing risk of 
      cardiovascular events. Aspirin resistance can be detected by laboratory tests of 
      platelet thromboxane A2 production or platelet function that depend on platelet 
      thromboxane production. Potential causes of aspirin resistance include inadequate 
      dose, drug interactions, genetic polymorphisms of COX-1 and other genes involved 
      in thromboxane biosynthesis, upregulation of non-platelet sources of thromboxane 
      biosynthesis, and increased platelet turnover. Aspirin resistance can be overcome 
      by treating the cause or causes, and reduced by minimising thromboxane production 
      and activity, and blocking other pathways of platelet activation. Future research 
      is aimed at defining aspirin resistance, developing reliable tests for it, and 
      establishing the risk of associated cardiovascular events. Potential mechanisms 
      of aspirin resistance can then be explored and treatments assessed.
FAU - Hankey, Graeme J
AU  - Hankey GJ
AD  - Department of Neurology, Royal Perth Hospital and School of Medicine and 
      Pharmacology, University of Western Australia, Perth, WA, Australia.
FAU - Eikelboom, John W
AU  - Eikelboom JW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2006 Jun 24;367(9528):2059-60. PMID: 16798385
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics/*therapeutic use
MH  - Aspirin/pharmacokinetics/*therapeutic use
MH  - Biological Availability
MH  - Drug Resistance/*physiology
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Prevalence
MH  - Prognosis
RF  - 113
EDAT- 2006/02/21 09:00
MHDA- 2006/03/03 09:00
CRDT- 2006/02/21 09:00
PHST- 2006/02/21 09:00 [pubmed]
PHST- 2006/03/03 09:00 [medline]
PHST- 2006/02/21 09:00 [entrez]
AID - S0140-6736(06)68040-9 [pii]
AID - 10.1016/S0140-6736(06)68040-9 [doi]
PST - ppublish
SO  - Lancet. 2006 Feb 18;367(9510):606-17. doi: 10.1016/S0140-6736(06)68040-9.

PMID- 37003144
OWN - NLM
STAT- MEDLINE
DCOM- 20230505
LR  - 20230614
IS  - 1532-2823 (Electronic)
IS  - 0952-3278 (Linking)
VI  - 192
DP  - 2023 May
TI  - Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic 
      acid treatment in the seAFOod polyp prevention trial.
PG  - 102570
LID - S0952-3278(23)00039-X [pii]
LID - 10.1016/j.plefa.2023.102570 [doi]
AB  - BACKGROUND: Aspirin and eicosapentaenoic acid (EPA) have colorectal polyp 
      prevention activity, alone and in combination. This study measured levels of 
      plasma and rectal mucosal oxylipins in participants of the seAFOod 2 × 2 
      factorial, randomised, placebo-controlled trial, who received aspirin 300 mg 
      daily and EPA 2000 mg free fatty acid, alone and in combination, for 12 months. 
      METHODS: Resolvin (Rv) E1, 15-epi-lipoxin (LX) A(4) and respective precursors 
      18-HEPE and 15-HETE (with chiral separation) were measured by ultra-high 
      performance liquid chromatography-tandem mass spectrometry in plasma taken at 
      baseline, 6 months and 12 months, as well as rectal mucosa obtained at trial exit 
      colonoscopy at 12 months, in 401 trial participants. RESULTS: Despite detection 
      of S- and R- enantiomers of 18-HEPE and 15-HETE in ng/ml concentrations, RvE1 or 
      15‑epi-LXA(4) were not detected above a limit of detection of 20 pg/ml in plasma 
      or rectal mucosa, even in individuals randomised to both aspirin and EPA. We have 
      confirmed in a large clinical trial cohort that prolonged (12 months) treatment 
      with EPA is associated with increased plasma 18-HEPE concentrations (median 
      [inter-quartile range] total 18-HEPE 0.51 [0.21-1.95] ng/ml at baseline versus 
      0.95 [0.46-4.06] ng/ml at 6 months [P<0.0001] in those randomised to EPA alone), 
      which correlate strongly with respective rectal mucosal 18-HEPE levels (r = 0.82; 
      P<0.001), but which do not predict polyp prevention efficacy by EPA or aspirin. 
      CONCLUSION: Analysis of seAFOod trial plasma and rectal mucosal samples has not 
      provided evidence of synthesis of the EPA-derived specialised pro-resolving 
      mediator RvE1 or aspirin-trigged lipoxin 15‑epi-LXA(4). We cannot rule out 
      degradation of individual oxylipins during sample collection and storage but 
      readily measurable precursor oxylipins argues against widespread degradation.
CI  - Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Fuller, H
AU  - Fuller H
AD  - Leeds Institute of Medical Research, University of Leeds, UK.
FAU - Race, A D
AU  - Race AD
AD  - Institute of Cancer Therapeutics, University of Bradford, UK.
FAU - Fenton, H
AU  - Fenton H
AD  - Leeds Institute of Medical Research, University of Leeds, UK.
FAU - Burke, L
AU  - Burke L
AD  - Institute of Cancer Therapeutics, University of Bradford, UK.
FAU - Downing, A
AU  - Downing A
AD  - Leeds Institute of Medical Research, University of Leeds, UK.
FAU - Williams, E A
AU  - Williams EA
AD  - Department of Oncology and Metabolism, University of Sheffield, UK.
FAU - Rees, C J
AU  - Rees CJ
AD  - Population Health Science Institute, Newcastle University, UK.
FAU - Brown, L C
AU  - Brown LC
AD  - MRC Clinical Trials Unit at University College, London, UK.
FAU - Loadman, P M
AU  - Loadman PM
AD  - Institute of Cancer Therapeutics, University of Bradford, UK.
FAU - Hull, M A
AU  - Hull MA
AD  - Leeds Institute of Medical Research, University of Leeds, UK. Electronic address: 
      M.A.Hull@leeds.ac.uk.
LA  - eng
GR  - NIHR128210/DH_/Department of Health/United Kingdom
GR  - MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20230323
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - R16CO5Y76E (Aspirin)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - 0 (Oxylipins)
RN  - 0 (Lipoxins)
SB  - IM
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - Eicosapentaenoic Acid/therapeutic use
MH  - Oxylipins
MH  - *Lipoxins
MH  - Mucous Membrane
OTO - NOTNLM
OT  - Colorectal cancer
OT  - Colorectal polyp
OT  - HEPE
OT  - HETE
OT  - Lipoxin
OT  - Oxylipin
OT  - Resolvin
COIS- Declaration of Competing Interest CJR has received grant funding from Medtronic 
      and was an expert witness for Olympus and ARC Medical. All the other Authors 
      declare no conflict of interest.
EDAT- 2023/04/02 06:00
MHDA- 2023/05/05 06:42
CRDT- 2023/04/01 18:07
PHST- 2022/12/12 00:00 [received]
PHST- 2023/03/20 00:00 [revised]
PHST- 2023/03/21 00:00 [accepted]
PHST- 2023/05/05 06:42 [medline]
PHST- 2023/04/02 06:00 [pubmed]
PHST- 2023/04/01 18:07 [entrez]
AID - S0952-3278(23)00039-X [pii]
AID - 10.1016/j.plefa.2023.102570 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2023 May;192:102570. doi: 
      10.1016/j.plefa.2023.102570. Epub 2023 Mar 23.

PMID- 28657417
OWN - NLM
STAT- MEDLINE
DCOM- 20170823
LR  - 20221208
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 7
DP  - 2017 Aug 17
TI  - Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.
PG  - 613-622
LID - 10.1056/NEJMoa1704559 [doi]
AB  - BACKGROUND: Preterm preeclampsia is an important cause of maternal and perinatal 
      death and complications. It is uncertain whether the intake of low-dose aspirin 
      during pregnancy reduces the risk of preterm preeclampsia. METHODS: In this 
      multicenter, double-blind, placebo-controlled trial, we randomly assigned 1776 
      women with singleton pregnancies who were at high risk for preterm preeclampsia 
      to receive aspirin, at a dose of 150 mg per day, or placebo from 11 to 14 weeks 
      of gestation until 36 weeks of gestation. The primary outcome was delivery with 
      preeclampsia before 37 weeks of gestation. The analysis was performed according 
      to the intention-to-treat principle. RESULTS: A total of 152 women withdrew 
      consent during the trial, and 4 were lost to follow up, which left 798 
      participants in the aspirin group and 822 in the placebo group. Preterm 
      preeclampsia occurred in 13 participants (1.6%) in the aspirin group, as compared 
      with 35 (4.3%) in the placebo group (odds ratio in the aspirin group, 0.38; 95% 
      confidence interval, 0.20 to 0.74; P=0.004). Results were materially unchanged in 
      a sensitivity analysis that took into account participants who had withdrawn or 
      were lost to follow-up. Adherence was good, with a reported intake of 85% or more 
      of the required number of tablets in 79.9% of the participants. There were no 
      significant between-group differences in the incidence of neonatal adverse 
      outcomes or other adverse events. CONCLUSIONS: Treatment with low-dose aspirin in 
      women at high risk for preterm preeclampsia resulted in a lower incidence of this 
      diagnosis than placebo. (Funded by the European Union Seventh Framework Program 
      and the Fetal Medicine Foundation; EudraCT number, 2013-003778-29 ; Current 
      Controlled Trials number, ISRCTN13633058 .).
FAU - Rolnik, Daniel L
AU  - Rolnik DL
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Wright, David
AU  - Wright D
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Poon, Liona C
AU  - Poon LC
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - O'Gorman, Neil
AU  - O'Gorman N
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Syngelaki, Argyro
AU  - Syngelaki A
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - de Paco Matallana, Catalina
AU  - de Paco Matallana C
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Akolekar, Ranjit
AU  - Akolekar R
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Cicero, Simona
AU  - Cicero S
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Janga, Deepa
AU  - Janga D
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Singh, Mandeep
AU  - Singh M
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Molina, Francisca S
AU  - Molina FS
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Persico, Nicola
AU  - Persico N
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Jani, Jacques C
AU  - Jani JC
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Plasencia, Walter
AU  - Plasencia W
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Papaioannou, George
AU  - Papaioannou G
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Tenenbaum-Gavish, Kinneret
AU  - Tenenbaum-Gavish K
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Meiri, Hamutal
AU  - Meiri H
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Gizurarson, Sveinbjorn
AU  - Gizurarson S
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Maclagan, Kate
AU  - Maclagan K
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
AD  - From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton 
      University Hospital (S.C.), North Middlesex University Hospital (D.J.), and 
      University College London Comprehensive Clinical Trials Unit (K.M.), London, 
      University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), 
      and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United 
      Kingdom; Chinese University of Hong Kong, Hong Kong (L.C.P.); Hospital Clínico 
      Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San 
      Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain; 
      Ospedale Maggiore Policlinico, Milan (N.P.); University Hospital Brugmann, 
      Université Libre de Bruxelles, Brussels (J.C.J.); Attikon University Hospital, 
      Athens (G.P.); Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs 
      Diagnostics, Rehovot (H.M.) - both in Israel; and University of Iceland, 
      Reykjavik (S.G.).
LA  - eng
SI  - ISRCTN/ISRCTN13633058
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20170628
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2017 Aug 17;377(7):690-691. PMID: 28813213
CIN - N Engl J Med. 2017 Dec 14;377(24):2399-400. PMID: 29239588
CIN - Natl Med J India. 2018 Jan-Feb;31(1):26-27. PMID: 30348920
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Infant, Newborn
MH  - Intention to Treat Analysis
MH  - Kaplan-Meier Estimate
MH  - Pre-Eclampsia/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications
MH  - Pregnancy Outcome
MH  - Risk
EDAT- 2017/06/29 06:00
MHDA- 2017/08/24 06:00
CRDT- 2017/06/29 06:00
PHST- 2017/06/29 06:00 [pubmed]
PHST- 2017/08/24 06:00 [medline]
PHST- 2017/06/29 06:00 [entrez]
AID - 10.1056/NEJMoa1704559 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Aug 17;377(7):613-622. doi: 10.1056/NEJMoa1704559. Epub 2017 
      Jun 28.

PMID- 2239321
OWN - NLM
STAT- MEDLINE
DCOM- 19901210
LR  - 20131121
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 25
IP  - 2
DP  - 1990
TI  - [Application of ridge regression spectrophotometry to the determination of 
      multicomponents in aspirin compound tablet].
PG  - 137-41
AB  - In this paper, a ridge regression method of spectrophotometry in multiwavelength 
      is proposed. The basic principle and computing of this method applied to 
      multicomponent analysis were discussed. This method was applied to simultaneous 
      determination of multicomponents in aspirin compound tablet and satisfactory 
      results were obtained. The experiment clearly indicates that ridge regression may 
      provide a new approach to experimental measurement of multicomponent analysis 
      computations.
FAU - Liu, S Q
AU  - Liu SQ
AD  - Shenyang College of Pharmacy.
FAU - Yuan, B
AU  - Yuan B
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Caffeine/analysis
MH  - Drug Combinations
MH  - Phenacetin/analysis
MH  - Spectrophotometry/methods
MH  - Tablets
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - Yao Xue Xue Bao. 1990;25(2):137-41.

PMID- 10234539
OWN - NLM
STAT- MEDLINE
DCOM- 19990610
LR  - 20191103
IS  - 0939-6411 (Print)
IS  - 0939-6411 (Linking)
VI  - 47
IP  - 2
DP  - 1999 Mar
TI  - Influence of formulation technique for hydroxypropyl-beta-cyclodextrin on the 
      stability of aspirin in HFA 134a.
PG  - 145-52
AB  - The objective of this study was to determine the influence of the formulation 
      technique for 2-hydroxypropyl-beta-cyclodextrin (HP beta CD) on the stability of 
      aspirin in a suspension-based pressurized metered-dose inhaler (pMDI) formulation 
      containing a hydrofluoroalkane (HFA) propellant. HP beta CD was formulated in a 
      pMDI as a lyophilized inclusion complex or a physical mixture with aspirin. A 
      pMDI formulation containing aspirin alone was used as the control. The chemical 
      stability of aspirin in each pMDI formulation was determined over 6-months 
      storage at 5, 25 and 40 degrees C. The quantity of water taken up into the pMDI 
      canister was determined by Karl Fisher titration after storage for 6 months. 
      Differential scanning calorimetry (DSC) was used to confirm the formation of a 
      complex between HP beta CD and aspirin. Aspirin in the lyophilized inclusion 
      complex exhibited the most significant degree of degradation during the 6-months 
      storage, while aspirin alone in the pMDI demonstrated a moderate degree of 
      degradation. Aspirin formulated in the physical mixture displayed the least 
      degree of degradation. The water uptake study showed that water ingress occurred 
      to the greatest extent for formulations containing aspirin and HP beta CD 
      physical mixture, and to the least extent for formulations containing aspirin 
      alone. Finally, the DSC study indicated that an inclusion complex was formed in 
      situ in the pMDI formulations containing the HP beta CD and aspirin physical 
      mixture. In conclusion, HP beta CD may be used to enhance the stability of a 
      chemically labile drug, but the drug stability may be affected by the method of 
      preparation of the formulation.
FAU - Williams, R O 3rd
AU  - Williams RO 3rd
AD  - College of Pharmacy, University of Texas at Austin 78712-1074, USA.
FAU - Liu, J
AU  - Liu J
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharm Biopharm
JT  - European journal of pharmaceutics and biopharmaceutics : official journal of 
      Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
JID - 9109778
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclodextrins)
RN  - 0 (beta-Cyclodextrins)
RN  - 059QF0KO0R (Water)
RN  - 1I96OHX6EK (2-Hydroxypropyl-beta-cyclodextrin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2-Hydroxypropyl-beta-cyclodextrin
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*administration & dosage/chemistry
MH  - Calorimetry, Differential Scanning
MH  - Chromatography, High Pressure Liquid
MH  - Cyclodextrins/*administration & dosage
MH  - Drug Stability
MH  - Freeze Drying
MH  - Nebulizers and Vaporizers
MH  - Water/analysis
MH  - *beta-Cyclodextrins
EDAT- 1999/05/11 02:02
MHDA- 2001/03/28 10:01
CRDT- 1999/05/11 02:02
PHST- 1999/05/11 02:02 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1999/05/11 02:02 [entrez]
AID - S0939641198000721 [pii]
AID - 10.1016/s0939-6411(98)00072-1 [doi]
PST - ppublish
SO  - Eur J Pharm Biopharm. 1999 Mar;47(2):145-52. doi: 10.1016/s0939-6411(98)00072-1.

PMID- 1914366
OWN - NLM
STAT- MEDLINE
DCOM- 19911025
LR  - 20190510
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 50
IP  - 3
DP  - 1991 Sep
TI  - Headache pain model for assessing and comparing the efficacy of over-the-counter 
      analgesic agents.
PG  - 322-9
AB  - To refine the assessment of over-the-counter analgesic agents in the treatment of 
      muscle-contraction headache, we designed a single-dose model with attention to 
      specific methodologic features and two relevant assessments--the percentage of 
      subjects who achieve complete relief and the time until pain is no longer 
      experienced. Subjects were randomly assigned to receive a single dose of 1000 mg 
      acetaminophen, 1000 mg aspirin with 64 mg caffeine, or placebo. Under 
      double-blind conditions, subjects rated headache pain intensity and relief over 4 
      hours and provided a Comparative Evaluation at the end of the trial. Both active 
      agents were significantly distinguished from placebo on the time-point analyses 
      (p less than 0.05) and summary end point measurements (sum of pain intensity 
      difference [SPID], total of pain relief, percentage of patients with complete 
      relief, percentage of treatment failures, and the Comparative Evaluation), as 
      well as causing a faster elimination of headache (p less than 0.05). The 
      aspirin-caffeine combination was rated higher than acetaminophen on all summary 
      measurements, particularly SPID (p less than 0.05), with significantly more 
      patients obtaining complete relief with aspirin-caffeine (p less than 0.01) than 
      with acetaminophen. We conclude that this headache pain model can be used to 
      demonstrate the efficacy of over-the-counter analgesic agents and to assess their 
      relative efficacy.
FAU - Schachtel, B P
AU  - Schachtel BP
AD  - Medical Department, Whitehall Laboratories, Inc., New York 10017.
FAU - Thoden, W R
AU  - Thoden WR
FAU - Konerman, J P
AU  - Konerman JP
FAU - Brown, A
AU  - Brown A
FAU - Chaing, D S
AU  - Chaing DS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Analgesics)
RN  - 0 (Drug Combinations)
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Adult
MH  - Analgesics/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Caffeine/administration & dosage
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Drug Evaluation
MH  - Female
MH  - Headache/*drug therapy
MH  - Humans
MH  - Male
MH  - Medical History Taking
MH  - Middle Aged
MH  - Models, Biological
MH  - Nonprescription Drugs/*therapeutic use
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
AID - 10.1038/clpt.1991.143 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1991 Sep;50(3):322-9. doi: 10.1038/clpt.1991.143.

PMID- 33706984
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 144 Suppl 1
DP  - 2021 Apr 1
TI  - Evolution of Clinical Thinking and Practice Regarding Aspirin: What Has Changed 
      and Why?
PG  - S10-S14
LID - S0002-9149(20)31348-5 [pii]
LID - 10.1016/j.amjcard.2020.12.021 [doi]
AB  - Aspirin (ASA) is the original antiplatelet agent. Its routine use, long 
      unquestioned for both primary and secondary prevention in cardiovascular disease, 
      is under increasing scrutiny as the risk:benefit balance for ASA becomes less 
      clear and other disease- and risk-modifying approaches are validated. It can be 
      viewed as a significant advance in evidence-based medicine that the use of an 
      inexpensive, readily available, long-validated therapy is being questioned in 
      large, rigorous trials. In this overview we present the important questions 
      surrounding a more informed approach to ASA therapy: duration of therapy, 
      assessment of net clinical benefit, and timing of start and stop strategies. We 
      also consider potential explanations for "breakthrough" thrombosis when patients 
      are on ASA therapy. Other manuscripts in this Supplement address the specifics of 
      primary prevention, secondary prevention, triple oral antithrombotic therapy, and 
      the future of ASA in cardiovascular medicine.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Pollack, Charles V Jr
AU  - Pollack CV Jr
AD  - Department of Emergency Medicine, University of Mississippi Medical Center, 
      Jackson, Mississippi. Electronic address: cvpollack@gmail.com.
FAU - Wang, Tracy Y
AU  - Wang TY
AD  - Duke Clinical Research Institute, Duke University, Durham, North Carolina.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Drug Administration Schedule
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Assessment
EDAT- 2021/03/13 06:00
MHDA- 2021/04/10 06:00
CRDT- 2021/03/12 06:01
PHST- 2020/11/19 00:00 [received]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2021/03/12 06:01 [entrez]
PHST- 2021/03/13 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - S0002-9149(20)31348-5 [pii]
AID - 10.1016/j.amjcard.2020.12.021 [doi]
PST - ppublish
SO  - Am J Cardiol. 2021 Apr 1;144 Suppl 1:S10-S14. doi: 10.1016/j.amjcard.2020.12.021.

PMID- 22313430
OWN - NLM
STAT- MEDLINE
DCOM- 20120620
LR  - 20181201
IS  - 1744-7631 (Electronic)
IS  - 1472-8222 (Linking)
VI  - 16 Suppl 1
DP  - 2012 Mar
TI  - The role of low-dose aspirin in the prevention of colorectal cancer.
PG  - S51-62
LID - 10.1517/14728222.2011.647810 [doi]
AB  - INTRODUCTION: Colorectal cancer (CRC) is a prevalent disease that is associated 
      with considerable morbidity and mortality. The progression of normal mucosa 
      through adenomatous polyps to overt cancer can span for 10 - 15 years, making 
      early detection, as well as the use of chemopreventive agents such as aspirin, an 
      attractive option. The effects of aspirin in reducing CRC incidence and mortality 
      have consistently been demonstrated in a number of studies. However, a greater 
      understanding of how aspirin exerts its anti-cancer effects is warranted. AREAS 
      COVERED: The aim of this non-systematic review, which was developed using 
      published randomized and epidemiological studies, as well as key references known 
      to the authors, was to consider the role of aspirin in CRC prevention. Areas 
      covered include the effects of aspirin on cardiovascular disease, CRC and 
      colorectal adenoma (CRA) prevention, mode of action of aspirin and the 
      benefit-to-risk of aspirin in disease prevention. EXPERT OPINION: Incorporating 
      CRC and CRA benefits into coronary heart disease (CHD) risk scores would be 
      particularly useful for determining the benefit-to-risk ratio for aspirin use in 
      borderline cases. For instance, patients with an annual CHD risk around 0.7 - 
      1.4%, but with a high risk of colorectal neoplasm may benefit from aspirin. The 
      strong association between CRC and age may also be useful for re-examining the 
      benefit-to-risk ratio for aspirin use in older patients. However, it has to be 
      noted that a cancer prevention indication for aspirin is not approved 
      regulatory-wise anywhere.
FAU - Avivi, Doran
AU  - Avivi D
AD  - Tel-Aviv University, Integrated Cancer Prevention Center, Tel-Aviv Medical Center 
      and Sackler School of Medicine, Tel-Aviv, Israel.
FAU - Moshkowitz, Menachem
AU  - Moshkowitz M
FAU - Detering, Elmar
AU  - Detering E
FAU - Arber, Nadir
AU  - Arber N
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20120208
PL  - England
TA  - Expert Opin Ther Targets
JT  - Expert opinion on therapeutic targets
JID - 101127833
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Antineoplastic Agents/pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Cardiovascular Diseases/prevention & control
MH  - Colorectal Neoplasms/*prevention & control
MH  - Cyclooxygenase 2 Inhibitors/pharmacology
MH  - Humans
EDAT- 2012/02/09 06:00
MHDA- 2012/06/21 06:00
CRDT- 2012/02/09 06:00
PHST- 2012/02/09 06:00 [entrez]
PHST- 2012/02/09 06:00 [pubmed]
PHST- 2012/06/21 06:00 [medline]
AID - 10.1517/14728222.2011.647810 [doi]
PST - ppublish
SO  - Expert Opin Ther Targets. 2012 Mar;16 Suppl 1:S51-62. doi: 
      10.1517/14728222.2011.647810. Epub 2012 Feb 8.

PMID- 16719999
OWN - NLM
STAT- MEDLINE
DCOM- 20060711
LR  - 20220310
IS  - 1478-7083 (Electronic)
IS  - 0035-8843 (Print)
IS  - 0035-8843 (Linking)
VI  - 88
IP  - 3
DP  - 2006 May
TI  - The management of aspirin in transurethral prostatectomy: current practice in the 
      UK.
PG  - 280-3
AB  - INTRODUCTION: Stopping aspirin prior to transurethral prostatectomy (TURP) may 
      minimise peri-operative blood loss, but it may also increase the risk of a 
      significant cardiovascular event. There are no guidelines on the management of 
      aspirin in TURP. This study sought to determine the variation in the 
      peri-operative management of transurethral prostatectomy (TURP) patients that are 
      taking aspirin. MATERIALS AND METHODS: A questionnaire was sent to 444 consultant 
      urologists in the UK from a list obtained from the British Association of 
      Urologists. This resulted in 290 anonymous replies (65%), of which 287 were 
      suitable for analysis. RESULTS: Of these 287 urologists, 178 (62%) ask patients 
      to stop aspirin prior to TURP. Aspirin is stopped 9.8 days (median, 10 days; 
      range, 2-30 days) prior to surgery, and recommenced 8.8 days (median, 7 days; 
      range, 1-42 days) after surgery. In those that stop aspirin, 62% will stop 
      aspirin in all patients, regardless of the indication, and 40% will cancel a TURP 
      if aspirin use has inadvertently continued. Of the 287 urologists, 109 (38%) do 
      not stop aspirin. CONCLUSIONS: There is a wide variation in the management of 
      aspirin in TURP patients in the UK. Aspirin is being stopped in patients at high 
      risk of serious cardiovascular disease, often for longer than necessary. There is 
      a need for multidisciplinary guidelines to reduce variation in practice.
FAU - Enver, Mohamed Khalid
AU  - Enver MK
AD  - Department of Urology, St Bartholomew's Hospital, London, UK. mkenver@hotmail.com
FAU - Hoh, Ivan
AU  - Hoh I
FAU - Chinegwundoh, Frank I
AU  - Chinegwundoh FI
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ann R Coll Surg Engl
JT  - Annals of the Royal College of Surgeons of England
JID - 7506860
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Loss, Surgical/*prevention & control
MH  - Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Practice Patterns, Physicians'
MH  - Prostatic Diseases/*surgery
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - *Transurethral Resection of Prostate
PMC - PMC1963700
EDAT- 2006/05/25 09:00
MHDA- 2006/07/13 09:00
CRDT- 2006/05/25 09:00
PHST- 2006/05/25 09:00 [pubmed]
PHST- 2006/07/13 09:00 [medline]
PHST- 2006/05/25 09:00 [entrez]
AID - 10.1308/003588406X95084 [doi]
PST - ppublish
SO  - Ann R Coll Surg Engl. 2006 May;88(3):280-3. doi: 10.1308/003588406X95084.

PMID- 36035295
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20230721
IS  - 1748-6718 (Electronic)
IS  - 1748-670X (Print)
IS  - 1748-670X (Linking)
VI  - 2022
DP  - 2022
TI  - Anticancer and Anti-Inflammatory Mechanisms of NOSH-Aspirin and Its Biological 
      Effects.
PG  - 4463294
LID - 10.1155/2022/4463294 [doi]
LID - 4463294
AB  - NOSH-Aspirin, which is generated from NO, H(2)S, and aspirin, affects a variety 
      of essential pathophysiological processes, including anti-inflammatory, 
      analgesic, antipyretic, antiplatelet, and anticancer properties. Although many 
      people acknowledge the biological significance of NOSH-Aspirin and its 
      therapeutic effects, the mechanism of action of NOSH-Aspirin and its regulation 
      of tissue levels remains obscure. This is in part due to its chemical and 
      physical features, which make processing and analysis difficult. This review 
      focuses on the biological effects of NOSH-Aspirin and provides a comprehensive 
      analysis to elucidate the mechanism underlying its disease-protective benefits.
CI  - Copyright © 2022 Jun Zhou et al.
FAU - Zhou, Jun
AU  - Zhou J
AUID- ORCID: 0000-0003-4519-6433
AD  - Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer 
      Research Institute, Hengyang Medical School, University of South China, Hengyang, 
      Hunan 421001, China.
FAU - Zeng, Weihong
AU  - Zeng W
AD  - Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer 
      Research Institute, Hengyang Medical School, University of South China, Hengyang, 
      Hunan 421001, China.
FAU - Zeng, Ying
AU  - Zeng Y
AD  - Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer 
      Research Institute, Hengyang Medical School, University of South China, Hengyang, 
      Hunan 421001, China.
AD  - School of Nursing, Hengyang Medical School, University of South China, Hengyang, 
      Hunan 421001, China.
FAU - Li, Yukun
AU  - Li Y
AD  - Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer 
      Research Institute, Hengyang Medical School, University of South China, Hengyang, 
      Hunan 421001, China.
FAU - Xiao, Zheng
AU  - Xiao Z
AD  - Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer 
      Research Institute, Hengyang Medical School, University of South China, Hengyang, 
      Hunan 421001, China.
FAU - Zou, Juan
AU  - Zou J
AD  - Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer 
      Research Institute, Hengyang Medical School, University of South China, Hengyang, 
      Hunan 421001, China.
FAU - Peng, Lijun
AU  - Peng L
AD  - Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer 
      Research Institute, Hengyang Medical School, University of South China, Hengyang, 
      Hunan 421001, China.
AD  - Department of Spine Surgery, The First Affiliated Hospital, University of South 
      China, Hengyang, Hunan 421001, China.
FAU - Xia, Jiliang
AU  - Xia J
AUID- ORCID: 0000-0003-1749-7810
AD  - Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer 
      Research Institute, Hengyang Medical School, University of South China, Hengyang, 
      Hunan 421001, China.
FAU - Zeng, Xi
AU  - Zeng X
AUID- ORCID: 0000-0002-2603-9910
AD  - Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer 
      Research Institute, Hengyang Medical School, University of South China, Hengyang, 
      Hunan 421001, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
PT  - Review
DEP - 20220817
PL  - United States
TA  - Comput Math Methods Med
JT  - Computational and mathematical methods in medicine
JID - 101277751
RN  - 0 (4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Disulfides)
RN  - 0 (Nitrates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
RIN - Comput Math Methods Med. 2023 Jul 12;2023:9861539. PMID: 37475941
MH  - Anti-Inflammatory Agents
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - *Aspirin/analogs & derivatives
MH  - *Disulfides
MH  - Humans
MH  - Nitrates
PMC - PMC9402325
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/08/30 06:00
MHDA- 2022/08/31 06:00
CRDT- 2022/08/29 05:21
PHST- 2022/05/24 00:00 [received]
PHST- 2022/07/27 00:00 [revised]
PHST- 2022/07/29 00:00 [accepted]
PHST- 2022/08/29 05:21 [entrez]
PHST- 2022/08/30 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
AID - 10.1155/2022/4463294 [doi]
PST - epublish
SO  - Comput Math Methods Med. 2022 Aug 17;2022:4463294. doi: 10.1155/2022/4463294. 
      eCollection 2022.

PMID- 6839634
OWN - NLM
STAT- MEDLINE
DCOM- 19830610
LR  - 20190511
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 33
IP  - 5
DP  - 1983 May
TI  - Local aspirin analgesia in the oral cavity.
PG  - 642-8
AB  - Aspirin solution applied locally to the oral cavity produces an analgesic effect 
      on pain induced by electrical stimuli and by knife prick. Spontaneous pain is 
      also relieved. The effect is of a local nature and can be terminated by rinsing 
      the mouth with water, indicating that there is only a loose bond between aspirin 
      and the mucosa. The local nature is also demonstrated by the lack of analgesia in 
      areas of the tongue where exposure to aspirin solution is prevented by separation 
      with a rubber-dam.
FAU - Loch, W E
AU  - Loch WE
FAU - Wenger, A P
AU  - Wenger AP
FAU - Loch, M H
AU  - Loch MH
FAU - Loch, W E
AU  - Loch WE
FAU - Reiriz, H M
AU  - Reiriz HM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Solutions)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Analgesia
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Drug Evaluation
MH  - Electric Stimulation/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain/etiology
MH  - Random Allocation
MH  - Solutions
MH  - Time Factors
MH  - Tongue/*drug effects/physiology/physiopathology
EDAT- 1983/05/01 00:00
MHDA- 1983/05/01 00:01
CRDT- 1983/05/01 00:00
PHST- 1983/05/01 00:00 [pubmed]
PHST- 1983/05/01 00:01 [medline]
PHST- 1983/05/01 00:00 [entrez]
AID - 0009-9236(83)90055-3 [pii]
AID - 10.1038/clpt.1983.87 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1983 May;33(5):642-8. doi: 10.1038/clpt.1983.87.

PMID- 21742097
OWN - NLM
STAT- MEDLINE
DCOM- 20110913
LR  - 20141120
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 162
IP  - 1
DP  - 2011 Jul
TI  - Aspirin for the prevention of cardiovascular events in patients without clinical 
      cardiovascular disease: a meta-analysis of randomized trials.
PG  - 115-24.e2
LID - 10.1016/j.ahj.2011.04.006 [doi]
AB  - BACKGROUND: The benefit of aspirin to prevent cardiovascular events in subjects 
      without clinical cardiovascular disease relative to the increased risk of 
      bleeding is uncertain. METHODS: A meta-analysis of randomized trials of aspirin 
      versus placebo/control to assess the effect of aspirin on major cardiovascular 
      events (MCEs) (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular 
      death), individual components of the MCE, stroke subtype, all-cause mortality, 
      and major bleeding. Nine trials involving 102,621 patients were included: 52,145 
      allocated to aspirin and 50,476 to placebo/control. RESULTS: Over a mean 
      follow-up of 6.9 years, aspirin was associated with a reduction in MCE (risk 
      ratio [RR] 0.90, 95% CI 0.85-0.96, P < .001). There was no significant reduction 
      for myocardial infarction, stroke, ischemic stroke, or all-cause mortality. 
      Aspirin was associated with hemorrhagic stroke (RR 1.35, 95% CI 1.01-1.81, P = 
      .04) and major bleeding (RR 1.62, 95% CI 1.31-2.00, P < .001). In 
      meta-regression, the benefits and bleeding risks of aspirin were independent of 
      baseline cardiovascular risk, background therapy, age, sex, and aspirin dose. The 
      number needed to treat to prevent 1 MCE over a mean follow-up of 6.9 years was 
      253 (95% CI 163-568), which was offset by the number needed to harm to cause 1 
      major bleed of 261 (95% CI 182-476). CONCLUSIONS: The current totality of 
      evidence provides only modest support for a benefit of aspirin in patients 
      without clinical cardiovascular disease, which is offset by its risk. For every 
      1,000 subjects treated with aspirin over a 5-year period, aspirin would prevent 
      2.9 MCE and cause 2.8 major bleeds.
CI  - Copyright © 2011 Mosby, Inc. All rights reserved.
FAU - Berger, Jeffrey S
AU  - Berger JS
AD  - Department of Medicine, Division of Cardiology, New York University School of 
      Medicine, New York, NY 10016, USA. Jeffrey.berger@nyumc.org
FAU - Lala, Anuradha
AU  - Lala A
FAU - Krantz, Mori J
AU  - Krantz MJ
FAU - Baker, Gizelle S
AU  - Baker GS
FAU - Hiatt, William R
AU  - Hiatt WR
LA  - eng
GR  - U01 HL079160/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Global Health
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Morbidity/trends
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2011/07/12 06:00
MHDA- 2011/09/14 06:00
CRDT- 2011/07/12 06:00
PHST- 2011/03/03 00:00 [received]
PHST- 2011/04/06 00:00 [accepted]
PHST- 2011/07/12 06:00 [entrez]
PHST- 2011/07/12 06:00 [pubmed]
PHST- 2011/09/14 06:00 [medline]
AID - S0002-8703(11)00272-9 [pii]
AID - 10.1016/j.ahj.2011.04.006 [doi]
PST - ppublish
SO  - Am Heart J. 2011 Jul;162(1):115-24.e2. doi: 10.1016/j.ahj.2011.04.006.

PMID- 21901177
OWN - NLM
STAT- MEDLINE
DCOM- 20111101
LR  - 20131121
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 60
IP  - 9
DP  - 2011 Sep
TI  - Aspirin for CV prevention -- for which patients?
PG  - 518-23
AB  - Put your patient on aspirin? Take him off? Here's what you need to know to get it 
      right.
FAU - Jackson, Anita N
AU  - Jackson AN
AD  - University of Rhode Island College of Pharmacy, Kingston, RI 02881, USA. 
      anitaj@uri.edu
FAU - Hume, Anne L
AU  - Hume AL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus/drug therapy
MH  - Drug Resistance
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Selection
MH  - Practice Guidelines as Topic
MH  - Risk Assessment
MH  - Sex Factors
MH  - United States
EDAT- 2011/09/09 06:00
MHDA- 2011/11/02 06:00
CRDT- 2011/09/09 06:00
PHST- 2011/09/09 06:00 [entrez]
PHST- 2011/09/09 06:00 [pubmed]
PHST- 2011/11/02 06:00 [medline]
AID - jfp_6009d [pii]
PST - ppublish
SO  - J Fam Pract. 2011 Sep;60(9):518-23.

PMID- 36463859
OWN - NLM
STAT- MEDLINE
DCOM- 20230106
LR  - 20230111
IS  - 1423-0313 (Electronic)
IS  - 0031-7012 (Linking)
VI  - 108
IP  - 1
DP  - 2023
TI  - High On-Treatment Platelet Reactivity: Aspirin versus Clopidogrel.
PG  - 83-89
LID - 10.1159/000527816 [doi]
AB  - BACKGROUND: Antithrombotic regimen in patients on oral anticoagulation (OAC) 
      post-percutaneous coronary intervention (PCI) is challenging. At least, one 
      antiplatelet agent in combination with OAC is recommended after PCI for 6-12 
      months. Clopidogrel is used most frequently in this setting. However, data 
      comparing P2Y12 inhibition with clopidogrel versus cyclooxygenase inhibition by 
      acetylsalicylic acid (ASA, aspirin) is missing. It is well known that the 
      antiplatelet effects of ASA and clopidogrel are frequently impaired (high 
      on-treatment platelet reactivity [HTPR]). In this pilot investigation, we 
      compared the antiplatelet effects of clopidogrel versus ASA. METHODS: In this 
      retrospective single-center database analysis, we investigated platelet 
      reactivity by light transmission aggregometry in patients under different 
      antiplatelet regimes. Results were presented as maximum of aggregation (MoA). 
      HTPR to ASA and to clopidogrel were assessed. RESULTS: 755 patients were 
      enrolled. 677 were on ASA, 521 were on clopidogrel, and 198 had OAC. Overall mean 
      age was 73 ± 13.4 years, and 458 (60.7%) were male. HTPR to ASA occurred in 
      94/677 patients (13.9%), and mean arachidonic acid-induced MoA was 14.15 ± 
      19.04%. HTPR to clopidogrel occurred in 241/521 patients (46.3%), and mean 
      adenosine diphosphate-induced MoA was 50.06 ± 20.42%. HTPR to clopidogrel was 
      significantly more frequent than HTPR to ASA; single antiplatelet therapy 
      (SAPT)-mono ASA: 27/199 (13.6%) versus mono clopidogrel: 6/18 (33.3%); p = 0.037; 
      SAPT with OAC-OAC with ASA: 8/35 (22.9%) versus OAC with clopidogrel: 27/60 
      (45%); p = 0.046. Same difference in HTPR contingency could be shown in subgroups 
      of dual antiplatelet therapy and ASA + clopidogrel + OAC therapy. CONCLUSION: 
      Impaired pharmacodynamic response to clopidogrel was more frequent as HTPR to 
      ASA. Hence, ASA should be tested in combination with OAC post-PCI.
CI  - © 2022 The Author(s). Published by S. Karger AG, Basel.
FAU - M'Pembele, René
AU  - M'Pembele R
AD  - Department of Anesthesiology, Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Ahlbrecht, Samantha
AU  - Ahlbrecht S
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Cardiovascular 
      Research Institute Düsseldorf (CARID), Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Helten, Carolin
AU  - Helten C
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Cardiovascular 
      Research Institute Düsseldorf (CARID), Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Mourikis, Philipp
AU  - Mourikis P
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Cardiovascular 
      Research Institute Düsseldorf (CARID), Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Naguib, David
AU  - Naguib D
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Cardiovascular 
      Research Institute Düsseldorf (CARID), Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Zako, Saif
AU  - Zako S
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Cardiovascular 
      Research Institute Düsseldorf (CARID), Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany, saif.g.zako@gmail.com.
FAU - Trojovsky, Kajetan
AU  - Trojovsky K
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Cardiovascular 
      Research Institute Düsseldorf (CARID), Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Huhn, Ragnar
AU  - Huhn R
AD  - Department of Anesthesiology, Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Petzold, Tobias
AU  - Petzold T
AD  - Department of Anesthesiology, Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 
      Ludwig-Maximilians- University Munich, Munich, Germany.
FAU - Hohlfeld, Thomas
AU  - Hohlfeld T
AD  - Institute of Pharmacology and Clinical Pharmacology, Heinrich Heine University, 
      Düsseldorf, Germany.
FAU - Zeus, Tobias
AU  - Zeus T
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Cardiovascular 
      Research Institute Düsseldorf (CARID), Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Kelm, Malte
AU  - Kelm M
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Cardiovascular 
      Research Institute Düsseldorf (CARID), Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Dannenberg, Lisa
AU  - Dannenberg L
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Cardiovascular 
      Research Institute Düsseldorf (CARID), Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
FAU - Polzin, Amin
AU  - Polzin A
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Cardiovascular 
      Research Institute Düsseldorf (CARID), Heinrich Heine University Medical Center 
      Düsseldorf, Düsseldorf, Germany.
LA  - eng
PT  - Journal Article
DEP - 20221202
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Clopidogrel
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Ticlopidine/pharmacology/therapeutic use
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Retrospective Studies
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Blood Platelets
MH  - Platelet Aggregation
OTO - NOTNLM
OT  - Anticoagulation
OT  - Aspirin
OT  - Clopidogrel
OT  - High on-treatment platelet reactivity
OT  - Platelet function
EDAT- 2022/12/05 06:00
MHDA- 2023/01/07 06:00
CRDT- 2022/12/04 18:29
PHST- 2022/03/27 00:00 [received]
PHST- 2022/10/04 00:00 [accepted]
PHST- 2022/12/05 06:00 [pubmed]
PHST- 2023/01/07 06:00 [medline]
PHST- 2022/12/04 18:29 [entrez]
AID - 000527816 [pii]
AID - 10.1159/000527816 [doi]
PST - ppublish
SO  - Pharmacology. 2023;108(1):83-89. doi: 10.1159/000527816. Epub 2022 Dec 2.

PMID- 3529953
OWN - NLM
STAT- MEDLINE
DCOM- 19861023
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 81
IP  - 3
DP  - 1986 Sep
TI  - Effect of alternate-day regular and enteric-coated aspirin on platelet 
      aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood.
PG  - 400-4
AB  - The effectiveness of low-dose aspirin for primary prevention of cardiovascular 
      mortality is being assessed among the nearly 22,000 United States physicians 
      currently participating in the Physicians' Health Study. Because of occasional 
      reports of gastric irritation among study participants, two enteric-coated 
      aspirin preparations were tested as possible alternatives to regular compressed 
      aspirin for platelet inhibition. Thirty-three volunteers were assigned randomly 
      to one of four treatment groups: regular aspirin (325 mg), placebo, and two 
      enteric-coated aspirin preparations (325 mg). Pills were administered every other 
      day, duplicating the regimen used in the Physicians' Health Study. Bleeding 
      times, platelet aggregation, and thromboxane A2 levels produced by aggregating 
      platelets in vitro, as well as in collected bleeding-time blood, were determined. 
      Measurements were taken before and after a single dose as well as after seven 
      alternate-day doses. Regular and enteric-coated aspirin preparations were equally 
      efficacious in prolonging the bleeding time, inhibiting platelet aggregation, and 
      suppressing thromboxane A2 production. There was virtually complete suppression 
      of thromboxane A2 production (over 99 percent), by platelets in vitro and in 
      collected bleeding-time blood. The levels were still profoundly reduced (89 
      percent) 48 hours after the last dose. Enteric-coated aspirin may provide an 
      alternative to regular aspirin in a low-dose regimen designed to inhibit platelet 
      activity.
FAU - Stampfer, M J
AU  - Stampfer MJ
FAU - Jakubowski, J A
AU  - Jakubowski JA
FAU - Deykin, D
AU  - Deykin D
FAU - Schafer, A I
AU  - Schafer AI
FAU - Willett, W C
AU  - Willett WC
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA-40360/CA/NCI NIH HHS/United States
GR  - HL-34595/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Tablets, Enteric-Coated)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/metabolism
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Random Allocation
MH  - Tablets, Enteric-Coated
MH  - Thromboxane A2/*blood
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
AID - 0002-9343(86)90289-5 [pii]
AID - 10.1016/0002-9343(86)90289-5 [doi]
PST - ppublish
SO  - Am J Med. 1986 Sep;81(3):400-4. doi: 10.1016/0002-9343(86)90289-5.

PMID- 21842134
OWN - NLM
STAT- MEDLINE
DCOM- 20120327
LR  - 20220331
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 25
IP  - 6
DP  - 2011 Dec
TI  - Prospective cohort study of gastrointestinal complications and vascular diseases 
      in patients taking aspirin: rationale and design of the MAGIC Study.
PG  - 551-60
LID - 10.1007/s10557-011-6328-2 [doi]
AB  - OBJECTIVE: Although aspirin has been widely prescribed for the prevention of 
      cardiovascular events, its risk of gastrointestinal complications is of great 
      concern. Despite expectations for such, few data are available on the prevalence 
      or incidence of gastrointestinal complications in aspirin users in Japan. The 
      Management of Aspirin-induced GastroIntestinal Complications (MAGIC) is the first 
      attempt at collaboration among cardiologists, neurologists, and 
      gastroenterologists to obtain such findings. We aim to share all about the MAGIC 
      study. METHODS: The MAGIC is a prospective cohort study involving patients taking 
      low-dose aspirin (81 mg to 325 mg per day) for longer than 1 month. Participants 
      are recruited from multiple disease categories, including those with coronary 
      artery disease, cerebrovascular disease, atrial fibrillation, and other 
      cardiovascular conditions requiring antithrombotic therapy. Its duration of 
      follow-up is 1 year. At baseline and 1 year follow-up, all participants will 
      undergo endoscopic examination. The primary outcome is upper gastrointestinal 
      complications, classified as erosions, ulcers, and bleeding. Secondary outcomes 
      include LANZA score, non-fatal cardiovascular events, any bleeding, cancer, and 
      death. RESULTS: 1,533 participants were entered in the MAGIC cohort. By 
      underlying disease, about 45% of them had coronary artery diseases, followed by 
      cerebrovascular diseases (35%), atrial fibrillation (10%) and other 
      cardiovascular diseases (10%). CONCLUSIONS: The MAGIC study will yield important 
      findings with regard to the prevalence and incidence of gastrointestinal 
      complications and related risk factors for low-dose aspirin users. It may also 
      report that use of anti-secretory agents such as proton pump inhibitors reduces 
      the risk of such complications.
FAU - Origasa, Hideki
AU  - Origasa H
AD  - Division of Biostatistics and Clinical Epidemiology, University of Toyama, Japan. 
      horigasa@las.u-toyama.ac.jp
FAU - Goto, Shinya
AU  - Goto S
FAU - Shimada, Kazuyuki
AU  - Shimada K
FAU - Uchiyama, Shinichiro
AU  - Uchiyama S
FAU - Okada, Yasushi
AU  - Okada Y
FAU - Sugano, Kentaro
AU  - Sugano K
FAU - Hiraishi, Hideyuki
AU  - Hiraishi H
FAU - Uemura, Naomi
AU  - Uemura N
FAU - Ikeda, Yasuo
AU  - Ikeda Y
CN  - MAGIC Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Cardiovasc Drugs Ther. 2011 Dec;25(6):503-4. PMID: 22006010
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Cohort Studies
MH  - *Epidemiologic Research Design
MH  - Gastrointestinal Diseases/chemically induced/*epidemiology/prevention & control
MH  - Humans
MH  - Japan
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/administration & dosage/therapeutic use
MH  - Vascular Diseases/complications/*epidemiology/prevention & control
FIR - Tanaka, Shigemichi
IR  - Tanaka S
FIR - Tanuma, Tokuma
IR  - Tanuma T
FIR - Togashi, Nobuhiko
IR  - Togashi N
FIR - Tsuchihashi, Kazufumi
IR  - Tsuchihashi K
FIR - Tsukuda, Youko
IR  - Tsukuda Y
FIR - Tsutsui, Hiroyuki
IR  - Tsutsui H
FIR - Yamamoto, Hiroyuki
IR  - Yamamoto H
FIR - Yamashita, Kentaro
IR  - Yamashita K
FIR - Yamauchi, Hidenori
IR  - Yamauchi H
FIR - Yane, Kei
IR  - Yane K
FIR - Yokoyama, Akiko
IR  - Yokoyama A
FIR - Yonezawa, Kazuhiko
IR  - Yonezawa K
FIR - Chiba, Toshimi
IR  - Chiba T
FIR - Iijima, Katsunori
IR  - Iijima K
FIR - Ogasawara, Hitoshi
IR  - Ogasawara H
FIR - Sasaki, Masahiro
IR  - Sasaki M
FIR - Suzuki, Akifumi
IR  - Suzuki A
FIR - Takeda, Morihiko
IR  - Takeda M
FIR - Terayama, Yasuo
IR  - Terayama Y
FIR - Wada, Masahide
IR  - Wada M
FIR - Watanabe, Kuniko
IR  - Watanabe K
FIR - Yonezawa, Hisashi
IR  - Yonezawa H
FIR - Aizawa, Yoshifusa
IR  - Aizawa Y
FIR - Ajibe, Hironari
IR  - Ajibe H
FIR - Akamatsu, Taiji
IR  - Akamatsu T
FIR - Arai, Masashi
IR  - Arai M
FIR - Asano, Masamitsu
IR  - Asano M
FIR - Ebata, Atsuko
IR  - Ebata A
FIR - Fujii, Yukihiko
IR  - Fujii Y
FIR - Fukuda, Akihiro
IR  - Fukuda A
FIR - Hirasawa, Tomosuke
IR  - Hirasawa T
FIR - Hirata, Koichi
IR  - Hirata K
FIR - Hirayama, Tsuyoshi
IR  - Hirayama T
FIR - Hirono, Satoru
IR  - Hirono S
FIR - Hojo, Yukihiro
IR  - Hojo Y
FIR - Horinaka, Shigeo
IR  - Horinaka S
FIR - Hoshide, Satoshi
IR  - Hoshide S
FIR - Hoshino, Takafumi
IR  - Hoshino T
FIR - Ishikawa, Jun
IR  - Ishikawa J
FIR - Ishimura, Kimihiko
IR  - Ishimura K
FIR - Ito, Shinichi
IR  - Ito S
FIR - Iwamoto, Junichi
IR  - Iwamoto J
FIR - Kaneko, Yoshiaki
IR  - Kaneko Y
FIR - Kanemaru, Kazuya
IR  - Kanemaru K
FIR - Kanke, Kazunari
IR  - Kanke K
FIR - Kasai, Hiroki
IR  - Kasai H
FIR - Kawamura, Osamu
IR  - Kawamura O
FIR - Kinouchi, Hiroyuki
IR  - Kinouchi H
FIR - Kono, Koichi
IR  - Kono K
FIR - Kurabayashi, Masahiko
IR  - Kurabayashi M
FIR - Kusano, Motoyasu
IR  - Kusano M
FIR - Matsuoka, Hiroaki
IR  - Matsuoka H
FIR - Mihara, Ban
IR  - Mihara B
FIR - Nakano, Akihiko
IR  - Nakano A
FIR - Nishino, Kazuhiko
IR  - Nishino K
FIR - Okamoto, Koichi
IR  - Okamoto K
FIR - Okamoto, Yutaka
IR  - Okamoto Y
FIR - Okubo, Shinji
IR  - Okubo S
FIR - Osawa, Hiroyuki
IR  - Osawa H
FIR - Saifuku, Yasuyuki
IR  - Saifuku Y
FIR - Sasai, Takako
IR  - Sasai T
FIR - Sato, Yuichi
IR  - Sato Y
FIR - Satoh, Kiichi
IR  - Satoh K
FIR - Shimada, Kazuyuki
IR  - Shimada K
FIR - Shimpo, Masahisa
IR  - Shimpo M
FIR - Sugita, Masao
IR  - Sugita M
FIR - Suzuki, Makoto
IR  - Suzuki M
FIR - Tajima, Akihiro
IR  - Tajima A
FIR - Takahashi, Nozomu
IR  - Takahashi N
FIR - Takahashi, Takayuki
IR  - Takahashi T
FIR - Takekawa, Hidehiro
IR  - Takekawa H
FIR - Toma, Sachiko
IR  - Toma S
FIR - Tominaga, Keiichi
IR  - Tominaga K
FIR - Ueno, Shuichi
IR  - Ueno S
FIR - Watanabe, Hidetaka
IR  - Watanabe H
FIR - Yabe, Akihisa
IR  - Yabe A
FIR - Yagi, Hiroshi
IR  - Yagi H
FIR - Yamagata, Michiko
IR  - Yamagata M
FIR - Yamamoto, Keiji
IR  - Yamamoto K
FIR - Yoshida, Toru
IR  - Yoshida T
FIR - Akazawa, Hiroshi
IR  - Akazawa H
FIR - Arao, Kenshiro
IR  - Arao K
FIR - Chinen, Katsuya
IR  - Chinen K
FIR - Daimon, Michiko
IR  - Daimon M
FIR - Hasegawa, Hiroshi
IR  - Hasegawa H
FIR - Hokari, Ryota
IR  - Hokari R
FIR - Ishio, Naoki
IR  - Ishio N
FIR - Kani, Kazuhito
IR  - Kani K
FIR - Kawaguchi, Atsushi
IR  - Kawaguchi A
FIR - Kuroda, Nakabumi
IR  - Kuroda N
FIR - Kuwabara, Yoichi
IR  - Kuwabara Y
FIR - Maruyama, Hitoshi
IR  - Maruyama H
FIR - Miura, Soichiro
IR  - Miura S
FIR - Miyauchi, Hideyuki
IR  - Miyauchi H
FIR - Momomura, Shin-Ichi
IR  - Momomura S
FIR - Nagai, Toshio
IR  - Nagai T
FIR - Nagao, Tadashi
IR  - Nagao T
FIR - Nakagawa, Keiichi
IR  - Nakagawa K
FIR - Ohsuzu, Fumitaka
IR  - Ohsuzu F
FIR - Oka, Tohru
IR  - Oka T
FIR - Sakakura, Kenichi
IR  - Sakakura K
FIR - Satou, Keiko
IR  - Satou K
FIR - Shindo, Satoshi
IR  - Shindo S
FIR - Shiojima, Ichiro
IR  - Shiojima I
FIR - Toko, Haruhiro
IR  - Toko H
FIR - Uchiyama, Takashi
IR  - Uchiyama T
FIR - Yakabi, Koji
IR  - Yakabi K
FIR - Watanabe, Toshiti
IR  - Watanabe T
FIR - Yawata, Atsushi
IR  - Yawata A
FIR - Yoshida, Daisuke
IR  - Yoshida D
FIR - Mukoujima, Tsuyoshi
IR  - Mukoujima T
FIR - Shibata, Kenichi
IR  - Shibata K
FIR - Koshinetsu, Kitakanto
IR  - Koshinetsu K
FIR - Daimon, Yasuhisa
IR  - Daimon Y
FIR - Hosaka, Hiroko
IR  - Hosaka H
FIR - Tadashi, Ikegami
IR  - Tadashi I
FIR - Isimitsu, Toshihiko
IR  - Isimitsu T
FIR - Maeda, Mitsunori
IR  - Maeda M
FIR - Murata, Mitsunobu
IR  - Murata M
FIR - Ogura, Rieko
IR  - Ogura R
FIR - Sato, Tadashi
IR  - Sato T
FIR - Shimoyama, Yasuyuki
IR  - Shimoyama Y
FIR - Tomita, Yutaka
IR  - Tomita Y
FIR - Yamazaki, Kaoru
IR  - Yamazaki K
FIR - Harada, Youji
IR  - Harada Y
FIR - Isida, Shuko
IR  - Isida S
FIR - Murayama, Taichi
IR  - Murayama T
FIR - Nomura, Kyoichi
IR  - Nomura K
FIR - Takand, Hiroyuki
IR  - Takand H
FIR - Yokosuka, Osamu
IR  - Yokosuka O
FIR - Yoshida, Yukio
IR  - Yoshida Y
FIR - Akiyama, Junichi
IR  - Akiyama J
FIR - Bessho, Rieko
IR  - Bessho R
FIR - Chiku, Masaaki
IR  - Chiku M
FIR - Goto, Shinya
IR  - Goto S
FIR - Hagiwara, Nobuhisa
IR  - Hagiwara N
FIR - Hakuno, Daihiko
IR  - Hakuno D
FIR - Haruyama, Hiromi
IR  - Haruyama H
FIR - Hibi, Kiyoshi
IR  - Hibi K
FIR - Hiroe, Michiaki
IR  - Hiroe M
FIR - Honye, Junko
IR  - Honye J
FIR - Hosoe, Naoki
IR  - Hosoe N
FIR - Ida, Yousuke
IR  - Ida Y
FIR - Imaeda, Hiroyuki
IR  - Imaeda H
FIR - Inoue, Nagamu
IR  - Inoue N
FIR - Ishikawa, Shuichi
IR  - Ishikawa S
FIR - Isshiki, Takaaki
IR  - Isshiki T
FIR - Iwade, Kazunori
IR  - Iwade K
FIR - Iwasaki, Eisuke
IR  - Iwasaki E
FIR - Kawamura, Akio
IR  - Kawamura A
FIR - Kimura, Kazuo
IR  - Kimura K
FIR - Kishino, Maiko
IR  - Kishino M
FIR - Koike, Jun
IR  - Koike J
FIR - Kokawa, Atsushi
IR  - Kokawa A
FIR - Konishi, Hiroyuki
IR  - Konishi H
FIR - Kozuma, Ken
IR  - Kozuma K
FIR - Kunimoto, Satoshi
IR  - Kunimoto S
FIR - Kuyama, Yasushi
IR  - Kuyama Y
FIR - Matsuhashi, Nobuyuki
IR  - Matsuhashi N
FIR - Matsumae, Mitsunori
IR  - Matsumae M
FIR - Matsushima, Masashi
IR  - Matsushima M
FIR - Matsushima, Shozo
IR  - Matsushima S
FIR - Matsuzaki, Juntaro
IR  - Matsuzaki J
FIR - Mine, Tetsuya
IR  - Mine T
FIR - Miyake, Kazumasa
IR  - Miyake K
FIR - Mizuno, Shigeaki
IR  - Mizuno S
FIR - Murasaki, Kagari
IR  - Murasaki K
FIR - Murata, Mitsushige
IR  - Murata M
FIR - Nakamizo, Hiromasa
IR  - Nakamizo H
FIR - Nakamura, Shinichi
IR  - Nakamura S
FIR - Nomura, Motohiro
IR  - Nomura M
FIR - Ogata, Haruhiko
IR  - Ogata H
FIR - Ogawa, Satoshi
IR  - Ogawa S
FIR - Ohira, Masayuki
IR  - Ohira M
FIR - Okazaki, Osamu
IR  - Okazaki O
FIR - Saito, Yoshimasa
IR  - Saito Y
FIR - Sano, Motoaki
IR  - Sano M
FIR - Sato, Hiroo
IR  - Sato H
FIR - Shima, Hiroshi
IR  - Shima H
FIR - Shimizu, Toshihiko
IR  - Shimizu T
FIR - Shirai, Takayuki
IR  - Shirai T
FIR - Shiratori, Keiko
IR  - Shiratori K
FIR - Shiratori, Yoshitaka
IR  - Shiratori Y
FIR - Suzuki, Hidekazu
IR  - Suzuki H
FIR - Suzuki, Shigeaki
IR  - Suzuki S
FIR - Suzuki, Takayoshi
IR  - Suzuki T
FIR - Tagusari, Osamu
IR  - Tagusari O
FIR - Takagi, Shigeharu
IR  - Takagi S
FIR - Takahashi, Shinichi
IR  - Takahashi S
FIR - Takano, Hitoshi
IR  - Takano H
FIR - Tanabe, Teruhisa
IR  - Tanabe T
FIR - Tomita, Yutaka
IR  - Tomita Y
FIR - Tsukahara, Kengo
IR  - Tsukahara K
FIR - Uetsuka, Yoshio
IR  - Uetsuka Y
FIR - Hidenori, Watanabe
IR  - Hidenori W
FIR - Watanabe, Kenichi
IR  - Watanabe K
FIR - Yamamoto, Takatsugu
IR  - Yamamoto T
FIR - Yamaoka, Yumiko
IR  - Yamaoka Y
FIR - Yokoyama, Naoyuki
IR  - Yokoyama N
FIR - Yoshioka, Koichiro
IR  - Yoshioka K
FIR - Asakura, Kunihiko
IR  - Asakura K
FIR - Chujyou, Chiyuki
IR  - Chujyou C
FIR - Furuta, Takahisa
IR  - Furuta T
FIR - Hayasi, Takao
IR  - Hayasi T
FIR - Hiramatsu, Hisaya
IR  - Hiramatsu H
FIR - Hirata, Ichiro
IR  - Hirata I
FIR - Horiki, Noriyuki
IR  - Horiki N
FIR - Iguchi, Youichi
IR  - Iguchi Y
FIR - Ikuma, Mutsuhiro
IR  - Ikuma M
FIR - Imai, Hajime
IR  - Imai H
FIR - Imoto, Ichiro
IR  - Imoto I
FIR - Ishikawa, Shinichi
IR  - Ishikawa S
FIR - Isobe, Satoshi
IR  - Isobe S
FIR - Ito, Masaaki
IR  - Ito M
FIR - Iwase, Masatsugu
IR  - Iwase M
FIR - Kanamori, Shinichi
IR  - Kanamori S
FIR - Kannbara, Takahiro
IR  - Kannbara T
FIR - Kondo, Taizo
IR  - Kondo T
FIR - Matsuura, Tetsuo
IR  - Matsuura T
FIR - Mihara, Takateru
IR  - Mihara T
FIR - Miyata, Akihiro
IR  - Miyata A
FIR - Mizutani, Keiji
IR  - Mizutani K
FIR - Mutoh, Tatsuro
IR  - Mutoh T
FIR - Nakano, Arihiro
IR  - Nakano A
FIR - Nakashima, Hiroshi
IR  - Nakashima H
FIR - Namba, Hiroki
IR  - Namba H
FIR - Nishikawa, Masakatsu
IR  - Nishikawa M
FIR - Nishino, Masafumi
IR  - Nishino M
FIR - Ohyama, Itaru
IR  - Ohyama I
FIR - Oosawa, Masako
IR  - Oosawa M
FIR - Ozaki, Yukio
IR  - Ozaki Y
FIR - Sakata, Toyohiro
IR  - Sakata T
FIR - Sarai, Masayoshi
IR  - Sarai M
FIR - Sasaki, Yoji
IR  - Sasaki Y
FIR - Shibata, Tetsuo
IR  - Shibata T
FIR - Shibata, Tomoyuki
IR  - Shibata T
FIR - Simizu, Yuko
IR  - Simizu Y
FIR - Tachi, Kosuke
IR  - Tachi K
FIR - Takeuchi, Takako
IR  - Takeuchi T
FIR - Takeuti, Kazuhiko
IR  - Takeuti K
FIR - Tanaka, Kyosuke
IR  - Tanaka K
FIR - Taniguchi, Akira
IR  - Taniguchi A
FIR - Tanimura, Muneyoshi
IR  - Tanimura M
FIR - Tsuji, Akihiro
IR  - Tsuji A
FIR - Ueda, Akihiro
IR  - Ueda A
FIR - Ueda, Madoka
IR  - Ueda M
FIR - Uemura, Yusuke
IR  - Uemura Y
FIR - Umemura, Kazuo
IR  - Umemura K
FIR - Utsumi, Akiko
IR  - Utsumi A
FIR - Watanabe, Eiichi
IR  - Watanabe E
FIR - Watanabe, Hiroshi
IR  - Watanabe H
FIR - Yamada, Michiharu
IR  - Yamada M
FIR - Yamanaka, Toshihiro
IR  - Yamanaka T
FIR - Higaki, Tadashi
IR  - Higaki T
FIR - Mayumi, Kennji
IR  - Mayumi K
FIR - Sawada, Shohei
IR  - Sawada S
FIR - Shirai, Kaoru
IR  - Shirai K
FIR - Takeda, Nami
IR  - Takeda N
FIR - Endo, Shunro
IR  - Endo S
FIR - Hamada, Hideo
IR  - Hamada H
FIR - Hayashi, Nakamasa
IR  - Hayashi N
FIR - Hirai, Tadakazu
IR  - Hirai T
FIR - Hosokawa, Ayumu
IR  - Hosokawa A
FIR - Inoue, Hiroshi
IR  - Inoue H
FIR - Kameyama, Tomoki
IR  - Kameyama T
FIR - Kudo, Takahiko
IR  - Kudo T
FIR - Kuwayama, Naoya
IR  - Kuwayama N
FIR - Matsuki, Akira
IR  - Matsuki A
FIR - Miyazaki, Takako
IR  - Miyazaki T
FIR - Nozawa, Takashi
IR  - Nozawa T
FIR - Orihara, Tadahiro
IR  - Orihara T
FIR - Sugiyama, Toshiro
IR  - Sugiyama T
FIR - Taguchi, Yoshiharu
IR  - Taguchi Y
FIR - Takashima, Shutaro
IR  - Takashima S
FIR - Tanaka, Kortaro
IR  - Tanaka K
FIR - Bokura, Hirokazu
IR  - Bokura H
FIR - Furuta, Kenji
IR  - Furuta K
FIR - Hanaoka, Rie
IR  - Hanaoka R
FIR - Haruma, Ken
IR  - Haruma K
FIR - Higaki, Naoyuki
IR  - Higaki N
FIR - Higaki, Shingo
IR  - Higaki S
FIR - Imagawa, Hiroki
IR  - Imagawa H
FIR - Imagawa, Shinobu
IR  - Imagawa S
FIR - Ishibashi, Yutaka
IR  - Ishibashi Y
FIR - Ishimura, Norihisa
IR  - Ishimura N
FIR - Ito, Masanori
IR  - Ito M
FIR - Kai, Hirohisa
IR  - Kai H
FIR - Kawase, Tomoharu
IR  - Kawase T
FIR - Kinoshita, Yoshikazu
IR  - Kinoshita Y
FIR - Kitamura, Shosuke
IR  - Kitamura S
FIR - Koshino, Kenji
IR  - Koshino K
FIR - Kuwahara, Takayasu
IR  - Kuwahara T
FIR - Matsubara, Hiromi
IR  - Matsubara H
FIR - Matsumoto, Masayasu
IR  - Matsumoto M
FIR - Matsuo, Taiji
IR  - Matsuo T
FIR - Miura, Toshirou
IR  - Miura T
FIR - Murakami, Hidehiro
IR  - Murakami H
FIR - Neishi, Yoji
IR  - Neishi Y
FIR - Nishikawa, Jun
IR  - Nishikawa J
FIR - Oba, Sayaka
IR  - Oba S
FIR - Ogimoto, Akiyoshi
IR  - Ogimoto A
FIR - Oguro, Hiroaki
IR  - Oguro H
FIR - Ohnishi, Takanori
IR  - Ohnishi T
FIR - Ohtsuki, Toshiho
IR  - Ohtsuki T
FIR - Onitake, Toshiko
IR  - Onitake T
FIR - Oofuji, Yoshihiro
IR  - Oofuji Y
FIR - Sanomura, Youji
IR  - Sanomura Y
FIR - Shiotani, Akiko
IR  - Shiotani A
FIR - Shisido, Takayoshi
IR  - Shisido T
FIR - Takamura, Akemi
IR  - Takamura A
FIR - Tanaka, Shinji
IR  - Tanaka S
FIR - Tao, Seizi
IR  - Tao S
FIR - Tatsugami, Masana
IR  - Tatsugami M
FIR - Tokuyama, Takehito
IR  - Tokuyama T
FIR - Wada, Yoshihiro
IR  - Wada Y
FIR - Watanabe, Hideaki
IR  - Watanabe H
FIR - Yamaguchi, Shuhei
IR  - Yamaguchi S
FIR - Yoshida, Shigeto
IR  - Yoshida S
FIR - Fujisima, Hiromitu
IR  - Fujisima H
FIR - Hamada, Rikuzo
IR  - Hamada R
FIR - Harada, Naohiko
IR  - Harada N
FIR - Hashimoto, Shigemasa
IR  - Hashimoto S
FIR - Imamura, Takako
IR  - Imamura T
FIR - Kazuno, Yoshio
IR  - Kazuno Y
FIR - Kiyonaga, Kazuaki
IR  - Kiyonaga K
FIR - Kotoku, Munenori
IR  - Kotoku M
FIR - Koyama, Junjiroh
IR  - Koyama J
FIR - Kusumoto, Kazuhiro
IR  - Kusumoto K
FIR - Murakami, Kazunari
IR  - Murakami K
FIR - Naono, Shigeru
IR  - Naono S
FIR - Niihara, Tooru
IR  - Niihara T
FIR - Nishimata, Hiroto
IR  - Nishimata H
FIR - Node, Koichi
IR  - Node K
FIR - Ogata, Toshiyasu
IR  - Ogata T
FIR - Okada, Yasushi
IR  - Okada Y
FIR - Okimoto, Tadayoshi
IR  - Okimoto T
FIR - Sakata, Yasuhisa
IR  - Sakata Y
FIR - Sato, Takashi
IR  - Sato T
FIR - Satoh, Shinji
IR  - Satoh S
FIR - Shimaoka, Syunji
IR  - Shimaoka S
FIR - Shimoda, Ryo
IR  - Shimoda R
FIR - Tamura, Akira
IR  - Tamura A
FIR - Tanahashi, Jin
IR  - Tanahashi J
FIR - Toyoshima, Shinichirou
IR  - Toyoshima S
FIR - Tsubouchi, Naoko
IR  - Tsubouchi N
FIR - Tsunada, Seiji
IR  - Tsunada S
FIR - Uehara, Masayoshi
IR  - Uehara M
FIR - Yamamoto, Tadashi
IR  - Yamamoto T
FIR - Yokoyama, Shunichi
IR  - Yokoyama S
FIR - Yonehara, Toshiro
IR  - Yonehara T
FIR - Yoshida, Tomoharu
IR  - Yoshida T
EDAT- 2011/08/16 06:00
MHDA- 2012/03/28 06:00
CRDT- 2011/08/16 06:00
PHST- 2011/08/16 06:00 [entrez]
PHST- 2011/08/16 06:00 [pubmed]
PHST- 2012/03/28 06:00 [medline]
AID - 10.1007/s10557-011-6328-2 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2011 Dec;25(6):551-60. doi: 10.1007/s10557-011-6328-2.

PMID- 27426855
OWN - NLM
STAT- MEDLINE
DCOM- 20170412
LR  - 20170412
IS  - 1473-0766 (Electronic)
IS  - 0951-3590 (Linking)
VI  - 32
IP  - 12
DP  - 2016 Dec
TI  - The role of prophylactic use of low dose aspirin and calheparin in patients with 
      unexplained recurrent abortion.
PG  - 970-972
AB  - OBJECTIVE: To study the effect of prophylactic use of low dose aspirin and 
      heparin on patients with recurrent unexplained pregnancy loss. METHODS: 
      Prospective case control study conducted on 180 pregnant women randomized into 
      two equal groups. Group 1 received low-dose aspirin 75 mg and heparin 5000 IU 
      subcutaneous every 12 h. Group 2 received no treatment. RESULTS: There was a 
      statistically significant difference between the two study groups regarding 
      number of patients who completed their first trimester (66 versus 39) (p values 
      0.018). The outcome regarding completion of first trimester was not related to 
      age, BMI or number of previous abortions in both the study groups. Complications 
      of the use of aspirin calheparin occurred in 60% of the patients. The most common 
      complication was bruising at injection site occurring in 60% of the patients 
      followed by bleeding gums (14.4%), gastrointestinal troubles (12.2%), epistaxis 
      (10%) and transient thrombocytopenia in only 2.22% of the patients (Table 4). 
      CONCLUSION: The use of prophylactic dose of calheparin and aspirin is associated 
      with increased chance of passing 1st trimester safely regardless the age, body 
      mass index or number of abortion in women with unexplained recurrent spontaneous 
      abortion.
FAU - Maged, Ahmed M
AU  - Maged AM
AD  - a Obstetrics and Gynecology Department, Kasr AlAini Hospital Cairo University , 
      Cairo , Egypt and.
FAU - Abdelhafiz, Aly
AU  - Abdelhafiz A
AD  - a Obstetrics and Gynecology Department, Kasr AlAini Hospital Cairo University , 
      Cairo , Egypt and.
FAU - Mostafa, Walaa Ai
AU  - Mostafa WA
AD  - a Obstetrics and Gynecology Department, Kasr AlAini Hospital Cairo University , 
      Cairo , Egypt and.
FAU - El-Nassery, Noura
AU  - El-Nassery N
AD  - a Obstetrics and Gynecology Department, Kasr AlAini Hospital Cairo University , 
      Cairo , Egypt and.
FAU - Fouad, Mona
AU  - Fouad M
AD  - a Obstetrics and Gynecology Department, Kasr AlAini Hospital Cairo University , 
      Cairo , Egypt and.
FAU - Salah, Emad
AU  - Salah E
AD  - a Obstetrics and Gynecology Department, Kasr AlAini Hospital Cairo University , 
      Cairo , Egypt and.
FAU - Kotb, Amal
AU  - Kotb A
AD  - b Obstetrics and Gynecology Department, Beni Suef University , Beni-Suef , Egypt.
LA  - eng
PT  - Journal Article
DEP - 20160716
PL  - England
TA  - Gynecol Endocrinol
JT  - Gynecological endocrinology : the official journal of the International Society 
      of Gynecological Endocrinology
JID - 8807913
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*prevention & control
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Case-Control Studies
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*pharmacology
MH  - Heparin/administration & dosage/adverse effects/*pharmacology
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Trimester, First/*drug effects
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Calheparin
OT  - unexplained recurrent abortion
EDAT- 2016/07/19 06:00
MHDA- 2017/04/13 06:00
CRDT- 2016/07/19 06:00
PHST- 2016/07/19 06:00 [pubmed]
PHST- 2017/04/13 06:00 [medline]
PHST- 2016/07/19 06:00 [entrez]
AID - 10.1080/09513590.2016.1203408 [doi]
PST - ppublish
SO  - Gynecol Endocrinol. 2016 Dec;32(12):970-972. doi: 10.1080/09513590.2016.1203408. 
      Epub 2016 Jul 16.

PMID- 25273456
OWN - NLM
STAT- MEDLINE
DCOM- 20150706
LR  - 20141002
IS  - 1089-7690 (Electronic)
IS  - 0021-9606 (Linking)
VI  - 141
IP  - 12
DP  - 2014 Sep 28
TI  - Thermodynamics of surface defects at the aspirin/water interface.
PG  - 124702
LID - 10.1063/1.4895906 [doi]
AB  - We present a simulation scheme to calculate defect formation free energies at a 
      molecular crystal/water interface based on force-field molecular dynamics 
      simulations. To this end, we adopt and modify existing approaches to calculate 
      binding free energies of biological ligand/receptor complexes to be applicable to 
      common surface defects, such as step edges and kink sites. We obtain 
      statistically accurate and reliable free energy values for the aspirin/water 
      interface, which can be applied to estimate the distribution of defects using 
      well-established thermodynamic relations. As a show case we calculate the free 
      energy upon dissolving molecules from kink sites at the interface. This free 
      energy can be related to the solubility concentration and we obtain solubility 
      values in excellent agreement with experimental results.
FAU - Schneider, Julian
AU  - Schneider J
AD  - Chair for Theoretical Chemistry and Catalysis Research Center, Technische 
      Universität München, Lichtenbergstr. 4, D-85747 Garching, Germany.
FAU - Zheng, Chen
AU  - Zheng C
AD  - Chair for Theoretical Chemistry and Catalysis Research Center, Technische 
      Universität München, Lichtenbergstr. 4, D-85747 Garching, Germany.
FAU - Reuter, Karsten
AU  - Reuter K
AD  - Chair for Theoretical Chemistry and Catalysis Research Center, Technische 
      Universität München, Lichtenbergstr. 4, D-85747 Garching, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Chem Phys
JT  - The Journal of chemical physics
JID - 0375360
RN  - 0 (Solvents)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Aspirin/*chemistry
MH  - Dimerization
MH  - Molecular Dynamics Simulation
MH  - Solvents/chemistry
MH  - Thermodynamics
MH  - Water/*chemistry
EDAT- 2014/10/03 06:00
MHDA- 2015/07/07 06:00
CRDT- 2014/10/03 06:00
PHST- 2014/10/03 06:00 [entrez]
PHST- 2014/10/03 06:00 [pubmed]
PHST- 2015/07/07 06:00 [medline]
AID - 10.1063/1.4895906 [doi]
PST - ppublish
SO  - J Chem Phys. 2014 Sep 28;141(12):124702. doi: 10.1063/1.4895906.

PMID- 8596771
OWN - NLM
STAT- MEDLINE
DCOM- 19960418
LR  - 20190914
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 53
IP  - 5
DP  - 1995 Nov
TI  - Low-dose aspirin does not attenuate platelet aggregation or atherosclerosis in 
      miniature swine but decreases production of aortic wall prostacyclin.
PG  - 331-40
AB  - The objectives of this study were to determine if, and at what dose, aspirin 
      could attenuate atherosclerosis in hypercholesterolemic Yucatan miniature swine, 
      and to determine the influence of aspirin on aortic wall prostacyclin production 
      and platelet aggregation. 30 Yucatan miniature swine (age 3 months) were fed 
      either regular diet (RD), atherogenic diet (AD), or AD plus one of four aspirin 
      dosages (2,4,8, or 16 mg/kg/d) for 6 months. The extent of atherosclerotic 
      lesions in the abdominal aorta and coronary arteries was evaluated by 
      sudanophilic staining and histological grading using Stary's classification, 
      respectively. Aortic wall production of prostacyclin (PGI2) and platelet 
      aggregation were assessed. Lesions were similar among the AD groups (45.3 +/- 
      4.3%) and significantly higher than RD (1.4 +/- 0.4%). PGI2 production was 
      significantly lower (p < 0.05) in all aspirin-treated groups. Platelet 
      aggregation was not affected by treatment. It is concluded that the range of 
      aspirin dosages (2-16 mg/kg/d) does not attenuate the development of 
      atherosclerosis.
FAU - Smith, M J
AU  - Smith MJ
AD  - Department of Physiology, Colorado State University, Fort Collins 80523, USA.
FAU - Allen, K G
AU  - Allen KG
FAU - Norman, J F
AU  - Norman JF
FAU - Harris, M A
AU  - Harris MA
FAU - Miller, C W
AU  - Miller CW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Azo Compounds)
RN  - 0 (Coloring Agents)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - I35E9QU96C (Scarlet Red)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/biosynthesis
MH  - Animals
MH  - Aorta/*drug effects/metabolism/pathology
MH  - Arteriosclerosis/etiology/pathology/*prevention & control
MH  - Aspirin/*administration & dosage/pharmacology/*therapeutic use
MH  - Azo Compounds
MH  - Coloring Agents
MH  - Coronary Vessels/pathology
MH  - Epoprostenol/*biosynthesis
MH  - Female
MH  - Hypercholesterolemia/complications
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Swine
MH  - Swine, Miniature
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 10.1016/0952-3278(95)90052-7 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 1995 Nov;53(5):331-40. doi: 
      10.1016/0952-3278(95)90052-7.

PMID- 23109273
OWN - NLM
STAT- MEDLINE
DCOM- 20130912
LR  - 20191210
IS  - 1526-4998 (Electronic)
IS  - 1526-498X (Linking)
VI  - 69
IP  - 4
DP  - 2013 Apr
TI  - New formulation of paraquat with lysine acetylsalicylate with low mammalian 
      toxicity and effective herbicidal activity.
PG  - 553-8
LID - 10.1002/ps.3412 [doi]
AB  - BACKGROUND: Currently, the commercial formulations of the herbicide paraquat are 
      highly toxic to humans, and no effective antidote is available for paraquat 
      poisoning. The aim of the present study was to develop a safe formulation, 
      combining paraquat and the known antidote lysine acetylsalicylate. The toxicity 
      of a mixture of Gramoxone® (20% paraquat) and lysine acetylsalicylate in adult 
      Wistar male rats and the herbicidal efficacy against grass lawn (50% of Poa 
      pratensis and 50% of Festuca arundinacea) were evaluated. This new formulation 
      was administered to Wistar rats by gavage at 125 mg kg(-1) of paraquat ion and 
      lysine acetylsalicylate at 79, 158 or 316 mg kg(-1) body weight, and the survival 
      rate was observed for 30 days. RESULTS: The survival rate of the paraquat group 
      was only 40%, while lysine acetylsalicylate provided effective protection, with 
      full survival observed in the groups that received 125 mg kg(-1) of paraquat ion 
      and 316 mg kg(-1) of lysine acetylsalicylate. Both formulations of paraquat, 
      either in the absence or in the presence of lysine acetylsalicylate, provided the 
      same herbicidal activity against the tested herbal species. CONCLUSIONS: The 
      present formulation of paraquat containing lysine acetylsalicylate, significantly 
      decreases mammalian toxicity while maintaining effective herbicidal activity.
CI  - © 2012 Society of Chemical Industry.
FAU - Baltazar, Maria Teresa
AU  - Baltazar MT
AD  - REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of 
      Pharmacy, University of Porto, Porto, Portugal.
FAU - Dinis-Oliveira, Ricardo Jorge
AU  - Dinis-Oliveira RJ
FAU - Guilhermino, Lúcia
AU  - Guilhermino L
FAU - Bastos, Maria de Lourdes
AU  - Bastos Mde L
FAU - Duarte, José Alberto
AU  - Duarte JA
FAU - Carvalho, Félix
AU  - Carvalho F
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121029
PL  - England
TA  - Pest Manag Sci
JT  - Pest management science
JID - 100898744
RN  - 0 (Antidotes)
RN  - 0 (Herbicides)
RN  - K3Z4F929H6 (Lysine)
RN  - PLG39H7695 (Paraquat)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Antidotes/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Herbicides/*toxicity
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
MH  - Paraquat/*toxicity
MH  - Rats
MH  - Rats, Wistar
MH  - Toxicity Tests
EDAT- 2012/10/31 06:00
MHDA- 2013/09/13 06:00
CRDT- 2012/10/31 06:00
PHST- 2012/07/16 00:00 [received]
PHST- 2012/08/12 00:00 [revised]
PHST- 2012/08/21 00:00 [accepted]
PHST- 2012/10/31 06:00 [entrez]
PHST- 2012/10/31 06:00 [pubmed]
PHST- 2013/09/13 06:00 [medline]
AID - 10.1002/ps.3412 [doi]
PST - ppublish
SO  - Pest Manag Sci. 2013 Apr;69(4):553-8. doi: 10.1002/ps.3412. Epub 2012 Oct 29.

PMID- 10023111
OWN - NLM
STAT- MEDLINE
DCOM- 19990610
LR  - 20171101
IS  - 0014-3022 (Print)
IS  - 0014-3022 (Linking)
VI  - 41
IP  - 2
DP  - 1999
TI  - Lysine-acetylsalicylic acid in acute migraine attacks.
PG  - 88-93
AB  - Vasoconstrictive agents have been widely used in the treatment of migraine. These 
      types of drugs have various side effects and are not suitable for many patients. 
      Due to nausea or vomiting, nonoral treatment is often required, but only a few 
      nonvasoconstrictive drugs exist in a parenteral form and are suitable for the 
      treatment of acute migraine in the emergency setting. In a randomized, 
      double-blind, crossover trial we evaluated the efficacy of 1,000 mg 
      lysine-acetylsalicylic acid i.v. (LAS) compared to 0.5 mg ergotamine s.c. in 56 
      patients (112 attacks) with acute migraine. To gain further insight into the 
      possible role of vasoconstriction, blood flow velocities (BFV) were measured in 
      intra- and extracranial arteries using duplex sonography and transcranial Doppler 
      sonography. Both agents were equally potent in relieving headache. Intravenous 
      LAS resulted in a significantly faster relief and had fewer side effects. LAS had 
      no effect on BFV. Ergotamine increased BFV in the middle cerebral artery only. No 
      correlation was found between changes in BFV and the relief of headache. This is 
      the first trial to compare the intravenous formulation of LAS in the treatment of 
      migraine with another antimigraine medication and suggests that it is an 
      effective and safe drug for the parenteral treatment of acute migraine attacks.
FAU - Limmroth, V
AU  - Limmroth V
AD  - Neurologische Universitätsklinik Essen, Germany.
FAU - May, A
AU  - May A
FAU - Diener, H
AU  - Diener H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Eur Neurol
JT  - European neurology
JID - 0150760
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
EDAT- 1999/02/19 04:30
MHDA- 2000/08/16 11:00
CRDT- 1999/02/19 04:30
PHST- 1999/02/19 04:30 [pubmed]
PHST- 2000/08/16 11:00 [medline]
PHST- 1999/02/19 04:30 [entrez]
AID - 8009 [pii]
AID - 10.1159/000008009 [doi]
PST - ppublish
SO  - Eur Neurol. 1999;41(2):88-93. doi: 10.1159/000008009.

PMID- 21099031
OWN - NLM
STAT- MEDLINE
DCOM- 20101229
LR  - 20211020
IS  - 1600-5740 (Electronic)
IS  - 0108-7681 (Print)
IS  - 0108-7681 (Linking)
VI  - 66
IP  - Pt 6
DP  - 2010 Dec
TI  - Diffuse scattering study of aspirin forms (I) and (II).
PG  - 696-707
LID - 10.1107/S0108768110037055 [doi]
AB  - Full three-dimensional diffuse scattering data have been recorded for both 
      polymorphic forms [(I) and (II)] of aspirin and these data have been analysed 
      using Monte Carlo computer modelling. The observed scattering in form (I) is well 
      reproduced by a simple harmonic model of thermally induced displacements. The 
      data for form (II) show, in addition to thermal diffuse scattering (TDS) similar 
      to that in form (I), diffuse streaks originating from stacking fault-like defects 
      as well as other effects that can be attributed to strain induced by these 
      defects. The present study has provided strong evidence that the aspirin form 
      (II) structure is a true polymorph with a structure quite distinct from that of 
      form (I). The diffuse scattering evidence presented shows that crystals of form 
      (II) are essentially composed of large single domains of the form (II) lattice 
      with a relatively small volume fraction of intrinsic planar defects or faults 
      comprising misoriented bilayers of molecular dimers. There is evidence of some 
      local aggregation of these defect bilayers to form small included regions of the 
      form (I) structure. Evidence is also presented that shows that the strain effects 
      arise from the mismatch of molecular packing between the defect region and the 
      surrounding form (II) lattice. This occurs at the edges of the planar defects in 
      the b direction only.
FAU - Chan, E J
AU  - Chan EJ
AD  - Research School of Chemistry, Australian National University, Canberra, ACT 0200, 
      Australia.
FAU - Welberry, T R
AU  - Welberry TR
FAU - Heerdegen, A P
AU  - Heerdegen AP
FAU - Goossens, D J
AU  - Goossens DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20101110
PL  - United States
TA  - Acta Crystallogr B
JT  - Acta crystallographica. Section B, Structural science
JID - 8403252
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Computer Simulation
MH  - Crystallization
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Monte Carlo Method
MH  - Phase Transition
MH  - Temperature
PMC - PMC2992034
EDAT- 2010/11/26 06:00
MHDA- 2010/12/30 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/07/24 00:00 [received]
PHST- 2010/09/16 00:00 [accepted]
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2010/12/30 06:00 [medline]
AID - S0108768110037055 [pii]
AID - so5043 [pii]
AID - 10.1107/S0108768110037055 [doi]
PST - ppublish
SO  - Acta Crystallogr B. 2010 Dec;66(Pt 6):696-707. doi: 10.1107/S0108768110037055. 
      Epub 2010 Nov 10.

PMID- 16133960
OWN - NLM
STAT- MEDLINE
DCOM- 20050926
LR  - 20181113
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 50
IP  - 9
DP  - 2005 Sep
TI  - Minidose aspirin and gastrointestinal bleeding--a retrospective, case-control 
      study in hospitalized patients.
PG  - 1621-4
AB  - Low or minimal doses of aspirin are widely used for prevention of cardiovascular 
      diseases. Aspirin is known to produce severe adverse gastrointestinal effects, 
      such as bleeding and perforation. Less is known about the risk associated with 
      minidose aspirin. Our aim was to assess the possible association of upper 
      gastrointestinal tract bleeding with minidose aspirin therapy. A retrospective 
      controlled design was used. Patients hospitalized for melena or hematemesis 
      between January 1, 2000, and December 31, 2001, were identified by ICD-9 codes, 
      and their clinical findings were compared to these of patients without upper 
      gastrointestinal bleeding hospitalized during the same period and matched for age 
      and sex. Bleeding was attributed to therapy if patients used a nonsteroidal 
      anti-inflammatory drug or aspirin therapy within 30 days before hospitalization. 
      The study group included 318 patients (59% male), and the control group 141 (65% 
      male). Mean ages were 67 +/- 19 and 64 +/- 19 years, respectively. Study patients 
      had more accompanying diseases, used more medications, and required more blood 
      transfusions than controls (37%, vs. 2% of controls; P < 0.001). Minidose aspirin 
      was used by 28% of the study group and 18% of the controls (P = 0.03). The 
      average dose was 40 +/- 86 and 21 +/- 55 mg/day, respectively (P = 0.012). Only 
      26% of the study patients received a gastric protective agent. On multivariate 
      analysis, aspirin consumption was the only independent risk factor for upper 
      gastrointestinal tract bleeding. There appears to be an association between 
      minidose aspirin treatment and hospitalization for upper gastrointestinal tract 
      bleeding. Despite the advanced age of the patients, only one-quarter were treated 
      with gastric protective agent.
FAU - Sapoznikov, Boris
AU  - Sapoznikov B
AD  - Department of Gastroenterology, Rabin Medical Center, Beilinson Campus, Tel Aviv 
      University, Israel.
FAU - Vilkin, Alex
AU  - Vilkin A
FAU - Hershkovici, Marcella
AU  - Hershkovici M
FAU - Fishman, Michal
AU  - Fishman M
FAU - Eliakim, Rami
AU  - Eliakim R
FAU - Niv, Yaron
AU  - Niv Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse 
      effects/therapeutic use
MH  - Aspirin/*administration & dosage/*adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stomach Diseases/*chemically induced
EDAT- 2005/09/01 09:00
MHDA- 2005/09/27 09:00
CRDT- 2005/09/01 09:00
PHST- 2004/11/23 00:00 [received]
PHST- 2005/01/05 00:00 [accepted]
PHST- 2005/09/01 09:00 [pubmed]
PHST- 2005/09/27 09:00 [medline]
PHST- 2005/09/01 09:00 [entrez]
AID - 10.1007/s10620-005-2906-0 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2005 Sep;50(9):1621-4. doi: 10.1007/s10620-005-2906-0.

PMID- 3913725
OWN - NLM
STAT- MEDLINE
DCOM- 19860505
LR  - 20131121
IS  - 0025-7850 (Print)
IS  - 0025-7850 (Linking)
VI  - 16
IP  - 4
DP  - 1985
TI  - Fenoprofen calcium versus aspirin in the treatment of acute inflammatory 
      soft-tissue injuries.
PG  - 429-38
AB  - The efficacy and safety of fenoprofen calcium (Nalfon, Dista, Indianapolis, IN) 
      and aspirin for treating acute inflammatory soft tissue injuries were compared in 
      a 3 to 10-day randomized, double-blind, parallel study of 100 patients with 
      bruise (1), bursitis (33), ligamentous strain (8), myofascitis (43), and 
      tendinitis (15). Forty-seven of the 50 aspirin-treated and 48 of the 50 
      fenoprofen-treated patients were evaluable. Results of the study showed that 
      fenoprofen calcium and aspirin were equally effective in treating acute 
      inflammatory soft-tissue injuries; however, adverse experiences occurred in fewer 
      patients and at a lower frequency with fenoprofen calcium therapy. In global 
      assessments, 73% of the patients rated fenoprofen therapy as very good or good 
      compared to 64% of the patients who received aspirin therapy. There were no 
      significant differences in the clinician's and the patients' global assessments 
      of therapy. The study suggests that fenoprofen calcium is effective for use in 
      treating soft-tissue injuries since it is better tolerated than aspirin when 
      given in equally effective doses.
FAU - McIlwain, H H
AU  - McIlwain HH
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Med
JT  - Journal of medicine
JID - 7505566
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use/toxicity
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Fenoprofen/*therapeutic use/toxicity
MH  - Humans
MH  - Inflammation
MH  - Male
MH  - Middle Aged
MH  - Pain/physiopathology
MH  - Phenylpropionates/*therapeutic use
MH  - Wounds and Injuries/*drug therapy/physiopathology
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - J Med. 1985;16(4):429-38.

PMID- 19879442
OWN - NLM
STAT- MEDLINE
DCOM- 20100519
LR  - 20131121
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 29
IP  - 4
DP  - 2009 Nov
TI  - Aspirin intolerance: does desensitization alter the course of the disease?
PG  - 669-75
LID - 10.1016/j.iac.2009.07.008 [doi]
AB  - Intolerance to acetylsalicylic acid and to other nonsteroidal anti-inflammatory 
      drugs was first described in 1922. The clinical picture reveals a classic triad 
      of symptoms: aspirin-induced bronchial asthma, aspirin sensitivity, and chronic 
      rhinosinusitis with nasal polyps. In many cases, nasal polyps reveal as the first 
      symptom of ASA sensitivity, indicating that the upper airways are predominantly 
      involved in the pathogenetic process. The emphasis of this article is on the 
      upper airways of ASA-intolerant patients. Imbalance of the eicosanoids 
      leukotrienes and prostaglandins might be the pathophysiologic key to the disease. 
      The patient's history and challenge tests with lysine-aspirin are the diagnostic 
      tools of choice. Apart from surgical or pharmacologic therapy, 
      ASA-desensitization therapy is the treatment of choice. Various desensitization 
      protocols and routes of administration are discussed.
FAU - Klimek, L
AU  - Klimek L
AD  - Center for Rhinology and Allergy, An den Quellen 10, D-65183 Wiesbaden, Germany. 
      ludger.klimek@allergiezentrum.de
FAU - Pfaar, O
AU  - Pfaar O
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Leukotrienes)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/adverse effects/*immunology/therapeutic use
MH  - Bronchial Provocation Tests
MH  - Bronchoconstriction/drug effects
MH  - Cyclooxygenase 1/genetics/immunology/*metabolism
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/diagnosis/*immunology/*physiopathology/therapy
MH  - Gene Expression Regulation, Enzymologic
MH  - Humans
MH  - Leukotrienes/biosynthesis
MH  - Nasal Polyps
RF  - 34
EDAT- 2009/11/03 06:00
MHDA- 2010/05/21 06:00
CRDT- 2009/11/03 06:00
PHST- 2009/11/03 06:00 [entrez]
PHST- 2009/11/03 06:00 [pubmed]
PHST- 2010/05/21 06:00 [medline]
AID - S0889-8561(09)00057-5 [pii]
AID - 10.1016/j.iac.2009.07.008 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2009 Nov;29(4):669-75. doi: 
      10.1016/j.iac.2009.07.008.

PMID- 21229661
OWN - NLM
STAT- MEDLINE
DCOM- 20110411
LR  - 20190911
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 404
IP  - 1-2
DP  - 2011 Feb 14
TI  - Corrigendum to “The most appropriate storage method in unit-dose package and 
      correlation between color change and decomposition rate of aspirin tablets”.
PG  - 325-30
AB  - The most appropriate method to preserve Bufferin 81-mg tablets dispensed for 
      unit-dose packaging in the hospital pharmacy was examined. The surface color 
      change of the tablets was investigated over time by spectrophotometry, and the 
      decomposition rate of aspirin was measured by high-performance liquid 
      chromatography (HPLC). To overcome these, it was found that we can effectively 
      prevent color changes and preserve the quality by maintaining the humidity as 55% 
      or less, storage with drying agent in a plastic or aluminum pack. It was revealed 
      that the color changes became greater and the decomposition rate became higher as 
      time passed. Color changes markedly affect the patients' compliance, and are 
      found to be a very important factor. It was considered that the clarity of the 
      correlation between the color change and decomposition rate may contribute to a 
      decrease in the number of tablets discarded before the expiration date.
FAU - Yamazaki, Noriko
AU  - Yamazaki N
AD  - Department of Health Care and Sciences, Faculty of Pharmaceutical Sciences, Meiji 
      Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan.
FAU - Taya, Kumiko
AU  - Taya K
FAU - Shimokawa, Ken-ichi
AU  - Shimokawa K
FAU - Ishii, Fumiyoshi
AU  - Ishii F
LA  - eng
PT  - Corrected and Republished Article
PT  - Journal Article
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CRF - Int J Pharm. 2010 Aug 30;396(1-2):105-10. PMID: 20599601
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Color
MH  - Drug Packaging
MH  - Drug Stability
MH  - Drug Storage
MH  - Technology, Pharmaceutical
EDAT- 2011/01/14 06:00
MHDA- 2011/04/13 06:00
CRDT- 2011/01/14 06:00
PHST- 2011/01/14 06:00 [entrez]
PHST- 2011/01/14 06:00 [pubmed]
PHST- 2011/04/13 06:00 [medline]
AID - 10.1016/j.ijpharm.2010.11.033 [doi]
PST - ppublish
SO  - Int J Pharm. 2011 Feb 14;404(1-2):325-30. doi: 10.1016/j.ijpharm.2010.11.033.

PMID- 25040175
OWN - NLM
STAT- MEDLINE
DCOM- 20150514
LR  - 20151119
IS  - 1525-1470 (Electronic)
IS  - 0736-8046 (Linking)
VI  - 31
IP  - 5
DP  - 2014 Sep-Oct
TI  - Aspirin therapy in venous malformation: a retrospective cohort study of benefits, 
      side effects, and patient experiences.
PG  - 556-60
LID - 10.1111/pde.12373 [doi]
AB  - Venous malformations (VMs) are often painful and may enlarge over time. Chronic 
      coagulopathy is common in VMs and may contribute to phleboliths and potentially 
      to disease progression. Few studies have examined the effects of anticoagulation 
      on VMs and to our knowledge none have examined the use of aspirin therapy. A 
      survey was administered to patients and parents of patients with VMs who attended 
      the University of California at San Francisco Vascular Anomalies Center over a 
      4-year period (2008-2012) to whom aspirin had been recommended. They were 
      surveyed regarding whether they were taking aspirin and, if yes, whether aspirin 
      had resulted in any appreciable benefit. Sixty-five letters were sent to 
      potential subjects: 38 participated and 27 declined to participate or could not 
      be contacted. Twenty-eight of the 38 had begun aspirin and 22 reported current 
      use. Seventeen reported some benefit, including less aching (n = 2), less 
      shooting pain (n = 15), less fullness and swelling (n = 13), and shrinking of the 
      VM (n = 1). Discontinuation of aspirin was associated with worsening VM symptoms 
      in five of six patients. Side effects were reported in 6 of 28 patients, 
      including five episodes of minor bleeding or excessive bruising and one of nausea 
      and vomiting. This study suggests that aspirin may be a beneficial treatment for 
      VM, with a reduction in pain and soft tissue swelling and an acceptable 
      side-effect profile, but the retrospective nature of the study and the small size 
      of the cohort limited our conclusions. Larger prospective studies of aspirin for 
      VM using clinical and laboratory outcome measures are needed to confirm these 
      observations.
CI  - © 2014 Wiley Periodicals, Inc.
FAU - Nguyen, Jennifer T
AU  - Nguyen JT
AD  - Department of Dermatology, School of Medicine, University of California at San 
      Francisco, San Francisco, California.
FAU - Koerper, Marion A
AU  - Koerper MA
FAU - Hess, Christopher P
AU  - Hess CP
FAU - Dowd, Christopher F
AU  - Dowd CF
FAU - Hoffman, William Y
AU  - Hoffman WY
FAU - Dickman, Meghan
AU  - Dickman M
FAU - Frieden, Ilona J
AU  - Frieden IJ
LA  - eng
PT  - Journal Article
DEP - 20140721
PL  - United States
TA  - Pediatr Dermatol
JT  - Pediatric dermatology
JID - 8406799
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Infant
MH  - Middle Aged
MH  - Pain Management
MH  - Pain Measurement
MH  - Retrospective Studies
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Vascular Malformations/*drug therapy
MH  - Veins/*abnormalities
EDAT- 2014/07/22 06:00
MHDA- 2015/05/15 06:00
CRDT- 2014/07/22 06:00
PHST- 2014/07/22 06:00 [entrez]
PHST- 2014/07/22 06:00 [pubmed]
PHST- 2015/05/15 06:00 [medline]
AID - 10.1111/pde.12373 [doi]
PST - ppublish
SO  - Pediatr Dermatol. 2014 Sep-Oct;31(5):556-60. doi: 10.1111/pde.12373. Epub 2014 
      Jul 21.

PMID- 18420732
OWN - NLM
STAT- MEDLINE
DCOM- 20080702
LR  - 20190722
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 54
IP  - 6
DP  - 2008 Jun
TI  - Aspirin responsiveness in healthy volunteers measured with multiple assay 
      platforms.
PG  - 1060-5
LID - 10.1373/clinchem.2007.101014 [doi]
AB  - BACKGROUND: We evaluated the sensitivity, precision, and concordance of 4 assays 
      designed to detect aspirin responsiveness or resistance. METHODS: Twenty-nine 
      healthy laboratory volunteers took 80 mg aspirin for 7 days, and a subset of 
      volunteers took 325 mg aspirin for an additional 7 days. We measured platelet 
      function by light transmission aggregometry with arachidonic acid, PFA-100, and 
      VerifyNow. PFA-100 and VerifyNow assays were performed in duplicate to assess 
      method imprecision. Some volunteers had samples taken within 2-4 h of the final 
      dose of aspirin and again within 20-24 h of the final dose. We measured urinary 
      11-dehydro-thromboxane B(2) at baseline and after 80 or 325 mg aspirin. RESULTS: 
      No volunteers were nonresponsive to aspirin therapy as measured by the PFA-100. 
      One of 29 participants demonstrated lack of response to aspirin as measured by 
      VerifyNow and urinary 11-dehydro-thromboxane B(2); 2 of 29 demonstrated lack of 
      response as measured by light transmission aggregometry. Imprecision was <10% for 
      the PFA-100 and VerifyNow. Concordance was high (>90%) between all assays. 
      Neither aspirin dose (80 vs 325 mg) nor timing between final dose of aspirin and 
      blood draw (2-4 vs 20-24 h) affected any of the assays. CONCLUSIONS: Light 
      transmission aggregometry, PFA-100, VerifyNow, and urinary 11-dehydro-thromboxane 
      B(2) are all sensitive to the effects of aspirin in healthy individuals. 
      Variables such as aspirin dose, timing between final dose of aspirin and blood 
      collection, and imprecision do not affect the ability of the assays to detect 
      aspirin effect on platelet function.
FAU - Karon, Brad S
AU  - Karon BS
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
FAU - Wockenfus, Amy
AU  - Wockenfus A
FAU - Scott, Renee
AU  - Scott R
FAU - Hartman, Stacy J
AU  - Hartman SJ
FAU - McConnell, Joseph P
AU  - McConnell JP
FAU - Santrach, Paula J
AU  - Santrach PJ
FAU - Jaffe, Allan S
AU  - Jaffe AS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
DEP - 20080417
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance
MH  - Humans
MH  - Immunoassay
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Reference Values
MH  - Thromboxane B2/analogs & derivatives/urine
MH  - Time Factors
EDAT- 2008/04/19 09:00
MHDA- 2008/07/03 09:00
CRDT- 2008/04/19 09:00
PHST- 2008/04/19 09:00 [pubmed]
PHST- 2008/07/03 09:00 [medline]
PHST- 2008/04/19 09:00 [entrez]
AID - clinchem.2007.101014 [pii]
AID - 10.1373/clinchem.2007.101014 [doi]
PST - ppublish
SO  - Clin Chem. 2008 Jun;54(6):1060-5. doi: 10.1373/clinchem.2007.101014. Epub 2008 
      Apr 17.

PMID- 22942209
OWN - NLM
STAT- MEDLINE
DCOM- 20130416
LR  - 20220331
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Print)
IS  - 1058-4838 (Linking)
VI  - 55
IP  - 11
DP  - 2012 Dec
TI  - Underutilization of aspirin for primary prevention of cardiovascular disease 
      among HIV-infected patients.
PG  - 1550-7
LID - 10.1093/cid/cis752 [doi]
AB  - BACKGROUND: Individuals infected with human immunodeficiency virus (HIV) are at 
      increased risk for cardiovascular disease (CVD) events compared with uninfected 
      persons. However, little is known about HIV provider practices regarding aspirin 
      (ASA) for primary prevention of CVD. METHODS: A cross-sectional study was 
      conducted among patients attending the University of Alabama at Birmingham 1917 
      HIV Clinic during 2010 to determine the proportion receiving ASA for primary 
      prevention of CVD and identify factors associated with ASA prescription. Ten-year 
      risk for CVD events was calculated for men aged 45-79 and women aged 55-79. The 
      2009 US Preventive Services Task Force (USPSTF) guidelines were used to determine 
      those qualifying for primary CVD prevention. RESULTS: Among 397 patients who 
      qualified to receive ASA (mean age, 52.2 years, 94% male, 36% African American), 
      only 66 (17%) were prescribed ASA. In multivariable logistic regression analysis, 
      diabetes mellitus (odds ratio [OR], 2.60; 95% confidence interval [CI], 
      1.28-5.27), hyperlipidemia (OR, 3.42; 95% CI, 1.55-7.56), and current smoking 
      (OR, 1.87; 95% CI, 1.03-3.41) were significantly associated with ASA 
      prescription. Odds of ASA prescription more than doubled for each additional 
      CVD-related comorbidity present among hypertension, diabetes, hyperlipidemia, and 
      smoking (OR, 2.13, 95% CI, 1.51-2.99). CONCLUSIONS: In this HIV-infected cohort, 
      fewer than 1 in 5 patients in need received ASA for primary CVD prevention. 
      Escalating likelihood of ASA prescription with increasing CVD-related comorbidity 
      count suggests that providers may be influenced more by co-occurrence of these 
      diagnoses than by USPSTF guidelines. In the absence of HIV-specific guidelines, 
      interventions to improve HIV provider awareness of and adherence to existing 
      general population guidelines on CVD risk reduction are needed.
FAU - Burkholder, Greer A
AU  - Burkholder GA
AD  - Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, 
      AL 35294, USA. gburkhol@uab.edu
FAU - Tamhane, Ashutosh R
AU  - Tamhane AR
FAU - Salinas, Jorge L
AU  - Salinas JL
FAU - Mugavero, Michael J
AU  - Mugavero MJ
FAU - Raper, James L
AU  - Raper JL
FAU - Westfall, Andrew O
AU  - Westfall AO
FAU - Saag, Michael S
AU  - Saag MS
FAU - Willig, James H
AU  - Willig JH
LA  - eng
GR  - P30 AI027767/AI/NIAID NIH HHS/United States
GR  - K23 MH082641/MH/NIMH NIH HHS/United States
GR  - 5T32HS013852/HS/AHRQ HHS/United States
GR  - 1R24 AI067039-1/AI/NIAID NIH HHS/United States
GR  - T32 HS013852/HS/AHRQ HHS/United States
GR  - R24 AI067039/AI/NIAID NIH HHS/United States
GR  - K23MH082641/MH/NIMH NIH HHS/United States
GR  - P30-AI27767/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20120831
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Drug Utilization
MH  - Female
MH  - HIV Infections/*complications
MH  - Heart Diseases/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Risk Factors
PMC - PMC3491860
EDAT- 2012/09/04 06:00
MHDA- 2013/04/17 06:00
CRDT- 2012/09/04 06:00
PHST- 2012/09/04 06:00 [entrez]
PHST- 2012/09/04 06:00 [pubmed]
PHST- 2013/04/17 06:00 [medline]
AID - cis752 [pii]
AID - 10.1093/cid/cis752 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2012 Dec;55(11):1550-7. doi: 10.1093/cid/cis752. Epub 2012 Aug 
      31.

PMID- 3822942
OWN - NLM
STAT- MEDLINE
DCOM- 19870406
LR  - 20191030
IS  - 0277-0938 (Print)
IS  - 0277-0938 (Linking)
VI  - 6
IP  - 2-3
DP  - 1986
TI  - Cyclopia and maternal ingestion of salicylates.
PG  - 309-10
AB  - Salicylates are teratogens in animals, but their teratogenicity in man remains 
      controverted. The possibility that massive oral intake in the first 3 months of 
      pregnancy may induce malformations has not been eliminated. We report a second 
      case of cyclopia associated with daily maternal ingestion of up to 4 g of 
      acetylsalicylic acid in the first trimester.
FAU - Agapitos, M
AU  - Agapitos M
FAU - Georgiou-Theodoropoulou, M
AU  - Georgiou-Theodoropoulou M
FAU - Koutselinis, A
AU  - Koutselinis A
FAU - Papacharalampus, N
AU  - Papacharalampus N
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Pediatr Pathol
JT  - Pediatric pathology
JID - 8303527
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abnormalities, Drug-Induced/pathology
MH  - Abnormalities, Multiple/chemically induced
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Brain/abnormalities
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Nose/abnormalities
MH  - Orbit/*abnormalities
MH  - Pregnancy
MH  - Pregnancy Trimester, First
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.3109/15513818609037721 [doi]
PST - ppublish
SO  - Pediatr Pathol. 1986;6(2-3):309-10. doi: 10.3109/15513818609037721.

PMID- 6927884
OWN - NLM
STAT- MEDLINE
DCOM- 19800226
LR  - 20190708
IS  - 0002-8177 (Print)
IS  - 0002-8177 (Linking)
VI  - 100
IP  - 1
DP  - 1980 Jan
TI  - Evaluation of acetaminophen and aspirin in the relief of preoperative dental 
      pain.
PG  - 39-42
AB  - The effectiveness of nonprescription analgesics--acetaminophen and aspirin--in 
      providing subjective relief of preoperative dental pain was evaluated in a varied 
      population of adults. This study demonstrates for the first time the feasibility 
      of evaluating preoperative analgesic efficacy in preoperative dental pain and 
      provides evidence that acetaminophen (1 gm) and aspirin (1 gm) can alleviate 
      dental pain better than a placebo.
FAU - Korberly, B H
AU  - Korberly BH
FAU - Schreiber, G F
AU  - Schreiber GF
FAU - Kilkuts, A
AU  - Kilkuts A
FAU - Orkand, R K
AU  - Orkand RK
FAU - Segal, H
AU  - Segal H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mouth Diseases/*drug therapy
MH  - Pain/*drug therapy
MH  - Placebos
MH  - Time Factors
MH  - Toothache/drug therapy
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - S0002-8177(80)01014-8 [pii]
AID - 10.14219/jada.archive.1980.0038 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 1980 Jan;100(1):39-42. doi: 10.14219/jada.archive.1980.0038.

PMID- 36362006
OWN - NLM
STAT- MEDLINE
DCOM- 20221125
LR  - 20221125
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 21
DP  - 2022 Oct 30
TI  - Aspirin Inhibits the Inflammatory Response of Protease-Activated Receptor 1 in 
      Pregnancy Neutrophils: Implications for Treating Women with Preeclampsia.
LID - 10.3390/ijms232113218 [doi]
LID - 13218
AB  - Neutrophils expressing cyclooxygenase-2 (COX-2) extensively infiltrate maternal 
      blood vessels in preeclampsia, associated with vascular inflammation. Because 
      pregnancy neutrophils also express protease-activated receptor 1 (PAR-1, F2R 
      thrombin receptor), which they do not in non-pregnant subjects, they can be 
      activated by proteases. We tested the hypothesis that aspirin at a dose 
      sufficient to inhibit COX-2 would reduce inflammatory responses in preeclampsia 
      neutrophils. Neutrophils were isolated from normal pregnant and preeclamptic 
      women at approximately 30 weeks' gestation. Normal pregnancy neutrophils were 
      treated with elastase, a protease elevated in preeclampsia, or elastase plus 
      aspirin to inhibit COX-2, or elastase plus pinane thromboxane, a biologically 
      active structural analog of thromboxane and a thromboxane synthase inhibitor. 
      Preeclamptic pregnancy neutrophils were treated with the same doses of aspirin or 
      pinane thromboxane. Confocal microscopy with immunofluorescence staining was used 
      to determine the cellular localization of the p65 subunit of nuclear factor-kappa 
      B (NF-κB) and media concentrations of thromboxane were measured to evaluate the 
      inflammatory response. In untreated neutrophils of normal pregnant women, p65 was 
      localized to the cytosol. Upon stimulation with elastase, p65 translocated from 
      the cytosol to the nucleus coincident with increased thromboxane production. When 
      neutrophils were co-treated with aspirin or pinane thromboxane, elastase was not 
      able to cause nuclear translocation of p65 or increase thromboxane. In untreated 
      neutrophils of preeclamptic women, the p65 subunit was present in the nucleus and 
      thromboxane production was elevated, but when preeclamptic neutrophils were 
      treated with aspirin or pinane thromboxane, p65 was cleared from the nucleus and 
      returned to the cytosol along with decreased thromboxane production. These 
      findings suggest that COX-2 is a downstream mediator of PAR-1 and demonstrate 
      that PAR-1- mediated inflammation can be inhibited by aspirin. Given the 
      extensive and ubiquitous expression of PAR-1 and COX-2 in preeclamptic women, 
      consideration should be given to treating women with preeclampsia using a dose of 
      aspirin sufficient to inhibit COX-2.
FAU - Walsh, Scott W
AU  - Walsh SW
AUID- ORCID: 0000-0001-8234-025X
AD  - Department of Obstetrics and Gynecology, School of Medicine, Virginia 
      Commonwealth University, Richmond, VA 23298-0034, USA.
AD  - Department of Physiology and Biophysics, School of Medicine, Virginia 
      Commonwealth University, Richmond, VA 23298-0034, USA.
FAU - Al Dulaimi, Marwah
AU  - Al Dulaimi M
AD  - Department of Obstetrics and Gynecology, School of Medicine, Virginia 
      Commonwealth University, Richmond, VA 23298-0034, USA.
FAU - Strauss, Jerome F 3rd
AU  - Strauss JF 3rd
AUID- ORCID: 0000-0001-6199-0480
AD  - Department of Obstetrics and Gynecology, School of Medicine, Virginia 
      Commonwealth University, Richmond, VA 23298-0034, USA.
LA  - eng
GR  - 5R01 HD088386/Eunice Kennedy Shriver National Institute of Child Health and Human 
      Development/
PT  - Journal Article
DEP - 20221030
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Bicyclic Monoterpenes)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - 0 (Receptor, PAR-1)
RN  - 0 (Thromboxanes)
SB  - IM
MH  - Female
MH  - Humans
MH  - Pregnancy/drug effects
MH  - *Aspirin/pharmacology/therapeutic use/metabolism
MH  - Bicyclic Monoterpenes
MH  - Cyclooxygenase 2/metabolism
MH  - Inflammation/drug therapy/metabolism
MH  - Neutrophils/drug effects/metabolism
MH  - Peptide Hydrolases/metabolism
MH  - *Pre-Eclampsia/drug therapy/metabolism
MH  - *Receptor, PAR-1/drug effects/metabolism
MH  - Thromboxanes/metabolism
PMC - PMC9654155
OTO - NOTNLM
OT  - aspirin
OT  - cyclooxygenase-2
OT  - neutrophils
OT  - nuclear factor-kappa B
OT  - preeclampsia
OT  - pregnancy
OT  - protease-activated receptor 1
OT  - thromboxane
COIS- The authors declare no conflict of interest.
EDAT- 2022/11/12 06:00
MHDA- 2022/11/15 06:00
CRDT- 2022/11/11 01:27
PHST- 2022/09/23 00:00 [received]
PHST- 2022/10/20 00:00 [revised]
PHST- 2022/10/28 00:00 [accepted]
PHST- 2022/11/11 01:27 [entrez]
PHST- 2022/11/12 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
AID - ijms232113218 [pii]
AID - ijms-23-13218 [pii]
AID - 10.3390/ijms232113218 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Oct 30;23(21):13218. doi: 10.3390/ijms232113218.

PMID- 16959551
OWN - NLM
STAT- MEDLINE
DCOM- 20070402
LR  - 20220316
IS  - 1570-0232 (Print)
IS  - 1570-0232 (Linking)
VI  - 846
IP  - 1-2
DP  - 2007 Feb 1
TI  - Sensitive determination of aspirin and its metabolites in plasma by LC-UV using 
      on-line solid-phase extraction with methylcellulose-immobilized anion-exchange 
      restricted access media.
PG  - 132-8
AB  - We describe a sensitive determination of aspirin (ASA) and its three metabolites 
      (salicylic acid [SA], 2,3-dihydroxybenzoic acid [2,3-DHBA], and 
      2,5-dihydroxybenzoic acid [gentisic acid (GA)]) in rat plasma. Analysis was 
      carried out by on-line solid-phase extraction (SPE) using a 
      methylcellulose-immobilized-strong anion-exchanger (MC-SAX), followed by liquid 
      chromatography (LC) coupled with UV detection. The lower limits of quantitation 
      for ASA and SA were 60 ng/mL in 100 microL of plasma, respectively. This method 
      was validated with respect to intra- and inter-day precision, accuracy, and 
      linearity up to concentrations of 20,000 ng/mL for ASA, SA, 2,3-DHBA and gentisic 
      acid, respectively. The method was successfully applied to an analysis of the 
      pharmacokinetics of ASA and SA in rats.
FAU - Yamamoto, Eiichi
AU  - Yamamoto E
AD  - Analytical Research Laboratories, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, 
      Ibaraki 300-2635, Japan. e-yamamoto@hhc.eisai.co.jp
FAU - Takakuwa, Susumu
AU  - Takakuwa S
FAU - Kato, Takashi
AU  - Kato T
FAU - Asakawa, Naoki
AU  - Asakawa N
LA  - eng
PT  - Journal Article
DEP - 20060907
PL  - Netherlands
TA  - J Chromatogr B Analyt Technol Biomed Life Sci
JT  - Journal of chromatography. B, Analytical technologies in the biomedical and life 
      sciences
JID - 101139554
RN  - 0 (Anion Exchange Resins)
RN  - 9004-67-5 (Methylcellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anion Exchange Resins
MH  - Aspirin/*blood/pharmacokinetics
MH  - Chromatography, Ion Exchange/*methods
MH  - Male
MH  - Methylcellulose/*chemistry
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Spectrophotometry, Ultraviolet/*methods
EDAT- 2006/09/09 09:00
MHDA- 2007/04/03 09:00
CRDT- 2006/09/09 09:00
PHST- 2006/02/01 00:00 [received]
PHST- 2006/08/05 00:00 [revised]
PHST- 2006/08/22 00:00 [accepted]
PHST- 2006/09/09 09:00 [pubmed]
PHST- 2007/04/03 09:00 [medline]
PHST- 2006/09/09 09:00 [entrez]
AID - S1570-0232(06)00695-7 [pii]
AID - 10.1016/j.jchromb.2006.08.037 [doi]
PST - ppublish
SO  - J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):132-8. doi: 
      10.1016/j.jchromb.2006.08.037. Epub 2006 Sep 7.

PMID- 20377806
OWN - NLM
STAT- MEDLINE
DCOM- 20100716
LR  - 20220318
IS  - 1751-7141 (Electronic)
IS  - 1520-037X (Linking)
VI  - 13
IP  - 2
DP  - 2010 Spring
TI  - Effect of obesity on platelet reactivity and response to low-dose aspirin.
PG  - 56-62
LID - 10.1111/j.1751-7141.2009.00058.x [doi]
AB  - Insufficient platelet function suppression by aspirin is a predictor of 
      cardiovascular events in high-risk patients. The authors assessed the impact of 
      obesity on platelet responsiveness before and after 2 weeks of aspirin 81 mg/d in 
      2014 people. Obese individuals had greater baseline platelet reactivity. 
      Comparing obese and nonobese individuals after aspirin therapy, results for 
      aggregometry to collagen were 6.7 vs 6.1 ohms, P=.008; aggregometry to adenosine 
      diphosphate were 13.1 vs 11.8 ohms,P<.0001; aggregometry to arachidonic acid (AA) 
      were 4.9% vs 8.3% nonzero aggregation, P=.002; urinary excretion of 
      11-dehydro-thromboxane B2 (Tx-M) were 4.9% vs 8.3% nonzero aggregation, P=.002; 
      and aspirin resistance were 26.% vs 20.5%, P=.002; respectively. These remained 
      significantly different for AA aggregation and Tx-M excretion after adjustment 
      for covariates. Obese individuals have greater native platelet reactivity and 
      retain greater reactivity after suppression by aspirin.
FAU - Bordeaux, Bryan C
AU  - Bordeaux BC
AD  - Department of Population Medicine, Harvard Medical School, Boston, MA, USA.
FAU - Qayyum, Rehan
AU  - Qayyum R
FAU - Yanek, Lisa R
AU  - Yanek LR
FAU - Vaidya, Dhananjay
AU  - Vaidya D
FAU - Becker, Lewis C
AU  - Becker LC
FAU - Faraday, Nauder
AU  - Faraday N
FAU - Becker, Diane M
AU  - Becker DM
LA  - eng
GR  - HL072518/HL/NHLBI NIH HHS/United States
GR  - M01-RR000052/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Prev Cardiol
JT  - Preventive cardiology
JID - 9813731
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Case-Control Studies
MH  - Collagen
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Linear Models
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Obesity/*blood/complications
MH  - Phenotype
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/therapeutic 
      use
MH  - Platelet Function Tests
MH  - Time Factors
EDAT- 2010/04/10 06:00
MHDA- 2010/07/17 06:00
CRDT- 2010/04/10 06:00
PHST- 2010/04/10 06:00 [entrez]
PHST- 2010/04/10 06:00 [pubmed]
PHST- 2010/07/17 06:00 [medline]
AID - PRC58 [pii]
AID - 10.1111/j.1751-7141.2009.00058.x [doi]
PST - ppublish
SO  - Prev Cardiol. 2010 Spring;13(2):56-62. doi: 10.1111/j.1751-7141.2009.00058.x.

PMID- 24117703
OWN - NLM
STAT- MEDLINE
DCOM- 20140710
LR  - 20151119
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 68
IP  - 11
DP  - 2013 Nov
TI  - Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory 
      disease.
PG  - 1443-51
LID - 10.1111/all.12269 [doi]
AB  - BACKGROUND: Aspirin desensitization (AD) treatment at doses of up to 1300 mg/day 
      improves outcomes in aspirin-exacerbated respiratory disease (AERD). The aim of 
      this study was to investigate the efficacy of aspirin 300 mg/day in the treatment 
      of patients with AERD. METHODS: The study included 40 patients diagnosed in our 
      clinic as AERD that were desensitized and treated with aspirin 300 mg/day between 
      December 2005 and December 2012. Changes from the baseline status were analyzed 
      at 1 year and at 3 years of follow-up. RESULTS: Of the 40 patients included, 24 
      (60%) were female and median (interquartile range [IQR]) age was 45 (40-51) 
      years. Median (IQR) duration of AD was 31.5 (10.5-48.5) months. In total, 29 
      patients continued treatment for at least 1 year and 18 patients for at least 3 
      years. The annual rate of use of systemic corticosteroid regimens, episodes of 
      sinusitis, and surgery was significantly lower both at 1 year (P = 0.002, P = 
      0.01, and P < 0.001, respectively) and at 3 years (P = 0.001, P = 0.03, and P = 
      0.002, respectively). Significant improvement was observed in the nasal 
      congestion score (P = 0.01) and sense of smell score (P = 0.05) at 1 year and in 
      the postnasal drainage score (P = 0.01) at 3 years. CONCLUSION: Daily treatment 
      with aspirin 300 mg had beneficial effects in patients with AERD, especially for 
      the control of upper airway disease.
CI  - © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Comert, S
AU  - Comert S
AD  - Division of Immunology and Allergy, Department of Chest Diseases, School of 
      Medicine, Hacettepe University, Ankara, Turkey.
FAU - Celebioglu, E
AU  - Celebioglu E
FAU - Yucel, T
AU  - Yucel T
FAU - Erdogan, T
AU  - Erdogan T
FAU - Karakaya, G
AU  - Karakaya G
FAU - Onerci, M
AU  - Onerci M
FAU - Kalyoncu, A F
AU  - Kalyoncu AF
LA  - eng
PT  - Journal Article
DEP - 20131014
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Asthma/chemically induced/drug therapy
MH  - Asthma, Aspirin-Induced/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - aspirin desensitization treatment
OT  - asthma
OT  - desensitization
OT  - rhinitis
EDAT- 2013/10/15 06:00
MHDA- 2014/07/11 06:00
CRDT- 2013/10/15 06:00
PHST- 2013/08/15 00:00 [accepted]
PHST- 2013/10/15 06:00 [entrez]
PHST- 2013/10/15 06:00 [pubmed]
PHST- 2014/07/11 06:00 [medline]
AID - 10.1111/all.12269 [doi]
PST - ppublish
SO  - Allergy. 2013 Nov;68(11):1443-51. doi: 10.1111/all.12269. Epub 2013 Oct 14.

PMID- 24664666
OWN - NLM
STAT- MEDLINE
DCOM- 20141124
LR  - 20211021
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Linking)
VI  - 16
IP  - 5
DP  - 2014 May
TI  - Pharmacogenetics of antiplatelet therapy.
PG  - 411
LID - 10.1007/s11883-014-0411-7 [doi]
AB  - There has been substantial progress toward understanding and investigating the 
      specific genetic factors that influence interindividual variations in 
      platelet-directed therapy. There has also been substantial progress toward better 
      understanding of the pharmacogenetics of drug metabolism and phamacodynamic 
      response to platelet antagonists. We summarize the relationship between genetic 
      polymorphisms, response to platelet antagonists, and clinical impact on patient 
      treatment for the commonly used antiplatelet drugs. The challenge faced in 
      translating genotype identification into improved clinical outcomes reflects the 
      complexity involved in the genomic influence on drug metabolism and activation.
FAU - Daly, Patrick L
AU  - Daly PL
AD  - Division of Cardiovascular Health and Disease, University of Cincinnati Medical 
      Center, University of Cincinnati College of Medicine, 231 Albert Sabin Way, MLC 
      0542, Cincinnati, OH, 45267, USA, dalypk@ucmail.uc.edu.
FAU - Becker, Richard C
AU  - Becker RC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Genotype
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Polymorphism, Genetic
EDAT- 2014/03/26 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/03/26 06:00
PHST- 2014/03/26 06:00 [entrez]
PHST- 2014/03/26 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1007/s11883-014-0411-7 [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2014 May;16(5):411. doi: 10.1007/s11883-014-0411-7.

PMID- 14508622
OWN - NLM
STAT- MEDLINE
DCOM- 20040129
LR  - 20181113
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 59
IP  - 8-9
DP  - 2003 Nov
TI  - Statin compliance in the Umbrian population.
PG  - 659-61
AB  - OBJECTIVE: To explore compliance with statin treatment over a period of 4.5 years 
      follow-up in an Italian population and to investigate the degree of persistence 
      and continuity in subjects with cardiovascular diseases. METHODS: Pharmaceutical, 
      medical and demographic data were retrieved from the database of Umbria Regional 
      Government's Epidemiology Department. Statin users were stratified in different 
      cohorts according to drug use, aspirin use and hospital admission for 
      cardiovascular diseases. Compliance was considered in terms of persistence and 
      continuity. Persistence was defined as discontinued if the delay between the end 
      of the first period of treatment and the prescription renewal exceeded 30 days. 
      Continuity was defined as consecutive annual renewal of prescription. RESULTS: 
      Statin users (n=39,222) were identified. The median persistence on statin 
      treatment was 5.3 months. Only 12.8% subjects were found to be persistent, while 
      49.6% renewed their prescription for consecutive years. The cohorts of aspirin 
      use and major cardiovascular events were predictive of good compliance. In these 
      cohorts subjects under 45 years showed the best rate of persistence and 
      continuity. CONCLUSION: The study reveals low compliance among subjects who 
      presumably receive prescriptions for primary prevention. We consider it important 
      for these groups of patients to receive greater attention and better information.
FAU - Abraha, Iosief
AU  - Abraha I
AD  - Assessorato alla Sanità, Regione Umbria, Epidemiology Department, via Mario 
      Angeloni, 06124 Perugia, Italy. iosief_a@yahoo.it
FAU - Montedori, Alessandro
AU  - Montedori A
FAU - Stracci, Fabrizio
AU  - Stracci F
FAU - Rossi, Mariangela
AU  - Rossi M
FAU - Romagnoli, Carlo
AU  - Romagnoli C
LA  - eng
PT  - Journal Article
DEP - 20030924
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & 
      dosage/therapeutic use
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Patient Admission
MH  - *Patient Compliance
EDAT- 2003/09/26 05:00
MHDA- 2004/01/30 05:00
CRDT- 2003/09/26 05:00
PHST- 2003/03/03 00:00 [received]
PHST- 2003/07/10 00:00 [accepted]
PHST- 2003/09/26 05:00 [pubmed]
PHST- 2004/01/30 05:00 [medline]
PHST- 2003/09/26 05:00 [entrez]
AID - 10.1007/s00228-003-0675-2 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2003 Nov;59(8-9):659-61. doi: 10.1007/s00228-003-0675-2. 
      Epub 2003 Sep 24.

PMID- 19018951
OWN - NLM
STAT- MEDLINE
DCOM- 20100930
LR  - 20181201
IS  - 1552-6569 (Electronic)
IS  - 1051-2284 (Linking)
VI  - 20
IP  - 1
DP  - 2010 Jan
TI  - Measurement of antiplatelet inhibition during neurointerventional procedures: the 
      effect of antithrombotic duration and loading dose.
PG  - 64-9
LID - 10.1111/j.1552-6569.2008.00322.x [doi]
AB  - BACKGROUND/OBJECTIVE: Symptomatic thromboembolic events are the most common 
      complications associated with aneurysm coiling, and carotid and intracranial 
      stenting. Our objective is to assess the effect of aspirin (ASA) and clopidogrel 
      dose and duration on platelet inhibition using a point of care assay in 
      neurointerventional (NI) suite. METHOD: The dose, duration, and point of care 
      platelet function assay data for clopidogrel and aspirin therapy were 
      prospectively collected between February 2006 and November 2007. Inadequate 
      platelet inhibition for ASA was defined as >or=550 ASA reaction units (ARU), and 
      for clopidogrel was defined as <or=50% inhibition of the P2Y12/ADP receptor 
      RESULTS: We collected data from 216 consecutive patients. Inadequate platelet 
      inhibition was noted in 13% of patients on aspirin and 66% of patients on 
      clopidogrel (P-value < .0001). Patients taking clopidogrel 75 mg for >or=7 days, 
      300 mg for 24 hours, and 600 mg same day load had a mean P2Y12/ADP inhibition of 
      45%, 35% (P-value = .09), and 16%, respectively (P-value = .005). CONCLUSION: 
      Premedication with clopidogrel, in contrast to aspirin, does not achieve adequate 
      platelet inhibition in about two-third of the patients. Same day antiplatelet 
      loading may be insufficient to achieve adequate platelet inhibition and should be 
      avoided if clinically feasible.
FAU - Pandya, D J
AU  - Pandya DJ
AD  - Department of Neurology, Medical College of Wisconsin and Froedtert Hospital, 
      Milwaukee, WI 53226, USA.
FAU - Fitzsimmons, B F M
AU  - Fitzsimmons BF
FAU - Wolfe, T J
AU  - Wolfe TJ
FAU - Hussain, S I
AU  - Hussain SI
FAU - Lynch, J R
AU  - Lynch JR
FAU - Ortega-Gutierrez, S
AU  - Ortega-Gutierrez S
FAU - Zaidat, O O
AU  - Zaidat OO
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Neuroimaging
JT  - Journal of neuroimaging : official journal of the American Society of 
      Neuroimaging
JID - 9102705
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Brain Diseases/*drug therapy/surgery
MH  - Clopidogrel
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology/therapeutic 
      use
MH  - Prospective Studies
MH  - Stents
MH  - Ticlopidine/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
MH  - Time Factors
EDAT- 2008/11/21 09:00
MHDA- 2010/10/01 06:00
CRDT- 2008/11/21 09:00
PHST- 2008/11/21 09:00 [pubmed]
PHST- 2010/10/01 06:00 [medline]
PHST- 2008/11/21 09:00 [entrez]
AID - JON322 [pii]
AID - 10.1111/j.1552-6569.2008.00322.x [doi]
PST - ppublish
SO  - J Neuroimaging. 2010 Jan;20(1):64-9. doi: 10.1111/j.1552-6569.2008.00322.x.

PMID- 18448350
OWN - NLM
STAT- MEDLINE
DCOM- 20081204
LR  - 20131121
IS  - 1010-7940 (Print)
IS  - 1010-7940 (Linking)
VI  - 34
IP  - 1
DP  - 2008 Jul
TI  - Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an 
      old antithrombotic agent.
PG  - 93-108
LID - 10.1016/j.ejcts.2008.03.023 [doi]
AB  - The success of coronary artery bypass graft surgery (CABG) depends mainly on the 
      patency of the graft vessels. Aortocoronary vein graft disease is comprised of 
      three distinct but interrelated pathological processes: thrombosis, intimal 
      hyperplasia and atherosclerosis. Early thrombosis is a major cause of vein graft 
      attrition during the first month after CABG, while during the remainder of the 
      first year, intimal hyperplasia forms a template for subsequent atherogenesis, 
      which thereafter predominates. Platelets play a crucial role in the 
      pathophysiology of graft thrombosis and aspirin is the primary antiplatelet drug 
      that has been shown to improve vein graft patency within the first year after 
      CABG. Nevertheless, a significant number of grafts still occlude in the early 
      postoperative period despite 'appropriate' aspirin treatment. Moreover, 
      laboratory investigations showed that the expected inhibition of platelet 
      function is not always achieved. This has been called 'aspirin nonresponse' or 
      'aspirin resistance', although a uniform definition is lacking. The finding that 
      a considerable number of patients show an impaired antiplatelet effect of aspirin 
      after CABG brought new insight into the discussion concerning poor patency rates 
      of bypass grafts: the early period after CABG shows a coincidence of an increased 
      risk for bypass thrombosis (amongst others, due to platelet activation and 
      endothelial cell disruption of the graft) and an increased prevalence of aspirin 
      resistance. Hitherto, the underlying mechanisms of aspirin resistance are 
      uncertain and largely hypothetical; amongst others, increased platelet turnover, 
      enhanced platelet reactivity, systemic inflammation, and drug-drug interaction 
      are discussed. Up to now available data concerning the clinical outcome of 
      aspirin resistant CABG patients are limited, and there is evidence that platelets 
      of patients with graft thrombosis are more likely to be resistant to aspirin 
      compared with patients without thrombotic events. Many publications concerning 
      aspirin resistance are available today, but reports addressing this topic in CABG 
      patients are sparse. This review summarises recent insights into the antiplatelet 
      treatment after CABG and describes the clinical benefit, but also the therapeutic 
      failure of the well-established drug aspirin. Moreover, possible pharmacological 
      approaches to improve antithrombotic therapy in aspirin nonresponders among CABG 
      patients are discussed.
FAU - Zimmermann, Norbert
AU  - Zimmermann N
AD  - Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-Allee 3, 
      Bonn, Germany. nzimmermann@bfarm.de <nzimmermann@bfarm.de>
FAU - Gams, Emmeran
AU  - Gams E
FAU - Hohlfeld, Thomas
AU  - Hohlfeld T
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20080429
PL  - Germany
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European 
      Association for Cardio-thoracic Surgery
JID - 8804069
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Drug Administration Schedule
MH  - Drug Resistance
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Graft Occlusion, Vascular/prevention & control
MH  - Humans
MH  - Perioperative Care/methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
RF  - 112
EDAT- 2008/05/02 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/05/02 09:00
PHST- 2008/02/14 00:00 [received]
PHST- 2008/03/10 00:00 [revised]
PHST- 2008/03/19 00:00 [accepted]
PHST- 2008/05/02 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/05/02 09:00 [entrez]
AID - S1010-7940(08)00336-9 [pii]
AID - 10.1016/j.ejcts.2008.03.023 [doi]
PST - ppublish
SO  - Eur J Cardiothorac Surg. 2008 Jul;34(1):93-108. doi: 10.1016/j.ejcts.2008.03.023. 
      Epub 2008 Apr 29.

PMID- 23879687
OWN - NLM
STAT- MEDLINE
DCOM- 20140409
LR  - 20130822
IS  - 1520-5207 (Electronic)
IS  - 1520-5207 (Linking)
VI  - 117
IP  - 33
DP  - 2013 Aug 22
TI  - Solid-state 17O NMR of pharmaceutical compounds: salicylic acid and aspirin.
PG  - 9643-54
LID - 10.1021/jp405233f [doi]
AB  - We report solid-state NMR characterization of the (17)O quadrupole coupling (QC) 
      and chemical shift (CS) tensors in five site-specifically (17)O-labeled samples 
      of salicylic acid and o-acetylsalicylic acid (Aspirin). High-quality (17)O NMR 
      spectra were obtained for these important pharmaceutical compounds under both 
      static and magic angle spinning (MAS) conditions at two magnetic fields, 14.0 and 
      21.1 T. A total of 14 (17)O QC and CS tensors were experimentally determined for 
      the seven oxygen sites in salicylic acid and Aspirin. Although both salicylic 
      acid and Aspirin form hydrogen bonded cyclic dimers in the solid state, we found 
      that the potential curves for the concerted double proton transfer in these two 
      compounds are significantly different. In particular, while the double-well 
      potential curve in Aspirin is nearly symmetrical, it is highly asymmetrical in 
      salicylic acid. This difference results in quite different temperature 
      dependencies in (17)O MAS spectra of the two compounds. A careful analysis of 
      variable-temperature (17)O MAS NMR spectra of Aspirin allowed us to obtain the 
      energy asymmetry (ΔE) of the double-well potential, ΔE = 3.0 ± 0.5 kJ/mol. We 
      were also able to determine a lower limit of ΔE for salicylic acid, ΔE > 10 
      kJ/mol. These asymmetrical features in potential energy curves were confirmed by 
      plane-wave DFT computations, which yielded ΔE = 3.7 and 17.8 kJ/mol for Aspirin 
      and salicylic acid, respectively. To complement the solid-state (17)O NMR data, 
      we also obtained solid-state (1)H and (13)C NMR spectra for salicylic acid and 
      Aspirin. Using experimental NMR parameters obtained for all magnetic nuclei 
      present in salicylic acid and Aspirin, we found that plane-wave DFT computations 
      can produce highly accurate NMR parameters in well-defined crystalline organic 
      compounds.
FAU - Kong, Xianqi
AU  - Kong X
AD  - Department of Chemistry, Queen's University, Kingston, Ontario, Canada.
FAU - Shan, Melissa
AU  - Shan M
FAU - Terskikh, Victor
AU  - Terskikh V
FAU - Hung, Ivan
AU  - Hung I
FAU - Gan, Zhehong
AU  - Gan Z
FAU - Wu, Gang
AU  - Wu G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130808
PL  - United States
TA  - J Phys Chem B
JT  - The journal of physical chemistry. B
JID - 101157530
RN  - 0 (Oxygen Isotopes)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Dimerization
MH  - Hydrogen Bonding
MH  - *Magnetic Resonance Spectroscopy
MH  - Oxygen Isotopes/chemistry
MH  - Salicylic Acid/*chemistry
MH  - Thermodynamics
EDAT- 2013/07/25 06:00
MHDA- 2014/04/10 06:00
CRDT- 2013/07/25 06:00
PHST- 2013/07/25 06:00 [entrez]
PHST- 2013/07/25 06:00 [pubmed]
PHST- 2014/04/10 06:00 [medline]
AID - 10.1021/jp405233f [doi]
PST - ppublish
SO  - J Phys Chem B. 2013 Aug 22;117(33):9643-54. doi: 10.1021/jp405233f. Epub 2013 Aug 
      8.

PMID- 15244491
OWN - NLM
STAT- MEDLINE
DCOM- 20040928
LR  - 20181113
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 22
IP  - 10
DP  - 2004
TI  - Economic assessment of the secondary prevention of ischaemic stroke with 
      dipyridamole plus aspirin (Aggrenox/Asasantin) in France.
PG  - 661-70
AB  - OBJECTIVE: To assess the cost effectiveness of aspirin 25 mg plus dipyridamole 
      200 mg twice daily in the secondary prevention of ischaemic stroke, according to 
      the French social security perspective, using efficacy data from the second 
      European Stroke Prevention Study (ESPS-2). The ESPS-2 was a double-blind, 
      placebo-controlled clinical trial which assessed the efficacy of four secondary 
      prevention strategies: (i) placebo; (ii) aspirin (acetylsalicylic acid) 25 mg 
      twice daily; (iii) dipyridamole 200 mg twice daily; and (iv) aspirin 25 mg plus 
      dipyridamole 200 mg twice daily. METHOD: We performed a cost-effectiveness 
      analysis with Monte Carlo simulations to compute confidence intervals. We 
      combined data from various sources including the Dijon Stroke Registry, Institut 
      National de la Statistique et des Etudes Economiques, Etude du Coût de 
      l'Infarctus Cérébral (Study of the Cost of Cerebral Infarction [ECIC]) study and 
      the ESPS-2 trial. RESULTS: According to our findings, a preventive strategy with 
      aspirin 25 mg plus dipyridamole 200 mg twice daily is associated with net 
      benefits per avoided stroke recurrence amounting to USD 23,932 (95% CI -USD 
      32,609, USD 35,772) compared with aspirin 25 mg twice daily alone, and USD 31,555 
      (95% CI USD 4921, USD 74,515) compared with dipyridamole alone (1997 values). 
      Sensitivity analysis demonstrated that dipyridamole plus aspirin was still cost 
      effective when the average cost of adverse effects per episode (ignored in the 
      original estimation of the cost-effectiveness ratios due to a lack of data) was 
      assumed to be USD 8600 (50,000 French francs); this cost is unlikely as most of 
      the adverse effects associated with aspirin plus dipyridamole are only slight to 
      moderate in severity. CONCLUSIONS: In the secondary prevention of stroke in 
      France, this study suggests, given its underlying assumptions and data, that 
      aspirin 25 mg plus dipyridamole 200 mg twice daily is likely to be a 
      cost-effective strategy from the social security perspective, when compared with 
      other relevant strategies that were evaluated in the ESPS-2 trial.
FAU - Marissal, Jean-Pierre
AU  - Marissal JP
AD  - CRESGE-LABORES (URA-CNRS 362), Lille, France.
FAU - Selke, Bernard
AU  - Selke B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
EIN - Pharmacoeconomics. 2004;22(18):1234
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/*economics
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Confidence Intervals
MH  - Cost-Benefit Analysis
MH  - Dipyridamole/*administration & dosage/*economics
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - France
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Monte Carlo Method
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - Stroke/*economics/*prevention & control
EDAT- 2004/07/13 05:00
MHDA- 2004/09/29 05:00
CRDT- 2004/07/13 05:00
PHST- 2004/07/13 05:00 [pubmed]
PHST- 2004/09/29 05:00 [medline]
PHST- 2004/07/13 05:00 [entrez]
AID - 22104 [pii]
AID - 10.2165/00019053-200422100-00004 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2004;22(10):661-70. doi: 10.2165/00019053-200422100-00004.

PMID- 19293073
OWN - NLM
STAT- MEDLINE
DCOM- 20090408
LR  - 20190619
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 150
IP  - 6
DP  - 2009 Mar 17
TI  - Aspirin for the primary prevention of cardiovascular events: an update of the 
      evidence for the U.S. Preventive Services Task Force.
PG  - 405-10
AB  - BACKGROUND: Coronary heart disease and cerebrovascular disease are leading causes 
      of death in the United States. In 2002, the U.S. Preventive Services Task Force 
      (USPSTF) strongly recommended that clinicians discuss aspirin with adults who are 
      at increased risk for coronary heart disease. PURPOSE: To determine the benefits 
      and harms of taking aspirin for the primary prevention of myocardial infarctions, 
      strokes, and death. DATA SOURCES: MEDLINE and Cochrane Library (search dates, 1 
      January 2001 to 28 August 2008), recent systematic reviews, reference lists of 
      retrieved articles, and suggestions from experts. STUDY SELECTION: 
      English-language randomized, controlled trials (RCTs); case-control studies; 
      meta-analyses; and systematic reviews of aspirin versus control for the primary 
      prevention of cardiovascular disease (CVD) were selected to answer the following 
      questions: Does aspirin decrease coronary heart events, strokes, death from 
      coronary heart events or stroke, or all-cause mortality in adults without known 
      CVD? Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes? DATA 
      EXTRACTION: All studies were reviewed, abstracted, and rated for quality by using 
      predefined USPSTF criteria. DATA SYNTHESIS: New evidence from 1 good-quality RCT, 
      1 good-quality meta-analysis, and 2 fair-quality subanalyses of RCTs demonstrates 
      that aspirin use reduces the number of CVD events in patients without known CVD. 
      Men in these studies experienced fewer myocardial infarctions and women 
      experienced fewer ischemic strokes. Aspirin does not seem to affect CVD mortality 
      or all-cause mortality in either men or women. The use of aspirin for primary 
      prevention increases the risk for major bleeding events, primarily 
      gastrointestinal bleeding events, in both men and women. Men have an increased 
      risk for hemorrhagic strokes with aspirin use. A new RCT and meta-analysis 
      suggest that the risk for hemorrhagic strokes in women is not statistically 
      significantly increased. LIMITATIONS: New evidence on aspirin for the primary 
      prevention of CVD is limited. The dose of aspirin used in the RCTs varied, which 
      prevented the estimation of the most appropriate dose for primary prevention. 
      Several of the RCTs were conducted within populations of health professionals, 
      which potentially limits generalizability. CONCLUSION: Aspirin reduces the risk 
      for myocardial infarction in men and strokes in women. Aspirin use increases the 
      risk for serious bleeding events.
FAU - Wolff, Tracy
AU  - Wolff T
AD  - Agency for Healthcare Research and Quality, Rockville, Maryland 20850, USA.
FAU - Miller, Therese
AU  - Miller T
FAU - Ko, Stephen
AU  - Ko S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- Ann Intern Med. 2009 Mar 17;150(6):I-37. PMID: 19293068
MH  - Age Factors
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mortality
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention
MH  - Risk Assessment
MH  - Stroke/chemically induced
RF  - 15
EDAT- 2009/03/19 09:00
MHDA- 2009/04/09 09:00
CRDT- 2009/03/19 09:00
PHST- 2009/03/19 09:00 [entrez]
PHST- 2009/03/19 09:00 [pubmed]
PHST- 2009/04/09 09:00 [medline]
AID - 150/6/405 [pii]
AID - 10.7326/0003-4819-150-6-200903170-00009 [doi]
PST - ppublish
SO  - Ann Intern Med. 2009 Mar 17;150(6):405-10. doi: 
      10.7326/0003-4819-150-6-200903170-00009.

PMID- 6989432
OWN - NLM
STAT- MEDLINE
DCOM- 19800722
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 280
IP  - 6213
DP  - 1980 Feb 23
TI  - Prevention of venous thromboembolism after total knee replacement by high-dose 
      aspirin or intermittent calf and thigh compression.
PG  - 514-7
AB  - A prospective study of patients undergoing total knee replacement was carried out 
      by using a combination of 125I-fibrinogen scanning and phlebography, and showed a 
      high incidence of venous thromboembolic disease (TE). Ventilation-perfusion lung 
      scanning was performed to detect pulmonary emboli in most patients. High doses of 
      aspirin and an intermittent low-pressure pneumatic compression device (IPCD) were 
      effective, even in women, in preventing TE. Low doses of aspirin and placebo were 
      equally ineffective in preventing TE. Lung-scan abnormalities compatible with 
      pulmonary emboli were found in six out of 10 patients with isolated calf-vein 
      thrombi. Conventional tests of platelet function did not predict the development 
      of TE. No significant differences were found between the patients receiving low 
      and high doses of aspirin with respect to the mean template bleeding time or 
      platelet aggregation in response to adenosine diphosphate, collagen, and 
      epinephrine, although these variables were significantly abnormal in the two 
      groups receiving aspirin compared with those treated with placebo and the IPCD. 
      Thus high doses of aspirin and a new low-pressure IPCD were effective in 
      preventing venous TE in patients (predominantly women) undergoing total knee 
      replacement.
FAU - McKenna, R
AU  - McKenna R
FAU - Galante, J
AU  - Galante J
FAU - Bachmann, F
AU  - Bachmann F
FAU - Wallace, D L
AU  - Wallace DL
FAU - Kaushal, P S
AU  - Kaushal PS
FAU - Meredith, P
AU  - Meredith P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Coagulation Tests
MH  - Clinical Trials as Topic
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - *Knee Prosthesis
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
MH  - Pressure
MH  - Prospective Studies
MH  - Pulmonary Embolism/prevention & control
MH  - Random Allocation
MH  - Thrombophlebitis/*prevention & control
PMC - PMC1601413
EDAT- 1980/02/23 00:00
MHDA- 1980/02/23 00:01
CRDT- 1980/02/23 00:00
PHST- 1980/02/23 00:00 [pubmed]
PHST- 1980/02/23 00:01 [medline]
PHST- 1980/02/23 00:00 [entrez]
AID - 10.1136/bmj.280.6213.514 [doi]
PST - ppublish
SO  - Br Med J. 1980 Feb 23;280(6213):514-7. doi: 10.1136/bmj.280.6213.514.

PMID- 25090160
OWN - NLM
STAT- MEDLINE
DCOM- 20150513
LR  - 20140902
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 11
IP  - 9
DP  - 2014 Sep 2
TI  - Insights into pharmaceutical nanocrystal dissolution: a molecular dynamics 
      simulation study on aspirin.
PG  - 3009-16
LID - 10.1021/mp500148q [doi]
AB  - The presented molecular dynamics simulations are the first simulations to reveal 
      dynamic dissolution of a pharmaceutical crystal in its experimentally determined 
      shape. Continuous dissolution at constant undersaturation of the surrounding 
      medium is ensured by introducing a plane of sticky dummy atoms into the water 
      slab. These atoms have a strong interaction potential with dissolved aspirin 
      molecules, but interactions with water are excluded from the calculations. Thus, 
      the number of aspirin molecules diffusing freely in solution is kept at a low 
      value and continuous dissolution of the aspirin crystal is monitored. Further 
      insight into face-specific dissolution is drawn. The dissolution mechanism of 
      receding edges is found for the (001) plane. These findings are in good agreement 
      with experimental results. While the proposed dissolution mechanism for the (100) 
      plane is terrace sinking on a rough surface, no pronounced dissolution of the 
      perfectly flat face is seen in the present work. Molecular simulations of 
      pharmaceuticals in their experimentally obtained structure therefore have shown 
      to be especially suited for the investigation of dissolving faces, where the 
      edges have a pronounced effect. In contrast to previous studies a propagation of 
      the dissolution front into the crystal face is reported, and the crystal bulk is 
      stable over the whole simulation time of 150 ns.
FAU - Greiner, Maximilian
AU  - Greiner M
AD  - Chair for Process Systems Engineering, Technische Universität München , Freising 
      85354, Germany.
FAU - Elts, Ekaterina
AU  - Elts E
FAU - Briesen, Heiko
AU  - Briesen H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140811
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 0 (Solutions)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Molecular Dynamics Simulation
MH  - Nanoparticles/*chemistry
MH  - Solubility
MH  - Solutions/chemistry
MH  - Water/chemistry
EDAT- 2014/08/05 06:00
MHDA- 2015/05/15 06:00
CRDT- 2014/08/05 06:00
PHST- 2014/08/05 06:00 [entrez]
PHST- 2014/08/05 06:00 [pubmed]
PHST- 2015/05/15 06:00 [medline]
AID - 10.1021/mp500148q [doi]
PST - ppublish
SO  - Mol Pharm. 2014 Sep 2;11(9):3009-16. doi: 10.1021/mp500148q. Epub 2014 Aug 11.

PMID- 18095910
OWN - NLM
STAT- MEDLINE
DCOM- 20080403
LR  - 20131121
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 6
IP  - 1
DP  - 2008 Jan
TI  - The need for wider and appropriate utilization of aspirin and statins in the 
      treatment and prevention of cardiovascular disease.
PG  - 95-107
AB  - There is an increasing burden of occlusive cardiovascular disease (CVD) in 
      developed, as well as in developing, countries. In fact, the WHO has projected 
      that CVD will become the leading cause of death in the world in the next 10 
      years. The proximate cause of virtually all occlusive vascular events is 
      thrombosis and the principal underlying cause is atherosclerosis. Aspirin, which 
      inhibits platelet-dependent cyclooxygenase for the entire life of the platelet, 
      has clinically important antithrombotic effects. Statins, which principally 
      decrease low-density lipoprotein cholesterol, triglycerides and increase 
      high-density lipoprotein cholesterol, have clinically important antiatherogenic 
      effects. In secondary prevention, in a wide range of patients who have survived a 
      prior myocardial infarction (MI), occlusive stroke, transient ischemic attack, as 
      well as other high-risk conditions, long-term use of aspirin confers 
      statistically significant and clinically important reductions in MI, stroke and 
      CVD death. In addition, aspirin confers similar benefits when administered during 
      acute MI or acute occlusive stroke. In primary prevention, aspirin confers a 
      statistically significant and clinically important reduction in risk of a first 
      MI but the data on stroke and CVD death remain inconclusive, so aspirin should be 
      prescribed on an individual basis by the healthcare provider who weighs this 
      clear benefit against long-term side effects. In a meta-analysis of 14 randomized 
      trials of 90,056 subjects treated for 5 years, statins confer statistically 
      significant and clinically important reductions in MI, stroke, CVD death and 
      total mortality. In a meta-analysis of randomized trials of statins, in which 
      aspirin was used in varying frequencies, the combination of aspirin and statins 
      conferred greater clinical benefits than either agent alone on MI, occlusive 
      stroke and CVD death. At present, the wider and more appropriate use of aspirin 
      and statins will reduce premature MI, stroke and CVD death.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - Department of Clinical Science and Medical Education, florida Atlantic 
      University, Boca Raton, FL 33431, USA. chenneke@fau.edu
FAU - Schneider, Wendy R
AU  - Schneider WR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Anticholesteremic Agents/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Therapy, Combination
MH  - Evidence-Based Medicine
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Primary Prevention
MH  - Stroke/prevention & control
RF  - 59
EDAT- 2007/12/22 09:00
MHDA- 2008/04/04 09:00
CRDT- 2007/12/22 09:00
PHST- 2007/12/22 09:00 [pubmed]
PHST- 2008/04/04 09:00 [medline]
PHST- 2007/12/22 09:00 [entrez]
AID - 10.1586/14779072.6.1.95 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2008 Jan;6(1):95-107. doi: 10.1586/14779072.6.1.95.

PMID- 11794961
OWN - NLM
STAT- MEDLINE
DCOM- 20020205
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 94
IP  - 11 Suppl
DP  - 2001 Nov
TI  - [From the physiopathology of thrombosis to therapeutic targets].
PG  - 1210-7
AB  - Structural changes in blood vessels associated with atherosclerosis are at the 
      onset of arterial thrombosis. Thrombi form at the sites of plaque rupture. 
      Plateletrich masses accumulate in the vessel lumen perturb blood flow, thereby 
      aggravating ischemic syndromes. Other local modifications include the recruitment 
      of cells with inflammatory and immunologic potential, showing how complicated 
      this process is. The demonstration that aspirin lowered the number of thrombotic 
      events was an important step in proving the value of anti-platelet therapy. Since 
      then, newer strategies involving drugs acting on the fibrinogen receptor (the 
      GPIIb-IIIa complex) or on ADP receptors have evolved largely as a result of the 
      increased knowledge of the biological pathways of platelet aggregation. These 
      drugs have given superior results in many international trials and their 
      usefulness in interventional cardiology has been proven. Such encouraging 
      progress also incites efforts to find new and improved targets for anti-platelet 
      therapy as well as testing new associations of existing anti-platelet drugs which 
      may also be used with anticoagulant therapies, and in the future, be combined 
      with drugs directly preventing restenosis.
FAU - Nurden, P
AU  - Nurden P
AD  - UMR 5533 CNRS, hôpital cardiologique, 33604 Pessac.
FAU - Ndoko, S
AU  - Ndoko S
FAU - Nurden, A T
AU  - Nurden AT
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - De la physiopathologie de la thrombose aux cibles thérapeutiques.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis/*physiopathology
MH  - Aspirin/pharmacology/therapeutic use
MH  - Fibrinolytic Agents/*pharmacology/therapeutic use
MH  - Humans
MH  - Inflammation
MH  - Ischemia/physiopathology
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/physiology
MH  - Regional Blood Flow
MH  - Thrombosis/*drug therapy/*physiopathology
RF  - 32
EDAT- 2002/01/25 10:00
MHDA- 2002/02/06 10:01
CRDT- 2002/01/25 10:00
PHST- 2002/01/25 10:00 [pubmed]
PHST- 2002/02/06 10:01 [medline]
PHST- 2002/01/25 10:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1210-7.

PMID- 2517497
OWN - NLM
STAT- MEDLINE
DCOM- 19900604
LR  - 20161123
IS  - 0251-1649 (Print)
IS  - 0251-1649 (Linking)
VI  - 9
IP  - 6
DP  - 1989
TI  - Pharmacokinetics of salicylic acid following administration of aspirin tablets 
      and three different forms of soluble aspirin in normal subjects.
PG  - 385-9
AB  - The pharmacokinetic profile of an innovative formulation of soluble aspirin 
      (l-ornithine acetylsalicylate, ldB 1003) was compared with that of conventional 
      tablets and two other soluble dosage forms (d, l-lysine acetylsalicylate and a 
      buffered effervescent formulation of acetylsalicylic acid) after administration 
      of single oral doses in six normal volunteers. All soluble forms showed a rapid 
      absorption profile, peak plasma salicylic acid levels being attained after about 
      30 min on average and without statistically significant differences among the 
      solutions tested. As compared to the soluble formulations, acetylsalicylic acid 
      given as tablets resulted in slower absorption, with peak plasma salicylic acid 
      levels being reached more than 1 h after dosing. Despite these differences in 
      time course of plasma level profiles, the extent of absorption was similar for 
      all formulations. Apart from the potential advantages in terms of improved 
      gastric tolerability, the increased rate of absorption of aspirin solutions is 
      therapeutically useful whenever a rapid onset of action is required. In this 
      respect, the kinetic pattern of the innovative formulation compares favourably 
      with that of other available soluble dosage forms.
FAU - Gatti, G
AU  - Gatti G
AD  - Department of Internal Medicine and Therapeutics, University of Pavia, Italy.
FAU - Barzaghi, N
AU  - Barzaghi N
FAU - Attardo Parrinello, G
AU  - Attardo Parrinello G
FAU - Vitiello, B
AU  - Vitiello B
FAU - Perucca, E
AU  - Perucca E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Int J Clin Pharmacol Res
JT  - International journal of clinical pharmacology research
JID - 8110183
RN  - 0 (Buffers)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - K3Z4F929H6 (Lysine)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/analogs & derivatives/*pharmacokinetics
MH  - Buffers
MH  - Humans
MH  - Lysine/analogs & derivatives/pharmacokinetics
MH  - Salicylates/blood/*pharmacokinetics
MH  - Salicylic Acid
MH  - Solubility
MH  - Tablets
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Res. 1989;9(6):385-9.

PMID- 12138601
OWN - NLM
STAT- MEDLINE
DCOM- 20021217
LR  - 20161124
IS  - 1053-8569 (Print)
IS  - 1053-8569 (Linking)
VI  - 11
IP  - 4
DP  - 2002 Jun
TI  - Paracetamol pack size restriction: the impact on paracetamol poisoning and the 
      over-the-counter supply of paracetamol, aspirin and ibuprofen.
PG  - 329-31
AB  - PURPOSE: Self-poisoning occurs with over-the-counter (OTC) drugs, particularly 
      paracetamol (acetaminophen). In 1998, OTC pack sizes of paracetamol were reduced. 
      We have studied the effect of this pack size restriction on OTC supply of 
      paracetamol, aspirin and ibuprofen. METHODS: IMS Health UK provided data on the 
      UK sales of paracetamol, aspirin and ibuprofen. The total mass and number of 
      packs of each drug supplied were compared for the years 1998, 1999 and 2000. 
      RESULTS: The mass of aspirin and paracetamol sold fell, that of ibuprofen 
      increased. The number of paracetamol packs sold was unchanged, the analgesic dose 
      of aspirin fell and ibuprofen supply increased. CONCLUSIONS: It seems that the 
      paracetamol pack size reduction has not achieved as large an overdose rate 
      reduction as might have been expected. Instead, a shift to the use of ibuprofen 
      may lead to an increase in gastrointestinal adverse events and continue the 
      burden on healthcare resources.
FAU - Sheen, Christopher L
AU  - Sheen CL
AD  - Medicines Monitoring Unit, Ninewells Hospital, Dundee, Scotland, UK. 
      chris@memo.dundee.ac.uk
FAU - Dillon, John F
AU  - Dillon JF
FAU - Bateman, D Nicholas
AU  - Bateman DN
FAU - Simpson, Kenneth J
AU  - Simpson KJ
FAU - MacDonald, Thomas M
AU  - MacDonald TM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/*poisoning
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Drug Packaging/*methods/trends
MH  - Humans
MH  - Ibuprofen/*adverse effects/therapeutic use
MH  - Nonprescription Drugs/*adverse effects
MH  - Pharmacoepidemiology
MH  - United Kingdom
EDAT- 2002/07/26 10:00
MHDA- 2002/12/18 04:00
CRDT- 2002/07/26 10:00
PHST- 2002/07/26 10:00 [pubmed]
PHST- 2002/12/18 04:00 [medline]
PHST- 2002/07/26 10:00 [entrez]
AID - 10.1002/pds.701 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2002 Jun;11(4):329-31. doi: 10.1002/pds.701.

PMID- 27356773
OWN - NLM
STAT- MEDLINE
DCOM- 20170406
LR  - 20181113
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 14
IP  - 2
DP  - 2016 Aug
TI  - Aspirin inhibits glucose‑6‑phosphate dehydrogenase activity in HCT 116 cells 
      through acetylation: Identification of aspirin-acetylated sites.
PG  - 1726-32
LID - 10.3892/mmr.2016.5449 [doi]
AB  - Glucose-6-phosphate dehydrogenase (G6PD) catalyzes the first reaction in the 
      pentose phosphate pathway, and generates ribose sugars, which are required for 
      nucleic acid synthesis, and nicotinamide adenine dinucleotide phosphate (NADPH), 
      which is important for neutralization of oxidative stress. The expression of G6PD 
      is elevated in several types of tumor, including colon, breast and lung cancer, 
      and has been implicated in cancer cell growth. Our previous study demonstrated 
      that exposure of HCT 116 human colorectal cancer cells to aspirin caused 
      acetylation of G6PD, and this was associated with a decrease in its enzyme 
      activity. In the present study, this observation was expanded to HT‑29 colorectal 
      cancer cells, in order to compare aspirin‑mediated acetylation of G6PD and its 
      activity between HCT 116 and HT‑29 cells. In addition, the present study aimed to 
      determine the acetylation targets of aspirin on recombinant G6PD to provide an 
      insight into the mechanisms of inhibition. The results demonstrated that the 
      extent of G6PD acetylation was significantly higher in HCT 116 cells compared 
      with in HT‑29 cells; accordingly, a greater reduction in G6PD enzyme activity was 
      observed in the HCT 116 cells. Mass spectrometry analysis of aspirin‑acetylated 
      G6PD (isoform a) revealed that aspirin acetylated a total of 14 lysine residues, 
      which were dispersed throughout the length of the G6PD protein. One of the 
      important amino acid targets of aspirin included lysine 235 (K235, in isoform a) 
      and this corresponds to K205 in isoform b, which has previously been identified 
      as being important for catalysis. Acetylation of G6PD at several sites, including 
      K235 (K205 in isoform b), may mediate inhibition of G6PD activity, which may 
      contribute to the ability of aspirin to exert anticancer effects through 
      decreased synthesis of ribose sugars and NADPH.
FAU - Ai, Guoqiang
AU  - Ai G
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Avera Health and Sciences Center, Brookings, SD 57007, USA.
FAU - Dachineni, Rakesh
AU  - Dachineni R
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Avera Health and Sciences Center, Brookings, SD 57007, USA.
FAU - Kumar, D Ramesh
AU  - Kumar DR
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Avera Health and Sciences Center, Brookings, SD 57007, USA.
FAU - Alfonso, Lloyd F
AU  - Alfonso LF
AD  - D'Youville College School of Pharmacy, Buffalo, NY 14201, USA.
FAU - Marimuthu, Srinivasan
AU  - Marimuthu S
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Avera Health and Sciences Center, Brookings, SD 57007, USA.
FAU - Bhat, G Jayarama
AU  - Bhat GJ
AD  - Department of Pharmaceutical Sciences, South Dakota State University College of 
      Pharmacy, Avera Health and Sciences Center, Brookings, SD 57007, USA.
LA  - eng
GR  - R03 CA133061/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20160627
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Amino Acids)
RN  - 0 (Enzyme Inhibitors)
RN  - EC 1.1.1.49 (Glucosephosphate Dehydrogenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation/drug effects
MH  - Amino Acids
MH  - Aspirin/chemistry/*pharmacology
MH  - Binding Sites
MH  - Enzyme Activation/drug effects
MH  - Enzyme Inhibitors/chemistry/*pharmacology
MH  - Glucosephosphate Dehydrogenase/*antagonists & inhibitors/chemistry/*metabolism
MH  - HCT116 Cells
MH  - HT29 Cells
MH  - Humans
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Pentose Phosphate Pathway/drug effects
MH  - Protein Binding
PMC - PMC4940102
EDAT- 2016/07/01 06:00
MHDA- 2017/04/07 06:00
CRDT- 2016/07/01 06:00
PHST- 2016/02/19 00:00 [received]
PHST- 2016/05/18 00:00 [accepted]
PHST- 2016/07/01 06:00 [entrez]
PHST- 2016/07/01 06:00 [pubmed]
PHST- 2017/04/07 06:00 [medline]
AID - mmr-14-02-1726 [pii]
AID - 10.3892/mmr.2016.5449 [doi]
PST - ppublish
SO  - Mol Med Rep. 2016 Aug;14(2):1726-32. doi: 10.3892/mmr.2016.5449. Epub 2016 Jun 
      27.

PMID- 20944898
OWN - NLM
STAT- MEDLINE
DCOM- 20110627
LR  - 20190606
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Linking)
VI  - 95
IP  - 3
DP  - 2010 Sep
TI  - Aspirin resistance: fact or fiction?
PG  - e91-4
LID - S0066-782X2010001300024 [pii]
AB  - A meta-analysis of clinical studies of patients with cardiovascular disease 
      demonstrated that the use of aspirin was associated with a 22% decrease in death 
      rates and relevant ischemic vascular events. However, clinical studies 
      demonstrated that patients that regularly took aspirin presented recurrence of 
      cardiovascular events. Such observation led to the question whether, in some 
      patients, the aspirin was not effective in blocking platelet aggregation and 
      these patients were called unresponsive to aspirin or aspirin-resistant. The 
      clinical aspirin resistance is characterized as the occurrence of cardiovascular 
      events in patients during treatment with aspirin, whereas the laboratory 
      resistance is defined as the persistence of platelet aggregation, documented by 
      laboratory test, in patients regularly taking aspirin. Patients that are 
      aspirin-resistant presented, according to laboratory tests, on average 3.8 times 
      more cardiovascular events when compared to non-resistant ones.
FAU - Oliveira, Dinaldo Cavalcanti de
AU  - Oliveira DC
AD  - Hospital do Coração, Brazil.
FAU - Silva, Rogerio Ferreira
AU  - Silva RF
FAU - Silva, Diego Jantsk
AU  - Silva DJ
FAU - Lima, Valter Correia de
AU  - Lima VC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Brazil
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cardiovascular Diseases/chemically induced/epidemiology
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Recurrence
EDAT- 2010/10/15 06:00
MHDA- 2011/06/28 06:00
CRDT- 2010/10/15 06:00
PHST- 2008/12/16 00:00 [received]
PHST- 2009/07/23 00:00 [accepted]
PHST- 2010/10/15 06:00 [entrez]
PHST- 2010/10/15 06:00 [pubmed]
PHST- 2011/06/28 06:00 [medline]
AID - S0066-782X2010001300024 [pii]
AID - 10.1590/s0066-782x2010001300024 [doi]
PST - ppublish
SO  - Arq Bras Cardiol. 2010 Sep;95(3):e91-4. doi: 10.1590/s0066-782x2010001300024.

PMID- 16509753
OWN - NLM
STAT- MEDLINE
DCOM- 20070803
LR  - 20131121
IS  - 1520-6106 (Print)
IS  - 1520-5207 (Linking)
VI  - 110
IP  - 9
DP  - 2006 Mar 9
TI  - Dynamic study of interaction between beta-cyclodextrin and aspirin by the 
      ultrasonic relaxation method.
PG  - 4487-91
AB  - A single ultrasonic relaxational phenomenon was observed in aqueous solutions 
      containing both beta-cyclodextrin (beta-CD) as host and nonionized or ionized 
      acetylsalicylic acid (aspirin) as guest. The observed relaxation was responsible 
      for a dynamic complexation reaction between beta-CD and aspirin molecules, 
      concomitant with a volume change during the reaction. The kinetic and equilibrium 
      constants for the complexation in the acid (nonionized) form of the aspirin 
      system were derived from the guest concentration dependence of the relaxation 
      frequency. The equilibrium constant for the carboxylate (ionized) form of aspirin 
      was determined from the concentration dependence of a maximum absorption per 
      wavelength, and the rate constants were calculated by using the determined 
      equilibrium constant and the observed relaxation frequencies, which remained 
      nearly almost constant over the concentration range studied. The results showed 
      that the effect of charge on the aspirin molecule was reflected only in the 
      dissociation process from the beta-CD cavity, while no remarkable change was seen 
      in the association process whose rate was diffusion controlled. The results could 
      be explained on the basis of the difference of the hydrophobic moieties in the 
      two guests that were included in the host cavity. The results of the standard 
      volume change for the complexation reaction were closely related to the number of 
      expelled water molecules originally located in the beta-CD cavity and the volume 
      of the aspirin molecule incorporated into the beta-CD cavity.
FAU - Fukahori, Takanori
AU  - Fukahori T
AD  - Department of Chemistry and Applied Chemistry, Faculty of Science and 
      Engineering, Saga University, Saga 840-8502, Japan.
FAU - Kondo, Minako
AU  - Kondo M
FAU - Nishikawa, Sadakatsu
AU  - Nishikawa S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Phys Chem B
JT  - The journal of physical chemistry. B
JID - 101157530
RN  - 0 (Solutions)
RN  - 0 (beta-Cyclodextrins)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Hydrogen-Ion Concentration
MH  - *Solutions/chemistry
MH  - *Ultrasonics
MH  - Water/chemistry
MH  - beta-Cyclodextrins/*chemistry
EDAT- 2006/03/03 09:00
MHDA- 2007/08/04 09:00
CRDT- 2006/03/03 09:00
PHST- 2006/03/03 09:00 [pubmed]
PHST- 2007/08/04 09:00 [medline]
PHST- 2006/03/03 09:00 [entrez]
AID - 10.1021/jp058205n [doi]
PST - ppublish
SO  - J Phys Chem B. 2006 Mar 9;110(9):4487-91. doi: 10.1021/jp058205n.

PMID- 6995502
OWN - NLM
STAT- MEDLINE
DCOM- 19801024
LR  - 20131121
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 20
IP  - 5-6 Pt 2
DP  - 1980 May-Jun
TI  - Long-term safety of zomepirac: a double-blind comparison with aspirin in patients 
      with osteoarthritis.
PG  - 377-84
AB  - Zomepirac at daily doses of 400 to 600 mg was well tolerated and provided 
      continuing effective analgesia in the relief of chronic pain associated with 
      osteoarthritis. In this long-term safety study, patients treated with zomepirac 
      had significantly fewer adverse reactions and fewer limiting adverse reactions 
      than did patients treated with aspirin. Thus zomepirac, which has previously 
      shown efficacy in single-dose studies as well as good patient acceptability and 
      efficacy in circumstances typical of clinical practice, has been found in this 
      study to compare favorably to aspirin in a long-term (12-week) study in 238 
      patients with chronic pain secondary to osteoarthritis.
FAU - Ruoff, G E
AU  - Ruoff GE
FAU - Andelman, S Y
AU  - Andelman SY
FAU - Cannella, J J
AU  - Cannella JJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Analgesics)
RN  - 0 (Pyrroles)
RN  - 822G987U9J (zomepirac)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/administration & dosage/*adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Pyrroles/*adverse effects
MH  - Tolmetin/*adverse effects/analogs & derivatives/pharmacology/therapeutic use
EDAT- 1980/05/01 00:00
MHDA- 1980/05/01 00:01
CRDT- 1980/05/01 00:00
PHST- 1980/05/01 00:00 [pubmed]
PHST- 1980/05/01 00:01 [medline]
PHST- 1980/05/01 00:00 [entrez]
PST - ppublish
SO  - J Clin Pharmacol. 1980 May-Jun;20(5-6 Pt 2):377-84.

PMID- 10974199
OWN - NLM
STAT- MEDLINE
DCOM- 20001019
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 60
IP  - 7
DP  - 2000 Oct 1
TI  - Aspirin acetylation of betaLys-82 of human hemoglobin. NMR study of acetylated 
      hemoglobin Tsurumai.
PG  - 917-22
AB  - Acetylation of hemoglobin by aspirin and other compounds has been of interest for 
      the development of agents useful for the treatment of sickle cell disease. In the 
      present study, we have used 2D NMR methods in combination with 
      [1-(13)C-acetyl]salicylic acid to probe the acetylation sites of hemoglobin A and 
      hemoglobin Tsurumai, a mutant human hemoglobin characterized by a betaLys-82-Gln 
      substitution. In contrast to earlier studies by Klotz and coworkers (e.g. 
      Shamsuddin M, Mason RG, Ritchey JM, Honig GR and Klotz KM, Proc Natl Acad Sci USA 
      71: 4693-4697, 1974) in which it was concluded that betaLys-144 is the principal 
      target residue acetylated by aspirin, the present study confirms our previous but 
      less conclusive demonstration (Xu ASL, Macdonald JM, Labotka RJ and London RE, 
      Biochim Biophys Acta 1432: 333-349, 1999) that betaLys-82 is the primary 
      acetylation site of aspirin and related agents. The present studies also provide 
      conclusive evidence that acetylation of betaLys-82 produces multiple resonances, 
      probably as a consequence of additional acetylation of other sites, particularly 
      betaLys-82' on the second beta chain. The present results also resolve the 
      apparent discrepancy between the targets of modification by aspirin and 
      double-headed aspirin analogs, and provide an explanation for the changes in 
      oxygen affinity and aggregation threshold of aspirin-modified hemoglobin 
      previously observed under in vitro conditions. In light of the present 
      identification of the principal site of acetylation, the potential therapeutic 
      benefit of aspirin in the treatment of sickle cell disease is discussed.
FAU - Xu, A S
AU  - Xu AS
AD  - Laboratory of Structural Biology, NIEHS, Research Triangle Park, NC 27709, USA.
FAU - Ohba, Y
AU  - Ohba Y
FAU - Vida, L
AU  - Vida L
FAU - Labotka, R J
AU  - Labotka RJ
FAU - London, R E
AU  - London RE
LA  - eng
GR  - 5R01 HL57604/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hemoglobins)
RN  - 0 (Hemoglobins, Abnormal)
RN  - 0 (hemoglobin Tsurumai)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation/drug effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/metabolism/pharmacology
MH  - Aspirin/metabolism/*pharmacology
MH  - Hemoglobins/*metabolism
MH  - Hemoglobins, Abnormal/*metabolism
MH  - Humans
MH  - Lysine/metabolism
MH  - Magnetic Resonance Spectroscopy/methods
MH  - Models, Molecular
EDAT- 2000/09/07 11:00
MHDA- 2000/10/21 11:01
CRDT- 2000/09/07 11:00
PHST- 2000/09/07 11:00 [pubmed]
PHST- 2000/10/21 11:01 [medline]
PHST- 2000/09/07 11:00 [entrez]
AID - S0006-2952(00)00419-6 [pii]
AID - 10.1016/s0006-2952(00)00419-6 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2000 Oct 1;60(7):917-22. doi: 10.1016/s0006-2952(00)00419-6.

PMID- 2551162
OWN - NLM
STAT- MEDLINE
DCOM- 19891025
LR  - 20131121
IS  - 0309-3913 (Print)
IS  - 0309-3913 (Linking)
VI  - 18
IP  - 3
DP  - 1989 Sep
TI  - Detection and determination of salicylic acid impurity in aspirin tablet 
      formulations' by high performance liquid chromatography.
PG  - 215-8
AB  - Salicylic acid is a major hydrolytic degradation product of aspirin, responsible 
      especially for gastric irritation during oral aspirin administration. This 
      impurity was investigated in 12 different brands of aspirin formulation readily 
      available in our locality. A simple, rapid and sensitive high performance liquid 
      chromatographic method was adopted for this investigation. The mobile phase was 
      methanol/water (20/80, v/v) adjusted to pH 2.5 with phosphoric acid and was run 
      on a 50 mm reversed-phase column monitored at 240 nm. The limit of detection for 
      salicylic acid was 5 ng. Only three of these formulations showed the presence of 
      salicylic acid impurity and all these contained salicylic acid in excess of the 
      USP 1980 limit of 0.3% salicylic acid per tablet.
FAU - Salako, Q
AU  - Salako Q
AD  - Department of Pharmaceutical Chemistry, School of Pharmacy, College of Medicine, 
      University of Lagos, Nigeria.
FAU - Fadiran, E O
AU  - Fadiran EO
FAU - Thomas, W O
AU  - Thomas WO
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - Afr J Med Med Sci
JT  - African journal of medicine and medical sciences
JID - 7801013
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/standards
MH  - Chromatography, High Pressure Liquid
MH  - Drug Compounding/*standards
MH  - Gastritis/chemically induced
MH  - Humans
MH  - Nigeria
MH  - Salicylates/adverse effects/*analysis/standards
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
PST - ppublish
SO  - Afr J Med Med Sci. 1989 Sep;18(3):215-8.

PMID- 2660559
OWN - NLM
STAT- MEDLINE
DCOM- 19890721
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 86
IP  - 6A
DP  - 1989 Jun 9
TI  - Lack of gastric mucosal protection by sucralfate during long-term aspirin 
      ingestion in humans.
PG  - 66-9
AB  - The ability of sucralfate to prevent gastric mucosal erosions caused by long-term 
      aspirin ingestion was studied in 19 normal human subjects. A placebo-controlled, 
      double-blind, crossover design was used to study the capacity of 4 g sucralfate 
      daily to lessen the noxious effect on gastric mucosa of 3.6 g aspirin daily for 
      14 days. Gastric mucosal injury was assessed by endoscopic scoring of erosions. 
      There was no significant difference in mean erosion scores or the degree of 
      partial mucosal protection between the two groups. It was concluded that 
      sucralfate lacks a mucosal protection capacity at the dosage studied in human 
      subjects ingesting large doses of aspirin over a two-week period.
FAU - Stern, A I
AU  - Stern AI
AD  - Monash University Department of Medicine, Prince Henry's Hospital, Melbourne, 
      Australia.
FAU - Ward, F
AU  - Ward F
FAU - Sievert, W
AU  - Sievert W
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 54182-58-0 (Sucralfate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Gastric Mucosa/drug effects/*pathology
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Random Allocation
MH  - Sucralfate/*therapeutic use
EDAT- 1989/06/09 00:00
MHDA- 1989/06/09 00:01
CRDT- 1989/06/09 00:00
PHST- 1989/06/09 00:00 [pubmed]
PHST- 1989/06/09 00:01 [medline]
PHST- 1989/06/09 00:00 [entrez]
AID - 0002-9343(89)90160-5 [pii]
AID - 10.1016/0002-9343(89)90160-5 [doi]
PST - ppublish
SO  - Am J Med. 1989 Jun 9;86(6A):66-9. doi: 10.1016/0002-9343(89)90160-5.

PMID- 372525
OWN - NLM
STAT- MEDLINE
DCOM- 19790626
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 5
IP  - 3
DP  - 1978 Fall
TI  - Naproxen vs. aspirin in osteoarthritis of the hip and knee.
PG  - 338-46
AB  - This 12-week double-blind trial compared the efficacy and tolerance of naproxen 
      (750 mg/day) with that of aspirin (3.6 gm/day). There was no statistical 
      difference in efficacy between the two trial drugs for any of the objective 
      (e.g., 25-foot walking time) or subjective (e.g., overall severity of symptoms) 
      variables measured. No side effects were experienced by 69% of the naproxen 
      patients and 37.5% of the aspirin patients. There were a statistically greater 
      number and more severe side effects during aspirin therapy than during naproxen 
      therapy (p = 0.002). The results show naproxen to be a potentially useful drug 
      for the treatment of osteoarthritis.
FAU - Melton, J W 3rd
AU  - Melton JW 3rd
FAU - Lussier, A
AU  - Lussier A
FAU - Ward, J R
AU  - Ward JR
FAU - Neustadt, D
AU  - Neustadt D
FAU - Multz, C
AU  - Multz C
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Central Nervous System Diseases/chemically induced
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naproxen/adverse effects/*therapeutic use
MH  - Osteoarthritis/*drug therapy
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1978 Fall;5(3):338-46.

PMID- 34389629
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20220716
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 14
IP  - 12
DP  - 2021 Dec
TI  - Transcriptome-wide In Vitro Effects of Aspirin on Patient-derived Normal Colon 
      Organoids.
PG  - 1089-1100
LID - 10.1158/1940-6207.CAPR-21-0041 [doi]
AB  - Mechanisms underlying aspirin chemoprevention of colorectal cancer remain 
      unclear. Prior studies have been limited because of the inability of preclinical 
      models to recapitulate human normal colon epithelium or cellular heterogeneity 
      present in mucosal biopsies. To overcome some of these obstacles, we performed in 
      vitro aspirin treatment of colon organoids derived from normal mucosal biopsies 
      to reveal transcriptional networks relevant to aspirin chemoprevention. Colon 
      organoids derived from 38 healthy individuals undergoing endoscopy were treated 
      with 50 μmol/L aspirin or vehicle control for 72 hours and subjected to bulk RNA 
      sequencing. Paired regression analysis using DESeq2 identified differentially 
      expressed genes (DEG) associated with aspirin treatment. Cellular composition was 
      determined using CIBERSORTx. Aspirin treatment was associated with 1,154 
      significant (q < 0.10) DEGs prior to deconvolution. We provide replication of 
      these findings in an independent population-based RNA-sequencing dataset of 
      mucosal biopsies (BarcUVa-Seq), where a significant enrichment for overlap of 
      DEGs was observed (P < 2.2E(-16)). Single-cell deconvolution revealed changes in 
      cell composition, including a decrease in transit-amplifying cells following 
      aspirin treatment (P = 0.01). Following deconvolution, DEGs included novel 
      putative targets for aspirin such as TRABD2A (q = 0.055), a negative regulator of 
      Wnt signaling. Weighted gene co-expression network analysis identified 12 
      significant modules, including two that contained hubs for EGFR and PTGES2, the 
      latter being previously implicated in aspirin chemoprevention. In summary, 
      aspirin treatment of patient-derived colon organoids using physiologically 
      relevant doses resulted in transcriptome-wide changes that reveal altered cell 
      composition and improved understanding of transcriptional pathways, providing 
      novel insight into its chemopreventive properties. PREVENTION RELEVANCE: Numerous 
      studies have highlighted a role for aspirin in colorectal cancer chemoprevention, 
      though the mechanisms driving this association remain unclear. We addressed this 
      by showing that aspirin treatment of normal colon organoids diminished the 
      transit-amplifying cell population, inhibited prostaglandin synthesis, and 
      dysregulated expression of novel genes implicated in colon tumorigenesis.
CI  - ©2021 American Association for Cancer Research.
FAU - Devall, Matthew A M
AU  - Devall MAM
AD  - Center for Public Health Genomics, Department of Public Health Sciences, 
      University of Virginia, Charlottesville, Virginia.
FAU - Drew, David A
AU  - Drew DA
AUID- ORCID: 0000-0002-8813-0816
AD  - Clinical & Translational Epidemiology Unit, Massachusetts General Hospital and 
      Harvard Medical School, Boston, Massachusetts.
AD  - Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts.
FAU - Dampier, Christopher H
AU  - Dampier CH
AUID- ORCID: 0000-0003-3099-6462
AD  - Center for Public Health Genomics, Department of Public Health Sciences, 
      University of Virginia, Charlottesville, Virginia.
FAU - Plummer, Sarah J
AU  - Plummer SJ
AD  - Center for Public Health Genomics, Department of Public Health Sciences, 
      University of Virginia, Charlottesville, Virginia.
FAU - Eaton, Stephen
AU  - Eaton S
AD  - Center for Public Health Genomics, Department of Public Health Sciences, 
      University of Virginia, Charlottesville, Virginia.
FAU - Bryant, Jennifer
AU  - Bryant J
AD  - Center for Public Health Genomics, Department of Public Health Sciences, 
      University of Virginia, Charlottesville, Virginia.
FAU - Díez-Obrero, Virginia
AU  - Díez-Obrero V
AUID- ORCID: 0000-0002-0163-9872
AD  - Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, 
      Barcelona, Spain.
FAU - Mo, Jiancheng
AU  - Mo J
AD  - Clinical & Translational Epidemiology Unit, Massachusetts General Hospital and 
      Harvard Medical School, Boston, Massachusetts.
AD  - Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts.
FAU - Kedrin, Dmitriy
AU  - Kedrin D
AUID- ORCID: 0000-0001-6093-7282
AD  - Clinical & Translational Epidemiology Unit, Massachusetts General Hospital and 
      Harvard Medical School, Boston, Massachusetts.
AD  - Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts.
AD  - Division of Gastroenterology, Elliot Hospital, Manchester, New Hampshire.
FAU - Zerjav, Dylan C
AU  - Zerjav DC
AUID- ORCID: 0000-0002-3248-4340
AD  - Clinical & Translational Epidemiology Unit, Massachusetts General Hospital and 
      Harvard Medical School, Boston, Massachusetts.
AD  - Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts.
FAU - Takacsi-Nagy, Oliver
AU  - Takacsi-Nagy O
AD  - Clinical & Translational Epidemiology Unit, Massachusetts General Hospital and 
      Harvard Medical School, Boston, Massachusetts.
AD  - Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts.
FAU - Jennelle, Lucas T
AU  - Jennelle LT
AD  - Center for Public Health Genomics, Department of Public Health Sciences, 
      University of Virginia, Charlottesville, Virginia.
FAU - Ali, Mourad W
AU  - Ali MW
AD  - Center for Public Health Genomics, Department of Public Health Sciences, 
      University of Virginia, Charlottesville, Virginia.
FAU - Yilmaz, Ömer H
AU  - Yilmaz ÖH
AUID- ORCID: 0000-0002-7577-4612
AD  - Koch Institute for Integrative Cancer Research, Department of Biology, MIT 
      Cambridge, Massachusetts.
AD  - Department of Pathology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts.
FAU - Moreno, Victor
AU  - Moreno V
AUID- ORCID: 0000-0002-2818-5487
AD  - Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, 
      Barcelona, Spain.
FAU - Powell, Steven M
AU  - Powell SM
AD  - Digestive Health Center, University of Virginia, Charlottesville, Virginia.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Clinical & Translational Epidemiology Unit, Massachusetts General Hospital and 
      Harvard Medical School, Boston, Massachusetts.
AD  - Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical 
      School, Boston, Massachusetts.
FAU - Peters, Ulrike
AU  - Peters U
AUID- ORCID: 0000-0001-5666-9318
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Center Research 
      Institute, Seattle, Washington.
FAU - Casey, Graham
AU  - Casey G
AD  - Center for Public Health Genomics, Department of Public Health Sciences, 
      University of Virginia, Charlottesville, Virginia. gc8r@virginia.edu.
LA  - eng
GR  - R01 CA245314/CA/NCI NIH HHS/United States
GR  - R01 CA204279/CA/NCI NIH HHS/United States
GR  - L30 CA209764/CA/NCI NIH HHS/United States
GR  - R01 CA257523/CA/NCI NIH HHS/United States
GR  - R35 CA253185/CA/NCI NIH HHS/United States
GR  - K01 DK120742/DK/NIDDK NIH HHS/United States
GR  - R01 CA143237/CA/NCI NIH HHS/United States
GR  - R01 CA201407/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210813
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Colon/pathology
MH  - Humans
MH  - *Organoids
MH  - Sequence Analysis, RNA/methods
MH  - *Transcriptome
PMC - PMC8639779
MID - NIHMS1733277
COIS- Disclosures The authors declare that there are no conflict of interests.
EDAT- 2021/08/15 06:00
MHDA- 2022/04/05 06:00
CRDT- 2021/08/14 05:49
PHST- 2021/01/25 00:00 [received]
PHST- 2021/05/27 00:00 [revised]
PHST- 2021/07/27 00:00 [accepted]
PHST- 2021/08/15 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
PHST- 2021/08/14 05:49 [entrez]
AID - 1940-6207.CAPR-21-0041 [pii]
AID - 10.1158/1940-6207.CAPR-21-0041 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2021 Dec;14(12):1089-1100. doi: 
      10.1158/1940-6207.CAPR-21-0041. Epub 2021 Aug 13.

PMID- 34225470
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20220117
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
VI  - 78
IP  - 5
DP  - 2021 Nov
TI  - Effective Aspirin Treatment of Women at Risk for Preeclampsia Delays the 
      Metabolic Clock of Gestation.
PG  - 1398-1410
LID - 10.1161/HYPERTENSIONAHA.121.17448 [doi]
AB  - [Figure: see text].
FAU - Li, Xiqi
AU  - Li X
AUID- ORCID: 0000-0003-0875-8337
AD  - Molecular and Human Genetics Department, Baylor College of Medicine, Houston, TX 
      (X.L., A.M., S.H.E., F.S.).
FAU - Milosavljevic, Aleksandar
AU  - Milosavljevic A
AD  - Molecular and Human Genetics Department, Baylor College of Medicine, Houston, TX 
      (X.L., A.M., S.H.E., F.S.).
FAU - Elsea, Sarah H
AU  - Elsea SH
AUID- ORCID: 0000-0002-1400-8519
AD  - Molecular and Human Genetics Department, Baylor College of Medicine, Houston, TX 
      (X.L., A.M., S.H.E., F.S.).
FAU - Wang, Chi Chiu
AU  - Wang CC
AUID- ORCID: 0000-0002-3928-7278
AD  - Department of Obstetrics and Gynaecology (C.C.W., L.C.P.), The Chinese University 
      of Hong Kong.
AD  - Li Ka Shing Institute of Health Sciences, School of Biomedical Sciences, Chinese 
      University of Hong Kong-Sichuan University Joint Laboratory in Reproductive 
      Medicine (C.C.W., K.H.N.), The Chinese University of Hong Kong.
FAU - Scaglia, Fernando
AU  - Scaglia F
AD  - Molecular and Human Genetics Department, Baylor College of Medicine, Houston, TX 
      (X.L., A.M., S.H.E., F.S.).
AD  - Texas Children's Hospital, Houston (F.S.).
AD  - Joint BCM-CUHK Center of Medical Genetics, Prince of Wales Hospital, Shatin, Hong 
      Kong (F.S.).
FAU - Syngelaki, Argyro
AU  - Syngelaki A
AD  - Fetal Medicine Research Institute, Harris Birthright Centre, King's College 
      Hospital, London, United Kingdom (A.S.).
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
AD  - Li Ka Shing Institute of Health Sciences, School of Biomedical Sciences, Chinese 
      University of Hong Kong-Sichuan University Joint Laboratory in Reproductive 
      Medicine (C.C.W., K.H.N.), The Chinese University of Hong Kong.
FAU - Poon, Liona C
AU  - Poon LC
AUID- ORCID: 0000-0002-3944-4130
AD  - Department of Obstetrics and Gynaecology (C.C.W., L.C.P.), The Chinese University 
      of Hong Kong.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210706
PL  - United States
TA  - Hypertension
JT  - Hypertension (Dallas, Tex. : 1979)
JID - 7906255
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Hypertension. 2021 Nov;78(5):1411-1413. PMID: 34644167
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - *Metabolome
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - aspirin
OT  - gestational age
OT  - metabolomics
OT  - preeclampsia
EDAT- 2021/07/07 06:00
MHDA- 2022/01/18 06:00
CRDT- 2021/07/06 05:29
PHST- 2021/07/07 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
PHST- 2021/07/06 05:29 [entrez]
AID - 10.1161/HYPERTENSIONAHA.121.17448 [doi]
PST - ppublish
SO  - Hypertension. 2021 Nov;78(5):1398-1410. doi: 10.1161/HYPERTENSIONAHA.121.17448. 
      Epub 2021 Jul 6.

PMID- 8781669
OWN - NLM
STAT- MEDLINE
DCOM- 19961024
LR  - 20190821
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 51
IP  - 3
DP  - 1996 Mar
TI  - Inhaled lysine acetylsalicylate (L-ASA) attenuates histamine-induced 
      bronchoconstriction in asthma.
PG  - 157-63
AB  - When administered by inhalation, histamine provokes dose-related 
      bronchoconstriction in asthmatic subjects mainly by a direct activation of 
      histamine H1-receptors on airway smooth muscle. However, little is known of the 
      change in airway responsiveness to histamine after cyclooxygenase blockade. The 
      aim of the study was to investigate the effect of the potent cyclooxygenase 
      inhibitor, lysine acetylsalicylate (L-ASA), administered by inhalation on 
      histamine-induced bronchoconstriction in a group of 16 asthmatic subjects. The 
      subjects studied attended the laboratory on four separate occasions to receive 
      nebulized L-ASA (solution of 90 mg/ml) or matched placebo (glycine solution of 30 
      mg/ml) 15 min before bronchoprovocation tests with histamine and methacholine in 
      a randomized, double-blind order. Changes in airway caliber were followed as 
      forced expiratory volume in 1 s (FEV1), and agonist responsiveness was expressed 
      as the provocative concentration causing a 20% fall in FEV1 from baseline (PC20). 
      Administration of both L-ASA and glycine solution caused a small but significant 
      acute fall in FEV1 from baseline, which returned to normal within 15 min. When 
      compared to placebo, inhaled L-ASA reduced the airway responsiveness to histamine 
      in 13 of the 16 subjects studied, the geometric mean (range) values fro PC20 
      histamine increasing significantly (P < 0.001) from 1.72 (0.13-5.49) mg/ml to 
      3.31 (0.36-12.00) mg/ml after placebo and L-ASA, respectively. No significant 
      change in airway responsiveness to methacholine was recorded after L-ASA. Acute 
      administration of L-ASA by inhalation protects the asthmatic airways against 
      histamine-induced bronchoconstriction, thus suggesting that endogenous 
      prostaglandins may play a contributory role in the airways response to histamine 
      in human asthma.
FAU - Crimi, N
AU  - Crimi N
AD  - Istituto Malattie Apparato Respiratorio, Università di Catania, Italy.
FAU - Polosa, R
AU  - Polosa R
FAU - Magrì, S
AU  - Magrì S
FAU - Prosperini, G
AU  - Prosperini G
FAU - Paolino, G
AU  - Paolino G
FAU - Mastruzzo, C
AU  - Mastruzzo C
FAU - Mistretta, A
AU  - Mistretta A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0W5ETF9M2K (Methacholine Chloride)
RN  - 820484N8I3 (Histamine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Asthma/*physiopathology
MH  - Bronchoconstriction/*drug effects
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Histamine/*pharmacology
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Male
MH  - Methacholine Chloride/pharmacology
MH  - Middle Aged
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1996.tb04580.x [doi]
PST - ppublish
SO  - Allergy. 1996 Mar;51(3):157-63. doi: 10.1111/j.1398-9995.1996.tb04580.x.

PMID- 34130349
OWN - NLM
STAT- MEDLINE
DCOM- 20220322
LR  - 20220322
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 122
IP  - 1
DP  - 2022 Jan
TI  - Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive 
      Effects of Aspirin.
PG  - 92-104
LID - 10.1055/s-0041-1730312 [doi]
AB  - BACKGROUND:  Sunitinib is a multitarget tyrosine kinase inhibitor (TKI) used for 
      cancer treatment. In platelets, sunitinib affects collagen-induced activation 
      under noncoagulating conditions. We investigated (1) the effects of sunitinib on 
      thrombus formation induced by other TK-dependent receptors, and (2) the effects 
      under coagulating conditions. Cardiovascular disease is a comorbidity in cancer 
      patients, resulting in possible aspirin treatment. Sunitinib and aspirin are 
      associated with increased bleeding risk, and therefore we also investigated (3) 
      the synergistic effects of these compounds on thrombus and fibrin formation. 
      METHODS:  Blood or isolated platelets from healthy volunteers or cancer patients 
      were incubated with sunitinib and/or aspirin or vehicle. Platelet activation was 
      determined by TK phosphorylation, flow cytometry, changes in [Ca(2+)](i), 
      aggregometry, and whole blood perfusion over multiple surfaces, including 
      collagen with(out) tissue factor (TF) was performed. RESULTS:  Sunitinib reduced 
      thrombus formation and phosphatidylserine (PS) exposure under flow on collagen 
      type I and III. Also, sunitinib inhibited glycoprotein VI-induced TK 
      phosphorylation and Ca(2+) elevation. Upon TF-triggered coagulation, sunitinib 
      decreased PS exposure and fibrin formation. In blood from cancer patients more 
      pronounced effects of sunitinib were observed in lung and pancreatic as compared 
      to neuroglioblastoma and other cancer types. Compared to sunitinib alone, 
      sunitinib plus aspirin further reduced platelet aggregation, thrombus formation, 
      and PS exposure on collagen under flow with(out) coagulation. CONCLUSION: 
       Sunitinib suppresses collagen-induced procoagulant activity and delays fibrin 
      formation, which was aggravated by aspirin. Therefore, we urge for awareness of 
      the combined antiplatelet effects of TKIs with aspirin, as this may result in 
      increased risk of bleeding.
CI  - Thieme. All rights reserved.
FAU - Tullemans, Bibian M E
AU  - Tullemans BME
AD  - Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), 
      Maastricht University, The Netherlands.
FAU - Fernández, Delia I
AU  - Fernández DI
AD  - Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), 
      Maastricht University, The Netherlands.
AD  - Platelet Proteomics Group, Center for Research in Molecular Medicine and Chronic 
      Diseases (CIMUS), Universidade Santiago de Compostela, Santiago de Compostela, 
      Spain.
FAU - Veninga, Alicia
AU  - Veninga A
AD  - Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), 
      Maastricht University, The Netherlands.
FAU - Baaten, Constance C F M J
AU  - Baaten CCFMJ
AD  - Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), 
      Maastricht University, The Netherlands.
AD  - Institute for Molecular Cardiovascular Research (IMCAR), University Hospital 
      Aachen, Aachen, Germany.
AD  - Interdisciplinary Center for Clinical Research (IZKF), RWTH Aachen University, 
      Aachen, Germany.
FAU - Peters, Linsey J F
AU  - Peters LJF
AD  - Institute for Molecular Cardiovascular Research (IMCAR), University Hospital 
      Aachen, Aachen, Germany.
AD  - Interdisciplinary Center for Clinical Research (IZKF), RWTH Aachen University, 
      Aachen, Germany.
AD  - Department of Pathology, Maastricht University Medical Centre, Cardiovascular 
      Research Institute Maastricht (CARIM), Maastricht, Netherlands.
FAU - Aarts, Maureen J B
AU  - Aarts MJB
AD  - Department of Medical Oncology, Maastricht University Medical Centre, Maastricht, 
      The Netherlands.
FAU - Eble, Johannes A
AU  - Eble JA
AD  - Institute of Physiological Chemistry and Pathobiochemistry, University of 
      Münster, Münster, Germany.
FAU - Campello, Elena
AU  - Campello E
AD  - Department of Medicine, University of Padua Medical School, Padova, Italy.
FAU - Spiezia, Luca
AU  - Spiezia L
AD  - Department of Medicine, University of Padua Medical School, Padova, Italy.
FAU - Simioni, Paolo
AU  - Simioni P
AD  - Department of Medicine, University of Padua Medical School, Padova, Italy.
FAU - van der Vorst, Emiel P C
AU  - van der Vorst EPC
AD  - Institute for Molecular Cardiovascular Research (IMCAR), University Hospital 
      Aachen, Aachen, Germany.
AD  - Interdisciplinary Center for Clinical Research (IZKF), RWTH Aachen University, 
      Aachen, Germany.
AD  - Department of Pathology, Maastricht University Medical Centre, Cardiovascular 
      Research Institute Maastricht (CARIM), Maastricht, Netherlands.
AD  - Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University 
      Munich, Munich, Germany.
FAU - van der Meijden, Paola E J
AU  - van der Meijden PEJ
AD  - Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), 
      Maastricht University, The Netherlands.
AD  - Thrombosis Expertise Center, Heart and Vascular Center, Maastricht University 
      Medical Center, Maastricht, The Netherlands.
FAU - Heemskerk, Johan W M
AU  - Heemskerk JWM
AD  - Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), 
      Maastricht University, The Netherlands.
FAU - Kuijpers, Marijke J E
AU  - Kuijpers MJE
AD  - Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), 
      Maastricht University, The Netherlands.
AD  - Thrombosis Expertise Center, Heart and Vascular Center, Maastricht University 
      Medical Center, Maastricht, The Netherlands.
LA  - eng
GR  - Pfizer/WI209458/
GR  - European Union's Horizon 2020 research and innovation program under Marie 
      Sklodowska-Curie grant/766118/
GR  - Dutch Heart Foundation/2020T020/
GR  - START-Program of the Faculty of Medicine at the RWTH Aachen University/105/20/
GR  - Deutsche Forschungsgemeinschaft/SFP1009 project A09/
GR  - Interdisciplinary Center for Clinical Research within the faculty of Medicine at 
      the RWTH Aachen University and NWO-ZonMw Veni/91619053/
PT  - Journal Article
DEP - 20210615
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Protein Kinase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Aspirin/metabolism/pharmacology
MH  - Blood Coagulation/*drug effects/physiology
MH  - Humans
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Sunitinib/*pharmacology/therapeutic use
MH  - Thrombosis/drug therapy/prevention & control
COIS- J.W.M.H. is a cofounder and shareholder of FlowChamber B.V. The other authors 
      declare no relevant conflicts of interest.
EDAT- 2021/06/16 06:00
MHDA- 2022/03/23 06:00
CRDT- 2021/06/15 20:30
PHST- 2021/06/16 06:00 [pubmed]
PHST- 2022/03/23 06:00 [medline]
PHST- 2021/06/15 20:30 [entrez]
AID - 10.1055/s-0041-1730312 [doi]
PST - ppublish
SO  - Thromb Haemost. 2022 Jan;122(1):92-104. doi: 10.1055/s-0041-1730312. Epub 2021 
      Jun 15.

PMID- 12028039
OWN - NLM
STAT- MEDLINE
DCOM- 20020712
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 117
IP  - 3
DP  - 2002 Jun
TI  - Effects of desmopressin on thrombogenesis in aspirin-induced platelet 
      dysfunction.
PG  - 658-63
AB  - Aspirin causes a coagulation disorder. Desmopressin has haemostatic effects by 
      increasing the plasma levels of coagulation factor VIII and von Willebrand 
      factor. The precise effects of desmopressin on thrombogenesis are not known. In 
      an in vivo model, we investigated the effect of the drug on thrombus formation 
      and platelet function after aspirin use. Male Lewis rats weighing 250-300 g were 
      used. Four groups with 10 animals each were formed: control, aspirin, 
      desmopressin and aspirin + desmopressin. In each animal, the femoral artery was 
      dissected. A thrombogenic vessel injury was created by inverting a full thickness 
      portion of the proximal edge of the incised artery into the lumen. The following 
      parameters were measured: maximum thrombus size, time period until maximum 
      thrombus size was reached and overall platelet function. In addition, the thrombi 
      generated were investigated histologically. Thrombus formation time was 
      significantly shorter with desmopressin compared with the animals treated with 
      aspirin (P < 0.0001) and controls (P = 0.008). Maximum thrombus size was larger 
      in the desmopressin and desmopressin + aspirin groups when compared with the 
      group treated with aspirin only. Overall platelet function was significantly 
      enhanced with desmopressin compared with controls (P = 0.025) and with aspirin (P 
      < 0.0001). The differences were confirmed histologically. In conclusion, 
      desmopressin significantly accelerates thrombus formation in aspirin-treated 
      animals. It can also re-establish thrombus size after the use of aspirin. Overall 
      platelet function is significantly increased by desmopressin.
FAU - Peter, Frank W
AU  - Peter FW
AD  - Department of Plastic Surgery, Bergmannsheil University Hospital, Bochum, 
      Germany. f.peter.berlin@t-online.de
FAU - Benkovic, C
AU  - Benkovic C
FAU - Muehlberger, Thomas
AU  - Muehlberger T
FAU - Vogt, Peter M
AU  - Vogt PM
FAU - Homann, Heinz H
AU  - Homann HH
FAU - Kuhnen, Cornelius
AU  - Kuhnen C
FAU - Wiebalck, Albrecht
AU  - Wiebalck A
FAU - Steinau, Hans U
AU  - Steinau HU
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Hemostatics)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*antagonists & inhibitors/pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Deamino Arginine Vasopressin/*pharmacology
MH  - Hemostatics/*pharmacology
MH  - Male
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Rats
MH  - Rats, Inbred Lew
MH  - Thrombosis/*chemically induced/pathology
EDAT- 2002/05/25 10:00
MHDA- 2002/07/13 10:01
CRDT- 2002/05/25 10:00
PHST- 2002/05/25 10:00 [pubmed]
PHST- 2002/07/13 10:01 [medline]
PHST- 2002/05/25 10:00 [entrez]
AID - 3460 [pii]
AID - 10.1046/j.1365-2141.2002.03460.x [doi]
PST - ppublish
SO  - Br J Haematol. 2002 Jun;117(3):658-63. doi: 10.1046/j.1365-2141.2002.03460.x.

PMID- 10434816
OWN - NLM
STAT- MEDLINE
DCOM- 19990812
LR  - 20190515
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 82
IP  - 3
DP  - 1999 Mar
TI  - Magnitude and time course of impaired primary haemostasis after stopping chronic 
      low and medium dose aspirin in healthy volunteers.
PG  - 360-5
AB  - Aspirin ingestion within the previous 7-10 days is often considered a relative 
      contraindication to performing invasive procedures. However, aspirin is an 
      important component of many patients' treatment and withholding therapy for this 
      time may be dangerous. To measure both the magnitude of the impairment in primary 
      haemostasis induced by aspirin and how much recovery of platelet function occurs 
      within 48 h of stopping aspirin, we studied serial changes in bleeding time (BT) 
      in a randomized, double-blind, placebo-controlled study. Fifty-two healthy 
      volunteers had BT performed before and at 2, 9, 24 and 48 h after a 7-day course 
      of either aspirin 75 mg, 300 mg or placebo. The main outcome recorded was BT at 
      each time. Nearly 25% of subjects had extended BT to more than 10 min, but no BT 
      were greater than 10 min, 48 h after stopping aspirin. There was a small but 
      statistically significant (P < 0.01) difference between the 48-h and baseline BT 
      in both aspirin groups (49 and 64 s in the 75 mg and 300 mg groups, 
      respectively). There was no difference in the magnitude or time course of effect 
      between low and medium dose aspirin (P = 0.392 and P = 0.797, respectively). We 
      conclude that despite considerable inter-individual variability in the magnitude 
      of aspirin effect on primary haemostasis, the time course of effect was 
      consistent. In healthy volunteers, the defect in primary haemostasis had largely 
      disappeared 48 h after the last dose.
FAU - Sonksen, J R
AU  - Sonksen JR
AD  - Department of Anaesthesia, City Hospital, Birmingham, UK.
FAU - Kong, K L
AU  - Kong KL
FAU - Holder, R
AU  - Holder R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Hemoglobins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Hemoglobins/metabolism
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Count/drug effects
MH  - Time Factors
EDAT- 1999/08/06 00:00
MHDA- 1999/08/06 00:01
CRDT- 1999/08/06 00:00
PHST- 1999/08/06 00:00 [pubmed]
PHST- 1999/08/06 00:01 [medline]
PHST- 1999/08/06 00:00 [entrez]
AID - S0007-0912(17)38604-X [pii]
AID - 10.1093/bja/82.3.360 [doi]
PST - ppublish
SO  - Br J Anaesth. 1999 Mar;82(3):360-5. doi: 10.1093/bja/82.3.360.

PMID- 707407
OWN - NLM
STAT- MEDLINE
DCOM- 19781229
LR  - 20190509
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 70
IP  - 3
DP  - 1978 Sep
TI  - Development and evaluation of a disposable device for performing simultaneous 
      duplicate bleeding time determinations.
PG  - 406-8
AB  - A disposable bleeding time device that provides two simultaneous standardized 
      incisions is described. The mean bleeding time of 47 normal adults was 4.1 min 
      with a 95% range of 2.2--7.0 min. The standard deviation of duplicate bleeding 
      times was 0.7 min, and the day-to-day standard deviation for individuals was 0.9 
      min. In a double-blind crossover study of 20 normal adults, the mean bleeding 
      time increased from 3.7 to 6.2 min after ingestion of 1 g aspirin. The device is 
      extremely simple to use and is essentially painless. Physical trauma is minimal.
FAU - Babson, S R
AU  - Babson SR
FAU - Babson, A L
AU  - Babson AL
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Coagulation Tests/*instrumentation
MH  - *Disposable Equipment
MH  - Evaluation Studies as Topic
MH  - Humans
MH  - Reference Values
EDAT- 1978/09/01 00:00
MHDA- 1978/09/01 00:01
CRDT- 1978/09/01 00:00
PHST- 1978/09/01 00:00 [pubmed]
PHST- 1978/09/01 00:01 [medline]
PHST- 1978/09/01 00:00 [entrez]
AID - 10.1093/ajcp/70.3.406 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1978 Sep;70(3):406-8. doi: 10.1093/ajcp/70.3.406.

PMID- 432252
OWN - NLM
STAT- MEDLINE
DCOM- 19790626
LR  - 20161123
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 34
IP  - 1
DP  - 1979 Jan
TI  - Physico-chemical analysis of systems with a main component acetylsalicylic acid 
      in ethanol-water mixtures. Part 3: Systems containing calcium acetylsalicylate.
PG  - 25-7
AB  - The systems C9H8O4-(C9H7O4)2Ca-25% ethanol-water mixture (I), 
      C9H8O4-(C9H7O4)2Ca-50% ethanol-water mixture (II), C9H8O4-(C9H7O4)2Ca-95% 
      ethanol-water mixture (III) have been investigated at 15 degrees C by 
      physico-chemical analytical methods. It was established that under the conditions 
      of the no experiments no double or triple compounds of acetylsalicylic acid and 
      calcium acetylsalicylate have been formed. The fields of the crystallization of 
      the pure components are outlined. In systems I and II there exist crystallization 
      fields of (C9H7O4)2Ca - 2H2O and in system III field of (C9H7O4)2Ca. The 
      anhydrous salt and the crystalline hydrate were isolated and were investigated by 
      chemical analysis and X-ray diffraction analysis.
FAU - Ivanov, D S
AU  - Ivanov DS
FAU - Trendafelov, D
AU  - Trendafelov D
FAU - Karaivanova, V G
AU  - Karaivanova VG
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 059QF0KO0R (Water)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Aspirin/*analysis
MH  - Calcium
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Crystallization
MH  - Ethanol
MH  - Solubility
MH  - Water
MH  - X-Ray Diffraction
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1979 Jan;34(1):25-7.

PMID- 6833429
OWN - NLM
STAT- MEDLINE
DCOM- 19830527
LR  - 20190629
VI  - 272
IP  - 2
DP  - 1983 Feb 11
TI  - Determination of acetylsalicylic acid and metabolites in biological fluids by 
      high-performance liquid chromatography.
PG  - 325-31
AB  - A new method has been developed for the determination of acetylsalicylic acid, 
      salicylic acid, salicyluric acid and gentisic acid in plasma, urine and tissue 
      homogenates by simple extraction with ethyl acetate, evaporation and 
      redissolution and measuring by high-performance liquid chromatography. Linearity, 
      reproducibility and recovery were determined. Experiments were carried out to 
      investigate the decomposition of acetylsalicylic acid in plasma with fluoride at 
      different temperatures. The method has been used for pharmacokinetic experiments 
      and an example is given.
FAU - Reidl, U
AU  - Reidl U
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Chromatogr
JT  - Journal of chromatography
JID - 0427043
RN  - 0 (Gentisates)
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analysis/*metabolism
MH  - Chromatography, High Pressure Liquid/methods
MH  - Gentisates/analysis
MH  - Hippurates/analysis
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Rabbits
MH  - Salicylates/analysis
MH  - Salicylic Acid
MH  - Specimen Handling
EDAT- 1983/02/11 00:00
MHDA- 1983/02/11 00:01
CRDT- 1983/02/11 00:00
PHST- 1983/02/11 00:00 [pubmed]
PHST- 1983/02/11 00:01 [medline]
PHST- 1983/02/11 00:00 [entrez]
AID - 10.1016/s0378-4347(00)86135-6 [doi]
PST - ppublish
SO  - J Chromatogr. 1983 Feb 11;272(2):325-31. doi: 10.1016/s0378-4347(00)86135-6.

PMID- 21699808
OWN - NLM
STAT- MEDLINE
DCOM- 20111227
LR  - 20131121
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
VI  - 9
IP  - 9
DP  - 2011 Sep
TI  - Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a 
      meta-analysis.
PG  - 762-768.e6
LID - 10.1016/j.cgh.2011.05.020 [doi]
AB  - BACKGROUND & AIMS: We performed a meta-analysis of data from randomized trials to 
      estimate the risk of all-cause mortality and bleeding (and especially 
      gastrointestinal [GI] bleeding) in patients treated with low doses of 
      acetylsalicylic acid (ASA) (75-325 mg/d), alone or in combination with other 
      medications. METHODS: We searched 10 electronic databases (until October 2010) 
      and collected data on adverse events in randomized controlled studies that 
      evaluated low doses of ASA, alone (35 trials) or in combination with 
      anticoagulants (18 trials), clopidogrel (5 trials), or proton pump inhibitors 
      (PPIs; 3 trials). We analyzed data using random-effects meta-analysis and 
      meta-regression, applying Peto's odds ratio (OR) for adverse events. RESULTS: Low 
      doses of ASA alone decreased the risk for all-cause mortality (relative risk, 
      0.93, 95% confidence interval [CI], 0.87-0.99), largely because of effects in 
      secondary prevention populations. The risk of major GI bleeding increased with 
      low doses of ASA alone (OR, 1.55; 95% CI, 1.27-1.90), compared with inert control 
      reagents. The risk increased when ASA was combined with clopidogrel, compared 
      with aspirin alone (OR, 1.86; 95% CI, 1.49-2.31), anticoagulants vs low doses of 
      ASA alone (OR, 1.93; 95% CI, 1.42-2.61), or in studies that included patients 
      with a history of GI bleeding or of longer duration. Importantly, PPI use reduced 
      the risk for major GI bleeding in patients given low doses of ASA (OR, 0.34; 95% 
      CI, 0.21-0.57). CONCLUSIONS: In a meta-analysis, low doses of ASA increased the 
      risk for GI bleeding; risk increased with accompanying use of clopidogrel and 
      anticoagulant therapies, but decreased in patients who took PPIs.
CI  - Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
FAU - Lanas, Angel
AU  - Lanas A
AD  - Servicio de Aparato Digestivo, University of Zaragoza, IIS Aragón, CIBERehd, 
      Spain. alanas@unizar.es
FAU - Wu, Ping
AU  - Wu P
FAU - Medin, Jennie
AU  - Medin J
FAU - Mills, Edward J
AU  - Mills EJ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20110606
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal 
      of the American Gastroenterological Association
JID - 101160775
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Gastrointestinal Hemorrhage/*chemically induced/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Survival Analysis
EDAT- 2011/06/28 06:00
MHDA- 2011/12/28 06:00
CRDT- 2011/06/25 06:00
PHST- 2011/03/01 00:00 [received]
PHST- 2011/05/17 00:00 [revised]
PHST- 2011/05/18 00:00 [accepted]
PHST- 2011/06/25 06:00 [entrez]
PHST- 2011/06/28 06:00 [pubmed]
PHST- 2011/12/28 06:00 [medline]
AID - S1542-3565(11)00562-3 [pii]
AID - 10.1016/j.cgh.2011.05.020 [doi]
PST - ppublish
SO  - Clin Gastroenterol Hepatol. 2011 Sep;9(9):762-768.e6. doi: 
      10.1016/j.cgh.2011.05.020. Epub 2011 Jun 6.

PMID- 7954621
OWN - NLM
STAT- MEDLINE
DCOM- 19941221
LR  - 20190512
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 28
IP  - 8
DP  - 1994 Aug
TI  - Effects of diaspirin crosslinked haemoglobin during coronary angioplasty in the 
      swine.
PG  - 1188-92
AB  - OBJECTIVE: Percutaneous transluminal coronary angioplasty produces a transient 
      interruption of coronary blood flow during balloon inflation, giving rise to 
      temporary regional myocardial ischaemia. Diaspirin crosslinked haemoglobin 
      (DCLHbTM) transports oxygen in a similar way to whole blood and can be perfused 
      through the angioplasty catheter during balloon occlusion. The aim of this study 
      was to test the hypothesis that DCLHb may increase myocardial oxygenation and 
      reduce myocardial ischaemia during coronary angioplasty. METHODS: The effect of 
      DCLHb on cardiac function was measured in diazepam sedated swine. Mean arterial 
      blood pressure, peak systolic left intraventricular pressure, maximum rate of 
      left ventricular pressure development (dP/dtmax), pressure-rate product, cardiac 
      output (CO), and ECG were monitored continuously. Variables were compared during 
      control, during 1 min balloon occlusion of the proximal left anterior descending 
      coronary artery with a 2.5-3.5 F angioplasty catheter, during 1 min of DCLHb 
      perfusion (40 ml.min-1) without balloon occlusion, and during 4 min balloon 
      occlusion with DCLHb perfusion (40 ml.min-1) of the occluded region. Measurements 
      were made during balloon occlusion plus DCLHb at 1 min (B + D1), 2 min (B + D2), 
      and 4 min (B + D4). RESULTS: Balloon occlusion decreased cardiac function as 
      compared to control: arterial blood pressure -16%, intraventricular pressure 
      -14%, dP/dtmax -34%, and pressure-rate product -40%. DCLHb alone did not 
      significantly change haemodynamic measurements from control. At B + D4 
      haemodynamic variables were increased as compared to balloon occlusion alone: 
      arterial blood pressure +32%, intraventricular pressure +29%, dP/dtmax +20%, and 
      pressure-rate product +19%. Only intraventricular pressure and mean arterial 
      pressure were increased compared to control. The S-T segment of the ECG was 
      depressed by 0.109(SEM 0.019) mV during balloon occlusion without DCLHb, while 
      only decreasing by 0.069(0.027) mV at B + D1, by 0.046(0.018) mV at B + D2, and 
      by 0.058(0.018) mV at B + D4. CONCLUSIONS: There is an improvement in cardiac 
      function and a lessening of S-T segment depression during percutaneous 
      transluminal coronary angioplasty balloon occlusion with DCLHb perfusion.
FAU - McKenzie, J E
AU  - McKenzie JE
AD  - Department of Physiology, Uniformed Services University, Bethesda, Maryland 
      20814-4799.
FAU - Cost, E A
AU  - Cost EA
FAU - Scandling, D M
AU  - Scandling DM
FAU - Ahle, N W
AU  - Ahle NW
FAU - Savage, R W
AU  - Savage RW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Coronary Circulation
MH  - Electrocardiography
MH  - Female
MH  - Heart/physiopathology
MH  - Hemoglobins/*pharmacology
MH  - Intraoperative Complications/physiopathology/*prevention & control
MH  - Male
MH  - Myocardial Ischemia/physiopathology/*prevention & control
MH  - Swine
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
AID - 0008-6363(94)90355-7 [pii]
AID - 10.1093/cvr/28.8.1188 [doi]
PST - ppublish
SO  - Cardiovasc Res. 1994 Aug;28(8):1188-92. doi: 10.1093/cvr/28.8.1188.

PMID- 1783243
OWN - NLM
STAT- MEDLINE
DCOM- 19920317
LR  - 20131121
IS  - 0196-0202 (Print)
IS  - 0196-0202 (Linking)
VI  - 12
IP  - 5
DP  - 1991 Oct
TI  - Case history: asking the right questions.
PG  - 363-4
AB  - The importance of asking the right question is highlighted in this case study. 
      The patient was a 76-yr-old man with hearing loss that initially appeared to be a 
      classic case of presbycusis. Without asking the right question this patient might 
      have been managed in a manner inappropriate to his true hearing sensitivity.
FAU - Jordan, C E
AU  - Jordan CE
AD  - Department of Otolaryngology and Communicative Sciences, Baylor College of 
      Medicine, Houston, Texas.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ear Hear
JT  - Ear and hearing
JID - 8005585
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects
MH  - Audiometry, Pure-Tone
MH  - Diagnostic Errors
MH  - Hearing Loss, Sensorineural/chemically induced/*diagnosis
MH  - Humans
MH  - Male
MH  - Medical History Taking/*methods
MH  - Presbycusis/diagnosis
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
PST - ppublish
SO  - Ear Hear. 1991 Oct;12(5):363-4.

PMID- 9600492
OWN - NLM
STAT- MEDLINE
DCOM- 19980604
LR  - 20161124
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 101
IP  - 5
DP  - 1998 May
TI  - Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive 
      asthma.
PG  - 581-6
AB  - Nasal provocation tests (NPTs) with lysine-aspirin (L-ASA) have been recently 
      introduced for assessment of aspirin-induced asthma (AIA). They differ in dose 
      and means of aspirin instillation, duration of observation period, and criteria 
      for positivity. Thus far they have not become a routine part of clinical 
      diagnosis. Fifty-one patients with AIA, confirmed by oral challenge test, were 
      recruited to undergo diagnostic NPTs with L-ASA. In 10 of these patients (19.6%), 
      NPTs could not be performed because of total obstruction of at least one nostril 
      or marked fluctuations in nasal flows, leaving 41 patients with AIA for the 
      study. Control groups consisted of 13 aspirin-tolerant asthmatic patients and 10 
      healthy subjects. L-ASA at a total dose of 16 mg of acetylsalicylic acid applied 
      bilaterally into the inferior nasal conchae caused significant fall in 
      inspiratory nasal flow in at least one nostril (>40%), which was measured by 
      anterior rhinomanometry, and clinical symptoms of watery discharge and nasal 
      blockage in 35 of 41 patients with AIA, one of 10 healthy subjects, and none of 
      13 aspirin-tolerant asthmatic patients. No relationship was found between the 
      baseline nasal flow values and the intensity of response to L-ASA. No systemic 
      reactions, including bronchospasm, were noticed, even in patients whose initial 
      FEV1 was lower than 70% of predicted value. This test is highly specific (95.7%) 
      and sensitive (86.7%), but negative results do not exclude possible intolerance 
      to aspirin (predictive value of a negative result 78.6%). In conclusion, the NPT 
      described is a simple, safe, and quick test for diagnosis of AIA. It can be used 
      in patients with unstable asthma. It may be a method of choice to confirm 
      hypersensitivity to aspirin manifested only by symptoms from the upper 
      respiratory tract. Patients suspected of aspirin intolerance who have negative 
      NPT results should undergo bronchial or oral challenge tests with aspirin.
FAU - Milewski, M
AU  - Milewski M
AD  - Jagellonian University School of Medicine, Department of Medicine, Cracow, 
      Poland.
FAU - Mastalerz, L
AU  - Mastalerz L
FAU - Nizankowska, E
AU  - Nizankowska E
FAU - Szczeklik, A
AU  - Szczeklik A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Allergens)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - *Allergens
MH  - Aspirin/*adverse effects/*analogs & derivatives
MH  - Asthma/chemically induced/*diagnosis
MH  - Chi-Square Distribution
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Nasal Provocation Tests/*methods/statistics & numerical data
MH  - Sensitivity and Specificity
EDAT- 1998/05/26 00:00
MHDA- 1998/05/26 00:01
CRDT- 1998/05/26 00:00
PHST- 1998/05/26 00:00 [pubmed]
PHST- 1998/05/26 00:01 [medline]
PHST- 1998/05/26 00:00 [entrez]
AID - S0091-6749(98)70163-0 [pii]
AID - 10.1016/S0091-6749(98)70163-0 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1998 May;101(5):581-6. doi: 
      10.1016/S0091-6749(98)70163-0.

PMID- 7157830
OWN - NLM
STAT- MEDLINE
DCOM- 19830317
LR  - 20190909
IS  - 0049-8254 (Print)
IS  - 0049-8254 (Linking)
VI  - 12
IP  - 10
DP  - 1982 Oct
TI  - The metabolism of [carboxyl-14C]aspirin in man.
PG  - 601-10
AB  - 1. [carboxyl-14C]Aspirin has been orally administered to four male volunteers and 
      the urinary metabolites examined by paper chromatography, t.l.c., h.p.l.c. and 
      mass spectrometry. 2. 14C Radioactivity was eliminated rapidly in the urine, 94 
      to 98% of the dose in the first 24 h and approx. 1% in 24-48 h. 3. The major 
      urinary metabolite was salicyluric acid (56-68% dose). In addition, free 
      salicylic and gentisic acids were also detected as were both the acyl and 
      phenolic glucuronides of salicylate. 4. A phenolic glucuronide of salicyluric 
      acid has also been identified. The importance of this metabolite in relation to 
      analytical methods for salicylphenolic glucuronide determination is discussed. 5. 
      The presence of other di- and tri-hydroxybenzoic acids or gentisuric acid could 
      not be demonstrated.
FAU - Hutt, A J
AU  - Hutt AJ
FAU - Caldwell, J
AU  - Caldwell J
FAU - Smith, R L
AU  - Smith RL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Xenobiotica
JT  - Xenobiotica; the fate of foreign compounds in biological systems
JID - 1306665
RN  - 0 (Carbon Radioisotopes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*metabolism
MH  - Biotransformation
MH  - Carbon Radioisotopes
MH  - Chromatography, Paper
MH  - Humans
MH  - Isotope Labeling
MH  - Male
MH  - Middle Aged
EDAT- 1982/10/01 00:00
MHDA- 1982/10/01 00:01
CRDT- 1982/10/01 00:00
PHST- 1982/10/01 00:00 [pubmed]
PHST- 1982/10/01 00:01 [medline]
PHST- 1982/10/01 00:00 [entrez]
AID - 10.3109/00498258209042038 [doi]
PST - ppublish
SO  - Xenobiotica. 1982 Oct;12(10):601-10. doi: 10.3109/00498258209042038.

PMID- 7270604
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 140
IP  - 8
DP  - 1981 Aug 15
TI  - Endotoxic shock in the primate: effects of aspirin and dipyridamole 
      administration.
PG  - 914-22
AB  - A primate model was utilized to study the cardiovascular and coagulation effects 
      of endotoxic shock. The therapeutic effectiveness of drugs such as aspirin and 
      dipyridamole, which diminish platelet aggregation and adherence, were evaluated. 
      From the data, it appears that the kidney is a target organ in endotoxic shock, 
      at least when a bolus injection of endotoxin is administered. The precipitate 
      falls in the renal artery flow (p less than 0.01) and platelet count (p less than 
      0.01), which occur 3 minutes after the intravenous injection of endotoxin, can be 
      prevented in part by pretreatment with aspirin (40 mg/kg of body weight). The 
      changes in the coagulation profile were of less magnitude, and the fibrin 
      degradation products appeared late in the group pretreated with aspirin as 
      compared to the other groups. The combination of dipyridamole and aspirin was not 
      as effective as aspirin alone in achieving the apparently protective effect. The 
      study suggests that the administration of aspirin to patients with gram-negative 
      infections may be beneficial.
FAU - Rao, P S
AU  - Rao PS
FAU - Cavanagh, D
AU  - Cavanagh D
FAU - Gaston, L W
AU  - Gaston LW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Blood Pressure/drug effects
MH  - Depression, Chemical
MH  - Dipyridamole/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Papio
MH  - Platelet Aggregation/drug effects
MH  - Regional Blood Flow/drug effects
MH  - Renal Artery
MH  - Shock, Septic/*drug therapy/physiopathology
EDAT- 1981/08/15 00:00
MHDA- 1981/08/15 00:01
CRDT- 1981/08/15 00:00
PHST- 1981/08/15 00:00 [pubmed]
PHST- 1981/08/15 00:01 [medline]
PHST- 1981/08/15 00:00 [entrez]
AID - 0002-9378(81)90085-5 [pii]
AID - 10.1016/0002-9378(81)90085-5 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1981 Aug 15;140(8):914-22. doi: 
      10.1016/0002-9378(81)90085-5.

PMID- 36472920
OWN - NLM
STAT- MEDLINE
DCOM- 20230623
LR  - 20230625
IS  - 1532-4303 (Electronic)
IS  - 0277-0903 (Linking)
VI  - 60
IP  - 8
DP  - 2023 Aug
TI  - What happens to basophils and tryptase, LXA(4) and CysLTs during aspirin 
      desensitization?
PG  - 1524-1534
LID - 10.1080/02770903.2022.2156352 [doi]
AB  - INTRODUCTION: Aspirin desensitization (AD) is an effective treatment in patients 
      with non-steroidal anti-inflammatory drugs (NSAID)-exacerbated respiratory 
      disease (NERD) by providing inhibitory effect on symptoms and polyp recurrence. 
      However, limited data is available on how AD works. We aimed to study 
      comprehensively the mechanisms underlying AD by examining basophil activation 
      (CD203c upregulation), mediator-releases of tryptase, CysLT, and LXA(4), and 
      LTB(4) receptor expression for the first 3 months of AD. METHODS: The study was 
      conducted in patients with NERD who underwent AD (group 1: n = 23), patients with 
      NERD who received no desensitization (group 2: n = 22), and healthy volunteers 
      (group 3, n = 13). All participants provided blood samples for flow cytometry 
      studies (CD203c and LTB(4) receptor), and mediator releases (CysLT, LXA(4,) and 
      tryptase) for the relevant time points determined. RESULTS: All baseline 
      parameters of CD203c and LTB(4) receptor expressions, tryptase, CysLT, and LXA(4) 
      releases were similar in each group (p > 0.05). In group 1, CD203c started to be 
      upregulated at the time of reactions during AD, and continued to be high for 
      3 months when compared to controls. All other study parameters were comparable 
      with baseline and at the other time points in each group (p > 0.05). CONCLUSION: 
      Although basophils are active during the first 3 months of AD, no releases of 
      CysLT, tryptase or LXA(4) exist. Therefore, our results suggest that despite 
      active basophils, inhibition of mediators can at least partly explain underlying 
      the mechanism in the first three months of AD.
FAU - Çelik, Gülfem E
AU  - Çelik GE
AUID- ORCID: 0000-0001-8654-513X
AD  - Department of Chest Disease, Division of Immunology and Allergy, Ankara 
      University School of Medicine, Dikimevi/Ankara, Turkey.
FAU - Aydin, Ömür
AU  - Aydin Ö
AUID- ORCID: 0000-0002-3670-1728
AD  - Department of Chest Disease, Division of Immunology and Allergy, Ankara 
      University School of Medicine, Dikimevi/Ankara, Turkey.
FAU - Güloğlu, Deniz
AU  - Güloğlu D
AD  - Division of Pediatric Allergy and Immunology, Ankara University School of 
      Medicine, Dikimevi/Ankara, Turkey.
FAU - Seçil, Derya
AU  - Seçil D
AD  - Department of Chest Disease, Division of Immunology and Allergy, Ankara 
      University School of Medicine, Dikimevi/Ankara, Turkey.
FAU - Melli, Mehmet
AU  - Melli M
AD  - Department of Medical Pharmacology, Ankara University School of Medicine, 
      Dikimevi/Ankara, Turkey.
FAU - Doğu, Figen
AU  - Doğu F
AD  - Division of Pediatric Allergy and Immunology, Ankara University School of 
      Medicine, Dikimevi/Ankara, Turkey.
FAU - Ikinciogullari, Aydan
AU  - Ikinciogullari A
AD  - Division of Pediatric Allergy and Immunology, Ankara University School of 
      Medicine, Dikimevi/Ankara, Turkey.
FAU - Sin, Betül A
AU  - Sin BA
AD  - Department of Chest Disease, Division of Immunology and Allergy, Ankara 
      University School of Medicine, Dikimevi/Ankara, Turkey.
FAU - Demirel, Yavuz
AU  - Demirel Y
AD  - Department of Chest Disease, Division of Immunology and Allergy, Ankara 
      University School of Medicine, Dikimevi/Ankara, Turkey.
FAU - Misirligil, Zeynep
AU  - Misirligil Z
AUID- ORCID: 0000-0003-4624-4599
AD  - Department of Chest Disease, Division of Immunology and Allergy, Ankara 
      University School of Medicine, Dikimevi/Ankara, Turkey.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221230
PL  - England
TA  - J Asthma
JT  - The Journal of asthma : official journal of the Association for the Care of 
      Asthma
JID - 8106454
RN  - EC 3.4.21.59 (Tryptases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Basophils/metabolism
MH  - Tryptases/metabolism/pharmacology
MH  - *Asthma/metabolism
MH  - Desensitization, Immunologic/methods
MH  - Aspirin/adverse effects/metabolism
OTO - NOTNLM
OT  - Aspirin desensitization
OT  - CD203c
OT  - NERD
OT  - basophils
OT  - leukotrienes
EDAT- 2022/12/07 06:00
MHDA- 2023/06/23 06:42
CRDT- 2022/12/06 12:05
PHST- 2023/06/23 06:42 [medline]
PHST- 2022/12/07 06:00 [pubmed]
PHST- 2022/12/06 12:05 [entrez]
AID - 10.1080/02770903.2022.2156352 [doi]
PST - ppublish
SO  - J Asthma. 2023 Aug;60(8):1524-1534. doi: 10.1080/02770903.2022.2156352. Epub 2022 
      Dec 30.

PMID- 33594505
OWN - NLM
STAT- MEDLINE
DCOM- 20210716
LR  - 20220531
IS  - 1432-1262 (Electronic)
IS  - 0179-1958 (Linking)
VI  - 36
IP  - 8
DP  - 2021 Aug
TI  - Does aspirin reduce the incidence, recurrence, and mortality of colorectal 
      cancer? A meta-analysis of randomized clinical trials.
PG  - 1653-1666
LID - 10.1007/s00384-021-03889-8 [doi]
AB  - BACKGROUND: Colorectal cancer (CRC) is the third most common diagnosed cancer and 
      the third leading cause of all cancer deaths in the USA. Some evidences are shown 
      that aspirin can reduce the morbidity and mortality of different cancers, 
      including CRC. Aspirin has become a new focus of cancer prevention and treatment 
      research so far; clinical studies, however, found conflicting conclusions of its 
      anti-cancer characteristics. This study is to summarize the latest evidence of 
      correlation between aspirin use and CRC and/or colorectal adenomas. METHODS: 
      Databases were searched to identify randomized controlled trials (RCTs) in the 
      salvage setting. The pooled relative risk (RR) with 95% confidence interval (CI) 
      was used to estimate the effect of aspirin on colorectal cancer and/or colorectal 
      adenomas. Subgroup analysis and sensitivity analysis were also conducted. 
      RESULTS: The result showed that aspirin use was not associated with incidence of 
      CRC (RR 0.97; 95% CI 0.84-1.12; P = 0.66; I(2) = 34%), aspirin use was found to 
      be associated with reduced recurrence of colorectal adenomas (RR 0.83; 95% CI 
      0.72-0.95; P = 0.006; I(2) = 63%) and reduced mortality of CRC (RR 0.79; 95% CI 
      0.64-0.97; P = 0.02; I(2) = 14%). Subgroup analysis found a statistically 
      significant association in low dose with a pooled RR of 0.85 (95% CI 0.74-0.99; P 
      = 0.03; I(2) = 31%). CONCLUSIONS: This meta-analysis of randomized controlled 
      trial data indicates that aspirin reduces the overall risk of recurrence and 
      mortality of CRC and/or colorectal adenomas. Incidence of CRC was also reduced 
      with low-dose aspirin. The emerging evidence on aspirin's cancer protection role 
      highlights an exciting time for cancer prevention through low-cost interventions. 
      TRIAL REGISTRATION: Clinicaltrials.gov no: CRD42020208852; August 18, 2020; 
      https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020208852 ).
CI  - © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part 
      of Springer Nature.
FAU - Ma, Shaodi
AU  - Ma S
AD  - Department of Epidemiology and Health Statistics, School of Public Health Anhui 
      Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, People's Republic 
      of China.
FAU - Han, Tiantian
AU  - Han T
AD  - Department of Epidemiology and Health Statistics, School of Public Health Anhui 
      Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, People's Republic 
      of China.
FAU - Sun, Chenyu
AU  - Sun C
AUID- ORCID: 0000-0003-3812-3164
AD  - AMITA Health Saint Joseph Hospital Chicago, 2900 N. Lake Shore Drive, Chicago, 
      IL, 60657, USA. drsunchenyu@yeah.net.
FAU - Cheng, Ce
AU  - Cheng C
AD  - The University of Arizona College of Medicine at South Campus, 2800 E Ajo Way, 
      Tucson, AZ, 85713, USA.
FAU - Zhang, Huimei
AU  - Zhang H
AD  - Department of Epidemiology and Health Statistics, School of Public Health Anhui 
      Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, People's Republic 
      of China.
FAU - Qu, Guangbo
AU  - Qu G
AD  - Department of Epidemiology and Health Statistics, School of Public Health Anhui 
      Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, People's Republic 
      of China.
FAU - Bhan, Chandur
AU  - Bhan C
AD  - AMITA Health Saint Joseph Hospital Chicago, 2900 N. Lake Shore Drive, Chicago, 
      IL, 60657, USA.
FAU - Yang, Hongru
AU  - Yang H
AD  - Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Ave, Boston, 
      MA, 02115, USA.
FAU - Guo, Zhichun
AU  - Guo Z
AD  - Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Ave, Boston, 
      MA, 02115, USA.
FAU - Yan, Yue
AU  - Yan Y
AD  - Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Ave, Boston, 
      MA, 02115, USA.
FAU - Cao, Chenyu
AU  - Cao C
AD  - Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Ave, Boston, 
      MA, 02115, USA.
FAU - Ji, Ziwei
AU  - Ji Z
AD  - Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Ave, Boston, 
      MA, 02115, USA.
FAU - Zhou, Qin
AU  - Zhou Q
AD  - Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210216
PL  - Germany
TA  - Int J Colorectal Dis
JT  - International journal of colorectal disease
JID - 8607899
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - *Aspirin/therapeutic use
MH  - *Colorectal Neoplasms/drug therapy/epidemiology/prevention & control
MH  - Humans
MH  - Incidence
MH  - Neoplasm Recurrence, Local/epidemiology/prevention & control
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Aspirin
OT  - Bleed
OT  - Colorectal cancer
OT  - Meta-analysis
OT  - Non-steroidal anti-inflammatory drugs (NSAIDs)
OT  - RCT
EDAT- 2021/02/18 06:00
MHDA- 2021/07/17 06:00
CRDT- 2021/02/17 05:58
PHST- 2021/02/09 00:00 [accepted]
PHST- 2021/02/18 06:00 [pubmed]
PHST- 2021/07/17 06:00 [medline]
PHST- 2021/02/17 05:58 [entrez]
AID - 10.1007/s00384-021-03889-8 [pii]
AID - 10.1007/s00384-021-03889-8 [doi]
PST - ppublish
SO  - Int J Colorectal Dis. 2021 Aug;36(8):1653-1666. doi: 10.1007/s00384-021-03889-8. 
      Epub 2021 Feb 16.

PMID- 26504148
OWN - NLM
STAT- MEDLINE
DCOM- 20160707
LR  - 20220310
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 4
IP  - 10
DP  - 2015 Oct 26
TI  - Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study.
PG  - e002203
LID - 10.1161/JAHA.115.002203 [doi]
LID - e002203
AB  - BACKGROUND: While aspirin is a well-established and generally effective 
      anti-platelet agent, considerable inter-individual variation in drug response 
      exists, for which mechanisms are not completely understood. Metabolomics allows 
      for extensive measurement of small molecules in biological samples, enabling 
      detailed mapping of pathways involved in drug response. METHODS AND RESULTS: We 
      used a mass-spectrometry-based metabolomics platform to investigate the changes 
      in the serum oxylipid metabolome induced by an aspirin intervention (14 days, 81 
      mg/day) in healthy subjects (n=156). We observed a global decrease in serum 
      oxylipids in response to aspirin (25 metabolites decreased out of 30 measured) 
      regardless of sex. This decrease was concomitant with a significant decrease in 
      serum linoleic acid levels (-19%, P=1.3×10(-5)), one of the main precursors for 
      oxylipid synthesis. Interestingly, several linoleic acid-derived oxylipids were 
      not significantly associated with arachidonic-induced ex vivo platelet 
      aggregation, a widely accepted marker of aspirin response, but were significantly 
      correlated with platelet reactivity in response to collagen. CONCLUSIONS: 
      Together, these results suggest that linoleic acid-derived oxylipids may 
      contribute to the non-COX1 mediated variability in response to aspirin. 
      Pharmacometabolomics allowed for more comprehensive interrogation of mechanisms 
      of action of low dose aspirin and of variation in aspirin response.
CI  - © 2015 The Authors. Published on behalf of the American Heart Association, Inc., 
      by Wiley Blackwell.
FAU - Ellero-Simatos, Sandrine
AU  - Ellero-Simatos S
AD  - Analytical Biosciences Division, Leiden Academic Centre for Drug Research, 
      Leiden, The Netherlands (S.E.S., A.D., A.C.H., K.S., F.G., M.B.H., T.H.) 
      Netherlands Metabolomics Centre, Leiden, The Netherlands (S.E.S., A.D., A.C.H., 
      K.S., F.G., M.B.H., T.H.).
FAU - Beitelshees, Amber L
AU  - Beitelshees AL
AD  - Program Personalized and Genomic Medicine, Division of Endocrinology, Diabetes, 
      and Nutrition, Department of Medicine, University of Maryland School of Medicine, 
      Baltimore, MD (A.L.B., J.P.L., L.M.Y.A., R.B.H., A.R.S.).
FAU - Lewis, Joshua P
AU  - Lewis JP
AD  - Program Personalized and Genomic Medicine, Division of Endocrinology, Diabetes, 
      and Nutrition, Department of Medicine, University of Maryland School of Medicine, 
      Baltimore, MD (A.L.B., J.P.L., L.M.Y.A., R.B.H., A.R.S.).
FAU - Yerges-Armstrong, Laura M
AU  - Yerges-Armstrong LM
AD  - Program Personalized and Genomic Medicine, Division of Endocrinology, Diabetes, 
      and Nutrition, Department of Medicine, University of Maryland School of Medicine, 
      Baltimore, MD (A.L.B., J.P.L., L.M.Y.A., R.B.H., A.R.S.).
FAU - Georgiades, Anastasia
AU  - Georgiades A
AD  - Duke University Medical Center, Durham, NC (A.G., R.K.D.).
FAU - Dane, Adrie
AU  - Dane A
AD  - Analytical Biosciences Division, Leiden Academic Centre for Drug Research, 
      Leiden, The Netherlands (S.E.S., A.D., A.C.H., K.S., F.G., M.B.H., T.H.) 
      Netherlands Metabolomics Centre, Leiden, The Netherlands (S.E.S., A.D., A.C.H., 
      K.S., F.G., M.B.H., T.H.).
FAU - Harms, Amy C
AU  - Harms AC
AD  - Analytical Biosciences Division, Leiden Academic Centre for Drug Research, 
      Leiden, The Netherlands (S.E.S., A.D., A.C.H., K.S., F.G., M.B.H., T.H.) 
      Netherlands Metabolomics Centre, Leiden, The Netherlands (S.E.S., A.D., A.C.H., 
      K.S., F.G., M.B.H., T.H.).
FAU - Strassburg, Katrin
AU  - Strassburg K
AD  - Analytical Biosciences Division, Leiden Academic Centre for Drug Research, 
      Leiden, The Netherlands (S.E.S., A.D., A.C.H., K.S., F.G., M.B.H., T.H.) 
      Netherlands Metabolomics Centre, Leiden, The Netherlands (S.E.S., A.D., A.C.H., 
      K.S., F.G., M.B.H., T.H.).
FAU - Guled, Faisa
AU  - Guled F
AD  - Analytical Biosciences Division, Leiden Academic Centre for Drug Research, 
      Leiden, The Netherlands (S.E.S., A.D., A.C.H., K.S., F.G., M.B.H., T.H.) 
      Netherlands Metabolomics Centre, Leiden, The Netherlands (S.E.S., A.D., A.C.H., 
      K.S., F.G., M.B.H., T.H.).
FAU - Hendriks, Margriet M W B
AU  - Hendriks MM
AD  - Analytical Biosciences Division, Leiden Academic Centre for Drug Research, 
      Leiden, The Netherlands (S.E.S., A.D., A.C.H., K.S., F.G., M.B.H., T.H.) 
      Netherlands Metabolomics Centre, Leiden, The Netherlands (S.E.S., A.D., A.C.H., 
      K.S., F.G., M.B.H., T.H.).
FAU - Horenstein, Richard B
AU  - Horenstein RB
AD  - Program Personalized and Genomic Medicine, Division of Endocrinology, Diabetes, 
      and Nutrition, Department of Medicine, University of Maryland School of Medicine, 
      Baltimore, MD (A.L.B., J.P.L., L.M.Y.A., R.B.H., A.R.S.).
FAU - Shuldiner, Alan R
AU  - Shuldiner AR
AD  - Program Personalized and Genomic Medicine, Division of Endocrinology, Diabetes, 
      and Nutrition, Department of Medicine, University of Maryland School of Medicine, 
      Baltimore, MD (A.L.B., J.P.L., L.M.Y.A., R.B.H., A.R.S.).
FAU - Hankemeier, Thomas
AU  - Hankemeier T
AD  - Analytical Biosciences Division, Leiden Academic Centre for Drug Research, 
      Leiden, The Netherlands (S.E.S., A.D., A.C.H., K.S., F.G., M.B.H., T.H.) 
      Netherlands Metabolomics Centre, Leiden, The Netherlands (S.E.S., A.D., A.C.H., 
      K.S., F.G., M.B.H., T.H.).
FAU - Kaddurah-Daouk, Rima
AU  - Kaddurah-Daouk R
AD  - Duke University Medical Center, Durham, NC (A.G., R.K.D.) Department of 
      Psychiatry and Behavioral Sciences, Duke University, Durham, NC (R.K.D.) Duke 
      Institute for Brain Sciences, Duke University, Durham, NC (R.K.D.) Institute of 
      Genome Science and Policy, Durham, NC (R.K.D.).
CN  - Pharmacometabolomics Research Network
LA  - eng
GR  - P30 NR014129/NR/NINR NIH HHS/United States
GR  - U01 HL105198/HL/NHLBI NIH HHS/United States
GR  - K23-HL091120/HL/NHLBI NIH HHS/United States
GR  - P30-DK072488/DK/NIDDK NIH HHS/United States
GR  - M01 RR002719/RR/NCRR NIH HHS/United States
GR  - RC2GM092729/GM/NIGMS NIH HHS/United States
GR  - P30 DK072488/DK/NIDDK NIH HHS/United States
GR  - M01-RR-000052/RR/NCRR NIH HHS/United States
GR  - K23-GM102678/GM/NIGMS NIH HHS/United States
GR  - K23 GM102678/GM/NIGMS NIH HHS/United States
GR  - M01-RR-16500/RR/NCRR NIH HHS/United States
GR  - U01-HL72515/HL/NHLBI NIH HHS/United States
GR  - K01-HL116770/HL/NHLBI NIH HHS/United States
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, American Recovery and Reinvestment Act
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151026
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Biomarkers)
RN  - 0 (Lipids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9KJL21T0QJ (Linoleic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Amish
MH  - Aspirin/*administration & dosage/blood/*pharmacokinetics
MH  - Biomarkers/blood
MH  - Drug Administration Schedule
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Linoleic Acid/blood
MH  - Lipids/*blood
MH  - Male
MH  - Mass Spectrometry
MH  - Metabolomics/methods
MH  - Middle Aged
MH  - Oxidation-Reduction
MH  - Platelet Aggregation Inhibitors/*administration & dosage/blood/*pharmacokinetics
MH  - Platelet Function Tests
PMC - PMC4845113
OTO - NOTNLM
OT  - aspirin
OT  - drugs
OT  - fatty acids
OT  - lipids
OT  - pharmacology
OT  - platelets
EDAT- 2015/10/28 06:00
MHDA- 2016/07/09 06:00
CRDT- 2015/10/28 06:00
PHST- 2015/10/28 06:00 [entrez]
PHST- 2015/10/28 06:00 [pubmed]
PHST- 2016/07/09 06:00 [medline]
AID - JAHA.115.002203 [pii]
AID - JAH31161 [pii]
AID - 10.1161/JAHA.115.002203 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2015 Oct 26;4(10):e002203. doi: 10.1161/JAHA.115.002203.

PMID- 22710855
OWN - NLM
STAT- MEDLINE
DCOM- 20121128
LR  - 20131121
IS  - 1421-9786 (Electronic)
IS  - 1015-9770 (Linking)
VI  - 33
IP  - 6
DP  - 2012
TI  - Laboratory effect on platelet activity within 24 h of the first 300-mg oral dose 
      of aspirin given in hospital during the acute phase of ischemic cerebral events.
PG  - 574-8
LID - 10.1159/000338291 [doi]
AB  - BACKGROUND AND PURPOSE: Aspirin is the most commonly used antiplatelet treatment 
      during the acute phase of cerebral ischemic events. It inhibits the production of 
      thromboxane (TX) A(2), a powerful platelet activator. Despite this protection, 
      early ischemic recurrences are frequent and considered clinical failures of this 
      therapy. Only a few trials have focused on the use of antiplatelet therapy during 
      this phase, and none has described the laboratory effect of the first dose of 
      aspirin given after an ischemic cerebral event. However, this study may help 
      clinicians to understand the mechanisms of early recurrences, and to design new 
      therapeutic strategies, in particular for patients already treated with a daily 
      dose of aspirin. METHOD: We studied laboratory parameters of the first 300-mg 
      oral dose of aspirin given within 48 h after an ischemic cerebral event. Two 
      blood samples were taken from all of the patients: the first during the third 
      hour following aspirin intake (T1) and the second during the twenty-fourth hour 
      (T2). For patients already treated with a daily dose of aspirin, a supplementary 
      sample was taken before aspirin intake (T0). Platelet reactivity was studied on 
      the basis of serum TXB(2) levels, a metabolite of TXA(2), and light transmission 
      aggregometry after stimulation of platelet-rich plasma by arachidonic acid and by 
      two concentrations of collagen, i.e. 2 µg/ml (Col2), dependent on the TXA(2) 
      pathway, and 20 µg/ml (Col20), independent of the TXA(2) pathway. Results with 
      Col2 were related to results with Col20 (Col2/20 ratio) to limit the impact of 
      variations induced by the effects of preanalytical conditions. RESULTS: Fifty 
      patients were included. TXB(2) values (p < 0.001) and relative values of the 
      Col2/20 ratio (p = 0.037) were significantly higher at T2 compared to T1. For 
      patients already treated with aspirin, TXB(2) levels (p < 0.001) were 
      significantly lower at T1 compared to T0, and the Col2/20 ratio tended to 
      decrease (p = 0.096). CONCLUSION: Platelet reactivity recovers within 24 h 
      following the first 300-mg oral dose of aspirin during the acute phase of a 
      cerebral ischemic event as demonstrated by an increase in TXB(2) levels, and the 
      Col2/20 ratio, at T2 compared to T1. This would favor early ischemic recurrences. 
      However, for patients already treated with aspirin, this dose is able to decrease 
      TXB(2) levels and to complete the inhibition of the TXA(2) pathway, which shows 
      the utility of this prescription in this case.
CI  - Copyright © 2012 S. Karger AG, Basel.
FAU - Richard, S
AU  - Richard S
AD  - CHU Nancy, Service de Neurologie, Hopital Central, Nancy, France. 
      s.richard@chu-nancy.fr
FAU - Toussaint-Hacquard, M
AU  - Toussaint-Hacquard M
FAU - Fay, R
AU  - Fay R
FAU - Lacour, J C
AU  - Lacour JC
FAU - Ducrocq, X
AU  - Ducrocq X
FAU - Lecompte, T
AU  - Lecompte T
LA  - eng
PT  - Journal Article
DEP - 20120615
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Cerebrovasc Dis. 2012;33(6):579. PMID: 22710938
MH  - Acute Disease
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Brain Ischemia/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Thromboxanes/biosynthesis
MH  - Time Factors
EDAT- 2012/06/20 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/06/20 06:00
PHST- 2012/01/26 00:00 [received]
PHST- 2012/03/16 00:00 [accepted]
PHST- 2012/06/20 06:00 [entrez]
PHST- 2012/06/20 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 000338291 [pii]
AID - 10.1159/000338291 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2012;33(6):574-8. doi: 10.1159/000338291. Epub 2012 Jun 15.

PMID- 3210286
OWN - NLM
STAT- MEDLINE
DCOM- 19890222
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 260
IP  - 23
DP  - 1988 Dec 16
TI  - Spicy food and the stomach. Evaluation by videoendoscopy.
PG  - 3473-5
AB  - We used videoendoscopy to investigate the effect of eating spicy foods on the 
      gastric mucosa. We employed four meals: a bland meal of unpeppered steak and 
      french fries (negative control), a bland meal with 1950 mg of aspirin (positive 
      control), a spicy Mexican meal (30 g of jalapeño peppers), and a pepperoni pizza. 
      Twelve subjects (eight men and four women, aged 24 to 43 years) were studied in a 
      randomized, crossover trial with the test meal given at the noon and evening 
      meals; each subject received all four test meals. Each study consisted of a 
      baseline endoscopy, which was repeated approximately 12 hours after the last test 
      meal. Gastric and duodenal damage was scored using a modification of the Lanza 
      scale. Eleven of 12 individuals taking the bland meal plus aspirin developed 
      multiple gastric erosions (median score, C; which equates with "severe" injury). 
      In contrast, the median endoscopic score for the other three meals was 0. Single 
      cases of a single erosion were present after the Mexican meals and after the 
      pizza meals. Another experiment was done to examine the effect of spices directly 
      on the gastric mucosa; approximately 30 g of fresh jalapeño peppers was ground in 
      a food processor and then placed directly into the stomach. Endoscopy after 24 
      hours revealed no visible mucosal damage. The ingestion of highly spiced meals by 
      normal individuals is not associated with endoscopically demonstrable 
      gastroduodenal mucosal damage.
FAU - Graham, D Y
AU  - Graham DY
AD  - Digestive Disease Section, Veterans Administration Medical Center, Houston, TX 
      77030.
FAU - Smith, J L
AU  - Smith JL
FAU - Opekun, A R
AU  - Opekun AR
LA  - eng
GR  - RR-00350/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
RN  - S07O44R1ZM (Capsaicin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacology
MH  - Capsaicin/pharmacology
MH  - Computer Systems
MH  - Condiments/*adverse effects
MH  - Female
MH  - Food
MH  - *Gastric Mucosa/drug effects
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Random Allocation
EDAT- 1988/12/16 00:00
MHDA- 1988/12/16 00:01
CRDT- 1988/12/16 00:00
PHST- 1988/12/16 00:00 [pubmed]
PHST- 1988/12/16 00:01 [medline]
PHST- 1988/12/16 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1988 Dec 16;260(23):3473-5.

PMID- 24207016
OWN - NLM
STAT- MEDLINE
DCOM- 20150414
LR  - 20140424
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 133
IP  - 5
DP  - 2014 May
TI  - Evaluation of laboratory methods routinely used to detect the effect of aspirin 
      against new reference methods.
PG  - 811-6
LID - S0049-3848(13)00478-7 [pii]
LID - 10.1016/j.thromres.2013.10.008 [doi]
AB  - BACKGROUND: Aspirin, a commonly used antiplatelet agent, blocks platelet 
      thromboxane A₂ (TXA₂) formation from arachidonic acid (AA) by acetylating 
      platelet cyclooxygenase-1 (COX-1). Laboratory methods currently used to detect 
      this antiplatelet effect of aspirin provide variable results. We have reported 
      three methods that assess platelet COX-1 acetylation (inactivation) by aspirin 
      and its direct consequences. The first and second assays use monoclonal 
      anti-human-COX-1 antibodies that only detect acetylated (inactivated) COX-1 and 
      active (non-acetylated) COX-1, respectively. The third method measures platelet 
      production of TXB₂ (the stable metabolite of TXA₂) in vitro in response to AA. We 
      compared the results of these three reference methods with other routinely used 
      methods for assessing the functional consequences aspirin treatment. METHODS: 108 
      healthy volunteers were treated with low-dose aspirin for 7 days. On day 7 
      following aspirin treatment COX-1 in the platelets was fully acetylated whereas 
      only non-acetylated COX-1 was present in the day 0 platelets. Further, TXB2 
      production by day 7 platelets was completely blocked. The following tests were 
      performed on the samples obtained from study participants before and after seven 
      days of aspirin treatment: PFA-100 closure time with collagen/epinephrine 
      cartridge, VerifyNow (VN) Aspirin Assay, platelet aggregation and ATP secretion 
      using AA, ADP, epinephrine and collagen as agonists. RESULTS: Comparing the 
      pre-treatment and day 7 values, methods that use AA as platelet agonist 
      (AA-induced platelet aggregation/secretion and VN Aspirin Assay) showed high 
      discriminative power. In contrast, results of the other tests showed considerable 
      overlap between day 7 and day 0 values. CONCLUSIONS: Only assays that clearly 
      distinguish between acetylated and non-acetylated platelet COX-1 are useful for 
      establishing the antiplatelet effect of aspirin. The other tests are not suitable 
      for this purpose.
CI  - © 2013. Published by Elsevier Ltd. All rights reserved.
FAU - Kovács, Emese G
AU  - Kovács EG
AD  - Clinical Research Center, University of Debrecen, Medical and Health Science 
      Center, Debrecen, Hungary.
FAU - Katona, Éva
AU  - Katona É
AD  - Clinical Research Center, University of Debrecen, Medical and Health Science 
      Center, Debrecen, Hungary.
FAU - Bereczky, Zsuzsanna
AU  - Bereczky Z
AD  - Clinical Research Center, University of Debrecen, Medical and Health Science 
      Center, Debrecen, Hungary.
FAU - Homoródi, Nóra
AU  - Homoródi N
AD  - Institute of Cardiology, University of Debrecen, Medical and Health Science 
      Center, Debrecen, Hungary.
FAU - Balogh, László
AU  - Balogh L
AD  - Institute of Cardiology, University of Debrecen, Medical and Health Science 
      Center, Debrecen, Hungary.
FAU - Tóth, Eszter
AU  - Tóth E
AD  - Clinical Research Center, University of Debrecen, Medical and Health Science 
      Center, Debrecen, Hungary.
FAU - Péterfy, Hajna
AU  - Péterfy H
AD  - Diagnosticum Co., Research Laboratory, Budapest, Hungary.
FAU - Kiss, Róbert G
AU  - Kiss RG
AD  - State Health Center, Department of Cardiology, Budapest, Hungary.
FAU - Édes, István
AU  - Édes I
AD  - Institute of Cardiology, University of Debrecen, Medical and Health Science 
      Center, Debrecen, Hungary.
FAU - Muszbek, László
AU  - Muszbek L
AD  - Clinical Research Center, University of Debrecen, Medical and Health Science 
      Center, Debrecen, Hungary; Thrombosis, Haemostasis and Vascular Biology Research 
      Group of the Hungarian Academy of Sciences, University of Debrecen, Debrecen, 
      Hungary. Electronic address: muszbek@med.unideb.hu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131016
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Thromb Res. 2014 May;133(5):697-8. PMID: 24315499
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/drug effects/enzymology
MH  - Cyclooxygenase 1/blood
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Laboratories, Hospital
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Reference Values
MH  - Young Adult
OTO - NOTNLM
OT  - aspirin
OT  - aspirin resistance
OT  - platelet aggregation
OT  - platelet secretion
OT  - reference method
OT  - thromboxane
EDAT- 2013/11/12 06:00
MHDA- 2015/04/15 06:00
CRDT- 2013/11/12 06:00
PHST- 2013/07/19 00:00 [received]
PHST- 2013/10/01 00:00 [revised]
PHST- 2013/10/01 00:00 [accepted]
PHST- 2013/11/12 06:00 [entrez]
PHST- 2013/11/12 06:00 [pubmed]
PHST- 2015/04/15 06:00 [medline]
AID - S0049-3848(13)00478-7 [pii]
AID - 10.1016/j.thromres.2013.10.008 [doi]
PST - ppublish
SO  - Thromb Res. 2014 May;133(5):811-6. doi: 10.1016/j.thromres.2013.10.008. Epub 2013 
      Oct 16.

PMID- 7483055
OWN - NLM
STAT- MEDLINE
DCOM- 19951214
LR  - 20131121
IS  - 0041-5782 (Print)
IS  - 0041-5782 (Linking)
VI  - 157
IP  - 39
DP  - 1995 Sep 25
TI  - [Acute pancreatitis--induced by 5-aminosalicylic acid or an extraintestinal 
      manifestation of ulcerative colitis?].
PG  - 5400-1
AB  - 5-aminosalicylic acid has been reported to cause acute pancreatitis. We report 
      the first Scandinavian case. A 27 year-old woman with a three month history of 
      ulcerative colitis treated with Mesalazine developed acute abdominal pain. Serum 
      and urine amylase were raised, and ultrasonographic and computed tomography scan 
      showed oedema of the pancreas. Immediately following withdrawal of the drug, 
      serum and urine amylase returned to normal. We discuss the possibility of acute 
      pancreatitis as an extraintestinal manifestation of ulcerative colitis.
FAU - Petersen, H H
AU  - Petersen HH
AD  - Medicinsk afdeling, Amtssygehuset Skt. Elisabeth, København.
FAU - Skovbjerg, H
AU  - Skovbjerg H
LA  - dan
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Akut pancreatitis--induceret af 5-aminosalicylsyre eller en ekstraintestinal 
      manifestation ved colitis ulcerosa?
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Colitis, Ulcerative/*complications/diagnosis/drug therapy
MH  - Female
MH  - Humans
MH  - Pancreatitis/chemically induced/diagnosis/*etiology
EDAT- 1995/09/25 00:00
MHDA- 1995/09/25 00:01
CRDT- 1995/09/25 00:00
PHST- 1995/09/25 00:00 [pubmed]
PHST- 1995/09/25 00:01 [medline]
PHST- 1995/09/25 00:00 [entrez]
PST - ppublish
SO  - Ugeskr Laeger. 1995 Sep 25;157(39):5400-1.

PMID- 6432325
OWN - NLM
STAT- MEDLINE
DCOM- 19841016
LR  - 20161123
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 6
IP  - 4
DP  - 1984
TI  - Intravenous ketoprofen in renal colic: a placebo-controlled pilot study.
PG  - 483-7
AB  - In a double-blind trial 30 patients with renal colic were allocated at random to 
      receive 200 mg of ketoprofen, 1 gm of lysine acetylsalicylate, or placebo by 
      intravenous bolus injection. The patients were asked to rate their pain at 
      intervals within three hours of injection and to indicate on a visual analogue 
      scale the overall pain relief obtained. Both ketoprofen and lysine 
      acetylsalicylate proved significantly more effective than placebo, with no 
      apparent difference between them. Complete relief of pain was obtained in seven 
      of ten patients in each of the active treatment groups compared with only one of 
      ten patients given placebo. No untoward events were observed in any patient.
FAU - Magrini, M
AU  - Magrini M
FAU - Pavesi, G
AU  - Pavesi G
FAU - Liverta, C
AU  - Liverta C
FAU - Bruni, G
AU  - Bruni G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Analgesics)
RN  - 0 (Phenylpropionates)
RN  - 90Y4QC304K (Ketoprofen)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analgesics/therapeutic use
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Clinical Trials as Topic
MH  - Colic/*drug therapy
MH  - Female
MH  - Humans
MH  - Ketoprofen/*therapeutic use
MH  - Kidney Diseases/*drug therapy
MH  - Lysine/analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Phenylpropionates/*therapeutic use
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1984;6(4):483-7.

PMID- 380253
OWN - NLM
STAT- MEDLINE
DCOM- 19790925
LR  - 20191028
IS  - 0300-8835 (Print)
IS  - 0300-8835 (Linking)
VI  - 87
DP  - 1979
TI  - Effect of acetylsalicylic acid, paracetamol and placebo on pain and blood loss in 
      dysmenorrheic women.
PG  - 81-5
AB  - The analgesic effect of paracetamol, acetyl-salicylic acid, and placebo on 
      dysmenorrhea were compared in a double-blind cross-over study of 30 women. There 
      was a moderate placebo effect, but no significant difference was found between 
      the three treatments. Blood loss was also measured and it did not vary, with the 
      type of drug ingested. It is concluded that paracetamol and acetylsalicylic acid 
      in the doses used (0.5 g x 4 for 3 days) were not effective against heavy 
      dysmenorrhea, and that none of the drugs influenced the amount of blood lost.
FAU - Janbu, T
AU  - Janbu T
FAU - Løkken, P
AU  - Løkken P
FAU - Nesheim, B I
AU  - Nesheim BI
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Denmark
TA  - Acta Obstet Gynecol Scand Suppl
JT  - Acta obstetricia et gynecologica Scandinavica. Supplement
JID - 0337655
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/*therapeutic use
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Specimen Collection
MH  - Blood Volume
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Dysmenorrhea/*drug therapy
MH  - Female
MH  - Humans
MH  - Menstruation
MH  - Placebos
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.3109/00016347909157796 [doi]
PST - ppublish
SO  - Acta Obstet Gynecol Scand Suppl. 1979;87:81-5. doi: 10.3109/00016347909157796.

PMID- 343226
OWN - NLM
STAT- MEDLINE
DCOM- 19780417
LR  - 20190814
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 12
IP  - 8
DP  - 1977
TI  - Gastric mucosal damage caused by plain and microencapsulated acetylsalicylic acid 
      tablets in healthy subjects: a gastrocamera study.
PG  - 989-92
AB  - In a randomized, cross-over study plain acetylsalicylic acid (ASA) tablet and 
      microencapsulated ASA tablets were given in doses of 1 gram 3 times a day for 3 
      days to 8 healthy subjects with no previous gastrointestinal disturbances. 
      Gastrocamera examinations were performed before the ASA treatment and 1--2 hours 
      after the last dose of ASA. The gastric mucosa appeared macroscopically normal at 
      all the control examinations; whereas musocal bleeding was evident in all the 
      subjects after the ASA treatment. There was no statistically significant 
      difference between the plain ASA and the microencapsulated ASA preparations. No 
      correlation could be found between the ASA concentration in plasma and the 
      gastric mucosal damage.
FAU - Rutlin, E
AU  - Rutlin E
FAU - Berstad, A
AU  - Berstad A
FAU - Refsum, N
AU  - Refsum N
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clinical Trials as Topic
MH  - Female
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Photography
MH  - Tablets
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.3109/00365527709181362 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 1977;12(8):989-92. doi: 10.3109/00365527709181362.

PMID- 34644796
OWN - NLM
STAT- MEDLINE
DCOM- 20220118
LR  - 20220118
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 146
IP  - 20
DP  - 2021 Oct
TI  - [Aspirin in primary prevention of cardiovascular and cerebrovascular diseases].
PG  - 1353-1359
LID - 10.1055/a-1578-6802 [doi]
AB  - Acetylsalicylic acid (aspirin) is one of the most used medications worldwide. The 
      antithrombotic agent acts mainly through inhibition of cyclooxygenase-1 and 
      consequently thromboxane A(2) synthesis, causing an irreversible suppression of 
      platelet function. Despite of its proven benefit in the treatment and secondary 
      prevention of atherosclerotic diseases, its use for the primary prevention 
      remains controversial due to an unclear balance between the benefits and risks of 
      aspirin. Moreover, the recent evidence indicates that the risk of major bleeding 
      outweighs the potential to reduce ischemic events in patients without 
      atherosclerotic diseases, thus, precluding the general use of aspirin for the 
      primary prevention.
CI  - Thieme. All rights reserved.
FAU - Gassanov, Natig
AU  - Gassanov N
AD  - Medizinische Klinik II, Klinikum Idar-Oberstein, Idar-Oberstein.
FAU - Eicke, Martin
AU  - Eicke M
AD  - Klinik für Neurologie, Klinikum Idar-Oberstein, Idar-Oberstein.
FAU - Er, Fikret
AU  - Er F
AD  - Klinik I für Innere Medizin, Klinikum Gütersloh, Gütersloh.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Stellenwert der ASS-Therapie in der kardio- und zerebrovaskulären Prävention.
DEP - 20211013
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics/*therapeutic use
MH  - Aspirin/pharmacokinetics/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Humans
MH  - Primary Prevention/methods
MH  - Risk Factors
COIS- Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2021/10/14 06:00
MHDA- 2022/01/19 06:00
CRDT- 2021/10/13 20:13
PHST- 2021/10/13 20:13 [entrez]
PHST- 2021/10/14 06:00 [pubmed]
PHST- 2022/01/19 06:00 [medline]
AID - 10.1055/a-1578-6802 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2021 Oct;146(20):1353-1359. doi: 10.1055/a-1578-6802. Epub 
      2021 Oct 13.

PMID- 6223699
OWN - NLM
STAT- MEDLINE
DCOM- 19830923
LR  - 20131121
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 5
IP  - 4
DP  - 1983
TI  - Twelve-week study of etodolac, aspirin, and placebo in patients with rheumatoid 
      arthritis.
PG  - 436-44
AB  - Etodolac, aspirin, and placebo were evaluated for efficacy and safety in 20 
      patients with adult-onset active rheumatoid arthritis who entered a 12-week, 
      double-blind, parallel-group study divided into drug titration and maintenance 
      periods and preceded by a two-week washout period. During the maintenance period 
      the mean daily doses of etodolac and aspirin were 319 mg and 4,701 mg, 
      respectively. At the end of the study, patients treated with etodolac showed 
      significant improvement from baseline values in seven of ten clinical variables, 
      namely, painful joints, swollen joints, articular index, pain intensity, morning 
      stiffness, and investigator's and patient's overall assessments. In patients 
      treated with aspirin, only pain intensity was lessened significantly; in those 
      treated with placebo, only pain intensity lessened significantly and only the 
      patient's overall assessment improved significantly. No serious side effects were 
      noted in patients treated with etodolac. Three patients treated with aspirin were 
      withdrawn from the study because of adverse reactions--two experienced 
      gastrointestinal side effects and one had elevated liver enzyme levels.
FAU - del Toro, R A
AU  - del Toro RA
FAU - Concepción, R
AU  - Concepción R
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Acetates)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 2M36281008 (Etodolac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/adverse effects/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Etodolac
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1983;5(4):436-44.

PMID- 3680601
OWN - NLM
STAT- MEDLINE
DCOM- 19880111
LR  - 20131121
IS  - 0271-0749 (Print)
IS  - 0271-0749 (Linking)
VI  - 7
IP  - 5
DP  - 1987 Oct
TI  - The effects of caffeine and aspirin on mood and performance.
PG  - 315-20
AB  - Caffeine, in addition to being a food constituent, is also a common analgesic 
      adjuvant that is used in combination with aspirin in certain over-the-counter 
      preparations. Caffeine has previously been shown to significantly improve certain 
      aspects of human performance, particularly sustained vigilance, when administered 
      in low and moderate doses (32 to 256 mg). We therefore attempted to determine 
      whether caffeine, in the dose (64 mg) found in some over-the-counter drugs, 
      retains this beneficial property when combined with aspirin. We also measured 
      self-reported mood state, using various standardized questionnaires, since 
      caffeine has been reported to have both beneficial and adverse effects on 
      alertness and anxiety. We observed that caffeine (64 mg), when added to aspirin 
      (800 mg), significantly improves vigilance performance and increases 
      self-reported efficiency when compared with either placebo or aspirin alone. As 
      previously reported, this caffeine dose alone significantly increased vigilance 
      and decreased reaction time. No adverse effects of caffeine were detected on any 
      of the parameters that were assessed. This study therefore demonstrated that the 
      addition of caffeine to aspirin, in a dose commonly employed in over-the-counter 
      drugs, has significant beneficial consequences with respect to mood and 
      performance.
FAU - Lieberman, H R
AU  - Lieberman HR
AD  - Department of Brain and Cognitive Sciences, Massachusetts Institute of 
      Technology, Cambridge 02139.
FAU - Wurtman, R J
AU  - Wurtman RJ
FAU - Emde, G G
AU  - Emde GG
FAU - Coviella, I L
AU  - Coviella IL
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Drug Combinations)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Arousal/drug effects
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Caffeine/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Emotions/*drug effects
MH  - Humans
MH  - Male
MH  - Psychomotor Performance/*drug effects
MH  - Reaction Time/drug effects
OID - NASA: 88059794
EDAT- 1987/10/01 00:00
MHDA- 1987/10/01 00:01
CRDT- 1987/10/01 00:00
PHST- 1987/10/01 00:00 [pubmed]
PHST- 1987/10/01 00:01 [medline]
PHST- 1987/10/01 00:00 [entrez]
PST - ppublish
SO  - J Clin Psychopharmacol. 1987 Oct;7(5):315-20.

PMID- 782463
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20190717
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 19
IP  - 4
DP  - 1976 Jul-Aug
TI  - Combination therapy with naproxen and aspirin in rheumatoid arthritis.
PG  - 677-82
AB  - Thirty-six patients with rheumatoid arthritis were studied to determine the 
      effectiveness and safety of combined therapy with naproxen and aspirin. An 8-week 
      double-blind crossover trial was performed in which naproxen and placebo were 
      administered on a background of constant-dose aspirin. Combination therapy was 
      demonstrated to be more effective than aspirin alone. Tolerance of the two 
      regimens was comparable.
FAU - Willkens, R F
AU  - Willkens RF
FAU - Segre, E J
AU  - Segre EJ
LA  - eng
PT  - Case Reports
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Naphthaleneacetic Acids)
RN  - 0 (Placebos)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naphthaleneacetic Acids/*therapeutic use
MH  - Naproxen/adverse effects/*therapeutic use
MH  - Placebos
EDAT- 1976/07/01 00:00
MHDA- 1976/07/01 00:01
CRDT- 1976/07/01 00:00
PHST- 1976/07/01 00:00 [pubmed]
PHST- 1976/07/01 00:01 [medline]
PHST- 1976/07/01 00:00 [entrez]
AID - 10.1002/1529-0131(197607/08)19:4<677::aid-art1780190404>3.0.co;2-a [doi]
PST - ppublish
SO  - Arthritis Rheum. 1976 Jul-Aug;19(4):677-82. doi: 
      10.1002/1529-0131(197607/08)19:4<677::aid-art1780190404>3.0.co;2-a.

PMID- 25710565
OWN - NLM
STAT- MEDLINE
DCOM- 20150930
LR  - 20181113
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 100
IP  - 5
DP  - 2015 May
TI  - Preconception low dose aspirin and time to pregnancy: findings from the effects 
      of aspirin in gestation and reproduction randomized trial.
PG  - 1785-91
LID - 10.1210/jc.2014-4179 [doi]
AB  - OBJECTIVE: The objective was to determine the effect of preconception-initiated 
      daily low-dose aspirin (LDA; 81 mg/day) treatment on time to pregnancy in women 
      with a history of pregnancy loss. DESIGN: This was a multicenter, 
      block-randomized, double-blind, placebo-controlled trial. Participants were 
      block-randomized by center and eligibility stratum. SETTING: The study was 
      conducted at four U.S.A. medical centers (2007-2012). PARTICIPANTS: Participants 
      women aged 18-40 years actively attempting pregnancy, stratified by eligibility 
      criteria: the "original" stratum, women with one loss <20 weeks' gestation during 
      the previous year; and the "expanded" stratum, women with one or two previous 
      losses of any gestational age regardless of time since loss. INTERVENTION: Daily 
      LDA was compared with matching placebo for up to six menstrual cycles of 
      attempting pregnancy. MAIN OUTCOME MEASURE: Time to hCG detected pregnancy and 
      clinically confirmed pregnancy, analyzed by intention-to-treat, was measured. 
      RESULTS: Of the 1228 women randomly assigned to LDA (n = 615) or placebo (n = 
      613), 410 (67%) women receiving LDA achieved pregnancy compared to 382 (63%) 
      receiving placebo, corresponding to a fecundability odds ratio (FOR) of 1.14 (95% 
      CI: 0.97, 1.33). Among women in the original stratum (n = 541), LDA was 
      associated with increased fecundability compared to placebo (FOR: 1.28; 95%CI: 
      1.02, 1.62). CONCLUSIONS: Preconception-initiated LDA treatment resulted in a 
      nonsignificant increase in fecundability of 14% in women with a history of 1-2 
      pregnancy losses, and a significant increase of 28% in women with a history of 
      only one pregnancy loss of <20 weeks' gestation in the preceding year. 
      Preconception-initiated LDA may increase fecundability in certain women with a 
      recent early pregnancy loss.
FAU - Schisterman, Enrique F
AU  - Schisterman EF
AD  - Epidemiology Branch (E.F.S., S.L.M., K.C.S., L.A.S., N.J.P., S.M.Z.) and 
      Biostatistics and Bioinformatics Branch (Z.C.), Division of Intramural Population 
      Health Research, Eunice Kennedy Shriver National Institute of Child Health and 
      Human Development, Bethesda, Maryland 20892; Department of Family and Preventive 
      Medicine (J.B.S.), University of Utah, Salt Lake City, Utah 84112; Department of 
      Obstetrics and Gynecology (L.L.L., R.M.S.), University of Utah and Intermountain 
      Healthcare 84111, Salt Lake City, Utah; Department of Epidemiology and 
      Environmental Health (J.W-W.), University at Buffalo, Buffalo, New York 14260; 
      Department of Obstetrics and Gynecology (A.M.L.), University of Colorado, Denver, 
      Colorado 80045; Department of Family, Community and Rural Health (J.M.T.), 
      Commonwealth Medical College, Scranton, Pennsylvania 18509; Department of 
      Laboratory Medicine and Pathology (M.Y.T.), University of Minnesota Medical 
      School, Minneapolis, Minnesota 55455; and Department of Statistics (D.F., N.G.), 
      University of Haifa, Haifa, Israel 3498838.
FAU - Mumford, Sunni L
AU  - Mumford SL
FAU - Schliep, Karen C
AU  - Schliep KC
FAU - Sjaarda, Lindsey A
AU  - Sjaarda LA
FAU - Stanford, Joseph B
AU  - Stanford JB
FAU - Lesher, Laurie L
AU  - Lesher LL
FAU - Wactawski-Wende, Jean
AU  - Wactawski-Wende J
FAU - Lynch, Anne M
AU  - Lynch AM
FAU - Townsend, Janet M
AU  - Townsend JM
FAU - Perkins, Neil J
AU  - Perkins NJ
FAU - Zarek, Shvetha M
AU  - Zarek SM
FAU - Tsai, Michael Y
AU  - Tsai MY
FAU - Chen, Zhen
AU  - Chen Z
FAU - Faraggi, David
AU  - Faraggi D
FAU - Galai, Noya
AU  - Galai N
FAU - Silver, Robert M
AU  - Silver RM
LA  - eng
SI  - ClinicalTrials.gov/NCT00467363
GR  - HHSN267200603423/PHS HHS/United States
GR  - HHSN267200603424/PHS HHS/United States
GR  - HHSN267200603426/PHS HHS/United States
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
DEP - 20150224
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - *Time-to-Pregnancy
MH  - Treatment Outcome
MH  - United States
MH  - Young Adult
PMC - PMC4422888
EDAT- 2015/02/25 06:00
MHDA- 2015/10/01 06:00
CRDT- 2015/02/25 06:00
PHST- 2015/02/25 06:00 [entrez]
PHST- 2015/02/25 06:00 [pubmed]
PHST- 2015/10/01 06:00 [medline]
AID - 14-4179 [pii]
AID - 10.1210/jc.2014-4179 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2015 May;100(5):1785-91. doi: 10.1210/jc.2014-4179. Epub 
      2015 Feb 24.

PMID- 21688628
OWN - NLM
STAT- MEDLINE
DCOM- 20110722
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 69
IP  - 6
DP  - 2011 Jun
TI  - [Prevention and treatment of low-dose aspirin induced gastric ulcer in coronary 
      artery disease after coronary intervention].
PG  - 1061-6
AB  - Low-dose aspirin has been increasingly used to prevent cardiovascular and 
      cerebrovascular disease through its antiplatelet effect, mainly in the patients 
      with ischemic heart disease, but aspirin has been associated with 
      gastrointestinal injuries, especially peptic ulcer bleeding. However, 
      discontinuation of aspirin may cause cardiovascular and cerebrovascular events. 
      Therefore, high-risk patients for peptic ulcers should be prevented with 
      anti-secretory drugs, such as proton pump inhibitor of H2-receptor antagonists, 
      because ulcer bleedings in patients with treatment of low-dose aspirin can be 
      serious.
FAU - Yokoi, Hiroyoshi
AU  - Yokoi H
AD  - Department of Cardiology, Kokura Memorial Hospital.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Coronary Disease/drug therapy/*therapy
MH  - Humans
MH  - Stomach Ulcer/*chemically induced/drug therapy/*prevention & control
EDAT- 2011/06/22 06:00
MHDA- 2011/07/23 06:00
CRDT- 2011/06/22 06:00
PHST- 2011/06/22 06:00 [entrez]
PHST- 2011/06/22 06:00 [pubmed]
PHST- 2011/07/23 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2011 Jun;69(6):1061-6.

PMID- 21061524
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - [Pathogenesis of aspirin-induced gastric mucosal injury].
PG  - 2007-14
AB  - It is necessary for some conditions to occur at the same time so that aspirin 
      induced gastric mucosa injury occurs. The definite condition that is necessary 
      for the development of gastric mucosa injury by aspirin is the direct injury with 
      the aspirin and the presence of the gastric acid. The pathologic central 
      mechanism is the inhibition of cyclooxygenase, the disturbance of 
      microcirculation and pro-apoptotic signaling. At all events, it is a theme for 
      gastroenterologists to establish a mean to prevent the gastric mucosa injury 
      induced by aspirin.
FAU - Naito, Yuji
AU  - Naito Y
AD  - Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural 
      University of Medicine.
FAU - Yoshikawa, Toshikazu
AU  - Yoshikawa T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Rats
EDAT- 2010/11/11 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Nov;68(11):2007-14.

PMID- 21223359
OWN - NLM
STAT- MEDLINE
DCOM- 20120112
LR  - 20211020
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 72
IP  - 4
DP  - 2011 Oct
TI  - Current concepts of platelet activation: possibilities for therapeutic modulation 
      of heterotypic vs. homotypic aggregation.
PG  - 604-18
LID - 10.1111/j.1365-2125.2011.03906.x [doi]
AB  - Thrombogenic and inflammatory activity are two distinct aspects of platelet 
      biology, which are sustained by the ability of activated platelets to interact 
      with each other (homotypic aggregation) and to adhere to circulating leucocytes 
      (heterotypic aggregation). These two events are regulated by distinct 
      biomolecular mechanisms that are selectively activated in different 
      pathophysiological settings. They can occur simultaneously, for example, as part 
      of a pro-thrombotic/pro-inflammatory response induced by vascular damage, or 
      independently, as in certain clinical conditions in which abnormal heterotypic 
      aggregation has been observed in the absence of intravascular thrombosis. Current 
      antiplatelet drugs have been developed to target specific molecular signalling 
      pathways mainly implicated in thrombus formation, and their ever increasing 
      clinical use has resulted in clear benefits in the treatment and prevention of 
      arterial thrombotic events. However, the efficacy of currently available 
      antiplatelet drugs remains suboptimal, most likely because their therapeutic 
      action is limited to only few of the signalling pathways involved in platelet 
      homotypic aggregation. In this context, modulation of heterotypic aggregation, 
      which is believed to contribute importantly to acute thrombotic events, as well 
      to the pathophysiology of atherosclerosis itself, may offer benefits over and 
      above the classical antiplatelet approach. This review will focus on the distinct 
      biomolecular pathways that, following platelet activation, underlie homotypic and 
      heterotypic aggregation, aiming potentially to identify novel therapeutic 
      targets.
CI  - © 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British 
      Pharmacological Society.
FAU - Passacquale, Gabriella
AU  - Passacquale G
AD  - Department of Clinical Pharmacology, Cardiovascular Division, King's College 
      London, London, UK.
FAU - Ferro, Albert
AU  - Ferro A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thienopyridines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Humans
MH  - Leukocytes/drug effects
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Thienopyridines/pharmacology/therapeutic use
MH  - Thrombosis/prevention & control
PMC - PMC3195737
EDAT- 2011/01/13 06:00
MHDA- 2012/01/13 06:00
CRDT- 2011/01/13 06:00
PHST- 2011/01/13 06:00 [entrez]
PHST- 2011/01/13 06:00 [pubmed]
PHST- 2012/01/13 06:00 [medline]
AID - 10.1111/j.1365-2125.2011.03906.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2011 Oct;72(4):604-18. doi: 
      10.1111/j.1365-2125.2011.03906.x.

PMID- 19576352
OWN - NLM
STAT- MEDLINE
DCOM- 20090721
LR  - 20181201
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 104
IP  - 2
DP  - 2009 Jul 15
TI  - Assessment, mechanisms, and clinical implication of variability in platelet 
      response to aspirin and clopidogrel therapy.
PG  - 227-33
LID - 10.1016/j.amjcard.2009.03.022 [doi]
AB  - Antiplatelet therapy is the mainstay of treatment for patients with 
      cardiovascular disease. However, some patients experience adverse cardiac events 
      despite treatment with single- or dual-antiplatelet (aspirin and clopidogrel) 
      therapy. Some of those events could be caused by low responsiveness to aspirin or 
      clopidogrel. The frequency of this phenomenon has been reported to range from 1% 
      to 45% for the 2 drugs. This wide range arises from the lack of a "gold-standard" 
      definition to assess antiplatelet drug response and differences in assays, 
      agonist concentrations, and cut-off points. Regardless of the variability in the 
      incidence of aspirin or clopidogrel low responsiveness, several studies have 
      indicated a clear relation between clopidogrel or aspirin low responsiveness and 
      cardiovascular events. The evidence for an association between adverse clinical 
      events and the results of ex vivo platelet function tests is stronger for 
      clopidogrel than for aspirin. Currently, there is no established therapeutic 
      approach for managing low response to aspirin or clopidogrel that has been shown 
      in large trials to have clinical benefit. This review focuses on laboratory 
      testing of antiplatelet response to aspirin and clopidogrel, the prevalence of 
      low response, potential mechanisms, clinical significance, and prognostic value 
      of this phenomenon and alternative approaches to optimize treatment in patients 
      with low response to the drugs.
FAU - Ben-Dor, Itsik
AU  - Ben-Dor I
AD  - Department of Cardiology, Rabin Medical Center and Tel Aviv University, Tel Aviv, 
      Israel.
FAU - Kleiman, Neal S
AU  - Kleiman NS
FAU - Lev, Eli
AU  - Lev E
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090513
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Clopidogrel
MH  - Coronary Artery Disease/*drug therapy
MH  - Drug Resistance/drug effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Prognosis
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
RF  - 52
EDAT- 2009/07/07 09:00
MHDA- 2009/07/22 09:00
CRDT- 2009/07/07 09:00
PHST- 2008/11/13 00:00 [received]
PHST- 2009/03/12 00:00 [revised]
PHST- 2009/03/12 00:00 [accepted]
PHST- 2009/07/07 09:00 [entrez]
PHST- 2009/07/07 09:00 [pubmed]
PHST- 2009/07/22 09:00 [medline]
AID - S0002-9149(09)00732-2 [pii]
AID - 10.1016/j.amjcard.2009.03.022 [doi]
PST - ppublish
SO  - Am J Cardiol. 2009 Jul 15;104(2):227-33. doi: 10.1016/j.amjcard.2009.03.022. Epub 
      2009 May 13.

PMID- 32920022
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1523-1755 (Electronic)
IS  - 0085-2538 (Print)
IS  - 0085-2538 (Linking)
VI  - 99
IP  - 2
DP  - 2021 Feb
TI  - Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized 
      clinical trial suggests aspirin did not improve outcomes in older adults with 
      chronic kidney disease.
PG  - 466-474
LID - S0085-2538(20)30973-X [pii]
LID - 10.1016/j.kint.2020.08.011 [doi]
AB  - The role of aspirin for primary prevention in older adults with chronic kidney 
      disease (CKD) is unclear. Therefore, post hoc analysis of the randomized 
      controlled trial ASPirin in Reducing Events in the Elderly (ASPREE) was 
      undertaken comparing 100 mg of enteric-coated aspirin daily against matching 
      placebo. Participants were community dwelling adults aged 70 years and older in 
      Australia, 65 years and older in the United States, all free of a history of 
      dementia or cardiovascular disease and of any disease expected to lead to death 
      within five years. CKD was defined as present at baseline if either eGFR under 
      60mL/min/1.73m(2) or urine albumin to creatinine ratio 3 mg/mmol or more. In 4758 
      participants with and 13004 without CKD, the rates of a composite endpoint 
      (dementia, persistent physical disability or death), major adverse cardiovascular 
      events and clinically significant bleeding in the CKD participants were almost 
      double those without CKD. Aspirin's effects as estimated by hazard ratios were 
      generally similar between CKD and non-CKD groups for dementia, persistent 
      physical disability or death, major adverse cardiovascular events and clinically 
      significant bleeding. Thus, in our analysis aspirin did not improve outcomes in 
      older people while increasing the risk of bleeding, with mostly consistent 
      effects in participants with and without CKD.
CI  - Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. 
      All rights reserved.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Wetmore, James B
AU  - Wetmore JB
AD  - Department of Medicine, Hennepin Healthcare Systems, Minneapolis, Minnesota, USA; 
      Chronic Disease Research Group, Hennepin Healthcare Research Institute, 
      Minneapolis, Minnesota, USA.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Gallagher, Hugh
AU  - Gallagher H
AD  - Renal Services, Epsom and St Helier University Hospitals NHS Trust, London, UK.
FAU - Roderick, Paul
AU  - Roderick P
AD  - School of Primary Care, Population Sciences and Medical Education, University of 
      Southampton and Southampton General Hospital, Hampshire, UK.
FAU - Walker, Rowan
AU  - Walker R
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, 
      Australia.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia; School of Public Health, Curtin University, Perth, Western 
      Australia, Australia.
FAU - Shah, Raj C
AU  - Shah RC
AD  - Department of Family Medicine and Rush Alzheimer's Disease Center, Rush 
      University Medical Center, Chicago, Illinois, USA.
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - Department of Pharmacy Practice and Science, College of Pharmacy and Department 
      of Family Medicine, Carver College of Medicine, University of Iowa, Iowa City, 
      Iowa, USA.
FAU - Lockery, Jessica E
AU  - Lockery JE
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Tonkin, Andrew M
AU  - Tonkin AM
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Abhayaratna, Walter P
AU  - Abhayaratna WP
AD  - College of Medicine, Biology and Environment, Australian National University, 
      Canberra, Australian Capital Territory, Australia.
FAU - Gibbs, Peter
AU  - Gibbs P
AD  - Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, 
      Australia.
FAU - Wood, Erica M
AU  - Wood EM
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Mahady, Suzanne E
AU  - Mahady SE
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia; Department of Gastroenterology, Royal Melbourne Hospital, 
      Melbourne, Victoria, Australia.
FAU - Williamson, Jeff D
AU  - Williamson JD
AD  - Sticht Center on Healthy Aging and Alzheimer's Prevention, Section on Gerontology 
      and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of 
      Medicine, Winston-Salem, North Carolina, USA.
FAU - Donnan, Geoffrey A
AU  - Donnan GA
AD  - Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, 
      Parkville, Victoria, Australia.
FAU - Cloud, Geoffrey C
AU  - Cloud GC
AD  - Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital, Melbourne, Victoria, Australia.
FAU - Murray, Anne M
AU  - Murray AM
AD  - Department of Medicine, Hennepin Healthcare Systems, Minneapolis, Minnesota, USA.
FAU - Polkinghorne, Kevan R
AU  - Polkinghorne KR
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia; Department of Nephrology, Monash Medical Centre, Monash 
      Health, Melbourne, Victoria, Australia. Electronic address: 
      kevan.polkinghorne@monash.edu.
LA  - eng
GR  - P30 AG024824/AG/NIA NIH HHS/United States
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U19 AG062682/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Kidney Int. 2021 Feb;99(2):308-310. PMID: 33509351
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects
MH  - Australia
MH  - *Cardiovascular Diseases/epidemiology/prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - *Renal Insufficiency, Chronic/complications/diagnosis/drug therapy
MH  - United States
PMC - PMC7957958
MID - NIHMS1676962
OTO - NOTNLM
OT  - aspirin
OT  - bleeding
OT  - cardiovascular events
OT  - chronic kidney disease
OT  - elderly
OT  - randomized clinical trial
COIS- DISCLOSURE All the authors declared no competing interests.
EDAT- 2020/09/14 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/13 20:29
PHST- 2020/03/21 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/09/14 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/13 20:29 [entrez]
AID - S0085-2538(20)30973-X [pii]
AID - 10.1016/j.kint.2020.08.011 [doi]
PST - ppublish
SO  - Kidney Int. 2021 Feb;99(2):466-474. doi: 10.1016/j.kint.2020.08.011. Epub 2020 
      Sep 10.

PMID- 19439684
OWN - NLM
STAT- MEDLINE
DCOM- 20090721
LR  - 20131121
IS  - 1526-7598 (Electronic)
IS  - 0003-2999 (Linking)
VI  - 109
IP  - 1
DP  - 2009 Jul
TI  - Whole blood multiple electrode aggregometry is a reliable point-of-care test of 
      aspirin-induced platelet dysfunction.
PG  - 25-31
LID - 10.1213/ane.0b013e3181a27d10 [doi]
AB  - BACKGROUND: Aspirin is one of the most commonly ingested over-the-counter drugs. 
      In addition to its analgesic and antiinflammatory actions, it also potently 
      inhibits platelet aggregation. Evaluation of aspirin-induced platelet dysfunction 
      is relevant in various clinical situations, including during complex surgeries 
      with high bleeding risk in individuals who have ingested aspirin. In this study, 
      we examined the suitability of multiple electrode aggregometry (MEA) for time 
      course assessment of the antiplatelet effects of a single oral dose of 500 mg 
      aspirin. We also determined the applicability of this method in the point-of-care 
      (POC) setting by comparing the results of the test after different time intervals 
      after blood sampling. METHOD: Twenty-four adult volunteers were enrolled in the 
      study. After blood drawing at baseline, 500 mg aspirin was administered to all 
      volunteers. Blood samples were taken at 4, 24, 56, 80, and 124 h after aspirin 
      ingestion. At each time point, measurements were performed immediately and 30 and 
      60 min after drawing blood. Whole blood MEA was performed after stimulation with 
      thrombin receptor activating peptide (TRAPtest, 32 microM) and arachidonic acid 
      (ASPItest, 0.5 mM). Repeated measurement analysis of variance with a Bonferroni 
      correction for multiple comparisons was performed to detect differences between 
      time points. Assay imprecision was determined by calculating the coefficient of 
      variation. The level of statistical significance was set to P < 0.05. RESULTS: 
      Platelet aggregation by ASPItest was markedly decreased 4 h after aspirin intake. 
      From the second day after aspirin intake, ASPItest values recovered with high 
      interindividual variability, and 5 days after aspirin intake, ASPItest values did 
      not differ significantly from baseline. TRAP-induced platelet aggregation 
      (TRAPtest) showed no systematic changes during the study period. The resting time 
      of the sample did not affect TRAPtest or ASPItest values. The coefficients of 
      variation were 10% for the ASPItest and 7% for the TRAPtest. CONCLUSIONS: MEA 
      reliably detected the effects of aspirin. Notably, 500 mg aspirin caused complete 
      inhibition of arachidonic acid-induced platelet aggregation for 2 days in all 
      volunteers. Aggregation returned to baseline values with a wide interindividual 
      variation in time course by day 5. No resting time for the blood sample was 
      required for ASPItest or TRAPtest. These assays can be implemented as real POC 
      tests. The reproducibility of the assays studied here is within the range of 
      modern POC analyzers.
FAU - Jámbor, Csilla
AU  - Jámbor C
AD  - Clinic for Anesthesiology, University of Munich, Max-Lebsche-Platz 32, D-81377 
      Munich, Germany. csilla.jambor@web.de
FAU - Weber, Christian F
AU  - Weber CF
FAU - Gerhardt, Konstanze
AU  - Gerhardt K
FAU - Dietrich, Wulf
AU  - Dietrich W
FAU - Spannagl, Michael
AU  - Spannagl M
FAU - Heindl, Bernhard
AU  - Heindl B
FAU - Zwissler, Bernhard
AU  - Zwissler B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090513
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/blood
MH  - Blood Platelet Disorders/*blood/*chemically induced
MH  - Electrodes
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Function Tests/instrumentation/methods
MH  - *Point-of-Care Systems
MH  - Reproducibility of Results
EDAT- 2009/05/15 09:00
MHDA- 2009/07/22 09:00
CRDT- 2009/05/15 09:00
PHST- 2009/05/15 09:00 [entrez]
PHST- 2009/05/15 09:00 [pubmed]
PHST- 2009/07/22 09:00 [medline]
AID - ane.0b013e3181a27d10 [pii]
AID - 10.1213/ane.0b013e3181a27d10 [doi]
PST - ppublish
SO  - Anesth Analg. 2009 Jul;109(1):25-31. doi: 10.1213/ane.0b013e3181a27d10. Epub 2009 
      May 13.

PMID- 12162712
OWN - NLM
STAT- MEDLINE
DCOM- 20030123
LR  - 20131121
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 54
IP  - 7
DP  - 2002 Jul
TI  - Structural requirements for the neuroprotective effects of aspirin analogues 
      against N-methyl-D-aspartate and zinc ion neurotoxicity.
PG  - 935-44
AB  - In order to elucidate the structural requirements for the dual neuroprotective 
      activity of aspirin against N-methyl-D-aspartate (NMDA) and zinc ion 
      neurotoxicity, various aspirin analogues and derivatives, modified at the 
      carboxylic group, the acetyl group, and the chain length between the carboxylic 
      acid moiety and phenyl ring, were synthesized. Replacement of the carboxylic acid 
      group with alkyl groups (compounds 2c and 2d) resulted in a dramatic increase in 
      neuroprotective activity against NMDA neurotoxicity, while reduction of the 
      carboxylic acid group to the alcohol (compound 2g) completely abolished this 
      activity. In contrast to NMDA neurotoxicity, compounds that are devoid of the 
      carboxylic acid group did not show any activity against zinc ion neurotoxicity. 
      Replacement of the acetyl group with a propionyl (compound 5a) or butyryl group 
      (compound 5b) did not significantly change the activity against NMDA 
      neurotoxicity, but replacement of the acetyl group with a propionyl group 
      (compound 5a) resulted in a slight decrease in activity against zinc ion 
      neurotoxicity. Compound 12, which has ethylene units between the carboxylic acid 
      moiety and phenyl ring in the structure of aspirin, exhibited greater 
      neuroprotective activity against NMDA neurotoxicity than the compared compounds 
      (aspirin, compound 9 and compound 17), which have different chain lengths. A 
      similar trend was also observed in the neuroprotective activity against zinc ion 
      neurotoxicity. These results indicate that the carboxylic acid group in aspirin 
      is not indispensable for the inhibitory effect against NMDA neurotoxicity, but is 
      essential for the inhibitory effect against zinc ion neurotoxicity. The acetyl 
      group and ethylene unit's distance are favourable for the inhibitory effect 
      against NMDA neurotoxicity as well as zinc ion neurotoxicity.
FAU - Moon, Ho-Sang
AU  - Moon HS
AD  - Department of Molecular Science and Technology, Ajou University, Suwon, South 
      Korea.
FAU - Nam, Sung-Il
AU  - Nam SI
FAU - Kim, Su-Dong
AU  - Kim SD
FAU - Kim, DongYeon
AU  - Kim D
FAU - Gwag, Byoung Joo
AU  - Gwag BJ
FAU - Lee, Young Ae
AU  - Lee YA
FAU - Yoon, Sung-Hwa
AU  - Yoon SH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Carboxylic Acids)
RN  - 0 (Excitatory Amino Acid Agonists)
RN  - 0 (Ions)
RN  - 0 (Neuroprotective Agents)
RN  - 6384-92-5 (N-Methylaspartate)
RN  - J41CSQ7QDS (Zinc)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*pharmacology
MH  - Aspirin/analogs & derivatives/chemistry/*pharmacology
MH  - Carboxylic Acids/chemistry
MH  - Cerebral Cortex/cytology/embryology
MH  - Excitatory Amino Acid Agonists/*toxicity
MH  - Ions
MH  - Mice
MH  - Mice, Inbred ICR
MH  - N-Methylaspartate/*toxicity
MH  - Neuroprotective Agents/chemistry/*pharmacology
MH  - Zinc/*toxicity
EDAT- 2002/08/07 10:00
MHDA- 2003/01/24 04:00
CRDT- 2002/08/07 10:00
PHST- 2002/08/07 10:00 [pubmed]
PHST- 2003/01/24 04:00 [medline]
PHST- 2002/08/07 10:00 [entrez]
AID - 10.1211/002235702760089054 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2002 Jul;54(7):935-44. doi: 10.1211/002235702760089054.

PMID- 20027715
OWN - HSR
STAT- MEDLINE
DCOM- 20100112
LR  - 20131121
IS  - 1167-7422 (Print)
IS  - 1167-7422 (Linking)
VI  - 18
IP  - 104
DP  - 2009 Dec
TI  - Pre-eclampsia: aspirin beneficial.
PG  - 274
AB  - Two meta-analyses suggest that low-dose aspirin taken daily during pregnancy 
      reduces the incidence of pre-eclampsia in women at risk and reduces mortality 
      among the infants born to mothers at high risk of pre-eclampsia.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Prescrire Int
JT  - Prescrire international
JID - 9439295
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Fetal Mortality
MH  - Humans
MH  - Infant Mortality
MH  - Infant, Newborn
MH  - Male
MH  - Maternal Mortality
MH  - Meta-Analysis as Topic
MH  - Pre-Eclampsia/*drug therapy/mortality/prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Randomized Controlled Trials as Topic
EDAT- 2009/12/24 06:00
MHDA- 2010/01/13 06:00
CRDT- 2009/12/24 06:00
PHST- 2009/12/24 06:00 [entrez]
PHST- 2009/12/24 06:00 [pubmed]
PHST- 2010/01/13 06:00 [medline]
PST - ppublish
SO  - Prescrire Int. 2009 Dec;18(104):274.

PMID- 8466742
OWN - NLM
STAT- MEDLINE
DCOM- 19930510
LR  - 20190512
IS  - 0895-7061 (Print)
IS  - 0895-7061 (Linking)
VI  - 6
IP  - 3 Pt 2
DP  - 1993 Mar
TI  - Treatment of hypertension with calcium antagonists and aspirin. Effects on 24-h 
      platelet activity.
PG  - 98S-101S
AB  - The effects of calcium antagonists on platelets, and the effects of aspirin on 
      the antihypertensive efficacy of calcium antagonists and on the 24-h 
      platelet-activity profile were investigated in a double-blind study. Patients 
      with essential hypertension were treated for 8 weeks with either nitrendipine (10 
      mg once daily) or isradipine (2.5 mg once daily). Aspirin (100 mg once daily) was 
      added to both treatments for a further 8 weeks. Measurements were taken after 
      placebo, after 8 weeks of active treatment, and after 8 weeks of treatment plus 
      aspirin. Plasma levels of beta-thromboglobulin (beta-TG) and platelet aggregation 
      (PA) were measured six times over 24 h. Isradipine and nitrendipine significantly 
      lowered systolic and diastolic blood pressure. The addition of aspirin had no 
      effect on blood pressure. Platelet activity before treatment exhibited circadian 
      variations with the lowest values of beta-TG and PA at 0530 h and the steepest 
      increases between 0530 and 0900 h. Although both calcium antagonists decreased 
      beta-TG levels (P < .05), the effect with isradipine was more pronounced than 
      that with nitrendipine (P < .05). Aspirin added to nitrendipine produced a 
      significant decrease in beta-TG levels whereas isradipine plus aspirin was 
      accompanied by a partial increase in beta-TG. It is concluded that hypertensive 
      patients exhibit circadian increases in platelet activity that can be prevented 
      by either isradipine alone or by treatment with nitrendipine plus aspirin. 
      Chronic aspirin intake at a daily dose of 100 mg does not affect calcium 
      antagonist antihypertensive efficacy.
FAU - Fetkovska, N
AU  - Fetkovska N
AD  - Department of Clinical Pharmacology, Institute of Preventive and Clinical 
      Medicine, Bratislava, Slovak Republic.
FAU - Jakubovska, Z
AU  - Jakubovska Z
FAU - Oravcova, J
AU  - Oravcova J
FAU - Tison, P Jr
AU  - Tison P Jr
FAU - Ulicna, L
AU  - Ulicna L
FAU - Trnovec, T
AU  - Trnovec T
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am J Hypertens
JT  - American journal of hypertension
JID - 8803676
RN  - 9B627AW319 (Nitrendipine)
RN  - R16CO5Y76E (Aspirin)
RN  - YO1UK1S598 (Isradipine)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Circadian Rhythm/drug effects
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Hypertension/blood/*drug therapy/physiopathology
MH  - Isradipine/*pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Nitrendipine/*pharmacology/therapeutic use
MH  - Platelet Aggregation/*drug effects
MH  - Treatment Outcome
EDAT- 1993/03/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
AID - 0895-7061(93)90245-H [pii]
AID - 10.1093/ajh/6.3.98s [doi]
PST - ppublish
SO  - Am J Hypertens. 1993 Mar;6(3 Pt 2):98S-101S. doi: 10.1093/ajh/6.3.98s.

PMID- 1055751
OWN - NLM
STAT- MEDLINE
DCOM- 19750905
LR  - 20190708
IS  - 0002-8177 (Print)
IS  - 0002-8177 (Linking)
VI  - 91
IP  - 1
DP  - 1975 Jul
TI  - Aspirin-induced oral lesion: report of case.
PG  - 130-1
AB  - Aspirin is one of the most extensively used medications and has many beneficial 
      effects. However, its injudicious use can produced local as well as systemic 
      undesirable effects. A case of aspirin burn of the oral mucosa is presented. The 
      lesion was in an unusual location. However, the history and the successful 
      results from discontinuance of the drug supported the provisional diagnosis.
FAU - Kawashima, Z
AU  - Kawashima Z
FAU - Flagg, R H
AU  - Flagg RH
FAU - Cox, D E
AU  - Cox DE
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Burns, Chemical/*etiology
MH  - Humans
MH  - Male
MH  - Mouth Diseases/*chemically induced
MH  - *Palate
EDAT- 1975/07/01 00:00
MHDA- 1975/07/01 00:01
CRDT- 1975/07/01 00:00
PHST- 1975/07/01 00:00 [pubmed]
PHST- 1975/07/01 00:01 [medline]
PHST- 1975/07/01 00:00 [entrez]
AID - S0002-8177(75)11036-9 [pii]
AID - 10.14219/jada.archive.1975.0318 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 1975 Jul;91(1):130-1. doi: 10.14219/jada.archive.1975.0318.

PMID- 20693786
OWN - NLM
STAT- MEDLINE
DCOM- 20110104
LR  - 20181201
IS  - 1421-9786 (Electronic)
IS  - 1015-9770 (Linking)
VI  - 30
IP  - 4
DP  - 2010
TI  - Facts versus theories: an everlasting struggle. The Johann Jakob Wepfer Award 
      2010.
PG  - 330-9
LID - 10.1159/000319571 [doi]
AB  - Rather than a complete overview of the contribution of Utrecht to stroke 
      research, I have selected a few subjects and attempt to put these in historical 
      context. Johann Jakob Wepfer (1620-1695) was unique in that he approached 
      'apoplexy' through post-mortem observations, in the tradition of Padua. However, 
      the interpretation of his findings in haemorrhagic and especially 
      non-haemorrhagic stroke was still heavily influenced by the authority of Galen's 
      writings. Wepfer's category of 'serous apoplexy' assumed that extravasation of 
      blood serum might lead to compression of brain substance and blockage of 'nerve 
      pores' through which mental 'spirit' was supposed to flow. This notion of 
      'cerebral congestion' or 'cerebral hyperaemia' lived on, at least to the middle 
      of the 20th century! The pitfalls of theorizing are also evident from recent 
      history (the facile assumption that cerebral ischaemia occurs in the same way as 
      leg ischaemia). By implication, similar errors may well be hidden in present 
      ideas about stroke. Probable or possible examples are the idées reçues that 30 mg 
      of aspirin is less efficacious in the secondary prevention of stroke than 100 mg, 
      that vasospasm is the cause of delayed ischaemia after aneurysmal subarachnoid 
      haemorrhage and that perimesencephalic haemorrhage is not caused by rupture of an 
      artery. Physicians still speculate more often than they care to admit.
CI  - Copyright (c) 2010 S. Karger AG, Basel.
FAU - van Gijn, Jan
AU  - van Gijn J
AD  - Department of Neurology, University Medical Centre Utrecht, Utrecht, The 
      Netherlands.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Lecture
DEP - 20100805
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*history/therapeutic use
MH  - Awards and Prizes
MH  - Dose-Response Relationship, Drug
MH  - Europe
MH  - History, 17th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Neurology
MH  - Platelet Aggregation Inhibitors/*history/therapeutic use
MH  - Societies, Medical
MH  - Stroke/etiology/*history/physiopathology/prevention & control
PS  - Wepfer JJ
FPS - Wepfer, Johann Jakob
EDAT- 2010/08/10 06:00
MHDA- 2011/01/05 06:00
CRDT- 2010/08/10 06:00
PHST- 2010/08/10 06:00 [entrez]
PHST- 2010/08/10 06:00 [pubmed]
PHST- 2011/01/05 06:00 [medline]
AID - 000319571 [pii]
AID - 10.1159/000319571 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2010;30(4):330-9. doi: 10.1159/000319571. Epub 2010 Aug 5.

PMID- 1764877
OWN - NLM
STAT- MEDLINE
DCOM- 19920220
LR  - 20131121
IS  - 0095-5108 (Print)
IS  - 0095-5108 (Linking)
VI  - 18
IP  - 4
DP  - 1991 Dec
TI  - New concepts in the understanding of hypertensive diseases during pregnancy. An 
      overview.
PG  - 653-9
AB  - Preeclampsia is a syndrome of unknown etiology characterized by the sequential 
      development of facial and hand edema, hypertension, and proteinuria after the 
      20th week of gestation. Patients with preeclampsia may progress to a seizure-like 
      state: The patient is then said to have eclampsia. The major goal of prenatal 
      care is detecting the early onset of preeclampsia and to activate aggressive 
      therapy to prevent severe complications either for the mother or the fetus. There 
      currently are no specific forms of therapy to prevent the disease.
FAU - Zuspan, F P
AU  - Zuspan FP
AD  - Department of Obstetrics and Gynecology, Ohio State University College of 
      Medicine, Columbus.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Perinatol
JT  - Clinics in perinatology
JID - 7501306
RN  - 0 (Calcium, Dietary)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Bed Rest
MH  - Blood Pressure Determination
MH  - Calcium, Dietary/pharmacology/therapeutic use
MH  - Causality
MH  - Clinical Trials as Topic
MH  - *Eclampsia/diagnosis/epidemiology/therapy
MH  - Female
MH  - Humans
MH  - Incidence
MH  - *Pre-Eclampsia/diagnosis/epidemiology/therapy
MH  - Pregnancy
RF  - 19
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
PST - ppublish
SO  - Clin Perinatol. 1991 Dec;18(4):653-9.

PMID- 34940
OWN - NLM
STAT- MEDLINE
DCOM- 19790626
LR  - 20131121
IS  - 0044-2542 (Print)
IS  - 0044-2542 (Linking)
VI  - 34
IP  - 1
DP  - 1979 Jan 1
TI  - [Inhibition of blood platelet function].
PG  - 17-22
AB  - Blood platelets play a decisive role in haemostasis and thrombosis. Besides the 
      known approaches for preventing thrombosis by inhibition of the plasmatic 
      coagulation, it seems promising to prevent thrombus formation, particularly in 
      the arterial vasculature, by pharmacological control of platelet functions. Drugs 
      with antiaggregating effects are described from the clinico-pharmacological point 
      of view. Non-steroidal antiphlogistics - especially acetylsalicylic acid - 
      several vasodilators, alpha- and beta-adrenergic receptor blockers, as well as 
      some others have been used therapeutically. To test these drugs for the 
      prophylaxis of thrombosis, long-term prospective clinical trials are necessary.
FAU - Glusa, E
AU  - Glusa E
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Hemmung der Blutplättchenfunktionen.
PL  - Germany
TA  - Z Gesamte Inn Med
JT  - Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete
JID - 21730470R
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Antimalarials)
RN  - 0 (Vasodilator Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 886U3H6UFF (Chloroquine)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Adrenergic alpha-Antagonists/pharmacology
MH  - Adrenergic beta-Antagonists/pharmacology
MH  - Antimalarials/pharmacology
MH  - Aspirin/adverse effects/pharmacology
MH  - Chloroquine/pharmacology
MH  - Dipyridamole/pharmacology
MH  - Female
MH  - Humans
MH  - Maternal-Fetal Exchange
MH  - Platelet Aggregation/*drug effects
MH  - Pregnancy
MH  - Sulfinpyrazone/pharmacology
MH  - Vasodilator Agents/pharmacology
RF  - 104
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Gesamte Inn Med. 1979 Jan 1;34(1):17-22.

PMID- 2064587
OWN - NLM
STAT- MEDLINE
DCOM- 19910806
LR  - 20191029
IS  - 0389-2328 (Print)
IS  - 0389-2328 (Linking)
VI  - 17
IP  - 1
DP  - 1991 Mar
TI  - Treatment of severe pre-eclampsia by acetyl salicylic acid.
PG  - 19-26
AB  - Low-dose Aspirin inhibits thromboxane A2 with minimal effects on prostacyclin and 
      induces clinical improvements in pre-eclampsia. Two groups of pre-eclamptic women 
      (10 in each) were treated either by low-dose acetyl salicylic acid (group I) or 
      by conventional therapy (group II). Both groups showed a significant drop in 
      systolic and diastolic blood pressure, a decrease in temperature, edema and 
      albuminuria and an increase in urine volume. These effects were more significant 
      in group I than in group II, except for the diastolic blood pressure. The 
      obstetric progress and perinatal outcome were rather similar in both groups. 
      These data offer a new potential therapeutic measure for the management of severe 
      pre-eclampsia and call for further evaluation in a larger group of cases.
FAU - Toppozada, M
AU  - Toppozada M
AD  - Department of Obstetrics and Gynaecology, Shatby Hospital, University of 
      Alexandria, Egypt.
FAU - Khowessah, M
AU  - Khowessah M
FAU - Shaala, S
AU  - Shaala S
FAU - Abd-Rabbo, S
AU  - Abd-Rabbo S
FAU - Zoheir, A
AU  - Zoheir A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - Asia Oceania J Obstet Gynaecol
JT  - Asia-Oceania journal of obstetrics and gynaecology
JID - 8102781
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Albuminuria/drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Body Temperature/drug effects
MH  - Edema/drug therapy
MH  - Female
MH  - Humans
MH  - Hypertension/drug therapy
MH  - Pre-Eclampsia/*drug therapy
MH  - Pregnancy
MH  - Pregnancy Trimester, Third
EDAT- 1991/03/01 00:00
MHDA- 1991/03/01 00:01
CRDT- 1991/03/01 00:00
PHST- 1991/03/01 00:00 [pubmed]
PHST- 1991/03/01 00:01 [medline]
PHST- 1991/03/01 00:00 [entrez]
AID - 10.1111/j.1447-0756.1991.tb00246.x [doi]
PST - ppublish
SO  - Asia Oceania J Obstet Gynaecol. 1991 Mar;17(1):19-26. doi: 
      10.1111/j.1447-0756.1991.tb00246.x.

PMID- 3735085
OWN - NLM
STAT- MEDLINE
DCOM- 19860916
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 75
IP  - 5
DP  - 1986 May
TI  - Application of a radiotelemetric system to evaluate the performance of enteric 
      coated and plain aspirin tablets.
PG  - 469-74
AB  - The bioavailability of enteric coated and plain aspirin tablets was studied in 
      four beagle dogs. Blood sampling for enteric coated tablets was planned with the 
      aid of a radiotelemetric system. The release of aspirin from its dosage form was 
      detected by monitoring the change in intestinal pH. Aspirin and salicylic acid 
      levels in plasma obtained from the enteric coated dosage form exhibited familiar 
      concentration versus time absorption profiles. Variation in the plasma 
      concentrations of these two compounds within each dog studied (four runs each) 
      was relatively small when time zero was adjusted to the commencement of tablet 
      dissolution. The plasma levels obtained from plain aspirin (three runs each), 
      however, show atypical absorption. The estimated absolute bioavailability was 
      0.432 +/- 0.0213 and 0.527 +/- 0.0260 for enteric coated and plain aspirin, 
      respectively. Other pharmacokinetic parameters for these two dosage forms such as 
      the highest observed plasma concentration (Cmax) (10.9 +/- 0.535 microgram/mL 
      versus 13.6 +/- 1.88 micrograms/mL) and the time to reach Cmax (tmax) (26.6 +/- 
      1.94 min versus 31.0 +/- 7.04 min) agree well. The mean values for gastric 
      emptying time, in vivo coating dissolution time, and in vivo 
      disintegration/dissolution time of the tablet core for enteric coated aspirin are 
      48.7 +/- 7.23 min, 44.3 +/- 3.80 min, and 34.7 +/- 2.04 min, respectively.
FAU - Lui, C Y
AU  - Lui CY
FAU - Oberle, R
AU  - Oberle R
FAU - Fleisher, D
AU  - Fleisher D
FAU - Amidon, G L
AU  - Amidon GL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 0 (Tablets, Enteric-Coated)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*metabolism
MH  - Biological Availability
MH  - Blood Specimen Collection
MH  - Dogs
MH  - Injections, Intravenous
MH  - Kinetics
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Tablets
MH  - Tablets, Enteric-Coated
MH  - Telemetry
EDAT- 1986/05/01 00:00
MHDA- 1986/05/01 00:01
CRDT- 1986/05/01 00:00
PHST- 1986/05/01 00:00 [pubmed]
PHST- 1986/05/01 00:01 [medline]
PHST- 1986/05/01 00:00 [entrez]
AID - S0022-3549(15)47114-X [pii]
AID - 10.1002/jps.2600750510 [doi]
PST - ppublish
SO  - J Pharm Sci. 1986 May;75(5):469-74. doi: 10.1002/jps.2600750510.

PMID- 12049296
OWN - NLM
STAT- MEDLINE
DCOM- 20021113
LR  - 20191025
IS  - 0932-0067 (Print)
IS  - 0932-0067 (Linking)
VI  - 266
IP  - 2
DP  - 2002 Apr
TI  - A favorable outcome of pregnancies in women with primary and secondary recurrent 
      pregnancy loss associated with antiphospholipid syndrome.
PG  - 61-6
AB  - OBJECTIVE: To study the outcome of pregnancies in women with primary and 
      secondary recurrent pregnancy loss associated with antiphospholipid syndrome 
      treated with the standard treatment regimes including intravenous immunoglobulin 
      (IV Ig). METHODS: Forty three patients with recurrent pregnancy loss associated 
      with antiphospholipid syndrome diagnosed before pregnancy and subdivided into 
      primary (18) and secondary (25) subgroups were closely monitored all through 
      pregnancy with serial blood tests and ultrasonography until the pregnancy ended 
      in miscarriage or delivery. The patients were treated with low-dose aspirin and 
      heparin and or steroids and IV Ig given to some selected patients. The maternal 
      and fetal outcomes were analysed. RESULTS: The mean age of the patients in the 
      primary subgroup (24.60 +/- 4.30) years was significantly lower than the mean age 
      of the secondary recurrent pregnancy loss group (31.50 +/- 4.50) years, (p < 
      0.0001). 85.00% of all the previous miscarriages were in the first trimester. 
      There was no significant difference in the incidence of live births in the 
      primary (77.80%) and secondary (84.00%) groups, (p > 0.05); the babies were of 
      normal birth weight. The incidence of caesarean section in the primary and 
      secondary groups, 22.23% and 12.00% respectively, were not significantly 
      different (p > 0.05). Intravenous immunoglobulin added to the standard therapy 
      resulted in 100% live births. Maternal complications were negligible. 
      CONCLUSIONS: The fetal and maternal outcome of pregnancies in patients with 
      primary and secondary recurrent pregnancy loss associated with antiphospholipid 
      syndrome were virtually identical and quite satisfactory. Intravenous 
      immunoglobulin added to the standard therapy resulted in excellent fetal and 
      maternal outcome, although its definitive role will have to wait for the outcome 
      of randomised trials.
FAU - Diejomaoh, M F
AU  - Diejomaoh MF
AD  - Department of Obstetrics and Gynaecology, Faculty of Medicine, Kuwait University 
      and Maternal Hospital, Safat. michaeldiejo@hotmail.com
FAU - Al-Azemi, M M
AU  - Al-Azemi MM
FAU - Bandar, A
AU  - Bandar A
FAU - Egbase, P E
AU  - Egbase PE
FAU - Jirous, J
AU  - Jirous J
FAU - Al-Othman, S
AU  - Al-Othman S
FAU - Bukhadour, N
AU  - Bukhadour N
FAU - Al-Sweih, N
AU  - Al-Sweih N
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arch Gynecol Obstet
JT  - Archives of gynecology and obstetrics
JID - 8710213
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Steroids)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*drug therapy/*etiology
MH  - Adult
MH  - Antiphospholipid Syndrome/*complications
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Steroids/therapeutic use
EDAT- 2002/06/07 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/06/07 10:00
PHST- 2002/06/07 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/06/07 10:00 [entrez]
AID - 10.1007/s004040100179 [doi]
PST - ppublish
SO  - Arch Gynecol Obstet. 2002 Apr;266(2):61-6. doi: 10.1007/s004040100179.

PMID- 31163467
OWN - NLM
STAT- MEDLINE
DCOM- 20190927
LR  - 20190927
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 144
IP  - 11
DP  - 2019 Jun
TI  - [The Polypill - A Practicable Approach?].
PG  - 715-718
LID - 10.1055/a-0705-0188 [doi]
AB  - Polypills used in cardiovascular prevention contain combinations of aspirin, 
      lipid-lowering drugs and blood pressure-lowering drugs. The use of polypills can 
      improve adherence while physicians express concerns about therapy safety and 
      flexibility.
CI  - © Georg Thieme Verlag KG Stuttgart · New York.
FAU - Thürmann, Petra A
AU  - Thürmann PA
AD  - Philipp Klee-Institut für Klinische Pharmakologie, Wuppertal.
FAU - Kleinerüschkamp, Adina G
AU  - Kleinerüschkamp AG
AD  - Philipp Klee-Institut für Klinische Pharmakologie, Wuppertal.
FAU - Boehme, Philip
AU  - Boehme P
AD  - Philipp Klee-Institut für Klinische Pharmakologie, Wuppertal.
LA  - ger
PT  - Journal Article
TT  - Die Polypill – Ein praktikables Konzept?
DEP - 20190604
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - *Cardiovascular Agents/administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Drug Combinations
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverse 
      effects/therapeutic use
COIS- Philip Böhme ist Teilzeitmitarbeiter der Bayer AG. Alle anderen Autoren geben an, 
      dass keine Interessenkonflikte bestehen.
EDAT- 2019/06/05 06:00
MHDA- 2019/09/29 06:00
CRDT- 2019/06/05 06:00
PHST- 2019/06/05 06:00 [entrez]
PHST- 2019/06/05 06:00 [pubmed]
PHST- 2019/09/29 06:00 [medline]
AID - 10.1055/a-0705-0188 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2019 Jun;144(11):715-718. doi: 10.1055/a-0705-0188. Epub 
      2019 Jun 4.

PMID- 451489
OWN - NLM
STAT- MEDLINE
DCOM- 19790901
LR  - 20190907
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 8
IP  - 2
DP  - 1979
TI  - Plasma salicylate levels in rheumatoid arthritis: a comparison between 
      micro-encapsulated and conventional aspirin.
PG  - 106-8
AB  - Ten patients with rheumatoid arthritis were given identical amounts of 
      conventional aspirin (Magnecyl) tablets and micro-encapsulated aspirin (Reumyl) 
      capsules. Steady-state salicylate levels were determined after 4 days' treatment 
      at 8 a.m., 12 noon, 4 p.m., 10 p.m. and again at 8 a.m. No difference was noted 
      between the levels at 12 noon or 4 p.m. The 10 p.m. levels were slightly though 
      not significantly higher and the last set of 8 a.m. levels were significantly 
      higher during the capsule administration. A criterion for inclusion was good 
      tolerance of Magnecyl. The clinical effectiveness was not evaluated, but the 
      observed good absorption features of Reumyl indicate that this preparation may 
      prove to be of value in long-term treatment.
FAU - Hanson, A
AU  - Hanson A
FAU - Lindroth, Y
AU  - Lindroth Y
FAU - Sjöblom, K G
AU  - Sjöblom KG
FAU - Wollheim, F A
AU  - Wollheim FA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Capsules)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Capsules
MH  - Humans
MH  - Salicylates/*blood
MH  - Tablets
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.3109/03009747909105346 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 1979;8(2):106-8. doi: 10.3109/03009747909105346.

PMID- 722421
OWN - NLM
STAT- MEDLINE
DCOM- 19790212
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 93
IP  - 6
DP  - 1978 Dec
TI  - Hepatoxicity with encephalopathy associated with aspirin therapy in rheumatoid 
      arthritis.
PG  - 1034-7
AB  - Encephalopathy secondary to aspirin-induced hepatoxicity developed in three 
      patients with JRA. In each patient clinical and biochemical resolution occurred 
      after discontinuing the drug, but toxicity appeared on rechallenge. Liver 
      biopsies in two patients showed mild nonspecific changes. Acute hepatic 
      decompensation and encephalopathy may occur as a consequence of aspirin 
      hepatoxicity in JRA and justify sequential observations of liver function tests 
      and salicylate levels in such patients.
FAU - Ulshen, M H
AU  - Ulshen MH
FAU - Grand, R J
AU  - Grand RJ
FAU - Crain, J D
AU  - Crain JD
FAU - Gelfand, E W
AU  - Gelfand EW
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Arthritis, Juvenile/drug therapy
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Biopsy
MH  - Brain Diseases/*chemically induced
MH  - Chemical and Drug Induced Liver Injury/*etiology/pathology
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Liver/*drug effects/pathology
EDAT- 1978/12/01 00:00
MHDA- 1978/12/01 00:01
CRDT- 1978/12/01 00:00
PHST- 1978/12/01 00:00 [pubmed]
PHST- 1978/12/01 00:01 [medline]
PHST- 1978/12/01 00:00 [entrez]
AID - S0022-3476(78)81252-9 [pii]
AID - 10.1016/s0022-3476(78)81252-9 [doi]
PST - ppublish
SO  - J Pediatr. 1978 Dec;93(6):1034-7. doi: 10.1016/s0022-3476(78)81252-9.

PMID- 11174044
OWN - NLM
STAT- MEDLINE
DCOM- 20010517
LR  - 20171101
IS  - 0251-5350 (Print)
IS  - 0251-5350 (Linking)
VI  - 20
IP  - 1
DP  - 2001 Feb
TI  - Aspirin use and risk of stroke in the elderly: the Rotterdam Study.
PG  - 40-4
AB  - The objective of the study was to assess the association between aspirin use and 
      the risk of stroke in a population-based study in the elderly. The study was 
      carried out within the framework of the Rotterdam Study, a prospective 
      population-based cohort study. In the total study population there was a weak, 
      nonsignificant association between aspirin use and the risk of stroke (adjusted 
      relative risk 1.29, 95% CI 0.91-1.83). Stratification by history of vascular 
      diseases revealed that aspirin considerably increased the risk of first-ever 
      stroke in subjects free from vascular disease (adjusted relative risk 1.80; 95% 
      CI 1.03-3.13). In persons with vascular disease, no association was observed 
      between aspirin use and risk of stroke (adjusted relative risk 0.99, 95% CI 
      0.56-1.73). Our findings suggest that aspirin use may increase the risk of stroke 
      in elderly subjects free from vascular disease.
FAU - Vokó, Z
AU  - Vokó Z
AD  - Department of Epidemiology & Biostatistics, University Medical Center Utrecht, 
      The Netherlands.
FAU - Koudstaal, P J
AU  - Koudstaal PJ
FAU - Bots, M L
AU  - Bots ML
FAU - Hofman, A
AU  - Hofman A
FAU - Breteler, M M
AU  - Breteler MM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Neuroepidemiology
JT  - Neuroepidemiology
JID - 8218700
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Netherlands
MH  - Prospective Studies
MH  - Risk Factors
MH  - Stroke/*chemically induced/epidemiology/prevention & control
EDAT- 2001/02/15 11:00
MHDA- 2001/05/18 10:01
CRDT- 2001/02/15 11:00
PHST- 2001/02/15 11:00 [pubmed]
PHST- 2001/05/18 10:01 [medline]
PHST- 2001/02/15 11:00 [entrez]
AID - 54756 [pii]
AID - 10.1159/000054756 [doi]
PST - ppublish
SO  - Neuroepidemiology. 2001 Feb;20(1):40-4. doi: 10.1159/000054756.

PMID- 36284992
OWN - NLM
STAT- MEDLINE
DCOM- 20221027
LR  - 20230630
IS  - 1875-8630 (Electronic)
IS  - 0278-0240 (Print)
IS  - 0278-0240 (Linking)
VI  - 2022
DP  - 2022
TI  - The Efficacy of Rosuvastatin, Amlodipine, and Aspirin in the Treatment of 
      Hypertension with Coronary Heart Disease and Its Effect on Platelet Aggregation.
PG  - 1111438
LID - 10.1155/2022/1111438 [doi]
LID - 1111438
AB  - OBJECTIVE: This study was to study the efficacy of rosuvastatin, amlodipine, and 
      aspirin in the treatment of hypertension with coronary heart disease and its 
      effect on platelet aggregation. METHODS: The participants included 60 patients 
      with hypertension and coronary heart disease who were treated at our hospital 
      between January 2020 and May 2021 and were randomly assigned to receive either 
      rosuvastatin, amlodipine, and Ziyin Huoxue Recipe (observation group) or 
      rosuvastatin, amlodipine, Ziyin Huoxue Recipe, and aspirin (experimental group), 
      with 30 patients in each. Outcome measures included clinical effectiveness, blood 
      pressure indicators, blood lipid indices, plasma viscosity, platelet aggregation, 
      cardiac function, and adverse responses. RESULTS: The clinical efficacy in the 
      experimental group was significantly higher than that in the observation group (P 
      < 0.05). The differences were found in blood pressure indices and blood lipid 
      indices between the two groups before treatment (P > 0.05). However, after 
      treatment, the blood pressure indices in the experimental group were 
      significantly lower than those in the observation group (P < 0.05). After 
      treatment, the blood lipid indices, plasma viscosity, and platelet aggregation in 
      the experimental group were significantly lower than those in the observation 
      group (P < 0.05). The left ventricular ejection fraction (LVEF) of patients in 
      the experimental group after treatment was significantly higher than that of 
      patients in the observation group (P < 0.05). There was no significant difference 
      in the incidence of adverse reactions among patients in the two groups (P > 
      0.05). CONCLUSION: The clinical efficacy of rosuvastatin, amlodipine, and aspirin 
      markedly reduces the blood pressure indices, blood lipid indices, plasma 
      viscosity, and platelet aggregation of patients with hypertension and coronary 
      heart disease, improves LVEF, and has a good safety profile.
CI  - Copyright © 2022 Jianli Fu et al.
FAU - Fu, Jianli
AU  - Fu J
AD  - Department of Cardiovascular Medicine, Shaanxi Provincial People's Hospital, 
      Xi'an, Shaanxi, China 710068.
FAU - Wang, Ting
AU  - Wang T
AD  - Department of Cardiovascular Medicine, Shaanxi Provincial People's Hospital, 
      Xi'an, Shaanxi, China 710068.
FAU - Li, Botao
AU  - Li B
AD  - Department of Cardiovascular Medicine, Shaanxi Provincial People's Hospital, 
      Xi'an, Shaanxi, China 710068.
FAU - Zhao, Na
AU  - Zhao N
AUID- ORCID: 0000-0001-9275-0201
AD  - Department of Cardiovascular Medicine, Shaanxi Provincial People's Hospital, 
      Xi'an, Shaanxi, China 710068.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Retracted Publication
DEP - 20221015
PL  - United States
TA  - Dis Markers
JT  - Disease markers
JID - 8604127
RN  - 1J444QC288 (Amlodipine)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Lipids)
SB  - IM
RIN - Dis Markers. 2023 Jun 21;2023:9845626. PMID: 37387757
MH  - Humans
MH  - Amlodipine/therapeutic use/pharmacology
MH  - Rosuvastatin Calcium/therapeutic use/pharmacology
MH  - Antihypertensive Agents/pharmacology
MH  - Platelet Aggregation
MH  - Aspirin/therapeutic use/pharmacology
MH  - Stroke Volume
MH  - Ventricular Function, Left
MH  - *Hypertension/drug therapy
MH  - *Coronary Disease
MH  - Lipids
MH  - Treatment Outcome
PMC - PMC9588327
COIS- The authors declare's that they have no conflicts of interest.
EDAT- 2022/10/27 06:00
MHDA- 2022/10/28 06:00
CRDT- 2022/10/26 02:11
PHST- 2022/08/29 00:00 [received]
PHST- 2022/09/10 00:00 [revised]
PHST- 2022/09/12 00:00 [accepted]
PHST- 2022/10/26 02:11 [entrez]
PHST- 2022/10/27 06:00 [pubmed]
PHST- 2022/10/28 06:00 [medline]
AID - 10.1155/2022/1111438 [doi]
PST - epublish
SO  - Dis Markers. 2022 Oct 15;2022:1111438. doi: 10.1155/2022/1111438. eCollection 
      2022.

PMID- 29419381
OWN - NLM
STAT- MEDLINE
DCOM- 20180305
LR  - 20191207
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Print)
IS  - 0959-8138 (Linking)
VI  - 360
DP  - 2018 Feb 1
TI  - How to estimate the effect of treatment duration on survival outcomes using 
      observational data.
PG  - k182
LID - 10.1136/bmj.k182 [doi]
LID - k182
AB  - When using observational data, quantifying the effect of treatment duration on 
      survival outcomes is not straightforward because only people who live for a long 
      time can receive treatment for a long time. This problem doesn’t apply to 
      randomised trials because people are classified based on the treatment duration 
      they are assigned, rather than the treatment duration that they achieve. This 
      approach accepts that dead people do not deviate from their assigned treatment 
      strategy. By transferring this insight to the analysis of observational data, we 
      can follow three steps to estimate the effect of treatment duration from 
      observational data without the bias of naive comparisons between long term and 
      short term users. The first step is cloning people to assign them to multiple 
      treatment strategies. The second step is censoring clones when they deviate from 
      their assigned treatment strategy. The third step is performing inverse 
      probability weighting to adjust for the potential selection bias introduced by 
      censoring. The procedure can be used to compare any treatment strategies that are 
      sustained over time. Cloning, censoring, and weighting eliminates immortal time 
      bias in the estimates of absolute and relative risk, which helps researchers 
      focus their attention on other biases that may be present in observational 
      analyses and are not so easily eliminated.
FAU - Hernán, Miguel A
AU  - Hernán MA
LA  - eng
GR  - R01 AI102634/AI/NIAID NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
DEP - 20180201
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Humans
MH  - Long-Term Care/*methods
MH  - Randomized Controlled Trials as Topic
MH  - *Survival Analysis
MH  - *Treatment Outcome
PMC - PMC6889975
COIS- Competing interests: I have read and understood BMJ policy on declaration of 
      interests and declare the following interests: none.
EDAT- 2018/02/09 06:00
MHDA- 2018/03/06 06:00
CRDT- 2018/02/09 06:00
PHST- 2018/02/09 06:00 [entrez]
PHST- 2018/02/09 06:00 [pubmed]
PHST- 2018/03/06 06:00 [medline]
AID - hemm039057 [pii]
AID - 10.1136/bmj.k182 [doi]
PST - epublish
SO  - BMJ. 2018 Feb 1;360:k182. doi: 10.1136/bmj.k182.

PMID- 11009111
OWN - NLM
STAT- MEDLINE
DCOM- 20010215
LR  - 20191104
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 28
IP  - 5
DP  - 2000 Sep
TI  - Effect of alpha-alpha diaspirin crosslinked hemoglobin (DCLHb) on the potency of 
      sodium nitroprusside and nitroglycerine to decrease blood pressure in rats: a 
      dose-response study.
PG  - 385-96
AB  - The nitrovasodilators, sodium nitroprusside and nitroglycerine, effect a 
      dose-dependent decrease in mean arterial blood pressure (MABP) by liberating 
      nitric oxide. Alpha-alpha diaspirin crosslinked hemoglobin (DCLHb) is known to 
      bind nitric oxide. We studied the effect of DCLHb on the potency of sodium 
      nitroprusside (n=36) and nitroglycerine (n=36) to decrease MABP in rats which 
      received 1, 10, 100, 1,000, or 10,000 mg/kg of the DCLHb, or normal saline as the 
      Control. Six doses of sodium nitroprusside or nitroglycerine were given to each 
      rat in a systematically varied sequence. For both drugs, in rats given 1, 10, or 
      100 mg/kg of DCLHb there were no between groups differences in the change in MABP 
      compared to the Control group. For rats that received 1,000 or 10,000 mg/kg of 
      DCLHb, the potency of nitroglycerine and sodium nitroprusside to decrease MABP 
      was less (p<0.05) than the other groups. These data support the hypothesis that 
      small doses of DCLHb effect a minimal change in the potency of nitrovasodilators 
      to reduce blood pressure. However, they suggest that clinically relevant doses of 
      DCLHb attenuate the vasodilatory ability of sodium nitroprusside and 
      nitroglycerine.
FAU - Erhart, S M
AU  - Erhart SM
AD  - Department of Anesthesiology, Loma Linda University, CA 92354, USA.
FAU - Cole, D J
AU  - Cole DJ
FAU - Patel, P M
AU  - Patel PM
FAU - Drummond, J C
AU  - Drummond JC
FAU - Burhop, K E
AU  - Burhop KE
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Vasodilator Agents)
RN  - 169D1260KM (Nitroprusside)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Blood Substitutes/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Nitroglycerin/pharmacology
MH  - Nitroprusside/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - *Vasodilator Agents
EDAT- 2000/09/29 11:00
MHDA- 2001/03/03 10:01
CRDT- 2000/09/29 11:00
PHST- 2000/09/29 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2000/09/29 11:00 [entrez]
AID - 10.3109/10731190009118583 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 2000 Sep;28(5):385-96. doi: 
      10.3109/10731190009118583.

PMID- 22975385
OWN - NLM
STAT- MEDLINE
DCOM- 20130523
LR  - 20131121
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
VI  - 11
IP  - 1
DP  - 2013 Jan
TI  - Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases 
      risk of death and acute cardiovascular events.
PG  - 38-42
LID - S1542-3565(12)01038-5 [pii]
LID - 10.1016/j.cgh.2012.08.034 [doi]
AB  - BACKGROUND & AIMS: Little is known about how discontinuation of low-dose aspirin 
      therapy after peptic ulcer bleeding affects patient mortality or acute 
      cardiovascular events. METHODS: We performed a retrospective cohort study by 
      using data from patients who received low-dose aspirin therapy and were treated 
      for bleeding peptic ulcers between 2007 and 2010 at Karolinska University 
      Hospital, Stockholm, Sweden. We used a multivariable Cox regression model to 
      adjust for potential confounders and analyze associations between discontinuation 
      of low-dose aspirin therapy at discharge, death, and acute cardiovascular events. 
      RESULTS: Of the 118 patients who received low-dose aspirin therapy, the therapy 
      was discontinued for 47 (40%). During a median follow-up period of 2 years after 
      hospital discharge, 44 of the 118 patients (37%) either died or developed acute 
      cardiovascular events. Adjusting for confounders, patients with cardiovascular 
      comorbidities who discontinued low-dose aspirin therapy had an almost 7-fold 
      increase in risk for death or acute cardiovascular events (hazard ratio, 6.9; 95% 
      confidence interval, 1.4-34.8) compared with patients who continued this therapy 
      during the first 6 months of the follow-up period. A corresponding association 
      was not observed among patients without cardiovascular comorbidities when the 
      study began. CONCLUSIONS: In patients with cardiovascular disease, 
      discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases 
      risk of death and acute cardiovascular events almost 7-fold.
CI  - Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
FAU - Derogar, Maryam
AU  - Derogar M
AD  - Unit of Upper Gastrointestinal Research, Department of Molecular Medicine and 
      Surgery, Karolinska Institutet, Norra Stationsgatan 67, Stockholm, Sweden. 
      maryam.derogar@ki.se
FAU - Sandblom, Gabriel
AU  - Sandblom G
FAU - Lundell, Lars
AU  - Lundell L
FAU - Orsini, Nicola
AU  - Orsini N
FAU - Bottai, Matteo
AU  - Bottai M
FAU - Lu, Yunxia
AU  - Lu Y
FAU - Sadr-Azodi, Omid
AU  - Sadr-Azodi O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120910
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal 
      of the American Gastroenterological Association
JID - 101160775
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*mortality/*prevention & control
MH  - Cohort Studies
MH  - Female
MH  - Gastrointestinal Hemorrhage/*complications
MH  - Humans
MH  - Male
MH  - Peptic Ulcer/*complications
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Survival Analysis
MH  - Sweden
MH  - Withholding Treatment
EDAT- 2012/09/15 06:00
MHDA- 2013/05/25 06:00
CRDT- 2012/09/15 06:00
PHST- 2012/04/01 00:00 [received]
PHST- 2012/08/22 00:00 [revised]
PHST- 2012/08/23 00:00 [accepted]
PHST- 2012/09/15 06:00 [entrez]
PHST- 2012/09/15 06:00 [pubmed]
PHST- 2013/05/25 06:00 [medline]
AID - S1542-3565(12)01038-5 [pii]
AID - 10.1016/j.cgh.2012.08.034 [doi]
PST - ppublish
SO  - Clin Gastroenterol Hepatol. 2013 Jan;11(1):38-42. doi: 10.1016/j.cgh.2012.08.034. 
      Epub 2012 Sep 10.

PMID- 24157563
OWN - NLM
STAT- MEDLINE
DCOM- 20140609
LR  - 20131025
IS  - 1662-2804 (Electronic)
IS  - 0300-5186 (Linking)
VI  - 33
DP  - 2014
TI  - Antithrombotic therapy in transient ischemic attack patients.
PG  - 147-61
LID - 10.1159/000351915 [doi]
AB  - Historically, studies of antithrombotic therapy in ischemic cerebrovascular 
      disease have included both stroke and transient ischemic attack (TIA). Thus, 
      therapy regimes are very similar. Aspirin (75-325 mg within 48 h after onset of 
      symptoms) is still the standard antithrombotic treatment because other agents 
      have performed similarly (or worse). Combinations of agents have shown mixed 
      results. Aspirin combined with clopidogrel has failed to show a significant 
      reduction of stroke/TIA recurrences but increased the bleeding risk if taken for 
      more than several months. The combination of aspirin and dipyridamole is slightly 
      better than aspirin alone and in particular reduced nonfatal stroke/TIA - hence 
      it is recommended as an alternative and may be used in patients with recurrent 
      events while on regular aspirin. In contrast, combined treatment is regularly 
      recommended after endovascular interventions and if both cardio- and 
      cerebrovascular diseases are present. Warfarin and similar compounds have long 
      been the standard treatment for most patients with permanent, paroxysmal or 
      intermittent non-valvular atrial fibrillation, for which there is excellent 
      evidence in most patients (CHADS-VASc score >1). New compounds have been approved 
      in recent years and shown to reduce either ischemic events, intracranial bleeding 
      complications or both when compared with warfarin. None of them requires regular 
      therapy monitoring. Because there are no head-to-head comparisons of these newer 
      agents, definite recommendations as to which to choose, and when, are hard to 
      make. However, there are some notable differences as well as new approved 
      entities.
CI  - Copyright © 2014 S. Karger AG, Basel.
FAU - Held, V E
AU  - Held VE
AD  - Department of Neurology, UniversitätsMedizin Mannheim, University of Heidelberg, 
      Mannheim, Germany.
FAU - Wolf, M E
AU  - Wolf ME
FAU - Hennerici, M G
AU  - Hennerici MG
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131011
PL  - Switzerland
TA  - Front Neurol Neurosci
JT  - Frontiers of neurology and neuroscience
JID - 101274949
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
EDAT- 2013/10/26 06:00
MHDA- 2014/06/10 06:00
CRDT- 2013/10/26 06:00
PHST- 2013/10/26 06:00 [entrez]
PHST- 2013/10/26 06:00 [pubmed]
PHST- 2014/06/10 06:00 [medline]
AID - 000351915 [pii]
AID - 10.1159/000351915 [doi]
PST - ppublish
SO  - Front Neurol Neurosci. 2014;33:147-61. doi: 10.1159/000351915. Epub 2013 Oct 11.

PMID- 28573479
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20210109
IS  - 1179-1985 (Electronic)
IS  - 1120-9879 (Linking)
VI  - 24
IP  - 3
DP  - 2017 Sep
TI  - Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based 
      on Individualized, Integrated Estimation of Risk.
PG  - 331-339
LID - 10.1007/s40292-017-0213-4 [doi]
AB  - While the use of aspirin in the secondary prevention of cardiovascular (CVD) is 
      well established, aspirin in primary prevention is not systematically recommended 
      because the absolute CV event reduction is similar to the absolute excess in 
      major bleedings. Recently, emerging evidence suggests the possibility that the 
      assumption of aspirin, may also be effective in the prevention of cancer. By 
      adding to the CV prevention benefits the potential beneficial effect of aspirin 
      in reducing the incidence of mortality and cancer could tip the balance between 
      risks and benefits of aspirin therapy in the primary prevention in favour of the 
      latter and broaden the indication for treatment with in populations at average 
      risk. While prospective and randomized study are currently investigating the 
      effect of aspirin in prevention of both cancer and CVD, clinical efforts at the 
      individual level to promote the use of aspirin in global (or total) primary 
      prevention could be already based on a balanced evaluation of the benefit/risk 
      ratio.
FAU - Volpe, Massimo
AU  - Volpe M
AUID- ORCID: 0000-0002-9642-8380
AD  - Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of 
      Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, 
      Italy. massimo.volpe@uniroma1.it.
AD  - IRCCS Neuromed, Pozzilli, IS, Italy. massimo.volpe@uniroma1.it.
FAU - Battistoni, Allegra
AU  - Battistoni A
AD  - Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of 
      Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, 
      Italy.
FAU - Gallo, Giovanna
AU  - Gallo G
AD  - Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of 
      Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, 
      Italy.
FAU - Coluccia, Roberta
AU  - Coluccia R
AD  - IRCCS Neuromed, Pozzilli, IS, Italy.
FAU - De Caterina, Raffaele
AU  - De Caterina R
AUID- ORCID: 0000-0003-1637-574X
AD  - Institute and Chair of Cardiology G. d'Annunzio University-Chieti-Pescara C/o 
      Ospedale SS. Annunziata, Chieti, Italy.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PT  - Review
DEP - 20170601
PL  - New Zealand
TA  - High Blood Press Cardiovasc Prev
JT  - High blood pressure & cardiovascular prevention : the official journal of the 
      Italian Society of Hypertension
JID - 9421087
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiology/*standards
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/diagnosis/epidemiology/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Patient Selection
MH  - Primary Prevention/*methods
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer
OT  - Cardiovascular risk
OT  - Primary prevention
EDAT- 2017/06/03 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/06/03 06:00
PHST- 2017/02/20 00:00 [received]
PHST- 2017/05/07 00:00 [accepted]
PHST- 2017/06/03 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
PHST- 2017/06/03 06:00 [entrez]
AID - 10.1007/s40292-017-0213-4 [pii]
AID - 10.1007/s40292-017-0213-4 [doi]
PST - ppublish
SO  - High Blood Press Cardiovasc Prev. 2017 Sep;24(3):331-339. doi: 
      10.1007/s40292-017-0213-4. Epub 2017 Jun 1.

PMID- 6106689
OWN - NLM
STAT- MEDLINE
DCOM- 19801216
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 32
IP  - 8
DP  - 1980 Aug
TI  - Decrease in aspirin-induced gastric mucosal damage in rats by oral administration 
      of the cytotoxic drugs melphalan and methotrexate.
PG  - 544-6
AB  - Gastric mucosal damage by aspirin and chemotherapeutic drugs was studied in 
      Wistar rats. Aspirin 60 mg given by stomach tube caused substantial gastric 
      mucosal damage as judged by visual examination of the stomachs removed four hours 
      later. Melphalan and methotrexate given daily for four days had no significant 
      macroscopic effect on the gastric mucosa, but reduced the damage caused by 
      aspirin. This protective effect my involve a stimulation of prostaglandin 
      synthesis by the stomach, increased mucus secretion, and/or inhibition of acid 
      secretion.
FAU - Berstock, D A
AU  - Berstock DA
FAU - Frank, G J
AU  - Frank GJ
FAU - Stamford, I F
AU  - Stamford IF
FAU - Bennett, A
AU  - Bennett A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Prostaglandins)
RN  - Q41OR9510P (Melphalan)
RN  - R16CO5Y76E (Aspirin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Animals
MH  - Aspirin/*antagonists & inhibitors/toxicity
MH  - Female
MH  - Gastric Mucosa/*drug effects/metabolism
MH  - Male
MH  - Melphalan/*pharmacology
MH  - Methotrexate/*pharmacology
MH  - Prostaglandins/metabolism
MH  - Rats
EDAT- 1980/08/01 00:00
MHDA- 1980/08/01 00:01
CRDT- 1980/08/01 00:00
PHST- 1980/08/01 00:00 [pubmed]
PHST- 1980/08/01 00:01 [medline]
PHST- 1980/08/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1980.tb12992.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1980 Aug;32(8):544-6. doi: 10.1111/j.2042-7158.1980.tb12992.x.

PMID- 3414920
OWN - NLM
STAT- MEDLINE
DCOM- 19880930
LR  - 20190703
IS  - 0003-2409 (Print)
IS  - 0003-2409 (Linking)
VI  - 43
IP  - 7
DP  - 1988 Jul
TI  - Suxamethonium induced myalgia and the effect of pre-operative administration of 
      oral aspirin. A comparison with a standard treatment and an untreated group.
PG  - 565-7
AB  - Eighty-four fit, unpremedicated patients who presented for routine surgery and 
      received a standard anaesthetic technique were allocated randomly to three equal 
      groups. Group 1 received tubocurarine 0.05 mg/kg before induction of anaesthesia. 
      Group 2 received soluble aspirin 600 mg orally one hour before surgery, while 
      Group 3 received no pretreatment. Aspirin prophylaxis produced a significant 
      reduction in the incidence of subsequent suxamethonium-induced myalgia and the 
      improvement was similar to that achieved with tubocurarine pretreatment. 
      Pre-operative oral administration of aspirin effectively reduces muscle pains and 
      avoids many of the complications associated with pretreatment with 
      non-depolarising agents.
FAU - McLoughlin, C
AU  - McLoughlin C
AD  - Mater Infirmorum Hospital, Belfast, Northern Ireland.
FAU - Nesbitt, G A
AU  - Nesbitt GA
FAU - Howe, J P
AU  - Howe JP
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Anaesthesia
JT  - Anaesthesia
JID - 0370524
RN  - J2R869A8YF (Succinylcholine)
RN  - R16CO5Y76E (Aspirin)
RN  - W9YXS298BM (Tubocurarine)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Muscles
MH  - Pain/*prevention & control
MH  - *Premedication
MH  - Succinylcholine/*adverse effects
MH  - Tubocurarine/therapeutic use
EDAT- 1988/07/01 00:00
MHDA- 1988/07/01 00:01
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 1988/07/01 00:01 [medline]
PHST- 1988/07/01 00:00 [entrez]
AID - 10.1111/j.1365-2044.1988.tb06689.x [doi]
PST - ppublish
SO  - Anaesthesia. 1988 Jul;43(7):565-7. doi: 10.1111/j.1365-2044.1988.tb06689.x.

PMID- 33367621
OWN - NLM
STAT- MEDLINE
DCOM- 20220228
LR  - 20220228
IS  - 1758-535X (Electronic)
IS  - 1079-5006 (Print)
IS  - 1079-5006 (Linking)
VI  - 76
IP  - 11
DP  - 2021 Oct 13
TI  - Effect of Aspirin on Activities of Daily Living Disability in Community-Dwelling 
      Older Adults.
PG  - 2007-2014
LID - 10.1093/gerona/glaa316 [doi]
AB  - BACKGROUND: Cerebrovascular events, dementia, and cancer can contribute to 
      physical disability with activities of daily living (ADL). It is unclear whether 
      low-dose aspirin reduces this burden in aging populations. In a secondary 
      analysis, we now examine aspirin's effects on incident and persistent ADL 
      disability within a primary prevention aspirin trial in community-dwelling older 
      adults. METHODS: The ASPREE (ASPirin in Reducing Events in the Elderly) trial of 
      daily 100 mg aspirin versus placebo recruited 19 114 healthy adults aged 70+ 
      years (65+ years if U.S. minority) in Australia and the United States. Six basic 
      ADLs were assessed every 6 months. Incident ADL disability was defined as 
      inability or severe difficulty with ≥1 ADL; persistence was confirmed if the same 
      ADL disability remained after 6 months. Proportional hazards modeling compared 
      time to incident or persistent ADL disability for aspirin versus placebo; death 
      without prior disability was a competing risk. RESULTS: Over a median of 4.7 
      years, incident ADL disability was similar in those receiving aspirin (776/9525) 
      and placebo (787/9589) with walking, bathing, dressing, and transferring the most 
      commonly reported. Only 24% of incident ADL disability progressed to persistent. 
      Persistent ADL disability was lower in the aspirin group (4.3 vs 5.3 events/1000 
      py; hazard ratio [HR] = 0.81, 95% confidence interval [CI]: 0.66-1.00), with 
      bathing and dressing the most common ADL disabilities in both groups. Following 
      persistent ADL disability, there were more deaths in the aspirin group (24 vs 
      12). DISCUSSION: Low-dose aspirin in initially healthy older people did not 
      reduce the risk of incident ADL disability, although there was evidence of 
      reduced persistent ADL disability.
CI  - © The Author(s) 2020. Published by Oxford University Press on behalf of The 
      Gerontological Society of America. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - Woods, Robyn L
AU  - Woods RL
AUID- ORCID: 0000-0003-1249-6149
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Espinoza, Sara
AU  - Espinoza S
AD  - Division of Geriatrics, Gerontology and Palliative Medicine, Barshop Institute 
      for Longevity and Aging Studies, University of Texas Health Science Center, San 
      Antonio, USA.
AD  - Geriatrics Research, Education and Clinical Center, South Texas Veterans Health 
      Care System, San Antonio, USA.
FAU - Thao, Le T P
AU  - Thao LTP
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - Department of Pharmacy Practice and Science, College of Pharmacy and Department 
      of Family Medicine, Carver College of Medicine, The University of Iowa, Iowa 
      City, USA.
FAU - Ryan, Joanne
AU  - Ryan J
AUID- ORCID: 0000-0002-7039-6325
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Shah, Raj C
AU  - Shah RC
AD  - Department of Family Medicine and Rush Alzheimer's Disease Center, Rush 
      University Medical Center, Chicago, Illinois, USA.
FAU - Ward, Stephanie A
AU  - Ward SA
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
AD  - Centre for Healthy Brain Ageing, The University of New South Wales, Sydney, 
      Australia.
FAU - Storey, Elsdon
AU  - Storey E
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, 
      Australia.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - School of Public Health, Curtin University, Perth, Western Australia, Australia.
FAU - Lockery, Jessica E
AU  - Lockery JE
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Orchard, Suzanne G
AU  - Orchard SG
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Trevaks, Ruth E
AU  - Trevaks RE
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Fitzgerald, Sharyn M
AU  - Fitzgerald SM
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Stocks, Nigel P
AU  - Stocks NP
AD  - Discipline of General Practice, Adelaide Medical School, University of Adelaide, 
      South Australia, Australia.
FAU - Williamson, Jeff D
AU  - Williamson JD
AD  - Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest 
      School of Medicine, Winston-Salem, North Carolina, USA.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Murray, Anne M
AU  - Murray AM
AD  - Berman Center for Clinical Outcomes and Research, Minneapolis Medical Research 
      Foundation, Hennepin Healthcare Research Institute, Minneapolis, USA.
AD  - Division of Geriatrics, Department of Medicine, Hennepin County Medical Center 
      and University of Minnesota, Minneapolis, USA.
FAU - Newman, Anne B
AU  - Newman AB
AD  - Center for Aging and Population Health, University of Pittsburgh, Pennsylvania, 
      USA.
LA  - eng
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U01AG029824/NH/NIH HHS/United States
GR  - P30 AG024824/AG/NIA NIH HHS/United States
GR  - CA/NCI NIH HHS/United States
GR  - P30 AG024832/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Gerontol A Biol Sci Med Sci
JT  - The journals of gerontology. Series A, Biological sciences and medical sciences
JID - 9502837
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Activities of Daily Living
MH  - Aged
MH  - Aging
MH  - Aspirin
MH  - Disability Evaluation
MH  - *Disabled Persons
MH  - Humans
MH  - Independent Living
MH  - United States/epidemiology
PMC - PMC8514067
OTO - NOTNLM
OT  - Aspirin
OT  - Clinical trials
OT  - Functional performance
OT  - Physical function
OT  - Preventive health care
EDAT- 2020/12/29 06:00
MHDA- 2022/03/01 06:00
CRDT- 2020/12/28 12:16
PHST- 2020/05/19 00:00 [received]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2022/03/01 06:00 [medline]
PHST- 2020/12/28 12:16 [entrez]
AID - 6052481 [pii]
AID - glaa316 [pii]
AID - 10.1093/gerona/glaa316 [doi]
PST - ppublish
SO  - J Gerontol A Biol Sci Med Sci. 2021 Oct 13;76(11):2007-2014. doi: 
      10.1093/gerona/glaa316.

PMID- 6688218
OWN - NLM
STAT- MEDLINE
DCOM- 19830923
LR  - 20190913
IS  - 0012-6578 (Print)
IS  - 0012-6578 (Linking)
VI  - 17
IP  - 7-8
DP  - 1983 Jul-Aug
TI  - Effect of brand on the serum level of aspirin.
PG  - 550-1
AB  - The authors present a case of a four-year-old female, treated with aspirin for 
      juvenile rheumatoid arthritis. A generic preparation was given first, but plasma 
      salicylate levels remained significantly below the required therapeutic range. 
      Upon changing to a brand-name product, however, therapeutic levels were achieved 
      after one day. The authors conclude that the source of aspirin used had a marked 
      effect on the serum salicylate level.
FAU - Jochsberger, T
AU  - Jochsberger T
FAU - Kirschenbaum, H
AU  - Kirschenbaum H
FAU - Gaynor, H
AU  - Gaynor H
FAU - D'Agostino, J
AU  - D'Agostino J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Drug Intell Clin Pharm
JT  - Drug intelligence & clinical pharmacy
JID - 0212457
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Juvenile/drug therapy
MH  - Aspirin/*blood/therapeutic use
MH  - Biological Availability
MH  - Child, Preschool
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Solubility
MH  - Therapeutic Equivalency
EDAT- 1983/07/01 00:00
MHDA- 1983/07/01 00:01
CRDT- 1983/07/01 00:00
PHST- 1983/07/01 00:00 [pubmed]
PHST- 1983/07/01 00:01 [medline]
PHST- 1983/07/01 00:00 [entrez]
AID - 10.1177/106002808301700714 [doi]
PST - ppublish
SO  - Drug Intell Clin Pharm. 1983 Jul-Aug;17(7-8):550-1. doi: 
      10.1177/106002808301700714.

PMID- 10763207
OWN - NLM
STAT- MEDLINE
DCOM- 20000427
LR  - 20190826
IS  - 0248-8663 (Print)
IS  - 0248-8663 (Linking)
VI  - 21 Suppl 1
DP  - 2000 Mar
TI  - [Aspirin and prevention of pre-eclampsia].
PG  - 68s-74s
AB  - Aspirin is used in pregnant women in order to obviate the imbalance of 
      prostanoids caused by a defective placentation, and also to counteract the 
      widespread thrombotic tendency related to endothelial dysfunction. After a series 
      of controlled trials which showed a very consistent effect of aspirin t prevent 
      preeclampsia and fetal growth retardation, several recent large trials have cast 
      the doubt, and even unbelief. Their results are analyzed in an explicative way. 
      Discrepancies seem largely related to either studying very low-risk populations, 
      or strong differences in aspirin dosage and/or term of introduction. In the last 
      few years, several works have shown the critical importance of an early 
      treatment, and also of a measurable biologic effect, which requires larger 
      dosages than those used in the most recent trials. The doubt largely remains as 
      for the adequate indications of this treatment. New data in the physiology of 
      placentation suggest that it would be logical to give aspirin as early as the 
      first wave of throphoblastic invasion. The effect of so an early treatment need 
      to be evaluated. The search for early markers should be pursued. The combination 
      of aspirin and heparin is under investigation. Finally, other ways of prevention, 
      such as anti-oxidants, are also being studied.
FAU - Beaufils, M
AU  - Beaufils M
AD  - Service de médecine interne, hôpital Tenon, Paris, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspirine et prévention de la prééclampsie.
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cohort Studies
MH  - Controlled Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Humans
MH  - Infant, Newborn
MH  - Meta-Analysis as Topic
MH  - Multicenter Studies as Topic
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
RF  - 19
EDAT- 2000/04/14 09:00
MHDA- 2000/04/29 09:00
CRDT- 2000/04/14 09:00
PHST- 2000/04/14 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/04/14 09:00 [entrez]
AID - S0248-8663(00)88727-5 [pii]
AID - 10.1016/s0248-8663(00)88727-5 [doi]
PST - ppublish
SO  - Rev Med Interne. 2000 Mar;21 Suppl 1:68s-74s. doi: 10.1016/s0248-8663(00)88727-5.

PMID- 6996932
OWN - NLM
STAT- MEDLINE
DCOM- 19801124
LR  - 20190909
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 6
IP  - 9
DP  - 1980
TI  - A controlled evaluation of orally administered aspirin, dipyrone and placebo in 
      patients with post-operative pain.
PG  - 619-23
AB  - A double-blind controlled trial was carried out in 267 patients with moderate to 
      severe pain following episiotomy to compare the pain relief provided over a 
      6-hour period by a single oral dose of 500 mg dipyrone, 500 mg aspirin or 
      placebo. The results showed that dipyrone and aspirin were both significantly 
      superior to placebo. Pain relief with dipyrone was already apparent at 30 minutes 
      after drug intake, and was of significantly longer duration than that of aspirin. 
      No side-effects were reported.
FAU - Mukherjee, S
AU  - Mukherjee S
FAU - Sood, S
AU  - Sood S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Placebos)
RN  - 01704YP3MO (Aminopyrine)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aminopyrine/*analogs & derivatives
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyrone/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Episiotomy
MH  - Female
MH  - Humans
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1185/03007998009109498 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1980;6(9):619-23. doi: 10.1185/03007998009109498.

PMID- 6824996
OWN - NLM
STAT- MEDLINE
DCOM- 19830421
LR  - 20131121
IS  - 0008-428X (Print)
IS  - 0008-428X (Linking)
VI  - 26
IP  - 2
DP  - 1983 Mar
TI  - Preventing acetylsalicylic acid damage to human gastric mucosa by use of 
      prostaglandin E2.
PG  - 116-8
AB  - To determine the lowest dose of prostaglandin E2 (PGE2) capable of preventing the 
      acetylsalicylic acid (ASA)-induced fall in the gastric transmucosal potential 
      difference, six healthy men (mean age 24 years) were studied on 5 separate days, 
      in random sequence. In the control experiment, 100 ml of 140 mM hydrochloric acid 
      was instilled five times into the stomach for 15 minutes each time, during which 
      the transmucosal potential difference was measured continuously. In the test 
      experiments, 20 mM ASA plus PGE2 in doses of 0, 0.1, 0.5, or 1.0 mg were added to 
      the control solution during the second and third instillations. The mean control 
      potential difference (+/- standard error) was -50 +/- 2 mV. During the 
      administration of ASA there was a 25% reduction in the potential difference; this 
      change was statistically significant (p less than 0.01). With all three doses of 
      PGE2 the fall in potential difference was prevented. The results demonstrate that 
      ASA damage to human gastric mucosa can be prevented entirely by concurrent 
      administration of as little as 100 micrograms of PGE2. This supports the view 
      that mucosal protection is a physiologic function of PGE2.
FAU - Cohen, M M
AU  - Cohen MM
FAU - Clark, L
AU  - Clark L
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - Can J Surg
JT  - Canadian journal of surgery. Journal canadien de chirurgie
JID - 0372715
RN  - 0 (Drug Combinations)
RN  - 0 (Prostaglandins E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/antagonists & inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Male
MH  - Membrane Potentials/drug effects
MH  - Prostaglandins E/*pharmacology/physiology
EDAT- 1983/03/01 00:00
MHDA- 1983/03/01 00:01
CRDT- 1983/03/01 00:00
PHST- 1983/03/01 00:00 [pubmed]
PHST- 1983/03/01 00:01 [medline]
PHST- 1983/03/01 00:00 [entrez]
PST - ppublish
SO  - Can J Surg. 1983 Mar;26(2):116-8.

PMID- 404645
OWN - NLM
STAT- MEDLINE
DCOM- 19770630
LR  - 20201209
IS  - 0091-3057 (Print)
IS  - 0091-3057 (Linking)
VI  - 6
IP  - 2
DP  - 1977 Feb
TI  - Self-administration of codeine plus acetylsalicylic acid in rhesus monkeys with 
      unlimited access to the drugs.
PG  - 179-82
AB  - The reinforcing effects of codeine (5.0 mcg/kg/infusion), acetylsalicylic acid 
      (ASA) (2500 mcg/kg/infusion) and those of combinations of codeine (50 
      mcg/kg/infusion) plus (2500 or 10,000 mcg/kg/infusion) were studied in four 
      groups of drug naive rhesus monkeys. Responding was engendered and maintained by 
      infusions of 50 mcg/kg of codeine; maximal number of daily infusions being 500 to 
      1000. Infusions of 2500 mcg/kg of ASA plus 50 mcg/kg of codeine per infusion 
      initiated responding from the 9th to the 10th day of the drug period on. The 
      number of self-administered infusions did not exceed 200 daily. Monkeys self 
      administered codeine without signs of intoxication. All three monkeys 
      self-administering the combination of 50 mcg/kg of codeine plus 2500 mcg/kg of 
      ASA died during the experiment. They exhibited signs of severe intoxication. A 
      combination of 50 mcg/kg of codeine and 10,000 mcg/kg of ASA was not 
      self-administered until the 12th day of the drug period. Two out of three monkeys 
      initiated responding for the combination during the drug period. The number of 
      self-administered infusions did not exceed 50 per day. A third monkey did not 
      initiate self-administration during the 14 day drug period. Both monkeys which 
      engendered self-administration died on the 14th day of the experiment as a result 
      of general intoxication. These experiments suggest that even toxic doses of ASA 
      will not prevent monkeys from self-administration when offered together with a 
      positive reinforcing drug such as codeine under a schedule of continuous 
      self-administration.
FAU - Hoffmeister, F
AU  - Hoffmeister F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Codeine/administration & dosage/*pharmacology
MH  - Drug Synergism
MH  - Haplorhini
MH  - Humans
MH  - Macaca mulatta
MH  - *Substance-Related Disorders
EDAT- 1977/02/01 00:00
MHDA- 1977/02/01 00:01
CRDT- 1977/02/01 00:00
PHST- 1977/02/01 00:00 [pubmed]
PHST- 1977/02/01 00:01 [medline]
PHST- 1977/02/01 00:00 [entrez]
AID - 0091-3057(77)90070-3 [pii]
AID - 10.1016/0091-3057(77)90070-3 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 1977 Feb;6(2):179-82. doi: 10.1016/0091-3057(77)90070-3.

PMID- 28945927
OWN - NLM
STAT- MEDLINE
DCOM- 20190523
LR  - 20190523
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 45
IP  - 2
DP  - 2018 Feb
TI  - Co-ingestion of aspirin and acetaminophen promoting fulminant liver failure: A 
      critical review of Reye syndrome in the current perspective at the dawn of the 
      21st century.
PG  - 117-121
LID - 10.1111/1440-1681.12861 [doi]
AB  - In the paediatric population, there is some evidence of possible interaction, 
      synergism, and co-toxicity of aspirin and acetaminophen. The toxicity of 
      salicylates such as aspirin in this population is well known and documented, 
      specifically in the form of Reye syndrome. The possible toxic synergism with 
      aspirin and acetaminophen, however, is not previously described; though case 
      reports suggest such co-toxicities with low levels of aspirin and other compounds 
      can exist. In vitro studies into mechanistic processes of salicylate toxicity 
      propose that there is a bi-directional link and potentiation with glutathione 
      (GSH) depletion and salicylate toxicity. Data may suggest a plausible explanation 
      for salicylate and acetaminophen toxic synergism. Further studies investigating 
      this potential toxic synergism are warranted. Given the lack of awareness in the 
      clinical community about potential toxic synergism between these relatively 
      common medications, caution is advised in the co-administration of these drugs, 
      particularly in communities using natural or alternative therapy.
CI  - © 2017 John Wiley & Sons Australia, Ltd.
FAU - Dinakaran, Deepak
AU  - Dinakaran D
AD  - Department of Radiation Oncology, University of Alberta, Edmonton, AB, Canada.
FAU - Sergi, Consolato M
AU  - Sergi CM
AUID- ORCID: 0000-0002-2779-7879
AD  - Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, 
      AB, Canada.
AD  - Wuhan University of Science and Technology, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171204
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Child
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Liver Failure, Acute/*chemically induced
MH  - Reye Syndrome/*chemically induced
OTO - NOTNLM
OT  - Reye syndrome
OT  - acetaminophen
OT  - aspirin
OT  - glutathione
OT  - hepatotoxicity
OT  - herbal
OT  - salicylate
EDAT- 2017/09/26 06:00
MHDA- 2019/05/24 06:00
CRDT- 2017/09/26 06:00
PHST- 2016/07/12 00:00 [received]
PHST- 2017/09/08 00:00 [revised]
PHST- 2017/09/12 00:00 [accepted]
PHST- 2017/09/26 06:00 [pubmed]
PHST- 2019/05/24 06:00 [medline]
PHST- 2017/09/26 06:00 [entrez]
AID - 10.1111/1440-1681.12861 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2018 Feb;45(2):117-121. doi: 10.1111/1440-1681.12861. 
      Epub 2017 Dec 4.

PMID- 6401084
OWN - NLM
STAT- MEDLINE
DCOM- 19901015
LR  - 20190821
IS  - 0378-5955 (Print)
IS  - 0378-5955 (Linking)
VI  - 16
IP  - 3
DP  - 1984 Dec
TI  - Aspirin-induced hearing loss as a model of sensorineural hearing loss.
PG  - 251-60
AB  - Performance in forward-masking, temporal-integration, and gap-detection tasks was 
      measured in five normal-hearing subjects before and during a five-day period of 
      aspirin use. The drug regimen was 3.9 g per day, taken in four equal doses at 6-h 
      intervals. In the subjects showing substantial temporary hearing loss induced by 
      the aspirin, (1) forward masking declined at about a normal rate as the 
      masker-to-signal interval was increased, (2) the temporal-integration functions 
      were flatter than normal, and (3) detection of a temporal gap was worse than 
      normal at low sound-pressure levels (SPLs) but was essentially normal at levels 
      above about 60 dB SPL. These aspirin-induced changes in performance are similar 
      to the differences observed between normal listeners and listeners with mild 
      sensorineural hearing loss. Thus, temporary, aspirin-induced hearing loss offers 
      promise as a model condition for sensorineural hearing loss. The advantages 
      offered by this model include all those typically attributed to within-subjects 
      experimental designs, as well as the ability to manipulate the amount of hearing 
      loss. Its primary disadvantages are that the hearing loss is not asymmetrically 
      distributed toward the high-frequency region, as it typically is with 
      sensorineural deafness, and there are large individual differences in the amount 
      of temporary hearing loss induced by fixed doses of aspirin.
FAU - McFadden, D
AU  - McFadden D
AD  - Department of Psychology, University of Texas, Austin 78712.
FAU - Plattsmier, H S
AU  - Plattsmier HS
FAU - Pasanen, E G
AU  - Pasanen EG
LA  - eng
GR  - NS 15895/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Hear Res
JT  - Hearing research
JID - 7900445
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Hearing Loss/*chemically induced/physiopathology
MH  - Hearing Loss, Sensorineural/*etiology/physiopathology
MH  - Humans
MH  - Male
MH  - Models, Biological
EDAT- 1984/12/01 00:00
MHDA- 1984/12/01 00:01
CRDT- 1984/12/01 00:00
PHST- 1984/12/01 00:00 [pubmed]
PHST- 1984/12/01 00:01 [medline]
PHST- 1984/12/01 00:00 [entrez]
AID - 0378-5955(84)90114-X [pii]
AID - 10.1016/0378-5955(84)90114-x [doi]
PST - ppublish
SO  - Hear Res. 1984 Dec;16(3):251-60. doi: 10.1016/0378-5955(84)90114-x.

PMID- 20092028
OWN - NLM
STAT- MEDLINE
DCOM- 20100519
LR  - 20190917
IS  - 1540-0514 (Electronic)
IS  - 1073-2322 (Linking)
VI  - 33
IP  - 2
DP  - 2010 Feb
TI  - The lack of consistent diaspirin cross-linked hemoglobin infusion blood pressure 
      effects in the US and EU traumatic hemorrhagic shock clinical trials.
PG  - 123-33
AB  - Hemoglobin solutions have demonstrated a pressor effect that could adversely 
      affect hemorrhagic shock patient resuscitation through accelerated hemorrhage, 
      diminished perfusion, or inadequate resuscitation. Data from two parallel, 
      multicenter traumatic hemorrhagic shock clinical trials in 17 US emergency 
      departments and in 27 EU prehospital systems using diaspirin cross-linked 
      hemoglobin (DCLHb), a hemoglobin-based resuscitation fluid. In the 219 patients, 
      patients were 37 years old, 64% sustained blunt injury, 48% received DCLHb, and 
      36% expired. Although mean systolic blood pressure (SBP) and diastolic blood 
      pressure values differed at 2 of the 10 measured time points, blood pressure (BP) 
      curve analysis showed no SBP, diastolic blood pressure, or MAP differences based 
      on treatment. Although SBP values 160 and 120 mmHg or greater were 2.2x and 2.6x 
      more frequently noted in survivors, they were not more common with DCLHb use or 
      in DCLHb patients who expired in US study nonsurvivors or in any EU study 
      patients. Systolic blood pressure values 160 and 120 mmHg or greater were 2.8x 
      and 1.3x more frequently noted in DCLHb survivors as compared with normal saline 
      survivors. Only 3% of the BP variation noted could be attributed to DCLHb use, 
      and as expected, injury severity and baseline physiologic status were stronger 
      predictors. In the United States alone, treatment group was not correlated by 
      regression with BP at any time point. Neither mean BP readings nor elevated BP 
      readings were correlated with DCLHb treatment of traumatic hemorrhagic shock 
      patients. As such, no clinically demonstrable DCLHb pressor effect could be 
      directly related to the adverse mortality outcome observed in the US study.
FAU - Sloan, Edward P
AU  - Sloan EP
AD  - Department of Emergency Medicine, College of Medicine, Chicago, IL 60612, USA. 
      edsloan@uic.edu
FAU - Philbin, Nora B
AU  - Philbin NB
FAU - Koenigsberg, Max D
AU  - Koenigsberg MD
FAU - Gao, Weihua
AU  - Gao W
CN  - DCLHb Traumatic Hemorrhagic Shock Study Group
CN  - European HOST Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Shock
JT  - Shock (Augusta, Ga.)
JID - 9421564
RN  - 0 (Hemoglobins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Blood Pressure/drug effects
MH  - *Clinical Trials as Topic
MH  - Female
MH  - Hemoglobins/pharmacology/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Regression Analysis
MH  - Shock, Hemorrhagic/*drug therapy/pathology
MH  - Shock, Traumatic/pathology/*therapy
MH  - Young Adult
FIR - Sloan, Edward P
IR  - Sloan EP
FIR - Koenigsberg, Max D
IR  - Koenigsberg MD
FIR - Dalsey, William C
IR  - Dalsey WC
FIR - Kaplan, Mark
IR  - Kaplan M
FIR - Taggart, Pamela
IR  - Taggart P
FIR - Santora, Thomas A
IR  - Santora TA
FIR - Runge, Jeffrey
IR  - Runge J
FIR - Edwards, Lucinda A
IR  - Edwards LA
FIR - Gibbs, Michael A
IR  - Gibbs MA
FIR - Tinkoff, Glen
IR  - Tinkoff G
FIR - McGraw, Patty
IR  - McGraw P
FIR - O'Conner, Robert
IR  - O'Conner R
FIR - Cydulka, Rita K
IR  - Cydulka RK
FIR - Fallon, William F
IR  - Fallon WF
FIR - Plaisier, Brian
IR  - Plaisier B
FIR - Smith, J Stanley Jr
IR  - Smith JS Jr
FIR - Cooney, Robert N
IR  - Cooney RN
FIR - Shand, Margaret
IR  - Shand M
FIR - Cipolle, Mark D
IR  - Cipolle MD
FIR - Pasquale, Michael D
IR  - Pasquale MD
FIR - Robb, Wendy J
IR  - Robb WJ
FIR - Ochsner, M Gage
IR  - Ochsner MG
FIR - Davis, Frank E
IR  - Davis FE
FIR - Rondina, Joseph
IR  - Rondina J
FIR - Rodman, George H Jr
IR  - Rodman GH Jr
FIR - Miralgia, Charles
IR  - Miralgia C
FIR - Misinski, Maureen
IR  - Misinski M
FIR - Brunett, Patrick H
IR  - Brunett PH
FIR - Bryan, James H
IR  - Bryan JH
FIR - McDevitt, Colleen
IR  - McDevitt C
FIR - Provost, David
IR  - Provost D
FIR - Colpi, Mary Jane
IR  - Colpi MJ
FIR - Stoltzfus, Russel
IR  - Stoltzfus R
FIR - Bynoe, Raymond P
IR  - Bynoe RP
FIR - Hamm, Jay D
IR  - Hamm JD
FIR - Stewart, N John
IR  - Stewart NJ
FIR - Amsden, Dave
IR  - Amsden D
FIR - Walukewicz, Christine
IR  - Walukewicz C
FIR - Wachtel, Thomas
IR  - Wachtel T
FIR - Coniglio, Ray
IR  - Coniglio R
FIR - Hemminger, Lee
IR  - Hemminger L
FIR - Mallory, Mary Nan S
IR  - Mallory MN
FIR - Carillo, Eddy
IR  - Carillo E
FIR - Miller, Richard L
IR  - Miller RL
FIR - Miller, Ashlee
IR  - Miller A
FIR - Gens, David R
IR  - Gens DR
FIR - Joseph, Laura A
IR  - Joseph LA
FIR - Owens, Mehrunissa H
IR  - Owens MH
FIR - Peitzman, Andrew B
IR  - Peitzman AB
FIR - Borst, Marilyn J
IR  - Borst MJ
FIR - Woods, Randy J
IR  - Woods RJ
FIR - Morris, John A
IR  - Morris JA
FIR - Jenkins, Judy
IR  - Jenkins J
FIR - Harviel, J Duncan
IR  - Harviel JD
FIR - Jordan, Marion
IR  - Jordan M
FIR - Wang, Dennis
IR  - Wang D
FIR - Beylo, Lisa
IR  - Beylo L
FIR - Brandenburg, Kristin Y
IR  - Brandenburg KY
FIR - Dougherty, James A
IR  - Dougherty JA
FIR - White, Lynn J
IR  - White LJ
FIR - Muakkassa, Farid
IR  - Muakkassa F
FIR - Harchelroad, Fred
IR  - Harchelroad F
FIR - Potts, Kris
IR  - Potts K
FIR - Levitt, M Andrew
IR  - Levitt MA
FIR - Portoni, Ed
IR  - Portoni E
FIR - Hirvela, Eva
IR  - Hirvela E
FIR - Wall, Mathew J Jr
IR  - Wall MJ Jr
FIR - Mattox, Kenneth L
IR  - Mattox KL
FIR - Mendez, Alex
IR  - Mendez A
FIR - Holevar, Michele
IR  - Holevar M
FIR - Merlotti, Gary
IR  - Merlotti G
FIR - Berry, Sue
IR  - Berry S
FIR - Sloan, Edward P
IR  - Sloan EP
FIR - Barrett, John
IR  - Barrett J
FIR - Nagy, Kim
IR  - Nagy K
FIR - Stapleton, Steve
IR  - Stapleton S
FIR - March, Juan A
IR  - March JA
FIR - Copeland, Susan
IR  - Copeland S
FIR - Catrou, Paul
IR  - Catrou P
FIR - Perdrizet, George A
IR  - Perdrizet GA
FIR - Rescrol, Donna
IR  - Rescrol D
FIR - Jacobs, Lenworth
IR  - Jacobs L
FIR - Kowalenko, Terry
IR  - Kowalenko T
FIR - Dereczyk, Barry
IR  - Dereczyk B
FIR - Rivers, Emanuel P
IR  - Rivers EP
FIR - Nyachowe, Pascal
IR  - Nyachowe P
FIR - Mikhil, Judy
IR  - Mikhil J
FIR - Fantus, Richard
IR  - Fantus R
FIR - Ward, Sharon
IR  - Ward S
FIR - Langdorf, Mark
IR  - Langdorf M
FIR - Simon, Ronald
IR  - Simon R
FIR - Martinez, Dennis
IR  - Martinez D
FIR - Botner, Kate
IR  - Botner K
FIR - O'Neill, Patricia Ann
IR  - O'Neill PA
FIR - Sinert, Richard
IR  - Sinert R
FIR - Eisenberg, Karen Sue
IR  - Eisenberg KS
FIR - Howanitz, Joan H
IR  - Howanitz JH
FIR - Gore, Dennis C
IR  - Gore DC
FIR - Lockhart, Sherry
IR  - Lockhart S
FIR - Chibelski, Heather
IR  - Chibelski H
FIR - Zun, Les
IR  - Zun L
FIR - Kinsela, Annette
IR  - Kinsela A
FIR - Uehara, Dennis
IR  - Uehara D
FIR - Maves, Jeffrey
IR  - Maves J
FIR - Hevesy, George Z
IR  - Hevesy GZ
FIR - Badellino, Michael
IR  - Badellino M
FIR - Buckman, Robert
IR  - Buckman R
FIR - Go, Steven
IR  - Go S
FIR - Morse, Ginger
IR  - Morse G
FIR - Casper, Berna Sue
IR  - Casper BS
FIR - McSwain, Norman Jr
IR  - McSwain N Jr
FIR - Wanstrath, Ruth Ann
IR  - Wanstrath RA
FIR - Luchette, Fred A
IR  - Luchette FA
FIR - Branson, Richard D
IR  - Branson RD
FIR - Davis, Kenneth Jr
IR  - Davis K Jr
FIR - Fildes, John J
IR  - Fildes JJ
FIR - Clemmons-Brown, Connie A
IR  - Clemmons-Brown CA
FIR - Roehr, Cindy
IR  - Roehr C
FIR - Meislin, Harvey
IR  - Meislin H
FIR - Gomez, Cheryle
IR  - Gomez C
FIR - Velmahos, George C
IR  - Velmahos GC
FIR - Tatevossian, Raymond
IR  - Tatevossian R
FIR - Lewis, Roger J
IR  - Lewis RJ
FIR - Berry, Donald
IR  - Berry D
FIR - Cryer, Henry 3rd
IR  - Cryer H 3rd
FIR - Fost, Norman
IR  - Fost N
FIR - Krome, Ronald
IR  - Krome R
FIR - Washington, Geraldine
IR  - Washington G
FIR - Fisher, Marian
IR  - Fisher M
FIR - Bechhofer, Robin
IR  - Bechhofer R
FIR - Cook, Tom
IR  - Cook T
FIR - Schultz, Melissa
IR  - Schultz M
FIR - Przybelski, Robert
IR  - Przybelski R
FIR - Blue, John
IR  - Blue J
FIR - Goldberg, Cynthia
IR  - Goldberg C
FIR - Stern, Kathleen
IR  - Stern K
FIR - Houghton, Jaime
IR  - Houghton J
FIR - Nanavaty, Maulik
IR  - Nanavaty M
FIR - Estep, Timothy
IR  - Estep T
FIR - Saunders, Michael
IR  - Saunders M
FIR - Schmitz, Tom
IR  - Schmitz T
FIR - Pison, Ulrich
IR  - Pison U
FIR - Alted
IR  - Alted
FIR - Todorov
IR  - Todorov
FIR - Vanderpas
IR  - Vanderpas
FIR - Fox
IR  - Fox
FIR - Decroix
IR  - Decroix
FIR - Schtickzelle
IR  - Schtickzelle
FIR - Beaucourt
IR  - Beaucourt
FIR - Bouletreau
IR  - Bouletreau
FIR - Collombel
IR  - Collombel
FIR - Samii
IR  - Samii
FIR - Mazière
IR  - Mazière
FIR - Ossart
IR  - Ossart
FIR - Dabadie
IR  - Dabadie
FIR - Bertrand
IR  - Bertrand
FIR - Coriat
IR  - Coriat
FIR - Guerrini
IR  - Guerrini
FIR - Chauvin
IR  - Chauvin
FIR - Bladier
IR  - Bladier
FIR - Delacoux
IR  - Delacoux
FIR - Marty
IR  - Marty
FIR - Bemer
IR  - Bemer
FIR - Desmonts
IR  - Desmonts
FIR - Poussel
IR  - Poussel
FIR - Stoessel
IR  - Stoessel
FIR - Freysz
IR  - Freysz
FIR - Duvaldestin
IR  - Duvaldestin
FIR - Goossens
IR  - Goossens
FIR - Payen
IR  - Payen
FIR - Rouvier
IR  - Rouvier
FIR - Cathala
IR  - Cathala
FIR - Adenet
IR  - Adenet
FIR - Rousseaux
IR  - Rousseaux
FIR - Ducasse
IR  - Ducasse
FIR - Pasteyer
IR  - Pasteyer
FIR - Feiss
IR  - Feiss
FIR - Reinhart
IR  - Reinhart
FIR - Dick
IR  - Dick
FIR - Gotzen
IR  - Gotzen
FIR - Weinand
IR  - Weinand
FIR - Ellinger
IR  - Ellinger
FIR - Tappe
IR  - Tappe
FIR - Regel
IR  - Regel
FIR - Schmucker
IR  - Schmucker
FIR - Röse
IR  - Röse
FIR - Sokolowski
IR  - Sokolowski
FIR - Motsch
IR  - Motsch
FIR - Unertl
IR  - Unertl
FIR - Katz
IR  - Katz
FIR - Benad
IR  - Benad
FIR - Schuff-Werner
IR  - Schuff-Werner
FIR - Bergner
IR  - Bergner
FIR - Schüttler
IR  - Schüttler
FIR - Hergert
IR  - Hergert
FIR - Lestin
IR  - Lestin
FIR - Bion, J
IR  - Bion J
FIR - Ferdinande, P
IR  - Ferdinande P
FIR - Grootendorst, A
IR  - Grootendorst A
FIR - Little, R
IR  - Little R
FIR - Robertson, C
IR  - Robertson C
FIR - Spahn, D
IR  - Spahn D
FIR - Spiegelhalter, D
IR  - Spiegelhalter D
FIR - Webb, A
IR  - Webb A
FIR - Holmstrom, S
IR  - Holmstrom S
FIR - Gerard, D
IR  - Gerard D
FIR - Reppucci, T
IR  - Reppucci T
FIR - Morrison, A
IR  - Morrison A
FIR - Blue, J
IR  - Blue J
FIR - Goldberg, C
IR  - Goldberg C
FIR - Przybelski, R
IR  - Przybelski R
FIR - Stern, K
IR  - Stern K
FIR - Houghton, J
IR  - Houghton J
FIR - Sperelakis, R
IR  - Sperelakis R
FIR - Wallace, K
IR  - Wallace K
FIR - Petty, J
IR  - Petty J
FIR - Balma, D
IR  - Balma D
FIR - Bottoms, B
IR  - Bottoms B
FIR - Carli, P
IR  - Carli P
EDAT- 2010/01/22 06:00
MHDA- 2010/05/21 06:00
CRDT- 2010/01/22 06:00
PHST- 2010/01/22 06:00 [entrez]
PHST- 2010/01/22 06:00 [pubmed]
PHST- 2010/05/21 06:00 [medline]
AID - 10.1097/shk.0b013e3181ac482b [doi]
PST - ppublish
SO  - Shock. 2010 Feb;33(2):123-33. doi: 10.1097/shk.0b013e3181ac482b.

PMID- 4032405
OWN - NLM
STAT- MEDLINE
DCOM- 19851022
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 12
IP  - 2
DP  - 1985 Apr
TI  - Aspirin dosing using 15 grain enteric coated tablets.
PG  - 337-42
AB  - A high unit dose (15 grain/975 mg) enteric coated aspirin preparation was studied 
      in normal individuals and patients with arthritis to determine how readily well 
      tolerated, therapeutic (150-300 micrograms/ml) salicylate (SA) levels could be 
      achieved using a twice daily dosing regimen. Of 36 participants enrolled, 33 
      (92%) achieved this goal (mean SA = 224 micrograms/ml), while in the remaining 3 
      an initially toxic level fell below the therapeutic range after reducing the dose 
      by one tablet/day. Although the relationship between dose (mg/kg) and steady 
      state SA levels was roughly linear (r = 0.74), in some subjects there was a 
      striking incremental change in the SA level when the dose was adjusted. Over 90% 
      of subjects taking a starting dose between 45-60 mg/kg/day achieved a therapeutic 
      level. Thus, antiinflammatory therapy using 15 grain/975 mg enteric coated 
      aspirin given twice daily appears to be feasible.
FAU - Pollet, S
AU  - Pollet S
FAU - White, R H
AU  - White RH
FAU - Jang, H
AU  - Jang H
FAU - Yim, C W
AU  - Yim CW
FAU - Feigal, D
AU  - Feigal D
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Tablets, Enteric-Coated
MH  - Tinnitus/chemically induced
EDAT- 1985/04/01 00:00
MHDA- 1985/04/01 00:01
CRDT- 1985/04/01 00:00
PHST- 1985/04/01 00:00 [pubmed]
PHST- 1985/04/01 00:01 [medline]
PHST- 1985/04/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1985 Apr;12(2):337-42.

PMID- 10387945
OWN - NLM
STAT- MEDLINE
DCOM- 19990901
LR  - 20190910
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 184
IP  - 2
DP  - 1999 Jul 20
TI  - Incorporating batch effects in the estimation of drug stability parameters using 
      an Arrhenius model.
PG  - 165-73
AB  - The nonlinear estimation of drug stability parameters (energy of activation Ea 
      and shelf-life tY) by conventional approaches employs equations relating drug 
      content determination C at time t and temperature T. The identification 
      procedures lead to the determination of only one initial drug content C0 for 
      several different experiments. However, it is well known that because of 
      experimental concentration variation or of intentional modification of the 
      experimental schedule, there are as many initial drug contents as experiments. 
      For these reasons, a method which takes into account batch effects is proposed to 
      determine stability parameters and also all initial drug contents C0j where j is 
      the index of experiment in one step. This method is more accurate from a 
      statistical viewpoint and is suitable for data treatment in pharmaceutical 
      industries where the initial drug content of each batch entering the stability 
      program can be checked a posteriori. The application of this method is shown on 
      real kinetic data from the hydrolysis of acetylsalicylic acid (ASA).
CI  - Copyright.
FAU - Some, I T
AU  - Some IT
AD  - Laboratoire de Chimie Bioanalytique, de Toxicologie et de Chimie Physique 
      appliquée, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la 
      Plaine, CP 205/1, Boulevard du triomphe, B-1050, Brussels, Belgium.
FAU - Bogaerts, P
AU  - Bogaerts P
FAU - Hanus, R
AU  - Hanus R
FAU - Hanocq, M
AU  - Hanocq M
FAU - Dubois, J
AU  - Dubois J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Aspirin/chemistry
MH  - Chromatography, High Pressure Liquid
MH  - Drug Compounding/statistics & numerical data
MH  - *Drug Stability
MH  - Kinetics
MH  - Models, Theoretical
MH  - Nonlinear Dynamics
EDAT- 1999/07/01 00:00
MHDA- 1999/07/01 00:01
CRDT- 1999/07/01 00:00
PHST- 1999/07/01 00:00 [pubmed]
PHST- 1999/07/01 00:01 [medline]
PHST- 1999/07/01 00:00 [entrez]
AID - S0378517399000174 [pii]
AID - 10.1016/s0378-5173(99)00017-4 [doi]
PST - ppublish
SO  - Int J Pharm. 1999 Jul 20;184(2):165-73. doi: 10.1016/s0378-5173(99)00017-4.

PMID- 20524092
OWN - NLM
STAT- MEDLINE
DCOM- 20110602
LR  - 20220408
IS  - 1534-3111 (Electronic)
IS  - 1522-6417 (Linking)
VI  - 12
IP  - 4
DP  - 2010 Aug
TI  - Antihypertensive effects of aspirin: what is the evidence?
PG  - 282-9
LID - 10.1007/s11906-010-0115-5 [doi]
AB  - Nonsteroidal anti-inflammatory drugs are known to increase blood pressure and 
      blunt the effect of antihypertensive drugs. Surprisingly, it has been suggested 
      recently that aspirin lowers blood pressure and could be used for preventing 
      hypertension. This review summarizes published data on the effects of aspirin on 
      blood pressure. Trials suggesting that aspirin administered at bedtime lowers 
      blood pressure are uncontrolled, unmasked, and potentially biased. They also 
      conflict with cohort studies showing an 18% increase in the risk of hypertension 
      among aspirin users. Fortunately, short-term use of aspirin does not seem to 
      interfere with antihypertensive drugs. Regardless of its effect on blood 
      pressure, low-dose aspirin effectively prevents cardiovascular events in patients 
      with and without hypertension, but its benefits should be carefully weighed 
      against a potential increase in the risk of adverse effects such as gastric 
      bleeding and hemorrhagic stroke, as well as a small increase in the risk of 
      hypertension.
FAU - Bautista, Leonelo E
AU  - Bautista LE
AD  - Population Health Sciences, University of Wisconsin Medical School, 610 Walnut 
      Street, 703 WARF, Madison, WI 53726-2397, USA. lebautista@wisc.edu
FAU - Vera, Lina M
AU  - Vera LM
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Curr Hypertens Rep
JT  - Current hypertension reports
JID - 100888982
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Antihypertensive Agents/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Risk
MH  - Risk Factors
EDAT- 2010/06/05 06:00
MHDA- 2011/06/03 06:00
CRDT- 2010/06/05 06:00
PHST- 2010/06/05 06:00 [entrez]
PHST- 2010/06/05 06:00 [pubmed]
PHST- 2011/06/03 06:00 [medline]
AID - 10.1007/s11906-010-0115-5 [doi]
PST - ppublish
SO  - Curr Hypertens Rep. 2010 Aug;12(4):282-9. doi: 10.1007/s11906-010-0115-5.

PMID- 2664509
OWN - NLM
STAT- MEDLINE
DCOM- 19890815
LR  - 20220410
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 321
IP  - 3
DP  - 1989 Jul 20
TI  - Final report on the aspirin component of the ongoing Physicians' Health Study.
PG  - 129-35
AB  - The Physicians' Health Study is a randomized, double-blind, placebo-controlled 
      trial designed to determine whether low-dose aspirin (325 mg every other day) 
      decreases cardiovascular mortality and whether beta carotene reduces the 
      incidence of cancer. The aspirin component was terminated earlier than scheduled, 
      and the preliminary findings were published. We now present detailed analyses of 
      the cardiovascular component for 22,071 participants, at an average follow-up 
      time of 60.2 months. There was a 44 percent reduction in the risk of myocardial 
      infarction (relative risk, 0.56; 95 percent confidence interval, 0.45 to 0.70; P 
      less than 0.00001) in the aspirin group (254.8 per 100,000 per year as compared 
      with 439.7 in the placebo group). A slightly increased risk of stroke among those 
      taking aspirin was not statistically significant; this trend was observed 
      primarily in the subgroup with hemorrhagic stroke (relative risk, 2.14; 95 
      percent confidence interval, 0.96 to 4.77; P = 0.06). No reduction in mortality 
      from all cardiovascular causes was associated with aspirin (relative risk, 0.96; 
      95 percent confidence interval, 0.60 to 1.54). Further analyses showed that the 
      reduction in the risk of myocardial infarction was apparent only among those who 
      were 50 years of age and older. The benefit was present at all levels of 
      cholesterol, but appeared greatest at low levels. The relative risk of ulcer in 
      the aspirin group was 1.22 (169 in the aspirin group as compared with 138 in the 
      placebo group; 95 percent confidence interval, 0.98 to 1.53; P = 0.08), and the 
      relative risk of requiring a blood transfusion was 1.71. This trial of aspirin 
      for the primary prevention of cardiovascular disease demonstrates a conclusive 
      reduction in the risk of myocardial infarction, but the evidence concerning 
      stroke and total cardiovascular deaths remains inconclusive because of the 
      inadequate numbers of physicians with these end points.
CN  - Steering Committee of the Physicians' Health Study Research Group
LA  - eng
GR  - CA-34944/CA/NCI NIH HHS/United States
GR  - HL-26490/HL/NHLBI NIH HHS/United States
GR  - HL-34595/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 1989 Dec 28;321(26):1825-8. PMID: 2594041
CIN - N Engl J Med. 1989 Jul 20;321(3):183-5. PMID: 2747748
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Cerebrovascular Disorders/prevention & control
MH  - Cholesterol/blood
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - Peptic Ulcer/chemically induced
MH  - Physicians
MH  - Random Allocation
MH  - Risk
MH  - United States
EDAT- 1989/07/20 00:00
MHDA- 1989/07/20 00:01
CRDT- 1989/07/20 00:00
PHST- 1989/07/20 00:00 [pubmed]
PHST- 1989/07/20 00:01 [medline]
PHST- 1989/07/20 00:00 [entrez]
AID - 10.1056/NEJM198907203210301 [doi]
PST - ppublish
SO  - N Engl J Med. 1989 Jul 20;321(3):129-35. doi: 10.1056/NEJM198907203210301.

PMID- 2306267
OWN - NLM
STAT- MEDLINE
DCOM- 19900320
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 39
IP  - 3
DP  - 1990 Feb 1
TI  - Non-steroidal anti-inflammatory drug-copper complex modulation of 
      polymorphonuclear leukocyte migration.
PG  - 569-74
AB  - These studies were intended to compare the effects of aspirin, 
      3,5-diisopropysalicylic acid (3,5-DIPS), and indomethacin with those of their 
      copper complexes: Cu(II)2(aspirinate)4, Cu(II)2(3,5-DIPS)4, and 
      Cu(II)2(indomethacinate)4 as well as Cu(II)2(acetate)4 on polymorphonuclear 
      leukocyte (PMNL) random and directional migration, in addition to their 
      anti-inflammatory activities. Experiments were performed both in vivo and in 
      vitro. In vitro modifications of PMNL migration were measured with the Boyden 
      chamber using N-formyl-methionyl-leucyl-phenylalanine (fMLP) as the 
      chemoattractant and in the agarose assay using fMLP and serum chemotactic 
      derivatives of complement as chemoattractants. In vivo anti-inflammatory 
      activities of these compounds were determined after induction of a serum-induced 
      pleurisy in the rat, and measurement of exudate volume and number of exudative 
      cells 4 hr later. Copper complexes of non-steroidal anti-inflammatory drugs 
      (NSAIDs) were found to be more effective in decreasing random migration and 
      chemotaxis of PMNLs than their parent drugs or Cu(II)2(acetate)4 in in vitro 
      studies. Only chemotaxis was found to be reduced significantly for PMNLs obtained 
      from pleuritic rats after in vivo treatment and the order of copper complex 
      effectiveness was: Cu(II)2(indomethacinate)4 greater than Cu(II)2(3,5-DIPS)4 
      greater than Cu(II)2(aspirinate)4. All doses of Cu(II)2(acetate)4 administered in 
      vivo failed to affect chemotactic activity. Copper complexes of NSAIDs were also 
      more effective than their parent drugs as anti-inflammatory agents, and 
      Cu(II)2(acetate)4 had no anti-inflammatory activity in this model of 
      inflammation. The order of anti-inflammatory activity was: 
      Cu(II)2(indomethacinate)4 greater than Cu(II)2(3,5-DIPS)4 greater than 
      Cu(II)2(aspirinate)4.
FAU - Roch-Arveiller, M
AU  - Roch-Arveiller M
AD  - Department of Pharmacology, CNRS UA 595, Hospital Cochin, Paris, France.
FAU - Huy, D P
AU  - Huy DP
FAU - Maman, L
AU  - Maman L
FAU - Giroud, J P
AU  - Giroud JP
FAU - Sorenson, J R
AU  - Sorenson JR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Acetates)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Salicylates)
RN  - 21246-18-4 (copper bis(3,5-diisopropylsalicylate))
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - 57596-11-9 (cupric(indomethacinate)4complex)
RN  - Q40Q9N063P (Acetic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetates/pharmacology
MH  - Acetic Acid
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Cell Movement/*drug effects
MH  - Chemotaxis, Leukocyte/*drug effects
MH  - Indomethacin/*pharmacology/therapeutic use
MH  - Molecular Structure
MH  - Neutrophils/drug effects/*physiology
MH  - Organometallic Compounds/*pharmacology/therapeutic use
MH  - Pleurisy/drug therapy
MH  - Rats
MH  - Salicylates/*pharmacology/therapeutic use
EDAT- 1990/02/01 00:00
MHDA- 1990/02/01 00:01
CRDT- 1990/02/01 00:00
PHST- 1990/02/01 00:00 [pubmed]
PHST- 1990/02/01 00:01 [medline]
PHST- 1990/02/01 00:00 [entrez]
AID - 0006-2952(90)90065-S [pii]
AID - 10.1016/0006-2952(90)90065-s [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1990 Feb 1;39(3):569-74. doi: 10.1016/0006-2952(90)90065-s.

PMID- 899963
OWN - NLM
STAT- MEDLINE
DCOM- 19771020
LR  - 20190509
IS  - 0002-0729 (Print)
IS  - 0002-0729 (Linking)
VI  - 6
IP  - 3
DP  - 1977 Aug
TI  - The effect of ageing on drug absorption from the gut.
PG  - 138-43
AB  - Single oral doses of aspirin and practolol were given to young and old subjects. 
      The results of the plasma concentration-time curves were subjected to 
      pharmacokinetic appraisal. There was no difference with either drug between the 
      two age-groups in the mean absorption rate constant and the time at which maximum 
      concentration in the plasma occurred. However, the amount of drug in the plasma 
      of the elderly group was the same or higher than that in the younger group. It is 
      concluded that ageing has no significant effect on the rate or amount of these 
      drugs absorbed.
FAU - Castleden, C M
AU  - Castleden CM
FAU - Volans, C N
AU  - Volans CN
FAU - Raymond, K
AU  - Raymond K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Age Ageing
JT  - Age and ageing
JID - 0375655
RN  - R16CO5Y76E (Aspirin)
RN  - SUG9176GRW (Practolol)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - *Aging
MH  - Aspirin/administration & dosage/blood/*metabolism
MH  - Biological Availability
MH  - Humans
MH  - *Intestinal Absorption
MH  - Intestine, Small/metabolism
MH  - Practolol/administration & dosage/blood/*metabolism
EDAT- 1977/08/01 00:00
MHDA- 1977/08/01 00:01
CRDT- 1977/08/01 00:00
PHST- 1977/08/01 00:00 [pubmed]
PHST- 1977/08/01 00:01 [medline]
PHST- 1977/08/01 00:00 [entrez]
AID - 10.1093/ageing/6.3.138 [doi]
PST - ppublish
SO  - Age Ageing. 1977 Aug;6(3):138-43. doi: 10.1093/ageing/6.3.138.

PMID- 4593555
OWN - NLM
STAT- MEDLINE
DCOM- 19740517
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 1
IP  - 5905
DP  - 1974 Mar 9
TI  - A randomized controlled trial of acetyl salicylic acid in the secondary 
      prevention of mortality from myocardial infarction.
PG  - 436-40
AB  - The results of a randomized controlled trial of a single daily dose of acetyl 
      salicylic acid (aspirin) in the prevention of reinfarction in 1,239 men who had 
      had a recent myocardial infarct were statistically inconclusive. Nevertheless, 
      they showed a reduction in total mortality of 12% at six months and 25% at twelve 
      months after admission to the trial. Further trials are urgently required to 
      establish whether or not this effect is real.
FAU - Elwood, P C
AU  - Elwood PC
FAU - Cochrane, A L
AU  - Cochrane AL
FAU - Burr, M L
AU  - Burr ML
FAU - Sweetnam, P M
AU  - Sweetnam PM
FAU - Williams, G
AU  - Williams G
FAU - Welsby, E
AU  - Welsby E
FAU - Hughes, S J
AU  - Hughes SJ
FAU - Renton, R
AU  - Renton R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/mortality/*prevention & control
MH  - Placebos
MH  - Platelet Adhesiveness/drug effects
MH  - Recurrence
MH  - Time Factors
PMC - PMC1633246
EDAT- 1974/03/09 00:00
MHDA- 1974/03/09 00:01
CRDT- 1974/03/09 00:00
PHST- 1974/03/09 00:00 [pubmed]
PHST- 1974/03/09 00:01 [medline]
PHST- 1974/03/09 00:00 [entrez]
AID - 10.1136/bmj.1.5905.436 [doi]
PST - ppublish
SO  - Br Med J. 1974 Mar 9;1(5905):436-40. doi: 10.1136/bmj.1.5905.436.

PMID- 24984883
OWN - NLM
STAT- MEDLINE
DCOM- 20150410
LR  - 20161125
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 28
IP  - 4
DP  - 2014 Aug
TI  - Laboratory aspirin resistance reversibility in diabetic patients: a pilot study 
      using different pharmaceutical formulations.
PG  - 323-9
LID - 10.1007/s10557-014-6536-7 [doi]
AB  - PURPOSE: Aspirin resistance occurs most frequently in diabetic patients and is 
      associated with poor prognosis. The purpose of this study was to evaluate the 
      prevalence of aspirin resistance in a cohort of diabetic patients and whether it 
      can be reversed using more bioavailable aspirin formulations. METHODS: Platelets 
      function of 163 diabetic patients taking acetyl salicylic acid (ASA) 100 mg daily 
      has been evaluated with PFA100 and VerifyNow. Patients found resistant by at 
      least one test received an infusion of 288 mg of lysine acetylsalicylate 
      (Flectadol®) corresponding to ASA 160 mg. Platelets function was measured again 
      after 1 and 24 h. Patients whose the resistance was reversed received 288 mg of 
      soluble salt of lysine acetylsalicylate (Cardirene 160®) corresponding to ASA160 
      mg instead of aspirin and their aggregation status was re-evaluated after 1 month 
      of therapy. RESULTS: Prevalence of aspirin resistance in our population was 
      18,4 % (30/163). In 27 out of 30 patients (90 %) aspirin resistance was reversed 
      within 24 h from the infusion. 25 out of 27 patients (92 %) were found fully 
      aspirin-sensitive after 1 month of oral therapy with soluble salt; two patients 
      were found with borderline value. No adverse reactions were observed. 
      CONCLUSIONS: A significant number of diabetic patients are resistant to aspirin 
      therapy. A single intravenous dose of lysine acetylsalicylate can reverse the 
      platelet hyper-aggregability and laboratory aspirin resistance in large majority 
      of patients. The efficacy of antiaggregation can be maintained by chronic therapy 
      with an oral drug with a more favourable pharmacokinetic profile.
FAU - Grimaldi, Roberto
AU  - Grimaldi R
AD  - Division of Cardiology, Department of Internal Medicine, Città della Salute e 
      della Scienza, Turin, Italy.
FAU - Bisi, Marta
AU  - Bisi M
FAU - Lonni, Enrica
AU  - Lonni E
FAU - Beggiato, Eloise
AU  - Beggiato E
FAU - Valpreda, Alessandra
AU  - Valpreda A
FAU - Lococo, Marco Francesco
AU  - Lococo MF
FAU - Dosio, Enrico
AU  - Dosio E
FAU - Presutti, Davide Giacomo
AU  - Presutti DG
FAU - Tagliabue, Milena
AU  - Tagliabue M
FAU - Gaita, Fiorenzo
AU  - Gaita F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aged
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Chemistry, Pharmaceutical
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Laboratories
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2014/07/06 06:00
MHDA- 2015/04/11 06:00
CRDT- 2014/07/03 06:00
PHST- 2014/07/03 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2015/04/11 06:00 [medline]
AID - 10.1007/s10557-014-6536-7 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2014 Aug;28(4):323-9. doi: 10.1007/s10557-014-6536-7.

PMID- 28084009
OWN - NLM
STAT- MEDLINE
DCOM- 20170405
LR  - 20221121
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 1
IP  - 1
DP  - 2017 Jan 13
TI  - Aspirin for acute treatment of episodic tension-type headache in adults.
PG  - CD011888
LID - 10.1002/14651858.CD011888.pub2 [doi]
LID - CD011888
AB  - BACKGROUND: Tension-type headache (TTH) affects about 1 person in 5 worldwide. It 
      is divided into infrequent episodic TTH (fewer than one headache per month), 
      frequent episodic TTH (two to 14 headache days per month), and chronic TTH (15 
      headache days per month or more). Aspirin is one of a number of analgesics 
      suggested for acute treatment of episodic TTH. OBJECTIVES: To assess the efficacy 
      and safety of aspirin for acute treatment of episodic tension-type headache (TTH) 
      in adults compared with placebo or any active comparator. SEARCH METHODS: We 
      searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, 
      Embase, and the Oxford Pain Relief Database from inception to September 2016, and 
      also reference lists of relevant published studies and reviews. We sought 
      unpublished studies by asking personal contacts and searching online clinical 
      trial registers and manufacturers' websites. SELECTION CRITERIA: We included 
      randomised, double-blind, placebo-controlled studies (parallel-group or 
      cross-over) using oral aspirin for symptomatic relief of an acute episode of TTH. 
      Studies had to be prospective, with participants aged 18 years or over, and 
      include at least 10 participants per treatment arm. DATA COLLECTION AND ANALYSIS: 
      Two review authors independently assessed studies for inclusion and extracted 
      data. For various outcomes (predominantly those recommended by the International 
      Headache Society (IHS)), we calculated the risk ratio (RR) and number needed to 
      treat for one additional beneficial outcome (NNT), one additional harmful outcome 
      (NNH), or to prevent one event (NNTp) for oral aspirin compared to placebo or an 
      active intervention.We assessed the evidence using GRADE and created a 'Summary 
      of findings' table. MAIN RESULTS: We included five studies enrolling adults with 
      frequent episodic TTH; 1812 participants took medication, of which 767 were 
      included in comparisons of aspirin 1000 mg with placebo, and 405 in comparisons 
      of aspirin 500 mg or 650 mg with placebo. Not all of these participants provided 
      data for outcomes of interest in this review. Four studies specified using IHS 
      diagnostic criteria; one predated commonly recognised criteria, but described 
      comparable characteristics and excluded migraine. All participants treated 
      headaches of at least moderate pain intensity.None of the included studies were 
      at low risk of bias across all domains considered, although for most studies and 
      domains this was likely to be due to inadequate reporting rather than poor 
      methods. We judged one study to be at high risk of bias due to small size.There 
      were no data for aspirin at any dose for the IHS preferred outcome of being pain 
      free at two hours, or for being pain free at any other time, and only one study 
      provided data equivalent to having no or mild pain at two hours (very low quality 
      evidence). Use of rescue medication was lower with aspirin 1000 mg than with 
      placebo (2 studies, 397 participants); 14% of participants used rescue medication 
      with aspirin 1000 mg compared with 31% with placebo (NNTp 6.0, 95% confidence 
      interval (CI) 4.1 to 12) (low quality evidence). Two studies (397 participants) 
      reported a Patient Global Evaluation at the end of the study; we combined the top 
      two categories for both studies to determine the number of participants who were 
      'satisfied' with treatment. Aspirin 1000 mg produced more satisfied participants 
      (55%) than did placebo (37%) (NNT 5.7, 95% CI 3.7 to 12) (very low quality 
      evidence).Adverse events were not different between aspirin 1000 mg and placebo 
      (RR 1.1, 95% CI 0.8 to 1.5), or aspirin 500 mg or 650 mg and placebo (RR 1.3, 95% 
      CI 0.8 to 2.0) (low quality evidence). Studies reported no serious adverse 
      events.The quality of the evidence using GRADE comparing aspirin doses between 
      500 mg and 1000 mg with placebo was low or very low. Evidence was downgraded 
      because of the small number of studies and events, and because the most important 
      measures of efficacy were not reported.There were insufficient data to compare 
      aspirin with any active comparator (paracetamol alone, paracetamol plus codeine, 
      peppermint oil, or metamizole) at any of the doses tested. AUTHORS' CONCLUSIONS: 
      A single dose of aspirin between 500 mg and 1000 mg provided some benefit in 
      terms of less frequent use of rescue medication and more participants satisfied 
      with treatment compared with placebo in adults with frequent episodic TTH who 
      have an acute headache of moderate or severe intensity. There was no difference 
      between a single dose of aspirin and placebo for the number of people 
      experiencing adverse events. The amount and quality of the evidence was very 
      limited and should be interpreted with caution.
FAU - Derry, Sheena
AU  - Derry S
AD  - Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield 
      Division of Anaesthetics), University of Oxford, Pain Research Unit, Churchill 
      Hospital, Oxford, Oxfordshire, UK, OX3 7LE.
FAU - Wiffen, Philip J
AU  - Wiffen PJ
AD  - Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield 
      Division of Anaesthetics), University of Oxford, Pain Research Unit, Churchill 
      Hospital, Oxford, Oxfordshire, UK, OX3 7LE.
FAU - Moore, R Andrew
AU  - Moore RA
AD  - Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield 
      Division of Anaesthetics), University of Oxford, Pain Research Unit, Churchill 
      Hospital, Oxford, Oxfordshire, UK, OX3 7LE.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20170113
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Analgesics)
RN  - 0 (Plant Oils)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 6429L0L52Y (Dipyrone)
RN  - AV092KU4JH (peppermint oil)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
UOF - doi: 10.1002/14651858.CD011888
MH  - Acetaminophen/therapeutic use
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Analgesics/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Codeine/therapeutic use
MH  - Dipyrone/therapeutic use
MH  - Humans
MH  - Mentha piperita
MH  - Middle Aged
MH  - Pain Measurement
MH  - Plant Oils/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Tension-Type Headache/*drug therapy
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC6464783
COIS- SD: none known. PW: none known. RAM has received grant support from Grünenthal 
      relating to individual patient level analyses of trial data regarding tapentadol 
      in osteoarthritis and back pain (2015). He has received honoraria for attending 
      boards with Menarini concerning methods of analgesic trial design (2014), with 
      Novartis (2014) about the design of network meta‐analyses, and RB on 
      understanding pharmacokinetics of drug uptake (2015). He has received honoraria 
      from Omega Pharma (2016) and Futura Pharma (2016) for providing advice on trial 
      and data analysis methods.
EDAT- 2017/01/14 06:00
MHDA- 2017/04/06 06:00
CRDT- 2017/01/14 06:00
PHST- 2017/01/14 06:00 [pubmed]
PHST- 2017/04/06 06:00 [medline]
PHST- 2017/01/14 06:00 [entrez]
AID - CD011888.pub2 [pii]
AID - 10.1002/14651858.CD011888.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2017 Jan 13;1(1):CD011888. doi: 
      10.1002/14651858.CD011888.pub2.

PMID- 7136008
OWN - NLM
STAT- MEDLINE
DCOM- 19821216
LR  - 20181113
IS  - 0044-0086 (Print)
IS  - 1551-4056 (Electronic)
IS  - 0044-0086 (Linking)
VI  - 55
IP  - 2
DP  - 1982 Mar-Apr
TI  - Assessment of observer variability in the classification of human cataracts.
PG  - 81-8
AB  - An in vitro cataract classification system was developed in our laboratories and 
      used to demonstrate a relationship between sustained aspirin intake and the 
      apparent deceleration or retardation of human cataract formation. The purpose of 
      this investigation was to assess the reliability of this cataract classification 
      schema. Sets of extracted human cataractous lenses, which had been photographed 
      in vitro, were randomly assigned to five observers. The task was to classify the 
      lenses on the basis of nuclear and cortical involvement, as reflected in color 
      and area changes along five groupings. Assessments were made on the basis of both 
      intraobserver and interobserver agreement levels, corrected for chance (weighted 
      kappa values). All five examiners evidenced levels of intraobserver agreement 
      which ranged between "Good" and "Fair" and "Excellent" (.46-.83). Each of the 
      five observers was ranked on the basis of his agreement levels with the remaining 
      four observers. The results followed a predictable pattern such that the more 
      experienced the observer in classifying cataracts, the more consistent his 
      rankings vis-à-vis the remaining four evaluators. These results are discussed in 
      the general context of observer variability studies in the field of medicine.
FAU - Cicchetti, D V
AU  - Cicchetti DV
FAU - Sharma, Y
AU  - Sharma Y
FAU - Cotlier, E
AU  - Cotlier E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Yale J Biol Med
JT  - The Yale journal of biology and medicine
JID - 0417414
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology
MH  - Cataract/*classification/prevention & control
MH  - Evaluation Studies as Topic
MH  - Humans
MH  - Male
MH  - Middle Aged
PMC - PMC2596006
EDAT- 1982/03/01 00:00
MHDA- 1982/03/01 00:01
CRDT- 1982/03/01 00:00
PHST- 1982/03/01 00:00 [pubmed]
PHST- 1982/03/01 00:01 [medline]
PHST- 1982/03/01 00:00 [entrez]
PST - ppublish
SO  - Yale J Biol Med. 1982 Mar-Apr;55(2):81-8.

PMID- 15943479
OWN - NLM
STAT- MEDLINE
DCOM- 20050706
LR  - 20141120
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 48
IP  - 12
DP  - 2005 Jun 16
TI  - Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor 
      diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and 
      nitric oxide release studies.
PG  - 4061-7
AB  - A novel group of hybrid nitric oxide-releasing nonsteroidal antiinflammatory 
      drugs ((*)NO-NSAIDs) possessing a 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate 
      (11, 13, 15) or 1-(N,N-dimethylamino)diazen-1-ium-1,2-diolate (12, 14, 16) moiety 
      attached via a one-carbon methylene spacer to the carboxylic acid group of the 
      traditional NSAIDs aspirin, ibuprofen, and indomethacin were synthesized. 
      Although none of these ester prodrugs (11-16) exhibited in vitro cyclooxygenase 
      (COX) inhibitory activity against the COX-1 and COX-2 isozymes (IC(50) > 100 
      microM), all of the compounds (11-16) significantly decreased carrageenan-induced 
      rat paw edema. In this regard, the ester prodrugs 11-16 showed equipotent 
      antiinflammatory activities in vivo to that of the parent drugs aspirin, 
      ibuprofen, and indomethacin. All of the compounds released nitric oxide upon 
      incubation with either phosphate buffer solution at pH 7.4 (14-16% range) or 
      porcine liver esterase (16-19% range), but the percentage of (*)NO released was 
      up to sixfold higher (93%) when these ester prodrugs were incubated with guinea 
      pig serum. These incubation studies suggest that both (*)NO and the parent NSAID 
      would be released upon in vivo cleavage by nonspecific serum esterases. The 
      simultaneous release of aspirin and nitric oxide from the (*)NO-aspirin prodrugs 
      constitutes a potentially beneficial property for the prophylactic prevention of 
      thrombus formation and adverse cardiovascular events such as stroke and 
      myocardial infarction. The data acquired in an in vivo ulcer index (UI) assay 
      showed that for this group of ester prodrugs, particularly the (*)NO-aspirins 
      (11, 12) and (*)NO-ibuprofens (13, 14), no lesions were observed (UI = 0) when 
      compared to the parent drugs aspirin (UI = 57, 250 mg/kg po dose), ibuprofen (UI 
      = 45, 250 mg/kg po dose), or indomethacin (UI = 34, 30 mg/kg po dose) at 
      equivalent doses. Accordingly, these hybrid (*)NO-NSAID prodrugs possessing a 
      diazen-1-ium-1,2-diolate moiety, represent a new approach for the rational design 
      of antiinflammatory drugs with reduced gastric ulcerogenicity.
FAU - Velázquez, Carlos
AU  - Velázquez C
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Canada.
FAU - Praveen Rao, P N
AU  - Praveen Rao PN
FAU - Knaus, Edward E
AU  - Knaus EE
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Azo Compounds)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Esters)
RN  - 0 (Membrane Proteins)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Prodrugs)
RN  - 0 (Pyrrolidines)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EC 1.14.99.1 (Ptgs1 protein, rat)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*chemical 
      synthesis/pharmacology
MH  - Aspirin/administration & dosage/adverse effects/chemistry
MH  - Azo Compounds/adverse effects/*chemical synthesis/pharmacology
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/adverse effects/chemical synthesis/pharmacology
MH  - Esters/adverse effects/chemical synthesis/pharmacology
MH  - Guinea Pigs
MH  - Ibuprofen/administration & dosage/adverse effects/chemistry
MH  - In Vitro Techniques
MH  - Indomethacin/administration & dosage/adverse effects/chemistry
MH  - Membrane Proteins
MH  - Nitric Oxide/chemistry/metabolism
MH  - Nitric Oxide Donors/adverse effects/*chemical synthesis/pharmacology
MH  - Prodrugs/adverse effects/*chemical synthesis/pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/chemistry
MH  - Pyrrolidines/adverse effects/*chemical synthesis/pharmacology
MH  - Rats
MH  - Stomach Ulcer/chemically induced
MH  - Structure-Activity Relationship
EDAT- 2005/06/10 09:00
MHDA- 2005/07/07 09:00
CRDT- 2005/06/10 09:00
PHST- 2005/06/10 09:00 [pubmed]
PHST- 2005/07/07 09:00 [medline]
PHST- 2005/06/10 09:00 [entrez]
AID - 10.1021/jm050211k [doi]
PST - ppublish
SO  - J Med Chem. 2005 Jun 16;48(12):4061-7. doi: 10.1021/jm050211k.

PMID- 15240983
OWN - NLM
STAT- MEDLINE
DCOM- 20040930
LR  - 20131121
IS  - 0014-3022 (Print)
IS  - 0014-3022 (Linking)
VI  - 52
IP  - 1
DP  - 2004
TI  - Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in 
      treating associated migraine symptoms.
PG  - 50-6
AB  - Recently a new effervescent acetylsalicylic acid (ASA) tablet with high buffering 
      capacity has been developed. In this double-blind, 3-arm, multicenter, 
      parallel-group study, 433 patients were treated either with 1,000 mg effervescent 
      ASA or 50 mg encapsulated sumatriptan or placebo. The primary endpoint was the 
      percentage of patients with complete remission of the 3 accompanying symptoms 
      nausea, photophobia and phonophobia within 2 h after intake of the study drug. 
      43.8% of patients treated with ASA, 43.7% of patients treated with sumatriptan 
      and 30.9% of patients treated with placebo showed complete remission of all 3 
      accompanying symptoms (p < 0.05 for ASA and sumatriptan vs. placebo). Both active 
      treatments were superior to placebo regarding the individual symptoms photophobia 
      and phonophobia, but not for nausea. The percentage of patients with reduction in 
      headache severity from moderate or severe to mild or no pain (secondary 
      objective) was 49.3% for ASA, 48.8% for sumatriptan and 32.9% for placebo. All 
      active treatments were superior to placebo (p < 0.05). 25.3, 24.4 and 14.5% of 
      patients treated with ASA, sumatriptan or placebo were pain free at 2 h. 
      Drug-related adverse events were reported in 3.9, 4.7 and 6.7% of patients 
      treated with placebo, ASA or sumatriptan. The study showed that administration of 
      effervescent ASA leads to remission of the migraine symptoms nausea, photophobia 
      and phonophobia, reduces migraine headache and is comparable to sumatriptan.
CI  - Copyright 2004 S. Karger AG, Basel
FAU - Diener, H C
AU  - Diener HC
AD  - Department of Neurology, University of Essen, Hufelandstrasse 55, DE-45147 Essen, 
      Germany. h.diener@uni-essen.de
FAU - Eikermann, A
AU  - Eikermann A
FAU - Gessner, U
AU  - Gessner U
FAU - Göbel, H
AU  - Göbel H
FAU - Haag, G
AU  - Haag G
FAU - Lange, R
AU  - Lange R
FAU - May, A
AU  - May A
FAU - Müller-Schwefe, G
AU  - Müller-Schwefe G
FAU - Voelker, M
AU  - Voelker M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20040705
PL  - Switzerland
TA  - Eur Neurol
JT  - European neurology
JID - 0150760
RN  - 0 (Vasoconstrictor Agents)
RN  - 8R78F6L9VO (Sumatriptan)
RN  - R16CO5Y76E (Aspirin)
RN  - VBE72MCP5L (acetylsalicylsalicylic acid)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*analogs & derivatives/*therapeutic use
MH  - Demography
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Sumatriptan/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vasoconstrictor Agents/*therapeutic use
EDAT- 2004/07/09 05:00
MHDA- 2004/10/01 05:00
CRDT- 2004/07/09 05:00
PHST- 2003/10/02 00:00 [received]
PHST- 2004/04/06 00:00 [accepted]
PHST- 2004/07/09 05:00 [pubmed]
PHST- 2004/10/01 05:00 [medline]
PHST- 2004/07/09 05:00 [entrez]
AID - 79544 [pii]
AID - 10.1159/000079544 [doi]
PST - ppublish
SO  - Eur Neurol. 2004;52(1):50-6. doi: 10.1159/000079544. Epub 2004 Jul 5.

PMID- 18068522
OWN - NLM
STAT- MEDLINE
DCOM- 20080321
LR  - 20191210
IS  - 1474-4422 (Print)
IS  - 1474-4422 (Linking)
VI  - 7
IP  - 1
DP  - 2008 Jan
TI  - Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial.
PG  - 41-9
AB  - BACKGROUND: Cardiovascular risk factors and a history of vascular disease can 
      increase the risk of Alzheimer's disease (AD). AD is less common in aspirin users 
      than non-users, and there are plausible biological mechanisms whereby aspirin 
      might slow the progression of either vascular or Alzheimer-type pathology. We 
      assessed the benefits of aspirin in patients with AD. METHODS: 310 
      community-resident patients who had AD and who had no potential indication or 
      definite contraindication for aspirin were randomly assigned to receive 
      open-label aspirin (n=156; one 75-mg enteric-coated tablet per day, to continue 
      indefinitely) or to avoid aspirin (n=154). Primary outcome measures were 
      cognition (assessed with the mini-mental state examination [MMSE]) and functional 
      ability (assessed with the Bristol activities of daily living scale [BADLS]). 
      Secondary outcomes were time to formal domiciliary or institutional care, 
      progress of disability, behavioural symptoms, caregiver wellbeing, and care time. 
      Patients were assessed at 12-week intervals in the first year and once each year 
      thereafter. Analysis of the primary outcome measures was by intention to treat. 
      This study is registered as an International Standard Randomised Controlled 
      Trial, number ISRCTN96337233. FINDINGS: Patients had a median age of 75 years; 
      156 patients had mild AD, 154 had moderate AD, and 18 had concomitant vascular 
      dementia. Over the 3 years after randomisation, in patients who took aspirin, 
      mean MMSE score was 0.10 points higher (95% CI -0.37 to 0.57; p=0.7) and mean 
      BADLS score was 0.62 points lower (-1.37 to 0.13; p=0.11) than in patients 
      assigned to aspirin avoidance. There were no obvious differences between the 
      groups in any other outcome measurements. 13 (8%) patients on aspirin and two 
      (1%) patients in the control group had bleeds that led to admission to hospital 
      (relative risk=4.4, 95% CI 1.5-12.8; p=0.007); three (2%) patients in the aspirin 
      group had fatal cerebral bleeds. INTERPRETATION: Although aspirin is commonly 
      used in dementia, in patients with typical AD 2 years of treatment with low-dose 
      aspirin has no worthwhile benefit and increases the risk of serious bleeds.
CN  - AD2000 Collaborative Group
FAU - Bentham, P
AU  - Bentham P
FAU - Gray, R
AU  - Gray R
FAU - Sellwood, E
AU  - Sellwood E
FAU - Hills, R
AU  - Hills R
FAU - Crome, P
AU  - Crome P
FAU - Raftery, J
AU  - Raftery J
LA  - eng
SI  - ISRCTN/ISRCTN96337233
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet Neurol
JT  - The Lancet. Neurology
JID - 101139309
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet Neurol. 2008 Jan;7(1):20-1. PMID: 18068519
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*drug therapy/physiopathology
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Mental Status Schedule
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Outcome Assessment, Health Care
MH  - Retrospective Studies
EDAT- 2007/12/11 09:00
MHDA- 2008/03/22 09:00
CRDT- 2007/12/11 09:00
PHST- 2007/12/11 09:00 [pubmed]
PHST- 2008/03/22 09:00 [medline]
PHST- 2007/12/11 09:00 [entrez]
AID - S1474-4422(07)70293-4 [pii]
AID - 10.1016/S1474-4422(07)70293-4 [doi]
PST - ppublish
SO  - Lancet Neurol. 2008 Jan;7(1):41-9. doi: 10.1016/S1474-4422(07)70293-4.

PMID- 32304413
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210705
IS  - 1530-0293 (Electronic)
IS  - 0090-3493 (Linking)
VI  - 48
IP  - 7
DP  - 2020 Jul
TI  - Concomitant Aspirin and Anticoagulation Is Associated With Increased Risk for 
      Major Bleeding in Surgical Patients Requiring Postoperative Intensive Care.
PG  - 985-992
LID - 10.1097/CCM.0000000000004350 [doi]
AB  - OBJECTIVES: Critically ill surgical patients may receive concomitant aspirin and 
      therapeutic anticoagulation postoperatively, yet the safety of this practice 
      remains unknown. We evaluated the risk of major bleeding with concomitant therapy 
      compared with anticoagulation alone. DESIGN: Observational cohort study. Inverse 
      probability of treatment weighting was used to assess the association between 
      concomitant therapy and a primary outcome of major bleeding. SETTING: 
      Postoperative ICUs at an academic medical center. PATIENTS: Adults (≥ 18 yr old) 
      receiving anticoagulation during postoperative ICU admission between 2007 and 
      2016. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Nine thousand five 
      hundred eighteen anticoagulated patients were included, including 3,237 (34%) 
      receiving aspirin. A total of 1,874 unique patients (19.7%) experienced a major 
      bleeding event. In inverse probability of treatment weighting analyses, 
      concomitant therapy was associated with increased odds for major bleeding (odds 
      ratio, 1.20; 95% CI, 1.05-1.36; p = 0.006) compared with anticoagulation alone. 
      An interaction test suggested a differential relationship between aspirin use and 
      major bleeding based on aspirin use in the 7 days prior to anticoagulation, such 
      that a strong association between aspirin and major bleeding was observed for 
      recent initiators of aspirin (1.40; 1.13-1.72;p = 0.002) but not for those 
      continuing prior aspirin use. Aspirin use prior to anticoagulation did not modify 
      the relationship between concomitant therapy and new myocardial infarction or 
      stroke (i.e., rates were not increased with aspirin discontinuation prior to 
      anticoagulation). CONCLUSIONS: Concomitant aspirin and anticoagulation in 
      critically ill surgical patients was associated with an increased rate of major 
      bleeding. Future investigations are warranted to further define optimal 
      management of antiplatelet therapy during anticoagulation in surgical patients.
FAU - Rayes, Hamza A
AU  - Rayes HA
AD  - Division of Pulmonary and Critical Care Medicine, Department of Internal 
      Medicine, Mayo Clinic, Rochester, MN.
FAU - Subat, Yosuf W
AU  - Subat YW
AD  - Department of Internal Medicine, Mayo Clinic, Rochester, MN.
FAU - Weister, Timothy
AU  - Weister T
AD  - Department of Clinical Research, Department of Anesthesiology & Perioperative 
      Medicine, Mayo Clinic, Rochester, MN.
FAU - Johnson, Madeline Q
AU  - Johnson MQ
AD  - Department of Health Science Research, Mayo Clinic, Rochester, MN.
FAU - Hanson, Andrew
AU  - Hanson A
AD  - Department of Health Science Research, Mayo Clinic, Rochester, MN.
FAU - Schulte, Phillip J
AU  - Schulte PJ
AD  - Department of Health Science Research, Mayo Clinic, Rochester, MN.
FAU - Trivedi, Vrinda
AU  - Trivedi V
AD  - Division of Pulmonary and Critical Care Medicine, Department of Internal 
      Medicine, Mayo Clinic, Rochester, MN.
FAU - Gajic, Ognjen
AU  - Gajic O
AD  - Division of Pulmonary and Critical Care Medicine, Department of Internal 
      Medicine, Mayo Clinic, Rochester, MN.
FAU - Warner, Matthew A
AU  - Warner MA
AD  - Division of Critical Care, Department of Anesthesiology & Perioperative Medicine, 
      Mayo Clinic, Rochester, MN.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Crit Care Med. 2020 Jul;48(7):1083-1085. PMID: 32568905
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Critical Care/*methods
MH  - Female
MH  - Hemorrhage/chemically induced/*etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Care/adverse effects/*methods
MH  - Retrospective Studies
EDAT- 2020/04/19 06:00
MHDA- 2021/05/19 06:00
CRDT- 2020/04/19 06:00
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2020/04/19 06:00 [entrez]
AID - 10.1097/CCM.0000000000004350 [doi]
PST - ppublish
SO  - Crit Care Med. 2020 Jul;48(7):985-992. doi: 10.1097/CCM.0000000000004350.

PMID- 23532576
OWN - NLM
STAT- MEDLINE
DCOM- 20140120
LR  - 20220317
IS  - 1179-6901 (Electronic)
IS  - 1174-5886 (Print)
IS  - 1174-5886 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Mar
TI  - Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of 
      published randomized controlled trials.
PG  - 9-16
LID - 10.1007/s40268-013-0011-y [doi]
AB  - BACKGROUND AND OBJECTIVES: Aspirin is widely used for short-term treatment of 
      pain, fever or colds, but there are only limited data regarding the safety of 
      this use. To summarize the available data on this topic, we conducted a 
      meta-analysis of the published clinical trial literature regarding the 
      gastrointestinal adverse effects of short-term use of aspirin in comparison with 
      placebo and other medications commonly used for the same purpose. DATA SOURCES 
      AND METHODS: An extensive literature search identified 119,310 articles regarding 
      possible adverse effects of aspirin, among which 23,131 appeared to possibly 
      include relevant data. An automated text-mining procedure was used to score the 
      references for potential relevance for the meta-analysis. The 3,983 
      highest-scoring articles were reviewed individually to identify those with data 
      that could be included in this analysis. Ultimately, 78 relevant articles were 
      identified that contained gastrointestinal adverse event data from clinical 
      trials of aspirin versus placebo or an active comparator. Odds ratios (ORs) 
      computed using a Mantel-Haenszel estimator were used to summarize the comparative 
      effects on dyspepsia, nausea/vomiting, and abdominal pain, considered separately 
      and also aggregated as 'minor gastrointestinal events'. Gastrointestinal bleeds, 
      ulcers, and perforations were also investigated. RESULTS: Data were obtained 
      regarding 19,829 subjects (34 % treated with aspirin, 17 % placebo, and 49 % an 
      active comparator). About half of the aspirin subjects took a single dose. 
      Aspirin was associated with a higher risk of minor gastrointestinal events than 
      placebo or active comparators: the summary ORs were 1.46 (95 % confidence 
      interval [CI] 1.15-1.86) and 1.81 (95 % CI 1.61-2.04), respectively. Ulcers, 
      perforation, and serious bleeding were not seen after use of aspirin or any of 
      the other interventions. CONCLUSIONS: During short-term use, aspirin is 
      associated with a higher frequency of gastrointestinal complaints than other 
      medications commonly used for treatment of pain, colds, and fever. Serious 
      adverse events were not observed with aspirin or any of the comparators.
FAU - Baron, John A
AU  - Baron JA
AD  - University of North Carolina School of Medicine, Chapel Hill, NC, USA.
FAU - Senn, Stephen
AU  - Senn S
FAU - Voelker, Michael
AU  - Voelker M
FAU - Lanas, Angel
AU  - Lanas A
FAU - Laurora, Irene
AU  - Laurora I
FAU - Thielemann, Wolfgang
AU  - Thielemann W
FAU - Brückner, Andreas
AU  - Brückner A
FAU - McCarthy, Denis
AU  - McCarthy D
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Drugs R D
JT  - Drugs in R&D
JID - 100883647
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdominal Pain/chemically induced/diagnosis/epidemiology
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Gastrointestinal Diseases/*chemically induced/*diagnosis/epidemiology
MH  - Humans
MH  - *Randomized Controlled Trials as Topic/methods
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC3627011
EDAT- 2013/03/28 06:00
MHDA- 2014/01/21 06:00
CRDT- 2013/03/28 06:00
PHST- 2013/03/28 06:00 [entrez]
PHST- 2013/03/28 06:00 [pubmed]
PHST- 2014/01/21 06:00 [medline]
AID - 11 [pii]
AID - 10.1007/s40268-013-0011-y [doi]
PST - ppublish
SO  - Drugs R D. 2013 Mar;13(1):9-16. doi: 10.1007/s40268-013-0011-y.

PMID- 21212730
OWN - NLM
STAT- MEDLINE
DCOM- 20110329
LR  - 20131121
IS  - 0021-4884 (Print)
IS  - 0021-4884 (Linking)
VI  - 59
IP  - 12
DP  - 2010 Dec
TI  - [Case of food-dependent exercise-induced anaphylaxis diagnosed by the provocation 
      test with cuttlefish after the pretreatment with 1.5 g of aspirin].
PG  - 1634-41
AB  - A 29-year-old woman had an episode of urticaria at the age of 17 while exercising 
      after eating fried cuttlefish. For years thereafter, she experienced several 
      episodes of urticaria after eating seafood. At the age of 29, she ate grilled 
      seafood, including cuttlefish for supper after taking loxoprofen for lumbago. One 
      hour later, she developed generalized urticaria accompanied by nausea, abdominal 
      pain, swelling of the lips, and dyspnea while walking; she was taken to a 
      hospital. She was then referred to us for further examination of the etiology of 
      her anaphylactic reactions. The level of specific IgE measured using Immuno CAP 
      was negative for all kinds of foods, including cuttlefish. However, a skin prick 
      test was positive for raw and cooked cuttlefish. Provocation tests were performed 
      on admission by combining the intake of cuttlefish and aspirin under the 
      suspicion of cuttlefish allergy enhanced by nonsteroidal anti-inflammatory drugs 
      and exercise. As a result, she developed no symptoms except for slight itching of 
      the oral mucosa after eating 20 g or 100 g of cuttlefish with or without 
      concomitant administration of 0.5 g of aspirin. Finally, generalized urticaria 
      appeared after challenge with cuttlefish and 1.5 g of aspirin. She was diagnosed 
      with food-dependent exercise-induced anaphylaxis (FDEIA) caused by cuttlefish. 
      She has not developed urticaria since she started to avoid eating cuttlefish. Our 
      results indicated that in provocation tests for the diagnosis of FDEIA, allergic 
      reactions could not only be induced by food intake but could also be enhanced by 
      aspirin in a dose-dependent manner.
FAU - Nakamura, Kazuko
AU  - Nakamura K
AD  - Department of Dermatology, Yokohama City University School of Medicine.
FAU - Inomata, Naoko
AU  - Inomata N
FAU - Okawa, Tomoko
AU  - Okawa T
FAU - Maeda, Nobuko
AU  - Maeda N
FAU - Kirino, Mio
AU  - Kirino M
FAU - Shiomi, Kazuo
AU  - Shiomi K
FAU - Ikezawa, Zenro
AU  - Ikezawa Z
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Arerugi
JT  - Arerugi = [Allergy]
JID - 0241212
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anaphylaxis/*diagnosis/immunology
MH  - Animals
MH  - Aspirin/*administration & dosage/*immunology
MH  - Decapodiformes/*immunology
MH  - Dose-Response Relationship, Immunologic
MH  - Exercise/*physiology
MH  - Female
MH  - Food Hypersensitivity/*diagnosis/immunology
MH  - Humans
MH  - Immunologic Tests/methods
EDAT- 2011/01/08 06:00
MHDA- 2011/03/30 06:00
CRDT- 2011/01/08 06:00
PHST- 2009/08/12 00:00 [received]
PHST- 2010/11/01 00:00 [accepted]
PHST- 2011/01/08 06:00 [entrez]
PHST- 2011/01/08 06:00 [pubmed]
PHST- 2011/03/30 06:00 [medline]
AID - 059121634e [pii]
PST - ppublish
SO  - Arerugi. 2010 Dec;59(12):1634-41.

PMID- 10472428
OWN - NLM
STAT- MEDLINE
DCOM- 19991021
LR  - 20131121
IS  - 0753-3322 (Print)
IS  - 0753-3322 (Linking)
VI  - 53
IP  - 7
DP  - 1999 Aug
TI  - The prevention of colorectal cancer by aspirin use.
PG  - 303-8
AB  - Epidemiologic studies indicate strongly that aspirin use reduces the risk of 
      colorectal cancer and adenoma by approximately 40 to 50%. Perhaps up to ten years 
      of use may be required before a benefit is apparent in colorectal cancer. The 
      chemo-preventive actions of aspirin and other non-steroidal anti-inflammatory 
      agents (NSAIDs) in colorectal carcinogenesis are also supported by animal 
      studies, and by intervention studies that demonstrate that the anti-inflammatory 
      agent sulindac causes regression of adenomas in familial adenomatous polyposis. 
      Despite this evidence, the clinical implications are not clear because of 
      increased gastro-intestinal irritation and bleeding episodes related to chronic 
      aspirin use. Emerging evidence suggests that the anti-tumor properties of NSAIDs 
      may be related primarily to the inhibition of cyclooxygenase-2 (COX-2), one of 
      the two isoenzymes of the COX enzyme family. If confirmed, a new generation of 
      selective COX-2 inhibitors may retain some of the chemo-preventive properties of 
      NSAIDs with fewer side-effects. Firm recommendations regarding the use of aspirin 
      or other NSAIDs to prevent colorectal cancer must await further research. For 
      now, the decision must lie with the patient, in consultation with his or her 
      healthcare provider, after a careful weighing of all potential risks and 
      benefits.
FAU - Giovannucci, E
AU  - Giovannucci E
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Colorectal Neoplasms/*prevention & control
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Humans
MH  - Isoenzymes/*metabolism
MH  - Membrane Proteins
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
RF  - 53
EDAT- 1999/09/03 00:00
MHDA- 1999/09/03 00:01
CRDT- 1999/09/03 00:00
PHST- 1999/09/03 00:00 [pubmed]
PHST- 1999/09/03 00:01 [medline]
PHST- 1999/09/03 00:00 [entrez]
AID - S0753-3322(00)88500-5 [pii]
AID - 10.1016/S0753-3322(00)88500-5 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 1999 Aug;53(7):303-8. doi: 10.1016/S0753-3322(00)88500-5.

PMID- 12668896
OWN - NLM
STAT- MEDLINE
DCOM- 20030822
LR  - 20181113
IS  - 1080-0549 (Print)
IS  - 1080-0549 (Linking)
VI  - 24
IP  - 2
DP  - 2003 Apr
TI  - Aspirin desensitization in patients with AERD.
PG  - 159-68
AB  - All patients with aspirin exacerbated respiratory disease (AERD) can be 
      desensitized to ASA. After achieving this state, patients can then take ASA daily 
      without adverse effect. ASA desensitization can be maintained indefinitely as 
      long as the patient takes ASA each day. Crossdesensitization with older NSAIDs 
      also occurs. After ASA desensitization, patients can take daily ASA in order to 
      treat their underlying respiratory disease. In AERD patients treated with ASA 650 
      BID for at least a year, 115/172 (67%) improved in their clinical courses while 
      decreasing systemic and topical corticosteroids. Sixteen failed to improve, 24 
      stopped ASA because of intractable side effects (gastritis or hives) and 17 
      patients discontinued ASA treatment in the first year of study for unrelated 
      reasons. Therefore, treatment with daily ASA is a significant therapeutic option 
      for patients afflicted with AERD. It should be used for AERD patients who do not 
      respond to topical corticosteroids and leukotriene modifier drugs. Those who 
      respond to systemic steroids or have intractable or recurrent nasal polyps are 
      particularly well-suited for this therapeutic intervention.
FAU - Stevenson, Donald D
AU  - Stevenson DD
AD  - Division of Allergy, Asthma, and Immunology, Scripps Clinic and the Scripps 
      Research Institute, La Jolla, CA 92037, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse 
      effects/*immunology
MH  - Aspirin/administration & dosage/*adverse effects/*immunology
MH  - *Desensitization, Immunologic
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/etiology
MH  - Humans
MH  - Respiratory Hypersensitivity/*chemically induced/*immunology
RF  - 17
EDAT- 2003/04/02 05:00
MHDA- 2003/08/23 05:00
CRDT- 2003/04/02 05:00
PHST- 2003/04/02 05:00 [pubmed]
PHST- 2003/08/23 05:00 [medline]
PHST- 2003/04/02 05:00 [entrez]
AID - CRIAI:24:2:159 [pii]
AID - 10.1385/CRIAI:24:2:159 [doi]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2003 Apr;24(2):159-68. doi: 10.1385/CRIAI:24:2:159.

PMID- 3715804
OWN - NLM
STAT- MEDLINE
DCOM- 19860703
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 42
IP  - 3
DP  - 1986 May 1
TI  - Antithrombotic therapy in children and adolescents.
PG  - 289-301
AB  - This report documents our experience with long term antithrombotic therapy 
      (acenocoumarol plus aspirin) in 31 children and adolescents, from 5 months to 16 
      years of age. The valves replaced were mitral in 20 patients, aortic in 4, 
      mitral-aortic in 4 and tricuspid in 3; the overall follow-up time was of 1336 
      months. Anticoagulant requirement in each children was not in correlation with 
      age, but a significant increase (p less than 0.01) was found in association with 
      sexual development. Our total incidence of embolic episodes was 1.49/1000 
      patient-months. The embolic incidence on adequate anticoagulated patients was 
      0.74/1000 patient-months and 93.7% of all patients were free of thrombo-embolic 
      accidents up to 96 months of follow-up. Minor haemorrhage in relation to an 
      excess of anticoagulant was 1.49/1000 patient-months. There has been only one 
      major bleeding episode associated with severe sepsis, with an incidence of 
      0.74/1000 patient-months. No major difficulties were found in the management of 
      anticoagulant treatment and its association with antiplatelet drugs in children.
FAU - Woods, A
AU  - Woods A
FAU - Vargas, J
AU  - Vargas J
FAU - Berri, G
AU  - Berri G
FAU - Kreutzer, G
AU  - Kreutzer G
FAU - Meschengieser, S
AU  - Meschengieser S
FAU - Lazzari, M A
AU  - Lazzari MA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Fibrinolytic Agents)
RN  - I6WP63U32H (Acenocoumarol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acenocoumarol/administration & dosage/adverse effects/*therapeutic use
MH  - Adolescent
MH  - Age Factors
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - *Heart Valve Prosthesis
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Postoperative Complications/*prevention & control
MH  - Sex Factors
MH  - Sexual Maturation
MH  - Thromboembolism/*prevention & control
EDAT- 1986/05/01 00:00
MHDA- 1986/05/01 00:01
CRDT- 1986/05/01 00:00
PHST- 1986/05/01 00:00 [pubmed]
PHST- 1986/05/01 00:01 [medline]
PHST- 1986/05/01 00:00 [entrez]
AID - 10.1016/0049-3848(86)90258-6 [doi]
PST - ppublish
SO  - Thromb Res. 1986 May 1;42(3):289-301. doi: 10.1016/0049-3848(86)90258-6.

PMID- 23107943
OWN - NLM
STAT- MEDLINE
DCOM- 20130509
LR  - 20131121
IS  - 1873-4367 (Electronic)
IS  - 0927-7765 (Linking)
VI  - 102
DP  - 2013 Feb 1
TI  - Impact of osmotic pressure and gelling in the generation of highly stable single 
      core water-in-oil-in-water (W/O/W) nano multiple emulsions of aspirin assisted by 
      two-stage ultrasonic cavitational emulsification.
PG  - 653-8
LID - S0927-7765(12)00484-5 [pii]
LID - 10.1016/j.colsurfb.2012.08.036 [doi]
AB  - The present investigation focuses in investigating the effect of osmotic 
      pressure, gelling on the mean droplet diameter, polydispersity index, droplet 
      size stability of the developed novel Aspirin containing water-in-oil-in-water 
      (W/O/W) nano multiple emulsion. The aspirin-loaded nano multiple emulsion 
      formulation was successfully generated using two-stage ultrasonic cavitational 
      emulsification which had been reported in author's previous study. The osmotic 
      behavior of ultrasonically prepared nano multiple emulsions were also examined 
      with different glucose concentrations both in the inner and outer aqueous phases. 
      In addition, introducing gelatin into the formulation also observed to play an 
      important role in preventing the interdroplet coalescence via the formation of 
      interfacial rigid film. Detailed studies were also made on the possible 
      mechanisms of water migration under osmotic gradient which primarily caused by 
      the permeation of glucose. Besides, the experimental results have shown that the 
      interfacial tension between the two immiscible phases decreases with varying the 
      composition of organic phase. Although the W/O/W emulsion prepared with the 
      inner/outer glucose weight ratio of 1-0.5% (w/w) showed an excellent droplet 
      stability, the formulation containing 0.5% (w/w) glucose in the inner aqueous 
      phase appeared to be the most stable with minimum change in the mean droplet size 
      upon one-week storage period. Based on the optimization, nano multiple emulsion 
      droplets with the mean droplet diameter of around 400 nm were produced using 
      1.25% (w/w) Span 80 and 0.5% Cremophore EL. Overall, our investigation makes a 
      pathway in proving that the use of ultrasound cavitation is an efficient yet 
      promising approach in the generation of stable and uniform nano multiple 
      emulsions and could be used in the encapsulation of various active pharmaceutical 
      ingredients in the near future.
CI  - Copyright © 2012 Elsevier B.V. All rights reserved.
FAU - Tang, Siah Ying
AU  - Tang SY
AD  - Department of Chemical and Environmental Engineering, Faculty of Engineering, The 
      University of Nottingham, Malaysia Campus, Jalan Broga, 43500 Semenyih, Malaysia.
FAU - Sivakumar, Manickam
AU  - Sivakumar M
FAU - Nashiru, Billa
AU  - Nashiru B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120908
PL  - Netherlands
TA  - Colloids Surf B Biointerfaces
JT  - Colloids and surfaces. B, Biointerfaces
JID - 9315133
RN  - 0 (Emulsions)
RN  - 0 (Oils)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Emulsions/*chemistry
MH  - Oils/*chemistry
MH  - *Osmotic Pressure
MH  - *Ultrasonics
MH  - Water/*chemistry
EDAT- 2012/10/31 06:00
MHDA- 2013/05/10 06:00
CRDT- 2012/10/31 06:00
PHST- 2011/12/07 00:00 [received]
PHST- 2012/07/29 00:00 [revised]
PHST- 2012/08/23 00:00 [accepted]
PHST- 2012/10/31 06:00 [entrez]
PHST- 2012/10/31 06:00 [pubmed]
PHST- 2013/05/10 06:00 [medline]
AID - S0927-7765(12)00484-5 [pii]
AID - 10.1016/j.colsurfb.2012.08.036 [doi]
PST - ppublish
SO  - Colloids Surf B Biointerfaces. 2013 Feb 1;102:653-8. doi: 
      10.1016/j.colsurfb.2012.08.036. Epub 2012 Sep 8.

PMID- 15991121
OWN - NLM
STAT- MEDLINE
DCOM- 20051101
LR  - 20190911
IS  - 0883-5403 (Print)
IS  - 0883-5403 (Linking)
VI  - 20
IP  - 4 Suppl 2
DP  - 2005 Jun
TI  - Deep vein thrombosis prophylaxis: better living through chemistry--in the 
      affirmative.
PG  - 12-4
AB  - Venous thromboembolism is a recognized complication of total hip arthroplasty, 
      knee arthroplasty, and hip fracture surgery. Various pharmacological agents have 
      been introduced in orthopedic surgery in an attempt to reduce the mortality as 
      well as the short-term and long-term morbidity associated with the development of 
      deep vein thrombosis and pulmonary embolism. Clinical trials demonstrate the 
      increasing thromboprophylactic efficacy of newer generations of drugs. The most 
      current guidelines of the American College of Chest Physicians regarding 
      thromboprophylaxis after total hip arthroplasty, total knee arthroplasty, and hip 
      fracture surgery give the highest recommendations in support of the use of 
      low-molecular-weight heparin, warfarin, or fondaparinux. Their highest 
      recommendation is also given against the use of aspirin due to its lack of 
      demonstrated efficacy.
FAU - Kwong, Louis M
AU  - Kwong LM
AD  - Department of Orthopedic Surgery, Harbor/UCLA Medical Center, 1000 W. Carson 
      Street, Torrance, CA 90509, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Arthroplasty. 2005 Jun;20(4 Suppl 2):15-7. PMID: 15991122
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - *Arthroplasty, Replacement
MH  - Arthroplasty, Replacement, Hip
MH  - Arthroplasty, Replacement, Knee
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/therapeutic use
MH  - Humans
MH  - Postoperative Complications/*prevention & control
MH  - Venous Thrombosis/*prevention & control
EDAT- 2005/07/02 09:00
MHDA- 2005/11/03 09:00
CRDT- 2005/07/02 09:00
PHST- 2005/07/02 09:00 [pubmed]
PHST- 2005/11/03 09:00 [medline]
PHST- 2005/07/02 09:00 [entrez]
AID - S0883540305001634 [pii]
AID - 10.1016/j.arth.2005.03.013 [doi]
PST - ppublish
SO  - J Arthroplasty. 2005 Jun;20(4 Suppl 2):12-4. doi: 10.1016/j.arth.2005.03.013.

PMID- 6377249
OWN - NLM
STAT- MEDLINE
DCOM- 19840813
LR  - 20190913
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 4
IP  - 3
DP  - 1984 May-Jun
TI  - Diflunisal 500-750 mg versus aspirin 2600-3900 mg in the treatment of rheumatoid 
      arthritis.
PG  - 151-7
AB  - Diflunisal was compared to aspirin in a 12-week, double-blind, parallel, 
      multicenter rheumatoid arthritis study. One hundred twenty-six (126) patients 
      received diflunisal and 123 patients received aspirin. Both treatment groups 
      demonstrated significant improvement from baseline in joint pain, morning 
      stiffness, grip strength, walking time and painful and swollen joint scores. For 
      these parameters, the only statistically significant difference between the 
      groups was that diflunisal was more effective than aspirin for overall joint pain 
      at week 2. The overall evaluation by patients and by investigators showed 
      significantly better responses in those treated with diflunisal at weeks 1 and 
      12. Diflunisal produced significantly less gastrointestinal pain and tinnitus 
      than aspirin. Neither drug showed unusual frequency of adverse effects as 
      determined in the laboratory. Long-term studies using a higher-dose regimen are 
      suggested to further define the efficacy and tolerability of diflunisal in the 
      treatment of patients with rheumatoid arthritis.
FAU - Turner, R A
AU  - Turner RA
FAU - Whipple, J P
AU  - Whipple JP
FAU - Shackleford, R W
AU  - Shackleford RW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Salicylates)
RN  - 7C546U4DEN (Diflunisal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Diflunisal/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/*therapeutic use
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
AID - 10.1002/j.1875-9114.1984.tb03341.x [doi]
PST - ppublish
SO  - Pharmacotherapy. 1984 May-Jun;4(3):151-7. doi: 
      10.1002/j.1875-9114.1984.tb03341.x.

PMID- 7068938
OWN - NLM
STAT- MEDLINE
DCOM- 19820614
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 22
IP  - 2-3
DP  - 1982 Feb-Mar
TI  - A 12-hour evaluation of the analgesic efficacy of diflunisal, aspirin, and 
      placebo in postoperative dental pain.
PG  - 89-96
AB  - Two-hundred and one outpatients with postoperative pain following oral surgery 
      were randomly assigned, on a double-blind basis, a single oral dose of diflunisal 
      (250, 500, or 1000 mg), aspirin (650 mg), or placebo. Using a self-rating record, 
      the subjects rated their pain and its relief hourly for 12 hours after 
      medication. Measures of peak and total analgesia were derived from the patients' 
      subjective reports. Diflunisal 250 and 1000 mg were significantly superior to 
      aspirin for every measure of total and peak analgesia; the 500-mg diflunisal dose 
      was significantly superior to aspirin for measures of total analgesia only. All 
      doses of diflunisal were significantly superior to aspirin and placebo at each 
      hour from hour 3 through hour 12. Approximately 60 per cent of the patients 
      treated with diflunisal completed the 12-hour observation period without the need 
      for additional analgesic therapy. Adverse effects were mild and transitory and 
      occurred in less than 10 per cent of the patients.
FAU - Forbes, J A
AU  - Forbes JA
FAU - Calderazzo, J P
AU  - Calderazzo JP
FAU - Bowser, M W
AU  - Bowser MW
FAU - Foor, V M
AU  - Foor VM
FAU - Shackleford, R W
AU  - Shackleford RW
FAU - Beaver, W T
AU  - Beaver WT
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Placebos)
RN  - 0 (Salicylates)
RN  - 7C546U4DEN (Diflunisal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Diflunisal/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
MH  - Salicylates/*therapeutic use
MH  - Time Factors
MH  - Tooth Extraction
EDAT- 1982/02/01 00:00
MHDA- 1982/02/01 00:01
CRDT- 1982/02/01 00:00
PHST- 1982/02/01 00:00 [pubmed]
PHST- 1982/02/01 00:01 [medline]
PHST- 1982/02/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1982.tb02654.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1982 Feb-Mar;22(2-3):89-96. doi: 
      10.1002/j.1552-4604.1982.tb02654.x.

PMID- 2277129
OWN - NLM
STAT- MEDLINE
DCOM- 19910306
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 30
IP  - 9
DP  - 1990 Sep
TI  - A single-dose study of the efficacy and safety of FS 205-397 (250 mg or 500 mg) 
      versus aspirin and placebo in the treatment of postsurgery dental pain.
PG  - 815-23
AB  - The efficacy and safety of two dose levels of FS 205-397 (either 250 or 500 mg) 
      were compared with the efficacy and safety of aspirin 650 mg and placebo in a 
      6-hour, single-dose, double-blind study in 161 patients who had undergone 
      extraction of third molars. Each of the doses of FS 205-397, as well as aspirin, 
      produced analgesia. However, the analgesic effects of both the 500 mg dose of FS 
      205-397 and aspirin were at times significantly better and more prolonged than 
      those produced by the lower dose of FS 205-397. On the other hand, both doses of 
      FS 205-397 had a significantly faster onset of action than aspirin. Side effects, 
      reported by 17% of the 161 patients, did not differ significantly among the four 
      treatment groups with respect to frequency, type, or severity. The most commonly 
      reported side effects were nausea (7%) and drowsiness (6%). The results indicated 
      that FS 205-397, administered in single doses of either 500 or 250 mg, is a safe 
      and effective analgesic for the relief of pain following dental surgery, and may 
      offer particular advantages in terms of onset of effects.
FAU - Mehlisch, D R
AU  - Mehlisch DR
AD  - Biomedical Research Group, Inc., Austin, TX 78731.
FAU - Sterling, W R
AU  - Sterling WR
FAU - Mazza, F A
AU  - Mazza FA
FAU - Singer, J M
AU  - Singer JM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Indoles)
RN  - 116861-51-9 (FS 205-397)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*pharmacology
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Indoles/administration & dosage/adverse effects/*pharmacology
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Time Factors
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1990.tb01879.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1990 Sep;30(9):815-23. doi: 10.1002/j.1552-4604.1990.tb01879.x.

PMID- 32724907
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 69
IP  - 6
DP  - 2020 Jul/Aug
TI  - Dual antiplatelet Tx for stroke prevention: Worth the risk?
PG  - 272-279
AB  - Here's what the evidence tells us about the use of 2 regimens-clopidogrel + 
      aspirin and ER dipyridamole + aspirin-to prevent secondary ischemic stroke.
FAU - Helmer, Robert S
AU  - Helmer RS
AD  - Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, 
      Mobile, AL, USA. Email: Rsh0011@auburn.edu.
FAU - Helmer, Allison M
AU  - Helmer AM
AD  - Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, 
      Mobile, AL, USA.
FAU - Smithgall, Sean
AU  - Smithgall S
AD  - Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, 
      Mobile, AL, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Clopidogrel/adverse effects/pharmacology/therapeutic use
MH  - Drug Therapy, Combination/methods/*standards/statistics & numerical data
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/pharmacology/therapeutic use
MH  - Risk Assessment/methods
MH  - Stroke/*drug therapy/*prevention & control
EDAT- 2020/07/30 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - jfp_6906c [pii]
PST - ppublish
SO  - J Fam Pract. 2020 Jul/Aug;69(6):272-279.

PMID- 21492054
OWN - NLM
STAT- MEDLINE
DCOM- 20120105
LR  - 20131121
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 46
IP  - 7-8
DP  - 2011 Jul
TI  - The effect of probiotics on gastric mucosal permeability in humans administered 
      with aspirin.
PG  - 831-6
LID - 10.3109/00365521.2011.574730 [doi]
AB  - OBJECTIVE: To examine whether a probiotic strain, Lactobacillus gasseri OLL2716 
      (LG21), can protect the gastric mucosal integrity from aspirin using urinary 
      sucrose excretion (USE) test. MATERIALS AND METHODS: In the study using high-dose 
      aspirin, the USE tests were carried out in 29 volunteers before and after LG21 
      treatment for 4 weeks. In the study using patients undergoing low-dose aspirin 
      therapy, USE tests were performed in 37 subjects who took LG21 for 16 weeks. 
      Stool occult blood was examined by the guaiac method. RESULTS: In the former 
      study, the elevation in the USE value after aspirin loading significantly 
      decreased after LG21 treatment (Median ± SD; 0.244 ± 0.237 vs. 0.208 ± 0.112%, p 
      = 0.018). In the latter study, the USE value significantly decreased in the 
      period with LG21 treatment (p = 0.033), while no significant difference was found 
      in the period without LG21 (p = 0.113). The number of positive occult blood tests 
      decreased during LG21 treatment. CONCLUSIONS: The regular ingestion of LG21 may 
      protect the integrity of the gastric mucosal permeability against aspirin.
FAU - Akama, Fumiaki
AU  - Akama F
AD  - Laboratory for Infectious Diseases, Tokai University School of Medicine, Isehara, 
      Japan.
FAU - Nishino, Ryo
AU  - Nishino R
FAU - Makino, Seiya
AU  - Makino S
FAU - Kobayashi, Kiyoshi
AU  - Kobayashi K
FAU - Kamikaseda, Kazufumi
AU  - Kamikaseda K
FAU - Nagano, Jun
AU  - Nagano J
FAU - Koga, Yasuhiro
AU  - Koga Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110415
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 57-50-1 (Sucrose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Female
MH  - Gastric Mucosa/*drug effects/*metabolism
MH  - Humans
MH  - Lactobacillus/*physiology
MH  - Male
MH  - Middle Aged
MH  - Occult Blood
MH  - Permeability/drug effects
MH  - *Probiotics
MH  - Sucrose/urine
EDAT- 2011/04/16 06:00
MHDA- 2012/01/06 06:00
CRDT- 2011/04/16 06:00
PHST- 2011/04/16 06:00 [entrez]
PHST- 2011/04/16 06:00 [pubmed]
PHST- 2012/01/06 06:00 [medline]
AID - 10.3109/00365521.2011.574730 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2011 Jul;46(7-8):831-6. doi: 10.3109/00365521.2011.574730. 
      Epub 2011 Apr 15.

PMID- 6700375
OWN - NLM
STAT- MEDLINE
DCOM- 19840410
LR  - 20190701
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 34
IP  - 8
DP  - 1984 Feb 20
TI  - The effect of nicotine pretreatment on the gastric mucosal damage induced by 
      aspirin and reserpine in rats.
PG  - 751-6
AB  - The effect of nicotine pretreatment by feeding nicotine (5mcg/ml) in drinking 
      water ad libitum for 10 days was studied on the aspirin and reserpine induced 
      gastric mucosal damage in rats. The administration of nicotine resulted in the 
      significant augmentation of aspirin (P less than 0.01) and reserpine (P less than 
      0.05) induced gastric ulcers. The mechanism(s) involving the sensitization of 
      gastric mucosa towards the ulcerogenic effect of aspirin and reserpine may be 
      responsible for the increased intensity of gastric ulcers in both the groups. The 
      study indicates the possibility of a similar interaction in heavy smokers who 
      ingest these drugs.
FAU - Ageel, A M
AU  - Ageel AM
FAU - Parmar, N S
AU  - Parmar NS
FAU - Tariq, M
AU  - Tariq M
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 6M3C89ZY6R (Nicotine)
RN  - 8B1QWR724A (Reserpine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*pharmacology
MH  - Drug Synergism
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Nicotine/adverse effects/*pharmacology
MH  - Peptic Ulcer/chemically induced
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Reserpine/*pharmacology
EDAT- 1984/02/20 00:00
MHDA- 1984/02/20 00:01
CRDT- 1984/02/20 00:00
PHST- 1984/02/20 00:00 [pubmed]
PHST- 1984/02/20 00:01 [medline]
PHST- 1984/02/20 00:00 [entrez]
AID - 0024-3205(84)90382-5 [pii]
AID - 10.1016/0024-3205(84)90382-5 [doi]
PST - ppublish
SO  - Life Sci. 1984 Feb 20;34(8):751-6. doi: 10.1016/0024-3205(84)90382-5.

PMID- 2665172
OWN - NLM
STAT- MEDLINE
DCOM- 19890825
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 61
IP  - 2
DP  - 1989 Apr 25
TI  - Measurement of aspirin concentrations in portal and systemic blood in pigs: 
      effect on platelet aggregation, thromboxane and prostacyclin production.
PG  - 211-6
AB  - Low doses of enteric-coated aspirin were administered orally to pigs. Plasma 
      aspirin concentrations measured in blood obtained simultaneously from permanent 
      catheters in a systemic artery and portal vein for 6 hours after dosage showed a 
      large variation in the plasma aspirin concentration: time profile between pigs. 
      After 50 mg single dose the ratio of the arterial: portal area under the plasma 
      concentration versus time curve (AUC) was 0.63 +/- 0.08 (mean +/- SE, n = 6). In 
      three pigs which received all three dosage regimens, the arterial: portal AUC 
      ratios were 0.48 +/- 0.05 after 50 mg single dose, 0.52 +/- 0.02 after 100 mg 
      single dose and 0.47 +/- 0.02 after 100 mg daily for 1 week. Platelet aggregation 
      in response to sodium arachidonate (1.65 mM) was completely abolished after 
      chronic aspirin administration of 100 mg daily. Thromboxane production (pg/10(6) 
      platelets) induced by this stimulus decreased from 536 +/- 117 before aspirin to 
      57 +/- 14 after aspirin (mean +/- SE, n = 4; p = 0.03). Aortic prostacyclin 
      synthesis, measured as 6-keto PGF1 alpha (ng/disc after 10 min incubation), was 
      1.66 +/- 0.28 (mean +/- SE, n = 4) in untreated pigs and 0.95 +/- 0.25 (n = 5) in 
      treated pigs (p = 0.07). Results from this study support the idea that a 
      difference between aspirin concentrations in the portal and systemic circulations 
      can be achieved. Whether this can be translated into a clinically useful 
      differential effect on the vessel wall compared to the platelet remains to be 
      determined.
FAU - Bochner, F
AU  - Bochner F
AD  - Department of Clinical and Experimental Pharmacology, University of Adelaide, 
      South Australia.
FAU - Siebert, D M
AU  - Siebert DM
FAU - Rodgers, S E
AU  - Rodgers SE
FAU - McIntosh, G H
AU  - McIntosh GH
FAU - James, M J
AU  - James MJ
FAU - Lloyd, J V
AU  - Lloyd JV
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*blood/pharmacokinetics
MH  - Blood Platelets/metabolism
MH  - Epoprostenol/*biosynthesis
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Swine
MH  - Thromboxanes/*biosynthesis
EDAT- 1989/04/25 00:00
MHDA- 1989/04/25 00:01
CRDT- 1989/04/25 00:00
PHST- 1989/04/25 00:00 [pubmed]
PHST- 1989/04/25 00:01 [medline]
PHST- 1989/04/25 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1989 Apr 25;61(2):211-6.

PMID- 241600
OWN - NLM
STAT- MEDLINE
DCOM- 19760110
LR  - 20190907
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 3
IP  - 5
DP  - 1975
TI  - Double-blind comparison of alclofenac and aspirin in the treatment of rheumatoid 
      arthritis. Part II: high dosage regime for assessment of analgesic and 
      anti-inflammatory activity.
PG  - 309-20
AB  - A double-blind trial was carried out in 76 patients with active rheumatoid 
      arthritis to compare the analgesic and anti-inflammatory activity of 3 g. 
      alclofenac with 4.8 g. aspirin daily over a 6-week period. All patients selected 
      showed reversible inflammatory swelling of the finger joints. Of the 60 patients 
      successfully completing the trial, 30 were treated as out-patients and 30 
      patients received in-patient treatment for approximately the first 2 weeks. Both 
      groups were analysed separately. Treatment was randomised and patients received 
      the drugs in identical tablet form except for the last 16 patients who were 
      transferred to capsules. Results showed that though the activity potential, 
      morning stiffness, grip strength, joint pain and tenderness improved 
      significantly at the end of the 6-week period, there was no statistical 
      difference between the two drugs. However, functional capacity indicated slight 
      superiority of alclofenac over aspirin at a low level of significance. P.I.P. 
      joint swelling showed that both in-patients and out-patients on alclofenac 
      improved significantly (p less than .001)compared to patients in the aspirin 
      group. Laboratory investigations showed no difference between the two drugs as 
      far as changes in serum proteins, serum transaminase, haemoglobin and E.S.R. 
      levels were concerned. However, serum uric acid levels dropped significantly (.05 
      greater than p greater than .01) with aspirin. The incidence of side-effects was 
      slightly higher in the aspirin group but a high incidence of skin rash (30% 
      approx.) was recorded with alclofenac tablets. No incidence of skin rash was 
      recorded in patients taking alclofenac capsules, but the number of patients 
      taking capsules was too small to make any prediction. It appears from this study 
      that in active rheumatoid arthritis the analgesic and anti-inflammatory activity 
      of 3 g. alclofenac is equivalent to 4.8 g. aspirin, and alclofenac is superior to 
      aspirin in reducing the inflammatory swelling of rheumatoid joints.
FAU - Bedi, S S
AU  - Bedi SS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Phenylacetates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy/immunology/physiopathology
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Phenylacetates/adverse effects/*therapeutic use
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 10.1185/03007997509114781 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1975;3(5):309-20. doi: 10.1185/03007997509114781.

PMID- 8321816
OWN - NLM
STAT- MEDLINE
DCOM- 19930803
LR  - 20200313
IS  - 0032-5791 (Print)
IS  - 0032-5791 (Linking)
VI  - 72
IP  - 6
DP  - 1993 Jun
TI  - Response of layer breeders to dietary acetylsalicylic acid. 2. Effects on 
      circulating concentrations of prostaglandin F2 alpha.
PG  - 1093-9
AB  - White Leghorn breeder hens were fed 0, .05, or .40% acetylsalicylic acid (ASA) 
      for either 1 wk or 1 mo. Blood samples were collected 4 h postentrance of an egg 
      into the uterus (baseline) and at oviposition of a hardshelled (HS) egg. Plasma 
      samples were analyzed for prostaglandin (PG) F2 alpha by radioimmunoassay. 
      Peripheral PGF2 alpha concentrations peaked upon oviposition of a HS egg in both 
      ASA-fed hens as well as the controls (0% ASA). The levels of dietary ASA and the 
      duration of time the ASA was administered did not affect baseline or peak PGF2 
      alpha concentrations. It was concluded that either the timing or route of 
      administration of ASA resulted in the failure of ASA to effectively reduce peak 
      peripheral PGF2 alpha concentrations.
FAU - Balog, J M
AU  - Balog JM
AD  - Department of Animal Sciences, Purdue University, West Lafayette, Indiana 47907.
FAU - McDaniel, C D
AU  - McDaniel CD
FAU - Freed, M
AU  - Freed M
FAU - Elkin, R G
AU  - Elkin RG
FAU - Wellenreiter, R H
AU  - Wellenreiter RH
FAU - Hester, P Y
AU  - Hester PY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Poult Sci
JT  - Poultry science
JID - 0401150
RN  - B7IN85G1HY (Dinoprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chickens/*blood/physiology
MH  - Diet
MH  - Dinoprost/*blood
MH  - Female
MH  - Oviposition/drug effects/physiology
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - S0032-5791(19)45094-3 [pii]
AID - 10.3382/ps.0721093 [doi]
PST - ppublish
SO  - Poult Sci. 1993 Jun;72(6):1093-9. doi: 10.3382/ps.0721093.

PMID- 7017491
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Guacetisal: a new molecule with balsamic-antiphlogistic action. Clinical study].
PG  - 401-8
AB  - An open clinical trial was run on the therapeutic efficacy of a new 
      balsamic-antiinflammatory molecule, guacetisal (presented as 500 mg Broncaspin 
      capsules). The drug was given for a minimum of 7 days to 45 male and female 
      patients with an average age of 64 yr suffering from variously serious diseases 
      of the airways. The concomitant administration of fluidifying, balsamic, steroid, 
      antipyretic and anti-inflammatory drugs was avoided, whereas various combinations 
      of cardiokinetics, diuretics, theophyllines, and antibiotics were used where 
      required. Clinical assessment of the parameters chosen pointed to the good 
      therapeutic activity of the preparation, which is specifically indicated in 
      inflammatory conditions of the airways, especially chronic forms subject to 
      periodic recrudescence. Its equally good tolerability serves to make guacetisal 
      extremely easy to use, with the results that its employment in non-specialist 
      environments can also be recommended.
FAU - Marchesani, F
AU  - Marchesani F
FAU - Rizzo, S
AU  - Rizzo S
FAU - Salvini, P
AU  - Salvini P
LA  - ita
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Guacetisal: nuova molecola ad azione balsamico-antiflogistica. Studio clinico.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Asthma/drug therapy
MH  - Bronchitis/drug therapy
MH  - Bronchopneumonia/drug therapy
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiratory Tract Diseases/*drug therapy
MH  - Tracheitis/drug therapy
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):401-8.

PMID- 5531310
OWN - NLM
STAT- MEDLINE
DCOM- 19710304
LR  - 20181113
IS  - 0008-4409 (Print)
IS  - 0008-4409 (Linking)
VI  - 103
IP  - 10
DP  - 1970 Nov 7
TI  - Thrombosis prevention by acetylsalicylic acid in hyperlipemic rats.
PG  - 1037-40
AB  - In rats, administration of acetylsalicylic acid (ASA) by stomach tube two hours 
      before blood removal, or addition of the drug to platelet-rich plasma in vitro, 
      markedly inhibited platelet aggregation induced by thrombin, ADP and collagen. 
      Addition of ASA in vitro to human platelet-rich plasma also inhibited platelet 
      aggregation by thrombin, ADP and collagen. In hyperlipemic rats, ASA (100 to 200 
      mg./kg.), administered by stomach tube once or five times, markedly inhibited the 
      production of thrombosis initiated by intravenous injection of S. typhosa 
      endotoxin. In these experiments, thrombosis prevention by ASA was associated with 
      both a decrease in platelet aggregation and an increase in the recalcification 
      plasma clotting time.
FAU - Renaud, S
AU  - Renaud S
FAU - Godu, J
AU  - Godu J
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Med Assoc J
JT  - Canadian Medical Association journal
JID - 0414110
RN  - 0 (Adenine Nucleotides)
RN  - 0 (Endotoxins)
RN  - 9007-34-5 (Collagen)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenine Nucleotides
MH  - Adult
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Coagulation Tests
MH  - Collagen
MH  - Disease Models, Animal
MH  - Endotoxins
MH  - Humans
MH  - Hyperlipidemias/*complications
MH  - Injections, Intravenous
MH  - Intubation, Gastrointestinal
MH  - Male
MH  - Middle Aged
MH  - Platelet Adhesiveness/drug effects
MH  - Rats
MH  - Salmonella typhi
MH  - Species Specificity
MH  - Thrombin
MH  - Thrombosis/*prevention & control
PMC - PMC1930708
EDAT- 1970/11/07 00:00
MHDA- 1970/11/07 00:01
CRDT- 1970/11/07 00:00
PHST- 1970/11/07 00:00 [pubmed]
PHST- 1970/11/07 00:01 [medline]
PHST- 1970/11/07 00:00 [entrez]
PST - ppublish
SO  - Can Med Assoc J. 1970 Nov 7;103(10):1037-40.

PMID- 1290296
OWN - NLM
STAT- MEDLINE
DCOM- 19930325
LR  - 20131121
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 81 Suppl 4
DP  - 1992
TI  - [Acetylsalicylic acid in unstable angina, after coronary revascularization and in 
      prevention of cardiac thromboembolism].
PG  - 177-84
AB  - Acetylsalicylic acid (ASA) inhibits platelet function via cyclooxygenase 
      inhibition. The selective inhibition of platelet cyclooxygenase is possible with 
      the use of low doses of ASA due to presystemic acetylation of the platelet enzyme 
      in the portal circulation. The clinical efficacy of ASA has been demonstrated for 
      a number of indications. ASA reduces the rate of myocardial infarctions and 
      cardiovascular deaths in patients with unstable angina. Simultaneous intravenous 
      infusion of heparin has an additional positive effect. The prevention of acute 
      coronary thromboses during PTCA and of early bypass graft occlusion has been 
      convincingly demonstrated, if therapy is initiated immediately after surgery. 
      Neither ASA nor any other drug has been effective in the prevention of late 
      restenosis following PTCA and of late bypass graft occlusions. Thromboembolic 
      complication after implantation of biological valve prostheses is significantly 
      reduced by ASA, if no rheumatic valve disease is present. The rate of peripheral 
      or cerebral thromboembolic events is markedly increased in patients with lone 
      atrial fibrillation. In contrast to the very positive results obtained for 
      anticoagulants, the reports with ASA were contradictory. ASA may be effective in 
      preventing thromboembolic complications in younger patients with a lower risk or 
      in elderly patients with contraindications for anticoagulation. For most clinical 
      indications the efficacy of ASA has been demonstrated for doses of 75-324 mg/d. 
      Following a loading dose of 300 mg on the first day, continuation of therapy with 
      100 mg/d should combine maximal therapeutic efficacy with a low rate of unwanted 
      drug effects.
FAU - Darius, H
AU  - Darius H
AD  - II. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz.
FAU - Meyer, J
AU  - Meyer J
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Acetylsalizylsäure bei instabiler Angina, nach koronarer Revaskularisation und 
      bei der Prävention kardialer Thrombembolien.
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/*drug therapy
MH  - Aspirin/*administration & dosage/adverse effects
MH  - *Coronary Artery Bypass
MH  - Graft Occlusion, Vascular/*drug therapy
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Postoperative Complications/*drug therapy
MH  - Thromboembolism/*drug therapy
RF  - 38
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Kardiol. 1992;81 Suppl 4:177-84.

PMID- 7180498
OWN - NLM
STAT- MEDLINE
DCOM- 19830225
LR  - 20190830
IS  - 0001-6683 (Print)
IS  - 0001-6683 (Linking)
VI  - 51
IP  - 4
DP  - 1982 Oct
TI  - Systemic availability of acetylsalicylic acid in human subjects after oral 
      ingestion of three different formulations.
PG  - 285-91
AB  - Systemic availability of acetylsalicylic acid (ASA) in normal human subjects 
      after oral ingestion of 1 g in three different formulations was determined by 
      using high-pressure liquid chromatography for ASA assay. For an effervescent, a 
      plain and a sustained release preparation systemic availabilities expressed in 
      percent of the ingested dose were 16.9 +/- 3.2, 8.6 +/- 1.2 and 2.6 +/- 0.4%, 
      respectively. All subjects had clearly measureable amounts of ASA in plasma after 
      oral intake of a sustained release preparation with an average peak concentration 
      of 15 mumol/l. Peak concentration after an effervescent and plain formulation was 
      on the average 80 and 40 mumol/l, respectively. Half-life of ASA in plasma was 
      18.1 +/- 1.2 min. for the effervescent and 28.7 +/- 5.3 min. for the plain 
      preparation, while the elimination phase was too ill defined for the sustained 
      release formulation. Average plasma half-life of salicylic acid (SA) was similar 
      after the three different administration forms with values between 3.0 and 3.7 
      hrs. Further, no difference in SA distribution volumes or amounts of SA absorbed 
      was found. The present study demonstrates that oral ingestion of ASA in 
      effervescent, plain and sustained release formulations gives rise to significant 
      amounts of ASA in plasma. Concentrations found indicate that long-term 
      antithrombotic therapy with ASA in a sustained release formulation may be 
      possible.
FAU - Petersen, T
AU  - Petersen T
FAU - Husted, S E
AU  - Husted SE
FAU - Pedersen, A K
AU  - Pedersen AK
FAU - Geday, E
AU  - Geday E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Acta Pharmacol Toxicol (Copenh)
JT  - Acta pharmacologica et toxicologica
JID - 0370572
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/*administration & dosage/metabolism
MH  - Biological Availability
MH  - Biotransformation
MH  - Delayed-Action Preparations
MH  - Humans
MH  - Kinetics
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1982/10/01 00:00
MHDA- 1982/10/01 00:01
CRDT- 1982/10/01 00:00
PHST- 1982/10/01 00:00 [pubmed]
PHST- 1982/10/01 00:01 [medline]
PHST- 1982/10/01 00:00 [entrez]
AID - 10.1111/j.1600-0773.1982.tb01028.x [doi]
PST - ppublish
SO  - Acta Pharmacol Toxicol (Copenh). 1982 Oct;51(4):285-91. doi: 
      10.1111/j.1600-0773.1982.tb01028.x.

PMID- 19968088
OWN - NLM
STAT- MEDLINE
DCOM- 20121119
LR  - 20131121
IS  - 1000-503X (Print)
IS  - 1000-503X (Linking)
VI  - 31
IP  - 5
DP  - 2009 Oct
TI  - [Research advances in aspirin resistance].
PG  - 644-50
AB  - Aspirin is an important antithrombotic agent. However, its clinical benefit is 
      impaired by aspirin resistance. The term of "aspirin resistance" usually refers 
      to laboratory resistance. It can be identified by measuring thromboxane A2 or 
      thromboxane-dependent platelet function. Clinical trials have shown that 
      laboratory aspirin resistance is correlated with vascular events.
FAU - Si, Xiao-Yan
AU  - Si XY
AD  - Department of Hematology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
FAU - Zhao, Yong-Qiang
AU  - Zhao YQ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao
JT  - Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
JID - 8006230
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Drug Resistance
MH  - Humans
MH  - Thromboxane A2/blood
EDAT- 2009/12/09 06:00
MHDA- 2012/12/10 06:00
CRDT- 2009/12/09 06:00
PHST- 2009/12/09 06:00 [entrez]
PHST- 2009/12/09 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
PST - ppublish
SO  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Oct;31(5):644-50.

PMID- 8738589
OWN - NLM
STAT- MEDLINE
DCOM- 19961204
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 26
IP  - 3
DP  - 1996 May-Jun
TI  - Protective effects of ticlopidine and aspirin, administered alone and in 
      combination, on thrombus formation in rat cerebral vessels.
PG  - 150-6
AB  - The protective effects of ticlopidine and d,l-lysine acetylsalicylate (L-ASA), 
      used alone and in combination, on the pathogenesis of thrombosis in cerebral 
      blood vessels were investigated in a rat animal model using a He-Ne laser method. 
      Ticlopidine and L-ASA, given orally at a concentration from 100 mg/kg, inhibited 
      thrombus formation in a dose-dependent manner. Ticlopidine (300 mg/kg p.o.) 
      inhibited thrombosis in arterioles and venules for 3 days after administration. 
      The inhibitory activity of L-ASA (300 mg/kg p.o.) was less prolonged than that of 
      ticlopidine and was observed for only approximately 24 h. Combined administration 
      of ticlopidine and L-ASA significantly enhanced and prolonged the antithrombotic 
      effects of either drug given alone. The results demonstrate that ticlopidine and 
      L-ASA have potent antithrombotic properties in rat cerebral blood vessels in 
      vivo.
FAU - Sasaki, Y
AU  - Sasaki Y
AD  - Laboratory of Physiology, Faculty of Nutrition, Kobe Gakuin University, Japan.
FAU - Ishii, I
AU  - Ishii I
FAU - Giddings, J C
AU  - Giddings JC
FAU - Yamamoto, J
AU  - Yamamoto J
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - K3Z4F929H6 (Lysine)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Intracranial Embolism and Thrombosis/*prevention & control
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Rats
MH  - Rats, Wistar
MH  - Ticlopidine/*therapeutic use
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 10.1159/000217200 [doi]
PST - ppublish
SO  - Haemostasis. 1996 May-Jun;26(3):150-6. doi: 10.1159/000217200.

PMID- 367358
OWN - NLM
STAT- MEDLINE
DCOM- 19790328
LR  - 20190918
IS  - 0067-7957 (Print)
IS  - 0067-7957 (Linking)
VI  - 44
DP  - 1977
TI  - Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
PG  - 197-205
AB  - A review is given on the clinical studies performed with aspirin in patients with 
      chronic vascular occlusions of the limbs and on studies in cerebral ischemia 
      using aspirin and sulfinpyrazone. Aspirin reduces the risk of reocclusions in 
      patients after vascular surgery and also reduces the risk of peripheral vascular 
      occlusions in diabetic patients. In doses of 1.2-1.5 g/day it also reduces the 
      frequency of transient ischemic attacks. Conclusive results of similar studies 
      with sulfinpyrazone and dipyridamole can be expected of the ongoing studies. 
      Aspirin has no effect on the course of glomerulonephritis in children. Warfarin 
      plus dipyridamole seem to have some effect in patients renal allografts. 
      Sulfinpyrazone and ASA reduced the incidence of shunt thromboses in hemodialyzed 
      patients. Several case reports in patients with thrombocytemia or Raynaud's 
      syndrome made it likely that treatment with antiplatelet drug reduces the 
      incidence of vascular occlusions.
FAU - Breddin, K
AU  - Breddin K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Bibl Haematol
JT  - Bibliotheca haematologica
JID - 0372513
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/drug therapy
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Brain Ischemia/blood
MH  - Cell Survival
MH  - Clinical Trials as Topic
MH  - Dipyridamole/pharmacology
MH  - Extremities/blood supply
MH  - Humans
MH  - Kidney Diseases/blood
MH  - Thrombosis/blood
RF  - 25
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1159/000402173 [doi]
PST - ppublish
SO  - Bibl Haematol. 1977;44:197-205. doi: 10.1159/000402173.

PMID- 3114525
OWN - NLM
STAT- MEDLINE
DCOM- 19870928
LR  - 20190725
IS  - 0021-5198 (Print)
IS  - 0021-5198 (Linking)
VI  - 44
IP  - 1
DP  - 1987 May
TI  - Antithrombotic and ulcerogenic effects of fenflumizole, a new anti-inflammatory 
      imidazole derivative, in rats.
PG  - 93-6
AB  - Fenflumizole (2-(2,4-difluorophenyl)-4,5-bis(4-methoxyphenyl) imidazole) was 
      given to rats in a single oral dose of 30 mg/kg. The plasma concentration of 
      fenflumizole reached a peak 2-3 hr after the dosing in non-fasted as well as 
      fasted rats. Two metabolites (demethylation products) of fenflumizole were also 
      detected in the plasma, but only in traces. Fenflumizole (30 and 100 mg/kg) and 
      aspirin (100 mg/kg), given orally 2 hr prior to i.v. arachidonate (80 mg/kg), 
      were effective in protecting the rats from death. Fenflumizole in single oral 
      doses of 100 to 800 mg/kg dose-dependently developed erosions in the rat gastric 
      mucosa, but was much less ulcerogenic than aspirin (3.12-200 mg/kg). Thus, 
      fenflumizole seems to possess a potent antithrombotic activity and a relatively 
      low gastro-ulcerogenicity in rats.
FAU - Nabata, H
AU  - Nabata H
FAU - Uchino, M
AU  - Uchino M
FAU - Okazaki, A
AU  - Okazaki A
FAU - Yamazaki, T
AU  - Yamazaki T
FAU - Sakai, K
AU  - Sakai K
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Jpn J Pharmacol
JT  - Japanese journal of pharmacology
JID - 2983305R
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Imidazoles)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - PD0931191Q (fenflumizole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents/blood/*therapeutic use/toxicity
MH  - Arachidonic Acid
MH  - Arachidonic Acids
MH  - Aspirin/blood/therapeutic use/toxicity
MH  - Imidazoles/blood/*therapeutic use/toxicity
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach Ulcer/*chemically induced
MH  - Thromboembolism/chemically induced/*prevention & control
EDAT- 1987/05/01 00:00
MHDA- 1987/05/01 00:01
CRDT- 1987/05/01 00:00
PHST- 1987/05/01 00:00 [pubmed]
PHST- 1987/05/01 00:01 [medline]
PHST- 1987/05/01 00:00 [entrez]
AID - 10.1254/jjp.44.93 [doi]
PST - ppublish
SO  - Jpn J Pharmacol. 1987 May;44(1):93-6. doi: 10.1254/jjp.44.93.

PMID- 16141240
OWN - NLM
STAT- MEDLINE
DCOM- 20060309
LR  - 20131121
IS  - 0143-3334 (Print)
IS  - 0143-3334 (Linking)
VI  - 27
IP  - 2
DP  - 2006 Feb
TI  - NO-donating aspirin isomers downregulate peroxisome proliferator-activated 
      receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor 
      inhibitory effect: Implications for the role of PPARdelta in carcinogenesis.
PG  - 232-9
AB  - Nitric oxide donating aspirin (NO-ASA), consisting of a traditional ASA to which 
      a NO-releasing moiety is covalently attached, is a promising chemopreventive 
      agent against colon cancer. Its mechanism of action is not fully delineated. Here 
      we examined its effect on the expression of the nuclear receptor PPARdelta, whose 
      role in colon carcinogenesis remains highly controversial. We studied 
      histochemically the effect of the meta and para positional isomers of NO-ASA on 
      PPARdelta expression in Min (multiple intestinal neoplasia) and wild-type mice, 
      and on cell proliferation and apoptosis. PPARdelta, minimally expressed in 
      wild-type mice, was significantly expressed in Min mice. para NO-ASA inhibited 
      intestinal tumor incidence (59%) and PPARdelta expression (55.3%) more than meta 
      NO-ASA (38 and 41.5%, respectively). Neither isomer affected cell proliferation, 
      but both induced apoptosis in Min mice (para 52.5% for normal mucosa and 70.3% 
      for tumors; meta 31.4 and 21.9%, respectively). The changes in PPARdelta 
      expression correlated significantly with changes in apoptosis. Furthermore, 
      NO-ASA induced areas of necrosis in intestinal tumors are probably resulting from 
      the induction of atypical apoptosis. Our data suggest that NO-ASA suppresses 
      intestinal tumorigenesis possibly in part through its inhibitory effect on 
      PPARdelta, the expression of which may contribute to intestinal carcinogenesis.
FAU - Ouyang, Nengtai
AU  - Ouyang N
AD  - Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, Stony 
      Brook, NY 11794-5200, USA.
FAU - Williams, Jennie L
AU  - Williams JL
FAU - Rigas, Basil
AU  - Rigas B
LA  - eng
GR  - R01-CA92423/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20050901
PL  - England
TA  - Carcinogenesis
JT  - Carcinogenesis
JID - 8008055
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (PPAR delta)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Apoptosis
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cell Proliferation
MH  - *Cell Transformation, Neoplastic/drug effects
MH  - Chemoprevention
MH  - Colonic Neoplasms/*prevention & control
MH  - Down-Regulation
MH  - Female
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - PPAR delta/*biosynthesis
EDAT- 2005/09/06 09:00
MHDA- 2006/03/10 09:00
CRDT- 2005/09/06 09:00
PHST- 2005/09/06 09:00 [pubmed]
PHST- 2006/03/10 09:00 [medline]
PHST- 2005/09/06 09:00 [entrez]
AID - bgi221 [pii]
AID - 10.1093/carcin/bgi221 [doi]
PST - ppublish
SO  - Carcinogenesis. 2006 Feb;27(2):232-9. doi: 10.1093/carcin/bgi221. Epub 2005 Sep 
      1.

PMID- 15732898
OWN - NLM
STAT- MEDLINE
DCOM- 20070117
LR  - 20131121
IS  - 0003-2700 (Print)
IS  - 0003-2700 (Linking)
VI  - 77
IP  - 5
DP  - 2005 Mar 1
TI  - Thin-layer chromatography and mass spectrometry coupled using desorption 
      electrospray ionization.
PG  - 1207-15
AB  - Desorption electrospray ionization (DESI) was demonstrated as a means to couple 
      thin-layer chromatography (TLC) with mass spectrometry. The experimental setup 
      and its optimization are described. Development lanes were scanned by moving the 
      TLC plate under computer control while directing the stationary DESI emitter 
      charged droplet plume at the TLC plate surface. Mass spectral data were recorded 
      in either selected reaction monitoring mode or in full scan ion trap mode using a 
      hybrid triple quadrupole linear ion trap mass spectrometer. Fundamentals and 
      practical applications of the technique were demonstrated in positive ion mode 
      using selected reaction monitoring detection of rhodamine dyes separated on 
      hydrophobic reversed-phase C8 plates and reversed-phase C2 plates, in negative 
      ion full scan mode using a selection of FD&C dyes separated on a wettable 
      reversed-phase C18 plate, and in positive ion full scan mode using a mixture of 
      aspirin, acetaminophen, and caffeine from an over-the-counter pain medication 
      separated on a normal-phase silica gel plate.
FAU - Van Berkel, Gary J
AU  - Van Berkel GJ
AD  - Organic and Biological Mass Spectrometry Group, Chemical Sciences Division, Oak 
      Ridge National Laboratory, Oak Ridge, Tennessee 37831-6131, USA. 
      vanberkelgj@ornl.gov
FAU - Ford, Michael J
AU  - Ford MJ
FAU - Deibel, Michael A
AU  - Deibel MA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
RN  - 0 (Drug Combinations)
RN  - 0 (Food Coloring Agents)
RN  - 0 (Organic Chemicals)
RN  - 0 (Rhodamines)
RN  - 0 (acetaminophen, aspirin, caffeine drug combination)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/analysis/chemistry
MH  - Aspirin/analysis/chemistry
MH  - Caffeine/analysis/chemistry
MH  - Chromatography, Thin Layer/instrumentation/methods
MH  - Drug Combinations
MH  - Food Coloring Agents/analysis
MH  - Molecular Structure
MH  - Organic Chemicals/*analysis
MH  - Rhodamines/analysis
MH  - Spectrometry, Mass, Electrospray Ionization/instrumentation/*methods
EDAT- 2005/03/01 09:00
MHDA- 2007/01/18 09:00
CRDT- 2005/03/01 09:00
PHST- 2005/03/01 09:00 [pubmed]
PHST- 2007/01/18 09:00 [medline]
PHST- 2005/03/01 09:00 [entrez]
AID - 10.1021/ac048217p [doi]
PST - ppublish
SO  - Anal Chem. 2005 Mar 1;77(5):1207-15. doi: 10.1021/ac048217p.

PMID- 8779464
OWN - NLM
STAT- MEDLINE
DCOM- 19960917
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 125
IP  - 6
DP  - 1996 Sep 15
TI  - Lowering risk without lowering cholesterol: implications for national cholesterol 
      policy.
PG  - 502-6
AB  - Current recommendations for the treatment of hypercholesterolemia include drug 
      therapy for persons at sufficiently elevated risk for coronary heart disease. 
      However, no guidelines incorporate the effects of alternative interventions that 
      decrease risk for coronary heart disease but are not used specifically to alter 
      blood lipids. We did a simulation study to estimate the number of 
      hypercholesterolemic adults who would continue to exceed a high-risk threshold 
      after receiving aspirin, antihypertensive medication, and estrogen-replacement 
      therapy. We found that of all persons who are currently candidates for 
      hypolipidemic medication because they are at high risk for coronary heart 
      disease, 6 to 8 million would no longer have this therapy recommended if the 
      abilities of alternative interventions to reduce risk were considered. 
      Pharmaceutical cost savings associated with alternative interventions range from 
      $3 to $4 billion per year. Current guidelines should be revised to account for 
      this effect.
FAU - Avins, A L
AU  - Avins AL
AD  - Veterans Affairs Medical Center, San Francisco, California, USA.
FAU - Browner, W S
AU  - Browner WS
LA  - eng
GR  - HL46297/HL/NHLBI NIH HHS/United States
GR  - HL51024/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antihypertensive Agents/economics/therapeutic use
MH  - Aspirin/economics/therapeutic use
MH  - Coronary Disease/*prevention & control
MH  - Drug Costs
MH  - Estrogen Replacement Therapy/economics
MH  - Humans
MH  - Hypercholesterolemia/complications/*drug therapy
MH  - Risk Factors
RF  - 35
EDAT- 1996/09/15 00:00
MHDA- 1996/09/15 00:01
CRDT- 1996/09/15 00:00
PHST- 1996/09/15 00:00 [pubmed]
PHST- 1996/09/15 00:01 [medline]
PHST- 1996/09/15 00:00 [entrez]
AID - 10.7326/0003-4819-125-6-199609150-00012 [doi]
PST - ppublish
SO  - Ann Intern Med. 1996 Sep 15;125(6):502-6. doi: 
      10.7326/0003-4819-125-6-199609150-00012.

PMID- 2628615
OWN - NLM
STAT- MEDLINE
DCOM- 19900426
LR  - 20131121
IS  - 0023-2149 (Print)
IS  - 0023-2149 (Linking)
VI  - 67
IP  - 12
DP  - 1989 Dec
TI  - [Hemosorption in the treatment of aspirin-induced bronchial asthma].
PG  - 40-4
AB  - Oral aspirin test was performed in 50 asthma patients. Of them 18 patients 
      exhibited idiosyncrasy to the drug. All the patients were subjected to 
      hemosorption. Subsequently, 16 patients achieved remission. The hemosorption 
      resulted in reduction of tracheobronchial hypersensitivity, especially to PGE2 
      alpha. Phagocytosis and T-cell immunity returned to normal. Sixteen patients 
      underwent aspirin desensitization which had a more potent action on the function 
      of beta-adrenergic receptors of the smooth muscles of the bronchi. Complete 
      desensitization in 3 patients was recorded only after 1-3 hemosorption sessions.
FAU - Didkovskiĭ, N A
AU  - Didkovskiĭ NA
FAU - Treskunov, V K
AU  - Treskunov VK
FAU - Zakharzhevskaia, T V
AU  - Zakharzhevskaia TV
FAU - Evseev, N G
AU  - Evseev NG
FAU - Shmeleva, T K
AU  - Shmeleva TK
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Gemosorbtsiia v lechenii bol'nykh aspirinovoĭ bronkhial'noĭ astmoĭ.
PL  - Russia (Federation)
TA  - Klin Med (Mosk)
JT  - Klinicheskaia meditsina
JID - 2985204R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/chemically induced/*therapy
MH  - Bronchi/*drug effects/immunology
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/complications/*therapy
MH  - Female
MH  - *Hemoperfusion
MH  - Humans
MH  - Male
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
PST - ppublish
SO  - Klin Med (Mosk). 1989 Dec;67(12):40-4.

PMID- 36422187
OWN - NLM
STAT- MEDLINE
DCOM- 20221128
LR  - 20230308
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 58
IP  - 11
DP  - 2022 Nov 15
TI  - Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 
      Infected Patients.
LID - 10.3390/medicina58111649 [doi]
LID - 1649
AB  - Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug 
      that has been demonstrated to reduce venous thromboembolism. The aim was to 
      analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) 
      treatment prior to hospitalization differ in hospital outcome compared to 
      patients without previous ASA therapy. Materials and Methods: An observational 
      retrospective study was carried out using an anonymized database including 
      geriatric COVID-19 patients (March to April 2020) admitted to Madrid Hospitals 
      Group. A group of COVID-19 patients were treated with low ASA (100 mg/day) prior 
      to COVID-19 infection. Results: Geriatric ASA-treated patients were older (mean 
      age over 70 years; n = 41), had higher frequency of hypertension and 
      hyperlipidemia, and upon admission had higher D-dimer levels than non-ASA-treated 
      patients (mean age over 73 years; n = 160). However, patients under ASA treatment 
      did not show more frequent pulmonary thromboembolism (PE) than non-ASA-treated 
      patients. ASA-treated geriatric COVID-19-infected patients in-hospital < 30 days 
      all-cause mortality was more frequent than in non-ASA-treated COVID-19 patients. 
      In ASA-treated COVID-19-infected geriatric patients, anticoagulant therapy with 
      low molecular weight heparin (LMWH) significantly reduced need of ICU care, but 
      tended to increase in-hospital < 30 days all-cause mortality. Conclusions: Prior 
      treatment with a low dose of ASA in COVID-19-infected geriatric patients 
      increased frequency of in-hospital < 30 days all-cause mortality, although it 
      seemed to not increase PE frequency despite D-dimer levels upon admission being 
      higher than in non-ASA users. In ASA-treated geriatric COVID-19-infected 
      patients, addition of LMWH therapy reduced frequency of ICU care, but tended to 
      increase in-hospital < 30 days all-cause mortality.
FAU - Zekri-Nechar, Khaoula
AU  - Zekri-Nechar K
AD  - Medicine Department, School of Medicine, Universidad Complutense de Madrid, 28040 
      Madrid, Spain.
FAU - Barberán, José
AU  - Barberán J
AD  - Internal Medicine Department HM Hospital, 28250 Madrid, Spain.
FAU - Zamorano-León, José J
AU  - Zamorano-León JJ
AD  - Public Health and Maternal and Child Health Department, School of Medicine, 
      Universidad Complutense de Madrid, IdISSC, 28040 Madrid, Spain.
FAU - Durbán, María
AU  - Durbán M
AD  - Statistics Department, Universidad Carlos III, 28903 Madrid, Spain.
FAU - Andrés-Castillo, Alcira
AU  - Andrés-Castillo A
AD  - Medicine Department, School of Medicine, Universidad Complutense de Madrid, 28040 
      Madrid, Spain.
FAU - Navarro-Cuellar, Carlos
AU  - Navarro-Cuellar C
AUID- ORCID: 0000-0001-9869-9240
AD  - Maxillofacial Surgery Department, Hospital General Universitario Gregorio 
      Marañón, 28007 Madrid, Spain.
FAU - López-Farré, Antonio
AU  - López-Farré A
AD  - Medicine Department, School of Medicine, Universidad Complutense de Madrid, 28040 
      Madrid, Spain.
FAU - López-de-Andrés, Ana
AU  - López-de-Andrés A
AUID- ORCID: 0000-0001-5551-5181
AD  - Public Health and Maternal and Child Health Department, School of Medicine, 
      Universidad Complutense de Madrid, IdISSC, 28040 Madrid, Spain.
FAU - Jiménez-García, Rodrigo
AU  - Jiménez-García R
AD  - Public Health and Maternal and Child Health Department, School of Medicine, 
      Universidad Complutense de Madrid, IdISSC, 28040 Madrid, Spain.
FAU - Martínez-Martínez, Carlos H
AU  - Martínez-Martínez CH
AD  - Medicine Department, School of Medicine, Universidad Complutense de Madrid, 28040 
      Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20221115
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Humans
MH  - Aged
MH  - *Aspirin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Retrospective Studies
MH  - Hospitals
MH  - *COVID-19 Drug Treatment
PMC - PMC9694688
OTO - NOTNLM
OT  - COVID-19
OT  - aspirin
OT  - elderly population
OT  - hospital stay
OT  - low molecular weight heparin
OT  - mortality
OT  - pulmonary thromboembolism
COIS- The authors declare that they have no conflict of interest.
EDAT- 2022/11/25 06:00
MHDA- 2022/11/29 06:00
CRDT- 2022/11/24 10:33
PHST- 2022/10/06 00:00 [received]
PHST- 2022/11/05 00:00 [revised]
PHST- 2022/11/10 00:00 [accepted]
PHST- 2022/11/24 10:33 [entrez]
PHST- 2022/11/25 06:00 [pubmed]
PHST- 2022/11/29 06:00 [medline]
AID - medicina58111649 [pii]
AID - medicina-58-01649 [pii]
AID - 10.3390/medicina58111649 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2022 Nov 15;58(11):1649. doi: 10.3390/medicina58111649.

PMID- 21740818
OWN - NLM
STAT- MEDLINE
DCOM- 20111214
LR  - 20131121
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 124
IP  - 10
DP  - 2011 May
TI  - Cigarette smoking inhibits the anti-platelet activity of aspirin in patients with 
      coronary heart disease.
PG  - 1569-72
AB  - OBJECTIVE: Tobacco smoking results in increased platelet aggregability, which 
      suggests that low-dose aspirin used in common clinical practice may not 
      effectively inhibit platelet activity in smokers with coronary heart disease 
      (CHD). This review was performed to assess the effect of aspirin on platelet 
      aggregation in patients with CHD. DATA SOURCES: We performed an electronic 
      literature search of MEDLINE (starting from the beginning to March 15, 2009) 
      using the term "smoking" or "tobacco" paired with the following: "platelet", 
      "aspirin" or "coronary heart disease". STUDY SELECTION: We looked for review 
      articles regarding the effect of tobacco smoking on platelet activity and on the 
      anti-platelet efficacy of aspirin in healthy people and patients with CHD. The 
      search was limited in "core clinical journal". In total, 1321 relevant articles 
      were retrieved, and 36 articles were ultimately cited. RESULTS: Tobacco smoking 
      results in increased platelet aggregability, which can be inhibited by low-dose 
      aspirin in the healthy population. However, in patients with CHD, the increased 
      platelet aggregability can not be effectively inhibited by the same low-dose of 
      aspirin. A recent study indicated that clopidogrel or an increased dose of 
      aspirin can effectively inhibit the increased platelet aggregability induced by 
      tobacco smoking in patients with CHD. CONCLUSIONS: It is important for patients 
      with CHD to quit smoking. For the current smoker, it may be necessary to take 
      larger doses of aspirin than normal or take an adenosine diphosphate receptor 
      inhibitor along with aspirin to effectively inhibit the increased platelet 
      activity.
FAU - Li, Wei-Ju
AU  - Li WJ
AD  - Department of Cardiology, Peking University Hospital, Beijing 100871, China.
FAU - Zhang, Hong-Yin
AU  - Zhang HY
FAU - Miao, Cheng-Long
AU  - Miao CL
FAU - Tang, Ri-Bo
AU  - Tang RB
FAU - DU, Xin
AU  - DU X
FAU - Shi, Ji-Hui
AU  - Shi JH
FAU - Ma, Chang-Sheng
AU  - Ma CS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Drug Interactions
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Smoking/*adverse effects
EDAT- 2011/07/12 06:00
MHDA- 2011/12/15 06:00
CRDT- 2011/07/12 06:00
PHST- 2011/07/12 06:00 [entrez]
PHST- 2011/07/12 06:00 [pubmed]
PHST- 2011/12/15 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2011 May;124(10):1569-72.

PMID- 31828534
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201119
IS  - 2190-3948 (Electronic)
IS  - 2190-393X (Linking)
VI  - 10
IP  - 2
DP  - 2020 Apr
TI  - Experiments and modeling of controlled release behavior of commercial and model 
      polymer-drug formulations using dialysis membrane method.
PG  - 515-528
LID - 10.1007/s13346-019-00696-1 [doi]
AB  - Standard dissolution testing methods typically do not correlate strongly with the 
      in vivo drug release behavior for the oral delivery products, since they only 
      focus on the drug dissolution in the gastric/intestinal fluid and do not account 
      for the intestinal absorption of drug. Artificial gastrointestinal systems 
      attempt to bridge this gap by using dialysis membranes as a proxy for the 
      intestinal membranes. We present a systematic proof-of-concept study of how the 
      drug dissolution and drug absorption are mimicked in such systems for the case of 
      polymer-drug formulations. We utilize a modified version of the conventional 
      shaking-flask test, in which the drug formulation is placed inside a dialysis 
      bag. Dissolution experiments are performed on a commercial aspirin formulation 
      and model formulations of aspirin with varying amounts of 
      poly-methyl-methacrylate-co-methacrylic acid (PMA-MAA), both for conventional and 
      modified shaking-flask test. Results are successfully interpreted using a simple 
      model that assumes first-order kinetics for both the drug release from the 
      formulation and drug permeation through the membrane. The differences between the 
      model and commercial formulations and the effects of shaking speed and drug 
      loading are established by comparison of the first-order rate constants. Finally, 
      comparison with a reported in vivo study demonstrates how the modified 
      shaking-flask setup can be used to improve the in vitro in vivo correlation. 
      Graphical abstract.
FAU - Ranjan, Alok
AU  - Ranjan A
AD  - Department of Chemical Engineering, Indian Institute of Technology Roorkee, 
      Roorkee, Uttarakhand, 247667, India.
FAU - Jha, Prateek K
AU  - Jha PK
AUID- ORCID: 0000-0001-9844-2875
AD  - Department of Chemical Engineering, Indian Institute of Technology Roorkee, 
      Roorkee, Uttarakhand, 247667, India. pkjchfch@iitr.ac.in.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Drug Deliv Transl Res
JT  - Drug delivery and translational research
JID - 101540061
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Membranes, Artificial)
RN  - 0 (Polymethacrylic Acids)
RN  - 9011-14-7 (Polymethyl Methacrylate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/chemistry/*pharmacokinetics
MH  - Delayed-Action Preparations/*chemistry
MH  - Drug Compounding
MH  - Drug Liberation
MH  - Intestinal Absorption
MH  - Membranes, Artificial
MH  - Models, Theoretical
MH  - Polymethacrylic Acids/*chemistry
MH  - Polymethyl Methacrylate/*chemistry
MH  - Proof of Concept Study
MH  - Renal Dialysis
OTO - NOTNLM
OT  - Controlled release
OT  - Dialysis bag
OT  - Diffusion
OT  - Dissolution testing
OT  - Mass transfer effects
OT  - Polymer matrix
EDAT- 2019/12/13 06:00
MHDA- 2020/11/20 06:00
CRDT- 2019/12/13 06:00
PHST- 2019/12/13 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2019/12/13 06:00 [entrez]
AID - 10.1007/s13346-019-00696-1 [pii]
AID - 10.1007/s13346-019-00696-1 [doi]
PST - ppublish
SO  - Drug Deliv Transl Res. 2020 Apr;10(2):515-528. doi: 10.1007/s13346-019-00696-1.

PMID- 2270452
OWN - NLM
STAT- MEDLINE
DCOM- 19910221
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 120
IP  - 50
DP  - 1990 Dec 15
TI  - [Central analgesic effect of paracetamol].
PG  - 1950-1
AB  - Although biochemical data suggest a direct effect of paracetamol on the CNS, its 
      mode of action is still poorly understood. We investigated the central impact of 
      paracetamol compared to acetylsalicylate in response to transcutaneous electrical 
      nerve stimulation in man. Healthy volunteers received i.v. paracetamol, 
      acetylsalicylic acid, and placebo. Analgesia was assessed by measurement of 
      objective (R-III reflex) and subjective (VAS) pain thresholds. A close 
      correlation was observed between both objective and subjective thresholds. 
      Paracetamol raised the objective and subjective thresholds. In contrast, 
      acetylsalicylic acid had no noticeable effect on either threshold. These data 
      demonstrate a central analgesic effect of paracetamol.
FAU - Piletta, P
AU  - Piletta P
AD  - Division de pharmacologie clinique et consultation de la douleur, Hôpital 
      cantonal universitaire, Genève.
FAU - Porchet, H C
AU  - Porchet HC
FAU - Dayer, P
AU  - Dayer P
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - L'effet analgésique central du paracétamol.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Aspirin/therapeutic use
MH  - Central Nervous System/*drug effects
MH  - Humans
MH  - Sensory Thresholds/drug effects
EDAT- 1990/12/15 00:00
MHDA- 1990/12/15 00:01
CRDT- 1990/12/15 00:00
PHST- 1990/12/15 00:00 [pubmed]
PHST- 1990/12/15 00:01 [medline]
PHST- 1990/12/15 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1990 Dec 15;120(50):1950-1.

PMID- 31691997
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 1096-987X (Electronic)
IS  - 0192-8651 (Linking)
VI  - 41
IP  - 4
DP  - 2020 Feb 5
TI  - A metadynamics perspective on the reduction mechanism of the Pt(IV) asplatin 
      prodrug.
PG  - 290-294
LID - 10.1002/jcc.26100 [doi]
AB  - Enhanced sampling molecular dynamics has been used to model the reduction 
      mechanism of the antitumoral Asplatin Pt(IV) complex, 
      c,c,t-[PtCl2(NH3)2(OH)(aspirin)] in the presence of l-ascorbic acid as reducing 
      agent. In order to overcome the timescale problem, characteristic of many 
      chemical reactions, we enhanced the sampling of the free energy landscape using 
      Metadynamics. To achieve such a goal, the selection of adequate collective 
      variables is crucial for the application of the method. Recently, a new method 
      called Multi-Class Harmonic Linear Discriminant Analysis (MC-HLDA) has been 
      proposed as a tool for constructing collective variables (CVs) for complex 
      chemical processes. The method reduces the dimensionality of the variable space 
      by generating appropriate linear combinations of several relevant chemical 
      descriptors. The aim of this work is to assess the ability and performance of 
      this method in describing the fundamental features of complex chemical reactions 
      such as the Asplatin reduction mechanism in a compact, simple, and physically 
      transparent manner. © 2019 Wiley Periodicals, Inc.
CI  - © 2019 Wiley Periodicals, Inc.
FAU - Ponte, Fortuna
AU  - Ponte F
AUID- ORCID: 0000-0002-4431-9510
AD  - Dipartimento di Chimica e Tecnologie Chimiche, Università della Calabria, Ponte 
      P. Bucci, Cubo 14C, Arcavacata di Rende, 87030, Italy.
FAU - Piccini, GiovanniMaria
AU  - Piccini G
AD  - Department of Chemistry and Applied Biosciences, ETH Zurich, c/o USI Campus, Via 
      Giuseppe Buffi 13, Lugano, 6900, Switzerland.
AD  - Facoltà di Informatica, Istituto di Scienze Computazionali, Università della 
      SvizzeraItaliana (USI), Via Giuseppe Buffi 13, Lugano, 6900, Switzerland.
FAU - Sicilia, Emilia
AU  - Sicilia E
AUID- ORCID: 0000-0001-5952-9927
AD  - Dipartimento di Chimica e Tecnologie Chimiche, Università della Calabria, Ponte 
      P. Bucci, Cubo 14C, Arcavacata di Rende, 87030, Italy.
FAU - Parrinello, Michele
AU  - Parrinello M
AD  - Department of Chemistry and Applied Biosciences, ETH Zurich, c/o USI Campus, Via 
      Giuseppe Buffi 13, Lugano, 6900, Switzerland.
AD  - Facoltà di Informatica, Istituto di Scienze Computazionali, Università della 
      SvizzeraItaliana (USI), Via Giuseppe Buffi 13, Lugano, 6900, Switzerland.
AD  - Istituto Italiano di Tecnologia, Via Morego 30, Genova, 16163, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191106
PL  - United States
TA  - J Comput Chem
JT  - Journal of computational chemistry
JID - 9878362
RN  - 0 (Organoplatinum Compounds)
RN  - 0 (Prodrugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Discriminant Analysis
MH  - Molecular Dynamics Simulation
MH  - Organoplatinum Compounds/*chemistry
MH  - Oxidation-Reduction
MH  - Prodrugs/*chemistry
OTO - NOTNLM
OT  - Asplatin
OT  - MC-HLDA
OT  - Pt(IV)-prodrugs
OT  - metadynamics simulation
OT  - reduction mechanism
EDAT- 2019/11/07 06:00
MHDA- 2021/04/01 06:00
CRDT- 2019/11/07 06:00
PHST- 2019/07/03 00:00 [received]
PHST- 2019/10/16 00:00 [revised]
PHST- 2019/10/17 00:00 [accepted]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
PHST- 2019/11/07 06:00 [entrez]
AID - 10.1002/jcc.26100 [doi]
PST - ppublish
SO  - J Comput Chem. 2020 Feb 5;41(4):290-294. doi: 10.1002/jcc.26100. Epub 2019 Nov 6.

PMID- 1264926
OWN - NLM
STAT- MEDLINE
DCOM- 19760706
LR  - 20190501
IS  - 0032-5473 (Print)
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 52
IP  - 604
DP  - 1976 Feb
TI  - Inhibition of platelet release reaction by acetylsalicylic acid.
PG  - 71-5
AB  - The inhibitory potency and duration of action of single doses of aspirin B.P., 
      claradin (a low sodium effervescent preparation of acetylsalicylic acid) and 
      aloxiprin (an aluminium co-polymer of acetylsalicylic acid) on platelet release 
      reaction induced by adenosine diphosphate (ADP) were studied in seventeen 
      volunteers. Aspirin B.P. and claradin at 300 mg and 150 mg inhibited release 
      reaction in all subjects within 24 hr; 75 mg was effective only in some subjects. 
      Aloxiprin gave less marked response and a dose of 300 mg was required to inhibit 
      the effect in all volunteers. Where occurring, inhibition of release reaction 
      persisted for three days after treatment with all preparations and restoration to 
      normal occurred in most subjects by the sixth day. A daily dose of 50 mg claradin 
      for 12-15 days in five volunteers produced complete inhibition of release 
      reaction for most of the treatment period. Inhibition of release reaction took up 
      to 3 days to occur. Normal aggregation returned within 3 days of discontinuing 
      treatment in all subjects. A daily dose of 25 mg claradin gave inconsistent 
      results. It is suggested that if a trial of acetylsalicylic acid be undertaken 
      for the prevention of arterial thrombosis based on its ability to inhibit 
      platelet release reaction then a daily dose of 50 mg would be sufficient.
FAU - Rowan, R M
AU  - Rowan RM
FAU - McDonald, G A
AU  - McDonald GA
FAU - Renton, R L
AU  - Renton RL
FAU - Corne, S J
AU  - Corne SJ
FAU - Brown, D F
AU  - Brown DF
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Time Factors
PMC - PMC2496292
EDAT- 1976/02/01 00:00
MHDA- 1976/02/01 00:01
CRDT- 1976/02/01 00:00
PHST- 1976/02/01 00:00 [pubmed]
PHST- 1976/02/01 00:01 [medline]
PHST- 1976/02/01 00:00 [entrez]
AID - 10.1136/pgmj.52.604.71 [doi]
PST - ppublish
SO  - Postgrad Med J. 1976 Feb;52(604):71-5. doi: 10.1136/pgmj.52.604.71.

PMID- 30064683
OWN - NLM
STAT- MEDLINE
DCOM- 20181102
LR  - 20181102
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 168
DP  - 2018 Aug
TI  - Benefits and risks of extended treatment of venous thromboembolism with 
      rivaroxaban or with aspirin.
PG  - 121-129
LID - S0049-3848(18)30383-9 [pii]
LID - 10.1016/j.thromres.2018.06.009 [doi]
AB  - BACKGROUND: Full- or lower-dose anticoagulant therapy or aspirin can be used for 
      extended therapy in patients with venous thromboembolism (VTE), but information 
      on their relative benefit-risk profiles is limited. METHODS: Data from the 
      EINSTEIN-CHOICE trial were used to compare the benefit-risk profiles of extended 
      treatment with rivaroxaban (20 or 10 mg once daily) and aspirin (100 mg once 
      daily) in VTE patients who had completed 6 to 12 months of anticoagulation 
      therapy. One-year cumulative incidences of recurrent VTE and major bleeding were 
      estimated and benefits and risks were calculated by determining the between group 
      differences in a hypothetical population of 10,000 VTE patients treated for 
      1 year. FINDINGS: A total of 1107 patients were treated with 20 mg of 
      rivaroxaban, 1127 with 10 mg of rivaroxaban, and 1131 with aspirin. The 
      cumulative incidences of recurrent VTE in the rivaroxaban 20-mg, rivaroxaban 
      10-mg and aspirin groups were 1.9%, 1.6%, and 5.0%, respectively, whereas the 
      cumulative incidences of major bleeding were 0.7%, 0.4% and 0.5%, respectively. 
      The incidences of the combined outcome of recurrent VTE and major bleeding were 
      2.8% and 3.4% lower in the rivaroxaban 20-mg and 10-mg groups than in the aspirin 
      group. For 10,000 patients treated for 1 year, there would be 284 (95% confidence 
      interval [CI] 106 to 462) and 339 (95% CI 165 to 512) fewer events with 
      rivaroxaban 20 mg or 10 mg than with aspirin. INTERPRETATION: Compared with 
      aspirin, extended anticoagulation with once daily rivaroxaban reduces recurrent 
      VTE with a favourable benefit-risk profile. FUNDING: Bayer AG.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Prandoni, Paolo
AU  - Prandoni P
AD  - Department of Cardiothoracic & Vascular Sciences, Vascular Medicine Unit, 
      University of Padua, Italy.
FAU - Lensing, Anthonie W A
AU  - Lensing AWA
AD  - Bayer AG, Leverkusen, Germany.
FAU - Prins, Martin H
AU  - Prins MH
AD  - Department of Epidemiology and Technology Assessment, University of Maastricht, 
      Maastricht, The Netherlands.
FAU - Gebel, Martin
AU  - Gebel M
AD  - Bayer AG, Leverkusen, Germany.
FAU - Pap, Akos F
AU  - Pap AF
AD  - Bayer AG, Leverkusen, Germany.
FAU - Homering, Martin
AU  - Homering M
AD  - Bayer AG, Leverkusen, Germany.
FAU - Bauersachs, Rupert
AU  - Bauersachs R
AD  - Department of Vascular Medicine, Klinikum Darmstadt GmbH, Germany.
FAU - Beyer-Westendorf, Jan
AU  - Beyer-Westendorf J
AD  - Department of Hematology, Medical Clinic I, University Hospital "Carl Gustav 
      Carus" Dresden, Germany; Department of Haematology, Oncology Kings College 
      London, UK.
FAU - Bounameaux, Henri
AU  - Bounameaux H
AD  - Division of Angiology and Hemostasis, University Hospitals of Geneva, Faculty of 
      Medicine, Geneva, Switzerland.
FAU - Cohen, Alexander T
AU  - Cohen AT
AD  - Department of Haematological Medicine, Guys and St Thomas' Hospitals, King's 
      College Hospital, London, UK.
FAU - Davidson, Bruce L
AU  - Davidson BL
AD  - University of Washington School of Medicine, Seattle, WA, USA.
FAU - van Bellen, Bonno
AU  - van Bellen B
AD  - Hospital Beneficência Portuguesa, São Paulo, Brazil.
FAU - Verhamme, Peter
AU  - Verhamme P
AD  - Vascular Medicine and Hemostasis, University of Leuven, Belgium.
FAU - Wells, Philip S
AU  - Wells PS
AD  - Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, 
      Ontario, Canada.
FAU - Yuan, Zhong
AU  - Yuan Z
AD  - Janssen Research & Development, Raritan, NJ, USA.
FAU - Levitan, Bennett
AU  - Levitan B
AD  - Janssen Research & Development, Raritan, NJ, USA.
FAU - Weitz, Jeffrey I
AU  - Weitz JI
AD  - Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, 
      Ontario, Canada. Electronic address: weitzj@taari.ca.
LA  - eng
PT  - Journal Article
DEP - 20180710
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/pharmacology/therapeutic use
MH  - Factor Xa Inhibitors/*adverse effects/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*adverse effects/pharmacology/therapeutic use
MH  - Risk Factors
MH  - Rivaroxaban/*adverse effects/pharmacology/therapeutic use
MH  - Venous Thromboembolism/*drug therapy/pathology
EDAT- 2018/08/02 06:00
MHDA- 2018/11/06 06:00
CRDT- 2018/08/02 06:00
PHST- 2018/04/04 00:00 [received]
PHST- 2018/05/25 00:00 [revised]
PHST- 2018/06/13 00:00 [accepted]
PHST- 2018/08/02 06:00 [entrez]
PHST- 2018/08/02 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
AID - S0049-3848(18)30383-9 [pii]
AID - 10.1016/j.thromres.2018.06.009 [doi]
PST - ppublish
SO  - Thromb Res. 2018 Aug;168:121-129. doi: 10.1016/j.thromres.2018.06.009. Epub 2018 
      Jul 10.

PMID- 1334726
OWN - NLM
STAT- MEDLINE
DCOM- 19930128
LR  - 20131121
IS  - 0365-9615 (Print)
IS  - 0365-9615 (Linking)
VI  - 114
IP  - 8
DP  - 1992 Jul
TI  - [Fibrinolytic complexes of low-molecular heparin and acetylsalicylic acid].
PG  - 141-3
AB  - Complexes of low-molecular heparin with acetylsalicilic acid was formed in vitro 
      when the weight ratio of components was 1:1, 1:5 and 5:1, respectively. All the 
      complexes possessed fibrinolytic and anticoagulating activities. The complex 
      possessed the highest activity when the ratio of heparin to acetylsalicilic acid 
      was 5:1. This complex at a dose 1 mg/200 g of rat weight had the largest 
      thrombolytic effect on the experimental fresh thrombus.
FAU - Kudriashov, B A
AU  - Kudriashov BA
FAU - Pastorova, V E
AU  - Pastorova VE
FAU - Liapina, L A
AU  - Liapina LA
FAU - Kondashevskaia, M V
AU  - Kondashevskaia MV
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Fibrinoliticheskie kompleksy nizkomolekuliarnogo geparina s atsetilsalitsilovoĭ 
      kislotoĭ.
PL  - Russia (Federation)
TA  - Biull Eksp Biol Med
JT  - Biulleten' eksperimental'noi biologii i meditsiny
JID - 0370627
RN  - 0 (Anticoagulants)
RN  - 0 (Drug Combinations)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Coagulation Tests
MH  - Drug Combinations
MH  - Drug Evaluation, Preclinical
MH  - Fibrinolytic Agents/pharmacology/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/pharmacology/*therapeutic use
MH  - Jugular Veins
MH  - Male
MH  - Rats
MH  - Thrombosis/blood/drug therapy
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
PST - ppublish
SO  - Biull Eksp Biol Med. 1992 Jul;114(8):141-3.

PMID- 6780647
OWN - NLM
STAT- MEDLINE
DCOM- 19810424
LR  - 20161123
IS  - 0398-0499 (Print)
IS  - 0398-0499 (Linking)
VI  - 5
IP  - 2
DP  - 1980
TI  - [Characteristic rheograms of pathological bloods. Application to dynamic 
      pharmacology (author's transl)].
PG  - 135-7
AB  - The viscosity of normal and pathological blood samples is determined using a 
      Couette viscometer (5.10-2s-1 less than or equal to shear rate less than to equal 
      to 125 s-1). In different pathological cases, the rheograms show an abnormal 
      behaviour. The viscosity curves exhibits a break between 0.1 and 1 s-1. This work 
      shows the results obtained in the case of a patient suffering from Raynaud's 
      disease. During therapy with lysine acetylsalycilate one observed the gradual 
      shift of the breack to low shaer values, then, the return to a normal rheogram. 
      In the same time, acroyanosis has completely disappeared, recovering normal nail 
      growth.
FAU - Dufaux, J
AU  - Dufaux J
FAU - Quemada, D
AU  - Quemada D
FAU - Mills, P
AU  - Mills P
FAU - Lambert, M
AU  - Lambert M
LA  - fre
PT  - Case Reports
PT  - Journal Article
TT  - Rhéogrammes caractéristiques de sangs pathologiques. Applications à pharmacologie 
      dynamique.
PL  - France
TA  - J Mal Vasc
JT  - Journal des maladies vasculaires
JID - 7707965
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aged
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - *Blood Viscosity
MH  - Female
MH  - Humans
MH  - Lysine/analogs & derivatives/therapeutic use
MH  - Plethysmography, Impedance
MH  - Raynaud Disease/*blood/drug therapy
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - J Mal Vasc. 1980;5(2):135-7.

PMID- 30767579
OWN - NLM
STAT- MEDLINE
DCOM- 20190902
LR  - 20190902
IS  - 1520-5762 (Electronic)
IS  - 0363-9045 (Linking)
VI  - 45
IP  - 6
DP  - 2019 Jun
TI  - Preparing of aspirin sustained-release granules by hot-melt granulation and 
      micro-crystal coating.
PG  - 959-967
LID - 10.1080/03639045.2019.1583756 [doi]
AB  - In this work, aspirin (ASP) sustained granules were prepared using micro-crystal 
      coating and hot-melt granulation, respectively. In the process of micro-crystal 
      coating, PVP was used to form the isolation layer and then coated with either 
      Eudragit RS/RL30D or ethyl cellulose (EC) as sustained-release layers to prepare 
      sustained granules (the granules from this method were denoted m-cG). And in the 
      process of hot-melt granulation, the granules were obtained with stearyl alcohol 
      as a binder and EC as matrix material to prepare sustained granules (the granules 
      were denoted h-mG). The in vitro release of ASP sustained-release granules was 
      investigated by dissolution apparatus and the stability of the granules was 
      studied. Since both methods effectively prevented the hydrolysis of ASP, the 
      sustained granules by micro-crystal coating and hot-melt granulation were stable. 
      However, there was a clear difference in the in vitro release of h-mG and m-cG. 
      The h-mG was completely released in 4 h, while the m-cG with EC as 
      sustained-release layer released 80% in 24 h and the m-cG with the Eudragit RS/RL 
      30 D as sustained-release layer released completely in 5 h. The results showed 
      that micro-crystal coating was more suitable for the preparation of ASP sustained 
      granules, and the granules with EC as sustained layer could achieve a better 
      sustained-release effect.
FAU - Li, Ran
AU  - Li R
AD  - a School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China.
FAU - Yin, Tian
AU  - Yin T
AD  - b School of Functional food and Wine , Shenyang Pharmaceutical University 
      Shenyang , Shenyang , China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - a School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China.
FAU - Gou, Jingxin
AU  - Gou J
AD  - a School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China.
FAU - He, Haibing
AU  - He H
AD  - a School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China.
FAU - Tang, Xing
AU  - Tang X
AD  - a School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China.
LA  - eng
PT  - Journal Article
DEP - 20190320
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Excipients)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 7Z8S9VYZ4B (ethyl cellulose)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/chemistry/*pharmacokinetics
MH  - Cellulose/analogs & derivatives/chemistry
MH  - Delayed-Action Preparations/chemistry/pharmacokinetics
MH  - Drug Compounding/*methods
MH  - Drug Liberation
MH  - Drug Stability
MH  - Excipients/*chemistry
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/chemistry/*pharmacokinetics
MH  - Solubility
MH  - Stroke/prevention & control
OTO - NOTNLM
OT  - release
OT  - Aspirin
OT  - hot-melt granulation
OT  - micro-crystal coating
OT  - stability
OT  - sustained-release
EDAT- 2019/02/16 06:00
MHDA- 2019/09/03 06:00
CRDT- 2019/02/16 06:00
PHST- 2019/02/16 06:00 [pubmed]
PHST- 2019/09/03 06:00 [medline]
PHST- 2019/02/16 06:00 [entrez]
AID - 10.1080/03639045.2019.1583756 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 2019 Jun;45(6):959-967. doi: 10.1080/03639045.2019.1583756. 
      Epub 2019 Mar 20.

PMID- 8815139
OWN - NLM
STAT- MEDLINE
DCOM- 19961009
LR  - 20161123
IS  - 0368-2315 (Print)
IS  - 0150-9918 (Linking)
VI  - 25
IP  - 4
DP  - 1996
TI  - [Uterine velocimetry and vascular pregnancy pathologies prevented with low-dose 
      aspirin].
PG  - 396-404
AB  - Several trials have been published about the usefulness of early uterine Doppler 
      waveform in the prediction of pre-eclampsia and intrauterine growth retardation 
      in nulliparous or low risk patients. We reviewed 3 trials introducing aspirin 
      therapy in patients selected by an early abnormal uterine Doppler waveform. In 
      one trial, serum alpha fetoprotein above 2.5 median at 16 weeks was used as a 
      first selection criterion. In two studies, the incidence of pre-eclampsia was 
      significantly decreased in aspirin treated groups: McParland's trial (odds ratio: 
      0.08; 95% CI:0.01-0.63) and Campbell's preliminary report (odds ratio: 0.15; 95% 
      CI:0.02-0.91). In contrast, the rate of intra-uterine growth retardation was 
      found similar in aspirin and placebo treated patients. To clarify the usefulness 
      of aspirin therapy in patients with early abnormal uterine Doppler in improving 
      maternal and fetal outcome, other prospective large studies are needed.
FAU - Haddad, B
AU  - Haddad B
AD  - Service de Gynécologie-Obstétrique, CHI.
FAU - Uzan, M
AU  - Uzan M
FAU - Bréart, G
AU  - Bréart G
FAU - Paniel, B J
AU  - Paniel BJ
FAU - Uzan, S
AU  - Uzan S
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Examen vélocimétrique utérin et traitement préventif des pathologies vasculaires 
      gravidiques par aspirine à faible dose.
PL  - France
TA  - J Gynecol Obstet Biol Reprod (Paris)
JT  - Journal de gynecologie, obstetrique et biologie de la reproduction
JID - 0322206
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fetal Growth Retardation/*diagnostic imaging/*prevention & control
MH  - Humans
MH  - Incidence
MH  - Odds Ratio
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*diagnostic imaging/*prevention & control
MH  - Pregnancy
MH  - Rheology
MH  - *Ultrasonography, Prenatal
MH  - Uterus/*blood supply
RF  - 51
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
PST - ppublish
SO  - J Gynecol Obstet Biol Reprod (Paris). 1996;25(4):396-404.

PMID- 30913329
OWN - NLM
STAT- MEDLINE
DCOM- 20190521
LR  - 20190521
IS  - 1521-3765 (Electronic)
IS  - 0947-6539 (Linking)
VI  - 25
IP  - 28
DP  - 2019 May 17
TI  - Anticancer Ir(III) -Aspirin Conjugates for Enhanced Metabolic Immuno-Modulation 
      and Mitochondrial Lifetime Imaging.
PG  - 7012-7022
LID - 10.1002/chem.201900851 [doi]
AB  - The chemo-anti-inflammatory strategy is attracting ever more attention for the 
      treatment of cancer. Here, two cyclometalated Ir(III) complexes Ir2 and Ir3 
      formed by conjugation of Ir1 with two antiphlogistics (aspirin and salicylic 
      acid) have been designed. Ir2 and Ir3 exhibit higher antitumor and 
      anti-inflammatory potencies than a mixture of Ir1 and aspirin/salicylic acid. We 
      show that they can be hydrolyzed, accumulate in mitochondria, and induce 
      mitochondrial dysfunction. Due to their intense long-lived phosphorescence, Ir2 
      and Ir3 can track mitochondrial morphological changes. Phosphorescence lifetime 
      imaging shows that Ir2 and Ir3 can aggregate during mitochondrial dysfunction. As 
      expected, Ir2 and Ir3 exhibit immunomodulatory properties by regulating the 
      activity of immune factors. Both Ir2 and Ir3 can induce caspase-dependent 
      apoptosis and caspase-independent paraptosis and inhibit several events related 
      to metastasis. Moreover, Ir2 and Ir3 show potent tumor growth inhibition in vivo. 
      Our study demonstrates that the combination of mitochondrial-targeting and 
      immunomodulatory activities is feasible to develop multifunctional metal-based 
      anticancer agents.
CI  - © 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Wu, Xiao-Wen
AU  - Wu XW
AD  - MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, 
      Sun Yat-Sen University, Guangzhou, 510275, P.R. China.
FAU - Zheng, Yue
AU  - Zheng Y
AD  - MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, 
      Sun Yat-Sen University, Guangzhou, 510275, P.R. China.
FAU - Wang, Fang-Xin
AU  - Wang FX
AD  - MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, 
      Sun Yat-Sen University, Guangzhou, 510275, P.R. China.
FAU - Cao, Jian-Jun
AU  - Cao JJ
AD  - MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, 
      Sun Yat-Sen University, Guangzhou, 510275, P.R. China.
FAU - Zhang, Hang
AU  - Zhang H
AD  - MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, 
      Sun Yat-Sen University, Guangzhou, 510275, P.R. China.
FAU - Zhang, Dong-Yang
AU  - Zhang DY
AD  - MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, 
      Sun Yat-Sen University, Guangzhou, 510275, P.R. China.
FAU - Tan, Cai-Ping
AU  - Tan CP
AD  - MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, 
      Sun Yat-Sen University, Guangzhou, 510275, P.R. China.
FAU - Ji, Liang-Nian
AU  - Ji LN
AD  - MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, 
      Sun Yat-Sen University, Guangzhou, 510275, P.R. China.
FAU - Mao, Zong-Wan
AU  - Mao ZW
AUID- ORCID: 0000-0001-7131-1154
AD  - MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, 
      Sun Yat-Sen University, Guangzhou, 510275, P.R. China.
LA  - eng
GR  - 21778078/National Natural Science Foundation of China/
GR  - 21837006/National Natural Science Foundation of China/
GR  - 21571196/National Natural Science Foundation of China/
GR  - 21572282/National Natural Science Foundation of China/
GR  - 2015A030306023/Natural Science Foundation of Guangdong Province/
GR  - IRT_17R111/the Innovative Research Team in University of Ministry of Education of 
      China/
PT  - Journal Article
DEP - 20190426
PL  - Germany
TA  - Chemistry
JT  - Chemistry (Weinheim an der Bergstrasse, Germany)
JID - 9513783
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Coordination Complexes)
RN  - 44448S9773 (Iridium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/chemistry/pharmacology/*therapeutic use
MH  - Antineoplastic Agents/chemistry/pharmacology/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/chemistry/pharmacology/*therapeutic use
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Coordination Complexes/chemistry/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immunomodulation/*drug effects
MH  - Iridium/chemistry/pharmacology/*therapeutic use
MH  - Luminescent Measurements/methods
MH  - Mice, Inbred BALB C
MH  - Mitochondria/drug effects/pathology
MH  - Neoplasms/diagnostic imaging/*drug therapy/pathology
MH  - Optical Imaging/methods
OTO - NOTNLM
OT  - anticancer agents
OT  - aspirin
OT  - fluorescence
OT  - immunomodulation
OT  - iridium
OT  - mitochondrion
EDAT- 2019/03/27 06:00
MHDA- 2019/05/22 06:00
CRDT- 2019/03/27 06:00
PHST- 2019/02/24 00:00 [received]
PHST- 2019/03/24 00:00 [revised]
PHST- 2019/03/27 06:00 [pubmed]
PHST- 2019/05/22 06:00 [medline]
PHST- 2019/03/27 06:00 [entrez]
AID - 10.1002/chem.201900851 [doi]
PST - ppublish
SO  - Chemistry. 2019 May 17;25(28):7012-7022. doi: 10.1002/chem.201900851. Epub 2019 
      Apr 26.

PMID- 5543878
OWN - NLM
STAT- MEDLINE
DCOM- 19710403
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 50
IP  - 1
DP  - 1971 Jan
TI  - The effect of salicylate on the metabolism of normal and stimulated human 
      lymphocytes in vitro.
PG  - 226-30
AB  - The effect of salicylate on the metabolism of peripheral blood lymphocytes in 
      tissue culture was investigated. Lymphocytes incubated with sodium salicylate at 
      a concentration of 30 mg/100 ml showed increased glucose consumption, lactic acid 
      production, and oxygen consumption, evidence for uncoupling of oxidative 
      phosphorylation. No decrease in cell number or viability (trypan blue dye 
      exclusion) was noted in salicylate-treated cultures. Normal DNA, RNA, and total 
      protein synthesis measured by radioisotope incorporation was depressed in the 
      salicylate-treated cultures. Increased DNA synthesis after the addition of a 
      mitogen (PHA) or antigen (PPD) to the culture was strikingly suppressed by 
      salicylate. The degree of suppression was proportional to the concentration of 
      salicylate used. The effect on RNA and protein synthesis in stimulated 
      lymphocytes was much less pronounced. Acetylsalicylic acid was found to be as 
      active as sodium salicylate in suppressing DNA synthesis, but the p-OH congener 
      (p-OH benzoic acid) did not alter cell respiration, glycolysis, viability, or DNA 
      synthesis. The salicylate effect was reversible as evidenced by return of 
      cellular reactivity upon removal of the drug from the media.
FAU - Pachman, L M
AU  - Pachman LM
FAU - Esterly, N B
AU  - Esterly NB
FAU - Peterson, R D
AU  - Peterson RD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Antigens)
RN  - 9007-49-2 (DNA)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antigens
MH  - Aspirin/pharmacology
MH  - Cell Division/drug effects
MH  - DNA/biosynthesis
MH  - Depression, Chemical
PMC - PMC291911
EDAT- 1971/01/01 00:00
MHDA- 1971/01/01 00:01
CRDT- 1971/01/01 00:00
PHST- 1971/01/01 00:00 [pubmed]
PHST- 1971/01/01 00:01 [medline]
PHST- 1971/01/01 00:00 [entrez]
AID - 10.1172/JCI106478 [doi]
PST - ppublish
SO  - J Clin Invest. 1971 Jan;50(1):226-30. doi: 10.1172/JCI106478.

PMID- 11248498
OWN - NLM
STAT- MEDLINE
DCOM- 20010614
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 24
IP  - 5-6
DP  - 2001 Mar
TI  - Potentiometric determination of acetylsalicylic acid by sequential injection 
      analysis (SIA) using a tubular salicylate-selective electrode.
PG  - 1027-36
AB  - This paper deals with the development of an automated procedure for formulation 
      assays and dissolution tests based on a sequential injection analysis (SIA) 
      system involving an ion-selective electrode as sensing device. Construction of a 
      tubular salicylate (Sal) selective electrode suitable for potentiometric 
      determination of acetylsalicylic acid (Asa) in pharmaceutical formulations is 
      described. The flow-through electrode is formed by a PVC membrane containing 
      29.2% (w/w) PVC, 5.8% (w/w) tetraoctylammonium salicylate (ionic sensor), 58.5% 
      o-nitrophenyloctylether (plasticizer) and 6.5% (w/w) p-tert-octylphenol 
      (stabilising additive which increases electrode selectivity). The calibration 
      range is 0.05--10 mM Sal, the limit of detection (LOD) is 0.05 mM Sal, the slope 
      is 56.0 mV per decade at 22 degrees C. The R.S.D. is 0.20% (15 readings) when 
      determining 2.5 mM Sal in standard solution. The electrode is used for sensing 
      Asa after its on-line chemical hydrolysis to Sal in a SIA system. The sampling 
      rate is 6 h(-1) but for the dissolution tests the frequency is increased to 20 
      h(-1). The SIA set-up is employed for the assay of Asa in plain tablets, composed 
      tablets and effervescent tablets and for performing dissolution tests of normal 
      and sustained release tablets. Results obtained by this technique compare well 
      with those required by the US Pharmacopoeia XXIV.
FAU - Paseková, H
AU  - Paseková H
AD  - Department of Analytical Chemistry, Faculty of Pharmacy, Charles University, 
      Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. pasekova@faf.cuni.cz
FAU - Sales, M G
AU  - Sales MG
FAU - Montenegro, M C
AU  - Montenegro MC
FAU - Araújo, A N
AU  - Araújo AN
FAU - Polásek, M
AU  - Polásek M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Calibration
MH  - Electrochemistry/*instrumentation
MH  - *Electrodes
MH  - Sensitivity and Specificity
MH  - Solubility
EDAT- 2001/03/15 10:00
MHDA- 2001/06/15 10:01
CRDT- 2001/03/15 10:00
PHST- 2001/03/15 10:00 [pubmed]
PHST- 2001/06/15 10:01 [medline]
PHST- 2001/03/15 10:00 [entrez]
AID - S0731708500005379 [pii]
AID - 10.1016/s0731-7085(00)00537-9 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2001 Mar;24(5-6):1027-36. doi: 
      10.1016/s0731-7085(00)00537-9.

PMID- 9990467
OWN - NLM
STAT- MEDLINE
DCOM- 19990413
LR  - 20220129
IS  - 0960-894X (Print)
IS  - 0960-894X (Linking)
VI  - 9
IP  - 1
DP  - 1999 Jan 4
TI  - Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from 
      reduced indolequinones.
PG  - 113-8
AB  - A series of regioisomeric derivatives of a 1-methylindole-4,7-dione were 
      synthesised, substituted with a 2-acetoxybenzoate leaving group linked through 
      the (indol-2-yl)methyl or (indol-3-yl)methyl (or propenyl) positions. Reductive 
      elimination of the leaving group occurred from the (indol-3-yl)methyl derivatives 
      but not the 2-substituted regioisomers, indicating that only the C-3 position may 
      be utilised in bioreductively-activated drug delivery, which was demonstrated 
      with an aspirin prodrug.
FAU - Jaffar, M
AU  - Jaffar M
AD  - School of Pharmacy, University of Manchester, UK.
FAU - Everett, S A
AU  - Everett SA
FAU - Naylor, M A
AU  - Naylor MA
FAU - Moore, S G
AU  - Moore SG
FAU - Ulhaq, S
AU  - Ulhaq S
FAU - Patel, K B
AU  - Patel KB
FAU - Stratford, M R
AU  - Stratford MR
FAU - Nolan, J
AU  - Nolan J
FAU - Wardman, P
AU  - Wardman P
FAU - Stratford, I J
AU  - Stratford IJ
LA  - eng
GR  - G0500366/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Free Radicals)
RN  - 0 (Indoles)
RN  - 0 (Prodrugs)
RN  - 0 (Quinones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Arthritis/metabolism
MH  - Aspirin/*chemistry/metabolism
MH  - Free Radicals/metabolism
MH  - Humans
MH  - Hypoxia/drug therapy/metabolism
MH  - Indoles/*chemistry/metabolism
MH  - Neoplasms/metabolism
MH  - Oxidation-Reduction
MH  - Prodrugs/*chemistry/metabolism
MH  - Quinones/*chemistry/metabolism
MH  - Structure-Activity Relationship
EDAT- 1999/02/17 00:00
MHDA- 1999/02/17 00:01
CRDT- 1999/02/17 00:00
PHST- 1999/02/17 00:00 [pubmed]
PHST- 1999/02/17 00:01 [medline]
PHST- 1999/02/17 00:00 [entrez]
AID - S0960894X98006957 [pii]
AID - 10.1016/s0960-894x(98)00695-7 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 1999 Jan 4;9(1):113-8. doi: 10.1016/s0960-894x(98)00695-7.

PMID- 3978776
OWN - NLM
STAT- MEDLINE
DCOM- 19850426
LR  - 20191022
IS  - 0009-9090 (Print)
IS  - 0009-9090 (Linking)
VI  - 15
IP  - 1
DP  - 1985 Jan
TI  - Aspirin intolerance and asthmal induction of a tolerance and long-term 
      monitoring.
PG  - 37-42
AB  - Acetylsalicylic-acid (ASA) intolerance is well recognized as a possible cause for 
      exacerbating asthma. It has been postulated that if this could be overcome, 
      long-term aspirin administration could improve asthma symptoms and enable 
      reduction of the use of other anti-asthmatic drugs. We succeeded in inducing an 
      ASA tolerance in nine corticosteroid-dependent asthmatics, and this tolerance 
      lasted at least 1 month and at most 1 year. Progressive deterioration in lung 
      function was seen, however, in all patients taking ASA for more than 1 month, 
      unless the corticosteroid intake was increased. These results suggest that ASA 
      long-term treatment is of no help to severe corticosteroid-dependent, 
      ASA-sensitive asthmatics. This conclusion differs from other reports on ASA 
      intolerance in asthma.
FAU - Dor, P J
AU  - Dor PJ
FAU - Vervloet, D
AU  - Vervloet D
FAU - Baldocchi, G
AU  - Baldocchi G
FAU - Charpin, J
AU  - Charpin J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Clin Allergy
JT  - Clinical allergy
JID - 0311172
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Asthma/*immunology/physiopathology/therapy
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/*immunology/therapy
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Respiratory System/physiopathology
MH  - Time Factors
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1111/j.1365-2222.1985.tb02252.x [doi]
PST - ppublish
SO  - Clin Allergy. 1985 Jan;15(1):37-42. doi: 10.1111/j.1365-2222.1985.tb02252.x.

PMID- 3091522
OWN - NLM
STAT- MEDLINE
DCOM- 19861003
LR  - 20131121
IS  - 0250-0868 (Print)
IS  - 0250-0868 (Linking)
VI  - 8
IP  - 4
DP  - 1986
TI  - Two modes of analgesic action of aspirin, and the site of analgesic action of 
      salicylic acid.
PG  - 327-31
AB  - The analgesic activities of aspirin and salicylic acid were investigated by means 
      of the lame-walking test in adjuvant-induced hind-paw-oedematous rats. Aspirin 
      showed ca. 4 times more potent analgesic activity than did salicylic acid in the 
      lame-walking test. The analgesic activity of aspirin was decreased to the level 
      of that of salicylic acid by injection of prostaglandin E2 into the inflamed 
      tissue. The analgesic activity of salicylic acid was not decreased by the same 
      treatment. Salicylic acid inhibited the lame-walking reaction when given 
      intracerebroventricularly. On the other hand, salicylic acid did not inhibit the 
      lame-walking reaction by topical administration on the inflamed hind paw. 
      However, with topical administration, salicylic acid inhibited the 
      carrageenin-induced hind-paw oedema. These results suggest that aspirin has two 
      analgesic effects on the inflammatory pain; one may be the inhibition of 
      prostaglandin biosynthesis by acetylation of cyclo-oxygenase, and the other may 
      be an action due to salicylic acid. Salicylic acid may produce its analgesic 
      action mainly via a central mechanism.
FAU - Higuchi, S
AU  - Higuchi S
FAU - Tanaka, N
AU  - Tanaka N
FAU - Shioiri, Y
AU  - Shioiri Y
FAU - Otomo, S
AU  - Otomo S
FAU - Aihara, H
AU  - Aihara H
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int J Tissue React
JT  - International journal of tissue reactions
JID - 8302116
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesia
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cyclooxygenase Inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Inflammation/drug therapy
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Salicylates/administration & dosage/*pharmacology
MH  - Salicylic Acid
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Tissue React. 1986;8(4):327-31.

PMID- 18160362
OWN - NLM
STAT- MEDLINE
DCOM- 20080221
LR  - 20131121
IS  - 1308-0032 (Electronic)
IS  - 1302-8723 (Linking)
VI  - 7 Suppl 2
DP  - 2007 Dec
TI  - [Use of aspirin in patients taking angiotensin converting enzyme inhibitors].
PG  - 14-9
AB  - Aspirin and angiotensin converting enzyme (ACE) inhibitors both have beneficial 
      effects on prognosis in patients with cardiovascular disease. For this reason, 
      they are usually prescribed together. Some of the beneficial effects of ACE 
      inhibitors are thought to be due to reduced degradation of bradykinin. Bradykinin 
      enhances nitric oxide and vasodilatory prostaglandins. Theoretically, aspirin, 
      which inhibits cyclooxygenase enzyme, may reduce bradykinin mediated 
      prostaglandin synthesis and blunt the beneficial effects of ACE inhibitors, when 
      used together. Although some hemodynamic studies support this hypothesis, 
      clinical studies have conflicting results. In this article, we reviewed the 
      possible interaction between aspirin and ACE inhibitors in light of literature 
      findings.
FAU - Altin, Timuçin
AU  - Altin T
AD  - Ankara Universitesi Tip Fakültesi Kardiyoloji Anabilim Dali, Ankara, Türkiye. 
      alitimaltin@yahoo.com
FAU - Kiliçkap, Mustafa
AU  - Kiliçkap M
LA  - tur
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Anjiyotensin dönüştürücü enzim inhibitörü kullanan hastalarda aspirin.
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*drug therapy
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
RF  - 43
EDAT- 2008/02/09 09:00
MHDA- 2008/02/22 09:00
CRDT- 2008/02/09 09:00
PHST- 2008/02/09 09:00 [pubmed]
PHST- 2008/02/22 09:00 [medline]
PHST- 2008/02/09 09:00 [entrez]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2007 Dec;7 Suppl 2:14-9.

PMID- 26219647
OWN - NLM
STAT- MEDLINE
DCOM- 20151203
LR  - 20161122
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 46
IP  - 9
DP  - 2015 Sep
TI  - Clinical Implications of Changes in Individual Platelet Reactivity to Aspirin 
      Over Time in Acute Ischemic Stroke.
PG  - 2534-40
LID - 10.1161/STROKEAHA.115.009428 [doi]
AB  - BACKGROUND AND PURPOSE: Time-dependent changes in individual platelet reactivity 
      have been detected in patients with coronary artery disease. Therefore, we sought 
      to evaluate the time-dependent changes in platelet reactivity to aspirin during 
      the acute stage after ischemic stroke and the clinical implications of variable 
      patient responses to aspirin in acute ischemic stroke. METHODS: We conducted a 
      single-center, prospective, observational study. The acute aspirin reaction unit 
      (ARU) was measured after 3 hours of aspirin loading, with higher values 
      indicating increased platelet reactivity despite aspirin therapy. The follow-up 
      ARU was measured on the fifth day of consecutive aspirin intake. The numeric 
      difference between the follow-up ARU and the acute ARU was defined as ΔARU and 
      was stratified into quartiles. Early neurological deterioration was regarded as 
      an early clinical outcome. RESULTS: Both the acute ARU (476±69 IU) and the 
      follow-up ARU (451±68 IU) were measured in 349 patients in this study. Early 
      neurological deterioration was observed in 72 patients (20.6%). Changes in 
      aspirin platelet reactivity over time showed an approximately Gaussian 
      distribution. The highest ΔARU quartile was independently associated with early 
      neurological deterioration (odds ratio, 3.19; 95% confidence interval, 1.43-7.10; 
      P=0.005) by multivariate logistic regression analysis. CONCLUSIONS: The results 
      of our study showed that the increase in platelet reactivity to aspirin over time 
      is independently associated with early neurological deterioration in patients 
      with acute ischemic stroke. In addition, during the acute stage of ischemic 
      stroke, serial platelet reactivity assays may be more useful than a single assay 
      for identifying the clinical implications of aspirin platelet reactivity after 
      ischemic stroke.
CI  - © 2015 American Heart Association, Inc.
FAU - Kim, Joon-Tae
AU  - Kim JT
AD  - From the Department of Neurology, Chonnam National University Hospital, Gwangju, 
      Korea (J.-T.K., K.-H.C., T.-S.N., S.-M.C., S.-H.L., M.-S.P., B.C.K., M.-K.K., 
      K.-H.C.); Department of Radiology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea (S.-H.H.); and Stroke Center and Department of Neurology, David 
      Geffen School of Medicine, University of California, Los Angeles (J.L.S.). 
      alldelight2@jnu.ac.kr.
FAU - Heo, Suk-Hee
AU  - Heo SH
AD  - From the Department of Neurology, Chonnam National University Hospital, Gwangju, 
      Korea (J.-T.K., K.-H.C., T.-S.N., S.-M.C., S.-H.L., M.-S.P., B.C.K., M.-K.K., 
      K.-H.C.); Department of Radiology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea (S.-H.H.); and Stroke Center and Department of Neurology, David 
      Geffen School of Medicine, University of California, Los Angeles (J.L.S.).
FAU - Choi, Kang-Ho
AU  - Choi KH
AD  - From the Department of Neurology, Chonnam National University Hospital, Gwangju, 
      Korea (J.-T.K., K.-H.C., T.-S.N., S.-M.C., S.-H.L., M.-S.P., B.C.K., M.-K.K., 
      K.-H.C.); Department of Radiology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea (S.-H.H.); and Stroke Center and Department of Neurology, David 
      Geffen School of Medicine, University of California, Los Angeles (J.L.S.).
FAU - Nam, Tai-Seung
AU  - Nam TS
AD  - From the Department of Neurology, Chonnam National University Hospital, Gwangju, 
      Korea (J.-T.K., K.-H.C., T.-S.N., S.-M.C., S.-H.L., M.-S.P., B.C.K., M.-K.K., 
      K.-H.C.); Department of Radiology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea (S.-H.H.); and Stroke Center and Department of Neurology, David 
      Geffen School of Medicine, University of California, Los Angeles (J.L.S.).
FAU - Choi, Seong-Min
AU  - Choi SM
AD  - From the Department of Neurology, Chonnam National University Hospital, Gwangju, 
      Korea (J.-T.K., K.-H.C., T.-S.N., S.-M.C., S.-H.L., M.-S.P., B.C.K., M.-K.K., 
      K.-H.C.); Department of Radiology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea (S.-H.H.); and Stroke Center and Department of Neurology, David 
      Geffen School of Medicine, University of California, Los Angeles (J.L.S.).
FAU - Lee, Seung-Han
AU  - Lee SH
AD  - From the Department of Neurology, Chonnam National University Hospital, Gwangju, 
      Korea (J.-T.K., K.-H.C., T.-S.N., S.-M.C., S.-H.L., M.-S.P., B.C.K., M.-K.K., 
      K.-H.C.); Department of Radiology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea (S.-H.H.); and Stroke Center and Department of Neurology, David 
      Geffen School of Medicine, University of California, Los Angeles (J.L.S.).
FAU - Park, Man-Seok
AU  - Park MS
AD  - From the Department of Neurology, Chonnam National University Hospital, Gwangju, 
      Korea (J.-T.K., K.-H.C., T.-S.N., S.-M.C., S.-H.L., M.-S.P., B.C.K., M.-K.K., 
      K.-H.C.); Department of Radiology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea (S.-H.H.); and Stroke Center and Department of Neurology, David 
      Geffen School of Medicine, University of California, Los Angeles (J.L.S.).
FAU - Kim, Byeong C
AU  - Kim BC
AD  - From the Department of Neurology, Chonnam National University Hospital, Gwangju, 
      Korea (J.-T.K., K.-H.C., T.-S.N., S.-M.C., S.-H.L., M.-S.P., B.C.K., M.-K.K., 
      K.-H.C.); Department of Radiology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea (S.-H.H.); and Stroke Center and Department of Neurology, David 
      Geffen School of Medicine, University of California, Los Angeles (J.L.S.).
FAU - Kim, Myeong-Kyu
AU  - Kim MK
AD  - From the Department of Neurology, Chonnam National University Hospital, Gwangju, 
      Korea (J.-T.K., K.-H.C., T.-S.N., S.-M.C., S.-H.L., M.-S.P., B.C.K., M.-K.K., 
      K.-H.C.); Department of Radiology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea (S.-H.H.); and Stroke Center and Department of Neurology, David 
      Geffen School of Medicine, University of California, Los Angeles (J.L.S.).
FAU - Saver, Jeffrey L
AU  - Saver JL
AD  - From the Department of Neurology, Chonnam National University Hospital, Gwangju, 
      Korea (J.-T.K., K.-H.C., T.-S.N., S.-M.C., S.-H.L., M.-S.P., B.C.K., M.-K.K., 
      K.-H.C.); Department of Radiology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea (S.-H.H.); and Stroke Center and Department of Neurology, David 
      Geffen School of Medicine, University of California, Los Angeles (J.L.S.).
FAU - Cho, Ki-Hyun
AU  - Cho KH
AD  - From the Department of Neurology, Chonnam National University Hospital, Gwangju, 
      Korea (J.-T.K., K.-H.C., T.-S.N., S.-M.C., S.-H.L., M.-S.P., B.C.K., M.-K.K., 
      K.-H.C.); Department of Radiology, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea (S.-H.H.); and Stroke Center and Department of Neurology, David 
      Geffen School of Medicine, University of California, Los Angeles (J.L.S.).
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150728
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Brain Ischemia/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Individuality
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Function Tests
MH  - Stroke/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin
OT  - platelet function tests
OT  - stroke
EDAT- 2015/07/30 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/07/30 06:00
PHST- 2015/03/13 00:00 [received]
PHST- 2015/06/22 00:00 [accepted]
PHST- 2015/07/30 06:00 [entrez]
PHST- 2015/07/30 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - STROKEAHA.115.009428 [pii]
AID - 10.1161/STROKEAHA.115.009428 [doi]
PST - ppublish
SO  - Stroke. 2015 Sep;46(9):2534-40. doi: 10.1161/STROKEAHA.115.009428. Epub 2015 Jul 
      28.

PMID- 23528915
OWN - NLM
STAT- MEDLINE
DCOM- 20140129
LR  - 20130520
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 28
IP  - 6
DP  - 2013 Jun
TI  - Preconceptional low-dose aspirin for the prevention of hypertensive pregnancy 
      complications and preterm delivery after IVF: a meta-analysis with individual 
      patient data.
PG  - 1480-8
LID - 10.1093/humrep/det022 [doi]
AB  - STUDY QUESTION: Does preconceptionally started low-dose aspirin prevent 
      hypertensive pregnancy complications and preterm delivery in IVF patients? 
      SUMMARY ANSWER: The current data do not support the use of preconceptionally 
      started low-dose aspirin treatment for the prevention of hypertensive pregnancy 
      complications and preterm delivery in IVF women. WHAT IS KNOWN ALREADY: Studies 
      starting low-dose aspirin treatment as prevention in the second trimester of 
      pregnancy found no or only moderate reductions in the relative risk of developing 
      pre-eclampsia. Low-dose aspirin was possibly started too late, that is after the 
      first episode of trophoblast invasion. STUDY DESIGN, SIZE, DURATION: We performed 
      a meta-analysis with individual patient data (IPD), in which four authors could 
      provide IPD on a total of 268 pregnancies (n = 131 treated with aspirin, n = 137 
      placebo). Data on hypertensive pregnancy complications and preterm delivery were 
      collected. PARTICIPANTS/MATERIALS, SETTING, METHODS: All separate databases were 
      merged into a summary database. Treatment effect of aspirin on the incidence of 
      hypertensive pregnancy complications (n = 187) and preterm delivery (n = 180) 
      were estimated with odds ratios (OR) and 95% confidence intervals (95% CI) using 
      multivariable logistic regression. MAIN RESULTS AND THE ROLE OF CHANCE: There 
      were significantly fewer twin pregnancies in the aspirin group (OR 0.55 95% CI 
      0.30-0.98), but no significant differences for hypertensive pregnancy 
      complications and preterm delivery: for singletons OR 0.62 (95% CI 0.22-1.7) and 
      OR 0.52 (95% CI 0.16-1.7), respectively, as well as for twin pregnancies OR 1.2 
      (95% CI 0.35-4.4) and OR 1.6 (95% CI 0.51-5.0), respectively. LIMITATIONS, 
      REASONS FOR CAUTION: We have to bear in mind that the included studies showed 
      clinical heterogeneity; there was variation in the duration of low-dose aspirin 
      therapy and degree of hypertension between the different studies. Although we 
      combined IPD from four studies, we have to realize that the studies were not 
      powered for the outcome of the current IPD meta-analysis. WIDER IMPLICATIONS OF 
      THE FINDINGS: Based on the current meta-analysis with IPD we found no 
      confirmation for the hypothesis that preconceptionally started low-dose aspirin 
      reduces the incidence of hypertensive pregnancy complications or preterm delivery 
      in IVF women. Larger studies are warranted.
FAU - Groeneveld, E
AU  - Groeneveld E
AD  - Department of Obstetrics and Gynaecology, Centre for Reproductive Medicine, VU 
      University Medical Centre, P.O. Box 7057, Amsterdam 1007 MB, The Netherlands. 
      e.groeneveld@vumc.nl
FAU - Lambers, M J
AU  - Lambers MJ
FAU - Lambalk, C B
AU  - Lambalk CB
FAU - Broeze, K A
AU  - Broeze KA
FAU - Haapsamo, M
AU  - Haapsamo M
FAU - de Sutter, P
AU  - de Sutter P
FAU - Schoot, B C
AU  - Schoot BC
FAU - Schats, R
AU  - Schats R
FAU - Mol, B W J
AU  - Mol BW
FAU - Hompes, P G A
AU  - Hompes PG
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20130325
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Fertilization in Vitro/adverse effects
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/*prevention & control
MH  - Logistic Models
MH  - Odds Ratio
MH  - Preconception Care
MH  - Pregnancy
MH  - Pregnancy, Twin
MH  - Premature Birth/*prevention & control
MH  - Risk Assessment
OTO - NOTNLM
OT  - IVF
OT  - aspirin
OT  - early pregnancy
OT  - hypertensive pregnancy complications
OT  - pre-eclampsia
EDAT- 2013/03/27 06:00
MHDA- 2014/01/30 06:00
CRDT- 2013/03/27 06:00
PHST- 2013/03/27 06:00 [entrez]
PHST- 2013/03/27 06:00 [pubmed]
PHST- 2014/01/30 06:00 [medline]
AID - det022 [pii]
AID - 10.1093/humrep/det022 [doi]
PST - ppublish
SO  - Hum Reprod. 2013 Jun;28(6):1480-8. doi: 10.1093/humrep/det022. Epub 2013 Mar 25.

PMID- 23839753
OWN - NLM
STAT- MEDLINE
DCOM- 20130715
LR  - 20161017
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 310
IP  - 2
DP  - 2013 Jul 10
TI  - Medical management after coronary stent implantation: a review.
PG  - 189-98
LID - 10.1001/jama.2013.7086 [doi]
AB  - IMPORTANCE: Percutaneous coronary intervention (PCI) with stents is currently the 
      most commonly performed coronary revascularization procedure; hence, optimizing 
      post-PCI outcomes is important for all physicians treating such patients. 
      OBJECTIVE: To review the contemporary literature on optimal medical therapy after 
      PCI. EVIDENCE REVIEW: We performed a comprehensive search of the PubMed and 
      Cochrane Library databases for manuscripts on medical therapy after PCI, 
      published between 2000 and February 2013. Bibliographies of the retrieved studies 
      were searched by hand for other relevant studies. Priority was given to data from 
      large randomized controlled trials, systematic reviews, and meta-analyses. Of the 
      6852 publications retrieved, 91 were included. FINDINGS: Dual antiplatelet 
      therapy with aspirin and a P2Y12 inhibitor (eg, ticlopidine, clopidogrel, 
      prasugrel, ticagrelor) reduces the risk of stent thrombosis and subsequent 
      cardiovascular events post-PCI (number needed to treat, 33-53) and is the current 
      standard of care. Aspirin should be continued indefinitely and low dose (75-100 
      mg daily) is preferred over higher doses. A P2Y12 inhibitor should be 
      administered for 12 months after PCI, unless the patient is at high risk for 
      bleeding; however, ongoing studies are assessing the value of shorter or longer 
      duration of P2Y12 inhibitor administration. In patients with acute coronary 
      syndromes, prasugrel and ticagrelor further reduce cardiovascular ischemic events 
      compared with clopidogrel but are associated with higher bleeding risk. If 
      possible, noncardiac surgery should be delayed until 12 months after coronary 
      stenting. Patients receiving coronary stents who require warfarin are at high 
      risk for bleeding if they also receive dual antiplatelet therapy. Omission of 
      aspirin may be advantageous in such patients. Routine platelet function or 
      genetic testing is currently not recommended to tailor antiplatelet therapy after 
      PCI. CONCLUSIONS AND RELEVANCE: Dual antiplatelet therapy remains the cornerstone 
      of medical therapy after PCI. Continuous advances in pharmacotherapy can further 
      enhance our capacity to improve outcomes in this high-risk patient group.
FAU - Brilakis, Emmanouil S
AU  - Brilakis ES
AD  - VA North Texas Health Care System and University of Texas Southwestern Medical 
      Center at Dallas, Dallas, TX 75216, USA. emmanouil.brilakis@va.gov
FAU - Patel, Vishal G
AU  - Patel VG
FAU - Banerjee, Subhash
AU  - Banerjee S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Stents/*adverse effects
MH  - Thrombosis/prevention & control
MH  - Treatment Outcome
EDAT- 2013/07/11 06:00
MHDA- 2013/07/17 06:00
CRDT- 2013/07/11 06:00
PHST- 2013/07/11 06:00 [entrez]
PHST- 2013/07/11 06:00 [pubmed]
PHST- 2013/07/17 06:00 [medline]
AID - 1710463 [pii]
AID - 10.1001/jama.2013.7086 [doi]
PST - ppublish
SO  - JAMA. 2013 Jul 10;310(2):189-98. doi: 10.1001/jama.2013.7086.

PMID- 22041037
OWN - NLM
STAT- MEDLINE
DCOM- 20120301
LR  - 20190221
IS  - 1532-9488 (Electronic)
IS  - 1043-0679 (Linking)
VI  - 23
IP  - 2
DP  - 2011 Summer
TI  - Killing two birds with one salicylate: aspirin's dual roles in preventative 
      health.
PG  - 96-8
LID - 10.1053/j.semtcvs.2011.06.001 [doi]
AB  - In a recent article published in The Lancet, investigators studied the impact of 
      daily aspirin use on subsequent cancer deaths. Utilizing data from more than 
      25,000 patients enrolled in 8 large trials, which were originally intended to 
      study the impact of daily aspirin use on the incidence of cardiovascular events, 
      the authors found a substantial decrease in risk of fatal solid organ 
      malignancies. In particular, the risk reduction was specific to adenocarcinomas. 
      The findings from this study are highly relevant to the thoracic surgeon, with 
      adenocarcinomas of the lung and esophagus among those tumors demonstrating the 
      most profound risk reduction.
CI  - Copyright Â© 2011 Elsevier Inc. All rights reserved.
FAU - Antonoff, Mara B
AU  - Antonoff MB
AD  - Division of Thoracic and Foregut Surgery, Department of Surgery, University of 
      Minnesota, Minneapolis, Minnesota 55455, USA.
FAU - D'Cunha, Jonathan
AU  - D'Cunha J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Semin Thorac Cardiovasc Surg
JT  - Seminars in thoracic and cardiovascular surgery
JID - 8917640
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenocarcinoma/mortality/prevention & control
MH  - Adenocarcinoma of Lung
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Agents/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Esophageal Neoplasms/mortality/prevention & control
MH  - Humans
MH  - Incidence
MH  - Lung Neoplasms/mortality/prevention & control
MH  - Neoplasms/mortality/*prevention & control
MH  - *Preventive Health Services
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2011/11/02 06:00
MHDA- 2012/03/02 06:00
CRDT- 2011/11/02 06:00
PHST- 2011/06/15 00:00 [accepted]
PHST- 2011/11/02 06:00 [entrez]
PHST- 2011/11/02 06:00 [pubmed]
PHST- 2012/03/02 06:00 [medline]
AID - S1043-0679(11)00087-6 [pii]
AID - 10.1053/j.semtcvs.2011.06.001 [doi]
PST - ppublish
SO  - Semin Thorac Cardiovasc Surg. 2011 Summer;23(2):96-8. doi: 
      10.1053/j.semtcvs.2011.06.001.

PMID- 6206005
OWN - NLM
STAT- MEDLINE
DCOM- 19840925
LR  - 20131121
IS  - 0251-1649 (Print)
IS  - 0251-1649 (Linking)
VI  - 3
IP  - 5
DP  - 1983
TI  - Plasma thromboglobulin and platelet aggregation index in transient ischaemic 
      attack: effect of aspirin and dipyridamole therapy.
PG  - 339-42
AB  - Beta-thromboglobulin (beta TG) plasma levels and platelet aggregation index (PAI) 
      were determined in 14 transient ischaemic attack (TIA) patients, before and two 
      weeks after starting therapy with aspirin and dipyridamole. Thirty healthy men 
      were the control group. Decrement in beta TG plasma levels (without statistical 
      significance) was found in treated patients when compared to the period before 
      treatment. It is noteworthy that both these levels were significantly higher than 
      plasma beta TG levels of normal controls. A highly significant difference was 
      found between PAI of patients before treatment compared with PAI of patients 
      treated with aspirin and dipyridamole. PAI was higher and similar to PAI of 
      controls in the treated patients. No correlation between these two tests was 
      established. It is concluded that the beta TG test is efficient as an aid for 
      diagnosis of TIA, while PAI is better tool for follow-up.
FAU - Aushri, Z
AU  - Aushri Z
FAU - Berginer, V
AU  - Berginer V
FAU - Nathan, I
AU  - Nathan I
FAU - Dvilansky, A
AU  - Dvilansky A
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int J Clin Pharmacol Res
JT  - International journal of clinical pharmacology research
JID - 8110183
RN  - 0 (Beta-Globulins)
RN  - 0 (beta-Thromboglobulin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Beta-Globulins/*analysis
MH  - Dipyridamole/pharmacology/*therapeutic use
MH  - Humans
MH  - Ischemic Attack, Transient/*blood/drug therapy
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - beta-Thromboglobulin/*analysis
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Res. 1983;3(5):339-42.

PMID- 14582459
OWN - NLM
STAT- MEDLINE
DCOM- 20031218
LR  - 20171116
IS  - 1472-4472 (Print)
IS  - 1472-4472 (Linking)
VI  - 4
IP  - 9
DP  - 2003 Sep
TI  - NCX-4016 NicOx.
PG  - 1126-39
AB  - NCX-4016 is a nitric oxide-aspirin conjugate non-steroidal anti-inflammatory drug 
      that is under investigation by NicOx for the potential treatment of 
      cardiovascular disorders and colon cancer. In April 2002, a phase II clinical 
      trial was initiated in symptomatic peripheral arterial disease, and in March 
      2003, the University of Michigan was awarded a grant by the NIH to conduct a 
      phase II trial in individuals at risk of colon cancer.
FAU - Di Napoli, Mario
AU  - Di Napoli M
AD  - Neurological Section, SMDN-Center for Cardiovascular Medicine and Cerebrovascular 
      Disease Prevention, 41 Via Trento, I-67039-Sulmona, AQ, Italy. 
      mariodinapoli@katamail.com
FAU - Papa, Francesca
AU  - Papa F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Investig Drugs
JT  - Current opinion in investigational drugs (London, England : 2000)
JID - 100965718
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/analogs & derivatives/chemistry/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/enzymology/*prevention & control
MH  - Clinical Trials, Phase I as Topic
MH  - Clinical Trials, Phase II as Topic
MH  - Colonic Neoplasms/enzymology/*prevention & control
MH  - Cyclooxygenase Inhibitors/administration & dosage/chemistry/*therapeutic use
MH  - Humans
MH  - Molecular Structure
MH  - Nitric Oxide/biosynthesis
MH  - Platelet Aggregation Inhibitors/administration & dosage/chemistry/*therapeutic 
      use
MH  - Randomized Controlled Trials as Topic
MH  - Structure-Activity Relationship
RF  - 133
EDAT- 2003/10/30 05:00
MHDA- 2003/12/19 05:00
CRDT- 2003/10/30 05:00
PHST- 2003/10/30 05:00 [pubmed]
PHST- 2003/12/19 05:00 [medline]
PHST- 2003/10/30 05:00 [entrez]
PST - ppublish
SO  - Curr Opin Investig Drugs. 2003 Sep;4(9):1126-39.

PMID- 31514789
OWN - NLM
STAT- MEDLINE
DCOM- 20200714
LR  - 20210715
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 40
IP  - 5
DP  - 2019 Sep 1
TI  - Long-term assessment of aspirin desensitization shows successful bridging with 
      non-aspirin nonsteroidal anti-inflammatory drugs for procedures.
PG  - 311-315
LID - 10.2500/aap.2019.40.4239 [doi]
AB  - Background: Aspirin (ASA) desensitization and continuous daily ASA therapy is the 
      criterion standard treatment for ASA-exacerbated respiratory disease (AERD). 
      However, the optimal maintenance dosage of ASA and safety of "bridging" patients 
      with AERD and with alternative cyclooxygenase-1 inhibitors for surgery have not 
      been determined and require further investigation. Objective: This study was 
      designed to compare the long-term effects of different maintenance doses of ASA 
      and to assess the success of bridging subjects with AERD for surgery without 
      losing desensitization. Methods: We retrospectively assessed 36 subjects with 
      AERD who successfully underwent ASA desensitization from 2011 to 2017. We 
      performed comprehensive medical record reviews and subsequent telephone 
      interviews with a questionnaire. Results: Of 36 subjects, the average age was 
      52.8 years, with an average of 3.2 years since desensitization, and 65% were 
      women. The subjects reported a decrease in frequency of nasal symptoms (p < 
      0.001), asthma symptoms (p = 0.016), and sinus infections (p < 0.001) after 
      desensitization. Improvements were reported in sense of smell, taste, quality of 
      sleep, and quality of life (p < 0.001) in all dosage groups. Thirteen subjects 
      required stopping of ASA for surgeries. Six subjects (46%) were bridged with 
      ibuprofen on an average of 5.9 days before surgery and restarted ASA on an 
      average of 1.3 days after surgery, with no incidence of major adverse events or 
      loss of desensitization. Seven subjects (54%) were not bridged, with three 
      subjects restarting ASA after surgery without symptoms and four subjects losing 
      desensitization. Conclusion: There did not seem to be a difference of benefits 
      between 325 mg once or twice a day compared with 650 mg once or twice a day, but 
      our small subject numbers made this conclusion difficult to prove. 
      Desensitization improved subjective reporting on sleep quality as well as quality 
      of life. Bridging the subjects with AERD who required surgery by using ibuprofen 
      seemed to be safe and effective in maintaining ASA desensitization.
FAU - Do, Toan
AU  - Do T
AD  - From the Penn State College of Medicine, Hershey, Pennsylvania.
FAU - Canty, Ethan
AU  - Canty E
AD  - From the Penn State College of Medicine, Hershey, Pennsylvania.
FAU - Bajaj, Puneet
AU  - Bajaj P
AD  - Department of Allergy and Immunology, Geisinger Health System, Danville, 
      Pennsylvania.
FAU - Ishmael, Faoud
AU  - Ishmael F
AD  - Department of Internal Medicine and Department of Allergy, Asthma and Immunology, 
      Hershey, Pennsylvania.
FAU - Craig, Timothy
AU  - Craig T
AD  - Department of Internal Medicine and Department of Allergy, Asthma and Immunology, 
      Hershey, Pennsylvania.
LA  - eng
GR  - TL1 TR002016/TR/NCATS NIH HHS/United States
GR  - UL1 TR002014/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/administration & dosage/*immunology
MH  - *Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Preoperative Care/methods
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Surveys and Questionnaires
PMC - PMC8242988
COIS- The authors have no conflicts of interest to declare pertaining to this article
EDAT- 2019/09/14 06:00
MHDA- 2020/07/15 06:00
CRDT- 2019/09/14 06:00
PHST- 2019/09/14 06:00 [entrez]
PHST- 2019/09/14 06:00 [pubmed]
PHST- 2020/07/15 06:00 [medline]
AID - AAP049-19 [pii]
AID - 10.2500/aap.2019.40.4239 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2019 Sep 1;40(5):311-315. doi: 10.2500/aap.2019.40.4239.

PMID- 11156107
OWN - NLM
STAT- MEDLINE
DCOM- 20010201
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 70
IP  - 6
DP  - 2000 Dec
TI  - Effect of preoperative aspirin use on mortality in coronary artery bypass 
      grafting patients.
PG  - 1986-90
AB  - BACKGROUND: Discontinuing aspirin use in patients before coronary artery bypass 
      grafting (CABG) has focused on bleeding risks. The effect of aspirin use on 
      overall mortality with this procedure has not been studied. METHODS: We performed 
      a case patient-control patient study of the 8,641 consecutive isolated CABG 
      procedures performed between July 1987 and May 1991 in Maine, New Hampshire, and 
      Vermont. Patients included all 368 deaths. Each case patient was paired with 
      approximately two matched survivors (control patients). Aspirin use was defined 
      by identification of ingestion within 7 days before the operation. RESULTS: CABG 
      patients using preoperative aspirin were less likely to experience in-hospital 
      mortality in univariate (odds ratio [OR] = 0.73, 95% confidence interval [0.54, 
      0.97]) and multivariate [OR = 0.55, (0.31, 0.98)] analysis compared to nonusers. 
      No significant difference was seen in the amount of chest tube drainage, 
      transfusion of blood products, or need for reexploration for hemorrhage between 
      patients who did and did not receive aspirin. CONCLUSIONS: Preoperative aspirin 
      use appears to be associated with a decreased risk of mortality in CABG patients 
      without significant increase in hemorrhage, blood product requirements, or 
      related morbidities.
FAU - Dacey, L J
AU  - Dacey LJ
AD  - Department of Surgery, Center for the Evaluative Clinical Sciences, Community & 
      Family Medicine, Lebanon, New Hampshire, USA. lawrence.j.dacey@dartmouth.edu
FAU - Munoz, J J
AU  - Munoz JJ
FAU - Johnson, E R
AU  - Johnson ER
FAU - Leavitt, B J
AU  - Leavitt BJ
FAU - Maloney, C T
AU  - Maloney CT
FAU - Morton, J R
AU  - Morton JR
FAU - Olmstead, E M
AU  - Olmstead EM
FAU - Birkmeyer, J D
AU  - Birkmeyer JD
FAU - O'Connor, G T
AU  - O'Connor GT
CN  - Northern New England Cardiovascular Disease Study Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Thorac Surg. 2001 Nov;72(5):1797-8. PMID: 11722108
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Case-Control Studies
MH  - Cause of Death
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - New England
MH  - Postoperative Complications/*mortality
MH  - *Premedication
MH  - Prospective Studies
MH  - Registries/statistics & numerical data
MH  - Survival Rate
EDAT- 2001/01/13 11:00
MHDA- 2001/02/28 10:01
CRDT- 2001/01/13 11:00
PHST- 2001/01/13 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2001/01/13 11:00 [entrez]
AID - S0003-4975(00)02133-0 [pii]
AID - 10.1016/s0003-4975(00)02133-0 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 2000 Dec;70(6):1986-90. doi: 10.1016/s0003-4975(00)02133-0.

PMID- 11865824
OWN - NLM
STAT- MEDLINE
DCOM- 20020826
LR  - 20191105
IS  - 0966-0844 (Print)
IS  - 0966-0844 (Linking)
VI  - 15
IP  - 1
DP  - 2002 Mar
TI  - Biochemical properties and mechanism of action of a vanadyl(IV)-aspirin complex 
      on bone cell lines in culture.
PG  - 37-49
AB  - A recently synthesized vanadyl(IV) complex with aspirin [VO(aspirin)ClH2O]2, has 
      been thoroughly investigated by physicochemical techniques. In order to support 
      the proposed structure, stoichiometry and the coordination sphere of the vanadium 
      center, some studies such as elemental analysis, electronic (diffuse reflectance) 
      and vibrational (infrared) spectroscopies, magnetic susceptibility, as well as 
      the thermal behavior, were carried out. The bioactivity of the vanadium complex 
      (VOAspi) was evaluated on two osteoblast-like cell lines in culture, being its 
      cytotoxic effects stronger than the vanadyl cation as assessed by morphological 
      changes and lipid peroxidation. These effects may be partially explained through 
      the induction of the expression of Erks (Extracellular signal-regulated kinases) 
      and the inhibition of the PTPases (Phosphotyrosine phosphatases) present in the 
      cellular extracts.
FAU - Etcheverry, Susana B
AU  - Etcheverry SB
AD  - Bioquímica Patológica, CEQUINOR (Centro de Química Inorgánica, UNLP-CONICET), 
      Universidad Nacional de La Plata, Argentina.
FAU - Williams, Patricia A M
AU  - Williams PA
FAU - Sálice, Viviana C
AU  - Sálice VC
FAU - Barrio, Daniel A
AU  - Barrio DA
FAU - Ferrer, Evelina G
AU  - Ferrer EG
FAU - Cortizo, Ana M
AU  - Cortizo AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Biometals
JT  - Biometals : an international journal on the role of metal ions in biology, 
      biochemistry, and medicine
JID - 9208478
RN  - 0 (Enzyme Inhibitors)
RN  - 3WHH0066W5 (Vanadates)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 3T3 Cells
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Cell Line
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Enzyme Inhibitors/pharmacology
MH  - Lipid Peroxidation/drug effects
MH  - Mice
MH  - Mitogen-Activated Protein Kinase 1/metabolism
MH  - Mitogen-Activated Protein Kinase 3
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - Osteoblasts/cytology/*drug effects/*metabolism
MH  - Protein Tyrosine Phosphatases/antagonists & inhibitors
MH  - Rats
MH  - Spectrophotometry, Infrared
MH  - Vanadates/chemistry/*pharmacology
EDAT- 2002/02/28 10:00
MHDA- 2002/08/27 10:01
CRDT- 2002/02/28 10:00
PHST- 2002/02/28 10:00 [pubmed]
PHST- 2002/08/27 10:01 [medline]
PHST- 2002/02/28 10:00 [entrez]
AID - 10.1023/a:1013183910203 [doi]
PST - ppublish
SO  - Biometals. 2002 Mar;15(1):37-49. doi: 10.1023/a:1013183910203.

PMID- 1293944
OWN - NLM
STAT- MEDLINE
DCOM- 19930402
LR  - 20131121
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 27
IP  - 9
DP  - 1992
TI  - [Zero-crossing derivative spectrophotometry for the determination of three 
      components in paracetamol compound tablets].
PG  - 701-4
AB  - The zero-order derivative absorption spectra of aspirin, paracetamol and caffeine 
      are closely overlapping. In this paper, a zero-crossing derivative 
      spectrophotometry combined with simultaneous equations is proposed for the 
      determination of the three components in a mixture without the need of prior 
      separation. Satisfactory results were obtained. The method is reproducible, 
      accurate and rapid. Calculation is not complicated. This method could be applied 
      to biological fluid analysis.
FAU - Li, H L
AU  - Li HL
AD  - Shandong Medical University, Jinan.
FAU - Cheng, X M
AU  - Cheng XM
FAU - Chen, Z X
AU  - Chen ZX
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Aspirin/analysis
MH  - Caffeine/analysis
MH  - Drug Combinations
MH  - Spectrophotometry/methods
MH  - Tablets
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Yao Xue Xue Bao. 1992;27(9):701-4.

PMID- 33759495
OWN - NLM
STAT- MEDLINE
DCOM- 20210720
LR  - 20210720
IS  - 1944-8252 (Electronic)
IS  - 1944-8244 (Print)
IS  - 1944-8244 (Linking)
VI  - 13
IP  - 13
DP  - 2021 Apr 7
TI  - Role of Self-Assembled Surface Functionalization on Nucleation Kinetics and 
      Oriented Crystallization of a Small-Molecule Drug: Batch and Thin-Film Growth of 
      Aspirin as a Case Study.
PG  - 15847-15856
LID - 10.1021/acsami.1c00460 [doi]
AB  - The present paper assesses the heterogeneous nucleation of a small-molecule drug 
      and its relationship with the surface chemistry of engineered heteronucleants. 
      The nucleation of aspirin (ASA) was tuned by different functional groups exposed 
      by self-assembled monolayers (SAMs) immobilized on glass surfaces. Smooth 
      topographies and defect-free surface modification allowed the deconvolution of 
      chemical and topographical effects on nucleation. The nucleation induction time 
      of ASA in batch crystallization was mostly enhanced by methacrylate and amino 
      groups, whereas it was repressed by thiol groups. In this perspective, we also 
      present a novel strategy for the evaluation of surface-drug interactions by 
      confining drug crystallization to thin films and studying the preferential growth 
      of crystal planes on different surfaces. Crystallization by spin coating improved 
      the study of oriented crystallization, enabling reproducible sample preparation, 
      minimal amounts of drug required, and short processing time. Overall, the acid 
      surface tension of SAMs dictated the nucleation kinetics and the extent of 
      relative growth of the ASA crystal planes. Moreover, the face-selective action of 
      monolayers was investigated by force spectroscopy and attributed to the 
      preferential interaction of exposed groups with the (100) crystal plane of ASA.
FAU - Artusio, Fiora
AU  - Artusio F
AUID- ORCID: 0000-0002-8996-0053
AD  - Department of Applied Science and Technology, Politecnico di Torino, corso Duca 
      degli Abruzzi 24, 10129 Torino, Italy.
FAU - Fumagalli, Francesco
AU  - Fumagalli F
AD  - European Commission, Joint Research Centre (JRC), via E. Fermi 2749, 21027 Ispra, 
      Italy.
FAU - Valsesia, Andrea
AU  - Valsesia A
AD  - European Commission, Joint Research Centre (JRC), via E. Fermi 2749, 21027 Ispra, 
      Italy.
FAU - Ceccone, Giacomo
AU  - Ceccone G
AD  - European Commission, Joint Research Centre (JRC), via E. Fermi 2749, 21027 Ispra, 
      Italy.
FAU - Pisano, Roberto
AU  - Pisano R
AUID- ORCID: 0000-0001-6990-3126
AD  - Department of Applied Science and Technology, Politecnico di Torino, corso Duca 
      degli Abruzzi 24, 10129 Torino, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210324
PL  - United States
TA  - ACS Appl Mater Interfaces
JT  - ACS applied materials & interfaces
JID - 101504991
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Crystallization/methods
MH  - Glass/chemistry
MH  - Kinetics
MH  - Surface Properties
PMC - PMC8041258
OTO - NOTNLM
OT  - SAM
OT  - aspirin
OT  - crystallization
OT  - functionalization
OT  - thin film
COIS- The authors declare no competing financial interest.
EDAT- 2021/03/25 06:00
MHDA- 2021/07/21 06:00
CRDT- 2021/03/24 12:21
PHST- 2021/03/25 06:00 [pubmed]
PHST- 2021/07/21 06:00 [medline]
PHST- 2021/03/24 12:21 [entrez]
AID - 10.1021/acsami.1c00460 [doi]
PST - ppublish
SO  - ACS Appl Mater Interfaces. 2021 Apr 7;13(13):15847-15856. doi: 
      10.1021/acsami.1c00460. Epub 2021 Mar 24.

PMID- 35869624
OWN - NLM
STAT- MEDLINE
DCOM- 20220726
LR  - 20220728
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 50
IP  - 7
DP  - 2022 Jul
TI  - The combination of decitabine and aspirin inhibits tumor growth and metastasis in 
      non-small cell lung cancer.
PG  - 3000605221112024
LID - 10.1177/03000605221112024 [doi]
LID - 03000605221112024
AB  - OBJECTIVE: Combination therapy has become the hallmark of lung cancer treatment, 
      as it reduces the dosage intensity of individual drugs while increasing their 
      efficacy. In the current study, we analyzed the combinatorial effect of 
      decitabine and aspirin on non-small cell lung cancer (NSCLC) cell growth. 
      METHODS: In this study, we investigated the combinatorial effect of decitabine 
      and aspirin by MTT, colony formation, and Transwell assays. We also explored the 
      underlying molecular mechanism via a series of in vitro and in vivo experiments. 
      RESULTS: The combination of decitabine and aspirin regulated cell viability and 
      migration in vitro. Moreover, the combination therapy suppressed tumor cell 
      growth by inhibiting the β-catenin/STAT3 signaling pathway. Our study also found 
      that the regimen increased the phosphorylation of β-catenin and decreased the 
      expression of STAT3 and β-catenin. CONCLUSION: The combined administration of 
      decitabine and aspirin significantly reduced tumor growth compared with 
      single-agent treatment and the control in vivo. The study results indicated that 
      decitabine and aspirin could suppress NSCLC cell growth and metastasis via the 
      β-catenin/STAT3 signaling pathway.
FAU - Xu, Maoyi
AU  - Xu M
AD  - Department of Oncology, The First Hospital of Jiaxing (The Affiliated Hospital of 
      Jiaxing University), Jiaxing, Zhejiang, PR China.
FAU - Song, Binbin
AU  - Song B
AD  - Department of Oncology, The First Hospital of Jiaxing (The Affiliated Hospital of 
      Jiaxing University), Jiaxing, Zhejiang, PR China.
FAU - Yang, Xinmei
AU  - Yang X
AD  - Department of Oncology, The First Hospital of Jiaxing (The Affiliated Hospital of 
      Jiaxing University), Jiaxing, Zhejiang, PR China.
FAU - Li, Na
AU  - Li N
AUID- ORCID: 0000-0003-4997-0668
AD  - Department of Pathology, Jiaxing Maternity and Child Health Care Hospital, 
      College of Medicine, Jiaxing University, Jiaxing, Zhejiang, PR China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (beta Catenin)
RN  - 776B62CQ27 (Decitabine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Carcinoma, Non-Small-Cell Lung/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Decitabine/pharmacology
MH  - Humans
MH  - *Lung Neoplasms/pathology
MH  - Wnt Signaling Pathway
MH  - beta Catenin/genetics/metabolism
PMC - PMC9315258
OTO - NOTNLM
OT  - Decitabine
OT  - STAT3
OT  - aspirin
OT  - cell proliferation
OT  - metastasis
OT  - non-small cell lung cancer
OT  - β-catenin
COIS- Declaration of conflicting interest: The authors report no conflicts of interest 
      in this work.
EDAT- 2022/07/24 06:00
MHDA- 2022/07/27 06:00
CRDT- 2022/07/23 01:32
PHST- 2022/07/23 01:32 [entrez]
PHST- 2022/07/24 06:00 [pubmed]
PHST- 2022/07/27 06:00 [medline]
AID - 10.1177_03000605221112024 [pii]
AID - 10.1177/03000605221112024 [doi]
PST - ppublish
SO  - J Int Med Res. 2022 Jul;50(7):3000605221112024. doi: 10.1177/03000605221112024.

PMID- 26551178
OWN - NLM
STAT- MEDLINE
DCOM- 20160321
LR  - 20210107
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 126
IP  - 6
DP  - 2015 Dec
TI  - A Cost-Benefit Analysis of Low-Dose Aspirin Prophylaxis for the Prevention of 
      Preeclampsia in the United States.
PG  - 1242-1250
LID - 10.1097/AOG.0000000000001115 [doi]
AB  - OBJECTIVE: To develop a decision model to evaluate the risks, benefits, and costs 
      of different approaches to aspirin prophylaxis for the approximately 4 million 
      pregnant women in the United States annually. METHODS: We created a decision 
      model to evaluate four approaches to aspirin prophylaxis in the United States: no 
      prophylaxis, prophylaxis per American College of Obstetricians and Gynecologists 
      (the College) recommendations, prophylaxis per U.S. Preventive Services Task 
      Force recommendations, and universal prophylaxis. We included the costs 
      associated with aspirin, preeclampsia, preterm birth, and potential 
      aspirin-associated adverse effects. TreeAge Pro 2011 was used to perform the 
      analysis. RESULTS: The estimated rate of preeclampsia would be 4.18% without 
      prophylaxis compared with 4.17% with the College approach in which 0.35% 
      (n=14,000) of women receive aspirin, 3.83% with the U.S. Preventive Services Task 
      Force approach in which 23.5% (n=940,800) receive aspirin, and 3.81% with 
      universal prophylaxis. Compared with no prophylaxis, the U.S. Preventive Services 
      Task Force approach would save $377.4 million in direct medical care costs 
      annually, and universal prophylaxis would save $365 million assuming 4 million 
      births each year. The U.S. Preventive Services Task Force approach is the most 
      cost-beneficial in 79% of probabilistic simulations. Assuming a willingness to 
      pay of $100,000 per neonatal quality-adjusted life-year gained, the universal 
      approach is the most cost-effective in more than 99% of simulations. CONCLUSION: 
      Both the U.S. Preventive Services Task Force approach and universal prophylaxis 
      would reduce morbidity, save lives, and lower health care costs in the United 
      States to a much greater degree than the approach currently recommended by the 
      College.
FAU - Werner, Erika F
AU  - Werner EF
AD  - Department of Obstetrics and Gynecology, Alpert Medical School of Brown 
      University, Women & Infants Hospital of Rhode Island, and the Department of 
      Epidemiology, School of Public Health, Brown University, Providence, Rhode 
      Island.
FAU - Hauspurg, Alisse K
AU  - Hauspurg AK
FAU - Rouse, Dwight J
AU  - Rouse DJ
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/*administration & dosage/economics/therapeutic use
MH  - *Cost-Benefit Analysis
MH  - Decision Support Techniques
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Health Care Costs/*statistics & numerical data
MH  - Humans
MH  - Models, Economic
MH  - Platelet Aggregation Inhibitors/*administration & dosage/economics/therapeutic 
      use
MH  - Pre-Eclampsia/economics/*prevention & control
MH  - Pregnancy
MH  - Premature Birth/economics/prevention & control
MH  - Prenatal Care/*economics/methods
MH  - Quality-Adjusted Life Years
MH  - United States
EDAT- 2015/11/10 06:00
MHDA- 2016/03/22 06:00
CRDT- 2015/11/10 06:00
PHST- 2015/11/10 06:00 [entrez]
PHST- 2015/11/10 06:00 [pubmed]
PHST- 2016/03/22 06:00 [medline]
AID - 00006250-201512000-00020 [pii]
AID - 10.1097/AOG.0000000000001115 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2015 Dec;126(6):1242-1250. doi: 10.1097/AOG.0000000000001115.

PMID- 21219209
OWN - NLM
STAT- MEDLINE
DCOM- 20110606
LR  - 20220224
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Linking)
VI  - 33
IP  - 1
DP  - 2011
TI  - Minocycline with aspirin: an approach to attenuate diabetic nephropathy in rats.
PG  - 72-8
LID - 10.3109/0886022X.2010.528117 [doi]
AB  - Degradation of extracellular matrix (ECM) by enhanced production of matrix 
      metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in diabetes 
      leads to nephropathy. Cyclooxygenases (COX) further increase levels of these 
      MMPs. The objective of present study was to inhibit MMP-2 and MMP-9 by 
      combination of minocycline and aspirin to treat diabetic nephropathy. Diabetes 
      was induced in male Wistar rats by streptozotocin (STZ, 55 mg/kg i.p.). Four 
      weeks after diabetes induction, the rats were treated with minocycline (50 mg/kg, 
      p.o.), aspirin (50 mg/kg, p.o.), or minocycline (50 mg/kg, p.o.) plus aspirin (50 
      mg/kg, p.o.) for a period of 4 weeks. At the end of eighth week fluid input, 
      urine output, and renal function tests were carried out for diagnosis of diabetic 
      nephropathy. Renal hypertrophy was measured and histopathology was done to 
      evaluate renal damage. Diabetes produced significant loss of body weight, 
      polyuria, polydipsia, hyperglycemia, and increase in blood pressure. Serum 
      creatinine, urea, and blood urea nitrogen levels were found to be increased 
      significantly in the STZ group diabetic rats. Treatment with combination of 
      minocycline and aspirin significantly prevented the rise in creatinine, urea, and 
      blood urea nitrogen levels and increased creatinine clearance. Image analysis of 
      kidneys revealed that collagen level was significantly decreased in combined 
      treated group when compared with control. Results of present study suggest that 
      MMP-2 and MMP-9 inhibition in presence of COX inhibitor prevents the development 
      of experimental diabetic nephropathy in rats and can be a potential approach for 
      the treatment.
FAU - Kumar Bhatt, Lokesh
AU  - Kumar Bhatt L
AD  - Department of Pharmacology, School of Pharmacy and Technology Management, NMIMS 
      University, Mumbai, India.
FAU - Addepalli, Veeranjaneyulu
AU  - Addepalli V
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Matrix Metalloproteinase Inhibitors)
RN  - FYY3R43WGO (Minocycline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Diabetic Nephropathies/enzymology/*prevention & control
MH  - Male
MH  - Matrix Metalloproteinase Inhibitors
MH  - Minocycline/pharmacology/*therapeutic use
MH  - Rats
MH  - Rats, Wistar
EDAT- 2011/01/12 06:00
MHDA- 2011/06/07 06:00
CRDT- 2011/01/12 06:00
PHST- 2011/01/12 06:00 [entrez]
PHST- 2011/01/12 06:00 [pubmed]
PHST- 2011/06/07 06:00 [medline]
AID - 10.3109/0886022X.2010.528117 [doi]
PST - ppublish
SO  - Ren Fail. 2011;33(1):72-8. doi: 10.3109/0886022X.2010.528117.

PMID- 18855644
OWN - NLM
STAT- MEDLINE
DCOM- 20081209
LR  - 20191111
IS  - 1871-5257 (Print)
IS  - 1871-5257 (Linking)
VI  - 6
IP  - 4
DP  - 2008 Oct
TI  - Clopidogrel and aspirin in cardiovascular medicine: responders or not--current 
      best available evidence.
PG  - 312-22
AB  - Dual antiplatelet therapy represents an important advance for patients with 
      established coronary artery disease. It is an important strategy for patients 
      with acute coronary syndromes and those undergoing percutaneous transcatheter 
      coronary interventions. Clopidogrel effectively inhibits ADP-induced platelet 
      activation and aggregation by selectively and irreversibly blocking the P2Y(12) 
      receptor on the platelet membrane. Aspirin works by irreversibly acetylating the 
      cyclooxygenase (COX-1) enzyme, thus suppressing the production of thromboxane 
      A(2) (TxA(2)) and inhibiting platelet activation and aggregation. Variable 
      platelet response and potential resistance to therapy has emerged with aspirin 
      and clopidogrel. The definitions of antiplatelet agents variability in 
      responsiveness and nonresponsiveness are discussed. Clopidogrel and aspirin 
      responsiveness as they are measured in the laboratory by various techniques 
      (platelet aggregometry and point-of-care assays such as platelet function 
      analyzer [PFA-100] and rapid platelet function assay [RPFA]) are evaluated. The 
      mechanisms responsible for variations in responsiveness to antiplatelet agents 
      such as clinical, cellular and genetic factors are defined. Aspirin and 
      clopidogrel resistance are emerging clinical entities with potentially severe 
      consequences such as myocardial infarction, stroke or death. The therapeutic 
      interventions to deal with nonresponsiveness are reported, although specific 
      recommendations are not clearly established. In the future, routine measurement 
      of platelet function in patients with cardiovascular disease may become the 
      standard of care. Personalized antithrombotic treatment strategies may be 
      determined by ex-vivo measurements that identify critical pathways influencing 
      thrombotic risk in the individual patient.
FAU - Tourmousoglou, C E
AU  - Tourmousoglou CE
AD  - Department of Cardiothoracic Surgery, University of Athens School of Medicine, 
      Attikon Hospital, 1 Rimini St, 12462, Haidari, Athens, Greece. 
      christostourmousoglou@hotmail.com
FAU - Rokkas, C K
AU  - Rokkas CK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cardiovasc Hematol Agents Med Chem
JT  - Cardiovascular & hematological agents in medicinal chemistry
JID - 101266881
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clopidogrel
MH  - Coronary Artery Disease/drug therapy
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
RF  - 140
EDAT- 2008/10/16 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/10/16 09:00
PHST- 2008/10/16 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/10/16 09:00 [entrez]
AID - 10.2174/187152508785909483 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):312-22. doi: 
      10.2174/187152508785909483.

PMID- 25551707
OWN - NLM
STAT- MEDLINE
DCOM- 20150529
LR  - 20150101
IS  - 1318-0207 (Print)
IS  - 1318-0207 (Linking)
VI  - 61
IP  - 4
DP  - 2014
TI  - Feasibility of clinoptilolite application as a microporous carrier for 
      pH-controlled oral delivery of aspirin.
PG  - 688-93
AB  - Clinoptilolite is a natural zeolite which due to high surface area/volume ratio 
      has found many applications in industries and medicine. Aspirin is a 
      non-steroidal anti-inflammatory drug which is currently used as an anticoagulant, 
      antinociceptive, antipyretic, and anti-inflammatory drug. It is an acidic drug 
      which induces gastric irritation due to inhibition of cyclooxygenase I located in 
      gastric mucosa. In the present work, adsorption and desorption of aspirin on 
      Iranian clinoptilolite micronized particles were studied in acidic and relatively 
      alkaline pHs. Effect of particle size of clinoptilolite was also investigated on 
      adsorption and desorption of aspirin. Specific surfaces, particle sizes, and zeta 
      potentials of clinoptilolite particles were also determined. Scanning electron 
      micrograph was used to study the morphology and crystallinity of clinoptilolite 
      particles. The results showed that adsorption and desorption of aspirin on 
      clinoptilolite are particle size- and pH-dependent. The present work proposes 
      clinoptilolite as an inexpensive, efficient, and non-toxic natural available 
      microporous material for aspirin oral delivery.
FAU - Tondar, Mahdi
AU  - Tondar M
FAU - Parsa, Mohammad Javad
AU  - Parsa MJ
FAU - Yousefpour, Yaser
AU  - Yousefpour Y
FAU - Sharifi, Ali Mohammad
AU  - Sharifi AM
FAU - Shetab-Boushehri, Seyed Vahid
AU  - Shetab-Boushehri SV
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Slovenia
TA  - Acta Chim Slov
JT  - Acta chimica Slovenica
JID - 101247110
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Carriers)
RN  - 12173-10-3 (clinoptilolite)
RN  - 1318-02-1 (Zeolites)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adsorption
MH  - Anti-Inflammatory Agents/chemistry
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/chemistry
MH  - Aspirin/*administration & dosage/*chemistry
MH  - Chemistry, Pharmaceutical
MH  - Dose-Response Relationship, Drug
MH  - *Drug Carriers
MH  - Hydrogen-Ion Concentration
MH  - Microscopy, Electron, Scanning
MH  - Particle Size
MH  - Porosity
MH  - Spectrophotometry, Ultraviolet
MH  - Zeolites/*chemistry
EDAT- 2015/01/01 06:00
MHDA- 2015/05/30 06:00
CRDT- 2015/01/01 06:00
PHST- 2015/01/01 06:00 [entrez]
PHST- 2015/01/01 06:00 [pubmed]
PHST- 2015/05/30 06:00 [medline]
AID - Tondar-2014-4 [pii]
PST - ppublish
SO  - Acta Chim Slov. 2014;61(4):688-93.

PMID- 11442551
OWN - NLM
STAT- MEDLINE
DCOM- 20010830
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 21
IP  - 3
DP  - 2001 Apr
TI  - Low-dose aspirin for migraine prophylaxis in women.
PG  - 175-83
AB  - Although migraine is more common among women than men, the only two large, 
      randomized trials of low-dose aspirin for migraine prophylaxis have been 
      conducted in men. As part of the Women's Health Study, an ongoing randomized 
      trial of low-dose aspirin and vitamin E among 39 876 female health professionals 
      aged 45 and older, 1001 women with frequent migraine attacks were assigned to 100 
      mg of aspirin every other day (n = 525) or aspirin placebo (n = 476). Migraine 
      frequency, as well as severity, duration, and degree of incapacitation, were 
      assessed by self-report on questionnaires 12 months and 36 months after 
      randomization, and also by monthly diaries kept before and after randomization. 
      Women assigned to aspirin reported small and consistent decreases in migraine 
      frequency (59.6% vs. 56.4% assigned to placebo reporting improvement at 36 
      months; odds ratio 1.13, 95% confidence interval, 0.86--1.48), as well as 
      decreases in severity, duration, and migraine-related incapacitation. These 
      reductions were not, however, statistically significant. These data are 
      compatible with a small treatment effect of low-dose aspirin in the prophylaxis 
      of migraine among middle-aged women.
FAU - Benseñor, I M
AU  - Benseñor IM
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital and Harvard Medical School, Boston, Massachusetts 02215-1204, USA.
FAU - Cook, N R
AU  - Cook NR
FAU - Lee, I M
AU  - Lee IM
FAU - Chown, M J
AU  - Chown MJ
FAU - Hennekens, C H
AU  - Hennekens CH
FAU - Buring, J E
AU  - Buring JE
LA  - eng
GR  - CA-47988/CA/NCI NIH HHS/United States
GR  - HL-43851/HL/NHLBI NIH HHS/United States
GR  - NS-34108/NS/NINDS NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Cephalalgia. 2001 Apr;21(3):167-8. PMID: 11442549
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Migraine Disorders/*prevention & control
MH  - Treatment Outcome
MH  - Vitamin E/administration & dosage/adverse effects
EDAT- 2001/07/10 10:00
MHDA- 2001/08/31 10:01
CRDT- 2001/07/10 10:00
PHST- 2001/07/10 10:00 [pubmed]
PHST- 2001/08/31 10:01 [medline]
PHST- 2001/07/10 10:00 [entrez]
AID - cha194 [pii]
AID - 10.1046/j.0333-1024.2001.00194.x [doi]
PST - ppublish
SO  - Cephalalgia. 2001 Apr;21(3):175-83. doi: 10.1046/j.0333-1024.2001.00194.x.

PMID- 2705648
OWN - NLM
STAT- MEDLINE
DCOM- 19890519
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 40
IP  - 5
DP  - 1989 May
TI  - Individually controlled aspirin in the long-term treatment of patients with 
      chronic arterial diseases.
PG  - 464-71
AB  - A simple method of measuring the biological effect of acetylsalicylic acid (ASA), 
      based on the determination of the disaggregation rate (DR) of platelet 
      aggregation induced by adenosine diphosphate (ADP), is described. The DR was 
      found to correlate with the inhibition of the production of malondialdehyde (MDA) 
      by platelets (r = 0.66, P less than 0.001). Therefore, the DR was used for 
      laboratory monitoring of the ASA effect. The study included 63 arteriosclerotic 
      patients--patients with ischemic heart disease (IHD), peripheral arterial disease 
      (PAD), or cerebrovascular insufficiency (CVI) -- who were analyzed before 
      treatment and after receiving ASA in an individually controlled dosage. Before 
      treatment the authors found an increased level of MDA and a longer euglobulin 
      clot lysis time in patients when compared with healthy volunteers (n = 16). 
      Extremely different doses of ASA were required to normalize initially elevated 
      MDA levels in patients. Normalization of the MDA level corresponds to a DR of at 
      least 50% (in comparison with 0-13% without treatment). When judging the ASA dose 
      individually from the 50% DR, the authors demonstrated that there were no 
      differences in the levels of cyclooxygenase- and lipoxygenase-derived eicosanoids 
      between healthy volunteers (n = 16) and arteriosclerotic patients receiving 
      100-250 mg (n = 18), 500 mg (n = 17), or 750-1500 mg ASA per day (n = 6). Thus, 
      their results support the idea of using individually controlled ASA as the most 
      promising way of resolving the "aspirin dilemma" and provide a simple and 
      reproducible method of measuring the biological effect of ASA.
FAU - Misselwitz, F
AU  - Misselwitz F
AD  - Central Institute for Cardiovascular Research, Academy of Sciences of the GDR, 
      Berlin-Buch.
FAU - Norden, C
AU  - Norden C
FAU - Heine, H
AU  - Heine H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Arteriosclerosis/*drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/metabolism
MH  - Brain Ischemia/*drug therapy
MH  - Coronary Disease/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
AID - 10.1177/000331978904000507 [doi]
PST - ppublish
SO  - Angiology. 1989 May;40(5):464-71. doi: 10.1177/000331978904000507.

PMID- 3090027
OWN - NLM
STAT- MEDLINE
DCOM- 19860917
LR  - 20210210
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 261
IP  - 21
DP  - 1986 Jul 25
TI  - Isolation and characterization of a new hemoglobin derivative cross-linked 
      between the alpha chains (lysine 99 alpha 1----lysine 99 alpha 2).
PG  - 9929-37
AB  - Bis(3,5-dibromosalicyl) fumarate and a number of related bifunctional reagents 
      react preferentially with oxyhemoglobin to cross-link the beta chains within the 
      2,3-diphosphoglycerate-binding site. In this report we describe a new derivative 
      cross-linked between the alpha chains which is formed specifically in the 
      reaction with deoxyhemoglobin. X-ray crystallographic studies show that the 
      cross-link lies between Lys-99 alpha 1 and Lys-99 alpha 2, spanning the central 
      cavity of the tetramer. Lys-99 alpha 1 and Lys-99 alpha 2 are located within a 
      cluster of charged residues very near the middle of the hemoglobin molecule. In 
      oxyhemoglobin, this site is completely inaccessible to the cross-linking agent. 
      Competition experiments with inositol hexaphosphate indicate that the compound 
      enters the central cavity in deoxyhemoglobin through the cleft between the alpha 
      chains. Despite the presence of the cross-link between the alpha chains, the 
      modified hemoglobin remains highly cooperative. The Hill coefficient for HbXL99 
      alpha is 2.6. The oxygen affinity of the cross-linked derivative is decreased by 
      approximately 2-fold; at pH 7.0 in the presence of 0.1 M NaCl the P50 is 13.9 mm 
      Hg compared to 6.6 mm Hg for HbA. This difference appears to be due to relatively 
      small changes in both KR, the association constant for binding of oxygen to the R 
      state, and the allosteric constant L. Surprisingly, the isoelectric point of 
      oxyHbXL99 alpha is almost identical to that of oxyHbA, whereas in the deoxy form 
      the isoelectric point of the cross-linked derivative is decreased relative to 
      native hemoglobin as expected due to the loss of the two positive charges of the 
      modified amino groups. In agreement with these findings, the alkaline Bohr effect 
      of HbXL99 alpha is decreased by more than 50%. Earlier studies argue strongly 
      against the possibility that Lys-99 alpha is directly responsible for this large 
      fraction of the Bohr effect in HbA. Analysis of the structure suggests that in 
      the cross-linked derivative Glu-101 beta, which is in close proximity to Lys-99 
      alpha in oxyhemoglobin, becomes an acid Bohr group.
FAU - Chatterjee, R
AU  - Chatterjee R
FAU - Welty, E V
AU  - Welty EV
FAU - Walder, R Y
AU  - Walder RY
FAU - Pruitt, S L
AU  - Pruitt SL
FAU - Rogers, P H
AU  - Rogers PH
FAU - Arnone, A
AU  - Arnone A
FAU - Walder, J A
AU  - Walder JA
LA  - eng
GR  - AM-17563/AM/NIADDK NIH HHS/United States
GR  - HL-26745/HL/NHLBI NIH HHS/United States
GR  - HL-33555/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Oxyhemoglobins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cross-Linking Reagents/*pharmacology
MH  - Crystallography
MH  - Hemoglobins/*isolation & purification
MH  - Humans
MH  - Isoelectric Focusing
MH  - *Lysine
MH  - Mathematics
MH  - Molecular Conformation
MH  - Oxyhemoglobins/analysis
MH  - Stereoisomerism
MH  - X-Ray Diffraction
EDAT- 1986/07/25 00:00
MHDA- 1986/07/25 00:01
CRDT- 1986/07/25 00:00
PHST- 1986/07/25 00:00 [pubmed]
PHST- 1986/07/25 00:01 [medline]
PHST- 1986/07/25 00:00 [entrez]
AID - S0021-9258(18)67605-7 [pii]
PST - ppublish
SO  - J Biol Chem. 1986 Jul 25;261(21):9929-37.

PMID- 2082483
OWN - NLM
STAT- MEDLINE
DCOM- 19910509
LR  - 20191029
IS  - 0896-0569 (Print)
IS  - 0896-0569 (Linking)
VI  - 12
DP  - 1990
TI  - Prevention of aortocoronary vein bypass graft occlusion: which antithrombotic 
      treatment and for how long?
PG  - 11-21
AB  - The effects of 50 mg aspirin combined with 400 mg dipyridamole were compared with 
      those of standard anticoagulant therapy, in the prevention of aortocoronary vein 
      bypass graft occlusion. Early graft occlusion in 249 patients, with 749 distal 
      vein graft anastomoses, were angiographically assessed 11.5 +/- 2 days after 
      surgery and were almost equal in both treatment groups. In half of the patients 
      in each group, active treatment was replaced by placebo after 3 months. Repeat 
      angiography after 1 year (360 +/- 24 days) showed that more new late graft 
      occlusions occurred in patients with only 3 months active medication (either 
      regimen). The incidence of major complications was significantly higher in 
      patients treated with anticoagulants, with minor side-effects more common in the 
      antiplatelet group. Thus, this antiplatelet drug regimen was as effective as 
      standard anticoagulant therapy in the prevention of early and late bypass graft 
      occlusion, but carried a significantly lower risk of severe complications. In 
      addition, as replacement of active treatment by placebo after 3 months resulted 
      in significantly more graft occlusions, antithrombotic treatment should be 
      continued for at least one year after coronary artery bypass graft surgery.
FAU - Pfisterer, M
AU  - Pfisterer M
AD  - Division of Cardiology, Angiography, University Hospital Basel, Switzerland.
FAU - Burkart, F
AU  - Burkart F
FAU - Jockers, G
AU  - Jockers G
FAU - Meyer, B
AU  - Meyer B
FAU - Regenass, S
AU  - Regenass S
FAU - Burckhardt, D
AU  - Burckhardt D
FAU - Schmitt, H E
AU  - Schmitt HE
FAU - Müller-Brand, J
AU  - Müller-Brand J
FAU - Skarvan, K
AU  - Skarvan K
FAU - Stulz, P
AU  - Stulz P
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Thromb Res Suppl
JT  - Thrombosis research. Supplement
JID - 8309239
RN  - 0 (Anticoagulants)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Time Factors
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1016/0049-3848(90)90434-e [doi]
PST - ppublish
SO  - Thromb Res Suppl. 1990;12:11-21. doi: 10.1016/0049-3848(90)90434-e.

PMID- 35536579
OWN - NLM
STAT- MEDLINE
DCOM- 20220512
LR  - 20220716
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 5
IP  - 5
DP  - 2022 May 2
TI  - Association of a Community Population and Clinic Education Intervention Program 
      With Guideline-Based Aspirin Use for Primary Prevention of Cardiovascular 
      Disease: A Nonrandomized Controlled Trial.
PG  - e2211107
LID - 10.1001/jamanetworkopen.2022.11107 [doi]
LID - e2211107
AB  - IMPORTANCE: Low-dose aspirin is used for primary prevention of cardiovascular 
      disease in approximately one-third of the US adult population. Overuse and 
      underuse are common and not concordant with guidelines. OBJECTIVE: To test a 
      community and clinic education intervention to improve guideline-based aspirin 
      use for the primary prevention of cardiovascular disease. DESIGN, SETTING, AND 
      PARTICIPANTS: The Ask About Aspirin project was a nonrandomized controlled trial 
      conducted from, July 1, 2015, to March 31, 2020, using professional education, 
      traditional media, and digital media to improve guideline-based aspirin use. The 
      adult population (aged 45-79 years for men and 55-79 years for women) and primary 
      care clinics in Minnesota were the education targets. The 4 adjacent states were 
      controls. INTERVENTIONS: The statewide campaign distributed billboards, newspaper 
      articles and other print material, and radio announcements. An Ask About Aspirin 
      website was heavily promoted. Primary care clinics identified appropriate aspirin 
      candidates, and clinicians received continuing education about aspirin. MAIN 
      OUTCOMES AND MEASURES: Guideline-based aspirin use by the target population. 
      RESULTS: Cross-sectional random telephone surveys of 8342 men aged 45 to 79 years 
      and women aged 55 to 79 years were conducted at baseline, 2 years, and 4 years 
      after the intervention. Participation was similar between men and women 
      (baseline: 973 [49%] vs 1001 [51%]; year 4: 912 [50%] vs 930 [50%]). Age during 
      the study also was similar (baseline: 64.7 [IQR, 64.4-65.1] years; year 4: 66.2 
      [IQR, 65.8-66.5] years). A validated questionnaire evaluated aspirin use. The Ask 
      About Aspirin website had more than 1 million visits; 124 primary care clinics 
      with more than 1000 participating clinicians were part of the education program. 
      Small, nonsignificant increases in discussions with clinicians regarding aspirin 
      resulted (baseline: 341 of 1001 [34%]; year 4: 339 of 930 [36%]; P = .27). 
      Overall aspirin use decreased after the release of new US Preventive Services 
      Task Force guidelines in 2016 and 3 aspirin randomized clinical trials in 2018 
      suggested reduced aspirin use (baseline: 816 of 1974 [41%]; year 4: 629 of 1842 
      [34%]; P < .001). Decreases were also noted from year 2 to year 4 in appropriate 
      use (year 2: 597 of 1208 [49%]; year 4: 478 of 1191 [40%]; P < .001) and overuse 
      (year 2: 170 of 602 [28%]; year 4: 151 of 651 [23%]; P = .04). There were no 
      significant differences between Minnesota and the control states. CONCLUSIONS AND 
      RELEVANCE: In this nonrandomized controlled trial, a multiyear statewide campaign 
      was not associated with increased appropriate aspirin use for cardiovascular 
      disease prevention. Contextual factors during the project, including guideline 
      changes and media controversy following the new trials, undermined study goals. 
      These findings suggest that although education programs using social media for 
      cardiovascular disease prevention can result in millions of hits, the use of this 
      strategy to encourage behavior change is problematic, even with supportive 
      clinical sites. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02607917.
FAU - Luepker, Russell V
AU  - Luepker RV
AD  - Division of Epidemiology and Community Health, School of Public Health, 
      University of Minnesota, Minneapolis.
AD  - Cardiovascular Division and Lillehei Heart Institute, University of Minnesota 
      Medical School, Minneapolis.
FAU - Eder, Milton
AU  - Eder M
AD  - Department of Family Medicine and Community Health, University of Minnesota 
      Medical School, Minneapolis.
FAU - Finnegan, John R
AU  - Finnegan JR
AD  - Division of Epidemiology and Community Health, School of Public Health, 
      University of Minnesota, Minneapolis.
FAU - Van't Hof, Jeremy R
AU  - Van't Hof JR
AD  - Cardiovascular Division and Lillehei Heart Institute, University of Minnesota 
      Medical School, Minneapolis.
FAU - Oldenburg, Niki
AU  - Oldenburg N
AD  - Cardiovascular Division and Lillehei Heart Institute, University of Minnesota 
      Medical School, Minneapolis.
FAU - Duval, Sue
AU  - Duval S
AD  - Cardiovascular Division and Lillehei Heart Institute, University of Minnesota 
      Medical School, Minneapolis.
LA  - eng
SI  - ClinicalTrials.gov/NCT02607917
GR  - R01 HL126041/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220502
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA Netw Open. 2022 May 2;5(5):e2211113. PMID: 35536584
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/epidemiology/prevention & control
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Internet
MH  - Male
MH  - Primary Prevention
PMC - PMC9092209
COIS- Conflict of Interest Disclosures: Dr Luepker reported receiving grants from the 
      National Institutes of Health (NIH) National Heart, Lung, and Blood Institute and 
      the Lillehei Heart Institute at the University of Minnesota during the conduct of 
      the study. Dr Eder reported receiving grants from the NIH that were outside the 
      submitted work. Dr Van’t Hof reported receiving grants from the NIH during the 
      conduct of the study. Dr Oldenburg reported receiving grants from the NIH during 
      the conduct of the study and outside the submitted work. Dr Duval reported 
      receiving grants from NIH during the conduct of the study. No other disclosures 
      were reported.
EDAT- 2022/05/11 06:00
MHDA- 2022/05/14 06:00
CRDT- 2022/05/10 11:34
PHST- 2022/05/10 11:34 [entrez]
PHST- 2022/05/11 06:00 [pubmed]
PHST- 2022/05/14 06:00 [medline]
AID - 2792125 [pii]
AID - zoi220333 [pii]
AID - 10.1001/jamanetworkopen.2022.11107 [doi]
PST - epublish
SO  - JAMA Netw Open. 2022 May 2;5(5):e2211107. doi: 
      10.1001/jamanetworkopen.2022.11107.

PMID- 26747390
OWN - NLM
STAT- MEDLINE
DCOM- 20160922
LR  - 20181202
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 201 Suppl 1
DP  - 2015 Dec
TI  - The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary 
      cardiovascular prevention.
PG  - S15-22
LID - S0167-5273(15)31028-7 [pii]
LID - 10.1016/S0167-5273(15)31028-7 [doi]
AB  - During the last decade, there has been a tremendous effort to develop different 
      cardiovascular polypills in response to the upsurge in global cardiovascular 
      disease worldwide. The pharmacological development of such a strategy has proven 
      to be extremely complex from a formulation standpoint. Not all drugs are suitable 
      for use in a polypill because of potential drug incompatibilities between them. 
      Candidate agents must be safe, well tolerated, effective, guideline recommended 
      and physiochemically compatible with the other components of the pill. The 
      Fuster-CNIC-Ferrer cardiovascular (CV) polypill has been found to be the 
      first-in-class polypill to be approved and commercialized in Europe and 
      Latinamerican Countries. In this article, we review the pharmacological 
      properties of its three components, including the clinical evidence supporting 
      their use in patients with established cardiovascular disease, their 
      pharmacokinetic properties, adverse effects, drug interactions and 
      contraindications.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Tamargo, Juan
AU  - Tamargo J
AD  - Department of Pharmacology, School of Medicine, Universidad Complutense, 28040, 
      Madrid, Spain.
FAU - Castellano, José M
AU  - Castellano JM
AD  - Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, Madrid, 
      Spain; HM Hospitales, Hospital Universitario Montepríncipe, Madrid, Spain; Mount 
      Sinai Cardiovascular Institute, New York, USA.
FAU - Fuster, Valentín
AU  - Fuster V
AD  - Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, Madrid, 
      Spain; Mount Sinai Cardiovascular Institute, New York, USA. Electronic address: 
      valentin.fuster@mountsinai.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Drug Combinations)
RN  - A0JWA85V8F (Atorvastatin)
RN  - L35JN3I7SJ (Ramipril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Atorvastatin/*administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Agents/*administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/drug therapy/economics/*prevention & control
MH  - Drug Combinations
MH  - Humans
MH  - Ramipril/*administration & dosage/adverse effects/therapeutic use
MH  - Secondary Prevention/*methods
OTO - NOTNLM
OT  - Aspirin
OT  - Atorvastatin
OT  - Iltria(®) cardiovascular polypill
OT  - Ramipril
OT  - Secondary prevention
OT  - Simvastatin
OT  - Sincronium(®)
OT  - Trinomia(®)
EDAT- 2016/01/10 06:00
MHDA- 2016/09/23 06:00
CRDT- 2016/01/10 06:00
PHST- 2016/01/10 06:00 [entrez]
PHST- 2016/01/10 06:00 [pubmed]
PHST- 2016/09/23 06:00 [medline]
AID - S0167-5273(15)31028-7 [pii]
AID - 10.1016/S0167-5273(15)31028-7 [doi]
PST - ppublish
SO  - Int J Cardiol. 2015 Dec;201 Suppl 1:S15-22. doi: 10.1016/S0167-5273(15)31028-7.

PMID- 36822711
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20230227
IS  - 1558-0474 (Electronic)
IS  - 0889-8545 (Linking)
VI  - 50
IP  - 1
DP  - 2023 Mar
TI  - Aspirin and Pravastatin for Preeclampsia Prevention in High-Risk Pregnancy.
PG  - 79-88
LID - S0889-8545(22)00096-1 [pii]
LID - 10.1016/j.ogc.2022.10.005 [doi]
AB  - Preeclampsia is a hypertensive disorder of pregnancy affecting up to 8% of 
      pregnancies. It is associated with significant neonatal and maternal morbidities 
      and mortality. Although its pathogenesis is not completely understood, abnormal 
      placentation resulting in imbalance in angiogenic factors, increased 
      inflammation, and endothelial dysfunction are thought to be key pathways in the 
      development of the disease. Administration of low-dose aspirin is recommended by 
      professional societies for the prevention of preeclampsia in high-risk 
      individuals. In this review, we summarize the evidence behind the use of low-dose 
      aspirin and pravastatin in pregnant individuals at high risk of preeclampsia.
CI  - Copyright © 2022 Elsevier Inc. All rights reserved.
FAU - Eid, Joe
AU  - Eid J
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The 
      Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic 
      address: Eid07@osumc.edu.
FAU - Rood, Kara M
AU  - Rood KM
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The 
      Ohio State University Wexner Medical Center, Columbus, OH, USA.
FAU - Costantine, Maged M
AU  - Costantine MM
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The 
      Ohio State University Wexner Medical Center, Columbus, OH, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Obstet Gynecol Clin North Am
JT  - Obstetrics and gynecology clinics of North America
JID - 8709551
RN  - R16CO5Y76E (Aspirin)
RN  - KXO2KT9N0G (Pravastatin)
SB  - IM
MH  - Pregnancy
MH  - Infant, Newborn
MH  - Female
MH  - Humans
MH  - Aspirin/therapeutic use
MH  - *Pre-Eclampsia
MH  - Pravastatin/therapeutic use
MH  - Pregnancy, High-Risk
MH  - *Hypertension
OTO - NOTNLM
OT  - Aspirin
OT  - Pravastatin
OT  - Preeclampsia
EDAT- 2023/02/24 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/02/23 20:59
PHST- 2023/02/23 20:59 [entrez]
PHST- 2023/02/24 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
AID - S0889-8545(22)00096-1 [pii]
AID - 10.1016/j.ogc.2022.10.005 [doi]
PST - ppublish
SO  - Obstet Gynecol Clin North Am. 2023 Mar;50(1):79-88. doi: 
      10.1016/j.ogc.2022.10.005.

PMID- 20128418
OWN - NLM
STAT- MEDLINE
DCOM- 20100611
LR  - 20161125
IS  - 1018-9068 (Print)
IS  - 1018-9068 (Linking)
VI  - 19
IP  - 6
DP  - 2009
TI  - Diagnosis of aspirin-induced asthma combining the bronchial and the oral 
      challenge tests: a pilot study.
PG  - 446-52
AB  - BACKGROUND: We investigated the usefulness of the bronchial challenge (BC) with 
      lysine-acetylsalicylate (L-ASA) in the diagnosis of aspirin-exacerbated 
      respiratory disease (AERD) using a protocol that combined both the oral challenge 
      (OC) and the BC tests. METHODS: Adult asthmatic patients with suspected AERD who 
      underwent BC with L-ASA were included in the study. If the BC result with L-ASA 
      was negative, an OC was carried out to establish the diagnosis. AERD was ruled 
      out if both the BC and the OC results were negative (nonresponders). Both 
      responders and nonresponders were compared for age, gender, a personal or family 
      history of atopy, underlying disease, current asthma treatment, and presence of 
      nasal polyps. Six patients with asthma but no suggestive history of AERD were 
      included as controls. RESULTS: Twenty-two patients completed the study. Ten 
      patients tested positive to the BC and/or OC (responders), whereas 12 did not 
      (nonresponders). Seven out of the 10 responders had a positive BC result and 3 a 
      positive OC result. After BC, 4 patients had an early asthmatic response, 1 had a 
      dual response, and 2 had isolated late responses. No significant differences were 
      observed in the aforementioned variables between responders and nonresponders. 
      The results of both challenges were negative in the 6 controls. CONCLUSIONS: The 
      BC had a high positive predictive value, was safe, and when negative, the 
      subsequent OC did not result in any severe adverse reactions. The BC elicited an 
      isolated late asthmatic response that has not been previously described in the 
      literature.
FAU - Barranco, P
AU  - Barranco P
AD  - Department of Allergology, Hospital Universitario La Paz, Madrid, Spain.
FAU - Bobolea, I
AU  - Bobolea I
FAU - Larco, J I
AU  - Larco JI
FAU - Prior, N
AU  - Prior N
FAU - López-Serrano, M C
AU  - López-Serrano MC
FAU - Quirce, S
AU  - Quirce S
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - J Investig Allergol Clin Immunol
JT  - Journal of investigational allergology & clinical immunology
JID - 9107858
RN  - 0 (Allergens)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Allergens/*administration & dosage/adverse effects/immunology
MH  - Aspirin/administration & dosage/adverse effects/*analogs & derivatives/immunology
MH  - Asthma, Aspirin-Induced/*diagnosis/physiopathology
MH  - *Bronchial Provocation Tests
MH  - Cross-Sectional Studies
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - *Immunization
MH  - Lysine/administration & dosage/adverse effects/*analogs & derivatives/immunology
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps
MH  - Pilot Projects
MH  - Predictive Value of Tests
EDAT- 2010/02/05 06:00
MHDA- 2010/06/12 06:00
CRDT- 2010/02/05 06:00
PHST- 2010/02/05 06:00 [entrez]
PHST- 2010/02/05 06:00 [pubmed]
PHST- 2010/06/12 06:00 [medline]
PST - ppublish
SO  - J Investig Allergol Clin Immunol. 2009;19(6):446-52.

PMID- 4029385
OWN - NLM
STAT- MEDLINE
DCOM- 19851024
LR  - 20131121
IS  - 0014-8318 (Print)
IS  - 0014-8318 (Linking)
VI  - 48
IP  - 3
DP  - 1985 May-Jun
TI  - [Effect of courses of acetylsalicylic acid and sodium salicylate administration 
      on the carbohydrate-phosphorus metabolic indices in vascular tissue].
PG  - 80-3
AB  - Experiments on 78 adult rats were made to study the effects of acetylsalicylic 
      acid and sodium salicylate administered daily for 7 and 14 days on the content of 
      pyruvic, lactic, citric acids and inorganic phosphate in the wall of blood 
      vessels of different function. Salicylates were demonstrated to reduce the 
      content of citric acid by the 7th day and that of pyruvic acid by the 14th day, 
      to increase the level of lactate and inorganic phosphorus during both observation 
      periods. The degree of the changes revealed is unequal in different vessels, 
      being more pronounced after sodium salicylate administration.
FAU - Riabkov, A N
AU  - Riabkov AN
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Vliianie kursovykh vvedeniĭ atsetilsalitsilovoĭ kisloty i natriia salitsilata na 
      pokazateli uglevodno-fosfornogo obmena v sosudistoĭ tkani.
PL  - Russia (Federation)
TA  - Farmakol Toksikol
JT  - Farmakologiia i toksikologiia
JID - 16920420R
RN  - 27YLU75U4W (Phosphorus)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Vessels/*drug effects/metabolism
MH  - *Carbohydrate Metabolism
MH  - Female
MH  - Male
MH  - Phosphorus/*metabolism
MH  - Rats
MH  - Sodium Salicylate/administration & dosage/*pharmacology
MH  - Time Factors
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
PST - ppublish
SO  - Farmakol Toksikol. 1985 May-Jun;48(3):80-3.

PMID- 17714922
OWN - NLM
STAT- MEDLINE
DCOM- 20071220
LR  - 20191210
IS  - 0928-0987 (Print)
IS  - 0928-0987 (Linking)
VI  - 32
IP  - 3
DP  - 2007 Nov
TI  - Simultaneous determination of two active components in compound aspirin tablets 
      using principal component artificial neural networks (PC-ANNs) on NIR 
      spectroscopy.
PG  - 193-9
AB  - A method for simultaneous, non-destructive analysis of aspirin and phenacetin in 
      compound aspirin tablets with different concentrations has been developed by 
      principal component artificial neural networks (PC-ANNs) on near-infrared (NIR) 
      spectroscopy. In PC-ANNs models, the spectra data were first analyzed by 
      principal component analysis (PCA). Then the scores of the principal compounds 
      (PCs) were chosen as input nodes for input layer instead of the spectra data. The 
      artificial neural networks (ANNs) models using the spectra data as input nodes 
      were also established, which were compared with the PC-ANNs models. Four 
      different preprocessing methods (first-derivation, second-derivation, standard 
      normal variate (SNV) and multiplicative scatter correction (MSC)) were applied to 
      NIR conventional spectra. The result shows the first-derivative model of PC-ANNs 
      multivariate calibration has the lowest training errors and predicting errors. 
      The concept of the degree of approximation was introduced and performed as the 
      selective criterion of the optimum network parameters.
FAU - Dou, Y
AU  - Dou Y
AD  - College of Science, Tianjin University of Science & Technology, Tianjin 300222, 
      China.
FAU - Qu, N
AU  - Qu N
FAU - Wang, B
AU  - Wang B
FAU - Chi, Y Z
AU  - Chi YZ
FAU - Ren, Y L
AU  - Ren YL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070712
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Tablets)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - *Neural Networks, Computer
MH  - Phenacetin/*analysis
MH  - *Principal Component Analysis
MH  - *Spectroscopy, Near-Infrared
MH  - Tablets
MH  - Technology, Pharmaceutical/*methods
EDAT- 2007/08/24 09:00
MHDA- 2007/12/21 09:00
CRDT- 2007/08/24 09:00
PHST- 2007/04/03 00:00 [received]
PHST- 2007/07/05 00:00 [revised]
PHST- 2007/07/09 00:00 [accepted]
PHST- 2007/08/24 09:00 [pubmed]
PHST- 2007/12/21 09:00 [medline]
PHST- 2007/08/24 09:00 [entrez]
AID - S0928-0987(07)00285-0 [pii]
AID - 10.1016/j.ejps.2007.07.002 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2007 Nov;32(3):193-9. doi: 10.1016/j.ejps.2007.07.002. Epub 2007 
      Jul 12.

PMID- 35837769
OWN - NLM
STAT- MEDLINE
DCOM- 20220718
LR  - 20220718
IS  - 1672-7347 (Print)
IS  - 1672-7347 (Linking)
VI  - 47
IP  - 6
DP  - 2022 Jun 28
TI  - Aspirin inhibits the growth of hypertrophic scar in rabbit ears via regulating 
      Wnt/β-catenin signal pathway.
PG  - 698-706
LID - 1672-7347(2022)06-0698-09 [pii]
LID - 10.11817/j.issn.1672-7347.2022.220038 [doi]
AB  - OBJECTIVES: Steroidal anti-inflammatory drugs have certain side effects in the 
      treatment of hypertrophic scar, and the scar recurrence is easy after withdrawal 
      of steroid anti-inflammatory drugs. Finding reliable alternative drugs is an 
      effective means to improve this defect. Aspirin, a traditional non-steroidal 
      anti-inflammatory drug, is safe for topical use and has anti-inflammatory effects 
      similar to those of steroidal anti-inflammatory drugs, which may have similar 
      effects on the treatment of hypertrophic scar. This study aims to investigate the 
      inhibitory effect of aspirin on the proliferation of hypertrophic scar in rabbit 
      ears and the underlying mechanism. METHODS: The rabbit ear hypertrophic scar 
      models were prepared. The rabbits were randomly divided into a normal skin group 
      (group A), a blank control group (group B), a 0.9% NaCl group (group C), a 0.2% 
      aspirin group (group D), a 0.5% aspirin group (group E), a 2% aspirin group 
      (group F), and a triamcinolone acetonide group (group G). Macroscopic observation 
      of hyperplasia was performed 8 weeks after local injection of the scar, followed 
      by collecting the scar tissue samples for HE staining, Masson staining, and 
      immunohistochemistry, respectively to assess the proliferation of fibroblasts and 
      collagen fibers, and calculate the hypertrophic index, microvessel density, and 
      immunohistochemical score. RESULTS: All rabbit ear hypertrophic scar models were 
      successfully constructed. In groups B and C, the hypertrophic scar edge was 
      irregular, with reddish protruding epidermis, significant contracture and hard 
      touch. In group D, E, and F, with the increase of aspirin administration 
      concentration, the scar became thinner and gradually flat, the proliferation of 
      fibrocytes and collagen fibers was weakened, and the hypertrophic index was 
      gradually decreased (P<0.05). Immunohistochemistry showed that the expression of 
      β-catenin was decreased in the group D, E and F in turn, and the 
      immunohistochemical score was gradually decreased (P<0.05). There was no 
      significant difference in hypertrophic index, microvessel density, and 
      immunohistochemical score (all P>0.05). CONCLUSIONS: Local injection of aspirin 
      can reduce the generation of hypertrophic scar in a dose-dependent manner within 
      a certain concentration range; aspirin inhibits the growth of hypertrophic scar 
      in rabbit ears by inhibiting Wnt/β-catenin signal pathway; 2% aspirin and 40 
      mg/mL triamcinolone acetonide have similar curative efficacy on hypertrophic 
      scar.
FAU - Lin, Zhihu
AU  - Lin Z
AD  - Department of Burn and Plastic Surgery, Third Xiangya Hospital, Central South 
      University, Changsha 410013. swiftxiaohu@126.com.
AD  - Department of Burn and Skin Repair Surgery, Hainan General Hospital, Haikou 
      570311. swiftxiaohu@126.com.
FAU - Han, Xiao
AU  - Han X
AD  - Department of Burn and Plastic Surgery, Third Xiangya Hospital, Central South 
      University, Changsha 410013.
FAU - Zhang, Mengyao
AU  - Zhang M
AD  - Department of Burn and Plastic Surgery, Third Xiangya Hospital, Central South 
      University, Changsha 410013.
FAU - Xu, Jiaqin
AU  - Xu J
AD  - Department of Burn and Skin Repair Surgery, Hainan General Hospital, Haikou 
      570311.
FAU - Li, Haihong
AU  - Li H
AD  - Department of Wound Repair and Dermatologic Surgery, Taihe Hospital, Hubei 
      University of Medicine, Shiyan Hubei 442000.
FAU - Zhou, Jianda
AU  - Zhou J
AD  - Department of Burn and Plastic Surgery, Third Xiangya Hospital, Central South 
      University, Changsha 410013.
FAU - Xie, Huiqing
AU  - Xie H
AD  - Department of Rehabilitation Medicine, Third Xiangya Hospital, Central South 
      University, Changsha 410013, China. xiaoxiang0733@126.com.
LA  - eng
LA  - chi
GR  - ysptzx202028/the Innovation Platform for Academinicians of Hainan Province, 
      China/
PT  - Journal Article
TT  - 阿司匹林通过调控Wnt/β-catenin信号通路抑制兔耳增生性瘢痕的生长.
PL  - China
TA  - Zhong Nan Da Xue Xue Bao Yi Xue Ban
JT  - Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. 
      Medical sciences
JID - 101230586
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (beta Catenin)
RN  - 9007-34-5 (Collagen)
RN  - F446C597KA (Triamcinolone Acetonide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Cicatrix, Hypertrophic/drug therapy/metabolism/pathology
MH  - Collagen
MH  - Rabbits
MH  - Signal Transduction
MH  - Triamcinolone Acetonide/therapeutic use
MH  - beta Catenin/metabolism
OTO - NOTNLM
OT  - Wnt/β-catenin signal pathway
OT  - aspirin
OT  - hypertrophic scar
OT  - triamcinolone acetonide
EDAT- 2022/07/16 06:00
MHDA- 2022/07/19 06:00
CRDT- 2022/07/15 03:44
PHST- 2022/07/15 03:44 [entrez]
PHST- 2022/07/16 06:00 [pubmed]
PHST- 2022/07/19 06:00 [medline]
AID - 1672-7347(2022)06-0698-09 [pii]
AID - 10.11817/j.issn.1672-7347.2022.220038 [doi]
PST - ppublish
SO  - Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Jun 28;47(6):698-706. doi: 
      10.11817/j.issn.1672-7347.2022.220038.

PMID- 11323270
OWN - NLM
STAT- MEDLINE
DCOM- 20010809
LR  - 20191104
IS  - 1471-4906 (Print)
IS  - 1471-4906 (Linking)
VI  - 22
IP  - 5
DP  - 2001 May
TI  - NO-releasing NSAIDs are caspase inhibitors.
PG  - 232-5
AB  - Nitrosation of thiol-containing proteins is a mechanism for cell regulation. 
      Nitric-oxide-releasing nonsteroidal anti-inflammatory drugs (NO-NSAIDs) are 
      chemical entities obtained by adding a nitroxybutyl moiety to a conventional 
      NSAID. NO-NSAIDs inhibit inflammation via cyclo-oxygenase (COX)-dependent and 
      -independent effects. Similarly to endogenous NO, NO-NSAIDs are potent inhibitors 
      of T helper1 (Th1) type cytokines. This effect is largely owing to 
      post-translational nitrosation and therefore inactivation of cysteine proteases, 
      such as the interleukin (IL)-1beta converting enzyme (ICE/caspase-1) involved in 
      pro-cytokine processing.
FAU - Fiorucci, S
AU  - Fiorucci S
AD  - Clinica di Gastroenterologia ed Endoscopia Digestiva, Dipartimento di Medicina 
      Clinica e Sperimentale, Universitá di Perugia, 06100 Perugia, Italy. 
      fiorucci@unipg.it
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Trends Immunol
JT  - Trends in immunology
JID - 100966032
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Caspase Inhibitors)
RN  - 0 (Cytokines)
RN  - 0 (Nitrogen Oxides)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - GFQ4MMS07W (nitroxyl)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/classification/*pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - *Caspase Inhibitors
MH  - Cytokines/metabolism
MH  - Nitric Oxide/*metabolism
MH  - Nitrogen Oxides/*metabolism
MH  - Protein Processing, Post-Translational
MH  - Th1 Cells
RF  - 19
EDAT- 2001/04/27 10:00
MHDA- 2001/08/10 10:01
CRDT- 2001/04/27 10:00
PHST- 2001/04/27 10:00 [pubmed]
PHST- 2001/08/10 10:01 [medline]
PHST- 2001/04/27 10:00 [entrez]
AID - S1471-4906(01)01904-4 [pii]
AID - 10.1016/s1471-4906(01)01904-4 [doi]
PST - ppublish
SO  - Trends Immunol. 2001 May;22(5):232-5. doi: 10.1016/s1471-4906(01)01904-4.

PMID- 1205340
OWN - NLM
STAT- MEDLINE
DCOM- 19760402
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 4
IP  - 2
DP  - 1975
TI  - Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in 
      prevention of postoperative deep vein thrombosis in high risk patients.
PG  - 94-100
AB  - In a prospective randomised trial, three groups of 20 patients each were 
      compared. A first group served as a control, a second group received dipyridamole 
      and acetylsalicylic acid and a third group received low doses of heparin. The 
      incidence of deep vein thrombosis determined by the 125I-fibrinogen test was 40% 
      in the first group, 50% in the second group, and 5% in the third group. The 
      differences between the heparin group and the two other groups are statistically 
      significant. No wound complication and no haematoma at the injection site 
      occurred.
FAU - Dechavanne, M
AU  - Dechavanne M
FAU - Ville, D
AU  - Ville D
FAU - Viala, J J
AU  - Viala JJ
FAU - Kher, A
AU  - Kher A
FAU - Faivre, J
AU  - Faivre J
FAU - Pousset, M B
AU  - Pousset MB
FAU - Dejour, H
AU  - Dejour H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/metabolism
MH  - Dipyridamole/*pharmacology/therapeutic use
MH  - Female
MH  - Heparin/administration & dosage/*pharmacology/therapeutic use
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Postoperative Complications/*prevention & control
MH  - Prospective Studies
MH  - Thromboembolism/*prevention & control
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 10.1159/000214092 [doi]
PST - ppublish
SO  - Haemostasis. 1975;4(2):94-100. doi: 10.1159/000214092.

PMID- 15492769
OWN - NLM
STAT- MEDLINE
DCOM- 20050222
LR  - 20191109
IS  - 0897-5957 (Print)
IS  - 0897-5957 (Linking)
VI  - 22
IP  - 3
DP  - 2004 Fall
TI  - Prevention of cardiovascular complications of diabetes mellitus by aspirin.
PG  - 215-26
AB  - Eighteen million Americans have type 2 Diabetes Mellitus (DM) while another 40 
      million have impaired glucose tolerance. Atherosclerotic heart disease is the 
      leading cause of death in patients with diabetes mellitus. In addition to the 
      increased risk for CardioVascular Disease (CVD), patients with diabetes have a 
      worse prognosis than nondiabetics when they suffer an ischemic event. Insulin 
      resistance is increasingly recognized as a chronic, low-level, inflammatory 
      state. Hyperinsulinemia has been proposed as the forerunner of hypertension, low 
      high-density lipoprotein cholesterolemia, hypertriglyceridemia, abdominal 
      obesity, and altered glucose tolerance, linking all these abnormalities to the 
      development of coronary vascular disease. Atherosclerosis and insulin resistance 
      share similar pathophysiological mechanisms, due to the actions of 
      proinflammatory cytokines. The dynamic inflammatory milieu found in diabetes 
      explains the susceptibility of diabetics to CVD and the potential mechanism by 
      which aspirin may prevent CVD in diabetics. Aspirin decreases the risk for CVD in 
      diabetic patients by a variety of established and novel mechanisms. Therapeutic 
      strategies that lesson the CVD risk in diabetic patients, including the use of 
      aspirin for primary and secondary prevention, are potentially very important. 
      This review article addresses the antiatherosclerotic effects of aspirin, the 
      potential anti-diabetic effects of aspirin, and the clinical trial evidence for 
      CVD prevention by aspirin in diabetics. We also present recommendations for the 
      use of aspirin in the diabetic population and the current guidelines put forth by 
      the American Heart Association and by the American Diabetes Association.
FAU - Nobles-James, Candi
AU  - Nobles-James C
AD  - Department of Medicine, University of Missouri School of Medicine and VA Medical 
      Center, Columbia, Missouri, USA. james_cn@mercer.edu.
FAU - James, Erskine A
AU  - James EA
FAU - Sowers, James R
AU  - Sowers JR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiovasc Drug Rev
JT  - Cardiovascular drug reviews
JID - 9006912
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hypoglycemic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Clinical Trials as Topic
MH  - Coronary Artery Disease/etiology/prevention & control
MH  - Diabetes Complications/etiology/*prevention & control
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Practice Guidelines as Topic
RF  - 68
EDAT- 2004/10/20 09:00
MHDA- 2005/02/23 09:00
CRDT- 2004/10/20 09:00
PHST- 2004/10/20 09:00 [pubmed]
PHST- 2005/02/23 09:00 [medline]
PHST- 2004/10/20 09:00 [entrez]
AID - 10.1111/j.1527-3466.2004.tb00142.x [doi]
PST - ppublish
SO  - Cardiovasc Drug Rev. 2004 Fall;22(3):215-26. doi: 
      10.1111/j.1527-3466.2004.tb00142.x.

PMID- 20938039
OWN - NLM
STAT- MEDLINE
DCOM- 20110303
LR  - 20211020
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Print)
IS  - 1074-2484 (Linking)
VI  - 15
IP  - 4
DP  - 2010 Dec
TI  - A randomized trial of aspirin at clinically relevant doses and nitric oxide 
      formation in humans.
PG  - 344-8
LID - 10.1177/1074248410375091 [doi]
AB  - BACKGROUND: we performed the first test in humans of whether aspirin at 
      clinically relevant doses increases nitric oxide (NO) formation. METHODS: seventy 
      primary prevention patients with metabolic syndrome were randomly assigned to 81 
      mg, 162.5 mg, 325 mg, 650 mg, or 1300 mg aspirin daily for 12 weeks to test 
      changes in heme oxygenase (HO-1), a downstream target of NO formation and 
      asymmetrical dimethylarginine (ADMA), a competitive inhibitor of NO synthase. 
      FINDINGS: for HO-1, the mean was 29.37 nanograms per milliliter at baseline and 
      57.45 at 12 weeks giving a mean ratio (MR) of 1.96 (P < .001) and 95% confidence 
      interval (CI) from 1.91 to 2.00. There was no effect modification by dose or 
      gender (P = .341). For ADMA, the mean was 1.70 micromoles per liter at baseline 
      and 0.81 at 12 weeks, giving an MR of 0.48 (P < .001) and CI from 0.46 to 0.49. 
      There was no effect modification by dose but a possible difference by gender (P = 
      .055). INTERPRETATION: in high-risk primary prevention patients, aspirin 
      significantly increases markers of NO formation. All doses produce similar 
      increases in HO-1 and decreases in ADMA. The antiplatelet properties of aspirin 
      to irreversibly inhibit platelet dependent cyclooxygenase are sufficient to 
      explain benefits in patients with occlusive vascular diseases. Nonetheless, these 
      data contribute to the formulation of the hypothesis that aspirin has additional 
      beneficial effects mediated through NO formation. Further research, including 
      direct randomized comparisons on atherosclerosis using noninvasive techniques as 
      well as on occlusive vascular disease events, is necessary to test whether this 
      hypothesis has clinical or public health relevance.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - Charles E. Schmidt College of Biomedical Science, Department of Clinical Science 
      and Medical Education & Center of Excellence, Florida Atlantic University, Boca 
      Raton, FL, USA. profchhmd@prodigy.net
FAU - Schneider, Wendy R
AU  - Schneider WR
FAU - Pokov, Alex
AU  - Pokov A
FAU - Hetzel, Scott
AU  - Hetzel S
FAU - Demets, David
AU  - Demets D
FAU - Serebruany, Victor
AU  - Serebruany V
FAU - Schröder, Henning
AU  - Schröder H
LA  - eng
GR  - UL1 RR025011/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20101011
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Biomarkers
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/*prevention & control
MH  - Nitric Oxide/*metabolism
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - *Primary Prevention
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Vascular Diseases/drug therapy/prevention & control
PMC - PMC4014199
MID - NIHMS561585
COIS- Declaration of Conflicting Interests The author(s) declared no conflicts of 
      interest with respect to the authorship and/or publication of this article.
EDAT- 2010/10/13 06:00
MHDA- 2011/03/04 06:00
CRDT- 2010/10/13 06:00
PHST- 2010/10/13 06:00 [entrez]
PHST- 2010/10/13 06:00 [pubmed]
PHST- 2011/03/04 06:00 [medline]
AID - 1074248410375091 [pii]
AID - 10.1177/1074248410375091 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):344-8. doi: 10.1177/1074248410375091. 
      Epub 2010 Oct 11.

PMID- 19271475
OWN - NLM
STAT- MEDLINE
DCOM- 20100528
LR  - 20131121
IS  - 1000-0593 (Print)
IS  - 1000-0593 (Linking)
VI  - 28
IP  - 11
DP  - 2008 Nov
TI  - [Effect of host MCM-41 on the luminescence properties of Tb(aspirin)3phen].
PG  - 2498-502
AB  - Highly ordered mesoporous material MCM-41A(after calcination) and MCM-41B (before 
      calcination) were synthesized in ethylenediamine (EDA) medium at room 
      temperature, and the rare earth complexes Tb(aspirin)3phen which had been heat 
      treated as an active optical guest was incorporated into the one-dimensional 
      channels of MCM-41A(B). The photoluminescence properties of the organic/inorganic 
      composites Tb(aspirin)3phen-MCM-41A(B) were investigated based on the analyses of 
      excitation and emission spectra to provide information about the relationship 
      between the organic host and the inorganic optical guest. The results from the 
      characterization of PL show that the wide excitation band in the range of 240-375 
      nm of Tb(aspirin)3 phen is assigned to the carbonyl group n --> pi* transition 
      absorption, benzene ring pi --> pi* transition absorption of aspirin, and 
      phenanthrene absorption of phen. As no excitation band appears in ultraviolet 
      ranges, the characteristic emission peaks of Tb3+ in the emission spectra are 
      related to antenna effect Relative to the excitation band of Tb(aspirin)3phen, 
      the excitation band of Tb(aspirin)3phen-MCM-41B and Tb(aspirin)3phen/MCM-41A 
      splits obviously, and only one narrow excitation peak at 353 nm appears in the 
      excitation spectrum of Tb(aspirin)3 phen-MCM-41A. The excitation bands of 
      Tb(aspirin)3 phen-MCM-41B and Tb (aspirin)3 phen/MCM-41A at short wavelength 
      weakens and disappears gradually, while excitation peaks at long wavelengths is 
      enhanced gradually, and the IL/ILn ratio I, where IL is the emission intensity at 
      405 nm under 335 nm excitation, and I(Ln) is the emission intensity at 544 nm 
      under 335 nm excitation, also decreases correspondingly. It is suggested that the 
      triplet states and single states of aspirin and phen reduce with different degree 
      after Tb(aspirin)3phen is banded with MCM-41 framework, and the effect of silicon 
      framework on the states of phen is more than that of aspirin. The degree of the 
      effect on the states of organic ligands is in the order of: MCM-41B external 
      surface > MCM-41A external surface > MCM-41A inside surface. In addition, the 
      ratio I also could indicates the degree of the effect of MCM-41 surface lattice 
      field on the ligand energy level and the content of Tb (aspirin)3phen on the 
      MCM-41 surface.
FAU - Peng, Chun-Jia
AU  - Peng CJ
AD  - School of Materials Science and Engineering, Changchun University of Science and 
      Technology, Changchun 130022, China. pcj728@163.com
FAU - Wei, Chang-Ping
AU  - Wei CP
FAU - Zhu, Cui-Mei
AU  - Zhu CM
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Guang Pu Xue Yu Guang Pu Fen Xi
JT  - Guang pu xue yu guang pu fen xi = Guang pu
JID - 9424805
RN  - 0 (MCM-41)
RN  - 0 (Phenanthrenes)
RN  - 06SSF7P179 (Terbium)
RN  - 448J8E5BST (phenanthrene)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - *Luminescence
MH  - Phenanthrenes/*chemistry
MH  - Silicon Dioxide/*chemistry
MH  - Spectrometry, Fluorescence
MH  - Terbium/*chemistry
EDAT- 2009/03/11 09:00
MHDA- 2010/05/29 06:00
CRDT- 2009/03/11 09:00
PHST- 2009/03/11 09:00 [entrez]
PHST- 2009/03/11 09:00 [pubmed]
PHST- 2010/05/29 06:00 [medline]
PST - ppublish
SO  - Guang Pu Xue Yu Guang Pu Fen Xi. 2008 Nov;28(11):2498-502.

PMID- 19608566
OWN - NLM
STAT- MEDLINE
DCOM- 20091207
LR  - 20131121
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 24
IP  - 10
DP  - 2009 Oct
TI  - Lower incidence of hypertensive complications during pregnancy in patients 
      treated with low-dose aspirin during in vitro fertilization and early pregnancy.
PG  - 2447-50
LID - 10.1093/humrep/dep245 [doi]
AB  - BACKGROUND: The use of aspirin during in vitro fertilization (IVF) has been 
      investigated for its effect on pregnancy rates after IVF. In most of these 
      studies, aspirin administration was then prolonged throughout the first trimester 
      of pregnancy. By inhibiting vasoconstriction, the use of low-dose aspirin in the 
      first trimester could influence placentation and therefore prevent or delay 
      development of hypertensive pregnancy complications, such as pregnancy-induced 
      hypertension (PIH) and pre-eclampsia (PE). METHODS: This study involved the 
      follow-up by questionnaires and hospital records of patients with an ongoing 
      pregnancy in a prospective, randomized, double-blind, placebo-controlled trial on 
      the effect of low-dose aspirin during IVF. Aspirin treatment was continued 
      throughout the first trimester of pregnancy. The primary end-point of this 
      follow-up study was the incidence of pregnancy complications. The original trial 
      is registered with the Dutch Trial Register and as an International Standard 
      Randomized Clinical Trial, No. ISRNCTM97507474. RESULTS: There were 54 patients 
      who had ongoing pregnancies in the original trial; 90.7% returned the 
      questionnaire and all Dutch hospital records were retrieved. A significant 
      difference was found in the incidence of hypertensive pregnancy complications: 
      3.6% in the aspirin group and 26.9% in the placebo group (P < 0.05), resulting in 
      numbers-needed-to-treat (NNT) of 10.3 to prevent hypertensive complications in 
      one pregnancy after IVF treatment. CONCLUSIONS: The incidence of hypertensive 
      complications was significantly lower in the group of women treated with low-dose 
      aspirin throughout IVF treatment and first trimester of pregnancy. These results 
      suggest a potential benefit of low-dose aspirin during IVF and first trimester to 
      prevent hypertensive pregnancy complications. The findings justify further 
      investigation in placebo-controlled randomized trials.
FAU - Lambers, Marieke J
AU  - Lambers MJ
AD  - Department of Obstetrics, Gynecology and Reproductive Medicine, Free University 
      Medical Center (VUmc), PO Box 7057, 1007 MB, Amsterdam, The Netherlands. 
      mj.lambers@vumc.nl
FAU - Groeneveld, Els
AU  - Groeneveld E
FAU - Hoozemans, Diederik A
AU  - Hoozemans DA
FAU - Schats, Roel
AU  - Schats R
FAU - Homburg, Roy
AU  - Homburg R
FAU - Lambalk, Cornelis B
AU  - Lambalk CB
FAU - Hompes, Peter G A
AU  - Hompes PG
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20090716
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - *Fertilization in Vitro
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/*epidemiology/prevention & control
MH  - Incidence
MH  - Pilot Projects
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*epidemiology/prevention & control
EDAT- 2009/07/18 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/07/18 09:00
PHST- 2009/07/18 09:00 [entrez]
PHST- 2009/07/18 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - dep245 [pii]
AID - 10.1093/humrep/dep245 [doi]
PST - ppublish
SO  - Hum Reprod. 2009 Oct;24(10):2447-50. doi: 10.1093/humrep/dep245. Epub 2009 Jul 
      16.

PMID- 12237259
OWN - NLM
STAT- MEDLINE
DCOM- 20030430
LR  - 20181113
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 137
IP  - 3
DP  - 2002 Oct
TI  - Oral single high-dose aspirin results in a long-lived inhibition of anodal 
      current-induced vasodilatation.
PG  - 384-90
AB  - 1 Acetyl salicyclic acid (aspirin) irreversibly blocks cyclo-oxygenase (COX). 
      This effect is short-lived in endothelial or smooth muscle cells due to 
      resynthesis but long-lived in platelets devoid of synthesis ability. Aspirin 
      blocks the anodal current-induced vasodilatation, suggesting participation by 
      prostaglandin (PG). We analysed the time course of the effect of aspirin as an 
      indirect indicator of the origin of the PG possibly involved in anodal 
      current-induced vasodilatation. 2 In healthy volunteers, vasodilatation, 
      estimated from the peak cutaneous vascular conductance (CVC(peak)), was recorded 
      in the forearm during and in the 20 min following 5 min, 0.10 mA transcutaneous 
      anodal current application, using deionized water as a vehicle. CVC(peak) was 
      normalized to 44 degrees C heat-induced maximal vasodilatation and expressed in 
      per cent values. Experiments were performed before and at 2 and 10 h, 3, 7, 10 
      and 14 days after blinded 1-g aspirin or placebo treatment. 3 CVC(peak) 
      (mean+/-s.d.mean) after aspirin vs placebo was 13.6+/-14.5 vs 65.0+/-32.1 
      (P<0.05) 14.7+/-4.2 vs 87.5+/-31.9 (P<0.05), 18.1+/-10.2 vs 71.6+/-26.8 (P<0.05), 
      42.5+/-23.4 vs 73.3+/-26.8 (non significant, NS), 60.2+/-24.3 vs 75.2+/-26.9 
      (NS), 52.1+/-18.5 vs 67.9+/-32.1 (NS) at 2 and 10 h and at days 3, 7, 10 and 14 
      respectively. 4 Aspirin inhibition of anodal current-induced vasodilatation 
      persists long after endothelial and smooth muscle cyclo-oxygenases are assumed to 
      be restored. This suggests that the PG involved in this response are not 
      endothelial- or smooth muscle-derived. The underlying mechanism of this 
      unexpected long-lived inhibition of vasodilatation by single high dose aspirin 
      remains to be studied.
FAU - Durand, S
AU  - Durand S
AD  - Laboratoire de Physiologie et Explorations Vasculaires, Centre Hospitalier 
      Universitaire, 49033 Angers Cedex, France.
FAU - Fromy, B
AU  - Fromy B
FAU - Koïtka, A
AU  - Koïtka A
FAU - Tartas, M
AU  - Tartas M
FAU - Saumet, J L
AU  - Saumet JL
FAU - Abraham, P
AU  - Abraham P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cyclooxygenase Inhibitors/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Electric Stimulation
MH  - Female
MH  - Humans
MH  - Male
MH  - Skin/blood supply/drug effects
MH  - Time Factors
MH  - Vasodilation/*drug effects
PMC - PMC1573494
EDAT- 2002/09/19 10:00
MHDA- 2003/05/06 05:00
CRDT- 2002/09/19 10:00
PHST- 2002/09/19 10:00 [pubmed]
PHST- 2003/05/06 05:00 [medline]
PHST- 2002/09/19 10:00 [entrez]
AID - 0704868 [pii]
AID - 10.1038/sj.bjp.0704868 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2002 Oct;137(3):384-90. doi: 10.1038/sj.bjp.0704868.

PMID- 29175294
OWN - NLM
STAT- MEDLINE
DCOM- 20190729
LR  - 20190729
IS  - 1873-6327 (Electronic)
IS  - 0306-4603 (Linking)
VI  - 78
DP  - 2018 Mar
TI  - Parachuting psychoactive substances: Pharmacokinetic clues for harm reduction.
PG  - 173-177
LID - S0306-4603(17)30429-X [pii]
LID - 10.1016/j.addbeh.2017.11.021 [doi]
AB  - BACKGROUND: Parachuting, also called bombing, is a way to ingest psychoactive 
      substances wrapped into cigarette paper, toilet paper, etc. There is little data 
      describing parachuting in terms of substances use, context of use and, most 
      importantly, the motivations for using such wrappers, although some authors 
      hypothesized that parachute could be used for pharmacokinetic reason. However, 
      inconsistently, some authors report that parachutes are used for 
      sustained-release whereas others report that users are looking for an immediate 
      effect. RESEARCH DESIGN AND METHODS: Considering parachute as a "home-made" 
      dosage form, we have applied the dissolution testing to characterize the 
      dissolution performance of a substance wrapped into a parachute and to 
      characterize whether a parachute represents an immediate-release form or not. 
      RESULTS: This in-vitro study provides the first pharmacokinetic data for drugs 
      wrapped in parachutes. It shows that parachute acts as sustained-release form 
      when made with a cigarette paper wrapper, but as immediate release form in the 
      presence of alcohol or if wrapped with toilet paper. CONCLUSIONS: An important 
      message to harm reduction is that users must be aware that a parachute can have 
      unexpected pharmacokinetics and have to avoid taking another parachute in the 
      absence of an immediate-effect to avoid overdose.
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - Daveluy, Amélie
AU  - Daveluy A
AD  - Centre d'addictovigilance, Service de pharmacologie médicale, CHU Bordeaux, 
      F-33000 Bordeaux, France; Univ. Bordeaux, Inserm, Bordeaux Population Health 
      Research Center, Team, Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France. 
      Electronic address: amelie.daveluy@u-bordeaux.fr.
FAU - Géniaux, Hélène
AU  - Géniaux H
AD  - Centre d'addictovigilance, Service de pharmacologie médicale, CHU Bordeaux, 
      F-33000 Bordeaux, France.
FAU - Baumevieille, Marie
AU  - Baumevieille M
AD  - Centre d'addictovigilance, Service de pharmacologie médicale, CHU Bordeaux, 
      F-33000 Bordeaux, France; Univ. Bordeaux, Inserm, Bordeaux Population Health 
      Research Center, Team, Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France; 
      Laboratoire de droit et économie pharmaceutiques, Univ. Bordeaux, F-33000 
      Bordeaux, France.
FAU - Létinier, Louis
AU  - Létinier L
AD  - Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team, 
      Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France.
FAU - Matta, Marie-Noëlle
AU  - Matta MN
AD  - Laboratoire de technologies pharmaceutiques industrielles (LTPIB), Univ. 
      Bordeaux, F-33000 Bordeaux, France.
FAU - Lazès-Charmetant, Aurélie
AU  - Lazès-Charmetant A
AD  - Comité d'étude et d'information sur la drogue et les addictions 
      (CEID-Addictions), F-33000 Bordeaux, France.
FAU - Haramburu, Françoise
AU  - Haramburu F
AD  - Centre d'addictovigilance, Service de pharmacologie médicale, CHU Bordeaux, 
      F-33000 Bordeaux, France; Univ. Bordeaux, Inserm, Bordeaux Population Health 
      Research Center, Team, Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France.
FAU - Guéroult, Pascale
AU  - Guéroult P
AD  - Laboratoire de technologies pharmaceutiques industrielles (LTPIB), Univ. 
      Bordeaux, F-33000 Bordeaux, France.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20171116
PL  - England
TA  - Addict Behav
JT  - Addictive behaviors
JID - 7603486
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Psychotropic Drugs)
RN  - R16CO5Y76E (Aspirin)
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*pharmacokinetics/poisoning
MH  - Delayed-Action Preparations
MH  - Drug Overdose/prevention & control
MH  - Gastrointestinal Transit/physiology
MH  - *Harm Reduction
MH  - Humans
MH  - Psychotropic Drugs/administration & dosage/*pharmacokinetics/poisoning
MH  - Substance-Related Disorders/complications
OTO - NOTNLM
OT  - Dosage forms
OT  - Harm reduction
OT  - Parachuting
OT  - Pharmacokinetics
OT  - Substance-related disorders
EDAT- 2017/11/28 06:00
MHDA- 2019/07/30 06:00
CRDT- 2017/11/28 06:00
PHST- 2017/07/24 00:00 [received]
PHST- 2017/11/10 00:00 [revised]
PHST- 2017/11/12 00:00 [accepted]
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2019/07/30 06:00 [medline]
PHST- 2017/11/28 06:00 [entrez]
AID - S0306-4603(17)30429-X [pii]
AID - 10.1016/j.addbeh.2017.11.021 [doi]
PST - ppublish
SO  - Addict Behav. 2018 Mar;78:173-177. doi: 10.1016/j.addbeh.2017.11.021. Epub 2017 
      Nov 16.

PMID- 10737937
OWN - NLM
STAT- MEDLINE
DCOM- 20000428
LR  - 20131121
IS  - 0887-3585 (Print)
IS  - 0887-3585 (Linking)
VI  - 39
IP  - 2
DP  - 2000 May 1
TI  - Adipyl crosslinked bovine hemoglobins as new models of allosteric systems.
PG  - 166-9
AB  - As indicated by peptide analyses and mass spectrometry estimations, 
      intramolecular crosslink with bis(3,5-dibromosalicyl)adipate of bovine hemoglobin 
      results in the formation of two main components covalently bridged across the 
      beta-cleft. In one component the crosslink joins the beta(1)V1-beta(2)K81 
      residues (XL-Peak-1), in the other the bridge is between the 
      beta(1)K81-beta(2)K81 residues (XL-Peak-2). Both components are tetrameric with a 
      mass near MW = 67 kDa as estimated by gel filtration, and a hydrodynamic radius 
      near 3. 20 nm, estimated by dynamic light scattering. They have very low oxygen 
      affinity with Pm near 100 mmHg (XL-Peak-1) and near 70 mmHg (XL-Peak-2) 
      respectively at 37 degrees C, at neutral pH. The Bohr effect is almost absent in 
      XL-Peak-1, while in XL-Peak-2 it is very near normal. Both systems show oxygen 
      binding cooperativity with an index near n = 2.0. Flash photolysis kinetics of 
      the recombination with CO could be resolved into a fast and a slow component. The 
      amplitude of the fast rates were not concentration-dependent. The stopped-flow 
      kinetics were autoaccelerating, consistent with their ligand-binding 
      cooperativity. All rates were very similar to those of normal hemoglobin, 
      suggesting that the oxy- rather than the deoxy-forms of the systems were affected 
      by the crosslink. Proteins 2000;39:166-169.
CI  - Copyright 2000 Wiley-Liss, Inc.
FAU - Kwansa, H E
AU  - Kwansa HE
AD  - Department of Biochemistry and Molecular Biology, University of Maryland Medical 
      School, Baltimore, Maryland 21201, USA.
FAU - Young, A D
AU  - Young AD
FAU - Arosio, D
AU  - Arosio D
FAU - Razynska, A
AU  - Razynska A
FAU - Bucci, E
AU  - Bucci E
LA  - eng
GR  - P01-GM-58890-03/GM/NIGMS NIH HHS/United States
GR  - P01-HL-48517/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Proteins
JT  - Proteins
JID - 8700181
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Oxyhemoglobins)
RN  - 75848-76-9 (bis(3,5-dibromosalicyl)adipate)
RN  - 7U1EE4V452 (Carbon Monoxide)
RN  - EC 3.4.21.4 (Trypsin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - *Allosteric Site
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/metabolism
MH  - Carbon Monoxide/metabolism
MH  - Cattle
MH  - Chromatography, Ion Exchange
MH  - Cross-Linking Reagents/chemistry/metabolism
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Hemoglobins/*chemistry/*metabolism
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Models, Chemical
MH  - Models, Molecular
MH  - Molecular Weight
MH  - Oxygen/metabolism
MH  - Oxyhemoglobins/metabolism
MH  - Peptide Mapping
MH  - Protein Structure, Quaternary
MH  - Trypsin/metabolism
EDAT- 2000/03/29 09:00
MHDA- 2000/05/08 09:00
CRDT- 2000/03/29 09:00
PHST- 2000/03/29 09:00 [pubmed]
PHST- 2000/05/08 09:00 [medline]
PHST- 2000/03/29 09:00 [entrez]
AID - 10.1002/(SICI)1097-0134(20000501)39:2<166::AID-PROT6>3.0.CO;2-H [pii]
PST - ppublish
SO  - Proteins. 2000 May 1;39(2):166-9.

PMID- 15671726
OWN - NLM
STAT- MEDLINE
DCOM- 20050208
LR  - 20131121
IS  - 1549-1684 (Print)
IS  - 1549-1684 (Linking)
VI  - 7
IP  - 4
DP  - 2004 Winter
TI  - Lifelong aspirin supplementation as a means to extending life span.
PG  - 243-51
AB  - Arising from an initiative by the National Institute of Aging (NIA) requesting 
      novel proposals challenged with increasing lifespan and longevity, our laboratory 
      has generated a hypothesis to test the efficacy of lifelong, low-dosage aspirin 
      administration as a means to achieving this goal. The intervention testing 
      program (currently underway) proposing aspirin as an anti-aging agent evolved 
      from the multitude of properties encompassed in aspirin and the potential of 
      these attributes to prevent the cellular and functional declines, particularly 
      from inflammatory and oxidative sources, evidenced to contribute to aging. 
      Aspirin is a widely administered, cheap, anti-inflammatory, and antioxidant 
      compound that has a variety of positive effects on the immune system and 
      cardiovascular health. Notably, aspirin may affect oxidant production, cytokine 
      responses, and block glycooxidation reactions, thus posing it as a triple threat 
      against the symptoms of aging. Whether aging is molded by interplay between 
      oxidative stress and inflammatory mediators has received little attention; 
      however, we and other laboratories have explored this notion and have observed an 
      elevated inflammatory status with age. Stemming from these observations and in 
      view of the limited success of antioxidant therapies in improving lifespan in 
      long-lived species, in this article we propose a protocol to examine life-long 
      use of a very low dose anti-inflammatory compound such as aspirin to engage the 
      inflammatory and endogenous oxidative insults accompanying aging and, in so 
      doing, attempt to increase maximum and mean life span.
FAU - Phillips, Tracey
AU  - Phillips T
AD  - Biochemistry of Aging Laboratory, University of Florida, Gainesville, FL 32611, 
      USA.
FAU - Leeuwenburgh, Christiaan
AU  - Leeuwenburgh C
LA  - eng
GR  - AG17994/AG/NIA NIH HHS/United States
GR  - AG21042/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Rejuvenation Res
JT  - Rejuvenation research
JID - 101213381
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Antioxidants/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Humans
MH  - Longevity/*drug effects
RF  - 64
EDAT- 2005/01/27 09:00
MHDA- 2005/02/09 09:00
CRDT- 2005/01/27 09:00
PHST- 2005/01/27 09:00 [pubmed]
PHST- 2005/02/09 09:00 [medline]
PHST- 2005/01/27 09:00 [entrez]
AID - 10.1089/rej.2004.7.243 [doi]
PST - ppublish
SO  - Rejuvenation Res. 2004 Winter;7(4):243-51. doi: 10.1089/rej.2004.7.243.

PMID- 18339241
OWN - NLM
STAT- MEDLINE
DCOM- 20080508
LR  - 20161124
IS  - 0003-7028 (Print)
IS  - 0003-7028 (Linking)
VI  - 62
IP  - 3
DP  - 2008 Mar
TI  - Narrow-line waveguide terahertz time-domain spectroscopy of aspirin and aspirin 
      precursors.
PG  - 319-26
LID - 10.1366/000370208783759768 [doi]
AB  - Low frequency vibrational modes of pharmaceutical molecules are dependent on the 
      molecule as a whole and can be used for identification purposes. However, 
      conventional Fourier transform far-infrared spectroscopy (FT-IR) and terahertz 
      time-domain spectroscopy (THz-TDS) often result in broad, overlapping features 
      that are difficult to distinguish. The technique of waveguide THz-TDS has been 
      recently developed, resulting in sharper spectral features. Waveguide THz-TDS 
      consists of forming an ordered polycrystalline film on a metal plate and 
      incorporating that plate in a parallel-plate waveguide, where the film is probed 
      by THz radiation. The planar order of the film on the metal surface strongly 
      reduces the inhomogeneous broadening, while cooling the waveguide to 77 K reduces 
      the homogeneous broadening. This combination results in sharper absorption lines 
      associated with the vibrational modes of the molecule. Here, this technique has 
      been demonstrated with aspirin and its precursors, benzoic acid and salicylic 
      acid, as well as the salicylic acid isomers 3- and 4-hydroxybenzoic acid. 
      Linewidths as narrow as 20 GHz have been observed, rivaling single crystal 
      measurements.
FAU - Laman, N
AU  - Laman N
AD  - School of Electrical and Computer Engineering, Oklahoma State University, 
      Stillwater, Oklahoma 74078, USA.
FAU - Harsha, S Sree
AU  - Harsha SS
FAU - Grischkowsky, D
AU  - Grischkowsky D
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Appl Spectrosc
JT  - Applied spectroscopy
JID - 0372406
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Parabens)
RN  - 2ZFW40OJ7U (3-hydroxybenzoic acid)
RN  - 8SKN0B0MIM (Benzoic Acid)
RN  - JG8Z55Y12H (4-hydroxybenzoic acid)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/analysis/*chemistry
MH  - Aspirin/*analogs & derivatives/analysis/*chemistry
MH  - Benzoic Acid/analysis/chemistry
MH  - Hydroxybenzoates/analysis/chemistry
MH  - *Microwaves
MH  - Parabens/analysis/chemistry
MH  - Radio Waves
MH  - Salicylic Acid/analysis/chemistry
MH  - Spectrum Analysis/instrumentation/methods
EDAT- 2008/03/15 09:00
MHDA- 2008/05/09 09:00
CRDT- 2008/03/15 09:00
PHST- 2008/03/15 09:00 [pubmed]
PHST- 2008/05/09 09:00 [medline]
PHST- 2008/03/15 09:00 [entrez]
AID - 10.1366/000370208783759768 [doi]
PST - ppublish
SO  - Appl Spectrosc. 2008 Mar;62(3):319-26. doi: 10.1366/000370208783759768.

PMID- 3684392
OWN - NLM
STAT- MEDLINE
DCOM- 19880107
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 80
IP  - 6
DP  - 1987 Dec
TI  - Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk 
      factors and role of aspirin.
PG  - 828-35
AB  - Since January 1980, 110 children having 113 attacks of Kawasaki syndrome were 
      studied. Age at onset was 7 weeks to 12 years (mean 3 6/12 years, median 2 9/12 
      years); 77% were younger than 5 years of age; the male to female ratio was 1.8; 
      racial distribution was 52% white, 19% black, 14% Hispanic, and 16% Asian. 
      Protocol of management consisted of high-dose aspirin (100 mg/kg/d) until 
      afebrile, and then 81 mg every day until free of coronary aneurysm. 
      Two-dimensional echocardiograms were done weekly during the acute stage, at 2 and 
      6 months after onset, and yearly if a coronary abnormality was detected. At 1 
      month, 51 coronary arterial abnormalities were present in 25 patients. Risk 
      factors for a coronary abnormality were duration of fever greater than or equal 
      to 2 weeks, level of platelet count, marked elevation of ESR, and age younger 
      than 5 years. No statistically significant difference in incidence of aneurysms 
      was detected between patients on high-dose aspirin and those on medium-or 
      low-dose aspirin.
FAU - Ichida, F
AU  - Ichida F
AD  - Division of Pediatric Cardiology, New York Hospital-Cornell Medical Center, NY 
      10021.
FAU - Fatica, N S
AU  - Fatica NS
FAU - Engle, M A
AU  - Engle MA
FAU - O'Loughlin, J E
AU  - O'Loughlin JE
FAU - Klein, A A
AU  - Klein AA
FAU - Snyder, M S
AU  - Snyder MS
FAU - Ehlers, K H
AU  - Ehlers KH
FAU - Levin, A R
AU  - Levin AR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Coronary Aneurysm/etiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/complications/*drug therapy
MH  - New York
MH  - Risk Factors
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1987 Dec;80(6):828-35.

PMID- 3886498
OWN - NLM
STAT- MEDLINE
DCOM- 19850603
LR  - 20180217
IS  - 0378-7346 (Print)
IS  - 0378-7346 (Linking)
VI  - 19
IP  - 1
DP  - 1985
TI  - Effect of small doses of aspirin and acetaminophen on total menstrual loss and 
      pain of cramps and headache.
PG  - 32-7
AB  - 90 women participated in a 4-month study. During the first 2 periods, they took 
      no pain relievers whatsoever; during their last 2 periods they took 2 X 325 mg 
      aspirin, acetaminophen or an identically packaged placebo every 4 h to total 8 
      tablets during the first 24 h of their periods beginning with spotting. For 
      statistical analysis, periods 1 and 2 were combined and averaged, then compared 
      with periods 3 and 4 combined and averaged. Total menstrual loss in grams, number 
      of days of flow, and pain of cramps and headaches were analyzed by MANOVA for 
      each of the three treatment groups. An ANOVA for each of these variables as well 
      as for daily menstrual loss for the first 3 menstrual days was also performed. 
      The MANOVA for all variables by the three treatment groups failed to show any 
      significant differences. Similarly, ANOVAs for the individual variables failed to 
      indicate significant differences except for the variable pain of cramps (p = 
      0.0072). The Duncan's Multiple Range Test for pain of cramps showed that the 
      average pain for the placebo group was higher than for either the aspirin or the 
      acetaminophen group, although the means for these two groups were not 
      significantly different. These results indicate that neither aspirin nor 
      acetaminophen in the doses given alter either total menstrual loss or the pattern 
      of loss during the first 3 menstrual days. However, both preparations were found 
      to be more effective than placebo in reducing pain of cramps.
FAU - Pendergrass, P B
AU  - Pendergrass PB
FAU - Scott, J N
AU  - Scott JN
FAU - Ream, L J
AU  - Ream LJ
FAU - Agna, M A
AU  - Agna MA
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Gynecol Obstet Invest
JT  - Gynecologic and obstetric investigation
JID - 7900587
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*administration & dosage/therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Headache/*drug therapy
MH  - Humans
MH  - Menstruation/*drug effects
MH  - Muscle Cramp/*drug therapy
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1159/000299005 [doi]
PST - ppublish
SO  - Gynecol Obstet Invest. 1985;19(1):32-7. doi: 10.1159/000299005.

PMID- 2858710
OWN - NLM
STAT- MEDLINE
DCOM- 19850517
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 8433
DP  - 1985 Apr 13
TI  - Prevention of pre-eclampsia by early antiplatelet therapy.
PG  - 840-2
AB  - 102 patients at high risk of pre-eclampsia and/or fetal growth retardation were 
      randomly allocated to treatment with 300 mg dipyridamole and 150 mg aspirin daily 
      from 3 months' gestation onwards (group A) or to the control group (group B, no 
      treatment). Group A was twice as likely as group B to have a normal pregnancy. 
      Pre-eclampsia occurred in 6 patients in group B and none in group A. Major 
      complications (fetal death or severe growth retardation) occurred in 9 patients 
      in group B and none in group A. Platelet count and plasma volume were 
      significantly higher in group A than in group B throughout pregnancy. The 
      treatment did not produce serious adverse effects. Antiplatelet therapy given 
      early in pregnancy to high-risk patients may thus protect against pre-eclampsia 
      and fetal growth retardation.
FAU - Beaufils, M
AU  - Beaufils M
FAU - Uzan, S
AU  - Uzan S
FAU - Donsimoni, R
AU  - Donsimoni R
FAU - Colau, J C
AU  - Colau JC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
EDAT- 1985/04/13 00:00
MHDA- 1985/04/13 00:01
CRDT- 1985/04/13 00:00
PHST- 1985/04/13 00:00 [pubmed]
PHST- 1985/04/13 00:01 [medline]
PHST- 1985/04/13 00:00 [entrez]
AID - S0140-6736(85)92207-X [pii]
AID - 10.1016/s0140-6736(85)92207-x [doi]
PST - ppublish
SO  - Lancet. 1985 Apr 13;1(8433):840-2. doi: 10.1016/s0140-6736(85)92207-x.

PMID- 10256780
OWN - NLM
STAT- MEDLINE
DCOM- 19821029
LR  - 20191103
IS  - 0190-2040 (Print)
IS  - 0190-2040 (Linking)
VI  - 4
IP  - 1
DP  - 1982
TI  - Development of effective teaching strategies on drug information for teenagers.
PG  - 41-3
AB  - A pilot study was carried out to compare two methods of teaching teenage girls 
      about aspirin use. Both individual and group instruction were effective in 
      increasing knowledge after the intervention. Individual instruction appeared to 
      result in better retention of knowledge six weeks later, although the difference 
      in test scores was not significant. The pilot study helped to identify 
      deficiencies in research methods and instruments, which will be revised before we 
      undertake a larger scale study.
FAU - Zerr, S J
AU  - Zerr SJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Patient Couns Health Educ
JT  - Patient counselling and health education
JID - 7806110
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
MH  - Adolescent
MH  - Analysis of Variance
MH  - Aspirin/*therapeutic use
MH  - Canada
MH  - Female
MH  - *Health Education
MH  - Humans
MH  - *Nonprescription Drugs
MH  - Pilot Projects
EDAT- 1981/12/12 00:00
MHDA- 1981/12/12 00:01
CRDT- 1981/12/12 00:00
PHST- 1981/12/12 00:00 [pubmed]
PHST- 1981/12/12 00:01 [medline]
PHST- 1981/12/12 00:00 [entrez]
AID - 10.1016/s0738-3991(82)80034-7 [doi]
PST - ppublish
SO  - Patient Couns Health Educ. 1982;4(1):41-3. doi: 10.1016/s0738-3991(82)80034-7.

PMID- 6408056
OWN - NLM
STAT- MEDLINE
DCOM- 19830817
LR  - 20190919
IS  - 0277-0903 (Print)
IS  - 0277-0903 (Linking)
VI  - 20 Suppl 1
DP  - 1983
TI  - Possible mechanisms underlying mucus secretion in aspirin-sensitive asthma.
PG  - 9-13
AB  - To study the hypersecretion of mucus in human airways, an in vitro model was 
      developed. The effect of prostaglandins, nonsteroidal anti-inflammatory drugs, 
      lipoxygenase products of arachidonic acid, and other mucus-stimulating and 
      mucus-inhibiting agents was studied. The data suggest that arachidonic acid 
      metabolized through its lipoxygenase pathway leads to the formation of potent 
      stimulators of mucus release. Among them are the monohydroxyeicosatetraenoic 
      acids, which are produced in large quantities by human airways, and the 
      leukotrienes, which are generated during allergic reactions of the lung. As the 
      lipoxygenase pathway is the only operant metabolic system available for 
      arachidonic acid in the presence of aspirin and non-steroidal anti-inflammatory 
      drugs--and as the nonsteroidal anti-inflammatory drugs themselves stimulate mucus 
      production--it is possible that the mechanism responsible for mucus release in 
      aspirin-sensitive asthmatics is the formation of these lipoxygenase products.
FAU - Kaliner, M
AU  - Kaliner M
FAU - Marom, Z
AU  - Marom Z
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Asthma
JT  - The Journal of asthma : official journal of the Association for the Care of 
      Asthma
JID - 8106454
RN  - 0 (Prostaglandins)
RN  - EC 1.13.11.12 (Lipoxygenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*pharmacology
MH  - Asthma/chemically induced/*physiopathology
MH  - Bronchi/*drug effects
MH  - Humans
MH  - Lipoxygenase/pharmacology
MH  - Models, Biological
MH  - Mucus/*drug effects/metabolism
MH  - Prostaglandins/pharmacology
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.3109/02770908309078047 [doi]
PST - ppublish
SO  - J Asthma. 1983;20 Suppl 1:9-13. doi: 10.3109/02770908309078047.

PMID- 6361791
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20180214
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 27 Suppl 1
DP  - 1983
TI  - Long-term clinical evaluation of suprofen and aspirin in patients with 
      osteoarthritis.
PG  - 48-54
AB  - The safety and efficacy of suprofen 200 mg q.i.d. and aspirin 650 mg q.i.d. in 
      the treatment of chronic pain due to osteoarthritis were compared in a 
      double-blind, randomized, parallel group study over a 12-week period. Suprofen 
      was comparable to aspirin in the relief of pain and improvement in activity 
      impairment. Results of ocular examination, laboratory data, and vital signs 
      examinations indicated no clinically significant changes for suprofen. No serious 
      side effects were reported by either group.
FAU - Willkens, R F
AU  - Willkens RF
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Phenylpropionates)
RN  - 988GU2F9PE (Suprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/blood/*drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - Random Allocation
MH  - Suprofen/adverse effects/*therapeutic use
MH  - Time Factors
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1159/000137899 [doi]
PST - ppublish
SO  - Pharmacology. 1983;27 Suppl 1:48-54. doi: 10.1159/000137899.

PMID- 15641826
OWN - NLM
STAT- MEDLINE
DCOM- 20060728
LR  - 20161124
IS  - 0743-7463 (Print)
IS  - 0743-7463 (Linking)
VI  - 21
IP  - 2
DP  - 2005 Jan 18
TI  - Deposition and aggregation of aspirin molecules on a phospholipid bilayer 
      pattern.
PG  - 578-85
AB  - Aspirin and 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE) are deposited 
      from their alcoholic mixed solution onto highly oriented pyrolytic graphite 
      (HOPG) by spin coating. The film structure and morphology are characterized by 
      atomic force microscopy (AFM). The barely soluble DMPE forms a highly oriented 
      stripe phase as a result of its one-dimensional epitaxy with the HOPG lattice. 
      The bilayer stripe pattern exposes the cross section of the lipid bilayer 
      lamellae and enables the direct visualization of the molecular interactions of 
      drug or biological molecules with either the hydrophobic or the hydrophilic part 
      of the phospholipid bilayer. The bilayer pattern affects the aspirin molecular 
      deposition and aggregation. AFM shows that the aspirin molecules prefer to 
      deposit and aggregate along the aliphatic interior part of the bilayer pattern, 
      giving rise to parallel dimer rods in registry with the underlying pattern. The 
      nonpolar interactions between aspirin and the phospholipid bilayer are consistent 
      with the lipophilic nature of aspirin. The bilayer pattern not only stabilizes 
      the rodlike aggregate structure of aspirin at low aspirin concentration but also 
      inhibits crystallization of aspirin at high aspirin concentration. Molecular 
      models show that the width of the DMPE aliphatic chain interior can accommodate 
      no more than two aspirin dimers. The bilayer confinement may prevent aspirin from 
      reaching its critical nucleus size. This study illustrates a general method to 
      induce a metastable or amorphous form of an active pharmaceutical ingredient 
      (API) by chemical confinement under high undercooling conditions. Metastable and 
      amorphous solids often display better solubility and bioavailability than the 
      stable crystalline form of the API.
FAU - Mao, Guangzhao
AU  - Mao G
AD  - Department of Chemical Engineering and Materials Science, Wayne State University, 
      5050 Anthony Wayne Drive, Detroit, Michigan 48202, USA. gzmao@eng.wayne.edu
FAU - Chen, Dongzhong
AU  - Chen D
FAU - Handa, Hitesh
AU  - Handa H
FAU - Dong, Wenfei
AU  - Dong W
FAU - Kurth, Dirk G
AU  - Kurth DG
FAU - Möhwald, Helmuth
AU  - Möhwald H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Langmuir
JT  - Langmuir : the ACS journal of surfaces and colloids
JID - 9882736
RN  - 0 (Lipid Bilayers)
RN  - 0 (Phosphatidylethanolamines)
RN  - 0 (Phospholipids)
RN  - R16CO5Y76E (Aspirin)
RN  - Y4S76JWI15 (Methanol)
RN  - Z37OX1ASNK (1,2-dimyristoylphosphatidylethanolamine)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Lipid Bilayers/*chemistry
MH  - Methanol/chemistry
MH  - Microscopy, Atomic Force
MH  - Phosphatidylethanolamines/chemistry
MH  - Phospholipids/*chemistry
MH  - Surface Properties
EDAT- 2005/01/12 09:00
MHDA- 2006/07/29 09:00
CRDT- 2005/01/12 09:00
PHST- 2005/01/12 09:00 [pubmed]
PHST- 2006/07/29 09:00 [medline]
PHST- 2005/01/12 09:00 [entrez]
AID - 10.1021/la047802i [doi]
PST - ppublish
SO  - Langmuir. 2005 Jan 18;21(2):578-85. doi: 10.1021/la047802i.

PMID- 28290901
OWN - NLM
STAT- MEDLINE
DCOM- 20180816
LR  - 20191113
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 56
IP  - 7
DP  - 2016 Jul
TI  - [Ability to Overcome the Thrombocyte Resistance to Acetylsalicylic Acid in 
      Patients With Coronary Artery Disease After Myocardial Revascularization With 
      Coronary Stenting].
PG  - 5-9
AB  - Resistance to acetylsalicylic acid (ASA) in patients with coronary artery disease 
      is a poor predictor for the development of atherothrombotic complications. In 277 
      patients with coronary artery disease suffered uncomplicated coronary angioplasty 
      with stent implantation, we was estimated arachidon-induced platelet aggregation 
      during treatment with acetylsalicylic acid by bedside VerifyNow Assay test at 
      28-90 days after the intervention. It was found that 18.9% of the 144 patients 
      receiving a combination of ASA 75 mg with 15.2 mg of magnesium hydroxide had true 
      (laboratory) resistance to ASA. At the same time on the original enteric coated 
      ASA 100 mg, we can found only 0.8% resistance to ASA among 129 patients. We made 
      switch from combination of ASA 75 mg with 15.2 mg of magnesium hydroxide to 
      original enteric coated ASA 100 mg and repeat VerifyNow Assay test at 2-4 days 
      and found lost of resistance in 92% of 28 patients. Thus, resistance to the ASA 
      is not constant, it depends on the form and the applied dose of ASA, and 
      eliminating more than 92% when ASA changes from ineffective to effective form.
FAU - Pershukov, I V
AU  - Pershukov IV
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Ostaschenko, S L
AU  - Ostaschenko SL
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Kuznetsova, T N
AU  - Kuznetsova TN
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Scherbo, S N
AU  - Scherbo SN
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Karben, Z A
AU  - Karben ZA
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Sokryukina, E V
AU  - Sokryukina EV
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Omarov, A A
AU  - Omarov AA
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Ramazanov, D M
AU  - Ramazanov DM
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Bosak, N V
AU  - Bosak NV
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Shulzhenko, L V
AU  - Shulzhenko LV
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Kalmatov, R K
AU  - Kalmatov RK
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Batyraliev, T A
AU  - Batyraliev TA
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
FAU - Sidorenko, B A
AU  - Sidorenko BA
AD  - Central State Medical Academy, President Management Department RF, Moscow, 
      Russia.
AD  - Voronezh Regional Clinical Hospital 1, Voronezh, Russia.
AD  - N.I. Pirogov Russian National Research State Medical University, Moscow, Russia.
AD  - Sani Konukoglu Medical Center, Gaziantep ,Turkey.
AD  - Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, 
      Kazakhstan.
AD  - Central Hospital of Oilworkers, Baku, Azerbaijan.
AD  - Krasnodar City Emergency Clinical Hospital, Krasnodar, Russia.
AD  - Kuban State Medical University, Krasnodar, Russia.
AD  - Osh State University, Osh, Kyrgyzstan.
LA  - rus
PT  - Journal Article
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/*pharmacology/therapeutic use
MH  - *Coronary Artery Disease/drug therapy/surgery
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Stents
OTO - NOTNLM
OT  - VerifyNow
OT  - acetylsalicylic acid
OT  - coronary artery disease
OT  - coronary stenting
OT  - laboratory resistance
EDAT- 2017/03/16 06:00
MHDA- 2018/08/17 06:00
CRDT- 2017/03/15 06:00
PHST- 2017/03/15 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2018/08/17 06:00 [medline]
AID - 10.18565/cardio.2016.7.5-9 [doi]
PST - ppublish
SO  - Kardiologiia. 2016 Jul;56(7):5-9. doi: 10.18565/cardio.2016.7.5-9.

PMID- 21490920
OWN - NLM
STAT- MEDLINE
DCOM- 20110825
LR  - 20211020
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 6
IP  - 4
DP  - 2011 Apr 7
TI  - Delphi-consensus weights for ischemic and bleeding events to be included in a 
      composite outcome for RCTs in thrombosis prevention.
PG  - e18461
LID - 10.1371/journal.pone.0018461 [doi]
LID - e18461
AB  - BACKGROUND AND OBJECTIVES: To weight ischemic and bleeding events according to 
      their severity to be used in a composite outcome in RCTs in the field of 
      thrombosis prevention. METHOD: Using a Delphi consensus method, a panel of 
      anaesthesiology and cardiology experts rated the severity of thrombotic and 
      bleeding clinical events. The ratings were expressed on a 10-point scale. The 
      median and quartiles of the ratings of each item were returned to the experts. 
      Then, the panel members evaluated the events a second time with knowledge of the 
      group responses from the first round. Cronbach's a was used as a measure of 
      homogeneity for the ratings. The final rating for each event corresponded to the 
      median rating obtained at the last Delphi round. RESULTS: Of 70 experts invited, 
      32 (46%) accepted to participate. Consensus was reached at the second round as 
      indicated by Cronbach's a value (0.99 (95% CI 0.98-1.00)) so the Delphi was 
      stopped. Severity ranged from under-popliteal venous thrombosis (median = 3, 
      Q1 = 2; Q3 = 3) to ischemic stroke or intracerebral hemorrhage with severe 
      disability at 7 days and massive pulmonary embolism (median = 9, Q1 = 9; Q3 = 9). 
      Ratings did not differ according to the medical specialty of experts. 
      CONCLUSIONS: These ratings could be used to weight ischemic and bleeding events 
      of various severity comprising a composite outcome in the field of thrombosis 
      prevention.
FAU - Dechartres, Agnes
AU  - Dechartres A
AD  - UMR-S 738, INSERM, Paris, France.
FAU - Albaladejo, Pierre
AU  - Albaladejo P
FAU - Mantz, Jean
AU  - Mantz J
FAU - Samama, Charles Marc
AU  - Samama CM
FAU - Collet, Jean-Philippe
AU  - Collet JP
FAU - Steg, Philippe Gabriel
AU  - Steg PG
FAU - Ravaud, Philippe
AU  - Ravaud P
FAU - Tubach, Florence
AU  - Tubach F
LA  - eng
PT  - Journal Article
DEP - 20110407
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Hemorrhage/*diagnosis/etiology
MH  - Humans
MH  - Ischemia/*diagnosis/etiology
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/diagnosis/etiology
MH  - Thrombosis/*prevention & control
MH  - Treatment Outcome
PMC - PMC3072399
COIS- Competing Interests: P. Albaladejo: Research grants (to the institution) from 
      Bristol Myers Squibb, Pfizer, Daiichi Sankyo, Eli-Lilly, Boehringer Ingelheim, 
      LFB, consulting or lecture fees from Bayer, Bristol-Myers Squibb, Pfizer, 
      Daichi-Sankyo, Eli-Lilly, Boehringer Ingelheim, Sanofi-Aventis, LFB, and Vifor. 
      J. Mantz: Consulting fees from Baxter, Pall Medical and Orionpharma. C.M. Samama: 
      Research grants (to the institution) from LFB, NovoNordisk, CSL Behring, 
      SanofiAventis, Bayer, consulting or lecture fees from AstraZeneca, Bayer, 
      Bristol-Myers Squibb, Daichi-Sankyo, Eli-Lilly, Sanofi-Aventis Group, Pfizer, 
      Boehringer-Ingelheim, and GSK. J.P. Collet: Research grants (to the institution) 
      from Abbott Vascular, Bristol-Myers Squibb, Boston Scientific, Cordis, Eli-Lilly, 
      Fédération Française de Cardiologie, Fondation de France, Guerbet Medical, 
      INSERM, Medtronic, Sanofi-Aventis Group, Société Française de Cardiologie, 
      consulting or lecture fees from Zsra-Zeneca, Bayer, Bristol-Myers Squibb, 
      Daichi-Sankyo, Eli-Lilly, Sanofi-Aventis Group, and Servier. P.G. Steg: Hamilton 
      Health Services Astellas, AstraZeneca, Boerhinger-Ingelheim, Bristol-Myers 
      Squibb, GSK, Daiichi-Sankyio/Eli-Lilly Alliance, Medtronic, Merck Sharpe Dohme, 
      Roche, Sanofi-Aventis, Servier, The Medicines Company, and Aterovax. P. Ravaud: 
      None. F. Tubach: Research grants (to the institution) from Abbott, AstraZeneca, 
      Pfizer, and Schering Plough.
EDAT- 2011/04/15 06:00
MHDA- 2011/08/27 06:00
CRDT- 2011/04/15 06:00
PHST- 2010/09/07 00:00 [received]
PHST- 2011/03/08 00:00 [accepted]
PHST- 2011/04/15 06:00 [entrez]
PHST- 2011/04/15 06:00 [pubmed]
PHST- 2011/08/27 06:00 [medline]
AID - PONE-D-10-01330 [pii]
AID - 10.1371/journal.pone.0018461 [doi]
PST - epublish
SO  - PLoS One. 2011 Apr 7;6(4):e18461. doi: 10.1371/journal.pone.0018461.

PMID- 8306217
OWN - NLM
STAT- MEDLINE
DCOM- 19940317
LR  - 20131121
IS  - 0008-428X (Print)
IS  - 0008-428X (Linking)
VI  - 37
IP  - 1
DP  - 1994 Feb
TI  - Use of desmopressin acetate to reduce blood transfusion requirements during 
      cardiac surgery in patients with acetylsalicylic-acid-induced platelet 
      dysfunction.
PG  - 33-6
AB  - OBJECTIVE: To determine whether desmopressin acetate (DDAVP) has the ability to 
      reduce blood loss in patients with a known bleeding tendency. DESIGN: A 
      randomized, double-blind, placebo controlled study. SETTING: A university 
      teaching hospital. PATIENTS: Men under the age of 70 years who had taken 
      acetylsalicylic acid within 7 days of scheduled coronary artery bypass surgery. 
      Patients with an abnormal hematologic profile or a history of bleeding or who 
      were receiving heparin or undergoing repeat coronary bypass surgery were 
      excluded. Forty-four patients were randomized with restriction in blocks of 10; 
      20 received DDAVP and 24 received a placebo. MAIN OUTCOME MEASURES: Blood loss 
      and blood transfusion requirements. RESULTS: Patients treated with DDAVP lost 
      significantly (p < 0.01) less blood than those receiving a placebo (1543 mL 
      versus 2376 mL respectively). Nineteen patients had a blood loss of more than 
      2000 mL; 15 of these were in the placebo group. Significantly (p < 0.02) fewer 
      patients receiving DDAVP required blood transfusion (9 versus 18). CONCLUSIONS: 
      DDAVP reduces blood loss during cardiac bypass surgery in patients who have taken 
      acetylsalicylic acid within 7 days before operation.
FAU - Sheridan, D P
AU  - Sheridan DP
AD  - Department of Medicine, University of Saskatchewan, Saskatoon.
FAU - Card, R T
AU  - Card RT
FAU - Pinilla, J C
AU  - Pinilla JC
FAU - Harding, S M
AU  - Harding SM
FAU - Thomson, D J
AU  - Thomson DJ
FAU - Gauthier, L
AU  - Gauthier L
FAU - Drotar, D
AU  - Drotar D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - Can J Surg
JT  - Canadian journal of surgery. Journal canadien de chirurgie
JID - 0372715
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Loss, Surgical/*prevention & control
MH  - Blood Platelets/drug effects
MH  - Blood Transfusion
MH  - Blood Volume
MH  - *Coronary Artery Bypass
MH  - Deamino Arginine Vasopressin/pharmacology/*therapeutic use
MH  - Double-Blind Method
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
PST - ppublish
SO  - Can J Surg. 1994 Feb;37(1):33-6.

PMID- 27127038
OWN - NLM
STAT- MEDLINE
DCOM- 20170403
LR  - 20170805
IS  - 1873-0191 (Electronic)
IS  - 0928-4931 (Linking)
VI  - 64
DP  - 2016 Jul 1
TI  - Sustained release of aspirin and vitamin C from titanium nanotubes: An 
      experimental and stimulation study.
PG  - 139-147
LID - S0928-4931(16)30229-6 [pii]
LID - 10.1016/j.msec.2016.03.055 [doi]
AB  - Anodization is a promising method to change the topography and wettability of 
      titanium (Ti) implant. The formed TiO2 nanotubes (TiNTs) arrays could enhance the 
      biological properties of Ti implants. In this study, to investigate the 
      possibility of TiNTs arrays on a Ti implant surface as nano-reservoirs for small 
      molecular drugs when using in orthopedic and dental prosthesis, TiNTs on a Ti 
      implant surface were prepared. Then, aspirin and/or vitamin C were loaded into 
      TiNTs as model drugs. Meanwhile, low molecular weight polylactic acid (PLA, 
      Mw=3000) was synthesized and loaded alternately along with aspirin or vitamin C. 
      The release rates of aspirin and vitamin C with/or without PLA loading were 
      investigated by using a UV-Vis spectrometer. The results showed that when loading 
      without PLA, drugs released quickly with presence of burst release. However, when 
      loading with PLA, the cumulative release duration of aspirin and vitamin C was 
      prolonged to over 240h. Molecular dynamics (MD) simulation and dissipative 
      particle dynamics (DPD) simulation results proved that when loading with PLA, PLA 
      molecules aggregated gradually and formed clusters or micelles in these 
      nanotubes. Meanwhile, drug molecules were captured and distributed inside the PLA 
      matrix, which retarding the release of drugs. Only when PLA micelles degrade 
      gradually in body fluid, drugs could be released slowly from nanotubes. These 
      knowledge laid ground basis for the following biological experiments.
CI  - Copyright © 2016. Published by Elsevier B.V.
FAU - Yang, Weihu
AU  - Yang W
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education, 
      College of Bioengineering, Chongqing University, Chongqing 400044, China. 
      Electronic address: yangweihu@cqu.edu.cn.
FAU - Deng, Conghui
AU  - Deng C
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education, 
      College of Bioengineering, Chongqing University, Chongqing 400044, China.
FAU - Liu, Peng
AU  - Liu P
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education, 
      College of Bioengineering, Chongqing University, Chongqing 400044, China.
FAU - Hu, Yan
AU  - Hu Y
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education, 
      College of Bioengineering, Chongqing University, Chongqing 400044, China.
FAU - Luo, Zhong
AU  - Luo Z
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education, 
      College of Bioengineering, Chongqing University, Chongqing 400044, China.
FAU - Cai, Kaiyong
AU  - Cai K
AD  - Key Laboratory of Biorheological Science and Technology, Ministry of Education, 
      College of Bioengineering, Chongqing University, Chongqing 400044, China. 
      Electronic address: kaiyong_cai@cqu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20160324
PL  - Netherlands
TA  - Mater Sci Eng C Mater Biol Appl
JT  - Materials science & engineering. C, Materials for biological applications
JID - 101484109
RN  - 0 (Delayed-Action Preparations)
RN  - D1JT611TNE (Titanium)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Ascorbic Acid/chemistry/pharmacokinetics
MH  - *Aspirin/chemistry/pharmacokinetics
MH  - Delayed-Action Preparations/chemistry/pharmacokinetics
MH  - *Molecular Dynamics Simulation
MH  - Nanotubes/*chemistry
MH  - Titanium/*chemistry
OTO - NOTNLM
OT  - Drug release
OT  - Molecular dynamics simulation
OT  - Polylactic acid
OT  - Small molecule drugs
OT  - Titanium nanotubes
EDAT- 2016/04/30 06:00
MHDA- 2017/04/04 06:00
CRDT- 2016/04/30 06:00
PHST- 2016/01/05 00:00 [received]
PHST- 2016/02/21 00:00 [revised]
PHST- 2016/03/16 00:00 [accepted]
PHST- 2016/04/30 06:00 [entrez]
PHST- 2016/04/30 06:00 [pubmed]
PHST- 2017/04/04 06:00 [medline]
AID - S0928-4931(16)30229-6 [pii]
AID - 10.1016/j.msec.2016.03.055 [doi]
PST - ppublish
SO  - Mater Sci Eng C Mater Biol Appl. 2016 Jul 1;64:139-147. doi: 
      10.1016/j.msec.2016.03.055. Epub 2016 Mar 24.

PMID- 3540033
OWN - NLM
STAT- MEDLINE
DCOM- 19870204
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 26
IP  - 8
DP  - 1986 Nov-Dec
TI  - A double-blind, parallel comparison of ketoprofen, aspirin, and placebo in 
      patients with postpartum pain.
PG  - 706-11
AB  - Our purpose was to evaluate the analgesic efficacy of single oral doses of 
      ketoprofen 25, 50, and 100 mg compared with aspirin 650 mg and placebo in the 
      relief of moderate to severe postepisiotomy, uterine cramping, or cesarean 
      section pain. One hundred and fifty-six patients participated in a randomized, 
      double-blind, stratified, parallel-group study. They were observed over a 
      six-hour period by one nurse-observer. Several of the standard summary measures 
      of analgesia were derived from the interview data, including the sum of pain 
      intensity differences (SPID) and the sum of the hourly relief values (TOTAL). The 
      study showed significant differences between aspirin and placebo for four-hour 
      SPID and several other parameters and between ketoprofen at all dose levels and 
      placebo for the four- and six-hour SPID and many other parameters. The two higher 
      doses of ketoprofen were significantly more effective than aspirin as as assessed 
      by the four- and six-hour SPID, TOTAL, and other summary measures. The low dose 
      of ketoprofen, although not significantly different from aspirin for SPID and 
      TOTAL, showed a significantly faster onset of relief and had a better global 
      rating. This study suggests that 50 mg of ketoprofen may be the clinical dose of 
      choice as an analgesic. There were no adverse effects reported.
FAU - Sunshine, A
AU  - Sunshine A
FAU - Zighelboim, I
AU  - Zighelboim I
FAU - Laska, E
AU  - Laska E
FAU - Siegel, C
AU  - Siegel C
FAU - Olson, N Z
AU  - Olson NZ
FAU - De Castro, A
AU  - De Castro A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Phenylpropionates)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Ketoprofen/adverse effects/*therapeutic use
MH  - Pain/*drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - *Postpartum Period
MH  - Pregnancy
MH  - Random Allocation
EDAT- 1986/11/01 00:00
MHDA- 1986/11/01 00:01
CRDT- 1986/11/01 00:00
PHST- 1986/11/01 00:00 [pubmed]
PHST- 1986/11/01 00:01 [medline]
PHST- 1986/11/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1986.tb02977.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1986 Nov-Dec;26(8):706-11. doi: 
      10.1002/j.1552-4604.1986.tb02977.x.

PMID- 27712765
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20180124
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 36
IP  - 4
DP  - 2016 Nov
TI  - Clinical Trials of Aspirin Treatment After Desensitization in Aspirin-Exacerbated 
      Respiratory Disease.
PG  - 705-717
LID - S0889-8561(16)30052-2 [pii]
LID - 10.1016/j.iac.2016.06.007 [doi]
AB  - The clinical efficacy of aspirin treatment after desensitization in patients with 
      respiratory disease exacerbated by nonsteroidal anti-inflammatory drugs has been 
      documented in observational studies and in double-blind placebo-controlled 
      trials. There is no general agreement with regard to the optimal maintenance dose 
      or duration of treatment with acetylsalicylic acid after desensitization, thus 
      further studies are necessary to offer clear guidelines to clinicians. This 
      article summarizes data from noncontrolled, active-control, and 
      placebo-controlled trials assessing clinical effectiveness and reporting on 
      safety of treatment with acetylsalicylic acid in desensitized patients with 
      respiratory disease exacerbated by nonsteroidal anti-inflammatory drugs.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Kowalski, Marek L
AU  - Kowalski ML
AD  - Department of Immunology, Rheumatology and Allergy, Healthy Ageing Research 
      Center, Medical University of Łódź, 251 Pomorska Street, Łódź 92-213, Poland. 
      Electronic address: Marek.Kowalski@csk.umed.lodz.pl.
FAU - Wardzyńska, Aleksandra
AU  - Wardzyńska A
AD  - Department of Immunology, Rheumatology and Allergy, Healthy Ageing Research 
      Center, Medical University of Łódź, 251 Pomorska Street, Łódź 92-213, Poland.
FAU - Makowska, Joanna S
AU  - Makowska JS
AD  - Department of Rheumatology, Medical University of Łódź, 30 Pieniny Street, Łódź 
      92-115, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160913
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - *Clinical Trials as Topic
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/etiology/therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Respiratory Tract Diseases/etiology/therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin desensitization
OT  - Aspirin hypersensitivity
OT  - Asthma
OT  - Chronic rhinosinusitis
OT  - NSAIDs-exacerbated respiratory disease
OT  - Nonsteroidal anti-inflammatory drugs
EDAT- 2016/10/08 06:00
MHDA- 2017/12/23 06:00
CRDT- 2016/10/08 06:00
PHST- 2016/10/08 06:00 [entrez]
PHST- 2016/10/08 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - S0889-8561(16)30052-2 [pii]
AID - 10.1016/j.iac.2016.06.007 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2016 Nov;36(4):705-717. doi: 
      10.1016/j.iac.2016.06.007. Epub 2016 Sep 13.

PMID- 22647033
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20220321
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 24
IP  - 4
DP  - 2013
TI  - The effect of aspirin on mean platelet volume in patients with paroxysmal atrial 
      fibrillation.
PG  - 263-6
LID - 10.3109/09537104.2012.682106 [doi]
AB  - Aspirin is one of the preferred therapies in the primary prevention of ischemic 
      stroke in paroxysmal atrial fibrillation (PAF). Mean platelet volume (MPV) is a 
      marker of platelet size and activation. Increased MPV reflects active and large 
      platelets. The present observational study was designed to investigate whether 
      aspirin treatment does affect MPV levels in patients with PAF. The study included 
      101 patients who were detected to have PAF by 24-hour Holter monitoring and 
      divided into two groups based on aspirin treatment [ASA (+) and ASA (-)]. MPV was 
      measured. Patients with aortic and mitral stenosis, hyperthyroidism, 
      hypothyroidism, malignancy, infection, and pregnancy were excluded from the 
      study. Of the 101 patients, 50 had no antiplatelet therapy and 51 had daily 
      aspirin (100 mg) intake. Mean age of the patients was 66 ± 10 years and 35 (68%) 
      were male in ASA (+) group. There was no difference in median levels of MPV (9.9 
      vs. 10.2 fl, respectively; p = 0.9) between groups. Both uni- and multivariate 
      logistic regression analyses did not show an association between MPV and ASA use. 
      Our results indicate that MPV as a predictive marker of platelet size and 
      activity is not affected by aspirin use in patients with PAF.
FAU - Colkesen, Yucel
AU  - Colkesen Y
AD  - Department of Cardiology, Faculty of Medicine, Baskent University, Adana, Turkey. 
      kardiyoloji@yahoo.com
FAU - Coskun, Isa
AU  - Coskun I
FAU - Muderrisoglu, Haldun
AU  - Muderrisoglu H
LA  - eng
PT  - Journal Article
DEP - 20120530
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Atrial Fibrillation/*blood/drug therapy
MH  - Blood Platelets/*cytology/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Count
EDAT- 2012/06/01 06:00
MHDA- 2013/10/18 06:00
CRDT- 2012/06/01 06:00
PHST- 2012/06/01 06:00 [entrez]
PHST- 2012/06/01 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - 10.3109/09537104.2012.682106 [doi]
PST - ppublish
SO  - Platelets. 2013;24(4):263-6. doi: 10.3109/09537104.2012.682106. Epub 2012 May 30.

PMID- 37505502
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230731
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 6
IP  - 7
DP  - 2023 Jul 3
TI  - Accuracy of Electronic Health Record-Documented Aspirin for Primary Prevention in 
      Adult Outpatients.
PG  - e2326237
LID - 10.1001/jamanetworkopen.2023.26237 [doi]
LID - e2326237
FAU - Chipalkatti, Naina
AU  - Chipalkatti N
AD  - Department of Internal Medicine, University of Michigan, Ann Arbor.
FAU - Barnes, Geoffrey D
AU  - Barnes GD
AD  - Division of Cardiovascular Medicine, Department of Internal Medicine, University 
      of Michigan, Ann Arbor.
AD  - Institute for Healthcare Policy and Innovation, Ann Arbor, Michigan.
FAU - Davie, Adam
AU  - Davie A
AD  - Department of Internal Medicine, University of Michigan, Ann Arbor.
FAU - Griggs, Jennifer J
AU  - Griggs JJ
AD  - Institute for Healthcare Policy and Innovation, Ann Arbor, Michigan.
AD  - Division of Hematology/Oncology, Department of Internal Medicine, University of 
      Michigan, Ann Arbor.
AD  - Department of Health Management and Policy, University of Michigan, Ann Arbor.
FAU - Harrod, Molly
AU  - Harrod M
AD  - Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann 
      Arbor, Michigan.
FAU - Medaugh, Christine
AU  - Medaugh C
AD  - Department of Family Medicine, University of Michigan, Ann Arbor.
FAU - Schaefer, Jordan K
AU  - Schaefer JK
AD  - Division of Hematology/Oncology, Department of Internal Medicine, University of 
      Michigan, Ann Arbor.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230703
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - Adult
MH  - *Aspirin/therapeutic use
MH  - *Electronic Health Records
MH  - Outpatients
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Primary Prevention
PMC - PMC10383008
OAB - This quality improvement study examines the accuracy of electronic health record 
      (EHR) documentation of aspirin use for primary prevention of atherosclerotic 
      cardiovascular disease in adult outpatients.
OABL- eng
COIS- Conflict of Interest Disclosures: Dr Barnes reported receiving personal fees for 
      consulting from Bayer, Pfizer, Bristol-Myers Squibb, Janssen, Astra Zeneca, 
      Sanofi, Boston Scientific, and Abbott Vascular and funding grants to his 
      institution from Boston Scientific outside the submitted work. No other 
      disclosures were reported.
EDAT- 2023/07/28 13:10
MHDA- 2023/07/31 06:43
CRDT- 2023/07/28 11:33
PHST- 2023/07/31 06:43 [medline]
PHST- 2023/07/28 13:10 [pubmed]
PHST- 2023/07/28 11:33 [entrez]
AID - 2807714 [pii]
AID - zld230135 [pii]
AID - 10.1001/jamanetworkopen.2023.26237 [doi]
PST - epublish
SO  - JAMA Netw Open. 2023 Jul 3;6(7):e2326237. doi: 
      10.1001/jamanetworkopen.2023.26237.

PMID- 27449765
OWN - NLM
STAT- MEDLINE
DCOM- 20170612
LR  - 20181113
IS  - 1179-6901 (Electronic)
IS  - 1174-5886 (Print)
IS  - 1174-5886 (Linking)
VI  - 16
IP  - 3
DP  - 2016 Sep
TI  - Gastrointestinal Safety of Aspirin for a High-Dose, Multiple-Day Treatment 
      Regimen: A Meta-Analysis of Three Randomized Controlled Trials.
PG  - 263-269
AB  - BACKGROUND AND AIM: Aspirin is a commonly used over-the-counter (OTC) agent for 
      the symptomatic treatment of acute pain, fever, or the common cold, but data 
      regarding safety in this context are limited. In order to characterize the safety 
      of aspirin beyond single-dose or long-term use data, we conducted a meta-analysis 
      of multiple-dose, multiple-day studies of OTC aspirin at a label-approved dosage. 
      METHODS: We conducted a meta-analysis of individual patient data from three 
      Bayer-sponsored studies. The meta-analysis was performed in 2015; the individual 
      studies were conducted between 2008 and 2012 and were of a randomized, 
      parallel-group, placebo-controlled design. Patients received a minimum dosage of 
      aspirin of 2000 mg/day over at least 3 days. The endpoints were patient-reported 
      adverse events (AEs) with an emphasis on the system organ class gastrointestinal 
      system. Event incidences were estimated and an analysis of the odds ratios (ORs) 
      and risk differences (RDs) of aspirin versus placebo were performed. RESULTS: Of 
      the 819 patients included, 433 were treated with aspirin and 386 were treated 
      with placebo. The majority of patients (85.7 %) received a median dose of aspirin 
      of 3000 mg/day for 3 days. The incidence of the overall AEs was low and rates 
      were comparable between the aspirin (10.9 %) and placebo (12.4 %) groups [OR: 
      0.86 (95 % confidence interval [CI] 0.56, 1.34); RD: -1.49 (95 % CI -6.01, 
      3.03)]. Gastrointestinal AEs were more common in subjects treated with aspirin 
      (7.4 %) than with placebo (5.4 %), and although this difference did not reach 
      statistical significance, a trend towards increased risk was observed with 
      aspirin use [OR: 1.41 (95 % CI 0.78, 2.54); RD: 2.00 (95 % CI -1.35, 5.35)]. 
      Nausea, upper abdominal pain, dyspepsia, and diarrhea were the most frequently 
      reported gastrointestinal AEs. There were no reports of serious gastrointestinal 
      complications such as bleeding, perforation, or ulceration. CONCLUSIONS: The 
      multiple-dose regimen of aspirin used for several days according to the OTC label 
      is well-tolerated by otherwise healthy non-elderly subjects for short-term and 
      symptomatic treatment of pain, fever, and the common cold. There were no reports 
      of serious gastrointestinal complications in either of the groups.
FAU - Forder, Samantha
AU  - Forder S
AD  - Bayer, Whippany, NJ, USA.
FAU - Voelker, Michael
AU  - Voelker M
AD  - Bayer, Leverkusen, Germany. michael.voelker@bayer.com.
FAU - Lanas, Angel
AU  - Lanas A
AD  - IIS Aragón, CIBERehd, University of Zaragoza, Zaragoza, Spain.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - New Zealand
TA  - Drugs R D
JT  - Drugs in R&D
JID - 100883647
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdominal Pain/chemically induced
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Female
MH  - Gastrointestinal Diseases/*drug therapy
MH  - Heartburn/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nausea/chemically induced
MH  - Randomized Controlled Trials as Topic
MH  - Vomiting/chemically induced
MH  - Young Adult
PMC - PMC5045830
COIS- Compliance with Ethical Standards This study was funded by Bayer AG, Leverkusen, 
      Germany, and performed by M.A.R.C.O., Dusseldorf, Germany, an independent 
      institute for clinical research and statistics. During the development of this 
      manuscript, Samantha Forder was completing a post-doctoral fellowship through a 
      partnership between Bayer and Rutgers University, New Brunswick, NJ, USA. Michael 
      Voelker is a full-time employee of Bayer AG. Angel Lanas is supported by the 
      University of Zaragoza, Zaragoza, Spain. Dr. Lanas has received honoraria for 
      participation in advisory boards and for a previous related study from Bayer. All 
      authors contributed sufficiently to the development, review, and revision of this 
      manuscript.
EDAT- 2016/07/28 06:00
MHDA- 2017/06/13 06:00
CRDT- 2016/07/25 06:00
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/06/13 06:00 [medline]
PHST- 2016/07/25 06:00 [entrez]
AID - 10.1007/s40268-016-0138-8 [pii]
AID - 138 [pii]
AID - 10.1007/s40268-016-0138-8 [doi]
PST - ppublish
SO  - Drugs R D. 2016 Sep;16(3):263-269. doi: 10.1007/s40268-016-0138-8.

PMID- 20421472
OWN - NLM
STAT- MEDLINE
DCOM- 20100602
LR  - 20220129
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 107
IP  - 19
DP  - 2010 May 11
TI  - Dichotomy in duration and severity of acute inflammatory responses in humans 
      arising from differentially expressed proresolution pathways.
PG  - 8842-7
LID - 10.1073/pnas.1000373107 [doi]
AB  - Lipoxins (Lxs) and aspirin-triggered epi-Lxs (15-epi-LxA(4)) act through the 
      ALX/FPRL1 receptor to block leukocyte trafficking, dampen cytokine/chemokine 
      synthesis, and enhance phagocytic clearance of apoptotic leukocytes-key 
      requisites for inflammatory resolution. Although studies using primarily inbred 
      rodents have highlighted resolution as an active event, little is known about the 
      role resolution pathways play in controlling the duration/profile of inflammatory 
      responses in humans. To examine this, we found two types of responders to 
      cantharidin-induced skin blisters in male healthy volunteers: those with 
      immediate leukocyte accumulation and cytokine/chemokine synthesis followed by 
      early resolution and a second group whose inflammation increased gradually over 
      time followed by delayed resolution. In early resolvers, blister 15-epi-LxA(4) 
      and leukocyte ALX were low, but increased as inflammation abated. In contrast, in 
      delayed resolvers, 15-epi-LxA(4) and ALX were high early in the response but 
      waned as inflammation progressed. Elevating 15-epi-LxA(4) in early resolvers 
      using aspirin increased blister leukocyte ALX but reduced cytokines/chemokines as 
      well as polymorphonuclear leukocyte and macrophage numbers. These findings show 
      that two phenotypes exist in humans with respect to inflammation 
      severity/longevity controlled by proresolution mediators, namely 15-epi-LxA(4). 
      These data have implications for understanding the etiology of chronic 
      inflammation and future directions in antiinflammatory therapy.
FAU - Morris, Thea
AU  - Morris T
AD  - Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, 
      University College London, London WC1E 6JJ, UK.
FAU - Stables, Melanie
AU  - Stables M
FAU - Colville-Nash, Paul
AU  - Colville-Nash P
FAU - Newson, Justine
AU  - Newson J
FAU - Bellingan, Geoffrey
AU  - Bellingan G
FAU - de Souza, Patricia M
AU  - de Souza PM
FAU - Gilroy, Derek W
AU  - Gilroy DW
LA  - eng
GR  - 087520/WT_/Wellcome Trust/United Kingdom
GR  - G0500017/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100426
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (FPR2 protein, human)
RN  - 0 (Lipoxins)
RN  - 0 (Receptors, Formyl Peptide)
RN  - 0 (Receptors, Lipoxin)
RN  - 0 (lipoxin A4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacology
MH  - Humans
MH  - Inflammation/chemically induced/*immunology/*pathology
MH  - Lipoxins/metabolism
MH  - Male
MH  - Middle Aged
MH  - Receptors, Formyl Peptide/metabolism
MH  - Receptors, Lipoxin/metabolism
MH  - Time Factors
PMC - PMC2889345
COIS- The authors declare no conflict of interest.
EDAT- 2010/04/28 06:00
MHDA- 2010/06/03 06:00
CRDT- 2010/04/28 06:00
PHST- 2010/04/28 06:00 [entrez]
PHST- 2010/04/28 06:00 [pubmed]
PHST- 2010/06/03 06:00 [medline]
AID - 1000373107 [pii]
AID - 201000373 [pii]
AID - 10.1073/pnas.1000373107 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2010 May 11;107(19):8842-7. doi: 
      10.1073/pnas.1000373107. Epub 2010 Apr 26.

PMID- 11920766
OWN - NLM
STAT- MEDLINE
DCOM- 20020627
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 91
IP  - 3
DP  - 2002 Mar
TI  - Hard to swallow dry: kinetics and mechanism of the anhydrous thermal 
      decomposition of acetylsalicylic acid.
PG  - 800-9
AB  - The methods of thermal analysis and mass spectrometry have been used to study the 
      kinetics and mechanism of the anhydrous thermal decomposition of acetylsalicylic 
      acid. Both thermogravimetric analysis (TGA) and differential scanning calorimetry 
      (DSC) show that decomposition occurs in two steps. Mass-spectrometric analysis of 
      the residue left after the first decomposition step (approximately equal to 60% 
      mass loss) suggests that in the condensed phase, acetylsalicylic acid decomposes 
      by first forming linear oligomers that are further converted into cyclic 
      oligomers. Model-free isoconversional kinetic analysis of TGA traces has been 
      used to determine global activation energies as a function of the extent of 
      reaction. This method of analysis has also been used to make kinetic predictions 
      of shelf life at ambient temperatures (20-40 degrees C) under anhydrous 
      conditions for acetylsalicylic acid. Our estimate of a shelf life of 876 days 
      (approximately equal to 2.4 years) for 5% decomposition at 30 degrees C is in 
      good agreement with shelf lives of 2-3 years that are stamped on over-the-counter 
      aspirin bottles. Hence, this approach can be used to systematically study the 
      factors that determine the decomposition kinetics of aspirin and may be used for 
      express screening of pharmaceuticals in order to identify those with desirable 
      thermal stabilities.
CI  - Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association.
FAU - Long, Gregory T
AU  - Long GT
AD  - Department of Chemistry, Center for Thermal Analysis, University of Utah, Salt 
      Lake City, UT 84112, USA.
FAU - Vyazovkin, Sergey
AU  - Vyazovkin S
FAU - Gamble, Nicoleigh
AU  - Gamble N
FAU - Wight, Charles A
AU  - Wight CA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Excipients)
RN  - 0 (Stearic Acids)
RN  - 0 (Tablets)
RN  - 4ELV7Z65AP (stearic acid)
RN  - 9005-25-8 (Starch)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*chemistry
MH  - Aspirin/*administration & dosage/*chemistry
MH  - Calorimetry, Differential Scanning
MH  - Drug Stability
MH  - Excipients
MH  - Humidity
MH  - Kinetics
MH  - Pressure
MH  - Starch
MH  - Stearic Acids
MH  - Tablets
MH  - Temperature
MH  - Thermodynamics
EDAT- 2002/03/29 10:00
MHDA- 2002/06/28 10:01
CRDT- 2002/03/29 10:00
PHST- 2002/03/29 10:00 [pubmed]
PHST- 2002/06/28 10:01 [medline]
PHST- 2002/03/29 10:00 [entrez]
AID - S0022-3549(16)30937-6 [pii]
AID - 10.1002/jps.10029 [doi]
PST - ppublish
SO  - J Pharm Sci. 2002 Mar;91(3):800-9. doi: 10.1002/jps.10029.

PMID- 30445361
OWN - NLM
STAT- MEDLINE
DCOM- 20190204
LR  - 20190215
IS  - 1873-2682 (Electronic)
IS  - 1011-1344 (Linking)
VI  - 189
DP  - 2018 Dec
TI  - Detection and monitoring of in vitro formation of salicylic acid from aspirin 
      using fluorescence spectroscopic technique and DFT calculations.
PG  - 292-297
LID - S1011-1344(18)30807-8 [pii]
LID - 10.1016/j.jphotobiol.2018.11.004 [doi]
AB  - Acetylsalicylic acid commonly termed as aspirin (AS) is a well known antipyretic 
      and anti-inflammatory drug which can also be used to reduce death risks due to 
      heart attack. In addition to this, it also exhibits some adverse effect such as 
      gastrointestinal, tinnitus, Reye's syndrome. The side effects of AS such as 
      gastrointestinal ulcer, tinnitus and Reye's syndrome are caused due to conversion 
      of AS into its active metabolite salicylic acid (SAL). Conversion of AS into SAL 
      has been investigated generally at basic pH. Since the pH of Gastrointestinal 
      tract is on average neutral ranging from 6.5-7.4. Therefore in the present 
      research work, in vitro conversion of AS to SAL was detected at neutral pH in 
      both aqueous medium and human blood serum samples by time series fluorescence 
      measurements and DFT study. The SAL obtained from AS at neutral pH was observed 
      to be stable for ~ 6 and ~ 4 days in aqueous medium and blood serum, 
      respectively. The mechanism of conversion of AS into SAL was investigated using 
      the transition state theory employing density functional theory (DFT). On the 
      basis of DFT calculation the in vitro formation of SAL from AS at neutral pH was 
      found to involve two intermediate transition states.
CI  - Copyright © 2018. Published by Elsevier B.V.
FAU - Singh, Ranjana
AU  - Singh R
AD  - Department of Physics, Institute of Science, Banaras Hindu University, Varanasi 
      221005, India; Department of Physics, Central University of South Bihar, 
      Panchanpur, Gaya, India. Electronic address: singh.ranjana413@gmail.com.
FAU - Tiwari, Manish Kumar
AU  - Tiwari MK
AD  - Department of Physics, Institute of Science, Banaras Hindu University, Varanasi 
      221005, India.
FAU - Gangopadhyay, Debraj
AU  - Gangopadhyay D
AD  - Department of Physics, Lucknow University, Lucknow 226007, India.
FAU - Mishra, Phool Chand
AU  - Mishra PC
AD  - Department of Physics, Institute of Science, Banaras Hindu University, Varanasi 
      221005, India.
FAU - Mishra, Hirdyesh
AU  - Mishra H
AD  - Department of Physics, MMV, Institute of Science, Banaras Hindu University, 
      Varanasi 221005, India. Electronic address: hmishra@bhu.ac.in.
FAU - Srivastava, Anchal
AU  - Srivastava A
AD  - Department of Physics, Institute of Science, Banaras Hindu University, Varanasi 
      221005, India.
FAU - Singh, Ranjan K
AU  - Singh RK
AD  - Department of Physics, Institute of Science, Banaras Hindu University, Varanasi 
      221005, India. Electronic address: ranjanksingh65@rediffmail.com.
LA  - eng
PT  - Journal Article
DEP - 20181108
PL  - Switzerland
TA  - J Photochem Photobiol B
JT  - Journal of photochemistry and photobiology. B, Biology
JID - 8804966
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Density Functional Theory
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Salicylic Acid/*chemistry
MH  - Spectrometry, Fluorescence
OTO - NOTNLM
OT  - Aspirin
OT  - Fluorescence
OT  - Rate constant
OT  - Salicylic acid
OT  - Transition State
EDAT- 2018/11/18 06:00
MHDA- 2019/02/05 06:00
CRDT- 2018/11/17 06:00
PHST- 2018/07/20 00:00 [received]
PHST- 2018/08/23 00:00 [revised]
PHST- 2018/11/06 00:00 [accepted]
PHST- 2018/11/18 06:00 [pubmed]
PHST- 2019/02/05 06:00 [medline]
PHST- 2018/11/17 06:00 [entrez]
AID - S1011-1344(18)30807-8 [pii]
AID - 10.1016/j.jphotobiol.2018.11.004 [doi]
PST - ppublish
SO  - J Photochem Photobiol B. 2018 Dec;189:292-297. doi: 
      10.1016/j.jphotobiol.2018.11.004. Epub 2018 Nov 8.

PMID- 59015
OWN - NLM
STAT- MEDLINE
DCOM- 19760823
LR  - 20221207
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 7974
DP  - 1976 Jun 26
TI  - Perinatal mortality and birth-weight in relation to aspirin taken during 
      pregnancy.
PG  - 1375-6
AB  - In a cohort of 41 337 gravidas and their offspring in the U.S.A. there was no 
      evidence that aspirin taken in pregnancy is a cause of stillbirth, neonatal 
      death, or reduced birth-weight. The women were divided into those who were not 
      exposed to aspirin (14 956), those with intermediate exposure (24 866), and those 
      who were heavily exposed (1515). Stillbirth-rates were similar for all three 
      groups. Differences in neonatal death-rates and mean birth-weights were slight 
      and none were statistically significant. Trends were opposite among approximately 
      equal numbers of White and Black children.
FAU - Shapiro, S
AU  - Shapiro S
FAU - Siskind, V
AU  - Siskind V
FAU - Monson, R R
AU  - Monson RR
FAU - Heinonen, O P
AU  - Heinonen OP
FAU - Kaufman, D W
AU  - Kaufman DW
FAU - Slone, D
AU  - Slone D
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Birth Weight/*drug effects
MH  - Black People
MH  - Female
MH  - Fetal Death/*chemically induced
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Newborn, Diseases/*mortality
MH  - Maternal-Fetal Exchange
MH  - Parity
MH  - Pregnancy
MH  - Smoking/complications
MH  - White People
EDAT- 1976/06/26 00:00
MHDA- 1976/06/26 00:01
CRDT- 1976/06/26 00:00
PHST- 1976/06/26 00:00 [pubmed]
PHST- 1976/06/26 00:01 [medline]
PHST- 1976/06/26 00:00 [entrez]
AID - S0140-6736(76)93026-9 [pii]
AID - 10.1016/s0140-6736(76)93026-9 [doi]
PST - ppublish
SO  - Lancet. 1976 Jun 26;1(7974):1375-6. doi: 10.1016/s0140-6736(76)93026-9.

PMID- 480048
OWN - NLM
STAT- MEDLINE
DCOM- 19791129
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 95
IP  - 4
DP  - 1979 Oct
TI  - Comparative effects of naproxen and aspirin on fever in children.
PG  - 626-9
AB  - The antipyretic effect of single doses of naproxen, 2.5 mg/kg or 7.5 mg/kg, was 
      compared to that of aspirin, 15 mg/kg, and of a placebo in a double-blind study. 
      Febrile children, hospitalized overnight, were randomly assigned to one of the 
      treatment or placebo groups, and their temperatures were recorded hourly. 
      Naproxen, 7.5 mg/kg, was at least as effective as aspirin in onset of action and 
      reduction of fever, and had a longer duration of action. Each of the three 
      treatments had a significant effect as compared to that of the placebo. There was 
      no difference in the total incidence of side effects among the four groups, but 
      mild gastrointestinal complaints were more common among the patients in the 
      high-dose naproxen group, whereas CNS complaints were more prevalent among the 
      patients in the placebo group.
FAU - Cashman, T M
AU  - Cashman TM
FAU - Starns, R J
AU  - Starns RJ
FAU - Johnson, J
AU  - Johnson J
FAU - Oren, J
AU  - Oren J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 0 (Placebos)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Double-Blind Method
MH  - Fever/*drug therapy
MH  - Humans
MH  - Naproxen/administration & dosage/adverse effects/*therapeutic use
MH  - Placebos
EDAT- 1979/10/01 00:00
MHDA- 1979/10/01 00:01
CRDT- 1979/10/01 00:00
PHST- 1979/10/01 00:00 [pubmed]
PHST- 1979/10/01 00:01 [medline]
PHST- 1979/10/01 00:00 [entrez]
AID - S0022-3476(79)80784-2 [pii]
AID - 10.1016/s0022-3476(79)80784-2 [doi]
PST - ppublish
SO  - J Pediatr. 1979 Oct;95(4):626-9. doi: 10.1016/s0022-3476(79)80784-2.

PMID- 2518872
OWN - NLM
STAT- MEDLINE
DCOM- 19911112
LR  - 20190828
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 3
IP  - 6
DP  - 1989 Dec
TI  - Acute damage of gastroduodenal mucosa by acetylsalicylic acid: no prolonged 
      protection by antacids.
PG  - 585-90
AB  - Twenty healthy volunteers participated in a double-blind, crossover study to 
      evaluate endoscopically whether low-dose antacids have any prolonged and 
      pH-independent protective capacity against gastroduodenal mucosal damage induced 
      by acetylsalicylic acid. Antacid or placebo one tablet q.d.s. was given for 1.5 
      days. Acetylsalicylic acid (1.5 g) was administered 3 h after the last dose of 
      antacid/placebo, and gastroscopy was performed 1 h thereafter. Thirteen of 20 
      subjects showed a decrease in total damage with antacids as compared with 
      placebo, but the difference did not reach statistical significance. Thus, 
      protection by antacids against acetylsalicylic acid-induced gastric mucosal 
      lesions could not be documented at a time when intragastric pH presumably had 
      returned to normal.
FAU - Berstad, K
AU  - Berstad K
AD  - Medical Department, Haukeland University Hospital, Bergen, Norway.
FAU - Haram, E M
AU  - Haram EM
FAU - Weberg, R
AU  - Weberg R
FAU - Berstad, A
AU  - Berstad A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Antacids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antacids/*pharmacology
MH  - Aspirin/*adverse effects/antagonists & inhibitors
MH  - Double-Blind Method
MH  - Duodenum/drug effects
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Intestinal Mucosa/*drug effects
MH  - Male
MH  - Middle Aged
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
AID - 10.1111/j.1365-2036.1989.tb00251.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 1989 Dec;3(6):585-90. doi: 
      10.1111/j.1365-2036.1989.tb00251.x.

PMID- 415081
OWN - NLM
STAT- MEDLINE
DCOM- 19780417
LR  - 20170214
IS  - 0022-0345 (Print)
IS  - 0022-0345 (Linking)
VI  - 56
IP  - 10
DP  - 1977 Oct
TI  - Effects of repeated ingestion of large quantities of acetylsalicylic acid on 
      membranous bone growth and dentin apposition in young monkeys.
PG  - 1265-70
AB  - Four daily doses of ASA were administered by mouth to young growing monkeys which 
      received six injections of lead acetate every seven days as an intravital stain 
      to indicate sites of bone and dentin mineralization. Microscopic evaluation of 
      the inhibitory effects on membranous bone growth and dentin apposition was made. 
      Four doses of ASA at 325 mg/kg inhibited membranous bone growth as well as the 
      remodeling of the Haversian canal systems for about 16-18 days, with incomplete 
      recovery during the experimental period. No comparable effect on dentinogenesis 
      was observed. This preliminary study indicates that four doses of ASA at this 
      level caused a toxic effect directly on membranous bone growth but not on dentin 
      apposition.
FAU - Yen, P K
AU  - Yen PK
FAU - Shaw, J H
AU  - Shaw JH
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Dent Res
JT  - Journal of dental research
JID - 0354343
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bone Development/*drug effects
MH  - Bone and Bones/*drug effects
MH  - Dentin/*drug effects
MH  - Dentinogenesis/*drug effects
MH  - Haplorhini
MH  - Macaca mulatta
MH  - Male
MH  - Mandible/drug effects/growth & development
EDAT- 1977/10/01 00:00
MHDA- 1977/10/01 00:01
CRDT- 1977/10/01 00:00
PHST- 1977/10/01 00:00 [pubmed]
PHST- 1977/10/01 00:01 [medline]
PHST- 1977/10/01 00:00 [entrez]
AID - 10.1177/00220345770560103101 [doi]
PST - ppublish
SO  - J Dent Res. 1977 Oct;56(10):1265-70. doi: 10.1177/00220345770560103101.

PMID- 791318
OWN - NLM
STAT- MEDLINE
DCOM- 19770129
LR  - 20190509
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 2
IP  - 1
DP  - 1975 Feb
TI  - The effect of metoclopramide on the absorption of effervescent aspirin in 
      migraine.
PG  - 57-63
AB  - 1 The absorption of effervescent aspirin was studied in two groups of patients 
      during attacks of migraine. The first group received effervescent aspirin alone 
      whilst the second group received intramuscular metoclopramide before effervescent 
      aspirin. 2 After effervescent aspirin alone there was significant impairment in 
      the rate of aspirin absorption during migraine attacks compared with the rate of 
      aspirin absorption in normal volunteers and in the same patients when 
      headache-free. 3 When metoclopramide was given before effervescent aspirin the 
      rate of aspirin absorption during migraine attacks was not significantly 
      different from that obtained in normal volunteers given effervescent aspirin 
      alone or from that obtained in the patients themselves when given both 
      metoclopramide and effervescent aspirin when headache-free. 4 It is concluded 
      that the impairment of absorption of effervescent aspirin during migraine attacks 
      is related to impaired gastro-intestinal motility with delayed gastric emptying 
      and that this impaired motility can be overcome by parenteral metoclopramide.
FAU - Volans, G N
AU  - Volans GN
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*metabolism/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastrointestinal Motility/drug effects
MH  - Humans
MH  - Intestinal Absorption/*drug effects
MH  - Male
MH  - Metoclopramide/*pharmacology/therapeutic use
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
PMC - PMC1402484
EDAT- 1975/02/01 00:00
MHDA- 1975/02/01 00:01
CRDT- 1975/02/01 00:00
PHST- 1975/02/01 00:00 [pubmed]
PHST- 1975/02/01 00:01 [medline]
PHST- 1975/02/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1975.tb00472.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1975 Feb;2(1):57-63. doi: 
      10.1111/j.1365-2125.1975.tb00472.x.

PMID- 29409080
OWN - NLM
STAT- MEDLINE
DCOM- 20180608
LR  - 20180608
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 143
IP  - 3
DP  - 2018 Feb
TI  - [Prolonged Secondary Prevention After Venous Thromboembolism].
PG  - 137-142
LID - 10.1055/s-0043-113679 [doi]
AB  - Recent studies: Shortly after discontinuation of the oral anticoagulation (OAC) 
      there is a 2- to 3 fold increase in VTE recurrences. The risk for recurrence is 
      particularly high in VTE events that occurred without provoking risk factor, with 
      minor provoking factors and in cases with persistent risk factors such as active 
      cancer.Guidance document for the categorization of risk factors for VTE: A recent 
      guidance document defined underlying risk factors for the occurrence of VTE and 
      categorized them into three groups. Direct oral anticoagulants (DOACs): For 
      long-term secondary prevention, a reduced dosing regimen of DOACs was found to be 
      effective with a low bleeding risk. Aspirin should no longer be used for 
      secondary prevention of VTE because the efficacy to prevent recurrent events is 
      lower, while there was no difference in the risk of major bleeding.A Traffic 
      light system helps to select the appropriate duration of anticoagulation. 
      Patients are risk stratified into three groups according to their presumed risk 
      of recurrence. For the majority of the patients this leads to a clear decision to 
      stop or continue OAC (green or red traffic light, respectively). In case of 
      prolonged anticoagulation, the use of a reduced dose DOAC regimen may be 
      considered in view of risk-benefit-balancing.
CI  - © Georg Thieme Verlag KG Stuttgart · New York.
FAU - Bauersachs, Rupert
AU  - Bauersachs R
AD  - Klinik für Gefäßmedizin, Angiologie, Klinikum Darmstadt GmbH, Darmstadt.
AD  - Centrum für Thrombose und Hämostase, Universitätsmedizin der Johannes 
      Gutenberg-Universität Mainz.
LA  - ger
PT  - Journal Article
TT  - Verlängerte Sekundärprophylaxe nach venöser Thromboembolie.
DEP - 20180206
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Humans
MH  - Recurrence
MH  - Risk Factors
MH  - Secondary Prevention
MH  - *Venous Thromboembolism/drug therapy/epidemiology/prevention & control
COIS- Prof. Dr. Rupert Bauersachs erhielt Vortrags- und Beraterhonorare von Bayer, 
      BMS-Pfizer, Boehringer Ingelheim, Daiichi Sankyo.
EDAT- 2018/02/07 06:00
MHDA- 2018/06/09 06:00
CRDT- 2018/02/07 06:00
PHST- 2018/02/07 06:00 [entrez]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2018/06/09 06:00 [medline]
AID - 10.1055/s-0043-113679 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2018 Feb;143(3):137-142. doi: 10.1055/s-0043-113679. Epub 
      2018 Feb 6.

PMID- 34130339
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20220531
IS  - 1098-9064 (Electronic)
IS  - 0094-6176 (Linking)
VI  - 47
IP  - 7
DP  - 2021 Oct
TI  - Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, 
      Unresolved Questions, and Future Perspectives.
PG  - 800-814
LID - 10.1055/s-0041-1726096 [doi]
AB  - The ability of aspirin to inhibit platelet aggregation has positioned this agent 
      within the most frequently used drugs worldwide. The aim of this article is to 
      review the contemporary clinical use of aspirin and also to discuss unresolved 
      issues not yet translated into clinical practice. Results from several clinical 
      trials have led to strong guideline recommendations for aspirin use in the acute 
      management and secondary prevention of cardiovascular disease. On the contrary, 
      guidelines regarding aspirin use as primary prevention of cardiovascular disease 
      are almost conservative, supported by recent trials reporting that the bleeding 
      risk outweighs the potential benefits in most patients. In pregnancy, aspirin has 
      proved efficient in preventing preeclampsia and small-for-gestational-age births 
      in women at high risk, and is hence widely recommended in clinical guidelines. 
      Despite the vast amount of clinical data on aspirin, several unresolved questions 
      remain. Randomized trials have reported that aspirin reduces the risk of 
      recurrent venous thromboembolism, but the clinical relevance remains limited, 
      because direct oral anticoagulants are more effective. Laboratory studies suggest 
      that a twice-daily dosing regimen or evening intake may lead to more efficient 
      platelet inhibition, and the potential clinical benefit of such strategies is 
      currently being explored in ongoing clinical trials. Enteric-coated formulations 
      of aspirin are frequently used, but it remains unclear if they are safer and as 
      efficient as plain aspirin. In the future, aspirin use after percutaneous 
      coronary interventions might not be mandatory in patients who also need 
      anticoagulant therapy, as several trials support shorter aspirin duration 
      strategies. On the other hand, new treatment indications for aspirin will likely 
      arise, as there is growing evidence that aspirin may reduce the risk of 
      colorectal cancer and other types of cancer.
CI  - Thieme. All rights reserved.
FAU - Christiansen, Mikael
AU  - Christiansen M
AD  - Department of Clinical Biochemistry, Regional Hospital in Horsens, Horsens, 
      Denmark.
FAU - Grove, Erik Lerkevang
AU  - Grove EL
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, 
      Denmark.
FAU - Hvas, Anne-Mette
AU  - Hvas AM
AD  - Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, 
      Denmark.
AD  - Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210615
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants
MH  - *Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Pregnancy
MH  - *Venous Thromboembolism
COIS- E.L.G. has received speaker honoraria or consultancy fees from AstraZeneca, 
      Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, MSD, Lundbeck, 
      MundiPharma, Portola Pharmaceuticals, and Roche. He is an investigator in the 
      SATELLITE, FLAVOUR, and ETESIAN studies (AstraZeneca) and has received 
      unrestricted research grants from Boehringer Ingelheim.
EDAT- 2021/06/16 06:00
MHDA- 2022/01/18 06:00
CRDT- 2021/06/15 20:30
PHST- 2021/06/16 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
PHST- 2021/06/15 20:30 [entrez]
AID - 10.1055/s-0041-1726096 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2021 Oct;47(7):800-814. doi: 10.1055/s-0041-1726096. Epub 
      2021 Jun 15.

PMID- 36184313
OWN - NLM
STAT- MEDLINE
DCOM- 20230207
LR  - 20230402
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 151
IP  - 2
DP  - 2023 Feb
TI  - Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
PG  - 301-309
LID - S0091-6749(22)01171-X [pii]
LID - 10.1016/j.jaci.2022.08.021 [doi]
AB  - Aspirin-exacerbated respiratory disease has fascinated and frustrated specialists 
      in allergy/immunology, pulmonology, and otorhinolaryngology for decades. It 
      generally develops in previously healthy young adults and is unremitting and 
      challenging to treat. The classical triad of asthma, nasal polyposis, and 
      pathognomonic respiratory reactions to aspirin and other cyclooxygenase-1 
      inhibitors is accompanied by high levels of mast cell activation, cysteinyl 
      leukotriene production, platelet activation, and severe type 2 respiratory 
      inflammation. The "unbraking" of mast cell activation and further cysteinyl 
      leukotriene generation induced by cyclooxygenase-1 inhibition reflect an 
      idiosyncratic dependency on cyclooxygenase-1-derived products, likely 
      prostaglandin E(2), to maintain a tenuous homeostasis. Although cysteinyl 
      leukotrienes are clear disease effectors, little else was known about their 
      cellular sources and targets, and the contributions from other mediators and type 
      2 respiratory inflammation effector cells to disease pathophysiology were unknown 
      until recently. The applications of targeted biological therapies, single-cell 
      genomics, and transgenic animal approaches have substantially advanced our 
      understanding of aspirin-exacerbated respiratory disease pathogenesis and 
      treatment and have also revealed disease heterogeneity. This review covers novel 
      insights into the immunopathogenesis of aspirin-exacerbated respiratory disease 
      from each of these lines of research, including the roles of lipid mediators, 
      effector cell populations, and inflammatory cytokines, discusses unanswered 
      questions regarding cause and pathogenesis, and considers potential future 
      therapeutic options.
CI  - Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Laidlaw, Tanya M
AU  - Laidlaw TM
AD  - Department of Medicine, the Division of Allergy and Clinical Immunology, Brigham 
      and Women's Hospital, Harvard Medical School, Jeff and Penny Vinik Center for 
      Translational Immunology Research, Boston, Mass. Electronic address: 
      tlaidlaw@bwh.harvard.edu.
FAU - Boyce, Joshua A
AU  - Boyce JA
AD  - Department of Medicine, the Division of Allergy and Clinical Immunology, Brigham 
      and Women's Hospital, Harvard Medical School, Jeff and Penny Vinik Center for 
      Translational Immunology Research, Boston, Mass.
LA  - eng
GR  - R01 AI078908/AI/NIAID NIH HHS/United States
GR  - R01 AI136041/AI/NIAID NIH HHS/United States
GR  - R37 AI052353/AI/NIAID NIH HHS/United States
GR  - U19 AI095219/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220930
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (cysteinyl-leukotriene)
RN  - 0 (Leukotrienes)
SB  - IM
MH  - Animals
MH  - Cyclooxygenase 1
MH  - *Asthma, Aspirin-Induced
MH  - Aspirin/adverse effects
MH  - Leukotrienes
MH  - Inflammation
PMC - PMC9905222
MID - NIHMS1839874
OTO - NOTNLM
OT  - AERD
OT  - CRSwNP
OT  - leukotriene E4
OT  - mast cells
OT  - mechanisms
OT  - prostaglandin E2
COIS- Conflict of Interest: TM Laidlaw has served on scientific advisory boards for 
      GlaxoSmithKline and Sanofi-Genzyme, Novartis, and Regeneron. JA Boyce has served 
      on the advisory boards of Sanofi-Genzyme, Siolta Therapeutics, and Third Harmonic 
      Bio.
EDAT- 2022/10/03 06:00
MHDA- 2023/02/08 06:00
PMCR- 2024/02/01
CRDT- 2022/10/02 22:12
PHST- 2022/06/21 00:00 [received]
PHST- 2022/08/03 00:00 [revised]
PHST- 2022/08/10 00:00 [accepted]
PHST- 2024/02/01 00:00 [pmc-release]
PHST- 2022/10/03 06:00 [pubmed]
PHST- 2023/02/08 06:00 [medline]
PHST- 2022/10/02 22:12 [entrez]
AID - S0091-6749(22)01171-X [pii]
AID - 10.1016/j.jaci.2022.08.021 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2023 Feb;151(2):301-309. doi: 10.1016/j.jaci.2022.08.021. 
      Epub 2022 Sep 30.

PMID- 20657891
OWN - NLM
STAT- MEDLINE
DCOM- 20101007
LR  - 20191111
IS  - 0048-7449 (Print)
IS  - 0048-7449 (Linking)
VI  - 62
IP  - 2
DP  - 2010 Apr-Jun
TI  - [A short history of anti-rheumatic therapy. II. Aspirin].
PG  - 148-56
AB  - The discovery of aspirin, an antipyretic, anti-inflammatory and analgesic drug, 
      undoubtedly represents a milestone in the history of medical therapy. Since 
      ancient times the derivatives of willow (Salix alba) were used to treat a variety 
      of fevers and pain syndromes, although the first report dates back to 1763 when 
      the English Reverend Edward Stone described the effect of an extract of the bark 
      willow in treating malaria. In the XIX century many apothecaries and chemists, 
      including the Italian Raffaele Piria and Cesare Bertagnini, developed the 
      biological processes of extraction and chemical synthesis of salicylates, and 
      then analyzed their therapeutic properties and pharmacokinetic and 
      pharmacodynamic characteristics. In 1899 the Bayer Company, where Felix Hoffmann, 
      Heinrich Dreser and Arthur Eichengrün worked, recorded acetyl-salicylic acid 
      under the name "Aspirin". In the XX century, besides the definition of the 
      correct applications of aspirin in the anti-rheumatic therapy being defined, 
      Lawrence L. Crawen identified the property of this drug as an anti-platelet 
      agent, thus opening the way for more widespread uses in cardiovascular diseases.
FAU - Pasero, G
AU  - Pasero G
AD  - Università di Pisa, Italia.
FAU - Marson, P
AU  - Marson P
LA  - ita
PT  - Historical Article
PT  - Journal Article
PT  - Portrait
TT  - Piccola storia della terapia antireumatica. II. L'aspirina.
PL  - Italy
TA  - Reumatismo
JT  - Reumatismo
JID - 0401302
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Plant Extracts)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*history/therapeutic use
MH  - Aspirin/*history/therapeutic use
MH  - England
MH  - France
MH  - Germany
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Italy
MH  - Phytotherapy
MH  - Plant Bark
MH  - Plant Extracts
MH  - Rheumatic Diseases/drug therapy/*history
MH  - Salicylates/history
MH  - Salix
MH  - United States
EDAT- 2010/07/27 06:00
MHDA- 2010/10/12 06:00
CRDT- 2010/07/27 06:00
PHST- 2010/07/27 06:00 [entrez]
PHST- 2010/07/27 06:00 [pubmed]
PHST- 2010/10/12 06:00 [medline]
AID - 10.4081/reumatismo.2010.148 [doi]
PST - ppublish
SO  - Reumatismo. 2010 Apr-Jun;62(2):148-56. doi: 10.4081/reumatismo.2010.148.

PMID- 1099526
OWN - NLM
STAT- MEDLINE
DCOM- 19751204
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 56
IP  - 3
DP  - 1975 Sep
TI  - Aspirin intolerance in chronic childhood asthma: Detected by oral challenge.
PG  - 443-8
AB  - Most previously reported individuals with acetylsalicylic acid (aspirin, 
      ASA)-induced asthma have been adults. This study was undertaken to define the 
      prevalence of ASA intolerance among children with intractable asthma. Fifty 
      children (34 boys and 16 girls) ranging in age from 6 to 18 years with extrinsic 
      (atopic) asthma were studied. None had a history of ASA sensitivity or nasal 
      polyps; all required continuous medication including cromolyn sodium and daily or 
      intermittent steroids. Anti-asthmatic medications were stopped 12 hours prior to 
      testing. At the same time of day, each subject, in a doubleblind manner, on two 
      separate days, ingested either 300 mg of ASA or 100 mg of lactose (placebo). 
      Measurements of FVC, FEV1, and FEF25-75 were obtained prior to challenge and one 
      half, one, two, three, and four hours after. ASA intolerance required a decrease 
      of 30% in lung function with ASA as compared to placebo. Fourteen of 50 (28%) 
      were ASA-intolerant; a greater number were girls, and they had more sinusitis and 
      an onset of disease prior to 2 years of age. Steroid dependency, frequency of 
      eczema, nasal eosinophilia, serum IgE levels, and peripheral eosinophil counts 
      did not differ between the two groups. The use of aspirin in childhood asthma 
      should be limited.
FAU - Rachelefsky, G S
AU  - Rachelefsky GS
FAU - Coulson, A
AU  - Coulson A
FAU - Siegel, S C
AU  - Siegel SC
FAU - Stiehm, E R
AU  - Stiehm ER
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/adverse effects/*immunology
MH  - Asthma/chemically induced/*immunology
MH  - California
MH  - Child
MH  - Clinical Trials as Topic
MH  - Drug Hypersensitivity/*epidemiology
MH  - Female
MH  - Humans
MH  - Lung Volume Measurements
MH  - Male
MH  - Placebos
MH  - Sex Factors
EDAT- 1975/09/01 00:00
MHDA- 1975/09/01 00:01
CRDT- 1975/09/01 00:00
PHST- 1975/09/01 00:00 [pubmed]
PHST- 1975/09/01 00:01 [medline]
PHST- 1975/09/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1975 Sep;56(3):443-8.

PMID- 8255837
OWN - NLM
STAT- MEDLINE
DCOM- 19940112
LR  - 20190501
IS  - 0032-5473 (Print)
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 69
IP  - 815
DP  - 1993 Sep
TI  - Gastro-duodenal injury associated with intake of 100-325 mg aspirin daily.
PG  - 712-4
AB  - During the year 1991, 43 patients with upper gastrointestinal bleeding and one 
      with severe epigastric pain associated with intake of non-steroidal 
      anti-inflammatory drugs were admitted for emergency endoscopy to our unit. 
      Fourteen patients (33%) had been treated with 100-325 mg aspirin daily, 11 of 
      them for at least one year. The mean age of this group was 71. Only two patients 
      had a previous history of peptic ulcer. Five patients used anticoagulants or 
      antiplatelet drugs concomitantly with aspirin. The endoscopic diagnosis of the 
      sources of bleeding was erosive gastritis in eight patients, gastric ulcer in 
      four, duodenal ulcer in five and oesophageal ulcer in one. Our results support 
      findings by other groups, showing that doses of aspirin as low as 75 mg daily 
      should be used in the management of elderly patients with thrombo-embolic 
      disease.
FAU - Oren, R
AU  - Oren R
AD  - Gastroenterology Service, Hadassah University Hospital, Jerusalem, Israel.
FAU - Ligumsky, M
AU  - Ligumsky M
FAU - Lysy, J
AU  - Lysy J
FAU - Gonzales, J
AU  - Gonzales J
FAU - Zimmerman, J
AU  - Zimmerman J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Duodenal Ulcer/chemically induced
MH  - Female
MH  - Gastritis/chemically induced
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Stomach Ulcer/chemically induced
PMC - PMC2399780
EDAT- 1993/09/01 00:00
MHDA- 1993/09/01 00:01
CRDT- 1993/09/01 00:00
PHST- 1993/09/01 00:00 [pubmed]
PHST- 1993/09/01 00:01 [medline]
PHST- 1993/09/01 00:00 [entrez]
AID - 10.1136/pgmj.69.815.712 [doi]
PST - ppublish
SO  - Postgrad Med J. 1993 Sep;69(815):712-4. doi: 10.1136/pgmj.69.815.712.

PMID- 3931514
OWN - NLM
STAT- MEDLINE
DCOM- 19851112
LR  - 20131121
IS  - 0002-9645 (Print)
IS  - 0002-9645 (Linking)
VI  - 46
IP  - 9
DP  - 1985 Sep
TI  - Effects of aspirin and propranolol on feline platelet aggregation.
PG  - 1820-3
AB  - Three groups of cats were given aspirin in single dosages of 5, 10, and 25 mg/kg. 
      A 4th group was given 2 dosages of 25 mg/kg, 3 days between doses. The degree of 
      inhibition of platelet function and the duration of antagonism to platelet 
      aggregation were studied. The dosage of 25 mg/kg (single and repeated) 
      consistently inhibited platelet function, and the effects lasted 3 to 5 days. 
      Additive drug effect was not noted in group 4, since the 2nd dosage antagonized 
      platelet function to a degree and duration similar to the effects of the 1st. The 
      dosage of aspirin recommended for antiplatelet activity in the average-sized cat 
      (3 kg) equals approximately 1 pediatric aspirin (90 mg) given twice a week. 
      Propranolol, given to cats at dosages of 2.5 to 15 mg had no effect on platelet 
      aggregation.
FAU - Greene, C E
AU  - Greene CE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 0 (Arachidonic Acids)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 9Y8NXQ24VQ (Propranolol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Cats/*blood
MH  - Depression, Chemical
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Propranolol/*pharmacology
EDAT- 1985/09/01 00:00
MHDA- 1985/09/01 00:01
CRDT- 1985/09/01 00:00
PHST- 1985/09/01 00:00 [pubmed]
PHST- 1985/09/01 00:01 [medline]
PHST- 1985/09/01 00:00 [entrez]
PST - ppublish
SO  - Am J Vet Res. 1985 Sep;46(9):1820-3.

PMID- 340334
OWN - NLM
STAT- MEDLINE
DCOM- 19780329
LR  - 20181130
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 74
IP  - 2 Pt 2
DP  - 1978 Feb
TI  - Reduction of aspirin-induced gastrointestinal bleeding with cimetidine.
PG  - 459-63
AB  - Aspirin induces gastric mucosal damage and bleeding in the presence of acid. 
      Cimetidine, the histamine H2-receptor antagonist, reduces basal and stimulated 
      acid secretion. Arthritic patients taking fixed doses of aspirin who were found 
      to have aspirin-induced occult gastrointestinal bleeding were given cimetidine in 
      a randomized double blind, crossover study. Autologous 51Cr-labeled blood was 
      measured in 4-day stool collections at the end of each 4-week period of placebo 
      and cimetidine therapy in 22 acid-producing patients. Mean daily fecal blood loss 
      was reduced during cimetidine therapy to 2.2 +/- 0.3 ml per day, compared with 
      4.1 +/- 0.7 ml per day during placebo therapy (P= 0.002).
FAU - Welch, R W
AU  - Welch RW
FAU - Bentch, H L
AU  - Bentch HL
FAU - Harris, S C
AU  - Harris SC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Guanidines)
RN  - 0 (Placebos)
RN  - 80061L1WGD (Cimetidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis/drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cimetidine/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Gastric Juice/metabolism
MH  - Gastrointestinal Hemorrhage/chemically induced/metabolism/*prevention & control
MH  - Guanidines/*therapeutic use
MH  - Humans
MH  - Placebos
EDAT- 1978/02/01 00:00
MHDA- 1978/02/01 00:01
CRDT- 1978/02/01 00:00
PHST- 1978/02/01 00:00 [pubmed]
PHST- 1978/02/01 00:01 [medline]
PHST- 1978/02/01 00:00 [entrez]
AID - S0016508578000347 [pii]
PST - ppublish
SO  - Gastroenterology. 1978 Feb;74(2 Pt 2):459-63.

PMID- 36122518
OWN - NLM
STAT- MEDLINE
DCOM- 20221212
LR  - 20221212
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 155
DP  - 2022 Nov
TI  - Xiaojianzhong decoction attenuates gastric mucosal injury by activating the 
      p62/Keap1/Nrf2 signaling pathway to inhibit ferroptosis.
PG  - 113631
LID - S0753-3322(22)01020-4 [pii]
LID - 10.1016/j.biopha.2022.113631 [doi]
AB  - Gastric mucosal injury is the initial stage of the occurrence and development of 
      gastric diseases. Oxidative stress and ferroptosis caused by the imbalance of 
      redox and iron dynamics in gastric mucosal epithelial cells are present 
      throughout the occurrence and development of gastric mucosal injury. Therefore, 
      the inhibition of oxidative stress and ferroptosis is a potential target for the 
      treatment of the gastric mucosal injury. Xiaojianzhong decoction (XJZ), which 
      consists of six Chinese herbal medicines and extracts, is used for the treatment 
      of diseases related to gastrointestinal mucosal injury; however, its specific 
      mechanism of action has yet to be clarified. In this study, we clarified the 
      protective effect of XJZ on gastric mucosa and revealed its underlying mechanism. 
      We established a gastric mucosal injury model using aspirin and administered XJZ. 
      Furthermore, we systematically evaluated the mucosal injury and examined the 
      expression of genes related to oxidative stress, ferroptosis, and inflammation. 
      The study found that XJZ significantly counteracted aspirin-induced gastric 
      mucosal injury and inhibited oxidative stress and ferroptosis in mice. Upon 
      examining SQSTM1/p62(p62)/Kelch-like ECH-associated protein 1 (Keap1)/Nuclear 
      Factor erythroid 2-Related Factor 2 (Nrf2), a well-known signaling pathway 
      involved in the regulation of oxidative stress and ferroptosis, we found that its 
      activation was significantly inhibited by aspirin treatment and that this 
      signaling pathway was activated after XJZ intervention. Our study suggests that 
      XJZ may inhibit aspirin induced oxidative stress and ferroptosis via the 
      p62/Keap1/Nrf2 signaling pathway, thereby attenuating gastric mucosal injury.
CI  - Copyright © 2022. Published by Elsevier Masson SAS.
FAU - Chen, Juan
AU  - Chen J
AD  - College of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang 
      712046, PR China; Key Laboratory of Gastrointestinal Diseases and Prescriptions 
      in Shaanxi Province, Shaanxi University of Chinese Medicine, Xianyang 712046, PR 
      China. Electronic address: 1447984660@qq.com.
FAU - Zhang, Jiaxiang
AU  - Zhang J
AD  - College of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang 
      712046, PR China; Key Laboratory of Gastrointestinal Diseases and Prescriptions 
      in Shaanxi Province, Shaanxi University of Chinese Medicine, Xianyang 712046, PR 
      China. Electronic address: 2072170949@qq.com.
FAU - Chen, Ting
AU  - Chen T
AD  - College of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang 
      712046, PR China; Key Laboratory of Gastrointestinal Diseases and Prescriptions 
      in Shaanxi Province, Shaanxi University of Chinese Medicine, Xianyang 712046, PR 
      China. Electronic address: 1059963642@qq.com.
FAU - Bao, Shengchuan
AU  - Bao S
AD  - College of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang 
      712046, PR China; Key Laboratory of Gastrointestinal Diseases and Prescriptions 
      in Shaanxi Province, Shaanxi University of Chinese Medicine, Xianyang 712046, PR 
      China. Electronic address: bsc00724213@163.com.
FAU - Li, Jingtao
AU  - Li J
AD  - Department of General Surgery, The Affliated Hospital of Shaanxi University of 
      Chinese Medicine, Xianyang 712000, PR China. Electronic address: 
      lijingtao555@163.com.
FAU - Wei, Hailiang
AU  - Wei H
AD  - Departments of Infectious Disease, The Affliated Hospital of Shaanxi University 
      of Chinese Medicine, Xianyang 712000, PR China. Electronic address: 
      86888694@qq.com.
FAU - Hu, Xin
AU  - Hu X
AD  - State Forestry and Grassland Administration Engineering Research Center of Fu 
      Tea, Xianyang 712044, Shaanxi, PR China. Electronic address: 
      sysu-huxin@hotmail.com.
FAU - Liang, Yan
AU  - Liang Y
AD  - State Forestry and Grassland Administration Engineering Research Center of Fu 
      Tea, Xianyang 712044, Shaanxi, PR China. Electronic address: lianyan5517@126.com.
FAU - Liu, Fanrong
AU  - Liu F
AD  - Department of Gastroenterology, Yulin Hospital of Traditional Chinese Medicine in 
      Shaanxi Province, Yulin 719000, PR China. Electronic address: 
      lfr13669149300@163.com.
FAU - Yan, Shuguang
AU  - Yan S
AD  - College of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang 
      712046, PR China; Key Laboratory of Gastrointestinal Diseases and Prescriptions 
      in Shaanxi Province, Shaanxi University of Chinese Medicine, Xianyang 712046, PR 
      China. Electronic address: ysg2002.student@sina.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220916
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - R16CO5Y76E (Aspirin)
RN  - E1UOL152H7 (Iron)
RN  - 0 (Keap1 protein, mouse)
RN  - 0 (Kelch-Like ECH-Associated Protein 1)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Sequestosome-1 Protein)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Aspirin/pharmacology/metabolism
MH  - *Ferroptosis
MH  - Gastric Mucosa/metabolism
MH  - Iron/metabolism
MH  - Kelch-Like ECH-Associated Protein 1/metabolism
MH  - NF-E2-Related Factor 2/metabolism
MH  - Oxidative Stress
MH  - Sequestosome-1 Protein/metabolism
MH  - Signal Transduction
MH  - *Stomach Diseases
OTO - NOTNLM
OT  - Aspirin
OT  - Ferroptosis
OT  - Oxidative stress
OT  - Xiaojianzhong decoction
OT  - p62/Keap1/Nrf2 signaling pathway
COIS- Conflict of interest The author declares no conflict of interest.
EDAT- 2022/09/20 06:00
MHDA- 2022/10/22 06:00
CRDT- 2022/09/19 18:21
PHST- 2022/06/25 00:00 [received]
PHST- 2022/08/24 00:00 [revised]
PHST- 2022/08/30 00:00 [accepted]
PHST- 2022/09/20 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
PHST- 2022/09/19 18:21 [entrez]
AID - S0753-3322(22)01020-4 [pii]
AID - 10.1016/j.biopha.2022.113631 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2022 Nov;155:113631. doi: 10.1016/j.biopha.2022.113631. Epub 
      2022 Sep 16.

PMID- 9579285
OWN - NLM
STAT- MEDLINE
DCOM- 19980701
LR  - 20131121
IS  - 0362-5664 (Print)
IS  - 0362-5664 (Linking)
VI  - 21
IP  - 1
DP  - 1998 Jan-Feb
TI  - Intravenously administered acetylsalicylic acid in combination with low-dose 
      heparin in acute ischemic stroke: a safety analysis.
PG  - 48-51
AB  - Although therapy with acetylsalicylic acid (aspirin, ASA) is well established in 
      secondary prevention of stroke, efficacy and side effects of this substance in 
      acute stroke treatment are undetermined. ASA may be useful in acute cerebral 
      ischemia because of its potential to prevent thrombus propagation and neuronal 
      damage. A total of 268 patients with an acute cerebral ischemia, who were 
      admitted to our stroke unit within 24 hours after stroke, were treated with 
      intravenously administered ASA (0.5 g/day) in combination with low-dose heparin. 
      The functional status of the patients was assessed after 1 month using the 
      modified Rankin Scale. Eighteen (6.7%) patients died during the observation 
      period. The functional status according to Rankin Scale was classified as stage 0 
      in 76 (28.3%), 1 in 59 (22.0%), 2 in 39 (14.6%), 3 in 32 (12.3%), 4 in 36 
      (13.4%), and 5 in 7 (2.6%) patients. A symptomatic secondary intracerebral 
      hemorrhage was seen in one patient. Gastrointestinal symptoms were observed in 13 
      (4.8%) patients, including five instances of gastrointestinal bleeding. Further 
      complications were allergic reactions to aspirin (one) and hematuria (one). 
      Recurrent cerebral ischemia occurred in nine (3.3%) patients (five with transient 
      ischemic attack or minor stroke) during the observation period. We conclude that 
      treatment of acute ischemic stroke with intravenously applied aspirin in 
      combination with low-dose heparin is safe. Efficacy of this therapy should be 
      elucidated in a controlled trial.
FAU - Büttner, T
AU  - Büttner T
AD  - Department of Neurology, Ruhr-University, St. Josef-Hospital Bochum, Germany.
FAU - Hellwig, K
AU  - Hellwig K
FAU - Müller, T
AU  - Müller T
FAU - Kuhn, W
AU  - Kuhn W
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Neuropharmacol
JT  - Clinical neuropharmacology
JID - 7607910
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 1998/05/14 00:00
MHDA- 1998/05/14 00:01
CRDT- 1998/05/14 00:00
PHST- 1998/05/14 00:00 [pubmed]
PHST- 1998/05/14 00:01 [medline]
PHST- 1998/05/14 00:00 [entrez]
PST - ppublish
SO  - Clin Neuropharmacol. 1998 Jan-Feb;21(1):48-51.

PMID- 16340173
OWN - NLM
STAT- MEDLINE
DCOM- 20060123
LR  - 20190727
IS  - 0040-8727 (Print)
IS  - 0040-8727 (Linking)
VI  - 208
IP  - 1
DP  - 2006 Jan
TI  - Lack of an association between a newly identified promoter polymorphism (-1702G > 
      A) of the leukotriene C4 synthase gene and aspirin-intolerant asthma in a Korean 
      population.
PG  - 49-56
AB  - Aspirin-intolerant asthma (AIA) is a distinct clinical syndrome that refers to 
      the development of bronchoconstriction in asthmatic individuals following the 
      ingestion of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). It 
      is widely recognized that increased cysteinyl leukotriene (cysLT) biosynthesis is 
      associated with the development and progression of AIA. Leukotriene C4 synthase 
      (LTC4S) is the terminal enzyme in cysLT production and is a strong candidate gene 
      in the pathogenesis of aspirin-intolerant asthma (AIA). In this paper, we report 
      a new single nucleotide polymorphism (SNP) of the LTC4S promoter, -1702G>A, in 
      AIA patients and evaluate its genetic role in the association with the LTC4S-444 
      A>C polymorphism. We enrolled 110 AIA patients, 125 aspirin-tolerant asthma (ATA) 
      patients, and 125 normal controls. SNP genotyping of the LTC4S-1702G>A and 
      -444A>C polymorphisms was performed using SNP-IT assays. Haplotype analyses were 
      performed using Haploview version 2.05, which is based on an 
      estimation-maximization (EM) algorithm. There were no significant differences in 
      the allele or genotype frequencies of the LTC4S-1702G>A and -444A>C polymorphisms 
      among the three groups (p > 0.05), with no significant differences in the 
      observed haplotype frequencies (p > 0.05). Moreover, no significant associations 
      were found between the genotype of each SNP in AIA patients with the clinical 
      characteristics, including a forced expiratory volume in one second (FEV1) %, a 
      provocation concentration of methacholine to induce more than 20% decrease of 
      FEV1 (PC20) to methacholine, and serum total IgE levels (p > 0.05). These results 
      indicate that there is no association between these two promoter polymorphisms of 
      LTC4S and the phenotype of AIA in a Korean population.
FAU - Choi, Jeong-Hee
AU  - Choi JH
AD  - Department of Pulmonology and Allergies, Bundang Jesaeng General Hospital, 
      Seongnam, Korea.
FAU - Kim, Seung-Hyun
AU  - Kim SH
FAU - Bae, Jin-Sik
AU  - Bae JS
FAU - Yu, Hong-Lei
AU  - Yu HL
FAU - Suh, Chang-Hee
AU  - Suh CH
FAU - Nahm, Dong-Ho
AU  - Nahm DH
FAU - Park, Hae-Sim
AU  - Park HS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Tohoku J Exp Med
JT  - The Tohoku journal of experimental medicine
JID - 0417355
RN  - EC 2.5.1.18 (Glutathione Transferase)
RN  - EC 4.4.1.20 (leukotriene-C4 synthase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Aspirin/adverse effects/immunology
MH  - *Asthma/chemically induced/genetics
MH  - Female
MH  - Glutathione Transferase/*genetics
MH  - Humans
MH  - Korea
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
MH  - *Promoter Regions, Genetic
EDAT- 2005/12/13 09:00
MHDA- 2006/01/24 09:00
CRDT- 2005/12/13 09:00
PHST- 2005/12/13 09:00 [pubmed]
PHST- 2006/01/24 09:00 [medline]
PHST- 2005/12/13 09:00 [entrez]
AID - JST.JSTAGE/tjem/208.49 [pii]
AID - 10.1620/tjem.208.49 [doi]
PST - ppublish
SO  - Tohoku J Exp Med. 2006 Jan;208(1):49-56. doi: 10.1620/tjem.208.49.

PMID- 3232135
OWN - NLM
STAT- MEDLINE
DCOM- 19890417
LR  - 20131121
IS  - 0171-6425 (Print)
IS  - 0171-6425 (Linking)
VI  - 36
IP  - 6
DP  - 1988 Dec
TI  - Implantation of 20 cm long polyurethane vascular prostheses in the femoral artery 
      of dogs. Preliminary results.
PG  - 348-50
AB  - In a preliminary experiment externally reinforced polyurethane prostheses 
      measuring 20 cm in length, with an inner diameter of 3 mm, were implanted in a 
      loop in the femoral artery of six dogs. The dogs received 250 mg acetylsalicylic 
      acid and 25 mg dipyridamol three times a day as anti-thrombocyte aggregation 
      therapy starting three weeks prior to surgery. Anti-thrombocyte aggregation 
      therapy was continued throughout the study. All prostheses remained patent 8, 9, 
      15 and 17 months after implantation. Patency was confirmed by palpation and 
      Doppler ultrasound measurements. Preliminary results suggest that in clinically 
      relevant situations, these prostheses could function well over prolonged periods 
      of time.
FAU - Hess, F
AU  - Hess F
AD  - Laboratory for Cellbiology and Histology, University of Nijmegen, The 
      Netherlands.
FAU - Steeghs, S
AU  - Steeghs S
FAU - Jerusalem, C
AU  - Jerusalem C
FAU - Braun, B
AU  - Braun B
FAU - Grande, P
AU  - Grande P
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thorac Cardiovasc Surg
JT  - The Thoracic and cardiovascular surgeon
JID - 7903387
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - *Blood Vessel Prosthesis
MH  - Dipyridamole/therapeutic use
MH  - Dogs
MH  - Femoral Artery/*surgery
MH  - Vascular Patency
EDAT- 1988/12/01 00:00
MHDA- 1988/12/01 00:01
CRDT- 1988/12/01 00:00
PHST- 1988/12/01 00:00 [pubmed]
PHST- 1988/12/01 00:01 [medline]
PHST- 1988/12/01 00:00 [entrez]
AID - 10.1055/s-2007-1022979 [doi]
PST - ppublish
SO  - Thorac Cardiovasc Surg. 1988 Dec;36(6):348-50. doi: 10.1055/s-2007-1022979.

PMID- 31401653
OWN - NLM
STAT- MEDLINE
DCOM- 20200323
LR  - 20230214
IS  - 1938-3207 (Electronic)
IS  - 0002-9165 (Print)
IS  - 0002-9165 (Linking)
VI  - 110
IP  - 4
DP  - 2019 Oct 1
TI  - Folic acid supplementation and risk of colorectal neoplasia during long-term 
      follow-up of a randomized clinical trial.
PG  - 903-911
LID - 10.1093/ajcn/nqz160 [doi]
AB  - BACKGROUND: The Aspirin/Folate Polyp Prevention Study previously found folic acid 
      increased risk of advanced and multiple colorectal adenomas during a surveillance 
      colonoscopy interval starting about 3 y after randomization. OBJECTIVE: We 
      conducted secondary analyses to evaluate folic acid effects with additional 
      follow-up after treatment was stopped. METHODS: In total, 1021 participants 
      recently diagnosed with colorectal adenomas were randomly assigned to 1 mg/d of 
      folic acid (n = 516) or placebo (n = 505), with or without aspirin, beginning 6 
      July 1994. The original 3-y treatment period was extended into a subsequent 
      colonoscopy interval, but eventually stopped prematurely on 1 October 2004. With 
      additional post-treatment follow-up, a total of 663 participants who extended 
      treatment completed a second colonoscopic surveillance interval after the initial 
      3-y follow-up. In addition, 490 participants provided information regarding a 
      subsequent surveillance colonoscopy occurring before completion of follow-up on 
      31 May 2012, including 325 who had agreed to extended treatment. Study endpoints 
      included conventional adenomas, sessile serrated adenomas/polyps (SSA/Ps), or 
      colorectal cancer, and RRs with 95% CIs were adjusted for baseline 
      characteristics associated with availability of follow-up. RESULTS: Among those 
      who extended treatment, any colorectal neoplasia was found in 118 (36%) 
      participants assigned to placebo and 146 (43%) assigned to folic acid during the 
      second surveillance interval (RR: 1.21; 95% CI: 0.99, 1.47; P = 0.06). Increased 
      risk of SSA/P with extended folic acid supplementation was statistically 
      significant during the second surveillance interval (RR: 1.94; 95% CI: 1.02, 
      3.68; P = 0.04). There was no evidence of post-treatment effects for any 
      colorectal neoplasia (RR: 1.01; 95% CI: 0.80, 1.28; P = 0.94), and the 
      post-treatment effect for SSA/P was no longer statistically significant (RR: 
      1.38; 95% CI: 0.59, 3.19; P = 0.46). CONCLUSIONS: Delayed treatment effects were 
      not observed, but folic acid may increase SSA/P risk. This trial was registered 
      at clinicaltrials.gov as NCT00272324.
CI  - Copyright © American Society for Nutrition 2019.
FAU - Passarelli, Michael N
AU  - Passarelli MN
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, 
      USA.
FAU - Barry, Elizabeth L
AU  - Barry EL
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, 
      USA.
FAU - Rees, Judy R
AU  - Rees JR
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, 
      USA.
FAU - Mott, Leila A
AU  - Mott LA
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, 
      USA.
FAU - Zhang, Dongyu
AU  - Zhang D
AD  - Department of Oncology, Georgetown University School of Medicine, Washington, DC, 
      USA.
FAU - Ahnen, Dennis J
AU  - Ahnen DJ
AD  - Department of Medicine, University of Colorado School of Medicine, Denver, CO, 
      USA.
FAU - Bresalier, Robert S
AU  - Bresalier RS
AD  - Department of Gastroenterology, Hepatology, and Nutrition, University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Haile, Robert W
AU  - Haile RW
AD  - Population Health Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
FAU - McKeown-Eyssen, Gail
AU  - McKeown-Eyssen G
AD  - Dalla Lana School of Public Health, University of Toronto, Ontario, Canada.
FAU - Snover, Dale C
AU  - Snover DC
AD  - Department of Pathology, Fairview Southdale Hospital, Edina, MN, USA.
FAU - Cole, Bernard F
AU  - Cole BF
AD  - Department of Mathematics and Statistics, University of Vermont, Burlington, VT, 
      USA.
FAU - Baron, John A
AU  - Baron JA
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, 
      USA.
AD  - Department of Medicine, University of North Carolina School of Medicine, Chapel 
      Hill, NC, USA.
AD  - Department of Epidemiology, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill, NC, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00272324
GR  - P20 GM104416/GM/NIGMS NIH HHS/United States
GR  - R01 CA059005/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
RN  - 935E97BOY8 (Folic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology
MH  - Colorectal Neoplasms/*prevention & control
MH  - *Dietary Supplements
MH  - Female
MH  - Folic Acid/administration & dosage/*pharmacology
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Time Factors
PMC - PMC6766439
OTO - NOTNLM
OT  - clinical trial
OT  - colorectal adenoma
OT  - colorectal cancer
OT  - folic acid
OT  - sessile serrated adenoma/polyp
EDAT- 2019/08/12 06:00
MHDA- 2020/03/24 06:00
CRDT- 2019/08/12 06:00
PHST- 2019/01/07 00:00 [received]
PHST- 2019/06/27 00:00 [accepted]
PHST- 2019/08/12 06:00 [pubmed]
PHST- 2020/03/24 06:00 [medline]
PHST- 2019/08/12 06:00 [entrez]
AID - S0002-9165(22)01265-5 [pii]
AID - nqz160 [pii]
AID - 10.1093/ajcn/nqz160 [doi]
PST - ppublish
SO  - Am J Clin Nutr. 2019 Oct 1;110(4):903-911. doi: 10.1093/ajcn/nqz160.

PMID- 20980946
OWN - NLM
STAT- MEDLINE
DCOM- 20110310
LR  - 20170306
VI  - 120
IP  - 10
DP  - 2010 Oct
TI  - Aspirin chemoprevention of gastrointestinal cancer in the next decade. A review 
      of the evidence.
PG  - 407-12
LID - 497 [pii]
AB  - Together, gastrointestinal (GI) cancers now account for 25% of neoplastic deaths 
      in the West. In Poland, GI cancer rates are likely to increase further as 
      westernization progresses. Given that conventional cancer therapies have made 
      only modest reductions in cancer mortality, there is a great interest in 
      chemoprevention to prevent or slow malignant transformation from premalignant 
      lesions. The financial pressures in the immediate future require even more 
      stringent criteria for chemopreventive agents - they must be cheap but also safe 
      and efficacious. In this regard, several reviews have indicated that aspirin 
      possesses many favorable qualities for chemoprevention. Furthermore, 
      meta-analyses indicate that aspirin may decrease cancer by approximately 30%. 
      Several large clinical trials are underway, including AspECT (Aspirin and 
      Esomeprazole Chemoprevention Trial) that aims not only to prevent cancer but also 
      decrease the gastric side effects by combining aspirin with potent 
      acid-suppressing drugs. In conclusion, whether aspirin will be the world's first 
      proven chemopreventive agent is currently unknown but the evidence looks hopeful.
FAU - Jankowska, Helena
AU  - Jankowska H
AD  - Richard Hill School, Thurcaston, Leicestershire, United Kingdom.
FAU - Hooper, Patricia
AU  - Hooper P
FAU - Jankowski, Janusz A
AU  - Jankowski JA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Poland
TA  - Pol Arch Med Wewn
JT  - Polskie Archiwum Medycyny Wewnetrznej
JID - 0401225
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Chemoprevention
MH  - Gastrointestinal Neoplasms/*prevention & control
MH  - Humans
EDAT- 2010/10/29 06:00
MHDA- 2011/03/11 06:00
CRDT- 2010/10/29 06:00
PHST- 2010/10/29 06:00 [entrez]
PHST- 2010/10/29 06:00 [pubmed]
PHST- 2011/03/11 06:00 [medline]
AID - 497 [pii]
PST - ppublish
SO  - Pol Arch Med Wewn. 2010 Oct;120(10):407-12.

PMID- 16490462
OWN - NLM
STAT- MEDLINE
DCOM- 20060302
LR  - 20220330
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 119
IP  - 3
DP  - 2006 Mar
TI  - Aspirin to prevent heart attack and stroke: what's the right dose?
PG  - 198-202
AB  - Despite hundreds of clinical trials, the appropriate dose of aspirin to prevent 
      myocardial infarction (MI) and stroke is uncertain. In the US, the doses most 
      frequently recommended are 80, 160, or 325 mg per day. Because aspirin can cause 
      major bleeding, the appropriate dose is the lowest dose that is effective in 
      preventing both MI and stroke because these two diseases frequently co-exist. 
      Five randomized clinical trials have compared aspirin with placebo or no therapy 
      for the prevention of stroke and MI. These trials varied with regard to the dose 
      of aspirin, the duration of treatment, and, most important, the populations 
      selected for study varied in their baseline risk of stroke and MI. In men, 160 
      mg/day consistently lowered the risk of MI. In women, doses of 50 mg, 75, and 100 
      mg/day did not significantly decrease the risk of MI; therefore, the appropriate 
      dose in women must exceed 100 mg/day. The appropriate dose for the primary 
      prevention of stroke in men and women has not been established. Doses of 75 and 
      100 mg/day have been ineffective in men and women. The appropriate dose must be 
      at least 160 mg/day. The lowest dose to prevent recurrent MI or death in patients 
      with stable coronary artery disease (CAD) is 75 mg/day. In acute MI the lowest 
      dose is 160 mg/day. In patients with a history of stroke or transient ischemic 
      attack (TIA), 50 mg/day has been shown to be effective in men and women. In acute 
      stroke, 160 mg/day is effective in preventing recurrent stroke or death. The risk 
      of major bleeding with 160 mg/day is the same as with 80 mg/day: 1 to 2 cases per 
      1000 patient years of treatment, and the risk of fatal bleeding is the same with 
      80 and 160 mg/day. These studies indicate that the most appropriate dose for the 
      primary and secondary prevention of stroke and MI is 160 mg/day.
FAU - Dalen, James E
AU  - Dalen JE
AD  - University of Arizona, Tucson 85718, USA. jamesdalen@yahoo.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Med. 2007 Apr;120(4):e5; author reply e7. PMID: 17398214
CIN - Am J Med. 2007 Apr;120(4):e9. PMID: 17398216
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Primary Prevention/*organization & administration
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/*prevention & control
RF  - 21
EDAT- 2006/02/24 09:00
MHDA- 2006/03/03 09:00
CRDT- 2006/02/24 09:00
PHST- 2005/11/10 00:00 [received]
PHST- 2005/11/11 00:00 [accepted]
PHST- 2006/02/24 09:00 [pubmed]
PHST- 2006/03/03 09:00 [medline]
PHST- 2006/02/24 09:00 [entrez]
AID - S0002-9343(05)01079-X [pii]
AID - 10.1016/j.amjmed.2005.11.013 [doi]
PST - ppublish
SO  - Am J Med. 2006 Mar;119(3):198-202. doi: 10.1016/j.amjmed.2005.11.013.

PMID- 23971989
OWN - NLM
STAT- MEDLINE
DCOM- 20150302
LR  - 20181202
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 25
IP  - 5
DP  - 2014
TI  - PlaCor PRT measurement of shear-activated platelet aggregate formation in stable 
      patients treated with single and dual antiplatelet therapy.
PG  - 337-42
LID - 10.3109/09537104.2013.825710 [doi]
AB  - Shear forces play a key role in thrombus formation and shear-based tests may 
      better reflect physiological conditions in vivo compared with agonist-based 
      tests. We evaluated the PlaCor PRT®, a novel platelet reactivity test based on 
      shear-induced platelet aggregation, in patients with stable coronary artery 
      disease (CAD) treated with single (SAPT) and dual antiplatelet therapy (DAPT). We 
      examined 100 patients with multiple risk factors for CAD and/or documented stable 
      CAD: 38 treated with SAPT, aspirin 100 mg qd, 62 treated with DAPT, aspirin 
      100 mg + clopidogrel 75 mg qd, compared with age- and sex-matched healthy 
      volunteers without antiplatelet therapy (HV, n = 35). Measures of shear-induced 
      platelet aggregation were performed with the PlaCor PRT®. In 25 patients in SAPT, 
      the PlaCor test was also performed before and after a 12-hour-loading dose of 
      clopidogrel 600 mg. The mean ± SD PRT time (seconds) in HV was 78 ± 13 and was 
      significantly lower compared with SAPT (118 ± 16, p = 0.030) and to DAPT patients 
      (242 ± 11, p < 0.0001). A statistically significant difference was also reported 
      between SAPT and DAPT patients (p < 0.0001). After a loading dose of clopidogrel, 
      the PRT time of SAPT patients increased significantly from 112 ± 20 to 254 ± 17, 
      p < 0.0001. 2.7 and 26% of patients were considered as "poor responders" to 
      single and dual antiplatelet therapy, respectively. This study shows that in 
      patients with multiple risk factors for CAD and/or documented stable CAD, SAPT 
      and DAPT play an important role in reducing platelet aggregation mediated by 
      shear forces as evaluated with the novel PlaCor PRT®. Further studies will be 
      required to confirm and assess the extent of these findings in patients with 
      acute coronary syndromes.
FAU - Godino, Cosmo
AU  - Godino C
AD  - Cardio-Thoracic-Vascular Department, San Raffaele Institute , Milan , Italy.
FAU - Pavon, Anna Giulia
AU  - Pavon AG
FAU - Mangieri, Antonio
AU  - Mangieri A
FAU - Viani, Giacomo Maria
AU  - Viani GM
FAU - Galaverna, Stefano
AU  - Galaverna S
FAU - Spartera, Marco
AU  - Spartera M
FAU - Chieffo, Alaide
AU  - Chieffo A
FAU - Cappelletti, Alberto
AU  - Cappelletti A
FAU - Margonato, Alberto
AU  - Margonato A
FAU - Colombo, Antonio
AU  - Colombo A
LA  - eng
PT  - Journal Article
DEP - 20130823
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Blood Platelets/cytology/*drug effects
MH  - Blood Specimen Collection/*methods
MH  - Clopidogrel
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests/instrumentation/*methods
MH  - Risk Factors
MH  - Shear Strength
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Aggregation
OT  - aspirin
OT  - clopidogrel
OT  - platelets
OT  - shear stress
EDAT- 2013/08/27 06:00
MHDA- 2015/03/03 06:00
CRDT- 2013/08/27 06:00
PHST- 2013/08/27 06:00 [entrez]
PHST- 2013/08/27 06:00 [pubmed]
PHST- 2015/03/03 06:00 [medline]
AID - 10.3109/09537104.2013.825710 [doi]
PST - ppublish
SO  - Platelets. 2014;25(5):337-42. doi: 10.3109/09537104.2013.825710. Epub 2013 Aug 
      23.

PMID- 31226053
OWN - NLM
STAT- MEDLINE
DCOM- 20190708
LR  - 20190708
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 393
IP  - 10186
DP  - 2019 May 25
TI  - The rise and fall of aspirin in the primary prevention of cardiovascular disease.
PG  - 2155-2167
LID - S0140-6736(19)30541-0 [pii]
LID - 10.1016/S0140-6736(19)30541-0 [doi]
AB  - Aspirin is one of the most frequently used drugs worldwide and is generally 
      considered effective for the secondary prevention of cardiovascular disease. By 
      contrast, the role of aspirin in primary prevention of cardiovascular disease is 
      controversial. Early trials evaluating aspirin for primary prevention, done 
      before the turn of the millennium, suggested reductions in myocardial infarction 
      and stroke (although not mortality), and an increased risk of bleeding. In an 
      effort to balance the risks and benefits of aspirin, international guidelines on 
      primary prevention of cardiovascular disease have typically recommended aspirin 
      only when a substantial 10-year risk of cardiovascular events exists. However, in 
      2018, three large randomised clinical trials of aspirin for the primary 
      prevention of cardiovascular disease showed little or no benefit and have even 
      suggested net harm. In this narrative Review, we reappraise the role of aspirin 
      in primary prevention of cardiovascular disease, contextualising data from 
      historical and contemporary trials.
CI  - Copyright © 2019 Elsevier Ltd. All rights reserved.
FAU - Raber, Inbar
AU  - Raber I
AD  - Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA, USA.
FAU - McCarthy, Cian P
AU  - McCarthy CP
AD  - Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, USA.
FAU - Vaduganathan, Muthiah
AU  - Vaduganathan M
AD  - Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 
      Boston, MA, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 
      Boston, MA, USA.
FAU - Wood, David A
AU  - Wood DA
AD  - National Institute for Prevention and Cardiovascular Health, National University 
      of Ireland, Galway, Ireland; National Heart and Lung Institute, Imperial College, 
      London, UK.
FAU - Cleland, John G F
AU  - Cleland JGF
AD  - National Heart and Lung Institute, Imperial College, London, UK; Robertson Centre 
      for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, UK.
FAU - Blumenthal, Roger S
AU  - Blumenthal RS
AD  - Ciccarone Center for the Prevention of Cardiovascular Disease, Division of 
      Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, 
      Baltimore, MD, USA.
FAU - McEvoy, John W
AU  - McEvoy JW
AD  - National Institute for Prevention and Cardiovascular Health, National University 
      of Ireland, Galway, Ireland; Ciccarone Center for the Prevention of 
      Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns 
      Hopkins Medical Institutions, Baltimore, MD, USA; Division of Cardiology, 
      Department of Medicine, Saolta University Healthcare Group, University College 
      Hospital Galway, Galway, Ireland. Electronic address: 
      johnwilliam.mcevoy@nuigalway.ie.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Diabetic Angiopathies/prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Primary Prevention
MH  - Sex Factors
EDAT- 2019/06/22 06:00
MHDA- 2019/07/10 06:00
CRDT- 2019/06/22 06:00
PHST- 2019/02/19 00:00 [received]
PHST- 2019/03/04 00:00 [revised]
PHST- 2019/03/05 00:00 [accepted]
PHST- 2019/06/22 06:00 [entrez]
PHST- 2019/06/22 06:00 [pubmed]
PHST- 2019/07/10 06:00 [medline]
AID - S0140-6736(19)30541-0 [pii]
AID - 10.1016/S0140-6736(19)30541-0 [doi]
PST - ppublish
SO  - Lancet. 2019 May 25;393(10186):2155-2167. doi: 10.1016/S0140-6736(19)30541-0.

PMID- 17078596
OWN - NLM
STAT- MEDLINE
DCOM- 20061120
LR  - 20191210
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 35
IP  - 9 Spec No 1
DP  - 2006 Sep
TI  - [Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?].
PG  - 1S53-60
AB  - OBJECTIVES: Some studies have recently suggested a potential pharmacodynamic 
      interaction between aspirin and some non-selective non-steroidal 
      anti-inflammatory drugs (NSAIDs). We have evaluated the reality of this 
      pharmacodynamic interaction and analyse its clinical pertinence. METHODS: 
      Literature review (Medline search - December 2005). RESULTS: Several ex vivo 
      studies show that some non-selective NSAIDs can block the active site of Cox1 
      thus preventing aspirin from exerting its platelet anti-aggregating 
      cardio-preventive action. Cox2 selective molecules do not act at this site. The 
      few studies, mainly case reports, have analysed the potential loss of the 
      cardiovascular preventive benefit of aspirin in patients receiving concomitantly 
      non-selective anti-inflammatory drugs with controversial results. IN PRACTICE: It 
      seems necessary to know the existence of this pharmacodynamic interaction between 
      aspirin at a low dose and some non-selective anti-inflammatory drugs notably 
      ibuprofen and naproxen. In the absence of a clear clinical demonstration, it is 
      advisable to avoid the non-selective NSAIDs in patients treated with a low dose 
      of aspirin. It might be advisable to switch to an anti-aggregating treatment 
      other than aspirin (clopidrogel, etc.) in these cases. At the present time, 
      however, there are no data on which to base such a recommendation.
FAU - Flipo, René-Marc
AU  - Flipo RM
AD  - Service de Rhumatologie, CHU Roger Salengro, Lille 59000. rmflipo@chu-lille.fr
LA  - fre
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Review
TT  - Les AINS sont-ils susceptibles de compromettre l'efficacité cardiopréventive de 
      l'aspirine?
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57Y76R9ATQ (Naproxen)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Clopidogrel
MH  - Cohort Studies
MH  - Cyclooxygenase Inhibitors/*adverse effects/pharmacology
MH  - Drug Interactions
MH  - Follow-Up Studies
MH  - Humans
MH  - Ibuprofen/adverse effects/pharmacology/therapeutic use
MH  - MEDLINE
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Naproxen/adverse effects/pharmacology/therapeutic use
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Randomized Controlled Trials as Topic
MH  - Risk
MH  - Thromboxane B2/blood
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
MH  - Time Factors
RF  - 23
EDAT- 2006/11/03 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/11/03 09:00
PHST- 2006/11/03 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/11/03 09:00 [entrez]
AID - S0755-4982(06)74941-7 [pii]
PST - ppublish
SO  - Presse Med. 2006 Sep;35(9 Spec No 1):1S53-60.

PMID- 6362497
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20181130
IS  - 0002-9645 (Print)
IS  - 0002-9645 (Linking)
VI  - 44
IP  - 12
DP  - 1983 Dec
TI  - Effect of salicylates on intestinal secretion in calves given (intestinal loops) 
      Escherichia coli heat-stable enterotoxin.
PG  - 2221-5
AB  - The inhibitory effect of salicylates on intestinal secretion in 1- to 5-day-old 
      calves given Escherichia coli heat-stable enterotoxin (ST)-induced intestinal 
      fluid response was investigated. Purified ST was diluted in isotonic saline 
      solution to obtain 1:10, 1:25, 1:50, 1:75, and 1:100 dilutions. Each dilution (1 
      ml) was inoculated into ligated loops in the distal part of the jejunum of each 
      calf. Acetylsalicylic acid (aspirin) given orally (100 mg/kg) at 4 hours before 
      ST was inoculated did not substantially alter the intestinal fluid response to 
      ST. Sodium salicylate (IV) infusion, begun simultaneously when, or at 1 hour 
      after, ST was inoculated, significantly (P less than 0.05) decreased fluid 
      accumulation in those loops inoculated with ST dilutions of 1:25 or greater. The 
      sodium and potassium concentrations of the accumulated fluid did not differ 
      significantly between or within treatment groups. These results indicate that 
      sodium salicylate infusion may be beneficial in treating enterotoxic 
      colibacillosis in calves. Aspirin given orally at the dose used in the present 
      study, would not have any beneficial effect.
FAU - Wise, C M
AU  - Wise CM
FAU - Knight, A P
AU  - Knight AP
FAU - Lucas, M J
AU  - Lucas MJ
FAU - Morris, C J
AU  - Morris CJ
FAU - Ellis, R P
AU  - Ellis RP
FAU - Phillips, R W
AU  - Phillips RW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 0 (Enterotoxins)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cattle
MH  - Cattle Diseases/drug therapy
MH  - Diarrhea/drug therapy/veterinary
MH  - Enterotoxins/*pharmacology
MH  - *Escherichia coli
MH  - Intestinal Secretions/*drug effects/metabolism
MH  - Male
MH  - Mice
MH  - Osmolar Concentration
MH  - Salicylates/*pharmacology/therapeutic use
MH  - Salicylic Acid
EDAT- 1983/12/01 00:00
MHDA- 1983/12/01 00:01
CRDT- 1983/12/01 00:00
PHST- 1983/12/01 00:00 [pubmed]
PHST- 1983/12/01 00:01 [medline]
PHST- 1983/12/01 00:00 [entrez]
PST - ppublish
SO  - Am J Vet Res. 1983 Dec;44(12):2221-5.

PMID- 32809173
OWN - NLM
STAT- MEDLINE
DCOM- 20211026
LR  - 20211026
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 21
IP  - 2
DP  - 2021 Mar
TI  - The Use of Aspirin in Contemporary Primary Prevention of Atherosclerotic 
      Cardiovascular Diseases Revisited: The Increasing Need and Call for a 
      Personalized Therapeutic Approach.
PG  - 139-151
LID - 10.1007/s40256-020-00424-y [doi]
AB  - The use of aspirin has been widely accepted for the secondary prevention of 
      atherosclerotic cardiovascular disease (ASCVD) in all patient populations, as the 
      benefits linked to the reduction of clinical events outweigh the risk of major 
      bleeding. However, despite the undisputable, though modest, potential of aspirin 
      to reduce atherothrombotic events, its overall efficacy and safety in primary 
      ASCVD prevention remains debatable, despite being used for this purpose for 
      decades. The net clinical benefit of aspirin was brought into question by three 
      recent large contemporary randomized controlled trials evaluating its role in 
      various primary prevention populations (individuals with diabetes [ASCEND], an 
      elderly population [ASPREE], and middle-aged adults at high estimated 
      cardiovascular risk [ARRIVE]) and numerous large meta-analyses published during 
      the past year. As a result, the usual generalized recommendations for the use of 
      aspirin in patients with estimated intermediate to high ASCVD risk but without 
      overt ASCVD have already been removed from most international guidelines. Since 
      the primary prevention framework encompasses heterogenous groups of subjects with 
      variable absolute ASCVD risk, a more individualized approach based on the best 
      possible estimated ratio between the potential health benefits from fewer 
      atherothrombotic events and harms because of potential increases in major 
      bleeding is warranted in clinical practice. With this compromise, clinicians can 
      better decide on the personalized use of aspirin in patients at high risk of 
      major adverse cardiovascular events.
FAU - Fras, Zlatko
AU  - Fras Z
AUID- ORCID: 0000-0003-0442-6175
AD  - Division of Medicine, Department of Vascular Medicine, Centre for Preventive 
      Cardiology, University Medical Centre Ljubljana, Zaloška 7, 1525, Ljubljana, 
      Slovenia. zlatko.fras@kclj.si.
AD  - Medical Faculty, University of Ljubljana, Ljubljana, Slovenia. 
      zlatko.fras@kclj.si.
FAU - Sahebkar, Amirhossein
AU  - Sahebkar A
AD  - Halal Research Center of IRI, FDA, Tehran, Iran.
AD  - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
AD  - Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
FAU - Banach, Maciej
AU  - Banach M
AD  - Cardiovascular Research Centre, University of Zielona-Gora, Zielona Gora, Poland.
AD  - Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Atherosclerosis/*prevention & control
MH  - Cardiovascular Diseases/prevention & control
MH  - Diabetes Mellitus/epidemiology
MH  - Dose-Response Relationship, Drug
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Multicenter Studies as Topic
MH  - Neoplasms/prevention & control
MH  - Primary Prevention/*methods
MH  - Randomized Controlled Trials as Topic
EDAT- 2020/08/19 06:00
MHDA- 2021/10/27 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/10/27 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - 10.1007/s40256-020-00424-y [pii]
AID - 10.1007/s40256-020-00424-y [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2021 Mar;21(2):139-151. doi: 10.1007/s40256-020-00424-y.

PMID- 3537440
OWN - NLM
STAT- MEDLINE
DCOM- 19870113
LR  - 20170310
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 26
IP  - 9
DP  - 1986 Sep
TI  - [Prevention of recurrent myocardial infarcts by long-term aspirin therapy].
PG  - 66-70
AB  - Daily 500 mg doses of aspirin were shown to be sufficient to produce lasting (one 
      year long) inhibition of platelet aggregation. Two matched samples of 
      postmyocardial infarction patients were compared: 844 untreated controls and 570 
      patients treated with 500 mg aspirin daily for 1 year following myocardial 
      infarction. In the treated sample, the incidence of recurrent myocardial 
      infarction, including sudden death, dropped from 13.1 to 8.9%, coronary 
      mortality, including sudden death, from 7.2 to 4.7%, sudden death rate, from 3.2 
      to 1.9%, and total mortality, from 9.3 to 6.6%, as compared to the untreated 
      sample.
FAU - Khalfen, E Sh
AU  - Khalfen ESh
FAU - Ivanova, I A
AU  - Ivanova IA
LA  - rus
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Profilaktika povtornykh infarktov miokarda dlitel'nym priemom aspirina.
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Death, Sudden
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/mortality/*prevention & control
MH  - Patient Compliance
MH  - Recurrence
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 1986 Sep;26(9):66-70.

PMID- 9352057
OWN - NLM
STAT- MEDLINE
DCOM- 19980202
LR  - 20191102
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 25
IP  - 6
DP  - 1997 Nov
TI  - Validation of the heat treatment step used in the production of diaspirin 
      crosslinked hemoglobin (DCLHb) for viral inactivation--effect of crosslinking.
PG  - 521-6
AB  - Two experiments were performed to assess viral inactivation during the 
      crosslinking and heat treatment steps of the DCLHb manufacturing process. Stroma 
      free hemoglobin (SFHb) collected from a large scale manufacturing lot was tested 
      in a 1:680 scaled down system in which the key parameters used in the 
      manufacturing process were replicated. In the first study Porcine Parvovirus 
      (PPV), a non-enveloped virus, was used to assess inactivation, while in the 
      second study Bovine Viral Diarrhea Virus (BVDV), an enveloped virus, was 
      utilized. In both experiments, the SFHb solution was deoxygenated and an aliquot 
      of virus suspension was added. To initiate the crosslinking reaction, a solution 
      of bis (3,5-dibromosalicyl) fumarate (DBBF) in HEPES buffer was added to the test 
      solution. In both experiments the reaction times and the degree of crosslinking 
      were normal. After crosslinking, the reaction mixtures were heated to 74 +/- 1 
      degrees C over 30 minutes, held at 74 +/- 1 degrees C for 90 minutes, and cooled 
      to less than 10 degrees C over 30 minutes. In each experiment the degree of 
      crosslinking of final product was 100% and yield of hemoglobin recovery was 
      normal. Samples were removed prior to crosslinking, after crosslinking and 
      before, during and after heat treatment for determination of virus titer and 
      evaluation of key process parameters. The results from these experiments were 
      consistent with those obtained from the full scale manufacturing process for the 
      deoxygenation, crosslinking and the heat treatment step during the production of 
      DCLHb. The results of virus assays showed that crosslinking has no effect on 
      viruses and their subsequent inactivation by heat treatment.
FAU - Azari, M
AU  - Azari M
AD  - Blood Substitutes Program, Baxter Healthcare Corporation, Round Lake, Illinois 
      60073, USA.
FAU - Catarello, J
AU  - Catarello J
FAU - Burhop, K
AU  - Burhop K
FAU - Camacho, T
AU  - Camacho T
FAU - Ebeling, A
AU  - Ebeling A
FAU - Estep, T
AU  - Estep T
FAU - Guzder, S
AU  - Guzder S
FAU - Krause, K
AU  - Krause K
FAU - Marshall, T
AU  - Marshall T
FAU - Rohn, K
AU  - Rohn K
FAU - Sarajari, R
AU  - Sarajari R
FAU - Boose, J A
AU  - Boose JA
FAU - Gauvin, G
AU  - Gauvin G
FAU - Horner, R
AU  - Horner R
FAU - Lu, B
AU  - Lu B
FAU - Pearson, L
AU  - Pearson L
FAU - Vacante, D
AU  - Vacante D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/metabolism
MH  - Cattle
MH  - Cross-Linking Reagents/*metabolism
MH  - Diarrhea Viruses, Bovine Viral/*growth & development
MH  - Hemoglobins/*metabolism
MH  - *Hot Temperature
MH  - Parvovirus/*growth & development
MH  - Swine
MH  - *Viral Plaque Assay
EDAT- 1997/11/14 00:00
MHDA- 1997/11/14 00:01
CRDT- 1997/11/14 00:00
PHST- 1997/11/14 00:00 [pubmed]
PHST- 1997/11/14 00:01 [medline]
PHST- 1997/11/14 00:00 [entrez]
AID - 10.3109/10731199709117449 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1997 Nov;25(6):521-6. doi: 
      10.3109/10731199709117449.

PMID- 28280082
OWN - NLM
STAT- MEDLINE
DCOM- 20170320
LR  - 20200225
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 2017
DP  - 2017 Mar 9
TI  - Bumpy road to the diagnosis of polycythaemia vera.
LID - 10.1136/bcr-2016-218851 [doi]
LID - bcr2016218851
AB  - Polycythaemia vera (PV) is the most common myeloproliferative neoplasm, 
      characterised by increased red cell mass that can present as an unspecified 
      symptom or a thrombohaemorrhagic event. Its diagnosis is based on the presence of 
      erythrocytosis, the identification of the Janus kinase 2 mutation and bone marrow 
      aspirate or biopsy alterations. The challenge of this disease lies on the 
      treatment approach. Its cornerstone is phlebotomy, but depending on the vascular 
      risk, it can include cytoreductive agents, low-dose aspirin or even 
      anticoagulation. We present the case of a 75-year-old woman, whose inaugural 
      presentation of PV was an arterial peripheral occlusion followed by three 
      recurrent events in the same arterial region and a pulmonary embolism. A 
      phlebotomy was initially performed and, after the diagnosis was made, the patient 
      was initiated on low-dose aspirin and anticoagulation with favourable outcome.
CI  - 2017 BMJ Publishing Group Ltd.
FAU - Gameiro, Rita de Sousa
AU  - Gameiro RS
AD  - Medicina Interna, Hospital Beatriz Ângelo, Loures, Portugal.
FAU - Rodrigues, Ana
AU  - Rodrigues A
AD  - Medicina Interna, Hospital Beatriz Ângelo, Loures, Portugal.
FAU - Gonçalves, Fernando Martos
AU  - Gonçalves FM
AD  - Medicina Interna, Hospital Beatriz Ângelo, Loures, Portugal.
FAU - Graça, José Pimenta da
AU  - Graça JP
AD  - Medicina Interna, Hospital Beatriz Ângelo, Loures, Portugal.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20170309
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Female
MH  - Humans
MH  - Phlebotomy
MH  - Polycythemia Vera/complications/*diagnosis/*therapy
MH  - Pulmonary Embolism/*diagnosis
MH  - Treatment Outcome
PMC - PMC5353380
COIS- Competing interests: None declared.
EDAT- 2017/03/11 06:00
MHDA- 2017/03/21 06:00
CRDT- 2017/03/11 06:00
PHST- 2017/03/11 06:00 [entrez]
PHST- 2017/03/11 06:00 [pubmed]
PHST- 2017/03/21 06:00 [medline]
AID - bcr-2016-218851 [pii]
AID - 10.1136/bcr-2016-218851 [doi]
PST - epublish
SO  - BMJ Case Rep. 2017 Mar 9;2017:bcr2016218851. doi: 10.1136/bcr-2016-218851.

PMID- 21223644
OWN - NLM
STAT- MEDLINE
DCOM- 20110418
LR  - 20190513
IS  - 1945-239X (Electronic)
IS  - 0021-9665 (Linking)
VI  - 49
IP  - 2
DP  - 2011 Feb
TI  - Simultaneous determination of clopidogrel and aspirin by RP-HPLC from bulk 
      material and dosage formulations using multivariate calibration technique.
PG  - 165-9
AB  - A rapid, simple, and easy method for the simultaneous determination of 
      clopidogrel and aspirin from bulk material and dosage formulations in the 
      presence of meloxicam as internal standard has been developed. Separation was 
      carried out on a Purospher star C(18) (5 μm, 250 × 4.6 mm) column at ambient 
      temperature. The mobile phase consisted of methanol-water (80:20, v/v), the pH of 
      the mobile phase was adjusted to 3.4 with ortho-phosphoric acid and pumped at a 
      flow rate of 1 mL/min using isocratic pump system. Multivariate chromatographic 
      calibration technique was subjected to high-performance liquid chromatography 
      (HPLC) data for simultaneous quantitative analysis of binary mixtures of 
      clopidogrel and aspirin. HPLC data based on the analyte peak areas were obtained 
      at five wavelengths (225, 230, 235, 240, and 245 nm). The mathematical algorithm 
      of multivariate chromatographic calibration technique is based on the use of the 
      linear regression equations. Calibration plots for clopidogrel and aspirin were 
      constructed at each wavelength by using the peak areas corresponding to the 
      concentrations of each active compound. This multivariate chromatographic method 
      was also applied to a commercial pharmaceutical dosage form containing 
      clopidogrel and aspirin.
FAU - Sultana, Najma
AU  - Sultana N
AD  - Research Institute of Pharmaceutical Sciences, Department of Pharmaceutical 
      Chemistry, Faculty of Pharmacy, University of Karachi, Karachi-75270, Pakistan.
FAU - Arayne, Muhammad S
AU  - Arayne MS
FAU - Ali, Kiran A
AU  - Ali KA
FAU - Nawaz, Muhammad
AU  - Nawaz M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Chromatogr Sci
JT  - Journal of chromatographic science
JID - 0173225
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/chemistry
MH  - Calibration
MH  - Chemistry, Pharmaceutical
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Chromatography, Reverse-Phase/*methods
MH  - Clopidogrel
MH  - Linear Models
MH  - Multivariate Analysis
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Ticlopidine/*analogs & derivatives/analysis/chemistry
EDAT- 2011/01/13 06:00
MHDA- 2011/04/19 06:00
CRDT- 2011/01/13 06:00
PHST- 2011/01/13 06:00 [entrez]
PHST- 2011/01/13 06:00 [pubmed]
PHST- 2011/04/19 06:00 [medline]
AID - 10.1093/chrsci/49.2.165 [doi]
PST - ppublish
SO  - J Chromatogr Sci. 2011 Feb;49(2):165-9. doi: 10.1093/chrsci/49.2.165.

PMID- 8647365
OWN - NLM
STAT- MEDLINE
DCOM- 19960719
LR  - 20131121
IS  - 0016-5751 (Print)
IS  - 0016-5751 (Linking)
VI  - 56
IP  - 2
DP  - 1996 Feb
TI  - [-Is prevention of pre-eclampsia with low dosage aspirin possible? Critical 
      assessment of available studies-].
PG  - 88-92
AB  - The efficacy of low-dose aspirin treatment to prevent preeclampsia was assessed 
      by reviewing studies of the available literature. 9 studies were performed 
      examining nearly 13,000 pregnant women. Aspirin treatment compared with untreated 
      control groups led to a significant reduction of preeclampsia in 5 small-scale 
      studies. However, no prophylaxis could be achieved in 4 studies comprising more 
      than 12,000 pregnant women. A assessment of low-dose aspirin treatment is 
      difficult, since no dose-response study was performed to determine the optimal 
      dose; the duration of treatment--beginning and end--was not defined and the drug 
      risk for mother and child was not documented in accordance with GCP guidelines. 
      The major problem of all studies, however, consisted in the recruitment of the 
      patients since there are no easily performable and well-recognised screening 
      tests available to estimate the risk of preeclampsia. In conclusion, at present 
      no statement is possible if and under which conditions low-dose aspirin treatment 
      will be able to prevent preeclampsia.
FAU - Lippert, T H
AU  - Lippert TH
AD  - Sektion für Klinische Pharmakologie in Gynäkologie und Geburtshilfe an der 
      Universitäts-Frauenklinik Tübingen.
FAU - Mück, A O
AU  - Mück AO
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Review
TT  - Ist mit niedrigdosierter Aspirinbehandlung eine Prophylaxe der Pr-aeklampsie 
      m"oglich? Kritische Betrachtung der vorliegenden Studien.
PL  - Germany
TA  - Geburtshilfe Frauenheilkd
JT  - Geburtshilfe und Frauenheilkunde
JID - 0370732
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Pre-Eclampsia/etiology/*prevention & control
MH  - Pregnancy
MH  - Risk Factors
MH  - Treatment Outcome
RF  - 23
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - 10.1055/s-2007-1022248 [doi]
PST - ppublish
SO  - Geburtshilfe Frauenheilkd. 1996 Feb;56(2):88-92. doi: 10.1055/s-2007-1022248.

PMID- 26270593
OWN - NLM
STAT- MEDLINE
DCOM- 20161226
LR  - 20170519
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 27
IP  - 3
DP  - 2016
TI  - Aspirin response: Differences in serum thromboxane B2 levels between clinical 
      studies.
PG  - 196-202
LID - 10.3109/09537104.2015.1072147 [doi]
AB  - Serum thromboxane B2 (TxB2) is a specific marker of platelet inhibition by 
      aspirin. Yet, TxB2 levels differ by up to 10-fold between some aspirin-treated 
      patient cohorts. This study aimed to identify factors responsible for differences 
      in serum TxB2 between cohorts in the ADRIE study (n = 657) and the BOSTON study 
      (n = 678) of aspirin-treated cardiovascular patients originally tested with 
      different ELISA assays. TxB2 levels were assessed in representative subgroups of 
      the two cohorts (34 samples in BOSTON and 39 in ADRIE) by both ELISAs, as well as 
      liquid chromatography and tandem mass spectroscopy (MS). A multivariate analysis 
      was performed on the whole cohort database to identify determinants of the 
      difference of TxB2 levels between cohorts. There was no systematic bias between 
      the original ELISA TxB2 values and the MS values and the median difference was 
      small, 0.12 ng/ml, thus not explaining the difference between median TxB2 levels 
      in the two study populations (7 and 0.6 ng/ml in the ADRIE and BOSTON studies, 
      respectively). In the combined dataset of the ADRIE and BOSTON cohorts (n = 
      1342), body mass index, age, gender, aspirin dose, time from aspirin intake to 
      blood draw, NSAID intake, platelet count and C-reactive protein were 
      significantly associated with TxB2 levels. After adjustment for patient 
      characteristics, the difference between cohorts did not decrease. Unexplained 
      differences in serum TxB2 levels in different populations of aspirin-treated 
      cardiovascular patients suggest that further studies are needed to confirm the 
      role of serum TxB2 level as a prognostic factor or rather as a marker of 
      therapeutic observance.
FAU - Brun, Charlotte
AU  - Brun C
AD  - a Division of General Internal Medicine , Geneva University Hospitals , Geneva , 
      Switzerland .
AD  - b Geneva Platelet Group, University of Geneva School of Medicine , Geneva , 
      Switzerland .
FAU - Daali, Youssef
AU  - Daali Y
AD  - b Geneva Platelet Group, University of Geneva School of Medicine , Geneva , 
      Switzerland .
AD  - c Division of Clinical Pharmacology , Geneva University Hospitals , Geneva , 
      Switzerland .
FAU - Combescure, Christophe
AU  - Combescure C
AD  - d Division of Clinical Epidemiology , Geneva University Hospitals , Geneva , 
      Switzerland .
FAU - Zufferey, Anne
AU  - Zufferey A
AD  - b Geneva Platelet Group, University of Geneva School of Medicine , Geneva , 
      Switzerland .
FAU - Michelson, Alan D
AU  - Michelson AD
AD  - e Center for Platelet Research Studies, Division of Hematology/Oncology, Boston 
      Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School , 
      Boston , MA , USA .
FAU - Fontana, Pierre
AU  - Fontana P
AD  - b Geneva Platelet Group, University of Geneva School of Medicine , Geneva , 
      Switzerland .
AD  - f Division of Angiology and Haemostasis , Geneva University Hospitals , Geneva , 
      Switzerland , and.
FAU - Reny, Jean-Luc
AU  - Reny JL
AD  - b Geneva Platelet Group, University of Geneva School of Medicine , Geneva , 
      Switzerland .
AD  - g Division of Internal Medicine and Rehabilitation, Trois-Chêne, Department of 
      Internal Medicine, Rehabilitation and Geriatrics , Geneva University Hospitals , 
      Geneva , Switzerland.
FAU - Frelinger, Andrew L 3rd
AU  - Frelinger AL 3rd
AD  - e Center for Platelet Research Studies, Division of Hematology/Oncology, Boston 
      Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School , 
      Boston , MA , USA .
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150813
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Platelets. 2017 May;28(3):310-311. PMID: 27897081
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Biomarkers
MH  - Blood Platelets/drug effects/metabolism
MH  - Cardiovascular Diseases/blood/drug therapy
MH  - Chromatography, Liquid
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Tandem Mass Spectrometry
MH  - Thromboxane B2/*blood
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - blood platelets
OT  - cardiovascular diseases
OT  - cohort studies
OT  - thromboxane B2
EDAT- 2015/08/14 06:00
MHDA- 2016/12/27 06:00
CRDT- 2015/08/14 06:00
PHST- 2015/08/14 06:00 [entrez]
PHST- 2015/08/14 06:00 [pubmed]
PHST- 2016/12/27 06:00 [medline]
AID - 10.3109/09537104.2015.1072147 [pii]
AID - 10.3109/09537104.2015.1072147 [doi]
PST - ppublish
SO  - Platelets. 2016;27(3):196-202. doi: 10.3109/09537104.2015.1072147. Epub 2015 Aug 
      13.

PMID- 25140341
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20211021
IS  - 1537-744X (Electronic)
IS  - 2356-6140 (Print)
IS  - 1537-744X (Linking)
VI  - 2014
DP  - 2014
TI  - Extract of Antrodia camphorata exerts neuroprotection against embolic stroke in 
      rats without causing the risk of hemorrhagic incidence.
PG  - 686109
LID - 10.1155/2014/686109 [doi]
LID - 686109
AB  - In this study, the neuroprotective effect of an extract of Antrodia camphorata 
      (A. camphorata), a fungus commonly used in Chinese folk medicine for treatment of 
      viral hepatitis and cancer, alone or in combination with aspirin was investigated 
      in a rat embolic stroke model. An ischemic stroke was induced in rats by a 
      selective occlusion of the middle cerebral artery (MCA) with whole blood clots 
      and then orally treated with A. camphorata (0.25 and 0.75 g/kg/day) alone and 
      combined with aspirin (5 mg/kg/day). Sixty days later, the brains were removed, 
      sectioned, and stained with triphenyltetrazolium chloride and analysed by a 
      commercial image processing software program. Brain infarct volume, 
      neurobehavioral score, cerebral blood perfusion, and subarachnoid and 
      intracerebral hemorrhage incidence were perceived. In addition, potential 
      bleeding side effect of the combinative therapy was assessed by measuring 
      hemoglobin (Hb) content during intracerebral hemorrhage and gastric bleeding, 
      prothrombin time (PT), and occlusion time (OT) after oral administration. 
      Posttreatment with high dose A. camphorata significantly reduced infarct volume 
      and improved neurobehavioral score (P < 0.05). Since A. camphorata alone or with 
      aspirin did not alter the Hb level, this treatment is safe and does not cause 
      hemorrhagic incident. Remarkably, the combination of A. camphorata and aspirin 
      did not show a significant effect on the bleeding time, PT and OT increase 
      suggesting that A. camphorata may have the neuroprotective effect without the 
      prolongation of bleeding time or coagulation time. From these observations, we 
      suggest that combinative therapy of A. camphorata and aspirin might offer 
      enhanced neuroprotective efficacies without increasing side effects.
FAU - Lee, Ye-Ming
AU  - Lee YM
AD  - Department of Surgery, Hsinchu Mackay Memorial Hospital, Hsinchu 300, Taiwan ; 
      Department of Nursing, Mackay Medicine, Nursing and Management College, Taipei 
      112, Taiwan ; Graduate Institute of Medical Sciences, College of Medicine, Taipei 
      Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan.
FAU - Chang, Chiu-Yun
AU  - Chang CY
AD  - Department of Anatomy, School of Medicine, Taipei Medical University, Taipei 110, 
      Taiwan.
FAU - Yen, Ting-Lin
AU  - Yen TL
AD  - Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical 
      University, 250 Wu-Hsing Street, Taipei 110, Taiwan.
FAU - Geraldine, Pitchairaj
AU  - Geraldine P
AD  - Department of Animal Science, School of Life Sciences, Tiruchirappalli, Tamil 
      Nadu 620 024, India.
FAU - Lan, Chang-Chou
AU  - Lan CC
AD  - Sheen Chain Biotechnology, Co., Ltd., Taipei 115, Taiwan.
FAU - Sheu, Joen-Rong
AU  - Sheu JR
AD  - Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical 
      University, 250 Wu-Hsing Street, Taipei 110, Taiwan.
FAU - Lee, Jie-Jen
AU  - Lee JJ
AD  - Department of Nursing, Mackay Medicine, Nursing and Management College, Taipei 
      112, Taiwan ; Graduate Institute of Medical Sciences, College of Medicine, Taipei 
      Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan ; Mackay Junior 
      College of Medicine, Nursing, and Management, Mackay Memorial Hospital, Taipei 
      112, Taiwan ; Department of Surgery, Mackay Memorial Hospital, No. 92, Section 2, 
      Zhongshan N. Road, Taipei 104, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140721
PL  - United States
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
RN  - 0 (Hemoglobins)
RN  - 0 (Neuroprotective Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antrodia/*chemistry
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Brain/*drug effects/pathology
MH  - Drug Therapy, Combination
MH  - Hemoglobins/metabolism
MH  - Hemorrhage/chemically induced
MH  - Male
MH  - Neuroprotective Agents/administration & dosage/adverse effects/isolation & 
      purification/*therapeutic use
MH  - Prothrombin Time
MH  - Rats, Wistar
MH  - Stroke/complications/*drug therapy
PMC - PMC4130302
EDAT- 2014/08/21 06:00
MHDA- 2015/05/12 06:00
CRDT- 2014/08/21 06:00
PHST- 2014/06/03 00:00 [received]
PHST- 2014/07/07 00:00 [accepted]
PHST- 2014/08/21 06:00 [entrez]
PHST- 2014/08/21 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - 10.1155/2014/686109 [doi]
PST - ppublish
SO  - ScientificWorldJournal. 2014;2014:686109. doi: 10.1155/2014/686109. Epub 2014 Jul 
      21.

PMID- 34949585
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20220131
IS  - 1755-5248 (Electronic)
IS  - 0012-6543 (Linking)
VI  - 60
IP  - 2
DP  - 2022 Feb
TI  - More evidence for low-dose aspirin in preventing pre-eclampsia.
PG  - 19
LID - 10.1136/dtb.2021.000071 [doi]
AB  - Overview of: Henderson JT, Vesco KK, Senger CA, et al Aspirin use to prevent 
      preeclampsia and related morbidity and mortality: updated evidence report and 
      systematic review for the US Preventive Services Task Force. JAMA 
      2021;326:1192-1206.
CI  - © BMJ Publishing Group Limited 2022. No commercial re-use. See rights and 
      permissions. Published by BMJ.
LA  - eng
PT  - Journal Article
DEP - 20211223
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Advisory Committees
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/drug therapy/prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - access
OT  - and evaluation
OT  - drug-related side effects and adverse reactions
OT  - health care quality
EDAT- 2021/12/25 06:00
MHDA- 2022/02/01 06:00
CRDT- 2021/12/24 05:33
PHST- 2021/12/25 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
PHST- 2021/12/24 05:33 [entrez]
AID - dtb.2021.000071 [pii]
AID - 10.1136/dtb.2021.000071 [doi]
PST - ppublish
SO  - Drug Ther Bull. 2022 Feb;60(2):19. doi: 10.1136/dtb.2021.000071. Epub 2021 Dec 
      23.

PMID- 710312
OWN - NLM
STAT- MEDLINE
DCOM- 19790124
LR  - 20131121
IS  - 0012-0472 (Print)
IS  - 0012-0472 (Linking)
VI  - 103
IP  - 47
DP  - 1978 Nov 24
TI  - [Heparin in the prevention of thromboembolism after elective hip-joint operations 
      (author's transl)].
PG  - 1877-81
AB  - Using the 125I-fibrinogen test, the antithrombotic effect of three different 
      heparin schedules was examined in 113 patients untergoing elective hip surgery. 
      Low-dose heparin (3 X 5000 IU/24 h) reduced the incidence of postoperative 
      thrombosis from 60% in the control subjects (not receiving any heparin) to 33%. 
      Combined low-dose heparin and acetylsalicyl-lysine, given intravenously, further 
      reduced the incidence slightly to 27%. Increasing the heparin dosage 
      postoperatively to 3 X 7500 IU/24 h effectively prevented the incidence of 
      thrombosis by reducing it to 11% in these high-risk patients.
FAU - Schöndorf, T H
AU  - Schöndorf TH
LA  - ger
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Thromboembolieprophylaxe mit Heparin bei elektiven Hüftgelenksoperationen.
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Female
MH  - Germany, West
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Hip Joint/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications
MH  - Pulmonary Embolism/prevention & control
MH  - Thromboembolism/*prevention & control
MH  - Thrombophlebitis/epidemiology
EDAT- 1978/11/24 00:00
MHDA- 1978/11/24 00:01
CRDT- 1978/11/24 00:00
PHST- 1978/11/24 00:00 [pubmed]
PHST- 1978/11/24 00:01 [medline]
PHST- 1978/11/24 00:00 [entrez]
AID - 10.1055/s-0028-1129361 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 1978 Nov 24;103(47):1877-81. doi: 10.1055/s-0028-1129361.

PMID- 32901573
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 1520-5762 (Electronic)
IS  - 0363-9045 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Preparation and characterization of polypills containing aspirin and simvastatin 
      using 3D printing technology for the prevention of cardiovascular diseases.
PG  - 1665-1675
LID - 10.1080/03639045.2020.1820034 [doi]
AB  - Three-dimensional (3D) printing has become a promising manufacturing technique 
      for pharmaceutical products. Fused deposition modeling (FDM) is the most 
      affordable printing technology. But this technique has two major drawbacks: 
      limited drug-loading capacity and the stability of thermolabile drugs. So, other 
      techniques such as melt casting could be associated with FDM to overcome these 
      limitations. In the melt casting method, the drug is mixed with a molten polymer 
      and is poured in the mold and allowed to solidify. The present study for the 
      first time describes the preparation of a multi-compartment polypill permits the 
      physical separation of incompatible drugs by combination of FDM and melt casting 
      techniques. A two-compartment polypill was made using FDM by Eudragit(®) L100-55 
      and simultaneously its compartments were filled by aspirin and simvastatin 
      containing molten PEG 6000. Simultaneous usage of FDM and melt casting techniques 
      could increase the drug-loading capacity of 3D-printed polypills. The low 
      temperatures used in melt casting and the absence of solvent in this method would 
      warrant the integrity of polypills, the complete separation of incompatible 
      drugs, and their stability. The prepared polypills showed good uniformity in drug 
      content which confirms the precision of FDM and melt casting techniques. Drug 
      interaction was investigated before and after the accelerated stability test 
      using DSC, which showed that 3D-printed polypills successfully preserved drugs 
      from the interaction. For the first time, this study demonstrates the feasibility 
      of the combination of FDM and melt casting techniques as an innovative platform 
      for CVD polypills production.
FAU - Keikhosravi, Niloufar
AU  - Keikhosravi N
AD  - Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, Faculty 
      of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Mirdamadian, Seyedeh Zahra
AU  - Mirdamadian SZ
AD  - Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, Faculty 
      of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Varshosaz, Jaleh
AU  - Varshosaz J
AD  - Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, Faculty 
      of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Taheri, Azade
AU  - Taheri A
AD  - Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, Faculty 
      of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - AGG2FN16EV (Simvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - *Cardiovascular Diseases
MH  - Humans
MH  - Printing, Three-Dimensional
MH  - Simvastatin/chemistry
MH  - *Technology, Pharmaceutical
OTO - NOTNLM
OT  - Eudragit L100-55
OT  - FDM 3D printing
OT  - cardiovascular disease
OT  - hot-melt extrusion
OT  - melt casting
OT  - polypills
EDAT- 2020/09/10 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/09/09 08:46
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
PHST- 2020/09/09 08:46 [entrez]
AID - 10.1080/03639045.2020.1820034 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 2020 Oct;46(10):1665-1675. doi: 
      10.1080/03639045.2020.1820034. Epub 2020 Sep 25.

PMID- 3622207
OWN - NLM
STAT- MEDLINE
DCOM- 19871020
LR  - 20190515
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 10
IP  - 4
DP  - 1987 Jul-Aug
TI  - Is aspirin use associated with lower rates of cataracts in diabetic individuals?
PG  - 495-9
AB  - The relationship between a history of aspirin use and cataracts in diabetic 
      individuals is examined in this report from a population-based study of 1370 
      individuals who developed diabetes after 30 yr of age. After pupil dilation 
      lenses were examined for the presence and severity of nuclear sclerotic and 
      posterior subcapsular cataracts and for surgical aphakia. A history of aspirin 
      usage was obtained. Seven hundred eighty-four individuals had used aspirin in the 
      month before the exam. There was no relationship between such usage and 
      cataracts. For 338 people who reported using aspirin daily for at least 3 mo 
      while having diabetes, there was also no association. These data suggest that 
      aspirin usage as measured here has little effect on the prevalence of cataract in 
      older-onset diabetic patients.
FAU - Klein, B E
AU  - Klein BE
FAU - Klein, R
AU  - Klein R
FAU - Moss, S E
AU  - Moss SE
LA  - eng
GR  - EY-03083/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cataract/etiology/*prevention & control
MH  - *Diabetes Complications
MH  - Humans
MH  - Middle Aged
MH  - Regression Analysis
EDAT- 1987/07/01 00:00
MHDA- 1987/07/01 00:01
CRDT- 1987/07/01 00:00
PHST- 1987/07/01 00:00 [pubmed]
PHST- 1987/07/01 00:01 [medline]
PHST- 1987/07/01 00:00 [entrez]
AID - 10.2337/diacare.10.4.495 [doi]
PST - ppublish
SO  - Diabetes Care. 1987 Jul-Aug;10(4):495-9. doi: 10.2337/diacare.10.4.495.

PMID- 1185735
OWN - NLM
STAT- MEDLINE
DCOM- 19760117
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 2
IP  - 1
DP  - 1975 Mar
TI  - Hospital-acquired salicylate intoxication. report of a case with psychosis, 
      acidosis, and coma.
PG  - 52-60
AB  - A case of salicylate intoxication from repeated therapeutic doses of aspirin is 
      reported in an adult with impairment of salicylate elimination. Evolution of 
      acid-base disturbance from respiratory alkalosis to metablic acidosis is 
      documented. Serum salicylate levels during several years of therapy demonstrate 
      the acquisition of impaired elimination of the drug. This case illustrates the 
      practical importance of special features of salicylate accumulation kinetics 
      emphasized in a recent review.
FAU - Good, A E
AU  - Good AE
FAU - Welch, M H
AU  - Welch MH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acidosis/*chemically induced
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*poisoning
MH  - Coma/*chemically induced
MH  - Hospitalization
MH  - Humans
MH  - Iatrogenic Disease
MH  - Male
MH  - Middle Aged
MH  - Psychoses, Substance-Induced/*etiology
EDAT- 1975/03/01 00:00
MHDA- 1975/03/01 00:01
CRDT- 1975/03/01 00:00
PHST- 1975/03/01 00:00 [pubmed]
PHST- 1975/03/01 00:01 [medline]
PHST- 1975/03/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1975 Mar;2(1):52-60.

PMID- 10834181
OWN - NLM
STAT- MEDLINE
DCOM- 20000801
LR  - 20131121
IS  - 0914-5087 (Print)
IS  - 0914-5087 (Linking)
VI  - 35
IP  - 5
DP  - 2000 May
TI  - [Risk factors for thromboembolism in patients with atrial fibrillation during 
      treatment with aspirin: a multicenter, cooperative retrospective study. Research 
      Group for Antiarrhythmic Drug Therapy].
PG  - 373-9
AB  - Warfarin is effective in preventing thromboembolism in patients with atrial 
      fibrillation, but aspirin is frequently used as an alternative treatment. A 
      multicenter, retrospective study was undertaken to identify patients at risk for 
      thromboembolism during treatment with aspirin. The study group consisted of 470 
      patients (318 males, 152 females, mean age 59.9 +/- 11.8 years at initial 
      examination) with atrial fibrillation who were treated with aspirin. Thirty-seven 
      percent of patients had paroxysmal atrial fibrillation and 65% of patients 
      received aspirin at a daily dose of 81 mg. Thromboembolism occurred in 31 
      patients (6.6%) during the follow-up period, resulting in cerebral infarction in 
      19 patients, transient ischemic attack in 7, and embolism of peripheral arteries 
      in 5. Patients with thromboembolism had lower prevalence of New York Heart 
      Association (NYHA) functional class I (52% vs 72%, p < 0.02) and paroxysmal 
      atrial fibrillation (23% vs 38%, p = 0.085) compared with patients without 
      thromboembolism. Multivariate analysis with the Cox proportional hazard model 
      determined age (> or = 65 years, relative risk 2.29, p = 0.032) as an independent 
      risk factor. NYHA functional class (> or = class II) tended to indicate an 
      increased risk of thromboembolic events (relative risk 1.90, p = 0.076). These 
      results suggest that aspirin has limited efficacy for prevention of 
      thromboembolism in patients with atrial fibrillation who are old (> or = 65 
      years) or have symptomatic heart failure.
LA  - jpn
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Female
MH  - Heart Diseases/complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thromboembolism/*prevention & control
EDAT- 2000/06/02 09:00
MHDA- 2000/08/06 11:00
CRDT- 2000/06/02 09:00
PHST- 2000/06/02 09:00 [pubmed]
PHST- 2000/08/06 11:00 [medline]
PHST- 2000/06/02 09:00 [entrez]
PST - ppublish
SO  - J Cardiol. 2000 May;35(5):373-9.

PMID- 9163687
OWN - NLM
STAT- MEDLINE
DCOM- 19970612
LR  - 20190512
IS  - 0143-3334 (Print)
IS  - 0143-3334 (Linking)
VI  - 18
IP  - 5
DP  - 1997 May
TI  - Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in 
      A/J mice.
PG  - 1001-6
AB  - Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely 
      prescribed drugs. In this study, we demonstrated the efficacy of aspirin to 
      inhibit lung tumorigenesis in A/J mice. Lung tumors (9.9 tumors/mouse) were 
      induced by the tobacco-specific nitrosamine, 
      4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), administered in drinking 
      water between week 0 and week +7. Groups of mice were fed sulindac (123 mg/kg 
      diet), acetylsalicylic acid (ASA; 294 mg/kg), non-buffered Aspirin (294 mg/kg) or 
      buffered Aspirin (294 mg/kg) in AIN-76A diet from week -2 to the end of the 
      bioassay (week +23). These doses are comparable to the maximal doses recommended 
      for humans. ASA and non-buffered Aspirin were the most effective inhibitors and 
      reduced lung multiplicities by 60 and 62%, respectively. Sulindac inhibited lung 
      tumor multiplicity by 52%. Inhibition by buffered Aspirin was not statistically 
      significant. We evaluated the efficacies of NSAIDs to inhibit NNK activation by 
      h1A2 v2 cells expressing human P-450 1A2. Salicylates, at doses of 500 microM and 
      1 mM, had no effect on NNK activation. Sulindac and its sulfide and sulfone 
      metabolites (1 mM) inhibited NNK metabolism by 90, 92 and 65%, respectively. We 
      observed a 76% inhibition with SKF 525A, a P-450 inhibitor. Taken together, these 
      results indicate that salicylates and sulindac could be equally effective as 
      chemopreventive agents, but they could differ in their mode of action.
FAU - Duperron, C
AU  - Duperron C
AD  - Laboratory of Cancer Etiology and Chemoprevention, School of Pharmacy, Laval 
      University, Quebec City, Canada.
FAU - Castonguay, A
AU  - Castonguay A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Carcinogenesis
JT  - Carcinogenesis
JID - 8008055
RN  - 0 (Nitrosamines)
RN  - 0 (Prodrugs)
RN  - 184SNS8VUH (Sulindac)
RN  - 7S395EDO61 (4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/*chemically induced
MH  - Animals
MH  - Aspirin/metabolism/*pharmacology
MH  - Cells, Cultured
MH  - Cytochrome P-450 CYP1A2/metabolism
MH  - Enzyme Activation
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*chemically induced
MH  - Mice
MH  - Mice, Inbred A
MH  - Nitrosamines/*metabolism
MH  - Prodrugs/pharmacology
MH  - Sulindac/*pharmacology
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - 10.1093/carcin/18.5.1001 [doi]
PST - ppublish
SO  - Carcinogenesis. 1997 May;18(5):1001-6. doi: 10.1093/carcin/18.5.1001.

PMID- 34078519
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20220131
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 76
IP  - 6
DP  - 2021 Jun 1
TI  - MiR-877-5p targets PDK-1 to promote aspirin-induced apoptosis in gastric mucosal 
      cells.
PG  - 256-260
LID - 10.1691/ph.2021.0926 [doi]
AB  - This study aimed to investigate the role of miR-877-5p in aspirin-induced gastric 
      mucosal injury. MiRNA microarray analysis was performed using paired gastric 
      mucosal samples to find differentially expressed miRNAs. miR-877-5p was selected 
      for subsequent analyses. Used as a model system, gastric epithelial cells (GES-1) 
      were transfected with miR-877-5p mimic/inhibitor, then treated with aspirin. The 
      expression of miR-877-5p in GES-1 cells was examined using quantitative real-time 
      PCR (qRT-PCR). Flow cytometry analysis was used to detect cell apoptosis. Western 
      blot assay was used to measure the protein levels of PDK1. The interaction 
      between miR-877-5p and PDK1 was determined by luciferase reporter assay. The 
      expression of miR-877-5p in gastric mucosal injury samples was higher than that 
      in normal samples. Also, depletion of miR-877-5p reduced the apoptosis of GES-1 
      cells. Luciferase reporting assay confirmed that PDK1 was a target gene of 
      miR-877-5p. PDK1 inhibited the apoptosis of GES-1 cells treated by aspirin. 
      Moreover, this inhibitory effect was abrogated after PDK1 knockdown. 
      Downregulation of miR-877-5p reduced the apoptosis by targeting PDK1 in GES-1 
      cells treated by aspirin, indicating that miR-877-5p may be a potential 
      therapeutic target for gastric mucosal injury caused by aspirin.
FAU - Yuyu, Lu
AU  - Yuyu L
AD  - Department of ICU, The Affiliated Jiangning Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Shikun, Zhang
AU  - Shikun Z
AD  - Department of Police Physcial Education of Jiangsu Police Institute, Nanjing, 
      China.
FAU - Zhenyu, Zhang
AU  - Zhenyu Z
AD  - Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, China.
FAU - Zongdan, Jiang
AU  - Zongdan J
AD  - Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, China;, Email: jzongdan@sina.com.
FAU - Weihao, Sun
AU  - Weihao S
AD  - Department of Geriatric Gastroenterology, the First Affiliated Hospital to 
      Nanjing Medical University, Nanjing, China;, Email: swh@njmu.edu.cn.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (MicroRNAs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis
MH  - *Aspirin/pharmacology
MH  - Down-Regulation
MH  - Gastric Mucosa
MH  - *MicroRNAs/genetics
EDAT- 2021/06/04 06:00
MHDA- 2022/02/01 06:00
CRDT- 2021/06/03 05:47
PHST- 2021/06/03 05:47 [entrez]
PHST- 2021/06/04 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
AID - 10.1691/ph.2021.0926 [doi]
PST - ppublish
SO  - Pharmazie. 2021 Jun 1;76(6):256-260. doi: 10.1691/ph.2021.0926.

PMID- 31039213
OWN - NLM
STAT- MEDLINE
DCOM- 20191218
LR  - 20191218
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 68
IP  - 3
DP  - 2019 Apr
TI  - Aspirin for primary prevention: USPSTF recommendations for CVD and colorectal 
      cancer.
PG  - 146-151
AB  - Patient age, baseline cardiovascular disease risk, bleeding risk, and personal 
      preference regarding aspirin use are key to decision making. A clinical decision 
      tool can help.
FAU - Smith, Dustin K
AU  - Smith DK
AD  - Naval Branch Clinic Diego Garcia. Email: dustinksmith@yahoo.com.
FAU - Demetriou, Theodore
AU  - Demetriou T
AD  - Penn State University Family and Community Medicine Residency Program, USA.
FAU - Weber, Christopher
AU  - Weber C
AD  - Naval Hospital Okinawa.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Fam Pract. 2019 Apr;68(3):144. PMID: 31039218
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Decision-Making
MH  - Colorectal Neoplasms/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic/methods
MH  - *Practice Guidelines as Topic
MH  - Primary Prevention/methods
MH  - Randomized Controlled Trials as Topic
MH  - Sensitivity and Specificity
EDAT- 2019/05/01 06:00
MHDA- 2019/12/19 06:00
CRDT- 2019/05/01 06:00
PHST- 2019/05/01 06:00 [entrez]
PHST- 2019/05/01 06:00 [pubmed]
PHST- 2019/12/19 06:00 [medline]
AID - jfp_6803b [pii]
PST - ppublish
SO  - J Fam Pract. 2019 Apr;68(3):146-151.

PMID- 7246342
OWN - NLM
STAT- MEDLINE
DCOM- 19810810
LR  - 20190825
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 11
IP  - 1-2
DP  - 1981 Apr
TI  - Histaminemia after aspirin challenge in aspirin-sensitive asthmatics.
PG  - 105-7
AB  - To determine the role of mast cells in aspirin-induced bronchoconstriction, 
      venous histaminemia was measured in 17 aspirin-sensitive patients before and 
      after administration of aspirin. Ventilatory disturbances were measured 
      spirographically. Venous histaminemia was determined according to Lorenz. In 11 
      patients the mean increase of histaminemia was from 39.6 ng/ml to 107.0 ng/ml. In 
      the remaining 6 patients no change in histaminemia was observed after the 
      challenge. In patients exhibiting the increase of histaminemia, symptoms of 
      hypersensitivity to aspirin, other than dyspnea, were not common and stronger. 
      The authors discuss a possible relationship of the aspirin effect, disturbances 
      in prostaglandin synthesis and histamine release.
FAU - Szmidt, M
AU  - Szmidt M
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
FAU - Rozniecki, J
AU  - Rozniecki J
FAU - Kowalski, M L
AU  - Kowalski ML
FAU - Rychlicka, I
AU  - Rychlicka I
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 820484N8I3 (Histamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/immunology/*pharmacology
MH  - Asthma/*immunology
MH  - Bronchi/physiopathology
MH  - Drug Hypersensitivity/*metabolism
MH  - Female
MH  - Forced Expiratory Volume
MH  - Histamine/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1981/04/01 00:00
MHDA- 1981/04/01 00:01
CRDT- 1981/04/01 00:00
PHST- 1981/04/01 00:00 [pubmed]
PHST- 1981/04/01 00:01 [medline]
PHST- 1981/04/01 00:00 [entrez]
AID - 10.1007/BF01991472 [doi]
PST - ppublish
SO  - Agents Actions. 1981 Apr;11(1-2):105-7. doi: 10.1007/BF01991472.

PMID- 26964594
OWN - NLM
STAT- MEDLINE
DCOM- 20170306
LR  - 20181202
IS  - 1476-5373 (Electronic)
IS  - 0007-0610 (Linking)
VI  - 220
IP  - 5
DP  - 2016 Mar 11
TI  - Exodontia in dual antiplatelet therapy: the evidence.
PG  - 235-8
LID - 10.1038/sj.bdj.2016.173 [doi]
AB  - BACKGROUND: Haemostasis is crucial for the success of oral surgical treatment as 
      bleeding problems can cause complications both pre- and post-operatively. 
      Patients on antiplatelet drugs present a challenge due to their increased risk of 
      bleeding. AIMS: To identify a protocol for the management of oral surgery 
      patients on dual antiplatelet therapy (aspirin and clopidogrel). METHODS: A 
      literature review was conducted in January 2016 of free-text and MESH searches 
      (keywords: aspirin, clopidogrel and dental extractions) in the Cochrane Library, 
      PubMed and CINAHL. Trial registers, professional bodies for guidelines and 
      OpenGrey for unpublished literature were also searched. Studies were selected for 
      appraisal after limits were applied (adult, human and English only studies) and 
      inclusion/exclusion criteria imposed. RESULTS: Eight studies were identified for 
      critical appraisal using the CASP tools. These were a combination of 
      retrospective, prospective, cohort and case control studies. Napenas et al. and 
      Park et al. found no statistically significant risk of postoperative bleeding 
      complications in patients on dual antiplatelet therapy. Girotra et al., Lillis et 
      al., Omar et al. and Olmos-Carrasco et al., however, found statistically 
      significant risk of postoperative bleeding in this group of patients, all of 
      which can be controlled with local measures. CONCLUSION: Patients on dual 
      antiplatelet therapy - although at an increased risk of postoperative bleeding 
      complications - can be managed safely with local haemostatic measures and without 
      the need to discontinue antiplatelet therapy.
FAU - Nathwani, S
AU  - Nathwani S
AD  - Department of Oral and Maxillofacial Surgery, Luton and Dunstable University 
      Hospital, Lewsey Road, Luton, Bedfordshire, LU4 0DZ.
FAU - Martin, K
AU  - Martin K
AD  - Department of Oral and Maxillofacial Surgery, Luton and Dunstable University 
      Hospital, Lewsey Road, Luton, Bedfordshire, LU4 0DZ.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br Dent J
JT  - British dental journal
JID - 7513219
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br Dent J. 2016 Jun 24;220(12 ):611. PMID: 27338890
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Oral Surgical Procedures/*methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & 
      derivatives/therapeutic use
EDAT- 2016/03/12 06:00
MHDA- 2017/03/07 06:00
CRDT- 2016/03/12 06:00
PHST- 2016/02/09 00:00 [accepted]
PHST- 2016/03/12 06:00 [entrez]
PHST- 2016/03/12 06:00 [pubmed]
PHST- 2017/03/07 06:00 [medline]
AID - sj.bdj.2016.173 [pii]
AID - 10.1038/sj.bdj.2016.173 [doi]
PST - ppublish
SO  - Br Dent J. 2016 Mar 11;220(5):235-8. doi: 10.1038/sj.bdj.2016.173.

PMID- 37127334
OWN - NLM
STAT- MEDLINE
DCOM- 20230503
LR  - 20230509
IS  - 1939-2869 (Electronic)
IS  - 0891-1150 (Linking)
VI  - 90
IP  - 5
DP  - 2023 May 1
TI  - Aspirin for primary prevention of cardiovascular disease: What do the current 
      USPSTF guidelines say?
PG  - 287-291
LID - 10.3949/ccjm.90a.22087 [doi]
AB  - The 2022 US Preventive Services Task Force (USPSTF) recommendation notes that the 
      decision to initiate daily aspirin therapy for primary prevention of 
      cardiovascular disease (CVD) should be made on a case-by-case basis for adults 
      ages 40 to 59 with a 10% or greater 10-year CVD risk. The recommendation applies 
      to those without signs or symptoms of clinically evident CVD who are not at an 
      increased risk of bleeding. Clinicians are encouraged to use their judgment in 
      weighing the risks and benefits of aspirin therapy, while taking patient 
      preference into account for patients ages 40 to 60.
CI  - Copyright © 2023 The Cleveland Clinic Foundation. All Rights Reserved.
FAU - Mallick, Sanjoyita
AU  - Mallick S
AD  - Department of Medicine, Hennepin Healthcare, Minneapolis, MN 
      Sanjoyita.mallick@hcmed.org.
FAU - Shroff, Gautam R
AU  - Shroff GR
AD  - Department of Medicine, Hennepin Healthcare, Minneapolis, MN; University of 
      Minnesota, Minneapolis, MN.
FAU - Linzer, Mark
AU  - Linzer M
AD  - Department of Medicine, Hennepin Healthcare, Minneapolis, MN; University of 
      Minnesota, Minneapolis, MN.
LA  - eng
PT  - Journal Article
DEP - 20230501
PL  - United States
TA  - Cleve Clin J Med
JT  - Cleveland Clinic journal of medicine
JID - 8703441
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Middle Aged
MH  - *Aspirin/adverse effects
MH  - *Cardiovascular Diseases/prevention & control
MH  - Primary Prevention
MH  - Preventive Health Services
EDAT- 2023/05/02 00:42
MHDA- 2023/05/03 06:42
CRDT- 2023/05/01 20:43
PHST- 2023/05/03 06:42 [medline]
PHST- 2023/05/02 00:42 [pubmed]
PHST- 2023/05/01 20:43 [entrez]
AID - 90/5/287 [pii]
AID - 10.3949/ccjm.90a.22087 [doi]
PST - epublish
SO  - Cleve Clin J Med. 2023 May 1;90(5):287-291. doi: 10.3949/ccjm.90a.22087.

PMID- 19235631
OWN - NLM
STAT- MEDLINE
DCOM- 20091222
LR  - 20151119
IS  - 1097-9867 (Electronic)
IS  - 1083-7450 (Linking)
VI  - 14
IP  - 4
DP  - 2009
TI  - Drug dissolution rate measurements--evaluation of the rotating disc method.
PG  - 400-8
LID - 10.1080/10837450802712641 [doi]
AB  - Dissolution rate measurements are important to understand the behaviour of drugs 
      or drug formulations. Many methods for measuring dissolution rates are available 
      and a good choice should be based on method limitations as well as drug 
      characteristics. In the present study the rotating disc method was critically 
      evaluated for dissolution rate measurements, using aspirin and benzoic acid as 
      model substances. Existing theory for the rotating disc was compared with 
      experiments and a computational fluid dynamics (CFD) model simulating the USP 
      vessel. Simulations showed that it is possible to predict mass transfer 
      controlled drug release rates within the laminar flow regime. Mass transfer 
      coefficients obtained from the CFD model were in better agreement with 
      experimental data than those obtained from existing theory. It was concluded that 
      the hydrodynamic boundary layer controlling release rates was in reality thicker 
      than existing theory would suggest.
FAU - Kaunisto, Erik
AU  - Kaunisto E
AD  - Department of Chemical Engineering, Lund University, Lund, Sweden. 
      Erik.Kaunisto@chemeng.lth.se
FAU - Nilsson, Bernt
AU  - Nilsson B
FAU - Axelsson, Anders
AU  - Axelsson A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharm Dev Technol
JT  - Pharmaceutical development and technology
JID - 9610932
RN  - 8SKN0B0MIM (Benzoic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Benzoic Acid/*chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - *Models, Theoretical
MH  - Solubility
MH  - Technology, Pharmaceutical/methods
EDAT- 2009/02/25 09:00
MHDA- 2009/12/23 06:00
CRDT- 2009/02/25 09:00
PHST- 2009/02/25 09:00 [entrez]
PHST- 2009/02/25 09:00 [pubmed]
PHST- 2009/12/23 06:00 [medline]
AID - 908975786 [pii]
AID - 10.1080/10837450802712641 [doi]
PST - ppublish
SO  - Pharm Dev Technol. 2009;14(4):400-8. doi: 10.1080/10837450802712641.

PMID- 15989905
OWN - NLM
STAT- MEDLINE
DCOM- 20050825
LR  - 20131121
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 118
IP  - 7
DP  - 2005 Jul
TI  - Low-dose aspirin increases aspirin resistance in patients with coronary artery 
      disease.
PG  - 723-7
AB  - PURPOSE: We sought to investigate the association of aspirin dose and aspirin 
      resistance in stable coronary artery disease patients measured by a point-of-care 
      assay. METHODS: We studied 468 consecutive stable coronary artery disease 
      patients in a referral cardiac center who were taking aspirin 80 to 325 mg daily 
      for > or =4 weeks. The VerifyNow Aspirin (Ultegra RPFA-ASA, Accumetrics Inc, San 
      Diego, Calif) was used to determine aspirin responsiveness. An aspirin reaction 
      unit (ARU) > or =550 indicates the absence of aspirin-induced platelet 
      dysfunction, based on correlation with epinephrine-induced light transmission 
      aggregometry. Demographic and clinical data were collected to analyze the 
      predictors of aspirin resistance. RESULTS: Aspirin resistance was noted in 128 
      (27.4%) patients. Univariate predictors of aspirin resistance include elderly (P 
      = 0.002), women (P <0.001), anemia (P <0.001), renal insufficiency (P = 0.009) 
      and aspirin dose < or =100 mg (P = 0.004). Multivariate analysis revealed 
      hemoglobin (odds ratio [OR] 0.6; 95% confidence interval [CI] 0.51 to 0.69; P 
      <0.001) and aspirin dose < or =100 mg (OR 2.23; 95% CI 1.12 to 4.44; P = 0.022) 
      to be independent predictors of aspirin resistance. Daily aspirin dose < or = 100 
      mg was associated with increased prevalence of aspirin resistance compared with 
      150 mg and 300 mg daily (30.2% vs 16.7% vs 0%, P = 0.0062). CONCLUSION: A 100 mg 
      or less daily dose of aspirin, which may have lower side effects, is associated 
      with a higher incidence of aspirin resistance in patients with coronary artery 
      disease. Prospective randomized studies are warranted to elucidate the optimal 
      aspirin dosage for preventing ischemic complications of atherothrombotic disease.
FAU - Lee, Pui-Yin
AU  - Lee PY
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, China.
FAU - Chen, Wai-Hong
AU  - Chen WH
FAU - Ng, William
AU  - Ng W
FAU - Cheng, Xi
AU  - Cheng X
FAU - Kwok, Jeanette Yat-Yin
AU  - Kwok JY
FAU - Tse, Hung-Fat
AU  - Tse HF
FAU - Lau, Chu-Pak
AU  - Lau CP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Hemoglobins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Med. 2006 Mar;119(3):287; author reply 287-8. PMID: 16490484
CIN - Am J Med. 2006 Mar;119(3):288; author reply 289. PMID: 16490485
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Disease/blood/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Female
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Retrospective Studies
EDAT- 2005/07/02 09:00
MHDA- 2005/08/27 09:00
CRDT- 2005/07/02 09:00
PHST- 2005/01/14 00:00 [received]
PHST- 2005/03/18 00:00 [accepted]
PHST- 2005/07/02 09:00 [pubmed]
PHST- 2005/08/27 09:00 [medline]
PHST- 2005/07/02 09:00 [entrez]
AID - S0002-9343(05)00316-5 [pii]
AID - 10.1016/j.amjmed.2005.03.041 [doi]
PST - ppublish
SO  - Am J Med. 2005 Jul;118(7):723-7. doi: 10.1016/j.amjmed.2005.03.041.

PMID- 31504399
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20201022
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 40
IP  - 46
DP  - 2019 Dec 7
TI  - Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to 
      aspirin for patients with stable cardiovascular disease: results from the COMPASS 
      trial.
PG  - 3771-3778a
LID - 10.1093/eurheartj/ehz404 [doi]
AB  - AIMS: Adding rivaroxaban to aspirin in patients with stable atherosclerotic 
      disease reduces the recurrence of cardiovascular disease (CVD) but increases the 
      risk of major bleeding. The aim of this study was to estimate the individual 
      lifetime treatment benefit and harm of adding low-dose rivaroxaban to aspirin in 
      patients with stable cardiovascular disease. METHODS AND RESULTS: Patients with 
      established CVD from the COMPASS trial (n = 27 390) and SMART prospective cohort 
      study (n = 8139) were used. Using the pre-existing lifetime SMART-REACH model for 
      recurrent CVD, and a newly developed Fine and Gray competing risk-adjusted 
      lifetime model for major bleeding, individual treatment effects from adding 
      low-dose rivaroxaban to aspirin in patients with stable CVD were estimated, 
      expressed in terms of (i) life-years free of stroke or myocardial infarction (MI) 
      gained; and (ii) life-years free from major bleeding lost. Calibration of the 
      SMART-REACH model for prediction of recurrent CVD events in the COMPASS study was 
      good. The major bleeding risk model as derived in the COMPASS trial showed good 
      external calibration in the SMART cohort. Predicted individual gain in life 
      expectancy free of stroke or MI from added low-dose rivaroxaban had a median of 
      16 months (range 1-48 months), while predicted individualized lifetime lost in 
      terms of major bleeding had a median of 2 months (range 0-20 months). CONCLUSION: 
      There is a wide distribution in lifetime gain and harm from adding low-dose 
      rivaroxaban to aspirin in individual patients with stable CVD. Using these 
      lifetime models, benefits and bleeding risk can be weighed for each individual 
      patient, which could facilitate treatment decisions in clinical practice.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved. © 
      The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.
FAU - de Vries, Tamar I
AU  - de Vries TI
AD  - Department of Vascular Medicine, University Medical Center Utrecht, University 
      Utrecht, GA Utrecht, The Netherlands.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences, 237 Barton Street East, Hamilton, ON, Canada.
FAU - Bosch, Jackie
AU  - Bosch J
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences, 237 Barton Street East, Hamilton, ON, Canada.
FAU - Westerink, Jan
AU  - Westerink J
AD  - Department of Vascular Medicine, University Medical Center Utrecht, University 
      Utrecht, GA Utrecht, The Netherlands.
FAU - Dorresteijn, Jannick A N
AU  - Dorresteijn JAN
AD  - Department of Vascular Medicine, University Medical Center Utrecht, University 
      Utrecht, GA Utrecht, The Netherlands.
FAU - Alings, Marco
AU  - Alings M
AD  - Department of Cardiology, Amphia Hospital, Langendijk 75, EV Breda, The 
      Netherlands.
FAU - Dyal, Leanne
AU  - Dyal L
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences, 237 Barton Street East, Hamilton, ON, Canada.
FAU - Berkowitz, Scott D
AU  - Berkowitz SD
AD  - Clinical Development, Thrombosis, Bayer U.S. LLC, Whippany, NJ, USA.
FAU - van der Graaf, Yolanda
AU  - van der Graaf Y
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center 
      Utrecht, University Utrecht, Universiteitsweg 100, CG Utrecht, The Netherlands.
FAU - Fox, Keith A A
AU  - Fox KAA
AD  - Centre for Cardiovascular Science, University of Edinburgh, 49 Little France 
      Crescent, Edinburgh, UK.
FAU - Visseren, Frank L J
AU  - Visseren FLJ
AD  - Department of Vascular Medicine, University Medical Center Utrecht, University 
      Utrecht, GA Utrecht, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2019 Dec 7;40(46):3779-3781. PMID: 31504403
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/mortality
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Rivaroxaban/administration & dosage/adverse effects/*therapeutic use
MH  - Stroke/prevention & control
OTO - NOTNLM
OT  - Antithrombotic therapy
OT  - Life expectancy
OT  - Predictive model
OT  - Secondary prevention
OT  - Treatment effect
EDAT- 2019/09/11 06:00
MHDA- 2020/10/23 06:00
CRDT- 2019/09/11 06:00
PHST- 2019/02/21 00:00 [received]
PHST- 2019/04/29 00:00 [revised]
PHST- 2019/06/24 00:00 [accepted]
PHST- 2019/09/11 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
PHST- 2019/09/11 06:00 [entrez]
AID - 5552549 [pii]
AID - 10.1093/eurheartj/ehz404 [doi]
PST - ppublish
SO  - Eur Heart J. 2019 Dec 7;40(46):3771-3778a. doi: 10.1093/eurheartj/ehz404.

PMID- 2791406
OWN - NLM
STAT- MEDLINE
DCOM- 19891108
LR  - 20131121
IS  - 0009-918X (Print)
IS  - 0009-918X (Linking)
VI  - 29
IP  - 5
DP  - 1989 May
TI  - [Antiplatelet effects of combination therapy with low-dose aspirin and 
      ticlopidine in cerebral ischemia].
PG  - 579-83
AB  - Antiplatelet effects of combination therapy with aspirin and ticlopidine were 
      investigated in comparison with single aspirin or ticlopidine therapy in 62 
      patients with cerebral thrombosis or transient ischemic attack. The 14, 21 and 27 
      patients were given orally daily aspirin 300mg, ticlopidine 200mg and aspirin 
      81mg with ticlopidine 100mg, respectively. Various platelet function tests were 
      performed before and a week after medication. They included platelet aggregation 
      (PA) to adenosine diphosphate (ADP), arachidonic acid (AA) and platelet 
      activating factor (PAF) with turbidimetry, plasma beta-thromboglobulin (beta TG), 
      platelet factor 4(PF4), thromboxane B2(TXB2) and 6keto-prostaglandin-F1 
      alpha(6keto PGF1 alpha) with radioimmunoassay, bleeding time with Simplate 
      device, and platelet survival and lysis with Indium-111-tropolone-labelled 
      platelets. Aspirin inhibited PA to ADP and AA but not to PAF, while ticlopidine 
      inhibited PA to ADP and PAF but not to AA. In contrast, aspirin with ticlopidine 
      inhibited PA to all of these agonists despite their smaller doses used. Aspirin 
      reduced plasma TXB2 but not beta TG or PF4, while ticlopidine reduced beta TG and 
      PF4 but not TXB2. On the contrary, aspirin with ticlopidine reduced TXB2 as well 
      as beta TG and PF4. 6keto PGF1 alpha tended to be reduced by aspirin 300mg alone 
      but not by ticlopidine with or without aspirin 81mg. Bleeding time was 
      significantly prolonged by aspirin or ticlopidine alone, although most 
      prolongation was produced by combination of aspirin and ticlopidine. Platelet 
      survival and lysis remained unaltered in 4 patients treated with aspirin or 
      ticlopidine alone, whereas platelet survival was prolonged and platelet lysis was 
      reduced in 4 patients treated with both aspirin and ticlopidine.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Uchiyama, S
AU  - Uchiyama S
FAU - Tsutsumi, Y
AU  - Tsutsumi Y
FAU - Nagayama, T
AU  - Nagayama T
FAU - Kobayashi, I
AU  - Kobayashi I
FAU - Maruyama, S
AU  - Maruyama S
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Shinkeigaku
JT  - Rinsho shinkeigaku = Clinical neurology
JID - 0417466
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Ticlopidine/*administration & dosage/*therapeutic use
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
PST - ppublish
SO  - Rinsho Shinkeigaku. 1989 May;29(5):579-83.

PMID- 34482301
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20220902
IS  - 2053-2296 (Electronic)
IS  - 2053-2296 (Linking)
VI  - 77
IP  - Pt 9
DP  - 2021 Sep 1
TI  - Mechanochemical synthesis insights and solid-state characterization of quininium 
      aspirinate, a glass-forming drug-drug salt.
PG  - 566-576
LID - 10.1107/S2053229621008275 [doi]
AB  - Quinine (an antimalarial) and aspirin (a nonsteroidal anti-inflammatory drug) 
      were combined into a new drug-drug salt, quininium aspirinate, 
      C(20)H(25)N(2)O(2)(+)·C(9)H(7)O(4)(-), by liquid-assisted grinding using 
      stoichiometric amounts of the reactants in a 1:1 molar ratio, and water, EtOH, 
      toluene, or heptane as additives. A tetrahydrofuran (THF) solution of the 
      mechanochemical product prepared using EtOH as additive led to a single crystal 
      of the same material obtained by mechanochemistry, which was used for crystal 
      structure determination at 100 K. Powder X-ray diffraction ruled out 
      crystallographic phase transitions in the 100-295 K interval. Neat mechanical 
      treatment (in a mortar and pestle, or in a ball mill at 20 or 30 Hz milling 
      frequencies) gave rise to an amorphous phase, as shown by powder X-ray 
      diffraction; however, FT-IR spectroscopy unambiguously indicates that a 
      mechanochemical reaction has occurred. Neat milling the reactants at 10 and 15 Hz 
      led to incomplete reactions. Thermogravimetry and differential scanning 
      calorimetry indicate that the amorphous and crystalline mechanochemical products 
      form glasses/supercooled liquids before melting, and do not recrystallize upon 
      cooling. However, the amorphous material obtained by neat grinding crystallizes 
      upon storage into the salt reported. The mechanochemical synthesis, crystal 
      structure analysis, Hirshfeld surfaces, powder X-ray diffraction, 
      thermogravimetry, differential scanning calorimetry, FT-IR spectroscopy, and 
      aqueous solubility of quininium aspirinate are herein reported.
FAU - Harris, Nehemiah
AU  - Harris N
AD  - Department of Chemistry and Biochemistry, Old Dominion University, 4402 Elkhorn 
      Ave., Norfolk, VA 23529, USA.
FAU - Benedict, Jubilee
AU  - Benedict J
AD  - Department of Chemistry and Biochemistry, Old Dominion University, 4402 Elkhorn 
      Ave., Norfolk, VA 23529, USA.
FAU - Dickie, Diane A
AU  - Dickie DA
AD  - Department of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.
FAU - Pagola, Silvina
AU  - Pagola S
AUID- ORCID: 0000-0003-2083-7599
AD  - Department of Chemistry and Biochemistry, Old Dominion University, 4402 Elkhorn 
      Ave., Norfolk, VA 23529, USA.
LA  - eng
GR  - T34 GM118259/GM/NIGMS NIH HHS/United States
GR  - T34GM118259/National Institutes of Health, National Institute of General Medical 
      Sciences/
GR  - GIA 08-04/International Centre for Diffraction Data/
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210825
PL  - England
TA  - Acta Crystallogr C Struct Chem
JT  - Acta crystallographica. Section C, Structural chemistry
JID - 101620313
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pharmaceutical Preparations)
RN  - A7V27PHC7A (Quinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemical synthesis/chemistry
MH  - Aspirin/*chemical synthesis/chemistry
MH  - Calorimetry, Differential Scanning
MH  - Crystallography, X-Ray
MH  - Hydrogen Bonding
MH  - Pharmaceutical Preparations
MH  - Phase Transition
MH  - Quinine/*chemical synthesis/chemistry
MH  - Solubility
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Thermogravimetry
MH  - X-Ray Diffraction
PMC - PMC8418670
OTO - NOTNLM
OT  - NSAID
OT  - antimalarial
OT  - aspirin
OT  - crystal structure
OT  - drug–drug salt
OT  - liquid-assisted grinding
OT  - mechanochemistry
OT  - quinine
EDAT- 2021/09/06 06:00
MHDA- 2021/09/28 06:00
CRDT- 2021/09/05 20:54
PHST- 2021/03/30 00:00 [received]
PHST- 2021/08/11 00:00 [accepted]
PHST- 2021/09/05 20:54 [entrez]
PHST- 2021/09/06 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
AID - S2053229621008275 [pii]
AID - ep3016 [pii]
AID - 10.1107/S2053229621008275 [doi]
PST - ppublish
SO  - Acta Crystallogr C Struct Chem. 2021 Sep 1;77(Pt 9):566-576. doi: 
      10.1107/S2053229621008275. Epub 2021 Aug 25.

PMID- 3523307
OWN - NLM
STAT- MEDLINE
DCOM- 19860818
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 77
IP  - 27
DP  - 1986 Jun 30
TI  - [Acetylsalicylic acid in the treatment of ischemic cerebrovascular disorders].
PG  - 1299-308
AB  - An examination of 80 patients with ischaemic cerebrovascular disease, subdivided 
      into 5 groups according to platelet antiaggregant treatment, demonstrated the 
      insufficient effectiveness of acetylsalicylic acid in preventing recurrences. The 
      drug failure can most probably be attributed to its particular action mechanism 
      or to dosage.
FAU - Caneschi, S
AU  - Caneschi S
FAU - Bonaventi, C
AU  - Bonaventi C
FAU - Finzi, F
AU  - Finzi F
FAU - Tito, P
AU  - Tito P
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - L'acido acetil-salicilico nella terapia delle vasculopatie cerebrali ischemiche.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Cerebrovascular Disorders/blood/*drug therapy/prevention & control
MH  - Clinical Trials as Topic
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/blood/drug therapy/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Random Allocation
MH  - Time Factors
EDAT- 1986/06/30 00:00
MHDA- 1986/06/30 00:01
CRDT- 1986/06/30 00:00
PHST- 1986/06/30 00:00 [pubmed]
PHST- 1986/06/30 00:01 [medline]
PHST- 1986/06/30 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1986 Jun 30;77(27):1299-308.

PMID- 34051259
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20221217
IS  - 1879-0003 (Electronic)
IS  - 0141-8130 (Print)
IS  - 0141-8130 (Linking)
VI  - 182
DP  - 2021 Jul 1
TI  - Ethyl cellulose coated sustained release aspirin spherules for treating COVID-19: 
      DOE led rapid optimization using arbitrary interface; applicable for emergency 
      situations.
PG  - 1769-1784
LID - S0141-8130(21)01131-4 [pii]
LID - 10.1016/j.ijbiomac.2021.05.156 [doi]
AB  - This work attempts to resolve one of the key issues related to the design and 
      development of sustained-release spherule of aspirin for oral formulations, 
      tailored to treat COVID-19. For that, in the Design of Experiments (DOE) an 
      arbitrary interface, "coating efficiency" (CE) is introduced and scaled the 
      cumulative percentage coating (CPC) to get predictable control over drug release 
      (DR). Subsequently, the granules containing ASP are converted to spherules and 
      then to Ethyl cellulose (EC) Coated spherules (CS) by a novel bed coating during 
      the rolling (BCDR) process. Among spherules, one with 0.35 mm than 0.71 mm shows 
      required properties. The CS has a low 120(0) angle by Optical Microscopy (OM), 
      smooth surface without cracks by scanning electron microscopy (SEM), and better 
      flow properties (Angle of repose 29.69 ± 0.78(0), Carr's index 6.73 ± 2.24%, 
      Hausner's Ratio 1.07 ± 0.03) than granules and spherules. Once certain 
      structure-dependent control over release is attained (EC coated spherules shows 
      10% reduction in burst release (BR) than uncoated spherules showing a release of 
      80-91%) the predictability is achieved and Design of space (DOS) by DOE 
      (CE-70.14%and CPC-200% and DR-61.54%) is established. The results of DOE to 
      experimentally validated results were within 20% deviation. The aspirin is 
      changing its crystal structure by powder X-ray diffraction (PXRD) and 
      differential scanning calorimetry (DSC) from Form-I to Form-II showing 
      polymorphism inside the drug reservoir with respect to the process. This CE and 
      CPC approach in DOE can be used for delivery system design of other labile drugs 
      similar to aspirin in emergency situations.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Thrivikraman Nair, Sreejith
AU  - Thrivikraman Nair S
AD  - Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Institute of 
      Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa 
      Vidyapeetham, Kochi 682041, Kerala, India.
FAU - Kamalasanan, Kaladhar
AU  - Kamalasanan K
AD  - Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Institute of 
      Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa 
      Vidyapeetham, Kochi 682041, Kerala, India. Electronic address: 
      kaladhar22654@aims.amrita.edu.
FAU - Moidu, Ashna
AU  - Moidu A
AD  - Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Institute of 
      Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa 
      Vidyapeetham, Kochi 682041, Kerala, India.
FAU - Shyamsundar, Pooja
AU  - Shyamsundar P
AD  - Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Institute of 
      Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa 
      Vidyapeetham, Kochi 682041, Kerala, India.
FAU - Nair, Lakshmi J
AU  - Nair LJ
AD  - Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Institute of 
      Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa 
      Vidyapeetham, Kochi 682041, Kerala, India.
FAU - P, Venkatesan
AU  - P V
AD  - Department of Pharmacy, Annamalai University, Annamalainagar, Tamil Nadu, India.
LA  - eng
PT  - Journal Article
DEP - 20210526
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
RN  - 0 (Delayed-Action Preparations)
RN  - 7Z8S9VYZ4B (ethyl cellulose)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/chemistry/pharmacokinetics
MH  - Cellulose/*analogs & derivatives/chemistry
MH  - Delayed-Action Preparations/chemistry/pharmacokinetics
MH  - Drug Compounding
MH  - Drug Liberation
MH  - Humans
MH  - *SARS-CoV-2
MH  - *COVID-19 Drug Treatment
PMC - PMC8152213
OTO - NOTNLM
OT  - Aspirin
OT  - Central composite design
OT  - Ethyl cellulose
OT  - Granules
OT  - Spheronization
OT  - Sustained-release
COIS- The authors hereby declare that they don't have any conflict of interest on this 
      manuscript.
EDAT- 2021/05/30 06:00
MHDA- 2021/07/13 06:00
CRDT- 2021/05/29 20:10
PHST- 2021/03/23 00:00 [received]
PHST- 2021/05/21 00:00 [revised]
PHST- 2021/05/23 00:00 [accepted]
PHST- 2021/05/30 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2021/05/29 20:10 [entrez]
AID - S0141-8130(21)01131-4 [pii]
AID - 10.1016/j.ijbiomac.2021.05.156 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2021 Jul 1;182:1769-1784. doi: 
      10.1016/j.ijbiomac.2021.05.156. Epub 2021 May 26.

PMID- 29112548
OWN - NLM
STAT- MEDLINE
DCOM- 20190923
LR  - 20190923
IS  - 1365-2346 (Electronic)
IS  - 0265-0215 (Linking)
VI  - 35
IP  - 2
DP  - 2018 Feb
TI  - European guidelines on perioperative venous thromboembolism prophylaxis: Aspirin.
PG  - 123-129
LID - 10.1097/EJA.0000000000000728 [doi]
AB  - : There is a good rationale for the use of aspirin in venous thromboembolism 
      prophylaxis in some orthopaedic procedures, as already proposed by the 9th 
      American College of Chest Physicians' guidelines (Grade 1C). We recommend using 
      aspirin, considering that it may be less effective than or as effective as low 
      molecular weight heparin for prevention of deep vein thrombosis and pulmonary 
      embolism after total hip arthroplasty, total knee arthroplasty and hip fracture 
      surgery (Grade 1C). Aspirin may be less effective than or as effective as low 
      molecular weight heparins for prevention of deep vein thrombosis and pulmonary 
      embolism after other orthopaedic procedures (Grade 2C). Aspirin may be associated 
      with a low rate of bleeding after total hip arthroplasty, total knee arthroplasty 
      and hip fracture surgery (Grade 1B). Aspirin may be associated with less bleeding 
      after total hip arthroplasty, total knee arthroplasty and hip fracture surgery 
      than other pharmacological agents (Grade 1B). No data are available for other 
      orthopaedic procedures. We do not recommend aspirin as thromboprophylaxis in 
      general surgery (Grade 1C). However, this type of prophylaxis could be 
      interesting especially in low-income countries (Grade 2C) and adequate 
      large-scale trials with proper study designs should be carried out (Grade 1C).
FAU - Jenny, Jean-Yves
AU  - Jenny JY
AD  - From the Orthopaedic Surgery Unit, Hôpitaux Universitaires de Strasbourg, CCOM, 
      Illkirch, France (J-YJ), Clinical Division of Haematology & Haemostaseology, 
      Department of Medicine I, Medical University Vienna, Waehringer Guertel, Vienna, 
      Austria (IP); and Department of Anaesthesia and Intensive Care Medicine, Cochin 
      University Hospital, Assistance-Publique Hôpitaux de Paris, Université Paris 
      Descartes, Paris, France (CMS).
FAU - Pabinger, Ingrid
AU  - Pabinger I
FAU - Samama, Charles Marc
AU  - Samama CM
CN  - ESA VTE Guidelines Task Force
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - England
TA  - Eur J Anaesthesiol
JT  - European journal of anaesthesiology
JID - 8411711
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anesthesiology/economics/methods/standards
MH  - Aspirin/*administration & dosage/adverse effects/economics/standards
MH  - Critical Care/economics/methods/standards
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Costs
MH  - Europe
MH  - Humans
MH  - Orthopedic Procedures/*adverse effects
MH  - Perioperative Care/economics/methods/*standards
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/economics/standards
MH  - Risk Factors
MH  - Societies, Medical/standards
MH  - Time Factors
MH  - Treatment Outcome
MH  - Venous Thromboembolism/etiology/*prevention & control
EDAT- 2017/11/08 06:00
MHDA- 2019/09/24 06:00
CRDT- 2017/11/08 06:00
PHST- 2017/11/08 06:00 [pubmed]
PHST- 2019/09/24 06:00 [medline]
PHST- 2017/11/08 06:00 [entrez]
AID - 10.1097/EJA.0000000000000728 [doi]
PST - ppublish
SO  - Eur J Anaesthesiol. 2018 Feb;35(2):123-129. doi: 10.1097/EJA.0000000000000728.

PMID- 9857467
OWN - NLM
STAT- MEDLINE
DCOM- 19990222
LR  - 20131121
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 87 Suppl 4
DP  - 1998
TI  - [Inhibition of thrombocyte aggregation after heart valve replacement].
PG  - 46-55
AB  - After implantation of a mechanical cardiac valve, lifelong, full anticoagulation 
      has been the tradition. After implantation of a biological valve, anticoagulation 
      during 3 months subsequent to the operation is customary. This review evaluates 
      the role of platelet inhibition after cardiac valve replacement. Platelet 
      aggregation is inhibited effectively by aspirin in a daily dose of 100-160 mg. At 
      this dose, episodes of severe bleeding are not significantly more frequent than 
      during placebo, whereas patients on full anticoagulation bleed at a rate of 2% 
      per year. After implantation of a mechanical cardiac valve, sole platelet 
      inhibition is inferior to full anticoagulation. With a lower rate of bleeding, 
      aspirin appears to prevent thromboembolic episodes caused by mechanical bileaflet 
      prostheses (e.g., St. Jude) in the aortic position, and is almost as efficient as 
      full anticoagulation. In Germany, patients with a porcine bioprosthesis, as 
      currently in use, in the aortic position, frequently receive 100 mg aspiring per 
      day. For patients with porcine bioprostheses in the mitral plus eventually in the 
      aortic position in stable sinus rhythm, 100 mg aspirin per day is preferred to 
      anticoagulation. For children with mechanical aortic valves, aspirin (2 
      mg/kg/day) needs to be considered an effective and convenient alternative to 
      anticoagulation. Combining anticoagulation with 100 mg aspirin per day after 
      implantation of a left-sided mechanical cardiac valve is pathophysiologically 
      sound, but used to be considered as rendering the patients too bleeding-prone. 
      Recently, total mortality and morbidity definitely have been demonstrated to be 
      reduced by combined anticoagulation and platelet inhibition as compared to sole 
      anticoagulation. Combining platelet inhibition with moderate anticoagulation (INR 
      2.0-3.0) was superior to combining it with full anticoagulation in terms of 
      safety (INR > 3.0). Thus, current evidence favors combining moderate 
      anticoagulation with 100 mg aspirin per day after left-sided mechanical cardiac 
      valve replacement.
FAU - von Schacky, C
AU  - von Schacky C
AD  - Medizinische Klinik Klinikum Innenstadt der Universität München.
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
TT  - Thrombozytenaggregationshemmung nach Herzklappenersatz.
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - *Heart Valve Prosthesis Implantation
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Postoperative Complications/etiology/*prevention & control
MH  - Risk Factors
MH  - Thromboembolism/etiology/*prevention & control
RF  - 64
EDAT- 1998/12/19 00:00
MHDA- 1998/12/19 00:01
CRDT- 1998/12/19 00:00
PHST- 1998/12/19 00:00 [pubmed]
PHST- 1998/12/19 00:01 [medline]
PHST- 1998/12/19 00:00 [entrez]
PST - ppublish
SO  - Z Kardiol. 1998;87 Suppl 4:46-55.

PMID- 6698337
OWN - NLM
STAT- MEDLINE
DCOM- 19840327
LR  - 20131121
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 8
IP  - 1
DP  - 1984 Jan
TI  - [Aspirin and gastroduodenal toxicity. A double-blind endoscopic study of the 
      effects of placebo, aspirin and lysine acetylsalicylate in healthy subjects].
PG  - 28-32
AB  - The aim of this double-blind endoscopic study was to compare the effects of 
      placebo (group I, 5 patients), lysine acetylsalicylate (group II, 7 patients) and 
      acetylsalicylic acid (group III, 7 patients) on the gastric and duodenal mucosa 
      in healthy humans. Endoscopy was performed before and one hour after endoscopic 
      instillation of aspirin (500 mg) or placebo in the stomach. Endoscopy was 
      repeated after one week of aspirin-treatment (2 g per day) or placebo. Endoscopic 
      findings were graded from 0 to 6 with regard to the aspect of the lesions 
      (petechiae, erosions, ulcers) and to their number (less than 10; greater than 
      10). One hour after placebo instillation endoscopic findings were normal in all 
      the patients of group I. Three and 5 patients of groups II and III, respectively, 
      developed gastric lesions but none had duodenal lesions. At day 8 only one 
      subject from group I had gastric petechiae. After one week of aspirin-treatment, 
      13 out of the 14 subjects of groups II and III developed gastric lesions and 3 in 
      each group had duodenal lesions. The endoscopic score was significantly higher in 
      group III than in group II for the following localisations: fundus, antrum, 
      entire stomach, and stomach + duodenum. However the duodenal score was not 
      significantly different between these 2 groups. It is concluded that, after a 
      one-week treatment in normal patients, standard aspirin produces 2 fold more 
      gastric mucosal damage than does soluble aspirin.
FAU - Bretagne, J F
AU  - Bretagne JF
FAU - Feuillu, A
AU  - Feuillu A
FAU - Gosselin, M
AU  - Gosselin M
FAU - Gastard, J
AU  - Gastard J
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Aspirine et toxicité gastroduodénale. Etude endoscopique en double insu des 
      effets d'un placebo, de l'aspirine et de l'acétylsalicylate de lysine chez le 
      sujet sain.
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - 0 (Salicylates)
RN  - 0 (lysinsalicylate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Double-Blind Method
MH  - Duodenal Diseases/*chemically induced
MH  - Duodenum/pathology
MH  - Endoscopy
MH  - Female
MH  - Gastric Mucosa/pathology
MH  - Humans
MH  - Male
MH  - Salicylates/adverse effects/blood
MH  - Stomach/pathology
MH  - Stomach Diseases/*chemically induced
MH  - Time Factors
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Gastroenterol Clin Biol. 1984 Jan;8(1):28-32.

PMID- 22338573
OWN - NLM
STAT- MEDLINE
DCOM- 20130107
LR  - 20220409
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 10
IP  - 5
DP  - 2012 Sep
TI  - Mechanisms of platelet activation in acute coronary syndromes.
PG  - 578-88
AB  - Platelets are known to play a fundamental role in acute coronary syndromes. After 
      atherosclerotic plaque rupture, platelets can form pathogenic, occlusive thrombi 
      leading to acute ischemic events. Today there are promising results from recently 
      developed antiplatelet agents. However, morbidity and mortality from acute 
      coronary syndromes remain significant despite the administration of combination 
      therapies (aspirin, thienopyridines). Sharing similar mechanisms, platelets may 
      also form a thin monolayer in areas of damaged endothelium contributing to 
      primary hemostasis. For this reason, administration of antiplatelet drugs is 
      often associated with increased bleeding risk. As a result, currently available 
      antiplatelet therapy cannot be characterized as optimal. The precise mechanisms 
      of platelet activation in acute coronary syndromes are still under investigation. 
      The study of basic mechanisms of platelet adhesion, activation and aggregation 
      after atherosclerotic plaque rupture may help to define new targets for their 
      inhibition. In the future, newer antiplatelet agents may offer more comprehensive 
      platelet inhibition without interfering with primary hemostasis, thus offering 
      greater protection with lower hemorrhagic risk.
FAU - Stakos, Dimitrios A
AU  - Stakos DA
AD  - Department of Cardiology, Democritus University of Thrace, Alexandroupolis, 
      Greece. dstakos@med.duth.gr
FAU - Tziakas, Dimitrios N
AU  - Tziakas DN
FAU - Stellos, Konstantinos
AU  - Stellos K
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thienopyridines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy/*physiopathology
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/*metabolism
MH  - Drug Design
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - *Platelet Activation/drug effects
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/therapeutic 
      use
MH  - Thienopyridines/administration & dosage/pharmacology/therapeutic use
EDAT- 2012/02/18 06:00
MHDA- 2013/01/08 06:00
CRDT- 2012/02/18 06:00
PHST- 2011/06/30 00:00 [received]
PHST- 2011/10/15 00:00 [revised]
PHST- 2012/01/05 00:00 [accepted]
PHST- 2012/02/18 06:00 [entrez]
PHST- 2012/02/18 06:00 [pubmed]
PHST- 2013/01/08 06:00 [medline]
AID - CVP-EPUB-20120215-009 [pii]
AID - 10.2174/157016112801784477 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2012 Sep;10(5):578-88. doi: 10.2174/157016112801784477.

PMID- 1751342
OWN - NLM
STAT- MEDLINE
DCOM- 19920130
LR  - 20161123
IS  - 0391-9005 (Print)
IS  - 0391-9005 (Linking)
VI  - 12
IP  - 8-9
DP  - 1991 Aug-Sep
TI  - [Ketoprofen in the prevention of postoperative pain in abdominal surgery. A 
      multicenter study].
PG  - 456-8
AB  - Two-hundred-forty-eight patients undergoing abdominal surgery were admitted to a 
      multicentric clinical trial. The patients were randomly assigned to a single i.v. 
      dose of ketoprofen or acetylsalicylic acid, 15 minutes after the end of 
      operation. Ketoprofen showed a better analgesic activity with a statistically 
      significant difference at 2 and 4 hours after administration. Two patients 
      treated with ketoprofen reported vomiting and skin rash respectively. The results 
      of this study confirm the efficacy of ketoprofen for the prophylaxis of 
      postoperative pain in abdominal surgery.
FAU - Avila, G
AU  - Avila G
AD  - Divisione Chirurgica 2a, Ospedale Consorziale di Treviglio.
FAU - Balbo, G
AU  - Balbo G
FAU - Biasiato, R
AU  - Biasiato R
FAU - Brighenti, F M
AU  - Brighenti FM
FAU - Conte, R
AU  - Conte R
FAU - Donini, I
AU  - Donini I
FAU - Landi, E
AU  - Landi E
FAU - Marzocca, G
AU  - Marzocca G
FAU - Mazzi, U
AU  - Mazzi U
FAU - Morino, F
AU  - Morino F
AU  - et al.
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Il ketoprofene nella profilassi del dolore postoperatorio in chirurgia 
      addominale. Studio multicentrico.
PL  - Italy
TA  - G Chir
JT  - Il Giornale di chirurgia
JID - 9011768
RN  - 0 (Analgesics)
RN  - 90Y4QC304K (Ketoprofen)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Abdomen/*surgery
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analgesics/therapeutic use
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Ketoprofen/*therapeutic use
MH  - Lysine/analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*prevention & control
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
PST - ppublish
SO  - G Chir. 1991 Aug-Sep;12(8-9):456-8.

PMID- 7094976
OWN - NLM
STAT- MEDLINE
DCOM- 19820917
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 22
IP  - 1
DP  - 1982
TI  - Gastric emptying and absorption of acetylsalicylic acid administered as 
      enteric-coated micro-granules.
PG  - 57-61
AB  - Enteric-coated and uncoated microgranules of acetylsalicylic acid (ASA), labelled 
      with 51Cr, were administered orally to six healthy male volunteers in a 
      cross-over study. Gastric emptying was studied using a profile scanning radiation 
      technique. Absorption of ASA was followed by measuring the plasma concentration 
      of salicylate. Gastric emptying both of uncoated and enteric-coated granules 
      varied considerably between individuals, but in most cases was gradual and 
      extended over a period of several hours. The median time until 50% and 90% were 
      emptied from the stomach was 1 and 3-3.5 h, respectively, for both the uncoated 
      and enteric-coated granules. The absorption of ASA from the uncoated granules 
      occurred in parallel with the gastric emptying. However, with the enteric-coated 
      granules, absorption was delayed for about 3 h after gastric emptying. It was 
      concluded that the slow absorption of ASA from enteric-coated granules could be 
      explained partly by gradual gastric emptying and partly by slow dissolution of 
      the ASA granules in the intestine.
FAU - Alpsten, M
AU  - Alpsten M
FAU - Bogentoft, C
AU  - Bogentoft C
FAU - Ekenved, G
AU  - Ekenved G
FAU - Sölvell, L
AU  - Sölvell L
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Capsules)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*metabolism
MH  - Capsules
MH  - Delayed-Action Preparations
MH  - *Gastric Emptying
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - *Intestinal Absorption
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1007/BF00606426 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1982;22(1):57-61. doi: 10.1007/BF00606426.

PMID- 30257623
OWN - NLM
STAT- MEDLINE
DCOM- 20190711
LR  - 20221222
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 209
IP  - 7
DP  - 2018 Sep 1
TI  - <em>Helicobacter pylori</em> infection and the risk of upper gastrointestinal 
      bleeding in low dose aspirin users: systematic review and meta-analysis.
PG  - 306-311
AB  - OBJECTIVE: To determine whether the risk of upper gastrointestinal bleeding in 
      patients taking low dose aspirin (≤ 325 mg/day) is increased in people with 
      Helicobacter pylori infections. STUDY DESIGN: A systematic search for all 
      publications since 1989 (when H. pylori was named) using search term equivalents 
      for "upper gastrointestinal haemorrhage" and "aspirin". Articles were assessed 
      individually for inclusion of data on H. pylori infection, as not all relevant 
      papers were indexed with this term. Data that could be pooled were then subjected 
      to meta-analysis, using a random effects model. DATA SOURCES: MEDLINE, Embase, 
      Scopus, the Cochrane Library. DATA SYNTHESIS: Of 7599 retrieved publications, 
      reports for seven case-control studies contained data suitable for meta-analysis; 
      four were deemed high quality on the Newcastle-Ottawa scale. Upper 
      gastrointestinal haemorrhage was more frequent in aspirin users infected with H. 
      pylori than in those who were not (odds ratio [OR], 2.32; 95% CI, 1.25-4.33; P = 
      0.008). The heterogeneity of the studies was significant (Q = 19.3, P = 0.004; 
      I(2) = 68.9%, 95% CI, 31.5-85.9%), but the pooled odds ratio was similar after 
      removing the two studies that contributed most to heterogeneity (OR, 2.34; 95% 
      CI, 1.56-3.53; P < 0.001). The number needed to treat to prevent one bleeding 
      event annually was estimated to be between 100 and more than 1000. CONCLUSIONS: 
      The odds of upper gastrointestinal bleeding in patients taking low dose aspirin 
      is about twice as great in those infected with H. pylori. Testing for and 
      treating the infection should be considered in such patients, especially if their 
      underlying risk of peptic ulcer bleeding is already high.
FAU - Ng, Justin Ch
AU  - Ng JC
AD  - University of Melbourne, Melbourne, VIC JNg@phcn.vic.gov.au.
FAU - Yeomans, Neville David
AU  - Yeomans ND
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - *Helicobacter Infections/complications/epidemiology
MH  - Helicobacter pylori
MH  - Humans
MH  - Middle Aged
MH  - *Peptic Ulcer Hemorrhage/complications/epidemiology
MH  - Risk Factors
OTO - NOTNLM
OT  - Cardiovascular agents
OT  - Gastrointestinal diseases
OT  - Helicobacter pylori
EDAT- 2018/09/28 06:00
MHDA- 2019/07/12 06:00
CRDT- 2018/09/28 06:00
PHST- 2017/12/21 00:00 [received]
PHST- 2018/05/25 00:00 [accepted]
PHST- 2018/09/28 06:00 [entrez]
PHST- 2018/09/28 06:00 [pubmed]
PHST- 2019/07/12 06:00 [medline]
AID - 10.5694/mja17.01274 [pii]
AID - 10.5694/mja17.01274 [doi]
PST - ppublish
SO  - Med J Aust. 2018 Sep 1;209(7):306-311. doi: 10.5694/mja17.01274.

PMID- 23516561
OWN - NLM
STAT- MEDLINE
DCOM- 20130917
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 3
DP  - 2013
TI  - Aspirin use and risk of age-related macular degeneration: a meta-analysis.
PG  - e58821
LID - 10.1371/journal.pone.0058821 [doi]
LID - e58821
AB  - BACKGROUND: Age-related macular degeneration (AMD) is the main cause of blindness 
      and the curative options are limited. The objective of this meta-analysis was to 
      determine the association between aspirin use and risk of AMD. METHODS: A 
      comprehensive literature search was performed in PubMed, Embase, Web of Science, 
      and reference lists. A meta-analysis was performed by STATA software. RESULTS: 
      Ten studies involving 171,729 individuals examining the association between 
      aspirin use and risk of AMD were included. Among the included studies, 2 were 
      randomized-controlled trials (RCTs), 4 were case-control studies and 4 were 
      cohort studies. The relative risks (RRs) were pooled using a random-effects 
      model. Relative risks with 95% confidence intervals (CIs) of aspirin use as a 
      risk for AMD. The pooled RR of 10 included studies between the use of aspirin and 
      risk of AMD was 1.09 (95% CI, 0.96-1.24). The same result was detected in early 
      and late stage AMD subgroup analysis. In the subgroup analyses, the pooled RR of 
      RCTs, case-control studies and cohort studies were 0.81 (95% CI, 0.64-1.02), 1.02 
      (95% CI, 0.92-1.14) and 1.08 (95% CI, 0.91-1.28), respectively. CONCLUSIONS: The 
      use of aspirin was not associated with the risk of AMD.
FAU - Zhu, Wei
AU  - Zhu W
AD  - Department of Ophthalmology, Affiliated Tenth People's Hospital of Tongji 
      University, Shanghai, China.
FAU - Wu, Yan
AU  - Wu Y
FAU - Xu, Ding
AU  - Xu D
FAU - Li, Yan-Hong
AU  - Li YH
FAU - Jun, Ba
AU  - Jun B
FAU - Zhang, Xiao-Long
AU  - Zhang XL
FAU - Wang, Fang
AU  - Wang F
FAU - Yu, Jing
AU  - Yu J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20130314
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Macular Degeneration/*chemically induced
MH  - Risk
PMC - PMC3597550
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2013/03/22 06:00
MHDA- 2013/09/18 06:00
CRDT- 2013/03/22 06:00
PHST- 2012/12/03 00:00 [received]
PHST- 2013/02/07 00:00 [accepted]
PHST- 2013/03/22 06:00 [entrez]
PHST- 2013/03/22 06:00 [pubmed]
PHST- 2013/09/18 06:00 [medline]
AID - PONE-D-12-38531 [pii]
AID - 10.1371/journal.pone.0058821 [doi]
PST - ppublish
SO  - PLoS One. 2013;8(3):e58821. doi: 10.1371/journal.pone.0058821. Epub 2013 Mar 14.

PMID- 17685000
OWN - NLM
STAT- MEDLINE
DCOM- 20071010
LR  - 20161026
IS  - 0006-9248 (Print)
IS  - 0006-9248 (Linking)
VI  - 108
IP  - 1
DP  - 2007
TI  - Aspirin resistance.
PG  - 7-13
AB  - Acetylsalicylic acid, is one of the most effective antiplatelet agents. It 
      effectively reduces the risk of thrombotic events across wide spectrum of 
      patients with cardiovascular disease. However, the treatment failures are 
      relatively common and significant number of patients don't benefit from aspirin 
      therapy. In the last decade the term "aspirin resistance" has been used to 
      describe several different phenomena. This article exposes the difficulties in 
      defining aspirin resistance, discusses the mechanisms by which resistance may 
      occur and deals with its clinical impact. It is necessary to standardize a 
      definition of aspirin resistance, to develop reliable tests for it, and to assess 
      the clinical utility of testing on patients outcomes (Tab. 3, Ref. 60).
FAU - Mosorjakova, D
AU  - Mosorjakova D
AD  - Department of Internal Medicine I, Thomayer Faculty Hospital, and Institute for 
      Postgraduate Medical Education, Prague, Czech Republic.
FAU - Paluch, Z
AU  - Paluch Z
FAU - Alusík, S
AU  - Alusík S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Slovakia
TA  - Bratisl Lek Listy
JT  - Bratislavske lekarske listy
JID - 0065324
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/blood/prevention & control
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thrombosis/prevention & control
RF  - 60
EDAT- 2007/08/10 09:00
MHDA- 2007/10/11 09:00
CRDT- 2007/08/10 09:00
PHST- 2007/08/10 09:00 [pubmed]
PHST- 2007/10/11 09:00 [medline]
PHST- 2007/08/10 09:00 [entrez]
PST - ppublish
SO  - Bratisl Lek Listy. 2007;108(1):7-13.

PMID- 6221436
OWN - NLM
STAT- MEDLINE
DCOM- 19830610
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 29
IP  - 2
DP  - 1983 Jan 15
TI  - The sex-related differences in aspirin pharmacokinetics in rabbits and man and 
      its relationship to antiplatelet effects.
PG  - 125-39
AB  - There are a number of reports which suggest that the antithrombotic effect of 
      aspirin is limited to males. It is unclear whether this effect is due to 
      sex-related differences in the effect of aspirin on platelets, the vessel wall, 
      or the pharmacokinetics of aspirin. To test these possibilities we examined the 
      sex-related differences in (1) vessel wall PGI2 release and its inhibition by and 
      recovery from aspirin in rabbits; (2) the effects of aspirin on platelet 
      aggregation, thromboxane B2 and beta-thromboglobulin (BTG) release in man, and 
      (3) the pharmacokinetic characteristics of aspirin, in both rabbits and man. 
      Vascular wall PGI2 measured as 6-keto-PGF1 alpha, was not different in male and 
      females rabbits, and was inhibited to a similar extent by identical 
      concentrations of aspirin. The duration of this inhibitory effect was also the 
      same in males and females. The pattern of inhibition of collagen-induced platelet 
      aggregation, and collagen-induced thromboxane B2 and BTG release by aspirin were 
      not different in either sex. There was, however, a sex-related difference in a 
      number of pharmacokinetic characteristics of aspirin both in rabbits and man. 
      Thus, aspirin was absorbed more rapidly, distributed in larger apparent volume 
      and was hydrolysed more rapidly in females. These observations suggest that the 
      sex-related differences in the antithrombotic effects of aspirin seen in clinical 
      studies are not due to differences in the effects of aspirin on the inhibition of 
      platelet function mediated by the inhibition of cyclo-oxygenase in either the 
      platelet or the vessel wall. An effect of aspirin on platelet function 
      independent of the inhibition of cyclo-oxygenase has been described and it is 
      possible that this effect may be influenced by sex-related differences in the 
      pharmacokinetics of aspirin.
FAU - Buchanan, M R
AU  - Buchanan MR
FAU - Rischke, J A
AU  - Rischke JA
FAU - Butt, R
AU  - Butt R
FAU - Turpie, A G
AU  - Turpie AG
FAU - Hirsh, J
AU  - Hirsh J
FAU - Rosenfeld, J
AU  - Rosenfeld J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (beta-Thromboglobulin)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 9007-34-5 (Collagen)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/metabolism
MH  - Adult
MH  - Animals
MH  - Aorta, Thoracic
MH  - Aspirin/administration & dosage/metabolism/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cells, Cultured
MH  - Collagen/physiology
MH  - Dose-Response Relationship, Drug
MH  - Endothelium
MH  - Epoprostenol/biosynthesis/metabolism
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
MH  - Sex Factors
MH  - Thromboxane B2/metabolism
MH  - beta-Thromboglobulin/metabolism
EDAT- 1983/01/15 00:00
MHDA- 1983/01/15 00:01
CRDT- 1983/01/15 00:00
PHST- 1983/01/15 00:00 [pubmed]
PHST- 1983/01/15 00:01 [medline]
PHST- 1983/01/15 00:00 [entrez]
AID - 0049-3848(83)90134-2 [pii]
AID - 10.1016/0049-3848(83)90134-2 [doi]
PST - ppublish
SO  - Thromb Res. 1983 Jan 15;29(2):125-39. doi: 10.1016/0049-3848(83)90134-2.

PMID- 372867
OWN - NLM
STAT- MEDLINE
DCOM- 19790626
LR  - 20131121
IS  - 0028-8446 (Print)
IS  - 0028-8446 (Linking)
VI  - 89
IP  - 628
DP  - 1979 Jan 24
TI  - Diclofenac in rheumatoid disease.
PG  - 43-5
AB  - The clinical activity and side effects of a new phenyl acetic-acid derivative, 
      diclofenac, have been assessed in 24 patients with rheumatoid disease. Diclofenac 
      25 mg q.i.d. was compared with 750mg of aspirin BP q.i.d. using a double-blind 
      crossover technique involving four weeks on each drug. Benefits were similar for 
      the two preparations but with improvement in morning stiffness and incidence of 
      dyspepsia favouring diclofenac, and a more marked reduction of the sedimentation 
      rate occurring with aspirin. A moderate elevation of liver enzymes was seen in 
      one patient on diclofenac, and of lactate dehydrogenase in one other. It is 
      concluded that diclofenac is a therapeutically active analgesic anti-inflammatory 
      agent.
FAU - Treadwell, B L
AU  - Treadwell BL
FAU - Tweed, J M
AU  - Tweed JM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - New Zealand
TA  - N Z Med J
JT  - The New Zealand medical journal
JID - 0401067
RN  - 0 (Phenylacetates)
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Diclofenac/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Humans
MH  - Liver/drug effects/enzymology
MH  - Phenylacetates/*therapeutic use
EDAT- 1979/01/24 00:00
MHDA- 1979/01/24 00:01
CRDT- 1979/01/24 00:00
PHST- 1979/01/24 00:00 [pubmed]
PHST- 1979/01/24 00:01 [medline]
PHST- 1979/01/24 00:00 [entrez]
PST - ppublish
SO  - N Z Med J. 1979 Jan 24;89(628):43-5.

PMID- 18044220
OWN - NLM
STAT- MEDLINE
DCOM- 20080123
LR  - 20131121
IS  - 0914-3777 (Print)
IS  - 0914-3777 (Linking)
VI  - 20
IP  - 4
DP  - 2007 Oct
TI  - [Autopsy case of aspirin intoxication: distribution of salicylic acid and 
      salicyluric acid in body fluid and organs].
PG  - 375-80
AB  - A 52 year-old woman ingested approximately 300 tablets (325 mg) of aspirin in a 
      suicide attempt. We analyzed the concentrations of salicylic acid (SA) and 
      salicyluric acid (SUA) in body fluids and organs using a modified previous 
      high-performance liquid chromatographic method. The concentrations of SA in heart 
      and femoral blood were 1.1 mg/mL and 1.3 mg/mL, respectively; the results were 
      far higher than the lethal level. The concentration of SA was 0.3-0.4 mg/g in 
      brain, 0.9-1.4 mg/g in lung, 0.6-0.8 mg/g in liver and 0.9 mg/mL in kidney.
FAU - Ihama, Yoko
AU  - Ihama Y
AD  - Department of Legal Medicine, School of Medicine, University of the Ryukyus, 
      Okinawa.
FAU - Ageda, Saori
AU  - Ageda S
FAU - Fuke, Chiaki
AU  - Fuke C
FAU - Miyazaki, Tetsuji
AU  - Miyazaki T
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Chudoku Kenkyu
JT  - Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of 
      toxicology
JID - 9310053
RN  - 0 (Hippurates)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*metabolism/*poisoning
MH  - *Autopsy
MH  - Body Fluids/*chemistry
MH  - *Brain Chemistry
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Hippurates/*analysis
MH  - Humans
MH  - Kidney/chemistry
MH  - Liver/chemistry
MH  - Lung/chemistry
MH  - Middle Aged
MH  - Myocardium/*chemistry
MH  - Salicylic Acid/*analysis
MH  - Tissue Distribution
EDAT- 2007/11/30 09:00
MHDA- 2008/01/24 09:00
CRDT- 2007/11/30 09:00
PHST- 2007/11/30 09:00 [pubmed]
PHST- 2008/01/24 09:00 [medline]
PHST- 2007/11/30 09:00 [entrez]
PST - ppublish
SO  - Chudoku Kenkyu. 2007 Oct;20(4):375-80.

PMID- 17275250
OWN - NLM
STAT- MEDLINE
DCOM- 20070720
LR  - 20151119
IS  - 0753-3322 (Print)
IS  - 0753-3322 (Linking)
VI  - 61
IP  - 2-3
DP  - 2007 Feb-Apr
TI  - Suppressive effect of post- or pre-treatment of aspirin metabolite on mitomycin 
      C-induced genotoxicity using the somatic mutation and recombination test in 
      Drosophila melanogaster.
PG  - 113-9
AB  - In our previous paper, we found that aspirin suppressed in a somatic mutation and 
      recombination test (SMART) of mitomycin C (MMC) in Drosophila melanogaster. In 
      order to reveal the mechanism of bio-antimutagenicity and/or preventive effect of 
      aspirin, we evaluated the suppressive ability of each aspirin metabolite, such as 
      salicylic acid (SA), salicyluric acid (SUA), gentisic acid (GA), gentisuric acid 
      (GUA) and 2,3-dihydroxybenzoic acid (DHBA), in SMART in D. melanogaster using 
      post- and pre-treatments. As for the post-treatment, SA reduced the numbers of 
      large single and twin spots. GA reduced the small single and large single spots, 
      and GUA reduced the single spots, large single and twin spots. The inhibition of 
      GUA is slightly stronger than that of any other metabolites; the inhibition 
      percentage is 49 at the dose of 5 mg/bottle. On the other hand, as for the 
      pre-treatment, aspirin, SUA, GA and DHBA reduced the numbers of small single 
      spots. SUA, GE and DHBA reduced the number of large single spots. Aspirin and its 
      metabolites did not reduce the number of twin spots. The results of the present 
      study suggest that SA, GA and GUA repair or replicate DNA-damage by MMC and SUA, 
      GA, GUA and DHBA prevent DNA-damage by MMC. It is suggested that secondary cancer 
      is prevented by aspirin post-treatment without losing the medicinal effectiveness 
      (anti-tumor activity). Therefore, we consider there are effective doses and/or 
      administration timing of aspirin and MMC to prevent secondary cancer.
FAU - Niikawa, Miki
AU  - Niikawa M
AD  - Department of Hygienics, Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, 
      Gifu 502-8585, Japan. niikawam@tim.hi-ho.ne.jp
FAU - Shin, Seizai
AU  - Shin S
FAU - Nagase, Hisamitsu
AU  - Nagase H
LA  - eng
PT  - Journal Article
DEP - 20070116
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antimutagenic Agents)
RN  - 0 (Gentisates)
RN  - 0 (Hippurates)
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Mutagens)
RN  - 25351-24-0 (gentisuric acid)
RN  - 487-54-7 (salicylurate)
RN  - 50SG953SK6 (Mitomycin)
RN  - 70D5FBB392 (2,3-dihydroxybenzoic acid)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - VP36V95O3T (2,5-dihydroxybenzoic acid)
SB  - IM
MH  - Animals
MH  - Antimutagenic Agents/administration & dosage/analysis/metabolism/*pharmacology
MH  - Aspirin/administration & dosage/analysis/metabolism/*pharmacology
MH  - DNA Damage
MH  - DNA Repair/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drosophila melanogaster/drug effects/genetics
MH  - Drug Antagonism
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gentisates/pharmacology
MH  - Hippurates/pharmacology
MH  - Hydroxybenzoates/pharmacology
MH  - Male
MH  - Mitomycin/*toxicity
MH  - Mutagens/*toxicity
MH  - Mutation/drug effects
MH  - Recombination, Genetic/*drug effects
MH  - Salicylic Acid/pharmacology
EDAT- 2007/02/06 09:00
MHDA- 2007/07/21 09:00
CRDT- 2007/02/06 09:00
PHST- 2006/06/12 00:00 [received]
PHST- 2006/07/11 00:00 [accepted]
PHST- 2007/02/06 09:00 [pubmed]
PHST- 2007/07/21 09:00 [medline]
PHST- 2007/02/06 09:00 [entrez]
AID - S0753-3322(06)00347-7 [pii]
AID - 10.1016/j.biopha.2006.07.094 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2007 Feb-Apr;61(2-3):113-9. doi: 
      10.1016/j.biopha.2006.07.094. Epub 2007 Jan 16.

PMID- 36626242
OWN - NLM
STAT- MEDLINE
DCOM- 20230216
LR  - 20230309
IS  - 1520-4812 (Electronic)
IS  - 1043-1802 (Linking)
VI  - 34
IP  - 2
DP  - 2023 Feb 15
TI  - Aspirin-Loaded Cross-Linked Lipoic Acid Nanodrug Prevents Postoperative Tumor 
      Recurrence by Residual Cancer Cell Killing and Inflammatory Microenvironment 
      Improvement.
PG  - 366-376
LID - 10.1021/acs.bioconjchem.2c00548 [doi]
AB  - In addition to residual cancer cells, the surgery resection-induced 
      hyperinflammatory microenvironment is a key factor that leads to postsurgical 
      cancer recurrence. Herein, we developed a dual-functional nanodrug Asp@cLANVs for 
      postsurgical recurrence inhibition by loading the classical anti-inflammatory 
      drug aspirin (Asp) into cross-linked lipoic acid nanovesicles (cLANVs). The 
      Asp@cLANVs can not only kill residual cancer cells at the doses comparable to 
      common cytotoxic drugs by synergistic interaction between Asp and cLANVs, but 
      also improve the postsurgical inflammatory microenvironment by their strongly 
      synergistic anti-inflammation activity between Asp and cLANVs. Using mice bearing 
      partially removed NCI-H460 tumors, we found that Asp@cLANVs gave a much lower 
      recurrence rate (33.3%) compared with the first-line cytotoxic drug cisplatin 
      (100%), and no mice died for at least 60 days after Asp@cLANV treatment while no 
      mouse survived beyond day 43 in the cisplatin group. This dual-functional 
      nanodrug constructs the first example that combines residual cancer cell killing 
      and postoperative inflammation microenvironment improvement to suppress 
      postsurgical cancer recurrence.
FAU - Jing, Pei
AU  - Jing P
AD  - College of Biomedical Engineering and National Engineering Research Center for 
      Biomaterials, Sichuan University, 29 Wangjiang Road, Chengdu 610064, P.R. China.
AD  - Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, Sichuan Province 646000, P.R. China.
FAU - Luo, Yuling
AU  - Luo Y
AD  - Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 
      Luzhou, Sichuan Province 646000, P.R. China.
FAU - Chen, Yun
AU  - Chen Y
AD  - MOE International Joint Research Laboratory on Synthetic Biology and Medicines, 
      School of Biology and Biological Engineering, South China University of 
      Technology, Guangzhou 510006, P.R. China.
FAU - Tan, Jiangbing
AU  - Tan J
AD  - College of Biomedical Engineering and National Engineering Research Center for 
      Biomaterials, Sichuan University, 29 Wangjiang Road, Chengdu 610064, P.R. China.
FAU - Liao, Chunyan
AU  - Liao C
AD  - College of Biomedical Engineering and National Engineering Research Center for 
      Biomaterials, Sichuan University, 29 Wangjiang Road, Chengdu 610064, P.R. China.
FAU - Zhang, Shiyong
AU  - Zhang S
AUID- ORCID: 0000-0001-7633-358X
AD  - College of Biomedical Engineering and National Engineering Research Center for 
      Biomaterials, Sichuan University, 29 Wangjiang Road, Chengdu 610064, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230110
PL  - United States
TA  - Bioconjug Chem
JT  - Bioconjugate chemistry
JID - 9010319
RN  - Q20Q21Q62J (Cisplatin)
RN  - 73Y7P0K73Y (Thioctic Acid)
RN  - 0 (Antineoplastic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Cisplatin/pharmacology
MH  - *Thioctic Acid/pharmacology/therapeutic use
MH  - Neoplasm Recurrence, Local/drug therapy/prevention & control
MH  - Neoplasm, Residual/drug therapy
MH  - *Antineoplastic Agents/pharmacology/therapeutic use
MH  - Cell Death
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Nanoparticles/therapeutic use
MH  - Cell Line, Tumor
MH  - Tumor Microenvironment
EDAT- 2023/01/11 06:00
MHDA- 2023/02/17 06:00
CRDT- 2023/01/10 12:13
PHST- 2023/01/11 06:00 [pubmed]
PHST- 2023/02/17 06:00 [medline]
PHST- 2023/01/10 12:13 [entrez]
AID - 10.1021/acs.bioconjchem.2c00548 [doi]
PST - ppublish
SO  - Bioconjug Chem. 2023 Feb 15;34(2):366-376. doi: 10.1021/acs.bioconjchem.2c00548. 
      Epub 2023 Jan 10.

PMID- 18239256
OWN - NLM
STAT- MEDLINE
DCOM- 20080519
LR  - 20131121
IS  - 1386-0291 (Print)
IS  - 1386-0291 (Linking)
VI  - 38
IP  - 3
DP  - 2008
TI  - Hemorheological background of acetylsalicylic acid resistance.
PG  - 143-52
AB  - BACKGROUND: Pathologic hemorheological parameters and increased platelet 
      aggregation in association with other risk factors significantly increase the 
      possibility of the development of ischemia. Acetylsalicylic acid (ASA) is an 
      effective antithrombotic agent, which prevents a variety of cardiovascular 
      diseases. OBJECTIVES: The aim of our present study was to compare the 
      hemorheological parameters of patients with effective platelet inhibition by ASA 
      to those with ineffective one. METHODS: 2045 patients taking 100 mg ASA daily 
      were involved in our study (1255 males, mean age: 63+/-11 yrs, 790 females, mean 
      age: 63+/-12 yrs). To exclude the effect of risk profile, previous diseases and 
      medication, 323 patients (197 males, mean age 60+/-13 yrs and 126 females, mean 
      age 60+/-12 yrs) were selected from the examined group with matching parameters. 
      Blood was taken after an overnight fast between 8:00 and 9:00 a.m. Platelet 
      aggregation was measured in Carat TX-4 optical platelet aggregometer. Blood 
      hematocrit was measured by Heraeus microhematocrit centrifuge and red blood cell 
      aggregation was detected by Myrenne aggregometer. Plasma fibrinogen was measured 
      by Clauss' method. Plasma and whole blood viscosities were measured in Hevimet 40 
      capillary viscosimeter. RESULTS: Patients with effective ASA inhibition had 
      significantly lower plasma fibrinogen level (p<0.05) and red blood cell 
      aggregation values both in the heterogenous and the selected populations 
      (p<0.01). The other hemorheological parameters were not statistically different 
      in the two groups. CONCLUSION: The background of ineffective ASA medication has 
      not yet been fully elucidated. Higher fibrinogen concentration increases red 
      blood cell aggregation and can also result in increased platelet aggregation. 
      Thus, increased plasma fibrinogen level may play an important role in the in 
      vitro and in vivo platelet resistance to ASA.
FAU - Feher, Gergely
AU  - Feher G
AD  - 1st Department of Medicine, University of Pecs, Medical School, Pecs, Hungary. 
      gerely.feher@aok.pte.hu
FAU - Koltai, Katalin
AU  - Koltai K
FAU - Kesmarky, Gabor
AU  - Kesmarky G
FAU - Toth, Kalman
AU  - Toth K
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/*adverse effects/*pharmacology/therapeutic use
MH  - Blood Viscosity/drug effects
MH  - Cerebrovascular Disorders/drug therapy/physiopathology
MH  - Erythrocyte Aggregation/drug effects
MH  - Female
MH  - Fibrinogen/metabolism
MH  - Heart Diseases/drug therapy/physiopathology
MH  - Hematocrit
MH  - *Hemorheology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Assessment
EDAT- 2008/02/02 09:00
MHDA- 2008/05/20 09:00
CRDT- 2008/02/02 09:00
PHST- 2008/02/02 09:00 [pubmed]
PHST- 2008/05/20 09:00 [medline]
PHST- 2008/02/02 09:00 [entrez]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 2008;38(3):143-52.

PMID- 8898452
OWN - NLM
STAT- MEDLINE
DCOM- 19970121
LR  - 20190920
IS  - 0085-5928 (Print)
IS  - 0085-5928 (Linking)
VI  - 220
DP  - 1996
TI  - Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal 
      cancer: a review of the epidemiological evidence.
PG  - 137-41
AB  - There is substantial experimental, clinical and epidemiological evidence that 
      regular use of non-steroid anti-inflammatory drugs (NSAIDs), particularly 
      aspirin, is associated with a reduced risk of colorectal cancer. The protective 
      effect is thought to arise from inhibition of prostaglandin synthesis, although 
      the precise mechanism remains unclear. Of the epidemiological studies carried 
      out, all but one have found that regular use of NSAIDs reduces the risk of 
      colorectal cancer by 30-50%. The consistency of this finding across studies and 
      the magnitude of the reduced risk tend to support a causal association between 
      NSAID use and reduced risk of colorectal cancer. Further, the protective effect 
      increases with longer duration of use, and persists after controlling for other 
      colorectal cancer risk factors. However, these observational studies are limited 
      by inherent biases, potential confounding with other lifestyle factors, and 
      sparse information on dose and duration of use. Only one randomized controlled 
      trial has been carried out, and no reduction in risk was associated with intake 
      of one aspirin per day, though this may be due to the short follow-up period and 
      the low dose of aspirin taken. Further observational studies and randomized 
      controlled trials are needed to confirm the association, to quantify the dosage 
      required for a protective effect, and to identify those patients most likely to 
      benefit.
FAU - Weiss, H A
AU  - Weiss HA
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethesda, MD 20892-7374, USA.
FAU - Forman, D
AU  - Forman D
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Scand J Gastroenterol Suppl
JT  - Scandinavian journal of gastroenterology. Supplement
JID - 0437034
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/epidemiology/*prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Case-Control Studies
MH  - Colorectal Neoplasms/epidemiology/*prevention & control
MH  - Humans
RF  - 29
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.3109/00365529609094766 [doi]
PST - ppublish
SO  - Scand J Gastroenterol Suppl. 1996;220:137-41. doi: 10.3109/00365529609094766.

PMID- 34883315
OWN - NLM
STAT- MEDLINE
DCOM- 20220325
LR  - 20220325
IS  - 1532-3072 (Electronic)
IS  - 0040-8166 (Linking)
VI  - 74
DP  - 2022 Feb
TI  - Aspirin impacts on stem cells: Implications for therapeutic targets.
PG  - 101707
LID - S0040-8166(21)00223-8 [pii]
LID - 10.1016/j.tice.2021.101707 [doi]
AB  - Despite the regenerative potential of stem cell therapy in pre-clinical 
      investigations, clinical translation of cell-based therapy has not been 
      completely clarified. In recent years, the importance of lifestyle, patient 
      comorbidities, and prescribed medication has attracted more attention in the 
      efficacy of cell therapy. As a nonsteroidal anti-inflammatory drug, aspirin is 
      one of the most prevalent prescribed medications in the clinic for various 
      disorders. Hence, aspirin treatment might affect the efficacy of stem cell 
      therapy. In this regard, the current review focused on the impacts of aspirin on 
      the viability, proliferation, differentiation, and immunomodulatory properties of 
      stem cells in vitro as well as in experimental animal models.
CI  - Copyright © 2021. Published by Elsevier Ltd.
FAU - Zafarmand, Seyedeh Shaghayegh
AU  - Zafarmand SS
AD  - Clinical Neurology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Karimi-Haghighi, Saeideh
AU  - Karimi-Haghighi S
AD  - Clinical Neurology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Salehi, Mohammad Saied
AU  - Salehi MS
AD  - Clinical Neurology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Hooshmandi, Etrat
AU  - Hooshmandi E
AD  - Clinical Neurology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Owjfard, Maryam
AU  - Owjfard M
AD  - Clinical Neurology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Bayat, Mahnaz
AU  - Bayat M
AD  - Clinical Neurology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Karimlou, Sedigheh
AU  - Karimlou S
AD  - Clinical Neurology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Pandamooz, Sareh
AU  - Pandamooz S
AD  - Stem Cells Technology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Dianatpour, Mehdi
AU  - Dianatpour M
AD  - Stem Cells Technology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Borhani-Haghighi, Afshin
AU  - Borhani-Haghighi A
AD  - Clinical Neurology Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran. Electronic address: aborhani@sums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211202
PL  - Scotland
TA  - Tissue Cell
JT  - Tissue & cell
JID - 0214745
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cell Differentiation/*drug effects
MH  - Humans
MH  - *Stem Cell Transplantation
MH  - Stem Cells/*metabolism
OTO - NOTNLM
OT  - Aspirin
OT  - Differentiation
OT  - Immunomodulatory properties
OT  - Proliferation
OT  - Stem cell
EDAT- 2021/12/10 06:00
MHDA- 2022/03/26 06:00
CRDT- 2021/12/09 20:18
PHST- 2021/09/06 00:00 [received]
PHST- 2021/11/30 00:00 [revised]
PHST- 2021/12/01 00:00 [accepted]
PHST- 2021/12/10 06:00 [pubmed]
PHST- 2022/03/26 06:00 [medline]
PHST- 2021/12/09 20:18 [entrez]
AID - S0040-8166(21)00223-8 [pii]
AID - 10.1016/j.tice.2021.101707 [doi]
PST - ppublish
SO  - Tissue Cell. 2022 Feb;74:101707. doi: 10.1016/j.tice.2021.101707. Epub 2021 Dec 
      2.

PMID- 25706957
OWN - NLM
STAT- MEDLINE
DCOM- 20151201
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 2
DP  - 2015
TI  - Effect of preoperatively continued aspirin use on early and mid-term outcomes in 
      off-pump coronary bypass surgery: a propensity score-matched study of 1418 
      patients.
PG  - e0116311
LID - 10.1371/journal.pone.0116311 [doi]
LID - e0116311
AB  - BACKGROUND: To date, effect of preoperatively continued aspirin administration in 
      off-pump coronary artery bypass grafting (CABG) is less known. We aimed to assess 
      the effect of preoperatively continued aspirin use on early and mid-term outcomes 
      in patients receiving off-pump CABG. METHODS: From October 2009 to September 2013 
      at the Fuwai Hospital, 709 preoperative aspirin users were matched with unique 
      709 nonaspirin users using propensity score matching to obtain risk-adjusted 
      outcome comparisons between the two groups. Early outcomes were in-hospital 
      death, stroke, intra- and post-operative blood loss, reoperation for bleeding and 
      blood product transfusion. Major adverse cardiac events (death, myocardial 
      infarction or repeat revascularization), angina recurrence and cardiogenic 
      readmission were considered as mid-term endpoints. RESULTS: There were no 
      significant differences among the groups in baseline characteristics after 
      propensity score matching. The median intraoperative blood loss (600 ml versus 
      450 ml, P = 0.56), median postoperative blood loss (800 ml versus 790 ml, P = 
      0.60), blood transfusion requirements (25.1% versus 24.4%, P = 0.76) and 
      composite outcome of in-hospital death, stroke and reoperation for bleeding (2.8% 
      versus 1.6%, P = 0.10) were similar in aspirin and nonaspirin use group. At about 
      4 years follow-up, no significant difference was observed among the aspirin and 
      nonaspirin use group in major adverse cardiac events free survival estimates 
      (95.7% versus 91.5%, P = 0.23) and freedom from cardiogenic readmission (88.5% 
      versus 85.3%, P = 0.77) whereas the angina recurrence free survival rates was 
      83.7% and 73.9% in the aspirin and nonaspirin use group respectively (P = 0.02), 
      with odd ratio for preoperative aspirin estimated at 0.71 (95% confidence 
      interval, 0.49-1.04, P = 0.08). CONCLUSIONS: Preoperatively continued aspirin use 
      was not associated with increased risk of intra- and post-operative blood loss, 
      blood transfusion requirements and composite outcome of in-hospital death, stroke 
      and reoperation for bleeding in off-pump CABG. Preoperative aspirin use tended to 
      decrease the hazard of mid-term angina recurrence.
FAU - Xiao, Fucheng
AU  - Xiao F
AD  - Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular 
      Disease, Fu Wai Hospital and Cardiovascular Institute, National Center for 
      Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of 
      Medical Sciences, Beijing, China.
FAU - Wu, Hengchao
AU  - Wu H
AD  - Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular 
      Disease, Fu Wai Hospital and Cardiovascular Institute, National Center for 
      Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of 
      Medical Sciences, Beijing, China.
FAU - Sun, Hansong
AU  - Sun H
AD  - Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular 
      Disease, Fu Wai Hospital and Cardiovascular Institute, National Center for 
      Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of 
      Medical Sciences, Beijing, China.
FAU - Pan, Shiwei
AU  - Pan S
AD  - Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular 
      Disease, Fu Wai Hospital and Cardiovascular Institute, National Center for 
      Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of 
      Medical Sciences, Beijing, China.
FAU - Xu, Jianping
AU  - Xu J
AD  - Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular 
      Disease, Fu Wai Hospital and Cardiovascular Institute, National Center for 
      Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of 
      Medical Sciences, Beijing, China.
FAU - Song, Yunhu
AU  - Song Y
AD  - Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular 
      Disease, Fu Wai Hospital and Cardiovascular Institute, National Center for 
      Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of 
      Medical Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20150223
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Coronary Artery Bypass, Off-Pump/*mortality
MH  - Coronary Artery Disease/*surgery
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*etiology
MH  - Propensity Score
MH  - Reoperation
MH  - Stroke/*etiology
MH  - Treatment Outcome
PMC - PMC4338036
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/02/24 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/02/24 06:00
PHST- 2014/06/24 00:00 [received]
PHST- 2014/12/09 00:00 [accepted]
PHST- 2015/02/24 06:00 [entrez]
PHST- 2015/02/24 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - PONE-D-14-27797 [pii]
AID - 10.1371/journal.pone.0116311 [doi]
PST - epublish
SO  - PLoS One. 2015 Feb 23;10(2):e0116311. doi: 10.1371/journal.pone.0116311. 
      eCollection 2015.

PMID- 34356987
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 57
IP  - 7
DP  - 2021 Jul 12
TI  - N-Terminal Pro-Brain Natriuretic Peptide and Right Ventricular Diameter Are 
      Related to Aspirin Resistance in Coronary Artery Disease Patients.
LID - 10.3390/medicina57070706 [doi]
LID - 706
AB  - Background and Objectives: Resistance to ASA (ASAres) is a multifactorial 
      phenomenon defined as insufficient reduction of platelet reactivity through 
      incomplete inhibition of thromboxane A2 synthesis. The aim is to reassess the 
      prevalence and predictors of ASAres in a contemporary cohort of coronary artery 
      disease (CAD) patients (pts) on stable therapy with ASA, 75 mg o.d. Materials and 
      Methods: We studied 205 patients with stable CAD treated with daily dose of 75 mg 
      ASA for a minimum of one month. ASAres was defined as ARU (aspirin reaction 
      units) ≥550 using the point-of-care VerifyNow Aspirin test. Results: ASAres was 
      detected in 11.7% of patients. Modest but significant correlations were detected 
      between ARU and concentration of N-terminal pro-brain natriuretic peptide 
      (NT-proBNP) (r = 0.144; p = 0.04), body weight, body mass index, red blood cell 
      distribution width, left ventricular mass, and septal end-systolic thickness, 
      with trends for left ventricular mass index and prothrombin time. In multivariate 
      regression analysis, log(NT-proBNP) was identified as the only independent 
      predictor of ARU-partial r = 0.15, p = 0.03. Median concentrations of NT-proBNP 
      were significantly higher in ASAres patients (median value 311.4 vs. 646.3 pg/mL; 
      p = 0.046) and right ventricular diameter was larger, whereas mean corpuscular 
      hemoglobin concentration was lower as compared to patients with adequate response 
      to ASA. Conclusions: ASAres has significant prevalence in this contemporary CAD 
      cohort and NT-proBNP has been identified as the independent correlate of 
      on-treatment ARU, representing a predictor for ASAres, along with right 
      ventricular enlargement and lower hemoglobin concentration in erythrocytes.
FAU - Cygulska, Kamila Marika
AU  - Cygulska KM
AD  - Department of Cardiology, Medical University of Lodz, Bieganski Hospital, 1/5 
      Kniaziewicza, 91-347 Lodz, Poland.
FAU - Figiel, Łukasz
AU  - Figiel Ł
AD  - Department of Cardiology, Medical University of Lodz, Bieganski Hospital, 1/5 
      Kniaziewicza, 91-347 Lodz, Poland.
FAU - Sławek, Dariusz
AU  - Sławek D
AD  - Department of Cardiology, Medical University of Lodz, Bieganski Hospital, 1/5 
      Kniaziewicza, 91-347 Lodz, Poland.
FAU - Wraga, Małgorzata
AU  - Wraga M
AD  - Department of Cardiology, Medical University of Lodz, Bieganski Hospital, 1/5 
      Kniaziewicza, 91-347 Lodz, Poland.
FAU - Dąbrowa, Marek
AU  - Dąbrowa M
AD  - Department of Biopharmacy, Chair of Biopharmacy, Medical University of Lodz, 1/5 
      Kniaziewicza, 91-347 Lodz, Poland.
FAU - Kasprzak, Jarosław D
AU  - Kasprzak JD
AUID- ORCID: 0000-0002-5850-8187
AD  - Department of Cardiology, Medical University of Lodz, Bieganski Hospital, 1/5 
      Kniaziewicza, 91-347 Lodz, Poland.
LA  - eng
PT  - Journal Article
DEP - 20210712
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Biomarkers
MH  - *Coronary Artery Disease/drug therapy
MH  - Humans
MH  - Natriuretic Peptide, Brain
MH  - Peptide Fragments
PMC - PMC8303911
OTO - NOTNLM
OT  - N-terminal pro-brain natriuretic peptide
OT  - acetylsalicylic acid
OT  - aspirin resistance
OT  - coronary disease
COIS- The study was supported by unrestricted research grant from Aflofarm Farmacja 
      Polska sp z o.o.
EDAT- 2021/08/07 06:00
MHDA- 2021/08/11 06:00
CRDT- 2021/08/06 12:22
PHST- 2021/06/03 00:00 [received]
PHST- 2021/07/01 00:00 [revised]
PHST- 2021/07/05 00:00 [accepted]
PHST- 2021/08/06 12:22 [entrez]
PHST- 2021/08/07 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
AID - medicina57070706 [pii]
AID - medicina-57-00706 [pii]
AID - 10.3390/medicina57070706 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2021 Jul 12;57(7):706. doi: 10.3390/medicina57070706.

PMID- 8651230
OWN - NLM
STAT- MEDLINE
DCOM- 19960723
LR  - 20190512
IS  - 0002-9262 (Print)
IS  - 0002-9262 (Linking)
VI  - 143
IP  - 7
DP  - 1996 Apr 1
TI  - Aspirin use and cognitive function in the elderly.
PG  - 683-91
AB  - Decline in cognitive function in the elderly is common and represents a major 
      clinical and public health concern. Aspirin may reduce the decline in cognitive 
      function by influencing multi-infarct dementia, but data are sparse. The East 
      Boston Senior Health Project is a population-based cohort study that enrolled 
      3,809 community-dwelling residents aged 65 years and older in 1982-1983 and 
      followed them with home visits every 3 years until 1988-1989. Trained 
      interviewers assessed cognitive function by using the Short Portable Mental 
      Status Questionnaire and assessed medication use, including over-the-counter 
      drugs. Response to the Short Portable Mental Status Questionnaire was scored as 
      high, medium, or low, and decline was defined as transition to a lower category. 
      Participants who used drugs containing aspirin in the 2 weeks prior to the 
      interview were classified as aspirin users. Multiple logistic regression was used 
      to obtain adjusted odds ratios and their 95% confidence intervals for decline of 
      cognitive function. The estimating equation approach was used to adjust the 
      standard errors for repeated measurements. Aspirin users had an odds ratio for 
      cognitive decline of 0.97 (95% confidence interval 0.82-1.15). Low frequency of 
      aspirin use (less than daily) was associated with an odds ratio of 0.87 (95% 
      confidence interval 0.69-1.09). Although no substantial effect was observed, the 
      data are also compatible with a modest benefit of aspirin, especially with 
      intermittent use, on decline of cognitive function. Concern about small residual 
      biases from self-selection or confounding suggests that randomized trials will be 
      necessary to provide definitive data on this question.
FAU - Stürmer, T
AU  - Stürmer T
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Glynn, R J
AU  - Glynn RJ
FAU - Field, T S
AU  - Field TS
FAU - Taylor, J O
AU  - Taylor JO
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - AG02107/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Epidemiol
JT  - American journal of epidemiology
JID - 7910653
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cognition/*drug effects
MH  - Confidence Intervals
MH  - Follow-Up Studies
MH  - Humans
MH  - Interviews as Topic
MH  - Logistic Models
MH  - Massachusetts
MH  - Memory/drug effects
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Prospective Studies
MH  - Psychological Tests/statistics & numerical data
MH  - Risk Factors
MH  - Time Factors
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.aje.a008801 [doi]
PST - ppublish
SO  - Am J Epidemiol. 1996 Apr 1;143(7):683-91. doi: 
      10.1093/oxfordjournals.aje.a008801.

PMID- 34245748
OWN - NLM
STAT- MEDLINE
DCOM- 20220106
LR  - 20220106
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 908
DP  - 2021 Oct 5
TI  - Aspirin ameliorates pulmonary vascular remodeling in pulmonary hypertension by 
      dampening endothelial-to-mesenchymal transition.
PG  - 174307
LID - S0014-2999(21)00460-X [pii]
LID - 10.1016/j.ejphar.2021.174307 [doi]
AB  - Pulmonary vascular remodeling (PVR) is the pathological basis of pulmonary 
      hypertension (PH). Incomplete understanding of PVR etiology has hindered drug 
      development for this devastating disease, which exhibits poor prognosis despite 
      the currently available therapies. Endothelial-to-mesenchymal transition (EndMT), 
      a process of cell transdifferentiation, has been recently implicated in 
      cardiovascular diseases, including PH. But the questions of how EndMT occurs and 
      how to pharmacologically target EndMT in vivo have yet to be further answered. 
      Herein, by performing hematoxylin-eosin and immunofluorescence staining, 
      transmission electron microscopy and Western blotting, we found that EndMT plays 
      a key role in the pathogenesis of PH, and importantly that aspirin, a 
      FDA-approved widely used drug, was capable of ameliorating PVR in a preclinical 
      rat model of hypoxia-induced PH. Moreover, aspirin exerted its inhibitory effects 
      on EndMT in vitro and in vivo by suppressing HIF-1α/TGF-β1/Smads/Snail signaling 
      pathway. Our data suggest that EndMT represents an intriguing drug target for the 
      prevention and treatment of hypoxic PH and that aspirin may be repurposed to meet 
      the urgent therapeutic needs of hypoxic PH patients.
CI  - Copyright © 2021. Published by Elsevier B.V.
FAU - Huang, Ning
AU  - Huang N
AD  - Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central 
      South University, Changsha, Hunan, 410078, China.
FAU - Zhu, Tian-Tian
AU  - Zhu TT
AD  - College of Pharmacy, Xinxiang Medical University, Xinxiang, Henan, 453000, China; 
      Henan International Joint Laboratory of Cardiovascular Remodeling and Drug 
      Intervention, Xinxiang, Henan, 453000, China.
FAU - Liu, Ting
AU  - Liu T
AD  - Department of Pharmacy, Hangzhou First Peoples Hospital, Zhejiang University 
      School of Medicine, Hangzhou, 310000, Zhejiang, China.
FAU - Ge, Xiao-Yue
AU  - Ge XY
AD  - Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central 
      South University, Changsha, Hunan, 410078, China.
FAU - Wang, Di
AU  - Wang D
AD  - Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central 
      South University, Changsha, Hunan, 410078, China.
FAU - Liu, Hong
AU  - Liu H
AD  - Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central 
      South University, Changsha, Hunan, 410078, China.
FAU - Zhu, Guang-Xuan
AU  - Zhu GX
AD  - Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central 
      South University, Changsha, Hunan, 410078, China.
FAU - Zhang, Zheng
AU  - Zhang Z
AD  - Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central 
      South University, Changsha, Hunan, 410078, China; Hunan Provincial Key Laboratory 
      of Cardiovascular Research, Central South University, Changsha, Hunan, 410078, 
      China. Electronic address: zzhang@csu.edu.cn.
FAU - Hu, Chang-Ping
AU  - Hu CP
AD  - Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central 
      South University, Changsha, Hunan, 410078, China; Hunan Provincial Key Laboratory 
      of Cardiovascular Research, Central South University, Changsha, Hunan, 410078, 
      China. Electronic address: huchangping@csu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20210708
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Smad3 Protein)
RN  - 0 (Transforming Growth Factor beta1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Endothelium
MH  - Epithelial-Mesenchymal Transition
MH  - *Hypertension, Pulmonary
MH  - Rats
MH  - Smad3 Protein
MH  - Transforming Growth Factor beta1
MH  - *Vascular Remodeling
OTO - NOTNLM
OT  - Aspirin
OT  - Endothelial-to-mesenchymal transition
OT  - Hypoxia
OT  - Pulmonary hypertension
EDAT- 2021/07/11 06:00
MHDA- 2022/01/07 06:00
CRDT- 2021/07/10 20:08
PHST- 2021/03/10 00:00 [received]
PHST- 2021/07/01 00:00 [revised]
PHST- 2021/07/05 00:00 [accepted]
PHST- 2021/07/11 06:00 [pubmed]
PHST- 2022/01/07 06:00 [medline]
PHST- 2021/07/10 20:08 [entrez]
AID - S0014-2999(21)00460-X [pii]
AID - 10.1016/j.ejphar.2021.174307 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2021 Oct 5;908:174307. doi: 10.1016/j.ejphar.2021.174307. Epub 
      2021 Jul 8.

PMID- 6996929
OWN - NLM
STAT- MEDLINE
DCOM- 19801124
LR  - 20190909
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 6
IP  - 9
DP  - 1980
TI  - A controlled trial of magnesium dithiosalicylate compared with aspirin in 
      rheumatoid arthritis.
PG  - 589-92
AB  - The anti-inflammamtory effectiveness and side-effects of magnesium 
      dithiosalicylate were compared to aspirin in a 3-month, parallel, double-blind 
      trial in 40 patients suffering from active rheumatoid arthritis. The results 
      showed that 3 g magnesium dithiosalicylate daily had anti-inflammatory properties 
      similar to those of 3 g aspirin daily in rheumatoid arthritis. A statistically 
      significant change in morning stiffness, number of tender joints, pain score and 
      erythrocyte sedimentation rate was observed in the magnesium dithiosalicylate 
      group. In the magnesium dithiosalicylate group, 8 patients had to be withdrawn 
      from the trial because of serious side-effects compared to 5 in the aspirin 
      group. Gastro-intestinal intolerance occurred as frequently in both treatment 
      groups. Hypersensitivity to magnesium dithiosalicylate was a serious problem and 
      the reason for withdrawal in 4 cases. The high frequency of side-effects to 
      magnesium dithiosalicylate makes this drug unacceptable for treatment of 
      rheumatoid arthritis at the present time. Further pharmacological studies might 
      reveal new derivatives which are as effective but with less side-effects. The 
      anti-inflammatory activity of magnesium dithiosalicylate resembled that observed 
      with gold and penicillamine. The fact that all these drugs have a sulphhydril 
      group in common is stressed.
FAU - Dequeker, J
AU  - Dequeker J
FAU - Stevens, E
AU  - Stevens E
FAU - Wuyts, L
AU  - Wuyts L
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Salicylates)
RN  - 8LV29H49A3 (dithiosalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/adverse effects/therapeutic use
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1185/03007998009109493 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1980;6(9):589-92. doi: 10.1185/03007998009109493.

PMID- 35761756
OWN - NLM
STAT- MEDLINE
DCOM- 20220811
LR  - 20220811
IS  - 1757-7861 (Electronic)
IS  - 1757-7853 (Print)
IS  - 1757-7853 (Linking)
VI  - 14
IP  - 8
DP  - 2022 Aug
TI  - Preoperative Use of Aspirin in Total Knee Arthroplasty: Safe or Not?
PG  - 1673-1680
LID - 10.1111/os.13321 [doi]
AB  - OBJECTIVE: To compare the blood loss, transfusion rates and complications between 
      the aspirin and non-aspirin group in unilateral and bilateral total knee 
      arthroplasties (TKAs) with a nested case-control design. METHODS: The present 
      study retrospectively selected TKA cases from the Joint Arthroplasty Database at 
      the Peking Union Medical College Hospital from January 2014 to December 2019 
      following strict inclusion and exclusion criteria, and divided them into the 
      aspirin and non-aspirin group based on the use of aspirin preoperatively. 
      Bleeding was measured by blood loss, transfusion rate, drainage volume, 
      hemoglobin (HGB) and hematocrit (HCT), while complications (cardiovascular 
      events, venous thromboembolism events, cerebrovascular events and wound events) 
      were compared between the groups. Student's unpaired t-test and Mann-Whitney 
      U-test were used to compare the differences of continuous variables between the 
      two groups while chi-square test and Fisher's exact test were applied in 
      categorical variables. RESULTS: A total of 560 patients with unilateral TKA and 
      285 patients with bilateral TKA were extracted. Among these, 280 patients used 
      aspirin preoperatively. No other differences were found in demographic and 
      surgical characteristics between the two groups except for the proportion of 
      coronary artery diseases (P < 0.001). For primary outcomes, there was no 
      significant higher blood loss and transfusion rate in the aspirin group, while 
      the drainage of aspirin group was higher than the control group in bilateral TKAs 
      (P = 0.043). The HGB and HCT of the aspirin group was significant lower in both 
      unilateral and bilateral TKAs at POD5 (P < 0.05). For complications, there was a 
      lower vascular related complication rate in aspirin group after unilateral TKAs 
      (P = 0.040), but the wound event rate in aspirin group was higher than the 
      control group (P = 0.049). CONCLUSIONS: Preoperative use of aspirin could prevent 
      vascular related events during the perioperative period of TKA. However, it might 
      also increase the risk of bleeding and wound complications.
CI  - © 2022 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John 
      Wiley & Sons Australia, Ltd.
FAU - Li, Zeng
AU  - Li Z
AD  - Department of Orthopedics Surgery, Guangdong Provincial People's Hospital, 
      Guangdong Academy of Medical Sciences, Guangzhou, China.
AD  - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking 
      Union Medical College, Chinese Academy of Medical Science, Beijing, China.
FAU - Xiang, Shuai
AU  - Xiang S
AD  - Department of Joint Surgery, The Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Du, Yan
AU  - Du Y
AD  - Clinical Research, Obstetrics and Gynecology Hospital of Fudan University, 
      Shanghai, China.
FAU - Zhang, Mo
AU  - Zhang M
AD  - Clinical Research, Obstetrics and Gynecology Hospital of Fudan University, 
      Shanghai, China.
FAU - Bian, Yanyan
AU  - Bian Y
AD  - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking 
      Union Medical College, Chinese Academy of Medical Science, Beijing, China.
FAU - Feng, Bin
AU  - Feng B
AD  - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking 
      Union Medical College, Chinese Academy of Medical Science, Beijing, China.
FAU - Weng, Xisheng
AU  - Weng X
AUID- ORCID: 0000-0003-1706-5997
AD  - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking 
      Union Medical College, Chinese Academy of Medical Science, Beijing, China.
LA  - eng
GR  - 2021A1515110345/Guangdong Basic and Applied Basic Research Foundation/
GR  - B2021165/Guangdong Science and Technology Department/
GR  - Peking Union Medical College Hospital/
PT  - Journal Article
DEP - 20220627
PL  - Australia
TA  - Orthop Surg
JT  - Orthopaedic surgery
JID - 101501666
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/therapeutic use
MH  - Blood Loss, Surgical/prevention & control
MH  - Blood Transfusion
MH  - Hemoglobins
MH  - Humans
MH  - Retrospective Studies
PMC - PMC9363720
OTO - NOTNLM
OT  - Aspirin
OT  - Blood loss
OT  - Complication
OT  - Total knee arthroplasty
OT  - Transfusion
EDAT- 2022/06/29 06:00
MHDA- 2022/08/12 06:00
CRDT- 2022/06/28 01:12
PHST- 2022/05/11 00:00 [revised]
PHST- 2022/01/22 00:00 [received]
PHST- 2022/05/13 00:00 [accepted]
PHST- 2022/06/29 06:00 [pubmed]
PHST- 2022/08/12 06:00 [medline]
PHST- 2022/06/28 01:12 [entrez]
AID - OS13321 [pii]
AID - 10.1111/os.13321 [doi]
PST - ppublish
SO  - Orthop Surg. 2022 Aug;14(8):1673-1680. doi: 10.1111/os.13321. Epub 2022 Jun 27.

PMID- 26753771
OWN - NLM
STAT- MEDLINE
DCOM- 20160613
LR  - 20181202
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Linking)
VI  - 18
IP  - 1
DP  - 2016 Jan
TI  - Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease.
PG  - 5
LID - 10.1007/s11883-015-0553-2 [doi]
AB  - Dual antiplatelet therapy (DAPT) is the use of a P2Y12 receptor antagonist 
      (clopidogrel, prasugrel, or ticagrelor) in combination with aspirin. 
      Recommendations for its use are primarily in patients who have experienced acute 
      coronary syndrome (ACS) or percutaneous coronary intervention (PCI) in the 
      preceding 12 months. There is a growing body of evidence, however, investigating 
      the use of long-duration DAPT in patients with stable ischemic heart disease 
      (SIHD). SIHD is defined as clinical evidence of ischemic heart disease, without 
      an ACS event in the preceding 12 months, and includes patients with stable 
      angina, elective PCI, and remote history of ACS. The use of DAPT in the SIHD 
      population and the recent advancements in our understanding of its use are the 
      focus of this review.
FAU - Keach, Joseph Walker
AU  - Keach JW
AD  - Department of Medicine, University of Colorado School of Medicine, Aurora, CO, 
      USA.
AD  - Department of Medicine, Denver Health Hospital Authority, Denver, CO, USA.
FAU - Yeh, Robert W
AU  - Yeh RW
AD  - Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess 
      Medical Center, Boston, MA, USA.
FAU - Maddox, Thomas M
AU  - Maddox TM
AD  - Cardiology Section, Veterans Affairs Eastern Colorado Health Care System, 1055 
      Clermont Street, Mail Stop 111B, Denver, CO, 80220, USA. thomas.maddox@va.gov.
AD  - Department of Medicine (Cardiology), University of Colorado School of Medicine, 
      Aurora, CO, USA. thomas.maddox@va.gov.
AD  - Colorado Cardiovascular Outcomes Research (CCOR) Consortium, Denver, CO, USA. 
      thomas.maddox@va.gov.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Drug Combinations
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Myocardial Ischemia/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Clopidogrel
OT  - Coronary artery disease
OT  - Dual antiplatelet therapy
OT  - Myocardial infarction
OT  - Prasugrel
OT  - Stable ischemic heart disease
OT  - Ticagrelor
EDAT- 2016/01/13 06:00
MHDA- 2016/06/14 06:00
CRDT- 2016/01/13 06:00
PHST- 2016/01/13 06:00 [entrez]
PHST- 2016/01/13 06:00 [pubmed]
PHST- 2016/06/14 06:00 [medline]
AID - 10.1007/s11883-015-0553-2 [pii]
AID - 10.1007/s11883-015-0553-2 [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2016 Jan;18(1):5. doi: 10.1007/s11883-015-0553-2.

PMID- 2887430
OWN - NLM
STAT- MEDLINE
DCOM- 19871016
LR  - 20131121
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 8
IP  - 6
DP  - 1987 Jun
TI  - Randomized factorial trial of high-dose intravenous streptokinase, of oral 
      aspirin and of intravenous heparin in acute myocardial infarction. ISIS 
      (International Studies of Infarct Survival) pilot study.
PG  - 634-42
AB  - 619 patients with suspected acute myocardial infarction (MI) were randomized to 
      receive either a high-dose short-term intravenous infusion of streptokinase (1.5 
      MU over one hour) or placebo. Using a '2 X 2 X 2 factorial' design, patients were 
      also randomized to receive either oral aspirin (325 mg on alternate days for 28 
      days) or placebo, and separately randomized to receive either intravenous heparin 
      (1000 IU h-1 for 48 hours) or no heparin. Streptokinase (SK) was associated with 
      a nonsignificant (NS) increase in non-fatal reinfarction (3.9% SK vs 2.9% 
      placebo) and decrease in mortality (7.5% vs 9.7% in hospital plus 6.1% vs 8.7% 
      after discharge). After SK, there were significantly fewer strokes (0.5% vs 2.4%; 
      2P less than 0.05), but significantly more minor adverse events (e.g. hypotension 
      and bradycardia, allergies, bruises or minor bleeds, nausea). Aspirin was 
      associated with fewer non-fatal reinfarctions (3.2% aspirin vs 3.9% placebo; NS), 
      deaths (in hospital: 6.1% vs 10.5%; 2P less than 0.05, and after discharge: 7.0% 
      vs 6.9%; NS), and strokes (0.3% vs 2.0%; NS). Heparin was associated with a 
      decrease in reinfarction (2.2% heparin vs 4.9% no heparin; NS), though not in 
      mortality (in hospital: 8.0% vs 8.5%; NS, and after discharge: 7.0% vs 6.9%; NS), 
      and with a trend towards more strokes (1.6% vs 0.7%; NS) and more bruising and 
      bleeding (14% vs 12%; NS). To assess more reliably the effects of aspirin and of 
      this SK regimen on mortality, about 400 hospitals worldwide are now collaborating 
      in a large (about 20,000 patients planned) randomized trial (ISIS-2), for which 
      the present study was a pilot.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Heparin/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Myocardial Infarction/*drug therapy
MH  - Pilot Projects
MH  - Random Allocation
MH  - Streptokinase/administration & dosage/adverse effects/*therapeutic use
EDAT- 1987/06/01 00:00
MHDA- 1987/06/01 00:01
CRDT- 1987/06/01 00:00
PHST- 1987/06/01 00:00 [pubmed]
PHST- 1987/06/01 00:01 [medline]
PHST- 1987/06/01 00:00 [entrez]
PST - ppublish
SO  - Eur Heart J. 1987 Jun;8(6):634-42.

PMID- 20550971
OWN - NLM
STAT- MEDLINE
DCOM- 20101228
LR  - 20151119
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 126
IP  - 3
DP  - 2010 Sep
TI  - Aspirin resistance following pediatric cardiac surgery.
PG  - 200-6
LID - 10.1016/j.thromres.2010.05.017 [doi]
AB  - INTRODUCTION: Aspirin is often used to prevent thrombosis in pediatric cardiac 
      surgery. The primary study aim was to assess aspirin resistance in this context. 
      Secondary aims were to evaluate (1) the relationship between elevated 
      inflammatory markers and thrombosis and (2) aspirin's effect on these levels. 
      MATERIALS AND METHODS: This was a prospective observational study of children 
      undergoing cardiac surgery managed with and without aspirin. Aspirin response was 
      assessed using the VerifyNow system and urinary 11-dehydrothromboxane B2 (uTxB2) 
      measurements. Laboratory studies of inflammation were also obtained. RESULTS: 101 
      subjects were studied; 50 received aspirin. Six subjects (5.9%), 5 
      aspirin-treated, experienced symptomatic thrombosis. When measured by VerifyNow 
      resistance was 43% after aspirin suppositories and 14% after additional days of 
      oral aspirin. There was no correlation with thrombosis. Upper quartile 
      post-operative day (POD) #5 uTxB2 was correlated with thrombosis in aspirin 
      treated subjects (p<0.01). High risk aspirin-treated subjects who experienced 
      thrombosis had higher POD#5 uTxB2. This finding did not reach statistical 
      significance (p=0.07). Elevated pre-operative C-reactive protein (CRP) was 
      independently associated with thrombosis (p<0.02) in all subjects and in high 
      risk subjects (p=0.01). Inflammatory markers were not affected by aspirin. 
      CONCLUSIONS: Aspirin inhibited ex-vivo platelet function with a low incidence of 
      resistance. Elevated POD#5 uTxB2 and pre-operative CRP were correlated with 
      thrombosis in aspirin treated subjects. Further studies are needed to determine 
      whether children with high levels of uTxB2 despite aspirin therapy and/or those 
      with elevated preoperative CRP are at increased risk for thrombosis.
CI  - Copyright (c) 2010 Elsevier Ltd. All rights reserved.
FAU - Cholette, Jill M
AU  - Cholette JM
AD  - Department of Pediatrics, University of Rochester Medical Center 601 Elmwood 
      Avenue Rochester, New York 14642, USA. Jill_Cholette@urmc.rochester.edu
FAU - Mamikonian, Lara
AU  - Mamikonian L
FAU - Alfieris, George M
AU  - Alfieris GM
FAU - Blumberg, Neil
AU  - Blumberg N
FAU - Lerner, Norma B
AU  - Lerner NB
LA  - eng
GR  - K24 NS048323/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100613
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Biomarkers)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Suppositories)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Thromb Res. 2010 Sep;126(3):163. PMID: 20667585
MH  - Administration, Oral
MH  - Administration, Rectal
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Biomarkers/blood/urine
MH  - C-Reactive Protein/analysis
MH  - Cardiac Surgical Procedures/*adverse effects
MH  - *Drug Resistance
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Heart Defects, Congenital/blood/*surgery
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Inflammation Mediators/blood
MH  - Logistic Models
MH  - New York
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Suppositories
MH  - Thrombosis/blood/etiology/*prevention & control
MH  - Thromboxane B2/analogs & derivatives/urine
MH  - Time Factors
MH  - Treatment Outcome
MH  - Up-Regulation
EDAT- 2010/06/17 06:00
MHDA- 2010/12/29 06:00
CRDT- 2010/06/17 06:00
PHST- 2009/10/06 00:00 [received]
PHST- 2010/04/28 00:00 [revised]
PHST- 2010/05/03 00:00 [accepted]
PHST- 2010/06/17 06:00 [entrez]
PHST- 2010/06/17 06:00 [pubmed]
PHST- 2010/12/29 06:00 [medline]
AID - S0049-3848(10)00300-2 [pii]
AID - 10.1016/j.thromres.2010.05.017 [doi]
PST - ppublish
SO  - Thromb Res. 2010 Sep;126(3):200-6. doi: 10.1016/j.thromres.2010.05.017. Epub 2010 
      Jun 13.

PMID- 23839601
OWN - NLM
STAT- MEDLINE
DCOM- 20131122
LR  - 20220310
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 94
IP  - 4
DP  - 2013 Oct
TI  - Purine pathway implicated in mechanism of resistance to aspirin therapy: 
      pharmacometabolomics-informed pharmacogenomics.
PG  - 525-32
LID - 10.1038/clpt.2013.119 [doi]
AB  - Although aspirin is a well-established antiplatelet agent, the mechanisms of 
      aspirin resistance remain poorly understood. Metabolomics allows for measurement 
      of hundreds of small molecules in biological samples, enabling detailed mapping 
      of pathways involved in drug response. We defined the metabolic signature of 
      aspirin exposure in subjects from the Heredity and Phenotype Intervention Heart 
      Study. Many metabolites, including known aspirin catabolites, changed on exposure 
      to aspirin, and pathway enrichment analysis identified purine metabolism as 
      significantly affected by drug exposure. Furthermore, purines were associated 
      with aspirin response, and poor responders had higher postaspirin adenosine and 
      inosine levels than did good responders (n = 76; both P < 4 × 10(-3)). Using our 
      established "pharmacometabolomics-informed pharmacogenomics" approach, we 
      identified genetic variants in adenosine kinase associated with aspirin response. 
      Combining metabolomics and genomics allowed for more comprehensive interrogation 
      of mechanisms of variation in aspirin response--an important step toward 
      personalized treatment approaches for cardiovascular disease.
FAU - Yerges-Armstrong, L M
AU  - Yerges-Armstrong LM
AD  - Program in Personalized and Genomic Medicine, Division of Endocrinology, 
      Diabetes, and Nutrition, Department of Medicine, University of Maryland School of 
      Medicine, Baltimore, Maryland, USA.
FAU - Ellero-Simatos, S
AU  - Ellero-Simatos S
FAU - Georgiades, A
AU  - Georgiades A
FAU - Zhu, H
AU  - Zhu H
FAU - Lewis, J P
AU  - Lewis JP
FAU - Horenstein, R B
AU  - Horenstein RB
FAU - Beitelshees, A L
AU  - Beitelshees AL
FAU - Dane, A
AU  - Dane A
FAU - Reijmers, T
AU  - Reijmers T
FAU - Hankemeier, T
AU  - Hankemeier T
FAU - Fiehn, O
AU  - Fiehn O
FAU - Shuldiner, A R
AU  - Shuldiner AR
FAU - Kaddurah-Daouk, R
AU  - Kaddurah-Daouk R
LA  - eng
GR  - U01 HL105198/HL/NHLBI NIH HHS/United States
GR  - K23-HL091120/HL/NHLBI NIH HHS/United States
GR  - T32-HL72751/HL/NHLBI NIH HHS/United States
GR  - P30-DK072488/DK/NIDDK NIH HHS/United States
GR  - T32 HL072751/HL/NHLBI NIH HHS/United States
GR  - U01-HL105198/HL/NHLBI NIH HHS/United States
GR  - U01-GM074518/GM/NIGMS NIH HHS/United States
GR  - RC2GM092729/GM/NIGMS NIH HHS/United States
GR  - M01 RR000052/RR/NCRR NIH HHS/United States
GR  - M01 RR016500/RR/NCRR NIH HHS/United States
GR  - K23 GM102678/GM/NIGMS NIH HHS/United States
GR  - M01-RR-16500/RR/NCRR NIH HHS/United States
GR  - RC2 GM092729/GM/NIGMS NIH HHS/United States
GR  - K23 HL091120/HL/NHLBI NIH HHS/United States
GR  - P30 DK072488/DK/NIDDK NIH HHS/United States
GR  - M01-RR-000052/RR/NCRR NIH HHS/United States
GR  - U01 HL072515/HL/NHLBI NIH HHS/United States
GR  - K23-GM102678/GM/NIGMS NIH HHS/United States
GR  - U01-HL72515/HL/NHLBI NIH HHS/United States
GR  - U01 GM074518/GM/NIGMS NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, American Recovery and Reinvestment Act
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130611
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purines)
RN  - EC 2.7.1.20 (Adenosine Kinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Kinase/genetics
MH  - Adult
MH  - Alleles
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Drug Resistance/*genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - *Metabolomics
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/*pharmacology
MH  - Purines/*metabolism
PMC - PMC4001726
MID - NIHMS560347
COIS- CONFLICT OF INTEREST STATEMENT Dr. Kaddurah-Daouk is an inventor on patents in 
      the metabolomics field.
EDAT- 2013/07/11 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/07/11 06:00
PHST- 2013/01/30 00:00 [received]
PHST- 2013/05/20 00:00 [accepted]
PHST- 2013/07/11 06:00 [entrez]
PHST- 2013/07/11 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - clpt2013119 [pii]
AID - 10.1038/clpt.2013.119 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2013 Oct;94(4):525-32. doi: 10.1038/clpt.2013.119. Epub 2013 
      Jun 11.

PMID- 904011
OWN - NLM
STAT- MEDLINE
DCOM- 19771125
LR  - 20181113
IS  - 0027-9684 (Print)
IS  - 0027-9684 (Linking)
VI  - 69
IP  - 8
DP  - 1977 Aug
TI  - Aspirin for reducing cancer metastases?
PG  - 581-4
AB  - Distant metastases are the principal cause of death from cancer. Many animal 
      experiments in the last 25 years have shown consistently that distant metastases 
      can be significantly reduced by anticoagulants and fibrinolytic agents. Since 
      aspirin inhibits platelet function and increases fibrinolytic activity in humans, 
      it may be effective in preventing metastases in cancer patients. It is suggested 
      that aspirin be offered as an option to cancer patients who are at risk for 
      distant metastases.
FAU - Henschke, U K
AU  - Henschke UK
FAU - Luande, G J
AU  - Luande GJ
FAU - Choppala, J D
AU  - Choppala JD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Natl Med Assoc
JT  - Journal of the National Medical Association
JID - 7503090
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage
MH  - Dogs
MH  - Humans
MH  - Neoplasm Metastasis/*prevention & control
PMC - PMC2609613
EDAT- 1977/08/01 00:00
MHDA- 1977/08/01 00:01
CRDT- 1977/08/01 00:00
PHST- 1977/08/01 00:00 [pubmed]
PHST- 1977/08/01 00:01 [medline]
PHST- 1977/08/01 00:00 [entrez]
PST - ppublish
SO  - J Natl Med Assoc. 1977 Aug;69(8):581-4.

PMID- 33895438
OWN - NLM
STAT- MEDLINE
DCOM- 20210702
LR  - 20210702
IS  - 1873-6750 (Electronic)
IS  - 0160-4120 (Linking)
VI  - 154
DP  - 2021 Sep
TI  - Interference of C6O4 on platelet aggregation pathways: Cues on the new-generation 
      of perfluoro-alkyl substance.
PG  - 106584
LID - S0160-4120(21)00209-9 [pii]
LID - 10.1016/j.envint.2021.106584 [doi]
AB  - BACKGROUND: Health concerns associated with the exposure to legacy 
      perfluoro-alkyl substances (PFAS) led to the development of new-generation PFAS, 
      such as C6O4. Here we investigated the possible effects of C6O4 on the platelet's 
      activation profile, by incubating human platelets from healthy donors with C6O4 
      at different concentrations and evaluating the effects on activation, production 
      and phenotype of platelets micro-particles (MPV) and aggregation under-flow. 
      Based on the eventual platelet pro-aggregation profile detected, the preventive 
      effect of acetylsalicylic acid (ASA) was also explored. METHODS: Adhesion-induced 
      platelet aggregation of platelet rich plasma (PRP) under flow was evaluated on 
      collagen-coated microchip at a shear stress of 10 Dyne. The turbidimetric method 
      was used to investigate platelet aggregation. Finally, the in vitro generation of 
      pro-coagulant MPV in PRP was evaluated by flow cytometry, as characterized by 
      CD41 and annexin V positive events, under resting conditions and after 
      stimulation with agonists at low shear stress. RESULTS: The generation of 
      platelet aggregates under flow was significantly increased by the pretreatment of 
      PRP with 100-200 ng/mL C6O4, compared to both the control condition and the 
      experiment performed in presence of ASA. Arachidonic acid (AA), ADP and collagen 
      induced an higher maximal aggregation, at turbidimetric evaluation, when PRP was 
      pretreated with 100-500 ng/mL C6O4. In addition, PRP stimulated with AA also 
      showed a steeper slope of the aggregation curve. The aggregation induced by the 
      tested agonists was almost abolished by ASA. Finally, pretreatment with C6O4 
      increased the number of MPV in resting conditions and in presence of ADP and 
      TRAP. ASA tended to reduce MPV generation. CONCLUSIONS: Exposure to C6O4 
      associates with an increased platelet response to agonists, translating into a 
      possible increased risk of cardiovascular events. Pending a further clarification 
      on the toxicokinetics of this compound, our results claim the possible 
      prophylactic use of ASA.
CI  - Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Minuz, Pietro
AU  - Minuz P
AD  - Department of Medicine, Section of Internal Medicine C, University of Verona, 
      Verona, Italy.
FAU - De Toni, Luca
AU  - De Toni L
AD  - Department of Medicine and Unit of Andrology and Reproduction Medicine, 
      University of Padova, Padova, Italy.
FAU - Dall'Acqua, Stefano
AU  - Dall'Acqua S
AD  - Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 
      Padova, Italy.
FAU - Di Nisio, Andrea
AU  - Di Nisio A
AD  - Department of Medicine and Unit of Andrology and Reproduction Medicine, 
      University of Padova, Padova, Italy.
FAU - Sabovic, Iva
AU  - Sabovic I
AD  - Department of Medicine and Unit of Andrology and Reproduction Medicine, 
      University of Padova, Padova, Italy.
FAU - Castelli, Marco
AU  - Castelli M
AD  - Department of Medicine, Section of Internal Medicine C, University of Verona, 
      Verona, Italy.
FAU - Meneguzzi, Alessandra
AU  - Meneguzzi A
AD  - Department of Medicine, Section of Internal Medicine C, University of Verona, 
      Verona, Italy.
FAU - Foresta, Carlo
AU  - Foresta C
AD  - Department of Medicine and Unit of Andrology and Reproduction Medicine, 
      University of Padova, Padova, Italy. Electronic address: carlo.foresta@unipd.it.
LA  - eng
PT  - Journal Article
DEP - 20210423
PL  - Netherlands
TA  - Environ Int
JT  - Environment international
JID - 7807270
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets
MH  - *Cues
MH  - Humans
MH  - *Platelet Aggregation
MH  - Platelet Function Tests
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Cardiovascular risk
OT  - Flow cytometry
OT  - Platelets micro-particles
OT  - Toxicokinetics
EDAT- 2021/04/26 06:00
MHDA- 2021/07/03 06:00
CRDT- 2021/04/25 20:34
PHST- 2021/01/11 00:00 [received]
PHST- 2021/03/23 00:00 [revised]
PHST- 2021/04/12 00:00 [accepted]
PHST- 2021/04/26 06:00 [pubmed]
PHST- 2021/07/03 06:00 [medline]
PHST- 2021/04/25 20:34 [entrez]
AID - S0160-4120(21)00209-9 [pii]
AID - 10.1016/j.envint.2021.106584 [doi]
PST - ppublish
SO  - Environ Int. 2021 Sep;154:106584. doi: 10.1016/j.envint.2021.106584. Epub 2021 
      Apr 23.

PMID- 6481719
OWN - NLM
STAT- MEDLINE
DCOM- 19841121
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 11
IP  - 4
DP  - 1984 Aug
TI  - Controlled trial of clinical utility of serum salicylate monitoring in rheumatoid 
      arthritis.
PG  - 457-61
AB  - A crossover double-blind controlled trial was performed on 36 patients with 
      rheumatoid arthritis to assess the necessity for serum salicylate monitoring in 
      determining optimal dosage. There was no clinically or statistically significant 
      increase in the clinical improvement of patients associated with serum monitoring 
      but potentially toxic serum levels occurred without tinnitus when serum 
      monitoring was not used.
FAU - Tugwell, P
AU  - Tugwell P
FAU - Hart, L
AU  - Hart L
FAU - Kraag, G
AU  - Kraag G
FAU - Park, A
AU  - Park A
FAU - Dok, C
AU  - Dok C
FAU - Bianchi, F
AU  - Bianchi F
FAU - Goldsmith, C
AU  - Goldsmith C
FAU - Buchanan, W W
AU  - Buchanan WW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Deafness/chemically induced
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/*blood
MH  - Tinnitus/chemically induced
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1984 Aug;11(4):457-61.

PMID- 33658298
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20210730
IS  - 1755-5248 (Electronic)
IS  - 0012-6543 (Linking)
VI  - 59
IP  - 4
DP  - 2021 Apr
TI  - Aspirin to prevent pre-eclampsia.
PG  - 56-59
LID - 10.1136/dtb.2020.000009 [doi]
AB  - Topics for DTB review articles are selected by DTB's editorial board to provide 
      concise overviews of medicines and other treatments to help patients get the best 
      care. Articles include a summary of key points and a brief overview for patients. 
      Articles may also have a series of multiple choice CME questions.
CI  - © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Tong, Stephen
AU  - Tong S
AD  - Translational Obstetrics Group, Department of Obstetrics and Gynaecology, 
      University of Melbourne, Heidelberg, Victoria, Australia stong@unimelb.edu.au.
AD  - Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, Australia.
FAU - Walker, Susan
AU  - Walker S
AD  - Translational Obstetrics Group, Department of Obstetrics and Gynaecology, 
      University of Melbourne, Heidelberg, Victoria, Australia.
AD  - Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, Australia.
FAU - Cluver, Catherine
AU  - Cluver C
AD  - Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, Australia.
AD  - Stellenbosch University, Stellenbosch, Western Cape, South Africa.
FAU - Hastie, Roxanne
AU  - Hastie R
AD  - Translational Obstetrics Group, Department of Obstetrics and Gynaecology, 
      University of Melbourne, Heidelberg, Victoria, Australia.
AD  - Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210303
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Practice Guidelines as Topic
MH  - Pre-Eclampsia/diagnosis/*prevention & control
MH  - Pregnancy
MH  - Premature Birth/prevention & control
OTO - NOTNLM
OT  - blood pressure
OT  - pharmacy
OT  - pregnancy
OT  - primary health care
COIS- Competing interests: None declared. Refer to the online supplementary files to 
      view the ICMJE form(s).
EDAT- 2021/03/05 06:00
MHDA- 2021/07/31 06:00
CRDT- 2021/03/04 05:45
PHST- 2021/03/05 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
PHST- 2021/03/04 05:45 [entrez]
AID - dtb.2020.000009 [pii]
AID - 10.1136/dtb.2020.000009 [doi]
PST - ppublish
SO  - Drug Ther Bull. 2021 Apr;59(4):56-59. doi: 10.1136/dtb.2020.000009. Epub 2021 Mar 
      3.

PMID- 25495315
OWN - NLM
STAT- MEDLINE
DCOM- 20150420
LR  - 20190902
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 201
IP  - 11
DP  - 2014 Dec 11
TI  - An economic case for a cardiovascular polypill? A cost analysis of the Kanyini 
      GAP trial.
PG  - 671-3
AB  - OBJECTIVE: To measure the costs of a polypill strategy and compare them with 
      those of usual care in people with established cardiovascular disease (CVD) or at 
      similarly high cardiovascular risk. DESIGN: A within-trial cost analysis of 
      polypill-based care versus usual care with separate medications, using data from 
      the Kanyini Guidelines Adherence with the Polypill (GAP) trial and linked health 
      service and medication administrative claims data. PARTICIPANTS: Kanyini GAP 
      participants who consented to Australian Medicare record access. MAIN OUTCOME 
      MEASURES: Mean health service and pharmaceutical expenditure per patient per 
      year, estimated with generalised linear models. Costs during the trial 
      (randomisation January 2010 - May 2012, median follow-up 19 months, maximum 
      follow-up 36 months) were inflated to 2012 costs. RESULTS: Our analysis showed a 
      statistically significantly lower mean pharmaceutical expenditure of $989 (95% 
      CI, $648-$1331) per patient per year in the polypill arm compared with usual care 
      (P < 0.001; adjusted, excluding polypill cost). No significant difference was 
      shown in health service expenditure. CONCLUSIONS: This study provides evidence of 
      significant cost savings to the taxpayer and Australian Government through the 
      introduction of a CVD polypill strategy. The savings will be less now than during 
      the trial due to subsequent reductions in the costs of usual care. Nonetheless, 
      given the prevalence of CVD in Australia, the introduction of this polypill could 
      increase considerably the efficiency of health care expenditure in Australia. 
      TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry 
      ACTRN126080005833347.
FAU - Laba, Tracey-Lea
AU  - Laba TL
AD  - The George Institute for Global Health, Sydney, NSW, Australia. 
      tlaba@georgeinstitute.org.au.
FAU - Hayes, Alison
AU  - Hayes A
AD  - School of Public Health, University of Sydney, Sydney, NSW, Australia.
FAU - Lo, Serigne
AU  - Lo S
AD  - The George Institute for Global Health, Sydney, NSW, Australia.
FAU - Peiris, David P
AU  - Peiris DP
AD  - The George Institute for Global Health, Sydney, NSW, Australia.
FAU - Usherwood, Tim
AU  - Usherwood T
AD  - Department of General Practice, Sydney Medical School, University of Sydney, 
      Sydney, NSW, Australia.
FAU - Hillis, Graham S
AU  - Hillis GS
AD  - The George Institute for Global Health, Sydney, NSW, Australia.
FAU - Rafter, Natasha
AU  - Rafter N
AD  - National Institute for Health Innovation, University of Auckland, Auckland, New 
      Zealand.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - Centre of Cardiovascular Research and Education in Therapeutics , Monash 
      University, Melbourne, VIC, Australia.
FAU - Tonkin, Andrew M
AU  - Tonkin AM
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
FAU - Webster, Ruth
AU  - Webster R
AD  - The George Institute for Global Health, Sydney, NSW, Australia.
FAU - Neal, Bruce C
AU  - Neal BC
AD  - The George Institute for Global Health, Sydney, NSW, Australia.
FAU - Cass, Alan
AU  - Cass A
AD  - Menzies School of Health Research, Darwin, NT, Australia.
FAU - Patel, Anushka
AU  - Patel A
AD  - The George Institute for Global Health, Sydney, NSW, Australia.
FAU - Rodgers, Anthony
AU  - Rodgers A
AD  - The George Institute for Global Health, Sydney, NSW, Australia.
FAU - Jan, Stephen
AU  - Jan S
AD  - The George Institute for Global Health, Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticholesteremic Agents/administration & dosage/economics/therapeutic use
MH  - Antihypertensive Agents/administration & dosage/economics/therapeutic use
MH  - Aspirin/administration & dosage/economics/therapeutic use
MH  - Australia
MH  - Cardiovascular Diseases/*drug therapy/economics/prevention & control
MH  - Cost Savings
MH  - Cost-Benefit Analysis
MH  - Drug Combinations
MH  - Drug Costs/statistics & numerical data
MH  - Health Expenditures/statistics & numerical data
MH  - Humans
MH  - Medication Adherence
EDAT- 2014/12/17 06:00
MHDA- 2015/04/22 06:00
CRDT- 2014/12/16 06:00
PHST- 2014/02/27 00:00 [received]
PHST- 2014/07/09 00:00 [accepted]
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/04/22 06:00 [medline]
AID - 10.5694/mja14.00266 [pii]
AID - 10.5694/mja14.00266 [doi]
PST - ppublish
SO  - Med J Aust. 2014 Dec 11;201(11):671-3. doi: 10.5694/mja14.00266.

PMID- 6501320
OWN - NLM
STAT- MEDLINE
DCOM- 19850110
LR  - 20210210
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 259
IP  - 23
DP  - 1984 Dec 10
TI  - Structural features required for the reactivity and intracellular transport of 
      bis(3,5-dibromosalicyl)fumarate and related anti-sickling compounds that modify 
      hemoglobin S at the 2,3-diphosphoglycerate binding site.
PG  - 14863-73
AB  - Bis(3,5-dibromosalicyl)fumarate (I) reacts preferentially with oxyhemoglobin to 
      cross-link the two beta 82 lysine residues within the 2,3-diphosphoglycerate 
      (DPG) binding site and as a result markedly increases the solubility of 
      deoxyhemoglobin S. The cross-link acts by perturbing the acceptor site for Val 6 
      within the sickle cell fiber (Chatterjee, R., Walder, R. Y., Arnone, A., and 
      Walder, J. A. (1982) Biochemistry 21, 5901-5909). In the present studies we have 
      compared a large number of analogs of I to determine the structural features of 
      the reagent required for specificity and for transport into the red cell. Both 
      electrostatic and hydrophobic interactions contribute to the binding of these 
      compounds at the DPG site. The optimal position for the negatively charged groups 
      on the cross-linking agent for productive binding is adjacent to the ester as in 
      the original salicylic acid derivatives. There is a direct correlation between 
      the reactivity toward hemoglobin and the hydrophobicity of the substituent 
      attached at the para position. Phenyl and substituted phenyl derivatives as in 
      the analgesic, antiinflammatory drug diflunisal are particularly effective. These 
      groups probably interact with hydrophobic residues of the amino-terminal 
      tripeptide and the EF corner of the beta chains adjacent to the DPG binding site. 
      Although bis(3,5-dibromosalicyl)fumarate is very reactive toward hemoglobin in 
      solution, it is much less effective in modifying hemoglobin within the red cell. 
      The reaction with intracellular hemoglobin was shown to be limited by competing 
      hydrolysis of the reagent catalyzed at the outer surface of the erythrocyte 
      membrane. Inactivation of the red cell membrane acetylcholinesterase with 
      phenylmethylsulfonyl fluoride did not inhibit this reaction. Introduction of a 
      single methyl group onto the carbon-carbon double bond of the fumaryl moiety 
      decreases the lability of the ester 10-fold, due to steric effects, and allows 
      the reagent to be taken up by the red cell and modify intracellular hemoglobin. 
      The kinetics of transport of the methylfumarate derivative, 
      bis(3,5-dibromosalicyl)mesaconate, are first-order, consistent with passive 
      diffusion. The attachment of larger alkyl groups onto the cross-link bridge 
      further enhances the transport of the reagent into the red cell. The solubility 
      of deoxyhemoglobin S cross-linked with the butylfumarate derivative was found to 
      be increased by almost 10% compared to the original fumarate diester.(ABSTRACT 
      TRUNCATED AT 400 WORDS)
FAU - Chatterjee, R
AU  - Chatterjee R
FAU - Iwai, Y
AU  - Iwai Y
FAU - Walder, R Y
AU  - Walder RY
FAU - Walder, J A
AU  - Walder JA
LA  - eng
GR  - HL-26745/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Antisickling Agents)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Diphosphoglyceric Acids)
RN  - 0 (Hemoglobin, Sickle)
RN  - 0 (Indicators and Reagents)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 138-81-8 (2,3-Diphosphoglycerate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2,3-Diphosphoglycerate
MH  - Antisickling Agents/*blood/chemical synthesis
MH  - Aspirin/*analogs & derivatives/blood/chemical synthesis
MH  - Binding Sites
MH  - Biological Transport
MH  - Cross-Linking Reagents/*metabolism
MH  - Diphosphoglyceric Acids/*blood
MH  - Hemoglobin, Sickle/*metabolism
MH  - Humans
MH  - Indicators and Reagents
MH  - Kinetics
MH  - Protein Binding
MH  - Structure-Activity Relationship
EDAT- 1984/12/10 00:00
MHDA- 1984/12/10 00:01
CRDT- 1984/12/10 00:00
PHST- 1984/12/10 00:00 [pubmed]
PHST- 1984/12/10 00:01 [medline]
PHST- 1984/12/10 00:00 [entrez]
AID - S0021-9258(17)42684-6 [pii]
PST - ppublish
SO  - J Biol Chem. 1984 Dec 10;259(23):14863-73.

PMID- 31059112
OWN - NLM
STAT- MEDLINE
DCOM- 20200210
LR  - 20200210
IS  - 2543-6767 (Electronic)
IS  - 0017-0011 (Linking)
VI  - 90
IP  - 4
DP  - 2019
TI  - Short-term dexamethasone plus acetylsalicylic acid treatment during in vitro 
      fertilization procedure.
PG  - 201-205
LID - 10.5603/GP.2019.0036 [doi]
AB  - OBJECTIVES: Embryo implantation represents the major limiting step during in 
      vitro fertilization (IVF) procedure. Immu- nological and coagulation 
      abnormalities were shown to have a substantial part in multifactorial etiology of 
      IVF failure. We aimed to investigate the effect of short-term low-dose 
      dexamethasone plus acetylsalicylic acid (ASA) treatment, starting at the time of 
      embryo transfer, on the implantation and clinical pregnancy rates in general IVF 
      population. MATERIAL AND METHODS: Out of 233 consecutive patients undergoing 
      fresh IVF/intracytoplasmic sperm injection (ICSI) cycles 64 received an adjuvant 
      treatment consisting of dexamethasone (0.5 mg/day) plus ASA (100 mg/day) (DA 
      group), starting on the day of embryo transfer. Patients not receiving these 
      medications comprised a control group. RESULTS: Significantly more patients in DA 
      group had positive ß-hCG values than controls (59.38% vs. 37.67%, p = 0.004) (OR 
      = 2.42, 95% CI: 1.33-4.41). Implantation rate was 26.53% in DA group and 15.92% 
      in controls (p = 0.0294). Clinical preg- nancy rate per started cycle was higher 
      in DA group (43.59%) than controls (28.92%), but the difference was not 
      significant (p = 0.0879; OR = 1.99, 95% CI: 0.89-4.41). CONCLUSIONS: Our study 
      shows a potential benefit of dexamethasone plus ASA adjuvant treatment in females 
      undergoing IVF/ICSI procedure. As these results show improvement of IVF outcome, 
      a greater number of patients undergoing this type and regime of adjuvant 
      treatment should be investigated.
FAU - Mitic, Dejan
AU  - Mitic D
AD  - Gynecology and Obstetrics Clinic, Clinical Center Nis, Faculty of Medicine, 
      University of Nis, Serbia.
FAU - Milenkovic, Jelena M
AU  - Milenkovic JM
AD  - Department of Pathophysiology, Faculty of Medicine, University of Nis, Serbia. 
      jelenaradovic982@gmail.com.
FAU - Milojkovic, Maja
AU  - Milojkovic M
AD  - Department of Pathophysiology, Faculty of Medicine, University of Nis, Serbia.
FAU - Jeremic, Miljan
AU  - Jeremic M
AD  - Faculty of Medicine, University of Nis, Serbia.
FAU - Petric, Aleksandra
AU  - Petric A
AD  - Gynecology and Obstetrics Clinic, Clinical Center Nis, Faculty of Medicine, 
      University of Nis, Serbia.
FAU - Basic, Marin
AU  - Basic M
AD  - Gynecology and Obstetrics Clinic, Clinical Center Nis, Faculty of Medicine, 
      University of Nis, Serbia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Poland
TA  - Ginekol Pol
JT  - Ginekologia polska
JID - 0374641
RN  - 0 (Anti-Inflammatory Agents)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Case-Control Studies
MH  - Dexamethasone/administration & dosage/adverse effects/*therapeutic use
MH  - Embryo Implantation
MH  - Female
MH  - Fertilization in Vitro/*methods
MH  - Humans
MH  - Pregnancy/*statistics & numerical data
MH  - Prospective Studies
OTO - NOTNLM
OT  - assisted reproductive techniques
OT  - coagulation disorders
OT  - embryo implantation
OT  - glucocorticoid effects
OT  - pregnancy rate
OT  - spontaneous abortion
EDAT- 2019/05/07 06:00
MHDA- 2020/02/11 06:00
CRDT- 2019/05/07 06:00
PHST- 2018/12/20 00:00 [received]
PHST- 2019/03/17 00:00 [accepted]
PHST- 2019/03/15 00:00 [revised]
PHST- 2019/05/07 06:00 [entrez]
PHST- 2019/05/07 06:00 [pubmed]
PHST- 2020/02/11 06:00 [medline]
AID - VM/OJS/J/62323 [pii]
AID - 10.5603/GP.2019.0036 [doi]
PST - ppublish
SO  - Ginekol Pol. 2019;90(4):201-205. doi: 10.5603/GP.2019.0036.

PMID- 458583
OWN - NLM
STAT- MEDLINE
DCOM- 19790927
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 68
IP  - 6
DP  - 1979 Jun
TI  - Modified USP assay for simultaneous determination of aspirin and nonaspirin 
      salicylates in aspirin and buffered aspirin tablets.
PG  - 780-2
AB  - Modified USP procedures are described for the simultaneous determination of 
      nonaspirin salicylates and aspirin in aspirin and buffered aspirin tablets. The 
      existing USP procedures are not stability indicating for intact aspirin when 
      significant levels of nonaspirin salicylates are present, as is often the case in 
      short-term, high temperature stability programs. The modified procedures yeld 
      considerably shorter analysis times and stability-indicating assays for intact 
      aspirin without the need for sophisticated equipment other than that presently 
      required by USP XIX.
FAU - Luber, J R
AU  - Luber JR
FAU - Visalli, A J
AU  - Visalli AJ
FAU - Patel, D M
AU  - Patel DM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Buffers)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
RN  - Y4S76JWI15 (Methanol)
SB  - IM
MH  - Aspirin/*analysis
MH  - Buffers
MH  - Drug Stability
MH  - Indicators and Reagents
MH  - Methanol
MH  - Methods
MH  - Pharmacopoeias as Topic
MH  - Salicylates/*analysis
MH  - Tablets/analysis
MH  - United States
EDAT- 1979/06/01 00:00
MHDA- 1979/06/01 00:01
CRDT- 1979/06/01 00:00
PHST- 1979/06/01 00:00 [pubmed]
PHST- 1979/06/01 00:01 [medline]
PHST- 1979/06/01 00:00 [entrez]
AID - S0022-3549(15)42690-5 [pii]
AID - 10.1002/jps.2600680630 [doi]
PST - ppublish
SO  - J Pharm Sci. 1979 Jun;68(6):780-2. doi: 10.1002/jps.2600680630.

PMID- 32328776
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20210813
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 146
IP  - 8
DP  - 2020 Aug
TI  - Effect of aspirin use on neoadjuvant chemoradiotherapy for rectal cancer: a 
      meta-analysis with trial sequential analysis.
PG  - 2161-2171
LID - 10.1007/s00432-020-03222-w [doi]
AB  - BACKGROUND: Numerous studies have reported the preventive and protective effects 
      of aspirin in patients with rectal cancer. However, it is not clear whether 
      aspirin can be used as an assistance drug in preoperative neoadjuvant 
      chemoradiotherapy. Therefore, this study will explore the efficacy of aspirin as 
      an adjuvant agent in rectal cancer neoadjuvant chemoradiotherapy. METHODS: A 
      literature search was performed using the electronic platforms to obtain relevant 
      research studies published up to Jan 2020. The search was limited to papers 
      published in English or Chinese language. Confidence intervals of research 
      endpoints in each study were extracted and merged. The meta-analysis was 
      performed using Stata12.0 software. Furthermore, we performed trial sequential 
      analysis (TSA) to evaluate the robustness of our findings and to obtain a more 
      conservative estimation. RESULTS: A total of 5 studies including 977 patients 
      were identified to be eligible for this meta-analysis. Compared with control 
      group, aspirin group significantly increased pathologic complete response rate 
      from 16.5 to 22.3% (RR 1.41, 95% CI 1.01-1.96, P = 0.041), partial remission rate 
      from 21.8 to 45.7% (RR 1.87, 95% CI 1.37-2.54, P < 0.001), and tumor down-staging 
      rate from 44.4 to 63.8% (RR 1.43, 95% CI 1.17-1.75, P = 0.001). Moreover, aspirin 
      group can reduce local recurrence rate (RR 0.37, 95% CI 0.17-0.84, P = 0.017), 
      improve 3-year survival rate (RR 1.24, 95% CI 1.12-1.36, P < 0.001), and 5-year 
      survival rate (RR 1.29, 95% CI 1.14-1.46, P < 0.001). TSA shows that the 
      meta-analysis results of pathologic complete response rate and local recurrence 
      rate may be a false positive. Furthermore, the meta-analysis results of other 
      study endpoints were further confirmed by TSA. CONCLUSION: Aspirin, as an 
      adjuvant agent, can enhance the effect of neoadjuvant chemoradiotherapy and 
      improve the prognosis of patients with rectal cancer. Neoadjuvant therapy 
      combined with aspirin may be considered a better option for preoperative rectal 
      cancer patients.
FAU - Wang, Bolin
AU  - Wang B
AUID- ORCID: 0000-0001-8086-0681
AD  - Weifang Medical University, Weifang, 261031, China.
FAU - Huang, Yan
AU  - Huang Y
AUID- ORCID: 0000-0002-1599-9086
AD  - Department of Oncology, Affiliated Hospital of Weifang Medical University, 
      Weifang, 261031, China. Yanhuangdr@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200423
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & 
      dosage/pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Chemoradiotherapy, Adjuvant
MH  - Drug Synergism
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - Randomized Controlled Trials as Topic
MH  - Rectal Neoplasms/*drug therapy/*radiotherapy
OTO - NOTNLM
OT  - Aspirin
OT  - Meta-analysis
OT  - Neoadjuvant therapy
OT  - Rectal cancer
EDAT- 2020/04/25 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/02/20 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1007/s00432-020-03222-w [pii]
AID - 10.1007/s00432-020-03222-w [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2020 Aug;146(8):2161-2171. doi: 
      10.1007/s00432-020-03222-w. Epub 2020 Apr 23.

PMID- 33979377
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 16
IP  - 5
DP  - 2021
TI  - Effect of aspirin treatment duration on clinical outcomes in acute coronary 
      syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor 
      monotherapy.
PG  - e0251109
LID - 10.1371/journal.pone.0251109 [doi]
LID - e0251109
AB  - Recent clinical trials showed that short aspirin duration (1 or 3 months) in dual 
      antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy reduced the 
      risk of bleeding and did not increase the ischemic risk compared to 12-month DAPT 
      in acute coronary syndrome (ACS) patients undergoing percutaneous coronary 
      intervention (PCI). However, it is unclear about the optimal duration of aspirin 
      in P2Y12 inhibitor monotherapy. The purpose of this study was to evaluate the 
      influence of aspirin treatment duration on clinical outcomes in a cohort of ACS 
      patients with early aspirin interruption and received P2Y12 inhibitor 
      monotherapy. From January 1, 2014 to December 31, 2018, we included 498 ACS 
      patients (age 70.18 ± 12.84 years, 71.3% men) with aspirin stopped for various 
      reasons before 6 months after PCI and received P2Y12 inhibitor monotherapy. The 
      clinical outcomes between those with aspirin treatment ≤ 1 month and > 1 month 
      were compared in 12-month follow up after PCI. Inverse probability of treatment 
      weighting was used to balance the covariates between groups. The mean duration of 
      aspirin treatment was 7.52 ± 8.10 days vs. 98.05 ± 56.70 days in the 2 groups 
      (p<0.001). The primary composite endpoint of all-cause mortality, recurrent ACS 
      or unplanned revascularization and stroke occurred in 12.6% and 14.4% in the 2 
      groups (adjusted HR 1.19, 95% CI 0.85-1.68). The safety outcome of BARC 3 or 5 
      bleeding was also similar (adjusted HR 0.69, 95% CI 0.34-1.40) between the 2 
      groups. In conclusion, patients with ≤ 1 month aspirin treatment had similar 
      clinical outcomes to those with treatment > 1 month. Our results indicated that ≤ 
      1-month aspirin may be enough in P2Y12 inhibitor monotherapy strategy for ACS 
      patients undergoing PCI.
FAU - Ho, Ming-Yun
AU  - Ho MY
AD  - Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, 
      Taiwan.
FAU - Chen, Po-Wei
AU  - Chen PW
AUID- ORCID: 0000-0003-2300-0698
AD  - National Cheng Kung University Hospital, College of Medicine, National Cheng Kung 
      University, Tainan, Taiwan.
FAU - Feng, Wen-Han
AU  - Feng WH
AUID- ORCID: 0000-0002-1994-6205
AD  - Kaohsiung Municipal Ta-Tung Hospital and Kaohsiung Medical University Hospital, 
      Kaohsiung, Taiwan.
FAU - Su, Chun-Hung
AU  - Su CH
AUID- ORCID: 0000-0003-4003-008X
AD  - Chung Shan Medical University Hospital and Chung Shan Medical University, 
      Taichung, Taiwan.
FAU - Huang, Sheng-Wei
AU  - Huang SW
AD  - Chung Shan Medical University Hospital and Chung Shan Medical University, 
      Taichung, Taiwan.
FAU - Cheng, Chung-Wei
AU  - Cheng CW
AD  - MacKay Memorial Hospital, Taipei, Taiwan.
FAU - Yeh, Hung-I
AU  - Yeh HI
AUID- ORCID: 0000-0003-3206-0908
AD  - MacKay Memorial Hospital, Taipei, Taiwan.
FAU - Chen, Ching-Pei
AU  - Chen CP
AUID- ORCID: 0000-0003-2823-2025
AD  - Changhua Christian Hospital, Changhua, Taiwan.
FAU - Huang, Wei-Chun
AU  - Huang WC
AD  - Kaohsiung Veterans General Hospital, Fooyin University, Kaohsiung and National 
      Yang Ming University, Taipei, Taiwan.
FAU - Fang, Ching-Chang
AU  - Fang CC
AD  - Tainan Municipal Hospital, Tainan, Taiwan.
FAU - Lin, Hui-Wen
AU  - Lin HW
AD  - National Cheng Kung University Hospital, College of Medicine, National Cheng Kung 
      University, Tainan, Taiwan.
FAU - Lin, Sheng-Hsiang
AU  - Lin SH
AD  - Institute of Clinical Medicine, College of Medicine, National Cheng Kung 
      University, Tainan, Taiwan.
AD  - Department of Public Health, College of Medicine, National Cheng Kung University, 
      Tainan, Taiwan.
AD  - Biostatistics Consulting Center, National Cheng Kung University Hospital, College 
      of Medicine, National Cheng Kung University, Tainan, Taiwan.
FAU - Hsieh, I-Chang
AU  - Hsieh IC
AD  - Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, 
      Taiwan.
FAU - Li, Yi-Heng
AU  - Li YH
AD  - National Cheng Kung University Hospital, College of Medicine, National Cheng Kung 
      University, Tainan, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210512
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (P2RY12 protein, human)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - 0 (Receptors, Purinergic P2Y12)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination/methods
MH  - Dual Anti-Platelet Therapy/methods
MH  - Duration of Therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
MH  - Receptors, Purinergic P2Y12/metabolism
MH  - Taiwan
PMC - PMC8115803
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/05/13 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/05/12 17:19
PHST- 2021/01/03 00:00 [received]
PHST- 2021/04/20 00:00 [accepted]
PHST- 2021/05/12 17:19 [entrez]
PHST- 2021/05/13 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - PONE-D-21-00131 [pii]
AID - 10.1371/journal.pone.0251109 [doi]
PST - epublish
SO  - PLoS One. 2021 May 12;16(5):e0251109. doi: 10.1371/journal.pone.0251109. 
      eCollection 2021.

PMID- 1354274
OWN - NLM
STAT- MEDLINE
DCOM- 19920917
LR  - 20190610
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 340
IP  - 8818
DP  - 1992 Aug 29
TI  - Prevention of serious cardiac events by low-dose aspirin in patients with silent 
      myocardial ischaemia. The Research Group on Instability in Coronary Artery 
      Disease in Southeast Sweden.
PG  - 497-501
AB  - On exercise testing after an episode of unstable coronary artery disease (CAD; 
      unstable angina or non-Q-wave myocardial infarction), a proportion of patients 
      show ST-segment depression, indicating myocardial ischaemia, but do not report 
      concomitant symptoms of angina. Treatment of such "silent" ischaemia aims mainly 
      to reduce the risk of subsequent cardiac events. We have studied the effect of 
      low-dose aspirin in patients with myocardial ischaemia defined at the 
      predischarge test as silent (though patients might have had symptomatic ischaemia 
      at other times) or symptomatic. 740 men with unstable CAD aged 70 years or less 
      underwent symptom-limited exercise testing before hospital discharge; 144 showed 
      ST depression without pain and 230 ST depression with simultaneous chest pain. Of 
      the silent ischaemia group, 67 were randomly assigned placebo and 77 aspirin (75 
      mg daily); the corresponding numbers in the symptomatic group were 125 and 105. 
      Angina symptoms were less common in the silent than in the symptomatic ischaemia 
      group both before inclusion and during follow-up, and a greater proportion of the 
      silent ischaemia group were included because of myocardial infarction. In both 
      ischaemia groups aspirin treatment reduced the risk of subsequent myocardial 
      infarction or death by 3 months' follow-up (silent 4% of aspirin-treated vs 21% 
      of placebo-treated patients, p = 0.004; symptomatic 9% vs 18%, p = 0.05); at 12 
      months' follow-up a significant benefit of aspirin was still apparent in the 
      silent ischaemia group (9% vs 28%, p = 0.005) but not in the symptomatic group 
      (13% vs 22%, p = 0.109). Low-dose aspirin reduced the risk of subsequent 
      myocardial infarction at least as well in silent as in symptomatic myocardial 
      ischaemia. Since improvement of outlook is the main treatment objective in 
      symptom-free patients, aspirin should be a mainstay of their treatment.
FAU - Nyman, I
AU  - Nyman I
AD  - Department of Internal Medicine, District Hospital, Eksjö, Sweden.
FAU - Larsson, H
AU  - Larsson H
FAU - Wallentin, L
AU  - Wallentin L
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/*prevention & control
MH  - Double-Blind Method
MH  - Electrocardiography
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1992/08/29 00:00
MHDA- 1992/08/29 00:01
CRDT- 1992/08/29 00:00
PHST- 1992/08/29 00:00 [pubmed]
PHST- 1992/08/29 00:01 [medline]
PHST- 1992/08/29 00:00 [entrez]
AID - 0140-6736(92)91706-E [pii]
AID - 10.1016/0140-6736(92)91706-e [doi]
PST - ppublish
SO  - Lancet. 1992 Aug 29;340(8818):497-501. doi: 10.1016/0140-6736(92)91706-e.

PMID- 7974553
OWN - NLM
STAT- MEDLINE
DCOM- 19941129
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 25
IP  - 11
DP  - 1994 Nov
TI  - Diaspirin cross-linked hemoglobin improves neurological outcome following 
      reversible but not irreversible CNS ischemia in rabbits.
PG  - 2253-7
AB  - BACKGROUND AND PURPOSE: Hemodilution using modified hemoglobin solutions may 
      reduce ischemic central nervous system injury. Purified diaspirin cross-linked 
      hemoglobin (DCLHb) is a cell-free hemoglobin that is intramolecularly 
      cross-linked between the two alpha subunits, resulting in enhanced oxygen 
      offloading to tissues and increased half-life. In the present experiments, we 
      evaluated the ability of DCLHb to reduce neurological damage in two rabbit stroke 
      models. METHODS: In a reversible spinal cord ischemia model, ischemia of the 
      caudal lumbar spinal cord was produced by temporary occlusion of the abdominal 
      aorta. In an irreversible model of cerebral ischemia, plastic microspheres (50 
      microns) were injected into the internal carotid artery and lodged in the 
      cerebral microvasculature. DCLHb was administered 5 minutes after initiation of 
      ischemia as either a 10-mL/kg infusion, 10-mL/kg exchange transfusion, or a 
      20-mL/kg infusion. Control animals received human serum albumin that was 
      oncotically matched to the DCLHb. RESULTS: In the spinal cord model, DCLHb 
      significantly increased the duration of ischemia required to produce permanent 
      paralysis from 27.33 +/- 8.71 minutes (mean +/- SD) in controls to 42.59 +/- 
      10.10 minutes in the 10-mL/kg exchange transfusion group and to 40.82 +/- 18.16 
      minutes in the 20-mL/kg infusion condition (P < .05). DCLHb did not significantly 
      reduce neurological damage in the microsphere embolization model. CONCLUSIONS: 
      These data suggest that cross-linked hemoglobin reduces neurological damage after 
      reversible central nervous system ischemia and that this is not attributable to 
      hemodilution or hypervolemia only.
FAU - Bowes, M P
AU  - Bowes MP
AD  - Department of Neurosciences, School of Medicine, University of California San 
      Diego, La Jolla 92093-0624.
FAU - Burhop, K E
AU  - Burhop KE
FAU - Zivin, J A
AU  - Zivin JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Hemoglobins/*therapeutic use
MH  - Intracranial Embolism and Thrombosis/drug therapy/physiopathology
MH  - Ischemia/*drug therapy/*physiopathology
MH  - Male
MH  - Nervous System/drug effects/*physiopathology
MH  - Rabbits
MH  - Spinal Cord/*blood supply
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
AID - 10.1161/01.str.25.11.2253 [doi]
PST - ppublish
SO  - Stroke. 1994 Nov;25(11):2253-7. doi: 10.1161/01.str.25.11.2253.

PMID- 8342184
OWN - NLM
STAT- MEDLINE
DCOM- 19930831
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 24
IP  - 8
DP  - 1993 Aug
TI  - Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A 
      double-blind, placebo-controlled randomized trial.
PG  - 1125-8
AB  - BACKGROUND AND PURPOSE: The aim of this randomized double-blind, 
      placebo-controlled trial was to evaluate whether neurological deficits could be 
      prevented with low-dose acetylsalicylic acid (ASA) as an adjunct to carotid 
      endarterectomy. METHODS: A total of 232 patients were randomized to two groups, 
      75 mg/d ASA starting preoperatively and continued for 6 months (n = 117) or 
      placebo (identical tablets) (n = 115). The patients were followed up regularly 
      for 1 year. RESULTS: The groups were well matched regarding laboratory data and 
      indication for operation. The number of patients with intraoperative or 
      postoperative stroke without complete recovery within 1 week were 0 and 2 at 30 
      days and 6 months, respectively, in the ASA group, compared with 7 and 11 in the 
      placebo group (P = .01). Including all neurological events within 6 months, this 
      was found in 15 patients in the ASA group compared with 24 in the placebo group 
      (P = .12). Mortality was 0.8% and 3.4% at 30 days and 6 months, respectively, in 
      the ASA group. In the placebo group, the corresponding figures were 4.3% and 
      6.0%, respectively (P = .12). The intraoperative bleeding did not differ between 
      the groups nor did the number of reoperations due to bleeding or other 
      complications related to pharmacology. CONCLUSIONS: This study indicates that 
      low-dose ASA (75 mg/d) reduces the number of postoperative strokes without 
      complete recovery within 1 week. Overall neurological events are insignificantly 
      reduced, as also mortality. The use of low-dose ASA (75 mg) seems safe and 
      effective in reducing cerebrovascular events after carotid endarterectomy.
FAU - Lindblad, B
AU  - Lindblad B
AD  - Department of Surgery, Malmö General Hospital, Lund University, Sweden.
FAU - Persson, N H
AU  - Persson NH
FAU - Takolander, R
AU  - Takolander R
FAU - Bergqvist, D
AU  - Bergqvist D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - *Endarterectomy, Carotid
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Postoperative Complications/mortality/*prevention & control
MH  - Treatment Outcome
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
AID - 10.1161/01.str.24.8.1125 [doi]
PST - ppublish
SO  - Stroke. 1993 Aug;24(8):1125-8. doi: 10.1161/01.str.24.8.1125.

PMID- 1400651
OWN - NLM
STAT- MEDLINE
DCOM- 19921125
LR  - 20151119
IS  - 0271-678X (Print)
IS  - 0271-678X (Linking)
VI  - 12
IP  - 6
DP  - 1992 Nov
TI  - Focal cerebral ischemia in rats: effect of hemodilution with alpha-alpha 
      cross-linked hemoglobin on CBF.
PG  - 971-6
AB  - Hemodilution has had limited success as a treatment of cerebral ischemia. When 
      using a nonoxygen binding fluid, the therapeutic efficacy of hemodilution-induced 
      increases in CBF are offset by concomitant decreases in oxygen content. The 
      effect of hemodilution, with diaspirin alpha-alpha cross-linked hemoglobin 
      (DCLHb), on CBF during middle cerebral artery occlusion was assessed. Rats were 
      hemodiluted to one of the following hematocrits (Hct): (a) 44/Hct, (b) 37/Hct, 
      (c) 30/Hct, (d) 23/Hct, (e) 16/Hct, or (f) 9/Hct. After 10 min of ischemia, CBF 
      was determined with 14C-iodoantipyrine. Coronal brain sections were evaluated for 
      areas with a CBF of 0-10 and 11-20 ml 100 g-1 min-1. In addition, oxygen delivery 
      was calculated. In the center of the ischemic zone, both areas of low CBF were 
      less in the 30/Hct, 23/Hct, and 16/Hct groups compared with the 44/Hct and 37/Hct 
      groups; and both areas were less in the 9/Hct group compared with the other five 
      groups (p < 0.05). For the hemisphere contralateral to occlusion, there was a 
      direct correlation between hematocrit and oxygen delivery. However, for the 
      hemisphere ipsilateral to occlusion, oxygen delivery increased as hematocrit 
      decreased (44/Hct, 8.6 +/- 0.3 vs. 9/Hct, 13.6 +/- 0.4 [mean +/- SD, ml 100 g-1 
      min-1]). The results of this study support a hypothesis that hemodilution with 
      DCLHb decreases the extent of focal cerebral ischemia.
FAU - Cole, D J
AU  - Cole DJ
AD  - Department of Anesthesiology, Loma Linda University, CA 92354.
FAU - Schell, R M
AU  - Schell RM
FAU - Przybelski, R J
AU  - Przybelski RJ
FAU - Drummond, J C
AU  - Drummond JC
FAU - Bradley, K
AU  - Bradley K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Cereb Blood Flow Metab
JT  - Journal of cerebral blood flow and metabolism : official journal of the 
      International Society of Cerebral Blood Flow and Metabolism
JID - 8112566
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Brain/blood supply
MH  - Brain Ischemia/*drug therapy
MH  - Cerebrovascular Circulation/*drug effects
MH  - Cross-Linking Reagents/*pharmacology
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - *Hemodilution
MH  - Hemoglobins/chemistry/*therapeutic use
MH  - Male
MH  - Rats
MH  - Rats, Inbred SHR
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
AID - 10.1038/jcbfm.1992.134 [doi]
PST - ppublish
SO  - J Cereb Blood Flow Metab. 1992 Nov;12(6):971-6. doi: 10.1038/jcbfm.1992.134.

PMID- 11096182
OWN - NLM
STAT- MEDLINE
DCOM- 20010104
LR  - 20181130
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 10 Suppl 5
DP  - 2000
TI  - Antiplatelet agents in stroke prevention. combination therapy: present and 
      future.
PG  - 41-8
AB  - Platelets contribute to arterial thrombosis by multiple mechanisms that promote 
      blood clotting, favor vasoconstriction, activate the procoagulant capacity of 
      endothelium, and stimulate inflammation. These activities are augmented by 
      turbulent blood flow. Classic antiplatelet therapy with aspirin to prevent 
      occlusive stroke offers significant clinical benefit (20-25% risk reduction), yet 
      is less effective than in prevention of coronary artery occlusion (up to 50% risk 
      reduction of myocardial infarction in unstable angina). Since aspirin's 
      antiplatelet effects are limited to blocking a single metabolic pathway - namely 
      inhibition of thromboxane A(2) formation -, and aspirin fails to alter platelet 
      adhesion, other antiplatelet agents that target ADP receptors, platelet surface 
      glycoproteins (such as the GPIIb/IIIa complex), or platelet-dependent thrombin 
      generation offer additional clinical benefits by blocking additional separate 
      pathways or the final common pathway of platelet activation. Combinations of 
      antiplatelet agents, such as aspirin/dipyridamole, aspirin/clopidogrel, or 
      aspirin/GPIIb/IIIa inhibitors, have recently been tested for improved efficacy in 
      clinical trials. Soluble recombinant CD39, an ecto-ADPase, protects against 
      stroke in animal models by metabolizing released ADP/ATP to antiplatelet 
      derivatives. In general, combinations of antiplatelet agents promise greater 
      efficacy than single drugs in preventing stroke, since interactions among 
      different antiplatelet mechanisms can be synergistic. However, such combinations 
      may also increase the risk of bleeding, so that precise understanding of 
      risk/benefit ratios that address the possibility of intracranial as well as 
      gastrointestinal bleeding will require careful monitoring in large clinical 
      trials of patients at risk of stroke, with particular attention to the elderly.
CI  - Copyright 2000 S. Karger AG, Basel
FAU - Weksler, B B
AU  - Weksler BB
AD  - Department of Medicine, New York Presbyterian Hospital-Weill Cornell Medical 
      Center, New York, NY 10021, USA. babette@med.cornell.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Purinergic P2 Receptor Antagonists)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Clopidogrel
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Immunoglobulin Fab Fragments/therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Purinergic P2 Receptor Antagonists
MH  - Stroke/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
RF  - 43
EDAT- 2000/11/30 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/30 11:00
PHST- 2000/11/30 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/30 11:00 [entrez]
AID - 47603 [pii]
AID - 10.1159/000047603 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2000;10 Suppl 5:41-8. doi: 10.1159/000047603.

PMID- 6733366
OWN - NLM
STAT- MEDLINE
DCOM- 19840813
LR  - 20190511
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 82
IP  - 2
DP  - 1984 Jun
TI  - The inhibitory effect of aspirin on lymphatic contractility.
PG  - 509-14
AB  - Spontaneous contractions and those elicited by two different methods of 
      electrical stimulation were studied in isolated segments of bovine mesenteric 
      lymphatic vessels. The effect of aspirin (a cyclo-oxygenase inhibitor) on 
      spontaneous and evoked contractions of isolated lymphatic vessels was 
      investigated. Aspirin at doses of 10(-6) M or greater depressed both spontaneous 
      and action potential-dependent evoked contractions, but failed to inhibit 
      contractions evoked by high current field stimulation. These latter contractions 
      were rapidly depressed by the application of D600. When aspirin was applied for 
      five minute periods, inhibition never occurred within the period of drug 
      administration but was delayed, with maximum inhibition occurring approximately 
      10 min after washout of the drug. It is concluded that the inhibitory action of 
      aspirin is unlikely to be a non-specific depression of the contractile mechanism, 
      but rather a reduction in excitability probably as a result of cyclo-oxygenase 
      inhibition.
FAU - Allen, J M
AU  - Allen JM
FAU - Burke, E P
AU  - Burke EP
FAU - Johnston, M G
AU  - Johnston MG
FAU - McHale, N G
AU  - McHale NG
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Action Potentials/drug effects
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cattle
MH  - Electric Stimulation
MH  - In Vitro Techniques
MH  - Lymphatic System/*drug effects
MH  - Muscle Contraction/drug effects
MH  - Muscle, Smooth/drug effects
PMC - PMC1987037
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1984.tb10787.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1984 Jun;82(2):509-14. doi: 10.1111/j.1476-5381.1984.tb10787.x.

PMID- 7011688
OWN - NLM
STAT- MEDLINE
DCOM- 19810613
LR  - 20190909
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 7
IP  - 3
DP  - 1981
TI  - Clinical therapeutic trial of aspirin and azapropazone in rheumatoid arthritis 
      when prescribed singly and in combination.
PG  - 164-7
AB  - A double-blind, crossover trial was carried out to assess the clinical efficacy 
      of 3.6 g aspirin, 1200 mg azapropazone and the two drugs together in 24 adult 
      patients with classical or definite rheumatoid disease. Pain score, morning 
      stiffness and patients' assessment of pain were significantly improved for each 
      drug regimen when compared to placebo. There was no significant difference among 
      the individual drug regimens. Azapropazone was the best drug regimen in terms of 
      improving pain score, morning stiffness and patient assessment of pain, but this 
      was not statistically significant. It is concluded that there is no justification 
      for prescribing aspirin with azapropazone in patients with rheumatoid disease.
FAU - Kean, W F
AU  - Kean WF
FAU - Kraag, G R
AU  - Kraag GR
FAU - Rooney, P J
AU  - Rooney PJ
FAU - Capell, H A
AU  - Capell HA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 0 (Triazines)
RN  - K2VOT966ZI (Apazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/administration & dosage/*therapeutic use
MH  - Apazone/administration & dosage/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tablets, Enteric-Coated
MH  - Triazines/*therapeutic use
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1185/03007998109114257 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1981;7(3):164-7. doi: 10.1185/03007998109114257.

PMID- 11576827
OWN - NLM
STAT- MEDLINE
DCOM- 20011211
LR  - 20220311
IS  - 0928-0987 (Print)
IS  - 0928-0987 (Linking)
VI  - 14
IP  - 3
DP  - 2001 Oct
TI  - Synthesis, hydrolysis kinetics and anti-platelet effects of isosorbide 
      mononitrate derivatives of aspirin.
PG  - 221-7
AB  - Two isomeric aspirin derivatives of isosorbide-5-mononitrate (ISMN) were prepared 
      and evaluated as potential mutual prodrugs of aspirin and nitric oxide. The 
      hydrolysis of both compounds was studied in pH 7.4 phosphate buffer solution, 
      buffered alpha-chymotrypsin solution and 10% buffered rabbit plasma. The 
      benzodioxin-4-one derivative was hydrolysed to salicylic acid and ISMN acetate in 
      buffer solution (t(1/2) 32.1 h), 10% buffered rabbit plasma (t(1/2) 25.7 min) and 
      alpha-chymotrypsin (t(1/2) 86.6 min). The carboxylic acid ester derivative ISMNA 
      was hydrolysed via the salicylate ester in buffer solution (t(1/2) 48.5 h) but 
      was rapidly and almost exclusively hydrolysed to aspirin and ISMN in plasma 
      solution (t(1/2) 2.8 min). The hydrolysis appeared to be enzyme mediated as it 
      was suppressed by co-incubation with eserine. ISMNA was evaluated for its ability 
      to inhibit platelet aggregation in rabbit PRP in response to the following 
      agonists: arachidonic acid (AA) (100 microM), ADP (1.2 microM), phorbol ester 
      (0.5 microM), platelet activating factor (PAF) (5 nM) and the thromboxane mimic 
      U46619 (1.5 microM). ISMNA suppressed platelet response to AA at 1 microM whereas 
      10 microM aspirin showed no inhibitory effects.
FAU - Gilmer, J F
AU  - Gilmer JF
AD  - Department of Pharmaceutical Chemistry, School of Pharmacy, Trinity College, 2, 
      Dublin, Ireland. gilmerjf@tcd.ie
FAU - Moriarty, L M
AU  - Moriarty LM
FAU - McCafferty, D F
AU  - McCafferty DF
FAU - Clancy, J M
AU  - Clancy JM
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - IA7306519N (Isosorbide Dinitrate)
RN  - LX1OH63030 (isosorbide-5-mononitrate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood/drug effects
MH  - Hydrolysis
MH  - Isosorbide Dinitrate/*analogs & derivatives/*chemical synthesis/pharmacology
MH  - Nitric Oxide Donors/chemistry/pharmacology
MH  - Platelet Aggregation Inhibitors/*chemical synthesis/chemistry/pharmacology
MH  - Rabbits
EDAT- 2001/09/29 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/09/29 10:00
PHST- 2001/09/29 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/09/29 10:00 [entrez]
AID - S092809870100183X [pii]
AID - 10.1016/s0928-0987(01)00183-x [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2001 Oct;14(3):221-7. doi: 10.1016/s0928-0987(01)00183-x.

PMID- 3741521
OWN - NLM
STAT- MEDLINE
DCOM- 19860917
LR  - 20190718
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 29
IP  - 8
DP  - 1986 Aug
TI  - Influence of age, gender, and obesity on salicylate kinetics following single 
      doses of aspirin.
PG  - 971-80
AB  - Salicylate kinetics following single, 650-mg intravenous and oral doses of 
      aspirin were evaluated in humans in 2 studies. Complete conversion of aspirin to 
      salicylate was assumed. The first study involved 25 young (25-40 years) and 21 
      elderly (66-89 years) healthy male and female volunteers. Mean salicylate 
      clearance was lower in elderly females compared with that in young females; 
      however, the difference between young men and elderly men was not significant. 
      Salicylate free fraction in plasma increased significantly with age in men and 
      women. After correction for free fraction, unbound mean clearance was reduced in 
      elderly men compared with young men, and in elderly women compared with young 
      women. Peak plasma salicylate concentrations after taking oral aspirin were not 
      significantly influenced by age, and systemic availability of salicylate in all 
      groups was complete. The second study compared 20 obese subjects (mean weight 113 
      kg) with 20 normal weight controls (mean weight 67 kg) matched for age, sex, 
      height, and smoking habits. Small differences between obese and control groups 
      were observed in total salicylate volume of distribution (Vd), unbound Vd, and 
      mean clearance of total or unbound salicylate. Following normalization for total 
      weight, however, values of total Vd and mean clearance were significantly smaller 
      in obese subjects than in normal weight subjects. Rate and completeness of 
      salicylate absorption were not influenced by obesity when aspirin was ingested, 
      although peak levels were lower in obese subjects. If applied to multiple doses, 
      the reduced unbound clearance of salicylate in the elderly would imply increased 
      accumulation unless doses are appropriately adjusted downward. During long-term 
      therapy, salicylate dosage for obese individuals should not be adjusted upward in 
      proportion to total weight.
FAU - Greenblatt, D J
AU  - Greenblatt DJ
FAU - Abernethy, D R
AU  - Abernethy DR
FAU - Boxenbaum, H G
AU  - Boxenbaum HG
FAU - Matlis, R
AU  - Matlis R
FAU - Ochs, H R
AU  - Ochs HR
FAU - Harmatz, J S
AU  - Harmatz JS
FAU - Shader, R I
AU  - Shader RI
LA  - eng
GR  - AM-MH-32050/AM/NIADDK NIH HHS/United States
GR  - MH-34223/MH/NIMH NIH HHS/United States
GR  - RR-00054/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aspirin/administration & dosage/*metabolism
MH  - Body Weight
MH  - Female
MH  - Humans
MH  - Infusions, Parenteral
MH  - Kinetics
MH  - Male
MH  - Obesity/*metabolism
MH  - Salicylates/*metabolism
MH  - Salicylic Acid
MH  - Sex Factors
EDAT- 1986/08/01 00:00
MHDA- 1986/08/01 00:01
CRDT- 1986/08/01 00:00
PHST- 1986/08/01 00:00 [pubmed]
PHST- 1986/08/01 00:01 [medline]
PHST- 1986/08/01 00:00 [entrez]
AID - 10.1002/art.1780290805 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1986 Aug;29(8):971-80. doi: 10.1002/art.1780290805.

PMID- 3924533
OWN - NLM
STAT- MEDLINE
DCOM- 19850809
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 30
IP  - 7
DP  - 1985 Jul
TI  - Reduction of aspirin-induced fecal blood loss with low-dose misoprostol tablets 
      in man.
PG  - 605-11
AB  - Misoprostol (SC-29333), a synthetic prostaglandin E1 methyl ester analog, was 
      given simultaneously with acetylsalicylic acid in a double-blind, 
      placebo-controlled randomized prospective study of 32 healthy human male 
      subjects. Fecal blood loss was measured for eight days using the 51Cr-labeled red 
      blood cell technique. Aspirin (650 mg qid) and misoprostol (25 micrograms qid) or 
      placebo were given during days 3, 4, and 5. There was a significant (P less than 
      0.05) increase in median blood loss (modified Friedman test) from 0.81 to 6.05 
      ml/day in the aspirin with placebo group (N = 16). Median blood loss was 
      increased (from 0.75 to 3.75 ml/day) in the aspirin with misoprostol group (N = 
      16), but this was significantly less (Mann-Whitney U test, P less than 0.01) than 
      the placebo group. Mean serum salicylate concentrations in the placebo and 
      misoprostol groups were similar (7.8 and 6.8 micrograms/ml, respectively). There 
      were no significant changes in laboratory values in any of the subjects studied, 
      nor were any major side-effects encountered. This study demonstrates that oral 
      misoprostol reduces aspirin-induced gastrointestinal bleeding even when 
      administered simultaneously and at a dose level below its threshold for 
      significant acid inhibition. This indicates a potential role for misoprostol in 
      the prevention of gastric mucosal damage in selected patients.
FAU - Cohen, M M
AU  - Cohen MM
FAU - Clark, L
AU  - Clark L
FAU - Armstrong, L
AU  - Armstrong L
FAU - D'Souza, J
AU  - D'Souza J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Prostaglandins E, Synthetic)
RN  - 0E43V0BB57 (Misoprostol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*antagonists & inhibitors
MH  - Chromium Radioisotopes
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Feces/analysis
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Humans
MH  - Male
MH  - Misoprostol
MH  - Prostaglandins E, Synthetic/*therapeutic use
MH  - Random Allocation
EDAT- 1985/07/01 00:00
MHDA- 1985/07/01 00:01
CRDT- 1985/07/01 00:00
PHST- 1985/07/01 00:00 [pubmed]
PHST- 1985/07/01 00:01 [medline]
PHST- 1985/07/01 00:00 [entrez]
AID - 10.1007/BF01308407 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1985 Jul;30(7):605-11. doi: 10.1007/BF01308407.

PMID- 7066822
OWN - NLM
STAT- MEDLINE
DCOM- 19820624
LR  - 20181113
IS  - 0008-4409 (Print)
IS  - 0008-4409 (Linking)
VI  - 126
IP  - 6
DP  - 1982 Mar 15
TI  - In healthy habitual smokers acetylsalicylic acid abolishes the effects of tobacco 
      smoke on the platelet aggregate ratio.
PG  - 637-9
AB  - After abstinence for at least 8 hours, 20 healthy habitual smokers smoked two 
      unfiltered cigarettes during each of two 20-minute periods separated by 48 hours. 
      They had taken one 0.32-g tablet of acetylsalicylic acid (ASA) the night before 
      the second period. The mean platelet aggregate ratios in venous blood taken 
      immediately before and after each period of smoking were 0.79 and 0.70 
      respectively when ASA had not been taken beforehand and 0.89 and 0.91 when it 
      had. The mean after smoking was significantly higher when ASA had been taken 
      beforehand. In conjunction with the previous finding that in nonsmokers ASA 
      prevented a lowering of the platelet aggregate ratio by experimental smoking 
      without affecting the ratio before smoking, the data from the present study 
      suggest that ASA abolishes both acute and longer-lasting effects of tobacco smoke 
      on the platelet aggregate ratio in healthy habitual smokers.
FAU - Davis, J W
AU  - Davis JW
FAU - Davis, R F
AU  - Davis RF
FAU - Hassanein, K M
AU  - Hassanein KM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - Canada
TA  - Can Med Assoc J
JT  - Canadian Medical Association journal
JID - 0414110
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - *Smoking
PMC - PMC1863228
EDAT- 1982/03/15 00:00
MHDA- 1982/03/15 00:01
CRDT- 1982/03/15 00:00
PHST- 1982/03/15 00:00 [pubmed]
PHST- 1982/03/15 00:01 [medline]
PHST- 1982/03/15 00:00 [entrez]
PST - ppublish
SO  - Can Med Assoc J. 1982 Mar 15;126(6):637-9.

PMID- 30680862
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20200827
IS  - 1521-3773 (Electronic)
IS  - 1433-7851 (Print)
IS  - 1433-7851 (Linking)
VI  - 58
IP  - 13
DP  - 2019 Mar 22
TI  - Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution 
      by Hyperpolarized Magnetic Resonance Spectroscopy.
PG  - 4179-4183
LID - 10.1002/anie.201812759 [doi]
AB  - Hyperpolarized magnetic resonance spectroscopy enables quantitative, 
      non-radioactive, real-time measurement of imaging probe biodistribution and 
      metabolism in vivo. Here, we investigate and report on the development and 
      characterization of hyperpolarized acetylsalicylic acid (aspirin) and its use as 
      a nuclear magnetic resonance (NMR) probe. Aspirin derivatives were synthesized 
      with single- and double-(13) C labels and hyperpolarized by dynamic nuclear 
      polarization with 4.7 % and 3 % polarization, respectively. The longitudinal 
      relaxation constants (T(1) ) for the labeled acetyl and carboxyl carbonyls were 
      approximately 30 seconds, supporting in vivo imaging and spectroscopy 
      applications. In vitro hydrolysis, transacetylation, and albumin binding of 
      hyperpolarized aspirin were readily monitored in real time by (13) C-NMR 
      spectroscopy. Hyperpolarized, double-labeled aspirin was well tolerated in mice 
      and could be observed by both (13) C-MR imaging and (13) C-NMR spectroscopy 
      in vivo.
CI  - © 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Zacharias, Niki M
AU  - Zacharias NM
AD  - Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer 
      Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
AD  - Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 
      Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Ornelas, Argentina
AU  - Ornelas A
AD  - Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer 
      Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Lee, Jaehyuk
AU  - Lee J
AD  - Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer 
      Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Hu, Jingzhe
AU  - Hu J
AD  - Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer 
      Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Davis, Jennifer S
AU  - Davis JS
AUID- ORCID: 0000-0001-9456-1682
AD  - Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 
      1515 Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Uddin, Nasir
AU  - Uddin N
AD  - Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer 
      Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Pudakalakatti, Shivanand
AU  - Pudakalakatti S
AD  - Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer 
      Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Menter, David G
AU  - Menter DG
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Karam, Jose A
AU  - Karam JA
AD  - Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 
      Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Wood, Christopher G
AU  - Wood CG
AD  - Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 
      Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Hawk, Ernest T
AU  - Hawk ET
AD  - Department of Clinical Cancer Prevention, The University of Texas MD Anderson 
      Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Kopetz, Scott
AU  - Kopetz S
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Vilar, Eduardo
AU  - Vilar E
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
AD  - Department of Clinical Cancer Prevention, The University of Texas MD Anderson 
      Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Bhattacharya, Pratip K
AU  - Bhattacharya PK
AD  - Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer 
      Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
FAU - Millward, Steven W
AU  - Millward SW
AUID- ORCID: 0000-0002-3231-7075
AD  - Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer 
      Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
LA  - eng
GR  - P50 CA221707/CA/NCI NIH HHS/United States
GR  - 5R01CA1722670/CA/NCI NIH HHS/United States
GR  - R21 CA181994/CA/NCI NIH HHS/United States
GR  - PC110065/Congressionally Directed Medical Research Programs/International
GR  - RP180164/Cancer Prevention and Research Institute of Texas/International
GR  - R44 CA206771/CA/NCI NIH HHS/United States
GR  - R21 CA185536/CA/NCI NIH HHS/United States
GR  - RP170593/Cancer Prevention and Research Institute of Texas/International
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R25 CA057730/CA/NCI NIH HHS/United States
GR  - R01 CA184843/CA/NCI NIH HHS/United States
GR  - R01 CA187238/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20190220
PL  - Germany
TA  - Angew Chem Int Ed Engl
JT  - Angewandte Chemie (International ed. in English)
JID - 0370543
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Carbon Isotopes)
RN  - 27432CM55Q (Serum Albumin, Bovine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*pharmacokinetics
MH  - Aspirin/chemistry/*pharmacokinetics
MH  - Carbon Isotopes/*analysis
MH  - Hydrolysis
MH  - Male
MH  - Mice
MH  - Serum Albumin, Bovine/*metabolism
MH  - Tissue Distribution
PMC - PMC6467058
MID - NIHMS1022168
OTO - NOTNLM
OT  - aspirin
OT  - chemopreventive
OT  - hyperpolarization
OT  - magnetic resonance imaging
OT  - magnetic resonance spectroscopy
COIS- Conflict of interest The authors declare no conflict of interest.
EDAT- 2019/01/27 06:00
MHDA- 2020/08/28 06:00
CRDT- 2019/01/26 06:00
PHST- 2018/11/06 00:00 [received]
PHST- 2019/01/21 00:00 [revised]
PHST- 2019/01/27 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2019/01/26 06:00 [entrez]
AID - 10.1002/anie.201812759 [doi]
PST - ppublish
SO  - Angew Chem Int Ed Engl. 2019 Mar 22;58(13):4179-4183. doi: 
      10.1002/anie.201812759. Epub 2019 Feb 20.

PMID- 21091728
OWN - NLM
STAT- MEDLINE
DCOM- 20120125
LR  - 20191210
IS  - 1365-2885 (Electronic)
IS  - 0140-7783 (Linking)
VI  - 34
IP  - 4
DP  - 2011 Aug
TI  - Analytical determination and pharmacokinetics of major metabolites of carbasalate 
      calcium in broilers following oral administration.
PG  - 410-6
LID - 10.1111/j.1365-2885.2010.01250.x [doi]
AB  - As a newer anti-inflammatory agent, carbasalate calcium is used in various animal 
      species. In this study, the pharmacokinetics of carbasalate calcium was 
      investigated in broilers. Broilers, with body weight of 2.0 ± 0.3 kg, were 
      administrated carbasalate calcium soluble powder at a single dose of 40 mg/kg 
      body weight orally. The plasma concentrations of its metabolites, aspirin (ASA), 
      salicylic acid (SA) and gentisic acid (GA) were determined by LC-MS/MS method and 
      the pharmacokinetic parameters were calculated by noncompartmental analysis. 
      After oral administration of carbasalate calcium, the plasma drug concentration 
      for ASA, SA and GA reached a peak (C(max) ) of 8.88 ± 1.31, 42.6 ± 4.62 and 10.1 
      ± 2.16 μg/mL at 0.170, 2.00 and 2.00 h, respectively. The terminal half-life 
      (t(1/2λz) ) of ASA, SA and GA was 11.2 ± 8.04, 23.7 ± 17.1 and 28.6 ± 4.90 h, 
      respectively. In conclusion, analytical method for the quantification of ASA, SA 
      and GA in plasma in the broilers was developed and validated. In broilers, 
      carbasalate calcium is quickly metabolized in ASA and ASA is rapidly converted to 
      SA and one of the metabolites of SA is GA.
CI  - © 2010 Blackwell Publishing Ltd.
FAU - Wang, X
AU  - Wang X
AD  - National Reference Laboratory of Veterinary Drug Residues and MOA Key Laboratory 
      of Food Safety Evaluation, Huazhong Agricultural University, Wuhan, China.
FAU - Huang, L-L
AU  - Huang LL
FAU - Chen, D-M
AU  - Chen DM
FAU - Ihsan, A
AU  - Ihsan A
FAU - Yuan, Z-H
AU  - Yuan ZH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Validation Study
DEP - 20101122
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Gentisates)
RN  - 8W8T17847W (Urea)
RN  - N667F17JP1 (carbaspirin calcium)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - VP36V95O3T (2,5-dihydroxybenzoic acid)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/metabolism/*pharmacokinetics
MH  - Aspirin/administration & dosage/*analogs & 
      derivatives/blood/metabolism/pharmacokinetics
MH  - Chickens/*metabolism
MH  - Chromatography, High Pressure Liquid/veterinary
MH  - Chromatography, Liquid/veterinary
MH  - Drug Administration Schedule/veterinary
MH  - Female
MH  - Gentisates/blood
MH  - Male
MH  - Salicylic Acid/blood
MH  - Tandem Mass Spectrometry/veterinary
MH  - Urea/administration & dosage/*analogs & derivatives/metabolism/pharmacokinetics
EDAT- 2010/11/26 06:00
MHDA- 2012/01/26 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2012/01/26 06:00 [medline]
AID - 10.1111/j.1365-2885.2010.01250.x [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 2011 Aug;34(4):410-6. doi: 
      10.1111/j.1365-2885.2010.01250.x. Epub 2010 Nov 22.

PMID- 35403510
OWN - NLM
STAT- MEDLINE
DCOM- 20230414
LR  - 20230414
IS  - 1477-111X (Electronic)
IS  - 0267-6591 (Linking)
VI  - 38
IP  - 4
DP  - 2023 May
TI  - Ticagrelor for patients undergoing coronary artery bypass grafting: A 
      meta-analysis of randomized controlled trials.
PG  - 698-705
LID - 10.1177/02676591221076284 [doi]
AB  - OBJECTIVE: Ticagrelor may be an alternative to aspirin as it provides robust and 
      consistent platelet inhibition. However, the effect of ticagrelor treatment in 
      patients undergoing coronary artery bypass grafting (CABG) has not been well 
      confirmed. We conducted a meta-analysis to appraise whether ticagrelor therapy 
      affects outcomes in CABG patients. METHODS: We searched PubMed, Embase, EBSCO, 
      and Cochrane databases from its inception up to 4 December 2020 for randomized 
      controlled trials that assessed ticagrelor versus non-ticagrelor in patients 
      undergoing CABG. The primary outcome was the incidence of saphenous vein graft 
      (SVG) occlusion at 1 year after CABG. Secondary outcomes were SVG occlusion at 
      7 days, major adverse cardiovascular events (MACE), and bleeding requiring 
      reoperation. RESULTS: Seven trials including 4305 patients (2153 randomized to 
      ticagrelor therapy and 2152 to non-ticagrelor therapy) were included. One-hundred 
      and thirty of 1140 patients (11.4%) randomized to the ticagrelor group versus 175 
      of 1220 patients (14.3%) randomized to the non-ticagrelor group experienced SVG 
      occlusion at 1 year after CABG. Compared to the control group, ticagrelor therapy 
      yielded a significantly lower risk of SVG occlusion [RR 0.79 (0.64-0.97), p = 
      0.03]. In the subgroup analysis, ticagrelor plus aspirin compared with aspirin 
      alone did not decrease the risk of SVG occlusion after 1 year [RR 0.65 
      (0.40-1.07), p = 0.09]. There was no difference in the incidence of SVG occlusion 
      at 7 days [RR 0.67 (0.42-1.06), p = 0.09], MACE up to 1 year [RR 0.99 
      (0.81-1.21), p = 0.90], or bleeding requiring reoperation [RR 1.16 (0.80-1.70), p 
      = 0.44]. CONCLUSIONS: Compared with non-ticagrelor therapy, ticagrelor decreased 
      the risk of saphenous vein graft occlusion after 1 year in patients undergoing 
      elective CABG with saphenous vein grafting.
FAU - Xiang, Feng
AU  - Xiang F
AD  - Department of Pharmacy, The Second Affiliated Hospital, Yuying Children's 
      Hospital of Wenzhou Medical University, Wenzhou, China.
FAU - Lin, Yifeng
AU  - Lin Y
AD  - Department of Pharmacy, The Second Affiliated Hospital, Yuying Children's 
      Hospital of Wenzhou Medical University, Wenzhou, China.
FAU - Chen, Binwu
AU  - Chen B
AUID- ORCID: 0000-0003-2287-3139
AD  - Department of Pharmacy, The Second Affiliated Hospital, Yuying Children's 
      Hospital of Wenzhou Medical University, Wenzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220410
PL  - England
TA  - Perfusion
JT  - Perfusion
JID - 8700166
RN  - GLH0314RVC (Ticagrelor)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Ticagrelor/therapeutic use
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Coronary Artery Bypass/adverse effects
MH  - Aspirin/therapeutic use/adverse effects
MH  - Hemorrhage/etiology
MH  - *Vascular Diseases/etiology
MH  - Treatment Outcome
MH  - Saphenous Vein
MH  - Graft Occlusion, Vascular/etiology
OTO - NOTNLM
OT  - Ticagrelor
OT  - coronary artery bypass grafting
OT  - meta-analysis
OT  - occlusion
OT  - randomized controlled trial
OT  - saphenous vein graft
EDAT- 2022/04/12 06:00
MHDA- 2023/04/14 06:41
CRDT- 2022/04/11 08:43
PHST- 2023/04/14 06:41 [medline]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/04/11 08:43 [entrez]
AID - 10.1177/02676591221076284 [doi]
PST - ppublish
SO  - Perfusion. 2023 May;38(4):698-705. doi: 10.1177/02676591221076284. Epub 2022 Apr 
      10.

PMID- 35904919
OWN - NLM
STAT- MEDLINE
DCOM- 20220802
LR  - 20220802
IS  - 1669-9106 (Electronic)
IS  - 0025-7680 (Linking)
VI  - 82
IP  - 4
DP  - 2022
TI  - Medium-pressure hyperbaric oxygen therapy for livedoid vasculopathy.
PG  - 613-616
AB  - Livedoid vasculopathy (LV) is a cutaneous manifestation of several diseases that 
      lead to noninflammatory thrombosis of dermal vessels. We report the case of a 
      26-year-old female with a 4 years and 8 months-old history of diagnosis of LV and 
      a non-healing ulcer of more than a year of evolution. Because of refractory 
      response to standard care, low-pressure hyperbaric oxygen (LPHBOT) was added to 
      the therapeutic scheme (azathiopine 2.5 mg/kg, folic acid and acetylsalicylic 
      acid). After 12 sessions of LHBOT (60 min, 1.45 ATA ≈ 100% O2), ulcers achieved 
      complete healing with significant pain relief and no recurrence was present over 
      6 months. More studies are necessary to determine the effectiveness of HBOT for 
      LV treatment.
FAU - Herrera-Sánchez, Alejandro
AU  - Herrera-Sánchez A
AD  - FisioSport Costa Rica, Biobarica Costa Rica, Costa Rica.
FAU - Madriagal-Alvarado, María José
AU  - Madriagal-Alvarado MJ
AD  - Caja Costarricense del Seguro Social, Costa Rica.
FAU - Moncayo, Gabriela
AU  - Moncayo G
AD  - Asociación Argentina de Medicina Hiperbárica e Investigación (AAMHEI), Buenos 
      Aires, Argentina.
FAU - Verdini, Fabrizio
AU  - Verdini F
AD  - Asociación Argentina de Medicina Hiperbárica e Investigación (AAMHEI), Buenos 
      Aires, Argentina. E-mail: investigacion@aamhei.org.
LA  - eng
PT  - Case Reports
TT  - Terapia de oxigenación hiperbárica de media presión en vasculopatía livedoide.
PL  - Argentina
TA  - Medicina (B Aires)
JT  - Medicina
JID - 0204271
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Hyperbaric Oxygenation
MH  - Infant
MH  - *Livedoid Vasculopathy
MH  - *Thrombosis
MH  - Wound Healing
OTO - NOTNLM
OT  - hyperbaric oxygen therapy
OT  - livedoid vasculopathy
OT  - ulcers
EDAT- 2022/07/30 06:00
MHDA- 2022/08/03 06:00
CRDT- 2022/07/29 12:22
PHST- 2022/07/29 12:22 [entrez]
PHST- 2022/07/30 06:00 [pubmed]
PHST- 2022/08/03 06:00 [medline]
PST - ppublish
SO  - Medicina (B Aires). 2022;82(4):613-616.

PMID- 1106038
OWN - NLM
STAT- MEDLINE
DCOM- 19760301
LR  - 20131121
IS  - 0340-1855 (Print)
IS  - 0340-1855 (Linking)
VI  - 34
IP  - 9-10
DP  - 1975 Sep-Oct
TI  - [Clinical study on a new acetylsalicylic acid/paracetamol preparation with 
      gastric acid resistant coating (Safapryn), and on two various phenylbutazone 
      dosages in patients with primary chronic polyarthritis as based on a new 
      evaluation method].
PG  - 350-65
AB  - The authors describe a simple non-crossover-blind test for the evaluation of 
      subjective indices. A table for recording pains during the 14 days' study is 
      described. The patient's satisfaction with the treatment and the number of days 
      until withdrawal from the trial are recorded. The statistical procedure takes 
      into consideration differences between the treatment groups and makes possible a 
      valuable comparison with drugs tested in other clinical trials. The three dose 
      schedules of antirheumatic treatment were tested on 122 patients and the results 
      compared with those of 342 patients treated with the 6 other antirheumatic drugs 
      (enteric-coated aspirin, paracetamol, indomethacin, flurbiprofen, mefenamic acid, 
      and prednisolone) and those of 41 patients who received placebos. The results 
      show that Safapryn (3,6 g aspirin + 3.0 g paracetamol daily) compared with 3.9 g 
      enteric coated aspirin does not offer any advantage in its analgesic effect, 
      although it gives rise to fewer side effects. Phenylbutazone (3000 mg) was almost 
      as effective as 15 mg prednisolone daily. Between the effects of this dosage of 
      phenylbutazone and other non-steroidal antirheumatic drugs, however, no 
      significant difference could be detected. 50 mg phenylbutazone daily and placebo 
      treatment could not be distinguished. The authors thank the Arthritis and 
      Rheumatism Council for Research in Great Britain for its financial support. One 
      of the authors (PL) was a Merck, Sharp, and Dohme Research Fellow and another one 
      (PMB) received a Robins research scholarship.
FAU - Brooks, P M
AU  - Brooks PM
FAU - Walker, J J
AU  - Walker JJ
FAU - Lee, P
AU  - Lee P
FAU - Bell, A M
AU  - Bell AM
FAU - Buchanan, W W
AU  - Buchanan WW
FAU - Fowler, P D
AU  - Fowler PD
FAU - Anderson, J A
AU  - Anderson JA
LA  - ger
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Erprobung eines neuen Acetylsalicylsäure/Paracetamol-Präparates mit 
      magensaftresistentem Uberzug (Safapryn) und zwei verschiedenen Dosierungen von 
      Phenylbutazon bei Patienten mit primär chronischer Polyarthritis anhand eines 
      neuen Bewertungsverfahrens.
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Drug Combinations)
RN  - 0 (Placebos)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 362O9ITL9D (Acetaminophen)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Administration Schedule
MH  - Drug Combinations
MH  - Drug Evaluation/methods
MH  - Humans
MH  - Middle Aged
MH  - Phenylbutazone/administration & dosage/adverse effects/*therapeutic use
MH  - Placebos
MH  - Tablets, Enteric-Coated
EDAT- 1975/09/01 00:00
MHDA- 1975/09/01 00:01
CRDT- 1975/09/01 00:00
PHST- 1975/09/01 00:00 [pubmed]
PHST- 1975/09/01 00:01 [medline]
PHST- 1975/09/01 00:00 [entrez]
PST - ppublish
SO  - Z Rheumatol. 1975 Sep-Oct;34(9-10):350-65.

PMID- 7138740
OWN - NLM
STAT- MEDLINE
DCOM- 19830107
LR  - 20190512
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 14
IP  - 4
DP  - 1982 Oct
TI  - Urinary excretion of aspirin.
PG  - 562-4
AB  - Six human volunteers were each given single oral doses of aspirin (ASA) ranging 
      from 300-1,500 mg. The unchanged ASA excreted in the urine was proportional to 
      dose and urinary pH. The mean percent (+/- s.d.) of dose excreted was 1.9 +/- 
      0.67. The clearance for ASA was 1.42 +/- 0.28 1/h. The rate of in vitro 
      hydrolysis of ASA to salicylic acid in urine at 37 degrees C was 4 micrograms/min 
      for an initial ASA concentration of 7.5 mg in 100 ml human urine.
FAU - Elliot Cham, B
AU  - Elliot Cham B
FAU - Dykman, J H
AU  - Dykman JH
FAU - Bochner, F
AU  - Bochner F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*urine
MH  - Chromatography, High Pressure Liquid/methods
MH  - Humans
MH  - Hydrogen-Ion Concentration
PMC - PMC1427592
EDAT- 1982/10/01 00:00
MHDA- 1982/10/01 00:01
CRDT- 1982/10/01 00:00
PHST- 1982/10/01 00:00 [pubmed]
PHST- 1982/10/01 00:01 [medline]
PHST- 1982/10/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1982.tb02030.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1982 Oct;14(4):562-4. doi: 
      10.1111/j.1365-2125.1982.tb02030.x.

PMID- 32060649
OWN - NLM
STAT- MEDLINE
DCOM- 20210429
LR  - 20230809
IS  - 1432-1327 (Electronic)
IS  - 0949-8257 (Print)
IS  - 0949-8257 (Linking)
VI  - 25
IP  - 2
DP  - 2020 Mar
TI  - Top-down mass spectrometry reveals multiple interactions of an acetylsalicylic 
      acid bearing Zeise's salt derivative with peptides.
PG  - 285-293
LID - 10.1007/s00775-020-01760-9 [doi]
AB  - Synergistic effects and promising anticancer activities encourage the combination 
      of non-steroidal anti-inflammatory drugs with metallodrugs. Here, we discuss the 
      interactions of an organometallic complex consisting of an acetylsalicylic acid 
      (ASA) moiety attached to a Pt(II) center via an alkenol linker in a Zeise's 
      salt-type coordination (ASA-buten-PtCl(3)) with model peptides angiotensin 1 
      (AT), substance P (Sub P), and ubiquitin (UQ). Top-down mass spectrometry 
      experiments show that the amino acid involved in the initial binding to the metal 
      complex controls the coordination sphere of Pt(II) in the adducts. The strong 
      trans labilizing effect of the coordinating sulfur atom in Met causes fast 
      release of the organic moiety and leads to the formation of dimers and oligomers 
      in the case of Sub P. In contrast, interactions with nitrogen donors in AT result 
      in stable adducts containing the intact ASA-buten-Pt(II) complex. UQ forms two 
      sets of Pt(II) adducts, only one of them retains the ASA moiety, which is 
      presumably the result of an unexpected binding geometry. Importantly, UQ is 
      additionally acetylated at various Ser and Lys residues by the ASA-buten-PtCl(3) 
      complex. Control experiments with ASA are negative. This is the first example of 
      concomitant platination and acetylation of a peptide with an ASA metal complex.
FAU - Cziferszky, Monika
AU  - Cziferszky M
AD  - Department of Pharmaceutical Chemistry, CMBI-Center for Molecular Biosciences, 
      CCB-Centrum for Chemistry and Biomedicine, Innsbruck, Institute of Pharmacy, 
      University of Innsbruck, Innrain 80-82, 6020, Innsbruck, Austria.
FAU - Gust, Ronald
AU  - Gust R
AUID- ORCID: 0000-0002-0427-4012
AD  - Department of Pharmaceutical Chemistry, CMBI-Center for Molecular Biosciences, 
      CCB-Centrum for Chemistry and Biomedicine, Innsbruck, Institute of Pharmacy, 
      University of Innsbruck, Innrain 80-82, 6020, Innsbruck, Austria. 
      ronald.gust@uibk.ac.at.
LA  - eng
GR  - P 31166/FWF_/Austrian Science Fund FWF/Austria
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200214
PL  - Germany
TA  - J Biol Inorg Chem
JT  - Journal of biological inorganic chemistry : JBIC : a publication of the Society 
      of Biological Inorganic Chemistry
JID - 9616326
RN  - 0 (Alcohols)
RN  - 0 (Peptides)
RN  - 0 (Platinum Compounds)
RN  - 0 (Salts)
RN  - 12648-47-4 (platinum chloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alcohols/*chemistry
MH  - Aspirin/*chemistry
MH  - Mass Spectrometry
MH  - Molecular Structure
MH  - Peptides/*chemistry
MH  - Platinum Compounds/*chemistry
MH  - Salts/chemistry
PMC - PMC7082381
OTO - NOTNLM
OT  - Acetylation
OT  - Anticancer drug
OT  - Binding site identification
OT  - Metallodrug
OT  - Peptide
OT  - Zeise’s salt
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/02/16 06:00
MHDA- 2021/04/30 06:00
CRDT- 2020/02/16 06:00
PHST- 2019/12/03 00:00 [received]
PHST- 2020/01/24 00:00 [accepted]
PHST- 2020/02/16 06:00 [pubmed]
PHST- 2021/04/30 06:00 [medline]
PHST- 2020/02/16 06:00 [entrez]
AID - 10.1007/s00775-020-01760-9 [pii]
AID - 1760 [pii]
AID - 10.1007/s00775-020-01760-9 [doi]
PST - ppublish
SO  - J Biol Inorg Chem. 2020 Mar;25(2):285-293. doi: 10.1007/s00775-020-01760-9. Epub 
      2020 Feb 14.

PMID- 12716570
OWN - NLM
STAT- MEDLINE
DCOM- 20160422
LR  - 20201128
IS  - 1578-1275 (Electronic)
IS  - 0212-6567 (Print)
IS  - 0212-6567 (Linking)
VI  - 31
IP  - 6
DP  - 2003
TI  - [Use of anti-aggregant drugs in primary and secondary cardiovascular prevention 
      in diabetics in town and country in the León area].
PG  - 361-5
AB  - OBJECTIVES: To find how many diabetics should receive anti-aggregant treatment 
      according to the recommendations made since 2001 by the American Diabetes 
      Association (ADA), how many cardiovascular events could be avoided by 100 mg 
      daily of acetylsalicylic acid (ASA), and the cost per event avoided by this 
      measure. DESIGN: Transversal, descriptive, multi-centre study. SETTING. Primary 
      care. 8 clinics in 5 health districts (3 rural, 1 semi-urban, 4 urban) in the 
      León area. PARTICIPANTS. Diabetics aged 14 or over diagnosed through the ADA 
      criteria since 1997. MAIN MEASUREMENTS. Audit of clinical records, collecting age 
      and sex, the presence of the criteria of the ADA for anti-aggregation, the 
      existence of established cardiovascular disease (CVD) and the anti-aggregant 
      treatment patients receive. RESULTS. 544 diabetics. 97.2% (95% CI, 95.8%-98.6%) 
      comply with anti-aggregation criteria. 101 had established CVD (18.6%; CI, 
      15.3%-21.9%); 77.2% received anti-aggregants (CI, 73.7%-80.7%).428 had no CVD and 
      did have anti-aggregation criteria (78.7%; CI, 75.3%-82.1%); 9.3% (CI, 
      6.9%-11.7%) received treatment. CONCLUSIONS. There was basically little follow-up 
      of the ADA anti-aggregation recommendations in primary prevention. Treatment of 
      our diabetics with 100 mg/day of ASA would avoid 7.64 cardiovascular events in 
      five years (CI, 5.56-9.72). The cost per cardiovascular event avoided was 
      6,625.37 euros (CI, 4821.60-8429.14 euros).
FAU - López De La Iglesia, J
AU  - López De La Iglesia J
AD  - Médico de Familia. Centro de Salud Condesa. León. España.
FAU - Escudero Alvarez, S
AU  - Escudero Alvarez S
FAU - González García, A M
AU  - González García AM
FAU - Mencía Mieres, A
AU  - Mencía Mieres A
FAU - García Andrés, L E
AU  - García Andrés LE
FAU - Morán Fernández, B
AU  - Morán Fernández B
LA  - spa
PT  - Journal Article
TT  - Empleo de antiagregantes en la prevención primaria y secundaria cardiovascular 
      del diabético en el medio urbano y rural del área de León.
PL  - Spain
TA  - Aten Primaria
JT  - Atencion primaria
JID - 9111075
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Diabetes Mellitus
MH  - Humans
MH  - Primary Health Care
MH  - *Primary Prevention
PMC - PMC7681639
EDAT- 2003/04/30 05:00
MHDA- 2016/04/23 06:00
CRDT- 2003/04/30 05:00
PHST- 2003/04/30 05:00 [pubmed]
PHST- 2016/04/23 06:00 [medline]
PHST- 2003/04/30 05:00 [entrez]
AID - 13046194 [pii]
AID - 10.1016/s0212-6567(03)70699-4 [doi]
PST - ppublish
SO  - Aten Primaria. 2003;31(6):361-5. doi: 10.1016/s0212-6567(03)70699-4.

PMID- 8443469
OWN - NLM
STAT- MEDLINE
DCOM- 19930406
LR  - 20180216
IS  - 1018-2438 (Print)
IS  - 1018-2438 (Linking)
VI  - 100
IP  - 2
DP  - 1993
TI  - The effect of aspirin on mononuclear cells in aspirin-sensitive asthmatics and 
      control subjects.
PG  - 156-63
AB  - Three groups, comprising normal subjects (n = 10), aspirin-sensitive asthmatics 
      (ASA+; n = 10) and aspirin-insensitive asthmatics (ASA-; n = 10) were entered 
      into a blinded, parallel group study to asses the modulating effect of aspirin 
      (ASA; 0.0275, 0.275, 1.385, 2.75, 6.9, 13.8 and 27.5 microM) on lymphocyte 
      proliferation in vitro, either alone or in combination with the mitogen, 
      phytohemagglutinin (PHA; 10, 25, 50, 100, 200 and 500 micrograms/ml). The 
      percentage and absolute numbers of CD4-positive T cells (normals: 51.3%; ASA+: 
      51.1%; ASA-: 46.1%; p = 0.4038) and CD8-positive T cells (normal: 27.5%; ASA+: 
      26.4%; ASA-: 28.4%; p = 0.8408) did not differ significantly between the groups. 
      Significant differences in mean PHA responses between ASA+, ASA- and normal 
      subjects were observed when peripheral blood lymphocytes (PBL) were exposed to 
      PHA concentrations over the range 10-50 micrograms/ml; PHA 10 micrograms/ml (p < 
      0.005), PHA 25 micrograms/ml (p < 0.005) and PHA 50 micrograms/ml (p < 0.01), the 
      lowest and highest proliferative responses being obtained with PBL from ASA+ and 
      ASA-, respectively. However, at higher PHA concentrations (100-500 
      micrograms/ml), differences between the three groups were not observed. When ASA 
      was added in combination with PHA, augmentation of the PHA response was observed 
      with cells from all three groups but was most marked in the ASA+ group, 
      especially at lower PHA concentrations (10-50 micrograms/ml) in combination with 
      0.275-13.8 microM ASA.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Taylor, M L
AU  - Taylor ML
AD  - Department of Medicine, University of Western Australia, Queen Elizabeth II 
      Medical Centre, Nedlands.
FAU - Stewart, G A
AU  - Stewart GA
FAU - Thompson, P J
AU  - Thompson PJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (Phytohemagglutinins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/immunology/*pharmacology
MH  - Asthma/*physiopathology
MH  - Humans
MH  - Hypersensitivity/*physiopathology
MH  - In Vitro Techniques
MH  - *Lymphocyte Activation
MH  - Lymphocyte Subsets/immunology
MH  - Lymphocytes/*immunology
MH  - Phytohemagglutinins/pharmacology
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1159/000236403 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 1993;100(2):156-63. doi: 10.1159/000236403.

PMID- 9574888
OWN - NLM
STAT- MEDLINE
DCOM- 19980611
LR  - 20190822
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 53
IP  - 4
DP  - 1998 Apr
TI  - Growth inhibition of fibroblasts from nasal polyps and normal skin by lysine 
      acetylsalicylate.
PG  - 431-4
AB  - Some authors have shown that lysine acetylsalicylate (LAS) may help prevent nasal 
      polyp relapses. As some anti-inflammatory drugs have been found to regulate cell 
      growth, we investigated the antiproliferative effect of LAS on fibroblasts 
      derived from nasal polyps. Moreover, we studied the effect of LAS on the growth 
      of fibroblasts derived from normal skin to determine whether the response was 
      similar to that obtained in the above-mentioned cells. Fibroblasts were obtained 
      from tissue samples of nasal polyps from two aspirin-tolerant and two 
      aspirin-intolerant patients, and from the normal skin of a healthy donor. The 
      cells were treated with LAS (20-2000 microg/ml of culture medium). Cell growth 
      and viability were evaluated after 3 and 6 days of culture. LAS had a 
      growth-inhibitory effect on cells independently of their derivation. A reduction 
      in cell growth was seen at the concentrations of LAS tested, which correspond to 
      those used in the local treatment of nasal polyposis.
FAU - Bruzzese, N
AU  - Bruzzese N
AD  - Institute of Histology and Embryology, Catholic University of the Sacred Heart, 
      Rome, Italy.
FAU - Sica, G
AU  - Sica G
FAU - Iacopino, F
AU  - Iacopino F
FAU - Paludetti, G
AU  - Paludetti G
FAU - Schiavino, D
AU  - Schiavino D
FAU - Nucera, E
AU  - Nucera E
FAU - Scarano, E
AU  - Scarano E
FAU - Patriarca, G
AU  - Patriarca G
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cell Division/drug effects
MH  - Cell Survival/drug effects
MH  - Fibroblasts/drug effects
MH  - Humans
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Nasal Polyps/*drug therapy/pathology
MH  - Skin/cytology
EDAT- 1998/05/09 00:00
MHDA- 1998/05/09 00:01
CRDT- 1998/05/09 00:00
PHST- 1998/05/09 00:00 [pubmed]
PHST- 1998/05/09 00:01 [medline]
PHST- 1998/05/09 00:00 [entrez]
AID - 10.1111/j.1398-9995.1998.tb03918.x [doi]
PST - ppublish
SO  - Allergy. 1998 Apr;53(4):431-4. doi: 10.1111/j.1398-9995.1998.tb03918.x.

PMID- 33161777
OWN - NLM
STAT- MEDLINE
DCOM- 20211224
LR  - 20211224
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 26
IP  - 3
DP  - 2021 May
TI  - Current-Induced Vasodilation Specifically Detects, and Correlates With the Time 
      Since, Last Aspirin Intake: An Interventional Study of 830 Patients.
PG  - 269-278
LID - 10.1177/1074248420971165 [doi]
AB  - BACKGROUND: Galvanic current-induced vasodilation (CIV) is impaired in patients 
      under low-dose aspirin (ASA; ≤ 500 mg/day), but potential covariates and the 
      impact of the time since the last ASA intake are unknown. OBJECTIVES: We used 
      tissue viability imaging (TiVi) in patients at risk of cardiovascular disease and 
      examined its association with self-reported treatments. PATIENTS/METHODS: We 
      recorded the age, gender, height, weight, smoking status, and use of 14 different 
      drug categories in 822 patients either with known peripheral artery disease or at 
      risk thereof. The difference between TiVi arbitrary units (TAUs) where 
      stimulation was applied and an adjacent skin area was recorded, as well as the 
      time since the last ASA intake. Step-by-step regression analysis was used to 
      determine the factors that affect CIV amplitude. RESULTS AND CONCLUSIONS: CIV was 
      28.2 ± 22.9 vs. 14.6 ± 18.0 TAUs (P < 0.001) in patients treated with ASA (n = 
      287) and not treated with ASA (n = 535), respectively. The main determinants of 
      CIV amplitude, by order of importance, were: aspirin intake, diabetes mellitus, 
      age, and male sex. In ASA-treated patients, the main determinants were diabetes 
      mellitus, time since the last ASA intake, male gender, and age. Non-invasive 
      determination of the physiological effects of low-dose ASA is feasible in routine 
      clinical practice. It could be a clinical approach to provide objective evidence 
      of ASA intake, and potentially could be used to test adherence to treatment in 
      ASA-treated patients.
FAU - Ramondou, Pierre
AU  - Ramondou P
AUID- ORCID: 0000-0002-1288-8866
AD  - Vascular Medicine, Angers University Hospital, Angers, France.
FAU - Hersant, Jeanne
AU  - Hersant J
AD  - Vascular Medicine, Angers University Hospital, Angers, France.
FAU - Fouquet, Olivier
AU  - Fouquet O
AD  - Cardiac Surgery, Angers University Hospital, Angers, France.
FAU - Sempore, Wendsendate Yves
AU  - Sempore WY
AD  - 551563Sports and Exercise Medicine, Angers University Hospital, Angers, France.
AD  - UMR CNRS 1083 INSERM 6015, LUNAM University, Angers, France.
AD  - Université Nazi Boni, Bobo Dioulasso, Burkina Faso.
FAU - Abraham, Pierre
AU  - Abraham P
AD  - 551563Sports and Exercise Medicine, Angers University Hospital, Angers, France.
AD  - UMR CNRS 1083 INSERM 6015, LUNAM University, Angers, France.
FAU - Henni, Samir
AU  - Henni S
AD  - Vascular Medicine, Angers University Hospital, Angers, France.
AD  - UMR CNRS 1083 INSERM 6015, LUNAM University, Angers, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03357367
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201107
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Body Mass Index
MH  - Diabetes Mellitus/epidemiology
MH  - Female
MH  - *Heart Disease Risk Factors
MH  - Humans
MH  - Male
MH  - Microcirculation/drug effects
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Sex Factors
MH  - Skin/blood supply
MH  - Vasodilation/*drug effects
OTO - NOTNLM
OT  - antiplatelet agents
OT  - aspirin
OT  - microcirculation
OT  - therapeutic adherence
OT  - vasodilation
EDAT- 2020/11/10 06:00
MHDA- 2021/12/25 06:00
CRDT- 2020/11/09 05:21
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/12/25 06:00 [medline]
PHST- 2020/11/09 05:21 [entrez]
AID - 10.1177/1074248420971165 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2021 May;26(3):269-278. doi: 
      10.1177/1074248420971165. Epub 2020 Nov 7.

PMID- 10200865
OWN - NLM
STAT- MEDLINE
DCOM- 19990602
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 33
IP  - 3
DP  - 1999 Mar
TI  - Interaction of ACE inhibitors and aspirin in patients with congestive heart 
      failure.
PG  - 375-7
AB  - The beneficial effects of aspirin and ACE inhibitors in CHF have been well 
      established; however, the clinical relevance of the drug interaction between 
      these agents remains controversial. The exact mechanism of this interaction is 
      not known, but the proposed theory involves the opposing effects of aspirin and 
      ACE inhibitors on prostaglandins. The medical literature dose not provide a clear 
      picture of the clinical significance of concomitant aspirin and ACE inhibitor 
      therapy. Some studies suggest that the dose of aspirin may influence the clinical 
      relevance of this interaction. Short-term use of aspirin > or = 300 mg was found 
      to attenuate enalapril's effect on hemodynamic variables. However, short-term use 
      of low-dose aspirin (236 mg) produced no effect on blood pressure. Patients with 
      CHF who require therapy with both aspirin and ACE inhibitors may want to consider 
      low doses of aspirin with active monitoring of hemodynamic parameters. However, 
      chronic aspirin therapy in patients with CHF on concomitant ACE inhibitors has 
      not been adequately studied at this time. Data concerning a possible interaction 
      between angiotensin II receptor antagonists and aspirin are not available. 
      However, because angiotensin II receptor antagonists do not interfere with 
      kininase II activity, it would seem unlikely that aspirin would interact 
      similarly with an angiotensin II receptor antagonist. Further studies are needed 
      to examine the exact mechanism of the interaction between aspirin and ACE 
      inhibitors. These studies should focus on the effects of different doses of 
      aspirin given concomitantly with ACE inhibitors in patients with CHF. 
      Prospective, randomized studies are also needed to determine the long-term 
      effects of aspirin and ACE inhibitor therapy on mortality in patients with CHF.
FAU - Song, K H
AU  - Song KH
AD  - Roche Laboratories, Inc., Nutley, NJ 07110, USA.
FAU - Fedyk, R
AU  - Fedyk R
FAU - Hoover, R
AU  - Hoover R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 20
EDAT- 1999/04/14 00:00
MHDA- 1999/04/14 00:01
CRDT- 1999/04/14 00:00
PHST- 1999/04/14 00:00 [pubmed]
PHST- 1999/04/14 00:01 [medline]
PHST- 1999/04/14 00:00 [entrez]
AID - 10.1345/aph.18129 [doi]
PST - ppublish
SO  - Ann Pharmacother. 1999 Mar;33(3):375-7. doi: 10.1345/aph.18129.

PMID- 35900749
OWN - NLM
STAT- MEDLINE
DCOM- 20221024
LR  - 20221106
IS  - 2374-2445 (Electronic)
IS  - 2374-2437 (Linking)
VI  - 8
IP  - 10
DP  - 2022 Oct 1
TI  - Aspirin and the USPSTF-What About Cancer?
PG  - 1392-1394
LID - 10.1001/jamaoncol.2022.2967 [doi]
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, 
      Boston, Massachusetts.
AD  - Division of Gastroenterology, Massachusetts General Hospital, Boston, 
      Massachusetts.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA Oncol
JT  - JAMA oncology
JID - 101652861
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Aspirin/adverse effects
MH  - Primary Prevention
MH  - Risk Assessment
MH  - *Neoplasms/drug therapy
OAB - This Viewpoint discusses the potential misinterpretations in the 2022 US 
      Preventive Services Task Force recommendation statement on the use of aspirin for 
      the prevention of colorectal cancer.
OABL- eng
EDAT- 2022/07/29 06:00
MHDA- 2022/10/25 06:00
CRDT- 2022/07/28 11:37
PHST- 2022/07/29 06:00 [pubmed]
PHST- 2022/10/25 06:00 [medline]
PHST- 2022/07/28 11:37 [entrez]
AID - 2794801 [pii]
AID - 10.1001/jamaoncol.2022.2967 [doi]
PST - ppublish
SO  - JAMA Oncol. 2022 Oct 1;8(10):1392-1394. doi: 10.1001/jamaoncol.2022.2967.

PMID- 16025089
OWN - NLM
STAT- MEDLINE
DCOM- 20050808
LR  - 20151119
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 146
IP  - 1
DP  - 2005 Jul
TI  - A Thrombelastograph whole blood assay for clinical monitoring of 
      NSAID-insensitive transcellular platelet activation by arachidonic acid.
PG  - 30-5
AB  - Optical platelet aggregation (OPA) with platelet-rich plasma (PRP) was compared 
      with a Thrombelastograph (TEG) whole blood assay for monitoring arachidonic acid 
      (AA)-induced platelet activation. Assays were performed on 47 interventional 
      cardiology and 24 general surgery patients receiving aspirin therapy for 
      cardiovascular disease, as well as 48 volunteers asked to take nonsteroidal 
      anti-inflammatory drugs (NSAIDs) or 12 volunteers on chronic NSAID therapy 
      unrelated to diagnosed cardiovascular disease. Whole blood TEG monitoring of 
      NSAID inhibition detected NSAID-insensitive AA activation of platelets in a 
      significantly higher number of cardiology (23%) and surgery (25%) patients and 
      normal volunteers on chronic NSAID (25%) therapy relative to normal subjects not 
      on chronic NSAID therapy (0%). Whole blood NSAID insensitivity was observed with 
      cyclooxygenase-I inhibitors, such as aspirin and ibuprofen; was not affected by 
      Celebrex, a cyclooxygenase-II inhibitor; but was completely inhibited by 
      thromboxane-receptor antagonists. This was not due to platelet NSAID 
      insensitivity, because complete inhibition of AA-activation responses in PRP was 
      observed with either TEG or OPA assays. We confirmed that thromboxane B(2) 
      formation in PRP from NSAID-insensitive subjects was completely inhibited by 
      NSAIDs. However, significant amounts were formed in whole blood from 
      NSAID-insensitive subjects, but not in whole blood from NSAID-sensitive subjects. 
      Thromboxane formation after AA addition was not found in washed blood cells with 
      90% reduced platelet counts or in leukocyte-rich buffy coat fractions, but could 
      be restored by addition of PRP. NSAID-insensitive activation was inhibited by 
      nordihydroguaiaretic acid, with an IC(50) of 30 micromol, implicating 12- and/or 
      15-lipoxygenases in this transcellular pathway.
FAU - Carroll, Roger C
AU  - Carroll RC
AD  - Department of Anesthesiology and Medicine, University of Tennessee Graduate 
      School of Medicine, Knoxville, TN 37920, USA. RCarroll@utk.edu
FAU - Craft, Robert M
AU  - Craft RM
FAU - Chavez, Jack J
AU  - Chavez JJ
FAU - Snider, Carolyn C
AU  - Snider CC
FAU - Bresee, Stuart J
AU  - Bresee SJ
FAU - Cohen, Eli
AU  - Cohen E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Arachidonic Acid/*physiology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Celecoxib
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Ibuprofen/pharmacology
MH  - Platelet Activation/*drug effects/*physiology
MH  - Platelet Aggregation/drug effects
MH  - Pyrazoles/pharmacology
MH  - Sulfonamides/pharmacology
MH  - *Thrombelastography
EDAT- 2005/07/19 09:00
MHDA- 2005/08/09 09:00
CRDT- 2005/07/19 09:00
PHST- 2005/07/19 09:00 [pubmed]
PHST- 2005/08/09 09:00 [medline]
PHST- 2005/07/19 09:00 [entrez]
AID - S0022214305001319 [pii]
AID - 10.1016/j.lab.2005.03.014 [doi]
PST - ppublish
SO  - J Lab Clin Med. 2005 Jul;146(1):30-5. doi: 10.1016/j.lab.2005.03.014.

PMID- 22304357
OWN - NLM
STAT- MEDLINE
DCOM- 20120416
LR  - 20170310
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 52
IP  - 1
DP  - 2012
TI  - [Comparative evaluation of antiplatelet efectiveness drugs of original and 
      reproduced enteric forms of acetylsalicylic acid (clinical study ICAR))].
PG  - 74-82
AB  - The purpose of the study was a comparative study of antiplatelet activity of 
      acetylsalicylic acid drugs, produced in gastro-resistant form trombopol 75 mg and 
      aspirin cardio 100 mg in patients with high risk of cardiovascular events. Effect 
      of trombopol 75 mg versus 100 mg aspirin cardio on platelet aggregation in 30 
      patients with high risk of cardiovascular events during 3 week treatment period 
      was studied. Design method: blind, randomized, crossover method. Three weeks 
      before the initial therapy, for those patients, who received antiplatelet 
      platelet therapy at the time of inclusion in the study, this therapy was withdrew 
      ("wash-out period"), after which patient was given one of the study drug 
      (sequence of courses was s determined according to the scheme of randomization) 
      with the recommendation of taking it daily in the morning at the same time. At 
      each visit, before the next dose of the drug, blood samples for determination of 
      ADP-induced platelet aggregation were taken, physical examination, measurement of 
      blood pressure (BP) and heart rate were recorded, adverse events were recorded. 
      Follow-up visit was performed 3 weeks later. 21 days after first study drug 
      withdrawal, a second similar course of therapy with another drug was performed. 
      Antiplatelet efficacy of aspirin was assessed by its effect on spontaneous and 
      ADP- induced platelet aggregation. Aggregation activity was determined by 
      turbidometric method by changing of translucent ability of the blood sample 
      during the formation of aggregates after 2 minutes of exposure. As an inducer of 
      aggregation ADP solutions of three concentrations (0.5, 1 and 2 mM) were used. No 
      significant difference between compared drugs in influence on aggregation ability 
      of platelets after 3 weeks of daily intake was found. No adverse events 
      associated with taking of studied drugs were registered. It was concluded that, 
      generic APD - trombopol 75 mg and aspirin cardio 100 mg were equivalent on 
      antiplatelet efficacy and tolerability.
FAU - Martsevich, S Iu
AU  - Martsevich SIu
FAU - Tolpygina, S N
AU  - Tolpygina SN
FAU - Lukina, Iu V
AU  - Lukina IuV
FAU - Voronina, V P
AU  - Voronina VP
FAU - Kiseleva, N V
AU  - Kiseleva NV
FAU - Boĭchenko, E S
AU  - Boĭchenko ES
FAU - Dubinskaia, R É
AU  - Dubinskaia RÉ
FAU - Khoseva, E N
AU  - Khoseva EN
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Dosage Forms)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/metabolism
MH  - Administration, Oral
MH  - Aged
MH  - *Aspirin/administration & dosage/adverse effects/pharmacokinetics
MH  - Cardiovascular Diseases/*drug therapy/metabolism/physiopathology
MH  - Dosage Forms
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Monitoring/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/pharmacokinetics
MH  - Therapeutic Equivalency
MH  - Treatment Outcome
EDAT- 2012/02/07 06:00
MHDA- 2012/04/17 06:00
CRDT- 2012/02/07 06:00
PHST- 2012/02/07 06:00 [entrez]
PHST- 2012/02/07 06:00 [pubmed]
PHST- 2012/04/17 06:00 [medline]
PST - ppublish
SO  - Kardiologiia. 2012;52(1):74-82.

PMID- 8085092
OWN - NLM
STAT- MEDLINE
DCOM- 19941013
LR  - 20191101
IS  - 8756-0437 (Print)
IS  - 1098-2388 (Linking)
VI  - 10
IP  - 3
DP  - 1994 May-Jun
TI  - Aspirin and the prevention of colorectal cancer: a review of the evidence.
PG  - 158-64
AB  - In all but one of seven recent epidemiologic case-control and cohort studies 
      directly examining the association between aspirin and colorectal cancer and 
      polyps, regular aspirin use reduced the risk of these diseases by about half. 
      Although these studies show a biologically plausible relationship between aspirin 
      and colorectal cancer, information regarding dose and duration and risk change 
      after discontinuation of aspirin is limited and contradictory. Additionally, 
      selection bias, recall bias, and confounding cannot be completed discounted. The 
      one randomized trial of aspirin and placebo showed that aspirin at a dose 
      adequate for preventing myocardial infarction (325 mg every other day) did not 
      reduce colorectal cancer incidence during five years of randomized treatment and 
      follow-up. Further studies need to determine the biologic effects of aspirin, the 
      minimum dose required, and whether other factors, such as age, illnesses, and 
      reasons for aspirin use, modify or confound colorectal cancer development.
FAU - Paganini-Hill, A
AU  - Paganini-Hill A
AD  - Department of Preventive Medicine, University of Southern California School of 
      Medicine, Los Angeles 90031.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Semin Surg Oncol
JT  - Seminars in surgical oncology
JID - 8503713
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Colonic Polyps/drug therapy/epidemiology/prevention & control
MH  - Colorectal Neoplasms/drug therapy/epidemiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
AID - 10.1002/ssu.2980100303 [doi]
PST - ppublish
SO  - Semin Surg Oncol. 1994 May-Jun;10(3):158-64. doi: 10.1002/ssu.2980100303.

PMID- 36323060
OWN - NLM
STAT- MEDLINE
DCOM- 20221130
LR  - 20221130
IS  - 2210-7797 (Electronic)
IS  - 2210-7789 (Linking)
VI  - 30
DP  - 2022 Dec
TI  - Short communication: Is there any benefit of initiating aspirin before the 11th 
      week of gestation?
PG  - 189-191
LID - S2210-7789(22)00110-6 [pii]
LID - 10.1016/j.preghy.2022.10.009 [doi]
AB  - Aspirin initiated between 11 and 14 weeks of gestation reduces the risk of 
      preterm preeclampsia and other placenta-mediated complications in screen-positive 
      women. Most of these adverse outcomes are associated with maternal vascular 
      malperfusion of the placenta, a disease that begins during the early first 
      trimester. Assuming that aspirin has direct beneficial actions on the developing 
      placenta, tempts clinicians to believe in the maxim that "the earlier the 
      better", however neither the safety nor the effectiveness of aspirin started 
      before 11th week of gestation has been demonstrated. Therefore, outside of 
      research protocols, aspirin should not be started before the 11th week of 
      pregnancy for the prevention of preeclampsia.
CI  - Copyright © 2022 International Society for the Study of Hypertension in 
      Pregnancy. Published by Elsevier B.V. All rights reserved.
FAU - Ghesquiere, Louise
AU  - Ghesquiere L
AD  - Department of Obstetrics, Université de Lille, CHU de Lille, Lille, France.
FAU - Vachon-Marceau, Chantale
AU  - Vachon-Marceau C
AD  - Department of Obstetrics, Gynecology and Reproduction, CHU de Québec-Université 
      Laval, Québec City, QC, Canada.
FAU - Kingdom, John C
AU  - Kingdom JC
AD  - Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of 
      Toronto, Toronto, ON, Canada.
FAU - Ferreira, Ema
AU  - Ferreira E
AD  - Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada.
FAU - Côté, Stephane
AU  - Côté S
AD  - Department of Medicine, CHU de Québec-Université Laval, Québec City, QC, Canada.
FAU - Guerby, Paul
AU  - Guerby P
AD  - Department of Obstetrics, Paule de Viguier Hospital, CHU Toulouse, Toulouse, 
      France.
FAU - Maheux-Lacroix, Sarah
AU  - Maheux-Lacroix S
AD  - Department of Obstetrics, Gynecology and Reproduction, CHU de Québec-Université 
      Laval, Québec City, QC, Canada; Reproduction, Mother and Child Health Unit, 
      Research Center of the CHU de Québec - Université Laval, Québec City, QC, Canada.
FAU - Bujold, Emmanuel
AU  - Bujold E
AD  - Department of Obstetrics, Gynecology and Reproduction, CHU de Québec-Université 
      Laval, Québec City, QC, Canada; Reproduction, Mother and Child Health Unit, 
      Research Center of the CHU de Québec - Université Laval, Québec City, QC, Canada. 
      Electronic address: emmanuel.bujold@crchudequebec.ulaval.ca.
LA  - eng
PT  - Journal Article
DEP - 20221022
PL  - Netherlands
TA  - Pregnancy Hypertens
JT  - Pregnancy hypertension
JID - 101552483
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Pregnancy
MH  - Infant, Newborn
MH  - Female
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - *Pre-Eclampsia/prevention & control
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Pregnancy Trimester, First
MH  - Placenta
OTO - NOTNLM
OT  - Aspirin
OT  - Preeclampsia
OT  - Pregnancy
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/11/03 06:00
MHDA- 2022/12/01 06:00
CRDT- 2022/11/02 19:13
PHST- 2022/07/16 00:00 [received]
PHST- 2022/09/21 00:00 [revised]
PHST- 2022/10/17 00:00 [accepted]
PHST- 2022/11/03 06:00 [pubmed]
PHST- 2022/12/01 06:00 [medline]
PHST- 2022/11/02 19:13 [entrez]
AID - S2210-7789(22)00110-6 [pii]
AID - 10.1016/j.preghy.2022.10.009 [doi]
PST - ppublish
SO  - Pregnancy Hypertens. 2022 Dec;30:189-191. doi: 10.1016/j.preghy.2022.10.009. Epub 
      2022 Oct 22.

PMID- 8426017
OWN - NLM
STAT- MEDLINE
DCOM- 19930301
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 21
IP  - 2
DP  - 1993 Feb
TI  - High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits 
      thrombus formation and stabilizes blood flow in experimental coronary vascular 
      injury.
PG  - 502-10
AB  - OBJECTIVES: The purpose of this study was to assess the anti-thrombotic potential 
      of various forms of aspirin administration. BACKGROUND: Platelet activation in 
      response to endothelial injury has been implicated in acute coronary syndromes. 
      METHODS: Delivering 100-microA anodal direct current to the intima of the left 
      circumflex coronary artery in dogs at a site of moderate external stenosis 
      provides a thrombogenic model of vascular injury. Animals were treated with 
      aspirin (Group I, 20 mg/kg intravenously [n = 11]; Group II, 4.6 mg/kg 
      intravenously [n = 6]; Group III, 4.6 mg/kg orally 18 h before the experiment [n 
      = 7]) or vehicle (Group IV, control [n = 11]). RESULTS: The time required for 
      thrombotic occlusion to occur was longer and the incidence of thrombosis was 
      lower in Group I (Group I, 238 +/- 7 min [n = 2]; Group II, 127 +/- 25 min [n = 
      3]; Group III, 156 +/- 35 min [n = 6]; Group IV, 90 +/- 11 min [n = 11]) (p < 
      0.05). Thrombus mass was smaller in Group I (Group I, 5.0 +/- 0.8 mg; Group II, 
      12.2 +/- 2.6 mg; Group III, 11.6 +/- 3.9 mg; Group IV, 9.1 +/- 1.6 mg) (p < 
      0.05). Initial hemodynamic variables did not differ among groups. An increase in 
      mean arterial pressure was noted for several hours after intravenous aspirin 
      administration in Group I (99 +/- 5 to 110 +/- 4 mm Hg) (p < 0.05). Left 
      circumflex coronary artery blood flow was stable for 5 h in Group I (Group I, 31 
      +/- 2 to 26 +/- 4 ml/min) but decreased in all the other groups (Group II, 26 +/- 
      4 to 10 +/- 5 ml/min; Group III, 27 +/- 5 to 7 +/- 7 ml/min; Group IV, 29 +/- 4 
      to 0 ml/min) (p < or = 0.05). The in vivo area of left ventricle perfused by the 
      left circumflex coronary artery was not different among groups. Platelet counts 
      were similar and did not change over the course of the protocol. Ex vivo 
      arachidonic acid-induced platelet aggregation decreased in all groups after 
      aspirin (p < or = 0.001). Indium-111-labeled platelet adherence to the coronary 
      vasculature was decreased in distal vessel segments after all doses of aspirin (p 
      < 0.05). Platelet deposition in thrombi was similar for all treatment groups. 
      CONCLUSIONS: High dose intravenous aspirin has salutary effects. It stabilizes 
      left circumflex coronary artery blood flow, prolongs the time to thrombosis, 
      reduces the incidence of thrombotic occlusion, reduces thrombus mass and limits 
      platelet adherence to sites of arterial injury. Low dose aspirin given 
      intravenously or orally was ineffective. When persistent intracoronary thrombi 
      precipitate unstable coronary syndromes, high dose intravenous aspirin may be 
      useful in the acute period even though platelets continue to interact with 
      injured vascular segments through aspirin-insensitive mechanisms.
FAU - Mickelson, J K
AU  - Mickelson JK
AD  - Department of Internal Medicine (Cardiology), University of Michigan School of 
      Medicine, Ann Arbor.
FAU - Hoff, P T
AU  - Hoff PT
FAU - Homeister, J W
AU  - Homeister JW
FAU - Fantone, J C
AU  - Fantone JC
FAU - Lucchesi, B R
AU  - Lucchesi BR
LA  - eng
GR  - HL-19782-11/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 1993 Feb;21(2):511-3. PMID: 8426018
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Coronary Circulation/*drug effects
MH  - Coronary Thrombosis/blood/etiology/*prevention & control
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Injections, Intravenous
MH  - Male
MH  - Platelet Activation/drug effects
MH  - Platelet Adhesiveness/drug effects
MH  - Time Factors
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
AID - 0735-1097(93)90695-W [pii]
AID - 10.1016/0735-1097(93)90695-w [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1993 Feb;21(2):502-10. doi: 10.1016/0735-1097(93)90695-w.

PMID- 7395939
OWN - NLM
STAT- MEDLINE
DCOM- 19800928
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 137
IP  - 6
DP  - 1980 Jul 15
TI  - Prediction of fetal drug concentrations.
PG  - 735-8
AB  - Equations are derived for the fetal concentrations of a drug [F(t)] during and 
      after the slow release of the drug into the maternal circulation. To solve these 
      equations it is necessary to know the placental drug clearance (Cp), the 
      clearance of the drug from the fetal circulation by the fetal tissues (Cf), and 
      the volume of distribution of the drug in the fetal compartment (V). With these 
      values for acetylsalicylic acid (aspirin) it can be shown that the maximum fetal 
      aspirin concentration will be much less than the maximum maternal concentration 
      and that after the release of aspirin has stopped, some drug is trapped in the 
      fetal circulation. Therefore, there will be a period of time when the fetal 
      plasma aspirin concentration is greater than maternal plasma aspirin 
      concentration.
FAU - Anderson, D F
AU  - Anderson DF
FAU - Phernetton, T M
AU  - Phernetton TM
FAU - Rankin, J H
AU  - Rankin JH
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Pharmaceutical Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism
MH  - Biological Availability
MH  - Female
MH  - Fetus/metabolism
MH  - Humans
MH  - Kinetics
MH  - *Maternal-Fetal Exchange
MH  - Models, Biological
MH  - Pharmaceutical Preparations/*metabolism
MH  - Pregnancy
EDAT- 1980/07/15 00:00
MHDA- 1980/07/15 00:01
CRDT- 1980/07/15 00:00
PHST- 1980/07/15 00:00 [pubmed]
PHST- 1980/07/15 00:01 [medline]
PHST- 1980/07/15 00:00 [entrez]
AID - S0002-9378(15)33251-8 [pii]
AID - 10.1016/s0002-9378(15)33251-8 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1980 Jul 15;137(6):735-8. doi: 
      10.1016/s0002-9378(15)33251-8.

PMID- 28483309
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20180226
IS  - 2213-2201 (Electronic)
VI  - 5
IP  - 3
DP  - 2017 May-Jun
TI  - Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs.
PG  - 537-545
LID - S2213-2198(16)30559-1 [pii]
LID - 10.1016/j.jaip.2016.10.021 [doi]
AB  - Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) are some of the most 
      common culprits of drug-induced hypersensitivity reactions, and can lead to a 
      wide array of adverse effects. The accurate and timely diagnosis of aspirin and 
      NSAID-induced hypersensitivity reactions is important for both patient safety and 
      for the initiation of appropriate disease-specific management and treatment. 
      Because there are no reliably validated in vitro tests available, aspirin and 
      NSAID challenges are considered to be the criterion standard for the diagnosis of 
      these hypersensitivity reactions, though in some patients the diagnosis can be 
      made on the basis of a clear clinical history.
CI  - Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Laidlaw, Tanya M
AU  - Laidlaw TM
AD  - Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, 
      Boston, Mass. Electronic address: tlaidlaw@partners.org.
FAU - Cahill, Katherine N
AU  - Cahill KN
AD  - Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, 
      Boston, Mass.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Allergy Clin Immunol Pract
JT  - The journal of allergy and clinical immunology. In practice
JID - 101597220
RN  - 0 (Allergens)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Allergens/immunology/*therapeutic use
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*diagnosis/therapy
MH  - Humans
MH  - Immunization
MH  - Medical History Taking
OTO - NOTNLM
OT  - AERD
OT  - Aspirin
OT  - Aspirin challenge
OT  - Aspirin desensitization
OT  - NSAID
OT  - Oral challenge
OT  - Samter triad
EDAT- 2017/05/10 06:00
MHDA- 2018/02/27 06:00
CRDT- 2017/05/10 06:00
PHST- 2016/09/21 00:00 [received]
PHST- 2016/10/21 00:00 [revised]
PHST- 2016/10/28 00:00 [accepted]
PHST- 2017/05/10 06:00 [entrez]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
AID - S2213-2198(16)30559-1 [pii]
AID - 10.1016/j.jaip.2016.10.021 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):537-545. doi: 
      10.1016/j.jaip.2016.10.021.

PMID- 21600123
OWN - NLM
STAT- MEDLINE
DCOM- 20111115
LR  - 20131121
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 91
IP  - 13
DP  - 2011 Apr 5
TI  - [Effect of aspirin administration for the treatment of osteoporosis in 
      ovariectomized rat model].
PG  - 925-9
AB  - OBJECTIVE: To explore the therapeutic effects of aspirin on postmenopausal 
      osteoporosis and understand its action mechanism. METHODS: Forty three-month-old 
      female SD rats were randomly divided into 5 groups (n = 8 each): sham group, OVX 
      group and aspirin groups (A1, A2 & A3). The OVX and aspirin groups were 
      ovariectomized (OVX). All rats underwent BMD (bone mineral density) scan at the 
      time of OVX and 3 months after OVX. After the animal model of osteoporosis was 
      established, aspirin groups were intragastrically administered at a dose of 8.93 
      mg×kg(-1)×d(-1) (A1), 26.79 mg×kg(-1)×d(-1) (A2) and 80.36 mg×kg(-1)×d(-1) (A3) 
      daily in OVX rats. Three months later, the BMD and micro-architecture of 
      vertebrae were measured by dual-energy X-ray absorptiometry and microtomography. 
      Alkaline phosphatase and osteocalcin were measured in peripheral blood. The 
      trabecular architecture changes were observed by histomorphology. Axial 
      compression tests were used to evaluate the mechanical properties of vertebral 
      specimens and three-point bending tests used for femur shaft. RESULTS: Three 
      months after ovariectomy, BMD was significantly lower than preoperative. BMD in 
      aspirin treated groups was significantly higher than that in OVX group. Alkaline 
      phosphatase in peripheral blood decreased significantly in aspirin groups than 
      those in OVX, but osteocalcin had no significant difference between aspirin and 
      OVX groups. The microtomography reconstruction analysis also showed that the 
      trabecular thickness, trabecular number and BMD increased significantly in 
      aspirin groups than those in OVX. And there was no significant difference between 
      A3 and sham groups. The results of biomechanical test showed that the maximum 
      compression load of lumbar spine and three-point bending load of femur shaft were 
      significantly higher in aspirin groups than those in OVX group. CONCLUSION: 
      Aspirin can promote trabecular bone remodeling, improve three-dimensional 
      structure of trabecular bone and increase bone density of cancellous in 
      osteoporotic rats by stimulating bone formation. It may become a new drug for the 
      treatment of osteoporosis.
FAU - Chen, Zhi-wen
AU  - Chen ZW
AD  - Department of Orthopedics, Xijing Hospital, Fourth Military Medical University, 
      Xi'an 710032, China.
FAU - Wu, Zi-xiang
AU  - Wu ZX
FAU - Sang, Hong-xun
AU  - Sang HX
FAU - Qin, Guo-liang
AU  - Qin GL
FAU - Wang, Li-song
AU  - Wang LS
FAU - Feng, Jing
AU  - Feng J
FAU - Wang, Jun
AU  - Wang J
FAU - Li, Xiao-juan
AU  - Li XJ
FAU - Wang, Jian-chao
AU  - Wang JC
FAU - Zhang, Da
AU  - Zhang D
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Disease Models, Animal
MH  - Female
MH  - Osteoporosis/*drug therapy
MH  - Ovariectomy
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2011/05/24 06:00
MHDA- 2011/11/16 06:00
CRDT- 2011/05/24 06:00
PHST- 2011/05/24 06:00 [entrez]
PHST- 2011/05/24 06:00 [pubmed]
PHST- 2011/11/16 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2011 Apr 5;91(13):925-9.

PMID- 850778
OWN - NLM
STAT- MEDLINE
DCOM- 19770527
LR  - 20131121
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 6
IP  - 1
DP  - 1977
TI  - Dissociation of acetylsalicylic acid in blood and joint fluid.
PG  - 17-22
AB  - Assay method in blood of 30 patients, who had ingested 0.6 g buffered aspirin, 
      showed earlier appearance of acetylsalicylate (ASA) than of de-acetylated 
      salicylate (SA); the values for ASA averaged 7.7 min, and for SA, 10.9 min. 
      Similarly in joint fluid, ASA appeared earlier than SA; the values of ASA 
      averaged 19.4 min, and those for SA, 21.9 min. Transport times did not differ 
      significantly between ASA and SA in most types of synovitis. Close to maximum 
      concentrations in blood averaged 18.9 mg/l for total salicylates (TSA), 3.3 mg/l 
      for ASA, and 23.3 mg/l for SA, whereas maximum concentrations in joint fluid 
      averaged 15.7 mg/l for TSA, 2.5 mg/l for ASA, and 14.5 mg/l for SA. ASA in blood 
      initially consituted 65% of TSA and decreased to less than measurable amounts 75 
      min after intake. Joint fluid initially contained a somewhat smaller maximal 
      proportion of ASA, but de-acetylation progressed more slowly than in blood; ASA 
      decreased to undetectable levels within 140-145 min after intake.
FAU - Soren, A
AU  - Soren A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Buffers)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/metabolism
MH  - Aspirin/administration & dosage/blood/*metabolism
MH  - Buffers
MH  - Crohn Disease/complications
MH  - Delayed-Action Preparations
MH  - Focal Infection/complications
MH  - Humans
MH  - Joint Diseases/*metabolism
MH  - Knee Joint
MH  - Male
MH  - Metabolic Clearance Rate
MH  - Middle Aged
MH  - Osteoarthritis/metabolism
MH  - Synovial Fluid/analysis/*metabolism
MH  - Synovitis/etiology/metabolism
MH  - Tablets
MH  - Time Factors
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Rheumatol. 1977;6(1):17-22.

PMID- 31082853
OWN - NLM
STAT- MEDLINE
DCOM- 20200306
LR  - 20200306
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 34
IP  - 4
DP  - 2019 Jul
TI  - Clinical trials in long-term antiplatelet therapies: focus on the role of 
      aspirin.
PG  - 315-322
LID - 10.1097/HCO.0000000000000640 [doi]
AB  - PURPOSE OF REVIEW: The purpose of this review is to summarize the existing 
      evidence for use of long-term antiplatelet therapies for primary and secondary 
      prevention of adverse cardiovascular events. RECENT FINDINGS: In the setting of 
      primary prevention, several contemporary trials have shown a lack of net clinical 
      benefit with use of aspirin across different patient groups, including those with 
      diabetes mellitus, older age or high estimated cardiac risk. For secondary 
      prevention, the addition of either ticagrelor or low-dose rivaroxaban to aspirin 
      monotherapy significantly lowered recurrent vascular events, albeit with excess 
      bleeding. Aspirin withdrawal did not result in excess thrombotic risk or less 
      bleeding among patients undergoing percutaneous coronary intervention (PCI) 
      treated with ticagrelor. SUMMARY: In the contemporary era, routine use of aspirin 
      is not beneficial in the majority of patients free of cardiac disease. In 
      contrast, for secondary prevention, aspirin monotherapy is not sufficient to 
      lower recurrent vascular risk. Antiplatelet monotherapy with ticagrelor may 
      emerge as an alternative to lower bleeding whereas maintaining ischemic efficacy 
      in selected patients undergoing PCI.
FAU - Goel, Ridhima
AU  - Goel R
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, New York, USA.
FAU - Baber, Usman
AU  - Baber U
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors
MH  - Ticagrelor
MH  - Treatment Outcome
EDAT- 2019/05/15 06:00
MHDA- 2020/03/07 06:00
CRDT- 2019/05/15 06:00
PHST- 2019/05/15 06:00 [pubmed]
PHST- 2020/03/07 06:00 [medline]
PHST- 2019/05/15 06:00 [entrez]
AID - 10.1097/HCO.0000000000000640 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2019 Jul;34(4):315-322. doi: 10.1097/HCO.0000000000000640.

PMID- 35907019
OWN - NLM
STAT- MEDLINE
DCOM- 20221108
LR  - 20221108
IS  - 1432-2307 (Electronic)
IS  - 0945-6317 (Linking)
VI  - 481
IP  - 5
DP  - 2022 Nov
TI  - Low-dose aspirin therapy improves decidual arteriopathy in pregnant women with a 
      history of preeclampsia.
PG  - 713-720
LID - 10.1007/s00428-022-03388-3 [doi]
AB  - Preeclampsia, a multisystem pregnancy-specific hypertensive disorder, results in 
      significant maternal and perinatal morbidity and mortality. This condition is 
      associated with placental histopathological abnormalities and particularly 
      affects the decidual spiral arteries. Reportedly, aspirin prevents preeclampsia, 
      specifically early-onset preeclampsia, although findings in decidual arteries in 
      women treated with aspirin therapy remain unclear. We compared the clinical and 
      histopathological placental findings between women with a history of 
      preeclampsia, who did and did not receive low-dose aspirin therapy (LDA and 
      non-LDA groups, respectively). We identified 26 women with a history of 
      preeclampsia; 9 women received LDA (aspirin ≤ 100 mg/day, initiated 
      at < 16 weeks, LDA group), and 17 women did not receive LDA (non-LDA group). The 
      mean gestational age was higher (36.7 weeks vs. 32.3 weeks, P = 0.0221) and the 
      incidence of preeclampsia was lower (11% vs. 59%, P = 0.0362) in the LDA than in 
      the non-LDA group. Histopathologically, the incidence of decidual arteriopathy, 
      particularly that of fibrinoid necrosis and thrombosis, was lower in the LDA than 
      in the non-LDA group (44% vs. 88%, P = 0.0283). Immunohistologically, endothelial 
      marker (CD31 and CD39) expression was stronger in the LDA than in the non-LDA 
      group. Notably, we observed no significant intergroup differences in inflammatory 
      changes (chronic perivasculitis, protease-activated receptor 1 expression, and 
      CD3-positive cells). This study highlights that LDA inhibits hypertension-induced 
      endothelial injury and thrombosis, and thereby protects maternal placental 
      perfusion and prevents preeclampsia.
CI  - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Tomimori-Gi, Kayo
AU  - Tomimori-Gi K
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of 
      Miyazaki, Miyazaki, Japan.
FAU - Katsuragi, Shinji
AU  - Katsuragi S
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of 
      Miyazaki, Miyazaki, Japan.
FAU - Kodama, Yuki
AU  - Kodama Y
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of 
      Miyazaki, Miyazaki, Japan.
FAU - Yamada, Naoshi
AU  - Yamada N
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of 
      Miyazaki, Miyazaki, Japan.
FAU - Sameshima, Hiroshi
AU  - Sameshima H
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of 
      Miyazaki, Miyazaki, Japan.
FAU - Maekawa, Kazunari
AU  - Maekawa K
AD  - Department of Diagnostic Pathology, Faculty of Medicine, Miyazaki University 
      Hospital, University of Miyazaki, 5200 Kihara, Miyazaki, Miyazaki, 889-1692, 
      Japan.
FAU - Yamashita, Atsushi
AU  - Yamashita A
AD  - Department of Diagnostic Pathology, Faculty of Medicine, Miyazaki University 
      Hospital, University of Miyazaki, 5200 Kihara, Miyazaki, Miyazaki, 889-1692, 
      Japan.
FAU - Gi, Toshihiro
AU  - Gi T
AD  - Department of Diagnostic Pathology, Faculty of Medicine, Miyazaki University 
      Hospital, University of Miyazaki, 5200 Kihara, Miyazaki, Miyazaki, 889-1692, 
      Japan.
FAU - Sato, Yuichiro
AU  - Sato Y
AUID- ORCID: 0000-0003-1171-2620
AD  - Department of Diagnostic Pathology, Faculty of Medicine, Miyazaki University 
      Hospital, University of Miyazaki, 5200 Kihara, Miyazaki, Miyazaki, 889-1692, 
      Japan. yuichiro_sato@med.miyazaki-u.ac.jp.
LA  - eng
GR  - JP21K07775/Japan Society for the Promotion of Science/
PT  - Journal Article
DEP - 20220730
PL  - Germany
TA  - Virchows Arch
JT  - Virchows Archiv : an international journal of pathology
JID - 9423843
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Pregnancy
MH  - Humans
MH  - Infant
MH  - *Pre-Eclampsia/drug therapy
MH  - Pregnant Women
MH  - Placenta
MH  - Aspirin/therapeutic use
MH  - Gestational Age
MH  - *Placenta Diseases
OTO - NOTNLM
OT  - Decidual arteriopathy
OT  - Low-dose aspirin
OT  - Pathology
OT  - Placenta
OT  - Preeclampsia
EDAT- 2022/07/31 06:00
MHDA- 2022/11/09 06:00
CRDT- 2022/07/30 11:13
PHST- 2022/05/08 00:00 [received]
PHST- 2022/07/25 00:00 [accepted]
PHST- 2022/07/08 00:00 [revised]
PHST- 2022/07/31 06:00 [pubmed]
PHST- 2022/11/09 06:00 [medline]
PHST- 2022/07/30 11:13 [entrez]
AID - 10.1007/s00428-022-03388-3 [pii]
AID - 10.1007/s00428-022-03388-3 [doi]
PST - ppublish
SO  - Virchows Arch. 2022 Nov;481(5):713-720. doi: 10.1007/s00428-022-03388-3. Epub 
      2022 Jul 30.

PMID- 8147267
OWN - NLM
STAT- MEDLINE
DCOM- 19940505
LR  - 20190825
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 40
IP  - 1-2
DP  - 1993 Sep
TI  - Influence of acetylsalicylic acid on a Listeria monocytogenes infection.
PG  - 119-23
AB  - The influence of acetylsalicylic acid (ASA, CAS 50-78-2) on the Listeria 
      monocytogenes infection in balb/c mice was investigated. One day prior to lethal 
      or sublethal infection, balb/c mice were treated intravenously with therapeutic 
      concentrations of ASA alone or ASA in combination with murine recombinant 
      interferon gamma, a lymphokine produced by T-helper cells. Three days 
      post-infection, parasite burdens of spleen and liver were determined by the 
      colony-forming unit assay. It was shown that the prophylactic application of ASA 
      in a concentration of 5 mg/kg body weight resulted in a more than 10-fold 
      reduction of viable Listeria monocytogenes in spleen and liver of balb/c mice. In 
      addition, the combination of a suboptimal dosage of interferon gamma with ASA 
      resulted in a significantly higher survival rate compared to the untreated 
      controls.
FAU - Hockertz, S
AU  - Hockertz S
AD  - Fraunhofer Institute for Toxicology, Hannover, FRG.
FAU - Paulini, I
AU  - Paulini I
FAU - Rogalla, K
AU  - Rogalla K
FAU - Schettler, T
AU  - Schettler T
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Recombinant Proteins)
RN  - 82115-62-6 (Interferon-gamma)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Colony Count, Microbial
MH  - Female
MH  - Injections, Intravenous
MH  - Interferon-gamma/therapeutic use
MH  - Listeriosis/microbiology/*prevention & control
MH  - Liver/microbiology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Recombinant Proteins
MH  - Spleen/microbiology
EDAT- 1993/09/01 00:00
MHDA- 1993/09/01 00:01
CRDT- 1993/09/01 00:00
PHST- 1993/09/01 00:00 [pubmed]
PHST- 1993/09/01 00:01 [medline]
PHST- 1993/09/01 00:00 [entrez]
AID - 10.1007/BF01976760 [doi]
PST - ppublish
SO  - Agents Actions. 1993 Sep;40(1-2):119-23. doi: 10.1007/BF01976760.

PMID- 3741065
OWN - NLM
STAT- MEDLINE
DCOM- 19860916
LR  - 20200511
IS  - 0344-8444 (Print)
IS  - 0344-8444 (Linking)
VI  - 105
IP  - 3
DP  - 1986
TI  - Effects of acetylsalicylic acid and naproxen on bone resorption and formation in 
      rats.
PG  - 137-41
AB  - The influence of acetylsalicylic acid (ASA) (150 mg/kg/12 h) and naproxen (20 
      mg/kg/12 h) on bone metabolism in young male rats has been studied. The doses 
      were chosen to provide serum concentrations comparable with ordinary 
      anti-inflammatory steady-state levels in humans. After the rats had been 
      prelabeled with collagen- and mineral-tracing radioisotopes the rats received the 
      drugs by gavage twice a day for 9 and 18 days. Bone resorption was measured as 
      loss of carbon-labeled hydroxyproline (collagen) and strontium-85 (minerals). At 
      9 days ASA had retarded both collagen and mineral resorption in the femur by 
      about 10% compared with controls. The resorption of both collagen and minerals 
      was inhibited. After 18 days' treatment there were no differences regarding bone 
      resorption, but bone formation had decreased by about 10% in the ASA-treated 
      animals, as measured by net increases of collagen and calcium in the femur. 
      Naproxen did not influence bone resorption or formation significantly. The 
      results indicate an inhibitory effect of ASA on bone resorption and formation in 
      growing rats, whereas the effect of naproxen seems negligible.
FAU - Solheim, L F
AU  - Solheim LF
FAU - Rönningen, H
AU  - Rönningen H
FAU - Langeland, N
AU  - Langeland N
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arch Orthop Trauma Surg (1978)
JT  - Archives of orthopaedic and traumatic surgery. Archiv fur orthopadische und 
      Unfall-Chirurgie
JID - 7803037
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*pharmacology
MH  - Bone Resorption/*drug effects
MH  - Male
MH  - Naproxen/blood/*pharmacology
MH  - Osteogenesis/*drug effects
MH  - Rats
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1007/BF00433929 [doi]
PST - ppublish
SO  - Arch Orthop Trauma Surg (1978). 1986;105(3):137-41. doi: 10.1007/BF00433929.

PMID- 837964
OWN - NLM
STAT- MEDLINE
DCOM- 19770425
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 11
IP  - 2
DP  - 1977 Jan 3
TI  - Acute effects of acetylsalicylic acid on renal function in normal man.
PG  - 117-23
AB  - The acute effects of therapeutic doses of acetylsalicylic acid (ASA) on renal 
      water and solute output, and the possible interaction of ASA with the diuretic 
      effects of furosemide, have been studied in a double blind double cross over 
      study in healthy human subjects. There was a significant decrease in 24 h sodium 
      excretion and Na/K ratio in urine in the ASA-treated subjects. The effect of ASA 
      on urinary sodium excretion was most prominent during day time (8 a.m.-10 p.m.) 
      and on days with low sodium intake, as confirmed by control sodium excretion and 
      plasma renin activity. A decrease in urine volume and an increase in tubular 
      reabsorption of free water were caused by ASA, the antidiuretic effect being most 
      marked at night (10 p.m.-8 a.m.). No action of ASA on the effect of furosemide on 
      urinary sodium excretion was found. Creatinine clearance remained unaltered by 
      ASA treatment, and ASA did not interfere with the increase in urinary creatinine 
      excretion after furosemide treatment.
FAU - Berg, K J
AU  - Berg KJ
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Placebos)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Aspirin/blood/*pharmacology
MH  - Diuresis/drug effects
MH  - Drug Interactions
MH  - Furosemide/pharmacology
MH  - Humans
MH  - Kidney/*drug effects
MH  - Placebos
MH  - Potassium/urine
MH  - Sodium/urine
MH  - Time Factors
EDAT- 1977/01/03 00:00
MHDA- 1977/01/03 00:01
CRDT- 1977/01/03 00:00
PHST- 1977/01/03 00:00 [pubmed]
PHST- 1977/01/03 00:01 [medline]
PHST- 1977/01/03 00:00 [entrez]
AID - 10.1007/BF00562902 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1977 Jan 3;11(2):117-23. doi: 10.1007/BF00562902.

PMID- 1101907
OWN - NLM
STAT- MEDLINE
DCOM- 19760102
LR  - 20151119
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 25
IP  - 8
DP  - 1975 Aug
TI  - [Comparison of the effects of niflumic acid and aloxiprin in patients with 
      progressive chronic rheumatoid arthritis in a double blind trial].
PG  - 1308-11
AB  - The effects of niflumic acid (trifluoro-methyl-3-phenylamino-2-nicotinic acid) 
      and of aloxiprin (aluminium acetyl-salicylate) in patients with rheumatoid 
      arthritis were compared in a double-blind cross-over trial. Check-up examinations 
      prior to the institution and after the termination of the therapy, as well as 
      after individual treatment periods of two weeks with alternating sequential 
      administration of the two drugs, were carried out with a standardized method. The 
      assessment included subjective (pain intensity) and objective criteria 
      (Lansbury's index), as well as laboratory results (erythrocyte sedimentation 
      rate, uricaemia). With the exception of the articular index disclosing a superior 
      effect of niflumic acid, the other criteria showed no statistically significant 
      differences between the effects of the two drugs.
FAU - Vojtisek, O
AU  - Vojtisek O
FAU - Kanková, D
AU  - Kanková D
FAU - Pavelka, K
AU  - Pavelka K
FAU - Hándlová, D
AU  - Hándlová D
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Wirkungsvergleich zwischen Niflumsäure und Aloxiprin bei Kranken mit progredient 
      chronischer Polyarthritis im Doppelblindversuch.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Nicotinic Acids)
RN  - 4U5MP5IUD8 (Niflumic Acid)
RN  - CPD4NFA903 (Aluminum)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aluminum/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Sedimentation
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nicotinic Acids/*therapeutic use
MH  - Niflumic Acid/*therapeutic use
MH  - Surveys and Questionnaires
MH  - Time Factors
EDAT- 1975/08/01 00:00
MHDA- 1975/08/01 00:01
CRDT- 1975/08/01 00:00
PHST- 1975/08/01 00:00 [pubmed]
PHST- 1975/08/01 00:01 [medline]
PHST- 1975/08/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1975 Aug;25(8):1308-11.

PMID- 17097412
OWN - NLM
STAT- MEDLINE
DCOM- 20070308
LR  - 20181201
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 98
IP  - 10A
DP  - 2006 Nov 20
TI  - Aspirin resistance or variable response or both?
PG  - 11N-17N
AB  - Numerous clinical trials have demonstrated that aspirin is effective in secondary 
      prevention and in high-risk primary prevention of adverse cardiovascular events. 
      However, a constellation of clinical and laboratory evidence exists that 
      demonstrates diminished or absent response to aspirin in some patients. This has 
      led to the concept of "aspirin resistance," which is a poorly defined, somewhat 
      misleading term. The mechanism for aspirin resistance has not been fully 
      established, but it is almost certainly due to a combination of clinical, 
      biological, and genetic properties affecting platelet function. There are no 
      criteria for distinguishing true resistance from treatment failure, and there is 
      no consensus on whether the definition of aspirin resistance should be based on 
      clinical outcomes, laboratory evidence, or both. Studies in large populations are 
      needed to define antiplatelet resistance using consistent and reproducible assays 
      and correlate the measurements with clinical outcomes. One such prospective 
      randomized trial is completed, and 2 others are under way: the Clopidogrel for 
      High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance 
      (CHARISMA) trial compared clopidogrel and aspirin with placebo and aspirin for 
      high-risk primary or secondary prevention, and the Aspirin Nonresponsiveness and 
      Clopidogrel Endpoint Trial (ASCET) is evaluating whether switching to clopidogrel 
      will be superior to continued aspirin therapy in improving clinical outcomes in 
      aspirin-resistant patients with angiographically documented coronary artery 
      disease. The Research Evaluation to Study Individuals Who Show Thromboxane or 
      P2Y(12) Receptor Resistance (RESISTOR) trial is investigating whether modifying 
      antiplatelet regimens could prevent myonecrosis after percutaneous coronary 
      intervention in patients with aspirin and clopidogrel resistance.
FAU - Cheng, Xi
AU  - Cheng X
AD  - Division of Cardiology, Department of Medicine, University of Hong Kong, Queen 
      Mary Hospital, Hong Kong, China.
FAU - Chen, Wai-Hong
AU  - Chen WH
FAU - Simon, Daniel I
AU  - Simon DI
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060928
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
RF  - 47
EDAT- 2006/11/14 09:00
MHDA- 2007/03/09 09:00
CRDT- 2006/11/14 09:00
PHST- 2006/11/14 09:00 [pubmed]
PHST- 2007/03/09 09:00 [medline]
PHST- 2006/11/14 09:00 [entrez]
AID - S0002-9149(06)01730-9 [pii]
AID - 10.1016/j.amjcard.2006.09.009 [doi]
PST - ppublish
SO  - Am J Cardiol. 2006 Nov 20;98(10A):11N-17N. doi: 10.1016/j.amjcard.2006.09.009. 
      Epub 2006 Sep 28.

PMID- 35810407
OWN - NLM
STAT- MEDLINE
DCOM- 20230119
LR  - 20230119
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 160
IP  - 2
DP  - 2023 Feb
TI  - Low-dose aspirin use in the first trimester of pregnancy and odds of congenital 
      anomalies: A meta-analysis of randomized controlled trials.
PG  - 526-537
LID - 10.1002/ijgo.14334 [doi]
AB  - BACKGROUND: Daily low-dose aspirin (LDA) is recommended in high-risk pregnancies. 
      However, its safety profile in the first trimester has not been well documented. 
      OBJECTIVES: To determine if LDA exposure during the first trimester of pregnancy 
      is associated with higher odds of congenital structural anomalies. SEARCH 
      STRATEGY: PubMed, Embase, Web of Science, Cochrane Central Register of Controlled 
      Trials, and ClinicalTrials.gov were systematically searched. SELECTION CRITERIA: 
      Randomized controlled trials (RCTs) that assigned participants to LDA (≤150 mg) 
      or placebo/no intervention at less than 14 weeks of pregnancy were eligible. DATA 
      COLLECTION AND ANALYSIS: Random-effects models were performed using the 
      inverse-variance method to calculate pooled effect sizes. Quality of evidence was 
      appraised according to Grading of Recommendations, Assessment, Development and 
      Evaluations (GRADE) criteria. MAIN RESULTS: Eight RCTs that included 7564 
      participants assigned to receive daily LDA and 7670 participants that served as 
      controls were analyzed. Low-certainty evidence showed no significant difference 
      in the odds of congenital anomalies (odds ratio 0.87, 95% confidence interval 
      0.62-1.23, I(2)  = 0%). CONCLUSIONS: In this meta-analysis, there is no evidence 
      to suggest safety concerns regarding LDA teratogenicity. However, given the 
      overall low quality of evidence, further research (e.g. individual participant 
      data meta-analysis) is needed to confirm LDA safety profile.
CI  - © 2022 International Federation of Gynecology and Obstetrics.
FAU - Garza-Galvan, Maria E
AU  - Garza-Galvan ME
AD  - Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Monterrey, 
      Mexico.
FAU - Ferrigno, Ana S
AU  - Ferrigno AS
AD  - Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Monterrey, 
      Mexico.
FAU - Campos-Zamora, Melissa
AU  - Campos-Zamora M
AD  - Postgraduate Medical Education, Harvard Medical School, Boston, Massachusetts, 
      USA.
FAU - Bain, Paul A
AU  - Bain PA
AD  - Countway Library of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Easter, Sarah Rae
AU  - Easter SR
AD  - Department of Obstetrics and Gynecology, Brigham & Women's Hospital, Harvard 
      Medical School, Boston, Massachusetts, USA.
FAU - Kim, Jimin
AU  - Kim J
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Brigham & Women's 
      Hospital, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Figueras, Francesc
AU  - Figueras F
AD  - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic), 
      IDIBAPS, University of Barcelona, Barcelona, Spain.
FAU - Farber, Michaela K
AU  - Farber MK
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Brigham & Women's 
      Hospital, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Lumbreras-Marquez, Mario I
AU  - Lumbreras-Marquez MI
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Brigham & Women's 
      Hospital, Harvard Medical School, Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220727
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - Pregnancy Trimester, First
MH  - Randomized Controlled Trials as Topic
MH  - *Aspirin/adverse effects
OTO - NOTNLM
OT  - aspirin
OT  - congenital anomalies
OT  - first trimester
OT  - pregnancy
OT  - randomized controlled trials
EDAT- 2022/07/11 06:00
MHDA- 2023/01/20 06:00
CRDT- 2022/07/10 13:58
PHST- 2022/06/16 00:00 [revised]
PHST- 2022/02/10 00:00 [received]
PHST- 2022/07/07 00:00 [accepted]
PHST- 2022/07/11 06:00 [pubmed]
PHST- 2023/01/20 06:00 [medline]
PHST- 2022/07/10 13:58 [entrez]
AID - 10.1002/ijgo.14334 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2023 Feb;160(2):526-537. doi: 10.1002/ijgo.14334. Epub 
      2022 Jul 27.

PMID- 8913204
OWN - NLM
STAT- MEDLINE
DCOM- 19961211
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 41
IP  - 5
DP  - 1996 Nov
TI  - Diaspirin cross-linked hemoglobin resuscitation improves cerebral perfusion after 
      head injury and shock.
PG  - 781-8
AB  - BACKGROUND: Shock associated with traumatic brain injury (TBI) doubles the 
      mortality of TBI alone by inducing a secondary ischemic injury. Rapid correction 
      of cerebral perfusion pressure (CPP) is thought to be essential to improving 
      outcome. Diaspirin cross-linked hemoglobin (DCLHb) has been shown to improve 
      cerebral blood flow, increase mean arterial pressure (MAP), and reduce lesion 
      size in models of occlusive cerebral ischemia but has not been evaluated in a 
      model of TBI combined with hemorrhagic shock. METHODS: We studied the effects of 
      DCLHb resuscitation in a porcine model of cryogenic TBI and hemorrhagic shock 
      (MAP = 50 mmHg). After combined insults, animals were randomized to receive a 
      bolus of 4 mliters/kg of either lactated Ringer's solution (n = 5) or DCLHb (n = 
      6). Lactated Ringer's solution was then infused in both groups to maintain MAP at 
      baseline. Shed blood was returned 1 hour after the initiation of resuscitation 
      (R1). Animals were studied for 24 hours. RESULTS: DCLHb infusion resulted in a 
      significantly greater MAP at R1 and R24 (95 +/- 4 vs. 82 +/- 2 and 99 +/- 3 vs. 
      85 +/- 3 mm Hg, respectively) and a significantly greater CPP at R1 and R24 (83 
      +/- 10 vs. 68 +/- 5 and 89 +/- 6 vs. 71 +/- 11 mm Hg, respectively). Intracranial 
      pressure was lower in the DCLHb group, but this difference was not significant. 
      There was no significant difference between the groups in cerebral oxygen 
      delivery. DCLHb animals required less fluid to maintain MAP (12,094 +/- 552 vs. 
      15,542 +/- 1094 mliters, p < 0.05). CONCLUSION: These data suggest that DCLHb is 
      beneficial in the early resuscitation of head injury and shock and that further 
      investigation is warranted. Key Words: Diaspirin cross-linked hemoglobin, Head 
      injury, Shock, Cerebral perfusion pressure.
FAU - Chappell, J E
AU  - Chappell JE
AD  - Department of Surgery, University of Vermont, Burlington 05401, USA.
FAU - McBride, W J
AU  - McBride WJ
FAU - Shackford, S R
AU  - Shackford SR
LA  - eng
GR  - P20-NS30324-03/NS/NINDS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Brain Injuries/complications/*physiopathology/*therapy
MH  - Cerebrovascular Circulation/*drug effects
MH  - Fluid Therapy
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/*pharmacology/therapeutic use
MH  - Intracranial Pressure/drug effects
MH  - Models, Biological
MH  - Oxygen/blood
MH  - Resuscitation/*methods
MH  - Shock/etiology/*physiopathology/*therapy
MH  - Swine
MH  - Swine, Miniature
MH  - Vascular Resistance/drug effects
EDAT- 1996/11/01 00:00
MHDA- 1996/11/01 00:01
CRDT- 1996/11/01 00:00
PHST- 1996/11/01 00:00 [pubmed]
PHST- 1996/11/01 00:01 [medline]
PHST- 1996/11/01 00:00 [entrez]
AID - 10.1097/00005373-199611000-00003 [doi]
PST - ppublish
SO  - J Trauma. 1996 Nov;41(5):781-8. doi: 10.1097/00005373-199611000-00003.

PMID- 34208905
OWN - NLM
STAT- MEDLINE
DCOM- 20210727
LR  - 20210727
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 13
IP  - 7
DP  - 2021 Jun 30
TI  - Simultaneous Pretreatment of Aspirin and Omega-3 Fatty Acid Attenuates Nuclear 
      Factor-κB Activation in a Murine Model with Ventilator-Induced Lung Injury.
LID - 10.3390/nu13072258 [doi]
LID - 2258
AB  - Ventilator-induced lung injury (VILI) is an important critical care complication. 
      Nuclear factor-κB (NF-κB) activation, a critical signaling event in the 
      inflammatory response, has been implicated in the tracking of the lung injury. 
      The present study aimed to determine the effect of simultaneous pretreatment with 
      enteral aspirin and omega-3 fatty acid on lung injury in a murine VILI model. We 
      compared the lung inflammation after the sequential administration of 
      lipopolysaccharides and mechanical ventilation between the pretreated 
      simultaneous enteral aspirin and omega-3 fatty acid group and the 
      non-pretreatment group, by quantifying NF-κB activation using an in vivo imaging 
      system to detect bioluminescence signals. The pretreated group with enteral 
      aspirin and omega-3 fatty acid exhibited a smaller elevation of bioluminescence 
      signals than the non-pretreated group (p = 0.039). Compared to the non-pretreated 
      group, the pretreatment group with simultaneous enteral aspirin and omega-3 fatty 
      acid showed reduced expression of the pro-inflammatory cytokine, tumor necrosis 
      factor-α, in bronchoalveolar lavage fluid (p = 0.038). Histopathological lung 
      injury scores were also lower in the pretreatment groups compared to the only 
      injury group. Simultaneous pretreatment with enteral administration of aspirin 
      and omega-3 fatty acid could be a prevention method for VILI in patients with 
      impending mechanical ventilation therapy.
FAU - Kwack, Won-Gun
AU  - Kwack WG
AD  - Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal 
      Medicine, Kyung Hee University Hospital, Seoul 02447, Korea.
FAU - Lee, Yoon-Je
AU  - Lee YJ
AD  - Division of Pulmonary and Critical Care Medicine, Department of Internal 
      Medicine, Seoul National University College of Medicine, Seoul National 
      University Bundang Hospital, Seongnam 13620, Korea.
FAU - Eo, Eun-Young
AU  - Eo EY
AD  - Division of Pulmonary and Critical Care Medicine, Department of Internal 
      Medicine, Seoul National University College of Medicine, Seoul National 
      University Bundang Hospital, Seongnam 13620, Korea.
FAU - Chung, Jin-Haeng
AU  - Chung JH
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul 
      National University Bundang Hospital, Seongnam 13620, Korea.
FAU - Lee, Jae-Ho
AU  - Lee JH
AD  - Division of Pulmonary and Critical Care Medicine, Department of Internal 
      Medicine, Seoul National University College of Medicine, Seoul National 
      University Bundang Hospital, Seongnam 13620, Korea.
FAU - Cho, Young-Jae
AU  - Cho YJ
AD  - Division of Pulmonary and Critical Care Medicine, Department of Internal 
      Medicine, Seoul National University College of Medicine, Seoul National 
      University Bundang Hospital, Seongnam 13620, Korea.
LA  - eng
GR  - 09-2014-006/Seoul National University Bundang Hospital/
GR  - HI16C1787/the Ministry of Health &Welfare, Republic of Korea/
PT  - Journal Article
DEP - 20210630
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 0 (Cytokines)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Inflammation Mediators)
RN  - 0 (NF-kappa B)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Bronchoalveolar Lavage Fluid
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Fatty Acids, Omega-3/pharmacology/*therapeutic use
MH  - Female
MH  - Inflammation Mediators/metabolism
MH  - Lung/drug effects/pathology
MH  - Machine Learning
MH  - Mice, Inbred C57BL
MH  - NF-kappa B/*metabolism
MH  - Ventilator-Induced Lung Injury/*drug therapy
PMC - PMC8308446
OTO - NOTNLM
OT  - aspirin
OT  - nuclear factor-κB
OT  - omega-3 fatty acid
OT  - tumor necrosis factor-α
OT  - ventilator-induced lung injury
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/28 06:00
CRDT- 2021/07/02 01:36
PHST- 2021/06/01 00:00 [received]
PHST- 2021/06/17 00:00 [revised]
PHST- 2021/06/24 00:00 [accepted]
PHST- 2021/07/02 01:36 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/28 06:00 [medline]
AID - nu13072258 [pii]
AID - nutrients-13-02258 [pii]
AID - 10.3390/nu13072258 [doi]
PST - epublish
SO  - Nutrients. 2021 Jun 30;13(7):2258. doi: 10.3390/nu13072258.

PMID- 11373478
OWN - NLM
STAT- MEDLINE
DCOM- 20010614
LR  - 20190706
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 29
IP  - 4
DP  - 2001 Apr
TI  - Diaspirin crosslinked hemoglobin enables extreme hemodilution beyond the critical 
      hematocrit.
PG  - 829-38
AB  - BACKGROUND: Normovolemic hemodilution is an effective strategy to limit 
      perioperative homologous blood transfusions. The reduction of hematocrit related 
      to hemodilution results in reduced arterial oxygen content, which initially is 
      compensated for by an increase in cardiac output and oxygen extraction ratio. To 
      increase the efficacy of hemodilution, a low hematocrit should be aimed for; 
      however, this implies the risk of myocardial ischemia and tissue hypoxia. 
      OBJECTIVE: To assess whether hemodilution can be extended to lower hematocrit 
      values by the use of a hemoglobin-based artificial oxygen carrier solution. 
      DESIGN: Prospective, randomized, controlled. SETTING: Animal laboratory of a 
      university hospital. SUBJECTS: Twelve anesthetized, mechanically ventilated pigs. 
      INTERVENTIONS: Isovolemic hemodilution was performed with either 10% diaspirin 
      crosslinked hemoglobin (DCLHb Baxter Healthcare, Boulder, CO; n = 6) or 8% human 
      albumin solution (HSA, oncotically matched to DCLHb, Baxter Healthcare; n = 6) to 
      a hematocrit of 15%, 8%, 4%, 2%, and 1%. MEASUREMENTS AND MAIN RESULTS: In both 
      groups, measurements were performed at baseline at the previously mentioned 
      preset hematocrit values and at the onset of myocardial ischemia characterized by 
      critical hematocrit (significant ST-segment depression >0.1 mV and/or 
      arrhythmia). To determine peripheral tissue oxygenation and myocardial perfusion 
      and function, the following variables were evaluated: total body oxygen transport 
      variables, tissue oxygen partial pressure (tPo2, MDO-Electrode, Eschweiler Kiel, 
      Germany) on the surface of the skeletal muscle, coronary perfusion pressure, left 
      ventricular (LV) end-diastolic pressure, global and regional myocardial 
      contractility (maximal change in pressure over time, LV segmental shortening, 
      microsonometry method), LV myocardial blood flow (fluorescent microsphere 
      technique), LV oxygen delivery, and the ratio between LV subendocardial and 
      subepicardial myocardial perfusion. In the HSA group, critical hematocrit was 
      found at 6.1 (1.8)% (hemoglobin, 2 g x dL(-1)), whereas all DCLHb-treated animals 
      survived hemodilution until hematocrit 1.2 (0.2)% (hemoglobin, 4.7 g x dL(-1)) 
      was achieved without signs of hemodynamic instability. Although arterial oxygen 
      content was higher in the DCLHb group at 1.2% hematocrit than in the HSA group at 
      critical hematocrit (i.e., hematocrit, 6.1%; hemoglobin, 2 g.dL-1) neither oxygen 
      delivery and oxygen uptake nor median tPo2 and hypoxic tPo2 values on the 
      skeletal muscle were different between groups. In contrast, subendocardial 
      ischemia was absent in DCLHb-diluted animals until 1.2% hematocrit was achieved. 
      This was attributable to a higher coronary perfusion pressure (65 (22) mm Hg vs. 
      19 (8) mm Hg; p <.05), higher subendocardial perfusion (4.1 (2.6) mL.min-1.g-1 
      vs. 1.2 (0.4) mL x min(-1) x g(-1)), and subendocardial oxygen delivery (5.7 (2) 
      mL x min(-1) x g(-1), p <.05) in DCLHb-diluted animals, resulting in superior 
      myocardial contractility reflected by maximal change in pressure over time (3829 
      (1914) vs. 1678 (730); p <.05) and higher regional myocardial contractility (11 
      (8)% vs. 6 (2)%; p <.05). An increased LV end-diastolic pressure reflected LV 
      myocardial pump failure in HSA-diluted animals but was unchanged in DCLHb-diluted 
      animals. In the DCLHb group, systemic vascular resistance index remained at 
      baseline values throughout the protocol, whereas coronary vascular resistance 
      decreased. In contrast, both variables decreased in HSA-diluted animals. 
      CONCLUSION: DCLHb as a diluent allowed for hemodilution beyond the hematocrit 
      value, determined "critical" after hemodilution with HSA (6.1% (1.8)%). Even at 
      1.2% hematocrit (hemoglobin, 4.7 g x dL(-1)) myocardial perfusion and function 
      were maintained, although at the expense of peripheral tissue oxygenation. This 
      discrepancy in regional oxygenation might be caused by a redistribution of blood 
      flow favoring the heart, which is related to a disproportionate decrease of 
      coronary vascular resistance index during hemodilution with DCLHb.
FAU - Meisner, F G
AU  - Meisner FG
AD  - Institute for Surgical Research, Klinikum Grobetahadern, 
      Ludwig-Maximilians-University Munich, Germany.
FAU - Kemming, G I
AU  - Kemming GI
FAU - Habler, O P
AU  - Habler OP
FAU - Kleen, M S
AU  - Kleen MS
FAU - Tillmanns, J H
AU  - Tillmanns JH
FAU - Hutter, J W
AU  - Hutter JW
FAU - Bottino, D A
AU  - Bottino DA
FAU - Thein, E
AU  - Thein E
FAU - Meier, J M
AU  - Meier JM
FAU - Wojtczyk, C J
AU  - Wojtczyk CJ
FAU - Pape, A
AU  - Pape A
FAU - Messmer, K
AU  - Messmer K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Hemoglobins)
RN  - 0 (Serum Albumin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Crit Care Med. 2001 Apr;29(4):908-10. PMID: 11373498
MH  - Animals
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Blood Volume
MH  - Coronary Circulation/drug effects
MH  - *Hematocrit
MH  - *Hemodilution
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/*pharmacology
MH  - Humans
MH  - Myocardial Contraction/drug effects
MH  - *Oxygen Consumption
MH  - Serum Albumin/pharmacology
MH  - Swine
EDAT- 2001/05/25 10:00
MHDA- 2001/06/23 10:01
CRDT- 2001/05/25 10:00
PHST- 2001/05/25 10:00 [pubmed]
PHST- 2001/06/23 10:01 [medline]
PHST- 2001/05/25 10:00 [entrez]
AID - 10.1097/00003246-200104000-00030 [doi]
PST - ppublish
SO  - Crit Care Med. 2001 Apr;29(4):829-38. doi: 10.1097/00003246-200104000-00030.

PMID- 421810
OWN - NLM
STAT- MEDLINE
DCOM- 19790516
LR  - 20190629
IS  - 0014-4754 (Print)
IS  - 0014-4754 (Linking)
VI  - 35
IP  - 1
DP  - 1979 Jan 15
TI  - Acetylsalicylic acid-induced morphological changes in the ductus arteriosus of 
      the chick embryo.
PG  - 92-3
AB  - The effect of acetylsalicyclic acid upon the ducti arteriosi of the embryonic 
      chick was studied. A spectrum of gross malformations and histological findings 
      associated with premature closure of the right ductus arteriosus is presented.
FAU - Ishikawa, S
AU  - Ishikawa S
FAU - Cheung, M O
AU  - Cheung MO
FAU - Gilbert, E F
AU  - Gilbert EF
FAU - Bruyère, H J Jr
AU  - Bruyère HJ Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Switzerland
TA  - Experientia
JT  - Experientia
JID - 0376547
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced/pathology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Chick Embryo
MH  - Ductus Arteriosus/*drug effects/pathology
EDAT- 1979/01/15 00:00
MHDA- 2001/03/28 10:01
CRDT- 1979/01/15 00:00
PHST- 1979/01/15 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1979/01/15 00:00 [entrez]
AID - 10.1007/BF01917898 [doi]
PST - ppublish
SO  - Experientia. 1979 Jan 15;35(1):92-3. doi: 10.1007/BF01917898.

PMID- 7817363
OWN - NLM
STAT- MEDLINE
DCOM- 19950209
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 76
IP  - 1
DP  - 1994 Oct 1
TI  - Platelet response to vascular surgery--a preliminary study on the effect of 
      aspirin and heparin.
PG  - 79-87
AB  - Patients with peripheral arterial disease (PAD) demonstrate high cardiovascular 
      mortality, which is further increased after arterial reconstruction. Enhanced 
      platelet reactivity has been postulated for these patients. The effect of surgery 
      and of periprocedural aspirin and heparin therapy on platelet reactivity was 
      assessed with the Stagnation Point Flow Adhesio-Aggregometer (SPAA). The platelet 
      adhesivity and aggregability of 44 PAD patients was quantitated perioperatively. 
      Aspirin was administered during the entire course, low molecular weight heparin 
      (LMWH) preoperatively and as of the fourth postoperative (pOP) day and 
      unfractionated heparin (UH) upon surgery and three days thereafter. A group of 15 
      aspirin-free general surgical patients receiving LMWH and with no evidence of PAD 
      served as controls. Plasma fibrinogen levels and platelet count were determined. 
      The heparin-induced platelet activation (HIPA) assay for detection of 
      heparin-associated thrombocytopenia (HAT) antibodies was also performed. Baseline 
      values of SPAA-measured platelet reactivity (p < 0.001) and plasma fibrinogen (p 
      < 0.01) were higher for patients as compared to controls and increased markedly 
      after surgery. In the PAD group maximum platelet activation and fibrinogen levels 
      coincided with a marked drop in platelet count and were concomitant to 
      administration of unfractionated heparin. Thereby, a drop in platelet count of > 
      30% was observed in 25 patients (57%). The HIPA test verified HAT antibodies in 3 
      (12%) of these patients, two of which suffered postoperative thrombosis. In the 
      control group significant pOP increases were noted only for plasma fibrinogen. 
      Changes in platelet count and reactivity were minimal and nonsignificant. No 
      thrombosis occurred and no HAT antibodies were detected.(ABSTRACT TRUNCATED AT 
      250 WORDS)
FAU - Reininger, C B
AU  - Reininger CB
AD  - Chirurgische Klinik und Poliklinik Innenstadt, Ludwig-Maximilians-Universität 
      München, Germany.
FAU - Reininger, A J
AU  - Reininger AJ
FAU - Steckmeier, B
AU  - Steckmeier B
FAU - Greinacher, A
AU  - Greinacher A
FAU - Lasser, R
AU  - Lasser R
FAU - Schweiberer, L
AU  - Schweiberer L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9001-32-5 (Fibrinogen)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Female
MH  - Fibrinogen/analysis
MH  - Heparin/administration & dosage/*pharmacology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Postoperative Complications/blood
MH  - Vascular Diseases/blood/*surgery
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 0049-3848(94)90209-7 [pii]
AID - 10.1016/0049-3848(94)90209-7 [doi]
PST - ppublish
SO  - Thromb Res. 1994 Oct 1;76(1):79-87. doi: 10.1016/0049-3848(94)90209-7.

PMID- 17188339
OWN - NLM
STAT- MEDLINE
DCOM- 20071018
LR  - 20220311
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 120
IP  - 4
DP  - 2007
TI  - Variation and importance of aspirin resistance in patients with known 
      cardiovascular disease.
PG  - 477-84
AB  - AIM: To investigate whether aspirin resistance is a persistent condition, and to 
      evaluate if aspirin resistance affects one-year clinical outcome. METHODS AND 
      RESULTS: Previously we studied 298 patients admitted to hospital with symptoms 
      suggestive of an acute myocardial infarction (MI) despite treatment with aspirin, 
      and 70 patients (23.5%) were aspirin resistant. In the present study, platelet 
      function was reassessed by use of a Platelet Function Analyzer-100 one year 
      later. A total of 187 patients were re-examined, and 17 (9.1%) demonstrated 
      aspirin resistance. Of these 17 patients, 12 also exhibited aspirin resistance at 
      baseline resulting in a 6% (12/187) prevalence of persistent aspirin resistance. 
      A total of 34 patients had changed from aspirin resistant at baseline to aspirin 
      sensitive at follow-up. We found a significant decrease in the prevalence of 
      aspirin resistance from baseline (43%) to follow-up (11%) in patients with MI at 
      baseline (p=0.0018). Furthermore, a significant decrease was found for patients 
      without MI at baseline (20% to 9%, p=0.0009). During follow-up, 17% (12/70) of 
      the patients with aspirin resistance at baseline suffered death, MI or stroke 
      compared to 16% (37/227) of aspirin sensitive patients (p=0.868). CONCLUSION: The 
      prevalence of aspirin resistance varies with the clinical status of the patients, 
      and indeed an acute MI is associated with temporary aspirin resistance. We also 
      found that 6% of patients demonstrate persistent aspirin resistance. The presence 
      of aspirin resistance did not affect one-year clinical outcome.
FAU - Poulsen, Tina Svenstrup
AU  - Poulsen TS
AD  - Department of Cardiology, Odense University Hospital, Sdr. Boulevard 29, DK-5000 
      Odense C, Denmark. tina.poulsen@ouh.fyms-amt.dk
FAU - Kristensen, Søren Risom
AU  - Kristensen SR
FAU - Korsholm, Lars
AU  - Korsholm L
FAU - Haghfelt, Torben
AU  - Haghfelt T
FAU - Jørgensen, Bo
AU  - Jørgensen B
FAU - Licht, Peter Bjørn
AU  - Licht PB
FAU - Mickley, Hans
AU  - Mickley H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061222
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cardiovascular Diseases/*complications/drug therapy/mortality
MH  - *Drug Resistance
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/etiology
MH  - Platelet Function Tests
MH  - Prevalence
MH  - Stroke/drug therapy/etiology
EDAT- 2006/12/26 09:00
MHDA- 2007/10/19 09:00
CRDT- 2006/12/26 09:00
PHST- 2006/04/29 00:00 [received]
PHST- 2006/10/16 00:00 [revised]
PHST- 2006/10/23 00:00 [accepted]
PHST- 2006/12/26 09:00 [pubmed]
PHST- 2007/10/19 09:00 [medline]
PHST- 2006/12/26 09:00 [entrez]
AID - S0049-3848(06)00432-4 [pii]
AID - 10.1016/j.thromres.2006.10.022 [doi]
PST - ppublish
SO  - Thromb Res. 2007;120(4):477-84. doi: 10.1016/j.thromres.2006.10.022. Epub 2006 
      Dec 22.

PMID- 11524320
OWN - NLM
STAT- MEDLINE
DCOM- 20010920
LR  - 20190704
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 93
IP  - 3
DP  - 2001 Sep
TI  - The effect of perioperative aspirin therapy in peripheral vascular surgery: a 
      decision analysis.
PG  - 573-80
AB  - Patients who undergo infrainguinal revascularization surgery are at increased 
      risk for perioperative thrombotic complications. Aspirin decreases thrombotic 
      events in the nonoperative setting; however, aspirin is often discontinued to 
      avoid perioperative hemorrhagic complications. We used a decision analysis to 
      determine whether aspirin should be discontinued before infrainguinal 
      revascularization surgery. Two strategies were compared: aspirin cessation 2 wk 
      before surgery and aspirin continuation throughout the perioperative period. 
      Clinical events examined included myocardial infarction, thrombotic 
      cerebrovascular accident, hemorrhagic cerebrovascular accident, gastrointestinal 
      hemorrhage, and incisional hemorrhagic complications. Event rates and effect of 
      aspirin were obtained by using MEDLINE. The outcomes were perioperative 
      mortality, life expectancy, and quality-adjusted life expectancy. According to 
      the model, continued aspirin use decreased perioperative mortality rates from 
      2.78% to 2.05%. Continued aspirin use increased life expectancy from 14.83 to 
      14.89 yr and increased quality-adjusted life expectancy from 14.72 to 14.79 yr. 
      Aspirin increased the number of hemorrhagic complications by 2.46%, primarily 
      because of an increased incidence of non-life-threatening complications.
FAU - Neilipovitz, D T
AU  - Neilipovitz DT
AD  - Department of Anesthesiology, The Ottawa Hospital, Ottawa, Ontario, Canada. 
      dneilipovitz@ottawahospital.on.ca
FAU - Bryson, G L
AU  - Bryson GL
FAU - Nichol, G
AU  - Nichol G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Decision Support Techniques
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Intraoperative Complications/prevention & control
MH  - Peripheral Vascular Diseases/surgery
MH  - Risk Assessment
MH  - Treatment Outcome
MH  - *Vascular Surgical Procedures/mortality
EDAT- 2001/08/29 10:00
MHDA- 2001/09/21 10:01
CRDT- 2001/08/29 10:00
PHST- 2001/08/29 10:00 [pubmed]
PHST- 2001/09/21 10:01 [medline]
PHST- 2001/08/29 10:00 [entrez]
AID - 10.1097/00000539-200109000-00009 [doi]
PST - ppublish
SO  - Anesth Analg. 2001 Sep;93(3):573-80. doi: 10.1097/00000539-200109000-00009.

PMID- 12960371
OWN - NLM
STAT- MEDLINE
DCOM- 20031029
LR  - 20181113
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 100
IP  - 19
DP  - 2003 Sep 16
TI  - Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and 
      NO-releasing aspirin in the human gastric mucosa.
PG  - 10937-41
AB  - In addition to inhibiting cyclooxygenase (COX)-1-derived prostanoid biosynthesis, 
      aspirin acetylates COX-2, enabling the conversion of arachidonic acid to 
      15(R)-epi lipoxin A4, or aspirin-triggered lipoxin (ATL). Selective COX-2 
      inhibitors block ATL formation and exacerbate mucosal injury in rats treated with 
      aspirin. In the present study, we have examined whether inhibition of COX-2 
      activity in healthy volunteers taking aspirin exacerbates gastric mucosal injury 
      and if such an effect would be prevented by NCX-4016, a NO-releasing derivative 
      of aspirin. Thirty-two volunteers were randomized to receive 2 wk of treatment 
      with NCX-4016 (800 mg twice a day) or aspirin (100 mg once a day) alone or in 
      combination with 200 mg of celecoxib twice a day. Mucosal damage was assessed by 
      endoscopy. The mean mucosal injury score was 5.8 +/- 1.8 in subjects treated with 
      aspirin and 2.4 +/- 0.7 (P < 0.01 vs. aspirin) in subjects treated with NCX-4016. 
      Administration of celecoxib increased the injury score in volunteers treated with 
      aspirin (9.9 +/- 1.9) but not in subjects taking NCX-4016 (1.5 +/- 0.8). Aspirin 
      and NCX-4016 caused a comparable suppression of serum thromboxane B2 levels and 
      increased urinary excretion of ATL. Celecoxib inhibited endotoxin-induced 
      prostaglandin E2 generation in whole blood by approximately 80% and abolished ATL 
      formation. These findings suggests that (i) aspirin and NCX-4016 trigger ATL 
      formation in humans, (ii) celecoxib inhibits ATL formation and exacerbates the 
      mucosal injury caused by low doses of aspirin, and (iii) the NO-donating moiety 
      of NCX-4016 protects the gastric mucosa even in the presence of suppression of 
      COX-1 and COX-2.
FAU - Fiorucci, Stefano
AU  - Fiorucci S
AD  - Clinica di Gastroenterologia ed Epatologia, Dipartimento di Medicina Clinica e 
      Sperimentale, Università di Perugia, Italy. fiorucci@unipg.it
FAU - Santucci, Luca
AU  - Santucci L
FAU - Wallace, John L
AU  - Wallace JL
FAU - Sardina, Marco
AU  - Sardina M
FAU - Romano, Mario
AU  - Romano M
FAU - del Soldato, Piero
AU  - del Soldato P
FAU - Morelli, Antonio
AU  - Morelli A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20030905
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Lipoxins)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EH04H13L6B (nitroaspirin)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Celecoxib
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Female
MH  - Gastric Mucosa/*drug effects/enzymology
MH  - Humans
MH  - Isoenzymes/*drug effects
MH  - Lipoxins/metabolism
MH  - Male
MH  - Prostaglandin-Endoperoxide Synthases/*drug effects
MH  - Pyrazoles
MH  - Sulfonamides/*pharmacology
PMC - PMC196906
EDAT- 2003/09/10 05:00
MHDA- 2003/10/30 05:00
CRDT- 2003/09/10 05:00
PHST- 2003/09/10 05:00 [pubmed]
PHST- 2003/10/30 05:00 [medline]
PHST- 2003/09/10 05:00 [entrez]
AID - 1933204100 [pii]
AID - 10010937 [pii]
AID - 10.1073/pnas.1933204100 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10937-41. doi: 
      10.1073/pnas.1933204100. Epub 2003 Sep 5.

PMID- 3241821
OWN - NLM
STAT- MEDLINE
DCOM- 19890519
LR  - 20190912
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 34
IP  - 2
DP  - 1988 Nov
TI  - Diminished platelet residence time on active human atherosclerotic lesions 
      in-vivo--evidence for an optimal dose of aspirin?
PG  - 89-93
AB  - Although aspirin is an old drug, its optimal dose for the treatment of human 
      atherosclerosis has not been finally proven. Various in-vitro and ex-vivo 
      platelet function tests revealed a dose range from 1 to 3000 mg as being optimal. 
      It was thus the goal to examine its in-vivo efficacy in human suffering from 
      peripheral vascular disease in 7 different doses ranging from 1 mg to 1000 mg a 
      day. All these patients have been treated for 3 months. Platelet half-life and 
      platelet uptake ratio show an in part significant improvement being most 
      pronounced at the daily doses of 20 and 1000 mg respectively. No change occurs in 
      the placebo treated controls. These findings indicate, that 20 or 1000 mg aspirin 
      taken daily per os, are superior to the other doses examined concerning the 
      in-vivo platelet function (as measured by platelet half-life) and rendering the 
      arterial surface less thrombogenic (as reflected by platelet uptake 
      ratio-measurements).
FAU - Sinzinger, H
AU  - Sinzinger H
AD  - Dept. of Nuclear Medicine, University of Vienna, Austria.
FAU - Kaliman, J
AU  - Kaliman J
FAU - Fitscha, P
AU  - Fitscha P
FAU - O'Grady, J
AU  - O'Grady J
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Arteriosclerosis/*drug therapy
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - Blood Platelets/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Thromboxane B2/blood
MH  - Time Factors
EDAT- 1988/11/01 00:00
MHDA- 1988/11/01 00:01
CRDT- 1988/11/01 00:00
PHST- 1988/11/01 00:00 [pubmed]
PHST- 1988/11/01 00:01 [medline]
PHST- 1988/11/01 00:00 [entrez]
AID - 10.1016/0952-3278(88)90068-3 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 1988 Nov;34(2):89-93. doi: 
      10.1016/0952-3278(88)90068-3.

PMID- 33796492
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 9
DP  - 2021
TI  - Promoting Aspirin Use for Cardiovascular Disease Prevention Among an Adult 
      Internet-Using Population: A Pilot Study.
PG  - 500296
LID - 10.3389/fpubh.2021.500296 [doi]
LID - 500296
AB  - Cardiovascular disease prevention strategies include aspirin use as a preventive 
      measure. The internet can be used to raise public awareness, promote healthy 
      lifestyles, and improve disease management. This pilot study describes the 
      feasibility of an educational website to recruit and follow adult internet users 
      to examine whether they talked to their physician about aspirin and initiated 
      aspirin use. As part of a statewide intervention promoting an aspirin regimen to 
      prevent heart attacks and strokes in Minnesota, visitors to the website were 
      encouraged to complete an aspirin candidacy tool. Between October, 2015 and 
      February, 2016, men 45-79 and women 55-79 who identified as aspirin candidates 
      were invited to participate in a 6-month study involving four, 5 min online 
      surveys to examine physician discussions about aspirin, aspirin use, and mobile 
      technology use. During the 5-month recruitment period, 234 adults enrolled in the 
      study. Of the 174 who completed the baseline survey and at least one follow-up 
      survey, 74 (43.5%) did not use aspirin at baseline. During follow-up, 12 (16.2%) 
      talked to their doctor about aspirin and 31 (41.8%) initiated aspirin use. 
      Internet, social media, and mobile technology use were high among this 
      population. An educational website may have provided a cue to action for aspirin 
      discussions with physicians and aspirin initiation. More research is needed to 
      evaluate the utility of on-line tools to increase appropriate aspirin use among 
      internet-using populations.
CI  - Copyright © 2021 Oldenburg, Horvath, Van't Hof, Misialek and Hirsch.
FAU - Oldenburg, Niki C
AU  - Oldenburg NC
AD  - Lillehei Heart Institute and Cardiovascular Division, University of Minnesota 
      Medical School, Minneapolis, MN, United States.
FAU - Horvath, Keith J
AU  - Horvath KJ
AD  - Division of Epidemiology and Community Health, School of Public Health, 
      University of Minnesota, Minneapolis, MN, United States.
FAU - Van't Hof, Jeremy
AU  - Van't Hof J
AD  - Lillehei Heart Institute and Cardiovascular Division, University of Minnesota 
      Medical School, Minneapolis, MN, United States.
FAU - Misialek, Jeffrey R
AU  - Misialek JR
AD  - Lillehei Heart Institute and Cardiovascular Division, University of Minnesota 
      Medical School, Minneapolis, MN, United States.
FAU - Hirsch, Alan T
AU  - Hirsch AT
AD  - Lillehei Heart Institute and Cardiovascular Division, University of Minnesota 
      Medical School, Minneapolis, MN, United States.
LA  - eng
GR  - R01 HL126041/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210316
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/epidemiology
MH  - Female
MH  - Humans
MH  - Internet
MH  - Male
MH  - Minnesota/epidemiology
MH  - Pilot Projects
PMC - PMC8007760
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular disease
OT  - health education
OT  - internet
OT  - prevention
COIS- NO has received funding from a grant provided by the Council on Aspirin for 
      Health and Prevention for a separate research study. The remaining authors 
      declare that the research was conducted in the absence of any commercial or 
      financial relationships that could be construed as a potential conflict of 
      interest. The reviewer HB declared a shared affiliation, with the authors to the 
      handling editor at the time of the review.
EDAT- 2021/04/03 06:00
MHDA- 2021/05/28 06:00
CRDT- 2021/04/02 06:36
PHST- 2019/09/24 00:00 [received]
PHST- 2021/02/11 00:00 [accepted]
PHST- 2021/04/02 06:36 [entrez]
PHST- 2021/04/03 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - 10.3389/fpubh.2021.500296 [doi]
PST - epublish
SO  - Front Public Health. 2021 Mar 16;9:500296. doi: 10.3389/fpubh.2021.500296. 
      eCollection 2021.

PMID- 2434960
OWN - NLM
STAT- MEDLINE
DCOM- 19870403
LR  - 20161123
IS  - 1011-6206 (Print)
IS  - 1011-6206 (Linking)
VI  - 23
IP  - 4
DP  - 1986 Oct-Dec
TI  - The diagnostic value of intradermal tests with penicilloyl-dextran and 
      aspiryl-polylysine.
PG  - 237-43
AB  - Intradermal tests (i.d.t.) with penicillin (P) and penicilloyl-dextran (P-Dex) 
      were performed in 32 penicillin allergic patients and in 37 controls with allergy 
      to other drugs. The incidence of the positive i.d.t. was much higher in the group 
      of penicillin allergy of immediate type (17 of 18 patients) than in the group of 
      penicillin allergy of half-late or late type (4 of 14 cases). I.d.t. with P and 
      P-Dex were concordant in 75% of cases. Among 28 patients with penicillin allergy 
      tested with both reagents, i.d.t. positive only to P-Dex were found in two cases. 
      The utilisation of i.d.t. with P-Dex or penicilloyl-polylysine (PPL) in 
      penicillin allergy furnishes, therefore, only very modest additional information 
      besides that furnished by i.d.t. performed with plain penicillin. I.d.t. with 
      aspiryl-polylysine (APL) were performed in 23 patients with aspirin 
      allergy/intolerance and in 60 controls with allergy to other drugs. 70% of the 
      individuals with aspirin allergy and 27% of the patients with allergy to other 
      drugs showed positive i.d.t. to APL. Although the specificity of i.d.t. with APL 
      in aspirin allergy seems lower than that of i.d.t. with P-Dex and PPL in 
      penicillin allergy, a positive cutaneous test with APL may constitute an 
      important argument for the allergic nature of an aspirin adverse reaction evoking 
      an allergic mechanism.
FAU - Cîrstea, M
AU  - Cîrstea M
FAU - Cîrje, M
AU  - Cîrje M
FAU - Suhaciu, G
AU  - Suhaciu G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Romania
TA  - Physiologie
JT  - Physiologie (Bucarest)
JID - 7510964
RN  - 0 (Benzeneacetamides)
RN  - 0 (Dextrans)
RN  - 0 (Penicillins)
RN  - 0 (penicilloyl-dextran)
RN  - 87-53-6 (Penicillanic Acid)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aspirin/adverse effects/*analogs & derivatives
MH  - Benzeneacetamides
MH  - *Dextrans
MH  - Drug Evaluation
MH  - Drug Hypersensitivity/diagnosis
MH  - Drug Tolerance
MH  - Humans
MH  - Intradermal Tests/*methods
MH  - Lysine/*analogs & derivatives
MH  - *Penicillanic Acid
MH  - Penicillins/adverse effects
MH  - Skin Tests/*methods
EDAT- 1986/10/01 00:00
MHDA- 1986/10/01 00:01
CRDT- 1986/10/01 00:00
PHST- 1986/10/01 00:00 [pubmed]
PHST- 1986/10/01 00:01 [medline]
PHST- 1986/10/01 00:00 [entrez]
PST - ppublish
SO  - Physiologie. 1986 Oct-Dec;23(4):237-43.

PMID- 3516755
OWN - NLM
STAT- MEDLINE
DCOM- 19860613
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 14
IP  - 2
DP  - 1986
TI  - Diclofenac sodium versus acetylsalicylic acid: a randomized study in febrile 
      patients.
PG  - 95-100
AB  - One hundred and twenty adult patients with high temperatures (greater than or 
      equal to 38 degrees C) brought about by influenza viruses or other conditions 
      were randomly treated with two different antipyretics: a) a 25 mg sodium 
      diclofenac tablet (Novapirina) every 12 hours for 2 consecutive days; b) a 500 mg 
      tablet of acetylsalicylic acid (Aspirin) every 8 hours for 2 consecutive days. 
      Antipyretic action (assessed at 6 hours following the first administration) was 
      found to be equally rapid and consistent in both cases but significantly 
      longer-lasting in the Novapirina-treated group than the Aspirin-treated group (p 
      less than 0.01). Mean temperature changes over the 48 hours of observation and 
      the over-all judgement on the antipyretic effect expressed at the end of each day 
      of treatment were similar for both groups and good in all cases. The 
      antiphlogistic-painkilling properties of both drugs were found to be effective in 
      improving the symptomatology accompanying the high temperature during the course 
      of the bout of influenza. The effectiveness/tolerability ratio was found to be 
      satisfactory for both groups: only one case of gastric intolerance to Novapirina 
      was recorded and five cases of gastric intolerance to Aspirin.
FAU - Bettini, R
AU  - Bettini R
FAU - Grossi, E
AU  - Grossi E
FAU - Rapazzini, P
AU  - Rapazzini P
FAU - Giardina, G
AU  - Giardina G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Diclofenac/administration & dosage/*therapeutic use
MH  - Drug Tolerance
MH  - Female
MH  - Fever/*drug therapy/etiology
MH  - Humans
MH  - Influenza, Human/complications
MH  - Male
MH  - Random Allocation
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1177/030006058601400208 [doi]
PST - ppublish
SO  - J Int Med Res. 1986;14(2):95-100. doi: 10.1177/030006058601400208.

PMID- 31305180
OWN - NLM
STAT- MEDLINE
DCOM- 20191114
LR  - 20191114
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 17
IP  - 8
DP  - 2019 Aug
TI  - An aspirin a day? Clinical utility of aspirin therapy for the primary prevention 
      of cardiovascular disease.
PG  - 561-573
LID - 10.1080/14779072.2019.1642108 [doi]
AB  - Introduction: Cardiovascular disease remains a leading cause of morbidity and 
      mortality. Since the description of its therapeutic potential, aspirin has been a 
      cornerstone of therapy following vascular events. However, aspirin in the primary 
      prevention setting is controversial and major guideline groups provide 
      inconsistent recommendations. Thus, there is variability in practice as providers 
      are faced with a balance of therapeutic benefit and drug-induced harm. Areas 
      covered: This article provides a critical appraisal of both past and present data 
      for aspirin in the primary prevention setting. PubMed and Cochrane Central 
      Register databases were searched from inception to May 1(st), 2019. Expert 
      opinion: The decision to initiate or withdraw aspirin for primary prevention 
      requires an understanding of the equilibrium between efficacy and safety. In 
      adults greater than 70 years of age, low to moderate cardiovascular risk, 
      controlled diabetes, or at high risk of bleeding, initiation of aspirin for 
      primary prevention should generally be avoided. Instead, risk factor modification 
      should be prioritized. The net benefit of aspirin in those at high risk for 
      cardiovascular disease and in those with uncontrolled diabetes is largely 
      unknown. Ultimately, initiation or withdrawal of aspirin therapy must involve 
      discussion of the patient's wishes and treatment expectations.
FAU - Plazak, Michael E
AU  - Plazak ME
AUID- ORCID: 0000-0001-8616-4724
AD  - Department of Pharmacy Practice and Science, University of Maryland School of 
      Pharmacy , Baltimore , MD , USA.
FAU - Mouradjian, Mallory T
AU  - Mouradjian MT
AD  - Department of Pharmacy Practice and Science, University of Maryland School of 
      Pharmacy , Baltimore , MD , USA.
FAU - Watson, Kristin
AU  - Watson K
AD  - Department of Pharmacy Practice and Science, University of Maryland School of 
      Pharmacy , Baltimore , MD , USA.
FAU - Reed, Brent N
AU  - Reed BN
AD  - Department of Pharmacy Practice and Science, University of Maryland School of 
      Pharmacy , Baltimore , MD , USA.
FAU - Noel, Zachary R
AU  - Noel ZR
AD  - Department of Pharmacy Practice and Science, University of Maryland School of 
      Pharmacy , Baltimore , MD , USA.
FAU - Devabhakthuni, Sandeep
AU  - Devabhakthuni S
AD  - Department of Pharmacy Practice and Science, University of Maryland School of 
      Pharmacy , Baltimore , MD , USA.
FAU - Gale, Stormi E
AU  - Gale SE
AD  - Department of Pharmacy Practice and Science, University of Maryland School of 
      Pharmacy , Baltimore , MD , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190718
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus
MH  - Hemorrhage
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Primary Prevention
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - bleeding
OT  - cardiovascular disease
OT  - cerebrovascular disease
OT  - myocardial infarction
OT  - primary prevention
EDAT- 2019/07/16 06:00
MHDA- 2019/11/15 06:00
CRDT- 2019/07/16 06:00
PHST- 2019/07/16 06:00 [pubmed]
PHST- 2019/11/15 06:00 [medline]
PHST- 2019/07/16 06:00 [entrez]
AID - 10.1080/14779072.2019.1642108 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2019 Aug;17(8):561-573. doi: 
      10.1080/14779072.2019.1642108. Epub 2019 Jul 18.

PMID- 32057371
OWN - NLM
STAT- MEDLINE
DCOM- 20200918
LR  - 20200918
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 75
IP  - 6
DP  - 2020 Feb 18
TI  - Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.
PG  - 578-586
LID - S0735-1097(19)38693-0 [pii]
LID - 10.1016/j.jacc.2019.11.056 [doi]
AB  - BACKGROUND: An evolving strategy in the setting of percutaneous coronary 
      intervention (PCI) involves withdrawal of acetylsalicylic acid (ASA), or aspirin, 
      while maintaining P2Y(12) inhibition. However, the pharmacodynamic effects of 
      this approach on blood thrombogenicity and platelet reactivity remain unknown. 
      OBJECTIVES: This study sought to compare the antithrombotic potency of ticagrelor 
      alone versus ticagrelor plus ASA among high-risk patients undergoing PCI with 
      drug-eluting stents. METHODS: This was a mechanistic substudy within the TWILIGHT 
      (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary 
      Intervention) trial, which randomized patients undergoing PCI to ticagrelor plus 
      placebo versus ticagrelor plus ASA following 3 months of dual antiplatelet 
      therapy. Substudy participants were enrolled after randomization, at which time 
      ex vivo assays to quantify thrombus size under dynamic flow conditions and 
      platelet reactivity were performed. Pharmacodynamic assessments were repeated 1 
      to 6 months thereafter. The primary endpoint was thrombus size at the 
      post-randomization visit with platelet reactivity following stimuli to 
      arachidonic acid, collagen, adenosine diphosphate, and thrombin as secondary 
      endpoints. Results were analyzed using analysis of covariance. RESULTS: A total 
      of 51 patients were enrolled, among whom 42 underwent perfusion assays at 
      baseline and follow-up with a median time between studies of 1.5 months. The 
      adjusted mean difference in post-randomization thrombus area was similar between 
      groups: -218.2 μm(2) (95% confidence interval [CI]: -575.9 to 139.9 μm(2); 
      p = 0.22). Markers sensitive to cyclo-oxygenase-1 blockade, including platelet 
      reactivity in response to arachidonic acid (mean difference: 10.9 U; 95% CI: 1.9 
      to 19.9 U) and collagen (mean difference: 9.8 U; 95% CI: 0.8 to 18.8 U) stimuli 
      were higher among patients receiving placebo, whereas levels of platelet 
      reactivity were similar with adenosine diphosphate and thrombin. CONCLUSIONS: 
      Among high-risk patients receiving drug-eluting stents, the antithrombotic 
      potency of ticagrelor monotherapy is similar to that of ticagrelor plus ASA with 
      respect to ex vivo blood thrombogenicity, whereas markers sensitive to 
      cyclo-oxygenase-1 blockade are increased in the absence of ASA. (Platelet 
      Substudy of the TWILIGHT Trial; NCT04001374).
CI  - Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Baber, Usman
AU  - Baber U
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Zafar, M Urooj
AU  - Zafar MU
AD  - Atherothrombosis Research Unit, Icahn School of Medicine at Mount Sinai, New 
      York, New York.
FAU - Dangas, George
AU  - Dangas G
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Escolar, Ginés
AU  - Escolar G
AD  - Atherothrombosis Research Unit, Icahn School of Medicine at Mount Sinai, New 
      York, New York.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - Division of Cardiology, University of Florida College of Medicine, Jacksonville, 
      Florida.
FAU - Sharma, Samin K
AU  - Sharma SK
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Kini, Annapoorna S
AU  - Kini AS
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Sartori, Samantha
AU  - Sartori S
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Joyce, Lauren
AU  - Joyce L
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Vogel, Birgit
AU  - Vogel B
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Farhan, Serdar
AU  - Farhan S
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Gurbel, Paul
AU  - Gurbel P
AD  - Inova Center for Thrombosis Research and Translational Medicine, Falls Church, 
      Virginia.
FAU - Gibson, C Michael
AU  - Gibson CM
AD  - Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical, 
      Harvard Medical School, Boston, Massachusetts.
FAU - Fuster, Valentin
AU  - Fuster V
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New 
      York. Electronic address: roxana.mehran@mountsinai.org.
FAU - Badimon, Juan J
AU  - Badimon JJ
AD  - Atherothrombosis Research Unit, Icahn School of Medicine at Mount Sinai, New 
      York, New York.
LA  - eng
SI  - ClinicalTrials.gov/NCT04001374
GR  - UL1 TR000064/TR/NCATS NIH HHS/United States
GR  - U01 HG007269/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2020 Feb 18;75(6):587-589. PMID: 32057372
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood/drug effects
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Thrombosis/*prevention & control
MH  - Ticagrelor/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - blood thrombogenicity
OT  - platelet aggregation
OT  - ticagrelor
EDAT- 2020/02/15 06:00
MHDA- 2020/09/20 06:00
CRDT- 2020/02/15 06:00
PHST- 2019/10/28 00:00 [received]
PHST- 2019/11/20 00:00 [accepted]
PHST- 2020/02/15 06:00 [entrez]
PHST- 2020/02/15 06:00 [pubmed]
PHST- 2020/09/20 06:00 [medline]
AID - S0735-1097(19)38693-0 [pii]
AID - 10.1016/j.jacc.2019.11.056 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2020 Feb 18;75(6):578-586. doi: 10.1016/j.jacc.2019.11.056.

PMID- 11593836
OWN - NLM
STAT- MEDLINE
DCOM- 20011101
LR  - 20181113
IS  - 0960-1643 (Print)
IS  - 0960-1643 (Linking)
VI  - 51
IP  - 470
DP  - 2001 Sep
TI  - Aspirin use for the prevention of cardiovascular disease: the British Women's 
      Heart and Health Study.
PG  - 743-5
AB  - Low dose aspirin is effective, safe, and economical in the secondary prevention 
      of cardiovascular disease. We have found that only one-third of post-menopausal 
      women with cardiovascular disease are using aspirin and that the majority of 
      women who are using aspirin are doing so for primary prevention. Improvements in 
      this area of medical practice are both necessary and feasible.
FAU - Lawlor, D A
AU  - Lawlor DA
AD  - Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies 
      Road, Bristol BS8 2PR. D.A.Lawlor@bristol.ac.uk
FAU - Bedford, C
AU  - Bedford C
FAU - Taylor, M
AU  - Taylor M
FAU - Ebrahim, S
AU  - Ebrahim S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of 
      General Practitioners
JID - 9005323
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Confidence Intervals
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postmenopause
MH  - United Kingdom
PMC - PMC1314103
EDAT- 2001/10/12 10:00
MHDA- 2001/11/03 10:01
CRDT- 2001/10/12 10:00
PHST- 2001/10/12 10:00 [pubmed]
PHST- 2001/11/03 10:01 [medline]
PHST- 2001/10/12 10:00 [entrez]
PST - ppublish
SO  - Br J Gen Pract. 2001 Sep;51(470):743-5.

PMID- 6792691
OWN - NLM
STAT- MEDLINE
DCOM- 19811118
LR  - 20191031
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - 20
IP  - 2
DP  - 1981 May
TI  - Enteric-coated aspirin in rheumatoid arthritis.
PG  - 116-21
AB  - Sixty patients with active rheumatoid arthritis (mean ESR = 51 mm/h) were treated 
      for six months with D-penicillamine (15 patients), sodium aurothiomalate (15 
      patients), hydroxychloroquine (15 patients) or enteric-coated aspirin (15 
      patients). The three groups receiving specific anti-rheumatoid therapy were also 
      allowed enteric-coated aspirin in the dose of their choice as the only 'back-up' 
      drug; the group treated with aspirin alone was encouraged to take the maximum 
      tolerated dose. The mean duration of treatment tolerated by patients receiving 
      aspirin alone was 12.3 weeks. Only four patients completed a 24-week treatment 
      period and n improvement was seen in acute-phase reactants. Those patients 
      receiving an anti-rheumatoid drug showed serial improvements in ESR as the dose 
      of aspirin required fell. Plasma salicylate concentrations correlated well with 
      aspirin dosage. Even as an enteric-coated formulation, aspirin alone is not the 
      treatment of choice for active rheumatoid disease.
FAU - Bird, H A
AU  - Bird HA
FAU - Rhind, V
AU  - Rhind V
FAU - Leatham, P
AU  - Leatham P
FAU - Saunders, A
AU  - Saunders A
FAU - Wright, V
AU  - Wright V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 12244-57-4 (Gold Sodium Thiomalate)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - GNN1DV99GX (Penicillamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Sedimentation
MH  - Gold Sodium Thiomalate/therapeutic use
MH  - Humans
MH  - Hydroxychloroquine/therapeutic use
MH  - Penicillamine/therapeutic use
MH  - Salicylates/blood
MH  - Tablets, Enteric-Coated
EDAT- 1981/05/01 00:00
MHDA- 1981/05/01 00:01
CRDT- 1981/05/01 00:00
PHST- 1981/05/01 00:00 [pubmed]
PHST- 1981/05/01 00:01 [medline]
PHST- 1981/05/01 00:00 [entrez]
AID - 10.1093/rheumatology/20.2.116 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1981 May;20(2):116-21. doi: 10.1093/rheumatology/20.2.116.

PMID- 7105394
OWN - NLM
STAT- MEDLINE
DCOM- 19821012
LR  - 20191023
IS  - 0009-9090 (Print)
IS  - 0009-9090 (Linking)
VI  - 12
IP  - 3
DP  - 1982 May
TI  - Tartrazine and benzoate challenge and dietary avoidance in chronic asthma.
PG  - 303-12
AB  - This study undertook to determine the usefulness of tartrazine and benzoate 
      challenge and dietary avoidance in the management of patients with chronic 
      asthma. Double-blind ingestion-challenge tests were performed on separate days 
      with lactose, tartrazine, benzoate and acetylsalicyclic acid (ASA). Of the 
      twenty-eight subjects challenged, one responded to tartrazine and one to 
      benzoate. Two additional subjects responded to ASA and a further eight were not 
      tested with this material because of a definite history of sensitivity. 
      Twenty-four subjects completed 1 month periods of observation while first on a 
      normal diet and then while on a tartrazine-benzoate avoidance diet. No 
      improvement occurred during the modified diet in anyone with positive 
      challenge-tests or in all, but one, of those with a history of ASA idiosyncrasy; 
      paradoxically, several of these subjects worsened during this period. We conclude 
      that tartrazine-benzoate dietary avoidance was not of value in the management of 
      the chronic asthmatic in this study, even among patients who respond to challenge 
      with these substances or have ASA idiosyncrasy.
FAU - Tarlo, S M
AU  - Tarlo SM
FAU - Broder, I
AU  - Broder I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Allergy
JT  - Clinical allergy
JID - 0311172
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Azo Compounds)
RN  - 0 (Benzoates)
RN  - I753WB2F1M (Tartrazine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Asthma/*chemically induced/diagnosis/diet therapy
MH  - Azo Compounds/*administration & dosage
MH  - Benzoates/*administration & dosage/adverse effects
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peak Expiratory Flow Rate
MH  - Tartrazine/*administration & dosage/adverse effects
EDAT- 1982/05/01 00:00
MHDA- 1982/05/01 00:01
CRDT- 1982/05/01 00:00
PHST- 1982/05/01 00:00 [pubmed]
PHST- 1982/05/01 00:01 [medline]
PHST- 1982/05/01 00:00 [entrez]
AID - 10.1111/j.1365-2222.1982.tb02532.x [doi]
PST - ppublish
SO  - Clin Allergy. 1982 May;12(3):303-12. doi: 10.1111/j.1365-2222.1982.tb02532.x.

PMID- 22495898
OWN - NLM
STAT- MEDLINE
DCOM- 20121214
LR  - 20181201
IS  - 1098-8785 (Electronic)
IS  - 0735-1631 (Linking)
VI  - 29
IP  - 7
DP  - 2012 Aug
TI  - Early administration of low-dose aspirin for the prevention of severe and mild 
      preeclampsia: a systematic review and meta-analysis.
PG  - 551-6
LID - 10.1055/s-0032-1310527 [doi]
AB  - OBJECTIVE: To determine whether early administration of aspirin prevents severe 
      and mild preeclampsia. STUDY DESIGN: A systematic review and meta-analysis of 
      randomized controlled trials were performed. Studies in which women were 
      randomized at or before 16 weeks' gestation to low-dose aspirin versus placebo or 
      no treatment were included. The outcomes of interest were severe preeclampsia and 
      mild preeclampsia. Pooled relative risks with their 95% confidence intervals 
      (CIs) were calculated. RESULTS: Among 7941 citations retrieved, 352 were 
      completely reviewed and four studies (392 women) fulfilled the inclusion criteria 
      and were analyzed. When compared with controls, aspirin started at ≤16 weeks was 
      associated with a significant reduction in severe (relative risk: 0.22, 95% CI: 
      0.08 to 0.57) but not mild (relative risk: 0.81, 95% CI: 0.33 to 1.96) 
      preeclampsia. CONCLUSION: Low-dose aspirin initiated at or before 16 weeks 
      reduces the risk of severe preeclampsia, but not mild preeclampsia.
CI  - Copyright © 2012 by Thieme Medical Publishers
FAU - Roberge, Stéphanie
AU  - Roberge S
AD  - Department of Social and Preventive Medicine, Faculty of Medicine, Université 
      Laval, Quebec, Canada.
FAU - Giguère, Yves
AU  - Giguère Y
FAU - Villa, Pia
AU  - Villa P
FAU - Nicolaides, Kypros
AU  - Nicolaides K
FAU - Vainio, Merja
AU  - Vainio M
FAU - Forest, Jean-Claude
AU  - Forest JC
FAU - von Dadelszen, Peter
AU  - von Dadelszen P
FAU - Vaiman, Daniel
AU  - Vaiman D
FAU - Tapp, Sylvie
AU  - Tapp S
FAU - Bujold, Emmanuel
AU  - Bujold E
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20120411
PL  - United States
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Am J Perinatol. 2014 Jun;31(6):e3. von Dadelzen, Peter [corrected to von 
      Dadelszen, Peter]
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Severity of Illness Index
EDAT- 2012/04/13 06:00
MHDA- 2012/12/15 06:00
CRDT- 2012/04/13 06:00
PHST- 2012/04/13 06:00 [entrez]
PHST- 2012/04/13 06:00 [pubmed]
PHST- 2012/12/15 06:00 [medline]
AID - 10.1055/s-0032-1310527 [doi]
PST - ppublish
SO  - Am J Perinatol. 2012 Aug;29(7):551-6. doi: 10.1055/s-0032-1310527. Epub 2012 Apr 
      11.

PMID- 8477912
OWN - NLM
STAT- MEDLINE
DCOM- 19930525
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 23
IP  - 1
DP  - 1993
TI  - Effects of aspirin on embolization in an arterial model of laser-induced thrombus 
      formation.
PG  - 8-12
AB  - This model of arterial thrombosis induced by laser was used to evaluate the 
      effect of aspirin (Aspegic) on embolization. A partial occlusion was induced in 
      small mesenteric arterioles (diameter 35-40 microns) with an Argon Laser. The 
      laser induced the formation of a vessel wall lesion with damage of endothelial 
      cells. Thrombus formed within seconds after the laser lesion and grew rapidly. 
      Embolization began within the minute following the laser flash. Thrombus 
      formation and embolization were repetitive phenomena. The duration of 
      embolization was 6.50 +/- 0.84 min in the control group. Then the thrombus became 
      stable and partially obstructed the vessel lumen. The administration of aspirin 
      at three doses (50, 100, 200 mg/kg) by intramuscular injection, 15 min before the 
      laser injury, induced three different phenomena: (1) an increase of the number of 
      laser injuries required for the thrombus formation; (2) a dose-dependent decrease 
      in the duration of embolization, and (3) a dose-dependent decrease in the number 
      of emboli. The highest dose injected induced the strongest reduction in the 
      duration of embolization and the number of emboli.
FAU - Vesvres, M H
AU  - Vesvres MH
AD  - Laboratoire d'Hématologie, CJF INSERM 88/13, Bordeaux, France.
FAU - Doutremepuich, F
AU  - Doutremepuich F
FAU - Lalanne, M C
AU  - Lalanne MC
FAU - Doutremepuich, C
AU  - Doutremepuich C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Arterioles/injuries
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - *Disease Models, Animal
MH  - Embolism/etiology/*prevention & control
MH  - Lasers/*adverse effects
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Thrombosis/*complications
MH  - Time Factors
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1159/000216846 [doi]
PST - ppublish
SO  - Haemostasis. 1993;23(1):8-12. doi: 10.1159/000216846.

PMID- 2657048
OWN - NLM
STAT- MEDLINE
DCOM- 19890705
LR  - 20151119
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 16
IP  - 3
DP  - 1989 Mar
TI  - Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of 
      salicylic acid in the treatment of rheumatoid arthritis? The Multicenter 
      Salsalate/Aspirin Comparison Study Group.
PG  - 321-7
AB  - In a multicenter, double blind, parallel group study, 233 patients with classical 
      or definite rheumatoid arthritis (RA) were randomized to 12 weeks of either 
      salsalate (salicylsalicylic acid, nonacetylated salicylate) or aspirin following 
      disease flare. One hundred-fifty patients completed, 83 taking salsalate and 67 
      taking aspirin. Patients received initial doses of 3 g/day of salsalate or 3.6 
      g/day of aspirin. Doses were adjusted during the first 5 weeks for efficacy and 
      tolerance. Both treatments were equally effective as measured by all the usual 
      variables, but there was a higher incidence of severe gastrointestinal problems 
      among patients taking aspirin. Thus, this study demonstrated that the acetyl 
      group of aspirin does not enhance the antiinflammatory efficacy of salicylic acid 
      in RA.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - V9MO595C9I (salicylsalicylic acid)
SB  - IM
MH  - Acetylation
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Random Allocation
MH  - Salicylates/administration & dosage/adverse effects/*therapeutic use
MH  - Therapeutic Equivalency
EDAT- 1989/03/01 00:00
MHDA- 1989/03/01 00:01
CRDT- 1989/03/01 00:00
PHST- 1989/03/01 00:00 [pubmed]
PHST- 1989/03/01 00:01 [medline]
PHST- 1989/03/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1989 Mar;16(3):321-7.

PMID- 22425676
OWN - NLM
STAT- MEDLINE
DCOM- 20120927
LR  - 20131121
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 428
IP  - 1-2
DP  - 2012 May 30
TI  - Small- and wide-angle X-ray scattering (SWAXS) for quantification of aspirin 
      content in a binary powder mixture.
PG  - 91-5
LID - 10.1016/j.ijpharm.2012.02.048 [doi]
AB  - This article presents a novel application of small and wide angle X-ray 
      scattering (SWAXS) in the assessment of aspirin and lactose content in a binary 
      pharmaceutical powder formulation. It is shown that the content correlates with 
      the intensity of the SAXS signal and the intensity of polymorph fingerprints in 
      the WAXS spectra that are collected from the same samples. Because the polymorph 
      WAXS fingerprints and the SAXS signal are two independent characteristics of the 
      same sample, simultaneous SWAXS analysis provides the basis for a dual 
      independent assessment of the same contents.
CI  - Copyright © 2012 Elsevier B.V. All rights reserved.
FAU - Hodzic, A
AU  - Hodzic A
AD  - Research Center Pharmaceutical Engineering GmbH, A-8010 Graz, Austria.
FAU - Llusa, M
AU  - Llusa M
FAU - Fraser, S D
AU  - Fraser SD
FAU - Scheibelhofer, O
AU  - Scheibelhofer O
FAU - Koller, D M
AU  - Koller DM
FAU - Reiter, F
AU  - Reiter F
FAU - Laggner, P
AU  - Laggner P
FAU - Khinast, J G
AU  - Khinast JG
LA  - eng
PT  - Journal Article
DEP - 20120308
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Powders)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Lactose/chemistry
MH  - Particle Size
MH  - Powders/*chemistry
MH  - *Scattering, Small Angle
MH  - X-Ray Diffraction/*methods
MH  - X-Rays
EDAT- 2012/03/20 06:00
MHDA- 2012/09/28 06:00
CRDT- 2012/03/20 06:00
PHST- 2011/12/06 00:00 [received]
PHST- 2012/01/31 00:00 [revised]
PHST- 2012/02/26 00:00 [accepted]
PHST- 2012/03/20 06:00 [entrez]
PHST- 2012/03/20 06:00 [pubmed]
PHST- 2012/09/28 06:00 [medline]
AID - S0378-5173(12)00198-6 [pii]
AID - 10.1016/j.ijpharm.2012.02.048 [doi]
PST - ppublish
SO  - Int J Pharm. 2012 May 30;428(1-2):91-5. doi: 10.1016/j.ijpharm.2012.02.048. Epub 
      2012 Mar 8.

PMID- 37051996
OWN - NLM
STAT- MEDLINE
DCOM- 20230414
LR  - 20230414
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 73
IP  - 4
DP  - 2023 Apr
TI  - Role of aspirin in the prevention of preeclampsia in previously hypertensive 
      pregnant women: A Meta-Analysis.
PG  - 838-842
LID - 10.47391/JPMA.5544 [doi]
AB  - OBJECTIVE: To determine the role of low-dose aspirin in preventing preeclampsia 
      for previously hypertensive pregnant women. METHODS: The meta-analysis was 
      conducted from February to May 2021 and comprised search on PubMed and Cochrane 
      Library databases for randomised controlled trials consisting of previously 
      hypertensive women aged 18-55 years, aspirin dosage range 60-100mg, and a 
      comparison between aspirin and placebo groups. Duration of intervention till the 
      end of gestation, the dosage of aspirin given, risk ratios or odds ratio with the 
      confidence intervals, and preeclampsia were the main variables recorded. Data was 
      analysed using RevMan 5.4. RESULTS: Of the 144 articles found, 4(%) were 
      included, having 2238 participants. Pooled estimates revealed that aspirin, 
      compared to placebo, did not significantly reduce the manifestation of 
      preeclampsia (p=0.06). Besides, heterogeneity between the different trials was 
      moderate at 59%. CONCLUSIONS: Aspirin was not found to substantially diminish the 
      risk of incidence of preeclampsia, but it did show some beneficial effects. .
FAU - Ashraf Jahangeer, Syed Muhammad
AU  - Ashraf Jahangeer SM
AD  - Department of Community Medicine, Dow Medical College, Dow University of Health 
      Sciences, Karachi, Pakistan.
FAU - Khan, Asma Ashraf
AU  - Khan AA
AD  - 2nd Year MBBS Student, Dow Medical College, Dow University Health Sciences, 
      Karachi, Pakistan.
FAU - Mansoor, Mahnoor
AU  - Mansoor M
AD  - 2nd Year MBBS Student, Dow Medical College, Dow University Health Sciences, 
      Karachi, Pakistan.
LA  - eng
PT  - Meta-Analysis
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Female
MH  - Pregnancy
MH  - Humans
MH  - Aspirin/therapeutic use
MH  - *Pre-Eclampsia/prevention & control
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Pregnant Women
MH  - *Hypertension/drug therapy
OTO - NOTNLM
OT  - Preeclampsia, Low-dose aspirin, Hypertensive pregnant women.
EDAT- 2023/04/14 06:00
MHDA- 2023/04/14 06:41
CRDT- 2023/04/13 05:23
PHST- 2023/04/14 06:41 [medline]
PHST- 2023/04/13 05:23 [entrez]
PHST- 2023/04/14 06:00 [pubmed]
AID - 11932 [pii]
AID - 10.47391/JPMA.5544 [doi]
PST - ppublish
SO  - J Pak Med Assoc. 2023 Apr;73(4):838-842. doi: 10.47391/JPMA.5544.

PMID- 11060172
OWN - NLM
STAT- MEDLINE
DCOM- 20001220
LR  - 20190501
IS  - 0032-5473 (Print)
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 76
IP  - 901
DP  - 2000 Nov
TI  - The real cost of aspirin.
PG  - 734-5
AB  - Aspirin is a widely used drug and perceived by most physicians to be inexpensive. 
      High rates of concurrent gastroprotective agents are reported from a study of 
      cardiology outpatients. Aspirin takers are more likely to also be taking a proton 
      pump inhibitor, H(2) antagonist, or antacid than non-aspirin takers. They are 
      more than 10 times as likely to be experiencing upper gastrointestinal symptoms. 
      Although aspirin is inexpensive, it is emphasised that the overall cost 
      implications for therapy can be significant and it is suggested that it may be 
      more appropriate to consider the use of alternative antiplatelet agents in 
      patients who tolerate aspirin poorly.
FAU - Burgess, M I
AU  - Burgess MI
AD  - Department of Cardiology, Wythenshawe Hospital, Southmoor Road, Manchester M23 
      9LT, UK. MalcB10@aol.com
FAU - Densem, C G
AU  - Densem CG
FAU - Brooks, N H
AU  - Brooks NH
FAU - Levy, R D
AU  - Levy RD
FAU - Lee, H S
AU  - Lee HS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Postgrad Med J. 2001 Jun;77(908):423. PMID: 11409387
MH  - Aged
MH  - Aspirin/adverse effects/*economics
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Gastrointestinal Agents/economics/therapeutic use
MH  - Gastrointestinal Diseases/chemically induced/drug therapy/economics
MH  - Health Care Costs
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/adverse effects/*economics
MH  - Prospective Studies
PMC - PMC1741813
EDAT- 2000/11/04 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/04 11:00
PHST- 2000/11/04 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/04 11:00 [entrez]
AID - 10.1136/pmj.76.901.734 [doi]
PST - ppublish
SO  - Postgrad Med J. 2000 Nov;76(901):734-5. doi: 10.1136/pmj.76.901.734.

PMID- 16097693
OWN - NLM
STAT- MEDLINE
DCOM- 20100610
LR  - 20131121
IS  - 1000-0593 (Print)
IS  - 1000-0593 (Linking)
VI  - 25
IP  - 4
DP  - 2005 Apr
TI  - [Simultaneous determination of aspirin and salicyclic acid by synchronous 
      fluorescence spectrometry].
PG  - 588-90
AB  - A simple, rapid and inexpensive fluorimetric method for simultaneously 
      determining ASA and SA in a single scan of the co-existing specimen had been 
      established. When the wavelength interval (delta lambda) is 80 nm for scaning, 
      the amounts of ASA and AS could be quantitatively determined respectively. The 
      fluorescence intensity was linearly related to the aspirin concentration in the 
      range of 4.0 x 10(-6)-1.0 x 10(-4) mol x L(-1) with correlation coefficient 
      0.9949; the fluorescence intensity was linearly related to the salicyclic acid 
      concentration in the range of 8.0 x 10(-7)-1.0 x 10(-4) mol x L(-1) with 
      correlation coefficient 0.9975, the determination limit was 4.0 x 10(-7) mol x 
      L(-1). The method is simple, rapid and inexpensive, it can be used for medicament 
      analysis.
FAU - Wei, Yong-feng
AU  - Wei YF
AD  - Department of Chemistry, Northwest University, Xi'an, China.
FAU - Li, Xiao-hua
AU  - Li XH
FAU - Ma, Dong-mei
AU  - Ma DM
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Guang Pu Xue Yu Guang Pu Fen Xi
JT  - Guang pu xue yu guang pu fen xi = Guang pu
JID - 9424805
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Reproducibility of Results
MH  - Salicylates/*analysis
MH  - Spectrometry, Fluorescence/*methods
EDAT- 2005/08/16 09:00
MHDA- 2010/06/11 06:00
CRDT- 2005/08/16 09:00
PHST- 2005/08/16 09:00 [pubmed]
PHST- 2010/06/11 06:00 [medline]
PHST- 2005/08/16 09:00 [entrez]
PST - ppublish
SO  - Guang Pu Xue Yu Guang Pu Fen Xi. 2005 Apr;25(4):588-90.

PMID- 21647198
OWN - NLM
STAT- MEDLINE
DCOM- 20111104
LR  - 20211020
IS  - 1759-5053 (Electronic)
IS  - 1759-5045 (Linking)
VI  - 8
IP  - 7
DP  - 2011 Jun 7
TI  - Gastrointestinal effects of aspirin.
PG  - 385-94
LID - 10.1038/nrgastro.2011.97 [doi]
AB  - Aspirin is being used as an effective analgesic and anti-inflammatory agent at 
      doses >325 mg daily. At low doses (75-325 mg daily), aspirin is the key 
      antiplatelet drug in the pharmacological prevention of cardiovascular diseases. 
      Topical and systemic effects of aspirin in the gastrointestinal mucosa are 
      associated with mucosal damage in the upper and lower gastrointestinal tract. The 
      risk of upper gastrointestinal bleeding with aspirin is increased with old age, 
      male sex, ulcer history and concomitant medication with NSAIDs, cyclooxygenase 2 
      selective inhibitors, corticosteroids or other antithrombotic agents. In some 
      patients, the cardiovascular benefits of low-dose aspirin might be overcome by 
      the risk of gastrointestinal complications, but withdrawal of aspirin therapy can 
      precipitate a cardiovascular event. These patients will need concomitant therapy 
      with antisecretory agents, especially PPIs, to reduce the gastrointestinal risk. 
      Eradication of Helicobacter pylori infection might be an additional option in 
      patients with a history of ulcer. Furthermore, there is growing evidence that 
      long-term use of aspirin decreases the risk of colorectal cancer, even at low 
      doses. As aspirin is one of the most prescribed drugs worldwide and its clinical 
      impact is huge, physicians need to consider the benefits and harms for each 
      individual patient in order to maximize the benefits of aspirin.
FAU - Sostres, Carlos
AU  - Sostres C
AD  - Servico de Aparato Digestivo, Hospital Clínico Univeristario Lozano Blesa, C/San 
      Juan Bosco 15, 50009 Zaragoza, Spain.
FAU - Lanas, Angel
AU  - Lanas A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110607
PL  - England
TA  - Nat Rev Gastroenterol Hepatol
JT  - Nature reviews. Gastroenterology & hepatology
JID - 101500079
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology/therapeutic 
      use
MH  - Aspirin/*adverse effects/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Gastric Mucosa/drug effects/pathology
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Helicobacter Infections/complications
MH  - Humans
MH  - Risk Factors
MH  - Stomach Ulcer/*chemically induced/epidemiology
EDAT- 2011/06/08 06:00
MHDA- 2011/11/05 06:00
CRDT- 2011/06/08 06:00
PHST- 2011/06/08 06:00 [entrez]
PHST- 2011/06/08 06:00 [pubmed]
PHST- 2011/11/05 06:00 [medline]
AID - nrgastro.2011.97 [pii]
AID - 10.1038/nrgastro.2011.97 [doi]
PST - epublish
SO  - Nat Rev Gastroenterol Hepatol. 2011 Jun 7;8(7):385-94. doi: 
      10.1038/nrgastro.2011.97.

PMID- 11773732
OWN - NLM
STAT- MEDLINE
DCOM- 20020207
LR  - 20190812
IS  - 0148-7043 (Print)
IS  - 0148-7043 (Linking)
VI  - 48
IP  - 1
DP  - 2002 Jan
TI  - Heat shock protein and high-dose aspirin: effects on random skin flap survival in 
      a rat model.
PG  - 60-7
AB  - The heat shock response is known to have a protective effect against flap 
      ischemia. It has been shown that heat shock protein (hsp) expression can be 
      augmented in vivo with the administration of high-dose aspirin before heat 
      treatment. The authors hypothesized that administration of aspirin before hsp 
      induction through heat stress would enhance further the protective effects of the 
      heat shock response against skin flap ischemia. They used a random dorsal skin 
      flap model in 32 rats divided into four groups (N = 8 each): control, heat shock, 
      aspirin plus heat shock, and aspirin. Before surgery, rats in the two heat shock 
      groups were placed in a 45 degrees C water bath until core body temperature 
      measured 42 degrees C, and they were maintained at 42 degrees C for 15 minutes. 
      Rats in the two aspirin groups received a single oral dose of aspirin (100 mg per 
      kilogram) 1 hour before heat bath or surgery. Immunohistochemistry confirmed hsp 
      expression in the two heat groups. Skin flap survival was improved significantly 
      (p < 0.05) in the heat shock (55%), aspirin plus heat shock (58%), and aspirin 
      (60%) groups when compared with controls (45%). Contrary to their hypothesis, 
      aspirin combined with hsp induction did not offer greater protection from 
      ischemia than hsp induction alone (p > 0.05). However, high-dose aspirin 
      administration alone did improve skin flap survival when compared with controls. 
      Future studies are needed to investigate further the role of pharmacological 
      therapy combined with hsp induction in improving skin flap survival and to 
      delineate the dose-response relationship between aspirin and hsp.
FAU - Ghavami, Ashkan
AU  - Ghavami A
AD  - Department of Surgery, Division of Plastic and Reconstructive Surgery, University 
      of Wisconsin Medical School, H4/397 Clinical Science Center, 600 Highland Avenue, 
      Madison, WI 53792, USA.
FAU - Nutt, Mary P
AU  - Nutt MP
FAU - Hardy, Stephen P
AU  - Hardy SP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Plast Surg
JT  - Annals of plastic surgery
JID - 7805336
RN  - 0 (HSP70 Heat-Shock Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - *Graft Survival/drug effects/physiology
MH  - HSP70 Heat-Shock Proteins/biosynthesis/drug effects/*physiology
MH  - Hot Temperature
MH  - Immunohistochemistry
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Skin/metabolism
MH  - Skin Transplantation/physiology
MH  - *Surgical Flaps/physiology
EDAT- 2002/01/05 10:00
MHDA- 2002/02/08 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/02/08 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
AID - 10.1097/00000637-200201000-00009 [doi]
PST - ppublish
SO  - Ann Plast Surg. 2002 Jan;48(1):60-7. doi: 10.1097/00000637-200201000-00009.

PMID- 24246172
OWN - NLM
STAT- MEDLINE
DCOM- 20140930
LR  - 20141124
IS  - 1743-9159 (Electronic)
IS  - 1743-9159 (Linking)
VI  - 12
IP  - 5
DP  - 2014
TI  - Should patients taking aspirin for secondary prevention continue or discontinue 
      the medication prior to elective, abdominal surgery? Best evidence topic (BET).
PG  - 16-21
LID - S1743-9191(13)01096-0 [pii]
LID - 10.1016/j.ijsu.2013.11.004 [doi]
AB  - This best evidence topic was investigated according to a described protocol. The 
      question asked was: should patients on acetylsalicylic acid (ASA) for secondary 
      prevention stop or continue the medication prior to elective, abdominal surgery. 
      Using the reported search 826 papers were found of which five represented the 
      best evidence to answer the clinical question. The strongest evidence was from a 
      randomized controlled trial (RCT) specifically looking at elective abdominal 
      surgery, which showed no statistically significant difference between ASA 
      continuation and discontinuation in terms of haemorrhagic or thrombotic events. 
      Two other RCT's examined elective non-cardiac surgery but only a minor proportion 
      (20.6% and 23.6%) of patients underwent abdominal surgery and data were 
      unavailable regarding adverse events in these patients. However, one of these 
      trials did show a 7.2% absolute risk reduction in postoperative cardiac adverse 
      events when ASA was continued. One prospective cohort study found no difference 
      between ASA maintenance and cessation except for longer duration of surgery in 
      the ASA continuation group. Finally one recent retrospective cohort study 
      revealed similar bleeding rates between ASA-treated and non-ASA-treated patients 
      but increased cardiac complication rates in the ASA group. Only two studies 
      compared continuation versus discontinuation of ASA, while the remaining three 
      looked at patients on ASA versus those not on ASA. This heterogeneity in 
      methodology makes it difficult to draw justifiable conclusions from the data. 
      However, it appears that continuing ASA isn't associated with excessive bleeding. 
      Further adequately powered trials with well-defined end points are needed to 
      answer this important clinical question.
CI  - Copyright © 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights 
      reserved.
FAU - Sahebally, Shaheel M
AU  - Sahebally SM
AD  - Department of Surgery, University Hospital Limerick, Ireland.
FAU - Healy, Donagh
AU  - Healy D
AD  - Department of Surgery, University Hospital Limerick, Ireland.
FAU - Coffey, J Calvin
AU  - Coffey JC
AD  - Department of Surgery, University Hospital Limerick, Ireland.
FAU - Walsh, Stewart R
AU  - Walsh SR
AD  - Department of Surgery, University Hospital Limerick, Ireland. Electronic address: 
      stewart.walsh@ul.ie.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131115
PL  - United States
TA  - Int J Surg
JT  - International journal of surgery (London, England)
JID - 101228232
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdomen/*surgery
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Elective Surgical Procedures/*methods
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Secondary Prevention/methods/*statistics & numerical data
MH  - Thrombosis/drug therapy/prevention & control
OTO - NOTNLM
OT  - Abdominal surgery
OT  - Acetylsalicylic acid
OT  - Bleeding
OT  - Elective
OT  - Thrombotic events
EDAT- 2013/11/20 06:00
MHDA- 2014/10/01 06:00
CRDT- 2013/11/20 06:00
PHST- 2013/08/15 00:00 [received]
PHST- 2013/10/07 00:00 [revised]
PHST- 2013/11/02 00:00 [accepted]
PHST- 2013/11/20 06:00 [entrez]
PHST- 2013/11/20 06:00 [pubmed]
PHST- 2014/10/01 06:00 [medline]
AID - S1743-9191(13)01096-0 [pii]
AID - 10.1016/j.ijsu.2013.11.004 [doi]
PST - ppublish
SO  - Int J Surg. 2014;12(5):16-21. doi: 10.1016/j.ijsu.2013.11.004. Epub 2013 Nov 15.

PMID- 3617157
OWN - NLM
STAT- MEDLINE
DCOM- 19870828
LR  - 20190903
IS  - 0163-4356 (Print)
IS  - 0163-4356 (Linking)
VI  - 9
IP  - 2
DP  - 1987 Jun
TI  - Corticosteroids-salicylate interaction in a case of juvenile rheumatoid 
      arthritis.
PG  - 177-9
AB  - In an 11-year-old child with juvenile rheumatoid arthritis (JRA), the addition of 
      prednisone caused a significant decrease in salicylate serum concentrations. A 
      pharmacokinetic assessment suggested that these changes were not the result of 
      altered compliance or impaired absorption of salicylate but rather an increase in 
      salicylate clearance induced by the corticosteroid.
FAU - Koren, G
AU  - Koren G
FAU - Roifman, C
AU  - Roifman C
FAU - Gelfand, E
AU  - Gelfand E
FAU - Lavi, S
AU  - Lavi S
FAU - Suria, D
AU  - Suria D
FAU - Stein, L
AU  - Stein L
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ther Drug Monit
JT  - Therapeutic drug monitoring
JID - 7909660
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/administration & dosage/metabolism
MH  - Child
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Prednisone/administration & dosage/*pharmacology
MH  - Salicylates/*metabolism
EDAT- 1987/06/01 00:00
MHDA- 1987/06/01 00:01
CRDT- 1987/06/01 00:00
PHST- 1987/06/01 00:00 [pubmed]
PHST- 1987/06/01 00:01 [medline]
PHST- 1987/06/01 00:00 [entrez]
AID - 10.1097/00007691-198706000-00009 [doi]
PST - ppublish
SO  - Ther Drug Monit. 1987 Jun;9(2):177-9. doi: 10.1097/00007691-198706000-00009.

PMID- 17803242
OWN - NLM
STAT- MEDLINE
DCOM- 20080325
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 31
IP  - 1
DP  - 2008 Jan
TI  - The role of aspirin resistance in the treatment of acute coronary syndromes.
PG  - 11-7
AB  - The TIMI Risk Score recognizes prior aspirin use as an independent risk factor 
      for adverse outcomes in subjects presenting with an acute coronary syndrome. The 
      etiology of this increased risk awaits clarification, but prior aspirin use may 
      be associated with altered thrombus composition which is more resistant to 
      current treatment modalities as compared to thrombus formation in subjects 
      without prior aspirin use. Post hoc analysis of acute coronary syndrome trials 
      has shown that prior aspirin users treated with unfractionated heparin are at 
      particularly high risk. The addition of glycoprotein IIb/IIIa receptor inhibitor 
      to unfractionated heparin or substitution of low-molecular-weight heparin 
      significantly improves outcomes in prior aspirin users. The prognostic 
      significance of prior aspirin use in acute coronary syndromes has important 
      implications not only in clinical practice, but also in the design and 
      interpretation of clinical trials.
CI  - 2007 Wiley Periodicals, Inc
FAU - Lancaster, Gilead I
AU  - Lancaster GI
AD  - Department of Medicine, Division of Cardiovascular Medicine, Department of 
      Medicine, Bridgeport Hospital, Bridgeport, Connecticut 06610, USA. 
      pglanc@bpthosp.org
FAU - Jain, Hitender
AU  - Jain H
FAU - Zarich, Stuart W
AU  - Zarich SW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Syndrome
MH  - Treatment Outcome
PMC - PMC6653551
EDAT- 2007/09/07 09:00
MHDA- 2008/03/26 09:00
CRDT- 2007/09/07 09:00
PHST- 2007/09/07 09:00 [pubmed]
PHST- 2008/03/26 09:00 [medline]
PHST- 2007/09/07 09:00 [entrez]
AID - CLC20157 [pii]
AID - 10.1002/clc.20157 [doi]
PST - ppublish
SO  - Clin Cardiol. 2008 Jan;31(1):11-7. doi: 10.1002/clc.20157.

PMID- 17900952
OWN - NLM
STAT- MEDLINE
DCOM- 20080327
LR  - 20131121
IS  - 1093-3263 (Print)
IS  - 1093-3263 (Linking)
VI  - 26
IP  - 6
DP  - 2008 Feb
TI  - Visualizing the locality of intermolecular interactions in organic crystals.
PG  - 962-5
AB  - Density functional theory (DFT) provides a rigorous theoretical framework for 
      analyzing and interpreting electronic structures of molecules and crystals. One 
      electron density-based concept is the Fukui function, which describes the 
      responding sensitivity of a molecular system to electronic perturbations. As a 
      local property, the Fukui function is directly associated with local 
      polarizability, so it may be capable of describing the intermolecular interaction 
      in an organic crystal with regard to molecular packing. Herein, we demonstrate 
      such an application to the aspirin single crystal and discuss potentials of the 
      DFT-based concepts for studying electronic structures of organic crystals.
FAU - Li, Tonglei
AU  - Li T
AD  - Department of Pharmaceutical Sciences, 514 College of Pharmacy, University of 
      Kentucky, 725 Rose Street, Lexington, KY 40536-0082, United States. 
      tonglei@uky.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20070810
PL  - United States
TA  - J Mol Graph Model
JT  - Journal of molecular graphics & modelling
JID - 9716237
RN  - 0 (Organic Chemicals)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Computational Biology/methods
MH  - Crystallization
MH  - Electronics
MH  - Electrons
MH  - Models, Chemical
MH  - Models, Molecular
MH  - Organic Chemicals/*chemistry
MH  - Static Electricity
MH  - Surface Properties
EDAT- 2007/09/29 09:00
MHDA- 2008/03/28 09:00
CRDT- 2007/09/29 09:00
PHST- 2007/01/16 00:00 [received]
PHST- 2007/08/04 00:00 [revised]
PHST- 2007/08/05 00:00 [accepted]
PHST- 2007/09/29 09:00 [pubmed]
PHST- 2008/03/28 09:00 [medline]
PHST- 2007/09/29 09:00 [entrez]
AID - S1093-3263(07)00135-0 [pii]
AID - 10.1016/j.jmgm.2007.08.001 [doi]
PST - ppublish
SO  - J Mol Graph Model. 2008 Feb;26(6):962-5. doi: 10.1016/j.jmgm.2007.08.001. Epub 
      2007 Aug 10.

PMID- 2344984
OWN - NLM
STAT- MEDLINE
DCOM- 19900703
LR  - 20131121
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 118
IP  - 5
DP  - 1990 Mar 1
TI  - [Loeffler syndrome in a child treated with aspirin].
PG  - 262-4
AB  - A 5-year-old girl was treated with acetyl-salicylic acid (Aspirin) for 3 months 
      because rheumatic disease was suspected. She developed hemoptysis which was later 
      followed by the clinical and roentgenological findings of Loeffler's syndrome.
FAU - Sandhaus, Y
AU  - Sandhaus Y
AD  - Dept. of Pediatrics, Laniado Hospital, Kiryat Sanz, Netanya.
FAU - Weisbrod, M
AU  - Weisbrod M
FAU - Schreiber, M
AU  - Schreiber M
LA  - heb
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Pulmonary Eosinophilia/*chemically induced
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
PST - ppublish
SO  - Harefuah. 1990 Mar 1;118(5):262-4.

PMID- 7010003
OWN - NLM
STAT- MEDLINE
DCOM- 19810513
LR  - 20131213
IS  - 0025-6196 (Print)
IS  - 0025-6196 (Linking)
VI  - 56
IP  - 3
DP  - 1981 Mar
TI  - 10. Antithrombotic therapy: role of platelet-inhibitor drugs. II. Pharmacologic 
      effects of platelet-inhibitor drugs (second of three parts).
PG  - 185-95
AB  - In this three-part series, the first part described the role of platelets in 
      thrombogenesis, this second part considers the pharmacologic effects of 
      platelet-inhibitor drugs, and the third part will discuss their clinical 
      application. This second article comprises (1) the physiologic contribution of 
      the vessel wall to the prevention of thrombosis, particularly the role of 
      prostacyclin, (2) the mechanisms of action of platelet-inhibitor drugs in the 
      prevention of thrombosis, (3) the ideal dose and ideal therapeutic combinations 
      of conventional platelet-inhibitor drugs, (4) other agents and new agents that 
      inhibit platelet function, and (5) drug side effects.
FAU - Fuster, V
AU  - Fuster V
FAU - Chesebro, J H
AU  - Chesebro JH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Prostaglandins)
RN  - 64ALC7F90C (Dipyridamole)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Dipyridamole/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Epoprostenol/*therapeutic use
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandins/*therapeutic use
MH  - Sulfinpyrazone/adverse effects/therapeutic use
MH  - Thrombosis/drug therapy/*prevention & control
RF  - 171
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
PST - ppublish
SO  - Mayo Clin Proc. 1981 Mar;56(3):185-95.

PMID- 8384187
OWN - NLM
STAT- MEDLINE
DCOM- 19930422
LR  - 20140603
VI  - 17 Suppl 1
DP  - 1993 Feb
TI  - Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human 
      obesity.
PG  - S73-8
AB  - The safety and efficacy of a mixture of ephedrine (75-150mg), caffeine (150mg) 
      and aspirin (330mg), in divided premeal doses, were investigated in 24 obese 
      humans (mean BMI 37.0) in a randomized double blind placebo-controlled trial. 
      Energy intake was not restricted. Overall weight loss over 8 weeks was 2.2kg for 
      ECA vs. 0.7 kg for placebo (p < 0.05). 8 of 13 placebo subjects returned 5 months 
      later and received ECA in an unblinded crossover. After 8 weeks, mean weight loss 
      with ECA was 3.2 kg vs 1.3 kg for placebo (p = 0.036). 6 subjects continued on 
      ECA for 7 to 26 months. After 5 months on ECA, average weight loss in 5 of these 
      was 5.2 kg compared to 0.03 kg gained during 5 months between studies with no 
      intervention (p = 0.03). The sixth subject lost 66 kg over 13 months by 
      self-imposed caloric restriction. In all studies, no significant changes in heart 
      rate, blood pressure, blood glucose, insulin, and cholesterol levels, and no 
      differences in the frequency of side effects were found. ECA in these doses is 
      thus well tolerated in otherwise healthy obese subjects, and supports modest, 
      sustained weight loss even without prescribed caloric restriction, and may be 
      more effective in conjunction with restriction of energy intake.
FAU - Daly, P A
AU  - Daly PA
AD  - Dept of Medicine, Harvard Medical School, Boston.
FAU - Krieger, D R
AU  - Krieger DR
FAU - Dulloo, A G
AU  - Dulloo AG
FAU - Young, J B
AU  - Young JB
FAU - Landsberg, L
AU  - Landsberg L
LA  - eng
GR  - M01 RR01032/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Int J Obes Relat Metab Disord
JT  - International journal of obesity and related metabolic disorders : journal of the 
      International Association for the Study of Obesity
JID - 9313169
RN  - 3G6A5W338E (Caffeine)
RN  - GN83C131XS (Ephedrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Caffeine/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Energy Intake
MH  - Ephedrine/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Obesity/*drug therapy
MH  - Weight Loss
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
PST - ppublish
SO  - Int J Obes Relat Metab Disord. 1993 Feb;17 Suppl 1:S73-8.

PMID- 35256843
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20220405
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 16
DP  - 2022
TI  - Alleviating Aspirin-Induced Gastric Injury by Binding Aspirin to β-Lactoglobulin.
PG  - 571-586
LID - 10.2147/DDDT.S351100 [doi]
AB  - PURPOSE: Gastric injury is a major issue for long-term administration of aspirin. 
      In this work, we tried to explore the possibility of using BLG to alleviate 
      aspirin-induced gastric injury, because of excellent abilities of BLG in loading 
      drug molecules. METHODS: Various spectroscopic techniques and molecular docking 
      methods were applied to investigate the interaction mechanism between BLG and 
      aspirin. Animal experiments were performed to figure out the effects of taking 
      aspirin-BLG on the stomach. RESULTS: Our results demonstrate that aspirin could 
      bind with BLG to form stable aspirin-BLG complex (the binding constant K(b) = 
      2.051 × 10(3) M(-1)). The formation process is endothermic (∆H>0) and the main 
      acting force is hydrophobic force. Our data also show that the aspirin-BLG 
      complex is formed with a higher affinity in simulated gastric fluid and could 
      remain stable for several hours, which might arise from its special binding mode 
      under acidic condition and the resistance of BLG to gastric digestion. 
      Furthermore, animal models (rats with aspirin-induced gastric damage) were built. 
      The results of animal experiments reveal that the oral administration of 
      aspirin-BLG could cause less damage to gastric tissue, and it also hardly 
      triggers obvious inflammatory responses. CONCLUSION: This study would contribute 
      to an in-depth understanding of the interaction mechanism between BLG and 
      aspirin. It is reasonable to believe that using BLG to bind with aspirin would be 
      a potential way to alleviate the aspirin-induced gastric injury.
CI  - © 2022 Chen et al.
FAU - Chen, Jin
AU  - Chen J
AUID- ORCID: 0000-0003-4757-512X
AD  - Key Laboratory of Biology and Medical Engineering/Immune Cells and Antibody 
      Engineering Research Center of Guizhou Province, School of Biology and 
      Engineering, Guizhou Medical University, Guiyang, 550025, People's Republic of 
      China.
FAU - Gong, Min
AU  - Gong M
AD  - Key Laboratory of Biology and Medical Engineering/Immune Cells and Antibody 
      Engineering Research Center of Guizhou Province, School of Biology and 
      Engineering, Guizhou Medical University, Guiyang, 550025, People's Republic of 
      China.
FAU - Huang, Zhuo
AU  - Huang Z
AD  - Key Laboratory of Biology and Medical Engineering/Immune Cells and Antibody 
      Engineering Research Center of Guizhou Province, School of Biology and 
      Engineering, Guizhou Medical University, Guiyang, 550025, People's Republic of 
      China.
FAU - Wang, Fang
AU  - Wang F
AD  - Key Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, 
      School of Basic Medical Sciences, Guizhou Medical University, Guiyang, 550025, 
      People's Republic of China.
FAU - Wang, Yajing
AU  - Wang Y
AD  - The Affiliated Stomatological Hospital of Guizhou Medical University, Guizhou 
      Medical University, Guiyang, 550025, People's Republic of China.
FAU - Hu, Zuquan
AU  - Hu Z
AUID- ORCID: 0000-0003-4978-4363
AD  - Key Laboratory of Biology and Medical Engineering/Immune Cells and Antibody 
      Engineering Research Center of Guizhou Province, School of Biology and 
      Engineering, Guizhou Medical University, Guiyang, 550025, People's Republic of 
      China.
FAU - Zeng, Zhu
AU  - Zeng Z
AD  - Key Laboratory of Biology and Medical Engineering/Immune Cells and Antibody 
      Engineering Research Center of Guizhou Province, School of Biology and 
      Engineering, Guizhou Medical University, Guiyang, 550025, People's Republic of 
      China.
FAU - Wang, Yun
AU  - Wang Y
AD  - Key Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, 
      School of Basic Medical Sciences, Guizhou Medical University, Guiyang, 550025, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20220301
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Lactoglobulins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Aspirin/pharmacology
MH  - Hydrophobic and Hydrophilic Interactions
MH  - *Lactoglobulins/chemistry/metabolism
MH  - Molecular Docking Simulation
MH  - Rats
PMC - PMC8898184
OTO - NOTNLM
OT  - aspirin
OT  - beta-lactoglobulin
OT  - gastric injury
OT  - molecular docking
OT  - static quenching
COIS- The authors have no conflicts of interest for this work to declare.
EDAT- 2022/03/09 06:00
MHDA- 2022/04/05 06:00
CRDT- 2022/03/08 05:38
PHST- 2021/11/25 00:00 [received]
PHST- 2022/02/20 00:00 [accepted]
PHST- 2022/03/08 05:38 [entrez]
PHST- 2022/03/09 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
AID - 351100 [pii]
AID - 10.2147/DDDT.S351100 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2022 Mar 1;16:571-586. doi: 10.2147/DDDT.S351100. 
      eCollection 2022.

PMID- 23892404
OWN - NLM
STAT- MEDLINE
DCOM- 20131223
LR  - 20220310
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 94
IP  - 5
DP  - 2013 Nov
TI  - Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel 
      insights into antiplatelet therapy.
PG  - 570-3
LID - 10.1038/clpt.2013.153 [doi]
AB  - Interindividual variability in response to antiplatelet therapy results in higher 
      platelet reactivity as well as higher rates of cardiovascular events. Despite 
      substantial effort, the genetic and nongenetic determinants of antiplatelet 
      variability remain poorly understood. Emerging pharmacometabolomic paradigms that 
      integrate systems approaches such as pharmacogenomics have the potential to 
      unveil novel biology regarding disease pathogenesis, reveal the effect of drugs 
      on pathways, and allow better understanding of response variability. Such 
      approaches offer great potential for personalized antiplatelet treatment.
FAU - Lewis, J P
AU  - Lewis JP
AD  - Division of Endocrinology, Diabetes, and Nutrition and Program in Personalized 
      and Genomic Medicine, University of Maryland School of Medicine, Baltimore, 
      Maryland, USA.
FAU - Yerges-Armstrong, L M
AU  - Yerges-Armstrong LM
FAU - Ellero-Simatos, S
AU  - Ellero-Simatos S
FAU - Georgiades, A
AU  - Georgiades A
FAU - Kaddurah-Daouk, R
AU  - Kaddurah-Daouk R
FAU - Hankemeier, T
AU  - Hankemeier T
LA  - eng
GR  - U01 HL105198/HL/NHLBI NIH HHS/United States
GR  - P30-DK072488/DK/NIDDK NIH HHS/United States
GR  - RC2 GM092729/GM/NIGMS NIH HHS/United States
GR  - RC2GM092729/GM/NIGMS NIH HHS/United States
GR  - M01 RR000052/RR/NCRR NIH HHS/United States
GR  - M01 RR016500/RR/NCRR NIH HHS/United States
GR  - K23 GM102678/GM/NIGMS NIH HHS/United States
GR  - M01-RR-16500/RR/NCRR NIH HHS/United States
GR  - P30 DK072488/DK/NIDDK NIH HHS/United States
GR  - M01-RR-000052/RR/NCRR NIH HHS/United States
GR  - U01 HL072515/HL/NHLBI NIH HHS/United States
GR  - K23-GM102678/GM/NIGMS NIH HHS/United States
GR  - U01-HL72515/HL/NHLBI NIH HHS/United States
GR  - U01 GM074518/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130726
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism/pharmacology
MH  - Cardiovascular Diseases/drug therapy/metabolism
MH  - Humans
MH  - Metabolomics/*methods
MH  - Pharmacogenetics/*methods
MH  - Platelet Aggregation/drug effects/genetics
MH  - Platelet Aggregation Inhibitors/metabolism/*pharmacology
PMC - PMC4116100
MID - NIHMS604479
COIS- CONFLICT OF INTEREST R.K.-D. has patents in the field of metabolomics. The other 
      authors declared no conflict of interest.
EDAT- 2013/07/31 06:00
MHDA- 2013/12/24 06:00
CRDT- 2013/07/30 06:00
PHST- 2013/05/22 00:00 [received]
PHST- 2013/07/23 00:00 [accepted]
PHST- 2013/07/30 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2013/12/24 06:00 [medline]
AID - clpt2013153 [pii]
AID - 10.1038/clpt.2013.153 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2013 Nov;94(5):570-3. doi: 10.1038/clpt.2013.153. Epub 2013 
      Jul 26.

PMID- 9691869
OWN - NLM
STAT- MEDLINE
DCOM- 19980813
LR  - 20190515
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 80
IP  - 5
DP  - 1998 May
TI  - Effects of diaspirin cross-linked haemoglobin on post-traumatic cerebral 
      perfusion pressure and blood flow in a rodent model of diffuse brain injury.
PG  - 639-43
AB  - Diaspirin cross-linked haemoglobin (DCLHb) is a new oxygen carrying blood 
      substitute with vasoactive properties. Vasoactive properties may be mediated via 
      high affinity binding of nitric oxide by the haem moiety. Using a rodent model of 
      head injury combined with ischaemia, we studied the effects of DCLHb on cerebral 
      blood flow (CBF) and intracranial pressure (ICP). Twenty anaesthetized rats were 
      allocated randomly to receive treatment with DCLHb 400 mg kg-1 i.v. or placebo 
      (oncotically matched plasma protein substitute 4.5% i.v.). To produce diffusely 
      increased ICP, after a severe weight drop injury, all animals underwent a 30-min 
      period of bilateral carotid ligation combined with a period of induced 
      hypotension. After reperfusion, DCLHb or placebo was infused and the animals 
      instrumented for measurement of intraventricular ICP and CBF in the region of the 
      sensorimotor cortex using the hydrogen clearance technique. Mean arterial 
      pressure (MAP), ICP, cerebral perfusion pressure (CPP) (CPP = MAP - ICP) and CBF 
      were measured 4 h after injury in all animals. DCLHb significantly reduced ICP 
      from mean 13 (SEM 2) to 3 (1) mm Hg (P < 0.001), increased CPP from 52 (8) to 95 
      (6) mm Hg (P < 0.001) and increased CBF from 21 (2) to 29 (2) ml 100 g-1 min-1 (P 
      = 0.032). We conclude that DCLHb improved CPP without a reduction in CBF in a 
      rodent model of post-traumatic brain swelling.
FAU - Piper, I R
AU  - Piper IR
AD  - Department of Clinical Neurosciences, Western General Hospital, Edinburgh.
FAU - Garrioch, M A
AU  - Garrioch MA
FAU - Souter, M J
AU  - Souter MJ
FAU - Andrews, P J
AU  - Andrews PJ
FAU - Thomson, D
AU  - Thomson D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Pressure/drug effects
MH  - Blood Substitutes/*pharmacology
MH  - Brain Injuries/*physiopathology
MH  - Cerebrovascular Circulation/*drug effects
MH  - Hemoglobins/*pharmacology
MH  - Intracranial Pressure/*drug effects
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1998/08/06 00:00
MHDA- 1998/08/06 00:01
CRDT- 1998/08/06 00:00
PHST- 1998/08/06 00:00 [pubmed]
PHST- 1998/08/06 00:01 [medline]
PHST- 1998/08/06 00:00 [entrez]
AID - S0007-0912(17)40430-2 [pii]
AID - 10.1093/bja/80.5.639 [doi]
PST - ppublish
SO  - Br J Anaesth. 1998 May;80(5):639-43. doi: 10.1093/bja/80.5.639.

PMID- 8439029
OWN - NLM
STAT- MEDLINE
DCOM- 19930325
LR  - 20151119
IS  - 0003-3022 (Print)
IS  - 0003-3022 (Linking)
VI  - 78
IP  - 2
DP  - 1993 Feb
TI  - Focal cerebral ischemia in rats. Effect of hypervolemic hemodilution with 
      diaspirin cross-linked hemoglobin versus albumin on brain injury and edema.
PG  - 335-42
AB  - BACKGROUND: Hemodilution has had limited success as a treatment of cerebral 
      ischemia. When using a non-oxygen-binding fluid, the therapeutic efficacy of 
      hemodilution-induced increases in blood flow are offset by concomitant decreases 
      in oxygen content. METHODS: The effect of hemodilution, with diaspirin 
      cross-linked hemoglobin (DCLHb), on brain injury and edema was assessed during 
      middle cerebral artery occlusion (180 min) and reperfusion (120 min) in rats 
      (blood volume increased by approximately 30% and n = 10 for each group): (1) 
      44/B: 8.0 ml of donor blood was given; (2) 30/albumin: hematocrit was decreased 
      to 30% with 10% albumin; (3) 30/DCLHb: hematocrit was decreased to 30% with 10% 
      DCLHb; or (4) 9/DCLHb: hematocrit was decreased to 9% with DCLHb. Infarct size 
      was analyzed with 2,3,5-triphenyltetrazolium chloride, and edema by 
      microgravimetry. RESULTS: Brain injury (percent of the hemispheric area 
      ipsilateral to ischemia, mean +/- SD) was greater in the 44/B group (44 +/- 4) 
      versus the 30/albumin group (37 +/- 3). In addition, brain injury was greater in 
      the 44/B and 30/albumin groups versus the 30/DCLHb group (27 +/- 4); which was in 
      turn greater than the 9/DLCHb group (18 +/- 3). Specific gravity was greater 
      (less brain water) in all hemodiluted groups versus the 44/B group. CONCLUSIONS: 
      These results support a hypothesis that hemodilution decreases focal cerebral 
      ischemic injury, and when an oxygen-binding fluid is used, there is a 
      dose-dependent effect of hemodilution on ischemia. In addition, these results 
      suggest that hemodilution, as achieved with DCLHb, was more effective in reducing 
      ischemic brain damage than was the same degree of hemodilution as achieved with 
      albumin.
FAU - Cole, D J
AU  - Cole DJ
AD  - Department of Anesthesiology, Loma Linda University, California 92354.
FAU - Schell, R M
AU  - Schell RM
FAU - Drummond, J C
AU  - Drummond JC
FAU - Reynolds, L
AU  - Reynolds L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesthesiology
JT  - Anesthesiology
JID - 1300217
RN  - 0 (Albumins)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Albumins/*therapeutic use
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Brain Edema/*drug therapy
MH  - Brain Injuries/*drug therapy
MH  - Brain Ischemia/*therapy
MH  - Cross-Linking Reagents/*therapeutic use
MH  - Hemodilution/*methods
MH  - Hemoglobins/therapeutic use
MH  - Male
MH  - Rats
MH  - Rats, Inbred SHR
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
PST - ppublish
SO  - Anesthesiology. 1993 Feb;78(2):335-42.

PMID- 4089795
OWN - NLM
STAT- MEDLINE
DCOM- 19860226
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 54
IP  - 3
DP  - 1985 Oct 30
TI  - Aspirin and the prevention of experimental arterial thrombosis: difficulty in 
      establishing unequivocal effectiveness.
PG  - 619-21
AB  - A trial of the efficacy of aspirin in the prevention of thrombotic occlusion of 
      an "aortic loop" in rats was made simultaneously by two experimental surgeons. A 
      relatively large dose of aspirin (80-100 mg/kg/day) was used, starting two days 
      before operation. It appeared that aspirin was of limited benefit, reducing 
      thrombotic occlusions by about 17% seven days after the insertion of the loop 
      into the abdominal aorta. Although the average occlusion time was prolonged by 
      about 17% in aspirin-treated animals, the separate trials gave no conclusive 
      result. When the data from both operators were pooled, a statistically 
      significant protection by aspirin was apparent (p = 0.02), by a two-tailed 
      Student's t test. However, on using the powerful non-parametric randomization 
      test, the occlusion times in control and aspirin-treated groups appeared not 
      statistically different (p = 0.07). No significant difference was also found 
      between control and treated groups when data were analyzed by X2 test. 
      Independently of the statistical analysis, these data are quite similar to those 
      obtained from aspirin trials in men surviving myocardial infarction. This finding 
      points to the usefulness of the aorta loop as an animal model for arterial 
      thrombosis.
FAU - Reyers, I
AU  - Reyers I
FAU - Hennissen, A
AU  - Hennissen A
FAU - Donati, M B
AU  - Donati MB
FAU - Hornstra, G
AU  - Hornstra G
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Disease Models, Animal
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Statistics as Topic
MH  - Thrombosis/*prevention & control
EDAT- 1985/10/30 00:00
MHDA- 1985/10/30 00:01
CRDT- 1985/10/30 00:00
PHST- 1985/10/30 00:00 [pubmed]
PHST- 1985/10/30 00:01 [medline]
PHST- 1985/10/30 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1985 Oct 30;54(3):619-21.

PMID- 15862983
OWN - NLM
STAT- MEDLINE
DCOM- 20050707
LR  - 20131121
IS  - 0965-2302 (Print)
IS  - 0965-2302 (Linking)
VI  - 13
IP  - 2
DP  - 2005 Apr
TI  - What every emergency nurse needs to know about aspirin.
PG  - 105-9
AB  - As the most commonly recommended medication in the world, aspirin is a medication 
      with which emergency nurses are intimately familiar. Although this medication has 
      been used for more than a century, health-care researchers are discovering new 
      information about the utility of aspirin every year. Within this paper, we 
      provide a review of recent findings related to the use of aspirin in the 
      Emergency Department. In particular, we focus on understanding the 
      pharmacokinetics of the medication as several drugs introduced in the past 
      decade, interact with aspirin and create side effects harmful to patients. As 
      well, we highlight current research around optimal dosage and other issues 
      related to aspirin administration. This review is timely as several issues have 
      arisen in the literature, in relation to the effectiveness of aspirin as an 
      anti-platelet agent.
FAU - Turris, Sheila A
AU  - Turris SA
AD  - British Columbia Institute of Technology, 3700 Willingdon Avenue, Burnaby, BC, 
      Canada V5G 3H2. Sheila_Turris@bcit.ca
FAU - Smith, Sue
AU  - Smith S
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20050401
PL  - England
TA  - Accid Emerg Nurs
JT  - Accident and emergency nursing
JID - 9305090
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects/pharmacokinetics/*therapeutic use
MH  - Colorectal Neoplasms/prevention & control
MH  - Coronary Disease/prevention & control
MH  - Delayed-Action Preparations
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Drug Resistance
MH  - Emergency Nursing/education/*organization & administration
MH  - Humans
MH  - Neoplasm Recurrence, Local/prevention & control
MH  - Nurse's Role
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacokinetics/*therapeutic use
MH  - Stroke/prevention & control
MH  - Treatment Outcome
RF  - 18
EDAT- 2005/05/03 09:00
MHDA- 2005/07/08 09:00
CRDT- 2005/05/03 09:00
PHST- 2004/12/28 00:00 [received]
PHST- 2005/02/11 00:00 [accepted]
PHST- 2005/05/03 09:00 [pubmed]
PHST- 2005/07/08 09:00 [medline]
PHST- 2005/05/03 09:00 [entrez]
AID - S0965-2302(05)00013-5 [pii]
AID - 10.1016/j.aaen.2005.02.003 [doi]
PST - ppublish
SO  - Accid Emerg Nurs. 2005 Apr;13(2):105-9. doi: 10.1016/j.aaen.2005.02.003. Epub 
      2005 Apr 1.

PMID- 20410617
OWN - NLM
STAT- MEDLINE
DCOM- 20100907
LR  - 20190819
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 74
IP  - 6
DP  - 2010 Jun
TI  - Characterization of the antiplatelet effect of aspirin at enrollment and after 
      2-year follow-up in a real clinical setting in Japan.
PG  - 1227-35
AB  - BACKGROUND: Aspirin is an antiplatelet drug widely used for the prevention of 
      cardiovascular diseases. It has been reported that some patients who exhibit a 
      reduced antiplatelet effect of aspirin have higher cardiovascular risk. It is 
      still controversial whether the antiplatelet effect of aspirin diminishes after a 
      few years of treatment. This study aimed to evaluate the antiplatelet effect of 
      aspirin and its 2-year change in Japanese patients. METHODS AND RESULTS: 
      Collagen-induced platelet-aggregability was measured at enrollment by 
      conventional optical aggregometer in 239 patients undergoing antiplatelet therapy 
      with aspirin alone. Among them, 167 patients were evaluated after 2 years. Whole 
      blood aggregability based on the screen-filtration method was also evaluated. 
      Optical aggregometer studies showed that 27% of patients were low-responders. 
      Multivariate analyses revealed that female sex and non-use of calcium-channel 
      blockers were associated with low responsiveness. The antiplatelet effect of 
      aspirin did not decrease after 2 years. Similar data were obtained with the whole 
      blood aggregometer. CONCLUSIONS: In this Japanese patient group, 27% were 
      low-responders to aspirin, and the antiplatelet effect of aspirin did not 
      decrease after a 2-year interval.
FAU - Ikeda, Tomoyuki
AU  - Ikeda T
AD  - Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto 
      University, Kyoto, Japan.
FAU - Taniguchi, Ryoji
AU  - Taniguchi R
FAU - Watanabe, Shin
AU  - Watanabe S
FAU - Kawato, Mitsunori
AU  - Kawato M
FAU - Kondo, Hirokazu
AU  - Kondo H
FAU - Shirakawa, Ryutaro
AU  - Shirakawa R
FAU - Yamane, Keiichiro
AU  - Yamane K
FAU - Toma, Masanao
AU  - Toma M
FAU - Tamura, Toshihiro
AU  - Tamura T
FAU - Takahashi, Kanako
AU  - Takahashi K
FAU - Watanabe, Haruyo
AU  - Watanabe H
FAU - Yoshikawa, Yuka
AU  - Yoshikawa Y
FAU - Tabuchi, Arata
AU  - Tabuchi A
FAU - Kita, Toru
AU  - Kita T
FAU - Kimura, Takeshi
AU  - Kimura T
FAU - Horiuchi, Hisanori
AU  - Horiuchi H
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100410
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circ J. 2010 Jun;74(6):1077-8. PMID: 20472961
MH  - Aged
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Blood Coagulation Tests
MH  - Calcium Channel Blockers/pharmacology
MH  - Collagen/pharmacology
MH  - *Drug Resistance/drug effects
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/*pharmacology
MH  - Platelet Function Tests
MH  - Sex Factors
MH  - Time Factors
EDAT- 2010/04/23 06:00
MHDA- 2010/09/08 06:00
CRDT- 2010/04/23 06:00
PHST- 2010/04/23 06:00 [entrez]
PHST- 2010/04/23 06:00 [pubmed]
PHST- 2010/09/08 06:00 [medline]
AID - JST.JSTAGE/circj/CJ-09-0927 [pii]
AID - 10.1253/circj.cj-09-0927 [doi]
PST - ppublish
SO  - Circ J. 2010 Jun;74(6):1227-35. doi: 10.1253/circj.cj-09-0927. Epub 2010 Apr 10.

PMID- 2509683
OWN - NLM
STAT- MEDLINE
DCOM- 19891221
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 251
IP  - 2
DP  - 1989 Nov
TI  - Rioprostil heals pre-existing aspirin-induced gastric lesions in dogs during 
      daily aspirin administration without altering the anti-inflammatory or analgesic 
      efficacy of aspirin.
PG  - 774-81
AB  - Rioprostil (3-100 micrograms/kg/day p.o.), but not cimetidine (30 mg/kg/day 
      p.o.), healed pre-existing aspirin (1950 mg)-induced gastric lesions in dogs 
      despite daily aspirin (975 mg) administration. Gastric antisecretory doses of 
      rioprostil (10 and 100 micrograms/kg/day) decreased lesion scores by 71 to 77 and 
      90 to 93% after 7 and 11 days, respectively. A nonantisecretory dose of 
      rioprostil (3 micrograms/kg/day) decreased lesion scores by 80% after 14 days. In 
      contrast, lesion scores in dogs receiving either vehicle or a maximal gastric 
      antisecretory dose of cimetidine (30 mg/kg/day) remained unchanged during the 
      28-day course of treatment. In addition, rioprostil prevented the weight loss 
      which accompanied daily administration of aspirin (975 mg) in vehicle- or 
      cimetidine-treated dogs. When cimetidine-treated dogs were switched to daily 
      rioprostil (100 micrograms/kg/day) and aspirin (975 mg/day) therapy, lesions 
      healed within 6 days. In separate studies, rioprostil had no effect on the 
      sensitivity of the gastric mucosa to subsequent aspirin administration. In 
      addition, discontinuation of maintenance therapy during rioprostil treatment was 
      of no increased benefit (i.e., lesions did not heal faster). Finally, in a model 
      of urate-induced knee-joint synovitis, rioprostil treatment did not inhibit the 
      anti-inflammatory or analgesic efficacy of aspirin, or have any proinflammatory 
      effect of its own.
FAU - Katz, L B
AU  - Katz LB
AD  - R. W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey.
FAU - Shriver, D A
AU  - Shriver DA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Prostaglandins E)
RN  - 7JL402PVQR (Rioprostil)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesia
MH  - Animals
MH  - Anti-Ulcer Agents/*pharmacology
MH  - Aspirin/pharmacology/*toxicity
MH  - Body Weight/drug effects
MH  - Dinoprostone/metabolism
MH  - Dogs
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Male
MH  - Prostaglandins E/*pharmacology
MH  - Rioprostil
MH  - Synovitis/drug therapy
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1989 Nov;251(2):774-81.

PMID- 24660383
OWN - NLM
STAT- MEDLINE
DCOM- 20140424
LR  - 20140325
IS  - 0012-7183 (Print)
IS  - 0012-7183 (Linking)
VI  - 130
IP  - 3
DP  - 2014
TI  - [Acetylsalicylic acid and prevention of preeclampsia].
PG  - 243-50
AB  - Two to six percent of all pregnant women develop preeclampsia. In the worst case 
      its complications threaten the life of both the fetus and the mother. It seems 
      that especially an early and severe preeclampsia diagnosed before 34 weeks of 
      pregnancy can be prevented by using low-dose acetylsalicylic acid medication, 
      which shall be started sufficiently early, not later than pregnancy week 16. 
      Acetylsalicylic acid is safe during pregnancy at a daily dose of 100 mg. For the 
      prevention of preeclampsia, it is worth considering for women who are at high 
      risk of developing the disease.
FAU - Villa, Pia M
AU  - Villa PM
FAU - Kajantie, Eero
AU  - Kajantie E
FAU - Laivuori, Hannele
AU  - Laivuori H
LA  - fin
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Asetyylisalisyylihappo ja pre-eklampsian ehkäisy.
PL  - Finland
TA  - Duodecim
JT  - Duodecim; laaketieteellinen aikakauskirja
JID - 0373207
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
EDAT- 2014/03/26 06:00
MHDA- 2014/04/25 06:00
CRDT- 2014/03/26 06:00
PHST- 2014/03/26 06:00 [entrez]
PHST- 2014/03/26 06:00 [pubmed]
PHST- 2014/04/25 06:00 [medline]
PST - ppublish
SO  - Duodecim. 2014;130(3):243-50.

PMID- 20493652
OWN - NLM
STAT- MEDLINE
DCOM- 20100916
LR  - 20131121
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 53
IP  - 3
DP  - 2010 Nov 2
TI  - Attenuated total reflection infrared spectroscopy (ATR-IR) as an in situ 
      technique for dissolution studies.
PG  - 269-73
LID - 10.1016/j.jpba.2010.04.023 [doi]
AB  - Dissolution studies are critical tests for measuring the performance of a drug 
      product. We have developed a novel technique using in situ ATR-IR spectroscopy to 
      monitor dissolutions of pharmaceutical drug products. The accuracy of this 
      technique is +/-3% relative to HPLC using salicylic acid calibrator tablets and 
      acetaminophen OTC tablets. This novel approach also gives the research laboratory 
      the capability of analyzing individual ingredients in multiple tablets; for 
      example, individual components of salicylic acid and acetaminophen tablets are 
      easily distinguished. In addition, the individual ingredients of a 
      multi-component tablet containing acetylsalicylic acid and acetaminophen are 
      readily distinguished. The ATR-IR system was found to have good sensitivity and 
      can analyze samples as low as 0.03 mg/ml. With improved sensitivity, this is a 
      promising method for monitoring dissolution of pharmaceutical tablets with an 
      excellent in situ capability for distinguishing individual components.
CI  - Copyright (c) 2010 Elsevier B.V. All rights reserved.
FAU - Kassis, Abe
AU  - Kassis A
AD  - Department of Chemistry and Biochemistry, Seton Hall University, 400 South Orange 
      Ave, South Orange, NJ 07079, USA.
FAU - Bhawtankar, Vrushali M
AU  - Bhawtankar VM
FAU - Sowa, John R Jr
AU  - Sowa JR Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100427
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*chemistry
MH  - Aspirin/*chemistry
MH  - Hydrogen-Ion Concentration
MH  - Solubility
MH  - Spectroscopy, Fourier Transform Infrared/*methods
MH  - Tablets
EDAT- 2010/05/25 06:00
MHDA- 2010/09/18 06:00
CRDT- 2010/05/25 06:00
PHST- 2010/02/05 00:00 [received]
PHST- 2010/04/16 00:00 [revised]
PHST- 2010/04/19 00:00 [accepted]
PHST- 2010/05/25 06:00 [entrez]
PHST- 2010/05/25 06:00 [pubmed]
PHST- 2010/09/18 06:00 [medline]
AID - S0731-7085(10)00264-5 [pii]
AID - 10.1016/j.jpba.2010.04.023 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2010 Nov 2;53(3):269-73. doi: 10.1016/j.jpba.2010.04.023. 
      Epub 2010 Apr 27.

PMID- 25219631
OWN - NLM
STAT- MEDLINE
DCOM- 20150415
LR  - 20140915
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 10
IP  - 10
DP  - 2014 Oct
TI  - Pharmacokinetics and safety of a new aspirin formulation for the acute treatment 
      of primary headaches.
PG  - 1381-95
LID - 10.1517/17425255.2014.952631 [doi]
AB  - INTRODUCTION: For more than a century, aspirin has been used for the acute 
      treatment of primary headaches. However, the many formulations available are 
      characterized by differences in the pharmacokinetic profile that could affect 
      therapy effectiveness. AREAS COVERED: The formulations of aspirin affect the 
      speed of absorption of the drug. This feature, in turn, moduates the peak 
      plasmatic concentration (the faster the absorption, the higher the peak plasmatic 
      concentration of aspirin). Recently, a new formulation, consisting in a 
      micronized tablet with an effervescent nucleus, has been shown to be comparable 
      to the formulations associated to the faster absorption. The efficacy of aspirin 
      in migraine is well characterized: the drug is able to rapidly reduce pain and 
      restore functionality, acting also on associated symptoms, in a manner comparable 
      to that of oral sumatriptan. In tension-type headache, aspirin acts in a 
      dose-dependent fashion. The safety profile of the drug is favorable: 
      gastrointestinal complaints are generally mild in intensity and with an incidence 
      comparable to that of ibuprofen and paracetamol. EXPERT OPINION: According to 
      international guidelines, aspirin should be considered as first-line therapy in 
      primary headaches. Formulations that allow fast absorption, like the new 
      micronized tablets, and portability, are to be preferred.
FAU - Lecchi, Marzia
AU  - Lecchi M
AD  - University of Milan, Department of Biotechnology and Biosciences , Bicocca, Milan 
      , Italy.
FAU - D'Alonzo, Lidia
AU  - D'Alonzo L
FAU - Negro, Andrea
AU  - Negro A
FAU - Martelletti, Paolo
AU  - Martelletti P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets)
RN  - 8R78F6L9VO (Sumatriptan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/pharmacokinetics/*therapeutic use
MH  - Aspirin/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Headache/*drug therapy
MH  - Humans
MH  - Migraine Disorders/drug therapy
MH  - Practice Guidelines as Topic
MH  - Sumatriptan/administration & dosage/therapeutic use
MH  - Tablets
OTO - NOTNLM
OT  - aspirin
OT  - headache treatment
OT  - micronized aspirin
OT  - migraine
OT  - pharmacokinetics
OT  - safety
OT  - speed of action
OT  - tension-type headache
EDAT- 2014/09/16 06:00
MHDA- 2015/04/16 06:00
CRDT- 2014/09/16 06:00
PHST- 2014/09/16 06:00 [entrez]
PHST- 2014/09/16 06:00 [pubmed]
PHST- 2015/04/16 06:00 [medline]
AID - 10.1517/17425255.2014.952631 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1381-95. doi: 
      10.1517/17425255.2014.952631.

PMID- 18485921
OWN - NLM
STAT- MEDLINE
DCOM- 20080917
LR  - 20211020
IS  - 1089-8611 (Electronic)
IS  - 1089-8603 (Print)
IS  - 1089-8603 (Linking)
VI  - 19
IP  - 2
DP  - 2008 Sep
TI  - Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: in vitro evidence 
      querying the NO donor functionality.
PG  - 115-24
LID - 10.1016/j.niox.2008.04.013 [doi]
AB  - Properties of the NO-ASA family of NO-donating NSAIDs (NO-NSAIDs), notably NCX 
      4016 (mNO-ASA) and NCX 4040 (pNO-ASA), reported in more than one hundred 
      publications, have included positive preclinical data in cancer chemoprevention 
      and therapy. Evidence is presented that the antiproliferative, the 
      chemopreventive (antioxidant/electrophile response element (ARE) activation), and 
      the anti-inflammatory activity of NO-ASA in cell cultures is replicated by X-ASA 
      derivatives that are incapable of acting as NO donors. pBr-ASA and mBr-ASA are 
      conisogenic with NO-ASA, but are not NO donors. The biological activity of 
      pNO-ASA is replicated by pBr-ASA; and both pNO-ASA and pBr-ASA are bioactivated 
      to the same quinone methide electrophile. The biological activity of mNO-ASA is 
      replicated by mBr-ASA; mNO-ASA and mBr-ASA are bioactivated to different benzyl 
      electrophiles. The observed activity is likely initiated by trapping of thiol 
      biomolecules by the quinone and benzyl electrophiles, leading to depletion of GSH 
      and modification of Cys-containing sensor proteins. Whereas all NO-NSAIDs 
      containing the same structural "linker" as NCX 4040 and NCX 4016 are anticipated 
      to possess activity resulting from bioactivation to electrophilic metabolites, 
      this expectation does not extend to other linker structures. Nitrates require 
      metabolic bioactivation to liberate NO bioactivity, which is often poorly 
      replicated in vitro, and NO bioactivity provided by NO-NSAIDs in vivo provides 
      proven therapeutic benefits in mitigation of NSAID gastrotoxicity. The in vivo 
      properties of X-ASA drugs await discovery.
FAU - Dunlap, Tareisha
AU  - Dunlap T
AD  - Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, 
      University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612, USA.
FAU - Abdul-Hay, Samer O
AU  - Abdul-Hay SO
FAU - Chandrasena, R Esala P
AU  - Chandrasena RE
FAU - Hagos, Ghenet K
AU  - Hagos GK
FAU - Sinha, Vaishali
AU  - Sinha V
FAU - Wang, Zhiqiang
AU  - Wang Z
FAU - Wang, Huali
AU  - Wang H
FAU - Thatcher, Gregory R J
AU  - Thatcher GR
LA  - eng
GR  - R01 CA102590/CA/NCI NIH HHS/United States
GR  - R01 CA102590-04/CA/NCI NIH HHS/United States
GR  - R01 CA121107/CA/NCI NIH HHS/United States
GR  - CA102590/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20080423
PL  - United States
TA  - Nitric Oxide
JT  - Nitric oxide : biology and chemistry
JID - 9709307
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (NCX 4040)
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Nitro Compounds)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Antineoplastic Agents/pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology/therapeutic use
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Chemoprevention/methods
MH  - Humans
MH  - Macrophages
MH  - Mice
MH  - Neoplasms/drug therapy/*prevention & control
MH  - Nitrates/metabolism
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Donors/*pharmacology/therapeutic use
MH  - Nitro Compounds/pharmacology/therapeutic use
PMC - PMC2572831
MID - NIHMS60730
EDAT- 2008/05/20 09:00
MHDA- 2008/09/18 09:00
CRDT- 2008/05/20 09:00
PHST- 2008/02/21 00:00 [received]
PHST- 2008/04/14 00:00 [revised]
PHST- 2008/04/15 00:00 [accepted]
PHST- 2008/05/20 09:00 [pubmed]
PHST- 2008/09/18 09:00 [medline]
PHST- 2008/05/20 09:00 [entrez]
AID - S1089-8603(08)00066-9 [pii]
AID - 10.1016/j.niox.2008.04.013 [doi]
PST - ppublish
SO  - Nitric Oxide. 2008 Sep;19(2):115-24. doi: 10.1016/j.niox.2008.04.013. Epub 2008 
      Apr 23.

PMID- 3665485
OWN - NLM
STAT- MEDLINE
DCOM- 19871214
LR  - 20190824
IS  - 0010-7824 (Print)
IS  - 0010-7824 (Linking)
VI  - 35
IP  - 6
DP  - 1987 Jun
TI  - Influence of aspirin on the pharmacokinetics of norethindrone.
PG  - 611-8
AB  - The influence of a single dose of aspirin on the pharmacokinetics of the 
      synthetic progestogen norethindrone was studied in rabbits. It was found that 
      neither the 24-hr plasma levels nor the pharmacokinetic parameters of 
      norethindrone following intravenous dosing were significantly altered by aspirin. 
      However, after oral administration of norethindrone, the area under the plasma 
      norethindrone versus time curve was significantly decreased by aspirin from 0.72 
      +/- 0.058 ng/ml X hr to 0.49 +/- 0.046 ng/ml X hr (mean +/- S.E) and the oral 
      bioavailability was reduced from 56 +/- 4.2% to 38 +/- 3.6%, perhaps due to 
      increased gut wall metabolism of norethindrone by aspirin.
FAU - Gomaa, A A
AU  - Gomaa AA
AD  - Department of Pharmacology, Faculty of Medicine, Assiut University, Egypt.
FAU - Makarm, M H
AU  - Makarm MH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Contraception
JT  - Contraception
JID - 0234361
RN  - R16CO5Y76E (Aspirin)
RN  - T18F433X4S (Norethindrone)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Biological Availability
MH  - Drug Interactions
MH  - Female
MH  - Kinetics
MH  - Norethindrone/*pharmacokinetics
MH  - Rabbits
EDAT- 1987/06/01 00:00
MHDA- 1987/06/01 00:01
CRDT- 1987/06/01 00:00
PHST- 1987/06/01 00:00 [pubmed]
PHST- 1987/06/01 00:01 [medline]
PHST- 1987/06/01 00:00 [entrez]
AID - S0010-7824(87)80020-3 [pii]
AID - 10.1016/s0010-7824(87)80020-3 [doi]
PST - ppublish
SO  - Contraception. 1987 Jun;35(6):611-8. doi: 10.1016/s0010-7824(87)80020-3.

PMID- 6318343
OWN - NLM
STAT- MEDLINE
DCOM- 19840220
LR  - 20131121
VI  - 59
IP  - 46
DP  - 1983 Dec 12
TI  - [Drug concentrations in blood, synovial fluid, synovial membrane, periarticular 
      bone, muscle and adipose tissue in patients with rheumatoid polyarthritis 
      receiving a single intramuscular injection of ketoprofen or acetylsalicylic acid 
      (3 hours after the injection)].
PG  - 3210-3
AB  - The therapeutic activity of antiinflammatory agents in rheumatic joint disease is 
      related to their presence at the target site of action, i.e. the joints. Tissue 
      concentrations of such agents have been previously determined in patients with 
      rheumatic disorders under long-term treatment with acemetacin and indomethacin 
      (Köhler et al., 1981). The purpose of the present study was to determine 
      concentrations of ketoprofen and acetylsalicylic acid in blood as well as 
      synovial fluid, synovial membrane and periarticular bone and adipose tissue, 
      three hours after administration of a single dose. Drug concentrations found in 
      each of these tissues following a single intramuscular injection were sufficient 
      to ensure therapeutic efficiency.
FAU - Köhler, G
AU  - Köhler G
FAU - Mohing, W
AU  - Mohing W
FAU - Lutz, D
AU  - Lutz D
FAU - Morand, J
AU  - Morand J
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Teneur en principe actif du sang, du liquide synovial, de la membrane synoviale 
      et des tissus osseux, musculaires et adipeux avoisinants chez des malades 
      atteints de polyarthrite rhumatoïde et ayant reçu une injection intramusculaire 
      unique de kétoprofène ou d'acide acétylsalicylique (trois heures après 
      injection).
PL  - France
TA  - Sem Hop
JT  - La semaine des hopitaux : organe fonde par l'Association d'enseignement medical 
      des hopitaux de Paris
JID - 9410059
RN  - 0 (Phenylpropionates)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adipose Tissue/metabolism
MH  - Arthritis, Rheumatoid/*metabolism
MH  - Aspirin/administration & dosage/blood/*metabolism
MH  - Bone and Bones/metabolism
MH  - Chromatography, Gas
MH  - Female
MH  - Humans
MH  - Injections, Intramuscular
MH  - Ketoprofen/administration & dosage/blood/*metabolism
MH  - Male
MH  - Muscles/metabolism
MH  - Phenylpropionates/*metabolism
MH  - Synovial Fluid/metabolism
MH  - Synovial Membrane/metabolism
EDAT- 1983/12/12 00:00
MHDA- 1983/12/12 00:01
CRDT- 1983/12/12 00:00
PHST- 1983/12/12 00:00 [pubmed]
PHST- 1983/12/12 00:01 [medline]
PHST- 1983/12/12 00:00 [entrez]
PST - ppublish
SO  - Sem Hop. 1983 Dec 12;59(46):3210-3.

PMID- 12846440
OWN - NLM
STAT- MEDLINE
DCOM- 20031202
LR  - 20191107
IS  - 1590-8658 (Print)
IS  - 1590-8658 (Linking)
VI  - 35 Suppl 2
DP  - 2003 May
TI  - NCX4016: a novel antithrombotic agent.
PG  - S20-6
AB  - Despite great advantages in antithrombotic treatments, important limitations of 
      the presently available drugs encourage the search of more effective agents. 
      Within the cardiovascular system, nitric oxide exerts several activities which 
      may have an antithrombotic potential. Nitroaspirin in vitro inhibits platelet 
      aggregation and adhesion under shear conditions and smooth muscle cell 
      proliferation--all activities not exerted by aspirin. In vivo nitroaspirin exerts 
      antithrombotic properties and prevents restenosis in hypercholesterolemic mice 
      while aspirin is inactive. Nitroaspirin has shown a number of significant 
      advantages over the presently available antiplatelet agents; however, only 
      clinical studies will say whether nitroaspirin represents a step forward in 
      antithrombotic treatment.
FAU - Gresele, P
AU  - Gresele P
AD  - Division of Internal and Cardiovascular Medicine, Department of Internal 
      Medicine, University of Perugia, Via Enrico dal Pozzo, 06126 Perugia, Italy. 
      grespa@unipg.it
FAU - Momi, S
AU  - Momi S
FAU - Mezzasoma, A M
AU  - Mezzasoma AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Disease Models, Animal
MH  - Fibrinolytic Agents/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Mice
MH  - Monocytes/drug effects
MH  - Nitric Oxide/*pharmacology
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Pulmonary Embolism/drug therapy
MH  - Rabbits
MH  - Rats
EDAT- 2003/07/09 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/07/09 05:00
PHST- 2003/07/09 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/07/09 05:00 [entrez]
AID - S1590-8658(03)00048-3 [pii]
AID - 10.1016/s1590-8658(03)00048-3 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2003 May;35 Suppl 2:S20-6. doi: 10.1016/s1590-8658(03)00048-3.

PMID- 36122261
OWN - NLM
STAT- MEDLINE
DCOM- 20220922
LR  - 20221031
IS  - 2150-1149 (Electronic)
IS  - 1533-3159 (Linking)
VI  - 25
IP  - 6
DP  - 2022 Sep
TI  - Aspirin Cessation Before Interventional Procedures: Not Blindly Following 
      Guidelines but Making Test-based Decisions.
PG  - 501-507
AB  - BACKGROUND: Deciding whether to continue or discontinue aspirin prior to 
      interventional procedures is a major concern for pain physicians. Many guidelines 
      have been published on the discontinuation of aspirin before invasive procedures; 
      however, the recommendations are inconsistent and do not consider individual 
      platelet function. Furthermore, many studies have shown a high prevalence of 
      aspirin resistance  in patients taking this medication. OBJECTIVES: To determine 
      the necessity of discontinuing aspirin prior to interventional pain procedures in 
      relation to individual platelet function. STUDY DESIGN: Multicenter, 
      cross-sectional study. SETTING: University-affiliated hospitals. METHODS: We 
      examined platelet function among patients scheduled for an interventional pain 
      procedure by measuring their closure time using collagen/epinephrine cartridges 
      in a commercial platelet-function analyzer. The patients were categorized into 
      either an aspirin-taking or nonaspirin-taking group (Group A or Group N, 
      respectively). The proportion of patients who showed normal/abnormal platelet 
      function was calculated and compared between the groups. RESULTS: A total of 
      1,111 patients were included in this study. In Group A, 56.4% (102/181) showed 
      normal platelet function, whereas 43.6% (79/181) showed abnormal platelet 
      function. In Group N, 85.8% (798/930) and 14.2% (132/930) showed normal and 
      abnormal platelet function, respectively. LIMITATION: The proportion of 
      laboratory, not clinical aspirin resistance was evaluated. Factors affecting 
      platelet function were not investigated exhaustively. CONCLUSION: The high 
      prevalence of normal platelet function in patients taking aspirin suggests no 
      necessity of discontinuation before procedures in such patients. Abnormal 
      platelet function can occur even in patients who are not taking aspirin. 
      Therefore, platelet function should be measured and considered on a case-by-case 
      basis prior to interventional procedures, and discontinuation of aspirin should 
      be decided based on these factors.
FAU - Seo, Kyeong Hwan
AU  - Seo KH
AD  - Keimyung University School of Medicine, South Korea.
FAU - Nahm, Francis Sahngun
AU  - Nahm FS
AD  - Seoul National University College of Medicine, South Korea; Seoul National 
      University Bundang Hospital, South Korea.
FAU - Han, Woong Ki
AU  - Han WK
AD  - Deaheal Pain Clinic, South Korea.
FAU - Gil, Ho Young
AU  - Gil HY
AD  - Ajou University School of Medicine, Suwon, Korea.
FAU - Kim, Jung Eun
AU  - Kim JE
AD  - Kangnam Sacred Heart Hospital, Hallym University College of Medicine, South 
      Korea.
FAU - Choi, Eun Joo
AU  - Choi EJ
AD  - Seoul National University Bundang Hospital, South Korea.
FAU - Lee, Pyung Bok
AU  - Lee PB
AD  - Seoul National University College of Medicine, South Korea; Seoul National 
      University Bundang Hospital, South Korea.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Pain Physician
JT  - Pain physician
JID - 100954394
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Collagen
MH  - Cross-Sectional Studies
MH  - Drug Resistance
MH  - Epinephrine
MH  - Humans
MH  - Pain
MH  - *Platelet Aggregation
OTO - NOTNLM
OT  - collagen
OT  - epinephrine
OT  - guideline
OT  - nerve block
OT  - pain
OT  - platelet aggregation
OT  - ; platelet-function tests
OT  - Aspirin
EDAT- 2022/09/20 06:00
MHDA- 2022/09/23 06:00
CRDT- 2022/09/19 15:29
PHST- 2022/09/19 15:29 [entrez]
PHST- 2022/09/20 06:00 [pubmed]
PHST- 2022/09/23 06:00 [medline]
PST - ppublish
SO  - Pain Physician. 2022 Sep;25(6):501-507.

PMID- 3055941
OWN - NLM
STAT- MEDLINE
DCOM- 19881205
LR  - 20131121
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 83
IP  - 11
DP  - 1988 Nov
TI  - Comparative evaluation of gastrointestinal intolerance produced by plain and 
      tri-buffered aspirin tablets.
PG  - 1220-5
AB  - Two multi-investigator, double-blind, randomized, placebo-controlled, crossover 
      trials were conducted to determine whether tri-buffered formulations of both 
      regular strength aspirin and extra strength aspirin would be less likely than 
      plain aspirin to provoke subjective gastrointestinal (GI) intolerance. Each trial 
      was divided into two phases, a qualification phase and a test phase. During the 
      qualification phase, subjects with a history of gastrointestinal intolerance to 
      aspirin were randomized to a double-blind crossover treatment with aspirin and 
      placebo (325 mg aspirin per tablet in study 1 and 500 mg aspirin per tablet in 
      study 2), two tablets four times a day for 3 days or until the occurrence of 
      stomach upset. Subjects who reported gastrointestinal symptoms with aspirin and 
      not with placebo qualified to participate in the test phase of the study. They 
      were rerandomized to participate in a three-way crossover study of plain aspirin, 
      tri-buffered aspirin, and placebo in the test phase. Tri-buffered aspirin was 
      associated with an appreciable reduction in the incidence of gastrointestinal 
      upset relative to plain aspirin, 34 percentage points in study 1 (p less than 
      0.001) and 33 percentage points in study 2 (p less than 0.001). Similar results 
      were obtained in the evaluation of the reduction of the severity of 
      gastrointestinal symptoms.
FAU - Sabesin, S M
AU  - Sabesin SM
AD  - Section of Digestive Diseases, Rush-Presbyterian-St. Luke's Medical Center, 
      Chicago, Illinois.
FAU - Boyce, H W Jr
AU  - Boyce HW Jr
FAU - King, C E
AU  - King CE
FAU - Mann, J A
AU  - Mann JA
FAU - Ruoff, G
AU  - Ruoff G
FAU - Wall, E
AU  - Wall E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Gases)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Gases
MH  - Heartburn/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Nausea/chemically induced
MH  - Pain/chemically induced
MH  - Random Allocation
MH  - Stomach Diseases/*chemically induced
MH  - Tablets, Enteric-Coated
EDAT- 1988/11/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1988/11/01 00:00
PHST- 1988/11/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1988/11/01 00:00 [entrez]
PST - ppublish
SO  - Am J Gastroenterol. 1988 Nov;83(11):1220-5.

PMID- 31479884
OWN - NLM
STAT- MEDLINE
DCOM- 20191202
LR  - 20191202
IS  - 1873-2828 (Electronic)
IS  - 1350-4177 (Linking)
VI  - 59
DP  - 2019 Dec
TI  - Enhancing pharmaceutical crystallization in a flow crystallizer with ultrasound: 
      Anti-solvent crystallization.
PG  - 104743
LID - S1350-4177(19)30384-0 [pii]
LID - 10.1016/j.ultsonch.2019.104743 [doi]
AB  - Continuous crystallization is a fast growing application domain in the 
      pharmaceutical industry. Application of ultrasound has been proven to have 
      positive effects like reduction in induction time and Metastable Zone Width 
      (MSZW) in both batch and flow systems. Further understanding of flow-based 
      sonocrystallization is required to achieve industrial level scale up. This work 
      investigates the sonocrystallization of pharmaceutical compounds in a tubular 
      flow crystallizer. Acetyl Salicylic Acid (ASA-Aspirin) is used as a model 
      compound with ethanol and water as solvent and anti-solvent, respectively. 
      Experiments were conducted in silent and sonicated conditions to study the MSZW. 
      Ultrasound made it possible to achieve crystallization within the crystallizer 
      which was not possible in silent conditions, under the tested conditions. 
      Continuous crystallization was achieved at as low as 48 wt% of anti-solvent and 
      crystallization was already seen at a supersaturation of 1.02. In some 
      experiments, temperature rise with ultrasound caused the crystals to re-dissolve 
      within the channels. Better crystallization - no re-dissolution - was achieved by 
      using low ultrasonic power without any loss in the yield. Particle sizes of 
      product crystals were in the range of 4-46 µm. In conclusion, ultrasound was 
      highly effective in enabling anti-solvent crystallization of a pharmaceutical 
      compound in a tubular flow crystallizer.
CI  - Copyright © 2019 Elsevier B.V. All rights reserved.
FAU - Hussain, M N
AU  - Hussain MN
AD  - Department of Chemical Engineering, KU Leuven, 3001 Leuven, Belgium.
FAU - Jordens, J
AU  - Jordens J
AD  - Department of Chemical Engineering, KU Leuven, 3001 Leuven, Belgium.
FAU - John, J J
AU  - John JJ
AD  - Department of Chemical Engineering, KU Leuven, 3001 Leuven, Belgium.
FAU - Braeken, L
AU  - Braeken L
AD  - Faculty of Engineering Technology, KU Leuven, Agoralaan Building B Box 8, 3590 
      Diepenbeek, Belgium.
FAU - Van Gerven, T
AU  - Van Gerven T
AD  - Department of Chemical Engineering, KU Leuven, 3001 Leuven, Belgium. Electronic 
      address: tom.vangerven@kuleuven.be.
LA  - eng
PT  - Journal Article
DEP - 20190822
PL  - Netherlands
TA  - Ultrason Sonochem
JT  - Ultrasonics sonochemistry
JID - 9433356
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Solvents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Crystallization/instrumentation/*methods
MH  - Particle Size
MH  - Pharmaceutical Preparations/*chemistry
MH  - Solvents/*chemistry
MH  - Time Factors
MH  - *Ultrasonic Waves
EDAT- 2019/09/04 06:00
MHDA- 2019/12/04 06:00
CRDT- 2019/09/04 06:00
PHST- 2019/03/12 00:00 [received]
PHST- 2019/08/08 00:00 [revised]
PHST- 2019/08/21 00:00 [accepted]
PHST- 2019/09/04 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2019/09/04 06:00 [entrez]
AID - S1350-4177(19)30384-0 [pii]
AID - 10.1016/j.ultsonch.2019.104743 [doi]
PST - ppublish
SO  - Ultrason Sonochem. 2019 Dec;59:104743. doi: 10.1016/j.ultsonch.2019.104743. Epub 
      2019 Aug 22.

PMID- 17242311
OWN - NLM
STAT- MEDLINE
DCOM- 20070216
LR  - 20181201
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 167
IP  - 2
DP  - 2007 Jan 22
TI  - Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant 
      therapy alone among patients at risk for cardiovascular disease: a meta-analysis 
      of randomized trials.
PG  - 117-24
AB  - BACKGROUND: For patients receiving oral anticoagulant (OAC) therapy, deciding 
      whether to add aspirin to their treatment is a common clinical scenario with no 
      clear guidelines to aid practice. We performed a systematic review and 
      meta-analysis of randomized controlled trials comparing these 2 treatment 
      strategies (combined aspirin-OAC therapy vs OAC therapy alone) to assess the 
      therapeutic benefits and risks. DATA SOURCES: Randomized controlled trials 
      published up to June 2005 in MEDLINE, EMBASE, and Cochrane Library databases. 
      STUDY SELECTION: Randomized controlled trials with at least 3 months of follow-up 
      that compared aspirin-OAC therapy with OAC therapy alone, in which OAC was 
      administered to achieve the same target international normalized ratio or was 
      given at the same fixed dose in both treatment arms. DATA EXTRACTION: Two 
      reviewers independently extracted data on study characteristics and outcomes. 
      Pooled odds ratios (ORs) and associated 95% confidence intervals (CIs) were 
      calculated for study outcomes in patients receiving aspirin-OAC therapy and OAC 
      therapy alone. DATA SYNTHESIS: Ten studies were included, totaling 4180 patients. 
      The risk for arterial thromboembolism was lower in patients receiving combined 
      aspirin-OAC therapy compared with OAC therapy alone (OR, 0.66; 95% CI, 
      0.52-0.84). However, these benefits were limited to patients with a mechanical 
      heart valve (OR, 0.27; 95% CI, 0.15-0.49). There was no difference in the risk 
      for arterial thromboembolism with these treatments in patients with atrial 
      fibrillation (OR, 0.99; 95% CI, 0.47-2.07) or coronary artery disease (OR, 0.69; 
      95% CI, 0.35-1.36). There was no difference in all-cause mortality with either 
      treatment (OR, 0.98; 95% CI, 0.77-1.25). The risk for major bleeding was higher 
      in patients receiving aspirin-OAC therapy compared with OAC therapy alone (OR, 
      1.43; 95% CI, 1.00-2.02). CONCLUSION: Our findings question the current practice 
      of using combined aspirin-OAC therapy except in patients with a mechanical heart 
      valve, given the questionable benefits in reducing thromboembolic events and the 
      increased risk of major bleeding.
FAU - Dentali, Francesco
AU  - Dentali F
AD  - Department of Medicine, McMaster University, and St Joseph's Healthcare, 
      Hamilton, Ontario, Canada.
FAU - Douketis, James D
AU  - Douketis JD
FAU - Lim, Wendy
AU  - Lim W
FAU - Crowther, Mark
AU  - Crowther M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Evid Based Nurs. 2007 Jul;10(3):79. PMID: 17596384
CIN - J Fam Pract. 2007 Jun;56(6):430. PMID: 17607844
MH  - Administration, Oral
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Heart Valve Prosthesis
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Mortality
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Thromboembolism/mortality/*prevention & control
RF  - 54
EDAT- 2007/01/24 09:00
MHDA- 2007/02/17 09:00
CRDT- 2007/01/24 09:00
PHST- 2007/01/24 09:00 [pubmed]
PHST- 2007/02/17 09:00 [medline]
PHST- 2007/01/24 09:00 [entrez]
AID - 167/2/117 [pii]
AID - 10.1001/archinte.167.2.117 [doi]
PST - ppublish
SO  - Arch Intern Med. 2007 Jan 22;167(2):117-24. doi: 10.1001/archinte.167.2.117.

PMID- 8644081
OWN - NLM
STAT- MEDLINE
DCOM- 19960715
LR  - 20131121
IS  - 0029-2001 (Print)
IS  - 0029-2001 (Linking)
VI  - 116
IP  - 6
DP  - 1996 Feb 28
TI  - [Sensitivity to acetylsalicylic acid].
PG  - 754-6
AB  - Because of its ability of prevent platelet aggregation, the use of aspirin in 
      Norway is rising abruptly, after some years of fairly low consumption. The author 
      reviews of aspirin-sensitivity, including chronic rhinosinusitis, nasal polyposis 
      and corticosteroid-dependent asthma. Non-steroidal anti-inflammatory drugs have 
      widespread cross-reactions with aspirin, while azo-dyes and food preservatives 
      may induce a similar chronic inflammation of the airways. Why some people develop 
      aspirin-sensitivity is unknown. The basic biochemical mechanisms of 
      aspirin-sensitivity are discussed. Specific treatment based on desensitisation 
      and development of leukotriene receptor antagonists may be rewarding in the 
      future. Possible beneficial or adverse effects of life-long, low-dose use of 
      aspirin on aspirin-sensitivity should be monitored.
FAU - Elverland, H H
AU  - Elverland HH
AD  - Ore-nese-halsavdelingen, Regionsykehuset i Tromsø.
LA  - nor
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Sensitivitet ved bruk av acetylsalisylsyre.
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny 
      raekke
JID - 0413423
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/immunology
MH  - Cyclooxygenase Inhibitors/*adverse effects/immunology
MH  - Drug Hypersensitivity/*etiology/immunology
MH  - Humans
RF  - 22
EDAT- 1996/02/28 00:00
MHDA- 1996/02/28 00:01
CRDT- 1996/02/28 00:00
PHST- 1996/02/28 00:00 [pubmed]
PHST- 1996/02/28 00:01 [medline]
PHST- 1996/02/28 00:00 [entrez]
PST - ppublish
SO  - Tidsskr Nor Laegeforen. 1996 Feb 28;116(6):754-6.

PMID- 1158188
OWN - NLM
STAT- MEDLINE
DCOM- 19751204
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 16
IP  - 7
DP  - 1975 Jul
TI  - Electronmicroscopic observations on the effects of orally administered aspirin 
      and aspirin-bicarbonate mixtures on the development of gastric mucosal damage in 
      the rat.
PG  - 514-27
AB  - The effects of administering a single dose of (200 mg to 50 mg/kg body weight) 
      aspirin or an equimolar mixture of aspirin (200 mg/kg body wt) with sodium 
      bicarbonate on the fine structure of the rat gastric mucosa were investigated in 
      order to establish the role of particles of the drug in the development of 
      gastric damage. The sequence of cellular events involved in the development of a 
      lesion and the influence of short-term starvation were also investigated. 
      Aspirin-bicarbonate solutions produced much less damage in starved rats than 
      aspirin suspensions given at low (50 mg/kg body weight) or high therapeutic doses 
      (200 mg/kg body weight). Also, when non-starved rats were given 200 mg/kg 
      aspirin, only slight damage was observed. The presence of particles of the drug 
      in intimate contact with the mucosa is thus important in the development of 
      gastric damage. A sequence of events with time involving direct physical 
      exfoliation of mucosal cells and selective structural damage to parietal cells 
      followed by structural damage indicative of a disturbance to oxidative and 
      biosynthetic functions in cells near the developing erosion was observed. The 
      implications of these results on the development of aspirin-induced lesions are 
      discussed.
FAU - Rainsford, K D
AU  - Rainsford KD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Bicarbonates)
RN  - 0 (Solutions)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Bicarbonates/*pharmacology
MH  - Gastric Mucosa/*drug effects/metabolism/ultrastructure
MH  - Male
MH  - Mitochondria/ultrastructure
MH  - Rats
MH  - Solutions
MH  - Starvation
PMC - PMC1410981
EDAT- 1975/07/01 00:00
MHDA- 1975/07/01 00:01
CRDT- 1975/07/01 00:00
PHST- 1975/07/01 00:00 [pubmed]
PHST- 1975/07/01 00:01 [medline]
PHST- 1975/07/01 00:00 [entrez]
AID - 10.1136/gut.16.7.514 [doi]
PST - ppublish
SO  - Gut. 1975 Jul;16(7):514-27. doi: 10.1136/gut.16.7.514.

PMID- 36455245
OWN - NLM
STAT- MEDLINE
DCOM- 20221205
LR  - 20230408
IS  - 1531-5487 (Electronic)
IS  - 1044-3983 (Print)
IS  - 1044-3983 (Linking)
VI  - 34
IP  - 1
DP  - 2023 Jan 1
TI  - Estimation of the Time-Varying Incremental Effect of Low-dose Aspirin on 
      Incidence of Pregnancy.
PG  - 38-44
LID - 10.1097/EDE.0000000000001545 [doi]
AB  - BACKGROUND: In many research settings, the intervention implied by the average 
      causal effect of a time-varying exposure is impractical or unrealistic, and we 
      might instead prefer a more realistic target estimand. Instead of requiring all 
      individuals to be always exposed versus unexposed, incremental effects quantify 
      the impact of merely shifting each individual's probability of being exposed. 
      METHODS: We demonstrate the estimation of incremental effects in the time-varying 
      setting, using data from the Effects of Aspirin in Gestation and Reproduction 
      trial, which assessed the effect of preconception low-dose aspirin on pregnancy 
      outcomes. Compliance to aspirin or placebo was summarized weekly and was affected 
      by time-varying confounders such as bleeding or nausea. We sought to estimate 
      what the incidence of pregnancy by 26 weeks postrandomization would have been if 
      we shifted each participant's probability of taking aspirin or placebo each week 
      by odds ratios (OR) between 0.30 and 3.00. RESULTS: Under no intervention (OR = 
      1), the incidence of pregnancy was 77% (95% CI: 74%, 80%). Decreasing women's 
      probability of complying with aspirin had little estimated effect on pregnancy 
      incidence. When we increased women's probability of taking aspirin, estimated 
      incidence of pregnancy increased, from 83% (95% confidence interval [CI] = 79%, 
      87%) for OR = 2 to 89% (95% CI = 84%, 93%) for OR=3. We observed similar results 
      when we shifted women's probability of complying with a placebo. CONCLUSIONS: 
      These results estimated that realistic interventions to increase women's 
      probability of taking aspirin would have yielded little to no impact on the 
      incidence of pregnancy, relative to similar interventions on placebo.
CI  - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Rudolph, Jacqueline E
AU  - Rudolph JE
AUID- ORCID: 0000-0001-7177-1847
AD  - Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins 
      University, Baltimore, MD.
FAU - Kim, Kwangho
AU  - Kim K
AD  - Department of Health Care Policy, Harvard Medical School, Boston, MA.
FAU - Kennedy, Edward H
AU  - Kennedy EH
AD  - Department of Statistics, Carnegie Mellon University, Pittsburgh, PA.
FAU - Naimi, Ashley I
AU  - Naimi AI
AD  - Department of Epidemiology, Rollins School of Public Health, Emory University, 
      Atlanta, GA.
LA  - eng
GR  - R01 AI170240/AI/NIAID NIH HHS/United States
GR  - R01 CA250851/CA/NCI NIH HHS/United States
GR  - R01 HD093602/HD/NICHD NIH HHS/United States
GR  - U01 DA036297/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20220927
PL  - United States
TA  - Epidemiology
JT  - Epidemiology (Cambridge, Mass.)
JID - 9009644
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Humans
MH  - Female
MH  - Incidence
MH  - Odds Ratio
MH  - *Aspirin/therapeutic use
MH  - Probability
MH  - *Nausea
PMC - PMC9718380
MID - NIHMS1836138
COIS- The authors report no conflicts of interest.
EDAT- 2022/12/02 06:00
MHDA- 2022/12/06 06:00
PMCR- 2024/01/01
CRDT- 2022/12/01 17:02
PHST- 2024/01/01 00:00 [pmc-release]
PHST- 2022/12/02 06:00 [pubmed]
PHST- 2022/12/06 06:00 [medline]
PHST- 2022/12/01 17:02 [entrez]
AID - 00001648-202301000-00006 [pii]
AID - 10.1097/EDE.0000000000001545 [doi]
PST - ppublish
SO  - Epidemiology. 2023 Jan 1;34(1):38-44. doi: 10.1097/EDE.0000000000001545. Epub 
      2022 Sep 27.

PMID- 1519760
OWN - NLM
STAT- MEDLINE
DCOM- 19921007
LR  - 20190627
IS  - 0003-2697 (Print)
IS  - 0003-2697 (Linking)
VI  - 202
IP  - 2
DP  - 1992 May 1
TI  - The use of a layering technique for enhancing stability of lyophilized reagents.
PG  - 331-6
AB  - An enzyme-mediated assay has been developed for the measurement of salicylate 
      using salicylate monooxygenase purified from Pseudomonas cepacia ATCC 29351. Two 
      assay formulations were produced, based on either a multiple-reagent or a 
      single-reagent formulation, to allow sufficient flexibility for automated use. 
      The multiple-reagent formulation was especially suited to diagnostic laboratories 
      performing infrequent manual salicylate estimation where stability of the 
      reconstituted reagent is of paramount importance. This was achieved by preparing 
      the enzyme and color reagents in separate vials, so keeping the enzyme at a 
      stable pH. For more frequent assay use where a reconstituted reagent shelf life 
      was less important, the single-reagent system offers advantages of convenience. 
      However, the working reagent required a pH of 10.0 upon reconstitution. Although 
      the enzyme was sufficiently active at this pH to give a reliable assay, its 
      storage stability was poor at pH 10.0, preventing lyophilization of the reagent 
      at a pH suitable for immediate use on reconstitution. This incompatibility was 
      overcome by use of a layering technique. The enzyme was separated from the 
      buffering solution in the same vial by freezing the buffering solution and then 
      overlayering with the enzyme reagent prior to a second freezing cycle and 
      subsequent freeze drying.
FAU - Ramsay, J R
AU  - Ramsay JR
AD  - Division of Biotechnology, PHLS Centre for Applied Microbiology & Research, 
      Porton Down, Salisbury, Wiltshire, UK.
FAU - Adams, G D
AU  - Adams GD
FAU - Morris, H C
AU  - Morris HC
FAU - Campbell, R S
AU  - Campbell RS
FAU - Price, C P
AU  - Price CP
FAU - Hammond, P M
AU  - Hammond PM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anal Biochem
JT  - Analytical biochemistry
JID - 0370535
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - EC 1.14.13.1 (salicylate 1-monooxygenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Drug Stability
MH  - Freeze Drying
MH  - Mixed Function Oxygenases/analysis/*chemistry
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
AID - 0003-2697(92)90113-L [pii]
AID - 10.1016/0003-2697(92)90113-l [doi]
PST - ppublish
SO  - Anal Biochem. 1992 May 1;202(2):331-6. doi: 10.1016/0003-2697(92)90113-l.

PMID- 6103930
OWN - NLM
STAT- MEDLINE
DCOM- 19800815
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 32
IP  - 3
DP  - 1980 Mar
TI  - The influence of drug and diluent particle size on the in vitro release of drug 
      from hard gelatin capsules.
PG  - 167-71
AB  - The in vitro release of a drug from capsules containing different proportions of 
      controlled particle size fractions of acetylsalicylic acid and lactose, has been 
      assessed in terms of the time for 50% of the drug content of the capsule to be 
      released into solution during a dissolution test (T50), and by a standard 
      disintegration test. In general the two types of test gave closely related 
      responses although some discrepancies existed with certain systems. For capsules 
      containing only the drug, the value of T50 increased as the particle size of the 
      drug decreased. The addition of lactose generally reduced the T50 value, the 
      extent of the reduction showing greater dependence on the proportion of lactose 
      added than its particle size. Capsule formulations containing 80% w/w of lactose 
      had values of T50 which were independent of drug or diluent particle size. 
      Capsule formulations containing lower proportions of lactose usually had an 
      optimum combination of particle size fractions of drug and diluent for maximum 
      drug release. The relationship between drug release and the porosity within the 
      capsule was dependent on the particle size of the drug.
FAU - Newton, J M
AU  - Newton JM
FAU - Bader, F
AU  - Bader F
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Capsules)
RN  - 0 (Excipients)
RN  - 9000-70-8 (Gelatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - *Capsules
MH  - Drug Compounding
MH  - Excipients
MH  - *Gelatin
MH  - Particle Size
MH  - Solubility
MH  - Time Factors
EDAT- 1980/03/01 00:00
MHDA- 1980/03/01 00:01
CRDT- 1980/03/01 00:00
PHST- 1980/03/01 00:00 [pubmed]
PHST- 1980/03/01 00:01 [medline]
PHST- 1980/03/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1980.tb12883.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1980 Mar;32(3):167-71. doi: 
      10.1111/j.2042-7158.1980.tb12883.x.

PMID- 26521717
OWN - NLM
STAT- MEDLINE
DCOM- 20170104
LR  - 20170105
IS  - 1527-3792 (Electronic)
IS  - 0022-5347 (Linking)
VI  - 195
IP  - 4 Pt 1
DP  - 2016 Apr
TI  - Outcomes of Laparoscopic Partial Nephrectomy in Patients Continuing Aspirin 
      Therapy.
PG  - 859-64
LID - S0022-5347(15)05152-6 [pii]
LID - 10.1016/j.juro.2015.10.132 [doi]
AB  - PURPOSE: A clinical dilemma surrounds the use of aspirin therapy during 
      laparoscopic partial nephrectomy. Despite reduced cardiac morbidity with 
      perioperative aspirin use, fear of bleeding related complications often prompts 
      discontinuation of therapy before surgery. We evaluate perioperative outcomes 
      among patients continuing aspirin and those in whom treatment is stopped 
      preoperatively. MATERIALS AND METHODS: A total of 430 consecutive cases of 
      laparoscopic partial nephrectomy performed between January 2012 and October 2014 
      were reviewed. Patients on chronic aspirin therapy were stratified into on 
      aspirin and off aspirin groups based on perioperative status of aspirin use. 
      Primary end points evaluated included estimated intraoperative blood loss and 
      incidence of bleeding related complications, major postoperative complications, 
      and thromboembolic events. Secondary outcomes included operative time, 
      transfusion rate, length of hospital stay, rehospitalization rate and surgical 
      margin status. RESULTS: Among 101 (23.4%) patients on chronic aspirin therapy, 
      antiplatelet treatment was continued in 17 (16.8%). Bleeding developed in 1 
      patient in the on aspirin group postoperatively and required angioembolization. 
      Conversely 1 myocardial infarction was observed in the off aspirin cohort. There 
      was no significant difference in the incidence of major postoperative 
      complications, intraoperative blood loss, transfusion rate, length of hospital 
      stay and rehospitalization rate. Operative time was increased with continued 
      aspirin use (181 vs 136 minutes, p=0.01). CONCLUSIONS: Laparoscopic partial 
      nephrectomy is safe and effective in patients on chronic antiplatelet therapy who 
      require perioperative aspirin for cardioprotection. Larger, prospective studies 
      are necessary to discern the true cardiovascular benefit derived from continued 
      aspirin therapy as well as better characterize associated bleeding risk.
CI  - Copyright © 2016 American Urological Association Education and Research, Inc. 
      Published by Elsevier Inc. All rights reserved.
FAU - Leavitt, David A
AU  - Leavitt DA
AD  - Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ 
      School of Medicine, New Hyde Park, New York.
FAU - Keheila, Mohamed
AU  - Keheila M
AD  - Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ 
      School of Medicine, New Hyde Park, New York. Electronic address: 
      uro.m.esmat@gmail.com.
FAU - Siev, Michael
AU  - Siev M
AD  - Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ 
      School of Medicine, New Hyde Park, New York.
FAU - Shah, Paras H
AU  - Shah PH
AD  - Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ 
      School of Medicine, New Hyde Park, New York.
FAU - Moreira, Daniel M
AU  - Moreira DM
AD  - Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ 
      School of Medicine, New Hyde Park, New York.
FAU - George, Arvin K
AU  - George AK
AD  - Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ 
      School of Medicine, New Hyde Park, New York.
FAU - Salami, Simpa S
AU  - Salami SS
AD  - Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ 
      School of Medicine, New Hyde Park, New York.
FAU - Schwartz, Michael J
AU  - Schwartz MJ
AD  - Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ 
      School of Medicine, New Hyde Park, New York.
FAU - Richstone, Lee
AU  - Richstone L
AD  - Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ 
      School of Medicine, New Hyde Park, New York.
FAU - Vira, Manish A
AU  - Vira MA
AD  - Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ 
      School of Medicine, New Hyde Park, New York.
FAU - Kavoussi, Louis R
AU  - Kavoussi LR
AD  - Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ 
      School of Medicine, New Hyde Park, New York.
LA  - eng
PT  - Journal Article
DEP - 20151029
PL  - United States
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Loss, Surgical
MH  - Feasibility Studies
MH  - Humans
MH  - *Laparoscopy
MH  - Length of Stay
MH  - Nephrectomy/*methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Complications/*chemically induced/epidemiology
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin
OT  - kidney neoplasms
OT  - laparoscopy
OT  - nephrectomy
EDAT- 2015/11/03 06:00
MHDA- 2017/01/05 06:00
CRDT- 2015/11/03 06:00
PHST- 2015/10/22 00:00 [accepted]
PHST- 2015/11/03 06:00 [entrez]
PHST- 2015/11/03 06:00 [pubmed]
PHST- 2017/01/05 06:00 [medline]
AID - S0022-5347(15)05152-6 [pii]
AID - 10.1016/j.juro.2015.10.132 [doi]
PST - ppublish
SO  - J Urol. 2016 Apr;195(4 Pt 1):859-64. doi: 10.1016/j.juro.2015.10.132. Epub 2015 
      Oct 29.

PMID- 3821177
OWN - NLM
STAT- MEDLINE
DCOM- 19870331
LR  - 20190516
IS  - 0025-6196 (Print)
IS  - 0025-6196 (Linking)
VI  - 62
IP  - 3
DP  - 1987 Mar
TI  - Influence of aspirin and ethanol on fecal blood levels as determined by using the 
      HemoQuant assay.
PG  - 159-63
AB  - We sought to determine the short-term effects of use of aspirin and ethanol on 
      fecal occult blood levels measured with the HemoQuant assay. A factorial design 
      was used to study 68 healthy volunteers randomized to receive various doses of 
      aspirin, ethanol, or a combination of both for either 1 or 3 days. Fecal 
      hemoglobin concentrations were measured before and after drug ingestions. 
      Moderate quantities of ethanol (300 ml of 5% or 30 ml of 50% three times nightly) 
      did not cause significant fecal blood elevation unless aspirin was administered 
      concomitantly (P = 0.05). High-dose aspirin alone, 975 mg three times daily, 
      induced abnormal blood loss (P less than 0.01). The highest HemoQuant levels were 
      usually noted after concomitant administration of aspirin and ethanol at maximal 
      doses for 3 days (P less than 0.005), some HemoQuant levels approaching 5 times 
      the normal value. We conclude that, in a short-term analysis, social consumption 
      of ethanol is unlikely to interfere with fecal blood testing but therapeutic 
      doses of aspirin will.
FAU - Fleming, J L
AU  - Fleming JL
FAU - Ahlquist, D A
AU  - Ahlquist DA
FAU - McGill, D B
AU  - McGill DB
FAU - Zinsmeister, A R
AU  - Zinsmeister AR
FAU - Ellefson, R D
AU  - Ellefson RD
FAU - Schwartz, S
AU  - Schwartz S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
RN  - 0 (Indicators and Reagents)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Ethanol/*adverse effects
MH  - Female
MH  - Humans
MH  - Indicators and Reagents
MH  - Male
MH  - Middle Aged
MH  - *Occult Blood
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - S0025-6196(12)62437-9 [pii]
AID - 10.1016/s0025-6196(12)62437-9 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 1987 Mar;62(3):159-63. doi: 10.1016/s0025-6196(12)62437-9.

PMID- 237091
OWN - NLM
STAT- MEDLINE
DCOM- 19750905
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 27
IP  - 6
DP  - 1975 Jun
TI  - A simultaneous determination of acetylsalicylic acid, salicylic acid and 
      salicylamide in plasma by gas liquid chromatography.
PG  - 425-9
AB  - A novel method for the simultaneous determination of acetylsalicylic acid, 
      salicylic acid and salicylamide in biological fluids by gas liquid chromatography 
      is described. The assay has been used to determine the plasma concentration of 
      salicylates in 10 volunteers after oral ingestion of three commercially available 
      aspirin-containing formulations. No difficulty was encountered in determining low 
      concentrations of acetylsalicylic acid in the presence of higher concentrations 
      of salicylic acid. The in vivo plasma half life of acetylsalicylic acid in man 
      was found to be 15.5 min.
FAU - Rance, M J
AU  - Rance MJ
FAU - Jordan, B J
AU  - Jordan BJ
FAU - Nichols, J D
AU  - Nichols JD
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Salicylamides)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*blood
MH  - Chromatography, Gas/*methods
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Salicylamides/*blood
MH  - Salicylates/*blood
MH  - Time Factors
EDAT- 1975/06/01 00:00
MHDA- 1975/06/01 00:01
CRDT- 1975/06/01 00:00
PHST- 1975/06/01 00:00 [pubmed]
PHST- 1975/06/01 00:01 [medline]
PHST- 1975/06/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1975.tb09472.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1975 Jun;27(6):425-9. doi: 10.1111/j.2042-7158.1975.tb09472.x.

PMID- 22749649
OWN - NLM
STAT- MEDLINE
DCOM- 20130612
LR  - 20131121
IS  - 1878-3562 (Electronic)
IS  - 1590-8658 (Linking)
VI  - 44
IP  - 10
DP  - 2012 Oct
TI  - Differences in the severity of small bowel mucosal injury based on the type of 
      aspirin as evaluated by capsule endoscopy.
PG  - 833-8
LID - 10.1016/j.dld.2012.05.016 [doi]
AB  - BACKGROUND: The differences in the small intestinal toxicity of low-dose aspirin 
      based on the type of aspirin used remains unclear. The purpose of this study was 
      to evaluate the differences in the small bowel mucosal injury between buffered 
      and enteric-coated aspirin users by capsule endoscopy. METHODS: We 
      retrospectively reviewed the findings in chronic low-dose aspirin users (>3 
      months) who underwent capsule endoscopy for the investigation of obscure 
      gastrointestinal bleeding. The patients were classified into two groups based on 
      the type of low-dose aspirin that they had been prescribed (enteric-coated 
      aspirin group or buffered aspirin group), and evaluated the numbers of small 
      bowel lesions and the Lewis score. RESULTS: Capsule-endoscopic findings of a 
      total of 70 patients taking low-dose aspirin were reviewed. Significant 
      differences in the number of erosions and ulcers were observed between the 
      buffered and enteric-coated aspirin groups (P=0.017 and P=0.037, respectively). 
      The median Lewis score for the small bowel mucosal inflammatory change was 
      significantly higher in the enteric-coated aspirin group than in the buffered 
      aspirin group (P=0.035). CONCLUSIONS: The results of this study suggested that 
      enteric-coated aspirin might be more injurious to the small bowel mucosa than 
      buffered aspirin.
CI  - Copyright © 2012 Editrice Gastroenterologica Italiana S.r.l. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Endo, Hiroki
AU  - Endo H
AD  - Division of Endoscopy, Yokohama City University School of Medicine, 3-9 Fukuura, 
      Kanazawa-ku, Yokohama, Japan. endo1978@yokohama-cu.ac.jp
FAU - Sakai, Eiji
AU  - Sakai E
FAU - Higurashi, Takuma
AU  - Higurashi T
FAU - Yamada, Eiji
AU  - Yamada E
FAU - Ohkubo, Hidenori
AU  - Ohkubo H
FAU - Iida, Hiroshi
AU  - Iida H
FAU - Koide, Tomoko
AU  - Koide T
FAU - Yoneda, Masato
AU  - Yoneda M
FAU - Abe, Yasunobu
AU  - Abe Y
FAU - Inamori, Masahiko
AU  - Inamori M
FAU - Hosono, Kunihiro
AU  - Hosono K
FAU - Takahashi, Hirokazu
AU  - Takahashi H
FAU - Kubota, Kensuke
AU  - Kubota K
FAU - Nakajima, Atsushi
AU  - Nakajima A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120628
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Capsule Endoscopy
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/*pathology
MH  - Humans
MH  - Intestinal Mucosa/drug effects/*pathology
MH  - Intestine, Small/drug effects/*pathology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
EDAT- 2012/07/04 06:00
MHDA- 2013/06/13 06:00
CRDT- 2012/07/04 06:00
PHST- 2011/12/26 00:00 [received]
PHST- 2012/04/04 00:00 [revised]
PHST- 2012/05/16 00:00 [accepted]
PHST- 2012/07/04 06:00 [entrez]
PHST- 2012/07/04 06:00 [pubmed]
PHST- 2013/06/13 06:00 [medline]
AID - S1590-8658(12)00199-5 [pii]
AID - 10.1016/j.dld.2012.05.016 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2012 Oct;44(10):833-8. doi: 10.1016/j.dld.2012.05.016. Epub 2012 
      Jun 28.

PMID- 19477488
OWN - NLM
STAT- MEDLINE
DCOM- 20100513
LR  - 20171116
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 125
IP  - 2
DP  - 2010 Feb
TI  - Parnaparin versus aspirin in the treatment of retinal vein occlusion. A 
      randomized, double blind, controlled study.
PG  - 137-41
LID - 10.1016/j.thromres.2009.05.007 [doi]
AB  - INTRODUCTION: Retinal vein occlusion (RVO) is a common cause of unilateral visual 
      loss. Evidence based treatment recommendations for patients with RVO cannot be 
      made because of the lack of adequate clinical trials. To compare the efficacy and 
      safety of aspirin and of a low molecular weight heparin, parnaparin, in the 
      treatment of RVO. MATERIALS AND METHODS: In a multicenter, randomized, double 
      blind, controlled trial eligible patients with a delay between symptoms onset and 
      objective diagnosis of less than 15 days were randomized to aspirin 100 mg/day 
      for 3 months or to a fixed daily dose of parnaparin, 12.800 IU for 7 days 
      followed by 6.400 IU for a total of 3 months. Primary end-point of the study was 
      the incidence of functional worsening of the eye with RVO at 6 months, as 
      assessed by fluorescein angiography, visual acuity, and visual field. Study 
      end-points were adjudicated by an independent committee. RESULTS: Sixty-seven 
      patients were enrolled in the study and 58 of them (28 treated with parnaparin, 
      30 with aspirin) were evaluable for the analysis. Baseline characteristics were 
      well balanced between groups. Functional worsening was adjudicated in 20.7% of 
      patients treated with parnaparin and in 59.4% of patients treated with ASA 
      (p=0.002). Recurrent RVO was diagnosed in 3 patients, all treated with ASA 
      (p=n.s.). Bleeding rates were similar between the two groups. CONCLUSIONS: 
      Parnaparin appears to be more effective than aspirin in preventing functional 
      worsening in patients with RVO. The results of this study need to be confirmed in 
      a larger clinical trial.
CI  - Copyright 2009 Elsevier Ltd. All rights reserved.
FAU - Ageno, Walter
AU  - Ageno W
AD  - University of Insubria, Varese, Italy. agewal@yahoo.com
FAU - Cattaneo, Roberto
AU  - Cattaneo R
FAU - Manfredi, Elisa
AU  - Manfredi E
FAU - Chelazzi, Paolo
AU  - Chelazzi P
FAU - Venco, Luigi
AU  - Venco L
FAU - Ghirarduzzi, Angelo
AU  - Ghirarduzzi A
FAU - Cimino, Luca
AU  - Cimino L
FAU - Filippucci, Esmeralda
AU  - Filippucci E
FAU - Ricci, Angela Luisa
AU  - Ricci AL
FAU - Romanelli, Donatella
AU  - Romanelli D
FAU - Incorvaia, Carlo
AU  - Incorvaia C
FAU - D'Angelo, Sergio
AU  - D'Angelo S
FAU - Campana, Fiamma
AU  - Campana F
FAU - Molfino, Francesco
AU  - Molfino F
FAU - Scannapieco, Gianluigi
AU  - Scannapieco G
FAU - Rubbi, Flavia
AU  - Rubbi F
FAU - Imberti, Davide
AU  - Imberti D
LA  - eng
SI  - ClinicalTrials.gov/NCT00732927
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090527
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - M316WT19D8 (parnaparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Hemorrhage
MH  - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Retinal Vein Occlusion/*drug therapy
MH  - Treatment Outcome
EDAT- 2009/05/30 09:00
MHDA- 2010/05/14 06:00
CRDT- 2009/05/30 09:00
PHST- 2009/03/24 00:00 [received]
PHST- 2009/05/05 00:00 [revised]
PHST- 2009/05/06 00:00 [accepted]
PHST- 2009/05/30 09:00 [entrez]
PHST- 2009/05/30 09:00 [pubmed]
PHST- 2010/05/14 06:00 [medline]
AID - S0049-3848(09)00222-9 [pii]
AID - 10.1016/j.thromres.2009.05.007 [doi]
PST - ppublish
SO  - Thromb Res. 2010 Feb;125(2):137-41. doi: 10.1016/j.thromres.2009.05.007. Epub 
      2009 May 27.

PMID- 26820772
OWN - NLM
STAT- MEDLINE
DCOM- 20170523
LR  - 20171107
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 105
IP  - 5
DP  - 2016 May
TI  - Subchorionic hematomas are increased in early pregnancy in women taking low-dose 
      aspirin.
PG  - 1241-1246
LID - S0015-0282(16)00044-3 [pii]
LID - 10.1016/j.fertnstert.2016.01.009 [doi]
AB  - OBJECTIVE: To determine the frequency of subchorionic hematomas (SCH) in 
      first-trimester ultrasound examinations of patients with infertility and 
      recurrent pregnancy loss (RPL) and in patients from a general obstetric 
      population. To determine if the method of assisted reproduction utilized or the 
      use of anticoagulants, such as heparin and aspirin (ASA), influenced frequency of 
      SCH. DESIGN: Prospective, cohort study. SETTING: Fertility clinic and general 
      obstetrics clinic. PATIENT(S): Five hundred and thirty-three women who were 
      pregnant in the first-trimester. INTERVENTIONS: Not applicable. MAIN OUTCOME 
      MEASURE(S): Frequencies of subchorionic hematomas in women based on diagnosis, 
      use of anticoagulants, and fertility treatment. RESULT(S): SCH were identified in 
      129/321 (40.2%) in the study group compared to 23/212 (10.9%) in the control 
      group. Fertility diagnosis and the use of heparin did not appear to affect the 
      frequency of SCH in the first trimester; however, SCH occurred at an almost 
      four-fold increase in patients taking ASA compared to those not taking ASA, 
      regardless of fertility diagnosis or method of fertility treatment. 
      CONCLUSION(S): The use of ASA may be associated with an increased risk of 
      developing a SCH during the first trimester. The increased frequencies of SCH in 
      pregnancies of patients attending a fertility clinic compared to women from a 
      general obstetrical practice was highly correlated with the use of ASA.
CI  - Copyright © 2016 American Society for Reproductive Medicine. Published by 
      Elsevier Inc. All rights reserved.
FAU - Truong, Ashley
AU  - Truong A
AD  - Department of Biochemistry and Molecular Biology, Rhodes College, Memphis, 
      Tennessee.
FAU - Sayago, M Mercedes
AU  - Sayago MM
AD  - Newport Beach Women's Wellness Center, Newport Beach, California.
FAU - Kutteh, William H
AU  - Kutteh WH
AD  - Department of Obstetrics and Gynecology, Fertility Associates of Memphis, 
      Vanderbilt University, Memphis, Tennessee. Electronic address: 
      wkutteh@fertilitymemphis.com.
FAU - Ke, Raymond W
AU  - Ke RW
AD  - Department of Obstetrics and Gynecology, Fertility Associates of Memphis, 
      Vanderbilt University, Memphis, Tennessee.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160125
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Chorion/*diagnostic imaging/drug effects
MH  - Cohort Studies
MH  - Female
MH  - Hematoma/chemically induced/*diagnostic imaging
MH  - Humans
MH  - Middle Aged
MH  - Pregnancy
MH  - Pregnancy Complications/chemically induced/*diagnostic imaging
MH  - Prospective Studies
OTO - NOTNLM
OT  - anticoagulants
OT  - aspirin
OT  - infertility
OT  - recurrent pregnancy loss
OT  - subchorionic hematomas
EDAT- 2016/01/29 06:00
MHDA- 2017/05/24 06:00
CRDT- 2016/01/29 06:00
PHST- 2015/11/03 00:00 [received]
PHST- 2016/01/07 00:00 [revised]
PHST- 2016/01/07 00:00 [accepted]
PHST- 2016/01/29 06:00 [entrez]
PHST- 2016/01/29 06:00 [pubmed]
PHST- 2017/05/24 06:00 [medline]
AID - S0015-0282(16)00044-3 [pii]
AID - 10.1016/j.fertnstert.2016.01.009 [doi]
PST - ppublish
SO  - Fertil Steril. 2016 May;105(5):1241-1246. doi: 10.1016/j.fertnstert.2016.01.009. 
      Epub 2016 Jan 25.

PMID- 36877278
OWN - NLM
STAT- MEDLINE
DCOM- 20230418
LR  - 20230524
IS  - 1573-7284 (Electronic)
IS  - 0393-2990 (Print)
IS  - 0393-2990 (Linking)
VI  - 38
IP  - 4
DP  - 2023 Apr
TI  - Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort 
      study of one million women.
PG  - 413-426
LID - 10.1007/s10654-023-00976-8 [doi]
AB  - Several studies evaluated the association between aspirin use and risk of breast 
      cancer (BC), with inconsistent results. We identified women aged ≥ 50 years 
      residing in Norway between 2004 and 2018, and linked data from nationwide 
      registries; including the Cancer Registry of Norway, the Norwegian Prescription 
      Database, and national health surveys. We used Cox regression models to estimate 
      the association between low-dose aspirin use and BC risk, overall and by BC 
      characteristics, women's age and body mass index (BMI), adjusting for 
      sociodemographic factors and use of other medications. We included 1,083,629 
      women. During a median follow-up of 11.6 years, 257,442 (24%) women used aspirin, 
      and 29,533 (3%) BCs occurred. For current use of aspirin, compared to never use, 
      we found an indication of a reduced risk of oestrogen receptor-positive (ER +) BC 
      (hazard ratio [HR] = 0.96, 95% confidence interval [CI]: 0.92-1.00), but not 
      ER-negative BC (HR = 1.01, 95%CI: 0.90-1.13). The association with ER + BC was 
      only found in women aged ≥ 65 years (HR = 0.95, 95%CI: 0.90-0.99), and became 
      stronger as the duration of use increased (use of ≥ 4 years HR = 0.91, 95%CI: 
      0.85-0.98). BMI was available for 450,080 (42%) women. Current use of aspirin was 
      associated with a reduced risk of ER + BC in women with BMI ≥ 25 (HR = 0.91, 
      95%CI: 0.83-0.99; HR = 0.86, 95%CI: 0.75-0.97 for use of ≥ 4 years), but not in 
      women with BMI < 25.Use of low-dose aspirin was associated with reduced risk of 
      ER + BC, in particular in women aged ≥ 65 years and overweight women.
CI  - © 2023. The Author(s).
FAU - Løfling, Lukas
AU  - Løfling L
AUID- ORCID: 0000-0002-2731-8532
AD  - Department of Research, Cancer Registry of Norway, Postboks 5313 Majorstuen, 
      0304, Oslo, Norway.
FAU - Støer, Nathalie C
AU  - Støer NC
AUID- ORCID: 0000-0001-8994-9332
AD  - Department of Research, Cancer Registry of Norway, Postboks 5313 Majorstuen, 
      0304, Oslo, Norway.
AD  - Norwegian Research Centre for Women's Health, Women's Clinic, Oslo University 
      Hospital, Oslo, Norway.
FAU - Nafisi, Sara
AU  - Nafisi S
AUID- ORCID: 0000-0003-3142-0596
AD  - Department of Research, Cancer Registry of Norway, Postboks 5313 Majorstuen, 
      0304, Oslo, Norway.
AD  - Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, 
      Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
FAU - Ursin, Giske
AU  - Ursin G
AUID- ORCID: 0000-0002-0835-9507
AD  - Cancer Registry of Norway, Oslo, Norway.
AD  - Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, 
      Oslo, Norway.
AD  - Department of Preventive Medicine, University of Southern California, Los 
      Angeles, USA.
FAU - Hofvind, Solveig
AU  - Hofvind S
AUID- ORCID: 0000-0003-0178-8939
AD  - Section for Breast Cancer Screening, Cancer Registry of Norway, Oslo, Norway.
AD  - Department of Health and Care Sciences, UiT The Arctic University of Norway, 
      Tromsø, Norway.
FAU - Botteri, Edoardo
AU  - Botteri E
AUID- ORCID: 0000-0002-9023-8068
AD  - Department of Research, Cancer Registry of Norway, Postboks 5313 Majorstuen, 
      0304, Oslo, Norway. edoardo.botteri@kreftregisteret.no.
AD  - Section for Colorectal Cancer Screening, Cancer Registry of Norway, Postboks 5313 
      Majorstuen, 0304, Oslo, Norway. edoardo.botteri@kreftregisteret.no.
LA  - eng
GR  - 301628/Norwegian Research Council/
PT  - Journal Article
DEP - 20230306
PL  - Netherlands
TA  - Eur J Epidemiol
JT  - European journal of epidemiology
JID - 8508062
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - *Aspirin/administration & dosage/adverse effects
MH  - *Breast Neoplasms/epidemiology/prevention & control
MH  - Cohort Studies
MH  - Proportional Hazards Models
MH  - Risk
MH  - Risk Factors
MH  - Norway/epidemiology
MH  - Case-Control Studies
PMC - PMC10082109
OTO - NOTNLM
OT  - Aspirin
OT  - Breast cancer
OT  - Cohort
OT  - Incidence
OT  - Nested case–control
OT  - Population-based
COIS- LL’s spouse is employed by MSD Norway AS.
EDAT- 2023/03/07 06:00
MHDA- 2023/04/11 06:41
CRDT- 2023/03/06 11:14
PHST- 2022/11/09 00:00 [received]
PHST- 2023/02/03 00:00 [accepted]
PHST- 2023/04/11 06:41 [medline]
PHST- 2023/03/07 06:00 [pubmed]
PHST- 2023/03/06 11:14 [entrez]
AID - 10.1007/s10654-023-00976-8 [pii]
AID - 976 [pii]
AID - 10.1007/s10654-023-00976-8 [doi]
PST - ppublish
SO  - Eur J Epidemiol. 2023 Apr;38(4):413-426. doi: 10.1007/s10654-023-00976-8. Epub 
      2023 Mar 6.

PMID- 23253701
OWN - NLM
STAT- MEDLINE
DCOM- 20131203
LR  - 20121220
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 125
IP  - 24
DP  - 2012 Dec
TI  - Anticoagulation therapy in Chinese patients with non-valvular atrial 
      fibrillation: a prospective, multi-center, randomized, controlled study.
PG  - 4355-60
AB  - BACKGROUND: Non-valvular atrial fibrillation is associated with an increased risk 
      of ischemic stroke; however, the appropriate intensity of anticoagulation therapy 
      for Chinese patients has not been determined. The purpose of this study was to 
      compare the safety and the efficacy of standard-intensity warfarin therapy, 
      low-intensity warfarin therapy, and aspirin therapy for the prevention of 
      ischemic events in Chinese patients with non-valvular atrial fibrillation (NVAF). 
      METHODS: A total of 786 patients from 75 Chinese hospitals were enrolled in this 
      study and randomized into three therapy groups: standard-intensity warfarin 
      (international normalized ratio (INR) 2.1 to 2.5) group, low-intensity warfarin 
      (INR 1.6 to 2.0) group and aspirin (200 mg per day) group. All patients were 
      evaluated by physicians at 1, 3, 6, 9, 12, 15, 18, 21 and 24 months after 
      randomization to obtain a patient questionnaire, physical examination and related 
      laboratory tests. RESULTS: The annual event rates of ischemic stroke, transient 
      ischemic attack (TIA) or systemic thromboembolism were 2.6%, 3.1% and 6.9% in the 
      standard-intensity warfarin, low-intensity warfarin and aspirin groups, 
      respectively (P = 0.027). Thromboembolic event rates in both warfarin groups were 
      significantly lower than that in the aspirin group (P = 0.018, P = 0.044), and 
      there was no significant difference between the two warfarin groups. Severe 
      hemorrhagic events occurred in 15 patients, 7 (2.6%) in the standard-intensity 
      warfarin group, 7 (2.4%) in the low-intensity warfarin group and 1 (0.4%) in the 
      aspirin group. The severe hemorrhagic event rates in the warfarin groups were 
      higher than that in the aspirin group, but the difference did not reach 
      statistical significance (P = 0.101). The mild hemorrhagic and total hemorrhagic 
      event rates in the warfarin groups (whether in the standard-intensity warfarin 
      group or low-intensity warfarin group) were much higher than that in the aspirin 
      group with the annual event rates of total hemorrhages of 10.2%, 7.6% and 2.2%, 
      respectively, in the 3 groups (P = 0.001). Furthermore, there was no significant 
      difference in all cause mortality among the three study groups. CONCLUSION: In 
      Chinese patients with NVAF, the warfarin therapy (INR 1.6 - 2.5) for the 
      prevention of thromboembolic events was superior to aspirin.
FAU - Chen, Ke-ping
AU  - Chen KP
AD  - Chinese Academy of Medical Sciences, Beijing, China.
FAU - Huang, Cong-xin
AU  - Huang CX
FAU - Huang, De-jia
AU  - Huang DJ
FAU - Cao, Ke-jiang
AU  - Cao KJ
FAU - Ma, Chang-sheng
AU  - Ma CS
FAU - Wang, Fang-zheng
AU  - Wang FZ
FAU - Zhang, Shu
AU  - Zhang S
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Warfarin/administration & dosage/therapeutic use
EDAT- 2012/12/21 06:00
MHDA- 2013/12/16 06:00
CRDT- 2012/12/21 06:00
PHST- 2012/12/21 06:00 [entrez]
PHST- 2012/12/21 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2012 Dec;125(24):4355-60.

PMID- 15115665
OWN - NLM
STAT- MEDLINE
DCOM- 20050131
LR  - 20221207
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 113
IP  - 2
DP  - 2004
TI  - Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic 
      acid (aspirin)-its relation to metabolic control.
PG  - 101-13
AB  - Aspirin (acetylsalicylic acid, ASA), which is recommended for primary and 
      secondary prevention in diabetes mellitus (DM), has been shown to have a lower 
      antiplatelet activity in diabetic patients. We conducted a crossover designed 
      observational study to evaluate whether there is an association between the 
      parameters relevant to metabolic control of diabetes and platelet sensitivity to 
      aspirin in type 2 diabetic patients. Platelets' ability to adhere and aggregate 
      was monitored with the use of platelet function analyser (PFA-100 
      collagen/epinephrine closure time, CT(CEPI) or collagen/ADP closure time, 
      CT(CADP)), classical turbidimetric aggregometry and whole blood electrical 
      aggregometry (WBEA), using collagen (WBEA(coll)), ADP (WBEA(ADP)) and arachidonic 
      acid (WBEA(AA)) as platelet agonists, in 48 control healthy volunteers (mean 
      age+/-S.D., 49+/-9 years) and 31 type 2 DM patients (50+/-9 years; HbA(1c) 
      9.4+/-1.6%). In majority of control subjects (69%) and minority of diabetic 
      patients (29%, p=0.0006), the use of 150 mg aspirin daily for 1 week 
      significantly reduced platelet adhesiveness and reactivity (by 14.1% in diabetes 
      vs. 78.6% in control, p(np)=0.0035, as expressed by the relative changes in 
      CT(CEPI)). Aspirin reduced WBEA(coll) and WBEA(AA) to a lesser extent in diabetic 
      patients (by 2.1% vs. 8.3% in controls, p(np)=0.0397, and by 97.3+/-12.8% vs. 
      100% in controls, p(np)=0.0383, respectively), which corresponded to ASA-mediated 
      decreased aggregation in platelet-rich plasma (PRP, r(S)=0.45 and r(S)=0.78 for 
      collagen- or arachidonate-agonized platelets, p<0.01 or lower). The maximal 
      inhibition of platelet aggregation was lower and IC(50) higher in diabetic 
      compared to control subjects, both in the presence of arachidonic acid (71% vs. 
      39%, p(np)0.0001; 0.5 microg/ml vs. 1.3 microg/ml, p<0.0001) and collagen (52% 
      vs. 35%, p<0.0004; 1.6 microg/ml vs. 2.1 microg/ml, p<0.01). The reduced response 
      of platelets from diabetic subjects to aspirin was associated with a higher level 
      of HbA(1c), lower concentration of HDL-cholesterol and a higher total cholesterol 
      concentration. Overall, there is evidence that reduced platelets response to 
      aspirin may occur more often in diabetic patients. Poor metabolic control may 
      play a role in the reduced platelet sensitivity to aspirin in DM patients. Thus, 
      our findings strongly support the requirements for an excellent near-normal 
      metabolic control and may suggest a need for alternative ASA dosing schedules in 
      DM patients.
FAU - Watala, Cezary
AU  - Watala C
AD  - Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz 
      ul., Zeromskiego 113 90-549 Lodz, Poland. cwatala@csk.am.lodz.pl
FAU - Golanski, Jacek
AU  - Golanski J
FAU - Pluta, Justyna
AU  - Pluta J
FAU - Boncler, Magdalena
AU  - Boncler M
FAU - Rozalski, Marcin
AU  - Rozalski M
FAU - Luzak, Boguslawa
AU  - Luzak B
FAU - Kropiwnicka, Anna
AU  - Kropiwnicka A
FAU - Drzewoski, Józef
AU  - Drzewoski J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Lipids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Thromb Res. 2004;113(2):97-9. PMID: 15115664
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - *Drug Resistance
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests
EDAT- 2004/04/30 05:00
MHDA- 2005/02/03 09:00
CRDT- 2004/04/30 05:00
PHST- 2003/12/22 00:00 [received]
PHST- 2003/12/31 00:00 [accepted]
PHST- 2004/04/30 05:00 [pubmed]
PHST- 2005/02/03 09:00 [medline]
PHST- 2004/04/30 05:00 [entrez]
AID - S0049384804000052 [pii]
AID - 10.1016/j.thromres.2003.12.016 [doi]
PST - ppublish
SO  - Thromb Res. 2004;113(2):101-13. doi: 10.1016/j.thromres.2003.12.016.

PMID- 36332896
OWN - NLM
STAT- MEDLINE
DCOM- 20221122
LR  - 20221122
IS  - 1873-0329 (Electronic)
IS  - 1383-5769 (Linking)
VI  - 92
DP  - 2023 Feb
TI  - Beneficial effects of acetylsalicylic acid (aspirin) on the actions of 
      extracellular vesicles shed by Trypanosoma cruzi in macrophages.
PG  - 102697
LID - S1383-5769(22)00161-1 [pii]
LID - 10.1016/j.parint.2022.102697 [doi]
AB  - Trypomastigote forms of Trypanosoma cruzi, the causative agent of Chagas disease, 
      shed extracellular vesicles (EVs) that promote the susceptibility of host cells 
      to infection. During T. cruzi infection, the immune response of the host is 
      important for controlling parasitism, which is necessary for survival. 
      Macrophages produce inflammatory mediators, such as eicosanoids and nitric oxide 
      (NO), with trypanocidal effects that control the parasite load in the early 
      stages of the disease. In this study, we evaluated the contribution of host 
      cyclooxygenase (COX) to the actions of EVs shed by T. cruzi strain Y (EVs-Y) in 
      infected macrophages. RAW 264.7 macrophages exposed to EVs-Y and then infected 
      with trypomastigote forms of T. cruzi produced less NO, and an increased number 
      of trypomastigote forms were internalized in the cell compared to the controls, 
      indicating that the effects exerted by EVs-Y favor the parasite. Interestingly, 
      when macrophages were pretreated with acetylsalicylic acid, a dual COX inhibitor, 
      before exposure to EVs-Y and subsequent infection with trypomastigote forms, 
      there was an increase in NO production and a decrease in trypomastigote uptake 
      compared to the controls. These results suggest that EVs-Y modulates the 
      macrophage response in favor of T. cruzi and indicate a role for COX in the 
      effects of EVs.
CI  - Copyright © 2022. Published by Elsevier B.V.
FAU - Dos Santos, Lucas Felipe
AU  - Dos Santos LF
AD  - Laboratory of Experimental Immunopathology, Department of Pathological Sciences, 
      State University of Londrina, Londrina, Brazil; Postgraduate Program of 
      Microbiology, Department of Microbiology, UEL, Londrina, Paraná, Brazil.
FAU - Rodrigues, Gabriella Ferreira
AU  - Rodrigues GF
AD  - Laboratory of Experimental Immunopathology, Department of Pathological Sciences, 
      State University of Londrina, Londrina, Brazil.
FAU - Malvezi, Aparecida Donizette
AU  - Malvezi AD
AD  - Laboratory of Experimental Immunopathology, Department of Pathological Sciences, 
      State University of Londrina, Londrina, Brazil.
FAU - de Souza, Mariana
AU  - de Souza M
AD  - Laboratory of Experimental Immunopathology, Department of Pathological Sciences, 
      State University of Londrina, Londrina, Brazil.
FAU - Nakama, Raquel Pires
AU  - Nakama RP
AD  - Laboratory of Experimental Immunopathology, Department of Pathological Sciences, 
      State University of Londrina, Londrina, Brazil.
FAU - Lovo-Martins, Maria Isabel
AU  - Lovo-Martins MI
AD  - Laboratory of Experimental Immunopathology, Department of Pathological Sciences, 
      State University of Londrina, Londrina, Brazil.
FAU - Pinge-Filho, Phileno
AU  - Pinge-Filho P
AD  - Laboratory of Experimental Immunopathology, Department of Pathological Sciences, 
      State University of Londrina, Londrina, Brazil; Postgraduate Program of 
      Microbiology, Department of Microbiology, UEL, Londrina, Paraná, Brazil. 
      Electronic address: pingefilho@uel.br.
LA  - eng
PT  - Journal Article
DEP - 20221101
PL  - Netherlands
TA  - Parasitol Int
JT  - Parasitology international
JID - 9708549
RN  - R16CO5Y76E (Aspirin)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - 31C4KY9ESH (Nitric Oxide)
SB  - IM
MH  - Humans
MH  - *Trypanosoma cruzi
MH  - Aspirin/pharmacology
MH  - *Chagas Disease
MH  - *Extracellular Vesicles
MH  - Macrophages
MH  - Cyclooxygenase 2
MH  - Nitric Oxide
OTO - NOTNLM
OT  - Cellular invasion
OT  - Chagas disease
OT  - Cyclooxygenase
OT  - Extracellular vesicles
OT  - Nitric oxide
OT  - RAW264.7 cells
EDAT- 2022/11/05 06:00
MHDA- 2022/11/23 06:00
CRDT- 2022/11/04 20:30
PHST- 2022/08/03 00:00 [received]
PHST- 2022/10/28 00:00 [revised]
PHST- 2022/10/28 00:00 [accepted]
PHST- 2022/11/05 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2022/11/04 20:30 [entrez]
AID - S1383-5769(22)00161-1 [pii]
AID - 10.1016/j.parint.2022.102697 [doi]
PST - ppublish
SO  - Parasitol Int. 2023 Feb;92:102697. doi: 10.1016/j.parint.2022.102697. Epub 2022 
      Nov 1.

PMID- 27981528
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180318
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 20
IP  - 23
DP  - 2016 Dec
TI  - Clinical study on influences of enteric coated aspirin on blood pressure and 
      blood pressure variability.
PG  - 5017-5020
LID - 11872 [pii]
AB  - OBJECTIVE: We investigated the effects of oral administration of enteric coated 
      aspirin (ASA) on blood pressure and blood pressure variability of hypertension 
      patients before sleep. PATIENTS AND METHODS: We observed 150 hypertension cases, 
      classified as Grade 1-2, from September 2006 to March 2008. They are divided into 
      a control group with 30 cases, ASA I group with 60 cases and ASA II group with 60 
      cases randomly. Subjects in the control group had proper diets, were losing 
      weight, exercising and maintaining a healthy mentality and were taking 30 mg 
      Adalat orally once a day. Based on the treatment of control group, patients in 
      ASA I group were administered 0.1 g Bayaspirin (produced by Bayer Company) at 
      drought in the morning. Also, based on the treatment of control group, patients 
      in ASA II group were administered 0.1 g Bayaspirin at draught before sleep. 
      RESULTS: The course of treatment is 3 months and then after the treatment, 
      decreasing blood pressure and blood pressure variability conditions in three 
      groups will be compared. Through the comparison of ASA II group with the control 
      group, they have differences in terms of systolic blood pressure (SBP), diastolic 
      blood pressure (DBP), decreasing range of blood pressure and blood pressure 
      variability (p < 0.05). CONCLUSIONS: The oral administration of ASA before sleep 
      has synergistic effects on decreasing blood pressure of hypertension patients and 
      improving blood pressure variability.
FAU - Ji, A-L
AU  - Ji AL
AD  - Department of Neurology, The Third People Hospital of XuZhou, XuZhou, China. 
      ftmlb8556215@163.com.
FAU - Chen, W-W
AU  - Chen WW
FAU - Huang, W-J
AU  - Huang WJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/*therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Sleep
EDAT- 2016/12/17 06:00
MHDA- 2017/06/22 06:00
CRDT- 2016/12/17 06:00
PHST- 2016/12/17 06:00 [entrez]
PHST- 2016/12/17 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - 11872 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2016 Dec;20(23):5017-5020.

PMID- 20635715
OWN - NLM
STAT- MEDLINE
DCOM- 20101207
LR  - 20131121
IS  - 1027-6661 (Print)
IS  - 1027-6661 (Linking)
VI  - 16
IP  - 1
DP  - 2010
TI  - [Antiplatelet therapy in patients with chronic obliterating diseases of 
      lower-limb arteries].
PG  - 43-7
AB  - The article deals with present-day evidence concerning the role of blood-platelet 
      activity in the development of a pathological process and acute ischemia in 
      patients presenting with chronic arterial insufficiency of the lower extremities. 
      Proved herein is the necessity of long-term administration of antiplatelet drugs 
      in order to prevent vascular complications on the part of the heart, brain, and 
      peripheral arteries, with a description of the drugs most commonly used for these 
      purposes.
FAU - Kuznetsov, M R
AU  - Kuznetsov MR
FAU - Tepliakov, S A
AU  - Tepliakov SA
FAU - Sizarev, A V
AU  - Sizarev AV
FAU - Tugdumov, B V
AU  - Tugdumov BV
FAU - Dzhalilova, N S
AU  - Dzhalilova NS
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Angiol Sosud Khir
JT  - Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery
JID - 9604504
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis Obliterans/*drug therapy/surgery
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Leg/*blood supply
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Stomach/drug effects
MH  - Time Factors
EDAT- 2010/07/20 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/07/20 06:00
PHST- 2010/07/20 06:00 [entrez]
PHST- 2010/07/20 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
PST - ppublish
SO  - Angiol Sosud Khir. 2010;16(1):43-7.

PMID- 30861689
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20200831
IS  - 2047-4881 (Electronic)
IS  - 2047-4873 (Linking)
VI  - 26
IP  - 7
DP  - 2019 May
TI  - Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: 
      A meta-analysis of randomized trials.
PG  - 746-749
LID - 10.1177/2047487318816387 [doi]
AB  - Numerous studies have investigated use of acetylsalicylic acid (ASA) for 
      prevention of cardiovascular deaths. The vast majority of the work in this area 
      has focused on secondary prevention. However, underuse of ASA still remains a 
      major issue. Fewer studies have investigated the impact of ASA on primary 
      prevention of cardiovascular death. A meta-analysis of individual participant 
      data from six randomized studies, published in 2009, showed decrease in serious 
      vascular events but at the cost of causing increased bleeding and hemorrhagic 
      stroke. Recent studies have raised a number of key questions regarding the 
      benefits and risks of using ASA for primary prevention.
FAU - Upadhaya, Sunil
AU  - Upadhaya S
AD  - 1 Department of Medicine, Vidant Medical Center, Greenville, USA.
FAU - Madala, Seetharamprasad
AU  - Madala S
AD  - 1 Department of Medicine, Vidant Medical Center, Greenville, USA.
FAU - Baniya, Ramkaji
AU  - Baniya R
AD  - 2 Department of Medicine, Our Lady of the Lake Regional Medical Center, Baton 
      Rouge, USA.
FAU - Saginala, Kalyan
AU  - Saginala K
AD  - 3 Department of Medicine, Michigan State University/Hurley Medical Center, Flint, 
      USA.
FAU - Khan, Jahangir
AU  - Khan J
AD  - 4 Department of Medicine, Mercy Hospitals, Ardmore, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20181130
PL  - England
TA  - Eur J Prev Cardiol
JT  - European journal of preventive cardiology
JID - 101564430
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur J Prev Cardiol. 2019 May;26(7):743-745. PMID: 30861700
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/diagnosis/mortality/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - *Primary Prevention
MH  - Prognosis
MH  - Protective Factors
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
OTO - NOTNLM
OT  - ASA
OT  - Primary prevention
OT  - cardiovascular diseases
EDAT- 2019/03/14 06:00
MHDA- 2020/09/01 06:00
CRDT- 2019/03/14 06:00
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
PHST- 2019/03/14 06:00 [entrez]
AID - 10.1177/2047487318816387 [doi]
PST - ppublish
SO  - Eur J Prev Cardiol. 2019 May;26(7):746-749. doi: 10.1177/2047487318816387. Epub 
      2018 Nov 30.

PMID- 8852524
OWN - NLM
STAT- MEDLINE
DCOM- 19961212
LR  - 20181113
IS  - 0114-5916 (Print)
IS  - 0114-5916 (Linking)
VI  - 14
IP  - 2
DP  - 1996 Feb
TI  - Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs.
PG  - 94-103
AB  - Aspirin (acetylsalicylic acid) and other NSAIDs are responsible for many adverse 
      effects. Among them, pseudo-allergic reactions (urticaria/angioedema, asthma, 
      anaphylaxis) affect up to 9% of the population and up to 30% of asthmatic 
      patients. The mechanisms provoking these reactions have not been fully 
      elucidated, but it appears that inhibition of cyclo-oxygenase (COX) plays a 
      central role. The anti-inflammatory action of nimesulide differs from that of 
      other NSAIDs, possibly because of its chemical structure. In particular, 
      nimesulide is selective for COX-2 and displays additional properties in terms of 
      its effects on inflammatory mediator synthesis and release. For these reasons, 
      nimesulide is generally well tolerated by NSAID-intolerant patients and patients 
      with NSAID-induced asthma. The good tolerability of nimesulide as an alternative 
      drug for use in patients with NSAID intolerance has been demonstrated in a large 
      number of clinical studies.
FAU - Senna, G E
AU  - Senna GE
AD  - Allergy Unit, Verona General Hospital, Italy.
FAU - Passalacqua, G
AU  - Passalacqua G
FAU - Andri, G
AU  - Andri G
FAU - Dama, A R
AU  - Dama AR
FAU - Albano, M
AU  - Albano M
FAU - Fregonese, L
AU  - Fregonese L
FAU - Andri, L
AU  - Andri L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Sulfonamides)
RN  - R16CO5Y76E (Aspirin)
RN  - V4TKW1454M (nimesulide)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Humans
MH  - Rhinitis/drug therapy
MH  - Sulfonamides/pharmacology/*therapeutic use
RF  - 73
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - 10.2165/00002018-199614020-00004 [doi]
PST - ppublish
SO  - Drug Saf. 1996 Feb;14(2):94-103. doi: 10.2165/00002018-199614020-00004.

PMID- 2336547
OWN - NLM
STAT- MEDLINE
DCOM- 19900614
LR  - 20190814
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 25
IP  - 4
DP  - 1990 Apr
TI  - Effect of topical acid on pepsinogen secretion in man.
PG  - 372-8
AB  - The stimulation of pepsinogen secretion by the presence of topical acid has 
      previously been demonstrated in the dog (by a locally mediated, cholinergic 
      mechanism) and suggested in man. The current experiments quantified the effect of 
      luminal acid on pepsin secretion in man by using gastric instillations of acid 
      solutions and recoveries with gastric washes. Solutions tested (pH 0.84-5.0) 
      included buffered solutions, hydrochloric and acetic acid solutions, and an 
      aspirin-acid solution. Decreasing pH or increasing acid concentration led to a 
      significant increase in pepsin output, with a mean maximum increase of 70% over 
      basal (pH 5.0) at the lowest pH (pH 0.84). The secretion of pepsin as a result of 
      similar concentrations of hydrochloric or acetic acid did not differ, nor was 
      pepsin secretion augmented by aspirin, used as a 'barrier breaker', and it was 
      not related to calculated duodenal delivery of acid. Thus, any in vivo study of 
      pepsin secretion should be interpreted in the light of the possible stimulatory 
      contribution of acid.
FAU - Smith, J L
AU  - Smith JL
AD  - Digestive Disease Section, Houston VA Medical Center, Texas.
FAU - Torres, E L
AU  - Torres EL
LA  - eng
GR  - 2-507-RR-5425-21/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Acetates)
RN  - 0 (Pepsinogens)
RN  - QTT17582CB (Hydrochloric Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/administration & dosage/*pharmacology
MH  - Administration, Topical
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Humans
MH  - Hydrochloric Acid/administration & dosage/*pharmacology
MH  - Intestinal Secretions/*drug effects
MH  - Male
MH  - Pepsinogens/*metabolism
MH  - Single-Blind Method
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
AID - 10.3109/00365529009095501 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 1990 Apr;25(4):372-8. doi: 10.3109/00365529009095501.

PMID- 35385617
OWN - NLM
STAT- MEDLINE
DCOM- 20220408
LR  - 20220408
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 18
IP  - 776
DP  - 2022 Apr 6
TI  - [Idiopathic recurrent pericarditis: review of the literature and the Geneva 
      experience].
PG  - 660-668
LID - 10.53738/REVMED.2022.18.776.660 [doi]
AB  - The notion of idiopathic recurrent pericarditis (IRP) appeared in the scientific 
      literature in the 1930s. In 1955, W. Dressler published a case series of IRP in 
      which treatment of cortisone and salicylates (i.e. Aspirin) was effective. About 
      30 years later, De La Serna et al. in 1987 and Guindo et al. in 1990, reported a 
      beneficial effect of colchicine. In recent years, several clinical studies have 
      helped to i mprove the management of this disease. In this present literature 
      review of IRP, we will focus on the definition, differential diagnoses, 
      pathophysiological hypotheses and available treatments. We will also discuss the 
      clinical experience at the division of clinical immunology at the University 
      Hospitals of Geneva.
FAU - Dominati, Arnaud
AU  - Dominati A
AD  - Service d'allergologie et d'immunologie clinique, Département de médecine, 
      Hôpitaux universitaires de Genève, 1211 Genève 14.
FAU - Meyer, Philippe
AU  - Meyer P
AD  - Service de cardiologie, Département de médecine, Hôpitaux universitaires de 
      Genève, 1211 Genève 14.
FAU - Seebach, Jörg D
AU  - Seebach JD
AD  - Service d'allergologie et d'immunologie clinique, Département de médecine, 
      Hôpitaux universitaires de Genève, 1211 Genève 14.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Péricardite récurrente idiopathique : revue de littérature et expérience 
      genevoise.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Chronic Disease
MH  - Colchicine/therapeutic use
MH  - Humans
MH  - *Pericarditis/diagnosis/drug therapy/etiology
MH  - Recurrence
COIS- Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
EDAT- 2022/04/07 06:00
MHDA- 2022/04/09 06:00
CRDT- 2022/04/06 17:13
PHST- 2022/04/06 17:13 [entrez]
PHST- 2022/04/07 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
AID - RMS0776-006 [pii]
AID - 10.53738/REVMED.2022.18.776.660 [doi]
PST - ppublish
SO  - Rev Med Suisse. 2022 Apr 6;18(776):660-668. doi: 10.53738/REVMED.2022.18.776.660.

PMID- 20932071
OWN - NLM
STAT- MEDLINE
DCOM- 20110304
LR  - 20220311
IS  - 1179-1934 (Electronic)
IS  - 1172-7047 (Linking)
VI  - 24
IP  - 12
DP  - 2010 Dec
TI  - Aspirin and antiplatelet agent resistance: implications for prevention of 
      secondary stroke.
PG  - 1027-40
AB  - Oral antiplatelet drugs, including aspirin, clopidogrel and extended-release 
      dipyridamole, are widely prescribed for the secondary prevention of vascular 
      events, including stroke. Despite the benefits of antiplatelet therapy, 10−20% of 
      patients experience a recurrent vascular event while taking antiplatelet 
      medication. This article discusses the concept of antiplatelet resistance in 
      general, focusing on aspirin resistance in particular, as a poorly defined cause 
      of recurrent vascular events. Factors such as the lack of a standardized method 
      to diagnose aspirin resistance and a poor clinical correlation with laboratory 
      assays make the treatment of aspirin nonresponders difficult. In addition, there 
      are confounding conditions such as diabetes mellitus that can affect aspirin 
      resistance and determine a different course of treatment for these patients. 
      Other antiplatelet options may also have resistant subpopulations; thus, 
      alternative strategies for the secondary stroke patient must be explored.
FAU - Greer, David M
AU  - Greer DM
AD  - Massachusetts General Hospital, Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - CNS Drugs
JT  - CNS drugs
JID - 9431220
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Dipyridamole/pharmacology/therapeutic use
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Secondary Prevention/methods
MH  - Stroke/*prevention & control
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
EDAT- 2010/10/12 06:00
MHDA- 2011/03/05 06:00
CRDT- 2010/10/12 06:00
PHST- 2010/10/12 06:00 [entrez]
PHST- 2010/10/12 06:00 [pubmed]
PHST- 2011/03/05 06:00 [medline]
AID - 10.2165/11539160-0000000000-00000 [doi]
PST - ppublish
SO  - CNS Drugs. 2010 Dec;24(12):1027-40. doi: 10.2165/11539160-0000000000-00000.

PMID- 790555
OWN - NLM
STAT- MEDLINE
DCOM- 19761223
LR  - 20131121
IS  - 0301-3847 (Print)
IS  - 0301-3847 (Linking)
VI  - 1976
IP  - 0
DP  - 1976
TI  - A double-blind cross-over evaluation of ketoprofen and aspirin in rheumatoid 
      arthritis.
PG  - 99-104
AB  - Thirty rheumatoid patients participated in a 6-week double-blind cross-over 
      assessment of ketoprofen (200 mg daily) and aspirin (3.6 g daily). Regular 
      clinical and laboratory assessments were conducted and revealed that at the 
      dosages employed, the two drugs exerted a statistically comparable therapeutic 
      effect. Side-effects were more frequent with aspirin. Ketoprofen was preferred 
      more often by the patients while the investigator found it acceptable as often as 
      aspirin.
FAU - Lussier, A
AU  - Lussier A
FAU - Camerlain, M
AU  - Camerlain M
FAU - Menard, H
AU  - Menard H
FAU - Myhal, D
AU  - Myhal D
FAU - Wehner, S
AU  - Wehner S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Norway
TA  - Scand J Rheumatol Suppl
JT  - Scandinavian journal of rheumatology. Supplement
JID - 0400360
RN  - 0 (Analgesics)
RN  - 0 (Benzophenones)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analgesics/administration & dosage/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Benzophenones/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Evaluation
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Headache/chemically induced
MH  - Humans
MH  - Ketoprofen/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Rheumatol Suppl. 1976;1976(0):99-104.

PMID- 7205221
OWN - NLM
STAT- MEDLINE
DCOM- 19810528
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 2
DP  - 1981 Feb
TI  - Simultaneous GLC analysis of aspirin and nonaspirin salicylates in pharmaceutical 
      tablet formulations.
PG  - 167-9
AB  - The analysis of aspirin and nonaspirin salicylates in buffered and plain tablet 
      formulations employing nearly nonaqueous extraction is described. The results 
      obtained compare favorably with those obtained from USP procedures. A 
      simultaneous assay for aspirin and nonaspirin salicylates in buffered tablets 
      involves the use of an acidified chromatographic siliceous earth column for the 
      separation of the aspirin and nonaspirin salicylates from various buffers or 
      antacids. The methods described here have definite advantages over USP XX 
      procedures, and the buffered aspirin tablet procedures also is adaptable to 
      aspirin formulations containing codeine, acetaminophen, propoxyphene, caffeine, 
      and many antihistamines.
FAU - Galante, R N
AU  - Galante RN
FAU - Egoville, J C
AU  - Egoville JC
FAU - Visalli, A J
AU  - Visalli AJ
FAU - Patel, D M
AU  - Patel DM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - NBZ3QY004S (Magnesium Hydroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aluminum Hydroxide
MH  - Aspirin/*analysis
MH  - Chromatography, Gas/methods
MH  - Hydrolysis
MH  - Magnesium Hydroxide
MH  - Salicylates/*analysis
MH  - Tablets/analysis
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
AID - S0022-3549(15)43565-8 [pii]
AID - 10.1002/jps.2600700213 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Feb;70(2):167-9. doi: 10.1002/jps.2600700213.

PMID- 31424405
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20210601
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Print)
IS  - 1387-2877 (Linking)
VI  - 71
IP  - 2
DP  - 2019
TI  - PPARα Between Aspirin and Plaque Clearance.
PG  - 389-397
LID - 10.3233/JAD-190586 [doi]
AB  - Mounting evidence has identified that impaired amyloid-β (Aβ) clearance might 
      contribute to Alzheimer's disease (AD) pathology. The lysosome-autophagy network 
      plays an important role in protein homeostasis and cell health by removing 
      abnormal protein aggregates via intracellular degradation. Therefore, stimulation 
      of cellular degradative machinery for efficient removal of Aβ has emerged as a 
      growing field in AD research. However, mechanisms controlling such pathways and 
      drugs to promote such mechanisms are poorly understood. Aspirin is a widely used 
      drug throughout the world and recent studies have identified a new function of 
      this drug. At low doses, aspirin stimulates lysosomal biogenesis and autophagy to 
      clear amyloid plaques in an animal model of AD. This review delineates such 
      functions of aspirin and analyzes underlying mechanisms that involve peroxisome 
      proliferator-activated receptor alpha (PPARα)-mediated transcription of 
      transcription factor EB (TFEB), the master regulator of lysosomal biogenesis.
FAU - Chandra, Sujyoti
AU  - Chandra S
AD  - Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, 
      USA.
FAU - Roy, Avik
AU  - Roy A
AD  - Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, 
      USA.
AD  - Division of Research and Development, Jesse Brown Veterans Affairs Medical 
      Center, Chicago, IL, USA.
FAU - Patel, Dhruv R
AU  - Patel DR
AD  - Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, 
      USA.
FAU - Pahan, Kalipada
AU  - Pahan K
AD  - Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, 
      USA.
AD  - Division of Research and Development, Jesse Brown Veterans Affairs Medical 
      Center, Chicago, IL, USA.
LA  - eng
GR  - I01 BX002174/BX/BLRD VA/United States
GR  - R01 AG050431/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (PPAR alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism/therapeutic use
MH  - Aspirin/*metabolism/therapeutic use
MH  - Humans
MH  - PPAR alpha/chemistry/*metabolism
MH  - Plaque, Amyloid/*drug therapy/*metabolism
MH  - Protein Binding/drug effects/physiology
MH  - Protein Structure, Secondary
PMC - PMC8163018
MID - NIHMS1705058
OTO - NOTNLM
OT  - Alzheimer’s disease
OT  - PPARα
OT  - TFEB
OT  - amyloid plaques
OT  - autophagy
OT  - lysosomal biogenesis
EDAT- 2019/08/20 06:00
MHDA- 2020/11/05 06:00
CRDT- 2019/08/20 06:00
PHST- 2019/08/20 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
PHST- 2019/08/20 06:00 [entrez]
AID - JAD190586 [pii]
AID - 10.3233/JAD-190586 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2019;71(2):389-397. doi: 10.3233/JAD-190586.

PMID- 22713120
OWN - NLM
STAT- MEDLINE
DCOM- 20130221
LR  - 20131121
IS  - 1520-5762 (Electronic)
IS  - 0363-9045 (Linking)
VI  - 38
IP  - 10
DP  - 2012 Oct
TI  - Preparation of lipid aspirin sustained-release pellets by solvent-free 
      extrusion/spheronization and an investigation of their stability.
PG  - 1221-9
LID - 10.3109/03639045.2011.645829 [doi]
AB  - A novel solvent-free extrusion/spheronization technique was investigated for 
      preparing stable aspirin sustained-release pellets. Lipids as binders and the 
      matrix in this technique were extruded below their melting points, and 
      spheronized in a thermomechanical process. Four types of lipids (adeps solidus, 
      Compritol(®) 888 ATO, Precirol(®) ATO5 and Compritol(®) HD5 ATO) and their 
      admixture in different ratios were used to obtain spherical and extended-release 
      pellets. Pellets containing 80% aspirin, 15% adeps solidus and 5% Compritol(®) 
      888 ATO had the best spherical geometry and met the dissolution requirements of 
      aspirin extended-release tablets in USP 31. Storage stability studies showed that 
      the content of free salicylic acid increased sharply in the traditional pellets 
      produced by wet extrusion/spheronization, from 1.91 to 7.84%, whereas there was 
      little increase in the lipid pellets (from 0.48 to 1.08%). The dissolution rate 
      from the optimal pellets (F11) stored at 26°C did not change, but became faster 
      at 40°C/RH75% after 5 months. Powder X-ray diffraction, scanning electron 
      microscopy (SEM) and differential scanning calorimetry were used to investigate 
      the physical properties of the pellets during stability testing. The increase in 
      the rate of drug release from aged pellets (40°C/RH75%) may result from the 
      partially melted adeps solidus observed in SEM photographs. This study suggests 
      that it is possible to prepare sustained-release pellets by solvent-free 
      extrusion/spheronization using an appropriate mixture of lipids with high 
      stability. In particular, this novel technique is excellent for hygroscopic 
      drugs.
FAU - Yan, Xiaonan
AU  - Yan X
AD  - College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, PR China.
FAU - He, Haibing
AU  - He H
FAU - Meng, Jia
AU  - Meng J
FAU - Zhang, Chungang
AU  - Zhang C
FAU - Hong, Mo
AU  - Hong M
FAU - Tang, Xing
AU  - Tang X
LA  - eng
PT  - Journal Article
DEP - 20120619
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Implants)
RN  - 0 (Lipids)
RN  - 0 (Solvents)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*chemistry
MH  - Calorimetry, Differential Scanning/methods
MH  - Chemistry, Pharmaceutical/*methods
MH  - Delayed-Action Preparations
MH  - Drug Implants/chemistry
MH  - Drug Stability
MH  - Lipids/*administration & dosage/*chemistry
MH  - Microscopy, Electron, Scanning/methods
MH  - Salicylic Acid/chemistry
MH  - Solubility
MH  - Solvents/chemistry
MH  - Technology, Pharmaceutical/*methods
MH  - Transition Temperature
MH  - X-Ray Diffraction/methods
EDAT- 2012/06/21 06:00
MHDA- 2013/02/22 06:00
CRDT- 2012/06/21 06:00
PHST- 2012/06/21 06:00 [entrez]
PHST- 2012/06/21 06:00 [pubmed]
PHST- 2013/02/22 06:00 [medline]
AID - 10.3109/03639045.2011.645829 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 2012 Oct;38(10):1221-9. doi: 10.3109/03639045.2011.645829. 
      Epub 2012 Jun 19.

PMID- 7190431
OWN - NLM
STAT- MEDLINE
DCOM- 19800928
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 30
IP  - 5
DP  - 1980
TI  - [In vivo drug release from microencapsulated acetylsalicylic acid with 
      simultaneous alcohol uptake].
PG  - 836-9
AB  - Simultaneous uptake of different amounts of ethanol with microencapsulated 
      acetylsalicyclic acid (Colfarit tablets) did not influence the urinary excretion 
      of total salicylates in 7 volunteers. There was no relation to in vitro drug 
      release.
FAU - Frömming, K H
AU  - Frömming KH
FAU - Schwabe, L
AU  - Schwabe L
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Wirkstoff-Freisetzung aus mikroverkapselter Acetylsalicylsäure unter 
      Alkoholbelastung.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Capsules)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Salicylates)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Alcoholic Beverages
MH  - Aspirin/administration & dosage/*metabolism
MH  - Capsules
MH  - Delayed-Action Preparations
MH  - Drug Interactions
MH  - Ethanol/*metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Microspheres
MH  - Middle Aged
MH  - Salicylates/urine
MH  - Time Factors
MH  - Wine
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1980;30(5):836-9.

PMID- 19213573
OWN - NLM
STAT- MEDLINE
DCOM- 20090305
LR  - 20190907
IS  - 0080-0015 (Print)
IS  - 0080-0015 (Linking)
VI  - 181
DP  - 2009
TI  - Aspirin and cancer risk: a summary review to 2007.
PG  - 231-51
AB  - Aspirin has been associated with a reduced risk of colorectal cancer and--based 
      on limited evidence--to cancers of the oesophagus, stomach, breast, ovary and 
      lung. The role of aspirin on other cancers, such as pancreatic, prostate and 
      bladder cancer and non-Hodgkin's lymphomas and myeloma is less clear, and an 
      increase of risk has been suggested for kidney cancer. For most cancer sites, 
      however, significant heterogeneity between studies, and particularly between 
      study design, was found, with a reduction in risk generally stronger in 
      case-control studies than in cohort ones.
FAU - Bosetti, Cristina
AU  - Bosetti C
AD  - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
FAU - Gallus, Silvano
AU  - Gallus S
FAU - La Vecchia, Carlo
AU  - La Vecchia C
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Recent Results Cancer Res
JT  - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans 
      les recherches sur le cancer
JID - 0044671
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Neoplasms/*prevention & control
MH  - Risk Factors
MH  - Time Factors
RF  - 126
EDAT- 2009/02/14 09:00
MHDA- 2009/03/06 09:00
CRDT- 2009/02/14 09:00
PHST- 2009/02/14 09:00 [entrez]
PHST- 2009/02/14 09:00 [pubmed]
PHST- 2009/03/06 09:00 [medline]
AID - 10.1007/978-3-540-69297-3_22 [doi]
PST - ppublish
SO  - Recent Results Cancer Res. 2009;181:231-51. doi: 10.1007/978-3-540-69297-3_22.

PMID- 24189281
OWN - NLM
STAT- MEDLINE
DCOM- 20140319
LR  - 20190318
IS  - 1873-0183 (Electronic)
IS  - 1568-9972 (Linking)
VI  - 13
IP  - 3
DP  - 2014 Mar
TI  - Efficacy of aspirin for the primary prevention of thrombosis in patients with 
      antiphospholipid antibodies: an international and collaborative meta-analysis.
PG  - 281-91
LID - S1568-9972(13)00207-3 [pii]
LID - 10.1016/j.autrev.2013.10.014 [doi]
AB  - We performed a meta-analysis to determine whether aspirin has a significant 
      protective effect on risk of first thrombosis among patients with 
      antiphospholipid antibodies (aPL+). Observational and interventional studies 
      identified from the Medline, Embase and Cochrane databases were selected if they 
      assessed the incidence of first thrombosis in aPL+ patients treated with aspirin 
      versus those without. Pooled effect estimates were obtained using a 
      random-effects model. Of 1211 citation retrieved, 11 primary studies (10 
      observational and 1 interventional) met inclusion criteria, including a total of 
      1208 patients and 139 thrombotic events. The pooled odds ratio (OR) for the risk 
      of first thrombosis in patients treated with aspirin (n=601) was 0.50 (95%CI: 
      0.27 to 0.93) compared to those without aspirin (n=607), with significant 
      heterogeneity across studies (I(2)=46%, p=0.05). Subgroup analysis showed a 
      protective effect of aspirin against arterial (OR: 0.48 [95%CI: 0.28-0.82]) but 
      not venous (OR: 0.58 [95% CI: 0.32-1.06]) thrombosis, as well as in retrospective 
      (OR: 0.23 [0.13-0.42]) but not prospective studies (OR: 0.91 [0.52-1.59]). 
      Subgroup analysis according to underlying disease revealed a significant 
      protective effect of aspirin for asymptomatic aPL+ individuals (OR: 0.50 
      [0.25-0.99]), for systemic lupus erythematosus (SLE) (OR: 0.55 [0.31-0.98]) and 
      obstetrical antiphospholipid syndrome (APS) (OR: 0.25 [0.10-0.62]). This 
      meta-analysis shows that the risk of first thrombotic event is significantly 
      decreased by low dose aspirin among asymptomatic aPL individuals, patients with 
      SLE or obstetrical APS. Importantly, no significant risk reduction was observed 
      when considering only prospective studies or those with the best methodological 
      quality.
CI  - © 2013.
FAU - Arnaud, Laurent
AU  - Arnaud L
AD  - Department of Internal Medicine, French National Reference Center for Systemic 
      Lupus and Antiphospholipid Syndrome, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, 
      47-83 bd de l'hôpital, 75013 Paris, France; Institut National de la Santé et de 
      la Recherche Médicale (INSERM), UMR-S 945, Paris, France; Université Pierre et 
      Marie Curie, UPMC Univ Paris 06, Paris, France. Electronic address: 
      Laurent.arnaud@psl.aphp.fr.
FAU - Mathian, Alexis
AU  - Mathian A
AD  - Department of Internal Medicine, French National Reference Center for Systemic 
      Lupus and Antiphospholipid Syndrome, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, 
      47-83 bd de l'hôpital, 75013 Paris, France; Institut National de la Santé et de 
      la Recherche Médicale (INSERM), UMR-S 945, Paris, France; Université Pierre et 
      Marie Curie, UPMC Univ Paris 06, Paris, France.
FAU - Ruffatti, Amelia
AU  - Ruffatti A
AD  - Rheumatology Unit, Department of Clinical and Experimental Medicine, University 
      of Padua, Padua, Italy.
FAU - Erkan, Doruk
AU  - Erkan D
AD  - Hospital for Special Surgery, Weill Cornell Medical College, New York, USA.
FAU - Tektonidou, Maria
AU  - Tektonidou M
AD  - First Department of Internal Medicine, School of Medicine, National University of 
      Athens, Athens, Greece.
FAU - Cervera, Ricard
AU  - Cervera R
AD  - Department of Autoimmune Diseases, Hospital Clínic-Institut d'Investigacions 
      Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, 
      Spain.
FAU - Forastiero, Ricardo
AU  - Forastiero R
AD  - Department of Physiology, Favaloro University, Buenos Aires, Argentina.
FAU - Pengo, Vittorio
AU  - Pengo V
AD  - Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, 
      University of Padova, Padova, Italy.
FAU - Lambert, Marc
AU  - Lambert M
AD  - Internal Medicine Department, Universitary Hospital, Lille, France.
FAU - Martinez-Zamora, Maria Angeles
AU  - Martinez-Zamora MA
AD  - Institut Clínic of Gynecology, Obstetrics and Neonatology, Hospital 
      Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Faculty of 
      Medicine, University of Barcelona, Barcelona, Spain.
FAU - Balasch, Juan
AU  - Balasch J
AD  - Institut Clínic of Gynecology, Obstetrics and Neonatology, Hospital 
      Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Faculty of 
      Medicine, University of Barcelona, Barcelona, Spain.
FAU - Zuily, Stephane
AU  - Zuily S
AD  - Nancy University Hospital, Université de Lorraine, INSERM U961, 
      Vandœuvre-Les-Nancy, France.
FAU - Wahl, Denis
AU  - Wahl D
AD  - Nancy University Hospital, Université de Lorraine, INSERM U961, 
      Vandœuvre-Les-Nancy, France.
FAU - Amoura, Zahir
AU  - Amoura Z
AD  - Department of Internal Medicine, French National Reference Center for Systemic 
      Lupus and Antiphospholipid Syndrome, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, 
      47-83 bd de l'hôpital, 75013 Paris, France; Institut National de la Santé et de 
      la Recherche Médicale (INSERM), UMR-S 945, Paris, France; Université Pierre et 
      Marie Curie, UPMC Univ Paris 06, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20131102
PL  - Netherlands
TA  - Autoimmun Rev
JT  - Autoimmunity reviews
JID - 101128967
RN  - 0 (Antibodies, Antiphospholipid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Antiphospholipid/*therapeutic use
MH  - Antiphospholipid Syndrome/drug therapy/epidemiology
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Lupus Erythematosus, Systemic/drug therapy/epidemiology
MH  - Risk Factors
MH  - Thrombosis/epidemiology/*prevention & control
OTO - NOTNLM
OT  - Antiphospholipid antibodies
OT  - Aspirin
OT  - Meta-analysis
OT  - Thrombosis
EDAT- 2013/11/06 06:00
MHDA- 2014/03/22 06:00
CRDT- 2013/11/06 06:00
PHST- 2013/10/01 00:00 [received]
PHST- 2013/10/25 00:00 [accepted]
PHST- 2013/11/06 06:00 [entrez]
PHST- 2013/11/06 06:00 [pubmed]
PHST- 2014/03/22 06:00 [medline]
AID - S1568-9972(13)00207-3 [pii]
AID - 10.1016/j.autrev.2013.10.014 [doi]
PST - ppublish
SO  - Autoimmun Rev. 2014 Mar;13(3):281-91. doi: 10.1016/j.autrev.2013.10.014. Epub 
      2013 Nov 2.

PMID- 17641669
OWN - NLM
STAT- MEDLINE
DCOM- 20080320
LR  - 20181113
IS  - 0007-1188 (Print)
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Linking)
VI  - 152
IP  - 4
DP  - 2007 Oct
TI  - Building a better aspirin: gaseous solutions to a century-old problem.
PG  - 421-8
AB  - The gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs 
      (NSAIDs) have been recognized since shortly after the introduction of aspirin to 
      the marketplace over a century ago. However, the underlying pathogenesis of 
      NSAID-induced gastropathy remains incompletely understood. Advances in 
      understanding some of the factors that contribute to the mucosal injury have 
      provided clues for the development of safer NSAIDs. The inhibitory effects of 
      nitric oxide (NO) on NSAID-induced leukocyte adherence were exploited in the 
      development of NO-releasing NSAIDs. As well as eliciting less gastrointestinal 
      damage than conventional NSAIDs, these drugs do not elevate blood pressure and 
      show anti-inflammatory effects, additional to those of the parent drugs. 
      Modification of other drugs in a similar manner (i.e., NO-releasing derivatives) 
      has similarly resulted in more effective drugs. More recently, hydrogen 
      sulphide-releasing derivatives of NSAIDs and of other drugs, have been developed, 
      based on the observed ability of H(2)S to reduce inflammation and pain in 
      experimental models. H(2)S-releasing NSAIDs produce negligible gastric damage and 
      exhibit enhanced anti-inflammatory potency as compared to the parent drugs. The 
      NO-NSAIDs and H(2)S-releasing NSAIDs represent examples of new anti-inflammatory 
      drugs with greatly reduced toxicity and improved therapeutic activity, both 
      created through the concept of exploiting the beneficial effects of endogenous 
      gaseous mediators.
FAU - Wallace, J L
AU  - Wallace JL
AD  - Inflammation Research Network, Department of Pharmacology and Therapeutics, 
      University of Calgary, Calgary, Alberta, Canada. wallacej@ucalgary.ca
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20070716
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/chemistry/therapeutic use
MH  - Aspirin/*adverse effects/chemistry/therapeutic use
MH  - Chemistry, Pharmaceutical/*methods/trends
MH  - Gastrointestinal Hemorrhage/*chemically induced/prevention & control
MH  - Humans
MH  - Hydrogen Sulfide/metabolism
MH  - Models, Biological
MH  - Molecular Structure
MH  - Stomach Ulcer/*chemically induced/prevention & control
PMC - PMC2050827
EDAT- 2007/07/21 09:00
MHDA- 2008/03/21 09:00
CRDT- 2007/07/21 09:00
PHST- 2007/07/21 09:00 [pubmed]
PHST- 2008/03/21 09:00 [medline]
PHST- 2007/07/21 09:00 [entrez]
AID - 0707396 [pii]
AID - 10.1038/sj.bjp.0707396 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2007 Oct;152(4):421-8. doi: 10.1038/sj.bjp.0707396. Epub 2007 Jul 
      16.

PMID- 2150736
OWN - NLM
STAT- MEDLINE
DCOM- 19910516
LR  - 20131121
IS  - 0302-6469 (Print)
IS  - 0302-6469 (Linking)
VI  - 52
IP  - 6
DP  - 1990
TI  - Aspirin as an antithrombotic drug: from the aggregometer to clinical trials.
PG  - 459-71; discussion 471-3
AB  - Aspirin inhibits thromboxane A2 and prostaglandin formation in platelets and 
      prostaglandin I2 (prostacyclin) in vascular cells. It prevents platelet 
      aggregation by irreversible acetylation of cyclooxygenase, a key enzyme in the 
      arachidonic acid metabolism. Oral aspirin can be extensively hydrolyzed to 
      inactive salicylate in the stomach and the liver (first-pass) before it enters 
      the systemic circulation. Presystemic acetylation of platelets thus occurs during 
      aspirin absorption, with a concomitant sparing of peripheral vascular 
      cyclo-oxygenase, mainly exposed to salicylate. On the basis of its antiplatelet 
      effect, aspirin has been assessed during the past two decades in patients with a 
      history of myocardial infarction, stroke, transient ischemic attack or unstable 
      angina. A meta-analysis of randomized controlled trials of long term aspirin 
      treatment for secondary prevention of vascular disease indicated that aspirin 
      (300-1500 mg daily) significantly reduced fatal and non-fatal vascular events. 
      More recently aspirin (160 mg daily) produced a significant reduction in hospital 
      vascular mortality and in non-fatal events in patients with suspected acute 
      myocardial infarction. Combination of aspirin with streptokinase was 
      significantly better than either drug alone. On the other hand two primary 
      prevention trials of aspirin in healthy doctors did not show any modification of 
      vascular mortality despite an overall reduction of non-fatal myocardial 
      infarction. Resolution of some problems related to the mechanism of action of 
      aspirin and to selection of trial populations will possibly increase the 
      benefit/risk ratio of aspirin treatment for prevention of vascular disease.
FAU - de Gaetano, G
AU  - de Gaetano G
AD  - Istituto di Ricerche Farmacologiche Mario Negri, Imbaro, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - Belgium
TA  - Verh K Acad Geneeskd Belg
JT  - Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie
JID - 0413210
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prostaglandin Antagonists)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Prostaglandin Antagonists/pharmacology
MH  - Randomized Controlled Trials as Topic
MH  - Thrombosis/*prevention & control
MH  - Thromboxane A2/antagonists & inhibitors
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - Verh K Acad Geneeskd Belg. 1990;52(6):459-71; discussion 471-3.

PMID- 10590187
OWN - NLM
STAT- MEDLINE
DCOM- 20000301
LR  - 20220310
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 9
IP  - 1
DP  - 2000 Jan
TI  - Effect of short-term aspirin use on C-reactive protein.
PG  - 37-41
AB  - Markers of inflammation, such as C-reactive protein (CRP) and fibrinogen, have 
      been shown to be predictive of cardiovascular disease. In the Physicians Health 
      Study, the magnitude of reduction in the risk of myocardial infarction with 
      aspirin therapy was related to baseline CRP levels, raising the possibility that 
      the protective effect of aspirin may be due to antiinflammatory properties in 
      addition to its antiplatelet effect. We therefore investigated whether aspirin 
      therapy lowers CRP levels. Because heavy physical exertion is a well-known 
      trigger of myocardial infarction, we also investigated the effect of aspirin on 
      CRP levels before and after strenuous exercise. Thirty-two healthy men, aged 29 
      +/- 6 years, were enrolled in a randomized, double-blind, parallel study. Blood 
      samples were obtained immediately before and after maximal treadmill exercise at 
      baseline and following 7 days of aspirin therapy (81 or 325 mg). The levels of 
      CRP, as measured by ELISA, increased by 13% following exercise (P < 0.0001). 
      However, aspirin did not significantly alter CRP levels, either at rest (0.81 +/- 
      0.13 mg/L before aspirin vs. 0.78 +/- 0.13 mg/L on aspirin) or following exercise 
      (0.92 +/- 0.13 mg/L before aspirin vs. 0.86 +/- 0. 13 mg/L on aspirin), P = 0.73. 
      When the resting and postexercise data were combined, the levels were 0.87 +/- 
      0.13 mg/L before aspirin and 0.82 +/- 0.13 mg/L on aspirin (a nonsignificant 6% 
      reduction, P = 0.20). In conclusion, in healthy male subjects CRP levels were not 
      significantly reduced by short-term aspirin therapy. Our data, taking together 
      with other reports, suggest that aspirin may not affect the levels of 
      inflammatory markers. However, further studies are needed with a longer duration 
      of therapy, among subjects with coronary heart disease, and using additional 
      markers of inflammation besides CRP to determine the long-term effects of aspirin 
      use.
FAU - Feng, D
AU  - Feng D
AD  - Institute for Prevention of Cardiovascular Disease, Beth Israel Deaconess Medical 
      Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
FAU - Tracy, R P
AU  - Tracy RP
FAU - Lipinska, I
AU  - Lipinska I
FAU - Murillo, J
AU  - Murillo J
FAU - McKenna, C
AU  - McKenna C
FAU - Tofler, G H
AU  - Tofler GH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Acute-Phase Proteins)
RN  - 0 (Orosomucoid)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute-Phase Proteins/drug effects
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - C-Reactive Protein/*drug effects/metabolism
MH  - Double-Blind Method
MH  - Exercise
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/etiology/metabolism
MH  - Orosomucoid/drug effects
MH  - Time Factors
EDAT- 1999/12/10 09:00
MHDA- 2000/03/04 09:00
CRDT- 1999/12/10 09:00
PHST- 1999/12/10 09:00 [pubmed]
PHST- 2000/03/04 09:00 [medline]
PHST- 1999/12/10 09:00 [entrez]
AID - 10.1023/a:1018644212794 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2000 Jan;9(1):37-41. doi: 10.1023/a:1018644212794.

PMID- 677095
OWN - NLM
STAT- MEDLINE
DCOM- 19780915
LR  - 20190823
IS  - 0002-9211 (Print)
IS  - 0002-9211 (Linking)
VI  - 23
IP  - 5
DP  - 1978 May
TI  - Effects of E prostaglandins on canine gastric potential difference.
PG  - 436-42
AB  - Measurement of the gastric transmucosal potential difference (PD) was used to 
      study the effect of gastric antisecretory prostaglandins on the integrity of the 
      gastric mucosa of the Heidenhain pouch dog. Intragastric administration of 
      SC-29333 [(+/-)-15-deoxy-16-alpha,beta-hydroxy-16-methyl PGE1 methyl ester] 
      slightly but significantly increased the transmucosal PD when compared to vehicle 
      control. In addition, SC-29333 administered either intravenously or 
      intragastrically, significantly inhibited the PD fall induced by aspirin, a 
      well-established barrier breaker. In contrast, the intragastric administration of 
      16,16-dimethyl PGE2 methyl ester (Me-PGE2) significantly lowered the transmucosal 
      PD and failed to modify the actions of aspirin on the integrity of the gastric 
      mucosa. However, the intravenous administration of either prostaglandin did not 
      affect the basal transmucosal PD values. These studies suggest that SC-29333 may 
      strengthen the integrity of the gastric mucosal barrier against aspirin, and this 
      could have important therapeutic potential.
FAU - Dajani, E Z
AU  - Dajani EZ
FAU - Callison, D A
AU  - Callison DA
FAU - Bertermann, R E
AU  - Bertermann RE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Dig Dis
JT  - The American journal of digestive diseases
JID - 0404011
RN  - 0 (Prostaglandins E, Synthetic)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Dogs
MH  - Electrophysiology
MH  - Female
MH  - Gastric Mucosa/*physiology
MH  - Prostaglandins E, Synthetic/*pharmacology
EDAT- 1978/05/01 00:00
MHDA- 1978/05/01 00:01
CRDT- 1978/05/01 00:00
PHST- 1978/05/01 00:00 [pubmed]
PHST- 1978/05/01 00:01 [medline]
PHST- 1978/05/01 00:00 [entrez]
AID - 10.1007/BF01072927 [doi]
PST - ppublish
SO  - Am J Dig Dis. 1978 May;23(5):436-42. doi: 10.1007/BF01072927.

PMID- 34480600
OWN - NLM
STAT- MEDLINE
DCOM- 20220408
LR  - 20220809
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Print)
IS  - 0937-4477 (Linking)
VI  - 279
IP  - 5
DP  - 2022 May
TI  - A retrospective study on long-term efficacy of intranasal lysine-aspirin in 
      controlling NSAID-exacerbated respiratory disease.
PG  - 2473-2484
LID - 10.1007/s00405-021-07063-2 [doi]
AB  - PURPOSE: Aspirin treatment after desensitization (ATAD) represents an effective 
      therapeutic option suitable for NSAID-exacerbated respiratory disease (N-ERD) 
      patients with recalcitrant disease. Intranasal administration of lysine-aspirin 
      (LAS) has been suggested as a safer and faster route than oral ATAD but evidence 
      for its use is less strong. We investigated nasal LAS therapy long-term efficacy 
      based on objective outcomes, smell function, polyp recurrence and need for 
      surgery or rescue therapy. Clinical biomarkers predicting response to intranasal 
      LAS, long-term side effects and consequences of discontinuing treatment have been 
      evaluated. METHODS: A retrospective analysis of a database of 60 N-ERD patients 
      seen between 2012 and 2020 was performed in March 2021. They were followed up at 
      3-months, 1-, 2- and 3-years with upper and lower airway functions assessed at 
      each follow-up. RESULTS: Higher nasal airflow and smell scores were found at each 
      follow-up in patients taking LAS (p < 0.001 and p = 0.048 respectively). No 
      influence of LAS on pulmonary function measurements was observed. Patient on 
      intranasal LAS showed a lower rate of revision sinus surgery when compared to 
      those who discontinued the treatment (p < 0.001). None of the variables studied 
      was found to influence LAS treatment response. CONCLUSION: Our study demonstrates 
      the clinical effectiveness of long-term intranasal LAS in the management of N-ERD 
      in terms of improved nasal airflow and olfaction and a reduced need for revision 
      sinus surgery. Intranasal LAS is safe, being associated with a lower rate of side 
      effects when compared to oral ATAD. However, discontinuation of the treatment at 
      any stage is associated with a loss of clinical benefit.
CI  - © 2021. The Author(s).
FAU - Pendolino, Alfonso Luca
AU  - Pendolino AL
AUID- ORCID: 0000-0002-6348-5303
AD  - Department of ENT, Royal National ENT & Eastman Dental Hospitals, 47-49 Huntley 
      St, Bloomsbury, London, WC1E 6DG, UK. alfonso.pendolino@nhs.net.
AD  - Ear Institute, University College London, London, UK. alfonso.pendolino@nhs.net.
FAU - Scadding, Glenis K
AU  - Scadding GK
AD  - Department of ENT, Royal National ENT & Eastman Dental Hospitals, 47-49 Huntley 
      St, Bloomsbury, London, WC1E 6DG, UK.
AD  - Faculty of Medical Sciences, University College London, London, UK.
FAU - Scarpa, Bruno
AU  - Scarpa B
AD  - Department of Statistical Sciences and Department of Mathematics Tullio 
      Levi-Civita, University of Padua, Padua, Italy.
FAU - Andrews, Peter J
AU  - Andrews PJ
AUID- ORCID: 0000-0001-5731-3276
AD  - Department of ENT, Royal National ENT & Eastman Dental Hospitals, 47-49 Huntley 
      St, Bloomsbury, London, WC1E 6DG, UK.
AD  - Ear Institute, University College London, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20210904
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Intranasal
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/adverse effects/analogs & derivatives
MH  - Humans
MH  - Lysine/analogs & derivatives
MH  - *Nasal Polyps/surgery
MH  - *Respiration Disorders
MH  - Retrospective Studies
MH  - *Sinusitis/surgery
PMC - PMC8986745
OTO - NOTNLM
OT  - Anti-inflammatory agents non-steroidal
OT  - Aspirin
OT  - Aspirin-induced
OT  - Asthma
OT  - Nasal polyps
OT  - Smell
COIS- None.
EDAT- 2021/09/05 06:00
MHDA- 2022/04/09 06:00
CRDT- 2021/09/04 12:08
PHST- 2021/07/15 00:00 [received]
PHST- 2021/08/27 00:00 [accepted]
PHST- 2021/09/05 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
PHST- 2021/09/04 12:08 [entrez]
AID - 10.1007/s00405-021-07063-2 [pii]
AID - 7063 [pii]
AID - 10.1007/s00405-021-07063-2 [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2022 May;279(5):2473-2484. doi: 
      10.1007/s00405-021-07063-2. Epub 2021 Sep 4.

PMID- 18574279
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20170602
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 133
IP  - 6 Suppl
DP  - 2008 Jun
TI  - Antithrombotic therapy for peripheral artery occlusive disease: American College 
      of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
PG  - 815S-843S
LID - S0012-3692(08)60131-2 [pii]
LID - 10.1378/chest.08-0686 [doi]
AB  - This chapter is devoted to antithrombotic therapy for peripheral artery occlusive 
      disease as part of the American College of Chest Physicians Evidence-Based 
      Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong 
      and indicate that the benefits do, or do not, outweigh risks, burden, and costs. 
      Grade 2 suggests that individual patients' values may lead to different choices 
      (for a full understanding of the grading see the "Grades of Recommendation" 
      chapter by Guyatt et al, CHEST 2008; 133:123S-131S). Among the key 
      recommendations in this chapter are the following: We recommend lifelong 
      antiplatelet therapy in comparison to no antiplatelet therapy in pulmonary artery 
      disease (PAD) patients with clinically manifest coronary or cerebrovascular 
      disease (Grade 1A), and also in those without clinically manifest coronary or 
      cerebrovascular disease (Grade 1B). In patients with PAD and intermittent 
      claudication, we recommend against the use of anticoagulants (Grade 1A). For 
      patients with moderate to severe disabling intermittent claudication who do not 
      respond to exercise therapy, and who are not candidates for surgical or 
      catheter-based intervention, we recommend cilostazol (Grade 1A). We suggest that 
      clinicians not use cilostazol in those with less-disabling claudication (Grade 
      2A). In patients with short-term (< 14 days) arterial thrombosis or embolism, we 
      suggest intraarterial thrombolytic therapy (Grade 2B), provided they are at low 
      risk of myonecrosis and ischemic nerve damage developing during the time to 
      achieve revascularization. For patients undergoing major vascular reconstructive 
      procedures, we recommend IV unfractionated heparin (UFH) prior to the application 
      of vascular cross clamps (Grade 1A). For all patients undergoing infrainguinal 
      arterial reconstruction, we recommend aspirin (75-100 mg, begun preoperatively) 
      [Grade 1A]. For routine autogenous vein infrainguinal bypass, we recommend 
      aspirin (75-100 mg, begun preoperatively) [Grade 1A]. For routine prosthetic 
      infrainguinal bypass, we recommend aspirin (75-100 mg, begun preoperatively) 
      [Grade 1A]. In patients undergoing carotid endarterectomy, we recommend that 
      aspirin, 75-100 mg, be administered preoperatively and continued indefinitely 
      (75-100 mg/d) [Grade 1A]. In nonoperative patients with asymptomatic carotid 
      stenosis (primary or recurrent), we suggest that dual antiplatelet therapy with 
      aspirin and clopidogrel be avoided (Grade 1B). For all patients undergoing 
      lower-extremity balloon angioplasty (with or without stenting), we recommend 
      long-term aspirin, 75-100 mg/d (Grade 1C).
FAU - Sobel, Michael
AU  - Sobel M
AD  - VA Puget Sound Health Care System and University of Washington School of 
      Medicine, Seattle, WA. Electronic address: michael.sobel@va.gov.
FAU - Verhaeghe, Raymond
AU  - Verhaeghe R
AD  - Katholieke Universiteit Leuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/*drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - *Evidence-Based Medicine
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/administration & dosage/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Thrombolytic Therapy
EDAT- 2008/07/24 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/07/24 09:00
PHST- 2008/07/24 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/24 09:00 [entrez]
AID - S0012-3692(08)60131-2 [pii]
AID - 10.1378/chest.08-0686 [doi]
PST - ppublish
SO  - Chest. 2008 Jun;133(6 Suppl):815S-843S. doi: 10.1378/chest.08-0686.

PMID- 10662482
OWN - NLM
STAT- MEDLINE
DCOM- 20000124
LR  - 20181113
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 16
IP  - 5 Pt 2
DP  - 1999 Nov
TI  - Cost-effectiveness analysis of antiplatelet therapy in the prevention of 
      recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
PG  - 577-93
AB  - OBJECTIVES: To evaluate the cost effectiveness from a UK health and social 
      services perspective of antiplatelet therapies tested in the Second European 
      Stroke Prevention Study (ESPS-2) in preventing recurrent stroke. To demonstrate 
      the value of modelling studies in this area. DESIGN AND SETTING: A 
      decision-analytic model was developed to evaluate health outcomes and associated 
      costs. Sources of data for efficacy, adverse events, background event risks, 
      disability and mortality were ESPS-2, the Oxfordshire Community Stroke Project 
      and UK national statistics. Published national unit costs were applied to 
      clinician panel estimates of resource use for acute stroke, rehabilitation and 
      long term care. Outcome measures were strokes or disabled life-years averted, and 
      disability-free, stroke-free or quality-adjusted life-years gained. PATIENTS AND 
      INTERVENTIONS: 30-day survivors of ischaemic stroke treated with low dose 
      aspirin, modified-release dipyridamole; the coformulation of low dose aspirin 
      plus modified-release dipyridamole, or no antiplatelet therapy. MAIN OUTCOME 
      MEASURES AND RESULTS: The model predicted that over 5 years the coformulation 
      prevented 29 more strokes than aspirin alone per 1000 patients, at an additional 
      cost of 1900 Pounds per stroke averted (1996 values). Over 5 years, each 
      antiplatelet therapy was cost saving compared with no therapy. Results were 
      sensitive to the cost of acute care, the cost of long term care of disabled 
      stroke survivors, the effectiveness of therapy and the background risk of 
      recurrent stroke. In sensitivity analyses, the cost effectiveness did not exceed 
      7000 Pounds per stroke averted or 11,000 Pounds per quality-adjusted life-year 
      (QALY) gained, except when varying the effectiveness parameter. CONCLUSIONS: 
      Application of a decision-analytic model to the results of ESPS-2 indicated that 
      first-line therapy with the coformulation of modified-release dipyridamole and 
      low dose aspirin to patients with a previous ischaemic stroke is likely to 
      generate significant health benefits at modest extra costs to health and social 
      services. The extra costs of treatment are balanced by the savings in future 
      costs of acute care and long term care of the disabled. Future economic 
      evaluations in this area should pay particular attention to the cost perspective, 
      the duration of analysis, the selection of trials from which effectiveness data 
      are derived, and the impact of the pooling of outcome events with potentially 
      different economic consequences.
FAU - Chambers, M
AU  - Chambers M
AD  - MEDTAP International, London, England. chambers@medtap.co.uk
FAU - Hutton, J
AU  - Hutton J
FAU - Gladman, J
AU  - Gladman J
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
EIN - Pharmacoeconomics 2000 Jan;17(1):69
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*economics/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Decision Support Techniques
MH  - Dipyridamole/*economics/*therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Models, Economic
MH  - Platelet Aggregation Inhibitors/*economics/*therapeutic use
MH  - Secondary Prevention
MH  - Stroke/*economics/*therapy
MH  - United Kingdom
EDAT- 2000/02/08 09:00
MHDA- 2000/06/10 09:00
CRDT- 2000/02/08 09:00
PHST- 2000/02/08 09:00 [pubmed]
PHST- 2000/06/10 09:00 [medline]
PHST- 2000/02/08 09:00 [entrez]
AID - 10.2165/00019053-199916050-00013 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 1999 Nov;16(5 Pt 2):577-93. doi: 
      10.2165/00019053-199916050-00013.

PMID- 1860215
OWN - NLM
STAT- MEDLINE
DCOM- 19910830
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 84
IP  - 2
DP  - 1991 Aug
TI  - Clinical characteristics of nonfatal myocardial infarction among individuals on 
      prophylactic low-dose aspirin therapy.
PG  - 708-11
AB  - BACKGROUND: The influence of prophylactic low-dose aspirin on the clinical 
      characteristics of subsequent nonfatal myocardial infarction was examined in the 
      Physicians' Health Study, a randomized, double-blind placebo-controlled trial of 
      alternate-day aspirin (325 mg) among 22,071 US male physicians. METHODS AND 
      RESULTS: During 60.2 months of follow-up, 342 incident cases of nonfatal 
      myocardial infarction were confirmed (95.2% of all reports): 129 on aspirin and 
      213 on placebo (p less than 0.00001). Despite this statistically extreme 
      reduction in occurrence of a first nonfatal infarction attributable to aspirin, 
      there were no significant differences in the size, location, electrocardiographic 
      features, or postinfarction left ventricular ejection fraction between the 
      aspirin and placebo groups. Furthermore, among those undergoing angiography, 
      there were no differences in the distribution or number of coronary vessels 
      obstructed. CONCLUSIONS: These data indicate that chronic platelet inhibition 
      with alternate-day aspirin therapy reduces the risk of a first myocardial 
      infarction but does not appear to have a significant effect on the clinical 
      characteristics of events that are survived. This finding may result from a 
      direct effect of aspirin or from an aspirin-induced shift in infarction severity. 
      Regardless of mechanism, these clinical observations suggest that treatment 
      decisions for acute infarction patients should be made independently of a history 
      of aspirin use.
FAU - Ridker, P M
AU  - Ridker PM
AD  - Division of Cardiology, Brigham and Women's Hospital, Brookline, MA 02215.
FAU - Manson, J E
AU  - Manson JE
FAU - Buring, J E
AU  - Buring JE
FAU - Goldhaber, S Z
AU  - Goldhaber SZ
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA-34944/CA/NCI NIH HHS/United States
GR  - HL-26490/HL/NHLBI NIH HHS/United States
GR  - HL-34595/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Isoenzymes)
RN  - EC 2.7.3.2 (Creatine Kinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cardiac Catheterization
MH  - Creatine Kinase/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Electrocardiography
MH  - Humans
MH  - Isoenzymes
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/physiopathology/*prevention & control
MH  - Myocardium/enzymology
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
AID - 10.1161/01.cir.84.2.708 [doi]
PST - ppublish
SO  - Circulation. 1991 Aug;84(2):708-11. doi: 10.1161/01.cir.84.2.708.

PMID- 26243656
OWN - NLM
STAT- MEDLINE
DCOM- 20160420
LR  - 20150929
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 15
IP  - 5
DP  - 2015 Oct
TI  - Pharmacotherapeutic considerations for using colchicine to treat idiopathic 
      pericarditis in the USA.
PG  - 295-306
LID - 10.1007/s40256-015-0133-4 [doi]
AB  - The clinical significance of colchicine in the treatment of acute idiopathic 
      (viral) pericarditis (IP) was only elucidated less than a decade ago. Multiple 
      trials have shown the benefit of colchicine in decreasing the rate of recurrence, 
      primarily in the European population. However, the colchicine formulation used in 
      these trials is not available in Western countries such as the USA. In the USA, 
      two formulations are available: the 0.6 mg capsule and the 0.6 mg tablet. As a 
      result, higher doses than administered in the European trials must be utilized to 
      treat IP. However, the use of these dosage forms has never been studied in the 
      treatment of IP. Pharmacokinetic and pharmacodynamic knowledge of colchicine 
      germane to clinicians such as drug disposition and drug-drug or drug-disease 
      interactions have not been extensively reviewed in recent years. Furthermore, the 
      safety of colchicine in the treatment of IP has not been extensively studied, and 
      literature regarding adverse drug events originates from data in patients treated 
      for familial Mediterranean fever and gout. This review will help the clinician 
      understand pharmacotherapeutic considerations and thereby optimize therapy and 
      ensure patient safety when using colchicine to treat IP.
FAU - Schwier, Nicholas C
AU  - Schwier NC
AD  - Department of Pharmacy, Clinical and Administrative Sciences, University of 
      Oklahoma College of Pharmacy, 1110 N. Stonewall Avenue, CPB 214, Oklahoma City, 
      OK, 73117, USA. Nicholas-Schwier@ouhsc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/pharmacokinetics/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use
MH  - Colchicine/administration & dosage/adverse effects/pharmacokinetics/*therapeutic 
      use
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Pericarditis/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - United States
MH  - Virus Diseases/*drug therapy
EDAT- 2015/08/06 06:00
MHDA- 2016/04/21 06:00
CRDT- 2015/08/06 06:00
PHST- 2015/08/06 06:00 [entrez]
PHST- 2015/08/06 06:00 [pubmed]
PHST- 2016/04/21 06:00 [medline]
AID - 10.1007/s40256-015-0133-4 [pii]
AID - 10.1007/s40256-015-0133-4 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2015 Oct;15(5):295-306. doi: 10.1007/s40256-015-0133-4.

PMID- 2117935
OWN - NLM
STAT- MEDLINE
DCOM- 19901002
LR  - 20191210
IS  - 0741-8329 (Print)
IS  - 0741-8329 (Linking)
VI  - 7
IP  - 4
DP  - 1990 Jul-Aug
TI  - Cyclooxygenase inhibitors antagonize the rate-depressant effects of ethanol on 
      fixed-ratio responding.
PG  - 355-60
AB  - Prostaglandin synthetase inhibitors (PGSIs), which inhibit actions of the enzyme 
      complex cyclooxygenase, significantly antagonize the effects of alcohols but not 
      other sedative-hypnotics across a broad range of measures. This suggests that 
      certain actions of alcohols, in particular ethanol, are mediated at least 
      partially through a prostaglandin-related pathway. This study examined changes in 
      the rate-depressant effects of ethanol in an operant task following pretreatment 
      with either of two PGSIs, indomethacin (INDO) or aspirin (ASP). Water 
      reinforcement maintained the responding of male Sprague-Dawley (SD) rats under a 
      Fixed-Ratio (FR) 32 schedule. Saline, INDO or ASP had no significant effect on 
      control rates of responding. INDO pretreatment significantly antagonized the 
      rate-depressant effects of 1.0 and 1.5 g/kg ethanol. ASP pretreatment also 
      resulted in significant antagonism of ethanol's rate-decreasing effects. INDO was 
      more potent than ASP in antagonizing the rate-depressant effects of ethanol. 
      These results provide further support for the hypothesis that alcohols, by 
      fluidizing neuronal membranes and mobilizing the release of arachidonate, serve 
      to increase prostaglandin production, resulting in some of the behavioral and 
      physiological sequellae of ethanol administration.
FAU - George, F R
AU  - George FR
AD  - National Institute on Drug Abuse, Addiction Research Center, Baltimore, MD 21224.
FAU - Meisch, R A
AU  - Meisch RA
LA  - eng
GR  - AA-06104/06924/AA/NIAAA NIH HHS/United States
GR  - AA-07754/AA/NIAAA NIH HHS/United States
GR  - DA-00944/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Alcohol
JT  - Alcohol (Fayetteville, N.Y.)
JID - 8502311
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology
MH  - Behavior, Animal/drug effects
MH  - *Cyclooxygenase Inhibitors
MH  - Ethanol/administration & dosage/*antagonists & inhibitors/pharmacology
MH  - Indomethacin/administration & dosage/pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Reinforcement, Psychology
MH  - Time Factors
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
AID - 0741-8329(90)90095-T [pii]
AID - 10.1016/0741-8329(90)90095-t [doi]
PST - ppublish
SO  - Alcohol. 1990 Jul-Aug;7(4):355-60. doi: 10.1016/0741-8329(90)90095-t.

PMID- 27138793
OWN - NLM
STAT- MEDLINE
DCOM- 20171113
LR  - 20181113
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 9
IP  - 7
DP  - 2016 Jul
TI  - Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice.
PG  - 624-34
LID - 10.1158/1940-6207.CAPR-15-0344 [doi]
AB  - Pancreatic cancer is a deadly disease with a dismal 5-year survival rate of <6%. 
      The currently limited treatment options for pancreatic cancer underscore the need 
      for novel chemopreventive and therapeutic agents. Accumulating evidence indicates 
      that aspirin use is associated with a decreased risk of pancreatic cancer. 
      However, the anticancer properties of aspirin are restricted by its 
      gastrointestinal toxicity and its limited efficacy. Therefore, we developed 
      phospho-aspirin (MDC-22), a novel derivative of aspirin, and evaluated its 
      chemopreventive efficacy in preclinical models of pancreatic cancer. 
      Phospho-aspirin inhibited the growth of human pancreatic cancer cell lines 8- to 
      12-fold more potently than aspirin; based on the 24-hour IC50 values. In a Panc-1 
      xenograft model, phospho-aspirin, at a dose of 100 mg/kg/d 5 times per week for 
      30 days, reduced tumor growth by 78% (P < 0.01 vs. vehicle control). Furthermore, 
      phospho-aspirin prevented pancreatitis-accelerated acinar-to-ductal metaplasia in 
      mice with activated Kras. In p48-Cre;Kras(G12D) mice, cerulein treatment (6 
      hourly injections two times per week for 3 weeks) led to a significant increase 
      in ductal metaplasia, replacing the majority of the exocrine compartment. 
      Administration of phospho-aspirin 100 mg/kg/day five times per week for 21 days 
      (starting on the first day of cerulein injection) inhibited the acinar-to-ductal 
      metaplasia, reducing it by 87% (P < 0.01, vs. cerulein-treated control). 
      Phospho-aspirin appeared to be safe, with the animals showing no signs of 
      toxicity during treatment. Mechanistically, phospho-aspirin inhibited EGFR 
      activation in pancreatic cancer, an effect consistently observed in pancreatic 
      cancer cells, primary acinar explants and in vivo In conclusion, our findings 
      indicate that phospho-aspirin has strong anticancer efficacy in preclinical 
      models of pancreatic cancer, warranting its further evaluation. Cancer Prev Res; 
      9(7); 624-34. ©2016 AACR.
CI  - ©2016 American Association for Cancer Research.
FAU - Mattheolabakis, George
AU  - Mattheolabakis G
AD  - Department of Medicine, Stony Brook University, Stony Brook, New York.
FAU - Papayannis, Ioannis
AU  - Papayannis I
AD  - Department of Medicine, Stony Brook University, Stony Brook, New York.
FAU - Yang, Jennifer
AU  - Yang J
AD  - Department of Family, Population and Preventive Medicine, Stony Brook University, 
      Stony Brook, New York.
FAU - Vaeth, Brandon M
AU  - Vaeth BM
AD  - Department of Family, Population and Preventive Medicine, Stony Brook University, 
      Stony Brook, New York.
FAU - Wang, Ruixue
AU  - Wang R
AD  - Department of Family, Population and Preventive Medicine, Stony Brook University, 
      Stony Brook, New York.
FAU - Bandovic, Jela
AU  - Bandovic J
AD  - Department of Pathology, Stony Brook University, Stony Brook, New York.
FAU - Ouyang, Nengtai
AU  - Ouyang N
AD  - Department of Medicine, Stony Brook University, Stony Brook, New York.
FAU - Rigas, Basil
AU  - Rigas B
AD  - Department of Medicine, Stony Brook University, Stony Brook, New York. Medicon 
      Pharmaceuticals Inc, Setauket, New York.
FAU - Mackenzie, Gerardo G
AU  - Mackenzie GG
AD  - Department of Medicine, Stony Brook University, Stony Brook, New York. Department 
      of Family, Population and Preventive Medicine, Stony Brook University, Stony 
      Brook, New York. Stony Brook Cancer Center, Stony Brook University, Stony Brook, 
      New York. Gerardo.Mackenzie@stonybrookmedicine.edu.
LA  - eng
GR  - R01 CA154172/CA/NCI NIH HHS/United States
GR  - R21 CA185209/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20160502
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Antineoplastic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Carcinogenesis/*drug effects
MH  - Cell Proliferation/drug effects
MH  - Chemoprevention/methods
MH  - Female
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Mice, Transgenic
MH  - Pancreatic Neoplasms/*pathology/prevention & control
MH  - Xenograft Model Antitumor Assays
PMC - PMC4930743
MID - NIHMS784690
COIS- Conflicts of interest: The authors have nothing to disclose except for Basil 
      Rigas, who has an equity position in Medicon Pharmaceuticals, Inc.
EDAT- 2016/05/04 06:00
MHDA- 2017/11/14 06:00
CRDT- 2016/05/04 06:00
PHST- 2015/09/17 00:00 [received]
PHST- 2016/04/22 00:00 [accepted]
PHST- 2016/05/04 06:00 [entrez]
PHST- 2016/05/04 06:00 [pubmed]
PHST- 2017/11/14 06:00 [medline]
AID - 1940-6207.CAPR-15-0344 [pii]
AID - 10.1158/1940-6207.CAPR-15-0344 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2016 Jul;9(7):624-34. doi: 
      10.1158/1940-6207.CAPR-15-0344. Epub 2016 May 2.

PMID- 21720137
OWN - NLM
STAT- MEDLINE
DCOM- 20120227
LR  - 20190724
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 131
IP  - 7
DP  - 2011
TI  - [Investigation of the combination of aspirin with non-steroidal anti-inflammatory 
      drugs].
PG  - 1073-7
AB  - It has been reported that non-steroidal anti-inflammatory drugs (NSAIDs) interact 
      with aspirin to influence its antiplatelet effect. For example, there have been 
      reported that the rate of platelet aggregation inhibition associated with aspirin 
      was significantly decreased when ibuprofen was taken before administration of 
      aspirin, as compared with aspirin alone. In this study, we investigated the 
      prescriptions on combination of aspirin with NSAIDs. The subjects were consisted 
      of 1212 patients who were prescribed aspirin in March, 2008 in Tokai University 
      Hachioji Hospital. The patients prescribed combination of aspirin with NSAIDs 
      were 8.1% and 18.6% of those were prescribed in the order of adminstration to 
      induce drug interaction. The pharmacists should provide information about drug 
      interactions of aspirin with NSAIDs to the doctors and patients, and it is 
      necessary to pay attention of these interactions.
FAU - Ito, Naoko
AU  - Ito N
AD  - Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo 
      University of Pharmacy and Life Sciences, Tokyo, Japan.
FAU - Yokoyama, Haruko
AU  - Yokoyama H
FAU - Soeda, Shinji
AU  - Soeda S
FAU - Suzuki, Yuji
AU  - Suzuki Y
FAU - Ikeda, Noriyuki
AU  - Ikeda N
FAU - Tokuoka, Kentaro
AU  - Tokuoka K
FAU - Watanabe, Masayuki
AU  - Watanabe M
FAU - Kitagawa, Yasuhisa
AU  - Kitagawa Y
FAU - Yamada, Yasuhiko
AU  - Yamada Y
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ibuprofen/*administration & dosage/pharmacology
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Prescriptions
EDAT- 2011/07/02 06:00
MHDA- 2012/03/01 06:00
CRDT- 2011/07/02 06:00
PHST- 2011/07/02 06:00 [entrez]
PHST- 2011/07/02 06:00 [pubmed]
PHST- 2012/03/01 06:00 [medline]
AID - JST.JSTAGE/yakushi/131.1073 [pii]
AID - 10.1248/yakushi.131.1073 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2011;131(7):1073-7. doi: 10.1248/yakushi.131.1073.

PMID- 31781767
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 1741-3850 (Electronic)
IS  - 1741-3842 (Linking)
VI  - 43
IP  - 2
DP  - 2021 Jun 7
TI  - Low-dose aspirin use and cancer-specific mortality: a meta-analysis of cohort 
      studies.
PG  - 308-315
LID - 10.1093/pubmed/fdz114 [doi]
AB  - BACKGROUND: Considering the increased risk of bleeding caused by aspirin, and the 
      observed benefit in all-cause mortality may be due to an improvement in 
      cardiovascular-related mortality. We carried out this meta-analysis to estimate 
      the association of low-dose aspirin use and risk of cancer-specific mortality. 
      METHODS: We searched the PubMed and China National Knowledge Infrastructure 
      (CNKI) databases for all articles within a range of published years from 1980 to 
      2018. RESULTS: Finally, 13 published cohort studies with 65 768 patients were 
      available for estimating overall risk of cancer-specific mortality associating 
      with post-diagnosis low-dose aspirin use, and 4 cohort studies were available for 
      pre-diagnosis low-dose aspirin use with 16 654 patients. Overall, statistical 
      evidence of significantly decreased cancer-specific mortality was found to be 
      associated with post-diagnosis low-dose aspirin use (OR = 0.84, 95% 
      CI = 0.75-0.93), but not with pre-diagnosis low-dose aspirin use. In terms of 
      subgroup analyses by cancer type, post-diagnosis low-dose aspirin use was 
      significantly with decreased cancer-specific mortality for digestive tract cancer 
      including colorectal cancer, esophageal cancer and gastric cancer. CONCLUSION: 
      Our meta-analysis indicated that post-diagnosis but not pre-diagnosis low-dose 
      aspirin use may reduce cancer-specific mortality.
CI  - © The Author(s) 2019. Published by Oxford University Press on behalf of Faculty 
      of Public Health. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Wang, Xianmin
AU  - Wang X
AD  - Department of Pediatric Cardiology, Chengdu Women's and Children's Central 
      Hospital, Chengdu 610091, People's Republic of China.
FAU - Luo, Yupeng
AU  - Luo Y
AD  - West China Hospital, Sichuan University, Chengdu 610041, People's Republic of 
      China.
FAU - Chen, Tingting
AU  - Chen T
AD  - Department of Pediatric Cardiology, Chengdu Women's and Children's Central 
      Hospital, Chengdu 610091, People's Republic of China.
FAU - Zhang, Kui
AU  - Zhang K
AUID- ORCID: 0000-0001-5576-3775
AD  - Department of Forensic Pathology, West China School of Basic Medical Sciences & 
      Forensic Medicine, Sichuan University, Chengdu 610041, People's Republic of 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - J Public Health (Oxf)
JT  - Journal of public health (Oxford, England)
JID - 101188638
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - China
MH  - Cohort Studies
MH  - *Colorectal Neoplasms
MH  - Databases, Factual
MH  - Humans
OTO - NOTNLM
OT  - aspirin
OT  - cancer-specific mortality
OT  - low dose
OT  - meta-analysis
EDAT- 2019/11/30 06:00
MHDA- 2021/08/07 06:00
CRDT- 2019/11/30 06:00
PHST- 2019/05/22 00:00 [received]
PHST- 2019/07/16 00:00 [revised]
PHST- 2019/08/12 00:00 [accepted]
PHST- 2019/11/30 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
PHST- 2019/11/30 06:00 [entrez]
AID - 5645099 [pii]
AID - 10.1093/pubmed/fdz114 [doi]
PST - ppublish
SO  - J Public Health (Oxf). 2021 Jun 7;43(2):308-315. doi: 10.1093/pubmed/fdz114.

PMID- 590598
OWN - NLM
STAT- MEDLINE
DCOM- 19780218
LR  - 20191028
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 5
IP  - 6
DP  - 1977
TI  - The interactions of ticlopidine and aspirin in normal subjects.
PG  - 405-11
AB  - This trial was performed on 24 health volunteers in order to study the possible 
      interactions between aspirin and ticlopidine. The results confirm the inhibitory 
      activity of aspirin on collagen-induced aggregation and that of ticlopidine on 
      ADP-induced aggregation. If aspirin does not modify the inhibitory effect of 
      ticlopidine on ADP-induced aggregation, ticlopidine on the other hand potentiates 
      the effect of aspirin on collagen-induced aggregation.
FAU - Thebault, J J
AU  - Thebault JJ
FAU - Blatrix, C E
AU  - Blatrix CE
FAU - Blanchard, J F
AU  - Blanchard JF
FAU - Panak, E A
AU  - Panak EA
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Pyridines)
RN  - 0 (Thiophenes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Pyridines/*pharmacology
MH  - Thiophenes/*pharmacology
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1177/030006057300100204 [doi]
PST - ppublish
SO  - J Int Med Res. 1977;5(6):405-11. doi: 10.1177/030006057300100204.

PMID- 7213048
OWN - NLM
STAT- MEDLINE
DCOM- 19810521
LR  - 20131121
IS  - 0098-6127 (Print)
IS  - 0098-6127 (Linking)
VI  - 8
IP  - 5
DP  - 1980
TI  - Paradoxical effect of high and low dose aspirin in experimental arterial 
      thrombosis.
PG  - 422-5
AB  - The effect of different dosage regimens of aspirin was investigated in an 
      experimental model of arterial thrombosis. A paradoxical effect with an increase 
      of the arterial thrombus growth could be seen after a first single dose of 100 mg 
      aspirin/kg body weight. When the high dose of aspirin was given repeatedly, a 
      thrombus size minor than under low dose aspirin therapy with 10 mg/kg body weight 
      has been observed. Our experimental thrombosis experiments do not provide 
      sufficient evidence to support antithrombotic therapy with low doses of aspirin.
FAU - Zimmermann, R
AU  - Zimmermann R
FAU - Thiessen, M
AU  - Thiessen M
FAU - Walter, E
AU  - Walter E
FAU - Mörl, H
AU  - Mörl H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Artery
JT  - Artery
JID - 7508494
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta, Abdominal
MH  - Arteries
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation
MH  - Body Weight
MH  - Dose-Response Relationship, Drug
MH  - Rabbits
MH  - Thrombosis/*physiopathology
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Artery. 1980;8(5):422-5.

PMID- 569841
OWN - NLM
STAT- MEDLINE
DCOM- 19790324
LR  - 20190726
IS  - 0031-6768 (Print)
IS  - 0031-6768 (Linking)
VI  - 378
IP  - 2
DP  - 1978 Dec 28
TI  - Effects of sodium acetylsalicylate on thermoregulatory responses of rats to 
      different ambient temperatures.
PG  - 181-4
AB  - The effects of intraperitoneal administration of sodium acetylsalicylate 
      (aspirin) on thermoregulatory responses (Ta) of 15, 22 and 29 degrees C were 
      assessed. Intraperitoneal administration of aspirin produced dose-dependent 
      hypothermia at both 15 and 22 degrees C. The hypothermia was brought about by 
      cutaneous vasodilation (as indicated by an increase of the tail and foot skin 
      temperatures). However, in the heat (29 degrees C), i.p. administration of the 
      same amount of aspirin produced no change in rectal temperature, since the 
      thermo-regulatory responses were unaffected by aspirin application at this Ta. 
      Thus it appears that aspirin increases heat loss and leads to hypothermia in 
      rats.
FAU - Lin, M T
AU  - Lin MT
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pflugers Arch
JT  - Pflugers Archiv : European journal of physiology
JID - 0154720
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Back
MH  - Body Temperature
MH  - Body Temperature Regulation/*drug effects
MH  - Foot
MH  - Male
MH  - Oxygen Consumption
MH  - Rats
MH  - Rectum
MH  - Respiration
MH  - Skin
MH  - Tail
EDAT- 1978/12/28 00:00
MHDA- 1978/12/28 00:01
CRDT- 1978/12/28 00:00
PHST- 1978/12/28 00:00 [pubmed]
PHST- 1978/12/28 00:01 [medline]
PHST- 1978/12/28 00:00 [entrez]
AID - 10.1007/BF00584454 [doi]
PST - ppublish
SO  - Pflugers Arch. 1978 Dec 28;378(2):181-4. doi: 10.1007/BF00584454.

PMID- 17592082
OWN - NLM
STAT- MEDLINE
DCOM- 20070807
LR  - 20131121
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 116
IP  - 3
DP  - 2007 Jul 17
TI  - Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery 
      shunt in infants with cyanotic congenital heart disease: does aspirin make a 
      difference?
PG  - 293-7
AB  - BACKGROUND: Aspirin (ASA) often is used to prevent thrombosis in infants with 
      congenital heart disease after placement of a systemic-to-pulmonary artery shunt, 
      but its effect on outcomes is unknown. METHODS AND RESULTS: The present 
      multicenter study prospectively collected data on 1-year postoperative rates of 
      death, shunt thrombosis, or hospitalization age <4 months for bidirectional 
      Glenn/hemi-Fontan surgery in 1004 infants. The use and dose of ASA were recorded. 
      Kaplan-Meier event rates were calculated for each event and the composite 
      outcome, and a Cox regression model was constructed for time to event. Model 
      terms were ASA use and type of surgery, with adjustment for age at surgery. 
      Diagnoses were hypoplastic left heart syndrome (n=346), tricuspid atresia 
      (n=103), tetralogy of Fallot (n=127), pulmonary atresia (n=177), heterotaxy 
      syndrome (n=38), and other (n=213). There were 344 shunts placed without 
      cardiopulmonary bypass (closed shunt), 287 shunts with bypass (open shunt), 323 
      Norwood procedures, and 50 Sano procedures. Overall, 80% of patients received 
      ASA. One-year postoperative events rates were high: 38% for the composite end 
      point, 26% for death, and 12% for shunt thrombosis. After the exclusion of 
      patients with early mortality, patients receiving ASA had a lower risk of shunt 
      thrombosis (hazard ratio, 0.13; P=0.008) and death (closed shunt: hazard ratio, 
      0.41, P=0.057; open shunt: hazard ratio, 0.10, P<0.001; Norwood: hazard ratio, 
      0.34, P<0.001; Sano: hazard ratio, 0.68, P=NS) compared with those not receiving 
      ASA. CONCLUSIONS: The morbidity and mortality for infants after surgical 
      placement of a systemic-to-pulmonary artery shunt are high. ASA appears to lower 
      the risk of death and shunt thrombosis in the present observational study.
FAU - Li, Jennifer S
AU  - Li JS
AD  - Division of Pediatric Cardiology, Department of Pediatrics, Duke University 
      Medical Center, Durham, NC, USA. jennifer.li@duke.edu
FAU - Yow, Eric
AU  - Yow E
FAU - Berezny, Katherine Y
AU  - Berezny KY
FAU - Rhodes, John F
AU  - Rhodes JF
FAU - Bokesch, Paula M
AU  - Bokesch PM
FAU - Charpie, John R
AU  - Charpie JR
FAU - Forbus, Geoffrey A
AU  - Forbus GA
FAU - Mahony, Lynn
AU  - Mahony L
FAU - Boshkov, Lynn
AU  - Boshkov L
FAU - Lambert, Virginie
AU  - Lambert V
FAU - Bonnet, Damien
AU  - Bonnet D
FAU - Michel-Behnke, Ina
AU  - Michel-Behnke I
FAU - Graham, Thomas P
AU  - Graham TP
FAU - Takahashi, Masato
AU  - Takahashi M
FAU - Jaggers, James
AU  - Jaggers J
FAU - Califf, Robert M
AU  - Califf RM
FAU - Rakhit, Amit
AU  - Rakhit A
FAU - Fontecave, Sylvie
AU  - Fontecave S
FAU - Sanders, Stephen P
AU  - Sanders SP
LA  - eng
GR  - 1UL 1RR024128-01/RR/NCRR NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20070625
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 2007 Jul 17;116(3):236-7. PMID: 17638938
MH  - Aspirin/pharmacology/*therapeutic use
MH  - *Cardiac Surgical Procedures/methods
MH  - Heart Defects, Congenital/*drug therapy/mortality/*surgery
MH  - Humans
MH  - Infant
MH  - *Palliative Care/methods
MH  - Prospective Studies
MH  - Pulmonary Artery/drug effects/*surgery
MH  - Treatment Outcome
EDAT- 2007/06/27 09:00
MHDA- 2007/08/08 09:00
CRDT- 2007/06/27 09:00
PHST- 2007/06/27 09:00 [pubmed]
PHST- 2007/08/08 09:00 [medline]
PHST- 2007/06/27 09:00 [entrez]
AID - CIRCULATIONAHA.106.652172 [pii]
AID - 10.1161/CIRCULATIONAHA.106.652172 [doi]
PST - ppublish
SO  - Circulation. 2007 Jul 17;116(3):293-7. doi: 10.1161/CIRCULATIONAHA.106.652172. 
      Epub 2007 Jun 25.

PMID- 7044799
OWN - NLM
STAT- MEDLINE
DCOM- 19820814
LR  - 20141120
IS  - 0140-1610 (Print)
IS  - 0140-1610 (Linking)
VI  - 5
IP  - 2
DP  - 1982
TI  - A double-blind study comparing benoxaprofen, aspirin, and benoxaprofen plus 
      aspirin in patients with rheumatoid arthritis.
PG  - 239-45
AB  - Ten patients with rheumatoid arthritis completed a study that consisted of 30-day 
      treatment periods with aspirin, benoxaprofen, and benoxaprofen plus aspirin. 
      There were two-week placebo washouts between each treatment. The patients were 
      evaluated biweekly for 15 variables. Each variable was compared for each period; 
      a pooled index was calculated on three combinations of variables. The 
      benoxaprofen-plus-aspirin combination was significantly better than aspirin and 
      better than benoxaprofen alone. This study indicates that combining nonsteroidal 
      anti-inflammatory drugs which inhibit different sites of the inflammatory 
      response (i.e., benoxaprofen, an inhibitor of the directional migration of 
      monocytes, with aspirin, a potent inhibitor of prostaglandin synthesis) may be 
      advantageous in treating patients with rheumatoid arthritis.
FAU - Ridolfo, A S
AU  - Ridolfo AS
FAU - Ashbrook, E M
AU  - Ashbrook EM
FAU - Schmid, G E
AU  - Schmid GE
FAU - Vogel, J A
AU  - Vogel JA
FAU - Rockhold, F W
AU  - Rockhold FW
FAU - Offen, W W
AU  - Offen WW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Eur J Rheumatol Inflamm
JT  - European journal of rheumatology and inflammation
JID - 7805765
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Propionates)
RN  - 17SZX404IM (benoxaprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Propionates/adverse effects/*therapeutic use
MH  - Time Factors
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - Eur J Rheumatol Inflamm. 1982;5(2):239-45.

PMID- 12512029
OWN - NLM
STAT- MEDLINE
DCOM- 20030127
LR  - 20181130
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 124
IP  - 1
DP  - 2003 Jan
TI  - Protective association of aspirin/NSAIDs and esophageal cancer: a systematic 
      review and meta-analysis.
PG  - 47-56
AB  - BACKGROUND & AIMS: Esophageal carcinomas have high fatality rates, making 
      chemoprevention agents desirable. We performed a systematic review with 
      meta-analysis of observational studies evaluating the association of 
      aspirin/nonsteroidal anti-inflammatory drug (NSAID) use and esophageal cancer. 
      METHODS: We evaluated the MEDLINE, BIOSIS, and Web of Science electronic 
      databases (1980-2001); manually reviewed the literature; and consulted with 
      experts. Studies were included if they: (1) evaluated exposure to NSAIDs, 
      aspirin, or both; (2) evaluated esophageal cancer; and (3) reported relative 
      risks or odds ratios or provided data for their calculation. Data were 
      independently abstracted by 2 investigators. The primary and sensitivity analyses 
      used both fixed and random-effects models. RESULTS: Nine studies (2 cohort, 7 
      case control) containing 1813 cancer cases were identified. All primary summary 
      estimates were homogeneous. Statistical pooling showed a protective association 
      between any use of aspirin/NSAID and esophageal cancer (odds ratio [OR] = 0.57; 
      95% confidence interval [CI], 0.47-0.71). Both intermittent (OR = 0.82; CI, 
      0.67-0.99) and frequent medication use were protective (OR = 0.54; CI, 
      0.43-0.67), with greater protection with more frequent use. Stratified by 
      medication type, aspirin use was protective (OR = 0.5; CI, 0.38-0.66), and NSAIDs 
      had a borderline protective association (OR = 0.75; CI, 0.54-1.0). Any use was 
      protective against both esophageal adenocarcinoma (OR = 0.67; CI, 0.51-0.87) and 
      squamous cell carcinoma (OR = 0.58; CI, 0.43-0.78). CONCLUSIONS: Pooled results 
      support a protective association between aspirin and NSAIDs and esophageal cancer 
      (of both histological types) and provide evidence for a dose effect. These 
      findings support evaluating these agents in clinical trials of high-risk 
      patients.
FAU - Corley, Douglas A
AU  - Corley DA
AD  - Northern California Kaiser Division of Research, Department of Medicine, 
      University of California-San Francisco, 2238 Geary Boulevard, GI 2-West, San 
      Francisco, CA 94115, USA. corley@itsa.ucsf.edu
FAU - Kerlikowske, Karla
AU  - Kerlikowske K
FAU - Verma, Rajiv
AU  - Verma R
FAU - Buffler, Patricia
AU  - Buffler P
LA  - eng
GR  - K08 DK 02697/DK/NIDDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 2003 Jan;124(1):246-8. PMID: 12512047
CIN - Gastroenterology. 2003 Dec;125(6):1914-5; author reply 1915. PMID: 14727630
MH  - Adenocarcinoma/*prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Carcinoma, Squamous Cell/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Esophageal Neoplasms/*prevention & control
MH  - Humans
RF  - 85
EDAT- 2003/01/04 04:00
MHDA- 2003/01/28 04:00
CRDT- 2003/01/04 04:00
PHST- 2003/01/04 04:00 [pubmed]
PHST- 2003/01/28 04:00 [medline]
PHST- 2003/01/04 04:00 [entrez]
AID - S001650850350018X [pii]
AID - 10.1053/gast.2003.50008 [doi]
PST - ppublish
SO  - Gastroenterology. 2003 Jan;124(1):47-56. doi: 10.1053/gast.2003.50008.

PMID- 32091012
OWN - NLM
STAT- MEDLINE
DCOM- 20220225
LR  - 20220802
IS  - 1804-7521 (Electronic)
IS  - 1213-8118 (Linking)
VI  - 165
IP  - 2
DP  - 2021 Jun
TI  - Granulation tissue enriched by aspirin and omega-3 fatty acids in healing 
      experimental periodontal lesion.
PG  - 216-223
LID - 10.5507/bp.2020.003 [doi]
AB  - AIMS: Granulation tissue (GT) and specialized pro‑resolving mediators such as 
      lipoxins and resolvins are key elements in the successful resolution of 
      periodontitis. Aspirin‑triggered lipoxins and resolvins are even more powerful 
      than their natural analogues. Their biosynthesis can be accelerated by omega-3 
      fatty acids. The aim of this study was to evaluate the use of GT enriched by 
      aspirin and omega-3 fatty acids during the surgical treatment of periodontitis in 
      an experimental animal model (rabbit). METHODS: In each of 24 rabbits, two 
      experimental periodontal defects were created. In total, 47 defects were treated 
      with open-flap debridement and one of three procedures: (1) GT extracted and 
      soaked with aspirin and omega-3 fatty acids (ASA+OMEGA3 group); (2) GT soaked 
      with saline (PLACEBO group); or (3) GT left untreated (CONTROL group). Then, the 
      GT was replaced in situ. Primary evaluated criteria were the probing pocket depth 
      (PPD) and the clinical attachment level (CAL). Necropsies were harvested 2, 6, 
      and 12 weeks after surgery. The samples were used for histological and molecular 
      biological assessment. RESULTS: A trend of greater PPD and CAL in the ASA+OMEGA3 
      group was observed at 6 weeks. However, there was no significant difference 
      between them. During the observation period, tissue levels of FGF-7, IL-1β and 
      TIMP-1 showed a statistically significant decrease (P<0.05). For the other 
      variables, the ASA+OMEGA3 group was comparable with the PLACEBO and CONTROL 
      groups. CONCLUSION: This experiment did not demonstrate the superiority of the 
      proposed approach. However, the enriched granulation tissue did not impair 
      healing outcomes.
FAU - Hromcik, Filip
AU  - Hromcik F
AD  - Clinic of Dentistry, St. Anne's Faculty Hospital, Pekarska 53, 656 91, Brno, 
      Czech Republic.
AD  - Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech 
      Republic.
FAU - Vokurka, Jan
AU  - Vokurka J
AD  - Clinic of Dentistry, St. Anne's Faculty Hospital, Pekarska 53, 656 91, Brno, 
      Czech Republic.
AD  - Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech 
      Republic.
FAU - Gopfert, Eduard
AU  - Gopfert E
AD  - Veterinary Research Institute, Hudcova 70, 621 00, Brno, Czech Republic.
FAU - Faldyna, Martin
AU  - Faldyna M
AD  - Veterinary Research Institute, Hudcova 70, 621 00, Brno, Czech Republic.
FAU - Hermanova, Marketa
AU  - Hermanova M
AD  - Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech 
      Republic.
AD  - First Department of Pathology, St. Anne's Faculty Hospital, Pekarska 53, 656 91, 
      Brno, Czech Republic.
FAU - Kyr, Michal
AU  - Kyr M
AD  - Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech 
      Republic.
AD  - Department of Pediatric Oncology, University Hospital Brno, Cernopolni 9, 613 00, 
      Brno, Czech Republic.
FAU - Vicenova, Monika
AU  - Vicenova M
AD  - Veterinary Research Institute, Hudcova 70, 621 00, Brno, Czech Republic.
FAU - Izakovicova Holla, Lydie
AU  - Izakovicova Holla L
AD  - Clinic of Dentistry, St. Anne's Faculty Hospital, Pekarska 53, 656 91, Brno, 
      Czech Republic.
AD  - Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech 
      Republic.
LA  - eng
PT  - Journal Article
DEP - 20200211
PL  - Czech Republic
TA  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
JT  - Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, 
      Czechoslovakia
JID - 101140142
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Lipoxins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - *Fatty Acids, Omega-3/pharmacology
MH  - Granulation Tissue
MH  - *Lipoxins
MH  - *Periodontitis/drug therapy
MH  - Rabbits
OTO - NOTNLM
OT  - granulation tissue
OT  - inflammation mediators
OT  - lipoxin
OT  - oral surgery
OT  - periodontitis
EDAT- 2020/02/25 06:00
MHDA- 2022/02/26 06:00
CRDT- 2020/02/25 06:00
PHST- 2019/11/03 00:00 [received]
PHST- 2020/01/22 00:00 [accepted]
PHST- 2020/02/25 06:00 [pubmed]
PHST- 2022/02/26 06:00 [medline]
PHST- 2020/02/25 06:00 [entrez]
AID - 10.5507/bp.2020.003 [doi]
PST - ppublish
SO  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Jun;165(2):216-223. 
      doi: 10.5507/bp.2020.003. Epub 2020 Feb 11.

PMID- 22090175
OWN - NLM
STAT- MEDLINE
DCOM- 20120131
LR  - 20131121
IS  - 0301-1526 (Print)
IS  - 0301-1526 (Linking)
VI  - 40
IP  - 6
DP  - 2011 Nov
TI  - "Aspirin - resistance"? A few critical considerations on definition, terminology, 
      diagnosis, clinical value, natural course of atherosclerotic disease, and 
      therapeutic consequences.
PG  - 429-38
LID - 10.1024/0301-1526/a000145 [doi]
AB  - Based upon various platelet function tests and the fact that patients experience 
      vascular events despite taking acetylsalicylic acid (ASA or aspirin), it has been 
      suggested that patients may become resistant to the action of this 
      pharmacological compound. However, the term "aspirin resistance" was created 
      almost two decades ago but is still not defined. Platelet function tests are not 
      standardized, providing conflicting information and cut-off values are 
      arbitrarily set. Interest comparison reveals low agreement. Even point of care 
      tests have been introduced before appropriate validation. Inflammation may 
      activate platelets, co-medication(s) may interfere significantly with aspirin 
      action on platelets. Platelet function and Cox-inhibition are only some of the 
      effects of aspirin on haemostatic regulation. One single test is not reliable to 
      identify an altered response. Therefore, it may be more appropriate to speak 
      about "treatment failure" to aspirin therapy than using the term "aspirin 
      resistance". There is no evidence based justification from either the laboratory 
      or the clinical point of view for platelet function testing in patients taking 
      aspirin as well as from an economic standpoint. Until evidence based data from 
      controlled studies will be available the term "aspirin resistance" should not be 
      further used. A more robust monitoring of factors resulting in cardiovascular 
      events such as inflammation is recommended.
FAU - Berent, R
AU  - Berent R
AD  - Center for Cardiovascular Rehabilitation, Rehabilitationszentrum, Bad 
      Schallerbach, Austria.
FAU - Sinzinger, H
AU  - Sinzinger H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Vasa
JT  - VASA. Zeitschrift fur Gefasskrankheiten
JID - 0317051
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atherosclerosis/*blood/*drug therapy
MH  - *Bleeding Time
MH  - Drug Resistance
MH  - Humans
MH  - Inflammation/blood/drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Point-of-Care Systems
MH  - Treatment Failure
EDAT- 2011/11/18 06:00
MHDA- 2012/02/01 06:00
CRDT- 2011/11/18 06:00
PHST- 2011/11/18 06:00 [entrez]
PHST- 2011/11/18 06:00 [pubmed]
PHST- 2012/02/01 06:00 [medline]
AID - 10.1024/0301-1526/a000145 [doi]
PST - ppublish
SO  - Vasa. 2011 Nov;40(6):429-38. doi: 10.1024/0301-1526/a000145.

PMID- 21728147
OWN - NLM
STAT- MEDLINE
DCOM- 20130419
LR  - 20131121
IS  - 1439-0221 (Electronic)
IS  - 0032-0943 (Linking)
VI  - 77
IP  - 17
DP  - 2011 Nov
TI  - Protocatechualdehyde synergizes with aspirin at the platelet cyclooxygenase-1 
      level.
PG  - 1898-904
LID - 10.1055/s-0031-1280008 [doi]
AB  - Polyphenol-aspirin interactions were recently identified; however, the 
      interaction mode and underlying mechanisms remained elusive. Here, we 
      quantitatively assessed the potential interactions among two important 
      polyphenolic compounds, caffeic acid (CA) and protocatechualdehyde (Pro), and 
      aspirin in the AA-induced platelet aggregation model by applying the isobologram 
      and universal response surface approach (URSA) methods. A molecular docking 
      approach and an originally developed platelet-associated aspirin clearance 
      approach (PAACA) were then applied to explore the potential interaction 
      mechanisms. Although Pro and CA themselves exhibited weak inhibitory effect on 
      arachidonic acid (AA)-induced platelet aggregation and the production of 
      thromboxane B₂ (TXB₂), both Pro and CA potentiated aspirin action in a 
      synergistic manner. The most prominent synergism was found between Pro and 
      aspirin. Pro formed a stable complex into the cyclooxygenase-1 (COX-1) channel by 
      in silico docking and significantly promoted the platelet-associated aspirin 
      clearance, suggesting that the Pro interaction with COX-1 was favorable to the 
      binding of aspirin with COX-1. Taken together, our findings suggest that the 
      capacity of Pro and potentially other structurally similar polyphenolic compounds 
      on promoting the binding of aspirin on platelet COX-1 might be the main mechanism 
      of their synergism with aspirin.
CI  - © Georg Thieme Verlag KG Stuttgart · New York.
FAU - Sun, Shiqing
AU  - Sun S
AD  - Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 
      Nanjing, China.
FAU - Hao, Haiping
AU  - Hao H
FAU - Gong, Ping
AU  - Gong P
FAU - Tang, Zhiyuan
AU  - Tang Z
FAU - Li, Feiyan
AU  - Li F
FAU - Chen, Xiaohu
AU  - Chen X
FAU - Shi, Haibo
AU  - Shi H
FAU - Wang, Guangji
AU  - Wang G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110704
PL  - Germany
TA  - Planta Med
JT  - Planta medica
JID - 0066751
RN  - 0 (Anticoagulants)
RN  - 0 (Antioxidants)
RN  - 0 (Benzaldehydes)
RN  - 0 (Caffeic Acids)
RN  - 0 (Catechols)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 4PVP2HCH4T (protocatechualdehyde)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
RN  - U2S3A33KVM (caffeic acid)
SB  - IM
MH  - Animals
MH  - Anticoagulants/*pharmacology
MH  - Antioxidants/*pharmacology
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*metabolism/pharmacology
MH  - Benzaldehydes/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Caffeic Acids/*pharmacology
MH  - Catechols/*pharmacology
MH  - Cyclooxygenase 1/*metabolism
MH  - Drug Synergism
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*metabolism/pharmacology
MH  - Protein Binding
MH  - Rabbits
EDAT- 2011/07/06 06:00
MHDA- 2013/04/23 06:00
CRDT- 2011/07/06 06:00
PHST- 2011/07/06 06:00 [entrez]
PHST- 2011/07/06 06:00 [pubmed]
PHST- 2013/04/23 06:00 [medline]
AID - 10.1055/s-0031-1280008 [doi]
PST - ppublish
SO  - Planta Med. 2011 Nov;77(17):1898-904. doi: 10.1055/s-0031-1280008. Epub 2011 Jul 
      4.

PMID- 12512737
OWN - NLM
STAT- MEDLINE
DCOM- 20030124
LR  - 20131121
IS  - 1088-0224 (Print)
IS  - 1088-0224 (Linking)
VI  - 8
IP  - 22 Suppl
DP  - 2002 Dec
TI  - Gastrointestinal safety of low-dose aspirin.
PG  - S701-8
AB  - The cardioprotective benefits of aspirin support the use of low-dose regimens for 
      primary and secondary prevention of cardiovascular disease. However, these 
      cardioprotective benefits must often be balanced against the well-documented 
      gastrointestinal (GI) effects of aspirin. Recent research suggests that the GI 
      effects of aspirin may be dose-dependent; however, even low-dose aspirin can 
      cause significant GI sequelae. Similarly, the use of nonaspirin nonsteroidal 
      antiinflammatory drugs (NSAIDs), including cyclooxygenase (COX)-2 inhibitors, has 
      also been shown to increase the risk of GI effects, and the concomitant use of 
      aspirin and nonaspirin NSAIDs can significantly increase the risk of GI 
      ulceration and bleeding. Therefore, clinicians should use the lowest effective 
      dose of aspirin (ie, 75 to 150 mg/day) that affords cardiovascular benefits 
      without increasing the risk of GI effects. Low-dose aspirin therapy can 
      complicate the concurrent use of analgesics. When an analgesic is needed in 
      addition to aspirin, concomitant use of aspirin and nonaspirin NSAIDs or COX-2 
      inhibitors should be used with caution, or with concomitant gastroprotective 
      agents, to minimize the risk of GI complications. In contrast, because 
      acetaminophen does not cause GI irritation, it should therefore be considered 
      when an analgesic is needed.
FAU - Cryer, Byron
AU  - Cryer B
AD  - Department of Medicine, University of Texas Southwestern Medical School, Dallas 
      VA Medical Center, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Consumer Product Safety
MH  - Digestive System/*drug effects
MH  - Drug Interactions
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - United States
RF  - 22
EDAT- 2003/01/07 04:00
MHDA- 2003/01/25 04:00
CRDT- 2003/01/07 04:00
PHST- 2003/01/07 04:00 [pubmed]
PHST- 2003/01/25 04:00 [medline]
PHST- 2003/01/07 04:00 [entrez]
AID - 148 [pii]
PST - ppublish
SO  - Am J Manag Care. 2002 Dec;8(22 Suppl):S701-8.

PMID- 24462645
OWN - NLM
STAT- MEDLINE
DCOM- 20140507
LR  - 20181202
IS  - 1873-0183 (Electronic)
IS  - 1568-9972 (Linking)
VI  - 13
IP  - 4-5
DP  - 2014 Apr-May
TI  - Unmet needs in the treatment of autoimmunity: from aspirin to stem cells.
PG  - 331-46
LID - S1568-9972(14)00064-0 [pii]
LID - 10.1016/j.autrev.2014.01.052 [doi]
AB  - As rheumatologic diseases became understood to be autoimmune in nature, the drugs 
      used to treat this group of conditions has evolved from herbal or plant derived 
      anti-inflammatory agents, such as salicylates, quinine and colchicine to the many 
      recently approved biological response modifiers. These new drugs, especially the 
      anti-tumor necrosis factor agents, have shown remarkable efficacy in autoimmune 
      diseases, and there are new agents under investigation that will provide 
      additional treatment options. In between, the world was introduced to cortisone 
      and all of its derivatives, as chemical synthesis led to better, more efficacious 
      drugs with lesser side effects. Disease modifying anti-rheumatic agents have 
      actually been around since the first half of the 20th century, but only began to 
      be used in the treatment of autoimmune diseases in the 1970s and 1980s. One 
      advantage is that they have been invaluable in their ability to offer "steroid 
      sparing" to decrease the adverse effects of steroids. Research over the past 
      decade has resulted in a new class of drugs that influence cytokine regulatory 
      pathways such as the Janus associated kinase inhibitors. The promise of 
      personalized medicine now permeates current research into new pharmacological 
      agents for the treatment of autoimmune disease. The new appreciation for the 
      gene-environment interaction in the pathogenesis of most diseases especially 
      those as heterogeneous as autoimmune diseases, has led to our focus on targeted 
      therapies. Add to that the new knowledge of epigenetics and how changes in DNA 
      and histone structure affect expression of genes that can play a role in immune 
      signaling, and we now have a new exciting frontier for cutting edge drug 
      development. The history of treatment of autoimmune diseases is really only a 
      little over a century, but so much has changed, leading to increasing lifespans 
      and improved quality of life of those who suffer from these ailments.
CI  - Copyright © 2014. Published by Elsevier B.V.
FAU - Chang, Christopher
AU  - Chang C
AD  - Division of Allergy and Immunology, Thomas Jefferson University, Nemours/A.I. 
      duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE 19803, USA. 
      Electronic address: cchang@nemours.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140121
PL  - Netherlands
TA  - Autoimmun Rev
JT  - Autoimmunity reviews
JID - 101128967
RN  - 0 (Antirheumatic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antirheumatic Agents/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Autoimmune Diseases/*therapy
MH  - *Autoimmunity
MH  - Genomics
MH  - Humans
MH  - *Stem Cells
OTO - NOTNLM
OT  - Biological response modifiers
OT  - DMARDS
OT  - Glucocorticoids
OT  - Janus associated kinase inhibitors
OT  - Rheumatoid arthritis
OT  - Systemic lupus erythematosus
EDAT- 2014/01/28 06:00
MHDA- 2014/05/08 06:00
CRDT- 2014/01/28 06:00
PHST- 2013/11/13 00:00 [accepted]
PHST- 2014/01/28 06:00 [entrez]
PHST- 2014/01/28 06:00 [pubmed]
PHST- 2014/05/08 06:00 [medline]
AID - S1568-9972(14)00064-0 [pii]
AID - 10.1016/j.autrev.2014.01.052 [doi]
PST - ppublish
SO  - Autoimmun Rev. 2014 Apr-May;13(4-5):331-46. doi: 10.1016/j.autrev.2014.01.052. 
      Epub 2014 Jan 21.

PMID- 28905988
OWN - NLM
STAT- MEDLINE
DCOM- 20190708
LR  - 20190708
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 103
IP  - 6
DP  - 2018 Jun
TI  - Lack of Bioequivalence Among Low-dose, Enteric-coated Aspirin Preparations.
PG  - 1047-1051
LID - 10.1002/cpt.874 [doi]
AB  - Low-dose aspirin (75 mg or 81 mg) is considered to be the lowest effective dose 
      for cardiovascular protection; however, the use of enteric preparations has 
      created a source of variability in bioavailability. As part of regulatory 
      requirements, we carried out bioequivalence tests for two 75 mg enteric-coated 
      aspirin preparations (Caprin and Protek) using Nu-Seals 75 mg aspirin as the 
      comparator. The primary endpoint was serum thromboxane levels after 14 days of 
      treatment. Protek failed to meet bioequivalence, as it was significantly less 
      effective than Nu-Seals. In contrast, Caprin was not bioequivalent with Nu-Seals 
      but as it was more effective it was granted approval. However, 75 mg plain 
      aspirin was found to be more effective than Nu-Seals at inhibiting serum 
      thromboxane production. Thus, there is significant variation in the ability of 
      low-dose aspirin preparations to inhibit serum thromboxane production.
CI  - © 2017 American Society for Clinical Pharmacology and Therapeutics.
FAU - Cox, Dermot
AU  - Cox D
AD  - Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 
      Dublin, Ireland.
FAU - Fitzgerald, Desmond J
AU  - Fitzgerald DJ
AD  - Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 
      Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171025
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Peptide Fragments)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 145229-76-1 (thrombin receptor peptide SFLLRNP)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Peptide Fragments/metabolism
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacokinetics
MH  - Tablets, Enteric-Coated
MH  - Therapeutic Equivalency
MH  - Thromboxane A2/metabolism
EDAT- 2017/09/15 06:00
MHDA- 2019/07/10 06:00
CRDT- 2017/09/15 06:00
PHST- 2017/06/12 00:00 [received]
PHST- 2017/07/20 00:00 [revised]
PHST- 2017/08/26 00:00 [accepted]
PHST- 2017/09/15 06:00 [pubmed]
PHST- 2019/07/10 06:00 [medline]
PHST- 2017/09/15 06:00 [entrez]
AID - 10.1002/cpt.874 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2018 Jun;103(6):1047-1051. doi: 10.1002/cpt.874. Epub 2017 
      Oct 25.

PMID- 8012645
OWN - NLM
STAT- MEDLINE
DCOM- 19940725
LR  - 20161123
IS  - 1018-9068 (Print)
IS  - 1018-9068 (Linking)
VI  - 3
IP  - 6
DP  - 1993 Nov-Dec
TI  - Effect of aspirin on beta-receptors in lymphocytes from patients with 
      aspirin-induced asthma.
PG  - 288-93
AB  - We studied the effect of aspirin on beta-adrenergic receptors in lymphocytes from 
      three groups of subjects: 5 asthmatic patients presenting sensitivity to aspirin, 
      10 asthmatic patients with tolerance to aspirin and a control group. Lymphocytes 
      were incubated with aspirin-lysine (36 micrograms/ml). The number of 
      beta-receptors/cell and the dissociation constants (Kd) were assessed by means of 
      [125I]-cyanopindolol (ICYP). There was a decrease in the number of beta-receptors 
      after incubation with aspirin in all asthmatic patients with sensitivity. The 
      differences between mean basal (660 +/- 171 receptors/cell) and postincubation 
      (398 +/- 110 receptors/cell) values were significant (p < 0.05). There were also 
      significant differences (p < 0.01) between basal (23.4 +/- 6 pM) and 
      postincubation (15 +/- 5.1 pM) Kd values, which indicates that the affinity of 
      ICYP increased. In the subjects in the other two groups, aspirin both increased 
      and decreased the number of beta-receptors, but the effects were not significant. 
      It is suggested that in patients with sensitivity, aspirin could induce changes 
      in the plasmatic membrane, thus altering beta-receptors or inducing the release 
      of inflammatory mediators that exert their effect upon these receptors.
FAU - Costa-Manso, E
AU  - Costa-Manso E
AD  - Department of Allergology and Clinical Immunology, University Clinic, School of 
      Medicine, University of Navarra, Pamplona, Spain.
FAU - Sanz, M L
AU  - Sanz ML
FAU - Croce, M
AU  - Croce M
FAU - Córdoba, H
AU  - Córdoba H
FAU - Oehling, A
AU  - Oehling A
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - J Investig Allergol Clin Immunol
JT  - Journal of investigational allergology & clinical immunology
JID - 9107858
RN  - 0 (Receptors, Adrenergic, beta)
RN  - 4K0SD5SNFS (cyanopindolol)
RN  - BJ4HF6IU1D (Pindolol)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/analogs & derivatives/*pharmacology
MH  - Asthma/*chemically induced/immunology
MH  - Down-Regulation/drug effects
MH  - Drug Hypersensitivity/*immunology
MH  - Female
MH  - Humans
MH  - Lymphocytes/*drug effects
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Pindolol/analogs & derivatives/metabolism
MH  - Receptors, Adrenergic, beta/*drug effects/metabolism
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PST - ppublish
SO  - J Investig Allergol Clin Immunol. 1993 Nov-Dec;3(6):288-93.

PMID- 9635947
OWN - NLM
STAT- MEDLINE
DCOM- 19980710
LR  - 20220408
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 351
IP  - 9118
DP  - 1998 Jun 13
TI  - Effects of intensive blood-pressure lowering and low-dose aspirin in patients 
      with hypertension: principal results of the Hypertension Optimal Treatment (HOT) 
      randomised trial. HOT Study Group.
PG  - 1755-62
AB  - BACKGROUND: Despite treatment, there is often a higher incidence of 
      cardiovascular complications in patients with hypertension than in normotensive 
      individuals. Inadequate reduction of their blood pressure is a likely cause, but 
      the optimum target blood pressure is not known. The impact of acetylsalicylic 
      acid (aspirin) has never been investigated in patients with hypertension. We 
      aimed to assess the optimum target diastolic blood pressure and the potential 
      benefit of a low dose of acetylsalicylic acid in the treatment of hypertension. 
      METHODS: 18790 patients, from 26 countries, aged 50-80 years (mean 61.5 years) 
      with hypertension and diastolic blood pressure between 100 mm Hg and 115 mm Hg 
      (mean 105 mm Hg) were randomly assigned a target diastolic blood pressure. 6264 
      patients were allocated to the target pressure < or =90 mm Hg, 6264 to < or =85 
      mm Hg, and 6262 to < or =80 mm Hg. Felodipine was given as baseline therapy with 
      the addition of other agents, according to a five-step regimen. In addition, 9399 
      patients were randomly assigned 75 mg/day acetylsalicylic acid (Bamycor, Astra) 
      and 9391 patients were assigned placebo. FINDINGS: Diastolic blood pressure was 
      reduced by 20.3 mm Hg, 22.3 mm Hg, and 24.3 mm Hg, in the < or =90 mm Hg, < or 
      =85 mm Hg, and < or =80 mm Hg target groups, respectively. The lowest incidence 
      of major cardiovascular events occurred at a mean achieved diastolic blood 
      pressure of 82.6 mm Hg; the lowest risk of cardiovascular mortality occurred at 
      86.5 mm Hg. Further reduction below these blood pressures was safe. In patients 
      with diabetes mellitus there was a 51% reduction in major cardiovascular events 
      in target group < or =80 mm Hg compared with target group < or =90 mm Hg (p for 
      trend=0.005). Acetylsalicylic acid reduced major cardiovascular events by 15% 
      (p=0.03) and all myocardial infarction by 36% (p=0.002), with no effect on 
      stroke. There were seven fatal bleeds in the acetylsalicylic acid group and eight 
      in the placebo group, and 129 versus 70 non-fatal major bleeds in the two groups, 
      respectively (p<0.001). INTERPRETATION: Intensive lowering of blood pressure in 
      patients with hypertension was associated with a low rate of cardiovascular 
      events. The HOT Study shows the benefits of lowering the diastolic blood pressure 
      down to 82.6 mm Hg. Acetylsalicylic acid significantly reduced major 
      cardiovascular events with the greatest benefit seen in all myocardial 
      infarction. There was no effect on the incidence of stroke or fatal bleeds, but 
      non-fatal major bleeds were twice as common.
FAU - Hansson, L
AU  - Hansson L
AD  - University of Uppsala, Department of Public Health and Social Sciences, Clinical 
      Hypertension Research, Sweden.
FAU - Zanchetti, A
AU  - Zanchetti A
FAU - Carruthers, S G
AU  - Carruthers SG
FAU - Dahlöf, B
AU  - Dahlöf B
FAU - Elmfeldt, D
AU  - Elmfeldt D
FAU - Julius, S
AU  - Julius S
FAU - Ménard, J
AU  - Ménard J
FAU - Rahn, K H
AU  - Rahn KH
FAU - Wedel, H
AU  - Wedel H
FAU - Westerling, S
AU  - Westerling S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 1998 Jun 13;351(9118):1748-9. PMID: 9635941
CIN - Lancet. 1998 Aug 15;352(9127):571; author reply 574-5. PMID: 9716078
CIN - Lancet. 1998 Aug 15;352(9127):571-2; author reply 574-5. PMID: 9716079
CIN - Lancet. 1998 Aug 15;352(9127):572; author reply 574-5. PMID: 9716080
CIN - Lancet. 1998 Aug 15;352(9127):572-3; author reply 574-5. PMID: 9716081
CIN - Lancet. 1998 Aug 15;352(9127):573; author reply 574-5. PMID: 9716082
CIN - Lancet. 1998 Aug 15;352(9127):573; author reply 574-5. PMID: 9716083
CIN - Lancet. 1998 Aug 15;352(9127):573-4; author reply 574-5. PMID: 9716084
CIN - Lancet. 1998 Aug 15;352(9127):574-5. PMID: 9716085
CIN - Lancet. 1999 Jan 9;353(9147):148-50. PMID: 10023923
CIN - Lancet. 1999 Feb 20;353(9153):676. PMID: 10030365
CIN - Lancet. 2000 Feb 19;355(9204):652; author reply 653. PMID: 10697002
CIN - Lancet. 2000 Aug 5;356(9228):508-9. PMID: 10981915
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Cardiovascular Diseases/etiology/mortality/*prevention & control
MH  - Drug Therapy, Combination
MH  - Electrocardiography
MH  - Female
MH  - Humans
MH  - Hypertension/complications/*drug therapy
MH  - Male
MH  - Middle Aged
EDAT- 1998/06/23 00:00
MHDA- 2000/06/10 00:00
CRDT- 1998/06/23 00:00
PHST- 1998/06/23 00:00 [pubmed]
PHST- 2000/06/10 00:00 [medline]
PHST- 1998/06/23 00:00 [entrez]
AID - S0140673698043116 [pii]
AID - 10.1016/s0140-6736(98)04311-6 [doi]
PST - ppublish
SO  - Lancet. 1998 Jun 13;351(9118):1755-62. doi: 10.1016/s0140-6736(98)04311-6.

PMID- 24335397
OWN - NLM
STAT- MEDLINE
DCOM- 20140210
LR  - 20180126
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 111 Suppl 1
DP  - 2013 Dec
TI  - Perioperative management of antiplatelet therapy.
PG  - i3-17
LID - 10.1093/bja/aet402 [doi]
AB  - Worldwide, cardiovascular events represent the major cause of morbidity and 
      mortality. A key role in the pathogenesis of these events is played by platelets. 
      Interventional procedures, with placement of coronary and vascular stents, often 
      represent the preferred therapeutic strategy. Antiplatelet medications are 
      considered first-line therapy in preventing cardiovascular thrombotic events. A 
      wide array of antiplatelet agents is available, each with different 
      pharmacological properties. When patients on antiplatelet agents present for 
      surgery, the perioperative team must design an optimal strategy to manage 
      antiplatelet medications. Each patient is stratified according to risk of 
      developing a cardiovascular thrombotic event and inherent risk of surgical 
      bleeding. After risk stratification analysis, various therapeutic pathways 
      include continuing or discontinuing all antiplatelet agents or maintaining one 
      antiplatelet agent and discontinuing the other. This review focuses on the 
      pharmacological and pharmacokinetic properties of both older and novel 
      antiplatelet drugs, and reviews current literature and guidelines addressing 
      options for perioperative antiplatelet management.
FAU - Oprea, A D
AU  - Oprea AD
AD  - Department of Anesthesiology, Yale University School of Medicine, New Haven, CT, 
      USA.
FAU - Popescu, W M
AU  - Popescu WM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Coagulation
MH  - Coronary Artery Disease/prevention & control
MH  - Humans
MH  - *Perioperative Care
MH  - Platelet Activation
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
MH  - Stroke/prevention & control
OTO - NOTNLM
OT  - antiplatelet agents
OT  - haemorrhage
OT  - perioperative period
EDAT- 2013/12/18 06:00
MHDA- 2014/02/11 06:00
CRDT- 2013/12/17 06:00
PHST- 2013/12/17 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2014/02/11 06:00 [medline]
AID - S0007-0912(17)30927-3 [pii]
AID - 10.1093/bja/aet402 [doi]
PST - ppublish
SO  - Br J Anaesth. 2013 Dec;111 Suppl 1:i3-17. doi: 10.1093/bja/aet402.

PMID- 15771135
OWN - NLM
STAT- MEDLINE
DCOM- 20050519
LR  - 20161124
IS  - 1426-9686 (Print)
IS  - 1426-9686 (Linking)
VI  - 17
IP  - 102
DP  - 2004 Dec
TI  - [Assessment of efficacy of migraine attack treatment with lysine acetylsalicylate 
      and metoclopramide].
PG  - 615-9
AB  - Migraine is a common medical condition affecting nearly 10% of population in 
      Poland. The aim of the study was to evaluate the efficacy, tolerability and 
      safety of migraine abortive treatment with the combination of lysine 
      acetylsalicylate and metoclopramide (1620 mg LAS + 10 mg MTC--Migpriv). 1620 
      patients with migraine, meeting International Headache Society (IHS) criteria 
      were included in the study. The aim of the study was also determination of the 
      number of patients having headache relief and no nausea or vomiting two hours 
      after the drug intake. In most patients the migraine symptoms disappeared after a 
      single dose administration. Reported adverse events were rare and short lasting. 
      The study showed that metoclopramide was well tolerated and effective at 
      relieving migraine attack symptoms.
FAU - Stepień, Adam
AU  - Stepień A
AD  - Wojskowy Instytut Medyczny, Klinika Neurologii w Warszawie.
FAU - Kozubski, Wojciech
AU  - Kozubski W
LA  - pol
PT  - Clinical Trial
PT  - Journal Article
TT  - Ocena skuteczności leczenia napadu migreny acetylosalicylanem lizyny w połaczeniu 
      z chlorowodorkiem metoklopramidu.
PL  - Poland
TA  - Pol Merkur Lekarski
JT  - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
JID - 9705469
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Dopamine Antagonists)
RN  - K3Z4F929H6 (Lysine)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*analogs & derivatives/*therapeutic use
MH  - Dopamine Antagonists/*therapeutic use
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/*therapeutic use
MH  - Male
MH  - Metoclopramide
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
EDAT- 2005/03/18 09:00
MHDA- 2005/05/20 09:00
CRDT- 2005/03/18 09:00
PHST- 2005/03/18 09:00 [pubmed]
PHST- 2005/05/20 09:00 [medline]
PHST- 2005/03/18 09:00 [entrez]
PST - ppublish
SO  - Pol Merkur Lekarski. 2004 Dec;17(102):615-9.

PMID- 2126726
OWN - NLM
STAT- MEDLINE
DCOM- 19910320
LR  - 20190824
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 20
IP  - 5
DP  - 1990 Oct
TI  - Selective inhibition of platelet cyclooxygenase with controlled release, low-dose 
      aspirin.
PG  - 652-6
AB  - The hypothesis that slow administration of low doses of aspirin may selectively 
      inhibit platelet cyclooxygenase and thromboxane A2 formation was evaluated using 
      controlled release aspirin formulations. In the first study, doses of either 50, 
      100, 325 and 1,300 mg of these formulations and 300 mg soluble aspirin were 
      ingested daily by healthy volunteers for one week. In the second study, doses of 
      5, 10, 25 and 50 mg controlled release aspirin, 50 mg soluble aspirin and 100 mg 
      aspirin and glycine formulation were ingested daily for ten days. Platelet 
      function and urinary prostaglandin production were assessed immediately before 
      and on the seventh day of dosing in both studies and in the second study, 
      repeated on the tenth day of dosing. Platelet function and serum thromboxane B2 
      production were fully inhibited by all formulations of 50 mg aspirin and above, 
      but not by doses of controlled release aspirin below 50 mg doses. The excretion 
      of urinary 6-keto-PGF1 alpha (a major metabolite of prostacyclin) was 
      significantly reduced at controlled release aspirin doses above 100 mg and at all 
      doses of rapidly absorbed aspirin tested. As no significant reduction in the 
      urinary 6-keto-PGF1 alpha production was observed at doses of controlled release 
      aspirin of 50 and 100 mg and below, it appeared that these doses did not inhibit 
      the systemic vascular cyclooxygenase. These data are consistent with a selective 
      inhibition of platelet function by daily doses of 50 and 100 mg of the controlled 
      release formulation of aspirin.
FAU - Vial, J H
AU  - Vial JH
AD  - Department of Medicine, University of Tasmania, Hobart, Australia.
FAU - McLeod, L J
AU  - McLeod LJ
FAU - Roberts, M S
AU  - Roberts MS
FAU - Seville, P R
AU  - Seville PR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/urine
MH  - Aspirin/*administration & dosage/pharmacokinetics/pharmacology
MH  - Blood Platelets/*enzymology/metabolism
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/*blood
MH  - Thromboxane B2/blood/urine
EDAT- 1990/10/01 00:00
MHDA- 1990/10/01 00:01
CRDT- 1990/10/01 00:00
PHST- 1990/10/01 00:00 [pubmed]
PHST- 1990/10/01 00:01 [medline]
PHST- 1990/10/01 00:00 [entrez]
AID - 10.1111/j.1445-5994.1990.tb00394.x [doi]
PST - ppublish
SO  - Aust N Z J Med. 1990 Oct;20(5):652-6. doi: 10.1111/j.1445-5994.1990.tb00394.x.

PMID- 17243603
OWN - NLM
STAT- MEDLINE
DCOM- 20070206
LR  - 20131121
IS  - 0023-2149 (Print)
IS  - 0023-2149 (Linking)
VI  - 84
IP  - 11
DP  - 2006
TI  - [The modern view on the use of aspirin for the primary prophylaxis of 
      cardiovascular diseases in women].
PG  - 10-5
AB  - Cardiovascular diseases (CVD) occupy the first place in the world among all 
      causes of disability and death. Aspirin is an effective antithrombocyte agent, 
      the efficiency and safety of which has been demonstrated by numerous studies. 
      Despite its high effectiveness in treatment of acute myocardial infarction and 
      secondary prophylaxis of CVD both in men and women, the use of aspirin for 
      primary prophylaxis is still questionable. Presently, the appropriateness of 
      aspirin application as a means of primary prevention of CVD in women older than 
      45 has not been clarified yet. The present article discusses this question.
FAU - Zakharov, O V
AU  - Zakharov OV
FAU - Arablinskiĭ, A V
AU  - Arablinskiĭ AV
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Russia (Federation)
TA  - Klin Med (Mosk)
JT  - Klinicheskaia meditsina
JID - 2985204R
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Primary Prevention/*trends
MH  - *Women's Health
RF  - 40
EDAT- 2007/01/25 09:00
MHDA- 2007/02/07 09:00
CRDT- 2007/01/25 09:00
PHST- 2007/01/25 09:00 [pubmed]
PHST- 2007/02/07 09:00 [medline]
PHST- 2007/01/25 09:00 [entrez]
PST - ppublish
SO  - Klin Med (Mosk). 2006;84(11):10-5.

PMID- 16872724
OWN - NLM
STAT- MEDLINE
DCOM- 20061020
LR  - 20161124
IS  - 0248-8663 (Print)
IS  - 0248-8663 (Linking)
VI  - 27
IP  - 8
DP  - 2006 Aug
TI  - [Kawasaki adult disease: case report].
PG  - 646-9
AB  - INTRODUCTION: Kawasaki disease is a systemic necrotizing vasculitides concerning 
      medium arteries and affecting predominantly young children. CASE RECORD: We 
      describe here an incomplete Kawasaki disease occurring in an adult with an 
      unusual manifestation presenting as aseptic purulent meningitis. DISCUSSION: 
      Diagnosis and treatment management of incomplete Kawasaki disease.
FAU - Galempoix, J-M
AU  - Galempoix JM
AD  - Service de médecine interne, hôpital Corvisart, 28, rue d'Aubilly, 08000 
      Charleville Mézières, France. galempoix@ch-charleville-mezieres.fr
FAU - Kaeppler, E
AU  - Kaeppler E
FAU - Lanoux, P
AU  - Lanoux P
FAU - Belaïda, A
AU  - Belaïda A
FAU - Aboutara, M
AU  - Aboutara M
FAU - Penalba, C
AU  - Penalba C
LA  - fre
PT  - Case Reports
PT  - Comparative Study
PT  - Journal Article
TT  - Maladie de Kawasaki de l'adulte: à propos d'un cas.
DEP - 20060526
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/analogs & derivatives/therapeutic use
MH  - Emergencies
MH  - Humans
MH  - Lysine/administration & dosage/analogs & derivatives/therapeutic use
MH  - Male
MH  - *Mucocutaneous Lymph Node Syndrome/diagnosis/drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2006/07/29 09:00
MHDA- 2006/10/21 09:00
CRDT- 2006/07/29 09:00
PHST- 2005/09/20 00:00 [received]
PHST- 2006/04/10 00:00 [accepted]
PHST- 2006/07/29 09:00 [pubmed]
PHST- 2006/10/21 09:00 [medline]
PHST- 2006/07/29 09:00 [entrez]
AID - S0248-8663(06)00200-1 [pii]
AID - 10.1016/j.revmed.2006.04.007 [doi]
PST - ppublish
SO  - Rev Med Interne. 2006 Aug;27(8):646-9. doi: 10.1016/j.revmed.2006.04.007. Epub 
      2006 May 26.

PMID- 11828616
OWN - NLM
STAT- MEDLINE
DCOM- 20020226
LR  - 20131121
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 55
IP  - 5
DP  - 2000 May
TI  - Determination of caffeine in pharmaceutical preparations by the linear 
      absorbances method.
PG  - 362-3
AB  - In this work a fast Linear Absorbance Method for the determination of caffeine in 
      pharmaceutical preparations in the presence of paracetamol or acetylsalicylic 
      acid is presented. The determination of acetylsalicylic acid or paracetamol is 
      also possible by means of a tabulated parameter fB, which values are included in 
      this paper. The method avoids the use of separation steps or multicalibration 
      methods. The determination was carried out in commercial preparations with good 
      results.
FAU - Pascual-Martí, M C
AU  - Pascual-Martí MC
AD  - Departamento de Química Analítica, Facultad de Químicas, Universitat de Valencia, 
      Burjassot, Valencia, Spain. Carmen.Pascual@uv.es
FAU - Llobat-Estellés, M
AU  - Llobat-Estellés M
FAU - Roig-Marco, M I
AU  - Roig-Marco MI
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/analysis
MH  - Algorithms
MH  - Aspirin/analysis
MH  - Caffeine/*analysis
MH  - Calibration
MH  - Drug Combinations
MH  - Spectrophotometry, Ultraviolet
EDAT- 2002/02/07 10:00
MHDA- 2002/02/28 10:01
CRDT- 2002/02/07 10:00
PHST- 2002/02/07 10:00 [pubmed]
PHST- 2002/02/28 10:01 [medline]
PHST- 2002/02/07 10:00 [entrez]
PST - ppublish
SO  - Pharmazie. 2000 May;55(5):362-3.

PMID- 25663486
OWN - NLM
STAT- MEDLINE
DCOM- 20150716
LR  - 20181202
IS  - 1534-6315 (Electronic)
IS  - 1529-7322 (Linking)
VI  - 15
IP  - 3
DP  - 2015 Mar
TI  - Update on aspirin desensitization for chronic rhinosinusitis with polyps in 
      aspirin-exacerbated respiratory disease (AERD).
PG  - 508
LID - 10.1007/s11882-014-0508-7 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which 
      results in adverse upper and lower respiratory symptoms, particularly rhinitis, 
      conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to 
      cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal 
      anti-inflammatory drugs (NSAIDs). A provocative aspirin challenge is the gold 
      standard for diagnosis of AERD. Aspirin desensitization and continuous aspirin 
      therapy has been highly efficacious in those patients with suboptimal control of 
      their disease on current available pharmacotherapy or those with other underlying 
      conditions (i.e., cardiovascular disease) who may require frequent treatment with 
      aspirin or NSAIDs. This review article focuses on aspirin desensitization and the 
      management of patients with AERD with a particular emphasis on outcomes in those 
      patients with chronic rhinosinusitis and nasal polyposis.
FAU - Simon, Ronald A
AU  - Simon RA
AD  - Division of Allergy, Asthma and Immunology, Scripps Clinic, 3811 Valley Centre 
      Drive, San Diego, CA, 92130, USA, Simon.Ronald@scrippshealth.org.
FAU - Dazy, Kristen M
AU  - Dazy KM
FAU - Waldram, Jeremy D
AU  - Waldram JD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Allergy Asthma Rep
JT  - Current allergy and asthma reports
JID - 101096440
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Desensitization, Immunologic
MH  - Humans
MH  - Nasal Polyps/*drug therapy
MH  - Respiration Disorders/*chemically induced
MH  - Rhinitis/*drug therapy
MH  - Sinusitis/*drug therapy
EDAT- 2015/02/11 06:00
MHDA- 2015/07/17 06:00
CRDT- 2015/02/10 06:00
PHST- 2015/02/10 06:00 [entrez]
PHST- 2015/02/11 06:00 [pubmed]
PHST- 2015/07/17 06:00 [medline]
AID - 10.1007/s11882-014-0508-7 [doi]
PST - ppublish
SO  - Curr Allergy Asthma Rep. 2015 Mar;15(3):508. doi: 10.1007/s11882-014-0508-7.

PMID- 857970
OWN - NLM
STAT- MEDLINE
DCOM- 19770630
LR  - 20131121
IS  - 0365-9615 (Print)
IS  - 0365-9615 (Linking)
VI  - 83
IP  - 4
DP  - 1977 Apr
TI  - [Mechanism of the effect of aspirin on the functional properties of 
      thrombocytes].
PG  - 434-5
AB  - As shown the inhibitory effect of aspirin administered in vivo on platelet 
      aggregation and factor 3 release in vitro was due to the action of aspirin on the 
      blood platelets and plasma cofactors: plasma from aspirinized rats dimished 
      aggregability of platelets from untreated animals; plasma from untreated rats 
      increased the aggregability and factor 3 availability of platelets from 
      aspirinized animals.
FAU - Baluda, V P
AU  - Baluda VP
FAU - Shiriaev, V V
AU  - Shiriaev VV
FAU - Simova, N
AU  - Simova N
FAU - Georgievskaia, B
AU  - Georgievskaia B
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - O mekhanizme vozdeĭstviia aspirina na funktsional'nye svoĭstva trombotsitov.
PL  - Russia (Federation)
TA  - Biull Eksp Biol Med
JT  - Biulleten' eksperimental'noi biologii i meditsiny
JID - 0370627
RN  - 37270-93-2 (Platelet Factor 3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Depression, Chemical
MH  - Platelet Aggregation/drug effects
MH  - Platelet Factor 3
MH  - Rats
EDAT- 1977/04/01 00:00
MHDA- 1977/04/01 00:01
CRDT- 1977/04/01 00:00
PHST- 1977/04/01 00:00 [pubmed]
PHST- 1977/04/01 00:01 [medline]
PHST- 1977/04/01 00:00 [entrez]
PST - ppublish
SO  - Biull Eksp Biol Med. 1977 Apr;83(4):434-5.

PMID- 8331682
OWN - NLM
STAT- MEDLINE
DCOM- 19930816
LR  - 20220321
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 85
IP  - 15
DP  - 1993 Aug 4
TI  - Low-dose aspirin and incidence of colorectal tumors in a randomized trial.
PG  - 1220-4
AB  - BACKGROUND: Laboratory, clinical, and epidemiologic studies have recently 
      suggested that regular use of aspirin can reduce colorectal cancer incidence or 
      mortality. However, observational epidemiologic analyses have had limited 
      opportunity to control for confounding bias or to specify aspirin doses used. 
      PURPOSE: Our purpose was to examine the relationship between regular use of 
      low-dose aspirin and incidence of invasive and noninvasive colorectal tumors by 
      utilizing data from the Physicians' Health Study, a randomized, double-blinded, 
      placebo-controlled trial of aspirin and beta carotene. We also attempted to 
      determine whether invasive cancers among aspirin users were associated with 
      rectal bleeding and early stage at diagnosis. METHODS: The Physicians' Health 
      Study includes 22071 U.S. male physicians. The aspirin arm was terminated in 1988 
      after a mean follow-up of 5 years. Stage at diagnosis and signs and/or symptoms 
      during presentation were abstracted from medical records. Cox proportional 
      hazards models were used to estimate relative risk (RR), 95% confidence intervals 
      (CIs), and the association between aspirin and bleeding. Differences between 
      aspirin and placebo groups in tumor risk over time were visualized with 
      Kaplan-Meier curves. We assessed the association between aspirin and stage at 
      diagnosis with a Mann-Whitney rank sum statistic for non-parametric comparison of 
      two ordinal distributions. RESULTS: The RR of developing colorectal cancer for 
      aspirin compared with placebo was 1.15 (95% CI = 0.80-1.65). For in situ cancers 
      and polyps, the RR was 0.86 (95% CI = 0.68-1.10). There was no significant trend 
      for decreasing RR by year of follow-up for invasive cancers (P = .09) or 
      noninvasive tumors (P = .96). Aspirin and placebo groups did not differ in stage 
      or prevalence of rectal bleeding at diagnosis. CONCLUSIONS: Regular aspirin use, 
      at a dose adequate for preventing myocardial infarction, was not associated with 
      a substantial reduction in the incidence of colorectal cancer during 5 years of 
      randomized treatment and follow-up. A small decrease in polyps in the aspirin 
      group could not be reliably distinguished from a chance association. Our results 
      suggest that among low-dose aspirin users, (a) colorectal cancer mortality is not 
      likely to be reduced by earlier detection and (b) incidence is not likely to be 
      increased due to aspirin-induced gastrointestinal bleeding. IMPLICATIONS: The 
      potential for a benefit from higher doses of aspirin or longer duration of use 
      should be addressed by more detailed observational epidemiologic studies and 
      prevention trials with longer follow-up of randomized participants.
FAU - Gann, P H
AU  - Gann PH
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, Mass.
FAU - Manson, J E
AU  - Manson JE
FAU - Glynn, R J
AU  - Glynn RJ
FAU - Buring, J E
AU  - Buring JE
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA34944/CA/NCI NIH HHS/United States
GR  - HL26490/HL/NHLBI NIH HHS/United States
GR  - HL34595/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Natl Cancer Inst. 1993 Aug 4;85(15):1182-4. PMID: 8331674
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Colorectal Neoplasms/*epidemiology
MH  - Follow-Up Studies
MH  - Gastrointestinal Hemorrhage/chemically induced/complications
MH  - Humans
MH  - Intestinal Polyps/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Risk
EDAT- 1993/08/04 00:00
MHDA- 1993/08/04 00:01
CRDT- 1993/08/04 00:00
PHST- 1993/08/04 00:00 [pubmed]
PHST- 1993/08/04 00:01 [medline]
PHST- 1993/08/04 00:00 [entrez]
AID - 10.1093/jnci/85.15.1220 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 1993 Aug 4;85(15):1220-4. doi: 10.1093/jnci/85.15.1220.

PMID- 33877270
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20220422
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 325
IP  - 15
DP  - 2021 Apr 20
TI  - Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
PG  - 1545-1555
LID - 10.1001/jama.2021.0716 [doi]
AB  - IMPORTANCE: Acute coronary syndrome (ACS) is a major cause of morbidity and 
      mortality in the United States with an annual incidence of approximately 1 
      million. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 
      inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces cardiovascular event 
      rates after ACS. OBSERVATIONS: In 2016, the updated guidelines from the American 
      College of Cardiology/American Heart Association (ACC/AHA) recommended aspirin 
      plus a P2Y12 inhibitor for at least 12 months for patients with ACS. Since these 
      recommendations were published, new randomized clinical trials have studied 
      different regimens and durations of antiplatelet therapy. Recommendations vary 
      according to the risk of bleeding. If bleeding risk is low, prolonged DAPT may be 
      considered, although the optimal duration of prolonged DAPT beyond 1 year is not 
      well established. If bleeding risk is high, shorter duration (ie, 3-6 months) of 
      DAPT may be reasonable. A high risk of bleeding traditionally is defined as a 
      1-year risk of serious bleeding (either fatal or associated with a ≥3-g/dL drop 
      in hemoglobin) of at least 4% or a risk of an intracranial hemorrhage of at least 
      1%. Patients at higher risk are 65 years old or older; have low body weight (BMI 
      <18.5), diabetes, or prior bleeding; or take oral anticoagulants. The newest 
      P2Y12 inhibitors, prasugrel and ticagrelor, are more potent, with high 
      on-treatment residual platelet reactivity of about 3% vs 30% to 40% with 
      clopidogrel and act within 30 minutes compared with 2 hours for clopidogrel. 
      Clinicians should avoid prescribing prasugrel to patients with a history of 
      stroke or transient ischemic attack because of an increased risk of 
      cerebrovascular events (6.5% vs 1.2% with clopidogrel, P = .002) and should avoid 
      prescribing it to patients older than 75 years or who weigh less than 60 kg. The 
      ISAR-REACT-5 trial found that prasugrel reduced rates of death, myocardial 
      infarction, or stroke at 1 year compared with ticagrelor among patients with ACS 
      undergoing percutaneous coronary intervention (9.3% vs 6.9%, P = .006) with no 
      significant difference in bleeding. Recent trials suggested that discontinuing 
      aspirin rather than the P2Y12 inhibitor may be associated with better outcomes. 
      CONCLUSIONS AND RELEVANCE: Dual antiplatelet therapy reduces rates of 
      cardiovascular events in patients with acute coronary syndrome. Specific 
      combinations and duration of dual antiplatelet therapy should be based on patient 
      characteristics-risk of bleeding myocardial ischemia.
FAU - Kamran, Hassan
AU  - Kamran H
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas.
FAU - Jneid, Hani
AU  - Jneid H
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas.
AD  - Section of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical 
      Center, Houston, Texas.
FAU - Kayani, Waleed T
AU  - Kayani WT
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas.
FAU - Virani, Salim S
AU  - Virani SS
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas.
AD  - Section of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical 
      Center, Houston, Texas.
FAU - Levine, Glenn N
AU  - Levine GN
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas.
AD  - Section of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical 
      Center, Houston, Texas.
FAU - Nambi, Vijay
AU  - Nambi V
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas.
AD  - Section of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical 
      Center, Houston, Texas.
FAU - Khalid, Umair
AU  - Khalid U
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas.
AD  - Section of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical 
      Center, Houston, Texas.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - JAMA. 2021 Jul 13;326(2):190. PMID: 34255019
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Administration, Oral
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Clopidogrel/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prasugrel Hydrochloride/therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/pharmacology/*therapeutic use
MH  - Ticagrelor/therapeutic use
EDAT- 2021/04/21 06:00
MHDA- 2021/05/06 06:00
CRDT- 2021/04/20 12:18
PHST- 2021/04/20 12:18 [entrez]
PHST- 2021/04/21 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
AID - 2778801 [pii]
AID - 10.1001/jama.2021.0716 [doi]
PST - ppublish
SO  - JAMA. 2021 Apr 20;325(15):1545-1555. doi: 10.1001/jama.2021.0716.

PMID- 359255
OWN - NLM
STAT- MEDLINE
DCOM- 19781220
LR  - 20190907
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 5
IP  - 7
DP  - 1978
TI  - Difunisal in general practice.
PG  - 589-92
AB  - A large-scale, double-blind comparative study was carried out in general practice 
      to assess the relative efficacy and tolerance of difunisal and aspirin in 
      patients suffering from acute painful conditions such as sprains and trains, 
      osteoarthritis, etc. Patients received either 250 mg or 500 mg difunisal twice 
      daily, or 600 mg aspirin 4-times daily for 5 days. The results of subjective 
      assessments of pain relief from the daily records of 1902 patients (967 on 
      diflunisal, 935 on aspirin), and the overall assessment of response by both 
      doctors and patients, showed that diflunisal was significantly better than 
      aspirin. Gastric side-effects were more common and more severe in patients 
      receiving aspirin, and more often led to withdrawal of treatment.
FAU - Huskisson, E C
AU  - Huskisson EC
FAU - Williams, T N
AU  - Williams TN
FAU - Shaw, L D
AU  - Shaw LD
FAU - Kerry, J
AU  - Kerry J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Analgesics)
RN  - 0 (Biphenyl Compounds)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Biphenyl Compounds/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Family Practice
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain/*drug therapy
MH  - Substance Withdrawal Syndrome/etiology
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1185/03007997809109007 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1978;5(7):589-92. doi: 10.1185/03007997809109007.

PMID- 17982321
OWN - NLM
STAT- MEDLINE
DCOM- 20080108
LR  - 20211203
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 18
IP  - 8
DP  - 2007 Dec
TI  - Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and 
      platelet function analysis among older adults at risk of cardiovascular disease: 
      a randomized clinical trial.
PG  - 787-93
AB  - Several case reports have implicated Ginkgo biloba in clinically adverse bleeding 
      disorders. Ginkgo biloba has been reported to increase pain-free walking distance 
      among patients with peripheral artery disease (PAD). Standard PAD therapy 
      includes 325 mg/day aspirin. The objective of this study was to examine potential 
      adverse effects of concomitant aspirin and Ginkgo biloba on platelet function. 
      Ginkgo biloba (EGb 761, 300 mg/day) was compared with placebo for effects on 
      measures of platelet aggregation among adults consuming 325 mg/day aspirin in a 
      randomized, double-blind, placebo-controlled, parallel design trial of 4-week 
      duration. Participants were adults, age 69 +/- 10 years, with PAD or risk factors 
      for cardiovascular disease. Outcome measures included platelet function analysis 
      (PFA-100 analyzer) using ADP as an agonist (n = 26 placebo; n = 29 ginkgo), and 
      platelet aggregation using ADP, epinephrine, collagen and ristocetin as agonists 
      (n = 21 placebo; n = 23 ginkgo). Participants kept daily logs of bleeding or 
      bruising episodes. There were no clinically or statistically significant 
      differences between treatment groups for any agonists, for either PFA-100 
      analysis or platelet aggregation. Reports of bleeding or bruising were infrequent 
      and similar for both study groups. In conclusion, in older adults with PAD or 
      cardiovascular disease risk, a relatively high dose of Ginkgo biloba combined 
      with 325 mg/day daily aspirin did not have a clinically or statistically 
      detectable impact on indices of coagulation examined over 4 weeks, compared with 
      the effect of aspirin alone. No adverse bleeding events were observed, although 
      the trial was limited to a small sample size.
FAU - Gardner, Christopher D
AU  - Gardner CD
AD  - Stanford Prevention Research Center and the Department of Medicine, Stanford 
      University Medical School, Stanford, California, USA. cgardner@stanford.edu
FAU - Zehnder, James L
AU  - Zehnder JL
FAU - Rigby, Alison J
AU  - Rigby AJ
FAU - Nicholus, Joel R
AU  - Nicholus JR
FAU - Farquhar, John W
AU  - Farquhar JW
LA  - eng
GR  - 2 M01-RR000070/RR/NCRR NIH HHS/United States
GR  - R01 AT00204/AT/NCCIH NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Plant Extracts)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 19FUJ2C58T (Ginkgo biloba extract)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Agents/*pharmacology/therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Ginkgo biloba
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/*drug therapy
MH  - Plant Extracts/*pharmacology/therapeutic use
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests/methods
EDAT- 2007/11/06 09:00
MHDA- 2008/01/09 09:00
CRDT- 2007/11/06 09:00
PHST- 2007/11/06 09:00 [pubmed]
PHST- 2008/01/09 09:00 [medline]
PHST- 2007/11/06 09:00 [entrez]
AID - 00001721-200712000-00012 [pii]
AID - 10.1097/MBC.0b013e3282f102b1 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2007 Dec;18(8):787-93. doi: 
      10.1097/MBC.0b013e3282f102b1.

PMID- 7697403
OWN - NLM
STAT- MEDLINE
DCOM- 19950504
LR  - 20131121
IS  - 0963-276X (Print)
IS  - 0963-276X (Linking)
VI  - 4
IP  - 12
DP  - 1994 Dec
TI  - Pre-eclampsia. III: The role of aspirin in prevention.
PG  - 20-2
AB  - Despite optimism generated by earlier, smaller studies, the Collaborative 
      Low-dose Aspirin Study in Pregnancy (CLASP) trial showed that aspirin is not 
      sufficiently effective to recommend its widespread use for the prevention of 
      pre-eclampsia. However, secondary analysis of the CLASP data suggests that 
      aspirin may be effective in reducing the risk of recurrent early onset 
      pre-eclampsia (starting before 32 weeks'gestation). The rationale for low-dose 
      aspirin prophylaxis is the inhibition of synthesis of the prostaglandin 
      thromboxane, which has been been found to be elevated in severe pre-eclampsia. 
      Low-dose aspirin (60 mg per day) is safe for pregnant mothers and their fetuses. 
      Calcium supplementation and fish oil may also reduce the risk of pre-eclampsia, 
      but their use is unproven, and more research is needed on these. Diuretics and 
      dietary salt reduction are not recommended.
FAU - de Swiet, M
AU  - de Swiet M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Mod Midwife
JT  - Modern midwife
JID - 9443126
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*drug therapy
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
PST - ppublish
SO  - Mod Midwife. 1994 Dec;4(12):20-2.

PMID- 8495988
OWN - NLM
STAT- MEDLINE
DCOM- 19930624
LR  - 20131121
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 98
DP  - 1993 Feb
TI  - Enhancement of anti-inflammatory activity of aspirin by verapamil.
PG  - 34-6
AB  - Verapamil in minimum therapeutic equivalent dose, failed to show 
      anti-inflammatory activity as did sub-anti-inflammatory dose of aspirin (54 
      mg/kg) however, when combined with sub-antiinflammatory dose of aspirin, 
      significant (P < 0.001) inhibition of carrageenan and cotton pellet induced 
      inflammation was observed. The anti-inflammatory activity of this combination 
      treatment was almost comparable to that of the anti-inflammatory dose of aspirin 
      (200 mg/kg), as confirmed by granuloma histology. Adrenal weight in the 
      combination treatment group was similar to that of aspirin (200 mg) treated group 
      and was significantly lower, as compared to controls. Further, a reduced ulcer 
      index in the animals treated with combination (aspirin + verapamil), as compared 
      to aspirin alone (200 mg) group, suggests its therapeutic potential.
FAU - Viswanadham, C K
AU  - Viswanadham CK
AD  - Department of Pharmacology, KLE Society's College of Pharmacy, J.N. Medical 
      College, Belgaum.
FAU - Patil, P A
AU  - Patil PA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 9000-07-1 (Carrageenan)
RN  - CJ0O37KU29 (Verapamil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Glands/anatomy & histology
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Carrageenan/antagonists & inhibitors
MH  - Drug Synergism
MH  - Female
MH  - Foreign Bodies
MH  - Inflammation/*drug therapy/etiology
MH  - Male
MH  - Organ Size/drug effects
MH  - Rats
MH  - Stomach Ulcer/prevention & control
MH  - Therapeutic Equivalency
MH  - Verapamil/administration & dosage/*pharmacology
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Med Res. 1993 Feb;98:34-6.

PMID- 24908358
OWN - NLM
STAT- MEDLINE
DCOM- 20150209
LR  - 20140625
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 83
IP  - 2
DP  - 2014 Aug
TI  - Aspirin may modify tumor microenvironment via antiplatelet effect.
PG  - 148-50
LID - S0306-9877(14)00211-4 [pii]
LID - 10.1016/j.mehy.2014.05.007 [doi]
AB  - High-quality evidence suggests that aspirin is a promising agent for cancer 
      prevention and treatment. Direct inhibition of cyclooxygenase-2 (COX-2) pathway 
      is generally thought to be the main mechanism by which aspirin inhibits cancer 
      development. However, either pharmacological properties of aspirin or recent 
      results of epidemiologic studies do not support that mechanism. To address this 
      inconsistency, we hypothesize that antiplatelet effect of aspirin via inhibition 
      of COX-1 may be one of potential mechanisms to inhibit carcinogenesis. Aberrant 
      platelet activation will lead to promote hostility of tumor microenvironment by 
      releasing an abundant array of angiogenesis regulators. Given the outstanding 
      ability of antiplatelet, aspirin may restore balance of pro- and anti-angiogenic 
      factors released from platelet to "normalize" tumor vasculature and shape tumor 
      microenvironment to some extent, which will not only diminish tumor 
      aggressiveness and progression, but also enhance the sensitivity to therapeutic 
      treatment. Thus, targeting the platelet activation leading to alter tumor 
      microenvironment may provide a novel way to tumor therapy.
CI  - Copyright © 2014 Elsevier Ltd. All rights reserved.
FAU - Su, B B
AU  - Su BB
AD  - Department of Gastroenterology, South Building, Chinese PLA General Hospital, 
      Beijing 100853, China.
FAU - Chen, J H
AU  - Chen JH
AD  - Department of Medical Oncology, Shenzhen People's Hospital, Shen Zhen 518020, 
      Guangdong Province, China.
FAU - Shi, H
AU  - Shi H
AD  - Department of Gastroenterology, South Building, Chinese PLA General Hospital, 
      Beijing 100853, China.
FAU - Chen, Q Q
AU  - Chen QQ
AD  - Department of Gastroenterology, South Building, Chinese PLA General Hospital, 
      Beijing 100853, China.
FAU - Wan, J
AU  - Wan J
AD  - Department of Gastroenterology, South Building, Chinese PLA General Hospital, 
      Beijing 100853, China. Electronic address: wanjunpla@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140520
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Humans
MH  - Neoplasms/*prevention & control
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Tumor Microenvironment/*drug effects
EDAT- 2014/06/09 06:00
MHDA- 2015/02/11 06:00
CRDT- 2014/06/09 06:00
PHST- 2014/01/22 00:00 [received]
PHST- 2014/04/10 00:00 [revised]
PHST- 2014/05/01 00:00 [accepted]
PHST- 2014/06/09 06:00 [entrez]
PHST- 2014/06/09 06:00 [pubmed]
PHST- 2015/02/11 06:00 [medline]
AID - S0306-9877(14)00211-4 [pii]
AID - 10.1016/j.mehy.2014.05.007 [doi]
PST - ppublish
SO  - Med Hypotheses. 2014 Aug;83(2):148-50. doi: 10.1016/j.mehy.2014.05.007. Epub 2014 
      May 20.

PMID- 14716871
OWN - NLM
STAT- MEDLINE
DCOM- 20041028
LR  - 20131121
IS  - 1001-5515 (Print)
IS  - 1001-5515 (Linking)
VI  - 20
IP  - 4
DP  - 2003 Dec
TI  - [Study on relative bioavailability of aspirin in afenca tablet].
PG  - 661-3
AB  - Salicylic acid is a kind of active metabolite of aspirin in vivo. In this study, 
      its concentration in plasma was detected by RP-HPLC after twenty four healthy 
      male volunteers were given each a single dose of oral Afenca test and reference 
      preparations. The experiment data were calculated with 3P97 program. The results 
      were analyzed by ANOVA and two- and one-sided t tests. The relative 
      bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic 
      acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 
      98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 
      0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml. 
      Bioequivalent evaluation of two preparations by analyzing with two- and one-sided 
      t tests showed that the two preparations were bioequivalent on the basis of 
      salicylic acid (t1 > or = t1-0.05(22), t2 > or = t1-0.06(22)).
FAU - Yang, Junyi
AU  - Yang J
AD  - School of Pharmacy, Sichuan University, Chengdu 610041.
FAU - Jiang, Xuehua
AU  - Jiang X
FAU - He, Lin
AU  - He L
FAU - Zhou, Jing
AU  - Zhou J
FAU - Li, Suhua
AU  - Li S
FAU - Lin, Shu
AU  - Lin S
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
JT  - Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = 
      Shengwu yixue gongchengxue zazhi
JID - 9426398
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Cross-Over Studies
MH  - Humans
MH  - Male
MH  - Salicylic Acid/blood
MH  - Tablets
MH  - Therapeutic Equivalency
EDAT- 2004/01/14 05:00
MHDA- 2004/10/29 09:00
CRDT- 2004/01/14 05:00
PHST- 2004/01/14 05:00 [pubmed]
PHST- 2004/10/29 09:00 [medline]
PHST- 2004/01/14 05:00 [entrez]
PST - ppublish
SO  - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2003 Dec;20(4):661-3.

PMID- 1907114
OWN - NLM
STAT- MEDLINE
DCOM- 19910829
LR  - 20161123
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 67
IP  - 1
DP  - 1991 Jul
TI  - Nasal provocation test with lysine acetylsalicylate in aspirin-sensitive 
      patients.
PG  - 60-2
AB  - The authors have studied nasal provocation testing (NPT) with aspirin in 45 
      aspirin-sensitive patients (40 affected by nasal polyposis) and in 38 
      aspirin-tolerant patients (27 affected by nasal polyposis). The test was positive 
      in 37.7% of aspirin-intolerant subjects, but only in 7.9% of subjects in the 
      control group (P less than .01).
FAU - Patriarca, G
AU  - Patriarca G
AD  - Catholic University of Rome, Italy.
FAU - Nucera, E
AU  - Nucera E
FAU - DiRienzo, V
AU  - DiRienzo V
FAU - Schiavino, D
AU  - Schiavino D
FAU - Pellegrino, S
AU  - Pellegrino S
FAU - Fais, G
AU  - Fais G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - 0 (Analgesics)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analgesics/*adverse effects
MH  - Aspirin/*adverse effects/*analogs & derivatives
MH  - Drug Hypersensitivity/*diagnosis/pathology
MH  - Female
MH  - Humans
MH  - Lysine/adverse effects/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Nasal Mucosa/pathology
MH  - *Nasal Provocation Tests
EDAT- 1991/07/01 00:00
MHDA- 1991/07/01 00:01
CRDT- 1991/07/01 00:00
PHST- 1991/07/01 00:00 [pubmed]
PHST- 1991/07/01 00:01 [medline]
PHST- 1991/07/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1991 Jul;67(1):60-2.

PMID- 11273013
OWN - NLM
STAT- MEDLINE
DCOM- 20010614
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 53
IP  - 2
DP  - 2001 Feb
TI  - Pharmacokinetics of diaspirin cross-linked haemoglobin in a rat model of hepatic 
      cirrhosis.
PG  - 179-85
AB  - The aim of the study was to evaluate the effect of cirrhosis on the disposition 
      of the haemoglobin-based oxygen carrier, diaspirin cross-linked haemoglobin 
      (DCLHb). Cirrhosis was induced in male Sprague-Dawley rats (200-250 g) by 
      inhalational exposure to carbon tetrachloride (CCl4), over a period of 6 weeks. 
      Pharmacokinetic evaluation was performed after a single intravenous bolus 
      administration of DCLHb (400 mg kg(-1)). Serum biochemistry, including aspartate 
      transaminase, alkaline phosphatase, bile acids, serum albumin, and serum 
      creatinine, were measured in CCl4-treated (n = 6) and age-matched control (n = 6) 
      rats. After 6 weeks, the jugular vein and carotid artery were cannulated for 
      bolus DCLHb administration (400 mg kg(-1)) and blood sampling, respectively, in 
      both groups of rats. Cirrhosis produced significant (P < 0.05) elevations in 
      alkaline phosphatase (497.4 +/- 84.8 U L(-1) vs 241.2 +/- 5.1 U L(-1)), aspartate 
      transaminase (920.5 +/- 190.9 U L(-1) vs 238.2 +/- 118.1 U L(-1)) and bile acids 
      (333.8 +/- 77.3 mg dL(-1) vs 43.8 +/- 4.2 mg dL(-1)) compared with the control 
      group. No significant renal dysfunction was observed as a result of CCl4 
      exposure. Plasma DCLHb concentrations declined approximately log-linearly. 
      Systemic clearance of DCLHb was estimated to be 2.2 +/- 0.7 mL h(-1) in the 
      treatment group and was slightly, but not significantly, less in the control 
      group (3.6 +/- 1.7 mL h(-1)). There was also a trend toward a longer elimination 
      half-life in the treatment group (4.7 +/- 2.2 h) compared with the control group 
      (3.8 +/- 0.8 h), although this difference was not statistically significant. 
      Cirrhosis does not significantly alter the disposition of DCLHb perhaps due to 
      increased extra-hepatic metabolism by the reticulo-endothelial system.
FAU - Palaparthy, R
AU  - Palaparthy R
AD  - Department of Pharmaceutics and Pharmacodynamics, The University of Illinois at 
      Chicago, 60612, USA.
FAU - Kastrissios, H
AU  - Kastrissios H
FAU - Gulati, A
AU  - Gulati A
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Biomarkers)
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Area Under Curve
MH  - Aspirin/analogs & derivatives/blood/*pharmacokinetics
MH  - Biomarkers
MH  - Biopharmaceutics
MH  - Blood Substitutes/*pharmacokinetics
MH  - Carbon Tetrachloride Poisoning/metabolism
MH  - Half-Life
MH  - Hemoglobins/*pharmacokinetics
MH  - Liver Cirrhosis, Experimental/*metabolism
MH  - Liver Function Tests
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2001/03/29 10:00
MHDA- 2001/06/15 10:01
CRDT- 2001/03/29 10:00
PHST- 2001/03/29 10:00 [pubmed]
PHST- 2001/06/15 10:01 [medline]
PHST- 2001/03/29 10:00 [entrez]
AID - 10.1211/0022357011775370 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2001 Feb;53(2):179-85. doi: 10.1211/0022357011775370.

PMID- 1245606
OWN - NLM
STAT- MEDLINE
DCOM- 19760402
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 16
IP  - 1
DP  - 1976 Jan
TI  - Effect of clonixin and aspirin on platelet aggregation in human volunteers.
PG  - 30-3
AB  - The effect of clonixin and aspirin on platelet function was assessed in healthy 
      volunteers. Both drugs inhibited secondary platelet aggregation and prolonged 
      bleeding time, but the effect of clonixin was significantly less than that of 
      aspirin. Hemorrhagic complications are less likely after clonixin than after 
      aspirin.
FAU - Arkel, Y S
AU  - Arkel YS
FAU - Schrogie, J J
AU  - Schrogie JJ
FAU - Williams, R
AU  - Williams R
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Nicotinic Acids)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - V7DXN0M42R (Clonixin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Clonixin/administration & dosage/*pharmacology
MH  - Collagen/pharmacology
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Nicotinic Acids/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Time Factors
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1976.tb01488.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1976 Jan;16(1):30-3. doi: 10.1002/j.1552-4604.1976.tb01488.x.

PMID- 3886333
OWN - NLM
STAT- MEDLINE
DCOM- 19850619
LR  - 20191030
IS  - 0379-8305 (Print)
IS  - 0379-8305 (Linking)
VI  - 8
IP  - 1
DP  - 1985
TI  - Antipyretics and analgesics in children.
PG  - 68-84
AB  - Physicians must carefully consider the appropriate use of antipyretic drugs in 
      children. Despite the ubiquitous presence of acetaminophen and acetylsalicylic 
      acid in the home, there are many factors to weigh prior to their use. The 
      following is a discussion of these factors: efficacy versus toxicity, known 
      effects versus uncertain complications of drug therapy. Acetaminophen and 
      acetylsalicylic acid have equivalent antipyretic effects. Acetysalicylic acid is 
      clearly the better anti-inflammatory drug. Therapeutic misadventures with both 
      drugs have resulted in childhood fatalities. Since these medications are not 
      restricted to prescription order by a physician, instructions as to their safe 
      and appropriate use should become part of 'normal child' counselling by 
      physicians to all parents.
FAU - Peterson, R G
AU  - Peterson RG
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Dev Pharmacol Ther
JT  - Developmental pharmacology and therapeutics
JID - 8003947
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandin Antagonists)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/metabolism/therapeutic use
MH  - Acid-Base Equilibrium/drug effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/history/*therapeutic use
MH  - Aspirin/pharmacology/poisoning/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - History, 20th Century
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Kinetics
MH  - Pregnancy
MH  - Prostaglandin Antagonists
MH  - Reye Syndrome/chemically induced
RF  - 19
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1159/000457023 [doi]
PST - ppublish
SO  - Dev Pharmacol Ther. 1985;8(1):68-84. doi: 10.1159/000457023.

PMID- 18171211
OWN - NLM
STAT- MEDLINE
DCOM- 20080228
LR  - 20131121
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
VI  - 46
IP  - 1
DP  - 2008 Jan 1
TI  - Effect of long-term aspirin use on embolic events in infective endocarditis.
PG  - 37-41
LID - 10.1086/524021 [doi]
AB  - BACKGROUND: In a recent clinical trial, aspirin therapy was initiated 
      approximately 34 days after the onset of symptoms but did not reduce the risk of 
      embolism in patients with endocarditis. However, it is possible that aspirin used 
      early in the course of the disease may be beneficial. The purpose of the study is 
      to assess the effect of long-term daily aspirin use on the risk of embolic events 
      in patients with infective endocarditis. METHODS: The clinical characteristics 
      and outcomes of patients excluded from the Multi-Centre Aspirin Trial in 
      Infective Endocarditis because of long-term aspirin use (n = 84) were compared 
      with the data for patients randomized to the placebo arm (n = 55). The former 
      patients took aspirin before and during the early stages of infective 
      endocarditis, whereas the latter patients were not exposed to aspirin before and 
      during the entire hospitalization. Logistic modeling was used to assess the 
      effect of long-term aspirin use on embolism and bleeding. RESULTS: There was a 
      trend toward excess bleeding in long-term aspirin recipients, compared with 
      placebo recipients (P = .065). Logistic modeling revealed that long-term aspirin 
      use may be associated with excess bleeding (unadjusted odds ratio, 2.35 [P = 
      .059]; adjusted odds ratio, 2.08 [P = .118]), but it had no impact on the risk of 
      embolic events in either model. CONCLUSIONS: In patients with endocarditis, 
      long-term daily use of aspirin does not reduce the risk of embolic events but may 
      be associated with a higher risk of bleeding. In the acute phase of endocarditis, 
      aspirin should be used with caution.
FAU - Chan, Kwan-Leung
AU  - Chan KL
AD  - University of Ottawa Heart Institute, Ottawa, Ontario, Canada. 
      kchan@ottawaheart.ca
FAU - Tam, James
AU  - Tam J
FAU - Dumesnil, Jean G
AU  - Dumesnil JG
FAU - Cujec, Bibiana
AU  - Cujec B
FAU - Sanfilippo, Anthony J
AU  - Sanfilippo AJ
FAU - Jue, John
AU  - Jue J
FAU - Turek, Michele
AU  - Turek M
FAU - Robinson, Trevor
AU  - Robinson T
FAU - Williams, Kathryn
AU  - Williams K
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Clin Infect Dis. 2008 May 1;46(9):1481-2. PMID: 18419461
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Embolism/etiology/*prevention & control
MH  - Endocarditis, Bacterial/blood/*complications
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
EDAT- 2008/01/04 09:00
MHDA- 2008/02/29 09:00
CRDT- 2008/01/04 09:00
PHST- 2008/01/04 09:00 [pubmed]
PHST- 2008/02/29 09:00 [medline]
PHST- 2008/01/04 09:00 [entrez]
AID - 10.1086/524021 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2008 Jan 1;46(1):37-41. doi: 10.1086/524021.

PMID- 386118
OWN - NLM
STAT- MEDLINE
DCOM- 19791227
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 301
IP  - 18
DP  - 1979 Nov 1
TI  - Failure of antiplatelet and anticoagulant therapy to improve patency of grafts 
      after coronary-artery bypass: a controlled, randomized study.
PG  - 962-6
AB  - Fifty patients who underwent aortocoronary saphenous-vein bypass-graft surgery 
      were randomly assigned to one of three groups to determine the effects of 
      antiplatelet or anticoagulant therapy on graft patency. Twenty-four patients 
      served as controls; 13 patients received aspirin (325 mg three times a day) and 
      dipyridamole (75 mg three times a day); and 13 patients received closely 
      regulated warfarin therapy. Medications were begun on the third post-operative 
      day. Six months after surgery, all patients underwent coronary angiography to 
      assess graft patency. There were no statistically significant differences between 
      groups in various clinical, hemodynamic and angios, 27 of 33 grafts (82 per cent) 
      with aspirin and dipyridamole and 29 of 37 grafts (78 per cent) with warfarin (P 
      less than 0.5), all patients had at least one patent graft. Postoperative 
      treatment either with aspirin and dipyridamole or with warfarin failed to improve 
      the patency of the grafts.
FAU - Pantely, G A
AU  - Pantely GA
FAU - Goodnight, S H Jr
AU  - Goodnight SH Jr
FAU - Rahimtoola, S H
AU  - Rahimtoola SH
FAU - Harlan, B J
AU  - Harlan BJ
FAU - DeMots, H
AU  - DeMots H
FAU - Calvin, L
AU  - Calvin L
FAU - Rösch, J
AU  - Rösch J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Clinical Trials as Topic
MH  - *Coronary Artery Bypass/adverse effects
MH  - Dipyridamole/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
MH  - Warfarin/administration & dosage/therapeutic use
EDAT- 1979/11/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1979/11/01 00:00
PHST- 1979/11/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1979/11/01 00:00 [entrez]
AID - 10.1056/NEJM197911013011803 [doi]
PST - ppublish
SO  - N Engl J Med. 1979 Nov 1;301(18):962-6. doi: 10.1056/NEJM197911013011803.

PMID- 34577854
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20211001
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 57
IP  - 9
DP  - 2021 Sep 4
TI  - Aspirin Is Related to Worse Clinical Outcomes of COVID-19.
LID - 10.3390/medicina57090931 [doi]
LID - 931
AB  - Backgroundand Objectives: Aspirin is used globally to reduce pain and 
      inflammation; however, its effect in patients with coronavirus disease (COVID-19) 
      is not fully investigated and remains controversial. We evaluated the association 
      between aspirin and COVID-19 outcomes using nationwide data from the Korean 
      National Health Insurance System. Materials and Methods: This was a retrospective 
      observational cohort study that included 22,660 eligible patients who underwent 
      COVID-19 testing in South Korea between 1 January-31 July 2020. We identified all 
      aspirin users prescribed aspirin within two weeks before or after the index date. 
      The primary outcome was positivity for the COVID-19 test, and secondary outcomes 
      included conventional oxygen therapy, intensive care unit, mechanical 
      ventilation, or death. We applied the propensity score matching method to reduce 
      the possible bias originating from the differences in patients' baseline 
      characteristics. Results: Of those eligible, 662 patients were prescribed 
      aspirin. Among them, 136 patients were on aspirin within two weeks before 
      diagnosis and 526 patients were on aspirin after diagnosis. The COVID-19 test 
      positivity rate was not significantly different according to aspirin use. Aspirin 
      use before COVID-19 was related to an increased death rate and aspirin use after 
      COVID-19 was related to a higher risk of the conventional oxygen therapy. 
      Conclusion: Aspirin use was associated with adverse effects in COVID-19 patients. 
      Further studies for mechanisms are needed.
FAU - Kim, Isaac
AU  - Kim I
AUID- ORCID: 0000-0001-6808-7390
AD  - Department of General Surgery, CHA Bundang Medical Center, CHA University School 
      of Medicine, Seongnam 13488, Korea.
FAU - Yoon, Siyeong
AU  - Yoon S
AD  - Department of Orthopedic Surgery, CHA Bundang Medical Center, CHA University 
      School of Medicine, Seongnam 13488, Korea.
FAU - Kim, Minsup
AU  - Kim M
AD  - inCerebro Drug Discovery Institute, Seoul Technopark, Seoul 01811, Korea.
FAU - Lee, Hyunil
AU  - Lee H
AUID- ORCID: 0000-0002-0957-0988
AD  - Department of Orthopedic Surgery, Ilsan Paik Hospital, Inje University, Goyang 
      10380, Korea.
FAU - Park, Sinhyung
AU  - Park S
AD  - Department of Orthopedic Surgery, Bucheon Hospital, Soonchunhyang University, 
      Bucheon 14584, Korea.
FAU - Kim, Wonsang
AU  - Kim W
AD  - inCerebro Drug Discovery Institute, Seoul Technopark, Seoul 01811, Korea.
FAU - Lee, Soonchul
AU  - Lee S
AD  - Department of Orthopedic Surgery, CHA Bundang Medical Center, CHA University 
      School of Medicine, Seongnam 13488, Korea.
LA  - eng
GR  - No.2020R1G1A1099728/National Research Foundation of Korea/
PT  - Journal Article
PT  - Observational Study
DEP - 20210904
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - *COVID-19
MH  - COVID-19 Testing
MH  - Cohort Studies
MH  - Humans
MH  - SARS-CoV-2
PMC - PMC8465059
OTO - NOTNLM
OT  - COVID-19
OT  - aspirin
OT  - outcome
COIS- The authors declare no conflict of interest.
EDAT- 2021/09/29 06:00
MHDA- 2021/09/30 06:00
CRDT- 2021/09/28 01:24
PHST- 2021/07/20 00:00 [received]
PHST- 2021/09/01 00:00 [revised]
PHST- 2021/09/02 00:00 [accepted]
PHST- 2021/09/28 01:24 [entrez]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
AID - medicina57090931 [pii]
AID - medicina-57-00931 [pii]
AID - 10.3390/medicina57090931 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2021 Sep 4;57(9):931. doi: 10.3390/medicina57090931.

PMID- 977701
OWN - NLM
STAT- MEDLINE
DCOM- 19761230
LR  - 20190629
VI  - 126
DP  - 1976 Nov 3
TI  - Application of gas-liquid chromatography and high-performance liquid 
      chromatography to the analysis of trace amounts of salicylic acid, 
      acetylsalicylic anhydride and acetylsalicylsalicylic acid in aspirin samples and 
      aspirin formulations.
PG  - 651-63
AB  - The gas-liquid chromatographic (GLC) determination of salicylic acid (SA) in 12 
      commercial acetylsalicylic acid (aspirin, ASA) samples and 12 ASA formulations is 
      reported. The GLC determination of SA as an impurity in ASA, utilising 
      methylation with methyl iodide in the presence of potassium carbonate, requires a 
      column chromatographic separation of SA prior to derivatization. Trace amounts of 
      SA in ASA have also been determined by high-performance liquid chromatography 
      (HPLC) on a Sil-X-I adsorption column using light petroleum-ethyl acetate-acetic 
      acid as the mobile phase. Acetylsalicylic anhydride (ASN) and 
      acetylsalicylsalicylic acid (ASSA) were determined by HPLC on a reversed-phase 
      C18 column with water-methanol mixtures as the mobile phase. GLC was also applied 
      to the determination of ASN as an impurity in ASA formulations.
FAU - Ali, S L
AU  - Ali SL
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Chromatogr
JT  - Journal of chromatography
JID - 0427043
RN  - 0 (Anhydrides)
RN  - 0 (Buffers)
RN  - 0 (Salicylates)
RN  - 0 (Solvents)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anhydrides/analysis
MH  - Aspirin/*analysis
MH  - Buffers
MH  - *Chromatography, Gas
MH  - *Chromatography, High Pressure Liquid
MH  - Chromatography, Liquid
MH  - Salicylates/*analysis
MH  - Solvents
MH  - Tablets
EDAT- 1976/11/03 00:00
MHDA- 1976/11/03 00:01
CRDT- 1976/11/03 00:00
PHST- 1976/11/03 00:00 [pubmed]
PHST- 1976/11/03 00:01 [medline]
PHST- 1976/11/03 00:00 [entrez]
AID - 10.1016/s0021-9673(01)84109-1 [doi]
PST - ppublish
SO  - J Chromatogr. 1976 Nov 3;126:651-63. doi: 10.1016/s0021-9673(01)84109-1.

PMID- 28162023
OWN - NLM
STAT- MEDLINE
DCOM- 20180810
LR  - 20180810
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 31
IP  - 5
DP  - 2018 Mar
TI  - Comparison of two-risk assessment algorithms for preeclampsia in first trimester 
      with consecutive intake of low-dose aspirin in the high-risk group - an 
      observational study.
PG  - 549-552
LID - 10.1080/14767058.2017.1291621 [doi]
AB  - We analyzed outcome of women screened for preeclampsia with two different 
      multifactorial risk algorithms (Predictor(®)Software by PerkinElmer, PerkinElmer, 
      Waltham, MA; PERK-group: n = 214 and Viewpoint(®) by GE Healthcare, Dornstadt, 
      Germany; VIEW-group: n = 209) in first trimester. Women at high risk for 
      developing preeclampsia were advised to take low-dose acetylsalicylic acid (LDA). 
      Screening positive rates for early onset preeclampsia differed significantly 
      between the two groups (7.9% versus 26.3%; p = 0.000). According the clinical use 
      of screening test criteria, LDA was prescribed in 63 (29.4%) women in the 
      PE-group and 55 (26.3%) in the VP-group (p = 0.516). There were no differences in 
      onset of preeclampsia [4 (1.9%) versus 6 (2.9%); p = 0.540]. No early or severe 
      preeclampsia occurred in the whole population.
FAU - Lakovschek, Ioana-Claudia
AU  - Lakovschek IC
AD  - a Division of Obstetrics, Department of Obstetrics and Gynaecology , Medical 
      University of Graz , Graz , Austria.
FAU - Csapo, Bence
AU  - Csapo B
AD  - a Division of Obstetrics, Department of Obstetrics and Gynaecology , Medical 
      University of Graz , Graz , Austria.
FAU - Kolovetsiou-Kreiner, Vassiliki
AU  - Kolovetsiou-Kreiner V
AD  - a Division of Obstetrics, Department of Obstetrics and Gynaecology , Medical 
      University of Graz , Graz , Austria.
FAU - Mayer-Pickel, Karoline
AU  - Mayer-Pickel K
AD  - a Division of Obstetrics, Department of Obstetrics and Gynaecology , Medical 
      University of Graz , Graz , Austria.
FAU - Reif, Philipp
AU  - Reif P
AD  - a Division of Obstetrics, Department of Obstetrics and Gynaecology , Medical 
      University of Graz , Graz , Austria.
FAU - Stern, Christina
AU  - Stern C
AD  - a Division of Obstetrics, Department of Obstetrics and Gynaecology , Medical 
      University of Graz , Graz , Austria.
FAU - Ulrich, Daniela
AU  - Ulrich D
AD  - a Division of Obstetrics, Department of Obstetrics and Gynaecology , Medical 
      University of Graz , Graz , Austria.
FAU - Lang, Uwe
AU  - Lang U
AD  - a Division of Obstetrics, Department of Obstetrics and Gynaecology , Medical 
      University of Graz , Graz , Austria.
FAU - Obermayer-Pietsch, Barbara
AU  - Obermayer-Pietsch B
AD  - b Division of Endocrinology and Metabolism, Department of Internal Medicine , 
      Endocrinology Lab Platform, Medical University of Graz , Graz , Austria.
FAU - Cervar-Zivkovic, Mila
AU  - Cervar-Zivkovic M
AD  - a Division of Obstetrics, Department of Obstetrics and Gynaecology , Medical 
      University of Graz , Graz , Austria.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20170303
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Algorithms
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - *Decision Support Techniques
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Pre-Eclampsia/*diagnosis/prevention & control
MH  - Pregnancy
MH  - *Pregnancy Trimester, First
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Preeclampsia
OT  - aspirin
OT  - first-trimester screening
OT  - low-dose acetylsalicylic acid
EDAT- 2017/02/07 06:00
MHDA- 2018/08/11 06:00
CRDT- 2017/02/07 06:00
PHST- 2017/02/07 06:00 [pubmed]
PHST- 2018/08/11 06:00 [medline]
PHST- 2017/02/07 06:00 [entrez]
AID - 10.1080/14767058.2017.1291621 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2018 Mar;31(5):549-552. doi: 
      10.1080/14767058.2017.1291621. Epub 2017 Mar 3.

PMID- 25447610
OWN - NLM
STAT- MEDLINE
DCOM- 20150420
LR  - 20150126
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 128
IP  - 2
DP  - 2015 Feb
TI  - Impact of aspirin according to type of stable coronary artery disease: insights 
      from a large international cohort.
PG  - 137-43
LID - S0002-9343(14)00907-3 [pii]
LID - 10.1016/j.amjmed.2014.09.028 [doi]
AB  - BACKGROUND: Aspirin is recommended in stable coronary artery disease based on 
      myocardial infarction and stroke studies. However, benefit among stable coronary 
      artery disease patients who have not suffered an acute ischemic event is 
      uncertain. The objective of this study was to evaluate the impact of aspirin in 
      stable coronary artery disease. We hypothesized that aspirin's benefit would be 
      attenuated among individuals with stable coronary artery disease but no prior 
      ischemic event. METHODS: An observational study was conducted from the 
      INternational VErapamil-SR/Trandolapril STudy cohort. Ambulatory patients ≥ 50 
      years of age with clinically stable coronary artery disease requiring 
      antihypertensive drug therapy (n = 22,576) were classified "ischemic" if they had 
      a history of unstable angina, myocardial infarction, transient ischemic attack, 
      or stroke at the baseline visit. All others were classified "non-ischemic." 
      Aspirin use was updated at each clinic visit and considered as a time-varying 
      covariate in a Cox regression model. The primary outcome was first occurrence of 
      all-cause mortality, myocardial infarction, or stroke. RESULTS: At baseline, 
      56.7% of all participants used aspirin, which increased to 69.3% at study close 
      out. Among the "non-ischemic" group (n = 13,091), aspirin was not associated with 
      a reduction in risk (hazard ratio [HR] 1.11; 95% confidence interval [CI], 
      0.97-1.28; P = .13); however, among the "ischemic" group (n = 9485), aspirin was 
      associated with a reduction in risk (HR 0.87; 95% CI, 0.77-0.99; P = .033). 
      CONCLUSIONS: In patients with stable coronary artery disease and hypertension, 
      aspirin use was associated with reduced risk for adverse cardiovascular outcomes 
      among those with prior ischemic events. Among patients with no prior ischemic 
      events, aspirin use was not associated with a reduction in risk.
CI  - Published by Elsevier Inc.
FAU - Bavry, Anthony A
AU  - Bavry AA
AD  - North Florida/South Georgia Veterans Health System, Gainesville, Fla; College of 
      Medicine, University of Florida, Gainesville. Electronic address: 
      Anthony.bavry@va.gov.
FAU - Gong, Yan
AU  - Gong Y
AD  - College of Pharmacy, University of Florida, Gainesville.
FAU - Handberg, Eileen M
AU  - Handberg EM
AD  - College of Medicine, University of Florida, Gainesville.
FAU - Cooper-DeHoff, Rhonda M
AU  - Cooper-DeHoff RM
AD  - College of Medicine, University of Florida, Gainesville; College of Pharmacy, 
      University of Florida, Gainesville.
FAU - Pepine, Carl J
AU  - Pepine CJ
AD  - College of Medicine, University of Florida, Gainesville.
LA  - eng
SI  - ClinicalTrials.gov/NCT00133692
PT  - Journal Article
PT  - Observational Study
DEP - 20141015
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/complications/*drug therapy/mortality
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - Myocardial Ischemia/complications/drug therapy
MH  - Proportional Hazards Models
MH  - Stroke/prevention & control
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse cardiovascular events
OT  - Aspirin
OT  - Coronary artery disease
OT  - Ischemic heart disease
EDAT- 2014/12/03 06:00
MHDA- 2015/04/22 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/04/25 00:00 [received]
PHST- 2014/09/09 00:00 [revised]
PHST- 2014/09/10 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/04/22 06:00 [medline]
AID - S0002-9343(14)00907-3 [pii]
AID - 10.1016/j.amjmed.2014.09.028 [doi]
PST - ppublish
SO  - Am J Med. 2015 Feb;128(2):137-43. doi: 10.1016/j.amjmed.2014.09.028. Epub 2014 
      Oct 15.

PMID- 2122251
OWN - NLM
STAT- MEDLINE
DCOM- 19901207
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 323
IP  - 21
DP  - 1990 Nov 22
TI  - A comparison between heparin and low-dose aspirin as adjunctive therapy with 
      tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin 
      Reperfusion Trial (HART) Investigators.
PG  - 1433-7
AB  - BACKGROUND: We report the results of the Heparin-Aspirin Reperfusion Trial, a 
      collaborative study comparing early intravenous heparin with oral aspirin as 
      adjunctive treatment when recombinant tissue plasminogen activator (rt-PA) is 
      used for coronary thrombolysis during acute myocardial infarction. METHODS: Two 
      hundred five patients were randomly assigned to receive either immediate and then 
      continuous intravenous heparin (starting with a 5000-unit bolus; n = 106) or 
      immediate and then daily oral aspirin (80 mg; n = 99) together with rt-PA (100 mg 
      intravenously over a six-hour period) initiated within six hours of the onset of 
      symptoms. We evaluated the patency of the infarct-related artery by angiography 7 
      to 24 hours after beginning rt-PA infusion, the frequency of reocclusion of the 
      artery by repeat angiography on day 7, and ischemic or hemorrhagic complications 
      during the hospital stay. RESULTS: At the time of the first angiogram, 82 percent 
      of the infarct-related arteries in the patients assigned to heparin were patent, 
      as compared with only 52 percent in the aspirin group (P less than 0.0001). Of 
      the initially patent vessels, 88 percent remained patent after seven days in the 
      heparin group, as compared with 95 percent in the aspirin group (P not 
      significant). The numbers of hemorrhagic events (18 in the heparin and 15 in the 
      aspirin group) and recurrent ischemic events (8 in the heparin and 2 in the 
      aspirin group) were similar in the two groups. CONCLUSIONS: Coronary patency 
      rates associated with rt-PA are higher with early concomitant systemic heparin 
      treatment than with concomitant low-dose oral aspirin. This observation has 
      important implications for clinical practice and should be considered in the 
      design and interpretation of clinical trials involving coronary thrombolytic 
      therapy.
FAU - Hsia, J
AU  - Hsia J
AD  - Department of Medicine, George Washington University, Washington, DC 20037.
FAU - Hamilton, W P
AU  - Hamilton WP
FAU - Kleiman, N
AU  - Kleiman N
FAU - Roberts, R
AU  - Roberts R
FAU - Chaitman, B R
AU  - Chaitman BR
FAU - Ross, A M
AU  - Ross AM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 1991 Apr 25;324(17):1217-8. PMID: 1901380
CIN - N Engl J Med. 1990 Nov 22;323(21):1483-5. PMID: 2233922
MH  - Administration, Oral
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Heparin/*administration & dosage/adverse effects/therapeutic use
MH  - Humans
MH  - Infusions, Intravenous
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Random Allocation
MH  - Recombinant Proteins/administration & dosage/therapeutic use
MH  - Tissue Plasminogen Activator/administration & dosage/*therapeutic use
MH  - Vascular Patency
EDAT- 1990/11/22 00:00
MHDA- 1990/11/22 00:01
CRDT- 1990/11/22 00:00
PHST- 1990/11/22 00:00 [pubmed]
PHST- 1990/11/22 00:01 [medline]
PHST- 1990/11/22 00:00 [entrez]
AID - 10.1056/NEJM199011223232101 [doi]
PST - ppublish
SO  - N Engl J Med. 1990 Nov 22;323(21):1433-7. doi: 10.1056/NEJM199011223232101.

PMID- 11579350
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20131121
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 142
IP  - 4
DP  - 2001 Oct
TI  - Uniform platelet activation exists before coronary stent implantation despite 
      aspirin therapy.
PG  - 611-6
AB  - BACKGROUND: Platelets play an important role in the natural history of coronary 
      artery disease. Enhanced platelet aggregation and receptor expression 
      unquestionably occur after coronary stent implantation; however, the functional 
      characteristics of platelets before stenting have not been fully elucidated. 
      METHODS: Platelets were assessed before intervention by platelet-rich plasma 
      aggregation (PA) with 5 mmol adenosine diphosphate (ADP) and 1 mg/mL collagen; 
      whole blood aggregation (WBA) by 1 mg/mL collagen; shear-induced closure time 
      (CT); contractile force (CF); and expression of 9 surface receptors by flow 
      cytometry in 126 patients undergoing elective coronary artery stent placement. 
      All patients received aspirin for at least 7 days. The data were compared with 
      those from 64 healthy volunteers. RESULTS: Each test revealed sustained platelet 
      activation in patients undergoing coronary stenting compared with control values. 
      These differences were significant for collagen-induced PA (P =.031); CF (P 
      =.0001); expression of glycoprotein (GP) IIb/IIIa (P =.0001); P-selectin (P 
      =.0008); platelet/endothelial cell adhesion molecule (PECAM)-1 (P =.0001); CD107a 
      (P =.0001); CD107b (P =.0004); and CD63 (P =.009). CONCLUSION: Platelets are 
      indeed activated before coronary stenting despite antecedent therapy with 
      aspirin.
FAU - Serebruany, V L
AU  - Serebruany VL
AD  - Center for Thrombosis Research, Sinai Hospital, Baltimore, MD 21215, USA. 
      Heartdrug@aol.com
FAU - Cummings, C C
AU  - Cummings CC
FAU - Malinin, A I
AU  - Malinin AI
FAU - Steinhubl, S R
AU  - Steinhubl SR
FAU - Gurbel, P A
AU  - Gurbel PA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Coronary Disease/*blood/drug therapy/*surgery
MH  - Coronary Vessels/surgery
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - *Preoperative Care
MH  - *Stents
EDAT- 2001/10/02 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/02 10:00
PHST- 2001/10/02 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/02 10:00 [entrez]
AID - S0002-8703(01)54711-0 [pii]
AID - 10.1067/mhj.2001.116478 [doi]
PST - ppublish
SO  - Am Heart J. 2001 Oct;142(4):611-6. doi: 10.1067/mhj.2001.116478.

PMID- 82144
OWN - NLM
STAT- MEDLINE
DCOM- 19790126
LR  - 20190610
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8101
DP  - 1978 Dec 2
TI  - Aspirin prophylaxis in migraine.
PG  - 1179-81
AB  - A prospective double-blind trial of aspirin prophylaxis demonstrated a reduction 
      of more than 50% in headache frequency in 9 of 12 migraine patients. Response to 
      aspirin did not correlate with age, duration of headache history, family history, 
      or platelet ultrastructure. There is some evidence that response to aspirin is 
      associated with raised platelet aggregation. This pilot study indicates that 
      aspirin is effective in migraine prophylaxis.
FAU - O'Neill, B P
AU  - O'Neill BP
FAU - Mann, J D
AU  - Mann JD
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/blood/epidemiology/*prevention & control
MH  - Placebos
MH  - Platelet Aggregation/drug effects
MH  - Prospective Studies
MH  - Time Factors
EDAT- 1978/12/02 00:00
MHDA- 1978/12/02 00:01
CRDT- 1978/12/02 00:00
PHST- 1978/12/02 00:00 [pubmed]
PHST- 1978/12/02 00:01 [medline]
PHST- 1978/12/02 00:00 [entrez]
AID - S0140-6736(78)92159-1 [pii]
AID - 10.1016/s0140-6736(78)92159-1 [doi]
PST - ppublish
SO  - Lancet. 1978 Dec 2;2(8101):1179-81. doi: 10.1016/s0140-6736(78)92159-1.

PMID- 7264888
OWN - NLM
STAT- MEDLINE
DCOM- 19811029
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 3
DP  - 1981 Mar
TI  - Kinetics of aspirin, salicylic acid, and salicyluric acid following oral 
      administration of aspirin as a tablet and two buffered solutions.
PG  - 262-5
AB  - Twelve fasting normal volunteers received three aspirin dosage forms in a 
      single-dose, complete crossover study; the plasma and urine levels of aspirin, 
      salicylic acid, and salicyluric acid were measured for 10 hr. The three dosage 
      forms were an unbuffered tablet, an effervescent solution with 16 mEq of buffer, 
      and an effervescent solution with 34 mEq of buffer. Significant differences in 
      the absorption rate were observed, with the solution having 16 mEQ of buffer 
      being fastest, the solution having 34 mEq of buffer being intermediate, and the 
      tablet being slowest. These differences are attributed to gastric emptying rates 
      and tablet dissolution. Urine pH and renal clearance for all three acid compounds 
      are influenced by the buffer during the first 2 hr following dosing but not 
      later. Area under the curve comparisons suggest that approximately 20% more 
      aspirin reaches the general circulation intact following the tablet but that the 
      total amount of salicylate absorbed is not different. Further studies are 
      required to select the optimal buffer content to provide rapid absorption with 
      minimal sodium dose and urine alkalinization.
FAU - Mason, W D
AU  - Mason WD
FAU - Winer, N
AU  - Winer N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Buffers)
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 487-54-7 (salicylurate)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Absorption
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*metabolism
MH  - Buffers
MH  - Glycine/*analogs & derivatives/metabolism
MH  - Half-Life
MH  - Hippurates/*metabolism
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Regression Analysis
MH  - Salicylates/*metabolism
MH  - Tablets
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
AID - S0022-3549(15)43608-1 [pii]
AID - 10.1002/jps.2600700308 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Mar;70(3):262-5. doi: 10.1002/jps.2600700308.

PMID- 15871850
OWN - NLM
STAT- MEDLINE
DCOM- 20051104
LR  - 20131121
IS  - 0939-4753 (Print)
IS  - 0939-4753 (Linking)
VI  - 15
IP  - 1
DP  - 2005 Feb
TI  - Use of antiplatelet therapy in a diabetic outpatient service of a large urban 
      public hospital.
PG  - 42-6
AB  - BACKGROUND AND AIM: Cardiovascular disease is the most important cause of 
      mortality in type 2 diabetes. Aspirin treatment is effective in diabetic patients 
      with cardiovascular disease and it does not significantly increase the risk of 
      retinal haemorrhage, gastrointestinal bleeding or hemorrhagic stroke. The 
      American Diabetes Association (ADA) recommends the use of aspirin in all adult 
      patients with diabetes and macrovascular disease, and suggests to start treatment 
      with aspirin for primary prevention in diabetic patients >or=40 years of age and 
      with one or more other cardiovascular risk factors in the absence of specific 
      contraindications. METHODS: In this observational retrospective study, we have 
      selected from our database (17,732 clinical reports) all the type 2 diabetic 
      patients 41--80 years of age, who had at least one visit to our outpatient 
      service in the following two periods: A (from 1 July 1995 to 30 June 1996) and B 
      (from 1 July 2002 to 30 June 2003), then analysed the patient-records for 
      prescription of antiplatelet agents. RESULTS: Our analysis has shown that 
      antiplatelet agents were prescribed to 15% of the type 2 diabetic patients in 
      period A (10.8% and 53.4% -- primary and secondary prevention, respectively) and 
      to 22.8% of the patients in period B (19.1% and 60.5% -- primary and secondary 
      prevention, respectively). CONCLUSIONS: Patients with type 2 diabetes and high 
      cardiovascular risk are not always under antiplatelet treatment despite the ADA 
      recommendations, particularly for primary prevention. However, our data show an 
      increased trend in prescriptions from 1997, when the first ADA specific 
      guidelines for aspirin therapy were published.
FAU - Bruno, Alberto
AU  - Bruno A
AD  - Diabetic Outpatient Department, San Giovanni Battista di Torino Hospital, Corso 
      Bramante, 88, 10126 Turin, Italy. abruno@molinette.piemonte.it
FAU - Grassi, Giorgio
AU  - Grassi G
FAU - Dani, Franco
AU  - Dani F
FAU - Degiovanni, Mariella
AU  - Degiovanni M
FAU - Maghenzani, Giorgio
AU  - Maghenzani G
FAU - Pagano, Gianfranco
AU  - Pagano G
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/epidemiology/*prevention & control
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention/methods
MH  - Retrospective Studies
MH  - Risk Factors
EDAT- 2005/05/06 09:00
MHDA- 2005/11/05 09:00
CRDT- 2005/05/06 09:00
PHST- 2004/01/17 00:00 [received]
PHST- 2004/03/22 00:00 [revised]
PHST- 2004/04/02 00:00 [accepted]
PHST- 2005/05/06 09:00 [pubmed]
PHST- 2005/11/05 09:00 [medline]
PHST- 2005/05/06 09:00 [entrez]
AID - S0939-4753(04)00008-0 [pii]
AID - 10.1016/j.numecd.2004.04.001 [doi]
PST - ppublish
SO  - Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):42-6. doi: 
      10.1016/j.numecd.2004.04.001.

PMID- 7762497
OWN - NLM
STAT- MEDLINE
DCOM- 19950627
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 75
IP  - 16
DP  - 1995 Jun 1
TI  - Design of a placebo-controlled clinical trial of long-acting diltiazem and 
      aspirin versus aspirin alone in patients receiving thrombolysis with a first 
      acute myocardial infarction. Incomplete Infarction Trial of European Research 
      Collaborators Evaluating Prognosis Post-Thrombolysis (diltiazem) (INTERCEPT) 
      Research Group.
PG  - 1120-3
AB  - Several pharmacologic forms of adjunctive therapy, designed to enhance the 
      efficacy of thrombolysis following acute myocardial infarction (AMI), are being 
      explored. However, few studies have assessed the use of standard secondary 
      prevention therapies (beta-blockers, angiotensin-converting enzyme inhibitors, 
      magnesium, calcium antagonists, etc.) for antecedent thrombolysis. Although 
      calcium antagonists have not been shown to alter post-AMI mortality, diltiazem 
      has been shown to reduce recurrent nonfatal infarction and myocardial ischemia 
      following non-Q-wave AMI. Because both non-Q-wave AMI and AMI treated with 
      thrombolytic therapy result in early reperfusion and clinical manifestations of 
      "incomplete infarction" (i.e., aborted transmural infarction), we hypothesize 
      that prophylactic administration of diltiazem to AMI patients who receive 
      thrombolysis before other therapies might decrease ischemic complications. We 
      have initiated a multicenter, randomized, placebo-controlled, double-blind, 
      parallel-group comparison of long-acting diltiazem 300 mg/day and aspirin 160 
      mg/day versus aspirin 160 mg/day alone in up to 920 patients with an 
      uncomplicated first AMI (no heart failure or left ventricular dysfunction) within 
      36 to 96 hours of receiving thrombolysis. Active enrollment is under way at 46 
      centers in the United Kingdom, Belgium, The Netherlands, and Denmark. This trial 
      (known as the Incomplete INfarction Trial of European Research Collaborators 
      Evaluating Prognosis Post-Thrombolysis [diltiazem], or INTERCEPT) represents the 
      first long-term, large-scale, prospective study of a calcium antagonist 
      administered post-thrombolysis as adjunctive therapy to AMI patients in which the 
      primary trial objective is to assess the effect of blinded therapy on the 6-month 
      cumulative occurrence of a combined clinical end point (cardiac death, recurrent 
      nonfatal AMI, and medically refractory ischemia).
FAU - Boden, W E
AU  - Boden WE
AD  - Boston VA Medical Center, Massachusetts 02130, USA.
FAU - Scheldewaert, R
AU  - Scheldewaert R
FAU - Walters, E G
AU  - Walters EG
FAU - Whitehead, A
AU  - Whitehead A
FAU - Coltart, D J
AU  - Coltart DJ
FAU - Santoni, J P
AU  - Santoni JP
FAU - Belgrave, G
AU  - Belgrave G
FAU - Starkey, I R
AU  - Starkey IR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Delayed-Action Preparations)
RN  - EE92BBP03H (Diltiazem)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Diltiazem/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Electrocardiography
MH  - Europe
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Prognosis
MH  - Prospective Studies
MH  - Research Design
MH  - *Thrombolytic Therapy
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
AID - S0002914999807425 [pii]
AID - 10.1016/s0002-9149(99)80742-5 [doi]
PST - ppublish
SO  - Am J Cardiol. 1995 Jun 1;75(16):1120-3. doi: 10.1016/s0002-9149(99)80742-5.

PMID- 24931228
OWN - NLM
STAT- MEDLINE
DCOM- 20150406
LR  - 20140616
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 127
IP  - 12
DP  - 2014
TI  - Aspirin combined with mechanical measures to prevent venous thromboembolism after 
      total knee arthroplasty: a randomized controlled trial.
PG  - 2201-5
AB  - BACKGROUND: Venous thromboembolism (VTE) is an important complication after major 
      orthopedic surgery. Pharmaceutical methods represent the main strategy of VTE 
      prevention. The use of aspirin in VTE prevention is still controversial 
      worldwide, especially in China. The purpose of this study was to evaluate the 
      role of aspirin combined with mechanical measures in the prevention of VTE after 
      total knee arthroplasty (TKA). METHODS: Between January 2012 and May 2013 and in 
      accordance with the inclusion criteria, 120 patients undergoing TKA were randomly 
      allocated to two groups. To prevent VTE, patients in group A received aspirin 
      combined with mechanical measures postoperatively, while patients in group B 
      received low-molecular-weight heparin (LMWH) sodium and rivaroxaban sequentially 
      in combination with mechanical measures postoperatively. All surgeries were 
      performed by one surgeon using a posterior-stabilized cemented prosthesis. The 
      two groups were followed up and compared for the incidence of deep vein 
      thrombosis (DVT) by duplex ultrasound scan and clinical VTE events. The adverse 
      events, the blood loss index, and the cost of VTE prevention were also compared. 
      RESULTS: DVT was detected in 10 of 60 patients in group A (16.7%, 95% CI: 
      7.3%-26.1%) compared with 11 of 60 in group B (18.3%, 95% CI: 8.5%-27.8%) (P = 
      0.500). There is no statistical evidence supporting the inferior effect of 
      aspirin in preventing DVT as compared with the other medications. There were no 
      cases of symptomatic VTE or death during the follow-up period. Area of ecchymosis 
      was lower in group A than in group B, and the differences were statistically 
      significant. Patients in group A had the lower blood loss index as compared with 
      patients in group B. No transfusion cases were found in both groups. The 
      differences were statistically significant. The cost of VTE prevention analysis 
      indicated a cost reduction using aspirin in group A compared with using LMWH and 
      rivaroxaban in group B. CONCLUSION: Aspirin combined with mechanical measures had 
      a good effect on prevention of VTE after TKA and resulted in lower cost, less 
      blood loss, and less subcutaneous ecchymosis.
FAU - Jiang, Yi
AU  - Jiang Y
AD  - Department of Joint Reconstructive Surgery, Beijing Jishuitan Hospital, Beijing 
      100035, China.
FAU - Du, Hui
AU  - Du H
AD  - Department of Joint Reconstructive Surgery, Beijing Jishuitan Hospital, Beijing 
      100035, China.
FAU - Liu, Jian
AU  - Liu J
AD  - Department of Joint Reconstructive Surgery, Beijing Jishuitan Hospital, Beijing 
      100035, China.
FAU - Zhou, Yixin
AU  - Zhou Y
AD  - Department of Joint Reconstructive Surgery, Beijing Jishuitan Hospital, Beijing 
      100035, China. Email: orthoyixin@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Venous Thromboembolism/*prevention & control
EDAT- 2014/06/17 06:00
MHDA- 2015/04/07 06:00
CRDT- 2014/06/17 06:00
PHST- 2014/06/17 06:00 [entrez]
PHST- 2014/06/17 06:00 [pubmed]
PHST- 2015/04/07 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2014;127(12):2201-5.

PMID- 1173655
OWN - NLM
STAT- MEDLINE
DCOM- 19751003
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 233
IP  - 4
DP  - 1975 Jul 28
TI  - Evaluation of ibuprofen (Motrin). A new antirheumatic agent.
PG  - 364-5
AB  - Ibuprofen is a new, mild analgesic agent that may be useful in the symptomatic 
      treatment of rheumatoid arthritis and osteoarthritis. Results of clinical studies 
      have shown that its beneficial effects in these conditions are comparable, but 
      not superior, to those of aspirin. However, at recommended doses it has less 
      anti-inflammatory effect than aspirin. Its usefulness as an analgesic in the 
      treatment of other types of pain and as an antipyretic has not yet been 
      established. Ibuprofen causes fewer adverse effects on the gastrointestinal 
      system, including occult bleeding, than aspirin. Serious adverse reactions have 
      not been reported. Thus, ibuprofen may be acceptable for use in patients who 
      cannot tolerate aspirin or other antirheumatic drugs.
FAU - Lewis, J R
AU  - Lewis JR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Propionates)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Administration, Oral
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Central Nervous System/drug effects
MH  - Digestive System/drug effects
MH  - Drug Evaluation
MH  - Drug Synergism
MH  - Eye/drug effects
MH  - Humans
MH  - Ibuprofen/administration & dosage/adverse effects/*therapeutic use
MH  - Osteoarthritis/drug therapy
MH  - Propionates/*therapeutic use
EDAT- 1975/07/28 00:00
MHDA- 1975/07/28 00:01
CRDT- 1975/07/28 00:00
PHST- 1975/07/28 00:00 [pubmed]
PHST- 1975/07/28 00:01 [medline]
PHST- 1975/07/28 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1975 Jul 28;233(4):364-5.

PMID- 6726059
OWN - NLM
STAT- MEDLINE
DCOM- 19840629
LR  - 20141120
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 103
IP  - 6
DP  - 1984 Jun
TI  - Aspirin and folate binding: in vivo and in vitro studies of serum binding and 
      urinary excretion of endogenous folate.
PG  - 944-8
AB  - To clarify the effect of aspirin on folate balance, we studied serum 
      concentration, protein binding, and urinary excretion of endogenous folate. A 
      healthy woman twice followed an 11-day protocol of constant diet, blood sampling 
      twice daily, collection of all urine, and 650 mg of aspirin by mouth every 4 
      hours on the middle 3 days. As determined by equilibrium dialysis and 
      Lactobacillus casei assay, aspirin induced a brisk, significant but reversible 
      fall in total and bound serum folate and a small but insignificant rise in 
      urinary folate excretion. Aspirin in vitro also displaced significant amounts of 
      bound serum folate. Thus, aspirin in therapeutic doses can contribute to 
      subnormal serum folate values, and if it increases urinary folate excretion even 
      slightly, may impair folate balance.
FAU - Lawrence, V A
AU  - Lawrence VA
FAU - Loewenstein, J E
AU  - Loewenstein JE
FAU - Eichner, E R
AU  - Eichner ER
LA  - eng
PT  - Case Reports
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Carrier Proteins)
RN  - 0 (Folate Receptors, GPI-Anchored)
RN  - 0 (Receptors, Cell Surface)
RN  - 935E97BOY8 (Folic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/blood/*pharmacology
MH  - Carrier Proteins/*metabolism
MH  - Depression, Chemical
MH  - Female
MH  - Folate Receptors, GPI-Anchored
MH  - Folic Acid/blood/*metabolism/urine
MH  - Humans
MH  - In Vitro Techniques
MH  - Protein Binding/drug effects
MH  - *Receptors, Cell Surface
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
PST - ppublish
SO  - J Lab Clin Med. 1984 Jun;103(6):944-8.

PMID- 1410729
OWN - NLM
STAT- MEDLINE
DCOM- 19921103
LR  - 20161123
IS  - 0034-9356 (Print)
IS  - 0034-9356 (Linking)
VI  - 39
IP  - 3
DP  - 1992 May-Jun
TI  - [Administration of lysine acetylsalicylate and meperidine in acute postoperative 
      pain].
PG  - 149-54
AB  - INTRODUCTION: Postoperative analgesia is insufficiently done due, among others, 
      to the undesirable effects of analgesic agents. OBJECTIVE: The aim of this study 
      was to analyze the effects of the simultaneous administration of opiates 
      (meperidine) and AINES (lysine acetylsalicylate, ASL). MATERIAL AND METHODS: We 
      studied 160 patients during the immediate postoperative phase. All of them 
      underwent programmed surgery with the same general anesthetic technique. Patients 
      were allocated into 8 groups of treatment: A) ASL 900 mg and 1.800 mg/8 h, B) ASL 
      900 mg and 3.600 mg/8 h, C) ASL 900 mg and meperidine 100 mg/8 h, D) ASL 900 mg 
      and 1.800 mg/8 h together with meperidine 100 mg/8 h, E) meperidine 50 mg and ASL 
      1.800 mg/8 h, F) meperidine 50 mg and ASL 3.600 mg/8 h, G) meperidine 50 mg and 
      100 mg/8 h, and H) meperidine 50 mg and 100 mg/8 h together with ASL 1.800 mg/8 
      h. The effects of analgesic agents were evaluated on the basis of patient's 
      appreciation of the degree of pain and relief and on the basis of an observer who 
      did not know the therapeutic regime administered. Results were compared according 
      to the analysis of variance in a graded factorial design. A p value less than 
      0.05 was considered significant. RESULTS: The degree of pain was significantly 
      lower in groups C, D, G and H (specially in G and H) than in the remaining 
      groups, but there were no significant differences between them. The lowest pain 
      relief was observed in groups A, B, E and F. The highest attenuation of pain was 
      achieved in groups G and H. The highest attenuation of pain was achieved in 
      groups G and H. The observer considered that the two latter groups were those 
      with the highest pain relief, followed by groups C and D. The remaining patients 
      failed to show appreciable improvement. Nausea and vomiting only occurred in some 
      patients after administration of a bolus of meperidine. There were no other 
      secondary effects. CONCLUSIONS: The best degree of postoperative analgesia is 
      achieved after administration of continuous infusion of meperidine 100 mg/8 h. 
      Simultaneous infusion of ASL 1.800 mg/8 h did not improve the analgesia obtained 
      with a bolus of 900 mg of ASL nor with a bolus of 50 mg of meperidine. Secondary 
      effects were only nausea and vomiting and coincided with the administration of a 
      bolus of meperidine.
FAU - Miralles, F S
AU  - Miralles FS
AD  - Servicio de Anestesiología, Hospitales de la Vega Baja, Orihuela.
FAU - Cárceles, M D
AU  - Cárceles MD
FAU - Micol, J A
AU  - Micol JA
FAU - Hernández-Palazón, J
AU  - Hernández-Palazón J
FAU - Delpino, A L
AU  - Delpino AL
FAU - Guillamón, L
AU  - Guillamón L
LA  - spa
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
TT  - Administración de acetilsalicilato de lisina y meperidina en el dolor agudo 
      postoperatorio.
PL  - Spain
TA  - Rev Esp Anestesiol Reanim
JT  - Revista espanola de anestesiologia y reanimacion
JID - 0134516
RN  - 0 (Analgesics)
RN  - 9E338QE28F (Meperidine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analgesics/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Meperidine/administration & dosage/*therapeutic use
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Single-Blind Method
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
PST - ppublish
SO  - Rev Esp Anestesiol Reanim. 1992 May-Jun;39(3):149-54.

PMID- 30092418
OWN - NLM
STAT- MEDLINE
DCOM- 20181116
LR  - 20200106
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 70
IP  - 5
DP  - 2018 Oct
TI  - Effects of low and high doses of acetylsalicylic acid on penicillin-induced 
      epileptiform activity.
PG  - 885-889
LID - S1734-1140(17)30216-5 [pii]
LID - 10.1016/j.pharep.2018.03.002 [doi]
AB  - BACKGROUND: The most common headache associated with epilepsy occurs after 
      seizure activity and is called a postictal headache. Therefore, the objective of 
      this study was to investigate the effects of low and high doses acetylsalicylic 
      acid (aspirin) on a penicillin-induced experimental epilepsy model. METHODS: 
      Adult male Wistar rats (n = 28, weighing 220 ± 40 g) were used in the 
      experiments. The rats were divided into four groups as Control, Penicillin, 
      Aspirin 150 mg/kg, Aspirin 500 mg/kg. Seizure activity was triggered by an 
      intracortical injection of penicillin G potassium (500 IU/2.5 μl) into the 
      sensory motor cortex. An electrocorticogram was recorded by using conductive 
      screw electrodes. Aspirin at the doses of 500 mg/kg and 150 mg/kg was given 
      intraperitoneally (ip) 30 min after penicillin administration. RESULTS: 
      Anticonvulsant activity appeared at the 30th and 40th min after an 
      intracortically administered injection of penicillin in the groups given aspirin 
      doses of 500 mg/kg (ip) and 150 mg/kg (ip) respectively. The amplitude of 
      epileptiform activity at both doses of aspirin decreased but the difference was 
      not statistically significant. CONCLUSIONS: The results of the present study 
      suggest that low and high doses of aspirin may decrease epileptiform activity in 
      penicillin-induced epilepsy. Aspirin might be suggested for headache associated 
      with epilepsy.
CI  - Copyright © 2018 Institute of Pharmacology, Polish Academy of Sciences. Published 
      by Elsevier B.V. All rights reserved.
FAU - Tasdemir, Abdulkadir
AU  - Tasdemir A
AD  - Department of Biology, Faculty of Science, Erciyes University, Kayseri, Turkey. 
      Electronic address: tasdemira@erciyes.edu.tr.
FAU - Taskiran, Mehmet
AU  - Taskiran M
AD  - Department of Biology, Faculty of Science, Erciyes University, Kayseri, Turkey. 
      Electronic address: mtaskiran@erciyes.edu.tr.
FAU - Ayyildiz, Nusret
AU  - Ayyildiz N
AD  - Department of Biology, Faculty of Science, Erciyes University, Kayseri, Turkey. 
      Electronic address: nayildiz@erciyes.edu.tr.
LA  - eng
PT  - Journal Article
DEP - 20180314
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - Q42T66VG0C (Penicillin G)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Electrocorticography
MH  - Epilepsy/*chemically induced/*prevention & control
MH  - Male
MH  - *Penicillin G
MH  - Rats
OTO - NOTNLM
OT  - Acute effect
OT  - Aspirin
OT  - Dosage
OT  - ECoG
OT  - Epileptiform activity
EDAT- 2018/08/10 06:00
MHDA- 2018/11/18 06:00
CRDT- 2018/08/10 06:00
PHST- 2017/03/21 00:00 [received]
PHST- 2018/03/09 00:00 [revised]
PHST- 2018/03/13 00:00 [accepted]
PHST- 2018/08/10 06:00 [pubmed]
PHST- 2018/11/18 06:00 [medline]
PHST- 2018/08/10 06:00 [entrez]
AID - S1734-1140(17)30216-5 [pii]
AID - 10.1016/j.pharep.2018.03.002 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2018 Oct;70(5):885-889. doi: 10.1016/j.pharep.2018.03.002. Epub 
      2018 Mar 14.

PMID- 1263101
OWN - NLM
STAT- MEDLINE
DCOM- 19760706
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 65
IP  - 3
DP  - 1976 Mar
TI  - Influence of aspirin formulation and dose on concentration of total salicylate in 
      rat kidney.
PG  - 447-50
AB  - Rats received the equivalent of 100, 250, 500, or 700 mg/kg of 14C-aspirin orally 
      as a suspension or as a solution of a buffered, effervescent, aspirin-containing 
      product. Animals in each dose group were sacrificed at time intervals ranging 
      from 0.5 to 24 hr after dosing. The 14C content of whole blood, plasma, and 
      homogenized whole kidney (after perfusion) was determined. The concentration of 
      total salicylate proved to be dose dependent and was lower in tissues from rats 
      receiving the buffered, effervescent product, especially at the higher doses. The 
      results suggest that salicylate-induced renal toxicity should be less likely to 
      occur after administration of the buffered, effervescent formulation.
FAU - Leeling, J L
AU  - Leeling JL
FAU - Phillips, B M
AU  - Phillips BM
FAU - Kowalski, T L
AU  - Kowalski TL
FAU - Kowalski, R L
AU  - Kowalski RL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Buffers)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*metabolism
MH  - Buffers
MH  - Kidney/*metabolism
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Salicylates/blood/*metabolism
MH  - Time Factors
EDAT- 1976/03/01 00:00
MHDA- 1976/03/01 00:01
CRDT- 1976/03/01 00:00
PHST- 1976/03/01 00:00 [pubmed]
PHST- 1976/03/01 00:01 [medline]
PHST- 1976/03/01 00:00 [entrez]
AID - S0022-3549(15)40651-3 [pii]
AID - 10.1002/jps.2600650337 [doi]
PST - ppublish
SO  - J Pharm Sci. 1976 Mar;65(3):447-50. doi: 10.1002/jps.2600650337.

PMID- 19056109
OWN - NLM
STAT- MEDLINE
DCOM- 20090303
LR  - 20220331
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 123
IP  - 2
DP  - 2009 Feb
TI  - Rational approach to aspirin dosing during oral challenges and desensitization of 
      patients with aspirin-exacerbated respiratory disease.
PG  - 406-10
LID - 10.1016/j.jaci.2008.09.048 [doi]
AB  - BACKGROUND: Aspirin desensitization improves clinical outcomes in most patients 
      with aspirin-exacerbated respiratory disease. Most protocols for desensitization 
      are time-consuming. OBJECTIVE: Our objective was to use historical information 
      about the course of aspirin desensitization to enhance the efficiency of the 
      desensitization protocol. METHODS: Four hundred twenty subjects with suspected 
      aspirin-exacerbated respiratory disease underwent oral aspirin challenges. Their 
      clinical characteristics were analyzed in relation to features of reactions 
      during aspirin challenges. RESULTS: Large (FEV(1) decrease >30%) and moderate 
      (FEV(1) decrease 21% to 30%) bronchial reactions occurred in 9% and 20% of 
      subjects, respectively. Multivariate analysis identified risk factors associated 
      with these larger reactions, including lack of leukotriene modifier use, baseline 
      FEV(1) of less than 80% of predicted value, and previous asthma-related emergency 
      department visits. Seventy-five percent of patients reacted to a provoking dose 
      of either 45 or 60 mg. Only 3% of initial reactions occurred after 150- or 325-mg 
      provoking doses, and none occurred after the 650-mg dose. CONCLUSIONS: Most 
      bronchial and naso-ocular reactions during oral aspirin challenges occurred 
      within a narrow dosing range (45-100 mg). Only 1 of 26 patients without risk 
      factors had a moderate reaction.
FAU - Hope, Andrew P
AU  - Hope AP
AD  - Allergy Department, Kaiser Permanente Santa Clara, Santa Clara, Calif, USA.
FAU - Woessner, Katharine A
AU  - Woessner KA
FAU - Simon, Ronald A
AU  - Simon RA
FAU - Stevenson, Donald D
AU  - Stevenson DD
LA  - eng
PT  - Journal Article
DEP - 20081203
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects/immunology
MH  - Asthma/chemically induced/immunology/physiopathology/*therapy
MH  - Bronchi/drug effects/physiopathology
MH  - Bronchial Provocation Tests
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*complications/immunology/physiopathology
MH  - Humans
MH  - Middle Aged
MH  - Risk Factors
EDAT- 2008/12/06 09:00
MHDA- 2009/03/04 09:00
CRDT- 2008/12/06 09:00
PHST- 2008/03/08 00:00 [received]
PHST- 2008/09/24 00:00 [revised]
PHST- 2008/09/29 00:00 [accepted]
PHST- 2008/12/06 09:00 [pubmed]
PHST- 2009/03/04 09:00 [medline]
PHST- 2008/12/06 09:00 [entrez]
AID - S0091-6749(08)01853-8 [pii]
AID - 10.1016/j.jaci.2008.09.048 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2009 Feb;123(2):406-10. doi: 10.1016/j.jaci.2008.09.048. 
      Epub 2008 Dec 3.

PMID- 9655849
OWN - NLM
STAT- MEDLINE
DCOM- 19980803
LR  - 20181201
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 286
IP  - 1
DP  - 1998 Jul
TI  - Effect of nitric oxide-releasing aspirin derivative on gastric functional and 
      ulcerogenic responses in rats: comparison with plain aspirin.
PG  - 115-21
AB  - The effects of a nitric oxide (NO)-releasing derivative of aspirin, NCX-4016, on 
      gastric functional and ulcerogenic responses in rat stomachs were examined in 
      comparison with those of aspirin. Topical application of aspirin (80 mM) to the 
      stomach markedly decreased transmucosal potential difference and slightly 
      increased luminal pH (acid back-diffusion) with minimal effect on mucosal blood 
      flow, whereas NCX-4016 caused a marked increase in mucosal blood flow with no 
      effect on potential difference and pH. Aspirin itself was ulcerogenic, causing 
      damage in the mucosa when administered p.o., and it markedly potentiated gastric 
      ulcerogenic response to hypothermic stress (28 degrees C-30 degrees C) with no 
      effect on acid secretion when given s.c. NCX-4016, however, was not ulcerogenic 
      by itself, did not modify the ulcerogenic response to stress and even showed a 
      dose-dependent protection against HCl/ethanol-induced gastric lesions. When 
      NCX-4016 was given intragastrically to pylorus-ligated rats, a large amount of NO 
      was detected in both gastric contents and serum. NCX-4016 administered either 
      p.o. or s.c. produced an equipotent inhibition of mucosal PGE2 generation in the 
      stomach, as compared with aspirin. In addition, both aspirin and NCX-4016 
      suppressed carrageenan-induced rat paw edema. These results suggest that, unlike 
      aspirin, the NO-releasing derivative of aspirin NCX-4016 neither had a topical 
      irritating action on the stomach nor exerted a worsening effect on gastric 
      ulcerogenic response to stress, but rather provided gastric protection against 
      ethanol, despite inhibiting cyclo-oxygenase activity and showing 
      anti-inflammatory action much as aspirin does. NCX-4016, probably by releasing 
      NO, exerted protective effects that counteracted the potential damaging effects 
      of cyclo-oxygenase inhibition.
FAU - Takeuchi, K
AU  - Takeuchi K
AD  - Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical 
      University, Japan.
FAU - Ukawa, H
AU  - Ukawa H
FAU - Konaka, A
AU  - Konaka A
FAU - Kitamura, M
AU  - Kitamura M
FAU - Sugawa, Y
AU  - Sugawa Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*toxicity
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Dinoprostone/analysis
MH  - Gastric Acid/metabolism
MH  - Gastric Acidity Determination
MH  - Male
MH  - Nitric Oxide/*physiology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/drug effects
MH  - Stomach Ulcer/chemically induced
EDAT- 1998/07/10 00:00
MHDA- 1998/07/10 00:01
CRDT- 1998/07/10 00:00
PHST- 1998/07/10 00:00 [pubmed]
PHST- 1998/07/10 00:01 [medline]
PHST- 1998/07/10 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1998 Jul;286(1):115-21.

PMID- 36189951
OWN - NLM
STAT- MEDLINE
DCOM- 20221216
LR  - 20230415
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 180
IP  - 1
DP  - 2023 Jan
TI  - Fifty years with aspirin and platelets.
PG  - 25-43
LID - 10.1111/bph.15966 [doi]
AB  - In 2021, we reached the 50th anniversary of the publication of Sir John Vane's 
      seminal paper in Nature New Biology describing the experiments supporting his 
      mechanistic hypothesis that inhibition of prostaglandin synthesis might explain 
      the main pharmacological effects of aspirin and aspirin-like drugs, that is, 
      reduction in pain, fever and inflammation. Bengt Samuelsson's subsequent 
      discoveries elucidating the cyclooxygenase pathway of platelet arachidonic acid 
      metabolism motivated my research interest towards measuring platelet thromboxane 
      A(2) biosynthesis as a tool to investigate the clinical pharmacology of 
      cyclooxygenase inhibition by aspirin in health and disease. What followed was a 
      long, winding road of clinical research leading to the characterization of 
      low-dose aspirin as a life-saving antiplatelet drug that still represents the 
      cornerstone of antithrombotic therapy. Having witnessed and participated in these 
      50 years of aspirin research, I thought of providing a personal testimony of how 
      things developed and eventually led to a remarkable success story of independent 
      research.
CI  - © 2022 The Author. British Journal of Pharmacology published by John Wiley & Sons 
      Ltd on behalf of British Pharmacological Society.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221103
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
SB  - IM
MH  - *Aspirin/pharmacology
MH  - *Cyclooxygenase Inhibitors/pharmacology
MH  - Blood Platelets
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Cyclooxygenase 2/metabolism
PMC - PMC10099789
OTO - NOTNLM
OT  - aspirin
OT  - cardiac pharmacology
OT  - clinical pharmacology
OT  - cyclo-oxygenase
OT  - pharmacodynamics
OT  - platelets/thrombocytes
OT  - prostaglandins
COIS- During the past 20 years, I have received grant support for 
      investigator‐initiated research from the Italian Drug Agency (AIFA), Bayer AG, 
      Cancer Research UK and the European Commission, FP6 and FP7 Programmes. During 
      the past 5 years, I have received consultant and speaker fees from Acticor 
      Biotech, Amgen, Bayer, Eli Lilly, GlaxoSmithKline, Tremeau and Zambon. I chair 
      the Scientific Advisory Board of the International Aspirin Foundation.
EDAT- 2022/10/04 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/10/03 07:03
PHST- 2022/09/23 00:00 [revised]
PHST- 2022/06/22 00:00 [received]
PHST- 2022/09/26 00:00 [accepted]
PHST- 2022/10/04 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
PHST- 2022/10/03 07:03 [entrez]
AID - BPH15966 [pii]
AID - 10.1111/bph.15966 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2023 Jan;180(1):25-43. doi: 10.1111/bph.15966. Epub 2022 Nov 3.

PMID- 27096951
OWN - NLM
STAT- MEDLINE
DCOM- 20160825
LR  - 20190219
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 4
DP  - 2016
TI  - Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in 
      Mortality: A Systematic Review and Meta-Analyses of Published Studies.
PG  - e0152402
LID - 10.1371/journal.pone.0152402 [doi]
LID - e0152402
AB  - BACKGROUND: Low-dose aspirin has been shown to reduce the incidence of cancer, 
      but its role in the treatment of cancer is uncertain. OBJECTIVES: We conducted a 
      systematic search of the scientific literature on aspirin taken by patients 
      following a diagnosis of cancer, together with appropriate meta-analyses. 
      METHODS: Searches were completed in Medline and Embase in December 2015 using a 
      pre-defined search strategy. References and abstracts of all the selected papers 
      were scanned and expert colleagues were contacted for additional studies. Two 
      reviewers applied pre-determined eligibility criteria (cross-sectional, cohort 
      and controlled studies, and aspirin taken after a diagnosis of cancer), assessed 
      study quality and extracted data on cancer cause-specific deaths, overall 
      mortality and incidence of metastases. Random effects meta-analyses and planned 
      sub-group analyses were completed separately for observational and experimental 
      studies. Heterogeneity and publication bias were assessed in sensitivity analyses 
      and appropriate omissions made. Papers were examined for any reference to 
      bleeding and authors of the papers were contacted and questioned. RESULTS: Five 
      reports of randomised trials were identified, together with forty two 
      observational studies: sixteen on colorectal cancer, ten on breast and ten on 
      prostate cancer mortality. Pooling of eleven observational reports of the effect 
      of aspirin on cause-specific mortality from colon cancer, after the omission of 
      one report identified on the basis of sensitivity analyses, gave a hazard ratio 
      (HR) of 0.76 (95% CI 0.66, 0.88) with reduced heterogeneity (P = 0.04). The cause 
      specific mortality in five reports of patients with breast cancer showed 
      significant heterogeneity (P<0.0005) but the omission of one outlying study 
      reduced heterogeneity (P = 0.19) and led to an HR = 0.87 (95% CI 0.69, 1.09). 
      Heterogeneity between nine studies of prostate cancer was significant, but again, 
      the omission of one study led to acceptable homogeneity (P = 0.26) and an overall 
      HR = 0.89 (95% CI 0.79-0.99). Six single studies of other cancers suggested 
      reductions in cause specific mortality by aspirin, and in five the effect is 
      statistically significant. There were no significant differences between the 
      pooled HRs for the three main cancers and after the omission of three reports 
      already identified in sensitivity analyses heterogeneity was removed and revealed 
      an overall HR of 0.83 (95% CI 0.76-0.90). A mutation of PIK3CA was present in 
      about 20% of patients, and appeared to explain most of the reduction in colon 
      cancer mortality by aspirin. Data were not adequate to examine the importance of 
      this or any other marker in the effect of aspirin in the other cancers. On 
      bleeding attributable to aspirin two reports stated that there had been no side 
      effect or bleeding attributable to aspirin. Authors on the other reports were 
      written to and 21 replied stating that no data on bleeding were available. 
      CONCLUSIONS AND IMPLICATIONS: The study highlights the need for randomised trials 
      of aspirin treatment in a variety of cancers. While these are awaited there is an 
      urgent need for evidence from observational studies of aspirin and the less 
      common cancers, and for more evidence of the relevance of possible bio-markers of 
      the aspirin effect on a wide variety of cancers. In the meantime it is urged that 
      patients in whom a cancer is diagnosed should be given details of this research, 
      together with its limitations, to enable each to make an informed decision as to 
      whether or not to take low-dose aspirin. SYSTEMATIC REVIEW PROTOCOL NUMBER: 
      CRD42015014145.
FAU - Elwood, Peter C
AU  - Elwood PC
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
FAU - Morgan, Gareth
AU  - Morgan G
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
AD  - Hywel Dda University Health Board, Llanelli SA14 8QF, United Kingdom.
FAU - Pickering, Janet E
AU  - Pickering JE
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
FAU - Galante, Julieta
AU  - Galante J
AD  - Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom.
FAU - Weightman, Alison L
AU  - Weightman AL
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
AD  - Specialist Unit for Review Evidence, Cardiff University, Cardiff, United Kingdom.
FAU - Morris, Delyth
AU  - Morris D
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
FAU - Kelson, Mark
AU  - Kelson M
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
FAU - Dolwani, Sunil
AU  - Dolwani S
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160420
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 2016;353:i2284. PMID: 27101832
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Neoplasms/*mortality/pathology/*prevention & control
PMC - PMC4838306
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2016/04/21 06:00
MHDA- 2016/08/26 06:00
CRDT- 2016/04/21 06:00
PHST- 2015/06/26 00:00 [received]
PHST- 2016/03/14 00:00 [accepted]
PHST- 2016/04/21 06:00 [entrez]
PHST- 2016/04/21 06:00 [pubmed]
PHST- 2016/08/26 06:00 [medline]
AID - PONE-D-15-25730 [pii]
AID - 10.1371/journal.pone.0152402 [doi]
PST - epublish
SO  - PLoS One. 2016 Apr 20;11(4):e0152402. doi: 10.1371/journal.pone.0152402. 
      eCollection 2016.

PMID- 15645632
OWN - NLM
STAT- MEDLINE
DCOM- 20050211
LR  - 20191026
IS  - 1049-023X (Print)
IS  - 1049-023X (Linking)
VI  - 19
IP  - 4
DP  - 2004 Oct-Dec
TI  - Prehospital use of aspirin rarely is associated with adverse events.
PG  - 362-5
AB  - INTRODUCTION: Aspirin is commonly administered for acute coronary syndromes in 
      the prehospital setting. Few studies have addressed the incidence of adverse 
      effects associated with prehospital administration of aspirin. OBJECTIVE: To 
      determine the incidence of adverse events following the administration of aspirin 
      by prehospital personnel. METHODS: Multi-center, retrospective, case series that 
      involved all patients who received aspirin in the prehospital setting from (01 
      August 1999-31 January 2000). Patient encounter forms of the emergency medical 
      services (EMS) of a metropolitan fire department were reviewed. All patients who 
      had a potential cardiac syndrome (i.e., chest pain, dyspnea) as documented on the 
      EMS forms were included in the review. Exclusion criteria included failure to 
      meet inclusion criteria, and chest pain secondary to apparent non-cardiac causes 
      (i.e., trauma). Hospital charts were reviewed from a subset of patients at the 
      participating hospitals. The major outcome was an adverse event following 
      prehospital administration of aspirin. This outcome was evaluated during the EMS 
      encounter, at emergency department discharge, or at six and 24-hours post-aspirin 
      ingestion. An adverse event secondary to aspirin ingestion was defined as 
      anaphylaxis or allergic reactions, such as rash or respiratory changes. RESULTS: 
      A total of 25,600 EMS encounter forms were reviewed, yielding 2,399 patients with 
      a potential cardiac syndrome. Prior to EMS arrival, 585 patients had received 
      aspirin, and 893 were administered aspirin by EMS personnel. No patients had an 
      adverse event during the EMS encounter. Of these patients, 229 were transported 
      to participating hospitals and 219 medical records were available for review with 
      no adverse reactions recorded during their hospital course. CONCLUSION: Aspirin 
      is rarely associated with adverse events when administered by prehospital 
      personnel for presumed coronary syndromes.
FAU - Quan, Dan
AU  - Quan D
AD  - Midwestern University/Arizona College of Osteopathic Medicine, Glendale, Arizona, 
      USA.
FAU - LoVecchio, Frank
AU  - LoVecchio F
FAU - Clark, Bryan
AU  - Clark B
FAU - Gallagher, John V 3rd
AU  - Gallagher JV 3rd
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Prehosp Disaster Med
JT  - Prehospital and disaster medicine
JID - 8918173
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Chest Pain/diagnosis/*drug therapy
MH  - Drug Hypersensitivity/*epidemiology
MH  - Emergency Medical Services/*methods
MH  - Emergency Treatment/methods
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Sampling Studies
MH  - Treatment Outcome
EDAT- 2005/01/14 09:00
MHDA- 2005/02/12 09:00
CRDT- 2005/01/14 09:00
PHST- 2005/01/14 09:00 [pubmed]
PHST- 2005/02/12 09:00 [medline]
PHST- 2005/01/14 09:00 [entrez]
AID - 10.1017/s1049023x00001990 [doi]
PST - ppublish
SO  - Prehosp Disaster Med. 2004 Oct-Dec;19(4):362-5. doi: 10.1017/s1049023x00001990.

PMID- 1448821
OWN - NLM
STAT- MEDLINE
DCOM- 19921229
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 23
IP  - 12
DP  - 1992 Dec
TI  - Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of 
      patients with minor stroke from the Ticlopidine Aspirin Stroke Study.
PG  - 1723-7
AB  - BACKGROUND AND PURPOSE: Ticlopidine has not been formally compared with aspirin 
      in patients with a completed stroke. We therefore performed an analysis on a 
      subgroup of patients from the Ticlopidine Aspirin Stroke Study (TASS) with a 
      recent minor completed stroke as the qualifying ischemic event. METHODS: This was 
      a multicenter, double-blind, randomized trial of patients with a recent history 
      of cerebral ischemia. Eligible patients had a qualifying minor stroke within 3 
      months of study entry. All patients received either 650 mg aspirin twice daily or 
      250 mg ticlopidine twice daily for up to 5.8 years. The primary study end point 
      was the first occurrence of nonfatal stroke or death from any cause. A secondary 
      end point was the first occurrence of a fatal or nonfatal stroke. RESULTS: Minor 
      stroke was the qualifying ischemic event in 927 patients (463 received 
      ticlopidine and 464 received aspirin). The cumulative event rate at 1 year for 
      nonfatal stroke or death was 6.3% for patients receiving ticlopidine and 10.8% 
      for patients receiving aspirin, a 42% risk reduction in favor of ticlopidine. For 
      fatal or nonfatal stroke, the cumulative event rate at 1 year was 4.8% for 
      patients receiving ticlopidine and 7.5% for those receiving aspirin, a risk 
      reduction of 36% for ticlopidine relative to aspirin. The overall risk reductions 
      were 22.1% for nonfatal stroke or death and 19.9% for fatal or nonfatal stroke. 
      Adverse reactions were reported in 58% of the ticlopidine patients and 51% of the 
      aspirin patients. CONCLUSIONS: The results in this subgroup are consistent with 
      the overall TASS results and show that ticlopidine is somewhat more effective 
      than aspirin for reducing the risk of stroke in patients with a completed minor 
      stroke.
FAU - Harbison, J W
AU  - Harbison JW
AD  - Department of Neurology, Medical College of Virginia, Richmond 23298-0599.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Diarrhea/chemically induced
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neutropenia/chemically induced
MH  - Recurrence
MH  - Ticlopidine/adverse effects/*therapeutic use
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
AID - 10.1161/01.str.23.12.1723 [doi]
PST - ppublish
SO  - Stroke. 1992 Dec;23(12):1723-7. doi: 10.1161/01.str.23.12.1723.

PMID- 3780693
OWN - NLM
STAT- MEDLINE
DCOM- 19870105
LR  - 20171116
IS  - 0265-0215 (Print)
IS  - 0265-0215 (Linking)
VI  - 3
IP  - 3
DP  - 1986 May
TI  - Aspirin and probenecid pretreatment influences the potency of thiopentone and the 
      onset of action of midazolam.
PG  - 247-51
AB  - The effects of pretreatment with aspirin and probenecid, two drugs which are 
      highly bound to albumin, on an induction dose of thiopentone and time to onset of 
      action of a fixed dose of midazolam were investigated. Both drugs significantly 
      potentiate thiopentone and shorten the induction time with midazolam. The 
      importance of individual variations in plasma proteins in influencing the action 
      of highly bound drugs is stressed.
FAU - Dundee, J W
AU  - Dundee JW
FAU - Halliday, N J
AU  - Halliday NJ
FAU - McMurray, T J
AU  - McMurray TJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Eur J Anaesthesiol
JT  - European journal of anaesthesiology
JID - 8411711
RN  - JI8Z5M7NA3 (Thiopental)
RN  - PO572Z7917 (Probenecid)
RN  - R16CO5Y76E (Aspirin)
RN  - R60L0SM5BC (Midazolam)
SB  - IM
MH  - Adult
MH  - *Anesthesia
MH  - Aspirin/*pharmacology
MH  - Drug Interactions
MH  - Humans
MH  - *Midazolam
MH  - Preanesthetic Medication
MH  - Probenecid/*pharmacology
MH  - *Thiopental
EDAT- 1986/05/01 00:00
MHDA- 1986/05/01 00:01
CRDT- 1986/05/01 00:00
PHST- 1986/05/01 00:00 [pubmed]
PHST- 1986/05/01 00:01 [medline]
PHST- 1986/05/01 00:00 [entrez]
PST - ppublish
SO  - Eur J Anaesthesiol. 1986 May;3(3):247-51.

PMID- 31069402
OWN - NLM
STAT- MEDLINE
DCOM- 20190920
LR  - 20200225
IS  - 1433-0458 (Electronic)
IS  - 0017-6192 (Linking)
VI  - 67
IP  - 8
DP  - 2019 Aug
TI  - [Nasal provocation with increased ASA dose: improved "non-steroidal 
      anti-inflammatory drugs (NSAIDs)-exacerbated disease" (N‑ERD) detection rate in 
      chronic rhinosinusitis patients].
PG  - 620-627
LID - 10.1007/s00106-019-0668-9 [doi]
AB  - BACKGROUND: Analgesic intolerance (AI) is an important diagnostic feature of 
      disease progression in patients with chronic rhinosinusitis (CRS) accompanied by 
      nasal polyps (CRSwNP) and asthma. OBJECTIVE: The aim of the present study was to 
      determine whether increasing the concentration of acetylsalicylic acid (ASA) used 
      in the diagnostic nasal challenge would improve detection of ASA intolerance 
      (NSAIDs-exacerbated respiratory disease, N‑ERD). METHODS: Patients with CRSwNP, 
      asthma, and with (CRSwNP-AAI, n = 20) or without (CRSwNP-A, n = 15) 
      anamnestically reported AI, as well as control subjects with CRS but no nasal 
      polyps, asthma, or AI (n = 15), were challenged nasally with 16 mg ASA and, in 
      case of a negative result, with 25 mg of ASA. RESULTS: In CRSwNP-AAI subjects, 
      the challenge with 16 mg ASA resulted in detection of AI in 80% of cases; 
      increasing the challenge of ASA to 25 mg improved the AI detection to 95%. In 
      CRSwNP-A subjects, the detection of AI increased from 40% (16 mg ASA) to 53% 
      (25 mg ASA). In the control group, no reaction to nasal ASA challenge was 
      detected. No difference in the diagnosis of positive reactions after provocation 
      was found when using the German vs. the European recommended evaluation criteria. 
      Mild pulmonary symptoms occurred in 2 (10%) CRSwNP-AAI patients following the 
      16 mg ASA challenge. CONCLUSION: In patients with CRSwNP, asthma, and anamnestic 
      AI, nasal provocation can effectively confirm the diagnosis of N‑ERD and can also 
      be recommended for patients with recurrent CRSwNP and asthma but without reported 
      AI. Increasing the ASA challenge to 25 mg increases the overall detection rate.
FAU - Förster-Ruhrmann, U
AU  - Förster-Ruhrmann U
AD  - Klinik für Hals-Nasen-Ohren-Heilkunde, Campus Virchow-Klinikum, Charité - 
      Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland. 
      ulrike.foerster@charite.de.
FAU - Behrbohm, W
AU  - Behrbohm W
AD  - Klinik für Hals-Nasen-Ohren-Heilkunde, Campus Virchow-Klinikum, Charité - 
      Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland.
FAU - Pierchalla, G
AU  - Pierchalla G
AD  - Klinik für Hals-Nasen-Ohren-Heilkunde Campus Mitte, Charité -Universitätsmedizin 
      Berlin, Charitéplatz 1, 13353, Berlin, Deutschland.
FAU - Szczepek, A J
AU  - Szczepek AJ
AD  - Klinik für Hals-Nasen-Ohren-Heilkunde Campus Mitte, Charité -Universitätsmedizin 
      Berlin, Charitéplatz 1, 13353, Berlin, Deutschland.
FAU - Fluhr, J W
AU  - Fluhr JW
AD  - Klinik für Dermatologie and Allergologie, Charité -Universitätsmedizin Berlin, 
      Charitéplatz 1, 13353, Berlin, Deutschland.
FAU - Olze, H
AU  - Olze H
AD  - Klinik für Hals-Nasen-Ohren-Heilkunde, Campus Virchow-Klinikum, Charité - 
      Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland.
AD  - Klinik für Hals-Nasen-Ohren-Heilkunde Campus Mitte, Charité -Universitätsmedizin 
      Berlin, Charitéplatz 1, 13353, Berlin, Deutschland.
LA  - ger
PT  - Journal Article
TT  - Nasale ASS-Provokationen mit erhöhter Dosierung: verbesserte Detektionsrate der 
      ASS-Intoleranz bei chronischer Rhinosinusitis.
PL  - Germany
TA  - HNO
JT  - HNO
JID - 2985099R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/*administration & dosage/immunology
MH  - Asthma, Aspirin-Induced/*diagnosis
MH  - Chronic Disease
MH  - Humans
MH  - *Nasal Polyps/diagnosis
MH  - *Rhinitis/diagnosis
MH  - *Sinusitis/diagnosis
OTO - NOTNLM
OT  - Analgesic intolerance
OT  - CRSwNP
OT  - N-ERD
OT  - Nasal ASA challenge
OT  - Nasal polyps
EDAT- 2019/05/10 06:00
MHDA- 2019/09/21 06:00
CRDT- 2019/05/10 06:00
PHST- 2019/05/10 06:00 [pubmed]
PHST- 2019/09/21 06:00 [medline]
PHST- 2019/05/10 06:00 [entrez]
AID - 10.1007/s00106-019-0668-9 [pii]
AID - 10.1007/s00106-019-0668-9 [doi]
PST - ppublish
SO  - HNO. 2019 Aug;67(8):620-627. doi: 10.1007/s00106-019-0668-9.

PMID- 11133598
OWN - NLM
STAT- MEDLINE
DCOM- 20010118
LR  - 20190704
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 92
IP  - 1
DP  - 2001 Jan
TI  - Hemoglobin and methemoglobin concentrations after large-dose infusions of 
      diaspirin cross-linked hemoglobin.
PG  - 44-8
AB  - Diaspirin cross-linked hemoglobin (DCLHb) solution is a purified human hemoglobin 
      product chemically stabilized to deliver oxygen to tissues. We determined the 
      peak plasma hemoglobin concentration and assessed changes in methemoglobin 
      concentration after the infusion of 1 g/kg DCLHb in large blood loss surgical 
      patients. This prospective, randomized study included 26 surgical patients who 
      were either infused with up to three 250-mL units of 10% DCLHb or transfused with 
      up to three units of packed red blood cells during the study infusion period. 
      Serial plasma hemoglobin, plasma methemoglobin, and whole blood methemoglobin 
      levels were measured before and at intervals up to 48 h after the study infusion 
      period. Plasma hemoglobin and blood methemoglobin concentrations increased during 
      the infusion of DCLHb. The plasma hemoglobin values in the DCLHb group continued 
      to increase during each of the infusion periods to reach a peak plasma 
      concentration of 1450 +/- 176 mg/dL. The fraction of whole blood methemoglobin 
      increased from 0.84 +/- 0.77% at baseline to 4.08 +/- 1.36%. With a median DCLHb 
      dose of 936 mg/kg (range 658-1500 mg/kg), the harmonic mean half-life was 10 h, 
      and the increased whole blood methemoglobin reached a range not associated with 
      complications. IMPLICATIONS: The dose of diaspirin cross-linked hemoglobin 
      (DCLHb) (936 +/- 276 mg/kg) used in this study was one of the largest reported in 
      humans to date. The DCLHb mean half-life was 10 h. The half-life observed was 2-4 
      times that found at smaller doses in previous studies. Whole blood methemoglobin 
      fraction increased during DCLHb infusion but did not reach a range associated 
      with complications.
FAU - O'Hara, J F Jr
AU  - O'Hara JF Jr
AD  - Department of General Anesthesiology, The Cleveland Clinic Foundation, Cleveland, 
      Ohio 44195, USA.
FAU - Colburn, W A
AU  - Colburn WA
FAU - Tetzlaff, J E
AU  - Tetzlaff JE
FAU - Novick, A C
AU  - Novick AC
FAU - Angermeier, K W
AU  - Angermeier KW
FAU - Schubert, A
AU  - Schubert A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 9008-37-1 (Methemoglobin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/*therapeutic use
MH  - Blood Loss, Surgical/prevention & control
MH  - Blood Substitutes/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Erythrocyte Transfusion
MH  - Hemoglobins/*metabolism/*therapeutic use
MH  - Humans
MH  - Infusions, Intravenous
MH  - Methemoglobin/*metabolism
MH  - Prospective Studies
EDAT- 2001/01/03 11:00
MHDA- 2001/02/28 10:01
CRDT- 2001/01/03 11:00
PHST- 2001/01/03 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2001/01/03 11:00 [entrez]
AID - 10.1097/00000539-200101000-00009 [doi]
PST - ppublish
SO  - Anesth Analg. 2001 Jan;92(1):44-8. doi: 10.1097/00000539-200101000-00009.

PMID- 7015489
OWN - NLM
STAT- MEDLINE
DCOM- 19810723
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 111
IP  - 14
DP  - 1981 Apr 4
TI  - [The platelet inhibitor problem].
PG  - 478-82
AB  - Some problems encountered in interpreting randomized clinical trials on the 
      secondary prevention of myocardial infarction and transient cerebral ischemic 
      attacks are discussed. With regard to acetylsalicylic acid, the dosage, and some 
      general side effects such as those observed in transfusions, are considered.
FAU - Straub, P W
AU  - Straub PW
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Das Plättchenhemmer-Problem.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Transfusion
MH  - Brain Ischemia/prevention & control
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation/*drug effects
MH  - Recurrence
MH  - Sulfinpyrazone/adverse effects/*therapeutic use
EDAT- 1981/04/04 00:00
MHDA- 1981/04/04 00:01
CRDT- 1981/04/04 00:00
PHST- 1981/04/04 00:00 [pubmed]
PHST- 1981/04/04 00:01 [medline]
PHST- 1981/04/04 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1981 Apr 4;111(14):478-82.

PMID- 29611728
OWN - NLM
STAT- MEDLINE
DCOM- 20190429
LR  - 20190429
IS  - 1029-2470 (Electronic)
IS  - 1029-2470 (Linking)
VI  - 52
IP  - 11-12
DP  - 2018 Dec
TI  - A review of the mechanism and prophylaxis of acetyl salicylic acid-induced injury 
      of the small intestine.
PG  - 1266-1270
LID - 10.1080/10715762.2018.1455003 [doi]
AB  - Besides the preventive effect of aspirin on cerebrocardiovascular diseases, 
      aspirin has adverse effects, especially on the gastrointestinal system and 
      kidneys. Especially, a recent advancement in endoscopy revealed that 
      aspirin-induced small intestinal mucosal injury is considerably higher than 
      previously believed. However, the mechanism of this phenomenon is not clear yet. 
      Moreover, effective prophylaxis does not exist. First, we investigated the 
      cytotoxic effect of aspirin on the intestinal epithelial cell line in rats at a 
      high concentration, and found that aspirin significantly decreased heat shock 
      protein 70 expression, increased reactive oxygen species production, and 
      increased epithelial cell apoptosis. These phenomena were prevented by the 
      increment of heat shock protein 70 expression. Next, we investigated the effect 
      of a lower concentration of aspirin on epithelial cell permeability, and found 
      that aspirin significantly increased reactive oxygen species production, 
      decreased tight junction protein expression, and increased epithelial 
      permeability. These phenomena were suppressed by an antioxidant. Finally, we 
      investigated the role of intestinal mucus on aspirin-induced mucosal damage using 
      an in vivo model, and found that mucus prevented a high concentration of 
      aspirin-induced mucosal damage. The investigation of chronic users of aspirin 
      revealed that mucus-increasing therapy might be useful for preventing 
      aspirin-induced small intestinal mucosal injury.
FAU - Handa, Osamu
AU  - Handa O
AD  - a Molecular Gastroenterology and Hepatology , Kyoto Prefectural University of 
      Medicine , Kyoto , Japan.
FAU - Takayama, Shun
AU  - Takayama S
AD  - a Molecular Gastroenterology and Hepatology , Kyoto Prefectural University of 
      Medicine , Kyoto , Japan.
FAU - Mukai, Rieko
AU  - Mukai R
AD  - a Molecular Gastroenterology and Hepatology , Kyoto Prefectural University of 
      Medicine , Kyoto , Japan.
FAU - Suyama, Yosuke
AU  - Suyama Y
AD  - a Molecular Gastroenterology and Hepatology , Kyoto Prefectural University of 
      Medicine , Kyoto , Japan.
FAU - Majima, Atsushi
AU  - Majima A
AD  - a Molecular Gastroenterology and Hepatology , Kyoto Prefectural University of 
      Medicine , Kyoto , Japan.
FAU - Fukui, Akifumi
AU  - Fukui A
AD  - a Molecular Gastroenterology and Hepatology , Kyoto Prefectural University of 
      Medicine , Kyoto , Japan.
FAU - Omatsu, Tatsushi
AU  - Omatsu T
AD  - b Department of Gastroenterology, Asahi University Hospital, Asahi University , 
      Gifu , Japan.
FAU - Naito, Yuji
AU  - Naito Y
AD  - a Molecular Gastroenterology and Hepatology , Kyoto Prefectural University of 
      Medicine , Kyoto , Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180403
PL  - England
TA  - Free Radic Res
JT  - Free radical research
JID - 9423872
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Aspirin/*pharmacology
MH  - Epithelial Cells/drug effects/pathology
MH  - Humans
MH  - Intestine, Small/*drug effects/pathology
OTO - NOTNLM
OT  - Acetyl salycilic acid
OT  - apoptosis
OT  - mucusIntroduction
OT  - permeability
OT  - small intestine
EDAT- 2018/04/04 06:00
MHDA- 2019/04/30 06:00
CRDT- 2018/04/04 06:00
PHST- 2018/04/04 06:00 [pubmed]
PHST- 2019/04/30 06:00 [medline]
PHST- 2018/04/04 06:00 [entrez]
AID - 10.1080/10715762.2018.1455003 [doi]
PST - ppublish
SO  - Free Radic Res. 2018 Dec;52(11-12):1266-1270. doi: 10.1080/10715762.2018.1455003. 
      Epub 2018 Apr 3.

PMID- 8446967
OWN - NLM
STAT- MEDLINE
DCOM- 19930402
LR  - 20220311
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 24
IP  - 3
DP  - 1993 Mar
TI  - Aspirin response and failure in cerebral infarction.
PG  - 345-50
AB  - BACKGROUND AND PURPOSE: The purpose of this study was to assess the biological 
      effect of aspirin as measured by the inhibition of platelet aggregation in 
      patients taking aspirin for stroke prevention and in patients with acute stroke. 
      METHODS: We administered increasing doses of aspirin (325, 650, 975, and 1,300 mg 
      daily) to 113 patients for stroke prevention and measured the inhibition of 
      platelet aggregation in these patients and in 33 patients with acute stroke 
      taking aspirin before stroke onset. RESULTS: Eighty-five patients on < or = 325 
      and six on > or = 650 mg aspirin had complete inhibition of platelet aggregation. 
      Increase of the dose by 325 mg in nine of the 22 patients with partial inhibition 
      of platelet aggregation produced complete inhibition in five patients at 650 mg 
      and in one at 975 mg. At 1,300 mg, three patients still had only partial 
      inhibition of platelet aggregation (aspirin resistance). Of the 33 inpatients 
      with acute stroke, 24 had platelet aggregation studies done before further 
      administration of aspirin. Of these, 19 had complete inhibition of platelet 
      aggregation and three had partial inhibition, with production of complete 
      inhibition of platelet aggregation at dose escalation; one patient was 
      aspirin-resistant and the other noncompliant. CONCLUSIONS: How the inhibition of 
      platelet aggregation relates to stroke prevention remains unclear. The ability of 
      aspirin and the dose required to inhibit platelet aggregation may depend upon the 
      individual.
FAU - Helgason, C M
AU  - Helgason CM
AD  - Department of Neurology, University of Illinois, Chicago College of Medicine 
      60612.
FAU - Tortorice, K L
AU  - Tortorice KL
FAU - Winkler, S R
AU  - Winkler SR
FAU - Penney, D W
AU  - Penney DW
FAU - Schuler, J J
AU  - Schuler JJ
FAU - McClelland, T J
AU  - McClelland TJ
FAU - Brace, L D
AU  - Brace LD
LA  - eng
GR  - R01ND27863-01/ND/ONDIEH CDC HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 1993 Aug;24(8):1259-61. PMID: 8342203
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
EDAT- 1993/03/01 00:00
MHDA- 1993/03/01 00:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 1993/03/01 00:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
AID - 10.1161/01.str.24.3.345 [doi]
PST - ppublish
SO  - Stroke. 1993 Mar;24(3):345-50. doi: 10.1161/01.str.24.3.345.

PMID- 32626731
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20220415
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2020
DP  - 2020
TI  - Aspirin Administration Affects Neurochemical Characterization of Substance P-Like 
      Immunoreactive (SP-LI) Nodose Ganglia Neurons Supplying the Porcine Stomach.
PG  - 1049179
LID - 10.1155/2020/1049179 [doi]
LID - 1049179
AB  - BACKGROUND: Acetylsalicylic acid (ASA) is a commonly used anti-inflammatory, 
      antipyretic, and analgesic drug, which has many side effects on the gastric 
      mucosal layer. Despite this, knowledge concerning the influence of ASA on 
      neuronal cells supplying the stomach is very scanty. METHODS: This investigation 
      was performed on ten immature gilts of the Large White Polish race divided into 
      two groups (five animals in each): a control group and animals which were treated 
      with ASA. The retrograde neuronal tracer Fast Blue (FB) was injected into the 
      prepyloric region of the stomach in all animals. ASA was then given orally to the 
      experimental (ASA) group of gilts from the seventh day after FB injection to the 
      27th day of the experiment. After this period, all animals were euthanized. 
      Immediately after euthanasia, nodose ganglia (NG) were collected and subjected to 
      a standard double-labelling immunofluorescence technique using antibodies 
      directed toward substance P (SP) and other selected neuronal factors, such as 
      galanin (GAL), neuronal isoform of nitric oxide synthase (nNOS), vasoactive 
      intestinal polypeptide (VIP), and calcitonin gene-related peptide (CGRP). Key 
      Results. The obtained results show that SP-LI neurons located in NG supplying the 
      porcine stomach were also immunoreactive to all the above-mentioned neuronal 
      factors. Moreover, ASA administration caused an increase in the degree of 
      colocalization of SP with other neuronal active substances, and the most visible 
      changes concerned the number of neurons simultaneously immunoreactive to SP and 
      CGRP. Conclusions and Inferences. These observations indicate that the population 
      of SP-LI neurons supplying the stomach is not homogeneous and may undergo changes 
      after ASA administration. These changes are probably connected with inflammatory 
      processes and/or neuroprotective reactions although their exact mechanisms remain 
      unknown.
CI  - Copyright © 2020 Liliana Rytel and Jarosław Całka.
FAU - Rytel, Liliana
AU  - Rytel L
AUID- ORCID: 0000-0001-5762-9908
AD  - Department of Internal Disease with Clinic, Faculty of Veterinary Medicine, 
      University of Warmia and Mazury, Poland.
FAU - Całka, Jarosław
AU  - Całka J
AUID- ORCID: 0000-0003-4679-5737
AD  - Department of Clinical Physiology, Faculty of Veterinary Medicine, University of 
      Warmia and Mazury, Poland.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Neuropeptides)
RN  - 33507-63-0 (Substance P)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Female
MH  - Neuropeptides/metabolism
MH  - Nodose Ganglion/chemistry/*drug effects
MH  - Stomach/chemistry/*innervation
MH  - Substance P/*metabolism
MH  - Swine
PMC - PMC7306837
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/07/07 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/07/07 06:00
PHST- 2019/09/15 00:00 [received]
PHST- 2020/04/09 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
AID - 10.1155/2020/1049179 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Jun 12;2020:1049179. doi: 10.1155/2020/1049179. eCollection 
      2020.

PMID- 34717789
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20211102
IS  - 2639-9636 (Print)
IS  - 2639-9636 (Linking)
VI  - 36
IP  - 11
DP  - 2021 Nov 1
TI  - Evaluation of Provider Implementation of the 2019 American College of Cardiology 
      and American Heart Association Aspirin for Primary Prevention Guideline 
      Recommendations for Older People.
PG  - 573-579
LID - 10.4140/TCP.n.2021.573 [doi]
AB  - Design Retrospective chart review study using electronic medical record data from 
      Inova Health System patients. Setting All cardiology, endocrinology, and primary 
      care outpatient clinics operated by Inova Medical Group (IMG) in Northern 
      Virginia. Participants Participants included were 70 years of age or older and 
      taking aspirin 81 mg as of April 1, 2019. They had completed at least one visit 
      with an IMG provider in primary care, cardiology, or endocrinology clinics 
      between April 1, 2019, and February 17, 2020. Main Outcome Measures The primary 
      outcome of this study was percentage of older people seen by a primary care 
      physician, cardiologist, or endocrinologist since guideline publication who were 
      continued on aspirin for primary prevention. Results The percentage of 
      participants continued on aspirin for primary prevention was 92% versus 8.0% who 
      were discontinued (P < 0.0001). Differences in subgroup analyses based on smoking 
      history, diagnosis of diabetes, or history of venous thromboembolism were not 
      statistically significant. Conclusion There was a significantly greater rate of 
      aspirin continuation versus discontinuation among patients 70 years of age and 
      older in the setting of primary cardiovascular prevention. Based on this result, 
      most primary care physicians, endocrinologists, and cardiologists at this 
      institution have chosen to continue aspirin in older people following the 2019 
      American College of Cardiology/American Heart Association guideline statement 
      publication.
FAU - Prather, Caitlin S
AU  - Prather CS
AD  - 1 Inova Health System, Fairfax, Virginia.
FAU - Adams, Erin N
AU  - Adams EN
AD  - 2 Shenandoah University, Fairfax, Virginia.
FAU - Zentgraf, Whitney
AU  - Zentgraf W
AD  - 3 Bon Secours Mercy Health, Richmond, Virginia.
FAU - Puhl, Jonathan
AU  - Puhl J
AD  - 1 Inova Health System, Fairfax, Virginia.
FAU - Barnett, Scott
AU  - Barnett S
AD  - 1 Inova Health System, Fairfax, Virginia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Sr Care Pharm
JT  - The Senior care pharmacist
JID - 101737969
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *American Heart Association
MH  - Aspirin/therapeutic use
MH  - *Cardiology
MH  - Humans
MH  - Primary Prevention
MH  - Retrospective Studies
MH  - United States/epidemiology
EDAT- 2021/11/01 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/10/31 20:40
PHST- 2021/10/31 20:40 [entrez]
PHST- 2021/11/01 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
AID - 10.4140/TCP.n.2021.573 [doi]
PST - ppublish
SO  - Sr Care Pharm. 2021 Nov 1;36(11):573-579. doi: 10.4140/TCP.n.2021.573.

PMID- 3258124
OWN - NLM
STAT- MEDLINE
DCOM- 19880420
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 84
IP  - 2A
DP  - 1988 Feb 22
TI  - Role of H2-receptor blockers in the prevention of gastric injury resulting from 
      nonsteroidal anti-inflammatory agents.
PG  - 49-52
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) can produce injury to the gastric 
      and duodenal mucosa. The histamine (H2)-receptor blocker cimetidine was studied 
      to determine whether protection of the gastric mucosa of normal volunteers could 
      be provided against a single dose of aspirin, 1,300 mg. Gastric mucosal injury 
      was assessed with gastroscopy performed two hours after aspirin intake. Three 
      liquid cimetidine doses were administered over 24 hours prior to the aspirin 
      dose, the last dose one hour before the aspirin. The 200-mg and 400-mg doses of 
      cimetidine protected a sufficient number of subjects to warrant further study. In 
      the second study, these two doses were further examined to determine whether 
      three doses were necessary and whether the final dose could be coadministered 
      with the aspirin instead of one hour before. Concomitant administration of a 
      single dose of cimetidine with aspirin was found to protect the gastric mucosa 
      from aspirin damage as effectively as the other cimetidine regimens employed. A 
      final, double-blind comparison of cimetidine, 200 mg, with placebo administered 
      with the aspirin, 1,300 mg, confirmed that cimetidine protected the gastric 
      mucosa from the hemorrhagic effects of aspirin.
FAU - Kimmey, M B
AU  - Kimmey MB
AD  - Department of Medicine, University of Washington, Seattle 98195.
FAU - Silverstein, F E
AU  - Silverstein FE
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 80061L1WGD (Cimetidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*antagonists & inhibitors/toxicity
MH  - Cimetidine/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Gastric Mucosa/*drug effects
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Gastroscopy
MH  - Humans
MH  - Male
EDAT- 1988/02/22 00:00
MHDA- 1988/02/22 00:01
CRDT- 1988/02/22 00:00
PHST- 1988/02/22 00:00 [pubmed]
PHST- 1988/02/22 00:01 [medline]
PHST- 1988/02/22 00:00 [entrez]
AID - 0002-9343(88)90254-9 [pii]
AID - 10.1016/0002-9343(88)90254-9 [doi]
PST - ppublish
SO  - Am J Med. 1988 Feb 22;84(2A):49-52. doi: 10.1016/0002-9343(88)90254-9.

PMID- 17196475
OWN - NLM
STAT- MEDLINE
DCOM- 20070208
LR  - 20131121
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 99
IP  - 1
DP  - 2007 Jan 1
TI  - Effect of ranitidine on the antiplatelet effects of aspirin in healthy human 
      subjects.
PG  - 124-8
AB  - Aspirin is often taken with H2-receptor antagonists. In vitro data suggest that 
      certain antagonists, such as ranitidine, have inhibitory effects on platelet 
      function. There are no reports on the combined effect of aspirin and H2-receptor 
      antagonists on platelet function in humans. Therefore, this study's aim was to 
      evaluate the effects of aspirin, ranitidine, and their combination on platelet 
      function in humans. Ten healthy men aged 34.7 +/- 2 years received aspirin 325 
      mg/day for 4 days followed by a 9-day washout period, 3 days of ranitidine 
      treatment (150 mg twice daily), and 4 days of dual-drug treatment. Blood samples 
      were drawn at baseline and on the last days of aspirin monotherapy, the washout 
      period, ranitidine monotherapy, and dual-drug treatment. Platelet aggregation was 
      measured in response to 0.5 mg/ml arachidonic acid, 5 and 10 mumol/L adenosine 
      diphosphate, and 1 micro g/ml collagen. The Platelet Function Analyzer 100 test 
      was performed, and blood salicylate levels were measured in 6 subjects. Aspirin 
      caused a marked reduction in platelet aggregation and prolongation of Platelet 
      Function Analyzer 100 closure time. Ranitidine caused a modest decrease in 
      platelet aggregation. Unexpectedly, the combination of aspirin and ranitidine 
      caused less inhibition of platelet aggregation and prolongation of Platelet 
      Function Analyzer 100 time than aspirin alone (p = 0.02 to 0.07 compared with 
      aspirin alone). Blood salicylate levels were lower when subjects took aspirin 
      with ranitidine than when they took aspirin alone (1 +/- 0.8 vs 1.6 +/- 0.7 
      mg/dl, p = 0.005). In conclusion, ranitidine appears to attenuate the 
      antiplatelet effects of aspirin in healthy volunteers. The most likely mechanism 
      for these findings is a change in the absorption conditions of aspirin in the 
      presence of ranitidine.
FAU - Lev, Eli I
AU  - Lev EI
AD  - The Methodist Hospital Research Institute and The Methodist DeBakey Heart Center, 
      The Methodist Hospital, Houston, TX, USA.
FAU - Ramabadran, Ramanujam S
AU  - Ramabadran RS
FAU - Guthikonda, Sasidhar
AU  - Guthikonda S
FAU - Patel, Rajnikant
AU  - Patel R
FAU - Kleiman, Amanda
AU  - Kleiman A
FAU - Granada, Juan F
AU  - Granada JF
FAU - DeLao, Timothy
AU  - DeLao T
FAU - Kleiman, Neal S
AU  - Kleiman NS
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20061109
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 884KT10YB7 (Ranitidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Histamine H2 Antagonists/administration & dosage/*pharmacology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Ranitidine/administration & dosage/*pharmacology
EDAT- 2007/01/02 09:00
MHDA- 2007/02/09 09:00
CRDT- 2007/01/02 09:00
PHST- 2006/05/26 00:00 [received]
PHST- 2006/07/13 00:00 [revised]
PHST- 2006/07/13 00:00 [accepted]
PHST- 2007/01/02 09:00 [pubmed]
PHST- 2007/02/09 09:00 [medline]
PHST- 2007/01/02 09:00 [entrez]
AID - S0002-9149(06)01828-5 [pii]
AID - 10.1016/j.amjcard.2006.07.074 [doi]
PST - ppublish
SO  - Am J Cardiol. 2007 Jan 1;99(1):124-8. doi: 10.1016/j.amjcard.2006.07.074. Epub 
      2006 Nov 9.

PMID- 25475646
OWN - NLM
STAT- MEDLINE
DCOM- 20150930
LR  - 20161126
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1848
IP  - 3
DP  - 2015 Mar
TI  - Aspirin inhibits formation of cholesterol rafts in fluid lipid membranes.
PG  - 805-12
LID - S0005-2736(14)00422-2 [pii]
LID - 10.1016/j.bbamem.2014.11.023 [doi]
AB  - Aspirin and other non-steroidal anti-inflammatory drugs have a high affinity for 
      phospholipid membranes, altering their structure and biophysical properties. 
      Aspirin has been shown to partition into the lipid head groups, thereby 
      increasing membrane fluidity. Cholesterol is another well known mediator of 
      membrane fluidity, in turn increasing membrane stiffness. As well, cholesterol is 
      believed to distribute unevenly within lipid membranes leading to the formation 
      of lipid rafts or plaques. In many studies, aspirin has increased positive 
      outcomes for patients with high cholesterol. We are interested if these effects 
      may be, at least partially, the result of a non-specific interaction between 
      aspirin and cholesterol in lipid membranes. We have studied the effect of aspirin 
      on the organization of 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) 
      membranes containing cholesterol. Through Langmuir-Blodgett experiments we show 
      that aspirin increases the area per lipid and decreases compressibility at 32.5 
      mol% cholesterol, leading to a significant increase of fluidity of the membranes. 
      Differential scanning calorimetry provides evidence for the formation of 
      meta-stable structures in the presence of aspirin. The molecular organization of 
      lipids, cholesterol and aspirin was studied using neutron diffraction. While the 
      formation of rafts has been reported in binary DPPC/cholesterol membranes, 
      aspirin was found to locally disrupt membrane organization and lead to the 
      frustration of raft formation. Our results suggest that aspirin is able to 
      directly oppose the formation of cholesterol structures through non-specific 
      interactions with lipid membranes.
CI  - Copyright © 2014 Elsevier B.V. All rights reserved.
FAU - Alsop, Richard J
AU  - Alsop RJ
AD  - Department of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.
FAU - Toppozini, Laura
AU  - Toppozini L
AD  - Department of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.
FAU - Marquardt, Drew
AU  - Marquardt D
AD  - Department of Physics, Brock University, St. Catharines, ON, Canada.
FAU - Kučerka, Norbert
AU  - Kučerka N
AD  - Canadian Neutron Beam Centre, Chalk River, ON, Canada; Department of Physical 
      Chemistry of Drugs, Comenius University, Bratislava, Slovakia; Frank Laboratory 
      of Neutron Physics, Joint Institute for Nuclear Research, Dubna, Russia.
FAU - Harroun, Thad A
AU  - Harroun TA
AD  - Department of Physics, Brock University, St. Catharines, ON, Canada.
FAU - Rheinstädter, Maikel C
AU  - Rheinstädter MC
AD  - Department of Physics and Astronomy, McMaster University, Hamilton, ON, Canada; 
      Canadian Neutron Beam Centre, Chalk River, ON, Canada. Electronic address: 
      rheinstadter@mcmaster.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141202
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipid Bilayers)
RN  - 0 (Membrane Lipids)
RN  - 2644-64-6 (1,2-Dipalmitoylphosphatidylcholine)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 1,2-Dipalmitoylphosphatidylcholine/chemistry
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/pharmacology
MH  - Aspirin/*chemistry/pharmacology
MH  - Calorimetry, Differential Scanning
MH  - Cell Membrane/chemistry/drug effects
MH  - Cholesterol/*chemistry
MH  - Humans
MH  - Kinetics
MH  - Lipid Bilayers/*chemistry
MH  - Membrane Fluidity
MH  - Membrane Lipids/*chemistry
MH  - Membrane Microdomains/*chemistry
MH  - Models, Chemical
MH  - Models, Molecular
MH  - Molecular Structure
MH  - Neutron Diffraction
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirin–cholesterol interaction
OT  - Cholesterol
OT  - Cholesterol rafts
OT  - Lipid membranes
EDAT- 2014/12/06 06:00
MHDA- 2015/10/01 06:00
CRDT- 2014/12/06 06:00
PHST- 2014/08/21 00:00 [received]
PHST- 2014/11/18 00:00 [revised]
PHST- 2014/11/19 00:00 [accepted]
PHST- 2014/12/06 06:00 [entrez]
PHST- 2014/12/06 06:00 [pubmed]
PHST- 2015/10/01 06:00 [medline]
AID - S0005-2736(14)00422-2 [pii]
AID - 10.1016/j.bbamem.2014.11.023 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2015 Mar;1848(3):805-12. doi: 10.1016/j.bbamem.2014.11.023. 
      Epub 2014 Dec 2.

PMID- 11727969
OWN - NLM
STAT- MEDLINE
DCOM- 20020510
LR  - 20131121
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 39
IP  - 11
DP  - 2001 Nov
TI  - Co- and multimedication in users of ASA and vitamin E drugs in the Federal 
      Republic of Germany. Results of the Federal Health Surveys 1984-1999.
PG  - 488-91
AB  - OBJECTIVE: Because ASA- and vitamin E-drugs belong to the most used 
      OTC-medications and adverse drug reactions are depending on the quantity and type 
      of comedication we describe the pattern of usage for ASA- and vitamin E-drugs 
      along with the total drug consumption in Germany. STUDY POPULATION, MATERIAL AND 
      METHODS: Study participants (n = 22.560) were screened in five German health 
      surveys (1984-1999). Total drug usage was monitored with a standardized 
      questionnaire. Blood and serum samples were examined for clinical chemistry and 
      hematological data as well as for selected active substances of drugs. The 
      tocopherols and salicylic acid as the main metabolite of ASA were measured by 
      HPLC in serum samples. RESULTS: The incidence of OTC-drug usage is high in our 
      population. The salicylic acid concentration in the serum samples depends clearly 
      on the reason of usage and remains fairly stable for analgesic use but decreases 
      steadily from 1984 to 1999 for use as antiplatelet drug due to formulations with 
      lower amount of ASA/tablet. The serum concentration of alpha-tocopherol was 
      steadily increasing in users of vitamin E-drugs as well as in no-drug-users. 
      CONCLUSION: Because the frequency of comedication is very high, the risk of 
      adverse drug reactions seems to be a problem that should be considered more 
      seriously by physicians.
FAU - Melchert, H U
AU  - Melchert HU
AD  - Robert Koch Institute, Pharmacoepidemiology Group, Berlin, Germany. 
      MelchertH@rki.de
FAU - Knopf, H
AU  - Knopf H
FAU - Pabel, E
AU  - Pabel E
FAU - Braemer-Hauth, M
AU  - Braemer-Hauth M
FAU - Du, Y
AU  - Du Y
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/blood/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Drug Utilization
MH  - Female
MH  - Germany, West
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Vitamin E/blood/*therapeutic use
EDAT- 2001/12/01 10:00
MHDA- 2002/05/11 10:01
CRDT- 2001/12/01 10:00
PHST- 2001/12/01 10:00 [pubmed]
PHST- 2002/05/11 10:01 [medline]
PHST- 2001/12/01 10:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2001 Nov;39(11):488-91.

PMID- 2880743
OWN - NLM
STAT- MEDLINE
DCOM- 19870330
LR  - 20181217
IS  - 0232-7384 (Print)
IS  - 0232-7384 (Linking)
VI  - 88
IP  - 1
DP  - 1986 Nov
TI  - The effect of lysine acetylsalicylate on somatostatin inhibition of insulin 
      secretion induced by arginine.
PG  - 119-22
AB  - The inhibitory effect of somatostatin (SRIF) on immunoreactive insulin release 
      and on many other hormonal secretions has been widely studied in both animal and 
      man. However, the mechanism by which SRIF acts on these functions remains poorly 
      defined. Aim of this study is to determine the inhibitory effect of SRIF on 
      insulin secretion induced by arginine after the administration of lysine 
      acetylsalicylate (LAS) in a dose which inhibits the endogenous synthesis of 
      prostaglandins. Ten healthy informed volunteer subjects were studied. Four 
      studies were carried out in randomized order, each one separated by a three day 
      interval. The first study was a test of arginine (25 g i.v. in 30 min). The 
      second study was a test of arginine with SRIF infusion (150 micrograms bolus 
      followed by 100 micrograms/h for 120 min). The third study was a test of arginine 
      with an infusion of SRIF and LAS (66 mg/min for 120 min). The fourth study was a 
      test of arginine with LAS infusion. Plasma insulin levels were determined by 
      radioimmunoassay. After arginine administration the typical biphasic insulin 
      response was observed with a precocious peak at 3 min and a late peak at 30 min. 
      This response is not significantly modified under LAS infusion. With the infusion 
      of SRIF at a dose of 100 micrograms/hr after arginine administration only a very 
      modest insulin response was observed. The addition of LAS does not modify the 
      inhibitory effect of SRIF on insulin secretion induced by arginine. This result 
      demonstrates that the inhibitory action of SRIF on the secretion of insulin is 
      not dependent upon the activation of the endocellular prostaglandin system.
FAU - Altomonte, L
AU  - Altomonte L
FAU - Zoli, A
AU  - Zoli A
FAU - Accili, D
AU  - Accili D
FAU - Ghirlanda, G
AU  - Ghirlanda G
FAU - Manna, R
AU  - Manna R
FAU - Bertoli, A
AU  - Bertoli A
FAU - Greco, A V
AU  - Greco AV
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Exp Clin Endocrinol
JT  - Experimental and clinical endocrinology
JID - 8302802
RN  - 0 (Insulin)
RN  - 0 (Prostaglandins)
RN  - 51110-01-1 (Somatostatin)
RN  - 94ZLA3W45F (Arginine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Arginine/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Humans
MH  - Insulin/*metabolism
MH  - Insulin Secretion
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Prostaglandins/physiology
MH  - Secretory Rate/drug effects
MH  - Somatostatin/*pharmacology
EDAT- 1986/11/01 00:00
MHDA- 1986/11/01 00:01
CRDT- 1986/11/01 00:00
PHST- 1986/11/01 00:00 [pubmed]
PHST- 1986/11/01 00:01 [medline]
PHST- 1986/11/01 00:00 [entrez]
AID - 10.1055/s-0029-1210586 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol. 1986 Nov;88(1):119-22. doi: 10.1055/s-0029-1210586.

PMID- 36692333
OWN - NLM
STAT- MEDLINE
DCOM- 20230316
LR  - 20230316
IS  - 1099-0801 (Electronic)
IS  - 0269-3879 (Linking)
VI  - 37
IP  - 4
DP  - 2023 Apr
TI  - An effective and stability-indicating method development and optimization 
      utilizing the Box-Behnken design for the simultaneous determination of 
      acetaminophen, caffeine, and aspirin in tablet formulation.
PG  - e5585
LID - 10.1002/bmc.5585 [doi]
AB  - Analytical techniques must be sensitive, specific, and accurate to assess the 
      active pharmaceutical ingredients in pharmaceutical dosage forms. The 
      quality-by-design (QbD) application has proven to be a practical method for 
      magnifying HPLC operations. This article discusses the successfully developed 
      QbD-based stability-indicative LC method for evaluating acetaminophen, caffeine, 
      and aspirin (ASP) in tablet dosage form. To achieve the necessary chromatographic 
      separation, Milli-Q water, methanol, and glacial acetic acid were employed in the 
      following ratios: 63:35:2 (v/v/v) for mobile phase A and 18:80:2 (v/v/v) for 
      mobile phase B. The flow rate, column temperature, and detecting wavelength were 
      1.0 ml/min, 40°C, and 275 nm, respectively, and an InertSustain C18 analytical 
      column (150 × 4.6 mm, 3 μm) was used. Linearity was between 10.0 and 150.0 μg/ml 
      for ASP and acetaminophen and between 2.6 and 39.0 μg/ml for caffeine. The 
      accuracy findings were more than 97%, and the correlation coefficient for all 
      three components was found to be greater than 0.999. The validated HPLC method 
      yielded reliable and accurate results. ASP was shown to be vulnerable to both 
      acid and alkaline hydrolysis in the forced degradation study. The described 
      method is capable of separating the degradants produced during stress testing and 
      is regarded as stability indicating. The proposed method can be used for a wider 
      range of other formulations with an appropriate diluent selection and sample 
      preparation procedure optimization.
CI  - © 2023 John Wiley & Sons, Ltd.
FAU - Yenda, Parvateesam
AU  - Yenda P
AD  - Department of Chemistry, School of Science, GITAM Deemed to Be University, 
      Hyderabad, India.
FAU - Katari, Naresh Kumar
AU  - Katari NK
AUID- ORCID: 0000-0002-5737-8528
AD  - Department of Chemistry, School of Science, GITAM Deemed to Be University, 
      Hyderabad, India.
FAU - Ettaboina, Santhosh Kumar
AU  - Ettaboina SK
AUID- ORCID: 0000-0002-7094-9161
AD  - Department of Quality Control, Aurex Laboratories LLC, East Windsor, New Jersey, 
      USA.
FAU - Satheesh, Balasubramanian
AU  - Satheesh B
AD  - Analytical Research and Development, Slayback Pharma India LLP, Manjeera Trinity 
      Corporate, JNTU, Hyderabad, India.
FAU - Muchakayala, Siva Krishna
AU  - Muchakayala SK
AUID- ORCID: 0000-0002-1171-5189
AD  - Analytical Research and Development, Catalent Pharma Solutions, 1100 Enterprise 
      Dr, Winchester, Kentucky, 40391, USA.
FAU - Gundla, Rambabu
AU  - Gundla R
AUID- ORCID: 0000-0003-0390-6505
AD  - Department of Chemistry, School of Science, GITAM Deemed to Be University, 
      Hyderabad, India.
LA  - eng
GR  - GITAM University/
PT  - Journal Article
DEP - 20230211
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acetaminophen/analysis
MH  - *Caffeine/analysis
MH  - Tablets/chemistry
MH  - Chromatography, High Pressure Liquid/methods
MH  - Aspirin/analysis
OTO - NOTNLM
OT  - Box-Behnken design
OT  - acetaminophen
OT  - aspirin
OT  - caffeine
OT  - simultaneous determination
EDAT- 2023/01/25 06:00
MHDA- 2023/03/17 06:00
CRDT- 2023/01/24 09:22
PHST- 2023/01/02 00:00 [revised]
PHST- 2022/12/19 00:00 [received]
PHST- 2023/01/11 00:00 [accepted]
PHST- 2023/01/25 06:00 [pubmed]
PHST- 2023/03/17 06:00 [medline]
PHST- 2023/01/24 09:22 [entrez]
AID - 10.1002/bmc.5585 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2023 Apr;37(4):e5585. doi: 10.1002/bmc.5585. Epub 2023 Feb 11.

PMID- 25220474
OWN - NLM
STAT- MEDLINE
DCOM- 20150528
LR  - 20140923
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 12
IP  - 10
DP  - 2014 Oct
TI  - Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, 
      interactions and cardiovascular outcomes.
PG  - 1185-203
LID - 10.1586/14779072.2014.964687 [doi]
AB  - NSAIDs are used worldwide by more than 30 million people everyday, given their 
      anti-inflammatory, analgesic and antipyretic effects. NSAIDs are approved for 
      several common adult diseases, including acute and chronic musculoskeletal or 
      inflammatory disease, osteoarthritis, rheumatoid arthritis and other arthritic 
      conditions, as well as for children with juvenile idiopathic arthritis. 
      Importantly, the population commonly taking NSAIDs is that of older individuals 
      who also represent the population with the highest risk for cardiovascular (CV) 
      and gastrointestinal adverse effects. In recent years, a growing body of evidence 
      regarding potential risks from chronic use of NSAIDs has emerged. The aim of this 
      review is to update the available data concerning chronic use of NSAIDs in 
      patients with and without CV disease by analyzing the mechanisms of action, the 
      interference of specific NSAIDs with the established CV protective role of 
      low-dose aspirin, and the potential increased risk of myocardial infarction, 
      stroke, hypertension, heart failure and atrial fibrillation.
FAU - Gargiulo, Giuseppe
AU  - Gargiulo G
AD  - Division of Cardiology, Ferrarotto Hospital, University of Catania, Via Citelli 
      6, 95124 Catania, Italy.
FAU - Capodanno, Davide
AU  - Capodanno D
FAU - Longo, Giovanni
AU  - Longo G
FAU - Capranzano, Piera
AU  - Capranzano P
FAU - Tamburino, Corrado
AU  - Tamburino C
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140915
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/*chemically induced/epidemiology/physiopathology
MH  - Coronary Artery Disease/*complications
MH  - Drug Interactions
MH  - Humans
MH  - Risk
OTO - NOTNLM
OT  - aspirin interaction
OT  - atrial fibrillation
OT  - cardiovascular disease
OT  - heart failure
OT  - hypertension
OT  - myocardial infarction
OT  - non-steroidal anti-inflammatory drugs
OT  - risk
OT  - stroke
EDAT- 2014/09/16 06:00
MHDA- 2015/05/29 06:00
CRDT- 2014/09/16 06:00
PHST- 2014/09/16 06:00 [entrez]
PHST- 2014/09/16 06:00 [pubmed]
PHST- 2015/05/29 06:00 [medline]
AID - 10.1586/14779072.2014.964687 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1185-203. doi: 
      10.1586/14779072.2014.964687. Epub 2014 Sep 15.

PMID- 30056389
OWN - NLM
STAT- MEDLINE
DCOM- 20191022
LR  - 20191022
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 8
IP  - 7
DP  - 2018 Jul 28
TI  - Trial of feasibility and acceptability of routine low-dose aspirin versus Early 
      Screening Test indicated aspirin for pre-eclampsia prevention (TEST study): a 
      multicentre randomised controlled trial.
PG  - e022056
LID - 10.1136/bmjopen-2018-022056 [doi]
LID - e022056
AB  - OBJECTIVE: Evaluate the feasibility and acceptability of routine aspirin in 
      low-risk women, compared with screening-test indicated aspirin for the prevention 
      of pre-eclampsia and fetal growth restriction. DESIGN: Multicentre open-label 
      feasibility randomised controlled trial. SETTING: Two tertiary maternity 
      hospitals in Dublin, Ireland. PARTICIPANTS: 546 low-risk nulliparous women 
      completed the study. INTERVENTIONS: Women underwent computerised randomisation 
      to: Group 1-routine aspirin 75 mg from 11 until 36 weeks; Group 2-no aspirin and; 
      Group 3-aspirin based on the Fetal Medicine Foundation screening test. PRIMARY 
      AND SECONDARY OUTCOME MEASURES: (1) Proportion agreeing to participate; (2) 
      compliance with protocol; (3) proportion where first trimester uterine artery 
      Doppler was obtainable and; (4) time taken to issue a screening result. Secondary 
      outcomes included rates of pre-eclampsia and small-for-gestational-age fetuses. 
      RESULTS: 546 were included in the routine aspirin (n=179), no aspirin (n=183) and 
      screen and treat (n=184) groups. 546 of 1054 were approached (51.8%) and 
      enrolled. Average aspirin adherence was 90%. The uterine artery Doppler was 
      obtained in 98.4% (181/184) and the average time to obtain a screening result was 
      7.6 (0-26) days. Of those taking aspirin, vaginal spotting was greater; n=29 
      (15.1%), non-aspirin n=28 (7.9%), OR 2.1 (95% CI 1.2 to 3.6). Postpartum 
      haemorrhage >500 mL was also greater; aspirin n=26 (13.5%), no aspirin n=20 
      (5.6%), OR 2.6 (95% CI 1.4 to 4.8). CONCLUSION: Low-risk nulliparous women are 
      open to taking aspirin in pregnancy and had high levels of adherence. Aspirin use 
      was associated with greater rates of vaginal bleeding. An appropriately powered 
      randomised controlled trial is now required to address the efficacy and safety of 
      universal low-dose aspirin in low-risk pregnancy compared with a screening 
      approach. TRIAL REGISTRATION NUMBER: ISRCTN (15191778); Post-results.
CI  - © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mone, Fionnuala
AU  - Mone F
AD  - UCD Perinatal Research Centre, School of Medicine, University College Dublin, 
      National Maternity Hospital, Dublin, Ireland.
FAU - Mulcahy, Cecilia
AU  - Mulcahy C
AD  - UCD Perinatal Research Centre, School of Medicine, University College Dublin, 
      National Maternity Hospital, Dublin, Ireland.
FAU - McParland, Peter
AU  - McParland P
AD  - UCD Perinatal Research Centre, School of Medicine, University College Dublin, 
      National Maternity Hospital, Dublin, Ireland.
FAU - Breathnach, Fionnuala
AU  - Breathnach F
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - Downey, Paul
AU  - Downey P
AD  - Department of Pathology and Laboratory Medicine, National Maternity Hospital, 
      Dublin, Ireland.
FAU - McCormack, Dorothy
AU  - McCormack D
AD  - Department of Pharmacy, National Maternity Hospital, Dublin, Ireland.
FAU - Culliton, Marie
AU  - Culliton M
AD  - Department of Pathology and Laboratory Medicine, National Maternity Hospital, 
      Dublin, Ireland.
FAU - Stanton, Alice
AU  - Stanton A
AD  - Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 
      Dublin, Ireland.
FAU - Cody, Fiona
AU  - Cody F
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - Morrison, John J
AU  - Morrison JJ
AD  - Department of Obstetrics and Gynaecology, National University of Ireland, Galway, 
      Ireland.
FAU - Daly, Sean
AU  - Daly S
AD  - Department of Obstetrics and Gynaecology, Coombe Women's and Infant's University 
      Hospital, Dublin, Ireland.
FAU - Higgins, John
AU  - Higgins J
AD  - Department of Obstetrics and Gynaecology, University College Cork, Cork, Ireland.
FAU - Cotter, Amanda
AU  - Cotter A
AD  - Department of Obstetrics and Gynaecology, Graduate Entry Medical School, 
      University of Limerick, Limerick, Ireland.
FAU - Hunter, Alyson
AU  - Hunter A
AD  - Royal Jubilee Maternity Hospital, Belfast, UK.
FAU - Tully, Elizabeth C
AU  - Tully EC
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - Dicker, Patrick
AU  - Dicker P
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - Alfirevic, Zarko
AU  - Alfirevic Z
AD  - Department of Women's and Children's Health, Institute of Translational Medicine, 
      University of Liverpool, Liverpool, UK.
FAU - Malone, Fergal D
AU  - Malone FD
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - McAuliffe, Fionnuala M
AU  - McAuliffe FM
AD  - UCD Perinatal Research Centre, School of Medicine, University College Dublin, 
      National Maternity Hospital, Dublin, Ireland.
LA  - eng
SI  - ISRCTN/ISRCTN 15191778
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180728
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - *Chemoprevention
MH  - Feasibility Studies
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Ireland
MH  - Medication Adherence/statistics & numerical data
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - *Prenatal Care
MH  - Risk Factors
MH  - Treatment Outcome
MH  - *Ultrasonography, Doppler
MH  - Uterine Artery/*diagnostic imaging
PMC - PMC6067363
OTO - NOTNLM
OT  - aspirin
OT  - feasibility
OT  - low risk
OT  - preeclampsia
OT  - screening
COIS- Competing interests: None declared.
EDAT- 2018/07/30 06:00
MHDA- 2019/10/23 06:00
CRDT- 2018/07/30 06:00
PHST- 2018/07/30 06:00 [entrez]
PHST- 2018/07/30 06:00 [pubmed]
PHST- 2019/10/23 06:00 [medline]
AID - bmjopen-2018-022056 [pii]
AID - 10.1136/bmjopen-2018-022056 [doi]
PST - epublish
SO  - BMJ Open. 2018 Jul 28;8(7):e022056. doi: 10.1136/bmjopen-2018-022056.

PMID- 24043375
OWN - NLM
STAT- MEDLINE
DCOM- 20150212
LR  - 20211021
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 37
IP  - 4
DP  - 2014 May
TI  - Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey 
      ventricular assist device.
PG  - 499-506
LID - 10.1007/s11239-013-0997-6 [doi]
AB  - Ventricular assist devices (VADs) are implanted in patients with end-stage heart 
      failure to provide both short- and long-term hemodynamic support. Unfortunately, 
      bleeding and thromboembolic complications due to the severely disturbed, dynamic 
      flow conditions generated within these devices require complex, long-term 
      antiplatelet and anticoagulant therapy. While several studies have examined the 
      effectiveness of one such agent, aspirin, under flow conditions, data comparing 
      the efficacy of in vitro and in vivo metabolized aspirin is lacking. Two sets of 
      studies were conducted in vitro with purified human platelets circulating for 
      30 min in a flow loop containing the DeBakey VAD (MicroMed Cardiovascular, 
      Houston, TX, USA): (a) 20 μM aspirin was added exogenously in vitro to platelets 
      isolated from aspirin-free subjects, and (b) platelets were obtained from donors 
      2 h (n = 14) and 20 h (n = 13) after ingestion of 1,000 mg aspirin. Near 
      real-time platelet activation state (PAS) was measured with a modified 
      prothrombinase-based assay. Platelets exposed to aspirin in vitro and in vivo 
      (metabolized) showed 28.2 and 25.3 % reduction in platelet activation rate, 
      respectively, compared to untreated controls. Our results demonstrate that in 
      vitro treatment with antiplatelet drugs such as aspirin is as effective as in 
      vivo metabolized aspirin in testing the effect of reducing shear-induced platelet 
      activation in the VAD. Using the PAS assay provides a practical in vitro 
      alternative to in vivo testing of antiplatelet efficacy, as well as for testing 
      the thrombogenic performance of devices during their research and development.
FAU - Sheriff, Jawaad
AU  - Sheriff J
AD  - Department of Biomedical Engineering, Stony Brook University, T15-090 Health 
      Sciences Center, Stony Brook, NY, 11794-8151, USA.
FAU - Girdhar, Gaurav
AU  - Girdhar G
FAU - Chiu, Wei-Che
AU  - Chiu WC
FAU - Jesty, Jolyon
AU  - Jesty J
FAU - Slepian, Marvin J
AU  - Slepian MJ
FAU - Bluestein, Danny
AU  - Bluestein D
LA  - eng
GR  - U01 EB012487/EB/NIBIB NIH HHS/United States
GR  - 5U01EB012487-00/EB/NIBIB NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacokinetics/pharmacology
MH  - Blood Donors
MH  - Blood Platelets/*metabolism/pathology
MH  - Female
MH  - *Heart-Assist Devices
MH  - Humans
MH  - Male
MH  - Platelet Activation/*drug effects
MH  - *Platelet Aggregation Inhibitors/pharmacokinetics/pharmacology
MH  - Thrombosis/blood/etiology/prevention & control
PMC - PMC4160029
MID - NIHMS623822
EDAT- 2013/09/18 06:00
MHDA- 2015/02/13 06:00
CRDT- 2013/09/18 06:00
PHST- 2013/09/18 06:00 [entrez]
PHST- 2013/09/18 06:00 [pubmed]
PHST- 2015/02/13 06:00 [medline]
AID - 10.1007/s11239-013-0997-6 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2014 May;37(4):499-506. doi: 10.1007/s11239-013-0997-6.

PMID- 28493889
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20220321
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 5
DP  - 2017
TI  - Characterization of a novel antibiofilm effect of nitric oxide-releasing aspirin 
      (NCX-4040) on Candida albicans isolates from denture stomatitis patients.
PG  - e0176755
LID - 10.1371/journal.pone.0176755 [doi]
LID - e0176755
AB  - Candida albicans biofilms play a key role in denture stomatitis, one of the most 
      common oral pathologies in elderly people. Because biofilms are highly resistant 
      to antifungals, new pharmacological strategies are needed. Aspirin and nitric 
      oxide-donor molecules have both shown antibiofilm effects on C. albicans, making 
      them promising candidates for treatment. In this study, we evaluated the 
      antifungal/antibiofilm effect of a nitric-oxide releasing aspirin (NO-ASA) on C. 
      albicans isolates from denture stomatitis patients in vitro. Disk diffusion 
      assays showed that while NO-ASA had no antifungal effect, the drug potentiated 
      fluconazole inhibition zone diameters, increasing the effect of fluconazole by 
      20-30% (p<0.05). The effect of NO-ASA on the morphogenesis of C. albicans was 
      evaluated using light microscopy after inducing hyphae formation. For all 
      clinical strains assayed, 125 μM NO-ASA significantly decreased the number of 
      filamentous cells present (p<0.01). Adhesion to abiotic surfaces, a critical 
      event for biofilm formation, was evaluated in 96-well polystyrene plates using 
      crystal violet assay; 125 μM NO-ASA significantly inhibited adhesion. Biofilms 
      were observed with scanning electron microscopy (SEM) and quantified using XTT 
      reduction assay. NO-ASA decreased biofilm formation (IC50 ranging from 300 μM to 
      700 μM), consistent with SEM findings of altered biofilm microarchitecture. PGE2 
      and carboxy-PTIO (an NO scavenger) both blocked the antibiofilm effects of 
      NO-ASA, suggesting that the efficacy of NO-ASA may be associated with both 
      inhibition of PGE2 synthesis and release of NO. NO-ASA is a promising novel 
      antibiofilm agent for treating fluconazole-resistant strains of C. albicans.
FAU - Madariaga-Venegas, Francisco
AU  - Madariaga-Venegas F
AD  - Institute for Research in Dental Sciences, Faculty of Dentistry, University of 
      Chile, Santiago, Chile.
FAU - Fernández-Soto, Roberto
AU  - Fernández-Soto R
AD  - Institute for Research in Dental Sciences, Faculty of Dentistry, University of 
      Chile, Santiago, Chile.
FAU - Duarte, Luisa Fernanda
AU  - Duarte LF
AD  - Institute for Research in Dental Sciences, Faculty of Dentistry, University of 
      Chile, Santiago, Chile.
FAU - Suarez, Nicole
AU  - Suarez N
AD  - Institute for Research in Dental Sciences, Faculty of Dentistry, University of 
      Chile, Santiago, Chile.
FAU - Delgadillo, Daniela
AU  - Delgadillo D
AD  - Institute for Research in Dental Sciences, Faculty of Dentistry, University of 
      Chile, Santiago, Chile.
FAU - Jara, José A
AU  - Jara JA
AD  - Institute for Research in Dental Sciences, Faculty of Dentistry, University of 
      Chile, Santiago, Chile.
FAU - Fernández-Ramires, Ricardo
AU  - Fernández-Ramires R
AD  - Department of Pathology and Oral Medicine, Faculty of Dentistry, University of 
      Chile, Santiago, Chile.
FAU - Urzúa, Blanca
AU  - Urzúa B
AD  - Institute for Research in Dental Sciences, Faculty of Dentistry, University of 
      Chile, Santiago, Chile.
FAU - Molina-Berríos, Alfredo
AU  - Molina-Berríos A
AD  - Institute for Research in Dental Sciences, Faculty of Dentistry, University of 
      Chile, Santiago, Chile.
LA  - eng
PT  - Journal Article
DEP - 20170511
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antifungal Agents)
RN  - 0 (Free Radical Scavengers)
RN  - 0 (NCX 4040)
RN  - 0 (Nitro Compounds)
RN  - 8VZV102JFY (Fluconazole)
RN  - EH04H13L6B (nitroaspirin)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antifungal Agents/pharmacology/therapeutic use
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Bacterial Adhesion/drug effects
MH  - Biofilms/*drug effects
MH  - Candida albicans/drug effects/*isolation & purification/ultrastructure
MH  - Dinoprostone/metabolism
MH  - Drug Resistance, Fungal/drug effects
MH  - Fluconazole/pharmacology/therapeutic use
MH  - Free Radical Scavengers/pharmacology
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Microbial Viability/drug effects
MH  - Nitro Compounds/*pharmacology/therapeutic use
MH  - Stomatitis, Denture/drug therapy/*microbiology
PMC - PMC5426659
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2017/05/12 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/05/12 06:00
PHST- 2016/09/06 00:00 [received]
PHST- 2017/04/17 00:00 [accepted]
PHST- 2017/05/12 06:00 [entrez]
PHST- 2017/05/12 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
AID - PONE-D-16-35796 [pii]
AID - 10.1371/journal.pone.0176755 [doi]
PST - epublish
SO  - PLoS One. 2017 May 11;12(5):e0176755. doi: 10.1371/journal.pone.0176755. 
      eCollection 2017.

PMID- 628675
OWN - NLM
STAT- MEDLINE
DCOM- 19780426
LR  - 20180214
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 16
IP  - 3
DP  - 1978
TI  - A new mechanical method for measuring rat paw edema.
PG  - 153-8
AB  - A new method is presented for measuring swelling or rat paw edema in inflammation 
      induced by carrageenin injection. This technique is compared to other widely used 
      ones. A spring-loaded dial indicator produces results that are accurate, precise 
      and reproducible. It is recommended for investigators seeking the advantages of a 
      noninvasive, low cost, rapid method quantifying the swelling of inflammation.
FAU - Petricevic, M
AU  - Petricevic M
FAU - Wanek, K
AU  - Wanek K
FAU - Denko, C W
AU  - Denko CW
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Carrageenan
MH  - *Disease Models, Animal
MH  - Edema/*chemically induced/drug therapy
MH  - Male
MH  - Methods
MH  - Rats
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1159/000136761 [doi]
PST - ppublish
SO  - Pharmacology. 1978;16(3):153-8. doi: 10.1159/000136761.

PMID- 10440565
OWN - NLM
STAT- MEDLINE
DCOM- 19991014
LR  - 20191024
IS  - 0197-2456 (Print)
IS  - 0197-2456 (Linking)
VI  - 20
IP  - 4
DP  - 1999 Aug
TI  - Primary prevention of arterial thromboembolism in nonrheumatic atrial 
      fibrillation: the PATAF trial study design.
PG  - 386-93
AB  - Patients with nonrheumatic atrial fibrillation (NRAF) have a higher risk of 
      thromboembolism than patients in sinus rhythm. Several trials have been conducted 
      to establish the best preventive regimen in patients with NRAF, but not in the 
      primary-care setting. The Primary Prevention of Arterial Thromboembolism in 
      Nonrheumatic Atrial Fibrillation (PATAF) study, a primary-care-based trial, was 
      set up to compare the preventive efficacy of low-intensity anticoagulation (AC), 
      target range International Normalized Ratio (INR) 1.1 < INR < 1.6 and 
      regular-intensity AC (2.5 < INR < 3.5) therapies with that of aspirin 150 mg/d 
      for the occurrence of thromboembolism in NRAF patients. Patients eligible for 
      regular-intensity AC were randomly assigned to aspirin at 150 mg/d, low-intensity 
      AC, or regular AC in group I. In cases of noneligibility for regular AC, the 
      trial randomized patients between aspirin and low-intensity AC (assigned to group 
      II). Primary outcome events were stroke (including intracranial hemorrhage), 
      systemic embolism, major hemorrhage, or vascular death. Analysis of the data was 
      based on Cox regression to compute the hazard ratio (HR) with a 95% confidence 
      interval, using the likelihood ratio test. The trial randomized 729 patients. 
      Patient enrollment and follow-up has been stopped, and the final analysis is now 
      complete. We shall publish the main results as soon as possible.
FAU - Hellemons, B S
AU  - Hellemons BS
AD  - Department of General Practice, University of Maastricht, The Netherlands.
FAU - Langenberg, M
AU  - Langenberg M
FAU - Lodder, J
AU  - Lodder J
FAU - Vermeer, F
AU  - Vermeer F
FAU - Schouten, H J
AU  - Schouten HJ
FAU - Lemmens, T G
AU  - Lemmens TG
FAU - van Ree, J W
AU  - van Ree JW
FAU - Knottnerus, J A
AU  - Knottnerus JA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Control Clin Trials
JT  - Controlled clinical trials
JID - 8006242
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Atrial Fibrillation/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - Netherlands
MH  - Primary Health Care
MH  - Thromboembolism/*prevention & control
MH  - Treatment Outcome
EDAT- 1999/08/10 00:00
MHDA- 1999/08/10 00:01
CRDT- 1999/08/10 00:00
PHST- 1999/08/10 00:00 [pubmed]
PHST- 1999/08/10 00:01 [medline]
PHST- 1999/08/10 00:00 [entrez]
AID - S0197-2456(99)00010-0 [pii]
AID - 10.1016/s0197-2456(99)00010-0 [doi]
PST - ppublish
SO  - Control Clin Trials. 1999 Aug;20(4):386-93. doi: 10.1016/s0197-2456(99)00010-0.

PMID- 14633783
OWN - NLM
STAT- MEDLINE
DCOM- 20040923
LR  - 20191108
IS  - 1520-4391 (Print)
IS  - 1520-4383 (Linking)
DP  - 2003
TI  - Chronic myeloproliferative disorders.
PG  - 200-24
AB  - The Philadelphia chromosome-negative chronic myeloproliferative disorders (CMPD), 
      polycythemia vera (PV), essential thrombocythemia (ET) and chronic idiopathic 
      myelofibrosis (IMF), have overlapping clinical features but exhibit different 
      natural histories and different therapeutic requirements. Phenotypic mimicry 
      amongst these disorders and between them and nonclonal hematopoietic disorders, 
      lack of clonal diagnostic markers, lack of understanding of their molecular basis 
      and paucity of controlled, prospective therapeutic trials have made the diagnosis 
      and management of PV, ET and IMF difficult. In Section I, Dr. Jerry Spivak 
      introduces current clinical controversies involving the CMPD, in particular the 
      diagnostic challenges. Two new molecular assays may prove useful in the diagnosis 
      and classification of CMPD. In 2000, the overexpression in PV granulocytes of the 
      mRNA for the neutrophil antigen NBI/CD177, a member of the uPAR/Ly6/CD59 family 
      of plasma membrane proteins, was documented. Overexpression of PRV-1 mRNA 
      appeared to be specific for PV since it was not observed in secondary 
      erythrocytosis. At this time, it appears that overexpression of granulocyte PRV-1 
      in the presence of an elevated red cell mass supports a diagnosis of PV; absence 
      of PRV-1 expression, however, should not be grounds for excluding PV as a 
      diagnostic possibility. Impaired expression of Mpl, the receptor for 
      thrombopoietin, in platelets and megakaryocytes has been first described in PV, 
      but it has also been observed in some patients with ET and IMF. The biologic 
      basis appears to be either alternative splicing of Mpl mRNA or a single 
      nucleotide polymorphism, both of which involve Mpl exon 2 and both of which lead 
      to impaired posttranslational glycosylation and a dominant negative effect on 
      normal Mpl expression. To date, no Mpl DNA structural abnormality or mutation has 
      been identified in PV, ET or IMF. In Section II, Dr. Tiziano Barbui reviews the 
      best clinical evidence for treatment strategy design in PV and ET. Current 
      recommendations for cytoreductive therapy in PV are still largely similar to 
      those at the end of the PVSG era. Phlebotomy to reduce the red cell mass and keep 
      it at a safe level (hematocrit < 45%) remains the cornerstone of treatment. 
      Venesection is an effective and safe therapy and previous concerns about 
      potential side effects, including severe iron deficiency and an increased 
      tendency to thrombosis or myelofibrosis, were erroneous. Many patients require no 
      other therapy for many years. For others, however, poor compliance to phlebotomy 
      or progressive myeloproliferation, as indicated by increasing splenomegaly or 
      very high leukocyte or platelet counts, may call for the introduction of 
      cytoreductive drugs. In ET, the therapeutic trade-off between reducing thrombotic 
      events and increasing the risk of leukemia with the use of cytoreductive drugs 
      should be approached by patient risk stratification. Thrombotic deaths seem very 
      rare in low-risk ET subjects and there are no data indicating that fatalities can 
      be prevented by starting cytoreductive drugs early. Therefore, withholding 
      chemotherapy might be justifiable in young, asymptomatic ET patients with a 
      platelet count below 1500000/mm(3) and with no additional risk factors for 
      thrombosis. If cardiovascular risk factors together with ET are identified 
      (smoking, obesity, hypertension, hyperlipidemia) it is wise to consider 
      platelet-lowering agents on an individual basis. In Section III, Dr. Gianni 
      Tognoni discusses the role of aspirin therapy in PV based on the recently 
      completed European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) 
      Study, a multi-country, multicenter project aimed at describing the natural 
      history of PV as well as the efficacy of low-dose aspirin. Aspirin treatment 
      lowered the risk of cardiovascular death, non-fatal myocardial infarction, and 
      non-fatal stroke (relative risk 0.41 [95% CI 0.15-1.15], P =.0912). Total and 
      cardiovascular mortality were also reduced by 46% and 59%, respectively. Major 
      bleedings were slightly increased nonsignificnsignificantly by aspirin (relative 
      risk 1.62, 95% CI 0.27-9.71). In Section IV, Dr. Giovanni Barosi reviews our 
      current understanding of the pathophysiology of IMF and, in particular, the 
      contributions of anomalous megakaryocyte proliferation, neoangiogenesis and 
      abnormal CD34(+) stem cell trafficking to disease pathogenesis. The role of newer 
      therapies, such as low-conditioning stem cell transplantation and thalidomide, is 
      discussed in the context of a general treatment strategy for IMF. The results of 
      a Phase II trial of low-dose thalidomide as a single agent in 63 patients with 
      myelofibrosis with meloid metaplasia (MMM) using a dose-escalation design and an 
      overall low dose of the drug (The European Collaboration on MMM) will be 
      presented. Considering only patients who completed 4 weeks of treatment, 31% had 
      a response: this was mostly due to a beneficial effect of thalidomide on patients 
      with transfusion dependent anemia, 39% of whom abolished transfusions, patients 
      with moderate to severe thrombocytopenia, 28% of whom increased their platelet 
      count by more than 50 x 10(9)/L, and patients with the largest splenomegalies, 
      42% of whom reduced spleen size of more than 2 cm.
FAU - Spivak, Jerry L
AU  - Spivak JL
AD  - Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, 
      MD 21205-2109, USA.
FAU - Barosi, Giovanni
AU  - Barosi G
FAU - Tognoni, Gianni
AU  - Tognoni G
FAU - Barbui, Tiziano
AU  - Barbui T
FAU - Finazzi, Guido
AU  - Finazzi G
FAU - Marchioli, Roberto
AU  - Marchioli R
FAU - Marchetti, Monia
AU  - Marchetti M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hematology Am Soc Hematol Educ Program
JT  - Hematology. American Society of Hematology. Education Program
JID - 100890099
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunologic Factors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/drug therapy/prevention & control
MH  - Chronic Disease
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunologic Factors/pharmacology/therapeutic use
MH  - Molecular Diagnostic Techniques
MH  - Myeloproliferative Disorders/complications/diagnosis/*therapy
MH  - Phlebotomy
MH  - Practice Guidelines as Topic
MH  - Treatment Outcome
RF  - 143
EDAT- 2003/11/25 05:00
MHDA- 2004/09/24 05:00
CRDT- 2003/11/25 05:00
PHST- 2003/11/25 05:00 [pubmed]
PHST- 2004/09/24 05:00 [medline]
PHST- 2003/11/25 05:00 [entrez]
AID - 10.1182/asheducation-2003.1.200 [doi]
PST - ppublish
SO  - Hematology Am Soc Hematol Educ Program. 2003:200-24. doi: 
      10.1182/asheducation-2003.1.200.

PMID- 37169520
OWN - NLM
STAT- MEDLINE
DCOM- 20230602
LR  - 20230602
IS  - 1755-5248 (Electronic)
IS  - 0012-6543 (Linking)
VI  - 61
IP  - 6
DP  - 2023 Jun
TI  - Aspirin does not reduce fracture and fall risk in healthy older people.
PG  - 85
LID - 10.1136/dtb.2023.000023 [doi]
AB  - Overview of: Barker AL, Morello R, Thao LTP, et al Daily low-dose aspirin and 
      risk of serious falls and fractures in healthy older people: a substudy of the 
      ASPREE randomized clinical trial. JAMA Intern Med 2022;182:1289-97.
CI  - © BMJ Publishing Group Limited 2023. No commercial re-use. See rights and 
      permissions. Published by BMJ.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20230511
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Aged
MH  - *Aspirin/adverse effects
MH  - Accidental Falls/prevention & control
MH  - *Fractures, Bone/prevention & control
OTO - NOTNLM
OT  - Drug-Related Side Effects and Adverse Reactions
OT  - Health Care Quality, Access, and Evaluation
EDAT- 2023/05/12 01:07
MHDA- 2023/06/02 06:42
CRDT- 2023/05/11 21:13
PHST- 2023/06/02 06:42 [medline]
PHST- 2023/05/12 01:07 [pubmed]
PHST- 2023/05/11 21:13 [entrez]
AID - dtb.2023.000023 [pii]
AID - 10.1136/dtb.2023.000023 [doi]
PST - ppublish
SO  - Drug Ther Bull. 2023 Jun;61(6):85. doi: 10.1136/dtb.2023.000023. Epub 2023 May 
      11.

PMID- 453740
OWN - NLM
STAT- MEDLINE
DCOM- 19790829
LR  - 20131121
IS  - 0003-4886 (Print)
IS  - 0003-4886 (Linking)
VI  - 11
IP  - 3
DP  - 1979 Mar
TI  - The detrimental effect of aspirin on hyphema rebleed.
PG  - 351-5
AB  - One hundred ninety-five cases of traumatic hyphema admitted to 2 medical centers 
      over an 8 year period were studied in terms of factors effecting the rebleeding 
      rate. It was found that aspirin given for analgesia had a detrimental effect on 
      the rebleeding rate, and that dilating the iris offered some protection against 
      this complication. This report is the second one to show association of higher 
      rebleeding rate and aspirin.
FAU - Gorn, R A
AU  - Gorn RA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Ophthalmol
JT  - Annals of ophthalmology
JID - 0210137
RN  - 0 (Mydriatics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Eye Injuries/*complications/drug therapy
MH  - Humans
MH  - Hyphema/*chemically induced/drug therapy/etiology
MH  - Iris/drug effects
MH  - Middle Aged
MH  - Mydriatics/pharmacology
MH  - Recurrence
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
PST - ppublish
SO  - Ann Ophthalmol. 1979 Mar;11(3):351-5.

PMID- 29989808
OWN - NLM
STAT- MEDLINE
DCOM- 20190715
LR  - 20190715
IS  - 1520-5126 (Electronic)
IS  - 0002-7863 (Linking)
VI  - 140
IP  - 30
DP  - 2018 Aug 1
TI  - Metal-Organic Frameworks as Efficient Oral Detoxifying Agents.
PG  - 9581-9586
LID - 10.1021/jacs.8b04435 [doi]
AB  - Poisoning and accidental oral intoxication are major health problems worldwide. 
      Considering the insufficient efficacy of the currently available detoxification 
      treatments, a pioneering oral detoxifying adsorbent agent based on a single 
      biocompatible metal-organic framework (MOF) is here proposed for the efficient 
      decontamination of drugs commonly implicated in accidental or voluntary 
      poisoning. Furthermore, the in vivo toxicity and biodistribution of a MOF via 
      oral administration have been investigated for the first time. Orally 
      administered upon a salicylate overdose, this MOF is able to reduce the 
      salicylate gastrointestinal absorption and toxicity more than 40-fold (avoiding 
      histological damage) while exhibiting exceptional gastrointestinal stability (<9% 
      degradation), poor intestinal permeation, and safety.
FAU - Rojas, Sara
AU  - Rojas S
AUID- ORCID: 0000-0002-7874-2122
AD  - Institut Lavoisier, CNRS UMR 8180, UVSQ , Université Paris-Saclay , 45 Av. Des 
      Etats Unis , Versailles 78035 Cedex , France.
FAU - Baati, Tarek
AU  - Baati T
AD  - Institut Lavoisier, CNRS UMR 8180, UVSQ , Université Paris-Saclay , 45 Av. Des 
      Etats Unis , Versailles 78035 Cedex , France.
AD  - Laboratoire des Substances Naturelles , Institut National de Recherche et 
      d'Analyse Physico-Chimique (INRAP), BiotechPole Sidi Thabet , 2020 Sidi Thabet , 
      Ariana , Tunisie.
FAU - Njim, Leila
AU  - Njim L
AD  - Service d'Anatomie et de Cytologie Pathologiques , CHU de Monastir , Monastir , 
      Tunisie.
FAU - Manchego, Lisbeth
AU  - Manchego L
AD  - Institut Lavoisier, CNRS UMR 8180, UVSQ , Université Paris-Saclay , 45 Av. Des 
      Etats Unis , Versailles 78035 Cedex , France.
FAU - Neffati, Fadoua
AU  - Neffati F
AD  - Laboratoire de Biochimie et de Toxicologie , CHU de Monastir , Monastir , 
      Tunisie.
FAU - Abdeljelil, Nissem
AU  - Abdeljelil N
AD  - Institut Lavoisier, CNRS UMR 8180, UVSQ , Université Paris-Saclay , 45 Av. Des 
      Etats Unis , Versailles 78035 Cedex , France.
AD  - Laboratoire de Biophysique, Faculté de Médecine de Sousse , Université de Sousse 
      , Sousse , Tunisie.
FAU - Saguem, Saad
AU  - Saguem S
AD  - Laboratoire de Biophysique, Faculté de Médecine de Sousse , Université de Sousse 
      , Sousse , Tunisie.
FAU - Serre, Christian
AU  - Serre C
AD  - Institut Lavoisier, CNRS UMR 8180, UVSQ , Université Paris-Saclay , 45 Av. Des 
      Etats Unis , Versailles 78035 Cedex , France.
AD  - Institut des Matériaux Poreux de Paris, FRE 2000 CNRS Ecole Normale Supérieure, 
      Ecole Supérieure de Physique et de Chimie Industrielles de Paris , PSL Research 
      University , 24 rue Lhomond , Paris 75005 , France.
FAU - Najjar, Mohamed Fadhel
AU  - Najjar MF
AD  - Laboratoire de Biochimie et de Toxicologie , CHU de Monastir , Monastir , 
      Tunisie.
FAU - Zakhama, Abdelfateh
AU  - Zakhama A
AD  - Service d'Anatomie et de Cytologie Pathologiques , CHU de Monastir , Monastir , 
      Tunisie.
FAU - Horcajada, Patricia
AU  - Horcajada P
AUID- ORCID: 0000-0002-6544-5911
AD  - Institut Lavoisier, CNRS UMR 8180, UVSQ , Université Paris-Saclay , 45 Av. Des 
      Etats Unis , Versailles 78035 Cedex , France.
AD  - Advanced Porous Materials Unit , IMDEA Energy Institute . Av. Ramón de la Sagra 3 
      , 28935 Móstoles-Madrid , Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180720
PL  - United States
TA  - J Am Chem Soc
JT  - Journal of the American Chemical Society
JID - 7503056
RN  - 0 (Antidotes)
RN  - 0 (Metal-Organic Frameworks)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adsorption
MH  - Animals
MH  - Antidotes/administration & dosage/metabolism/*therapeutic use/toxicity
MH  - Aspirin/blood/chemistry/*poisoning/urine
MH  - Drug Overdose/*prevention & control
MH  - Female
MH  - Gastrointestinal Absorption/drug effects
MH  - Jejunum/pathology
MH  - Liver/pathology
MH  - Metal-Organic Frameworks/administration & dosage/metabolism/*therapeutic 
      use/toxicity
MH  - Rats, Wistar
MH  - Stomach/pathology
MH  - Tissue Distribution
EDAT- 2018/07/11 06:00
MHDA- 2019/07/16 06:00
CRDT- 2018/07/11 06:00
PHST- 2018/07/11 06:00 [pubmed]
PHST- 2019/07/16 06:00 [medline]
PHST- 2018/07/11 06:00 [entrez]
AID - 10.1021/jacs.8b04435 [doi]
PST - ppublish
SO  - J Am Chem Soc. 2018 Aug 1;140(30):9581-9586. doi: 10.1021/jacs.8b04435. Epub 2018 
      Jul 20.

PMID- 17160149
OWN - NLM
STAT- MEDLINE
DCOM- 20070215
LR  - 20171116
IS  - 0214-0934 (Print)
IS  - 0214-0934 (Linking)
VI  - 19
IP  - 8
DP  - 2006 Oct
TI  - Chronicles in drug discovery.
PG  - 485-9
AB  - Chronicles in Drug Discovery features special interest reports on advances in 
      drug discovery and development. This month we focus on the progress of the 
      ongoing search for safe and effective chemopreventive agents. Chemoprevention is 
      a strategy to decrease the risk of developing cancer by using agents that prevent 
      or abrogate carcinogenic processes. Bowman- Birk inhibitor concentrate, 
      budesonide, NCX-4016 and statins are all undergoing investigation in the clinical 
      setting as potential chemopreventive agents for head and neck, lung, colon and 
      breast cancers, respectively.
CI  - (c) 2006 Prous Science. All rights reserved.
FAU - Moral, Maria Angels
AU  - Moral MA
AD  - Prous Science Medical Information Department, Barcelona, Spain. 
      journals@prous.com
FAU - Khurdayan, Valeria K
AU  - Khurdayan VK
FAU - Bozzo, Jordi
AU  - Bozzo J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Drug News Perspect
JT  - Drug news & perspectives
JID - 8809164
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Glucocorticoids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Trypsin Inhibitor, Bowman-Birk Soybean)
RN  - 0 (Trypsin Inhibitors)
RN  - 51333-22-3 (Budesonide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Anticarcinogenic Agents/pharmacology/*therapeutic use
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Budesonide/pharmacology/*therapeutic use
MH  - Cell Transformation, Neoplastic/drug effects
MH  - Chemoprevention
MH  - Clinical Trials as Topic
MH  - Drug Evaluation, Preclinical
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/*therapeutic use
MH  - Neoplasms/prevention & control
MH  - Precancerous Conditions/drug therapy
MH  - Trypsin Inhibitor, Bowman-Birk Soybean/pharmacology/*therapeutic use
MH  - Trypsin Inhibitors/therapeutic use
RF  - 38
EDAT- 2006/12/13 09:00
MHDA- 2007/02/16 09:00
CRDT- 2006/12/13 09:00
PHST- 2006/12/13 09:00 [pubmed]
PHST- 2007/02/16 09:00 [medline]
PHST- 2006/12/13 09:00 [entrez]
AID - 3372 [pii]
PST - ppublish
SO  - Drug News Perspect. 2006 Oct;19(8):485-9.

PMID- 7034196
OWN - NLM
STAT- MEDLINE
DCOM- 19820313
LR  - 20190909
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 10
IP  - 4
DP  - 1981
TI  - Comparison of diflunisal and acetylsalicylic acid in patients with rheumatoid 
      arthritis.
PG  - 289-95
AB  - A double-blind comparison of the clinical efficacy and tolerance of varying doses 
      of diflunisal (DFS) and acetylsalicylic acid (ASA) was carried out in 15 patients 
      with rheumatoid arthritis who were given no other antirheumatic medication. An 
      effort was made to select appropriate anamnestic, functional and sociofunctional 
      tests and to optimize their validity by careful measurements performed by the 
      same specialized physiotherapist and occupational therapist. In addition, the 
      serum concentration of DFS and salicylic acid were monitored by high-pressure 
      liquid chromatography. The therapeutic effects of DFS was at least as good as 
      that of ASA. Moreover, DFS was better tolerated; all 7 patients on DFS could 
      sustain the maximum dose (1g) of this drug, while that of ASA (4g) was tolerated 
      by only one of 8 patients. All these experienced side effects, necessitating drug 
      withdrawal in 3 cases, one being a serious hepatotoxic reaction. DFS treatment, 
      on the other hand, was associated with only one minor side effect. The side 
      effect difference was statistically significant (p less than 0.01). The analyses 
      of drug concentrations in serum verified that all patients were exposed to DFS 
      and ASA as planned, adding safety to the judgement of the therapeutic effects. 
      The findings support the view that the novel salicylic acid derivative DFS may 
      offer a therapeutic advantage in the treatment of rheumatoid arthritis; it seems 
      to have at least the same therapeutic effect as ASA an may be better tolerated.
FAU - Lindholm, L
AU  - Lindholm L
FAU - Ekdahl, C
AU  - Ekdahl C
FAU - Håkansson, E
AU  - Håkansson E
FAU - Melander, A
AU  - Melander A
FAU - Olsson, S
AU  - Olsson S
FAU - Svensson, B
AU  - Svensson B
FAU - Wählin-Boll, E
AU  - Wählin-Boll E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Salicylates)
RN  - 7C546U4DEN (Diflunisal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/blood/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Diflunisal/adverse effects/blood/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/*therapeutic use
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.3109/03009748109095317 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 1981;10(4):289-95. doi: 10.3109/03009748109095317.

PMID- 375668
OWN - NLM
STAT- MEDLINE
DCOM- 19790728
LR  - 20190819
IS  - 0001-656X (Print)
IS  - 0001-656X (Linking)
VI  - 68
IP  - 3
DP  - 1979 May
TI  - Dosage of salicylates for children with juvenile rheumatoid arthritis. A 
      prospective clinical trial with three different preparations of acetylsalicylic 
      acid.
PG  - 423-30
AB  - 41 children with juvenile rheumatoid arthritis (JRA) and 6 with postinfectious 
      arthropathies, aged 3--15 years, were treated with acetylsalicylic acid for 14 
      days during which time the patients were hospitalized. Three different 
      acetylsalicylic acid preparations were used: a microencapsulated form, an 
      enteric-coated form and standard acetylsalicylic acid tablets. Serum salicylate 
      concentrations were measured by Trinder's photometric method. With doses of 
      90--120 mg/kg/day symptoms of salicylism appeared in about 50% of the cases. 
      Daily doses of 2 g/m2 (not exceeding 70 mg/kg) proved relatively safe in this 
      study, whereas symptoms and signs of intoxication appeared at doses exceeding 3 
      g/m2/day. In this respect there were no significant differences between the three 
      acetylsalicylic acid preparations used. The results of this study also suggest 
      that the serum salicylate concentrations should not exceed 2000 mumol/l (about 27 
      mg/100 ml). The symptoms of salicylism correlated closely with serum salicylate 
      levels, which, in turn, correlated well with the dosage in g/m2. Elevation of 
      serum aspartate aminotransferase was noted in 1/3 of the cases. All of these had 
      a dose exceeding 2 g/m2, and the frequency of elevated enzyme activities 
      increased with increasing dosage. In the group receiving enteric coated form of 
      acetylsalicylic acid, there were fewer positive benzidine tests (12%) than in the 
      two other groups (22--28%).
FAU - Mäkela, A L
AU  - Mäkela AL
FAU - Yrjänä, T
AU  - Yrjänä T
FAU - Mattila, M
AU  - Mattila M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Sweden
TA  - Acta Paediatr Scand
JT  - Acta paediatrica Scandinavica
JID - 0000211
RN  - 0 (Benzidines)
RN  - 0 (Tablets)
RN  - 0 (Tablets, Enteric-Coated)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Arthritis/blood/*drug therapy
MH  - Arthritis, Juvenile/blood/*drug therapy
MH  - Aspartate Aminotransferases/blood
MH  - Aspirin/*administration & dosage/adverse effects/blood
MH  - Benzidines
MH  - Body Weight
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Tablets
MH  - Tablets, Enteric-Coated
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
AID - 10.1111/j.1651-2227.1979.tb05031.x [doi]
PST - ppublish
SO  - Acta Paediatr Scand. 1979 May;68(3):423-30. doi: 
      10.1111/j.1651-2227.1979.tb05031.x.

PMID- 7288271
OWN - NLM
STAT- MEDLINE
DCOM- 19811215
LR  - 20181130
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 98
IP  - 4
DP  - 1981 Oct
TI  - Intestinal absorption of aspirin. Influence of pH, taurocholate, ascorbate, and 
      ethanol.
PG  - 591-8
AB  - The small intestinal absorption of aspirin at pharmacological concentrations was 
      studied in the unanesthetized rat by using a single-pass perfusion technique. The 
      rate of aspirin absorption remained linear with its concentration (0.5 to 10 mM). 
      Intestinal aspirin absorption increased as the concentration of hydrogen ion, 
      sodium taurocholate, and ascorbic acid in the perfusate increased. Aspirin 
      absorption did not change after ethanol addition. At pH 3.5 or 6.5, intestinal 
      absorption of aspirin was greater than gastric absorption of the compound. 
      Aspirin was not absorbed by the stomach at pH 6.5. These experiments indicate 
      that aspirin can be absorbed to an appreciable extent in its ionized form by the 
      small intestine but not by the stomach.
FAU - Hollander, D
AU  - Hollander D
FAU - Dadufalza, V D
AU  - Dadufalza VD
FAU - Fairchild, P A
AU  - Fairchild PA
LA  - eng
GR  - 25637/PHS HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Bile Acids and Salts)
RN  - 3K9958V90M (Ethanol)
RN  - 5E090O0G3Z (Taurocholic Acid)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Ascorbic Acid/*pharmacology
MH  - Aspirin/*metabolism/pharmacology
MH  - Bile Acids and Salts/pharmacology
MH  - Ethanol/*pharmacology
MH  - Gastric Mucosa/drug effects/metabolism
MH  - *Hydrogen-Ion Concentration
MH  - Intestinal Absorption/drug effects
MH  - Intestinal Mucosa/drug effects
MH  - Kinetics
MH  - Male
MH  - Perfusion
MH  - Rats
MH  - Taurocholic Acid/*pharmacology
EDAT- 1981/10/01 00:00
MHDA- 1981/10/01 00:01
CRDT- 1981/10/01 00:00
PHST- 1981/10/01 00:00 [pubmed]
PHST- 1981/10/01 00:01 [medline]
PHST- 1981/10/01 00:00 [entrez]
AID - 0022-2143(81)90014-7 [pii]
PST - ppublish
SO  - J Lab Clin Med. 1981 Oct;98(4):591-8.

PMID- 7634259
OWN - NLM
STAT- MEDLINE
DCOM- 19950914
LR  - 20131121
IS  - 0393-1978 (Print)
IS  - 0393-1978 (Linking)
VI  - 39
IP  - 12 Suppl 1
DP  - 1994 Dec
TI  - [Low-dose aspirin in the long-term treatment of the patient with ischemic heart 
      disease].
PG  - 15-21
AB  - Coronary atherosclerosis is the process underlying virtually all the clinical 
      manifestations of ischemic heart disease. When ulcer or fissure in the fibrous 
      cap of the atheroma occur, platelet adhesion to subendothelium, aggregation and 
      further platelet recruitment culminate in thrombus formation. These mechanisms 
      are known to be responsible for most cases of acute events in patients with 
      ischemic heart disease. Inside platelets, aspirin blocks the synthesis of 
      thromboxane A2 by irreversibly inhibiting cyclooxygenase. Aspirin is recommended 
      not only for treatment of patients with acute coronary syndromes (unstable 
      angina, acute myocardial infarction), but also for secondary prevention of 
      vascular events in chronic coronary syndromes. Aspirin prevents myocardial 
      infarction in patients with chronic stable angina and reduces mortality, 
      reinfarction and stroke in survivors of an acute myocardial infarction. Aspirin, 
      alone or in combination with dipyridamole, prevents early and late occlusion of 
      aortocoronary vein grafts. It is useful also in patients undergoing coronary 
      angioplasty. Such benefits extend to all patients regardless of age, sex, history 
      of hypertension or diabetes. Higher daily doses (900-1500 mg) are not more 
      effective than lower doses (75-325 mg). Other antiplatelet drugs are not more 
      effective than aspirin, which has the best risk-to-benefit and cost-to-benefit 
      ratios. Ticlopidine is a reasonable alternative for use in preventing vascular 
      events among patients intolerant to aspirin. Warfarin is an effective 
      antithrombotic alternative to aspirin for secondary prevention after a myocardial 
      infarction. However aspirin is easier to administer and follow-up when compared 
      with warfarin. Warfarin should be preferred in high risk patients with left 
      ventricular dysfunction with or without a mural thrombus, and those with 
      associated atrial fibrillation.
FAU - Magnani, B
AU  - Magnani B
AD  - Istituto di Malattie dell'Apparato Cardiovascolare, Università degli Studi, 
      Bologna.
FAU - Semprini, F
AU  - Semprini F
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Aspirina a basse dosi nel trattamento a lungo termine del paziente con 
      cardiopatia ischemica.
PL  - Italy
TA  - Cardiologia
JT  - Cardiologia (Rome, Italy)
JID - 8506637
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina Pectoris/drug therapy
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Coronary Artery Bypass
MH  - Humans
MH  - Myocardial Infarction/drug therapy/therapy
MH  - Myocardial Ischemia/*drug therapy/therapy
MH  - Time Factors
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
PST - ppublish
SO  - Cardiologia. 1994 Dec;39(12 Suppl 1):15-21.

PMID- 23996718
OWN - NLM
STAT- MEDLINE
DCOM- 20140424
LR  - 20130902
IS  - 1735-1502 (Print)
IS  - 1735-1502 (Linking)
VI  - 12
IP  - 4
DP  - 2013 Aug 28
TI  - Short-term beneficial effect of aspirin in patient with chronic rhinosinusitis 
      and tolerant to acetylsalicylic acid.
PG  - 400-3
AB  - It is well known that desensitization treatment with aspirin can significantly 
      improve symptoms and quality of life in patient with aspirin-exacerbated 
      respiratory disease. However, its mechanism has not been clearly understood yet. 
      In this case report, 41-year-old male patient was referred to our allergy and 
      immunology department with complaints of chronic rhinosinusitis including 
      postnasal discharge, sneezing, facial pain/pressure, waking up tired, nasal 
      obstruction, smell loss for a long time. According to the patient, the complaints 
      were controlled partially with nasal steroid and antihistamines, and single dose 
      parenteral depot steroids were highly effective in controlling the symptoms and 
      each time this effect lasted at least three weeks. The patient was told to use 
      aspirin when needed analgesic and he started to use aspirin 500 mg bid. po for 10 
      days for his pain in the joints. The patient stressed the superiority of aspirin 
      over other drugs including oral antihistamine and LTA and its equality to 
      systemic steroid drugs in suppressing symptoms. It seemed that aspirin had 
      positive effects in allergic inflammation at least in some subset of aspirin 
      tolerant patients with chronic sinusitis.
FAU - Kutlu, Ali
AU  - Kutlu A
AD  - Department of Immunulogy and Allergology, GATA Haydarpasa Training Hospital, 
      Istanbul, Turkey. kotiloglu@hotmail.com.
FAU - Salihoglu, Murat
AU  - Salihoglu M
FAU - Haholu, Aptullah
AU  - Haholu A
FAU - Cesmeci, Enver
AU  - Cesmeci E
FAU - Cincik, Hakan
AU  - Cincik H
FAU - Ozturk, Sami
AU  - Ozturk S
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20130828
PL  - Iran
TA  - Iran J Allergy Asthma Immunol
JT  - Iranian journal of allergy, asthma, and immunology
JID - 101146178
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Chronic Disease
MH  - Humans
MH  - Male
MH  - Rhinitis/*drug therapy
MH  - Sinusitis/*drug therapy
EDAT- 2013/09/03 06:00
MHDA- 2014/04/25 06:00
CRDT- 2013/09/03 06:00
PHST- 2012/10/14 00:00 [received]
PHST- 2013/01/21 00:00 [accepted]
PHST- 2013/01/13 00:00 [revised]
PHST- 2013/09/03 06:00 [entrez]
PHST- 2013/09/03 06:00 [pubmed]
PHST- 2014/04/25 06:00 [medline]
PST - epublish
SO  - Iran J Allergy Asthma Immunol. 2013 Aug 28;12(4):400-3.

PMID- 36652191
OWN - NLM
STAT- MEDLINE
DCOM- 20230614
LR  - 20230616
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Print)
IS  - 0391-4097 (Linking)
VI  - 46
IP  - 7
DP  - 2023 Jul
TI  - Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort.
PG  - 1423-1428
LID - 10.1007/s40618-022-02001-3 [doi]
AB  - PURPOSE: Aspirin use among patients with diabetes in primary prevention is still 
      a matter of debate. We aimed to evaluate the potential cardiovascular risk 
      benefit of aspirin in primary prevention, using data from a contemporary cohort. 
      METHODS: Retrospective analysis of the VITAL cohort with > 20,000 individuals at 
      primary prevention who were followed for a median of 5.3 years. The population 
      was evaluated according to the baseline diabetes status, and then aspirin use was 
      evaluated among diabetic patients. Cox regression models were used to estimate 
      the risks of mortality and cardiovascular outcomes. The estimates were reported 
      using adjusted hazard ratio (HR) and 95% confidence intervals (95%CI). RESULTS: 
      Diabetic patients (n = 3549; 13.7%) showed to increase the risk of all-cause 
      mortality (HR 1.61, 95%CI 1.33-1.94), and major adverse cardiovascular events 
      (MACE) (HR 1.36 95%CI 1.11-1.68) than non-diabetic population. Diabetic patients 
      taking aspirin were older, more frequently man, hypertensive, current users of 
      statins, and current smokers compared with diabetic patients who did not use 
      aspirin at baseline. There was no difference between diabetic aspirin users and 
      non-users regarding all-cause mortality (HR 0.80, 95%CI 0.59, 1.10), MACE (HR 
      0.92, 95%CI 0.64, 1.33), coronary heart disease (HR 0.98, 95%CI 0.67, 1.43), or 
      stroke (HR 0.87, 95%CI 0.48, 1.58). CONCLUSIONS: The VITAL data confirmed 
      diabetes as an important risk factor for cardiovascular events in a contemporary 
      cohort but did not show cardiovascular benefits of aspirin in primary prevention 
      among people with diabetes who were shown to be at higher risk of cardiovascular 
      events.
CI  - © 2023. The Author(s).
FAU - Caldeira, D
AU  - Caldeira D
AD  - Centro Cardiovascular da Universidade de Lisboa-CCUL (CCUL@RISE), Faculdade de 
      Medicina, CEMBE, CAML, Universidade de Lisboa, Lisbon, Portugal. 
      dgcaldeira@hotmail.com.
AD  - Serviço de Cardiologia, Hospital Universitário de Santa Maria-CHULN, Lisbon, 
      Portugal. dgcaldeira@hotmail.com.
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, 
      Universidade de Lisboa, Lisbon, Portugal. dgcaldeira@hotmail.com.
FAU - Alves, M
AU  - Alves M
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, 
      Universidade de Lisboa, Lisbon, Portugal.
AD  - Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, 
      Lisbon, Portugal.
AD  - Serviço de Medicina III, Hospital Pulido Valente, CHLN, Lisbon, Portugal.
FAU - Ferreira, J J
AU  - Ferreira JJ
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, 
      Universidade de Lisboa, Lisbon, Portugal.
AD  - Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, 
      Lisbon, Portugal.
FAU - Pinto, F J
AU  - Pinto FJ
AD  - Centro Cardiovascular da Universidade de Lisboa-CCUL (CCUL@RISE), Faculdade de 
      Medicina, CEMBE, CAML, Universidade de Lisboa, Lisbon, Portugal.
AD  - Serviço de Cardiologia, Hospital Universitário de Santa Maria-CHULN, Lisbon, 
      Portugal.
LA  - eng
PT  - Journal Article
DEP - 20230118
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Male
MH  - Humans
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/epidemiology
MH  - Retrospective Studies
MH  - *Diabetes Mellitus
MH  - *Hypertension
PMC - PMC10261209
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Diabetes
OT  - Primary prevention
COIS- DC has participated in educational meetings and/or attended a conferences or 
      symposia (including travel, accommodation and/or hospitality) with Bial, 
      Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Merck Serono, 
      Ferrer, Pfizer, Novartis and Roche. JJF is a consultant for Ipsen, 
      GlaxoSmithKline, Novartis, Teva, Lundbeck, Solvay, Abbott, BIAL, Merck Serono, 
      and Merz and received grants from GlaxoSmithKline, Grunenthal, Teva, and Fundação 
      MSD. FJP had consultant and speaker fees with Astra Zeneca, Bayer, BMS, 
      Boehringer Ingelheim and Daiichi Sankyo. The remaining authors have nothing to 
      declare.
EDAT- 2023/01/19 06:00
MHDA- 2023/06/14 06:42
CRDT- 2023/01/18 11:28
PHST- 2022/10/05 00:00 [received]
PHST- 2022/12/29 00:00 [accepted]
PHST- 2023/06/14 06:42 [medline]
PHST- 2023/01/19 06:00 [pubmed]
PHST- 2023/01/18 11:28 [entrez]
AID - 10.1007/s40618-022-02001-3 [pii]
AID - 2001 [pii]
AID - 10.1007/s40618-022-02001-3 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2023 Jul;46(7):1423-1428. doi: 10.1007/s40618-022-02001-3. 
      Epub 2023 Jan 18.

PMID- 2505243
OWN - NLM
STAT- MEDLINE
DCOM- 19891010
LR  - 20190713
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 86
IP  - 3
DP  - 1989 Sep 1
TI  - Therapies to limit infarct size. Timing, dosage, and effectiveness.
PG  - 54-9, 63
AB  - Rapid diagnosis of an evolving acute myocardial infarction and institution of 
      thrombolytic therapy in appropriate patients can markedly decrease infarct size 
      and thus reduce cardiovascular morbidity and mortality. Streptokinase 
      (Kabikinase, Streptase) and recombinant tissue plasminogen activator (Activase) 
      are both widely used, effective clot-dissolving agents. Patients who are not 
      candidates for thrombolytic therapy can be treated with other methods, such as 
      anticoagulant therapy, which can greatly reduce infarct size. Intravenous 
      heparin, beta blockers, nitroglycerin, and aspirin have all been shown to limit 
      infarct size, decrease mortality, or do both in patients with acute myocardial 
      infarction.
FAU - Peterson, J E
AU  - Peterson JE
AD  - Cardiovascular Department, University of Kansas Medical Center, Kansas City 
      66103.
FAU - Emmot, W W
AU  - Emmot WW
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Fibrinolytic Agents)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Calcium Channel Blockers/administration & dosage/*therapeutic use
MH  - Drug Administration Schedule
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Nitroglycerin/administration & dosage
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
AID - 10.1080/00325481.1989.11704382 [doi]
PST - ppublish
SO  - Postgrad Med. 1989 Sep 1;86(3):54-9, 63. doi: 10.1080/00325481.1989.11704382.

PMID- 7589229
OWN - NLM
STAT- MEDLINE
DCOM- 19951204
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 293
IP  - 2
DP  - 1995 Jul 1
TI  - Chronopharmacological study of acetylsalicylic acid in mice.
PG  - 151-7
AB  - Influence of dosing time on pharmacological effects and toxicity of 
      acetylsalicylic acid was investigated in ICR male mice under light-dark (12:12) 
      cycle. Significant circadian rhythms (day-night rhythms) were demonstrated for 
      hypothermal and analgesic effects at 1 h after an injection of acetylsalicylic 
      acid (200 mg/kg, i.p.) (P < 0.01, respectively). The rhythmic patterns of 
      acetylsalicylic acid induced analgesia and hypothermia resembled overall the 
      rhythms occurring in the non-drugged state. Injection of acetylsalicylic acid 
      resulted in a parallel increase in latency to hot plate and a parallel decrease 
      in rectal temperature. The relationship between plasma salicylate concentrations 
      and responses was not clear. There was also a significant circadian rhythm in 
      acetylsalicylic acid (850 mg/kg, i.p.) induced toxicity with the highest 
      mortality at 17:00 and the lowest one at 05:00 (P < 0.05). Dosing time dependent 
      kinetics of salicylate seems to be related to the rhythm of toxicity of the drug. 
      The time in circadian stage at which acetylsalicylic acid is administered is 
      essentially important in the actions of acetylsalicylic acid.
FAU - Ohdo, S
AU  - Ohdo S
AD  - Department of Clinical Pharmacokinetics Graduate School, Kyushu University, 
      Fukuoka, Japan.
FAU - Ogawa, N
AU  - Ogawa N
FAU - Song, J G
AU  - Song JG
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Analgesics)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/pharmacokinetics/*pharmacology/toxicity
MH  - Animals
MH  - Aspirin/pharmacokinetics/*pharmacology/toxicity
MH  - Body Temperature/drug effects
MH  - Circadian Rhythm/*physiology
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Pain Measurement/drug effects
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
AID - S0014-2999(05)80007-X [pii]
AID - 10.1016/0926-6917(95)00011-9 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1995 Jul 1;293(2):151-7. doi: 10.1016/0926-6917(95)00011-9.

PMID- 10349556
OWN - NLM
STAT- MEDLINE
DCOM- 19990830
LR  - 20190921
IS  - 0363-9045 (Print)
IS  - 0363-9045 (Linking)
VI  - 25
IP  - 6
DP  - 1999 Jun
TI  - Effects of hydrophilic excipients and compression pressure on physical properties 
      and release behavior of aspirin-tableted microcapsules.
PG  - 711-6
AB  - Aspirin ethylcellulose microcapsules were tableted by compression with or without 
      excipients (lactose or polyvinylpyrrolidone [PVP]). The effects of the amount of 
      the excipients and microcapsule size on the crushing strength and release rate of 
      aspirin from tableted microcapsules were investigated. Tablets without excipients 
      had a crushing strength that was independent of the applied pressure and 
      microcapsule size. An increase in compression pressure from 15 to 60 MPa resulted 
      in an increase in the crushing strength of tablets containing 20% or 40% w/w 
      lactose, but the reverse results were obtained for the tableted microcapsules 
      containing 20% or 40% w/w PVP. Results showed that the release rate of aspirin 
      from microcapsules containing lactose or PVP was independent of the compression 
      pressure with the exception of tablets containing 40% w/w lactose. In vitro 
      release profiles of aspirin from tableted microcapsules containing lactose or PVP 
      showed that increasing the concentration of the excipients resulted in an 
      increase in the release rate of aspirin. Values of n were changed by the 
      compression pressure and the added excipients.
FAU - Nokhodchi, A
AU  - Nokhodchi A
AD  - Division of Pharmaceutics, School of Pharmacy, Tabriz Medical Sciences 
      University, Iran.
FAU - Bolourtchian, N
AU  - Bolourtchian N
FAU - Farid, D
AU  - Farid D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - 0 (Capsules)
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - 059QF0KO0R (Water)
RN  - 9004-34-6 (Cellulose)
RN  - FZ989GH94E (Povidone)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/pharmacokinetics
MH  - Capsules/*pharmacokinetics
MH  - Cellulose/chemistry
MH  - Excipients/*pharmacology
MH  - Lactose/chemistry
MH  - Povidone/chemistry
MH  - Pressure
MH  - Solubility
MH  - Tablets/chemistry/*pharmacokinetics
MH  - Water/*chemistry
EDAT- 1999/06/01 00:00
MHDA- 1999/06/01 00:01
CRDT- 1999/06/01 00:00
PHST- 1999/06/01 00:00 [pubmed]
PHST- 1999/06/01 00:01 [medline]
PHST- 1999/06/01 00:00 [entrez]
AID - 10.1081/ddc-100102230 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 1999 Jun;25(6):711-6. doi: 10.1081/ddc-100102230.

PMID- 1869800
OWN - NLM
STAT- MEDLINE
DCOM- 19910916
LR  - 20131121
IS  - 0253-8768 (Print)
IS  - 0253-8768 (Linking)
VI  - 9
IP  - 1
DP  - 1991 Mar
TI  - Failure of aspirin in symptomatic treatment of acute diarrhoea.
PG  - 29-32
AB  - Aspirin-mediated prostaglandin inhibition has been suggested in symptomatic 
      relief of diarrhoea. The aim of the study was to evaluate in a controlled 
      double-blind trial if a short-term treatment with aspirin could limit the 
      clinical course of acute diarrhoea in adults. Seventy patients attending the 
      Department of Infectious Diseases, General Hospital of Malmö, Sweden, with acute 
      diarrhoea due to different causal agents, received either 1500 mg aspirin per day 
      (n = 33) or placebo (n = 37) for two days. No difference was observed in the 
      duration of diarrhoea, frequency and consistency of stools during treatment or 
      subjective general discomfort. The previously reported effect of aspirin on acute 
      diarrhoea could not be confirmed in this clinical study.
FAU - Castor, B
AU  - Castor B
AD  - Department of Infectious Diseases, University of Lund, General Hospital, Malmö, 
      Sweden.
FAU - Thorén, A
AU  - Thorén A
FAU - Barkenius, G
AU  - Barkenius G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Bangladesh
TA  - J Diarrhoeal Dis Res
JT  - Journal of diarrhoeal diseases research
JID - 8402695
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Diarrhea/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1991/03/01 00:00
MHDA- 1991/03/01 00:01
CRDT- 1991/03/01 00:00
PHST- 1991/03/01 00:00 [pubmed]
PHST- 1991/03/01 00:01 [medline]
PHST- 1991/03/01 00:00 [entrez]
PST - ppublish
SO  - J Diarrhoeal Dis Res. 1991 Mar;9(1):29-32.

PMID- 26204233
OWN - NLM
STAT- MEDLINE
DCOM- 20151116
LR  - 20181202
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 58
IP  - 16
DP  - 2015 Aug 27
TI  - Novel Resveratrol-Based Aspirin Prodrugs: Synthesis, Metabolism, and Anticancer 
      Activity.
PG  - 6494-506
LID - 10.1021/acs.jmedchem.5b00536 [doi]
AB  - Regular aspirin use has been convincingly shown to reduce the risk of colorectal 
      cancer. However, long-term use of aspirin leads to gastrotoxicity. Herein, we 
      designed and synthesized a novel class of resveratrol-based aspirin prodrugs to 
      simultaneously release aspirin and resveratrol to attenuate the side effects 
      caused by aspirin. Prodrug RAH exerted enhanced anticancer activities which are 
      better than a physical mixture of aspirin and resveratrol as well as each 
      individually. Metabolism of RAH in mice showed that the majority of RAH is 
      decomposed to release resveratrol and aspirin or salicylic acid either in the 
      intestine or after absorption. Mechanistic studies demonstrate RAH inhibits cell 
      cycle arrest through downregulation of cyclins and induces apoptosis by 
      activation of caspase-3 in cancer cells. These findings highlighted the improved 
      anticancer properties of resveratrol-based aspirin prodrugs. RAH may represent 
      novel and safe alternatives of aspirin for the purpose of daily use in the 
      future.
FAU - Zhu, Yingdong
AU  - Zhu Y
AD  - Center for Excellence in Post-Harvest Technologies, North Carolina Agricultural 
      and Technical State University , North Carolina Research Campus, 500 Laureate 
      Way, Kannapolis, North Carolina 28081, United States.
FAU - Fu, Junsheng
AU  - Fu J
AD  - Center for Excellence in Post-Harvest Technologies, North Carolina Agricultural 
      and Technical State University , North Carolina Research Campus, 500 Laureate 
      Way, Kannapolis, North Carolina 28081, United States.
AD  - College of Life Sciences, Fujian Agriculture and Forestry University , No. 15 
      Shangxiadian Road, Cangshan District, Fuzhou, Fujian Province 350002, P. R. 
      China.
FAU - Shurlknight, Kelly L
AU  - Shurlknight KL
AD  - Center for Excellence in Post-Harvest Technologies, North Carolina Agricultural 
      and Technical State University , North Carolina Research Campus, 500 Laureate 
      Way, Kannapolis, North Carolina 28081, United States.
FAU - Soroka, Dominique N
AU  - Soroka DN
AD  - Center for Excellence in Post-Harvest Technologies, North Carolina Agricultural 
      and Technical State University , North Carolina Research Campus, 500 Laureate 
      Way, Kannapolis, North Carolina 28081, United States.
FAU - Hu, Yuhui
AU  - Hu Y
AD  - Cancer Research Program, Julius L. Chambers Biomedical/Biotechnology Research 
      Institute, North Carolina Central University , 700 George Street, Durham, North 
      Carolina 27707, United States.
FAU - Chen, Xiaoxin
AU  - Chen X
AD  - Cancer Research Program, Julius L. Chambers Biomedical/Biotechnology Research 
      Institute, North Carolina Central University , 700 George Street, Durham, North 
      Carolina 27707, United States.
FAU - Sang, Shengmin
AU  - Sang S
AD  - Center for Excellence in Post-Harvest Technologies, North Carolina Agricultural 
      and Technical State University , North Carolina Research Campus, 500 Laureate 
      Way, Kannapolis, North Carolina 28081, United States.
LA  - eng
GR  - CA159353/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150805
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Cyclins)
RN  - 0 (Prodrugs)
RN  - 0 (Stilbenes)
RN  - EC 3.4.22.- (Caspase 3)
RN  - Q369O8926L (Resveratrol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*chemical synthesis/metabolism/*pharmacology
MH  - Antioxidants/*chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*analogs & derivatives/*chemistry/pharmacology
MH  - Caspase 3/metabolism
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Cyclins/biosynthesis
MH  - Enzyme Activation/drug effects
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Prodrugs/*chemical synthesis/metabolism/pharmacology
MH  - Resveratrol
MH  - Stilbenes/*chemistry/*pharmacology
EDAT- 2015/07/24 06:00
MHDA- 2015/11/17 06:00
CRDT- 2015/07/24 06:00
PHST- 2015/07/24 06:00 [entrez]
PHST- 2015/07/24 06:00 [pubmed]
PHST- 2015/11/17 06:00 [medline]
AID - 10.1021/acs.jmedchem.5b00536 [doi]
PST - ppublish
SO  - J Med Chem. 2015 Aug 27;58(16):6494-506. doi: 10.1021/acs.jmedchem.5b00536. Epub 
      2015 Aug 5.

PMID- 1868633
OWN - NLM
STAT- MEDLINE
DCOM- 19910919
LR  - 20190828
IS  - 0009-9201 (Print)
IS  - 0009-9201 (Linking)
VI  - 34
IP  - 2
DP  - 1991 Jun
TI  - Low-dose aspirin to improve perinatal outcome.
PG  - 251-61
AB  - The list of clinical conditions for which aspirin may produce abatement or 
      reversal of pathologic processes continues to be expanded. There are, however, 
      definite risks reported from the use of aspirin during pregnancy, even though 
      some of the findings have been contradictory. Some of the potential adverse 
      effects on the infant also remain unclear. Potential benefits from the use of low 
      doses of aspirin during pregnancy (although promising) are still experimental. 
      Large clinical trials in the United States and overseas are currently assessing 
      the effectiveness of low-dose aspirin in preventing preeclampsia and fetal growth 
      retardation. A review of the world's literature to date describes over 300 
      pregnancies in which low-dose aspirin has been used with no evidence of major 
      adverse effects. Until more conclusive evidence emerges, however, caution against 
      the indiscriminate use of aspirin in any dose during pregnancy is urged. 
      Clinicians who decide to manage complicated or potentially complicated patients 
      with chronic administration of aspirin must continue to study these mothers, 
      fetuses, and neonates intensively and to document their results. Because of the 
      fear of teratogenic effects in the first trimester, initiation of aspirin therapy 
      should be withheld until the 13th week of gestation. However, current data 
      indicates it can be continued until delivery without complication. Monitoring of 
      these patients should include: warning signs and symptoms of bleeding, serial 
      ultrasonography for fetal growth and fluid, serial fetal echocardiography, and 
      neonatal evaluation for bleeding complications. Such clinical experience will add 
      immensely to our understanding of the safety and efficacy of aspirin during 
      pregnancy.
FAU - Barton, J R
AU  - Barton JR
AD  - University of Tennessee, Memphis.
FAU - Sibai, B M
AU  - Sibai BM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Obstet Gynecol
JT  - Clinical obstetrics and gynecology
JID - 0070014
RN  - 0 (Antibodies)
RN  - 0 (Blood Coagulation Factors)
RN  - 0 (Cardiolipins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies/blood
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Coagulation Factors/analysis
MH  - Cardiolipins/immunology
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Fetus/drug effects
MH  - Humans
MH  - Infant, Newborn
MH  - Lupus Erythematosus, Systemic/drug therapy
MH  - Pre-Eclampsia/*drug therapy
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Purpura, Thrombotic Thrombocytopenic/drug therapy
RF  - 31
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
AID - 10.1097/00003081-199106000-00005 [doi]
PST - ppublish
SO  - Clin Obstet Gynecol. 1991 Jun;34(2):251-61. doi: 
      10.1097/00003081-199106000-00005.

PMID- 25023355
OWN - NLM
STAT- MEDLINE
DCOM- 20140902
LR  - 20211021
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Print)
IS  - 0093-7754 (Linking)
VI  - 41
IP  - 3
DP  - 2014 Jun
TI  - Prevention and treatment of cancer with aspirin: where do we stand?
PG  - 397-401
LID - S0093-7754(14)00117-1 [pii]
LID - 10.1053/j.seminoncol.2014.04.012 [doi]
AB  - Aspirin is arguably the synthesized drug that has been used most commonly in 
      human history. Aspirin was originally developed and marketed for the treatment of 
      inflammatory disorders at the end of the 19th century, but its mechanism of 
      action remained unknown until the second half of the 20th century. Since the 
      latter part of the 20th century aspirin also has been used for the primary and 
      secondary prevention of cardiovascular diseases given its anti-thrombotic 
      properties. An association between intake of aspirin and decreased cancer risk 
      was identified in the past decades. Whether aspirin can be used as an anticancer 
      agent in patients with a diagnosis of cancer was unknown until recently. Recent 
      studies suggest that aspirin might provide therapeutic benefit in the adjuvant 
      treatment of certain forms of cancer. This review provides a critical update on 
      this topic, which has potential implications for oncologists and their patients.
CI  - Copyright © 2014 Elsevier Inc. All rights reserved.
FAU - Pasche, Boris
AU  - Pasche B
AD  - Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest 
      University, Medical Center Blvd, Winston Salem, NC. Electronic address: 
      bpasche@wakehealth.edu.
FAU - Wang, Minghui
AU  - Wang M
AD  - Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest 
      University, Medical Center Blvd, Winston Salem, NC.
FAU - Pennison, Michael
AU  - Pennison M
AD  - Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest 
      University, Medical Center Blvd, Winston Salem, NC.
FAU - Jimenez, Hugo
AU  - Jimenez H
AD  - Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest 
      University, Medical Center Blvd, Winston Salem, NC.
LA  - eng
GR  - P30 CA012197/CA/NCI NIH HHS/United States
GR  - R01 CA108741/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20140424
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Humans
MH  - Neoplasms/blood/*prevention & control
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
PMC - PMC4099965
MID - NIHMS589281
EDAT- 2014/07/16 06:00
MHDA- 2014/09/03 06:00
CRDT- 2014/07/16 06:00
PHST- 2014/07/16 06:00 [entrez]
PHST- 2014/07/16 06:00 [pubmed]
PHST- 2014/09/03 06:00 [medline]
AID - S0093-7754(14)00117-1 [pii]
AID - 10.1053/j.seminoncol.2014.04.012 [doi]
PST - ppublish
SO  - Semin Oncol. 2014 Jun;41(3):397-401. doi: 10.1053/j.seminoncol.2014.04.012. Epub 
      2014 Apr 24.

PMID- 9558035
OWN - NLM
STAT- MEDLINE
DCOM- 19980505
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 43
IP  - 4
DP  - 1998 Apr
TI  - Phosphatidylcholine-associated aspirin accelerates healing of gastric ulcers in 
      rats.
PG  - 786-90
AB  - Based on our previous studies that aspirin (ASA) -induced gastric ulceration in 
      rats can be significantly reduced if the drug is chemically associated with 
      phosphatidylcholine (PC), we undertook the present study to compare gastric ulcer 
      healing rates in rats administered either unmodified or PC-complexed ASA. Gastric 
      ulcers were induced in anesthetized rats by briefly exposing the mucosal surface 
      to 0.2 ml 60% acetic acid followed by randomization of the rats to study groups; 
      daily intragastrically administered saline (control), ASA (36, 54 mg/kg), or 
      ASA-PC complex. In contrast to the 65-70% reduction in ulcer size recorded in 
      controls, ulcer healing was significantly retarded in rats administered 
      unmodified ASA. Conversely, the size of the experimentally induced ulcers was 
      less than control values in rats daily administered the PC-associated ASA, 
      suggesting an acceleration in the rate of ulcer healing. Daily intragastric 
      administration of ASA to rats over the study period also resulted in a 
      significant decrease in surface hydrophobicity from control values as measured by 
      contact angle analysis. However, surface hydrophobicity was partially restored in 
      rats administered the PC-complexed ASA. Consistent with these findings, it was 
      determined that ASA-treated rats had a lower hematocrit than control values, as 
      an index of gastrointestinal bleeding, whereas this parameter remained at control 
      levels in rats administered the PC-complexed ASA. We conclude that PC-associated 
      ASA promotes ulcer healing above the values measured in rats treated with ASA or 
      saline. This property may be attributable to the fact that in contrast to 
      unmodified ASA, which aggravates ulcer healing by transforming the stomach to an 
      acid-permeable state, the protective hydrophobic lining of the stomach is 
      maintained in rats administered PC-associated ASA, thereby allowing ulcer healing 
      of the tissue to proceed.
FAU - Kurinets, A
AU  - Kurinets A
AD  - Department of Integrative Biology, Pharmacology and Physiology, The University of 
      Texas-Houston Medical School, 77030, USA.
FAU - Lichtenberger, L M
AU  - Lichtenberger LM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 0 (Phosphatidylcholines)
RN  - Q40Q9N063P (Acetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetic Acid
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/*pharmacology/toxicity
MH  - Aspirin/administration & dosage/*pharmacology/toxicity
MH  - Drug Combinations
MH  - Male
MH  - Phosphatidylcholines/administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Stomach Ulcer/*chemically induced/*drug therapy
EDAT- 1998/04/29 00:00
MHDA- 1998/04/29 00:01
CRDT- 1998/04/29 00:00
PHST- 1998/04/29 00:00 [pubmed]
PHST- 1998/04/29 00:01 [medline]
PHST- 1998/04/29 00:00 [entrez]
AID - 10.1023/a:1018870131886 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1998 Apr;43(4):786-90. doi: 10.1023/a:1018870131886.

PMID- 27787837
OWN - NLM
STAT- MEDLINE
DCOM- 20180306
LR  - 20181113
IS  - 1534-3111 (Electronic)
IS  - 1522-6417 (Print)
IS  - 1522-6417 (Linking)
VI  - 18
IP  - 11
DP  - 2016 Nov
TI  - Effects of Aspirin on Endothelial Function and Hypertension.
PG  - 83
LID - 83
AB  - PURPOSE OF REVIEW: Endothelial dysfunction is intimately related to the 
      development of various cardiovascular diseases, including hypertension, and is 
      often used as a target for pharmacological treatment. The scope of this review is 
      to assess effects of aspirin on endothelial function and their clinical 
      implication in arterial hypertension. RECENT FINDINGS: Emerging data indicate the 
      role of platelets in the development of vascular inflammation due to the release 
      of proinflammatory mediators, for example, triggered largely by thromboxane. 
      Vascular inflammation further promotes oxidative stress, diminished synthesis of 
      vasodilators, proaggregatory and procoagulant state. These changes translate into 
      vasoconstriction, impaired circulation and thrombotic complications. Aspirin 
      inhibits thromboxane synthesis, abolishes platelets activation and acetylates 
      enzymes switching them to the synthesis of anti-inflammatory substances. Aspirin 
      pleiotropic effects have not been fully elucidated yet. In secondary prevention 
      studies, the decrease in cardiovascular events with aspirin outweighs bleeding 
      risks, but this is not the case in primary prevention settings. Ongoing trials 
      will provide more evidence on whether to expand the use of aspirin or stay within 
      current recommendations.
FAU - Dzeshka, Mikhail S
AU  - Dzeshka MS
AD  - University of Birmingham Institute of Cardiovascular Sciences, City Hospital, 
      Dudley Road, Birmingham, B18 7QH, UK.
AD  - Grodno State Medical University, Grodno, Belarus.
FAU - Shantsila, Alena
AU  - Shantsila A
AD  - University of Birmingham Institute of Cardiovascular Sciences, City Hospital, 
      Dudley Road, Birmingham, B18 7QH, UK.
FAU - Lip, Gregory Y H
AU  - Lip GY
AD  - University of Birmingham Institute of Cardiovascular Sciences, City Hospital, 
      Dudley Road, Birmingham, B18 7QH, UK. g.y.h.lip@bham.ac.uk.
AD  - Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg 
      University, Aalborg, Denmark. g.y.h.lip@bham.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Hypertens Rep
JT  - Current hypertension reports
JID - 100888982
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Clinical Trials as Topic
MH  - Endothelium, Vascular/drug effects
MH  - Humans
MH  - *Hypertension/drug therapy
MH  - Thrombosis
MH  - Vasoconstriction
PMC - PMC5083775
OTO - NOTNLM
OT  - Arterial hypertension
OT  - Aspirin
OT  - Cyclooxygenase
OT  - Endothelial function
OT  - Inflammation
OT  - Platelets
COIS- Drs. Dzeshka, Shantsila, and Lip declare no conflicts of interest relevant to 
      this manuscript. Human and Animal Rights and Informed Consent This article does 
      not contain any studies with human or animal subjects performed by any of the 
      authors.
EDAT- 2016/10/28 06:00
MHDA- 2018/03/07 06:00
CRDT- 2016/10/28 06:00
PHST- 2016/10/28 06:00 [pubmed]
PHST- 2018/03/07 06:00 [medline]
PHST- 2016/10/28 06:00 [entrez]
AID - 10.1007/s11906-016-0688-8 [pii]
AID - 688 [pii]
AID - 10.1007/s11906-016-0688-8 [doi]
PST - ppublish
SO  - Curr Hypertens Rep. 2016 Nov;18(11):83. doi: 10.1007/s11906-016-0688-8.

PMID- 31530207
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20201125
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 31
IP  - 4
DP  - 2020 May 18
TI  - Weight as an assay-independent predictor of poor response to enteric aspirin in 
      cardiovascular patients.
PG  - 530-535
LID - 10.1080/09537104.2019.1667495 [doi]
AB  - Aspirin non-response is associated with poor outcome but there is no agreement 
      between the different methods to asses it. Weight has been shown to be a 
      predictor of poor response but only using one method. In this study, we determine 
      the effects of weight on different assays of platelet function. The response to 
      aspirin was determined in 138 cardiology patients using serum thromboxane, 
      arachidonic acid-induced platelet aggregation and VerifyNow©. Twenty-five percent 
      of patients showed an inadequate response to aspirin in at least one assay on the 
      initial test. After ensuring patient compliance only 5% of patients were 
      considered to be non-responders. Only 9% of non-responders were non-responsive in 
      all three assays. When switched to plain aspirin, only 2% of patients were 
      non-responsive. All patients responded adequately to 150 mg aspirin. The 
      non-responders were significantly heavier than responders (78.5 kg ± 14.0 (SD); 
      BMI: 28.4 kg/m(2)± 4.4 v's 102.6 kg ± 20.6, P = .0016; BMI: 38.3 kg/m(2) ± 7.6, 
      P= .0015). A rule-based approach of using plain aspirin in patients over 90 kg or 
      BMI 32 along with patient education to ensure compliance will ensure that all 
      patients respond to their aspirin without the need for testing.
FAU - McCall, Meadhbh
AU  - McCall M
AD  - Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland , Dublin, 
      Ireland.
FAU - Peace, Aaron
AU  - Peace A
AD  - Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland , Dublin, 
      Ireland.
FAU - Tedesco, Anthony F
AU  - Tedesco AF
AD  - Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland , Dublin, 
      Ireland.
FAU - Foley, David
AU  - Foley D
AD  - Department of cardiology, Beaumont Hospital , Dublin, Ireland.
FAU - Conroy, Ronán M
AU  - Conroy RM
AD  - Department of Epidemiology and Public Health Medicine, Royal College of Surgeons 
      in Ireland , Dublin, Ireland.
FAU - Cox, Dermot
AU  - Cox D
AD  - Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland , Dublin, 
      Ireland.
LA  - eng
PT  - Journal Article
DEP - 20190918
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - *Body Mass Index
MH  - Cardiovascular Diseases/*blood/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Platelet Function Tests
MH  - Thromboxane A2/*blood/therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - aspirin non-response
OT  - enteric-coating
OT  - noncompliance
OT  - thromboxane
EDAT- 2019/09/19 06:00
MHDA- 2020/11/26 06:00
CRDT- 2019/09/19 06:00
PHST- 2019/09/19 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
PHST- 2019/09/19 06:00 [entrez]
AID - 10.1080/09537104.2019.1667495 [doi]
PST - ppublish
SO  - Platelets. 2020 May 18;31(4):530-535. doi: 10.1080/09537104.2019.1667495. Epub 
      2019 Sep 18.

PMID- 26194372
OWN - NLM
STAT- MEDLINE
DCOM- 20180308
LR  - 20181202
IS  - 2005-9256 (Electronic)
IS  - 1598-2998 (Print)
IS  - 1598-2998 (Linking)
VI  - 48
IP  - 2
DP  - 2016 Apr
TI  - Long-Term Low-Dose Aspirin Use Reduces Gastric Cancer Incidence: A Nationwide 
      Cohort Study.
PG  - 798-805
LID - 10.4143/crt.2015.117 [doi]
AB  - PURPOSE: The aim of this study was to investigate whether aspirin use can reduce 
      the incidence of gastric cancer in patients with hypertension or type 2 diabetes. 
      MATERIALS AND METHODS: A total of 200,000 patients with hypertension or type 2 
      diabetes were randomly selected from the Korean National Health Insurance claim 
      database. Of these, 3,907 patients who used 100 mg of aspirin regularly (regular 
      aspirin users) and 7,808 patients who did not use aspirin regularly (aspirin 
      non-users) were selected at a frequency of 1:2, matched by age, sex, comorbid 
      illnesses (type 2 diabetes and hypertension), and observation periods. The 
      incidence of gastric cancer in this cohort was then assessed during the 
      observation period of 2004 to 2010. RESULTS: In the matched cohort, the incidence 
      rates of gastric cancer were 0.8% (31/3,907) for regular aspirin users and 1.1% 
      (86/7,808) for aspirin non-users, but the cumulative incidence rates were not 
      significantly different between groups (p=0.116, log-rank test). However, in 
      multivariate analysis, regular aspirin users had a reduced risk of gastric cancer 
      (adjusted hazard ratio [aHR], 0.71; 95% confidential interval [CI], 0.47 to 1.08; 
      p=0.107). Duration of aspirin use showed significant association with reduction 
      of gastric cancer risk (aHR for each year of aspirin use, 0.85; 95% CI, 0.73 to 
      0.99; p=0.044), particularly in patients who used aspirin for more than 3 years 
      (aHR, 0.40; 95% CI, 0.16 to 0.98; p=0.045). CONCLUSION: Long-term low-dose 
      aspirin use was associated with reduced gastric cancer risk in patients with 
      hypertension or type 2 diabetes.
FAU - Kim, Young-Il
AU  - Kim YI
AD  - Center for Gastric Cancer, National Cancer Center, Goyang, Korea.
FAU - Kim, So Young
AU  - Kim SY
AD  - Office of Public Health, Chungbuk National University Hospital, Cheongju, Korea.
FAU - Kim, Ji Hyun
AU  - Kim JH
AD  - Statistics and Actuarial Science, Soongsil University, Seoul, Korea.
FAU - Lee, Jun Ho
AU  - Lee JH
AD  - Center for Gastric Cancer, National Cancer Center, Goyang, Korea.
AD  - Department of Surgery, Sungkyunkwan University School of Medicine, Samsung 
      Medical Center, Seoul, Korea.
FAU - Kim, Young-Woo
AU  - Kim YW
AD  - Center for Gastric Cancer, National Cancer Center, Goyang, Korea.
FAU - Ryu, Keun Won
AU  - Ryu KW
AD  - Center for Gastric Cancer, National Cancer Center, Goyang, Korea.
FAU - Park, Jong-Hyock
AU  - Park JH
AD  - Department of Preventive Medicine, College of Medicine, Chungbuk National 
      University, Cheongju, Korea.
AD  - Graduate School of Health Science Business Convergence, Chungbuk National 
      University, Cheongju, Korea.
FAU - Choi, Il Ju
AU  - Choi IJ
AD  - Center for Gastric Cancer, National Cancer Center, Goyang, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150714
PL  - Korea (South)
TA  - Cancer Res Treat
JT  - Cancer research and treatment
JID - 101155137
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Cohort Studies
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/epidemiology
MH  - Female
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Republic of Korea/epidemiology
MH  - Stomach Neoplasms/*drug therapy/*epidemiology
PMC - PMC4843744
OTO - NOTNLM
OT  - Aspirin
OT  - Low-dose
OT  - Risk
OT  - Stomach neoplasms
COIS- Conflict of interest relevant to this article was not reported.
EDAT- 2015/07/22 06:00
MHDA- 2018/03/09 06:00
CRDT- 2015/07/22 06:00
PHST- 2015/03/25 00:00 [received]
PHST- 2015/05/31 00:00 [accepted]
PHST- 2015/07/22 06:00 [entrez]
PHST- 2015/07/22 06:00 [pubmed]
PHST- 2018/03/09 06:00 [medline]
AID - crt.2015.117 [pii]
AID - crt-2015-117 [pii]
AID - 10.4143/crt.2015.117 [doi]
PST - ppublish
SO  - Cancer Res Treat. 2016 Apr;48(2):798-805. doi: 10.4143/crt.2015.117. Epub 2015 
      Jul 14.

PMID- 26270530
OWN - NLM
STAT- MEDLINE
DCOM- 20160506
LR  - 20220408
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 8
DP  - 2015
TI  - Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A 
      Meta-Analysis.
PG  - e0135372
LID - 10.1371/journal.pone.0135372 [doi]
LID - e0135372
AB  - BACKGROUND AND PURPOSE: Antiplatelet therapy is widely used for the primary or 
      secondary prevention of stroke. Drugs like clopidogrel have emerged as 
      alternatives for traditional antiplatelet therapy, and dual therapy with 
      clopidogrel and aspirin is of particular interest. We conducted this 
      meta-analysis to systematically review studies about dual therapy comparing 
      monotherapy with aspirin alone. METHODS: Randomized controlled trials were 
      searched in PubMed (1966-May, 2015), EMBASE (1947-May, 2015), the Cochrane 
      Central Register of Controlled Trials (CENTRAL) (1948-May, 2015), WHO 
      International Clinical Trial (ICTRP) (2004-May, 2015), China Biology Medicine 
      disc (CBM disc) (1978-May, 2015) and were included into the final analysis 
      according to the definite inclusion criteria mentioned in the study selection 
      section. Risk ratio (RR) was pooled with 95% confidence interval (CI) for 
      dichotomous data. The heterogeneity was considered significant if the χ2 test was 
      significant (P value < 0.10) or the I2 > 50.00%. Subgroup analyses were carried 
      out on the long and short time periods, the race and region. RESULTS: We included 
      5 studies involving 24,084 patients. A pooled analysis showed that dual therapy 
      with clopidogrel and aspirin had a lower stroke incidence than monotherapy in 
      both the short term and long term (RR = 0.69, 95% CI: 0.59-0.82, P <0.05; RR = 
      0.84, 95% CI: 0.72-0.98, P = 0.03, respectively). With regard to safety, dual 
      therapy had a higher risk of bleeding than monotherapy for both periods (RR = 
      1.51, 95% CI: 1.03-2.23, P = 0.04; RR = 1.54, 95% CI: 1.32-1.79, P<0.05, 
      respectively). CONCLUSIONS: Dual therapy with clopidogrel and aspirin could be a 
      preferable choice to prevent stroke in patients who have had a previous stroke or 
      transient ischemic attack, as well as those who are at high risk for stroke. And 
      the effect of dual therapy seems to be more obvious for short-term. However, it 
      is associated with a higher risk of bleeding.
FAU - Tan, Shuai
AU  - Tan S
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou 510080, People's Republic of China.
FAU - Xiao, Xiaojuan
AU  - Xiao X
AD  - Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou 510080, People's Republic of China.
FAU - Ma, Hanyu
AU  - Ma H
AD  - Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou 510080, People's Republic of China.
FAU - Zhang, Zhaohui
AU  - Zhang Z
AD  - Department of Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou 510080, People's Republic of China.
FAU - Chen, Jiangbo
AU  - Chen J
AD  - Department of Interventional Radiology, The First Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou 510080, People's Republic of China.
FAU - Ding, Lei
AU  - Ding L
AD  - Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou 510080, People's Republic of China.
FAU - Yu, Shenping
AU  - Yu S
AD  - Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou 510080, People's Republic of China.
FAU - Xu, Rulin
AU  - Xu R
AD  - Department of Cardiology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou 510080, People's Republic of China.
FAU - Yang, Shiliang
AU  - Yang S
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou 510080, People's Republic of China.
FAU - Huang, Xinyi
AU  - Huang X
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou 510080, People's Republic of China.
FAU - Hong, Hua
AU  - Hong H
AD  - Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou 510080, People's Republic of China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150813
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Stroke/*prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
PMC - PMC4536208
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/08/14 06:00
MHDA- 2016/05/07 06:00
CRDT- 2015/08/14 06:00
PHST- 2015/01/03 00:00 [received]
PHST- 2015/07/21 00:00 [accepted]
PHST- 2015/08/14 06:00 [entrez]
PHST- 2015/08/14 06:00 [pubmed]
PHST- 2016/05/07 06:00 [medline]
AID - PONE-D-14-55981 [pii]
AID - 10.1371/journal.pone.0135372 [doi]
PST - epublish
SO  - PLoS One. 2015 Aug 13;10(8):e0135372. doi: 10.1371/journal.pone.0135372. 
      eCollection 2015.

PMID- 3993867
OWN - NLM
STAT- MEDLINE
DCOM- 19850528
LR  - 20190820
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 40
IP  - 2
DP  - 1985 Feb
TI  - The effect of aspirin during aspirin "desensitisation" on compound 48/80 and 
      histamine-induced skin responses in aspirin-sensitive asthmatics.
PG  - 130-5
AB  - In a group of aspirin-sensitive asthmatics we studied skin weal and flare 
      responses to intradermal injections of compound 48/80 and histamine during oral 
      aspirin (ASA) provocation and after ASA "desensitisation". During provocation 
      (bronchospasm accompanied by naso-ocular symptoms) the mean weal area after 
      compound 48/80 increased to about 42.4% (P less than 0.05). Neither the threshold 
      (provocative) doses of ASA nor 600 mg ASA, when given after ASA-desensitisation, 
      significantly influenced the weal reactions to compound 48/80 (mean changes of 
      area were -1.8% and -16.5% respectively). Aspirin did not change flare reactions 
      to compound 48/80 and weal and flare reactions to histamine on any of the three 
      study occasions. Initial (pre-aspirin) weal reactions to compound 48/80 after 
      desensitisation to the threshold ASA doses were significantly reduced, but after 
      desensitisation to 600 mg ASA were significantly increased as compared with the 
      reactions before. These data suggest that ASA-"desensitisation" may influence the 
      skin reactivity to non-specific mast cell degranulating stimulus in ASA-sensitive 
      asthmatics.
FAU - Kowalski, M L
AU  - Kowalski ML
FAU - Szmidt, M
AU  - Szmidt M
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
FAU - Rozniecki, J
AU  - Rozniecki J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 4091-50-3 (p-Methoxy-N-methylphenethylamine)
RN  - 820484N8I3 (Histamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*pharmacology
MH  - Asthma/immunology
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/*immunology/therapy
MH  - Female
MH  - Histamine/*pharmacology
MH  - Humans
MH  - Intradermal Tests
MH  - Male
MH  - Middle Aged
MH  - Skin/drug effects/immunology
MH  - p-Methoxy-N-methylphenethylamine/*pharmacology
EDAT- 1985/02/01 00:00
MHDA- 1985/02/01 00:01
CRDT- 1985/02/01 00:00
PHST- 1985/02/01 00:00 [pubmed]
PHST- 1985/02/01 00:01 [medline]
PHST- 1985/02/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1985.tb02672.x [doi]
PST - ppublish
SO  - Allergy. 1985 Feb;40(2):130-5. doi: 10.1111/j.1398-9995.1985.tb02672.x.

PMID- 32698591
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 1559-4106 (Electronic)
IS  - 1559-4106 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Jul 22
TI  - General and adaptive synthesis protocol for high-quality organosilane 
      self-assembled monolayers as tunable surface chemistry platforms for biochemical 
      applications.
PG  - 041005
LID - 10.1116/6.0000250 [doi]
AB  - The controlled modification of surface properties represents a pervasive 
      requirement to be fulfilled when developing new technologies. In this paper, we 
      propose an easy-to-implement protocol for the functionalization of glass with 
      self-assembled monolayers (SAMs). The adaptivity of the synthesis route was 
      demonstrated by the controlled anchoring of thiol, amino, glycidyloxy, and 
      methacrylate groups onto the glass surface. The optimization of the synthetic 
      pathway was mirrored by extremely smooth SAMs (approximately 150 pm roughness), 
      layer thickness comparable to the theoretical molecule length, absence of silane 
      islands along the surface, quasi-unitary degree of packing, and tailored 
      wettability and charge. The functionalization kinetics of two model silanes, 
      3-mercapto- and 3-amino-propyltrimethoxysilane, was determined by cross-comparing 
      x-ray photoelectron spectroscopy and time of flight secondary ion mass 
      spectrometry data. Our SAMs with tailored physicochemical attributes will be 
      implemented as supports for the crystallization of pharmaceuticals and 
      biomolecules in upcoming studies. Here, the application to a small molecule drug 
      model, namely aspirin, was discussed as a proof of concept.
FAU - Artusio, Fiora
AU  - Artusio F
AUID- ORCID: 0000000289960053
AD  - Department of Applied Science and Technology, Politecnico di Torino, Corso Duca 
      degli Abruzzi 24, 10129, Torino, Italy.
FAU - Fumagalli, Francesco
AU  - Fumagalli F
AUID- ORCID: 0000000321729469
AD  - European Commission, Joint Research Centre (JRC), Via E. Fermi, 2749, 2102, 
      Ispra, Italy.
FAU - Bañuls-Ciscar, Jorge
AU  - Bañuls-Ciscar J
AUID- ORCID: 0000000184379377
AD  - European Commission, Joint Research Centre (JRC), Via E. Fermi, 2749, 2102, 
      Ispra, Italy.
FAU - Ceccone, Giacomo
AU  - Ceccone G
AUID- ORCID: 0000000346370771
AD  - European Commission, Joint Research Centre (JRC), Via E. Fermi, 2749, 2102, 
      Ispra, Italy.
FAU - Pisano, Roberto
AU  - Pisano R
AUID- ORCID: 0000000169903126
AD  - Department of Applied Science and Technology, Politecnico di Torino, Corso Duca 
      degli Abruzzi 24, 10129, Torino, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200722
PL  - United States
TA  - Biointerphases
JT  - Biointerphases
JID - 101275679
RN  - 0 (Biocompatible Materials)
RN  - 0 (Organosilicon Compounds)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Biocompatible Materials/chemistry
MH  - Crystallization
MH  - Glass/chemistry
MH  - Kinetics
MH  - Organosilicon Compounds/*chemistry
MH  - Photoelectron Spectroscopy
MH  - Surface Properties
EDAT- 2020/07/24 06:00
MHDA- 2021/10/05 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
AID - 10.1116/6.0000250 [doi]
PST - epublish
SO  - Biointerphases. 2020 Jul 22;15(4):041005. doi: 10.1116/6.0000250.

PMID- 2049688
OWN - NLM
STAT- MEDLINE
DCOM- 19910725
LR  - 20131121
IS  - 0828-282X (Print)
IS  - 0828-282X (Linking)
VI  - 7
IP  - 2
DP  - 1991 Mar
TI  - Effect of aspirin on intimal hyperplasia and cholesterol uptake in experimental 
      bypass grafts.
PG  - 87-90
AB  - The effects of aspirin on intimal and medial smooth muscle cell proliferation and 
      cholesterol uptake in experimental bypass grafts were examined in a 
      hypercholesterolemic canine model. Ten animals receiving a 2% cholesterol diet 
      served as controls, while a further 10 animals received the same diet and 160 mg 
      aspirin daily. Segments of external jugular vein were implanted between 
      bilaterally divided femoral arteries. Tissue cholesterol and intimal and medial 
      thicknesses were measured at six weeks. Graft cholesterol had increased 1.7 
      mumol/g at six weeks in the control group but only rose by 0.28 mumol/g in 
      animals receiving aspirin (P less than 0.002). Intimal and medial smooth muscle 
      cell proliferation was evident in all experimental bypass grafts and was 
      unaffected by aspirin. It is concluded that cholesterol uptake and smooth muscle 
      proliferation may be controlled by different mechanisms, and that aspirin reduces 
      cholesterol uptake but does not prevent smooth muscle cell proliferation in 
      experimental bypass grafts.
FAU - Landymore, R W
AU  - Landymore RW
AD  - Department of Surgery, Dalhousie University, Halifax, Nova Scotia.
FAU - MacAulay, M A
AU  - MacAulay MA
FAU - Fris, J
AU  - Fris J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteriosclerosis/prevention & control
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cell Division/drug effects
MH  - Cholesterol/*analysis
MH  - Dogs
MH  - Graft Occlusion, Vascular/prevention & control
MH  - Hyperplasia/*prevention & control
MH  - Muscle, Smooth, Vascular/*drug effects/physiology/transplantation
MH  - Thrombosis/prevention & control
MH  - *Vascular Surgical Procedures/methods
EDAT- 1991/03/01 00:00
MHDA- 1991/03/01 00:01
CRDT- 1991/03/01 00:00
PHST- 1991/03/01 00:00 [pubmed]
PHST- 1991/03/01 00:01 [medline]
PHST- 1991/03/01 00:00 [entrez]
PST - ppublish
SO  - Can J Cardiol. 1991 Mar;7(2):87-90.

PMID- 29989599
OWN - NLM
STAT- MEDLINE
DCOM- 20190930
LR  - 20190930
IS  - 1827-6806 (Print)
IS  - 1827-6806 (Linking)
VI  - 19
IP  - 7
DP  - 2018 Jul-Aug
TI  - [Dual antiplatelet therapy in elderly patients with acute coronary syndrome: does 
      age make the difference?].
PG  - 420-428
LID - 10.1714/2938.29538 [doi]
AB  - The appropriate use of dual antiplatelet therapy (DAPT) in elderly patients with 
      acute coronary syndrome (ACS) remains a highly debated subject. In fact, 
      achieving the correct balance between the reduction of ischemic risk and the 
      increase in hemorrhagic events is more difficult in this population than in 
      younger subjects, especially in the case of very potent drug therapy. As a 
      consequence of this, despite guideline recommendations, antiplatelet therapy is 
      currently underutilized in elderly patients with ACS.In current clinical 
      practice, the antiplatelet drugs that can be used in combination with aspirin are 
      clopidogrel, prasugrel and ticagrelor. The efficacy of these molecules is 
      supported by randomized clinical trials, which gave variable results in terms of 
      the extent of reduction in ischemic events and increase in hemorrhagic 
      complications. The purpose of this article is to identify, based on the results 
      of a consensus meeting, common elements in the use of DAPT in the elderly and to 
      identify areas where further scientific evidence is required to better define the 
      role of the individual antiplatelet agents.
FAU - Tarantini, Giuseppe
AU  - Tarantini G
AD  - Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari, Università degli 
      Studi, Padova.
FAU - Cirillo, Plinio
AU  - Cirillo P
AD  - Dipartimento di Scienze Biomediche Avanzate, Università degli Studi "Federico 
      II", Napoli.
FAU - De Servi, Stefano
AU  - De Servi S
AD  - Divisione di Cardiologia, IRCCS Multimedica, Sesto San Giovanni (MI).
FAU - Parodi, Guido
AU  - Parodi G
AD  - Cardiologia Clinica ed Interventistica, Azienda Ospedaliero-Universitaria 
      Sassari, Sassari.
FAU - Capodanno, Davide
AU  - Capodanno D
AD  - Dipartimento Cardio-Toraco-Vascolare, Azienda-Ospedaliero Universitaria 
      "Policlinico Vittorio Emanuele", Catania, e Dipartimento di Chirurgia Generale e 
      Specialità Medico-Chirurgiche, Università degli Studi, Catania.
FAU - D'Amico, Gianpiero
AU  - D'Amico G
AD  - Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari, Università degli 
      Studi, Padova.
FAU - Boccanelli, Alessandro
AU  - Boccanelli A
AD  - Dipartimento di Malattie dell'Apparato Cardiocircolatorio, A.O. San 
      Giovanni-Addolorata, Roma.
FAU - Cattaneo, Marco
AU  - Cattaneo M
AD  - Unità di Medicina 3, Ospedale San Paolo, Dipartimento di Scienze della Salute, 
      Università degli Studi, Milano.
FAU - Bolognese, Leonardo
AU  - Bolognese L
AD  - Dipartimento Cardiovascolare e Neurologico, Ospedale San Donato, Arezzo.
FAU - Cavallini, Claudio
AU  - Cavallini C
AD  - Divisione di Cardiologia, Ospedale S. Maria della Misericordia, Perugia.
FAU - Musumeci, Giuseppe
AU  - Musumeci G
AD  - U.S.C. Cardiologia, Ospedale Santa Croce e Carle, Cuneo.
FAU - Marchionni, Niccolò
AU  - Marchionni N
AD  - Cattedra di Geriatria, Università degli Studi, e S.O.D. Cardiologia e Medicina 
      Geriatrica, Azienda Ospedaliero-Universitaria Careggi, Firenze.
LA  - ita
PT  - Journal Article
TT  - Scelta della duplice terapia antiaggregante nel paziente anziano con sindrome 
      coronarica acuta: l’età fa la differenza?
PL  - Italy
TA  - G Ital Cardiol (Rome)
JT  - Giornale italiano di cardiologia (2006)
JID - 101263411
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Age Factors
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Practice Guidelines as Topic
MH  - Randomized Controlled Trials as Topic
EDAT- 2018/07/11 06:00
MHDA- 2019/10/01 06:00
CRDT- 2018/07/11 06:00
PHST- 2018/07/11 06:00 [entrez]
PHST- 2018/07/11 06:00 [pubmed]
PHST- 2019/10/01 06:00 [medline]
AID - 10.1714/2938.29538 [doi]
PST - ppublish
SO  - G Ital Cardiol (Rome). 2018 Jul-Aug;19(7):420-428. doi: 10.1714/2938.29538.

PMID- 32878672
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1467-1107 (Electronic)
IS  - 1047-9511 (Linking)
VI  - 30
IP  - 10
DP  - 2020 Oct
TI  - Compliance with aspirin in paediatric CHD post-percutaneous transcatheter 
      occlusion: a cross-sectional study.
PG  - 1462-1468
LID - 10.1017/S1047951120002322 [doi]
AB  - BACKGROUND: Predictors of compliance with aspirin in children following cardiac 
      catheterisation have not been identified. The aim of this study is to identify 
      the caregivers' knowledge, compliance with aspirin medication, and predictors of 
      compliance with aspirin in children with Congenital Heart Disease (CHD) 
      post-percutaneous transcatheter occlusion. METHODS: A cross-sectional explorative 
      design was adopted using a self-administered questionnaire and conducted between 
      May 2017 and May 2018. Recruited were 220 caregivers of children with CHD 
      post-percutaneous transcatheter occlusion. Questionnaires included child and 
      caregivers' characteristics, a self-designed and tested knowledge about aspirin 
      scale (scoring scale 0-2), and the 8-item Morisky Medication Adherence Scale 
      (scoring scale 0-8). Data were analysed using multivariate binary logistic 
      regression analysis to identify predictors of compliance with aspirin. RESULTS: 
      Of the 220 eligible children and caregivers, 210 (95.5%) responded and 209 
      surveys were included in the analysis. The mean score of knowledge was 7.25 
      (standard deviation 2.27). The mean score of compliance was 5.65 (standard 
      deviation 1.36). Child's age, length of aspirin use, health insurance policies, 
      relationship to child, monthly income, and knowledge about aspirin of caregivers 
      were independent predictors of compliance with aspirin (p < 0.05). CONCLUSION: 
      Caregivers of children with CHD had an adequate level of knowledge about aspirin. 
      Compliance to aspirin medication reported by caregivers was low. Predictors of 
      medium to high compliance with aspirin were related to the child's age and 
      socio-economic reasons. Further studies are needed to identify effective 
      strategies to improve knowledge, compliance with medication, and long-term 
      outcomes of children with CHD.
FAU - Song, Qing-Qing
AU  - Song QQ
AUID- ORCID: 0000-0001-5083-9961
AD  - Department of Cardiology, Hunan Children's Hospital, Changsha, Hunan Province, 
      People's Republic of China.
FAU - Zhu, Li-Hui
AU  - Zhu LH
AD  - Department of Nursing, Hunan Children's Hospital, Changsha, Hunan Province, 
      People's Republic of China.
FAU - Chen, Ou-Ying
AU  - Chen OY
AD  - Department of Nursing, Hunan University of Chinese Medicine, Changsha, Hunan 
      Province, People's Republic of China.
FAU - Xiao, Zhi-Rong
AU  - Xiao ZR
AD  - Department of Cardiology, Hunan Children's Hospital, Changsha, Hunan Province, 
      People's Republic of China.
FAU - Chen, Zhi
AU  - Chen Z
AD  - Department of Cardiology, Hunan Children's Hospital, Changsha, Hunan Province, 
      People's Republic of China.
FAU - Xiao, Yun-Bin
AU  - Xiao YB
AD  - Department of Cardiology, Hunan Children's Hospital, Changsha, Hunan Province, 
      People's Republic of China.
FAU - Meng, Jian-Chao
AU  - Meng JC
AD  - Department of Cardiology, Hunan Children's Hospital, Changsha, Hunan Province, 
      People's Republic of China.
FAU - Zuo, Chao
AU  - Zuo C
AD  - Department of Cardiology, Hunan Children's Hospital, Changsha, Hunan Province, 
      People's Republic of China.
FAU - Latour, Jos M
AU  - Latour JM
AD  - Department of Nursing, Hunan Children's Hospital, Changsha, Hunan Province, 
      People's Republic of China.
AD  - School of Nursing and Midwifery, Faculty of Health, University of Plymouth, 
      Plymouth, UK.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - England
TA  - Cardiol Young
JT  - Cardiology in the young
JID - 9200019
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Caregivers
MH  - Child
MH  - Cross-Sectional Studies
MH  - Health Knowledge, Attitudes, Practice
MH  - *Heart Defects, Congenital/therapy
MH  - Humans
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - CHD
OT  - adherence
OT  - aspirin
OT  - catheterisation
OT  - children
OT  - medication
EDAT- 2020/09/04 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - S1047951120002322 [pii]
AID - 10.1017/S1047951120002322 [doi]
PST - ppublish
SO  - Cardiol Young. 2020 Oct;30(10):1462-1468. doi: 10.1017/S1047951120002322. Epub 
      2020 Sep 3.

PMID- 3671471
OWN - NLM
STAT- MEDLINE
DCOM- 19871216
LR  - 20131121
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 42
IP  - 7
DP  - 1987 Jul
TI  - [Preparations of acetylsalicylic acid sustained-release tablets on hydrophilic 
      matrix forms].
PG  - 457-8
AB  - The aim of this study was to prepare a tablet with acetylsalicylic acid based on 
      hydrophilic matrix form by means of polyvinyl alcohol. The liberation was carried 
      out with the column dissolution-rate method. In contrast to other studies, the 
      percentage of the cumulative liberation is decreased by increasing the drug 
      concentration. Acetylsalicylic acid caused a decrease of the wetting and the rate 
      of swelling.
FAU - Süss, W
AU  - Süss W
AD  - Pharmazeutisches Zentrum Oschatz, Klinikapotheke Hubertusburg, Wermsdorf.
FAU - Bruder, K
AU  - Bruder K
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Herstellung von Acetylsalicylsäuretabletten mit verzögerter Wirkstoffliberation 
      auf der Basis hydrophiler Matrixformen.
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Excipients)
RN  - 9002-89-5 (Polyvinyl Alcohol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Chemistry, Pharmaceutical
MH  - Delayed-Action Preparations
MH  - Excipients
MH  - Polyvinyl Alcohol
EDAT- 1987/07/01 00:00
MHDA- 1987/07/01 00:01
CRDT- 1987/07/01 00:00
PHST- 1987/07/01 00:00 [pubmed]
PHST- 1987/07/01 00:01 [medline]
PHST- 1987/07/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1987 Jul;42(7):457-8.

PMID- 3567491
OWN - NLM
STAT- MEDLINE
DCOM- 19870529
LR  - 20190719
IS  - 0007-1331 (Print)
IS  - 0007-1331 (Linking)
VI  - 59
IP  - 3
DP  - 1987 Mar
TI  - Effect of single dose aspirin on the development of penile hypercoagulability 
      during erection.
PG  - 267-71
AB  - The effect of aspirin on the development of hypercoagulability in the penile 
      blood during erection was studied in five Chacma baboons. Aspirin prevented the 
      generation of hypercoagulability and may be of importance in delaying the 
      development of penile atherosclerosis and ageing impotence.
FAU - Bornman, M S
AU  - Bornman MS
FAU - Franz, R C
AU  - Franz RC
FAU - Jacobs, D J
AU  - Jacobs DJ
FAU - Du Plessis, D J
AU  - Du Plessis DJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Urol
JT  - British journal of urology
JID - 15740090R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Male
MH  - Papio
MH  - Penile Diseases/*blood
MH  - Penile Erection/*drug effects
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 10.1111/j.1464-410x.1987.tb04621.x [doi]
PST - ppublish
SO  - Br J Urol. 1987 Mar;59(3):267-71. doi: 10.1111/j.1464-410x.1987.tb04621.x.

PMID- 1427414
OWN - NLM
STAT- MEDLINE
DCOM- 19921218
LR  - 20180217
IS  - 0378-7346 (Print)
IS  - 0378-7346 (Linking)
VI  - 34
IP  - 3
DP  - 1992
TI  - Low-dose aspirin in primigravidae with positive roll-over test.
PG  - 146-50
AB  - In a prospective, randomized, double-blind study for the prevention of 
      pregnancy-induced hypertension and preeclampsia, 41 primigravidae with positive 
      roll-over test (28th-32nd week of pregnancy) received 80 mg aspirin/day or 
      placebo until the end of the 37th week. In the patients treated with 
      acetylsalicylic acid (n = 22), 3 cases of proteinuria occurred, but no 
      hypertensive pregnancy complication. In the placebo group (n = 19), 10 patients 
      developed pregnancy-induced hypertension (6 of them preeclampsia). Group-specific 
      differences concerning the occurrence of hypertension were statistically highly 
      significant (p = 0.0004). No relevant differences were observed with regard to 
      pregnancy duration, birth weight and umbilical artery pH value. The placebo group 
      included 1 intrauterine death. No increased tendency to maternal or fetal 
      bleeding was noticed.
FAU - Schröcksnadel, H
AU  - Schröcksnadel H
AD  - Department of Obstetrics and Gynecology, University of Innsbruck, Austria.
FAU - Sitte, B
AU  - Sitte B
FAU - Alge, A
AU  - Alge A
FAU - Steckel-Berger, G
AU  - Steckel-Berger G
FAU - Schwegel, P
AU  - Schwegel P
FAU - Pastner, E
AU  - Pastner E
FAU - Daxenbichler, G
AU  - Daxenbichler G
FAU - Hansen, H
AU  - Hansen H
FAU - Dapunt, O
AU  - Dapunt O
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Gynecol Obstet Invest
JT  - Gynecologic and obstetric investigation
JID - 7900587
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Pressure/physiology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypertension/diagnosis/*prevention & control
MH  - Infant, Newborn
MH  - Male
MH  - Parity
MH  - Posture
MH  - Pre-Eclampsia/*prevention & control
MH  - Predictive Value of Tests
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/diagnosis/*prevention & control
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1159/000292748 [doi]
PST - ppublish
SO  - Gynecol Obstet Invest. 1992;34(3):146-50. doi: 10.1159/000292748.

PMID- 35683034
OWN - NLM
STAT- MEDLINE
DCOM- 20220613
LR  - 20220716
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 11
DP  - 2022 Jun 6
TI  - Accumulation of Deleterious Effects in Gastric Epithelial Cells and Vascular 
      Endothelial Cells In Vitro in the Milieu of Helicobacter pylori Components, 
      7-Ketocholesterol and Acetylsalicylic Acid.
LID - 10.3390/ijms23116355 [doi]
LID - 6355
AB  - The Gastric pathogen Helicobacter pylori (HP) may influence the development of 
      coronary heart disease (CHD). H. pylori induce reactive oxygen species (ROS), 
      which transform cholesterol to 7-ketocholesterol (7-kCh), a CHD risk factor. 
      Acetylsalicylic acid (ASA)-an Anti-aggregation drug used in CHD patients-may 
      increase gastric bleeding and inflammation. We examined whether H. pylori driven 
      ROS effects in the cell cultures of gastric epithelial cells (AGS) and vascular 
      endothelial cells (HUVEC) progress in the milieu of 7-kCh and ASA. Cell cultures, 
      exposed to 7-kCh or ASA alone or pulsed with the H. pylori antigenic 
      complex-Glycine acid extract (GE), urease (UreA), cytotoxin associated gene A 
      (CagA) protein or lipopolysaccharide (LPS), alone or with 7-kCh and ASA-were 
      examined for ROS, apoptosis, cell integrity, interleukin (IL)-8, the activation 
      of signal transducer, the activator of transcription 3 (STAT3), and wound 
      healing. ASA and 7-kCh alone, and particularly in conjunction with H. pylori 
      components, increased the ROS level and the rate of apoptosis, which was followed 
      by cell disintegration, the activation of STAT3, and IL-8 elevation. AGS cells 
      were unable to undergo wound healing. The cell ROS response to H. pylori 
      components may be elevated by 7-kCh and ASA.
FAU - Gajewski, Adrian Ł
AU  - Gajewski AŁ
AD  - Department of Immunology and Allergy, Medical University of Lodz, Pomorska 251, 
      92-213 Lodz, Poland.
AD  - Department of Immunology and Infectious Biology, Faculty of Biology and 
      Environmental Protection, Institute of Microbiology, Biotechnology and 
      Immunology, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.
FAU - Gawrysiak, Mateusz
AU  - Gawrysiak M
AUID- ORCID: 0000-0002-9772-2047
AD  - Department of Immunology and Allergy, Medical University of Lodz, Pomorska 251, 
      92-213 Lodz, Poland.
AD  - Department of Immunology and Infectious Biology, Faculty of Biology and 
      Environmental Protection, Institute of Microbiology, Biotechnology and 
      Immunology, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.
FAU - Krupa, Agnieszka
AU  - Krupa A
AUID- ORCID: 0000-0003-1303-4608
AD  - Department of Immunology and Infectious Biology, Faculty of Biology and 
      Environmental Protection, Institute of Microbiology, Biotechnology and 
      Immunology, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.
FAU - Rechciński, Tomasz
AU  - Rechciński T
AUID- ORCID: 0000-0001-7800-785X
AD  - Department and Chair of Cardiology, Medical University of Łodz, Kniaziewicza 1/5, 
      91-347 Lodz, Poland.
FAU - Chałubiński, Maciej
AU  - Chałubiński M
AD  - Department of Immunology and Allergy, Medical University of Lodz, Pomorska 251, 
      92-213 Lodz, Poland.
FAU - Gonciarz, Weronika
AU  - Gonciarz W
AUID- ORCID: 0000-0002-5231-5341
AD  - Department of Immunology and Infectious Biology, Faculty of Biology and 
      Environmental Protection, Institute of Microbiology, Biotechnology and 
      Immunology, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.
FAU - Chmiela, Magdalena
AU  - Chmiela M
AD  - Department of Immunology and Infectious Biology, Faculty of Biology and 
      Environmental Protection, Institute of Microbiology, Biotechnology and 
      Immunology, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.
LA  - eng
GR  - DEC-2015/17/N/NZ6/03490/National Science Center/
PT  - Journal Article
DEP - 20220606
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antigens, Bacterial)
RN  - 0 (Ketocholesterols)
RN  - 0 (Reactive Oxygen Species)
RN  - O7676FE78M (7-ketocholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antigens, Bacterial
MH  - Aspirin/metabolism/pharmacology
MH  - Endothelial Cells/metabolism
MH  - Epithelial Cells/metabolism
MH  - Gastric Mucosa/metabolism
MH  - *Helicobacter Infections/metabolism
MH  - *Helicobacter pylori/metabolism
MH  - Humans
MH  - Ketocholesterols
MH  - Reactive Oxygen Species/metabolism
PMC - PMC9181086
OTO - NOTNLM
OT  - 7-ketocholesterol
OT  - Helicobacter pylori
OT  - acetylsalicylic acid
OT  - reactive oxygen species
COIS- The authors declare no conflict of interest.
EDAT- 2022/06/11 06:00
MHDA- 2022/06/14 06:00
CRDT- 2022/06/10 01:16
PHST- 2022/05/12 00:00 [received]
PHST- 2022/05/27 00:00 [revised]
PHST- 2022/06/02 00:00 [accepted]
PHST- 2022/06/10 01:16 [entrez]
PHST- 2022/06/11 06:00 [pubmed]
PHST- 2022/06/14 06:00 [medline]
AID - ijms23116355 [pii]
AID - ijms-23-06355 [pii]
AID - 10.3390/ijms23116355 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Jun 6;23(11):6355. doi: 10.3390/ijms23116355.

PMID- 707596
OWN - NLM
STAT- MEDLINE
DCOM- 19781227
LR  - 20190627
IS  - 0002-9394 (Print)
IS  - 0002-9394 (Linking)
VI  - 86
IP  - 4
DP  - 1978 Oct
TI  - Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin.
PG  - 516-9
AB  - A 67-year-old woman and a 75-year-old woman taking carbonic anhydrase inhibitors 
      for therapy of glaucoma and high doses of aspirin for therapy of arthritis 
      developed severe acid-base imbalance and salicylate intoxication. Neither patient 
      exhibited ill effects when taking high aspirin doses without carbonic anhydrase 
      inhibitor. Carbonic anhydrose inhibitor-induced acidemia increases the risk of 
      developing salicylate intoxication in patients receiving high aspirin doses.
FAU - Anderson, C J
AU  - Anderson CJ
FAU - Kaufman, P L
AU  - Kaufman PL
FAU - Sturm, R J
AU  - Sturm RJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Carbonic Anhydrase Inhibitors)
RN  - O3FX965V0I (Acetazolamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetazolamide/adverse effects/therapeutic use
MH  - Acid-Base Imbalance/*etiology/therapy
MH  - Aged
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Carbonic Anhydrase Inhibitors/*adverse effects/therapeutic use
MH  - Drug Synergism
MH  - Female
MH  - Glaucoma/drug therapy
MH  - Humans
EDAT- 1978/10/01 00:00
MHDA- 1978/10/01 00:01
CRDT- 1978/10/01 00:00
PHST- 1978/10/01 00:00 [pubmed]
PHST- 1978/10/01 00:01 [medline]
PHST- 1978/10/01 00:00 [entrez]
AID - 0002-9394(78)90299-4 [pii]
AID - 10.1016/0002-9394(78)90299-4 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 1978 Oct;86(4):516-9. doi: 10.1016/0002-9394(78)90299-4.

PMID- 7840650
OWN - NLM
STAT- MEDLINE
DCOM- 19950302
LR  - 20151119
IS  - 0003-9861 (Print)
IS  - 0003-9861 (Linking)
VI  - 316
IP  - 1
DP  - 1995 Jan 10
TI  - Reaction of human hemoglobin HbA0 and two cross-linked derivatives with hydrogen 
      peroxide: differential behavior of the ferryl intermediate.
PG  - 461-9
AB  - Functional concerns regarding hemoglobin-based red cell substitutes have 
      generally centered on two parameters: (a) oxygen binding and delivery properties 
      and (b) stabilization of the hemoglobin tetramer to prevent dimerization. 
      Strategic chemical cross-linking and site-directed mutagenesis have produced 
      proteins that have both physiological oxygen binding characteristics and a 
      markedly prolonged retention time in the circulation. The presence of a large 
      amount of redoxactive iron outside the red blood cell, however, raises some 
      concerns about the potential for toxic side effects, many involving the 
      production or participation of oxygen free radicals. In the present study, HPLC 
      purified human hemoglobin HbA0 and two derivatives, one cross-linked between the 
      lysine 99 residues of the alpha subunits (alpha-DBBF) and the other between the 
      lysine 82 residues of the beta subunits (beta-DBBF) were tested for their 
      susceptibility to oxidation and oxidative damage caused by H2O2. We show that 
      chemical cross-linking resulting in alpha-DBBF induces an increased tendency to 
      form ferryl radical in the presence of H2O2 and stabilizes the radical once 
      formed. The in vitro oxidative modification of alpha-DBBF seen here is a 
      plausible mechanism for some of the in vivo toxicities associated with the 
      infusion of this hemoglobin.
FAU - Cashon, R E
AU  - Cashon RE
AD  - Department of Biochemistry, Microbiology, and Molecular Biology, University of 
      Maine, Orono 04469.
FAU - Alayash, A I
AU  - Alayash AI
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Arch Biochem Biophys
JT  - Archives of biochemistry and biophysics
JID - 0372430
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 14127-53-8 (ferryl iron)
RN  - 54651-57-9 (hemoglobin A(0))
RN  - 9034-51-9 (Hemoglobin A)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - E1UOL152H7 (Iron)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/chemistry
MH  - Blood Substitutes/*chemistry
MH  - Cross-Linking Reagents/chemistry
MH  - Hemoglobin A/*analogs & derivatives/*chemistry
MH  - Humans
MH  - Hydrogen Peroxide/chemistry
MH  - Iron/*chemistry
MH  - Kinetics
MH  - Models, Chemical
MH  - Oxidation-Reduction
MH  - Spectrophotometry
EDAT- 1995/01/10 00:00
MHDA- 1995/01/10 00:01
CRDT- 1995/01/10 00:00
PHST- 1995/01/10 00:00 [pubmed]
PHST- 1995/01/10 00:01 [medline]
PHST- 1995/01/10 00:00 [entrez]
AID - S0003-9861(85)71061-2 [pii]
AID - 10.1006/abbi.1995.1061 [doi]
PST - ppublish
SO  - Arch Biochem Biophys. 1995 Jan 10;316(1):461-9. doi: 10.1006/abbi.1995.1061.

PMID- 12959298
OWN - NLM
STAT- MEDLINE
DCOM- 20030917
LR  - 20190513
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 36
IP  - 5
DP  - 1993 Nov
TI  - Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release 
      aspirin formulation.
PG  - 470-3
AB  - The release of aspirin from a 75 mg controlled-release formulation, designed to 
      inhibit maximally thromboxane A2 production while sparing stimulated prostacyclin 
      biosynthesis, was characterised in healthy subjects. The calculated in vivo 
      release rate of aspirin matched the design goal of approximately 10 mg h(-1). The 
      C(max) of aspirin associated with the controlled-release formulation was lowered 
      15-fold relative to a solution formulation of the same dose. The bioavailability 
      of aspirin (based on salicylate concentrations) from the controlled-release 
      formulation was approximately 90% relative to the solution, and drug release was 
      not affected by co-administration of a standard breakfast.
FAU - Charman, W N
AU  - Charman WN
AD  - Department of Pharmaceutical Sciences, Sterling Research Group, Rensselear, NY 
      12144, USA.
FAU - Charman, S A
AU  - Charman SA
FAU - Monkhouse, D C
AU  - Monkhouse DC
FAU - Frisbee, S E
AU  - Frisbee SE
FAU - Lockhart, E A
AU  - Lockhart EA
FAU - Weisman, S
AU  - Weisman S
FAU - Fitzgerald, G A
AU  - Fitzgerald GA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Biological Availability
MH  - Delayed-Action Preparations
MH  - Food
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacokinetics
MH  - Thromboxane A2/*antagonists & inhibitors
PMC - PMC1364623
EDAT- 1993/11/01 00:00
MHDA- 2003/09/18 05:00
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 2003/09/18 05:00 [medline]
PHST- 1993/11/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1993.tb00399.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1993 Nov;36(5):470-3. doi: 
      10.1111/j.1365-2125.1993.tb00399.x.

PMID- 18435972
OWN - NLM
STAT- MEDLINE
DCOM- 20080617
LR  - 20211020
IS  - 0002-9149 (Print)
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 101
IP  - 9
DP  - 2008 May 1
TI  - Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without 
      clinically apparent cardiovascular disease.
PG  - 1359-63
LID - 10.1016/j.amjcard.2007.12.038 [doi]
AB  - Compared with men, women have greater platelet aggregation before and after 
      low-dose aspirin. It is not known whether high-dose aspirin therapy brings 
      residual platelet aggregation in women closer to that in men. Our objective was 
      to compare inhibition of platelet aggregation in women and men after low- and 
      high-dose aspirin. We enrolled healthy subjects (n=106) in a trial of 14 days of 
      aspirin 81 mg/day followed by 14 days of 325 mg/day. Platelet function was 
      measured at baseline and after the 2 aspirin doses. Women had greater baseline 
      platelet activation measurements. After the 2 aspirin doses, men and women had 
      near complete suppression of platelet aggregation to arachidonic acid in whole 
      blood and in platelet-rich plasma (PRP), the direct cyclo-oxygenase-1 pathway 
      affected by aspirin. For indirect pathways, women had significantly greater 
      residual platelet activation to collagen and adenosine diphosphate (ADP) in whole 
      blood after the 2 aspirin doses and in response to collagen and ADP in PRP after 
      aspirin 325 mg/day only. After aspirin 325 mg/day, women continued to have 
      greater residual platelet aggregation compared with men after aspirin 81 mg/day 
      in response to collagen (p=0.016 in whole blood, p=0.037 in PRP), ADP (p<0.001 in 
      whole blood, p=0.012 in PRP), and epinephrine (p=0.03 in PRP). Excretion of 
      urinary thromboxane metabolite (urinary 11-dehydrothromboxane B2) decreased after 
      aspirin to a similar extent in men and women. In conclusion, women continue to 
      have greater residual platelet activity after high-dose aspirin compared with men 
      treated with a lower dose of aspirin.
FAU - Qayyum, Rehan
AU  - Qayyum R
AD  - Division of General Internal Medicine, Department of Medicine, The Johns Hopkins 
      University School of Medicine, Baltimore, Maryland, USA. rqayyum@jhmi.edu
FAU - Becker, Diane M
AU  - Becker DM
FAU - Yanek, Lisa R
AU  - Yanek LR
FAU - Moy, Taryn F
AU  - Moy TF
FAU - Becker, Lewis C
AU  - Becker LC
FAU - Faraday, Nauder
AU  - Faraday N
FAU - Vaidya, Dhananjay
AU  - Vaidya D
LA  - eng
GR  - M01 RR000052/RR/NCRR NIH HHS/United States
GR  - U01 HL072518/HL/NHLBI NIH HHS/United States
GR  - U01 HL072518-04/HL/NHLBI NIH HHS/United States
GR  - HL-072518/HL/NHLBI NIH HHS/United States
GR  - M01-RR000052/RR/NCRR NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20080317
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Lipids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cardiovascular Diseases/blood/drug therapy
MH  - Female
MH  - Hematocrit
MH  - Humans
MH  - Lipids/blood
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Count
MH  - Platelet Function Tests
MH  - Sex Factors
MH  - Statistics, Nonparametric
PMC - PMC3038606
MID - NIHMS47834
COIS- Conflicts of Interest: Dr. D. Becker received research support from Bayer 
      Healthcare, LLC, Consumer Division. Dr. Faraday received additional research 
      support from NovoNordisk. The other authors report no conflicts of interest.
EDAT- 2008/04/26 09:00
MHDA- 2008/06/18 09:00
CRDT- 2008/04/26 09:00
PHST- 2007/09/11 00:00 [received]
PHST- 2007/12/19 00:00 [revised]
PHST- 2007/12/19 00:00 [accepted]
PHST- 2008/04/26 09:00 [pubmed]
PHST- 2008/06/18 09:00 [medline]
PHST- 2008/04/26 09:00 [entrez]
AID - S0002-9149(08)00103-3 [pii]
AID - 10.1016/j.amjcard.2007.12.038 [doi]
PST - ppublish
SO  - Am J Cardiol. 2008 May 1;101(9):1359-63. doi: 10.1016/j.amjcard.2007.12.038. Epub 
      2008 Mar 17.

PMID- 21847126
OWN - NLM
STAT- MEDLINE
DCOM- 20111121
LR  - 20220317
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 105
IP  - 8
DP  - 2011 Oct 11
TI  - Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
PG  - 1107-13
LID - 10.1038/bjc.2011.289 [doi]
AB  - Aspirin inhibits the enzyme cyclooxygenase (Cox), and there is a significant body 
      of epidemiological evidence demonstrating that regular aspirin use is associated 
      with a decreased incidence of developing cancer. Interest focussed on selective 
      Cox-2 inhibitors both as cancer prevention agents and as therapeutic agents in 
      patients with proven malignancy until concerns were raised about their toxicity 
      profile. Aspirin has several additional mechanisms of action that may contribute 
      to its anti-cancer effect. It also influences cellular processes such as 
      apoptosis and angiogenesis that are crucial for the development and growth of 
      malignancies. Evidence suggests that these effects can occur through 
      Cox-independent pathways questioning the rationale of focussing on Cox-2 
      inhibition alone as an anti-cancer strategy. Randomised studies with aspirin 
      primarily designed to prevent cardiovascular disease have demonstrated a 
      reduction in cancer deaths with long-term follow-up. Concerns about toxicity, 
      particularly serious haemorrhage, have limited the use of aspirin as a cancer 
      prevention agent, but recent epidemiological evidence demonstrating regular 
      aspirin use after a diagnosis of cancer improves outcomes suggests that it may 
      have a role in the adjuvant setting where the risk:benefit ratio will be 
      different.
FAU - Langley, R E
AU  - Langley RE
AD  - MRC Clinical Trials Unit, London, UK. rel@ctu.mrc.ac.uk
FAU - Burdett, S
AU  - Burdett S
FAU - Tierney, J F
AU  - Tierney JF
FAU - Cafferty, F
AU  - Cafferty F
FAU - Parmar, M K B
AU  - Parmar MK
FAU - Venning, G
AU  - Venning G
LA  - eng
GR  - MC_U122861323/MRC_/Medical Research Council/United Kingdom
GR  - MC_U122861325/MRC_/Medical Research Council/United Kingdom
GR  - MC_U122861330/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20110816
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br J Cancer. 2011 Oct 11;105(8):1105-6. PMID: 21989214
CIN - Br J Cancer. 2012 Jan 3;106(1):240. PMID: 22075944
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cyclooxygenase 2 Inhibitors/*therapeutic use
MH  - Humans
MH  - Neoplasms/*prevention & control
PMC - PMC3208483
EDAT- 2011/08/19 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/08/18 06:00
PHST- 2011/08/18 06:00 [entrez]
PHST- 2011/08/19 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - bjc2011289 [pii]
AID - 10.1038/bjc.2011.289 [doi]
PST - ppublish
SO  - Br J Cancer. 2011 Oct 11;105(8):1107-13. doi: 10.1038/bjc.2011.289. Epub 2011 Aug 
      16.

PMID- 15949525
OWN - NLM
STAT- MEDLINE
DCOM- 20050809
LR  - 20131121
IS  - 0033-3506 (Print)
IS  - 0033-3506 (Linking)
VI  - 119
IP  - 8
DP  - 2005 Aug
TI  - A health impact assessment of increased aspirin use in Wales.
PG  - 734-7
AB  - AIM: To estimate the likely magnitude of health impact if all individuals at 
      increased risk of cardiovascular events in Wales (total population 2.9 million) 
      took low-dose aspirin. METHODS: Data from a variety of different sources were 
      collected and systematically combined using simple methods and conservative 
      assumptions. RESULTS: Aspirin may reduce cardiovascular mortality by 2-25% and 
      avoid 330-3250 deaths per annum after allowing for a small number of fatal 
      undesirable effects. COMMENT: Wales might lead the way in developing an aspirin 
      programme.
FAU - Morgan, G
AU  - Morgan G
AD  - Welsh Aspirin Group Secretary, 41 Ffordd Beck, Gowerton, Swansea, Wales SA4 3GE, 
      UK. morgan@ffordbeck.fsnet.co.uk
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Public Health
JT  - Public health
JID - 0376507
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Public Health. 2006 May;120(5):480; author reply 481. PMID: 16549078
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Factors
MH  - Wales/epidemiology
EDAT- 2005/06/14 09:00
MHDA- 2005/08/10 09:00
CRDT- 2005/06/14 09:00
PHST- 2004/06/17 00:00 [received]
PHST- 2004/08/31 00:00 [revised]
PHST- 2004/09/27 00:00 [accepted]
PHST- 2005/06/14 09:00 [pubmed]
PHST- 2005/08/10 09:00 [medline]
PHST- 2005/06/14 09:00 [entrez]
AID - S0033-3506(04)00275-6 [pii]
AID - 10.1016/j.puhe.2004.09.003 [doi]
PST - ppublish
SO  - Public Health. 2005 Aug;119(8):734-7. doi: 10.1016/j.puhe.2004.09.003.

PMID- 11016021
OWN - NLM
STAT- MEDLINE
DCOM- 20010118
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 23
IP  - 9
DP  - 2000 Sep
TI  - Fast platelet suppression by lysine acetylsalicylate in chronic stable coronary 
      patients. Potential clinical impact over regular aspirin for coronary syndromes.
PG  - 697-700
AB  - BACKGROUND: The rapid utilization of fibrinolytics following Q-wave myocardial 
      infarction has clearly modified the evolution of this disease. However, it is 
      still not known whether the immediate inhibition of platelet aggregation (PA) 
      during the coronary event improves outcomes. HYPOTHESIS: The present study was 
      designed to test, in patients with known coronary artery disease (chronic stable 
      angina), whether the particular kinetic pattern of lysine acetylsalicylate (LA) 
      compared with aspirin may affect the time to onset of inhibition of platelet 
      aggregation. METHODS: Ten patients suffering from chronic stable angina 
      participated in this study to compare the efficacy and speed of the inhibition of 
      PA with 320 mg of LA versus 320 mg of aspirin. All patients discontinued the use 
      of aspirin and any other anti-inflammatory agents for 15 days prior to the 
      beginning of the study. They were randomly assigned to LA or aspirin. Blood 
      specimens were obtained to measure the PA at admission, and 5, 10, 20, 30, and 60 
      min after ingestion. Patients continued to take the assigned drug once a day for 
      the following 4 days. On Day 5, a new blood sample was taken. After this, 
      patients underwent a 15-day wash-out period, and then crossed over to the 
      opposite drug. The samples were analyzed immediately using platelet-rich plasma 
      stimulated with adenosine diphosphate (ADP) 2 mumol/l, collagen 1 microgram/ml, 
      epinephrine 20 mumol/l, and sodium arachidonate acid 0.75 mm/l. RESULTS: The same 
      level of PA inhibition after 30 and 60 min of aspirin administration can be 
      obtained with LA 5 min following ingestion (sodium arachidonate acid: LA: 16.3 
      +/- 25.9 vs. aspirin 57.6 +/- 8.2; p = 0.00014; collagen: LA 18.9 +/- 20.1 vs. 
      aspirin 47.2 +/- 10.5; p = 0.00092; ADP: LA 27.3 +/- 18.4 vs. aspirin 39.7 +/- 
      21.8, p = 0.18; epinephrine: LA 22.0 +/- 9.9 vs. aspirin 55.4 +/- 10.9, p = 
      0.00002. CONCLUSIONS: Platelet aggregation inhibition immediately following LA 
      may have significant clinical implications for the treatment of coronary 
      syndromes.
FAU - Gurfinkel, E P
AU  - Gurfinkel EP
AD  - Centro de Estudios Medicos y Bioquímicos, Buenos Aires, Argentina.
FAU - Altman, R
AU  - Altman R
FAU - Scazziota, A
AU  - Scazziota A
FAU - Heguilen, R
AU  - Heguilen R
FAU - Mautner, B
AU  - Mautner B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Analysis of Variance
MH  - Angina Pectoris/*drug therapy/metabolism/physiopathology
MH  - Aspirin/*analogs & derivatives/*pharmacokinetics/pharmacology
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/*pharmacokinetics/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacokinetics/pharmacology
MH  - Single-Blind Method
MH  - Time Factors
PMC - PMC6654778
EDAT- 2000/10/04 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/04 11:00
PHST- 2000/10/04 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/04 11:00 [entrez]
AID - CLC4960230912 [pii]
AID - 10.1002/clc.4960230912 [doi]
PST - ppublish
SO  - Clin Cardiol. 2000 Sep;23(9):697-700. doi: 10.1002/clc.4960230912.

PMID- 22990948
OWN - NLM
STAT- MEDLINE
DCOM- 20130625
LR  - 20211021
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 36
IP  - 1
DP  - 2013 Jan
TI  - Safety of aspirin desensitization in patients with reported aspirin allergy and 
      cardiovascular disease.
PG  - 25-30
LID - 10.1002/clc.22054 [doi]
AB  - BACKGROUND: Aspirin (ASA) is the drug of choice in patients with coronary artery 
      disease for primary and secondary prevention. This poses a problem for those 
      patients reporting hypersensitivity to this drug or class of drugs. HYPOTHESIS: 
      Desensitization to ASA may be carried out safely and effectively in patients with 
      reported ASA or nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity 
      needing ASA for cardiac indications. Our 7-step protocol is one choice for a 
      rapid desensitization protocol. METHODS: A retrospective chart review was 
      conducted evaluating ASA desensitization in patients with reported ASA or NSAID 
      hypersensitivity and a cardiac indication for ASA. RESULTS: In 160 evaluations 
      over 15 years, 89 desensitizations were performed in both the inpatient and 
      outpatient setting with only 16 reactions (18%). Eleven of these 16 patients 
      (68.7%) were able to take daily ASA. Twenty-six desensitization procedures were 
      performed with our 7-step rapid desensitization protocol in 10 inpatients and 16 
      outpatients with 3 reactions (18.75% of reactions). Initial reaction to ASA 
      involving angioedema and reacting to ASA within the past year increased the risk 
      of having a reaction to desensitization. CONCLUSIONS: Desensitization may be 
      safely performed in patients with reported ASA or NSAID hypersensitivity and a 
      cardiac indication for ASA. Our 7-step rapid protocol may be used in both the 
      inpatient and outpatient setting to desensitize these patients. Patients who had 
      angioedema with ASA ingestion or a reaction to ASA within the past year are at 
      higher risk for reaction during the desensitization protocol. The authors have no 
      funding, financial relationships, or conflicts of interest to disclose.
CI  - © 2012 Wiley Periodicals, Inc.
FAU - McMullan, Kathryn L
AU  - McMullan KL
AD  - Division of Allergy and Immunology, Department of Medicine, Washington University 
      School of Medicine, St. Louis, Missouri 63110, USA. lbmcmullan@hotmail.com
FAU - Wedner, H James
AU  - Wedner HJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20120918
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Outpatients
MH  - Retrospective Studies
PMC - PMC6649559
EDAT- 2012/09/20 06:00
MHDA- 2013/06/26 06:00
CRDT- 2012/09/20 06:00
PHST- 2012/06/04 00:00 [received]
PHST- 2012/08/01 00:00 [accepted]
PHST- 2012/09/20 06:00 [entrez]
PHST- 2012/09/20 06:00 [pubmed]
PHST- 2013/06/26 06:00 [medline]
AID - CLC22054 [pii]
AID - 10.1002/clc.22054 [doi]
PST - ppublish
SO  - Clin Cardiol. 2013 Jan;36(1):25-30. doi: 10.1002/clc.22054. Epub 2012 Sep 18.

PMID- 31701855
OWN - NLM
STAT- MEDLINE
DCOM- 20200421
LR  - 20210110
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Print)
IS  - 0002-9637 (Linking)
VI  - 102
IP  - 1
DP  - 2020 Jan
TI  - Continuation of Dual Antiplatelet Therapy in a Patient with a Coronary Artery 
      Stent with Dengue Hemorrhagic Fever: A Clinical Conundrum.
PG  - 17-19
LID - 10.4269/ajtmh.19-0512 [doi]
AB  - Severe thrombocytopenia with impairment of the activity of platelets and 
      impairment of blood clotting occurs in dengue hemorrhagic fever (DHF). 
      Continuation of dual antiplatelet therapy in such patients can result in 
      life-threatening hemorrhages. On the other hand, withholding of antiplatelets in 
      a patient undergone coronary stenting lately can lead to stent thrombosis, 
      resulting in myocardial infarctions and sudden cardiac death. There are no 
      guidelines on management of DHF in patients with coronary stents. Here, we 
      discuss about several divergent factors that need to be considered and balanced 
      when managing such patients. We describe a case as an example to illustrate how 
      we balanced the risk of serious bleeding versus the risk of stent thrombosis 
      successfully according to evolution of the disease process, by temporary 
      withholding of antiplatelets in such a patient.
FAU - Ehelepola, N D B
AU  - Ehelepola NDB
AD  - The Teaching (General) Hospital - Kandy, Kandy, Sri Lanka.
FAU - Athurupana, A A S D
AU  - Athurupana AASD
AD  - The Teaching (General) Hospital - Kandy, Kandy, Sri Lanka.
FAU - Bowatte, P G C S
AU  - Bowatte PGCS
AD  - The Teaching (General) Hospital - Kandy, Kandy, Sri Lanka.
FAU - Dissanayake, Wasantha P
AU  - Dissanayake WP
AD  - The Teaching (General) Hospital - Kandy, Kandy, Sri Lanka.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clopidogrel/administration & dosage/adverse effects/therapeutic use
MH  - Coronary Stenosis
MH  - Drug-Eluting Stents/*adverse effects
MH  - *Dual Anti-Platelet Therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/therapeutic use
MH  - Severe Dengue/*complications
PMC - PMC6947787
COIS- Disclosure: This is a perspectives article. However, we report clinical data of 
      one patient, and written informed consent from him was obtained. All the 
      information supporting our conclusions and relevant references are included in 
      the manuscript. There are no data sheets related to this article.
EDAT- 2019/11/09 06:00
MHDA- 2020/04/22 06:00
CRDT- 2019/11/09 06:00
PHST- 2019/11/09 06:00 [pubmed]
PHST- 2020/04/22 06:00 [medline]
PHST- 2019/11/09 06:00 [entrez]
AID - tpmd190512 [pii]
AID - 10.4269/ajtmh.19-0512 [doi]
PST - ppublish
SO  - Am J Trop Med Hyg. 2020 Jan;102(1):17-19. doi: 10.4269/ajtmh.19-0512.

PMID- 7676685
OWN - NLM
STAT- MEDLINE
DCOM- 19951017
LR  - 20131121
IS  - 0043-5325 (Print)
IS  - 0043-5325 (Linking)
VI  - 107
IP  - 15
DP  - 1995
TI  - [Thrombocyte function of healthy probands taking 50 mg of acetylsalicylic acid 
      per day].
PG  - 457-63
AB  - The antithrombotic effect of acetylsalicylic acid (ASS) is attributed in part to 
      its inhibitory action on platelet cyclooxygenase and, thereby, thromboxane A2 
      (TXA2) formation. The therapeutic goal of low-dose ASS regimens was the 
      development of a preparation showing a high inhibitory capacity on platelet TXA2 
      generation whilst leaving vascular prostaglandin I2 (PGI2) synthesis unaffected, 
      thereby minimizing side effects. The effect of a new acid-resistant preparation 
      of 50 mg ASS (Thrombo-ASS 50 mg) on plasma levels of ASS, salicylate, TXB2, 
      11-dehydro-thromboxane B2, serum thromboxane B2 and malonyl dialdehyde, the 
      conversion of exogenous 14C-arachidonic acid to TXB2 and 
      hydroxy-5,8,10-heptadecatrienoic acid (HHT), as well as on the urinary 
      metabolites 2,3-dinor-6-oxo-PGF1 alpha and 2,3-dinor TXB2, were compared in a 
      crossover trial to those of a marketed preparation (Aspirin 100 mg) in healthy 
      volunteers after a single dose and repeated administration of ASS. While platelet 
      activity was inhibited by both the test and the reference substance to a 
      comparable extent, vascular PGI2 production (as determined by urinary 
      2,3-dinor-6-oxo-PGF1 alpha excretion) was less affected by the test substance. 
      These findings confirm the claim that a dosage of 50 mg ASS administered daily as 
      an enteric coated or uncoated tablet is sufficient to almost completely block 
      platelet cyclooxygenase, while the respective vascular enzyme is only minimally 
      affected.
FAU - Sinzinger, H
AU  - Sinzinger H
AD  - Wilhelm-Auerswald-Atheroskleroseforschungsgruppe Wien.
FAU - Kritz, H
AU  - Kritz H
FAU - Pirich, C
AU  - Pirich C
FAU - Karanikas, G
AU  - Karanikas G
FAU - Kurtaran, A
AU  - Kurtaran A
FAU - Banyai, M
AU  - Banyai M
FAU - Peskar, B A
AU  - Peskar BA
FAU - Rehak, P
AU  - Rehak P
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Thrombozytenfunktion gesunder Probanden unter einer Gabe von 50 mg 
      Acetylsalicylsäure pro Tag.
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - *Platelet Function Tests
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Wien Klin Wochenschr. 1995;107(15):457-63.

PMID- 7506178
OWN - NLM
STAT- MEDLINE
DCOM- 19940204
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 46 Suppl 1
DP  - 1993
TI  - Efficacy and tolerability of nimesulide and lysine-acetylsalicylate in the 
      treatment of paediatric acute upper respiratory tract inflammation.
PG  - 222-5
AB  - In a single-blind study that recruited 70 children aged 5 to 12 years with acute 
      upper respiratory tract infection and fever (in- or outpatients), the 
      effectiveness and tolerability of nimesulide 50 mg/dose were compared with those 
      of lysine-acetylsalicylate 720 mg/dose (equivalent to 200mg of salicylate). Each 
      agent was administered to 35 children, and both groups were simultaneously 
      treated with antibiotics. General and respiratory symptoms were evaluated daily. 
      Nimesulide treatment was associated with a more rapid and greater antipyretic 
      effect than lysine-acetylsalicylate: 94% of nimesulide recipients and 77% of 
      lysine-acetylsalicylate recipients were considered by physicians to have a good 
      or very good response to therapy (p < 0.05). Furthermore, fewer doses of 
      nimesulide than lysine-acetylsalicylate were required for resolution of fever and 
      associated symptoms (nausea, vomiting, headache). The 2 drugs had similar global 
      efficacy. Tolerability was good or very good in all patients.
FAU - Cappella, L
AU  - Cappella L
AD  - Paediatric Clinic, University of Modena, Italy.
FAU - Guerra, A
AU  - Guerra A
FAU - Laudizi, L
AU  - Laudizi L
FAU - Cavazzuti, G B
AU  - Cavazzuti GB
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Sulfonamides)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - V4TKW1454M (nimesulide)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acute Disease
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Respiratory Tract Infections/*drug therapy
MH  - Single-Blind Method
MH  - Sulfonamides/adverse effects/*therapeutic use
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.2165/00003495-199300461-00057 [doi]
PST - ppublish
SO  - Drugs. 1993;46 Suppl 1:222-5. doi: 10.2165/00003495-199300461-00057.

PMID- 2548436
OWN - NLM
STAT- MEDLINE
DCOM- 19890911
LR  - 20131121
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 9
IP  - 3
DP  - 1989 May-Jun
TI  - Changes of serum iron transferrin and copper ceruloplasmin in rats given Cu(II)2 
      (acetylsalicylate)4 during acute inflammation.
PG  - 771-3
AB  - Modifications of serum levels of iron transferrin and copper ceruloplasmin after 
      acute inflammation by carrageenan and treatment with acetyl salicylic acid [ASA] 
      or Cu(II)2(acetylsalicylate)4 [Cu(II)2(AS)4] were studied in the rat by EPR 
      spectroscopy. Furthermore, the ulcerogenic potential of the two drugs was 
      investigated after a single high oral dose. Our results indicate that 
      Cu(II)2(AS)4 is more effective than ASA in limiting the inflammation provoked by 
      the phlogogen. In these conditions the iron(III) non-heme and copper(II) 
      ceruloplasmin concentration in serum was modified either during inflammation or 
      after treatment with antiphlogistic agents: in carrageenan-injected rats the 
      level of serum iron(III) non-heme was found to be very low, while the copper(II) 
      ceruloplasmin concentration was partially reduced. On the other hand, after the 
      pharmacological treatments, no changes of iron transferrin were observed and the 
      concentration of copper ceruloplasmin was increased. With regard to their 
      ulcerogenic effect, ASA appeared to be more irritating for gastric mucosa than 
      Cu(II)2(AS)4.
FAU - Ferrari, R P
AU  - Ferrari RP
AD  - Dipartimento di Chimica Inorganica, Università di Torino, Italy.
FAU - Paradisi, L
AU  - Paradisi L
FAU - Torrielli, M
AU  - Torrielli M
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Transferrin)
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - EC 1.16.3.1 (Ceruloplasmin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Ceruloplasmin/*analysis
MH  - Electron Spin Resonance Spectroscopy
MH  - Inflammation/*blood/drug therapy
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Transferrin/*analysis
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 1989 May-Jun;9(3):771-3.

PMID- 30396226
OWN - NLM
STAT- MEDLINE
DCOM- 20200618
LR  - 20200618
IS  - 1098-8785 (Electronic)
IS  - 0735-1631 (Linking)
VI  - 36
IP  - 8
DP  - 2019 Jul
TI  - The Impact of Aspirin on Ultrasound Markers of Uteroplacental Flow in Low-Risk 
      Pregnancy: Secondary Analysis of a Multicenter RCT.
PG  - 855-863
LID - 10.1055/s-0038-1675208 [doi]
AB  - OBJECTIVE: This article evaluates the effect of low-dose aspirin on uterine 
      artery (UtA) Doppler, placental volume, and vascularization flow indices in 
      low-risk pregnancy. STUDY DESIGN: In this secondary analysis of the TEST 
      randomized controlled trial, low-risk nulliparous women were originally 
      randomized at 11 weeks to: (1) routine aspirin 75 mg; (2) no aspirin; and (3) 
      aspirin based upon the preeclampsia Fetal Medicine Foundation screening test. UtA 
      Doppler, three-dimensional (3D) placental volume, and vascularization flow 
      indices were assessed prior to and 6 weeks postaspirin commencement. RESULTS: A 
      total of 546 women were included (aspirin n = 192, no aspirin n = 354). Between 
      first and second trimesters, aspirin use was not associated with a change in UtA 
      Doppler, placental volume, or vascular flow indices. There was no significant 
      difference in the change in UtA Doppler pulsatility index (PI) Z-scores or 
      notching (PI Z-score -0.2 vs. -0.2, p = 0.17), nor was there a significant change 
      in placental volume Z-score and vascular flow indices (volume Z-score change: 
      0.74 vs. 0.62, p = 0.34). CONCLUSION: Low-dose aspirin commenced at 11 weeks in 
      low-risk women does not appear to improve uterine and placental perfusion or 
      placental volume. Any perceived effect on uteroplacental vasculature is not 
      reflected in changes in placental volume nor uteroplacental flow as assessed by 
      two-dimensional and 3D ultrasound.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Mulcahy, Cecilia
AU  - Mulcahy C
AD  - Department of Fetal Medicine, National Maternity Hospital, Dublin, Ireland.
FAU - Mone, Fionnuala
AU  - Mone F
AD  - UCD Perinatal Research Centre, School of Medicine, National Maternity Hospital, 
      University College Dublin, Dublin, Ireland.
FAU - McParland, Peter
AU  - McParland P
AD  - UCD Perinatal Research Centre, School of Medicine, National Maternity Hospital, 
      University College Dublin, Dublin, Ireland.
FAU - Breathnach, Fionnuala
AU  - Breathnach F
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - Cody, Fiona
AU  - Cody F
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - Morrison, John J
AU  - Morrison JJ
AD  - Department of Obstetrics and Gynaecology, National University of Ireland, Galway, 
      Ireland.
FAU - Higgins, John
AU  - Higgins J
AD  - Department of Obstetrics and Gynaecology, University College Cork, Cork, Ireland.
FAU - Daly, Sean
AU  - Daly S
AD  - Department of Obstetrics and Gynaecology, Coombe Women's and Infant's University 
      Hospital, Dublin, Ireland.
FAU - Dornan, Samina
AU  - Dornan S
AD  - Royal Jubilee Maternity Hospital, Belfast, United Kingdom.
FAU - Cotter, Amanda
AU  - Cotter A
AD  - Department of Obstetrics and Gynaecology, Graduate Entry Medical School, 
      University of Limerick, Limerick, Ireland.
FAU - Dicker, Patrick
AU  - Dicker P
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - Tully, Elizabeth
AU  - Tully E
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - Malone, Fergal D
AU  - Malone FD
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - McAuliffe, Fionnuala M
AU  - McAuliffe FM
AD  - UCD Perinatal Research Centre, School of Medicine, National Maternity Hospital, 
      University College Dublin, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20181105
PL  - United States
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Female
MH  - Humans
MH  - Placenta/blood supply/*diagnostic imaging
MH  - Placental Circulation/*drug effects
MH  - Pre-Eclampsia/diagnostic imaging/prevention & control
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Pregnancy Trimester, Second
MH  - Ultrasonography, Doppler, Color
MH  - *Ultrasonography, Prenatal
MH  - Uterine Artery/*diagnostic imaging/drug effects
MH  - Uterus/blood supply/*diagnostic imaging/drug effects
COIS- None.
EDAT- 2018/11/06 06:00
MHDA- 2020/06/19 06:00
CRDT- 2018/11/06 06:00
PHST- 2018/11/06 06:00 [pubmed]
PHST- 2020/06/19 06:00 [medline]
PHST- 2018/11/06 06:00 [entrez]
AID - 10.1055/s-0038-1675208 [doi]
PST - ppublish
SO  - Am J Perinatol. 2019 Jul;36(8):855-863. doi: 10.1055/s-0038-1675208. Epub 2018 
      Nov 5.

PMID- 22361089
OWN - NLM
STAT- MEDLINE
DCOM- 20120724
LR  - 20211021
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Print)
IS  - 0277-9536 (Linking)
VI  - 74
IP  - 7
DP  - 2012 Apr
TI  - Aspirin use and cardiovascular events in social networks.
PG  - 1125-9
LID - 10.1016/j.socscimed.2011.12.033 [doi]
AB  - We tested whether friends' and family members' cardiovascular health events and 
      also their own aspirin use are associated with the likelihood that an individual 
      takes aspirin regularly. Analyses were based on longitudinal data on 2724 members 
      of the Framingham Heart Study (based in Massachusetts, U.S.A.) who were linked to 
      friends and family members who were also participants in the same study. Men were 
      more likely to take aspirin if a male friend had recently been taking aspirin, 
      and women were more likely to take aspirin if a brother had recently been taking 
      aspirin. Men were also more likely to take aspirin if a brother recently had a 
      cardiovascular event, and women were more likely to take aspirin if a female 
      friend recently experienced a cardiovascular event. Aspirin use is correlated 
      with the health and behavior of friends and family. These findings add to a 
      growing body of evidence which suggests that behavioral changes that promote 
      cardiovascular health may spread through social networks.
CI  - Copyright Â© 2012 Elsevier Ltd. All rights reserved.
FAU - Strully, Kate W
AU  - Strully KW
AD  - Department of Sociology, University at Albany, State University of New York, 1400 
      Washington Ave, Albany, NY 12222, USA. kstrully@albany.edu
FAU - Fowler, James H
AU  - Fowler JH
FAU - Murabito, Joanne M
AU  - Murabito JM
FAU - Benjamin, Emelia J
AU  - Benjamin EJ
FAU - Levy, Daniel
AU  - Levy D
FAU - Christakis, Nicholas A
AU  - Christakis NA
LA  - eng
GR  - N01-HC-25195/HC/NHLBI NIH HHS/United States
GR  - P41 GM103504/GM/NIGMS NIH HHS/United States
GR  - P01 AG031093-05/AG/NIA NIH HHS/United States
GR  - P01 AG031093/AG/NIA NIH HHS/United States
GR  - N01HC25195/HL/NHLBI NIH HHS/United States
GR  - R24 HD044943/HD/NICHD NIH HHS/United States
GR  - P-01 AG031093/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120204
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Female
MH  - *Health Behavior
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Social Support
PMC - PMC3298609
MID - NIHMS353576
EDAT- 2012/03/01 06:00
MHDA- 2012/07/25 06:00
CRDT- 2012/02/25 06:00
PHST- 2011/04/23 00:00 [received]
PHST- 2011/11/15 00:00 [revised]
PHST- 2011/12/06 00:00 [accepted]
PHST- 2012/02/25 06:00 [entrez]
PHST- 2012/03/01 06:00 [pubmed]
PHST- 2012/07/25 06:00 [medline]
AID - S0277-9536(12)00066-4 [pii]
AID - 10.1016/j.socscimed.2011.12.033 [doi]
PST - ppublish
SO  - Soc Sci Med. 2012 Apr;74(7):1125-9. doi: 10.1016/j.socscimed.2011.12.033. Epub 
      2012 Feb 4.

PMID- 3327353
OWN - NLM
STAT- MEDLINE
DCOM- 19880412
LR  - 20190820
IS  - 0001-6470 (Print)
IS  - 0001-6470 (Linking)
VI  - 58
IP  - 6
DP  - 1987 Dec
TI  - Prevention of thromboembolism in total hip replacement. Aspirin versus 
      dihydroergotamine-heparin.
PG  - 626-9
AB  - In a prospective and controlled study, we compared the prophylactic effect of 
      high-dose acetylsalicylic acid (ASA) and dihydroergotamine-heparin (DHEH) in 82 
      patients over 50 years of age undergoing total hip replacement. The patients were 
      screened by pulmonary scan and 125I fibrinogen uptake. Phlebography was done if 
      the 125 I fibrinogen test was positive. According to our criteria, 
      thromboembolism developed in 9 of 40 receiving ASA and in 5 of 42 patients 
      receiving DHEH. The effect of ASA was limited to men; in 16 men on this therapy, 
      none had thromboembolism versus 9 of 24 women. Twenty-two patients showed wound 
      hematomas, but none needed surgical intervention.
FAU - Josefsson, G
AU  - Josefsson G
AD  - Department of Orthopedics, Gävle County Hospital, Sweden.
FAU - Dahlqvist, A
AU  - Dahlqvist A
FAU - Bodfors, B
AU  - Bodfors B
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Acta Orthop Scand
JT  - Acta orthopaedica Scandinavica
JID - 0370352
RN  - 0 (Drug Combinations)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (heparin-dihydergot)
RN  - 436O5HM03C (Dihydroergotamine)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dihydroergotamine/*therapeutic use
MH  - Drug Combinations/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/*therapeutic use
MH  - *Heparin, Low-Molecular-Weight
MH  - *Hip Prosthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
MH  - Prospective Studies
MH  - Pulmonary Embolism/etiology
MH  - Random Allocation
MH  - Sex Factors
MH  - Thromboembolism/*prevention & control
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
AID - 10.3109/17453678709146500 [doi]
PST - ppublish
SO  - Acta Orthop Scand. 1987 Dec;58(6):626-9. doi: 10.3109/17453678709146500.

PMID- 26709600
OWN - NLM
STAT- MEDLINE
DCOM- 20160314
LR  - 20160127
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 54
IP  - 2
DP  - 2016 Feb
TI  - Evaluation of the effect of angiotensin converting enzyme inhibitors and 
      angiotensin receptors blockers on aspirin antiplatelet effect.
PG  - 96-101
LID - 10.5414/CP202503 [doi]
AB  - OBJECTIVE: Cardiovascular disease (CVD) is one of the major burdens on societies 
      and healthcare systems. Antiplatelet aspirin is used to prevent the occurrence or 
      reoccurrence of cardiovascular events. However, studies have shown that a good 
      portion of patients still suffer from cardiovascular events in spite of using 
      aspirin (also called aspirin nonresponders). On the other hand, 
      angiotensin-converting enzyme inhibitors (ACEIs) as well as angiotensin-receptor 
      blockers (ARBs) are widely used in patients with different spectrums of 
      cardiovascular diseases. In this study, the possible interactive effect of ACEIs 
      and ARBs on aspirin response was evaluated in vitro. METHODS: A multiplate 
      analyzer was used to assay the possible interactions between ACEIs and ARBs drugs 
      on antiplatelet effect of aspirin using blood obtained from 6 healthy volunteers. 
      Means of area under the aggregation curves (AUCs) of the blood samples treated 
      with 10 μg/mL aspirin were calculated before and after exposure to captopril, 
      lisinopril, candesartan, or losartan. RESULTS: Results showed potential 
      antithrombotic effect of ACEIs and ARBs only at high concentrations (3.3 
      μg/mL).The antiplatelet effect of aspirin 10 μg/mL was significantly enhanced by 
      the addition of captopril or lisinopril at high dose (3.3 μg/mL), candesartan at 
      all tested doses (0.03 μg/mL, 0.33 μg/mL, 3.3 μg/mL), and losartan at doses of 
      0.33 μg/mL and 3.3 μg/m. CONCLUSION: Treatment with ACEIs (captopril and 
      lisinopril) and ARBs (candesartan and losartan) improved the antiplatelet 
      response to aspirin. Further studies are needed to confirm this action and 
      potentially apply it to clinical practice.
FAU - Al-Azzam, Sayer I
AU  - Al-Azzam SI
FAU - Alzoubi, Karem H
AU  - Alzoubi KH
FAU - Khabour, Omar F
AU  - Khabour OF
FAU - Quttina, Maram
AU  - Quttina M
FAU - Zayadeen, Raya
AU  - Zayadeen R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Angiotensin Receptor Antagonists/*pharmacology
MH  - Angiotensin-Converting Enzyme Inhibitors/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 2015/12/29 06:00
MHDA- 2016/03/15 06:00
CRDT- 2015/12/29 06:00
PHST- 2016/01/26 00:00 [accepted]
PHST- 2015/12/29 06:00 [entrez]
PHST- 2015/12/29 06:00 [pubmed]
PHST- 2016/03/15 06:00 [medline]
AID - 14008 [pii]
AID - 10.5414/CP202503 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2016 Feb;54(2):96-101. doi: 10.5414/CP202503.

PMID- 11953775
OWN - NLM
STAT- MEDLINE
DCOM- 20020610
LR  - 20131121
IS  - 0379-5284 (Print)
IS  - 0379-5284 (Linking)
VI  - 23
IP  - 4
DP  - 2002 Apr
TI  - Low aspirin use in diabetics.
PG  - 457-60
AB  - OBJECTIVE: To determine the percentage of adult diabetics with cardiovascular 
      disease, or risk factors for cardiovascular disease who are using aspirin, and to 
      report on any differences between males and females, or Saudis and non-Saudis. 
      METHODS: Medical records of diabetics seen at King Abdulaziz University Hospital 
      during the period January 1998 through to December 2000 were analyzed. The 
      following data were collected: patients age, sex, nationality, body mass index, 
      duration of diabetes, history of cardiovascular disease, risk factors for 
      cardiovascular disease (hypertension, hyperlipidemia, obesity, smoking, family 
      history of ischemic heart disease) and aspirin use. RESULTS: A total of 550 
      patients were studied with a mean age of 53 years and male: female ratio 1.1:1. 
      Saudis constitute 260/550 (47%) of the study group. In patients with 
      cardiovascular disease 110/174 (63%) were using aspirin versus 64/174 (37%) (p 
      0.001). In patients with one or more risk factors for cardiovascular disease but 
      no cardiovascular disease, aspirin was used in 27/223 (12%) versus 195/223 (88%) 
      (p 0.0001). Aspirin was used by 85/291 (29%) male versus 56/259 (22%) females (p 
      0.2). Sixty-three of 260 (24%) Saudis used aspirin versus 77/290 (27%) non-Saudis 
      (p 0.7). CONCLUSION: Aspirin use is low in diabetics with cardiovascular disease 
      and one or more risk factor of cardiovascular disease, with no significant 
      difference between males and females, or Saudis and non-Saudis. Physicians should 
      be encouraged to use aspirin more in diabetics for both primary and secondary 
      prevention of cardiovascular disease.
FAU - Akbar, Daad H
AU  - Akbar DH
AD  - Department of Medicine, King Abdulaziz University Hospital, PO Box 18298, Jeddah 
      21415, Kingdom of Saudi Arabia. daadakb@yahoo.com
FAU - Ahmed, Maimona M
AU  - Ahmed MM
FAU - Siddique, Aisha M
AU  - Siddique AM
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi Med J
JT  - Saudi medical journal
JID - 7909441
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Diabetic Angiopathies/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
EDAT- 2002/04/16 10:00
MHDA- 2002/06/11 10:01
CRDT- 2002/04/16 10:00
PHST- 2002/04/16 10:00 [pubmed]
PHST- 2002/06/11 10:01 [medline]
PHST- 2002/04/16 10:00 [entrez]
PST - ppublish
SO  - Saudi Med J. 2002 Apr;23(4):457-60.

PMID- 12612897
OWN - NLM
STAT- MEDLINE
DCOM- 20030327
LR  - 20171116
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 124
IP  - 3
DP  - 2003 Mar
TI  - Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a 
      proof of concept endoscopic study.
PG  - 600-7
AB  - BACKGROUND AND AIMS: NCX-4016 is a nitric oxide-releasing derivative of aspirin 
      with antiplatelet activity. The aim of this study was to investigate the effect 
      of NCX-4016 on gastrointestinal mucosa and platelet functions in healthy human 
      volunteers. METHODS: This was a parallel-group, double-blind, placebo-controlled 
      study. Forty healthy subjects were randomly allocated to receive 7 days of 
      treatment with NCX-4016 (400 and 800 mg twice daily), equimolar doses of aspirin 
      (200 and 420 mg twice daily), or placebo. Upper endoscopies were performed before 
      and at the end of the treatment period, and gastroduodenal lesions were graded 
      using a predefined scoring system. Basal and posttreatment platelet aggregation 
      in response to arachidonic acid (AA) and serum thromboxane (TX) B(2) and 
      AA-stimulated platelet TXB(2) production were investigated. RESULTS: Mucosal 
      endoscopic injury score on day 7 was 0.63 +/- 0.16 in the placebo group and 11.0 
      +/- 3.0 and 16.1 +/- 1.6 in healthy volunteers treated with 200 and 420 mg 
      aspirin twice daily (P < 0.0001 vs. placebo). NCX-4016 was virtually devoid of 
      gastric and duodenal toxicity, resulting in a total gastric and duodenal 
      endoscopic score of 1.38 +/- 0.3 and 1.25 +/- 0.5 (P < 0.0001 vs. aspirin, not 
      significant vs. placebo). NCX-4016 inhibited AA-induced platelet aggregation as 
      well as serum TXB(2) and platelet TXB(2) generation induced by AA to the same 
      extent as aspirin (not significant vs. aspirin). CONCLUSIONS: In this study, we 
      have proven the concept that addition of an NO-donating moiety to aspirin results 
      in a new chemical entity that maintains cyclooxygenase-1 and platelet inhibitory 
      activity while nearly avoiding gastrointestinal damage.
FAU - Fiorucci, Stefano
AU  - Fiorucci S
AD  - Clinica di Gastroenterologia ed Epatologia, Dipartimento di Medicina Clinica e 
      Sperimentale, Università di Perugia, Perugia, Italy. fiorucci@unipg.it
FAU - Santucci, Luca
AU  - Santucci L
FAU - Gresele, Paolo
AU  - Gresele P
FAU - Faccino, Roberto Maffei
AU  - Faccino RM
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Morelli, Antonio
AU  - Morelli A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Placebos)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 2003 Mar;124(3):842-4. PMID: 12612918
CIN - Gastroenterology. 2003 Dec;125(6):1918-9. PMID: 14727635
CIN - Gastroenterology. 2004 Sep;127(3):1018-9; author reply 1019. PMID: 15362075
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology
MH  - Aspirin/adverse effects/*analogs & derivatives/*pharmacology
MH  - Cardiotonic Agents/adverse effects/*pharmacology
MH  - Digestive System/*drug effects/pathology
MH  - Double-Blind Method
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Gastric Mucosa/drug effects
MH  - Humans
MH  - Intestinal Mucosa/drug effects
MH  - Male
MH  - Pilot Projects
MH  - Placebos/adverse effects/pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Thromboxane B2/metabolism
EDAT- 2003/03/04 04:00
MHDA- 2003/03/28 05:00
CRDT- 2003/03/04 04:00
PHST- 2003/03/04 04:00 [pubmed]
PHST- 2003/03/28 05:00 [medline]
PHST- 2003/03/04 04:00 [entrez]
AID - S0016508502159749 [pii]
AID - 10.1053/gast.2003.50096 [doi]
PST - ppublish
SO  - Gastroenterology. 2003 Mar;124(3):600-7. doi: 10.1053/gast.2003.50096.

PMID- 18497555
OWN - NLM
STAT- MEDLINE
DCOM- 20080814
LR  - 20161124
IS  - 1016-5169 (Print)
IS  - 1016-5169 (Linking)
VI  - 36
IP  - 2
DP  - 2008 Mar
TI  - [The relationship between aspirin resistance and endothelial dysfunction in 
      patients with stable coronary artery disease].
PG  - 103-7
AB  - OBJECTIVES: Endothelial dysfunction may enhance platelet aggregation despite 
      regular aspirin therapy. We investigated the relationship between 
      aspirin-resistant platelet aggregation and endothelial dysfunction in patients 
      with stable coronary artery disease. STUDY DESIGN: The study included 98 patients 
      (60 males, 38 females; mean age 62+/-8 years) receiving medical treatment for 
      stable coronary artery disease. Platelet function assays were performed with the 
      Platelet Function Analyzer (PFA)-100 with collagen and epinephrine (Col/Epi) and 
      collagen and adenosine diphosphate cartridges. Aspirin resistance was defined as 
      a closure time of less than 186 seconds with Col/Epi cartridges despite regular 
      aspirin therapy. Endothelial function was assessed via measurement of 
      flow-mediated dilatation by brachial artery ultrasonography. RESULTS: Twenty 
      patients (20.4%) were found to be aspirin-resistant by the PFA-100. There were no 
      significant differences between patients with and without aspirin resistance with 
      respect to the mean aspirin dose administered and other medications. The mean 
      basal diameter of the brachial artery was 4.11 mm and the mean flow-mediated 
      dilatation (percentage change from basal diameter) was 4.7% in patients with 
      aspirin resistance. The corresponding figures were 4.14 mm and 5.3% in the 
      absence of aspirin resistance (p>0.05). CONCLUSION: In our study, endothelial 
      dysfunction was found in all the patients with stable coronary artery disease, 
      without any association of its presence and severity with aspirin resistance.
FAU - Pamukçu, Burak
AU  - Pamukçu B
AD  - Department of Cardiology, Istanbul Medical Faculty of Istanbul University, 
      Istanbul, Turkey. bpamukcu@gmail.com
FAU - Onür, Imran
AU  - Onür I
FAU - Oflaz, Hüseyin
AU  - Oflaz H
FAU - Elitok, Ali
AU  - Elitok A
FAU - Buğra, Zehra
AU  - Buğra Z
FAU - Nişanci, Yilmaz
AU  - Nişanci Y
LA  - tur
PT  - Journal Article
TT  - Kararli koroner arter hastaliğinda aspirin direnci ile endotel disfonksiyonu 
      arasindaki ilişki.
PL  - Turkey
TA  - Turk Kardiyol Dern Ars
JT  - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
JID - 9426239
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arm/blood supply
MH  - Aspirin/*adverse effects/pharmacology/therapeutic use
MH  - Brachial Artery/diagnostic imaging/physiology
MH  - Case-Control Studies
MH  - Coronary Artery Disease/blood/drug therapy/*physiopathology
MH  - Drug Resistance
MH  - Endothelium, Vascular/*drug effects/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*adverse effects/pharmacology/therapeutic use
MH  - Pulsatile Flow
MH  - Regional Blood Flow
MH  - Ultrasonography, Doppler
EDAT- 2008/05/24 09:00
MHDA- 2008/08/15 09:00
CRDT- 2008/05/24 09:00
PHST- 2008/05/24 09:00 [pubmed]
PHST- 2008/08/15 09:00 [medline]
PHST- 2008/05/24 09:00 [entrez]
PST - ppublish
SO  - Turk Kardiyol Dern Ars. 2008 Mar;36(2):103-7.

PMID- 10812933
OWN - NLM
STAT- MEDLINE
DCOM- 20000623
LR  - 20191103
IS  - 0031-6865 (Print)
IS  - 0031-6865 (Linking)
VI  - 74
IP  - 4
DP  - 2000 Apr
TI  - Stability studies of aspirin-magaldrate double layer tablets.
PG  - 351-60
AB  - Accelerated stability testing was performed on aspirin-magaldrate double layer 
      tablets as well as aspirin-maalox marketed double layer tablets (Ascriptin) in 
      order to evaluate the effect of the presence of the alkaline moieties of the 
      antacid (magaldrate and maalox) on the chemical stability of aspirin. The results 
      were compared simultaneously with that obtained from the marketed Aspro plain 
      tablets. The results revealed that the presence of the alkaline moieties in the 
      tested tablets has increased the rate of aspirin decomposition and reduced its 
      shelf-life. This effect was more pronounced for aspirin tablets containing 
      magaldrate antacid. Determination of shelf-lives at 25 degrees C for the prepared 
      and the marketed tablets was carried out using Arrhenius plots and the results 
      showed that they were 35, 34.5 and 13.5 months for Aspro, Ascriptin and 
      aspirin-magaldrate double layer tablets, respectively. The effect of storage for 
      50 days and at different temperatures, on the crushing strength and the 
      disintegration time of the prepared and the marked tablets showed a slight 
      decrease in the disintegration time and the crushing strength of the tablets as 
      the storage temperature increased. Aspro tablets did not produce the same 
      results. The in vitro release data of the prepared aspirin-magaldrate double 
      layer tablets and the marketed Ascriptin tablets stored for 50 days and at 
      different storage temperatures as well as Aspro tablets stored at 70 degrees C 
      were best fitted to the first-order kinetics model. The release data of Aspro 
      tablets stored at 50 and 60 degrees C for 50 days were best fitted to Higuchi's 
      model.
FAU - al-Gohary, O M
AU  - al-Gohary OM
AD  - Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 
      Saudi Arabia.
FAU - al-Kassas, R S
AU  - al-Kassas RS
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pharm Acta Helv
JT  - Pharmaceutica acta Helvetiae
JID - 0401134
RN  - 0 (Antacids)
RN  - 0 (Drug Combinations)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - 6V88E24N5T (magaldrate)
RN  - NBZ3QY004S (Magnesium Hydroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aluminum Hydroxide/*chemistry
MH  - Antacids/*chemistry
MH  - Aspirin/*chemistry
MH  - Drug Combinations
MH  - Drug Stability
MH  - Magnesium Hydroxide/*chemistry
MH  - Spectrophotometry, Ultraviolet
EDAT- 2000/05/17 09:00
MHDA- 2000/07/06 11:00
CRDT- 2000/05/17 09:00
PHST- 2000/05/17 09:00 [pubmed]
PHST- 2000/07/06 11:00 [medline]
PHST- 2000/05/17 09:00 [entrez]
AID - S003168659900045X [pii]
AID - 10.1016/s0031-6865(99)00045-x [doi]
PST - ppublish
SO  - Pharm Acta Helv. 2000 Apr;74(4):351-60. doi: 10.1016/s0031-6865(99)00045-x.

PMID- 16510297
OWN - NLM
STAT- MEDLINE
DCOM- 20070920
LR  - 20131121
IS  - 1079-9796 (Print)
IS  - 1079-9796 (Linking)
VI  - 36
IP  - 2
DP  - 2006 Mar-Apr
TI  - Platelet-mediated thrombotic complications in patients with ET: Reversal by 
      aspirin, platelet reduction, and not by coumadin.
PG  - 199-205
AB  - The broad spectrum of aspirin-sensitive erythromelalgia, its microvascular 
      ischemic complications, migraine-like atypical or typical transient ischemic 
      attacks (cerebral and ocular) as well as acute coronary syndromes in 
      thrombocythemia vera (essential thrombocythemia and thrombocythemia associated 
      with polycythemia vera in maintained remission by phlebotomy) is caused by 
      platelet cyclo-oxygenase-mediated arteriolar inflammation, fibromuscular intimal 
      proliferation without and with occlusive thrombosis by platelet-rich thrombi in 
      the end-arterial microvasculature of the peripheral, cerebral, ocular and 
      coronary circulation. These microvascular ischemic and thrombotic complications 
      does not respond to Coumadin, but are immediately relieved by a loading dose of 
      500 mg aspirin, and does not recur when the patient is maintained on low dose 
      aspirin (50 mg per day) or after reduction of platelet counts to normal 
      (<400.000/microl).
FAU - Michiels, Jan Jacques
AU  - Michiels JJ
AD  - Hemostasis Thrombosis Research, Department of Hematology, University Hospital 
      Antwerp, Belgium. jan.michiels@uza.be
FAU - Berneman, Zwi
AU  - Berneman Z
FAU - Schroyens, Wilfried
AU  - Schroyens W
FAU - Koudstaal, Peter J
AU  - Koudstaal PJ
FAU - Lindemans, Jan
AU  - Lindemans J
FAU - van Vliet, Huub H D M
AU  - van Vliet HH
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060228
PL  - United States
TA  - Blood Cells Mol Dis
JT  - Blood cells, molecules & diseases
JID - 9509932
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/pathology/physiology
MH  - Erythromelalgia/etiology/pathology
MH  - Humans
MH  - Platelet Count
MH  - Thrombocythemia, Essential/*complications
MH  - Thrombosis/drug therapy/*etiology/pathology
MH  - Warfarin/pharmacology/therapeutic use
RF  - 17
EDAT- 2006/03/03 09:00
MHDA- 2007/09/21 09:00
CRDT- 2006/03/03 09:00
PHST- 2005/12/06 00:00 [received]
PHST- 2005/12/16 00:00 [accepted]
PHST- 2006/03/03 09:00 [pubmed]
PHST- 2007/09/21 09:00 [medline]
PHST- 2006/03/03 09:00 [entrez]
AID - S1079-9796(06)00027-1 [pii]
AID - 10.1016/j.bcmd.2005.12.021 [doi]
PST - ppublish
SO  - Blood Cells Mol Dis. 2006 Mar-Apr;36(2):199-205. doi: 10.1016/j.bcmd.2005.12.021. 
      Epub 2006 Feb 28.

PMID- 10971209
OWN - NLM
STAT- MEDLINE
DCOM- 20001030
LR  - 20181130
IS  - 0042-9007 (Print)
IS  - 0042-9007 (Linking)
VI  - 79
IP  - 1
DP  - 2000
TI  - alphaalpha-crosslinked hemoglobin: was failure predicted by preclinical testing?
PG  - 1-20
AB  - In 1998, Baxter Healthcare announced that it was abandoning its product, 
      diaspirin-crosslinked hemoglobin (DCLHb), the first 'blood substitute' to 
      complete all phases of human trials. The company announced that the phase III 
      (pivotal) trials in humans had resulted in an unexpectedly high survival in a 
      group of patients serving as controls for those who received their product in a 
      trauma setting. It is not possible to quantitate the time, efforts and money that 
      were expended in the course of developing this product, from 1985 to 1998. It is 
      rumored that the giant healthcare company had expended more than a half billion 
      dollars on this product, not to mention the investment in the same product by the 
      US Army, the National Institutes of Health and many independent university-based 
      scientists. The disappointment was profound and far-reaching. Although the threat 
      of HIV transmission by banked blood has all but disappeared in the developed 
      world, still the bulk of the world's population faces blood shortages, which this 
      product and its future generations might have helped alleviate. Only Baxter and 
      the Food and Drug Administration may forever know key elements of the history of 
      development of this product. However, because the US Army decided to make its 
      version of the product widely available to scientists, there is a substantial 
      published record, contributed to by both Baxter and independent scientists. 
      Examination of this record leads to the conclusion that there is no single reason 
      for failure. However, it shows that the characteristic hemodynamic response 
      caused by alphaalphaHb increased vascular resistance, and probably eliminates its 
      potential as a red cell substitute. Newer solutions that overcome this limitation 
      should fare better in clinical development when this problem is overcome.
FAU - Winslow, R M
AU  - Winslow RM
AD  - Sangart, Inc., San Diego, CA, USA.
LA  - eng
GR  - P01 HL48018/HL/NHLBI NIH HHS/United States
GR  - R01 HL64579/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - England
TA  - Vox Sang
JT  - Vox sanguinis
JID - 0413606
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives
MH  - Blood Substitutes
MH  - Cross-Linking Reagents
MH  - *Hemoglobins
MH  - Humans
RF  - 175
EDAT- 2000/09/06 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/06 11:00
PHST- 2000/09/06 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/06 11:00 [entrez]
AID - 31200 [pii]
AID - 10.1159/000031200 [doi]
PST - ppublish
SO  - Vox Sang. 2000;79(1):1-20. doi: 10.1159/000031200.

PMID- 19246922
OWN - NLM
STAT- MEDLINE
DCOM- 20090707
LR  - 20220330
IS  - 1421-9867 (Electronic)
IS  - 0012-2823 (Linking)
VI  - 79
IP  - 1
DP  - 2009
TI  - Incidence of small bowel injury induced by low-dose aspirin: a crossover study 
      using capsule endoscopy in healthy volunteers.
PG  - 44-51
LID - 10.1159/000204465 [doi]
AB  - BACKGROUND AND AIMS: Small intestinal toxicity of low-dose aspirin remains 
      unclear. The purpose of this capsule endoscopy study was to assess the incidence 
      of small bowel injury in healthy volunteers treated with short-term low-dose 
      aspirin. METHODS: Healthy subjects were randomly assigned to receive low-dose 
      aspirin for 14 days (Aspirin group) or no drugs for 14 days (Control group). The 
      two treatment occasions were separated by a washout period of at least 4 weeks. 
      All subjects underwent capsule endoscopy at the end of each treatment period. 
      RESULTS: After 2 weeks of treatment, the percentages of subjects with small bowel 
      pathology were 80% in the Aspirin group compared with 20% in the Control group (p 
      = 0.023). The incidence of small bowel mucosal breaks in the Aspirin group was 
      higher than that in the Control group, although the difference was not 
      significant (30 vs. 0%; p = 0.210). CONCLUSIONS: This is the first pilot study 
      using capsule endoscopy to report on the relation between small bowel injury and 
      low-dose aspirin. Among the healthy subjects, the short-term administration of 
      low-dose aspirin was associated with a mild mucosal inflammation of the small 
      bowel.
FAU - Endo, Hiroki
AU  - Endo H
AD  - Division of Gastroenterology, Yokohama City University School of Medicine, 
      Kanazawa-ku, Yokohama, Japan. t066011b@yokohama-cu.ac.jp
FAU - Hosono, Kunihiro
AU  - Hosono K
FAU - Inamori, Masahiko
AU  - Inamori M
FAU - Kato, Shingo
AU  - Kato S
FAU - Nozaki, Yuichi
AU  - Nozaki Y
FAU - Yoneda, Kyoko
AU  - Yoneda K
FAU - Akiyama, Tomoyuki
AU  - Akiyama T
FAU - Fujita, Koji
AU  - Fujita K
FAU - Takahashi, Hirokazu
AU  - Takahashi H
FAU - Yoneda, Masato
AU  - Yoneda M
FAU - Abe, Yasunobu
AU  - Abe Y
FAU - Kirikoshi, Hiroyuki
AU  - Kirikoshi H
FAU - Kobayashi, Noritoshi
AU  - Kobayashi N
FAU - Kubota, Kensuke
AU  - Kubota K
FAU - Saito, Satoru
AU  - Saito S
FAU - Matsuhashi, Nobuyuki
AU  - Matsuhashi N
FAU - Nakajima, Atsushi
AU  - Nakajima A
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090226
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Digestion. 2009;79(1):40-1. PMID: 19246920
CIN - Digestion. 2009;79(1):42-3. PMID: 19246921
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Capsule Endoscopy
MH  - Chi-Square Distribution
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Incidence
MH  - Intestinal Diseases/*chemically induced/diagnosis
MH  - Intestinal Mucosa/*drug effects/pathology
MH  - *Intestine, Small
MH  - Male
MH  - Pilot Projects
MH  - Statistics, Nonparametric
EDAT- 2009/02/28 09:00
MHDA- 2009/07/08 09:00
CRDT- 2009/02/28 09:00
PHST- 2008/08/19 00:00 [received]
PHST- 2008/11/27 00:00 [accepted]
PHST- 2009/02/28 09:00 [entrez]
PHST- 2009/02/28 09:00 [pubmed]
PHST- 2009/07/08 09:00 [medline]
AID - 000204465 [pii]
AID - 10.1159/000204465 [doi]
PST - ppublish
SO  - Digestion. 2009;79(1):44-51. doi: 10.1159/000204465. Epub 2009 Feb 26.

PMID- 14532740
OWN - NLM
STAT- MEDLINE
DCOM- 20040415
LR  - 20170309
IS  - 1598-9992 (Print)
IS  - 1598-9992 (Linking)
VI  - 42
IP  - 3
DP  - 2003 Sep
TI  - [Gastroduodenal injury in patients with low-dose enteric coated aspirin 
      treatment].
PG  - 190-4
AB  - BACKGROUND/AIMS: Low-dose aspirin therapy is widely used to prevent 
      cardiovascular thrombotic events. However, the safety of low-dose aspirin therapy 
      in the gastrointestinal tract is uncertain. Our aim was to evaluate endoscopic 
      findings in patients taking low-dose aspirin. METHODS: Sixty-two patients who 
      received 100 mg enteric coated aspirin daily more than 30 days were included in 
      this study. Patients' medical records and endoscopic data were reviewed 
      retrospectively. As controls, 70 of age- and gender-matched patients who received 
      an endoscopy without gastrointestinal symptoms were employed. RESULTS: The 
      overall prevalence of gastroduodenal mucosal injury was higher in the aspirin 
      group than in the control group. Erosive gastritis was noted more frequently in 
      the aspirin group than in the control group. However, the prevalence of ulcer was 
      not different between the aspirin group and the control group. CONCLUSIONS: 
      Patients treated with low-dose aspirin therapy are more likely to have endoscopic 
      evidence of mucosal damage. Our study suggests that even a low-dose aspirin 
      therapy can induce a gastroduodenal mucosal injury. In the future, a prospective 
      randomized control study is needed.
FAU - Lee, Hang Lak
AU  - Lee HL
AD  - Department of Internal Medicine, Hanyang University College of Medicine, 
      Gyeonggi, Korea.
FAU - Han, Dong Soo
AU  - Han DS
FAU - Kim, Jin Bae
AU  - Kim JB
FAU - Park, Joon Yong
AU  - Park JY
FAU - Sohn, Joo Hyun
AU  - Sohn JH
FAU - Hahm, Joon Soo
AU  - Hahm JS
FAU - Ahn, You Hern
AU  - Ahn YH
LA  - kor
PT  - English Abstract
PT  - Journal Article
PL  - Korea (South)
TA  - Korean J Gastroenterol
JT  - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JID - 101189416
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Esophagitis/chemically induced
MH  - Female
MH  - Gastritis/chemically induced
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Tablets, Enteric-Coated/adverse effects
EDAT- 2003/10/09 05:00
MHDA- 2004/04/16 05:00
CRDT- 2003/10/09 05:00
PHST- 2003/10/09 05:00 [pubmed]
PHST- 2004/04/16 05:00 [medline]
PHST- 2003/10/09 05:00 [entrez]
AID - 200309190 [pii]
PST - ppublish
SO  - Korean J Gastroenterol. 2003 Sep;42(3):190-4.

PMID- 625136
OWN - NLM
STAT- MEDLINE
DCOM- 19780417
LR  - 20131121
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 75
IP  - 2
DP  - 1978 Feb
TI  - Incidence of emboli with cloth-covered Starr-Edwards valve without 
      anticoagulation and with varying forms of anticoagulation. Analysis of 183 
      patients followed for 3 1/2 years.
PG  - 296-9
AB  - One hundred eighty-three patients with cloth-covered valves were studied from 1 
      1/2 to 8 years after operation, with an average follow-up time of 3 1/2 years. 
      Over the total period, patients taking Coumadin sustained a 4 percent embolic 
      incidence (1.2 per 100 patient-years); those taking aspirin had a 7 percent 
      incidence (2.6 per 100 patient-years); and those taking Persantine had a 43 
      percent incidence (10 per 100 patient-years). Patients on no regimen of 
      anticoagulation had a 16 percent embolic rate (four per 100 patient-years), 
      whereas another group of patients who stopped anticoagulants after a year 
      incurred a 13 percent embolic incidence in the subsequent 2 years (6.4 per 100 
      patient-years). These data showed a significantly lowered embolic rate with 
      anticoagulation and suggest that all patients with cloth-covered valves should be 
      taking anticoagulants. That these valves become epithelialized and do not form 
      thrombus after a year was not borne out by this study. Persantine alone is not a 
      satisfactory anticoagulant. Coumadin appears to be the superior anticoagulant, 
      but if careful monitoring of its use is in question or if serious bleeding 
      complications ensue, aspirin may provide satisfactory protection.
FAU - Moggio, R A
AU  - Moggio RA
FAU - Hammond, G L
AU  - Hammond GL
FAU - Stansel, H C Jr
AU  - Stansel HC Jr
FAU - Glenn, W W
AU  - Glenn WW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aortic Valve/surgery
MH  - Aspirin/adverse effects/therapeutic use
MH  - Connecticut
MH  - Dipyridamole/therapeutic use
MH  - Embolism/epidemiology/*etiology/prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Male
MH  - Mitral Valve/surgery
MH  - *Postoperative Complications
MH  - Warfarin/therapeutic use
EDAT- 1978/02/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1978/02/01 00:00
PHST- 1978/02/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1978/02/01 00:00 [entrez]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1978 Feb;75(2):296-9.

PMID- 22781376
OWN - NLM
STAT- MEDLINE
DCOM- 20121025
LR  - 20131121
IS  - 1827-6806 (Print)
IS  - 1827-6806 (Linking)
VI  - 13
IP  - 7-8
DP  - 2012 Jul-Aug
TI  - [Aspirin in primary prevention of cardiovascular diseases: how to balance risks 
      and benefits].
PG  - 494-502
LID - 10.1714/1114.12245 [doi]
AB  - While the use of aspirin in the secondary prevention of cardiovascular 
      atherothrombotic disease is well established, many aspects of primary prevention 
      are still unclear. Uncertainties mostly depend on a doubtful risk-benefit ratio, 
      because of the low atherothrombotic risk of populations involved on the one hand, 
      and the non-negligible bleeding risk of treatment on the other. Areas of specific 
      doubt are those of diabetes and asymptomatic peripheral arterial disease, where 
      neither single trials nor meta-analyses allow issuing high-grade specific 
      recommendations at the moment. The present review aims at giving an account on 
      this topic, highlighting areas for further studies, but also attempting at 
      providing a rationale for what to do practically now, while awaiting more 
      conclusive evidence. Based on the results of a number of clinical trials and 
      meta-analyses, and especially considering the absolute figures of the benefit 
      (major cardiovascular events avoided) and of the harm (major bleeding events 
      occurred related to aspirin), the authors recommend to limit primary 
      cardiovascular prevention with aspirin (in apparently healthy subjects with no 
      previous cardiovascular events) to subjects with an estimated global 
      cardiovascular risk ≥2 major cardiovascular events per 100 patients-year, as 
      assessed by the risk score assessments proposed in the Italian "Progetto Cuore" 
      (www.progettocuore.it). This cut-off should also be adopted for primary 
      prevention in patients with type 2 diabetes and/or asymptomatic peripheral 
      arterial disease.
FAU - De Caterina, Raffaele
AU  - De Caterina R
AD  - Università degli Studi, G. d'Annunzio, Chieti.
FAU - Orlando, Donatella
AU  - Orlando D
FAU - Berti, Valentina
AU  - Berti V
FAU - Coccheri, Sergio
AU  - Coccheri S
LA  - ita
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspirina nella prevenzione primaria delle malattie cardiovascolari: come 
      bilanciare rischi e benefici.
PL  - Italy
TA  - G Ital Cardiol (Rome)
JT  - Giornale italiano di cardiologia (2006)
JID - 101263411
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - *Primary Prevention
MH  - Risk Assessment
EDAT- 2012/07/12 06:00
MHDA- 2012/10/26 06:00
CRDT- 2012/07/12 06:00
PHST- 2012/07/12 06:00 [entrez]
PHST- 2012/07/12 06:00 [pubmed]
PHST- 2012/10/26 06:00 [medline]
AID - 10.1714/1114.12245 [doi]
PST - ppublish
SO  - G Ital Cardiol (Rome). 2012 Jul-Aug;13(7-8):494-502. doi: 10.1714/1114.12245.

PMID- 16943621
OWN - NLM
STAT- MEDLINE
DCOM- 20061002
LR  - 20131121
IS  - 1085-9195 (Print)
IS  - 1085-9195 (Linking)
VI  - 46
IP  - 1
DP  - 2006
TI  - Aspirin interaction with ribonuclease A.
PG  - 27-33
AB  - Aspirin is an anti-inflammatory drug and a main source of protein acetylation 
      that can alter enzymatic activity and protein functions. Ribonuclease A (RNase A) 
      with several high-affinity binding sites is a possible target for many organic 
      and inorganic molecules (Leonidas at al., [2003] Protein Sci. 12, 2559-2574). 
      This study was designed to examine the interaction of aspirin with RNase Aat 
      physiologic conditions. Reaction mixtures of constant protein concentration (3 
      mM) and different aspirin contents (0.0002-2 mM) are studied by 
      ultraviolet-visible, Fourier transform infrared, and circular dichroism 
      spectroscopic methods to determine the drug binding mode, the drug-binding 
      constant, and the effects of drug complexation on the protein conformation in 
      aqueous solution. Spectroscopic results showed one major binding for the 
      aspirin-RNase complexes with overall binding constant of K = 3.57 x 10(4) M-1. 
      Minor reductions in the protein alpha-helix from 15.5 to 14.1% (circular 
      dichroism) using CDPro program and 26 to 21% (infrared) were observed on aspirin 
      interaction. The changes are indicative of some degree of protein unfolding on 
      drug complexation.
FAU - Neault, J F
AU  - Neault JF
AD  - Department of Chemistry-Biology, University of Québec at Trois-Rivières, C.P. 
      500, Trois-Rivières (Québec) Canada G9A 5H7.
FAU - Ragi, C
AU  - Ragi C
FAU - Novetta-Dellen, A
AU  - Novetta-Dellen A
FAU - Tajmir-Riahi, H A
AU  - Tajmir-Riahi HA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cell Biochem Biophys
JT  - Cell biochemistry and biophysics
JID - 9701934
RN  - 0 (Anti-Inflammatory Agents)
RN  - EC 3.1.27.5 (Ribonuclease, Pancreatic)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*chemistry
MH  - Aspirin/*chemistry
MH  - Cattle
MH  - Circular Dichroism
MH  - Protein Folding
MH  - Ribonuclease, Pancreatic/*chemistry
MH  - Spectrophotometry, Ultraviolet
MH  - Spectroscopy, Fourier Transform Infrared
EDAT- 2006/09/01 09:00
MHDA- 2006/10/03 09:00
CRDT- 2006/09/01 09:00
PHST- 1999/11/30 00:00 [received]
PHST- 1999/11/30 00:00 [revised]
PHST- 1999/11/30 00:00 [accepted]
PHST- 2006/09/01 09:00 [pubmed]
PHST- 2006/10/03 09:00 [medline]
PHST- 2006/09/01 09:00 [entrez]
AID - CBB:46:1:27 [pii]
AID - 10.1385/CBB:46:1:27 [doi]
PST - ppublish
SO  - Cell Biochem Biophys. 2006;46(1):27-33. doi: 10.1385/CBB:46:1:27.

PMID- 22421408
OWN - NLM
STAT- MEDLINE
DCOM- 20120717
LR  - 20131121
IS  - 1096-0961 (Electronic)
IS  - 1079-9796 (Linking)
VI  - 48
IP  - 4
DP  - 2012 Apr 15
TI  - Effect of aspirin administration on reversal of tumor-induced suppression of 
      myelopoiesis in T-cell lymphoma bearing host.
PG  - 238-46
LID - 10.1016/j.bcmd.2012.02.006 [doi]
AB  - The present investigation studied the effect of aspirin administration in 
      tumor-bearing hosts on bone marrow cellularity and myelopoiesis. Aspirin 
      administration to mice bearing a transplantable T-cell lymphoma, designated as 
      Dalton's lymphoma (DL), augmented proliferation of bone marrow cells (BMC). BMC 
      of aspirin-administered tumor-bearing mice were found to be predominantly in the 
      S phase of cell cycle releasing them from G0/G1 arrest. Aspirin-exposed BMC also 
      showed an altered expression of survival and cell cycle regulatory proteins p53, 
      bcl2, caspase-activated deoxyribonuclease (CAD), cyclin B1 and cyclin D. 
      Moreover, the BMC of aspirin-administered tumor-bearing mice showed an augmented 
      colony-forming ability and differentiation in the macrophage lineage with an 
      activated phenotype of bone marrow-derived macrophages (BMDM) with respect to 
      macrophage-mediated tumoricidal activity and production of nitric oxide, IL-1β, 
      TNFα and VEGF. On the other hand aspirin administration to normal mice showed 
      little effect on bone marrow cellularity and myeloid differentiation. In this 
      model, aspirin had a myelopoetic action in tumor-bearing host.
CI  - Copyright Â© 2012 Elsevier Inc. All rights reserved.
FAU - Kumar, Anjani
AU  - Kumar A
AD  - School of Biotechnology, Banaras Hindu University, Varanasi-221005, U.P., India.
FAU - Bharti, Alok Chandra
AU  - Bharti AC
FAU - Singh, Sukh Mahendra
AU  - Singh SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120314
PL  - United States
TA  - Blood Cells Mol Dis
JT  - Blood cells, molecules & diseases
JID - 9509932
RN  - 0 (Cell Cycle Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bone Marrow Cells/drug effects
MH  - Cell Cycle/drug effects
MH  - Cell Cycle Proteins/metabolism
MH  - Cell Proliferation
MH  - Lymphoma, T-Cell/*metabolism
MH  - Macrophages/drug effects/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Myelopoiesis/*drug effects
EDAT- 2012/03/17 06:00
MHDA- 2012/07/18 06:00
CRDT- 2012/03/17 06:00
PHST- 2011/11/11 00:00 [received]
PHST- 2012/02/17 00:00 [revised]
PHST- 2012/02/18 00:00 [accepted]
PHST- 2012/03/17 06:00 [entrez]
PHST- 2012/03/17 06:00 [pubmed]
PHST- 2012/07/18 06:00 [medline]
AID - S1079-9796(12)00059-9 [pii]
AID - 10.1016/j.bcmd.2012.02.006 [doi]
PST - ppublish
SO  - Blood Cells Mol Dis. 2012 Apr 15;48(4):238-46. doi: 10.1016/j.bcmd.2012.02.006. 
      Epub 2012 Mar 14.

PMID- 8994418
OWN - NLM
STAT- MEDLINE
DCOM- 19970204
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 95
IP  - 1
DP  - 1997 Jan 7
TI  - Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by 
      aspirin.
PG  - 63-8
AB  - BACKGROUND: Aspirin effectively reduces the incidence of secondary vascular 
      occlusive events in only 25% of patients. Low-dose aspirin as currently used 
      blocks platelet production of prothrombotic thromboxane A2 and allows endothelial 
      synthesis of antithrombotic prostacyclin. This regimen minimizes gastrointestinal 
      toxicity. We previously showed that intact erythrocytes markedly enhance platelet 
      reactivity. Therefore we investigated whether supplementation of low-dose aspirin 
      with a single high dose at 2-week intervals could more effectively block 
      erythrocyte promotion of platelet reactivity. METHODS AND RESULTS: Effects of 
      different aspirin regimens on erythrocyte enhancement of platelet reactivity in 
      normal volunteers were measured with the use of an assay that evaluates both 
      platelet activation and recruitment. After 15 days of daily ingestion of 50 mg 
      aspirin, reactivity of platelets alone was inhibited. However, erythrocyte 
      promotion of platelet activation and recruitment was only inhibited by 
      approximately 50% and persisted in the total absence of thromboxane synthesis. In 
      contrast, if 50 mg/d aspirin was preceded by a single loading dose of 500 mg 
      aspirin, the erythrocyte prothrombotic effect was strongly inhibited 
      (approximately 90%) for 2 to 3 weeks. However, over time, erythrocytes "escaped" 
      from this inhibition, and once again became prothrombotic, even on a daily 
      regimen of 50 mg aspirin. CONCLUSIONS: For clinical purposes, we recommend a 
      loading dose of aspirin (500 mg), followed by daily administration of 50 mg. The 
      loading dose should be repeated at 2-week intervals. This regimen blocks recovery 
      of the erythrocyte capacity to promote platelet reactivity and may amplify the 
      therapeutic potential of aspirin in cardiovascular disease.
FAU - Santos, M T
AU  - Santos MT
AD  - Research Center, University Hospital La Fé, Valencia, Spain.
FAU - Valles, J
AU  - Valles J
FAU - Aznar, J
AU  - Aznar J
FAU - Marcus, A J
AU  - Marcus AJ
FAU - Broekman, M J
AU  - Broekman MJ
FAU - Safier, L B
AU  - Safier LB
LA  - eng
GR  - HL-18828/HL/NHLBI NIH HHS/United States
GR  - HL-46403/HL/NHLBI NIH HHS/United States
GR  - HL-47073/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Thromboxanes)
RN  - 333DO1RDJY (Serotonin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 1997 Jan 7;95(1):11-3. PMID: 8994408
CIN - Circulation. 1998 Jan 6-13;97(1):118-9. PMID: 9443445
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/metabolism/*physiology
MH  - Drug Administration Schedule
MH  - Erythrocytes/*drug effects/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/drug effects
MH  - Serotonin/metabolism
MH  - Thromboxanes/biosynthesis
MH  - Time Factors
EDAT- 1997/01/07 00:00
MHDA- 1997/01/07 00:01
CRDT- 1997/01/07 00:00
PHST- 1997/01/07 00:00 [pubmed]
PHST- 1997/01/07 00:01 [medline]
PHST- 1997/01/07 00:00 [entrez]
AID - 10.1161/01.cir.95.1.63 [doi]
PST - ppublish
SO  - Circulation. 1997 Jan 7;95(1):63-8. doi: 10.1161/01.cir.95.1.63.

PMID- 10700490
OWN - NLM
STAT- MEDLINE
DCOM- 20000323
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 31
IP  - 3
DP  - 2000 Mar
TI  - Increased platelet sensitivity to collagen in individuals resistant to low-dose 
      aspirin.
PG  - 591-5
AB  - BACKGROUND AND PURPOSE: The purpose of this study was to assess individual 
      differences in the pharmacological effects of acetylsalicylic acid (ASA) on 
      bleeding time as measured by in vitro platelet aggregation and to examine the 
      consistency of responses over time. METHODS: We measured template IIR bleeding 
      time and platelet aggregation in 8 healthy male volunteers before and 2 hours 
      after ingestion of 324 mg of ASA. An individual was considered a nonresponder if 
      his post-ASA bleeding time was not 2 SDs above his baseline bleeding time, where 
      SD was estimated from the baseline bleeding times of the 8 volunteers. The same 
      experiment was done after a 30-month interval. RESULTS: Five volunteers were 
      identified as ASA responders, and 3 were identified as nonresponders. Bleeding 
      time before and after ingestion of ASA was 408+/-121 seconds (mean+/-SD) and 
      720+/-225 seconds, respectively, in ASA responders and 330+/-30 seconds and 
      330+/-52 seconds, respectively, in ASA nonresponders. The mean ED(50) for 
      collagen-induced platelet aggregation, that is, the mean concentration of 
      collagen that caused a response at 50% of maximum, was 0.91 microg/mL (95% CI, 
      0.73 to 1. 14) in ASA responders and 0.48 microg/mL (95% CI, 0.38 to 0.60) in 
      nonresponders. When optimum concentrations of collagen, ie, concentrations that 
      yielded 90% maximum aggregation, were used as stimuli, the mean IC(50) for ASA, 
      that is, the mean concentration that yielded 50% inhibition, was 322.5 micromol/L 
      (95% CI, 264.8 to 392.6) in ASA responders and 336.1 micromol/L (95% CI, 261.0 to 
      432. 8) in nonresponders. The variability in individual responsiveness in the 
      second experiment remained consistent with that in the first experiment. 
      CONCLUSIONS: ASA resistance may be caused by an increased sensitivity of 
      platelets to collagen. A platelet aggregation study specific for collagen dose 
      response may be useful for strict selection of ASA responders for low-dose ASA 
      therapy and for identifying ASA nonresponders for high-dose ASA therapy.
FAU - Kawasaki, T
AU  - Kawasaki T
AD  - Department of Surgery 2, Osaka University Medical School, Osaka, Japan. 
      kawasaki@surg2.med.osaka-u.ac.jp
FAU - Ozeki, Y
AU  - Ozeki Y
FAU - Igawa, T
AU  - Igawa T
FAU - Kambayashi, J
AU  - Kambayashi J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects
MH  - Clinical Trials as Topic
MH  - Collagen/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance
MH  - Humans
MH  - Male
MH  - Osmolar Concentration
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
EDAT- 2000/03/04 09:00
MHDA- 2000/03/25 09:00
CRDT- 2000/03/04 09:00
PHST- 2000/03/04 09:00 [pubmed]
PHST- 2000/03/25 09:00 [medline]
PHST- 2000/03/04 09:00 [entrez]
AID - 10.1161/01.str.31.3.591 [doi]
PST - ppublish
SO  - Stroke. 2000 Mar;31(3):591-5. doi: 10.1161/01.str.31.3.591.

PMID- 12494176
OWN - NLM
STAT- MEDLINE
DCOM- 20031106
LR  - 20170310
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 42
IP  - 4
DP  - 2002
TI  - [Aspirin in primary prevention of ischemic heart disease].
PG  - 91-5
AB  - High efficacy of aspirin in secondary prevention after myocardial infarction and 
      stroke is well established. However the place of aspirin in primary prevention of 
      coronary heart disease and other cardiovascular diseases remains questionable. 
      Analysis of results of large controlled studies of efficacy and safety of aspirin 
      in high risk subjects shows that low doses of aspirin should be used in men with 
      high risk of coronary heart disease but without main risk factors of stroke.
FAU - Preobrazhenskiĭ, D V
AU  - Preobrazhenskiĭ DV
FAU - Sidorenko, B A
AU  - Sidorenko BA
FAU - Malysheva, N V
AU  - Malysheva NV
FAU - Tsurko, V V
AU  - Tsurko VV
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Mesto aspirina v pervichnoĭ profilaktike ishemicheskoxĭ bolezni serdtsa.
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*prevention & control
RF  - 17
EDAT- 2002/12/21 04:00
MHDA- 2003/11/07 05:00
CRDT- 2002/12/21 04:00
PHST- 2002/12/21 04:00 [pubmed]
PHST- 2003/11/07 05:00 [medline]
PHST- 2002/12/21 04:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 2002;42(4):91-5.

PMID- 376030
OWN - NLM
STAT- MEDLINE
DCOM- 19790901
LR  - 20190705
IS  - 0007-1323 (Print)
IS  - 0007-1323 (Linking)
VI  - 66
IP  - 5
DP  - 1979 May
TI  - The effect of aspirin on the fibrinolytic activity of gastric juice.
PG  - 344-7
AB  - Fibrinolytic activity in the gastric juice of normal subjects has been studied by 
      a double-blind cross-over technique comparing the effect of placebo and 
      pentagastrin against aspirin and pentagastrin. Aspirin effectively produced a 
      gastritis and pure fibrinolytic activity was detected in the gastric juice, but 
      the number of samples showing pure fibrinolytic activity did not differ between 
      the two groups. In both the placebo and the aspirin groups the presence of a 
      protease active at neutral pH and capable of dissolving fibrin is confirmed. 
      Aspirin is unlikely to cause gastric bleeding by increasing local fibrinolytic 
      activity within the stomach. The model, so constructed, is not sensitive enough 
      to be of value in investigating further the role of gastric fibrinolytic activity 
      in gastric haemorrhage.
FAU - O'Brien, T E
AU  - O'Brien TE
FAU - Hadley, H
AU  - Hadley H
FAU - Irving, M H
AU  - Irving MH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Fibrinolysis/*drug effects
MH  - Gastric Juice/*drug effects
MH  - Humans
MH  - Male
MH  - Placebos
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
AID - 10.1002/bjs.1800660514 [doi]
PST - ppublish
SO  - Br J Surg. 1979 May;66(5):344-7. doi: 10.1002/bjs.1800660514.

PMID- 17301509
OWN - NLM
STAT- MEDLINE
DCOM- 20070306
LR  - 20190606
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 46
IP  - 4
DP  - 2007
TI  - A health economic evaluation of aspirin in the primary prevention of 
      cardiovascular disease in Japan.
PG  - 157-62
AB  - OBJECTIVE: Low-dose aspirin is standard care in patients with a history of 
      cardiovascular disease (CVD). But, the use of low-dose aspirin in primary 
      prevention has not yet been fully established in Japan although meta-analyses and 
      US/European guidelines support its use in persons at increased CVD risk. This 
      study assessed the health economic consequences of the use of low-dose aspirin in 
      the primary prevention of CVD in Japan. PATIENTS AND METHODS: Based on results 
      reported in two recent meta-analyses of Hayden (2002) and Eidelman (2003), a 
      Markov model was constructed to predict the cost-effectiveness of low-dose 
      aspirin in the primary prevention of CVD. The model consists of 5 health states: 
      1) no history of CVD, 2) history of stroke, 3) history of myocardial infarction, 
      4) history of CVD, and 5) death, with a 10-year time horizon and 1-year cycles. 
      Direct costs from the insurers' perspective were used, while health outcome was 
      expressed in Life-Years Gained (LYG). 'Discounting Rate' with 3% was applied on 
      effectiveness and costs. RESULTS: For patients with a 1-year risk of coronary 
      heart disease (CHD) of 1.5% (10-year risk of +/-15%), the model demonstrated 
      'dominance' of the 'aspirin' arm versus 'no aspirin' arm; the 10-year costs were 
      Japanese Yen (JPY) 634,000 (Euro 4,857) and JPY 518,000 (Euro 3,968) in the 'no 
      aspirin' arm and 'aspirin' arm, respectively, while LYG was 8.33 and 8.36, 
      respectively. Low-dose aspirin treatment saved on average JPY 116,000 (Euro 889) 
      [95% confidence interval (CI) JPY 57,077-175,151] per patient. Dominance was 
      demonstrated (non-significant) in the first year of treatment and, low-dose 
      aspirin was dominant to 'no aspirin' arm from an annual risk of 0.20%. Other 
      results of sensitivity analysis on gastrointestinal (GI) bleeding rate, stroke 
      rate, cost of each event and discounting showed the robustness of the results. 
      CONCLUSIONS: Administering low-dose aspirin to patients with a 1-year risk of CHD 
      of 1.5% and more is significantly cost-saving from the insurers' perspective in 
      Japan.
FAU - Tsutani, Kiichiro
AU  - Tsutani K
AD  - The Department of Pharmacoeconomics, Graduate School of Pharmaceutical Sciences, 
      The University of Tokyo, Tokyo, Japan.
FAU - Igarashi, Ataru
AU  - Igarashi A
FAU - Fujikawa, Keita
AU  - Fujikawa K
FAU - Evers, Thomas
AU  - Evers T
FAU - Kubin, Maria
AU  - Kubin M
FAU - Lamotte, Mark
AU  - Lamotte M
FAU - Annemans, Lieven
AU  - Annemans L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20070215
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Intern Med. 2007;46(8):431-3. PMID: 17443030
CIN - Intern Med. 2007;46(15):1281. PMID: 17675791
MH  - Adult
MH  - Aged
MH  - Aspirin/*economics/therapeutic use
MH  - Cardiovascular Diseases/economics/mortality/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Costs
MH  - Economics, Pharmaceutical/*statistics & numerical data
MH  - Evaluation Studies as Topic
MH  - Female
MH  - *Health Care Costs
MH  - Humans
MH  - Japan
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Primary Prevention/*economics
MH  - Risk Assessment
MH  - Sensitivity and Specificity
MH  - Survival Analysis
EDAT- 2007/02/16 09:00
MHDA- 2007/03/07 09:00
CRDT- 2007/02/16 09:00
PHST- 2007/02/16 09:00 [pubmed]
PHST- 2007/03/07 09:00 [medline]
PHST- 2007/02/16 09:00 [entrez]
AID - JST.JSTAGE/internalmedicine/46.1843 [pii]
AID - 10.2169/internalmedicine.46.1843 [doi]
PST - ppublish
SO  - Intern Med. 2007;46(4):157-62. doi: 10.2169/internalmedicine.46.1843. Epub 2007 
      Feb 15.

PMID- 10974346
OWN - NLM
STAT- MEDLINE
DCOM- 20001207
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 99
IP  - 6
DP  - 2000 Sep 15
TI  - Effects of acetyl salicylic acid therapy on an experimental thrombosis induced by 
      laser beam.
PG  - 595-602
AB  - Aspirin inhibits the synthesis of both platelet and vascular arachidonic acid 
      metabolism which have opposite effects on platelet functions. The rationale for 
      its clinical use as an antithrombotic drug has therefore been questioned. 
      Therefore, we investigated the effects of acetylsalicylic acid (ASA) at 100 mg/kg 
      on an experimental thrombosis induced by laser beams using different groups of 
      rats that were previously treated with the same dose (100 mg/kg), according to 
      the delay between the first and second injections. A partial occlusion was 
      induced by laser beams in the rat mesenteric microvessels (15-25 m). The thrombus 
      formed within seconds after the laser lesion; both it and the embolization which 
      began within minutes after, were continuously accounted. Experiments were done on 
      11 groups of 5 animals each: 45 rats received a first injection of ASA at j(0) 
      and a second injection 30 minutes before thrombosis induction at j(0)+x (x=2, 4, 
      6, 8, 9, 10, 12, 14 and 16 days). Different groups are defined according to the x 
      value. The rats receiving NaCl 0.9% or a single injection of ASA at 100 mg/kg 30 
      minutes before thrombosis induction were used as control (Group I) and reference 
      group (Group II) respectively. In this study, ASA treatment showed two types of 
      results. The administration of ASA (100 mg/kg) 30 minutes before laser-induced 
      thrombosis prevented thrombus formation. In the same way, ASA injected to rats 
      already treated with the same dose 2 or 4 day later also demonstrated a potent 
      antithrombotic effect. The same trends were observed with animals receiving the 
      second injection (100 mg ASA) at j(0+8), j(0+12), j(0+14), and j(0+16). However, 
      when injected to rats at j(0+6) and at j(0+10), ASA did not shown any effects on 
      thrombus formation compared to the control (p>/=0.05). The same phases of ASA 
      action were observed on the induced hemorrhagic time. The antithrombotic effects 
      of the later second injection of ASA (100 mg/kg) were neutralized in rats 
      previously receiving the same dose of this drug. This phenomenon seems to be 
      periodic and is of great importance for the observance of ASA treatment.
FAU - Aguejouf, O
AU  - Aguejouf O
AD  - Laboratoire d'Hématologie, Faculté de Pharmacie, 146, Rue Léo-Saignat, 33 076 
      Cedex, Bordeaux, France.
FAU - Malfatti, E
AU  - Malfatti E
FAU - Belon, P
AU  - Belon P
FAU - Doutremepuich, C
AU  - Doutremepuich C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Bleeding Time
MH  - Disease Models, Animal
MH  - Fibrinogen/drug effects
MH  - Lasers
MH  - Male
MH  - Partial Thromboplastin Time
MH  - Platelet Aggregation/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Thrombosis/*drug therapy/etiology/prevention & control
EDAT- 2000/09/07 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/07 11:00
PHST- 2000/09/07 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/07 11:00 [entrez]
AID - S0049-3848(00)00270-X [pii]
AID - 10.1016/s0049-3848(00)00270-x [doi]
PST - ppublish
SO  - Thromb Res. 2000 Sep 15;99(6):595-602. doi: 10.1016/s0049-3848(00)00270-x.

PMID- 32564638
OWN - NLM
STAT- MEDLINE
DCOM- 20210909
LR  - 20210909
IS  - 1525-6065 (Electronic)
IS  - 1064-1955 (Linking)
VI  - 39
IP  - 4
DP  - 2020 Nov
TI  - Patients' perspective on aspirin during pregnancy: a survey.
PG  - 371-378
LID - 10.1080/10641955.2020.1777299 [doi]
AB  - OBJECTIVE: To elucidate patients' knowledge and counseling perspective on aspirin 
      reducing the risk of hypertensive disorders of pregnancy (HDP). METHODS: A 
      quantitative survey was performed including women who are members of the patient 
      orgasnization Dutch HELLP Foundation due to a history of HDP. RESULTS: Awareness 
      of the risk-reducing effect of aspirin on HDP was present in 51.9% of the 189 
      women. The majority was informed by their gynecologist (89.8%) and preferred to 
      be informed by a gynecologist (79.4%), at the postpartum checkup (42.3%) or in 
      the consecutive pregnancy (30.7%), both orally and written (62.4%). CONCLUSION: 
      Half of the women with a history of HDP were aware of the risk-reducing effect of 
      aspirin in a consecutive pregnancy.
FAU - Bij de Weg, Jeske M
AU  - Bij de Weg JM
AD  - Department of Obstetrics and Gynecology, Reproduction and Development, Amsterdam 
      UMC, Location VUmc Amsterdam , Amsterdam, The Netherlands.
FAU - Abheiden, Carolien N H
AU  - Abheiden CNH
AD  - Department of Obstetrics and Gynecology, Reproduction and Development, Amsterdam 
      UMC, Location VUmc Amsterdam , Amsterdam, The Netherlands.
FAU - de Boer, Marjon A
AU  - de Boer MA
AD  - Department of Obstetrics and Gynecology, Reproduction and Development, Amsterdam 
      UMC, Location VUmc Amsterdam , Amsterdam, The Netherlands.
FAU - de Groot, Conni
AU  - de Groot C
AD  - Dutch HELLP Foundation , DC Zwolle, The Netherlands.
FAU - de Vries, Johanna I P
AU  - de Vries JIP
AD  - Department of Obstetrics and Gynecology, Reproduction and Development, Amsterdam 
      UMC, Location VUmc Amsterdam , Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200620
PL  - England
TA  - Hypertens Pregnancy
JT  - Hypertension in pregnancy
JID - 9421297
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/*prevention & control
MH  - Pregnancy
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Aspirin
OT  - HELLP
OT  - gestational hypertension
OT  - placenta
OT  - preeclampsia
EDAT- 2020/06/23 06:00
MHDA- 2021/09/10 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/09/10 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - 10.1080/10641955.2020.1777299 [doi]
PST - ppublish
SO  - Hypertens Pregnancy. 2020 Nov;39(4):371-378. doi: 10.1080/10641955.2020.1777299. 
      Epub 2020 Jun 20.

PMID- 17014185
OWN - NLM
STAT- MEDLINE
DCOM- 20070814
LR  - 20131121
IS  - 0021-9606 (Print)
IS  - 0021-9606 (Linking)
VI  - 125
IP  - 12
DP  - 2006 Sep 28
TI  - On the nonlinear variation of dc conductivity with dielectric relaxation time.
PG  - 124501
AB  - The long-known observations that dc conductivity sigma(dc) of an ultraviscous 
      liquid varies nonlinearly with the dielectric relaxation time tau, and the slope 
      of the log sigma(dc) against log tau plot deviates from -1 are currently seen as 
      two of the violations of the Debye-Stokes-Einstein equation. Here we provide a 
      formalism using a zeroth order Bjerrum description for ion association to show 
      that in addition to its variation with temperature T and pressure P, impurity ion 
      population varies with a liquid's equilibrium dielectric permittivity. Inclusion 
      of this electrostatic effect modifies the Debye-Stokes-Einstein equation to 
      log(sigma(dc)tau)=constant+log alpha, where alpha is the T and P-dependent degree 
      of ionic dissociation of an electrolytic impurity. Variation of a liquid's shear 
      modulus with T and P would add to the nonlinearity of sigma(dc)-tau relation, as 
      would a nonequivalence of the shear and dielectric relaxation times, proton 
      transfer along the hydrogen bonds, or occurrence of another chemical process. 
      This is illustrated by using the data for ultraviscous acetaminophen-aspirin 
      liquid.
FAU - Johari, G P
AU  - Johari GP
AD  - Department of Materials Science and Engineering, McMaster University, Hamilton, 
      Ontario L8S 4L7, Canada. joharig@mcmaster.ca
FAU - Andersson, Ove
AU  - Andersson O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Chem Phys
JT  - The Journal of chemical physics
JID - 0375360
RN  - 0 (Ions)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/chemistry
MH  - Aspirin/chemistry
MH  - *Electric Conductivity
MH  - *Electrons
MH  - Ions/chemistry
MH  - *Nonlinear Dynamics
MH  - Static Electricity
MH  - Time Factors
EDAT- 2006/10/04 09:00
MHDA- 2007/08/19 09:00
CRDT- 2006/10/04 09:00
PHST- 2006/10/04 09:00 [pubmed]
PHST- 2007/08/19 09:00 [medline]
PHST- 2006/10/04 09:00 [entrez]
AID - 10.1063/1.2353833 [doi]
PST - ppublish
SO  - J Chem Phys. 2006 Sep 28;125(12):124501. doi: 10.1063/1.2353833.

PMID- 30347414
OWN - NLM
STAT- MEDLINE
DCOM- 20190401
LR  - 20190401
IS  - 1098-9064 (Electronic)
IS  - 0094-6176 (Linking)
VI  - 45
IP  - 2
DP  - 2019 Mar
TI  - Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular 
      Disease: A Narrative Overview.
PG  - 157-163
LID - 10.1055/s-0038-1675380 [doi]
AB  - Aspirin is one of the most often used drugs for prevention and treatment of a 
      variety of thrombotic disorders. This narrative review aims to provide an 
      overview of evidence highlighting potential benefits and relative harms of 
      aspirin in primary prevention of cardiovascular disease. The authors summarize 
      key findings of the ASPirin in Reducing Events in the Elderly (ASPREE) 
      Investigator Group randomized trial and also provide a comparative overview of 
      recent meta-analyses. Overall, all-cause mortality was largely heterogeneous, 
      with some meta-analyses showing a modestly decreased risk in patients taking 
      aspirin, with others reporting no effects, but the ASPREE Investigator Group 
      trial evidencing 14% higher risk. Regarding cardiovascular disease, the most 
      favorable impact could be noted for major adverse cardiovascular events, with 
      most meta-analyses reporting a decreased risk in people receiving aspirin. 
      Conversely, the ASPREE Investigator Group trial demonstrated no significant 
      impact of aspirin on risk of cardiovascular mortality or ischemic stroke. A 
      modest favorable effect of aspirin in decreasing the risk of myocardial 
      infarction was noted in two meta-analyses, but not in other reports or in the 
      ASPREE Investigator Group trial. Furthermore, one meta-analysis reported a lower 
      risk of future cancer, others failed to report a significant effect, and the 
      ASPREE Investigator Group trial reported a 31% increased risk. Unlike these 
      conflicting outcomes, the bleeding risk of patients receiving aspirin was found 
      to be consistently enhanced in all reports reviewed. These recent findings would 
      lead us to conclude that the harms of aspirin in primary prevention of 
      cardiovascular disease may be larger than the benefits, especially in the elderly 
      general population.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Lippi, Giuseppe
AU  - Lippi G
AD  - Section of Clinical Biochemistry, University of Verona, Verona, Italy.
FAU - Danese, Elisa
AU  - Danese E
AD  - Section of Clinical Biochemistry, University of Verona, Verona, Italy.
FAU - Favaloro, Emmanuel J
AU  - Favaloro EJ
AD  - Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, 
      Institute of Clinical Pathology and Medical Research, NSW Health Pathology, 
      Westmead Hospital, Westmead, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181022
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Neoplasms/chemically induced
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Primary Prevention/*methods
MH  - Risk Assessment/methods/statistics & numerical data
MH  - Risk Factors
COIS- None.
EDAT- 2018/10/23 06:00
MHDA- 2019/04/02 06:00
CRDT- 2018/10/23 06:00
PHST- 2018/10/23 06:00 [pubmed]
PHST- 2019/04/02 06:00 [medline]
PHST- 2018/10/23 06:00 [entrez]
AID - 10.1055/s-0038-1675380 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2019 Mar;45(2):157-163. doi: 10.1055/s-0038-1675380. Epub 
      2018 Oct 22.

PMID- 6467268
OWN - NLM
STAT- MEDLINE
DCOM- 19841016
LR  - 20190511
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 18
IP  - 8
DP  - 1984 Aug
TI  - The effect of aspirin on peripheral haemodynamic changes following submaximal 
      exercise in normal volunteers.
PG  - 511-3
AB  - Eight normal healthy volunteers participated in a study to determine the effect 
      of 1800 mg of aspirin on the peripheral haemodynamic changes that occur following 
      upright exercise. Aspirin reduced the extent of calf hyperaemia (p less than 
      0.05) and accentuated the reduction in forearm blood flow (p less than 0.05) 
      following exercise. It had no effect on either calf or forearm blood flow at 
      rest. These results indicate that aspirin, possibly by inhibiting prostacyclin 
      production, modifies the circulatory changes following upright exercise.
FAU - Cowley, A J
AU  - Cowley AJ
FAU - Stainer, K
AU  - Stainer K
FAU - Rowley, J M
AU  - Rowley JM
FAU - Hanley, S P
AU  - Hanley SP
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Forearm/*blood supply
MH  - Humans
MH  - Leg/*blood supply
MH  - Male
MH  - *Physical Exertion
MH  - Regional Blood Flow/drug effects
MH  - Time Factors
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 10.1093/cvr/18.8.511 [doi]
PST - ppublish
SO  - Cardiovasc Res. 1984 Aug;18(8):511-3. doi: 10.1093/cvr/18.8.511.

PMID- 21708235
OWN - NLM
STAT- MEDLINE
DCOM- 20120402
LR  - 20131121
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 418
IP  - 2
DP  - 2011 Oct 14
TI  - Anisotropic crystal deformation measurements determined using powder X-ray 
      diffraction and a new in situ compression stage.
PG  - 199-206
LID - 10.1016/j.ijpharm.2011.06.021 [doi]
AB  - This report addresses the development of experimental and computational 
      estimations of the anisotropic elastic moduli (EM) of single crystals to aid in 
      the a priori (i.e., starting with the crystal structure) prediction of the trend 
      as a function of the direction of applied stress. Experimentally EM values in the 
      normal direction to the X-, Y- and Z-planes of block shaped aspirin and 
      acetaminophen crystals were determined using data generated by the newly designed 
      compression stage housed in our powder X-ray diffractometer. Computational 
      estimations of EM were made using the applicable modules in Material Studio 5.5. 
      The measured EM values normal to the (100), (020) and (002) planes of aspirin, 
      and (20-1), (020) and (001) planes of acetaminophen crystals by both methods 
      succeeded in detected the anisotropic behavior. However, disparity in the 
      relative values between measured EM values by different techniques was observed. 
      This may be attributed to deformation sources other than lattice compression 
      including inelastic processes such as local failure and plasticity as well as 
      deformation at the crystal-probe interfaces due to crystal surface roughness 
      (asperities). The trend of the ratio of the values from the respective methods 
      showed reasonable agreement and promise for the technique. The present approach 
      demonstrated the suitability of the compression stage to determine and predict 
      anisotropic EM of subjected small molecular organic crystals.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Haware, Rahul V
AU  - Haware RV
AD  - College of Pharmacy, University of Hawai'i at Hilo, 34 Rainbow Drive, Hilo, HI 
      96720, USA. rahulh@hawaii.edu
FAU - Kim, Paul
AU  - Kim P
FAU - Ruffino, Lauren
AU  - Ruffino L
FAU - Nimi, Brian
AU  - Nimi B
FAU - Fadrowsky, Catherine
AU  - Fadrowsky C
FAU - Doyle, Michael
AU  - Doyle M
FAU - Boerrigter, Stephan X M
AU  - Boerrigter SX
FAU - Cuitino, Alberto
AU  - Cuitino A
FAU - Morris, Ken
AU  - Morris K
LA  - eng
PT  - Journal Article
DEP - 20110617
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*chemistry
MH  - Anisotropy
MH  - Aspirin/*chemistry
MH  - Computer Simulation
MH  - *Crystallization
MH  - Humans
MH  - *Powder Diffraction
MH  - Pressure
MH  - *X-Ray Diffraction
EDAT- 2011/06/29 06:00
MHDA- 2012/04/03 06:00
CRDT- 2011/06/29 06:00
PHST- 2011/01/21 00:00 [received]
PHST- 2011/06/05 00:00 [revised]
PHST- 2011/06/12 00:00 [accepted]
PHST- 2011/06/29 06:00 [entrez]
PHST- 2011/06/29 06:00 [pubmed]
PHST- 2012/04/03 06:00 [medline]
AID - S0378-5173(11)00555-2 [pii]
AID - 10.1016/j.ijpharm.2011.06.021 [doi]
PST - ppublish
SO  - Int J Pharm. 2011 Oct 14;418(2):199-206. doi: 10.1016/j.ijpharm.2011.06.021. Epub 
      2011 Jun 17.

PMID- 9851479
OWN - NLM
STAT- MEDLINE
DCOM- 19981222
LR  - 20220408
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 280
IP  - 22
DP  - 1998 Dec 9
TI  - Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled 
      trials.
PG  - 1930-5
AB  - CONTEXT: Aspirin has been widely used to prevent myocardial infarction and 
      ischemic stroke but some studies have suggested it increases risk of hemorrhagic 
      stroke. OBJECTIVE: To estimate the risk of hemorrhagic stroke associated with 
      aspirin treatment. DATA SOURCES: Studies were retrieved using MEDLINE (search 
      terms, aspirin, cerebrovascular disorders, and stroke), bibliographies of the 
      articles retrieved, and the authors' reference files. STUDY SELECTION: All trials 
      published in English-language journals before July 1997 in which participants 
      were randomized to aspirin or a control treatment for at least 1 month and in 
      which the incidence of stroke subtype was reported. DATA EXTRACTION: Information 
      on country of origin, sample size, duration, study design, aspirin dosage, 
      participant characteristics, and outcomes was abstracted independently by 2 
      authors who used a standardized protocol. DATA SYNTHESIS: Data from 16 trials 
      with 55462 participants and 108 hemorrhagic stroke cases were analyzed. The mean 
      dosage of aspirin was 273 mg/d and mean duration of treatment was 37 months. 
      Aspirin use was associated with an absolute risk reduction in myocardial 
      infarction of 137 events per 10000 persons (95% confidence interval [CI], 
      107-167; P<.001) and in ischemic stroke, a reduction of 39 events per 10000 
      persons (95% CI, 17-61; P<.001). However, aspirin treatment was also associated 
      with an absolute risk increase in hemorrhagic stroke of 12 events per 10000 
      persons (95% CI, 5-20; P<.001). This risk did not differ by participant or study 
      design characteristics. CONCLUSIONS: These results indicate that aspirin therapy 
      increases the risk of hemorrhagic stroke. However, the overall benefit of aspirin 
      use on myocardial infarction and ischemic stroke may outweigh its adverse effects 
      on risk of hemorrhagic stroke in most populations.
FAU - He, J
AU  - He J
AD  - Department of Biostatistics and Epidemiology, Tulane University School of Public 
      Health and Tropical Medicine, New Orleans, LA 70112, USA. 
      jhe@mailhost.tcs.tulane.edu
FAU - Whelton, P K
AU  - Whelton PK
FAU - Vu, B
AU  - Vu B
FAU - Klag, M J
AU  - Klag MJ
LA  - eng
GR  - R29HL60300/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 1998 Dec 9;280(22):1949-50. PMID: 9851483
CIN - JAMA. 1999 Aug 25;282(8):731-2; author reply 732-3. PMID: 10463702
CIN - JAMA. 1999 Aug 25;282(8):732; author reply 732-3. PMID: 10463703
CIN - JAMA. 1999 Aug 25;282(8):732-3. PMID: 10463704
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Brain Ischemia/prevention & control
MH  - Cerebral Hemorrhage/*etiology
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Regression Analysis
MH  - Risk
EDAT- 1998/12/16 16:59
MHDA- 2001/08/14 10:01
CRDT- 1998/12/16 16:59
PHST- 1998/12/16 16:59 [pubmed]
PHST- 2001/08/14 10:01 [medline]
PHST- 1998/12/16 16:59 [entrez]
AID - jma80014 [pii]
AID - 10.1001/jama.280.22.1930 [doi]
PST - ppublish
SO  - JAMA. 1998 Dec 9;280(22):1930-5. doi: 10.1001/jama.280.22.1930.

PMID- 29362950
OWN - NLM
STAT- MEDLINE
DCOM- 20181109
LR  - 20190318
IS  - 1437-2320 (Electronic)
IS  - 0344-5607 (Linking)
VI  - 41
IP  - 4
DP  - 2018 Oct
TI  - Aspirin therapy discontinuation and intraoperative blood loss in spinal surgery: 
      a systematic review.
PG  - 1029-1036
LID - 10.1007/s10143-018-0945-1 [doi]
AB  - The purpose of this study was to determine the effect of aspirin therapy 
      discontinuation on intraoperative blood loss in spinal surgery. We searched 
      Medline and Google Scholar 1946 to January 2017 inclusive for case-control 
      studies, cohort studies, and controlled trials reporting intraoperative blood 
      loss during spinal surgery in patients on pre-operative aspirin. Other outcome 
      measures reported in the eligible studies were collected as secondary outcomes. 
      Two reviewers independently screened and extracted data from each study. Five 
      retrospective cohort and two case-control studies were eligible for inclusion. Of 
      the 1173 patients identified, 587 patients were never on aspirin (Ax), 416 
      patients had aspirin discontinued before surgery (Ad), ranging from 3 to 10 days, 
      and 170 patients had aspirin continued until surgery (Ac). Six out of seven 
      studies reported no statistically significant difference in intraoperative blood 
      loss irrespective of aspirin discontinuation. Meta-analysis was not possible due 
      to high risk of bias. Of the secondary outcome measures, operative time and 
      postoperative complications were most commonly reported. One of six studies 
      evaluating operative time reported a significantly longer operative time in the 
      Ad group compared with the Ac group. The overall risk of postoperative haematoma 
      in Ax, Ad, and Ac groups is 0.2% (n/N = 1/587), 0.2% (n/N = 1/416), and 1.2% 
      (n/N = 2/170), respectively. No study reported a statistically significant 
      difference in postoperative complications. There is no strong evidence 
      demonstrating a difference in intraoperative blood loss, operation time, and 
      postoperative complications, irrespective of aspirin discontinuation. This is, 
      however, based on a limited number of studies and higher-quality research is 
      required to answer this question with a higher degree of confidence.
FAU - Cheng, Ann
AU  - Cheng A
AD  - College of Medicine and Veterinary Medicine, The University of Edinburgh, 
      Edinburgh, UK.
AD  - Edinburgh Spinal Surgery Outcomes Study Group, Department of Clinical 
      Neurosciences, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, 
      UK.
FAU - Poon, Michael T C
AU  - Poon MTC
AD  - Edinburgh Spinal Surgery Outcomes Study Group, Department of Clinical 
      Neurosciences, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, 
      UK.
AD  - Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.
FAU - Demetriades, Andreas K
AU  - Demetriades AK
AD  - Edinburgh Spinal Surgery Outcomes Study Group, Department of Clinical 
      Neurosciences, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, 
      UK. andreas.demetriades@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20180123
PL  - Germany
TA  - Neurosurg Rev
JT  - Neurosurgical review
JID - 7908181
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Loss, Surgical/*statistics & numerical data
MH  - Humans
MH  - Operative Time
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Spine/*surgery
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Anti-platelet agent
OT  - Aspirin
OT  - Blood loss
OT  - Haemorrhage
OT  - Spinal neurosurgery
EDAT- 2018/01/25 06:00
MHDA- 2018/11/10 06:00
CRDT- 2018/01/25 06:00
PHST- 2017/12/19 00:00 [received]
PHST- 2018/01/10 00:00 [accepted]
PHST- 2018/01/25 06:00 [pubmed]
PHST- 2018/11/10 06:00 [medline]
PHST- 2018/01/25 06:00 [entrez]
AID - 10.1007/s10143-018-0945-1 [pii]
AID - 10.1007/s10143-018-0945-1 [doi]
PST - ppublish
SO  - Neurosurg Rev. 2018 Oct;41(4):1029-1036. doi: 10.1007/s10143-018-0945-1. Epub 
      2018 Jan 23.

PMID- 36572105
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20230324
IS  - 2589-9333 (Electronic)
IS  - 2589-9333 (Linking)
VI  - 5
IP  - 3
DP  - 2023 Mar
TI  - The effects of heparin, aspirin, and maternal clinical factors on the rate of 
      nonreportable cell-free DNA results: a retrospective cohort study.
PG  - 100846
LID - S2589-9333(22)00276-2 [pii]
LID - 10.1016/j.ajogmf.2022.100846 [doi]
AB  - BACKGROUND: Technological advances in the analysis of cell-free DNA in maternal 
      serum have allowed expanded prenatal screening possibilities for fetal 
      aneuploidies. The sensitivity and positive predictive value of the assay are 
      partly dependent on the amount of cell-free DNA present in maternal circulation. 
      Thus, it is important to know what fetal and maternal factors influence the level 
      of cell-free DNA in maternal circulation. Maternal heparin use has been 
      associated with an increase in nonreportable cell-free DNA results because of a 
      low fetal fraction in some, but not all, previous studies. In addition, there are 
      likely additional factors that affect cell-free DNA that remain uncharacterized. 
      OBJECTIVE: This study aimed to determine whether heparins, low-dose aspirin, and 
      maternal clinical factors affect the rate of nonreportable cell-free DNA testing 
      results. STUDY DESIGN: A retrospective cohort study was conducted using pregnant 
      people receiving cell-free fetal DNA testing from January 1, 2014, to June 30, 
      2018. Data were collected on patient demographics, medical comorbidities, 
      medication use, and cell-free DNA test results. Univariate and multivariate 
      analyses were performed to determine which factors were independently associated 
      with the rate of nonreportable results. RESULTS: From an original sample of 1117 
      pregnant people, 743 met the inclusion criteria. Maternal weight (odds ratio, 
      1.02), heparin use (odds ratio, 12.06), aspirin use (odds ratio, 4.70), chronic 
      hypertension (odds ratio, 5.26), pregestational diabetes mellitus (odds ratio, 
      2.46), and autoimmune disease (odds ratio, 3.59) were significantly associated 
      with an increased rate of nonreportable results in the univariate analysis. 
      Moreover, the association was present for maternal weight (odds ratio, 1.02), 
      heparin use (odds ratio, 21.87),and aspirin use (odds ratio, 2.85) in the 
      multivariate analysis. CONCLUSION: The previously seen association between 
      maternal heparin use and an increase in nonreportable cell-free DNA results was 
      confirmed. Furthermore, there seems to be an increase in nonreportable results in 
      pregnant people taking low-dose aspirin. Providers should consider the effect of 
      these medications when counseling patients on prenatal genetic screening options.
CI  - Copyright © 2022 Elsevier Inc. All rights reserved.
FAU - Nitsche, Joshua F
AU  - Nitsche JF
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Wake Forest University School of Medicine, Winston-Salem, NC (Dr Nitsche). 
      Electronic address: jnitsche@wakehealth.edu.
FAU - Lovell, Daniel
AU  - Lovell D
AD  - Department of Obstetrics and Gynecology, Atrium Health Carolinas Medical Center, 
      Charlotte, NC (Dr Lovell).
FAU - Stephens, Nicole
AU  - Stephens N
AD  - Department of Obstetrics and Gynecology, Sinai Chicago, Chicago, IL (Dr 
      Stephens).
FAU - Conrad, Sarah
AU  - Conrad S
AD  - Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX 
      (Dr Conrad).
FAU - Bebeau, Katherine
AU  - Bebeau K
AD  - Department of Obstetrics and Gynecology, St. Joseph's/Candler Hospital, Savannah, 
      GA (Dr Bebeau).
FAU - Brost, Brian C
AU  - Brost BC
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      University of Kansas Medical Center, Kansas City, KS (Dr Brost).
LA  - eng
PT  - Journal Article
DEP - 20221223
PL  - United States
TA  - Am J Obstet Gynecol MFM
JT  - American journal of obstetrics & gynecology MFM
JID - 101746609
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Cell-Free Nucleic Acids)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - *Heparin/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Cell-Free Nucleic Acids
MH  - Retrospective Studies
MH  - Prenatal Diagnosis/methods
OTO - NOTNLM
OT  - aspirin
OT  - cell-free DNA
OT  - chronic hypertension
OT  - diabetes mellitus
OT  - heparin
OT  - low-molecular-weight heparin
OT  - noninvasive prenatal screening
EDAT- 2022/12/27 06:00
MHDA- 2023/03/03 06:00
CRDT- 2022/12/26 19:13
PHST- 2022/09/30 00:00 [received]
PHST- 2022/12/02 00:00 [revised]
PHST- 2022/12/20 00:00 [accepted]
PHST- 2022/12/27 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2022/12/26 19:13 [entrez]
AID - S2589-9333(22)00276-2 [pii]
AID - 10.1016/j.ajogmf.2022.100846 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol MFM. 2023 Mar;5(3):100846. doi: 10.1016/j.ajogmf.2022.100846. 
      Epub 2022 Dec 23.

PMID- 36829232
OWN - NLM
STAT- MEDLINE
DCOM- 20230228
LR  - 20230301
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 21
IP  - 1
DP  - 2023 Feb 25
TI  - The role of non-steroidal anti-inflammatory drugs as adjuncts to periodontal 
      treatment and in periodontal regeneration.
PG  - 149
LID - 10.1186/s12967-023-03990-2 [doi]
LID - 149
AB  - Periodontitis is the sixth most prevalent chronic disease globally and places 
      significant burdens on societies and economies worldwide. Behavioral 
      modification, risk factor control, coupled with cause-related therapy have been 
      the "gold standard" treatment for managing periodontitis. Given that host 
      inflammatory and immunological responses play critical roles in the pathogenesis 
      of periodontitis and impact treatment responses, several adjunctive strategies 
      aimed at modulating host responses and improving the results of periodontal 
      therapy and maintenance have been proposed. Of the many pharmacological host 
      modulators, we focused on non-steroidal anti-inflammatory drugs (NSAIDs), due to 
      their long history and extensive use in relieving inflammation and pain and 
      reducing platelet aggregation. NSAIDs have been routinely indicated for treating 
      rheumatic fever and osteoarthritis and utilized for the prevention of 
      cardiovascular events. Although several efforts have been made to incorporate 
      NSAIDs into the treatment of periodontitis, their effects on periodontal health 
      remain poorly characterized, and concerns over the risk-benefit ratio were also 
      raised. Moreover, there is emerging evidence highlighting the potential of 
      NSAIDs, especially aspirin, for use in periodontal regeneration. This review 
      summarizes and discusses the use of NSAIDs in various aspects of periodontal 
      therapy and regeneration, demonstrating that the benefits of NSAIDs as adjuncts 
      to conventional periodontal therapy remain controversial. More recent evidence 
      suggests a promising role for NSAIDs in periodontal tissue engineering and 
      regeneration.
CI  - © 2023. The Author(s).
FAU - Ren, Jianhan
AU  - Ren J
AD  - Division of Paediatric Dentistry and Orthodontics, Faculty of Dentistry, the 
      University of Hong Kong, Hong Kong SAR, China.
FAU - Fok, Melissa Rachel
AU  - Fok MR
AD  - Division of Periodontology and Implant Dentistry, Faculty of Dentistry, the 
      University of Hong Kong, Hong Kong SAR, China.
FAU - Zhang, Yunfan
AU  - Zhang Y
AD  - Department of Orthodontics, Cranial-Facial Growth and Development Center, Peking 
      University School and Hospital of Stomatology, Beijing, China.
FAU - Han, Bing
AU  - Han B
AUID- ORCID: 0000-0003-4584-1092
AD  - Department of Orthodontics, Cranial-Facial Growth and Development Center, Peking 
      University School and Hospital of Stomatology, Beijing, China. 
      kqbinghan@bjmu.edu.cn.
FAU - Lin, Yifan
AU  - Lin Y
AUID- ORCID: 0000-0002-2614-9159
AD  - Division of Paediatric Dentistry and Orthodontics, Faculty of Dentistry, the 
      University of Hong Kong, Hong Kong SAR, China. yflin@hku.hk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230225
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Periodontitis
MH  - Inflammation/drug therapy
MH  - Regeneration
PMC - PMC9960225
OTO - NOTNLM
OT  - Aspirin
OT  - Non-steroidal anti-inflammatory drug
OT  - Periodontal regeneration
OT  - Periodontitis
COIS- All the authors declare no competing interests.
EDAT- 2023/02/25 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/02/24 23:48
PHST- 2023/01/03 00:00 [received]
PHST- 2023/02/14 00:00 [accepted]
PHST- 2023/02/24 23:48 [entrez]
PHST- 2023/02/25 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
AID - 10.1186/s12967-023-03990-2 [pii]
AID - 3990 [pii]
AID - 10.1186/s12967-023-03990-2 [doi]
PST - epublish
SO  - J Transl Med. 2023 Feb 25;21(1):149. doi: 10.1186/s12967-023-03990-2.

PMID- 22465277
OWN - NLM
STAT- MEDLINE
DCOM- 20120719
LR  - 20131121
IS  - 1873-376X (Electronic)
IS  - 1570-0232 (Linking)
VI  - 895-896
DP  - 2012 May 1
TI  - Simultaneous determination and pharmacokinetics of protein unbound aspirin and 
      salicylic acid in rat blood and brain by microdialysis: an application to 
      herbal-drug interaction.
PG  - 31-8
LID - 10.1016/j.jchromb.2012.03.010 [doi]
AB  - Aspirin is commonly used for the prevention of myocardial infarction and ischemic 
      stroke; whereas the Chinese people employ the bu-yang-huan-wu-tang (BYHWT) as a 
      routine herbal formulation for the treatment and prevention of transient ischemic 
      stroke. The current study develops a microdialysis technique coupled to a 
      validated liquid chromatography system to measure free-form aspirin and salicylic 
      acid for herbal-drug interaction in rat blood and brain. The intra- and inter-day 
      precisions in biological dialysates were within 0.1-9.4% in the concentration 
      ranges of 0.1-50 μg/mL and the accuracies ranged from -4.7 to 6.1%. The 
      pharmacokinetic data demonstrate that the area under the concentration time curve 
      (AUC) of the aspirin was 2031 ± 266 min μg/mL after aspirin administration 
      (100mg/kg, i.v.). The AUC of salicylic acid was 12660 ± 1799 min μg/mL, which 
      suggests that aspirin is quickly hydrolyzed to salicylic acid in blood and the 
      metabolite can also be detected within 15 min in brain dialysate. The herbal-drug 
      pharmacokinetic interaction showed no significant effect in blood and brain. The 
      results of pharmacodynamics for the bleeding time suggested that there were no 
      significant differences between the aspirin alone group and the BYHWT pretreated 
      group. However, the bleeding time has been prolonged when compared aspirin alone 
      or the group pretreated with BYHWT to the blank control. The conclusion provides 
      practical information for clinical practice for the herbal formulation BYHWT and 
      aspirin used concurrently.
CI  - Copyright © 2012 Elsevier B.V. All rights reserved.
FAU - Shaw, Lee-Hsin
AU  - Shaw LH
AD  - Institute of Traditional Medicine, National Yang-Ming University, Taipei 112, 
      Taiwan.
FAU - Tsai, Tung-Hu
AU  - Tsai TH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120315
PL  - Netherlands
TA  - J Chromatogr B Analyt Technol Biomed Life Sci
JT  - Journal of chromatography. B, Analytical technologies in the biomedical and life 
      sciences
JID - 101139554
RN  - 0 (Drugs, Chinese Herbal)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Area Under Curve
MH  - Aspirin/*analysis/blood/pharmacokinetics
MH  - Bleeding Time
MH  - Brain Chemistry
MH  - Drug Stability
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - *Herb-Drug Interactions
MH  - Male
MH  - Microdialysis/*methods
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reproducibility of Results
MH  - Salicylic Acid/*analysis/blood/pharmacokinetics
EDAT- 2012/04/03 06:00
MHDA- 2012/07/20 06:00
CRDT- 2012/04/03 06:00
PHST- 2011/11/08 00:00 [received]
PHST- 2012/01/30 00:00 [revised]
PHST- 2012/03/09 00:00 [accepted]
PHST- 2012/04/03 06:00 [entrez]
PHST- 2012/04/03 06:00 [pubmed]
PHST- 2012/07/20 06:00 [medline]
AID - S1570-0232(12)00159-6 [pii]
AID - 10.1016/j.jchromb.2012.03.010 [doi]
PST - ppublish
SO  - J Chromatogr B Analyt Technol Biomed Life Sci. 2012 May 1;895-896:31-8. doi: 
      10.1016/j.jchromb.2012.03.010. Epub 2012 Mar 15.

PMID- 15998890
OWN - NLM
STAT- MEDLINE
DCOM- 20050712
LR  - 20220408
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 294
IP  - 1
DP  - 2005 Jul 6
TI  - Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a 
      randomized controlled trial.
PG  - 47-55
AB  - CONTEXT: Basic research and observational evidence as well as results from trials 
      of colon polyp recurrence suggest a role for aspirin in the chemoprevention of 
      cancer. OBJECTIVE: To examine the effect of aspirin on the risk of cancer among 
      healthy women. DESIGN, SETTING, AND PARTICIPANTS: In the Women's Health Study, a 
      randomized 2 x 2 factorial trial of aspirin and vitamin E conducted between 
      September 1992 and March 2004, 39 876 US women aged at least 45 years and 
      initially without previous history of cancer, cardiovascular disease, or other 
      major chronic illness were randomly assigned to receive either aspirin or aspirin 
      placebo and followed up for an average of 10.1 years. INTERVENTION: A dose of 100 
      mg of aspirin (n=19 934) or aspirin placebo (n=19 942) administered every other 
      day. MAIN OUTCOME MEASURES: Confirmed newly diagnosed invasive cancer at any 
      site, except for nonmelanoma skin cancer. Incidence of breast, colorectal, and 
      lung cancer were secondary end points. RESULTS: No effect of aspirin was observed 
      on total cancer (n = 2865; relative risk [RR], 1.01; 95% confidence interval 
      [CI], 0.94-1.08; P = .87), breast cancer (n = 1230; RR, 0.98; 95% CI, 0.87-1.09; 
      P = .68), colorectal cancer (n = 269; RR, 0.97; 95% CI, 0.77-1.24; P = .83), or 
      cancer of any other site, with the exception of lung cancer for which there was a 
      trend toward reduction in risk (n = 205; RR, 0.78; 95% CI, 0.59-1.03; P = .08). 
      There was also no reduction in cancer mortality either overall (n = 583; RR, 
      0.95; 95% CI, 0.81-1.11; P = .51) or by site, except for lung cancer mortality (n 
      = 140; RR, 0.70; 95% CI, 0.50-0.99; P = .04). No evidence of differential effects 
      of aspirin by follow-up time or interaction with vitamin E was found. 
      CONCLUSIONS: Results from this large-scale, long-term trial suggest that 
      alternate day use of low-dose aspirin (100 mg) for an average 10 years of 
      treatment does not lower risk of total, breast, colorectal, or other 
      site-specific cancers. A protective effect on lung cancer or a benefit of higher 
      doses of aspirin cannot be ruled out.
FAU - Cook, Nancy R
AU  - Cook NR
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, Boston, MA 02215, USA. 
      ncook@rics.bwh.harvard.edu
FAU - Lee, I-Min
AU  - Lee IM
FAU - Gaziano, J Michael
AU  - Gaziano JM
FAU - Gordon, David
AU  - Gordon D
FAU - Ridker, Paul M
AU  - Ridker PM
FAU - Manson, JoAnn E
AU  - Manson JE
FAU - Hennekens, Charles H
AU  - Hennekens CH
FAU - Buring, Julie E
AU  - Buring JE
LA  - eng
GR  - CA-47988/CA/NCI NIH HHS/United States
GR  - HL-43851/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2005 Jul 6;294(1):105-6. PMID: 15998897
CIN - ACP J Club. 2006 Jan-Feb;144(1):8-9. PMID: 16388558
CIN - Evid Based Med. 2006 Feb;11(1):10. PMID: 17213052
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cyclooxygenase Inhibitors/*administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasms/epidemiology/mortality/*prevention & control
MH  - Risk Factors
EDAT- 2005/07/07 09:00
MHDA- 2005/07/13 09:00
CRDT- 2005/07/07 09:00
PHST- 2005/07/07 09:00 [pubmed]
PHST- 2005/07/13 09:00 [medline]
PHST- 2005/07/07 09:00 [entrez]
AID - 294/1/47 [pii]
AID - 10.1001/jama.294.1.47 [doi]
PST - ppublish
SO  - JAMA. 2005 Jul 6;294(1):47-55. doi: 10.1001/jama.294.1.47.

PMID- 8675638
OWN - NLM
STAT- MEDLINE
DCOM- 19960813
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 96
IP  - 6
DP  - 1995 Dec
TI  - Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin 
      derivative.
PG  - 2711-8
AB  - Effects of a nitroxybutylester derivative of aspirin (NCX 4215) on platelet 
      aggregation and prostanoid synthesis were compared to the effects of aspirin. NCX 
      4215 was approximately seven times more potent than aspirin as an inhibitor of 
      thrombin-induced human platelet aggregation in vitro, but did not inhibit 
      platelet thromboxane synthesis or gastric prostaglandin synthesis. NCX 4215 
      released nitric oxide when incubated in the presence of platelets and increased 
      platelet levels of cGMP within 10 min of exposure, while aspirin did not. The 
      anti-aggregatory effects of NCX 4215 in vitro were significantly attenuated by 10 
      microM hemoglobin. In ex vivo studies of ADP- or collagen- or thrombin-induced 
      rat platelet aggregation, aspirin and NCX 4215 had comparable inhibitory effects 
      3 h after administration. Aspirin (10-120 mg/kg) caused extensive hemorrhagic 
      erosion formation in the stomach of the rat within 3 h of oral administration, 
      while NCX 4215 did not produce significant damage at doses of up to 300 mg/kg, 
      nor when given daily for two weeks at 166 mg/kg. NCX 4215 did not alter systemic 
      arterial blood pressure when administered intravenously to the rat. These studies 
      demonstrate that NCX 4215 has comparable or enhanced anti-thrombotic activity to 
      that of aspirin, but does not cause gastric damage or alter systemic blood 
      pressure. The anti-thrombotic actions of NCX 4215 are, at least in part, due to 
      generation of nitric oxide.
FAU - Wallace, J L
AU  - Wallace JL
AD  - Department of Pharmacology and Therapeutics, University of Calgary, Alberta, 
      Canada.
FAU - McKnight, W
AU  - McKnight W
FAU - Del Soldato, P
AU  - Del Soldato P
FAU - Baydoun, A R
AU  - Baydoun AR
FAU - Cirino, G
AU  - Cirino G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (NCX 4215)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 169D1260KM (Nitroprusside)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/*pharmacology
MH  - Blood Platelets/drug effects/*physiology
MH  - Blood Pressure/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Fibrinolytic Agents/*pharmacology
MH  - Gastric Mucosa/*drug effects/pathology/physiology
MH  - Humans
MH  - Injections, Intravenous
MH  - Luminescent Measurements
MH  - Male
MH  - Nitric Oxide/*blood
MH  - Nitroprusside/pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Rats
MH  - Rats, Wistar
PMC - PMC185978
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
AID - 10.1172/JCI118338 [doi]
PST - ppublish
SO  - J Clin Invest. 1995 Dec;96(6):2711-8. doi: 10.1172/JCI118338.

PMID- 11878089
OWN - NLM
STAT- MEDLINE
DCOM- 20020424
LR  - 20161124
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 56
IP  - 6
DP  - 2001 Nov-Dec
TI  - [Pharmacokinetics after oral and intravenous administration of d,l-monolysine 
      acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers].
PG  - 669-74
AB  - We studied the ASA pharmacokinetics of single doses of 500 mg and 1000 mg of 
      D,L-lysine-monoacetylsalicylate (Lys-ASA) administered both orally (Delgesic) and 
      500 mg parenterally (Aspisol) as well as 500 mg acetylsalicylate (ASA, Aspirin) 
      in 13 healthy volunteers. Blood samples were taken before and at defined times up 
      to 48 h after application of Lys-ASA and ASA. Analysis for ASA and its metabolite 
      salicylic acid were performed by HPLC. All concentration versus time data were 
      presented descriptively. As far as ASA was concerned, differences were assessed 
      by means of ANOVA according to Friedman including post hoc Wilcoxon tests for 
      each time point. Pharmacokinetic parameters were calculated based on a 
      one-compartment model. The concentration vs. time curves after oral intake of 500 
      mg of ASA and Lys-ASA differed significantly (p < 0.001). Peak serum ASA 
      concentrations (Cmax) were 6.8 mg/l for oral Lys-ASA and 2.7 mg/l for ASA per os. 
      The corresponding tmax-values were 14.2 and 38.0 min. Absolute bioavailabilities 
      for 500 mg doses were 75.4 and 63.4 pour cent, respectively. After intake of 100 
      mg and 1000 mg oral doses of Lys-ASA Cmax was 2.7 mg/l and 15.9 mg/l, tmax being 
      14.2 min for the 1000 mg dose. The shortest half-life was found after i.v. 
      injection with 7.5 min. Metabolism was fast with maximum rise of salicylic acid 
      concentration after injection of Lys-ASS. We conclude that concerning time 
      dimension oral administration of Lys-ASA is almost equivalent to i.v. Lys-ASA and 
      may be an alternative for i.v. administration in cases of acute heart attacks.
FAU - Raschka, C
AU  - Raschka C
AD  - Medizinische Klinik, Städtisches Klinikum Fulda, Pacelliallee 4, D-36043 Fulda.
FAU - Koch, H J
AU  - Koch HJ
LA  - fre
PT  - Comparative Study
PT  - Journal Article
TT  - Etude pharmacocinétique après administration orale et intraveineuse 
      d'acétylsalicylate de DL-lysine et administration orale d'acide acétylsalicylique 
      chez des volontaires sains.
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacokinetics
MH  - Aspirin/administration & dosage/*analogs & derivatives/*pharmacokinetics
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Lysine/administration & dosage/*analogs & derivatives/*pharmacokinetics
MH  - Male
MH  - Middle Aged
EDAT- 2002/03/07 10:00
MHDA- 2002/04/25 10:01
CRDT- 2002/03/07 10:00
PHST- 2002/03/07 10:00 [pubmed]
PHST- 2002/04/25 10:01 [medline]
PHST- 2002/03/07 10:00 [entrez]
PST - ppublish
SO  - Therapie. 2001 Nov-Dec;56(6):669-74.

PMID- 35533971
OWN - NLM
STAT- MEDLINE
DCOM- 20220919
LR  - 20220919
IS  - 1469-0691 (Electronic)
IS  - 1198-743X (Linking)
VI  - 28
IP  - 9
DP  - 2022 Sep
TI  - Chronic aspirin use and survival following sepsis-A propensity-matched, 
      observational cohort study.
PG  - 1287.e1-1287.e7
LID - S1198-743X(22)00218-X [pii]
LID - 10.1016/j.cmi.2022.04.010 [doi]
AB  - OBJECTIVES: The use of antiplatelet agents is postulated to lead to improved 
      outcomes in sepsis. We aimed to evaluate whether chronic, pre-hospitalization 
      aspirin use leads to improved outcomes in patients with sepsis. METHODS: We 
      conducted an observational cohort study among patients with sepsis, hospitalized 
      in internal medicine wards in a single university-affiliated medical center. A 
      propensity-score model was used to match and compare patients on chronic aspirin 
      use to non-users. Patients with established cardiovascular disease were excluded. 
      The primary outcome was survival rates at 30 days. Secondary outcomes included 
      survival rates at 90 days, days of fever, length of hospital stay, and hospital 
      readmission within 90 days. RESULTS: A total of 1671 patients fulfilled the 
      inclusion criteria. 533 chronic aspirin users were matched to 533 aspirin 
      non-users. Survival rates were significantly higher among patients on chronic 
      aspirin use (hazard ratio (HR) 0.67; 95% CI, 0.51-0.89)). This effect was 
      highlighted in several subgroups of patients, as patients with chronic 
      obstructive pulmonary disease (COPD) or those with chronic use of beta blockers 
      showed the greatest survival benefit with aspirin use. Patients in the aspirin 
      group also showed significantly higher 90 days survival rates (HR 0.69; 95% CI, 
      0.57-0.92; p = 0.006) and experienced less days of fever in comparison to the 
      control group. DISCUSSION: Pre-hospitalization treatment with aspirin for 
      patients without established cardiovascular disease may be associated with 
      mortality reduction, as shown in this is hypothesis-generating single center 
      observational study.
CI  - Copyright © 2022 European Society of Clinical Microbiology and Infectious 
      Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Lavie, Inbar
AU  - Lavie I
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Electronic 
      address: inbarlavie@gmail.com.
FAU - Lavie, Michael
AU  - Lavie M
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Tel-Aviv 
      Souraski Medical Center, Israel.
FAU - Gafter-Gvili, Anat
AU  - Gafter-Gvili A
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Department of 
      Medicine A, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel.
FAU - Halperin, Erez
AU  - Halperin E
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Tel-Aviv 
      Souraski Medical Center, Israel.
FAU - Abramovich-Yoffe, Hadar
AU  - Abramovich-Yoffe H
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Tel-Aviv 
      Souraski Medical Center, Israel.
FAU - Avni, Tomer
AU  - Avni T
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Tel-Aviv 
      Souraski Medical Center, Israel. Electronic address: boskko2001@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220506
PL  - England
TA  - Clin Microbiol Infect
JT  - Clinical microbiology and infection : the official publication of the European 
      Society of Clinical Microbiology and Infectious Diseases
JID - 9516420
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/chemically induced/drug therapy
MH  - Cohort Studies
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - *Sepsis
OTO - NOTNLM
OT  - Aspirin
OT  - Cohort
OT  - Mortality
OT  - Sepsis
OT  - Survival
EDAT- 2022/05/10 06:00
MHDA- 2022/09/20 06:00
CRDT- 2022/05/09 19:28
PHST- 2022/01/21 00:00 [received]
PHST- 2022/04/08 00:00 [revised]
PHST- 2022/04/13 00:00 [accepted]
PHST- 2022/05/10 06:00 [pubmed]
PHST- 2022/09/20 06:00 [medline]
PHST- 2022/05/09 19:28 [entrez]
AID - S1198-743X(22)00218-X [pii]
AID - 10.1016/j.cmi.2022.04.010 [doi]
PST - ppublish
SO  - Clin Microbiol Infect. 2022 Sep;28(9):1287.e1-1287.e7. doi: 
      10.1016/j.cmi.2022.04.010. Epub 2022 May 6.

PMID- 12512736
OWN - NLM
STAT- MEDLINE
DCOM- 20030124
LR  - 20131121
IS  - 1088-0224 (Print)
IS  - 1088-0224 (Linking)
VI  - 8
IP  - 22 Suppl
DP  - 2002 Dec
TI  - Update on aspirin in the treatment and prevention of cardiovascular disease.
PG  - S691-700
AB  - Antiplatelet therapy, most notably aspirin, has been well documented to reduce 
      risks of subsequent cardiovascular disease (CVD) in secondary prevention, acute 
      myocardial infarction (MI), acute occlusive stroke, as well as in primary 
      prevention. In secondary prevention, the most recent Antithrombotic Trialists' 
      Collaboration reviewed 194 published randomized trials of antiplatelet therapy, 
      mostly aspirin, involving more than 212 000 patients (ie, 135 000 using 
      antiplatelet therapy or control and 77 000 using different antiplatelet 
      regimens). In a very wide range of patients who have survived a prior occlusive 
      vascular event-including MI, transient ischemic attacks, occlusive stroke, 
      unstable and stable angina, percutaneous coronary interventions, and coronary 
      artery bypass graft-aspirin prevents about 25% of serious vascular events. Among 
      patients suffering acute Ml or acute occlusive stroke, aspirin begun promptly and 
      continued long-term reduces risks of subsequent MI, stroke, and vascular death. 
      In acute coronary syndromes, clopidogrel added to aspirin further reduces the 
      risk of important vascular events, but not mortality, and causes more side 
      effects, especially bleeding. For patients undergoing percutaneous coronary 
      interventions, the addition of a short-term infusion of a glycoprotein IIb/IIIa 
      receptor antagonist to aspirin prevents additional vascular events during the 
      early in-hospital period but also increases the risk of major bleeding. Ongoing 
      research is investigating other combinations of different antiplatelet drugs. In 
      all these high-risk patients, there is a small excess of major bleeding among 
      those assigned at random to aspirin, which is far outweighed by the magnitude of 
      benefits on CVD. During an acute MI, after a loading dose of 160 mg to 325 mg 
      aspirin, daily doses ranging from 75 to 150 mg daily are as effective as higher 
      doses. For long-term treatment, the effects of doses < 75 mg daily are less 
      certain. Although side effects are dose-related, especially in doses > 325 mg 
      daily, no antiplatelet regimen is more effective than aspirin for long-term use. 
      In primary prevention, 5 randomized trials have been published involving more 
      than 60 000 apparently healthy men and women. Persons randomized to receive 
      aspirin in these trials had significant reductions in risk of a first MI (32%) 
      and important vascular events (15%). Since the numbers of strokes and vascular 
      deaths were insufficient to distinguish between the benefits found in secondary 
      prevention and no effect, use of aspirin in primary prevention should be weighed 
      in light of the cardiovascular risk profile, the side effects of the drug, and 
      its clear benefit in reducing risk of a first MI. Aspirin should be an adjunct, 
      not an alternative, to managing other cardiovascular risk factors. Recently, the 
      US Preventive Services Task Force and the American Heart Association recommended 
      aspirin use for all men and women whose 10-year risks are > 6% and > or = 10%, 
      respectively. In all these patient categories, including secondary prevention, 
      acute MI and acute occlusive stroke, as well as primary prevention, increased and 
      appropriate use of aspirin will prevent large numbers of premature deaths and 
      MIs.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - University of Miami School of Medicine, Florida, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/epidemiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/drug therapy
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention
MH  - Risk Factors
MH  - Stroke/drug therapy
MH  - Treatment Outcome
MH  - United States/epidemiology
RF  - 25
EDAT- 2003/01/07 04:00
MHDA- 2003/01/25 04:00
CRDT- 2003/01/07 04:00
PHST- 2003/01/07 04:00 [pubmed]
PHST- 2003/01/25 04:00 [medline]
PHST- 2003/01/07 04:00 [entrez]
AID - 147 [pii]
PST - ppublish
SO  - Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700.

PMID- 30168042
OWN - NLM
STAT- MEDLINE
DCOM- 20181114
LR  - 20181114
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 46
IP  - 4
DP  - 2018 Nov
TI  - Effect of remote ischaemic conditioning on platelet aggregation and platelet 
      turnover.
PG  - 528-533
LID - 10.1007/s11239-018-1728-9 [doi]
AB  - Remote ischaemic conditioning (RIC) is a new beneficial treatment for patients 
      with ST-elevation myocardial infarction. RIC may inhibit thrombus formation and, 
      therefore, we investigated whether RIC affects platelet aggregation and turnover. 
      30 healthy male volunteers were subjected to intervention on day 1 (sham 
      intervention, no aspirin), day 2 (RIC, no aspirin), and day 16 (RIC, treated 
      7 days with aspirin 75 mg/day). RIC was performed as four cycles of 5 min 
      interchangeable inflation and deflation using an automated cuff. Blood samples 
      were collected 5 min before, as well as 5 and 45 min after RIC. Platelet 
      aggregation was measured by Multiplate® using collagen (COLtest), adenosine 
      diphosphate (ADPtest), and arachidonic acid (ASPItest) as agonists. Platelet 
      turnover was evaluated by flow cytometry. Serum thromboxane B(2) was determined 
      by ELISA to confirm aspirin compliance. We found no significant change in 
      platelet aggregation at visit 1 (COLtest: p = 0.32; ADPtest: p = 0.24; ASPItest: 
      p = 0.07), visit 2, except for ADP-induced platelet aggregation evaluated 5 min 
      after RIC (COLtest: p = 0.39; ADPtest: p = 0.02; ASPItest: p = 0.39), or visit 3 
      (COLtest: p = 0.48; ADPtest: p = 0.61; ASPItest: p = 0.90). Platelet turnover was 
      not influenced by RIC, neither on nor off aspirin (all p-values > 0.07). (1) RIC 
      did not affect platelet aggregation in healthy young men. (2) RIC did not affect 
      platelet turnover in healthy young men. (3) Aspirin did not influence the effect 
      of RIC on platelet aggregation and turnover. (4) Future studies exploring the 
      effect of RIC on platelet aggregation and turnover in patients with ischaemic 
      heart disease are warranted.
FAU - Rise, Nina
AU  - Rise N
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 99, 8200, Aarhus, Denmark.
AD  - Department of Clinical Biochemistry, Aarhus University Hospital, Palle 
      Juul-Jensens Boulevard 99, 8200, Aarhus, Denmark.
FAU - Kristiansen, Jacobina
AU  - Kristiansen J
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 99, 8200, Aarhus, Denmark.
AD  - Department of Clinical Biochemistry, Aarhus University Hospital, Palle 
      Juul-Jensens Boulevard 99, 8200, Aarhus, Denmark.
FAU - Hvas, Anne-Mette
AU  - Hvas AM
AD  - Department of Clinical Biochemistry, Aarhus University Hospital, Palle 
      Juul-Jensens Boulevard 99, 8200, Aarhus, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health, Aarhus University, Palle 
      Juul-Jensens Boulevard 82, 8200, Aarhus, Denmark.
FAU - Grove, Erik L
AU  - Grove EL
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 99, 8200, Aarhus, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health, Aarhus University, Palle 
      Juul-Jensens Boulevard 82, 8200, Aarhus, Denmark.
FAU - Würtz, Morten
AU  - Würtz M
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 99, 8200, Aarhus, Denmark.
FAU - Neergaard-Petersen, Søs
AU  - Neergaard-Petersen S
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 99, 8200, Aarhus, Denmark.
FAU - Kristensen, Steen Dalby
AU  - Kristensen SD
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 99, 8200, Aarhus, Denmark. steendk@dadlnet.dk.
AD  - Department of Clinical Medicine, Faculty of Health, Aarhus University, Palle 
      Juul-Jensens Boulevard 82, 8200, Aarhus, Denmark. steendk@dadlnet.dk.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/cytology
MH  - Healthy Volunteers
MH  - Humans
MH  - *Ischemia/etiology
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Therapeutics
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Ischaemic conditioning
OT  - Platelet aggregation
OT  - Platelet function tests
OT  - Platelet turnover
EDAT- 2018/09/01 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/09/01 06:00
PHST- 2018/09/01 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
PHST- 2018/09/01 06:00 [entrez]
AID - 10.1007/s11239-018-1728-9 [pii]
AID - 10.1007/s11239-018-1728-9 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2018 Nov;46(4):528-533. doi: 10.1007/s11239-018-1728-9.

PMID- 7249506
OWN - NLM
STAT- MEDLINE
DCOM- 19810925
LR  - 20190512
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 30
IP  - 2
DP  - 1981 Aug
TI  - Ketoprofen-aspirin interactions.
PG  - 226-31
AB  - To assess an interaction between ketoprofen and aspirin we gave both drugs 
      orally, to steady state, to healthy men. Although ketoprofen did not alter 
      salicylate absorption and disposition, we observed that concurrent administration 
      of aspirin decreased ketoprofen protein binding and increased its plasma 
      clearance. Salicylate also appeared to reduce metabolic ketoprofen conversion to 
      conjugates and their renal elimination. The data suggested that salicylate also 
      enhanced the metabolic conversion of ketoprofen to nonconjugate metabolites (p = 
      0.091). Our findings indicate that the drug-drug interaction between aspirin and 
      ketoprofen is complex.
FAU - Williams, R L
AU  - Williams RL
FAU - Upton, R A
AU  - Upton RA
FAU - Buskin, J N
AU  - Buskin JN
FAU - Jones, R M
AU  - Jones RM
LA  - eng
GR  - 07546/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Blood Proteins)
RN  - 0 (Phenylpropionates)
RN  - 0 (Salicylates)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Blood Proteins/metabolism
MH  - Drug Interactions
MH  - Humans
MH  - Ketoprofen/blood/*pharmacology
MH  - Kinetics
MH  - Male
MH  - Phenylpropionates/*pharmacology
MH  - Protein Binding/drug effects
MH  - Salicylates/blood
EDAT- 1981/08/01 00:00
MHDA- 1981/08/01 00:01
CRDT- 1981/08/01 00:00
PHST- 1981/08/01 00:00 [pubmed]
PHST- 1981/08/01 00:01 [medline]
PHST- 1981/08/01 00:00 [entrez]
AID - 0009-9236(81)90033-3 [pii]
AID - 10.1038/clpt.1981.152 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1981 Aug;30(2):226-31. doi: 10.1038/clpt.1981.152.

PMID- 27241836
OWN - NLM
STAT- MEDLINE
DCOM- 20170501
LR  - 20170501
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 118
IP  - 2
DP  - 2016 Jul 15
TI  - Effect of Aspirin Supplementation on Hemostatic Responses in Firefighters Aged 40 
      to 60 Years.
PG  - 275-80
LID - S0002-9149(16)30554-9 [pii]
LID - 10.1016/j.amjcard.2016.04.032 [doi]
AB  - Sudden cardiovascular events account for approximately 45% to 50% of all 
      duty-related deaths among firefighters and a disproportionate number of these 
      fatalities occur after strenuous fire suppression activities. The purpose of this 
      study was to evaluate the effect of acute and chronic aspirin supplementation on 
      hemostatic function before and after live firefighting activities in older 
      firefighters. A double-blind, crossover design included 4 treatments: a 2-week 
      aspirin/placebo treatment ("chronic") and a single prefirefighting 
      aspirin/placebo treatment ("acute"). Hemostatic function was assessed in 24 male 
      firefighters (mean age = 48.2 ± 5.9 years) immediately before and after 
      18 minutes of live-fire firefighting activity. An acute bout of firefighting 
      activity significantly decreased platelet aggregation time and decreased 
      activated partial thromboplastin time. Compared with placebo, acute aspirin 
      supplementation resulted in a significant increase in epinephrine closure time, 
      which was further augmented by chronic supplementation. Aspirin supplementation 
      had no effect on coagulatory or fibrinolytic factors. Our findings suggest that 
      an acute bout of firefighting leads to increased coagulatory potential in older 
      firefighters. In conclusion, aspirin supplementation had an antiplatelet effect 
      that decreased platelet aggregability at rest and after an acute bout of 
      firefighting compared with placebo.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Smith, Denise L
AU  - Smith DL
AD  - Illinois Fire Service Institute, University of Illinois at Urbana-Champaign, 
      Champaign, Illinois; Department of Health and Exercise Sciences, Skidmore 
      College, Saratoga Springs, New York. Electronic address: dsmith@skidmore.edu.
FAU - Horn, Gavin P
AU  - Horn GP
AD  - Illinois Fire Service Institute, University of Illinois at Urbana-Champaign, 
      Champaign, Illinois.
FAU - Woods, Jeffrey
AU  - Woods J
AD  - Department of Kinesiology and Community Health, University of Illinois at 
      Urbana-Champaign, Urbana, Illinois.
FAU - Ploutz-Snyder, Robert
AU  - Ploutz-Snyder R
AD  - Division of Space Life Sciences, Universities Space Research Association, 
      Houston, Texas.
FAU - Fernhall, Bo
AU  - Fernhall B
AD  - Department of Kinesiology and Nutrition, University of Illinois at Chicago, 
      Chicago, Illinois.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160505
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Cardiovascular Diseases/drug therapy/prevention & control
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Epinephrine
MH  - Fibrinolysis/drug effects
MH  - *Firefighters
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Partial Thromboplastin Time
MH  - *Physical Exertion
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
EDAT- 2016/06/01 06:00
MHDA- 2017/05/02 06:00
CRDT- 2016/06/01 06:00
PHST- 2015/12/08 00:00 [received]
PHST- 2016/04/20 00:00 [revised]
PHST- 2016/04/20 00:00 [accepted]
PHST- 2016/06/01 06:00 [entrez]
PHST- 2016/06/01 06:00 [pubmed]
PHST- 2017/05/02 06:00 [medline]
AID - S0002-9149(16)30554-9 [pii]
AID - 10.1016/j.amjcard.2016.04.032 [doi]
PST - ppublish
SO  - Am J Cardiol. 2016 Jul 15;118(2):275-80. doi: 10.1016/j.amjcard.2016.04.032. Epub 
      2016 May 5.

PMID- 6709143
OWN - NLM
STAT- MEDLINE
DCOM- 19840516
LR  - 20190511
IS  - 0148-396X (Print)
IS  - 0148-396X (Linking)
VI  - 14
IP  - 2
DP  - 1984 Feb
TI  - Effect of different aspirin doses on arterial thrombosis after canine carotid 
      endarterectomy: a scanning electron microscope and indium-111-labeled platelet 
      study.
PG  - 198-203
AB  - Although it is widely accepted that aspirin inhibits platelet aggregation in 
      arterial thrombosis, the appropriate dosage of aspirin remains quite 
      controversial. The purpose of this study was to determine the effect of different 
      doses of aspirin (0.5 mg/kg vs. 10 mg/kg) on mural thrombus formation after 
      carotid endarterectomy. Eighteen hours after oral aspirin administration, 20 
      endarterectomies were performed on mongrel dogs with the use of the operating 
      microscope. Blood flow was then restored for 3 hours and the vessels were 
      prepared for investigation with the scanning electron microscope. Ten 
      endarterectomies were also performed on unmedicated dogs as controls. Five 
      minutes before vessel unclamping, autologous indium-111-labeled platelets were 
      administered intravenously, and the endarterectomized portions of the vessels 
      were studied with a gamma counter system after harvesting. Group 1, the control 
      group, revealed extensive mural thrombus consisting of platelet aggregates, 
      fibrin, red blood cells, and white blood cells. Six of the 10 vessels in Group 2, 
      premedicated with 0.5 mg of aspirin per kg, demonstrated varying amounts of mural 
      thrombus. Group 3 (10 vessels), premedicated with 10 mg of aspirin per kg, 
      revealed a platelet monolayer completely covering the exposed vessel wall media, 
      with scattered white blood cells and infrequent fine fibrin strands overlying the 
      platelet surface. The mean (+/- SD) radioactivity per group expressed as 
      counts/minute/mm2 was: Group 1--2055.3 +/- 1905.5, log = 7.253 +/- 0.926; Group 
      2--1235.6 +/- 1234.3, log = 6.785 +/- 0.817; Group 3--526 +/- 433.06, log = 5.989 
      +/- 0.774.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Ercius, M S
AU  - Ercius MS
FAU - Chandler, W F
AU  - Chandler WF
FAU - Ford, J W
AU  - Ford JW
FAU - Swanson, D P
AU  - Swanson DP
FAU - Burke, J C
AU  - Burke JC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - 0 (Radioisotopes)
RN  - 045A6V3VFX (Indium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Carotid Arteries/ultrastructure
MH  - Carotid Artery Thrombosis/pathology/*prevention & control
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Endarterectomy/*adverse effects
MH  - Indium
MH  - Microscopy, Electron, Scanning
MH  - *Platelet Aggregation
MH  - Preoperative Care
MH  - Radioisotopes
EDAT- 1984/02/01 00:00
MHDA- 1984/02/01 00:01
CRDT- 1984/02/01 00:00
PHST- 1984/02/01 00:00 [pubmed]
PHST- 1984/02/01 00:01 [medline]
PHST- 1984/02/01 00:00 [entrez]
AID - 10.1227/00006123-198402000-00014 [doi]
PST - ppublish
SO  - Neurosurgery. 1984 Feb;14(2):198-203. doi: 10.1227/00006123-198402000-00014.

PMID- 31280451
OWN - NLM
STAT- MEDLINE
DCOM- 20190902
LR  - 20200225
IS  - 1179-1985 (Electronic)
IS  - 1120-9879 (Linking)
VI  - 26
IP  - 4
DP  - 2019 Aug
TI  - Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled 
      Trials.
PG  - 283-291
LID - 10.1007/s40292-019-00325-5 [doi]
AB  - INTRODUCTION: The role of aspirin as a means of primary prevention remains 
      controversial. AIM: We have conducted a meta-analysis of all randomized 
      controlled trials (RCTs) to evaluate the role of aspirin in primary prevention. 
      METHODS: Literature search was performed via PubMed, Embase, and the Cochrane 
      Library for all related RCTs. All-cause mortality was the primary endpoint. 
      Secondary endpoints included major adverse cardiovascular events (MACE), 
      myocardial infarction (MI), cardiovascular mortality, cerebrovascular events, and 
      bleeding events. We used a random effects model to report the risk ratios (RRs) 
      with 95% confidence intervals (CIs). RESULTS: Our analysis included 17 RCTs 
      (164,862 patients; 83,309 received aspirin and 81,744 received placebo). Our 
      study did not demonstrate any significant reduction in all-cause mortality for 
      patients treated with aspirin when compared with placebo (RR 0.97; 95% CI 
      0.93-1.01; P = 0.13). Sensitivity analysis performed by excluding healthy elderly 
      (≥ 65) showed significant reductions in all-cause mortality in the 
      aspirin-treated patients (RR 0.94; 95% CI 0.90-0.99; P = 0.01). There were no 
      significant differences between both groups regarding cardiovascular mortality 
      and cerebrovascular events (P > 0.05). However, aspirin-treated patients 
      significantly reduced MACE and MI events (RR 0.89; 95% CI 0.85-0.93; P < 0.001 
      and RR 0.88; 95% CI 0.78-0.98; P = 0.02, respectively), respectively. However, 
      aspirin was associated with a significantly higher incidence of bleeding, 
      including major bleeding and intracranial bleeding (P < 0.001). CONCLUSIONS: 
      Aspirin use in primary prevention has resulted in a lower incidence of MACE and 
      MI without significantly effecting cerebrovascular events. However, aspirin was 
      associated with a higher bleeding risk. Use of aspirin as a means of primary 
      prevention should be thoroughly discussed with patients and pursued based on the 
      risk of cardiovascular disease while also considering bleeding risk.
FAU - Barbarawi, Mahmoud
AU  - Barbarawi M
AUID- ORCID: 0000-0001-8218-2466
AD  - Department of Internal Medicine, Hurley Medical Center/Michigan State University, 
      One Hurley Plaza, Flint, Michigan, 48503, USA. Mahmoud.albarbarawi@gmail.com.
FAU - Kheiri, Babikir
AU  - Kheiri B
AD  - Department of Internal Medicine, Hurley Medical Center/Michigan State University, 
      One Hurley Plaza, Flint, Michigan, 48503, USA.
FAU - Zayed, Yazan
AU  - Zayed Y
AD  - Department of Internal Medicine, Hurley Medical Center/Michigan State University, 
      One Hurley Plaza, Flint, Michigan, 48503, USA.
FAU - Gakhal, Inderdeep
AU  - Gakhal I
AD  - Department of Internal Medicine, Hurley Medical Center/Michigan State University, 
      One Hurley Plaza, Flint, Michigan, 48503, USA.
FAU - Al-Abdouh, Ahmad
AU  - Al-Abdouh A
AD  - Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD, USA.
FAU - Barbarawi, Owais
AU  - Barbarawi O
AD  - Department of Internal medicine, Mutah University, Al-Karak, Jordan.
FAU - Rashdan, Laith
AU  - Rashdan L
AD  - Department of Internal Medicine, Hurley Medical Center/Michigan State University, 
      One Hurley Plaza, Flint, Michigan, 48503, USA.
FAU - Rizk, Fatima
AU  - Rizk F
AD  - College of Osteopathic Medicine, Michigan State University, East Lansing, MI, 
      USA.
FAU - Bachuwa, Ghassan
AU  - Bachuwa G
AD  - Department of Internal Medicine, Hurley Medical Center/Michigan State University, 
      One Hurley Plaza, Flint, Michigan, 48503, USA.
FAU - Alkotob, Mohammad Luay
AU  - Alkotob ML
AD  - Division of Cardiology, Hurley Medical Center/Michigan State University, Flint, 
      MI, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190706
PL  - New Zealand
TA  - High Blood Press Cardiovasc Prev
JT  - High blood pressure & cardiovascular prevention : the official journal of the 
      Italian Society of Hypertension
JID - 9421087
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/diagnosis/*mortality/*prevention & control
MH  - Clinical Decision-Making
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Incidence
MH  - Primary Prevention/*methods
MH  - Protective Factors
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Meta-analysis
OT  - Primary prevention
EDAT- 2019/07/08 06:00
MHDA- 2019/09/03 06:00
CRDT- 2019/07/08 06:00
PHST- 2019/03/30 00:00 [received]
PHST- 2019/07/01 00:00 [accepted]
PHST- 2019/07/08 06:00 [pubmed]
PHST- 2019/09/03 06:00 [medline]
PHST- 2019/07/08 06:00 [entrez]
AID - 10.1007/s40292-019-00325-5 [pii]
AID - 10.1007/s40292-019-00325-5 [doi]
PST - ppublish
SO  - High Blood Press Cardiovasc Prev. 2019 Aug;26(4):283-291. doi: 
      10.1007/s40292-019-00325-5. Epub 2019 Jul 6.

PMID- 6729828
OWN - NLM
STAT- MEDLINE
DCOM- 19840702
LR  - 20190819
IS  - 0300-483X (Print)
IS  - 0300-483X (Linking)
VI  - 30
IP  - 4
DP  - 1984 Apr 16
TI  - Protection against paracetamol-induced hepatotoxicity by acetylsalicylic acid in 
      rats.
PG  - 297-304
AB  - Acetylsalicylic acid (ASA) given simultaneously with paracetamol decreased 
      paracetamol-induced hepatotoxicity (measured by plasma transaminase activities as 
      well as histology) without any effect on glutathione depletion, indicating that 
      ASA prevents a process (or processes) subsequent to the metabolic activation of 
      paracetamol. Delayed treatment with ASA also reduced paracetamol-induced liver 
      toxicity, suggesting that reduction of the absorption rate of paracetamol does 
      not contribute essentially to the protection by ASA. Combinations of paracetamol 
      and ASA may have potential use in the development of safer analgesic combinations 
      containing paracetamol (or ASA).
FAU - De Vries, J
AU  - De Vries J
FAU - De Jong, J
AU  - De Jong J
FAU - Lock, F M
AU  - Lock FM
FAU - Van Bree, L
AU  - Van Bree L
FAU - Mullink, H
AU  - Mullink H
FAU - Veldhuizen, R W
AU  - Veldhuizen RW
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Toxicology
JT  - Toxicology
JID - 0361055
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - EC 2.6.1.- (Transaminases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/metabolism/*toxicity
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Drug Combinations
MH  - Liver/*drug effects
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Transaminases/blood
EDAT- 1984/04/16 00:00
MHDA- 1984/04/16 00:01
CRDT- 1984/04/16 00:00
PHST- 1984/04/16 00:00 [pubmed]
PHST- 1984/04/16 00:01 [medline]
PHST- 1984/04/16 00:00 [entrez]
AID - 0300-483X(84)90140-9 [pii]
AID - 10.1016/0300-483x(84)90140-9 [doi]
PST - ppublish
SO  - Toxicology. 1984 Apr 16;30(4):297-304. doi: 10.1016/0300-483x(84)90140-9.

PMID- 7017496
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20201209
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Treatment of bronchial inflammatory disorders with guacetisal].
PG  - 443-9
AB  - A comparative trial conducted on 48 male and 9 female patients suitably selected 
      in terms of indication consisted of a first stage in which a completely random, 
      doubleblind comparison was made between acetylsalicylic acid, guacetisal and 
      guaiacol carbonate (preparations A, B, and C) while in the second stage an 
      association of bromexine, acetylsalicylic acid and codeine phosphate (preparation 
      D) was examined in terms of activity and tolerance in an open trial. Statistical 
      analysis showed the superiority of preparation B with respect to most of the 
      parameters taken into consideration.
FAU - Zanierato, G
AU  - Zanierato G
FAU - Ranghino, E
AU  - Ranghino E
FAU - Negri, L
AU  - Negri L
FAU - Morandini, G C
AU  - Morandini GC
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Trattamento delle forme infiammatorie bronchiali con guacetisal.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Carbonates)
RN  - 6JKA7MAH9C (Guaiacol)
RN  - Q1J152VB1P (Bromhexine)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Bromhexine/therapeutic use
MH  - Bronchitis/*drug therapy
MH  - Carbonates/therapeutic use
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Codeine/therapeutic use
MH  - Cough/drug therapy
MH  - Female
MH  - Guaiacol/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):443-9.

PMID- 7017484
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Guacetisal in the treatment of acute and chronic bronchopneumopathy].
PG  - 347-53
AB  - 30 patients of senile age suffering from acute and chronic bronchopneumopathies, 
      the latter in acute phase, have been treated with guacetisal, a new 
      pharmacological substance with anti-inflammatory, fluidifying and bechic 
      properties. The therapeutic results, obtained with 1.2 g suppositories, were 
      definitely positive in a high percentage of case (83.3%).
FAU - Carpinteri, F
AU  - Carpinteri F
FAU - Carosi, M
AU  - Carosi M
LA  - ita
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - II guacetisal nel trattamento delle broncopneumopatie acute e croniche.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Asthma/drug therapy
MH  - Bronchitis/*drug therapy
MH  - Bronchodilator Agents/therapeutic use
MH  - Bronchopneumonia/drug therapy
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Lung Diseases, Obstructive/*drug therapy
MH  - Male
MH  - Middle Aged
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):347-53.

PMID- 21688629
OWN - NLM
STAT- MEDLINE
DCOM- 20110722
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 69
IP  - 6
DP  - 2011 Jun
TI  - [Management of NSAIDs and low-dose-aspirin-induced ulcer in patients with 
      cerebral infarction].
PG  - 1067-71
AB  - Use of low-dose aspirin (LDA) is increasing with guideline recommendation for 
      stroke prevention. The risk of gastrointestinal symptoms and bleeding with 
      aspirin is dose-dependent, but still increases even at low doses. The principal 
      treatment for NSAIDs-induced ulcer is discontinuation of NSAIDs use. However, 
      discontinuation of LDA administration in stroke patients can increase the risk of 
      stroke recurrence. Therefore, use of LDA cannot easily be discontinued. In 
      patients who experience gastric intolerance to aspirin, options are to reduce the 
      dose of aspirin to the minimum effective dose; to change to dispersable or 
      enteric-coated preparations; to add concomitant gastro-protective drugs such as 
      antacids, misoprostol, proton pump inhibitors, or H2-receptor antagonists; or to 
      change to another antithrombotic agent: clopidogrel, cilostazol or warfarin if 
      appropriate.
FAU - Kimura, Yumi
AU  - Kimura Y
AD  - Department of Neurology, Tokyo Women's Medical University.
FAU - Uchiyama, Shinichiro
AU  - Uchiyama S
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Cerebral Infarction/*drug therapy
MH  - Humans
MH  - Peptic Ulcer/chemically induced/*prevention & control
EDAT- 2011/06/22 06:00
MHDA- 2011/07/23 06:00
CRDT- 2011/06/22 06:00
PHST- 2011/06/22 06:00 [entrez]
PHST- 2011/06/22 06:00 [pubmed]
PHST- 2011/07/23 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2011 Jun;69(6):1067-71.

PMID- 8847955
OWN - NLM
STAT- MEDLINE
DCOM- 19961021
LR  - 20190701
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 56
IP  - 17
DP  - 1995 Mar 17
TI  - Effect of diaspirin crosslinked and stroma-reduced hemoglobin on mean arterial 
      pressure and endothelin-1 concentration in rats.
PG  - 1433-42
AB  - The effect of unmodified stroma reduced (SRHb) and modified diaspirin crosslinked 
      (DCLHb) hemoglobin solutions on the mean arterial pressure and endothelin-1 
      (ET-1) concentration in blood plasma and various tissues was studied. Infusion of 
      DCLHb or SRHb increased mean arterial blood pressure by 96% and 39%, 
      respectively. Heart rate was not significantly affected by DCLHb or SRHb. A 
      significant increase (P < 0.003) in the ET-1 levels in blood plasma after DCLHb 
      and SRHb infusion was observed. The increase in plasma ET-1 concentration was 
      significantly more marked with SRHb (141%) as compared to DCLHb (78%) treated 
      rats. The concentration of ET-1 in the heart and brain regions was not altered in 
      DCLHb or SRHb treated rats as compared to control. However, ET-1 concentration 
      was significantly increased in the thoracic aorta (151%) and renal medulla (272%) 
      of DCLHb treated rats. SRHb treated rats also showed a significant increase in 
      ET-1 concentration in the thoracic aorta (141%) and renal medulla (429%). The 
      effect of SRHb on the renal medulla was found to be significantly greater than 
      that of DCLHb. ET may be one of the factors responsible for the cardiovascular 
      effects of hemoglobin solutions.
FAU - Gulati, A
AU  - Gulati A
AD  - Department of Pharmaceutics and Pharmacodynamics, University of Illinois at 
      Chicago 60612, USA.
FAU - Singh, G
AU  - Singh G
FAU - Rebello, S
AU  - Rebello S
FAU - Sharma, A C
AU  - Sharma AC
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Blood Substitutes)
RN  - 0 (Endothelins)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Pressure/*drug effects
MH  - Blood Substitutes/pharmacology
MH  - Endothelins/*analysis/blood
MH  - Heart Rate/drug effects
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1995/03/17 00:00
MHDA- 1995/03/17 00:01
CRDT- 1995/03/17 00:00
PHST- 1995/03/17 00:00 [pubmed]
PHST- 1995/03/17 00:01 [medline]
PHST- 1995/03/17 00:00 [entrez]
AID - 002432059500095X [pii]
AID - 10.1016/0024-3205(95)00095-x [doi]
PST - ppublish
SO  - Life Sci. 1995 Mar 17;56(17):1433-42. doi: 10.1016/0024-3205(95)00095-x.

PMID- 31219876
OWN - NLM
STAT- MEDLINE
DCOM- 20200403
LR  - 20200403
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 34
IP  - 5
DP  - 2019 Sep
TI  - Aspirin for primary prevention of cardiovascular disease: is it time to move on?
PG  - 510-513
LID - 10.1097/HCO.0000000000000648 [doi]
AB  - PURPOSE OF REVIEW: Aspirin has been used for decades for the primary prevention 
      of cardiovascular disease. However, several recent trials evaluating the benefits 
      and risks of aspirin for primary prevention have been published, creating the 
      need to reevaluate this important topic. RECENT FINDINGS: Three large randomized 
      trials studying aspirin in various primary prevention populations including 
      individuals with diabetes, an elderly population, and middle-aged adults at high 
      cardiovascular risk have recently been completed. These trials found a small 
      benefit for individuals with diabetes and no benefit in the elderly and high risk 
      middle-aged adult populations. Additionally, all three trials demonstrated a 
      clear increase in risk for bleeding events. SUMMARY: The recent trials confirm 
      that, in modern primary prevention populations, the cardiovascular benefit of 
      aspirin is small and comes with a clear increase in risk for bleeding. For the 
      majority of adults without established cardiovascular disease, the risk of a 
      daily aspirin outweighs the benefit.
FAU - Knickelbine, Thomas
AU  - Knickelbine T
AD  - Minneapolis Heart Institute Foundation, Minneapolis Heart Institute, Minneapolis, 
      Minnesota, USA.
FAU - Miedema, Michael D
AU  - Miedema MD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Atherosclerosis/prevention & control
MH  - Cardiovascular Diseases/*prevention & control
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Primary Prevention/methods
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
EDAT- 2019/06/21 06:00
MHDA- 2020/04/04 06:00
CRDT- 2019/06/21 06:00
PHST- 2019/06/21 06:00 [pubmed]
PHST- 2020/04/04 06:00 [medline]
PHST- 2019/06/21 06:00 [entrez]
AID - 10.1097/HCO.0000000000000648 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2019 Sep;34(5):510-513. doi: 10.1097/HCO.0000000000000648.

PMID- 26997718
OWN - NLM
STAT- MEDLINE
DCOM- 20170109
LR  - 20181202
IS  - 1998-3751 (Electronic)
IS  - 0253-7613 (Print)
IS  - 0253-7613 (Linking)
VI  - 48
IP  - 1
DP  - 2016 Jan-Feb
TI  - Comparative evaluation of antiplatelet effect of lycopene with aspirin and the 
      effect of their combination on platelet aggregation: An in vitro study.
PG  - 26-31
LID - 10.4103/0253-7613.174428 [doi]
AB  - INTRODUCTION: The objective was to compare antiplatelet effect of lycopene with 
      aspirin and to study effect of combination of the two on platelet aggregation in 
      vitro, using platelets from healthy volunteers. MATERIALS AND METHODS: Platelets 
      were harvested; platelet count of platelet-rich plasma adjusted to 2.5 Χ 
      10(5)/μL. Aspirin (140 μmol/L) and lycopene (4, 6, 8, 10, and 12 μmol/L) were 
      studied in vitro against adenosine-5'- diphosphate (ADP) (2.5 μM/L) and collagen. 
      RESULTS: All the concentrations of lycopene (4-12 μmol/L) exhibited reduction in 
      maximum platelet aggregation induced by aggregating agents ADP and collagen (P < 
      0.01 vs. vehicle) and were comparable with aspirin. Lycopene at concentration 10 
      μmol/L showed maximum platelet inhibition (47.05% ± 19.56%) against ADP, whereas 
      lycopene at concentration 8 μmol/L showed maximum platelet inhibition (54.26% ± 
      30.71%) against collagen. Four μmol/L of lycopene combined with 140 μmol/L and 70 
      μmol/L aspirin showed greater inhibition of platelets as compared to aspirin 140 
      μmol/L alone, against both ADP and collagen. CONCLUSION: The study favorably 
      compares lycopene and aspirin with respect to their antiplatelet activities 
      against ADP and collagen. Lycopene can be considered as a potential target for 
      modifying the thrombotic and pro-inflammatory events associated with platelet 
      activation.
FAU - Sawardekar, Swapna B
AU  - Sawardekar SB
AD  - Department of Pharmacology and Therapeutics, Seth G.S. Medical College and K.E.M. 
      Hospital, Mumbai, Maharashtra, India.
FAU - Patel, Tejal C
AU  - Patel TC
AD  - Department of Pharmacology and Therapeutics, Seth G.S. Medical College and K.E.M. 
      Hospital, Mumbai, Maharashtra, India.
FAU - Uchil, Dinesh
AU  - Uchil D
AD  - Department of Pharmacology and Therapeutics, Seth G.S. Medical College and K.E.M. 
      Hospital, Mumbai, Maharashtra, India.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Pharmacol
JT  - Indian journal of pharmacology
JID - 7902477
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 36-88-4 (Carotenoids)
RN  - R16CO5Y76E (Aspirin)
RN  - SB0N2N0WV6 (Lycopene)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Carotenoids/administration & dosage/*pharmacology
MH  - Drug Therapy, Combination
MH  - Humans
MH  - In Vitro Techniques
MH  - Lycopene
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
PMC - PMC4778201
OTO - NOTNLM
OT  - Adenosine-5’- diphosphate
OT  - antiplatelet
OT  - aspirin
OT  - collagen
OT  - lycopene
OT  - optical aggregometry
EDAT- 2016/03/22 06:00
MHDA- 2017/01/10 06:00
CRDT- 2016/03/22 06:00
PHST- 2016/03/22 06:00 [entrez]
PHST- 2016/03/22 06:00 [pubmed]
PHST- 2017/01/10 06:00 [medline]
AID - IJPharm-48-26 [pii]
AID - 10.4103/0253-7613.174428 [doi]
PST - ppublish
SO  - Indian J Pharmacol. 2016 Jan-Feb;48(1):26-31. doi: 10.4103/0253-7613.174428.

PMID- 9711467
OWN - NLM
STAT- MEDLINE
DCOM- 19981109
LR  - 20191024
IS  - 0767-3981 (Print)
IS  - 0767-3981 (Linking)
VI  - 12
IP  - 4
DP  - 1998
TI  - Enhancement of aspirin-induced gastric damage by cholestasis in rats.
PG  - 442-5
AB  - In this study the severity of aspirin-induced gastric mucosal damage was 
      investigated in rats with obstructive cholestasis. Cholestasis was induced by 
      ligation and resection of the bile duct under general anesthesia. Two weeks after 
      operation, the rats were fasted for 24 hours. Aspirin was administered orally in 
      doses of 0, 128, 192, 266 and 335 mg/kg, and the animals were killed four hours 
      after dosing. The dose of 266 mg/kg was chosen for a study of the 
      time-dependency; other groups of animals were killed at time intervals of one, 
      three, five, seven and nine hours after aspirin administration. The results 
      showed that aspirin induces more severe gastric damage in bile duct resected rats 
      compared with sham-operated and control animals. Salicylate levels of serums were 
      also measured but there was no significant difference in serum salicylate levels 
      between bile duct resected, sham-operated and control rats. It can be concluded 
      that cholestasis can potentiate aspirin-induced gastric damage in rats.
FAU - Dehpour, A R
AU  - Dehpour AR
AD  - Department of Pharmacology, School of Medicine, Tehran University of Medical 
      Sciences, Iran.
FAU - Mani, A R
AU  - Mani AR
FAU - Alikhani, Z
AU  - Alikhani Z
FAU - Zeinoddini, M
AU  - Zeinoddini M
FAU - Toor Savadkoohi, S
AU  - Toor Savadkoohi S
FAU - Ghaffari, K
AU  - Ghaffari K
FAU - Sharif, A
AU  - Sharif A
FAU - Sabbagh, B
AU  - Sabbagh B
FAU - Nowroozi, A
AU  - Nowroozi A
FAU - Sadr, S
AU  - Sadr S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Irritants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*toxicity
MH  - Bile Ducts/surgery
MH  - Cholestasis/*complications
MH  - Disease Models, Animal
MH  - Gastric Mucosa/*drug effects
MH  - Irritants/blood/toxicity
MH  - Laparotomy
MH  - Male
MH  - Rats
MH  - Rats, Wistar
EDAT- 1998/08/26 00:00
MHDA- 1998/08/26 00:01
CRDT- 1998/08/26 00:00
PHST- 1998/08/26 00:00 [pubmed]
PHST- 1998/08/26 00:01 [medline]
PHST- 1998/08/26 00:00 [entrez]
AID - S0767398198803010 [pii]
AID - 10.1111/j.1472-8206.1998.tb00969.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 1998;12(4):442-5. doi: 10.1111/j.1472-8206.1998.tb00969.x.

PMID- 22371106
OWN - NLM
STAT- MEDLINE
DCOM- 20120821
LR  - 20211021
IS  - 1759-5010 (Electronic)
IS  - 1759-5002 (Linking)
VI  - 9
IP  - 5
DP  - 2012 Feb 28
TI  - Prevention. Aspirin in primary prevention--good news and bad news.
PG  - 262-3
LID - 10.1038/nrcardio.2012.26 [doi]
AB  - The balance of benefits and risks of aspirin in primary prevention is far less 
      clear than in secondary prevention; further data from randomized trials of 
      individuals at intermediate cardiovascular risk are needed. Decisions about 
      aspirin in primary prevention should be made on a case-by-case basis, and general 
      guidelines are not justified.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, 777 Glades 
      Road, Research Park, Boca Raton, FL 33431, USA. chenneke@fau.edu
FAU - Baigent, Colin
AU  - Baigent C
LA  - eng
PT  - Journal Article
DEP - 20120228
PL  - England
TA  - Nat Rev Cardiol
JT  - Nature reviews. Cardiology
JID - 101500075
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Humans
MH  - *Primary Prevention
MH  - Risk Factors
EDAT- 2012/03/01 06:00
MHDA- 2012/08/22 06:00
CRDT- 2012/02/29 06:00
PHST- 2012/02/29 06:00 [entrez]
PHST- 2012/03/01 06:00 [pubmed]
PHST- 2012/08/22 06:00 [medline]
AID - nrcardio.2012.26 [pii]
AID - 10.1038/nrcardio.2012.26 [doi]
PST - epublish
SO  - Nat Rev Cardiol. 2012 Feb 28;9(5):262-3. doi: 10.1038/nrcardio.2012.26.

PMID- 7103841
OWN - NLM
STAT- MEDLINE
DCOM- 19820917
LR  - 20191023
IS  - 0020-6091 (Print)
IS  - 0020-6091 (Linking)
VI  - 21
IP  - 4
DP  - 1982
TI  - Effects of acetylsalicylic acid on speech discrimination.
PG  - 342-9
AB  - Speech discrimination scores were obtained in quiet and against a background of 
      competing noise for 5 persons both before and after they had ingested large doses 
      of acetyl-salicylic acid (aspirin). The results indicate that for some persons, 
      aspirin produces a substantial decrease in speech understanding in noise, even 
      though there may not be a decrease in pure-tone sensitivity or speech 
      discrimination in quiet.
FAU - Young, L L Jr
AU  - Young LL Jr
FAU - Wilson, K A
AU  - Wilson KA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Audiology
JT  - Audiology : official organ of the International Society of Audiology
JID - 1273752
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Auditory Threshold/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Noise
MH  - Speech Perception/*drug effects
EDAT- 1982/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.3109/00206098209072749 [doi]
PST - ppublish
SO  - Audiology. 1982;21(4):342-9. doi: 10.3109/00206098209072749.

PMID- 27822013
OWN - NLM
STAT- MEDLINE
DCOM- 20170303
LR  - 20181202
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 10
DP  - 2016
TI  - Pharmacokinetics and relative bioavailability of fixed-dose combination of 
      clopidogrel and aspirin versus coadministration of individual formulations in 
      healthy Korean men.
PG  - 3493-3499
AB  - BACKGROUND: Simultaneous prescription of clopidogrel and low-dose aspirin is 
      recommended for the treatment of acute coronary syndrome because of improvements 
      in efficacy and patient compliance. In this study, the pharmacokinetics of a 
      fixed-dose combination (FDC) of clopidogrel and aspirin was compared with 
      coadministration of individual formulations to clarify the equivalence of the 
      FDC. METHODS: This was a randomized, open-label, two-period, two-treatment, 
      crossover study in healthy Korean men aged 20-55 years. Subjects received two FDC 
      capsules of clopidogrel/aspirin 75/100 mg (test) or two tablets of clopidogrel 75 
      mg and two capsules of aspirin 100 mg (reference) with a 14-day washout period. 
      Plasma concentrations of clopidogrel, aspirin, and salicylic acid were measured 
      using validated ultraperformance liquid chromatography-tandem mass spectrometry. 
      Bioequivalence was assessed by analysis of variance and calculation of the 90% 
      confidence intervals (CIs) of the ratios of the geometric means (GMRs) for 
      AUC(last) and C(max) for clopidogrel and aspirin. RESULTS: Sixty healthy subjects 
      were enrolled, and 53 completed the study. Clopidogrel, aspirin, and salicylic 
      acid showed similar absorption profiles and no significant differences in C(max), 
      AUC(last), and T(max) between FDC administration and coadministration of 
      individual formulations. The GMRs (90% CI) for the C(max) and AUC(last) of 
      clopidogrel were 1.08 (0.95, 1.23) and 0.93 (0.84, 1.03), respectively. The GMRs 
      (90% CI) for the C(max) and AUC(last) of aspirin were 0.98 (0.84, 1.13) and 0.98 
      (0.93, 1.04), respectively. Both treatments were well tolerated in the study 
      subjects. CONCLUSION: The FDC of clopidogrel and aspirin was bioequivalent to 
      coadministration of each individual formulation. The FDC capsule exhibited 
      similar safety and tolerability profiles to the individual formulations. 
      Therefore, clopidogrel/aspirin 75 mg/100 mg FDC capsules can be prescribed to 
      improve patient compliance.
FAU - Choi, Hyang-Ki
AU  - Choi HK
AD  - Department of Pharmacology, Inje University College of Medicine, Busan, Republic 
      of Korea.
FAU - Ghim, Jong-Lyul
AU  - Ghim JL
AD  - Department of Clinical Pharmacology and Toxicology, Anam Hospital, Korea 
      University College of Medicine, Seoul, Republic of Korea.
FAU - Shon, Jihong
AU  - Shon J
AD  - Department of Pharmacology, Inje University College of Medicine, Busan, Republic 
      of Korea; Department of Clinical Pharmacology, Inje University Busan Paik 
      Hospital, Busan, Republic of Korea.
FAU - Choi, Young-Kyung
AU  - Choi YK
AD  - Department of Pharmacology, Inje University College of Medicine, Busan, Republic 
      of Korea.
FAU - Jung, Jin Ah
AU  - Jung JA
AD  - Department of Pharmacology, Inje University College of Medicine, Busan, Republic 
      of Korea; Department of Clinical Pharmacology, Inje University Busan Paik 
      Hospital, Busan, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20161025
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Drug Combinations)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy
MH  - Administration, Oral
MH  - Adult
MH  - Area Under Curve
MH  - Aspirin/*administration & dosage/pharmacokinetics/therapeutic use
MH  - Biological Availability
MH  - Clopidogrel
MH  - Cross-Over Studies
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Therapeutic Equivalency
MH  - Ticlopidine/administration & dosage/*analogs & 
      derivatives/pharmacokinetics/therapeutic use
MH  - Young Adult
PMC - PMC5087785
OTO - NOTNLM
OT  - bioequivalence
OT  - clopidogrel/aspirin
OT  - comparative pharmacokinetics
OT  - fixed-dose combination
COIS- Jihong Shon is currently employed in the US Food and Drug Administration. His 
      contribution to the manuscript was based on his prior employment, and the current 
      manuscript does not necessarily reflect any position of the US Food and Drug 
      Administration or the US government. The authors report no other conflicts of 
      interest in this work.
EDAT- 2016/11/09 06:00
MHDA- 2017/03/04 06:00
CRDT- 2016/11/09 06:00
PHST- 2016/11/09 06:00 [entrez]
PHST- 2016/11/09 06:00 [pubmed]
PHST- 2017/03/04 06:00 [medline]
AID - dddt-10-3493 [pii]
AID - 10.2147/DDDT.S109080 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2016 Oct 25;10:3493-3499. doi: 10.2147/DDDT.S109080. 
      eCollection 2016.

PMID- 7002356
OWN - NLM
STAT- MEDLINE
DCOM- 19810226
LR  - 20131121
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 62
IP  - 6 Pt 2
DP  - 1980 Dec
TI  - Controlled trial of aspirin in cerebral ischemia.
PG  - V90-6
AB  - The findings from a double-blind multicenter clinical trial of aspirin for 
      treatment of cerebral ischemia are reviewed. Of 303 patients who had carotid 
      transient ischemic attacks (TIAs), 125 were selected for carotid reconstructive 
      surgery and were then randomly assigned treatment with aspirin or placebo. The 
      remaining 178 patients were also randomly assigned to an aspirin or placebo 
      regimen. Analysis of the first 6 months of follow-up showed a differential in 
      favor of aspirin when death, nonfatal cerebral or retinal infarction and the 
      occurrence of TIAs were grouped and considered together as end points. 
      Restriction of end points to death or nonfatal cerebral or retinal infarction 
      yielded no statistically significant differential between the aspirin and placebo 
      groups. After these results were published, a study group from Canada reported 
      that aspirin was effective in preventing threatened stroke, but that this effect 
      was limited to males. Review of our nonsurgical group with respect to sex shows 
      findings consistent with those of the Canadian study for the end points of stroke 
      or death. Inclusion of the occurrence of TIAs in the group of end points, 
      however, revealed that aspirin is effective in females as well as males.
FAU - Fields, W S
AU  - Fields WS
FAU - Lemak, N A
AU  - Lemak NA
FAU - Frankowski, R F
AU  - Frankowski RF
FAU - Hardy, R J
AU  - Hardy RJ
FAU - Bigelow, R H
AU  - Bigelow RH
LA  - eng
GR  - HL-14340-03/HL/NHLBI NIH HHS/United States
GR  - NHLBI/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Actuarial Analysis
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/prevention & control
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/mortality/surgery
MH  - Male
MH  - Patient Compliance
MH  - Placebos
MH  - Risk
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
PST - ppublish
SO  - Circulation. 1980 Dec;62(6 Pt 2):V90-6.

PMID- 25444455
OWN - NLM
STAT- MEDLINE
DCOM- 20150730
LR  - 20141202
IS  - 1873-2615 (Electronic)
IS  - 1050-1738 (Linking)
VI  - 24
IP  - 8
DP  - 2014 Nov
TI  - Aspirin in the primary prevention of cardiovascular disease: current knowledge 
      and future research needs.
PG  - 360-6
LID - S1050-1738(14)00110-8 [pii]
LID - 10.1016/j.tcm.2014.08.006 [doi]
AB  - In secondary prevention, among a very wide range of survivors of prior occlusive 
      cardiovascular disease (CVD) events and those suffering acute myocardial 
      infarction (MI) or occlusive stroke, aspirin decreases risks of MI, stroke, and 
      CVD death. In these high risk patients, the absolute benefits are large and 
      absolute risks are far smaller so aspirin should be more widely prescribed. In 
      contrast, in primary prevention, aspirin reduces risks of first MI but the 
      evidence on stroke and CVD death remain inconclusive. Based on the current 
      totality of evidence from predominantly low risk subjects where the absolute 
      benefits is low and side effects the same as in secondary prevention, any 
      decision to prescribe aspirin for primary prevention should be an individual 
      clinical judgment by the healthcare provider that weighs the absolute benefit in 
      reducing the risk of a first MI against the absolute risk of major bleeding. If 
      the ongoing trials of intermediate risks subjects show net benefits then general 
      guidelines may be justified with several caveats. First, any decision to use 
      aspirin should continue to be made by the healthcare provider. Second, 
      therapeutic lifestyle changes and other drugs of life saving benefit such as 
      statins should be considered with aspirin as an adjunct, not alternative. The 
      more widespread and appropriate use of aspirin in primary prevention is 
      particularly attractive, especially in developing countries where CVD is emerging 
      as the leading cause of death. In addition, aspirin is generally widely available 
      over the counter and is extremely inexpensive.
CI  - Copyright © 2014. Published by Elsevier Inc.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, 777 Glades 
      Road, Building 71, Room 337, Boca Raton, FL 33431. Electronic address: 
      chenneke@fau.edu.
FAU - Dalen, James E
AU  - Dalen JE
AD  - Weil Foundation, University of Arizona College of Medicine, Tucson, AZ.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140901
PL  - United States
TA  - Trends Cardiovasc Med
JT  - Trends in cardiovascular medicine
JID - 9108337
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
EDAT- 2014/12/03 06:00
MHDA- 2015/08/01 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/07/20 00:00 [received]
PHST- 2014/08/25 00:00 [revised]
PHST- 2014/08/26 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/08/01 06:00 [medline]
AID - S1050-1738(14)00110-8 [pii]
AID - 10.1016/j.tcm.2014.08.006 [doi]
PST - ppublish
SO  - Trends Cardiovasc Med. 2014 Nov;24(8):360-6. doi: 10.1016/j.tcm.2014.08.006. Epub 
      2014 Sep 1.

PMID- 26980654
OWN - NLM
STAT- MEDLINE
DCOM- 20160712
LR  - 20181202
IS  - 1002-0098 (Print)
IS  - 1002-0098 (Linking)
VI  - 51
IP  - 3
DP  - 2016 Mar
TI  - [Effect of aspirin on cell biological activities in murine bone marrow stromal 
      cells].
PG  - 160-5
LID - 10.3760/cma.j.issn.1002-0098.2016.03.007 [doi]
AB  - OBJECTIVE: To determine the effect of aspirin on cell proliferation, alkaline 
      phosphatase (ALP) activity, cell cycle and apoptosis in murine bone marrow 
      stromal cells, so as to explore an appropriate dose range to improve bone 
      regeneration in periodontal treatment. METHODS: ST2 cells were stimulated with 
      aspirin (concentrations of 1, 10, 100 and 1 000 μmol/L) for 1, 2, 3, 5 and 7 d. 
      Cell proliferation was measured by methyl thiazolyl tetrazolium (MTT) assay. 
      After ST2 cells were treated for 1, 3 and 7 d, ALP activity was measured by ALP 
      kit, cell cycle and apoptosis were measured by flow cytometry (FCM) after treated 
      for 48 h. RESULTS: MTT assays showed that various doses of aspirin have different 
      effects on the cell growth. Briefly, lower concentrations (1, 10 μmol/L) of 
      aspirin promoted the cell growth, the A value of 0, 1 and 10 μmol/L aspirin 
      7-day-treated cells were 0.313±0.012, 0.413±0.010 and 0.387±0.017 respectively (P 
      <0.01 vs control), and so did the ALP level ([4.3±0.9], [6.0±0.3] and [7.7±0.4] 
      μmol·min(-1)·g(-1), P <0.05 vs control), while higher concentrations, especially 
      1000 μmol/L of aspirin might inhibit the cell growth with time going, A value and 
      ALP level were 0.267±0.016, (4.3±1.3) μmol·min(-1)·g(-1) respectively (P <0.05 vs 
      control). Cell cycle analysis revealed no changes in comparison to control cells 
      after treatment with 1 or 10 μmol/L aspirin, but it was observed that cell 
      mitosis from S phase to G2/M phase proceeded at higher concentrations of 100 
      μmol/L aspirin, and the cell cycle in phase G0/G1 arrested at 1000 μmol/L. 
      Parallel apoptosis/necrosis studies showed that the percentage of cells in 
      apoptosis decreased dramatically at all doses of aspirin, the apoptosis rates of 
      ST2 cells responded to 0, 1, 10, 100 and 1000 μmol/L aspirin were (11.50±0.90)%, 
      (5.30±0.10)%, (5.50±0.10)%, (4.90±0.90)% and (7.95±0.25)% respectively (P<0.05 vs 
      control). CONCLUSIONS: This study demonstrated that lower dosage of aspirin can 
      promote ST2 cells growth, osteogenic activity and inhibit its apoptosis. Aspirin 
      maybe used for the bone reconstruction with a proper concentration.
FAU - Du, Mi
AU  - Du M
AD  - Department of Periodontology, School of Stomatology, Shandong University; 
      Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Jinan 250012, 
      China.
FAU - Pan, Wan
AU  - Pan W
FAU - Yang, Pishan
AU  - Yang P
FAU - Ge, Shaohua
AU  - Ge S
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Kou Qiang Yi Xue Za Zhi
JT  - Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese 
      journal of stomatology
JID - 8711066
RN  - 0 (Formazans)
RN  - 0 (Tetrazolium Salts)
RN  - 23305-68-2 (MTT formazan)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alkaline Phosphatase/metabolism
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bone Regeneration
MH  - Cell Cycle/drug effects
MH  - Cell Division
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Flow Cytometry
MH  - Formazans
MH  - Mesenchymal Stem Cells/cytology/*drug effects/enzymology
MH  - Mice
MH  - Periodontics
MH  - Tetrazolium Salts
MH  - Time Factors
EDAT- 2016/03/17 06:00
MHDA- 2016/07/13 06:00
CRDT- 2016/03/17 06:00
PHST- 2016/03/17 06:00 [entrez]
PHST- 2016/03/17 06:00 [pubmed]
PHST- 2016/07/13 06:00 [medline]
AID - 10.3760/cma.j.issn.1002-0098.2016.03.007 [doi]
PST - ppublish
SO  - Zhonghua Kou Qiang Yi Xue Za Zhi. 2016 Mar;51(3):160-5. doi: 
      10.3760/cma.j.issn.1002-0098.2016.03.007.

PMID- 15477774
OWN - NLM
STAT- MEDLINE
DCOM- 20160423
LR  - 20181130
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 44
IP  - 9
DP  - 2004
TI  - [The Use of Clopidogrel in Conjunction With Thrombolytic Therapy in PatientsWith 
      ST-Elevation Acute Myocardial Infarction.].
PG  - 42-4
AB  - Clopidogrel (300 mg before initiation of thrombolysis and 75 mg/day thereafter) 
      was given to 46 of 131 patients with streptokinase treated ST-elevation acute 
      myocardial infarction. Mortality and efficacy of thrombolysis were similar in 2 
      groups, however deaths of acute heart failure were distributed unevenly (0 in 
      clopidogrel group and 8 or 9.4% among other patients, p <0.03). Clopidogrel 
      treated compared with other patients had significantly higher left ventricular 
      ejection fraction on days 1-2 of disease (52.5+/-2.2 and 45.9+/-2.0%, 
      respectively, p<0.03). Number of bleedings did not differ significantly between 2 
      groups. Thus patients addition of clopidogrel to aspirin and thrombolysis with 
      streptokinase was associated with better myocardial contractile function and 
      lower mortality due to acute heart failure.
FAU - Dyskin, Iu A
AU  - Dyskin IuA
AD  - Moscow State Medical Dental University; ul. Delegatskaya 20, 103473 Moscow, 
      Russia.
FAU - Makarycheva, O V
AU  - Makarycheva OV
FAU - Vasil'eva, E Iu
AU  - Vasil'eva EIu
FAU - Shpektor, A V
AU  - Shpektor AV
LA  - rus
PT  - Journal Article
TT  - Primenenie klopidogrelia v sochetanii s tromboliticheskoĭ terapieĭ u bol'nykh 
      ostrym infarktom miokarda s pod''emom segmenta ST.
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - *Myocardial Infarction
MH  - Streptokinase/therapeutic use
MH  - *Thrombolytic Therapy
MH  - Ventricular Function, Left
EDAT- 2004/10/13 09:00
MHDA- 2016/04/24 06:00
CRDT- 2004/10/13 09:00
PHST- 2004/10/13 09:00 [pubmed]
PHST- 2016/04/24 06:00 [medline]
PHST- 2004/10/13 09:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 2004;44(9):42-4.

PMID- 30042067
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 55
DP  - 2018 Sep
TI  - The application of point-of-care platelet function assay in guiding platelet 
      transfusion in aspirin-users with intracranial haemorrhages.
PG  - 52-56
LID - S0967-5868(18)30513-7 [pii]
LID - 10.1016/j.jocn.2018.06.037 [doi]
AB  - BACKGROUND: An increasing number of patients with intracranial haemorrhages are 
      aspirin-users. Neurosurgeons commonly attempt to minimize the risk of re-bleeding 
      by withholding the medication and giving platelet transfusion. However, recent 
      studies raised safety concerns and showed poorer outcome with platelet 
      transfusion when the latter was not guided by changes in platelet function. AIM 
      OF STUDY: To study the temporal pattern and degree of changes in platelet 
      activities following a fixed dose of platelet transfusion in aspirin-users with 
      intracranial haemorrhages. METHODS: Aspirin-users with intracranial haemorrhages 
      underwent baseline aspirin response units (ARU) using the VerifyNow® assay. Those 
      who showed abnormal platelet activity received a single dose of 4 units of 
      platelet concentrate. ARU were then repeated at 4 h, 24 h and 48 h 
      post-transfusion. Patients were classified according to their responses to 
      transfusion. RESULTS: Twenty patients were recruited. At 4 h after transfusion, 
      11 (55%) patients had normalised platelet activities while the rest may show 
      delayed or absent of normalization. Overall, eight (40%) patients were 'early and 
      persistent transfusion responders', five 'delayed transfusion responders', and 
      five (25%) had persistently abnormal platelet function. Two (10%) patients who 
      initially responded to transfusion failed to maintain normalized platelet 
      activity. CONCLUSION: Platelet activities in aspirin-users showed considerable 
      heterogeneity up to 48 h following a blanket approach of platelet transfusion. 
      The need for repeated transfusion or alternative therapy strongly argues for a 
      guided practice for transfusion based on point-of-care platelet function assay. 
      Future research should also adopt this approach to re-examine the safety and 
      effectiveness of platelet transfusion in these patients.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Cheng, Ka Yu
AU  - Cheng KY
AD  - Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, 
      The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong.
FAU - Tsang, Chun Pong
AU  - Tsang CP
AD  - Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, 
      The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong.
FAU - Leung, Gilberto Ka Kit
AU  - Leung GKK
AD  - Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, 
      The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong. 
      Electronic address: gilberto@hku.hk.
FAU - Lui, Wai Man
AU  - Lui WM
AD  - Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, 
      The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20180702
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - Blood Platelets/drug effects
MH  - Female
MH  - Humans
MH  - Intracranial Hemorrhages/*therapy
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Platelet Function Tests/*methods
MH  - Platelet Transfusion/*methods
MH  - *Point-of-Care Testing
OTO - NOTNLM
OT  - Aspirin
OT  - Intracranial haemorrhages
OT  - Platelet function test
OT  - Platelet transfusion
OT  - Point-of-care
EDAT- 2018/07/26 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/07/26 06:00
PHST- 2018/03/26 00:00 [received]
PHST- 2018/06/25 00:00 [accepted]
PHST- 2018/07/26 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/07/26 06:00 [entrez]
AID - S0967-5868(18)30513-7 [pii]
AID - 10.1016/j.jocn.2018.06.037 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2018 Sep;55:52-56. doi: 10.1016/j.jocn.2018.06.037. Epub 2018 
      Jul 2.

PMID- 343970
OWN - NLM
STAT- MEDLINE
DCOM- 19780524
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 23
IP  - 4
DP  - 1978 Apr
TI  - Gastrointestinal microbleeding after aspirin and naproxen.
PG  - 402-7
AB  - Gastrointestinal bleeding is the most serious side effect encountered with the 
      anti-inflammatory antirheumatic drugs. Using the 51Cr labeling technique, the 
      comparative quantity of blood loss with aspirin or naproxen has been previously 
      done on normal volunteers. With the present study, 12 rheumatoid arthritic 
      patients were controlled in a double-blind crossover study with the same 
      radioactive technique. There is a difference in favor of naproxen. The difference 
      between the baseline period and naproxen administration was not statistically 
      significant.
FAU - Lussier, A
AU  - Lussier A
FAU - Arsenault, A
AU  - Arsenault A
FAU - Varady, J
AU  - Varady J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naproxen/*adverse effects/therapeutic use
EDAT- 1978/04/01 00:00
MHDA- 1978/04/01 00:01
CRDT- 1978/04/01 00:00
PHST- 1978/04/01 00:00 [pubmed]
PHST- 1978/04/01 00:01 [medline]
PHST- 1978/04/01 00:00 [entrez]
AID - 0009-9236(78)90398-3 [pii]
AID - 10.1002/cpt1978234402 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1978 Apr;23(4):402-7. doi: 10.1002/cpt1978234402.

PMID- 34209594
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20230120
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 13
DP  - 2021 Jun 29
TI  - The Road to Low-Dose Aspirin Therapy for the Prevention of Preeclampsia Began 
      with the Placenta.
LID - 10.3390/ijms22136985 [doi]
LID - 6985
AB  - The road to low-dose aspirin therapy for the prevention of preeclampsia began in 
      the 1980s with the discovery that there was increased thromboxane and decreased 
      prostacyclin production in placentas of preeclamptic women. At the time, low-dose 
      aspirin therapy was being used to prevent recurrent myocardial infarction and 
      other thrombotic events based on its ability to selectively inhibit thromboxane 
      synthesis without affecting prostacyclin synthesis. With the discovery that 
      thromboxane was increased in preeclamptic women, it was reasonable to evaluate 
      whether low-dose aspirin would be effective for preeclampsia prevention. The 
      first clinical trials were very promising, but then two large multi-center trials 
      dampened enthusiasm until meta-analysis studies showed aspirin was effective, but 
      with caveats. Low-dose aspirin was most effective when started <16 weeks of 
      gestation and at doses >100 mg/day. It was effective in reducing preterm 
      preeclampsia, but not term preeclampsia, and patient compliance and patient 
      weight were important variables. Despite the effectiveness of low-dose aspirin 
      therapy in correcting the placental imbalance between thromboxane and 
      prostacyclin and reducing oxidative stress, some aspirin-treated women still 
      develop preeclampsia. Alterations in placental sphingolipids and 
      hydroxyeicosatetraenoic acids not affected by aspirin, but with biologic actions 
      that could cause preeclampsia, may explain treatment failures. Consideration 
      should be given to aspirin's effect on neutrophils and pregnancy-specific 
      expression of protease-activated receptor 1, as well as additional mechanisms of 
      action to prevent preeclampsia.
FAU - Walsh, Scott W
AU  - Walsh SW
AD  - Department of Obstetrics and Gynecology, Virginia Commonwealth University, 
      Richmond, VA 23298, USA.
FAU - Strauss, Jerome F 3rd
AU  - Strauss JF 3rd
AUID- ORCID: 0000-0001-6199-0480
AD  - Department of Obstetrics and Gynecology, Virginia Commonwealth University, 
      Richmond, VA 23298, USA.
LA  - eng
GR  - IK6 BX004603/BX/BLRD VA/United States
GR  - R01 HD088386/HD/NICHD NIH HHS/United States
GR  - U01 HD087198/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20210629
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Biomarkers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage
MH  - Biomarkers
MH  - Disease Management
MH  - Disease Susceptibility
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Leukocytes/drug effects/immunology/metabolism/pathology
MH  - Placenta/*drug effects/*metabolism/pathology
MH  - Pre-Eclampsia/etiology/*metabolism/*prevention & control
MH  - Pregnancy
MH  - Stromal Cells/drug effects/metabolism
MH  - Trophoblasts/drug effects/metabolism
PMC - PMC8268135
OTO - NOTNLM
OT  - eicosanoids
OT  - isoprostanes
OT  - low-dose aspirin
OT  - neutrophils
OT  - placenta
OT  - preeclampsia
OT  - prostacyclin
OT  - protease-activated receptor 1
OT  - sphingolipids
OT  - thromboxane
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/27 06:00
CRDT- 2021/07/02 01:39
PHST- 2021/05/31 00:00 [received]
PHST- 2021/06/23 00:00 [revised]
PHST- 2021/06/23 00:00 [accepted]
PHST- 2021/07/02 01:39 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
AID - ijms22136985 [pii]
AID - ijms-22-06985 [pii]
AID - 10.3390/ijms22136985 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Jun 29;22(13):6985. doi: 10.3390/ijms22136985.

PMID- 25200125
OWN - NLM
STAT- MEDLINE
DCOM- 20150312
LR  - 20220330
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 161
IP  - 11
DP  - 2014 Dec 2
TI  - Low-dose aspirin use for the prevention of morbidity and mortality from 
      preeclampsia: U.S. Preventive Services Task Force recommendation statement.
PG  - 819-26
LID - 10.7326/M14-1884 [doi]
AB  - DESCRIPTION: Update of the 1996 U.S. Preventive Services Task Force (USPSTF) 
      recommendation on aspirin prophylaxis in pregnancy. METHODS: The USPSTF reviewed 
      the evidence on the effectiveness of low-dose aspirin in preventing preeclampsia 
      in women at increased risk and in decreasing adverse maternal and perinatal 
      health outcomes, and assessed the maternal and fetal harms of low-dose aspirin 
      during pregnancy. POPULATION: This recommendation applies to asymptomatic 
      pregnant women who are at increased risk for preeclampsia and who have no prior 
      adverse effects with or contraindications to low-dose aspirin. RECOMMENDATION: 
      The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive 
      medication after 12 weeks of gestation in women who are at high risk for 
      preeclampsia. (B recommendation).
FAU - LeFevre, Michael L
AU  - LeFevre ML
CN  - U.S. Preventive Services Task Force
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- Ann Intern Med. 2014 Dec 2;161(11):I28. PMID: 25200275
CIN - Nat Rev Nephrol. 2014 Nov;10(11):613. PMID: 25266208
CIN - Nat Rev Endocrinol. 2015 Jan;11(1):6-8. PMID: 25404015
CIN - J Midwifery Womens Health. 2015 Mar-Apr;60(2):222-3. PMID: 25782856
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Biomedical Research
MH  - Cost of Illness
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Pre-Eclampsia/mortality/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Risk Assessment
EDAT- 2014/09/10 06:00
MHDA- 2015/03/13 06:00
CRDT- 2014/09/10 06:00
PHST- 2014/09/10 06:00 [entrez]
PHST- 2014/09/10 06:00 [pubmed]
PHST- 2015/03/13 06:00 [medline]
AID - 1902275 [pii]
AID - 10.7326/M14-1884 [doi]
PST - ppublish
SO  - Ann Intern Med. 2014 Dec 2;161(11):819-26. doi: 10.7326/M14-1884.

PMID- 9022487
OWN - NLM
STAT- MEDLINE
DCOM- 19970307
LR  - 20220331
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 314
IP  - 7076
DP  - 1997 Jan 25
TI  - Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women 
      with recurrent miscarriage associated with phospholipid antibodies (or 
      antiphospholipid antibodies).
PG  - 253-7
AB  - OBJECTIVE: To determine whether treatment with low dose aspirin and heparin leads 
      to a higher rate of live births than that achieved with low dose aspirin alone in 
      women with a history of recurrent miscarriage associated with phospholipid 
      antibodies (or antiphospholipid antibodies), lupus anticoagulant, and cardiolipin 
      antibodies (or anticardiolipin antibodies). DESIGN: Randomised controlled trial. 
      SETTING: Specialist clinic for recurrent miscarriages. SUBJECTS: 90 women (median 
      age 33 (range 22-43)) with a history of recurrent miscarriage (median number 4 
      (range 3-15)) and persistently positive results for phospholipid antibodies. 
      INTERVENTION: Either low dose aspirin (75 mg daily) or low dose aspirin and 5000 
      U of unfractionated heparin subcutaneously 12 hourly. All women started treatment 
      with low dose aspirin when they had a positive urine pregnancy test. Women were 
      randomly allocated an intervention when fetal heart activity was seen on 
      ultrasonography. Treatment was stopped at the time of miscarriage or at 34 weeks' 
      gestation. MAIN OUTCOME MEASURES: Rate of live births with the two treatments. 
      RESULTS: There was no significant difference in the two groups in age or the 
      number and gestation of previous miscarriages. The rate of live births with low 
      dose aspirin and heparin was 71% (32/45 pregnancies) and 42% (19/45 pregnancies) 
      with low dose aspirin alone (odds ratio 3.37 (95% confidence interval 1.40 to 
      8.10)). More than 90% of miscarriages occurred in the first trimester. There was 
      no difference in outcome between the two treatments in pregnancies that advanced 
      beyond 13 weeks' gestation. Twelve of the 51 successful pregnancies (24%) were 
      delivered before 37 weeks' gestation. Women randomly allocated aspirin and 
      heparin had a median decrease in lumbar spine bone density of 5.4% (range -8.6% 
      to 1.7%). CONCLUSION: Treatment with aspirin and heparin leads to a significantly 
      higher rate of live births in women with a history of recurrent miscarriage 
      associated with phospholipid antibodies than that achieved with aspirin alone.
FAU - Rai, R
AU  - Rai R
AD  - Imperial College, School of Medicine at St Mary's, London.
FAU - Cohen, H
AU  - Cohen H
FAU - Dave, M
AU  - Dave M
FAU - Regan, L
AU  - Regan L
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 1997 Jan 25;314(7076):244. PMID: 9022479
CIN - BMJ. 1997 Aug 9;315(7104):372; author reply 373. PMID: 9270477
CIN - BMJ. 1997 Aug 9;315(7104):372. PMID: 9270478
CIN - BMJ. 1997 Aug 9;315(7104):372-3; author reply 373. PMID: 9270479
MH  - Abortion, Habitual/*prevention & control
MH  - Adult
MH  - Antibodies, Anticardiolipin/analysis
MH  - Antiphospholipid Syndrome/*complications
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Immunoglobulin G/analysis
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - Pregnancy Outcome
PMC - PMC2125731
EDAT- 1997/01/25 00:00
MHDA- 1997/01/25 00:01
CRDT- 1997/01/25 00:00
PHST- 1997/01/25 00:00 [pubmed]
PHST- 1997/01/25 00:01 [medline]
PHST- 1997/01/25 00:00 [entrez]
AID - 10.1136/bmj.314.7076.253 [doi]
PST - ppublish
SO  - BMJ. 1997 Jan 25;314(7076):253-7. doi: 10.1136/bmj.314.7076.253.

PMID- 34050970
OWN - NLM
STAT- MEDLINE
DCOM- 20220106
LR  - 20220106
IS  - 1875-9114 (Electronic)
IS  - 0277-0008 (Linking)
VI  - 41
IP  - 7
DP  - 2021 Jul
TI  - A Retrospective Analysis Comparing Post-Operative Bleeding with Various Doses of 
      Aspirin after Lower Extremity Joint Arthroplasty or Revision.
PG  - 616-622
LID - 10.1002/phar.2598 [doi]
AB  - STUDY OBJECTIVE: Previous studies have shown that aspirin is noninferior to other 
      anticoagulation therapies in preventing postoperative venous thromboembolism 
      following lower extremity arthroplasty or revision; however, its optimal dosing 
      for this indication is less clear. This study aims to compare the odds of 
      bleeding between different aspirin dosages following lower extremity joint 
      arthroplasty or revision. DESIGN: This is a 3-year retrospective multi-center 
      cohort study across the United States and its territories. SETTING: This study 
      included patients admitted for total hip or knee arthroplasty or revision and 
      were treated with prophylactic aspirin. PATIENTS, INTERVENTION, MEASUREMENTS: 
      Patients were assigned to groups based on a total daily aspirin dose of 81, 162, 
      325, or 650 mg. Data were analyzed for postsurgical bleeding and thromboembolism 
      events occurring during the initial admission and up to 40 days following 
      surgery. Other exploratory variables included type of surgery, hip or knee 
      arthroplasty, length of stay, and patient demographic data. MAIN RESULTS: Among 
      53,848 patients receiving aspirin, 3922 received a total daily dose of 81 mg, 
      19,341 received a total daily dose of 162 mg, 5256 received a total daily dose of 
      325 mg, and 25,329 received a total daily dose of 650 mg. Bleeding occurred in 
      466 (0.87%) patients and venous thromboembolism (VTE) in 209 patients (0.39%). 
      The odds of bleeding were compared using logistic regression, with the 650-mg 
      dose as the reference group. None were statistically significant for bleeding 
      between all studied aspirin doses: 81 mg (OR 1.12, 95% CI 0.83-1.51, p = 0.451), 
      162 mg (OR 0.83, 95% CI 0.67-1.03, p = 0.097), and 325 mg (OR 0.83, 95% CI 
      0.59-1.13, p = 0.245). The odds of VTE were also not statistically significant: 
      81 mg (OR 0.71, 95% CI 0.40-1.17, p = 0.181), 162 mg (OR 0.75 95% CI 0.54-1.03, p 
      = 0.072), and 325 mg (OR 1.00, 95% CI 0.64-1.53, p = 0.989). CONCLUSIONS: There 
      were no significant differences in the odds of bleeding or venous thromboembolism 
      among all studied aspirin dosages in patients receiving aspirin for 
      thromboprophylaxis following lower extremity joint arthroplasty or revision.
CI  - © 2021 Pharmacotherapy Publications, Inc.
FAU - Watts, Paula J
AU  - Watts PJ
AUID- ORCID: 0000-0002-0017-7565
AD  - Graduate Medical Education, HCA HealthONE - Sky Ridge Medical Center, Lone Tree, 
      Colorado, USA.
AD  - Rocky Vista University, Parker, Colorado, USA.
AD  - Critical Care and Pulmonary Consultants, Greenwood Village, Colorado, USA.
FAU - Kopstein, Michael
AU  - Kopstein M
AD  - Graduate Medical Education, HCA HealthONE - Sky Ridge Medical Center, Lone Tree, 
      Colorado, USA.
AD  - Rocky Vista University, Parker, Colorado, USA.
AD  - Inova Loudoun Hospital, Leesburg, Virginia, USA.
FAU - Harkness, Weston
AU  - Harkness W
AD  - Graduate Medical Education, HCA HealthONE - Sky Ridge Medical Center, Lone Tree, 
      Colorado, USA.
AD  - Rocky Vista University, Parker, Colorado, USA.
AD  - Graduate Medical Education, Samaritan Health Services, Corvallis, Oregon, USA.
FAU - Cornett, Brendon
AU  - Cornett B
AD  - HCA Healthcare, Denver, Colorado, USA.
FAU - Dziadkowiec, Oliwier
AU  - Dziadkowiec O
AD  - HCA Healthcare, Denver, Colorado, USA.
FAU - Jenkins, Patrick
AU  - Jenkins P
AD  - Graduate Medical Education, HCA HealthONE - Sky Ridge Medical Center, Lone Tree, 
      Colorado, USA.
AD  - Rocky Vista University, Parker, Colorado, USA.
FAU - Hicks, Mary E
AU  - Hicks ME
AD  - Graduate Medical Education, HCA HealthONE - Sky Ridge Medical Center, Lone Tree, 
      Colorado, USA.
AD  - Rocky Vista University, Parker, Colorado, USA.
AD  - Critical Care and Pulmonary Consultants, Greenwood Village, Colorado, USA.
FAU - Hassan, Shakib
AU  - Hassan S
AD  - Graduate Medical Education, HCA HealthONE - Sky Ridge Medical Center, Lone Tree, 
      Colorado, USA.
AD  - Rocky Vista University, Parker, Colorado, USA.
AD  - Critical Care and Pulmonary Consultants, Greenwood Village, Colorado, USA.
FAU - Scherbak, Dmitriy
AU  - Scherbak D
AD  - Graduate Medical Education, HCA HealthONE - Sky Ridge Medical Center, Lone Tree, 
      Colorado, USA.
AD  - Rocky Vista University, Parker, Colorado, USA.
AD  - Critical Care and Pulmonary Consultants, Greenwood Village, Colorado, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20210618
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects
MH  - Arthroplasty
MH  - *Aspirin/administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Lower Extremity/surgery
MH  - *Postoperative Hemorrhage/chemically induced/epidemiology
MH  - Reoperation
MH  - Retrospective Studies
MH  - *Venous Thromboembolism/epidemiology/prevention & control
OTO - NOTNLM
OT  - arthroplasty
OT  - aspirin
OT  - bleed
OT  - revision
OT  - thromboprophylaxis
EDAT- 2021/05/30 06:00
MHDA- 2022/01/07 06:00
CRDT- 2021/05/29 12:16
PHST- 2021/04/21 00:00 [revised]
PHST- 2021/02/25 00:00 [received]
PHST- 2021/04/22 00:00 [accepted]
PHST- 2021/05/30 06:00 [pubmed]
PHST- 2022/01/07 06:00 [medline]
PHST- 2021/05/29 12:16 [entrez]
AID - 10.1002/phar.2598 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2021 Jul;41(7):616-622. doi: 10.1002/phar.2598. Epub 2021 Jun 
      18.

PMID- 27304196
OWN - NLM
STAT- MEDLINE
DCOM- 20170424
LR  - 20181113
IS  - 1752-8062 (Electronic)
IS  - 1752-8054 (Print)
IS  - 1752-8054 (Linking)
VI  - 9
IP  - 4
DP  - 2016 Aug
TI  - Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and 
      Platelet Aggregation in Healthy Adult Subjects.
PG  - 221-7
LID - 10.1111/cts.12405 [doi]
AB  - The effect of the protease-activated receptor-1 (PAR-1) antagonist vorapaxar on 
      human bleeding time is not known. This was a randomized, two-period, open-label 
      trial in healthy men (n = 31) and women (n = 5). In period 1, subjects received 
      81 mg aspirin q.d. or a vorapaxar regimen achieving steady-state plasma 
      concentrations equivalent to chronic 2.5 mg q.d. doses, for 7 days. In period 2, 
      each group added 7 days of the therapy alternate to that of period 1 without 
      washout. Bleeding time and platelet aggregation using arachidonic acid, ADP, and 
      TRAP agonists were assessed. Bleeding time geometric mean ratio (90% CI) for 
      vorapaxar/baseline was 1.01 (0.88-1.15), aspirin/baseline was 1.32 (1.15-1.51), 
      vorapaxar + aspirin/vorapaxar was 1.47 (1.26-1.70), and vorapaxar + 
      aspirin/aspirin was 1.12 (0.96-1.30). Unlike aspirin, vorapaxar did not prolong 
      bleeding time compared with baseline. Bleeding time following administration of 
      vorapaxar with aspirin was similar to that following aspirin alone.
CI  - © 2016 The Authors. Clinical and Translational Science published by Wiley 
      Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and 
      Therapeutics.
FAU - Kraft, W K
AU  - Kraft WK
AD  - Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
FAU - Gilmartin, J H
AU  - Gilmartin JH
AD  - Merck & Co, Kenilworth, New Jersey, USA.
FAU - Chappell, D L
AU  - Chappell DL
AD  - Merck & Co, Kenilworth, New Jersey, USA.
FAU - Gheyas, F
AU  - Gheyas F
AD  - Merck & Co, Kenilworth, New Jersey, USA.
FAU - Walker, B M
AU  - Walker BM
AD  - Merck & Co, Kenilworth, New Jersey, USA.
FAU - Nagalla, S
AU  - Nagalla S
AD  - Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
FAU - Naik, U P
AU  - Naik UP
AD  - Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
FAU - Horrow, J C
AU  - Horrow JC
AD  - Merck & Co, Kenilworth, New Jersey, USA.
FAU - Wrishko, R E
AU  - Wrishko RE
AD  - Merck & Co, Kenilworth, New Jersey, USA.
FAU - Zhang, S
AU  - Zhang S
AD  - Merck & Co, Kenilworth, New Jersey, USA.
FAU - Anderson, M S
AU  - Anderson MS
AD  - Merck & Co, Kenilworth, New Jersey, USA.
LA  - eng
GR  - R01 HL113188/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160615
PL  - United States
TA  - Clin Transl Sci
JT  - Clinical and translational science
JID - 101474067
RN  - 0 (Lactones)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, Thrombin)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
RN  - ZCE93644N2 (vorapaxar)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation Tests
MH  - Drug Therapy, Combination
MH  - Female
MH  - *Healthy Volunteers
MH  - Humans
MH  - Lactones/administration & dosage/blood/pharmacokinetics/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Pyridines/administration & dosage/blood/pharmacokinetics/*pharmacology
MH  - Receptors, Thrombin/agonists
MH  - Young Adult
PMC - PMC5351335
EDAT- 2016/06/16 06:00
MHDA- 2017/04/25 06:00
CRDT- 2016/06/16 06:00
PHST- 2016/01/20 00:00 [received]
PHST- 2016/05/17 00:00 [revised]
PHST- 2016/05/12 00:00 [accepted]
PHST- 2016/06/16 06:00 [entrez]
PHST- 2016/06/16 06:00 [pubmed]
PHST- 2017/04/25 06:00 [medline]
AID - CTS12405 [pii]
AID - 10.1111/cts.12405 [doi]
PST - ppublish
SO  - Clin Transl Sci. 2016 Aug;9(4):221-7. doi: 10.1111/cts.12405. Epub 2016 Jun 15.

PMID- 8329296
OWN - NLM
STAT- MEDLINE
DCOM- 19930819
LR  - 20190512
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 35
IP  - 6
DP  - 1993 Jun
TI  - A clinical trial of a slow-release formulation of acetylsalicylic acid in 
      patients at risk for preeclampsia.
PG  - 664-7
AB  - The formation of thromboxane A2 (TXA2) in maternal and foetal cord serum was 
      measured at birth in eight control patients and in 13 patients taking 100 mg of a 
      slow-release formulation of acetylsalicylic acid. The serum concentrations of 
      TXB2 (a stable end product of TXA2 hydrolysis) in both maternal and cord serum 
      from patients who ingested the acetylsalicylic acid formulation were 
      significantly lower (P < 0.01) than those in control subjects. Acetylsalicylic 
      acid was not detected (< 30 ng ml-1) in maternal plasma from six mothers and in 
      cord plasma from seven foetuses in the acetylsalicylic acid-treated group. The 
      mean cord to maternal plasma concentration ratios for detectable acetylsalicylic 
      acid and salicylate were 0.62 +/- 0.19 (s.d.) (n = 6) and 0.84 +/- 0.16 (n = 13), 
      respectively. We conclude that low doses of acetylsalicylic acid given in a 
      slow-release form to mothers during pregnancy cause depression of TXA2 formation 
      in the foetal blood.
FAU - Shen, J
AU  - Shen J
AD  - School of Pharmacy, University of Otago, Dunedin, New Zealand.
FAU - Wanwimolruk, S
AU  - Wanwimolruk S
FAU - Wilson, P D
AU  - Wilson PD
FAU - Seddon, R J
AU  - Seddon RJ
FAU - Roberts, M S
AU  - Roberts MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Salicylates)
RN  - 57576-52-0 (Thromboxane A2)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Delayed-Action Preparations
MH  - Female
MH  - Fetal Blood/chemistry
MH  - Humans
MH  - Indicators and Reagents
MH  - Infant, Newborn
MH  - Maternal-Fetal Exchange
MH  - Pre-Eclampsia/*blood
MH  - Pregnancy
MH  - Risk
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Thromboxane A2/*blood
PMC - PMC1381614
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1993.tb04200.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1993 Jun;35(6):664-7. doi: 
      10.1111/j.1365-2125.1993.tb04200.x.

PMID- 20930165
OWN - NLM
STAT- MEDLINE
DCOM- 20101116
LR  - 20181201
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 41
IP  - 11
DP  - 2010 Nov
TI  - Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause 
      for concern?
PG  - 2690-2
LID - 10.1161/STROKEAHA.109.576975 [doi]
AB  - BACKGROUND AND PURPOSE: In a randomized controlled trial in Alzheimer's disease 
      (AD), we found a higher number of intracerebral hemorrhages (ICHs) in patients 
      randomized to aspirin treatment. Here, we evaluate the literature on the risk of 
      ICH as a complication in patients with AD treated with aspirin. METHODS: 
      Systematic review and comparison of the occurrence of events over time between 
      the aspirin and control group in each trial using Cox regression analysis. 
      Estimated hazard ratios (HRs) were combined in a pooled HR. RESULTS: Two 
      randomized controlled trials on aspirin for AD were found. In the Evaluation of 
      Vascular Care in Alzheimer's Disease (EVA) trial (conducted in our center), 4.6% 
      of patients in the group receiving a multicomponent treatment that included 
      aspirin had an ICH (3/65; 95% confidence interval [CI], 1.0 to 12.9) versus 0% in 
      the control group (0/58; 95% CI, 0 to 6.2). In the Aspirin in Alzheimer's Disease 
      (AD2000) trial, these proportions were, respectively, 2.6% (4/156; 95% CI, 0.7 to 
      6.4) and 0% (0/154; 95% CI, 0 to 2.4). The pooled proportion of ICHs in the 
      aspirin group is 3.2% (7/221; 95% CI, 1.3 to 6.4) versus 0% in the control group 
      (0/212; 95% CI, 0 to 1.7). The pooled HR for an ICH in AD patients using aspirin 
      is 7.63 (95% CI, 0.72 to 81.00; P=0.09). CONCLUSIONS: Although the number of 
      cases in both trials is small, our findings suggest that aspirin use in AD might 
      pose an increased risk of ICH, whereas it has no effect on cognition. If there is 
      an unequivocal cardiovascular indication for aspirin, it should not be withheld 
      in AD patients.
FAU - Thoonsen, Hanneke
AU  - Thoonsen H
AD  - Department of Neurology, Academic Medical Center, University of Amsterdam, 
      Amsterdam, The Netherlands.
FAU - Richard, Edo
AU  - Richard E
FAU - Bentham, Peter
AU  - Bentham P
FAU - Gray, Richard
AU  - Gray R
FAU - van Geloven, Nan
AU  - van Geloven N
FAU - De Haan, Rob J
AU  - De Haan RJ
FAU - Van Gool, Willem A
AU  - Van Gool WA
FAU - Nederkoorn, Paul J
AU  - Nederkoorn PJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20101007
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Evid Based Nurs. 2011 Jul;14(3):74. PMID: 21393306
MH  - Aged
MH  - Alzheimer Disease/*drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cerebral Hemorrhage/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Proportional Hazards Models
MH  - Risk Factors
EDAT- 2010/10/12 06:00
MHDA- 2010/11/17 06:00
CRDT- 2010/10/09 06:00
PHST- 2010/10/09 06:00 [entrez]
PHST- 2010/10/12 06:00 [pubmed]
PHST- 2010/11/17 06:00 [medline]
AID - STROKEAHA.109.576975 [pii]
AID - 10.1161/STROKEAHA.109.576975 [doi]
PST - ppublish
SO  - Stroke. 2010 Nov;41(11):2690-2. doi: 10.1161/STROKEAHA.109.576975. Epub 2010 Oct 
      7.

PMID- 34638150
OWN - NLM
STAT- MEDLINE
DCOM- 20220322
LR  - 20220809
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 122
IP  - 3
DP  - 2022 Mar
TI  - Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in 
      Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 
      Subjects from 21 Randomized Studies.
PG  - 445-455
LID - 10.1055/a-1667-7427 [doi]
AB  - AIMS: The efficacy and safety of aspirin for primary cardiovascular disease (CVD) 
      prevention is controversial. The aim of this study was to investigate the 
      efficacy and safety of aspirin in subjects with no overt CVD, with a focus on age 
      as a treatment modifier. METHODS AND RESULTS: Randomized trials comparing aspirin 
      use versus no aspirin use or placebo were included. The primary efficacy outcome 
      was all-cause death. The primary safety outcome was major bleeding. Secondary 
      ischemic and bleeding outcomes were explored. Subgroup analyses were conducted to 
      investigate the consistency of the effect sizes in studies including younger and 
      older individuals, using a cut-off of 65 years. A total of 21 randomized trials 
      including 173,810 individuals at a mean follow-up of 5.3 years were included. 
      Compared with control, aspirin did not reduce significantly the risk of all-cause 
      death (risk ratio: 0.96; 95% confidence interval: 0.92-1.00, p = 0.057). Major 
      adverse cardiovascular events were significantly reduced by 11%, paralleled by 
      significant reductions in myocardial infarction and transient ischemic attack. 
      Major bleeding, intracranial hemorrhage, and gastrointestinal bleeding were 
      significantly increased by aspirin. There was a significant age interaction for 
      death (p for interaction = 0.007), with aspirin showing a statistically 
      significant 7% relative benefit on all-cause death in studies including younger 
      patients. CONCLUSION: The use of aspirin in subjects with no overt CVD was 
      associated with a neutral effect on all-cause death and a modest lower risk of 
      major cardiovascular events at the price of an increased risk in major bleeding. 
      The benefit of aspirin might be more pronounced in younger individuals.
CI  - Thieme. All rights reserved.
FAU - Calderone, Dario
AU  - Calderone D
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco" University of Catania, Catania, Italy.
FAU - Greco, Antonio
AU  - Greco A
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco" University of Catania, Catania, Italy.
FAU - Ingala, Salvatore
AU  - Ingala S
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco" University of Catania, Catania, Italy.
FAU - Agnello, Federica
AU  - Agnello F
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco" University of Catania, Catania, Italy.
FAU - Franchina, Gabriele
AU  - Franchina G
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco" University of Catania, Catania, Italy.
FAU - Scalia, Lorenzo
AU  - Scalia L
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco" University of Catania, Catania, Italy.
FAU - Buccheri, Sergio
AU  - Buccheri S
AD  - Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
AD  - Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
FAU - Capodanno, Davide
AU  - Capodanno D
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco" University of Catania, Catania, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20211012
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - *Aspirin/administration & dosage/adverse effects
MH  - *Cardiovascular Diseases/epidemiology/prevention & control
MH  - Heart Disease Risk Factors
MH  - *Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Mortality
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Primary Prevention/methods
MH  - Treatment Outcome
COIS- D.C. reports advisory board or speaker's honoraria from Amgen, Daiichi Sankyo, 
      and Sanofi. All the other authors report no conflicts of interest.
EDAT- 2021/10/13 06:00
MHDA- 2022/03/23 06:00
CRDT- 2021/10/12 20:27
PHST- 2021/12/31 00:00 [accepted]
PHST- 2021/10/13 06:00 [pubmed]
PHST- 2022/03/23 06:00 [medline]
PHST- 2021/10/12 20:27 [entrez]
AID - 10.1055/a-1667-7427 [doi]
PST - ppublish
SO  - Thromb Haemost. 2022 Mar;122(3):445-455. doi: 10.1055/a-1667-7427. Epub 2021 Oct 
      12.

PMID- 8125801
OWN - NLM
STAT- MEDLINE
DCOM- 19940411
LR  - 20161123
IS  - 0017-6192 (Print)
IS  - 0017-6192 (Linking)
VI  - 41
IP  - 12
DP  - 1993 Dec
TI  - [Intranasal provocation with lysine acetylsalicylic acid].
PG  - 577-81
AB  - At present provocation tests are indispensible tools for diagnosing 
      acetylsalicylic acid (ASA) intolerance, which is often associated with nasal 
      polyps. Reliable oral and inhalation provocation tests are time-consuming 
      procedures that often cause the patient discomfort because of accompanying 
      reactions. These tests are therefore best done with the patient hospitalized. 
      Studies concerning the sensitivity, specificity and tolerance of the new 
      intranasal provocation procedure using lysine-ASA were based primarily on cases 
      of bronchial asthma and yielded differing results. Our aim was to examine the 
      above parameters in a large group of patients with nasal polyps (n = 153) and to 
      compare this method with the oral ASA procedure. Intranasal provocation with 2 mg 
      lysine-ASA revealed a sensitivity of 0.47 (n = 30) and a specificity of 0.91 (n = 
      105), with the test period lasting 40 min. A modified provocation test with 2, 4 
      and 10 mg lysine-ASA and a 100 min test period resulted in a sensitivity of 0.67 
      (n = 15) and a specificity of 0.84 (n = 37). All in all, only 2 patients reacted 
      to the test with signs of bronchial asthma. Other reactions to the provocations 
      were limited to the upper respiratory tract or were only found with 
      rhinomanometry. These findings show that nasal provocation with lysine-ASA can be 
      helpful in determining whether an oral provocation test is indicated. The 
      procedure does not take very long, is well-tolerated and can be done in the 
      outpatient department.
FAU - Wellbrock, M
AU  - Wellbrock M
AD  - Klinik für Hals-, Nasen- und Ohrenheilkunde, Kopf- und Halschirurgie, Universität 
      Kiel.
FAU - Mertens, J
AU  - Mertens J
FAU - Cornelius, M
AU  - Cornelius M
FAU - Brasch, J
AU  - Brasch J
LA  - ger
PT  - Journal Article
TT  - Intranasale Provokation mit Lysinazetylsalizylsäure.
PL  - Germany
TA  - HNO
JT  - HNO
JID - 2985099R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/*adverse effects/*analogs & derivatives
MH  - Asthma/*diagnosis
MH  - Child
MH  - Drug Hypersensitivity/*diagnosis
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/complications
MH  - Nasal Provocation Tests/*methods
MH  - Recurrence
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
PST - ppublish
SO  - HNO. 1993 Dec;41(12):577-81.

PMID- 1363390
OWN - NLM
STAT- MEDLINE
DCOM- 19930402
LR  - 20161013
IS  - 0929-6646 (Print)
IS  - 0929-6646 (Linking)
VI  - 91
IP  - 9
DP  - 1992 Sep
TI  - Dissociation of inhibitory effects of low-dose ASA on thromboxane production and 
      platelet aggregation in ischemic stroke patients.
PG  - 891-7
AB  - Acetylsalicylic acid (ASA) inhibits thromboxane production and hence platelet 
      aggregation. However, individual variations in platelet aggregability and serum 
      thromboxane B2 (TxB2) concentration after a low dose of ASA (40 mg/day) have been 
      reported. To clarify this issue, we studied plasma thromboxane levels and 
      platelet aggregation in 43 ischemic stroke patients. Of the 22 patients who 
      received 100 mg of ASA daily, dissociation between inhibitory effects of ASA on 
      the plasma TxB2 level and threshold concentrations of adenosine diphosphate was 
      found in three cases after one month of drug administration, and in three cases 
      after six, 12 and 18 months of ASA therapy. This dissociation also developed in 
      two patients after one month and six months, respectively, of treatment in the 21 
      patients who received 300 mg of ASA daily. The dissociation between the 
      inhibitory effects on plasma TxB2 and the circulating platelet aggregate ratio 
      was found in two cases after taking medication for one month, and in four cases 
      after six, 12, 18 and 24 months of therapy in the 100 mg ASA group. In the 300 mg 
      ASA group, dissociation was noted in two cases after one month of medication, and 
      in two cases after six and 12 months of medication. In these patients, although 
      their TxB2 levels were inhibited to almost unmeasurable levels, platelet 
      aggregation was still not inhibited. This ASA inhibitory dissociation phenomenon 
      on platelet function may be due to the low dose of ASA, individual differences in 
      platelet function in response to ASA therapy, or factors other than those 
      involved in the cyclooxygenase system.
FAU - Lee, T K
AU  - Lee TK
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei, 
      R.O.C.
FAU - Ng, S K
AU  - Ng SK
FAU - Huang, Z S
AU  - Huang ZS
FAU - Chen, Y C
AU  - Chen YC
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - J Formos Med Assoc
JT  - Journal of the Formosan Medical Association = Taiwan yi zhi
JID - 9214933
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cerebrovascular Disorders/*blood/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane B2/*blood
EDAT- 1992/09/01 00:00
MHDA- 1992/09/01 00:01
CRDT- 1992/09/01 00:00
PHST- 1992/09/01 00:00 [pubmed]
PHST- 1992/09/01 00:01 [medline]
PHST- 1992/09/01 00:00 [entrez]
PST - ppublish
SO  - J Formos Med Assoc. 1992 Sep;91(9):891-7.

PMID- 25938899
OWN - NLM
STAT- MEDLINE
DCOM- 20150814
LR  - 20220408
IS  - 1211-4286 (Print)
IS  - 1211-4286 (Linking)
VI  - 57
IP  - 4
DP  - 2014
TI  - ASPIRIN RESISTANCE IN NEUROVASCULAR DISEASES.
PG  - 157-61
LID - 10.14712/18059694.2015.81 [doi]
AB  - INTRODUCTION: The issue of resistance to antiplatelet therapy has raised many 
      questions in the area of neurovascular diseases. The first objective of this work 
      was to determine the prevalence of aspirin resistance in neurovascular patients 
      with clinical non-responsiveness to aspirin treatment and a high-risk of 
      atherothrombotic complications using two interpretable and independent methods 
      (aggregation and PFA 100). The second objective was to find the correlation 
      between both assays and to evaluate the results in groups at risk for various 
      cerebrovascular diseases. MATERIAL AND METHODS: Laboratory tests of aspirin 
      resistance were performed in 79 patients with clinical non-responsiveness to 
      aspirin treatment suffering from neurovascular diseases. Patients were divided 
      into the two groups: expected low risk for aspirin resistance due to the first 
      manifestation of a neurovascular disease (n = 34) and expected high risk due to 
      the second clinical manifestation of a neurovascular disease (n = 45). RESULTS: 
      The prevalence of aspirin resistance in both groups combined as determined by the 
      PFA-100 and CPG techniques were 50.6% and 17.7%, respectively. No correlation was 
      found between the two techniques. CONCLUSIONS: No significant prevalence of 
      aspirin resistance was demonstrated by either method despite the heterogeneous 
      pathophysiological mechanisms. However, we are presently unable to provide an 
      accurate opinion on the value of laboratory test result or routine monitoring in 
      clinical neurology.
FAU - Vališ, Martin
AU  - Vališ M
AD  - University Hospital Hradec Králové and Charles University in Prague, Faculty of 
      Medicine in Hradec Králové, Comprehensive Department of Neurology, Stroke Center, 
      Czech Republic. Valismar@seznam.cz.
FAU - Krajíčková, Dagmar
AU  - Krajíčková D
AD  - University Hospital Hradec Králové and Charles University in Prague, Faculty of 
      Medicine in Hradec Králové, Comprehensive Department of Neurology, Stroke Center, 
      Czech Republic.
FAU - Malý, Jaroslav
AU  - Malý J
AD  - University Hospital Hradec Králové and Charles University in Prague, Faculty of 
      Medicine in Hradec Králové, Department of Internal Medicine, Czech Republic.
FAU - Malý, Radovan
AU  - Malý R
AD  - University Hospital Hradec Králové and Charles University in Prague, Faculty of 
      Medicine in Hradec Králové, Department of Internal Medicine, Czech Republic.
FAU - Fátorová, Ilona
AU  - Fátorová I
AD  - University Hospital Hradec Králové and Charles University in Prague, Faculty of 
      Medicine in Hradec Králové, Department of Internal Medicine, Czech Republic.
FAU - Vyšata, Oldřich
AU  - Vyšata O
AD  - Department of Computing and Control Engineering, Institute of Chemical 
      Technology, Prague, Czech Republic.
FAU - Herzig, Roman
AU  - Herzig R
AD  - University Hospital Hradec Králové and Charles University in Prague, Faculty of 
      Medicine in Hradec Králové, Comprehensive Department of Neurology, Stroke Center, 
      Czech Republic.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Czech Republic
TA  - Acta Medica (Hradec Kralove)
JT  - Acta medica (Hradec Kralove)
JID - 9705947
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Cerebrovascular Disorders/*drug therapy
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Prevalence
EDAT- 2015/05/06 06:00
MHDA- 2015/08/15 06:00
CRDT- 2015/05/05 06:00
PHST- 2015/05/05 06:00 [entrez]
PHST- 2015/05/06 06:00 [pubmed]
PHST- 2015/08/15 06:00 [medline]
AID - 10.14712/18059694.2015.81 [doi]
PST - ppublish
SO  - Acta Medica (Hradec Kralove). 2014;57(4):157-61. doi: 10.14712/18059694.2015.81.

PMID- 1941549
OWN - NLM
STAT- MEDLINE
DCOM- 19911224
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 80
IP  - 6
DP  - 1991 Jun
TI  - Solid-state reaction between sulfadiazine and acetylsalicylic acid.
PG  - 564-6
AB  - Kinetic data for the solid-state reaction of sulfadiazine and acetylsalicylic 
      acid are presented. A compaction method was used to observe the influence of 
      applied pressure, particle size, and temperature on the reaction rate.
FAU - Liu, L R
AU  - Liu LR
AD  - College of Pharmacy, University of Iowa, Iowa City 52242.
FAU - Parrott, E L
AU  - Parrott EL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0N7609K889 (Sulfadiazine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/*chemistry
MH  - Chemistry, Pharmaceutical
MH  - Drug Stability
MH  - Kinetics
MH  - Pressure
MH  - Sulfadiazine/*chemistry
MH  - Temperature
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
AID - S0022-3549(15)48575-2 [pii]
AID - 10.1002/jps.2600800614 [doi]
PST - ppublish
SO  - J Pharm Sci. 1991 Jun;80(6):564-6. doi: 10.1002/jps.2600800614.

PMID- 18422393
OWN - NLM
STAT- MEDLINE
DCOM- 20080925
LR  - 20181201
IS  - 1175-3277 (Print)
IS  - 1175-3277 (Linking)
VI  - 8
IP  - 2
DP  - 2008
TI  - Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary 
      syndromes and percutaneous coronary intervention: role in therapy and strategies 
      to overcome resistance.
PG  - 91-112
AB  - Platelet activation and aggregation are key components in the cascade of events 
      causing thrombosis following plaque rupture. Antiplatelet therapy is essential in 
      the treatment of patients with acute coronary syndromes (ACS) and for those 
      requiring percutaneous coronary intervention (PCI). Aspirin (acetylsalicylic 
      acid) is a well established antiplatelet therapy and is mandated for secondary 
      prevention of cardiovascular events following ACS. In patients with ACS, the 
      addition of clopidogrel to aspirin is more effective than aspirin alone. For 
      patients undergoing PCI, dual antiplatelet therapy with aspirin and clopidogrel 
      is warranted. Aspirin should be continued indefinitely after PCI. Pretreatment of 
      patients with clopidogrel prior to PCI lowers the incidence of cardiovascular 
      events, yet the optimum timing of drug administration and dose are still being 
      investigated, as is the duration of therapy following PCI. Late-stent thrombosis 
      with drug-eluting stents has pushed the recommendation for duration of 
      clopidogrel therapy up to 1 year and perhaps beyond, in patients without risks 
      for bleeding. The concepts of aspirin and clopidogrel resistance are important 
      clinical questions. No uniform definition exists for aspirin or clopidogrel 
      resistance. Measurements of resistance are often highly variable and do not 
      necessarily correlate with clinical resistance. Noncompliance remains the most 
      prominent mode of resistance. Screening of selected patient populations for 
      resistance or pharmacologic intervention of those patients termed 'resistant' 
      warrants further study.
FAU - Depta, Jeremiah P
AU  - Depta JP
AD  - Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA. 
      DLBHATTMD@ALUM.MIT.EDU
FAU - Bhatt, Deepak L
AU  - Bhatt DL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2 Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Purinergic P2 Receptor Antagonists
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
MH  - Treatment Outcome
RF  - 223
EDAT- 2008/04/22 09:00
MHDA- 2008/09/26 09:00
CRDT- 2008/04/22 09:00
PHST- 2008/04/22 09:00 [pubmed]
PHST- 2008/09/26 09:00 [medline]
PHST- 2008/04/22 09:00 [entrez]
AID - 824 [pii]
AID - 10.1007/BF03256587 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2008;8(2):91-112. doi: 10.1007/BF03256587.

PMID- 34330595
OWN - NLM
STAT- MEDLINE
DCOM- 20211210
LR  - 20211214
IS  - 0965-206X (Print)
IS  - 0965-206X (Linking)
VI  - 30
IP  - 4
DP  - 2021 Nov
TI  - Once daily 300 mg aspirin with compression versus compression alone in patients 
      with chronic venous leg ulcers (ASPiVLU): A randomised, double-blinded, 
      multicentre, placebo-controlled, clinical trial.
PG  - 509-516
LID - S0965-206X(21)00090-5 [pii]
LID - 10.1016/j.jtv.2021.07.005 [doi]
AB  - AIM: Venous leg ulcers are lower limb skin ulcers characterised by a cycle of 
      healing and recurrence due to underlying chronic venous insufficiency. While 
      compression improves healing outcomes, many ulcers do not heal. As a daily 300 mg 
      oral dose of aspirin in conjunction with compression may improve healing 
      outcomes, we investigated the effect of adjuvant aspirin on venous leg ulcer 
      healing in participants already receiving compression. MATERIALS AND METHODS: We 
      conducted a prospective, randomised, double-blinded, placebo-controlled, clinical 
      trial (known as ASPiVLU). Participants were recruited from six wound clinics in 
      Australia. We screened 844 participants. Community-dwelling adult participants 
      identified at six hospital outpatient clinics and clinically diagnosed with a 
      venous leg ulcer present for 6+ weeks were eligible between April 13, 2015 to 
      June 30, 2018. We randomised 40 participants (n = 19 aspirin, n = 21 placebo) and 
      evaluated against the primary outcome. There were no dropouts. Ten serious 
      adverse events in six participants were recorded. None were study related. The 
      primary outcome measure was healing at 12 weeks based on blinded assessment. 
      RESULTS: We found no difference in the number of ulcers healed at 12 weeks 
      between the intervention and control groups. CONCLUSION: This study could not 
      detect whether or not aspirin affected VLU healing speed. This is likely because 
      we recruited fewer participants than expected due to the high number of people 
      with venous leg ulcers in Australia who were already taking Aspirin; future 
      research should investigate other adjuvant therapies or different study designs.
CI  - Copyright © 2021 Tissue Viability Society. Published by Elsevier Ltd. All rights 
      reserved.
FAU - Weller, Carolina D
AU  - Weller CD
AD  - Monash Nursing and Midwifery, Level 5 Alfred Centre, 99 Commercial Road, 
      Melbourne, VIC, 3004, Australia. Electronic address: carolina.weller@monash.edu.
FAU - Martin, Catherine
AU  - Martin C
AD  - Monash Public Health and Preventive Medicine, 553 St Kilda Road, Melbourne, VIC, 
      3800, Australia. Electronic address: cathy.martin@monash.edu.
FAU - Bouguettaya, Ayoub
AU  - Bouguettaya A
AD  - University of Birmingham, School of Psychology, Edgbaston, Birmingham, B152TT, 
      United Kingdom. Electronic address: a.bouguettaya@bham.ac.uk.
FAU - Underwood, Martin
AU  - Underwood M
AD  - The University of Warwick, Clinical Trials Unit, Coventry, CV4 7AL, United 
      Kingdom. Electronic address: Martin.Underwood@monash.edu.
FAU - Barker, Anna L
AU  - Barker AL
AD  - Monash Public Health and Preventive Medicine, 553 St Kilda Road, Melbourne, VIC, 
      3800, Australia. Electronic address: anna.barker@monash.edu.
FAU - Haines, Terry
AU  - Haines T
AD  - Monash University, School of Primary and Allied Health Care, McMahons Rd, 
      Frankston, VIC, 3199, Australia. Electronic address: terry.haines@monash.edu.
FAU - Pouniotis, Dodie
AU  - Pouniotis D
AD  - School of Health and Biomedical Sciences, RMIT University, Plenty Road, Bundoora, 
      VIC, 3083, Australia. Electronic address: dodie.pouniotis@rmit.edu.au.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - Monash Public Health and Preventive Medicine, 553 St Kilda Road, Melbourne, VIC, 
      3800, Australia. Electronic address: Rory.Wolfe@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20210725
PL  - England
TA  - J Tissue Viability
JT  - Journal of tissue viability
JID - 9306822
RN  - R16CO5Y76E (Aspirin)
MH  - Adult
MH  - *Aspirin/therapeutic use
MH  - Compression Bandages
MH  - Humans
MH  - Prospective Studies
MH  - *Varicose Ulcer/drug therapy
MH  - Wound Healing
OTO - NOTNLM
OT  - Adjuvant
OT  - Aspirin
OT  - Compression
OT  - Randomised controlled trial
OT  - Venous leg ulcers
EDAT- 2021/08/01 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/07/31 06:25
PHST- 2020/11/27 00:00 [received]
PHST- 2021/07/21 00:00 [revised]
PHST- 2021/07/22 00:00 [accepted]
PHST- 2021/08/01 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/07/31 06:25 [entrez]
AID - S0965-206X(21)00090-5 [pii]
AID - 10.1016/j.jtv.2021.07.005 [doi]
PST - ppublish
SO  - J Tissue Viability. 2021 Nov;30(4):509-516. doi: 10.1016/j.jtv.2021.07.005. Epub 
      2021 Jul 25.

PMID- 14762100
OWN - NLM
STAT- MEDLINE
DCOM- 20040701
LR  - 20171116
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 309
IP  - 3
DP  - 2004 Jun
TI  - Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates 
      antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl 
      ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence.
PG  - 1174-82
AB  - 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) is a nitric 
      oxide (NO)-releasing derivative of aspirin that inhibits cyclooxygenase (COX) 
      activity and releases NO. Acetylation of COX-2 by aspirin activates a 
      transcellular biosynthetic pathway that switches eicosanoid biosynthesis from 
      prostaglandin E(2) to 15-epi-lipoxin (LX)A(4) or aspirin-triggered lipoxin (ATL). 
      Here, we demonstrate that exposure of neutrophil (PMN)/human umbilical vein 
      endothelial cell (HUVEC) cocultures to aspirin and NCX-4016 triggers ATL 
      formation and inhibits cell-to-cell adhesion induced by endotoxin (LPS) and 
      interleukin (IL)-1beta by 70 to 90%. However, although selective and nonselective 
      COX-2 inhibitors (celecoxib, rofecoxib, and naproxen) or 
      N-t-butoxycarbonylmethionine-leucine-phenylalanine (Boc-1), an LXA(4) receptor 
      antagonist, reduced the antiadhesive properties of aspirin by approximately 70%, 
      antiadhesive effects of NCX-4016 were only marginally affected ( approximately 
      30%) by COX inhibitors and Boc-1, implying that COX-independent mechanisms 
      mediate the antiadhesive properties of NCX-4016. Indeed, NCX-4016 causes a 
      long-lasting (up to 12 h) release of NO and cGMP accumulation in HUVEC. 
      Scavenging NO with 10 mM hemoglobin, in the presence of celecoxib, reduced the 
      antiadhesive properties of NCX-4016 by approximately 80%. Confirming a role for 
      NO, the NO donor diethylenetriamine-NO also inhibited PMN/HUVEC adhesion by 
      approximately 80%. NCX-4016, but not aspirin, decreased DNA binding of nuclear 
      factor-kappaB (NF-kappaB) on gel shift analysis and HUVEC's overexpression of 
      CD54 and CD62E induced by LPS/IL-1beta. Reduction of binding of the two NF-kappaB 
      subunits p50-p50 and p50-p65 was reversed by dithiothreitol, implying 
      S-nitrosylation as mechanism of inhibition. In summary, our results support that 
      ATL and NO are formed at the PMN/HUVEC interface after exposure to NCX-4016 and 
      mediate the antiadhesive properties of this compound.
FAU - Fiorucci, Stefano
AU  - Fiorucci S
AD  - Clinica di Gastroenterologia ed Endoscopia Digestiva, Policlinico Monteluce, 
      06100 Perugia, Italy. fiorucci@unipg.it
FAU - Distrutti, Eleonora
AU  - Distrutti E
FAU - Mencarelli, Andrea
AU  - Mencarelli A
FAU - Rizzo, Giovanni
AU  - Rizzo G
FAU - Lorenzo, Anna Rita Di
AU  - Lorenzo AR
FAU - Baldoni, Monia
AU  - Baldoni M
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Morelli, Antonio
AU  - Morelli A
FAU - Wallace, John L
AU  - Wallace JL
LA  - eng
PT  - Journal Article
DEP - 20040204
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipoxins)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Pharmacol Exp Ther. 2009 May;329(2):848. PMID: 19389939
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Cell Adhesion/*drug effects
MH  - Cells, Cultured
MH  - Drug Interactions
MH  - Endothelium, Vascular/cytology/*drug effects
MH  - Humans
MH  - Lipoxins/pharmacology
MH  - Neutrophils/cytology/*drug effects
MH  - Nitric Oxide/physiology
EDAT- 2004/02/06 05:00
MHDA- 2004/07/02 05:00
CRDT- 2004/02/06 05:00
PHST- 2004/02/06 05:00 [pubmed]
PHST- 2004/07/02 05:00 [medline]
PHST- 2004/02/06 05:00 [entrez]
AID - jpet.103.063651 [pii]
AID - 10.1124/jpet.103.063651 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2004 Jun;309(3):1174-82. doi: 10.1124/jpet.103.063651. Epub 
      2004 Feb 4.

PMID- 21150234
OWN - NLM
STAT- MEDLINE
DCOM- 20110620
LR  - 20131121
IS  - 1423-0313 (Electronic)
IS  - 0031-7012 (Linking)
VI  - 87
IP  - 1-2
DP  - 2011
TI  - Hemoptysis under diclofenac and antiplatelet doses of aspirin.
PG  - 1-4
LID - 10.1159/000321728 [doi]
AB  - A previously healthy 60-year-old man receiving aspirin for primary prevention of 
      cardiovascular disease presented with hemoptysis after 1 week of treatment for 
      his back pain with diclofenac. He had not suffered from any bleeding episode in 
      the past and his family history was negative for hemorrhagic disorders. He had 
      been a heavy smoker until his thirties, but had stopped smoking since then. After 
      extensive workup, other pulmonary and nonpulmonary causes of hemoptysis were 
      ruled out. Thus, in this case, because of the temporal relationship between 
      exposure to the drug and the onset of symptoms, diclofenac was considered as the 
      most probable cause of hemoptysis either alone or as a result of its 
      pharmacodynamic interaction with aspirin. The adverse reaction was considered 
      probable according to the Naranjo scale. Diclofenac treatment was discontinued 
      and occasional use of acetaminophen for the back pain was recommended. Regular 
      use of antiplatelet doses of aspirin was also discontinued.
CI  - Copyright © 2010 S. Karger AG, Basel.
FAU - Yiannakopoulou, Eugenia C
AU  - Yiannakopoulou EC
AD  - Department of Basic Medical Lessons, Faculty of Health and Caring Professions, 
      Technological Educational Institute of Athens, Athens, Greece. nyiannak@teiath.gr
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20101208
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Back Pain/drug therapy
MH  - Cardiovascular Diseases/prevention & control
MH  - Diclofenac/*adverse effects/therapeutic use
MH  - Drug Interactions
MH  - Hemoptysis/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nonprescription Drugs/administration & dosage/adverse effects/therapeutic use
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Treatment Outcome
EDAT- 2010/12/15 06:00
MHDA- 2011/06/21 06:00
CRDT- 2010/12/15 06:00
PHST- 2010/09/13 00:00 [received]
PHST- 2010/10/04 00:00 [accepted]
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/06/21 06:00 [medline]
AID - 000321728 [pii]
AID - 10.1159/000321728 [doi]
PST - ppublish
SO  - Pharmacology. 2011;87(1-2):1-4. doi: 10.1159/000321728. Epub 2010 Dec 8.

PMID- 7028626
OWN - NLM
STAT- MEDLINE
DCOM- 19820128
LR  - 20200304
IS  - 0360-3997 (Print)
IS  - 0360-3997 (Linking)
VI  - 5
IP  - 3
DP  - 1981 Sep
TI  - Diflunisal in rheumatoid arthritis.
PG  - 253-61
AB  - In an eight-week double-blind study comparing the new long-acting aspirin 
      derivative, diflunisal, in doses up to 1 g/day with aspirin in doses up to 4 
      g/day in 16 patients with classical or definite rheumatoid arthritis, diflunisal 
      was more effective in reducing the total articular index (Ritchie) and 
      erythrocyte sedimentation rate and in increasing grip strength. Diflunisal had an 
      earlier effect on erythrocyte sedimentation rate than antiinflammatory doses of 
      aspirin. Patients on diflunisal experienced fewer side effects than patients on 
      aspirin. Ten patients with rheumatoid arthritis who previously participated in 
      the eight-week study comparing diflunisal to aspirin (five patients from each 
      group) were continued on 1 g diflunisal per day for six months. The efficacy of 
      diflunisal therapy persisted during a six-month period, and there were no side 
      effects. The switchover from 4g aspirin to 1g diflunisal a day was accompanied by 
      further improvement in the Ritchie total score, erythrocyte sedimentation rate, 
      and grip strength and by disappearance of side effects. Diflunisal 1 g/day proved 
      to be an efficient and well-tolerated drug in patients with rheumatoid arthritis.
FAU - Fishel, B
AU  - Fishel B
FAU - Weiss, S
AU  - Weiss S
FAU - Yaron, M
AU  - Yaron M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Inflammation
JT  - Inflammation
JID - 7600105
RN  - 0 (Salicylates)
RN  - 7C546U4DEN (Diflunisal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Sedimentation
MH  - Clinical Trials as Topic
MH  - Diflunisal/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/*therapeutic use
MH  - Time Factors
EDAT- 1981/09/01 00:00
MHDA- 1981/09/01 00:01
CRDT- 1981/09/01 00:00
PHST- 1981/09/01 00:00 [pubmed]
PHST- 1981/09/01 00:01 [medline]
PHST- 1981/09/01 00:00 [entrez]
AID - 10.1007/BF00914448 [doi]
PST - ppublish
SO  - Inflammation. 1981 Sep;5(3):253-61. doi: 10.1007/BF00914448.

PMID- 2214185
OWN - NLM
STAT- MEDLINE
DCOM- 19901106
LR  - 20131121
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 31
IP  - 7
DP  - 1990 Jul
TI  - [Fetal survival after the corticosteroid and low-dose aspirin regimen in a case 
      of anti-phospholipid antibody syndrome].
PG  - 1034-5
AB  - A 27-year-old woman with anti-phospholipid antibody syndrome, whose first 
      pregnancy had ended in intrauterine fetal death, was treated with prednisolone 
      0.6 mg/kg/day before second pregnancy. Suppression of anti-cardiolipin antibody 
      activity was rapidly achieved and maintained during the pregnancy. After 
      conception, low-dose aspirin 81 mg/day was started and continued until delivery. 
      She gave birth to a normal live infant with natural full-term delivery. It is 
      strongly suggested that the corticosteroid and low-dose aspirin regimen can lead 
      to successful pregnancy in cases with anti-phospholipid antibody syndrome like 
      the present case.
FAU - Shimmyozu, K
AU  - Shimmyozu K
AD  - Third Department of Internal Medicine, Kagoshima University, School of Medicine, 
      Japan.
FAU - Okadome, T
AU  - Okadome T
FAU - Maruyama, Y
AU  - Maruyama Y
FAU - Maruyama, I
AU  - Maruyama I
FAU - Osame, M
AU  - Osame M
FAU - Tara, M
AU  - Tara M
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - 0 (Autoantibodies)
RN  - 0 (Phospholipids)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Autoantibodies/*metabolism
MH  - Autoimmune Diseases/*drug therapy/immunology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fetal Death/*prevention & control
MH  - Humans
MH  - Phospholipids/*immunology
MH  - Prednisolone/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy/immunology
MH  - Syndrome
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
PST - ppublish
SO  - Rinsho Ketsueki. 1990 Jul;31(7):1034-5.

PMID- 1909906
OWN - NLM
STAT- MEDLINE
DCOM- 19911024
LR  - 20131121
IS  - 0921-8319 (Print)
IS  - 0921-8319 (Linking)
VI  - 4
IP  - 1
DP  - 1991 Jul-Aug
TI  - Dipyridamole potentiates the inhibition of platelet aggregation by aspirin (in 
      human platelet rich plasma and whole blood).
PG  - 61-7
AB  - This study investigates the influence of dipyridamole on platelet aggregation as 
      evaluated by a single agonist or a pair of agonists in human platelet rich plasma 
      and whole blood. Dipyridamole up to 30 microM was not found to influence the 
      platelet aggregation of platelet rich plasma or whole blood; aspirin (100 
      microM), on the contrary, did inhibit platelet aggregation. The inhibition of 
      platelet aggregation by aspirin could be reversed by using high concentrations of 
      agonists or pairs of agonists. In this model dipyridamole inhibited platelet 
      aggregation in both platelet rich plasma and whole blood in a dose-dependent 
      fashion. Thromboxane A2 was less than 10% of controls in aspirin-treated PRP 
      stimulated with low or high concentrations of collagen or with a pair of 
      agonists. This study suggests that dipyridamole has direct antiplatelet activity 
      in platelet rich plasma and whole blood when the cyclooxygenase pathway is 
      blocked by aspirin.
FAU - Violi, F
AU  - Violi F
AD  - University of Rome, La Sapienza, Italy.
FAU - Praticò, D
AU  - Praticò D
FAU - Iuliano, L
AU  - Iuliano L
FAU - Balsano, F
AU  - Balsano F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Lipid Mediat
JT  - Journal of lipid mediators
JID - 8913460
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Cyclooxygenase Inhibitors
MH  - Dipyridamole/blood/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Plasma/*drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thromboxane A2/blood
EDAT- 1991/07/01 00:00
MHDA- 1991/07/01 00:01
CRDT- 1991/07/01 00:00
PHST- 1991/07/01 00:00 [pubmed]
PHST- 1991/07/01 00:01 [medline]
PHST- 1991/07/01 00:00 [entrez]
PST - ppublish
SO  - J Lipid Mediat. 1991 Jul-Aug;4(1):61-7.

PMID- 8411288
OWN - NLM
STAT- MEDLINE
DCOM- 19931117
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 35
IP  - 4
DP  - 1993 Oct
TI  - Use of base deficit to compare resuscitation with lactated Ringer's solution, 
      Haemaccel, whole blood, and diaspirin cross-linked hemoglobin following 
      hemorrhage in rats.
PG  - 619-25; discussion 625-6
AB  - Base deficit (BD) has been shown to be a sensitive measure of the degree and 
      duration of inadequate perfusion. We developed a rat model of hemorrhagic shock 
      based on achieving a fixed BD of 13 +/- 1 mmol/L before resuscitation. Using this 
      model, we compared the efficacy of resuscitation with lactated Ringer's solution 
      (LR), Haemaccel (a colloid), and whole blood with that of diaspirin cross-linked 
      hemoglobin (DCLHb, Baxter Healthcare Corp.) by evaluating improvements in BD and 
      restoration of base excess (BE, positive correlate of BD) for 60 minutes 
      following resuscitation. The DCLHb was superior to LR and Haemaccel in restoring 
      and maintaining BE following resuscitation, and was able to restore BE as rapidly 
      as whole blood at half the volume. At 60 minutes, DCLHb at twice the shed blood 
      volume maintained BE at higher (more positive) values compared with all other 
      treatment groups. We conclude that DCLHb is at least as effective as whole blood 
      and superior to LR and Haemaccel in restoring BE within the first 60 minutes 
      following resuscitation in this hemorrhagic shock model.
FAU - Schultz, S C
AU  - Schultz SC
AD  - Department of Surgery, Uniformed Services University of the Health Sciences, 
      Bethesda, Maryland 20814-4799.
FAU - Hamilton, I N Jr
AU  - Hamilton IN Jr
FAU - Malcolm, D S
AU  - Malcolm DS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Hemoglobins)
RN  - 0 (Isotonic Solutions)
RN  - 0 (Ringer's Lactate)
RN  - 9015-56-9 (Polygeline)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acid-Base Equilibrium/physiology
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Disease Models, Animal
MH  - Hemoglobins/*therapeutic use
MH  - Isotonic Solutions/*therapeutic use
MH  - Male
MH  - Polygeline/*therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Resuscitation/*methods
MH  - Ringer's Lactate
MH  - Shock, Hemorrhagic/*physiopathology/*therapy
EDAT- 1993/10/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
AID - 10.1097/00005373-199310000-00019 [doi]
PST - ppublish
SO  - J Trauma. 1993 Oct;35(4):619-25; discussion 625-6. doi: 
      10.1097/00005373-199310000-00019.

PMID- 15154
OWN - NLM
STAT- MEDLINE
DCOM- 19770512
LR  - 20190725
IS  - 0021-5198 (Print)
IS  - 0021-5198 (Linking)
VI  - 26
IP  - 6
DP  - 1976 Dec
TI  - Effects of L-glutamine on acetylsalycylic acid induced gastric lesions and acid 
      back diffusion in dogs.
PG  - 703-9
AB  - Effects of L-glutamine on acetylsalicylic acid (ASA)-induced gastric mucosal 
      lesions were studied in mongrel dogs. It was confirmed that when oral ASA at 1.0 
      or 2.0 g per dog is given in two divided doses, there is severe and consistent 
      dose-dependent mucosal damage in the glandular portion of the stomach in fasted 
      dogs. However, when L-glutamine 2.0 or 4.0 g per dog in two divided doses is 
      given concomitantly with ASA 2.0 g per dog orally, the gastric irritation is 
      significantly inhibited. Instillation of 20 mM of ASA in 100 mM HCl solution into 
      the Heidenhain pouch of Beagle dogs produced a significant loss of H+ from the 
      pouch and a gain of Na+ in the lumen compared with ASA-free controls. When 
      L-glutamine (100 mM) was given concomitantly with ASA (20 mM) into the pouch, 
      changes of electrolyte fluxes in response to ASA alone were significantly 
      suppressed. However, 50 mM of L-glutamine had no appreciable effect on acid back 
      diffusion caused by ASA 20 mM. The amino acid itself had little effect on the 
      ionic movement in the pouch. Gross bleeding from the pouch treated with ASA was 
      never observed with the concomitant dosing of ASA and L-glutamine 50 or 100 mM.
FAU - Hung, C R
AU  - Hung CR
FAU - Takeuchi, K
AU  - Takeuchi K
FAU - Okabe, S
AU  - Okabe S
FAU - Murata, T
AU  - Murata T
FAU - Takagi, K
AU  - Takagi K
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Jpn J Pharmacol
JT  - Japanese journal of pharmacology
JID - 2983305R
RN  - 0RH81L854J (Glutamine)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Animals
MH  - Aspirin/*antagonists & inhibitors/toxicity
MH  - Diffusion
MH  - Dogs
MH  - Gastric Mucosa/*drug effects
MH  - Glutamine/*pharmacology
MH  - Hydrogen-Ion Concentration
MH  - In Vitro Techniques
MH  - Male
MH  - Potassium/metabolism
MH  - Sodium/metabolism
MH  - Stomach Diseases/chemically induced/*prevention & control
EDAT- 1976/12/01 00:00
MHDA- 1976/12/01 00:01
CRDT- 1976/12/01 00:00
PHST- 1976/12/01 00:00 [pubmed]
PHST- 1976/12/01 00:01 [medline]
PHST- 1976/12/01 00:00 [entrez]
AID - 10.1254/jjp.26.703 [doi]
PST - ppublish
SO  - Jpn J Pharmacol. 1976 Dec;26(6):703-9. doi: 10.1254/jjp.26.703.

PMID- 22834712
OWN - NLM
STAT- MEDLINE
DCOM- 20130114
LR  - 20181201
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 8
IP  - 9
DP  - 2012 Sep
TI  - Combining aspirin and proton pump inhibitors: for whom the warning bell tolls?
PG  - 1051-5
LID - 10.1517/17425255.2012.711318 [doi]
AB  - Aspirin and clopidogrel are well-known antiplatelet agents that are widely used 
      across the spectrum of cardio- and cerebrovascular disease. Upper 
      gastrointestinal complications, including ulcer and bleeding, are relatively 
      common during antiplatelet treatment and, therefore, many patients are also 
      treated with a proton pump inhibitor (PPI). PPIs exert gastroprotection by 
      raising intragastric pH. In recent years, it has been heavily discussed whether 
      PPIs may reduce the cardiovascular protection by aspirin and, even more so, 
      clopidogrel. Initially, pharmacodynamic and pharmacokinetic studies suggested a 
      considerable drug interaction between PPIs and clopidogrel, and subsequent 
      clinical studies were conducted to evaluate the clinical impact of this 
      interaction. More recently, it has been reported that PPIs may also attenuate the 
      antiplatelet effect of aspirin. This is particularly interesting, because a fixed 
      combination of aspirin and a PPI (esomeprazole) has been developed and is 
      currently under approval. Given the large number of patients taking aspirin and 
      PPIs, even a small attenuation of the antiplatelet effect of aspirin may have 
      substantial clinical impact. The present editorial summarizes current evidence on 
      this drug interaction and discusses potential clinical implications.
FAU - Würtz, Morten
AU  - Würtz M
FAU - Grove, Erik Lerkevang
AU  - Grove EL
LA  - eng
PT  - Editorial
DEP - 20120727
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Drug Therapy, Combination/methods
MH  - Gastrointestinal Hemorrhage/etiology/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Proton Pump Inhibitors/*adverse effects/therapeutic use
MH  - Ticlopidine/analogs & derivatives/therapeutic use
EDAT- 2012/07/28 06:00
MHDA- 2013/01/15 06:00
CRDT- 2012/07/28 06:00
PHST- 2012/07/28 06:00 [entrez]
PHST- 2012/07/28 06:00 [pubmed]
PHST- 2013/01/15 06:00 [medline]
AID - 10.1517/17425255.2012.711318 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1051-5. doi: 
      10.1517/17425255.2012.711318. Epub 2012 Jul 27.

PMID- 28670938
OWN - NLM
STAT- MEDLINE
DCOM- 20181026
LR  - 20181026
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 31
IP  - 19
DP  - 2018 Oct
TI  - The effect of low-dose aspirin on fetal weight of idiopathic asymmetrically 
      intrauterine growth restricted fetuses with abnormal umbilical artery Doppler 
      indices: a randomized clinical trial.
PG  - 2611-2616
LID - 10.1080/14767058.2017.1350160 [doi]
AB  - OBJECTIVE: To investigate the effect of aspirin on fetal weight in fetuses with 
      idiopathic asymmetrical intrauterine growth restriction (IUGR) complicated by 
      abnormal umbilical artery Doppler indices. MATERIALS AND METHODS: The study was a 
      randomized controlled trial conducted at Woman's Health Hospital, Assiut, Egypt, 
      between June 2016 and the January 2017 included 60 pregnant women (28-30 weeks) 
      with idiopathic asymmetrical IUGR associated with abnormal umbilical artery 
      Doppler indices. Women were randomly assigned to group I (aspirin 75 mg) daily 
      for four weeks or group II (no intervention). The primary outcome was the fetal 
      weight after four weeks. Secondary outcomes included Doppler blood flow changes 
      in the umbilical artery plus delivery and neonatal outcomes. RESULTS: The 
      estimated fetal weight and umbilical artery blood flow increased significantly in 
      aspirin group (p = .00) when compared with no intervention group. As regard 
      neonatal outcomes; aspirin group showed better results and encouraging outcomes 
      (p < .05). CONCLUSIONS: Aspirin improves fetal weight and umbilical artery blood 
      flow in idiopathic asymmetrical IUGR fetuses complicated by abnormal umbilical 
      artery Doppler blood flow.
FAU - Ali, Mohammed K
AU  - Ali MK
AD  - a Department of Obstetrics & Gynecology , Woman's Health Hospital, Faculty of 
      Medicine, Assiut University , Assiut , Egypt.
FAU - Abbas, Ahmed M
AU  - Abbas AM
AD  - a Department of Obstetrics & Gynecology , Woman's Health Hospital, Faculty of 
      Medicine, Assiut University , Assiut , Egypt.
FAU - Yosef, Ali H
AU  - Yosef AH
AD  - a Department of Obstetrics & Gynecology , Woman's Health Hospital, Faculty of 
      Medicine, Assiut University , Assiut , Egypt.
FAU - Bahloul, Mustafa
AU  - Bahloul M
AD  - a Department of Obstetrics & Gynecology , Woman's Health Hospital, Faculty of 
      Medicine, Assiut University , Assiut , Egypt.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170711
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Birth Weight/*drug effects
MH  - Female
MH  - Fetal Growth Retardation/diagnostic imaging/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Pregnancy
MH  - Ultrasonography, Doppler
MH  - Ultrasonography, Prenatal
MH  - Umbilical Arteries/diagnostic imaging
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Doppler
OT  - fetal weight
OT  - intrauterine growth restriction
EDAT- 2017/07/04 06:00
MHDA- 2018/10/27 06:00
CRDT- 2017/07/04 06:00
PHST- 2017/07/04 06:00 [pubmed]
PHST- 2018/10/27 06:00 [medline]
PHST- 2017/07/04 06:00 [entrez]
AID - 10.1080/14767058.2017.1350160 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2018 Oct;31(19):2611-2616. doi: 
      10.1080/14767058.2017.1350160. Epub 2017 Jul 11.

PMID- 26367099
OWN - NLM
STAT- MEDLINE
DCOM- 20161226
LR  - 20161230
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 27
IP  - 3
DP  - 2016
TI  - Reduced aspirin responsiveness as assessed by impedance aggregometry is not 
      associated with adverse outcome after cardiac surgery in a small low-risk cohort.
PG  - 254-61
LID - 10.3109/09537104.2015.1083969 [doi]
AB  - Reduced aspirin responsiveness (i.e. persistent high platelet reactivity in 
      platelet function testing) might be associated with increased risk of myocardial 
      ischemia and cardiac mortality in patients with coronary disease. However, the 
      impact in patients undergoing coronary artery bypass grafting (CABG) is unclear. 
      The aim of this prospective cohort study was to evaluate the predictive value of 
      reduced aspirin responsiveness on cardiac and thromboembolic events in patients 
      undergoing elective isolated CABG surgery with aspirin intake until at least two 
      days before surgery. We included 304 patients in this prospective single-center 
      cohort study. Impedance platelet aggregometry (Multiplate®) was performed 
      directly before and on the first day after surgery. Reduced aspirin 
      responsiveness was defined as area under the curve in ASPItest (AUCASPI) ≥300 U. 
      The primary outcome was a composite of all-cause mortality and/or major adverse 
      cardiac or thromboembolic events within 1 year. Reduced aspirin responsiveness 
      was found in 13 and 24% of patients pre and postoperatively, respectively. There 
      was no difference in the outcomes between patients with normal and reduced 
      aspirin responsiveness in the preoperative measurement (log-rank test, p = 
      0.540). Multivariate analysis including logistic EuroSCORE I and postoperative 
      troponin T levels did not show any association of reduced aspirin responsiveness 
      with adverse outcome (hazard ratio, 0.576; (95% CI 0.128-2.585; p = 0.471). 
      Similarly, postoperative reduced aspirin responsiveness was not associated with 
      adverse events. To conclude, reduced aspirin responsiveness as evaluated by 
      Multiplate® platelet function analyzer was not associated with increased 
      incidence of major adverse cardiac and thromboembolic events and mortality after 
      CABG surgery.
FAU - Bolliger, Daniel
AU  - Bolliger D
AD  - a Department of Anesthesia, Surgical Intensive Care, Prehospital Emergency 
      Medicine and Pain Therapy , University Hospital Basel , Basel , Switzerland .
FAU - Filipovic, Miodrag
AU  - Filipovic M
AD  - a Department of Anesthesia, Surgical Intensive Care, Prehospital Emergency 
      Medicine and Pain Therapy , University Hospital Basel , Basel , Switzerland .
AD  - b Institute of Anesthesiology, Cantonal Hospital , St. Gallen , Switzerland .
FAU - Matt, Peter
AU  - Matt P
AD  - c Division of Cardiac Surgery , University Hospital Basel , Basel , Switzerland .
FAU - Tanaka, Kenichi A
AU  - Tanaka KA
AD  - d Department of Anesthesiology, Cardiothoracic Anesthesia Division , University 
      of Maryland , Baltimore , MD , USA , and.
FAU - Gregor, Michael
AU  - Gregor M
AD  - a Department of Anesthesia, Surgical Intensive Care, Prehospital Emergency 
      Medicine and Pain Therapy , University Hospital Basel , Basel , Switzerland .
FAU - Zenklusen, Urs
AU  - Zenklusen U
AD  - a Department of Anesthesia, Surgical Intensive Care, Prehospital Emergency 
      Medicine and Pain Therapy , University Hospital Basel , Basel , Switzerland .
AD  - c Division of Cardiac Surgery , University Hospital Basel , Basel , Switzerland .
FAU - Seeberger, Manfred D
AU  - Seeberger MD
AD  - a Department of Anesthesia, Surgical Intensive Care, Prehospital Emergency 
      Medicine and Pain Therapy , University Hospital Basel , Basel , Switzerland .
AD  - e Institute for Anesthesiology and Intensive Care, Hirslanden Klinik , Zurich , 
      Switzerland.
FAU - Lurati Buse, Giovanna
AU  - Lurati Buse G
AD  - a Department of Anesthesia, Surgical Intensive Care, Prehospital Emergency 
      Medicine and Pain Therapy , University Hospital Basel , Basel , Switzerland .
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150914
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Area Under Curve
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Biomarkers
MH  - Blood Platelets/*drug effects/*metabolism
MH  - Cardiac Surgical Procedures
MH  - *Drug Resistance
MH  - *Electric Impedance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Count
MH  - Platelet Function Tests
MH  - Postoperative Period
MH  - Prospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - cardiac surgery
OT  - thromboembolism
OT  - treatment outcome
EDAT- 2015/09/15 06:00
MHDA- 2016/12/27 06:00
CRDT- 2015/09/15 06:00
PHST- 2015/09/15 06:00 [entrez]
PHST- 2015/09/15 06:00 [pubmed]
PHST- 2016/12/27 06:00 [medline]
AID - 10.3109/09537104.2015.1083969 [doi]
PST - ppublish
SO  - Platelets. 2016;27(3):254-61. doi: 10.3109/09537104.2015.1083969. Epub 2015 Sep 
      14.

PMID- 7008732
OWN - NLM
STAT- MEDLINE
DCOM- 19810413
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 141
IP  - 3 Spec No
DP  - 1981 Feb 23
TI  - Comparative efficacy of aspirin and acetaminophen in the reduction of fever in 
      children.
PG  - 286-92
AB  - Antipyretics should be employed in the pediatric population whenever it is the 
      clinical judgment of the attending physician that fever should be lowered. 
      Aspirin and acetaminophen are equally effective as antipyretics. The efficacy and 
      safety of these two most common antipyretic agents are examined, and various 
      studies with these agents are critically reviewed. Since acetaminophen has a 
      greater margin of safety at antipyretic dosages, it is preferred to aspirin when 
      an anti-inflammatory effect is not required. The efficacy and safety of 
      combination therapy with acetaminophen and aspirin in pediatric patients--or an 
      alternative treatment regimen with both these drugs--warrant investigation.
FAU - Yaffe, S J
AU  - Yaffe SJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/adverse effects/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Fever/*drug therapy
MH  - Humans
MH  - Infant
EDAT- 1981/02/23 00:00
MHDA- 1981/02/23 00:01
CRDT- 1981/02/23 00:00
PHST- 1981/02/23 00:00 [pubmed]
PHST- 1981/02/23 00:01 [medline]
PHST- 1981/02/23 00:00 [entrez]
AID - 10.1001/archinte.141.3.286 [doi]
PST - ppublish
SO  - Arch Intern Med. 1981 Feb 23;141(3 Spec No):286-92. doi: 
      10.1001/archinte.141.3.286.

PMID- 1065299
OWN - NLM
STAT- MEDLINE
DCOM- 19760901
LR  - 20190823
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 6
IP  - 1
DP  - 1976 Feb
TI  - Evaluation of an enteric coated aspirin preparation.
PG  - 45-50
AB  - The bioavailability and gastrointestinal site of release of enteric coated 
      aspirin tablets ("Rhusal", G.P. Laboratories) were investigated following dosage 
      with single tablets. A delay of one to more than eight hours was observed between 
      dosage and the appearance of salicylate in plasma or saliva. This delay was 
      decreased by pretreatment with metoclopramide. No aspirin or salicylate was 
      detected in gastric aspirates. The mean urinary recovery of salicylate was 
      equivalent to 92% of the administered dose. All these tests were consistent with 
      the designed function of the enteric coating. The time course of concentrations 
      of salicylate in saliva rather than in plasma was confirmed as a useful technique 
      for the evaluation of different formulations of aspirin. The acceleration of 
      gastric emptying by metoclopramide is a useful technique for the evaluation of 
      enteric coated tablets.
FAU - Day, R O
AU  - Day RO
FAU - Paull, P D
AU  - Paull PD
FAU - Champion, G D
AU  - Champion GD
FAU - Graham, G G
AU  - Graham GG
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*metabolism
MH  - Biological Availability
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Intestinal Absorption/drug effects
MH  - Male
MH  - Metoclopramide/pharmacology
MH  - Middle Aged
MH  - Salicylates/analysis
MH  - Saliva/analysis
MH  - Stimulation, Chemical
MH  - Stomach/analysis
MH  - Tablets, Enteric-Coated
EDAT- 1976/02/01 00:00
MHDA- 1976/02/01 00:01
CRDT- 1976/02/01 00:00
PHST- 1976/02/01 00:00 [pubmed]
PHST- 1976/02/01 00:01 [medline]
PHST- 1976/02/01 00:00 [entrez]
AID - 10.1111/j.1445-5994.1976.tb03290.x [doi]
PST - ppublish
SO  - Aust N Z J Med. 1976 Feb;6(1):45-50. doi: 10.1111/j.1445-5994.1976.tb03290.x.

PMID- 10915461
OWN - NLM
STAT- MEDLINE
DCOM- 20000608
LR  - 20171116
IS  - 0097-6326 (Print)
IS  - 0097-6326 (Linking)
VI  - 64
IP  - 177
DP  - 1999 Sep 14
TI  - Internal analgesic, antipyretic, and antirheumatic drug products for 
      over-the-counter human use; final rule for professional labeling of aspirin, 
      buffered aspirin, and aspirin in combination with antacid drug products; 
      technical amendments. Department of Health and Human Services (HHS), Public 
      Health Service (PHS), Food and Drug Administration (FDA). Final rule; technical 
      amendments.
PG  - 49652-5
AB  - The Food and Drug Administration (FDA) is amending the regulations for internal 
      analgesic, antipyretic, and antirheumatic drug products for over-the-counter 
      (OTC) use to correct inadvertent errors and to clarify the labeling for 
      over-the-counter drug products written for health professionals.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Fed Regist
JT  - Federal register
JID - 7808722
RN  - 0 (Antacids)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
MH  - Animals
MH  - Antacids
MH  - *Anti-Inflammatory Agents, Non-Steroidal/adverse 
      effects/pharmacokinetics/toxicity
MH  - *Aspirin/adverse effects/pharmacokinetics/toxicity
MH  - Contraindications
MH  - Drug Combinations
MH  - *Drug Labeling/legislation & jurisprudence
MH  - Humans
MH  - Nonprescription Drugs
MH  - Rats
MH  - United States
MH  - United States Food and Drug Administration
EDAT- 2000/08/01 00:00
MHDA- 2000/08/01 00:01
CRDT- 2000/08/01 00:00
PHST- 2000/08/01 00:00 [pubmed]
PHST- 2000/08/01 00:01 [medline]
PHST- 2000/08/01 00:00 [entrez]
PST - ppublish
SO  - Fed Regist. 1999 Sep 14;64(177):49652-5.

PMID- 22561563
OWN - NLM
STAT- MEDLINE
DCOM- 20131114
LR  - 20151119
IS  - 1672-7347 (Print)
IS  - 1672-7347 (Linking)
VI  - 37
IP  - 4
DP  - 2012 Apr
TI  - [Prevalence of laboratory aspirin resistance in 431 old patients].
PG  - 338-42
LID - 10.3969/j.issn.1672-7347.2012.04.003 [doi]
AB  - OBJECTIVE: To evaluate correlation between and agreement in light transmittance 
      aggregation (LTA) and thromboelastography (TEG) in laboratory diagnosing aspirin 
      resistance (AR), and to determine the prevalence of AR in old patients. METHODS: 
      Patients in the Wanshoulu District of Beijing with ischemic atherothrombotic 
      diseases were recruited. Inclusion criteria were age ≥ 65 years, and having 
      received regular aspirin therapy (75-100 mg daily) for at least 4 weeks. On the 
      basis of LTA assay, the definition of AR was taken as aggregation of ≥ 20% with 
      AA (arachidonic acid), and of ≥ 70% with ADP (adenosine diphosphate). 
      Aspirin-sensitivity was indicated by the absence of either of these criteria; 
      aspirinsensitivity was indicated as both criteria being met. The definition of AR 
      by TEG is ≥ 50% via AA-induced whole blood aggregation. RESULTS: There were 
      13.69% prevalence of aspirin resistance for LTA using AA as the agonist, 30.16% 
      prevalence of aspirin resistance for LTA using ADP as the agonist, and 23.67% 
      prevalence of aspirin resistance for TEG using AA as the agonist. Results from 
      these tests showed poor agreement (Kappa<0.4). However, by the method of LTA 
      using AA and ADP as the agonists, prevalence of AR was 8.35%. By methods of 
      AA-induced LTA and AA-induced TEG, prevalence of AR was 8.82%. Results from these 
      two latter methods showed good agreement (Kappa = 0.793). CONCLUSION: Combined 
      methods, as described here, have good correlation and agreement in the assays of 
      AR, and the results with them represent a realistic measure of the prevalence of 
      AR. Prevalence of AR of elderly patients from Wanshoulu district of Beijing is 
      about 9%.
FAU - Li, Xiaoli
AU  - Li X
AD  - First Department of Geriatric Cardiology of South Building, Chinese People's 
      Liberation Army General Hospital, Beijing 100853, China.
FAU - Fan, Li
AU  - Fan L
FAU - Cao, Jian
AU  - Cao J
FAU - Wang, Qiang
AU  - Wang Q
FAU - Liu, Lin
AU  - Liu L
FAU - Hu, Guoliang
AU  - Hu G
FAU - Hu, Yixin
AU  - Hu Y
FAU - Wang, Yazhen
AU  - Wang Y
FAU - Wu, Ruojun
AU  - Wu R
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhong Nan Da Xue Xue Bao Yi Xue Ban
JT  - Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. 
      Medical sciences
JID - 101230586
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cerebrovascular Disorders/blood/drug therapy
MH  - Coronary Disease/blood/drug therapy
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Prevalence
MH  - Surveys and Questionnaires
EDAT- 2012/05/09 06:00
MHDA- 2013/11/15 06:00
CRDT- 2012/05/08 06:00
PHST- 2012/05/08 06:00 [entrez]
PHST- 2012/05/09 06:00 [pubmed]
PHST- 2013/11/15 06:00 [medline]
AID - 10.3969/j.issn.1672-7347.2012.04.003 [doi]
PST - ppublish
SO  - Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012 Apr;37(4):338-42. doi: 
      10.3969/j.issn.1672-7347.2012.04.003.

PMID- 14683695
OWN - NLM
STAT- MEDLINE
DCOM- 20040817
LR  - 20190917
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 70
IP  - 2
DP  - 2004 Feb
TI  - Eicosanoids in preeclampsia.
PG  - 223-32
AB  - Preeclampsia is characterized by an imbalance between two cyclooxygenase 
      metabolites of arachidonic acid, thromboxane and prostacyclin, that favors 
      thromboxane. Because of the biologic actions of these two eicosanoids, this 
      imbalance might explain major clinical symptoms of preeclampsia, such as 
      hypertension, platelet aggregation and reduced uteroplacental blood flow. In the 
      maternal circulation, this imbalance is primarily manifested by decreased 
      production of prostacyclin by endothelial cells. Platelet thromboxane synthesis 
      is only increased in severe preeclampsia. In the placenta and in leukocytes, the 
      imbalance is exacerbated by increased production of thromboxane coupled with 
      decreased production of prostacyclin in both mild and severe preeclampsia. 
      Longitudinal measurements of urinary metabolites of thromboxane and prostacyclin 
      reveal that the thromboxane/prostacyclin imbalance predates the onset of clinical 
      symptoms of preeclampsia. The imbalance between thromboxane and prostacyclin is 
      most likely caused by oxidative stress, which is manifest in preeclampsia by 
      increased lipid peroxidation and decreased antioxidant protection. Oxidative 
      stress may drive this imbalance because lipid peroxides activate the 
      cyclooxygenase enzyme to increase thromboxane synthesis, but at the same time 
      they inhibit prostacyclin synthase to decrease prostacyclin synthesis. Low-dose 
      aspirin therapy (50-150 mg/day) has been considered for the prevention of 
      preeclampsia because it selectively inhibits thromboxane synthesis. Several 
      studies reported dramatic decreases in the incidence of preeclampsia with 
      low-dose aspirin therapy. However, two large multicenter studies reported only 
      modest decreases, which dampened enthusiasm. The two large studies were "intent 
      to treat" studies which included patients who were noncompliant and who 
      discontinued the use of aspirin. In one of the studies for which compliance 
      statistics were available only 53% of the aspirin group had a compliance rate 
      greater than 75%, which raises a question as to whether the effectiveness of 
      aspirin was being tested. Low-dose aspirin therapy should not yet be dismissed 
      for the prevention of preeclampsia, but be reconsidered with emphasis on 
      compliance using doses of aspirin in the range of 100-150 mg/day combined with 
      antioxidants.
FAU - Walsh, Scott W
AU  - Walsh SW
AD  - Department of Obstetrics and Gynecology, Virginia Commonwealth University, 1101 E 
      Marshall St., PO Box 980034, Richmond, VA 23298-0034, USA. swwalsh@hsc.vcu.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Antioxidants)
RN  - 0 (Eicosanoids)
RN  - 0 (Thromboxanes)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antioxidants/metabolism/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Eicosanoids/*metabolism
MH  - Epoprostenol/*metabolism
MH  - Female
MH  - Humans
MH  - Lipid Peroxidation/physiology
MH  - Oxidative Stress/physiology
MH  - Pre-Eclampsia/*metabolism
MH  - Pregnancy
MH  - Thromboxanes/*metabolism
RF  - 110
EDAT- 2003/12/20 05:00
MHDA- 2004/08/18 05:00
CRDT- 2003/12/20 05:00
PHST- 2003/12/20 05:00 [pubmed]
PHST- 2004/08/18 05:00 [medline]
PHST- 2003/12/20 05:00 [entrez]
AID - S0952327803001844 [pii]
AID - 10.1016/j.plefa.2003.04.010 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2004 Feb;70(2):223-32. doi: 
      10.1016/j.plefa.2003.04.010.

PMID- 31060007
OWN - NLM
STAT- MEDLINE
DCOM- 20200114
LR  - 20200114
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 115
DP  - 2019 Jul
TI  - Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and 
      thrombus formation in rodents due to its decreased metabolic inactivation.
PG  - 108906
LID - S0753-3322(19)30816-9 [pii]
LID - 10.1016/j.biopha.2019.108906 [doi]
AB  - Both aspirin and vicagrel are effective antiplatelet drugs, with the potential 
      for concomitant use as another dual-antiplatelet therapy for the prevention of 
      recurrent thrombotic or ischemic events. Because they both are the substrates of 
      carboxylesterase 2 (CES2), aspirin attenuated the metabolic activation of and 
      platelet response to vicagrel in mice treated with the two drugs concomitantly. 
      In this study, we sought to clarify whether vicagrel could affect platelet 
      responses to aspirin and their underlying mechanisms. Plasma levels of aspirin 
      and salicylic acid were determined by liquid chromatography-tandem mass 
      spectrometry, inhibition of arachidonic acid (AA)-induced whole-blood platelet 
      aggregation by aspirin was assessed with an aggregometer, and their 
      antithrombotic effects were evaluated by arteriovenous shunt thrombosis model. 
      The results showed that concomitant use of vicagrel (5, 10, or 20 mg/kg) led to 
      an average of 55% and 77% increases in systemic exposure of aspirin (C(max) and 
      AUC(0-t)) and 2.8-fold increase in suppression of AA-induced platelet aggregation 
      in mice when compared with use of aspirin alone. In the rat thrombus formation 
      model, vicagrel (1 mg/kg) enhanced inhibition of thrombosis formation by aspirin 
      (5 mg/kg), but not vice versa. We conclude that vicagrel increases platelet 
      responses to aspirin and also enhances inhibition of thrombus formation of 
      aspirin due to decreased CES2-catalyzed aspirin inactivation in rodents, and that 
      an integrated net effect on thrombus formation in vivo is superior to inhibition 
      of AA- or ADP-induced platelet aggregation ex vivo by either of the two drugs if 
      taken concomitantly.
CI  - Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Jia, Yu-Meng
AU  - Jia YM
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, 210006, China; Department of Pharmacology, College of Basic 
      Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, 
      China.
FAU - Ge, Peng-Xin
AU  - Ge PX
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, 210006, China; Department of Pharmacology, College of Basic 
      Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, 
      China.
FAU - Zhou, Huan
AU  - Zhou H
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, 210006, China; Department of Pharmacology, College of Basic 
      Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, 
      China.
FAU - Ji, Jin-Zi
AU  - Ji JZ
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, 210006, China.
FAU - Tai, Ting
AU  - Tai T
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, 210006, China.
FAU - Gu, Tong-Tong
AU  - Gu TT
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, 210006, China.
FAU - Zhu, Ting
AU  - Zhu T
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, 210006, China; Department of Pharmacology, College of Basic 
      Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, 
      China.
FAU - Li, Yi-Fei
AU  - Li YF
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, 210006, China.
FAU - Mi, Qiong-Yu
AU  - Mi QY
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, 210006, China.
FAU - Huang, Bei-Bei
AU  - Huang BB
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, 210006, China.
FAU - Xie, Hong-Guang
AU  - Xie HG
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, 210006, China; Department of Pharmacology, College of Basic 
      Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, 
      China; Department of Clinical Pharmacy, Nanjing Medical University School of 
      Pharmacy, Nanjing, 210009, China. Electronic address: hongg.xie@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20190503
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Phenylacetates)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0 (methyl 
      2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/metabolism/*pharmacology
MH  - Blood Platelets/drug effects/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Inactivation, Metabolic
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Phenylacetates/administration & dosage/metabolism/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/metabolism/*pharmacology
MH  - Rats, Sprague-Dawley
MH  - Thiophenes/administration & dosage/metabolism/*pharmacology
MH  - Thrombosis/*drug therapy/metabolism
OTO - NOTNLM
OT  - Aspirin
OT  - Carboxylesterase 2
OT  - Drug-drug interaction
OT  - Hydrolysis
OT  - Platelet aggregation
OT  - Vicagrel
EDAT- 2019/05/07 06:00
MHDA- 2020/01/15 06:00
CRDT- 2019/05/07 06:00
PHST- 2019/02/26 00:00 [received]
PHST- 2019/04/12 00:00 [revised]
PHST- 2019/04/22 00:00 [accepted]
PHST- 2019/05/07 06:00 [pubmed]
PHST- 2020/01/15 06:00 [medline]
PHST- 2019/05/07 06:00 [entrez]
AID - S0753-3322(19)30816-9 [pii]
AID - 10.1016/j.biopha.2019.108906 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2019 Jul;115:108906. doi: 10.1016/j.biopha.2019.108906. Epub 
      2019 May 3.

PMID- 22442793
OWN - NLM
STAT- MEDLINE
DCOM- 20120706
LR  - 20190813
IS  - 1573-8221 (Electronic)
IS  - 0007-4888 (Linking)
VI  - 151
IP  - 1
DP  - 2011 May
TI  - Parameters of microcirculation in paired formations after single aspirin 
      administration: laser Doppler flowmetry data.
PG  - 16-21
AB  - Laser Doppler flowmetry showed that aspirin can induce blood flow reduction and 
      transitory manifold increase or decrease in vascular tone in rat skin and 
      kidneys. The dynamics is more illustrative when parameters of individual animals 
      are evaluated and depends on the areas of blood flow recording. Deaths and 
      reduction of narcotic sleep duration were noted in concomitant use of nembutal 
      and aspirin.
FAU - Mikhailichenko, L A
AU  - Mikhailichenko LA
AD  - Research Institute of General Pathology and Pathophysiology, Russian Academy of 
      Medical Sciences, Moscow, Russia. ilmen2006@rambler.ru
FAU - Tikhomirova, I A
AU  - Tikhomirova IA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bull Exp Biol Med
JT  - Bulletin of experimental biology and medicine
JID - 0372557
RN  - I4744080IR (Pentobarbital)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/antagonists & inhibitors
MH  - Kidney/blood supply/drug effects
MH  - Laser-Doppler Flowmetry
MH  - Microcirculation/*drug effects
MH  - Microvessels/*drug effects
MH  - Pentobarbital/administration & dosage/antagonists & inhibitors
MH  - Rats
MH  - Skin/blood supply/drug effects
MH  - Sleep/drug effects
EDAT- 2012/03/24 06:00
MHDA- 2012/07/07 06:00
CRDT- 2012/03/24 06:00
PHST- 2012/03/24 06:00 [entrez]
PHST- 2012/03/24 06:00 [pubmed]
PHST- 2012/07/07 06:00 [medline]
AID - 10.1007/s10517-011-1249-4 [doi]
PST - ppublish
SO  - Bull Exp Biol Med. 2011 May;151(1):16-21. doi: 10.1007/s10517-011-1249-4.

PMID- 6752253
OWN - NLM
STAT- MEDLINE
DCOM- 19821218
LR  - 20190709
IS  - 0002-8614 (Print)
IS  - 0002-8614 (Linking)
VI  - 30
IP  - 11 Suppl
DP  - 1982 Nov
TI  - The use of non-prescription analgesics in an older population.
PG  - S76-80
AB  - Older patients are frequent users of aspirin and acetaminophen, either 
      recommended by physicians or self-prescribed, for the aches and pains that 
      accompany aging. These mild analgesics provide effective pain relief when used 
      appropriately. Aspirin and acetaminophen are equianalgesic on a 
      milligram-for-milligram basis for most indications. Both are safe for most 
      patients. Aspirin use may be associated with salicylate intoxication or 
      salicylate interactions with other agents. There have been reports of an 
      association of hepatotoxicity with acute massive overdosages of acetaminophen.
FAU - Cupit, G C
AU  - Cupit GC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - 0 (Analgesics)
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects
MH  - Aged
MH  - *Analgesics/adverse effects
MH  - Aspirin/adverse effects/poisoning
MH  - Blood Coagulation/drug effects
MH  - Chemical and Drug Induced Liver Injury/etiology
MH  - Drug Interactions
MH  - *Drug Utilization
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Nonprescription Drugs/adverse effects
RF  - 49
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
AID - 10.1111/j.1532-5415.1982.tb01360.x [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 1982 Nov;30(11 Suppl):S76-80. doi: 
      10.1111/j.1532-5415.1982.tb01360.x.

PMID- 7292954
OWN - NLM
STAT- MEDLINE
DCOM- 19811221
LR  - 20141120
IS  - 0145-6296 (Print)
IS  - 0145-6296 (Linking)
VI  - 23
IP  - 2
DP  - 1981 Apr
TI  - The in vitro and in vivo availability of commercial aspirin in dogs.
PG  - 84-8
AB  - Dissolution rates of 11 commercial brands of aspirin was assessed in vitro using 
      simulated gastric juice. Excedrin dissolved fastest of all the brands of aspirin, 
      followed by Ascriptin; the slowest was Excedrin PM. In dogs dosed orally with 
      Excedrin or Ascriptin, total plasma salicylate peaked about 2.5 hr after dosing 
      with Excedrin and 3 hr post-dosing with Ascriptin. About 96% of the salicylate 
      was bound to plasma proteins. The rate at which Excedrin left the plasma was 
      different from that of Ascriptin. Plasma salicylate concentrations from Excedrin 
      dropped to an average of 12 mg/dl in 6 hr while Ascriptin peaked and remained 
      virtually level for more than 12 hr.
FAU - Owonubi, M O
AU  - Owonubi MO
FAU - Oehme, F W
AU  - Oehme FW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Vet Hum Toxicol
JT  - Veterinary and human toxicology
JID - 7704194
RN  - 0 (Blood Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*metabolism
MH  - Biological Availability
MH  - Blood Proteins/metabolism
MH  - Dogs
MH  - In Vitro Techniques
MH  - Intestinal Absorption
MH  - Protein Binding
MH  - Solubility
EDAT- 1981/04/01 00:00
MHDA- 1981/04/01 00:01
CRDT- 1981/04/01 00:00
PHST- 1981/04/01 00:00 [pubmed]
PHST- 1981/04/01 00:01 [medline]
PHST- 1981/04/01 00:00 [entrez]
PST - ppublish
SO  - Vet Hum Toxicol. 1981 Apr;23(2):84-8.

PMID- 19151047
OWN - NLM
STAT- MEDLINE
DCOM- 20090220
LR  - 20181201
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 102
IP  - 2
DP  - 2009 Feb
TI  - Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic 
      review and meta-analysis.
PG  - 168-78
LID - 10.1093/bja/aen377 [doi]
AB  - While conventional practice is to discontinue aspirin prior to elective cardiac 
      surgery there is evidence that its continuation may be associated with improved 
      perioperative outcomes. However, uncertainty exists regarding the efficacy of 
      antifibrinolytic agents in the presence of aspirin. We performed a systematic 
      review and meta-analysis of the literature to address the question of the effects 
      of antifibrinolytic agents in cardiac surgery patients maintained on aspirin in 
      terms of both efficacy and adverse events. We conducted an extensive search for 
      randomized controlled trials of antifibrinolytic use in adult patients undergoing 
      coronary artery bypass grafting +/- valve surgery, where aspirin therapy was 
      maintained or initiated through the preoperative period. Data from 17 trials 
      (n=1620) confirmed the efficacy of antifibrinolytic therapy to reduce both 
      chest-tube drainage (weighted mean difference 374 ml, 95% CI 275-473 ml; 
      P<0.00001) and blood transfusion requirements (odds ratio 0.37, 95% CI 0.27-0.49; 
      P<0.00001) in cardiac surgical patients receiving aspirin. We found no difference 
      in the rates of adverse events between groups but observed a trend towards a 
      reduced risk for the composite outcome of thrombotic complications (odds ratio 
      0.49, 95% CI 0.21-1.13; P=0.09). Antifibrinolytic agents are effective for 
      reducing both chest-tube drainage and transfusion requirements in cardiac 
      surgical patients receiving aspirin. We found no difference between 
      antifibrinolytic and placebo in terms of adverse events but the population was 
      predominantly low-risk. Further studies are required to determine the optimal 
      balance between antiplatelet and antifibrinolytic effects in cardiac surgery.
FAU - McIlroy, D R
AU  - McIlroy DR
AD  - Department of Anaesthesia & Perioperative Medicine, Alfred Hospital, Commercial 
      Road, Melbourne, Victoria 3004, Australia. dm2655@columbia.edu
FAU - Myles, P S
AU  - Myles PS
FAU - Phillips, L E
AU  - Phillips LE
FAU - Smith, J A
AU  - Smith JA
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Antifibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antifibrinolytic Agents/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Transfusion
MH  - *Cardiac Surgical Procedures
MH  - Chest Tubes
MH  - Drainage
MH  - Drug Interactions
MH  - Humans
MH  - Perioperative Care/*methods
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Respiratory Insufficiency/chemically induced
RF  - 46
EDAT- 2009/01/20 09:00
MHDA- 2009/02/21 09:00
CRDT- 2009/01/20 09:00
PHST- 2009/01/20 09:00 [entrez]
PHST- 2009/01/20 09:00 [pubmed]
PHST- 2009/02/21 09:00 [medline]
AID - S0007-0912(17)34527-0 [pii]
AID - 10.1093/bja/aen377 [doi]
PST - ppublish
SO  - Br J Anaesth. 2009 Feb;102(2):168-78. doi: 10.1093/bja/aen377.

PMID- 30012602
OWN - NLM
STAT- MEDLINE
DCOM- 20180924
LR  - 20230821
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 115
IP  - 31
DP  - 2018 Jul 31
TI  - Aspirin binds to PPARα to stimulate hippocampal plasticity and protect memory.
PG  - E7408-E7417
LID - 10.1073/pnas.1802021115 [doi]
AB  - Despite its long history, until now, no receptor has been identified for aspirin, 
      one of the most widely used medicines worldwide. Here we report that peroxisome 
      proliferator-activated receptor alpha (PPARα), a nuclear hormone receptor 
      involved in fatty acid metabolism, serves as a receptor of aspirin. Detailed 
      proteomic analyses including cheminformatics, thermal shift assays, and TR-FRET 
      revealed that aspirin, but not other structural homologs, acts as a PPARα ligand 
      through direct binding at the Tyr314 residue of the PPARα ligand-binding domain. 
      On binding to PPARα, aspirin stimulated hippocampal plasticity via 
      transcriptional activation of cAMP response element-binding protein (CREB). 
      Finally, hippocampus-dependent behavioral analyses, calcium influx assays in 
      hippocampal slices and quantification of dendritic spines demonstrated that 
      low-dose aspirin treatment improved hippocampal plasticity and memory in FAD5X 
      mice, but not in FAD5X/Ppara-null mice. These findings highlight a property of 
      aspirin: stimulating hippocampal plasticity via direct interaction with PPARα.
FAU - Patel, Dhruv
AU  - Patel D
AUID- ORCID: 0000-0002-5438-1051
AD  - Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 
      60612.
FAU - Roy, Avik
AU  - Roy A
AD  - Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 
      60612.
AD  - Division of Research and Development, Jesse Brown Veterans Affairs Medical 
      Center, Chicago, IL 60612.
FAU - Kundu, Madhuchhanda
AU  - Kundu M
AD  - Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 
      60612.
FAU - Jana, Malabendu
AU  - Jana M
AD  - Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 
      60612.
AD  - Division of Research and Development, Jesse Brown Veterans Affairs Medical 
      Center, Chicago, IL 60612.
FAU - Luan, Chi-Hao
AU  - Luan CH
AD  - High-Throughput Analysis Laboratory and Department of Molecular Biosciences, 
      Northwestern University, Evanston, IL 60208.
FAU - Gonzalez, Frank J
AU  - Gonzalez FJ
AD  - Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, 
      National Institutes of Health, Bethesda, MD 20892.
FAU - Pahan, Kalipada
AU  - Pahan K
AD  - Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 
      60612; Kalipada_Pahan@rush.edu.
AD  - Division of Research and Development, Jesse Brown Veterans Affairs Medical 
      Center, Chicago, IL 60612.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20180716
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Cyclic AMP Response Element-Binding Protein)
RN  - 0 (PPAR alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/metabolism/*pharmacology
MH  - Cyclic AMP Response Element-Binding Protein/genetics
MH  - Hippocampus/*drug effects/physiology
MH  - Memory/*drug effects
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neuronal Plasticity/*drug effects/physiology
MH  - PPAR alpha/*metabolism
MH  - Synapses/drug effects/physiology
PMC - PMC6077698
OTO - NOTNLM
OT  - PPARα
OT  - aspirin
OT  - memory and learning
OT  - plasticity
COIS- The authors declare no conflict of interest.
EDAT- 2018/07/18 06:00
MHDA- 2018/09/25 06:00
CRDT- 2018/07/18 06:00
PHST- 2018/07/18 06:00 [pubmed]
PHST- 2018/09/25 06:00 [medline]
PHST- 2018/07/18 06:00 [entrez]
AID - 1802021115 [pii]
AID - 201802021 [pii]
AID - 10.1073/pnas.1802021115 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7408-E7417. doi: 
      10.1073/pnas.1802021115. Epub 2018 Jul 16.

PMID- 16112645
OWN - NLM
STAT- MEDLINE
DCOM- 20051228
LR  - 20181201
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 338
IP  - 1
DP  - 2005 Dec 9
TI  - The contributions of aspirin and microbial oxygenase to the biosynthesis of 
      anti-inflammatory resolvins: novel oxygenase products from omega-3 
      polyunsaturated fatty acids.
PG  - 149-57
AB  - Resolvins (Rvs) are oxygenated products derived from omega-3 polyunsaturated 
      fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid 
      that carry potent protective bioactions present in resolving inflammatory 
      exudates. Resolvin E1 (RvE1) is biosynthesized in vivo from EPA via transcellular 
      biosynthetic routes during cell-cell interactions, and thus RvE1 is formed in 
      vivo during multicellular responses such as inflammation and microbial 
      infections. RvE1 protects tissues from leukocyte-mediated injury and 
      counterregulates proinflammatory gene expression. These newly identified Rvs may 
      underlie the beneficial actions of omega-3 PUFAs especially in chronic disorders 
      where unresolved inflammation is a key mechanism of pathogenesis. Here, we 
      present an overview of the biosynthesis of RvE1, with a focus on the 
      aspirin-triggered and microbial P450-initiated pathways. The generation of RvE1 
      and its actions appear to dampen acute leukocyte responses and facilitate the 
      resolution of inflammation.
FAU - Arita, Makoto
AU  - Arita M
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital 
      and Harvard Medical School, Boston, MA 02115, USA.
FAU - Clish, Clary B
AU  - Clish CB
FAU - Serhan, Charles N
AU  - Serhan CN
LA  - eng
GR  - GM38675/GM/NIGMS NIH HHS/United States
GR  - P50-DE016191/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20050810
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Fatty Acids, Omega-3)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - EC 1.13.- (Oxygenases)
RN  - GND3JH08JA (5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry/*metabolism
MH  - Eicosapentaenoic Acid/*analogs & derivatives/biosynthesis
MH  - Fatty Acids, Omega-3/chemistry/*metabolism
MH  - Humans
MH  - Oxygenases/chemistry/*physiology
RF  - 42
EDAT- 2005/08/23 09:00
MHDA- 2005/12/29 09:00
CRDT- 2005/08/23 09:00
PHST- 2005/07/11 00:00 [received]
PHST- 2005/07/22 00:00 [revised]
PHST- 2005/07/30 00:00 [accepted]
PHST- 2005/08/23 09:00 [pubmed]
PHST- 2005/12/29 09:00 [medline]
PHST- 2005/08/23 09:00 [entrez]
AID - S0006-291X(05)01684-0 [pii]
AID - 10.1016/j.bbrc.2005.07.181 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2005 Dec 9;338(1):149-57. doi: 
      10.1016/j.bbrc.2005.07.181. Epub 2005 Aug 10.

PMID- 26030214
OWN - NLM
STAT- MEDLINE
DCOM- 20160414
LR  - 20220321
IS  - 1528-1159 (Electronic)
IS  - 0362-2436 (Linking)
VI  - 40
IP  - 9
DP  - 2015 May 1
TI  - Does aspirin administration increase perioperative morbidity in patients with 
      cardiac stents undergoing spinal surgery?
PG  - 629-35
LID - 10.1097/BRS.0000000000000695 [doi]
AB  - STUDY DESIGN: Cohort. OBJECTIVE: To compare the perioperative morbidity of 
      patients with cardiac stents after spine surgery who continue to take aspirin 
      before and after the operation with a similar group of patients who 
      preoperatively discontinued aspirin. SUMMARY OF BACKGROUND DATA: The preoperative 
      discontinuation of anticoagulant therapy has been the standard of care for 
      orthopedic surgical procedures. However, recent literature has demonstrated 
      significant cardiac risk associated with aspirin withdrawal in patients with 
      cardiac stents. Although it has recently been demonstrated that performing 
      orthopedic surgery while continuing low-dose aspirin therapy seems to be safe, 
      studies focused on spinal surgery have not yet been performed. Because of the 
      risk of intraspinal bleeding and the serious consequences of subsequent epidural 
      hematoma with associated spinal cord compression, spinal surgeons have been 
      reluctant to operate on patients taking aspirin. METHODS: This institutional 
      review board-approved study included 200 patients. Preoperative parameters and 
      postoperative outcome measures were analyzed for 100 patients who underwent 
      spinal surgery after the discontinuation of anticoagulation therapy and 100 
      patients who continued to take daily aspirin through the perioperative period. 
      The primary outcome measure was serious bleeding-related postoperative 
      complications such as spinal epidural hematoma. The operative time, 
      intraoperative estimated blood loss, hospital length of stay, transfusion of 
      blood products, and 30-day hospital readmission rates were also recorded and 
      compared. RESULTS: The patients who continued taking aspirin in the perioperative 
      period had a shorter hospital length of stay on average (4.1 ± 2.7 vs. 6.2 ± 5.8; 
      P < 0.005), as well as a reduced operative time (210 ± 136 vs. 266 ± 143; P < 
      0.01), whereas there was no significant difference in the estimated blood loss 
      (642 ± 905 vs. 697 ± 1187), the amount of blood products transfused, overall 
      intra- and postoperative complication rate (8% vs. 11%), or 30-day hospital 
      readmission rate (5% vs. 5%). No clinically significant spinal epidural hematomas 
      were observed in either of the study groups. CONCLUSION: The current study has 
      observed no appreciable increase in bleeding-related complication rates in 
      patients with cardiac stents undergoing spine surgery while continuing to take 
      aspirin compared with patients who discontinued aspirin prior to surgery. 
      Although very large studies will be needed to determine whether aspirin 
      administration results in a small complication rate increase, the current study 
      provides evidence that perioperative aspirin therapy is relatively safe in 
      patients undergoing spinal surgery. LEVEL OF EVIDENCE: 2.
FAU - Cuellar, Jason M
AU  - Cuellar JM
AD  - *Department of Orthopaedic Surgery and †Division of spine surgery, NYU Hospital 
      for Joint Diseases, New York, NY; and ‡NYU School of Medicine, New York, NY.
FAU - Petrizzo, Anthony
AU  - Petrizzo A
FAU - Vaswani, Ravi
AU  - Vaswani R
FAU - Goldstein, Jeffrey A
AU  - Goldstein JA
FAU - Bendo, John A
AU  - Bendo JA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Spine (Phila Pa 1976)
JT  - Spine
JID - 7610646
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiac Surgical Procedures
MH  - Cohort Studies
MH  - Endovascular Procedures
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Morbidity
MH  - Orthopedic Procedures/*statistics & numerical data
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Postoperative Complications/*epidemiology
MH  - Postoperative Hemorrhage/epidemiology
MH  - Spine/*surgery
MH  - *Stents
MH  - Thrombosis/prevention & control
EDAT- 2015/06/02 06:00
MHDA- 2016/04/15 06:00
CRDT- 2015/06/02 06:00
PHST- 2015/06/02 06:00 [entrez]
PHST- 2015/06/02 06:00 [pubmed]
PHST- 2016/04/15 06:00 [medline]
AID - 00007632-201505010-00008 [pii]
AID - 10.1097/BRS.0000000000000695 [doi]
PST - ppublish
SO  - Spine (Phila Pa 1976). 2015 May 1;40(9):629-35. doi: 
      10.1097/BRS.0000000000000695.

PMID- 33741381
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 900
DP  - 2021 Jun 5
TI  - Preparation of novel anthraquinone-based aspirin derivatives with anti-cancer 
      activity.
PG  - 174020
LID - S0014-2999(21)00173-4 [pii]
LID - 10.1016/j.ejphar.2021.174020 [doi]
AB  - Gastric cancer is one of the most common and deadly cancers among men and women 
      and is the third leading cause of cancer mortality worldwide. Thus, discovering 
      and developing novel therapeutics for gastric cancer has become a global 
      priority. In this study, we synthesized two novel anthraquinone-based aspirin 
      derivatives, Asp-X(3) and Asp-X(3)-CH(3), with therapeutic potential for gastric 
      cancer. The structures of the two compounds were determined by 1D, 2D-NMR, and 
      High-Resolution Mass (HRSM). Asp-X(3) and Asp-X(3)-CH(3) could inhibit the growth 
      of gastric cancer cells (SGC7901), yielding IC(50) values 10-fold lower than that 
      of Aspirin. Asp-X(3) and Asp-X(3)-CH(3) were less toxic to gastric mucosal cells, 
      yielding IC(50) values that were about 2-fold higher than the corresponding 
      IC(50) values determined with SGC7901 cells. Asp-X(3)-CH(3) and Asp-X(3) also 
      induced SGC7901 cells to undergo apoptosis, yielding apoptotic rates that were 
      about twice the rate induced by Aspirin. Asp-X(3)-CH(3) did not cause significant 
      loss of COX-1 expression in gastric mucosal cells, whereas Asp-X(3) and Aspirin 
      both caused significant loss of COX-1 expression as demonstrated by Western blot, 
      consistent with their effects on the content of PGE(2) in these cells as 
      determined by ELISA assay. However, both Asp-X(3)-CH(3) and Asp-X(3) exerted a 
      similar effect on the level of COX-2 in gastric cancer cells, causing as much as 
      90% and 95% reduction in COX-2 expression, respectively. Taken together, the 
      results suggested that Asp-X(3)-CH(3) and Asp-X(3) were potentially better agents 
      than Aspirin for the inhibition of gastric cancer cell growth, but Asp-X(3)-CH(3) 
      was more effective.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Lin, Shan
AU  - Lin S
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      163319, China.
FAU - Zhang, Yue
AU  - Zhang Y
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      163319, China.
FAU - Wang, Zeyu
AU  - Wang Z
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Institute of 
      Chinese Medical Sciences, University of Macau, Macau, China.
FAU - Zhang, Shuang
AU  - Zhang S
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      163319, China.
FAU - Li, Yingjie
AU  - Li Y
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      163319, China.
FAU - Fan, Yuhua
AU  - Fan Y
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      163319, China.
FAU - Li, Dan
AU  - Li D
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      163319, China.
FAU - Li, Sen
AU  - Li S
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      163319, China. Electronic address: lisen_116@163.com.
FAU - Bai, Yuhua
AU  - Bai Y
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      163319, China. Electronic address: 934320968@qq.com.
LA  - eng
PT  - Journal Article
DEP - 20210317
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Anthraquinones)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anthraquinones/*chemical synthesis/*pharmacology
MH  - Antineoplastic Agents/*chemical synthesis/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*analogs & derivatives/chemical synthesis/*pharmacology
MH  - Cell Line, Tumor
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase 2 Inhibitors/pharmacology
MH  - Dinoprostone/metabolism
MH  - Gastric Mucosa/cytology/drug effects
MH  - Humans
MH  - Magnetic Resonance Spectroscopy
MH  - Stomach Neoplasms/chemically induced/*prevention & control
MH  - Structure-Activity Relationship
OTO - NOTNLM
OT  - Anthraquinone
OT  - Aspirin
OT  - Derivatives
OT  - Gastric cancer
OT  - Synthesis
EDAT- 2021/03/21 06:00
MHDA- 2021/05/19 06:00
CRDT- 2021/03/20 05:58
PHST- 2020/12/06 00:00 [received]
PHST- 2021/02/26 00:00 [revised]
PHST- 2021/03/10 00:00 [accepted]
PHST- 2021/03/21 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2021/03/20 05:58 [entrez]
AID - S0014-2999(21)00173-4 [pii]
AID - 10.1016/j.ejphar.2021.174020 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2021 Jun 5;900:174020. doi: 10.1016/j.ejphar.2021.174020. Epub 
      2021 Mar 17.

PMID- 7635003
OWN - NLM
STAT- MEDLINE
DCOM- 19950908
LR  - 20191031
IS  - 0012-6543 (Print)
IS  - 0012-6543 (Linking)
VI  - 32
IP  - 1
DP  - 1994 Jan 20
TI  - Aspirin to prevent heart attack or stroke.
PG  - 1-3
AB  - Each year in the United Kingdom about 250,000 people die from acute myocardial 
      infarction, other ischaemic heart disease or stroke. Many will already have 
      evidence of established vascular disease that predisposes to such an event--such 
      as angina, peripheral vascular disease, atrial fibrillation, transient ischaemic 
      attacks or a previous myocardial infarction or stroke. Others will have risk 
      factors such as hypertension, diabetes mellitus or hyperlipidaemia, but the 
      stroke or heart attack is the first evidence of established vascular disease. 
      Aspirin was first discovered to have antiplatelet properties 30 years ago and 
      since then many randomised clinical trials have sought to determine whether it 
      (or other antiplatelet agents) can protect patients from heart attack or stroke. 
      In this article we review the evidence and update our earlier conclusions on 
      stroke, myocardial infarction, and unstable angina, arguing that aspirin should 
      be widely used to reduce cardiovascular morbidity and mortality in certain 
      high-risk patients.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
RF  - 11
EDAT- 1994/01/20 00:00
MHDA- 1994/01/20 00:01
CRDT- 1994/01/20 00:00
PHST- 1994/01/20 00:00 [pubmed]
PHST- 1994/01/20 00:01 [medline]
PHST- 1994/01/20 00:00 [entrez]
AID - 10.1136/dtb.1994.3211 [doi]
PST - ppublish
SO  - Drug Ther Bull. 1994 Jan 20;32(1):1-3. doi: 10.1136/dtb.1994.3211.

PMID- 2107584
OWN - NLM
STAT- MEDLINE
DCOM- 19900418
LR  - 20190820
IS  - 0090-3019 (Print)
IS  - 0090-3019 (Linking)
VI  - 33
IP  - 3
DP  - 1990 Mar
TI  - Pharmacologic response of endothelium to microvascular temporary clip 
      application.
PG  - 192-4
AB  - To assess the effects of microvascular temporary clip application on vessel 
      relaxing capability and endothelial substance release, the carotid rings of rats 
      clipped for various durations were studied via bioassay. Noradrenaline and 
      phenylephrine produced an immediate contraction and subsequent relaxation that 
      failed to be suppressed by lysine acetylsalicylate or nicotine in the controls 
      and in the arteries clipped for 0.5, 1, and 5 minutes; however, this relaxation 
      was greatly reduced when the duration was 10 minutes. The results suggest the 
      possible role of inadequate endothelium-derived relaxing factor release following 
      prolonged application of the clips.
FAU - Orbay, T
AU  - Orbay T
AD  - Department of Neurosurgery, Gazi University Faculty of Medicine, Ankara, Turkey.
FAU - Ercan, S Z
AU  - Ercan SZ
FAU - Seçkin, Z
AU  - Seçkin Z
FAU - Göksel, M
AU  - Göksel M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Surg Neurol
JT  - Surgical neurology
JID - 0367070
RN  - 1WS297W6MV (Phenylephrine)
RN  - 6M3C89ZY6R (Nicotine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W3ENH1CV (Norepinephrine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cerebrovascular Circulation
MH  - Constriction
MH  - Endothelium, Vascular/*drug effects
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Microcirculation
MH  - Nicotine/pharmacology
MH  - Norepinephrine/pharmacology
MH  - Phenylephrine/pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Time Factors
MH  - Vasoconstriction/*drug effects
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
AID - 0090-3019(90)90183-P [pii]
AID - 10.1016/0090-3019(90)90183-p [doi]
PST - ppublish
SO  - Surg Neurol. 1990 Mar;33(3):192-4. doi: 10.1016/0090-3019(90)90183-p.

PMID- 6776161
OWN - NLM
STAT- MEDLINE
DCOM- 19810126
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 20
IP  - 7
DP  - 1980 Jul
TI  - The analgesic effect of intravenous indoprofen and lysine acetylsalicylate in 
      patients with postoperative pain.
PG  - 475-9
AB  - Indoprofen, as isoindolinyl derivative, was evaluated as a postoperative 
      analgesic in a randomized double-blind, between-patients study on 40 men with 
      postgastrectomy pain. Single intravenous doses of 100 and 300 mg indoprofen and 
      0.5 and 1.5 Gm lysine acetylsalicylate (ASA) were compared in a four-point assay. 
      The method of evaluation relied on subjective appraisal of pain relief by the 
      patient for 6 hours after medication. The results demonstrate the analgesic 
      efficacy of indoprofen in patients with severe postoperative pain, a 
      dose-dependent effect, and a 13-to-16 potency ratio to ASA as judged from total 
      pain relief.
FAU - Cattaneo, A D
AU  - Cattaneo AD
FAU - Roccatagliata, D
AU  - Roccatagliata D
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Phenylpropionates)
RN  - CPE46ZU14N (Indoprofen)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Gastrectomy
MH  - Humans
MH  - Indoprofen/*therapeutic use
MH  - Injections, Intravenous
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Phenylpropionates/*therapeutic use
EDAT- 1980/07/01 00:00
MHDA- 1980/07/01 00:01
CRDT- 1980/07/01 00:00
PHST- 1980/07/01 00:00 [pubmed]
PHST- 1980/07/01 00:01 [medline]
PHST- 1980/07/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1980.tb01721.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1980 Jul;20(7):475-9. doi: 10.1002/j.1552-4604.1980.tb01721.x.

PMID- 16673284
OWN - NLM
STAT- MEDLINE
DCOM- 20060725
LR  - 20131121
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 32
IP  - 3
DP  - 2006 Apr
TI  - Vascular complications in Chuvash polycythemia.
PG  - 289-94
AB  - Chuvash polycythemia is characterized by a homozygous 598C> T germline mutation 
      in the von Hippel-Lindau gene ( VHL), upregulation of hypoxia-inducible 
      factor-1alpha during normoxia, and resulting augmentation of erythropoietin and 
      several other hypoxia-controlled genes. Although endemic to the Chuvash 
      population of Russia, this mutation occurs worldwide and usually originates from 
      a single ancient event. Matched-cohort and case-control analyses have shown that 
      VHL 598C> T homozygosity is associated with lower peripheral blood pressures, 
      varicose veins, vertebral hemangiomas, lower white blood cell and platelet 
      counts, and elevated serum concentrations of vascular endothelial growth factor 
      and plasminogen activator inhibitor-1. These studies have also shown associations 
      with arterial and venous thrombosis, major bleeding episodes, cerebral vascular 
      events, and premature mortality. Spinocerebellar hemangioblastomas, renal 
      carcinomas, and pheochromocytomas typical of classical VHL tumor predisposition 
      syndrome have not been found, and no increased risk of cancer has been 
      demonstrated. Retrospective analyses among patients with Chuvash polycythemia 
      have not shown benefit for therapy with phlebotomy or aspirin, but these and 
      other modes of therapy should be studied prospectively. Further investigation of 
      the vascular complications of Chuvash polycythemia may increase our fundamental 
      knowledge of thrombophilia, bleeding diatheses, and protection from cancer.
FAU - Gordeuk, Victor R
AU  - Gordeuk VR
AD  - Department of Medicine and Center for Sickle Cell Disease, Howard University, 
      Washington, District of Columbia, USA. vgordeuk@howard.edu
FAU - Prchal, Josef T
AU  - Prchal JT
LA  - eng
GR  - 2 R25-HL003679-08/HL/NHLBI NIH HHS/United States
GR  - M01-RR10284/RR/NCRR NIH HHS/United States
GR  - R01HL5007-09/HL/NHLBI NIH HHS/United States
GR  - R01HL66333-01/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Phlebotomy
MH  - Polycythemia/*complications/therapy
MH  - Vascular Diseases/*etiology
RF  - 23
EDAT- 2006/05/05 09:00
MHDA- 2006/07/26 09:00
CRDT- 2006/05/05 09:00
PHST- 2006/05/05 09:00 [pubmed]
PHST- 2006/07/26 09:00 [medline]
PHST- 2006/05/05 09:00 [entrez]
AID - 10.1055/s-2006-939441 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2006 Apr;32(3):289-94. doi: 10.1055/s-2006-939441.

PMID- 32510839
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 1860-7187 (Electronic)
IS  - 1860-7179 (Linking)
VI  - 15
IP  - 15
DP  - 2020 Aug 5
TI  - Surface Modification of Luminescent Ln(III) Fluoride Core-Shell Nanoparticles 
      with Acetylsalicylic acid (Aspirin): Synthesis, Spectroscopic and in Vitro 
      Hemocompatibility Studies.
PG  - 1490-1496
LID - 10.1002/cmdc.202000269 [doi]
AB  - Luminescent lanthanide fluoride core-shell (LaF(3) :Tb(3+) ,Ce(3+) @SiO(2) -NH(2) 
      ) nanoparticles, with acetylsalicylic acid (aspirin) coated on the surface have 
      been obtained. The synthesized products, which combine the potential located in 
      the silica shell with the luminescent activity of the core, were characterized in 
      detail with the use of luminescence spectroscopy, Fourier transform infrared 
      spectroscopy (FTIR), X-ray diffraction (XRD), and transmission electron 
      microscopy (TEM) methods. The in vitro effects of the modified luminescent 
      nanoparticles on human red blood cell (RBC) membrane permeability, RBC shape, and 
      sedimentation rate were investigated to assess the hemocompatibility of the 
      obtained compounds. This study demonstrates that LaF(3) : Tb(3+) 5 %, Ce(3+) 
      10 %@SiO(2) -NH(2) nanoparticles with acetylsalicylic acid (aspirin) coated on 
      the surface are very good precursors for multifunctional drug-delivery systems or 
      bio-imaging probes that can be used safely in potential biomedical applications.
CI  - © 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Kwiatek, Dorota
AU  - Kwiatek D
AD  - Department of Rare Earths, Faculty of Chemistry, Adam Mickiewicz University, 
      Uniwersytetu Poznańskiego 8, 61-614, Poznań, Poland.
AD  - Current address, Department of Molecular Probes and Prodrugs, Institute of 
      Bioorganic Chemistry, Polish Academy of Sciences Z., Noskowskiego 12/14, 61-704, 
      Poznań, Poland.
FAU - Mrówczyńska, Lucyna
AU  - Mrówczyńska L
AD  - Department of Cell Biology, Institute of Experimental Biology, Faculty of 
      Biology, Adam Mickiewicz University, Uniwersytetu Poznańskiego 6, 61-614, Poznań, 
      Poland.
FAU - Stopikowska, Natalia
AU  - Stopikowska N
AD  - Department of Rare Earths, Faculty of Chemistry, Adam Mickiewicz University, 
      Uniwersytetu Poznańskiego 8, 61-614, Poznań, Poland.
FAU - Runowski, Marcin
AU  - Runowski M
AD  - Department of Rare Earths, Faculty of Chemistry, Adam Mickiewicz University, 
      Uniwersytetu Poznańskiego 8, 61-614, Poznań, Poland.
FAU - Lesicki, Andrzej
AU  - Lesicki A
AD  - Department of Cell Biology, Institute of Experimental Biology, Faculty of 
      Biology, Adam Mickiewicz University, Uniwersytetu Poznańskiego 6, 61-614, Poznań, 
      Poland.
FAU - Lis, Stefan
AU  - Lis S
AUID- ORCID: 0000-0002-3989-3913
AD  - Department of Rare Earths, Faculty of Chemistry, Adam Mickiewicz University, 
      Uniwersytetu Poznańskiego 8, 61-614, Poznań, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200624
PL  - Germany
TA  - ChemMedChem
JT  - ChemMedChem
JID - 101259013
RN  - 0 (Biocompatible Materials)
RN  - 0 (Lanthanoid Series Elements)
RN  - Q80VPU408O (Fluorides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry/*pharmacology
MH  - Biocompatible Materials/chemistry/*pharmacology
MH  - Cell Membrane Permeability/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Erythrocytes/drug effects
MH  - Fluorides/chemistry/*pharmacology
MH  - Hemolysis/*drug effects
MH  - Humans
MH  - Lanthanoid Series Elements/chemistry/*pharmacology
MH  - Luminescence
MH  - Luminescent Measurements
MH  - Molecular Structure
MH  - Nanoparticles/*chemistry
MH  - Particle Size
MH  - Structure-Activity Relationship
MH  - Surface Properties
OTO - NOTNLM
OT  - aspirin
OT  - blood contacting applications
OT  - human erythrocytes
OT  - luminescent nanoparticles
OT  - surface-modified core-shell NPs
EDAT- 2020/06/09 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/04/24 00:00 [received]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - 10.1002/cmdc.202000269 [doi]
PST - ppublish
SO  - ChemMedChem. 2020 Aug 5;15(15):1490-1496. doi: 10.1002/cmdc.202000269. Epub 2020 
      Jun 24.

PMID- 9074898
OWN - NLM
STAT- MEDLINE
DCOM- 19970618
LR  - 20181113
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 21
IP  - 4
DP  - 1996 Oct-Dec
TI  - Comparative pharmacokinetics of Aspegic 1000 mg i.v. versus 1000 mg i.m. thrice 
      daily.
PG  - 333-8
AB  - The comparative pharmacokinetics of Aspegic, the lysine salt of acetylsalicylic 
      acid, administered in multi doses either through i.v. or i.m. route was studied. 
      1 g of drug was injected each time with a frequency of 3 times a day. The 
      pharmacokinetic parameters were determined using the experimental data in the 
      literature. From these results, three categories of patients were considered, 
      depending on their response to the drug. A numerical model was established in 
      order to evaluate the following results: the drug level in the blood compartment 
      obtained with the i.v. or i.m. administration, as well as the area under the 
      curve for the first day and the third day when the so-called stationary state was 
      obtained. Approximately similar values for AUC were obtained for each route of 
      administration, for a given category of patients. The effect of the 
      inter-variability of the patients characterised by their response to the drug was 
      found to be of prime importance.
FAU - Nia, B
AU  - Nia B
AD  - Laboratory of Materials and Chemical Engineering, Faculty of Sciences, University 
      of St-Etienne, France.
FAU - Vergnaud, J M
AU  - Vergnaud JM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & 
      dosage/*pharmacokinetics
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacokinetics
MH  - Humans
MH  - Injections, Intramuscular
MH  - Injections, Intravenous
MH  - Lysine/administration & dosage/*analogs & derivatives/pharmacokinetics
MH  - Models, Biological
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - 10.1007/BF03189735 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 1996 Oct-Dec;21(4):333-8. doi: 
      10.1007/BF03189735.

PMID- 32744056
OWN - NLM
STAT- MEDLINE
DCOM- 20210819
LR  - 20220425
IS  - 1724-6016 (Electronic)
IS  - 1120-6721 (Linking)
VI  - 31
IP  - 4
DP  - 2021 Jul
TI  - Continuation of aspirin therapy before pars plana vitrectomy: Safe or not?
PG  - 2013-2019
LID - 10.1177/1120672120946930 [doi]
AB  - PURPOSE: To assess the safety of pars plana vitrectomy (PPV) in patients 
      undergoing systemic treatment with aspirin. METHODS: This prospective study 
      enrolled consecutive patients undergoing PPV under percutaneous retrobulbar 
      anesthesia between February 2016 and July 2018. Sixty-seven eyes from 67 patients 
      on regular aspirin therapy were randomized into two groups: the continuation 
      group (33 eyes), with aspirin continued during the perioperative period; and the 
      discontinuation group (34 eyes), with aspirin discontinued for 3 to 7 days before 
      surgery. Forty-three eyes from 43 patients who had no antiplatelet/anticoagulant 
      therapy were used as a control group. RESULTS: There was no significant 
      difference in the incidence of hemorrhagic complications or the need for 
      additional operations due to hemorrhagic complications among the three groups 
      (p = 0.740 and p = 0.324, respectively). None of the patients in these three 
      groups suffered from thromboembolic events during the follow-up period. Except 
      for one case (3.0%) of lid ecchymosis in the continuation group, no eye 
      experienced bleeding complications associated with the retrobulbar local 
      anesthesia. In the continuation group, three eyes (9.1%) demonstrated 
      postoperative hyphema that resolved spontaneously. In the discontinuation group, 
      two eyes (5.9%) suffered from postoperative vitreous hemorrhage, of which one eye 
      required secondary surgery and the other cleared spontaneously. One eye (2.9%) in 
      the discontinuation group demonstrated postoperative hyphema that absorbed 
      spontaneously. Three eyes (7.0%) in the control group experienced hyphema that 
      absorbed spontaneously. CONCLUSION: The outcomes of our study indicate that PPV 
      under retrobulbar anesthesia can be safely performed without discontinuing 
      systemic aspirin therapy.
FAU - Wang, Jin
AU  - Wang J
AD  - Department of Cardiology, Ninth People's Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Li, Qingjian
AU  - Li Q
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.
AD  - Eye Institute of Xiamen University, School of Medicine, Xiamen University, 
      Xiamen, Fujian, China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Che, Xin
AU  - Che X
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Jiang, Jing
AU  - Jiang J
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Qian, Yiwen
AU  - Qian Y
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Wang, Zhiliang
AU  - Wang Z
AUID- ORCID: 0000-0003-0944-8584
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200802
PL  - United States
TA  - Eur J Ophthalmol
JT  - European journal of ophthalmology
JID - 9110772
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anesthesia, Local
MH  - Aspirin/adverse effects
MH  - Humans
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - *Thromboembolism
MH  - *Vitrectomy
OTO - NOTNLM
OT  - Aspirin
OT  - hemorrhagic complication
OT  - pars plana vitrectomy
EDAT- 2020/08/04 06:00
MHDA- 2021/08/20 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/08/20 06:00 [medline]
PHST- 2020/08/04 06:00 [entrez]
AID - 10.1177/1120672120946930 [doi]
PST - ppublish
SO  - Eur J Ophthalmol. 2021 Jul;31(4):2013-2019. doi: 10.1177/1120672120946930. Epub 
      2020 Aug 2.

PMID- 10656972
OWN - NLM
STAT- MEDLINE
DCOM- 20000502
LR  - 20190610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1495
IP  - 2
DP  - 2000 Feb 2
TI  - Effects of hypoxia and glutathione depletion on hemoglobin- and 
      myoglobin-mediated oxidative stress toward endothelium.
PG  - 150-9
AB  - We investigated the toxicity of hemoglobin/myoglobin on endothelial cells under 
      oxidative stress conditions that include cellular hypoxia and reduced antioxidant 
      capacity. Bovine aorta endothelial cells (BAECs), grown on microcarrier beads, 
      were subjected to cycles of hypoxia and reoxygenation in a small volume of 
      medium, and endothelial cell monolayers were depleted of their intracellular 
      glutathione (GSH) by treatment with buthionine sulfoximine. Incubation of 
      diaspirin cross-linked hemoglobin (DBBF-Hb) or horse skeletal myoglobin (Mb) with 
      BAECs subjected to 3 h of hypoxia caused transient oxidation of the hemoproteins 
      to the ferryl form (Fe(4+)). Formation of the ferryl intermediate was decreased 
      in a concentration-dependent manner by the addition of L-arginine, a substrate of 
      NO synthase, after 3 h of hypoxia. Optimal inhibition of ferryl formation, 
      possibly due to the antioxidant action of NO, was achieved with 900 microM 
      L-arginine. Addition of hydrogen peroxide to GSH-depleted cells in the presence 
      of DBBF-Hb or Mb significantly decreased cell viability. Ferryl Mb, but not 
      ferryl DBBF-Hb, was observed in samples analyzed at the end of treatment, which 
      may explain the greater toxicity observed with Mb as opposed to DBBF-Hb. This 
      model may be utilized to identify causative agent(s) associated with hemoprotein 
      cytotoxicity and in designing strategies to suppress or control heme-mediated 
      injury under physiologically relevant conditions.
FAU - D'Agnillo, F
AU  - D'Agnillo F
AD  - Laboratory of Plasma Derivatives, Division of Hematology, Center for Biologics 
      Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bldg. 
      29, Rm. 112, Bethesda, MD 20892, USA.
FAU - Wood, F
AU  - Wood F
FAU - Porras, C
AU  - Porras C
FAU - Macdonald, V W
AU  - Macdonald VW
FAU - Alayash, A I
AU  - Alayash AI
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Myoglobin)
RN  - 0 (bis(3,5-dibromosalicyl)fumarate-crosslinked hemoglobin A(0))
RN  - 9034-51-9 (Hemoglobin A)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cattle
MH  - *Cell Hypoxia
MH  - Cell Survival
MH  - Cells, Cultured
MH  - Endothelium, Vascular/*metabolism
MH  - Glutathione/*deficiency
MH  - Hemoglobin A/pharmacology
MH  - Hydrogen Peroxide/pharmacology
MH  - Lipid Peroxidation/drug effects
MH  - Myoglobin/pharmacology
MH  - Oxidative Stress
MH  - Spectrophotometry
EDAT- 2000/02/05 09:00
MHDA- 2000/05/08 09:00
CRDT- 2000/02/05 09:00
PHST- 2000/02/05 09:00 [pubmed]
PHST- 2000/05/08 09:00 [medline]
PHST- 2000/02/05 09:00 [entrez]
AID - S0167-4889(99)00163-9 [pii]
AID - 10.1016/s0167-4889(99)00163-9 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2000 Feb 2;1495(2):150-9. doi: 
      10.1016/s0167-4889(99)00163-9.

PMID- 8773739
OWN - NLM
STAT- MEDLINE
DCOM- 19961122
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 24
IP  - 3
DP  - 1996 May
TI  - Diaspirin crosslinked hemoglobin (DCLHb): more effective than lactated Ringer's 
      solution in restoring central venous oxygen saturation after hemorrhagic shock in 
      rats.
PG  - 197-200
AB  - Central venous oxygen saturation (ScvO2) has been shown to reflect tissue oxygen 
      consumption in hemorrhagic shock. The purpose of this study was to test whether 
      the "blood substitute" diaspirin crosslinked hemoglobin (DCLHb, Baxter 
      Healthcare, Round Lake, IL) might be more effective than lactated Ringer's 
      solution (LR) at restoring tissue oxygenation, as measured by ScvO2, when used as 
      a resuscitative fluid following hemorrhage. Conscious male Sprague-Dawley rats 
      (250-350 gm) were bled through a jugular venous catheter to a target central 
      venous base deficit of 15 +/- 2 mmol/L. Animals were immediately resuscitated 
      with either 10% DCLHb (1:1) or LR (3:1), based on shed blood volume, followed by 
      a maintenance infusion of LR until completion of the experiment. Central venous 
      blood was sampled at baseline, prior to resuscitation and every 15 minutes for 
      the first hour following resuscitation. While the baseline and pre-resuscitation 
      ScvO2 values were not significantly different between groups, ScvO2 values were 
      greater (P < or = 0.01) in the DCLHb group at all times following resuscitation. 
      Furthermore, DCLHb restored SvO2 to baseline by 15 minutes after resuscitation, 
      whereas LR resuscitation never restored ScvO2 to baseline. Since venous 
      desaturation is one of the major compensatory mechanisms by which oxygen 
      consumption is maintained under conditions of limited oxygen supply, these data 
      suggest that animals resuscitated with DCLHb had a more rapid restoration of 
      tissue oxygenation than those resuscitated with LR in this model of hemorrhagic 
      shock.
FAU - Powell, C C
AU  - Powell CC
AD  - Department of Surgery, Uniformed Services University of the Health Sciences, 
      Bethesda, MD, USA.
FAU - Schultz, S C
AU  - Schultz SC
FAU - Malcolm, D S
AU  - Malcolm DS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Hemoglobins)
RN  - 0 (Isotonic Solutions)
RN  - 0 (Ringer's Lactate)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Disease Models, Animal
MH  - Hemoglobins/*therapeutic use
MH  - Isotonic Solutions/*therapeutic use
MH  - Jugular Veins
MH  - Male
MH  - Oxygen/*blood
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Ringer's Lactate
MH  - Shock, Hemorrhagic/blood/*drug therapy
MH  - Treatment Outcome
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 10.3109/10731199609117435 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1996 May;24(3):197-200. doi: 
      10.3109/10731199609117435.

PMID- 7889440
OWN - NLM
STAT- MEDLINE
DCOM- 19950419
LR  - 20131121
IS  - 0828-282X (Print)
IS  - 0828-282X (Linking)
VI  - 11
IP  - 3
DP  - 1995 Mar
TI  - Individual variation in the effects of ASA on platelet function: implications for 
      the use of ASA clinically.
PG  - 221-7
AB  - OBJECTIVE: To determine whether acetylsalicylic acid (ASA) inhibits hemostasis 
      and platelet function in some individuals (ASA responders) but not in others (ASA 
      nonresponders). DESIGN: In this two-part study, part 1 was a randomized, 
      double-blind crossover study of the effects of various single doses of ASA (80 to 
      1300 mg) on primary hemostasis and platelet function. Part 2 was a prospective 
      cohort study of the effects of a chronic dose of ASA (325 mg) on primary 
      hemostasis and platelet function. SETTING: A hospital research laboratory and a 
      cardiac care ward. SUBJECTS: Part 1: 10 healthy volunteers (five male, five 
      female). Part 2: 40 consecutive patients undergoing elective coronary artery 
      bypass grafting (CABG). RESULTS: Part 1: ASA, in a dose-related manner, prolonged 
      the bleeding time in 60% of volunteers (ASA responders), which was associated 
      with decreases in platelet thromboxane (Tx) A2 and 12-hydroxyeicosatetraenoic 
      acid (12-HETE) synthesis and in platelet aggregation and adhesion. However, in 
      volunteers whose bleeding time was not prolonged (ASA nonresponders), platelet 
      12-HETE synthesis and platelet adhesion were unchanged or increased (P < 0.001), 
      despite platelet TxA2 and platelet aggregation being inhibited. Part 2: 
      similarly, 58% of the CABG patients were ASA responders and all of their platelet 
      biochemistry and function tests were inhibited, while in the CABG patient ASA 
      nonresponders (no prolongation of bleeding time), platelet 12-HETE and platelet 
      adhesion were increased (P < 0.001).
FAU - Buchanan, M R
AU  - Buchanan MR
AD  - Department of Pathology, McMaster University, Hamilton, Ontario.
FAU - Brister, S J
AU  - Brister SJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects/physiology
MH  - *Coronary Artery Bypass
MH  - Coronary Disease/drug therapy/*physiopathology/surgery
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
PST - ppublish
SO  - Can J Cardiol. 1995 Mar;11(3):221-7.

PMID- 7894282
OWN - NLM
STAT- MEDLINE
DCOM- 19950427
LR  - 20181113
IS  - 0008-350X (Print)
IS  - 1715-5258 (Electronic)
IS  - 0008-350X (Linking)
VI  - 41
DP  - 1995 Jan
TI  - Low-dose acetylsalicylic acid use and hemoglobin levels. Effects in a primary 
      care population.
PG  - 64-8
AB  - OBJECTIVE: To determine the prevalence of acetylsalicylic acid therapy and effect 
      of the drug on hemoglobin concentration over time. DESIGN: Retrospective, 
      observational study. SETTING: Primary care population in a university-affiliated 
      family medicine clinic. PATIENTS: A population-based sample of 80 patients 
      receiving low-dose ASA for secondary prevention of cardiovascular disease was 
      studied. Of 84 patients receiving the drug after a cardiovascular problem, four 
      were excluded: one man died of a recurrent stroke during the study; the file of a 
      second man was unavailable; another man developed a bleeding ulcer; and one woman 
      had been taking ASA for only 1 month when the data were collated. MAIN OUTCOME 
      MEASURES: Demographic variables of patients taking low-dose ASA, duration of ASA 
      use, and two successive measures of hemoglobin level. RESULTS: The frequency of 
      ASA administration was 7.7% for men aged 60 and older and 2.9% for women. Women 
      had no significant change in hemoglobin levels, while men had a mean loss of 
      0.472 g/dL (95% confidence interval, .198 to .746; P = .009). For the study 
      population as a whole (80 patients), the average decline was 0.294 g/dL (95% 
      confidence interval, .039 to .549; P = .029). CONCLUSIONS: Although the clinical 
      significance of these findings is uncertain, they suggest the need for a 
      prospective investigation of the influence of low-dose ASA on hemoglobin levels.
FAU - Leibovici, A
AU  - Leibovici A
AD  - Department of Family Medicine, Faculty of Health Sciences, Ben-Gurion University 
      of the Negev.
FAU - Lavi, N
AU  - Lavi N
FAU - Wainstok, S
AU  - Wainstok S
FAU - Herman, J
AU  - Herman J
FAU - Greene, V W
AU  - Greene VW
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Fam Physician
JT  - Canadian family physician Medecin de famille canadien
JID - 0120300
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Family Practice
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Hemoglobins/*analysis
MH  - Humans
MH  - Israel
MH  - Male
MH  - Middle Aged
MH  - Outpatient Clinics, Hospital
MH  - Prevalence
MH  - Retrospective Studies
PMC - PMC2145980
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Can Fam Physician. 1995 Jan;41:64-8.

PMID- 27488919
OWN - NLM
STAT- MEDLINE
DCOM- 20170526
LR  - 20200214
IS  - 1521-0103 (Electronic)
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 359
IP  - 1
DP  - 2016 Oct
TI  - Development of Poly Unsaturated Fatty Acid Derivatives of Aspirin for Inhibition 
      of Platelet Function.
PG  - 134-41
LID - 10.1124/jpet.116.234781 [doi]
AB  - The inhibition of platelet aggregation is key to preventing conditions such as 
      myocardial infarction and ischemic stroke. Aspirin is the most widely used drug 
      to inhibit platelet aggregation. Aspirin absorption can be improved further to 
      increase its permeability across biologic membranes via esterification or 
      converting the carboxylic acid to an anhydride. There are several reports 
      indicating that ω-3 and ω-6 fatty acids such as linoleic acid, eicosapentaenoic 
      acid (EPA), and docosahexaenoic acid (DHA) separately inhibit platelet 
      aggregation. Herein, we synthesize anhydride conjugates of aspirin with linoleic 
      acid, EPA, and DHA to form aspirin anhydrides that are expected to have higher 
      permeability across cellular membranes. These aspirin-fatty acid anhydrides 
      inhibited platelet aggregation in washed human platelets and platelet-rich plasma 
      in a dose-dependent manner. In particular, the aspirin-DHA anhydride displayed 
      similar effectiveness to aspirin. Platelet aggregation studies conducted in the 
      presence of various platelet agonists indicated that the aspirin-lipid conjugates 
      act through inhibition of the cyclooxygenase (COX)-thromboxane synthase (TXAS) 
      pathway. Hence, we performed detailed biochemical studies using purified COX-1 as 
      well as TXAS stabilized in nanoscale lipid bilayers of nanodiscs to confirm 
      results from the platelet aggregation studies. We show that although all of the 
      aspirin conjugates act through the COX-TXAS pathway by inhibiting COX-1, the 
      parent fatty acids do not act via this pathway. Finally, we studied the 
      hydrolysis of these compounds in buffer and human plasma, and we demonstrate that 
      all of the aspirin-fatty acid conjugates hydrolyze to the parent molecules 
      aspirin and fatty acid in a controlled manner.
CI  - Copyright © 2016 by The American Society for Pharmacology and Experimental 
      Therapeutics.
FAU - Roy, Jahnabi
AU  - Roy J
AD  - Department of Chemistry (J.R.), Division of Nutritional Sciences, Departments of 
      Comparative Biosciences, Biochemistry, and Bioengineering, Center for Biophysics 
      and Quantitative Biology, Beckman Institute for Advanced Science (A.D.), 
      University of Illinois at Urbana-Champaign, Urbana, Illinois; Division of 
      Cardiovascular Medicine (M.H.), Department of Pharmacology (R.A., M.H.), 
      University of Michigan Medical School, Ann Arbor, Michigan; and Department of 
      Internal Medicine, Texas Health Science Center, McGovern Medical School, Houston, 
      Texas (R.K.).
FAU - Adili, Reheman
AU  - Adili R
AD  - Department of Chemistry (J.R.), Division of Nutritional Sciences, Departments of 
      Comparative Biosciences, Biochemistry, and Bioengineering, Center for Biophysics 
      and Quantitative Biology, Beckman Institute for Advanced Science (A.D.), 
      University of Illinois at Urbana-Champaign, Urbana, Illinois; Division of 
      Cardiovascular Medicine (M.H.), Department of Pharmacology (R.A., M.H.), 
      University of Michigan Medical School, Ann Arbor, Michigan; and Department of 
      Internal Medicine, Texas Health Science Center, McGovern Medical School, Houston, 
      Texas (R.K.).
FAU - Kulmacz, Richard
AU  - Kulmacz R
AD  - Department of Chemistry (J.R.), Division of Nutritional Sciences, Departments of 
      Comparative Biosciences, Biochemistry, and Bioengineering, Center for Biophysics 
      and Quantitative Biology, Beckman Institute for Advanced Science (A.D.), 
      University of Illinois at Urbana-Champaign, Urbana, Illinois; Division of 
      Cardiovascular Medicine (M.H.), Department of Pharmacology (R.A., M.H.), 
      University of Michigan Medical School, Ann Arbor, Michigan; and Department of 
      Internal Medicine, Texas Health Science Center, McGovern Medical School, Houston, 
      Texas (R.K.).
FAU - Holinstat, Michael
AU  - Holinstat M
AD  - Department of Chemistry (J.R.), Division of Nutritional Sciences, Departments of 
      Comparative Biosciences, Biochemistry, and Bioengineering, Center for Biophysics 
      and Quantitative Biology, Beckman Institute for Advanced Science (A.D.), 
      University of Illinois at Urbana-Champaign, Urbana, Illinois; Division of 
      Cardiovascular Medicine (M.H.), Department of Pharmacology (R.A., M.H.), 
      University of Michigan Medical School, Ann Arbor, Michigan; and Department of 
      Internal Medicine, Texas Health Science Center, McGovern Medical School, Houston, 
      Texas (R.K.).
FAU - Das, Aditi
AU  - Das A
AD  - Department of Chemistry (J.R.), Division of Nutritional Sciences, Departments of 
      Comparative Biosciences, Biochemistry, and Bioengineering, Center for Biophysics 
      and Quantitative Biology, Beckman Institute for Advanced Science (A.D.), 
      University of Illinois at Urbana-Champaign, Urbana, Illinois; Division of 
      Cardiovascular Medicine (M.H.), Department of Pharmacology (R.A., M.H.), 
      University of Michigan Medical School, Ann Arbor, Michigan; and Department of 
      Internal Medicine, Texas Health Science Center, McGovern Medical School, Houston, 
      Texas (R.K.) aditidas@illinois.edu.
LA  - eng
GR  - R01 GM105671/GM/NIGMS NIH HHS/United States
GR  - R01 GM115584/GM/NIGMS NIH HHS/United States
GR  - R01 HL114405/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160803
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fatty Acids, Omega-3)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 5.3.99.5 (Thromboxane-A Synthase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*chemistry/*pharmacology
MH  - Blood Platelets/*drug effects/*physiology
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase Inhibitors/*chemistry/*pharmacology
MH  - Drug Discovery
MH  - Fatty Acids, Omega-3/*chemistry
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Sf9 Cells
MH  - Spodoptera
MH  - Thromboxane-A Synthase/antagonists & inhibitors
PMC - PMC6047226
EDAT- 2016/08/05 06:00
MHDA- 2017/05/27 06:00
CRDT- 2016/08/05 06:00
PHST- 2016/04/27 00:00 [received]
PHST- 2016/08/01 00:00 [accepted]
PHST- 2016/08/05 06:00 [entrez]
PHST- 2016/08/05 06:00 [pubmed]
PHST- 2017/05/27 06:00 [medline]
AID - jpet.116.234781 [pii]
AID - JPET_234781 [pii]
AID - 10.1124/jpet.116.234781 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2016 Oct;359(1):134-41. doi: 10.1124/jpet.116.234781. Epub 
      2016 Aug 3.

PMID- 670028
OWN - NLM
STAT- MEDLINE
DCOM- 19780925
LR  - 20171213
IS  - 0161-7567 (Print)
IS  - 0161-7567 (Linking)
VI  - 45
IP  - 1
DP  - 1978 Jul
TI  - Influence of aspirin and indomethacin on variability of alveolar hypoxic 
      vasoconstriction.
PG  - 33-9
AB  - Alveolar hypoxia induces pulmonary vasoconstriction but the strength of alveolar 
      hypoxic vasoconstriction (AHV) is variable even within the same species. The 
      influence of aspirin and indomethacin, cyclo-oxygenase inhibitors, was examined 
      in two groups of dogs, those with weak AHV and those with vigorous AHV. A 
      double-lumen endotracheal tube allowed ventilation of one lung with nitrogen as 
      an alveolar hypoxic stimulus and ventilation of the other lung with O2 to 
      maintain systemic oxygenation. Perfusion to each lung was measured with xenon-133 
      and external counters. In weak reactors both aspirin and indomethacin induced 
      fourfold enhancement of AHV (P less than 0.01), whereas no significant influence 
      on vigorous reactors was noted. Cyclo-oxygenase inhibitors also produced enhanced 
      reactivity in the isolated lung to alveolar hypoxia and prostaglandin F2alpha but 
      not to angiotensin II and norepinephrine. Aspirin-enhanced AHV in the isolated 
      lung could not be diminished with blockade of angiotensin II receptors or of 
      alpha receptors. In summary, weak AHV in intact or isolated dog lung may be due 
      to an excess of a prostaglandin or prostacyclin vasodilator.
FAU - Hales, C A
AU  - Hales CA
FAU - Rouse, E T
AU  - Rouse ET
FAU - Slate, J L
AU  - Slate JL
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Appl Physiol Respir Environ Exerc Physiol
JT  - Journal of applied physiology: respiratory, environmental and exercise physiology
JID - 7801242
RN  - N762921K75 (Nitrogen)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dogs
MH  - Hypoxia
MH  - In Vitro Techniques
MH  - Indomethacin/*pharmacology
MH  - Nitrogen
MH  - Oxygen
MH  - Pulmonary Alveoli/*blood supply
MH  - Respiration
MH  - Vasoconstriction/*drug effects
EDAT- 1978/07/01 00:00
MHDA- 1978/07/01 00:01
CRDT- 1978/07/01 00:00
PHST- 1978/07/01 00:00 [pubmed]
PHST- 1978/07/01 00:01 [medline]
PHST- 1978/07/01 00:00 [entrez]
AID - 10.1152/jappl.1978.45.1.33 [doi]
PST - ppublish
SO  - J Appl Physiol Respir Environ Exerc Physiol. 1978 Jul;45(1):33-9. doi: 
      10.1152/jappl.1978.45.1.33.

PMID- 16520473
OWN - NLM
STAT- MEDLINE
DCOM- 20060327
LR  - 20190619
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 144
IP  - 5
DP  - 2006 Mar 7
TI  - Aspirin, statins, or both drugs for the primary prevention of coronary heart 
      disease events in men: a cost-utility analysis.
PG  - 326-36
AB  - BACKGROUND: Aspirin and statins are both effective for primary prevention of 
      coronary heart disease (CHD), but their combined use has not been well studied. 
      OBJECTIVE: To perform a cost-utility analysis of the effects of aspirin therapy, 
      statin therapy, combination therapy with both drugs, and no pharmacotherapy for 
      the primary prevention of CHD events in men. DESIGN: Markov model. DATA SOURCES: 
      Published literature. TARGET POPULATION: Middle-aged men without a history of 
      cardiovascular disease at 6 levels of 10-year risk for CHD (2.5%, 5%, 7.5%, 10%, 
      15%, and 25%). TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. 
      INTERVENTIONS: Low-dose aspirin, a statin, both drugs as combination therapy, or 
      no therapy. OUTCOME MEASURE: Cost per quality-adjusted life-year gained. RESULTS 
      OF BASE-CASE ANALYSIS: For 45-year-old men who do not smoke, are not 
      hypertensive, and have a 10-year risk for CHD of 7.5%, aspirin was more effective 
      and less costly than no treatment. The addition of a statin to aspirin therapy 
      produced an incremental cost-utility ratio of 56,200 dollars per quality-adjusted 
      life-year gained compared with aspirin alone. RESULTS OF SENSITIVITY ANALYSIS: 
      Excess risk for hemorrhagic stroke and gastrointestinal bleeding with aspirin, 
      risk for CHD, the cost of statins, and the disutility of taking medication had 
      important effects on the cost-utility ratios. LIMITATIONS: Several input 
      parameters, particularly adverse event rates and utility values, are supported by 
      limited empirical data. Results are applicable to middle-aged men only. 
      CONCLUSIONS: Compared with no treatment, aspirin is less costly and more 
      effective for preventing CHD events in middle-aged men whose 10-year risk for CHD 
      is 7.5% or higher. The addition of a statin to aspirin therapy becomes more 
      cost-effective when the patient's 10-year CHD risk before treatment is higher 
      than 10%.
FAU - Pignone, Michael
AU  - Pignone M
AD  - University of North Carolina Division of General Internal Medicine, and 
      RTI-University of North Carolina Center for Health Promotion Economics, Chapel 
      Hill, North Carolina 27599-7110, USA. pignone@med.unc.edu
FAU - Earnshaw, Stephanie
AU  - Earnshaw S
FAU - Tice, Jeffrey A
AU  - Tice JA
FAU - Pletcher, Mark J
AU  - Pletcher MJ
LA  - eng
GR  - 1P30CD000138-01/CD/ODCDC CDC HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- Ann Intern Med. 2006 Mar 7;144(5):I29. PMID: 16520469
CIN - Ann Intern Med. 2006 Aug 1;145(3):233; author reply 233-4. PMID: 16880474
MH  - Aspirin/adverse effects/*economics/*therapeutic use
MH  - Computer Simulation
MH  - Coronary Disease/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Drug Costs
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/adverse effects/*economics/*therapeutic use
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*economics/*therapeutic use
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Primary Prevention
MH  - Quality-Adjusted Life Years
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Stroke/chemically induced
EDAT- 2006/03/08 09:00
MHDA- 2006/03/28 09:00
CRDT- 2006/03/08 09:00
PHST- 2006/03/08 09:00 [pubmed]
PHST- 2006/03/28 09:00 [medline]
PHST- 2006/03/08 09:00 [entrez]
AID - 144/5/326 [pii]
AID - 10.7326/0003-4819-144-5-200603070-00007 [doi]
PST - ppublish
SO  - Ann Intern Med. 2006 Mar 7;144(5):326-36. doi: 
      10.7326/0003-4819-144-5-200603070-00007.

PMID- 25849465
OWN - NLM
STAT- MEDLINE
DCOM- 20160104
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 4
DP  - 2015
TI  - Aspirin use and lung cancer risk: a possible relationship? Evidence from an 
      updated meta-analysis.
PG  - e0122962
LID - 10.1371/journal.pone.0122962 [doi]
LID - e0122962
AB  - BACKGROUND AND PURPOSE: Growing evidence has emerged and controversial results 
      reported on possible relationship between aspirin use and lung cancer risk. We, 
      therefore, conducted this updated and comprehensive meta-analysis to evaluate 
      this issue, with focus on dose-risk and duration-risk relationships. METHODS: We 
      searched electronic databases including PUBMED, EMBASE and Cochrane library to 
      identify eligible studies. Relative risk (RR) and its 95% confidence interval 
      (CI) were used for cohort studies, while odds ratio (OR) were employed for 
      case-control studies. The random effects and fixed effects models were used for 
      analyses. RESULTS: 18 studies were identified including 19835 lung cancer cases, 
      which were eligible for inclusion in the present meta-analysis. Pooled data from 
      case-control studies showed a significant inverse association between regular 
      aspirin use and lung cancer risk. But for cohort studies, insignificant 
      association was detected with little evidence of heterogeneity (RR: 1.05, 95%CI: 
      0.95 - 1.16; I2: 10.3%, p value: 0.351). In case-control studies, standard 
      aspirin use (>325mg) was related to lower lung cancer incidence, compared with 
      low-dose aspirin use (75-100mg). A similar trend was observed in cohort studies. 
      Besides, when analysis was restricted to long time regular aspirin use (>5 
      years), insignificant results were reported in both cohort and case-control 
      studies. Finally, regular aspirin use might result in higher reduction of 
      non-small cell lung cancer incidence among men. CONCLUSIONS: Our findings do not 
      support the protective effect of regular aspirin use on lung cancer risk. Long 
      time aspirin use, sex, dose and type of lung cancer might alter the effect of 
      aspirin use on lung cancer risk. More well-designed studies are needed to further 
      clarify these associations.
FAU - Jiang, Hai-yan
AU  - Jiang HY
AD  - Electrocardiographic room, Shanghai Tenth People's Hospital, Tongji University, 
      Shanghai, China.
FAU - Huang, Tian-bao
AU  - Huang TB
AD  - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, 
      Shanghai, China; Department of First Clinical Medical College, Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Xu, Lei
AU  - Xu L
AD  - Department of First Clinical Medical College, Nanjing Medical University, 
      Nanjing, Jiangsu, China; Department of respiratory medicine, Shanghai Tenth 
      People's Hospital, Tongji University, Shanghai, China.
FAU - Yu, Jing
AU  - Yu J
AD  - Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University, 
      Shanghai, China.
FAU - Wu, Yan
AU  - Wu Y
AD  - Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University, 
      Shanghai, China.
FAU - Geng, Jiang
AU  - Geng J
AD  - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, 
      Shanghai, China.
FAU - Yao, Xu-dong
AU  - Yao XD
AD  - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, 
      Shanghai, China; Department of First Clinical Medical College, Nanjing Medical 
      University, Nanjing, Jiangsu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20150407
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Anticarcinogenic Agents/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*prevention & control
MH  - Case-Control Studies
MH  - Humans
MH  - Lung Neoplasms/*chemically induced
MH  - Risk Assessment
MH  - Sex Distribution
PMC - PMC4388842
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/04/08 06:00
MHDA- 2016/01/05 06:00
CRDT- 2015/04/08 06:00
PHST- 2014/10/11 00:00 [received]
PHST- 2015/02/17 00:00 [accepted]
PHST- 2015/04/08 06:00 [entrez]
PHST- 2015/04/08 06:00 [pubmed]
PHST- 2016/01/05 06:00 [medline]
AID - PONE-D-14-38707 [pii]
AID - 10.1371/journal.pone.0122962 [doi]
PST - epublish
SO  - PLoS One. 2015 Apr 7;10(4):e0122962. doi: 10.1371/journal.pone.0122962. 
      eCollection 2015.

PMID- 14651540
OWN - NLM
STAT- MEDLINE
DCOM- 20040226
LR  - 20191108
IS  - 1328-8067 (Print)
IS  - 1328-8067 (Linking)
VI  - 45
IP  - 6
DP  - 2003 Dec
TI  - Tolmetin and salicylate therapy in acute rheumatic fever: Comparison of clinical 
      efficacy and side-effects.
PG  - 676-9
AB  - BACKGROUND: The arthritis of rheumatic fever is very responsive to treatment with 
      salicylates, but there are many adverse reactions, especially hepatotoxicity, due 
      to aspirin (acetylsalicylic acid) therapy. These side-effects change the course 
      and duration of rheumatic fever. Other non-steroidal anti-inflammatory drugs may 
      be equally effective, although no reports are available. METHODS: We studied 72 
      patients with rheumatic fever who were admitted to Dr Sami Ulus Children's 
      Hospital between 1995 and 1999. Twenty patients with arthritis were treated with 
      tolmetin (25 mg/kg per day; group I) and 52 patients with arthritis and/or mild 
      carditis were put on aspirin therapy (75-100 mg/kg per day) for 4-6 weeks (group 
      II). Arthritis had disappeared at the same time in both the aspirin and tolmetin 
      groups (P = 0.675). RESULTS: The erythrocyte sedimentation rates of patients upon 
      admission, at the first week and at the end of therapy were not different in the 
      two groups (P > 0.05). No adverse effect of tolmetin therapy was observed, 
      whereas side-effects of salicylate were observed in 19 patients (36.5%) in the 
      aspirin group. Hepatotoxicity, gastric irritation and salicylism were found in 
      16, four and three patients, respectively. Renal toxicity and Reye syndrome were 
      not demonstrated. Because of these side-effects of aspirin, therapy had to be 
      stopped for 10-20 days and the duration of hospitalization in this group was 
      lengthened unnecessarily. CONCLUSION: Tolmetin was safe and effective treatment 
      for arthritic rheumatic fever patients without carditis. Tolmetin can be used 
      particularly in patients who cannot tolerate aspirin.
FAU - Karademir, Selmin
AU  - Karademir S
AD  - Department of Pediatric Cardiology, Dr Sami Ulus Children's Hospital, Ankara, 
      Turkey. ckarakurt@yahoo.com
FAU - Oğuz, Deniz
AU  - Oğuz D
FAU - Senocak, Filiz
AU  - Senocak F
FAU - Ocal, Burhan
AU  - Ocal B
FAU - Karakurt, Cemşit
AU  - Karakurt C
FAU - Cabuk, Feryal
AU  - Cabuk F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Australia
TA  - Pediatr Int
JT  - Pediatrics international : official journal of the Japan Pediatric Society
JID - 100886002
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Rheumatic Fever/*drug therapy
MH  - Tolmetin/adverse effects/*therapeutic use
EDAT- 2003/12/04 05:00
MHDA- 2004/02/27 05:00
CRDT- 2003/12/04 05:00
PHST- 2003/12/04 05:00 [pubmed]
PHST- 2004/02/27 05:00 [medline]
PHST- 2003/12/04 05:00 [entrez]
AID - 1801 [pii]
AID - 10.1111/j.1442-200x.2003.01801.x [doi]
PST - ppublish
SO  - Pediatr Int. 2003 Dec;45(6):676-9. doi: 10.1111/j.1442-200x.2003.01801.x.

PMID- 1342901
OWN - NLM
STAT- MEDLINE
DCOM- 19940222
LR  - 20161123
IS  - 1018-9068 (Print)
IS  - 1018-9068 (Linking)
VI  - 2
IP  - 4
DP  - 1992 Jul-Aug
TI  - Bronchial challenge with aspirin lysine in the diagnosis of asthmatics with 
      sensitization to aspirin and its inhibition by aerosolized furosemide.
PG  - 196-204
AB  - We performed bronchial challenge with ASA lysine in 9 patients with a history of 
      aspirin-induced asthma, 4 asthmatics with no history of hypersensitization to 
      aspirin and 4 control subjects. The test consisted of successive inhalations of 
      increasing concentrations of ASA lysine (11.25, 22.5, 45, 90, 180 and 360 mg/ml) 
      and was interrupted when FEV1 showed a decrease of at least 20%. In order to 
      determine the degree of bronchial hyperreactivity, we first carried out a 
      bronchial challenge with histamine. All patients in the group sensitive to 
      aspirin had a positive reaction to ASA lysine, while this was negative for 
      patients in the two control groups. There was no significant correlation between 
      PC20 to histamine and ASA lysine in any of the groups. On the other hand, 6 
      patients with sensitivity to ASA repeated the bronchial challenge with ASA lysine 
      after previously inhaling furosemide, and in this second test, none of the 6 had 
      a positive reaction. The variation of ASA lysine PC20 in both tests was positive 
      for these patients (p < 0.001).
FAU - Croce, M
AU  - Croce M
AD  - Allergy and Clinical Immunology Service, Clinical Hospital, Faculty of Medicine, 
      University of São Paulo, Brazil.
FAU - Costa Manso, E
AU  - Costa Manso E
FAU - Croce, J
AU  - Croce J
FAU - Gato, J J
AU  - Gato JJ
FAU - Vargas, F
AU  - Vargas F
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - J Investig Allergol Clin Immunol
JT  - Journal of investigational allergology & clinical immunology
JID - 9107858
RN  - 0 (Aerosols)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aerosols
MH  - Aspirin/administration & dosage/*adverse effects/*analogs & derivatives
MH  - Asthma/drug therapy/*etiology/physiopathology
MH  - Bronchial Hyperreactivity/drug therapy/etiology
MH  - Bronchial Provocation Tests
MH  - Child
MH  - Drug Hypersensitivity/*diagnosis/drug therapy/*etiology
MH  - Female
MH  - Furosemide/administration & dosage
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Middle Aged
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
PST - ppublish
SO  - J Investig Allergol Clin Immunol. 1992 Jul-Aug;2(4):196-204.

PMID- 17697437
OWN - NLM
STAT- MEDLINE
DCOM- 20080310
LR  - 20161124
IS  - 1748-5460 (Electronic)
IS  - 0022-2151 (Linking)
VI  - 121
IP  - 12
DP  - 2007 Dec
TI  - Intranasal lysine-aspirin administration decreases polyp volume in patients with 
      aspirin-intolerant asthma.
PG  - 1156-60
AB  - INTRODUCTION: Nasal polyposis associated with aspirin-intolerant asthma tends to 
      be difficult to control, with frequent recurrences. We examined the effect of 
      intranasal lysine-aspirin administration on resistant nasal polyps of asthmatic, 
      aspirin-intolerant patients, when used in addition to routine therapy. PATIENTS 
      AND METHODS: Thirteen patients with asthma and intolerance to aspirin were 
      recruited. All but one had undergone numerous polypectomies and were uncontrolled 
      on standard therapy with intranasal corticosteroids, leukotriene receptor 
      antagonists and nasal douching. Aspirin treatment involved one drop (100 microl) 
      of 30 mg/ml lysine-aspirin solution to each nostril, initially daily, increased 
      every two or three days up to a maximal of 18 drops (54 mg lysine-aspirin) a day. 
      Nasal symptoms, nitric oxide level, nasal inspiratory peak flow rate, peak 
      expiratory flow rate and nasendoscopic grading were assessed prior to therapy and 
      three months later. We also compared the change in endoscopic polyp scores during 
      three months of lysine-aspirin administration with the changes which had occurred 
      during the three months prior to administration (during which time other 
      therapies had been identical). RESULTS: Nasal blockage symptoms tended to 
      decrease; other nasal symptoms were unchanged. Significant changes were seen in 
      nasal inspiratory peak flow rate (103.3 +/- 18.9 and 140.0 +/- 16.7 l/min before 
      and after aspirin, respectively; p = 0.014), but not in peak expiratory flow rate 
      (438.7 +/- 33.4 and 440.0 +/- 28.4 l/min before and after aspirin, respectively; 
      p = 0.700). Nasal nitric oxide levels rose significantly (in both sides, p = 
      0.028). Expired chest nitric oxide levels did not change. Nasal polyp scores on 
      nasendoscopic examination were significantly reduced (right side, p = 0.027; left 
      side, p = 0.018). Compared with the preceding three months, adding intranasal 
      lysine-aspirin application had the effect on decreasing nasal polyp volume (right 
      side, p = 0.031; left side, p = 0.016). CONCLUSION: This open study suggests that 
      intranasal lysine-aspirin administration reduces nasal polyp volume in 
      aspirin-intolerant patients, without any adverse affect on concomitant asthma. 
      This was a preliminary study and should be followed by a placebo-controlled, 
      double-blind trial.
FAU - Ogata, N
AU  - Ogata N
AD  - Department of Rhinology, Royal National Throat, Nose and Ear Hospital, London, 
      UK.
FAU - Darby, Y
AU  - Darby Y
FAU - Scadding, G
AU  - Scadding G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20070815
PL  - England
TA  - J Laryngol Otol
JT  - The Journal of laryngology and otology
JID - 8706896
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Intranasal
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Asthma/chemically induced/*complications
MH  - Endoscopy
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic 
      use
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/*drug therapy/etiology/metabolism/pathology
MH  - Nitric Oxide/metabolism
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2007/08/19 09:00
MHDA- 2008/03/11 09:00
CRDT- 2007/08/19 09:00
PHST- 2007/08/19 09:00 [pubmed]
PHST- 2008/03/11 09:00 [medline]
PHST- 2007/08/19 09:00 [entrez]
AID - S0022215107000515 [pii]
AID - 10.1017/S0022215107000515 [doi]
PST - ppublish
SO  - J Laryngol Otol. 2007 Dec;121(12):1156-60. doi: 10.1017/S0022215107000515. Epub 
      2007 Aug 15.

PMID- 10548640
OWN - NLM
STAT- MEDLINE
DCOM- 19991230
LR  - 20190513
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 14
IP  - 11
DP  - 1999 Nov
TI  - Bone density changes in pregnant women treated with heparin: a prospective, 
      longitudinal study.
PG  - 2876-80
AB  - Heparin plus aspirin significantly improves the live birth rate of women with 
      primary antiphospholipid syndrome. Osteopenia is a major concern of long-term 
      heparin therapy. We studied prospectively the bone mineral density (BMD) changes 
      during pregnancy and the puerperium in 123 women with primary antiphospholipid 
      syndrome treated with low-dose aspirin and subcutaneous low-dose heparin (46 
      women took unfractionated heparin and 77 took low-molecular-weight heparin). 
      Lumbar spine, neck of femur and forearm BMD were measured, using dual energy 
      X-ray absorptiometry, at 12 weeks gestation, immediately postpartum and 12 weeks 
      postpartum. The mean heparin duration was 27 weeks (range 22-29). During 
      pregnancy, BMD decreased by 3.7% (P < 0.001) at the lumbar spine and by 0.9% (P < 
      0.05) at the neck of femur with no significant change at the forearm. Lactation 
      was associated with a significant decrease in the lumbar spine and neck of femur 
      BMD. There was no significant difference in BMD changes between the two heparin 
      preparations. No woman suffered a symptomatic fracture. Long-term heparin 
      treatment during pregnancy is associated with a small but significant decrease in 
      BMD at the lumbar spine and neck of femur. This decrease is similar to that 
      previously reported to occur in untreated pregnancies.
FAU - Backos, M
AU  - Backos M
AD  - Departments of Obstetrics & Gynaecology, ICSM at St Mary's and Hammersmith 
      Hospital, Praed Street, London W2 1PG, UK.
FAU - Rai, R
AU  - Rai R
FAU - Thomas, E
AU  - Thomas E
FAU - Murphy, M
AU  - Murphy M
FAU - Doré, C
AU  - Doré C
FAU - Regan, L
AU  - Regan L
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorptiometry, Photon
MH  - Adult
MH  - Antiphospholipid Syndrome/drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - *Bone Density
MH  - Bone Diseases, Metabolic/chemically induced
MH  - Female
MH  - Femur Neck
MH  - Forearm
MH  - Heparin/*adverse effects/therapeutic use
MH  - Humans
MH  - Lactation
MH  - Longitudinal Studies
MH  - Lumbar Vertebrae
MH  - Middle Aged
MH  - Pregnancy
MH  - Pregnancy Complications
MH  - Prospective Studies
EDAT- 1999/11/05 00:00
MHDA- 1999/11/05 00:01
CRDT- 1999/11/05 00:00
PHST- 1999/11/05 00:00 [pubmed]
PHST- 1999/11/05 00:01 [medline]
PHST- 1999/11/05 00:00 [entrez]
AID - 10.1093/humrep/14.11.2876 [doi]
PST - ppublish
SO  - Hum Reprod. 1999 Nov;14(11):2876-80. doi: 10.1093/humrep/14.11.2876.

PMID- 950959
OWN - NLM
STAT- MEDLINE
DCOM- 19761002
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 295
IP  - 10
DP  - 1976 Sep 2
TI  - Closure of the ductus arteriosus in premature infants by inhibition of 
      prostaglandin synthesis.
PG  - 530-3
AB  - Inhibition of prostaglandin synthesis constricts the ductus arteriosus in fetal 
      lambs in utero. We administered the inhibitors, aspirin or indomethacin to 18 
      premature infants with patent ductus arteriosus, and assessed the effects 
      clinically and by echocardiography (left atrial/aortic-root ratio). After aspirin 
      (20 mg per kilogram, every six hours for four doses) the ductus closed 
      permanently in one infant within 24 hours; in another, constriction occurred with 
      clinical improvement, and the third did not respond. In five infants given 0.3 mg 
      per kilogram of indomethacin, complete closure occurred within one day; two of 
      them, who received three doses had an elevated serum creatinine for one week. In 
      one infant the ductus reopened, requiring a second dose of indomethacin 11 days 
      after the first. Ten infants received 0.1 mg per kilogram of indomethacin, and 
      closure occurred within 24 to 30 hours in eight. One had a soft murmur for four 
      days, and one did not respond to two doses of indomethacin. A murmur reappeared 
      after three to seven days in three infants but only one required further 
      treatment. In infants receiving a single dose of 0.3 mg per kilogram, or one or 
      more doses of 0.1 mg per kilogram, renal function was unaltered.
FAU - Heymann, M A
AU  - Heymann MA
FAU - Rudolph, A M
AU  - Rudolph AM
FAU - Silverman, N H
AU  - Silverman NH
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Depression, Chemical
MH  - Ductus Arteriosus/drug effects
MH  - Ductus Arteriosus, Patent/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Indomethacin/administration & dosage/pharmacology/*therapeutic use
MH  - Infant, Newborn
MH  - Infant, Premature, Diseases/*drug therapy
MH  - Male
MH  - Prostaglandins/*biosynthesis
EDAT- 1976/09/02 00:00
MHDA- 1976/09/02 00:01
CRDT- 1976/09/02 00:00
PHST- 1976/09/02 00:00 [pubmed]
PHST- 1976/09/02 00:01 [medline]
PHST- 1976/09/02 00:00 [entrez]
AID - 10.1056/NEJM197609022951004 [doi]
PST - ppublish
SO  - N Engl J Med. 1976 Sep 2;295(10):530-3. doi: 10.1056/NEJM197609022951004.

PMID- 7527725
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20191031
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Functional capillary density changes during blood substitution with alpha alpha 
      Hb and dextran 70: influence on oxygen delivery.
PG  - 841-7
AB  - The effectiveness of a blood substitute is ultimately determined by the rate at 
      which O2 arrives to the capillaries and the functional capillary density i.e., 
      the number of flowing capillaries per unit volume of tissue. We use this 
      rationale to analyze the effectiveness of isovolemic blood substitution with 
      alpha alpha Hb (3,5-bis(dibromosalicyl)fumarate) compared to isooncotic and 
      isovolemic hemodilution with dextran 70. Progressive hemodilution with each 
      solution was performed in the awake hamster skinfold model by simultaneous 
      isovolemic exchange of blood until the systemic hematocrit was reduced to 30% of 
      control. Systemic hematocrit, blood pressure, heart rate were monitored. To 
      determine O2 delivery at the microcirculatory level, functional capillary 
      density, RBC velocity, RBC flux, capillary hematocrit were measured. Functional 
      capillary density was maintained during moderate hemodilution with dextran 70, 
      whereas alpha alpha Hb exchange caused a gradual reduction in the number of 
      flowing capillaries. O2 delivery to tissue was calculated from total O2 content 
      (RBC and plasma Hb or RBC only), blood flow, and functional capillary density. 
      Our findings suggest that augmentation of the O2 content of blood with alpha 
      alpha Hb substitution produces similar results in terms of capillary O2 delivery 
      and capacity as isovolemic and isooncotic hemodilution with dextran 70.
FAU - Tsai, A G
AU  - Tsai AG
AD  - Dept. of AMES-Bioengineering, University of California, San Diego 92093-0412.
FAU - Friesenecker, B
AU  - Friesenecker B
FAU - Winslow, R M
AU  - Winslow RM
FAU - Intaglietta, M
AU  - Intaglietta M
LA  - eng
GR  - HL 17421/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Dextrans)
RN  - 0 (Hemoglobins)
RN  - 0 (hemoglobin XL99alpha)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Biological Transport, Active
MH  - Blood Substitutes/*pharmacology
MH  - Capillaries/*drug effects/*metabolism
MH  - Cricetinae
MH  - Dextrans/*pharmacology
MH  - Exchange Transfusion, Whole Blood
MH  - Hemodilution
MH  - Hemoglobins/*pharmacology
MH  - Oxygen/blood/*metabolism
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117919 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):841-7. doi: 
      10.3109/10731199409117919.

PMID- 4036839
OWN - NLM
STAT- MEDLINE
DCOM- 19851022
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 56
IP  - 8
DP  - 1985 Sep 15
TI  - Anticoagulation therapy in children with mechanical prosthetic cardiac valves.
PG  - 533-5
AB  - From 1980 through 1984, 28 children younger than 19 years (mean 7.9) underwent 
      cardiac valve replacement with 30 mechanical prostheses. Patients were followed 
      for a total of 471 months (mean 15.7) and received either warfarin (mean 0.16 
      mg/kg/day) or acetylsalicylic acid and dipyridamole (mean 6.1 and 1.9 mg/kg/day, 
      respectively) as thromboembolism prophylaxis. The frequency and incidence of 
      thromboembolism and hemorrhage were compared. Warfarin-treated patients were at 
      increased risk of hemorrhage (5 of 20 [25%], or 22 per 100 patient-years, vs 0 of 
      10 [0%], or 0 per 100 patient-years, p less than 0.05). Three of the 5 
      hemorrhagic episodes were mild, and in no case was hemorrhage life-threatening. 
      Patients who did not receive warfarin had a greater risk of thromboembolism (2 of 
      10 [20%], or 12 per 100 patient-years, vs 0 of 20 [0%], or 0 per 100 
      patient-years, p less than 0.05). Both episodes of thromboembolism were 
      life-threatening and necessitated emergency valve replacement. Although warfarin 
      is associated with greater risk of hemorrhage than is acetylsalicylic acid and 
      dipyridamole, warfarin is better than antiplatelet drugs in thromboembolism 
      prophylaxis and is indicated for anticoagulation therapy in children with 
      mechanical cardiac prostheses.
FAU - Bradley, L M
AU  - Bradley LM
FAU - Midgley, F M
AU  - Midgley FM
FAU - Watson, D C
AU  - Watson DC
FAU - Getson, P R
AU  - Getson PR
FAU - Scott, L P 3rd
AU  - Scott LP 3rd
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - *Heart Valve Prosthesis
MH  - Hemorrhage/prevention & control
MH  - Humans
MH  - Thromboembolism/*prevention & control
MH  - Warfarin/administration & dosage/*therapeutic use
EDAT- 1985/09/15 00:00
MHDA- 1985/09/15 00:01
CRDT- 1985/09/15 00:00
PHST- 1985/09/15 00:00 [pubmed]
PHST- 1985/09/15 00:01 [medline]
PHST- 1985/09/15 00:00 [entrez]
AID - 0002-9149(85)91179-8 [pii]
AID - 10.1016/0002-9149(85)91179-8 [doi]
PST - ppublish
SO  - Am J Cardiol. 1985 Sep 15;56(8):533-5. doi: 10.1016/0002-9149(85)91179-8.

PMID- 15094329
OWN - NLM
STAT- MEDLINE
DCOM- 20040520
LR  - 20171116
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 74
IP  - 26
DP  - 2004 May 14
TI  - Nitric oxide release and distribution following oral and intraperitoneal 
      administration of nitroaspirin (NCX 4016) in the rat.
PG  - 3291-305
AB  - The metabolic fate of nitric oxide (NO) released from nitroaspirin, benzoic acid, 
      2-(acetyloxy)-3-[(nitrooxy)methyl]phenyl ester (NCX 4016), the lead compound of a 
      new class of NO-releasing non steroidal anti-inflammatory drugs (NO-NSAIDs), has 
      been studied in the rat following p.o. and i.p. administration of 100 mg/kg, by 
      monitoring in plasma the bioactive storage forms of NO (S-nitrosothiols, RS-NO) 
      and its oxidation products (nitrites/nitrates, NOx) by a chemiluminescent assay. 
      In parallel, plasma was analyzed for unchanged drug and metabolites by 
      reverse-phase HPLC. In orally treated rats, no unchanged drug is observed in the 
      0-24 h interval post-dosing, but only salicylic acid (SA), NOx and RS-NO. The 
      time-course of SA formation parallels that of plasma NOx (plateau after 6 h). 
      Nitrosothiols in plasma are detectable at 1 h, peak at 4 h post-administration, 
      and decline thereafter. The results relative to i.p. administration show a more 
      pronounced and rapid NO delivery (peak of both NOx and RS-NO at 1 h and plateau 
      between 1 and 2 h), still coincident with the peak of SA, and the presence in 
      plasma of NCX 4015 (a metabolite of NCX 4016 which still bears the nitrate 
      function). In myocardial tissue from p.o. treated rats, no drug or metabolites 
      were ever detected, and the NOx levels were always in the range of the controls. 
      Conversely, following i.p. treatment, we observed a rapid compartmentalization 
      within the heart of the unchanged drug, which rapidly disappears in favour of its 
      breakdown products NCX 4015 and SA, with a concomitant rise in myocardial NOx 
      levels up to 2 h. To check the stability of NCX 4016 in the acidic gastric milieu 
      and to explain the different distribution of the drug following p.o. or i.p. 
      administration, the gastric content of the orally-treated animals at different 
      post-dosing times was analysed by HPLC. The unchanged drug was detected up to 8 h 
      post-dosing (levels slowly decreased with time), and the only metabolite to be 
      detected was the O-deacetylated derivative (NCX 4023), which was present in low 
      concentrations up to 4 h post-dosing. This indicates that NCX 4016 does not 
      undergo biotransformation in the upper part of gastrointestinal tract (no direct 
      release of NO in this district) and that the stomach acts as a reservoir for the 
      drug.
FAU - Carini, Marina
AU  - Carini M
AD  - Istituto Chimico Farmaceutico Tossicologico, University of Milan, Viale Abruzzi 
      42, 20131 Milan, Italy. marina.carini@unimi.it
FAU - Aldini, Giancarlo
AU  - Aldini G
FAU - Orioli, Marica
AU  - Orioli M
FAU - Piccoli, Angela
AU  - Piccoli A
FAU - Rossoni, Giuseppe
AU  - Rossoni G
FAU - Maffei Facino, Roberto
AU  - Maffei Facino R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/metabolism
MH  - Aspirin/*administration & dosage/analogs & derivatives/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Injections, Intraperitoneal
MH  - Male
MH  - Nitric Oxide/blood/*pharmacokinetics
MH  - Rats
MH  - Rats, Wistar
MH  - Tissue Distribution
EDAT- 2004/04/20 05:00
MHDA- 2004/05/21 05:00
CRDT- 2004/04/20 05:00
PHST- 2003/07/14 00:00 [received]
PHST- 2003/11/21 00:00 [accepted]
PHST- 2004/04/20 05:00 [pubmed]
PHST- 2004/05/21 05:00 [medline]
PHST- 2004/04/20 05:00 [entrez]
AID - S0024320504002000 [pii]
AID - 10.1016/j.lfs.2003.11.018 [doi]
PST - ppublish
SO  - Life Sci. 2004 May 14;74(26):3291-305. doi: 10.1016/j.lfs.2003.11.018.

PMID- 7976349
OWN - NLM
STAT- MEDLINE
DCOM- 19941213
LR  - 20131121
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 29
IP  - 5
DP  - 1994
TI  - [The normal body temperature lowering effect of aspirin in mice and its circadian 
      rhythm].
PG  - 330-4
AB  - It is generally believed that the effectiveness of salicylates, such as aspirin 
      (ASP), is restricted to the lowering of the body temperature (BT) previously 
      elevated by pyrogens and that salicylates have no effect on normal BT. We present 
      here evidences which demonstrate that ASP does lower the normal BT of mice kept 
      in a 24 degrees C environment. Male ICR mice, housed under a light-dark cycle (LD 
      12:12h) at a room temperature of 24 +/- 1 degree C and a humidity of 60 +/- 10% 
      with food and water ad libitum, received intraperitoneal injections of ASP 25, 
      100 and 200 mg.kg-1. The animals showed a significant decline in their rectal 
      temperature and the BT returned to the values that prevailed before drug 
      administration within 4 h. There was an orderly, progressive dose-dependent 
      decrease in BT. A significant circadian rhythm was demonstrated for ASP-induced 
      hypothermal effect in mice. Although a significant circadian rhythm was also 
      demonstrated for the plasma salicylate concentrations at 1 h after dosing, there 
      seems to be no positive relationship between plasma drug concentrations and the 
      drug response. The results suggest that ASP does affect normal BT regulation in 
      mice and that the circadian rhythm change in ASP-induced hypothermal effect may 
      be mainly due to the rhythms in the sensitivity of mice to the drug.
FAU - Song, J G
AU  - Song JG
AD  - Department of Pharmacology, Wannan Medical College, Wuhu.
FAU - Ohdo, S
AU  - Ohdo S
FAU - Ogawa, N
AU  - Ogawa N
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Body Temperature/*drug effects
MH  - *Circadian Rhythm
MH  - Dose-Response Relationship, Drug
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Yao Xue Xue Bao. 1994;29(5):330-4.

PMID- 17147301
OWN - NLM
STAT- MEDLINE
DCOM- 20070329
LR  - 20191110
IS  - 1135-5727 (Print)
IS  - 1135-5727 (Linking)
VI  - 80
IP  - 6
DP  - 2006 Nov-Dec
TI  - [Aspirin for the primary prevention of cardiovascular diseases in diabetic 
      patients. A review of currently available tests].
PG  - 613-20
AB  - The benefits of aspirin treatment in reducing the risk of myocardial infarction, 
      cerebrovascular accidents and vascular death is well-documented among individuals 
      having prior cardiovascular disease, including the subgroup with diabetes 
      mellitus. The role of aspirin in primary prevention is less clear and debatable: 
      the results of the clinical trials currently available are not consistent, 
      although the meta-analyses are favorable in some aspects. There seems to be a 
      disparity between the type of benefit (when found to exist) and gender, the 
      findings being particularly contradictory for diabetic subjects, totalling a 
      minor percentage of the population sample included in the studies. Despite this 
      fact, in 1997, the American Diabetes Association and more recently other 
      scientific societies (including several Spanish societies) have been recommending 
      the use of aspirin in low doses in primary prevention in all type 1 or type 2 
      diabetic patients over 40 years of age and in all those within the 21-40 age 
      range having any other cardiovascular risk factor in addition to diabetes (family 
      history of vascular disease, hypertension, smoking, dyslipidemia or albuminuria). 
      This study reviews the findings of the randomized, controlled clinical trials on 
      primary cardiovascular prevention with aspirin, on which the official American 
      Diabetes Association guidelines might be based, the conclusion being reached that 
      there is not currently sufficient scientific evidence to uphold these guidelines.
FAU - Maciá Bobes, Carmen
AU  - Maciá Bobes C
AD  - (1) Sección de Endocrinología, Hospital San Agustín, Avilés, Asturias. 
      cmacb@arrakis.es
FAU - Ronzón Fernández, Aránzazu
AU  - Ronzón Fernández A
FAU - Fernández García, Elisa
AU  - Fernández García E
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - La prevención primaria con aspirina de enfermedades cardiovasculares en personas 
      diabéticas. Revisión de las pruebas disponibles.
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Rev Esp Salud Publica. 2006 Nov-Dec;80(6):609-12. PMID: 17147300
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Complications/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Primary Prevention
MH  - Risk Factors
RF  - 29
EDAT- 2006/12/07 09:00
MHDA- 2007/03/30 09:00
CRDT- 2006/12/07 09:00
PHST- 2006/12/07 09:00 [pubmed]
PHST- 2007/03/30 09:00 [medline]
PHST- 2006/12/07 09:00 [entrez]
AID - 10.1590/s1135-57272006000600002 [doi]
PST - ppublish
SO  - Rev Esp Salud Publica. 2006 Nov-Dec;80(6):613-20. doi: 
      10.1590/s1135-57272006000600002.

PMID- 17569678
OWN - NLM
STAT- MEDLINE
DCOM- 20080227
LR  - 20131121
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 28
IP  - 14
DP  - 2007 Jul
TI  - A comparison of six major platelet function tests to determine the prevalence of 
      aspirin resistance in patients with stable coronary artery disease.
PG  - 1702-8
AB  - AIMS: We sought to compare the results obtained from six major platelet function 
      tests in the assessment of the prevalence of aspirin resistance in patients with 
      stable coronary artery disease. METHODS AND RESULTS: 201 patients with stable 
      coronary artery disease receiving daily aspirin therapy (> or =80 mg) were 
      recruited. Platelet aggregation was measured by: (i) light transmission 
      aggregometry (LTA) after stimulation with 1.6 mM of arachidonic acid (AA), (ii) 
      LTA after adenosine diphosphate (ADP) (5, 10, and 20 microM) stimulation, (iii) 
      whole blood aggregometry, (iv) PFA-100, (v) VerifyNow Aspirin; urinary 
      11-dehydro-thromboxane B(2) concentrations were also measured. Eight patients 
      (4%, 95% CI 0.01-0.07) were deemed resistant to aspirin by LTA and AA. The 
      prevalence of aspirin resistance varied according to the assay used: 10.3-51.7% 
      for LTA using ADP as the agonist, 18.0% for whole blood aggregometry, 59.5% for 
      PFA-100, 6.7% for VerifyNow Aspirin, and finally, 22.9% by measuring urinary 
      11-dehydro-thromboxane B(2) concentrations. Results from these tests showed poor 
      correlation and agreement between themselves. CONCLUSION: Platelet function tests 
      are not equally effective in measuring aspirin's antiplatelet effect and 
      correlate poorly amongst themselves. The clinical usefulness of the different 
      assays to classify correctly patients as aspirin resistant remains undetermined.
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
AD  - Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada.
FAU - Pharand, Chantal
AU  - Pharand C
FAU - Schampaert, Erick
AU  - Schampaert E
FAU - Turgeon, Jacques
AU  - Turgeon J
FAU - Palisaitis, Donald A
AU  - Palisaitis DA
FAU - Diodati, Jean G
AU  - Diodati JG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070614
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2007 Jul;28(14):1673-5. PMID: 17586540
CIN - Eur Heart J. 2008 Jan;29(1):138; author reply 138-9. PMID: 17993637
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Coronary Artery Disease/blood/*drug therapy
MH  - Cyclooxygenase 1/metabolism
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/drug effects/physiology
MH  - Platelet Aggregation/drug effects/physiology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests/methods
MH  - Reference Values
MH  - Thromboxane A2/metabolism
EDAT- 2007/06/16 09:00
MHDA- 2008/02/28 09:00
CRDT- 2007/06/16 09:00
PHST- 2007/06/16 09:00 [pubmed]
PHST- 2008/02/28 09:00 [medline]
PHST- 2007/06/16 09:00 [entrez]
AID - ehm226 [pii]
AID - 10.1093/eurheartj/ehm226 [doi]
PST - ppublish
SO  - Eur Heart J. 2007 Jul;28(14):1702-8. doi: 10.1093/eurheartj/ehm226. Epub 2007 Jun 
      14.

PMID- 16461058
OWN - NLM
STAT- MEDLINE
DCOM- 20060322
LR  - 20131121
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 97
IP  - 4
DP  - 2006 Feb 15
TI  - Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus.
PG  - 567-70
AB  - This study sought to determine the frequency of aspirin resistance in an 
      ambulatory population of patients with type 1 diabetes mellitus (T1D) or type 2 
      diabetes mellitus (T2D). Platelet aggregation was assessed during the routine 
      clinical evaluation of 203 ambulatory patients with diabetes (T1D, n = 92; T2D, n 
      = 111) who were recommended aspirin for primary or secondary cardiovascular 
      protection. Consecutively received laboratory samples were evaluated using the 
      Ultegra Rapid Platelet Function Assay-ASA. Resistance to aspirin was detected in 
      18.7% of diabetic aspirin users, with similar rates in T1D (21.7%, p = 0.5) and 
      T2D (16.2%, p = 0.6). Aspirin resistance was not related to age, glycohemoglobin, 
      total cholesterol, or a history of cardiovascular disease. Female gender was a 
      strong independent predictor of aspirin resistance in patients with T1D (p = 
      0.001). Platelet aggregation was correlated with high-density lipoprotein (HDL) 
      cholesterol in the entire cohort (r = 0.21, p = 0.005) and in patients with T1D 
      (r = 0.32, p = 0.04) or T2D (r = 0.21, p = 0.04), such that patients with low HDL 
      cholesterol levels were more likely to be aspirin sensitive. The results suggest 
      that aspirin can inhibit platelet aggregation in most patients with diabetes and 
      is a reasonable first-line antiplatelet agent in patients with diabetes.
FAU - Mehta, Sheena S
AU  - Mehta SS
AD  - Joslin Diabetes Center, Harvard Medical School, Boston Massachusetts, USA.
FAU - Silver, Robert J
AU  - Silver RJ
FAU - Aaronson, Arthur
AU  - Aaronson A
FAU - Abrahamson, Martin
AU  - Abrahamson M
FAU - Goldfine, Allison B
AU  - Goldfine AB
LA  - eng
GR  - K23-DK02795/DK/NIDDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20060106
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Cholesterol, HDL)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Cholesterol, HDL/blood
MH  - Diabetes Mellitus, Type 1/*physiopathology
MH  - Diabetes Mellitus, Type 2/*physiopathology
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Sex Factors
EDAT- 2006/02/08 09:00
MHDA- 2006/03/23 09:00
CRDT- 2006/02/08 09:00
PHST- 2005/06/08 00:00 [received]
PHST- 2005/09/08 00:00 [revised]
PHST- 2005/09/08 00:00 [accepted]
PHST- 2006/02/08 09:00 [pubmed]
PHST- 2006/03/23 09:00 [medline]
PHST- 2006/02/08 09:00 [entrez]
AID - S0002-9149(05)01916-8 [pii]
AID - 10.1016/j.amjcard.2005.09.093 [doi]
PST - ppublish
SO  - Am J Cardiol. 2006 Feb 15;97(4):567-70. doi: 10.1016/j.amjcard.2005.09.093. Epub 
      2006 Jan 6.

PMID- 2746495
OWN - NLM
STAT- MEDLINE
DCOM- 19890811
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 250
IP  - 1
DP  - 1989 Jul
TI  - Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is 
      independent of changes in plasminogen activator levels.
PG  - 154-61
AB  - In addition to its antiplatelet effect, aspirin has been reported to have 
      fibrinolytic and hypoprothrombinemic effects. The objective of this study was to 
      investigate possible mechanisms underlying the enhanced fibrinolysis after 
      aspirin. Five healthy subjects received 650 mg of aspirin every 12 hr for 5 days. 
      Blood samples were collected before aspirin (control), and immediately before (0 
      hr) and 2 hr after (2 hr) the last dose for determinations of clot lysis time, 
      time course of thrombin-induced fibrin aggregation, tissue plasminogen activator 
      activity, intrinsic pathway fibrinolytic activity, plasminogen, fibrinogen, 
      aspirin and salicylic acid, and the coagulation tests activated partial 
      thromboplastin time, thrombin time and prothrombin time. Clot lysis time was 
      shorter after aspirin, control: 9.1 +/- 12.4 min (mean +/- S.D.); 0 hr: 4.6 +/- 
      4.0 min; 2 hr: 5.7 +/- 6.2 min (P: .04) and the fibrin aggregation curves showed 
      increased relative absorbance at 10 min, control: 8.4 +/- 2.2; 0 hr: 11.2 +/- 
      0.2; 2 hr: 13.3 +/- 5.4 (P: .02). Control values of tissue plasminogen activator 
      (0.11 +/- 0.04 IU/ml), intrinsic pathway fibrinolytic activity (2.20 +/- 0.54 
      IU/ml), plasminogen (10.9 +/- 1.0 mg/dl), fibrinogen (288 +/- 37 mg/dl) and the 
      coagulation tests were not different from those after aspirin. Aspirin 
      concentration was below detection limits at 0 hr and 1.63 +/- 0.97 micrograms/ml 
      at 2 hr, whereas salicylic acid concentration was 55.0 +/- 35.8 and 136 +/- 71.9 
      micrograms/ml at 0 and 2 hr, respectively. In vitro studies using fibrinogen-free 
      plasma and added acetylated fibrinogen showed an inverse relationship between the 
      extent of acetylation and clot lysis time.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Bjornsson, T D
AU  - Bjornsson TD
AD  - Department of Medicine, Jefferson Medical College, Thomas Jefferson University, 
      Philadelphia, Pennsylvania.
FAU - Schneider, D E
AU  - Schneider DE
FAU - Berger, H Jr
AU  - Berger H Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 9001-31-4 (Fibrin)
RN  - 9001-32-5 (Fibrinogen)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/blood/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Female
MH  - Fibrin/physiology
MH  - Fibrinogen/*metabolism
MH  - Fibrinolysis/*drug effects
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Plasminogen Activators/blood
MH  - Reference Values
EDAT- 1989/07/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1989 Jul;250(1):154-61.

PMID- 12452016
OWN - NLM
STAT- MEDLINE
DCOM- 20030102
LR  - 20150313
VI  - 21
IP  - 4
DP  - 2002 Apr
TI  - [Effects of combination of octreotide and aspirin on proliferation of human 
      hepatocellular carcinoma].
PG  - 383-7
AB  - BACKGROUND & OBJECTIVE: Both octreotide and aspirin are promising non-cytotoxitic 
      agents for treatment of the patients with hepatocellar carcinoma (HCC). However, 
      the anti-neoplasm mechanism of two agents are different. Combination therapy may 
      produce synergic effects with better tumor inhibition as well as lower dosage or 
      side affects. This study was aimed to understand whether octreotide combined with 
      aspirin could enhance the inhibition effects of proliferation in HCC. METHODS: 
      The proliferation of SMMC-7721 HCC cells was measured by 3H-thymidine 
      incorporation into DNA. To determine the synergic effects of anti-neoplasm, the 
      interaction between octreotide and aspirin on SMMC-7721 cell were evaluated 
      according to the median-response principle. We also assessed the effects of 
      octreotide combined with aspirin on the growth of SMMC-7721 xenografts in nude 
      mice. RESULTS: The combination of octreotide and aspirin significantly inhibited 
      3H-thymidine incorporation in SMMC-7721 cell line in a dose-dependent manner (r = 
      -0.9594, P < 0.01). The combination indexes for octreotide plus aspirin in the 
      range of majority responses especially in the high responses were less than 1. 
      The inhibition rate (89.47%) for HCC xenografts in nude mice in the combine group 
      was significantly enhanced when compared with aspirin group (69.92%). In 
      addition, more fibroplasia was observed in combine group. No severe side effect 
      was happened in all of the treatment groups. CONCLUSION: The inhibition effects 
      occur not only in HCC cell line but also in the growth of HCC transplant tumor in 
      nude mice were markedly improved by octreotide combined with aspirin when 
      compared with either drug alone. These synergic results may be of potential 
      therapeutic benefit to those patients with unresectable HCC.
FAU - Tang, Cheng-wei
AU  - Tang CW
AD  - Department of Gastroenterology, First Hospital, Chongqing University of Medical 
      Sciences, Chongqing 400016, P. R. China. cwtang@public.cta.cq.cn
FAU - Tang, Li-ping
AU  - Tang LP
FAU - Wang, Chun-hui
AU  - Wang CH
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
RN  - RWM8CCW8GP (Octreotide)
SB  - IM
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse 
      effects/*pharmacology/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Carcinoma, Hepatocellular/pathology
MH  - Cell Division/drug effects
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Humans
MH  - Liver Neoplasms/pathology
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasm Transplantation
MH  - Neoplasms, Experimental/drug therapy
MH  - Octreotide/administration & dosage/adverse effects/*pharmacology
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
EDAT- 2002/11/28 04:00
MHDA- 2003/01/03 04:00
CRDT- 2002/11/28 04:00
PHST- 2002/11/28 04:00 [pubmed]
PHST- 2003/01/03 04:00 [medline]
PHST- 2002/11/28 04:00 [entrez]
PST - ppublish
SO  - Ai Zheng. 2002 Apr;21(4):383-7.

PMID- 318951
OWN - NLM
STAT- MEDLINE
DCOM- 19770321
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 21
IP  - 1
DP  - 1977 Jan
TI  - Analgesic efficacy of an orally administered combination of pentazocine and 
      aspirin. With observations on the use and statistical efficiency of GLOBAL 
      subjective efficacy ratings.
PG  - 34-43
AB  - The analgesic efficacy of a combination of pentazocine and aspirin (PA) in the 
      ration 1:13 was compared with that of 650 mg of aspirin alone (A650) and with 
      placebo (PBO), in 98 patients with postoperative pain. Two dose levels of the 
      combination were compared: the lower dose (PA-L) consisted of pentazocine 25 mg 
      and aspirin 325 mg, while the higher dose (PA-H) consisted of pentazocine 50 mg 
      and aspirin 650 mg. All active treatments performed significantly better than 
      PBO. PA-L performed as well as A650, while PA-H performed significantly better 
      than A650. In addition to the usual subjective measures of analgesia, we obtained 
      in 74 patients an evaluation of the overall (GLOBAL) performance of the 
      treatment. This was rated on an ordinal scale of 1 ("poor") to 5 ("excellent"). 
      On the GLOBAL scale, PBO had a mean score of 2.4 (fair-good); A650 and PA-L had 
      scores of 3.6 and 3.9 respectively (good-very good): and PA-H had a score of 4.5 
      (very good-excellent). In five of six comparisons between treatment means, GLOBAL 
      had the best discriminating power of all six measures. In the two comparisons of 
      greatest interest (A650 against PBO and PA-H against A650), GLOBAL was more than 
      twice as efficient as the TOTAL (summed pain score) measure. In comparing the 
      statistical efficiency of different measures of the same analgesic effect, there 
      is a problem in determining what are "clinically equivalent differences" on the 
      various analgesic scales employed. We propose the use of the observed sample 
      differences and the safeguard of repeating the comparisons over several studies 
      to minimize the effect of random-origin bias.
FAU - Calimlim, J F
AU  - Calimlim JF
FAU - Wardell, W M
AU  - Wardell WM
FAU - Davis, H T
AU  - Davis HT
FAU - Lasagna, L
AU  - Lasagna L
FAU - Gillies, A J
AU  - Gillies AJ
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Analgesics)
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
RN  - RP4A60D26L (Pentazocine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analgesics/*administration & dosage
MH  - Aspirin/*administration & dosage/adverse effects/pharmacology
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Drug Evaluation/*methods
MH  - Humans
MH  - Middle Aged
MH  - Pain/*drug therapy/physiopathology
MH  - Pentazocine/*administration & dosage/adverse effects/pharmacology
MH  - Time Factors
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1002/cpt197721134 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1977 Jan;21(1):34-43. doi: 10.1002/cpt197721134.

PMID- 25261702
OWN - NLM
STAT- MEDLINE
DCOM- 20151231
LR  - 20150411
IS  - 1098-8785 (Electronic)
IS  - 0735-1631 (Linking)
VI  - 32
IP  - 5
DP  - 2015 Apr
TI  - Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth.
PG  - 445-50
LID - 10.1055/s-0034-1390352 [doi]
AB  - OBJECTIVE: We evaluated the relationship between aspirin supplementation and 
      perinatal outcomes for potential effect modification by smoking status. STUDY 
      DESIGN: A secondary analysis of two multicenter trials for which prophylactic 
      aspirin supplementation was given to either low- or high-risk women for 
      prevention of preeclampsia (PE). We examined the effect of aspirin by smoking 
      status using the Breslow-Day test. Primary outcomes for this analysis were PE and 
      preterm birth (PTB) < 37 weeks. We also examined PTB subtypes, small for 
      gestational age (SGA), and neonatal intensive care unit (NICU) admission. 
      RESULTS: The effect of prenatal aspirin on the risk of PE did not differ by 
      smoking status (relative risk [RR] 95% confidence interval [CI] for smokers; RR 
      95% CI for nonsmokers) in low-risk (Breslow-Day p = 0.32) or high-risk (RR 95% CI 
      for smokers; RR 95% CI for nonsmokers) (Breslow-Day p = 0.58) women. Among women 
      at low risk for PE, the effect of aspirin supplementation on PTB was not 
      different for nonsmokers (RR 1.00 [95% CI 0.8-1.3]) or smokers (RR 0.80 [95% CI 
      0.4-1.7]), (Breslow-Day p = 0.54). Aspirin was protective for PTB in nonsmokers 
      (RR 0.80 [95% CI 0.7-0.9]), but not in smokers (RR 1.1 [95% CI 0.9-1.4]) in the 
      high-risk group (Breslow-Day p = 0.03). Aspirin was also associated with 
      increased spontaneous and early PTB and NICU admission in smokers and not 
      nonsmokers in the high-risk group only. CONCLUSION: Aspirin supplementation was 
      associated with worse outcomes related to preterm birth in smokers in a high-risk 
      but not low-risk cohort.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Abramovici, Adi
AU  - Abramovici A
AD  - Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, 
      Center for Women's Reproductive Health, University of Alabama at Birmingham, 
      Birmingham, Alabama.
FAU - Jauk, Victoria
AU  - Jauk V
AD  - Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, 
      Center for Women's Reproductive Health, University of Alabama at Birmingham, 
      Birmingham, Alabama.
FAU - Wetta, Luisa
AU  - Wetta L
AD  - Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, 
      Center for Women's Reproductive Health, University of Alabama at Birmingham, 
      Birmingham, Alabama.
FAU - Cantu, Jessica
AU  - Cantu J
AD  - Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, 
      Center for Women's Reproductive Health, University of Alabama at Birmingham, 
      Birmingham, Alabama.
FAU - Edwards, Rodney
AU  - Edwards R
AD  - Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, 
      Center for Women's Reproductive Health, University of Alabama at Birmingham, 
      Birmingham, Alabama.
FAU - Biggio, Joseph
AU  - Biggio J
AD  - Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, 
      Center for Women's Reproductive Health, University of Alabama at Birmingham, 
      Birmingham, Alabama.
FAU - Tita, Alan
AU  - Tita A
AD  - Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, 
      Center for Women's Reproductive Health, University of Alabama at Birmingham, 
      Birmingham, Alabama.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20140927
PL  - United States
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cohort Studies
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Small for Gestational Age
MH  - Intensive Care Units, Neonatal
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications/*prevention & control
MH  - Premature Birth/*prevention & control
MH  - Risk Factors
MH  - Smoking/*adverse effects
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2014/09/28 06:00
MHDA- 2016/01/01 06:00
CRDT- 2014/09/28 06:00
PHST- 2014/09/28 06:00 [entrez]
PHST- 2014/09/28 06:00 [pubmed]
PHST- 2016/01/01 06:00 [medline]
AID - 10.1055/s-0034-1390352 [doi]
PST - ppublish
SO  - Am J Perinatol. 2015 Apr;32(5):445-50. doi: 10.1055/s-0034-1390352. Epub 2014 Sep 
      27.

PMID- 8477902
OWN - NLM
STAT- MEDLINE
DCOM- 19930521
LR  - 20190512
IS  - 0263-2136 (Print)
IS  - 0263-2136 (Linking)
VI  - 10
IP  - 1
DP  - 1993 Mar
TI  - Selections from current literature: using aspirin for primary or secondary 
      prevention.
PG  - 88-92
AB  - It seems evident that low doses (75 mg/day) of aspirin are adequate for attempts 
      to prevent thrombotic occlusion of blood vessels. There are no data to suggest 
      that different doses should be used based on whether primary or secondary 
      prophylaxis is planned. However, even low doses of aspirin are associated with 
      relatively small numbers of serious haemorrhagic complications. These 
      complications are outweighed by the benefits of therapy in many examples of 
      secondary prevention in high-risk groups that have already experienced an event 
      or symptoms because of underlying vascular disease. Primary prophylaxis is a more 
      controversial area. There is generally less to gain, and more to lose, when 
      measures are applied to large numbers of asymptomatic people. Based on the 
      available data, the conservative approach for aspirin use will be to reserve 
      primary prophylaxis for those people with the highest estimated risk.
FAU - Kelly, R
AU  - Kelly R
AD  - Department of Family Medicine, State University of New York, Stony Brook 11794.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Fam Pract
JT  - Family practice
JID - 8500875
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/prevention & control
MH  - Colonic Neoplasms/prevention & control
MH  - Humans
MH  - Primary Prevention
RF  - 7
EDAT- 1993/03/01 00:00
MHDA- 1993/03/01 00:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 1993/03/01 00:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
AID - 10.1093/fampra/10.1.88 [doi]
PST - ppublish
SO  - Fam Pract. 1993 Mar;10(1):88-92. doi: 10.1093/fampra/10.1.88.

PMID- 24102713
OWN - NLM
STAT- MEDLINE
DCOM- 20150421
LR  - 20211021
IS  - 1742-481X (Electronic)
IS  - 1742-4801 (Print)
IS  - 1742-4801 (Linking)
VI  - 11
IP  - 4
DP  - 2014 Aug
TI  - Unusual burn injury due to application of white vinegar and aspirin mixture.
PG  - 348-9
LID - 10.1111/iwj.12148 [doi]
AB  - Traditional medicine remedies are believed to provide relief from pain; 
      nevertheless, it can be a risky procedure if these remedies are prepared 
      inappropriately. Here, we describe a patient who suffered from a split-thickness 
      leg burn after applying a self-inflicted mixture consisting of white vinegar and 
      aspirin prepared for knee pain. This case report highlights a rare cause of a 
      chemical burn that could become more common with increasing use of traditional 
      remedies worldwide.
CI  - © 2013 The Authors. International Wound Journal © 2013 Medicalhelplines.com Inc 
      and John Wiley & Sons Ltd.
FAU - Irkoren, Saime
AU  - Irkoren S
AD  - Department of Plastic and Reconstructive Surgery, Adnan Menderes University 
      Faculty of Medicine, Aydin, Turkey.
FAU - Sivrioglu, Nazan
AU  - Sivrioglu N
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20130919
PL  - England
TA  - Int Wound J
JT  - International wound journal
JID - 101230907
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Drug Combinations)
RN  - Q40Q9N063P (Acetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetic Acid/administration & dosage/*adverse effects
MH  - Administration, Topical
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Bandages
MH  - Burns, Chemical/diagnosis/*etiology/therapy
MH  - Drug Combinations
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Therapy Modalities
PMC - PMC7950897
OTO - NOTNLM
OT  - Aspirin
OT  - Burn
OT  - Injury
OT  - White vinegar
EDAT- 2013/10/10 06:00
MHDA- 2015/04/22 06:00
CRDT- 2013/10/10 06:00
PHST- 2013/07/22 00:00 [received]
PHST- 2013/08/02 00:00 [accepted]
PHST- 2013/10/10 06:00 [entrez]
PHST- 2013/10/10 06:00 [pubmed]
PHST- 2015/04/22 06:00 [medline]
AID - IWJ12148 [pii]
AID - 10.1111/iwj.12148 [doi]
PST - ppublish
SO  - Int Wound J. 2014 Aug;11(4):348-9. doi: 10.1111/iwj.12148. Epub 2013 Sep 19.

PMID- 22951204
OWN - NLM
STAT- MEDLINE
DCOM- 20130319
LR  - 20131121
IS  - 2245-1919 (Electronic)
IS  - 2245-1919 (Linking)
VI  - 59
IP  - 9
DP  - 2012 Sep
TI  - Antiplatelet effect of aspirin in patients with coronary artery disease.
PG  - B4506
AB  - Cardiovascular disease is the number one cause of death globally, and 
      atherothrombosis is the underlying cause of most cardiovascular events. Several 
      studies have shown that antiplatelet therapy, including aspirin (acetylsalicylic 
      acid), reduces the risk of cardiovascular events and death. However, it is 
      well-known that many patients experience cardiovascular events despite treatment 
      with aspirin, often termed "aspirin low-responsiveness". This fact has caused 
      considerable debate: does biochemical aspirin low-responsiveness have prognostic 
      value? Can low-responders be reliably identified? And if so, should 
      antithrombotic treatment be changed? Is the whole discussion of antiplatelet drug 
      response merely a result of low compliance? Compliance should be carefully 
      optimised, before evaluating the pharmacological effect of a drug. It is 
      well-known that cardiovascular disease is multifactorial, and, therefore, total 
      risk reduction is not feasible. Aetiological factors to the variable platelet 
      inhibition by aspirin seem to include genetic factors, pharmacological 
      interactions, smoking, diabetes mellitus, and increased platelet turnover. It is 
      a captivating thought that antiplatelet therapy may be improved by individually 
      tailored therapy based on platelet function testing. Ongoing studies are 
      challenging the current one-size-fits-all dosing strategy, but the preceding 
      evaluation of platelet function assays has not been adequate. The overall 
      objective of this thesis was to evaluate the reproducibility of and aggreement 
      between a number of widely used platelet function tests and to explore the 
      importance of platelet turnover for the antiplatelet effect of aspirin in 
      patients with coronary artery disease. In the intervention studies (studies 1, 3, 
      and 4), optimal compliance was confirmed by measurements of serum thromboxane, 
      which is the most sensitive assay to confirm compliance with aspirin. In study 1, 
      platelet function tests widely used to measure the antiplatelet effect of aspirin 
      were evaluated in healthy individuals and patients with coronary artery disease. 
      Pharmaco-specific metabolites were measured in urine and serum to investigate the 
      pharmacodynamic effect of aspirin and to enable the comparison with the more 
      global tests of platelet function. Based on repeated duplicate measurements, we 
      evaluated the reproducibility of each test. We found that reproducibility of the 
      classical reference method was not impressive and that the newer, so-called 
      point-of-care tests differed markedly on reproducibility. With coefficients of 
      variation of about 3%, the VerifyNow Aspirin test was clearly the most 
      reproducible test - even after correction of the official scale, which begins at 
      about 350 aspirin reaction units and, therefore, results in artificially low 
      coefficients of variation. Among the platelet function tests investigated, 
      Multiplate was most sensitive for aspirin treatment. In study 2 we performed the 
      hitherto largest study of newly released, immature platelets as a marker of 
      platelet turnover. The study population included healthy individuals, patients 
      with stable coronary artery disease, and patients with acute coronary syndromes. 
      The main finding was an increased fraction of immature platelets in patients with 
      ST-segment myocardial infarction, indicating an increased platelet turnover. 
      Smoking and type 2 diabetes were identified as independent determinants of 
      platelet turnover. In study 3 we explored the relationship between platelet 
      turnover and the antiplatelet effect of aspirin in patients with stable coronary 
      artery disease. The study results support the hypothesis that an increased 
      platelet turnover reduces the antiplatelet effect of aspirin. The main findings 
      were: 1) platelet turnover correlated with platelet aggregation measured by 
      Multiplate and with sP-selectin, a marker of platelet activation. 2) Patients 
      with diabetes mellitus type 2 had reduced antiplatelet effect of aspirin compared 
      with patients without diabetes. 3) Widely used platelet function tests differ 
      with respect to dependence on platelet parameters, including platelet count. 4) 
      Smoking, diabetes mellitus type 2, and thrombopoietin were identified as 
      independent determinants of platelet turnover. 5) The relative fraction of 
      immature platelets has been employed in most previous studies, but in stable 
      patients the absolute immature platelet count does not seem dependent on the 
      total platelet count, and it has a stronger correlation with both platelet 
      activation measured by sP-selectin and with platelet aggregation during treatment 
      with aspirin. In study 4 we investigated platelet turnover and the antiplatelet 
      effect of aspirin in a nested case-control study on patients with previous 
      definite stent thrombosis. Patients with stent thrombosis were compared with 
      patients without stent thrombosis, with whom they were matched at a 1:2 ratio 
      with respect to risk factors for stent thrombosis: age, sex, stent type, and 
      indication for percutaneous coronary intervention. The study showed that patients 
      with previous stent thrombosis have reduced antiplatelet effect of aspirin and a 
      tendency towards increased platelet turnover. In conclusion, widely used platelet 
      function tests markedly differ on reproducibility, and the agreement between 
      tests is relatively poor. An increased platelet turnover as suggested by the 
      presence of newly formed immature platelets is important for the antiplatelet 
      effect of aspirin, and, perhaps also for the development of acute coronary 
      thrombosis. In the future, individually tailored antiplatelet therapy may 
      potentially improve the benefit-risk ratio of antiplatelet therapy.
FAU - Grove, Erik Lerkevang
AU  - Grove EL
AD  - Department of Cardiology, Aarhus University Hospital, Skejby, Brendstrupgaardsvej 
      100, 8200 Aarhus N, Denmark. erikgrove@dadlnet.dk
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Denmark
TA  - Dan Med J
JT  - Danish medical journal
JID - 101576205
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/*physiology
MH  - Coronary Artery Disease/complications/*drug therapy
MH  - Coronary Thrombosis/complications/*prevention & control
MH  - Drug Resistance
MH  - Humans
MH  - Medication Adherence
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests
EDAT- 2012/09/07 06:00
MHDA- 2013/03/21 06:00
CRDT- 2012/09/07 06:00
PHST- 2012/09/07 06:00 [entrez]
PHST- 2012/09/07 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
AID - B4496 [pii]
PST - ppublish
SO  - Dan Med J. 2012 Sep;59(9):B4506.

PMID- 31237833
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1747-4949 (Electronic)
IS  - 1747-4930 (Print)
IS  - 1747-4930 (Linking)
VI  - 15
IP  - 1
DP  - 2020 Jan
TI  - Aspirin for primary prevention of stroke in individuals without cardiovascular 
      disease-A meta-analysis.
PG  - 9-17
LID - 10.1177/1747493019858780 [doi]
AB  - BACKGROUND: The benefits of aspirin for primary prevention of stroke are 
      uncertain. METHODS: We performed a cumulative meta-analysis of trials 
      investigating aspirin for primary prevention of cardiovascular disease with a 
      focus on stroke. We assessed the effects of aspirin on non-fatal stroke, 
      hemorrhagic stroke, non-fatal myocardial infarction, all-cause mortality, 
      cardiovascular mortality, major gastrointestinal bleeding, and an analysis of net 
      clinical effect, in populations without a history of clinical or subclinical 
      cardiovascular disease. SUMMARY OF REVIEW RESULTS: Among 11 trials (157,054 
      participants), aspirin was not associated with a statistically significant 
      reduction in non-fatal stroke (odds ratio, 0.94; 95% CI, 0.85 to 1.04) but was 
      associated with an increased risk of hemorrhagic stroke (odds ratio, 1.29; 95% 
      CI, 1.06 to 1.56). Aspirin was not associated with a statistically significant 
      reduction in all-cause mortality (odds ratio, 0.97; 95% CI, 0.92 to 1.03) or 
      cardiovascular mortality (odds ratio, 0.94; 95% CI, 0.85 to 1.03). Aspirin was 
      associated with a reduction in non-fatal myocardial infarction (odds ratio, 0.80; 
      95% CI, 0.69 to 0.94) and an increased risk of major gastrointestinal bleeding 
      (odds ratio, 1.83; 95% CI, 1.43 to 2.35). Using equal weighting for non-fatal 
      events and major bleeding, we observed no net clinical benefit with aspirin use 
      for primary prevention. CONCLUSION: Our meta-analysis reports no benefit of 
      aspirin for primary stroke prevention.
FAU - Judge, Conor
AU  - Judge C
AUID- ORCID: 0000-0001-9473-2920
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
AD  - Translational Medical Device Lab, NUI Galway, Galway, Ireland.
AD  - Wellcome Trust-HRB, Irish Clinical Academic Training, NUI Galway, Galway, 
      Ireland.
FAU - Ruttledge, Sarah
AU  - Ruttledge S
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
FAU - Murphy, Robert
AU  - Murphy R
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
FAU - Loughlin, Elaine
AU  - Loughlin E
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
FAU - Gorey, Sarah
AU  - Gorey S
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
FAU - Costello, Maria
AU  - Costello M
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
FAU - Nolan, Aoife
AU  - Nolan A
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
FAU - Ferguson, John
AU  - Ferguson J
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
FAU - Halloran, Martin O
AU  - Halloran MO
AD  - Translational Medical Device Lab, NUI Galway, Galway, Ireland.
FAU - O'Canavan, Michelle
AU  - O'Canavan M
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
FAU - O'Donnell, Martin J
AU  - O'Donnell MJ
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
LA  - eng
GR  - 203930/B/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20190625
PL  - United States
TA  - Int J Stroke
JT  - International journal of stroke : official journal of the International Stroke 
      Society
JID - 101274068
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Humans
MH  - Primary Prevention/*methods
MH  - Stroke/*prevention & control
PMC - PMC7003154
OTO - NOTNLM
OT  - Stroke
OT  - aspirin
OT  - cardiovascular
OT  - prevention
EDAT- 2019/06/27 06:00
MHDA- 2021/01/26 06:00
CRDT- 2019/06/26 06:00
PHST- 2019/06/27 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2019/06/26 06:00 [entrez]
AID - 10.1177_1747493019858780 [pii]
AID - 10.1177/1747493019858780 [doi]
PST - ppublish
SO  - Int J Stroke. 2020 Jan;15(1):9-17. doi: 10.1177/1747493019858780. Epub 2019 Jun 
      25.

PMID- 7017490
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Clinical evaluation of the activity of 2 preparations with similar action in 
      bronchopneumopathies in the aged].
PG  - 393-400
AB  - The results obtained in a single blind controlled study using a new preparation, 
      guacetisal, and an already available similar product based on 
      dimethylaminophenazone guaiacolglycolate and calcium ethylcamphorate, are 
      reported. The drugs were administered to 28 elderly patients of both sexes 
      suffering from bronchopneumopathies for a period of 7 consecutive days with 2 
      suppositories/day. The results generally favoured the new product. Tolerance was 
      very good at all levels.
FAU - Lauri, D
AU  - Lauri D
FAU - Salvini, P
AU  - Salvini P
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Valutazione clinica dell'attività di due preparati ad azione similare nelle 
      broncopneumopatie in età senile.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Drug Combinations)
RN  - 01704YP3MO (Aminopyrine)
RN  - 495W7451VQ (Guaifenesin)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Aged
MH  - Aminopyrine/therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood/drug effects
MH  - Bronchitis/*drug therapy
MH  - Clinical Trials as Topic
MH  - Cough/drug therapy
MH  - Drug Combinations
MH  - Drug Evaluation
MH  - Female
MH  - Guaifenesin/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiration/drug effects
MH  - Tracheitis/*drug therapy
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):393-400.

PMID- 385873
OWN - NLM
STAT- MEDLINE
DCOM- 19791220
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 6
IP  - 3
DP  - 1979 May-Jun
TI  - Oxaprozin: a once-daily treatment regimen in rheumatoid arthritis.
PG  - 345-50
AB  - The development of oxaprozin provided an opportunity to evaluate the control of 
      inflammation in rheumatoid arthritis by a drug that can be administered once 
      daily. A double-blind 12-week evaluation suggested comparable efficacy between 
      1,200 mg oxaprozin given as a single daily dose and 3,900 mg ASA given in 4 
      equally divided doses. A lower incidence of side effects was noted in the 
      oxaprozin group. An open 6-month study substantiated the efficacy and safety of 
      oxaprozin.
FAU - Reynolds, W J
AU  - Reynolds WJ
FAU - Shaar, S F
AU  - Shaar SF
FAU - Buik, A
AU  - Buik A
FAU - Lancee, W J
AU  - Lancee WJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Oxazoles)
RN  - 0 (Propionates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Humans
MH  - Oxazoles/*administration & dosage/therapeutic use
MH  - Propionates/administration & dosage/therapeutic use
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1979 May-Jun;6(3):345-50.

PMID- 16153930
OWN - NLM
STAT- MEDLINE
DCOM- 20051103
LR  - 20131121
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 130
IP  - 3
DP  - 2005 Sep
TI  - Prediction of the excessive perioperative bleeding in patients undergoing 
      coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa 
      polymorphism.
PG  - 791-6
AB  - OBJECTIVE: The presence of the glycoprotein IIIa allele PlA2 is associated with 
      enhanced thrombin formation and an impaired antithrombotic action of aspirin, 
      which could favor coronary thrombosis. We wondered whether PlA1/A2 genetic 
      polymorphism could affect the postoperative bleeding in patients undergoing 
      coronary artery bypass grafting. We also aimed to assess the effects of aspirin 
      pretreatment and to ascertain the value of platelet function studies as 
      predictors of postoperative bleeding. METHODS: In a randomized, double-blind 
      study, patients undergoing coronary artery bypass grafting were pretreated with a 
      150-mg dose of aspirin orally 12 and 3 hours before surgery (n = 51, 41 elective) 
      or with placebo (n = 51, 43 elective). The hemostasis was monitored by Simplate 
      (bioMérieux, Inc, Durham, NC) bleeding time and capillary closure time (platelet 
      function analyzer PFA 100; Sysmex UK Ltd, Milton Keynes, United Kingdom). 
      Postoperative bleeding and blood products transfusions were recorded. The 
      glycoprotein IIIa polymorphism was analyzed. RESULTS: Bleeding was significantly 
      greater in PlA1 homozygotes from control group. Blood loss was significantly 
      greater (by 25%) in aspirin group. The volume of blood products transfusions in 
      aspirin patients was significantly larger (by 137%). When subjects were 
      stratified accordingly to blood platelet glycoprotein IIb/IIIa genotype, in the 
      aspirin group PlA2 carriers had greater blood loss than PlA1 homozygotes (1858 
      +/- 932 mL vs 1216 +/- 525 mL, P < .05). CONCLUSION: PlA1 homozygotes normally 
      had a greater risk of perioperative bleeding. Capillary closure time had no 
      advantage relative to Simplate bleeding time in predicting postoperative blood 
      loss. Aspirin pretreatment revealed no beneficial effects and resulted in 
      increased postoperative bleeding and requirement for blood product transfusions 
      after coronary artery bypass grafting in patients with stable angina. It was most 
      unfavorable for PlA2 carriers.
FAU - Morawski, W
AU  - Morawski W
AD  - First Cardiac Surgery Department, Medical University of Silesia, Katowice, 
      Poland. wmorski@wp.pl
FAU - Sanak, M
AU  - Sanak M
FAU - Cisowski, M
AU  - Cisowski M
FAU - Szczeklik, M
AU  - Szczeklik M
FAU - Szczeklik, W
AU  - Szczeklik W
FAU - Dropinski, J
AU  - Dropinski J
FAU - Waclawczyk, T
AU  - Waclawczyk T
FAU - Ulczok, R
AU  - Ulczok R
FAU - Bochenek, A
AU  - Bochenek A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Integrin beta3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alleles
MH  - Aspirin/administration & dosage/*adverse effects
MH  - *Blood Loss, Surgical
MH  - *Coronary Artery Bypass
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Integrin beta3/*genetics
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic
MH  - Postoperative Hemorrhage/chemically induced/genetics
MH  - Preoperative Care
EDAT- 2005/09/13 09:00
MHDA- 2005/11/04 09:00
CRDT- 2005/09/13 09:00
PHST- 2004/11/30 00:00 [received]
PHST- 2005/02/12 00:00 [revised]
PHST- 2005/02/24 00:00 [accepted]
PHST- 2005/09/13 09:00 [pubmed]
PHST- 2005/11/04 09:00 [medline]
PHST- 2005/09/13 09:00 [entrez]
AID - S0022-5223(05)00356-9 [pii]
AID - 10.1016/j.jtcvs.2005.02.041 [doi]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 2005 Sep;130(3):791-6. doi: 
      10.1016/j.jtcvs.2005.02.041.

PMID- 33078479
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20210830
IS  - 1875-9114 (Electronic)
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 40
IP  - 10
DP  - 2020 Oct
TI  - Prescription Medication Use in Older Adults Without Major Cardiovascular Disease 
      Enrolled in the Aspirin in Reducing Events in the Elderly (ASPREE) Clinical 
      Trial.
PG  - 1042-1053
LID - 10.1002/phar.2461 [doi]
AB  - BACKGROUND: Efforts to minimize medication risks among older adults include 
      avoidance of potentially inappropriate medications. Contemporary analysis of 
      medication use in community-dwelling older people compared with the general 
      population is lacking. PARTICIPANTS: A total of 19,114 community-dwelling adults 
      in Australia and the United States aged 70 years or older (65 years or older for 
      U.S. minorities) without histories of major cardiovascular disease, cognitive 
      impairment, or disability participated in a randomized, placebo-controlled trial 
      of aspirin: ASPirin in Reducing Events in the Elderly study. Measurements 
      Prescribed baseline medications obtained by self-report and medical record review 
      were grouped by World Health Organization Anatomic and Therapeutic Chemical 
      category. Potentially inappropriate medications were defined using a modified 
      American Geriatrics Society Beers Criteria. Polypharmacy was defined as 5 or more 
      medications, and hyperpolypharmacy defined as 10 or more medications. 
      Cross-sectional descriptive statistics and adjusted odds ratios were computed. 
      RESULTS: The median number of prescription medications per participant was three, 
      regardless of age. Women had a higher medication prevalence. Cardiovascular drugs 
      (primarily antihypertensives) were the most commonly reported (64%). Overall, 39% 
      of the cohort reported taking at least one potentially inappropriate medication, 
      with proton-pump inhibitors being the most commonly reported (21.2% of cohort). 
      Of the cohort, 27% had polypharmacy, and 2% hyperpolypharmacy. Age 75 years or 
      older, less than 12 years of education, hypertension, diabetes mellitus, chronic 
      kidney disease, frailty, gastrointestinal complaint, and depressive symptoms were 
      associated with an increased likelihood of potentially inappropriate medications 
      and polypharmacy. For almost all medication classes, prevalence was equivalent or 
      lower than the general older population. CONCLUSION: Overall medication burden 
      and polypharmacy are low in older adults free of major cardiovascular disease, 
      disability, and cognitive impairment. The prevalence of potentially inappropriate 
      medications is higher than previously reported and similar to more vulnerable 
      populations as a result of the introduction of proton-pump inhibitors to the 
      American Geriatrics Society Beers Criteria. Longitudinal follow-up is required to 
      further understand the balance of benefits and risks for potentially 
      inappropriate medications and polypharmacy in community-dwelling older people.
CI  - © 2020 Pharmacotherapy Publications, Inc.
FAU - Lockery, Jessica E
AU  - Lockery JE
AUID- ORCID: 0000-0001-6664-1239
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - Department of Pharmacy Practice and Science, College of Pharmacy and Department 
      of Family Medicine, Carver College of Medicine, The University of Iowa, Iowa 
      City, Iowa, USA.
FAU - Broder, Jonathan C
AU  - Broder JC
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Orchard, Suzanne G
AU  - Orchard SG
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Murray, Anne
AU  - Murray A
AD  - Hennepin Healthcare Research Institute, Hennepin Healthcare, Minneapolis, 
      Minnesota, USA.
AD  - Division of Geriatrics, Department of Medicine, University of Minnesota, 
      Minneapolis, Minnesota, USA.
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, 
      Australia.
FAU - Stocks, Nigel P
AU  - Stocks NP
AD  - Discipline of General Practice, University of Adelaide, Adelaide, South 
      Australia, Australia.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
AD  - School of Public Health, Curtin University, Perth, Western Australia, Australia.
FAU - Liew, Danny
AU  - Liew D
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
CN  - ASPREE Investigator Group
LA  - eng
SI  - ISRCTN/ISRCTN83772183
SI  - ClinicalTrials.gov/NCT01038583
GR  - P30 AG024824/AG/NIA NIH HHS/United States
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U19 AG062682/AG/NIA NIH HHS/United States
GR  - U01AG029824/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Australia
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cross-Sectional Studies
MH  - Double-Blind Method
MH  - Female
MH  - Health Services for the Aged
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Polypharmacy
MH  - *Potentially Inappropriate Medication List
MH  - Randomized Controlled Trials as Topic
MH  - United States
PMC - PMC7957955
MID - NIHMS1676982
OTO - NOTNLM
OT  - healthy aging
OT  - pharmacoepidemiology
OT  - polypharmacy
OT  - potentially inappropriate medications
COIS- Conflict of interest: The authors have declared no conflicts of interest for this 
      article.
EDAT- 2020/10/21 06:00
MHDA- 2021/08/31 06:00
CRDT- 2020/10/20 06:28
PHST- 2020/10/20 06:28 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
AID - 10.1002/phar.2461 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2020 Oct;40(10):1042-1053. doi: 10.1002/phar.2461.

PMID- 2590271
OWN - NLM
STAT- MEDLINE
DCOM- 19891229
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 39
IP  - 9
DP  - 1989 Sep
TI  - [Protective effect of an antacid against acetylsalicylic acid].
PG  - 1169-70
AB  - The protective action of an magnesium-aluminum-antacid (Mucal-Gel) against acute 
      doses of acetylsalicylic acid (ASA) was studied in healthy subjects (n = 30) by a 
      double-blind cross-over method. The severity of the lesion was determined by 
      endoscopy. In the corresponding placebo experiments, severe lesions of the 
      gastroduodenal mucosa were seen after administration of 1500 mg ASA. These 
      lesions could be prevented only in the presence of high doses of the antacidum 
      mixture. It is concluded from these studies that protective actions against ASA 
      can be achieved only if the intragastric pH-level is adequately raised above 3.5 
      and higher.
FAU - Müller, P
AU  - Müller P
AD  - Medizinische Universitätsklinik Heidelberg, Gastroenterologische, Abteilung.
FAU - Marinis, E
AU  - Marinis E
FAU - Dammann, H G
AU  - Dammann HG
FAU - Simon, B
AU  - Simon B
LA  - ger
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Schutzwirkung eines Antazidums gegenüber Acetylsalicylsäure.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Antacids)
RN  - CPD4NFA903 (Aluminum)
RN  - I38ZP9992A (Magnesium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aluminum
MH  - Antacids/*pharmacology
MH  - Aspirin/*adverse effects/antagonists & inhibitors
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastroscopy
MH  - Humans
MH  - Intestinal Mucosa/*drug effects/pathology
MH  - Magnesium
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1989 Sep;39(9):1169-70.

PMID- 15914011
OWN - NLM
STAT- MEDLINE
DCOM- 20050923
LR  - 20131121
IS  - 0968-0896 (Print)
IS  - 0968-0896 (Linking)
VI  - 13
IP  - 15
DP  - 2005 Aug 1
TI  - Design, synthesis, and biological evaluation of N-acetyl-2-(or 
      3-)carboxymethylbenzenesulfonamides as cyclooxygenase isozyme inhibitors.
PG  - 4694-703
AB  - A group of N-acetyl-2-(or 3-)carboxymethylbenzenesulfonamides, possessing either 
      a F or a substituted-phenyl ring substituent (4-F, 2,4-F2, 4-SO2Me, 4-OCHMe2) 
      attached to its C-4 or C-6 position, was prepared using a palladium-catalyzed 
      Suzuki cross-coupling reaction for evaluation as selective cyclooxygenase-2 
      (COX-2) inhibitors. Although N-acetyl-3-carboxymethyl-6-fluorobenzenesulfonamide 
      [14, COX-1 IC50 = 2.26 microM; COX-2 IC50 = 0.012 microM; COX-2 selectivity index 
      (SI) = 188] and N-acetyl-3-carboxymethyl-6-(4-isopropoxyphenyl)benzenesulfonamide 
      (20c, COX-1 IC50 >100 microM; COX-2 IC50 = 0.15 microM; COX-2 SI >667) exhibited 
      potent in vitro COX-2 inhibitory activity and high COX-2 selectivity, both 
      compounds were inactive anti-inflammatory agents in a carrageenan-induced rat paw 
      edema assay. In contrast, the less potent and less selective COX-2 inhibitors 
      N-acetyl-2-carboxymethyl-4-fluorobenzenesulfonamide (12, COX-1 IC50 = 4.25 
      microM; COX-2 IC50 = 0.978 microM; COX-2 SI = 4.3), 
      N-acetyl-2-carboxymethyl-4-(2,4-difluorophenyl)benzenesulfonamide (17c, COX-1 
      IC50 = 1.02 microM; COX-2 IC50 = 1.00 microM; COX-2 SI = 1.02), and 
      N-acetyl-3-carboxymethyl-6-(4-methanesulfonylphenyl)benzenesulfonamide (20e, 
      COX-1 IC50 = 0.109 microM; COX-2 IC50 = 1.14 microM; COX-2 SI = 0.095) exhibited 
      moderate anti-inflammatory activity where a 75 mg/kg oral dose reduced 
      inflammation 26%, 14%, and 20%, respectively, at 3 h postdrug administration 
      relative to the reference drug aspirin where a 50 mg/kg oral dose reduced 
      inflammation by 25% at 3 h postdrug administration.
FAU - Chen, Qiao-Hong
AU  - Chen QH
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Alberta, Canada T6G 2N8.
FAU - Rao, P N Praveen
AU  - Rao PN
FAU - Knaus, Edward E
AU  - Knaus EE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Bioorg Med Chem
JT  - Bioorganic & medicinal chemistry
JID - 9413298
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - 0 (N-acetyl-2-carboxymethylbenzenesulfonamide)
RN  - 0 (Sulfonamides)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EC 1.14.99.1 (Ptgs1 protein, mouse)
RN  - EC 1.14.99.1 (Ptgs1 protein, rat)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/chemical synthesis/chemistry/pharmacology
MH  - Aspirin/*analogs & derivatives/chemical synthesis/chemistry/pharmacology
MH  - Binding Sites
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*chemical synthesis/chemistry/*pharmacology
MH  - *Drug Design
MH  - Inhibitory Concentration 50
MH  - Isoenzymes/antagonists & inhibitors/metabolism
MH  - Membrane Proteins
MH  - Mice
MH  - Molecular Structure
MH  - Prostaglandin-Endoperoxide Synthases/chemistry/*metabolism
MH  - Rats
MH  - Structure-Activity Relationship
MH  - Sulfonamides/*chemical synthesis/chemistry/*pharmacology
EDAT- 2005/05/26 09:00
MHDA- 2005/09/24 09:00
CRDT- 2005/05/26 09:00
PHST- 2005/03/29 00:00 [received]
PHST- 2005/04/25 00:00 [revised]
PHST- 2005/04/26 00:00 [accepted]
PHST- 2005/05/26 09:00 [pubmed]
PHST- 2005/09/24 09:00 [medline]
PHST- 2005/05/26 09:00 [entrez]
AID - S0968-0896(05)00381-0 [pii]
AID - 10.1016/j.bmc.2005.04.069 [doi]
PST - ppublish
SO  - Bioorg Med Chem. 2005 Aug 1;13(15):4694-703. doi: 10.1016/j.bmc.2005.04.069.

PMID- 6703349
OWN - NLM
STAT- MEDLINE
DCOM- 19840330
LR  - 20181130
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 63
IP  - 3
DP  - 1984 Mar
TI  - Evaluation of the efficacy of Alka-Seltzer Effervescent in gastric acid 
      neutralization.
PG  - 325-9
AB  - A commercially available antacid, a mixture of sodium and potassium bicarbonates 
      and citric acid (Alka-Seltzer Effervescent), was evaluated experimentally and 
      clinically for its efficacy in neutralizing 0.1 N HCl and gastric contents. In an 
      in vitro titration study, Alka-Seltzer Effervescent buffered 5-30 times the 
      volume of HCl with a pH between 1.0 and 2.0 to above a pH of 2.5. In an isolated 
      canine pulmonary lobe model, aspiration of the antacid or acid-antacid mixture 
      caused only a mild increase in lobe weight and did not increase intrapulmonary 
      shunting. In the clinical study, when the antacid was given 5-40 min before 
      administration of general anesthesia in a group of patients for emergency 
      surgery, the pH of the gastric contents in each patient was increased to above 
      4.0. This contrasts with the control group of patients, which showed 50% (P less 
      than 0.05) of the patients were at risk when no antacid was administered. 
      Preoperative administration of Alka-Seltzer effectively increases the pH of the 
      gastric contents in patients undergoing emergency surgery.
FAU - Chen, C T
AU  - Chen CT
FAU - Toung, T J
AU  - Toung TJ
FAU - Haupt, H M
AU  - Haupt HM
FAU - Hutchins, G M
AU  - Hutchins GM
FAU - Cameron, J L
AU  - Cameron JL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Bicarbonates)
RN  - 0 (Citrates)
RN  - 0 (Drug Combinations)
RN  - 53663-74-4 (sodium acetylsalicylate, sodium bicarbonate, sodium citrate drug 
      combination)
RN  - 8MDF5V39QO (Sodium Bicarbonate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anesthesia, General
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology/standards
MH  - Bicarbonates/*administration & dosage/pharmacology/standards
MH  - Child
MH  - *Citrates
MH  - Dogs
MH  - Drug Combinations/administration & dosage/pharmacology/standards
MH  - Gastric Acid/*metabolism
MH  - Gastric Acidity Determination
MH  - Humans
MH  - In Vitro Techniques
MH  - Intraoperative Complications
MH  - Middle Aged
MH  - Pneumonia, Aspiration/physiopathology/*prevention & control
MH  - Premedication
MH  - *Sodium Bicarbonate
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
PST - ppublish
SO  - Anesth Analg. 1984 Mar;63(3):325-9.

PMID- 23751606
OWN - NLM
STAT- MEDLINE
DCOM- 20140624
LR  - 20130925
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 24
IP  - 7
DP  - 2013 Oct
TI  - In-vitro study of methylglyoxal and aspirin effects on fibrinolysis parameters.
PG  - 715-8
LID - 10.1097/MBC.0b013e328361bd68 [doi]
AB  - Methylglyoxal is a reactive α, β dicarbonyl aldehyde compound that originates 
      from various biochemical pathways. Some studies suggest that increased 
      methylglyoxal in blood leads to changes in fibrinolysis; however, the precise 
      mechanism is not clear. The aim of this study was to compare different 
      concentrations of methylglyoxal and aspirin on fibrinolysis in the plasma of 
      healthy individuals in vitro. Different concentrations of methylglyoxal (5, 50, 
      100, and 500 μmol/l) and aspirin (1, 10, and 100 mg/l) were added to the plasma 
      citrate. They were incubated at 37°C for 24 h. Then, fibrinolysis parameters were 
      analyzed by the turbidimetric procedure at 405 nm. The Independent Samples t-test 
      was utilized to compare them (P < 0.05). Findings revealed that methylglyoxal at 
      500 μmol/l with aspirin 100 mg/l had significant changes in the maximum lysis 
      velocity (0.163 ± 0.003), half-time lysis (240 ± 10.00), the total lysis time 
      (485 ± 5.00), lag time in lysis (126 ± 5.77), compared with methylglyoxal at 500 
      μmol/l (0.104 ± 0.005), (276 ± 5.77), (570 ± 10.00), and (186 ± 5.77), 
      respectively (P < 0.05). Methylglyoxal at 500 μmol/l with aspirin 1 mg/l did not 
      significantly change in either parameter (P > 0.05). Methylglyoxal at 100 μmol/l 
      with aspirin 1 mg/l did not significantly change in either fibrinolysis parameter 
      (P > 0.05), compared with methylglyoxal at 100 μmol/l. Methylglyoxal at 5 μmol/l 
      with aspirin (1, 10, 100  mg/l) changed in all fibrinolysis parameters (P < 
      0.05), compared with methylglyoxal at 5 μmol/l. The other concentrations were 
      compared in the same way. Aspirin (more than 1 mg/l) had more effect on higher 
      concentrations of methylglyoxal. It increased the velocity of lysis of the clot 
      and shortened clot lysis.
FAU - Pouya, Fahima D
AU  - Pouya FD
AD  - Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
FAU - Zavar-Reza, Javad
AU  - Zavar-Reza J
FAU - Jalali, Beman A
AU  - Jalali BA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 722KLD7415 (Pyruvaldehyde)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Atherosclerosis/drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fibrinolysis/*drug effects
MH  - Humans
MH  - Male
MH  - Pyruvaldehyde/*pharmacology
EDAT- 2013/06/12 06:00
MHDA- 2014/06/25 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/06/12 06:00 [entrez]
PHST- 2013/06/12 06:00 [pubmed]
PHST- 2014/06/25 06:00 [medline]
AID - 10.1097/MBC.0b013e328361bd68 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2013 Oct;24(7):715-8. doi: 
      10.1097/MBC.0b013e328361bd68.

PMID- 22792718
OWN - NLM
STAT- MEDLINE
DCOM- 20120912
LR  - 20191027
IS  - 0132-3423 (Print)
IS  - 0132-3423 (Linking)
VI  - 38
IP  - 2
DP  - 2012 Mar-Apr
TI  - [Identification of rat and human hemoglobin acetilation sites after its 
      interaction with acetylsalicylic acid].
PG  - 149-55
AB  - The possibility of interaction of 0.1 mg/mL acetylsalicylic acid with purified 
      human and rat globin in vitro during 24 h at 37 degrees C was investigated. The 
      rat globin can be modified with acetylsalicylic acid on aminoacid residues K-17, 
      K-57, K-91, K-140 in alpha subunit as well as on K-18, K-77 in beta subunit. The 
      human globin can be modified with acetylsalicylic acid on aminoacid residues 
      K-17, K-41, K-57 and K-91 in alpha subunit as well as on K-18, K-96 and K- 133 in 
      beta subunit. We identified of acetetylated lysines K-17 and K-57 in alpha 
      subunit of human hemoglobin after incubation whole blood with 0.1 mg/mL 
      acetylsalicylic acid during 3 h.
FAU - Shreĭner, E V
AU  - Shreĭner EV
FAU - Murashko, E A
AU  - Murashko EA
FAU - Dubrovskiĭ, Ia D
AU  - Dubrovskiĭ IaD
FAU - Krasnov, N V
AU  - Krasnov NV
FAU - Podol'skaia, E P
AU  - Podol'skaia EP
FAU - Babakov, V N
AU  - Babakov VN
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Bioorg Khim
JT  - Bioorganicheskaia khimiia
JID - 7804941
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Aspirin/*chemistry
MH  - Hemoglobins/*chemistry
MH  - Humans
MH  - Rats
MH  - Time Factors
EDAT- 2012/07/17 06:00
MHDA- 2012/09/13 06:00
CRDT- 2012/07/17 06:00
PHST- 2012/07/17 06:00 [entrez]
PHST- 2012/07/17 06:00 [pubmed]
PHST- 2012/09/13 06:00 [medline]
AID - 10.1134/s1068162012020094 [doi]
PST - ppublish
SO  - Bioorg Khim. 2012 Mar-Apr;38(2):149-55. doi: 10.1134/s1068162012020094.

PMID- 10890638
OWN - NLM
STAT- MEDLINE
DCOM- 20000803
LR  - 20190706
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 28
IP  - 6
DP  - 2000 Jun
TI  - Diaspirin-crosslinked hemoglobin reduces mortality of severe hemorrhagic shock in 
      pigs with critical coronary stenosis.
PG  - 1889-98
AB  - OBJECTIVE: To evaluate the effects of resuscitation with a 10% 
      diaspirin-crosslinked hemoglobin (DCLHb) solution on global hemodynamic 
      variables, systemic and myocardial oxygen transport and tissue oxygenation, and 
      contractile function of the left ventricle in an experimental model of severe 
      hemorrhagic shock and critical stenosis of the left anterior descending coronary 
      artery (LAD). DESIGN: Prospective, placebo-controlled, randomized study. SETTING: 
      Experimental animal laboratory. SUBJECTS: A total of 20 anesthetized pigs. 
      INTERVENTIONS: After implementation of a permanent critical LAD stenosis (ie, 
      maintenance of basal blood flow but absence of reactive hyperemia after a 10-sec 
      complete vessel occlusion), hemorrhagic shock (target mean aortic pressure, 45 mm 
      Hg) was induced within 15 mins by programmed withdrawal of blood and maintained 
      for 60 mins. Subsequently, the volume of plasma lost during hemorrhage was 
      replaced by either a balanced electrolyte solution containing 10 g/dL DCLHb 
      (DCLHb group; n = 10) or an 8 g/dL human albumin solution (HSA) oncotically 
      matched to DCLHb (HSA group; n = 10). Data were collected immediately after the 
      infusion of the different solutions and again after 60 mins had elapsed. 
      MEASUREMENTS AND MAIN RESULTS: Although five of ten HSA-treated animals died of 
      acute left ventricular failure within the first 20 mins after complete fluid 
      resuscitation, all of the DCLHb-treated animals survived the 60-min observation 
      period after resuscitation (p < .05). This significant difference in mortality is 
      explained by higher coronary perfusion pressure in DCLHb-treated animals (75 +/- 
      17 vs. 27 +/- 17 torr DCLHb vs. HSA group; p < .05) and persistence of 
      subendocardial ischemia and hypoxia (radioactive microspheres method) in 
      HSA-treated animals on resuscitation particularly affecting the LAD-supported 
      myocardium (subendocardial oxygen delivery: 20 +/- 11 vs. 3 +/- 1 mL oxygen x 
      g(-1) x min(-1), DCLHb vs. HSA group; p < .05). Except for enhanced myocardial 
      contractility immediately on infusion of DCLHb (maximal left ventricular pressure 
      increase: 2373 +/- 782 vs. 1730 +/- 543 torr x sec(-1) DCLHb vs. HSA group; p < 
      .05), no differences were detected between groups concerning the variables of 
      systemic oxygen transport, tissue oxygenation, and regional contractile function 
      of the myocardium (determined with microsonometry). CONCLUSIONS: Fluid 
      resuscitation with 10% DCLHb solution completely reverses hemorrhagic 
      shock-induced subendocardial ischemia and hypoxia in the presence of compromised 
      coronary circulation and thereby prevents early death after resuscitation.
FAU - Habler, O
AU  - Habler O
AD  - Clinic of Anesthesiology, Ludwig Maximilians University, Munich, Germany. 
      habler@icf.med.uni-muenchen.de
FAU - Kleen, M
AU  - Kleen M
FAU - Pape, A
AU  - Pape A
FAU - Meisner, F
AU  - Meisner F
FAU - Kemming, G
AU  - Kemming G
FAU - Messmer, K
AU  - Messmer K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Crit Care Med. 2000 Jun;28(6):2150-1. PMID: 10890689
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - Coronary Disease/*complications
MH  - Female
MH  - Hemoglobins/*therapeutic use
MH  - Male
MH  - Random Allocation
MH  - Resuscitation
MH  - Shock, Hemorrhagic/*drug therapy/etiology/*mortality
MH  - Swine
EDAT- 2000/07/13 11:00
MHDA- 2000/08/06 11:00
CRDT- 2000/07/13 11:00
PHST- 2000/07/13 11:00 [pubmed]
PHST- 2000/08/06 11:00 [medline]
PHST- 2000/07/13 11:00 [entrez]
AID - 10.1097/00003246-200006000-00034 [doi]
PST - ppublish
SO  - Crit Care Med. 2000 Jun;28(6):1889-98. doi: 10.1097/00003246-200006000-00034.

PMID- 6226358
OWN - NLM
STAT- MEDLINE
DCOM- 19831220
LR  - 20131121
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 5
IP  - 6
DP  - 1983
TI  - Etodolac, aspirin, and placebo in patients with degenerative joint disease: a 
      twelve-week study.
PG  - 651-61
AB  - Thirty patients from a private practice were enrolled in an investigation 
      designed to compare the efficacy and safety of a new nonsteroidal 
      anti-inflammatory drug, etodolac, with those of aspirin and placebo in 
      ameliorating pain, inflammation, and functional deficits associated with 
      degenerative joint disease. The 12-week, double-blind, parallel-group study was 
      divided into drug-titration and maintenance periods and was preceded by a washout 
      period of up to two weeks. There were ten patients in each of the three treatment 
      groups. The mean daily maintenance dosages of etodolac and aspirin were 384 mg 
      and 4,322 mg, respectively. Etodolac was significantly (less than or equal to 
      0.05) more effective than placebo according to 11 of 15 clinical indexes of 
      efficacy: three assessments of the range of motion of the knee joint, and one 
      each of pain while standing, pain while walking, pain while climbing stairs, the 
      average of pains while bearing weight, pain at night, joint tenderness, patient's 
      self-evaluation, and the time required to walk 50 feet. Aspirin was significantly 
      more effective than placebo in only three assessments: two of the range of motion 
      of the knee joint and one of pain while standing. One patient taking etodolac, 
      three patients taking aspirin, and six patients taking placebo withdrew from the 
      trial because of insufficient therapeutic response. There were four withdrawals 
      due to adverse effects, two in the aspirin group and two in the placebo group. 
      Adverse effects (tinnitus and hearing loss) leading to withdrawal of one of the 
      two aspirin patients were probably due to drug administration. No significant 
      side effects were reported by patients in the etodolac group.
FAU - Andelman, S Y
AU  - Andelman SY
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Acetates)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Placebos)
RN  - 2M36281008 (Etodolac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/adverse effects/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Etodolac
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Patient Compliance
MH  - Placebos
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1983;5(6):651-61.

PMID- 3515922
OWN - NLM
STAT- MEDLINE
DCOM- 19860502
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 80
IP  - 3A
DP  - 1986 Mar 24
TI  - Comparison of flurbiprofen and aspirin in the relief of postsurgical pain using 
      the dental pain model.
PG  - 36-40
AB  - This single-dose, double-blind, randomized, placebo-controlled study evaluated 
      the analgesic efficacy of both 25 and 50 mg of flurbiprofen (Ansaid, Upjohn) 
      compared with 650 mg of aspirin and placebo in 164 patients who had undergone 
      dental impaction surgery. Using the highly sensitive dental pain model, 
      flurbiprofen appears to be an effective, peripherally acting analgesic with a 
      rapid onset of activity. In the current study, it was superior to aspirin in 
      terms of peak effect and duration of action. Although flurbiprofen is much more 
      potent than ibuprofen, its side-effect profile did not differ markedly from that 
      of ibuprofen in this single-dose study.
FAU - Cooper, S A
AU  - Cooper SA
FAU - Mardirossian, G
AU  - Mardirossian G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Placebos)
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Flurbiprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
MH  - Propionates/*therapeutic use
MH  - Tooth Extraction
EDAT- 1986/03/24 00:00
MHDA- 1986/03/24 00:01
CRDT- 1986/03/24 00:00
PHST- 1986/03/24 00:00 [pubmed]
PHST- 1986/03/24 00:01 [medline]
PHST- 1986/03/24 00:00 [entrez]
AID - 0002-9343(86)90109-9 [pii]
AID - 10.1016/0002-9343(86)90109-9 [doi]
PST - ppublish
SO  - Am J Med. 1986 Mar 24;80(3A):36-40. doi: 10.1016/0002-9343(86)90109-9.

PMID- 22726765
OWN - NLM
STAT- MEDLINE
DCOM- 20120904
LR  - 20191210
IS  - 1878-5921 (Electronic)
IS  - 0895-4356 (Linking)
VI  - 65
IP  - 8
DP  - 2012 Aug
TI  - Investigating incoherence gives insight: clopidogrel is equivalent to 
      extended-release dipyridamole plus aspirin in secondary stroke prevention.
PG  - 835-45
LID - 10.1016/j.jclinepi.2012.01.019 [doi]
AB  - OBJECTIVE: To identify confounding factors that may explain the incoherence 
      between direct and indirect evidence in a published analysis comparing 
      extended-release dipyridamole (ERDP) plus aspirin to clopidogrel for the 
      reduction of stroke. STUDY DESIGN AND SETTING: An existing analysis was updated 
      with new studies from a systematic literature review. Clinicians reviewed the 
      studies for potential confounders. Network meta-analyses were conducted including 
      or excluding potential confounders, and were estimated based on direct, indirect, 
      or a combination of direct and indirect evidence. Model fit was compared using 
      the residual deviance and the deviance information criterion (DIC); node 
      splitting was used to test for incoherence between the networks. RESULTS: Six 
      trials and one meta-analysis were identified; aspirin dosage was identified as a 
      potential confounder. The odds ratio (OR) for stroke of aspirin plus ERDP vs. 
      clopidogrel based on indirect evidence without aspirin dosage adjustment is 0.85 
      (0.68-1.05); when accounting for the aspirin dose-response relationship it is 
      0.96 (0.73-1.25); and the direct evidence based on PRoFESS resulted in an OR of 
      1.02 (0.93-1.12). CONCLUSION: When analyzing networks of evidence, attention 
      should be paid to identifying and adjusting for potentially confounding factors. 
      Investigating rather than ignoring inconsistency in the data set leads to clearer 
      insight into relative efficacy.
CI  - Copyright © 2012 Elsevier Inc. All rights reserved.
FAU - Dewilde, Sarah
AU  - Dewilde S
AD  - Services in Health Economics, Rue des Eburons 55, 1000 Brussels, Belgium. 
      sd@SHE-consulting.be
FAU - Hawkins, Neil
AU  - Hawkins N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - J Clin Epidemiol
JT  - Journal of clinical epidemiology
JID - 8801383
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Confounding Factors, Epidemiologic
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Logistic Models
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2012/06/26 06:00
MHDA- 2012/09/05 06:00
CRDT- 2012/06/26 06:00
PHST- 2010/06/11 00:00 [received]
PHST- 2012/01/19 00:00 [revised]
PHST- 2012/01/22 00:00 [accepted]
PHST- 2012/06/26 06:00 [entrez]
PHST- 2012/06/26 06:00 [pubmed]
PHST- 2012/09/05 06:00 [medline]
AID - S0895-4356(12)00058-3 [pii]
AID - 10.1016/j.jclinepi.2012.01.019 [doi]
PST - ppublish
SO  - J Clin Epidemiol. 2012 Aug;65(8):835-45. doi: 10.1016/j.jclinepi.2012.01.019.

PMID- 32628428
OWN - NLM
STAT- MEDLINE
DCOM- 20211105
LR  - 20211105
IS  - 1728-7731 (Electronic)
IS  - 1726-4901 (Linking)
VI  - 83
IP  - 7
DP  - 2020 Jul
TI  - Efficacy and safety of clopidogrel and aspirin do not differ in patients with 
      stable ischemic stroke.
PG  - 651-656
LID - 10.1097/JCMA.0000000000000361 [doi]
AB  - BACKGROUND: The current study compared the efficacy and safety of clopidogrel vs 
      aspirin in the secondary prevention of ischemic stroke (IS). METHODS: We included 
      patients from the Taiwan National Health Insurance Research Database who were 
      aged between 20 and 80 years, had their first ever IS, had no diagnosis of atrial 
      fibrillation, and had not used an oral anticoagulant before the index IS between 
      2002 and 2010. We excluded patients who died or were admitted to a hospital due 
      to acute myocardial infarction, recurrent IS, or major bleeding within 3 months 
      of IS. Patients were then classified into clopidogrel as aspirin users. 
      Propensity score matching was adopted to select clopidogrel and aspirin groups 
      with similar baseline characteristics (n = 8457 vs 16,914, mean follow-up period 
      of 2.1 years and 1.9 years, respectively). Conditional Cox proportional hazard 
      regression was used to compare risks of all-cause death, cardiovascular death, 
      recurrent stroke, acute myocardial infarction, and major bleeding in clopidogrel 
      users and aspirin users. RESULTS: The risks of all-cause death, cardiovascular 
      death, recurrent stroke, and acute myocardial infarction did not differ between 
      clopidogrel and aspirin users. Subgroup analyses revealed that the results were 
      consistent regardless of age, disease severity, or comorbidity. CONCLUSION: 
      According to real-world data, the efficacy and safety of clopidogrel and aspirin 
      for secondary prevention of stable IS did not differ.
FAU - Chien, Li-Nien
AU  - Chien LN
AD  - School of Health Care Administration, College of Management, Taipei Medical 
      University, Taipei, Taiwan, ROC.
FAU - Liu, Hung-Yi
AU  - Liu HY
AD  - Health and Clinical Research Data Center, Office of Data, Taipei Medical 
      University, Taipei, Taiwan, ROC.
FAU - Chiou, Hung-Yi
AU  - Chiou HY
AD  - School of Public Health, College of Public Health, Taipei Medical University, 
      Taipei, Taiwan, ROC.
FAU - Chi, Nai-Fang
AU  - Chi NF
AD  - Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
AD  - Department of Neurology, Faculty of Medicine, School of Medicine, National 
      Yang-Ming University, Taipei, Taiwan, ROC.
AD  - Department of Neurology, School of Medicine, College of Medicine, Taipei Medical 
      University, Taipei, Taiwan, ROC.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Chin Med Assoc
JT  - Journal of the Chinese Medical Association : JCMA
JID - 101174817
RN  - 0 (Anticoagulants)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Ischemic Stroke/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Secondary Prevention
EDAT- 2020/07/07 06:00
MHDA- 2021/11/06 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/11/06 06:00 [medline]
AID - 02118582-202007000-00010 [pii]
AID - 10.1097/JCMA.0000000000000361 [doi]
PST - ppublish
SO  - J Chin Med Assoc. 2020 Jul;83(7):651-656. doi: 10.1097/JCMA.0000000000000361.

PMID- 4036935
OWN - NLM
STAT- MEDLINE
DCOM- 19851024
LR  - 20131121
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 80
IP  - 10
DP  - 1985 Oct
TI  - Ethanol, aspirin, ibuprofen, and the gastroduodenal mucosa: an endoscopic 
      assessment.
PG  - 767-9
AB  - The effect on the gastroduodenal mucosa of alcohol combined either with aspirin 
      or ibuprofen was studied in 60 normal volunteers. The volunteers were divided 
      into six groups comprised of 10 subjects receiving ibuprofen, placebo, or aspirin 
      with or without alcohol. Medications consisted of 1) three 325-mg aspirin 
      tablets, or three identical placebo tablets, 2) one 600-mg ibuprofen tablet, and 
      3), three ounces of 100 proof vodka diluted in 6 ounces of orange juice, or 
      alcohol placebo made by diluting 3 ounces of water in orange juice. All subjects 
      received 4 doses over a 24-hr period and underwent endoscopic examination the 
      following morning. The gastroduodenal mucosa was graded according to a 0 to 4 + 
      scale. Aspirin caused considerably greater duodenal and gastric damage than did 
      either ibuprofen or placebo. The addition of alcohol to all drugs increased the 
      damage seen in the stomach but not to a significant degree; this effect was 
      slightly more pronounced with ibuprofen than with placebo or aspirin and 
      approached significance (0.1 greater than p greater than 0.05). These results are 
      compatible with alcohol being a mild damaging agent or a potentiating agent for 
      damage from other drugs.
FAU - Lanza, F L
AU  - Lanza FL
FAU - Royer, G L Jr
AU  - Royer GL Jr
FAU - Nelson, R S
AU  - Nelson RS
FAU - Rack, M F
AU  - Rack MF
FAU - Seckman, C C
AU  - Seckman CC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*pharmacology
MH  - Drug Interactions
MH  - Drug Synergism
MH  - Duodenal Diseases/chemically induced
MH  - Ethanol/adverse effects/*pharmacology
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Gastroscopy
MH  - Humans
MH  - Ibuprofen/adverse effects/*pharmacology
MH  - Intestinal Mucosa/*drug effects
MH  - Male
MH  - Stomach Diseases/chemically induced
EDAT- 1985/10/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1985/10/01 00:00
PHST- 1985/10/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1985/10/01 00:00 [entrez]
PST - ppublish
SO  - Am J Gastroenterol. 1985 Oct;80(10):767-9.

PMID- 28063671
OWN - NLM
STAT- MEDLINE
DCOM- 20171120
LR  - 20171128
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 230
DP  - 2017 Mar 1
TI  - Meta-analysis of major bleeding events on aspirin versus vitamin K antagonists in 
      randomized trials.
PG  - 572-576
LID - S0167-5273(16)34543-0 [pii]
LID - 10.1016/j.ijcard.2016.12.055 [doi]
AB  - BACKGROUND AND OBJECTIVES: The relative bleeding risk of aspirin versus vitamin K 
      antagonists (VKA) is unclear. Most of previous meta-analyses included trials with 
      target INR for VKA therapy far beyond usually recommended range (2-3). The aim of 
      this study was to compare the bleeding risk of aspirin and VKA, as indicated by 
      the aggregate body of clinical evidence including data from the recently 
      published WARCEF trial. METHODS: In this meta-analysis we included randomized 
      controlled trials that compared aspirin to VKA (1.4<INR<3.5) for the prevention 
      of arterial thrombosis with a minimum of three month follow-up and of 50 patients 
      per treatment arm. The outcome measures were major bleedings and intracranial 
      bleedings. RESULTS: Ten eligible trials including 9047 patients were included, 
      451 of whom experienced major bleedings and 62 had intracranial bleeding. The 10 
      studies were homogeneous in spite of different clinical settings, including 
      atrial fibrillation, heart failure and cerebral ischemia from arterial origin. 
      Mean achieved INR on VKA varied from to 2.1 to 2.6. Compared with VKA, aspirin 
      had an overall lower major bleeding risk (relative risk=0.58; 95% CI: 0.46-0.75; 
      p<0.001). There was a non-significant trend for a lower intracranial bleeding 
      risk on aspirin versus VKA (relative risk=0.65; 95% CI: 0.40-1.06; p=0.09). 
      CONCLUSION: Major bleeding risk is substantially lower on aspirin than on VKA 
      targeting current usual INR range. Physicians should take into account this data 
      when choosing between different antithrombotic regimens.
CI  - Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.
FAU - Ambrosi, P
AU  - Ambrosi P
AD  - Department of Therapeutics, Hôpital de la Timone, 13385 Marseille, France; 
      Department of Cardiology, Hôpital de la Timone, 13385 Marseille, France. 
      Electronic address: pierre.ambrosi@ap-hm.fr.
FAU - Daumas, A
AU  - Daumas A
AD  - Department of Therapeutics, Hôpital de la Timone, 13385 Marseille, France.
FAU - Villani, P
AU  - Villani P
AD  - Department of Therapeutics, Hôpital de la Timone, 13385 Marseille, France.
FAU - Giorgi, R
AU  - Giorgi R
AD  - Aix-Marseille Université, UMR_S 912 (SESSTIM), IRD, 13385 Marseille, France; 
      INSERM, UMR_S 912 (SESSTIM), 13385 Marseille, France; APHM, hôpital Timone, 
      Service Biostatistique et Technologies de l'Information et de la Communication, 
      13005 Marseille, France.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20161227
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Global Health
MH  - Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - *Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Thrombosis/prevention & control
MH  - Vitamin K/*antagonists & inhibitors
OTO - NOTNLM
OT  - Aspirin
OT  - Bleeding
OT  - Meta-analysis
OT  - Vitamin K antagonists
OT  - Warfarin
EDAT- 2017/01/09 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/01/09 06:00
PHST- 2016/06/24 00:00 [received]
PHST- 2016/12/14 00:00 [revised]
PHST- 2016/12/16 00:00 [accepted]
PHST- 2017/01/09 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/01/09 06:00 [entrez]
AID - S0167-5273(16)34543-0 [pii]
AID - 10.1016/j.ijcard.2016.12.055 [doi]
PST - ppublish
SO  - Int J Cardiol. 2017 Mar 1;230:572-576. doi: 10.1016/j.ijcard.2016.12.055. Epub 
      2016 Dec 27.

PMID- 1207273
OWN - NLM
STAT- MEDLINE
DCOM- 19760320
LR  - 20131121
IS  - 0023-8236 (Print)
IS  - 0023-8236 (Linking)
VI  - Suppl
DP  - 1975
TI  - [Prevention of thrombosis using acetylsalicylic acid following vascular 
      prosthesis and endarterectomy].
PG  - 427-9
AB  - In 20 dogs one common iliac artery was intimectomized, an equal segment of the 
      other was replaced by a knitted dacron prosthesis. Ten animals were given 
      Acetylsalicylic Acid 30 mg/kg BW/d. Four weeks later these arterial segments were 
      examined grossly and histologically for the presence of thrombotic depositis. In 
      the treated animals these segments always remained patent. Three of the untreated 
      animals showed a complete thrombotic occlusion of the prosthesis. The amount of 
      thrombotic deposits on intimectomized and prosthetics segments was clearly 
      reduced in the treated animals.
FAU - Hetzer, R
AU  - Hetzer R
FAU - Dragojevic, D
AU  - Dragojevic D
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Thromboseprophylaxe mit Acetylsalicylsäure nach prothetischem Gefässersatz und 
      Endarteriektomie.
PL  - Germany
TA  - Langenbecks Arch Chir
JT  - Langenbecks Archiv fur Chirurgie
JID - 0204167
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Blood Vessel Prosthesis
MH  - Dogs
MH  - Endarterectomy
MH  - Platelet Adhesiveness
MH  - Postoperative Complications/*prevention & control
MH  - Thrombosis/*prevention & control
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
PST - ppublish
SO  - Langenbecks Arch Chir. 1975;Suppl:427-9.

PMID- 33483830
OWN - NLM
STAT- MEDLINE
DCOM- 20211119
LR  - 20220203
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 77
IP  - 7
DP  - 2021 Jul
TI  - Aspirin in people with dementia, long-term benefits, and harms: a systematic 
      review.
PG  - 943-954
LID - 10.1007/s00228-021-03089-x [doi]
AB  - PURPOSE: People with dementia may have indications for aspirin prescription and 
      clinicians are asked to balance the potential risks against benefits. This review 
      examines the evidence for the risk and benefit of long-term aspirin use in people 
      with dementia aged over 65 years, including randomised controlled trials and 
      observational studies. METHODS: We searched three databases for research 
      published between 2007 and 2020. Each eligible article was assessed for risk of 
      bias, and confidence in findings was rated using Grading of Recommendations 
      Assessment, Development and Evaluation (GRADE). RESULTS: Four papers met 
      inclusion criteria: one randomised controlled trial, two cohort studies, and one 
      with pooled data. All looked only at dementia of Alzheimer's type, and none 
      addressed myocardial or cerebral infarction as outcomes. Dementia progression was 
      reported by two studies, with conflicting results. The trial found no significant 
      effect of aspirin on mortality (odds ratio aspirin vs. no aspirin 1.07, 95% 
      confidence interval 0.58-1.97) but found more events of severe bleeding with 
      aspirin (OR aspirin vs. no aspirin 6.9, 1.5-31.2). An excess in intracranial 
      haemorrhage in the aspirin group was judged plausible based on two non-randomised 
      studies. CONCLUSIONS: The review findings are limited because studies include 
      only people with Alzheimer's-type dementia and lack confirmatory studies, 
      although an increased risk of bleeding events is recognised. Further research 
      that addresses the benefits and risks of aspirin in more representative groups of 
      people with dementia is needed to guide prescribing decisions.
FAU - Davis, Katrina A S
AU  - Davis KAS
AUID- ORCID: 0000-0001-5945-4646
AD  - King's College London Institute of Psychiatry Psychology and Neuroscience, 
      London, UK. katrina.davis@kcl.ac.uk.
AD  - South London and Maudsley NHS Foundation Trust, London, UK. 
      katrina.davis@kcl.ac.uk.
FAU - Bishara, Delia
AU  - Bishara D
AUID- ORCID: 0000-0002-6254-2054
AD  - King's College London Institute of Psychiatry Psychology and Neuroscience, 
      London, UK.
AD  - South London and Maudsley NHS Foundation Trust, London, UK.
FAU - Molokhia, Mariam
AU  - Molokhia M
AUID- ORCID: 0000-0002-1989-7327
AD  - King's College London Population Health Sciences, London, UK.
FAU - Mueller, Christoph
AU  - Mueller C
AUID- ORCID: 0000-0001-9816-1686
AD  - King's College London Institute of Psychiatry Psychology and Neuroscience, 
      London, UK.
AD  - South London and Maudsley NHS Foundation Trust, London, UK.
FAU - Perera, Gayan
AU  - Perera G
AUID- ORCID: 0000-0002-3414-303X
AD  - King's College London Institute of Psychiatry Psychology and Neuroscience, 
      London, UK.
AD  - South London and Maudsley NHS Foundation Trust, London, UK.
FAU - Stewart, Robert J
AU  - Stewart RJ
AUID- ORCID: 0000-0002-4435-6397
AD  - King's College London Institute of Psychiatry Psychology and Neuroscience, 
      London, UK.
AD  - South London and Maudsley NHS Foundation Trust, London, UK.
LA  - eng
GR  - Biomedical Research Centre at King's College London and South London and Maudsley 
      NHS Foundation Trust/National Institute of Health Research/
PT  - Journal Article
PT  - Systematic Review
DEP - 20210122
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur J Clin Pharmacol. 2021 Nov;77(11):1763-1764. PMID: 34189596
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*drug therapy/mortality
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Disease Progression
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Observational Studies as Topic
MH  - Randomized Controlled Trials as Topic
PMC - PMC8184554
OTO - NOTNLM
OT  - Aspirin
OT  - Dementia
OT  - Evidence-based medicine
OT  - Multimorbidity
OT  - Systematic review
COIS- RS declares research funding/support from Janssen, GSK, and Takeda in the last 
      3 years. All other authors declare that they have no conflicts of interests.
EDAT- 2021/01/24 06:00
MHDA- 2021/11/20 06:00
CRDT- 2021/01/23 05:40
PHST- 2020/09/28 00:00 [received]
PHST- 2021/01/11 00:00 [accepted]
PHST- 2021/01/24 06:00 [pubmed]
PHST- 2021/11/20 06:00 [medline]
PHST- 2021/01/23 05:40 [entrez]
AID - 10.1007/s00228-021-03089-x [pii]
AID - 3089 [pii]
AID - 10.1007/s00228-021-03089-x [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2021 Jul;77(7):943-954. doi: 10.1007/s00228-021-03089-x. 
      Epub 2021 Jan 22.

PMID- 22365313
OWN - NLM
STAT- MEDLINE
DCOM- 20140224
LR  - 20130617
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 167
IP  - 2
DP  - 2013 Jul 31
TI  - Aspirin desensitization in patients undergoing planned or urgent coronary stent 
      implantation. A single-center experience.
PG  - 561-3
LID - S0167-5273(12)00081-2 [pii]
LID - 10.1016/j.ijcard.2012.01.063 [doi]
AB  - INTRODUCTION: Dual antiplatelet therapy (aspirin and ADP-antagonists) is 
      mandatory after stent implantation in order to avoid stent thrombosis, especially 
      in the era of DES. In fact, a delayed re-endothelization process may enlarge the 
      window of occurrence of stent thrombosis beyond 1-year after implantation. 
      Allergy to acid acetylsalicylic is not a rare event and may influence the use and 
      the choice of coronary stent with an important impact in terms of outcome 
      especially in patients at high risk for in-stent restenosis. The aim of this 
      study was to evaluate the safety and efficacy of a new intravenous rapid 
      desensitization protocol in patients with acetylsalicylic acid sensitivity 
      undergoing coronary stent implantation. METHODS: Among a total of 1385 patients 
      undergoing coronary angioplasty at our catheterization laboratory from January 
      2007 to June 2011, a total of 43 patients (3.1%) had history of aspirin 
      sensitivity characterized by respiratory or cutaneous manifestations (none had 
      previous anaphylactic reactions). Twenty-three patients (53.5%) presented with 
      acute coronary syndromes. All patients underwent a novel rapid desensitization 
      procedure before or after cardiac catheterization (in case of ST-elevation 
      myocardial infarctions, n=5). The desensitization procedure was based on 
      intravenous administration of 9 sequential doses of aspirin (1, 2, 4, 8, 16, 32, 
      64, 128, 250 mg) over 4.5h without the use of corticosteroids or antihistamines. 
      Patients were followed for at least 30 days and up to 12 months to assess 
      compliance with aspirin therapy and adverse events. RESULTS: The desensitization 
      procedure was successful in 42 patients (97.6%). All patients underwent stent 
      implantation (1.6 stents/patient). Drug-eluting stents were used in 36 patients 
      (85.7%). At follow-up, all patients who successfully responded to the 
      desensitization procedure did not develop any allergic reaction. CONCLUSIONS: 
      This study showed the safety and efficacy of a new rapid intravenous protocol 
      desensitization for patients with history of aspirin sensitivity undergoing 
      planned or urgent coronary stent implantation.
CI  - Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
FAU - De Luca, Giuseppe
AU  - De Luca G
AD  - Division of Cardiology, Ospedale Maggiore della Carità, Eastern Piedmont 
      University, Novara, Italy. giuseppe.deluca@maggioreosp.novara.it
FAU - Verdoia, Monica
AU  - Verdoia M
FAU - Binda, Giulia
AU  - Binda G
FAU - Schaffer, Alon
AU  - Schaffer A
FAU - Suryapranata, Harry
AU  - Suryapranata H
FAU - Marino, Paolo
AU  - Marino P
LA  - eng
PT  - Journal Article
DEP - 20120224
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/epidemiology/*therapy
MH  - Aged
MH  - Aged, 80 and over
MH  - Ambulatory Care/*methods
MH  - Angioplasty, Balloon, Coronary/*methods
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug Hypersensitivity/epidemiology/*prevention & control
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
EDAT- 2012/03/01 06:00
MHDA- 2014/02/25 06:00
CRDT- 2012/02/28 06:00
PHST- 2011/09/15 00:00 [received]
PHST- 2011/12/14 00:00 [revised]
PHST- 2012/01/22 00:00 [accepted]
PHST- 2012/02/28 06:00 [entrez]
PHST- 2012/03/01 06:00 [pubmed]
PHST- 2014/02/25 06:00 [medline]
AID - S0167-5273(12)00081-2 [pii]
AID - 10.1016/j.ijcard.2012.01.063 [doi]
PST - ppublish
SO  - Int J Cardiol. 2013 Jul 31;167(2):561-3. doi: 10.1016/j.ijcard.2012.01.063. Epub 
      2012 Feb 24.

PMID- 10956369
OWN - NLM
STAT- MEDLINE
DCOM- 20001019
LR  - 20181130
IS  - 8750-7587 (Print)
IS  - 0161-7567 (Linking)
VI  - 89
IP  - 3
DP  - 2000 Sep
TI  - Acellular hemoglobin solution enters compressed lung capillaries more readily 
      than red blood cells.
PG  - 1198-204
AB  - High lung inflation pressures compress alveolar septal capillaries, impede red 
      cell transit, and interfere with oxygenation. However, recently introduced 
      acellular hemoglobin solutions may enter compressed lung capillaries more easily 
      than red blood cells. To test this hypothesis, we perfused isolated rat lungs 
      with fluorescently labeled diaspirin cross-linked hemoglobin (DCLHb; 10%) and/ or 
      autologous red cells (hematocrit, 20). Septal capillaries were compressed by 
      setting lung inflation pressure above vascular pressures (zone 1). Examination by 
      confocal microscopy showed that DCLHb was distributed throughout alveolar septa. 
      Furthermore, this distribution was not affected by adding red blood cells to the 
      perfusate. We estimated the maximum acellular hemoglobin mass within septa to be 
      equivalent to that of 15 red blood cells. By comparison, we found an average of 
      2.7 +/- 4.6 red cells per septum in zone 1. These values increased to 30.4 +/- 
      25.8 and 50.4 +/- 22.1 cells per septum in zones 2 and 3, respectively. We 
      conclude that perfusion in zone 1 with a 10% acellular hemoglobin solution may 
      increase the hemoglobin concentration per septum up to fivefold compared with red 
      cell perfusion.
FAU - Conhaim, R L
AU  - Conhaim RL
AD  - Department of Surgery, University of Wisconsin-Madison, and William S. Middleton 
      Memorial Veterans Hospital, Madison, Wisconsin 53705, USA.
FAU - Rodenkirch, L A
AU  - Rodenkirch LA
FAU - Watson, K E
AU  - Watson KE
FAU - Harms, B A
AU  - Harms BA
LA  - eng
GR  - HL49985/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Appl Physiol (1985)
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacokinetics
MH  - Capillaries/metabolism
MH  - *Capillary Permeability
MH  - Erythrocytes/*physiology
MH  - Hemoglobins/*pharmacokinetics
MH  - In Vitro Techniques
MH  - Microscopy, Confocal
MH  - Microscopy, Fluorescence
MH  - Pulmonary Alveoli/metabolism
MH  - *Pulmonary Circulation
MH  - Rats
MH  - Tissue Distribution
EDAT- 2000/08/24 11:00
MHDA- 2000/10/21 11:01
CRDT- 2000/08/24 11:00
PHST- 2000/08/24 11:00 [pubmed]
PHST- 2000/10/21 11:01 [medline]
PHST- 2000/08/24 11:00 [entrez]
AID - 10.1152/jappl.2000.89.3.1198 [doi]
PST - ppublish
SO  - J Appl Physiol (1985). 2000 Sep;89(3):1198-204. doi: 
      10.1152/jappl.2000.89.3.1198.

PMID- 12714200
OWN - NLM
STAT- MEDLINE
DCOM- 20030903
LR  - 20191210
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 88
IP  - 2-3
DP  - 2003 Apr
TI  - Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does 
      not worsen long-term survival in heart failure.
PG  - 207-14
AB  - BACKGROUND: A negative interaction has been shown to exist between aspirin and 
      angiotensin-converting enzyme inhibitors (ACE-I) in subjects with heart failure. 
      We explored the effect of combined ACE-I and aspirin therapy compared to ACE-I 
      without aspirin on clinical outcomes in patients with heart failure. METHODS: 430 
      consecutive subjects (70+/-14 years, 55% male, 41% with coronary artery disease) 
      released from the hospital with a primary diagnosis of heart failure were 
      classified into three groups based on the use of aspirin and ACE-I at discharge: 
      ACE-I without aspirin (group I, n=134), ACE-I with aspirin (group II, n=138) and 
      no ACE-I (group III, n=158). Follow-up (all-cause mortality and the composite 
      end-point of mortality or emergent heart transplant) was available in 406 (94%) 
      patients at a median duration of 28 months. Differences in outcomes between 
      patient groups were compared using contingency tables, Kaplan-Meier survival, and 
      Cox regression analyses. Similar analyses were conducted in four predefined 
      subsets (patients with and without coronary artery disease, and those with left 
      ventricular ejection fraction <or=45%, and >45%). RESULTS: Death and the 
      composite end-point occurred in 155 (38%) and 165 (41%) patients, respectively. 
      In the total cohort as well as in the four subsets, the treatment group showed no 
      association with clinical outcomes in univariate or multivariate analyses. 
      CONCLUSIONS: In patients with a principal discharge diagnosis of heart failure, 
      the use of aspirin, in combination with ACE-I, does not worsen long-term survival 
      compared to the use of ACE-I without aspirin.
FAU - Harjai, Kishore J
AU  - Harjai KJ
AD  - Department of Cardiology, Ochsner Clinic, New Orleans, USA. kharjai@beaumont.edu
FAU - Solis, Sergio
AU  - Solis S
FAU - Prasad, Ananth
AU  - Prasad A
FAU - Loupe, Jill
AU  - Loupe J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/*therapeutic use
MH  - Cohort Studies
MH  - *Drug Interactions
MH  - Drug Therapy, Combination
MH  - Echocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/diagnostic imaging/*drug therapy/*mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Outcome Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/*therapeutic use
MH  - Survival Rate
MH  - Time Factors
EDAT- 2003/04/26 05:00
MHDA- 2003/09/04 05:00
CRDT- 2003/04/26 05:00
PHST- 2003/04/26 05:00 [pubmed]
PHST- 2003/09/04 05:00 [medline]
PHST- 2003/04/26 05:00 [entrez]
AID - S0167527302004011 [pii]
AID - 10.1016/s0167-5273(02)00401-1 [doi]
PST - ppublish
SO  - Int J Cardiol. 2003 Apr;88(2-3):207-14. doi: 10.1016/s0167-5273(02)00401-1.

PMID- 7203849
OWN - NLM
STAT- MEDLINE
DCOM- 19810528
LR  - 20171117
IS  - 0300-9831 (Print)
IS  - 0300-9831 (Linking)
VI  - 50
IP  - 4
DP  - 1980
TI  - Protein-binding of ascorbic acid 2. Interaction with acetylsalicylic acid.
PG  - 387-92
AB  - The effect of aspirin (ASP) on the binding of ascorbic acid (AA) to bovine serum 
      albumin (BSA) has been investigated by the method of dynamic dialysis. Scatchard 
      plots were constructed which confirmed that binding with AA occurred in the 
      presence of BSA. When ASP was also present, greater curvature of the plot was 
      demonstrated indicating that less binding of AA to BSA was taking place. The 
      limiting slopes of the plots showed that ASP displaces both primary and secondary 
      sites previously occupied by AA and that the strengths of both primary and 
      secondary sites increased as a result of interaction with ASP. It is concluded 
      that primary sites for binding of AA to BSA consist of two or more types of 
      similar binding strengths, and that secondary binding also may involve binding on 
      two or more sites. The pathophysiological implications are discussed.
FAU - Molloy, T P
AU  - Molloy TP
FAU - Wilson, C W
AU  - Wilson CW
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int J Vitam Nutr Res
JT  - International journal for vitamin and nutrition research. Internationale 
      Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de 
      vitaminologie et de nutrition
JID - 1273304
RN  - 27432CM55Q (Serum Albumin, Bovine)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Ascorbic Acid
MH  - Aspirin/*pharmacology
MH  - Binding Sites/drug effects
MH  - Cattle
MH  - Dialysis
MH  - Kinetics
MH  - Protein Binding/drug effects
MH  - *Serum Albumin, Bovine
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Vitam Nutr Res. 1980;50(4):387-92.

PMID- 16872006
OWN - NLM
STAT- MEDLINE
DCOM- 20060915
LR  - 20131121
IS  - 0047-1860 (Print)
IS  - 0047-1860 (Linking)
VI  - 54
IP  - 6
DP  - 2006 Jun
TI  - [Attempts for aspirin monitoring with a new assay system, Ultegra Rapid Platelet 
      Function Assay (RPFA), based on turbidimetric platelet agglutination of whole 
      blood samples].
PG  - 576-82
AB  - Platelet aggregation measured by the optical density method has been applied for 
      the assessment of platelet functions. However, as the method has to use 
      platelet-rich plasma, it requires centrifugation of blood samples, which takes a 
      considerable period of time. Using whole blood as samples has advantage because 
      there is no pre-treatment of samples before measurement of platelet functions. 
      Additionally, it would be desirable to have a bedside assay that reflects 
      hyper-function of platelets and can monitor inhibitory effects of anti-platelet 
      drugs. Rapid Platelet Function Assay (RPFA) is a qualitative test to aid the 
      detection of platelet dysfunction due to anti-platelet drug ingestion, which uses 
      citrated whole blood for sample in point of care or laboratory settings. The RPFA 
      is a turbidimetric analysis, based on an optical detection system which measures 
      platelet agglutination as an increase in light transmission. The aim of this 
      study is to assess the accuracy and reproducibility of RPFA and to determine 
      whether RPFA can monitor the effects of anti-platelet drugs. During the first 30 
      minutes after blood collection, Aspirin Reaction Units (ARU) determined with RPFA 
      gradually increased, and reached its plateau after 30 minutes. The ARU values 
      remained almost constant thereafter until 6 hours after blood collection (Fig. 
      3). These findings suggest that platelet function is unstable immediately after 
      blood collection. Therefore, in this study ARU measurement was performed 60 
      minutes after blood collection. The reproducibility of ARU is very good both 
      before and after aspirin intake. Seven days after daily uptake aspirin, ARU was 
      decreased as compared with the control (440.8 +/- 39.4 vs. 663.4 +/- 2.4 ARU). 
      RPFA measurement provides rapid information on platelet function that mirrors 
      turbidimetric platelet agglutination and reflects COX1-depedent platelet 
      activity.
FAU - Satoh, Kaneo
AU  - Satoh K
AD  - Department of Clinical and Laboratory Medicine, School of Medicine, University of 
      Yamanashi, Chuo.
FAU - Ozaki, Yukio
AU  - Ozaki Y
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Byori
JT  - Rinsho byori. The Japanese journal of clinical pathology
JID - 2984781R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Drug Monitoring/*instrumentation
MH  - Humans
MH  - Male
MH  - Nephelometry and Turbidimetry/*instrumentation
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 2006/07/29 09:00
MHDA- 2006/09/16 09:00
CRDT- 2006/07/29 09:00
PHST- 2006/07/29 09:00 [pubmed]
PHST- 2006/09/16 09:00 [medline]
PHST- 2006/07/29 09:00 [entrez]
PST - ppublish
SO  - Rinsho Byori. 2006 Jun;54(6):576-82.

PMID- 25096604
OWN - NLM
STAT- MEDLINE
DCOM- 20150824
LR  - 20230807
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 26
IP  - 1
DP  - 2015 Jan
TI  - Estimates of benefits and harms of prophylactic use of aspirin in the general 
      population.
PG  - 47-57
LID - S0923-7534(19)31314-6 [pii]
LID - 10.1093/annonc/mdu225 [doi]
AB  - BACKGROUND: Accumulating evidence supports an effect of aspirin in reducing 
      overall cancer incidence and mortality in the general population. We reviewed 
      current data and assessed the benefits and harms of prophylactic use of aspirin 
      in the general population. METHODS: The effect of aspirin for site-specific 
      cancer incidence and mortality, cardiovascular events was collated from the most 
      recent systematic reviews. Studies identified through systematic Medline search 
      provided data regarding harmful effects of aspirin and baseline rates of harms 
      like gastrointestinal bleeding and peptic ulcer. RESULTS: The effects of aspirin 
      on cancer are not apparent until at least 3 years after the start of use, and 
      some benefits are sustained for several years after cessation in long-term users. 
      No differences between low and standard doses of aspirin are observed, but there 
      were no direct comparisons. Higher doses do not appear to confer additional 
      benefit but increase toxicities. Excess bleeding is the most important harm 
      associated with aspirin use, and its risk and fatality rate increases with age. 
      For average-risk individuals aged 50-65 years taking aspirin for 10 years, there 
      would be a relative reduction of between 7% (women) and 9% (men) in the number of 
      cancer, myocardial infarction or stroke events over a 15-year period and an 
      overall 4% relative reduction in all deaths over a 20-year period. CONCLUSIONS: 
      Prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 
      mg/day appears to have favourable benefit-harm profile; longer use is likely to 
      have greater benefits. Further research is needed to determine the optimum dose 
      and duration of use, to identify individuals at increased risk of bleeding, and 
      to test effectiveness of Helicobacter pylori screening-eradication before 
      starting aspirin prophylaxis.
CI  - © The Author 2014. Published by Oxford University Press on behalf of the European 
      Society for Medical Oncology.
FAU - Cuzick, J
AU  - Cuzick J
AD  - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen 
      Mary University of London, London, UK. Electronic address: j.cuzick@qmul.ac.uk.
FAU - Thorat, M A
AU  - Thorat MA
AD  - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen 
      Mary University of London, London, UK.
FAU - Bosetti, C
AU  - Bosetti C
AD  - Department of Epidemiology, IRCCS-Istituto di Ricerche Farmacologiche 'Mario 
      Negri', Milan, Italy.
FAU - Brown, P H
AU  - Brown PH
AD  - Department of Clinical Cancer Prevention, The University of Texas MD Anderson 
      Cancer Center, Houston, USA.
FAU - Burn, J
AU  - Burn J
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
FAU - Cook, N R
AU  - Cook NR
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical 
      School, Boston.
FAU - Ford, L G
AU  - Ford LG
AD  - Division of Cancer Prevention, National Cancer Institute, National Institutes of 
      Health, Bethesda.
FAU - Jacobs, E J
AU  - Jacobs EJ
AD  - Epidemiology Research Program, American Cancer Society, Atlanta, USA.
FAU - Jankowski, J A
AU  - Jankowski JA
AD  - Centre for Biomedical Research-Translational and Stratified Medicine, Peninsula 
      Schools of Medicine and Dentistry, Plymouth University, Plymouth; Centre for 
      Digestive Diseases, Blizard Institute of Cell and Molecular Science, Queen Mary 
      University of London, London, UK.
FAU - La Vecchia, C
AU  - La Vecchia C
AD  - Department of Epidemiology, IRCCS-Istituto di Ricerche Farmacologiche 'Mario 
      Negri', Milan, Italy; Department of Clinical Sciences and Community Health, 
      University of Milan, Milan, Italy.
FAU - Law, M
AU  - Law M
AD  - Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive 
      Medicine, Queen Mary University of London, London, UK.
FAU - Meyskens, F
AU  - Meyskens F
AD  - Chao Family Comprehensive Cancer Center, University of California, Irvine, 
      Irvine, USA.
FAU - Rothwell, P M
AU  - Rothwell PM
AD  - Stroke Prevention Research Unit, Nuffield Department of Clinical Neuroscience, 
      University of Oxford, Oxford, UK.
FAU - Senn, H J
AU  - Senn HJ
AD  - Tumor and Breast Center ZeTuP, St Gallen, Switzerland.
FAU - Umar, A
AU  - Umar A
AD  - Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, 
      National Cancer Institute, National Institutes of Health, Bethesda, USA.
LA  - eng
GR  - 095626/Wellcome Trust/United Kingdom
GR  - G0100496/MRC_/Medical Research Council/United Kingdom
GR  - BHF_/British Heart Foundation/United Kingdom
GR  - CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140805
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 2014;349:g5037. PMID: 25098322
CIN - Ann Oncol. 2015 Feb;26(2):442-3. PMID: 25403580
CIN - Ann Oncol. 2015 Feb;26(2):441-2. PMID: 25416686
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Neoplasms/*prevention & control
MH  - Stroke/*prevention & control
PMC - PMC4269341
OTO - NOTNLM
OT  - aspirin
OT  - benefit-harm
OT  - cancer
OT  - cardiovascular disease
OT  - gastrointestinal bleeding
OT  - prevention
EDAT- 2014/08/07 06:00
MHDA- 2015/08/25 06:00
CRDT- 2014/08/07 06:00
PHST- 2014/08/07 06:00 [entrez]
PHST- 2014/08/07 06:00 [pubmed]
PHST- 2015/08/25 06:00 [medline]
AID - S0923-7534(19)31314-6 [pii]
AID - mdu225 [pii]
AID - 10.1093/annonc/mdu225 [doi]
PST - ppublish
SO  - Ann Oncol. 2015 Jan;26(1):47-57. doi: 10.1093/annonc/mdu225. Epub 2014 Aug 5.

PMID- 16939558
OWN - NLM
STAT- MEDLINE
DCOM- 20070426
LR  - 20131121
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 60
IP  - 9
DP  - 2006 Sep
TI  - Which patients should receive aspirin for primary prevention of cardiovascular 
      disease? An economic evaluation.
PG  - 1129-37
AB  - Low-dose aspirin is a standard care for secondary prevention of cardiovascular 
      disease (CVD). Its use in primary prevention is less widely accepted, however, 
      despite recent meta-analyses and US and European guidelines supporting its use in 
      individuals at increased CVD risk. The aim of this study was to define which 
      patients should receive aspirin for primary prevention of CVD using data from 
      four European countries. Based on the clinical data from two meta-analyses, a 
      state-transition model was developed to compare the costs and effects of no 
      treatment and low-dose aspirin as primary prevention for CVD over 10 years. The 
      model was applied to patients at different 10-year risks (2-5%) of fatal CVD 
      according to the SCORE equation. Direct costs from the perspective of the 
      healthcare payer were used (base year 2003). Country-specific discounting was 
      applied. Treating patients with a 10-year risk of fatal CVD of 2% or higher with 
      low-dose aspirin resulted in lower total costs and more quality-adjusted 
      life-years gained in the UK, Germany and Spain. In Italy, savings started at a 
      10-year fatal CVD risk of 3%. This difference was due to the higher cost of 
      gastrointestinal bleeding in Italy. Monte Carlo analysis showed that aspirin was 
      dominant in more than 90% of patients at a 10-year risk of 4% and 5% in the four 
      countries. In conclusion, low-dose aspirin treatment becomes cost-saving at a 
      very low 10-year risk of fatal CVD. The cost of gastrointestinal bleeding defines 
      the level at which low-dose aspirin becomes cost-saving.
FAU - Annemans, L
AU  - Annemans L
AD  - Department of Public Health, Faculty of Medicine, Ghent University, Ghent, 
      Belgium. lieven.annemans@ugent.be
FAU - Lamotte, M
AU  - Lamotte M
FAU - Kubin, M
AU  - Kubin M
FAU - Evers, T
AU  - Evers T
FAU - Verheugt, F W A
AU  - Verheugt FW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/economics
MH  - Cardiovascular Diseases/economics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Models, Economic
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/*administration & dosage/economics
MH  - Primary Prevention/economics
MH  - Quality-Adjusted Life Years
MH  - Risk Factors
EDAT- 2006/08/31 09:00
MHDA- 2007/04/27 09:00
CRDT- 2006/08/31 09:00
PHST- 2006/08/31 09:00 [pubmed]
PHST- 2007/04/27 09:00 [medline]
PHST- 2006/08/31 09:00 [entrez]
AID - IJCP1089 [pii]
AID - 10.1111/j.1742-1241.2006.01089.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2006 Sep;60(9):1129-37. doi: 10.1111/j.1742-1241.2006.01089.x.

PMID- 359252
OWN - NLM
STAT- MEDLINE
DCOM- 19781220
LR  - 20190907
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 5
IP  - 7
DP  - 1978
TI  - Two trials of diflunisal in osteoarthritis.
PG  - 567-71
AB  - Two double-blind inter-group trials were carried out in which diflunisal was 
      compared for 12 weeks against aspirin in 30 patients with osteoarthritis of knees 
      or hips, and against naproxen for 8 weeks in 20 patients with osteoarthritic 
      knees. Diflunisal appeared to be somewhat better than aspirin in terms of both 
      effectiveness and tolerance, whilst it was similar in both repects to naproxen.
FAU - Grayson, M F
AU  - Grayson MF
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Analgesics)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Biphenyl Compounds/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Placebos
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1185/03007997809109003 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1978;5(7):567-71. doi: 10.1185/03007997809109003.

PMID- 31177222
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20200916
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Print)
IS  - 1387-2877 (Linking)
VI  - 70
IP  - 1
DP  - 2019
TI  - Exploring the Correlation between the Cognitive Benefits of Drug Combinations in 
      a Clinical Database and the Efficacies of the Same Drug Combinations Predicted 
      from a Computational Model.
PG  - 287-302
LID - 10.3233/JAD-190144 [doi]
AB  - Identification of drug combinations that could be effective in Alzheimer's 
      disease treatment is made difficult by the sheer number of possible combinations. 
      This analysis identifies as potentially therapeutic those drug combinations that 
      rank highest when their efficacy is determined jointly from two independent data 
      sources. Estimates of the efficacy of the same drug combinations were derived 
      from a clinical dataset on cognitively impaired elderly participants and from 
      pre-clinical data, in the form of a computational model of neuroinflammation. 
      Linear regression was used to show that the two sets of estimates were 
      correlated, and to rule out confounds. The ten highest ranking, jointly 
      determined drug combinations most frequently consisted of COX2 inhibitors and 
      aspirin, along with various antihypertensive medications. Ten combinations of 
      from five to nine drugs, and the three-drug combination of a COX2 inhibitor, 
      aspirin, and a calcium-channel blocker, are discussed as candidates for 
      consideration in future pre-clinical and clinical studies.
FAU - Anastasio, Thomas J
AU  - Anastasio TJ
AD  - Department of Molecular and Integrative Physiology, University of Illinois at 
      Urbana-Champaign, Urbana, IL, USA.
LA  - eng
GR  - P30 AG010161/AG/NIA NIH HHS/United States
GR  - R01 AG015819/AG/NIA NIH HHS/United States
GR  - R01 AG017917/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alzheimer Disease/*drug therapy
MH  - Antihypertensive Agents/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cognition/*drug effects
MH  - Computer Simulation
MH  - Cyclooxygenase 2 Inhibitors/*pharmacology/therapeutic use
MH  - Databases, Factual
MH  - Deep Learning
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Models, Theoretical
MH  - Treatment Outcome
PMC - PMC6700640
OTO - NOTNLM
OT  - Combination therapy
OT  - computational modeling
OT  - data mining
OT  - deep learning
OT  - machine learning
OT  - microglia
OT  - neural network
OT  - neuroinflammation
OT  - polypharmacy
OT  - research database
COIS- Authors’ disclosures available online 
      (https://www.j-alz.com/manuscript-disclosures/19-0144r1).
EDAT- 2019/06/10 06:00
MHDA- 2020/09/17 06:00
CRDT- 2019/06/10 06:00
PHST- 2019/06/10 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2019/06/10 06:00 [entrez]
AID - JAD190144 [pii]
AID - 10.3233/JAD-190144 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2019;70(1):287-302. doi: 10.3233/JAD-190144.

PMID- 15528452
OWN - NLM
STAT- MEDLINE
DCOM- 20050405
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 312
IP  - 3
DP  - 2005 Mar
TI  - In vitro metabolism of nitric oxide-donating aspirin: the effect of positional 
      isomerism.
PG  - 989-97
AB  - NO-donating aspirin (NO-ASA) is a potentially important chemopreventive agent 
      against cancer. Since positional isomerism affects strongly its potency in 
      inhibiting colon cancer cell growth, we studied the metabolic transformations of 
      its ortho-, meta-, and para-isomers in rat liver and colon cytosolic, microsomal, 
      and mitochondrial fractions as well as in intact HT-29 human colon cancer cells. 
      NO-ASA and metabolites were determined by high-performance liquid chromatography 
      and products identified by mass spectroscopy, as required. For all three isomers, 
      the acetyl group on the ASA moiety was hydrolyzed rapidly. This was followed by 
      hydrolysis of the ester bond linking the salicylate anion to the spacer. The 
      ortho- and para-isomers produced salicylic acid and a putative intermediate 
      consisting of the remainder of the molecule, which via a rapid step generated 
      nitrate, (hydroxymethyl)phenol, and a conjugate of spacer with glutathione. The 
      meta-isomer, in contrast, generated salicylic acid and (nitroxymethyl)phenol, the 
      latter leading to (hydroxymethyl)phenol and the glutathione-spacer conjugate. 
      This metabolic pathway takes place in its entirety only in the cytosolic fraction 
      of the tissues tested and in intact human colon cancer cells, perhaps reflecting 
      exposure to the cytosolic glutathione S-transferase, which catalyzes the 
      formation of the spacer-glutathione conjugate. Thus, the three positional isomers 
      of NO-ASA differ in their metabolism and these differences correlate with their 
      differential effects on cancer cell growth, underscoring the importance of 
      positional isomerism in modulating drug effects.
FAU - Gao, Jianjun
AU  - Gao J
AD  - Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, Stony 
      Brook, NY 11794-8160, USA.
FAU - Kashfi, Khosrow
AU  - Kashfi K
FAU - Rigas, Basil
AU  - Rigas B
LA  - eng
GR  - CA92423/CA/NCI NIH HHS/United States
GR  - CA92423-S1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20041104
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*metabolism
MH  - Colon/metabolism
MH  - HT29 Cells
MH  - Humans
MH  - Isomerism
MH  - Liver/metabolism
MH  - Male
MH  - Microsomes, Liver/metabolism
MH  - Mitochondria, Liver/metabolism
MH  - Nitric Oxide Donors/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2004/11/06 09:00
MHDA- 2005/04/06 09:00
CRDT- 2004/11/06 09:00
PHST- 2004/11/06 09:00 [pubmed]
PHST- 2005/04/06 09:00 [medline]
PHST- 2004/11/06 09:00 [entrez]
AID - jpet.104.076190 [pii]
AID - 10.1124/jpet.104.076190 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2005 Mar;312(3):989-97. doi: 10.1124/jpet.104.076190. Epub 
      2004 Nov 4.

PMID- 16793048
OWN - NLM
STAT- MEDLINE
DCOM- 20070626
LR  - 20220310
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 191
IP  - 2
DP  - 2007 Apr
TI  - Aspirin is a substrate for paraoxonase-like activity: implications in 
      atherosclerosis.
PG  - 272-5
AB  - Paraoxonase 1 (PON 1) is an enzyme that is promiscuous in its ability to 
      hydrolyze various types of substrates. It hydrolyzes aryl esters, phosphate 
      esters, lactones, and reduces lipid peroxides to hydroxides. Aspirin is an aryl 
      ester with a short plasma half life. We hypothesized that aspirin would be 
      effectively hydrolyzed by PON 1 and many of its anti-atherogenic effects, at 
      least in part, could be accounted for by its antioxidant product, salicylic acid. 
      In this study, we determined the ability of human plasma and PON 1-rich HDL to 
      hydrolyze acetyl ester of salicylic acid (aspirin). The ability of aspirin to 
      compete for the hydrolysis of paraoxon and p-nitrophenylacetate was determined. 
      In addition, nitrated aspirin was synthesized and tested directly for hydrolysis. 
      Aspirin competed for the hydrolysis of paraoxon and p-nitrophenylacetate by HDL 
      in a dose-dependent manner. Human plasma and HDL were also able to hydrolyze 
      nitroaspirin and aspirin and release nitrosalicylic acid and salicylic acid, 
      respectively. These findings suggest that salicylic acid might be generated in 
      the plasma from aspirin. The ability of long-term treatment with aspirin to 
      retard atherosclerosis might be dependent on the generation of free salicylic 
      acid, a scavenger of free radicals.
FAU - Santanam, Nalini
AU  - Santanam N
AD  - Department of Pathology, Louisiana State University Health Science Center, New 
      Orleans, LA 70112, USA.
FAU - Parthasarathy, Sampath
AU  - Parthasarathy S
LA  - eng
GR  - R01 HL074239/HL/NHLBI NIH HHS/United States
GR  - HL-069038/HL/NHLBI NIH HHS/United States
GR  - HL-74239/HL/NHLBI NIH HHS/United States
GR  - R01 DK056353/DK/NIDDK NIH HHS/United States
GR  - DK-56353/DK/NIDDK NIH HHS/United States
GR  - R01 HL069038/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20060621
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Antioxidants)
RN  - 0 (Nitrophenols)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 830-03-5 (4-nitrophenyl acetate)
RN  - EC 3.1.8.1 (Aryldialkylphosphatase)
RN  - EC 3.1.8.1 (PON1 protein, human)
RN  - EH04H13L6B (nitroaspirin)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - Q9CX8P80JW (Paraoxon)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antioxidants/*metabolism/therapeutic use
MH  - Aryldialkylphosphatase/blood/*metabolism
MH  - Aspirin/analogs & derivatives/blood/*metabolism/therapeutic use
MH  - Atherosclerosis/drug therapy/enzymology/*metabolism
MH  - Binding, Competitive
MH  - Biotransformation
MH  - Humans
MH  - Hydrolysis
MH  - In Vitro Techniques
MH  - Nitrophenols/metabolism
MH  - Paraoxon/metabolism
MH  - Platelet Aggregation Inhibitors/blood/*metabolism/therapeutic use
MH  - Salicylic Acid/blood/*metabolism
EDAT- 2006/06/24 09:00
MHDA- 2007/06/27 09:00
CRDT- 2006/06/24 09:00
PHST- 2006/01/12 00:00 [received]
PHST- 2006/03/25 00:00 [revised]
PHST- 2006/05/12 00:00 [accepted]
PHST- 2006/06/24 09:00 [pubmed]
PHST- 2007/06/27 09:00 [medline]
PHST- 2006/06/24 09:00 [entrez]
AID - S0021-9150(06)00316-9 [pii]
AID - 10.1016/j.atherosclerosis.2006.05.027 [doi]
PST - ppublish
SO  - Atherosclerosis. 2007 Apr;191(2):272-5. doi: 
      10.1016/j.atherosclerosis.2006.05.027. Epub 2006 Jun 21.

PMID- 15843709
OWN - NLM
STAT- MEDLINE
DCOM- 20050815
LR  - 20131121
IS  - 1472-0213 (Electronic)
IS  - 1472-0205 (Print)
IS  - 1472-0205 (Linking)
VI  - 22
IP  - 5
DP  - 2005 May
TI  - Best evidence topic report. Aspirin in the treatment of acute pulmonary embolism.
PG  - 365
AB  - A short cut review was carried out to establish whether aspirin is a useful 
      adjunct in the treatment of acute pulmonary embolism. No papers were found using 
      the reported search to answer the clinical question. A clinical bottom line is 
      stated.
FAU - Lee, Caroline
AU  - Lee C
FAU - Ferguson, Craig
AU  - Ferguson C
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Emerg Med J
JT  - Emergency medicine journal : EMJ
JID - 100963089
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/*therapeutic use
MH  - Emergencies
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pulmonary Embolism/*drug therapy
PMC - PMC1726781
EDAT- 2005/04/22 09:00
MHDA- 2005/08/16 09:00
CRDT- 2005/04/22 09:00
PHST- 2005/04/22 09:00 [pubmed]
PHST- 2005/08/16 09:00 [medline]
PHST- 2005/04/22 09:00 [entrez]
AID - 22/5/365 [pii]
AID - 10.1136/emj.2005.024398 [doi]
PST - ppublish
SO  - Emerg Med J. 2005 May;22(5):365. doi: 10.1136/emj.2005.024398.

PMID- 10629700
OWN - NLM
STAT- MEDLINE
DCOM- 20000118
LR  - 20220309
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 28
IP  - 39
DP  - 1999 Dec 11
TI  - [Risk factors in pre-eclampsia].
PG  - 2189-96
AB  - PATIENT-RELATED FACTORS: Multiparous patients with a past history of severe 
      pre-eclampsia are a high risk population which should be identified early in 
      pregnancy. Selection on this criterion alone is however insufficient for large 
      scale screening and prevention because most of the susceptible women are 
      nulliparous. Search for a particular familial or personal history of vascular 
      disorders can be helpful. The usefulness of blood pressure measurements during 
      the second trimester has not been proven. MARKERS: There is a significant 
      association between pre-eclampsia and a large number of biological markers. No 
      one assay can however fulfill the requirements for effective early screening 
      because sensitivity is too low or the rate of false positives is too high, or 
      because the examination is too invasive or costly. DOPPLER ANOMALIES: Doppler 
      exploration of the uterine arteries at 20 to 24 weeks gestation offers 
      satisfactory sensitivity and specificity but the positive predictive value is 
      low. Persistence of a bilateral notch beyond 24 weeks considerably limits the 
      number of false positives. More than half of the patients with this anomaly will 
      develop hypertension during pregnancy. While no one marker fulfills all the 
      prerequisites for effective screening, a combination of several tests may be 
      useful. hCG assay during the second trimester in association with Doppler 
      exploration of the uterine arteries appears to be a promising combination. 
      PREVENTION: Starting with these markers or risk factors, the goal is to develop a 
      prevention scheme using low-dose aspirin, the only evidence-based preventive 
      treatment to date. Further trials are required to test simultaneously the 
      predictive value and impact (versus placebo) of proposed strategies.
FAU - Dumont, A
AU  - Dumont A
AD  - Service de Gynécologie-Obstétrique, Hôpital Tenon, Paris.
FAU - Merviel, P
AU  - Merviel P
FAU - Berkane, N
AU  - Berkane N
FAU - Gaudet, R
AU  - Gaudet R
FAU - Uzan, S
AU  - Uzan S
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Facteurs de risque de la pré-éclampsie.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacology
MH  - Evidence-Based Medicine
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/pharmacology
MH  - Humans
MH  - Pre-Eclampsia/*diagnosis/diagnostic imaging/prevention & control
MH  - Pregnancy
MH  - Risk Factors
MH  - Ultrasonography, Prenatal
RF  - 61
EDAT- 2000/01/12 00:00
MHDA- 2000/01/12 00:01
CRDT- 2000/01/12 00:00
PHST- 2000/01/12 00:00 [pubmed]
PHST- 2000/01/12 00:01 [medline]
PHST- 2000/01/12 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1999 Dec 11;28(39):2189-96.

PMID- 3538450
OWN - NLM
STAT- MEDLINE
DCOM- 19870115
LR  - 20140912
IS  - 0256-9574 (Print)
VI  - 70
IP  - 12
DP  - 1986 Dec 6
TI  - Double-blind study of sulindac and aspirin in juvenile chronic arthritis.
PG  - 724-6
AB  - Sulindac (Clinoril; Frosst-MSD), a non-steroidal anti-inflammatory drug was 
      compared with aspirin in a randomized double-blind cross-over controlled study in 
      30 patients with juvenile chronic arthritis. Sulindac was found to be safe and 
      effective. Although it has the advantage of a twice-a-day dose regimen, both 
      patient and doctor may prefer to be guided by pain relief and cost.
FAU - Bhettay, E
AU  - Bhettay E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - 0 (Indenes)
RN  - 184SNS8VUH (Sulindac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Indenes/*therapeutic use
MH  - Male
MH  - Random Allocation
MH  - Sulindac/adverse effects/*therapeutic use
EDAT- 1986/12/06 00:00
MHDA- 1986/12/06 00:01
CRDT- 1986/12/06 00:00
PHST- 1986/12/06 00:00 [pubmed]
PHST- 1986/12/06 00:01 [medline]
PHST- 1986/12/06 00:00 [entrez]
PST - ppublish
SO  - S Afr Med J. 1986 Dec 6;70(12):724-6.

PMID- 615737
OWN - NLM
STAT- MEDLINE
DCOM- 19781018
LR  - 20180216
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 16
IP  - 1-2
DP  - 1977
TI  - Influence of aspirin on healing of chronic gastric ulcers in dogs.
PG  - 51-6
AB  - Gastric ulcers induced in dogs by transserosal injection of 1 ml of 40% acetic 
      acid healed completely by the 7th week after ulceration and never reulcerated 
      during the observation period up to 12 weeks. Acetic acid ulcers in the active 
      (at 1 week), quiescent (3 weeks) or healed (at 7 weeks) stages were not 
      influenced by the daily administration of aspirin 2 g/dog/day for for 5 
      consecutive weeks. All examinations were done by gastroscopy in addition to 
      macroscopical and histological observations at autopsy.
FAU - Takeuchi, K
AU  - Takeuchi K
FAU - Okabe, S
AU  - Okabe S
FAU - Takagi, K
AU  - Takagi K
FAU - Umeda, N
AU  - Umeda N
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Acetates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chronic Disease
MH  - Dogs
MH  - Gastric Mucosa/pathology
MH  - Gastroscopy
MH  - Male
MH  - Peptic Ulcer Perforation/pathology
MH  - Recurrence
MH  - Stomach Ulcer/chemically induced/pathology/*physiopathology
MH  - Wound Healing/drug effects
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1159/000198055 [doi]
PST - ppublish
SO  - Digestion. 1977;16(1-2):51-6. doi: 10.1159/000198055.

PMID- 27405873
OWN - NLM
STAT- MEDLINE
DCOM- 20180118
LR  - 20180118
IS  - 1618-2650 (Electronic)
IS  - 1618-2642 (Linking)
VI  - 408
IP  - 30
DP  - 2016 Dec
TI  - Quantification of ascorbic acid and acetylsalicylic acid in effervescent tablets 
      by CZE-UV and identification of related degradation products by heart-cut 
      CZE-CZE-MS.
PG  - 8701-8712
AB  - Capillary electrophoresis is commonly applied for the analysis of pharmaceutical 
      products due to its high separation efficiency and selectivity. For this purpose, 
      electrospray-ionization-(ESI)-interfering additives or electrolytes are often 
      required, which complicates the identification of impurities and degradation 
      products by mass spectrometry (MS). Here, a capillary zone electrophoresis (CZE) 
      method with ultraviolet (UV) absorption detection for the simultaneous 
      determination and quantification of ascorbic acid and acetylsalicylic acid in 
      effervescent tablets was developed. Related degradation products were identified 
      via CZE-CZE-MS. Systematic optimization yielded 100 mM tricine (pH = 8.8) as 
      appropriate background electrolyte, resulting in baseline separation of ascorbic 
      acid, acetylsalicylic acid, and related anionic UV-active degradation products. 
      The CZE-UV method was successfully validated regarding the guidelines of the Food 
      and Drug Administration. The validated method was applied to trace the 
      degradation rate of the active pharmaceutical ingredients at defined ambient 
      conditions. A heart-cut CZE-CZE-MS approach, including a 4-port-nL-valve, was 
      performed for the identification of the observed degradation products. This 2D 
      setup enables a precise cutting of accurate sample volumes (20 nL) and the 
      independent operation of two physically separated CZE dimensions, which is 
      especially beneficial regarding MS detection. Hence, the ESI-interfering tricine 
      electrolyte components were separated from the analytes in a second 
      electrophoretic dimension prior to ESI-MS detection. The degradation products 
      were identified as salicylic acid and mono- and diacetylated ascorbic acid. This 
      setup is expected to be generally applicable for the mass spectrometric 
      characterization of CZE separated analytes in highly ESI-interfering electrolyte 
      systems. Graphical Abstract A CZE-UV method for the quantification of 
      effervescent tablet ingredients and degradation products was developed and 
      validated. In order to identify unknown degradation products separated in the 
      CZE-UV, a 2D heart-cut approach was performed applying a mechanical 4-port-valve. 
      The unknown substances were transferred from the 1st to the 2nd dimension 
      followed by the separation of ESI-interfering tricine from the analytes prior to 
      mass spectrometric detection.
FAU - Neuberger, Sabine
AU  - Neuberger S
AD  - Faculty of Chemistry, Aalen University, Beethovenstraße 1, 73430, Aalen, Germany.
FAU - Jooß, Kevin
AU  - Jooß K
AD  - Faculty of Chemistry, Aalen University, Beethovenstraße 1, 73430, Aalen, Germany.
FAU - Ressel, Christian
AU  - Ressel C
AD  - Faculty of Chemistry, Aalen University, Beethovenstraße 1, 73430, Aalen, Germany.
FAU - Neusüß, Christian
AU  - Neusüß C
AD  - Faculty of Chemistry, Aalen University, Beethovenstraße 1, 73430, Aalen, Germany. 
      Christian.Neusuess@hs-aalen.de.
LA  - eng
PT  - Journal Article
DEP - 20160712
PL  - Germany
TA  - Anal Bioanal Chem
JT  - Analytical and bioanalytical chemistry
JID - 101134327
RN  - 0 (Buffers)
RN  - 0 (Tablets)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
RN  - W12LH4V8V3 (tricine)
SB  - IM
MH  - Ascorbic Acid/chemistry/*isolation & purification
MH  - Aspirin/chemistry/*isolation & purification
MH  - Buffers
MH  - Electrophoresis, Capillary/*methods
MH  - Glycine/analogs & derivatives/chemistry
MH  - Guidelines as Topic
MH  - Spectrometry, Mass, Electrospray Ionization/*methods
MH  - Spectrophotometry, Ultraviolet/*methods
MH  - Tablets
MH  - United States
MH  - United States Food and Drug Administration
OTO - NOTNLM
OT  - Capillary zone electrophoresis-mass spectrometry
OT  - Interface
OT  - Interference-free electrospray-ionization
OT  - Mechanical valve
OT  - Two-dimensional separation
EDAT- 2016/07/14 06:00
MHDA- 2018/01/19 06:00
CRDT- 2016/07/14 06:00
PHST- 2016/04/12 00:00 [received]
PHST- 2016/06/21 00:00 [accepted]
PHST- 2016/06/16 00:00 [revised]
PHST- 2016/07/14 06:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
PHST- 2016/07/14 06:00 [entrez]
AID - 10.1007/s00216-016-9734-2 [pii]
AID - 10.1007/s00216-016-9734-2 [doi]
PST - ppublish
SO  - Anal Bioanal Chem. 2016 Dec;408(30):8701-8712. doi: 10.1007/s00216-016-9734-2. 
      Epub 2016 Jul 12.

PMID- 26480611
OWN - NLM
STAT- MEDLINE
DCOM- 20151109
LR  - 20151020
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 154
IP  - 8
DP  - 2015 Aug
TI  - [INTERNATIONAL NORMALIZED RATIO VALUES AND HEMORRHAGE IN HOSPITALIZED PATIENTS 
      STARTING WARFARIN THERPY: AN OBSERVATIONAL STUDY].
PG  - 490-3, 541-2
AB  - INTRODUCTION: Vitamin K antagonist (VKA) therapy is challenging because of the 
      narrow therapeutic range, and the influence of numerous factors on the 
      international normalized ratio (INR). During the beginning of warfarin treatment, 
      INR must be assessed regularly in order to optimize treatment and minimize the 
      risk for hemorrhage. In this study we examined the laboratory and clinical 
      outcomes of a cohort of hospitalized patients starting warfarin treatment. AIMS: 
      To document the rate of patients with supra-therapeutic INR values and the rate 
      of major hemorrhage, during the first month after starting warfarin. METHODS: A 
      prospective observational study of all patients admitted to Meir Medical Center 
      starting warfarin treatment during a 3-month period. Baseline demographics, 
      clinical data, warfarin dose, INR levels and bleeding events were documented. 
      Patients were followed for 30 days after starting treatment with warfarin. 
      RESULTS: Fifty-seven patients who started VKA therapy were identified during the 
      study period. The mean age was 71.2±13.1 years. Atrial fibrillation was the 
      indication for treatment in 63.2% of patients, deep vein thrombosis in 19.3%, 
      pulmonary embolus in 10.5% and other indications in 7% of patients. In the first 
      30 days of treatment, 60% of the patients had at least one INR value of >3. Of 
      these patients, half had an INR of above 5. The number of concomitant medications 
      were associated with INR values of >3. Arab patients tended to have a higher INR. 
      Of note, there were 5 cases (8.8%) of major hemorrhage, which occurred with INR 
      values ranging from 3.29 to >10, 4 of these patients were treated concomitantly 
      with Aspirin. CONCLUSIONS: In this cohort of hospitalized patients starting 
      warfarin therapy, excessive INR values were commonly encountered. There was a 
      significant incidence of major hemorrhage among the patients. Further studies to 
      define risk factors for elevated INR values and hemorrhage in hospitalized 
      patients are needed.
FAU - Abadi, Uri
AU  - Abadi U
FAU - Ellis, Martin H
AU  - Ellis MH
LA  - heb
PT  - English Abstract
PT  - Journal Article
PT  - Observational Study
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Academic Medical Centers
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced/*epidemiology
MH  - Hospitalization
MH  - Humans
MH  - *International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Warfarin/administration & dosage/adverse effects/*therapeutic use
EDAT- 2015/10/21 06:00
MHDA- 2015/11/10 06:00
CRDT- 2015/10/21 06:00
PHST- 2015/10/21 06:00 [entrez]
PHST- 2015/10/21 06:00 [pubmed]
PHST- 2015/11/10 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2015 Aug;154(8):490-3, 541-2.

PMID- 2109328
OWN - NLM
STAT- MEDLINE
DCOM- 19900521
LR  - 20190712
IS  - 0031-9384 (Print)
IS  - 0031-9384 (Linking)
VI  - 47
IP  - 1
DP  - 1990 Jan
TI  - Amniotic fluid ingestion enhances opioid-mediated but not nonopioid-mediated 
      analgesia.
PG  - 79-81
AB  - Ingestion of amniotic fluid or placenta by rats has been shown to enhance several 
      types of opioid-mediated analgesia: that induced by morphine, footshock, 
      vaginal/cervical stimulation, and late pregnancy. This enhancement has also been 
      blocked by administration of opioid antagonists. The present study was designed 
      to examine further the specificity of the enhancement effect for opioid-mediated 
      analgesia by testing for enhancement following administration of aspirin, a 
      nonopioid analgesic. The formalin test was used as the pain threshold assay. 
      Amniotic fluid or beef bouillon was administered by orogastric tube to rats that 
      were treated either with morphine sulfate or saline, or pretreated with 
      naltrexone, then treated with aspirin or vehicle. Both morphine and aspirin 
      treatments produced analgesia. Amniotic fluid significantly enhanced the 
      analgesia produced by morphine, but did not enhance the analgesia produced by 
      aspirin, further suggesting that the enhancing effect of amniotic fluid ingestion 
      is specific for opioid-mediated analgesia, such as that existing at the start of 
      parturition.
FAU - Kristal, M B
AU  - Kristal MB
AD  - Department of Psychology, State University of New York, Buffalo 14260.
FAU - Tarapacki, J A
AU  - Tarapacki JA
FAU - Barton, D
AU  - Barton D
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
RN  - 76I7G6D29C (Morphine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amniotic Fluid/*physiology
MH  - *Analgesia
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Enteral Nutrition
MH  - Female
MH  - Morphine/*pharmacology
MH  - Pain Measurement
MH  - Rats
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 0031-9384(90)90044-5 [pii]
AID - 10.1016/0031-9384(90)90044-5 [doi]
PST - ppublish
SO  - Physiol Behav. 1990 Jan;47(1):79-81. doi: 10.1016/0031-9384(90)90044-5.

PMID- 12120179
OWN - NLM
STAT- MEDLINE
DCOM- 20020802
LR  - 20131121
IS  - 1533-001X (Print)
IS  - 1533-001X (Linking)
VI  - 1
IP  - 3
DP  - 2001
TI  - One hundred years of NSAID gastropathy: are coxibs the answer?
PG  - 121-7
AB  - One hundred years after the introduction of aspirin, greater understanding of the 
      mechanism of action of NSAIDs has led to the development of selective COX-2 
      inhibitors. These have been shown to reduce pain and inflammation with reduced 
      risk of GI complications. However, questions remain regarding such issues as 
      restriction of their use to patients at high risk for complications, 
      cost-effectiveness, effectiveness compared with prostaglandin replacement or acid 
      reduction therapy, and safety in patients also taking aspirin for platelet 
      inhibition.
FAU - Bjorkman, D J
AU  - Bjorkman DJ
AD  - University of Utah School of Medicine, Salt Lake City, UT, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Rev Gastroenterol Disord
JT  - Reviews in gastroenterological disorders
JID - 101140143
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Peptic Ulcer/chemically induced/prevention & control
RF  - 44
EDAT- 2002/07/18 10:00
MHDA- 2002/08/03 10:01
CRDT- 2002/07/18 10:00
PHST- 2002/07/18 10:00 [pubmed]
PHST- 2002/08/03 10:01 [medline]
PHST- 2002/07/18 10:00 [entrez]
PST - ppublish
SO  - Rev Gastroenterol Disord. 2001;1(3):121-7.

PMID- 8029790
OWN - NLM
STAT- MEDLINE
DCOM- 19940808
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 71
IP  - 3
DP  - 1994 Mar
TI  - Effects of low intensity antithrombotic regimes on the haemoglobin level.
PG  - 284-5
AB  - The effects on the haemoglobin level of low dose aspirin and of low intensity 
      oral anticoagulation with warfarin separately and in combination have been 
      established in men aged between 45 and 69 at high risk of ischaemic heart 
      disease. The findings confirm that combined treatment with warfarin and aspirin 
      (WA) leads to a clear excess of minor bleeding episodes over warfarin alone (W) 
      or aspirin alone (A). Each separate treatment on its own (either W or A) leads to 
      an increase in these episodes compared with those on placebo (P) treatment. 
      However, neither combined treatment (WA) nor the separate treatments (W or A) 
      cause a fall in haemoglobin levels over a period of up to two years.
FAU - Meade, T W
AU  - Meade TW
AD  - MEC Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, 
      Medical College of St Bartholomew's Hospital, London, UK.
FAU - Howarth, D J
AU  - Howarth DJ
FAU - Brennan, P J
AU  - Brennan PJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hemoglobins)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*pharmacology
MH  - Hemoglobins/*metabolism
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*prevention & control
MH  - Risk Factors
MH  - Warfarin/administration & dosage/adverse effects/*pharmacology
EDAT- 1994/03/01 00:00
MHDA- 1994/03/01 00:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 1994/03/01 00:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1994 Mar;71(3):284-5.

PMID- 11540747
OWN - NASA
STAT- MEDLINE
DCOM- 19980829
LR  - 20191105
IS  - 0094-5765 (Print)
IS  - 0094-5765 (Linking)
VI  - 36
IP  - 2
DP  - 1995 Jul
TI  - Effects of microgravity on the binding of acetylsalicylic acid by Rhizobium 
      leguminosarum bv. trifolii.
PG  - 129-33
AB  - Bacteroids can be induced in vitro by treating growing Rhizobium leguminosarum 
      bv. trifolii with succinic acid or succinic acid structural analogs like 
      acetysalicylic acid. Quantitating bacteroid induction by measuring 
      acetylsalicylic binding under normal (1 g) conditions showed two forms of binding 
      to occur. In one form of binding cells immediately bound comparatively high 
      levels of acetylsalicylic acid, but the binding was quickly reversed. The second 
      form of binding increased with time by first order kinetics and reached 
      saturation in 40 s. Similar experiments performed in the microgravity environment 
      aboard the NASA 930 aircraft showed only one form of binding and total 
      acetylsalicyclic acid bound was 32% higher than at 1 g.
FAU - Urban, J E
AU  - Urban JE
AD  - BioServe Space Technologies, Kansas State University, Manhattan 66506-4901, USA.
FAU - Gerren, R
AU  - Gerren R
FAU - Zoelle, J
AU  - Zoelle J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Acta Astronaut
JT  - Acta astronautica
JID - 9890631
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*metabolism/pharmacokinetics
MH  - Fabaceae
MH  - *Gravitation
MH  - Nitrogen Fixation
MH  - Plants, Medicinal
MH  - Protein Binding
MH  - Rhizobium leguminosarum/drug effects/growth & development/*metabolism
MH  - *Space Flight
MH  - Symbiosis
MH  - *Weightlessness
OID - NASA: 00022172
SFM - Flight Experiment
SFM - Parabolic Flight
SFM - manned
SFM - short duration
EDAT- 1995/07/01 00:00
MHDA- 2001/09/11 10:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 2001/09/11 10:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
AID - 0094576595000474 [pii]
AID - 10.1016/0094-5765(95)00047-4 [doi]
PST - ppublish
SO  - Acta Astronaut. 1995 Jul;36(2):129-33. doi: 10.1016/0094-5765(95)00047-4.

PMID- 3583229
OWN - NLM
STAT- MEDLINE
DCOM- 19870720
LR  - 20131121
IS  - 0018-5043 (Print)
IS  - 0018-5043 (Linking)
VI  - 19
IP  - 5
DP  - 1987 May
TI  - Reduction of exercise-induced albuminuria by aspirin-dipyridamole in patients 
      with diabetes mellitus.
PG  - 201-3
AB  - The exercise-induced increase in albumin excretion was measured in six patients 
      with insulin-dependent diabetes mellitus, in whom there was no evidence of 
      established diabetic renal disease. Urinary albumin excretion was measured on 
      urine samples taken at rest and immediately after a 20 minute period of exercise 
      on a bicycle ergometer at 600 kpm/min. Following a three week course of aspirin 
      (330 mg)--dipyridamole (75 mg) taken three times daily there was significant 
      reduction in exercise-induced albuminuria (expressed as the ratio of albumin 
      excretion rate during exercise to that at rest before exercise) when compared to 
      administration of placebo (P less than 0.05). These results suggest that 
      aspirin-dipyridamole might modify the development of persistent proteinuria in 
      patients with insulin-dependent diabetes mellitus.
FAU - Hopper, A H
AU  - Hopper AH
FAU - Tindall, H
AU  - Tindall H
FAU - Urquhart, S
AU  - Urquhart S
FAU - Davies, J A
AU  - Davies JA
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Albuminuria/*drug therapy/etiology
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Diabetes Mellitus, Type 1/*urine
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - *Physical Exertion
EDAT- 1987/05/01 00:00
MHDA- 1987/05/01 00:01
CRDT- 1987/05/01 00:00
PHST- 1987/05/01 00:00 [pubmed]
PHST- 1987/05/01 00:01 [medline]
PHST- 1987/05/01 00:00 [entrez]
AID - 10.1055/s-2007-1011778 [doi]
PST - ppublish
SO  - Horm Metab Res. 1987 May;19(5):201-3. doi: 10.1055/s-2007-1011778.

PMID- 33233169
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1873-7145 (Electronic)
IS  - 0963-9969 (Linking)
VI  - 137
DP  - 2020 Nov
TI  - Andean berry (Vaccinium meridionale Swartz) juice in combination with Aspirin 
      modulated anti-inflammatory markers on LPS-stimulated RAW 264.7 macrophages.
PG  - 109541
LID - S0963-9969(20)30566-4 [pii]
LID - 10.1016/j.foodres.2020.109541 [doi]
AB  - V. meridionale Swartz is an underutilized Andean Berry that has been linked to 
      several health benefits potentially derived from its anti-inflammatory effects. 
      This research aimed to evaluate the impact of Andean Berry Juice (ABJ) combined 
      with Aspirin in the modulation of anti-inflammatory markers from LPS-stimulated 
      RAW 264.7 macrophages. The chemical characterization of ABJ showed a high content 
      of polyphenols, mainly gallic acid (659-75 μg/g) and cyanidin chloride 
      (418.61 μg/mL). Compared to LPS-stimulated macrophages, ABJ, Aspirin, and its 
      combination reduced NO and ROS production (3.26-42.55 and 17.59-65.68%, 
      respectively). In comparison, the half inhibitory concentration of NO reduction 
      (IC(50)) was found at 7.69% v/v (ABJ) and 24.48 mM (Aspirin). Compared to the 
      pro-inflammatory control (LPS), ABJ reduced IL-1β, MCP-1, and GCSF; Aspirin 
      decreased IL1R1, MCP-1, GMCSF, GCSF, and TNF-α; and the ABJ + Aspirin treatment 
      reduced IL1R, GMCSF, and CXCL10. The in silico interaction of cytokines and the 
      prediction of potential binding interactions suggested CCR1, CCR5, and NF-kB 
      modulation. These results showed the anti-inflammatory potential of underutilized 
      South American berries and their co-adjuvant effect with known drugs such as 
      Aspirin in the resolution of inflammatory-derived conditions. This is the first 
      report of the anti-inflammatory effects of V. meridionale Swartz juice in 
      combination with Aspirin on LPS-challenged RAW 264.7 macrophages.
CI  - Copyright © 2020 Elsevier Ltd. All rights reserved.
FAU - Arango-Varela, Sandra S
AU  - Arango-Varela SS
AD  - Biomedical Research and Innovation Group (GIB) - Instituto Tecnológico 
      Metropolitano (ITM), Calle 54A #30-31, 050034 Medellin, Antioquia, Colombia.
FAU - Luzardo-Ocampo, Ivan
AU  - Luzardo-Ocampo I
AD  - Programa de Posgrado del Centro de la República (PROPAC), Research and Graduate 
      Program in Food Science, School of Chemistry, Universidad Autónoma de Querétaro, 
      Cerro de las Campanas S/N, 76010, Santiago de Querétaro, Qro., Mexico.
FAU - Maldonado-Celis, Maria E
AU  - Maldonado-Celis ME
AD  - Escuela de Nutrición y Dietética, Ciudadela de Robledo Cra. 75 # 65-87, 
      Universidad de Antioquia, 050010 Medellín, Antioquia, Colombia. Electronic 
      address: maria.maldonado@udea.edu.co.
FAU - Campos-Vega, Rocio
AU  - Campos-Vega R
AD  - Programa de Posgrado del Centro de la República (PROPAC), Research and Graduate 
      Program in Food Science, School of Chemistry, Universidad Autónoma de Querétaro, 
      Cerro de las Campanas S/N, 76010, Santiago de Querétaro, Qro., Mexico. Electronic 
      address: chio_cve@yahoo.com.mx.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200716
PL  - Canada
TA  - Food Res Int
JT  - Food research international (Ottawa, Ont.)
JID - 9210143
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Lipopolysaccharides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Aspirin/pharmacology
MH  - Fruit
MH  - *Lipopolysaccharides
MH  - Macrophages
MH  - Mice
MH  - *Vaccinium
OTO - NOTNLM
OT  - ABTS (PubChem CID: 9570474)
OT  - Andean berry (Vaccinium meridionale Swartz)
OT  - Aspirin
OT  - Aspirin (PubChem CID: 2244)
OT  - Cyanidin chloride (PubChem CID: 68247)
OT  - Cytokines
OT  - DPPH (PubChem CID: 74358)
OT  - Gallic acid (PubChem CID: 370)
OT  - H(2)DCFDA (PubChem CID: 77718)
OT  - Inflammation
OT  - Lipopolysaccharide (PubChem CID: 11970143)
OT  - Phenolic compounds
OT  - RAW 264.7 macrophages
OT  - Trolox (PubChem CID: 40634).
OT  - Underutilized fruits
EDAT- 2020/11/26 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/11/25 01:01
PHST- 2020/05/22 00:00 [received]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/11/25 01:01 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
AID - S0963-9969(20)30566-4 [pii]
AID - 10.1016/j.foodres.2020.109541 [doi]
PST - ppublish
SO  - Food Res Int. 2020 Nov;137:109541. doi: 10.1016/j.foodres.2020.109541. Epub 2020 
      Jul 16.

PMID- 12534583
OWN - NLM
STAT- MEDLINE
DCOM- 20030417
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 23
IP  - 1
DP  - 2003 Feb
TI  - Aspirin in episodic tension-type headache: placebo-controlled dose-ranging 
      comparison with paracetamol.
PG  - 59-66
AB  - Most people with episodic tension-type headache (TTH) treat themselves with 
      over-the-counter analgesics. In the absence of clear evidence of dose-related 
      efficacy of the two most commonly used analgesics, aspirin (acetylsalicylic acid) 
      and paracetamol (acetaminophen), this study compared two doses of each with 
      placebo. In a double-blind, double-dummy, randomized parallel-groups comparative 
      trial, 638 consenting subjects aged 16-65 years with episodic TTH (but not 
      migraine) by IHS criteria were recruited from the UK general population by 
      advertisement. They treated one episode of moderate or severe TTH with a single 
      dose of 500 or 1000 mg aspirin, 500 or 1000 mg paracetamol or placebo. The 
      primary objective was to compare aspirin 1000 mg with placebo, and the primary 
      end-point was subjective pain relief (total or worthwhile) 2 h after treatment 
      ('response'). Additionally, pain intensity on a 100-mm visual analogue scale and 
      functional impairment were monitored regularly for 4 h and at 24 h, although 
      rescue medication was allowed after 2 h. The analysis was of the 
      intention-to-treat population of 542 who took treatment (all providing outcome 
      data). Treatment groups were matched at baseline. Aspirin 1000 mg (75.7% response 
      rate; P = 0.0009) and to a lesser extent aspirin 500 mg (70.3%; P = 0.011) and 
      paracetamol 1000 mg (71.2%; P = 0.007), but not paracetamol 500 mg (63.8%; P = 
      0.104), were statistically more effective than placebo despite a high 
      placebo-response rate (54.5%). Outcome was not affected by headache intensity at 
      baseline. Secondary end-points including functional recovery (by median times of 
      4.0-13.5 h) were consistent with these findings, although a minority of subjects 
      recorded long-duration functional impairment (37-54 h). Adverse events reported 
      by 13.4-18.9% of subjects were mild or moderate, and transient. No safety 
      concerns arose.
FAU - Steiner, T J
AU  - Steiner TJ
AD  - Division of Neuroscience, Imperial College London, UK. t.steiner@ic.ac.uk
FAU - Lange, R
AU  - Lange R
FAU - Voelker, M
AU  - Voelker M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/adverse effects
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - England
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Tension-Type Headache/*drug therapy
MH  - Treatment Outcome
EDAT- 2003/01/22 04:00
MHDA- 2003/04/18 05:00
CRDT- 2003/01/22 04:00
PHST- 2003/01/22 04:00 [pubmed]
PHST- 2003/04/18 05:00 [medline]
PHST- 2003/01/22 04:00 [entrez]
AID - 470 [pii]
AID - 10.1046/j.1468-2982.2003.00470.x [doi]
PST - ppublish
SO  - Cephalalgia. 2003 Feb;23(1):59-66. doi: 10.1046/j.1468-2982.2003.00470.x.

PMID- 27108284
OWN - NLM
STAT- MEDLINE
DCOM- 20180129
LR  - 20191210
IS  - 1618-2650 (Electronic)
IS  - 1618-2642 (Linking)
VI  - 408
IP  - 17
DP  - 2016 Jul
TI  - Sequential SERS determination of aspirin and vitamin C using in situ 
      laser-induced photochemical silver substrate synthesis in a moving flow cell.
PG  - 4733-41
LID - 10.1007/s00216-016-9562-4 [doi]
AB  - In this contribution, the utility of sequential injection analysis in combination 
      with surface-enhanced Raman spectroscopy (SERS) as a detection technique was 
      investigated for simultaneous determination of aspirin and vitamin C in their 
      pharmaceutical dosage forms and in spiked urine samples. The silver substrate was 
      synthesized in situ by laser-induced photochemical procedure. By focusing the 
      laser on a flow cell at 1 ml/min of continuous flow of 0.5 mM silver nitrate and 
      5 mM sodium citrate mixture, an active silver spot on the inner wall of the flow 
      cell was prepared in a few seconds. The whole setup is fully computer controlled 
      using ATLAS software to combine the two techniques. The system allows sequential 
      determination of aspirin concentrations ranging from 100 to 500 ng/ml and vitamin 
      C concentrations between 10 and 110 ng/ml with good precision of relative 
      standard deviations (RSDs) of 0.85 and 1.7 %, respectively. A comparison of these 
      results with those of the reported procedures showed excellent results compared 
      with t and F values, indicating good accuracy and precision. The detection limits 
      were 32 and 3 ng/ml for aspirin and vitamin C, respectively.
FAU - El-Zahry, Marwa R
AU  - El-Zahry MR
AD  - Institute of Chemical Technologies and Analytics, Vienna University of 
      Technology, Getreidemarkt 9/151, 1060, Vienna, Austria. marwazahry@aun.edu.eg.
AD  - Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Assiut 
      University, 71526, Assiut, Egypt. marwazahry@aun.edu.eg.
FAU - Refaat, Ibrahim H
AU  - Refaat IH
AD  - Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Assiut 
      University, 71526, Assiut, Egypt.
FAU - Mohamed, Horria A
AU  - Mohamed HA
AD  - Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Assiut 
      University, 71526, Assiut, Egypt.
FAU - Lendl, Bernhard
AU  - Lendl B
AD  - Institute of Chemical Technologies and Analytics, Vienna University of 
      Technology, Getreidemarkt 9/151, 1060, Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20160423
PL  - Germany
TA  - Anal Bioanal Chem
JT  - Analytical and bioanalytical chemistry
JID - 101134327
RN  - 3M4G523W1G (Silver)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/*analysis
MH  - Aspirin/*analysis
MH  - Humans
MH  - Limit of Detection
MH  - Microscopy, Electron, Scanning
MH  - *Photochemistry
MH  - Silver/*chemistry
OTO - NOTNLM
OT  - Aspirin
OT  - In situ silver photoreduction
OT  - SERS
OT  - Sequential injection analysis
OT  - Vitamin C
EDAT- 2016/04/25 06:00
MHDA- 2018/01/30 06:00
CRDT- 2016/04/25 06:00
PHST- 2016/02/28 00:00 [received]
PHST- 2016/04/12 00:00 [accepted]
PHST- 2016/04/06 00:00 [revised]
PHST- 2016/04/25 06:00 [entrez]
PHST- 2016/04/25 06:00 [pubmed]
PHST- 2018/01/30 06:00 [medline]
AID - 10.1007/s00216-016-9562-4 [pii]
AID - 10.1007/s00216-016-9562-4 [doi]
PST - ppublish
SO  - Anal Bioanal Chem. 2016 Jul;408(17):4733-41. doi: 10.1007/s00216-016-9562-4. Epub 
      2016 Apr 23.

PMID- 3293263
OWN - NLM
STAT- MEDLINE
DCOM- 19880824
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 50
IP  - 3
DP  - 1988 May 1
TI  - Effects of low-dose aspirin on endogenous eicosanoid formation in normal and 
      atherosclerotic men.
PG  - 377-86
AB  - We have investigated the effects of a low-dose aspirin regimen (120 mg orally, 
      then 20 mg twice daily) on the in vivo synthesis of prostacyclin, thromboxane and 
      prostaglandin E in man by measurement of their urinary metabolites (PGI2-M, 
      TxB2-M, PGE-M) using gas chromatography-mass spectrometry. A comparison was made 
      between the selectivity of low-dose aspirin for thromboxane vs prostacyclin 
      synthesis in patients with atherosclerosis, age-matched controls without vascular 
      disease, and young healthy volunteers. After one week of treatment, aspirin 
      reduced TxB2-M synthesis to a similar extent in the three groups (mean declines 
      of 86, 84 and 78% respectively), while there was an unexpected difference in 
      effect on PGI2-M, with only a 27% fall in the young volunteers but 53% and 54% 
      declines in the patients with vascular disease and their age-matched controls. 
      Serum TxB2 was reduced greater than 98% in all groups while PGE-M excretion was 
      unchanged. These results indicate that bioselectivity for inhibition of Tx 
      synthesis by aspirin is more difficult to achieve in older subjects than in the 
      young volunteers previously studied and that very low, frequent dosing, or a 
      sustained-release preparation of aspirin would be needed to achieve 
      bioselectivity for Tx inhibition in patients with vascular disease.
FAU - Knapp, H R
AU  - Knapp HR
AD  - Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN 37232.
FAU - Healy, C
AU  - Healy C
FAU - Lawson, J
AU  - Lawson J
FAU - FitzGerald, G A
AU  - FitzGerald GA
LA  - eng
GR  - HL30400/HL/NHLBI NIH HHS/United States
GR  - HL35380/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Prostaglandins E)
RN  - 54397-85-2 (Thromboxane B2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Arteriosclerosis/*drug therapy/metabolism
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Epoprostenol/*biosynthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostaglandins E/*biosynthesis
MH  - Thromboxane B2/*biosynthesis
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
AID - 0049-3848(88)90267-8 [pii]
AID - 10.1016/0049-3848(88)90267-8 [doi]
PST - ppublish
SO  - Thromb Res. 1988 May 1;50(3):377-86. doi: 10.1016/0049-3848(88)90267-8.

PMID- 23337937
OWN - NLM
STAT- MEDLINE
DCOM- 20130416
LR  - 20140305
IS  - 2168-6114 (Electronic)
IS  - 2168-6106 (Linking)
VI  - 173
IP  - 4
DP  - 2013 Feb 25
TI  - The association of aspirin use with age-related macular degeneration.
PG  - 258-64
LID - 10.1001/jamainternmed.2013.1583 [doi]
AB  - OBJECTIVE: To determine whether regular aspirin use is associated with a higher 
      risk for developing age-related macular degeneration (AMD) by using analyzed data 
      from a 15-year prospective cohort. METHODS: A prospective analysis was conducted 
      of data from an Australian population-based cohort with 4 examinations during a 
      15-year period (1992-1994 to 2007-2009). Participants completed a detailed 
      questionnaire at baseline assessing aspirin use, cardiovascular disease status, 
      and AMD risk factors. Age-related macular degeneration was graded side-by-side 
      from retinal photographs taken at each study visit to assess the incidence of 
      neovascular (wet) AMD and geographic atrophy (dry AMD) according to the 
      international AMD classification. RESULTS: Of 2389 baseline participants with 
      follow-up data available, 257 individuals (10.8%) were regular aspirin users and 
      63 of the 2389 developed neovascular AMD. Persons who were regular aspirin users 
      were more likely to have incident neovascular AMD: the 15-year cumulative 
      incidence was 9.3% in users and 3.7% in nonusers. After adjustment for age, sex, 
      smoking, history of cardiovascular disease, systolic blood pressure, and body 
      mass index, persons who were regular aspirin users had a higher risk of 
      developing neovascular AMD (odds ratio [OR], 2.46; 95% CI, 1.25-4.83). The 
      association showed a dose-response effect (multivariate-adjusted P = .01 for 
      trend). Aspirin use was not associated with the incidence of geographic atrophy 
      (multivariate-adjusted OR, 0.99; 95% CI, 0.59-1.65). CONCLUSION: Regular aspirin 
      use is associated with increased risk of incident neovascular AMD, independent of 
      a history of cardiovascular disease and smoking.
FAU - Liew, Gerald
AU  - Liew G
AD  - Centre for Vision Research, Department of Ophthalmology, University of Sydney, 
      Sydney, Australia.
FAU - Mitchell, Paul
AU  - Mitchell P
FAU - Wong, Tien Yin
AU  - Wong TY
FAU - Rochtchina, Elena
AU  - Rochtchina E
FAU - Wang, Jie Jin
AU  - Wang JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA Intern Med
JT  - JAMA internal medicine
JID - 101589534
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA Intern Med. 2013 Feb 25;173(4):264-6. PMID: 23338290
CIN - JAMA Intern Med. 2013 Feb 25;173(4):266. PMID: 23338524
CIN - Praxis (Bern 1994). 2013 Jun 5;102(12):753-4. PMID: 23735769
CIN - Evid Based Med. 2014 Feb;19(1):e6. PMID: 23771726
CIN - JAMA Intern Med. 2013 Aug 12;173(15):1476. PMID: 23939525
CIN - JAMA Intern Med. 2013 Aug 12;173(15):1476-7. PMID: 23939526
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Australia
MH  - Cardiovascular Diseases/drug therapy/prevention & control
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Logistic Models
MH  - Macular Degeneration/classification/epidemiology/*etiology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Smoking
EDAT- 2013/01/23 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/01/23 06:00
PHST- 2013/01/23 06:00 [entrez]
PHST- 2013/01/23 06:00 [pubmed]
PHST- 2013/04/17 06:00 [medline]
AID - 1558450 [pii]
AID - 10.1001/jamainternmed.2013.1583 [doi]
PST - ppublish
SO  - JAMA Intern Med. 2013 Feb 25;173(4):258-64. doi: 10.1001/jamainternmed.2013.1583.

PMID- 28703304
OWN - NLM
STAT- MEDLINE
DCOM- 20180514
LR  - 20180514
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 69
IP  - 10
DP  - 2017 Oct
TI  - Assessing the influence of media composition and ionic strength on drug release 
      from commercial immediate-release and enteric-coated aspirin tablets.
PG  - 1327-1340
LID - 10.1111/jphp.12777 [doi]
AB  - OBJECTIVES: The objective of this test series was to elucidate the importance of 
      selecting the right media composition for a biopredictive in-vitro dissolution 
      screening of enteric-coated dosage forms. METHODS: Drug release from 
      immediate-release (IR) and enteric-coated (EC) aspirin formulations was assessed 
      in phosphate-based and bicarbonate-based media with different pH, electrolyte 
      composition and ionic strength. KEY FINDINGS: Drug release from aspirin IR 
      tablets was unaffected by media composition. In contrast, drug release from EC 
      aspirin formulations was affected by buffer species and ionic strength. In all 
      media, drug release increased with increasing ionic strength, but in 
      bicarbonate-based buffers was delayed when compared with that in phosphate-based 
      buffers. Interestingly, the cation species in the dissolution medium had also a 
      clear impact on drug release. Drug release profiles obtained in Blank CarbSIF, a 
      new medium simulating pH and average ionic composition of small intestinal fluid, 
      were different from those obtained in all other buffer compositions studied. 
      CONCLUSIONS: Results from this study in which the impact of various media 
      parameters on drug release of EC aspirin formulations was systematically screened 
      clearly show that when developing predictive dissolution tests, it is important 
      to simulate the ionic composition of intraluminal fluids as closely as possible.
CI  - © 2017 Royal Pharmaceutical Society.
FAU - Karkossa, Frank
AU  - Karkossa F
AD  - Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical 
      Technology, Center of Drug Absorption and Transport (C_DAT), University of 
      Greifswald, Greifswald, Germany.
FAU - Klein, Sandra
AU  - Klein S
AUID- ORCID: 0000-0001-7356-5780
AD  - Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical 
      Technology, Center of Drug Absorption and Transport (C_DAT), University of 
      Greifswald, Greifswald, Germany.
LA  - eng
PT  - Journal Article
DEP - 20170713
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Bicarbonates)
RN  - 0 (Buffers)
RN  - 0 (Pharmaceutical Solutions)
RN  - 0 (Phosphates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry/*metabolism
MH  - Bicarbonates/chemistry/*metabolism
MH  - Buffers
MH  - Chemistry, Pharmaceutical/*methods
MH  - *Drug Liberation
MH  - Hydrogen-Ion Concentration
MH  - Osmolar Concentration
MH  - Pharmaceutical Solutions/chemistry/metabolism
MH  - Phosphates/chemistry/*metabolism
MH  - Tablets, Enteric-Coated
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - bicarbonate buffer
OT  - biorelevant dissolution
OT  - enteric polymers
OT  - ionic strength
EDAT- 2017/07/14 06:00
MHDA- 2018/05/15 06:00
CRDT- 2017/07/14 06:00
PHST- 2017/02/28 00:00 [received]
PHST- 2017/05/28 00:00 [accepted]
PHST- 2017/07/14 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
PHST- 2017/07/14 06:00 [entrez]
AID - 10.1111/jphp.12777 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2017 Oct;69(10):1327-1340. doi: 10.1111/jphp.12777. Epub 2017 
      Jul 13.

PMID- 33973929
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20230911
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 36
IP  - 4
DP  - 2021 Jul 1
TI  - Antiplatelet therapy in percutaneous coronary intervention: latest evidence from 
      randomized controlled trials.
PG  - 390-396
LID - 10.1097/HCO.0000000000000879 [doi]
AB  - PURPOSE OF REVIEW: Antiplatelet therapy is key to reduce systemic and local 
      thrombotic events among patients undergoing percutaneous coronary interventions 
      (PCI). Antiplatelet treatment regimens have been subject to continuous changes 
      over the years, with a dual antiplatelet therapy (DAPT), consisting of aspirin 
      and a P2Y12 inhibitor representing the cornerstone of treatment in these 
      patients. RECENT FINDINGS: The need for less aggressive antithrombotic drugs to 
      prevent local ischemic events with newer generation drug-eluting stent together 
      with the increased understanding of the prognostic relevance of bleeding events 
      in PCI patients, have prompted investigations aimed at identifying antiplatelet 
      treatment regimens associated with a more favorable balance between ischemic and 
      bleeding risks. Several key randomized controlled trials (RCTs) on antiplatelet 
      regimens in patients undergoing PCI have been recently reported resulting in 
      updates in practice guidelines. SUMMARY: This manuscript provides an overview of 
      the advancements in the field deriving from key RCTs on antiplatelet regimens in 
      patients undergoing PCI.
CI  - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Galli, Mattia
AU  - Galli M
AD  - Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico 
      Universitario A. Gemelli IRCCS, Rome.
AD  - Division of Cardiology, University of Florida College of Medicine, Jacksonville, 
      Florida, USA.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - Division of Cardiology, University of Florida College of Medicine, Jacksonville, 
      Florida, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Randomized Controlled Trials as Topic
EDAT- 2021/05/12 06:00
MHDA- 2021/06/29 06:00
CRDT- 2021/05/11 12:16
PHST- 2021/05/12 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2021/05/11 12:16 [entrez]
AID - 00001573-202107000-00004 [pii]
AID - 10.1097/HCO.0000000000000879 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2021 Jul 1;36(4):390-396. doi: 10.1097/HCO.0000000000000879.

PMID- 10707125
OWN - NLM
STAT- MEDLINE
DCOM- 20000504
LR  - 20191103
IS  - 0792-5077 (Print)
IS  - 0792-5077 (Linking)
VI  - 15
IP  - 2-3
DP  - 1999
TI  - Simultaneous determination of acetaminophen, acetylsalicylic acid and ascorbic 
      acid in tablet form using HPLC.
PG  - 197-205
AB  - The purpose of the present study was to develop a simple and accurate HPLC method 
      to measure the amount of each agent in a multidrug pharmaceutical formulation. 
      Three drugs, acetaminophen, acetylsalicylic acid and ascorbic acid, were analyzed 
      simultaneously. A commercial pharmaceutical effervescent tablet was examined and 
      the amount of each of these agents successfully determined. The present method 
      appears to be more convenient than the current procedures described in American 
      and British Pharmacopoeias in which each drug is assayed separately.
FAU - Akay, C
AU  - Akay C
AD  - Military Drug Factory, Gazi University, Ankara, Turkey.
FAU - Gümüsel, B
AU  - Gümüsel B
FAU - Degim, T
AU  - Degim T
FAU - Tartilmis, S
AU  - Tartilmis S
FAU - Cevheroglu, S
AU  - Cevheroglu S
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Drug Metabol Drug Interact
JT  - Drug metabolism and drug interactions
JID - 8904736
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Ascorbic Acid/*analysis
MH  - Aspirin/*analysis
MH  - Chemistry, Pharmaceutical
MH  - Chromatography, High Pressure Liquid/methods
MH  - Drug Combinations
EDAT- 2000/03/09 09:00
MHDA- 2000/05/08 09:00
CRDT- 2000/03/09 09:00
PHST- 2000/03/09 09:00 [pubmed]
PHST- 2000/05/08 09:00 [medline]
PHST- 2000/03/09 09:00 [entrez]
AID - 10.1515/dmdi.1999.15.2-3.197 [doi]
PST - ppublish
SO  - Drug Metabol Drug Interact. 1999;15(2-3):197-205. doi: 
      10.1515/dmdi.1999.15.2-3.197.

PMID- 2869127
OWN - NLM
STAT- MEDLINE
DCOM- 19860414
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 38
IP  - 1
DP  - 1986 Jan
TI  - Investigation of the film formation of magnesium stearate by applying a 
      flow-through dissolution technique.
PG  - 51-4
AB  - The film formation of magnesium stearate on the surface of acetylsalicylic acid 
      was investigated by applying a flow-through dissolution technique. The effect of 
      mixing time, lubricant surface area, and the addition of colloidal silica was 
      studied. The film formation increased by increasing mixing time. The final level 
      reached was independent of the specific surface area of the lubricants, but 
      granular magnesium stearate gave a lower surface coverage than the powdered 
      lubricants. The lubricating effect was independent of the mixing time and 
      specific surface area of the lubricants. Colloidal silica was found to interact 
      primarily with the free fraction of magnesium stearate.
FAU - Johansson, M E
AU  - Johansson ME
FAU - Nicklasson, M
AU  - Nicklasson M
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Excipients)
RN  - 0 (Powders)
RN  - 0 (Stearic Acids)
RN  - 0 (Tablets)
RN  - 4ELV7Z65AP (stearic acid)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - *Excipients
MH  - Lubrication
MH  - Powders
MH  - Silicon Dioxide
MH  - *Stearic Acids
MH  - *Tablets
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1986.tb04466.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1986 Jan;38(1):51-4. doi: 10.1111/j.2042-7158.1986.tb04466.x.

PMID- 3134739
OWN - NLM
STAT- MEDLINE
DCOM- 19880825
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 50
IP  - 2
DP  - 1988 Apr 15
TI  - Inhibition of platelet function by low-dose plain and micro-encapsulated 
      acetylsalicylic acid.
PG  - 265-72
AB  - The effect of two acetylsalicylic acid (ASA) formulations, plain (Magnyl) and 
      micro-encapsulated (Globentyl), on platelet aggregation, thromboxane formation, 
      and bleeding time was studied in 12 healthy volunteers in a randomized 
      double-blind cross-over study. All subjects were treated with Magnyl and 
      Globentyl (75 mg daily) in periods of 2 weeks, separated by a wash-out period of 
      2 weeks. Both drugs significantly depressed platelet aggregation and thromboxane 
      formation and prolonged bleeding time without difference in mode of action of the 
      drugs. It is concluded that significant inhibition of platelet activity may be 
      achieved by low-dose ASA treatment with micro-encapsulated as well as with plain 
      formulations.
FAU - Waldemar, G
AU  - Waldemar G
AD  - Department of Neurology, Rigshospitalet, Copenhagen, Denmark.
FAU - Petersen, P
AU  - Petersen P
FAU - Boysen, G
AU  - Boysen G
FAU - Knudsen, J B
AU  - Knudsen JB
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Arachidonic Acids)
RN  - 0 (Tablets)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - *Bleeding Time
MH  - Blood Platelets/drug effects/metabolism
MH  - Double-Blind Method
MH  - Drug Compounding
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - *Platelet Function Tests
MH  - Tablets
MH  - Thromboxane B2/*biosynthesis
EDAT- 1988/04/15 00:00
MHDA- 1988/04/15 00:01
CRDT- 1988/04/15 00:00
PHST- 1988/04/15 00:00 [pubmed]
PHST- 1988/04/15 00:01 [medline]
PHST- 1988/04/15 00:00 [entrez]
AID - 10.1016/0049-3848(88)90227-7 [doi]
PST - ppublish
SO  - Thromb Res. 1988 Apr 15;50(2):265-72. doi: 10.1016/0049-3848(88)90227-7.

PMID- 17069096
OWN - NLM
STAT- MEDLINE
DCOM- 20061127
LR  - 20131121
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 97
IP  - 4
DP  - 2006 Oct
TI  - Failure to maintain an aspirin-desensitized state in a patient with 
      aspirin-exacerbated respiratory disease.
PG  - 446-8
AB  - BACKGROUND: Aspirin desensitization is a useful therapy in patients with 
      aspirin-exacerbated respiratory disease. OBJECTIVE: To describe the clinical 
      course of a man with aspirin-exacerbated respiratory disease who was unable to be 
      desensitized to oral aspirin. METHODS: A standard aspirin desensitization 
      protocol was used to achieve a maximum dose of 650 mg of oral aspirin. The 
      patient initially tolerated this dose of aspirin. RESULTS: Within days of 
      desensitization, the patient began to react to 650 mg of aspirin. Monitored 
      challenge with this dose of aspirin led to marked decrease in forced expiratory 
      volume in 1 second and pronounced nasal and ocular symptoms. CONCLUSIONS: We 
      present a patient with classic aspirin-exacerbated respiratory disease, who 
      despite undergoing a standard aspirin desensitization protocol was unable to 
      maintain his desensitized state.
FAU - White, Andrew A
AU  - White AA
AD  - Naval Medical Center San Diego, Allergy and Immunology Clinic, San Diego, 
      California 92106, USA. AAWhite@NMCSD.MED.NAVY.MIL
FAU - Hope, Andrew P
AU  - Hope AP
FAU - Stevenson, Donald D
AU  - Stevenson DD
LA  - eng
GR  - AI32834/AI/NIAID NIH HHS/United States
GR  - M01-RR00833/RR/NCRR NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - *Desensitization, Immunologic
MH  - *Drug Hypersensitivity
MH  - Humans
MH  - Male
MH  - Respiratory Tract Diseases/*immunology
MH  - Treatment Failure
EDAT- 2006/10/31 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/10/31 09:00
PHST- 2006/10/31 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/10/31 09:00 [entrez]
AID - S1081-1206(10)60932-5 [pii]
AID - 10.1016/S1081-1206(10)60932-5 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2006 Oct;97(4):446-8. doi: 
      10.1016/S1081-1206(10)60932-5.

PMID- 7557557
OWN - NLM
STAT- MEDLINE
DCOM- 19951109
LR  - 20131121
IS  - 0393-5264 (Print)
IS  - 0393-5264 (Linking)
VI  - 10
IP  - 2
DP  - 1995 Mar-Apr
TI  - Effect of picotamide and aspirin, combined or alone, on platelet aggregation in 
      patients with cerebral infarction.
PG  - 91-8
AB  - After 7 and 90 days of treatment, we studied the effect of picotamide, a 
      thromboxane synthase inhibitor (450 and 900 mg/day), aspirin (150 mg/day), and 
      aspirin plus picotamide (150 and 450 mg/day respectively) on platelet 
      aggregation, evaluated in platelet rich plasma of 48 patients affected by 
      ischemic stroke. Platelet aggregation, induced by collagen (1.0 and 2.0 
      micrograms/ml) and adenosine diphosphate (1.0 and 10 micrograms/L), was 
      significantly increased in patients in comparison with healthy controls. Aspirin 
      (150 mg/day) reduced collagen-induced platelet aggregation (1.0 microgram/ml) 
      after 7 days of treatment. Picotamide (450 mg/day) reduced platelet aggregation 
      induced by both concentrations of collagen, while the higher dose (900 mg/day) 
      had no significant effect. Aspirin plus picotamide reduced the aggregation 
      induced by 1.0 microgram/ml collagen and by 10 mumol/L adenosine diphosphate 
      after 90 days of therapy. This study has shown that patients during the acute 
      phase of stroke are characterized by an increased in vitro platelet aggregation. 
      Aspirin may be beneficial in the acute phase of the cerebral ischemic event. 
      Picotamide and picotamide plus aspirin could be useful for reducing platelet 
      aggregation in long term treatment.
FAU - D'Andrea, G
AU  - D'Andrea G
AD  - Department of Neurology, San Bortolo Hospital, Vicenza, Italy.
FAU - Perini, F
AU  - Perini F
FAU - Hasselmark, L
AU  - Hasselmark L
FAU - Alecci, M
AU  - Alecci M
FAU - Cananzi, A R
AU  - Cananzi AR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Italy
TA  - Funct Neurol
JT  - Functional neurology
JID - 8707746
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Phthalic Acids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 654G2VCI4Q (picotamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/*pharmacology/*therapeutic use
MH  - Aspirin/administration & dosage/*pharmacology/*therapeutic use
MH  - Brain/*drug effects/physiopathology
MH  - Brain Ischemia/*drug therapy/physiopathology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phthalic Acids/administration & dosage/*pharmacology/*therapeutic use
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/*pharmacology/*therapeutic use
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
PST - ppublish
SO  - Funct Neurol. 1995 Mar-Apr;10(2):91-8.

PMID- 19272375
OWN - NLM
STAT- MEDLINE
DCOM- 20090713
LR  - 20131121
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 609
IP  - 1-3
DP  - 2009 May 1
TI  - A randomized, controlled study on the influence of acetaminophen, diclofenac, or 
      naproxen on aspirin-induced inhibition of platelet aggregation.
PG  - 96-9
LID - 10.1016/j.ejphar.2009.02.042 [doi]
AB  - Nonsteroidal anti-inflammatory drugs (NSAID) may interfere with aspirin 
      (acetylsalicylic acid) and increase the risk for cardiovascular events. The 
      clinical relevance is uncertain. The aim of this study was to analyse the 
      influence of a co-administration of aspirin and NSAID on platelet aggregation. In 
      a randomized, placebo controlled trial, eleven healthy volunteers were studied 
      during 4 separate study periods of 4 days each. Individuals were treated on each 
      occasion with 100 mg aspirin daily in combination with either 3 x 1 g 
      acetaminophen, 3 x 50 mg diclofenac, 3 x 250 mg naproxen, or 3 x 1 placebo. 
      Primary hemostasis was assessed with a platelet function analyser (PFA-100), 
      which measures the closure time (CT) of a collagen- and epinephrine-coated pore 
      by aggregating platelets in flowing blood. Naproxen enhanced the anti-aggregatory 
      action of aspirin after 24 h (CT rising from 104+/-16 s at baseline to 212+/-69 s 
      at 24 h, P<0.001), which was not seen with any other drug combination. Diclofenac 
      reduced the anti-aggregatory action of aspirin in the first two days, since the 
      CT did not rise significantly (109+/-19 s, 148+/-56 s, and 168+/-66 s at 0 h, 24 
      h, 48 h, respectively, P>0.05). Acetaminophen had no effect compared with 
      placebo. After 4 days of treatment platelet aggregation was similarly inhibited 
      by all combinations. We conclude that a co-administration of NSAID and aspirin 
      may interfere with platelet inhibition at the beginning of a treatment with an 
      increase of naproxen and a decrease of diclofenac. This effect is lost after 4 
      days, suggesting that a regular daily co-administration of NSAID does not have an 
      influence on platelet inhibition by aspirin.
FAU - Galliard-Grigioni, Katja S
AU  - Galliard-Grigioni KS
AD  - Department of Internal Medicine, Kantonsspital Graubünden, CH-7000 Chur, 
      Switzerland.
FAU - Reinhart, Walter H
AU  - Reinhart WH
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090309
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Diclofenac/*pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naproxen/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Platelet Function Tests
MH  - Young Adult
EDAT- 2009/03/11 09:00
MHDA- 2009/07/14 09:00
CRDT- 2009/03/11 09:00
PHST- 2008/08/07 00:00 [received]
PHST- 2009/01/26 00:00 [revised]
PHST- 2009/02/09 00:00 [accepted]
PHST- 2009/03/11 09:00 [entrez]
PHST- 2009/03/11 09:00 [pubmed]
PHST- 2009/07/14 09:00 [medline]
AID - S0014-2999(09)00199-X [pii]
AID - 10.1016/j.ejphar.2009.02.042 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2009 May 1;609(1-3):96-9. doi: 10.1016/j.ejphar.2009.02.042. 
      Epub 2009 Mar 9.

PMID- 7441660
OWN - NLM
STAT- MEDLINE
DCOM- 19810219
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 7
IP  - 5
DP  - 1980 Sep-Oct
TI  - A comparison of naproxen, indomethacin and aspirin in osteoarthritis.
PG  - 711-6
AB  - Patients with osteoarthritis (OA) of the hip and know received naproxen (750 
      mg/d) or indomethacin (100 mg/d) in a 16-wk, double-blind, crossover study, in 
      which interspersion of repeated aspirin phases allowed a "detrending" adjustment 
      which compensated for changes in baseline activity with time. Results of the 24 
      variables studied showed a favorable comparison of naproxen and indomethacin in 
      reducing the symptoms of OA. Although most of the variables favored indomethacin, 
      the differences were small and few were statistically significant. Considerably 
      fewer side effects were seen with naproxen than with either indomethacin or 
      aspirin, and naproxen with tolerated considerably better than indomethacin. 
      Concurring with other studies, this trial showed that naproxen is a useful, 
      well-tolerated drug for the treatment of OA.
FAU - Martinez-Lavin, M
AU  - Martinez-Lavin M
FAU - Holman, K I
AU  - Holman KI
FAU - Smyth, C J
AU  - Smyth CJ
FAU - Vaughan, J H
AU  - Vaughan JH
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Central Nervous System Diseases/chemically induced
MH  - Drug Tolerance
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Indomethacin/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Naproxen/adverse effects/*therapeutic use
MH  - Osteoarthritis/*drug therapy
EDAT- 1980/09/01 00:00
MHDA- 1980/09/01 00:01
CRDT- 1980/09/01 00:00
PHST- 1980/09/01 00:00 [pubmed]
PHST- 1980/09/01 00:01 [medline]
PHST- 1980/09/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1980 Sep-Oct;7(5):711-6.

PMID- 2582661
OWN - NLM
STAT- MEDLINE
DCOM- 19900102
LR  - 20131121
IS  - 0009-921X (Print)
IS  - 0009-921X (Linking)
IP  - 249
DP  - 1989 Dec
TI  - The effect of indomethacin, aspirin, and ibuprofen on bone ingrowth into a 
      porous-coated implant.
PG  - 113-21
AB  - Therapeutic doses of indomethacin, aspirin, and ibuprofen were administered to 
      New Zealand White rabbits after implantation of a porous-coated chrome-cobalt 
      implant. Quantitative histomorphometric analysis was used to calculate the amount 
      of bone occupying the pores. There was a statistically significant decrease in 
      bone ingrowth in animals treated with indomethacin, ibuprofen, and high-dose 
      aspirin when compared to a control group. There was a dose-response effect for 
      the indomethacin and aspirin groups, with higher doses having a greater 
      inhibitory effect. Indomethacin, ibuprofen, and high-dose aspirin may be 
      contraindicated during the immediate postoperative period in patients having 
      cementless arthroplasty.
FAU - Trancik, T
AU  - Trancik T
AD  - Department of Orthopaedic Surgery, University of South Carolina, Columbia 29208.
FAU - Mills, W
AU  - Mills W
FAU - Vinson, N
AU  - Vinson N
LA  - eng
GR  - HC24935/HC/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
RN  - 0 (Chromium Alloys)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bone and Bones/anatomy & histology/*drug effects/physiology
MH  - *Chromium Alloys
MH  - Dose-Response Relationship, Drug
MH  - Femur
MH  - Ibuprofen/administration & dosage/*pharmacology
MH  - Indomethacin/administration & dosage/*pharmacology
MH  - Injections, Subcutaneous
MH  - *Prostheses and Implants
MH  - Rabbits
MH  - Surface Properties
MH  - Time Factors
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
PST - ppublish
SO  - Clin Orthop Relat Res. 1989 Dec;(249):113-21.

PMID- 20738228
OWN - NLM
STAT- MEDLINE
DCOM- 20110209
LR  - 20191210
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 26
IP  - 10
DP  - 2010 Oct
TI  - Potential economic impact of increasing low dose aspirin usage on CVD in the US.
PG  - 2365-73
LID - 10.1185/03007995.2010.514481 [doi]
AB  - BACKGROUND: Cardiovascular disease (CVD) is a leading cause of death in the US 
      and Western Europe, but regular use of preventive low-dose aspirin has proven 
      effective in preventing CVD events. The purpose of this study was to explore the 
      potential economic impact in the US if preventive aspirin usage were to be 
      increased in line with clinical guidelines for primary and secondary prevention. 
      METHODS: The risk profile of the US population was characterized using NHANES 
      data, and Framingham cardiovascular risk equations were applied to calculate risk 
      for myocardial infarction, angina and ischemic stroke according to age and 
      gender. Primary and secondary patients were considered separately. Using publicly 
      available unit costs, a budget impact model calculated the annual impact of 
      increased preventive aspirin usage considering gastrointestinal bleeding and 
      hemorrhagic stroke adverse events and diminishing aspirin adherence over a 
      10-year time horizon. RESULTS: In a base population of 1,000,000 patients, full 
      implementation of clinical guidelines would potentially prevent an additional 
      1273 myocardial infarctions, 2184 angina episodes and 565 ischemic strokes in 
      primary prevention patients and an additional 578 myocardial infarctions, and 607 
      ischemic strokes in secondary prevention patients. This represents a total 
      savings of $79.6 million for primary prevention and $32.2 million for secondary 
      and additional out-of-pocket expense to patients of $29.0 million for primary 
      prevention and $2.6 million for secondary prevention for the cost of aspirin. 
      CONCLUSIONS: This budgetary model suggests that there is a strong economic case, 
      both for payers and society, to encourage aspirin use for patients at appropriate 
      risk and per clinical guidelines. It also provides an example of how minimizing 
      costs do not necessarily have to imply a rationing of care. Limitations include 
      the exclusion of other CVD interventions in the analysis.
FAU - Manson, Stephanie C
AU  - Manson SC
AD  - United BioSource Corporation, London, UK. stephanie.manson@unitedbiosource.com
FAU - Benedict, Agnes
AU  - Benedict A
FAU - Pan, Feng
AU  - Pan F
FAU - Wittrup-Jensen, Kim U
AU  - Wittrup-Jensen KU
FAU - Fendrick, A Mark
AU  - Fendrick AM
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects/*economics
MH  - Cardiovascular Diseases/economics/epidemiology/*prevention & control
MH  - Chemoprevention/*economics/statistics & numerical data
MH  - Cost Savings/statistics & numerical data
MH  - Cost-Benefit Analysis
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/economics/epidemiology
MH  - Guidelines as Topic
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Models, Economic
MH  - Patient Compliance/statistics & numerical data
MH  - Primary Prevention/economics
MH  - United States/epidemiology
MH  - Young Adult
EDAT- 2010/08/27 06:00
MHDA- 2011/02/10 06:00
CRDT- 2010/08/27 06:00
PHST- 2010/08/27 06:00 [entrez]
PHST- 2010/08/27 06:00 [pubmed]
PHST- 2011/02/10 06:00 [medline]
AID - 10.1185/03007995.2010.514481 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2010 Oct;26(10):2365-73. doi: 10.1185/03007995.2010.514481.

PMID- 2190753
OWN - NLM
STAT- MEDLINE
DCOM- 19900716
LR  - 20131121
IS  - 0098-8243 (Print)
IS  - 0098-8243 (Linking)
VI  - 16
IP  - 5
DP  - 1990 May
TI  - Basic therapy of rheumatoid arthritis: nonsteroidal anti-inflammatory drugs.
PG  - 58-64
AB  - Aspirin is recommended for initial therapy of RA. If aspirin is not tolerated, an 
      NSAID is recommended. The choice of NSAID should be based on cost, convenience, 
      safety, and the personal experience of the physician. An adequate trial of at 
      least 2 weeks should be completed before changing to another NSAID. Therapy 
      should be closely monitored for adverse reactions, particularly renal and 
      gastrointestinal effects.
FAU - Williams, H J
AU  - Williams HJ
AD  - Division of Rheumatology, University of Utah, Salt Lake City.
FAU - Clegg, D O
AU  - Clegg DO
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Compr Ther
JT  - Comprehensive therapy
JID - 7605837
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Humans
RF  - 16
EDAT- 1990/05/01 00:00
MHDA- 1990/05/01 00:01
CRDT- 1990/05/01 00:00
PHST- 1990/05/01 00:00 [pubmed]
PHST- 1990/05/01 00:01 [medline]
PHST- 1990/05/01 00:00 [entrez]
PST - ppublish
SO  - Compr Ther. 1990 May;16(5):58-64.

PMID- 18480984
OWN - NLM
STAT- MEDLINE
DCOM- 20081014
LR  - 20211020
IS  - 1672-0733 (Print)
IS  - 1672-0733 (Linking)
VI  - 28
IP  - 2
DP  - 2008 Apr
TI  - Comparison of anticoagulant effects on vein grafts between human TFPI gene 
      transfection and aspirin oral administration.
PG  - 147-51
LID - 10.1007/s11596-008-0208-4 [doi]
AB  - To develop a more efficient antithrombotic way after coronary artery bypass 
      grafting (CABG), the anticoagulant effects were compared of human tissue factor 
      pathway inhibitor (TFPI) gene transfection and aspirin oral administration 
      (traditional method) on vein grafts. An eukaryotic expression plasmid 
      pCMV-(Kozak) TFPI was prepared. Animal model of carotid artery bypass grafting 
      was constructed. In operation, endothelial cells of vein grafts in TFPI group and 
      empty plasmid control group were transfected with pCMV-(Kozak) TFPI and empty 
      plasmid pCMV respectively, while no transfection was conducted in aspirin control 
      group. After operation, aspirin (2 mg.kg(-1).(-1)) was administered (i.g.) in 
      aspirin control group. Three days later, grafts (n=10) were harvested for RT-PCR, 
      Western blotting and immunohistochemical analyses of exogenous gene expression 
      and for pathological, scanning electron microscopic observation of thrombus. 
      Thirty days later, the patency rates of remnant grafts (n=10) were recorded by 
      vessel Doppler ultrasonography. Human TFPI gene products were detected in gene 
      transferred vein grafts. Three days later, thrombi were found in 7 animals of 
      aspirin control group and in 8 animals of empty plasmid control group, but in 
      only 1 of TFPI group (P<0.01). Thirty days later, 5 grafts were occluded in empty 
      plasmid control group, but none of grafts was occluded in the other groups 
      (P<0.05). The endothelial surfaces of grafts in both of the control groups were 
      covered with aggregated erythrocytes and platelets, and it were not seen in TFPI 
      group. It was suggested that the anticoagulant effects on vein grafts of human 
      TFPI gene transfection are better than those of aspirin.
FAU - Feng, Deguang
AU  - Feng D
AD  - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan 430022, China.
FAU - Li, Quan
AU  - Li Q
FAU - Zhang, Kailun
AU  - Zhang K
FAU - Jiang, Xionggang
AU  - Jiang X
FAU - Leng, Song
AU  - Leng S
FAU - Deng, Heping
AU  - Deng H
FAU - Feng, Jian'e
AU  - Feng J
FAU - Sun, Tucheng
AU  - Sun T
FAU - Wu, Long
AU  - Wu L
FAU - Zhou, Cheng
AU  - Zhou C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080515
PL  - China
TA  - J Huazhong Univ Sci Technolog Med Sci
JT  - Journal of Huazhong University of Science and Technology. Medical sciences = Hua 
      zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. 
      Yixue Yingdewen ban
JID - 101169627
RN  - 0 (Anticoagulants)
RN  - 0 (Lipoproteins)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anticoagulants/*metabolism
MH  - Aspirin/*administration & dosage/metabolism
MH  - Coronary Artery Bypass
MH  - Disease Models, Animal
MH  - Humans
MH  - Lipoproteins/*metabolism
MH  - Plasmids/metabolism
MH  - Rabbits
MH  - Tissue Transplantation/*methods
MH  - Transfection
MH  - Ultrasonography, Doppler/methods
MH  - Veins/*transplantation
MH  - Venous Thrombosis/metabolism
EDAT- 2008/05/16 09:00
MHDA- 2008/10/15 09:00
CRDT- 2008/05/16 09:00
PHST- 2007/12/10 00:00 [received]
PHST- 2008/05/16 09:00 [pubmed]
PHST- 2008/10/15 09:00 [medline]
PHST- 2008/05/16 09:00 [entrez]
AID - 10.1007/s11596-008-0208-4 [doi]
PST - ppublish
SO  - J Huazhong Univ Sci Technolog Med Sci. 2008 Apr;28(2):147-51. doi: 
      10.1007/s11596-008-0208-4. Epub 2008 May 15.

PMID- 34792904
OWN - NLM
STAT- MEDLINE
DCOM- 20211122
LR  - 20211122
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 71
IP  - 7
DP  - 2021 Sep
TI  - [Two decades later, the polypill revisited].
PG  - 713-716
AB  - TWO DECADES LATER, THE POLYPILL REVISITED Twenty years later, the promises of the 
      designers of the Polypill are far from being fulfilled. Its effectiveness is 
      still open to debate, while its long-term adverse effects in healthy subjects, 
      particularly due to aspirin, continue to cause concern. Its composition, which 
      varies from one Polypill to another, does not always appear to be as relevant as 
      it would be desirable. In short, it is not certain that its advantages far 
      outweigh its disadvantages. Its validation by the Authorities granting marketing 
      authorizations seems difficult as it stands because it requires demonstrating the 
      benefit of each of its components compared to a placebo and the contribution of 
      each component compared to the others. As for the idea of some of its upholders 
      to make it an over-the-counter drug, it is a headlong rush that is hardly 
      compatible with its target, healthy subjects, and its safety profile.
FAU - Bouvenot, Gilles
AU  - Bouvenot G
AD  - Professeur emerite a la faculte de medecine de Marseille. Membre de l'Academie 
      nationale de medecine.
LA  - fre
PT  - Journal Article
TT  - La polypill vingt ans après : était-ce une fausse bonne idée ?
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases
MH  - Drug Combinations
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors
OTO - NOTNLM
OT  - Cardiovascular risk
OT  - Primary Prevention
COIS- G. Bouvenot declare des liens ponctuels (activites de conseil) avec GSK et avec 
      les Clinical Research Organizations (CRO) Medi-Qualite Omega, Cemka, 
      White-Tillet, Evidera, CBPartners concernant des produits des entreprises Vifor 
      Pharma, Sage Therapeutics, Steba biotech, Jazz Pharmaceuticals, Insmed, Alnylan 
      Pharmaceuticals, Tesaro Bio France et Sanofi.
EDAT- 2021/11/19 06:00
MHDA- 2021/11/23 06:00
CRDT- 2021/11/18 12:39
PHST- 2021/11/18 12:39 [entrez]
PHST- 2021/11/19 06:00 [pubmed]
PHST- 2021/11/23 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2021 Sep;71(7):713-716.

PMID- 31902097
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 2008-2231 (Electronic)
IS  - 1560-8115 (Print)
IS  - 1560-8115 (Linking)
VI  - 28
IP  - 1
DP  - 2020 Jun
TI  - A new derivative of acetylsalicylic acid and carnosine: synthesis, physical and 
      chemical properties, biological activity.
PG  - 119-130
LID - 10.1007/s40199-019-00323-x [doi]
AB  - PURPOSE: The aim of this study was to create and assess biological activity of a 
      new compound based on carnosine and acetylsalicylic acid (ASA) that will comprise 
      antioxidant effect with antiplatelet activity, while simultaneously preventing 
      side effects on the gastrointestinal tract. METHODS: Salicyl-carnosine (SC) was 
      synthesized by condensation of ASA and carnosine. Antioxidant activity was 
      determined by spectrophotometric and chemiluminescence methods. Antiplatelet 
      activity was carried out by the light transmission-aggregometry method using the 
      inductor ADP. Chronic gastric ulcer in rats was modeled using glacial acetic 
      acid. RESULTS: Using SOD-like activity, iron-induced chemiluminescence, 
      BaSO4-activated respiratory burst, and evaluation of red blood cell structure 
      stabilization during oxidative damage induced by sodium hypochlorite, it was 
      shown that SC possesses antioxidant activity analogous, or better, than that of 
      carnosine. Antiplatelet activity of SC was evaluated in the blood of healthy 
      individuals, and was also shown to be comparable to, or exceeding that of ASA. 
      Also SC demonstrates high resistance to hydrolysis by tissue and serum 
      carnosinases. Most importantly, it was shown that SC has protected the gastric 
      mucosa against the formation of stomach ulcerative lesions and promoted their 
      epithelization, therefore overcoming the undesirable inherent side effects of 
      ASA. CONCLUSIONS: SC preserves pharmacologically significant properties of ASA 
      and carnosine while retaining an anti-ulcer activity and resistance to the 
      carnosinase hydrolysis at the same time. These properties are particularly 
      promising for the potential development of new anti-inflammatory and 
      antithrombotic drugs. Graphical abstract .
FAU - Kulikova, Olga I
AU  - Kulikova OI
AUID- ORCID: 0000-0002-1129-6033
AD  - Laboratory of Clinical and Experimental neurochemistry, Research Center of 
      Neurology, Volokolamskoe shosse, 80, Moscow, Russian Federation, 125367. 
      kulikova@neurology.ru.
FAU - Stvolinsky, Sergey L
AU  - Stvolinsky SL
AD  - Laboratory of Clinical and Experimental neurochemistry, Research Center of 
      Neurology, Volokolamskoe shosse, 80, Moscow, Russian Federation, 125367.
FAU - Migulin, Vasily A
AU  - Migulin VA
AD  - N. D. Zelinsky Institute of Organic Chemistry of the Russian Academy of Sciences, 
      Leninsky Prospect, 47, Moscow, Russian Federation, 119991.
FAU - Andreeva, Ludmila A
AU  - Andreeva LA
AD  - Department of Chemistry of Physiologically Active Substances, Institute of 
      Molecular Genetics of the Russian Academy of Sciences, Kurchatov Square 2, 
      Moscow, Russian Federation, 123182.
FAU - Nagaev, Igor Yu
AU  - Nagaev IY
AD  - Department of Chemistry of Physiologically Active Substances, Institute of 
      Molecular Genetics of the Russian Academy of Sciences, Kurchatov Square 2, 
      Moscow, Russian Federation, 123182.
FAU - Lopacheva, Olga M
AU  - Lopacheva OM
AD  - Laboratory of Clinical and Experimental neurochemistry, Research Center of 
      Neurology, Volokolamskoe shosse, 80, Moscow, Russian Federation, 125367.
FAU - Kulichenkova, Ksenia N
AU  - Kulichenkova KN
AD  - Laboratory of Clinical and Experimental neurochemistry, Research Center of 
      Neurology, Volokolamskoe shosse, 80, Moscow, Russian Federation, 125367.
FAU - Lopachev, Alexander V
AU  - Lopachev AV
AD  - Laboratory of Clinical and Experimental neurochemistry, Research Center of 
      Neurology, Volokolamskoe shosse, 80, Moscow, Russian Federation, 125367.
FAU - Trubitsina, Irina E
AU  - Trubitsina IE
AD  - Moscow Clinical Scientific Center after A.S. Loginov of the Moscow Healthcare 
      Department, Shosse Enthusiasts, 86, Moscow, Russian Federation, 111125.
FAU - Fedorova, Tatiana N
AU  - Fedorova TN
AD  - Laboratory of Clinical and Experimental neurochemistry, Research Center of 
      Neurology, Volokolamskoe shosse, 80, Moscow, Russian Federation, 125367.
LA  - eng
PT  - Journal Article
DEP - 20200104
PL  - Switzerland
TA  - Daru
JT  - Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
JID - 101125969
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 11062-77-4 (Superoxides)
RN  - 8HO6PVN24W (Carnosine)
RN  - Q40Q9N063P (Acetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetic Acid
MH  - Animals
MH  - *Anti-Ulcer Agents/chemistry/pharmacology/therapeutic use
MH  - *Antioxidants/chemistry/pharmacology/therapeutic use
MH  - *Aspirin/analogs & derivatives/chemistry/pharmacology/therapeutic use
MH  - *Carnosine/analogs & derivatives/chemistry/pharmacology/therapeutic use
MH  - Erythrocytes/drug effects
MH  - Hemolysis/drug effects
MH  - Humans
MH  - Hydrolysis
MH  - Leukocytes/drug effects
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - *Platelet Aggregation Inhibitors/chemistry/pharmacology/therapeutic use
MH  - Rats, Wistar
MH  - Respiratory Burst/drug effects
MH  - Stomach Ulcer/chemically induced/drug therapy
MH  - Superoxides/chemistry
PMC - PMC7214588
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Antioxidant
OT  - Antiplatelet action
OT  - Carnosine
OT  - Gastrointestinal ulcer
OT  - Salicylic acid
COIS- The authors declare no conflict of interest.
EDAT- 2020/01/07 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/01/06 06:00
PHST- 2019/07/16 00:00 [received]
PHST- 2019/12/17 00:00 [accepted]
PHST- 2020/01/07 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2020/01/06 06:00 [entrez]
AID - 10.1007/s40199-019-00323-x [pii]
AID - 323 [pii]
AID - 10.1007/s40199-019-00323-x [doi]
PST - ppublish
SO  - Daru. 2020 Jun;28(1):119-130. doi: 10.1007/s40199-019-00323-x. Epub 2020 Jan 4.

PMID- 31790151
OWN - NLM
STAT- MEDLINE
DCOM- 20200207
LR  - 20200207
IS  - 1465-3621 (Electronic)
IS  - 0368-2811 (Linking)
VI  - 49
IP  - 10
DP  - 2019 Oct 1
TI  - Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind 
      placebo-controlled trial (JCOG1503C, EPISODE-III trial).
PG  - 985-990
LID - 10.1093/jjco/hyz106 [doi]
AB  - Adjuvant chemotherapy is the current standard treatment for stage III colorectal 
      cancer after curative resection. However, the prognosis of stage III colorectal 
      cancer is still poor even after curative resection and adjuvant chemotherapy. 
      Several observational studies suggested that the anti-tumor effect of aspirin. 
      Therefore, we planned a randomized double-blind placebo-controlled phase III 
      trial, which commenced in Japan in March 2018, to confirm the superiority of 
      aspirin over placebo added to adjuvant chemotherapy in terms of disease-free 
      survival (DFS) for stage III colorectal cancer patients after curative resection. 
      A total of 880 patients will be accrued from 20 Japanese institutions within 3 
      years. The primary endpoint is DFS and the secondary endpoints are overall 
      survival, relapse-free survival, relative dose intensity, adverse events, and 
      serious adverse events. This trial has been registered at Japan Registry of 
      Clinical Trials as jRCTs031180009 (https://jrct.niph.go.jp/detail/589).
CI  - © The Author(s) 2019. Published by Oxford University Press. All rights reserved. 
      For permissions, please e-mail: journals.permissions@oup.com.
FAU - Miyamoto, Kenichi
AU  - Miyamoto K
AD  - Japan Clinical Oncology Group Data Center/Operations Office, National Cancer 
      Center Hospital, Tokyo, Japan.
FAU - Takashima, Atsuo
AU  - Takashima A
AD  - Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 
      Tokyo, Japan.
FAU - Mizusawa, Junki
AU  - Mizusawa J
AD  - Japan Clinical Oncology Group Data Center/Operations Office, National Cancer 
      Center Hospital, Tokyo, Japan.
FAU - Sato, Yuya
AU  - Sato Y
AD  - Japan Clinical Oncology Group Data Center/Operations Office, National Cancer 
      Center Hospital, Tokyo, Japan.
FAU - Shimada, Yasuhiro
AU  - Shimada Y
AD  - Clinical Oncology Division, Kochi Health Sciences Center, Kochi, Japan.
FAU - Katayama, Hiroshi
AU  - Katayama H
AD  - Japan Clinical Oncology Group Data Center/Operations Office, National Cancer 
      Center Hospital, Tokyo, Japan.
FAU - Nakamura, Kenichi
AU  - Nakamura K
AD  - Japan Clinical Oncology Group Data Center/Operations Office, National Cancer 
      Center Hospital, Tokyo, Japan.
FAU - Shibata, Taro
AU  - Shibata T
AD  - Japan Clinical Oncology Group Data Center/Operations Office, National Cancer 
      Center Hospital, Tokyo, Japan.
FAU - Fukuda, Haruhiko
AU  - Fukuda H
AD  - Japan Clinical Oncology Group Data Center/Operations Office, National Cancer 
      Center Hospital, Tokyo, Japan.
FAU - Shida, Dai
AU  - Shida D
AD  - Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
FAU - Kanemitsu, Yukihide
AU  - Kanemitsu Y
AD  - Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
FAU - Hamaguchi, Tetsuya
AU  - Hamaguchi T
AD  - Department of Gastroenterology, Saitama Medical University International Medical 
      Center, Saitama, Japan.
CN  - Colorectal Cancer Study Group of the Japan Clinical Oncology Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Jpn J Clin Oncol
JT  - Japanese journal of clinical oncology
JID - 0313225
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy/*pathology
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Neoplasm Staging
MH  - Placebos
MH  - Treatment Outcome
OTO - NOTNLM
OT  - IIIcolorectal cancer
OT  - adjuvant chemotherapy
OT  - aspirin
OT  - phase III
OT  - placebo
OT  - stage
EDAT- 2019/12/04 06:00
MHDA- 2020/02/08 06:00
CRDT- 2019/12/03 06:00
PHST- 2019/05/22 00:00 [received]
PHST- 2019/06/17 00:00 [revised]
PHST- 2019/06/26 00:00 [accepted]
PHST- 2019/12/03 06:00 [entrez]
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2020/02/08 06:00 [medline]
AID - 5530686 [pii]
AID - 10.1093/jjco/hyz106 [doi]
PST - ppublish
SO  - Jpn J Clin Oncol. 2019 Oct 1;49(10):985-990. doi: 10.1093/jjco/hyz106.

PMID- 10598030
OWN - NLM
STAT- MEDLINE
DCOM- 20000131
LR  - 20190719
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 22
IP  - 11
DP  - 1999 Nov
TI  - Deconvolution analysis for absorption and metabolism of aspirin in microcapsules.
PG  - 1212-6
AB  - We have previously proposed a novel deconvolution method, which can estimate 
      first-pass metabolism of orally administered drugs. In the present study, we 
      examined whether this deconvolution method is useful for evaluating oral dosage 
      forms. The absorption and first-pass metabolism of orally administered aspirin 
      formulated in several forms were analyzed. Two types of microcapsules consisting 
      of Eudragit L100 alone and Eudragit L100/ethylcellulose (4:6) were prepared as 
      sustained release formulations, for comparison with aspirin in powder form. The 
      deconvolution analysis revealed that absorption of aspirin was sustained by 
      encapsulating it in microcapsules. Interestingly, it also revealed that the 
      percentage metabolized during absorption was different among the three types of 
      formulations. Thus, the deconvolution method has enabled a comprehensive analysis 
      of orally administered drugs. This method is believed to contribute to the 
      evaluation of oral drug formulations.
FAU - Wu, X
AU  - Wu X
AD  - Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, 
      Kyoto University, Japan.
FAU - Yamashita, F
AU  - Yamashita F
FAU - Hashida, M
AU  - Hashida M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Acrylic Resins)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Capsules)
RN  - 0 (Excipients)
RN  - 0 (Gels)
RN  - 0 (Polymethacrylic Acids)
RN  - 25086-15-1 (methylmethacrylate-methacrylic acid copolymer)
RN  - 7Z8S9VYZ4B (ethyl cellulose)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Acrylic Resins
MH  - Algorithms
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacokinetics
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Capsules
MH  - Cellulose/analogs & derivatives
MH  - Chromatography, High Pressure Liquid
MH  - Excipients
MH  - Gels
MH  - Male
MH  - Models, Biological
MH  - Polymethacrylic Acids
MH  - Rats
MH  - Rats, Wistar
MH  - Solubility
EDAT- 1999/12/22 00:00
MHDA- 1999/12/22 00:01
CRDT- 1999/12/22 00:00
PHST- 1999/12/22 00:00 [pubmed]
PHST- 1999/12/22 00:01 [medline]
PHST- 1999/12/22 00:00 [entrez]
AID - 10.1248/bpb.22.1212 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 1999 Nov;22(11):1212-6. doi: 10.1248/bpb.22.1212.

PMID- 1617877
OWN - NLM
STAT- MEDLINE
DCOM- 19920804
LR  - 20180605
IS  - 0095-5108 (Print)
IS  - 0095-5108 (Linking)
VI  - 19
IP  - 2
DP  - 1992 Jun
TI  - An aspirin a day to prevent prematurity.
PG  - 305-17
AB  - Intrauterine fetal growth retardation and preeclampsia remain a substantial cause 
      of preterm birth world wide. There is evidence to suggest that a functional 
      imbalance between vascular prostacyclin and platelet-derived thromboxane A2 
      production plays a central role in the pathogenesis of these disorders. Low-dose 
      aspirin appears to reverse the above functional balance resulting in increased 
      prostacyclin to thromboxane ratio. The efficacy and safety of low-dose aspirin in 
      preventing preeclampsia and fetal growth retardation were tested in several 
      randomized and uncontrolled trials. The data in the literature suggest that 
      low-dose aspirin is effective in reducing preterm birth due to the above 
      complications in selected high-risk pregnant women.
FAU - Sibai, B M
AU  - Sibai BM
AD  - Department of Obstetrics/Gynecology, University of Tennessee, Memphis, Memphis.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Perinatol
JT  - Clinics in perinatology
JID - 7501306
RN  - 0 (Prostaglandins)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Birth Weight/drug effects
MH  - Female
MH  - Fetal Growth Retardation/drug therapy/prevention & control
MH  - Health Status Indicators
MH  - Humans
MH  - Obstetric Labor, Premature/*drug therapy/epidemiology/prevention & control
MH  - Pre-Eclampsia/drug therapy/prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Pregnancy, Multiple/drug effects
MH  - Prostaglandins/physiology
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Thromboxanes/physiology
RF  - 29
EDAT- 1992/06/01 00:00
MHDA- 1992/06/01 00:01
CRDT- 1992/06/01 00:00
PHST- 1992/06/01 00:00 [pubmed]
PHST- 1992/06/01 00:01 [medline]
PHST- 1992/06/01 00:00 [entrez]
AID - S0095-5108(18)30456-1 [pii]
PST - ppublish
SO  - Clin Perinatol. 1992 Jun;19(2):305-17.

PMID- 22542157
OWN - NLM
STAT- MEDLINE
DCOM- 20130320
LR  - 20211021
IS  - 1532-1916 (Electronic)
IS  - 1521-6918 (Linking)
VI  - 26
IP  - 2
DP  - 2012 Apr
TI  - Aspirin and NSAIDs; benefits and harms for the gut.
PG  - 197-206
LID - 10.1016/j.bpg.2012.01.007 [doi]
AB  - Despite modern advances in cancer research, screening and treatment options, 
      gastrointestinal tumours remain a leading cause of death worldwide. Both 
      oesophageal and colorectal malignancies carry high rates of morbidity and 
      mortality, presenting a challenge to clinicians in search of effective management 
      strategies. In recent years, the increasing burden of disease has led to a 
      paradigm shift in our approach from treatment to prevention. Among several agents 
      postulated as having a chemopreventive effect on the gastrointestinal tract, 
      aspirin has been most widely studied and has gained universal acknowledgement. 
      There is an expanding evidence base for aspirin as a key mediator in the 
      prevention of dysplastic change in Barrett's oesophagus and colorectal adenomas. 
      Its cardioprotective effects also impact positively on the patient population in 
      question, many of whom have ischaemic vascular disease. The major side effects of 
      aspirin have been well-characterised and may cause significant morbidity and 
      mortality in their own right. Complications such as peptic ulceration, upper 
      gastrointestinal bleeding and haemorrhagic stroke pose serious threats to the 
      routine administration of aspirin and hence a balance between the risks and 
      benefits must be struck if chemoprevention is to be effective on a large scale. 
      In this review, we address the current evidence base for aspirin use in 
      gastrointestinal oncology, as well as several key questions surrounding its 
      safety, cost effectiveness and optimal dose.
CI  - Copyright © 2012. Published by Elsevier Ltd.
FAU - Thiagarajan, Prarthana
AU  - Thiagarajan P
AD  - Department of Emergency Medicine, Balmoral Building, Leicester Royal Infirmary, 
      London, UK. prarthana.thiagarajan@uhl-tr.nhs.uk
FAU - Jankowski, Janusz A
AU  - Jankowski JA
LA  - eng
GR  - 4584/CRUK_/Cancer Research UK/United Kingdom
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Gastroenterol
JT  - Best practice & research. Clinical gastroenterology
JID - 101120605
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/economics/*therapeutic 
      use
MH  - Aspirin/adverse effects/economics/*therapeutic use
MH  - Barrett Esophagus/drug therapy
MH  - Cardiovascular Diseases/prevention & control
MH  - Colorectal Neoplasms/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Esophageal Neoplasms/*prevention & control
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Humans
EDAT- 2012/05/01 06:00
MHDA- 2013/03/21 06:00
CRDT- 2012/05/01 06:00
PHST- 2012/01/17 00:00 [received]
PHST- 2012/01/17 00:00 [accepted]
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
AID - S1521-6918(12)00008-X [pii]
AID - 10.1016/j.bpg.2012.01.007 [doi]
PST - ppublish
SO  - Best Pract Res Clin Gastroenterol. 2012 Apr;26(2):197-206. doi: 
      10.1016/j.bpg.2012.01.007.

PMID- 392744
OWN - NLM
STAT- MEDLINE
DCOM- 19800324
LR  - 20191210
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 8
IP  - 4
DP  - 1979
TI  - Gastrointestinal blood loss caused by controlled-release and conventional 
      acetylsalicylic acid tablets.
PG  - 209-13
AB  - Gastrointestinal blood loss has been studied following oral administration of the 
      novel controlled-release acetylsalicylic acid tablet preparation Acetard and the 
      instant-release acetylsalicylic acid tablet Magnecyl (Ph. Nord. 63). Acetard 
      contains micro-encapsulated acetylsalicylic acid crystals having an in vitro 
      release time of approximately 4 hours. The investigation was carried out as a 
      two-part, randomized cross-over trial, and with a test dosage of either 1 g X 4 
      or 2 g X 2 per day, given to 10 and 14 male students, respectively, during two 
      5-day periods separated by a one week interval. The dosage of the plain 
      formulation was maintained at 1 g X 4 daily in both parts of the investigation. 
      Faeces were collected every 24 hours throughout the trial, covering a total of 4 
      weeks. Blood loss was measured using the 51Cr labelling technique. Acetard was 
      found to cause statistically significantly less gastrointestinal blood loss as 
      compared with the plain formulation, irrespective of whether Acetard was given 
      twice or four times a day.
FAU - Brandslund, I
AU  - Brandslund I
FAU - Rask, H
AU  - Rask H
FAU - Klitgaard, N A
AU  - Klitgaard NA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 3A3U0GI71G (Magnesium Oxide)
RN  - 56333-49-4 (aspirin, magnesium oxide combination)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clinical Trials as Topic
MH  - Delayed-Action Preparations
MH  - Drug Combinations
MH  - Feces/analysis
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Magnesium Oxide/administration & dosage/adverse effects
MH  - Male
MH  - Random Allocation
MH  - Tablets
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.3109/03009747909114624 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 1979;8(4):209-13. doi: 10.3109/03009747909114624.

PMID- 16147476
OWN - NLM
STAT- MEDLINE
DCOM- 20051129
LR  - 20131121
IS  - 1090-3127 (Print)
IS  - 1090-3127 (Linking)
VI  - 9
IP  - 3
DP  - 2005 Jul-Sep
TI  - Treatment of suspected cardiac ischemia with aspirin by paramedics in an urban 
      emergency medical services system.
PG  - 282-4
AB  - BACKGROUND: Aspirin (ASA) has unquestioned benefit to patients with cardiac 
      ischemia. Previous studies indicate health care providers may not adequately 
      treat patients experiencing cardiac ischemia with ASA. OBJECTIVE: To determine 
      the rate of ASA use for patients being treated for chest pain suggestive of 
      cardiac ischemia in the prehospital setting. METHODS: This was a retrospective 
      study of paramedic encounters identified through billing records for all patients 
      receiving the combination of an intravenous catheter, supplemental oxygen, and 
      cardiac monitoring from November 2001 to January 2002. Prehospital medical 
      records were reviewed in order to determine the proportion of patients with 
      suspected cardiac ischemia who received ASA. The setting was a single prehospital 
      emergency medical services system serving an urban population. RESULTS: A total 
      of 2,457 paramedic encounters were reviewed over a three-month period. Two 
      hundred thirty-two patients were assessed as having cardiac ischemia, of whom 169 
      (73%) had no absolute or relative contraindication to ASA. Of the 169 patients, 
      only 92 (54%) received ASA. Of the 99 patients, who received nitroglycerin for 
      presumed cardiac ischemia and had no contraindication to receiving ASA, only 78 
      (79%) received ASA. Of the 453 patients complaining of nontraumatic chest pain 
      and without a contraindication, 157 (35%) received ASA. CONCLUSIONS: Paramedics 
      do not use ASA optimally and may choose therapies with less proven benefit.
FAU - McVaney, Kevin E
AU  - McVaney KE
AD  - Department of Emergency Medicine, Denver Health Medical Center, Colorado 80204, 
      USA. kevin.mcvaney@dhha.org
FAU - Macht, Marlow
AU  - Macht M
FAU - Colwell, Christopher B
AU  - Colwell CB
FAU - Pons, Peter T
AU  - Pons PT
LA  - eng
PT  - Journal Article
PL  - England
TA  - Prehosp Emerg Care
JT  - Prehospital emergency care
JID - 9703530
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Chest Pain/drug therapy/etiology
MH  - Colorado
MH  - *Emergency Medical Services
MH  - *Emergency Medical Technicians
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy/physiopathology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Urban Health Services
EDAT- 2005/09/09 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/09/09 09:00
PHST- 2005/09/09 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/09/09 09:00 [entrez]
AID - W7845236W5117806 [pii]
AID - 10.1080/10903120590962030 [doi]
PST - ppublish
SO  - Prehosp Emerg Care. 2005 Jul-Sep;9(3):282-4. doi: 10.1080/10903120590962030.

PMID- 2745065
OWN - NLM
STAT- MEDLINE
DCOM- 19890816
LR  - 20190828
IS  - 0017-8748 (Print)
IS  - 0017-8748 (Linking)
VI  - 29
IP  - 5
DP  - 1989 May
TI  - Successful aspirin prophylaxis in a child with chronic paroxysmal hemicrania.
PG  - 280-1
AB  - It is generally recognized that indomethacin prophylaxis is the treatment of 
      choice in adults with chronic paroxysmal hemicrania (CPH). Our case report is the 
      first to demonstrate complete control of CPH in a 9 year-old child using small 
      dose aspirin prophylaxis. This case also represents direct observation of the 
      youngest patient with CPH having the earliest reported onset.
FAU - Kudrow, D B
AU  - Kudrow DB
FAU - Kudrow, L
AU  - Kudrow L
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Humans
MH  - Male
MH  - Migraine Disorders/drug therapy/*prevention & control
MH  - Time Factors
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
AID - 10.1111/j.1526-4610.1989.hed2905280.x [doi]
PST - ppublish
SO  - Headache. 1989 May;29(5):280-1. doi: 10.1111/j.1526-4610.1989.hed2905280.x.

PMID- 25575876
OWN - NLM
STAT- MEDLINE
DCOM- 20150915
LR  - 20181113
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 5
IP  - 1
DP  - 2015 Jan 9
TI  - A short-term risk-benefit analysis of occasional and regular use of low-dose 
      aspirin in primary prevention of vascular diseases: a nationwide population-based 
      study.
PG  - e006694
LID - 10.1136/bmjopen-2014-006694 [doi]
LID - e006694
AB  - OBJECTIVE: To calculate the short-term risk-benefit effect of occasional and 
      regular use of low-dose aspirin (≤100 mg/day) in primary prevention. STUDY 
      DESIGN: Two retrospective cohort studies. SETTING: Taiwan. PARTICIPANTS: 63 788 
      and 24 910 patients of two nationwide population-based studies were examined. 
      METHODS: Two databases of 1 000 000 patients were randomly sampled from data of 
      Taiwan's National Health Insurance (NHI) for years 1997-2000 (NHI 2000) and 2005 
      (NHI 2005). In NHI 2000, 63 788 patients 30-95 years of age were found not to 
      have previously been prescribed aspirin before 1 January 2000, but to have first 
      been prescribed low-dose aspirin after that date. They were also found to be at 
      risk of first hospitalisation for any major vascular diseases including 
      haemorrhage (major gastrointestinal haemorrhage or cerebral haemorrhage) and 
      ischaemia (acute myocardial infarction or ischaemic stroke) after their first 
      prescription. We also applied it to NHI 2005, and the number of eligible patients 
      was 24 910. Patients prescribed low-dose aspirin for <20% of the days of a 60-day 
      follow-up period were considered to be occasional users, and those prescribed 
      low-dose aspirin for ≥80% of the days were considered to be regular users. 
      Differences in rate of haemorrhage and ischaemia between these users were used to 
      calculate their net clinical risk. PRIMARY OUTCOME: Vascular diseases. RESULTS: 
      In NHI 2000, the overall unadjusted rates of haemorrhage and ischaemia were 0.09% 
      and 0.21%, respectively, for occasional users and 0.32% and 2.30%, respectively, 
      for regular users. Adjusted net clinical risk of low-dose aspirin use between the 
      two groups was 2.24% (95% CI 2.03% to 2.48%; p<0.001). Similar results were also 
      found in NHI 2005. CONCLUSIONS: Short-term regular use of low-dose aspirin might 
      not be better than occasional use for preventing major vascular diseases in 
      primary prevention. Prescribing regular low-dose aspirin for primary prevention 
      should be done with caution. Future studies should explore the risk-benefit 
      effect of long-term low-dose aspirin use in primary prevention.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Wu, I-Chen
AU  - Wu IC
AD  - Department of Internal Medicine, Kaohsiung Medical University Hospital, 
      Kaohsiung, Taiwan Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, 
      Taiwan.
FAU - Hsieh, Hui-Min
AU  - Hsieh HM
AD  - Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan.
FAU - Wu, Ming-Tsang
AU  - Wu MT
AD  - Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan 
      Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung, 
      Taiwan Center of Environmental and Occupational Medicine, Kaohsiung Municipal 
      Hsiao-Kang Hospital, Kaohsiung, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150109
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Databases, Factual
MH  - Drug Administration Schedule
MH  - Female
MH  - Hemorrhage/prevention & control
MH  - Humans
MH  - Ischemia/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Primary Prevention
MH  - Risk
MH  - Stroke/prevention & control
PMC - PMC4289713
OTO - NOTNLM
OT  - EPIDEMIOLOGY
OT  - PREVENTIVE MEDICINE
OT  - PRIMARY CARE
EDAT- 2015/01/13 06:00
MHDA- 2015/09/16 06:00
CRDT- 2015/01/11 06:00
PHST- 2015/01/11 06:00 [entrez]
PHST- 2015/01/13 06:00 [pubmed]
PHST- 2015/09/16 06:00 [medline]
AID - bmjopen-2014-006694 [pii]
AID - 10.1136/bmjopen-2014-006694 [doi]
PST - epublish
SO  - BMJ Open. 2015 Jan 9;5(1):e006694. doi: 10.1136/bmjopen-2014-006694.

PMID- 26494395
OWN - NLM
STAT- MEDLINE
DCOM- 20160408
LR  - 20201209
IS  - 1466-609X (Electronic)
IS  - 1364-8535 (Print)
IS  - 1364-8535 (Linking)
VI  - 19
DP  - 2015 Oct 23
TI  - Aspirin as a potential treatment in sepsis or acute respiratory distress 
      syndrome.
PG  - 374
LID - 10.1186/s13054-015-1091-6 [doi]
LID - 374
AB  - Sepsis is a common condition that is associated with significant morbidity, 
      mortality and health-care cost. Pulmonary and non-pulmonary sepsis are common 
      causes of the acute respiratory distress syndrome (ARDS). The mortality from ARDS 
      remains high despite protective lung ventilation, and currently there are no 
      specific pharmacotherapies to treat sepsis or ARDS. Sepsis and ARDS are 
      characterised by activation of the inflammatory cascade. Although there is much 
      focus on the study of the dysregulated inflammation and its suppression, the 
      associated activation of the haemostatic system has been largely ignored until 
      recently. There has been extensive interest in the role that platelet activation 
      can have in the inflammatory response through induction, aggregation and 
      activation of leucocytes and other platelets. Aspirin can modulate multiple 
      pathogenic mechanisms implicated in the development of multiple organ dysfunction 
      in sepsis and ARDS. This review will discuss the role of the platelet, the 
      mechanisms of action of aspirin in sepsis and ARDS, and aspirin as a potential 
      therapy in treating sepsis and ARDS.
FAU - Toner, Philip
AU  - Toner P
AD  - Centre for Infection and Immunity, Queen's University of Belfast, Health Sciences 
      Building, Lisburn Road, Belfast, BT9 7AE, Northern Ireland, UK. 
      ptoner09@qub.ac.uk.
FAU - McAuley, Danny Francis
AU  - McAuley DF
AD  - Centre for Infection and Immunity, Queen's University of Belfast, Health Sciences 
      Building, Lisburn Road, Belfast, BT9 7AE, Northern Ireland, UK.
AD  - Regional Intensive Care Unit, Royal Victoria Hospital, 274 Grosvenor Road, 
      Belfast, BT12 6AB, Northern Ireland, UK.
FAU - Shyamsundar, Murali
AU  - Shyamsundar M
AD  - Centre for Infection and Immunity, Queen's University of Belfast, Health Sciences 
      Building, Lisburn Road, Belfast, BT9 7AE, Northern Ireland, UK.
AD  - Regional Intensive Care Unit, Royal Victoria Hospital, 274 Grosvenor Road, 
      Belfast, BT12 6AB, Northern Ireland, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT01659307
SI  - ClinicalTrials.gov/NCT02326350
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20151023
PL  - England
TA  - Crit Care
JT  - Critical care (London, England)
JID - 9801902
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Lung/physiopathology
MH  - Platelet Activation/drug effects
MH  - Respiratory Distress Syndrome/*drug therapy
MH  - Sepsis/*drug therapy
PMC - PMC4619098
EDAT- 2015/10/27 06:00
MHDA- 2016/04/09 06:00
CRDT- 2015/10/24 06:00
PHST- 2015/10/24 06:00 [entrez]
PHST- 2015/10/27 06:00 [pubmed]
PHST- 2016/04/09 06:00 [medline]
AID - 10.1186/s13054-015-1091-6 [pii]
AID - 1091 [pii]
AID - 10.1186/s13054-015-1091-6 [doi]
PST - epublish
SO  - Crit Care. 2015 Oct 23;19:374. doi: 10.1186/s13054-015-1091-6.

PMID- 14739625
OWN - NLM
STAT- MEDLINE
DCOM- 20041008
LR  - 20181130
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 15
IP  - 3
DP  - 2003 Jun
TI  - Synergism of aspirin and heparin with a low-frequency non-invasive ultrasound 
      system for augmentation of in-vitro clot lysis.
PG  - 165-9
AB  - BACKGROUND: Aspirin, glycoprotein IIb/IIIa inhibitors and heparin are routinely 
      used in acute coronary syndromes. Previously we showed that there is synergism 
      between ultrasound and heparin and tirofiban in augmenting blood clot disruption. 
      However, there is a little data on a possible synergism of low-frequency 
      ultrasound with aspirin for in-vitro clot dissolution, and especially on the 
      combination of aspirin with heparin and/or glycoprotein IIb/IIIa inhibitors. 
      MATERIALS AND METHODS: Human blood clots (n = 320) were incubated for 10 or 20 
      minutes in saline containing aspirin alone or combined with heparin and/or 
      tirofiban and/or eptifibatide. Clots were randomly treated with low-frequency 
      ultrasound (27.3 kHz) or incubation only. The percent clot weight loss and the 
      incremental effect of ultrasound were calculated. RESULTS: The most significant 
      incremental effect of ultrasound on clot weight reduction was detected with 
      aspirin alone (5.2 +/- 2.3% and 5.2 +/- 2.6% after 10' and 20', p = 0.04 and p = 
      0.06, respectively) and in combination with heparin (8.8 +/- 2.5% and 11.5 +/- 
      2.7% after 10' and 20', p = 0.01 and p = 0.0001, respectively). The greatest 
      absolute magnitude of clot weight reduction was observed with ultrasound combined 
      with aspirin and heparin (48.5 +/- 9.5% after 20'). The addition of tirofiban or 
      eptifibatide to aspirin, heparin and ultrasound did not increase clot lysis. 
      However, eptifibatide had significantly better synergism than tirofiban (p = 
      0.025 and p = 0.015, after 10 and 20 minutes, respectively). CONCLUSIONS: Aspirin 
      alone or in combination with heparin results in significant augmentation of clot 
      lysis and is synergistic with application of low-frequency ultrasound for 10 and 
      20 minutes only. These results may have important implications for a possible use 
      of low-frequency ultrasound in treatment algorithms of acute coronary syndromes.
FAU - Atar, Shaul
AU  - Atar S
AD  - Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los 
      Angeles, CA 90048, USA.
FAU - Neuman, Yoram
AU  - Neuman Y
FAU - Miyamoto, Takashi
AU  - Miyamoto T
FAU - Chen, Ming
AU  - Chen M
FAU - Birnbaum, Yochai
AU  - Birnbaum Y
FAU - Luo, Huai
AU  - Luo H
FAU - Kobal, Sergio
AU  - Kobal S
FAU - Siegel, Robert J
AU  - Siegel RJ
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Peptides)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 42HK56048U (Tyrosine)
RN  - 9005-49-6 (Heparin)
RN  - GGX234SI5H (Tirofiban)
RN  - NA8320J834 (Eptifibatide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Eptifibatide
MH  - Heparin/*pharmacology/therapeutic use
MH  - Humans
MH  - In Vitro Techniques
MH  - Peptides/pharmacology/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Thrombolytic Therapy/*methods
MH  - Tirofiban
MH  - Tyrosine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Ultrasonic Therapy/*methods
EDAT- 2004/01/24 05:00
MHDA- 2004/10/09 09:00
CRDT- 2004/01/24 05:00
PHST- 2004/01/24 05:00 [pubmed]
PHST- 2004/10/09 09:00 [medline]
PHST- 2004/01/24 05:00 [entrez]
AID - 5254964 [pii]
AID - 10.1023/B:THRO.0000011371.66978.e6 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2003 Jun;15(3):165-9. doi: 
      10.1023/B:THRO.0000011371.66978.e6.

PMID- 20145871
OWN - NLM
STAT- MEDLINE
DCOM- 20100428
LR  - 20131121
IS  - 1463-9084 (Electronic)
IS  - 1463-9076 (Linking)
VI  - 12
IP  - 8
DP  - 2010 Feb 28
TI  - In search of pure liquid salt forms of aspirin: ionic liquid approaches with 
      acetylsalicylic acid and salicylic acid.
PG  - 2011-7
LID - 10.1039/b923855g [doi]
AB  - We present an ionic liquid (IL) approach towards a dual functional liquid salt 
      form of aspirin using different pharmaceutically active cations composed of 
      antibacterials, analgesics, local anesthetics, and antiarrhythmic drugs in 
      combination with acetylsalicylic acid or its metabolite salicylic acid and 
      discuss stability of these ILs in comparison to solid salts. Several low-melting 
      or liquid salts of salicylic acid with dual functionality and promising 
      properties were isolated and characterized; however, although such ILs with 
      aspirin could be prepared, they suffer from limited stability and slowly 
      decompose into the corresponding salicylate ILs when exposed to moisture.
FAU - Bica, Katharina
AU  - Bica K
AD  - The Queen's University of Belfast, QUILL, School of Chemistry and Chemical 
      Engineering, Belfast, Northern Ireland BT9 5AG.
FAU - Rijksen, Christiaan
AU  - Rijksen C
FAU - Nieuwenhuyzen, Mark
AU  - Nieuwenhuyzen M
FAU - Rogers, Robin D
AU  - Rogers RD
LA  - eng
PT  - Journal Article
DEP - 20100122
PL  - England
TA  - Phys Chem Chem Phys
JT  - Physical chemistry chemical physics : PCCP
JID - 100888160
RN  - 0 (Ionic Liquids)
RN  - 0 (Salts)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Crystallography, X-Ray
MH  - Hydrogen Bonding
MH  - Hydrolysis
MH  - Ionic Liquids/*chemistry
MH  - Phase Transition
MH  - Salicylic Acid/*chemistry
MH  - Salts/*chemistry
MH  - Transition Temperature
EDAT- 2010/02/11 06:00
MHDA- 2010/04/29 06:00
CRDT- 2010/02/11 06:00
PHST- 2010/02/11 06:00 [entrez]
PHST- 2010/02/11 06:00 [pubmed]
PHST- 2010/04/29 06:00 [medline]
AID - 10.1039/b923855g [doi]
PST - ppublish
SO  - Phys Chem Chem Phys. 2010 Feb 28;12(8):2011-7. doi: 10.1039/b923855g. Epub 2010 
      Jan 22.

PMID- 25468861
OWN - NLM
STAT- MEDLINE
DCOM- 20160523
LR  - 20200225
IS  - 1473-4893 (Electronic)
IS  - 1470-2118 (Print)
IS  - 1470-2118 (Linking)
VI  - 14
IP  - 6
DP  - 2014 Dec
TI  - A stroke of bad luck.
PG  - 685-7
LID - 10.7861/clinmedicine.14-6-685 [doi]
AB  - Giant cell arteritis is a common cause of headache in patients aged more than 
      50 years. It is an easy diagnosis to make if classical features, ie temporal 
      headache, jaw claudication, visual symptoms, systemic symptoms of fever or weight 
      loss with high erythrocyte sedimentation rate and anemia, are present. However, 
      it may present atypically and stroke can be the presenting feature. A high index 
      of suspicion is needed in atypical presentations such as stroke. Once a diagnosis 
      is suspected it is imperative to start high dose steroids to prevent visual and 
      neurological complications.
CI  - © 2014 Royal College of Physicians.
FAU - Nagasayi, Subramaniam
AU  - Nagasayi S
AD  - University Hospital Llandough, Cardiff, UK drkamalsuja@doctors.net.uk.
FAU - White, Susan
AU  - White S
AD  - Llandough Hospital, Cardiff, UK, and clinical lecturer undergraduate medical 
      education, Cardiff University, Cardiff, UK.
FAU - Joshi, Yogesh
AU  - Joshi Y
AD  - University Hospital of Wales, Cardiff, UK.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Clin Med (Lond)
JT  - Clinical medicine (London, England)
JID - 101092853
RN  - 0 (Steroids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - *Giant Cell Arteritis
MH  - Headache/etiology
MH  - Humans
MH  - Middle Aged
MH  - Steroids/therapeutic use
MH  - *Stroke
PMC - PMC4954148
OTO - NOTNLM
OT  - Giant cell arteritis
OT  - aspirin
OT  - steroids
OT  - stroke
OT  - vasculitis
EDAT- 2014/12/04 06:00
MHDA- 2016/05/24 06:00
CRDT- 2014/12/04 06:00
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2016/05/24 06:00 [medline]
AID - 14/6/685 [pii]
AID - clinmedicine [pii]
AID - 10.7861/clinmedicine.14-6-685 [doi]
PST - ppublish
SO  - Clin Med (Lond). 2014 Dec;14(6):685-7. doi: 10.7861/clinmedicine.14-6-685.

PMID- 15240674
OWN - NLM
STAT- MEDLINE
DCOM- 20040827
LR  - 20190516
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 173
IP  - 2
DP  - 2004 Jul 15
TI  - Nitric oxide regulates immune cell bioenergetic: a mechanism to understand 
      immunomodulatory functions of nitric oxide-releasing anti-inflammatory drugs.
PG  - 874-82
AB  - The 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) is a 
      NO-releasing derivative of aspirin. In this study, we provide evidence that 
      NCX-4016 delivered to PMBC-derived T lymphocytes and monocytes causes a 
      transitory inhibition of cell respiration and approximately 50% reduction of 
      cellular ATP, which translates in a time-reversible inhibition of cell 
      proliferation and IL-2, IL-4, IL-5, and IFN-gamma secretion. Exposure of 
      lymphocytes and monocytes to aspirin, 2-(acetyloxy)benzoic acid 
      3-(hydroxymethyl)phenyl ester (NCX-4017), a non-NO-releasing analog of NCX-4016, 
      and cyclooxygenase inhibitors, reduced PG formation, but has no effect on 
      cytokine/chemokine release. In contrast, delivering NO with 
      (z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino] diazen-1-ium-1,2 diolate 
      (DETA-NO) reproduced most of the metabolic and anti-cytokine activities of 
      NCX-4016. Scavenging NO with hemoglobin or adding selective substrates of complex 
      II, III, and IV of the mitochondrial respiratory chain reverses NCX-4016' 
      inhibitory activities. Exposure to DETA-NO and NCX-4016 enhances glucose uptake, 
      glycolytic rate, and lactate generation in CD3/CD28-costimulated lymphocytes, 
      while reduced citric acid cycle intermediates. These effects were not reproduced 
      by selective and nonselective cyclooxygenase 2 inhibitors. In summary, we 
      demonstrated that exposure of lymphocytes to NCX-4016 causes a metabolic hypoxia 
      that inhibits lymphocyte reactivity to costimulatory molecules, providing a 
      potential counteregulatory mechanism to control activated immune system.
FAU - Fiorucci, Stefano
AU  - Fiorucci S
AD  - Dipartimento di Medicina Clinica e Sperimentale, Clinica di Gastroenterologia ed 
      Epatologia, Università degli Studi di Perugia, Perugia, Italy. fiorucci@unipg.it
FAU - Mencarelli, Andrea
AU  - Mencarelli A
FAU - Distrutti, Eleonora
AU  - Distrutti E
FAU - Baldoni, Monia
AU  - Baldoni M
FAU - del Soldato, Piero
AU  - del Soldato P
FAU - Morelli, Antonio
AU  - Morelli A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene)
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Triazenes)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Triphosphate/physiology
MH  - Adjuvants, Immunologic/*pharmacology
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Energy Metabolism/drug effects/*physiology
MH  - Glycolysis/drug effects
MH  - Humans
MH  - Mitochondria/drug effects/physiology
MH  - Nitric Oxide/*physiology
MH  - T-Lymphocytes/drug effects
MH  - Triazenes/pharmacology
EDAT- 2004/07/09 05:00
MHDA- 2004/08/28 05:00
CRDT- 2004/07/09 05:00
PHST- 2004/07/09 05:00 [pubmed]
PHST- 2004/08/28 05:00 [medline]
PHST- 2004/07/09 05:00 [entrez]
AID - 10.4049/jimmunol.173.2.874 [doi]
PST - ppublish
SO  - J Immunol. 2004 Jul 15;173(2):874-82. doi: 10.4049/jimmunol.173.2.874.

PMID- 20138334
OWN - NLM
STAT- MEDLINE
DCOM- 20100922
LR  - 20131121
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 125
IP  - 6
DP  - 2010 Jun
TI  - The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients 
      with stable coronary artery disease treated with aspirin.
PG  - e265-8
LID - 10.1016/j.thromres.2010.01.011 [doi]
AB  - BACKGROUND: Various genetic polymorphisms have been proposed to explain the 
      persistent platelet hyperactivity (HPR) under aspirin treatment. PlA polymorphism 
      of platelet GPIIIa receptor has been largely studied. However, its influence on 
      platelet sensitivity to aspirin remains controversial. OBJECTIVES: The aim of 
      this prospective study is to investigate whether this PlA polymorphism is 
      associated with a greater prevalence of HPR in stable coronary artery disease 
      patients Material and Methods: 188 stable coronary artery disease patients were 
      included. Platelet aspirin inhibitory effect was determined with PFA-100 using 
      Collagen/Epinephrine closure time (CEPI-CT). A CEPI-CT<160sec was defining the 
      HPR status. GPIIIa PlA polymorphism was established using polymerase chain 
      reaction and classical restriction fragments length polymorphism. RESULTS: The 
      observed frequencies of different genotypes were not different from those 
      predicted by the Hardy-Weinberg equilibrium: PlA1/lA1 (55.3%), PlA1/PlA2 (39.4%) 
      and PlA2/PlA2 (5.3%). HPR patients with inadequate aspirin inhibition were 
      significantly more often homozygous PlA1/A1 (65.4% vs. 47.7%, p=0.015). After 
      multivariate analysis, PlA1/A1 genotype was the only independent risk factor for 
      persistent HPR (OR: 2.07; 95% CI [1.14 to 3.76; p=0.016). CONCLUSION: In CAD 
      patients receiving daily low dose of aspirin, there is a significant and 
      independent association between the expression of GPIIIa PlA1 allele and the 
      occurrence of persistent HPR detected with PFA-100.
CI  - Copyright 2009 Elsevier Ltd. All rights reserved.
FAU - Abderrazek, Fatma
AU  - Abderrazek F
AD  - Haematology's Laboratory; Fattouma Bourguiba University Hospital, Monastir, 
      Tunisia.
FAU - Chakroun, Tahar
AU  - Chakroun T
FAU - Addad, Faouzi
AU  - Addad F
FAU - Dridi, Zohra
AU  - Dridi Z
FAU - Gerotziafas, Grigoris
AU  - Gerotziafas G
FAU - Gamra, Habib
AU  - Gamra H
FAU - Hassine, Mohsen
AU  - Hassine M
FAU - Elalamy, Ismail
AU  - Elalamy I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Integrin beta3)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Coronary Artery Disease/*drug therapy/epidemiology/genetics
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Integrin beta3/*genetics
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors
MH  - Platelet Function Tests
MH  - *Polymorphism, Genetic
MH  - Tunisia/epidemiology
EDAT- 2010/02/09 06:00
MHDA- 2010/09/24 06:00
CRDT- 2010/02/09 06:00
PHST- 2009/09/23 00:00 [received]
PHST- 2009/12/17 00:00 [revised]
PHST- 2010/01/17 00:00 [accepted]
PHST- 2010/02/09 06:00 [entrez]
PHST- 2010/02/09 06:00 [pubmed]
PHST- 2010/09/24 06:00 [medline]
AID - S0049-3848(10)00039-3 [pii]
AID - 10.1016/j.thromres.2010.01.011 [doi]
PST - ppublish
SO  - Thromb Res. 2010 Jun;125(6):e265-8. doi: 10.1016/j.thromres.2010.01.011.

PMID- 29075787
OWN - NLM
STAT- MEDLINE
DCOM- 20180723
LR  - 20181113
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 51
IP  - 6
DP  - 2017 Dec
TI  - Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights 
      into aspirin's chemopreventive effects against colorectal cancer.
PG  - 1661-1673
LID - 10.3892/ijo.2017.4167 [doi]
AB  - Aspirin's potential as a drug continues to be evaluated for the prevention of 
      colorectal cancer (CRC). Although multiple targets for aspirin and its 
      metabolite, salicylic acid, have been identified, no unifying mechanism has been 
      proposed to clearly explain its chemopreventive effects. Our goal here was to 
      investigate the ability of salicylic acid metabolites, known to be generated 
      through cytochrome P450 (CYP450) enzymes, and its derivatives as cyclin dependent 
      kinase (CDK) inhibitors to gain new insights into aspirin's chemopreventive 
      actions. Using in vitro kinase assays, for the first time, we demonstrate that 
      salicylic acid metabolites, 2,3-dihydroxybenzoic acid (2,3-DHBA) and 
      2,5-dihydroxybenzoic acid (2,5-DHBA), as well as derivatives 2,4-dihydroxybenzoic 
      acid (2,4-DHBA), 2,6-dihydroxybenzoic acid (2,6-DHBA), inhibited CDK1 enzyme 
      activity. 2,3-DHBA and 2,6-DHBA did not inhibit CDK2 and 4; however, both 
      inhibited CDK-6 activity. Interestingly, another derivative, 
      2,4,6-trihydroxybenzoic acid (2,4,6-THBA) was highly effective in inhibiting 
      CDK1, 2, 4 and 6 activity. Molecular docking studies showed that these compounds 
      potentially interact with CDK1. Immunoblotting experiments showed that aspirin 
      acetylated CDK1, and pre-incubation with salicylic acid and its derivatives 
      prevented aspirin-mediated CDK1 acetylation, which supported the data obtained 
      from molecular docking studies. We suggest that intracellularly generated 
      salicylic acid metabolites through CYP450 enzymes within the colonic epithelial 
      cells, or the salicylic acid metabolites generated by gut microflora may 
      significantly contribute to the preferential chemopreventive effect of aspirin 
      against CRC through inhibition of CDKs. This novel hypothesis and mechanism of 
      action in aspirin's chemopreventive effects opens a new area for future research. 
      In addition, structural modification to salicylic acid derivatives may prove 
      useful in the development of novel CDK inhibitors in cancer prevention and 
      treatment.
FAU - Dachineni, Rakesh
AU  - Dachineni R
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy and Allied Health Professions, 
      Brookings, SD 57007, USA.
FAU - Kumar, D Ramesh
AU  - Kumar DR
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy and Allied Health Professions, 
      Brookings, SD 57007, USA.
FAU - Callegari, Eduardo
AU  - Callegari E
AD  - SD-BRIN Proteomic Facility, University of South Dakota School of Medicine, 
      Vermillion, SD 57069, USA.
FAU - Kesharwani, Siddharth S
AU  - Kesharwani SS
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy and Allied Health Professions, 
      Brookings, SD 57007, USA.
FAU - Sankaranarayanan, Ranjini
AU  - Sankaranarayanan R
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy and Allied Health Professions, 
      Brookings, SD 57007, USA.
FAU - Seefeldt, Teresa
AU  - Seefeldt T
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy and Allied Health Professions, 
      Brookings, SD 57007, USA.
FAU - Tummala, Hemachand
AU  - Tummala H
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy and Allied Health Professions, 
      Brookings, SD 57007, USA.
FAU - Bhat, G Jayarama
AU  - Bhat GJ
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy and Allied Health Professions, 
      Brookings, SD 57007, USA.
LA  - eng
GR  - P20 GM103443/GM/NIGMS NIH HHS/United States
GR  - R03 CA133061/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171019
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (CCNB1 protein, human)
RN  - 0 (Cyclin B1)
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.22 (CDC2 Protein Kinase)
RN  - EC 2.7.11.22 (CDK1 protein, human)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Anticarcinogenic Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - CDC2 Protein Kinase/*antagonists & inhibitors/metabolism
MH  - Colorectal Neoplasms/enzymology/*prevention & control
MH  - Cyclin B1/metabolism
MH  - HCT116 Cells
MH  - Humans
MH  - Hydroxybenzoates/*pharmacology
MH  - Molecular Docking Simulation
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Salicylic Acid/metabolism/*pharmacology
PMC - PMC5673027
EDAT- 2017/10/28 06:00
MHDA- 2018/07/24 06:00
CRDT- 2017/10/28 06:00
PHST- 2017/07/26 00:00 [received]
PHST- 2017/09/20 00:00 [accepted]
PHST- 2017/10/28 06:00 [pubmed]
PHST- 2018/07/24 06:00 [medline]
PHST- 2017/10/28 06:00 [entrez]
AID - ijo-51-06-1661 [pii]
AID - 10.3892/ijo.2017.4167 [doi]
PST - ppublish
SO  - Int J Oncol. 2017 Dec;51(6):1661-1673. doi: 10.3892/ijo.2017.4167. Epub 2017 Oct 
      19.

PMID- 7768482
OWN - NLM
STAT- MEDLINE
DCOM- 19950630
LR  - 20191023
IS  - 0767-3981 (Print)
IS  - 0767-3981 (Linking)
VI  - 9
IP  - 1
DP  - 1995
TI  - Central analgesic effects of aspirin-like drugs.
PG  - 1-7
AB  - Aspirin-like drugs mainly include paracetamol, salicylates and other 
      non-steroidal anti-inflammatory drugs, and metamizole. Their analgesic effect is 
      classically ascribed to a peripheral site of action, within the pain-processing 
      site. There is, however, convincing evidence that a central component contributes 
      to the overall analgesia provided by these agents. Experimental and clinical 
      studies referring to this challenging proposal are reviewed here. The exact site 
      and mode of action of aspirin-like drugs within the central nervous system 
      remains controversial. It is likely that supraspinal mechanisms play an important 
      role. Some experiments lend support to the involvement of monoaminergic control 
      systems. Other data indicate that these drugs act centrally through the 
      inhibition of cyclo-oxygenase activity. The interactions between prostaglandins 
      and various neurotransmitters suggest that both mechanisms may be linked.
FAU - Bannwarth, B
AU  - Bannwarth B
AD  - Centre de Pharmacologie, Groupe Hospitalier Pellegrin, Bordeaux, France.
FAU - Demotes-Mainard, F
AU  - Demotes-Mainard F
FAU - Schaeverbeke, T
AU  - Schaeverbeke T
FAU - Labat, L
AU  - Labat L
FAU - Dehais, J
AU  - Dehais J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Analgesics)
RN  - 0 (Prostaglandin Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesia
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Brain/*drug effects
MH  - Humans
MH  - Prostaglandin Antagonists/pharmacology
MH  - Spinal Cord/*drug effects
RF  - 65
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1111/j.1472-8206.1995.tb00258.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 1995;9(1):1-7. doi: 10.1111/j.1472-8206.1995.tb00258.x.

PMID- 3103204
OWN - NLM
STAT- MEDLINE
DCOM- 19870407
LR  - 20211203
IS  - 0085-5928 (Print)
IS  - 0085-5928 (Linking)
VI  - 125
DP  - 1986
TI  - Strategies for preventing aspirin-induced gastric bleeding.
PG  - 170-3
AB  - Prostaglandins protect the gastric mucosa in animals, but the evidence of an 
      effect independent of pH changes in man is not overwhelming. Gastrointestinal 
      bleeding because of non-steroidal anti-inflammatory drugs is a major clinical 
      problem, which we have investigated in a model system measuring bleeding rates 
      caused by short-term administration of aspirin. Of the various strategies tested, 
      only those that elevated intra-gastric pH reduced aspirin-induced bleeding.
FAU - Hawkey, C J
AU  - Hawkey CJ
FAU - Prichard, P J
AU  - Prichard PJ
FAU - Somerville, K W
AU  - Somerville KW
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol Suppl
JT  - Scandinavian journal of gastroenterology. Supplement
JID - 0437034
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Fatty Acids, Essential)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Linoleic Acids)
RN  - 0 (Plant Oils)
RN  - 0 (Prostaglandins E, Synthetic)
RN  - 3Q9L08K71N (evening primrose oil)
RN  - 78YC2MAX4O (gamma-Linolenic Acid)
RN  - 884KT10YB7 (Ranitidine)
RN  - 9KJL21T0QJ (Linoleic Acid)
RN  - J4IP5Z9DAU (Enprostil)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/analogs & derivatives
MH  - Cattle
MH  - Enprostil
MH  - *Fatty Acids, Essential
MH  - Fatty Acids, Unsaturated/therapeutic use
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Humans
MH  - Linoleic Acid
MH  - Linoleic Acids/therapeutic use
MH  - Lysine/administration & dosage/analogs & derivatives
MH  - Male
MH  - Milk
MH  - Oenothera biennis
MH  - Plant Oils
MH  - Prostaglandins E, Synthetic/therapeutic use
MH  - Ranitidine/therapeutic use
MH  - gamma-Linolenic Acid
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.3109/00365528609093834 [doi]
PST - ppublish
SO  - Scand J Gastroenterol Suppl. 1986;125:170-3. doi: 10.3109/00365528609093834.

PMID- 32739494
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1559-2030 (Electronic)
IS  - 1551-7144 (Print)
IS  - 1551-7144 (Linking)
VI  - 96
DP  - 2020 Sep
TI  - Cancer history and risk factors in healthy older people enrolling in the ASPREE 
      clinical trial.
PG  - 106095
LID - S1551-7144(20)30173-7 [pii]
LID - 10.1016/j.cct.2020.106095 [doi]
AB  - BACKGROUND: Cancer is a leading cause of death globally. Given the elevated risk 
      of cancer with age and an ageing population, it is important to understand the 
      changing burden of cancer in older populations. The ASPirin in Reducing Events in 
      the Elderly (ASPREE) study randomised healthy older individuals to 100 mg aspirin 
      or placebo, with clinical outcomes and disability-free survival endpoints. 
      Detailed baseline data provides a rare opportunity to explore cancer burden in a 
      uniquely healthy older population. METHODS: At study enrolment (2010-2014), 
      self-reported personal cancer history, cancer type and cancer risk factor data 
      were sought from 19,114 participants (Australia, n = 16,703; U.S., n = 2411). 
      Eligible participants were healthy, free of major diseases and expected to 
      survive 5 years. RESULTS: Nearly 20% of enrolling ASPREE participants reported a 
      prior cancer diagnosis; 18% of women and 22% of men, with women diagnosed younger 
      (16% vs 6% of diagnoses <50 years). Cancer prevalence increased with age. 
      Prevalence of prostate and breast cancer history were higher in U.S. 
      participants; melanoma and colorectal cancer were higher in Australian 
      participants. Cancer history prevalence was not associated with contemporary 
      common risk factors nor previous aspirin use, but was associated with poor health 
      ratings in men. Blood and breast cancer history were more common with past 
      aspirin use. CONCLUSIONS: Personal cancer history in healthy older ASPREE 
      participants was as expected for the most common cancer types in the respective 
      populations, but was not necessarily aligned with known risk factors. We 
      attribute this to survivor bias, likely driven by entry criteria. TRIAL 
      REGISTRATION: International Standard Randomised Controlled Trial Number Register 
      (ISRCTN83772183) and clinicaltrials.gov (NCT01038583).
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Orchard, Suzanne G
AU  - Orchard SG
AD  - Department of Epidemiology & Preventive Medicine, Monash University, 99 
      Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: 
      Suzanne.orchard@monash.edu.
FAU - Lockery, Jessica E
AU  - Lockery JE
AD  - Department of Epidemiology & Preventive Medicine, Monash University, 99 
      Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: 
      Jessica.lockery@monash.edu.
FAU - Gibbs, Peter
AU  - Gibbs P
AD  - The Walter & Eliza Hall Institute of Medical Research, University of Melbourne,1G 
      Royal Parade, Parkville, Victoria 3052, Australia. Electronic address: 
      Peter.gibbs@petermac.org.
FAU - Polekhina, Galina
AU  - Polekhina G
AD  - Department of Epidemiology & Preventive Medicine, Monash University, 99 
      Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: 
      Galhina.polekhina@monash.edu.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - Department of Epidemiology & Preventive Medicine, Monash University, 99 
      Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: 
      Rory.wolfe@monash.edu.
FAU - Zalcberg, John
AU  - Zalcberg J
AD  - Department of Epidemiology & Preventive Medicine, Monash University, 99 
      Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: 
      John.zalcberg@monash.edu.
FAU - Haydon, Andrew
AU  - Haydon A
AD  - Department of Epidemiology & Preventive Medicine, Monash University, 99 
      Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: 
      Andrew.haydon@monash.edu.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Department of Epidemiology & Preventive Medicine, Monash University, 99 
      Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: 
      John.mcneil@monash.edu.
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool St 
      (Private Bag 23), Hobart 7000, Tasmania, Australia. Electronic address: 
      Mark.nelson@utas.edu.au.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - School of Public Health, Curtin University, Kent Street, Bentley, Perth 6102, 
      Western Australia, Australia. Electronic address: Christpher.reid@curtin.edu.au.
FAU - Kirpach, Brenda
AU  - Kirpach B
AD  - Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute (HHRI), 701 Park Avenue, Suite PP7.700, Minneapolis 55415, Minnesota, 
      USA. Electronic address: bkirpach@bermancenter.org.
FAU - Murray, Anne M
AU  - Murray AM
AD  - Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute (HHRI), 701 Park Avenue, Suite PP7.700, Minneapolis 55415, Minnesota, 
      USA; Division of Geriatrics, Department of Medicine, Hennepin Healthcare and 
      University of Minnesota, East River Parkway, Minneapolis 55455, Minnesota, USA. 
      Electronic address: AMurray@bermancenter.org.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - Department of Epidemiology & Preventive Medicine, Monash University, 99 
      Commercial Road, Melbourne, Victoria 3004, Australia. Electronic address: 
      Robyn.woods@monash.edu.
CN  - ASPREE Investigator Group
LA  - eng
SI  - ClinicalTrials.gov/NCT01038583
SI  - ISRCTN/ISRCTN83772183
GR  - P30 AG024824/AG/NIA NIH HHS/United States
GR  - R01 CA137178/CA/NCI NIH HHS/United States
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U19 AG062682/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - United States
TA  - Contemp Clin Trials
JT  - Contemporary clinical trials
JID - 101242342
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Aspirin/therapeutic use
MH  - Australia
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - *Neoplasms/epidemiology
MH  - Risk Factors
PMC - PMC8009087
MID - NIHMS1677394
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer epidemiology
OT  - Cancer prevalence
OT  - Cancer risk factors
OT  - Selection criteria
OT  - Survivor bias
COIS- Declaration of Competing Interest The ASPREE trial was supported by a National 
      Institute on Aging grant (U01AG029824) with supplemental funding from the 
      National Cancer Institute at the National Institutes of Health (R01 CA137178), by 
      grants (334047 and 1127060) from the National Health and Medical Research Council 
      of Australia, and by Monash University and the Victorian Cancer Agency. These 
      sponsors did not contribute to study design, data collection, analysis, data 
      interpretation, manuscript writing or the decision to submit this article for 
      publication, however, representatives of the NIA sit on the International 
      Executive Committee in an advisory role. Mark Nelson received travel and 
      financial support to attend an advisory board meeting sponsored by Bayer AG, 
      which provided study medication for the ASPREE trial. Anne Murray and John McNeil 
      received travel and consulting fees to present published results from the ASPREE 
      study at a Bayer AG sponsored conference. All other authors declare that there 
      has been no financial or personal interest that has affected their objectivity.
EDAT- 2020/08/03 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/08/03 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/07/09 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/03 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/08/03 06:00 [entrez]
AID - S1551-7144(20)30173-7 [pii]
AID - 10.1016/j.cct.2020.106095 [doi]
PST - ppublish
SO  - Contemp Clin Trials. 2020 Sep;96:106095. doi: 10.1016/j.cct.2020.106095. Epub 
      2020 Jul 31.

PMID- 19712557
OWN - NLM
STAT- MEDLINE
DCOM- 20091109
LR  - 20190917
IS  - 1472-6491 (Electronic)
IS  - 1472-6483 (Linking)
VI  - 19
IP  - 2
DP  - 2009 Aug
TI  - Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose 
      enoxaparin and aspirin.
PG  - 216-20
AB  - The aim of this retrospective, observational study was to determine the impact of 
      low-dose enoxaparin (20 mg) in conjunction with low-dose aspirin on the pregnancy 
      outcome of women with antiphospholipid syndrome and recurrent miscarriage. The 
      study was conducted in a tertiary referral teaching hospital. A total of 35 women 
      with antiphospholipid syndrome were treated with low-dose enoxaparin and aspirin 
      as soon as pregnancy was confirmed. The outcome of pregnancy was analysed. The 
      miscarriage rate was 7/35 (20%) whereas the live birth rate was 28/35 (80%). In 
      conclusion, low-dose (20 mg) enoxaparin in conjunction with low-dose aspirin 
      treatment produced encouraging results. The findings in this study suggest that 
      there is a case for randomized controlled trials to compare low-dose (20 mg) 
      enoxaparin with higher doses.
FAU - Mo, David
AU  - Mo D
AD  - Faculty of Pharmaceutical Sciences, University of British Colombia, Vancouver, 
      Canada.
FAU - Saravelos, Sotiris
AU  - Saravelos S
FAU - Metwally, Mostafa
AU  - Metwally M
FAU - Makris, Mike
AU  - Makris M
FAU - Li, T C
AU  - Li TC
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Reprod Biomed Online
JT  - Reproductive biomedicine online
JID - 101122473
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abortion, Habitual
MH  - Adult
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Antiphospholipid Syndrome/*drug therapy/physiopathology
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Enoxaparin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Retrospective Studies
EDAT- 2009/08/29 09:00
MHDA- 2009/11/10 06:00
CRDT- 2009/08/29 09:00
PHST- 2009/08/29 09:00 [entrez]
PHST- 2009/08/29 09:00 [pubmed]
PHST- 2009/11/10 06:00 [medline]
AID - S1472-6483(10)60075-2 [pii]
AID - 10.1016/s1472-6483(10)60075-2 [doi]
PST - ppublish
SO  - Reprod Biomed Online. 2009 Aug;19(2):216-20. doi: 10.1016/s1472-6483(10)60075-2.

PMID- 6333365
OWN - NLM
STAT- MEDLINE
DCOM- 19841212
LR  - 20180216
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 30
IP  - 1
DP  - 1984
TI  - Aspirin-induced damage in the dog Heidenhain pouch and cytoprotection with 
      16,16-dimethyl PGE2.
PG  - 53-8
AB  - The gastric mucosa of animals and man can be damaged by noxious agents and 
      protected by prostaglandins. We developed a Heidenhain pouch dog model which 
      allows the study of multiple doses of the protective or noxious agent. Mucosal 
      damage in the pouch caused by instillation of 160 mM aspirin suspended in 150 mM 
      HCl for two 15-min periods was determined by measuring hemoglobin concentration 
      in isotonic mannitol washes. Hemoglobin levels 24 h after the administration of 
      the acid-aspirin suspension were significantly higher than basal levels. 
      Pretreatment with oral doses of 0.3-3 micrograms/kg 16,16-dimethyl PGE2 at 24 and 
      18 h and 30 min before the acid-aspirin suspension decreased hemoglobin 
      concentrations in the washes (p less than 0.001).
FAU - Reele, S B
AU  - Reele SB
FAU - Gumbleton, T J
AU  - Gumbleton TJ
FAU - Stryd, R P
AU  - Stryd RP
FAU - Brunden, M N
AU  - Brunden MN
FAU - Gilbertson, T J
AU  - Gilbertson TJ
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Prostaglandins E, Synthetic)
RN  - M790V82VAC (16,16-Dimethylprostaglandin E2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 16,16-Dimethylprostaglandin E2/*therapeutic use
MH  - Animals
MH  - Aspirin/pharmacology/*toxicity
MH  - Disease Models, Animal
MH  - Dogs
MH  - Female
MH  - Gastric Mucosa/drug effects
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Male
MH  - Prostaglandins E, Synthetic/*therapeutic use
MH  - Stomach/*physiology
MH  - Stomach Diseases/*chemically induced/prevention & control
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1159/000199091 [doi]
PST - ppublish
SO  - Digestion. 1984;30(1):53-8. doi: 10.1159/000199091.

PMID- 103067
OWN - NLM
STAT- MEDLINE
DCOM- 19790226
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 62
IP  - 5 Pt 2 Suppl
DP  - 1978 Nov
TI  - Analgesic sensitivity in children with asthma.
PG  - 910-5
AB  - First described as a component of a triad seen among adults with nonallergic 
      asthma and nasal polyps, aspirin sensitivity has subsequently been documented as 
      a frequent concomitant of a wide range of patients with chronic asthma. Recent 
      reports suggest that its incidence among children with asthma is higher than 
      previously suspected. Among aspirin-sensitive asthmatics, indomethacin and newer, 
      nonsteroid anti-inflammatory agents precipitate airway obstruction with a high 
      frequency while phenylbutazone has a lesser effect. Reports related to 
      acetaminophen among these patients have been inconsistent. Salicylic acid and 
      salicylamide appear to be tolerated. A correlation between the potential for 
      causing airway obstruction among asthmatic patients and the drug's in vitro 
      prostaglandin synthetase activity has been suggested, and elevation of plasma 
      histamine level at the time of the pulmonary reaction has been described. Aspirin 
      and other analgesics may therefore mediate bronchospasm by means of their effects 
      on prostaglandin production and the resultant effects on intracellular cyclic 
      nucleotide activity, which modulates histamine release from mast cells in lung 
      tissue.
FAU - Weinberger, M
AU  - Weinberger M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (Analgesics)
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/antagonists & inhibitors/therapeutic use
MH  - Adolescent
MH  - Airway Obstruction/*chemically induced
MH  - Analgesics/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/antagonists & inhibitors/therapeutic use
MH  - Asthma/*drug therapy/physiopathology
MH  - Child
MH  - Clinical Trials as Topic
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Maximal Midexpiratory Flow Rate
MH  - Placebos
MH  - Prostaglandin-Endoperoxide Synthases/pharmacology
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1978 Nov;62(5 Pt 2 Suppl):910-5.

PMID- 36354294
OWN - NLM
STAT- MEDLINE
DCOM- 20221207
LR  - 20230821
IS  - 2327-6924 (Electronic)
IS  - 2327-6886 (Linking)
VI  - 34
IP  - 12
DP  - 2022 Dec 1
TI  - Low-dose aspirin as primary prevention for adults without cardiovascular disease.
PG  - 1271-1277
LID - 10.1097/JXX.0000000000000792 [doi]
AB  - BACKGROUND: Cardiovascular disease is the leading cause of death in the United 
      States. Patients with cardiovascular disease risk factors are often put on 
      low-dose aspirin to prevent future cardiovascular events and cardiovascular 
      death. However, the evidence supporting this practice is limited. OBJECTIVE: To 
      examine whether adults without a history of cardiovascular disease benefit from 
      taking daily low-dose aspirin as primary prevention for cardiovascular disease 
      and death. DATA SOURCES: The four databases of PubMed, CINAHL, Scopus, and Ovid 
      were used, and a total of 67 nonduplicate articles were reviewed. After examining 
      those articles, four studies were included. Of the four studies, three were 
      randomized controlled trials, and one was a retrospective cohort study. 
      CONCLUSIONS: All four studies concluded that daily low-dose aspirin used for 
      primary prevention does not lower the risk of death from cardiovascular disease. 
      IMPLICATIONS FOR PRACTICE: Further research needs to be conducted to determine 
      whether daily low-dose aspirin is beneficial in individuals without a history of 
      cardiovascular disease. Nurse practitioners need to know the most current 
      evidence-based practice recommendations to appropriately counsel patients about 
      whether they should be taking low-dose aspirin to prevent cardiovascular disease.
CI  - Copyright © 2022 American Association of Nurse Practitioners.
FAU - Klausner, Shira
AU  - Klausner S
AD  - The University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania.
LA  - eng
PT  - Journal Article
DEP - 20221201
PL  - United States
TA  - J Am Assoc Nurse Pract
JT  - Journal of the American Association of Nurse Practitioners
JID - 101600770
RN  - R16CO5Y76E (Aspirin)
MH  - Adult
MH  - Humans
MH  - United States
MH  - *Cardiovascular Diseases/prevention & control/drug therapy
MH  - Primary Prevention
MH  - Retrospective Studies
MH  - Aspirin/therapeutic use
MH  - Randomized Controlled Trials as Topic
COIS- Competing interests: The author reports no conflicts of interest.
EDAT- 2022/11/11 06:00
MHDA- 2023/02/25 06:00
CRDT- 2022/11/10 08:42
PHST- 2022/07/26 00:00 [received]
PHST- 2022/09/15 00:00 [accepted]
PHST- 2022/11/11 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2022/11/10 08:42 [entrez]
AID - 01741002-202212000-00007 [pii]
AID - 10.1097/JXX.0000000000000792 [doi]
PST - epublish
SO  - J Am Assoc Nurse Pract. 2022 Dec 1;34(12):1271-1277. doi: 
      10.1097/JXX.0000000000000792.

PMID- 23531229
OWN - NLM
STAT- MEDLINE
DCOM- 20130628
LR  - 20211021
IS  - 1746-6148 (Electronic)
IS  - 1746-6148 (Linking)
VI  - 9
DP  - 2013 Mar 26
TI  - Synovial distribution of "systemically" administered acetylsalicylic acid in the 
      isolated perfused equine distal limb.
PG  - 56
LID - 10.1186/1746-6148-9-56 [doi]
AB  - BACKGROUND: This study investigated synovial concentrations of acetylsalicylic 
      acid (ASA) and its metabolite salicylic acid (SA) in the equine fetlock joint 
      following systemic administration of ASA. Salicylates were chosen because SA is 
      the only nonsteroidal anti-inflammatory drug for which threshold levels exist for 
      plasma and urine in equine sports. To avoid animal experiments, the study was 
      conducted using an ex vivo model of the isolated perfused equine distal limb in 
      combination with plasma concentrations obtained from literature.Salicylate 
      concentrations in the joint were determined using microdialysis and high 
      performance liquid chromatography (HPLC). Any anti-inflammatory effect of 
      synovial ASA concentrations was assessed using an ASA EC50 (half maximal 
      effective concentration) determined in equine whole blood. RESULTS: The ASA 
      concentration in the synovial fluid (n=6) reached a maximum of 4 μg/mL, the mean 
      concentration over the entire perfusion period was 2 μg/mL. Maximum SA 
      concentration was 17 μg/mL, the average was 14 μg/mL. ASA and SA concentration in 
      the synovial fluid exceeded systemic concentrations 2 h and 3.5 h after 
      "systemic" administration, respectively. CONCLUSIONS: ASA and SA accumulated in 
      the in the synovial fluid of the ex vivo model despite decreasing systemic 
      concentrations. This suggests a prolonged anti-inflammatory effect within the 
      joint that remains to be further elucidated.
FAU - Friebe, Maren
AU  - Friebe M
AD  - Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary 
      Medicine Hannover, Foundation, Bünteweg 17, Hannover, 30559, Germany. 
      maren.friebe@tiho-hannover.de
FAU - Schumacher, Stephan
AU  - Schumacher S
FAU - Stahl, Jessica
AU  - Stahl J
FAU - Kietzmann, Manfred
AU  - Kietzmann M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130326
PL  - England
TA  - BMC Vet Res
JT  - BMC veterinary research
JID - 101249759
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Intravenous/veterinary
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/analysis/*pharmacokinetics
MH  - Aspirin/administration & dosage/analysis/*pharmacokinetics
MH  - Chromatography, High Pressure Liquid/veterinary
MH  - Female
MH  - Hemoperfusion/veterinary
MH  - Hindlimb
MH  - Horses
MH  - Male
MH  - Microdialysis/veterinary
MH  - Salicylic Acid/analysis
MH  - Synovial Fluid/*chemistry
PMC - PMC3617046
EDAT- 2013/03/28 06:00
MHDA- 2013/07/03 06:00
CRDT- 2013/03/28 06:00
PHST- 2012/11/01 00:00 [received]
PHST- 2013/03/20 00:00 [accepted]
PHST- 2013/03/28 06:00 [entrez]
PHST- 2013/03/28 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - 1746-6148-9-56 [pii]
AID - 10.1186/1746-6148-9-56 [doi]
PST - epublish
SO  - BMC Vet Res. 2013 Mar 26;9:56. doi: 10.1186/1746-6148-9-56.

PMID- 36713415
OWN - NLM
STAT- MEDLINE
DCOM- 20230131
LR  - 20230202
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Current experimental methods to investigate the impact of specialized 
      pro-resolving lipid mediators on Sjögren's syndrome.
PG  - 1094278
LID - 10.3389/fimmu.2022.1094278 [doi]
LID - 1094278
AB  - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by 
      diminished secretory function of the exocrine glands. Although extensive 
      investigation has been done to understand Sjögren's syndrome, the causes of the 
      disease are as yet unknown and treatments remain largely ineffective, with 
      established therapeutic interventions being limited to use of saliva substitutes 
      with modest effectiveness. A primary feature of Sjögren's syndrome is 
      uncontrolled inflammation of exocrine tissues and previous studies have 
      demonstrated that lipid-based specialized pro-resolving mediators reduce 
      inflammation and restores tissue integrity in salivary glands. However, these 
      studies are limited to a single specialized pro-resolving lipid mediator's family 
      member resolvin D1 or RvD1 and its aspirin-triggered epimer, AT-RvD1. 
      Consequently, additional studies are needed to explore the potential benefits of 
      other members of the specialized pro-resolving lipid mediator's family and 
      related molecules (e.g., additional resolvin subtypes as well as lipoxins, 
      maresins and protectins). In support of this goal, the current review aims to 
      briefly describe the range of current experimental methods to investigate the 
      impact of specialized pro-resolving lipid mediators on Sjögren's syndrome, 
      including both strengths and weaknesses of each approach where this information 
      is known. With this article, the possibilities presented by specialized 
      pro-resolving lipid mediators will be introduced to a wider audience in 
      immunology and practical advice is given to researchers who may wish to take up 
      this work.
CI  - Copyright © 2023 dos Santos, Nam, Gil, Yellepeddi and Baker.
FAU - Dos Santos, Harim T
AU  - Dos Santos HT
AD  - Bond Life Sciences Center, University of Missouri, Columbia, MO, United States.
AD  - Department of Otolaryngology-Head and Neck Surgery, School of Medicine, 
      University of Missouri, Columbia, MO, United States.
FAU - Nam, Kihoon
AU  - Nam K
AD  - Bond Life Sciences Center, University of Missouri, Columbia, MO, United States.
AD  - Department of Otolaryngology-Head and Neck Surgery, School of Medicine, 
      University of Missouri, Columbia, MO, United States.
FAU - Gil, Diana
AU  - Gil D
AD  - Department of Surgery, School of Medicine, University of Missouri, Columbia, MO, 
      United States.
AD  - Department of Molecular Microbiology and Immunology, School of Medicine, 
      University of Missouri, Columbia, MO, United States.
AD  - Department of Biological and Biomedical Engineering, College of Engineering, 
      University of Missouri, Columbia, MO, United States.
FAU - Yellepeddi, Venkata
AU  - Yellepeddi V
AD  - Division of Clinical Pharmacology, Department of Pediatrics, School of Medicine, 
      University of Utah, Salt Lake City, UT, United States.
AD  - Department of Molecular Pharmaceutics, College of Pharmacy, University of Utah, 
      Salt Lake City, UT, United States.
FAU - Baker, Olga J
AU  - Baker OJ
AD  - Bond Life Sciences Center, University of Missouri, Columbia, MO, United States.
AD  - Department of Otolaryngology-Head and Neck Surgery, School of Medicine, 
      University of Missouri, Columbia, MO, United States.
AD  - Department of Biochemistry, University of Missouri, Columbia, MO, United States.
LA  - eng
GR  - R01 DE022971/DE/NIDCR NIH HHS/United States
GR  - R01 DE027884/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20230112
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Lipids)
SB  - IM
MH  - Humans
MH  - *Sjogren's Syndrome
MH  - Salivary Glands
MH  - Inflammation
MH  - Aspirin/therapeutic use
MH  - Lipids/therapeutic use
PMC - PMC9878840
OTO - NOTNLM
OT  - cultures
OT  - immunology
OT  - mathematical modeling
OT  - mice
OT  - resolvins
OT  - saliva
OT  - salivary glands
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/31 06:00
MHDA- 2023/02/01 06:00
CRDT- 2023/01/30 04:15
PHST- 2022/11/09 00:00 [received]
PHST- 2022/12/27 00:00 [accepted]
PHST- 2023/01/30 04:15 [entrez]
PHST- 2023/01/31 06:00 [pubmed]
PHST- 2023/02/01 06:00 [medline]
AID - 10.3389/fimmu.2022.1094278 [doi]
PST - epublish
SO  - Front Immunol. 2023 Jan 12;13:1094278. doi: 10.3389/fimmu.2022.1094278. 
      eCollection 2022.

PMID- 626106
OWN - NLM
STAT- MEDLINE
DCOM- 19780417
LR  - 20190812
IS  - 0001-6101 (Print)
IS  - 0001-6101 (Linking)
VI  - 203
IP  - 1-2
DP  - 1978
TI  - Absorption and elimination of D-propoxyphene, acetyl salicylic acid, and 
      phenazone in a combination tablet (Doleron): comparison between young and elderly 
      subjects.
PG  - 121-4
AB  - The single-dose kinetics of D-propoxyphene, acetyl salicylic acid and phenazone, 
      given in a combination tablet (Doleron), were compared in young and elderly 
      subjects. Serial blood samples were taken 0--48 hours after administration. The 
      plasma concentrations of propoxyphene and of its major metabolite, 
      norporpoxyphene, were assessed by mass fragmentography, those of phenazone by gas 
      chromatography, and those of acetyl salicylic acid plus salicylic acid by 
      spectrofluorometry. Neither for propoxyphene, norpropoxyphene, acetyl salicylic 
      acid nor phenazone did the areas under the concentration curves or the 
      elimination half-lives differ between young and elderly subjects. These data do 
      not provide pharmacokinetic support for a general reduction of the Doleron dosage 
      in elderly subjects.
FAU - Melander, A
AU  - Melander A
FAU - Bodin, N O
AU  - Bodin NO
FAU - Danielson, K
AU  - Danielson K
FAU - Gustafsson, B
AU  - Gustafsson B
FAU - Haglund, G
AU  - Haglund G
FAU - Westerlund, D
AU  - Westerlund D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Sweden
TA  - Acta Med Scand
JT  - Acta medica Scandinavica
JID - 0370330
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
RN  - T3CHA1B51H (Antipyrine)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Antipyrine/administration & dosage/*metabolism
MH  - Aspirin/administration & dosage/*metabolism
MH  - Dextropropoxyphene/administration & dosage/*metabolism
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Tablets
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1111/j.0954-6820.1978.tb14841.x [doi]
PST - ppublish
SO  - Acta Med Scand. 1978;203(1-2):121-4. doi: 10.1111/j.0954-6820.1978.tb14841.x.

PMID- 3662653
OWN - NLM
STAT- MEDLINE
DCOM- 19871112
LR  - 20190503
IS  - 0003-4967 (Print)
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 46
IP  - 8
DP  - 1987 Aug
TI  - Serum salicylate levels in a breast fed infant.
PG  - 638-9
AB  - All drugs should be given with caution to pregnant or breast feeding women. 
      Recent concern about the role of salicylates in the aetiology of Reye's syndrome 
      has prompted the DHSS to restrict the use of aspirin in children. The case of a 9 
      week old breast fed infant whose serum contained 0.47 mmol/l of salicylate is 
      reported. Her mother was taking aspirin 2.4 g/day, and it is concluded that 
      salicylates must not be taken by breast feeding mothers.
FAU - Unsworth, J
AU  - Unsworth J
AD  - Department of Rheumatology, Medical School, University of Birmingham.
FAU - d'Assis-Fonseca, A
AU  - d'Assis-Fonseca A
FAU - Beswick, D T
AU  - Beswick DT
FAU - Blake, D R
AU  - Blake DR
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arthritis, Juvenile/drug therapy
MH  - Aspirin/metabolism/therapeutic use
MH  - *Breast Feeding
MH  - Female
MH  - Humans
MH  - Infant
MH  - Milk, Human/metabolism
MH  - Pregnancy
MH  - Salicylates/*blood
MH  - Salicylic Acid
PMC - PMC1002216
EDAT- 1987/08/01 00:00
MHDA- 1987/08/01 00:01
CRDT- 1987/08/01 00:00
PHST- 1987/08/01 00:00 [pubmed]
PHST- 1987/08/01 00:01 [medline]
PHST- 1987/08/01 00:00 [entrez]
AID - 10.1136/ard.46.8.638 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 1987 Aug;46(8):638-9. doi: 10.1136/ard.46.8.638.

PMID- 35393614
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20230215
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 43
IP  - 21
DP  - 2022 Jun 1
TI  - Effects of aspirin on dementia and cognitive function in diabetic patients: the 
      ASCEND trial.
PG  - 2010-2019
LID - 10.1093/eurheartj/ehac179 [doi]
AB  - AIMS: Aspirin is widely used in cardiovascular disease prevention but is also 
      associated with an increased risk of bleeding. The net effect of aspirin on 
      dementia and cognitive impairment is uncertain. METHODS AND RESULTS: In the 
      ASCEND trial, 15 480 people from the UK with diabetes and no history of 
      cardiovascular disease were randomized to aspirin 100 mg daily or matching 
      placebo for a mean of 7.4 years. The 15 427 ASCEND participants with no recorded 
      dementia prior to baseline were included in this cognitive study with a primary 
      pre-specified outcome of 'broad dementia', comprising dementia, cognitive 
      impairment, or confusion. This was ascertained through participant, carer, or 
      general practitioner report or hospital admission diagnosis, by 31 March 2019 (∼2 
      years beyond the scheduled treatment period). The broad dementia outcome occurred 
      in a similar percentage of participants in the aspirin group and placebo group: 
      548 participants (7.1%) vs. 598 (7.8%), rate ratio 0.91 [95% confidence interval 
      (CI), 0.81-1.02]. Thus, the CI excluded proportional hazards of >2% and 
      proportional benefits of >19%. CONCLUSION: Aspirin does not have a large 
      proportional effect on the risk of dementia. Trials or meta-analyses with larger 
      total numbers of incident dementia cases to increase statistical power are needed 
      to assess whether any modest proportional 10-15% benefits of 5-7 years of aspirin 
      use on dementia exist. CLINICAL TRIAL REGISTRATION: Current Controlled Trials 
      number, ISRCTN60635500; ClinicalTrials.gov number: NCT00135226.
CI  - © The Author(s) 2022. Published by Oxford University Press on behalf of European 
      Society of Cardiology.
FAU - Parish, Sarah
AU  - Parish S
AUID- ORCID: 0000-0003-3532-0832
AD  - MRC Population Health Research Unit, Nuffield Department of Population Health, 
      University of Oxford, Big Data Institute, Old Road Campus, Roosevelt Drive, 
      Oxford OX3 7LF, UK.
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Mafham, Marion
AU  - Mafham M
AUID- ORCID: 0000-0003-0562-3963
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Offer, Alison
AU  - Offer A
AUID- ORCID: 0000-0002-3367-3207
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Barton, Jill
AU  - Barton J
AUID- ORCID: 0000-0002-6534-6307
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Wallendszus, Karl
AU  - Wallendszus K
AUID- ORCID: 0000-0003-0971-3026
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Stevens, William
AU  - Stevens W
AUID- ORCID: 0000-0001-8474-4645
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Buck, Georgina
AU  - Buck G
AUID- ORCID: 0000-0001-5909-4265
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Haynes, Richard
AU  - Haynes R
AUID- ORCID: 0000-0002-1179-0023
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Collins, Rory
AU  - Collins R
AUID- ORCID: 0000-0001-8288-8602
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Bowman, Louise
AU  - Bowman L
AUID- ORCID: 0000-0003-1125-8616
AD  - MRC Population Health Research Unit, Nuffield Department of Population Health, 
      University of Oxford, Big Data Institute, Old Road Campus, Roosevelt Drive, 
      Oxford OX3 7LF, UK.
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Armitage, Jane
AU  - Armitage J
AUID- ORCID: 0000-0001-8691-9226
AD  - MRC Population Health Research Unit, Nuffield Department of Population Health, 
      University of Oxford, Big Data Institute, Old Road Campus, Roosevelt Drive, 
      Oxford OX3 7LF, UK.
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT00135226
SI  - ISRCTN/ISRCTN60635500
GR  - SP/03/002/BHF_/British Heart Foundation/United Kingdom
GR  - G0300622/MRC_/Medical Research Council/United Kingdom
GR  - MC_PC_12027/MRC_/Medical Research Council/United Kingdom
GR  - MC-UU_00017/3/MRC_/Medical Research Council/United Kingdom
GR  - SP/14/3/31114/BHF_/British Heart Foundation/United Kingdom
GR  - CH/1996001/9454/BHF_/British Heart Foundation/United Kingdom
GR  - MC_U137686854/MRC_/Medical Research Council/United Kingdom
GR  - MC_EX_G0801669/MRC_/Medical Research Council/United Kingdom
GR  - CRUK_/Cancer Research UK/United Kingdom
GR  - MC-UU_00017/5/MRC_/Medical Research Council/United Kingdom
GR  - MC_PC_12028/MRC_/Medical Research Council/United Kingdom
GR  - MC_PC_15067/MRC_/Medical Research Council/United Kingdom
GR  - MC_PC_12029/MRC_/Medical Research Council/United Kingdom
GR  - SP/08/010/25939/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2022 Apr 22;:. PMID: 35452114
MH  - Aspirin/therapeutic use
MH  - Cognition
MH  - *Cognitive Dysfunction
MH  - *Dementia/prevention & control
MH  - *Diabetes Mellitus/drug therapy
MH  - Humans
PMC - PMC9242621
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Dementia
EDAT- 2022/04/09 06:00
MHDA- 2022/06/03 06:00
CRDT- 2022/04/08 05:32
PHST- 2021/10/17 00:00 [received]
PHST- 2022/02/22 00:00 [revised]
PHST- 2022/03/22 00:00 [accepted]
PHST- 2022/04/09 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
PHST- 2022/04/08 05:32 [entrez]
AID - 6565186 [pii]
AID - ehac179 [pii]
AID - 10.1093/eurheartj/ehac179 [doi]
PST - ppublish
SO  - Eur Heart J. 2022 Jun 1;43(21):2010-2019. doi: 10.1093/eurheartj/ehac179.

PMID- 23482543
OWN - NLM
STAT- MEDLINE
DCOM- 20130830
LR  - 20161021
IS  - 1758-1125 (Electronic)
IS  - 0268-3555 (Linking)
VI  - 28 Suppl 1
DP  - 2013 Mar
TI  - Aspirin and recurrent venous thromboembolism.
PG  - 99-104
LID - 10.1177/0268355512475040 [doi]
AB  - While there is conclusive evidence that aspirin plays a role in reducing the risk 
      of clinically relevant venous thromboembolism (VTE) arising in a number of 
      surgical and non-surgical situations at risk, little is known of the potential of 
      aspirin for the long/term prevention of recurrent VTE. In two recent multicentre, 
      double-blind studies (WARFASA and ASPIRE), the efficacy and safety of a low dose 
      of aspirin (100 mg per day) were assessed in patients with unprovoked VTE who had 
      completed an initial period of conventional treatment with vitamin K antagonists. 
      The two studies used identical aspirin regimens and had similar enrollment 
      criteria and outcome measures. When data from these two trials were pooled, there 
      was a 32% reduction in the rate of recurrence of VTE (hazard ratio [HR], 0.68; 
      95% confidence interval [CI], 0.51-0.90) and a 34% reduction in the rate of major 
      vascular events (HR, 0.66; 95% CI, 0.51-0.86). Moreover, these benefits were 
      achieved with a low risk of bleeding. As patients with previous symptomatic 
      atherosclerosis were not enrolled in these two studies, whether these results 
      apply also to this category of patients is uncertain. We recently had the 
      opportunity to review the clinical charts of 1919 consecutive patients presented 
      with a first episode of VTE, which was either unprovoked or triggered by 
      transient risk factors, and were followed up for an average period of four years 
      after discontinuing anticoagulation. The rate of recurrent VTE in the 256 
      patients with a history of symptomatic atherosclerosis who had been given 80-160 
      mg of aspirin once daily (17.2%) did not differ from that (19.9%) observed in 
      those without atherosclerosis who were left without any antithrombotic 
      treatments. The implication of this observation is that whenever patients with 
      symptomatic atherosclerosis are deemed to require long-term protection against 
      recurrent VTE, they are unlikely to benefit from (resuming) aspirin. Conversely, 
      aspirin in low doses offers an appealing, safe and highly cost-effective option 
      for the long-term prevention of recurrent events in patients with unprovoked VTE 
      who are free from symptomatic atherosclerotic lesions.
FAU - Prandoni, P
AU  - Prandoni P
AD  - Department of Cardiothoracic and Vascular Sciences, Clinica Medica 2, Via 
      Giustiniani 2, 35128 Padua, Italy. paoloprandoni@tin.it
FAU - Noventa, F
AU  - Noventa F
FAU - Milan, M
AU  - Milan M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Phlebology
JT  - Phlebology
JID - 9012921
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Patient Selection
MH  - Risk Assessment
MH  - Risk Factors
MH  - Secondary Prevention/*methods
MH  - Treatment Outcome
MH  - Venous Thromboembolism/*prevention & control
EDAT- 2013/03/27 06:00
MHDA- 2013/08/31 06:00
CRDT- 2013/03/14 06:00
PHST- 2013/03/14 06:00 [entrez]
PHST- 2013/03/27 06:00 [pubmed]
PHST- 2013/08/31 06:00 [medline]
AID - 28/suppl_1/99 [pii]
AID - 10.1177/0268355512475040 [doi]
PST - ppublish
SO  - Phlebology. 2013 Mar;28 Suppl 1:99-104. doi: 10.1177/0268355512475040.

PMID- 22632754
OWN - NLM
STAT- MEDLINE
DCOM- 20130116
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 18
IP  - 26
DP  - 2012
TI  - Non-aspirin non-steroidal anti-inflammatory drugs for the primary chemoprevention 
      of non-gastrointestinal cancer: summary of evidence.
PG  - 4047-70
AB  - BACKGROUND: There is evidence that aspirin is effective for the chemoprevention 
      of colorectal cancer. Due to their similar pharmacodynamics, the use of other 
      non-steroidal anti-inflammatory drugs (NSAIDs) has been suggested for other 
      cancer sites. Although this possibility has been discussed in the literature, 
      uncertainty remains about the actual effects of NSAIDs other than aspirin in 
      nongastrointestinal cancer. OBJECTIVE: To summarize the best available evidence 
      of the primary chemopreventive effects of non-aspirin NSAIDs for 
      nongastrointestinal cancer. METHODS: Our inclusion criteria were narrative or 
      systematic reviews, clinical guidelines and, if they had not been previously 
      included, primary controlled studies that evaluated the effectiveness of 
      non-aspirin NSAIDs in preventing non-gastrointestinal cancer in healthy 
      individuals. Studies were retrieved from the following databases: Guidelines.gov, 
      BMJ Clinical Evidence, TRIP database, UpToDate, MEDLINE, CANCERLIT, Embase, 
      CINAHL, ISI Web of Science and Scopus. Two independent reviewers selected 
      eligible studies. Data were extracted by one reviewer and crosschecked by two 
      others. RESULTS: We found 9,984 non-duplicated articles and included 56 eligible 
      studies. Most of these studies were observational. The studies reported 
      conflicting results or no statistically significant associations between the use 
      of non-aspirin NSAIDs and risk of lung, ovary, bladder, prostate, skin, and head 
      and neck cancers. In contrast, an increased risk of renal cell carcinoma and a 
      reduced risk of breast cancer were found to be statistically significant. The 
      included studies had methodological limitations, which reduces our confidence in 
      their results. CONCLUSIONS: We did not find sufficient evidence to support the 
      use of the non-aspirin NSAIDs for the primary chemoprevention of a wide variety 
      of non-gastrointestinal cancers. This scenario suggests caution when considering 
      the routine use of non-aspirin NSAIDs. Additional well-conducted controlled 
      studies may provide more conclusive evidence on this issue, but there are 
      concerns about the risks of such exposure.
FAU - Silva, Marcus Tolentino
AU  - Silva MT
AD  - University of Brasilia, Faculty of Medicine, Brasilia, DF, Brazil. 
      marcusts@gmail.com
FAU - Galvao, Tais Freire
AU  - Galvao TF
FAU - Zimmerman, Ivan Ricardo
AU  - Zimmerman IR
FAU - Pereira, Mauricio Gomes
AU  - Pereira MG
FAU - Lopes, Luciane Cruz
AU  - Lopes LC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Chemoprevention/*methods
MH  - Colorectal Neoplasms/pathology/prevention & control
MH  - Humans
MH  - Neoplasms/pathology/*prevention & control
MH  - Primary Prevention/methods
MH  - Risk
EDAT- 2012/05/29 06:00
MHDA- 2013/01/17 06:00
CRDT- 2012/05/29 06:00
PHST- 2012/03/12 00:00 [received]
PHST- 2012/03/21 00:00 [accepted]
PHST- 2012/05/29 06:00 [entrez]
PHST- 2012/05/29 06:00 [pubmed]
PHST- 2013/01/17 06:00 [medline]
AID - CPD-EPUB-20120522-16 [pii]
AID - 10.2174/138161212802083699 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2012;18(26):4047-70. doi: 10.2174/138161212802083699.

PMID- 15504197
OWN - NLM
STAT- MEDLINE
DCOM- 20050207
LR  - 20181130
IS  - 0001-5172 (Print)
IS  - 0001-5172 (Linking)
VI  - 48
IP  - 10
DP  - 2004 Nov
TI  - Fluid resuscitation from severe hemorrhagic shock using diaspirin cross-linked 
      hemoglobin fails to improve pancreatic and renal perfusion.
PG  - 1328-37
AB  - BACKGROUND: Fluid resuscitation from hemorrhagic shock is intended to abolish 
      microcirculatory disorders and to restore adequate tissue oxygenation. Diaspirin 
      cross-linked hemoglobin (DCLHb) is a hemoglobin-based oxygen carrier (HBOC) with 
      vasoconstrictive properties. Therefore, fluid resuscitation from severe 
      hemorrhagic shock using DCLHb was expected to improve perfusion pressure and 
      tissue perfusion of kidneys and pancreas. METHODS: In 20 anesthetized domestic 
      pigs with an experimentally induced coronary stenosis, shock (mean arterial 
      pressure 45 mmHg) was induced by controlled withdrawal of blood and maintained 
      for 60 min. Fluid resuscitation (replacement of the plasma volume withdrawn 
      during hemorrhage) was performed with either 10% DCLHb (DCLHb group, n = 10) or 
      8% human serum albumin (HSA) oncotically matched to DCLHb (HSA group, n = 10). 
      Completion of resuscitation was followed by a 60-min observation period. Regional 
      blood flow to the kidneys and the pancreas was measured by use of the radioactive 
      microspheres method at baseline, after shock and 60 min after fluid 
      resuscitation. RESULTS: All animals (10/10) resuscitated with DCLHb survived the 
      60-min observation period, while 5/10 control animals died within 20 min due to 
      persisting subendocardial ischemia. In contrast to HSA survivors, pancreas and 
      kidneys of DCLHb-treated animals revealed lower total and regional organ 
      perfusion and regional oxygen delivery. Renal and pancreatic blood flow 
      heterogeneity was higher in the DCLHb group. CONCLUSION: DCLHb-induced 
      vasoconstriction afforded superior myocardial perfusion, but impaired regional 
      perfusion of the kidneys and the pancreas.
FAU - Pape, A
AU  - Pape A
AD  - Clinic of Anaesthesiology, Intensive Care and Pain Management, Johann Wolfgang 
      Goethe-University, Frankfurt/Main, Germany. a.pape@em.uni-frankfurt.de
FAU - Kleen, M
AU  - Kleen M
FAU - Kemming, G
AU  - Kemming G
FAU - Meisner, F
AU  - Meisner F
FAU - Meier, J
AU  - Meier J
FAU - Habler, O
AU  - Habler O
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Acta Anaesthesiol Scand
JT  - Acta anaesthesiologica Scandinavica
JID - 0370270
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Serum Albumin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - Female
MH  - *Fluid Therapy
MH  - Hemoglobins/*therapeutic use
MH  - Male
MH  - Microspheres
MH  - Pancreas/*blood supply
MH  - Regional Blood Flow/drug effects
MH  - Renal Circulation/*drug effects
MH  - Resuscitation
MH  - Serum Albumin/therapeutic use
MH  - Shock, Hemorrhagic/*physiopathology/*therapy
MH  - Swine
EDAT- 2004/10/27 09:00
MHDA- 2005/02/08 09:00
CRDT- 2004/10/27 09:00
PHST- 2004/10/27 09:00 [pubmed]
PHST- 2005/02/08 09:00 [medline]
PHST- 2004/10/27 09:00 [entrez]
AID - AAS475 [pii]
AID - 10.1111/j.1399-6576.2004.00475.x [doi]
PST - ppublish
SO  - Acta Anaesthesiol Scand. 2004 Nov;48(10):1328-37. doi: 
      10.1111/j.1399-6576.2004.00475.x.

PMID- 30095728
OWN - NLM
STAT- MEDLINE
DCOM- 20200327
LR  - 20200327
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
VI  - 37
IP  - 2
DP  - 2019 Feb
TI  - Evaluation of the antihypertensive effect of nocturnal administration of 
      acetylsalicylic acid: a cross-over randomized clinical trial.
PG  - 406-414
LID - 10.1097/HJH.0000000000001887 [doi]
AB  - OBJECTIVE: Several studies have shown that evening intake of aspirin has 
      antihypertensive effect in healthy adults, which has not been proven in patients 
      with cardiovascular disease, who mostly take aspirin in the morning. We have 
      evaluated the antihypertensive effect of bedtime administration of aspirin in 
      patients with cardiovascular disease already treated for hypertension. METHODS: 
      This is a multicenter randomized triple-blind placebo-controlled crossover trial, 
      with hypertensive patients treated with aspirin for secondary prevention. There 
      was a baseline-randomized assignment to 2-month periods of bedtime aspirin 
      (100 mg) first and morning-time aspirin later, or inversely, both periods 
      separated by an open label 2-4 weeks period of morning-time aspirin. At the start 
      and end of each treatment period, a 24-h ambulatory blood pressure monitoring was 
      performed. The main outcome measure was mean 24-h blood pressure. The analyses 
      were performed according to the intention-to-treat principle. RESULTS: Overall, 
      225 patients were randomized. No significant differences were observed in 
      ambulatory blood pressure by time of intake of usual low doses of aspirin. The 
      mean SBP/DBP was 123.2/69.9 (95% CI 121.58-124.9/68.86-76.86) with bedtime 
      administration and 122.4/68.8 (95% CI 120.76-124.01/67.85-69.83) with daytime 
      administration (P = 0.3 and P = 0.23 for SBP and DBP, respectively). CONCLUSION: 
      Administering aspirin at bedtime rather than in the morning does not modify the 
      24-h ambulatory blood pressure in hypertensive patients in secondary 
      cardiovascular prevention.The trial was registered with ClinicalTrials.gov 
      (number NCT01741922).
FAU - Ruiz Arzalluz, Maria Victoria
AU  - Ruiz Arzalluz MV
AD  - Primary Care Research Unit of Bizkaia, BioCruces Health Research Institute, 
      Bilbao.
AD  - Tolosaldea Health Region, Basque Health Service (Osakidetza).
FAU - Burgos-Alonso, Natalia
AU  - Burgos-Alonso N
AD  - Primary Care Research Unit of Bizkaia, BioCruces Health Research Institute, 
      Bilbao.
AD  - Preventive Medicine and Public Health Department, Faculty of Medicine and 
      Odontology, University of the Basque Country, UPV/EHU, Bilbao, Spain.
FAU - Garcia-Alvarez, Arturo
AU  - Garcia-Alvarez A
AD  - Primary Care Research Unit of Bizkaia, BioCruces Health Research Institute, 
      Bilbao.
FAU - Gomez Fernandez, Maria Cruz
AU  - Gomez Fernandez MC
AD  - Primary Care Research Unit of Bizkaia, BioCruces Health Research Institute, 
      Bilbao.
FAU - Vinyoles, Ernest
AU  - Vinyoles E
AD  - InstitutUniversitarid'Investigació en AtencióPrimària Jordi Gol Foundation (IDIAP 
      Jordi Gol) Barcelona.
FAU - Grandes, Gonzalo
AU  - Grandes G
AD  - Primary Care Research Unit of Bizkaia, BioCruces Health Research Institute, 
      Bilbao.
CN  - TAHPS Group
LA  - eng
SI  - ClinicalTrials.gov/NCT01741922
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Blood Pressure Monitoring, Ambulatory
MH  - Cardiovascular Diseases/complications/drug therapy/prevention & control
MH  - Cross-Over Studies
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Hypertension/drug therapy/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Secondary Prevention
EDAT- 2018/08/11 06:00
MHDA- 2020/03/28 06:00
CRDT- 2018/08/11 06:00
PHST- 2018/08/11 06:00 [pubmed]
PHST- 2020/03/28 06:00 [medline]
PHST- 2018/08/11 06:00 [entrez]
AID - 10.1097/HJH.0000000000001887 [doi]
PST - ppublish
SO  - J Hypertens. 2019 Feb;37(2):406-414. doi: 10.1097/HJH.0000000000001887.

PMID- 20150346
OWN - NLM
STAT- MEDLINE
DCOM- 20100318
LR  - 20220321
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 104
IP  - 3
DP  - 2010 Mar
TI  - To continue or discontinue aspirin in the perioperative period: a randomized, 
      controlled clinical trial.
PG  - 305-12
LID - 10.1093/bja/aeq003 [doi]
AB  - BACKGROUND: Major adverse cardiac events (MACEs) are a common cause of death 
      after non-cardiac surgery. Despite evidence for the benefit of aspirin for 
      secondary prevention, it is often discontinued in the perioperative period due to 
      the risk of bleeding. METHODS: We conducted a randomized, double-blind, 
      placebo-controlled trial in order to compare the effect of low-dose aspirin with 
      that of placebo on myocardial damage, cardiovascular, and bleeding complications 
      in high-risk patients undergoing non-cardiac surgery. Aspirin (75 mg) or placebo 
      was given 7 days before surgery and continued until the third postoperative day. 
      Patients were followed up for 30 days after surgery. RESULTS: A total of 220 
      patients were enrolled, 109 patients received aspirin and 111 received placebo. 
      Four patients (3.7%) in the aspirin group and 10 patients (9.0%) in the placebo 
      group had elevated troponin T levels in the postoperative period (P=0.10). Twelve 
      patients (5.4%) had an MACE during the first 30 postoperative days. Two of these 
      patients (1.8%) were in the aspirin group and 10 patients (9.0%) were in the 
      placebo group (P=0.02). Treatment with aspirin resulted in a 7.2% absolute risk 
      reduction [95% confidence interval (CI), 1.3-13%] for postoperative MACE. The 
      relative risk reduction was 80% (95% CI, 9.2-95%). Numbers needed to treat were 
      14 (95% CI, 7.6-78). No significant differences in bleeding complications were 
      seen between the two groups. CONCLUSIONS: In high-risk patients undergoing 
      non-cardiac surgery, perioperative aspirin reduced the risk of MACE without 
      increasing bleeding complications. However, the study was not powered to evaluate 
      bleeding complications.
FAU - Oscarsson, A
AU  - Oscarsson A
AD  - Division of Anaesthesiology, Department of Medical and Health Sciences, Linköping 
      University, Linkoping, Sweden. anna.oscarsson.tibblin@lio.se
FAU - Gupta, A
AU  - Gupta A
FAU - Fredrikson, M
AU  - Fredrikson M
FAU - Järhult, J
AU  - Järhult J
FAU - Nyström, M
AU  - Nyström M
FAU - Pettersson, E
AU  - Pettersson E
FAU - Darvish, B
AU  - Darvish B
FAU - Krook, H
AU  - Krook H
FAU - Swahn, E
AU  - Swahn E
FAU - Eintrei, C
AU  - Eintrei C
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Loss, Surgical
MH  - Cardiovascular Diseases/*prevention & control
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Perioperative Care/*methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Complications/*prevention & control
MH  - Postoperative Hemorrhage/chemically induced
EDAT- 2010/02/13 06:00
MHDA- 2010/03/20 06:00
CRDT- 2010/02/13 06:00
PHST- 2010/02/13 06:00 [entrez]
PHST- 2010/02/13 06:00 [pubmed]
PHST- 2010/03/20 06:00 [medline]
AID - S0007-0912(17)33677-2 [pii]
AID - 10.1093/bja/aeq003 [doi]
PST - ppublish
SO  - Br J Anaesth. 2010 Mar;104(3):305-12. doi: 10.1093/bja/aeq003.

PMID- 19213571
OWN - NLM
STAT- MEDLINE
DCOM- 20090305
LR  - 20190907
IS  - 0080-0015 (Print)
IS  - 0080-0015 (Linking)
VI  - 181
DP  - 2009
TI  - Pharmacologic effects of NSAIDs and implications for the risks and benefits of 
      long-term prophylactic use of aspirin to prevent cancer.
PG  - 215-21
AB  - This paper briefly reviews the pharmacologic effects of nonsteroidal 
      antiinflammatory drugs (NSAIDs) that influence the risks and benefits of using 
      these drugs prophylactically for cancer. It describes the metabolism of 
      arachidonic acid through the cyclooxygenase (COX) pathway, the physiologic 
      functions ofprostanoids (prostaglandins, prostacyclin, and thromboxane A2) 
      produced by this pathway, and the pharmacologic consequences of blocking the 
      enzymatic activity of the two COX isoforms. We mention other proposed mechanisms 
      by which NSAIDs may directly or indirectly affect non-COX pathways. The diverse 
      pharmacologic effects of NSAIDs, when combined with the relatively low 
      probability that an individual with average risk will develop any single type of 
      cancer over a lifetime, severely limit the tolerance for toxicity if aspirin or 
      related drugs are to be administered prophylactically to large numbers of 
      otherwise healthy people. Further research is needed to identify a drug, dose, 
      treatment regimen, and patient population(s) where the benefits of prophy- lactic 
      treatment will exceed the risks. A singular advantage of aspirin over all other 
      NSAIDs is the potential to combine reduced risk of certain cancers with 
      cardiovascular benefit. However, many elements that are needed to achieve this 
      remain unresolved.
FAU - Thun, Michael J
AU  - Thun MJ
AD  - Epidemiology and Surveillance Research, American Cancer Society, NW, Atlanta, GA 
      30303-1002, USA. mthun@cancer.org
FAU - Blackard, Bonny
AU  - Blackard B
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Recent Results Cancer Res
JT  - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans 
      les recherches sur le cancer
JID - 0044671
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Neoplasms/*prevention & control
MH  - Risk Factors
MH  - Time Factors
RF  - 9
EDAT- 2009/02/14 09:00
MHDA- 2009/03/06 09:00
CRDT- 2009/02/14 09:00
PHST- 2009/02/14 09:00 [entrez]
PHST- 2009/02/14 09:00 [pubmed]
PHST- 2009/03/06 09:00 [medline]
AID - 10.1007/978-3-540-69297-3_20 [doi]
PST - ppublish
SO  - Recent Results Cancer Res. 2009;181:215-21. doi: 10.1007/978-3-540-69297-3_20.

PMID- 856612
OWN - NLM
STAT- MEDLINE
DCOM- 19770622
LR  - 20190623
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 42
IP  - 4
DP  - 1977 Apr 21
TI  - Aspects of the spasmogenic effects of acetate esters on ileal smooth muscle.
PG  - 347-54
AB  - Acetate esters, such as aspirin methylester, aspirin and resorcinol monoacetate, 
      induced contractions of guinea-pig ileum. Their actions were selectively 
      antagonized by atropine, but were not affected by ganglion blocking agents, 
      conduction blockers, aging with cooling, anoxia or antihistaminics. On the other 
      hand, N-acetates, such as acetanilide and p-acetaminophenol, and no contractile 
      action on the ileum. These acetate esters thus seemed to have a cholinergic 
      action, and not a direct action on muscle or other known specific receptors for 
      endogenous active substances. The contractions induced by the acetate esters were 
      selectively potentiated by low concentrations of choline, whereas those induced 
      by acetylcholine, nicotine, 5-hydroxytryptamine and histamine were not. However, 
      N-acetates did not induce the contractions even in the presence of choline. 
      Organophosphorus cholinesterase inhibitors, such as diisopropyl fluorophosphate 
      and paraoxon, selectively and irreversibly inhibited the actions of aspirin and 
      N,O-diacetyl-p-aminophenol with or without choline. From these results, it is 
      concluded that the acetate esters with or without choline act through the 
      cholinergic system. However, their actions cannot be explained in terms of known 
      mechanisms, such as acetylcholine release, cholinesterase inhibition or a direct 
      muscarinic action. Therefore, the acetate esters, including phenyl acetate which 
      was supposed to be a releaser of acetylcholine, seem to have a hitherto 
      undescribed type of cholinergic action whose mechanism is unknown. It seems that 
      organophosphate-sensitive esterase(s) in the preparation may be essential for 
      initiation of the actions of the acetate esters with or without choline, but the 
      mechanism of the effect of choline is unknown.
FAU - Moritoki, H
AU  - Moritoki H
FAU - Ishida, Y
AU  - Ishida Y
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Acetates)
RN  - 0 (Insecticides)
RN  - 0 (Phenylacetates)
RN  - 0 (Resorcinols)
RN  - 12UHW9R67N (Isoflurophate)
RN  - N91BDP6H0X (Choline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/antagonists & inhibitors/*pharmacology
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Choline/pharmacology
MH  - Drug Interactions
MH  - Guinea Pigs
MH  - Ileum/drug effects
MH  - In Vitro Techniques
MH  - Insecticides/pharmacology
MH  - Isoflurophate/pharmacology
MH  - Muscle Contraction/*drug effects
MH  - Muscle, Smooth/*drug effects
MH  - Phenylacetates/pharmacology
MH  - Resorcinols/pharmacology
EDAT- 1977/04/21 00:00
MHDA- 1977/04/21 00:01
CRDT- 1977/04/21 00:00
PHST- 1977/04/21 00:00 [pubmed]
PHST- 1977/04/21 00:01 [medline]
PHST- 1977/04/21 00:00 [entrez]
AID - 0014-2999(77)90168-6 [pii]
AID - 10.1016/0014-2999(77)90168-6 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1977 Apr 21;42(4):347-54. doi: 10.1016/0014-2999(77)90168-6.

PMID- 20597903
OWN - NLM
STAT- MEDLINE
DCOM- 20100805
LR  - 20221207
IS  - 1469-1809 (Electronic)
IS  - 0003-4800 (Linking)
VI  - 74
IP  - 4
DP  - 2010 Jul
TI  - Association of SLC6A12 variants with aspirin-intolerant asthma in a Korean 
      population.
PG  - 326-34
LID - 10.1111/j.1469-1809.2010.00584.x [doi]
AB  - Aspirin-intolerant asthma (AIA) occurs from asthma exacerbation after exposure to 
      aspirin. However, the underlying mechanisms of AIA occurrence are still unclear. 
      The critical role of the solute carrier family 6 (neurotransmitter transporter, 
      betaine/GABA) member 12 (SLC6A12) gene in GABAergic transmission, which is 
      associated with mucus production in asthma, makes it a candidate gene for AIA 
      association study. Eight single nucleotide polymorphisms (SNPs) in SLC6A12 were 
      genotyped in 163 aspirin-intolerant asthma (AIA) and 429 aspirin-tolerant asthma 
      (ATA) patients of Korean ethnicity. Associations between polymorphisms of SLC6A12 
      and AIA were analysed using multivariate logistic analysis. Results showed that 
      two polymorphisms and a haplotype in SLC6A12, rs499368 (P= 0.005; P(corr)= 0.03), 
      rs557881 (non-synonymous C10R, P= 0.007; P(corr)= 0.04), and SLC6A12_BL1_ht1 (P= 
      0.009; P(corr)= 0.05) respectively, were significantly associated with AIA after 
      multiple testing corrections. In addition, SNPs of SLC6A12 were significantly 
      associated with the fall rate of FEV(1) by aspirin provocation suggesting that 
      SLC6A12 could affect reversibility of lung function abnormalities in AIA 
      patients. Although these results are preliminary and future replications are 
      needed to confirm these findings, this study showed evidence of association 
      between variants in SLC6A12 and AIA occurrence among asthmatics in a Korean 
      population.
FAU - Pasaje, Charisse Flerida A
AU  - Pasaje CF
AD  - Department of Life Science, Sogang University, Seoul, 121-742, Republic of Korea.
FAU - Kim, Jeong-Hyun
AU  - Kim JH
FAU - Park, Byung-Lae
AU  - Park BL
FAU - Cheong, Hyun Sub
AU  - Cheong HS
FAU - Chun, Ji-Yong
AU  - Chun JY
FAU - Park, Tae-Joon
AU  - Park TJ
FAU - Lee, Jin-Sol
AU  - Lee JS
FAU - Kim, Yongha
AU  - Kim Y
FAU - Bae, Joon Seol
AU  - Bae JS
FAU - Park, Jong Sook
AU  - Park JS
FAU - Yoon, Sang-Hyuk
AU  - Yoon SH
FAU - Uh, Soo-Taek
AU  - Uh ST
FAU - Choi, Jae-Sung
AU  - Choi JS
FAU - Kim, Yong-Hoon
AU  - Kim YH
FAU - Kim, Mi-Kyeong
AU  - Kim MK
FAU - Choi, Inseon S
AU  - Choi IS
FAU - Cho, Sang Heon
AU  - Cho SH
FAU - Choi, Byoung Whui
AU  - Choi BW
FAU - Park, Choon-Sik
AU  - Park CS
FAU - Shin, Hyoung Doo
AU  - Shin HD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ann Hum Genet
JT  - Annals of human genetics
JID - 0416661
RN  - 0 (Carrier Proteins)
RN  - 0 (GABA Plasma Membrane Transport Proteins)
RN  - 146313-33-9 (betaine plasma membrane transport proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Asian People/*genetics
MH  - Aspirin/adverse effects/*immunology
MH  - Asthma/*genetics
MH  - Carrier Proteins/*genetics
MH  - Drug Hypersensitivity/*genetics
MH  - Female
MH  - GABA Plasma Membrane Transport Proteins
MH  - Humans
MH  - Korea
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
MH  - Risk
EDAT- 2010/07/06 06:00
MHDA- 2010/08/06 06:00
CRDT- 2010/07/06 06:00
PHST- 2010/07/06 06:00 [entrez]
PHST- 2010/07/06 06:00 [pubmed]
PHST- 2010/08/06 06:00 [medline]
AID - AHG584 [pii]
AID - 10.1111/j.1469-1809.2010.00584.x [doi]
PST - ppublish
SO  - Ann Hum Genet. 2010 Jul;74(4):326-34. doi: 10.1111/j.1469-1809.2010.00584.x.

PMID- 23200555
OWN - NLM
STAT- MEDLINE
DCOM- 20140113
LR  - 20151029
IS  - 2300-8423 (Electronic)
IS  - 0030-6657 (Linking)
VI  - 66
IP  - 6
DP  - 2012 Nov-Dec
TI  - Current view on nasal polyps management in Samter's triad patients.
PG  - 373-8
LID - S0030-6657(12)00039-X [pii]
LID - 10.1016/j.otpol.2012.06.017 [doi]
AB  - The nasal polyps associated with Samter's triad are often very extensive, 
      difficult to treat, with great tendency to recurrence. In this paper the current 
      opinion on nasal polyps management in aspirin triad patients was presented. 
      PATHOGENESIS: Opinions on pathogenesis of these disease was remembered as well as 
      its epidemiology. DIAGNOSTIC METHODS: The available diagnostic methods were 
      presented. Treatment options: The available preservative treatment options was 
      analyzed including aspirin desensitization. The role of surgical treatment, 
      functional endoscopic sinus surgery was analyzed.
CI  - Copyright © 2012 Polish Otorhinolaryngology - Head and Neck Surgery Society. 
      Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
FAU - Mrówka-Kata, Katarzyna
AU  - Mrówka-Kata K
AD  - Katedra i Oddział Kliniczny Laryngologii w Zabrzu, Śląskiego Uniwersytetu 
      Medycznego w Katowicach, Poland. mrowkakata@wp.pl
FAU - Czecior, Eugeniusz
AU  - Czecior E
FAU - Kata, Dariusz
AU  - Kata D
FAU - Namysłowski, Grzegorz
AU  - Namysłowski G
FAU - Dziechciarz-Werbowska, Judyta
AU  - Dziechciarz-Werbowska J
FAU - Sowa, Paweł
AU  - Sowa P
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120701
PL  - Poland
TA  - Otolaryngol Pol
JT  - Otolaryngologia polska = The Polish otolaryngology
JID - 0404453
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/*diagnosis/etiology/*therapy
MH  - Humans
MH  - Nasal Polyps/*diagnosis/etiology/*therapy
MH  - Syndrome
MH  - Treatment Outcome
EDAT- 2012/12/04 06:00
MHDA- 2014/01/15 06:00
CRDT- 2012/12/04 06:00
PHST- 2012/03/30 00:00 [received]
PHST- 2012/05/29 00:00 [revised]
PHST- 2012/06/26 00:00 [accepted]
PHST- 2012/12/04 06:00 [entrez]
PHST- 2012/12/04 06:00 [pubmed]
PHST- 2014/01/15 06:00 [medline]
AID - S0030-6657(12)00039-X [pii]
AID - 10.1016/j.otpol.2012.06.017 [doi]
PST - ppublish
SO  - Otolaryngol Pol. 2012 Nov-Dec;66(6):373-8. doi: 10.1016/j.otpol.2012.06.017. Epub 
      2012 Jul 1.

PMID- 15370086
OWN - NLM
STAT- MEDLINE
DCOM- 20050301
LR  - 20131121
IS  - 1476-7058 (Print)
IS  - 1476-4954 (Linking)
VI  - 16
IP  - 1
DP  - 2004 Jul
TI  - Acute fatty liver of pregnancy after aspirin intake.
PG  - 65-6
AB  - Acute fatty liver is a rare but fatal complication of pregnancy. Here we describe 
      a patient presenting with stupor and jaundice after aspirin intake at 35 weeks of 
      gestation. Supportive management and delivery resulted in uneventful discharge of 
      the patient and the newborn. Differential diagnosis and management of this 
      condition are discussed.
FAU - Saygan-Karamürsel, B
AU  - Saygan-Karamürsel B
AD  - Hacettepe University, Department of Obstetrics and Gynecology, Perinatology Unit, 
      Ankara, Turkey.
FAU - Kizilkiliç-Parlakgümüş, A
AU  - Kizilkiliç-Parlakgümüş A
FAU - Deren, O
AU  - Deren O
FAU - Onderoğlu, L
AU  - Onderoğlu L
FAU - Durukan, T
AU  - Durukan T
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Component Transfusion
MH  - Diagnosis, Differential
MH  - Fatty Liver/*chemically induced/mortality/therapy
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*chemically induced/diagnosis/therapy
MH  - Pregnancy Trimester, Third
EDAT- 2004/09/17 05:00
MHDA- 2005/03/02 09:00
CRDT- 2004/09/17 05:00
PHST- 2004/09/17 05:00 [pubmed]
PHST- 2005/03/02 09:00 [medline]
PHST- 2004/09/17 05:00 [entrez]
AID - L70782QHM0DT6WD4 [pii]
AID - 10.1080/14767050412331283120 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2004 Jul;16(1):65-6. doi: 
      10.1080/14767050412331283120.

PMID- 9069483
OWN - NLM
STAT- MEDLINE
DCOM- 19970404
LR  - 20190501
IS  - 0022-3050 (Print)
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
VI  - 62
IP  - 3
DP  - 1997 Mar
TI  - Is there any evidence for a protective effect of antithrombotic medication on 
      cognitive function in men at risk of cardiovascular disease? Some preliminary 
      findings.
PG  - 269-72
AB  - To explore whether antithrombotic medication may protect against cognitive 
      decline, tests of verbal memory, attention, abstract reasoning, verbal fluency, 
      and mental flexibility were administered to 405 men at risk of cardiovascular 
      disease. These subjects were a subgroup of those who had been participating in a 
      randomised double blind factorial trial of low dose aspirin (75 mg daily) and low 
      intensity oral anticoagulation with warfarin (international normalised ratio of 
      1.5) at 35 general practices across the United Kingdom for at least five years, 
      were at least 55 years old at trial entry, and had been randomly allocated to one 
      of four groups: active warfarin and active aspirin, active warfarin and placebo 
      aspirin, placebo warfarin and active aspirin, and double placebo. Verbal fluency 
      and mental flexibility were significantly better in subjects taking 
      antithrombotic medication than in subjects taking placebo. Aspirin may have 
      contributed more than warfarin to any beneficial effect. These results provide 
      tentative evidence that antithrombotic medication may protect cognitive function 
      in men at risk of cardiovascular disease.
FAU - Richards, M
AU  - Richards M
AD  - Section of Old Age Psychiatry, Institute of Psychiatry, London, UK.
FAU - Meade, T W
AU  - Meade TW
FAU - Peart, S
AU  - Peart S
FAU - Brennan, P J
AU  - Brennan PJ
FAU - Mann, A H
AU  - Mann AH
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cognition/*drug effects
MH  - Cognition Disorders/*prevention & control
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neuropsychological Tests
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Risk Factors
MH  - Warfarin/pharmacology/*therapeutic use
PMC - PMC1064157
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
AID - 10.1136/jnnp.62.3.269 [doi]
PST - ppublish
SO  - J Neurol Neurosurg Psychiatry. 1997 Mar;62(3):269-72. doi: 10.1136/jnnp.62.3.269.

PMID- 8604744
OWN - NLM
STAT- MEDLINE
DCOM- 19960513
LR  - 20190627
IS  - 0002-9394 (Print)
IS  - 0002-9394 (Linking)
VI  - 121
IP  - 4
DP  - 1996 Apr
TI  - The effect of aspirin on the visual outcome of nonarteritic anterior ischemic 
      optic neuropathy.
PG  - 450-1
AB  - PURPOSE: To examine the effect of aspirin use on the visual outcome of 
      nonarteritic anterior ischemic optic neuropathy. METHODS: This retrospective 
      case-controlled study included 23 patients who used aspirin regularly before and 
      during the course of nonarteritic anterior ischemic optic neuropathy and 55 
      control patients with nonarteritic anterior ischemic optic neuropathy. Snellen 
      visual acuity in logMAR and mean deviation on automated perimetry were compiled 
      from the initial and final follow-up examinations. RESULTS: The comparisons of 
      patients who took aspirin with control patients disclosed that neither initial 
      logMAR (P = .36) nor the follow-up logMAR (P = .95) data differed significantly. 
      There was no significant difference between the groups for the initial (P = .60) 
      and the follow-up mean deviation (P = .41). CONCLUSIONS: Aspirin use does not 
      improve the visual outcome of patients with nonarteritic anterior ischemic optic 
      neuropathy. Additional studies are needed to further elucidate this issue.
FAU - Botelho, P J
AU  - Botelho PJ
AD  - Mason Institute of Ophthalmology, University of Missouri-Columbia, Missouri 
      65212, USA.
FAU - Johnson, L N
AU  - Johnson LN
FAU - Arnold, A C
AU  - Arnold AC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Optic Neuropathy, Ischemic/*drug therapy/physiopathology
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Visual Acuity/*drug effects/physiology
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
AID - S0002-9394(14)70448-9 [pii]
AID - 10.1016/s0002-9394(14)70448-9 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 1996 Apr;121(4):450-1. doi: 10.1016/s0002-9394(14)70448-9.

PMID- 19055028
OWN - NLM
STAT- MEDLINE
DCOM- 20090123
LR  - 20191111
IS  - 0015-5497 (Print)
IS  - 0015-5497 (Linking)
VI  - 56
IP  - 1-2
DP  - 2008
TI  - The effect of aspirin on Gomori-positive glia in mouse brain.
PG  - 73-5
AB  - Aspirin (acetylsalicylic acid, ASA) treatment resulted in a significant decrease 
      in the amount of the sulfur-rich Gomori-positive material present in the 
      cytoplasm of periventricular glia. It also caused the accumulation of the 
      Gomori-positive neurosecretory material in the supraoptic and paraventricular 
      nuclei and, most pronounced, in the neurosecretory axons of the paraventricular- 
      and supraoptic-neurophypophysial tract.
FAU - Sura, Piotr
AU  - Sura P
AD  - Departament of Human Developmental Biology, Collegium Medicum, Jagiellonian 
      University, Kopernika 7, 31-034 Kraków, Poland. mbsura@cyf-kr.edu.pl
FAU - Srebro, Zbigniew
AU  - Srebro Z
FAU - Wiliński, Bogdan
AU  - Wiliński B
FAU - Góralska, Marta
AU  - Góralska M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Poland
TA  - Folia Biol (Krakow)
JT  - Folia biologica
JID - 2984758R
RN  - R16CO5Y76E (Aspirin)
RN  - YKM8PY2Z55 (Hematoxylin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Brain/*cytology
MH  - Cytoplasm/metabolism
MH  - Hematoxylin
MH  - Mice
MH  - Neuroglia/*drug effects
MH  - Staining and Labeling
EDAT- 2008/12/06 09:00
MHDA- 2009/01/24 09:00
CRDT- 2008/12/06 09:00
PHST- 2008/12/06 09:00 [pubmed]
PHST- 2009/01/24 09:00 [medline]
PHST- 2008/12/06 09:00 [entrez]
AID - 10.3409/fb56_1-2.73-75 [doi]
PST - ppublish
SO  - Folia Biol (Krakow). 2008;56(1-2):73-5. doi: 10.3409/fb56_1-2.73-75.

PMID- 19381450
OWN - NLM
STAT- MEDLINE
DCOM- 20100402
LR  - 20211020
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 29
IP  - 1
DP  - 2010 Jan
TI  - Response variability to aspirin and one-year prediction of vascular events in 
      patients with stable coronary artery disease.
PG  - 108-13
LID - 10.1007/s11239-009-0335-1 [doi]
AB  - The aim of this study was to assess the association between "aspirin non 
      responsiveness" in patients with coronary artery diseases (CAD) and the risk of 
      major adverse cardiovascular events (MACE). 204 patients with CAD receiving 
      aspirin (250 mg/d) were included. Both Collagen/Epinephrine Closure Time 
      (CEPI-CT) and urinary Thromboxane B2 (uTxB2) concentration was used to determine 
      the patients aspirin responsiveness. The clinical primary endpoint was the 
      occurrence of MACE including: cardiovascular death, MI, stroke or transient 
      ischemic attack. The secondary endpoint was the occurrence of Recurrent Acute 
      Vascular Event (RAVE: MI, stroke or transient ischemic attack). After 1-year 
      follow-up, no responders diagnosed by CEPI-CT had a trend for higher risk of MACE 
      (13% vs 7.4%; P = 0.22) and significant higher risk of RAVE (OR = 2.1; 95%CI: 
      1.7-2.4; P = 0.01) when compared to good responders. Multivariate analysis showed 
      that CEPI-CT < 143 s was the only independent predictor of RAVE (OR = 6.3; 95% 
      CI: 1.2-32.2; P = 0.026). Aspirin non-responsiveness, diagnosed by the uTxB2, was 
      not associated with an increased risk of either MACE or RAVE. Our results, 
      reinforce the importance of being able to diagnose laboratory "aspirin non 
      responsiveness", and extend the evidence that aspirin non responsiveness may 
      explain in part the occurrence of RAVE.
FAU - Addad, Faouzi
AU  - Addad F
AD  - Department of Cardiology, Cardiac Thrombosis Research Unit, Fattouma Bourguiba 
      University Hospital, Monastir, Tunisia.
FAU - Chakroun, Tahar
AU  - Chakroun T
FAU - Abderazek, Fatma
AU  - Abderazek F
FAU - Ben-Farhat, Mohamed
AU  - Ben-Farhat M
FAU - Hamdi, Sonia
AU  - Hamdi S
FAU - Dridi, Zohra
AU  - Dridi Z
FAU - Gamra, Habib
AU  - Gamra H
FAU - Hassine, Mohsen
AU  - Hassine M
FAU - Samama, Meyer M
AU  - Samama MM
FAU - Elalamy, Ismail
AU  - Elalamy I
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Coronary Artery Disease/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Prospective Studies
MH  - Thromboxane B2/*analogs & derivatives/urine
EDAT- 2009/04/22 09:00
MHDA- 2010/04/03 06:00
CRDT- 2009/04/22 09:00
PHST- 2009/04/22 09:00 [entrez]
PHST- 2009/04/22 09:00 [pubmed]
PHST- 2010/04/03 06:00 [medline]
AID - 10.1007/s11239-009-0335-1 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2010 Jan;29(1):108-13. doi: 10.1007/s11239-009-0335-1.

PMID- 21660742
OWN - NLM
STAT- MEDLINE
DCOM- 20111025
LR  - 20151119
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 736
DP  - 2011
TI  - Atomic force microscopy studies on circular DNA structural changes by vincristine 
      and aspirin.
PG  - 425-35
LID - 10.1007/978-1-61779-105-5_26 [doi]
AB  - In this chapter, we have presented materials and methods to study the interaction 
      between DNA and small molecule drugs by AFM. The detailed AFM imaging of the 
      circular DNA after incubation with -various concentrations of vincristine and 
      aspirin have been demonstrated. The immobilization of DNA fragments on mica 
      surface as well as the force between tip and sample plays an important role for 
      successful imaging of DNA-drug complexes. How to quantitatively describe the 
      conformations and structures of circular DNA molecules and their changes is also 
      introduced. Our work indicates that the AFM is a powerful tool in studying the 
      interaction between DNA and small molecules.
FAU - Xiao, Zhongdang
AU  - Xiao Z
AD  - State Key Laboratory of Bioelectronics, School of Biological Science and Medical 
      Engineering, Southeast University, Nanjing, China. zdxiao@seu.edu.cn
FAU - Cao, Lili
AU  - Cao L
FAU - Zhu, Dan
AU  - Zhu D
FAU - Lu, Zuhong
AU  - Lu Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Aluminum Silicates)
RN  - 0 (DNA, Circular)
RN  - 5J49Q6B70F (Vincristine)
RN  - R16CO5Y76E (Aspirin)
RN  - V8A1AW0880 (mica)
SB  - IM
MH  - Aluminum Silicates/chemistry
MH  - Aspirin/chemistry/*pharmacology
MH  - DNA, Circular/*drug effects/*ultrastructure
MH  - Dose-Response Relationship, Drug
MH  - *Microscopy, Atomic Force
MH  - Molecular Imaging/*methods
MH  - Molecular Structure
MH  - Plasmids
MH  - Surface Properties
MH  - Vincristine/chemistry/*pharmacology
EDAT- 2011/06/11 06:00
MHDA- 2011/10/26 06:00
CRDT- 2011/06/11 06:00
PHST- 2011/06/11 06:00 [entrez]
PHST- 2011/06/11 06:00 [pubmed]
PHST- 2011/10/26 06:00 [medline]
AID - 10.1007/978-1-61779-105-5_26 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2011;736:425-35. doi: 10.1007/978-1-61779-105-5_26.

PMID- 3181281
OWN - NLM
STAT- MEDLINE
DCOM- 19881221
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 35
IP  - 3
DP  - 1988
TI  - Pharmacokinetics of low-dose oral modified release, soluble and intravenous 
      aspirin in man, and effects on platelet function.
PG  - 287-94
AB  - The pharmacokinetics of low-dose aspirin and the resulting salicylic acid were 
      studied in 6 healthy volunteers. Each received a single 50-mg dose of (1) oral 
      modified release capsules, (2) oral solution and (3) intravenous solution. The 
      volunteers also received 50 mg modified release capsules daily for 6 days to 
      determine the effect on collagen, ADP and arachidonate induced platelet 
      aggregation and thromboxane production, and to compare the pharmacokinetics after 
      repeated dosing with the parameters obtained after the single dose. The 
      formulation and route of administration profoundly influenced several 
      pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) 
      was 221 and 191 after modified release for single and chronic dosing 
      respectively, 1323 after the oral solution and 6000 after intravenous injection; 
      the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after 
      modified release for single and chronic dosing respectively, and 0.29 after the 
      oral solution; the area under the plasma drug concentration versus time curve 
      (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and 
      chronic dosing respectively, 0.68 after the oral solution and 1.57 after 
      intravenous injection. The elimination of aspirin after the two solutions was at 
      least biphasic. The terminal phase rate constant ranged from 1.52 h-1 after 
      intravenous injection to 1.88 h-1 after the oral modified release form. The 
      absorption of the oral forms of aspirin was complete as reflected by the total 
      recovery of the doses as salicylic acid in urine.(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Bochner, F
AU  - Bochner F
AD  - Department of Clinical and Experimental Pharmacology, University of Adelaide, 
      South Australia.
FAU - Williams, D B
AU  - Williams DB
FAU - Morris, P M
AU  - Morris PM
FAU - Siebert, D M
AU  - Siebert DM
FAU - Lloyd, J V
AU  - Lloyd JV
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Salicylates)
RN  - 57576-52-0 (Thromboxane A2)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Salicylates/blood/urine
MH  - Salicylic Acid
MH  - Thromboxane A2/*biosynthesis
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.1007/BF00558267 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1988;35(3):287-94. doi: 10.1007/BF00558267.

PMID- 1793694
OWN - NLM
STAT- MEDLINE
DCOM- 19920409
LR  - 20131121
IS  - 0007-0947 (Print)
IS  - 0007-0947 (Linking)
VI  - 45
IP  - 2
DP  - 1991 Summer
TI  - An evaluation of clinical aspects of post-operative autotransfusion, either alone 
      or in conjunction with pre-operative aspirin, in cardiac surgery.
PG  - 105-8
AB  - Two groups of 21 otherwise healthy patients undergoing coronary artery bypass 
      grafting (CABG) for the first time were studied in order to evaluate the 
      advantages and disadvantages of post-operative autotransfusion using a red cell 
      'salvage' method. Group 1 patients (control group) were transfused using donor 
      blood only. Group 2 patients were transfused with their own (autologous) blood, 
      salvaged post-operatively, although donor blood was also available to them if 
      needed. The two groups were further subdivided according to whether the patients 
      received aspirin pre-operatively or not. The four subgroups thus formed were 
      comparable pre- as well as intra-operatively, with respect to all available 
      clinical and laboratory criteria. The post-operative data, however, showed that 
      the combination of pre-operative aspirin and autotransfusion leads to excessive 
      post-operative bleeding, together with increased donor blood requirement. It was 
      also shown that autotransfusion without aspirin does reduce the need for donor 
      blood transfusion without any increase in post-operative bleeding. Although 
      aspirin alone did not increase post-operative bleeding or donor blood 
      requirement, its combination with autotransfusion should be avoided.
FAU - Shirvani, R
AU  - Shirvani R
AD  - United Medical School, Guy's Hospital, London.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pract
JT  - The British journal of clinical practice
JID - 0372546
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Blood Transfusion, Autologous
MH  - *Coronary Artery Bypass
MH  - Hemorrhage/etiology
MH  - Hemostasis, Surgical
MH  - Humans
MH  - Male
MH  - Postoperative Care/*methods
MH  - Postoperative Complications
MH  - Preoperative Care
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
PST - ppublish
SO  - Br J Clin Pract. 1991 Summer;45(2):105-8.

PMID- 37606674
OWN - NLM
STAT- MEDLINE
DCOM- 20230823
LR  - 20230828
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 330
IP  - 8
DP  - 2023 Aug 22
TI  - Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, 
      and High-Income Countries.
PG  - 715-724
LID - 10.1001/jama.2023.12905 [doi]
AB  - IMPORTANCE: Aspirin is an effective and low-cost option for reducing 
      atherosclerotic cardiovascular disease (CVD) events and improving mortality rates 
      among individuals with established CVD. To guide efforts to mitigate the global 
      CVD burden, there is a need to understand current levels of aspirin use for 
      secondary prevention of CVD. OBJECTIVE: To report and evaluate aspirin use for 
      secondary prevention of CVD across low-, middle-, and high-income countries. 
      DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analysis using pooled, 
      individual participant data from nationally representative health surveys 
      conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. 
      Included surveys contained data on self-reported history of CVD and aspirin use. 
      The sample of participants included nonpregnant adults aged 40 to 69 years. 
      EXPOSURES: Countries' per capita income levels and world region; individuals' 
      socioeconomic demographics. MAIN OUTCOMES AND MEASURES: Self-reported use of 
      aspirin for secondary prevention of CVD. RESULTS: The overall pooled sample 
      included 124 505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% 
      (95% CI, 49.9%-51.1%) were women. A total of 10 589 individuals had a 
      self-reported history of CVD (8.1% [95% CI, 7.6%-8.6%]). Among individuals with a 
      history of CVD, aspirin use for secondary prevention in the overall pooled sample 
      was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 
      12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in 
      lower-middle-income countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income 
      countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries. CONCLUSION 
      AND RELEVANCE: Worldwide, aspirin is underused in secondary prevention, 
      particularly in low-income countries. National health policies and health systems 
      must develop, implement, and evaluate strategies to promote aspirin therapy.
FAU - Yoo, Sang Gune K
AU  - Yoo SGK
AD  - Cardiovascular Division, Department of Internal Medicine, Washington University 
      in St Louis, St Louis, Missouri.
FAU - Chung, Grace S
AU  - Chung GS
AD  - Department of Internal Medicine, University of Michigan, Ann Arbor.
FAU - Bahendeka, Silver K
AU  - Bahendeka SK
AD  - Department of Internal Medicine, MKPGMS Uganda Martyrs University, Kampala, 
      Uganda.
AD  - St Francis Hospital, Nsambya, Kampala, Uganda.
FAU - Sibai, Abla M
AU  - Sibai AM
AD  - Epidemiology and Population Health Department, Faculty of Health Sciences, 
      American University of Beirut, Beirut, Lebanon.
FAU - Damasceno, Albertino
AU  - Damasceno A
AD  - Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.
AD  - Nucleo de Investigaçao, Departamento de Medicina, Hospital Central do Maputo, 
      Maputo, Mozambique.
FAU - Farzadfar, Farshad
AU  - Farzadfar F
AD  - Non-Communicable Diseases Research Center, Endocrinology and Metabolism 
      Population Sciences Institute, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Rohloff, Peter
AU  - Rohloff P
AD  - Center for Indigenous Health Research, Wuqu' Kawoq, Tecpán, Guatemala.
AD  - Division of Global Health Equity, Brigham and Women's Hospital, Boston, 
      Massachusetts.
FAU - Houehanou, Corine
AU  - Houehanou C
AD  - Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of 
      Health Sciences, University of Abomey-Calavi, Cotonou, Benin.
FAU - Norov, Bolormaa
AU  - Norov B
AD  - Nutrition Department, National Center for Public Health, Ulaanbaatar, Mongolia.
FAU - Karki, Khem B
AU  - Karki KB
AD  - Department of Community Medicine and Public Health, Institute of Medicine, 
      Tribhuvan University, Kathmandu, Nepal.
FAU - Azangou-Khyavy, Mohammadreza
AU  - Azangou-Khyavy M
AD  - Non-Communicable Diseases Research Center, Endocrinology and Metabolism 
      Population Sciences Institute, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Marcus, Maja E
AU  - Marcus ME
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Aryal, Krishna K
AU  - Aryal KK
AD  - Bergen Centre for Ethics and Priority Setting in Health, Department of Global 
      Public Health and Primary Care, University of Bergen, Bergen, Norway.
AD  - Public Health Promotion and Development Organization, Kathmandu, Nepal.
FAU - Brant, Luisa C C
AU  - Brant LCC
AD  - Serviço de Cardiologia e Cirurgia Cardiovascular, Hospital das Clínicas da 
      Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
AD  - Departamento de Clínica Médica, Universidade Federal de Minas Gerais, Belo 
      Horizonte, Brazil.
FAU - Theilmann, Michaela
AU  - Theilmann M
AD  - Heidelberg Institute of Global Health, Faculty of Medicine and University 
      Hospital, Heidelberg University, Heidelberg, Germany.
AD  - Department of Sport and Health Sciences, Technical University of Munich, Munich, 
      Germany.
FAU - Cífková, Renata
AU  - Cífková R
AD  - Center for Cardiovascular Prevention, First Faculty of Medicine, and Thomayer 
      University Hospital, Charles University in Prague, Prague, Czechia.
AD  - Department of Medicine II, First Faculty of Medicine, Charles University in 
      Prague, Prague, Czechia.
FAU - Lunet, Nuno
AU  - Lunet N
AD  - Department of Public Health and Forensic Sciences and Medical Education, Faculty 
      of Medicine, University of Porto, Porto, Portugal.
AD  - EPIUnit, Institute of Public Health, University of Porto, Porto, Portugal.
AD  - Laboratory for Integrative and Translational Research in Population Health, 
      Porto, Portugal.
FAU - Gurung, Mongal S
AU  - Gurung MS
AD  - Health Research and Epidemiology Unit, Ministry of Health, Thimphu, Bhutan.
FAU - Mwangi, Joseph Kibachio
AU  - Mwangi JK
AD  - Division of Non-Communicable Diseases, Ministry of Health, Nairobi, Kenya.
AD  - Faculty of Medicine, The Institute of Global Health, University of Geneva, 
      Geneva, Switzerland.
FAU - Martins, Joao
AU  - Martins J
AD  - Faculty of Medicine and Health Sciences, National University of East Timor, Dili, 
      Timor-Leste.
FAU - Haghshenas, Rosa
AU  - Haghshenas R
AD  - Non-Communicable Diseases Research Center, Endocrinology and Metabolism 
      Population Sciences Institute, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Sturua, Lela
AU  - Sturua L
AD  - Non-Communicable Disease Department, National Center for Disease Control and 
      Public Health, Tbilisi, Georgia.
AD  - Public Health Department, Petre Shotadze Tbilisi Medical Academy, Tbilisi, 
      Georgia.
FAU - Vollmer, Sebastian
AU  - Vollmer S
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Bärnighausen, Till
AU  - Bärnighausen T
AD  - Heidelberg Institute of Global Health, Faculty of Medicine and University 
      Hospital, Heidelberg University, Heidelberg, Germany.
AD  - Harvard Center for Population and Development Studies, Harvard University, 
      Cambridge, Massachusetts.
AD  - Africa Health Research Institute, Somkhele and Durban, South Africa.
FAU - Atun, Rifat
AU  - Atun R
AD  - Department of Global Health and Population, Harvard T. H. Chan School of Public 
      Health, Harvard University, Boston, Massachusetts.
AD  - Department of Global Health and Social Medicine, Harvard Medical School, Harvard 
      University, Boston, Massachusetts.
FAU - Sussman, Jeremy B
AU  - Sussman JB
AD  - Department of Internal Medicine, University of Michigan, Ann Arbor.
AD  - Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann 
      Arbor, Michigan.
FAU - Singh, Kavita
AU  - Singh K
AD  - Heidelberg Institute of Global Health, Faculty of Medicine and University 
      Hospital, Heidelberg University, Heidelberg, Germany.
AD  - Centre for Chronic Disease Control, New Delhi, India.
FAU - Saeedi Moghaddam, Sahar
AU  - Saeedi Moghaddam S
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism 
      Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AD  - Kiel Institute for the World Economy, Kiel, Germany.
FAU - Guwatudde, David
AU  - Guwatudde D
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Makerere 
      University, Kampala, Uganda.
FAU - Geldsetzer, Pascal
AU  - Geldsetzer P
AD  - Division of Primary Care and Population Health, Stanford University, Stanford, 
      California.
FAU - Manne-Goehler, Jennifer
AU  - Manne-Goehler J
AD  - Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical 
      School, Boston, Massachusetts.
AD  - Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard 
      Medical School, Boston, Massachusetts.
FAU - Huffman, Mark D
AU  - Huffman MD
AD  - Department of Medicine and Global Health Center, Washington University in St 
      Louis, St Louis, Missouri.
AD  - Department of Preventive Medicine, Northwestern University Feinberg School of 
      Medicine, Chicago, Illinois.
AD  - The George Institute for Global Health, University of New South Wales, Sydney, 
      Australia.
FAU - Davies, Justine I
AU  - Davies JI
AD  - Institute for Applied Health Research, University of Birmingham, Birmingham, 
      England.
AD  - Centre for Global Surgery, Department of Global Health, Stellenbosch University, 
      Cape Town, South Africa.
AD  - Medical Research Council/Wits University Rural Public Health and Health 
      Transitions Research Unit, Faculty of Health Sciences, School of Public Health, 
      University of the Witwatersrand, Johannesburg, South Africa.
FAU - Flood, David
AU  - Flood D
AD  - Department of Internal Medicine, University of Michigan, Ann Arbor.
AD  - Center for Indigenous Health Research, Wuqu' Kawoq, Tecpán, Guatemala.
AD  - INCAP Research Center for Prevention of Chronic Diseases, Institute of Nutrition 
      of Central America and Panama, Guatemala City, Guatemala.
LA  - eng
GR  - K23 HL161271/HL/NHLBI NIH HHS/United States
GR  - P30 DK092926/DK/NIDDK NIH HHS/United States
GR  - P30 AG024824/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - doi: 10.1001/jama.2022.4983
MH  - Adult
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Male
MH  - *Aspirin/therapeutic use
MH  - Secondary Prevention
MH  - *Cardiovascular Diseases/prevention & control
MH  - Cross-Sectional Studies
MH  - Developed Countries
PMC - PMC10445202
COIS- Conflict of Interest Disclosures: Dr Atun reported consulting and speaking 
      engagements for Novartis and F. Hoffmann-La Roche unrelated to the study or the 
      subject. Dr Manne-Goehler reported undertaking COVID-19 clinical trials for 
      Regeneron Pharmaceuticals. Dr Huffman reported that his employer, The George 
      Institute for Global Health, has a patent and license, and has received 
      investment funding with intent to commercialize fixed-dose combination therapy 
      through its social enterprise business, George Medicines; Dr Huffman also 
      reported travel support from the World Heart Federation and having a patent 
      pending for heart failure polypills. Dr Flood reported serving as a volunteer 
      physician for the Guatemala-based nongovernmental organization Maya Health 
      Alliance. No other disclosures were reported.
EDAT- 2023/08/22 13:42
MHDA- 2023/08/23 06:42
PMCR- 2024/02/22
CRDT- 2023/08/22 11:07
PHST- 2024/02/22 00:00 [pmc-release]
PHST- 2023/08/23 06:42 [medline]
PHST- 2023/08/22 13:42 [pubmed]
PHST- 2023/08/22 11:07 [entrez]
AID - 2808523 [pii]
AID - joi230085 [pii]
AID - 10.1001/jama.2023.12905 [doi]
PST - ppublish
SO  - JAMA. 2023 Aug 22;330(8):715-724. doi: 10.1001/jama.2023.12905.

PMID- 15309364
OWN - NLM
STAT- MEDLINE
DCOM- 20051207
LR  - 20160512
IS  - 1618-2642 (Print)
IS  - 1618-2642 (Linking)
VI  - 380
IP  - 1
DP  - 2004 Sep
TI  - Solution to spectroscopy challenge 6.
PG  - 5-6
AB  - The winner of the sixth spectroscopy challenge (published in issue 379/1) is: 
      Xiancui Li, Hong Kong University of Science and Technology, China The award 
      entitles the winner to select a Springer book from our catalogue up to a value of 
      euro 75.00. Our Congratulations!
FAU - Paasch, Silvia
AU  - Paasch S
AD  - Department of Analytical Chemistry, University of Dresden, 01062 Dresden, 
      Germany.
FAU - Salzer, Reiner
AU  - Salzer R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20040810
PL  - Germany
TA  - Anal Bioanal Chem
JT  - Analytical and bioanalytical chemistry
JID - 101134327
RN  - 0 (Carbon Isotopes)
RN  - 0 (Protons)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Carbon Isotopes
MH  - Magnetic Resonance Spectroscopy/*methods/standards
MH  - Molecular Structure
MH  - Protons
MH  - Reference Standards
MH  - Spectrophotometry, Infrared
EDAT- 2004/08/17 10:00
MHDA- 2005/12/13 09:00
CRDT- 2004/08/17 10:00
PHST- 2004/08/17 10:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2004/08/17 10:00 [entrez]
AID - 10.1007/s00216-004-2731-x [doi]
PST - ppublish
SO  - Anal Bioanal Chem. 2004 Sep;380(1):5-6. doi: 10.1007/s00216-004-2731-x. Epub 2004 
      Aug 10.

PMID- 29939936
OWN - NLM
STAT- MEDLINE
DCOM- 20190919
LR  - 20190919
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 132
IP  - 1
DP  - 2018 Jul
TI  - ACOG Committee Opinion No. 743 Summary: Low-Dose Aspirin Use During Pregnancy.
PG  - 254-256
LID - 10.1097/AOG.0000000000002709 [doi]
AB  - Low-dose aspirin has been used during pregnancy, most commonly to prevent or 
      delay the onset of preeclampsia. The American College of Obstetricians and 
      Gynecologists issued the Hypertension in Pregnancy Task Force Report recommending 
      daily low-dose aspirin beginning in the late first trimester for women with a 
      history of early-onset preeclampsia and preterm delivery at less than 34 0/7 
      weeks of gestation, or for women with more than one prior pregnancy complicated 
      by preeclampsia. The U.S. Preventive Services Task Force published a similar 
      guideline, although the list of indications for low-dose aspirin use was more 
      expansive. Daily low-dose aspirin use in pregnancy is considered safe and is 
      associated with a low likelihood of serious maternal, or fetal complications, or 
      both, related to use. The American College of Obstetricians and Gynecologists and 
      the Society for Maternal-Fetal Medicine support the U.S. Preventive Services Task 
      Force guideline criteria for prevention of preeclampsia. Low-dose aspirin (81 
      mg/day) prophylaxis is recommended in women at high risk of preeclampsia and 
      should be initiated between 12 weeks and 28 weeks of gestation (optimally before 
      16 weeks) and continued daily until delivery. Low-dose aspirin prophylaxis should 
      be considered for women with more than one of several moderate risk factors for 
      preeclampsia. Women at risk of preeclampsia are defined based on the presence of 
      one or more high-risk factors (history of preeclampsia, multifetal gestation, 
      renal disease, autoimmune disease, type 1 or type 2 diabetes, and chronic 
      hypertension) or more than one of several moderate-risk factors (first pregnancy, 
      maternal age of 35 years or older, a body mass index greater than 30, family 
      history of preeclampsia, sociodemographic characteristics, and personal history 
      factors). In the absence of high risk factors for preeclampsia, current evidence 
      does not support the use of prophylactic low-dose aspirin for the prevention of 
      early pregnancy loss, fetal growth restriction, stillbirth, or preterm birth.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*standards
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/*drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/*standards
MH  - *Practice Guidelines as Topic
MH  - Pre-Eclampsia/etiology/*prevention & control
MH  - Pregnancy
MH  - Risk Factors
MH  - Young Adult
EDAT- 2018/06/26 06:00
MHDA- 2019/09/20 06:00
CRDT- 2018/06/26 06:00
PHST- 2018/06/26 06:00 [entrez]
PHST- 2018/06/26 06:00 [pubmed]
PHST- 2019/09/20 06:00 [medline]
AID - 00006250-201807000-00052 [pii]
AID - 10.1097/AOG.0000000000002709 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2018 Jul;132(1):254-256. doi: 10.1097/AOG.0000000000002709.

PMID- 25141121
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 8
DP  - 2014
TI  - Impact of aspirin and clopidogrel interruption on platelet function in patients 
      undergoing major vascular surgery.
PG  - e104491
LID - 10.1371/journal.pone.0104491 [doi]
LID - e104491
AB  - AIMS: To investigate functional platelet recovery after preoperative withdrawal 
      of aspirin and clopidogrel and platelet function 5 days after treatment 
      resumption. METHODS/RESULTS: We conducted an observational study, which 
      prospectively included consecutive patients taking aspirin, taking clopidogrel, 
      and untreated controls (15 patients in each group). The antiplatelet drugs were 
      withdrawn five days before surgery (baseline) and were reintroduced two days 
      after surgery. Platelet function was evaluated by optical aggregation in the 
      presence of collagen, arachidonic acid (aspirin) and ADP (clopidogrel) and by 
      VASP assay (clopidogrel). Platelet-leukocyte complex (PLC) level was quantified 
      at each time-point. At baseline, platelet function was efficiently inhibited by 
      aspirin and had recovered fully in most patients 5 days after drug withdrawal. 
      PLC levels five days after aspirin reintroduction were similar to baseline 
      (+4±10%; p = 0.16), in line with an effective platelet inhibition. Chronic 
      clopidogrel treatment was associated with variable platelet inhibition and its 
      withdrawal led to variable functional recovery. PLC levels were significantly 
      increased five days after clopidogrel reintroduction (+10±15%; p = 0.02), 
      compared to baseline. CONCLUSIONS: Aspirin withdrawal 5 days before 
      high-bleeding-risk procedures was associated with functional platelet recovery, 
      and its reintroduction two days after surgery restored antiplaletet efficacy five 
      days later. This was not the case of clopidogrel, and further work is therefore 
      needed to define its optimal perioperative management.
FAU - Le Manach, Yannick
AU  - Le Manach Y
AD  - Departments of Anesthesia & Clinical Epidemiology and Biostatistics, Michael 
      DeGroote School of Medicine, Faculty of Health Sciences, McMaster University, 
      Hamilton, Ontario, Canada; Population Health Research Institute, David Braley 
      Cardiac, Vascular and Stroke Research Institute, Perioperative Medicine and 
      Surgical Research Unit, Hamilton, Ontario, Canada; AP-HP, Hôpital 
      Pitié-Salpêtrière, Department of Anesthesiology and Critical Care, Paris, France.
FAU - Kahn, David
AU  - Kahn D
AD  - AP-HP, Hôpital Pitié-Salpêtrière, Department of Anesthesiology and Critical Care, 
      Paris, France.
FAU - Bachelot-Loza, Christilla
AU  - Bachelot-Loza C
AD  - Inserm UMR-S1140, Faculté de Pharmacie, Paris, France; Université Paris 
      Descartes, Sorbonne Paris Cité, Paris, France.
FAU - Le Sache, Frederic
AU  - Le Sache F
AD  - AP-HP, Hôpital Pitié-Salpêtrière, Department of Anesthesiology and Critical Care, 
      Paris, France.
FAU - Smadja, David M
AU  - Smadja DM
AD  - Inserm UMR-S1140, Faculté de Pharmacie, Paris, France; Université Paris 
      Descartes, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Européen Georges 
      Pompidou, Service d'Hématologie Biologique, Paris, France.
FAU - Remones, Veronique
AU  - Remones V
AD  - AP-HP, Hôpital Européen Georges Pompidou, Service d'Hématologie Biologique, 
      Paris, France.
FAU - Loriot, Marie-Anne
AU  - Loriot MA
AD  - Université Paris Descartes, Sorbonne Paris Cité, Paris, France; INSERM UMR-S1147, 
      Paris, France; AP-HP, Hôpital Européen Georges Pompidou, Pharmacogénétique et 
      Oncologie Moléculaire, Paris, France.
FAU - Coriat, Pierre
AU  - Coriat P
AD  - AP-HP, Hôpital Pitié-Salpêtrière, Department of Anesthesiology and Critical Care, 
      Paris, France.
FAU - Gaussem, Pascale
AU  - Gaussem P
AD  - Inserm UMR-S1140, Faculté de Pharmacie, Paris, France; Université Paris 
      Descartes, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Européen Georges 
      Pompidou, Service d'Hématologie Biologique, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140820
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Preoperative Period
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - *Vascular Surgical Procedures
MH  - Withholding Treatment
PMC - PMC4139277
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/08/21 06:00
MHDA- 2015/05/12 06:00
CRDT- 2014/08/21 06:00
PHST- 2014/04/04 00:00 [received]
PHST- 2014/07/13 00:00 [accepted]
PHST- 2014/08/21 06:00 [entrez]
PHST- 2014/08/21 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - PONE-D-14-10837 [pii]
AID - 10.1371/journal.pone.0104491 [doi]
PST - epublish
SO  - PLoS One. 2014 Aug 20;9(8):e104491. doi: 10.1371/journal.pone.0104491. 
      eCollection 2014.

PMID- 8509554
OWN - NLM
STAT- MEDLINE
DCOM- 19930715
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 22
IP  - 1
DP  - 1993 Jul
TI  - Maintenance of patency after thrombolysis in stenotic coronary arteries requires 
      combined inhibition of thrombin and platelets.
PG  - 296-301
AB  - OBJECTIVES: This study was designed to determine whether maintenance of patency 
      in coronary arteries with high grade stenosis after thrombolysis with tissue-type 
      plasminogen activator requires inhibition of thrombin or platelets, or both. 
      BACKGROUND: Activation of both thrombin and platelets has been implicated in 
      delaying coronary recanalization induced with fibrinolytic drugs and in 
      predisposing to reocclusion. METHODS: Hirudin (1.5 mg/kg body weight) or aspirin 
      (5 mg/kg), or both, was given conjunctively with tissue-type plasminogen 
      activator in 28 conscious dogs with coronary thrombosis induced by electrical 
      stimulation of the vessel wall in the presence of a previously placed high grade 
      distal stenosis (85 +/- 12% [SEM] area reduction). RESULTS: Among 22 dogs 
      exhibiting coronary recanalization, hirudin plus aspirin, but neither agent 
      alone, modestly shortened the interval to recanalization (31 +/- 4 min with 
      saline solution, n = 6; 29 +/- 4 min with aspirin, n = 5; 23 +/- 9 min with 
      hirudin, n = 6; 21 +/- 7 min with hirudin+aspirin, n = 5). Reocclusion occurred 
      promptly and persisted in five of six dogs given only saline solution plus 
      tissue-type plasminogen activator, in four of six dogs given hirudin and five of 
      five dogs given aspirin; however, reocclusion was prevented in all five of the 
      dogs given both hirudin and aspirin with tissue-type plasminogen activator (p < 
      0.05 compared with saline-treated dogs). In dogs given both hirudin and aspirin, 
      the partial thromboplastin time was 2.4 +/- 0.3 times baseline, and the template 
      bleeding time was prolonged only modestly (1.6 +/- 0.3 times baseline). 
      CONCLUSIONS: Thus, the combination of hirudin and aspirin in doses that do not 
      markedly perturb hemostasis prevents early reocclusion after thrombolysis despite 
      the presence of severe stenosis. Accordingly, conjunctive administration of both 
      anti-thrombin and antiplatelet agents appears to be necessary for optimal 
      maintenance of patency after thrombolysis induced in the presence of high grade 
      coronary stenosis.
FAU - Prager, N A
AU  - Prager NA
AD  - Cardiovascular Division, Washington University, Saint Louis, Missouri.
FAU - Torr-Brown, S R
AU  - Torr-Brown SR
FAU - Sobel, B E
AU  - Sobel BE
FAU - Abendschein, D R
AU  - Abendschein DR
LA  - eng
GR  - SCOR HL17646/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Hirudins)
RN  - EC 3.4.21.5 (Thrombin)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Coronary Disease/*drug therapy/physiopathology
MH  - Dogs
MH  - Drug Therapy, Combination
MH  - Hirudin Therapy
MH  - Hirudins/*pharmacology
MH  - Male
MH  - Recurrence
MH  - Thrombin/*drug effects
MH  - *Thrombolytic Therapy
MH  - Tissue Plasminogen Activator/pharmacology/therapeutic use
MH  - Vascular Patency/*drug effects
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
AID - 0735-1097(93)90847-T [pii]
AID - 10.1016/0735-1097(93)90847-t [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1993 Jul;22(1):296-301. doi: 10.1016/0735-1097(93)90847-t.

PMID- 16542349
OWN - NLM
STAT- MEDLINE
DCOM- 20060510
LR  - 20221014
IS  - 0960-7722 (Print)
IS  - 1365-2184 (Electronic)
IS  - 0960-7722 (Linking)
VI  - 39
IP  - 2
DP  - 2006 Apr
TI  - The historical analysis of aspirin discovery, its relation to the willow tree and 
      antiproliferative and anticancer potential.
PG  - 147-55
AB  - For several millennia, the willow tree and salicin have been associated with 
      salicylic acid, the key precursor molecule that has contributed to the discovery 
      of acetylsalicylic acid, traded as aspirin. These molecules have been shown to 
      possess phyto- and chemotherapeutic activities as analgesic drugs. In recent 
      decades, aspirin has become the focus of extensive investigation into 
      antiproliferative and anticancer activities. The historical steps that led to the 
      discovery of aspirin, and its antiproliferative and anticancer potential are 
      highlighted in this review.
FAU - Mahdi, J G
AU  - Mahdi JG
AD  - School of Biosciences, Cardiff University, PO Box 911, Cardiff, CF10 3US, UK. 
      mahdijg@cf.ac.uk
FAU - Mahdi, A J
AU  - Mahdi AJ
FAU - Mahdi, A J
AU  - Mahdi AJ
FAU - Bowen, I D
AU  - Bowen ID
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - England
TA  - Cell Prolif
JT  - Cell proliferation
JID - 9105195
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Benzyl Alcohols)
RN  - 0 (Glucosides)
RN  - 4649620TBZ (salicin)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*history/therapeutic use
MH  - Antineoplastic Agents, Phytogenic/chemistry/*history/therapeutic use
MH  - Aspirin/chemistry/*history/therapeutic use
MH  - Benzyl Alcohols/chemistry/history/therapeutic use
MH  - Glucosides
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - History, Ancient
MH  - History, Medieval
MH  - Humans
MH  - Salicylic Acid/chemistry/*history/therapeutic use
MH  - Salix/*chemistry
PMC - PMC6496865
EDAT- 2006/03/18 09:00
MHDA- 2006/05/11 09:00
CRDT- 2006/03/18 09:00
PHST- 2006/03/18 09:00 [pubmed]
PHST- 2006/05/11 09:00 [medline]
PHST- 2006/03/18 09:00 [entrez]
AID - CPR377 [pii]
AID - 10.1111/j.1365-2184.2006.00377.x [doi]
PST - ppublish
SO  - Cell Prolif. 2006 Apr;39(2):147-55. doi: 10.1111/j.1365-2184.2006.00377.x.

PMID- 37029358
OWN - NLM
STAT- MEDLINE
DCOM- 20230411
LR  - 20230412
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Apr 7
TI  - Does chronic low-dose aspirin use benefit bone health? A cross-sectional study on 
      patients with type 2 diabetes mellitus.
PG  - 79
LID - 10.1186/s12902-023-01309-2 [doi]
LID - 79
AB  - INTRODUCTION: Numerous studies have reported the striking result that aspirin use 
      is associated with higher bone mineral density (BMD), suggesting its potential as 
      a population-wide osteoporosis prevention measure. Therefore, this study aimed to 
      examine the impact of chronic low-dose aspirin use on bone remodeling biomarkers 
      and BMD in an aging population. MATERIALS AND METHODS: Between September and 
      November of 2019, clinical data regarding the medication use, serum bone 
      remodeling biomarkers, and BMD of 567 consecutively hospitalized patients, a 
      minimum of 50 years old with type 2 diabetes mellitus (T2DM), were collected. The 
      cross-sectional associations between chronic low-dose aspirin use and serum 
      concentrations of bone remodeling biomarkers and BMD were estimated separately 
      using linear regression. Potential confounding variables were controlled for, 
      including age, sex, and comorbidities. RESULTS: Low-dose aspirin users had 
      significantly lower serum bone alkaline phosphatase (BAP) concentrations than 
      non-users (82.44 ± 28.03 U/L vs 90.71 ± 32.79 U/L, p = 0.025). On the other hand, 
      low-dose aspirin users had insignificantly higher vertebral BMD (0.95 ± 0.19 vs 
      0.91 ± 0.21, p = 0.185), femoral neck BMD (0.80 ± 0.15 vs 0.78 ± 0.17, p = 0.309) 
      and Ward's triangle BMD (0.46 ± 0.14 vs 0.44 ± 0.13, p = 0.209), regardless of 
      adjustment. CONCLUSIONS: This cross-sectional study demonstrated that chronic use 
      of low-dose aspirin was associated with significantly lower serum concentrations 
      of BAP in hospitalized patients with T2DM. The mechanism causing the 
      insignificantly higher BMD observed in chronic aspirin users in this study and 
      the significant increments in BMD reported in previous studies requires further 
      clarification in other clinical trials.
CI  - © 2023. The Author(s).
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Geriatrics, the Second People' Hospital of Wuhu, Anhui, 230032, 
      China.
FAU - Ji, Xuelei
AU  - Ji X
AD  - Department of Endocrinology, the Second People' Hospital of Wuhu, Anhui, 230032, 
      China.
FAU - Chen, Jun
AU  - Chen J
AD  - Department of Endocrinology, the Second People' Hospital of Wuhu, Anhui, 230032, 
      China.
FAU - Zhu, Yu
AU  - Zhu Y
AD  - School of Basic Medical Science, and the, First Clinical Medical College, Anhui 
      Medical University, 81# Mei Shan Road, Hefei, 230032, Anhui, China.
FAU - Wang, Zhen
AU  - Wang Z
AD  - Department of Trauma and Spine Surgery, the Second People' Hospital of Wuhu, 
      Anhui, 230032, China.
FAU - Ma, Zhen
AU  - Ma Z
AD  - Department of Trauma and Spine Surgery, the Second People' Hospital of Wuhu, 
      Anhui, 230032, China.
FAU - Wu, Yu
AU  - Wu Y
AD  - Department of Trauma and Spine Surgery, the Second People' Hospital of Wuhu, 
      Anhui, 230032, China.
FAU - Wu, Faguo
AU  - Wu F
AD  - Department of Geriatrics, the Second People' Hospital of Wuhu, Anhui, 230032, 
      China.
FAU - Zheng, Zhangan
AU  - Zheng Z
AD  - Department of Trauma and Spine Surgery, the Second People' Hospital of Wuhu, 
      Anhui, 230032, China. 114934833@qq.com.
LA  - eng
PT  - Journal Article
DEP - 20230407
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - Aged
MH  - Middle Aged
MH  - *Bone Density
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Aspirin/therapeutic use
MH  - Biomarkers
MH  - Absorptiometry, Photon
PMC - PMC10080941
OTO - NOTNLM
OT  - Aspirin
OT  - Bone
OT  - Cyclo-oxygenase
OT  - Nonsteroidal anti-inflammatory drugs
OT  - Osteoporosis
COIS- Li Zhang, Xuelei Ji, Jun Chen, Yu Zhu, Zhen Wang, Zhen Ma, Yu Wu, Faguo Wu and 
      Zhangan Zheng declare that they have no competing interests.
EDAT- 2023/04/08 06:00
MHDA- 2023/04/11 06:42
CRDT- 2023/04/07 23:33
PHST- 2022/08/15 00:00 [received]
PHST- 2023/02/28 00:00 [accepted]
PHST- 2023/04/11 06:42 [medline]
PHST- 2023/04/07 23:33 [entrez]
PHST- 2023/04/08 06:00 [pubmed]
AID - 10.1186/s12902-023-01309-2 [pii]
AID - 1309 [pii]
AID - 10.1186/s12902-023-01309-2 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2023 Apr 7;23(1):79. doi: 10.1186/s12902-023-01309-2.

PMID- 25045166
OWN - NLM
STAT- MEDLINE
DCOM- 20150514
LR  - 20220414
IS  - 1553-5606 (Electronic)
IS  - 1553-5592 (Linking)
VI  - 9
IP  - 9
DP  - 2014 Sep
TI  - Aspirin versus anticoagulation for prevention of venous thromboembolism major 
      lower extremity orthopedic surgery: a systematic review and meta-analysis.
PG  - 579-85
LID - 10.1002/jhm.2224 [doi]
AB  - BACKGROUND: Hip fracture surgery and lower extremity arthroplasty are associated 
      with increased risk of both venous thromboembolism and bleeding. The best 
      pharmacologic strategy for reducing these opposing risks is uncertain. PURPOSE: 
      To compare venous thromboembolism (VTE) and bleeding rates in adult patients 
      receiving aspirin versus anticoagulants after major lower extremity orthopedic 
      surgery. DATA SOURCES: Medline, Cumulative Index to Nursing and Allied Health 
      Literature, and the Cochrane Library through June 2013; reference lists, 
      ClinicalTrials.gov, and scientific meeting abstracts. STUDY SELECTION: Randomized 
      trials comparing aspirin to anticoagulants for prevention of VTE following major 
      lower extremity orthopedic surgery. DATA EXTRACTION: Two reviewers independently 
      extracted data on rates of VTE, bleeding, and mortality. DATA SYNTHESIS: Of 298 
      studies screened, 8 trials including 1408 participants met inclusion criteria; 
      all trials screened participants for deep venous thrombosis (DVT). Overall rates 
      of DVT did not differ statistically between aspirin and anticoagulants (relative 
      risk [RR]: 1.15 [95% confidence interval {CI}: 0.68-1.96]). Subgrouped by type of 
      surgery, there was a nonsignificant trend favoring anticoagulation following hip 
      fracture repair but not knee or hip arthroplasty (hip fracture RR: 1.60 [95% CI: 
      0.80-3.20], 2 trials; arthroplasty RR: 1.00 [95% CI: 0.49-2.05], 5 trials). The 
      risk of bleeding was lower with aspirin than anticoagulants following hip 
      fracture repair (RR: 0.32 [95% CI: 0.13-0.77], 2 trials), with a nonsignificant 
      trend favoring aspirin after arthroplasty (RR: 0.63 [95% CI: 0.33-1.21], 5 
      trials). Rates of pulmonary embolism were too low to provide reliable estimates. 
      CONCLUSION: Compared with anticoagulation, aspirin may be associated with higher 
      risk of DVT following hip fracture repair, although bleeding rates were 
      substantially lower. Aspirin was similarly effective after lower extremity 
      arthroplasty and may be associated with lower bleeding risk. Journal of Hospital 
      Medicine 2014;9:579-585. © 2014 Society of Hospital Medicine.
CI  - © 2014 Society of Hospital Medicine.
FAU - Drescher, Frank S
AU  - Drescher FS
AD  - Geisel School of Medicine at Dartmouth, Pulmonary and Critical Care Medicine, 
      Veterans Affairs Medical Center, White River Junction, Vermont.
FAU - Sirovich, Brenda E
AU  - Sirovich BE
FAU - Lee, Alexandra
AU  - Lee A
FAU - Morrison, Daniel H
AU  - Morrison DH
FAU - Chiang, Wesley H
AU  - Chiang WH
FAU - Larson, Robin J
AU  - Larson RJ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20140717
PL  - United States
TA  - J Hosp Med
JT  - Journal of hospital medicine
JID - 101271025
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Arthroplasty, Replacement, Hip
MH  - Arthroplasty, Replacement, Knee
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Hip Fractures/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Orthopedic Procedures
MH  - Randomized Controlled Trials as Topic
MH  - Venous Thromboembolism/*prevention & control
EDAT- 2014/07/22 06:00
MHDA- 2015/05/15 06:00
CRDT- 2014/07/22 06:00
PHST- 2014/02/12 00:00 [received]
PHST- 2014/05/09 00:00 [revised]
PHST- 2014/05/20 00:00 [accepted]
PHST- 2014/07/22 06:00 [entrez]
PHST- 2014/07/22 06:00 [pubmed]
PHST- 2015/05/15 06:00 [medline]
AID - 10.1002/jhm.2224 [doi]
PST - ppublish
SO  - J Hosp Med. 2014 Sep;9(9):579-85. doi: 10.1002/jhm.2224. Epub 2014 Jul 17.

PMID- 1189936
OWN - NLM
STAT- MEDLINE
DCOM- 19760130
LR  - 20151119
IS  - 0001-6772 (Print)
IS  - 0001-6772 (Linking)
VI  - 95
IP  - 3
DP  - 1975 Nov
TI  - Depression of taste responses by local or intravascular administration of 
      salicylates in the rat.
PG  - 286-92
AB  - The effects of aspirin and sodium salicylate on the taste response in the chorda 
      tympani proper nerve have been studied during stimulation of the taste receptors 
      in rats with salty, sweet, sour and bitter-tasting solutions. Three methods of 
      administering the drugs were used: locally on the tongue, intravenously into one 
      femoral vein and intraarterially close to the branching of the lingual artery. It 
      was observed that salicylates, given in any of these three ways, depressed the 
      response to taste stimuli. This is discussed in relation to present views on the 
      action of salicylates.
FAU - Hellekant, G
AU  - Hellekant G
FAU - Gopal, V
AU  - Gopal V
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Physiol Scand
JT  - Acta physiologica Scandinavica
JID - 0370362
RN  - 451W47IQ8X (Sodium Chloride)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Depression, Chemical
MH  - Indomethacin/pharmacology
MH  - Injections, Intra-Arterial
MH  - Injections, Intravenous
MH  - Male
MH  - Rats
MH  - Sodium Chloride
MH  - Sodium Salicylate/administration & dosage/*pharmacology
MH  - Taste Buds/*drug effects
EDAT- 1975/11/01 00:00
MHDA- 1975/11/01 00:01
CRDT- 1975/11/01 00:00
PHST- 1975/11/01 00:00 [pubmed]
PHST- 1975/11/01 00:01 [medline]
PHST- 1975/11/01 00:00 [entrez]
AID - 10.1111/j.1748-1716.1975.tb10052.x [doi]
PST - ppublish
SO  - Acta Physiol Scand. 1975 Nov;95(3):286-92. doi: 
      10.1111/j.1748-1716.1975.tb10052.x.

PMID- 32237005
OWN - NLM
STAT- MEDLINE
DCOM- 20210408
LR  - 20210408
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Print)
IS  - 1053-8569 (Linking)
VI  - 29
IP  - 5
DP  - 2020 May
TI  - A behavioral economics-based telehealth intervention to improve aspirin adherence 
      following hospitalization for acute coronary syndrome.
PG  - 513-517
LID - 10.1002/pds.4988 [doi]
AB  - PURPOSE: A significant number of patients with acute coronary syndrome (ACS) are 
      nonadherent to aspirin after hospital discharge, with an associated increased 
      risk of subsequent cardiovascular events. The purpose of this pilot study was to 
      test the efficacy of a telehealth intervention based on behavioral economics to 
      improve aspirin adherence following hospitalization for ACS. METHODS: We enrolled 
      130 participants (c¯X = 58 ± 10.7 years of age, 38% female, 45% black) from two 
      hospitals. Patients were eligible if they owned a smartphone and were admitted to 
      the hospital for ACS, prescribed aspirin at discharge, and responsible for 
      administering their own medications. Consenting participants were randomized to 
      the intervention or usual care group. The intervention group was eligible to 
      receive up to $50 per month if they took their medicine daily, with $2 per day 
      deducted if a dose was missed. All participants received an electronic monitoring 
      (EM) pill bottle containing a 90-day supply of aspirin, which was used to measure 
      adherence calculated as the proportion of prescribed drug taken using the EM 
      device. Based on the skewness in the adherence distribution, quantile regression 
      was used to evaluate the effect of the intervention on median adherence over 
      time. RESULTS: After 90 days, adherence fell in the control group but remained 
      high in the intervention group (median adherence 81% vs 90%, P = .18). 
      Rehospitalization was higher in the control group (24% vs 13%, P = .17). 
      CONCLUSION: A loss aversion behavioral economics-based telehealth intervention is 
      a promising approach to improving aspirin adherence following hospitalization for 
      ACS.
CI  - © 2020 John Wiley & Sons Ltd.
FAU - Riegel, Barbara
AU  - Riegel B
AUID- ORCID: 0000-0002-0970-136X
AD  - School of Nursing at the University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - Stephens-Shields, Alisa
AU  - Stephens-Shields A
AD  - Department of Biostatistics, Epidemiology and Informatics, Perelman School of 
      Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - Jaskowiak-Barr, Anne
AU  - Jaskowiak-Barr A
AD  - Department of Biostatistics, Epidemiology and Informatics, Perelman School of 
      Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - Daus, Marguerite
AU  - Daus M
AD  - School of Nursing at the University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - Kimmel, Stephen E
AU  - Kimmel SE
AD  - Department of Biostatistics, Epidemiology and Informatics, Perelman School of 
      Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
LA  - eng
GR  - T32 NR007104/NR/NINR NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200331
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Economics, Behavioral
MH  - Female
MH  - Humans
MH  - Male
MH  - *Medication Adherence
MH  - Middle Aged
MH  - *Patient Discharge
MH  - Pennsylvania
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Telemedicine/*economics
PMC - PMC7217735
MID - NIHMS1580519
OTO - NOTNLM
OT  - behavioral economics
OT  - loss aversion
OT  - medication adherence
OT  - myocardial infarction
OT  - pharmacoepidemiology
OT  - randomized controlled trial
OT  - technology
OT  - unstable angina
EDAT- 2020/04/03 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/04/03 06:00
PHST- 2019/08/10 00:00 [received]
PHST- 2020/02/08 00:00 [revised]
PHST- 2020/02/11 00:00 [accepted]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1002/pds.4988 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2020 May;29(5):513-517. doi: 10.1002/pds.4988. Epub 
      2020 Mar 31.

PMID- 10761956
OWN - NLM
STAT- MEDLINE
DCOM- 20000421
LR  - 20191210
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 160
IP  - 7
DP  - 2000 Apr 10
TI  - Self-selected posttrial aspirin use and subsequent cardiovascular disease and 
      mortality in the physicians' health study.
PG  - 921-8
AB  - BACKGROUND: The randomized aspirin component of the Physicians' Health Study 
      (PHS) was terminated early, after 5 years, primarily because of the emergence of 
      a statistically extreme (P<.00001) 44% reduction of first myocardial infarction 
      (MI) among those assigned to aspirin. As a result, there were insufficient 
      numbers of strokes or cardiovascular disease (CVD)-related deaths to evaluate 
      these end points definitively. METHODS: Data on self-selected aspirin use were 
      collected until the beta carotene component ended as scheduled after 12 years. 
      Posttrial use of aspirin was assessed at the 7-year follow-up among 18 496 
      participants with no previous reported CVD. Randomized and posttrial 
      observational results in the PHS were compared, and differences between those 
      self-selecting aspirin and those not were examined. RESULTS: At 7 years, 59.5% of 
      participants without CVD reported self-selected aspirin use for at least 180 d/y, 
      and 20.8% for 0 to 13 d/y. Use was significantly associated with family history 
      of MI, hypertension, elevated cholesterol levels, body mass index, alcohol 
      consumption, exercise, and use of vitamin E supplements. In multivariate 
      analyses, self-selected aspirin use for at least 180 vs 0 to 13 d/y was 
      associated with lower risk for subsequent MI (relative risk [RR], 0.72; 95% 
      confidence interval [CI], 0.55-0.95), no relation with stroke (RR, 1.02; 95% CI, 
      0.74-1.39), and significant reductions in CVD-related (RR, 0.65; CI, 0.47-0.89) 
      and total mortality (RR, 0.64; CI, 0.54-0.77). CONCLUSION: These associations 
      between self-selected aspirin use and CVD risk factors increase the likelihood of 
      residual confounding and emphasize the need for large-scale randomized trials, 
      such as the ongoing Women's Health Study, to detect reliably the most plausible 
      small to moderate effects of aspirin in the primary prevention of stroke and 
      CVD-related death.
FAU - Cook, N R
AU  - Cook NR
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, Mass 02215-1204, USA. ncook@rics.bwh.harvard.edu
FAU - Hebert, P R
AU  - Hebert PR
FAU - Manson, J E
AU  - Manson JE
FAU - Buring, J E
AU  - Buring JE
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA-34944/CA/NCI NIH HHS/United States
GR  - CA-40360/CA/NCI NIH HHS/United States
GR  - HL-26490/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/*mortality/*prevention & control
MH  - Confounding Factors, Epidemiologic
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Risk
MH  - Risk Factors
MH  - *Self Medication
MH  - Stroke/*mortality/*prevention & control
EDAT- 2000/04/13 09:00
MHDA- 2000/04/29 09:00
CRDT- 2000/04/13 09:00
PHST- 2000/04/13 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/04/13 09:00 [entrez]
AID - 10.1001/archinte.160.7.921 [doi]
PST - ppublish
SO  - Arch Intern Med. 2000 Apr 10;160(7):921-8. doi: 10.1001/archinte.160.7.921.

PMID- 28675268
OWN - NLM
STAT- MEDLINE
DCOM- 20180914
LR  - 20181202
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 12
IP  - 529
DP  - 2016 Sep 7
TI  - [News about pericardial diseases in 2016].
PG  - 1475-1478
AB  - The European Society of Cardiology published in 2015 the new Guidelines on the 
      management of pericardial diseases. Based on experts' opinions and recent 
      clinical studies of respectable size, the new guidelines thoroughly revisit the 
      criteria for hospitalization and precisely define severe cases. Another highlight 
      regards medication. From now, first-line medical therapy should include the 
      association of colchicine to the traditional non steroidal anti-inflammatory 
      drugs or aspirin. The bi-therapy is recommended as soon as the first episode of 
      pericarditis, for duration of 3 months. The experts also recommend systematically 
      performing a heart ultrasound for any form of pericardial disease and restricting 
      physical activities especially if myocardial damage (perimyocarditis) is 
      associated.
FAU - Karpuz, Baris
AU  - Karpuz B
AD  - Service de cardiologie, Hôpital du Valais, Centre hospitalier du centre du 
      Valais, Hôpital de Sion, Avenue du Grand-Champsec 80, 1950 Sion.
FAU - Duchatelle, Valèrie
AU  - Duchatelle V
AD  - Service de cardiologie, Hôpital du Valais, Centre hospitalier du centre du 
      Valais, Hôpital de Sion, Avenue du Grand-Champsec 80, 1950 Sion.
FAU - Tapponnier, Maxime
AU  - Tapponnier M
AD  - Service de cardiologie, Hôpital du Valais, Centre hospitalier du centre du 
      Valais, Hôpital de Sion, Avenue du Grand-Champsec 80, 1950 Sion.
FAU - Alexe, Raluca
AU  - Alexe R
AD  - Service de cardiologie, Hôpital du Valais, Centre hospitalier du centre du 
      Valais, Hôpital de Sion, Avenue du Grand-Champsec 80, 1950 Sion.
FAU - Sierro, Christophe
AU  - Sierro C
AD  - Service de cardiologie, Hôpital du Valais, Centre hospitalier du centre du 
      Valais, Hôpital de Sion, Avenue du Grand-Champsec 80, 1950 Sion.
FAU - Girod, Grègoire
AU  - Girod G
AD  - Service de cardiologie, Hôpital du Valais, Centre hospitalier du centre du 
      Valais, Hôpital de Sion, Avenue du Grand-Champsec 80, 1950 Sion.
LA  - fre
PT  - Journal Article
TT  - Maladies du péricarde : quoi de neuf en 2016 ?
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Colchicine/therapeutic use
MH  - Humans
MH  - Pericarditis/*drug therapy
COIS- Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
EDAT- 2017/07/05 06:00
MHDA- 2018/09/15 06:00
CRDT- 2017/07/05 06:00
PHST- 2017/07/05 06:00 [entrez]
PHST- 2017/07/05 06:00 [pubmed]
PHST- 2018/09/15 06:00 [medline]
PST - ppublish
SO  - Rev Med Suisse. 2016 Sep 7;12(529):1475-1478.

PMID- 2757898
OWN - NLM
STAT- MEDLINE
DCOM- 19890911
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 27
IP  - 6
DP  - 1989 Jun
TI  - Differential effects of flurbiprofen and aspirin on acetazolamide disposition in 
      humans.
PG  - 866-9
AB  - The plasma concentration-time profile of acetazolamide (AZ) following an 
      intravenous bolus dose (5 mg kg-1) was determined during control, aspirin and 
      flurbiprofen (FLU) treatment periods. The unbound fraction of AZ in plasma 
      increased three-fold in the presence of salicylate (SA) while, in contrast, FLU 
      produced consistent, but statistically insignificant, increases in binding. SA 
      caused a two-fold decrease in both unbound AZ renal clearance and apparent volume 
      of distribution at steady-state, while FLU produced a small, but significant, 
      increase only in the latter. The area under the concentration-time curve for AZ 
      in erythrocytes was increased by about 40% during SA treatment while FLU had no 
      effect. Our results suggest that on a pharmacokinetic basis FLU may be a safer 
      nonsteroidal anti-inflammatory drug (NSAID) to co-administer with AZ.
FAU - Sweeney, K R
AU  - Sweeney KR
AD  - School of Pharmacy, University of Connecticut, Storrs 06268.
FAU - Chapron, D J
AU  - Chapron DJ
FAU - Antal, E J
AU  - Antal EJ
FAU - Kramer, P A
AU  - Kramer PA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - O3FX965V0I (Acetazolamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetazolamide/blood/*pharmacokinetics
MH  - Adult
MH  - Aspirin/blood/pharmacokinetics/*pharmacology
MH  - Drug Interactions
MH  - Flurbiprofen/blood/pharmacokinetics/*pharmacology
MH  - Humans
MH  - Male
MH  - Propionates/*pharmacology
PMC - PMC1379816
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1989.tb03451.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1989 Jun;27(6):866-9. doi: 
      10.1111/j.1365-2125.1989.tb03451.x.

PMID- 713267
OWN - NLM
STAT- MEDLINE
DCOM- 19790126
LR  - 20190725
IS  - 0085-2538 (Print)
IS  - 0085-2538 (Linking)
VI  - 13
IP  - 1
DP  - 1978 Jan
TI  - Experimental renal papillary necrosis.
PG  - 5-14
AB  - Review of experimental work indicates that renal papillary necrosis (RPN) is more 
      readily induced by mixtures of analgesics which include phenacetin or 
      paracetamol, than by either of the latter drugs alone. In an experiment in which 
      moderate doses of analgesics were given to rats over a long period, it was shown 
      that aspirin had a greater nephrotoxic effect than either phenacetin or 
      paracetamol although less than in combination with either. In a study of the 
      evolution of aspirin-induced damage, the earliest changes were shown to occur in 
      the interstitial cells. There was also loss of medullary mucopolysaccharides. 
      Occlusive lesions were demonstrated in the vasa recta. Using partial 
      papillectomy, it was shown that the development of analgesic-induced cortical 
      lesions did not depend on the presence of papillary necrosis. It was suggested 
      that the early papillary changes might be due to ischemia, medullary blood flow 
      being reduced as a result of aspirin's action as an inhibitor of prostagladin 
      synthesis. The lesions in the vasa recta might cause ischemia at a late stage, 
      leading to total RPN.
FAU - Molland, E A
AU  - Molland EA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*toxicity
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Body Weight
MH  - Drug Combinations
MH  - Female
MH  - Kidney Cortex/pathology
MH  - Kidney Medulla/drug effects/pathology/ultrastructure
MH  - Kidney Papillary Necrosis/*chemically induced/pathology
MH  - Kidney Tubules, Collecting/drug effects/pathology
MH  - Loop of Henle/drug effects/pathology
MH  - Microscopy, Electron
MH  - Phenacetin/*toxicity
MH  - Rats
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - S0085-2538(15)31846-9 [pii]
AID - 10.1038/ki.1978.2 [doi]
PST - ppublish
SO  - Kidney Int. 1978 Jan;13(1):5-14. doi: 10.1038/ki.1978.2.

PMID- 6489846
OWN - NLM
STAT- MEDLINE
DCOM- 19841212
LR  - 20180217
IS  - 0378-7346 (Print)
IS  - 0378-7346 (Linking)
VI  - 18
IP  - 3
DP  - 1984
TI  - Do aspirin and acetaminophen affect total menstrual loss?
PG  - 129-33
AB  - Two commonly taken over-the-counter analgesics, aspirin and acetaminophen, were 
      compared for: effect on total menstrual loss, effect on total days of 
      menstruation, and effect in reduction of pain due to headaches and/or menstrual 
      cramps. Drugs were administered during a 4-month study according to a 
      double-blind format. During the first 2 months, subjects ingested no drugs 
      whatsoever during their menstrual periods. During the second 2 months, subjects 
      ingested aspirin, acetaminophen, or placebo at the rate of two 325-mg tablets 
      every 4 h to total 8 tablets per day during the first 3 days of their menstrual 
      periods. Statistical analysis of the first 2 periods compared to the last 2 
      showed no differences in total menstrual weights. The number of days of 
      menstruation in the placebo group was significantly lower (p = 0.0137) than in 
      its own control or in the other groups. Neither analgesic showed a significant 
      reduction in pain due to headache or cramps, although acetaminophen appeared to 
      be slightly more effective than aspirin in reducing menstrual cramps.
FAU - Pendergrass, P B
AU  - Pendergrass PB
FAU - Ream, L J
AU  - Ream LJ
FAU - Scott, J N
AU  - Scott JN
FAU - Agna, M A
AU  - Agna MA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Gynecol Obstet Invest
JT  - Gynecologic and obstetric investigation
JID - 7900587
RN  - 0 (Analgesics)
RN  - 0 (Prostaglandin Antagonists)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology/therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Analgesics/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Double-Blind Method
MH  - Dysmenorrhea/drug therapy
MH  - Female
MH  - Headache/drug therapy
MH  - Humans
MH  - Menstruation/*drug effects
MH  - Prostaglandin Antagonists/pharmacology/therapeutic use
MH  - Time Factors
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1159/000299067 [doi]
PST - ppublish
SO  - Gynecol Obstet Invest. 1984;18(3):129-33. doi: 10.1159/000299067.

PMID- 34581730
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20211013
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 326
IP  - 12
DP  - 2021 Sep 28
TI  - Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated 
      Evidence Report and Systematic Review for the US Preventive Services Task Force.
PG  - 1192-1206
LID - 10.1001/jama.2021.8551 [doi]
AB  - IMPORTANCE: Preeclampsia is a hypertensive disorder of pregnancy that poses 
      serious maternal and infant health risks. Previous systematic reviews have 
      established benefits of low-dose aspirin taken during pregnancy to prevent 
      preeclampsia and its sequelae. OBJECTIVE: To update evidence for the US 
      Preventive Services Task Force (USPSTF) on effectiveness of aspirin use in 
      preventing preeclampsia in individuals at increased risk based on clinical risk 
      factors or measurements associated with higher disease incidence than in the 
      general population. DATA SOURCES: Studies from previous USPSTF review (2014), 
      literature published January 2013 through May 15, 2020, in MEDLINE, PubMed (for 
      publisher-supplied records only), EMBASE, and Cochrane Central Register of 
      Controlled Trials. Ongoing surveillance through January 22, 2021. STUDY 
      SELECTION: Good- and fair-quality randomized clinical trials (RCTs) of low-dose 
      aspirin use during pregnancy to prevent preeclampsia among individuals at 
      increased risk; studies conducted in general populations to evaluate potential 
      harms. DATA EXTRACTION AND SYNTHESIS: Dual article screening and risk-of-bias 
      assessment. Study data abstracted into prespecified forms, checked for accuracy. 
      Random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Diagnosis of 
      preeclampsia; adverse pregnancy health outcomes and complications including 
      eclampsia, perinatal mortality, preterm birth, small for gestational age, and 
      potential bleeding harms or infant/child harms from aspirin exposure. RESULTS: A 
      total of 23 randomized clinical trials (RCTs) (N = 26 952) were included; 18 were 
      conducted among participants at increased preeclampsia risk. Aspirin dosages 
      ranged from 50 mg/d to 150 mg/d. Most trials enrolled majority White populations 
      selected based on a range of risk factors. The incidence of preeclampsia among 
      the trials of participants at increased risk ranged from 4% to 30%. Aspirin use 
      was significantly associated with lower risk of preeclampsia (pooled relative 
      risk [RR], 0.85 [95% CI, 0.75-0.95]; 16 RCTs [n = 14 093]; I2 = 0%), perinatal 
      mortality (pooled RR, 0.79 [95% CI, 0.66-0.96]; 11 RCTs [n = 13 860]; I2 = 0%), 
      preterm birth (pooled RR, 0.80 [95% CI, 0.67-0.95]; 13 RCTs [n = 13 619]; 
      I2 = 49%), and intrauterine growth restriction (pooled RR, 0.82 [95% CI, 
      0.68-0.99]; 16 RCTs [n = 14 385]; I2 = 41%). There were no significant 
      associations of aspirin use with risk of postpartum hemorrhage (pooled RR, 1.03 
      [95% CI, 0.94-1.12]; 9 RCTs [n = 23 133]; I2 = 0%) and other bleeding-related 
      harms, or with rare perinatal or longer-term harms. Absolute risk reductions for 
      preeclampsia associated with aspirin use ranged from -1% to -6% across larger 
      trials (n >300) and were greater in smaller trials. For perinatal mortality, 
      absolute risk reductions ranged from 0.5% to 1.1% in the 3 largest trials. 
      CONCLUSIONS AND RELEVANCE: Daily low-dose aspirin during pregnancy was associated 
      with lower risks of serious perinatal outcomes for individuals at increased risk 
      for preeclampsia, without evident harms.
FAU - Henderson, Jillian T
AU  - Henderson JT
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
FAU - Vesco, Kimberly K
AU  - Vesco KK
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
FAU - Senger, Caitlyn A
AU  - Senger CA
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
FAU - Thomas, Rachel G
AU  - Thomas RG
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
FAU - Redmond, Nadia
AU  - Redmond N
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Systematic Review
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Small for Gestational Age
MH  - Perinatal Death/prevention & control
MH  - Postpartum Hemorrhage/etiology
MH  - Practice Guidelines as Topic
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Premature Birth/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
EDAT- 2021/09/29 06:00
MHDA- 2021/10/14 06:00
CRDT- 2021/09/28 12:18
PHST- 2021/09/28 12:18 [entrez]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
AID - 2784500 [pii]
AID - 10.1001/jama.2021.8551 [doi]
PST - ppublish
SO  - JAMA. 2021 Sep 28;326(12):1192-1206. doi: 10.1001/jama.2021.8551.

PMID- 9147279
OWN - NLM
STAT- MEDLINE
DCOM- 19970717
LR  - 20131121
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 14
IP  - 3
DP  - 1997 May-Jun
TI  - The influence of microencapsulation using Eudragit RS100 on the hydrolysis 
      kinetics of acetylsalicylic acid.
PG  - 281-301
AB  - Homogeneous Eudragit RS100 matrix microspheres containing molecularly dispersed 
      acetylsalicylic acid (ASA) were prepared in order to investigate the effect of 
      encapsulation on the decomposition rate of a hydrolytically susceptible drug. 
      ASA-loaded microspheres of this non-eroding polymer matrix were analysed at 
      predetermined time points following immersion of the microspheres in temperature 
      controlled buffer systems at pH 1.2 or pH 12.1 at 30, 40 or 50 degrees C. The 
      mass balance of the total amount of solutes (ASA and SA) initially located within 
      the microsphere interior was equal to the sum of the amount of solutes remaining 
      in the microsphere interior and the amount of solutes in the aqueous phase at any 
      time during the course of the study. Each analysis involved the quantitation of 
      four species; the drug and decomposition product, salicylic acid (SA), in both 
      the microspheres phase and the external aqueous phase. A simple model system 
      using first-order rate approximations for the concurrent Fickian diffusion and 
      hydrolysis decomposition of the drug resulted in a multiexponential expression 
      which adequately described the time-course profile of the drug. SA-loaded 
      microspheres were used as a control under similar conditions to determine the 
      magnitude of the contribution of microsphere phase hydrolysis of ASA to the 
      overall rate of drug loss from the microspheres. Results indicated that 
      microspheres phase hydrolysis of ASA was minimal. Even after 900 h of immersion 
      in pH 12.1 buffer some ASA remained within the microsphere. It is postulated that 
      the matrix incorporated drug is essentially shielded from hydrolytic attack until 
      it is liberated into the external aqueous environment. Electrostatic association 
      of the drug with the charged quaternary residues in the polymer along with the 
      limiting availability of water within the microsphere may be responsible for the 
      observed stability of ASA in aqueous swollen ASA-loaded Eudragit microspheres.
FAU - Vachon, M G
AU  - Vachon MG
AD  - Faculty of Pharmacy, University of Toronto, Ontario, Canada.
FAU - Nairn, J G
AU  - Nairn JG
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Acrylic Resins)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Capsules)
RN  - 0 (Gels)
RN  - 0 (Polymethacrylic Acids)
RN  - 25086-15-1 (methylmethacrylate-methacrylic acid copolymer)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acrylic Resins
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*chemistry
MH  - Aspirin/*administration & dosage/*chemistry
MH  - Capsules
MH  - Diffusion
MH  - Drug Compounding
MH  - Gels
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - Kinetics
MH  - Models, Theoretical
MH  - Polymethacrylic Acids
MH  - Temperature
MH  - Thermodynamics
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - 10.3109/02652049709051133 [doi]
PST - ppublish
SO  - J Microencapsul. 1997 May-Jun;14(3):281-301. doi: 10.3109/02652049709051133.

PMID- 1771935
OWN - NLM
STAT- MEDLINE
DCOM- 19920227
LR  - 20131121
IS  - 0044-2771 (Print)
IS  - 0044-2771 (Linking)
VI  - 29
IP  - 11
DP  - 1991 Nov
TI  - [75 mg roxatidine nocte protects human gastric mucosa against 300 mg 
      acetylsalicylic acid nocte].
PG  - 599-601
AB  - In a randomized double-blind parallel study the gastroduodenal tolerability of 
      300 mg ASS nocte (8 p.m.) has been evaluated in the presence of 75 mg roxatidine 
      nocte (8 p.m.) or placebo in 20 healthy volunteers using upper GI-endoscopy. The 
      treatment periods lasted 14 days. Endoscopic controls were performed at entry, 
      and repeated at day 7 and day 14. At entry the mean endoscopic score averaged 0.9 
      +/- 0.1 in the ASS/placebo-group and 0.9 +/- 0.1 in the ASS/roxatidine-group. The 
      median values were 1.0 and 1.0. 300 mg ASS nocte induced in the 
      placebo-experiments marked gastroduodenal lesions both at day 7 and day 14 (6.5 
      +/- 1.2 and 7.9 +/- 0.7, respectively). The median values were 8.0 and 9.0, 
      respectively. Concomitant administration of 75 mg roxatidine nocte afforded 
      significant protection against 300 mg ASS nocte both on day 7 and day 14 (3.3 +/- 
      1.0 and 3.1 +/- 0.9, respectively) (p less than 0.05). The corresponding median 
      values were 1.0 and 1.0. Our data suggest that coadministration of roxatidine 
      nocte reduces significantly gastroduodenal lesions evoked by acetylsalicylic acid 
      300 mg nocte.
FAU - Simon, B
AU  - Simon B
AD  - Kreiskrankenhaus Schwetzingen, Bundesrepublik Deutschland.
FAU - Bergdolt, H
AU  - Bergdolt H
FAU - Dammann, H G
AU  - Dammann HG
FAU - Müller, P
AU  - Müller P
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - 75 mg Roxatidin nocte schützen die menschliche Magenschleimhaut gegenüber 300 mg 
      Acetylsalizylsäure nocte.
PL  - Germany
TA  - Z Gastroenterol
JT  - Zeitschrift fur Gastroenterologie
JID - 0033370
RN  - 884KT10YB7 (Ranitidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Intestinal Mucosa/*drug effects
MH  - Male
MH  - Peptic Ulcer/*chemically induced/*prevention & control
MH  - Ranitidine/*administration & dosage
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
PST - ppublish
SO  - Z Gastroenterol. 1991 Nov;29(11):599-601.

PMID- 5427355
OWN - NLM
STAT- MEDLINE
DCOM- 19700826
LR  - 20190618
IS  - 0036-8075 (Print)
IS  - 0036-8075 (Linking)
VI  - 169
IP  - 3941
DP  - 1970 Jul 10
TI  - Acetylsalicylic acid: no chromosome damage in human leukocytes.
PG  - 198-201
AB  - Acetylsalicylic acid was added to cultures of human leukocytes at several time 
      periods over a wide range of concentrations (0.1 to 300.0 micrograms per 
      milliliter). Leukocytes were also cultured from human volunteers during the 
      ingestion of two 300-milligram tablets four times daily (2400 milligrams per day) 
      over a 1-month period. No significant increase in chromosome aberrations was 
      detected in vitro or in vivo.
FAU - Mauer, I
AU  - Mauer I
FAU - Weinstein, D
AU  - Weinstein D
FAU - Solomon, H M
AU  - Solomon HM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Chromosome Aberrations/*drug effects
MH  - Culture Techniques
MH  - Humans
MH  - Leukocytes/*cytology
MH  - Mitosis
EDAT- 1970/07/10 00:00
MHDA- 1970/07/10 00:01
CRDT- 1970/07/10 00:00
PHST- 1970/07/10 00:00 [pubmed]
PHST- 1970/07/10 00:01 [medline]
PHST- 1970/07/10 00:00 [entrez]
AID - 10.1126/science.169.3941.198 [doi]
PST - ppublish
SO  - Science. 1970 Jul 10;169(3941):198-201. doi: 10.1126/science.169.3941.198.

PMID- 25340283
OWN - NLM
STAT- MEDLINE
DCOM- 20150814
LR  - 20141024
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 12
IP  - 11
DP  - 2014 Nov
TI  - Genotype- and phenotype-directed antiplatelet therapy selection in patients with 
      acute coronary syndromes.
PG  - 1289-303
LID - 10.1586/14779072.2014.970180 [doi]
AB  - Although dual antiplatelet therapy (DAPT) has been a standard treatment in 
      patients with acute coronary syndrome (ACS) for over a decade, only recently have 
      therapeutic options beyond aspirin and clopidogrel become available. Additional 
      treatment options are particularly useful because of the documented history of 
      variability in antiplatelet response. This article reviews the current treatment 
      options for DAPT in ACS, and reviews both genotype- and phenotype-guided methods 
      for determining optimal antiplatelet therapy for patients with ACS. Additionally, 
      recommendations from current guidelines as well as expert commentary are provided 
      for the use of available testing methods to determine optimal DAPT for ACS 
      patients.
FAU - Ismail, Sahar
AU  - Ismail S
AD  - Department of Medicine, University of Illinois, Chicago, IL, USA.
FAU - Lee, Yee Ming
AU  - Lee YM
FAU - Patel, Meet
AU  - Patel M
FAU - Duarte, Julio D
AU  - Duarte JD
FAU - Ardati, Amer K
AU  - Ardati AK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Genotype
MH  - Humans
MH  - Patient Selection
MH  - Phenotype
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - P2Y12 Inhibitors
OT  - acute coronary syndrome
OT  - antiplatelet
OT  - aspirin
OT  - clopidogrel
OT  - personalized medicine
OT  - pharmacogenetic
OT  - prasugrel
OT  - precision medicine
OT  - ticagrelor
EDAT- 2014/10/24 06:00
MHDA- 2015/08/15 06:00
CRDT- 2014/10/24 06:00
PHST- 2014/10/24 06:00 [entrez]
PHST- 2014/10/24 06:00 [pubmed]
PHST- 2015/08/15 06:00 [medline]
AID - 10.1586/14779072.2014.970180 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2014 Nov;12(11):1289-303. doi: 
      10.1586/14779072.2014.970180.

PMID- 28159420
OWN - NLM
STAT- MEDLINE
DCOM- 20170615
LR  - 20181202
IS  - 1532-8406 (Electronic)
IS  - 0883-5403 (Linking)
VI  - 32
IP  - 5
DP  - 2017 May
TI  - Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression 
      Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A 
      Randomized Control Trial.
PG  - 1478-1482
LID - S0883-5403(16)30912-3 [pii]
LID - 10.1016/j.arth.2016.12.027 [doi]
AB  - BACKGROUND: Aspirin at 325 mg twice daily is now included as a nationally 
      approved venous thromboembolism (VTE) prophylaxis protocol for low-risk total 
      knee arthroplasty (TKA) patients. The purpose of this study is to examine whether 
      there is a difference in deep vein thrombosis (DVT) occurrence after a limited 
      tourniquet TKA using aspirin-based prophylaxis with or without extended use of 
      mechanical compression device (MCD) therapy. METHODS: One hundred limited 
      tourniquet TKA patients, whose DVT risk was managed with aspirin 325 mg twice 
      daily for 3 weeks, were randomized to either using an MCD during hospitalization 
      only or extended use at home up to 6 weeks postoperatively. Lower extremity 
      duplex venous ultrasonography (LEDVU) was completed on the second postoperative 
      day, 14 days postoperatively, and at 3 months postoperatively to confirm the 
      absence of DVT after treatment. RESULTS: The DVT rate for the postdischarge MCD 
      therapy group was 0% and 23.1% for the inpatient MCD group (P < .001). All DVTs 
      resolved by 3 months postoperatively. Patient satisfaction was 9.56 (±0.82) for 
      postdischarge MCD patients vs 8.50 (±1.46) for inpatient MCD patients (P < .001). 
      CONCLUSION: Limited tourniquet TKA patients who were mobilized early, managed 
      with aspirin for 3 weeks postoperatively, and on MCD therapy for up to 6 weeks 
      postoperatively experienced superior DVT prophylaxis than patients receiving MCD 
      therapy only as an inpatient (P < .05). The 0% incidence of nonsymptomatic DVTs 
      prevented by aspirin and extended-use MCD further validates this type of 
      prophylaxis in low DVT risk TKA patients.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Snyder, Mark A
AU  - Snyder MA
AD  - Trihealth Orthopaedic and Sports Institute, Cincinnati, Ohio.
FAU - Sympson, Alexandra N
AU  - Sympson AN
AD  - Trihealth Hatton Research Institute, Good Samaritan Hospital, Cincinnati, Ohio.
FAU - Scheuerman, Christina M
AU  - Scheuerman CM
AD  - Trihealth Hatton Research Institute, Good Samaritan Hospital, Cincinnati, Ohio.
FAU - Gregg, Justin L
AU  - Gregg JL
AD  - Trihealth Hatton Research Institute, Good Samaritan Hospital, Cincinnati, Ohio.
FAU - Hussain, Lala R
AU  - Hussain LR
AD  - Trihealth Hatton Research Institute, Good Samaritan Hospital, Cincinnati, Ohio.
LA  - eng
SI  - ClinicalTrials.gov/NCT02102828
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20161223
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Arthroplasty. 2017 Jul;32(7):2317-2318. PMID: 28413137
CIN - J Arthroplasty. 2017 Jul;32(7):2316-2317. PMID: 28413138
MH  - Aged
MH  - Arthroplasty, Replacement, Knee/*adverse effects/*methods
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - *Intermittent Pneumatic Compression Devices
MH  - Male
MH  - Middle Aged
MH  - Postoperative Period
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Ultrasonography, Doppler
MH  - Venous Thromboembolism/etiology/*prevention & control
MH  - Venous Thrombosis/etiology/*prevention & control
MH  - Wound Healing
OTO - NOTNLM
OT  - aspirin
OT  - deep vein thrombosis
OT  - mechanical compression
OT  - mobilization
OT  - prophylaxis
OT  - total knee
EDAT- 2017/02/06 06:00
MHDA- 2017/06/16 06:00
CRDT- 2017/02/05 06:00
PHST- 2016/07/05 00:00 [received]
PHST- 2016/12/13 00:00 [revised]
PHST- 2016/12/14 00:00 [accepted]
PHST- 2017/02/06 06:00 [pubmed]
PHST- 2017/06/16 06:00 [medline]
PHST- 2017/02/05 06:00 [entrez]
AID - S0883-5403(16)30912-3 [pii]
AID - 10.1016/j.arth.2016.12.027 [doi]
PST - ppublish
SO  - J Arthroplasty. 2017 May;32(5):1478-1482. doi: 10.1016/j.arth.2016.12.027. Epub 
      2016 Dec 23.

PMID- 14510928
OWN - NLM
STAT- MEDLINE
DCOM- 20040120
LR  - 20220408
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 23
IP  - 8
DP  - 2003 Oct
TI  - Abnormal habituation of 'nociceptive' blink reflex in migraine--evidence for 
      increased excitability of trigeminal nociception.
PG  - 814-9
AB  - We studied the habituation of the 'nociceptive' blink reflex (nBR) in 15 healthy 
      subjects and 17 migraine patients interictally as well as during unilateral 
      migraine headache within six hours of onset and after treatment. In healthy 
      volunteers the mean regression coefficient (MRC) was - 3.9 following right sided 
      and - 4.9 left sided stimulation. This equals an amplitude loss of 19.5% (5 x 
      -3.9) and 24.5% (5 x -4.9), respectively, across five consecutive sweeps. An 
      augmentation of nBR responses was found in migraine patients interictally: MRC = 
      3.3 following stimulation of the headache side (HA) and MRC = 4.0 of the 
      non-headache side (non-HA). The differences were statistically significant 
      (anova: d.f. = 1, F = 25.8, P < 0.001). During the migraine attack MRCs were 
      negative both before (-5.0, HA and - 4.0, non-HA) and after treatment (-2.6, HA 
      and - 1.9 non-HA) and significantly differed from those outside the migraine 
      attack (anova: d.f. = 2, F = 12.4, P < 0.001). The demonstrated lack of 
      habituation of the nBR responses indicates an abnormal trigeminal nociceptive 
      processing in migraine patients outside the migraine attack.
FAU - Katsarava, Z
AU  - Katsarava Z
AD  - Department of Neurology, University of Essen, Germany.
FAU - Giffin, N
AU  - Giffin N
FAU - Diener, H-C
AU  - Diener HC
FAU - Kaube, H
AU  - Kaube H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Oxazolidinones)
RN  - 0 (Tryptamines)
RN  - 2FS66TH3YW (zolmitriptan)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Blinking/drug effects/*physiology
MH  - Female
MH  - Follow-Up Studies
MH  - Habituation, Psychophysiologic/drug effects/*physiology
MH  - Humans
MH  - Lysine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/drug therapy/*physiopathology
MH  - Oxazolidinones/pharmacology/therapeutic use
MH  - Pain Measurement/drug effects/*methods
MH  - Trigeminal Nerve/drug effects/*physiology
MH  - Tryptamines
EDAT- 2003/09/27 05:00
MHDA- 2004/01/21 05:00
CRDT- 2003/09/27 05:00
PHST- 2003/09/27 05:00 [pubmed]
PHST- 2004/01/21 05:00 [medline]
PHST- 2003/09/27 05:00 [entrez]
AID - 591 [pii]
AID - 10.1046/j.1468-2982.2003.00591.x [doi]
PST - ppublish
SO  - Cephalalgia. 2003 Oct;23(8):814-9. doi: 10.1046/j.1468-2982.2003.00591.x.

PMID- 7443215
OWN - NLM
STAT- MEDLINE
DCOM- 19810224
LR  - 20190726
IS  - 0161-6420 (Print)
IS  - 0161-6420 (Linking)
VI  - 87
IP  - 8
DP  - 1980 Aug
TI  - Excretion of salicylic acid into tears following oral administration of aspirin.
PG  - 815-20
AB  - The concentration of salicylic acid in human tears has been measured by using 
      reverse-phase, high-pressure liquid chromatography. Pharmacokinetic profiles in 
      tears and in plasma have been obtained following oral administration of 650, 
      1300, and 1950 mg of aspirin in normal subjects. Salicylate excretion in tears is 
      dose-dependent and is proportional to the plasma concentration. Tear and plasma 
      salicylate levels for rheumatology patients on salicylates are also included.
FAU - Valentic, J P
AU  - Valentic JP
FAU - Leopold, I H
AU  - Leopold IH
FAU - Dea, F J
AU  - Dea FJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ophthalmology
JT  - Ophthalmology
JID - 7802443
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Chromatography, High Pressure Liquid
MH  - Humans
MH  - Salicylates/*analysis/metabolism
MH  - Tears/*analysis/metabolism
EDAT- 1980/08/01 00:00
MHDA- 1980/08/01 00:01
CRDT- 1980/08/01 00:00
PHST- 1980/08/01 00:00 [pubmed]
PHST- 1980/08/01 00:01 [medline]
PHST- 1980/08/01 00:00 [entrez]
AID - S0161-6420(80)35157-9 [pii]
AID - 10.1016/s0161-6420(80)35157-9 [doi]
PST - ppublish
SO  - Ophthalmology. 1980 Aug;87(8):815-20. doi: 10.1016/s0161-6420(80)35157-9.

PMID- 7398002
OWN - NLM
STAT- MEDLINE
DCOM- 19801027
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 62
IP  - 3
DP  - 1980 Sep
TI  - Persantine and aspirin in coronary heart disease. The Persantine-Aspirin 
      Reinfarction Study Research Group.
PG  - 449-61
AB  - In the Persantine-Aspirin Reinfarction Study (PARIS) trial, 2026 persons who had 
      recovered from myocardial infarction (MI) were randomized into three groups: 
      Persantine plus aspirin (PR/A) (n = 810); aspirin alone (ASA) (n = 810); placebo 
      (PLBO) (n = 406). The average length of follow-up study was 41 months. Results 
      for the three specified primary end points were: total mortality 16% lower in 
      PR/A and 18% lower in ASA compared with PLBO; coronary mortality 24% and 21% 
      lower; incidence of nonfatal MI plus fatal coronary disease 25% and 24% lower. 
      These differences were not satistically significant by the study criterion (Z 
      greater than or equal to 2.6). By life-table analysis, the rates of coronary 
      mortality and coronary incidence were about 50% lower in the PR/A group than in 
      the PLBO group from 8-24 months, and for coronary incidence all Z values were 
      greater than or equal to 2.6; ASA rates were about 30% lower than PLBO rates, and 
      for coronary incidence, Z values were greater than or equal to 2.6 at two points. 
      For these end points, from 8-20 months, PR/A rates were about 30% lower than ASA 
      rates, but all Z values were less than 2.0 PR/A and ASA patients entering within 
      6 months of last MI showed the largest percentage reductions in mortality; only 
      the difference between PR/A and PLBO groups for 3-year coronary mortality yielded 
      a Z value of 2.6.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Placebos)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Actuarial Analysis
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Coronary Disease/*drug therapy/mortality
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physician-Patient Relations
MH  - Placebos
EDAT- 1980/09/01 00:00
MHDA- 1980/09/01 00:01
CRDT- 1980/09/01 00:00
PHST- 1980/09/01 00:00 [pubmed]
PHST- 1980/09/01 00:01 [medline]
PHST- 1980/09/01 00:00 [entrez]
AID - 10.1161/01.cir.62.3.449 [doi]
PST - ppublish
SO  - Circulation. 1980 Sep;62(3):449-61. doi: 10.1161/01.cir.62.3.449.

PMID- 27143073
OWN - NLM
STAT- MEDLINE
DCOM- 20170130
LR  - 20221207
IS  - 0578-1310 (Print)
IS  - 0578-1310 (Linking)
VI  - 54
IP  - 5
DP  - 2016 May
TI  - [Pharmacogenomics study of 620 whole-exome sequencing: focusing on aspirin 
      application].
PG  - 332-6
LID - 10.3760/cma.j.issn.0578-1310.2016.05.005 [doi]
AB  - OBJECTIVE: To investigate the allele frequencies of aspirin-response-related 
      variants in different population. METHOD: The allele frequencies of reported 
      clinically significant aspirin-response-related variants were evaluated based on 
      620 whole exome sequencing (WES) data collected from 2013 to 2016 in Children's 
      Hospital of Fudan University.Then the local allele frequencies were compared with 
      1 000 Genomes project database, and χ(2) test was used. RESULT: Thirty-eight 
      aspirin-response-related variants that had clinical significance had been 
      detected in the 620 WES data.Ten (26%) of them were related with drug efficacy 
      while 28 (74%) were related with toxicity or adverse drug reaction (ADR). These 
      variants were distributed in 33 genes.There were 23 aspirin-related variants 
      further analysised, and the frequency of 7 (rs1050891, rs6065, rs7862221, 
      rs1065776, rs3818822, rs3775291 and rs1126643) had no significant difference 
      compared with frequency of European and East Asian population of 1 000 Genome 
      project (P>0.01 for both), 10 (rs2228079, rs1613662, rs4523, rs28360521, 
      rs1131882, rs1047626, rs3856806, rs2768759, rs7572857 and rs1126510) of them had 
      no significant difference compared with East Asian but were significantly 
      different from European population, 1 (rs2075797) had no significant difference 
      compared with frequency of European and different with frequency of East Asian, 
      and 5 variants(rs10279545, rs730012, rs16851030, rs1353411, rs1800469)were 
      different from frequency of both East Asian(0.019, 0.058, 0.167, 0.452, 0.340 vs. 
      0.100, 0.151, 0.396, 0.568, 0.453, χ(2)=21.798, 20.400, 67.543, 16.531, 15.807, P 
      all<0.01) and European population(0.531, 0.312, 0.037, 0.179, 0.688, 
      χ(2)=325.799, 92.877, 144.811, 156.471, 174.533, P all<0.01). CONCLUSION: Most 
      variants that have clinical significance in aspirin response are related with 
      drug efficacy or drug toxicity or ADR, indicating the urgency of variants screen 
      in clinical practice.Significant population-specificity is detected in local 620 
      WES data in aspirin-response-related variants.
FAU - Yang, L
AU  - Yang L
AD  - Department of Endocrinology and Genetics, Children's Hospital of Fudan 
      University, Shanghai 201102, China.
FAU - Lu, Y L
AU  - Lu YL
AD  - Key Laboratory of Birth Defects, Children's Hospital of Fudan University, 
      Shanghai 201102, China.
FAU - Wang, H J
AU  - Wang HJ
FAU - Zhou, W H
AU  - Zhou WH
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Er Ke Za Zhi
JT  - Zhonghua er ke za zhi = Chinese journal of pediatrics
JID - 0417427
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Asian People
MH  - Aspirin/*adverse effects
MH  - Child
MH  - Drug-Related Side Effects and Adverse Reactions/*genetics
MH  - *Exome
MH  - *Gene Frequency
MH  - Humans
MH  - *Pharmacogenetics
EDAT- 2016/05/05 06:00
MHDA- 2017/01/31 06:00
CRDT- 2016/05/05 06:00
PHST- 2016/05/05 06:00 [entrez]
PHST- 2016/05/05 06:00 [pubmed]
PHST- 2017/01/31 06:00 [medline]
AID - 10.3760/cma.j.issn.0578-1310.2016.05.005 [doi]
PST - ppublish
SO  - Zhonghua Er Ke Za Zhi. 2016 May;54(5):332-6. doi: 
      10.3760/cma.j.issn.0578-1310.2016.05.005.

PMID- 8399312
OWN - NLM
STAT- MEDLINE
DCOM- 19931104
LR  - 20190610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1158
IP  - 2
DP  - 1993 Oct 3
TI  - The reaction of malondialdehyde with lens proteins and the protective effect of 
      aspirin.
PG  - 107-12
AB  - Malondialdehyde, a product of lipid peroxidation and a by-product of thromboxane 
      synthesis increases in human cataract. Malondialdehyde bound to soluble lens 
      proteins over 4 h of incubation. Pre-incubation of lens proteins with aspirin 
      offered protection against reaction with MDA. Gel chromatography was used to 
      monitor aggregation of the modified protein. Sodium dodecyl 
      sulfate-polyacrylamide gel electrophoresis showed that the reaction with 
      malondialdehyde led to non-disulphide covalent cross-linking of gamma-crystallin, 
      which was decreased by incubation with aspirin. Malondialdehyde has two carbonyl 
      groups which could react with primary amino groups, forming Schiff-base 
      conjugates and covalently cross-link proteins. The modification and cross-linking 
      could initiate the cataractogenic process.
FAU - Riley, M L
AU  - Riley ML
AD  - Nuffield Laboratory of Ophthalmology, University of Oxford, UK.
FAU - Harding, J J
AU  - Harding JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Crystallins)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cattle
MH  - Crystallins/*chemistry
MH  - Ibuprofen/pharmacology
MH  - Malondialdehyde/analysis/*chemistry
EDAT- 1993/10/03 00:00
MHDA- 1993/10/03 00:01
CRDT- 1993/10/03 00:00
PHST- 1993/10/03 00:00 [pubmed]
PHST- 1993/10/03 00:01 [medline]
PHST- 1993/10/03 00:00 [entrez]
AID - 0304-4165(93)90003-Q [pii]
AID - 10.1016/0304-4165(93)90003-q [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 1993 Oct 3;1158(2):107-12. doi: 
      10.1016/0304-4165(93)90003-q.

PMID- 33251773
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 61
IP  - 12
DP  - 2020 Dec
TI  - Long-Term Aspirin Use and 5-Year Survival in Healthy Adults: A Population-Based 
      Cohort Study in South Korea.
PG  - 997-1003
LID - 10.3349/ymj.2020.61.12.997 [doi]
AB  - PURPOSE: We investigated whether long-term aspirin use is associated with 5-year 
      all-cause mortality. MATERIALS AND METHODS: Participants were individuals aged 
      ≥40 years who were registered in the 2010 sample cohort database of the National 
      Health Insurance Service in South Korea. Aspirin users were divided into three 
      groups: continuous users (2006-2010), previous users (2006-2009), and new users 
      (2010). Individuals with a history of coronary artery disease and cerebrovascular 
      disease were excluded. Five-year all-cause mortality was defined as mortality due 
      to any cause from January 1, 2011 to December 31, 2015. Data were analyzed by 
      multivariable Cox regression. RESULTS: In total, 424444 individuals were 
      included. Five-year all-cause mortality was 9% lower in continuous aspirin users 
      than in unexposed individuals [hazard ratio (HR): 0.91, 95% confidence interval 
      (CI): 0.86-0.97; p=0.003]. Five-year all-cause mortality rates in the new aspirin 
      users (HR: 1.00, 95% CI: 0.90-1.11; p=0.995) and previous aspirin users (HR: 
      1.01, 95% CI: 0.94-1.09; p=0.776) were not significantly different from that in 
      unexposed individuals. In the 40-60-year age group, 5-year all-cause mortality in 
      the continuous aspirin users was 24% lower (HR: 0.76, 95% CI: 0.64-0.90; p=0.002) 
      than that in unexposed individuals. However, in the >60-year age group, there was 
      no significant association between aspirin use and 5-year all-cause mortality 
      (HR: 0.96, 95% CI: 0.90-1.02; p=0.199). CONCLUSION: Long-term aspirin use is 
      associated with reduced 5-year all-cause mortality in healthy adults, especially 
      those aged <60 years.
CI  - © Copyright: Yonsei University College of Medicine 2020.
FAU - Oh, Tak Kyu
AU  - Oh TK
AUID- ORCID: 0000-0002-4027-4423
AD  - Department of Anesthesiology and Pain Medicine, Seoul National University Bundang 
      Hospital, Seongnam, Korea.
FAU - Song, In Ae
AU  - Song IA
AUID- ORCID: 0000-0002-7814-4253
AD  - Department of Anesthesiology and Pain Medicine, Seoul National University Bundang 
      Hospital, Seongnam, Korea. songoficu@outlook.kr.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/mortality
MH  - Cause of Death
MH  - Cohort Studies
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mortality/trends
MH  - Neoplasms/mortality
MH  - Population Surveillance/*methods
MH  - Republic of Korea
MH  - Survival Analysis
MH  - Young Adult
PMC - PMC7700872
OTO - NOTNLM
OT  - Aspirin
OT  - cohort study
OT  - mortality
OT  - neoplasm
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2020/12/01 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/30 05:59
PHST- 2020/06/16 00:00 [received]
PHST- 2020/10/21 00:00 [revised]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/11/30 05:59 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 61.997 [pii]
AID - 10.3349/ymj.2020.61.12.997 [doi]
PST - ppublish
SO  - Yonsei Med J. 2020 Dec;61(12):997-1003. doi: 10.3349/ymj.2020.61.12.997.

PMID- 6313019
OWN - NLM
STAT- MEDLINE
DCOM- 19831217
LR  - 20161123
IS  - 0037-8771 (Print)
IS  - 0037-8771 (Linking)
VI  - 59
IP  - 8
DP  - 1983 Aug 30
TI  - [New contributions on extinction tests of essential headache. I. The test with 
      lysine acetylsalicylate].
PG  - 1130-3
AB  - We report some preliminary results of a study carried out in ten patients 
      observed during headache attack and concerning particularly the plasma values of 
      beta-ELI after acetylsalicylic acid (lysini acetylsalicylas: i.v. 1.8 g) 
      administration. Blood samples for beta-ELI determination were drawn every ten 
      minutes for 30 minutes beginning at time of drug administration. Plasma was 
      immediately separated and stored at -20 degrees C until assayed. Lysini 
      acetylsalicylas administration gave in our subjects a significant relief from 
      pain, with a disappearance of headache in all cases. We showed, in comparison 
      with basal conditions, increased-plasma beta-ELI values after drug 
      administration. The levels of pain were evaluated by the analogic visual scale.
FAU - Romiti, A
AU  - Romiti A
FAU - Martelletti, P
AU  - Martelletti P
FAU - Gallo, M F
AU  - Gallo MF
FAU - Perrotta, R A
AU  - Perrotta RA
FAU - Giacovazzo, M
AU  - Giacovazzo M
LA  - ita
PT  - Journal Article
TT  - Nuovi contributi su le prove di estinzione nelle cefalee essenziali: I) Il test 
      con acetilsalicilato di lisina.
PL  - Italy
TA  - Boll Soc Ital Biol Sper
JT  - Bollettino della Societa italiana di biologia sperimentale
JID - 7506962
RN  - 0 (Analgesics)
RN  - 0 (Endorphins)
RN  - 60617-12-1 (beta-Endorphin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - *Analgesics
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Endorphins/blood
MH  - Female
MH  - Headache/blood/*drug therapy
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - beta-Endorphin
EDAT- 1983/08/30 00:00
MHDA- 1983/08/30 00:01
CRDT- 1983/08/30 00:00
PHST- 1983/08/30 00:00 [pubmed]
PHST- 1983/08/30 00:01 [medline]
PHST- 1983/08/30 00:00 [entrez]
PST - ppublish
SO  - Boll Soc Ital Biol Sper. 1983 Aug 30;59(8):1130-3.

PMID- 331502
OWN - NLM
STAT- MEDLINE
DCOM- 19771031
LR  - 20140912
IS  - 0256-9574 (Print)
VI  - 52
IP  - 10
DP  - 1977 Aug 27
TI  - Bumadizone calcium in the treatment of rheumatoid arthritis.
PG  - 391-3
AB  - A double-blind crossover trial of bumadizone calcium (Eumotol), a non-steroidal 
      anti-inflammatory drug, has been carried out in 56 patients with rheumatoid 
      arthritis. On both objective and subjective criteria bumadizone was superior to 
      placebo and paracetamol at a statistically highly significant level (P less than 
      0,01). When tested against acetylsalicylic acid, bumadizone was more effective in 
      13 patients and less effective in 4 patients. Although this does not represent a 
      statistically significant difference it does suggest that its anti-inflammatory 
      and analgesic qualities are at least equal to those of salicylate in high 
      dosages. There were no serious side-effects in the patients who received 
      bumadizone and the drug was better tolerated than either acetylsalicylic acid or 
      paracetamol.
FAU - Solomon, L
AU  - Solomon L
FAU - Abrams, G
AU  - Abrams G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - 0 (Malonates)
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/therapeutic use
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Malonates/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Placebos
EDAT- 1977/08/27 00:00
MHDA- 1977/08/27 00:01
CRDT- 1977/08/27 00:00
PHST- 1977/08/27 00:00 [pubmed]
PHST- 1977/08/27 00:01 [medline]
PHST- 1977/08/27 00:00 [entrez]
PST - ppublish
SO  - S Afr Med J. 1977 Aug 27;52(10):391-3.

PMID- 31712099
OWN - NLM
STAT- MEDLINE
DCOM- 20200514
LR  - 20200514
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 133
IP  - 4
DP  - 2020 Apr
TI  - Aspirin in the Treatment and Prevention of Migraine Headaches: Possible 
      Additional Clinical Options for Primary Healthcare Providers.
PG  - 412-416
LID - S0002-9343(19)30966-0 [pii]
LID - 10.1016/j.amjmed.2019.10.023 [doi]
AB  - Migraine headaches are among the most common and potentially debilitating 
      disorders encountered by primary healthcare providers. In the treatment of acute 
      migraine and the prevention of recurrent attacks, there are prescription drugs of 
      proven benefit. However, for those without health insurance or high co-pays, 
      these drugs may be neither available nor affordable and, for all patients, they 
      may be either poorly tolerated or contraindicated. The totality of evidence, 
      which includes data from randomized trials, suggests that high-dose aspirin, in 
      doses from 900 to 1300 mg, taken at the onset of symptoms, is an effective and 
      safe treatment option for acute migraine headaches. In addition, the totality of 
      evidence, including some, but not all, randomized trials, suggests the 
      possibility that daily aspirin, in doses from 81 to 325 mg, may be an effective 
      and safe treatment option for the prevention of recurrent migraine headaches. The 
      relatively favorable side effect profile of aspirin and extremely low costs 
      compared with other prescription drug therapies may provide additional options 
      for primary healthcare providers in the treatment of both acute and recurrent 
      migraine headaches.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Biglione, Bianca
AU  - Biglione B
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton.
FAU - Gitin, Alexander
AU  - Gitin A
AD  - University of Florida College of Medicine, Gainesville.
FAU - Gorelick, Philip B
AU  - Gorelick PB
AD  - Department of Translational Neuroscience, Michigan State University College of 
      Medicine, Grand Rapids.
FAU - Hennekens, Charles
AU  - Hennekens C
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton. 
      Electronic address: PROFCHHMD@prodigy.net.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191109
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Med. 2020 Apr;133(4):397-398. PMID: 31805266
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Humans
MH  - Migraine Disorders/*drug therapy
MH  - *Primary Health Care
OTO - NOTNLM
OT  - Aspirin
OT  - Migraine
OT  - Prevention
OT  - Primary healthcare providers
OT  - Treatment
EDAT- 2019/11/13 06:00
MHDA- 2020/05/15 06:00
CRDT- 2019/11/13 06:00
PHST- 2019/10/09 00:00 [received]
PHST- 2019/10/13 00:00 [revised]
PHST- 2019/10/13 00:00 [accepted]
PHST- 2019/11/13 06:00 [pubmed]
PHST- 2020/05/15 06:00 [medline]
PHST- 2019/11/13 06:00 [entrez]
AID - S0002-9343(19)30966-0 [pii]
AID - 10.1016/j.amjmed.2019.10.023 [doi]
PST - ppublish
SO  - Am J Med. 2020 Apr;133(4):412-416. doi: 10.1016/j.amjmed.2019.10.023. Epub 2019 
      Nov 9.

PMID- 2907571
OWN - NLM
STAT- MEDLINE
DCOM- 19890526
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 40
IP  - 11
DP  - 1988 Nov
TI  - Ocular distribution of aspirin and salicylate following systematic administration 
      of aspirin to rabbits.
PG  - 823-4
AB  - The distribution of aspirin and salicylate 30 min after the intravenous 
      administration of different doses of aspirin has been investigated in the rabbit 
      eye. HPLC enabled a rapid and sensitive determination of both substances. A 
      considerable dose-dependent penetration into all ocular tissues was observed with 
      both aspirin and salicylate. Aspirin concentrations were higher than in plasma in 
      all ocular tissues with the exception of the lens. These results show that an 
      unhydrolysed drug may have a direct local effect by acetylating lens protein or 
      other ocular constituents.
FAU - Valeri, P
AU  - Valeri P
AD  - Institute of Pharmacology and Pharmacognosy, University of Rome La Sapienza, 
      Italy.
FAU - Romanelli, L
AU  - Romanelli L
FAU - De Paolis, L
AU  - De Paolis L
FAU - Martinelli, B
AU  - Martinelli B
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Eye/*metabolism
MH  - Injections, Intravenous
MH  - Male
MH  - Rabbits
MH  - Salicylates/administration & dosage/*pharmacokinetics
EDAT- 1988/11/01 00:00
MHDA- 1988/11/01 00:01
CRDT- 1988/11/01 00:00
PHST- 1988/11/01 00:00 [pubmed]
PHST- 1988/11/01 00:01 [medline]
PHST- 1988/11/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1988.tb05185.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1988 Nov;40(11):823-4. doi: 
      10.1111/j.2042-7158.1988.tb05185.x.

PMID- 11898722
OWN - NLM
STAT- MEDLINE
DCOM- 20020520
LR  - 20131121
IS  - 0023-2149 (Print)
IS  - 0023-2149 (Linking)
VI  - 80
IP  - 2
DP  - 2002
TI  - [Effects of aspirin standard therapy and chronotherapy on circadian organization 
      of hemocoagulation in patients with insulin-dependent diabetes mellitus].
PG  - 43-6
AB  - 24-h profile of hemocoagulation was assessed in 30 patients with 
      insulin-dependent diabetes mellitus type 1 aged 17-37 years. The patients were 
      randomized into 2 groups, 15 patients each. Patients of group 1 received aspirin 
      by conventional scheme: 125 mg 3 times a day for 16 days. Patients of group 2 
      received aspirin as preventive chronotherapy: once a day in a dose 125 mg for 16 
      days two hours before the acrophase of platelet aggregation rhythm--at 22 p.m. 
      Parameters of plasmic and platelet hemostasis in blood samples were measured at 
      3.00, 7.00, 11.00 a.m., 15.00, 19.00, 23.00. The above chronobiological 
      information was processed by Kosinor-analysis according to F. Halberg. Before the 
      treatment, hypercoagulation with night rise as well as external and internal 
      desynchronism of the hemostasis circadian rhythms were observed. Conventional 
      aspirin treatment improved hemostasis but influenced acrophases minimally. 
      Aspirin chronotherapy promoted normalization of circadian organization of 
      hemocoagulation.
FAU - Zaslavskaia, R M
AU  - Zaslavskaia RM
FAU - Tulemisov, E U
AU  - Tulemisov EU
FAU - Teĭblium, M M
AU  - Teĭblium MM
LA  - rus
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Vliianie traditsionnoĭ terapii i khronoterapii aspirinom na tsirkadiannuiu 
      organizatsiiu gemokoaguliatsii u bol'nykh insulinzavisimym sakharnym diabetom.
PL  - Russia (Federation)
TA  - Klin Med (Mosk)
JT  - Klinicheskaia meditsina
JID - 2985204R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/*therapeutic use
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Blood Coagulation/*drug effects
MH  - Chronotherapy
MH  - Circadian Rhythm/*drug effects/physiology
MH  - Diabetes Mellitus, Type 1/*drug therapy/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Treatment Outcome
EDAT- 2002/03/20 10:00
MHDA- 2002/05/22 10:01
CRDT- 2002/03/20 10:00
PHST- 2002/03/20 10:00 [pubmed]
PHST- 2002/05/22 10:01 [medline]
PHST- 2002/03/20 10:00 [entrez]
PST - ppublish
SO  - Klin Med (Mosk). 2002;80(2):43-6.

PMID- 6331971
OWN - NLM
STAT- MEDLINE
DCOM- 19841011
LR  - 20190908
IS  - 0770-3198 (Print)
IS  - 0770-3198 (Linking)
VI  - 3
IP  - 1
DP  - 1984 Mar
TI  - Salicylate-induced occult gastrointestinal blood loss: comparison between 
      different oral and parenteral forms of acetylsalicylates and salicylates.
PG  - 47-54
AB  - Gastrointestinal fecal blood loss, determined by injecting 51Cr-labelled 
      autologous red blood cells, was measured in 191 orthopaedic patients after oral 
      or parenteral intake of different forms of acetylsalicylates or salicylates. Oral 
      or parenteral administration of non-acetylated salicylates caused nearly no 
      gastrointestinal bleeding, but the anti-inflammatory activity of these products 
      can be questioned since they cannot inhibit prostaglandin synthetase. Buffered, 
      soluble forms of acetylsalicylates caused gastrointestinal bleeding in more than 
      50% of the patients. However, enteric-coated and intravenous forms resulted in 
      significantly less gastrointestinal bleeding. For both preparations a 
      relationship between serum salicylate level and amount of fecal blood loss was 
      found in the group of "bleeders" (an upper limit of physiological blood loss 
      could definitely be determined by this method). The findings suggested a similar 
      mode of action of enteric-coated and intravenous acetylsalicylates on gastric 
      mucosa through a systemic action. It was concluded that in long-term 
      anti-inflammatory salicylate treatment, enteric-coated forms are probably the 
      galenic form of first choice.
FAU - Mielants, H
AU  - Mielants H
FAU - Veys, E M
AU  - Veys EM
FAU - Verbruggen, G
AU  - Verbruggen G
FAU - Schelstraete, K
AU  - Schelstraete K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Dosage Forms)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dosage Forms
MH  - Female
MH  - Gastric Mucosa/drug effects
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - *Occult Blood
MH  - Salicylates/*adverse effects
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
AID - 10.1007/BF02715695 [doi]
PST - ppublish
SO  - Clin Rheumatol. 1984 Mar;3(1):47-54. doi: 10.1007/BF02715695.

PMID- 7500532
OWN - NLM
STAT- MEDLINE
DCOM- 19960117
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 274
IP  - 23
DP  - 1995 Dec 20
TI  - Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients 
      with nonvalvular atrial fibrillation.
PG  - 1839-45
AB  - OBJECTIVE: To examine the cost-effectiveness of prescribing warfarin sodium in 
      patients who have nonvalvular atrial fibrillation (NVAF) with or without 
      additional stroke risk factors (a prior stroke or transient ischemic attack, 
      diabetes, hypertension, or heart disease). DESIGN: Decision and 
      cost-effectiveness analyses. The probabilities for stroke, hemorrhage, and death 
      were obtained from published randomized controlled trials. The quality-of-life 
      estimates were obtained by interviewing 74 patients with atrial fibrillation. 
      Costs were estimated from literature review, phone survey, and Medicare 
      reimbursement. PATIENTS: In the base case, the patients were 65 years of age and 
      good candidates for warfarin therapy. INTERVENTIONS: Treatment with warfarin, 
      aspirin, or no therapy in the decision analytic model. MAIN OUTCOME MEASURES: 
      Quality-adjusted survival and marginal cost-effectiveness of warfarin as compared 
      with aspirin or no therapy. RESULTS: For patients with NVAF and additional risk 
      factors for stroke, warfarin therapy led to a greater quality-adjusted survival 
      and to cost savings. For patients with NVAF and one additional risk factor, 
      warfarin therapy cost $8000 per quality-adjusted life-year saved. For 65-year-old 
      patients with NVAF alone, warfarin cost about $370,000 per quality-adjusted 
      life-year saved, as compared with aspirin therapy. However, for 75-year-old 
      patients with NVAF alone, prescribing warfarin cost $110,000 per quality-adjusted 
      life-year saved. For patients who were not prescribed warfarin, aspirin was 
      preferred to no therapy on the basis of both quality-adjusted survival and cost 
      in all patients, regardless of the number of risk factors present. CONCLUSIONS: 
      Treatment with warfarin is cost-effective in patients with NVAF and one or more 
      additional risk factors for stroke. In 65-year-old patients with NVAF but no 
      other risk factors for stroke, prescribing warfarin instead of aspirin would 
      affect quality-adjusted survival minimally but increase costs significantly.
FAU - Gage, B F
AU  - Gage BF
AD  - Veterans Affairs Palo Alto Health Care System, CA, USA.
FAU - Cardinalli, A B
AU  - Cardinalli AB
FAU - Albers, G W
AU  - Albers GW
FAU - Owens, D K
AU  - Owens DK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 1996 May-Jun;124(3):81
CIN - JAMA. 1996 Mar 27;275(12):909; author reply 910. PMID: 8598612
MH  - Aged
MH  - Anticoagulants/economics/*therapeutic use
MH  - Aspirin/adverse effects/economics/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - California
MH  - Cerebrovascular Disorders/etiology/*prevention & control
MH  - Cost-Benefit Analysis
MH  - *Decision Support Techniques
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Quality-Adjusted Life Years
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Treatment Outcome
MH  - Warfarin/adverse effects/economics/*therapeutic use
EDAT- 1995/12/20 00:00
MHDA- 1995/12/20 00:01
CRDT- 1995/12/20 00:00
PHST- 1995/12/20 00:00 [pubmed]
PHST- 1995/12/20 00:01 [medline]
PHST- 1995/12/20 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1995 Dec 20;274(23):1839-45.

PMID- 17559741
OWN - NLM
STAT- MEDLINE
DCOM- 20080709
LR  - 20191210
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 23
IP  - 6
DP  - 2007 Jun
TI  - Antiplatelet therapy for the prevention of recurrent stroke and other serious 
      vascular events: a review of the clinical trial data and guidelines.
PG  - 1453-62
AB  - BACKGROUND: One strategy of reducing the burden of stroke is the prevention of 
      recurrent stroke, following an initial ischaemic stroke or transient ischaemic 
      attack (TIA) of arterial origin, by means of antiplatelet therapy. SCOPE: This 
      review article surveys and discusses the current clinical trial data and 
      guidelines for the use of antiplatelet therapy in the prevention of recurrent 
      stroke/TIA of arterial origin (not stroke due to atrial fibrillation). Based on 
      the latest available evidence, a new antiplatelet treatment algorithm for the 
      long-term treatment of patients following atherothromboembolic ischaemic stroke 
      or TIA is proposed. FINDINGS: Meta-analyses of randomised clinical trials in 
      patients with TIA and ischaemic stroke of arterial origin indicate that, compared 
      with control, the relative risk reduction (RRR) for recurrent stroke and other 
      serious vascular events is 13% (95% confidence interval [CI] 6% to 19%) with 
      aspirin, 13% (4% to 21%; p = 0.046) with dipyridamole and 34% (24% to 43%) with 
      the combination of aspirin and dipyridamole. Compared with aspirin, the relative 
      risk of recurrent stroke and other serious vascular events is reduced by 7.3% 
      (95% CI -5.7% to 18.7%) with clopidogrel and 18% (9% to 26%; p = 0.0003) with the 
      combination of aspirin and dipyridamole. The combination of aspirin and 
      clopidogrel is not significantly more effective in preventing serious vascular 
      events than clopidogrel alone (RRR 6.4%; -4.6% to 16.3%) in the long-term 
      treatment of patients with previous ischaemic stroke and TIA, mainly because of a 
      cumulative excess of bleeding complications. The relative risks and benefits of 
      long-term treatment with clopidogrel and the combination of aspirin and 
      dipyridamole are being compared in an ongoing large clinical trial (PRoFESS). 
      Current Australian therapeutic guidelines for antiplatelet therapy among patients 
      with TIA and ischaemic stroke of arterial origin have incorporated important new 
      findings from recently published clinical trials and recommend aspirin or the 
      combination of dipyridamole plus aspirin as the preferred long-term antiplatelet 
      therapy. CONCLUSION: Whilst awaiting the results of the PRoFESS trial, the 
      combination of dipyridamole plus aspirin is the preferred antiplatelet regimen to 
      reduce the risk of recurrent vascular events among patients with TIA and 
      ischaemic stroke of arterial origin.
FAU - Hankey, Graeme J
AU  - Hankey GJ
AD  - Stroke Unit, Department of Neurology, Royal Perth Hospital, Perth, WA 6000, 
      Australia. gjhankey@cyllene.uwa.edu.au
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20070517
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Guidelines as Topic
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy/prevention & control
MH  - Placebos
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Secondary Prevention
MH  - Stroke/*prevention & control
MH  - Vascular Diseases/*prevention & control
RF  - 42
EDAT- 2007/06/15 09:00
MHDA- 2008/07/10 09:00
CRDT- 2007/06/15 09:00
PHST- 2007/06/15 09:00 [pubmed]
PHST- 2008/07/10 09:00 [medline]
PHST- 2007/06/15 09:00 [entrez]
AID - 10.1185/030079907X199727 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2007 Jun;23(6):1453-62. doi: 10.1185/030079907X199727. Epub 
      2007 May 17.

PMID- 8400098
OWN - NLM
STAT- MEDLINE
DCOM- 19931028
LR  - 20190909
IS  - 1053-0770 (Print)
IS  - 1053-0770 (Linking)
VI  - 7
IP  - 4
DP  - 1993 Aug
TI  - Influence of desmopressin acetate on homologous blood requirements in cardiac 
      surgical patients pretreated with aspirin.
PG  - 425-30
AB  - Conflicting results have been reported concerning the effect of the synthetic 
      vasopressin analog desmopressin acetate (DDAVP) on perioperative bleeding and 
      homologous blood requirements in cardiac surgery. Because patients preoperatively 
      treated with platelet-inhibiting drugs are at increased risk of perioperative 
      bleeding, the blood-saving effect of DDAVP was investigated in 40 male patients 
      undergoing primary myocardial revascularization. All patients had taken aspirin 
      within the last 5 days prior to surgery. In a double-blind, randomized trial, the 
      effects of DDAVP (0.3 microgram/kg of body weight) were compared to those of 
      saline placebo on postoperative blood loss and the need to replace blood 
      products. To evaluate the drug's influence on the coagulation and fibrinolytic 
      systems, von Willebrand factor (vWF), the activities of tissue plasminogen 
      activator (tPA) and plasminogen activator inhibitor (PAI 1), and the split 
      products of cross-linked fibrin (D-dimers) were investigated. The total 
      homologous blood requirement was significantly lower in DDAVP recipients (median 
      2, range, 0 to 5 U) compared to placebo (median 3.5, range, 0 to 8 U; P < 0.05). 
      Although at all points of measurement (intraoperative and postoperative) 
      transfusion requirement was less in the DDAVP group, hematocrit values of these 
      patients always exceeded those of the placebo group, this difference being 
      significant at the end of the operation. Because no difference in postoperative 
      blood loss was found, the markedly reduced transfusion requirement of the 
      DDAVP-treated patients is explained either by reduced intraoperative bleeding or 
      by a reduced hematocrit of the chest-tube blood.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Dilthey, G
AU  - Dilthey G
AD  - German Heart Center, Müchen.
FAU - Dietrich, W
AU  - Dietrich W
FAU - Spannagl, M
AU  - Spannagl M
FAU - Richter, J A
AU  - Richter JA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Cardiothorac Vasc Anesth
JT  - Journal of cardiothoracic and vascular anesthesia
JID - 9110208
RN  - 0 (Placebos)
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Blood Coagulation Tests
MH  - Blood Loss, Surgical/*prevention & control
MH  - *Blood Transfusion
MH  - Deamino Arginine Vasopressin/*pharmacology/therapeutic use
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Erythrocyte Volume/drug effects
MH  - Hematocrit
MH  - Humans
MH  - Intraoperative Care
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Revascularization
MH  - Placebos
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
AID - 1053-0770(93)90164-G [pii]
AID - 10.1016/1053-0770(93)90164-g [doi]
PST - ppublish
SO  - J Cardiothorac Vasc Anesth. 1993 Aug;7(4):425-30. doi: 
      10.1016/1053-0770(93)90164-g.

PMID- 3820197
OWN - NLM
STAT- MEDLINE
DCOM- 19870402
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 13
IP  - 5
DP  - 1986 Oct
TI  - Patterns of in vitro aspirin hydrolysis rates in rheumatoid arthritis and 
      systemic lupus erythematosus.
PG  - 882-6
AB  - In previous in vitro studies of normal human blood and in vivo canine studies an 
      intracellular erythrocyte (RBC) esterase was identified which controlled the rate 
      of aspirin (ASA) hydrolysis and thus modulated the duration of intact ASA 
      survival and availability for transacetylations required for some therapeutic 
      effects. In whole blood from 30 patients with systemic lupus erythematosus (SLE), 
      10 normal subjects, and 40 patients with active seropositive rheumatoid arthritis 
      (RA), there were negative correlations between the hematocrit level and the ASA 
      half-life in vitro: r = -0.50, -0.83, and -0.61, respectively. When ASA 
      hydrolysis rates were normalized to approximate whole blood esterase content 
      (k/Hb [min-1 X g-1 X dl] X 10(-4) the mean rate was most rapid in patients with 
      RA (24.2 +/- 2.8) and lowest in patients with SLE (18.6 +/- 3.1), especially in 
      those with recently active disease. To differentiate intracellular and 
      extracellular factors, ASA hydrolysis rates were measured in washed RBC 
      suspensions from similar groups. The mean ASA hydrolysis rate (k/10(6) RBC X 
      10(-3) was significantly lower in SLE RBC (7.72 +/- 0.81). In RBC from patients 
      with RA the average rate (8.50 +/- 0.85) lay between the SLE group and controls 
      (9.08 +/- 1.04). Thus, an erythrocyte esterase defect in SLE patients resulted in 
      reduced ASA hydrolyzing capacity. In blood from patients with RA a small 
      reduction in esterase activity was compensated by extracellular factors 
      increasing ASA accessibility to the esterase.
FAU - Costello, P B
AU  - Costello PB
FAU - Green, F A
AU  - Green FA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/blood/*metabolism
MH  - Aspirin/blood/*metabolism
MH  - Erythrocytes/metabolism
MH  - Hematocrit
MH  - Humans
MH  - Hydrolysis
MH  - Lupus Erythematosus, Systemic/*metabolism
EDAT- 1986/10/01 00:00
MHDA- 1986/10/01 00:01
CRDT- 1986/10/01 00:00
PHST- 1986/10/01 00:00 [pubmed]
PHST- 1986/10/01 00:01 [medline]
PHST- 1986/10/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1986 Oct;13(5):882-6.

PMID- 4035630
OWN - NLM
STAT- MEDLINE
DCOM- 19851009
LR  - 20190503
IS  - 0040-6376 (Print)
IS  - 1468-3296 (Electronic)
IS  - 0040-6376 (Linking)
VI  - 40
IP  - 8
DP  - 1985 Aug
TI  - Bronchial hyperreactivity to histamine in aspirin sensitive asthmatics: 
      relationship to aspirin threshold and effect of aspirin desensitisation.
PG  - 598-602
AB  - Twenty seven aspirin sensitive asthmatic patients were studied to determine the 
      relationship between non-specific bronchial responsiveness to inhaled histamine 
      and the degree of sensitivity to aspirin (aspirin threshold dose). No correlation 
      was found between provocative concentration of histamine (PC20H) and aspirin 
      threshold dose. In 11 patients the influence of aspirin desensitisation on 
      bronchial reactivity to inhaled histamine was examined. Mean PC20H measured the 
      day after the patients were desensitised to 600 mg of aspirin did not change 
      significantly from the values before desensitisation. These observations suggest 
      that sensitivity to aspirin and non-specific bronchial hyperreactivity in 
      asthmatic patients are independent phenomena.
FAU - Kowalski, M L
AU  - Kowalski ML
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
FAU - Szmidt, M
AU  - Szmidt M
FAU - Rozniecki, J
AU  - Rozniecki J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Thorax
JT  - Thorax
JID - 0417353
RN  - 820484N8I3 (Histamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/physiopathology
MH  - Bronchi/*drug effects
MH  - Bronchial Provocation Tests
MH  - Desensitization, Immunologic
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/*physiopathology
MH  - Female
MH  - Forced Expiratory Volume
MH  - Histamine/*pharmacology
MH  - Humans
MH  - Male
MH  - Middle Aged
PMC - PMC1020598
EDAT- 1985/08/01 00:00
MHDA- 1985/08/01 00:01
CRDT- 1985/08/01 00:00
PHST- 1985/08/01 00:00 [pubmed]
PHST- 1985/08/01 00:01 [medline]
PHST- 1985/08/01 00:00 [entrez]
AID - 10.1136/thx.40.8.598 [doi]
PST - ppublish
SO  - Thorax. 1985 Aug;40(8):598-602. doi: 10.1136/thx.40.8.598.

PMID- 1904336
OWN - NLM
STAT- MEDLINE
DCOM- 19910717
LR  - 20131121
IS  - 0009-921X (Print)
IS  - 0009-921X (Linking)
IP  - 267
DP  - 1991 Jun
TI  - The use of aspirin to prevent heterotopic ossification after total hip 
      arthroplasty. A preliminary report.
PG  - 93-6
AB  - The reported incidence of heterotopic ossification (HO) after total hip 
      arthroplasty (THA) ranges up to 50%. HO causes pain and restricted range of 
      motion (ROM) in a significant number of these THA patients. From 1983 to 1988, 
      177 primary cemented THAs were performed in 131 consecutive patients. Six hundred 
      fifty milligrams of buffered aspirin administered twice daily for two weeks was 
      used as a prophylaxis for thromboembolic disease. There was an unusually low 
      incidence of HO in this group of patients. Aspirin treatment was instituted the 
      night before surgery and continued for two weeks, except in 13 patients (7%) who 
      had to stop treatment because of gastrointestinal symptoms. All patients had at 
      least one year of roentgenographic study postoperatively. According to the 
      Brooker Classification of HO, there were 169 (96%) Grade I and Grade 0 hips, six 
      (3%) Grade II, two (1%) Grade III, and no Grade IV. None of the patients had 
      symptomatic restriction of ROM attributable to heterotopic bone. Aspirin is a 
      safe and inexpensive agent for prevention of HO after THA.
FAU - Freiberg, A A
AU  - Freiberg AA
AD  - Department of Orthopaedic Surgery, University of Cincinnati College of Medicine, 
      Ohio.
FAU - Cantor, R
AU  - Cantor R
FAU - Freiberg, R A
AU  - Freiberg RA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Hip Prosthesis/*adverse effects
MH  - Humans
MH  - Male
MH  - Ossification, Heterotopic/etiology/*prevention & control
MH  - Retrospective Studies
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
PST - ppublish
SO  - Clin Orthop Relat Res. 1991 Jun;(267):93-6.

PMID- 360826
OWN - NLM
STAT- MEDLINE
DCOM- 19781227
LR  - 20190509
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 70
IP  - 4
DP  - 1978 Oct
TI  - Clinical trial of a new bleeding-time device.
PG  - 642-5
AB  - The authors report a clinical trial comparing a new bleeding time device 
      (Simplate II) with the Mielke Template. Bleeding times were determined at the 
      same time on the same arm using the two devices. Subjects of the study were 24 
      healthy volunteers, before and two hours after ingestion of 975 mg aspirin, and 
      28 patients. For the normal subjects the mean pre-aspirin bleeding times were 
      4.75 +/- 1.42 minutes (1 SD) with the Simplate II and 3.65 +/- 1.22 minutes with 
      the Mielke Template. The mean bleeding times two hours after ingestion of aspirin 
      were 7.86 +/- 2.76 minutes with the Simplate II and 7.84 +/- 2.94 minutes with 
      the Template. The pre- and the post-aspirin values with the two devices were not 
      significantly different from each other, nor were the bleeding times obtained in 
      the patients with the two devices. The extents of scarring were similar with the 
      two devices. The results were highly reproducible by both methods. The new device 
      was simpler and more rapid to use.
FAU - Kumar, R
AU  - Kumar R
FAU - Ansell, J E
AU  - Ansell JE
FAU - Canoso, R T
AU  - Canoso RT
FAU - Deykin, D
AU  - Deykin D
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Coagulation Tests/*instrumentation/methods
MH  - Clinical Trials as Topic
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Reference Values
EDAT- 1978/10/01 00:00
MHDA- 1978/10/01 00:01
CRDT- 1978/10/01 00:00
PHST- 1978/10/01 00:00 [pubmed]
PHST- 1978/10/01 00:01 [medline]
PHST- 1978/10/01 00:00 [entrez]
AID - 10.1093/ajcp/70.4.642 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1978 Oct;70(4):642-5. doi: 10.1093/ajcp/70.4.642.

PMID- 16006110
OWN - NLM
STAT- MEDLINE
DCOM- 20060120
LR  - 20131121
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 73
IP  - 3-4
DP  - 2005 Sep-Oct
TI  - Liver: the formation and actions of aspirin-triggered lipoxins.
PG  - 277-82
AB  - Eicosanoids play a key role in the initiation, progression and resolution of the 
      inflammatory response. Although most current anti-inflammatory strategies are 
      focused on the pharmacological inhibition of pro-inflammatory eicosanoids, such 
      as prostaglandins and leukotrienes, mounting evidence indicates the existence of 
      potent endogenous eicosanoids able to control inflammation and orchestrate its 
      resolution. The first eicosanoids recognized as anti-inflammatory compounds 
      generated by our own organism were the lipoxins (LXs). More recently, a new 
      series of carbon-15 epimers of LXs, with anti-inflammatory properties similar to 
      those of native LXs, was identified during aspirin treatment. Since their 
      formation is specific to this venerable non-steroidal anti-inflammatory drug, the 
      term aspirin-triggered LXs (ATLs) was coined for these compounds. This chapter 
      deals with the biosynthesis of LXs and ATLs in the liver, the largest solid 
      organ/gland in the body, and discusses the most relevant actions of these lipid 
      mediators in the context of liver inflammation and injury.
FAU - Clària, J
AU  - Clària J
AD  - DNA Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i 
      Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona 08036, Spain. 
      jclaria@clinic.ub.es
FAU - Planagumà, A
AU  - Planagumà A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Lipoxins/biosynthesis/*physiology
MH  - Liver/drug effects/*metabolism
RF  - 44
EDAT- 2005/07/12 09:00
MHDA- 2006/01/21 09:00
CRDT- 2005/07/12 09:00
PHST- 2005/07/12 09:00 [pubmed]
PHST- 2006/01/21 09:00 [medline]
PHST- 2005/07/12 09:00 [entrez]
AID - S0952-3278(05)00095-5 [pii]
AID - 10.1016/j.plefa.2005.05.017 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):277-82. doi: 
      10.1016/j.plefa.2005.05.017.

PMID- 29939940
OWN - NLM
STAT- MEDLINE
DCOM- 20190919
LR  - 20190919
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 132
IP  - 1
DP  - 2018 Jul
TI  - ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
PG  - e44-e52
LID - 10.1097/AOG.0000000000002708 [doi]
AB  - Low-dose aspirin has been used during pregnancy, most commonly to prevent or 
      delay the onset of preeclampsia. The American College of Obstetricians and 
      Gynecologists issued the Hypertension in Pregnancy Task Force Report recommending 
      daily low-dose aspirin beginning in the late first trimester for women with a 
      history of early-onset preeclampsia and preterm delivery at less than 34 0/7 
      weeks of gestation, or for women with more than one prior pregnancy complicated 
      by preeclampsia. The U.S. Preventive Services Task Force published a similar 
      guideline, although the list of indications for low-dose aspirin use was more 
      expansive. Daily low-dose aspirin use in pregnancy is considered safe and is 
      associated with a low likelihood of serious maternal, or fetal complications, or 
      both, related to use. The American College of Obstetricians and Gynecologists and 
      the Society for Maternal-Fetal Medicine support the U.S. Preventive Services Task 
      Force guideline criteria for prevention of preeclampsia. Low-dose aspirin (81 
      mg/day) prophylaxis is recommended in women at high risk of preeclampsia and 
      should be initiated between 12 weeks and 28 weeks of gestation (optimally before 
      16 weeks) and continued daily until delivery. Low-dose aspirin prophylaxis should 
      be considered for women with more than one of several moderate risk factors for 
      preeclampsia. Women at risk of preeclampsia are defined based on the presence of 
      one or more high-risk factors (history of preeclampsia, multifetal gestation, 
      renal disease, autoimmune disease, type 1 or type 2 diabetes, and chronic 
      hypertension) or more than one of several moderate-risk factors (first pregnancy, 
      maternal age of 35 years or older, a body mass index greater than 30, family 
      history of preeclampsia, sociodemographic characteristics, and personal history 
      factors). In the absence of high risk factors for preeclampsia, current evidence 
      does not support the use of prophylactic low-dose aspirin for the prevention of 
      early pregnancy loss, fetal growth restriction, stillbirth, or preterm birth.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*standards
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/*drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/*standards
MH  - *Practice Guidelines as Topic
MH  - Pre-Eclampsia/etiology/*prevention & control
MH  - Pregnancy
MH  - Risk Factors
MH  - Young Adult
EDAT- 2018/06/26 06:00
MHDA- 2019/09/20 06:00
CRDT- 2018/06/26 06:00
PHST- 2018/06/26 06:00 [entrez]
PHST- 2018/06/26 06:00 [pubmed]
PHST- 2019/09/20 06:00 [medline]
AID - 00006250-201807000-00057 [pii]
AID - 10.1097/AOG.0000000000002708 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2018 Jul;132(1):e44-e52. doi: 10.1097/AOG.0000000000002708.

PMID- 16702997
OWN - NLM
STAT- MEDLINE
DCOM- 20060816
LR  - 20181113
IS  - 0007-1188 (Print)
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Linking)
VI  - 148
IP  - 4
DP  - 2006 Jun
TI  - Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human 
      platelets.
PG  - 517-26
AB  - Incorporation of a nitric oxide (NO)-releasing moiety in aspirin can overcome its 
      gastric side effects. We investigated the NO-release patterns and antiplatelet 
      effects of novel furoxan derivatives of aspirin (B8 and B7) in comparison to 
      existing antiplatelet agents. Cyclooxygenase (COX) activity was investigated in 
      purified enzyme using an electron paramagnetic resonance-based technique. 
      Concentration-response curves for antiplatelet agents +/- the soluble guanylate 
      cyclase inhibitor, ODQ (50 microM) were generated in platelet-rich plasma (PRP) 
      and washed platelets (WP) activated with collagen using turbidometric 
      aggregometry. NO was detected using an isolated NO electrode. The furoxan 
      derivatives of aspirin (B8, B7) and their NO-free furazan equivalents (B16, B15; 
      all 100 microM) significantly inhibited COX activity (P < 0.01; n = 6) in vitro 
      and caused aspirin-independent, cGMP-dependent inhibition of collagen-induced 
      platelet aggregation in WP. B8 was more potent than B7 (PRP IC(50) = 0.62 +/- 0.1 
      microM for B8; 400 +/- 89 microM for B7; P < 0.0001. WP IC(50)s = 0.6 +/- 0.1 and 
      62 +/- 10 microM, respectively). The NO-free furazan counterparts were less 
      potent antiplatelet agents (WP IC(50)s = 54 +/- 3 microM and 62 +/- 10 microM, 
      respectively; P < 0.0001, B8 vs B16). Of the hybrids investigated, only B8 
      retained antiplatelet activity in PRP.NO release from furoxan-aspirin hybrids was 
      undetectable in buffer alone, but was accelerated in the presence of either 
      plasma or plasma components, albumin (4%), glutathione (GSH; 3 microM) and 
      ascorbate (50 microM), the effects of which were additive for B7 but not B8. NO 
      generation from furoxans was greatly enhanced by platelet extract, an effect that 
      could largely be explained by the synergistic effect of intracellular 
      concentrations of GSH (3 mM) and ascorbate (1 mM). We conclude that the 
      decomposition of furoxan-aspirin hybrids to generate biologically active NO is 
      catalysed by endogenous agents which may instil a potential for primarily 
      intracellular delivery of NO. The blunting of the aspirin effects of furoxan 
      hybrids is likely to be due to loss of the acetyl moiety in plasma; the observed 
      antiplatelet effects are thereby primarily mediated via NO release. Compounds of 
      this class might represent a novel means of inhibiting platelet aggregation by a 
      combination of NO generation and COX inhibition.
FAU - Turnbull, Catriona M
AU  - Turnbull CM
AD  - Centre for Cardiovascular Science, Queen's Medical Research Institute, University 
      of Edinburgh.
FAU - Cena, Clara
AU  - Cena C
FAU - Fruttero, Roberta
AU  - Fruttero R
FAU - Gasco, Alberto
AU  - Gasco A
FAU - Rossi, Adriano G
AU  - Rossi AG
FAU - Megson, Ian L
AU  - Megson IL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060515
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Oxadiazoles)
RN  - 0 (furoxans)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Humans
MH  - Middle Aged
MH  - Nitric Oxide/biosynthesis
MH  - Nitric Oxide Donors/*pharmacology
MH  - Oxadiazoles/*pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Salicylic Acid/pharmacology
PMC - PMC1751793
EDAT- 2006/05/17 09:00
MHDA- 2006/08/17 09:00
CRDT- 2006/05/17 09:00
PHST- 2006/05/17 09:00 [pubmed]
PHST- 2006/08/17 09:00 [medline]
PHST- 2006/05/17 09:00 [entrez]
AID - 0706743 [pii]
AID - 10.1038/sj.bjp.0706743 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2006 Jun;148(4):517-26. doi: 10.1038/sj.bjp.0706743. Epub 2006 
      May 15.

PMID- 37227560
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230731
IS  - 1936-0541 (Electronic)
IS  - 1936-0533 (Linking)
VI  - 17
IP  - 4
DP  - 2023 Aug
TI  - Polypill protects MAFLD patients from cardiovascular events and mortality: a 
      prospective trial.
PG  - 882-888
LID - 10.1007/s12072-023-10542-9 [doi]
AB  - BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a 
      novel term that distinguishes patients at risk of adverse clinical outcomes with 
      higher accuracy than those with non-alcoholic fatty liver disease (NAFLD). 
      Cardiovascular mortality is the leading cause of death in MAFLD. The current 
      literature lacks large-scale prospective studies that address preventive 
      approaches for cardiovascular health in MAFLD. We investigated whether MAFLD 
      patients benefit from a fixed-dose combination therapy (Aspirin, 
      hydrochlorothiazide, atorvastatin, valsartan), known as a Polypill. METHODS: 
      Analysis was performed (stratified based on MAFLD status) of a clinical trial 
      that included 1596 individuals randomly allocated to an intervention (polypill) 
      or a control (usual care) group. Patients were followed up for five years for any 
      adverse drug reaction, major cardiovascular events, and mortality. Univariable 
      and multivariable survival analyses were performed, and the interaction level was 
      assessed by R programming. RESULTS: Patients who consumed the polypill had 
      significantly lower hazard ratios of major cardiovascular events incidence (HR 
      0.56, 95% CI 0.41-0.78) and cardiovascular mortality (HR 0.41, 95% CI 0.2-0.86) 
      compared to the control group. Polypill showed significantly better results in 
      lowering cardiovascular events in MAFLD patients than in the general population. 
      (p-value for interaction: 0.028). Moreover, comparing those patients who had high 
      adherence to the Polypill, with the control group, further enhanced the results. 
      CONCLUSIONS: Major cardiovascular events are prevented in MAFLD patients who 
      consume the Polypill. MAFLD patients benefit from the Polypill more than the 
      general population.
CI  - © 2023. Asian Pacific Association for the Study of the Liver.
FAU - Ramandi, Alireza
AU  - Ramandi A
AD  - Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
AD  - Digestive Disease Research Center, Digestive Disease Research Institute, Tehran 
      University of Medical Sciences, Shariati Hospital, Tehran, Iran.
FAU - George, Jacob
AU  - George J
AD  - Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital 
      and University of Sydney, Westmead, NSW, Australia.
FAU - Merat, Shahin
AU  - Merat S
AD  - Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
AD  - Digestive Disease Research Center, Digestive Disease Research Institute, Tehran 
      University of Medical Sciences, Shariati Hospital, Tehran, Iran.
FAU - Jafari, Elham
AU  - Jafari E
AD  - Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Sharafkhah, Maryam
AU  - Sharafkhah M
AD  - Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
AD  - Digestive Disease Research Center, Digestive Disease Research Institute, Tehran 
      University of Medical Sciences, Shariati Hospital, Tehran, Iran.
FAU - Radmard, Amir Reza
AU  - Radmard AR
AD  - Department of Radiology, Shariati Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Nateghi Baygi, Alireza
AU  - Nateghi Baygi A
AD  - Research and Development Department, Alborz-Darou Pharmaceutical Co., Ghazvin, 
      Iran.
FAU - Delavari, Alireza
AU  - Delavari A
AD  - Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
AD  - Digestive Disease Research Center, Digestive Disease Research Institute, Tehran 
      University of Medical Sciences, Shariati Hospital, Tehran, Iran.
FAU - Mohammadi, Zahra
AU  - Mohammadi Z
AD  - Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Poustchi, Hossein
AU  - Poustchi H
AUID- ORCID: 0000-0003-4566-3628
AD  - Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research 
      Institute, Tehran University of Medical Sciences, Tehran, Iran. 
      h.poustchi@gmail.com.
FAU - Malekzadeh, Reza
AU  - Malekzadeh R
AD  - Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research 
      Institute, Tehran University of Medical Sciences, Tehran, Iran. malek@tums.ac.ir.
AD  - Digestive Disease Research Center, Digestive Disease Research Institute, Tehran 
      University of Medical Sciences, Shariati Hospital, Tehran, Iran. 
      malek@tums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20230525
PL  - United States
TA  - Hepatol Int
JT  - Hepatology international
JID - 101304009
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Drug Combinations)
SB  - IM
MH  - Humans
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/epidemiology
MH  - Drug Combinations
MH  - *Non-alcoholic Fatty Liver Disease/complications
MH  - Prospective Studies
OTO - NOTNLM
OT  - Major cardiovascular events
OT  - Metabolic dysfunction-associated fatty liver disease (MAFLD)
OT  - Prevention
OT  - Randomized open-labeled trial
EDAT- 2023/05/25 13:06
MHDA- 2023/07/31 06:43
CRDT- 2023/05/25 11:29
PHST- 2023/01/30 00:00 [received]
PHST- 2023/04/18 00:00 [accepted]
PHST- 2023/07/31 06:43 [medline]
PHST- 2023/05/25 13:06 [pubmed]
PHST- 2023/05/25 11:29 [entrez]
AID - 10.1007/s12072-023-10542-9 [pii]
AID - 10.1007/s12072-023-10542-9 [doi]
PST - ppublish
SO  - Hepatol Int. 2023 Aug;17(4):882-888. doi: 10.1007/s12072-023-10542-9. Epub 2023 
      May 25.

PMID- 16521633
OWN - NLM
STAT- MEDLINE
DCOM- 20060413
LR  - 20131121
IS  - 0019-4832 (Print)
IS  - 0019-4832 (Linking)
VI  - 57
IP  - 6
DP  - 2005 Nov-Dec
TI  - Profile and prevalence of aspirin resistance in Indian patients with coronary 
      artery disease.
PG  - 658-61
AB  - BACKGROUND: Aspirin resistance is considered to be an enigma and the data 
      available on aspirin resistance is scarce. This study was initiated to 
      prospectively evaluate the prevalence of aspirin resistance in patients with 
      stable coronary artery disease by using an established method of optical platelet 
      aggregation. METHODS AND RESULTS: We studied 50 patients who were on 150 mg of 
      aspirin for the previous 7 days. Fasting blood samples were assessed using 
      optical platelet aggregation (Chronolog Corp, USA). The mean platelet aggregation 
      with 10 microm of adenosine diphosphate in our patient group was 49.42 +/- 23.29% 
      and with 0.5 mg/ ml of arachidonic acid it was 13.58 +/- 21.40%. Aspirin 
      resistance was defined as a mean aggregation of > or =70% with 10 microm of 
      adenosine diphosphate and a mean aggregation of > or =20% with 0.5 mg/ml of 
      arachidonic acid. Aspirin semi responders were defined as those meeting only one 
      of the criteria. Based on these criteria, 2.08% patients were found to be 
      aspirin-resistant, 39.58% were aspirin semi responders and 58.33% were aspirin 
      responders. Females tended to be more aspirin semi responsive (p = 0.08). All 
      other parameters tested, namely, age, smoking, diabetes mellitus, hypertension, 
      obesity, lipids, hemoglobin, platelet count, ejection fraction and drug intake 
      did not show any statistically significant difference among the groups. Thus, in 
      our group 41.66% patients showed inadequate response to aspirin. CONCLUSIONS: 
      This study shows that aspirin resistance and aspirin semi responsiveness do occur 
      in the Indian patients and there are no reliable clinical predictors for this 
      condition. The diagnosis therefore relies primarily on laboratory tests.
FAU - Sadiq, P A
AU  - Sadiq PA
AD  - Department of Cardiology, King George Medical University, Lucknow.
FAU - Puri, Aniket
AU  - Puri A
FAU - Dixit, Madhu
AU  - Dixit M
FAU - Ghatak, A
AU  - Ghatak A
FAU - Dwivedi, Sudhanshu K
AU  - Dwivedi SK
FAU - Narain, Varun S
AU  - Narain VS
FAU - Saran, Ram K
AU  - Saran RK
FAU - Puri, Vijay K
AU  - Puri VK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - India
TA  - Indian Heart J
JT  - Indian heart journal
JID - 0374675
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chi-Square Distribution
MH  - Coronary Disease/*diagnosis/*drug therapy
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - India/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Probability
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Sex Distribution
EDAT- 2006/03/09 09:00
MHDA- 2006/04/14 09:00
CRDT- 2006/03/09 09:00
PHST- 2006/03/09 09:00 [pubmed]
PHST- 2006/04/14 09:00 [medline]
PHST- 2006/03/09 09:00 [entrez]
PST - ppublish
SO  - Indian Heart J. 2005 Nov-Dec;57(6):658-61.

PMID- 23896061
OWN - NLM
STAT- MEDLINE
DCOM- 20131115
LR  - 20211021
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Print)
IS  - 0145-2126 (Linking)
VI  - 37
IP  - 10
DP  - 2013 Oct
TI  - Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells 
      and modulates β-catenin expression.
PG  - 1302-8
LID - S0145-2126(13)00231-2 [pii]
LID - 10.1016/j.leukres.2013.07.004 [doi]
AB  - Hydrogen sulfide-releasing aspirin (HS-ASA) is a novel compound with potential 
      against cancer. It inhibited the growth of Jurkat T-leukemia cells with an IC₅₀ 
      of 1.9 ± 0.2 μM whereas that of ASA was >5000 μM. It dose-dependently inhibited 
      proliferation and induced apoptosis in these cells, causing a G₀/G₁ cell cycle 
      arrest. HS-ASA down-regulated β-catenin protein levels and reduced mRNA and 
      protein expression of β-catenin/TCF downstream target genes cyclinD1 and c-myc. 
      Aspirin up to 5 mM had no effect on β-catenin expression. HS-ASA also increased 
      caspase-3 protein levels and dose-dependently increased its activity. These 
      effects were substantially blocked by z-VAD-fmk, a pan-caspase inhibitor.
CI  - Copyright © 2013 Elsevier Ltd. All rights reserved.
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
AD  - Department of Physiology, Pharmacology, and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, NY 
      10031, USA.
FAU - Nath, Niharika
AU  - Nath N
FAU - Kodela, Ravinder
AU  - Kodela R
FAU - Sobocki, Tomasz
AU  - Sobocki T
FAU - Metkar, Shalaka
AU  - Metkar S
FAU - Gan, Zong Yuan
AU  - Gan ZY
FAU - Kashfi, Khosrow
AU  - Kashfi K
LA  - eng
GR  - R24 DA018055/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130726
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (beta Catenin)
RN  - EC 3.4.22.- (Caspase 3)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Aspirin/*chemistry/*pharmacology
MH  - Caspase 3/metabolism
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Enzyme Activation/drug effects
MH  - Gene Expression Regulation/*drug effects
MH  - Humans
MH  - Hydrogen Sulfide/*chemistry
MH  - Jurkat Cells
MH  - beta Catenin/*genetics/metabolism
PMC - PMC3769470
MID - NIHMS504633
OTO - NOTNLM
OT  - ALL
OT  - ASA
OT  - Apoptosis
OT  - CML
OT  - Caspase-3
OT  - Cell cycle
OT  - Chronic Myeloid Leukemia
OT  - HS-ASA
OT  - Hydrogen sulfide
OT  - Leukemia
OT  - NO
OT  - NSAIDs
OT  - Proliferation
OT  - acute lymphoblastic leukemia
OT  - aspirin
OT  - hydrogen sulfide-releasing aspirin
OT  - nitric oxide
OT  - nonsteroidal anti-inflammatory drugs
OT  - β-Catenin
COIS- Conflict of interest The authors reported no potential conflicts of interest.
EDAT- 2013/07/31 06:00
MHDA- 2013/11/16 06:00
CRDT- 2013/07/31 06:00
PHST- 2013/01/05 00:00 [received]
PHST- 2013/07/01 00:00 [accepted]
PHST- 2013/07/31 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2013/11/16 06:00 [medline]
AID - S0145-2126(13)00231-2 [pii]
AID - 10.1016/j.leukres.2013.07.004 [doi]
PST - ppublish
SO  - Leuk Res. 2013 Oct;37(10):1302-8. doi: 10.1016/j.leukres.2013.07.004. Epub 2013 
      Jul 26.

PMID- 15091007
OWN - NLM
STAT- MEDLINE
DCOM- 20040521
LR  - 20191210
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 15
IP  - 2
DP  - 2004 Mar
TI  - An in vitro model for the detection of reduced platelet sensitivity to 
      acetylsalicylic acid.
PG  - 187-95
AB  - A discovery of 'aspirin resistance' has prompted the search for fast and reliable 
      methods for the monitoring of antiplatelet efficacy of acetylsalicylic acid 
      (ASA). Our aims were: (1) to evaluate the in vitro model-based method for 
      detecting a reduced platelets' sensitivity to ASA using a point-of-care platelet 
      function analyser PFA-100; and (2) to propose a simple method of data analysis 
      that might be successfully employed to discriminate between 'good' and 'poor' 
      responders to aspirin. Whole blood platelets from healthy volunteers were 
      incubated in vitro with 30 microg/ml ASA (the in vitro method under evaluation) 
      or analysed following a 10-day intake of an average 150 mg ASA (Aspirin Protect) 
      daily (the reference ex vivo method). According to polynomial regression analysis 
      of the bimodally distributed data, the donors with lower ('ASA poor responders') 
      or higher platelet sensitivity to ASA ('ASA good responders') were discriminated 
      at 58.6% of platelet function inhibition. Despite the similar proportions of 'ASA 
      poor responders' (44 versus 41% using the ex vivo and in vitro tests, 
      respectively), 30% of discordant classifications point to a rather unsatisfactory 
      convergence between both methods. Due to a considerable discordance between the 
      in vitro and ex vivo tests of ASA efficacy performed with the use of the PFA-100 
      system, the former cannot be reliably and interchangeably used for the monitoring 
      of aspirin therapy and the selection of an effective therapeutic ASA dose. A 
      novel approach to data analysis of the distribution of platelet inhibition rates 
      facilitates an evaluation of cut-off points required to discriminate between 
      'poor responders' and 'good responders' to aspirin.
FAU - Golański, Jacek
AU  - Golański J
AD  - Department of Haemostasis and Haemostatic Disorders and Department of Social and 
      Preventive Medicine, Medical University of Lodz, Lodz, Poland.
FAU - Nocuń, Marek
AU  - Nocuń M
FAU - Rózalski, Marcin
AU  - Rózalski M
FAU - Drygas, Wojciech
AU  - Drygas W
FAU - Watała, Cezary
AU  - Watała C
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
CIN - Blood Coagul Fibrinolysis. 2004 Mar;15(2):129-30. PMID: 15090999
MH  - Adult
MH  - Algorithms
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Collagen/pharmacology
MH  - *Drug Resistance
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - *Platelet Function Tests/instrumentation
MH  - *Point-of-Care Systems
MH  - Reproducibility of Results
MH  - Risk
MH  - Sensitivity and Specificity
EDAT- 2004/04/20 05:00
MHDA- 2004/05/22 05:00
CRDT- 2004/04/20 05:00
PHST- 2004/04/20 05:00 [pubmed]
PHST- 2004/05/22 05:00 [medline]
PHST- 2004/04/20 05:00 [entrez]
AID - 00001721-200403000-00011 [pii]
AID - 10.1097/00001721-200403000-00011 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2004 Mar;15(2):187-95. doi: 
      10.1097/00001721-200403000-00011.

PMID- 19352314
OWN - NLM
STAT- MEDLINE
DCOM- 20090629
LR  - 20211020
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
VI  - 5
IP  - 4
DP  - 2009 Apr
TI  - Does aspirin use reduce cardiovascular risk in diabetes?
PG  - 188-90
LID - 10.1038/nrendo.2009.44 [doi]
AB  - The use of aspirin for the primary prevention of cardiovascular events in 
      patients with type 2 diabetes mellitus is controversial. According to the 
      findings of a Japanese trial, aspirin does not reduce the risk of cardiovascular 
      events in this group of patients, unless they are aged 65 years and above.
FAU - Colwell, John A
AU  - Colwell JA
AD  - Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 
      29425, USA. colwelja@musc.edu
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - England
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - JAMA. 2008 Nov 12;300(18):2134-41. PMID: 18997198
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Atherosclerosis/*complications/epidemiology/etiology/*prevention & control
MH  - Cardiovascular Diseases/epidemiology/etiology/*prevention & control
MH  - Diabetes Mellitus, Type 2/*complications/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
EDAT- 2009/04/09 09:00
MHDA- 2009/06/30 09:00
CRDT- 2009/04/09 09:00
PHST- 2009/04/09 09:00 [entrez]
PHST- 2009/04/09 09:00 [pubmed]
PHST- 2009/06/30 09:00 [medline]
AID - nrendo.2009.44 [pii]
AID - 10.1038/nrendo.2009.44 [doi]
PST - ppublish
SO  - Nat Rev Endocrinol. 2009 Apr;5(4):188-90. doi: 10.1038/nrendo.2009.44.

PMID- 33410332
OWN - NLM
STAT- MEDLINE
DCOM- 20211014
LR  - 20211014
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 10
IP  - 2
DP  - 2021 Jan 19
TI  - Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and 
      Meta-Analysis.
PG  - e018304
LID - 10.1161/JAHA.120.018304 [doi]
LID - e018304
AB  - Background The clinical impact of early aspirin discontinuation compared with 
      dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary 
      intervention with stenting remains poorly studied. We investigated the clinical 
      outcomes of patients assigned to either early aspirin discontinuation or DAPT 
      after percutaneous coronary intervention with stenting. Methods and Results We 
      performed a meta-analysis of aggregate data from randomized clinical trials 
      enrolling participants receiving a percutaneous coronary intervention with 
      stenting and assigned to either early aspirin discontinuation or DAPT. Scientific 
      databases were searched from inception through March 30, 2020. Trial-level hazard 
      ratios (HRs) and 95% CIs were pooled using a random effects model with inverse 
      variance weighting. The primary outcome was all-cause death. Secondary outcomes 
      were myocardial infarction, stent thrombosis, stroke, and major bleeding. 
      Overall, 36 206 participants were allocated to either early aspirin 
      discontinuation (experimental therapy, n=18 088) or DAPT (control therapy, 
      n=18 118) in 7 trials. Median follow-up was 12 months. All-cause death occurred 
      in 2.5% of patients assigned to experimental and 2.9% of patients assigned 
      control therapy (hazard ratio [HR], 0.91, 95% CI, 0.75-1.11; P=0.37). Overall, 
      patients treated with experimental versus control therapy showed no significant 
      difference in terms of myocardial infarction (HR, 1.02 [0.85-1.22], P=0.81), 
      stent thrombosis (HR, 1.02 [0.87-1.20], P=0.83), or stroke (HR, 1.01 [0.68-1.49], 
      P=0.96). However, the risk for major bleeding (HR, 0.58 [0.43-0.77], P<0.01) was 
      significantly reduced by experimental as compared with control therapy. 
      Conclusions In patients treated with percutaneous coronary intervention and 
      stenting, assigned to a strategy of early aspirin discontinuation versus DAPT, 
      the risk of death and ischemic events is not significantly different but the risk 
      of bleeding is lower.
FAU - Wiebe, Jens
AU  - Wiebe J
AD  - Klinik für Herz- und Kreislauferkrankungen Deutsches Herzzentrum 
      MünchenTechnische Universität München Munich Germany.
FAU - Ndrepepa, Gjin
AU  - Ndrepepa G
AD  - Klinik für Herz- und Kreislauferkrankungen Deutsches Herzzentrum 
      MünchenTechnische Universität München Munich Germany.
FAU - Kufner, Sebastian
AU  - Kufner S
AD  - Klinik für Herz- und Kreislauferkrankungen Deutsches Herzzentrum 
      MünchenTechnische Universität München Munich Germany.
FAU - Lahmann, Anna L
AU  - Lahmann AL
AD  - Klinik für Herz- und Kreislauferkrankungen Deutsches Herzzentrum 
      MünchenTechnische Universität München Munich Germany.
FAU - Xhepa, Erion
AU  - Xhepa E
AD  - Klinik für Herz- und Kreislauferkrankungen Deutsches Herzzentrum 
      MünchenTechnische Universität München Munich Germany.
FAU - Kuna, Constantin
AU  - Kuna C
AD  - Klinik für Herz- und Kreislauferkrankungen Deutsches Herzzentrum 
      MünchenTechnische Universität München Munich Germany.
FAU - Voll, Felix
AU  - Voll F
AD  - Klinik für Herz- und Kreislauferkrankungen Deutsches Herzzentrum 
      MünchenTechnische Universität München Munich Germany.
FAU - Gosetti, Rosanna
AU  - Gosetti R
AD  - 1. Medizinische Klinik Klinikum rechts der IsarTechnische Universität München 
      Munich Germany.
FAU - Laugwitz, Karl-Ludwig
AU  - Laugwitz KL
AD  - 1. Medizinische Klinik Klinikum rechts der IsarTechnische Universität München 
      Munich Germany.
AD  - DZHK (German Centre for Cardiovascular Research), partner site Munich Heart 
      Alliance Munich Germany.
FAU - Joner, Michael
AU  - Joner M
AD  - Klinik für Herz- und Kreislauferkrankungen Deutsches Herzzentrum 
      MünchenTechnische Universität München Munich Germany.
AD  - DZHK (German Centre for Cardiovascular Research), partner site Munich Heart 
      Alliance Munich Germany.
FAU - Kastrati, Adnan
AU  - Kastrati A
AD  - Klinik für Herz- und Kreislauferkrankungen Deutsches Herzzentrum 
      MünchenTechnische Universität München Munich Germany.
AD  - DZHK (German Centre for Cardiovascular Research), partner site Munich Heart 
      Alliance Munich Germany.
FAU - Cassese, Salvatore
AU  - Cassese S
AD  - Klinik für Herz- und Kreislauferkrankungen Deutsches Herzzentrum 
      MünchenTechnische Universität München Munich Germany.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210107
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage/adverse effects
MH  - Coronary Restenosis/*prevention & control
MH  - Dual Anti-Platelet Therapy/methods
MH  - Duration of Therapy
MH  - *Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Percutaneous Coronary Intervention/*adverse effects/instrumentation
MH  - Risk Assessment
MH  - Stents
MH  - Withholding Treatment/*statistics & numerical data
PMC - PMC7955304
OTO - NOTNLM
OT  - aspirin
OT  - coronary artery disease
OT  - meta‐analysis
OT  - stent
COIS- Joner is a consultant for Biotronik and OrbusNeich. The remaining authors have no 
      disclosures to report.
EDAT- 2021/01/08 06:00
MHDA- 2021/10/15 06:00
CRDT- 2021/01/07 08:38
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/10/15 06:00 [medline]
PHST- 2021/01/07 08:38 [entrez]
AID - JAH35827 [pii]
AID - 10.1161/JAHA.120.018304 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2021 Jan 19;10(2):e018304. doi: 10.1161/JAHA.120.018304. Epub 
      2021 Jan 7.

PMID- 4091879
OWN - NLM
STAT- MEDLINE
DCOM- 19860305
LR  - 20190718
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 58
IP  - 1-3
DP  - 1985 Dec
TI  - Inhibitors of "spontaneous" platelet aggregation in whole blood.
PG  - 199-203
AB  - In vitro 'spontaneous' platelet aggregation has been studied in whole blood. The 
      spectrum of activity of materials known to influence platelet aggregation in 
      platelet-rich plasma proved different in whole blood. Thus dipyridamole and one 
      of its analogues SH1242 had a striking effect in whole blood whilst aspirin, 
      chlorpromazine and K3920 had little or no effect. The combination of aspirin and 
      dipyridamole as currently employed in clinical practice had no greater inhibitory 
      effect than dipyridamole alone. The possible clinical relevance of these findings 
      is discussed.
FAU - Harrison, M J
AU  - Harrison MJ
FAU - Pollock, S S
AU  - Pollock SS
FAU - Steiner, M
AU  - Steiner M
FAU - Weisblatt, E
AU  - Weisblatt E
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - U42B7VYA4P (Chlorpromazine)
SB  - IM
MH  - Aspirin/pharmacology
MH  - *Blood Physiological Phenomena
MH  - Chlorpromazine/pharmacology
MH  - Dipyridamole/pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - *Platelet Aggregation/drug effects
EDAT- 1985/12/01 00:00
MHDA- 1985/12/01 00:01
CRDT- 1985/12/01 00:00
PHST- 1985/12/01 00:00 [pubmed]
PHST- 1985/12/01 00:01 [medline]
PHST- 1985/12/01 00:00 [entrez]
AID - 0021-9150(85)90066-8 [pii]
AID - 10.1016/0021-9150(85)90066-8 [doi]
PST - ppublish
SO  - Atherosclerosis. 1985 Dec;58(1-3):199-203. doi: 10.1016/0021-9150(85)90066-8.

PMID- 37011396
OWN - NLM
STAT- MEDLINE
DCOM- 20230419
LR  - 20230427
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 176
IP  - 4
DP  - 2023 Apr
TI  - After PCI and 6 to 18 mo of DAPT, clopidogrel reduced a composite of clinical 
      events vs. aspirin at 6 y.
PG  - JC38
LID - 10.7326/J23-0019 [doi]
AB  - Kang J, Park KW, Lee H, et al. Aspirin versus clopidogrel for long-term 
      maintenance monotherapy after percutaneous coronary intervention: The HOST-EXAM 
      extended study. Circulation. 2023;147:108-17. 36342475.
FAU - Lader, Ellis W
AU  - Lader EW
AD  - WMC Health Heart and Vascular Institute, Kingston, New York, USA (E.W.L.).
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20230404
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
RN  - A74586SNO7 (Clopidogrel)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
CON - Circulation. 2023 Jan 10;147(2):108-117. PMID: 36342475
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - Clopidogrel/therapeutic use
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Percutaneous Coronary Intervention
MH  - Treatment Outcome
MH  - Drug Therapy, Combination
EDAT- 2023/04/04 06:00
MHDA- 2023/04/19 06:41
CRDT- 2023/04/03 17:02
PHST- 2023/04/19 06:41 [medline]
PHST- 2023/04/04 06:00 [pubmed]
PHST- 2023/04/03 17:02 [entrez]
AID - 10.7326/J23-0019 [doi]
PST - ppublish
SO  - Ann Intern Med. 2023 Apr;176(4):JC38. doi: 10.7326/J23-0019. Epub 2023 Apr 4.

PMID- 33482738
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 1471-2318 (Electronic)
IS  - 1471-2318 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jan 22
TI  - Association between renal function and platelet reactivity during aspirin therapy 
      in elderly patients with atherosclerotic cardiovascular disease.
PG  - 75
LID - 10.1186/s12877-021-02018-y [doi]
LID - 75
AB  - BACKGROUND: Aspirin is the key treatment in the secondary prevention of 
      atherosclerotic cardiovascular disease. High on-treatment platelet reactivity 
      (HTPR) to aspirin has been reported to partially account for the enhanced risk of 
      thrombotic events. In particular, HTPR has been described more frequently among 
      elderly patients. The aim of this study was to identify the clinical and 
      biological factors associated with HTPR in a real-life elderly population. 
      METHODS: In this retrospective study, elderly patients with atherosclerotic 
      cardiovascular disease on regular aspirin treatment were enrolled. Cardiovascular 
      risk factors, routine biological parameters, comorbidities, and concomitant 
      medications were recorded. The upper quartile of the platelet aggregation rate, 
      determined by light transmission aggregometry with arachidonic acid, was defined 
      as the HTPR group. RESULTS: A total of 304 patients were included (mean age 
      77 ± 8 years, 76% men). Patients in the HTPR group were older than the patients 
      in the non-HTPR group (mean age: 79 ± 7 vs. 76 ± 8 years, p = 0.008). Patients 
      with moderately decreased estimated glomerular filtration rate (eGFR) had a 
      higher frequency of HTPR than patients with slightly decreased eGFR or normal 
      eGFR (35.8, 22.5, 12.2%, respectively, p < 0.05). In multivariate analysis, an 
      independent risk factor for HTPR was the eGFR (OR: 0.984, 95% CI: 0.980-0.988, 
      p < 0.001). CONCLUSIONS: Advanced age and decreased eGFR are correlated with poor 
      pharmacodynamic response to aspirin.
FAU - Liang, Wenyi
AU  - Liang W
AD  - Department of Geriatrics, Peking University First Hospital, No. 8, Xishiku 
      Street, Xicheng District, Beijing, 100034, People's Republic of China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Geriatrics, Peking University First Hospital, No. 8, Xishiku 
      Street, Xicheng District, Beijing, 100034, People's Republic of China.
FAU - Liu, Meilin
AU  - Liu M
AUID- ORCID: 0000-0001-9736-9864
AD  - Department of Geriatrics, Peking University First Hospital, No. 8, Xishiku 
      Street, Xicheng District, Beijing, 100034, People's Republic of China. 
      liumeilin@hotmail.com.
LA  - eng
GR  - 2017QN23/Research Foundation of Peking University First Hospital/
GR  - 2016YFC1301304/National Key Research &amp; Development Project of China/
GR  - 2012BAI37B05/National Science &amp; Technology Support Program of China/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210122
PL  - England
TA  - BMC Geriatr
JT  - BMC geriatrics
JID - 100968548
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - Blood Platelets
MH  - *Cardiovascular Diseases/diagnosis/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Retrospective Studies
PMC - PMC7821654
OTO - NOTNLM
OT  - Age
OT  - Aspirin
OT  - Atherosclerotic cardiovascular disease
OT  - Platelet reactivity
OT  - Renal function
COIS- The authors declare that they have no competing interests.
EDAT- 2021/01/24 06:00
MHDA- 2021/04/24 06:00
CRDT- 2021/01/23 05:25
PHST- 2020/08/21 00:00 [received]
PHST- 2021/01/11 00:00 [accepted]
PHST- 2021/01/23 05:25 [entrez]
PHST- 2021/01/24 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - 10.1186/s12877-021-02018-y [pii]
AID - 2018 [pii]
AID - 10.1186/s12877-021-02018-y [doi]
PST - epublish
SO  - BMC Geriatr. 2021 Jan 22;21(1):75. doi: 10.1186/s12877-021-02018-y.

PMID- 8077887
OWN - NLM
STAT- MEDLINE
DCOM- 19940930
LR  - 20190904
IS  - 0954-6820 (Print)
IS  - 0954-6820 (Linking)
VI  - 236
IP  - 3
DP  - 1994 Sep
TI  - Comparison of bleeding complications of warfarin and warfarin plus 
      acetylsalicylic acid: a study in 3166 outpatients.
PG  - 299-304
AB  - OBJECTIVE: The aim of the study was to compare the incidence of bleeding 
      complications in patients receiving warfarin alone and those receiving warfarin 
      in combination with acetylsalicylic acid. SUBJECTS AND METHODS: This 
      retrospective study comprises all outpatients in our hospital receiving warfarin 
      (n = 3166) in the period 1 January 1986 to 31 December 1990. Of these, 2026 
      patients received warfarin alone, aiming at an international normalized ratio 
      level of 4.2-2.5, whereas the combination of warfarin and acetylsalicylic acid 
      (150 mg daily) was given to 1140 patients, aiming at an international normalized 
      ratio level of 2.8-2.2. Total observation time represents 4420 treatment years. 
      RESULTS: A total of 175 bleeding episodes was observed, 18 of which were fatal, 
      and 96 were serious (requiring hospitalization). The incidence of minor bleedings 
      was significantly higher in the combined therapy group than in the group 
      receiving warfarin alone, 2.9% and 1.4% respectively (P < 0.003). However, there 
      was no difference in the therapy groups regarding the incidence of serious and 
      fatal bleedings. The overall incidence of gastrointestinal bleedings and was 
      equal to the two groups. CONCLUSIONS: The combination of warfarin and aspirin 150 
      mg daily aiming at a less intense level of anticoagulation than in warfarin 
      therapy alone does not increase the risk of major or fatal haemorrhage.
FAU - Hurlen, M
AU  - Hurlen M
AD  - Department of Internal Medicine, Central Hospital of Akershus, Nordbyhagen, 
      Norway.
FAU - Erikssen, J
AU  - Erikssen J
FAU - Smith, P
AU  - Smith P
FAU - Arnesen, H
AU  - Arnesen H
FAU - Rollag, A
AU  - Rollag A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Ambulatory Care
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Chi-Square Distribution
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Warfarin/*adverse effects/therapeutic use
EDAT- 1994/09/01 00:00
MHDA- 1994/09/01 00:01
CRDT- 1994/09/01 00:00
PHST- 1994/09/01 00:00 [pubmed]
PHST- 1994/09/01 00:01 [medline]
PHST- 1994/09/01 00:00 [entrez]
AID - 10.1111/j.1365-2796.1994.tb00800.x [doi]
PST - ppublish
SO  - J Intern Med. 1994 Sep;236(3):299-304. doi: 10.1111/j.1365-2796.1994.tb00800.x.

PMID- 11790071
OWN - NLM
STAT- MEDLINE
DCOM- 20020403
LR  - 20190619
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 136
IP  - 2
DP  - 2002 Jan 15
TI  - Aspirin for the primary prevention of cardiovascular events: recommendation and 
      rationale.
PG  - 157-60
AB  - This statement summarizes the recommendation of the third U.S. Preventive 
      Services Task Force (USPSTF) for aspirin for the primary prevention of 
      cardiovascular events, as well as the supporting scientific evidence. The 
      complete information on which this statement is based, including evidence tables 
      and references, can be found in a companion article in this issue. Copies of this 
      document, the summary of the evidence, and the systematic evidence review can be 
      obtained through the USPSTF Web site (http://www.ahrq.gov/clinic/uspstfix.htm) 
      and in print through the Agency for Healthcare Research and Quality Publications 
      Clearinghouse (800-358-9295).
CN  - U.S. Preventive Services Task Force
LA  - eng
PT  - Guideline
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- Ann Intern Med. 2002 Jan 15;136(2):I55. PMID: 11928737
CIN - Ann Intern Med. 2002 Oct 1;137(7):622-3. PMID: 12353960
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chemoprevention
MH  - Coronary Disease/epidemiology/*prevention & control
MH  - Evidence-Based Medicine
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention
MH  - Risk Factors
MH  - United States/epidemiology
EDAT- 2002/01/16 10:00
MHDA- 2002/04/04 10:01
CRDT- 2002/01/16 10:00
PHST- 2002/01/16 10:00 [pubmed]
PHST- 2002/04/04 10:01 [medline]
PHST- 2002/01/16 10:00 [entrez]
AID - 200201150-00015 [pii]
AID - 10.7326/0003-4819-136-2-200201150-00015 [doi]
PST - ppublish
SO  - Ann Intern Med. 2002 Jan 15;136(2):157-60. doi: 
      10.7326/0003-4819-136-2-200201150-00015.

PMID- 33479775
OWN - NLM
STAT- MEDLINE
DCOM- 20211216
LR  - 20220123
IS  - 1745-1701 (Electronic)
IS  - 0586-7614 (Print)
IS  - 0586-7614 (Linking)
VI  - 47
IP  - 4
DP  - 2021 Jul 8
TI  - Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two 
      Randomized Controlled Trials.
PG  - 1077-1087
LID - 10.1093/schbul/sbaa198 [doi]
AB  - Two previous randomized controlled trials (RCTs) suggested that adjunctive 
      aspirin is efficacious in treating schizophrenia. We conducted two 16-week 
      double-blind randomized placebo-controlled RCTs of adjunctive 1000 mg aspirin vs 
      placebo in schizophrenia. Study 1 included 200 patients, with Positive and 
      Negative Syndrome Scale (PANSS) total score as the primary outcome. Study 2 
      included 160 patients with C-reactive protein (CRP) >1 mg/L at baseline; the 
      primary outcome was PANSS-positive score. Dropout rates for aspirin/placebo were 
      12% in study 1 and 20% in study 2. Differences in outcome between aspirin and 
      placebo were calculated with linear regression, adjusting for the baseline value 
      of the outcome. No statistically significant between-group differences were found 
      in primary or secondary outcomes in either study. Study 1: mean difference in 
      PANSS at 16 weeks was -3.9 (95% CI: -8.4 to 0.5, P = .10, effect size (ES) = 
      -0.25) and at 8 weeks was -3.5 (95% CI: -7.5 to 0.5, P = .11, ES = -0.22). Study 
      2: mean difference in PANSS at 16 weeks was 0.3 (95% CI: -4.1 to 4.7, P = .90, ES 
      = 0.02) and in positive PANSS was 0.5 (95% CI: -1.0 to 2.1, P = .50, ES = 0.11). 
      A meta-analysis of these data with the existing studies, excluding one with large 
      baseline differences in total PANSS, found that the overall estimate of the 
      effect of adjunctive aspirin on the PANSS total score comparing group means at 
      the end of the study was -2.9 (95% CI: -6.6 to 0.7; P = .21), favoring aspirin. 
      Our studies and meta-analysis failed to find a statistically significant 
      improvement in the symptoms of schizophrenia from adjunctive aspirin therapy in 
      comparison to placebo in schizophrenia. Trial registration: study 1: 
      Clinicaltrials.gov: NCT01320982; study 2 (high CRP): EudraCT Number: 
      2014-000757-36.
CI  - © The Author(s) 2021. Published by Oxford University Press on behalf of the 
      Maryland Psychiatric Research Center.All rights reserved. For permissions, please 
      email: journals.permissions@oup.com.
FAU - Weiser, Mark
AU  - Weiser M
AD  - Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Zamora, Daisy
AU  - Zamora D
AD  - Department of Psychiatry, University of North Carolina, Chapel Hill, NC.
FAU - Levi, Linda
AU  - Levi L
AD  - Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel.
FAU - Nastas, Igor
AU  - Nastas I
AD  - Department of Psychiatry, Narcology and Medical Psychology, State University of 
      Medicine and Pharmacy Nicolae Testemitanu, Chisinau, Moldova.
FAU - Gonen, Ilan
AU  - Gonen I
AD  - Tangent Alzheimer Care, Breaza, Romania.
FAU - Radu, Paull
AU  - Radu P
AD  - Tangent Alzheimer Care, Breaza, Romania.
FAU - Matei, Valentin
AU  - Matei V
AD  - Department of Psychiatry, Obrejia Hospital, Bucharest, Romania.
FAU - Nacu, Anatol
AU  - Nacu A
AD  - Department of Psychiatry, Narcology and Medical Psychology, State University of 
      Medicine and Pharmacy Nicolae Testemitanu, Chisinau, Moldova.
FAU - Boronin, Larisa
AU  - Boronin L
AD  - Department of Psychiatry, Narcology and Medical Psychology, State University of 
      Medicine and Pharmacy Nicolae Testemitanu, Chisinau, Moldova.
FAU - Davidson, Michael
AU  - Davidson M
AD  - Nicosia School of Medicine, Nicosia, Cyprus.
FAU - Davis, John M
AU  - Davis JM
AD  - Department of Psychiatry, University of Illinois, Chicago, IL.
LA  - eng
SI  - ClinicalTrials.gov/NCT01320982
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Schizophr Bull
JT  - Schizophrenia bulletin
JID - 0236760
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Schizophrenia/*drug therapy
MH  - Treatment Outcome
PMC - PMC8266648
OTO - NOTNLM
OT  - anti-inflammatory
OT  - aspirin
OT  - schizophrenia
OT  - symptoms
EDAT- 2021/01/23 06:00
MHDA- 2021/12/17 06:00
CRDT- 2021/01/22 06:27
PHST- 2021/01/23 06:00 [pubmed]
PHST- 2021/12/17 06:00 [medline]
PHST- 2021/01/22 06:27 [entrez]
AID - 6105814 [pii]
AID - sbaa198 [pii]
AID - 10.1093/schbul/sbaa198 [doi]
PST - ppublish
SO  - Schizophr Bull. 2021 Jul 8;47(4):1077-1087. doi: 10.1093/schbul/sbaa198.

PMID- 35262718
OWN - NLM
STAT- MEDLINE
DCOM- 20220420
LR  - 20220613
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 5
IP  - 3
DP  - 2022 Mar 1
TI  - Use of Machine Learning to Estimate the Per-Protocol Effect of Low-Dose Aspirin 
      on Pregnancy Outcomes: A Secondary Analysis of a Randomized Clinical Trial.
PG  - e2143414
LID - 10.1001/jamanetworkopen.2021.43414 [doi]
LID - e2143414
AB  - IMPORTANCE: In randomized clinical trials (RCTs), per-protocol effects may be of 
      interest in the presence of nonadherence with the randomized treatment protocol. 
      Using machine learning in per-protocol effect estimation can help avoid model 
      misspecification owing to strong parametric assumptions, as is common with 
      standard methods (eg, logistic regression). OBJECTIVES: To demonstrate the use of 
      ensemble machine learning with augmented inverse probability weighting (AIPW) for 
      per-protocol effect estimation in RCTs and to evaluate the per-protocol effect 
      size of aspirin on pregnancy. DESIGN, SETTING, AND PARTICIPANTS: This secondary 
      analysis used data from 1227 women in the Effects of Aspirin in Gestation and 
      Reproduction (EAGeR) trial, a multicenter, block-randomized, double-blind, 
      placebo-controlled clinical trial of the effect of daily low-dose aspirin on 
      pregnancy outcomes in women at high risk of pregnancy loss. Participants were 
      recruited at 4 university medical centers in the US from June 15, 2007, to July 
      15, 2012. Women were followed up for 6 menstrual cycles for attempted pregnancy 
      and 36 weeks of gestation if pregnancy occurred. Follow-up was completed on 
      August 17, 2012. Data analyses were performed on July 9, 2021. EXPOSURES: Daily 
      low-dose (81 mg) aspirin taken at least 5 of 7 days per week for at least 80% of 
      follow-up time relative to placebo. MAIN OUTCOMES AND MEASURES: Pregnancy 
      detected using human chorionic gonadotropin (hCG) levels. RESULTS: Among the 1227 
      women included in the analysis (mean SD age, 28.74 [4.80] years), 1161 (94.6%) 
      were non-Hispanic White and 858 (69.9%) adhered to the protocol. Five machine 
      learning models were combined into 1 meta-algorithm, which was used to construct 
      an AIPW estimator for the per-protocol effect. Compared with adhering to placebo, 
      adherence to the daily low-dose aspirin protocol for at least 5 of 7 days per 
      week was associated with an increase in the probability of hCG-detected pregnancy 
      of 8.0 (95% CI, 2.5-13.6) more hCG-detected pregnancies per 100 women in the 
      sample, which is substantially larger than the estimated intention-to-treat 
      estimate of 4.3 (95% CI, -1.1 to 9.6) more hCG-detected pregnancies per 100 women 
      in the sample. CONCLUSIONS AND RELEVANCE: These findings suggest that a low-dose 
      aspirin protocol is associated with increased hCG-detected pregnancy in women who 
      adhere to treatment for at least 5 days per week. With the presence of 
      nonadherence, per-protocol treatment effect estimates differ from 
      intention-to-treat estimates in the EAGeR trial. The results of this secondary 
      analysis of clinical trial data suggest that machine learning could be used to 
      estimate per-protocol effects by adjusting for confounders related to 
      nonadherence in a more flexible way than traditional regressions. TRIAL 
      REGISTRATION: ClinicalTrials.gov Identifier: NCT00467363.
FAU - Zhong, Yongqi
AU  - Zhong Y
AD  - Department of Epidemiology, The Johns Hopkins University, Baltimore, Maryland.
FAU - Brooks, Maria M
AU  - Brooks MM
AD  - Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
FAU - Kennedy, Edward H
AU  - Kennedy EH
AD  - Department of Data Science and Statistics, Carnegie Mellon University, 
      Pittsburgh, Pennsylvania.
FAU - Bodnar, Lisa M
AU  - Bodnar LM
AD  - Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
FAU - Naimi, Ashley I
AU  - Naimi AI
AD  - Department of Epidemiology, Emory University, Atlanta, Georgia.
LA  - eng
SI  - ClinicalTrials.gov/NCT00467363
GR  - R01 HD093602/HD/NICHD NIH HHS/United States
GR  - R01 HD102313/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
DEP - 20220301
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA Netw Open. 2022 Mar 1;5(3):e2143422. PMID: 35262723
EIN - JAMA Netw Open. 2022 Apr 1;5(4):e229172. PMID: 35420668
MH  - *Abortion, Spontaneous
MH  - Adult
MH  - *Aspirin/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Machine Learning
MH  - Male
MH  - Pregnancy
MH  - Pregnancy Outcome
PMC - PMC8908068
COIS- Conflict of Interest Disclosures: Drs Brooks, Kennedy, Bodnar, and Naimi reported 
      receiving grants from the National Institutes of Health (NIH) during the conduct 
      of the study. Dr Brooks reported serving on the data safety and monitoring board 
      for Cerus Corporation. No other disclosures were reported.
EDAT- 2022/03/10 06:00
MHDA- 2022/04/21 06:00
CRDT- 2022/03/09 12:33
PHST- 2022/03/09 12:33 [entrez]
PHST- 2022/03/10 06:00 [pubmed]
PHST- 2022/04/21 06:00 [medline]
AID - 2789846 [pii]
AID - zoi211206 [pii]
AID - 10.1001/jamanetworkopen.2021.43414 [doi]
PST - epublish
SO  - JAMA Netw Open. 2022 Mar 1;5(3):e2143414. doi: 
      10.1001/jamanetworkopen.2021.43414.

PMID- 8038461
OWN - NLM
STAT- MEDLINE
DCOM- 19940825
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 28
IP  - 4
DP  - 1994 Apr
TI  - Safety of combination aspirin and anticoagulation in acute ischemic stroke.
PG  - 441-3
AB  - OBJECTIVE: To assess the risk of bleeding complications in patients treated with 
      combination aspirin and heparin for cerebral ischemia. DESIGN: A retrospective, 
      cohort study. SETTING: A large urban teaching hospital. PATIENTS: One hundred 
      charts of stroke patients who had received anticoagulation with or without 
      aspirin therapy were identified from the Stroke Data Bank. Bleeding rates were 
      compared between the two groups. RESULTS: Forty-two patients who had received 
      heparin and/or warfarin in combination with aspirin were compared with 33 
      patients who had received anticoagulation alone. The mean duration of 
      anticoagulant therapy was 8.0 and 8.4 days, respectively. Bleeding rates were not 
      different between the two groups: 23.8 percent (10/42) (p = 0.78) and 24.2 
      percent (8/33), respectively. Although the bleeding rate was substantial, there 
      was only one major bleed (severe epistaxis) occurring in a patient receiving 
      anticoagulation only. No patient had an intracerebral hemorrhage. CONCLUSIONS: 
      Our data suggest that combination antithrombotic therapy is safe in a controlled, 
      inpatient setting.
FAU - Fagan, S C
AU  - Fagan SC
AD  - College of Pharmacy, Wayne State University, Detroit, MI 48202.
FAU - Kertland, H R
AU  - Kertland HR
FAU - Tietjen, G E
AU  - Tietjen GE
LA  - eng
GR  - NS23393/NS/NINDS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Cerebrovascular Disorders/*drug therapy
MH  - Cohort Studies
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
AID - 10.1177/106002809402800401 [doi]
PST - ppublish
SO  - Ann Pharmacother. 1994 Apr;28(4):441-3. doi: 10.1177/106002809402800401.

PMID- 12593655
OWN - NLM
STAT- MEDLINE
DCOM- 20030331
LR  - 20220311
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 46
IP  - 5
DP  - 2003 Feb 27
TI  - Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor 
      esters of aspirin.
PG  - 747-54
AB  - A new series of NSAIDs in which aspirin is joined by an ester linkage to furoxan 
      moieties, with different ability to release NO, were synthesized and tested for 
      NO-releasing, antiinflammatory, antiaggregatory, and ulcerogenic properties. 
      Related furazan derivatives, aspirin, its propyl ester, and its 
      gamma-nitrooxypropyl ester were taken as references. All the products described 
      present an antiinflammatory trend, maximized in derivatives 12, 16, and 17, they 
      are devoid of acute gastrotoxicity, principally due to their ester nature, and 
      show an antiplatelet activity primarily determined by their ability to release 
      NO. They do not behave as aspirin prodrugs in human serum.
FAU - Cena, Clara
AU  - Cena C
AD  - Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di 
      Torino, via Pietro Giuria 9, 10125 Torino, Italy.
FAU - Lolli, Marco L
AU  - Lolli ML
FAU - Lazzarato, Loretta
AU  - Lazzarato L
FAU - Guaita, Elena
AU  - Guaita E
FAU - Morini, Giuseppina
AU  - Morini G
FAU - Coruzzi, Gabriella
AU  - Coruzzi G
FAU - McElroy, Stuart P
AU  - McElroy SP
FAU - Megson, Ian L
AU  - Megson IL
FAU - Fruttero, Roberta
AU  - Fruttero R
FAU - Gasco, Alberto
AU  - Gasco A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Esters)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemical synthesis/pharmacology/toxicity
MH  - Aspirin/*analogs & derivatives/*chemical synthesis/pharmacology/toxicity
MH  - Edema/drug therapy
MH  - Esters
MH  - Gastric Mucosa/drug effects/pathology
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - In Vitro Techniques
MH  - Male
MH  - Necrosis
MH  - Nitric Oxide/blood
MH  - Nitric Oxide Donors/*chemical synthesis/pharmacology/toxicity
MH  - Peptic Ulcer/chemically induced/pathology
MH  - Platelet Aggregation Inhibitors/*chemical synthesis/pharmacology/toxicity
MH  - Rats
MH  - Rats, Wistar
EDAT- 2003/02/21 04:00
MHDA- 2003/04/01 05:00
CRDT- 2003/02/21 04:00
PHST- 2003/02/21 04:00 [pubmed]
PHST- 2003/04/01 05:00 [medline]
PHST- 2003/02/21 04:00 [entrez]
AID - 10.1021/jm020969t [doi]
PST - ppublish
SO  - J Med Chem. 2003 Feb 27;46(5):747-54. doi: 10.1021/jm020969t.

PMID- 26219912
OWN - NLM
STAT- MEDLINE
DCOM- 20151116
LR  - 20171116
IS  - 1521-0111 (Electronic)
IS  - 0026-895X (Linking)
VI  - 88
IP  - 4
DP  - 2015 Oct
TI  - Aspirin Targets SIRT1 and AMPK to Induce Senescence of Colorectal Carcinoma 
      Cells.
PG  - 708-19
LID - 10.1124/mol.115.098616 [doi]
AB  - Cancer therapies attempt to destroy the entire tumor, but this tends to require 
      toxic compounds and high doses of radiation. Recently, considerable attention has 
      focused on therapy-induced senescence (TIS), which can be induced in cancer cells 
      by low doses of therapeutic drugs or radiation and provides a barrier to tumor 
      development. However, the molecular mechanisms governing TIS remain elusive. 
      Special attention has been paid to the potential chemopreventive effect of 
      aspirin against human colorectal cancer. In this study, we investigated the 
      effects of aspirin on TIS of human colorectal carcinoma (CRC) cells and show that 
      it occurs via sirtuin 1 (SIRT1) and AMP-activated protein kinase (AMPK), two key 
      regulators of cellular metabolism. Aspirin increased the senescence of CRC cells, 
      increased the protein levels of SIRT1, phospho-AMPK (T172), and phospho-acetyl 
      CoA carboxylase (S79), and reduced the cellular level of ATP. Small-interfering 
      RNA-mediated downregulation or pharmacological inhibition of SIRT1 or AMPK 
      significantly attenuated the aspirin-induced cellular senescence in CRC cells. In 
      contrast, treatment with a SIRT1 agonist or an AMP analog induced cellular 
      senescence. Remarkably, SIRT1 knockdown abrogated the aspirin-induced activation 
      of AMPK, and vice versa. During the progression of aspirin-induced cellular 
      senescence in CRC cells, SIRT1 showed increased deacetylase activity at a 
      relatively early time point but was characterized by decreased activity with 
      increased cytoplasmic localization at a later time point. Collectively, these 
      novel findings suggest that aspirin could provide anticancer effects by inducing 
      senescence in human CRC cells through the reciprocal regulation of SIRT1-AMPK 
      pathways.
CI  - Copyright © 2015 by The American Society for Pharmacology and Experimental 
      Therapeutics.
FAU - Jung, Yu Ri
AU  - Jung YR
AD  - Division of Radiation Effect (Y.R.J., E.J.K., H.J.C., Y.-J.L., M.L.), Division of 
      Radiation Cancer Research (M.-J.P.), Korea Institute of Radiological and Medical 
      Sciences, Seoul, Republic of Korea; Department of Biochemistry and Medical 
      Research Center (J.-J.P.), College of Medicine, Chungbuk National University, 
      Cheongju, Republic of Korea; and Department of Pharmacology and Hypoxia-Related 
      Diseases Research Center (H.-S.K.), College of Medicine, Inha University, 
      Incheon, Republic of Korea.
FAU - Kim, Eun Ju
AU  - Kim EJ
AD  - Division of Radiation Effect (Y.R.J., E.J.K., H.J.C., Y.-J.L., M.L.), Division of 
      Radiation Cancer Research (M.-J.P.), Korea Institute of Radiological and Medical 
      Sciences, Seoul, Republic of Korea; Department of Biochemistry and Medical 
      Research Center (J.-J.P.), College of Medicine, Chungbuk National University, 
      Cheongju, Republic of Korea; and Department of Pharmacology and Hypoxia-Related 
      Diseases Research Center (H.-S.K.), College of Medicine, Inha University, 
      Incheon, Republic of Korea.
FAU - Choi, Hyeong Jwa
AU  - Choi HJ
AD  - Division of Radiation Effect (Y.R.J., E.J.K., H.J.C., Y.-J.L., M.L.), Division of 
      Radiation Cancer Research (M.-J.P.), Korea Institute of Radiological and Medical 
      Sciences, Seoul, Republic of Korea; Department of Biochemistry and Medical 
      Research Center (J.-J.P.), College of Medicine, Chungbuk National University, 
      Cheongju, Republic of Korea; and Department of Pharmacology and Hypoxia-Related 
      Diseases Research Center (H.-S.K.), College of Medicine, Inha University, 
      Incheon, Republic of Korea.
FAU - Park, Jung-Jin
AU  - Park JJ
AD  - Division of Radiation Effect (Y.R.J., E.J.K., H.J.C., Y.-J.L., M.L.), Division of 
      Radiation Cancer Research (M.-J.P.), Korea Institute of Radiological and Medical 
      Sciences, Seoul, Republic of Korea; Department of Biochemistry and Medical 
      Research Center (J.-J.P.), College of Medicine, Chungbuk National University, 
      Cheongju, Republic of Korea; and Department of Pharmacology and Hypoxia-Related 
      Diseases Research Center (H.-S.K.), College of Medicine, Inha University, 
      Incheon, Republic of Korea.
FAU - Kim, Hak-Su
AU  - Kim HS
AD  - Division of Radiation Effect (Y.R.J., E.J.K., H.J.C., Y.-J.L., M.L.), Division of 
      Radiation Cancer Research (M.-J.P.), Korea Institute of Radiological and Medical 
      Sciences, Seoul, Republic of Korea; Department of Biochemistry and Medical 
      Research Center (J.-J.P.), College of Medicine, Chungbuk National University, 
      Cheongju, Republic of Korea; and Department of Pharmacology and Hypoxia-Related 
      Diseases Research Center (H.-S.K.), College of Medicine, Inha University, 
      Incheon, Republic of Korea.
FAU - Lee, Yoon-Jin
AU  - Lee YJ
AD  - Division of Radiation Effect (Y.R.J., E.J.K., H.J.C., Y.-J.L., M.L.), Division of 
      Radiation Cancer Research (M.-J.P.), Korea Institute of Radiological and Medical 
      Sciences, Seoul, Republic of Korea; Department of Biochemistry and Medical 
      Research Center (J.-J.P.), College of Medicine, Chungbuk National University, 
      Cheongju, Republic of Korea; and Department of Pharmacology and Hypoxia-Related 
      Diseases Research Center (H.-S.K.), College of Medicine, Inha University, 
      Incheon, Republic of Korea.
FAU - Park, Myung-Jin
AU  - Park MJ
AD  - Division of Radiation Effect (Y.R.J., E.J.K., H.J.C., Y.-J.L., M.L.), Division of 
      Radiation Cancer Research (M.-J.P.), Korea Institute of Radiological and Medical 
      Sciences, Seoul, Republic of Korea; Department of Biochemistry and Medical 
      Research Center (J.-J.P.), College of Medicine, Chungbuk National University, 
      Cheongju, Republic of Korea; and Department of Pharmacology and Hypoxia-Related 
      Diseases Research Center (H.-S.K.), College of Medicine, Inha University, 
      Incheon, Republic of Korea.
FAU - Lee, Minyoung
AU  - Lee M
AD  - Division of Radiation Effect (Y.R.J., E.J.K., H.J.C., Y.-J.L., M.L.), Division of 
      Radiation Cancer Research (M.-J.P.), Korea Institute of Radiological and Medical 
      Sciences, Seoul, Republic of Korea; Department of Biochemistry and Medical 
      Research Center (J.-J.P.), College of Medicine, Chungbuk National University, 
      Cheongju, Republic of Korea; and Department of Pharmacology and Hypoxia-Related 
      Diseases Research Center (H.-S.K.), College of Medicine, Inha University, 
      Incheon, Republic of Korea mylee@kcch.re.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150728
PL  - United States
TA  - Mol Pharmacol
JT  - Molecular pharmacology
JID - 0035623
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - EC 3.5.1.- (SIRT1 protein, human)
RN  - EC 3.5.1.- (Sirtuin 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - AMP-Activated Protein Kinases/*metabolism
MH  - Aspirin/administration & dosage/*metabolism
MH  - Cellular Senescence/drug effects/*physiology
MH  - Colorectal Neoplasms/*metabolism
MH  - Drug Delivery Systems/*methods
MH  - HCT116 Cells
MH  - Humans
MH  - Sirtuin 1/*metabolism
EDAT- 2015/07/30 06:00
MHDA- 2015/11/17 06:00
CRDT- 2015/07/30 06:00
PHST- 2015/03/05 00:00 [received]
PHST- 2015/07/27 00:00 [accepted]
PHST- 2015/07/30 06:00 [entrez]
PHST- 2015/07/30 06:00 [pubmed]
PHST- 2015/11/17 06:00 [medline]
AID - mol.115.098616 [pii]
AID - 10.1124/mol.115.098616 [doi]
PST - ppublish
SO  - Mol Pharmacol. 2015 Oct;88(4):708-19. doi: 10.1124/mol.115.098616. Epub 2015 Jul 
      28.

PMID- 28334544
OWN - NLM
STAT- MEDLINE
DCOM- 20170912
LR  - 20181202
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 63
IP  - 2
DP  - 2017 Winter
TI  - [Antiplatelet thromboprophylaxis of arterial vascular diseases and organovascular 
      ischemic diseases].
PG  - 124-132
AB  - Antiplatelet therapy by acetylsalicylic acid (ASA, aspirin) provided pivotal 
      advances in the prevention and treatment of organovascular (angiovascular, 
      cardiovascular, cerebrovascular, extremitovascular, renovascular, genitovascular, 
      mesenteriointestinokolonovascular, bronchopulmovascular, oculovascular, 
      otovascular and other) arterial ischemic diseases. Currently available 
      antiplatelet drugs have some limitations which might be overcomed by improved 
      dosing regimens, use of combination of agents affecting different platelet 
      functions and, in particular, by the new antiplatelet drugs (new arterial 
      antithrombotics) with distinct pharmacodynamic properties offering new 
      advantages, including faster onset of action, greater potency, and reversibility 
      of effects.Key words: arteriothromboprophylaxis - arterial thrombosis - classic 
      antiplatelet drugs - new antiplatelet agents - organovascular arterial diseases.
FAU - Gavorník, Peter
AU  - Gavorník P
FAU - Dukát, Andrej
AU  - Dukát A
FAU - Gašpar, Ľudovít
AU  - Gašpar Ľ
FAU - Gavorníková, Eva
AU  - Gavorníková E
FAU - Hučková, Naďa
AU  - Hučková N
FAU - Petrášová, Anna
AU  - Petrášová A
FAU - Gubo, Gabriela
AU  - Gubo G
FAU - Gašparová, Iveta
AU  - Gašparová I
FAU - Sabolová, Lujza
AU  - Sabolová L
LA  - cze
PT  - Journal Article
TT  - Antitrombocytová tromboprofylaxia artériových vaskulárnych chorôb 
      a orgánovaskulárnych ischemických chorôb.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Platelet Activation
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Thrombosis/*prevention & control
MH  - Vascular Diseases/drug therapy/*prevention & control
EDAT- 2017/03/24 06:00
MHDA- 2017/09/13 06:00
CRDT- 2017/03/24 06:00
PHST- 2017/03/24 06:00 [entrez]
PHST- 2017/03/24 06:00 [pubmed]
PHST- 2017/09/13 06:00 [medline]
AID - 60534 [pii]
PST - ppublish
SO  - Vnitr Lek. 2017 Winter;63(2):124-132.

PMID- 7118968
OWN - NLM
STAT- MEDLINE
DCOM- 19821202
LR  - 20160512
IS  - 0021-9355 (Print)
IS  - 0021-9355 (Linking)
VI  - 64
IP  - 7
DP  - 1982 Sep
TI  - The detection and prevention of pulmonary embolism in total hip replacement. A 
      study comparing aspirin and low-dose warfarin.
PG  - 1040-4
AB  - Because of the controversy surrounding prophylaxis for thromboembolism after 
      total hip surgery, we undertook a prospective study comparing the results of the 
      administration of aspirin with that of low doses of warfarin in 194 patients (200 
      hips) undergoing total hip replacement. The incidences of both clinically 
      apparent and silent (asymptomatic) pulmonary emboli were determined using the 
      objective criteria of preoperative and postoperative levels of arterial blood 
      gases, chest roentgenograms, electrocardiograms, and perfusion lung scans. With 
      this surveillance plan, the accuracy of diagnosis of clinically symptomatic 
      pulmonary emboli was improved and the detection of otherwise silent pulmonary 
      emboli became possible. The group of patients who received low doses of warfarin 
      showed a 6 per cent total incidence of pulmonary emboli compared with a 19 per 
      cent incidence in the group receiving aspirin (p less than 0.05). There was, 
      however, no significant difference when the incidences of only the clinically 
      suspected emboli were compared, the rates for the two groups being 5 and 8 per 
      cent, respectively (p greater than 0.05). There was also no significant 
      difference between men and women with regard to the prophylactic efficacy of 
      aspirin in preventing pulmonary embolism.
FAU - Guyer, R D
AU  - Guyer RD
FAU - Booth, R E Jr
AU  - Booth RE Jr
FAU - Rothman, R H
AU  - Rothman RH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Female
MH  - Hip Joint/*surgery
MH  - *Hip Prosthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/prevention & control
MH  - Prospective Studies
MH  - Pulmonary Embolism/diagnosis/*prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 1982/09/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1982/09/01 00:00
PHST- 1982/09/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1982/09/01 00:00 [entrez]
PST - ppublish
SO  - J Bone Joint Surg Am. 1982 Sep;64(7):1040-4.

PMID- 21372542
OWN - NLM
STAT- MEDLINE
DCOM- 20110825
LR  - 20190724
IS  - 0031-6903 (Print)
IS  - 0031-6903 (Linking)
VI  - 131
IP  - 3
DP  - 2011 Mar
TI  - [Investigation into the effect of gastric secretion inhibitor for the prevention 
      of upper gastrointestinal lesions associated with low-dose aspirin].
PG  - 445-52
AB  - In this study, we investigated the effect of histamin H₂ receptor antagonist 
      (H₂RA) or proton pump inhibitor (PPI) for the prevention of upper 
      gastrointestinal lesions associated with low-dose aspirin. We carried out a 
      retrospective study of 2811 patients who had been prescribed low-dose aspirin 
      (Bayaspirin® 100 mg) for more than 30 days at Tokai University Hachioji Hospital 
      from 2006 to 2008. We classified them into three groups: aspirin alone group 
      (n=1103), aspirin with H₂RA group (n=844) and aspirin with PPI group (n=864). 
      Patients who developed upper gastrointestinal lesions were diagnosed with gastric 
      ulcer, duodenal ulcer, gastritis or duodenitis by gastroscopy. We then compared 
      the incidence of upper gastrointestinal lesions among the groups. The incidence 
      in aspirin alone group, aspirin with H₂RA group and aspirin with PPI group was 
      2.54%, 1.54% and 1.04%, respectively; that of aspirin with PPI group being 
      significantly lower (p<0.05). Additively, the odds ratio (OR) of aspirin with 
      H₂RA group and aspirin with PPI group was 0.60 (95% confidence interval [95%CI]: 
      0.31-1.17) and 0.40 (95% CI: 0.19-0.86) as compared with aspirin alone group, 
      respectively. The upper gastrointestinal lesions were developed within two years 
      in all groups. Our results suggest that the combined administration of low-dose 
      aspirin and PPI is effective for the prevention of upper gastrointestinal lesions 
      associated with low-dose aspirin. Also, the pharmacists should be especially 
      careful for upper gastrointestinal lesions development within two years after 
      administration of low-dose aspirin, regardless of combined whether H₂RA or PPI.
FAU - Nakamura, Hironori
AU  - Nakamura H
AD  - Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo 
      University of Pharmacy and Life Sciences.
FAU - Yokoyama, Haruko
AU  - Yokoyama H
FAU - Yaguchi, Takehiro
AU  - Yaguchi T
FAU - Suzuki, Yuji
AU  - Suzuki Y
FAU - Tokuoka, Kentaro
AU  - Tokuoka K
FAU - Watanabe, Masayuki
AU  - Watanabe M
FAU - Kitagawa, Yasuhisa
AU  - Kitagawa Y
FAU - Yamada, Yasuhiko
AU  - Yamada Y
LA  - jpn
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Gastrointestinal Diseases/*chemically induced/epidemiology/*prevention & control
MH  - Histamine H2 Antagonists/administration & dosage/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Proton Pump Inhibitors/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - Time Factors
EDAT- 2011/03/05 06:00
MHDA- 2011/08/27 06:00
CRDT- 2011/03/05 06:00
PHST- 2011/03/05 06:00 [entrez]
PHST- 2011/03/05 06:00 [pubmed]
PHST- 2011/08/27 06:00 [medline]
AID - JST.JSTAGE/yakushi/131.445 [pii]
AID - 10.1248/yakushi.131.445 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2011 Mar;131(3):445-52. doi: 10.1248/yakushi.131.445.

PMID- 19689242
OWN - NLM
STAT- MEDLINE
DCOM- 20091109
LR  - 20191027
IS  - 1875-5453 (Electronic)
IS  - 1389-2002 (Linking)
VI  - 10
IP  - 5
DP  - 2009 Jun
TI  - Serum albumin complexation of acetylsalicylic acid metabolites.
PG  - 448-58
AB  - One possible origin of the type I hypersensitivity reaction is reaction of drugs 
      such as acetylsalicylic acid and its metabolites being complexed with human serum 
      albumin. Albumin, being transporting molecule abundant in blood plasma is able to 
      bind large array of ligands varying from small single carbon particles to long 
      hydrophobic tailed lipidic acids (e.g. myristic acid). This non specificity is 
      possible because of multi domain scaffold and large flexibility of inter-domain 
      loops, which results in serious reorientation of domains. Hypothesis that 
      acetylsalicylic acid metabolites may play indirect role in activation of allergic 
      reaction has been tested. Binding of acetylsalicylic acid metabolites in 
      intra-domain space causes significant increase of liability of domains IIIA and 
      IIIB. One of metabolites, salicyluric acid, once is bound causes distortion and 
      partial unfolding of helices in domains IA, IIB and IIIB. Changed are both 
      directions and amplitude of relative motions as well as intra-domain distances. 
      In result albumin is able to cross-link of adjacent IgE receptors which 
      subsequently starts allergic reaction.
FAU - Jurkowski, Wiktor
AU  - Jurkowski W
AD  - Department of Bioinformatics and Telemedicine, Jagiellonian University, Krakow, 
      Poland.
FAU - Porebski, Grzegorz
AU  - Porebski G
FAU - Obtułowicz, Krystyna
AU  - Obtułowicz K
FAU - Roterman, Irena
AU  - Roterman I
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Curr Drug Metab
JT  - Current drug metabolism
JID - 100960533
RN  - 0 (Hippurates)
RN  - 0 (Ligands)
RN  - 0 (Receptors, IgE)
RN  - 0 (Serum Albumin)
RN  - 487-54-7 (salicylurate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/immunology/*metabolism
MH  - Binding Sites
MH  - Drug Hypersensitivity/immunology
MH  - Hippurates/metabolism
MH  - Humans
MH  - Hypersensitivity, Immediate/*immunology
MH  - Ligands
MH  - Models, Molecular
MH  - Protein Binding
MH  - Protein Conformation
MH  - Receptors, IgE/metabolism
MH  - Serum Albumin/*metabolism
EDAT- 2009/08/20 09:00
MHDA- 2009/11/10 06:00
CRDT- 2009/08/20 09:00
PHST- 2009/08/20 09:00 [entrez]
PHST- 2009/08/20 09:00 [pubmed]
PHST- 2009/11/10 06:00 [medline]
AID - 10.2174/138920009788897984 [doi]
PST - ppublish
SO  - Curr Drug Metab. 2009 Jun;10(5):448-58. doi: 10.2174/138920009788897984.

PMID- 17703636
OWN - NLM
STAT- MEDLINE
DCOM- 20080225
LR  - 20181201
IS  - 1176-6344 (Print)
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Linking)
VI  - 3
IP  - 3
DP  - 2007
TI  - Risk reduction with clopidogrel in the management of peripheral arterial disease.
PG  - 289-97
AB  - Peripheral arterial disease (PAD) is a condition typified by decreased arterial 
      blood flow in the non-coronary branches of the aorta as a result of chronic 
      atherosclerosis. Despite the higher prevalence of PAD compared with other 
      cardiovascular entities such as myocardial infarction and stroke, far less import 
      is given to its diagnosis and treatment. In this review, we highlight principal 
      diagnostic and therapeutic considerations in the management of PAD and its 
      complications. We particularly emphasize the role of clopidogrel in the reduction 
      of risks associated with PAD.
FAU - Nayak, Keshav R
AU  - Nayak KR
AD  - Department of Cardiology, Naval Medical Center San Diego, San Diego, CA 92134, 
      USA.
FAU - Cavendish, Jeffrey J
AU  - Cavendish JJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Peripheral Vascular Diseases/diagnosis/*drug therapy
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
PMC - PMC2293969
EDAT- 2007/08/21 09:00
MHDA- 2008/02/26 09:00
CRDT- 2007/08/21 09:00
PHST- 2007/08/21 09:00 [pubmed]
PHST- 2008/02/26 09:00 [medline]
PHST- 2007/08/21 09:00 [entrez]
PST - ppublish
SO  - Vasc Health Risk Manag. 2007;3(3):289-97.

PMID- 22987197
OWN - NLM
STAT- MEDLINE
DCOM- 20140117
LR  - 20211021
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 36
IP  - 1
DP  - 2013 Jul
TI  - Increased risk of minor bleeding and antiplatelet therapy cessation in patients 
      with acute coronary syndromes and low on-aspirin platelet reactivity. A 
      prospective cohort study.
PG  - 22-30
LID - 10.1007/s11239-012-0808-5 [doi]
AB  - Bleeding negatively affects prognosis and adherence to antiplatelet therapy after 
      acute coronary syndromes (ACSs). The potential association of on-aspirin platelet 
      reactivity and bleeding is not established. We sought to determine whether low 
      on-aspirin platelet reactivity (LAPR) is associated with bleeding events and 
      antiplatelet therapy compliance in patients with ACSs receiving coronary 
      stenting. On-aspirin platelet reactivity was measured by the VerifyNow™ Aspirin 
      assay (Accumetrics Inc., San Diego, CA, USA) in 531 patients with ACS. Cut-offs 
      for LAPR were calculated by receiver-operating characteristic curve (ROC) 
      analysis. Bleeding was reported according to Bleeding Academic Research 
      Consortium (BARC) definition. The endpoints were minor bleeding (BARC types 1 or 
      2), major bleeding (BARC types 3 or 5) and antiplatelet therapy cessation during 
      6-months follow-up. By ROC analysis the VerifyNow™ Aspirin assay was able to 
      distinguish between patients with and without minor bleeding (area under the 
      curve [AUC] 0.66, 95 % confidence interval [CI] 0.62-0.70, P < 0.0001) whereas 
      major bleeding could not be predicted by the assay (AUC 0.54, 95 % CI 0.49-0.58, 
      P = 0.473). By logistic regression, LAPR was associated with increased risk of 
      minor bleeding (odds ratio [OR] 4.32, 95 % CI 2.78-6.71, P < 0.0001) but not 
      major bleeding (OR 2.05, 95 % CI 0.83-5.06, P = 0.117). Antiplatelet therapy 
      discontinuation was more frequent in patients with LAPR as compared to those with 
      no LAPR (21.6 vs. 9.1 %, P = 0.0008). In conclusion, early point-of-care 
      on-aspirin platelet reactivity testing in ACS may identify patients with 
      increased risk of minor bleeding events and subsequent discontinuation of 
      antiplatelet therapy. The possible impact of LAPR on major bleeding needs to be 
      determined in larger trials.
FAU - Huczek, Zenon
AU  - Huczek Z
AD  - Ist Chair and Department of Cardiology, The Medical University of Warsaw, 1a 
      Banacha Street, 02-097 Warsaw, Poland. zenon.huczek@wum.edu.pl
FAU - Filipiak, Krzysztof J
AU  - Filipiak KJ
FAU - Kochman, Janusz
AU  - Kochman J
FAU - Michalak, Marcin
AU  - Michalak M
FAU - Grabowski, Marcin
AU  - Grabowski M
FAU - Opolski, Grzegorz
AU  - Opolski G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/blood/diagnosis/*drug therapy
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects/pharmacokinetics
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/*chemically induced/diagnosis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/pharmacokinetics
MH  - *Point-of-Care Systems
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
MH  - Withholding Treatment
PMC - PMC3682102
EDAT- 2012/09/19 06:00
MHDA- 2014/01/18 06:00
CRDT- 2012/09/19 06:00
PHST- 2012/09/19 06:00 [entrez]
PHST- 2012/09/19 06:00 [pubmed]
PHST- 2014/01/18 06:00 [medline]
AID - 808 [pii]
AID - 10.1007/s11239-012-0808-5 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2013 Jul;36(1):22-30. doi: 10.1007/s11239-012-0808-5.

PMID- 1462452
OWN - NLM
STAT- MEDLINE
DCOM- 19930112
LR  - 20131121
IS  - 0041-5782 (Print)
IS  - 0041-5782 (Linking)
VI  - 154
IP  - 48
DP  - 1992 Nov 23
TI  - [Salicylic acid poisoning].
PG  - 3417-23
AB  - The study analyses the role of salicylic acid (SA) in fatal intoxications with 
      special reference to potentially avoidable, accidental poisonings. The study 
      indicates a relation between SA intoxication and the presence of an infection of 
      the respiratory tract. All deaths in Denmark in the period 1980 through 1989 
      registered as caused by SA were analysed as were all deaths submitted to forensic 
      toxicological examination in a defined region of Denmark in the years 1985 
      through 1989. During the decade 1980 through 1989 the number of fatal 
      intoxications due to SA increased from approx. five per year to approx. 23 per 
      year. During the same period the sales of SA decreased. Many deaths in the 
      material were registered as accidental, and an increasing frequency of accidental 
      deaths was seen with a lower social level. Frequently, an infection of the 
      respiratory tract was either indicated in a hospital case record or a police 
      report, or found at autopsy.
FAU - Jensen, S
AU  - Jensen S
AD  - Aarhus Universitet, Retsmedicinsk Institut.
FAU - Hansen, A C
AU  - Hansen AC
FAU - Kjeldsen, N J
AU  - Kjeldsen NJ
LA  - dan
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Salicylsyreforgiftninger.
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*poisoning
MH  - Denmark/epidemiology
MH  - Drug Utilization
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Registries
MH  - Respiratory Tract Infections/complications/drug therapy/pathology
MH  - Social Class
MH  - Suicide/*statistics & numerical data
EDAT- 1992/11/23 00:00
MHDA- 1992/11/23 00:01
CRDT- 1992/11/23 00:00
PHST- 1992/11/23 00:00 [pubmed]
PHST- 1992/11/23 00:01 [medline]
PHST- 1992/11/23 00:00 [entrez]
PST - ppublish
SO  - Ugeskr Laeger. 1992 Nov 23;154(48):3417-23.

PMID- 643896
OWN - NLM
STAT- MEDLINE
DCOM- 19780617
LR  - 20191210
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 16
IP  - 5
DP  - 1978
TI  - Effect of C 21 524-Su (pirprofen) on spontaneous osteoarthrosis in the mouse.
PG  - 268-72
AB  - Mice of the C57 Black strain, aged 11-12 weeks, were treated once daily on 5 days 
      a week for 4 months with C 21 524-Su (pirprofen) in doses of 10 and 30 mg/kg p.o. 
      In this genetically predisposed strain of mice, increases in the incidence of 
      gonarthrosis have been observed after the administration of certain 
      anti-inflammatory agents such as acetylsalicylic acid. Radiography and in 
      particular exact histological examination of the knee joints revealed, however, 
      that neither the overall incidence nor the severity of osteoarthrosis was greater 
      in the mice treated with C 21 524-Su than in the controls. On the contrary, in 
      the treated animals there was a tendency for the incidence and the intensity of 
      gonarthrosis to be lower.
FAU - Wilhelmi, G
AU  - Wilhelmi G
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyrroles)
RN  - R16CO5Y76E (Aspirin)
RN  - T7KN291890 (pirprofen)
SB  - IM
MH  - Animals
MH  - *Anti-Inflammatory Agents
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Knee Joint/diagnostic imaging/pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Osteoarthritis/*drug therapy
MH  - Phenylpropionates/administration & dosage/*therapeutic use
MH  - Pyrroles/administration & dosage/therapeutic use
MH  - Radiography
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1159/000136778 [doi]
PST - ppublish
SO  - Pharmacology. 1978;16(5):268-72. doi: 10.1159/000136778.

PMID- 902597
OWN - NLM
STAT- MEDLINE
DCOM- 19771125
LR  - 20131121
IS  - 0012-0472 (Print)
IS  - 0012-0472 (Linking)
VI  - 102
IP  - 37
DP  - 1977 Sep 16
TI  - [Low-dose heparin and acetyl-salicylic acid after elective operations on the hip 
      joint (author's transl)].
PG  - 1314-8
AB  - 3.6 g acetylsalicylic lysin was injected into 30 patients daily after operative 
      replacement of the hip-joint. Pulmonary embolism and (or) deep-vein thrombosis 
      were diagnosed in 19 patients. Low-dose heparin (3 X 5000 IU/24 h) significantly 
      reduced the incidence of deep-vein thrombosis (ten of thirty patients: P less 
      than 0.05) compared with the acetylsalicylic acid group. The results demonstrate 
      not only the inadequate thrombosis prophylaxis provided by acetylsalicylic acid, 
      but also that low-dose heparin prophylaxis in these specially at risk patients is 
      of limited efficacy.
FAU - Schöndorf, T H
AU  - Schöndorf TH
FAU - Weber, U
AU  - Weber U
FAU - Lasch, H G
AU  - Lasch HG
LA  - ger
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Niedrig dosiertes Heparin und Acetylsalicylsäure nach elektiven Operationen am 
      Hüftgelenk. Untersuchungen zur antithrombotischen Wirkung.
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Female
MH  - Heparin/*administration & dosage/therapeutic use
MH  - Hip Joint/*surgery
MH  - Humans
MH  - *Joint Prosthesis
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
MH  - Pulmonary Embolism/prevention & control
MH  - Thrombophlebitis/prevention & control
MH  - Thrombosis/prevention & control
EDAT- 1977/09/16 00:00
MHDA- 1977/09/16 00:01
CRDT- 1977/09/16 00:00
PHST- 1977/09/16 00:00 [pubmed]
PHST- 1977/09/16 00:01 [medline]
PHST- 1977/09/16 00:00 [entrez]
AID - 10.1055/s-0028-1105499 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 1977 Sep 16;102(37):1314-8. doi: 10.1055/s-0028-1105499.

PMID- 32466729
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1941-7705 (Electronic)
IS  - 1941-7713 (Print)
IS  - 1941-7713 (Linking)
VI  - 13
IP  - 6
DP  - 2020 Jun
TI  - Computable Phenotype Implementation for a National, Multicenter Pragmatic 
      Clinical Trial: Lessons Learned From ADAPTABLE.
PG  - e006292
LID - 10.1161/CIRCOUTCOMES.119.006292 [doi]
AB  - BACKGROUND: Many large-scale cardiovascular clinical trials are plagued with 
      escalating costs and low enrollment. Implementing a computable phenotype, which 
      is a set of executable algorithms, to identify a group of clinical 
      characteristics derivable from electronic health records or administrative claims 
      records, is essential to successful recruitment in large-scale pragmatic clinical 
      trials. This methods paper provides an overview of the development and 
      implementation of a computable phenotype in ADAPTABLE (Aspirin Dosing: a 
      Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness)-a 
      pragmatic, randomized, open-label clinical trial testing the optimal dose of 
      aspirin for secondary prevention of atherosclerotic cardiovascular disease 
      events. METHODS AND RESULTS: A multidisciplinary team developed and tested the 
      computable phenotype to identify adults ≥18 years of age with a history of 
      atherosclerotic cardiovascular disease without safety concerns around using 
      aspirin and meeting trial eligibility criteria. Using the computable phenotype, 
      investigators identified over 650 000 potentially eligible patients from the 40 
      participating sites from Patient-Centered Outcomes Research Network-a network of 
      Clinical Data Research Networks, Patient-Powered Research Networks, and Health 
      Plan Research Networks. Leveraging diverse recruitment methods, sites enrolled 
      15 076 participants from April 2016 to June 2019. During the process of 
      developing and implementing the ADAPTABLE computable phenotype, several key 
      lessons were learned. The accuracy and utility of a computable phenotype are 
      dependent on the quality of the source data, which can be variable even with a 
      common data model. Local validation and modification were required based on site 
      factors, such as recruitment strategies, data quality, and local coding patterns. 
      Sustained collaboration among a diverse team of researchers is needed during 
      computable phenotype development and implementation. CONCLUSIONS: The ADAPTABLE 
      computable phenotype served as an efficient method to recruit patients in a 
      multisite pragmatic clinical trial. This process of development and 
      implementation will be informative for future large-scale, pragmatic clinical 
      trials. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: 
      NCT02697916.
FAU - Ahmad, Faraz S
AU  - Ahmad FS
AD  - Department of Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, IL (F.S.A.).
FAU - Ricket, Iben M
AU  - Ricket IM
AD  - Louisiana Public Health Institute, New Orleans (I.M.R.).
FAU - Hammill, Bradley G
AU  - Hammill BG
AD  - Duke University School of Medicine, Durham, NC (B.G.H., M.T.R., W.S.J.).
AD  - Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., 
      W.S.J.).
FAU - Eskenazi, Lisa
AU  - Eskenazi L
AD  - Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., 
      W.S.J.).
FAU - Robertson, Holly R
AU  - Robertson HR
AD  - Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., 
      W.S.J.).
FAU - Curtis, Lesley H
AU  - Curtis LH
AD  - Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., 
      W.S.J.).
FAU - Dobi, Cecilia D
AU  - Dobi CD
AD  - Department of Clinical Sciences, Lewis Katz School of Medicine at Temple 
      University, Philadelphia, PA (C.D.D.).
FAU - Girotra, Saket
AU  - Girotra S
AD  - University of Iowa Carver College of Medicine, Iowa City (S.G.).
AD  - Iowa City Veteran Affairs Medical Center (S.G.).
FAU - Haynes, Kevin
AU  - Haynes K
AD  - Scientific Affairs, HealthCore, Inc., Wilmington, DE (K.H.).
FAU - Kizer, Jorge R
AU  - Kizer JR
AD  - Cardiology Section, San Francisco Veterans Affairs Health Care System, CA 
      (J.R.K.).
AD  - Department of Medicine and Department of Epidemiology and Biostatistics, 
      University of California San Francisco (J.R.K.).
FAU - Kripalani, Sunil
AU  - Kripalani S
AD  - Department of Medicine, Vanderbilt University Medical Center, Veterans Health 
      Administration-Tennessee Valley Healthcare System Geriatric Research Education 
      Clinical Center, Health Services Research and Development Center, Nashville, TN 
      (S.K., C.L.R.).
FAU - Roe, Mathew T
AU  - Roe MT
AD  - Duke University School of Medicine, Durham, NC (B.G.H., M.T.R., W.S.J.).
AD  - Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., 
      W.S.J.).
FAU - Roumie, Christianne L
AU  - Roumie CL
AD  - Department of Medicine, Vanderbilt University Medical Center, Veterans Health 
      Administration-Tennessee Valley Healthcare System Geriatric Research Education 
      Clinical Center, Health Services Research and Development Center, Nashville, TN 
      (S.K., C.L.R.).
FAU - Waitman, Russ
AU  - Waitman R
AD  - Department of Internal Medicine, University of Kansas Medical Center, Kansas 
      City, KS (R.W.).
FAU - Jones, W Schuyler
AU  - Jones WS
AD  - Duke University School of Medicine, Durham, NC (B.G.H., M.T.R., W.S.J.).
AD  - Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., 
      W.S.J.).
FAU - Weiner, Mark G
AU  - Weiner MG
AD  - Department of Population Health Sciences, Weill Cornell Medicine, New York 
      Presbyterian-Weill Cornell Campus, New York (M.G.W.).
LA  - eng
SI  - ClinicalTrials.gov/NCT02697916
GR  - K12 HS026385/HS/AHRQ HHS/United States
GR  - UL1 TR001422/TR/NCATS NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200529
PL  - United States
TA  - Circ Cardiovasc Qual Outcomes
JT  - Circulation. Cardiovascular quality and outcomes
JID - 101489148
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Algorithms
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/diagnosis/*drug therapy/physiopathology
MH  - Data Mining
MH  - *Electronic Health Records
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Patient Selection
MH  - Phenotype
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Pragmatic Clinical Trials as Topic
PMC - PMC7321832
MID - NIHMS1589988
OTO - NOTNLM
OT  - aspirin
OT  - electronic health records
OT  - heart disease
OT  - patient selection
OT  - pragmatic clinical trial
COIS- Disclosures The authors report no conflicts.
EDAT- 2020/05/30 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1161/CIRCOUTCOMES.119.006292 [doi]
PST - ppublish
SO  - Circ Cardiovasc Qual Outcomes. 2020 Jun;13(6):e006292. doi: 
      10.1161/CIRCOUTCOMES.119.006292. Epub 2020 May 29.

PMID- 11805546
OWN - NLM
STAT- MEDLINE
DCOM- 20020222
LR  - 20191105
IS  - 1070-5295 (Print)
IS  - 1070-5295 (Linking)
VI  - 7
IP  - 6
DP  - 2001 Dec
TI  - Potential of hemoglobin-based oxygen carriers in trauma patients.
PG  - 431-6
AB  - Injured patients have a unique requirement for early blood transfusion. A product 
      that can be used in the prehospital setting that adequately carries and delivers 
      oxygen to peripheral tissues would potentially be life saving for severely 
      injured patients. Allogeneic blood is not the ideal agent in the pre-hospital 
      setting. Present limitations in the allogeneic blood supply include the need for 
      cross-matching, refrigeration, marginal supply, transfusion reactions, infectious 
      disease transmission and immunomodulation increasing the risk of organ 
      dysfunction after transfusion.Hemoglobin-based oxygen carriers have been under 
      present development for the last 25 years. These compounds use either human or 
      bovine hemoglobin that is then chemically altered to improve safety. These 
      compounds exhibit many desirable characteristics that make them potential 
      therapeutic agents in the treatment of the injured patient. These compounds do 
      not need to be cross-matched, have favorable oxygen dissociation characteristics, 
      long half lives, do not transmit disease, appear to be less immunoreactive than 
      blood and theoretically can be used in the pre-hospital setting as a low volume 
      oxygen carrying solution without need for refrigeration. There are at least three 
      agents presently under development that use different techniques to alter the 
      basic hemoglobin tetramer. While there is no FDA approved hemoglobin-based oxygen 
      carrier approved for use in injured patients at this writing, phase III studies 
      are currently either underway or being developed. There is high likelihood that 
      one or more of these agents will be approved for clinical use in the near future.
FAU - Arnoldo, B D
AU  - Arnoldo BD
AD  - Department of Surgery, Division of Burn, Trauma and Critical Care University of 
      Texas Southwestern Medical Center, Dallas, TX 75390-9158, USA.
FAU - Minei, J P
AU  - Minei JP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Crit Care
JT  - Current opinion in critical care
JID - 9504454
RN  - 0 (Blood Substitutes)
RN  - 0 (Fluorocarbons)
RN  - 0 (Hemoglobins)
RN  - 0 (O-raffinose cross-linked human hemoglobin)
RN  - 0 (polyhemoglobin)
RN  - 1XQE66T19H (HBOC 201)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - N5O3QU595M (Raffinose)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Fluorocarbons/therapeutic use
MH  - Hemoglobins/chemistry/*therapeutic use
MH  - Humans
MH  - Oxygen/blood
MH  - Raffinose/analogs & derivatives/therapeutic use
MH  - Transfusion Reaction
MH  - Wounds and Injuries/*therapy
RF  - 56
EDAT- 2002/01/24 10:00
MHDA- 2002/02/23 10:01
CRDT- 2002/01/24 10:00
PHST- 2002/01/24 10:00 [pubmed]
PHST- 2002/02/23 10:01 [medline]
PHST- 2002/01/24 10:00 [entrez]
AID - 10.1097/00075198-200112000-00010 [doi]
PST - ppublish
SO  - Curr Opin Crit Care. 2001 Dec;7(6):431-6. doi: 10.1097/00075198-200112000-00010.

PMID- 8409706
OWN - NLM
STAT- MEDLINE
DCOM- 19931116
LR  - 20210105
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 122
IP  - 3
DP  - 1993 Sep
TI  - A role for endothelin and nitric oxide in the pressor response to diaspirin 
      cross-linked hemoglobin.
PG  - 301-8
AB  - Diaspirin-cross-linked hemoglobin (DCLHb; Baxter Healthcare Corp) has potential 
      for clinical use as a hemoglobin-based oxygen-carrying solution. We have 
      previously shown that DCLHb administration is associated with a self-limiting 
      increase in mean arterial pressure (MAP). Based on in vitro studies with other 
      hemoglobin solutions, this vasopressor effect is thought to be mediated at least 
      in part by the release or inhibition (or both) of endothelium-derived vasoactive 
      substances. The purpose of our studies was to determine the role of endothelin 
      (ET), a potent vasoconstrictor peptide, and nitric oxide, a vasodilator, in 
      mediating the pressor effect of DCLHb in conscious rats. Intravenous 
      administration of DCLHb has been shown to elicit an immediate increase in MAP 
      that peaks within 30 minutes and returns to baseline by 300 minutes in a 
      dose-dependent fashion. Phosphoramidon, an inhibitor of proendothelin conversion 
      to ET, attenuated the elevation of MAP when administered before DCLHb. 
      Administration of cyanomet DCLHb, a DCLHb molecule that is unable to interact 
      with NO, was not associated with an elevation of MAP. L-arginine, the substrate 
      for NO synthesis, and nitroglycerin, an NO donor, significantly reduced MAP when 
      infused 15 minutes after DCLHb administration. Based on these findings, we 
      conclude that the DCLHb-induced elevation of MAP in vivo is mediated at least in 
      part by ET and the inhibition of NO. Although these data support earlier reports 
      of hemoglobin binding NO, this is the first report of the pressor response to 
      hemoglobin being attenuated by an agent that blocks the conversion of 
      proendothelin to ET.
FAU - Schultz, S C
AU  - Schultz SC
AD  - Department of Surgery, Uniformed Services University of the Health Sciences, 
      Bethesda, MD 20814-4799.
FAU - Grady, B
AU  - Grady B
FAU - Cole, F
AU  - Cole F
FAU - Hamilton, I
AU  - Hamilton I
FAU - Burhop, K
AU  - Burhop K
FAU - Malcolm, D S
AU  - Malcolm DS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Endothelins)
RN  - 0 (Glycopeptides)
RN  - 0 (Hemoglobins)
RN  - 0 (diaspirin-cross-linked cyanomethemoglobin)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 9008-37-1 (Methemoglobin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - T3G94E2LB1 (phosphoramidon)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Pressure/*drug effects
MH  - Endothelins/*physiology
MH  - Glycopeptides/pharmacology
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Methemoglobin/analogs & derivatives/pharmacology
MH  - Nitric Oxide/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1993/09/01 00:00
MHDA- 1993/09/01 00:01
CRDT- 1993/09/01 00:00
PHST- 1993/09/01 00:00 [pubmed]
PHST- 1993/09/01 00:01 [medline]
PHST- 1993/09/01 00:00 [entrez]
AID - 0022-2143(93)90077-C [pii]
PST - ppublish
SO  - J Lab Clin Med. 1993 Sep;122(3):301-8.

PMID- 2226456
OWN - NLM
STAT- MEDLINE
DCOM- 19901213
LR  - 20190620
IS  - 0014-2956 (Print)
IS  - 0014-2956 (Linking)
VI  - 193
IP  - 2
DP  - 1990 Oct 24
TI  - Bovine hemoglobin pseudo-crosslinked with mono(3,5-dibromosalicyl)-fumarate.
PG  - 331-6
AB  - Under oxygenated conditions bovine hemoglobin reacts with 
      mono(3,5-dibromosalicyl)-fumarate which specifically acylates the EF5 lysines in 
      the beta-cleft of the protein. The chemical modification introduces in the 
      molecule a pseudo-crosslink which hinders the dissociation of the hemoglobin 
      molecule into dimers. Retention time in circulation of the chemically modified 
      bovine hemoglobin, measured in the rat, is increased fivefold with respect to 
      untreated bovine hemoglobin. The oxygen affinity at 37 degrees C and at pH 7.4, 
      has a P50 = 5.4 kPa and a value of n = 1.9. Under the same experimental 
      conditions the oxygen affinity is not sensitive to anions and polyanions whereas 
      it is sensitive to CO2. The Bohr effect is shifted toward the alkaline pH range 
      by 0.5-1: the maximum number of protons released is 1.5/tetramer, similar to 
      normal bovine hemoglobin (1.8 protons/tetramer). Analysis of the binding 
      isotherms, using the two-state Monod-Wyman-Changeux model and fixing the value of 
      the allosteric constant L = 10(5), shows that the oxygen affinity of the T 
      structure is not modified, and that the low oxygen affinity of the system is due 
      to a decrease of the oxygen affinity of the R structure. Analysis using the 
      sequential Adair model shows a modification of the overall binding constants and 
      suggests a redistribution of the intermediate species of oxygenation.
FAU - Fronticelli, C
AU  - Fronticelli C
AD  - Department of Biological Chemistry, Medical School, University of Maryland, 
      Baltimore 21212.
FAU - Bucci, E
AU  - Bucci E
FAU - Razynska, A
AU  - Razynska A
FAU - Sznajder, J
AU  - Sznajder J
FAU - Urbaitis, B
AU  - Urbaitis B
FAU - Gryczynski, Z
AU  - Gryczynski Z
LA  - eng
GR  - HL-13164/HL/NHLBI NIH HHS/United States
GR  - HL-33629/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Eur J Biochem
JT  - European journal of biochemistry
JID - 0107600
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Peptide Fragments)
RN  - 0 (hemoglobin XL99alpha)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry
MH  - Cattle
MH  - Centrifugation, Density Gradient
MH  - *Cross-Linking Reagents
MH  - Electrochemistry
MH  - Half-Life
MH  - Hemoglobins/*chemistry/metabolism/pharmacokinetics
MH  - Molecular Structure
MH  - Oxygen/chemistry
MH  - Peptide Fragments
MH  - Peptide Mapping
MH  - Rats
EDAT- 1990/10/24 00:00
MHDA- 1990/10/24 00:01
CRDT- 1990/10/24 00:00
PHST- 1990/10/24 00:00 [pubmed]
PHST- 1990/10/24 00:01 [medline]
PHST- 1990/10/24 00:00 [entrez]
AID - 10.1111/j.1432-1033.1990.tb19342.x [doi]
PST - ppublish
SO  - Eur J Biochem. 1990 Oct 24;193(2):331-6. doi: 10.1111/j.1432-1033.1990.tb19342.x.

PMID- 20716823
OWN - NLM
STAT- MEDLINE
DCOM- 20101220
LR  - 20131121
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 132
DP  - 2010 Aug
TI  - Evaluation of the anti-ulcer activity of NR-ANX-C (a polyherbal formulation) in 
      aspirin & pyloric ligature induced gastric ulcers in albino rats.
PG  - 218-23
AB  - BACKGROUND & OBJECTIVES: The aetiology of gastric ulcers is not completely 
      understood and continuous use of anti-ulcer agents leads to many side effects. In 
      this study we evaluated the anti-ulcer efficacy of a polyherbal formulation with 
      potent antioxidant activity in aspirin and pyloric ligature induced gastric 
      ulcers in rats. METHODS: The efficacy of the polyherbal formulation NR-ANX-C 
      (composed of the extracts from Withania somnifera, Camellia sinensis, Ocimum 
      sanctum, shilajith and triphala) was evaluated in terms of antioxidant potential 
      as assessed in terms of protection from lipid peroxidation and the antiulcer 
      activity as seen by the area of gastric lesions, gastric juice volume, gastric 
      pH, total acidity and total adherent gastric mucus content. RESULTS: In our 
      study, NR-ANX-C (25 and 50 mg/kg) was more efficacious than ranitidine in 
      reducing ulcer index in both the models. At the highest dose tested (50 mg/kg), 
      NR-ANX-C was comparable to omeprazole in preventing ulcer formation in the 
      pyloric ligature model. NR-ANX-C showed a dose- dependent decrease in gastric 
      juice volume and total acidity in both the models. A dose-dependent increase in 
      gastric pH and total adherent gastric mucus was also seen in NR-ANX-C treated 
      groups. The extent of lipid peroxidation was also reduced in the test drug 
      treated groups. INTERPRETATION & CONCLUSION: Based on our findings, we presume 
      that the cytoprotective, anti-secretary and antioxidant properties of NR-ANX-C 
      were responsible for its anti-ulcer activity. These findings suggest the 
      potential for use of NR-ANX-C as an adjuvant in the treatment of gastric ulcer.
FAU - Nair, Vinod
AU  - Nair V
AD  - Department of Pharmacology, Kasturba Medical College, Mangalore, India. 
      vinodnair1979@hotmail.com
FAU - Arjuman, Albina
AU  - Arjuman A
FAU - Gopalakrishna, H N
AU  - Gopalakrishna HN
FAU - Dorababu, P
AU  - Dorababu P
FAU - Mirshad, P V
AU  - Mirshad PV
FAU - Bhargavan, Divya
AU  - Bhargavan D
FAU - Chatterji, Dipsanker
AU  - Chatterji D
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (NR-ANX-C)
RN  - 0 (Plant Extracts)
RN  - 0 (Thiobarbituric Acid Reactive Substances)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Anti-Ulcer Agents/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Lipid Peroxidation/drug effects
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Plant Extracts/pharmacology/*therapeutic use
MH  - Rats
MH  - Rats, Mutant Strains
MH  - Stomach Ulcer/*drug therapy/etiology
MH  - Thiobarbituric Acid Reactive Substances
EDAT- 2010/08/19 06:00
MHDA- 2010/12/21 06:00
CRDT- 2010/08/19 06:00
PHST- 2010/08/19 06:00 [entrez]
PHST- 2010/08/19 06:00 [pubmed]
PHST- 2010/12/21 06:00 [medline]
PST - ppublish
SO  - Indian J Med Res. 2010 Aug;132:218-23.

PMID- 2868090
OWN - NLM
STAT- MEDLINE
DCOM- 19860320
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 37
IP  - 12
DP  - 1985 Dec
TI  - The adhesion characteristics of some pigmented and unpigmented aqueous-based film 
      coatings applied to aspirin tablets.
PG  - 849-53
AB  - The adhesion of pigmented (with talc and titanium dioxide) and unpigmented 
      aqueous-based films, derived from hydroxypropyl methylcellulose, to aspirin 
      tablets and the effect of ageing on the measured adhesion have been assessed. The 
      adhesion of hydroxypropyl methylcellulose film attained maximum values at 
      polyethylene glycol 400 and polyvinyl alcohol levels of 10 and 20 wt%, 
      respectively. Above these concentrations, adhesion decreased. For solid loaded 
      films it is proposed that the effect of pigments on film adhesion is dependent on 
      the balance between their influence on the internal stress of the film coating 
      and the strength of the film-tablet interface. Adhesion was enhanced when a 
      pigment increased the strength of the interface faster than it increased internal 
      stress, and vice versa. A simple relation between the measured adhesion and the 
      incidence of edge splitting of film-coated tablets was not observed. Generally, 
      film adhesion fell when the tablets were aged at 37 degrees C and 75% r.h. as a 
      result of swelling-induced stresses in the film and at the film tablet interface. 
      The effect of ageing on the adhesion of the system plasticized with polyethylene 
      glycol 400 was eased when the film was pigmented. Adhesion was largely unaffected 
      with film-coated tablets stored in tightly closed bottles at 20 degrees C for 
      five months.
FAU - Okhamafe, A O
AU  - Okhamafe AO
FAU - York, P
AU  - York P
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Tablets)
RN  - 3NXW29V3WO (Hypromellose Derivatives)
RN  - 9004-67-5 (Methylcellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chemistry, Pharmaceutical
MH  - Hypromellose Derivatives
MH  - Methylcellulose/analogs & derivatives/analysis
MH  - Pigmentation
MH  - Tablets
MH  - Time Factors
EDAT- 1985/12/01 00:00
MHDA- 1985/12/01 00:01
CRDT- 1985/12/01 00:00
PHST- 1985/12/01 00:00 [pubmed]
PHST- 1985/12/01 00:01 [medline]
PHST- 1985/12/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1985.tb04988.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1985 Dec;37(12):849-53. doi: 
      10.1111/j.2042-7158.1985.tb04988.x.

PMID- 23506529
OWN - NLM
STAT- MEDLINE
DCOM- 20140204
LR  - 20211021
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 11
DP  - 2013 Mar 18
TI  - Aspirin: a review of its neurobiological properties and therapeutic potential for 
      mental illness.
PG  - 74
LID - 10.1186/1741-7015-11-74 [doi]
AB  - There is compelling evidence to support an aetiological role for inflammation, 
      oxidative and nitrosative stress (O&NS), and mitochondrial dysfunction in the 
      pathophysiology of major neuropsychiatric disorders, including depression, 
      schizophrenia, bipolar disorder, and Alzheimer's disease (AD). These may 
      represent new pathways for therapy. Aspirin is a non-steroidal anti-inflammatory 
      drug that is an irreversible inhibitor of both cyclooxygenase (COX)-1 and COX-2, 
      It stimulates endogenous production of anti-inflammatory regulatory 'braking 
      signals', including lipoxins, which dampen the inflammatory response and reduce 
      levels of inflammatory biomarkers, including C-reactive protein, tumor necrosis 
      factor-α and interleukin (IL)--6, but not negative immunoregulatory cytokines, 
      such as IL-4 and IL-10. Aspirin can reduce oxidative stress and protect against 
      oxidative damage. Early evidence suggests there are beneficial effects of aspirin 
      in preclinical and clinical studies in mood disorders and schizophrenia, and 
      epidemiological data suggests that high-dose aspirin is associated with a reduced 
      risk of AD. Aspirin, one of the oldest agents in medicine, is a potential new 
      therapy for a range of neuropsychiatric disorders, and may provide 
      proof-of-principle support for the role of inflammation and O&NS in the 
      pathophysiology of this diverse group of disorders.
FAU - Berk, Michael
AU  - Berk M
AD  - School of Medicine, Deakin University, 75 Pigdon's Road, Waurn Ponds, Geelong, 
      Victoria 3216, Australia. mikebe@barwonhealth.org.au
FAU - Dean, Olivia
AU  - Dean O
FAU - Drexhage, Hemmo
AU  - Drexhage H
FAU - McNeil, John J
AU  - McNeil JJ
FAU - Moylan, Steven
AU  - Moylan S
FAU - O'Neil, Adrienne
AU  - O'Neil A
FAU - Davey, Christopher G
AU  - Davey CG
FAU - Sanna, Livia
AU  - Sanna L
FAU - Maes, Michael
AU  - Maes M
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130318
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Reactive Oxygen Species)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Encephalitis/drug therapy/metabolism/psychology
MH  - Humans
MH  - Mental Disorders/*drug therapy/*metabolism/psychology
MH  - Oxidative Stress/drug effects/physiology
MH  - Reactive Oxygen Species/antagonists & inhibitors/metabolism
PMC - PMC3751197
EDAT- 2013/03/20 06:00
MHDA- 2014/02/05 06:00
CRDT- 2013/03/20 06:00
PHST- 2012/11/26 00:00 [received]
PHST- 2013/03/18 00:00 [accepted]
PHST- 2013/03/20 06:00 [entrez]
PHST- 2013/03/20 06:00 [pubmed]
PHST- 2014/02/05 06:00 [medline]
AID - 1741-7015-11-74 [pii]
AID - 10.1186/1741-7015-11-74 [doi]
PST - epublish
SO  - BMC Med. 2013 Mar 18;11:74. doi: 10.1186/1741-7015-11-74.

PMID- 32232766
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210607
IS  - 1867-1462 (Electronic)
IS  - 1867-1462 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Sep
TI  - Clustering-Based Hybrid Approach for Identifying Quantitative Multidimensional 
      Associations Between Patient Attributes, Drugs and Adverse Drug Reactions.
PG  - 237-251
LID - 10.1007/s12539-020-00365-9 [doi]
AB  - The activity of post-marketing surveillance results in a collection of large 
      amount of data. The analysis of data is very useful for raising early warnings on 
      possible adverse reactions of drugs. Association rule mining techniques have been 
      heavily explored by the research community for identifying binary association 
      between drugs and their adverse effects. But these techniques perform poorly and 
      miss out several interesting associations when it comes to analysis of 
      multidimensional data which may include multiple patient attributes, drugs and 
      adverse drug reactions. In the present work, a clustering-based hybrid approach 
      has been presented for finding quantitative multidimensional association from the 
      large amount of data. Firstly, it employs clustering technique for segmentation 
      of data into semantically coherent clusters. Furthermore, disproportionality 
      method called proportional reporting ratio is applied on clustered data for 
      generating statistically strong associations. The performance of the proposed 
      methodology has been examined on the data taken from the U.S. Food and Drug 
      Administration Adverse Event Reporting System database corresponding to Aspirin 
      and nine other drugs which are prescribed along with Aspirin. The experimental 
      results show that the proposed approach discovered a number of association rules 
      which are very comprehensive and informative regarding relationship of patient 
      traits and drugs with adverse drug reactions. On comparing experimental results 
      with LPMiner, it is observed that the quantitative association rules discovered 
      by LPMiner are just 8.3% of what have been discovered by the proposed 
      methodology.
FAU - Yogita
AU  - Yogita
AD  - National Institute of Technology Meghalaya, Shillong, Meghalaya, India. 
      thakranyogita@gmail.com.
FAU - Sangma, Jerry W
AU  - Sangma JW
AD  - National Institute of Technology Meghalaya, Shillong, Meghalaya, India.
FAU - Anal, S R Ngamwal
AU  - Anal SRN
AD  - National Institute of Technology Meghalaya, Shillong, Meghalaya, India.
FAU - Pal, Vipin
AU  - Pal V
AD  - National Institute of Technology Meghalaya, Shillong, Meghalaya, India.
LA  - eng
PT  - Journal Article
DEP - 20200330
PL  - Germany
TA  - Interdiscip Sci
JT  - Interdisciplinary sciences, computational life sciences
JID - 101515919
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Aspirin/adverse effects
MH  - *Cluster Analysis
MH  - Data Mining
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Humans
OTO - NOTNLM
OT  - Adverse drug reactions
OT  - Clustering
OT  - Data mining
OT  - Pharmacovigilance
OT  - Quantitative multidimensional association rule
EDAT- 2020/04/02 06:00
MHDA- 2021/06/08 06:00
CRDT- 2020/04/02 06:00
PHST- 2019/09/09 00:00 [received]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/03/03 00:00 [revised]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - 10.1007/s12539-020-00365-9 [pii]
AID - 10.1007/s12539-020-00365-9 [doi]
PST - ppublish
SO  - Interdiscip Sci. 2020 Sep;12(3):237-251. doi: 10.1007/s12539-020-00365-9. Epub 
      2020 Mar 30.

PMID- 6197014
OWN - NLM
STAT- MEDLINE
DCOM- 19840127
LR  - 20191023
IS  - 0272-4936 (Print)
IS  - 0272-4936 (Linking)
VI  - 3
IP  - 2
DP  - 1983 Jun
TI  - Salicylate hepato toxicity in rheumatic fever.
PG  - 89-91
AB  - Two children with rheumatic fever developed anicteric hepatitis while on 
      high-dose aspirin therapy. The striking chemical abnormality was an elevation of 
      serum glutamic oxalacetic transaminase (SGOT) [aspartate aminotransferase (AST)]. 
      A percutaneous liver biopsy obtained from one of the patients showed 
      ultrastructural abnormalities consistent with a toxic hepatitis and hepatic 
      congestion. An awareness of this potential complication is important when 
      treating children with aspirin at doses previously considered to be non-toxic.
FAU - Hamdan, J A
AU  - Hamdan JA
FAU - Ahmad, M S
AU  - Ahmad MS
FAU - Sa'di, A R
AU  - Sa'di AR
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Ann Trop Paediatr
JT  - Annals of tropical paediatrics
JID - 8210625
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspartate Aminotransferases/blood
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Chemical and Drug Induced Liver Injury/blood/*etiology
MH  - Child
MH  - Child, Preschool
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Rheumatic Fever/*drug therapy
EDAT- 1983/06/01 00:00
MHDA- 1983/06/01 00:01
CRDT- 1983/06/01 00:00
PHST- 1983/06/01 00:00 [pubmed]
PHST- 1983/06/01 00:01 [medline]
PHST- 1983/06/01 00:00 [entrez]
AID - 10.1080/02724936.1983.11748274 [doi]
PST - ppublish
SO  - Ann Trop Paediatr. 1983 Jun;3(2):89-91. doi: 10.1080/02724936.1983.11748274.

PMID- 22004722
OWN - NLM
STAT- MEDLINE
DCOM- 20120418
LR  - 20131121
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 21
IP  - 23
DP  - 2011 Dec 1
TI  - Synthesis of novel 3-carboxamide-benzocoumarin derivatives as orally active 
      antithrombotic agents.
PG  - 7034-40
LID - 10.1016/j.bmcl.2011.09.100 [doi]
AB  - In an effort to develop potent antithrombotic agents, a series of novel 
      3-carboxamide-benzocoumarin derivatives were synthesized and screened for their 
      in vivo antithrombotic activity. Among 20 compounds tested, the compound 12b 
      showed the most promising antithrombotic activity which was comparable with 
      clinically used aspirin or warfarin, but, at variance with these standard drugs, 
      12b did not exhibit the increased bleeding time, suggesting its potential as a 
      novel antithrombotic agent.
CI  - Copyright Â© 2011 Elsevier Ltd. All rights reserved.
FAU - Sashidhara, Koneni V
AU  - Sashidhara KV
AD  - Medicinal and Process Chemistry Division, Central Drug Research Institute 
      (CDRI-CSIR), Lucknow, India. sashidhar123@gmail.com
FAU - Kumar, Abdhesh
AU  - Kumar A
FAU - Kumar, Manoj
AU  - Kumar M
FAU - Singh, S
AU  - Singh S
FAU - Jain, Manish
AU  - Jain M
FAU - Dikshit, Madhu
AU  - Dikshit M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110929
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (3-carboxy-5,6-benzocoumarinic acid)
RN  - 0 (Coumarins)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/chemistry/pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Coumarins/*chemical synthesis/chemistry/*pharmacology
MH  - Fibrinolytic Agents/*chemical synthesis/chemistry/*pharmacology
MH  - Mice
MH  - Molecular Structure
MH  - Warfarin/chemistry/pharmacology
EDAT- 2011/10/19 06:00
MHDA- 2012/04/19 06:00
CRDT- 2011/10/19 06:00
PHST- 2011/08/04 00:00 [received]
PHST- 2011/09/16 00:00 [revised]
PHST- 2011/09/26 00:00 [accepted]
PHST- 2011/10/19 06:00 [entrez]
PHST- 2011/10/19 06:00 [pubmed]
PHST- 2012/04/19 06:00 [medline]
AID - S0960-894X(11)01344-8 [pii]
AID - 10.1016/j.bmcl.2011.09.100 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2011 Dec 1;21(23):7034-40. doi: 10.1016/j.bmcl.2011.09.100. 
      Epub 2011 Sep 29.

PMID- 16620507
OWN - NLM
STAT- MEDLINE
DCOM- 20060504
LR  - 20190513
IS  - 0021-9665 (Print)
IS  - 0021-9665 (Linking)
VI  - 44
IP  - 3
DP  - 2006 Mar
TI  - Reversed headspace analysis for characterization, identification, and analysis of 
      solid and liquid matrices: Part I.
PG  - 123-31
AB  - This paper offers a methodology of an experimentally simple reversed headspace 
      (RHS) analysis for measuring of matrix effects and their use for identification 
      and characterization of condensed matrices such as pharmaceuticals, polymers, 
      chromatographic packing, etc. applicable for both quality control monitoring and 
      research and development investigation. In RHS methods, the matrix is spiked and 
      equilibrated with a mixture of volatile chemicals containing various functional 
      groups (molecular sensor array or MSA mixture). Headspace chromatograms of the 
      same spikes of a sample and an empty vial are compared. Examination of basic 
      headspace theory shows that matrix specific constants (M), rather than partition 
      coefficients (K), can be calculated from the headspace chromatograms and 
      M=(K-1)xbeta, where beta is a degree of matrix volume change during 
      equilibration. Matrix specific constants can be plotted against any property of 
      chemicals (polarity, dielectric constant, solubility parameter, vapor pressure, 
      etc.) or just against a set of consecutive numbers, each representing a chemical 
      in MSA. This plot is, in a sense, a molecular affinity spectrum (MAS) specific 
      for a given matrix at a given temperature and is independent of an instrument. 
      Changes in MAS that correspond to chemicals with a particular functional group 
      give an insight to the type of differences between matrices and may 
      quantitatively define them.
FAU - Markelov, M
AU  - Markelov M
AD  - ACS Labs, Cleveland, OH, USA. headspace@earthlink.net
FAU - Bershevits, O
AU  - Bershevits O
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Chromatogr Sci
JT  - Journal of chromatographic science
JID - 0173225
RN  - 0 (Polymers)
RN  - 0 (Solvents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis
MH  - Chromatography, Gas/*methods
MH  - Polymers/chemistry
MH  - Reproducibility of Results
MH  - Solvents/chemistry
MH  - Volatilization
EDAT- 2006/04/20 09:00
MHDA- 2006/05/05 09:00
CRDT- 2006/04/20 09:00
PHST- 2006/04/20 09:00 [pubmed]
PHST- 2006/05/05 09:00 [medline]
PHST- 2006/04/20 09:00 [entrez]
AID - 10.1093/chromsci/44.3.123 [doi]
PST - ppublish
SO  - J Chromatogr Sci. 2006 Mar;44(3):123-31. doi: 10.1093/chromsci/44.3.123.

PMID- 22910681
OWN - NLM
STAT- MEDLINE
DCOM- 20130307
LR  - 20211021
IS  - 1759-4782 (Electronic)
IS  - 1759-4774 (Linking)
VI  - 9
IP  - 10
DP  - 2012 Oct
TI  - Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms.
PG  - 561-70
LID - 10.1038/nrclinonc.2012.137 [doi]
AB  - A high-quality body of evidence supports the use of aspirin in reducing sporadic 
      and hereditary adenomatous polyps, and numerous observational studies point to a 
      reduction in colorectal cancer (CRC) risk. However, using aspirin as an adjuvant 
      therapy in established CRC was until recently inconceivable. Now, evidence from 
      both observational and clinical trials of aspirin for other indications suggests 
      that aspirin initiation after (or before) the diagnosis of CRC improves 
      CRC-specific mortality. These exciting findings need to be confirmed in 
      prospective randomized trials that are underway. The recent failure of adjuvant 
      irinotecan, bevacizumab, and cetuximab clinical trials compels us to reconsider 
      our assumptions and paradigms for treating CRC. In this Review, we summarize 
      clinical and preclinical evidence supporting aspirin use in established CRC and 
      outline a framework for better understanding aspirin activity in the pathogenesis 
      of CRC. We describe the data supporting adjuvant aspirin in resected CRC, 
      including the issues of dose, duration and toxicity, and discuss potential 
      biomarkers that may help better select patients for aspirin therapy.
FAU - Chia, Whay Kuang
AU  - Chia WK
AD  - National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. 
      johnchiawk@gmail.com
FAU - Ali, Raghib
AU  - Ali R
FAU - Toh, Han Chong
AU  - Toh HC
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120821
PL  - England
TA  - Nat Rev Clin Oncol
JT  - Nature reviews. Clinical oncology
JID - 101500077
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Colorectal Neoplasms/*drug therapy
MH  - Humans
MH  - Prognosis
EDAT- 2012/08/23 06:00
MHDA- 2013/03/08 06:00
CRDT- 2012/08/23 06:00
PHST- 2012/08/23 06:00 [entrez]
PHST- 2012/08/23 06:00 [pubmed]
PHST- 2013/03/08 06:00 [medline]
AID - nrclinonc.2012.137 [pii]
AID - 10.1038/nrclinonc.2012.137 [doi]
PST - ppublish
SO  - Nat Rev Clin Oncol. 2012 Oct;9(10):561-70. doi: 10.1038/nrclinonc.2012.137. Epub 
      2012 Aug 21.

PMID- 16418466
OWN - NLM
STAT- MEDLINE
DCOM- 20060123
LR  - 20220330
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 295
IP  - 3
DP  - 2006 Jan 18
TI  - Aspirin for the primary prevention of cardiovascular events in women and men: a 
      sex-specific meta-analysis of randomized controlled trials.
PG  - 306-13
AB  - CONTEXT: Aspirin therapy reduces the risk of cardiovascular disease in adults who 
      are at increased risk. However, it is unclear if women derive the same benefit as 
      men. OBJECTIVE: To determine if the benefits and risks of aspirin treatment in 
      the primary prevention of cardiovascular disease vary by sex. DATA SOURCES AND 
      STUDY SELECTION: MEDLINE and the Cochrane Central Register of Controlled Trials 
      databases (1966 to March 2005), bibliographies of retrieved trials, and reports 
      presented at major scientific meetings. Eligible studies were prospective, 
      randomized controlled trials of aspirin therapy in participants without 
      cardiovascular disease that reported data on myocardial infarction (MI), stroke, 
      and cardiovascular mortality. Six trials with a total of 95 456 individuals were 
      identified; 3 trials included only men, 1 included only women, and 2 included 
      both sexes. DATA EXTRACTION: Studies were reviewed to determine the number of 
      patients randomized, mean duration of follow-up, and end points (a composite of 
      cardiovascular events [nonfatal MI, nonfatal stroke, and cardiovascular 
      mortality], each of these individual components separately, and major bleeding). 
      DATA SYNTHESIS: Among 51,342 women, there were 1285 major cardiovascular events: 
      625 strokes, 469 MIs, and 364 cardiovascular deaths. Aspirin therapy was 
      associated with a significant 12% reduction in cardiovascular events (odds ratio 
      [OR], 0.88; 95% confidence interval [CI], 0.79-0.99; P = .03) and a 17% reduction 
      in stroke (OR, 0.83; 95% CI, 0.70-0.97; P = .02), which was a reflection of 
      reduced rates of ischemic stroke (OR, 0.76; 95% CI, 0.63-0.93; P = .008). There 
      was no significant effect on MI or cardiovascular mortality. Among 44,114 men, 
      there were 2047 major cardiovascular events: 597 strokes, 1023 MIs, and 776 
      cardiovascular deaths. Aspirin therapy was associated with a significant 14% 
      reduction in cardiovascular events (OR, 0.86; 95% CI, 0.78-0.94; P = .01) and a 
      32% reduction in MI (OR, 0.68; 95% CI, 0.54-0.86; P = .001). There was no 
      significant effect on stroke or cardiovascular mortality. Aspirin treatment 
      increased the risk of bleeding in women (OR, 1.68; 95% CI, 1.13-2.52; P = .01) 
      and in men (OR, 1.72; 95% CI, 1.35-2.20; P<.001). CONCLUSIONS: For women and men, 
      aspirin therapy reduced the risk of a composite of cardiovascular events due to 
      its effect on reducing the risk of ischemic stroke in women and MI in men. 
      Aspirin significantly increased the risk of bleeding to a similar degree among 
      women and men.
FAU - Berger, Jeffrey S
AU  - Berger JS
AD  - Department of Cardiovascular Medicine, Duke University, Durham, NC, USA.
FAU - Roncaglioni, Maria C
AU  - Roncaglioni MC
FAU - Avanzini, Fausto
AU  - Avanzini F
FAU - Pangrazzi, Ierta
AU  - Pangrazzi I
FAU - Tognoni, Gianni
AU  - Tognoni G
FAU - Brown, David L
AU  - Brown DL
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - JAMA. 2006 May 3;295(17):2002
CIN - Evid Based Nurs. 2006 Jul;9(3):76. PMID: 16865826
CIN - JAMA. 2006 Jul 26;296(4):391; author reply 391-2. PMID: 16868288
CIN - JAMA. 2006 Jul 26;296(4):391; author reply 391-2. PMID: 16868289
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Sex Factors
MH  - Stroke/prevention & control
EDAT- 2006/01/19 09:00
MHDA- 2006/01/24 09:00
CRDT- 2006/01/19 09:00
PHST- 2006/01/19 09:00 [pubmed]
PHST- 2006/01/24 09:00 [medline]
PHST- 2006/01/19 09:00 [entrez]
AID - 295/3/306 [pii]
AID - 10.1001/jama.295.3.306 [doi]
PST - ppublish
SO  - JAMA. 2006 Jan 18;295(3):306-13. doi: 10.1001/jama.295.3.306.

PMID- 21562370
OWN - NLM
STAT- MEDLINE
DCOM- 20110913
LR  - 20131121
IS  - 1535-2811 (Electronic)
IS  - 1535-2811 (Linking)
VI  - 10
IP  - 1
DP  - 2011 Mar
TI  - Outpatient aspirin desensitization for patients with aspirin hypersensitivity and 
      cardiac disease.
PG  - 17-21
LID - 10.1097/HPC.0b013e318213d5a6 [doi]
AB  - BACKGROUND: Cardiac disease is common and often treated with aspirin therapy. 
      Patients who develop an immunoglobulin E (IgE) hypersensitivity reaction to 
      aspirin must abort treatment and receive alternative antithrombotic agents. 
      Aspirin desensitization is a therapeutic procedure that may allow patients with a 
      history of hypersensitivity to safely resume aspirin treatment. A variety of 
      inpatient desensitization protocols have been published for IgE-mediated 
      reactions, but outpatient regimens have not been previously reported. OBJECTIVE: 
      We aimed to determine the efficacy and safety of a multiday outpatient aspirin 
      desensitization protocol for patients with an IgE-mediated aspirin 
      hypersensitivity. METHODS: We retrospectively assessed the efficacy of a 
      multidose aspirin desensitization protocol performed in a university 
      allergy-immunology clinic between July 2006 and December 2009. Patients were 
      referred for a diagnosis of aspirin hypersensitivity and required aspirin for 
      cardiac disease treatment. The protocol involved 10 or 12 aspirin doses depending 
      on the final dose of 81 or 325 mg. Patients were desensitized over 2 to 3 
      half-days and were able to return home in between desensitization sessions. 
      RESULTS: A total of 9 patients with cardiac disease and aspirin hypersensitivity 
      underwent an outpatient multiday aspirin desensitization. Eight patients (89%) 
      were successfully desensitized and 1 patient declined to continue with further 
      desensitization. No adverse reactions requiring inpatient hospital care occurred 
      during desensitization. CONCLUSIONS: This novel outpatient multiday aspirin 
      desensitization protocol was a safe and effective approach for the treatment of 
      aspirin hypersensitivity in patients with cardiac disease who require aspirin 
      therapy. This flexible protocol is convenient for patients by avoiding hospital 
      admission and full-day time commitments.
FAU - Fajt, Merritt L
AU  - Fajt ML
AD  - Division of Pulmonary, Allergy, and Critical Care Medicine, University of 
      Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
FAU - Petrov, Andrej A
AU  - Petrov AA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Crit Pathw Cardiol
JT  - Critical pathways in cardiology
JID - 101165286
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/immunology
MH  - Clinical Protocols
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/*drug therapy/immunology
MH  - Female
MH  - Heart Diseases/*drug therapy/immunology
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Male
MH  - Middle Aged
MH  - Outpatients
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2011/05/13 06:00
MHDA- 2011/09/14 06:00
CRDT- 2011/05/13 06:00
PHST- 2011/05/13 06:00 [entrez]
PHST- 2011/05/13 06:00 [pubmed]
PHST- 2011/09/14 06:00 [medline]
AID - 00132577-201103000-00003 [pii]
AID - 10.1097/HPC.0b013e318213d5a6 [doi]
PST - ppublish
SO  - Crit Pathw Cardiol. 2011 Mar;10(1):17-21. doi: 10.1097/HPC.0b013e318213d5a6.

PMID- 12831293
OWN - NLM
STAT- MEDLINE
DCOM- 20031209
LR  - 20181113
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 20
IP  - 9
DP  - 2003
TI  - NSAID and aspirin use by the elderly in general practice: effect on 
      gastrointestinal symptoms and therapies.
PG  - 701-10
AB  - BACKGROUND: The relationship between NSAID use and gastrointestinal (GI) symptoms 
      and their treatment in elderly patients is not well defined. OBJECTIVES: To 
      identify the prevalence of specific drug use in elderly outpatients and to 
      identify the relationship between NSAID use and GI disturbances and treatments in 
      elderly subjects treated by their general practitioner (GP). SETTING AND 
      PARTICIPANTS: The study was carried out by 63 GPs in north-eastern Italy; 3154 
      elderly subjects were included in the study over a 2-week period. DESIGN: By 
      using a structured interview, subjects' medical histories and current medication 
      were identified. In particular, the presence and use pattern (i.e. occasional, 
      'acute' or 'chronic') of NSAIDs and/or aspirin (acetylsalicylic acid) were 
      recorded. In all subjects, the presence of upper GI symptoms, i.e. abdominal 
      pain, reflux symptoms and indigestion syndrome, were noted. RESULTS: The 
      prevalence of drug use was 96.4% (males 96%, females 96.7%). The most prescribed 
      drugs were ACE inhibitors (38%), diuretics (26.7%), NSAIDs and regular-dose 
      aspirin (24.7%), GI drugs (20.6%), and anxiolytics/hypnotics (20.3%). Of 779 
      subjects who had taken NSAIDs or regular-dose aspirin, 32.9% were 'chronic' 
      users, 24.9% were 'acute' users and 42.1% occasional users. A significantly 
      higher prevalence of upper GI symptoms was observed in elderly NSAID and low-dose 
      aspirin users compared with non-users (24.9% vs 28% vs 16.6% respectively, p < 
      0.0001). GI symptoms were reported by 27.6% of 'chronic' NSAID users, 22.9% of 
      'acute' users and 24.7% of occasional users. A significantly higher prescription 
      rate for any GI drug was found in NSAID users than in low-dose aspirin users and 
      non-users (24.0% vs 19.6% vs 19.4% respectively, p = 0.007). This difference was 
      mainly because of a higher number of upper GI drugs taken by NSAID users than by 
      low-dose aspirin users and non-users (18.1% vs 16% vs 13.7% respectively, p = 
      0.004). Multivariate analysis demonstrated that female gender (odds ratio [OR] = 
      1.32, 95% CI = 1.16-1.44), low-dose aspirin (OR = 1.88, 95% CI = 1.33-2.65), 
      NSAIDs and/or regular-dose aspirin (OR = 1.48, 95% CI = 1.19-1.83) and multiple 
      therapies, i.e. taking more than four drugs per day (OR = 1.42, 95% CI = 
      1.14-1.77) were risk factors for GI symptoms in elderly outpatients. CONCLUSION: 
      NSAIDs and/or aspirin use was very high in this elderly outpatient population. 
      The use of these drugs was significantly associated with a greater number of 
      upper GI symptoms and prescriptions for GI drugs. Educational and clinical 
      strategies need to be implemented in order to reduce the GI impact of NSAID and 
      aspirin use in elderly people.
FAU - Pilotto, Alberto
AU  - Pilotto A
AD  - Geriatric Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Casa 
      Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy. 
      alberto.pilotto@libero.it
FAU - Franceschi, Marilisa
AU  - Franceschi M
FAU - Leandro, Gioacchino
AU  - Leandro G
FAU - Di Mario, Francesco
AU  - Di Mario F
CN  - Geriatric Gastroenterology Study Group (Societè Italiana Gerontologie Geriatria)
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Activities of Daily Living
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Utilization/*statistics & numerical data
MH  - *Family Practice
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced/prevention & control
MH  - Humans
MH  - Italy
MH  - Male
MH  - Prevalence
MH  - Self Medication/*statistics & numerical data
MH  - Surveys and Questionnaires
EDAT- 2003/07/02 05:00
MHDA- 2003/12/11 05:00
CRDT- 2003/07/02 05:00
PHST- 2003/07/02 05:00 [pubmed]
PHST- 2003/12/11 05:00 [medline]
PHST- 2003/07/02 05:00 [entrez]
AID - 2096 [pii]
AID - 10.2165/00002512-200320090-00006 [doi]
PST - ppublish
SO  - Drugs Aging. 2003;20(9):701-10. doi: 10.2165/00002512-200320090-00006.

PMID- 21696233
OWN - NLM
STAT- MEDLINE
DCOM- 20111031
LR  - 20131121
IS  - 1538-0254 (Electronic)
IS  - 0739-1102 (Linking)
VI  - 29
IP  - 1
DP  - 2011 Aug
TI  - Investigations with spectroscopy, zeta potential and molecular modeling of the 
      non-cooperative behaviour between cyclophosphamide hydrochloride and aspirin upon 
      interaction with human serum albumin: binary and ternary systems from multi-drug 
      therapy.
PG  - 181-206
AB  - The interaction between cyclophosphamide hydrochloride (CYC) and aspirin (ASA) 
      with human serum albumin (HSA) was studied by various kind of spectroscopic, ζ 
      potential and molecular modeling under physiological conditions. The fluorescence 
      data showed that the binding of drugs to proteins caused strong static 
      fluorescence quenching. The analysis of the fluorescence quenching of HSA in the 
      binary and ternary systems displayed that ASA was affected by the complex formed 
      between CYC and HSA. Moreover, CYC was influenced by the HSA-ASA complex. The 
      inherent binding information, including the quenching mechanism, binding 
      constants, number of binding sites, effective quenching constant, fraction of the 
      initial fluorescence and thermodynamic parameters were measured by the 
      fluorescence quenching technique at various temperatures. In addition, according 
      to the synchronous fluorescence spectra of HSA, the results showed that the 
      fluorescence quenching of HSA originated from the Trp and Tyr residues, and 
      indicated a conformational change of HSA with the addition of the drugs. Far-UV 
      CD spectra of HSA were recorded before and after the addition of ASA and CYC as 
      binary and ternary systems. An increase in intensity of the positive CD peak of 
      HSA was observed in the presence of the drugs. The results were interpreted by 
      excited interactions between the aromatic residues of the HSA binding sites and 
      the drugs bound to them. The distance r between donor and acceptor was obtained 
      by the Forster energy according to fluorescence resonance energy transfer (FRET) 
      and found to be 2.35 nm and 1.78 nm for CYC and ASA, respectively. This confirmed 
      the existence of static quenching for proteins in the presence of CYC and ASA. 
      Furthermore, docking studies pointed at a reduction of the affinity of each of 
      the drug compounds to the protein in the presence of the other in meaningful 
      amounts. Pre-binding of any of the said compounds forced the second to bind in a 
      non-optimized location and orientation. The potential at the electrokinetic shear 
      surface of the protein-drug solution were measured at several concentrations of 
      the drugs by the ζ potential technique, which confirmed experimental and 
      theoretical results.
FAU - Omidvar, Zahra
AU  - Omidvar Z
AD  - Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad 
      University, Mashhad, Iran.
FAU - Parivar, Kazem
AU  - Parivar K
FAU - Sanee, Hamideh
AU  - Sanee H
FAU - Amiri-Tehranizadeh, Zeinab
AU  - Amiri-Tehranizadeh Z
FAU - Baratian, Ali
AU  - Baratian A
FAU - Saberi, Mohammad Reza
AU  - Saberi MR
FAU - Asoodeh, Ahmad
AU  - Asoodeh A
FAU - Chamani, Jamshidkhan
AU  - Chamani J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Biomol Struct Dyn
JT  - Journal of biomolecular structure & dynamics
JID - 8404176
RN  - 0 (Serum Albumin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/metabolism
MH  - Binding Sites
MH  - Cyclophosphamide/*chemistry/metabolism
MH  - Fluorescence Resonance Energy Transfer
MH  - Humans
MH  - Models, Molecular
MH  - Molecular Dynamics Simulation
MH  - Protein Conformation
MH  - Serum Albumin/antagonists & inhibitors/*chemistry/metabolism
MH  - Spectrometry, Fluorescence
EDAT- 2011/06/24 06:00
MHDA- 2011/11/01 06:00
CRDT- 2011/06/24 06:00
PHST- 2011/06/24 06:00 [entrez]
PHST- 2011/06/24 06:00 [pubmed]
PHST- 2011/11/01 06:00 [medline]
AID - c4311/Investigations-with-Spectroscopy-Zeta-Potential-and-Molecular-Modeling-of-the-Non-Cooperative-Behaviour-Between-Cyclophosphamide-Hydrochloride-and-Aspirin-upon-Interaction-with-Human-Serum-Albumin-Binary-and-Ternary-Systems-from-Multi-drug-Therapy-p18264.html 
      [pii]
AID - 10.1080/07391102.2011.10507382 [doi]
PST - ppublish
SO  - J Biomol Struct Dyn. 2011 Aug;29(1):181-206. doi: 10.1080/07391102.2011.10507382.

PMID- 26165066
OWN - NLM
STAT- MEDLINE
DCOM- 20150918
LR  - 20150713
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 73
IP  - 7
DP  - 2015 Jul
TI  - [Diagnosis and treatment of aspirin--and NSAID-induced peptic ulcers].
PG  - 1110-5
AB  - A Japanese case-control study showed the odds ratio of upper gastrointestinal 
      bleeding was 5.5 for aspirin and 6.1 for other NSAIDs. A Japanese cohort study 
      showed that peptic ulcers were found in 6.5% of 1,454 patients receiving low-dose 
      aspirin (LDA). Some endoscopic studies reported that NSAID users often had 
      antral, multiple, and irregular ulcers, irrespective of Helicobacter pylori 
      status. Proton-pump inhibitor (PPI) and misoprostol should be used for therapy 
      for NSAID-ulcers. Maintenance therapy with PPI should be given for prevention of 
      relapse of ulcers of NSAIDs and LDA users. PPI and histamine 2-recetor antagonist 
      were effective for prevention of upper GI mucosal injury in patients receiving 
      LDA.
FAU - Satoh, Kiichi
AU  - Satoh K
FAU - Tanabe, Hiroki
AU  - Tanabe H
FAU - Ichiishi, Eiichiro
AU  - Ichiishi E
FAU - Ando, Katsuyoshi
AU  - Ando K
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Gastric Mucosa/drug effects
MH  - Humans
MH  - Peptic Ulcer/chemically induced/*diagnosis/*drug therapy/prevention & control
MH  - Practice Guidelines as Topic
MH  - Recurrence
EDAT- 2015/07/15 06:00
MHDA- 2015/09/19 06:00
CRDT- 2015/07/14 06:00
PHST- 2015/07/14 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2015/09/19 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2015 Jul;73(7):1110-5.

PMID- 10748949
OWN - NLM
STAT- MEDLINE
DCOM- 20000517
LR  - 20190607
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 21
IP  - 1
DP  - 2000 Jan-Feb
TI  - Approach to the patient with a history of adverse reactions to aspirin or NSAIDs: 
      diagnosis and treatment.
PG  - 25-31
AB  - Aspirin and nonsteroidal antiinflammatory drugs can induce several different 
      reactions. It is incumbant upon the astute physician to recognize the differences 
      between these reactions, the clinical settings in which they occur, and the 
      management of each type of reaction. In this article, I have attempted to clarify 
      and simplify, as much as possible, the approach I take in addressing the problems 
      of adverse reactions to these drugs. In addition, the problems of cross-reactions 
      are explained in terms of COX-1 and 2 isoenzymes. Aspirin desensitization and 
      treatment with daily ASA are also addressed.
FAU - Stevenson, D D
AU  - Stevenson DD
AD  - Division of Allergy, Asthma, and Immunology, Scripps Clinic, La Jolla, 
      California, USA.
LA  - eng
GR  - M01 RR00833/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cross Reactions
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/*diagnosis/etiology/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Prognosis
RF  - 31
EDAT- 2000/04/05 09:00
MHDA- 2000/05/20 09:00
CRDT- 2000/04/05 09:00
PHST- 2000/04/05 09:00 [pubmed]
PHST- 2000/05/20 09:00 [medline]
PHST- 2000/04/05 09:00 [entrez]
AID - 10.2500/108854100778248944 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2000 Jan-Feb;21(1):25-31. doi: 10.2500/108854100778248944.

PMID- 1706738
OWN - NLM
STAT- MEDLINE
DCOM- 19910501
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 17
IP  - 5
DP  - 1991 Apr
TI  - Bleeding time prolongation and bleeding during infusion of recombinant 
      tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal 
      with aprotinin.
PG  - 1213-22
AB  - Thrombolytic therapy is associated with a bleeding tendency that may be 
      exacerbated by adjunctive antiplatelet agents. The effect of recombinant 
      tissue-type plasminogen activator (rt-PA) alone or in combination with aspirin on 
      serial measurements of template bleeding time, ex vivo platelet aggregation and 
      coagulation factors and the frequency of bleeding was studied in dogs. During 
      infusion of rt-PA (15, 30 or 60 micrograms/kg per min for 90 min), a dose-related 
      increase in bleeding time was observed. In a randomized blinded study of 25 dogs, 
      the baseline bleeding time (mean +/- SD) was 3.5 +/- 1 min in control animals and 
      4 +/- 2 min after oral aspirin (15 mg/kg body weight). Infusion of rt-PA (15 
      micrograms/kg per min for 90 min) prolonged the bleeding time to a maximum of 15 
      +/- 12 min. In contrast, combined aspirin and rt-PA therapy produced an increase 
      to greater than 30 min during infusion, reverting to 13 +/- 10 min within 2 h 
      after cessation of infusion. Recurrent continuous bleeding from incision sites 
      occurred in one of six dogs given aspirin alone, two of seven given rt-PA alone 
      and all six dogs given both aspirin and rt-PA (p = 0.02). Bleeding time greater 
      than 9 min correlated significantly with bleeding frequency (p less than 0.0001), 
      with a sensitivity of 100% and a specificity of 87%. Intravenous bolus injection 
      of aprotinin (20,000 kallikrein inhibitor units/kg body weight) in six dogs given 
      both rt-PA and aspirin produced a decrease in bleeding time from greater than 30 
      min to 9.5 +/- 9 min and resulted in cessation of bleeding. Thus, bleeding and 
      bleeding time prolongation in this canine model are potentiated by a marked 
      interactive effect of rt-PA and aspirin that is rapidly reversible. Template 
      bleeding times may provide a useful quantitative index for monitoring the 
      bleeding tendency associated with thrombolytic therapy.
FAU - Garabedian, H D
AU  - Garabedian HD
AD  - Cardiac Division, Massachusetts General Hospital, Boston 02114.
FAU - Gold, H K
AU  - Gold HK
FAU - Leinbach, R C
AU  - Leinbach RC
FAU - Svizzero, T A
AU  - Svizzero TA
FAU - Finkelstein, D M
AU  - Finkelstein DM
FAU - Guerrero, J L
AU  - Guerrero JL
FAU - Collen, D
AU  - Collen D
LA  - eng
GR  - HL-26215/HL/NHLBI NIH HHS/United States
GR  - HL-35058/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Recombinant Proteins)
RN  - 9087-70-1 (Aprotinin)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aprotinin/*pharmacology
MH  - Aspirin/blood/*pharmacology
MH  - Bleeding Time
MH  - Dogs
MH  - Drug Synergism
MH  - Fibrinolysis/drug effects
MH  - Hemorrhage/*chemically induced
MH  - Hemostasis/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Random Allocation
MH  - Recombinant Proteins
MH  - Thrombolytic Therapy/*adverse effects
MH  - Tissue Plasminogen Activator/*pharmacology
EDAT- 1991/04/01 00:00
MHDA- 1991/04/01 00:01
CRDT- 1991/04/01 00:00
PHST- 1991/04/01 00:00 [pubmed]
PHST- 1991/04/01 00:01 [medline]
PHST- 1991/04/01 00:00 [entrez]
AID - 0735-1097(91)90856-5 [pii]
AID - 10.1016/0735-1097(91)90856-5 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1991 Apr;17(5):1213-22. doi: 10.1016/0735-1097(91)90856-5.

PMID- 16151642
OWN - NLM
STAT- MEDLINE
DCOM- 20060130
LR  - 20181201
IS  - 1360-8185 (Print)
IS  - 1360-8185 (Linking)
VI  - 10
IP  - 5
DP  - 2005 Oct
TI  - Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder 
      carcinoma cells.
PG  - 1095-103
AB  - Nitric oxide-releasing non steroidal anti-inflammatory drugs (NO-NSAIDs) are a 
      promising class of compounds that cause cell cycle perturbations and induce 
      apoptosis in cell lines from different tumors. We investigated the activity of a 
      recently developed NO-NSAID (NCX 4040) in bladder cancer cell lines (HT1376 and 
      MCR). Cells were treated with different drug concentrations for different 
      exposure times. Cytostatic and cytocidal activity was tested by SRB assay and 
      apoptosis was evaluated by TUNEL analysis, ANNEXIN V assay and fluorescence 
      microscopy. To further investigate the cell death-inducing mechanisms of NCX 
      4040, we analyzed gp-170, caspase expression and mitochondrial membrane potential 
      (Delta Psi) depolarization. NCX 4040 showed a striking cytocidal activity in both 
      cell lines, reaching LC(50) at a 10-microM and 50-microM concentrations in HT1376 
      and in MCR cells, respectively, after an exposure of only 6 h followed by an 18-h 
      washout. Apoptosis was triggered in up to 90% of cells and was associated with 
      active caspase-3 expression and Delta Psi depolarization in both cell lines after 
      a 6-h exposure. In conclusion, NCX 4040, which probably causes apoptosis via a 
      mitochondrial-dependent mechanism, could prove to be a useful agent for improving 
      bladder cancer treatment.
FAU - Fabbri, F
AU  - Fabbri F
AD  - Istituto Oncologico Romagnolo, Morgagni-Pierantoni Hospital, Via Forlanini 34, 
      47100 Forlì, Italy.
FAU - Brigliadori, G
AU  - Brigliadori G
FAU - Ulivi, P
AU  - Ulivi P
FAU - Tesei, A
AU  - Tesei A
FAU - Vannini, I
AU  - Vannini I
FAU - Rosetti, M
AU  - Rosetti M
FAU - Bravaccini, S
AU  - Bravaccini S
FAU - Amadori, D
AU  - Amadori D
FAU - Bolla, M
AU  - Bolla M
FAU - Zoli, W
AU  - Zoli W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Apoptosis
JT  - Apoptosis : an international journal on programmed cell death
JID - 9712129
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (NCX 4040)
RN  - 0 (NCX 4042)
RN  - 0 (Nitro Compounds)
RN  - 0 (Salicylates)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Apoptosis/drug effects/*physiology
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Humans
MH  - In Situ Nick-End Labeling
MH  - Membrane Potentials/drug effects
MH  - Nitric Oxide/*metabolism
MH  - Nitro Compounds/*pharmacology/therapeutic use
MH  - Salicylates/pharmacology/therapeutic use
MH  - Urinary Bladder Neoplasms/*drug therapy
EDAT- 2005/09/10 09:00
MHDA- 2006/01/31 09:00
CRDT- 2005/09/10 09:00
PHST- 2005/09/10 09:00 [pubmed]
PHST- 2006/01/31 09:00 [medline]
PHST- 2005/09/10 09:00 [entrez]
AID - 10.1007/s10495-005-0619-7 [doi]
PST - ppublish
SO  - Apoptosis. 2005 Oct;10(5):1095-103. doi: 10.1007/s10495-005-0619-7.

PMID- 6530452
OWN - NLM
STAT- MEDLINE
DCOM- 19850520
LR  - 20190629
VI  - 317
DP  - 1984 Dec 28
TI  - Simultaneous high-performance liquid chromatography assay of acetylsalicylic acid 
      and salicylic acid in film-coated aspirin tablets.
PG  - 507-11
AB  - A reversed-phase high-performance liquid chromatography (HPLC) method has been 
      developed for the simultaneous assay of acetylsalicylic acid (I) and salicylic 
      acid (II) in film-coated aspirin tablets. As little as 0.1% II (relative to I) 
      can be quantitatively determined. Using a 5-microns octadecylsilane column with 
      water-acetonitrile-phosphoric acid (76:24:0.5) as the mobile phase enabled the 
      chromatographic separation to be completed in 4 min. Due to the slow rate of 
      decomposition of I to II in the extraction solvent, 
      acetonitrile-methanol-phosphoric acid (92:8:0.5), the analysis of many samples 
      was routinely performed by means of automated HPLC equipment. Other compounds 
      (non-aspirin salicylates, caffeine and acetaminophen) were also separated by the 
      chromatographic system.
FAU - Fogel, J
AU  - Fogel J
FAU - Epstein, P
AU  - Epstein P
FAU - Chen, P
AU  - Chen P
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Chromatogr
JT  - Journal of chromatography
JID - 0427043
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid/methods
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets, Enteric-Coated/analysis
EDAT- 1984/12/28 00:00
MHDA- 1984/12/28 00:01
CRDT- 1984/12/28 00:00
PHST- 1984/12/28 00:00 [pubmed]
PHST- 1984/12/28 00:01 [medline]
PHST- 1984/12/28 00:00 [entrez]
AID - 10.1016/s0021-9673(01)91690-5 [doi]
PST - ppublish
SO  - J Chromatogr. 1984 Dec 28;317:507-11. doi: 10.1016/s0021-9673(01)91690-5.

PMID- 32251451
OWN - NLM
STAT- MEDLINE
DCOM- 20200710
LR  - 20200710
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 4
DP  - 2020
TI  - Unexpected effects of long-term treatment with acetylsalicylic acid on late phase 
      of pulmonary metastasis in murine model of orthotopic breast cancer.
PG  - e0230520
LID - 10.1371/journal.pone.0230520 [doi]
LID - e0230520
AB  - Long-term administration of acetylsalicylic acid (ASA) was effective in 
      prevention of colorectal cancer, whereas the efficacy of this compound in other 
      cancer types, including breast cancer, has been less convincingly documented. 
      Indeed, the antimetastatic effect of low-dose ASA was observed only in the early 
      intravascular phase of metastasis of breast cancer. In the present work, we 
      characterized the effects of long-term treatment with ASA on the late phase of 
      pulmonary metastasis in a mouse orthotopic 4T1 breast cancer model. Mice were 
      treated with ASA at a dose of 12 mg·kg-1 of body weight daily starting one week 
      prior to inoculation of 4T1 breast cancer cells, and the treatment was continued 
      throughout progression of the disease. ASA administration decreased platelet TXB2 
      production in ex vivo assays but did not change thrombin-induced platelet 
      reactivity. Although the number of metastases in the lungs remained unchanged in 
      ASA-treated mice, infiltration of inflammatory cells was increased concomitantly 
      with higher G-CSF and serotonin concentrations in the lungs. Pulmonary NO 
      production was compromised compared to control 4T1 mice. ASA treatment also 
      evoked an increase in platelet and granulocyte counts and decreased systemic NO 
      bioavailability along with increased markers of systemic oxidant stress such as 
      higher GSSG/lower GSH concentrations in RBC. Analysis of eicosanoids in stirred 
      blood demonstrated that administration of ASA at a dose of 12 mg·kg-1 to 
      cancer-bearing mice had an effect beyond inhibition of platelet COX-1, suggesting 
      long-term treatment with low-dose aspirin is not a selective murine platelet 
      COX-1/TXA2 pathway inhibitor in cancer-bearing mice. In summary, quite 
      surprisingly, long-term treatment with low-dose ASA administered until the 
      advanced phase of breast cancer in a murine orthotopic model of 4T1 breast cancer 
      negatively affected the phenotype of the disease.
FAU - Smeda, Marta
AU  - Smeda M
AUID- ORCID: 0000-0002-0219-2574
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
FAU - Kij, Agnieszka
AU  - Kij A
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
FAU - Proniewski, Bartosz
AU  - Proniewski B
AUID- ORCID: 0000-0002-5138-1451
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
FAU - Matyjaszczyk-Gwarda, Karolina
AU  - Matyjaszczyk-Gwarda K
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
FAU - Przyborowski, Kamil
AU  - Przyborowski K
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
FAU - Jasztal, Agnieszka
AU  - Jasztal A
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
FAU - Derszniak, Katarzyna
AU  - Derszniak K
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
FAU - Berkowicz, Piotr
AU  - Berkowicz P
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
AD  - Department of Pharmacology, Jagiellonian University Medical College, Krakow, 
      Poland.
FAU - Kieronska-Rudek, Anna
AU  - Kieronska-Rudek A
AUID- ORCID: 0000-0002-5447-0812
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
FAU - Stojak, Marta
AU  - Stojak M
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
FAU - Sternak, Magdalena
AU  - Sternak M
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
FAU - Chlopicki, Stefan
AU  - Chlopicki S
AD  - Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 
      Krakow, Poland.
AD  - Department of Pharmacology, Jagiellonian University Medical College, Krakow, 
      Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200406
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Female
MH  - Lung Neoplasms/*drug therapy/secondary
MH  - Mice
MH  - Platelet Aggregation Inhibitors/therapeutic use
PMC - PMC7135281
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/04/07 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/04/07 06:00
PHST- 2019/10/14 00:00 [received]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/04/07 06:00 [entrez]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
AID - PONE-D-19-28659 [pii]
AID - 10.1371/journal.pone.0230520 [doi]
PST - epublish
SO  - PLoS One. 2020 Apr 6;15(4):e0230520. doi: 10.1371/journal.pone.0230520. 
      eCollection 2020.

PMID- 16784013
OWN - NLM
STAT- MEDLINE
DCOM- 20061130
LR  - 20161124
IS  - 1018-9068 (Print)
IS  - 1018-9068 (Linking)
VI  - 16
IP  - 3
DP  - 2006
TI  - Amphotericin B and lysine acetylsalicylate in the combined treatment of nasal 
      polyposis associated with mycotic infection.
PG  - 188-93
AB  - BACKGROUND: Fungal infection may be secondary to nasal polyposis or represent a 
      real etiopathogenic factor in the infection itself. OBJECTIVE: The aim of this 
      study was to evaluate the effectiveness of a combined treatment with lysine 
      acetylsalicylate (LAS) and amphotericin B in preventing recurrence in patients 
      with nasal polyposis with accompanying mycotic infection in comparison with a 
      control group with nasal polyposis and fungal infection who did not receive 
      antifungal therapy. PATIENTS AND METHODS: A total of 115 patients with nasal 
      polyposis were randomly assigned to 4 different groups and treated as follows: 
      (1) group A, 25 patients were first surgically treated and then treated with LAS; 
      (2) group B, 25 patients received 40 mg of triamcinolone retard intramuscularly 3 
      times every 10 days (total dose 120 mg) and then they were treated with LAS; (3) 
      group C, 16 patients were surgically treated and then treated with LAS and 
      amphotericin B; (4) group D: 23 patients were treated with a medical polypectomy 
      and steroids (as in the group B) and then with LAS and amphotericin B. RESULTS: 
      We found no significant differences between groups C and D, groups C and A, or 
      groups B and D. However, the recurrence of nasal polyps in the groups treated 
      with amphotericin B plus LAS (C and D) was significantly lower (P = .018) than in 
      the 2 groups treated only with LAS (A and B). CONCLUSION: Our results indicate 
      that long term topical treatment with LAS and amphotericin B may be clinically 
      effective in the treatment of patients with nasal polyposis associated with 
      fungal infection.
FAU - Corradini, C
AU  - Corradini C
AD  - ENT Department, Catholic University of the Sacred Hearth, Rome, Italy.
FAU - Del Ninno, M
AU  - Del Ninno M
FAU - Buonomo, A
AU  - Buonomo A
FAU - Nucera, E
AU  - Nucera E
FAU - Paludetti, G
AU  - Paludetti G
FAU - Alonzi, C
AU  - Alonzi C
FAU - Sabato, V
AU  - Sabato V
FAU - Schiavino, D
AU  - Schiavino D
FAU - Patriarca, G
AU  - Patriarca G
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Spain
TA  - J Investig Allergol Clin Immunol
JT  - Journal of investigational allergology & clinical immunology
JID - 9107858
RN  - 0 (Antifungal Agents)
RN  - 7XU7A7DROE (Amphotericin B)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Intranasal
MH  - Amphotericin B/administration & dosage/*therapeutic use
MH  - Antifungal Agents/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Fungi/classification/isolation & purification
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Mycoses/*complications
MH  - Nasal Polyps/*drug therapy/etiology
MH  - Treatment Outcome
EDAT- 2006/06/21 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/06/21 09:00
PHST- 2006/06/21 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/06/21 09:00 [entrez]
PST - ppublish
SO  - J Investig Allergol Clin Immunol. 2006;16(3):188-93.

PMID- 9083629
OWN - NLM
STAT- MEDLINE
DCOM- 19970605
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 25
IP  - 1-2
DP  - 1997 Jan-Mar
TI  - Resuscitation with diaspirin crosslinked hemoglobin increases cerebral and renal 
      blood perfusion in hemorrhaged rats.
PG  - 85-94
AB  - Diaspirin crosslinked hemoglobin (DCLHb Baxter Healthcare Corp., Round Lake, IL, 
      USA), a hemoglobin-based blood substitute has been found to be an effective 
      resuscitative agent following hemorrhage in animals. The present study was 
      undertaken to determine the effect of DCLHb on microvascular perfusion in the 
      brain and kidney following hemorrhage in anaesthetized, male Sprague Dawley rats 
      using laser Doppler flowmetry. Hemorrhage was induced by withdrawal of arterial 
      blood at a rate of 0.5 to 1.0 ml/min until blood pressure of 35-40 mmHg was 
      achieved. This was maintained for up to 30 min. The arterial blood pH, pO2, pCO2 
      and total hemoglobin (THb) were monitored. Hemorrhage significantly decreased pH, 
      pCO2 and THb and increased pO. Hemorrhage significantly decreased (26%) brain 
      blood perfusion due to a decrease (17%) in the concentration of moving red blood 
      cells (CMBC). In the kidney there was a greater decrease (65%) in blood perfusion 
      due to a significant decrease in both CMBC (28%) and red blood cell velocity 
      (49%). Resuscitation with vehicle (Ringer's lactate, 4 ml/kg, i.v.) did not 
      produce any improvement in cerebral and renal blood perfusion. Resuscitation with 
      DCLHb (400 mg/kg, i.v.) improved perfusion in the brain (112%) due to an increase 
      in the CMBC (69%) and the velocity of red blood cells (33%). Similarly, in the 
      kidney, DCLHb increased perfusion (178%) by increasing CMBC (55%) and red blood 
      cell velocity (89%) of hemorrhaged rats. The increase in renal blood perfusion 
      was more marked (p < 0.001) than the changes in cerebral blood perfusion 
      following resuscitation with DCLHb in hemorrhaged rats. It is concluded that 
      DCLHb can significantly increase cerebral and renal blood perfusion of 
      hemorrhaged rats and this effect may contribute to its efficacy as a 
      resuscitative solution.
FAU - Kumar, A
AU  - Kumar A
AD  - Department of Pharmaceutics & Pharmacodynamics, University of Illinois at Chicago 
      60612, USA.
FAU - Sen, A P
AU  - Sen AP
FAU - Saxena, P R
AU  - Saxena PR
FAU - Gulati, A
AU  - Gulati A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acid-Base Equilibrium
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Blood Gas Analysis
MH  - Blood Pressure
MH  - Blood Substitutes/chemistry/pharmacology
MH  - Cerebrovascular Circulation/drug effects/*physiology
MH  - Cross-Linking Reagents/chemistry/pharmacology
MH  - Heart Rate
MH  - Hemoglobins/chemistry/*pharmacology
MH  - Hemorrhage/*drug therapy/physiopathology
MH  - Laser-Doppler Flowmetry
MH  - Male
MH  - Microcirculation/drug effects/physiology
MH  - Oximetry
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Renal Circulation/drug effects/*physiology
MH  - Resuscitation
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.3109/10731199709118900 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1997 Jan-Mar;25(1-2):85-94. doi: 
      10.3109/10731199709118900.

PMID- 12946035
OWN - NLM
STAT- MEDLINE
DCOM- 20031204
LR  - 20191026
IS  - 0957-5243 (Print)
IS  - 0957-5243 (Linking)
VI  - 14
IP  - 5
DP  - 2003 Jun
TI  - Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future 
      challenges in chemoprevention.
PG  - 413-8
AB  - There is a wealth of experimental, epidemiological, and most recently, randomized 
      trial evidence that suggests that aspirin and other NSAIDs can reduce the risk of 
      colorectal adenoma and cancer. As a result, these medications have emerged as 
      promising chemopreventative agents. However, routine use has not been recommended 
      in large part due to a lack of information on the optimal dose and duration of 
      treatment. In this issue, observational data drawn from a cohort within the Polyp 
      Prevention Trial strongly support the effectiveness of aspirin and NSAIDs in 
      reducing the risk of recurrent colorectal adenoma, including those with 
      morphologically or histologically advanced features. In particular, the 
      investigators demonstrate that participants who consumed more than one standard 
      aspirin tablet per day had the greatest reduction in risk. Because much potential 
      toxicity of these agents are dose-related, these findings highlight the need for 
      further investigation into the optimal dose and duration of the medications 
      before consideration of their use in widespread chemoprevention efforts. The 
      combination of future epidemiological data, in concert with continuing 
      experimental developments, will guide further research initiatives and better 
      inform cost-benefit and decision analyses. Hopefully, interpretation of this 
      large body of evidence ultimately will lead to concrete clinical guidelines which 
      will define a role, if any, for these medications as anticancer agents.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, USA. achan@partners.org
LA  - eng
GR  - T32DK07191/DK/NIDDK NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Cancer Causes Control. 2003 Jun;14(5):403-11. PMID: 12946034
MH  - Adenomatous Polyposis Coli/prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/*pharmacology
MH  - Aspirin/*administration & dosage/adverse effects/*pharmacology
MH  - Chemoprevention/trends
MH  - Colorectal Neoplasms/epidemiology/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Humans
RF  - 77
EDAT- 2003/08/30 05:00
MHDA- 2003/12/05 05:00
CRDT- 2003/08/30 05:00
PHST- 2003/08/30 05:00 [pubmed]
PHST- 2003/12/05 05:00 [medline]
PHST- 2003/08/30 05:00 [entrez]
AID - 10.1023/a:1024986220526 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2003 Jun;14(5):413-8. doi: 10.1023/a:1024986220526.

PMID- 1926064
OWN - NLM
STAT- MEDLINE
DCOM- 19911121
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 62
IP  - 6
DP  - 1991 Jun 15
TI  - Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis 
      vascular access thrombosis.
PG  - 737-43
AB  - We carried out a pilot study in 15 hemodialysis patients with recurrent vascular 
      access thrombosis to examine whether the combination of low dose aspirin (85 mg 
      once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective 
      in the prevention of vascular access thrombosis. Hemostatic measurements were 
      performed prior to and after four weeks of starting the drug combination. 
      Baseline values for fibrinopeptide A were elevated in all patients while those 
      for platelet factor 4, fibrinogen, antithrombin III and protein C were generally 
      within normal limits. A major reduction in the frequency of vascular access 
      thrombosis from 0.114 per month to 0.04 per month was noted during combined drug 
      treatment (p less than 0.001). Although in vitro platelet aggregation to various 
      stimuli was markedly suppressed and platelet thromboxane B2 formation was almost 
      completely inhibited in patients on aspirin/sulfinpyrazone, this was not 
      associated with a significant further prolongation of the bleeding time. A 
      relatively high rate of complications, particularly mild gastrointestinal 
      bleeding, was noted in patients on aspirin/sulfinpyrazone that could not be 
      predicted on the basis of pre-treatment hemostatic test results.
FAU - Domoto, D T
AU  - Domoto DT
AD  - Division of Nephrology, St. Louis University School of Medicine, Missouri 63110.
FAU - Bauman, J E
AU  - Bauman JE
FAU - Joist, J H
AU  - Joist JH
LA  - eng
GR  - HL 28227/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Coagulation Tests
MH  - Blood Platelets/drug effects/metabolism
MH  - *Catheters, Indwelling
MH  - Drug Evaluation
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Pilot Projects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Recurrence
MH  - *Renal Dialysis
MH  - Sulfinpyrazone/administration & dosage/adverse effects/*therapeutic use
MH  - Thrombosis/physiopathology/*prevention & control
MH  - Thromboxane B2/biosynthesis
EDAT- 1991/06/15 00:00
MHDA- 1991/06/15 00:01
CRDT- 1991/06/15 00:00
PHST- 1991/06/15 00:00 [pubmed]
PHST- 1991/06/15 00:01 [medline]
PHST- 1991/06/15 00:00 [entrez]
AID - 0049-3848(91)90377-9 [pii]
AID - 10.1016/0049-3848(91)90377-9 [doi]
PST - ppublish
SO  - Thromb Res. 1991 Jun 15;62(6):737-43. doi: 10.1016/0049-3848(91)90377-9.

PMID- 8293692
OWN - NLM
STAT- MEDLINE
DCOM- 19940228
LR  - 20161123
IS  - 0529-567X (Print)
IS  - 0529-567X (Linking)
VI  - 28
IP  - 8
DP  - 1993 Aug
TI  - [Prevention of fetal growth retardation by low dose aspirin].
PG  - 492-5, 508
AB  - A prospective randomized, double-blinded, controlled clinical trial was conducted 
      in 84 pregnant women with high risk of intrauterine growth retardation (IUGR). 
      From the 28th to 30th week of gestation, low dose aspirin 75 mg/day (study group, 
      n = 40) or placebo (control group, n = 44) was given consecutively for 6 to 8 
      weeks. It was found that the mean value of systolic/diastolic ratio of umbilical 
      artery flow velocity waveforms in the study group was significantly lower than 
      that of the control group after drug use. The occurrences of IUGR and 
      preeclampsia in the study group (7.5% and 10.0% respectively) were remarkably 
      lower than those in the control group (27.3% of both). The adverse effects of low 
      dose aspirin on both mother and fetus were not observed. These results suggest 
      that low dose aspirin administration (75 mg/day) beginning at earlier stage of 
      third trimester may improve the fetal placental circulation, and thus prevent 
      IUGR and/or preeclampsia effectively.
FAU - Wang, Z H
AU  - Wang ZH
AD  - Xiehe Hospital, Tongji Medical University, Wuhan.
FAU - Li, W J
AU  - Li WJ
LA  - chi
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Fu Chan Ke Za Zhi
JT  - Zhonghua fu chan ke za zhi
JID - 16210370R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Flow Velocity
MH  - Double-Blind Method
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Humans
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Pregnancy Trimester, Third
MH  - Prospective Studies
MH  - Ultrasonography, Prenatal
MH  - Umbilical Arteries/diagnostic imaging
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Fu Chan Ke Za Zhi. 1993 Aug;28(8):492-5, 508.

PMID- 26677672
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20181202
IS  - 1003-5370 (Print)
IS  - 1003-5370 (Linking)
VI  - 35
IP  - 10
DP  - 2015 Oct
TI  - [Recurrence of Cerebral Infarction Associated Aspirin Resistance or Chinese 
      Medical Constitutions: a Correlation Study].
PG  - 1205-9
AB  - OBJECTIVE: To explore the correlation between the recurrence of cerebral 
      infarction and aspirin resistance (AR)/Chinese medical (CM) constitutions. 
      METHODS: Totally 413 cerebral infarction patients took Aspirin Enteric-coated 
      Tablet (100 mg per day) while receiving routine therapy, 5 days at least in a 
      week. They were followed-up for 12 months. Aspirin sensitivity (AS) was 
      determined using turbidimetry. CM constitutions among patients with different AS 
      were compared. Ratios of AR patients and AS patients of different CM 
      constitutions in cerebral infarction recurrent patients were compared. Platelet 
      membrane glycoproteins (GP) II b HPA-3 gene polymorphism was detected by 
      polymerase chain reaction (PCR) method. Correlation between recurrence of 
      cerebral infarction and AR, bb genotypes, CM constitutions times AS were analyzed 
      by Logistic regression. RESULTS: Totally 11 patients dropped out, 101 
      (25.12%)with recurrent cerebral infarction and 301 (74.88%) without recurrent 
      cerebral infarction. There were 152 (37.81%) AR patients and 250 (62.19%) AS 
      patients. AR accounted for 26.6% (80/ 301) and AS accounted for 73.4% (221/301) 
      in non-recurrent cerebral infarction patients. AR accounted for 71.3% (72/101) 
      and AS accounted for 28.7% (29/101) in recurrent cerebral infarction patients. 
      There was statistical difference in AR and AS ratios (χ2 = 64.287, P = 0.000). 
      The proportion of yin deficiency constitution (YDC) was the largest [28.3% 
      (43/152)] in AR patients. The proportion of blood stasis constitution (BSC) was 
      the largest [23.6% (59/250)] in AS patients. There was statistical difference in 
      CM constitutions between AR patients and AS patients (χ2 = 21.574, P < 0.01). The 
      former 4 recurrent rates occurred in AR patients of YDC, BSC, damp-phlegm 
      constitution (DPC), qi deficiency constitution (QDC). YDC occupied the first 
      place [22.4% (34/152)]. The former 4 recurrent rates occurred in AS patients of 
      BSC, QDC, DPC, damp-heat constitution (DHC). BSC occupied the first place [3.2% 
      (2/250)]. Compared with non-recurrent cerebral infarction patients and AS 
      patients, bb gene occurred most often, but aa gene and ab gene occurred obviously 
      lesser in non-recurrent cerebral infarction patients and AR patients (χ2 = 
      20.171, χ2 = 55.139, P < 0.01). AR and bb gene were positively correlated with 
      recurrent cerebral infarction (OR = 18.423, P = 0.000; OR = 1.304, P = 0.028). 
      Body constitutions interacted with AS (OR = 0.707, P = 0.000). CONCLUSIONS: 
      Recurrent cerebral infarction was closely related to AR and constitutional types. 
      The recurrence rate was higher in AR patients of YDC. GP I b HPA-3 bb genotype 
      might be a risk factor for AR and recurrent cerebral infarction.
FAU - Yu, Li-hong
AU  - Yu LH
FAU - Wang, Dong-xian
AU  - Wang DX
FAU - Li, Ya-hui
AU  - Li YH
FAU - Lu, Qin-an
AU  - Lu QA
FAU - Zong, Shou-jian
AU  - Zong SJ
FAU - Wang, Xing-chen
AU  - Wang XC
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Xi Yi Jie He Za Zhi
JT  - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese 
      journal of integrated traditional and Western medicine
JID - 9211576
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Body Constitution
MH  - *Cerebral Infarction
MH  - *Drug Resistance
MH  - Humans
MH  - *Medicine, Chinese Traditional
MH  - Neoplasms
MH  - Recurrence
MH  - Yin Deficiency
EDAT- 2015/12/19 06:00
MHDA- 2016/09/16 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
PST - ppublish
SO  - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015 Oct;35(10):1205-9.

PMID- 17847705
OWN - NLM
STAT- MEDLINE
DCOM- 20071107
LR  - 20190516
IS  - 1475-6366 (Print)
IS  - 1475-6366 (Linking)
VI  - 22
IP  - 4
DP  - 2007 Aug
TI  - Kinetic, thermodynamic and statistical studies on the inhibition of adenosine 
      deaminase by aspirin and diclofenac.
PG  - 395-406
AB  - The kinetic and thermodynamic effects of aspirin and diclofenac on the activity 
      of adenosine deaminase (ADA) were studied in 50 mM phosphate buffer pH = 7.5 at 
      27 and 37 degrees C, using UV-Vis spectrophotometry and isothermal titration 
      calorimetry (ITC). Aspirin exhibits competitive inhibition at 27 and 37 degrees C 
      and the inhibition constants are 42.8 and 96.8 microM respectively, using 
      spectrophotometry. Diclofenac shows competitive behavior at 27 degrees C and 
      uncompetitive at 37 degrees C with inhibition constants of 56.4 and 30.0 microM, 
      at respectively. The binding constant and enthalpy of binding, at 27 degrees C 
      are 45 microM, - 64.5 kJ/mol and 61 microM, - 34.5 kJ/mol for aspirin and 
      diclofenac. Thermodynamic data revealed that the binding process for these ADA 
      inhibitors is enthalpy driven. QSAR studies by principal component analysis 
      implemented in SPSS show that the large, polar, planar, and aromatic nucleoside 
      and small, aromatic and polar non-nucleoside molecules have lower inhibition 
      constants.
FAU - Ajloo, Davood
AU  - Ajloo D
AD  - Faculty of Chemistry, Damghan University of Basic Science, Damghan, Iran. 
      ajloo@dubs.ac.ir
FAU - Saboury, Ali A
AU  - Saboury AA
FAU - Haghi-Asli, Niloofar
AU  - Haghi-Asli N
FAU - Ataei-Jafarai, Ghasem
AU  - Ataei-Jafarai G
FAU - Moosavi-Movahedi, Ali A
AU  - Moosavi-Movahedi AA
FAU - Ahmadi, Mosayeb
AU  - Ahmadi M
FAU - Mahnam, Karim
AU  - Mahnam K
FAU - Namaki, Saeed
AU  - Namaki S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Enzyme Inhib Med Chem
JT  - Journal of enzyme inhibition and medicinal chemistry
JID - 101150203
RN  - 0 (Adenosine Deaminase Inhibitors)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Nucleotides)
RN  - 144O8QL0L1 (Diclofenac)
RN  - EC 3.5.4.4 (Adenosine Deaminase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Deaminase/*chemistry
MH  - *Adenosine Deaminase Inhibitors
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*pharmacology
MH  - Aspirin/chemistry/*pharmacology
MH  - Binding, Competitive
MH  - Diclofenac/chemistry/*pharmacology
MH  - Enzyme Inhibitors/chemistry/*pharmacology
MH  - Kinetics
MH  - Models, Chemical
MH  - Models, Statistical
MH  - Nucleotides/chemistry
MH  - Principal Component Analysis
MH  - Spectrophotometry, Ultraviolet
MH  - Structure-Activity Relationship
MH  - Temperature
MH  - Thermodynamics
EDAT- 2007/09/13 09:00
MHDA- 2007/11/08 09:00
CRDT- 2007/09/13 09:00
PHST- 2007/09/13 09:00 [pubmed]
PHST- 2007/11/08 09:00 [medline]
PHST- 2007/09/13 09:00 [entrez]
AID - 10.1080/14756360701229085 [doi]
PST - ppublish
SO  - J Enzyme Inhib Med Chem. 2007 Aug;22(4):395-406. doi: 10.1080/14756360701229085.

PMID- 8561870
OWN - NLM
STAT- MEDLINE
DCOM- 19960307
LR  - 20190920
IS  - 1046-7408 (Print)
IS  - 1046-7408 (Linking)
VI  - 34
IP  - 3
DP  - 1995 Sep
TI  - Low-dose aspirin therapy and placental pathology in women with poor prior 
      pregnancy outcomes.
PG  - 141-7
AB  - PROBLEM: To determine if low dose aspirin therapy improves placental histology in 
      women with a prior complicated pregnancy demonstrating uterine vascular 
      pathology. METHOD: A retrospective chart review identified patients with a prior 
      complicated pregnancy with placental changes showing uterine vascular pathology 
      (control pregnancy, CP). In the treated pregnancy (TP), 81 mg/day of ASA was 
      started prior to 10 weeks. Placental reports from the CP and TP were reviewed. 
      Pregnancy outcomes and placental histology from the CP were compared to the TP 
      for each patient. RESULTS: Thirteen patients were enrolled. The majority of 
      patients (8/13, 61.5%) exhibited recurrent, histologic evidence of uterine 
      vascular pathology in the TP. The TP was more likely to be uncomplicated (P < 
      0.05), delivered after 36 weeks (P < 0.05), and result in the delivery of a 
      viable infant (P < 0.05) compared to the CP. CONCLUSIONS: Despite an improvement 
      in outcomes in the aspirin treated pregnancy, histologic evidence of uterine 
      vascular pathology persisted in the majority of women with a prior complicated 
      pregnancy demonstrating similar placental lesions. Abnormal placental histology 
      may be useful in identifying a group of women with poor obstetrical histories who 
      could benefit from low-dose aspirin therapy.
FAU - Cusick, W
AU  - Cusick W
AD  - Center for Human Reproduction, Division of Maternal-Fetal Medicine, Chicago, IL 
      60610, USA.
FAU - Salafia, C M
AU  - Salafia CM
FAU - Ernst, L
AU  - Ernst L
FAU - Rodis, J F
AU  - Rodis JF
FAU - Campbell, W A
AU  - Campbell WA
FAU - Vintzileos, A M
AU  - Vintzileos AM
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drug Administration Schedule
MH  - Eclampsia/prevention & control
MH  - Female
MH  - Fetal Death/prevention & control
MH  - Humans
MH  - Placenta/blood supply/*drug effects/*pathology
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*pathology/prevention & control
MH  - Retrospective Studies
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
AID - 10.1111/j.1600-0897.1995.tb00930.x [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 1995 Sep;34(3):141-7. doi: 
      10.1111/j.1600-0897.1995.tb00930.x.

PMID- 35321562
OWN - NLM
STAT- MEDLINE
DCOM- 20220429
LR  - 20220513
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
VI  - 42
IP  - 5
DP  - 2022 May
TI  - Role of Reticulated Platelets in Cardiovascular Disease.
PG  - 527-539
LID - 10.1161/ATVBAHA.121.316244 [doi]
AB  - Human platelets differ considerably with regard to their size, RNA content and 
      thrombogenicity. Reticulated platelets (RPs) are young, hyper-reactive platelets 
      that are newly released from the bone marrow. They are larger and contain more 
      RNA compared to older platelets. In comparison to more mature platelets, they 
      exhibit a significantly higher thrombogenicity and are known to be elevated in 
      patients with an increased platelet turnover such as, diabetics and after acute 
      myocardial infarction. Several studies have shown that RPs correlate with an 
      insufficient antiplatelet response to aspirin and specific P2Y(12) receptor 
      inhibitors. In addition, RPs are promising novel biomarkers for the prediction of 
      adverse cardiovascular events in cardiovascular disease. However, the reason for 
      RPs intrinsic hyper-reactivity and their association with ischemic events is not 
      completely understood and the biology of RPs is still under investigation. We 
      here present a structured review of preclinical and clinical findings concerning 
      the role of RPs in cardiovascular disease.
FAU - Bongiovanni, Dario
AU  - Bongiovanni D
AUID- ORCID: 0000-0002-4162-1482
AD  - Department of Internal Medicine I, School of Medicine, University hospital rechts 
      der Isar, Technical University of Munich, Germany (D.B., J.H., M.K., K.K., G.V., 
      N.S., K.-L.L., I.B.).
AD  - Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero 
      Cantonale, Lugano, Switzerland (D.B.).
AD  - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart 
      Alliance, Germany (D.B., M.K., M.v.S., K.-L.L., I.B.).
AD  - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, 
      Italy (D.B., G.C.).
AD  - IRCCS Humanitas Research Hospital, Department of Cardiovascular Medicine, 
      Rozzano, Milan, Italy (D.B., G.C.).
FAU - Han, Jiaying
AU  - Han J
AUID- ORCID: 0000-0003-4158-4826
AD  - Department of Internal Medicine I, School of Medicine, University hospital rechts 
      der Isar, Technical University of Munich, Germany (D.B., J.H., M.K., K.K., G.V., 
      N.S., K.-L.L., I.B.).
FAU - Klug, Melissa
AU  - Klug M
AUID- ORCID: 0000-0001-5193-2770
AD  - Department of Internal Medicine I, School of Medicine, University hospital rechts 
      der Isar, Technical University of Munich, Germany (D.B., J.H., M.K., K.K., G.V., 
      N.S., K.-L.L., I.B.).
AD  - Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan, Technical 
      University of Munich, Germany (M.K.).
FAU - Kirmes, Kilian
AU  - Kirmes K
AUID- ORCID: 0000-0001-6940-0983
AD  - Department of Internal Medicine I, School of Medicine, University hospital rechts 
      der Isar, Technical University of Munich, Germany (D.B., J.H., M.K., K.K., G.V., 
      N.S., K.-L.L., I.B.).
AD  - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart 
      Alliance, Germany (D.B., M.K., M.v.S., K.-L.L., I.B.).
FAU - Viggiani, Giacomo
AU  - Viggiani G
AD  - Department of Internal Medicine I, School of Medicine, University hospital rechts 
      der Isar, Technical University of Munich, Germany (D.B., J.H., M.K., K.K., G.V., 
      N.S., K.-L.L., I.B.).
FAU - von Scheidt, Moritz
AU  - von Scheidt M
AD  - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart 
      Alliance, Germany (D.B., M.K., M.v.S., K.-L.L., I.B.).
AD  - Department of Cardiology, Deutsches Herzzentrum München, Technical University of 
      Munich, Germany (M.v.S.).
FAU - Schreiner, Nina
AU  - Schreiner N
AD  - Department of Internal Medicine I, School of Medicine, University hospital rechts 
      der Isar, Technical University of Munich, Germany (D.B., J.H., M.K., K.K., G.V., 
      N.S., K.-L.L., I.B.).
FAU - Condorelli, Gianluigi
AU  - Condorelli G
AUID- ORCID: 0000-0003-0481-6843
AD  - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, 
      Italy (D.B., G.C.).
AD  - IRCCS Humanitas Research Hospital, Department of Cardiovascular Medicine, 
      Rozzano, Milan, Italy (D.B., G.C.).
FAU - Laugwitz, Karl-Ludwig
AU  - Laugwitz KL
AUID- ORCID: 0000-0003-4948-4846
AD  - Department of Internal Medicine I, School of Medicine, University hospital rechts 
      der Isar, Technical University of Munich, Germany (D.B., J.H., M.K., K.K., G.V., 
      N.S., K.-L.L., I.B.).
AD  - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart 
      Alliance, Germany (D.B., M.K., M.v.S., K.-L.L., I.B.).
FAU - Bernlochner, Isabell
AU  - Bernlochner I
AUID- ORCID: 0000-0002-0981-839X
AD  - Department of Internal Medicine I, School of Medicine, University hospital rechts 
      der Isar, Technical University of Munich, Germany (D.B., J.H., M.K., K.K., G.V., 
      N.S., K.-L.L., I.B.).
AD  - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart 
      Alliance, Germany (D.B., M.K., M.v.S., K.-L.L., I.B.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220324
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 63231-63-0 (RNA)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Blood Platelets/physiology
MH  - *Cardiovascular Diseases
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Platelet Count
MH  - RNA
OTO - NOTNLM
OT  - aspirin
OT  - biology
OT  - biomarker
OT  - myocardial infarction
OT  - reticulated platelets
EDAT- 2022/03/25 06:00
MHDA- 2022/04/30 06:00
CRDT- 2022/03/24 05:29
PHST- 2022/03/25 06:00 [pubmed]
PHST- 2022/04/30 06:00 [medline]
PHST- 2022/03/24 05:29 [entrez]
AID - 10.1161/ATVBAHA.121.316244 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2022 May;42(5):527-539. doi: 
      10.1161/ATVBAHA.121.316244. Epub 2022 Mar 24.

PMID- 23442317
OWN - NLM
STAT- MEDLINE
DCOM- 20130826
LR  - 20211021
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 2
DP  - 2013 Feb 26
TI  - Protocol for a systematic review of the diagnostic and prognostic utility of 
      tests currently available for the detection of aspirin resistance in patients 
      with established cardiovascular or cerebrovascular disease.
PG  - 16
LID - 10.1186/2046-4053-2-16 [doi]
AB  - BACKGROUND: The benefits of aspirin as an anti-platelet agent are well 
      established; however, there has been much debate about the lack of uniformity in 
      the efficacy of aspirin to inhibit platelet function. In some patients, aspirin 
      fails to inhibit platelets even where compliance has been verified, a phenomenon 
      which has been termed "aspirin resistance". These patients may in turn be at a 
      higher risk of future vascular events. The proportion of "resistant" patients 
      identified depends on the type of platelet function test. Therefore, the aim of 
      this systematic review is to determine which, if any, platelet function test has 
      utility in terms of identifying patients with a high risk of vascular events. The 
      review has been registered with PROSPERO (CRD42012002151). METHODS: Relevant 
      studies will be sought from bibliographic databases. Trials registers will be 
      searched for ongoing studies. Reference lists will be checked and subject experts 
      contacted. There will be no date or language restrictions. Standard reviewing 
      methodology to minimise bias will be employed. Any prospective studies in 
      patients on aspirin therapy and assessing platelet function in relation to 
      relevant clinical outcomes will be included, as will studies reporting prognostic 
      models. Risk of bias assessment will be based on the Quality Assessment of 
      Diagnostic Accuracy Studies guidelines, and suitable criteria for assessing 
      quality of prognostic studies. Data on test accuracy measures, relative risks, 
      odds or hazard ratios will be extracted and meta-analysed, where possible, using 
      a random-effects model to account for between-study heterogeneity. Where 
      appropriate, the causes of heterogeneity will be explored through meta-regression 
      and sub-group or sensitivity analyses. If platelet function testing is 
      demonstrated to have diagnostic/predictive utility in a specific population, the 
      potential for a cost-effectiveness analysis will be considered and, if possible, 
      an economic model constructed. This will be supported by a systematic review of 
      existing economic evaluation studies. DISCUSSION: The results of the review could 
      indicate if platelet function test(s) could lead to a reliable prediction of the 
      risk of clinically important events in a defined population, and thus support 
      investigations into adjustments to therapy in order to compensate for a predicted 
      poor response to standard aspirin.
FAU - Raichand, Smriti
AU  - Raichand S
AD  - Public Health, Epidemiology and Biostatistics, School of Health and Population 
      Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
FAU - Moore, David
AU  - Moore D
FAU - Riley, Richard D
AU  - Riley RD
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
FAU - Dretzke, Janine
AU  - Dretzke J
FAU - O'Donnell, Jennifer
AU  - O'Donnell J
FAU - Jowett, Sue
AU  - Jowett S
FAU - Bayliss, Sue
AU  - Bayliss S
FAU - Fitzmaurice, David A
AU  - Fitzmaurice DA
LA  - eng
GR  - 10/36/02/DH_/Department of Health/United Kingdom
GR  - G0800808/MRC_/Medical Research Council/United Kingdom
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130226
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Cardiovascular Diseases
MH  - Cost-Benefit Analysis
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests/*methods
MH  - Prognosis
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC3600664
EDAT- 2013/02/28 06:00
MHDA- 2013/08/27 06:00
CRDT- 2013/02/28 06:00
PHST- 2012/11/29 00:00 [received]
PHST- 2013/02/18 00:00 [accepted]
PHST- 2013/02/28 06:00 [entrez]
PHST- 2013/02/28 06:00 [pubmed]
PHST- 2013/08/27 06:00 [medline]
AID - 2046-4053-2-16 [pii]
AID - 10.1186/2046-4053-2-16 [doi]
PST - epublish
SO  - Syst Rev. 2013 Feb 26;2:16. doi: 10.1186/2046-4053-2-16.

PMID- 23677803
OWN - NLM
STAT- MEDLINE
DCOM- 20140107
LR  - 20211021
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 73
IP  - 8
DP  - 2013 Jun
TI  - Optimizing the use of aspirin for cardiovascular prevention.
PG  - 803-14
LID - 10.1007/s40265-013-0061-z [doi]
AB  - This article describes the mechanism of action, pharmacokinetics, and 
      pharmacodynamics of aspirin at doses used for cardiovascular prevention and 
      provides specific management recommendations for optimal use in clinical 
      practice. The paper highlights practical aspects related to antiplatelet therapy, 
      including the optimal dose of aspirin, concomitant treatment with other NSAIDs, 
      and strategies for the prevention of gastrointestinal toxicity. Specifically, we 
      revise the benefits and hazards in different clinical settings to help the 
      clinician in the decision-making process for individuals who have different risks 
      for cardiovascular and gastrointestinal bleeding events.
FAU - Casado-Arroyo, Rubén
AU  - Casado-Arroyo R
AD  - Heart Rhythm Management Center, Cardiovascular Division, Cardiovascular Center, 
      Free University of Brussels (UZ Brussels) VUB, Laarbeeklaan 101, Brussels, 
      Belgium. rbcasado@gmail.com
FAU - Sostres, Carlos
AU  - Sostres C
FAU - Lanas, Angel
AU  - Lanas A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & 
      dosage/pharmacokinetics/pharmacology
MH  - Aspirin/*administration & dosage/pharmacokinetics/pharmacology
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Hemorrhage/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & 
      dosage/pharmacokinetics/pharmacology
MH  - Practice Guidelines as Topic
MH  - Risk Factors
EDAT- 2013/05/17 06:00
MHDA- 2014/01/08 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/05/17 06:00 [entrez]
PHST- 2013/05/17 06:00 [pubmed]
PHST- 2014/01/08 06:00 [medline]
AID - 10.1007/s40265-013-0061-z [doi]
PST - ppublish
SO  - Drugs. 2013 Jun;73(8):803-14. doi: 10.1007/s40265-013-0061-z.

PMID- 2353611
OWN - NLM
STAT- MEDLINE
DCOM- 19900713
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 119
IP  - 6
DP  - 1990 Jun
TI  - Superiority of warfarin over aspirin long term after thrombolytic therapy for 
      acute myocardial infarction.
PG  - 1238-44
AB  - Results of recent clinical trials have unequivocally established the value of 
      intravenous thrombolytic therapy in enhancing survival after acute myocardial 
      infarction. However, the optimum long-term antithrombolytic strategy for 
      prevention of recurrent cardiac complications after thrombolysis is unknown at 
      the current time. To determine whether aspirin or warfarin best prevents 
      postdischarge recurrent cardiac events (unstable angina, reinfarction, pulmonary 
      edema, or/and death), we analyzed the long-term course of 203 patients at our 
      institution who received intravenous thrombolytic therapy (streptokinase, tissue 
      plasminogen activator, or urokinase) for acute myocardial infarction. Of these, 
      129 (64%) survived to hospital discharge without revascularization--92 patients 
      (71%) received aspirin (325 mg/day). whereas 37 (29%) received warfarin. The 
      choice of drug was made by the treating physician. By a mean of 2.5 years of 
      follow-up, 34 of 92 patients receiving aspirin (37%) versus 6 or 37 receiving 
      warfarin (16%) (p less than or equal to 0.02) had unstable angina, reinfarction, 
      pulmonary edema, and/or death. No life-threatening hemorrhage occurred in either 
      group. Warfarin appears to be superior to aspirin long term in patients with 
      postlysis myocardial infarction for the prevention of recurrent cardiac 
      complications.
FAU - Schreiber, T L
AU  - Schreiber TL
AD  - Division of Cardiology, William Beaumont Hospital.
FAU - Miller, D H
AU  - Miller DH
FAU - Silvasi, D
AU  - Silvasi D
FAU - McNulty, A
AU  - McNulty A
FAU - Zola, B E
AU  - Zola BE
LA  - eng
GR  - N0L-HV-38029/HV/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Evaluation
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Regression Analysis
MH  - Time Factors
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
AID - S0002-8703(05)80170-X [pii]
AID - 10.1016/s0002-8703(05)80170-x [doi]
PST - ppublish
SO  - Am Heart J. 1990 Jun;119(6):1238-44. doi: 10.1016/s0002-8703(05)80170-x.

PMID- 28292923
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20221207
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 26
IP  - 6
DP  - 2017 Jun
TI  - Aspirin Use Reduces the Risk of Aggressive Prostate Cancer and Disease Recurrence 
      in African-American Men.
PG  - 845-853
LID - 10.1158/1055-9965.EPI-16-1027 [doi]
AB  - Background: Men of African descent experience a disproportionately high prostate 
      cancer mortality. Intratumoral inflammation was found to be associated with 
      aggressive prostate cancer. We and others have shown that prostate tumors in 
      African-American (AA) patients harbor a distinct immune and inflammation 
      signature when compared with European-American (EA) patients. These observations 
      suggest that inflammation could be a driver of aggressive disease in men of 
      African descent, leading to the hypothesis that an anti-inflammatory drug like 
      aspirin could prevent disease progression.Methods: We examined the relationship 
      between aspirin use and prostate cancer in the NCI-Maryland Prostate Cancer 
      Case-Control Study consisting of 823 men with incident prostate cancer (422 AA 
      and 401 EA) and 1,034 population-based men without the disease diagnosis (486 AA 
      and 548 EA).Results: We observed a significant inverse association between 
      regular aspirin use and prostate cancer among AA men. Stratification of AA 
      patients by disease stage showed that daily and long-term (>3 years) aspirin use 
      significantly decreased the risk of advanced disease [adjusted ORs for T3/T4 
      disease: 0.35, 95% confidence interval (CI), 0.17-0.73; and 0.22, 95% CI, 
      0.08-0.60, respectively], but not early-stage disease (T1/T2). Regular aspirin 
      use also reduced disease recurrence in AA men.Conclusions: Regular aspirin use is 
      associated with a decreased risk of advanced stage prostate cancer and increased 
      disease-free survival in AA men.Impact: Regular aspirin use before and after a 
      prostate cancer diagnosis may prevent the development of aggressive disease in AA 
      men who are at risk of a lethal malignancy. Cancer Epidemiol Biomarkers Prev; 
      26(6); 845-53. ©2017 AACR.
CI  - ©2017 American Association for Cancer Research.
FAU - Smith, Cheryl Jacobs
AU  - Smith CJ
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland.
FAU - Dorsey, Tiffany H
AU  - Dorsey TH
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland.
FAU - Tang, Wei
AU  - Tang W
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland.
FAU - Jordan, Symone V
AU  - Jordan SV
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland.
FAU - Loffredo, Christopher A
AU  - Loffredo CA
AD  - Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, 
      Georgetown University Medical Center, Washington, DC.
FAU - Ambs, Stefan
AU  - Ambs S
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland. 
      ambss@mail.nih.gov.
LA  - eng
GR  - ZIA BC010624/ImNIH/Intramural NIH HHS/United States
GR  - Z01 BC010499-06/ImNIH/Intramural NIH HHS/United States
GR  - Z01 BC010499-05/ImNIH/Intramural NIH HHS/United States
GR  - ZIA BC010499/ImNIH/Intramural NIH HHS/United States
GR  - Z01 BC010624-03/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20170314
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Black or African American
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Case-Control Studies
MH  - Disease Progression
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/pathology
MH  - Prostatic Neoplasms/*drug therapy/pathology
MH  - Risk Factors
PMC - PMC5457351
MID - NIHMS859106
EDAT- 2017/03/16 06:00
MHDA- 2018/03/10 06:00
CRDT- 2017/03/16 06:00
PHST- 2016/12/16 00:00 [received]
PHST- 2017/01/18 00:00 [revised]
PHST- 2017/03/02 00:00 [accepted]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
PHST- 2017/03/16 06:00 [entrez]
AID - 1055-9965.EPI-16-1027 [pii]
AID - 10.1158/1055-9965.EPI-16-1027 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):845-853. doi: 
      10.1158/1055-9965.EPI-16-1027. Epub 2017 Mar 14.

PMID- 33242673
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20220531
IS  - 2213-7173 (Electronic)
IS  - 2213-7165 (Linking)
VI  - 24
DP  - 2021 Mar
TI  - Aspirin and verapamil increase the sensitivity of Candida albicans to caspofungin 
      under planktonic and biofilm conditions.
PG  - 32-39
LID - S2213-7165(20)30299-X [pii]
LID - 10.1016/j.jgar.2020.11.013 [doi]
AB  - OBJECTIVES: This study aimed to investigate the effects of caspofungin (CAS) 
      combined with aspirin (ASP) or verapamil (VPL) on the sensitivity of Candida 
      albicans under planktonic and biofilm conditions. METHODS: A total of 39 C. 
      albicans clinical strains were used to construct biofilms. Sensitivity to ASP or 
      VPL combined with CAS was analysed by broth microdilution. MIC(50) values were 
      obtained and the fractional inhibitory concentration index (FICI) was calculated. 
      Subsequently, C. albicans ZY22 was selected for time-growth curve analysis and 
      strains ZY15 and ZY22 were used for time-kill curve analysis. RESULTS: Under 
      planktonic condition the MIC(50) of CAS was 0.0313-8 μg/mL following treatment 
      with CAS alone, whereas it decreased to 0.0313-4 μg/mL following CAS combined 
      with ASP or VPL. Under biofilm condition the MIC(50) of CAS was 0.125-16 μg/mL 
      following treatment with CAS alone, whereas it decreased to 0.0625-16 μg/mL or 
      0.0625-8 μg/mL following CAS combined with ASP or VPL. FICI results showed 
      synergistic interactions between CAS and ASP under planktonic and biofilm 
      conditions in 17 and 16 strains, respectively. However, synergistic interactions 
      between CAS and VPL under planktonic and biofilm conditions were observed in 19 
      and 23 strains, respectively. Additionally, 8000 μg/mL ASP or 8 μg/mL VPL 
      combined with CAS had better inhibitory effects on C. albicans. CONCLUSION: ASP 
      and VPL may be a sensitiser for CAS, and the antifungal effects of CAS may be 
      sensitised by 8000 μg/mL ASP or 8 μg/mL VPL against C. albicans under planktonic 
      and biofilm conditions.
CI  - Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Feng, Wenli
AU  - Feng W
AD  - Department of Dermatovenereology, The Second Hospital of Shanxi Medical 
      University, No. 382 Wuyi Road, Taiyuan 030001, Shanxi, China. Electronic address: 
      fengwenli@sxmu.edu.cn.
FAU - Yang, Jing
AU  - Yang J
AD  - Department of Dermatovenereology, The Second Hospital of Shanxi Medical 
      University, No. 382 Wuyi Road, Taiyuan 030001, Shanxi, China. Electronic address: 
      yangjing7962@126.com.
FAU - Ma, Yan
AU  - Ma Y
AD  - Department of Dermatovenereology, The Second Hospital of Shanxi Medical 
      University, No. 382 Wuyi Road, Taiyuan 030001, Shanxi, China.
FAU - Xi, Zhiqin
AU  - Xi Z
AD  - Department of Dermatovenereology, The Second Hospital of Shanxi Medical 
      University, No. 382 Wuyi Road, Taiyuan 030001, Shanxi, China.
FAU - Ren, Qiao
AU  - Ren Q
AD  - Department of Dermatovenereology, The Second Hospital of Shanxi Medical 
      University, No. 382 Wuyi Road, Taiyuan 030001, Shanxi, China.
FAU - Wang, Shaoyan
AU  - Wang S
AD  - Department of Dermatovenereology, The Second Hospital of Shanxi Medical 
      University, No. 382 Wuyi Road, Taiyuan 030001, Shanxi, China.
FAU - Ning, Huan
AU  - Ning H
AD  - Department of Dermatovenereology, The Second Hospital of Shanxi Medical 
      University, No. 382 Wuyi Road, Taiyuan 030001, Shanxi, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201123
PL  - Netherlands
TA  - J Glob Antimicrob Resist
JT  - Journal of global antimicrobial resistance
JID - 101622459
RN  - CJ0O37KU29 (Verapamil)
RN  - F0XDI6ZL63 (Caspofungin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Biofilms
MH  - *Candida albicans/drug effects
MH  - Caspofungin/*pharmacology
MH  - Microbial Sensitivity Tests
MH  - Verapamil/*pharmacology
OTO - NOTNLM
OT  - Aspirin
OT  - Biofilm
OT  - Candida albicans
OT  - Caspofungin
OT  - Planktonic
OT  - Verapamil
EDAT- 2020/11/27 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/11/26 20:08
PHST- 2020/08/24 00:00 [received]
PHST- 2020/10/30 00:00 [revised]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/11/26 20:08 [entrez]
AID - S2213-7165(20)30299-X [pii]
AID - 10.1016/j.jgar.2020.11.013 [doi]
PST - ppublish
SO  - J Glob Antimicrob Resist. 2021 Mar;24:32-39. doi: 10.1016/j.jgar.2020.11.013. 
      Epub 2020 Nov 23.

PMID- 10789564
OWN - NLM
STAT- MEDLINE
DCOM- 20000717
LR  - 20170214
IS  - 0267-6591 (Print)
IS  - 0267-6591 (Linking)
VI  - 15
IP  - 2
DP  - 2000 Mar
TI  - Comparison of two doses of aprotinin in patients receiving aspirin before 
      coronary bypass surgery.
PG  - 105-10
AB  - This study was designed to evaluate efficacy and tolerability of two different 
      doses of aprotinin in patients receiving aspirin before undergoing coronary 
      artery bypass grafting. Forty-two patients were randomized to receive either 
      placebo (group I), or aprotinin in doses of 4,000,000 KIU (group II) or 6,000,000 
      KIU (group III). Drug efficacy was determined by measuring postoperative blood 
      loss and transfusion of blood products. Both doses were effective in reducing 
      blood loss and transfusion requirements. Blood loss through thoracotomy drainage 
      was 450 +/- 224, 182 +/- 144, 142 +/- 98 ml, respectively, for control and 
      treatment groups II and III (p = 0.0001). The numbers of patients with blood 
      transfusions were seven (50%), two (17%) and two (17%) for group I and treatment 
      groups II and III, respectively (p = 0.10). Tolerability was excellent and 
      complications few and reversible. In conclusion, high and medium doses of 
      aprotinin were well tolerated and reduced bleeding and transfusion requirements 
      in patients submitted to coronary bypass surgery under the effects of aspirin.
FAU - Moran, S V
AU  - Moran SV
AD  - Department of Cardiovascular Diseases, Catholic University of Chile, Santiago. 
      smoran@med.puc.cl
FAU - Lema, G
AU  - Lema G
FAU - Medel, J
AU  - Medel J
FAU - Irarrazaval, M J
AU  - Irarrazaval MJ
FAU - Zalaquett, R
AU  - Zalaquett R
FAU - Garayar, B
AU  - Garayar B
FAU - Flaskamp, R
AU  - Flaskamp R
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Perfusion
JT  - Perfusion
JID - 8700166
RN  - 0 (Hemostatics)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9087-70-1 (Aprotinin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aprotinin/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Blood Loss, Surgical/*prevention & control
MH  - Blood Transfusion/statistics & numerical data
MH  - *Cardiopulmonary Bypass
MH  - *Coronary Artery Bypass
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drainage
MH  - Female
MH  - Hemostatics/*administration & dosage/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Postoperative Hemorrhage/prevention & control
MH  - Postoperative Period
MH  - *Premedication
MH  - Prospective Studies
MH  - Safety
MH  - Thoracotomy
MH  - Treatment Outcome
EDAT- 2000/05/02 09:00
MHDA- 2000/07/25 11:00
CRDT- 2000/05/02 09:00
PHST- 2000/05/02 09:00 [pubmed]
PHST- 2000/07/25 11:00 [medline]
PHST- 2000/05/02 09:00 [entrez]
AID - 10.1177/026765910001500204 [doi]
PST - ppublish
SO  - Perfusion. 2000 Mar;15(2):105-10. doi: 10.1177/026765910001500204.

PMID- 6802154
OWN - NLM
STAT- MEDLINE
DCOM- 19820624
LR  - 20161123
IS  - 0037-8771 (Print)
IS  - 0037-8771 (Linking)
VI  - 58
IP  - 1-2
DP  - 1982 Jan
TI  - [Effect, on renal function, of a product rich in polyunsaturated fatty acids: 
      results obtained in healthy subjects].
PG  - 55-9
AB  - In 7 healthy subjects a 2,5 mg/Kg dose of i.v. phosphatidylcholine a drug with an 
      high content of polyunsaturated fatty acids, caused variations in renal 
      functionality as follows: a statistically significant increase of: urine flow, 
      renal blood flow, glomerular filtration rate and sodium excretion. The above 
      phenomena which resulted in a hypertonic poliuria, were detected during three 30 
      mins clearance periods. In other 5 subjects, a dose of lysine acetylsalicylate 
      (10,5 mg/Kg) either suppressed the phenomena induced by the previous 
      administration of phosphatidylcholine or prevented them to appear when the drug 
      was given successively. Authors suggest that the data obtained may be ascribed to 
      stimulation of local PG synthesis.
FAU - Bernardi, P
AU  - Bernardi P
FAU - Bastagli, L
AU  - Bastagli L
FAU - Pecoraro, F
AU  - Pecoraro F
FAU - Vitolo, A
AU  - Vitolo A
FAU - Minelli, C
AU  - Minelli C
FAU - Cavazza, M
AU  - Cavazza M
FAU - Adani, C
AU  - Adani C
LA  - ita
PT  - Journal Article
TT  - Effetti sulla funzionalita renale di un prodotto ricco di acidi grassi 
      polinsaturi: risultati ottenuti in soggetti sani.
PL  - Italy
TA  - Boll Soc Ital Biol Sper
JT  - Bollettino della Societa italiana di biologia sperimentale
JID - 7506962
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Phosphatidylcholines)
RN  - 9NEZ333N27 (Sodium)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Fatty Acids, Unsaturated/*pharmacology
MH  - Female
MH  - Glomerular Filtration Rate/drug effects
MH  - Humans
MH  - Kidney/blood supply/*drug effects
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Phosphatidylcholines/pharmacology
MH  - Regional Blood Flow/drug effects
MH  - Sodium/urine
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - Boll Soc Ital Biol Sper. 1982 Jan;58(1-2):55-9.

PMID- 30037494
OWN - NLM
STAT- MEDLINE
DCOM- 20190311
LR  - 20210702
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 28
IP  - 17
DP  - 2018 Sep 15
TI  - Novel cinnamaldehyde-based aspirin derivatives for the treatment of colorectal 
      cancer.
PG  - 2869-2874
LID - S0960-894X(18)30612-7 [pii]
LID - 10.1016/j.bmcl.2018.07.032 [doi]
AB  - Colorectal cancer (CRC) is a leading cause of mortality worldwide. Current 
      treatments of CRC involve anti-cancer agents with relatively good efficacy but 
      unselectively target both cancer and non-cancer cells. Thus, there is a need to 
      discover and develop novel CRC therapeutics that have potent anti-cancer effects, 
      but show reduced off-target cell effects. Here, a novel series of 
      cinnamaldehyde-based aspirin derivatives were designed and synthesized. 
      Biological evaluation indicated that the most active compound 1f exhibited more 
      than 10-fold increase in the anti-proliferation efficacy in HCT-8 cells compared 
      to the parent compounds. Its effects were similarly reproduced in another CRC 
      cell line, DLD-1, but with 7- to 11-fold less inhibitory activity in 
      non-tumorigenic colon cells. Flow cytometry analysis showed that 1f induced cell 
      cycle arrest and apoptosis, which was further validated with immunoblot analysis 
      of the relative protein levels of cleaved caspase 3 and PARP as well as the ROS 
      production in CRC cells. More so, 1f significantly inhibited the growth of 
      implanted CRC in vivo in mouse xenograft model. Taken together, our results show 
      that cinnamaldehyde-based aspirin derivatives such as 1f show promise as novel 
      anti-CRC agent for further pharmaceutical development.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Lu, Shan
AU  - Lu S
AD  - College of Pharmacy, Hubei University of Chinese Medicine, Hubei 430065, PR 
      China. Electronic address: lushan9805@163.com.
FAU - Obianom, Obinna N
AU  - Obianom ON
AD  - Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 
      Baltimore, MD 21201, United States.
FAU - Ai, Yong
AU  - Ai Y
AD  - Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 
      Baltimore, MD 21201, United States. Electronic address: aiyong0508@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180719
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (Antineoplastic Agents)
RN  - 7864XYD3JJ (Acrolein)
RN  - R16CO5Y76E (Aspirin)
RN  - SR60A3XG0F (cinnamaldehyde)
SB  - IM
MH  - Acrolein/*analogs & derivatives/chemistry/pharmacology
MH  - Animals
MH  - Antineoplastic Agents/chemical synthesis/chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/chemical synthesis/chemistry/*pharmacology
MH  - Cell Cycle Checkpoints/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Colorectal Neoplasms/*drug therapy/pathology
MH  - Dose-Response Relationship, Drug
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Molecular Structure
MH  - Neoplasms, Experimental/drug therapy/pathology
MH  - Structure-Activity Relationship
OTO - NOTNLM
OT  - Anti-proliferative activity
OT  - Apoptosis
OT  - Aspirin
OT  - Cinnamaldehyde
OT  - Colorectal cancer
EDAT- 2018/07/25 06:00
MHDA- 2019/03/12 06:00
CRDT- 2018/07/25 06:00
PHST- 2018/05/14 00:00 [received]
PHST- 2018/07/01 00:00 [revised]
PHST- 2018/07/18 00:00 [accepted]
PHST- 2018/07/25 06:00 [pubmed]
PHST- 2019/03/12 06:00 [medline]
PHST- 2018/07/25 06:00 [entrez]
AID - S0960-894X(18)30612-7 [pii]
AID - 10.1016/j.bmcl.2018.07.032 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2018 Sep 15;28(17):2869-2874. doi: 
      10.1016/j.bmcl.2018.07.032. Epub 2018 Jul 19.

PMID- 32925332
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20230721
IS  - 1526-7598 (Electronic)
IS  - 0003-2999 (Linking)
VI  - 131
IP  - 4
DP  - 2020 Oct
TI  - A Comprehensive Update on Aspirin Management During Noncardiac Surgery.
PG  - 1111-1123
LID - 10.1213/ANE.0000000000005064 [doi]
AB  - Aspirin is considered critical lifelong therapy for patients with established 
      cardiovascular (CV) disease (including coronary artery, cerebrovascular, and 
      peripheral arterial diseases) and is consequently one of the most widely used 
      medications worldwide. However, the indications for aspirin use continue to 
      evolve and recent trials question its efficacy for primary prevention. Although 
      one third of patients undergoing noncardiac surgery and at risk for a major 
      adverse CV event receive aspirin perioperatively, uncertainty still exists about 
      how aspirin should be optimally managed in this context, and significant practice 
      variability remains. Recent trials suggest that the risks of continuing aspirin 
      during the perioperative period outweigh the benefits in many cases, but data on 
      patients with high CV risk remain limited. We performed a comprehensive PubMed 
      and Medline literature search using the following keywords: aspirin, aspirin 
      withdrawal, perioperative, coronary artery disease, cerebrovascular disease, 
      peripheral artery disease, and CV disease; we manually reviewed all relevant 
      citations for inclusion. Patients taking aspirin for the primary prevention of CV 
      disease should likely discontinue it during the perioperative period, especially 
      when there is a high risk of bleeding. Patients with established CV disease but 
      without a coronary stent should likely continue aspirin during the perioperative 
      period unless undergoing closed-space surgery. Patients with a history of 
      coronary stenting also likely need aspirin continuation throughout the 
      perioperative period for nonclosed space procedures. Perioperative clinicians 
      need to balance the risks of ceasing aspirin before surgery against its 
      continuation during the perioperative interval using a patient-specific strategy. 
      The guidance on decision-making with regard to perioperative aspirin cessation or 
      continuation using currently available clinical data from studies in high-risk 
      patients along with nonclinical aspirin studies is conflicting and does not 
      enable a simplified or unified answer. However, pertinent guidelines on CV 
      disease management provide a basic framework for aspirin management, and large 
      trial findings provide some insight into the safety of perioperative aspirin 
      cessation in some contexts, although uncertainty on perioperative aspirin still 
      exists. This review provides an evidence-based update on perioperative aspirin 
      management in patients undergoing noncardiac surgery with a focus on 
      recommendations for perioperative clinicians on continuing versus holding aspirin 
      during this context.
FAU - Gerstein, Neal S
AU  - Gerstein NS
AD  - From the Department of Anesthesiology and Critical Care Medicine, University of 
      New Mexico School of Medicine, Albuquerque, New Mexico.
FAU - Albrechtsen, Cory L
AU  - Albrechtsen CL
AD  - L. Burrell College of Osteopathic Medicine, Las Cruces, New Mexico.
FAU - Mercado, Nestor
AU  - Mercado N
AD  - Division of Cardiology, Department of Internal Medicine, University of New Mexico 
      School of Medicine, Albuquerque, New Mexico.
FAU - Cigarroa, Joaquin E
AU  - Cigarroa JE
AD  - Division of Cardiology, Knight Cardiovascular Institute.
FAU - Schulman, Peter M
AU  - Schulman PM
AD  - Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science 
      University, Portland, Oregon.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Intraoperative Care/*methods
MH  - Intraoperative Period
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Surgical Procedures, Operative
EDAT- 2020/09/15 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/09/14 15:43
PHST- 2020/09/14 15:43 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
AID - 00000539-202010000-00020 [pii]
AID - 10.1213/ANE.0000000000005064 [doi]
PST - ppublish
SO  - Anesth Analg. 2020 Oct;131(4):1111-1123. doi: 10.1213/ANE.0000000000005064.

PMID- 19213572
OWN - NLM
STAT- MEDLINE
DCOM- 20090305
LR  - 20190907
IS  - 0080-0015 (Print)
IS  - 0080-0015 (Linking)
VI  - 181
DP  - 2009
TI  - Aspirin and NSAIDs for the prevention of colorectal cancer.
PG  - 223-9
AB  - With few exceptions, epidemiological studies have found that individuals who take 
      nonsteroidal antiinflammatory drugs (NSAIDs) have a reduced risk of colorectal 
      adenomas and carcinoma. Similarly, randomized studies in patients with familial 
      adenomatous polyposis have uniformly found that NSAIDs can lead to polyp 
      regression and prevention of new polyps, and trials in patients with sporadic 
      adenomas document that aspirin reduces the risk of adenoma recurrence. Together 
      these data provide convincing evidence for the chemopreventive efficacy ofNSAIDs 
      in the large bowel.
FAU - Baron, John A
AU  - Baron JA
AD  - Evergreen Center, Biostatistics and Epidemiology, Lebanon, NH 03756, USA. 
      John.A.Baron@Dartmouth.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Recent Results Cancer Res
JT  - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans 
      les recherches sur le cancer
JID - 0044671
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Colorectal Neoplasms/*prevention & control
MH  - Humans
RF  - 35
EDAT- 2009/02/14 09:00
MHDA- 2009/03/06 09:00
CRDT- 2009/02/14 09:00
PHST- 2009/02/14 09:00 [entrez]
PHST- 2009/02/14 09:00 [pubmed]
PHST- 2009/03/06 09:00 [medline]
AID - 10.1007/978-3-540-69297-3_21 [doi]
PST - ppublish
SO  - Recent Results Cancer Res. 2009;181:223-9. doi: 10.1007/978-3-540-69297-3_21.

PMID- 5101354
OWN - NLM
STAT- MEDLINE
DCOM- 19710403
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 1
IP  - 5747
DP  - 1971 Feb 27
TI  - Analgesic nephropathy: clinical syndrome and prognosis.
PG  - 479-82
AB  - Over a five-year period 86 patients presented to a renal unit with a history of 
      prolonged analgesic abuse and no other obvious cause of renal damage. Anaemia and 
      peptic ulceration were common, and neurological states suggestive of chronic 
      analgesic intoxication occurred in 22 patients. Thirty-two patients died during 
      follow-up, but the prognosis was much better in patients who ceased abuse of 
      compound analgesics, and improvement could occur even in advanced renal failure. 
      While 84 patients had taken mixtures containing both aspirin and phenacetin, 
      papillary necrosis was also found in two patients who had abused only aspirin, 
      and when phenacetin was withdrawn from several leading compound analgesics, renal 
      function continued to deteriorate in patients ingesting those preparations.
FAU - Murray, R M
AU  - Murray RM
FAU - Lawson, D H
AU  - Lawson DH
FAU - Linton, A L
AU  - Linton AL
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Adult
MH  - Aged
MH  - Anemia/chemically induced
MH  - Aspirin/*adverse effects
MH  - Humans
PMC - PMC1795214
EDAT- 1971/02/27 00:00
MHDA- 1971/02/27 00:01
CRDT- 1971/02/27 00:00
PHST- 1971/02/27 00:00 [pubmed]
PHST- 1971/02/27 00:01 [medline]
PHST- 1971/02/27 00:00 [entrez]
AID - 10.1136/bmj.1.5747.479 [doi]
PST - ppublish
SO  - Br Med J. 1971 Feb 27;1(5747):479-82. doi: 10.1136/bmj.1.5747.479.

PMID- 3197098
OWN - NLM
STAT- MEDLINE
DCOM- 19890124
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 8
IP  - 3
DP  - 1988 Sep
TI  - Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine 
      prophylaxis. A double-blind, placebo-controlled crossover study.
PG  - 187-92
AB  - The efficacy of the combination of dihydroergotamine (10 mg) with acetylsalicylic 
      acid (80 mg) (DHE + ASA) in the prophylaxis of migraine was studied in a 
      double-blind, placebo-controlled crossover trial (8 weeks twice). Of 45 patients 
      who entered the study, 38 completed it. The number of attacks was significantly 
      (p = 0.003) reduced during active treatment (11.5 +/- 6.2) compared with placebo 
      (16.6 +/- 9.9). The mean duration, the mean severity, and the mean score for 
      symptomatic acute medication of attacks did not differ significantly. The overall 
      assessment made by the patients themselves was in favor of DHE + ASA (p = 0.001). 
      These results indicate a moderately beneficial effect of the 
      dihydroergotamine/low-dose acetylsalicylic acid combination in migraine 
      prophylaxis.
FAU - Bousser, M G
AU  - Bousser MG
AD  - Clinique des Maladies du Système Nerveux, Hôpital de la Salpetriere, Paris, 
      France.
FAU - Chick, J
AU  - Chick J
FAU - Fuseau, E
AU  - Fuseau E
FAU - Soisson, T
AU  - Soisson T
FAU - Thevenet, R
AU  - Thevenet R
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Drug Combinations)
RN  - 0 (Placebos)
RN  - 436O5HM03C (Dihydroergotamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Dihydroergotamine/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy/prevention & control
MH  - Placebos
EDAT- 1988/09/01 00:00
MHDA- 1988/09/01 00:01
CRDT- 1988/09/01 00:00
PHST- 1988/09/01 00:00 [pubmed]
PHST- 1988/09/01 00:01 [medline]
PHST- 1988/09/01 00:00 [entrez]
AID - 10.1046/j.1468-2982.1988.0803187.x [doi]
PST - ppublish
SO  - Cephalalgia. 1988 Sep;8(3):187-92. doi: 10.1046/j.1468-2982.1988.0803187.x.

PMID- 9183923
OWN - NLM
STAT- MEDLINE
DCOM- 19970707
LR  - 20131121
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 52
IP  - 1
DP  - 1997 Jan-Feb
TI  - [Antiplatelet agents and cardiovascular prevention].
PG  - 53-8
AB  - The main contributions of meta-analysis methodology to antiplatelet therapy in 
      the field of cardiovascular prevention are presented with regard to the different 
      sectors of the health system: help with therapeutic information, help in the 
      planning of clinical trials for the pharmaceutical industry and help in 
      decision-making for Health Authorities. The results of meta-analysis of available 
      data concerning aspirin in cardio-vascular prevention are discussed, in an 
      attempt to define optimal daily dose and duration of aspirin treatment.
FAU - Barry, S
AU  - Barry S
AD  - RCTs, Lyon, France.
FAU - Mercier, S
AU  - Mercier S
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Anti-agrégants plaquettaires et prévention cardio-vasculaire.
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Industry
MH  - Drug Prescriptions
MH  - Humans
MH  - Legislation, Drug
MH  - Meta-Analysis as Topic
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Therapie. 1997 Jan-Feb;52(1):53-8.

PMID- 27351777
OWN - NLM
STAT- MEDLINE
DCOM- 20170210
LR  - 20170210
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 12
IP  - 10
DP  - 2016 Oct
TI  - Xenobiotic/medium chain fatty acid: CoA ligase - a critical review on its role in 
      fatty acid metabolism and the detoxification of benzoic acid and aspirin.
PG  - 1169-79
LID - 10.1080/17425255.2016.1206888 [doi]
AB  - INTRODUCTION: Activation of fatty acids by the acyl-CoA synthetases (ACSs) is the 
      vital first step in fatty acid metabolism. The enzymatic and physiological 
      characterization of the human xenobiotic/medium chain fatty acid: CoA ligases 
      (ACSMs) has been severely neglected even though xenobiotics, such as benzoate and 
      salicylate, are detoxified through this pathway. AREAS COVERED: This review will 
      focus on the nomenclature and substrate specificity of the human ACSM ligases; 
      the biochemical and enzymatic characterization of ACSM1 and ACSM2B; the high 
      sequence homology of the ACSM2 genes (ACSM2A and ACSM2B) as well as what is 
      currently known regarding disease association studies. EXPERT OPINION: Several 
      discrepancies exist in the current literature that should be taken note of. For 
      example, the single nucleotide polymorphisms (SNPs) reported to be associated 
      with aspirin metabolism and multiple risk factors of metabolic syndrome are 
      incorrect. Kinetic data on the substrate specificity of the human ACSM ligases 
      are non-existent and currently no data exist on the influence of SNPs on the 
      enzyme activity of these ligases. One of the biggest obstacles currently in the 
      field is that glycine conjugation is continuously studied as a one-step process, 
      which means that key regulatory factors of the two individual steps remain 
      unknown.
FAU - van der Sluis, Rencia
AU  - van der Sluis R
AD  - a Centre for Human Metabolomics, Biochemistry Division , North-West University , 
      Potchefstroom , South Africa.
FAU - Erasmus, Elardus
AU  - Erasmus E
AD  - a Centre for Human Metabolomics, Biochemistry Division , North-West University , 
      Potchefstroom , South Africa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160715
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Fatty Acids)
RN  - 0 (Xenobiotics)
RN  - 8SKN0B0MIM (Benzoic Acid)
RN  - EC 6.2.1.- (Coenzyme A Ligases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*metabolism
MH  - Benzoic Acid/adverse effects/*metabolism
MH  - Coenzyme A Ligases/genetics/*metabolism
MH  - Fatty Acids/metabolism
MH  - Humans
MH  - Polymorphism, Single Nucleotide
MH  - Substrate Specificity
MH  - Xenobiotics/adverse effects/metabolism
OTO - NOTNLM
OT  - ACSM
OT  - CoA ligase
OT  - acyl-coenzyme A
OT  - aspirin
OT  - benzoate
OT  - glycine conjugation
OT  - medium chain fatty acid
OT  - salicylate
EDAT- 2016/06/29 06:00
MHDA- 2017/02/12 06:00
CRDT- 2016/06/29 06:00
PHST- 2016/06/29 06:00 [entrez]
PHST- 2016/06/29 06:00 [pubmed]
PHST- 2017/02/12 06:00 [medline]
AID - 10.1080/17425255.2016.1206888 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1169-79. doi: 
      10.1080/17425255.2016.1206888. Epub 2016 Jul 15.

PMID- 11442269
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190818
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 18
IP  - 3
DP  - 2001 Mar
TI  - Transport properties of ionic drugs in the ammonio methacrylate copolymer 
      membranes.
PG  - 304-10
AB  - PURPOSE: Ammonio methacrylate copolymer is a pharmaceutical excipient widely used 
      as a coating material for encapsulation of pellet and tablet dosage forms. 
      Because of the charged ammonio function groups within the polymer, ionic drugs 
      may interact with the coating film while transporting through it. The kinetic 
      swelling and drug permeation properties of the ammonio methacrylate copolymer 
      membranes were studied to delineate the effect of ionic interaction between the 
      ionic drugs and the membranes. METHODS: The pH and ionic strength of the 
      solutions and the charged properties of drugs were varied to study the effects on 
      the transport properties through the membranes. Ambroxol was chosen as a model 
      cationic drug and aspirin as a model anionic drug. RESULTS: The degree of 
      membrane swelling in the drug-free solution decreases as the ionic strength 
      increases but it is irrelevant to the pH. With the presence of ionic drugs, the 
      degree of membrane swelling is affected by the drug species as well as the pH of 
      the solutions in addition to the effect of ionic strength. The degree of swelling 
      for a membrane in a solution containing aspirin is higher at a lower pH and 
      ambroxol is lower at a lower pH. Aspirin experiences a three-stage permeation and 
      ambroxol a two-stage one. The ion-exchange reaction between the anionic 
      carboxylic groups in aspirin and the cationic ammonio groups in the membranes 
      results in a slow permeation stage during the transient state. The pseudo 
      steady-state permeability for each drug follows the trend as the degree of 
      membrane swelling in the drug media at various pH and ionic strengths. However, 
      it is much higher for aspirin than ambroxol although the degree of membrane 
      swelling is higher in an ambroxol solution than that in an aspirin solution. The 
      permeability of ambroxol through the membrane is largely reduced because of the 
      Donnan exclusion effect. CONCLUSIONS: The interaction between ionic drugs with 
      the cationic groups in the membranes affects the ionic strength of the solutions 
      and results in a pH-dependent degree of swelling. The ionic interaction also 
      determines the drug permeation rates as well as the transient permeation 
      behaviors.
FAU - Sun, Y M
AU  - Sun YM
AD  - Department of Chemical Engineering, Yuan Ze University, Chung-Li, Taoyuan, 
      Taiwan, Republic of China. cesunym@saturn.yzu.edu.tw
FAU - Hsu, S C
AU  - Hsu SC
FAU - Lai, J Y
AU  - Lai JY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Buffers)
RN  - 0 (Drug Carriers)
RN  - 0 (Membranes, Artificial)
RN  - 0 (Polymethacrylic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Aspirin/chemistry
MH  - Buffers
MH  - Drug Carriers
MH  - *Drug Delivery Systems
MH  - Hydrogen-Ion Concentration
MH  - Membranes, Artificial
MH  - Permeability
MH  - Polymethacrylic Acids/*chemistry
EDAT- 2001/07/10 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/07/10 10:00
PHST- 2001/07/10 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/07/10 10:00 [entrez]
AID - 10.1023/a:1011098712693 [doi]
PST - ppublish
SO  - Pharm Res. 2001 Mar;18(3):304-10. doi: 10.1023/a:1011098712693.

PMID- 20095396
OWN - NLM
STAT- MEDLINE
DCOM- 20100217
LR  - 20131121
IS  - 0869-2092 (Print)
IS  - 0869-2092 (Linking)
VI  - 72
IP  - 6
DP  - 2009 Nov-Dec
TI  - [Antiaggregant activity of hypoglycemic drugs].
PG  - 27-9
AB  - We have compared the inhibitory effects of a series of hypoglycemic drugs, 
      including glyclazide, glibenclamide, glucophage, rosiglitazone, diabenol (a new 
      antidiabetic drug), and acetylsalicylic acid (reference antiaggregant 
      preparation), on rabbit platelet aggregation in vitro induced by adding 5 mM ADP 
      solution. All hypoglycemic drugs and acetylsalicylic acid inhibited platelet 
      aggregation in a dose-depended manner. Diabenol, glyclazide and glibenclamide 
      demonstrated the most pronounced activity in comparison to that of 
      acetylsalycilic acid. A comparison of the published data on maximum drug 
      concentrations in the blood plasma (Cmax) and the values of effective 
      concentrations (EC25) of drugs determined in this study suggests that diabenol 
      and glyclazide will produce direct antiaggregant effect under clinical 
      administration conditions. At the same time, it is concluded that the 
      antiaggregant effect of glibenclamide, glucophage and rosiglitazone is indirect 
      and can only be pronounced at concentrations significantly exceeding the 
      therapeutic level.
FAU - Spasov, A A
AU  - Spasov AA
FAU - Kucheriavenko, A F
AU  - Kucheriavenko AF
FAU - Maĭstrenko, B P
AU  - Maĭstrenko BP
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Eksp Klin Farmakol
JT  - Eksperimental'naia i klinicheskaia farmakologiia
JID - 9215981
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Hypoglycemic Agents/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rabbits
EDAT- 2010/01/26 06:00
MHDA- 2010/02/18 06:00
CRDT- 2010/01/26 06:00
PHST- 2010/01/26 06:00 [entrez]
PHST- 2010/01/26 06:00 [pubmed]
PHST- 2010/02/18 06:00 [medline]
PST - ppublish
SO  - Eksp Klin Farmakol. 2009 Nov-Dec;72(6):27-9.

PMID- 6906165
OWN - NLM
STAT- MEDLINE
DCOM- 19810324
LR  - 20190913
IS  - 0065-6100 (Print)
IS  - 0065-6100 (Linking)
VI  - 214
IP  - 2
DP  - 1980
TI  - Cyclocryokoagulation. Sequelae of induced alterations and effect of a 
      prostaglandin-inhibitor on the breakdown of the blood-aqueous barrier.
PG  - 129-37
AB  - Histopathological changes following cyclocryokoagulation in a group of rabbits 
      pretreated with acetylsalicyclic acid (ASA) were studied and compared with 
      similar changes in a control group. As observed clinically, macroscopical and 
      histological differences were only noted in the early phase after the procedure. 
      In this phase, all operated eyes revealed an immense vascular response with 
      edema, exudation and extravasation of blood cells. The treated animals, however, 
      showed some reduction of tissue edema than the animals not treated. At a later 
      stage there is an necrosis of the stroma with reduction of small vessels and 
      tissue cells. The reparative process, tending to restore both epithelial and 
      stromal lesions, begins already in the 3rd. week after cyclocryokoagulation. 
      Neither the epithelial nor the stromal alterations differed significantly in any 
      of the operated eyes at this stage. This indicates that ASA mainly affects an 
      obviously prostaglandin-mediated acute vascular response. The disruption of the 
      epithelial barrier may be aggravated by the subsequent stromal alterations, but 
      does not seem to be influenced by ASA.
FAU - Haddad, R
AU  - Haddad R
FAU - Grabner, G
AU  - Grabner G
FAU - Braun, F
AU  - Braun F
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Albrecht Von Graefes Arch Klin Exp Ophthalmol
JT  - Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 
      Albrecht von Graefe's archive for clinical and experimental ophthalmology
JID - 0044637
RN  - 0 (Prostaglandin Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aqueous Humor/*physiology
MH  - Aspirin/pharmacology
MH  - Ciliary Body
MH  - *Cryosurgery
MH  - Prostaglandin Antagonists/*pharmacology
MH  - Rabbits
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1007/BF00572791 [doi]
PST - ppublish
SO  - Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1980;214(2):129-37. doi: 
      10.1007/BF00572791.

PMID- 8477120
OWN - NLM
STAT- MEDLINE
DCOM- 19930521
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 27
IP  - 4
DP  - 1993 Apr
TI  - Prevalence and descriptors of aspirin use as an antiplatelet agent in two New 
      England communities.
PG  - 442-4
AB  - OBJECTIVE: To determine the overall prevalence of aspirin use as an antiplatelet 
      agent in a population-based sample of respondents between the ages of 18 and 64 
      years, and to describe their sociodemographic characteristics. DESIGN: Data were 
      derived from five biennial cross-sectional household surveys conducted between 
      1981 and 1990 in two southeastern New England communities by the Pawtucket Heart 
      Health Program. Individuals reporting aspirin use as an antiplatelet agent were 
      identified using data from a structured medication interview. RESULTS: The 
      prevalence of aspirin use per 1000 population was 2.5 (95 percent confidence 
      interval [CI] 0.5, 4.4), 5.0 (95 percent CI 2.4, 7.6), 7.8 (95 percent CI 4.6, 
      11.0), 7.5 (95 percent CI 4.3, 10.6), and 11.8 (95 percent CI 7.1, 16.5) in the 
      first through the fifth survey periods, respectively (p = 0.0002). The prevalence 
      of aspirin use per 1000 men increased from 4.9 (95 percent CI 0.6, 9.1), 8.7 (95 
      percent CI 3.3, 14.1), 12.3 (95 percent CI 6.1, 18.5), 8.5 (95 percent CI 3.5, 
      13.5) to 23.2 (95 percent CI 13.4, 32.9) for the first through the fifth survey 
      periods, respectively. The corresponding prevalence rates of aspirin use per 1000 
      women were 0.7 (95 percent CI 0, 2.1), 2.43 (95 percent CI 0.05, 4.80), 4.6 (95 
      percent CI 1.4, 7.8), 6.6 (95 percent CI 2.7, 10.6), and 2.7 (95 percent CI 0, 
      5.7). Both a gender trend (p = 0.0002) and a survey trend (p = 0.0001) were 
      detected. A gender-survey interaction was not found. CONCLUSIONS: In this 
      population, aspirin use was reported primarily by middle-aged men who had 
      coexisting cardiovascular disease as indicated by concurrent medications. Aspirin 
      use as antiplatelet therapy increased in the population-based samples of two New 
      England communities over the past nine years, with slightly more than one percent 
      of the respondents reporting its use in the fifth cross-sectional survey 
      conducted in 1989-1990. This finding may reflect the publication of important 
      clinical trials near the time the survey was performed and subsequent 
      dissemination of the findings both in the professional and lay press.
FAU - Hume, A L
AU  - Hume AL
AD  - College of Pharmacy, University of Rhode Island, Kingston.
FAU - Barbour, M M
AU  - Barbour MM
FAU - Lapane, K L
AU  - Lapane KL
FAU - Assaf, A R
AU  - Assaf AR
FAU - Carleton, R A
AU  - Carleton RA
LA  - eng
GR  - HL 23629/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Confidence Intervals
MH  - Cross-Sectional Studies
MH  - Drug Utilization
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rhode Island
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
AID - 10.1177/106002809302700409 [doi]
PST - ppublish
SO  - Ann Pharmacother. 1993 Apr;27(4):442-4. doi: 10.1177/106002809302700409.

PMID- 32633476
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1897-4279 (Electronic)
IS  - 0022-9032 (Linking)
VI  - 78
IP  - 7-8
DP  - 2020 Aug 25
TI  - New methodological approaches for assessing thrombus formation in cardiovascular 
      disease.
PG  - 667-673
LID - 10.33963/KP.15493 [doi]
AB  - Antiplatelet therapy is the mainstay preventive strategy for cardiovascular 
      diseases, and dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor 
      is the standard treatment for patients who underwent percutaneous coronary 
      intervention. The Total Thrombus‑Formation Analysis System (T‑TAS) is a microchip 
      flow‑chamber system developed to evaluate overall thrombus formation under flow 
      conditions, which is reportedly able to assess single and combined antithrombotic 
      therapy. Here, we focus on this new system, T‑TAS, and review its characteristics 
      together with those of the conventional systems available for evaluation of 
      antithrombotic therapies for cardiovascular diseases.
FAU - Hosokawa, Kazuya
AU  - Hosokawa K
AD  - Research Institute, Fujimori Kogyo Co., Ltd., Yokohama, Kanagawa, Japan. 
      kazuya-hosokawa@zacros.co.jp
FAU - Ohnishi-Wada, Tomoko
AU  - Ohnishi-Wada T
AD  - Research Institute, Fujimori Kogyo Co., Ltd., Yokohama, Kanagawa, Japan
FAU - Nagasato, Tomoka
AU  - Nagasato T
AD  - Research Institute, Fujimori Kogyo Co., Ltd., Yokohama, Kanagawa, Japan; 
      Department of System Biology in Thromboregulation, Graduate School of Medical and 
      Dental Sciences, Kagoshima, Japan
FAU - Sameshima-Kaneko, Hisayo
AU  - Sameshima-Kaneko H
AD  - Research Institute, Fujimori Kogyo Co., Ltd., Yokohama, Kanagawa, Japan
FAU - Oyamada, Chiaki
AU  - Oyamada C
AD  - Research Institute, Fujimori Kogyo Co., Ltd., Yokohama, Kanagawa, Japan
FAU - Dahlen, Jeffrey
AU  - Dahlen J
AD  - Hikari Dx, San Diego, California, United States
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Thrombosis/drug therapy
EDAT- 2020/07/08 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.33963/KP.15493 [doi]
PST - ppublish
SO  - Kardiol Pol. 2020 Aug 25;78(7-8):667-673. doi: 10.33963/KP.15493. Epub 2020 Jul 
      7.

PMID- 28220610
OWN - NLM
STAT- MEDLINE
DCOM- 20180522
LR  - 20180522
IS  - 1522-7243 (Electronic)
IS  - 1522-7235 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Sep
TI  - Comparison and analysis on the serum-binding characteristics of aspirin-zinc 
      complex and aspirin.
PG  - 1017-1024
LID - 10.1002/bio.3285 [doi]
AB  - This study was designed to compare the protein-binding characteristics of 
      aspirin-zinc complex (AZN) with those of aspirin itself. AZN was synthesized and 
      interacted with a model transport protein, human serum albumin (HSA). 
      Three-dimensional fluorescence, ultraviolet-visible and circular dichroism (CD) 
      spectra were used to characterize the interaction of AZN with HSA under 
      physiological conditions. The interaction mechanism was explored using a 
      fluorescence quenching method and thermodynamic calculation. The binding site and 
      binding locality of AZN on HSA were demonstrated using a fluorescence probe 
      technique and Förster non-radiation energy transfer theory. Synchronous 
      fluorescence and CD spectra were employed to reveal the effect of AZN on the 
      native conformation of the protein. The HSA-binding results for AZN were compared 
      with those for aspirin under consistent experimental conditions, and indicated 
      that aspirin acts as a guide in AZN when binding to Sudlow's site I, in subdomain 
      IIA of the HSA molecule. Moreover, compared with aspirin, AZN showed greater 
      observed binding constants with, but smaller changes in the α-helicity of, HSA, 
      which proved that AZN might be easier to transport and have less toxicity in 
      vivo.
CI  - Copyright © 2017 John Wiley & Sons, Ltd.
FAU - Zhang, Hua-Xin
AU  - Zhang HX
AD  - College of Chemical and Pharmaceutical Engineering, Jingchu University of 
      Technology, Jingmen, People's Republic of China.
FAU - Zhang, Qun
AU  - Zhang Q
AD  - College of Chemical and Pharmaceutical Engineering, Jingchu University of 
      Technology, Jingmen, People's Republic of China.
FAU - Wang, Hong-Lin
AU  - Wang HL
AD  - College of Chemical and Pharmaceutical Engineering, Jingchu University of 
      Technology, Jingmen, People's Republic of China.
FAU - Li, Li-Wei
AU  - Li LW
AD  - College of Chemical and Pharmaceutical Engineering, Jingchu University of 
      Technology, Jingmen, People's Republic of China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170221
PL  - England
TA  - Luminescence
JT  - Luminescence : the journal of biological and chemical luminescence
JID - 100889025
RN  - 0 (Serum Albumin)
RN  - J41CSQ7QDS (Zinc)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Binding Sites
MH  - Circular Dichroism
MH  - Energy Transfer
MH  - Fluorescence
MH  - Humans
MH  - Hydrogen Bonding
MH  - Protein Binding
MH  - Serum Albumin/*chemistry
MH  - Thermodynamics
MH  - Zinc/*chemistry
OTO - NOTNLM
OT  - aspirin-zinc complex
OT  - circular dichroism
OT  - energy transfer
OT  - fluorescence
OT  - thermodynamics
EDAT- 2017/02/22 06:00
MHDA- 2018/05/23 06:00
CRDT- 2017/02/22 06:00
PHST- 2016/09/06 00:00 [received]
PHST- 2016/10/20 00:00 [revised]
PHST- 2016/12/28 00:00 [accepted]
PHST- 2017/02/22 06:00 [pubmed]
PHST- 2018/05/23 06:00 [medline]
PHST- 2017/02/22 06:00 [entrez]
AID - 10.1002/bio.3285 [doi]
PST - ppublish
SO  - Luminescence. 2017 Sep;32(6):1017-1024. doi: 10.1002/bio.3285. Epub 2017 Feb 21.

PMID- 36084151
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20220927
IS  - 1553-7358 (Electronic)
IS  - 1553-734X (Print)
IS  - 1553-734X (Linking)
VI  - 18
IP  - 9
DP  - 2022 Sep
TI  - Utility of constraints reflecting system stability on analyses for biological 
      models.
PG  - e1010441
LID - 10.1371/journal.pcbi.1010441 [doi]
LID - e1010441
AB  - Simulating complex biological models consisting of multiple ordinary differential 
      equations can aid in the prediction of the pharmacological/biological responses; 
      however, they are often hampered by the availability of reliable kinetic 
      parameters. In the present study, we aimed to discover the properties of 
      behaviors without determining an optimal combination of kinetic parameter values 
      (parameter set). The key idea was to collect as many parameter sets as possible. 
      Given that many systems are biologically stable and resilient (BSR), we focused 
      on the dynamics around the steady state and formulated objective functions for 
      BSR by partial linear approximation of the focused region. Using the objective 
      functions and modified global cluster Newton method, we developed an algorithm 
      for a thorough exploration of the allowable parameter space for biological 
      systems (TEAPS). We first applied TEAPS to the NF-κB signaling model. This system 
      shows a damped oscillation after stimulation and seems to fit the BSR constraint. 
      By applying TEAPS, we found several directions in parameter space which 
      stringently determines the BSR property. In such directions, the experimentally 
      fitted parameter values were included in the range of the obtained parameter 
      sets. The arachidonic acid metabolic pathway model was used as a model related to 
      pharmacological responses. The pharmacological effects of nonsteroidal 
      anti-inflammatory drugs were simulated using the parameter sets obtained by 
      TEAPS. The structural properties of the system were partly extracted by analyzing 
      the distribution of the obtained parameter sets. In addition, the simulations 
      showed inter-drug differences in prostacyclin to thromboxane A2 ratio such that 
      aspirin treatment tends to increase the ratio, while rofecoxib treatment tends to 
      decrease it. These trends are comparable to the clinical observations. These 
      results on real biological models suggest that the parameter sets satisfying the 
      BSR condition can help in finding biologically plausible parameter sets and 
      understanding the properties of biological systems.
FAU - Kariya, Yoshiaki
AU  - Kariya Y
AUID- ORCID: 0000-0001-8227-2605
AD  - Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, 
      The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
FAU - Honma, Masashi
AU  - Honma M
AUID- ORCID: 0000-0001-8481-763X
AD  - Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, 
      The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
FAU - Tokuda, Keita
AU  - Tokuda K
AUID- ORCID: 0000-0002-0275-5541
AD  - Department of Computer Science, University of Tsukuba, Tsukuba, Ibaraki, Japan.
FAU - Konagaya, Akihiko
AU  - Konagaya A
AUID- ORCID: 0000-0001-6846-7449
AD  - Molecular Robotics Research Institute, Limited, Kyowa Create Dai-ichi, Minato-ku, 
      Tokyo, Japan.
FAU - Suzuki, Hiroshi
AU  - Suzuki H
AUID- ORCID: 0000-0002-9730-3133
AD  - Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, 
      The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220909
PL  - United States
TA  - PLoS Comput Biol
JT  - PLoS computational biology
JID - 101238922
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (NF-kappa B)
RN  - 0 (Prostaglandins I)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Anti-Inflammatory Agents
MH  - Arachidonic Acid
MH  - Aspirin/pharmacology
MH  - Models, Biological
MH  - *NF-kappa B
MH  - Prostaglandins I
MH  - *Thromboxane A2
PMC - PMC9491612
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/09/10 06:00
MHDA- 2022/09/24 06:00
CRDT- 2022/09/09 14:34
PHST- 2021/12/04 00:00 [received]
PHST- 2022/07/26 00:00 [accepted]
PHST- 2022/09/21 00:00 [revised]
PHST- 2022/09/10 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/09/09 14:34 [entrez]
AID - PCOMPBIOL-D-21-02175 [pii]
AID - 10.1371/journal.pcbi.1010441 [doi]
PST - epublish
SO  - PLoS Comput Biol. 2022 Sep 9;18(9):e1010441. doi: 10.1371/journal.pcbi.1010441. 
      eCollection 2022 Sep.

PMID- 24236750
OWN - NLM
STAT- MEDLINE
DCOM- 20140929
LR  - 20211021
IS  - 2000-1967 (Electronic)
IS  - 0300-9734 (Print)
IS  - 0300-9734 (Linking)
VI  - 119
IP  - 1
DP  - 2014 Mar
TI  - Aspirin resistance in patients with type II diabetes mellitus.
PG  - 25-31
LID - 10.3109/03009734.2013.861549 [doi]
AB  - BACKGROUND: Diabetic patients exhibit platelet hyperreactivity, which renders 
      them resistant to antithrombotic treatments. We aimed to investigate the 
      prevalence and predictors of aspirin resistance in diabetic patients. MATERIAL 
      AND METHODS: A total of 93 diabetic and 37 non-diabetic participants were 
      included into the study. Aspirin resistance was measured with a whole-blood 
      desktop platelet function analyzer (PFA-100) with an epinephrine agonist. 
      RESULTS: Altogether 41.9% patients with DM were aspirin non-responders. Aspirin 
      resistance was observed in 43.2% of non-diabetic patients (p = 0.89). Presence of 
      diabetes mellitus had no effect on aspirin response (RR 0.95 (95% CI 0.44-2.05), 
      p = 0.89) in the whole study population. Hypercholesterolemia was the only 
      predictor of aspirin resistance in multivariate analysis in diabetic patients (RR 
      3.09 (95% CI 1.17-8.16), p = 0.023). CONCLUSION: The prevalence of aspirin 
      resistance is comparable in diabetic and non-diabetic patients. 
      Hypercholesterolemia is the only independent predictor of aspirin resistance in 
      diabetic patients.
FAU - Tasdemir, Eyyup
AU  - Tasdemir E
AD  - Department of Internal Medicine, Van Training and Research Hospital , Van , 
      Turkey.
FAU - Toptas, Tayfur
AU  - Toptas T
FAU - Demir, Cengiz
AU  - Demir C
FAU - Esen, Ramazan
AU  - Esen R
FAU - Atmaca, Murat
AU  - Atmaca M
LA  - eng
PT  - Journal Article
DEP - 20131118
PL  - Sweden
TA  - Ups J Med Sci
JT  - Upsala journal of medical sciences
JID - 0332203
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ups J Med Sci. 2014 Aug;119(3):292-3. PMID: 24835796
CIN - Ups J Med Sci. 2014 Aug;119(3):294. PMID: 24835797
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
PMC - PMC3916714
EDAT- 2013/11/19 06:00
MHDA- 2014/09/30 06:00
CRDT- 2013/11/19 06:00
PHST- 2013/11/19 06:00 [entrez]
PHST- 2013/11/19 06:00 [pubmed]
PHST- 2014/09/30 06:00 [medline]
AID - UPS_A_861549_O [pii]
AID - 10.3109/03009734.2013.861549 [doi]
PST - ppublish
SO  - Ups J Med Sci. 2014 Mar;119(1):25-31. doi: 10.3109/03009734.2013.861549. Epub 
      2013 Nov 18.

PMID- 34702153
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220401
IS  - 1875-6638 (Electronic)
IS  - 1573-4064 (Linking)
VI  - 18
IP  - 5
DP  - 2022
TI  - Screening of Synthetic Heterocyclic Compounds as Antiplatelet Drugs.
PG  - 536-543
LID - 10.2174/1573406417666211026150658 [doi]
AB  - BACKGROUND: Antiplatelet drugs represent the keystone in the treatment and 
      prevention of diseases of ischemic origin, including coronary artery disease. The 
      current palette of drugs represents efficient modalities in most cases, but their 
      effect can be limited in certain situations or associated with specific side 
      effects. In this study, representatives of compounds selected from series having 
      scaffolds with known or potential antiplatelet activity were tested. These 
      compounds were previously synthetized by us, but their biological effects have 
      not yet been reported. OBJECTIVE: The aim of this study was to examine the 
      antiplatelet and anticoagulation properties of selected compounds and determine 
      their mechanism of action. METHODS: Antiplatelet activity of compounds and their 
      mechanisms of action were evaluated using human blood by impedance aggregometry 
      and various aggregation inducers and inhibitors and compared to appropriate 
      standards. Cytotoxicity was tested using breast adenocarcinoma cell cultures and 
      potential anticoagulation activity was also determined. RESULTS: In total, four 
      of 34 compounds tested were equally or more active than the standard antiplatelet 
      drug Acetylsalicylic Acid (ASA). In contrast to ASA, all 4 active compounds 
      decreased platelet aggregation triggered not only by collagen, but also partly by 
      ADP. The major mechanism of action is based on antagonism at thromboxane 
      receptors. In higher concentrations, inhibition of thromboxane synthase was also 
      noted. In contrast to ASA, the tested compounds did not block cyclooxygenase- 1. 
      CONCLUSION: The most active compound, 
      2-amino-4-(1H-indol-3-yl)-6-nitro-4H-chromene-3- carbonitrile (2-N), which is 
      4-5x times more potent than ASA, is a promising compound for the development of 
      novel antiplatelet drugs.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Hrubša, Marcel
AU  - Hrubša M
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles 
      University, Hradec Králové, Czech Republic.
FAU - Nurjamal, Khondekar
AU  - Nurjamal K
AD  - Department of Chemistry, Visva-Bharati (Central University), Santiniketan, India.
FAU - Carazo, Alejandro
AU  - Carazo A
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles 
      University, Hradec Králové, Czech Republic.
FAU - Nayek, Nayana
AU  - Nayek N
AD  - Department of Chemistry, Visva-Bharati (Central University), Santiniketan, India.
FAU - Karlíčková, Jana
AU  - Karlíčková J
AD  - Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, 
      Hradec Králové, Czech Republic.
FAU - Applová, Lenka
AU  - Applová L
AD  - Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, 
      Hradec Králové, Czech Republic.
FAU - Karmakar, Indrajit
AU  - Karmakar I
AD  - Department of Chemistry, Visva-Bharati (Central University), Santiniketan, India.
FAU - Parvin, Shamima
AU  - Parvin S
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Hradec 
      Králové, Czech Republic.
FAU - Fadraersada, Jaka
AU  - Fadraersada J
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles 
      University, Hradec Králové, Czech Republic.
FAU - Macáková, Kateřina
AU  - Macáková K
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Hradec 
      Králové, Czech Republic.
FAU - Mladěnka, Přemysl
AU  - Mladěnka P
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles 
      University, Hradec Králové, Czech Republic.
FAU - Brahmachari, Goutam
AU  - Brahmachari G
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Hradec 
      Králové, Czech Republic.
LA  - eng
GR  - CZ.02.1.01/0.0/0.0/16_019/0000841/EFSA-CDN project/
GR  - SVV 260 549/Charles University/
PT  - Journal Article
PL  - Netherlands
TA  - Med Chem
JT  - Medicinal chemistry (Shariqah (United Arab Emirates))
JID - 101240303
RN  - 0 (Heterocyclic Compounds)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets
MH  - *Heterocyclic Compounds/pharmacology
MH  - Humans
MH  - Platelet Aggregation
MH  - *Platelet Aggregation Inhibitors/pharmacology
OTO - NOTNLM
OT  - Pyridopyrimidine
OT  - acridine
OT  - aggregation
OT  - coagulation
OT  - coumarin
OT  - indole
EDAT- 2021/10/28 06:00
MHDA- 2022/04/01 06:00
CRDT- 2021/10/27 05:34
PHST- 2021/04/30 00:00 [received]
PHST- 2021/07/03 00:00 [revised]
PHST- 2021/08/25 00:00 [accepted]
PHST- 2021/10/28 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2021/10/27 05:34 [entrez]
AID - MC-EPUB-118568 [pii]
AID - 10.2174/1573406417666211026150658 [doi]
PST - ppublish
SO  - Med Chem. 2022;18(5):536-543. doi: 10.2174/1573406417666211026150658.

PMID- 15346099
OWN - NLM
STAT- MEDLINE
DCOM- 20050630
LR  - 20210818
IS  - 1530-6550 (Print)
IS  - 1530-6550 (Linking)
VI  - 5
IP  - 3
DP  - 2004 Summer
TI  - Aspirin resistance: current concepts.
PG  - 156-63
AB  - Aspirin is an effective antiplatelet agent with proven benefit in the prevention 
      of atherothrombotic complications of cardiovascular disease. The antithrombotic 
      effects of aspirin, however, are variable among individuals and this might 
      explain, in part, why the absolute risk of recurrent vascular events in patients 
      receiving aspirin therapy remains relatively high (8% - 18% after 2 years). 
      Although formal diagnostic criteria are lacking, aspirin resistance generally 
      describes the failure of aspirin to produce an expected biological response or 
      the failure of aspirin to prevent atherothrombotic events. Aspirin resistance has 
      been reported to occur in 5% to 45% of the general population; therefore, its 
      detection is potentially of clinical importance. The biological mechanisms, 
      population prevalence, laboratory methods for detection, and clinical relevance 
      of aspirin resistance are discussed in this review.
FAU - Mason, Peter J
AU  - Mason PJ
AD  - Section of Cardiology, Boston University Medical Center, Boston, Massachusetts, 
      USA.
FAU - Freedman, Jane E
AU  - Freedman JE
FAU - Jacobs, Alice K
AU  - Jacobs AK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Singapore
TA  - Rev Cardiovasc Med
JT  - Reviews in cardiovascular medicine
JID - 100960007
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Cardiovascular Diseases/drug therapy/physiopathology
MH  - Drug Resistance/*drug effects
MH  - Fibrinolytic Agents/pharmacokinetics/pharmacology
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/*pharmacology
RF  - 49
EDAT- 2004/09/04 05:00
MHDA- 2005/07/01 09:00
CRDT- 2004/09/04 05:00
PHST- 2004/09/04 05:00 [pubmed]
PHST- 2005/07/01 09:00 [medline]
PHST- 2004/09/04 05:00 [entrez]
PST - ppublish
SO  - Rev Cardiovasc Med. 2004 Summer;5(3):156-63.

PMID- 6689225
OWN - NLM
STAT- MEDLINE
DCOM- 19840224
LR  - 20190904
IS  - 0163-4356 (Print)
IS  - 0163-4356 (Linking)
VI  - 5
IP  - 4
DP  - 1983
TI  - Salicylic acid plasma levels following multiple doses of Norgesic Forte and 
      aspirin.
PG  - 401-4
AB  - Plasma salicyclic acid levels from the recommended multiple dose regimen of 
      Norgesic Forte (orphenadrine citrate, aspirin, and caffeine) were compared to 
      those from an equivalent multiple dose regimen of aspirin alone in 24 volunteers. 
      The drugs were administered double-blind so that side effects could also be 
      compared. No statistically significant differences were found between Norgesic 
      Forte and aspirin in peak or trough levels, time to peak level, area under the 
      curve, or mean steady-state level of salicylic acid. Mean steady-state levels 
      averaged 154 +/- 46 (+/- SD) and 152 +/- 49 micrograms/ml on days 5 and 10 
      following Norgesic Forte versus 161 +/- 49 and 154 +/- 47 micrograms/ml following 
      aspirin. Thus, the aspirin in Norgesic Forte provides an anti-inflammatory amount 
      of salicylic acid equivalent to that of plain aspirin. There was no evidence that 
      the combination of orphenadrine citrate, caffeine, and aspirin in Norgesic Forte 
      caused increased or unusual side effects compared with aspirin alone.
FAU - Harrison, L I
AU  - Harrison LI
FAU - Kehe, C R
AU  - Kehe CR
FAU - Goldlust, M B
AU  - Goldlust MB
FAU - Kvam, D C
AU  - Kvam DC
FAU - Bianchine, J R
AU  - Bianchine JR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ther Drug Monit
JT  - Therapeutic drug monitoring
JID - 7909660
RN  - 0 (Drug Combinations)
RN  - 0 (Salicylates)
RN  - 3G6A5W338E (Caffeine)
RN  - 88566-80-7 (Norgesic forte)
RN  - AL805O9OG9 (Orphenadrine)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*metabolism
MH  - Caffeine/*metabolism
MH  - Double-Blind Method
MH  - Drug Combinations/metabolism
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Orphenadrine/*metabolism
MH  - Salicylates/*blood
MH  - Salicylic Acid
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1097/00007691-198312000-00004 [doi]
PST - ppublish
SO  - Ther Drug Monit. 1983;5(4):401-4. doi: 10.1097/00007691-198312000-00004.

PMID- 16579883
OWN - NLM
STAT- MEDLINE
DCOM- 20060407
LR  - 20131121
IS  - 1603-6824 (Electronic)
IS  - 0041-5782 (Linking)
VI  - 168
IP  - 13
DP  - 2006 Mar 27
TI  - [Combination therapy with acetylsalicylic acid and non-aspirin nonsteroidal 
      anti-inflammatory drugs].
PG  - 1310-4
AB  - Patients may require both low-dose aspirin (ASA) and a nonsteroidal 
      anti-inflammatory drug (NSAID). This raises the questions of whether NSAIDs may 
      inhibit the cardioprotective effects of low-dose ASA; whether the 
      cardioprotective effect of low-dose ASA can be obtained by NSAIDs: and whether 
      the combination of low-dose ASA and NSAIDs increases the risk of adverse effects. 
      This review attempts to answer these questions.
FAU - Reuther, Lene Ørskov
AU  - Reuther LØ
AD  - H:S Bispebjerg Hospital, Klinisk Farmakologisk Enhed, København NV. 
      lr15@bbh.hosp.dk
FAU - Andersen, Stig Ejdrup
AU  - Andersen SE
LA  - dan
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Kombinationsbehandling med acetylsalicylsyre og nonsteroide antiinflammatoriske 
      laegemidler.
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cardiotonic Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects/antagonists & inhibitors
MH  - Cardiotonic Agents/administration & dosage/adverse effects/antagonists & 
      inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ibuprofen/administration & dosage/adverse effects
MH  - Risk Factors
RF  - 26
EDAT- 2006/04/04 09:00
MHDA- 2006/04/08 09:00
CRDT- 2006/04/04 09:00
PHST- 2006/04/04 09:00 [pubmed]
PHST- 2006/04/08 09:00 [medline]
PHST- 2006/04/04 09:00 [entrez]
AID - VP46104 [pii]
PST - ppublish
SO  - Ugeskr Laeger. 2006 Mar 27;168(13):1310-4.

PMID- 1303395
OWN - NLM
STAT- MEDLINE
DCOM- 19930624
LR  - 20161123
IS  - 0016-9919 (Print)
IS  - 0016-9919 (Linking)
IP  - 11-12
DP  - 1992
TI  - [Photometric and chromatographic methods of measuring the concentration of 
      acelysin in the air of a work area].
PG  - 35-7
AB  - Two methods were applied to evaluation of acelysine level. Spectrophotometric one 
      was based on reaction with p-nitrophenyldiasonium and evaluation of the product 
      optic density at 510 nm. The second was chromatography in thin layer, where a 
      mixture of n-butanol, formic acid and water was used as an eluent and 0.2% 
      ninhydrin solution in butanol and 3 ml of ice acetic acid (60-70 degrees C) 
      served as a developer. Both methods are supposed to evaluate acelysine level in 
      the air of working area, when a half of MAC and admixtures are present.
FAU - Ivaniuk, E G
AU  - Ivaniuk EG
FAU - Kolievskaia, Iu A
AU  - Kolievskaia IuA
FAU - Pisareva, N E
AU  - Pisareva NE
FAU - Mikhaĭlik, S V
AU  - Mikhaĭlik SV
FAU - Perets, I D
AU  - Perets ID
LA  - rus
PT  - Journal Article
TT  - Fotometricheskiĭ i khromatograficheskiĭ sposoby izmereniia kontsentratsii 
      atselizina v vozdukhe rabocheĭ zony.
PL  - Russia (Federation)
TA  - Gig Tr Prof Zabol
JT  - Gigiena truda i professional'nye zabolevaniia
JID - 2985104R
RN  - 0 (Aerosols)
RN  - 0 (Air Pollutants, Occupational)
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (acetylsalicylate, glycine, lysine drug combination)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aerosols
MH  - Air Pollutants, Occupational/*analysis
MH  - Anti-Infective Agents/*analysis
MH  - Aspirin/*analogs & derivatives/analysis
MH  - Calibration
MH  - Chromatography, Thin Layer/instrumentation/methods
MH  - Colorimetry/instrumentation/methods
MH  - Drug Combinations
MH  - Filtration/instrumentation
MH  - *Glycine
MH  - Lysine/*analogs & derivatives/analysis
MH  - Spectrophotometry/instrumentation/methods
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Gig Tr Prof Zabol. 1992;(11-12):35-7.

PMID- 20222062
OWN - NLM
STAT- MEDLINE
DCOM- 20100701
LR  - 20180816
IS  - 1521-4184 (Electronic)
IS  - 0365-6233 (Linking)
VI  - 343
IP  - 4
DP  - 2010 Apr
TI  - Novel conjugates of aspirin with phenolic acid as anti-inflammatory agents having 
      significantly reduced gastrointestinal toxicity.
PG  - 215-21
LID - 10.1002/ardp.200900217 [doi]
AB  - A series of novel conjugates of aspirin with natural phenolic acid antioxidants 
      connected through a diol linker were designed and synthesized as potential 
      bifunctional agents combining antioxidant and anti-inflammatory activity for 
      reducing gastrointestinal toxicity. In general, the conjugates were found to be 
      efficient antioxidants and many of them demonstrated much more potent 
      anti-inflammatory activity than aspirin. Among them, 5a and 5b which bear the 
      best anti-inflammatory activity exhibited significantly reduced ulcerogenic 
      potency and toxicity compared to aspirin. However, it is evident that the 
      anti-inflammatory activity of these dual-acting molecules in vivo, was not simply 
      consistent with their antioxidant ability in vitro.
FAU - Jiang, Shan
AU  - Jiang S
AD  - School of Medicine and Pharmacy, Ocean University of China, Qingdao, PR China.
FAU - Ding, Ning
AU  - Ding N
FAU - Zhang, Wei
AU  - Zhang W
FAU - Zhang, Yichun
AU  - Zhang Y
FAU - Geng, Meiyu
AU  - Geng M
FAU - Li, Yingxia
AU  - Li Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Arch Pharm (Weinheim)
JT  - Archiv der Pharmazie
JID - 0330167
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Picrates)
RN  - 8001-28-3 (Croton Oil)
RN  - DFD3H4VGDH (1,1-diphenyl-2-picrylhydrazyl)
RN  - I3P9R8317T (phenolic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/chemical synthesis/*pharmacology/toxicity
MH  - Antioxidants/chemical synthesis/*pharmacology/toxicity
MH  - Aspirin/analogs & derivatives/chemical synthesis/*pharmacology/toxicity
MH  - Biphenyl Compounds/chemistry
MH  - Croton Oil
MH  - Disease Models, Animal
MH  - *Drug Design
MH  - Hydroxybenzoates/chemical synthesis/*pharmacology/toxicity
MH  - Inflammation/chemically induced/metabolism/*prevention & control
MH  - Lipid Peroxidation/drug effects
MH  - Male
MH  - Mice
MH  - Molecular Structure
MH  - Picrates/chemistry
MH  - Stomach Ulcer/chemically induced/metabolism/*prevention & control
MH  - Structure-Activity Relationship
EDAT- 2010/03/12 06:00
MHDA- 2010/07/02 06:00
CRDT- 2010/03/12 06:00
PHST- 2010/03/12 06:00 [entrez]
PHST- 2010/03/12 06:00 [pubmed]
PHST- 2010/07/02 06:00 [medline]
AID - 10.1002/ardp.200900217 [doi]
PST - ppublish
SO  - Arch Pharm (Weinheim). 2010 Apr;343(4):215-21. doi: 10.1002/ardp.200900217.

PMID- 10634286
OWN - NLM
STAT- MEDLINE
DCOM- 20000128
LR  - 20191103
IS  - 1090-3127 (Print)
IS  - 1090-3127 (Linking)
VI  - 4
IP  - 1
DP  - 2000 Jan-Mar
TI  - Education of paramedics regarding aspirin use.
PG  - 62-4
AB  - OBJECTIVE: Paramedics (EMT-Ps) often care for patients having an acute myocardial 
      infarction (AMI). The benefit of early administration of aspirin in AMI is well 
      established. This study was undertaken to determine whether EMT-Ps are able to 
      retain information regarding the use of aspirin in AMI after a standard didactic 
      session. METHODS: The EMT-Ps from a suburban EMS system with an annual call 
      volume of 4,000 were given a 12-question test regarding the out-of-hospital use 
      of aspirin in AMI. They then received a 30-minute lecture about the use of 
      aspirin in the out-of-hospital venue. Aspirin was then put into the treatment 
      protocols for AMI. Three months after the educational session, a follow-up test 
      was administered. A paired, two-tailed t-test was used to compare pretest and 
      posttest scores with a p < or = 0.05 for statistical significance. RESULTS: The 
      study was completed by 22 of 25 EMT-Ps. The scores on the pretest ranged from 50% 
      to 100% correct, with an average score of 83%. The posttest scores ranged from 
      83% to 100%, with an average score of 94% (p = 0.002). The questions missed on 
      the posttest were regarding: 1) the length of the effects of aspirin, 2) the 
      bronchospastic effects of aspirin, and 3) the recently instituted indications for 
      its out-of-hospital use. All paramedics correctly identified the 
      contraindications to aspirin use. CONCLUSION: These results suggest that EMT-Ps 
      can retain information regarding the out-of-hospital use of aspirin for AMI after 
      a standard didactic session. Further study is needed to determine how this 
      information is clinically applicable.
FAU - Funk, D
AU  - Funk D
AD  - Department of Emergency Medicine, Albany Medical College, New York 12208, USA. 
      dfunk@empireone.net
FAU - Groat, C
AU  - Groat C
FAU - Verdile, V P
AU  - Verdile VP
LA  - eng
PT  - Journal Article
PL  - England
TA  - Prehosp Emerg Care
JT  - Prehospital emergency care
JID - 9703530
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Educational Measurement
MH  - *Emergency Medical Services
MH  - Emergency Medical Technicians/*education
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Suburban Health Services
MH  - United States
EDAT- 2000/01/14 00:00
MHDA- 2000/01/14 00:01
CRDT- 2000/01/14 00:00
PHST- 2000/01/14 00:00 [pubmed]
PHST- 2000/01/14 00:01 [medline]
PHST- 2000/01/14 00:00 [entrez]
AID - S1090312700501373 [pii]
AID - 10.1080/10903120090941678 [doi]
PST - ppublish
SO  - Prehosp Emerg Care. 2000 Jan-Mar;4(1):62-4. doi: 10.1080/10903120090941678.

PMID- 7789736
OWN - NLM
STAT- MEDLINE
DCOM- 19950727
LR  - 20190825
IS  - 0306-3623 (Print)
IS  - 0306-3623 (Linking)
VI  - 26
IP  - 3
DP  - 1995 May
TI  - Lipid peroxidation and antioxidant enzyme activity in aspirin-treated rats.
PG  - 613-7
AB  - 1. Malondialdehyde formation and antioxidant enzyme activity after oral or 
      intraperitoneal treatment of rats with various doses of aspirin was studied. 2. 
      Aspirin, orally, had no effect on spontaneous, Fe(II)- or 
      Fe(II)/ascorbate-induced malondialdehyde formation in liver homogenates; orally, 
      ascorbate-induced malondialdehyde production was inhibited but only after 5-day 
      treatment with 500 mg/kg aspirin; after intraperitoneal injection, the drug 
      inhibited ascorbate- and Fe(II)/ascorbate-induced production of malondialdehyde. 
      3. Aspirin had no effect on malondialdehyde formation in erythrocytes, 
      irrespective of the dose and route of drug administration. 4. Aspirin increased 
      glutathione peroxidase activity in liver after 5-day treatment with an oral dose 
      of 500 mg/kg and decreased enzyme activity in both liver and erythrocytes, 24 hr 
      after a single injection of the same dose. 5. Aspirin, in vivo slightly affected 
      lipid peroxidation and antioxidant enzyme activity.
FAU - Kirkova, M
AU  - Kirkova M
AD  - Institute of Physiology, Bulgarian Academy of Sciences, Sofia.
FAU - Ivancheva, E
AU  - Ivancheva E
FAU - Russanov, E
AU  - Russanov E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gen Pharmacol
JT  - General pharmacology
JID - 7602417
RN  - 0 (Antioxidants)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Antioxidants/*metabolism
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Erythrocytes/drug effects/enzymology
MH  - Glutathione Peroxidase/metabolism
MH  - In Vitro Techniques
MH  - Injections, Intraperitoneal
MH  - Lipid Peroxidation/*drug effects
MH  - Liver/drug effects/enzymology
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Rats
MH  - Rats, Wistar
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
AID - 030636239400234E [pii]
AID - 10.1016/0306-3623(94)00234-e [doi]
PST - ppublish
SO  - Gen Pharmacol. 1995 May;26(3):613-7. doi: 10.1016/0306-3623(94)00234-e.

PMID- 19905844
OWN - NLM
STAT- MEDLINE
DCOM- 20100305
LR  - 20131121
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 21
IP  - 1
DP  - 2010
TI  - Massive GI bleeding due to accidental ASA inhalation.
PG  - 67-9
LID - 10.3109/09537100903324227 [doi]
AB  - This report describes a 38-year-old man admitted to hospital for a massive rectal 
      bleeding and syncope. He was known to have idiopathic thrombocytopenia but he had 
      never complained of bleeding until he was admitted to hospital with uncontrolled 
      hemorrhage. Upper and lower endoscopic examination, performed 6 hours after 
      occurrence of bleeding, were negative for ulcers or other bleeding lesions. 
      However, capsule endoscopy did detect diffuse areas of petechial hemorrhage and 
      erosions in the small bowel. Thromboelastography performed on the day of 
      admission showed a marked decrease in platelet aggregation rate, that normalized 
      two days after. The patient recovered with conservative treatment only. Thorough 
      questioning did not evidence relevant events apart from inhalation of a massive 
      quantity of acetylsalicylic acid: the patient, working as a farmer, had prepared, 
      without protection, fodder for the animals containing a great amount of 
      acetylsalicylic acid. Bleeding had started few hours thereafter. After recovery, 
      bleeding did not recur despite persistent thrombocytopenia.
FAU - Bianchini, Marcello
AU  - Bianchini M
AD  - Gastroenterology and Hepatology Unit, Policlinico di Modena, Modena, Italy.
FAU - Cavina, Maurizio
AU  - Cavina M
FAU - Boarino, Valentina
AU  - Boarino V
FAU - Begliomini, Bruno
AU  - Begliomini B
FAU - De Maria, Nicola
AU  - De Maria N
FAU - Villa, Erica
AU  - Villa E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Animal Feed
MH  - Animals
MH  - *Aspirin/administration & dosage/poisoning
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Occupational Exposure
MH  - *Platelet Aggregation Inhibitors/administration & dosage/poisoning
MH  - Swine
MH  - Thrombelastography
EDAT- 2009/11/13 06:00
MHDA- 2010/03/06 06:00
CRDT- 2009/11/13 06:00
PHST- 2009/11/13 06:00 [entrez]
PHST- 2009/11/13 06:00 [pubmed]
PHST- 2010/03/06 06:00 [medline]
AID - 10.3109/09537100903324227 [pii]
AID - 10.3109/09537100903324227 [doi]
PST - ppublish
SO  - Platelets. 2010;21(1):67-9. doi: 10.3109/09537100903324227.

PMID- 7440766
OWN - NLM
STAT- MEDLINE
DCOM- 19810219
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 20
IP  - 10
DP  - 1980 Oct
TI  - Mild analgesics as an alternative to ergotamine in migraine. A comparative trial 
      with acetylsalicylic acid, ergotamine tartrate, and a dextropropoxyphene 
      compound.
PG  - 590-5
AB  - The effect of ergotamine tartrate was compared with that of acetylsalicylic acid 
      and a dextropropoxyphene compound (Doleron novum) on 525 acute migraine attacks 
      in a double-blind crossover study of 25 adult female patients. Ergotamine 
      tartrate and the dextropropoxyphene compound were equally effective and 
      significantly superior to acetylsalicylic acid in preventing the attacks 
      entirely. If the attacks were only partially prevented, the dextropropoxyphene 
      compound was significantly superior to acetylsalicylic acid in making the attacks 
      shorter and milder, while ergotamine tartrate did not differ significantly from 
      acetylsalicylic acid or the dextropropoxyphene compound. The incidence of nausea 
      and vomiting was lowest during treatment with the dextropropoxyphene compound. In 
      the patients' overall preference, the dextropropoxyphene compound and ergotamine 
      tartrate were significantly superior to acetyl-salicylic acid. In acute migraine 
      the combination of dextropropoxyphene, a centrally acting analgesic, with 
      acetylsalicylic acid and phenazone gives an alternative to ergotamine tartrate 
      that is equally effective and causes less nausea and vomiting.
FAU - Hakkarainen, H
AU  - Hakkarainen H
FAU - Quiding, H
AU  - Quiding H
FAU - Stockman, O
AU  - Stockman O
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - PR834Q503T (Ergotamine)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Dextropropoxyphene/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Ergotamine/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy/prevention & control
EDAT- 1980/10/01 00:00
MHDA- 1980/10/01 00:01
CRDT- 1980/10/01 00:00
PHST- 1980/10/01 00:00 [pubmed]
PHST- 1980/10/01 00:01 [medline]
PHST- 1980/10/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1980.tb01674.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1980 Oct;20(10):590-5. doi: 10.1002/j.1552-4604.1980.tb01674.x.

PMID- 3180636
OWN - NLM
STAT- MEDLINE
DCOM- 19881221
LR  - 20190510
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 44
IP  - 5
DP  - 1988 Nov
TI  - Persistent gastric-protective effect of antacid evaluated by measurement of 
      transmucosal gastric potential difference.
PG  - 546-9
AB  - The aim of this study was to determine the effect of 1 week of antacid dosing on 
      the aspirin-induced potential differences (PDs) across the gastric mucosa. The 
      study design was double blind and randomized with crossover. Ten healthy subjects 
      received aluminum hydroxide gel, 8 gm t.i.d., or placebo for 1 week. They then 
      received 1 gm aspirin after an overnight fast and the PD across the mucosa was 
      measured. Baseline potentials were the same before both treatment periods. 
      Antacids reduced the aspirin-induced PDs. The mean (+/- SD) maximal PD was 27.4 
      +/- 1.7 mV with placebo vs. 10.7 +/- 2.2 mV with antacids (p less than 0.001). 
      Recovery time was 65.5 +/- 5.2 minutes with placebo vs. 29.0 +/- 6.7 minutes with 
      antacids (p less than 0.001). These results suggest the effect is due to a 
      longer-term cytoprotective property of antacids rather than to acid-neutralizing 
      activity.
FAU - Bergmann, J F
AU  - Bergmann JF
AD  - Clinique Thérapeutique, Hôpital Lariboisière, Université Paris VII, France.
FAU - Caulin, C
AU  - Caulin C
FAU - Simoneau, G
AU  - Simoneau G
FAU - Dorf, G
AU  - Dorf G
FAU - Segrestaa, J M
AU  - Segrestaa JM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Antacids)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aluminum Hydroxide/pharmacology
MH  - Antacids/administration & dosage/*pharmacology
MH  - Aspirin/adverse effects/antagonists & inhibitors
MH  - Double-Blind Method
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Male
MH  - Membrane Potentials/drug effects
MH  - Random Allocation
MH  - Time Factors
EDAT- 1988/11/01 00:00
MHDA- 1988/11/01 00:01
CRDT- 1988/11/01 00:00
PHST- 1988/11/01 00:00 [pubmed]
PHST- 1988/11/01 00:01 [medline]
PHST- 1988/11/01 00:00 [entrez]
AID - 0009-9236(88)90524-3 [pii]
AID - 10.1038/clpt.1988.192 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1988 Nov;44(5):546-9. doi: 10.1038/clpt.1988.192.

PMID- 16100874
OWN - NLM
STAT- MEDLINE
DCOM- 20050906
LR  - 20180908
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 123 Suppl
DP  - 2005 Jun
TI  - Aspirin resistance: moving forward with multiple definitions, different assays, 
      and a clinical imperative.
PG  - S125-32
AB  - Many patients are treated with aspirin to prevent a serious vascular event, most 
      notably myocardial infarction and stroke. A growing number of studies have been 
      appearing in the literature that indicate a significant fraction of 
      aspirin-treated patients may be resistant to the antiplatelet effects of the 
      drug. Resistance to aspirin may be related to the concomitant ingestion of 
      aspirin and nonsteroidal anti-inflammatory drugs, which impairs the aspirin 
      effect, or to more complex situations, such as metabolic defects that diminish 
      the therapeutic effect of aspirin. The incidence of aspirin resistance is 
      unknown, but it may approach 20% to 30%. The diagnosis of aspirin resistance has 
      been evaluated using multiple assays, and because there are multiple assays, this 
      has resulted in multiple definitions for aspirin resistance. This review 
      considers aspirin resistance at a time when there is confusion about the 
      definition, and the clinical assay to best assess it, because there is a clinical 
      imperative to know now which patients taking aspirin are not receiving a 
      therapeutic effect.
FAU - Knoepp, Stewart M
AU  - Knoepp SM
AD  - Division of Laboratory Medicine, Department of Pathology, Massachusetts General 
      Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Laposata, Michael
AU  - Laposata M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation Tests/methods
MH  - Blood Platelets/drug effects
MH  - Drug Resistance/*physiology
MH  - Humans
RF  - 57
EDAT- 2005/08/17 09:00
MHDA- 2005/09/07 09:00
CRDT- 2005/08/17 09:00
PHST- 2005/08/17 09:00 [pubmed]
PHST- 2005/09/07 09:00 [medline]
PHST- 2005/08/17 09:00 [entrez]
AID - 10.1309/014UKWNQLN7CVYXX [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2005 Jun;123 Suppl:S125-32. doi: 10.1309/014UKWNQLN7CVYXX.

PMID- 25776467
OWN - NLM
STAT- MEDLINE
DCOM- 20160125
LR  - 20150429
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 135
IP  - 5
DP  - 2015 May
TI  - Characterization of platelet aggregation responses in microminipigs: Comparison 
      with miniature pigs and the influence of dual antiplatelet administration of 
      aspirin plus prasugrel.
PG  - 933-8
LID - S0049-3848(15)00086-9 [pii]
LID - 10.1016/j.thromres.2015.02.014 [doi]
AB  - We aimed to characterize platelet aggregation responses and the impact of dual 
      antiplatelet therapy in microminipigs. In this in vitro study, both 
      adenosine-5'-diphosphate (ADP, 5-50μM) and collagen (2-20μg/ml) induced 
      concentration-related platelet aggregation in the microminipigs; 20μM ADP and 5 
      and 12.5μg/ml collagen were selected for further ex vivo studies. Aspirin plus 
      prasugrel were administered orally for 7days (n=4/each group). Ex vivo platelet 
      aggregation was analyzed on Day 1 (1 and 4h after administration), Day 4 (4h), 
      and Day 7 (4h) under three different prasugrel dosing regimens: LD0/MD1 
      (1mg/kg/day), LD0/MD3 (3mg/kg/day), and LD10/MD1 (10mg/kg loading dose and 
      1mg/kg/day maintenance dose). Aspirin (10mg/kg/day) was administered to all 
      groups. In the presence of aspirin, prasugrel at 3 and 10mg/kg significantly 
      inhibited ADP-induced platelet aggregation on Day 1. On Days 4 and 7, significant 
      inhibition of platelet aggregation (IPA) was also observed in each group. With 
      5μg/ml collagen-induced platelet aggregation, all three groups showed significant 
      IPA at 4h on Day 1 or later. In 12.5μg/ml collagen-induced platelet aggregation, 
      all groups showed significant effects on Days 4 and 7; however, the 30%-35% IPA 
      was considerably lower than that (50%-60%) found with 5μg/ml collagen. In Clawn 
      miniature pigs, similar inhibitory patterns were observed for both ADP- and 
      collagen-induced ex vivo platelet aggregation. In conclusion, these results 
      indicated that microminipigs as well as miniature pigs may represent useful 
      experimental animals for thrombosis research.
CI  - Copyright © 2015 Elsevier Ltd. All rights reserved.
FAU - Ohno, Kousaku
AU  - Ohno K
AD  - Biological Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
FAU - Tomizawa, Atsuyuki
AU  - Tomizawa A
AD  - Biological Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
FAU - Jakubowski, Joseph A
AU  - Jakubowski JA
AD  - Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Mizuno, Makoto
AU  - Mizuno M
AD  - Biological Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
FAU - Sugidachi, Atsuhiro
AU  - Sugidachi A
AD  - Biological Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan. 
      Electronic address: sugidachi.atsuhiro.r7@daiichisankyo.co.jp.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20150221
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/cytology/*drug effects
MH  - Drug Therapy, Combination
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Function Tests
MH  - Prasugrel Hydrochloride/administration & dosage/*therapeutic use
MH  - Swine
MH  - Swine, Miniature
OTO - NOTNLM
OT  - Antiplatelet
OT  - Aspirin
OT  - Microminipig
OT  - Miniature Pig
OT  - Platelet Aggregation
OT  - Prasugrel
EDAT- 2015/03/18 06:00
MHDA- 2016/01/26 06:00
CRDT- 2015/03/18 06:00
PHST- 2014/10/06 00:00 [received]
PHST- 2015/02/03 00:00 [revised]
PHST- 2015/02/07 00:00 [accepted]
PHST- 2015/03/18 06:00 [entrez]
PHST- 2015/03/18 06:00 [pubmed]
PHST- 2016/01/26 06:00 [medline]
AID - S0049-3848(15)00086-9 [pii]
AID - 10.1016/j.thromres.2015.02.014 [doi]
PST - ppublish
SO  - Thromb Res. 2015 May;135(5):933-8. doi: 10.1016/j.thromres.2015.02.014. Epub 2015 
      Feb 21.

PMID- 1360557
OWN - NLM
STAT- MEDLINE
DCOM- 19930107
LR  - 20190610
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 340
IP  - 8833
DP  - 1992 Dec 12
TI  - Double-blind trial of aspirin in primary prevention of myocardial infarction in 
      patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin 
      Trial (SAPAT) Group.
PG  - 1421-5
AB  - Clinical trials have demonstrated a prophylactic role for aspirin in myocardial 
      infarction and in unstable angina pectoris. The Swedish Angina Pectoris Aspirin 
      Trial (SAPAT) is the first prospective study of aspirin in stable angina. 2035 
      patients were randomised double-blind to treatment with aspirin 75 mg daily or 
      placebo. All patients were treated with sotalol for control of symptoms. The 
      median duration of follow-up was 50 months. Compared with the placebo+sotalol 
      group, the aspirin+sotalol group had a 34% (81 vs 124 patients) reduction in 
      primary outcome events (myocardial infarction and sudden death; 95% confidence 
      interval 24-49%; p = 0.003) and the reduction observed in secondary outcome 
      events (vascular events, vascular death, all cause mortality, stroke) ranged from 
      22% to 32%. Treatment withdrawal caused by adverse events occurred in 109 
      patients in the aspirin+sotalol group and 100 in patients in the placebo+sotalol 
      group; major bleeds, including haemorrhagic stroke, occurred in 20 and 13 
      patients, respectively (not significant). The addition of a low dose of aspirin 
      to sotalol treatment showed significant benefit in terms of cardiovascular 
      events, including a significant reduction in the incidence of first myocardial 
      infarction in patients with symptoms of stable angina pectoris.
FAU - Juul-Möller, S
AU  - Juul-Möller S
AD  - Department of Medicine, General Hospital, Malmö, Sweden.
FAU - Edvardsson, N
AU  - Edvardsson N
FAU - Jahnmatz, B
AU  - Jahnmatz B
FAU - Rosén, A
AU  - Rosén A
FAU - Sørensen, S
AU  - Sørensen S
FAU - Omblus, R
AU  - Omblus R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - A6D97U294I (Sotalol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/*complications/drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sotalol/therapeutic use
EDAT- 1992/12/12 00:00
MHDA- 1992/12/12 00:01
CRDT- 1992/12/12 00:00
PHST- 1992/12/12 00:00 [pubmed]
PHST- 1992/12/12 00:01 [medline]
PHST- 1992/12/12 00:00 [entrez]
AID - 0140-6736(92)92619-Q [pii]
AID - 10.1016/0140-6736(92)92619-q [doi]
PST - ppublish
SO  - Lancet. 1992 Dec 12;340(8833):1421-5. doi: 10.1016/0140-6736(92)92619-q.

PMID- 21688615
OWN - NLM
STAT- MEDLINE
DCOM- 20110722
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 69
IP  - 6
DP  - 2011 Jun
TI  - [Low-dose aspirin (LDA)/nonsteroidal anti-inflammatory drugs(NSAIDs)-induced 
      gastrointestinal injury in Japan].
PG  - 977-81
AB  - Low-dose aspirin (LDA) and nonsteroidal anti-inflammatory drugs (NSAIDs) are 
      frequently prescribed in Japan mostly due to increasing elderly population. Since 
      LDA/NSAIDs cause gastrointestinal injury, serious side effects such as bleeding 
      accompanied with their usage have been frequently reported. Awareness of such 
      problems prompted clinical trials to facilitate a more effective approach to 
      prevent LDA/NSAIDs-induced gastrointestinal ulcer. Two drugs recently approved 
      for health insurance reimbursement, celecoxib, a cyclooxygenase (COX)-2 specific 
      inhibitor and low-dose lansoprazole for prevention of recurrent peptic ulcer due 
      to LDA/NSAIDs will be instrumental in mitigating the gastrointestinal injuries. 
      However, continuous, intensive educational programs will be required to the 
      change in the prescription behaviors of the general physicians. Furthermore, we 
      need to search for effective measures to detect and prevent mid and lower 
      gastrointestinal injury caused by LDA/NSAIDs which account for about 30% of all 
      GI bleedings.
FAU - Sugano, Kentaro
AU  - Sugano K
AD  - Department of Medicine, Jichi Medical University.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Humans
MH  - Japan
MH  - Peptic Ulcer/*chemically induced/prevention & control
EDAT- 2011/06/22 06:00
MHDA- 2011/07/23 06:00
CRDT- 2011/06/22 06:00
PHST- 2011/06/22 06:00 [entrez]
PHST- 2011/06/22 06:00 [pubmed]
PHST- 2011/07/23 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2011 Jun;69(6):977-81.

PMID- 6703927
OWN - NLM
STAT- MEDLINE
DCOM- 19840411
LR  - 20190829
IS  - 0160-564X (Print)
IS  - 0160-564X (Linking)
VI  - 8
IP  - 1
DP  - 1984 Feb
TI  - Prevention of platelet deposition and thrombus formation on hemodialysis 
      membranes: a double-blind randomized trial of aspirin and dipyridamole.
PG  - 57-61
AB  - A double-blind crossover study comparing low-dose aspirin (ASA) and dipyridamole 
      (DPM) (100 mg ASA + 75 mg DPM, t.d.s.), high-dose ASA and DPM (300 mg ASA + 75 mg 
      DPM, t.d.s.), and placebo on platelet deposition and thrombus formation on 
      hemodialysis membranes was undertaken in 17 long-term dialysis patients. The 
      high-dose combination significantly reduced the fall in platelet count during 
      dialysis and also significantly increased postdialysis heparin concentrations. 
      Scanning electron microscopy of the Cuprophan membranes showed a reduction in 
      platelet deposition and fibrin formation during both treatment schedules, but 
      this was most marked with the high-dose combination. The results of this study 
      indicate that there is a graded response to combined ASA-DPM treatment and that 
      this can significantly reduce platelet consumption and contact activation of 
      fibrin during hemodialysis with Cuprophan membranes.
FAU - Salter, M C
AU  - Salter MC
FAU - Crow, M J
AU  - Crow MJ
FAU - Donaldson, D R
AU  - Donaldson DR
FAU - Roberts, T G
AU  - Roberts TG
FAU - Rajah, S M
AU  - Rajah SM
FAU - Davison, A M
AU  - Davison AM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Artif Organs
JT  - Artificial organs
JID - 7802778
RN  - 0 (Membranes, Artificial)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9004-34-6 (Cellulose)
RN  - 9050-09-3 (cuprammonium cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Cellulose/analogs & derivatives
MH  - Dipyridamole/administration & dosage/*pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - *Membranes, Artificial
MH  - Random Allocation
MH  - Renal Dialysis/*adverse effects
MH  - Thrombosis/prevention & control
EDAT- 1984/02/01 00:00
MHDA- 1984/02/01 00:01
CRDT- 1984/02/01 00:00
PHST- 1984/02/01 00:00 [pubmed]
PHST- 1984/02/01 00:01 [medline]
PHST- 1984/02/01 00:00 [entrez]
AID - 10.1111/j.1525-1594.1984.tb04244.x [doi]
PST - ppublish
SO  - Artif Organs. 1984 Feb;8(1):57-61. doi: 10.1111/j.1525-1594.1984.tb04244.x.

PMID- 35410859
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220716
IS  - 2148-5607 (Electronic)
IS  - 1300-4948 (Print)
IS  - 1300-4948 (Linking)
VI  - 33
IP  - 3
DP  - 2022 Mar
TI  - In Vitro and In Vivo Effects of Nonsteroidal Anti-inflammatory Drugs and Aspirin 
      on Rabbit Esophageal Epithelium.
PG  - 257-270
LID - 10.5152/tjg.2022.201168 [doi]
AB  - BACKGROUND: Gastroesophageal reflux disease has a high incidence of 23%, with 29% 
      of those with gastroesophageal reflux disease consuming nonsteroidal 
      anti-inflammatory drugs. There are insufficient data concerning the effects of 
      nonsteroidal anti-inflammatory drugs on the esophageal tissue. We aimed to 
      examine the effects of well-known nonsteroidal anti-inflammatory drugs using 
      electrophysiologic criteria on the rabbit esophageal epithelium. METHODS: 
      Esophageal epithelium mounted on Ussing chambers enabled in vitro investigation 
      of the electrophysiological properties. Doses of 1 mg/mL, 2.5 mg/mL, 5 mg/mL 
      ibuprofen, naproxen, and aspirin were dissolved in dimethyl sulfoxide and added 
      to the luminal side. Esophagi were cannulated from both sides for the 
      administration of high-dose ibuprofen in vivo, and the potential difference was 
      monitored. RESULTS: Ibuprofen and aspirin inhibited tissue transport functions in 
      a dose-dependent manner. pH 4 acid and 0.1 mg/mL ibuprofen alone were not 
      harmful; however, the combination of these agents had an additive and 
      significance effect: 78% decrease in the potential difference and 85% decrease in 
      the short-circuited current (Isc). The change in the potential difference in the 
      in vivo experiments (5 mg/mL ibuprofen) was similar (52 ± 7% decrease) with in 
      vitro experiments in the first 30 minutes. CONCLUSION: Nonsteroidal 
      anti-inflammatory drugs were harmful to the rabbit esophageal epithelium in both 
      the in vitro and in vivo experiments. Even though aspirin and ibuprofen affected 
      the transport mechanisms of the esophageal epithelium, the dose-dependent 
      decrease of tissue potential difference and Isc with ibuprofen was more 
      pronounced than those with aspirin. The combination of harmless doses of 
      ibuprofen and acid demonstrated that even low acidic conditions can create a 
      disruptive environment.
FAU - Kıpçak, Sezgi
AU  - Kıpçak S
AD  - Department of Gastroenterology, Ege University Medical School Ege Reflux Study 
      Group, İzmir, Turkey; Department of Medical Biology, Ege University Medical 
      School, İzmir, Turkey.
FAU - Çağanoğlu, Doğa
AU  - Çağanoğlu D
AD  - Department of Gastroenterology, Ege University Medical School Ege Reflux Study 
      Group, İzmir, Turkey.
FAU - Ergün, Pelin
AU  - Ergün P
AD  - Department of Gastroenterology, Ege University Medical School Ege Reflux Study 
      Group, İzmir, Turkey; Department of Medical Biochemistry, Ege University Medical 
      School, İzmir, Turkey.
FAU - Bor, Serhat
AU  - Bor S
AD  - Department of Gastroenterology, Ege University Medical School Ege Reflux Study 
      Group, İzmir, Turkey.
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Turk J Gastroenterol
JT  - The Turkish journal of gastroenterology : the official journal of Turkish Society 
      of Gastroenterology
JID - 9515841
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - *Aspirin/pharmacology
MH  - Epithelium
MH  - *Gastroesophageal Reflux
MH  - Humans
MH  - Ibuprofen/pharmacology
MH  - Rabbits
PMC - PMC9128477
EDAT- 2022/04/13 06:00
MHDA- 2022/04/14 06:00
CRDT- 2022/04/12 05:29
PHST- 2022/04/12 05:29 [entrez]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
AID - tjg-33-3-257 [pii]
AID - 10.5152/tjg.2022.201168 [doi]
PST - ppublish
SO  - Turk J Gastroenterol. 2022 Mar;33(3):257-270. doi: 10.5152/tjg.2022.201168.

PMID- 18226435
OWN - NLM
STAT- MEDLINE
DCOM- 20080513
LR  - 20181201
IS  - 0268-960X (Print)
IS  - 0268-960X (Linking)
VI  - 22
IP  - 2
DP  - 2008 Mar
TI  - Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism.
PG  - 107-16
LID - 10.1016/j.blre.2007.11.001 [doi]
AB  - While there is good evidence for a protective effect of aspirin against occlusive 
      vascular events in individuals with arterial disease, its role in preventing 
      venous thromboembolism (VTE) is unclear. In this article we review the role of 
      aspirin and other antiplatelet drugs in prevention of venous thromboembolism in 
      surgical patients, high risk medical patients requiring aspirin for other 
      reasons, patients with myeloproliferative disorders, long distance travellers and 
      patients receiving treatment with the IMiD class of drugs. Overall, data from the 
      PEP study and Anti-Platelet Trialists' systematic review show that aspirin 
      reduces the risk of VTE by around 25% in high risk surgical patients. Data from 
      retrospective and before/after studies also suggest efficacy in reducing VTE in 
      myeloma patients on IMiD drugs in combination with dexamethasone or chemotherapy. 
      However, there has been no direct comparison with coumarins or heparin to 
      indicate that aspirin is the optimal form of thromboprophylaxis. In patients who 
      require aspirin because of high risk of arterial vascular occlusion (including 
      patients with polycythaemia vera and essential thrombocythaemia), the additional 
      small reduction in VTE risk is an added benefit with no additional risk 
      associated. There is no evidence for a role of aspirin in prevention of 
      travel-related thrombosis. At present there is no clear evidence that aspirin is 
      the drug of choice for the prevention of VTE in any patient group.
FAU - Watson, Henry G
AU  - Watson HG
AD  - Department of Haematology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 
      2ZN, UK. henry.watson@arh.grampian.scot.nhs.uk
FAU - Chee, Yen Lin
AU  - Chee YL
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20080115
PL  - England
TA  - Blood Rev
JT  - Blood reviews
JID - 8708558
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Venous Thromboembolism/*prevention & control
MH  - Venous Thrombosis/prevention & control
RF  - 88
EDAT- 2008/01/30 09:00
MHDA- 2008/05/14 09:00
CRDT- 2008/01/30 09:00
PHST- 2008/01/30 09:00 [pubmed]
PHST- 2008/05/14 09:00 [medline]
PHST- 2008/01/30 09:00 [entrez]
AID - S0268-960X(07)00070-7 [pii]
AID - 10.1016/j.blre.2007.11.001 [doi]
PST - ppublish
SO  - Blood Rev. 2008 Mar;22(2):107-16. doi: 10.1016/j.blre.2007.11.001. Epub 2008 Jan 
      15.

PMID- 25833406
OWN - NLM
STAT- MEDLINE
DCOM- 20160211
LR  - 20181113
IS  - 1574-4647 (Electronic)
IS  - 0161-9152 (Print)
IS  - 0161-9152 (Linking)
VI  - 37
IP  - 2
DP  - 2015
TI  - Impacts of metformin and aspirin on life history features and longevity of 
      crickets: trade-offs versus cost-free life extension?
PG  - 31
LID - 10.1007/s11357-015-9769-x [doi]
LID - 31
AB  - We examined the impacts of aspirin and metformin on the life history of the 
      cricket Acheta domesticus (growth rate, maturation time, mature body size, 
      survivorship, and maximal longevity). Both drugs significantly increased 
      survivorship and maximal life span. Maximal longevity was 136 days for controls, 
      188 days (138 % of controls) for metformin, and 194 days (143 % of controls) for 
      aspirin. Metformin and aspirin in combination extended longevity to a lesser 
      degree (163 days, 120 % of controls). Increases in general survivorship were even 
      more pronounced, with low-dose aspirin yielding mean longevity 234 % of controls 
      (i.e., health span). Metformin strongly reduced growth rates of both genders (<60 
      % of controls), whereas aspirin only slightly reduced the growth rate of females 
      and slightly increased that of males. Both drugs delayed maturation age relative 
      to controls, but metformin had a much greater impact (>140 % of controls) than 
      aspirin (~118 % of controls). Crickets maturing on low aspirin showed no evidence 
      of a trade-off between maturation mass and life extension. Remarkably, by 100 
      days of age, aspirin-treated females were significantly larger than controls 
      (largely reflecting egg complement). Unlike the reigning dietary restriction 
      paradigm, low aspirin conformed to a paradigm of "eat more, live longer." In 
      contrast, metformin-treated females were only ~67 % of the mass of controls. Our 
      results suggest that hormetic agents like metformin may derive significant 
      trade-offs with life extension, whereas health and longevity benefits may be 
      obtained with less cost by agents like aspirin that regulate geroprotective 
      pathways.
FAU - Hans, Harvir
AU  - Hans H
AD  - Department of Biology, McMaster University, 226 Life Science Building, 1280 Main 
      Street West, Hamilton, ON, L8S 4K1, Canada.
FAU - Lone, Asad
AU  - Lone A
FAU - Aksenov, Vadim
AU  - Aksenov V
FAU - Rollo, C David
AU  - Rollo CD
LA  - eng
PT  - Journal Article
DEP - 20150402
PL  - Netherlands
TA  - Age (Dordr)
JT  - Age (Dordrecht, Netherlands)
JID - 101250497
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Gryllidae/drug effects/*physiology
MH  - Longevity/drug effects/*physiology
MH  - Male
MH  - Metformin/*pharmacology
PMC - PMC4382469
EDAT- 2015/04/04 06:00
MHDA- 2016/02/13 06:00
CRDT- 2015/04/03 06:00
PHST- 2014/11/07 00:00 [received]
PHST- 2015/03/19 00:00 [accepted]
PHST- 2015/04/03 06:00 [entrez]
PHST- 2015/04/04 06:00 [pubmed]
PHST- 2016/02/13 06:00 [medline]
AID - 9769 [pii]
AID - 10.1007/s11357-015-9769-x [doi]
PST - ppublish
SO  - Age (Dordr). 2015;37(2):31. doi: 10.1007/s11357-015-9769-x. Epub 2015 Apr 2.

PMID- 12356838
OWN - NLM
STAT- MEDLINE
DCOM- 20021108
LR  - 20131121
IS  - 0146-0404 (Print)
IS  - 0146-0404 (Linking)
VI  - 43
IP  - 10
DP  - 2002 Oct
TI  - Ocular aspirin distribution: a comparison of intravenous, topical, and 
      coulomb-controlled iontophoresis administration.
PG  - 3299-306
AB  - PURPOSE: To evaluate the pharmacokinetics and safety of aspirin delivered by a 
      single, noninvasive, transscleral, coulomb-controlled iontophoresis (CCI) 
      treatment; topical application; or by one intravenous (IV) injection. METHODS: 
      Forty-one adult New Zealand White rabbits received either a single IV injection, 
      topical, or CCI administration of aspirin at a concentration of 10 mg/mL. 
      Histologic evaluation was performed in four CCI-treated eyes to assess safety. 
      Pharmacokinetic distribution in all ocular tissues and fluids was studied at 0.5, 
      1, 2, 4, 6, and 8 hours after the treatments. Immediately after death, the eyes 
      were dissected and salicylic acid (SA) concentration was determined by HPLC 
      analysis. Blood was sampled at 0.5, 1, 2, 4, 6, and 8 hours, and plasma SA levels 
      for systemic distribution were measured by HPLC analysis. RESULTS: No tissue 
      damage was observed clinically or histologically. SA was found in all tissues and 
      fluids throughout the study period of 8 hours. The highest concentrations of SA 
      were observed with CCI immediately after treatment for all tissues and were the 
      highest SA tissue peaks obtained by the studied delivery methods. IV 
      administration demonstrated a delayed tissue peak of salicylate at 2 hours after 
      administration. At 8 hours, ocular SA concentrations were in the same range for 
      CCI and IV administration. IV injection resulted in blood plasma levels up to 28 
      times higher than CCI and remained significantly elevated until 8 hours after the 
      treatments. CONCLUSIONS: CCI is a safe and effective method of administering 
      aspirin to the eye while avoiding the systemic side effects associated with IV 
      injection.
FAU - Voigt, Monika
AU  - Voigt M
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, 
      Miami, Florida, USA.
FAU - Kralinger, Martina
AU  - Kralinger M
FAU - Kieselbach, Gerhard
AU  - Kieselbach G
FAU - Chapon, Pascal
AU  - Chapon P
FAU - Anagnoste, Scott
AU  - Anagnoste S
FAU - Hayden, Brandy
AU  - Hayden B
FAU - Parel, Jean-Marie
AU  - Parel JM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*pharmacokinetics
MH  - Aspirin/administration & dosage/adverse effects/*pharmacokinetics
MH  - Drug Delivery Systems/instrumentation
MH  - Equipment Design
MH  - Eye/*metabolism
MH  - Injections, Intravenous
MH  - Iontophoresis/methods
MH  - Rabbits
MH  - Safety
MH  - Tissue Distribution
EDAT- 2002/10/03 04:00
MHDA- 2002/11/26 04:00
CRDT- 2002/10/03 04:00
PHST- 2002/10/03 04:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/10/03 04:00 [entrez]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3299-306.

PMID- 24263109
OWN - NLM
STAT- MEDLINE
DCOM- 20140815
LR  - 20220321
IS  - 1536-4828 (Electronic)
IS  - 0885-3177 (Linking)
VI  - 43
IP  - 1
DP  - 2014 Jan
TI  - High-dose aspirin consumption contributes to decreased risk for pancreatic cancer 
      in a systematic review and meta-analysis.
PG  - 135-40
LID - 10.1097/MPA.0b013e3182a8d41f [doi]
AB  - OBJECTIVES: The aim of this study was to analyze the association between aspirin 
      intake and its effect for chemoprevention of pancreatic cancer incidence by using 
      a meta-analysis method. METHODS: The databases of MEDLINE, EMBASE, and Wangfang 
      (Chinese database) were retrieved to identify eligible studies. Odds ratio (OR) 
      and 95% confidence interval (CI) were calculated using a random-effects model. 
      RESULTS: A total of 10 studies (4 case-control studies, 5 prospective cohort 
      studies, and 1 randomized controlled trial) with 7,252 cases of pancreatic cancer 
      and more than 120,0000 healthy control subjects were enrolled in the studies. 
      Pooled analyses showed that high-dose aspirin intake was marginally associated 
      with decreased risk for pancreatic cancer for overall analysis (OR, 0.88; 95% CI, 
      0.76-1.01) as well as for both cohort and case-control studies (OR, 0.70; 95% CI, 
      0.54-1.16, for the cohort studies; OR, 0.82; 95% CI, 0.62-1.02, for the 
      case-control studies), without between-study heterogeneity. Stratified analysis 
      for Americans showed a similar result (OR, 0.82; 95% CI, 0.65-1.02). In contrast, 
      our study inferred that low-dose aspirin intake was not associated with risk for 
      pancreatic cancer for the total and subgroup analyses. CONCLUSIONS: In summary, 
      our study indicated that high-dose aspirin, rather than low-dose aspirin, might 
      be associated with decreased risk for pancreatic cancer, especially for 
      Americans.
FAU - Cui, Xi-Jun
AU  - Cui XJ
AD  - From the *Department of General Surgery, Wendeng Central Hospital, Wei Hai City; 
      †Department of General Surgery, Linyi People's Hospital, Lin Yi City, Shan Dong 
      Province; ‡Department of Oncology, the First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou; and §Department of Gynaecology and Obstetrics, the First 
      Affiliated Hospital of Xinxiang Medical College, Xinxiang, China.
FAU - He, Qiang
AU  - He Q
FAU - Zhang, Jian-Min
AU  - Zhang JM
FAU - Fan, Hui-Jie
AU  - Fan HJ
FAU - Wen, Zheng-Fang
AU  - Wen ZF
FAU - Qin, Yan-Ru
AU  - Qin YR
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Pancreas
JT  - Pancreas
JID - 8608542
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Case-Control Studies
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Pancreatic Neoplasms/*prevention & control
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
EDAT- 2013/11/23 06:00
MHDA- 2014/08/16 06:00
CRDT- 2013/11/23 06:00
PHST- 2013/11/23 06:00 [entrez]
PHST- 2013/11/23 06:00 [pubmed]
PHST- 2014/08/16 06:00 [medline]
AID - 10.1097/MPA.0b013e3182a8d41f [doi]
PST - ppublish
SO  - Pancreas. 2014 Jan;43(1):135-40. doi: 10.1097/MPA.0b013e3182a8d41f.

PMID- 25537732
OWN - NLM
STAT- MEDLINE
DCOM- 20160408
LR  - 20181202
IS  - 1878-0938 (Electronic)
IS  - 1878-0938 (Linking)
VI  - 16
IP  - 4
DP  - 2015 Jun
TI  - Acute thrombosis during left main stenting using tap technique in a patient 
      presenting with non-ST-segment elevation acute coronary syndrome.
PG  - 249-53
LID - S1553-8389(14)00273-5 [pii]
LID - 10.1016/j.carrev.2014.11.004 [doi]
AB  - This case reports the sudden development of large burden of thrombi in the left 
      anterior descending coronary artery immediately following distal left main 
      stenting using TAP technique in a middle aged man who presented with non 
      ST-segment elevation acute coronary syndrome despite having been administered 
      7,500 units of unfractionated heparin and being given 325 mg of aspirin and 60 mg 
      of prasugrel prior to the procedure. The thrombi were managed effectively by 
      giving an intra-coronary high bolus dose of tirofiban (25 mcg/kg) without the 
      need for catheter thrombus extraction. Tirofiban intra-venous infusion was 
      maintained for 18 hours, and the patient was discharged in stable condition on 
      the third day. Importantly there is no controlled study on upstream 
      administration of glycoprotein IIb/IIIa inhibitors in addition to the newer more 
      potent anti-platelet agents in patients with unprotected distal left main disease 
      presenting with non ST-segment elevation acute coronary syndrome, nor is there 
      any data on safety and efficacy of mandatory usage of injectable anti-platelet 
      agents at the start of a procedure in a catheterization laboratory in such a 
      setting.
CI  - Copyright © 2014 Elsevier Inc. All rights reserved.
FAU - Natarajan, Deepak
AU  - Natarajan D
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20141210
PL  - United States
TA  - Cardiovasc Revasc Med
JT  - Cardiovascular revascularization medicine : including molecular interventions
JID - 101238551
RN  - 0 (Anticoagulants)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 42HK56048U (Tyrosine)
RN  - 9005-49-6 (Heparin)
RN  - GGX234SI5H (Tirofiban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/diagnosis/*drug therapy
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Drug Combinations
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Stents
MH  - Thrombosis/*drug therapy
MH  - Tirofiban
MH  - Treatment Outcome
MH  - Tyrosine/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Intra-coronary tirofiban
OT  - Non-ST-segment elevation acute coronary syndrome
OT  - TAP stenting
OT  - Unprotected distal left main disease
EDAT- 2014/12/30 06:00
MHDA- 2016/04/09 06:00
CRDT- 2014/12/25 06:00
PHST- 2014/11/01 00:00 [received]
PHST- 2014/11/21 00:00 [accepted]
PHST- 2014/12/25 06:00 [entrez]
PHST- 2014/12/30 06:00 [pubmed]
PHST- 2016/04/09 06:00 [medline]
AID - S1553-8389(14)00273-5 [pii]
AID - 10.1016/j.carrev.2014.11.004 [doi]
PST - ppublish
SO  - Cardiovasc Revasc Med. 2015 Jun;16(4):249-53. doi: 10.1016/j.carrev.2014.11.004. 
      Epub 2014 Dec 10.

PMID- 12035038
OWN - NLM
STAT- MEDLINE
DCOM- 20020619
LR  - 20190514
IS  - 0003-4932 (Print)
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 235
IP  - 6
DP  - 2002 Jun
TI  - Aspirin and postoperative bleeding after coronary artery bypass grafting.
PG  - 820-7
AB  - OBJECTIVE: To evaluate the relationship between aspirin ingestion and 
      postoperative bleeding complications, and to test the hypothesis that there is a 
      subset of patients who are aspirin hyperresponders with a proclivity toward 
      platelet dysfunction. SUMMARY BACKGROUND DATA: Despite numerous retrospective and 
      prospective analyses, it is still controversial as to whether aspirin ingestion 
      before coronary artery bypass grafting (CABG) is associated with significant 
      postoperative bleeding. METHODS: Between January 1995 and December 1999, the 
      records of 2,606 consecutive patients undergoing CABG were reviewed to identify 
      patients with a history of aspirin ingestion up until the time of surgery. 
      Aspirin ingestion was correlated with postoperative blood transfusion using 
      multivariate analysis. In a subset of preoperative aspirin users (n = 40), 
      bleeding times were measured before and after aspirin use. Flow cytometry was 
      performed in another cohort of patients with known heart disease (n = 30) to 
      determine the effect of aspirin on platelet surface receptors. RESULTS: During 
      the 5-year study period, 63% of the CABG patients were identified as aspirin 
      users. Among these, 23.1% required blood transfusions compared with 19% for the 
      nonusers. Non-red blood cell transfusions were more common in aspirin users, as 
      was reexploration for bleeding. Stratification of these results according to the 
      frequency of aspirin use showed that aspirin is an independent multivariate 
      predictor of postoperative blood transfusion only in high-risk patients. In the 
      prospective studies, aspirin treatment resulted in a significant increase in the 
      template bleeding time, an increase in platelet PAR-1 thrombin receptor activity, 
      and a decrease in the binding of platelets to monocytes. CONCLUSIONS: The 
      findings support the hypothesis that aspirin is associated with a greater 
      likelihood of postoperative bleeding. A platelet function testing algorithm that 
      combines preoperative risk factor assessment, template bleeding times, and flow 
      cytometry may allow the identification of aspirin hyperresponders who are at 
      increased risk for bleeding.
FAU - Ferraris, Victor A
AU  - Ferraris VA
AD  - Division of Cardiothoracic Surgery, University of Kentucky College of Medicine, 
      Lexington 40536-0084, USA. vferr2@uky.edu
FAU - Ferraris, Suellen P
AU  - Ferraris SP
FAU - Joseph, Oji
AU  - Joseph O
FAU - Wehner, Paulette
AU  - Wehner P
FAU - Mentzer, Robert M Jr
AU  - Mentzer RM Jr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Membrane Glycoproteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/pharmacology
MH  - Bleeding Time
MH  - Blood Transfusion
MH  - Coronary Artery Bypass/*adverse effects
MH  - Flow Cytometry
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/pharmacology
MH  - Platelet Membrane Glycoproteins/drug effects
MH  - Postoperative Hemorrhage/epidemiology/*etiology
MH  - Retrospective Studies
MH  - Risk Factors
PMC - PMC1422511
EDAT- 2002/05/30 10:00
MHDA- 2002/06/20 10:01
CRDT- 2002/05/30 10:00
PHST- 2002/05/30 10:00 [pubmed]
PHST- 2002/06/20 10:01 [medline]
PHST- 2002/05/30 10:00 [entrez]
AID - 0000658-200206000-00009 [pii]
AID - 10.1097/00000658-200206000-00009 [doi]
PST - ppublish
SO  - Ann Surg. 2002 Jun;235(6):820-7. doi: 10.1097/00000658-200206000-00009.

PMID- 501542
OWN - NLM
STAT- MEDLINE
DCOM- 19800119
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 68
IP  - 9
DP  - 1979 Sep
TI  - Isolation of salicylsalicylic acid, acetylsalicylsalicylic acid, and 
      acetylsalicylic anhydride from aspirin tablets by extraction and high-pressure 
      liquid chromatography.
PG  - 1167-9
AB  - Aspirin and four salicylate impurities of aspirin (salicylic acid, 
      acetylsalicylsalicylic acid, acetylsalicylic anhydride, and salicylsalicylic 
      acid) were resolved by silica gell TLC and by high-pressure liquid chromatography 
      (HPLC) on a reversed-phase C18 column. Care was necessary in the choice of a 
      column because of similar column failed to resolve these five compounds. 
      Salicylsalicylic acid was isolated from aspirin tablets by extraction followed by 
      reversed-phase C18 HPLC. The structure of this compound was confirmed by 
      comparison with an authentic sample of salicylsalicylic acid by HPLC, TLC, IR and 
      UV spectrophotometry, and mass spectrometry. Two other compounds, acetylsalicylic 
      anhydride and acetylsalicylsalicylic acid, which had been previously identified 
      by chromatography as impurities in aspirin, were isolated and further 
      characterized.
FAU - Reepmeyer, J C
AU  - Reepmeyer JC
FAU - Kirchhoefer, R D
AU  - Kirchhoefer RD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Anhydrides)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anhydrides/isolation & purification
MH  - Aspirin/*isolation & purification
MH  - Chromatography, High Pressure Liquid
MH  - Methods
MH  - Salicylates/*isolation & purification
MH  - Tablets/analysis
EDAT- 1979/09/01 00:00
MHDA- 1979/09/01 00:01
CRDT- 1979/09/01 00:00
PHST- 1979/09/01 00:00 [pubmed]
PHST- 1979/09/01 00:01 [medline]
PHST- 1979/09/01 00:00 [entrez]
AID - S0022-3549(15)42822-9 [pii]
AID - 10.1002/jps.2600680929 [doi]
PST - ppublish
SO  - J Pharm Sci. 1979 Sep;68(9):1167-9. doi: 10.1002/jps.2600680929.

PMID- 18095518
OWN - NLM
STAT- MEDLINE
DCOM- 20080212
LR  - 20131121
IS  - 0966-8519 (Print)
IS  - 0966-8519 (Linking)
VI  - 16
IP  - 6
DP  - 2007 Nov
TI  - Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. 
      Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial.
PG  - 667-71
AB  - BACKGROUND AND AIM OF THE STUDY: Patients with bioprosthetic heart valves have a 
      higher risk of developing peripheral arterial embolic phenomena than the normal 
      population. Antithrombotic therapy during the early postoperative period after 
      bioprosthetic aortic valve replacement (BAVR) is controversial. This prospective 
      pilot study sought to investigate the feasibility of a larger trial and the 
      efficacy of postoperative warfarin compared to acetyl salicylic acid (aspirin; 
      ASA) in patients after AVR with the St. Jude Epic porcine bioprosthesis (SJEP), 
      and the feasibility of conducting a larger trial. METHODS: Patients undergoing 
      isolated BAVR were allocated at random to two groups, each of which received 
      different antithrombotic therapies: (i) warfarin (INR; range 2-3) for the first 
      three months, followed by ASA (100 mg/day); or (ii) ASA alone (100 mg/day). 
      RESULTS: During 2003 and 2004, a total of 75 patients underwent isolated BAVR 
      with the SJEP. Six patients who developed postoperative de-novo atrial 
      fibrillation that did not revert to sinus rhythm were excluded from the analysis, 
      but included in the follow up. One postoperative cerebral ischemic event occurred 
      in each group between 24 h and three months (2.8% versus 2.9%, p = NS). The rates 
      of major bleeding, stroke-free survival and overall survival were similar in both 
      groups. CONCLUSION: The early results of this WoA Epic pilot trial did not 
      support the suggestion that patients receiving the SJEP, and tissue valves in 
      general, should be administered warfarin to prevent valve thrombosis and 
      peripheral arterial embolic phenomena.
FAU - Colli, Andrea
AU  - Colli A
AD  - Department of Cardiovascular Surgery, Hospital Clinic, Barcelona, c/Villarroel 
      170, 08036 Barcelona, Spain. colli.andrea@libero.it
FAU - Mestres, Carlos A
AU  - Mestres CA
FAU - Castella, Manuel
AU  - Castella M
FAU - Gherli, Tiziano
AU  - Gherli T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Heart Valve Dis
JT  - The Journal of heart valve disease
JID - 9312096
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aortic Valve/*surgery
MH  - Aspirin/adverse effects/*therapeutic use
MH  - *Bioprosthesis
MH  - Female
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Male
MH  - Pilot Projects
MH  - Postoperative Care
MH  - Thrombosis/prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2007/12/22 09:00
MHDA- 2008/02/13 09:00
CRDT- 2007/12/22 09:00
PHST- 2007/12/22 09:00 [pubmed]
PHST- 2008/02/13 09:00 [medline]
PHST- 2007/12/22 09:00 [entrez]
PST - ppublish
SO  - J Heart Valve Dis. 2007 Nov;16(6):667-71.

PMID- 8795448
OWN - NLM
STAT- MEDLINE
DCOM- 19961008
LR  - 20190821
IS  - 0143-5221 (Print)
IS  - 0143-5221 (Linking)
VI  - 91
IP  - 2
DP  - 1996 Aug
TI  - Effects of inhaled nitric oxide compared with aspirin on platelet function in 
      vivo in healthy subjects.
PG  - 225-31
AB  - 1. Nitric oxide has platelet-stabilizing effects. Inhaled nitric oxide is used to 
      treat pulmonary disorders, and may prolong bleeding times, suggesting that it has 
      effects on haemostasis. We therefore examined if inhaled nitric oxide influences 
      platelet function in vivo in healthy subjects. 2. Platelet aggregability 
      (filtragometry ex vivo, which reflects aggregability in vivo), bleeding time and 
      platelet secretion products and cGMP in plasma were studied during inhalation of 
      two different doses of nitric oxide (30 and 80 p.p.m.; 15 min at each dose level; 
      n = 19) and during prolonged (55 min; n = 18) inhalation of 30 p.p.m. nitric 
      oxide. For comparison, studies were also performed before and after ingestion of 
      640 mg aspirin in 13 of the healthy subjects. 3. Plasma cGMP increased dose 
      dependently during nitric oxide inhalation, suggesting guanylate cyclase 
      activation in vivo. Platelet aggregability was, however, little affected and 
      platelet secretion was not attenuated by nitric oxide inhalation. Bleeding time 
      tended to increase (by 16-33%), but was significantly increased only after 
      prolonged inhalation of nitric oxide at 30 p.p.m. 4. Aspirin (640 mg orally) 
      caused pronounced and significant prolongations of filtragometry readings and 
      bleeding time. Thus, the methods used were able to reveal platelet stabilization. 
      5. We conclude that nitric oxide inhalation causes only mild, if any, attenuation 
      of platelet function in healthy subjects with a normal endogenous nitric oxide 
      production. The effects may be different in disease states.
FAU - Albert, J
AU  - Albert J
AD  - Department of Anaesthesiology, Danderyd Hospital, Sweden.
FAU - Wallén, N H
AU  - Wallén NH
FAU - Bröijersén, A
AU  - Bröijersén A
FAU - Frostell, C
AU  - Frostell C
FAU - Hjemdahl, P
AU  - Hjemdahl P
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Inhalation
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects
MH  - Cyclic GMP/blood
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Nitric Oxide/administration & dosage/*pharmacology
MH  - Platelet Aggregation/drug effects
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - 10.1042/cs0910225 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 1996 Aug;91(2):225-31. doi: 10.1042/cs0910225.

PMID- 11837380
OWN - NLM
STAT- MEDLINE
DCOM- 20020813
LR  - 20190607
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 40
IP  - 1
DP  - 2002 Jan
TI  - Anthropometric data and acetylsalicylic acid pharmacokinetics.
PG  - 30-4
AB  - The relationship between anthropometric data and pharmacokinetic characteristics 
      of acetylsalicylic acid (ASA) after administration of a single oral dose of 500 
      mg ASA, an oral and intravenous dose of 500 mg D,L-lysine-mono-acetylsalicylate 
      (Lys-ASA) and an oral dose of 1,000 mg Lys-ASA were evaluated. Individual data 
      from an open, randomized crossover trial in 13 healthy volunteers (age 18-50 
      years, 6 female, 7 male, height 158-189 cm, weight 45-118 kg) were re-analyzed 
      using a non-compartmental approach. The influence of body weight, height, body 
      surface area and age on pharmacokinetic characteristics (Cmax, Tmax, AUClast, 
      MRTlast, t 1/2, Cl, Vd) was assessed using the multiple regression method and 
      pairwise multiple correlations were calculated. Multiple regression analysis 
      showed significant multiple correlation coefficients of approximately 0.86 for 
      Cmax (500 mg Lys-ASA i.v., 1,000 mg Lys-ASA per os and 500 mg ASA per os), Cl and 
      AUClast (1,000 mg Lys-ASA per os). Standardized regression values (beta) 
      reflected a major contribution for height, weight and body surface area, but age 
      was not a relevant factor. Pairwise comparisons confirmed negative correlations 
      between anthropometric characteristics and Cmax, AUClast and MRTlast and positive 
      correlations between anthropometric data, Cl and Vd. In conclusion, apart from 
      Tmax and t 1/2, all pharmacokinetic characteristics were influenced by body 
      weight, height and body surface area. Whereas repeated administration of high 
      doses in patients with low body weights may give rise to toxic effects, acute 
      single dose administration would not lead to significant under-dosing in tall or 
      stout patients.
FAU - Koch, H J
AU  - Koch HJ
AD  - Department of Gerontopsychiatry, Psychiatric University Clinic, Regensburg, 
      Germany. horst.koch@bkr-regensburg.de
FAU - Raschka, C
AU  - Raschka C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - *Anthropometry
MH  - Area Under Curve
MH  - Aspirin/*analogs & derivatives/blood/*pharmacokinetics
MH  - Body Height
MH  - Body Mass Index
MH  - Body Surface Area
MH  - Body Weight
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Lysine/*analogs & derivatives/blood/*pharmacokinetics
MH  - Male
MH  - Middle Aged
EDAT- 2002/02/12 10:00
MHDA- 2002/08/14 10:01
CRDT- 2002/02/12 10:00
PHST- 2002/02/12 10:00 [pubmed]
PHST- 2002/08/14 10:01 [medline]
PHST- 2002/02/12 10:00 [entrez]
AID - 10.5414/cpp40030 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2002 Jan;40(1):30-4. doi: 10.5414/cpp40030.

PMID- 26369681
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 21
IP  - 35
DP  - 2015
TI  - A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases.
PG  - 5101-7
AB  - This review highlights practical aspects related to aspirin therapy in 
      cardiovascular diseases, specifically, the benefits and hazards in different 
      clinical settings. Aspirin reduces one fourth of all major cardiovascular events 
      but also increases major gastrointestinal bleeds by about half. As with other 
      cardiovascular prevention strategies, the absolute benefit of aspirin is linearly 
      related to the cardiovascular risk of the patient. The risk-benefit of aspirin 
      can vary substantially in different settings: in secondary prevention, the 
      benefits usually outweigh the excess of major bleeding complications. In primary 
      prevention, it is not unusual that the number of vascular events avoided equals 
      the number of major bleeds induced by aspirin. Finally, there is a growing body 
      of evidence suggesting that aspirin may interfere with the early stages of 
      cancer, metastasis and mortality. For all these reasons, in this article new 
      developments in the field directed towards individualized risk assessment 
      strategies are also discussed.
FAU - Casado-Arroyo, Rubén
AU  - Casado-Arroyo R
AD  - Cardiology Department. Hôpital Erasme. Université Libre de Bruxelles, 1070 
      Brussels, Belgium. Belgium. rbcasado@gmail.com.
FAU - Lanas, Angel
AU  - Lanas A
FAU - Brugada, Pedro
AU  - Brugada P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Primary Prevention/methods
MH  - Risk
MH  - Risk Assessment/methods
MH  - Secondary Prevention/methods
EDAT- 2015/09/16 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/06/19 00:00 [received]
PHST- 2015/09/14 00:00 [accepted]
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - CPD-EPUB-70386 [pii]
AID - 10.2174/1381612821666150915110322 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2015;21(35):5101-7. doi: 10.2174/1381612821666150915110322.

PMID- 406909
OWN - NLM
STAT- MEDLINE
DCOM- 19770922
LR  - 20190509
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 4 Suppl 1
IP  - Suppl 1
DP  - 1977 Feb
TI  - Comparative effects of aspirin and diflunisal on prostaglandin synthetase from 
      human platelets and sheep seminal vesicles.
PG  - 15S-18S
AB  - 1. We have compared the effects of diflunisal on prostaglandin (PG) synthetase 
      from human platelets and sheep seminal vesicles (SSV) by measuring malonaldehyde, 
      PG products, and rabbit aorta contraction. 2. Aspirin inhibits PG synthetase by 
      covalently acetylating the enzyme. Inhibition is dependent on time and aspirin 
      concentration. Aspirin is 37-fold more potent in inhibiting enzyme in human 
      platelets compared with enzyme from SSV. 3. Diflunisal inhibits PG synthetase 
      from intact human platelets and SSV equally (50% inhibition at 3-5 micronM). The 
      drug does not covalently modify the enzyme, and inhibition is not time dependent. 
      Diflunisal probably acts at a site similar to aspirin since the drug will inhibit 
      acetylation of the enzyme by aspirin. 4. The results suggest that diflunisal is 
      relatively less inhibitory to platelet function than is aspirin.
FAU - Majerus, P W
AU  - Majerus PW
FAU - Stanford, N
AU  - Stanford N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fluorobenzenes)
RN  - 0 (Salicylates)
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Blood Platelets/drug effects/*enzymology
MH  - *Cyclooxygenase Inhibitors
MH  - Fluorobenzenes/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Mixed Function Oxygenases/*antagonists & inhibitors
MH  - Salicylates/*pharmacology
MH  - Seminal Vesicles/drug effects/*enzymology
MH  - Sheep
PMC - PMC1428838
EDAT- 1977/02/01 00:00
MHDA- 1977/02/01 00:01
CRDT- 1977/02/01 00:00
PHST- 1977/02/01 00:00 [pubmed]
PHST- 1977/02/01 00:01 [medline]
PHST- 1977/02/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1977.tb04509.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1977 Feb;4 Suppl 1(Suppl 1):15S-18S. doi: 
      10.1111/j.1365-2125.1977.tb04509.x.

PMID- 7588091
OWN - NLM
STAT- MEDLINE
DCOM- 19951207
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 50
IP  - 1
DP  - 1995 Jul
TI  - Antiplatelet drugs. A comparative review.
PG  - 7-28
AB  - Antiplatelet therapy has become a useful means of preventing acute thromboembolic 
      artery occlusions in cardiovascular diseases. The rationale for this is an 
      enhanced activity of circulating platelets and release of platelet-derived 
      vasoactive mediators, probably due to endothelial dysfunction. This review 
      discusses the current status of 4 major classes of antiplatelet compounds: (i) 
      aspirin and related drugs active via cyclo-oxygenase product formation; (ii) 
      thienopyridines (ticlopidine and clopidogrel); (iii) direct thrombin inhibitors 
      (e.g. hirudin); and (iv) GPIIb/IIIa receptor antagonists [e.g. abciximab (c7E3 
      Fab)]. It is concluded that aspirin is the drug of choice for long term oral 
      treatment, specifically for secondary prevention of myocardial infarction, and is 
      also a suitable basic but not maximally efficient drug in percutaneous 
      transluminal coronary angioplasty (PTCA) and platelet activation during clot 
      lysis. Ticlopidine has a similar indication and may be superior to aspirin in 
      prevention of ischaemic stroke and peripheral arterial occlusion. Direct thrombin 
      inhibitors and glycoprotein GPIIb/IIIa receptor antagonists need further 
      investigation in clinical trials. To date, these compounds have a higher bleeding 
      risk and currently they are available only for short term parenteral application. 
      They are superior to aspirin in acute platelet-dependent ischaemic syndromes, 
      such as unstable angina, and in connection with therapeutic PTCA because of their 
      high potency in preventing platelet-dependent reocclusion. Future developments 
      include more selective thromboxane inhibitors, i.e. combined-mode agents; 
      nonpeptide clot-specific thrombin inhibitors with longer lasting action and 
      nonpeptide fibrinogen receptor antagonists.
FAU - Schrör, K
AU  - Schrör K
AD  - Institut für Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Germany.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIb-IX Complex)
RN  - 0 (Platelet Membrane Glycoproteins)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Thromboxanes)
RN  - 0 (glycoprotein receptor GPIb-IX)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/antagonists & inhibitors
MH  - Animals
MH  - Aspirin/adverse effects/*pharmacology/therapeutic use
MH  - Base Sequence
MH  - Blood Platelets/*drug effects
MH  - Consensus Sequence
MH  - Humans
MH  - Molecular Sequence Data
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacology/therapeutic use
MH  - *Platelet Glycoprotein GPIb-IX Complex
MH  - *Platelet Membrane Glycoproteins
MH  - Receptors, Cell Surface/antagonists & inhibitors
MH  - Thrombin/antagonists & inhibitors
MH  - Thrombosis/drug therapy
MH  - Thromboxanes/*antagonists & inhibitors
RF  - 189
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
AID - 10.2165/00003495-199550010-00002 [doi]
PST - ppublish
SO  - Drugs. 1995 Jul;50(1):7-28. doi: 10.2165/00003495-199550010-00002.

PMID- 2096805
OWN - NLM
STAT- MEDLINE
DCOM- 19910715
LR  - 20131121
IS  - 0021-4884 (Print)
IS  - 0021-4884 (Linking)
VI  - 39
IP  - 12
DP  - 1990 Dec
TI  - [3 cases of food-dependent exercise-induced anaphylaxis in which aspirin intake 
      exacerbated anaphylactic symptoms].
PG  - 1598-604
AB  - Exercise-induced anaphylaxis (EIAn) is a distinct form of physical allergy. As 
      one of the predisposing factors of EIAn, food intake is often cited, and such 
      cases are classified as food-dependent EIAn. Another factor reported is the 
      administration of drugs. Recently we had 3 patients with food-dependent EIAn who 
      showed more severe symptoms when they took aspirin orally. None of them had shown 
      symptoms when they took aspirin alone. Symptoms were provoked only when they took 
      aspirin for common cold, headache or toothache followed by certain foods and 
      exercise. Two out of the 3 patients had experienced food-dependent EIAn before. 
      However, after taking aspirin, their anaphylactic symptoms were more severe with 
      more slight degree of exercise. Results of exercise challenge by treadmill showed 
      that exercise alone induced an increase in plasma histamine concentrations in 2 
      out of the 3 patients 5 to 15 minutes after the challenge. These data suggest the 
      possibility that our patients have an increased histamine releasability from mast 
      cells responding to exercise, and that aspirin intake might enhance the process.
FAU - Dohi, M
AU  - Dohi M
AD  - Department of Medicine and Physical Therapy, Faculty of Medicine, University of 
      Tokyo.
FAU - Suko, M
AU  - Suko M
FAU - Sugiyama, H
AU  - Sugiyama H
FAU - Yamashita, N
AU  - Yamashita N
FAU - Tadokoro, K
AU  - Tadokoro K
FAU - Okudaira, H
AU  - Okudaira H
FAU - Ito, K
AU  - Ito K
FAU - Miyamoto, T
AU  - Miyamoto T
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Arerugi
JT  - Arerugi = [Allergy]
JID - 0241212
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anaphylaxis/*etiology
MH  - Aspirin/*adverse effects
MH  - Eating/*physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Physical Exertion/*physiology
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
PST - ppublish
SO  - Arerugi. 1990 Dec;39(12):1598-604.

PMID- 37649612
OWN - NLM
STAT- MEDLINE
DCOM- 20230901
LR  - 20230909
IS  - 1838-7640 (Electronic)
IS  - 1838-7640 (Linking)
VI  - 13
IP  - 13
DP  - 2023
TI  - Aspirin synergizes with mineral particle-coated macroporous scaffolds for bone 
      regeneration through immunomodulation.
PG  - 4512-4525
LID - 10.7150/thno.85946 [doi]
AB  - Rationale: Mineral particles have been widely used in bone tissue engineering 
      scaffolds due to their osteoconductive and osteoinductive properties. Despite 
      their benefits, mineral particles can induce undesirable inflammation and 
      subsequent bone resorption. Aspirin (Asp) is an inexpensive and widely used 
      anti-inflammatory drug. The goal of this study is to assess the synergistic 
      effect of Asp and optimized mineral particle coating in macroporous scaffolds to 
      accelerate endogenous bone regeneration and reduce bone resorption in a 
      critical-sized bone defect model. Methods: Four commonly used mineral particles 
      with varying composition (hydroxyapatite v.s. tricalcium phosphate) and size 
      (nano v.s. micro) were used. Mineral particles were coated onto gelatin 
      microribbon (µRB) scaffolds. Macrophages (Mφ) were cultured on gelatin µRB 
      scaffolds containing various particles, and Mφ polarization was assessed using 
      PCR and ELISA. The effect of conditioned medium from Mφ on mesenchymal stem cell 
      (MSC) osteogenesis was also evaluated in vitro. Scaffolds containing optimized 
      mineral particles were then combined with varying dosages of Asp to assess the 
      effect in inducing endogenous bone regeneration using a critical-sized cranial 
      bone defect model. In vivo characterization and in vitro cell studies were 
      performed to elucidate the effect of tuning Asp dosage on Mφ polarization, 
      osteoclast (OC) activity, and MSC osteogenesis. Results: Micro-sized tricalcium 
      phosphate (mTCP) particles were identified as optimal in promoting M2 Mφ 
      polarization and rescuing MSC-based bone formation in the presence of conditioned 
      medium from Mφ. When implanted in vivo, incorporating Asp with mTCP-coated µRB 
      scaffolds significantly accelerated endogenous bone formation in a dose-dependent 
      manner. Impressively, mTCP-coated µRB scaffolds containing 20 µg Asp led to 
      almost complete bone healing of a critical-sized cranial bone defect as early as 
      week 2 with no subsequent bone resorption. Asp enhanced M2 Mφ polarization, 
      decreased OC activity, and promoted MSC osteogenesis in a dosage-dependent manner 
      in vivo. These results were further validated using in vitro cell studies. 
      Conclusions: Here, we demonstrate Asp and mineral particle-coated microribbon 
      scaffold provides a promising therapy for repairing critical-sized cranial bone 
      defects via immunomodulation. The leading formulation supports rapid endogenous 
      bone regeneration without the need for exogenous cells or growth factors, making 
      it attractive for translation. Our results also highlight the importance of 
      optimizing mineral particles and Asp dosage to achieve robust bone healing while 
      avoiding bone resorption by targeting Mφ and OCs.
CI  - © The author(s).
FAU - Su, Ni
AU  - Su N
AD  - Department of Orthopaedic Surgery, Stanford University School of Medicine, 
      Stanford, CA, 94305, USA.
FAU - Villicana, Cassandra
AU  - Villicana C
AD  - Department of Bioengineering, Stanford University School of Medicine, Stanford, 
      CA, 94305, USA.
FAU - Zhang, Carl
AU  - Zhang C
AD  - Department of Bioengineering, Stanford University School of Medicine, Stanford, 
      CA, 94305, USA.
FAU - Lee, Jeehee
AU  - Lee J
AD  - Department of Orthopaedic Surgery, Stanford University School of Medicine, 
      Stanford, CA, 94305, USA.
FAU - Sinha, Sauradeep
AU  - Sinha S
AD  - Department of Bioengineering, Stanford University School of Medicine, Stanford, 
      CA, 94305, USA.
FAU - Yang, Andrew
AU  - Yang A
AD  - Department of Bioengineering, Stanford University School of Medicine, Stanford, 
      CA, 94305, USA.
FAU - Yang, Fan
AU  - Yang F
AD  - Department of Orthopaedic Surgery, Stanford University School of Medicine, 
      Stanford, CA, 94305, USA.
AD  - Department of Bioengineering, Stanford University School of Medicine, Stanford, 
      CA, 94305, USA.
LA  - eng
GR  - R01 AR074502/AR/NIAMS NIH HHS/United States
GR  - R01 CA276872/CA/NCI NIH HHS/United States
GR  - R01 DE024772/DE/NIDCR NIH HHS/United States
GR  - T32 GM141819/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20230815
PL  - Australia
TA  - Theranostics
JT  - Theranostics
JID - 101552395
RN  - K4C08XP666 (tricalcium phosphate)
RN  - 0 (Culture Media, Conditioned)
RN  - 9000-70-8 (Gelatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Culture Media, Conditioned
MH  - *Gelatin/pharmacology
MH  - Bone Regeneration
MH  - Immunomodulation
MH  - *Bone Resorption
MH  - Aspirin/pharmacology
PMC - PMC10465219
OTO - NOTNLM
OT  - bone resorption
OT  - mineral particles
OT  - osteogenesis
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2023/08/31 06:42
MHDA- 2023/09/01 06:42
CRDT- 2023/08/31 04:00
PHST- 2023/05/08 00:00 [received]
PHST- 2023/08/01 00:00 [accepted]
PHST- 2023/09/01 06:42 [medline]
PHST- 2023/08/31 06:42 [pubmed]
PHST- 2023/08/31 04:00 [entrez]
AID - thnov13p4512 [pii]
AID - 10.7150/thno.85946 [doi]
PST - epublish
SO  - Theranostics. 2023 Aug 15;13(13):4512-4525. doi: 10.7150/thno.85946. eCollection 
      2023.

PMID- 19382573
OWN - NLM
STAT- MEDLINE
DCOM- 20090623
LR  - 20190729
IS  - 1060-3271 (Print)
IS  - 1060-3271 (Linking)
VI  - 92
IP  - 1
DP  - 2009 Jan-Feb
TI  - Validated column high-performance liquid chromatographic method for determination 
      of aspirin and clopidogrel in combined tablets in the presence of degradation 
      products formed under ICH-recommended stress conditions.
PG  - 152-7
AB  - The development and validation of a column high-performance liquid 
      chromatographic assay method for the determination of aspirin and clopidogrel in 
      tablet formulation are described. The combination formulation was subjected to 
      International Conference on Harmonization-recommended stress conditions. 
      Separation of the drugs from the degradation products formed under stress 
      conditions was achieved on an octasilyl (C8) column using 0.3% orthophosphoric 
      acid-acetonitrile (65 + 35, v/v) mobile phase. The method was validated for 
      specificity, linearity, limits of detection and quantification, precision, 
      accuracy, and robustness. The method was found to be specific against placebo 
      interference and during the forced degradation. The response was linear in the 
      concentration range of 30.0-120.0 microg/mL for aspirin and 15.0-60.0 microg/mL 
      for clopidogrel, with a correlation coefficient of 0.9999 for both. The relative 
      standard deviation values for intra- and interday precision were <2.0%. The 
      accuracy was between 99.12 and 99.83% for aspirin and 98.20 and 100.35% for 
      clopidogrel. Stress testing showed degradation products that were well-separated 
      from the parent compound, confirming the stability-indicating capacity of the 
      method.
FAU - Kachhadia, Pankaj K
AU  - Kachhadia PK
AD  - Saurashtra University, Department of Chemistry, Rajkot-360 005, Gujarat, India.
FAU - Doshi, Ashish S
AU  - Doshi AS
FAU - Joshi, Hitendra S
AU  - Joshi HS
LA  - eng
PT  - Journal Article
PL  - England
TA  - J AOAC Int
JT  - Journal of AOAC International
JID - 9215446
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis/isolation & purification
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Clopidogrel
MH  - Hydrogen-Ion Concentration
MH  - Platelet Aggregation Inhibitors/analysis/isolation & purification
MH  - Reproducibility of Results
MH  - Stress, Mechanical
MH  - Tablets/*analysis/*chemistry
MH  - Ticlopidine/*analogs & derivatives/analysis/isolation & purification
EDAT- 2009/04/23 09:00
MHDA- 2009/06/24 09:00
CRDT- 2009/04/23 09:00
PHST- 2009/04/23 09:00 [entrez]
PHST- 2009/04/23 09:00 [pubmed]
PHST- 2009/06/24 09:00 [medline]
PST - ppublish
SO  - J AOAC Int. 2009 Jan-Feb;92(1):152-7.

PMID- 12873912
OWN - NLM
STAT- MEDLINE
DCOM- 20030822
LR  - 20210902
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 97
IP  - 2
DP  - 2003 Aug
TI  - Diaspirin-crosslinked hemoglobin reduces blood transfusion in noncardiac surgery: 
      a multicenter, randomized, controlled, double-blinded trial.
PG  - 323-332
LID - 10.1213/01.ANE.0000068888.02977.DA [doi]
AB  - In this randomized, prospective, double-blinded clinical trial, we sought to 
      investigate whether diaspirin-crosslinked hemoglobin (DCLHb) can reduce the 
      perioperative use of allogeneic blood transfusion. One-hundred-eighty-one 
      elective surgical patients were enrolled at 19 clinical sites from 1996 to 1998. 
      Selection criteria included anticipated transfusion of 2-4 blood units, aortic 
      repair, and major joint or abdomino-pelvic surgery. Once a decision to transfuse 
      had been made, patients received initially up to 3 250-mL infusions of 10% DCLHb 
      (n = 92) or 3 U of packed red blood cells (PRBCs) (n = 89). DCLHb was infused 
      during a 36-h perioperative window. On the day of surgery, 58 of 92 (64%; 
      confidence interval [CI], 54%-74%) DCLHb-treated patients received no allogeneic 
      PRBC transfusions. On Day 1, this number was 44 of 92 (48%; CI, 37%-58%) and 
      decreased further until Day 7, when it was 21 of 92 (23%; CI, 15%-33%). During 
      the 7-day period, 2 (1-4) units of PRBC per patient were used in the DCLHb group 
      compared with 3 (2-4) units in the control patients (P = 0.002; medians and 25th 
      and 75th percentiles). Mortality (4% and 3%, respectively) and incidence of 
      suffering at least one serious adverse event (21% and 15%, respectively) were 
      similar in DCLHb and PRBC groups. The incidence of jaundice, urinary side 
      effects, and pancreatitis were more frequent in DCLHb patients. The study was 
      terminated early because of safety concerns. Whereas the side-effect profile of 
      modified hemoglobin solutions needs to be improved, our data show that hemoglobin 
      solutions can be effective at reducing exposure to allogeneic blood for elective 
      surgery. IMPLICATIONS: In a randomized, double-blinded red blood cell controlled, 
      multicenter trial, diaspirin-crosslinked hemoglobin spared allogeneic transfusion 
      in 23% of patients undergoing elective noncardiac surgery. The observed 
      side-effect profile indicates a need for improvement in hemoglobin development.
FAU - Schubert, Armin
AU  - Schubert A
AD  - Departments of *General Anesthesiology, †Department of Orthopedic Surgery, 
      ‡Department of Urology, §Department of Biostatistics & Epidemiology, The 
      Cleveland Clinic Foundation; ∥Cleveland Clinic Foundation Health Science Center 
      of the Ohio State University; ¶Department of Pathology, Ohio State University, 
      Cleveland; #Department of Medicine, University of Wisconsin, Madison; **Division 
      of Vascular Surgery, University of Arkansas for Medical Sciences, Little Rock; 
      ††Baxter Hemoglobin Therapeutics, Boulder, Colorado; ‡‡Pfizer Global Research and 
      Development, New York City; and §§Richard Prielipp, MD, Bowman Gray School of 
      Medicine; Gerald Fulda, MD, Christiana Health Care Services; Irwin Gratz, DO, 
      Cooper Hospital/UMC; Michael Salem, MD, George Washington University Medical 
      Center; Ronald Kline, MD, Harper Hospital; Benjamin Guslits, MD, Henry Ford 
      Hospital; Michael Pasquale, MD, Lehigh Valley Hospital; Lauraine Stewart, MD, 
      McGuire VA Medical Center; Larry Hollier, MD, Mt. Sinai Medical Center; Bhatar 
      Desai, MD, St. Anthony Hospital; Marc J. Shapiro, MD, St. Louis University 
      Hospital; Ronald Pearl, MD, Stanford University Medical Center; Michael J. 
      Williams, MD, Thomas Jefferson University; Dennis Doblar, PhD, MD, University of 
      Alabama-Birmingham; Marc Hudson, MD, University of Pittsburgh Medical Center; 
      Michael P. Eaton, MD, University of Rochester Medical Center; Lewis Gottschalk, 
      MB, University of Texas-Houston Health Sciences Center; Mali Mathru, MD, 
      University of Texas Medical Branch; Daniel Herr, MD, Washington Hospital Center.
FAU - Przybelski, Robert J
AU  - Przybelski RJ
FAU - Eidt, John F
AU  - Eidt JF
FAU - Lasky, Larry C
AU  - Lasky LC
FAU - Marks, Kenneth E
AU  - Marks KE
FAU - Karafa, Matthew
AU  - Karafa M
FAU - Novick, Andrew C
AU  - Novick AC
FAU - O'Hara, Jerome F Jr
AU  - O'Hara JF Jr
FAU - Saunders, Michael E
AU  - Saunders ME
FAU - Blue, John W
AU  - Blue JW
FAU - Tetzlaff, John E
AU  - Tetzlaff JE
FAU - Mascha, Edward
AU  - Mascha E
CN  - and the Perioperative Avoidance or Reduction of Transfusion Trial (PARTT) Study 
      Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Anesth Analg. 2004 Apr;98(4):1193; author reply 1193. PMID: 15041633
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects/*analogs & derivatives
MH  - Blood Substitutes/*administration & dosage/adverse effects
MH  - *Blood Transfusion
MH  - Double-Blind Method
MH  - Female
MH  - Hemoglobins/*administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - *Perioperative Care
MH  - Prospective Studies
EDAT- 2003/07/23 05:00
MHDA- 2003/08/23 05:00
CRDT- 2003/07/23 05:00
PHST- 2003/07/23 05:00 [pubmed]
PHST- 2003/08/23 05:00 [medline]
PHST- 2003/07/23 05:00 [entrez]
AID - 00000539-200308000-00004 [pii]
AID - 10.1213/01.ANE.0000068888.02977.DA [doi]
PST - ppublish
SO  - Anesth Analg. 2003 Aug;97(2):323-332. doi: 10.1213/01.ANE.0000068888.02977.DA.

PMID- 29976047
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20190128
IS  - 0048-7449 (Print)
IS  - 0048-7449 (Linking)
VI  - 70
IP  - 2
DP  - 2018 Jul 6
TI  - Acute myocarditis as a revealing clue of complete Kawasaki disease.
PG  - 115-116
LID - 10.4081/reumatismo.2018.1101 [doi]
AB  - Not available.
FAU - De Rosa, G
AU  - De Rosa G
AD  - Section of Pediatric Cardiology, Fondazione Policlinico Universitario A. Gemelli, 
      Università Cattolica Sacro Cuore, Rome. drigante@gmail.com.
FAU - Andreozzi, L
AU  - Andreozzi L
FAU - Piastra, M
AU  - Piastra M
FAU - Castelli, B
AU  - Castelli B
FAU - Rigante, D
AU  - Rigante D
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20180706
PL  - Italy
TA  - Reumatismo
JT  - Reumatismo
JID - 0401302
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/adverse effects/therapeutic use
MH  - Child, Preschool
MH  - Dipyridamole/therapeutic use
MH  - Drug Substitution
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Mucocutaneous Lymph Node Syndrome/*complications/diagnosis
MH  - Myocarditis/*etiology/therapy
MH  - Shock, Cardiogenic/etiology
EDAT- 2018/07/07 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/07/07 06:00
PHST- 2017/11/20 00:00 [received]
PHST- 2018/02/06 00:00 [accepted]
PHST- 2018/02/06 00:00 [revised]
PHST- 2018/07/07 06:00 [entrez]
PHST- 2018/07/07 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
AID - 10.4081/reumatismo.2018.1101 [doi]
PST - epublish
SO  - Reumatismo. 2018 Jul 6;70(2):115-116. doi: 10.4081/reumatismo.2018.1101.

PMID- 3410599
OWN - NLM
STAT- MEDLINE
DCOM- 19880926
LR  - 20131121
IS  - 0174-4879 (Print)
IS  - 0174-4879 (Linking)
VI  - 26
IP  - 5
DP  - 1988 May
TI  - Aspirin dose, bleeding time, platelet adhesion and aggregation in cerebral 
      thrombosis.
PG  - 237-42
AB  - Bleeding time, platelet aggregation and platelet adhesiveness were measured 
      before and after each of 11 consecutive therapeutic sequences in 17 patients who 
      had recently suffered a cerebro-vascular accident of atheromatous ischemic 
      origin. The first 10 sequences were each of 15 days duration and during the first 
      8 of these, aspirin was increased with each sequence from 300 mg/2 days to 3 
      g/day. During the 10th sequence a placebo was given. The final sequence (11th) 
      lasted 3 months and during this time the dose of aspirin was fixed at 1 g/day. 
      Significant modification of platelet aggregation was obtained with 300 mg/2 days, 
      platelet adhesiveness was significantly modified with 500 mg/2 days while 
      significant bleeding time modification required a minimum 500 mg/day. The results 
      did not vary significantly with higher doses of acetylsalicylic acid (ASA). Only 
      the results for the platelet aggregation were individually reproducible. There 
      was no statistical correlation between the results of the tests. As far as the 3 
      tests are considered, the best efficiency is obtained with the therapeutic range 
      of 500 mg to 1 g/day.
FAU - Lejeune, A
AU  - Lejeune A
AD  - Department of Neurosciences, Henri Mondor Hospital, Créteil, France.
FAU - Fattet, M
AU  - Fattet M
FAU - Degos, J D
AU  - Degos JD
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther Toxicol
JT  - International journal of clinical pharmacology, therapy, and toxicology
JID - 8003415
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Bleeding Time
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Intracranial Embolism and Thrombosis/blood/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/*drug effects
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther Toxicol. 1988 May;26(5):237-42.

PMID- 12032391
OWN - NLM
STAT- MEDLINE
DCOM- 20030711
LR  - 20190916
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 13
IP  - 4
DP  - 2002 Jun
TI  - Effect of aspirin treatment in patients with peripheral arterial disease 
      monitored with the platelet function analyzer PFA-100.
PG  - 277-81
AB  - We have used the platelet analyzer PFA-100TM to assess the effect of aspirin 
      (ASA) in patients with documented peripheral arterial disease (PAD). Thirty-one 
      previously untreated patients were recruited. Laboratory investigations, 
      including the collagen and adenosine diphosphate closure time (CADP-CT) and the 
      collagen and epinephrine closure time (CEPI-CT) were performed before and 7 days 
      after treatment with 100 mg ASA per day. Five patients were excluded from the 
      final analysis: one patient did not appear for second examination, in one patient 
      type I von Willebrand disease was diagnosed, and three patients with prolonged 
      CEPI-CT admitted the intake of non-steroidal anti-inflammatory drugs. Prior to 
      ASA treatment, CADP-CT was 90 +/- 15 s (range, 67-124 s) and CEPI-CT was 116 +/- 
      27 s (range, 78-164 s). There was a significant negative correlation between 
      CADP-CT and von Willebrand factor antigen (r = -0.57, P = 0.001). After treatment 
      with 100 mg ASA per day, CADP-CT was not significantly different (96 +/- 22 s; 
      range, 65-158 s). CEPI-CT, however, was prolonged in all patients, compared with 
      pre-ASA values (226 +/- 82 s; range, 89 to > 300 s). In 12 of 26 patients, 
      CEPI-CT was > 300 s and in another four of 26 patients CEPI-CT was prolonged to 
      more than the upper normal range ('responders'). In the remaining 10 patients, 
      CEPI-CT values did not exceed the upper limit of the normal range 
      ('non-responders'). Five non-responders were re-investigated after intake of 300 
      mg ASA per day for 3 weeks; in none of these was a CEPI-CT > 165 s recorded. We 
      conclude that 40% of PAD patients have an inadequate response to ASA, as 
      determined by the PFA-100TM CEPI-CT. Whether these patients have a reduced 
      benefit from this treatment remains to be investigated.
FAU - Roller, R E
AU  - Roller RE
AD  - Department of Internal Medicine, Division of Angiology, Karl Franzens University 
      School of Medicine, Graz, Austria. Regina.Korninger@kfunigraz.ac.at
FAU - Dorr, A
AU  - Dorr A
FAU - Ulrich, S
AU  - Ulrich S
FAU - Pilger, E
AU  - Pilger E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Blood Group Antigens)
RN  - 0 (von Willebrand Factor)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Triphosphate
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arterial Occlusive Diseases/blood/*drug therapy
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Group Antigens
MH  - Collagen
MH  - Epinephrine
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Function Tests/instrumentation
MH  - Reference Values
MH  - von Willebrand Factor/analysis
EDAT- 2002/05/29 10:00
MHDA- 2003/07/12 05:00
CRDT- 2002/05/29 10:00
PHST- 2002/05/29 10:00 [pubmed]
PHST- 2003/07/12 05:00 [medline]
PHST- 2002/05/29 10:00 [entrez]
AID - 10.1097/00001721-200206000-00001 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2002 Jun;13(4):277-81. doi: 
      10.1097/00001721-200206000-00001.

PMID- 2591925
OWN - NLM
STAT- MEDLINE
DCOM- 19900125
LR  - 20161020
IS  - 0257-7712 (Print)
IS  - 0257-7712 (Linking)
VI  - 20
IP  - 2
DP  - 1989 Jun
TI  - [Kinetics of solid-state decomposition of aspirin].
PG  - 153-6
AB  - The kinetics of the solid-state decomposition of aspirin was studied at 85 
      degrees, 80 degrees, 75 degrees, 70 degrees C and various relative humidities. 
      Decomposition percentage of aspirin (x) and time (t) could be described by the 
      equation: x = ktn where k is a constant which depends on the temperature and 
      relative humidity. The water vapour pressure effected on the solid-state 
      decomposition of aspirin may be presented by the Arrhenius equation: k = A.exp 
      (-E/RT).Ps where T is the absolute temperature, P is water vapour pressure, s is 
      a constant, R is the gas constant, A is another constant, E is the activation 
      energy. From this equation, the activation energy of the decomposition of aspirin 
      is calculated to be 122.17kJ.mol-1 (29.2 kcal.mol-1).
FAU - He, P
AU  - He P
FAU - Gao, Q Y
AU  - Gao QY
FAU - Yin, G K
AU  - Yin GK
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Hua Xi Yi Ke Da Xue Xue Bao
JT  - Hua xi yi ke da xue xue bao = Journal of West China University of Medical 
      Sciences = Huaxi yike daxue xuebao
JID - 8609552
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - Drug Stability
MH  - Kinetics
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
PST - ppublish
SO  - Hua Xi Yi Ke Da Xue Xue Bao. 1989 Jun;20(2):153-6.

PMID- 20035849
OWN - NLM
STAT- MEDLINE
DCOM- 20100520
LR  - 20131121
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 388
IP  - 1-2
DP  - 2010 Mar 30
TI  - Measurement and prediction of solubilities of active pharmaceutical ingredients.
PG  - 73-81
LID - 10.1016/j.ijpharm.2009.12.036 [doi]
AB  - Solubilities of 2-acetoxy benzoic acid (aspirin), N-acetyl-p-aminophenol 
      (paracetamol) and 2-(p-isobutylphenyl)propionic acid (ibuprofen) have been 
      measured in various solvents and compared with published and predicted data. For 
      the prediction besides the two group contribution models UNIFAC and modified 
      UNIFAC (Dortmund) the quantum chemical approach COSMO-RS (Ol) was used. 
      Additionally melting temperatures and heats of fusion for 2-acetoxy benzoic acid, 
      N-acetyl-p-aminophenol and 2-(p-isobutylphenyl)propionic acid required for the 
      calculations have been determined by differential scanning calorimetry.
CI  - Copyright (c) 2009 Elsevier B.V. All rights reserved.
FAU - Hahnenkamp, Inga
AU  - Hahnenkamp I
AD  - Carl von Ossietzky Universität Oldenburg, Technische Chemie, D-26111 Oldenburg, 
      Germany.
FAU - Graubner, Gitte
AU  - Graubner G
FAU - Gmehling, Jürgen
AU  - Gmehling J
LA  - eng
PT  - Journal Article
DEP - 20091224
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Solvents)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/*chemistry
MH  - Aspirin/*chemistry
MH  - Calorimetry, Differential Scanning
MH  - Chemistry, Pharmaceutical/methods
MH  - Ibuprofen/*chemistry
MH  - Models, Chemical
MH  - Solubility
MH  - Solvents/*chemistry
MH  - Transition Temperature
EDAT- 2009/12/29 06:00
MHDA- 2010/05/21 06:00
CRDT- 2009/12/29 06:00
PHST- 2008/10/29 00:00 [received]
PHST- 2009/12/11 00:00 [revised]
PHST- 2009/12/16 00:00 [accepted]
PHST- 2009/12/29 06:00 [entrez]
PHST- 2009/12/29 06:00 [pubmed]
PHST- 2010/05/21 06:00 [medline]
AID - S0378-5173(09)00910-7 [pii]
AID - 10.1016/j.ijpharm.2009.12.036 [doi]
PST - ppublish
SO  - Int J Pharm. 2010 Mar 30;388(1-2):73-81. doi: 10.1016/j.ijpharm.2009.12.036. Epub 
      2009 Dec 24.

PMID- 35381686
OWN - NLM
STAT- MEDLINE
DCOM- 20220505
LR  - 20220716
IS  - 2093-5978 (Electronic)
IS  - 2093-596X (Print)
IS  - 2093-596X (Linking)
VI  - 37
IP  - 2
DP  - 2022 Apr
TI  - Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in 
      Patients with Diabetes and High Risk of Cardiovascular Disease.
PG  - 233-242
LID - 10.3803/EnM.2021.1353 [doi]
AB  - BACKGROUND: The role of aspirin in primary cardiovascular disease prevention in 
      patients with diabetes remains controversial. However, some studies have 
      suggested beneficial effects of cilostazol on cardiovascular disease in patients 
      with diabetes. We prospectively investigated the antiplatelet effects of 
      cilostazol compared with aspirin in patients with diabetes and cardiovascular 
      risk factors. METHODS: We randomly assigned 116 patients with type 2 diabetes and 
      cardiovascular risk factors but no evident cardiovascular disease to receive 
      aspirin at a dose of 100 mg or cilostazol at a dose of 200 mg daily for 14 days. 
      The primary efficacy outcome was antiplatelet effects of aspirin and cilostazol 
      assessed with the VerifyNow system (aspirin response units [ARU]) and PFA-100 
      (closure time [CT]). Secondary outcomes were changes of clinical laboratory data 
      (ClinicalTrials.gov Identifier: NCT02933788). RESULTS: After 14 days, there was 
      greater decrease in ARU in aspirin (-28.9%±9.9%) compared cilostazol (-0.4%±7.1%, 
      P<0.001) and was greater increase in CT in aspirin (99.6%±63.5%) compared 
      cilostazol (25.7%±54.1%, P<0.001). The prevalence of aspirin resistance was 7.5% 
      according to VerifyNow (defined by ARU ≥550) and 18.9% according to PFA-100 (CT 
      <192 seconds). Compared with aspirin, cilostazol treatment was associated with 
      increased high density lipoprotein cholesterol (7.1%±12.7% vs. 4.2%±18.0%, 
      P=0.006) and decreased triglycerides (-9.4%±33.7% vs. 4.4%±17.57%, P=0.016). 
      However, there were no significant changes in total and low density lipoprotein 
      cholesterol, C-reactive protein level, and cluster of differentiation 40 ligand 
      between cilostazol and aspirin groups. CONCLUSION: Aspirin showed better 
      antiplatelet effects assessed with VerifyNow and PFA-100 compared with 
      cilostazol. However, there were favorable changes in atherogenic dyslipidemia 
      only in the cilostazol.
FAU - Hong, Sangmo
AU  - Hong S
AD  - Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang 
      University College of Medicine, Guri, Korea.
FAU - Lee, Woo Je
AU  - Lee WJ
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
FAU - Park, Cheol-Young
AU  - Park CY
AD  - Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan 
      University School of Medicine, Seoul, Korea.
LA  - eng
SI  - ClinicalTrials.gov/NCT02933788
GR  - 021-402-00003/Otsuka Korea/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220406
PL  - Korea (South)
TA  - Endocrinol Metab (Seoul)
JT  - Endocrinology and metabolism (Seoul, Korea)
JID - 101554139
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - *Cilostazol/therapeutic use
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
PMC - PMC9081299
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular diseases
OT  - Cilostazol
OT  - Platelet aggregation
OT  - Platelet aggregation inhibitors
COIS- CONFLICTS OF INTEREST This study was supported by Otsuka Korea (021-402-00003).
EDAT- 2022/04/07 06:00
MHDA- 2022/05/06 06:00
CRDT- 2022/04/06 00:18
PHST- 2021/12/07 00:00 [received]
PHST- 2022/02/07 00:00 [accepted]
PHST- 2022/04/07 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2022/04/06 00:18 [entrez]
AID - EnM.2021.1353 [pii]
AID - enm-2021-1353 [pii]
AID - 10.3803/EnM.2021.1353 [doi]
PST - ppublish
SO  - Endocrinol Metab (Seoul). 2022 Apr;37(2):233-242. doi: 10.3803/EnM.2021.1353. 
      Epub 2022 Apr 6.

PMID- 8313550
OWN - NLM
STAT- MEDLINE
DCOM- 19940318
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 89
IP  - 2
DP  - 1994 Feb
TI  - Low-dose aspirin inhibits platelet-induced contraction of the human isolated 
      coronary artery. A role for additional 5-hydroxytryptamine receptor antagonism 
      against coronary vasospasm?
PG  - 623-9
AB  - BACKGROUND: The beneficial effect of low-dose aspirin in the prevention of 
      coronary vasospasm is well documented. In this study, we investigated the 
      contractile effect of human washed platelets on the human isolated coronary 
      artery. We concentrated on the effect of low-dose aspirin (40 mg/d) taken by the 
      platelet donor and on the efficacy of thromboxane A2 (TXA2) and 
      5-hydroxytryptamine (5-HT) receptor antagonists. METHODS AND RESULTS: Human 
      coronary artery segments were suspended in an organ bath set-up for isometric 
      tension measurement. Platelets (10(9) to 3 x 10(10)/L) elicited 
      concentration-dependent contractile responses of the coronary artery segments, 
      reaching 28.4 +/- 7.1% of contractions induced by 100 mmol/L K+. The contractile 
      response tended to be decreased in vessel segments with histological signs of 
      early atherosclerosis. Contraction was significantly attenuated after 
      pretreatment of the vessel segments with ketanserin (5-HT2 receptor antagonist, 1 
      mumol/L) or SQ30741 (TXA2 receptor antagonist, 0.01 mumol/L), reaching 8.8 +/- 
      2.3% and 3.2 +/- 2.2% of contraction to 100 mmol/L K+, respectively. Platelets 
      obtained from the same platelet donors after they had taken aspirin (40 mg/d for 
      7 to 13 days) caused significantly lower contractile responses (7.6 +/- 2.7% of 
      100 mmol/L K+) associated with an almost selective inhibition of the synthesis of 
      thromboxane measured in the organ bath solution (untreated platelets, 2.19 +/- 
      0.43 nmol/L; aspirin-treated platelets, 0.66 +/- 0.05 nmol/L). The amount of 5-HT 
      secreted in the organ bath remained unaltered (65.17 +/- 9.94 and 64.03 +/- 8.98 
      nmol/L, respectively). This explains why ketanserin significantly attenuated the 
      residual contractile responses caused by platelets obtained from aspirin-treated 
      subjects, whereas SQ30741 caused minor, nonsignificant additional attenuation. 
      CONCLUSIONS: The results of the present study therefore suggest that additional 
      antagonism of the contractile 5-HT receptors in the coronary artery may increase 
      the efficacy of low-dose aspirin in vivo.
FAU - Bax, W A
AU  - Bax WA
AD  - Department of Pharmacology, Faculty of Medicine and Health Sciences, Erasmus 
      University Rotterdam, The Netherlands.
FAU - Renzenbrink, G J
AU  - Renzenbrink GJ
FAU - van der Linden, E A
AU  - van der Linden EA
FAU - Zijlstra, F J
AU  - Zijlstra FJ
FAU - van Heuven-Nolsen, D
AU  - van Heuven-Nolsen D
FAU - Fekkes, D
AU  - Fekkes D
FAU - Bos, E
AU  - Bos E
FAU - Saxena, P R
AU  - Saxena PR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Eicosanoids)
RN  - 0 (Serotonin Antagonists)
RN  - 333DO1RDJY (Serotonin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/*physiology
MH  - Child
MH  - Coronary Vasospasm/*prevention & control
MH  - Coronary Vessels/drug effects/pathology/physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Eicosanoids/pharmacology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Osmolar Concentration
MH  - Serotonin/pharmacology
MH  - *Serotonin Antagonists
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
AID - 10.1161/01.cir.89.2.623 [doi]
PST - ppublish
SO  - Circulation. 1994 Feb;89(2):623-9. doi: 10.1161/01.cir.89.2.623.

PMID- 35716933
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220927
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 364
DP  - 2022 Oct 1
TI  - Predictors of antiplatelet cessation in a real-world patient population 
      undergoing non-cardiac surgery after PCI.
PG  - 27-30
LID - S0167-5273(22)00921-4 [pii]
LID - 10.1016/j.ijcard.2022.06.023 [doi]
AB  - BACKGROUND: The optimal perioperative management of antiplatelet therapy (APT) 
      therapy in patients undergoing noncardiac surgery (NCS) following percutaneous 
      coronary intervention (PCI) is unclear. We sought to identify predictors of APT 
      cessation in a real-world cohort of patients undergoing NCS within 1 year of PCI. 
      METHODS: Consecutive patients undergoing PCI at a tertiary center between 2011 
      and 2018 were prospectively enrolled. Perioperative interruption of APT was 
      defined as cessation of either aspirin or P2Y(12) inhibitor between 1 and 14 days 
      prior to NCS. Predictors of APT discontinuation were identified by multivariable 
      Cox regression with stepwise selection of candidate variables. RESULTS: A total 
      of 1092 surgeries corresponding to 747 patients were identified. Overall, there 
      were 487 (44.6%) preoperative antiplatelet interruptions: discontinuation of 
      either P2Y(12) inhibitors only (47.4%), aspirin only (7.9%), or both agents 
      (44.7%). Both patient-specific risk factors (prior stroke, lower BMI, anemia, MI) 
      and procedure specific risk factors (chronic total occlusions, multivessel 
      disease, drug-eluting stent use) affected decisions regarding APT cessation. 
      Likelihood of APT cessation increased in higher-risk surgeries and in patients on 
      more potent P2Y(12) inhibitors (ticagrelor/prasugrel vs clopidogrel) whereas 
      those undergoing NCS <90 days post PCI were less likely to have cessation of APT. 
      CONCLUSION: In this contemporary cohort of post-PCI patients undergoing NCS, 
      patient-, angiographic- and surgery-specific factors all affected decision-making 
      regarding APT cessation. Our findings reflective of real-world practice, 
      highlight the importance of a multidisciplinary team approach to individualize 
      decision making in these patients.
CI  - Copyright © 2022 Elsevier B.V. All rights reserved.
FAU - Koshy, Anoop N
AU  - Koshy AN
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA; Department of Cardiology and The University of 
      Melbourne, Austin Health, Melbourne, Australia.
FAU - Cao, Davide
AU  - Cao D
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA; Cardiovascular Department, Humanitas 
      Gavazzeni, Bergamo, Italy.
FAU - Levin, Matthew A
AU  - Levin MA
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of 
      Medicine at Mount Sinai, New York, NY, USA.
FAU - Sartori, Samantha
AU  - Sartori S
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Giustino, Gennaro
AU  - Giustino G
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Kyaw, Htoo
AU  - Kyaw H
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Claessen, Bimmer
AU  - Claessen B
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Zhang, Zhongjie
AU  - Zhang Z
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Nicolas, Johny
AU  - Nicolas J
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Camaj, Anton
AU  - Camaj A
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Roumeliotis, Anastasios
AU  - Roumeliotis A
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Chandiramani, Rishi
AU  - Chandiramani R
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Bedekar, Rashi
AU  - Bedekar R
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Waseem, Zaha
AU  - Waseem Z
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Bagga, Shiv
AU  - Bagga S
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Kini, Annapoorna
AU  - Kini A
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Sharma, Samin K
AU  - Sharma SK
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA; Center for Interventional Cardiovascular 
      Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular 
      Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, 
      Box 1030, New York, NY 10029-6574, USA. Electronic address: 
      roxana.mehran@mountsinai.org.
LA  - eng
PT  - Journal Article
DEP - 20220615
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Drug-Eluting Stents
MH  - Humans
MH  - *Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation Inhibitors
MH  - Prasugrel Hydrochloride
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - Non-cardiac surgery
OT  - Percutaneous coronary intervention
EDAT- 2022/06/19 06:00
MHDA- 2022/08/10 06:00
CRDT- 2022/06/18 19:36
PHST- 2022/03/26 00:00 [received]
PHST- 2022/05/17 00:00 [revised]
PHST- 2022/06/10 00:00 [accepted]
PHST- 2022/06/19 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2022/06/18 19:36 [entrez]
AID - S0167-5273(22)00921-4 [pii]
AID - 10.1016/j.ijcard.2022.06.023 [doi]
PST - ppublish
SO  - Int J Cardiol. 2022 Oct 1;364:27-30. doi: 10.1016/j.ijcard.2022.06.023. Epub 2022 
      Jun 15.

PMID- 1333741
OWN - NLM
STAT- MEDLINE
DCOM- 19930107
LR  - 20161123
IS  - 0003-0805 (Print)
IS  - 0003-0805 (Linking)
VI  - 146
IP  - 6
DP  - 1992 Dec
TI  - Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects.
PG  - 1531-4
AB  - The FEV1 and urinary leukotriene E4 (LTE4) concentrations were determined in six 
      aspirin-sensitive and six non-aspirin-sensitive asthmatic subjects before and 
      after inhalation challenge with lysine-aspirin or placebo solution. 
      Lysine-aspirin produced a mean fall in FEV1 of 26.7 +/- 4.9% (mean +/- SEM) in 
      subjects with aspirin sensitivity and of 8.5 +/- 6.5% (mean +/- SEM) in 
      non-aspirin-sensitive asthmatic subjects. The mean baseline urinary LTE4 
      concentration of 83 pg/mg creatinine (geometric mean [GM], range 15 to 326 pg/mg 
      creatinine) in aspirin-sensitive subjects was significantly higher than the 33.8 
      pg/mg creatinine (GM, range 10 to 111 pg/mg creatinine) in non-aspirin-sensitive 
      subjects (p = 0.02). In aspirin-sensitive subjects, inhalation challenge with 
      lysine-aspirin produced a significant increase in urinary LTE4 concentration to 
      240 pg/mg creatinine (GM, range 60 to 1,113 pg/mg creatine), which was not 
      observed after placebo challenge. There was no significant change in urinary LTE4 
      concentration after inhalation challenge with either lysine-aspirin or placebo 
      solution in non-aspirin-sensitive asthmatic subjects. Thus, sulfidopeptide 
      leukotrienes are released after inhalation of lysine-aspirin in aspirin-sensitive 
      asthmatic patients.
FAU - Christie, P E
AU  - Christie PE
AD  - Swiss Institute for Asthma and Allergy Research, Davos.
FAU - Tagari, P
AU  - Tagari P
FAU - Ford-Hutchinson, A W
AU  - Ford-Hutchinson AW
FAU - Black, C
AU  - Black C
FAU - Markendorf, A
AU  - Markendorf A
FAU - Schmitz-Schumann, M
AU  - Schmitz-Schumann M
FAU - Lee, T H
AU  - Lee TH
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am Rev Respir Dis
JT  - The American review of respiratory disease
JID - 0370523
RN  - 0 (SRS-A)
RN  - 75715-89-8 (Leukotriene E4)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*analogs & derivatives
MH  - Asthma/physiopathology/*urine
MH  - Bronchial Provocation Tests
MH  - Bronchoconstriction/drug effects
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Leukotriene E4
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - SRS-A/*analogs & derivatives/urine
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
AID - 10.1164/ajrccm/146.6.1531 [doi]
PST - ppublish
SO  - Am Rev Respir Dis. 1992 Dec;146(6):1531-4. doi: 10.1164/ajrccm/146.6.1531.

PMID- 815913
OWN - NLM
STAT- MEDLINE
DCOM- 19760602
LR  - 20200930
IS  - 0037-9727 (Print)
IS  - 0037-9727 (Linking)
VI  - 151
IP  - 3
DP  - 1976 Mar
TI  - Potentiation of the anti-inflammatory and analgesic activity of aspirin by 
      caffeine in the rat.
PG  - 556-60
AB  - Caffeine has been found to potentiate the acute anti-inflammatory activity of 
      aspirin, indomethacin, and phenylbutazone, but not the activity of sodium 
      salicylate or hydrocortisone, in the carrageenan pleurisy or hindlimb models of 
      inflammation in the rat. The mobilization of inflammatory cells was not affected 
      by aspirin in the presence or absence of caffeine. The mild analgesia produced by 
      aspirin was confined to a hyperalgesic test in which this drug was able to reduce 
      inflammation and concomitant hyperalgesia and thereby produce an "apparent" 
      analgesic effect. This "apparent" analgesia produced by aspirin was potentiated 
      by caffeine. The mechanism responsible for the potentiated anti-inflammatory and 
      mild analgesic activity of aspirin remains unknown since caffeine did not alter 
      the plasma salicylate levels or prostaglandin synthetase inhibition produced by 
      aspirin.
FAU - Vinegar, R
AU  - Vinegar R
FAU - Truax, J F
AU  - Truax JF
FAU - Selph, J L
AU  - Selph JL
FAU - Welch, R M
AU  - Welch RM
FAU - White, H L
AU  - White HL
FAU - Ellis, C H
AU  - Ellis CH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Proc Soc Exp Biol Med
JT  - Proceedings of the Society for Experimental Biology and Medicine. Society for 
      Experimental Biology and Medicine (New York, N.Y.)
JID - 7505892
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Salicylates)
RN  - 3G6A5W338E (Caffeine)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Caffeine/pharmacology/*therapeutic use
MH  - Cyclooxygenase Inhibitors
MH  - Drug Therapy, Combination
MH  - Indomethacin/pharmacology
MH  - Inflammation/*drug therapy
MH  - Male
MH  - Phenylbutazone/pharmacology
MH  - Rats
MH  - Salicylates/blood
EDAT- 1976/03/01 00:00
MHDA- 1976/03/01 00:01
CRDT- 1976/03/01 00:00
PHST- 1976/03/01 00:00 [pubmed]
PHST- 1976/03/01 00:01 [medline]
PHST- 1976/03/01 00:00 [entrez]
AID - 10.3181/00379727-151-39257 [doi]
PST - ppublish
SO  - Proc Soc Exp Biol Med. 1976 Mar;151(3):556-60. doi: 10.3181/00379727-151-39257.

PMID- 7713299
OWN - NLM
STAT- MEDLINE
DCOM- 19950515
LR  - 20190816
IS  - 0301-2115 (Print)
IS  - 0301-2115 (Linking)
VI  - 57
IP  - 3
DP  - 1994 Dec
TI  - Conservative management of severe chronic hypertension in pregnancy.
PG  - 215-7
AB  - Severe chronic hypertension in pregnancy is a condition frequently associated 
      with poor maternal and fetal outcome. Meticulous antenatal care can lead to a 
      reduction in morbidity and mortality. The case described is that of a 
      primigravida who presented with severe chronic hypertension in the midtrimester 
      of pregnancy. She was treated with four antihypertensive drugs and aspirin, and a 
      favourable pregnancy outcome was achieved.
FAU - Rienhardt, G W
AU  - Rienhardt GW
AD  - Department of Obstetrics and Gynaecology, University of Stellenbosch, Tygerberg, 
      South Africa.
FAU - Steyn, P S
AU  - Steyn PS
FAU - Odendaal, H J
AU  - Odendaal HJ
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*drug therapy
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
AID - 0028-2243(94)90304-2 [pii]
AID - 10.1016/0028-2243(94)90304-2 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 1994 Dec;57(3):215-7. doi: 
      10.1016/0028-2243(94)90304-2.

PMID- 20482922
OWN - NLM
STAT- MEDLINE
DCOM- 20100607
LR  - 20131121
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 154
DP  - 2010
TI  - [Analysis of the intoxicated patient: pitfalls].
PG  - A1605
AB  - A 39-year-old man was admitted to the ICU after having taken 96 tablets of 500 mg 
      acetylsalicylic acid. Although a high plasma concentration (1040 mg/l) was found, 
      underestimation and misinterpretation of clinical signs and symptoms with 
      decreasing salicylate plasma concentrations led to haemodialysis being postponed. 
      One day after admission the patient suddenly died of cardiovascular collapse due 
      to severe salicylate toxicity. Doctors should be aware that underestimating the 
      severity of salicylate intoxication is a common and dangerous pitfall. Another 
      patient, a 60-year-old woman, was suspected of suffering from toxic alcohol 
      intoxication. She had marked hyperlactaemia (17 mmol/l), which could not be 
      explained from a clinical perspective. However, ethanol was administered 
      intravenously while awaiting the toxic alcohol test results (ethylene glycol: 
      1300 mg/l). The hyperlactaemia was artificial and caused by an interaction 
      between glycolic acid and lactate on a point-of-care analyser. Doctors should 
      consider artificial hyperlactaemia in patients with ethylene glycol intoxication. 
      The patient recovered.
FAU - de Bree, Godelieve J
AU  - de Bree GJ
AD  - Tergooiziekenhuizen, Afd. Intensive Care, Hilversum, The Netherlands.
FAU - Butterhoff-Terlingen, Madelon H
AU  - Butterhoff-Terlingen MH
FAU - Vermeer, Eric H J
AU  - Vermeer EH
FAU - Treskes, Marco
AU  - Treskes M
FAU - van der Linden, Paul D
AU  - van der Linden PD
FAU - Ruys, Thomas A
AU  - Ruys TA
LA  - dut
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Analyse van een patiënt met intoxicatie: valkuilen.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Alcoholic Intoxication/complications/*diagnosis/therapy
MH  - Aspirin/*administration & dosage/*poisoning
MH  - Diagnosis, Differential
MH  - Ethanol/poisoning
MH  - Female
MH  - Humans
MH  - Male
MH  - Poisoning/*diagnosis/*therapy
MH  - Renal Dialysis
MH  - Treatment Outcome
EDAT- 2010/05/21 06:00
MHDA- 2010/06/09 06:00
CRDT- 2010/05/21 06:00
PHST- 2010/05/21 06:00 [entrez]
PHST- 2010/05/21 06:00 [pubmed]
PHST- 2010/06/09 06:00 [medline]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2010;154:A1605.

PMID- 3096843
OWN - NLM
STAT- MEDLINE
DCOM- 19870114
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 16
IP  - 5
DP  - 1986
TI  - Salicylate antagonism of acetylsalicylic acid inhibition of platelet aggregation 
      in male and female subjects: influence of citrate concentration.
PG  - 369-77
AB  - Platelets from volunteers were exposed for 1 min to sodium salicylate (SA) before 
      and after the addition of acetylsalicylic acid (ASA) to produce greater than or 
      equal to 50% inhibition of aggregation induced by arachidonic acid (AA) or 
      collagen. SA:ASA concentrations = 20:1. SA protection against ASA inhibition was 
      always observed even if ASA exposure time was 15 min, whereas reversal could not 
      be demonstrated once exposure of platelets to ASA exceeded a minimum of 3-10 min 
      with AA as the stimulus. Reversal was even less effective when collagen was the 
      stimulus. An apparent, increased sensitivity to SA reversal of ASA inhibition in 
      females disappeared when citrate concentration was adjusted to compensate for 
      lower packed cell volume. The proposed male dependency for protection in ASA 
      treatment of thromboembolic disorders cannot be explained on the basis of 
      differences in the SA-ASA competition at platelet cyclooxygenase and, if collagen 
      is an important in vivo stimulus of platelet interaction with damaged vessel 
      wall, the antagonism of ASA by SA may not be important.
FAU - Philp, R B
AU  - Philp RB
FAU - Paul, M L
AU  - Paul ML
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Arachidonic Acids)
RN  - 0 (Citrates)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 2968PHW8QP (Citric Acid)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/*antagonists & inhibitors/pharmacology
MH  - Citrates/*blood
MH  - Citric Acid
MH  - Collagen/pharmacology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Sex Factors
MH  - Sodium Salicylate/*pharmacology
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1159/000215310 [doi]
PST - ppublish
SO  - Haemostasis. 1986;16(5):369-77. doi: 10.1159/000215310.

PMID- 22408905
OWN - NLM
STAT- MEDLINE
DCOM- 20120320
LR  - 20190715
IS  - 1533-4880 (Print)
IS  - 1533-4880 (Linking)
VI  - 11
IP  - 12
DP  - 2011 Dec
TI  - Thermal decomposition behavior of amino groups modified bimodal mesoporous 
      silicas as aspirin carrier.
PG  - 10324-32
AB  - Two kinds of amino groups were employed to functionalize bimodal mesoporous 
      silicas and related drug carriers were prepared. The characterization results of 
      XRD, N2 adsorption and desorption, FT-IR and TG all confirmed the structural 
      integrity of the bimodal mesopore architecture after introduction treatment of 
      functional groups and the successful adsorption of aspirin. In order to 
      investigate the interaction among the mesoporous structure, the functional groups 
      grafted onto the mesoporous surface and the existential microenvironment of the 
      drug molecules inside the mesoporous channels, the thermal decomposition 
      behaviors of amino groups modified and aspirin loaded carriers were studied based 
      on the thermogravimetric analysis in details. According to the thermogravimetry 
      and derivative thermogravimetry results, the apparent activation energies E(a) of 
      thermal decomposition for all related samples have been evaluated by Kissinger 
      and Flynn-Wall-Ozawa methods. Meanwhile, their thermal decomposition mechanisms 
      have been suggested by using Coats and Redfern methods. All these featured 
      consequence could provide a deeper understanding for large loading capacity and 
      controlled release of drug-carriers in the pharmaceutical application.
FAU - Gao, Lin
AU  - Gao L
AD  - Department of Chemistry and Chemical Engineering, College of Environmental and 
      Energy Engineering, Beijing University of Technology, Beijing 100124, PR China.
FAU - Sun, Jihong
AU  - Sun J
FAU - Zhang, Li
AU  - Zhang L
FAU - Li, Yuzhen
AU  - Li Y
FAU - Ren, Bo
AU  - Ren B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Nanosci Nanotechnol
JT  - Journal of nanoscience and nanotechnology
JID - 101088195
RN  - 0 (Drug Carriers)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Aspirin/*administration & dosage
MH  - *Drug Carriers
MH  - *Silicon Dioxide
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Temperature
MH  - X-Ray Diffraction
EDAT- 2012/03/14 06:00
MHDA- 2012/03/21 06:00
CRDT- 2012/03/14 06:00
PHST- 2012/03/14 06:00 [entrez]
PHST- 2012/03/14 06:00 [pubmed]
PHST- 2012/03/21 06:00 [medline]
AID - 10.1166/jnn.2011.5016 [doi]
PST - ppublish
SO  - J Nanosci Nanotechnol. 2011 Dec;11(12):10324-32. doi: 10.1166/jnn.2011.5016.

PMID- 36232870
OWN - NLM
STAT- MEDLINE
DCOM- 20221017
LR  - 20230308
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 19
DP  - 2022 Sep 30
TI  - Biological Activity of fac-[Re(CO)(3)(phen)(aspirin)], 
      fac-[Re(CO)(3)(phen)(indomethacin)] and Their Original Counterparts against 
      Ishikawa and HEC-1A Endometrial Cancer Cells.
LID - 10.3390/ijms231911568 [doi]
LID - 11568
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) are inhibitors of cyclooxygenase 
      enzyme (COX) and were found to have positive effects in reducing the risk of 
      developing gynecological cancers. However, long-term administration of NSAIDs 
      carries the risk of various side effects, including those in the digestive and 
      circulatory systems. Therefore, there is a constant need to develop new NSAID 
      derivatives. In this work, we investigated rhenium NSAIDs, comparing their 
      effects on endometrial cancer cells with original NSAIDs, demonstrating the high 
      activity of aspirin and indomethacin derivatives. The cytotoxic activity of 
      rhenium derivatives against the Ishikawa and HEC-1A cancer cell lines was higher 
      than that of the original NSAIDs. The IC50 after 24-h incubation of Ishikawa and 
      HEC-1A were 188.06 µM and 394.06 µM for rhenium aspirin and 228.6 µM and 1459.3 
      µM for rhenium indomethacin, respectively. At the same time, IC50 of aspirin and 
      indomethacin were 10,024.42 µM and 3295.3 µM for Ishikawa, and 27,255.8 µM and 
      5489.3 µM for HEC-1A, respectively. Moreover, these derivatives were found to 
      inhibit the proliferation of both cell lines in a time- and state-dependent 
      manner. The Ishikawa cell proliferation was strongly inhibited by rhenium aspirin 
      and rhenium indomethacin after 72-h incubation (*** = p < 0.001), while the 
      HEC-1A proliferation was inhibited by the same agents already after 24-h 
      incubation (*** = p < 0.001). Furthermore, the ROS level in the mitochondria of 
      the tested cells generated in the presence of rhenium derivatives was higher than 
      the original NSAIDs. That was associated with rhenium indomethacin exclusively, 
      which had a significant effect (*** = p < 0.001) on both Ishikawa and HEC-1A 
      cancer cells. Rhenium aspirin had a significant effect (*** = p < 0.001) on the 
      mitochondrial ROS level of Ishikawa cells only. Overall, the research revealed a 
      high potential of the rhenium derivatives of aspirin and indomethacin against 
      endometrial cancer cells compared with the original NSAIDs.
FAU - Kuźmycz, Olga
AU  - Kuźmycz O
AUID- ORCID: 0000-0002-1709-2971
AD  - Department of Molecular Microbiology, Institute of Microbiology, Biotechnology 
      and Immunology, Faculty of Biology and Environmental Protection, University of 
      Lodz, 12/16 Banacha, 90-237 Lodz, Poland.
FAU - Kowalczyk, Aleksandra
AU  - Kowalczyk A
AUID- ORCID: 0000-0001-9607-7173
AD  - Department of Molecular Microbiology, Institute of Microbiology, Biotechnology 
      and Immunology, Faculty of Biology and Environmental Protection, University of 
      Lodz, 12/16 Banacha, 90-237 Lodz, Poland.
FAU - Stączek, Paweł
AU  - Stączek P
AUID- ORCID: 0000-0003-4416-8289
AD  - Department of Molecular Microbiology, Institute of Microbiology, Biotechnology 
      and Immunology, Faculty of Biology and Environmental Protection, University of 
      Lodz, 12/16 Banacha, 90-237 Lodz, Poland.
LA  - eng
GR  - SONATA 17 UMO-2021/43/D/NZ7/01386/National Science Center/
GR  - B2111000000038.01/University of Lodz/
PT  - Journal Article
DEP - 20220930
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Reactive Oxygen Species)
RN  - 7440-15-5 (Rhenium)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Cyclooxygenase 2
MH  - *Endometrial Neoplasms/drug therapy/metabolism
MH  - Female
MH  - Humans
MH  - Indomethacin/pharmacology/therapeutic use
MH  - Reactive Oxygen Species
MH  - *Rhenium/pharmacology
PMC - PMC9569891
OTO - NOTNLM
OT  - NSAIDs
OT  - endometrial cancer
OT  - rhenium compounds
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/15 06:00
MHDA- 2022/10/18 06:00
CRDT- 2022/10/14 02:10
PHST- 2022/09/02 00:00 [received]
PHST- 2022/09/21 00:00 [revised]
PHST- 2022/09/27 00:00 [accepted]
PHST- 2022/10/14 02:10 [entrez]
PHST- 2022/10/15 06:00 [pubmed]
PHST- 2022/10/18 06:00 [medline]
AID - ijms231911568 [pii]
AID - ijms-23-11568 [pii]
AID - 10.3390/ijms231911568 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Sep 30;23(19):11568. doi: 10.3390/ijms231911568.

PMID- 10796639
OWN - NLM
STAT- MEDLINE
DCOM- 20000706
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 2
DP  - 2000
TI  - Aspirin for vascular dementia.
PG  - CD001296
AB  - BACKGROUND: For patients with a diagnosis of vascular dementia there is evidence 
      that aspirin is widely prescribed - in one study, completed by geriatricians and 
      psychiatrists in the UK, 80% of patients with cognitive impairment (with vascular 
      risk factors) were prescribed aspirin. However, a number of queries remain 
      unanswered: Is there convincing evidence that aspirin benefits patients with 
      vascular dementia? Does aspirin affect cognition or improve prognosis? In 
      addition, does the risk of cerebral or gastric haemorrhage outweigh any benefit? 
      The aim of this review is to assess the evidence of effectiveness of aspirin in 
      those with a diagnosis of vascular dementia. OBJECTIVES: To assess the evidence 
      of effectiveness of the use of aspirin for vascular dementia. SEARCH STRATEGY: 
      Computerised databases were searched independently by two reviewers. In addition, 
      relevant websites were searched and some journals were handsearched. Specialists 
      in the field were approached for unpublished material and also any publications 
      found were searched for additional references. SELECTION CRITERIA: All randomised 
      controlled trials investigating the effect of aspirin for vascular dementia are 
      included. Inclusion/exclusion of studies comprised systematic assessment of the 
      quality of study design and the risk of bias. DATA COLLECTION AND ANALYSIS: Data 
      were extracted independently by both reviewers, using a previously tested data 
      extraction form and, where required, authors were contacted for data not provided 
      in the papers. The aim was to evaluate data recorded via tools assessing 
      cognitive and behavioural changes along with mortality, morbidity and 
      institutionalisation data. MAIN RESULTS: One randomised controlled trial ( 
      approximately approximately Meyer 1989 approximately approximately ) was 
      included, and yielded data for analysis on a total of 70 patients. The only 
      relevant outcome assessed in this trial was cognition. Change in cognitive 
      outcome was towards being in favour of treatment. REVIEWER'S CONCLUSIONS: There 
      is very limited evidence that aspirin is effective in treating patients with a 
      diagnosis of vascular dementia. Further research is needed to assess the effect 
      of aspirin on cognition, and also on additional outcomes such as behaviour, and 
      quality of life. At present it is not possible to provide evidence for other 
      queries regarding the use of aspirin for dementia (these are described in the 
      Background section of this review).
FAU - Williams, P S
AU  - Williams PS
AD  - Child & Adolescent Psychiatry, Camden & Islington CHS NHS Trust, 186a Park Road, 
      Crouch End, London, UK, N8 8JJ. plastix@cableinet.co.uk
FAU - Spector, A
AU  - Spector A
FAU - Orrell, M
AU  - Orrell M
FAU - Rands, G
AU  - Rands G
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UIN - Cochrane Database Syst Rev. 2000;(4):CD001296. PMID: 11034710
MH  - Aspirin/*therapeutic use
MH  - Cognition Disorders/drug therapy
MH  - Dementia, Vascular/*drug therapy
MH  - Humans
RF  - 1
EDAT- 2000/05/05 09:00
MHDA- 2000/07/08 11:00
CRDT- 2000/05/05 09:00
PHST- 2000/05/05 09:00 [pubmed]
PHST- 2000/07/08 11:00 [medline]
PHST- 2000/05/05 09:00 [entrez]
AID - CD001296 [pii]
AID - 10.1002/14651858.CD001296 [doi]
PST - ppublish
SO  - Cochrane Database Syst Rev. 2000;(2):CD001296. doi: 10.1002/14651858.CD001296.

PMID- 2237853
OWN - NLM
STAT- MEDLINE
DCOM- 19901227
LR  - 20131121
IS  - 0029-2001 (Print)
IS  - 0029-2001 (Linking)
VI  - 110
IP  - 23
DP  - 1990 Sep 30
TI  - [Acetylsalicylic acid in the prevention of arterial thrombosis. Dosage problems 
      in general and in the authors' experiment].
PG  - 3009-11
AB  - Acetylsalicylic acid is now accepted as a clinically useful drug for secondary 
      prophylaxis against several thromboembolic complications, but there is still much 
      controversy about the dosage. We discuss this problem, in the light of data from 
      newly published clinical trials and of results from a pharmacological study 
      performed by ourselves. All in all it seems reasonable to recommend 100-150 mg 
      acetylsalicylic acid per day for prophylaxis after acute myocardial infarction. 
      As for cerebrovascular indications, no clinical data available so far justify a 
      dose reduction below 300 mg.
FAU - Stormorken, H
AU  - Stormorken H
AD  - Rikshospitalet, Oslo.
FAU - Berg, K J
AU  - Berg KJ
FAU - Bratvedt, A
AU  - Bratvedt A
FAU - Nygaard, B
AU  - Nygaard B
LA  - nor
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Acetylsalisylsyre ved arteriell tromboseprofylakse. Doseringsproblemet generelt 
      og belyst ved eget forsøk.
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny 
      raekke
JID - 0413423
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Thrombosis/*prevention & control
EDAT- 1990/09/30 00:00
MHDA- 1990/09/30 00:01
CRDT- 1990/09/30 00:00
PHST- 1990/09/30 00:00 [pubmed]
PHST- 1990/09/30 00:01 [medline]
PHST- 1990/09/30 00:00 [entrez]
PST - ppublish
SO  - Tidsskr Nor Laegeforen. 1990 Sep 30;110(23):3009-11.

PMID- 10199831
OWN - NLM
STAT- MEDLINE
DCOM- 19990518
LR  - 20190125
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 276
IP  - 4
DP  - 1999 Apr
TI  - LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate 
      PMN azurophilic degranulation.
PG  - C988-94
LID - 10.1152/ajpcell.1999.276.4.C988 [doi]
AB  - The eicosanoid lipoxin A4 (LXA4) is biosynthesized in vivo by cells present at 
      inflammatory sites and appears to be an endogenous anti-inflammatory mediator. 
      Further, in the presence of aspirin, the 15-epimer of LXA4 (15-epi-LXA4) is 
      biosynthesized and may mediate some of aspirin's desirable bioactions. LXA4, 
      15-epi-LXA4, and their stable analogs inhibit inflammation in established animal 
      models, indicating that these compounds may be useful for treating inflammatory 
      disease states. To investigate the cellular mechanisms by which these lipid 
      mediators downregulate inflammation, we investigated whether these eicosanoids 
      could influence receptor-mediated degranulation of human neutrophils, an event 
      thought to play a major causative role in several inflammatory disease states. 
      LXA4, 15-epi-LXA4, and their stable analogs potently (IC50 < 1 nM) and 
      selectively downregulated neutrophil release of azurophilic granule contents but 
      did not affect other neutrophil secretory functions. Thus the cellular basis of 
      action of these natural off-switches to inflammation appears to involve 
      downregulation of neutrophil azurophilic granule release.
FAU - Gewirtz, A T
AU  - Gewirtz AT
AD  - Department of Pathology and Laboratory Medicine, Emory University School of 
      Medicine, Atlanta, Georgia, USA. agewirt@emory.edu
FAU - Fokin, V V
AU  - Fokin VV
FAU - Petasis, N A
AU  - Petasis NA
FAU - Serhan, C N
AU  - Serhan CN
FAU - Madara, J L
AU  - Madara JL
LA  - eng
GR  - DK-35932/DK/NIDDK NIH HHS/United States
GR  - DK-47662/DK/NIDDK NIH HHS/United States
GR  - DK-50305/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - 0 (Lipoxins)
RN  - 0 (Receptors, IgG)
RN  - 0 (lipoxin A4)
RN  - 11062-77-4 (Superoxides)
RN  - EC 3.4.21.37 (Leukocyte Elastase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cell Degranulation/*drug effects/physiology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Hydroxyeicosatetraenoic Acids/*pharmacology
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Leukocyte Elastase/metabolism
MH  - *Lipoxins
MH  - Neutrophils/drug effects/*physiology
MH  - Receptors, IgG/drug effects/physiology
MH  - Superoxides/blood
EDAT- 1999/04/13 00:00
MHDA- 1999/04/13 00:01
CRDT- 1999/04/13 00:00
PHST- 1999/04/13 00:00 [pubmed]
PHST- 1999/04/13 00:01 [medline]
PHST- 1999/04/13 00:00 [entrez]
AID - 10.1152/ajpcell.1999.276.4.C988 [doi]
PST - ppublish
SO  - Am J Physiol. 1999 Apr;276(4):C988-94. doi: 10.1152/ajpcell.1999.276.4.C988.

PMID- 571667
OWN - NLM
STAT- MEDLINE
DCOM- 19790728
LR  - 20190812
IS  - 0001-6101 (Print)
IS  - 0001-6101 (Linking)
VI  - 205
IP  - 5
DP  - 1979
TI  - Thrombotic thrombocytopenic purpura: treatment with a combination of antiplatelet 
      drugs.
PG  - 437-9
AB  - Thrombotic thrombocytopenic purpura (TTP) is a rare disease with a vary high 
      mortality. Different modalities of therapy have been tried, but often with no 
      effect. Recently, interest has focused on drugs interfering with platelet 
      function, though few patients have received antiplatelet drugs as the only 
      therapy. We describe a patient with TTP, who recovered completely on a 
      combination therapy with dextran, aspirin and dipyridamole.
FAU - Birgens, H
AU  - Birgens H
FAU - Ernst, P
AU  - Ernst P
FAU - Hansen, M S
AU  - Hansen MS
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Sweden
TA  - Acta Med Scand
JT  - Acta medica Scandinavica
JID - 0370330
RN  - 0 (Dextrans)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Dextrans/administration & dosage/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Disseminated Intravascular Coagulation/drug therapy
MH  - Drug Evaluation
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Purpura, Thrombotic Thrombocytopenic/*drug therapy
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1111/j.0954-6820.1979.tb06078.x [doi]
PST - ppublish
SO  - Acta Med Scand. 1979;205(5):437-9. doi: 10.1111/j.0954-6820.1979.tb06078.x.

PMID- 3397675
OWN - NLM
STAT- MEDLINE
DCOM- 19880829
LR  - 20131121
IS  - 0398-0499 (Print)
IS  - 0398-0499 (Linking)
VI  - 13
IP  - 2
DP  - 1988
TI  - [Erythermalgia].
PG  - 159-61
AB  - Erythromelalgia is a vascular acrosyndrome affecting mainly the feet and 
      triggered by elevation of room temperature. It may be primary, or secondary, in 
      particular to a polycythemia, when an increased platelet count plays an essential 
      role, explaining the beneficial effect of aspirin or NSAI agents that inhibit 
      platelet prostaglandin cyclo-oxygenase. The favorable action of beta-blockers 
      could result from the possible existence of an anomaly of cutaneous adrenergic 
      nerves.
FAU - Hodara, M
AU  - Hodara M
AD  - Service des maladies cardio-vasculaires, Hôpital Cochin, Paris.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Erythermalgie.
PL  - France
TA  - J Mal Vasc
JT  - Journal des maladies vasculaires
JID - 7707965
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Erythromelalgia/drug therapy/*physiopathology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Skin Temperature
MH  - Vasodilation
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - J Mal Vasc. 1988;13(2):159-61.

PMID- 33518601
OWN - NLM
STAT- MEDLINE
DCOM- 20210610
LR  - 20210610
IS  - 1347-5223 (Electronic)
IS  - 0009-2363 (Linking)
VI  - 69
IP  - 2
DP  - 2021
TI  - Understanding Crystal Cleavability and Physical Properties of Crystal Surfaces 
      Using in Silico Simulation.
PG  - 185-198
LID - 10.1248/cpb.c20-00719 [doi]
AB  - In the drug formulation process, compound dissolution rate and wettability may be 
      improved by grinding. However, there is no method to understand the effects of 
      the wettability of the crystal facets of the ground product. Here, 
      acetylsalicylic acid (ASA) was used to evaluate the changes in crystal morphology 
      and dissolution rate by jet milling using powder X-ray diffraction and in silico 
      simulation. Several cleavage facets were observed in cube crystals, and the (0 0 
      2) facet was observed in plate crystals. Furthermore, the dissolution rate of the 
      ground samples per unit area decreased with the cleavage of the (1 0 0) and (0 0 
      2) facets. The polar surface energy of the ground sample decreased with 
      increasing grinding pressure. The simulation results showed that the absolute 
      attachment energy of the (1 0 0) and (0 0 2) facets was lower than that of the 
      other crystal facets. Moreover, atoms with low polarity were present on the 
      crystal surface of (0 0 2). The wettability and dissolution rate of the (0 0 2) 
      facet were worse than those of the (1 0 0) facet. It was suggested that the 
      dissolution rate of the ground sample was affected by the wettability of the 
      crystal facet caused by the cleavage. The cleavability and wettability may be 
      understood by simulation.
FAU - Hatanaka, Toshiaki
AU  - Hatanaka T
AD  - Tsumura Co., Ltd.
FAU - Yoshihashi, Yasuo
AU  - Yoshihashi Y
AD  - Faculty of Pharmaceutical Sciences, Toho University.
FAU - Terada, Katsuhide
AU  - Terada K
AD  - Faculty of Pharmacy, Takasaki University of Health and Welfare.
FAU - Yonemochi, Etsuo
AU  - Yonemochi E
AD  - School of Pharmacy and Pharmaceutical Sciences, Hoshi University.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - 0 (Powders)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - *Computer Simulation
MH  - Crystallization
MH  - Drug Compounding
MH  - Particle Size
MH  - Powders/*chemistry
MH  - Pressure
MH  - Solubility
MH  - Surface Properties
MH  - Wettability
MH  - X-Ray Diffraction
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - cleavage
OT  - crystal facet
OT  - in silico simulation
OT  - wettability
EDAT- 2021/02/02 06:00
MHDA- 2021/06/11 06:00
CRDT- 2021/02/01 05:49
PHST- 2021/02/01 05:49 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/06/11 06:00 [medline]
AID - 10.1248/cpb.c20-00719 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 2021;69(2):185-198. doi: 10.1248/cpb.c20-00719.

PMID- 21902904
OWN - NLM
STAT- MEDLINE
DCOM- 20111018
LR  - 20131121
IS  - 1479-1072 (Print)
IS  - 1479-1064 (Linking)
VI  - 19
IP  - 4
DP  - 2011
TI  - Aspirin bleeding in perspective.
PG  - 251-3
AB  - Aspirin therapy should be an adjunct to the medical management of patients who 
      have had a vascular event but the role of aspirin prophylaxis in the primary 
      prevention of vascular events is less clear. This benefit-versus-risk balance 
      may, however, be influenced by evidence that aspirin reduces bowel cancer risk. 
      Wider aspirin use could lead to more advice being sought on its use from 
      community pharmacists and general practitioners. Yet 10% of those taking aspirin 
      experience symptoms that negatively affect their daily quality of life. These 
      symptoms, such as heartburn, may discourage more individuals from taking aspirin 
      than would the risk of bleeding.
FAU - Morgan, Gareth
AU  - Morgan G
AD  - Department of Primary Care and Public Health, Cardiff University, University 
      Hospital of Wales, Wales, UK. morgan@fforrdbeck.fsnet.co.uk
FAU - Elwood, Peter
AU  - Elwood P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Qual Prim Care
JT  - Quality in primary care
JID - 101182136
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/administration & dosage/*adverse effects
MH  - Anticoagulants/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Colorectal Neoplasms/prevention & control
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Risk Assessment
EDAT- 2011/09/10 06:00
MHDA- 2011/10/19 06:00
CRDT- 2011/09/10 06:00
PHST- 2011/09/10 06:00 [entrez]
PHST- 2011/09/10 06:00 [pubmed]
PHST- 2011/10/19 06:00 [medline]
PST - ppublish
SO  - Qual Prim Care. 2011;19(4):251-3.

PMID- 6714643
OWN - NLM
STAT- MEDLINE
DCOM- 19840620
LR  - 20190825
IS  - 0306-3623 (Print)
IS  - 0306-3623 (Linking)
VI  - 15
IP  - 2
DP  - 1984
TI  - Interaction between frusemide and aspirin.
PG  - 163-6
AB  - The effects of the combination of aspirin and frusemide were studied on 
      salicylate excretion by aspirin and on the diuresis and excretion of K+ and Na+ 
      by frusemide in normal human subjects. There was a paradoxical net reduction in 
      the natriuresis induced by aspirin, from 29.4 +/- 3.57 m-equiv and frusemide from 
      31.9 +/- 1.27 to 23.7 +/- 1.56 m-equiv on combined administration. Frusemide 
      caused a reduction of the kalliuretic effect induced by aspirin from 48.86 +/- 
      8.36 to 18.3 +/- 3.76 m-equiv. The amount of salicylate excreted over a 3-hr 
      period gave increases of 9.6 and 12.0% when aspirin was administered before 
      frusemide and vice versa, respectively, while there was a 30.4% reduction when 
      administered concomitantly.
FAU - Oyekan, A O
AU  - Oyekan AO
FAU - Laniyonu, A A
AU  - Laniyonu AA
FAU - Ashorobi, R B
AU  - Ashorobi RB
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gen Pharmacol
JT  - General pharmacology
JID - 7602417
RN  - 0 (Salicylates)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Adult
MH  - Aspirin/metabolism/*pharmacology
MH  - Diuresis/drug effects
MH  - Female
MH  - Furosemide/antagonists & inhibitors/*pharmacology
MH  - Humans
MH  - Male
MH  - Natriuresis/drug effects
MH  - Potassium/metabolism
MH  - Salicylates/urine
MH  - Salicylic Acid
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 0306-3623(84)90102-2 [pii]
AID - 10.1016/0306-3623(84)90102-2 [doi]
PST - ppublish
SO  - Gen Pharmacol. 1984;15(2):163-6. doi: 10.1016/0306-3623(84)90102-2.

PMID- 1006255
OWN - NLM
STAT- MEDLINE
DCOM- 19770216
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 106
IP  - 40
DP  - 1976 Oct 2
TI  - [Methodological contribution to the controlled measurement of platelet 
      aggregation].
PG  - 1365-6
AB  - Collagen-induced platelet aggregation was investigated in healthy volunteers 
      under well defined experimental conditions. The Born aggregometer was used and 
      the two parameters studied were the maximum amount and velocity of aggregation. 
      Under these experimental conditions no significant differences in measurements on 
      3 consecutive days were found. In addition, identical results were obtained in 
      the same volunteers 4 and 8 weeks following the first experimental period. This 
      experimental procedure was therefore used to test a new nonsteroid 
      anti-inflammatory agent, RU 43-715, for its effect on platelet aggregation. 
      Furthermore, a controlled crossover study using 3 different substances was 
      performed. In the light of the results in the present study, controlled studies 
      on platelet aggregation can be performed even over on even longer period of time 
      under the experimental conditions described.
FAU - Ohnhaus, E E
AU  - Ohnhaus EE
FAU - Beveridge, T
AU  - Beveridge T
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Methodischer Beitrag zur Messung der Plättchenaggregation unter kontrollierten 
      Bedingungen.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 0 (Anti-Inflammatory Agents)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/standards
MH  - Aspirin/pharmacology
MH  - Collagen
MH  - Drug Evaluation
MH  - Humans
MH  - *Platelet Aggregation/drug effects
EDAT- 1976/10/02 00:00
MHDA- 1976/10/02 00:01
CRDT- 1976/10/02 00:00
PHST- 1976/10/02 00:00 [pubmed]
PHST- 1976/10/02 00:01 [medline]
PHST- 1976/10/02 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1976 Oct 2;106(40):1365-6.

PMID- 17917526
OWN - NLM
STAT- MEDLINE
DCOM- 20090717
LR  - 20191110
IS  - 1751-7141 (Electronic)
IS  - 1520-037X (Linking)
VI  - 10 Suppl 4
DP  - 2007 Fall
TI  - CON: Should aspirin be used in all women older than 65 years to prevent stroke?
PG  - 12-8
AB  - A goal of the Women's Health Study was to evaluate the balance of benefits and 
      risks of low-dose aspirin in the primary prevention of stroke in healthy women. A 
      total of 39,876 female health care professionals aged 45 years and older were 
      randomly assigned to either low-dose aspirin (100 mg every other day) or placebo 
      and followed for an average of 10 years. In the overall study population, aspirin 
      significantly lowered the risk of total and ischemic stroke without affecting the 
      risk of myocardial infarction or death from cardiovascular causes, leading to a 
      nonsignificant finding with respect to the primary end point of total 
      cardiovascular disease. In women aged 65 years or older, aspirin significantly 
      reduced the risk of ischemic stroke, as well as myocardial infarction and total 
      cardiovascular disease. While the findings suggest that aspirin should be 
      considered for primary prevention of stroke in women aged 65 years or older, the 
      balance of benefits and risks would not support recommending aspirin for all 
      women in this age group. The discussion on whether to use aspirin should be had 
      on an individual basis, assessing the net risks and benefits.
FAU - Buring, Julie E
AU  - Buring JE
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA 02215, 
      USA. jburing@rics.bwh.harvard.edu
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Prev Cardiol
JT  - Preventive cardiology
JID - 9813731
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Prev Cardiol. 2007 Fall;10 Suppl 4:6-11. PMID: 17917525
MH  - Age Factors
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/prevention & control
MH  - Female
MH  - Humans
MH  - *Patient Selection
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Stroke/epidemiology/*prevention & control
MH  - Treatment Outcome
MH  - *Women's Health
EDAT- 2007/10/01 00:00
MHDA- 2009/07/18 09:00
CRDT- 2007/10/01 00:00
PHST- 2007/10/01 00:00 [pubmed]
PHST- 2009/07/18 09:00 [medline]
PHST- 2007/10/01 00:00 [entrez]
AID - 10.1111/j.1520-037x.2007.07262.x [doi]
PST - ppublish
SO  - Prev Cardiol. 2007 Fall;10 Suppl 4:12-8. doi: 10.1111/j.1520-037x.2007.07262.x.

PMID- 27030613
OWN - NLM
STAT- MEDLINE
DCOM- 20170110
LR  - 20181202
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 55
IP  - 4
DP  - 2016 Apr 1
TI  - [The present status of aspirin use for primary prevention among hypertensive 
      outpatients in China].
PG  - 267-72
LID - 10.3760/cma.j.issn.0578-1426.2016.04.004 [doi]
AB  - OBJECTIVE: To evaluate the current status of aspirin for primary prevention in 
      hypertensive outpatients in China, and the gap between aspirin use and 
      guidelines. METHODS: This was a multi-center cross-sectional study and carried 
      out in hypertensive patients from 46 hospitals of twenty two cities in China from 
      June to December in 2009. At least 100 essential hypertensive outpatients were 
      consecutively recruited from each participant hospitals according to the 
      consistent inclusion criteria. The patients underwent physical examinations and 
      biochemical analyses, and answered questionnaires. Based on the relevant 
      guidelines, the risk assessment of cardiovascular disease (CVD) is a prerequisite 
      for the proper use of aspirin in primary prevention. RESULTS: A total of 5 206 
      hypertensive outpatients were included. Among them, 1 324 (25.4%) were with a 
      history of CVD. Among those with no history of CVD, 2 705 patients (69.7%) were 
      at high risk of CVD, and the aspirin utilization rate for primary prevention was 
      29.2%, with 32.2% patients at high risk and 22.4% patients at low-medium risk of 
      CVD, respectively. In the application of aspirin for CVD primary prevention, the 
      inappropriate aspirin use rate in patients at low-medium risk was 23.3%. 
      CONCLUSIONS: The proportion of subjects at high risk for CVD is high in 
      hypertensive outpatients suggesting a wide range of application space for 
      aspirin.There exists underutilization for high risk and overutilization for 
      low-medium risk patients in current aspirin primary prevention application.
FAU - Liu, J
AU  - Liu J
AD  - Department of Epidemiology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, 
      China.
FAU - Zhao, D
AU  - Zhao D
FAU - Liu, J
AU  - Liu J
FAU - Qi, Y
AU  - Qi Y
FAU - Sun, J Y
AU  - Sun JY
FAU - Wang, W
AU  - Wang W
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - China
MH  - Cross-Sectional Studies
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Hospitals
MH  - Humans
MH  - Hypertension/*prevention & control
MH  - Outpatients/*statistics & numerical data
MH  - Primary Prevention/*methods
MH  - Risk Assessment
EDAT- 2016/04/01 06:00
MHDA- 2017/01/11 06:00
CRDT- 2016/04/01 06:00
PHST- 2016/04/01 06:00 [entrez]
PHST- 2016/04/01 06:00 [pubmed]
PHST- 2017/01/11 06:00 [medline]
AID - 10.3760/cma.j.issn.0578-1426.2016.04.004 [doi]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2016 Apr 1;55(4):267-72. doi: 
      10.3760/cma.j.issn.0578-1426.2016.04.004.

PMID- 33919943
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 8
DP  - 2021 Apr 14
TI  - The Influence of UV Light on Photodegradation of Acetylsalicylic Acid.
LID - 10.3390/ijms22084046 [doi]
LID - 4046
AB  - Photodegradation of the aqueous solutions of acetylsalicylic acid, in the absence 
      (ASA) and the presence of excipients (ASE), is demonstrated by the 
      photoluminescence (PL). A shift of the PL bands from 342 and 338 nm to 358 and 
      361-397 nm for ASA and ASE in solid state and as aqueous solutions was reported. 
      By exposure of the solution of ASA 0.3 M to UV light, a decrease in the PL band 
      intensity was highlighted. This behavior was revealed for ASA in the presence of 
      phosphate buffer (PB) having the pH equal to 6.4, 7, and 8 or by the interaction 
      with NaOH 0.3 M. A different behavior was reported in the case of ASE. In the 
      presence of PB, an increase in the intensity of the PL band of ASE simultaneously 
      with a change of the ratio between the intensities of the bands at 361-364 and 
      394-397 nm was highlighted. The differences between PL spectra of ASA and ASE 
      have their origin in the presence of salicylic acid (SAL). The interaction of ASE 
      with NaOH induces a shift of the PL band at 405-407 nm. Arguments for the 
      reaction of ASA with NaOH are shown by Raman scattering and FTIR spectroscopy.
FAU - Daescu, Monica
AU  - Daescu M
AUID- ORCID: 0000-0003-3178-5237
AD  - Laboratory of Optical Processes in Nanostructured Materials, National Institute 
      of Materials Physics, Atomistilor Street 405A, POB MG 7, 077125 Bucharest, 
      Romania.
AD  - Faculty of Applied Chemistry & Material Science, University Politehnica of 
      Bucharest, Gh. Polizu Street 1-7, 011061 Bucharest, Romania.
FAU - Iota, Miruna
AU  - Iota M
AD  - Laboratory of Optical Processes in Nanostructured Materials, National Institute 
      of Materials Physics, Atomistilor Street 405A, POB MG 7, 077125 Bucharest, 
      Romania.
FAU - Serbschi, Constantin
AU  - Serbschi C
AD  - Bioelectronic SRL, Cercelus St 54, 100028 Ploiesti, Romania.
FAU - Ion, Alina C
AU  - Ion AC
AD  - Faculty of Applied Chemistry & Material Science, University Politehnica of 
      Bucharest, Gh. Polizu Street 1-7, 011061 Bucharest, Romania.
FAU - Baibarac, Mihaela
AU  - Baibarac M
AD  - Laboratory of Optical Processes in Nanostructured Materials, National Institute 
      of Materials Physics, Atomistilor Street 405A, POB MG 7, 077125 Bucharest, 
      Romania.
LA  - eng
GR  - POC 58/05.09.2016, subcontract D type, no. 2626/04.12.2017/European Regional 
      Development Fund under the Competitiveness Operational Program 2014-2020/
PT  - Journal Article
DEP - 20210414
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Cadmium Compounds)
RN  - 0 (Solutions)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/radiation effects
MH  - Cadmium Compounds/chemistry
MH  - Luminescence
MH  - Photolysis/*radiation effects
MH  - Quantum Dots/chemistry
MH  - Solutions/*radiation effects
MH  - Spectrum Analysis, Raman
MH  - Ultraviolet Rays/adverse effects
MH  - Water/*chemistry
PMC - PMC8070936
OTO - NOTNLM
OT  - IR spectroscopy
OT  - Raman scattering
OT  - acetylsalicylic acid
OT  - photoluminescence
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript; or in the decision to publish the results.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/13 06:00
CRDT- 2021/04/30 01:14
PHST- 2021/03/04 00:00 [received]
PHST- 2021/04/10 00:00 [revised]
PHST- 2021/04/12 00:00 [accepted]
PHST- 2021/04/30 01:14 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
AID - ijms22084046 [pii]
AID - ijms-22-04046 [pii]
AID - 10.3390/ijms22084046 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Apr 14;22(8):4046. doi: 10.3390/ijms22084046.

PMID- 7665973
OWN - NLM
STAT- MEDLINE
DCOM- 19951012
LR  - 20131121
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 126
IP  - 3
DP  - 1995 Sep
TI  - Renal and systemic-hemodynamic response to isovolemic exchange transfusion with 
      hemoglobin cross-linked with bis (3,5-dibromosalicyl) fumarate or albumin.
PG  - 250-60
AB  - Experiments were done in anesthetized rats to determine systemic hemodynamic and 
      renal functional effects of isovolemic exchange transfusion with either 5% 
      albumin or hemoglobin cross-linked with bis (3,5-dibromosalicyl) fumarate (XLHb) 
      in volumes ranging from 1 to 6.3 ml.100 gm-1. Hematocrit decreased in proportion 
      to increasing exchange volumes with either fluid. Exchange with increasing 
      volumes of albumin led to progressive decreases in blood pressure. Exchange of 1 
      ml.100 gm-1 of XLHb was associated with an increase in blood pressure, whereas 
      with larger exchanges, blood pressure returned to and was maintained at control 
      values even for exchanges as large as 6.3 ml.100 gm-1. An increase of similar 
      magnitude in glomerular filtration rate occurred with both fluids. Net and 
      fractional sodium excretion (FENa) increased significantly with both transfusion 
      fluids; the increase was significantly larger for XLHb than for albumin. Maximal 
      FENa excretion with albumin was about 8% but exceeded 6% with XLHb. Pretreatment 
      with indomethacin (5 mg.kg-1.day-1 for 3 days) did not blunt the diuresis that 
      occurred with an exchange of 2 ml.100 gm-1 XLHb. It is concluded that 5% XLHb, as 
      compared with 5% albumin, better supports systemic blood pressure, especially as 
      exchange volume increases, possibly as a result of hemoglobin-induced increased 
      vascular tone. Although a decrease in hematocrit may play a role in the diuresis 
      observed with either fluid, the greater diuresis with XLHb must be due to some 
      additional factor; the mechanism does not appear to involve prostaglandins.
FAU - Matheson-Urbaitis, B
AU  - Matheson-Urbaitis B
AD  - Department of Medicine (Nephrology), Medical School, University of Maryland at 
      Baltimore, USA.
FAU - Lu, Y S
AU  - Lu YS
FAU - Fronticelli, C
AU  - Fronticelli C
FAU - Bucci, E
AU  - Bucci E
LA  - eng
GR  - P01-HL-48517/HL/NHLBI NIH HHS/United States
GR  - R01-HL-13164/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Macromolecular Substances)
RN  - 0 (Serum Albumin)
RN  - 0 (hemoglobin XL99alpha)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
CIN - J Lab Clin Med. 1995 Sep;126(3):231-2. PMID: 7665970
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacokinetics
MH  - *Blood Substitutes
MH  - *Exchange Transfusion, Whole Blood
MH  - Glomerular Filtration Rate
MH  - Half-Life
MH  - *Hemodynamics
MH  - Hemoglobins/pharmacokinetics
MH  - Indomethacin/pharmacology
MH  - Kidney/*blood supply
MH  - Macromolecular Substances
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - *Serum Albumin
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
PST - ppublish
SO  - J Lab Clin Med. 1995 Sep;126(3):250-60.

PMID- 12067598
OWN - NLM
STAT- MEDLINE
DCOM- 20020909
LR  - 20191106
IS  - 1568-1637 (Print)
IS  - 1568-1637 (Linking)
VI  - 1
IP  - 3
DP  - 2002 Jun
TI  - Viewing molecular mechanisms of ageing through a lens.
PG  - 465-79
AB  - Many late-life diseases are conformational diseases in tissues where there are 
      unfolded or misfolded proteins which can form aggregates. These diseases have 
      other common features in their aetiology. Cataract is one such disease and 
      post-translational modifications of proteins in the lens during cataract 
      formation are described as a possible guide to the changes in other age-related 
      conditions. Delineation of common pathways in these diseases could lead to common 
      treatment regimes, and in this respect, there are promising results for 
      aspirin-like drugs in Alzheimer's disease, cataract, myocardial infarction, 
      stroke and various cancers.
FAU - Harding, John J
AU  - Harding JJ
AD  - Nuffield Laboratory of Ophthalmology, University of Oxford, Walton Street, OX2 
      6AW, Oxford, UK. john.harding@eye.ox.ac.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Ageing Res Rev
JT  - Ageing research reviews
JID - 101128963
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Crystallins)
RN  - 0 (Molecular Chaperones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aging/drug effects/*metabolism
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cataract/*etiology/*metabolism/pathology
MH  - Cellular Senescence/*physiology
MH  - Crystallins/metabolism
MH  - Humans
MH  - Lens, Crystalline/drug effects/*metabolism
MH  - Molecular Chaperones/metabolism
MH  - Protein Conformation
MH  - Protein Folding
RF  - 50
EDAT- 2002/06/18 10:00
MHDA- 2002/09/11 10:01
CRDT- 2002/06/18 10:00
PHST- 2002/06/18 10:00 [pubmed]
PHST- 2002/09/11 10:01 [medline]
PHST- 2002/06/18 10:00 [entrez]
AID - S1568163702000120 [pii]
AID - 10.1016/s1568-1637(02)00012-0 [doi]
PST - ppublish
SO  - Ageing Res Rev. 2002 Jun;1(3):465-79. doi: 10.1016/s1568-1637(02)00012-0.

PMID- 1355537
OWN - NLM
STAT- MEDLINE
DCOM- 19921002
LR  - 20220330
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 44
IP  - 4
DP  - 1992 Apr
TI  - Cross-linked chitosan microspheres: preparation and evaluation as a matrix for 
      the controlled release of pharmaceuticals.
PG  - 283-6
AB  - Chitosan microspheres having good spherical geometry and a smooth surface were 
      prepared by the glutaraldehyde cross-linking of an aqueous acetic acid dispersion 
      of chitosan in paraffin oil using dioctyl sulphosuccinate as the stabilizing 
      agent. Microspheres having different degrees of swelling were made by varying the 
      cross-linking density. Microspheres were prepared by incorporating theophylline, 
      aspirin or griseofulvin. Drug incorporation efficiencies exceeding 80% could be 
      achieved for these drugs. In-vitro release studies of these drugs were carried 
      out in simulated gastric and intestinal fluids at 37 degrees C. It was observed 
      that the drug release rates were influenced by the cross-linking density, 
      particle size and initial drug loading in the microspheres.
FAU - Thanoo, B C
AU  - Thanoo BC
AD  - Polymer Chemistry Division, Sree Chitra Tirunal Institute for Medical Sciences 
      and Technology, Trivandrum, India.
FAU - Sunny, M C
AU  - Sunny MC
FAU - Jayakrishnan, A
AU  - Jayakrishnan A
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Delayed-Action Preparations)
RN  - 1398-61-4 (Chitin)
RN  - 32HRV3E3D5 (Griseofulvin)
RN  - 9012-76-4 (Chitosan)
RN  - C137DTR5RG (Theophylline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/chemistry
MH  - Body Fluids/chemistry
MH  - Chitin/*analogs & derivatives/chemistry
MH  - Chitosan
MH  - Cross-Linking Reagents
MH  - *Delayed-Action Preparations
MH  - Griseofulvin/administration & dosage/chemistry
MH  - Microscopy, Electron, Scanning
MH  - Microspheres
MH  - Particle Size
MH  - Theophylline/administration & dosage/chemistry
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1992.tb03607.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1992 Apr;44(4):283-6. doi: 10.1111/j.2042-7158.1992.tb03607.x.

PMID- 3632148
OWN - NLM
STAT- MEDLINE
DCOM- 19871013
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 147
IP  - 8
DP  - 1987 Aug
TI  - Reversible adsorption (desorption) of aspirin from activated charcoal.
PG  - 1390-2
AB  - The potential desorption of aspirin from activated charcoal was investigated in 
      eight patients in a randomized cross-over study. Despite prebinding of aspirin, 
      systemic absorption did occur. Desorption from activated charcoal was 
      characterized by a peak salicylate concentration that was 16% of control and a 
      time to peak salicylate concentration that was delayed in the study group. 
      Bioavailability of aspirin from activated charcoal described by area under the 
      curve was 19% of control. Elimination half-lives were similar in both groups 
      until 12 hours after ingestion, but after 12 hours the half-life of the study 
      group was prolonged while salicylate concentrations were undetectable in the 
      control group. Fifteen percent to 20% of aspirin prebound to charcoal may desorb 
      leading to systemic absorption. Furthermore, release from activated charcoal is 
      initially delayed then sustained through 30 hours.
FAU - Filippone, G A
AU  - Filippone GA
FAU - Fish, S S
AU  - Fish SS
FAU - Lacouture, P G
AU  - Lacouture PG
FAU - Scavone, J M
AU  - Scavone JM
FAU - Lovejoy, F H Jr
AU  - Lovejoy FH Jr
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Adult
MH  - Aspirin/*metabolism
MH  - Biological Availability
MH  - *Charcoal
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Random Allocation
MH  - Time Factors
EDAT- 1987/08/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1987/08/01 00:00
PHST- 1987/08/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1987/08/01 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1987 Aug;147(8):1390-2.

PMID- 7469623
OWN - NLM
STAT- MEDLINE
DCOM- 19810413
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 141
IP  - 3 Spec No
DP  - 1981 Feb 23
TI  - Comparative effects of aspirin and acetaminophen on hemostasis.
PG  - 305-10
AB  - The influences of aspirin and of acetaminophen on hemostasis were studied in 
      normal healthy volunteers and in patients with either severe hemophilia A or 
      hemophilia B. Acetaminophen did not alter the template bleeding time or the 
      results of tests of platelet function in either group. Aspirin did prolong the 
      template bleeding time and impaired platelet aggregation; these changes were most 
      pronounced in patients with either form of hemophilia, and some (7/19) required 
      plasma component therapy. Neither drug influenced the coagulation proteins or the 
      fibrinolytic mechanism, as measured. The influences of a single dose (ranging 
      from 975 to 1,950 mg) of acetaminophen and of a single dose (ranging from 325 to 
      2,925 mg) of aspirin were similar to those observed in persons receiving multiple 
      doses. Acetaminophen is preferred in patients in whom a hemostatic influence is 
      undesirable. However, either aspirin or acetaminophen can be used in normal 
      healthy subjects.
FAU - Mielke, C H Jr
AU  - Mielke CH Jr
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Time Factors
EDAT- 1981/02/23 00:00
MHDA- 2001/03/28 10:01
CRDT- 1981/02/23 00:00
PHST- 1981/02/23 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1981/02/23 00:00 [entrez]
AID - 10.1001/archinte.141.3.305 [doi]
PST - ppublish
SO  - Arch Intern Med. 1981 Feb 23;141(3 Spec No):305-10. doi: 
      10.1001/archinte.141.3.305.

PMID- 33667470
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1096-0260 (Electronic)
IS  - 0091-7435 (Linking)
VI  - 147
DP  - 2021 Jun
TI  - Aspirin prescribing for cardiovascular disease in middle-aged and older adults in 
      Ireland: Findings from The Irish Longitudinal Study on Ageing.
PG  - 106504
LID - S0091-7435(21)00088-8 [pii]
LID - 10.1016/j.ypmed.2021.106504 [doi]
AB  - Aspirin use for cardiovascular indications is widespread despite evidence not 
      supporting use in patients without cardiovascular disease (CVD). This study 
      characterises aspirin prescribing among people aged ≥50 years in Ireland for 
      primary and secondary prevention, and factors associated with prescription. This 
      cross-sectional study includes participants from wave 3 (2014-2015) of The Irish 
      Longitudinal Study on Ageing. We identified participants reporting use of 
      prescribed aspirin, other antiplatelets/anticoagulants, and doctor-diagnosed CVD 
      (MI, angina, stroke, TIA) and other cardiovascular conditions. We examined 
      factors associated with aspirin use for primary and secondary prevention in 
      multivariate regression. For a subset, we also examined 10-year cardiovascular 
      risk (using the Framingham general risk score) as a predictor of aspirin use. 
      Among 6618 participants, the mean age was 66.9 years (SD 9.4) and 55.6% (3679) 
      were female. Prescribed aspirin was reported by 1432 participants (21.6%), and 
      77.6% of aspirin users had no previous CVD. Among participants with previous CVD, 
      16.5% were not prescribed aspirin/another antithrombotic. This equates to 201,000 
      older adults nationally using aspirin for primary prevention, and 16,000 with 
      previous CVD not prescribed an antithrombotic. Among those without CVD, older 
      age, male sex, free health care, and more GP visits were associated with aspirin 
      prescribing. Cardiovascular risk was significantly associated with aspirin use 
      (adjusted relative risk 1.15, 95%CI 1.08-1.23, per 1% increase in cardiovascular 
      risk). Almost four-fifths of people aged ≥50 years on aspirin have no previous 
      CVD, equivalent to 201,000 adults nationally, however prescribing appears to 
      target higher cardiovascular risk patients.
CI  - Copyright © 2021 Elsevier Inc. All rights reserved.
FAU - Moriarty, Frank
AU  - Moriarty F
AD  - HRB Centre for Primary Care Research, Department of General Practice, Royal 
      College of Surgeons in Ireland, Ireland; School of Pharmacy and Biomolecular 
      Sciences, Royal College of Surgeons in Ireland, Ireland; The Irish Longitudinal 
      Study on Ageing, Trinity College Dublin, Ireland. Electronic address: 
      frankmoriarty@rcsi.ie.
FAU - Barry, Alan
AU  - Barry A
AD  - HRB Centre for Primary Care Research, Department of General Practice, Royal 
      College of Surgeons in Ireland, Ireland.
FAU - Kenny, Rose Anne
AU  - Kenny RA
AD  - The Irish Longitudinal Study on Ageing, Trinity College Dublin, Ireland.
FAU - Fahey, Tom
AU  - Fahey T
AD  - HRB Centre for Primary Care Research, Department of General Practice, Royal 
      College of Surgeons in Ireland, Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210303
PL  - United States
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aging
MH  - *Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/drug therapy/prevention & control
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Ireland
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention
OTO - NOTNLM
OT  - Ageing
OT  - Anti-platelet
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Primary prevention
EDAT- 2021/03/06 06:00
MHDA- 2021/06/29 06:00
CRDT- 2021/03/05 20:10
PHST- 2020/09/09 00:00 [received]
PHST- 2021/01/19 00:00 [revised]
PHST- 2021/02/27 00:00 [accepted]
PHST- 2021/03/06 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2021/03/05 20:10 [entrez]
AID - S0091-7435(21)00088-8 [pii]
AID - 10.1016/j.ypmed.2021.106504 [doi]
PST - ppublish
SO  - Prev Med. 2021 Jun;147:106504. doi: 10.1016/j.ypmed.2021.106504. Epub 2021 Mar 3.

PMID- 8851268
OWN - NLM
STAT- MEDLINE
DCOM- 19961217
LR  - 20131121
IS  - 0301-1526 (Print)
IS  - 0301-1526 (Linking)
VI  - 25
IP  - 1
DP  - 1996
TI  - [The effect of Taprostene on platelet activation and clinical course after 
      percutaneous transluminal angioplasty].
PG  - 65-72
AB  - In a double blind pilot study, we examined the effects of the stable prostacyclin 
      derivate taprostene compared to a combination of aspirin and dipyridamole on 
      platelet uptake and clinical outcome after peripheral percutaneous angioplasty. 
      Taprostene was administered to 19 patients as a continuous intravenous infusion 
      from 2 hours before until 8 (n = 6) or 24 (n = 6) hours after angioplasty; 7 
      control patients were given a combination of 330 mg aspirin and 75 mg 
      dipyridamole. Uptake of 111-indium labelled platelets at the site of the PTA was 
      measured 3 hours before and 4 and 24 hours after angioplasty. Clinical parameters 
      were obtained one day before PTA, on the following day and 3 months after the 
      procedure. There was a tendency for slightly higher platelet uptake ratios in the 
      taprostene groups as compared to the control group especially in patients 
      requiring technically difficult procedures. There were no differences between the 
      3 groups with regard to primary success or periinterventional complications. In 
      the taprostene patients, 3 early reocclusions were found up to 72 hours after the 
      procedure and 1 late reocclusion within 3 months. In the control group, no 
      reocclusion was apparent in the observation time. No advantages were found when 
      taprostene was administered during angioplasty as compared to conventional 
      treatment with aspirine and dipyridamole.
FAU - Heinz, M
AU  - Heinz M
AD  - Medizinische Klinik und Poliklinik, Technischen Universität München.
FAU - Theiss, W
AU  - Theiss W
FAU - van de Flierdt, E
AU  - van de Flierdt E
FAU - Söhngen, M
AU  - Söhngen M
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Der Einfluss von Taprosten auf Thrombozyten-aktivierung und klinischen Verlauf 
      nach perkutaner transluminaler Angioplastie.
PL  - Switzerland
TA  - Vasa
JT  - VASA. Zeitschrift fur Gefasskrankheiten
JID - 0317051
RN  - 0 (Cardiovascular Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 7MS1HEY2IZ (taprostene)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - *Angioplasty, Balloon
MH  - Arterial Occlusive Diseases/blood/*therapy
MH  - Aspirin/administration & dosage
MH  - Cardiovascular Agents/*administration & dosage
MH  - Dipyridamole/administration & dosage
MH  - Drug Therapy, Combination
MH  - Epoprostenol/administration & dosage/*analogs & derivatives
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Activation/*drug effects
MH  - Recurrence
MH  - Treatment Outcome
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
PST - ppublish
SO  - Vasa. 1996;25(1):65-72.

PMID- 16518976
OWN - NLM
STAT- MEDLINE
DCOM- 20060411
LR  - 20131121
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 88
IP  - 12
DP  - 2005 Dec
TI  - Aspirin therapy as primary prevention in hypertensive patients at Srinagarind 
      hospital.
PG  - 1797-801
AB  - Aspirin is now a useful therapy for both primary and secondary prevention for 
      cardiovascular events especially in diabetic patients. Hypertension is also one 
      of the major atherosclerotic risk factors. The authors studied the rate of 
      aspirin use as primary prevention in hypertensive cases at Srinagarind Hospital, 
      Khon Kaen University. There were 164 of 231 hypertensive patients who were aged 
      over 50 years old and met the criteria for aspirin therapy with 2003 ESHs 
      guideline. Only 18.9% (31 of 164 cases) were prescribed aspirin. The most common 
      dose of aspirin was 60 mg/day which was lower than the suggested dose. Within 
      one-year follow up, there was no serious side effects of the aspirin such as 
      upper gastrointestinal bleeding.
FAU - Sawanyawisuth, Kittisak
AU  - Sawanyawisuth K
AD  - Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 
      40002, Thailand. kittisak@kku.ac.th
FAU - Limpawattana, Panita
AU  - Limpawattana P
FAU - Bumrerraj, Sauwanan
AU  - Bumrerraj S
FAU - Thongmee, Akaphot
AU  - Thongmee A
FAU - Kosakarn, Jakwida
AU  - Kosakarn J
FAU - Choenrungroj, Thanabat
AU  - Choenrungroj T
FAU - Pradit, Prachaya
AU  - Pradit P
FAU - Naranunn, Patsathorn
AU  - Naranunn P
FAU - Punyamee, Sarunyaporn
AU  - Punyamee S
FAU - Premgamone, Amorn
AU  - Premgamone A
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Hypertension/*complications
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Factors
EDAT- 2006/03/08 09:00
MHDA- 2006/04/12 09:00
CRDT- 2006/03/08 09:00
PHST- 2006/03/08 09:00 [pubmed]
PHST- 2006/04/12 09:00 [medline]
PHST- 2006/03/08 09:00 [entrez]
PST - ppublish
SO  - J Med Assoc Thai. 2005 Dec;88(12):1797-801.

PMID- 2759189
OWN - NLM
STAT- MEDLINE
DCOM- 19890921
LR  - 20190816
IS  - 0014-4835 (Print)
IS  - 0014-4835 (Linking)
VI  - 49
IP  - 1
DP  - 1989 Jul
TI  - The non-enzymic glycosylation of bovine lens proteins by glucosamine and its 
      inhibition by aspirin, ibuprofen and glutathione.
PG  - 31-41
AB  - Cataract is a long-term complication of diabetes mellitus. Diabetics have 
      increased glucosamine levels and it is possible that the non-enzymic 
      glycosylation of the lens structural proteins by glucosamine induces 
      conformational changes in the lens that contribute to cataract formation. Aspirin 
      and aspirin-like analgesics may protect against glycosylation. In this paper the 
      binding of glucosamine to bovine lens proteins and the effects of aspirin, 
      paracetamol and ibuprofen on this reaction were investigated. Significant binding 
      of glucosamine to the lens proteins was found. Gel-chromatography indicated that 
      beta H-crystallin was most reactive to the amino-sugar. Of the analgesics 
      studied, aspirin was the most effective inhibitor of glycosylation, followed by 
      the other anti-inflammatory drug, ibuprofen. Preincubation of the lens homogenate 
      with aspirin was no more effective at decreasing binding of glucosamine than was 
      simultaneous incubation with aspirin. Glutathione significantly inhibited 
      glucosamine binding. Glucosamine is active in non-enzymic glycosylation but the 
      reaction can be inhibited by agents thought to protect against cataract.
FAU - Ajiboye, R
AU  - Ajiboye R
AD  - Nuffield Laboratory of Ophthalmology, University of Oxford, U.K.
FAU - Harding, J J
AU  - Harding JJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 0 (Crystallins)
RN  - GAN16C9B8O (Glutathione)
RN  - N08U5BOQ1K (Glucosamine)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
EIN - Exp Eye Res 1989 Oct;49(4):704
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cattle
MH  - Crystallins/*metabolism
MH  - Glucosamine/*metabolism
MH  - Glutathione/*pharmacology
MH  - Glycosylation
MH  - Ibuprofen/*pharmacology
EDAT- 1989/07/01 00:00
MHDA- 1989/07/01 00:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 1989/07/01 00:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
AID - 10.1016/0014-4835(89)90073-0 [doi]
PST - ppublish
SO  - Exp Eye Res. 1989 Jul;49(1):31-41. doi: 10.1016/0014-4835(89)90073-0.

PMID- 31922419
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1535-3907 (Electronic)
IS  - 1535-3893 (Linking)
VI  - 19
IP  - 2
DP  - 2020 Feb 7
TI  - Aspirin Reshapes Acetylomes in Inflammatory and Cancer Cells via CoA-Dependent 
      and CoA-Independent Pathways.
PG  - 962-972
LID - 10.1021/acs.jproteome.9b00853 [doi]
AB  - Aspirin, or acetylsalicylic acid (ASA), is the most widely used medication to 
      relieve pain, fever, and inflammation. Recent studies have revealed new benefits 
      of aspirin, including reduction of heart attack and stroke, anticancer, and life 
      extension. Despite the profound effects of aspirin, the mechanism of its action 
      remains to be elucidated. Here, we used deuterium-labeled aspirin (D-aspirin) 
      together with mass spectrometry-based acetylomic analysis, termed DAcMS, to 
      investigate the landscape of protein acetylation induced by aspirin. The DAcMS 
      revealed the acetylomes of lipopolysaccharide-induced inflammatory BV2 cells and 
      colon cancer HCT116 cells. The acetylation level was substantially induced upon 
      aspirin treatment in both cell lines. In total, we identified 17,003 acetylation 
      sites on 4623 proteins in BV2 cells and 16,366 acetylated sites corresponding to 
      4702 acetylated proteins in HCT116 cells. Importantly, functional analyses of 
      these aspirin-induced acetylated proteins suggested that they were highly 
      enriched in many key biological categories, which function importantly in 
      inflammatory response. We further demonstrated that aspirin acetylates proteins 
      through both acetyl-CoA-dependent and acetyl-CoA-independent pathways, and the 
      accessible lysine residues at the protein surface are major acetylation targets 
      of aspirin. Hence, our study provides the comprehensive atlas of aspirin-induced 
      acetylome under disease conditions. This knowledge proffers new insight into the 
      aspirin-directed acetylome and perhaps new drug target sites relevant to human 
      cancer and inflammatory diseases. The MS data of this study have been deposited 
      under the accession number IPX0001923000 at iProX.
FAU - Guo, Lin
AU  - Guo L
AUID- ORCID: 0000-0002-2853-9556
AD  - Interdisciplinary Research Center on Biology and Chemistry , Shanghai Institute 
      of Organic Chemistry, Chinese Academy of Sciences , 26 Qiuyue Road , Pudong, 
      Shanghai 201210 , China.
AD  - University of Chinese Academy of Sciences , Beijing 100049 , China.
FAU - Gao, Jing
AU  - Gao J
AD  - Interdisciplinary Research Center on Biology and Chemistry , Shanghai Institute 
      of Organic Chemistry, Chinese Academy of Sciences , 26 Qiuyue Road , Pudong, 
      Shanghai 201210 , China.
AD  - University of Chinese Academy of Sciences , Beijing 100049 , China.
FAU - Gao, Yang
AU  - Gao Y
AD  - Interdisciplinary Research Center on Biology and Chemistry , Shanghai Institute 
      of Organic Chemistry, Chinese Academy of Sciences , 26 Qiuyue Road , Pudong, 
      Shanghai 201210 , China.
AD  - University of Chinese Academy of Sciences , Beijing 100049 , China.
FAU - Zhu, Zhengjiang
AU  - Zhu Z
AUID- ORCID: 0000-0002-3272-3567
AD  - Interdisciplinary Research Center on Biology and Chemistry , Shanghai Institute 
      of Organic Chemistry, Chinese Academy of Sciences , 26 Qiuyue Road , Pudong, 
      Shanghai 201210 , China.
FAU - Zhang, Yaoyang
AU  - Zhang Y
AUID- ORCID: 0000-0001-5363-9834
AD  - Interdisciplinary Research Center on Biology and Chemistry , Shanghai Institute 
      of Organic Chemistry, Chinese Academy of Sciences , 26 Qiuyue Road , Pudong, 
      Shanghai 201210 , China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200124
PL  - United States
TA  - J Proteome Res
JT  - Journal of proteome research
JID - 101128775
RN  - 0 (Proteome)
RN  - 72-89-9 (Acetyl Coenzyme A)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetyl Coenzyme A
MH  - Acetylation
MH  - Aspirin/pharmacology
MH  - Humans
MH  - Lysine/metabolism
MH  - *Neoplasms
MH  - Protein Processing, Post-Translational
MH  - *Proteome/metabolism
OTO - NOTNLM
OT  - acetylation
OT  - acetylome
OT  - aspirin
OT  - mass spectrometry
OT  - proteome
EDAT- 2020/01/11 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/01/11 06:00
PHST- 2020/01/11 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/01/11 06:00 [entrez]
AID - 10.1021/acs.jproteome.9b00853 [doi]
PST - ppublish
SO  - J Proteome Res. 2020 Feb 7;19(2):962-972. doi: 10.1021/acs.jproteome.9b00853. 
      Epub 2020 Jan 24.

PMID- 9329
OWN - NLM
STAT- MEDLINE
DCOM- 19761201
LR  - 20181130
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 71
IP  - 5
DP  - 1976 Nov
TI  - Mechanism of prevention of aspirin-induced gastric lesions by bile duct legation 
      in the rat.
PG  - 750-3
AB  - Gastric reflux of bile has been reported to be essential for the production of 
      acute gastric mucosal lesions by intragastric aspirin in the rat. The purpose of 
      the present study was to determine whether bile duct legation of pylorus ligation 
      in the rat inhibits asprin-induced gastric lesions, and, if so, what the 
      protective mechanisms are. Operations were performed under ether anesthesia. 
      Asprin, 200 mg per kg, was instilled into the stomach 1/2 hr postsurgery (bile 
      duct ligation or pylorus ligation). Four hours later the rats were killed, the 
      stomachs were examined, and mucosal lesions were scored. Bile duct ligation, but 
      not pylorus ligation, significantly protected against aspirin-induced 
      gastric-lesions. Bile duct ligation, in pylorus-ligated rats, inhibited gastric 
      acid output by 78%. Instilling HCl + aspirin in bile duct-ligated rats restored 
      lesion formation. Shunting bile to the colon (to prevent bile reflux) did not 
      prevent aspirin lesions. Salicylate determination, to ascertain whether bile duct 
      ligation altered asprin absorption, revealed no significant differences between 
      bile duct ligation and aspirin, shunt + aspirin, and sham shunt + aspirin in 
      plasma and gastric tissue salicylate concentrations. CONCLUSIONS: (1) Bile duct 
      legation protects against aspirin-induced gastric mucosal lesions by inhibiting 
      gastric HCl secretion. As a corollary, a certain amount of acid in the stomach is 
      necessary for aspirin-induced gastric lesions to form. (2) Bile reflux is not 
      necessary for aspirn-induced gastric lesions in the rat.
FAU - Guth, P H
AU  - Guth PH
FAU - Paulsen, G
AU  - Paulsen G
FAU - Lynn, D
AU  - Lynn D
FAU - Aures, D
AU  - Aures D
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/blood
MH  - Colon/surgery
MH  - Common Bile Duct/*surgery
MH  - Gastric Juice/metabolism
MH  - Gastric Mucosa/analysis
MH  - Hydrogen-Ion Concentration
MH  - Ligation
MH  - Male
MH  - Pylorus/surgery
MH  - Rats
MH  - Stomach Ulcer/chemically induced/*prevention & control
EDAT- 1976/11/01 00:00
MHDA- 1976/11/01 00:01
CRDT- 1976/11/01 00:00
PHST- 1976/11/01 00:00 [pubmed]
PHST- 1976/11/01 00:01 [medline]
PHST- 1976/11/01 00:00 [entrez]
AID - S0016508576002801 [pii]
PST - ppublish
SO  - Gastroenterology. 1976 Nov;71(5):750-3.

PMID- 3659736
OWN - NLM
STAT- MEDLINE
DCOM- 19871116
LR  - 20190510
IS  - 0161-8105 (Print)
IS  - 0161-8105 (Linking)
VI  - 10
IP  - 4
DP  - 1987 Aug
TI  - Slow wave sleep elevations after body heating: proximity to sleep and effects of 
      aspirin.
PG  - 383-92
AB  - On three different occasions, six healthy young adult subjects ahd their body 
      temperatures raised by an average of 2.0 degrees C for 30 min while sitting in 
      baths of warm water. This was done once at 1700 h and on two occasions at 2100 h, 
      once after the subjects had taken aspirin and once after a placebo. Nighttime 
      sleep was recorded after each experimental condition and for baseline nights 
      following nil heating. Records were scored both visually and by an automated 
      sleep stager. Electroencephalographic (EEG) power was computed over the night. 
      Results from the automated scoring were very similar to those of the visual 
      method. While the early bath caused no changes in sleep, the late bath + placebo 
      resulted in significant rises in stage 4 sleep and slow wave sleep (SWS) and 
      significant falls in sleep onset and in REM sleep. Aspirin mostly counteracted 
      these effects and, in particular, left stage 4 sleep and SWS at baseline levels. 
      EEG power was significantly increased only after the late bath plus placebo, 
      supporting the SWS outcome. These findings were assessed in light of other 
      comparable results from our laboratory. It seems that as the time of the day of 
      heating recedes from nighttime sleep, a larger "dose" of heating is required to 
      produce the same effect.
FAU - Horne, J A
AU  - Horne JA
AD  - Department of Human Sciences, Loughborough University, Leicestershire, England.
FAU - Shackell, B S
AU  - Shackell BS
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Sleep
JT  - Sleep
JID - 7809084
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - *Body Temperature
MH  - Electroencephalography
MH  - Female
MH  - Humans
MH  - *Hyperthermia, Induced
MH  - Male
MH  - Sleep/drug effects/*physiology
MH  - Time Factors
EDAT- 1987/08/01 00:00
MHDA- 1987/08/01 00:01
CRDT- 1987/08/01 00:00
PHST- 1987/08/01 00:00 [pubmed]
PHST- 1987/08/01 00:01 [medline]
PHST- 1987/08/01 00:00 [entrez]
AID - 10.1093/sleep/10.4.383 [doi]
PST - ppublish
SO  - Sleep. 1987 Aug;10(4):383-92. doi: 10.1093/sleep/10.4.383.

PMID- 646143
OWN - NLM
STAT- MEDLINE
DCOM- 19780628
LR  - 20190911
IS  - 0303-4569 (Print)
IS  - 0303-4569 (Linking)
VI  - 10
IP  - 2
DP  - 1978 Mar-Apr
TI  - Antispermatogenic effect of aspirin and its prevention by prostaglandin E2.
PG  - 137-41
AB  - Aspirin treatment causes a decrease in Leydig cell function, change in Sertoli 
      cell morphology and a subsequent decrease in Spermatid count. Administration of 
      Prostaglandin E2 prevents the effect of Aspirin on the Sertoli cell morphology 
      and Spermatid degeneration without significant improvement of the Leydig cell 
      function. On the basis of these findings, a possible relationship between 
      Prostaglandin and testicular spermatogenesis has been discussed.
FAU - Biswas, N M
AU  - Biswas NM
FAU - Sanyal, S
AU  - Sanyal S
FAU - Patra, P B
AU  - Patra PB
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Andrologia
JT  - Andrologia
JID - 0423506
RN  - 0 (Antispermatogenic Agents)
RN  - 0 (Prostaglandins E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Antispermatogenic Agents
MH  - Aspirin/antagonists & inhibitors/*pharmacology
MH  - Cell Count
MH  - Cell Nucleus/drug effects
MH  - Leydig Cells/drug effects
MH  - Male
MH  - Organ Size/drug effects
MH  - Prostaglandins E/*pharmacology
MH  - Rats
MH  - Sertoli Cells/drug effects
MH  - Spermatids/drug effects
MH  - Spermatogenesis/*drug effects
MH  - Testis/drug effects
EDAT- 1978/03/01 00:00
MHDA- 1978/03/01 00:01
CRDT- 1978/03/01 00:00
PHST- 1978/03/01 00:00 [pubmed]
PHST- 1978/03/01 00:01 [medline]
PHST- 1978/03/01 00:00 [entrez]
AID - 10.1111/j.1439-0272.1978.tb01328.x [doi]
PST - ppublish
SO  - Andrologia. 1978 Mar-Apr;10(2):137-41. doi: 10.1111/j.1439-0272.1978.tb01328.x.

PMID- 1259798
OWN - NLM
STAT- MEDLINE
DCOM- 19760525
LR  - 20190717
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 19
IP  - 2
DP  - 1976 Mar-Apr
TI  - Effect of aspirin on liver tests in patients with RA or SLE and in normal 
      volunteers.
PG  - 155-60
AB  - Aspirin was given to 20 patients with RA, 16 patients with SLE, and 3 normal 
      volunteers. Four of the RA patients, 7 of the SLE patients, and 1 normal 
      volunteer developed abnormal liver tests, during the study. The abnormalities 
      (elevated transaminases) were most frequent and of rapid onset in patients with 
      cliniclaly active SLE. Increases in BUN and creatinine related to aspirin were 
      observed in several subjects. In a retrospective survey of 80 patients with SLE, 
      aspirin appeared responsible for two-thirds of episodes of liver test 
      abnormalities in 19 patients.
FAU - Seaman, W E
AU  - Seaman WE
FAU - Plotz, P H
AU  - Plotz PH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - AYI8EX34EU (Creatinine)
RN  - EC 2.6.1.- (Transaminases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Blood Urea Nitrogen
MH  - Creatinine/blood
MH  - Female
MH  - Humans
MH  - Liver/*drug effects
MH  - Liver Function Tests
MH  - Lupus Erythematosus, Systemic/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Synovial Fluid/*immunology
MH  - Transaminases/blood
EDAT- 1976/03/01 00:00
MHDA- 1976/03/01 00:01
CRDT- 1976/03/01 00:00
PHST- 1976/03/01 00:00 [pubmed]
PHST- 1976/03/01 00:01 [medline]
PHST- 1976/03/01 00:00 [entrez]
AID - 10.1002/art.1780190205 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1976 Mar-Apr;19(2):155-60. doi: 10.1002/art.1780190205.

PMID- 16479096
OWN - NLM
STAT- MEDLINE
DCOM- 20060511
LR  - 20181201
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 21 Suppl 1
DP  - 2006
TI  - Antiplatelet therapy in stroke prevention: present and future.
PG  - 1-6
AB  - White platelet-fibrin thrombi often form on roughened endothelial surfaces and 
      unstable arterial plaques. Agents that reduce the tendency of platelets to 
      aggregate, agglutinate, and secrete and to attach to endothelial surfaces have 
      been explored as agents that prevent brain and heart infarction. Aspirin, 
      ticlopidine, clopidogrel, dipyridamole, cilostazol, and glycoprotein llb/llla 
      inhibitors are all used now and have various different modes of action and 
      functions.
CI  - Copyright (c) 2006 S. Karger AG, Basel.
FAU - Caplan, Louis R
AU  - Caplan LR
AD  - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, 
      USA. lcaplan@bidmc.harvard.edu
LA  - eng
PT  - Journal Article
DEP - 20060213
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Clopidogrel
MH  - Dipyridamole/pharmacology/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/*prevention & control
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
EDAT- 2006/02/16 09:00
MHDA- 2006/05/12 09:00
CRDT- 2006/02/16 09:00
PHST- 2006/02/16 09:00 [pubmed]
PHST- 2006/05/12 09:00 [medline]
PHST- 2006/02/16 09:00 [entrez]
AID - 90356 [pii]
AID - 10.1159/000090356 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2006;21 Suppl 1:1-6. doi: 10.1159/000090356. Epub 2006 Feb 13.

PMID- 350497
OWN - NLM
STAT- MEDLINE
DCOM- 19780828
LR  - 20191210
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 5
IP  - 6
DP  - 1978
TI  - Comparative study of salsalate and aspirin in osteoarthrosis of the hip or knee.
PG  - 450-3
AB  - A short-term, double-blind controlled crossover study was carried out in 20 
      patients with osteoarthrosis of the hip or knee to compare the effectiveness and 
      tolerance of salsalate and aspirin. After a 1-week placebo washout period, 
      patients received either 3 g salsalate per day or 3.6 g soluble aspirin per day 
      for 2 weeks before being crossed over to the alternative treatment. Paracetamol 
      was used as a rescue analgesic. The results of clinical assessments of pain, 
      stiffness and sleep disturbance, using visual analogue scales, showed that 
      salsalate produced a comparable clinical improvement to that with aspirin, and 
      similar serum salicylate levels. Salsalate, however, was significantly superior 
      to aspirin with regard to side-effects and faecal occult blood loss.
FAU - Liyanage, S P
AU  - Liyanage SP
FAU - Tambar, P K
AU  - Tambar PK
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Salicylates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - V9MO595C9I (salicylsalicylic acid)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Hip Joint
MH  - Humans
MH  - Knee Joint
MH  - Male
MH  - Middle Aged
MH  - Occult Blood
MH  - Osteoarthritis/*drug therapy
MH  - Salicylates/adverse effects/*therapeutic use
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1185/03007997809111914 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1978;5(6):450-3. doi: 10.1185/03007997809111914.

PMID- 31957546
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201119
IS  - 1744-8042 (Electronic)
IS  - 1462-2416 (Linking)
VI  - 21
IP  - 2
DP  - 2020 Jan
TI  - The emergent phenomenon of aspirin resistance: insights from genetic association 
      studies.
PG  - 125-140
LID - 10.2217/pgs-2019-0133 [doi]
AB  - Despite the clinical benefits of aspirin, the interindividual variation in 
      response to this antiplatelet drug is considerable. The manifestation of aspirin 
      resistance (AR) is frequently observed, although this complex process remains 
      poorly understood. While AR etiology is likely to be multifactorial, genetic 
      factors appear to be preponderant. According to several genetic association 
      studies, both genome-wide and candidate gene studies, numerous SNPs in 
      cyclooxygenase, thromboxane and platelet receptors-related genes have been 
      identified as capable of negatively affecting aspirin action. Thus, it is 
      essential to understand the clinical relevance of AR-related SNPs as potential 
      predictive and prognostic biomarkers as they may be essential to defining the AR 
      phenotype.
FAU - Ferreira, Márcia
AU  - Ferreira M
AD  - Molecular Oncology & Viral Pathology Group-Research Center, Portuguese Institute 
      of Oncology, Edifício Laboratórios, 4º piso, Rua Dr António Bernardino de 
      Almeida, 4200-4072 Porto, Portugal.
AD  - ICBAS, Abel Salazar Institute for the Biomedical Sciences, Rua de Jorge Viterbo 
      Ferreira, 228, 4050-313 Porto, Portugal.
FAU - Freitas-Silva, Margarida
AU  - Freitas-Silva M
AD  - FMUP, Faculty of Medicine, Porto University, & Department of Medicine, Centro 
      Hospitalar São João, Porto, Portugal, Alameda Prof Hernâni Monteiro, 4200-319 
      Porto, Portugal.
FAU - Assis, Joana
AU  - Assis J
AD  - Molecular Oncology & Viral Pathology Group-Research Center, Portuguese Institute 
      of Oncology, Edifício Laboratórios, 4º piso, Rua Dr António Bernardino de 
      Almeida, 4200-4072 Porto, Portugal.
AD  - FMUP, Faculty of Medicine, Porto University, & Department of Medicine, Centro 
      Hospitalar São João, Porto, Portugal, Alameda Prof Hernâni Monteiro, 4200-319 
      Porto, Portugal.
FAU - Pinto, Ricardo
AU  - Pinto R
AD  - Molecular Oncology & Viral Pathology Group-Research Center, Portuguese Institute 
      of Oncology, Edifício Laboratórios, 4º piso, Rua Dr António Bernardino de 
      Almeida, 4200-4072 Porto, Portugal.
FAU - Nunes, José P
AU  - Nunes JP
AD  - FMUP, Faculty of Medicine, Porto University, & Department of Medicine, Centro 
      Hospitalar São João, Porto, Portugal, Alameda Prof Hernâni Monteiro, 4200-319 
      Porto, Portugal.
FAU - Medeiros, Rui
AU  - Medeiros R
AD  - Molecular Oncology & Viral Pathology Group-Research Center, Portuguese Institute 
      of Oncology, Edifício Laboratórios, 4º piso, Rua Dr António Bernardino de 
      Almeida, 4200-4072 Porto, Portugal.
AD  - FMUP, Faculty of Medicine, Porto University, & Department of Medicine, Centro 
      Hospitalar São João, Porto, Portugal, Alameda Prof Hernâni Monteiro, 4200-319 
      Porto, Portugal.
AD  - Biomedical Research Center, Faculty of Health Sciences, Fernando Pessoa 
      University, Praça 9 de Abril, 349, 4249-004 Porto, Portugal.
AD  - Department of Research, Portuguese League Against Cancer (NRNorte), Estrada 
      Interior da Circunvalação, 6657, 4200-172 Porto, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Resistance/*genetics
MH  - *Genetic Association Studies
MH  - Genotype
MH  - Humans
MH  - Phenotype
MH  - Platelet Aggregation/drug effects/genetics
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Prostaglandin-Endoperoxide Synthases/genetics
MH  - Thromboxanes/genetics
OTO - NOTNLM
OT  - GWAS
OT  - SNPs
OT  - aspirin
OT  - aspirin resistance
OT  - candidate gene studies
OT  - genetic association studies
OT  - genetic polymorphisms
EDAT- 2020/01/21 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/01/21 06:00
PHST- 2020/01/21 06:00 [entrez]
PHST- 2020/01/21 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 10.2217/pgs-2019-0133 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2020 Jan;21(2):125-140. doi: 10.2217/pgs-2019-0133.

PMID- 36882036
OWN - NLM
STAT- MEDLINE
DCOM- 20230727
LR  - 20230727
IS  - 1423-002X (Electronic)
IS  - 0378-7346 (Linking)
VI  - 88
IP  - 3
DP  - 2023
TI  - Low-Dose Aspirin Has Antiproliferative and Apoptosis Effects in HPV16 Tumor Cells 
      and Delays Tumor Development and Growth in an Experimental Model.
PG  - 150-158
LID - 10.1159/000529302 [doi]
AB  - OBJECTIVES: The purpose of this study was to investigate the effect of aspirin on 
      epithelial HPV16-transformed cells and its antitumor effects, in an experimental 
      HPV16-positive tumor model. DESIGN: The design of the study is experimental (in 
      vitro and in vivo). PARTICIPANTS/MATERIALS, SETTING, AND METHODS: SiHa and 
      BMK-16/myc cells were treated with aspirin and cell proliferation was determined 
      by MTT; Caspase-Glo 3/7 Assay was used to determine apoptosis. The tumor-bearing 
      mice group was treated with 50 mg/gr/day of aspirin (orally) during 30 days and 
      the antitumor effect was determined. RESULTS: Here, we provide evidence that 
      aspirin has a negative effect on proliferation and induces apoptosis in the human 
      (SiHa) and murine (BMK-16/myc) HPV16 cells. Furthermore, aspirin showed 
      inhibition of tumor growth, and in mice treated with aspirin prior to 
      implantation of tumor cells, the tumor growth was delayed. Also, the effect of 
      aspirin increased survival in tumor-bearing mice and in mice pre-treated with 
      aspirin. LIMITATIONS: It is necessary to carry out in vitro and in vivo studies 
      of the molecular mechanisms involved in the effects of aspirin on tumor cells. 
      CONCLUSION: Aspirin showed antiproliferative effects in tumor cells and inhibited 
      tumor progression and could be effective as a chemopreventive agent. Thus, 
      aspirin deserves further exploration for the treatment of cervical cancer and 
      other neoplasms.
CI  - © 2023 S. Karger AG, Basel.
FAU - Zárate, Geny Del Socorro Fierros
AU  - Zárate GDSF
AD  - Division of Chronic Infection and Cancer, National Institute of Public Health, 
      Cuernavaca, Mexico.
FAU - Flores, Fernando Luis Reyna
AU  - Flores FLR
AD  - Division of Chronic Infection and Cancer, National Institute of Public Health, 
      Cuernavaca, Mexico.
FAU - Burguete, Ana Isabel
AU  - Burguete AI
AD  - Division of Chronic Infection and Cancer, National Institute of Public Health, 
      Cuernavaca, Mexico.
FAU - Marina, Vicente Madrid
AU  - Marina VM
AD  - Division of Chronic Infection and Cancer, National Institute of Public Health, 
      Cuernavaca, Mexico.
FAU - Olea, Eduardo Guzmán
AU  - Olea EG
AD  - Institute of Health Sciences, Autonomous University of Hidalgo, Pachuca, Mexico.
FAU - Carranza, Clarita Olvera
AU  - Carranza CO
AD  - Biotechnology Engineering Department, Institute of Biotechnology, National 
      Autonomous University of Mexico, Cuernavaca, Mexico.
FAU - Melendrez, Celina García
AU  - Melendrez CG
AD  - Biotechnology Engineering Department, Institute of Biotechnology, National 
      Autonomous University of Mexico, Cuernavaca, Mexico.
FAU - Morales, Victor Hugo Bermúdez
AU  - Morales VHB
AD  - Division of Chronic Infection and Cancer, National Institute of Public Health, 
      Cuernavaca, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20230307
PL  - Switzerland
TA  - Gynecol Obstet Invest
JT  - Gynecologic and obstetric investigation
JID - 7900587
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Female
MH  - Humans
MH  - Mice
MH  - *Apoptosis/drug effects
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - *Cell Proliferation/drug effects
MH  - *Human papillomavirus 16/drug effects
MH  - *Uterine Cervical Neoplasms/drug therapy/prevention & control/pathology
OTO - NOTNLM
OT  - Aspirin and tumor cells
OT  - Cervical cancer
OT  - Human papillomavirus infection
EDAT- 2023/03/08 06:00
MHDA- 2023/07/05 06:42
CRDT- 2023/03/07 18:24
PHST- 2021/11/09 00:00 [received]
PHST- 2023/01/12 00:00 [accepted]
PHST- 2023/07/05 06:42 [medline]
PHST- 2023/03/08 06:00 [pubmed]
PHST- 2023/03/07 18:24 [entrez]
AID - 000529302 [pii]
AID - 10.1159/000529302 [doi]
PST - ppublish
SO  - Gynecol Obstet Invest. 2023;88(3):150-158. doi: 10.1159/000529302. Epub 2023 Mar 
      7.

PMID- 2584901
OWN - NLM
STAT- MEDLINE
DCOM- 19900109
LR  - 20131121
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 72
IP  - 10
DP  - 1989 Oct
TI  - Effect of caffeine on the bioavailability and pharmacokinetics of aspirin.
PG  - 562-6
AB  - The objective of this study was to determine the influence of caffeine on aspirin 
      bioavailability and pharmacokinetics in man. Two lots of the drugs were compared. 
      The first lot (Lot # 1), which was caffeine-free, contained 650 mg aspirin plus 
      60 mg citric acid, whereas the second lot (Lot # 2) was caffeine-aspirin 
      combination (650 mg aspirin plus 120 mg caffeine citrate, equivalent to 60 mg 
      anhydrous caffeine). On two different occasions (2 weeks apart), the subjects 
      received these two lots of drugs orally, i.e., each volunteer was given 650 mg 
      aspirin (Lot # 1) or 650 mg aspirin plus 120 mg caffeine citrate (Lot # 2). It 
      was found that caffeine significantly increased the rate of appearance as well as 
      the maximum concentration of the salicylate in plasma by about 31 and 15 per 
      cent, respectively. The area under the plasma concentration-time curve (AUC0 
      affinity) of salicylate was statistically higher in the subjects given the drug 
      combination as compared to those given aspirin alone. Other pharmacokinetic 
      parameters of the salicylate remained unchanged. It was therefore concluded that 
      caffeine can increase the bioavailability of aspirin in man without any other 
      effects on the salicylate disposition.
FAU - Thithapandha, A
AU  - Thithapandha A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacokinetics
MH  - Biological Availability
MH  - Caffeine/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1989/10/01 00:00
MHDA- 1989/10/01 00:01
CRDT- 1989/10/01 00:00
PHST- 1989/10/01 00:00 [pubmed]
PHST- 1989/10/01 00:01 [medline]
PHST- 1989/10/01 00:00 [entrez]
PST - ppublish
SO  - J Med Assoc Thai. 1989 Oct;72(10):562-6.

PMID- 37120055
OWN - NLM
STAT- MEDLINE
DCOM- 20230828
LR  - 20230828
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 229
IP  - 3
DP  - 2023 Sep
TI  - Care plan for individuals at risk for preeclampsia: shared approach to education, 
      strategies for prevention, surveillance, and follow-up.
PG  - 193-213
LID - S0002-9378(23)00260-0 [pii]
LID - 10.1016/j.ajog.2023.04.023 [doi]
AB  - Preeclampsia is a multisystemic disorder of pregnancy that affects 250,000 
      pregnant individuals in the United States and approximately 10 million worldwide 
      per annum. Preeclampsia is associated with substantial immediate morbidity and 
      mortality but also long-term morbidity for both mother and offspring. It is now 
      clearly established that a low dose of aspirin given daily, beginning early in 
      pregnancy modestly reduces the occurrence of preeclampsia. Low-dose aspirin seems 
      safe, but because there is a paucity of information about long-term effects on 
      the infant, it is not recommended for all pregnant individuals. Thus, several 
      expert groups have identified clinical factors that indicate sufficient risk to 
      recommend low-dose aspirin preventive therapy. These risk factors may be 
      complemented by biochemical and/or biophysical tests that either indicate 
      increased probability of preeclampsia in individuals with clinical risk factors, 
      or more importantly, identify increased likelihood in those without other evident 
      risk. In addition, the opportunity exists to provide this population with 
      additional care that may prevent or mitigate the short- and long-term effects of 
      preeclampsia. Patient and provider education, increased surveillance, behavioral 
      modification, and other approaches to improve outcomes in these individuals can 
      improve the chance of a healthy outcome. We assembled a group with diverse, 
      relevant expertise (clinicians, investigators, advocates, and public and private 
      stakeholders) to develop a care plan in which providers and pregnant individuals 
      at risk can work together to reduce the risk of preeclampsia and associated 
      morbidities. The plan is for care of individuals at moderate to high risk for 
      developing preeclampsia, sufficient to receive low-dose aspirin therapy, as 
      identified by clinical and/or laboratory findings. The recommendations are 
      presented using the GRADE methodology with the quality of evidence upon which 
      each is based. In addition, printable appendices with concise summaries of the 
      care plan's recommendations for patients and healthcare providers are provided. 
      We believe that this shared approach to care will facilitate prevention of 
      preeclampsia and its attendant short- and long-term morbidity in patients 
      identified as at risk for development of this disorder.
CI  - Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Roberts, James M
AU  - Roberts JM
AD  - Magee-Womens Research Institute and Clinical and Translational Science Institute, 
      Department of Obstetrics, Gynecology and Reproductive Sciences and Department of 
      Epidemiology, University of Pittsburgh, Pittsburgh, PA. Electronic address: 
      jroberts@mwri.magee.edu.
FAU - King, Tekoa L
AU  - King TL
AD  - School of Nursing, University of California, San Francisco, Oakland, CA.
FAU - Barton, John R
AU  - Barton JR
AD  - Maternal-Fetal Medicine, Baptist Health, Lexington, KY.
FAU - Beck, Stacy
AU  - Beck S
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, University of 
      Pittsburgh, Pittsburgh, PA.
FAU - Bernstein, Ira M
AU  - Bernstein IM
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, University of 
      Vermont, Burlington, VT.
FAU - Buck, Tiffani E
AU  - Buck TE
AD  - Washington State Department of Health, Olympia, WA.
FAU - Forgues-Lackie, Michele A
AU  - Forgues-Lackie MA
AD  - Valley Medical Center, University of Washington Medicine, Renton, WA.
FAU - Facco, Francesca L
AU  - Facco FL
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, University of 
      Pittsburgh, Pittsburgh, PA.
FAU - Gernand, Alison D
AU  - Gernand AD
AD  - Nutritional Sciences, Pennsylvania State University, University Park, PA.
FAU - Graves, Cornelia R
AU  - Graves CR
AD  - Division of Maternal-Fetal Medicine, University of Tennessee College of Medicine, 
      Nashville, TN.
FAU - Jeyabalan, Arundhati
AU  - Jeyabalan A
AD  - Magee-Womens Research Institute, Department of Obstetrics, Gynecology and 
      Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA.
FAU - Hauspurg, Alisse
AU  - Hauspurg A
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, University of 
      Pittsburgh, Pittsburgh, PA.
FAU - Manuck, Tracy A
AU  - Manuck TA
AD  - Obstetrics and Gynecology, The University of North Carolina at Chapel Hill, 
      Chapel Hill, NC.
FAU - Myers, Jenny E
AU  - Myers JE
AD  - Division of Developmental Biology and Medicine, University of Manchester, 
      Manchester, United Kingdom.
FAU - Powell, Trashaun M
AU  - Powell TM
AD  - National Racial Disparity Taskforce, Preeclampsia Foundation and New Jersey 
      Family Planning League, Somerset, NJ.
FAU - Sutton, Elizabeth F
AU  - Sutton EF
AD  - Woman's Hospital, Baton Rouge, LA.
FAU - Tinker, Elizabeth
AU  - Tinker E
AD  - Washington State Health Care Authority, Olympia, WA.
FAU - Tsigas, Eleni
AU  - Tsigas E
AD  - Preeclampsia Foundation, Melbourne, FL.
FAU - Myatt, Leslie
AU  - Myatt L
AD  - Department of Obstetrics and Gynecology, Oregon Health & Science University, 
      Portland, OR.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230427
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/etiology
MH  - Follow-Up Studies
MH  - Aspirin/therapeutic use
MH  - Risk Factors
MH  - Educational Status
OTO - NOTNLM
OT  - GRADE
OT  - hypertensive disorders of pregnancy
OT  - low-dose aspirin therapy
OT  - preeclampsia
OT  - prevention
EDAT- 2023/04/30 00:42
MHDA- 2023/08/28 06:41
CRDT- 2023/04/29 19:28
PHST- 2022/10/23 00:00 [received]
PHST- 2023/04/11 00:00 [revised]
PHST- 2023/04/12 00:00 [accepted]
PHST- 2023/08/28 06:41 [medline]
PHST- 2023/04/30 00:42 [pubmed]
PHST- 2023/04/29 19:28 [entrez]
AID - S0002-9378(23)00260-0 [pii]
AID - 10.1016/j.ajog.2023.04.023 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2023 Sep;229(3):193-213. doi: 10.1016/j.ajog.2023.04.023. 
      Epub 2023 Apr 27.

PMID- 684792
OWN - NLM
STAT- MEDLINE
DCOM- 19781025
LR  - 20190727
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 18
IP  - 4
DP  - 1978 Jul-Aug
TI  - The effect of aspirin on the hypotonic shock response.
PG  - 423-8
AB  - The effect of aspirin on the hypotonic shock response was studied at 2, 6, 24, 
      and 48 hours after ingestion of 1.6 g of acetylsalicylic acid. There was a marked 
      acceleration of the recovery phase of the response at two hours. This steadily 
      decreased and by 48 hours had returned to near normal values. In most cases there 
      was also a change in the initial phase of the shock response. We have interpreted 
      these results to indicate a change in membrane permeability (first phase effect) 
      as well as an activation of the energy-dependent recovery (second phase). The 
      latter process possibly is the result of an increase in the levels of available 
      ATP. As previously reported, the response to aggregating agents was impaired in 
      the presence of ASA. Normal and aspirinated platelets were mixed in an attempt to 
      overcome the ASA effect. Using two hour postingestion samples we noted 
      considerable impairment of both the hypotonic shock response and aggregation even 
      in the presence of very high concentrations of normal platelets.
FAU - Rock, G
AU  - Rock G
FAU - Trepanier, J
AU  - Trepanier J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Collagen
MH  - Epinephrine
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Shock/*drug therapy
MH  - Time Factors
EDAT- 1978/07/01 00:00
MHDA- 1978/07/01 00:01
CRDT- 1978/07/01 00:00
PHST- 1978/07/01 00:00 [pubmed]
PHST- 1978/07/01 00:01 [medline]
PHST- 1978/07/01 00:00 [entrez]
AID - 10.1046/j.1537-2995.1978.18478251235.x [doi]
PST - ppublish
SO  - Transfusion. 1978 Jul-Aug;18(4):423-8. doi: 
      10.1046/j.1537-2995.1978.18478251235.x.

PMID- 2219758
OWN - NLM
STAT- MEDLINE
DCOM- 19901102
LR  - 20131121
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 36
IP  - 6
DP  - 1990 Jun
TI  - [Anticoagulantion and antiaggregation therapy in patients with unstableangina 
      pectoris].
PG  - 537-43
AB  - Heparin, aspirin with dipyridamol or 5% dextrose were administered to 266 
      patients admitted to the coronary unit with unstable angina. All patients were 
      concurrently treated with isosorbide dinitrate, a beta-blocker and nifedipine. 
      The number of patients who developed an acute myocardial infarction (IM) during 
      the subsequent 72 hours was comparable in all three groups. However, in the 
      heparin treated group only 3.2% patients developed Q IM, as compared with 20% 
      patients treated with aspirin and dipyridamol (p = 0.005) and with 19% in the 
      control group (p = 0.006). The magnitude of the IM was evaluated according to the 
      highest serum value of creatine phosphokinase. In the heparin treated group its 
      value was 810.5 +/- 538 i.u./l which was significantly less than in the aspirin + 
      dipyridamol group where it was 1229 +/- 829 i.u./l (p = 0.048) and in the control 
      group where it was 1417 +/- 919 i.u./l (p = 0.009). The authors defined the group 
      of patients with a high risk of development of IM who had protracted anginous 
      pain longer than 45 mins. with ST segment depression deeper than 1 mm on the ECG 
      on admission. 55% of these patients developed an infarction in the course of the 
      subsequent 72 hours.
FAU - Charvát, J
AU  - Charvát J
AD  - I. interní klinika Fakulty dĕtského lékarství Univerzity Karlovy, Praha.
FAU - Fiserová, J
AU  - Fiserová J
LA  - cze
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Antikoagulacní a antiagregacní lécba u nemocných s nestabilní anginou pectoris.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/*drug therapy/physiopathology
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Dipyridamole/*administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Electrocardiography
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
PST - ppublish
SO  - Vnitr Lek. 1990 Jun;36(6):537-43.

PMID- 16188050
OWN - NLM
STAT- MEDLINE
DCOM- 20091215
LR  - 20131121
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 33
IP  - 8
DP  - 2005 Aug
TI  - [Study on the relationship between aspirin resistance and incidence of 
      myonecrosis after non-emergent percutaneous coronary intervention].
PG  - 695-9
AB  - OBJECTIVE: To investigate the occurrence of aspirin resistance in coronary heart 
      disease (CHD) patients and its influence on myonecrosis among patients undergoing 
      non-emergent percutaneous coronary intervention (PCI). METHODS: 256 CHD patients 
      who have been on aspirin (100 mg/d) for at least 7 days were recruited based on 
      aspirin responsiveness determination. All the patients were divided into two 
      groups: aspirin-resistant group and aspirin-sensitive group. For all patients 
      scheduled for non-emergent PCI, a loading dose of 300 mg of clopidogrel was given 
      at least 12 h before PCI and a 75 mg maintenance dose was given every morning 
      before and after PCI. The incidence of myonecrosis was evaluated by the levels of 
      creatine kinase-myocardial band (CK-MB) and troponin I (TnI) before and after 
      PCI. RESULTS: Aspirin resistance was found in 67 (26.2%) patients and 189 (73.8%) 
      patients were aspirin-sensitive. There was a significantly higher proportion of 
      female subjects in the aspirin-resistant group. The incidence of any CK-MB 
      elevation was 38 (56.7%) in aspirin-resistant group and 42 (22.2%) in 
      aspirin-sensitive group (P < 0.01). The elevation of TnI was observed in 41 
      (61.2%) of the aspirin-resistant group and in 67 (35.4%) of the aspirin-sensitive 
      group (P < 0.05). Multivariate analysis revealed that aspirin resistance was an 
      independent predictor for CK-MB elevation after PCI (OR = 2.5; 95% CI 1.5 to 6.5; 
      P < 0.05). CONCLUSION: Aspirin resistance exists in some CHD patients, which 
      increases the risk of myonecrosis following non-emergent PCI.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Twelfth Ward, Anzhen Hospital, Capital University of Medical Sciences, Beijing 
      100029, China.
FAU - Liang, Jing
AU  - Liang J
FAU - Zhou, Yu-jie
AU  - Zhou YJ
FAU - Yuan, Hui
AU  - Yuan H
FAU - Zhang, Yong-zhi
AU  - Zhang YZ
FAU - Dong, Lei
AU  - Dong L
LA  - chi
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (Troponin I)
RN  - EC 2.7.3.2 (Creatine Kinase, MB Form)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/*adverse effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Coronary Disease/*therapy
MH  - Creatine Kinase, MB Form/analysis
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myocardium/*pathology
MH  - Necrosis
MH  - Platelet Activation
MH  - Platelet Aggregation
MH  - Stents
MH  - Troponin I/analysis
EDAT- 2005/09/29 09:00
MHDA- 2009/12/16 06:00
CRDT- 2005/09/29 09:00
PHST- 2005/09/29 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
PHST- 2005/09/29 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Aug;33(8):695-9.

PMID- 36944992
OWN - NLM
STAT- MEDLINE
DCOM- 20230329
LR  - 20230329
IS  - 1749-799X (Electronic)
IS  - 1749-799X (Linking)
VI  - 18
IP  - 1
DP  - 2023 Mar 22
TI  - Aspirin prevents estrogen deficiency-induced bone loss by inhibiting 
      osteoclastogenesis and promoting osteogenesis.
PG  - 227
LID - 10.1186/s13018-023-03710-y [doi]
LID - 227
AB  - BACKGROUND: Aspirin is a commonly used antipyretic, analgesic, and 
      anti-inflammatory drug. Numerous researches have demonstrated that aspirin exerts 
      multiple biological effects on bone metabolism. However, its spatiotemporal roles 
      remain controversial according to the specific therapeutic doses used for 
      different clinical conditions, and the detailed mechanisms have not been fully 
      elucidated. Hence, in the present study, we aimed to identify the dual effects of 
      different aspirin dosages on osteoclastic activity and osteoblastic bone 
      formation in vitro and in vivo. METHODS: The effects of varying doses of aspirin 
      on osteoclast and osteoblast differentiation were evaluated in vitro. The 
      underlying molecular mechanisms were detected using quantitative real-time 
      polymerase chain reaction, western blotting, and immunofluorescence techniques. 
      An ovariectomized rat osteoporosis model was used to assess the bone-protective 
      effects of aspirin in vivo. RESULTS: Aspirin dose-dependently suppressed 
      RANKL-induced osteoclasts differentiation and bone resorption in vitro and 
      reduced the expression of osteoclastic marker genes, including TRAP, cathepsin K, 
      and CTR. Further molecular analysis revealed that aspirin impaired the 
      RANKL-induced NF-κB and MAPK signaling pathways and prevented the nuclear 
      translocation of the NF-κB p65 subunit. Low-dose aspirin promoted osteogenic 
      differentiation, whereas these effects were attenuated when high-dose aspirin was 
      administered. Both low and high doses of aspirin prevented bone loss in an 
      ovariectomized rat osteoporosis model in vivo. CONCLUSION: Aspirin inhibits 
      RANKL-induced osteoclastogenesis and promotes osteogenesis in a dual regulatory 
      manner, thus preventing bone loss in vivo. These data indicate that aspirin has 
      potential applications in the prevention and treatment of osteopenia.
CI  - © 2023. The Author(s).
FAU - Chang, Yongyun
AU  - Chang Y
AD  - Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, 
      Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 
      No.639, Zhizaoju Road, Shanghai, China.
FAU - Kong, Keyu
AU  - Kong K
AD  - Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, 
      Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 
      No.639, Zhizaoju Road, Shanghai, China.
FAU - Tong, Zhicheng
AU  - Tong Z
AD  - Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, 
      Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 
      No.639, Zhizaoju Road, Shanghai, China.
FAU - Qiao, Hua
AU  - Qiao H
AD  - Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, 
      Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 
      No.639, Zhizaoju Road, Shanghai, China.
FAU - Hu, Yi
AU  - Hu Y
AD  - Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, 
      Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 
      No.639, Zhizaoju Road, Shanghai, China.
FAU - Xia, Runzhi
AU  - Xia R
AD  - Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, 
      Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 
      No.639, Zhizaoju Road, Shanghai, China.
FAU - Zhang, Jingwei
AU  - Zhang J
AD  - Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, 
      Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 
      No.639, Zhizaoju Road, Shanghai, China.
FAU - Zhai, Zanjing
AU  - Zhai Z
AD  - Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, 
      Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 
      No.639, Zhizaoju Road, Shanghai, China. zanjing_zhai@163.com.
FAU - Li, Huiwu
AU  - Li H
AD  - Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, 
      Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 
      No.639, Zhizaoju Road, Shanghai, China. huiwu1223@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230322
PL  - England
TA  - J Orthop Surg Res
JT  - Journal of orthopaedic surgery and research
JID - 101265112
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Estrogens)
RN  - 0 (NF-kappa B)
RN  - 0 (RANK Ligand)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Bone Resorption/etiology/prevention & control
MH  - Cell Differentiation
MH  - Estrogens
MH  - NF-kappa B/metabolism
MH  - Osteoclasts/metabolism
MH  - Osteogenesis
MH  - *Osteoporosis/drug therapy/etiology/prevention & control
MH  - RANK Ligand/genetics
PMC - PMC10031892
OTO - NOTNLM
OT  - Aspirin
OT  - MAPK
OT  - NF-κB
OT  - Osteoclastogenesis
OT  - Osteogenesis
OT  - Osteoporosis
COIS- The authors declare no competing interest.
EDAT- 2023/03/23 06:00
MHDA- 2023/03/24 06:00
CRDT- 2023/03/22 00:35
PHST- 2023/02/18 00:00 [received]
PHST- 2023/03/13 00:00 [accepted]
PHST- 2023/03/22 00:35 [entrez]
PHST- 2023/03/23 06:00 [pubmed]
PHST- 2023/03/24 06:00 [medline]
AID - 10.1186/s13018-023-03710-y [pii]
AID - 3710 [pii]
AID - 10.1186/s13018-023-03710-y [doi]
PST - epublish
SO  - J Orthop Surg Res. 2023 Mar 22;18(1):227. doi: 10.1186/s13018-023-03710-y.

PMID- 19752399
OWN - NLM
STAT- MEDLINE
DCOM- 20100507
LR  - 20211020
IS  - 1539-7262 (Electronic)
IS  - 0022-2275 (Print)
IS  - 0022-2275 (Linking)
VI  - 51
IP  - 3
DP  - 2010 Mar
TI  - Identification and absolute configuration of dihydroxy-arachidonic acids formed 
      by oxygenation of 5S-HETE by native and aspirin-acetylated COX-2.
PG  - 575-85
LID - 10.1194/jlr.M001719 [doi]
AB  - Biosynthesis of the prostaglandin endoperoxide by the cyclooxygenase (COX) 
      enzymes is accompanied by formation of a small amount of 
      11R-hydroxyeicosatetraenoic acid (HETE), 15R-HETE, and 15S-HETE as by-products. 
      Acetylation of COX-2 by aspirin abrogates prostaglandin synthesis and triggers 
      formation of 15R-HETE as the sole product of oxygenation of arachidonic acid. 
      Here, we investigated the formation of by-products of the transformation of 
      5S-HETE by native COX-2 and by aspirin-acetylated COX-2 using HPLC-ultraviolet, 
      GC-MS, and LC-MS analysis. 5S,15S- dihydroxy (di)HETE, 5S,15R-diHETE, and 
      5S,11R-diHETE were identified as by-products of native COX-2, in addition to the 
      previously described di-endoperoxide 
      (5S,15S-dihydroxy-9S,11R,8S,12S-diperoxy-6E,13E-eicosadienoic acid) as the major 
      oxygenation product. 5S,15R-diHETE was the only product formed by 
      aspirin-acetylated COX-2. Both 5,15-diHETE and 5,11-diHETE were detected in CT26 
      mouse colon carcinoma cells as well as in lipopolysaccharide-activated RAW264.7 
      cells incubated with 5S-HETE, and their formation was attenuated in the presence 
      of the COX-2 specific inhibitor, NS-398. Aspirin-treated CT26 cells gave 
      5,15-diHETE as the most prominent product formed from 5S-HETE. 5S,15S-diHETE has 
      been described as a product of the cross-over of 5-lipoxygenase (5-LOX) and 
      15-LOX activities in elicited rat mononuclear cells and human leukocytes, and our 
      studies implicate cross-over of the 5-LOX and COX-2 pathways as an additional 
      biosynthetic route.
FAU - Mulugeta, Surafel
AU  - Mulugeta S
AD  - Division of Clinical Pharmacology, Department of Pharmacology, Vanderbilt 
      University Medical School, Nashville, TN 37232, USA.
FAU - Suzuki, Takashi
AU  - Suzuki T
FAU - Hernandez, Noemi Tejera
AU  - Hernandez NT
FAU - Griesser, Markus
AU  - Griesser M
FAU - Boeglin, William E
AU  - Boeglin WE
FAU - Schneider, Claus
AU  - Schneider C
LA  - eng
GR  - R01 GM076592/GM/NIGMS NIH HHS/United States
GR  - R01GM076592/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20090914
PL  - United States
TA  - J Lipid Res
JT  - Journal of lipid research
JID - 0376606
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Acetylation/drug effects
MH  - Animals
MH  - Aspirin/chemistry/*pharmacology
MH  - Cell Line
MH  - Circular Dichroism
MH  - Cyclooxygenase 2/chemistry/*metabolism
MH  - Humans
MH  - Hydroxyeicosatetraenoic Acids/analysis/biosynthesis/*chemistry/*metabolism
MH  - Mice
MH  - Oxygen/*metabolism
MH  - Stereoisomerism
PMC - PMC2817587
EDAT- 2009/09/16 06:00
MHDA- 2010/05/08 06:00
CRDT- 2009/09/16 06:00
PHST- 2009/09/16 06:00 [entrez]
PHST- 2009/09/16 06:00 [pubmed]
PHST- 2010/05/08 06:00 [medline]
AID - S0022-2275(20)30515-0 [pii]
AID - m001719 [pii]
AID - 10.1194/jlr.M001719 [doi]
PST - ppublish
SO  - J Lipid Res. 2010 Mar;51(3):575-85. doi: 10.1194/jlr.M001719. Epub 2009 Sep 14.

PMID- 9403477
OWN - NLM
STAT- MEDLINE
DCOM- 19980102
LR  - 20131121
IS  - 0364-5134 (Print)
IS  - 0364-5134 (Linking)
VI  - 42
IP  - 6
DP  - 1997 Dec
TI  - A randomized trial of anticoagulants versus aspirin after cerebral ischemia of 
      presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial 
      (SPIRIT) Study Group.
PG  - 857-65
AB  - Aspirin is only modestly effective in the secondary prevention after cerebral 
      ischemia. Studies in other vascular disorders suggest that anticoagulant drugs in 
      patients with cerebral ischemia of presumed arterial (noncardiac) origin might be 
      more effective. The aim of the Stroke Prevention in Reversible Ischemia Trial 
      (SPIRIT) therefore was to compare the efficacy and safety of 30 mg aspirin daily 
      and oral anticoagulation (international normalized ratio [INR] 3.0-4.5). Patients 
      referred to a neurologist in one of 58 collaborating centers because of a 
      transient ischemic attack or minor ischemic stroke (Rankin grade < or =3) were 
      eligible. Randomization was concealed, treatment assignment was open, and 
      assessment of outcome events was masked. The primary measure of outcome was the 
      composite event "death from all vascular causes, nonfatal stroke, nonfatal 
      myocardial infarction, or nonfatal major bleeding complication." The trial was 
      stopped at the first interim analysis. A total of 1,316 patients participated; 
      their mean follow-up was 14 months. There was an excess of the primary outcome 
      event in the anticoagulated group (81 of 651) versus 36 of 665 in the aspirin 
      group (hazard ratio, 2.3; 95% confidence interval [CI], 1.6-3.5). This excess 
      could be attributed to 53 major bleeding complications (27 intracranial; 17 
      fatal) during anticoagulant therapy versus 6 on aspirin (3 intracranial; 1 
      fatal). The bleeding incidence increased by a factor of 1.43 (95% CI, 0.96-2.13) 
      for each 0.5 unit increase of the achieved INR. Anticoagulant therapy with an INR 
      range of 3.0 to 4.5 in patients after cerebral ischemia of presumed arterial 
      origin is not safe. The efficacy of a lower intensity anticoagulation regimen 
      remains to be determined.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Neurol
JT  - Annals of neurology
JID - 7707449
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/*drug therapy/*prevention & control
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 1997/12/24 00:00
MHDA- 1997/12/24 00:01
CRDT- 1997/12/24 00:00
PHST- 1997/12/24 00:00 [pubmed]
PHST- 1997/12/24 00:01 [medline]
PHST- 1997/12/24 00:00 [entrez]
AID - 10.1002/ana.410420606 [doi]
PST - ppublish
SO  - Ann Neurol. 1997 Dec;42(6):857-65. doi: 10.1002/ana.410420606.

PMID- 8768288
OWN - NLM
STAT- MEDLINE
DCOM- 19960924
LR  - 20131121
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 42
IP  - 5
DP  - 1996 May
TI  - [Changes in platelet activity in invasive cardiologic procedures].
PG  - 314-9
AB  - The authors revealed some changes in the platelet activity in patients with 
      invasive cardiological procedures. Changes of the platelet function were 
      manifested by an enhanced aggregation of platelets in vivo, an increased 
      secretion from alpha granules and increased release of prostaglandin metabolites 
      from platelets and from the vascular wall. Acetylsalicylic acid (ASA) suppressed 
      the formation of circulating platelet aggregates in vivo, but the platelet 
      activity was manifested by another mechanism, independent on ASA. The authors 
      recorded therefore an increase of prostaglandin metabolites and PF4 even in 
      patients who were treated with ASA before the invasive examination.
FAU - Malý, J
AU  - Malý J
AD  - 2, katedra vnitrních oborů LF UK, Hradec Králové.
FAU - Pecka, M
AU  - Pecka M
FAU - Pleskot, M
AU  - Pleskot M
FAU - Cernohorský, D
AU  - Cernohorský D
FAU - Pidrman, V
AU  - Pidrman V
FAU - Stásek, J
AU  - Stásek J
FAU - Bláha, M
AU  - Bláha M
FAU - Siroký, O
AU  - Siroký O
FAU - Jebavý, L
AU  - Jebavý L
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Zmĕny aktivity desticek pri invazivních kardiologických výkonech.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/pharmacology
MH  - *Cardiac Pacing, Artificial
MH  - *Coronary Angiography
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Platelet Activation/drug effects
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
PST - ppublish
SO  - Vnitr Lek. 1996 May;42(5):314-9.

PMID- 23009994
OWN - NLM
STAT- MEDLINE
DCOM- 20121211
LR  - 20141120
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 25
IP  - 4
DP  - 2012 Oct
TI  - Comparing the effects of salts of diclofenac and alminoprofen with aspirin on 
      serum electrolytes, creatinine and urea levels in rabbits.
PG  - 777-82
AB  - The effects of diclofenac sodium, diclofenac potassium, alminoprofen and aspirin 
      on serum electrolytes (serum Na(+) and K(+)), urea and creatinine were compared 
      in rabbits in acute and chronic phases of treatment. The data suggested that all 
      the four drugs markedly increased the serum electrolytes, urea and creatinine 
      levels in both post-treatment phases. In conclusion, present study does not 
      present any advantage of diclofenac sodium over diclofenac potassium at 
      electrolyte levels on short and long term treatment. Nevertheless, current data 
      support the evidence of renal function impairment by all the four drug therapies 
      used in the present study, which is generally caused by NSAIDS.
FAU - Syed, Nawazish-I-Husain
AU  - Syed NI
AD  - University College of Pharmacy, University of the Punjab, Lahore, Pakistan. 
      snihusain@yahoo.com
FAU - Zehra, Farnaz
AU  - Zehra F
FAU - Syed, Amir Ali-Rizvi
AU  - Syed AA
FAU - Karim, Sabiha
AU  - Karim S
FAU - Khan, Farrakh Zia
AU  - Khan FZ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Electrolytes)
RN  - 0 (Propionates)
RN  - 0255AHR9GJ (alminoprofen)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 8W8T17847W (Urea)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/chemistry/*pharmacology/toxicity
MH  - Aspirin/administration & dosage/chemistry/*pharmacology/toxicity
MH  - Chemistry, Pharmaceutical
MH  - Creatinine/*blood
MH  - Diclofenac/administration & dosage/chemistry/*pharmacology/toxicity
MH  - Electrolytes/*blood
MH  - Female
MH  - Kidney/*drug effects/metabolism
MH  - Male
MH  - Propionates/administration & dosage/chemistry/*pharmacology/toxicity
MH  - Rabbits
MH  - Time Factors
MH  - Urea/*blood
EDAT- 2012/09/27 06:00
MHDA- 2012/12/12 06:00
CRDT- 2012/09/27 06:00
PHST- 2012/09/27 06:00 [entrez]
PHST- 2012/09/27 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
PST - ppublish
SO  - Pak J Pharm Sci. 2012 Oct;25(4):777-82.

PMID- 34581729
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20211014
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 326
IP  - 12
DP  - 2021 Sep 28
TI  - Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US 
      Preventive Services Task Force Recommendation Statement.
PG  - 1186-1191
LID - 10.1001/jama.2021.14781 [doi]
AB  - IMPORTANCE: Preeclampsia is one of the most serious health problems that affect 
      pregnant persons. It is a complication in approximately 4% of pregnancies in the 
      US and contributes to both maternal and infant morbidity and mortality. 
      Preeclampsia also accounts for 6% of preterm births and 19% of medically 
      indicated preterm births in the US. There are racial and ethnic disparities in 
      the prevalence of and mortality from preeclampsia. Non-Hispanic Black women are 
      at greater risk for developing preeclampsia than other women and experience 
      higher rates of maternal and infant morbidity and perinatal mortality. OBJECTIVE: 
      To update its 2014 recommendation, the USPSTF commissioned a systematic review to 
      evaluate the effectiveness of low-dose aspirin use to prevent preeclampsia. 
      POPULATION: Pregnant persons at high risk for preeclampsia who have no prior 
      adverse effects with or contraindications to low-dose aspirin. EVIDENCE 
      ASSESSMENT: The USPSTF concludes with moderate certainty that there is a 
      substantial net benefit of daily low-dose aspirin use to reduce the risk for 
      preeclampsia, preterm birth, small for gestational age/intrauterine growth 
      restriction, and perinatal mortality in pregnant persons at high risk for 
      preeclampsia. RECOMMENDATION: The USPSTF recommends the use of low-dose aspirin 
      (81 mg/d) as preventive medication for preeclampsia after 12 weeks of gestation 
      in persons who are at high risk for preeclampsia. (B recommendation).
CN  - US Preventive Services Task Force
FAU - Davidson, Karina W
AU  - Davidson KW
AD  - Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New 
      York.
FAU - Barry, Michael J
AU  - Barry MJ
AD  - Harvard Medical School, Boston, Massachusetts.
FAU - Mangione, Carol M
AU  - Mangione CM
AD  - University of California, Los Angeles.
FAU - Cabana, Michael
AU  - Cabana M
AD  - Albert Einstein College of Medicine, New York, New York.
FAU - Caughey, Aaron B
AU  - Caughey AB
AD  - Oregon Health & Science University, Portland.
FAU - Davis, Esa M
AU  - Davis EM
AD  - University of Pittsburgh, Pittsburgh, Pennsylvania.
FAU - Donahue, Katrina E
AU  - Donahue KE
AD  - University of North Carolina at Chapel Hill.
FAU - Doubeni, Chyke A
AU  - Doubeni CA
AD  - Mayo Clinic, Rochester, Minnesota.
FAU - Kubik, Martha
AU  - Kubik M
AD  - George Mason University, Fairfax, Virginia.
FAU - Li, Li
AU  - Li L
AD  - University of Virginia, Charlottesville.
FAU - Ogedegbe, Gbenga
AU  - Ogedegbe G
AD  - New York University, New York, New York.
FAU - Pbert, Lori
AU  - Pbert L
AD  - University of Massachusetts Medical School, Worcester.
FAU - Silverstein, Michael
AU  - Silverstein M
AD  - Boston University, Boston, Massachusetts.
FAU - Simon, Melissa A
AU  - Simon MA
AD  - Northwestern University, Chicago, Illinois.
FAU - Stevermer, James
AU  - Stevermer J
AD  - University of Missouri, Columbia.
FAU - Tseng, Chien-Wen
AU  - Tseng CW
AD  - University of Hawaii, Honolulu.
AD  - Pacific Health Research and Education Institute, Honolulu, Hawaii.
FAU - Wong, John B
AU  - Wong JB
AD  - Tufts University School of Medicine, Boston, Massachusetts.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- JAMA. 2021 Sep 28;326(12):1222. PMID: 34581735
CIN - JAMA. 2021 Sep 28;326(12):1153-1155. PMID: 34581753
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Small for Gestational Age
MH  - Perinatal Death/prevention & control
MH  - Pre-Eclampsia/ethnology/*prevention & control
MH  - Pregnancy
MH  - Premature Birth/prevention & control
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2021/09/29 06:00
MHDA- 2021/10/14 06:00
CRDT- 2021/09/28 12:18
PHST- 2021/09/28 12:18 [entrez]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
AID - 2784499 [pii]
AID - 10.1001/jama.2021.14781 [doi]
PST - ppublish
SO  - JAMA. 2021 Sep 28;326(12):1186-1191. doi: 10.1001/jama.2021.14781.

PMID- 962220
OWN - NLM
STAT- MEDLINE
DCOM- 19761029
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 85
IP  - 3
DP  - 1976 Sep
TI  - Aspirin-induced ultrastructural changes in human gastric mucosa: correlation with 
      potential difference.
PG  - 299-303
AB  - Aspirin breaks the gastric mucosal barrier. We studied the effect of aspirin on 
      this barrier, correlating changes in potential difference and ultrastructure. 
      Mean control potential difference for seven subjects was -48 +/- 1.0 mV. Oral 
      aspirin, 600 mg in 100 ml of saline, reduced potential difference to -39 +/- 1.4 
      mV (P less than 0.001) within 10 minutes. Gastric biopsies were taken during 
      control, aspirin- instillation, and recovery periods. Damage was present in all 
      biopsies after aspirin. Light microscopy showed focal cell disruption, loss of 
      mucous granules, and apical membrane rupture. Transmission electron microscopy 
      showed intact tight junctions. Scanning electron microscopy showed loss of normal 
      cobblestone cell apices, giving a honeycombed surface. Ten minutes after aspirin, 
      25% of surface epithelial cells were damaged. Marked recovery was noted at 1 hr, 
      with a normal potential difference and only 9% cell damage. We conclude that 
      single "routine" doses of aspirin cause focal damage to normal human gastric 
      mucosa.
FAU - Baskin, W N
AU  - Baskin WN
FAU - Ivey, K J
AU  - Ivey KJ
FAU - Krause, W J
AU  - Krause WJ
FAU - Jeffrey, G E
AU  - Jeffrey GE
FAU - Gemmell, R T
AU  - Gemmell RT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cell Membrane/ultrastructure
MH  - Cytoplasmic Granules/ultrastructure
MH  - Female
MH  - Gastric Acidity Determination
MH  - Gastric Mucosa/drug effects/*ultrastructure
MH  - Humans
MH  - Male
MH  - Membrane Potentials/*drug effects
MH  - Microscopy, Electron, Scanning
MH  - Time Factors
EDAT- 1976/09/01 00:00
MHDA- 1976/09/01 00:01
CRDT- 1976/09/01 00:00
PHST- 1976/09/01 00:00 [pubmed]
PHST- 1976/09/01 00:01 [medline]
PHST- 1976/09/01 00:00 [entrez]
AID - 10.7326/0003-4819-85-3-299 [doi]
PST - ppublish
SO  - Ann Intern Med. 1976 Sep;85(3):299-303. doi: 10.7326/0003-4819-85-3-299.

PMID- 6735044
OWN - NLM
STAT- MEDLINE
DCOM- 19840808
LR  - 20131121
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 8
IP  - 4
DP  - 1984 Apr
TI  - [Effects of a shielding antacid on changes in the gastric potential difference 
      induced by aspirin in man].
PG  - 359-63
AB  - Acetyl salicylic acid (AAS) disrupts the gastric mucosal barrier, causing a drop 
      in the transmural potential difference (PD) and mucosal injuries. The decrease of 
      PD correlates with endoscopic assessment and mucosal damage. The gastric PD may 
      be used as a sensitive model for the assessement of drug-induced damage to the 
      gastric mucosa. We have studied the effects of a shielding antacid ( Gelox ) on 
      PD modifications induced by 500 mg of AAS in 12 healthy volunteers. Measures were 
      performed after administration of one unit of Gelox and after a 3 day treatment 
      period (1 unit, three times daily). Gelox induced a significant decrease of 
      maximal PD drop (10.7 +/- 3.1 mV and 7.5 +/- 2.8 mV respectively; p less than 
      0.001) and of PD recovery time (p less than 0.05). After the 3 day treatment 
      period and 14 h after the last intake, there was an increase of basal PD values 
      and a very significant decrease (p less than 0.001) of maximal PD drop induced by 
      AAS alone and AAS + Gelox (5.33 +/- 2.42 mV and 3.66 +/- 2.18 mV, respectively). 
      Since the antacid effect had disappeared 14 h after the last intake of Gelox ; 
      these results suggest an increase of the gastric mucosal barrier and a real 
      "shielding effect".
FAU - Florent, C
AU  - Florent C
FAU - Flourie, B
AU  - Flourie B
FAU - Bernier, J J
AU  - Bernier JJ
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Effets d'un pansement anti-acide sur les modifications de la différence de 
      potentiel gastrique induites par l'aspirine chez l'homme.
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - 0 (Aluminum Silicates)
RN  - 0 (Antacids)
RN  - 0 (Drug Combinations)
RN  - 1302-78-9 (Bentonite)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - 90954-79-3 (Gelox)
RN  - I38ZP9992A (Magnesium)
RN  - NBZ3QY004S (Magnesium Hydroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aluminum Hydroxide/*pharmacology
MH  - Aluminum Silicates/*pharmacology
MH  - Antacids/*pharmacology
MH  - Aspirin/antagonists & inhibitors
MH  - Bentonite/*pharmacology
MH  - Drug Combinations/pharmacology
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Magnesium/*pharmacology
MH  - Magnesium Hydroxide/*pharmacology
MH  - Male
EDAT- 1984/04/01 00:00
MHDA- 2000/06/01 09:00
CRDT- 1984/04/01 00:00
PHST- 1984/04/01 00:00 [pubmed]
PHST- 2000/06/01 09:00 [medline]
PHST- 1984/04/01 00:00 [entrez]
PST - ppublish
SO  - Gastroenterol Clin Biol. 1984 Apr;8(4):359-63.

PMID- 15271721
OWN - NLM
STAT- MEDLINE
DCOM- 20040823
LR  - 20131121
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 99
IP  - 2
DP  - 2004 Aug
TI  - Aspirin withdrawal and acute lower limb ischemia.
PG  - 440-3, table of contents
AB  - Aspirin is used mainly to prevent arterial events in patients with arteriopathy. 
      Myocardial infarction and cerebrovascular events have been described after recent 
      aspirin withdrawal. Experimental data suggest rebound platelet activity after 
      aspirin discontinuation. Among a retrospective cohort of 181 patients admitted 
      for acute lower limb ischemia for 4 yr, we studied 11 patients who had recently 
      stopped taking aspirin. Aspirin was administered for vascular event prevention. 
      The median duration of aspirin treatment without vascular events was 12 mo 
      (range, 6-60 mo). The median time between aspirin withdrawal and lower limb 
      ischemia was 23 days (range, 7-60 days). Four of the 11 patients stopped aspirin 
      before a surgical procedure, without any substitution. In five patients, a recent 
      diagnosis of neoplasia was observed. This study should alert clinicians to the 
      risk of discontinuing chronic aspirin therapy in patients with severe peripheral 
      vascular disease.
FAU - Albaladejo, Pierre
AU  - Albaladejo P
AD  - Service D'Anesthésie-Réanimation Chirurgicale, Centre Hospitalier Universitaire 
      Beaujon, 100 Avenue du Général Leclerc, F-92110 Clichy, France. 
      pierre.albaladejo@bjn.ap-hop-paris.fr
FAU - Geeraerts, Thomas
AU  - Geeraerts T
FAU - Francis, Fady
AU  - Francis F
FAU - Castier, Yves
AU  - Castier Y
FAU - Lesèche, Guy
AU  - Lesèche G
FAU - Marty, Jean
AU  - Marty J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Arterial Occlusive Diseases/complications/drug therapy/*physiopathology
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - Ischemia/physiopathology
MH  - Leg/blood supply
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Regional Blood Flow/physiology
MH  - Retrospective Studies
MH  - Substance Withdrawal Syndrome/*physiopathology
EDAT- 2004/07/24 05:00
MHDA- 2004/08/24 05:00
CRDT- 2004/07/24 05:00
PHST- 2004/07/24 05:00 [pubmed]
PHST- 2004/08/24 05:00 [medline]
PHST- 2004/07/24 05:00 [entrez]
AID - 99/2/440 [pii]
AID - 10.1213/01.ANE.0000131965.61686.BD [doi]
PST - ppublish
SO  - Anesth Analg. 2004 Aug;99(2):440-3, table of contents. doi: 
      10.1213/01.ANE.0000131965.61686.BD.

PMID- 580507
OWN - NLM
STAT- MEDLINE
DCOM- 19780617
LR  - 20191210
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 39
IP  - 1
DP  - 1978 Feb 28
TI  - Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an 
      anti-aggregating compound, on experimental thrombosis in rats.
PG  - 74-83
AB  - In ordder to evaluate 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141) as a 
      possible antithrombotic compound, a simple and reproducible method for 
      experimental thrombosis in rats was devised. A silken thread was inserted in the 
      extracorporeal shunt between the carotid artery and the jugular vein. 15 min 
      after the circulation of blood, wet weight of thrombus which developed on the 
      thread was measured to determine the degree and rate of thrombus formation. 
      Equalization of average body weight of rats for each group provided good 
      reproducibility. Microscopic examination demonstrated that the thrombus was 
      primarily composed of platelets. By use of the technique, the activities of 
      KC-6141 and two known inhbitors, aspirin and dipyridamole, were determined. Of 
      the three compounds, KC-6141 was the most potent inhibitor for the thrombosis. 
      Its ED50 was 60 mg/kg when given orally and the compound was activite for about 
      40 hr. Aspirin was about twice as less active than KC-6141 and dipyridamole 
      showed no effect on the thrombosis. The ranking order of potency against the 
      experimental thrombosis for the three compounds was the same as that for 
      inhibition of platelet aggregation in vitro and platelet retention in rats, as 
      reported previously by us. Therefore the method seems to be associated with 
      platelet aggregation and retention. The above result suggests that KC-6141 is of 
      value as antithrombotic drug in vivo.
FAU - Umetsu, T
AU  - Umetsu T
FAU - Sanai, K
AU  - Sanai K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Imidazoles)
RN  - 0 (Pyridines)
RN  - 51941-16-3 (1-methyl-2-mercapto-5-(3-pyridyl)imidazole)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Imidazoles/*therapeutic use
MH  - Male
MH  - Pyridines/*therapeutic use
MH  - Rats
MH  - Thrombosis/*drug therapy
EDAT- 1978/02/28 00:00
MHDA- 1978/02/28 00:01
CRDT- 1978/02/28 00:00
PHST- 1978/02/28 00:00 [pubmed]
PHST- 1978/02/28 00:01 [medline]
PHST- 1978/02/28 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1978 Feb 28;39(1):74-83.

PMID- 1524161
OWN - NLM
STAT- MEDLINE
DCOM- 19921015
LR  - 20131121
IS  - 0003-2417 (Print)
IS  - 0003-2417 (Linking)
VI  - 41
IP  - 8
DP  - 1992 Aug
TI  - [Long-term medication with acetylsalicylic acid--a problem in regional 
      anesthesia?].
PG  - 489-93
AB  - In patients medicated with acetylsalicylic acid (ASA) and undergoing regional 
      anaesthesia there is a risk of traumatically induced haematoma, particularly near 
      the spinal cord. The increased bleeding tendency following aspirin administration 
      is due to a change in thrombocyte aggregation caused by irreversible inhibition 
      of prostaglandin synthesis. In order to assess the bleeding risk, it was 
      investigated whether and how much subaqueous bleeding time (SBT) and aggregation 
      inhibition (AGI) change under low-dose medication, and when these values return 
      to normal after the end of administration. RESULTS. 1. SBT increased 
      significantly with daily ASA medication of 100 mg or of 300 mg. However, only 
      4.5% of the values measured were within a pathologic range. After discontinuation 
      of the medication SBT significantly dropped on the 2nd day, reaching the initial 
      level on the 4th day at the latest. 2. AGI was significantly reduced, to 20% of 
      the normal value. Depending on the dosage, the 100-mg group reached full 
      aggregation capacity on the 4th day and the 300-mg group on the 7th day following 
      discontinuation of medication. 3. AGI returned to normal 2-3 days later than SBT. 
      CONCLUSIONS. 1. In the case of pathologically increased values (greater than 6 
      min), the determination of SBT may indicate an increased bleeding risk. 2. If SBT 
      is within the normal range during or shortly after ASA administration, 
      thrombocytic function is still disturbed. Whether there is a correlation between 
      inhibition of thrombocyte aggregation and the occurrence of spinal haematomas is 
      not yet known. 3. In view of these results, the effect of ASA should be 
      investigated by determining SBT prior to scheduled regional anaesthetic 
      procedures near the spinal cord. 4. If SBT is increased (greater than 6 min) and 
      regional anaesthesia near the spinal cord is indicated, the procedure involving 
      the slightest trauma (spinal anaesthesia) should be chosen [31]. Careful 
      postoperative follow-up (1-2 days) should be guaranteed with regard to 
      neurological disorders.
FAU - Sauer, W
AU  - Sauer W
AD  - Institut für Anästhesiologie, Klinikum Minden.
FAU - Schwagmeier, R
AU  - Schwagmeier R
FAU - Nolte, H
AU  - Nolte H
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Dauermedikation mit Acetylsalicylsäure. Ein problem für die Regionalanästhesie?
PL  - Germany
TA  - Anaesthesist
JT  - Der Anaesthesist
JID - 0370525
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Anesthesia, Conduction
MH  - Aspirin/*administration & dosage/adverse effects
MH  - *Bleeding Time
MH  - Depression, Chemical
MH  - Hematoma/epidemiology/*etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Prospective Studies
MH  - Risk
MH  - Spinal Cord Diseases/epidemiology/*etiology
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
PST - ppublish
SO  - Anaesthesist. 1992 Aug;41(8):489-93.

PMID- 10362422
OWN - NLM
STAT- MEDLINE
DCOM- 19990623
LR  - 20190706
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 27
IP  - 5
DP  - 1999 May
TI  - Subarachnoid hemorrhage in rats: effect of singular or sustained hemodilution 
      with alpha-alpha diaspirin crosslinked hemoglobin on cerebral hypoperfusion.
PG  - 972-7
AB  - OBJECTIVE: To evaluate the effect of singular or sustained hemodilution, with 
      alpha-alpha diaspirin crosslinked hemoglobin (DCLHb), on the area of 
      hypoperfusion after subarachnoid hemorrhage. DESIGN: Prospective animal study. 
      SETTING: Animal research laboratory. SUBJECTS: Isoflurane anesthetized, 
      mechanically ventilated rats. INTERVENTIONS: Subarachnoid hemorrhage was induced 
      by injecting 0.3 mL of blood into the cisterna magna. The animals were randomly 
      assigned to one of the following groups (n = 16 in each hemodilution group; eight 
      animals received a single treatment of hemodilution after subarachnoid 
      hemorrhage; and, for eight animals, treatment was sustained for 48 hrs): control 
      group (n = 8), no hematocrit (45%) manipulation; DCLHb group (n = 16), hematocrit 
      decreased to 30% with DCLHb; or Alb group (n = 16), hematocrit decreased to 30% 
      with human serum albumin. After 48 hrs, the area of hypoperfusion (cerebral blood 
      flow < 40 ml/100g/min) was determined with 14C-iodoantipyrine in five coronal 
      brain sections. MEASUREMENTS AND MAIN RESULTS: For both singular and sustained 
      treatment, the area of hypoperfusion was less in both hemodilution groups than in 
      the control group (p<.05). For four of the five coronal brain sections, no 
      differences were found between the DCLHb and Alb groups within a given 
      hemodilution protocol. In addition, in four of the five coronal brain sections 
      for the DCLHb hemodilution groups and in all five sections for the albumin 
      hemodilution groups, the area of hypoperfusion was less for rats that received 
      sustained hemodilution compared with their respective groups in the singular 
      treatment protocol (p<.05). CONCLUSIONS: These data support the hypothesis that 
      hemodilution with molecular hemoglobin decreases hypoperfusion after subarachnoid 
      hemorrhage and that sustained hemodilution is more effective than singular 
      treatment. The data do not support the notion that intravascular DCLHb has an 
      adverse effect on cerebral ischemia after subarachnoid hemorrhage.
FAU - Cole, D J
AU  - Cole DJ
AD  - Department of Anesthesiology and Critical Care Medicine, Loma Linda University, 
      CA 92350-0002, USA.
FAU - Reynolds, L W
AU  - Reynolds LW
FAU - Nary, J C
AU  - Nary JC
FAU - Drummond, J C
AU  - Drummond JC
FAU - Patel, P M
AU  - Patel PM
FAU - Jacobsen, W K
AU  - Jacobsen WK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Hemoglobins)
RN  - 0 (Serum Albumin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/therapeutic use
MH  - Blood Flow Velocity/drug effects
MH  - Cerebrovascular Circulation/*drug effects
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Hematocrit
MH  - Hemodilution/*methods
MH  - Hemoglobins/chemistry/*therapeutic use
MH  - Male
MH  - Prospective Studies
MH  - Random Allocation
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Serum Albumin/therapeutic use
MH  - Subarachnoid Hemorrhage/blood/*physiopathology/*therapy
MH  - Time Factors
EDAT- 1999/06/11 00:00
MHDA- 1999/06/11 00:01
CRDT- 1999/06/11 00:00
PHST- 1999/06/11 00:00 [pubmed]
PHST- 1999/06/11 00:01 [medline]
PHST- 1999/06/11 00:00 [entrez]
AID - 10.1097/00003246-199905000-00038 [doi]
PST - ppublish
SO  - Crit Care Med. 1999 May;27(5):972-7. doi: 10.1097/00003246-199905000-00038.

PMID- 21061537
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - [Prophylaxis and treatment of gastric ulcer by low-dose aspirin in the aged].
PG  - 2083-8
AB  - Low-dose aspirin, one of non-steroidal anti-inflammatory drugs(NSAIDs), has been 
      increasingly used to prevent cardiovascular and cerebrovascular disease through 
      its antiplatelet effect, mainly in the aged population, but aspirin treatment has 
      been associated with gastrointestinal injures, especially peptic ulcer bleedings. 
      However, as discontinuation of aspirin, unlike NSAIDs, may precipitate 
      cardiovascular and cerebrovascular events, treatment of aspirin-associated ulcers 
      should re-start aspirin as soon as possible, using proton pump inhibitor (PPI). 
      Therefore, high risk patients for peptic ulcers should be prevented with 
      antisecretory drugs, such as PPI or histamine H2-receptor antagonists, because 
      ulcer bleedings in patients with treatment of low-dose aspirin can be serious.
FAU - Ueki, Nobue
AU  - Ueki N
AD  - Department of Internal Medicine, Division of Gastroenterology, Nippon Medical 
      School.
FAU - Miyake, Kazumasa
AU  - Miyake K
FAU - Sakamoto, Choitsu
AU  - Sakamoto C
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Humans
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Stomach Ulcer/*drug therapy/prevention & control
EDAT- 2010/11/11 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Nov;68(11):2083-8.

PMID- 12227131
OWN - NLM
STAT- MEDLINE
DCOM- 20030319
LR  - 20191106
IS  - 0889-8529 (Print)
IS  - 0889-8529 (Linking)
VI  - 31
IP  - 3
DP  - 2002 Sep
TI  - Aspirin in diabetic retinopathy. A systematic review.
PG  - 779-93
AB  - Diabetes mellitus is a risk factor for eye disease that can lead to blindness. 
      There have been both concerns that aspirin use might worsen diabetic retinopathy, 
      as well as hopes that aspirin might be beneficial in treating it. We investigated 
      whether there are beneficial effects of aspirin alone and in combination with 
      other antiplatelet agents in the treatment of diabetic retinopathy, and the 
      relative hazards for the development of high-risk proliferative retinopathy 
      following aspirin treatment. We conducted a sensitive search for randomized 
      controlled trials combined with index terms for identifying studies on aspirin 
      treatment in diabetic retinopathy in the Cochrane Library (issue 4, 2001) and 
      Medline (1966 to October, 2001). We examined randomized controlled clinical 
      trials in diabetic patients with (non) proliferative diabetic retinopathy and 
      aspirin treatment alone or in combination with dipyramidole versus placebo 
      administration. Two independent reviewers judged trial eligibility, collected 
      details of study population, interventions, and outcomes using a standard data 
      extraction form. One reviewer assessed the quality of trial reporting. We 
      identified six publications pertinent to our objective. Aspirin dosages ranged 
      from 650 mg to 990 mg daily, the dose of dipyridamole, used in only one trial, 
      was 225 mg per day. Studies lasted 8 weeks to 5 years. All trials showed that 
      aspirin alone or in combination with dipyridamole neither lowered nor increased 
      the risk of the development of diabetic retinopathy. The results suggest that 
      there are no ocular contraindications to taking aspirin if required as part of a 
      treatment for cardiovascular diseases or other medical indications.
FAU - Bergerhoff, Karla
AU  - Bergerhoff K
AD  - Cochrane Metabolic and Endocrine Disorders Group, Department of Metabolic 
      Diseases and Nutrition, Medizinische Einrichtungen, Heinrich-Heine University, 
      Moorenstrasse 5, D-40225 Düsseldorf, Germany. bergerhf@uni-duesseldorf.de
FAU - Clar, Christine
AU  - Clar C
FAU - Richter, Bernd
AU  - Richter B
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Endocrinol Metab Clin North Am
JT  - Endocrinology and metabolism clinics of North America
JID - 8800104
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Diabetic Retinopathy/*drug therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
RF  - 24
EDAT- 2002/09/14 10:00
MHDA- 2003/03/20 04:00
CRDT- 2002/09/14 10:00
PHST- 2002/09/14 10:00 [pubmed]
PHST- 2003/03/20 04:00 [medline]
PHST- 2002/09/14 10:00 [entrez]
AID - S0889-8529(02)00017-8 [pii]
AID - 10.1016/s0889-8529(02)00017-8 [doi]
PST - ppublish
SO  - Endocrinol Metab Clin North Am. 2002 Sep;31(3):779-93. doi: 
      10.1016/s0889-8529(02)00017-8.

PMID- 33345910
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20211204
IS  - 2589-9333 (Electronic)
IS  - 2589-9333 (Linking)
VI  - 2
IP  - 4
DP  - 2020 Nov
TI  - Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race.
PG  - 100184
LID - S2589-9333(20)30128-2 [pii]
LID - 10.1016/j.ajogmf.2020.100184 [doi]
AB  - BACKGROUND: Low-dose aspirin is recommended for the prevention of preeclampsia 
      among women at a high risk of developing the disease. Aspirin undergoes 
      polymorphic metabolism, and it is well known that common genetic polymorphisms 
      are related to aspirin intolerance. We hypothesized that the efficacy of aspirin 
      prophylaxis may differ by ethnicity and race. OBJECTIVE: This study aimed to 
      compare the rates of preeclampsia among low- and high-risk women who received 
      aspirin compared with placebo, stratifying results by ethnicity and race as a 
      first-pass approximation of genomic polymorphisms. STUDY DESIGN: This is a 
      secondary analysis of 2 randomized controlled trials previously performed by the 
      Maternal-Fetal Medicine Units Network: the Low-Risk Aspirin trial and the 
      High-Risk Aspirin trial. For the Low-Risk Aspirin trial, normotensive, 
      nulliparous women were enrolled between 13 and 26 weeks' gestation and randomized 
      to 60 mg aspirin daily or placebo. For the High-Risk Aspirin trial, women with 
      pregestational insulin-treated diabetes mellitus, chronic hypertension, multiple 
      gestations, or a history of preeclampsia in a previous pregnancy were enrolled 
      between 13 and 26 weeks' gestation and randomized to 60 mg aspirin daily or 
      placebo. The primary outcome of our secondary analysis was preeclampsia. 
      Secondary outcomes included gestational age at delivery, preterm delivery, 
      placental abruption, small for gestational age, stillbirth, and neonatal death. 
      Outcomes were stratified by ethnicity and race (Hispanic, non-Hispanic white, 
      non-Hispanic black, or other). RESULTS: In the Low-Risk Aspirin trial of 3135 
      women, the risk of preeclampsia was significantly reduced among non-Hispanic 
      white women who received aspirin compared with non-Hispanic white women who 
      received placebo (relative risk, 0.19; 95% confidence interval, 0.06-0.63; 
      P=.007). The risk of preeclampsia was not different when comparing the aspirin 
      and placebo groups among the Hispanic, non-Hispanic black, or other ethnicity and 
      race groups. The efficacy among non-Hispanic white women persisted after 
      consideration of compliance and gestational age at randomization (relative risk, 
      0.07; 95% confidence interval, 0.009-0.51; P=.009). As noted in the original 
      trial, there was an increased risk of placental abruption in the aspirin group 
      overall compared with placebo (P=.025). The risk of stillbirth was significantly 
      increased among non-Hispanic black women who received aspirin compared with 
      non-Hispanic black women who received placebo (P=.048). In the High-Risk Aspirin 
      trial of 2539 women, 269 were Hispanic (10.6%), 832 were non-Hispanic white 
      (32.8%), 1426 were non-Hispanic black (56.2%), and 12 were categorized as other 
      (0.5%). Stratification by ethnicity and race did not reveal a decreased incidence 
      of preeclampsia for any of the subgroups (P>.05). Moreover, there was no 
      significant difference in other measured outcomes including preterm delivery at 
      <37 weeks' gestation, placental abruption, small for gestational age, stillbirth, 
      or neonatal death. CONCLUSION: The incidence of preeclampsia was significantly 
      reduced among low-risk non-Hispanic white women who received aspirin compared 
      with placebo (P=.007), but not overall or among Hispanic or non-Hispanic black 
      women. The analysis of high-risk women did not indicate a difference in the 
      efficacy of aspirin by ethnicity and race.
CI  - Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Tolcher, Mary Catherine
AU  - Tolcher MC
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Baylor College of Medicine, Houston, TX.
FAU - Sangi-Haghpeykar, Haleh
AU  - Sangi-Haghpeykar H
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Baylor College of Medicine, Houston, TX.
FAU - Mendez-Figueroa, Hector
AU  - Mendez-Figueroa H
AD  - Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical 
      School, The University of Texas Health Science Center at Houston, Houston, TX.
FAU - Aagaard, Kjersti M
AU  - Aagaard KM
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Baylor College of Medicine, Houston, TX; Department of Molecular and Human 
      Genetics, Baylor College of Medicine, Houston, TX; Department of Molecular and 
      Cell Biology, Baylor College of Medicine, Houston, TX. Electronic address: 
      aagaardt@bcm.edu.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200721
PL  - United States
TA  - Am J Obstet Gynecol MFM
JT  - American journal of obstetrics & gynecology MFM
JID - 101746609
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Obstet Gynecol MFM. 2021 May;3(3):100314. PMID: 33476825
MH  - Aspirin/adverse effects
MH  - Ethnicity
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Placenta
MH  - *Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - *Premature Birth
OTO - NOTNLM
OT  - aspirin
OT  - ethnicity
OT  - health disparities
OT  - preeclampsia
OT  - prevention
OT  - race
EDAT- 2020/12/22 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/12/21 08:44
PHST- 2020/05/05 00:00 [received]
PHST- 2020/07/01 00:00 [revised]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/12/21 08:44 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - S2589-9333(20)30128-2 [pii]
AID - 10.1016/j.ajogmf.2020.100184 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol MFM. 2020 Nov;2(4):100184. doi: 10.1016/j.ajogmf.2020.100184. 
      Epub 2020 Jul 21.

PMID- 6359865
OWN - NLM
STAT- MEDLINE
DCOM- 19840126
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 75
IP  - 5A
DP  - 1983 Nov 14
TI  - Review of comparative antipyretic activity in children.
PG  - 38-46
AB  - Fever is one of the most common medical complaints referred to physicians for 
      diagnosis and therapy. In addition, consumers frequently medicate themselves for 
      fever associated with common, self-limited illnesses. The pathogenesis of fever 
      suggests that pharmacologic therapy, which lowers the hypothalamic set-point, is 
      an essential element in treatment. Not all fevers need to be treated; however, 
      when indicated, therapy with antipyretics is necessary. The major antipyretic 
      agents, acetaminophen, aspirin, and pyrazolone derivatives, are equally effective 
      in reducing fever. However, after comparing side effects and risks of toxicity, 
      acetaminophen may be the preferred agent in children.
FAU - Temple, A R
AU  - Temple AR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Body Temperature Regulation
MH  - Child
MH  - Drug Administration Schedule
MH  - Fever/*drug therapy/physiopathology
MH  - Humans
RF  - 72
EDAT- 1983/11/14 00:00
MHDA- 1983/11/14 00:01
CRDT- 1983/11/14 00:00
PHST- 1983/11/14 00:00 [pubmed]
PHST- 1983/11/14 00:01 [medline]
PHST- 1983/11/14 00:00 [entrez]
AID - 0002-9343(83)90231-0 [pii]
AID - 10.1016/0002-9343(83)90231-0 [doi]
PST - ppublish
SO  - Am J Med. 1983 Nov 14;75(5A):38-46. doi: 10.1016/0002-9343(83)90231-0.

PMID- 17238200
OWN - NLM
STAT- MEDLINE
DCOM- 20070928
LR  - 20161124
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 96
IP  - 8
DP  - 2007 Aug
TI  - Anisotropic surface chemistry of aspirin crystals.
PG  - 2134-44
AB  - The wettability of the (001), (100), and (011) crystallographic facets of 
      macroscopic aspirin crystals has been experimentally investigated using a sessile 
      drop contact angle (theta) method. theta for a nonpolar liquid was very similar 
      for all three facets, though significant theta differences were observed for 
      three polar probe liquids. The observed hydrophobicity of the (001) and (100) 
      facets is ascribed to a reduced hydrogen bonding potential at these surfaces, 
      whilst the observed hydrophilicity of facet (011) may be attributed to presence 
      of surface carboxylic functionalities as confirmed by X-ray photoelectron 
      spectroscopy (XPS). The dispersive component of the surface free energy 
      (gamma(s)(d)) was similar for all three facets (35 +/- 2 mJ/m2). The total 
      surface energy, gammas varied between 46 and 60 mJ/m2 due to significant 
      variations in the polar/acid-base components of gamma for all facets. Surface 
      polarity as determined by gamma measurements and XPS data were in good agreement, 
      linking the variations in wettability to the concentration of oxygen containing 
      surface functional groups. In conclusion, the wettability and the surface energy 
      of a crystalline organic solid, such as aspirin, was found to be anisotropic and 
      facet dependant, and in this case, related to the presence of surface carboxylic 
      functionalities.
CI  - (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.
FAU - Heng, Jerry Y Y
AU  - Heng JY
AD  - Department of Chemical Engineering, Imperial College London, South Kensington 
      Campus, London SW7 2AZ, United Kingdom.
FAU - Bismarck, Alexander
AU  - Bismarck A
FAU - Lee, Adam F
AU  - Lee AF
FAU - Wilson, Karen
AU  - Wilson K
FAU - Williams, Daryl R
AU  - Williams DR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Anisotropy
MH  - Aspirin/*chemistry
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Crystallization
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Oxygen/chemistry
MH  - Spectrometry, X-Ray Emission
MH  - Surface Properties
MH  - Water/chemistry
MH  - Wettability
EDAT- 2007/01/24 09:00
MHDA- 2007/09/29 09:00
CRDT- 2007/01/24 09:00
PHST- 2007/01/24 09:00 [pubmed]
PHST- 2007/09/29 09:00 [medline]
PHST- 2007/01/24 09:00 [entrez]
AID - S0022-3549(16)32326-7 [pii]
AID - 10.1002/jps.20841 [doi]
PST - ppublish
SO  - J Pharm Sci. 2007 Aug;96(8):2134-44. doi: 10.1002/jps.20841.

PMID- 3964776
OWN - NLM
STAT- MEDLINE
DCOM- 19850114
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 88
IP  - 1 Pt 2
DP  - 1985 Jan
TI  - Intracellular microelectrode studies of Necturus antral mucosa. Effect of aspirin 
      on cell membrane potentials.
PG  - 261-8
AB  - Intracellular microelectrode techniques were used to determine the effects of 
      luminal aspirin on epithelial cell membrane potentials of Necturus antral mucosa. 
      In this tissue, prolonged stable intracellular impalements were obtained with 
      15-50-M omega microelectrodes filled with 3 M KCl. In acidic mucosal solution (pH 
      4.0) the addition of aspirin at 5.0 mM resulted in a significant decrease of 
      apical cell membrane potential (Vmc) from -36.8 +/- 2.2 to -22.2 +/- 2.1 mV (p 
      less than 0.001) and basolateral cell membrane potentials (Vcs) from -38.8 +/- 
      1.7 to -25.3 +/- 2.1 mV (p less than 0.001). Upon removal of aspirin from the 
      mucosal solution, both cell membranes hyperpolarized for a brief period before 
      returning to their original potentials. In neutral mucosal solutions (pH 7.0), 
      addition of aspirin (5.0 mM) resulted in a significant increase in apical cell 
      membrane potential (Vmc) from -40.0 +/- 2.4 to -46.8 +/- 3.3 mV (p less than 
      0.001) and basolateral cell membrane potential (Vcs) from -41.5 +/- 2.0 to -49.7 
      +/- 2.5 mV (p less than 0.001). This hyperpolarization of the cell was associated 
      with an increase in transmucosal potential from -1.5 +/- 1.8 to -2.9 +/- 1.8 mV 
      (p less than 0.001) and an increase in the ratio of apical to basolateral 
      membrane resistances from 2.2 +/- 0.4 to 3.1 +/- 0.7 (p less than 0.05). These 
      changes in membrane potentials and the ratio of membrane resistances may be 
      caused by a change in ionic conductance of the cell membranes induced by aspirin.
FAU - Cheung, L Y
AU  - Cheung LY
FAU - De, L
AU  - De L
FAU - Ashley, S W
AU  - Ashley SW
LA  - eng
GR  - AM07178-01/AM/NIADDK NIH HHS/United States
GR  - AM25998-05/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Electric Conductivity
MH  - Gastric Mucosa/*drug effects
MH  - Hydrogen-Ion Concentration
MH  - Membrane Potentials/drug effects
MH  - Microelectrodes
MH  - Necturus
MH  - Pyloric Antrum
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - S0016508585000403 [pii]
AID - 10.1016/s0016-5085(85)80179-7 [doi]
PST - ppublish
SO  - Gastroenterology. 1985 Jan;88(1 Pt 2):261-8. doi: 10.1016/s0016-5085(85)80179-7.

PMID- 16771000
OWN - NLM
STAT- MEDLINE
DCOM- 20060721
LR  - 20191026
IS  - 1049-023X (Print)
IS  - 1049-023X (Linking)
VI  - 21
IP  - 2
DP  - 2006 Mar-Apr
TI  - Reasons prehospital personnel do not administer aspirin to all patients 
      complaining of chest pain.
PG  - 101-3
AB  - INTRODUCTION: Aspirin is administered to patients with acute coronary syndromes 
      (ACSs), but prehospital providers do not administer aspirin to all patients with 
      chest pain that could be secondary to an ACS. OBJECTIVE: To identify reasons 
      prehospital providers fail to administer aspirin to all patients complaining of 
      chest pain. METHODS: A convenience sample of prehospital providers was surveyed 
      as they transported patients with a chief complaint of chest pain to the 
      emergency department. The providers were asked if they had given aspirin, 
      nitroglycerin, or oxygen, or if they utilized a monitor. If the medications had 
      not been administered, the paramedic was asked about the reason. The patient's 
      age and previous cardiac history also was recorded. RESULTS: A total of 52 
      patients with chest pain who were transported were identified over eight weeks, 
      and all of the providers agreed to participate in the study. Only 13 of the 
      patients (25%) received aspirin. Reasons given for not administering aspirin to 
      the other 39 patients included: (1) chest pain was not felt to be cardiac in 13 
      patients (33%); (2) 10 patients already had taken aspirin that day (26%); (3) the 
      medical provider was a basic-level emergency medical technician (EMT)-Basic and 
      could not administer aspirin to six patients (15%); (4) pain subsided prior to 
      arrival of emergency medical services (EMS) in these three patients; and (5) 
      other reasons were provided for the remaining seven patients. CONCLUSIONS: The 
      most common reason that paramedics did not administer aspirin was the paramedic's 
      belief that the chest pain was not of a cardiac nature. Another common reason for 
      not giving aspirin was the inability of EMT-Basic providers to administer 
      aspirin.
FAU - Hooker, Edmond A
AU  - Hooker EA
AD  - Department of Health Services Administration, Xavier University, 3800 Victory 
      Parkway, Cincinnati, Ohio 45207-7331, USA. ehooker@fuse.net
FAU - Benoit, Taylor
AU  - Benoit T
FAU - Price, Timothy G
AU  - Price TG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prehosp Disaster Med
JT  - Prehospital and disaster medicine
JID - 8918173
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*therapeutic use
MH  - Chest Pain/diagnosis/*drug therapy
MH  - Decision Making
MH  - *Emergency Medical Technicians
MH  - Health Care Surveys
MH  - Humans
MH  - Kentucky
EDAT- 2006/06/15 09:00
MHDA- 2006/07/22 09:00
CRDT- 2006/06/15 09:00
PHST- 2006/06/15 09:00 [pubmed]
PHST- 2006/07/22 09:00 [medline]
PHST- 2006/06/15 09:00 [entrez]
AID - 10.1017/s1049023x00003435 [doi]
PST - ppublish
SO  - Prehosp Disaster Med. 2006 Mar-Apr;21(2):101-3. doi: 10.1017/s1049023x00003435.

PMID- 34989670
OWN - NLM
STAT- MEDLINE
DCOM- 20220110
LR  - 20220110
IS  - 1646-0758 (Electronic)
IS  - 0870-399X (Linking)
VI  - 34
IP  - 12
DP  - 2021 Dec 2
TI  - [Analysis of the Cochrane Review: Antiplatelet Agents for Preventing 
      Pre-Eclampsia and Its Complications. Cochrane Database Syst Rev. 
      2019;10:CD004659.].
PG  - 810-814
LID - 10.20344/amp.15995 [doi]
AB  - Pre-eclampsia is associated with deficient intravascular production of 
      prostacyclin, a vasodilator, and excessive production of thromboxane, a 
      vasoconstrictor and stimulant of platelet aggregation. These observations led to 
      the hypotheses that antiplatelet agents, low-dose aspirin in particular, might 
      prevent or delay development of pre-eclampsia. This Cochrane review aimed to 
      assess the effectiveness and safety of antiplatelet agents, such as aspirin and 
      dipyridamole, when given to women at risk of developing preeclampsia. A 
      systematic review of literature was carried out by searching the following 
      databases up to September 2019: Cochrane Pregnancy and Childbirth's Trials 
      Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry 
      Platform (ICTRP), and reference lists of retrieved studies. Seventy-seven trials 
      were included, including 40 249 women at risk of developing pre-eclampsia. About 
      80% of these women were evaluated in nine of the 77 trials included, with eight 
      of these nine trials providing individual data. Interventions were administration 
      of an antiplatelet agent, and comparisons were either placebo or no antiplatelet. 
      The present review provides high-quality evidence that administering low-dose 
      aspirin (50 - 150 mg) to pregnant women led to small-to-moderate benefits, 
      including reductions in the risk of pre-eclampsia, preterm birth, 
      small-for-gestational age fetus, and fetal or neonatal death. Overall, 
      administering antiplatelet agents to 1000 women led to 20 fewer pregnancies with 
      serious adverse outcomes.
FAU - Reis de Carvalho, Catarina
AU  - Reis de Carvalho C
AD  - Departamento de Obstetrícia, Ginecologia e Medicina da Reprodução. Faculdade de 
      Medicina. Universidade de Lisboa. Lisboa. Portugal.
FAU - Bigotte Vieira, Miguel
AU  - Bigotte Vieira M
AD  - Serviço de Nefrologia e Transplantação Renal. Centro Hospitalar Lisboa Norte. 
      Lisboa. Portugal.
FAU - Costa, João
AU  - Costa J
AD  - Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. 
      Universidade de Lisboa. Lisboa. Cochrane Portugal. Lisboa. Portugal.
FAU - Vaz Carneiro, António
AU  - Vaz Carneiro A
AD  - Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. 
      Universidade de Lisboa. Lisboa. Cochrane Portugal. Lisboa. Portugal.
LA  - por
PT  - Comment
PT  - Journal Article
TT  - Análise da Revisão Cochrane: O Papel dos Antiagregantes Plaquetários para 
      Prevenir a Pré-Eclâmpsia e as Suas Complicações. Cochrane Database Syst Rev. 
      2019;10:CD004659.
DEP - 20211202
PL  - Portugal
TA  - Acta Med Port
JT  - Acta medica portuguesa
JID - 7906803
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Cochrane Database Syst Rev. 2019 Oct 30;2019(10):. PMID: 31684684
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - *Premature Birth
OTO - NOTNLM
OT  - Platelet Aggregation Inhibitors/therapeutic use
OT  - Pre-Eclampsia/drug therapy
OT  - Pre-Eclampsia/prevention & control
OT  - Prenatal Care
OT  - Randomized Controlled Trials as Topic
EDAT- 2022/01/07 06:00
MHDA- 2022/01/11 06:00
CRDT- 2022/01/06 12:17
PHST- 2021/02/17 00:00 [received]
PHST- 2021/09/21 00:00 [accepted]
PHST- 2022/01/06 12:17 [entrez]
PHST- 2022/01/07 06:00 [pubmed]
PHST- 2022/01/11 06:00 [medline]
AID - 10.20344/amp.15995 [doi]
PST - ppublish
SO  - Acta Med Port. 2021 Dec 2;34(12):810-814. doi: 10.20344/amp.15995. Epub 2021 Dec 
      2.

PMID- 18302761
OWN - NLM
STAT- MEDLINE
DCOM- 20080328
LR  - 20211020
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 6
DP  - 2008 Feb 26
TI  - NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human 
      ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
PG  - 9
LID - 10.1186/1479-5876-6-9 [doi]
AB  - BACKGROUND: Ovarian carcinoma is the leading cause of mortality among 
      gynecological cancers in the world. The high mortality rate is associated with 
      lack of early diagnosis and development of drug resistance. The antitumor 
      efficacy and mechanism of NCX-4040, a nitric oxide-releasing aspirin derivative, 
      against ovarian cancer is studied. METHODS: NCX-4040, alone or in combination 
      with cisplatin (cis-diamminedichloroplatinum, cDDP), was studied in 
      cisplatin-sensitive (A2780 WT) and cisplatin-resistant (A2780 cDDP) cell lines as 
      well as xenograft tumors grown in nude mice. Electron paramagnetic resonance 
      (EPR) was used for measurements of nitric oxide and redox state. Immunoblotting 
      analysis of A2780 cDDP tumor xenografts from mice was used for mechanistic 
      studies. RESULTS: Cells treated with NCX-4040 (25 microM) showed a significant 
      reduction of cell viability (A2780 WT, 34.9 +/- 8.7%; A2780 cDDP, 41.7 +/- 7.6%; 
      p < 0.05). Further, NCX-4040 significantly enhanced the sensitivity of A2780 cDDP 
      cells (cisplatin alone, 80.6 +/- 11.8% versus NCX-4040+cisplatin, 26.4 +/- 7.6%; 
      p < 0.01) and xenograft tumors (cisplatin alone, 74.0 +/- 4.4% versus 
      NCX-4040+cisplatin, 56.4 +/- 7.8%; p < 0.05), to cisplatin treatment. EPR imaging 
      of tissue redox and thiol measurements showed a 5.5-fold reduction (p < 0.01) of 
      glutathione in NCX-4040-treated A2780 cDDP tumors when compared to untreated 
      controls. Immunoblotting analysis of A2780 cDDP tumor xenografts from mice 
      treated with NCX-4040 and cisplatin revealed significant downregulation of pEGFR 
      (Tyr845 and Tyr992) and pSTAT3 (Tyr705 and Ser727) expression. CONCLUSION: The 
      results suggested that NCX-4040 could resensitize drug-resistant ovarian cancer 
      cells to cisplatin possibly by depletion of cellular thiols. Thus NCX-4040 
      appears to be a potential therapeutic agent for the treatment of human ovarian 
      carcinoma and cisplatin-resistant malignancies.
FAU - Bratasz, Anna
AU  - Bratasz A
AD  - Center for Biomedical EPR Spectroscopy and Imaging, Davis Heart and Lung Research 
      Institute, Department of Internal Medicine, The Ohio State University, Columbus, 
      OH 43210, USA. kuppusamy.1@osu.edu
FAU - Selvendiran, Karuppaiyah
AU  - Selvendiran K
FAU - Wasowicz, Tomasz
AU  - Wasowicz T
FAU - Bobko, Andrey
AU  - Bobko A
FAU - Khramtsov, Valery V
AU  - Khramtsov VV
FAU - Ignarro, Louis J
AU  - Ignarro LJ
FAU - Kuppusamy, Periannan
AU  - Kuppusamy P
LA  - eng
GR  - K01 EB003519/EB/NIBIB NIH HHS/United States
GR  - R01 CA102264/CA/NCI NIH HHS/United States
GR  - K01 EB03519/EB/NIBIB NIH HHS/United States
GR  - CA102264/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20080226
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - 0 (Antineoplastic Agents)
RN  - 0 (NCX 4040)
RN  - 0 (Nitro Compounds)
RN  - 0 (Sulfhydryl Compounds)
RN  - EH04H13L6B (nitroaspirin)
RN  - Q20Q21Q62J (Cisplatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Cisplatin/*pharmacology/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance, Neoplasm/drug effects/physiology
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Molecular Structure
MH  - Nitro Compounds/chemistry/*pharmacology/therapeutic use
MH  - Ovarian Neoplasms/drug therapy/genetics/*metabolism/pathology
MH  - Sensitivity and Specificity
MH  - Statistics as Topic
MH  - Sulfhydryl Compounds/analysis/*metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC2267444
EDAT- 2008/02/28 09:00
MHDA- 2008/03/29 09:00
CRDT- 2008/02/28 09:00
PHST- 2007/11/17 00:00 [received]
PHST- 2008/02/26 00:00 [accepted]
PHST- 2008/02/28 09:00 [pubmed]
PHST- 2008/03/29 09:00 [medline]
PHST- 2008/02/28 09:00 [entrez]
AID - 1479-5876-6-9 [pii]
AID - 10.1186/1479-5876-6-9 [doi]
PST - epublish
SO  - J Transl Med. 2008 Feb 26;6:9. doi: 10.1186/1479-5876-6-9.

PMID- 31915847
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 76
IP  - 4
DP  - 2020 Apr
TI  - Intake of aspirin prior to metamizole does not completely prevent high on 
      treatment platelet reactivity.
PG  - 483-490
LID - 10.1007/s00228-019-02791-1 [doi]
AB  - PURPOSE: Metamizole can sterically inhibit aspirin (ASA) from binding to 
      cyclooxygenase 1 (COX1). It is recommended that ASA should be taken 30 min prior 
      to metamizole to maintain the irreversible inhibition of arachidonic acid 
      (AA)-induced platelet aggregation. We aimed to analyse the inhibitory effect of 
      ASA and metamizole on AA-induced platelet aggregation over the course of the day. 
      METHODS: We analysed hospitalized patients who ingested ASA at least 30 min prior 
      to metamizole (recommended dosing group, n = 15), metamizole prior or 
      simultaneously with ASA (not recommended dosing group, n = 16) and patients with 
      unknown or mixed intake (mixed dosing group, n = 5). AA-induced light 
      transmission (LTA) and impedance aggregometry (IA) were measured before, 1-2 and 
      5-6 h after the intake of ASA ± metamizole. RESULTS: Maximum AA-induced LTA prior 
      to the intake of ASA was significantly lower and the rate of high on treatment 
      platelet reactivity (HTPR) higher in the recommended compared with the not 
      recommended dosing group (19.6% vs. 46.9%, p = 0.011 and 4/15 vs. 12/16 patients, 
      p = 0.017). There was no difference when IA was used. Maximum AA-induced LTA 
      after the intake of ASA ± metamizole was lower in patients in the not recommended 
      but not in the recommended dosing group. All patients with HTPR in the 
      recommended dosing group had regular inhibition of AA-induced LTA after 
      discontinuation of metamizole. CONCLUSION: Co-medication of ASA and metamizole 
      significantly influences platelet inhibition with variations during the day and 
      can cause HTPR in patients taking ASA prior to metamizole or simultaneously.
FAU - Pfrepper, Christian
AU  - Pfrepper C
AUID- ORCID: 0000-0002-0485-7402
AD  - Division of Haemostaseology, Medical Department I, University Hospital Leipzig, 
      Leipzig, Germany. Christian.pfrepper@medizin.uni-leipzig.de.
FAU - Dietze, Carolin
AU  - Dietze C
AD  - Hospital Pharmacy, University Hospital Leipzig, Leipzig, Germany.
FAU - Remane, Yvonne
AU  - Remane Y
AD  - Hospital Pharmacy, University Hospital Leipzig, Leipzig, Germany.
FAU - Bertsche, Thilo
AU  - Bertsche T
AD  - Drug Safety Center and Department of Clinical Pharmacy, Leipzig University, 
      Leipzig, Germany.
FAU - Schiek, Susanne
AU  - Schiek S
AD  - Drug Safety Center and Department of Clinical Pharmacy, Leipzig University, 
      Leipzig, Germany.
FAU - Kaiser, Thorsten
AU  - Kaiser T
AD  - Institute of Laboratory Medicine, University Hospital Leipzig, Leipzig, Germany.
FAU - Gockel, Ines
AU  - Gockel I
AD  - Department of Visceral, Transplantation, Thoracic and Vascular Surgery, 
      University Hospital Leipzig, Leipzig, Germany.
FAU - Josten, Christoph
AU  - Josten C
AD  - Department of Orthopaedics, Trauma and Plastic Surgery, University Hospital 
      Leipzig, Leipzig, Germany.
FAU - Petros, Sirak
AU  - Petros S
AD  - Division of Haemostaseology, Medical Department I, University Hospital Leipzig, 
      Leipzig, Germany.
AD  - Medical ICU, University Hospital Leipzig, Leipzig, Germany.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20200108
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/blood/therapeutic use
MH  - Cardiovascular Diseases/*blood/drug therapy
MH  - Dipyrone/*administration & dosage/blood/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Dipyrone
OT  - Drug interactions
OT  - Metamizole
OT  - Platelet aggregation
OT  - Surgery
EDAT- 2020/01/10 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/01/10 06:00
PHST- 2019/07/19 00:00 [received]
PHST- 2019/10/30 00:00 [accepted]
PHST- 2020/01/10 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/01/10 06:00 [entrez]
AID - 10.1007/s00228-019-02791-1 [pii]
AID - 10.1007/s00228-019-02791-1 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2020 Apr;76(4):483-490. doi: 10.1007/s00228-019-02791-1. 
      Epub 2020 Jan 8.

PMID- 8942923
OWN - NLM
STAT- MEDLINE
DCOM- 19970103
LR  - 20190713
IS  - 0032-1052 (Print)
IS  - 0032-1052 (Linking)
VI  - 98
IP  - 7
DP  - 1996 Dec
TI  - Alcohol and preoperative management.
PG  - 1306-9
AB  - The French paradox is a recently coined term used to describe the lower incidence 
      of heart disease in the French as compared with Americans in the face of 
      increased cholesterol intake, higher serum cholesterol levels, and elevated blood 
      pressures. The principal lifestyle factor explaining this paradox is alcohol 
      intake. Research has shown that alcohol in general and wine in particular have 
      myriad effects on the cardiovascular system--raising high-density lipoprotein 
      levels, increasing antioxidant capabilities, and prolonging platelet aggregation. 
      The most impressive benefits of alcohol appear to be platelet-related. Research 
      has demonstrated an undeniable effect of alcohol on platelet function and 
      bleeding characteristics. This information has been used recently to modify risk 
      factors for heart disease; however, these data have a role in the preoperative 
      management of surgical patients. In order to decrease the incidence and severity 
      of intraoperative and postoperative bleeding, patients should be advised to 
      abstain from alcohol and particularly red wine before surgery. In addition, 
      alcohol has been found to have a synergistic effect with aspirin on bleeding 
      times. These two substances, both individually and in combination, should be 
      avoided preoperatively.
FAU - Wolfort, F G
AU  - Wolfort FG
AD  - Department of Plastic and Reconstructive Surgery, Harvard Medical School, Boston, 
      Mass., USA.
FAU - Pan, D
AU  - Pan D
FAU - Gee, J
AU  - Gee J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Plast Reconstr Surg
JT  - Plastic and reconstructive surgery
JID - 1306050
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Drug Synergism
MH  - Humans
MH  - *Preoperative Care
MH  - Wine
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - 10.1097/00006534-199612000-00033 [doi]
PST - ppublish
SO  - Plast Reconstr Surg. 1996 Dec;98(7):1306-9. doi: 
      10.1097/00006534-199612000-00033.

PMID- 9437744
OWN - NLM
STAT- MEDLINE
DCOM- 19980218
LR  - 20190818
IS  - 0196-9781 (Print)
IS  - 0196-9781 (Linking)
VI  - 19
IP  - 1
DP  - 1998
TI  - Structural requirements and mechanism of the pressor activity of 
      Leu-Val-Val-hemorphin-7, a fragment of hemoglobin beta-chain in rats.
PG  - 119-31
AB  - A rat blood pressure assay was used to perform a structure-activity relationship 
      study (SAR) of Leu-Val-Val-hemorphin-7 (LVV-H7), a fragment of hemoglobin (Hb) 
      beta-chain, elucidate the mechanisms of its cardiovascular effects, and test its 
      potential involvement in the pressor activity of diaspirin crosslinked Hb 
      (DCLHb), a recently developed Hb-based oxygen carrier. The SAR study revealed 
      that the C-terminal-Arg-Phe-amino acid sequence of LVV-H7 contained the main 
      determinants of the pressor activity of this peptide. Drug interaction studies 
      using various inhibitory drugs (e.g., phentolamine, clonidine, etc.) and LVV-H7 
      showed that the pressor effect and tachycardia elicited by LVV-H7 involved the 
      activation of the sympathetic nervous system (SNS). Additional studies using 
      phenytoin (sodium channel blocker), [Tic7]H7(5-7)-NH2 (putative antagonist of 
      receptors for LVV-H7) and H7(5-7)-NH2, an amidated C-terminal fragment of LVV-H7, 
      suggested that LVV-H7 activated the SNS by interacting with specific receptors 
      functionally coupled with phenytoin-sensitive sodium channels. The pressor effect 
      and tachycardia caused by LVV-H7 were potentiated by captopril, suggesting that 
      the angiotensin converting enzyme may contribute to the inactivation of LVV-H7 in 
      rats. The pressor activity of DCLHb, in contrast to that elicited by LVV-H7, was 
      not affected by animal pretreatment with LVV-H7 fragments shown to inhibit the 
      pressor effect of LVV-H7. We conclude that: 1) LVV-H7 is unlikely to mediate the 
      pressor activity of DCLHb in rats; 2) the pressor and tachycardic activities of 
      LVV-H7 are mediated by the SNS; 3) the C-terminal-Arg-Phe-amino acid sequence of 
      LVV-H7 contains the chemical groups responsible for the pressor effect of this 
      peptide in rats; 4) LVV-H7 and FMRF amide-related peptides may share the same 
      mechanism of pressor activity in rats.
FAU - Moisan, S
AU  - Moisan S
AD  - Research Center (Laval University), Hôtel-Dieu de Québec, Canada.
FAU - Harvey, N
AU  - Harvey N
FAU - Beaudry, G
AU  - Beaudry G
FAU - Forzani, P
AU  - Forzani P
FAU - Burhop, K E
AU  - Burhop KE
FAU - Drapeau, G
AU  - Drapeau G
FAU - Rioux, F
AU  - Rioux F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Peptides
JT  - Peptides
JID - 8008690
RN  - 0 (Hemoglobins)
RN  - 0 (Peptide Fragments)
RN  - 75808-66-1 (LVV-hemorphin-7)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Blood Pressure/*drug effects
MH  - Heart Rate/drug effects
MH  - Hemoglobins/*chemistry/*pharmacology
MH  - Male
MH  - Peptide Fragments/*chemistry/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Structure-Activity Relationship
MH  - Sympathetic Nervous System/*drug effects/physiopathology
MH  - Vagotomy
EDAT- 1998/01/23 00:00
MHDA- 1998/01/23 00:01
CRDT- 1998/01/23 00:00
PHST- 1998/01/23 00:00 [pubmed]
PHST- 1998/01/23 00:01 [medline]
PHST- 1998/01/23 00:00 [entrez]
AID - S0196-9781(97)00273-8 [pii]
AID - 10.1016/s0196-9781(97)00273-8 [doi]
PST - ppublish
SO  - Peptides. 1998;19(1):119-31. doi: 10.1016/s0196-9781(97)00273-8.

PMID- 8272018
OWN - NLM
STAT- MEDLINE
DCOM- 19940131
LR  - 20131121
IS  - 0723-5003 (Print)
IS  - 0723-5003 (Linking)
VI  - 88
IP  - 10
DP  - 1993 Oct 15
TI  - [Dose-dependent side effects of acetylsalicylic acid therapy. Results of a 
      prospective randomized clinical study in patients with peripheral arterial 
      occlusive disease].
PG  - 571-6
AB  - BACKGROUND AND METHODS: In 359 patients with peripheral arterial occlusive 
      disease who had undergone percutaneous transluminal angioplasty (PTA), a 
      randomized double-blind, controlled clinical study was done to investigate the 
      tolerability of acetyl salicylic acid (ASA) given for reocclusion prophylaxis. A 
      comparison was made between a conventional daily dose of 900 mg ASA and a dose of 
      50 mg ASA. RESULTS: Within an observation period of one year following PTA, 35 
      patients (20%) in the 900 mg group, and 32 patients (17%) in the 50 mg group left 
      the trial because of side effects (p = NS). Under the higher dose, however, 
      severe gastrointestinal side effects (ulcer, haemorrhagic gastritis requiring 
      transfusion) were significantly more common (nine patients delta 5.1% vs two 
      patients delta 1.1%, respectively; p = 0.03). Overall, 107 patients (30%) 
      reported subjective side effects such as upper abdominal pain, a sensation of 
      fullness or nausea during the course of the trial. 62 of these patients were from 
      the 900 mg group (35%) as compared with 45 patients (24%) in the 50 mg group (p = 
      0.02). Self-scoring of epigastric pain on the basis of a visual analogue scale 
      revealed a score of 1.3 (95% confidence interval 0.9 to 1.6) in the 900 mg group 
      and 0.8 (95% confidence interval 0.6 to 1.0) in the 50 mg group. The subjective 
      pain intensity showed a uniform time course for all three types of symptom, with 
      a maximum after three months. CONCLUSION: Our results confirm the superior 
      tolerability of the lower dose, in particular in elderly patients. For long-term 
      treatment, the smallest possible effective dose should be chosen.
FAU - Ranke, C
AU  - Ranke C
AD  - Abteilung Angiologie, Medizinische Hochschule, Hannover.
FAU - Creutzig, A
AU  - Creutzig A
FAU - Luska, G
AU  - Luska G
FAU - Wagner, H H
AU  - Wagner HH
FAU - Galanski, M
AU  - Galanski M
FAU - Bode-Böger, S
AU  - Bode-Böger S
FAU - Frölich, J
AU  - Frölich J
FAU - Avenarius, H J
AU  - Avenarius HJ
FAU - Hecker, H
AU  - Hecker H
FAU - Alexander, K
AU  - Alexander K
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Dosisabhängige Nebenwirkungen der Acetylsalicylsäuretherapie. Ergebnisse einer 
      prospektiven, randomisierten klinischen Studie bei Patienten mit peripherer 
      arterieller Verschlusskrankheit.
PL  - Germany
TA  - Med Klin (Munich)
JT  - Medizinische Klinik (Munich, Germany : 1983)
JID - 8303501
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angioplasty, Balloon
MH  - Arterial Occlusive Diseases/*drug therapy
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Gastritis/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/chemically induced
MH  - Prospective Studies
EDAT- 1993/10/15 00:00
MHDA- 2000/03/22 09:00
CRDT- 1993/10/15 00:00
PHST- 1993/10/15 00:00 [pubmed]
PHST- 2000/03/22 09:00 [medline]
PHST- 1993/10/15 00:00 [entrez]
PST - ppublish
SO  - Med Klin (Munich). 1993 Oct 15;88(10):571-6.

PMID- 32886529
OWN - NLM
STAT- MEDLINE
DCOM- 20210915
LR  - 20210915
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 142
IP  - 16
DP  - 2020 Oct 20
TI  - Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary 
      Syndrome: Still Sacrosanct or Is Reappraisal Warranted?
PG  - 1579-1590
LID - 10.1161/CIRCULATIONAHA.120.045695 [doi]
AB  - Four decades have passed since the first trial suggesting the efficacy of aspirin 
      in the secondary prevention of myocardial infarction. Further trials, 
      collectively summarized by the Antithrombotic Trialists' Collaboration, 
      solidified the historical role of aspirin in secondary prevention. Although the 
      benefit of aspirin in the immediate phase after a myocardial infarction remains 
      incontrovertible, a number of emerging lines of evidence, discussed in this 
      narrative review, raise some uncertainty as to the primacy of aspirin for the 
      lifelong management of all patients with chronic coronary syndrome (CCS). For 
      example, data challenging the previously unquestioned role of aspirin in CCS have 
      come from recent trials where aspirin was discontinued in specific clinical 
      scenarios, including early discontinuation of the aspirin component of dual 
      antiplatelet therapy after percutaneous coronary intervention and the withholding 
      of aspirin among patients with both CCS and atrial fibrillation who require 
      anticoagulation. Recent primary prevention trials have also failed to 
      consistently demonstrate net benefit for aspirin in patients treated to optimal 
      contemporary cardiovascular risk factor targets, indicating that the efficacy of 
      aspirin for secondary prevention of CCS may similarly have changed with the 
      addition of more modern secondary prevention therapies. The totality of recent 
      evidence supports further study of the universal need for lifelong aspirin in 
      secondary prevention for all adults with CCS, particularly in stable older 
      patients who are at highest risk for aspirin-induced bleeding.
FAU - Jacobsen, Alan P
AU  - Jacobsen AP
AD  - Ciccarone Center for the Prevention of Cardiovascular Disease, Division of 
      Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, 
      Baltimore, MD(A.P.J., R.S.B., J.W.M.).
FAU - Raber, Inbar
AU  - Raber I
AD  - Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical 
      School, Boston, MA (I.R.).
FAU - McCarthy, Cian P
AU  - McCarthy CP
AD  - Division of Cardiology, Department of Medicine, Massachusetts General Hospital, 
      Boston(C.P.M.).
FAU - Blumenthal, Roger S
AU  - Blumenthal RS
AD  - Ciccarone Center for the Prevention of Cardiovascular Disease, Division of 
      Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, 
      Baltimore, MD(A.P.J., R.S.B., J.W.M.).
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 
      Boston, MA(D.L.B.).
FAU - Cusack, Ronan W
AU  - Cusack RW
AD  - School of Medicine, National University of Ireland Galway, Ireland(R.W.C., 
      P.W.J.C.S., W.W., J.W.M.).
FAU - Serruys, Patrick W J C
AU  - Serruys PWJC
AD  - School of Medicine, National University of Ireland Galway, Ireland(R.W.C., 
      P.W.J.C.S., W.W., J.W.M.).
FAU - Wijns, William
AU  - Wijns W
AD  - School of Medicine, National University of Ireland Galway, Ireland(R.W.C., 
      P.W.J.C.S., W.W., J.W.M.).
FAU - McEvoy, John W
AU  - McEvoy JW
AD  - School of Medicine, National University of Ireland Galway, Ireland(R.W.C., 
      P.W.J.C.S., W.W., J.W.M.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200904
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy
MH  - Aspirin/*therapeutic use
MH  - Chronic Disease
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Secondary Prevention
OTO - NOTNLM
OT  - aspirin
OT  - myocardial ischemia
OT  - secondary prevention
EDAT- 2020/09/05 06:00
MHDA- 2021/09/16 06:00
CRDT- 2020/09/04 17:09
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/09/16 06:00 [medline]
PHST- 2020/09/04 17:09 [entrez]
AID - 10.1161/CIRCULATIONAHA.120.045695 [doi]
PST - ppublish
SO  - Circulation. 2020 Oct 20;142(16):1579-1590. doi: 
      10.1161/CIRCULATIONAHA.120.045695. Epub 2020 Sep 4.

PMID- 18815480
OWN - NLM
STAT- MEDLINE
DCOM- 20081209
LR  - 20131121
IS  - 1550-5111 (Electronic)
IS  - 0887-9303 (Linking)
VI  - 31
IP  - 4
DP  - 2008 Oct-Dec
TI  - Aspirin for the primary prevention of adverse cardiovascular events.
PG  - 324-39
LID - 10.1097/01.CNQ.0000336819.35042.cb [doi]
AB  - There is consideration controversy regarding the use of aspirin for the 
      prophylaxis of certain cardiovascular conditions, such as coronary thrombosis and 
      stroke. An exploration of current literature suggests that the decision to adopt 
      a routine aspirin regimen must follow a careful analysis of potential risks as 
      well as benefits. Nurses share a vital role in patient education related to 
      aspirin regimens, to guard against potential complications of low-dose aspirin 
      therapy, including gastrointestinal bleeding and stroke.
FAU - Estes, Krista
AU  - Estes K
AD  - Shawnee Mission Medical Center, The University of Kansas Hospital, Kansas City, 
      KS 66160, USA.
FAU - Thomure, Jessica
AU  - Thomure J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Crit Care Nurs Q
JT  - Critical care nursing quarterly
JID - 8704517
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Clinical Protocols
MH  - Critical Care
MH  - Decision Trees
MH  - Diffusion of Innovation
MH  - Drug Monitoring
MH  - Evidence-Based Medicine
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Nurse's Role
MH  - Patient Education as Topic
MH  - Patient Selection
MH  - Primary Prevention/*methods
MH  - Research Design
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2008/09/26 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/09/26 09:00
PHST- 2008/09/26 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/09/26 09:00 [entrez]
AID - 00002727-200810000-00008 [pii]
AID - 10.1097/01.CNQ.0000336819.35042.cb [doi]
PST - ppublish
SO  - Crit Care Nurs Q. 2008 Oct-Dec;31(4):324-39. doi: 
      10.1097/01.CNQ.0000336819.35042.cb.

PMID- 16807
OWN - NLM
STAT- MEDLINE
DCOM- 19770718
LR  - 20131121
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 73
IP  - 1
DP  - 1977 Jul
TI  - Aspirin esterase of gastric mucosal origin.
PG  - 15-8
AB  - The enzyme, aspirin esterase, which converts acetylsalicyclic acid to the less 
      toxic salicyclic acid, was found to be present in gastric mucosal specimens 
      obtained from surgically resected tissue. The enzyme was found to be stable to 
      storage and active at two pH optima. Alcohol in the reaction mixture produced a 
      net effect of slowing the rate of aspirin hydrolysis; this was attributable to a 
      marked inhibitory effect on aspirin esterase activity which was not completely 
      counteracted by the increased rate of spontaneous breakdown of aspirin by 
      alcohol. Age, sex, or gastric disease state of the patient from whom the tissue 
      was obtained, did not significantly alter the level of enzyme activity measured, 
      nor were different levels obtained from body or antral mucosa. In patients with 
      gastric ulcer, those with a previous history of regular aspirin consumption did 
      not show significantly different levels from those without such a history. It is 
      concluded that aspirin esterase activity of gastric mucosa is not alone a 
      significant factor in any role acetylsalicyclic acid may play in the etiology and 
      natural history of chronic peptic ulcer.
FAU - Builder, J
AU  - Builder J
FAU - Landecker, K
AU  - Landecker K
FAU - Whitecross, D
AU  - Whitecross D
FAU - Piper, D W
AU  - Piper DW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 3K9958V90M (Ethanol)
RN  - EC 3.1.- (Esterases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Alcoholic Beverages
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Drug Stability
MH  - Duodenal Ulcer/enzymology
MH  - *Esterases/analysis
MH  - Ethanol/pharmacology
MH  - Female
MH  - Gastric Mucosa/*enzymology
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - Male
MH  - Middle Aged
MH  - Sex Factors
MH  - Stomach Ulcer/*chemically induced/enzymology
EDAT- 1977/07/01 00:00
MHDA- 1977/07/01 00:01
CRDT- 1977/07/01 00:00
PHST- 1977/07/01 00:00 [pubmed]
PHST- 1977/07/01 00:01 [medline]
PHST- 1977/07/01 00:00 [entrez]
AID - S0016508577001887 [pii]
PST - ppublish
SO  - Gastroenterology. 1977 Jul;73(1):15-8.

PMID- 2910014
OWN - NLM
STAT- MEDLINE
DCOM- 19890209
LR  - 20220309
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 91
IP  - 1
DP  - 1989 Jan
TI  - A comparative study of variables affecting the bleeding time using two disposable 
      devices.
PG  - 45-51
AB  - A number of variables affect the result of the bleeding time, the most frequently 
      used test assessing primary hemostasis. Although the test is now usually 
      performed with one of several commercially available disposable devices, most 
      previous studies of the bleeding time have evaluated only the original template 
      device described nearly 20 years ago. Therefore, we compared two commonly used 
      bleeding time devices (Surgicutt and Simplate) with regard to multiple variables 
      affecting the test in 40 hematologically normal young adults. Bleeding time was 
      performed by the modified Ivy method according to the manufacturers' instructions 
      in both horizontal (transverse) and vertical directions, before and two hours 
      after a test dose of 650 mg of aspirin was administered. With both horizontal and 
      vertical incisions, Simplate bleeding time values were greater than with the 
      Surgicutt device (P = 0.0025). Bleeding time in the horizontal direction was 
      greater than vertical with both devices (P = 0.0001). Values in males and females 
      were not significantly different. Aspirin sensitivity, the difference between 
      preaspirin and postaspirin values, was greatest with the use of the Surgicutt 
      device in the horizontal position (mean postaspirin value 8.0 minutes). Both 
      devices produced a reproducible uniform incision, caused minimal discomfort, and 
      resulted in little or no scarring. The authors conclude that the results with 
      Surgicutt and Simplate devices were comparable in many respects but that a 
      horizontal Surgicutt bleeding time might be most sensitive in detecting disorders 
      of primary hemostasis. Comparative studies of different bleeding time devices in 
      normal subjects are necessary in order to accurately assess their clinical 
      utility.
FAU - Buchanan, G R
AU  - Buchanan GR
AD  - Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 
      75235-9063.
FAU - Holtkamp, C A
AU  - Holtkamp CA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology
MH  - *Bleeding Time
MH  - Blood Platelets/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Platelet Function Tests/*instrumentation
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1093/ajcp/91.1.45 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1989 Jan;91(1):45-51. doi: 10.1093/ajcp/91.1.45.

PMID- 24356627
OWN - NLM
STAT- MEDLINE
DCOM- 20140811
LR  - 20220410
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 25
IP  - 1
DP  - 2014 Jan
TI  - A cohort study investigating aspirin use and survival in men with prostate 
      cancer.
PG  - 154-9
LID - 10.1093/annonc/mdt428 [doi]
AB  - BACKGROUND: Aspirin use has been associated with reduced mortality from cancer 
      including prostate cancer in some studies. A number of anti-cancer mechanisms of 
      aspirin have been proposed, including the inhibition of the cyclooxygenase 
      enzymes, through which aspirin mediates both anti-platelet and anti-inflammatory 
      activities. This cohort study examines associations between pre-diagnostic 
      aspirin use (overall and by dose and dosing intensity) and mortality in men with 
      localised prostate cancer. PATIENTS AND METHODS: Men with stage I-III prostate 
      cancer were identified from Irish National Cancer Registry records, which have 
      been linked to national prescribing data from the Irish General Medical Services 
      scheme. Aspirin use in the year preceding prostate cancer diagnosis was 
      identified from this linked prescription-claims data. Adjusted hazard ratios 
      (HRs) and 95% confidence intervals (CIs) were estimated for associations between 
      aspirin use and all-cause and prostate cancer-specific mortality. Associations 
      between prescribed dose and dosing intensity were examined. The presence of 
      effect modification by the type of treatment received and tumour characteristics 
      was also assessed. RESULTS: Two thousand nine hundred and thirty-six men with a 
      diagnosis of stage I-III prostate cancer (2001-2006) were identified (aspirin 
      users, n = 1131). The median duration of patient follow-up was 5.5 years. In 
      adjusted analyses, aspirin use was associated with a small, but non-significant, 
      reduced risk of prostate cancer-specific mortality (HR = 0.88, 95% CI 0.67-1.15). 
      In dose-response analyses, stronger associations with prostate cancer-specific 
      mortality were observed in men with higher aspirin dosing intensity (HR = 0.73, 
      95% CI 0.51-1.05) and in men receiving >75 mg of aspirin (HR = 0.61, 95% CI 
      0.37-0.99). Analyses of effect modification by treatment type or tumour 
      characteristics were non-significant. CONCLUSIONS: Consistent with prior studies, 
      aspirin use was associated with a non-significant reduced risk of prostate 
      cancer-specific mortality in men with localised prostate cancer. Men receiving 
      higher doses of aspirin had a statistically significant reduced risk of prostate 
      cancer-specific mortality. These findings regarding an aspirin dose require 
      further investigation.
FAU - Flahavan, E M
AU  - Flahavan EM
AD  - Department of Pharmacology and Therapeutics, Trinity College, University of 
      Dublin, Dublin, Ireland.
FAU - Bennett, K
AU  - Bennett K
FAU - Sharp, L
AU  - Sharp L
FAU - Barron, T I
AU  - Barron TI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cohort Studies
MH  - Combined Modality Therapy
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prostatic Neoplasms/*mortality/therapy
MH  - Risk
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin
OT  - mortality
OT  - pharmacoepidemiology
OT  - prostate neoplasm
EDAT- 2013/12/21 06:00
MHDA- 2014/08/12 06:00
CRDT- 2013/12/21 06:00
PHST- 2013/12/21 06:00 [entrez]
PHST- 2013/12/21 06:00 [pubmed]
PHST- 2014/08/12 06:00 [medline]
AID - S0923-7534(19)35944-7 [pii]
AID - 10.1093/annonc/mdt428 [doi]
PST - ppublish
SO  - Ann Oncol. 2014 Jan;25(1):154-9. doi: 10.1093/annonc/mdt428.

PMID- 26395185
OWN - NLM
STAT- MEDLINE
DCOM- 20160711
LR  - 20181113
IS  - 1433-0458 (Electronic)
IS  - 0017-6192 (Linking)
VI  - 63
IP  - 10
DP  - 2015 Oct
TI  - [Adaptive desensitization for acetylsalicylic acid hypersensitivity: A success 
      story?].
PG  - 707-14
LID - 10.1007/s00106-015-0065-y [doi]
AB  - BACKGROUND: Adaptive desensitization still remains the only causative therapy for 
      acetylsalicylic acid (ASA) hypersensitivity and is carried out nearly worldwide. 
      To date there are hardly any data available on disease development under current 
      desensitization therapy and longitudinal data in particular are missing. STUDY 
      DESIGN: Out of a large collective of patients with proven hypersensitivity to 
      ASA, 194 patients with initiated desensitization treatment were observed for 
      periods up to 5 years (average 32 months). RESULTS: Patients with immediate 
      reactions to systemic challenge tests revealed a response rate of 77% after 12 
      months of therapy. In this period 12% reached complete remission, 38% showed a 
      clear reduction in symptoms, 32% reached partial remission, 13% remained 
      unchanged and 5% suffered from disease progression. CONCLUSION: Adaptive 
      desensitization therapy for hypersensitivity to ASA has been shown to be an 
      effective causative therapy and chronic hyperplastic sinusitis as well as 
      bronchial asthma could be improved. For the determination of maintenance dosages 
      and required time periods more data are needed.
FAU - Mühlmeier, G
AU  - Mühlmeier G
AD  - Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie, Bundeswehrkrankenhaus Ulm, 
      Oberer Eselsberg 40, 89081, Ulm, Deutschland. gmhno@t-online.de.
FAU - Hausch, R
AU  - Hausch R
AD  - Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie, Bundeswehrkrankenhaus Ulm, 
      Oberer Eselsberg 40, 89081, Ulm, Deutschland.
FAU - Maier, H
AU  - Maier H
AD  - Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie, Bundeswehrkrankenhaus Ulm, 
      Oberer Eselsberg 40, 89081, Ulm, Deutschland.
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Adaptive Desaktivierung bei ASS-Hypersensitivität: Eine Erfolgsgeschichte?
PL  - Germany
TA  - HNO
JT  - HNO
JID - 2985099R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/*adverse effects/immunology
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*etiology/immunology/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Young Adult
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Hypersensitivity
OT  - Longitudinal studies
OT  - Medication adherence
OT  - Salicylate
EDAT- 2015/09/24 06:00
MHDA- 2016/07/12 06:00
CRDT- 2015/09/24 06:00
PHST- 2015/09/24 06:00 [entrez]
PHST- 2015/09/24 06:00 [pubmed]
PHST- 2016/07/12 06:00 [medline]
AID - 10.1007/s00106-015-0065-y [pii]
AID - 10.1007/s00106-015-0065-y [doi]
PST - ppublish
SO  - HNO. 2015 Oct;63(10):707-14. doi: 10.1007/s00106-015-0065-y.

PMID- 9822515
OWN - NLM
STAT- MEDLINE
DCOM- 19981223
LR  - 20220330
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 179
IP  - 5
DP  - 1998 Nov
TI  - Prevention of preeclampsia: a big disappointment.
PG  - 1275-8
AB  - Preeclampsia is a multisystem disorder of unknown etiology. During the past 2 
      decades, numerous clinical reports and randomized trials described the use of 
      various methods to prevent or reduce the incidence and severity of preeclampsia. 
      These methods were used in an attempt to correct certain abnormalities such as 
      biochemical imbalance, a pathophysiologic mechanism, or a dietary deficiency. 
      There are at least 15 randomized trials evaluating the use of various 
      antihypertensive drugs including diuretics for the prevention of preeclampsia. 
      Results of these trials reveal no such benefit. There are few randomized trials 
      evaluating magnesium (n = 2), zinc (n = 2), or fish oil supplementation (n = 3) 
      to prevent preeclampsia. The majority of these trials had limited sample size; 
      however, results reveal minimal-to-no benefit. There are 7 placebo-controlled 
      trials evaluating calcium supplementation during pregnancy. Findings of these 
      trials reveal that calcium supplementation does not reduce the incidence of 
      preeclampsia in healthy nulliparous women. The majority of randomized trials for 
      the prevention of preeclampsia have used low-dose aspirin. Results of early 
      single-center trials demonstrated an average reduction of preeclampsia of 70% 
      with low-dose aspirin. However, results of recent large multicenter trials (n = 
      7) that included >27,000 women revealed minimal-to-no benefit. Until the 
      pathogenesis of preeclampsia is well defined, prevention of this syndrome with 
      any modality remains unlikely.
FAU - Sibai, B M
AU  - Sibai BM
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, 
      Universityof Tennessee, Memphis, TN, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cyclooxygenase Inhibitors/administration & dosage/therapeutic use
MH  - Dietary Supplements
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Failure
RF  - 32
EDAT- 1998/11/20 00:00
MHDA- 1998/11/20 00:01
CRDT- 1998/11/20 00:00
PHST- 1998/11/20 00:00 [pubmed]
PHST- 1998/11/20 00:01 [medline]
PHST- 1998/11/20 00:00 [entrez]
AID - S0002937898701462 [pii]
AID - 10.1016/s0002-9378(98)70146-2 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1998 Nov;179(5):1275-8. doi: 10.1016/s0002-9378(98)70146-2.

PMID- 7021070
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20190909
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 7
IP  - 7
DP  - 1981
TI  - Treatment of rheumatoid arthritis with flurbiprofen: a comparison with 
      enteric-coated aspirin.
PG  - 418-22
AB  - Forty patients with definite or classical rheumatoid arthritis were entered for 3 
      months in a double-blind trial, 20 patients each on 200 mg flurbiprofen or 4.0 g 
      enteric-coated aspirin daily. Statistically significant improvements (Page Test, 
      p less than 0.05) on flurbiprofen were reported during the course of the study 
      for 7 out of 20 parameters: degree of pain, duration of morning stiffness, grip 
      strength, torquometer, Ritchie articular index, number of swollen joints and 
      patient's overall assessment, while for aspirin a significant improvement was 
      reported for 5 parameters: degree of pain, PIP joint size, Ritchie articular 
      index and physician's overall assessment. The amount of improvement between 
      flurbiprofen and enteric-coated aspirin differed significantly (Kruskal-Wallis H 
      Test) only for 2 parameters: Ritchie articular index and number of swollen 
      joints. In both cases the degree of improvement was greater on flurbiprofen than 
      an aspirin. Side-effects were reported for 7 patients receiving aspirin (2 of 
      which were severe enough that treatment had to be stopped) and for 3 patients 
      receiving flurbiprofen. Except for 2 cases of tinnitus on aspirin, the 
      side-effects were mostly gastro-intestinal in nature. A significant decrease was 
      found for patients receiving aspirin. A significant increase in blood urea 
      occurred on flurbiprofen. Most values, however, remained within normal limits. 
      The results suggests that flurbiprofen is better tolerated and at least as 
      effective as enteric-coated aspirin in the treatment of patients with rheumatoid 
      arthritis.
FAU - Dequeker, J
AU  - Dequeker J
FAU - Mardjuardi, A
AU  - Mardjuardi A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Propionates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Flurbiprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Propionates/*therapeutic use
MH  - Random Allocation
MH  - Tablets, Enteric-Coated
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1185/03007998109114278 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1981;7(7):418-22. doi: 10.1185/03007998109114278.

PMID- 16395548
OWN - NLM
STAT- MEDLINE
DCOM- 20070530
LR  - 20220318
IS  - 1432-9417 (Print)
IS  - 1432-9417 (Linking)
VI  - 10
IP  - 1
DP  - 2006 Jan
TI  - [Tooth extraction under medication with acetylsalicylic acid].
PG  - 3-6
AB  - PURPOSE: The purpose of this prospective study was to show and analyze the 
      bleeding complications after teeth extraction under therapy with 100 mg 
      acetylsalicylic acid (ASA) and to compare them to bleeding complications after 
      teeth extraction in patients with a healthy blood profile. PATIENTS AND METHODS: 
      In 65 patients under medication with 100 mg ASA and in 252 healthy patients, 151/ 
      543 teeth were extracted and the bleeding complications monitored. RESULTS: The 
      postoperative bleeding frequency was 1.54% in the ASA 100 group and 1.59% in the 
      healthy control group without any medication. No serious or uncontrollable 
      postoperative bleedings arose in either group. All bleedings could be easily 
      handled. No obvious difference concerning the bleeding frequency between the two 
      groups was observed. The small number of bleeding events and the complexity of 
      affecting parameters did not permit statistical tests. CONCLUSION: It is not 
      necessary to interrupt the medication of 100 mg acetylsalicylic acid given to 
      prevent thromboembolism before tooth extractions.
FAU - Hemelik, M
AU  - Hemelik M
AD  - Poliklinik für Chirurgische Zahn-, Mund- und Kieferheilkunde, Universität Bonn, 
      Germany. g.wahl@uni-bonn.de
FAU - Wahl, G
AU  - Wahl G
FAU - Kessler, B
AU  - Kessler B
LA  - ger
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Zahnextraktionen unter Medikation mit Acetylsalicylsäure (ASS).
PL  - Germany
TA  - Mund Kiefer Gesichtschir
JT  - Mund-, Kiefer- und Gesichtschirurgie : MKG
JID - 9716576
RN  - 0 (Analgesics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Analgesics/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Loss, Surgical/prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Tooth Extraction
EDAT- 2006/01/06 09:00
MHDA- 2007/05/31 09:00
CRDT- 2006/01/06 09:00
PHST- 2006/01/06 09:00 [pubmed]
PHST- 2007/05/31 09:00 [medline]
PHST- 2006/01/06 09:00 [entrez]
AID - 10.1007/s10006-005-0666-9 [doi]
PST - ppublish
SO  - Mund Kiefer Gesichtschir. 2006 Jan;10(1):3-6. doi: 10.1007/s10006-005-0666-9.

PMID- 3044868
OWN - NLM
STAT- MEDLINE
DCOM- 19881011
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 16
IP  - 3
DP  - 1988 May-Jun
TI  - Analgesic effect of aspirin, mefenamic acid and their combination in 
      post-operative oral surgery pain.
PG  - 167-72
AB  - A double-blind randomized single dose study of the analgesic effects of 650 mg 
      aspirin, 250 mg mefenamic acid, the combination of 650 mg aspirin and 250 mg 
      mefenamic acid and placebo on 120 patients with pain following oral surgery was 
      conducted. Patients evaluated their pain intensity and extent of pain relief at 
      1, 2, 3 and 4 h after drug administration. For most parameters, including the sum 
      of the pain intensity differences and the sum of the hourly pain relief scores, 
      each of the drugs was more effective than placebo. Aspirin-mefenamic acid in 
      combination was more effective than both drugs alone, and aspirin and mefenamic 
      acid alone were equally effective for most of the analgesic variables.
FAU - Or, S
AU  - Or S
AD  - Faculty of Dentistry, Department of Oral and Maxillofacial Surgery, Ankara 
      University, Turkey.
FAU - Bozkurt, A
AU  - Bozkurt A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Analgesics)
RN  - 0 (Drug Combinations)
RN  - 367589PJ2C (Mefenamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesics
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Combinations
MH  - Humans
MH  - Mefenamic Acid/adverse effects/*therapeutic use
MH  - Mouth/*surgery
MH  - Pain, Postoperative/*drug therapy/physiopathology
MH  - Time Factors
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
AID - 10.1177/030006058801600301 [doi]
PST - ppublish
SO  - J Int Med Res. 1988 May-Jun;16(3):167-72. doi: 10.1177/030006058801600301.

PMID- 29253055
OWN - NLM
STAT- MEDLINE
DCOM- 20180725
LR  - 20181202
IS  - 1842-1121 (Electronic)
IS  - 1841-8724 (Linking)
VI  - 26
IP  - 4
DP  - 2017 Dec
TI  - PPIs Prevent Aspirin-Induced Gastrointestinal Bleeding Better than H2RAs. A 
      Systematic Review and Meta-analysis.
PG  - 395-402
LID - 10.15403/jgld.2014.1121.264.hra [doi]
AB  - BACKGROUND AND AIMS: Aspirin is one of the most widely used medication for its 
      analgesic and anti-platelet properties and thus a major cause for 
      gastrointestinal (GI) bleeding. This study compared the preventive effect of 
      histamine-2 receptor antagonists (H2RAs) and proton-pump inhibitors (PPIs) 
      against chronic low-dose aspirin (LDA)-related GI bleeding and ulcer formation. 
      METHODS: Electronic databases of Pubmed, Embase and Cochrane Central Register of 
      Controlled Trials were searched for human observations (randomised controlled 
      trials and observational studies) comparing the long term effects of PPIs and 
      H2RAs treatment in the prevention of GI bleeding or ulcer formation in patients 
      on chronic LDA treatment listed up till September 30, 2016. Two independent 
      authors searched databases using PICO questions (aspirin, H2RA, PPI, GI bleeding 
      or ulcer), and reviewed abstracts and articles for comprehensive studies keeping 
      adequate study quality. Data of weighted odds ratios were statistically evaluated 
      using Comprehensive Metaanalysis (Biostat, Inc., Engelwood, MJ, USA), potential 
      bias was checked. RESULTS: Nine studies for GI bleeding and eight studies for 
      ulcer formation were found meeting inclusion criteria, altogether 1,879 patients 
      were included into review. The H2RAs prevented less effectively LDA-related GI 
      bleeding (OR= 2.102, 95% CI: 1.008-4.385, p<0.048) and ulcer formation (OR= 
      2.257, 95% CI: 1.277-3.989, p<0.005) than PPIs. CONCLUSION: The meta-analysis 
      showed that H2RAs were less effective in the prevention of LDA-related GI 
      bleeding and ulcer formation suggesting the preferable usage of PPIs in case of 
      tolerance.
FAU - Szabó, Imre L
AU  - Szabó IL
AD  - First Department of Medicine, Division of Gastroenterology, Szekszárd, Hungary. 
      szaboimi@yahoo.com.
FAU - Mátics, Robert
AU  - Mátics R
AD  - Institute for Translational Medicine, University of Pécs, Pécs, Hungary.
FAU - Hegyi, Peter
AU  - Hegyi P
AD  - First Department of Medicine, Division of Gastroenterology; Institute for 
      Translational Medicine, University of Pécs, Pécs; Hungarian Academy of Sciences - 
      University of Szeged, Momentum Gastroenterology Multidisciplinary Research Group, 
      Szeged, Hungary.
FAU - Garami, Andras
AU  - Garami A
AD  - Institute for Translational Medicine, University of Pécs, Pécs, Hungary.
FAU - Illés, Anita
AU  - Illés A
AD  - First Department of Medicine, Division of Gastroenterology, Szekszárd, Hungary.
FAU - Sarlós, Patricia
AU  - Sarlós P
AD  - First Department of Medicine, Division of Gastroenterology, Szekszárd, Hungary.
FAU - Bajor, Judit
AU  - Bajor J
AD  - First Department of Medicine, Division of Gastroenterology, Szekszárd, Hungary.
FAU - Szűcs, Akos
AU  - Szűcs A
AD  - First Department of Surgery, Semmelweis University, Budapest, Hungary.
FAU - Mosztbacher, Dora
AU  - Mosztbacher D
AD  - Department of Pediatrics, County Hospital, Szekszárd, Hungary.
FAU - Márta, Katalin
AU  - Márta K
AD  - Institute for Translational Medicine, University of Pécs, Pécs, Hungary.
FAU - Szemes, Kata
AU  - Szemes K
AD  - First Department of Medicine, Division of Gastroenterology, Szekszárd, Hungary.
FAU - Csekő, Kata
AU  - Csekő K
AD  - First Department of Medicine, Division of Gastroenterology, Szekszárd, Hungary.
FAU - Kővári, Balint
AU  - Kővári B
AD  - First Department of Medicine, Division of Gastroenterology, Szekszárd, Hungary.
FAU - Rumbus, Zoltan
AU  - Rumbus Z
AD  - Institute for Translational Medicine, University of Pécs, Pécs, Hungary.
FAU - Vincze, Áron
AU  - Vincze Á
AD  - First Department of Medicine, Division of Gastroenterology, Szekszárd, Hungary.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - Romania
TA  - J Gastrointestin Liver Dis
JT  - Journal of gastrointestinal and liver diseases : JGLD
JID - 101272825
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Peptic Ulcer/chemically induced/prevention & control
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Proton Pump Inhibitors/*therapeutic use
EDAT- 2017/12/19 06:00
MHDA- 2018/07/26 06:00
CRDT- 2017/12/19 06:00
PHST- 2017/12/19 06:00 [entrez]
PHST- 2017/12/19 06:00 [pubmed]
PHST- 2018/07/26 06:00 [medline]
AID - 14 [pii]
AID - 10.15403/jgld.2014.1121.264.hra [doi]
PST - ppublish
SO  - J Gastrointestin Liver Dis. 2017 Dec;26(4):395-402. doi: 
      10.15403/jgld.2014.1121.264.hra.

PMID- 27215735
OWN - NLM
STAT- MEDLINE
DCOM- 20170130
LR  - 20181202
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 14
IP  - 7
DP  - 2016 Jul
TI  - Extended-release acetylsalicylic acid for secondary prevention of stroke and 
      cardiovascular events.
PG  - 779-91
LID - 10.1080/14779072.2016.1188005 [doi]
AB  - INTRODUCTION: Aspirin has been the bedrock of antiplatelet treatment strategies 
      for the secondary prevention of recurrent cardiovascular and cerebrovascular 
      events for the last 3 decades. The limitations of standard aspirin therapy 
      include bleeding, gastrotoxicity, and loss of antiplatelet effect over a 24-hour 
      period in selected high-risk patients. An extended-release (ER) aspirin 
      formulation, Durlaza® (New Haven Pharmaceuticals, Inc., North Haven, CT), has 
      been developed to address some of the latter limitations and may provide an 
      alternative to standard aspirin in the secondary prevention of cardiovascular 
      disease. AREAS COVERED: We searched articles describing the use aspirin for 
      secondary prevention of stroke and cardiovascular events in PubMed published 
      until May 2016. This is a comprehensive review which describes active- and 
      placebo-controlled clinical trials, overview of American and European 
      recommendations, controversies surrounding standard aspirin use, and a 
      description of pharmacodynamics of standard and extended release aspirin 
      formulations. Expert commentary: Available data indicates an increased bleeding 
      risk with the use of standard aspirin therapy in conjunction with potent P2Y12 
      receptor blockers, and/or oral anticoagulants. Trials evaluating the efficacy of 
      replacing aspirin with a low-dose oral anticoagulant in patients with stable 
      cardiovascular disease or acute coronary syndrome are ongoing. Future studies are 
      warranted to determine if the use of ER-ASA formulation may obviate safety 
      concerns surrounding standard aspirin therapy.
FAU - Bliden, Kevin P
AU  - Bliden KP
AD  - a Inova Center for Thrombosis Research and Drug Development , Inova Heart and 
      Vascular Institute , Fairfax , VA , USA.
FAU - Tantry, Udaya S
AU  - Tantry US
AD  - a Inova Center for Thrombosis Research and Drug Development , Inova Heart and 
      Vascular Institute , Fairfax , VA , USA.
FAU - Chaudhary, Rahul
AU  - Chaudhary R
AD  - a Inova Center for Thrombosis Research and Drug Development , Inova Heart and 
      Vascular Institute , Fairfax , VA , USA.
FAU - Byun, Seunghwan
AU  - Byun S
AD  - a Inova Center for Thrombosis Research and Drug Development , Inova Heart and 
      Vascular Institute , Fairfax , VA , USA.
FAU - Gurbel, Paul A
AU  - Gurbel PA
AD  - a Inova Center for Thrombosis Research and Drug Development , Inova Heart and 
      Vascular Institute , Fairfax , VA , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160602
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Secondary Prevention
MH  - Stroke/*prevention & control
OTO - NOTNLM
OT  - Antiplatelet
OT  - acetylsalicylic acid
OT  - aspirin
OT  - cardiovascular disease
OT  - platelet
OT  - secondary prevention
OT  - thromboxane
EDAT- 2016/05/25 06:00
MHDA- 2017/01/31 06:00
CRDT- 2016/05/25 06:00
PHST- 2016/05/25 06:00 [entrez]
PHST- 2016/05/25 06:00 [pubmed]
PHST- 2017/01/31 06:00 [medline]
AID - 10.1080/14779072.2016.1188005 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2016 Jul;14(7):779-91. doi: 
      10.1080/14779072.2016.1188005. Epub 2016 Jun 2.

PMID- 17663077
OWN - NLM
STAT- MEDLINE
DCOM- 20070731
LR  - 20161020
IS  - 1052-1577 (Print)
IS  - 1052-1577 (Linking)
VI  - 32
IP  - 9
DP  - 2007 Jul
TI  - By the way, doctor. Must I take aspirin?
PG  - 8
AB  - I am a 56-year-old woman with a 20-year history of ulcerative colitis. I also 
      happen to be diabetic. My new doctor has been pushing aspirin therapy. His 
      philosophy is that no one ever died from a flare-up of ulcerative colitis but 
      plenty of women have died from heart attacks and strokes. My gastroenterologist, 
      who has treated me for more than 20 years, feels that I should consider aspirin 
      if and when there are signs that I would benefit from it and not to risk having 
      problems with my colitis. I am in a real quandary.
FAU - Keating, Nancy
AU  - Keating N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Harv Health Lett
JT  - Harvard health letter
JID - 9425764
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Attitude of Health Personnel
MH  - Colitis, Ulcerative/*complications
MH  - Diabetic Angiopathies/*prevention & control
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Assessment
MH  - Stroke/*prevention & control
EDAT- 2007/08/01 09:00
MHDA- 2007/08/01 09:01
CRDT- 2007/08/01 09:00
PHST- 2007/08/01 09:00 [pubmed]
PHST- 2007/08/01 09:01 [medline]
PHST- 2007/08/01 09:00 [entrez]
PST - ppublish
SO  - Harv Health Lett. 2007 Jul;32(9):8.

PMID- 24373610
OWN - NLM
STAT- MEDLINE
DCOM- 20141009
LR  - 20211021
IS  - 1532-2823 (Electronic)
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 90
IP  - 2-3
DP  - 2014 Feb-Mar
TI  - The effects of aspirin and fish oil consumption on lysophosphatidylcholines and 
      lysophosphatidic acids and their correlates with platelet aggregation in adults 
      with diabetes mellitus.
PG  - 61-8
LID - S0952-3278(13)00232-9 [pii]
LID - 10.1016/j.plefa.2013.12.004 [doi]
AB  - Many diabetics are insensitive to aspirin's platelet anti-aggregation effects. 
      The influence of co-administration of aspirin and fish oil (FO) on plasma 
      lysophospholipids in subjects with diabetes is poorly characterized. Thirty 
      adults with type 2 diabetes mellitus were treated with aspirin (81mg/day) for 
      seven days, then with FO (4g/day) for 28 days, then in combination for another 
      seven days. Lysophospholipids and platelet measures were determined after acute 
      (4h) and chronic (7 days) ingestion of aspirin, FO, or both in combination. FO 
      ingestion reduced all lysophosphatidic acid (LPA) concentrations, while EPA 
      (20:5n-3) and DHA (22:6n-3) lysophosphatidylcholine (LPC) concentrations 
      significantly increased after FO alone and in combination with aspirin. In vitro 
      arachidonic acid-induced platelet aggregation was most strongly correlated with 
      palmitoleic (16:1) and oleic (18:1) LPA and LPC concentrations at all time 
      points. The ingestion of these agents may reduce cardiovascular disease risk in 
      diabetic adults, with a disrupted lipid milieu, via lysolipid mediated 
      mechanisms.
CI  - Copyright © 2013 Elsevier Ltd. All rights reserved.
FAU - Abdolahi, Amir
AU  - Abdolahi A
AD  - Department of Public Health Sciences, University of Rochester School of Medicine 
      and Dentistry, Rochester, NY, United States.
FAU - Georas, Steve N
AU  - Georas SN
AD  - Pulmonary and Critical Care Division, Department of Medicine, University of 
      Rochester School of Medicine and Dentistry, Rochester, NY, United States.
FAU - Brenna, J Thomas
AU  - Brenna JT
AD  - Division of Nutritional Sciences, Cornell University, Ithaca, New York, United 
      States.
FAU - Cai, Xueya
AU  - Cai X
AD  - Department of Public Health Sciences, University of Rochester School of Medicine 
      and Dentistry, Rochester, NY, United States; Department of Biostatistics and 
      Computational Biology, University of Rochester School of Medicine and Dentistry, 
      Rochester, NY, United States.
FAU - Thevenet-Morrison, Kelly
AU  - Thevenet-Morrison K
AD  - Department of Public Health Sciences, University of Rochester School of Medicine 
      and Dentistry, Rochester, NY, United States.
FAU - Phipps, Richard P
AU  - Phipps RP
AD  - Department of Environmental Medicine, University of Rochester School of Medicine 
      and Dentistry, Rochester, NY, United States.
FAU - Lawrence, Peter
AU  - Lawrence P
AD  - Division of Nutritional Sciences, Cornell University, Ithaca, New York, United 
      States.
FAU - Mousa, Shaker A
AU  - Mousa SA
AD  - Pharmaceutical Research Institute, Albany College of Pharmacy and Health 
      Sciences, Albany, NY, United States.
FAU - Block, Robert C
AU  - Block RC
AD  - Department of Public Health Sciences, University of Rochester School of Medicine 
      and Dentistry, Rochester, NY, United States. Electronic address: 
      robert_block@urmc.rochester.edu.
LA  - eng
SI  - ClinicalTrials.gov/NCT01181882
GR  - R21 HL102582/HL/NHLBI NIH HHS/United States
GR  - P30 ES001247/ES/NIEHS NIH HHS/United States
GR  - R21 ES023032/ES/NIEHS NIH HHS/United States
GR  - TL1 TR000096/TR/NCATS NIH HHS/United States
GR  - R01 HL071933/HL/NHLBI NIH HHS/United States
GR  - KL2 RR024136/RR/NCRR NIH HHS/United States
GR  - T32 HL007937/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20131218
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Fish Oils)
RN  - 0 (Lysophosphatidylcholines)
RN  - 0 (Lysophospholipids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Diabetes Mellitus, Type 2/*blood/*physiopathology
MH  - Eating/physiology
MH  - Feeding Behavior
MH  - Female
MH  - Fish Oils/*pharmacology
MH  - Fishes
MH  - Humans
MH  - Lysophosphatidylcholines/*blood
MH  - Lysophospholipids/*blood
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
PMC - PMC3939709
MID - NIHMS551858
OTO - NOTNLM
OT  - Aspirin
OT  - Docosahexaenoic acid
OT  - Eicosapentaenoic acid
OT  - Lysophosphatidic acid
OT  - Lysophosphatidylcholine
OT  - Omega-3 fatty acids
OT  - Platelet function
EDAT- 2014/01/01 06:00
MHDA- 2014/10/10 06:00
CRDT- 2013/12/31 06:00
PHST- 2013/09/09 00:00 [received]
PHST- 2013/12/04 00:00 [revised]
PHST- 2013/12/09 00:00 [accepted]
PHST- 2013/12/31 06:00 [entrez]
PHST- 2014/01/01 06:00 [pubmed]
PHST- 2014/10/10 06:00 [medline]
AID - S0952-3278(13)00232-9 [pii]
AID - 10.1016/j.plefa.2013.12.004 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2014 Feb-Mar;90(2-3):61-8. doi: 
      10.1016/j.plefa.2013.12.004. Epub 2013 Dec 18.

PMID- 31663590
OWN - NLM
STAT- MEDLINE
DCOM- 20200401
LR  - 20200401
IS  - 2047-4849 (Electronic)
IS  - 2047-4830 (Linking)
VI  - 7
IP  - 12
DP  - 2019 Nov 19
TI  - Sulfosalicylic acid/Fe(3+) based nanoscale coordination polymers for effective 
      cancer therapy by the Fenton reaction: an inspiration for understanding the role 
      of aspirin in the prevention of cancer.
PG  - 5482-5491
LID - 10.1039/c9bm00799g [doi]
AB  - Fenton reaction-based reactive oxygen species (ROS) generation provides a new 
      idea for the design of ROS-mediated anticancer agents. Finding ways to increase 
      iron uptake and to elevate the level of H2O2 in cells simultaneously is thus 
      crucial to this strategy. Meanwhile, salicylic acid (SA) or its analogue, as the 
      major metabolite of aspirin, has been reported to be closely associated with an 
      intracellular redox-active product. In this work, a PEG-modified nanoscale 
      coordination polymer (PFNC) via the self-assembly of 5-sulfosalicylic acid (SSA) 
      with Fe3+ ions has been designed for the first time. The results show that the 
      SSA dissociated from the PFNC can lead to the decrease of GSH and the 
      accumulation of H2O2 in cancer cells, and thus elevate cellular ROS via the 
      Fenton reaction. Owing to such intracellular oxidative stress, PFNC-induced 
      ferroptotic cell death was further confirmed. In vitro cytotoxicity studies show 
      that PFNCs display higher cytotoxicity on cancer cells than on normal cells. In 
      vivo experiments further demonstrate that PFNCs not only possess high tumor 
      accumulation, but also significantly inhibit the tumor growth without obvious 
      damage toward the major organs. Based on the results, we expect that this work 
      will provide an inspiration for understanding the role of SA, even aspirin, in 
      the prevention of cancer.
FAU - Liu, Qianqian
AU  - Liu Q
AD  - Pharmaceutical Research Center, Jiangsu Province Hi-Tech Key Laboratory for 
      Biomedical Research, School of Chemistry and Chemical Engineering, Southeast 
      University, Nanjing, Jiangsu 211189, China. zfwang@seu.edu.cn.
FAU - Du, Keke
AU  - Du K
FAU - Liu, Mei
AU  - Liu M
FAU - Lv, Rongmu
AU  - Lv R
FAU - Sun, Baiwang
AU  - Sun B
FAU - Cao, Dongwei
AU  - Cao D
FAU - He, Nongyue
AU  - He N
FAU - Wang, Zhifei
AU  - Wang Z
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biomater Sci
JT  - Biomaterials science
JID - 101593571
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzenesulfonates)
RN  - 0 (Fenton's reagent)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Salicylates)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - E1UOL152H7 (Iron)
RN  - L8XED79U3U (sulfosalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/chemistry/pharmacology
MH  - Aspirin/*chemistry/*pharmacology
MH  - Benzenesulfonates/*chemistry
MH  - Chemoprevention/*methods
MH  - Humans
MH  - Hydrogen Peroxide/chemistry
MH  - Iron/*chemistry
MH  - MCF-7 Cells
MH  - Oxidative Stress/drug effects
MH  - Polyethylene Glycols/*chemistry
MH  - Reactive Oxygen Species/metabolism
MH  - Salicylates/*chemistry
EDAT- 2019/10/31 06:00
MHDA- 2020/04/02 06:00
CRDT- 2019/10/31 06:00
PHST- 2019/10/31 06:00 [pubmed]
PHST- 2020/04/02 06:00 [medline]
PHST- 2019/10/31 06:00 [entrez]
AID - 10.1039/c9bm00799g [doi]
PST - ppublish
SO  - Biomater Sci. 2019 Nov 19;7(12):5482-5491. doi: 10.1039/c9bm00799g.

PMID- 22129580
OWN - NLM
STAT- MEDLINE
DCOM- 20120329
LR  - 20181201
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 26 Suppl 1
DP  - 2011 Dec
TI  - Unravelling the benefit against the risk of long-term dual antiplatelet therapy.
PG  - S22-30
LID - 10.1097/01.hco.0000409964.20588.8c [doi]
AB  - PURPOSE OF REVIEW: To evaluate whether long-term antiplatelet therapy may be 
      effective and well tolerated. RECENT FINDINGS: Five important studies assessed 
      the efficacy and safety of clopidogrel therapy in different settings. However, 
      the problems concerning the duration of therapy are based substantially on the 
      Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and 
      Percutaneous Coronary Intervention (PCI)-CURE studies designed to test the 
      hypothesis that the clopidogrel-aspirin combination is superior to aspirin alone 
      when initiated early and continued for the long-term in the prevention of 
      cardiovascular death, myocardial infarction, or stroke in patients with 
      non-ST-segment elevation acute coronary syndrome (ACS). These studies suffer from 
      some methodological flaws. Dual antiplatelet therapy (DAPT) beyond 1 month is 
      beneficial in terms of prevention of ischemic endpoints after ACS or after PCI. 
      However, the degree of benefit from long-term treatment post-PCI isolated from 
      pretreatment is still impossible to determine. Similarly, whether the benefit is 
      confined to the first few months after event/procedure or truly accrues over time 
      is not fully established. Regarding safety, long-term DAPT is associated with a 
      significant increase in major bleeding complications. Finally, the net clinical 
      effect of aspirin monotherapy in these settings is unknown in the current era. Of 
      the newer drugs, prasugrel and ticagrelor both showed favorable efficacy and 
      safety profiles in their respective trials. SUMMARY: Despite many large studies, 
      the efficacy of long-term DAPT remains elusive.
FAU - Bolognese, Leonardo
AU  - Bolognese L
AD  - Department of Cardiovascular Diseases, Arezzo Hospital, Arezzo, Italy.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2011/12/14 06:00
MHDA- 2012/03/30 06:00
CRDT- 2011/12/02 06:00
PHST- 2011/12/02 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/03/30 06:00 [medline]
AID - 00001573-201112001-00004 [pii]
AID - 10.1097/01.hco.0000409964.20588.8c [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2011 Dec;26 Suppl 1:S22-30. doi: 
      10.1097/01.hco.0000409964.20588.8c.

PMID- 312596
OWN - NLM
STAT- MEDLINE
DCOM- 19790716
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 43
IP  - 6
DP  - 1979 Jun
TI  - Reduction of intimal thickening in canine coronary bypass vein grafts with 
      dipyridamole and aspirin.
PG  - 1144-8
AB  - The potential benefit of platelet inhibitor drugs on coronary arterial bypass 
      vein grafts was assessed in dogs with magnification-corrected angiographic 
      luminal measurements and quantitative histologic evaluation of the vein grafts. 
      There were 11 control animals and 11 animals treated with dipyridamole, 55 
      mg/day, plus aspirin, 325 mg/day. Eighteen animals with patent grafts were 
      studied when electively killed 2, 4 or 6 months after grafting. At 14 days, there 
      was greater angiographic narrowing in the most distal 1 cm of vein grafts in 
      control than in treated dogs (P less than 0.01). This same angiographic narrowing 
      persisted in control dogs until they were killed (P less than 0.03). 
      Computer-assisted measurements of the entire area of intimal thickening were done 
      on vein graft cross sections taken 1 cm from the distal anastomosis. The 
      circumference of the vein grafts at the intimal-media junction was measured from 
      the same section and the potential maximal luminal area calculated. The 
      calculated luminal narrowing due to intimal thickening was greater in control 
      than in treated dogs (P less than 0.03). These data correlate well with the 
      demonstrated angiographic narrowing. The findings indicate that the degree of 
      early intimal thickening that persists 2 to 6 months postoperatively in canine 
      coronary bypass vein grafts may be reduced by the platelet inhibitor combination 
      of dipyridamole plus aspirin.
FAU - Metke, M P
AU  - Metke MP
FAU - Lie, J T
AU  - Lie JT
FAU - Fuster, V
AU  - Fuster V
FAU - Josa, M
AU  - Josa M
FAU - Kaye, M P
AU  - Kaye MP
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Angiography
MH  - *Coronary Artery Bypass
MH  - Coronary Disease/diagnostic imaging/pathology/*prevention & control
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Dogs
MH  - Drug Therapy, Combination
MH  - Saphenous Vein
MH  - Veins/drug effects/pathology/*transplantation
EDAT- 1979/06/01 00:00
MHDA- 1979/06/01 00:01
CRDT- 1979/06/01 00:00
PHST- 1979/06/01 00:00 [pubmed]
PHST- 1979/06/01 00:01 [medline]
PHST- 1979/06/01 00:00 [entrez]
AID - 0002-9149(79)90145-0 [pii]
AID - 10.1016/0002-9149(79)90145-0 [doi]
PST - ppublish
SO  - Am J Cardiol. 1979 Jun;43(6):1144-8. doi: 10.1016/0002-9149(79)90145-0.

PMID- 30487409
OWN - NLM
STAT- MEDLINE
DCOM- 20190130
LR  - 20200225
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 23
IP  - 12
DP  - 2018 Nov 28
TI  - A Simple and Cost-Effective TLC-Densitometric Method for the Quantitative 
      Determination of Acetylsalicylic Acid and Ascorbic Acid in Combined Effervescent 
      Tablets.
LID - 10.3390/molecules23123115 [doi]
LID - 3115
AB  - A new, simple, and cost-effective TLC-densitometric method has been established 
      for the simultaneous quantitative determination of acetylsalicylic acid and 
      ascorbic acid in combined effervescent tablets. Separation was performed on 
      aluminum silica gel 60F(254) plates using chloroform-ethanol-glacial acid at a 
      volume ratio of 5:4:0.03 as the mobile phase. UV densitometry was performed in 
      absorbance mode at 200 nm and 268 nm for acetylsalicylic acid and ascorbic acid, 
      respectively. The presented method was validated as per ICH guidelines by 
      specificity, linearity, accuracy, precision, limit of detection, limit of 
      quantification, and robustness. Method validations indicate a good sensitivity 
      with a low value of LOD and LOQ of both examined active substances. The linearity 
      range was found to be 1.50⁻9.00 μg/spot and 1.50⁻13.50 μg/spot for 
      acetylsalicylic and ascorbic acid, respectively. A coefficient of variation that 
      was less than 3% confirms the satisfactory accuracy and precision of the proposed 
      method. The results of the assay of combined tablet formulation equal 97.1% and 
      101.6% in relation to the label claim that acetylsalicylic acid and ascorbic acid 
      fulfill pharmacopoeial requirements. The developed TLC-densitometric method can 
      be suitable for the routine simultaneous analysis of acetylsalicylic acid and 
      ascorbic acid in combined pharmaceutical formulations. The proposed 
      TLC-densitometry may be an alternative method to the modern high-performance 
      liquid chromatography in the quality control of above-mentioned substances, and 
      it can be applied when HPLC or GC is not affordable in the laboratory.
FAU - Pyka-Pająk, Alina
AU  - Pyka-Pająk A
AUID- ORCID: 0000-0003-2672-7489
AD  - Department of Analytical Chemistry, School of Pharmacy with Division of 
      Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, 
      Jagiellońska 4, 41-200 Sosnowiec, Poland. apyka@sum.edu.pl.
FAU - Dołowy, Małgorzata
AU  - Dołowy M
AD  - Department of Analytical Chemistry, School of Pharmacy with Division of 
      Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, 
      Jagiellońska 4, 41-200 Sosnowiec, Poland. mdolowy@sum.edu.pl.
FAU - Parys, Wioletta
AU  - Parys W
AD  - Department of Analytical Chemistry, School of Pharmacy with Division of 
      Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, 
      Jagiellońska 4, 41-200 Sosnowiec, Poland. wparys@sum.edu.pl.
FAU - Bober, Katarzyna
AU  - Bober K
AD  - Department of Analytical Chemistry, School of Pharmacy with Division of 
      Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, 
      Jagiellońska 4, 41-200 Sosnowiec, Poland. bober@sum.edu.pl.
FAU - Janikowska, Grażyna
AU  - Janikowska G
AD  - Department of Analytical Chemistry, School of Pharmacy with Division of 
      Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, 
      Jagiellońska 4, 41-200 Sosnowiec, Poland. gjanikowska@sum.edu.pl.
LA  - eng
PT  - Journal Article
DEP - 20181128
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/*analysis
MH  - Aspirin/*analysis
MH  - Densitometry/*methods
MH  - Sensitivity and Specificity
PMC - PMC6320878
OTO - NOTNLM
OT  - TLC-densitometry
OT  - acetylsalicylic acid
OT  - ascorbic acid
OT  - validation
COIS- The authors have no conflict of interests or no financial gains in mentioning the 
      company names or trademarks.
EDAT- 2018/11/30 06:00
MHDA- 2019/01/31 06:00
CRDT- 2018/11/30 06:00
PHST- 2018/11/08 00:00 [received]
PHST- 2018/11/23 00:00 [revised]
PHST- 2018/11/24 00:00 [accepted]
PHST- 2018/11/30 06:00 [entrez]
PHST- 2018/11/30 06:00 [pubmed]
PHST- 2019/01/31 06:00 [medline]
AID - molecules23123115 [pii]
AID - molecules-23-03115 [pii]
AID - 10.3390/molecules23123115 [doi]
PST - epublish
SO  - Molecules. 2018 Nov 28;23(12):3115. doi: 10.3390/molecules23123115.

PMID- 15997132
OWN - NLM
STAT- MEDLINE
DCOM- 20051108
LR  - 20190706
IS  - 0009-2363 (Print)
IS  - 0009-2363 (Linking)
VI  - 53
IP  - 7
DP  - 2005 Jul
TI  - Microwave drying of granules containing a moisture-sensitive drug: a promising 
      alternative to fluid bed and hot air oven drying.
PG  - 770-5
AB  - The impact of microwave drying and binders (copolyvidone and povidone) on the 
      degradation of acetylsalicylic acid (ASA) and physical properties of granules 
      were compared with conventional drying methods. Moist granules containing ASA 
      were prepared using a high shear granulator and dried with hot air oven, fluid 
      bed or microwave (static or dynamic bed) dryers. Percent ASA degradation, size 
      and size distribution, friability and flow properties of the granules were 
      determined. Granules dried with the dynamic bed microwave dryer showed the least 
      amount of ASA degradation, followed by fluid bed dryer, static bed microwave oven 
      and hot air oven. The use of microwave drying with a static granular bed 
      adversely affected ASA degradation and drying capability. Dynamic bed microwave 
      dryer had the highest drying capability followed by fluid bed, static bed 
      microwave dryer and conventional hot air oven. The intensity of microwave did not 
      affect ASA degradation, size distribution, friability and flow properties of the 
      granules. Mixing/agitating of granules during drying affected the granular 
      physical properties studied. Copolyvidone resulted in lower amount of granular 
      residual moisture content and ASA degradation on storage than povidone, 
      especially for static bed microwave drying. In conclusion, microwave drying 
      technology has been shown to be a promising alternative for drying granules 
      containing a moisture-sensitive drug.
FAU - Chee, Sze Nam
AU  - Chee SN
AD  - Department of Pharmacy, Faculty of Science, National University of Singapore, 
      Singapore.
FAU - Johansen, Anne Lene
AU  - Johansen AL
FAU - Gu, Li
AU  - Gu L
FAU - Karlsen, Jan
AU  - Karlsen J
FAU - Heng, Paul Wan Sia
AU  - Heng PW
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - 0 (Pharmaceutical Preparations)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Air
MH  - Aspirin/chemistry
MH  - *Hot Temperature
MH  - *Microwaves
MH  - *Pharmaceutical Preparations
MH  - Water/*chemistry
EDAT- 2005/07/06 09:00
MHDA- 2005/11/09 09:00
CRDT- 2005/07/06 09:00
PHST- 2005/07/06 09:00 [pubmed]
PHST- 2005/11/09 09:00 [medline]
PHST- 2005/07/06 09:00 [entrez]
AID - JST.JSTAGE/cpb/53.770 [pii]
AID - 10.1248/cpb.53.770 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 2005 Jul;53(7):770-5. doi: 10.1248/cpb.53.770.

PMID- 32681774
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20210707
IS  - 2363-8915 (Electronic)
IS  - 2363-8915 (Linking)
VI  - 35
IP  - 3
DP  - 2020 Jul 20
TI  - Potential drug-drug interactions in ICU patients: a retrospective study.
LID - 10.1515/dmpt-2020-0114 [doi]
AB  - Objectives A "potential drug-drug interaction" (pDDI) is the possibility one drug 
      has to alter the effects of another when both are administered simultaneously. 
      Intensive care unit (ICU) patients are especially prone to these pDDIs. This 
      study aimed to determine the frequency and severity of pDDIs during the 
      hospitalization of patients in the ICU. Methods This study was conducted 
      retrospectively in three hospitals, including both governmental and 
      non-governmental hospitals in Nablus, Palestine, over the course of six months; 
      starting in January 2018 and ending in June 2018. The sample size included 232 
      ICU patients, and medications prescribed during the hospitalization of these 
      patients were evaluated for pDDIs using the drugs.com application. Results A 
      total of 167 patients (72%) were found to have at least one pDDI, while the total 
      number of pDDIs in the study was 422, resulting in an average of 1.82 pDDIs per 
      patient. Out of the total identified pDDIs, 41 interactions (9.7%) were major 
      interactions, 281 (66.6%) were moderate interactions and 100 (23.7%) were minor 
      interactions. The past medical history of these patients showed that many had 
      hypertension (29%), diabetes mellitus (25%) and ischemic heart disease (10%). A 
      serious combination, enoxaparin and aspirin, was found in six patients. 
      Furthermore, as the number of administered drugs increased, the number of 
      interactions increased as well. Conclusions The pDDIs are common in ICU patients. 
      The most common and clinically most important pDDIs require special attention. 
      Polypharmacy significantly increases the number and level of pDDIs, especially in 
      patients with multiple chronic illnesses. Adequate knowledge regarding the most 
      common pDDIs is necessary to enable healthcare professionals to implement ICU 
      strategies that ensure patient safety.
FAU - Ali, Iyad
AU  - Ali I
AUID- ORCID: 0000-0002-3921-6859
AD  - Department of Biochemistry, Faculty of Medicine and Health Sciences, An-Najah 
      National University, Nablus, Palestine.
FAU - Bazzar, Alaa
AU  - Bazzar A
AD  - Department of Human Medicine, Faculty of Medicine and Health Sciences, An-Najah 
      National University, Nablus, Palestine.
FAU - Hussein, Nadine
AU  - Hussein N
AD  - Department of Human Medicine, Faculty of Medicine and Health Sciences, An-Najah 
      National University, Nablus, Palestine.
FAU - Sahhar, Emile
AU  - Sahhar E
AD  - Department of Human Medicine, Faculty of Medicine and Health Sciences, An-Najah 
      National University, Nablus, Palestine.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - Germany
TA  - Drug Metab Pers Ther
JT  - Drug metabolism and personalized therapy
JID - 101653409
RN  - 0 (Enoxaparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Diabetes Mellitus/drug therapy
MH  - Drug Interactions
MH  - Enoxaparin/administration & dosage/*adverse effects
MH  - *Hospitalization
MH  - Humans
MH  - Hypertension/drug therapy
MH  - *Intensive Care Units
MH  - Myocardial Ischemia/drug therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Palestine
OT  - drug-drug interaction
OT  - intensive care unit
OT  - patient
EDAT- 2020/07/19 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/07/19 06:00
PHST- 2020/04/11 00:00 [received]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/07/19 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/07/19 06:00 [entrez]
AID - dmpt-2020-0114 [pii]
AID - 10.1515/dmpt-2020-0114 [doi]
PST - epublish
SO  - Drug Metab Pers Ther. 2020 Jul 20;35(3). doi: 10.1515/dmpt-2020-0114.

PMID- 17250878
OWN - NLM
STAT- MEDLINE
DCOM- 20071018
LR  - 20131121
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 120
IP  - 4
DP  - 2007
TI  - Platelet adhesion in atrial fibrillation.
PG  - 623-9
AB  - BACKGROUND: Increased platelet activation has been reported in nonvalvular atrial 
      fibrillation (AF) but it remains unclear whether or not this is due to the 
      underlying cardiovascular diseases, clinical subtype of AF and the influence of 
      anti-thrombotic therapy. METHODS: Platelet adhesion in AF patients was assessed 
      using a 'platelet adhesion assay', and compared to both 'healthy controls' and 
      'disease controls' (patients with hypertension, coronary artery disease, diabetes 
      or stroke but in sinus rhythm). RESULTS: AF patients on no anti-thrombotic 
      treatment (N=20) had increased platelet adhesion compared to 'healthy controls' 
      (N=57) (p=0.044). Initiating treatment with both aspirin and warfarin resulted in 
      significant reduction in platelet adhesion in AF patients (p=0.014 and 0.019 
      respectively). AF patients on optimal anti-thrombotic therapy (N=98) had no 
      significant difference in platelet adhesion compared to 'healthy controls' and 
      'disease controls' (p=0.312). Platelet adhesion failed to distinguish between 
      'high-risk' (i.e. CHADS score > or = 2) and 'low-risk' (i.e. CHADS score < 2) AF 
      patients (p=0.352). Amongst the clinical parameters that contribute to increased 
      stroke risk in AF, platelet adhesion was only correlated with age (r=0.215, 
      p=0.034), and not with other stroke risk factors. There was no significant 
      difference in platelet adhesion between paroxysmal and permanent AF (p=0.618). 
      CONCLUSION: There is a significant, albeit weak, excess of platelet adhesion in 
      AF patients on no anti-thrombotic therapy compared to 'healthy controls'. In 
      optimally treated AF patients, platelet adhesion is not different to both 
      'healthy' and 'disease controls'. It is possible that abnormal platelet adhesion 
      does not significantly contribute to the increased risk of stroke and 
      thromboembolism that persists despite anti-thrombotic treatment in AF or in 
      identifying 'high-risk' AF patients.
FAU - Choudhury, Anirban
AU  - Choudhury A
AD  - Haemostasis Thrombosis and Vascular Biology Unit, University Department of 
      Medicine, City Hospital, Birmingham B18 7QH, UK.
FAU - Chung, Irene
AU  - Chung I
FAU - Blann, Andrew
AU  - Blann A
FAU - Lip, Gregory Y H
AU  - Lip GY
LA  - eng
PT  - Journal Article
DEP - 20070123
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aspirin/pharmacology/therapeutic use
MH  - Atrial Fibrillation/*blood
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Adhesiveness/drug effects/*physiology
MH  - Risk Factors
MH  - Warfarin/pharmacology/therapeutic use
EDAT- 2007/01/26 09:00
MHDA- 2007/10/19 09:00
CRDT- 2007/01/26 09:00
PHST- 2006/08/16 00:00 [received]
PHST- 2006/11/06 00:00 [revised]
PHST- 2006/12/04 00:00 [accepted]
PHST- 2007/01/26 09:00 [pubmed]
PHST- 2007/10/19 09:00 [medline]
PHST- 2007/01/26 09:00 [entrez]
AID - S0049-3848(06)00516-0 [pii]
AID - 10.1016/j.thromres.2006.12.008 [doi]
PST - ppublish
SO  - Thromb Res. 2007;120(4):623-9. doi: 10.1016/j.thromres.2006.12.008. Epub 2007 Jan 
      23.

PMID- 23639713
OWN - NLM
STAT- MEDLINE
DCOM- 20131118
LR  - 20131121
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 33
IP  - 2
DP  - 2013 May
TI  - Cardiovascular prophylaxis and aspirin "allergy".
PG  - 263-74
LID - S0889-8561(12)00144-0 [pii]
LID - 10.1016/j.iac.2012.11.004 [doi]
AB  - Aspirin is an important antiplatelet agent in the treatment of cardiovascular 
      disease. Aspirin "allergy" often directs the physician away from this potentially 
      life-saving modality. The majority of patients with a history of "reactions to 
      aspirin" have aspirin/nonsteroidal anti-inflammatory drug (NSAID)-induced 
      gastritis, easy bruisability, or other side effects. The minority of these 
      patients has a "true allergy," referred to as a hypersensitivity reaction. The 
      former group can be started on aspirin without the need for special challenge. 
      Adding a proton-pump inhibitor can often mitigate the gastrointestinal side 
      effects. Patients with aspirin hypersensitivity can be safely challenged with 
      aspirin.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Woessner, Katharine M
AU  - Woessner KM
AD  - Division of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, CA 92130, 
      USA. Woessner.katharine@scrippshealth.org
FAU - Simon, Ronald A
AU  - Simon RA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20121227
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*complications/*drug therapy
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/*complications/diagnosis/*prevention & control
MH  - Humans
MH  - Premedication
EDAT- 2013/05/04 06:00
MHDA- 2013/11/19 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/05/04 06:00 [entrez]
PHST- 2013/05/04 06:00 [pubmed]
PHST- 2013/11/19 06:00 [medline]
AID - S0889-8561(12)00144-0 [pii]
AID - 10.1016/j.iac.2012.11.004 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2013 May;33(2):263-74. doi: 
      10.1016/j.iac.2012.11.004. Epub 2012 Dec 27.

PMID- 17444807
OWN - NLM
STAT- MEDLINE
DCOM- 20070607
LR  - 20171116
IS  - 1080-7683 (Print)
IS  - 1080-7683 (Linking)
VI  - 23
IP  - 2
DP  - 2007 Apr
TI  - Susceptibility of the ocular lens to nitric oxide: implications in 
      cataractogenesis.
PG  - 188-95
AB  - Oxides of nitrogen, such as nitric oxide (NO), are now biologically referred to 
      as reactive nitrogen species. The generation of NO gives rise to several other 
      reactive species, such as NO+, NO-, NO2, N2O3, and ONOO- and so forth, which are 
      all capable of inflicting tissue damage. Indeed, NO generation is known to be 
      associated with retinal degeneration and glaucoma. Its level has also been found 
      to increase in the aqueous and vitreous humors in diabetes. We hypothesize that 
      such an increase would have a detrimental effect on the biochemistry and 
      metabolism of tissues, including the lens, bathed by the aqueous containing 
      elevated levels of NO. The primary aim of our investigations was, therefore, to 
      examine the susceptibility of the lens to damage by NO in vitro in the presence 
      of nitroaspirin, a novel NO donating agent. The extent of physiologic damage to 
      the lens was initially assessed by determining the integrity of its active 
      transport mechanism. The overall status of tissue metabolism was determined by 
      measuring the adenosine triphosphate (ATP) levels. The levels of glutathione 
      (GSH) and glutathione disulfide, reflecting the status of its antioxidant 
      reserve, were also determined. That NO is indeed deleterious to the lens was 
      apparent by the inhibition of the active transport of Rb(+). This was associated 
      with a substantial decrease in the contents of ATP and GSH, the decrease in the 
      latter directly suggesting that the NO effects are caused by oxidative stress. 
      That the effects are caused by NO generated from nitroaspirin was proven by a 
      substantial increase in NO level in the medium during incubation of the lenses 
      with nitroaspirin, as compared to the controls. The results, therefore, were 
      highly suggestive of a contribution of the oxides of nitrogen in cataract 
      formation associated with diabetes and other aging diseases.
FAU - Varma, Shambhu D
AU  - Varma SD
AD  - Department of Ophthalmology and Visual Sciences, University of Maryland School of 
      Medicine, Baltimore, MD 21201, USA. svarma2384@aol.com
FAU - Hegde, Kavita R
AU  - Hegde KR
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Ocul Pharmacol Ther
JT  - Journal of ocular pharmacology and therapeutics : the official journal of the 
      Association for Ocular Pharmacology and Therapeutics
JID - 9511091
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Free Radicals)
RN  - 0 (Reactive Nitrogen Species)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - EH04H13L6B (nitroaspirin)
RN  - GAN16C9B8O (Glutathione)
RN  - MLT4718TJW (Rubidium)
RN  - R16CO5Y76E (Aspirin)
RN  - ULW86O013H (Glutathione Disulfide)
SB  - IM
MH  - Adenosine Triphosphate/metabolism
MH  - Aging
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism/pharmacology
MH  - Aspirin/*analogs & derivatives/metabolism/pharmacology
MH  - Biological Transport/drug effects
MH  - Cataract/*etiology
MH  - Diabetes Complications/physiopathology
MH  - Free Radicals
MH  - Glutathione/metabolism
MH  - Glutathione Disulfide/metabolism
MH  - Lens, Crystalline/*metabolism
MH  - Nitric Oxide/*pharmacology
MH  - *Oxidative Stress
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reactive Nitrogen Species
MH  - Rubidium/pharmacokinetics
EDAT- 2007/04/21 09:00
MHDA- 2007/06/08 09:00
CRDT- 2007/04/21 09:00
PHST- 2007/04/21 09:00 [pubmed]
PHST- 2007/06/08 09:00 [medline]
PHST- 2007/04/21 09:00 [entrez]
AID - 10.1089/jop.2006.0124 [doi]
PST - ppublish
SO  - J Ocul Pharmacol Ther. 2007 Apr;23(2):188-95. doi: 10.1089/jop.2006.0124.

PMID- 10229733
OWN - NLM
STAT- MEDLINE
DCOM- 19990527
LR  - 20210105
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 30
IP  - 5
DP  - 1999 May
TI  - Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute 
      ischemic stroke.
PG  - 993-6
AB  - BACKGROUND AND PURPOSE: Diaspirin cross-linked hemoglobin (DCLHb) is a purified, 
      cell-free human hemoglobin solution. In animal stroke models its use led to a 
      significant reduction in the extent of brain injury. The primary objective of 
      this study was to evaluate the safety of DCLHb in patients with acute ischemic 
      stroke. METHODS: DCLHb or saline was administered to 85 patients with acute 
      ischemic stroke in the anterior circulation, within 18 hours of onset of 
      symptoms, in a multicenter, randomized, single-blind, dose-finding, controlled 
      safety trial, consisting of 3 parts: 12 doses of 25, 50, and 100 mg/kg DCLHb over 
      72 hours. RESULTS: DCLHb caused a rapid rise in mean arterial blood pressure. The 
      pressor effect was not accompanied by complications or excessive need for 
      antihypertensive treatment. Two patients in the 100 mg/kg group had adverse 
      events that were possibly drug related: one suffered fatal brain and pulmonary 
      edema, the other transient renal and pancreatic insufficiency. Multivariate 
      logistic regression analysis showed that a severe stroke at baseline and 
      treatment with DCLHb (OR, 4.0; CI, 1.4 to 12.0) were independent predictors of a 
      worse outcome (Rankin Scale score of 3 to 6) at 3 months. CONCLUSIONS: Outcome 
      scale scores were worse in the DCLHb group, and more serious adverse events and 
      deaths occurred in DCLHb-treated patients than in control patients. We recommend 
      that additional safety studies be performed, preferably with a second generation, 
      genetically engineered hemoglobin.
FAU - Saxena, R
AU  - Saxena R
AD  - Department of Neurology, University Hospital Dijkzigt, Rotterdam, the 
      Netherlands. Koudstaal@neur.azr.nl
FAU - Wijnhoud, A D
AU  - Wijnhoud AD
FAU - Carton, H
AU  - Carton H
FAU - Hacke, W
AU  - Hacke W
FAU - Kaste, M
AU  - Kaste M
FAU - Przybelski, R J
AU  - Przybelski RJ
FAU - Stern, K N
AU  - Stern KN
FAU - Koudstaal, P J
AU  - Koudstaal PJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 2000 Feb;31(2):546-8. PMID: 10657437
MH  - Acute Disease
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/*analogs & derivatives
MH  - Blood Pressure
MH  - Blood Substitutes/*administration & dosage/adverse effects
MH  - Brain Ischemia/*drug therapy
MH  - Cerebrovascular Disorders/*drug therapy
MH  - Female
MH  - Hemoglobins/*administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Single-Blind Method
MH  - Treatment Outcome
EDAT- 1999/05/07 02:01
MHDA- 2000/04/25 09:00
CRDT- 1999/05/07 02:01
PHST- 1999/05/07 02:01 [pubmed]
PHST- 2000/04/25 09:00 [medline]
PHST- 1999/05/07 02:01 [entrez]
AID - 10.1161/01.str.30.5.993 [doi]
PST - ppublish
SO  - Stroke. 1999 May;30(5):993-6. doi: 10.1161/01.str.30.5.993.

PMID- 8687258
OWN - NLM
STAT- MEDLINE
DCOM- 19960822
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 156
IP  - 14
DP  - 1996 Jul 22
TI  - Prehospital administration of aspirin in patients with unstable angina and acute 
      myocardial infarction.
PG  - 1506-10
AB  - Both experimental and clinical studies suggest that the prehospital 
      administration of aspirin may be beneficial in patients with unstable angina and 
      acute myocardial infarction. Experimental studies indicate that within 1 hour of 
      aspirin administration, serum levels peak and significant inhibition of platelet 
      aggregation occurs. Clinical studies demonstrate that early treatment with 
      aspirin reduces mortality and reinfarction rates in patients with unstable angina 
      and acute myocardial infarction. However, these same studies also indicate that 
      prolonged delays often occur before in-hospital therapy with aspirin is 
      initiated. Since the potential benefits are great and the risks and costs are 
      low, physicians should encourage the prehospital administration of aspirin in 
      patients with symptoms suggestive of unstable angina or acute myocardial 
      infarction.
FAU - Eisenberg, M J
AU  - Eisenberg MJ
AD  - Department of Cardiology, Cleveland Clinic Foundation, Ohio, USA.
FAU - Topal, E J
AU  - Topal EJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/*drug therapy/economics
MH  - Animals
MH  - Aspirin/*administration & dosage/economics
MH  - Clinical Trials as Topic
MH  - Hospitalization
MH  - Humans
MH  - Myocardial Infarction/*drug therapy/economics
MH  - Recurrence
MH  - Time Factors
RF  - 34
EDAT- 1996/07/22 00:00
MHDA- 1996/07/22 00:01
CRDT- 1996/07/22 00:00
PHST- 1996/07/22 00:00 [pubmed]
PHST- 1996/07/22 00:01 [medline]
PHST- 1996/07/22 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1996 Jul 22;156(14):1506-10.

PMID- 3433258
OWN - NLM
STAT- MEDLINE
DCOM- 19880304
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 48
IP  - 3
DP  - 1987 Nov 1
TI  - Effective antiplatelet drug concentrations in experimental arterial 
      thromboembolism.
PG  - 337-48
AB  - Although drugs that modify platelet function have been widely studied as 
      antithrombotic agents in experimental and clinical studies, there is limited 
      information regarding the relationship between in vivo drug blood concentrations 
      and antithrombotic efficacy. This study compared the pharmacokinetics of three 
      antiplatelet agents with their antithrombotic effects in an experimental model of 
      arterial thromboembolism in baboons. Thrombus formation was measured as 
      steady-state platelet utilization induced by thrombogenic arteriovenous cannulae. 
      The drugs studied were aspirin, dipyridamole and sulfinpyrazone. Aspirin was 
      administered in daily doses of 20 mg/kg, dipyridamole in daily doses of 2.5 and 
      10 mg/kg, and sulfinpyrazone in daily doses of 20 and 100 mg/kg; each drug was 
      given in two equal doses per day. Multiple blood samples were collected for drug 
      analysis after steady-state had been reached. The average concentrations of 
      dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 
      mg/kg/day. These concentrations were associated with 28 and 87% inhibition of 
      cannula platelet consumption, respectively. The average steady-state 
      concentrations of acetylsalicylic and salicylic acids were 0.67 +/- 0.80 and 3.76 
      +/- 2.60 micrograms/ml, respectively, after 20 mg/kg/day. Aspirin had no effect 
      on platelet consumption. Average concentrations of sulfinpyrazone were 1.05 +/- 
      0.45 and 12.25 +/- 5.73 micrograms/ml after 20 and 100 mg/kg/day, with 
      significant concentrations of the sulfide metabolite. These concentrations were 
      associated with 23 and 85% inhibition of platelet consumption, respectively. No 
      significant pharmacokinetic interactions were observed after concurrent 
      administration of aspirin and dipyridamole or sulfinpyrazone. As the experimental 
      model used involves thrombus formation on an artificial surface, it is likely 
      that these results are most relevant to patients with arterial prosthetic 
      devices.
FAU - Bjornsson, T D
AU  - Bjornsson TD
AD  - Department of Medicine, Duke University Medical Center, Durham, North Carolina.
FAU - Hanson, S R
AU  - Hanson SR
FAU - Harker, L A
AU  - Harker LA
LA  - eng
GR  - HL 24343/HL/NHLBI NIH HHS/United States
GR  - HL 31469/HL/NHLBI NIH HHS/United States
GR  - HL 31950/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Animals
MH  - Arteriovenous Shunt, Surgical
MH  - Aspirin/blood/*therapeutic use
MH  - Dipyridamole/blood/*therapeutic use
MH  - Kinetics
MH  - Male
MH  - Papio
MH  - Sulfinpyrazone/blood/*therapeutic use
MH  - Thromboembolism/*blood/drug therapy
EDAT- 1987/11/01 00:00
MHDA- 1987/11/01 00:01
CRDT- 1987/11/01 00:00
PHST- 1987/11/01 00:00 [pubmed]
PHST- 1987/11/01 00:01 [medline]
PHST- 1987/11/01 00:00 [entrez]
AID - 10.1016/0049-3848(87)90446-4 [doi]
PST - ppublish
SO  - Thromb Res. 1987 Nov 1;48(3):337-48. doi: 10.1016/0049-3848(87)90446-4.

PMID- 22654634
OWN - NLM
STAT- MEDLINE
DCOM- 20120927
LR  - 20220408
IS  - 1537-744X (Electronic)
IS  - 2356-6140 (Print)
IS  - 1537-744X (Linking)
VI  - 2012
DP  - 2012
TI  - Effect of aspirin on cell growth of human MG-63 osteosarcoma line.
PG  - 834246
LID - 10.1100/2012/834246 [doi]
LID - 834246
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used in bone tissue 
      repair treatment for their pharmacological action. The objective of this study 
      was to determine the effect of aspirin, on osteoblast growth, using MG63 cell 
      line as osteoblast model. MTT spectrophotometry results showed that 20, 100, and 
      1000 μM aspirin doses have an inhibitory effect on growth. Cell cycle analysis 
      revealed that aspirin doses of 100 and 1000 μM arrest the cell cycle in phase 
      GO/G1. Parallel apoptosis/necrosis studies showed no changes in comparison to 
      control cells after treatment with 1 or 10 μM aspirin but a significantly 
      increased percentage of cells in apoptosis at doses of 20, 100, and 1000 μM. We 
      highlight that treatment of osteoblast-like cells with 1000 μM aspirin increased 
      not only the percentage of cells in apoptosis but also the percentage of necrotic 
      cells, which was not observed in aspirin treatments at lower doses.
FAU - De Luna-Bertos, E
AU  - De Luna-Bertos E
AD  - Biomedical Group, BIO277, Department of Nursing, Faculty of Health Sciences, 
      University of Granada, 18071 Granada, Spain.
FAU - Ramos-Torrecillas, J
AU  - Ramos-Torrecillas J
FAU - García-Martínez, O
AU  - García-Martínez O
FAU - Díaz-Rodríguez, L
AU  - Díaz-Rodríguez L
FAU - Ruiz, C
AU  - Ruiz C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120502
PL  - United States
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Aspirin/*pharmacology
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Osteosarcoma/pathology
PMC - PMC3354653
EDAT- 2012/06/02 06:00
MHDA- 2012/09/28 06:00
CRDT- 2012/06/02 06:00
PHST- 2011/10/11 00:00 [received]
PHST- 2011/12/22 00:00 [accepted]
PHST- 2012/06/02 06:00 [entrez]
PHST- 2012/06/02 06:00 [pubmed]
PHST- 2012/09/28 06:00 [medline]
AID - 10.1100/2012/834246 [doi]
PST - ppublish
SO  - ScientificWorldJournal. 2012;2012:834246. doi: 10.1100/2012/834246. Epub 2012 May 
      2.

PMID- 2104365
OWN - NLM
STAT- MEDLINE
DCOM- 19911022
LR  - 20170310
IS  - 0011-4553 (Print)
IS  - 0011-4553 (Linking)
VI  - 43
IP  - 6
DP  - 1990 Jun
TI  - [Solcoseryl--dental adhesive paste--in the treatment of postextraction 
      alveolitis].
PG  - 334-41
AB  - After a study in three maxillofacial surgery teaching hospital departments the 
      authors evaluated the usefulness of Solcoseryl dental adhesive paste as compared 
      to Apernyl in the treatment of postextraction alveolitis. Solcoseryl paste was 
      found to shorten the healing period by about 50% in comparison with Apernyl.
FAU - Kryst, L
AU  - Kryst L
FAU - Kowalik, S
AU  - Kowalik S
FAU - Bartkowski, S
AU  - Bartkowski S
FAU - Henning, G
AU  - Henning G
LA  - pol
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Solcoseryl--dentystyczna pasta przylegajaca--w leczeniu poekstrakcyjnego 
      zapalenia zebodołu.
PL  - Poland
TA  - Czas Stomatol
JT  - Czasopismo stomatologiczne
JID - 2984742R
RN  - 0 (Drug Combinations)
RN  - 0 (Parabens)
RN  - 37239-28-4 (Actihaemyl)
RN  - 57762-41-1 (aspirin, 4-hydroxybenzoic acid propyl ester, drug combination)
RN  - R16CO5Y76E (Aspirin)
MH  - Actihaemyl/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Combinations
MH  - Dry Socket/*drug therapy
MH  - Humans
MH  - Parabens/*therapeutic use
MH  - Wound Healing
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
PST - ppublish
SO  - Czas Stomatol. 1990 Jun;43(6):334-41.

PMID- 28213669
OWN - NLM
STAT- MEDLINE
DCOM- 20171012
LR  - 20181202
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Linking)
VI  - 19
IP  - 2
DP  - 2017 Feb
TI  - Aspirin Use Prior to Coronary Artery Bypass Grafting Surgery: a Systematic 
      Review.
PG  - 18
LID - 10.1007/s11886-017-0822-5 [doi]
AB  - PURPOSE OF REVIEW: Aspirin use before coronary artery bypass graft (CABG) surgery 
      has been a puzzling question for years. Controversy existed regarding the overall 
      benefits vs. risk of pre-operative aspirin use and was translated to conflicting 
      guidelines from major societies. RECENT FINDINGS: Observational studies have 
      suggested a reduced mortality with pre-operative aspirin use. A meta-analysis of 
      randomized controlled trials showed increased risk of post-operative bleeding 
      with aspirin, with no associated increased mortality risk. A recent large 
      randomized controlled trial did not find a significant difference in bleeding 
      risk or post-operative mortality with pre-CABG aspirin use. The results of 
      available studies showed a beneficial effect with pre-CABG aspirin use by 
      decreasing thrombotic complications and perioperative myocardial infarction, with 
      an associated adverse risk of bleeding that did not affect mortality rates. Given 
      overall benefit-risk assessment, we are in favor of pre-operative aspirin use in 
      CABG patients.
FAU - Elbadawi, Ayman
AU  - Elbadawi A
AD  - Department of Medicine, Rochester General Hospital, Rochester, NY, USA.
AD  - Department of Cardiovascular Medicine, Ain Shams University, Cairo, Egypt.
FAU - Saad, Marwan
AU  - Saad M
AD  - Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, 
      4301 W Markham St, Little Rock, AR, 72205,, USA.
FAU - Nairooz, Ramez
AU  - Nairooz R
AD  - Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, 
      4301 W Markham St, Little Rock, AR, 72205,, USA. ramez.nairooz@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Coronary Artery Disease/*therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Myocardial Infarction/chemically induced
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Postoperative Hemorrhage/chemically induced
MH  - Practice Guidelines as Topic
MH  - Preoperative Care
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiac surgery
OT  - Coronary artery bypass graft
OT  - Pre-operative
EDAT- 2017/02/19 06:00
MHDA- 2017/10/13 06:00
CRDT- 2017/02/19 06:00
PHST- 2017/02/19 06:00 [entrez]
PHST- 2017/02/19 06:00 [pubmed]
PHST- 2017/10/13 06:00 [medline]
AID - 10.1007/s11886-017-0822-5 [pii]
AID - 10.1007/s11886-017-0822-5 [doi]
PST - ppublish
SO  - Curr Cardiol Rep. 2017 Feb;19(2):18. doi: 10.1007/s11886-017-0822-5.

PMID- 36047054
OWN - NLM
STAT- MEDLINE
DCOM- 20220908
LR  - 20221018
IS  - 1940-6215 (Electronic)
IS  - 1940-6215 (Linking)
VI  - 15
IP  - 9
DP  - 2022 Sep 1
TI  - Aspirin for Colorectal Cancer Prevention: Age Matters.
PG  - 565-567
LID - 10.1158/1940-6207.CAPR-22-0176 [doi]
AB  - Further data from the Aspirin in Reducing Events in the Elderly (ASPREE) trial 
      heightens the concern regarding aspirin use for colorectal cancer prevention in 
      elderly subjects. A 95-variant colorectal cancer polygenic risk score (PRS) 
      failed to identify a subset of elderly individuals who could have benefited from 
      aspirin preventive activity. Further research to define predictive biomarkers of 
      aspirin preventive activity is needed. Meanwhile, the use of aspirin for 
      colorectal cancer prevention in the elderly becomes more questionable. See Cancer 
      Prev Res 15(7):447-53.
CI  - ©2022 American Association for Cancer Research.
FAU - Shureiqi, Imad
AU  - Shureiqi I
AUID- ORCID: 0000-0003-2019-938X
AD  - Department of Internal Medicine, Division of Hematology and Oncology, University 
      of Michigan, Ann Arbor, Michigan.
AD  - Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
LA  - eng
PT  - Comment
PT  - Editorial
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Cancer Prev Res (Phila). 2022 Jul 5;15(7):447-454. PMID: 35348611
MH  - Aged
MH  - *Aspirin/therapeutic use
MH  - *Colorectal Neoplasms/prevention & control
MH  - Double-Blind Method
MH  - Genetic Predisposition to Disease
MH  - Humans
EDAT- 2022/09/02 06:00
MHDA- 2022/09/09 06:00
CRDT- 2022/09/01 03:23
PHST- 2022/04/18 00:00 [received]
PHST- 2022/06/23 00:00 [revised]
PHST- 2022/06/30 00:00 [accepted]
PHST- 2022/09/01 03:23 [entrez]
PHST- 2022/09/02 06:00 [pubmed]
PHST- 2022/09/09 06:00 [medline]
AID - 708162 [pii]
AID - 10.1158/1940-6207.CAPR-22-0176 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2022 Sep 1;15(9):565-567. doi: 
      10.1158/1940-6207.CAPR-22-0176.

PMID- 23076773
OWN - NLM
STAT- MEDLINE
DCOM- 20141003
LR  - 20140228
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 20
IP  - 3
DP  - 2014 Apr
TI  - Aspirin-induced microscopic surface changes stimulate thrombopoiesis in rat 
      megakaryocytes.
PG  - 318-25
LID - 10.1177/1076029612461845 [doi]
AB  - During the process of thrombopoiesis, invaginations of the plasma membrane occur 
      in megakaryocytes. Since acetylsalicylic acid (aspirin), the most commonly used 
      anti-inflammatory and antiplatelet drug, interacts with the lipid bilayers of the 
      plasma membranes, this drug would affect the process of thrombopoiesis. In the 
      present study, employing a standard patch-clamp whole-cell recording technique, 
      we examined the effects of aspirin on delayed rectifier K(+)-channel (Kv1.3) 
      currents and the membrane capacitance in megakaryocytes. Using confocal imaging 
      of di-8-butyl-amino-naphthyl-ethylene-pyridinium-propyl-sulfonate (di-8-ANEPPS) 
      staining, we also monitored the membrane invaginations in megakaryocytes. Aspirin 
      suppressed both the peak and the pulse-end currents with a significant increase 
      in the membrane capacitance. Massive di-8-ANEPPS staining after treatment with 
      aspirin demonstrated the impaired membrane micro-architecture of megakaryocytes. 
      This study demonstrated for the first time that aspirin induces microscopic 
      surface changes in megakaryocytes. Such surface changes were thought to stimulate 
      thrombopoiesis in megakaryocytes as detected by the increase in the membrane 
      invaginations.
FAU - Kazama, Itsuro
AU  - Kazama I
AD  - 1Department of Physiology I, Tohoku University Graduate School of Medicine, 
      Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan.
FAU - Maruyama, Yoshio
AU  - Maruyama Y
FAU - Nakamichi, Satoshi
AU  - Nakamichi S
LA  - eng
PT  - Journal Article
DEP - 20121017
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Male
MH  - Megakaryocytes/*drug effects/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Thrombopoiesis/*drug effects
OTO - NOTNLM
OT  - acetylsalicylic acid (aspirin)
OT  - megakaryocytes
OT  - membrane capacitance
OT  - membrane invaginations
OT  - thrombopoiesis
EDAT- 2012/10/19 06:00
MHDA- 2014/10/04 06:00
CRDT- 2012/10/19 06:00
PHST- 2012/10/19 06:00 [entrez]
PHST- 2012/10/19 06:00 [pubmed]
PHST- 2014/10/04 06:00 [medline]
AID - 1076029612461845 [pii]
AID - 10.1177/1076029612461845 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2014 Apr;20(3):318-25. doi: 10.1177/1076029612461845. 
      Epub 2012 Oct 17.

PMID- 25891049
OWN - NLM
STAT- MEDLINE
DCOM- 20160209
LR  - 20171107
IS  - 1873-2607 (Electronic)
IS  - 0749-3797 (Linking)
VI  - 48
IP  - 5
DP  - 2015 May
TI  - Aspirin use among adults in the U.S.: results of a national survey.
PG  - 501-8
LID - S0749-3797(14)00661-8 [pii]
LID - 10.1016/j.amepre.2014.11.005 [doi]
AB  - INTRODUCTION: The use of aspirin in patients without cardiovascular disease 
      remains controversial. Patients' understanding of the risks and benefits of 
      aspirin likely contribute to the decision of whether or not to use aspirin 
      regularly. The purpose of this study is to assess patients' knowledge of aspirin 
      and identify factors contributing to regular use. METHODS: A survey of U.S. 
      adults aged 45-75 years was performed to ascertain aspirin use and factors that 
      may be associated with use. Multivariate logistic regression was used to identify 
      predictors of current use of aspirin among those with a primary prevention 
      indication. The survey was completed in 2012 with data analysis performed in 
      2013. RESULTS: Among 2,509 respondents, 52% reported current aspirin use. Among 
      2,039 respondents without a history of cardiovascular disease, current use of 
      aspirin was 47%. Regular use of aspirin for primary prevention was associated 
      with the presence of major cardiovascular disease risk factors (OR=3.0, 95% 
      CI=2.4, 3.7), high self-assessed knowledge of aspirin (OR=9.1, 95% CI=5.2, 15.7), 
      and having discussed aspirin therapy with a provider (OR=25.9, 95% CI=19.7, 
      34.1). Several markers of healthy lifestyle choices were also associated with 
      regular use. After multivariate analysis, the strongest independent predictor of 
      regular aspirin use was having discussed aspirin therapy with a provider 
      (OR=23.79, 95% CI=17.8, 31.5). CONCLUSIONS: Approximately half of the nationwide 
      survey of U.S. adults reported regular aspirin use. Among those with a primary 
      prevention indication, having discussed aspirin with a provider was the strongest 
      predictor of regular use.
CI  - Copyright © 2015 American Journal of Preventive Medicine. Published by Elsevier 
      Inc. All rights reserved.
FAU - Williams, Craig D
AU  - Williams CD
AD  - Department of Pharmacy Practice, Oregon State University/Oregon Health & Science 
      University College of Pharmacy, Portland, Oregon. Electronic address: 
      williacr@ohsu.edu.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Division of Gastroenterology, Massachusetts General Hospital, Boston, 
      Massachusetts.
FAU - Elman, Miriam R
AU  - Elman MR
AD  - Department of Pharmacy Practice, Oregon State University/Oregon Health & Science 
      University College of Pharmacy, Portland, Oregon.
FAU - Kristensen, Alyson H
AU  - Kristensen AH
AD  - Partnership for Prevention, Washington, District of Columbia.
FAU - Miser, W Fred
AU  - Miser WF
AD  - Division of Family Medicine, The Ohio State University, Columbus, Ohio.
FAU - Pignone, Michael P
AU  - Pignone MP
AD  - Department of Medicine, University of North Carolina, Chapel Hill, North 
      Carolina.
FAU - Stafford, Randall S
AU  - Stafford RS
AD  - Department of Medicine, Stanford University, Palo Alto, California.
FAU - McGregor, Jessina C
AU  - McGregor JC
AD  - Department of Pharmacy Practice, Oregon State University/Oregon Health & Science 
      University College of Pharmacy, Portland, Oregon.
LA  - eng
GR  - R01 CA137178/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Am J Prev Med
JT  - American journal of preventive medicine
JID - 8704773
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Surveys
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention
MH  - United States
EDAT- 2015/04/22 06:00
MHDA- 2016/02/10 06:00
CRDT- 2015/04/21 06:00
PHST- 2014/07/01 00:00 [received]
PHST- 2014/11/04 00:00 [revised]
PHST- 2014/11/13 00:00 [accepted]
PHST- 2015/04/21 06:00 [entrez]
PHST- 2015/04/22 06:00 [pubmed]
PHST- 2016/02/10 06:00 [medline]
AID - S0749-3797(14)00661-8 [pii]
AID - 10.1016/j.amepre.2014.11.005 [doi]
PST - ppublish
SO  - Am J Prev Med. 2015 May;48(5):501-8. doi: 10.1016/j.amepre.2014.11.005.

PMID- 19286636
OWN - NLM
STAT- MEDLINE
DCOM- 20090513
LR  - 20131121
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
VI  - 29
IP  - 5
DP  - 2009 May
TI  - Effects of aspirin on clot structure and fibrinolysis using a novel in vitro 
      cellular system.
PG  - 712-7
LID - 10.1161/ATVBAHA.109.183707 [doi]
AB  - OBJECTIVES: The purpose of this study was to investigate the direct effects of 
      aspirin on fibrin structure/function. METHODS AND RESULTS: Chinese Hamster Ovary 
      cell lines stably transfected with fibrinogen were grown in the absence (0) and 
      presence of increasing concentrations of aspirin. Fibrinogen was purified from 
      the media using affinity chromatography, and clots were made from recombinant 
      protein. Mean final turbidity [OD(+/-SEM)] was 0.083(+/-0.03), 0.093(+/-0.002), 
      0.101(+/-0.005), and 0.125(+/-0.003) in clots made from 0, 1, 10, and 100 mg/L 
      aspirin-treated fibrinogen, respectively (P<0.05). Permeability coefficient (Ks 
      cm2 x 10(-8)) was 1.68(+/-0.29) and 4.13(+/-0.33) comparing fibrinogen produced 
      from cells grown with 0 mg/L and 100 mg/L aspirin respectively (P<0.05). Scanning 
      electron microscopy confirmed a looser clot structure and increased fiber 
      thickness of clots made from aspirin-treated fibrinogen, whereas rheometer 
      studies showed a significant 30% reduction in clot rigidity. Fibrinolysis was 
      quicker in clots made from aspirin-treated fibrinogen. Ex vivo studies in 3 
      normal volunteers given 150 mg aspirin daily for 1 week demonstrated similar 
      changes in clot structure/function. CONCLUSION: Aspirin directly altered clot 
      structure resulting in the formation of clots with thicker fibers and bigger 
      pores, which are easier to lyse. This study clearly demonstrates an alternative 
      mode of action for aspirin, which should be considered in studies evaluating the 
      biochemical efficacy of this agent.
FAU - Ajjan, R A
AU  - Ajjan RA
AD  - Division of Cardiovascular and Diabetes Research, Leeds Institute for Genetics, 
      Health, and Therapeutics (LIGHT), University of Leeds, UK.
FAU - Standeven, K F
AU  - Standeven KF
FAU - Khanbhai, M
AU  - Khanbhai M
FAU - Phoenix, F
AU  - Phoenix F
FAU - Gersh, K C
AU  - Gersh KC
FAU - Weisel, J W
AU  - Weisel JW
FAU - Kearney, M T
AU  - Kearney MT
FAU - Ariëns, R A S
AU  - Ariëns RA
FAU - Grant, P J
AU  - Grant PJ
LA  - eng
GR  - G0000624/Medical Research Council/United Kingdom
GR  - G121/71/Department of Health/United Kingdom
GR  - G9900904/Medical Research Council/United Kingdom
GR  - HL30954/HL/NHLBI NIH HHS/United States
GR  - British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20090312
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - CHO Cells
MH  - Cricetinae
MH  - Cricetulus
MH  - Fibrinogen/*drug effects
MH  - Fibrinolysis/drug effects
EDAT- 2009/03/17 09:00
MHDA- 2009/05/14 09:00
CRDT- 2009/03/17 09:00
PHST- 2009/03/17 09:00 [entrez]
PHST- 2009/03/17 09:00 [pubmed]
PHST- 2009/05/14 09:00 [medline]
AID - ATVBAHA.109.183707 [pii]
AID - 10.1161/ATVBAHA.109.183707 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2009 May;29(5):712-7. doi: 
      10.1161/ATVBAHA.109.183707. Epub 2009 Mar 12.

PMID- 12803576
OWN - NLM
STAT- MEDLINE
DCOM- 20031027
LR  - 20191025
IS  - 0767-3981 (Print)
IS  - 0767-3981 (Linking)
VI  - 17
IP  - 3
DP  - 2003 Jun
TI  - Differences in the effects of extended-release aspirin and plain-formulated 
      aspirin on prostanoids and nitric oxide in healthy volunteers.
PG  - 363-72
AB  - This study was designed to evaluate the effects of extended-release aspirin on 
      platelet aggregation and the production of prostanoids and nitric oxide. The 
      participants in this double blind, randomized and crossover study were 20 healthy 
      volunteers. Interventions were 150 mg of plain-formulated aspirin (PFASA) and 150 
      mg of extended-release aspirin (ERASA). Blood samples were collected before and 
      10, 20, 60, 120, 240, 480 and 1440 min after the first dose; 3, 7 and 14 days 
      after daily administration and 24 h after the last dose. The main measures were 
      platelet aggregometry, thromboxane B2, 6-keto-prostaglandin (PG) F1alpha and 
      nitric oxide in each control. Platelet aggregation was inhibited by 50% with 
      ERASA, and by 77% with PFASA. No differences were found in chronic treatment. 
      Thromboxane B2 was inhibited more by the latter (51-67%), but 90% inhibition was 
      observed in both groups after 3 days. The levels of 6-keto-PGF1alpha was reduced 
      by 20% with ERASA and by 58% with PFASA. Nitric oxide production increased in 
      both groups, but after 24 h, and 7-14 days, elevated concentrations of nitric 
      oxide were found only in the ERASA. The antiplatelet effects of ERASA provide 
      pharmacological advantages (greater prostacyclin synthesis and prolonged increase 
      in nitric oxide production) over those provided by the plain formulation.
FAU - De La Cruz, J P
AU  - De La Cruz JP
AD  - Department of Pharmacology and Therapeutics, School of Medicine, University of 
      Malaga, 29071 Malaga, Spain. jpcruz@uma.es
FAU - González-Correa, J A
AU  - González-Correa JA
FAU - Guerrero, A
AU  - Guerrero A
FAU - Márquez, E
AU  - Márquez E
FAU - Martos, F
AU  - Martos F
FAU - Sánchez De La Cuesta, F
AU  - Sánchez De La Cuesta F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (6-keto-prostaglandin F2alpha)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 54397-85-2 (Thromboxane B2)
RN  - B7IN85G1HY (Dinoprost)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/blood/metabolism/*pharmacology
MH  - Cross-Over Studies
MH  - Delayed-Action Preparations
MH  - Dinoprost/*antagonists & inhibitors/biosynthesis
MH  - Double-Blind Method
MH  - Epoprostenol/*agonists
MH  - Female
MH  - Humans
MH  - Male
MH  - Nitric Oxide/*agonists/biosynthesis
MH  - Platelet Aggregation Inhibitors/administration & dosage/metabolism/*pharmacology
MH  - Salicylic Acid/blood
MH  - Thromboxane B2/antagonists & inhibitors
EDAT- 2003/06/14 05:00
MHDA- 2003/10/28 05:00
CRDT- 2003/06/14 05:00
PHST- 2003/06/14 05:00 [pubmed]
PHST- 2003/10/28 05:00 [medline]
PHST- 2003/06/14 05:00 [entrez]
AID - 137 [pii]
AID - 10.1046/j.1472-8206.2003.00137.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2003 Jun;17(3):363-72. doi: 
      10.1046/j.1472-8206.2003.00137.x.

PMID- 1558344
OWN - NLM
STAT- MEDLINE
DCOM- 19920507
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 116
IP  - 9
DP  - 1992 May 1
TI  - Failure of aspirin plus dipyridamole to prevent restenosis after carotid 
      endarterectomy.
PG  - 731-6
AB  - OBJECTIVE: To evaluate therapy with aspirin plus dipyridamole in reducing 
      restenosis after carotid endarterectomy. PATIENTS: A total of 163 patients having 
      175 surgical carotid endarterectomies. INTERVENTION: Eighty-three patients (90 
      endarterectomies) were randomly assigned to receive oral aspirin, 325 mg, plus 
      dipyridamole, 75 mg, beginning 12 hours preoperatively, followed by a second dose 
      administered within 8 hours after the operation, and given three times daily 
      thereafter for 1 year. Eighty patients (85 endarterectomies) received placebo 
      medication that was identical in appearance to the study drugs. MEASUREMENTS: 
      After the adequacy of the surgical procedure was confirmed by intraoperative 
      angiography, restenosis at the endarterectomy sites was evaluated using serial 
      duplex ultrasound studies before hospital discharge and at 3-month intervals 
      postoperatively for 1 year. RESULTS: Based on the time for developing 
      identifiable restenosis and on efficacy analysis, greater than 50% restenosis 
      developed in 11 operated vessels (16%) in the treated group and in 10 arteries 
      (14%) in the placebo group, yielding an observed risk increase of 14% (95% CI, 
      -52% to 167%; P greater than 0.2). By intention-to-treat analysis, greater than 
      50% restenosis developed in 16 of 90 operated vessels in treated patients and in 
      10 of 85 arteries in patients receiving placebo (26% for the treated group and 
      12% for the placebo group; P = 0.18, Mantel-Haenszel statistic), representing an 
      observed risk increase of 110% (CI, -5% to 365%). Similar differences were 
      observed for greater than 20% restenosis and for the comparison of patients 
      rather than operated vessels by either intention-to-treat or efficacy analyses. 
      CONCLUSIONS: Because therapy not only failed to reduce carotid restenosis but may 
      have actually increased its frequency, treatment with aspirin plus dipyridamole 
      probably has no clinically important benefit on restenosis in patients having 
      carotid endarterectomy.
FAU - Harker, L A
AU  - Harker LA
AD  - Scripps Clinic and Research Foundation, La Jolla, California.
FAU - Bernstein, E F
AU  - Bernstein EF
FAU - Dilley, R B
AU  - Dilley RB
FAU - Scala, T E
AU  - Scala TE
FAU - Sise, M J
AU  - Sise MJ
FAU - Hye, R J
AU  - Hye RJ
FAU - Otis, S M
AU  - Otis SM
FAU - Roberts, R S
AU  - Roberts RS
FAU - Gent, M
AU  - Gent M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Carotid Stenosis/*prevention & control/surgery
MH  - Combined Modality Therapy
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - *Endarterectomy, Carotid
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Statistics as Topic
MH  - Treatment Outcome
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
AID - 10.7326/0003-4819-116-9-731 [doi]
PST - ppublish
SO  - Ann Intern Med. 1992 May 1;116(9):731-6. doi: 10.7326/0003-4819-116-9-731.

PMID- 6361561
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20220330
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 310
IP  - 4
DP  - 1984 Jan 26
TI  - Effect of dipyridamole and aspirin on late vein-graft patency after coronary 
      bypass operations.
PG  - 209-14
AB  - To study the prevention of occlusion of aortocoronary-artery bypass grafts, we 
      concluded a prospective, randomized, double-blind trial comparing long-term 
      administration of dipyridamole (begun two days before operation) plus aspirin 
      (begun seven hours after operation) with placebo in 407 patients. Results at one 
      month showed a reduction in the rate of graft occlusion in patients receiving 
      dipyridamole and aspirin. At vein-graft angiography performed in 343 patients (84 
      per cent) 11 to 18 months (median, 12 months) after operation, 11 per cent of 478 
      vein-graft distal anastomoses were occluded in the treated group, and 25 per cent 
      of 486 were occluded in the placebo group. The proportion of patients with one or 
      more distal anastomoses occluded was 22 per cent of 171 patients in the treated 
      group and 47 per cent of 172 in the placebo group. All grafts were patent within 
      a month of operation in 94 patients in the placebo group and 116 patients in the 
      treated group; late development of occlusions was reduced from 27 per cent in the 
      placebo group to 16 per cent in the treatment group. The results show that 
      dipyridamole and aspirin continue to be effective in preventing vein-graft 
      occlusion late after operation, and we believe that such treatment should be 
      continued for at least one year.
FAU - Chesebro, J H
AU  - Chesebro JH
FAU - Fuster, V
AU  - Fuster V
FAU - Elveback, L R
AU  - Elveback LR
FAU - Clements, I P
AU  - Clements IP
FAU - Smith, H C
AU  - Smith HC
FAU - Holmes, D R Jr
AU  - Holmes DR Jr
FAU - Bardsley, W T
AU  - Bardsley WT
FAU - Pluth, J R
AU  - Pluth JR
FAU - Wallace, R B
AU  - Wallace RB
FAU - Puga, F J
AU  - Puga FJ
AU  - et al.
LA  - eng
GR  - CRC-RR585/RR/NCRR NIH HHS/United States
GR  - HL-21533/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Lipids)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Clinical Trials as Topic
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/prevention & control
MH  - Prospective Studies
MH  - Random Allocation
MH  - Saphenous Vein/transplantation
MH  - Time Factors
EDAT- 1984/01/26 00:00
MHDA- 2001/03/28 10:01
CRDT- 1984/01/26 00:00
PHST- 1984/01/26 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1984/01/26 00:00 [entrez]
AID - 10.1056/NEJM198401263100401 [doi]
PST - ppublish
SO  - N Engl J Med. 1984 Jan 26;310(4):209-14. doi: 10.1056/NEJM198401263100401.

PMID- 15080402
OWN - NLM
STAT- MEDLINE
DCOM- 20040618
LR  - 20190513
IS  - 1101-1262 (Print)
IS  - 1101-1262 (Linking)
VI  - 14
IP  - 1
DP  - 2004 Mar
TI  - Aspirin and colorectal cancer?
PG  - 105-6
AB  - This paper evaluates aspirin in the reduction of colorectal cancer risk against 
      the nine causality criteria suggested by Bradford-Hill in 1965. Although some 
      questions remain, the evidence is suggestive of a reduction by perhaps 20-30%. 
      Aspirin could make important contributions to public health programmes given that 
      it reduces cardiovascular disease risk and is relatively safe. It is appropriate 
      for bodies such as the World Health Organisation and national governments to 
      begin to consider the future use of aspirin for the reduction of two major 
      sources of death and disability.
FAU - Morgan, Gareth
AU  - Morgan G
AD  - National Public Health Service for Wales, 36 Orchard Street, Swansea SA1 5AQ, UK. 
      gareth.morgan@nphs.wales.nhs.uk
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Public Health
JT  - European journal of public health
JID - 9204966
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Colorectal Neoplasms/*prevention & control
MH  - Evidence-Based Medicine
MH  - Humans
EDAT- 2004/04/15 05:00
MHDA- 2004/06/24 05:00
CRDT- 2004/04/15 05:00
PHST- 2004/04/15 05:00 [pubmed]
PHST- 2004/06/24 05:00 [medline]
PHST- 2004/04/15 05:00 [entrez]
AID - 10.1093/eurpub/14.1.105 [doi]
PST - ppublish
SO  - Eur J Public Health. 2004 Mar;14(1):105-6. doi: 10.1093/eurpub/14.1.105.

PMID- 21030934
OWN - NLM
STAT- MEDLINE
DCOM- 20110210
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 101
IP  - 4
DP  - 2010 Aug
TI  - Aspirin for the prevention of cardiovascular morbidity.
PG  - 205-14
AB  - Aspirin (ASA) use for secondary prevention in patients with cardiovascular (CV) 
      disease is well established through its beneficial effects on the reduction of 
      myocardial infarction, ischemic stroke and CV mortality. This beneficial effect 
      of ASA seems to consistently outweigh the risk in most patient subsets. Current 
      guidelines endorse ASA for primary prevention of CV events in adults who are at 
      moderate-high risk of CV morbidity. Recent emerging data on the efficacy and 
      safety of ASA conflicts with former randomized clinical trials and raises 
      concerns regarding the validity of these recommendations. The following 
      manuscript describes the data emerging from contemporary trials regarding the 
      efficacy and safety of ASA in various patient subsets. The authors propose 
      certain strategies to enhance safety and efficacy in order to augment the 
      beneficial effects of ASA along with other modalities of primary prevention for 
      suitable candidates. When contemplating ASA prescription for primary prevention 
      of CV events, physicians should carefully weigh the potential benefits of risk 
      reduction versus likelihood of harm, mostly related to bleeding complications.
FAU - Sanchez-Ross, M
AU  - Sanchez-Ross M
AD  - University Hospital, UMDNJ, Newark, USA.
FAU - Waller, A H
AU  - Waller AH
FAU - Maher, J
AU  - Maher J
FAU - Klapholz, M
AU  - Klapholz M
FAU - Haider, B
AU  - Haider B
FAU - Kaluski, E
AU  - Kaluski E
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetic Angiopathies/prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/prevention & control
MH  - Thrombosis/prevention & control
EDAT- 2010/10/30 06:00
MHDA- 2011/02/11 06:00
CRDT- 2010/10/30 06:00
PHST- 2010/10/30 06:00 [entrez]
PHST- 2010/10/30 06:00 [pubmed]
PHST- 2011/02/11 06:00 [medline]
AID - R10103070 [pii]
PST - ppublish
SO  - Minerva Med. 2010 Aug;101(4):205-14.

PMID- 290726
OWN - NLM
STAT- MEDLINE
DCOM- 19791227
LR  - 20131121
IS  - 0025-7850 (Print)
IS  - 0025-7850 (Linking)
VI  - 10
IP  - 1-2
DP  - 1979
TI  - A multicenter study for analgesia involving fenoprofen, propoxyphene [alone or in 
      combination] with placebo and aspirin controls in postpartum pain.
PG  - 65-98
AB  - One investigator at each of 4 institutions followed the requirements of a core 
      protocol designed to evaluate propoxyphene napsylate (50, 100 and 150 mg), 
      fenoprofen calcium (200, 400 and 600 mg) and their combination (50/200, 100/400 
      and 150/600 mg) in patients reporting postpartum pain. Placebo and aspirin (650 
      mg) were included as control medications. Analyses were based on subgrouping 
      which isolated individually the interactions between medications and the 
      following factors: dose-observation criteria, the 
      investigator-observer-institution differences, the intensity of pain at the time 
      the medication was given, and postepisiotomy-wound compared to uterine-cramp 
      pain. Each of these factors influenced the absolute scores for analgesia 
      significantly, but had no significant influence on the relative rankings of the 
      medications. The analgesia scores for individual patients in each subgroup were 
      transformed to ridits and then pooled. A linear increase in effectiveness 
      occurred in response to increasing doses of propoxyphene, fenoprofen, and their 
      combination in this dose range. The dose responses were essentially parallel. The 
      combination was more effective than either drug alone.
FAU - Gruber, C M Jr
AU  - Gruber CM Jr
FAU - Bauer, R O
AU  - Bauer RO
FAU - Bettigole, J B
AU  - Bettigole JB
FAU - Lash, A F
AU  - Lash AF
FAU - McDonald, J S
AU  - McDonald JS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Med
JT  - Journal of medicine
JID - 7505566
RN  - 0 (Phenylpropionates)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
RN  - S2F83W92TK (Dextropropoxyphene)
SB  - IM
MH  - Analgesia/*methods
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Dextropropoxyphene/*administration & dosage/therapeutic use
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fenoprofen/*administration & dosage/therapeutic use
MH  - Humans
MH  - Pain/*drug therapy
MH  - Phenylpropionates/*administration & dosage
MH  - Placebos
MH  - *Postpartum Period
MH  - Pregnancy
EDAT- 1979/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - J Med. 1979;10(1-2):65-98.

PMID- 3614506
OWN - NLM
STAT- MEDLINE
DCOM- 19870828
LR  - 20131121
IS  - 0250-4960 (Print)
IS  - 0250-4960 (Linking)
VI  - 8
IP  - 2
DP  - 1987
TI  - [Extrarenal purification in severe salicylate poisoning in adults].
PG  - 55-7
AB  - About a new case of severe salicylate intoxication, the authors wanted to confirm 
      the advantages of extrarenal epuration in some circumstances. Besides of usual 
      treatments, it decreases the severity of this intoxication and the delay in its 
      treatment by reducing quickly blood salicylate level to a moderate or benign rate 
      whose prognosis is really better. Of course, the choice among the most common 
      treatments (hemodialysis, hemoperfusion, peritoneal dialysis) depends with 
      technical disposals, but hemodialysis seems the most efficient with minor risks 
      than the intoxication itself.
FAU - Montagnac, R
AU  - Montagnac R
FAU - Schillinger, F
AU  - Schillinger F
FAU - Milcent, T
AU  - Milcent T
FAU - Turret, M M
AU  - Turret MM
FAU - Dinh, A
AU  - Dinh A
FAU - Brones, B
AU  - Brones B
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - L'épuration extra-rénale dans les intoxications salicylées graves de l'adulte.
PL  - Switzerland
TA  - Nephrologie
JT  - Nephrologie
JID - 8011169
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*poisoning
MH  - Hemoperfusion
MH  - Humans
MH  - Male
MH  - Peritoneal Dialysis
MH  - *Renal Dialysis
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Nephrologie. 1987;8(2):55-7.

PMID- 11340976
OWN - NLM
STAT- MEDLINE
DCOM- 20010712
LR  - 20190822
IS  - 0003-2654 (Print)
IS  - 0003-2654 (Linking)
VI  - 126
IP  - 4
DP  - 2001 Apr
TI  - Fluorescence quenching high-performance thin-layer chromatographic analysis 
      utilizing a scientifically operated charge-coupled device detector.
PG  - 446-50
AB  - A scientifically operated charge-coupled device detector combined with 
      fluorescence quenching high-performance thin-layer chromatographic plates was 
      employed for the detection of organic compounds, The plates were excited with 254 
      nm light from a mercury lamp, and quantitative information was obtained from 
      organic compounds that absorbed the optimum conditions for detection. The linear 
      dynamic range, sensitivity, and reproducibility of the system were evaluated by 
      quantitative analysis of famotidine, acetaminophen, caffeine, and acetylsalicylic 
      acid. The detection limits of the system were found to be in the nanogram range.
FAU - Simon, R E
AU  - Simon RE
AD  - Department of Chemistry, University of Arizona, Tucson, AZ 85721, USA. 
      mbdenton@u.arizona.edu
FAU - Walton, L K
AU  - Walton LK
FAU - Liang, Y
AU  - Liang Y
FAU - Denton, M B
AU  - Denton MB
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - 5QZO15J2Z8 (Famotidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/analysis/chemistry
MH  - Aspirin/analysis/chemistry
MH  - Autoanalysis
MH  - Caffeine/analysis/chemistry
MH  - Chromatography, High Pressure Liquid/instrumentation/*methods
MH  - Chromatography, Thin Layer/instrumentation/*methods
MH  - Famotidine/analysis/chemistry
MH  - Sensitivity and Specificity
MH  - *Signal Processing, Computer-Assisted
EDAT- 2001/05/09 10:00
MHDA- 2001/07/13 10:01
CRDT- 2001/05/09 10:00
PHST- 2001/05/09 10:00 [pubmed]
PHST- 2001/07/13 10:01 [medline]
PHST- 2001/05/09 10:00 [entrez]
AID - 10.1039/b006799g [doi]
PST - ppublish
SO  - Analyst. 2001 Apr;126(4):446-50. doi: 10.1039/b006799g.

PMID- 10100880
OWN - NLM
STAT- MEDLINE
DCOM- 19990514
LR  - 20190720
IS  - 0008-4212 (Print)
IS  - 0008-4212 (Linking)
VI  - 76
IP  - 10-11
DP  - 1998 Oct-Nov
TI  - Nimodipine inhibits the pressor activity of diaspirin-crosslinked hemoglobin 
      (DCLHb) in the rat.
PG  - 983-8
AB  - Impaired nitric oxide (NO) activity is associated with an increase in blood 
      pressure in rats. Voltage-regulated calcium channels are believed to participate 
      in this hemodynamic event. To further test this hypothesis, we examined the 
      effect of nimodipine and verapamil (calcium antagonists) on the pressor activity 
      of diaspirin-crosslinked hemoglobin (DCLHb), a well-known NO scavenger, in 
      anesthetized rats. Nimodipine, the most potent of the two calcium antagonists 
      used, was also tested against phenylephrine (alpha1-adrenoceptor agonist). The 
      pressor effect of DCLHb was reduced markedly by nimodipine and verapamil, whereas 
      that elicited by phenylephrine, particularly the tonic phase of its pressor 
      response, was resistant to blockade by nimodipine. The bradycardia and 
      tachycardia associated with the pressor effects of DCLHb and phenylephrine, 
      respectively, were not affected by nimodipine. The pressor effect elicited by 
      DCLHb and its alteration by nimodipine were also examined in rats pretreated with 
      100% O2. This treatment was found to potentiate the pressor effect of DCLHb. 
      However, this synergism did not impair the inhibitory action of nimodipine 
      towards the pressor activity of DCLHb. Altogether these results suggest that the 
      pressor activity of DCLHb in our animal model might involve the participation of 
      voltage-regulated calcium channels.
FAU - Rioux, F
AU  - Rioux F
AD  - Centre de recherche (Université Laval), Hôtel-Dieu de Québec, QC, Canada.
FAU - St-Pierre, M
AU  - St-Pierre M
FAU - Harvey, N
AU  - Harvey N
FAU - Moisan, S
AU  - Moisan S
FAU - Burhop, K E
AU  - Burhop KE
FAU - Drapeau, G
AU  - Drapeau G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Hemoglobins)
RN  - 0 (Vasoconstrictor Agents)
RN  - 1WS297W6MV (Phenylephrine)
RN  - 57WA9QZ5WH (Nimodipine)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Pressure/*drug effects
MH  - Calcium Channel Blockers/*pharmacology
MH  - Heart Rate/*drug effects
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Nimodipine/*pharmacology
MH  - Oxygen/pharmacology
MH  - Phenylephrine/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Time Factors
MH  - Vasoconstrictor Agents/pharmacology
EDAT- 1999/04/01 00:00
MHDA- 1999/04/01 00:01
CRDT- 1999/04/01 00:00
PHST- 1999/04/01 00:00 [pubmed]
PHST- 1999/04/01 00:01 [medline]
PHST- 1999/04/01 00:00 [entrez]
AID - 10.1139/cjpp-76-10-11-983 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 1998 Oct-Nov;76(10-11):983-8. doi: 
      10.1139/cjpp-76-10-11-983.

PMID- 27100
OWN - NLM
STAT- MEDLINE
DCOM- 19780814
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 234
IP  - 6
DP  - 1978 Jun
TI  - Acetylsalicylic acid hydrolase of gastric mucosa.
PG  - E606-10
AB  - Acetylsalicylic acid hydrolase activity of rabbit fundic gastric mucosa has been 
      isolated from the soluble 100,000 X g supernate. The enzymatic activity was 
      partially purified by ammonium sulfate precipitation. The Km for acetylsalicylate 
      was 2 mM and pH optimum was 8.6. The activity was insensitive to ionic strength, 
      slightly inhibited by inclusion of 100 mM Cl-, and demonstrated no requirement 
      for Ca2+ or Mg2+. Acetylsalicylic acid esterase was markedly inhibited by sodium 
      cholate and sodium dodecyl sulfate. The enzyme was insensitive to sulfhydryl 
      reagents with the exception of p-chloromercuribenzenesulfonic acid, which 
      markedly inhibited the enzyme. Diisopropyl fluorophosphate (DFP) inhibited 
      enzymatic activity with a Ki of 9 X 10(-9)M. Eserine was also inhibitory with a 
      Ki of 0.25 mM. Inhibition by DFP at low concentration and by eserine at 
      millimolar concentrations suggests that this enzyme is related to the group of 
      aliphatic esterases. Identification of potent inhibitors will enable studies to 
      define the role of this enzyme with the use of experimental preparations in which 
      systemic toxicity can be avoided.
FAU - Spenney, J G
AU  - Spenney JG
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 12UHW9R67N (Isoflurophate)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*metabolism
MH  - Carboxylic Ester Hydrolases/antagonists & inhibitors/isolation & 
      purification/*metabolism
MH  - Gastric Mucosa/drug effects/*enzymology
MH  - Hydrogen-Ion Concentration
MH  - Isoflurophate/pharmacology
MH  - Kinetics
MH  - Rabbits
EDAT- 1978/06/01 00:00
MHDA- 1978/06/01 00:01
CRDT- 1978/06/01 00:00
PHST- 1978/06/01 00:00 [pubmed]
PHST- 1978/06/01 00:01 [medline]
PHST- 1978/06/01 00:00 [entrez]
AID - 10.1152/ajpendo.1978.234.6.E606 [doi]
PST - ppublish
SO  - Am J Physiol. 1978 Jun;234(6):E606-10. doi: 10.1152/ajpendo.1978.234.6.E606.

PMID- 699625
OWN - NLM
STAT- MEDLINE
DCOM- 19781220
LR  - 20190907
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 5
IP  - 7
DP  - 1978
TI  - Nephrotoxicity studies on aspirin and diflunisal.
PG  - 515-9
AB  - Some of the difficulties encountered in investigations of long-term drug 
      nephrotoxicity are reviewed, and the evidence for acute and chronic renal damage 
      induced by aspirin is discussed. Two studies were carried out to investigate the 
      acute effects of diflunisal on the kidney, and to compare its effects with those 
      of aspirin. Measurements were made before, during and after drug intake, of 
      epithelial cells and lysosomal enzyme (beta-d-n-acetyl glucosaminidase) excretion 
      in urine. Diflunisal caused no change in cell excretion and no increase in enzyme 
      secretion in 6 normal volunteers. In a comparative study against aspirin, two 
      groups of 12 patients being treated for osteoarthrosis were observed over an 
      8-week period. Enzyme excretion increased in both groups and appeared to be dose 
      related. The increase, however, was relatively greater in the aspirin group. The 
      possible significance of these findings is discussed.
FAU - Dieppe, P A
AU  - Dieppe PA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Analgesics)
RN  - 0 (Biphenyl Compounds)
RN  - R16CO5Y76E (Aspirin)
RN  - V956696549 (Acetylglucosamine)
SB  - IM
MH  - Acetylglucosamine/urine
MH  - Analgesics/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Biphenyl Compounds/*adverse effects/therapeutic use
MH  - Epithelial Cells
MH  - Female
MH  - Humans
MH  - Kidney Diseases/*chemically induced
MH  - Male
MH  - Osteoarthritis/drug therapy
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1185/03007997809108994 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1978;5(7):515-9. doi: 10.1185/03007997809108994.

PMID- 17062325
OWN - NLM
STAT- MEDLINE
DCOM- 20070112
LR  - 20131121
IS  - 1543-5946 (Print)
IS  - 1876-7761 (Linking)
VI  - 4
IP  - 3
DP  - 2006 Sep
TI  - Thirty-day mortality after peptic ulcer bleeding in hospitalized patients 
      receiving low-dose aspirin at time of admission.
PG  - 244-50
AB  - BACKGROUND: Use of low-dose aspirin increases the risk for peptic ulcer bleeding 
      (PUB) by approximately 60%. However, whether use of low-dose aspirin influences 
      the outcome of PUB is not known. OBJECTIVE: The aim of this study was to examine 
      the effect of low-dose aspirin use at the time of hospital admission on 30-day 
      mortality among hospitalized PUB patients. METHODS: This population-based study 
      was conducted using data from the hospital discharge registries in the Danish 
      counties of North Jutland, Aarhus, and Viborg. We identified all hospitalized 
      patients with a first-time diagnosis of PUB and their comorbidities between 1991 
      and 2003. This information was linked with data from the counties' prescription 
      databases and the Danish Civil Registration System to determine the preadmission 
      use of low-dose aspirin (75 or 150 mg) and mortality within 30 days after 
      admission. We calculated mortality ratios (MRs) according to the use of low-dose 
      aspirin, adjusted for age, sex, comorbidity, alcoholism, and use of other 
      PUB-associated or antiulcer drugs. RESULTS: We identified 7204 patients with a 
      discharge diagnosis of PUB (3751 men, 3453 women; median age, 71 years 
      [interquartile range, 62-82 years]). The overall mortality within 30 days after 
      admission with PUB was 10.7%. Among all patients with PUB, 1029 (14.3%) were 
      current (ie, at the time of admission) users of low-dose aspirin and 709 (9.8%) 
      were former low-dose aspirin users, respectively. Compared with those who never 
      used lowdose aspirin, current users had an adjusted 30-day MR of 0.83 (95% CI, 
      0.68-1.01). CONCLUSION: The results of this follow-up study suggest that current 
      use of low-dose aspirin was not associated with increased mortality in these 
      hospitalized patients with PUB.
FAU - Mose, Hanne
AU  - Mose H
AD  - Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Larsen, Mette
AU  - Larsen M
FAU - Riis, Anders
AU  - Riis A
FAU - Johnsen, Søren Paaske
AU  - Johnsen SP
FAU - Thomsen, Reimar Wernich
AU  - Thomsen RW
FAU - Sørensen, Henrik Toft
AU  - Sørensen HT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Geriatr Pharmacother
JT  - The American journal of geriatric pharmacotherapy
JID - 101190325
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Inpatients/*statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Nursing Homes
MH  - Peptic Ulcer Hemorrhage/*chemically induced/*mortality
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
EDAT- 2006/10/26 09:00
MHDA- 2007/01/16 09:00
CRDT- 2006/10/26 09:00
PHST- 2006/07/11 00:00 [accepted]
PHST- 2006/10/26 09:00 [pubmed]
PHST- 2007/01/16 09:00 [medline]
PHST- 2006/10/26 09:00 [entrez]
AID - S1543-5946(06)00050-X [pii]
AID - 10.1016/j.amjopharm.2006.09.006 [doi]
PST - ppublish
SO  - Am J Geriatr Pharmacother. 2006 Sep;4(3):244-50. doi: 
      10.1016/j.amjopharm.2006.09.006.

PMID- 3919745
OWN - NLM
STAT- MEDLINE
DCOM- 19850521
LR  - 20190515
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 57
IP  - 3
DP  - 1985 Mar
TI  - Comparison of infusions of morphine and lysine acetyl salicylate for the relief 
      of pain after surgery.
PG  - 255-8
AB  - The effect of a constant i.v. infusion of lysine acetyl salicylate (LAS) on pain 
      after operation was compared with that of a constant infusion of morphine in 30 
      patients undergoing unilateral inguinal herniorrhaphy. LAS provided analgesia 
      equivalent to that provided by morphine and was associated with significantly 
      less drowsiness, nausea and vomiting. No patient in either group was noted to 
      suffer from respiratory depression. No untoward side effects were noted during or 
      following the administration of LAS.
FAU - Cashman, J N
AU  - Cashman JN
FAU - Jones, R M
AU  - Jones RM
FAU - Foster, J M
AU  - Foster JM
FAU - Adams, A P
AU  - Adams AP
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Analgesics)
RN  - 76I7G6D29C (Morphine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*analogs & derivatives/therapeutic use
MH  - Bleeding Time
MH  - Double-Blind Method
MH  - Hernia, Inguinal/surgery
MH  - Humans
MH  - Lysine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Middle Aged
MH  - Morphine/adverse effects/*therapeutic use
MH  - Pain, Postoperative/*drug therapy
MH  - Time Factors
EDAT- 1985/03/01 00:00
MHDA- 1985/03/01 00:01
CRDT- 1985/03/01 00:00
PHST- 1985/03/01 00:00 [pubmed]
PHST- 1985/03/01 00:01 [medline]
PHST- 1985/03/01 00:00 [entrez]
AID - S0007-0912(17)41453-X [pii]
AID - 10.1093/bja/57.3.255 [doi]
PST - ppublish
SO  - Br J Anaesth. 1985 Mar;57(3):255-8. doi: 10.1093/bja/57.3.255.

PMID- 6837894
OWN - NLM
STAT- MEDLINE
DCOM- 19830527
LR  - 20190821
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 38
IP  - 1
DP  - 1983 Jan
TI  - Potentiation by acetylsalicylic acid of skin weal response to compound 48/80 in 
      ASA-sensitive asthmatics.
PG  - 43-8
AB  - The influence of acetylsalicylic acid (ASA) on skin response to intradermal 
      injection of compound 48/80 and histamine was studied in order to determine 
      whether ASA elicits any abnormalities also in the skin of asthmatics reacting 
      with bronchoconstriction to ingestion of this drug. The applied ASA dose (mean 
      dose 150 mg) elicited bronchoconstriction in all 16 patients with asthma and ASA 
      sensitivity (mean fall of FEV1 34%) and increased the weal response to compound 
      48/80 to about 51% (P less than 0.05) as compared with the response before the 
      ASA-challenge. In asthmatic persons without ASA sensitivity a 150 mg ASA dose did 
      not influence the skin response to any of the reagents. On the other hand, a 600 
      mg dose decreased skin response to histamine and compound 48/80 in persons 
      without ASA intolerance, although the decrease was statistically significant only 
      in the flare after compound 48/80 (P less than 0.05). The authors believe that 
      additional local defect is needed to reveal sensitivity to ASA in the skin of 
      ASA-sensitive asthmatics, just as bronchial hyperreactivity is indispensible for 
      revealing the action of ASA in the bronchi.
FAU - Szmidt, M
AU  - Szmidt M
FAU - Kowalski, M L
AU  - Kowalski ML
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
FAU - Rozniecki, J
AU  - Rozniecki J
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 4091-50-3 (p-Methoxy-N-methylphenethylamine)
RN  - 820484N8I3 (Histamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*pharmacology
MH  - Asthma/*chemically induced
MH  - Drug Synergism
MH  - Histamine/administration & dosage
MH  - Humans
MH  - Injections, Intradermal
MH  - Skin/*drug effects
MH  - Skin Tests
MH  - p-Methoxy-N-methylphenethylamine/*administration & dosage
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1983.tb00855.x [doi]
PST - ppublish
SO  - Allergy. 1983 Jan;38(1):43-8. doi: 10.1111/j.1398-9995.1983.tb00855.x.

PMID- 23228069
OWN - NLM
STAT- MEDLINE
DCOM- 20130528
LR  - 20211021
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 12
DP  - 2012 Dec 10
TI  - Prakriti (Ayurvedic concept of constitution) and variations in platelet 
      aggregation.
PG  - 248
LID - 10.1186/1472-6882-12-248 [doi]
AB  - BACKGROUND: Ayurveda, the Indian traditional system of medicine describes a 
      unique concept "prakriti", genetically determined, categorising the population 
      into several subgroups based on phenotypic characters like appearance, 
      temperament and habits. The concept is claimed to be useful in predicting an 
      individual's susceptibility to a particular disease, prognosis of that illness 
      and selection of therapy. The present study was carried out to study if the 
      platelet aggregatory response and its inhibition by aspirin varied in the 
      different prakriti subtypes. METHODS: After obtaining Institutional Ethics 
      Committee permission, normal healthy individuals of either sex between the age 
      group 18 to 30 years were recruited in the study. Their prakriti evaluation was 
      done using a standardized validated questionnaire (TNMC Prakriti 2004). Their 
      Platelet Rich Plasma was incubated with either aspirin [2.5 micro-mole (μM) and 5 
      μM] or distilled water as control for three minutes after which the aggregatory 
      response to 5 μM Adenosine Diphosphate (ADP) was measured over a period of 7 
      minutes. RESULTS: We observed that in the study population of normal healthy 
      participants (n= 137), ADP-induced maximal platelet aggregation (MPA) was highest 
      among the Vata-pitta prakriti individuals [Median (range), 83.33% (52.33-96)] as 
      compared to the other prakriti types and these individuals responded better to 
      lower dose of aspirin compared to other prakriti types. CONCLUSIONS: Our results 
      suggest that identifying the prakriti may help in individualising therapy or 
      predicting proneness to a disease.
FAU - Bhalerao, Supriya
AU  - Bhalerao S
AD  - Dept. of Clinical Pharmacology, TN Medical College & BYL Nair Ch. Hospital, 
      Mumbai Central, Mumbai 400 008, India.
FAU - Deshpande, Tejashree
AU  - Deshpande T
FAU - Thatte, Urmila
AU  - Thatte U
LA  - eng
PT  - Journal Article
DEP - 20121210
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Humans
MH  - India
MH  - Life Style
MH  - Male
MH  - *Medicine, Ayurvedic
MH  - Platelet Aggregation/*drug effects
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC3562518
EDAT- 2012/12/12 06:00
MHDA- 2013/05/29 06:00
CRDT- 2012/12/12 06:00
PHST- 2012/07/23 00:00 [received]
PHST- 2012/12/07 00:00 [accepted]
PHST- 2012/12/12 06:00 [entrez]
PHST- 2012/12/12 06:00 [pubmed]
PHST- 2013/05/29 06:00 [medline]
AID - 1472-6882-12-248 [pii]
AID - 10.1186/1472-6882-12-248 [doi]
PST - epublish
SO  - BMC Complement Altern Med. 2012 Dec 10;12:248. doi: 10.1186/1472-6882-12-248.

PMID- 36465622
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20221206
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Low-dose aspirin protects unexplained recurrent spontaneous abortion via 
      downregulation of HMGB1 inflammation activation.
PG  - 914030
LID - 10.3389/fendo.2022.914030 [doi]
LID - 914030
AB  - BACKGROUND: High mobility group box protein 1 (HMGB1) is considered as a kind of 
      sterile inflammatory mediators, which is an overexpression in patients with 
      unexplained recurrent spontaneous abortion (URSA). Specific targeting effect of 
      aspirin on HMGB1 has been revealed. Our previous studies have explored the 
      application of HMGB1 as a therapeutic target of aspirin in URSA disease of mice 
      model and human, but the dynamic process of aspirin downregulating HMGB1 
      concentration has not been demonstrated. METHODS: From December 2018 to November 
      2020, women with URSA (n = 91) and control women (n = 90) with no history of 
      recurrent abortion or adverse pregnancy were included in the Reproductive 
      Medicine Center of the First Affiliated Hospital of Anhui Medical University. 
      ELISA was applied to detect the concentrations of HMGB1 and IFN-γ in the 
      peripheral blood. Thirty-one URSA patients were monitored for low-dose aspirin 
      treatment (2 and 4 weeks), the changes of HMGB1 and IFN-γ concentrations in 
      peripheral blood of URSA patients before and after using aspirin were compared, 
      and pregnancy outcomes after aspirin treatment were followed up. RESULTS: The 
      levels of HMGB1 in peripheral blood were significantly higher in URSA patients 
      compared with controls, decreasing trends of HMGB1 and IFN-γ concentrations in 
      plasma of URSA patients were observed after treatment with low-dose aspirin 
      continuously, and the expression of HMGB1 was positively correlated with IFN-γ. 
      There were no birth abnormalities in the babies of the URSA patients treated with 
      aspirin. CONCLUSIONS: High levels of HMGB1 may be one of the pathogenesis of 
      URSA. Low-dose aspirin may provide protective effect on the HMGB1-triggered URSA.
CI  - Copyright © 2022 Xu, Wang, Zhu, Yin, Liu, Wu, Yang, Hu, Ren, Zhang, Zhou, Wei, 
      Zou and Cao.
FAU - Xu, Xiaofeng
AU  - Xu X
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - National Health Commission (NHC) Key Laboratory of Study on Abnormal Gametes and 
      Reproductive Tract (Anhui Medical University), Hefei, China.
AD  - Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), 
      Ministry of Education of the People's Republic of China, Hefei, Anhui, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Center for Reproductive Medicine, Ma'anshan Maternal and Child Health Hospital, 
      Ma'anshan, Anhui, China.
FAU - Zhu, Damin
AU  - Zhu D
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical 
      University), Hefei, Anhui, China.
AD  - Biopreservation and Artificial Organs, Anhui Provincial Engineering Research 
      Center, Anhui Medical University, Hefei, Anhui, China.
FAU - Yin, Jiaqian
AU  - Yin J
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical 
      University), Hefei, Anhui, China.
AD  - Biopreservation and Artificial Organs, Anhui Provincial Engineering Research 
      Center, Anhui Medical University, Hefei, Anhui, China.
FAU - Liu, Jinxian
AU  - Liu J
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical 
      University), Hefei, Anhui, China.
AD  - Biopreservation and Artificial Organs, Anhui Provincial Engineering Research 
      Center, Anhui Medical University, Hefei, Anhui, China.
FAU - Wu, Xiao
AU  - Wu X
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical 
      University), Hefei, Anhui, China.
AD  - Biopreservation and Artificial Organs, Anhui Provincial Engineering Research 
      Center, Anhui Medical University, Hefei, Anhui, China.
FAU - Yang, Wenjuan
AU  - Yang W
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical 
      University), Hefei, Anhui, China.
AD  - Biopreservation and Artificial Organs, Anhui Provincial Engineering Research 
      Center, Anhui Medical University, Hefei, Anhui, China.
FAU - Hu, Qian
AU  - Hu Q
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical 
      University), Hefei, Anhui, China.
AD  - Biopreservation and Artificial Organs, Anhui Provincial Engineering Research 
      Center, Anhui Medical University, Hefei, Anhui, China.
FAU - Ren, Yu
AU  - Ren Y
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical 
      University), Hefei, Anhui, China.
AD  - Biopreservation and Artificial Organs, Anhui Provincial Engineering Research 
      Center, Anhui Medical University, Hefei, Anhui, China.
FAU - Zhang, Zhiguo
AU  - Zhang Z
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical 
      University), Hefei, Anhui, China.
AD  - Biopreservation and Artificial Organs, Anhui Provincial Engineering Research 
      Center, Anhui Medical University, Hefei, Anhui, China.
FAU - Zhou, Ping
AU  - Zhou P
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical 
      University), Hefei, Anhui, China.
AD  - Biopreservation and Artificial Organs, Anhui Provincial Engineering Research 
      Center, Anhui Medical University, Hefei, Anhui, China.
FAU - Wei, Zhaolian
AU  - Wei Z
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical 
      University), Hefei, Anhui, China.
AD  - Biopreservation and Artificial Organs, Anhui Provincial Engineering Research 
      Center, Anhui Medical University, Hefei, Anhui, China.
FAU - Zou, Huijuan
AU  - Zou H
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - National Health Commission (NHC) Key Laboratory of Study on Abnormal Gametes and 
      Reproductive Tract (Anhui Medical University), Hefei, China.
AD  - Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), 
      Ministry of Education of the People's Republic of China, Hefei, Anhui, China.
FAU - Cao, Yunxia
AU  - Cao Y
AD  - Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First 
      Affiliated Hospital of Anhui Medical University, Hefei, China.
AD  - National Health Commission (NHC) Key Laboratory of Study on Abnormal Gametes and 
      Reproductive Tract (Anhui Medical University), Hefei, China.
AD  - Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), 
      Ministry of Education of the People's Republic of China, Hefei, Anhui, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221117
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (HMGB1 Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Infant
MH  - Animals
MH  - Mice
MH  - Humans
MH  - Female
MH  - *Abortion, Spontaneous
MH  - *HMGB1 Protein
MH  - Down-Regulation
MH  - Aspirin/pharmacology
MH  - Inflammation/drug therapy
PMC - PMC9712724
OTO - NOTNLM
OT  - aspirin
OT  - high mobility group box protein 1
OT  - inflammation
OT  - pregnancy
OT  - unexplained recurrent spontaneous abortion
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/06 06:00
MHDA- 2022/12/07 06:00
CRDT- 2022/12/05 03:46
PHST- 2022/04/06 00:00 [received]
PHST- 2022/10/28 00:00 [accepted]
PHST- 2022/12/05 03:46 [entrez]
PHST- 2022/12/06 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
AID - 10.3389/fendo.2022.914030 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Nov 17;13:914030. doi: 
      10.3389/fendo.2022.914030. eCollection 2022.

PMID- 2868341
OWN - NLM
STAT- MEDLINE
DCOM- 19860320
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 8478
DP  - 1986 Feb 22
TI  - Moderate doses of aspirin and risk of bleeding in renal failure.
PG  - 414-6
AB  - Uraemic patients have a bleeding tendency thought to be due to platelet 
      functional abnormalities, but haemodialysis paradoxically exposes patients to the 
      thrombotic complications of arteriovenous shunts. Possible treatments of the 
      latter have been debated. The effect of 100 mg/m2 aspirin on haemostatic function 
      was studied in 29 uraemic patients on chronic haemodialysis who had normal or 
      only slightly prolonged bleeding times. Aspirin did not significantly affect 
      bleeding time in healthy controls but prolonged it in uraemic patients. In 12 of 
      the 29 uraemic patients, the bleeding time after aspirin was longer than 15 min. 
      Aspirin completely abolished thromboxane A2 generation by both control and 
      uraemic platelets, indicating that its effect in uraemic patients is not due to 
      differential inhibition of platelet cyclo-oxygenase. Products of lipoxygenase 
      enzyme and factor VIII von Willebrand factor did not seem to have a role. A 
      careful risk-benefit evaluation is necessary before giving aspirin to uraemic 
      patients on haemodialysis to prevent thrombosis of the arteriovenous shunt.
FAU - Livio, M
AU  - Livio M
FAU - Benigni, A
AU  - Benigni A
FAU - Viganò, G
AU  - Viganò G
FAU - Mecca, G
AU  - Mecca G
FAU - Remuzzi, G
AU  - Remuzzi G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Bleeding Time
MH  - Female
MH  - Hemorrhage/*etiology
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Infusions, Parenteral
MH  - Kidney Failure, Chronic/*complications
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Renal Dialysis
MH  - Risk
MH  - Thrombophlebitis/prevention & control
EDAT- 1986/02/22 00:00
MHDA- 1986/02/22 00:01
CRDT- 1986/02/22 00:00
PHST- 1986/02/22 00:00 [pubmed]
PHST- 1986/02/22 00:01 [medline]
PHST- 1986/02/22 00:00 [entrez]
AID - S0140-6736(86)92372-X [pii]
AID - 10.1016/s0140-6736(86)92372-x [doi]
PST - ppublish
SO  - Lancet. 1986 Feb 22;1(8478):414-6. doi: 10.1016/s0140-6736(86)92372-x.

PMID- 1737967
OWN - NLM
STAT- MEDLINE
DCOM- 19920317
LR  - 20151119
IS  - 0094-3509 (Print)
IS  - 0094-3509 (Linking)
VI  - 34
IP  - 2
DP  - 1992 Feb
TI  - The effect of aspirin on niacin-induced cutaneous reactions.
PG  - 165-8
AB  - BACKGROUND: Niacin (nicotinic acid) is one of the first-line agents recommended 
      for the treatment of hyperlipidemia. Bothersome cutaneous reactions (flushing, 
      feeling of warmth, itching, and tingling), however, often limit patient 
      acceptability and tolerability. The National Cholesterol Education Program 
      recommends giving aspirin or another nonsteroidal anti-inflammatory drug before 
      administering niacin. Lack of scientific data supporting this recommendation, 
      however, led to this randomized, double-blind, placebo-controlled trial to 
      evaluate the efficacy of 80 mg of aspirin and 325 mg of aspirin in reducing these 
      cutaneous reactions. METHODS: Thirty-one healthy subjects were randomized into 
      one of four groups. Each group completed four different treatment regimens 
      (placebo-placebo; 80 mg of aspirin-500 mg of niacin; 325 mg of aspirin-500 mg of 
      niacin; and placebo-500 mg of niacin). Subjects received one of each of the four 
      treatment regimens on separate visits that were at least 24 hours apart. 
      Intensity and tolerability of cutaneous reactions were evaluated by an intensity 
      rating scale and a visual analog scale. RESULTS: Results indicate that 325 mg of 
      aspirin is significantly better than 80 mg of aspirin in decreasing 
      intolerability to niacin. Aspirin reduced the incidence of warmth and flushing 
      associated with niacin, but not the itching and tingling. CONCLUSIONS: It appears 
      from this pilot study that preceding niacin with 325 mg of aspirin will decrease 
      the warmth and flushing associated with niacin.
FAU - Whelan, A M
AU  - Whelan AM
AD  - Department of Family Medicine, Medical University of South Carolina, Charleston.
FAU - Price, S O
AU  - Price SO
FAU - Fowler, S F
AU  - Fowler SF
FAU - Hainer, B L
AU  - Hainer BL
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 2679MF687A (Niacin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Fam Pract. 1992 Jun;34(6):677, 680-1. PMID: 1593238
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Flushing/chemically induced/*prevention & control
MH  - Humans
MH  - Hyperlipidemias/drug therapy
MH  - Male
MH  - Niacin/*adverse effects/therapeutic use
MH  - Pilot Projects
MH  - Pruritus/chemically induced/*prevention & control
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
PST - ppublish
SO  - J Fam Pract. 1992 Feb;34(2):165-8.

PMID- 8238144
OWN - NLM
STAT- MEDLINE
DCOM- 19931126
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 169
IP  - 4
DP  - 1993 Oct
TI  - The effect of low-dose aspirin on fetal urine output and amniotic fluid volume.
PG  - 885-8
AB  - OBJECTIVE: Patients given prostaglandin synthetase inhibitors in doses sufficient 
      to inhibit labor are at risk for developing oligohydramnios (possibly related to 
      a reduction in fetal urine output). We sought to ascertain whether the fetuses of 
      women who received 60 mg of aspirin daily had a lower urine output than those 
      whose mothers were given a placebo. STUDY DESIGN: Nulliparous women with 
      singleton gestations in a double-blind preeclampsia prevention trial were 
      randomly selected at 24 weeks' gestation to receive either 60 mg of aspirin daily 
      or a placebo. Urine output was assessed in 59 fetuses (aspirin 32, placebo 27) by 
      serial ultrasonographic measurement of their bladder volume (volume = 4/3 pi r3). 
      Biochemical evidence of aspirin compliance was defined as an 80% reduction in 
      maternal serum thromboxane B2 levels when comparing values obtained at 
      randomization with those at 34 to 36 weeks' gestation. RESULTS: Visual assessment 
      of amniotic fluid volume was similar in both groups. Four-quadrant amniotic fluid 
      indexes also were similar (13.5 cm in aspirin group vs 12.2 cm in placebo group, 
      p = 0.15). Mean fetal urine outputs were similar in the aspirin (57.7 ml/hr) and 
      placebo (55.1 ml/hr) groups (p = 0.71). Moreover, the 23 women with a fourfold 
      thromboxane B2 reduction had a higher mean fetal urine output (63.5 vs 51.8 
      ml/hr, p = 0.08) than did the remaining 35 patients. This study has a 96% chance 
      (1-beta) of detecting a 50% (30 ml) reduction in fetal urine output. CONCLUSIONS: 
      Daily maternal ingestion of 60 mg of aspirin did not decrease fetal urine output 
      or amniotic fluid volume.
FAU - Maher, J E
AU  - Maher JE
AD  - Department of Obstetrics and Gynecology, University of Alabama at Birmingham 
      35233-7333.
FAU - Owen, J
AU  - Owen J
FAU - Hauth, J
AU  - Hauth J
FAU - Goldenberg, R
AU  - Goldenberg R
FAU - Parker, C R Jr
AU  - Parker CR Jr
FAU - Copper, R L
AU  - Copper RL
LA  - eng
GR  - 1 R01 HD 24496-01/HD/NICHD NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Amniotic Fluid/*drug effects
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chi-Square Distribution
MH  - Double-Blind Method
MH  - Female
MH  - Fetus/*drug effects/physiology
MH  - Gestational Age
MH  - Humans
MH  - Maternal-Fetal Exchange
MH  - Parity
MH  - Pregnancy
MH  - Regression Analysis
MH  - Thromboxane B2/blood
MH  - Ultrasonography, Prenatal
MH  - Urinary Bladder/diagnostic imaging
MH  - Urination/*drug effects
EDAT- 1993/10/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
AID - 0002-9378(93)90021-A [pii]
AID - 10.1016/0002-9378(93)90021-a [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1993 Oct;169(4):885-8. doi: 10.1016/0002-9378(93)90021-a.

PMID- 9815866
OWN - NLM
STAT- MEDLINE
DCOM- 19981217
LR  - 20201216
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 98
IP  - 20
DP  - 1998 Nov 17
TI  - Randomized evaluation of anticoagulation versus antiplatelet therapy after 
      coronary stent implantation in high-risk patients: the multicenter aspirin and 
      ticlopidine trial after intracoronary stenting (MATTIS).
PG  - 2126-32
AB  - BACKGROUND: Although the association of ticlopidine and aspirin has been shown to 
      be superior to anti-vitamin K agents and aspirin after coronary stent 
      implantation in low-risk patients, the latter combination has remained an 
      unproven reference regimen for high-risk patients until recently. METHODS AND 
      RESULTS: We randomized 350 high-risk patients within 6 hours after stent 
      implantation to receive during 30 days either aspirin 250 mg and ticlopidine 500 
      mg/d (A+T group) or aspirin 250 mg/d and oral anticoagulation (A+OAC group) 
      targeted at an international normalized ratio of 2.5 to 3. The primary composite 
      end point was defined as the occurrence of cardiovascular death, myocardial 
      infarction, or repeated revascularization at 30 days. Patients were eligible if 
      (1) the stent(s) were implanted to treat abrupt closure after PTCA; (2) the 
      angiographic result after implantation was suboptimal; (3) a long segment was 
      stented (>45 mm and/or >/=3 stents); or (4) the largest balloon inflated in the 
      stent had a nominal diameter of </=2.5 mm. The primary cardiac end point was 
      reached for 10 patients (5.6%) in the A+T group and 19 (11%) in the A+OAC group 
      (relative risk [RR], 1. 9; 95% CI, 0.9 to 4.1; P=0.07). Major vascular and 
      bleeding complications were less frequent in the A+T group (3 patients, 1.7%) 
      than in the A+OAC group (12 patients, 6.9%) (RR, 4.1; 95% CI, 1.2 to 14.3; 
      P=0.02). CONCLUSIONS: High-risk patients should be treated with A+T rather than 
      A+OAC after coronary stenting because the bleeding and vascular complications are 
      significantly reduced and there is a marked trend suggesting a decrease in 
      cardiac events.
FAU - Urban, P
AU  - Urban P
AD  - Department of Cardiology; La Tour Hospital, Genève, Switzerland.
FAU - Macaya, C
AU  - Macaya C
FAU - Rupprecht, H J
AU  - Rupprecht HJ
FAU - Kiemeneij, F
AU  - Kiemeneij F
FAU - Emanuelsson, H
AU  - Emanuelsson H
FAU - Fontanelli, A
AU  - Fontanelli A
FAU - Pieper, M
AU  - Pieper M
FAU - Wesseling, T
AU  - Wesseling T
FAU - Sagnard, L
AU  - Sagnard L
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Coronary Thrombosis/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stents/*adverse effects
MH  - Ticlopidine/adverse effects/*therapeutic use
EDAT- 1998/11/17 00:00
MHDA- 1998/11/17 00:01
CRDT- 1998/11/17 00:00
PHST- 1998/11/17 00:00 [pubmed]
PHST- 1998/11/17 00:01 [medline]
PHST- 1998/11/17 00:00 [entrez]
AID - 10.1161/01.cir.98.20.2126 [doi]
PST - ppublish
SO  - Circulation. 1998 Nov 17;98(20):2126-32. doi: 10.1161/01.cir.98.20.2126.

PMID- 26832316
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20191201
IS  - 1578-1275 (Electronic)
IS  - 0212-6567 (Print)
IS  - 0212-6567 (Linking)
VI  - 48
IP  - 6
DP  - 2016 Jun-Jul
TI  - [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the 
      prevention of stroke in patients with non-valvular atrial fibrillation in Spain].
PG  - 394-405
LID - S0212-6567(15)00260-7 [pii]
LID - 10.1016/j.aprim.2015.04.012 [doi]
AB  - OBJECTIVE: To assess the cost-effectiveness of apixaban versus acetylsalicylic 
      acid (ASA) in stroke prevention in patients with non-valvular atrial fibrillation 
      (NVAF) with contraindications of vitamin K antagonists in Spain. METHODS: A 
      Markov model was adapted, simulating the patient's lifetime. The safety and 
      efficacy of the drugs were obtained from AVERROES clinical trial. The analysis 
      was done from the Spanish National Health System (NHS) and societal perspective. 
      The cost of drugs was calculated according to the recommended doses. The cost of 
      NVAF complications and disease management was obtained from Spanish sources. 
      RESULTS: In a cohort of 1,000 patients with NVAF, during their lifetime numerous 
      complications could be avoided with apixaban versus ASA (48 ischemic strokes, 10 
      systemic embolism and 53 related deaths). In each patient treated with apixaban 
      more life-years (0.303 LYG) and more quality-adjusted life-years (0.277 QALYs) 
      could be gained. Apixaban would generate more costs per patient for the NHS 
      (€1,742 per patient) but savings would result from the social perspective (€2,887 
      saved per patient). The cost per LYG and QALY gained would be of €5,749 and 
      €6,289 for the NHS. Apixaban would be dominant (more effective with less costs 
      than ASA) from the societal perspective. The results were stable in both 
      deterministic and probabilistic sensitivity analyses. CONCLUSIONS: According to 
      this model, when costs and estimated lifetime outcomes achieved with apixaban are 
      compared with those of ASA, apixaban was assessed to be a cost-effective 
      treatment for the prevention of stroke in patients with NVAF in Spain.
CI  - Copyright © 2015 Elsevier España, S.L.U. All rights reserved.
FAU - Escolar-Albaladejo, Ginés
AU  - Escolar-Albaladejo G
AD  - Hospital Clínic, Barcelona, España.
FAU - Barón-Esquivias, Gonzalo
AU  - Barón-Esquivias G
AD  - Hospital Universitario Virgen del Rocío, Sevilla, España.
FAU - Zamorano, José Luis
AU  - Zamorano JL
AD  - Hospital Universitario Ramón y Cajal, Madrid, España.
FAU - Betegón-Nicolás, Lourdes
AU  - Betegón-Nicolás L
AD  - Departamento de Economía de la Salud, Bristol-Myers Squibb España, Madrid, 
      España.
FAU - Canal-Fontcuberta, Cristina
AU  - Canal-Fontcuberta C
AD  - Departamento de Economía de la Salud, Bristol-Myers Squibb España, Madrid, 
      España.
FAU - de Salas-Cansado, Marina
AU  - de Salas-Cansado M
AD  - Pfizer España, Madrid, España.
FAU - Rubio-Rodríguez, Darío
AU  - Rubio-Rodríguez D
AD  - Health Value, Madrid, España.
FAU - Rubio-Terrés, Carlos
AU  - Rubio-Terrés C
AD  - Health Value, Madrid, España. Electronic address: crubioterres@healthvalue.org.
LA  - spa
PT  - Comparative Study
PT  - Journal Article
TT  - Análisis coste-utilidad de apixabán frente al ácido acetilsalicílico en la 
      prevención del ictus en pacientes con fibrilación auricular no valvular en 
      España.
DEP - 20160130
PL  - Spain
TA  - Aten Primaria
JT  - Atencion primaria
JID - 9111075
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*economics/*therapeutic use
MH  - Atrial Fibrillation/complications
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Pyrazoles/*economics/*therapeutic use
MH  - Pyridones/*economics/*therapeutic use
MH  - Spain
MH  - Stroke/etiology/*prevention & control
PMC - PMC6877843
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Apixaban
OT  - Apixabán
OT  - Cost-effectiveness
OT  - Coste-utilidad
OT  - Fibrilación auricular no valvular
OT  - Non-valvular atrial fibrillation
OT  - Ácido acetilsalicílico
EDAT- 2016/02/03 06:00
MHDA- 2018/02/27 06:00
CRDT- 2016/02/03 06:00
PHST- 2014/05/06 00:00 [received]
PHST- 2015/04/14 00:00 [revised]
PHST- 2015/04/28 00:00 [accepted]
PHST- 2016/02/03 06:00 [entrez]
PHST- 2016/02/03 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
AID - S0212-6567(15)00260-7 [pii]
AID - 10.1016/j.aprim.2015.04.012 [doi]
PST - ppublish
SO  - Aten Primaria. 2016 Jun-Jul;48(6):394-405. doi: 10.1016/j.aprim.2015.04.012. Epub 
      2016 Jan 30.

PMID- 1841835
OWN - NLM
STAT- MEDLINE
DCOM- 19921203
LR  - 20191028
IS  - 0379-8305 (Print)
IS  - 0379-8305 (Linking)
VI  - 17
IP  - 3-4
DP  - 1991
TI  - Disposition of single-dose intravenous and oral aspirin in children.
PG  - 180-6
AB  - We described the pharmacokinetics of acetylsalicylic acid and salicylic acid in 5 
      children with prior Kawasaki disease receiving buffered aspirin tablets or 
      intravenous aspirin DL-lysine. Oral aspirin is characterized by its longer mean 
      residence time in the body (MRT), an indicator for duration of exposure, than 
      intravenous aspirin (1.18 vs. 0.37 h). The apparent elimination half-life (t1/2) 
      of acetylsalicylic acid was also longer after oral than after intravenous 
      administration of aspirin (40 vs. 17 min). The mean absorption time was 
      calculated to be as long as 0.8 h. In contrast, the two modes of administration 
      gave virtually identical results regarding MRT of salicylic acid proper and its 
      t1/2. After oral administration of aspirin, 51% of the dose is absorbed intact as 
      acetylsalicylic acid while 23% is converted to salicylic acid presystemically, 
      indicating that 74% of aspirin is actually absorbed. Our data suggest that an 
      equivalent intravenous aspirin dose to achieve the same salicylic acid 
      concentration is about 70% of the oral dose. However, the area under the curve of 
      acetylsalicylic acid itself, a more potent cyclooxygenase inhibitor than 
      salicylic acid, would be about 1.5 times higher than that following oral 
      administration. The clinical consequences of this exposure difference remain 
      uncertain.
FAU - Ito, S
AU  - Ito S
AD  - Department of Pediatrics, Asahikawa Medical College, Japan.
FAU - Oka, R
AU  - Oka R
FAU - Tsuchida, A
AU  - Tsuchida A
FAU - Yoshioka, H
AU  - Yoshioka H
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Dev Pharmacol Ther
JT  - Developmental pharmacology and therapeutics
JID - 8003947
RN  - 0 (Buffers)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Biological Availability
MH  - Buffers
MH  - Child, Preschool
MH  - Drug Administration Schedule
MH  - Half-Life
MH  - Humans
MH  - Infusions, Intravenous
MH  - Mucocutaneous Lymph Node Syndrome/metabolism
MH  - Salicylates/administration & dosage/blood/pharmacokinetics
MH  - Salicylic Acid
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1159/000457520 [doi]
PST - ppublish
SO  - Dev Pharmacol Ther. 1991;17(3-4):180-6. doi: 10.1159/000457520.

PMID- 31791903
OWN - NLM
STAT- MEDLINE
DCOM- 20210616
LR  - 20210616
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
VI  - 14
IP  - 3
DP  - 2020 Jun
TI  - Aspirin in the primary prevention of cardiovascular disease on diabetic patients: 
      Systematic review and meta-analysis.
PG  - 213-221
LID - S1751-9918(19)30439-5 [pii]
LID - 10.1016/j.pcd.2019.11.004 [doi]
AB  - AIMS: The publication of new trials brought additional data to the controversial 
      topic of aspirin use in diabetic patients for primary prevention. Therefore, we 
      aimed to systematically review all randomized controlled trials evaluating the 
      clinical impact of aspirin in this setting. METHODS: We searched for randomized 
      controlled trials (RCTs) evaluating the impact of aspirin in patients with 
      diabetes in primary prevention, in MEDLINE, EMBASE, CENTRAL (November/2018). The 
      primary outcomes were all-cause mortality and the composite outcome of major 
      adverse cardiovascular events (MACE). A meta-analysis was performed deriving risk 
      ratios (RR) and 95% confidence intervals (CI). RESULTS: All-cause mortality was 
      not significantly reduced with RR 0.96 (95% CI 0.90-1.03; 7RCT; 27,595 patients). 
      Regarding MACE, there was an 8% risk reduction (RR 0.92, 95% CI 0.84-0.999; 
      I(2)=0%; 8RCT; 29,814 patients). The risks of major bleeding (RR 1.30, 95% CI 
      1.10-1.53; 2RCTs, 18,019 patients), and major GI bleeding (RR 1.39, 95% CI 
      1.08-1.80; 2RCTs, 18,019 patients) were significantly increased. The risks of 
      cardiovascular mortality, myocardial infarction, stroke and amputation were not 
      significantly different from control arm. CONCLUSIONS: Aspirin use among diabetic 
      patients in primary prevention appears was associated with increased risk of 
      major bleeding, a modest decrease of MACE and lack of mortality benefit.
CI  - Copyright © 2019 Primary Care Diabetes Europe. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Caldeira, Daniel
AU  - Caldeira D
AD  - Centro Cardiovascular da Universidade de Lisboa - CCUL, CAML, Faculdade de 
      Medicina, Universidade de Lisboa, Portugal; Serviço de Cardiologia, Hospital 
      Universitário de Santa Maria - CHULN, Portugal; Laboratory of Clinical 
      Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, 
      Portugal; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de 
      Lisboa, Portugal. Electronic address: dgcaldeira@hotmail.com.
FAU - Alves, Mariana
AU  - Alves M
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, 
      Universidade de Lisboa, Portugal; Instituto de Medicina Molecular, Faculdade de 
      Medicina, Universidade de Lisboa, Portugal; Serviço de Medicina III, Hospital 
      Pulido Valente, CHLN, Lisboa, Portugal.
FAU - David, Cláudio
AU  - David C
AD  - Centro Cardiovascular da Universidade de Lisboa - CCUL, CAML, Faculdade de 
      Medicina, Universidade de Lisboa, Portugal; Serviço de Cardiologia, Hospital 
      Universitário de Santa Maria - CHULN, Portugal; Laboratory of Clinical 
      Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, 
      Portugal.
FAU - Costa, João
AU  - Costa J
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, 
      Universidade de Lisboa, Portugal; Instituto de Medicina Molecular, Faculdade de 
      Medicina, Universidade de Lisboa, Portugal.
FAU - Ferreira, Joaquim J
AU  - Ferreira JJ
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, 
      Universidade de Lisboa, Portugal; Instituto de Medicina Molecular, Faculdade de 
      Medicina, Universidade de Lisboa, Portugal.
FAU - Pinto, Fausto J
AU  - Pinto FJ
AD  - Centro Cardiovascular da Universidade de Lisboa - CCUL, CAML, Faculdade de 
      Medicina, Universidade de Lisboa, Portugal; Serviço de Cardiologia, Hospital 
      Universitário de Santa Maria - CHULN, Portugal.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20191130
PL  - England
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Diabetes Mellitus/*therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Primary Prevention/*methods
OTO - NOTNLM
OT  - Antiplatelet
OT  - Cardiovascular disease
OT  - Cerebrovascular disease
OT  - Coronary disease
OT  - Diabetes mellitus
OT  - Net clinical benefit
OT  - Peripheral arterial disease
OT  - Primary prevention
OT  - Revascularization
EDAT- 2019/12/04 06:00
MHDA- 2021/06/17 06:00
CRDT- 2019/12/04 06:00
PHST- 2019/10/03 00:00 [received]
PHST- 2019/11/02 00:00 [revised]
PHST- 2019/11/06 00:00 [accepted]
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2021/06/17 06:00 [medline]
PHST- 2019/12/04 06:00 [entrez]
AID - S1751-9918(19)30439-5 [pii]
AID - 10.1016/j.pcd.2019.11.004 [doi]
PST - ppublish
SO  - Prim Care Diabetes. 2020 Jun;14(3):213-221. doi: 10.1016/j.pcd.2019.11.004. Epub 
      2019 Nov 30.

PMID- 10427416
OWN - NLM
STAT- MEDLINE
DCOM- 19991006
LR  - 20190831
IS  - 0003-6072 (Print)
IS  - 0003-6072 (Linking)
VI  - 75
IP  - 3
DP  - 1999 Apr
TI  - An acetylsalicylic acid-sensitive aggregation phenomenon in Dipodascopsis 
      uninucleata.
PG  - 261-6
AB  - Aggregation of ascospores has been discovered in the yeast Dipodascopsis 
      uninucleata. When this yeast is cultivated to reach the sexual reproductive 
      stage, small ascospores are individually released from the tip of a sac-like 
      ascus which then aggregate in orderly clusters. Acetylsalicylic acid (ASA) 
      inhibited ascospore release and subsequent ordered aggregation process. We 
      suggest that novel ASA-sensitive oxidised fatty acids (3R-hydroxy-oxylipins) and 
      small hooks located on the surface of these ascospores, are involved.
FAU - Kock, J L
AU  - Kock JL
AD  - Department of Microbiology and Biochemistry, University of the Orange Free State, 
      South Africa. Kockjlf@micro.nw.uovs.ac.za
FAU - van Wyk, P W
AU  - van Wyk PW
FAU - Venter, P
AU  - Venter P
FAU - Coetzee, D J
AU  - Coetzee DJ
FAU - Smith, D P
AU  - Smith DP
FAU - Viljoen, B C
AU  - Viljoen BC
FAU - Nigam, S
AU  - Nigam S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Antonie Van Leeuwenhoek
JT  - Antonie van Leeuwenhoek
JID - 0372625
RN  - 0 (Fatty Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascomycota/drug effects/*physiology
MH  - Aspirin/*pharmacology
MH  - Fatty Acids/pharmacology
MH  - Spores, Fungal/drug effects/physiology
EDAT- 1999/07/31 00:00
MHDA- 1999/07/31 00:01
CRDT- 1999/07/31 00:00
PHST- 1999/07/31 00:00 [pubmed]
PHST- 1999/07/31 00:01 [medline]
PHST- 1999/07/31 00:00 [entrez]
AID - 10.1023/a:1001869410323 [doi]
PST - ppublish
SO  - Antonie Van Leeuwenhoek. 1999 Apr;75(3):261-6. doi: 10.1023/a:1001869410323.

PMID- 8143059
OWN - NLM
STAT- MEDLINE
DCOM- 19940504
LR  - 20220331
IS  - 1073-449X (Print)
IS  - 1073-449X (Linking)
VI  - 149
IP  - 4 Pt 1
DP  - 1994 Apr
TI  - Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with 
      asthma after aspirin challenge.
PG  - 940-6
AB  - We have recently shown that oral aspirin provocation leads to an increase in LTE4 
      and a reduction in 11-dehydro-TXB2 levels in urine of patients with aspirin 
      induced-asthma (AIA). To test the hypothesis that cyclooxygenase inhibition and 
      an enhancement of cysteinyl-leukotriene production occurs in the lungs of 
      patients with AIA, we examined the eicosanoid levels in bronchoalveolar lavage 
      fluid obtained 30 min after lysine-aspirin or placebo inhalation in 10 patients 
      with AIA. Eosinophil cationic protein (ECP) levels were determined to evaluate 
      eosinophil activation. Six asthmatics nonsensitive to aspirin (NA) underwent 
      challenge with placebo. The dose of lysine-aspirin inhaled by patients with AIA 
      was equal to that which had produced > or = 20% fall in FEV1. Compared with NA, 
      patients with AIA had: (1) eicosanoid levels, particularly PGE2 and TXB2, 
      elevated and (2) higher number of eosinophils and ECP. The overproduction of 
      eicosanoids could be related to a distinct eosinophilic inflammation in airways 
      of patients with AIA. Inhalation of lysine-aspirin had no effects on 12-HETE and 
      15-HETE levels, but it markedly depressed cyclooxygenase products and 
      significantly enhanced leukotriene production in the lungs of patients with AIA.
FAU - Sladek, K
AU  - Sladek K
AD  - Department of Medicine, University School of Medicine, Cracow, Poland.
FAU - Dworski, R
AU  - Dworski R
FAU - Soja, J
AU  - Soja J
FAU - Sheller, J R
AU  - Sheller JR
FAU - Nizankowska, E
AU  - Nizankowska E
FAU - Oates, J A
AU  - Oates JA
FAU - Szczeklik, A
AU  - Szczeklik A
LA  - eng
GR  - GM-15431/GM/NIGMS NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (Eicosanoids)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/*analogs & derivatives
MH  - Asthma/chemically induced/*metabolism
MH  - Bronchial Provocation Tests/methods/statistics & numerical data
MH  - Bronchoalveolar Lavage Fluid/*chemistry
MH  - Bronchoscopy
MH  - Drug Tolerance
MH  - Eicosanoids/*analysis
MH  - Female
MH  - Fiber Optic Technology
MH  - Humans
MH  - Lysine/*analogs & derivatives
MH  - Male
MH  - Middle Aged
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
AID - 10.1164/ajrccm.149.4.8143059 [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 1994 Apr;149(4 Pt 1):940-6. doi: 
      10.1164/ajrccm.149.4.8143059.

PMID- 2495079
OWN - NLM
STAT- MEDLINE
DCOM- 19890515
LR  - 20190501
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 298
IP  - 6672
DP  - 1989 Feb 25
TI  - Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin.
PG  - 493-6
AB  - OBJECTIVE: To investigate the suitability of treatment with low dose aspirin or 
      warfarin, or both, as possible prophylaxis against cardiovascular disease by 
      determining the effect on gastric mucosal bleeding. DESIGN: Randomised crossover 
      trial. SETTING: Academic department of therapeutics. SUBJECTS: Twenty healthy 
      male volunteers aged 19-22. INTERVENTIONS: On separate occasions and in 
      randomised order all subjects received aspirin 75 mg, warfarin, or aspirin 75 mg 
      combined with warfarin. Each treatment was given for 12 days or (when warfarin 
      was used) for longer if necessary until the international normalised ratio of the 
      prothrombin time was stable at 1.4-1.6. END POINT: Loss of blood over 10 minutes 
      into gastric washings. MEASUREMENTS AND MAIN RESULTS: Bleeding over 10 minutes 
      into gastric washings under baseline conditions and after five days, and at end 
      of each regimen of treatment. Aspirin 75 mg increased bleeding from 0.60 (95% 
      confidence interval 0.36 to 0.99) microliters/10 minutes to 1.26 (0.71 to 2.25) 
      microliters/10 minutes at five days, with no evidence of either progressive 
      change or adaptation thereafter. Warfarin had no effect on bleeding either alone 
      or when combined with aspirin. CONCLUSIONS: Aspirin 75 mg causes gastric mucosal 
      bleeding. Low dose warfarin neither induces gastric mucosal bleeding nor enhances 
      that caused by aspirin.
FAU - Prichard, P J
AU  - Prichard PJ
AD  - Department of Therapeutics, University Hospital, Nottingham.
FAU - Kitchingman, G K
AU  - Kitchingman GK
FAU - Walt, R P
AU  - Walt RP
FAU - Daneshmend, T K
AU  - Daneshmend TK
FAU - Hawkey, C J
AU  - Hawkey CJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cohort Studies
MH  - Drug Synergism
MH  - Gastric Mucosa/*drug effects
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Random Allocation
MH  - Warfarin/administration & dosage/*adverse effects
PMC - PMC1835778
EDAT- 1989/02/25 00:00
MHDA- 1989/02/25 00:01
CRDT- 1989/02/25 00:00
PHST- 1989/02/25 00:00 [pubmed]
PHST- 1989/02/25 00:01 [medline]
PHST- 1989/02/25 00:00 [entrez]
AID - 10.1136/bmj.298.6672.493 [doi]
PST - ppublish
SO  - BMJ. 1989 Feb 25;298(6672):493-6. doi: 10.1136/bmj.298.6672.493.

PMID- 32910340
OWN - NLM
STAT- MEDLINE
DCOM- 20211215
LR  - 20211215
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 35
IP  - 3
DP  - 2021 Jun
TI  - Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in 
      secondary prevention among patients with chronic cardiovascular diseases.
PG  - 539-547
LID - 10.1007/s10557-020-07059-w [doi]
AB  - PURPOSE: This study aimed to investigate the cost-effectiveness of low-dose 
      rivaroxaban plus aspirin versus aspirin alone for patients with stable 
      cardiovascular diseases in the Taiwan setting. METHODS: We constructed a Markov 
      model to project the lifetime direct medical costs and quality-adjusted 
      life-years of both therapies. Transitional probabilities were derived from the 
      COMPASS trial, and the costs and utilities were obtained from the Taiwan National 
      Health Insurance Database and published studies. One-way, scenario, subgroup, and 
      probabilistic sensitivity analyses were performed to assess the uncertainty. 
      Incremental cost-effectiveness ratio was presented as the outcome. The threshold 
      of willingness-to-pay was set at US$76,368 (3 times the gross domestic product 
      per capita of Taiwan). All analyses were operated by TreeAge 2019 and Microsoft 
      Excel. RESULTS: The incremental cost-effectiveness ratios of rivaroxaban plus 
      aspirin versus aspirin alone in the patients with stable cardiovascular diseases, 
      coronary artery diseases, and peripheral artery diseases were US$83,459, 
      US$69,852 and -US$13,823 per quality-adjusted life-year gained, respectively. The 
      probabilistic sensitivity analyses showed that the probabilities of 
      cost-effectiveness for the regimen with rivaroxaban among those with 
      cardiovascular diseases and coronary artery diseases were 44.1% and 65.3% at 
      US$76,368. CONCLUSION: Low-dose rivaroxaban plus aspirin is less likely to be a 
      cost-effective alternative to aspirin in secondary prevention for the patients 
      with stable cardiovascular diseases; however, among these patients, the regimen 
      may have pharmacoeconomic incentives for the group merely having chronic coronary 
      artery diseases from the Taiwan national payer's perspective. The 
      pharmacoeconomic incentives are influenced by the drug price, event treatment 
      fees, and willingness-to-pay threshold.
FAU - Lee, Mei-Chuan
AU  - Lee MC
AD  - Department of Pharmacy, Chi Mei Medical Center, Tainan, Taiwan.
AD  - Department of Public Health, College of Medicine, National Cheng Kung University, 
      Tainan, Taiwan.
FAU - Liao, Chia-Te
AU  - Liao CT
AD  - Department of Public Health, College of Medicine, National Cheng Kung University, 
      Tainan, Taiwan. drctliao@gmail.com.
AD  - Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, 
      No901, Rd. Zhonghua, Yong Kang District, Tainan City, Taiwan. drctliao@gmail.com.
FAU - Toh, Han Siong
AU  - Toh HS
AD  - Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.
AD  - Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan.
FAU - Chou, Chih-Chen
AU  - Chou CC
AD  - Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung 
      Veterans General Hospital, Kaohsiung City, Taiwan.
AD  - Department of Statistics, College of Management, National Cheng Kung University, 
      Tainan, Taiwan.
FAU - Chang, Wei-Ting
AU  - Chang WT
AD  - Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, 
      No901, Rd. Zhonghua, Yong Kang District, Tainan City, Taiwan.
AD  - Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan.
AD  - Department of Biotechnology, Southern Taiwan University of Science and 
      Technology, Tainan, Taiwan.
FAU - Chen, Zhih-Cherng
AU  - Chen ZC
AD  - Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, 
      No901, Rd. Zhonghua, Yong Kang District, Tainan City, Taiwan.
AD  - Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan, 
      Taiwan.
FAU - Wu, Wen-Shiann
AU  - Wu WS
AD  - Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, 
      No901, Rd. Zhonghua, Yong Kang District, Tainan City, Taiwan.
AD  - Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan, 
      Taiwan.
FAU - Yu, Tsung
AU  - Yu T
AD  - Department of Public Health, College of Medicine, National Cheng Kung University, 
      Tainan, Taiwan.
FAU - Strong, Carol
AU  - Strong C
AD  - Department of Public Health, College of Medicine, National Cheng Kung University, 
      Tainan, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20200910
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/adverse effects/economics/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/economics/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Coronary Artery Disease/drug therapy
MH  - Cost-Benefit Analysis
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Factor Xa Inhibitors/economics/therapeutic use
MH  - Health Expenditures
MH  - Humans
MH  - Markov Chains
MH  - Peripheral Arterial Disease/drug therapy
MH  - Quality-Adjusted Life Years
MH  - Rivaroxaban/administration & dosage/adverse effects/economics/*therapeutic use
MH  - Secondary Prevention/economics/methods
MH  - Taiwan
OTO - NOTNLM
OT  - Cardiovascular diseases
OT  - Coronary artery diseases
OT  - Cost-effectiveness
OT  - Rivaroxaban
OT  - Secondary prevention
EDAT- 2020/09/11 06:00
MHDA- 2021/12/16 06:00
CRDT- 2020/09/10 12:27
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/12/16 06:00 [medline]
PHST- 2020/09/10 12:27 [entrez]
AID - 10.1007/s10557-020-07059-w [pii]
AID - 10.1007/s10557-020-07059-w [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2021 Jun;35(3):539-547. doi: 10.1007/s10557-020-07059-w. 
      Epub 2020 Sep 10.

PMID- 35907319
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20220816
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 219
DP  - 2022 Sep 20
TI  - Monitoring of salicylic acid content in human saliva and its relationship with 
      plasma concentrations.
PG  - 114961
LID - S0731-7085(22)00382-X [pii]
LID - 10.1016/j.jpba.2022.114961 [doi]
AB  - Aspirin is a widely used anti-inflammatory drug. It is reported that a 
      relationship may exist between salicylic acid content in plasma and saliva after 
      taking aspirin. This study established a rapid, convenient, and safe method to 
      assess salicylic acid concentration in human saliva. A novel HPLC-ultraviolet 
      detector was used to measure salicylic acid concentrations in human saliva and 
      plasma. A C18 reversed-phase column with an aqueous solution of 0.1% 
      trifluoroacetic acid (TFA)-acetonitrile mobile phase was used, and drug peaks 
      were recorded at 303 nm. Salicylic acid was completely separated in saliva and 
      plasma. Excellent linearity and correlation (r(2) ≥ 0.9999) was observed between 
      0.1 and 2.0 μg/mL. The detection limit (S/N = 3) was 33 ng/mL, and intra- and 
      inter-day recoveries were 103.5-113.3% and 101.1-109.5%, respectively. Salicylic 
      acid was measured within nine hours after administration of acetylsalicylic acid 
      tablets. A positive correlation between salicylic acid content in saliva and 
      plasma was found (r = 0.867, p < 0.001). The proposed method was used 
      successfully to measure salicylic acid concentration in human saliva. Meanwhile, 
      we explored the relationship between salicylic acid levels in plasma and saliva. 
      Saliva might replace blood for monitoring aspirin treatment. In addition, the 
      research provides a reference for application to saliva samples.
CI  - Copyright © 2022 Elsevier B.V. All rights reserved.
FAU - Cheng, Shengyu
AU  - Cheng S
AD  - Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of 
      Education, Pharmaceutical Analysis, College of Pharmacy Yanbian University, Yanji 
      133002, Jilin Province, China.
FAU - Xu, Xianglin
AU  - Xu X
AD  - Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of 
      Education, Pharmaceutical Analysis, College of Pharmacy Yanbian University, Yanji 
      133002, Jilin Province, China.
FAU - Kong, Xinxin
AU  - Kong X
AD  - Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of 
      Education, Pharmaceutical Analysis, College of Pharmacy Yanbian University, Yanji 
      133002, Jilin Province, China.
FAU - Jiang, Yudi
AU  - Jiang Y
AD  - Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of 
      Education, Pharmaceutical Analysis, College of Pharmacy Yanbian University, Yanji 
      133002, Jilin Province, China.
FAU - Mo, Luxuan
AU  - Mo L
AD  - Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of 
      Education, Pharmaceutical Analysis, College of Pharmacy Yanbian University, Yanji 
      133002, Jilin Province, China.
FAU - Li, Mingxia
AU  - Li M
AD  - Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of 
      Education, Pharmaceutical Analysis, College of Pharmacy Yanbian University, Yanji 
      133002, Jilin Province, China.
FAU - Jin, Yueying
AU  - Jin Y
AD  - Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of 
      Education, Pharmaceutical Analysis, College of Pharmacy Yanbian University, Yanji 
      133002, Jilin Province, China.
FAU - Han, Yu
AU  - Han Y
AD  - Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of 
      Education, Pharmaceutical Analysis, College of Pharmacy Yanbian University, Yanji 
      133002, Jilin Province, China.
FAU - Li, Xi-Ling
AU  - Li XL
AD  - Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of 
      Education, Pharmaceutical Analysis, College of Pharmacy Yanbian University, Yanji 
      133002, Jilin Province, China.
FAU - Jin, Toufeng
AU  - Jin T
AD  - Department of General Surgery Yanbian University Hospital, Yanji 133002, Jilin 
      Province, China. Electronic address: tfjin@ybu.edu.cn.
FAU - Min, Jun Zhe
AU  - Min JZ
AD  - Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of 
      Education, Pharmaceutical Analysis, College of Pharmacy Yanbian University, Yanji 
      133002, Jilin Province, China. Electronic address: junzhemin23@163.com.
LA  - eng
PT  - Journal Article
DEP - 20220723
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Indicators and Reagents)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis
MH  - Chromatography, High Pressure Liquid/methods
MH  - Humans
MH  - Indicators and Reagents
MH  - *Salicylic Acid/analysis
MH  - *Saliva/chemistry
OTO - NOTNLM
OT  - Aspirin
OT  - Drug metabolism
OT  - Metabolite
OT  - Salicylic acid
OT  - Saliva monitoring
EDAT- 2022/07/31 06:00
MHDA- 2022/08/17 06:00
CRDT- 2022/07/30 18:18
PHST- 2022/05/30 00:00 [received]
PHST- 2022/07/18 00:00 [revised]
PHST- 2022/07/21 00:00 [accepted]
PHST- 2022/07/31 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
PHST- 2022/07/30 18:18 [entrez]
AID - S0731-7085(22)00382-X [pii]
AID - 10.1016/j.jpba.2022.114961 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2022 Sep 20;219:114961. doi: 10.1016/j.jpba.2022.114961. 
      Epub 2022 Jul 23.

PMID- 7996060
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20161123
IS  - 0025-7850 (Print)
IS  - 0025-7850 (Linking)
VI  - 25
IP  - 3-4
DP  - 1994
TI  - Potentiation of thrombolytic therapy by enzyme combinations and with aspirin or 
      pentoxifylline.
PG  - 145-61
AB  - Radioactively labeled human fibrin clots were placed into veins of Macaca 
      arctoides monkeys. Thrombolysis was recorded by the disappearance of 
      radioactivity and by angiography. Streptokinase (SK) and urokinase (UK) induced 
      thrombolysis was potentiated by low dose aspirin (ASA) and pentoxifylline (PE). 
      Studies on the mechanisms of action revealed that PE inhibits platelet 
      aggregation, releases tissue plasminogen activator (t-PA) from the endothelium, 
      increases red cell deformability and inhibits white cell adhesion. Thrombolysis 
      by pro-urokinase (pro-UK) was potentiated by low dose SK probably because of 
      streptokinase-plasmin activation of pro-UK to UK. Platelet aggregation inhibitory 
      effects, disaggregation of platelet aggregate inducing effects, and the t-PA 
      releasing activity of PE was demonstrated in patients with obstructive 
      cardiovascular disease. Pharmacodynamic studies suggested that PE metabolites one 
      and five are most effective from this point of view. These metabolites are 
      currently studied in combination with thrombolytic enzymes.
FAU - Ambrus, J L
AU  - Ambrus JL
AD  - Buffalo General Hospital, State University of New York at Buffalo 14203.
FAU - Ambrus, C M
AU  - Ambrus CM
FAU - Stadler, S
AU  - Stadler S
FAU - Toumbis, C
AU  - Toumbis C
FAU - Markus, G
AU  - Markus G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med
JT  - Journal of medicine
JID - 7505566
RN  - 0 (Recombinant Proteins)
RN  - EC 3.4.- (Streptokinase)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
RN  - U5NH2JV64T (saruplase)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Macaca
MH  - Pentoxifylline/pharmacology/*therapeutic use
MH  - Platelet Aggregation/drug effects
MH  - Recombinant Proteins/chemistry/therapeutic use
MH  - Streptokinase/*therapeutic use
MH  - Thrombolytic Therapy/*methods
MH  - Thrombosis/*drug therapy
MH  - Urokinase-Type Plasminogen Activator/chemistry/*therapeutic use
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - J Med. 1994;25(3-4):145-61.

PMID- 26489
OWN - NLM
STAT- MEDLINE
DCOM- 19780814
LR  - 20181113
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 31
IP  - 3
DP  - 1978 Mar
TI  - Interaction of [14C]acetylsalicylic acid with normal human peripheral blood 
      lymphocytes.
PG  - 482-9
AB  - Therapeutic concentrations of acetylsalicylic acid (ASA) have strikingly 
      inhibited in vitro and in vivo mitogen- and antigen-induced blastogenesis by 
      human lymphocytes. These observations may be pertinent to the anti-inflammatory 
      actions of ASA. To investigate further the possible effects of ASA on cellular 
      responses, we studied the in vitro interaction of [14C]ASA with lymphocytes. 
      Results indicated that the [14C]ASA association with cells was (a) proportional 
      to ASA concentrations, (b) non-saturable at high concentrations of ASA, (c) 
      dependent on pH, (d) independent of temperature, (e) dependent on cell 
      concentration, (f) not consistently displaced by unlabelled ASA or other drugs, 
      (g) rapid and unchanged over 1 min to 72 hr incubations and (h) reversed by 
      repeated cell washing. These data confirmed that ASA indeed interacted with 
      lymphocytes. The association was rapid, reversible, pH-dependent and not 
      demonstrably specific under these experimental conditions.
FAU - Anthony, C R
AU  - Anthony CR
FAU - Panush, R S
AU  - Panush RS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Immunologic
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Lymphocyte Activation/*drug effects
MH  - Temperature
MH  - Time Factors
PMC - PMC1541238
EDAT- 1978/03/01 00:00
MHDA- 1978/03/01 00:01
CRDT- 1978/03/01 00:00
PHST- 1978/03/01 00:00 [pubmed]
PHST- 1978/03/01 00:01 [medline]
PHST- 1978/03/01 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Immunol. 1978 Mar;31(3):482-9.

PMID- 1902673
OWN - NLM
STAT- MEDLINE
DCOM- 19910606
LR  - 20190612
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 176
IP  - 2
DP  - 1991 Apr 30
TI  - Inhibition of lipoxygenase and prostaglandin endoperoxide synthase by anacardic 
      acids.
PG  - 775-80
AB  - C22:1 omega 5-anacardic acid was found to be a good inhibitor of both potato 
      lipoxygenase and ovine prostaglandin endoperoxide synthase with approximate 
      IC50's of 6 and 27 microM, respectively. Very similar inhibition was seen with 
      the crude exudate, rich in omega 5-anacardic acids, from glandular trichomes of 
      an arthropod-resistant strain of geranium, Pelargonium xhortorum. The saturated 
      anacardic acid (C22:0 sat), abundant in the trichome exudate of susceptible 
      strains, was nearly as inhibitory toward both prostaglandin endoperoxide synthase 
      and lipoxygenase as the omega 5-unsaturated compound. However, the dimethyl 
      derivative of C22:1 omega 5-anacardic acid was a poor inhibitor of prostaglandin 
      endoperoxide synthase and caused only moderate (32%) inhibition of lipoxygenase 
      even at 135 microM. The possible role of prostaglandin endoperoxide synthase and 
      lipoxygenase inhibition in the enhanced pest resistance of geraniums which 
      produce the omega 5-AnAs is discussed.
FAU - Grazzini, R
AU  - Grazzini R
AD  - Interdepartmental Graduate Program in Genetics, Pennsylvania State University, 
      University Park 16802.
FAU - Hesk, D
AU  - Hesk D
FAU - Heininger, E
AU  - Heininger E
FAU - Hildenbrandt, G
AU  - Hildenbrandt G
FAU - Reddy, C C
AU  - Reddy CC
FAU - Cox-Foster, D
AU  - Cox-Foster D
FAU - Medford, J
AU  - Medford J
FAU - Craig, R
AU  - Craig R
FAU - Mumma, R O
AU  - Mumma RO
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - *Cyclooxygenase Inhibitors
MH  - *Lipoxygenase Inhibitors
MH  - Plants/analysis
MH  - Salicylates/*pharmacology
EDAT- 1991/04/30 00:00
MHDA- 1991/04/30 00:01
CRDT- 1991/04/30 00:00
PHST- 1991/04/30 00:00 [pubmed]
PHST- 1991/04/30 00:01 [medline]
PHST- 1991/04/30 00:00 [entrez]
AID - S0006-291X(05)80252-9 [pii]
AID - 10.1016/s0006-291x(05)80252-9 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1991 Apr 30;176(2):775-80. doi: 
      10.1016/s0006-291x(05)80252-9.

PMID- 18160610
OWN - NLM
STAT- MEDLINE
DCOM- 20090319
LR  - 20131121
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 15
IP  - 1
DP  - 2009 Feb
TI  - Aspirin-resistance frequency: a prospective study in 280 healthy Turkish 
      volunteers.
PG  - 98-102
AB  - This study reports the frequency of aspirin resistance and its correlation with 
      clinical and biochemical parameters among 280 healthy Turkish volunteers (179 
      men, 101 women) who were taking 100 mg of aspirin 7 days or more. Aspirin 
      resistance was detected by optical platelet aggregometry, using adenosine 
      diphosphate and arachidonic acid, and defined as a mean aggregation of 64% or 
      more with 5AmicroM adenosine diphosphate and a mean aggregation of 20% or more 
      with 0.5-mg/mL arachidonic acid. Of the study population, 27.5% (26 women [25.5 
      %] and 51 men [28.5 %]) were aspirin resistant. The current findings indicate 
      that aspirin resistance is an important and real laboratory diagnosis given its 
      frequency of 27.5% in the study population. These results of this large trial 
      evaluating the frequency of aspirin resistance in healthy subjects indicate that 
      aspirin resistance should be diagnosed so that individuals with no response can 
      receive alternative or additional antiplatelet therapy.
FAU - Akay, O Meltem
AU  - Akay OM
AD  - Department of Hematology Eskişehir Osmangazi University Medical School, 
      Eskişehir, Türkiye.
FAU - Canturk, Zerrin
AU  - Canturk Z
FAU - Akin, Enver
AU  - Akin E
FAU - Bal, Cengiz
AU  - Bal C
FAU - Gulbas, Zafer
AU  - Gulbas Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071226
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Turkey
EDAT- 2007/12/28 09:00
MHDA- 2009/03/20 09:00
CRDT- 2007/12/28 09:00
PHST- 2007/12/28 09:00 [pubmed]
PHST- 2009/03/20 09:00 [medline]
PHST- 2007/12/28 09:00 [entrez]
AID - 1076029607306806 [pii]
AID - 10.1177/1076029607306806 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2009 Feb;15(1):98-102. doi: 10.1177/1076029607306806. 
      Epub 2007 Dec 26.

PMID- 31653428
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20200828
IS  - 1097-685X (Electronic)
IS  - 0022-5223 (Linking)
VI  - 160
IP  - 3
DP  - 2020 Sep
TI  - Association between preoperative aspirin and acute kidney injury following 
      coronary artery bypass grafting.
PG  - 712-719
LID - S0022-5223(19)31931-2 [pii]
LID - 10.1016/j.jtcvs.2019.08.119 [doi]
AB  - OBJECTIVE: To test the hypothesis that preoperative aspirin administered within 
      24 hours before coronary artery bypass grafting (CABG) could reduce the incidence 
      of postoperative acute kidney injury (AKI) following CABG. METHODS: In this 
      retrospective study, 696 patients were assigned to groups according to the time 
      interval between their last aspirin dose administration and the time of surgery. 
      A total of 322 patients received aspirin ≤24 hours before CABG, and 374 patients 
      received aspirin between 24 and 48 hours before CABG. The primary outcome was 
      postoperative AKI of any stage as defined by the Kidney Disease Improving Global 
      Outcomes criteria. Propensity score matching selected 274 pairs for the final 
      comparison. RESULTS: Multivariable analysis showed that administration of aspirin 
      within 24 hours of CABG was independently associated with reduction of AKI 
      incidence by 36% (odds ratio, 0.64; 95% confidence interval, 0.45-0.91; 
      P = .014). It was also noted that patients receiving their last aspirin dose 
      ≤24 hours before CABG had a significantly higher glomerular filtration rate at 
      discharge compared with patients who received aspirin between 24 and 48 hours 
      before CABG. Propensity score matching analysis showed that patients receiving 
      aspirin within 24 hours before CABG had a lower incidence of AKI compared with 
      patients who discontinued aspirin between 24 and 48 hours before CABG (25.1% vs 
      36.8%; P = .004). CONCLUSIONS: Continuation of aspirin until the day of surgery, 
      with the last aspirin dose administered ≤24 hours before CABG, is associated with 
      a significant reduction of postoperative AKI.
CI  - Copyright © 2019 The American Association for Thoracic Surgery. Published by 
      Elsevier Inc. All rights reserved.
FAU - Aboul-Hassan, Sleiman Sebastian
AU  - Aboul-Hassan SS
AD  - Department of Cardiac Surgery, Medinet Heart Center Ltd, Nowa Sol, Poland. 
      Electronic address: s.aboulhassan@gmail.com.
FAU - Marczak, Jakub
AU  - Marczak J
AD  - Department of Cardiac Surgery, Trent Cardiac Centre, Nottingham University 
      Hospital, Nottingham, United Kingdom.
FAU - Stankowski, Tomasz
AU  - Stankowski T
AD  - Department of Cardiac Surgery, Sana-Heart Center Cottbus, Cottbus, Germany.
FAU - Peksa, Maciej
AU  - Peksa M
AD  - Department of Cardiac Surgery, Medinet Heart Center Ltd, Nowa Sol, Poland.
FAU - Nawotka, Marcin
AU  - Nawotka M
AD  - Department of Cardiac Surgery, Medinet Heart Center Ltd, Nowa Sol, Poland.
FAU - Stanislawski, Ryszard
AU  - Stanislawski R
AD  - Department of Cardiac Surgery, Medinet Heart Center Ltd, Nowa Sol, Poland.
FAU - Cichon, Romuald
AU  - Cichon R
AD  - Department of Cardiac Surgery, Medinet Heart Center Ltd, Nowa Sol, Poland; 
      Department of Cardiac Surgery, Warsaw Medical University, Warsaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20190925
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Thorac Cardiovasc Surg. 2020 Sep;160(3):720-721. PMID: 31718848
MH  - Acute Kidney Injury/*epidemiology/prevention & control
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Coronary Artery Bypass/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Postoperative Complications/*epidemiology/prevention & control
MH  - Retrospective Studies
OTO - NOTNLM
OT  - AKI
OT  - CABG
OT  - preoperative aspirin
OT  - renal failure
EDAT- 2019/10/28 06:00
MHDA- 2020/08/29 06:00
CRDT- 2019/10/27 06:00
PHST- 2019/04/09 00:00 [received]
PHST- 2019/08/28 00:00 [revised]
PHST- 2019/08/30 00:00 [accepted]
PHST- 2019/10/28 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
PHST- 2019/10/27 06:00 [entrez]
AID - S0022-5223(19)31931-2 [pii]
AID - 10.1016/j.jtcvs.2019.08.119 [doi]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 2020 Sep;160(3):712-719. doi: 
      10.1016/j.jtcvs.2019.08.119. Epub 2019 Sep 25.

PMID- 34657610
OWN - NLM
STAT- MEDLINE
DCOM- 20211019
LR  - 20211024
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 21
IP  - 1
DP  - 2021 Oct 17
TI  - Short-term aspirin and statin chemoprophylaxis did not reduce the risk of 
      developing advanced adenomatous polyps in Black patients.
PG  - 379
LID - 10.1186/s12876-021-01966-4 [doi]
LID - 379
AB  - BACKGROUND: Chemoprevention of colorectal neoplasia with aspirin and statins is 
      under-investigated in Black patients. Since Black patients suffer 
      disproportionately from colon cancer incidence and mortality compared to other 
      populations, we investigated the utility of aspirin and statin in reducing 
      advanced adenomatous polyp (AAP) risk in Black patients. METHODS: We carried out 
      a retrospective cohort study of screening colonoscopies performed at a large 
      urban academic center from 1/1/2011 through 12/31/2019. We analyzed 
      self-identified Black patients with > 1 colonoscopy and no personal history of 
      either inflammatory bowel disease or colon cancer syndromes. Our primary endpoint 
      was first AAP development after index colonoscopy among Black patients taking 
      both aspirin and a statin compared to those taking one or neither medication. We 
      used multivariate logistic regression modeling to investigate our outcomes. 
      RESULTS: We found data on chemoprophylaxis use in 560 patients. The mean 
      observation period between index colonoscopy and AAP identification was 4 years. 
      AAP developed in 106/560 (19%) of our cohort. We found no difference in AAP risk 
      among Black patients taking both chemoprevention medications compared to partial 
      or no chemoprophylaxis (20% vs 18% respectively, p = 0.49). This finding remained 
      after adjusting for age, body mass index, and tobacco use (odds ratio 1.04, 95% 
      CI 0.65-1.67; p = 0.87). CONCLUSIONS: Short-term aspirin-statin chemoprevention 
      did not reduce the risk of AAP development in our cohort of Black patients. 
      Larger and long-term prospective investigations are needed to investigate the 
      utility of chemoprophylaxis in this population. TRIAL REGISTRATION: Not 
      applicable.
CI  - © 2021. The Author(s).
FAU - Renelus, Benjamin D
AU  - Renelus BD
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins University School of 
      Medicine, Baltimore, MD, USA.
FAU - Dixit, Devika
AU  - Dixit D
AD  - Department of Internal Medicine, University of Florida, Gainesville, FL, USA.
FAU - Nguyen, Phuong T
AU  - Nguyen PT
AD  - Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA, USA.
FAU - Njoku, Kingsley K
AU  - Njoku KK
AD  - Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA, USA.
FAU - Patel, Parth B
AU  - Patel PB
AD  - Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA, USA.
FAU - Pintor-Jimenez, Katiria
AU  - Pintor-Jimenez K
AD  - Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA, USA.
FAU - Yan, Fengxia
AU  - Yan F
AD  - Department of Community Health and Preventative Medicine, Morehouse School of 
      Medicine, Atlanta, GA, USA.
FAU - Buscaglia, Jonathan M
AU  - Buscaglia JM
AD  - Division of Gastroenterology and Hepatology, Stony Brook Medicine, 101 Nicolls 
      Road, Stony Brook, NY, HSC T17-06011794, USA.
FAU - Woods, Kevin E
AU  - Woods KE
AD  - Therapuetic GI Associates, LLC, Atlanta, GA, USA.
FAU - Jamorabo, Daniel S
AU  - Jamorabo DS
AD  - Division of Gastroenterology and Hepatology, Stony Brook Medicine, 101 Nicolls 
      Road, Stony Brook, NY, HSC T17-06011794, USA. djambo85@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20211017
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Adenomatous Polyps
MH  - Aspirin/therapeutic use
MH  - Chemoprevention
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Prospective Studies
MH  - Retrospective Studies
PMC - PMC8520575
OTO - NOTNLM
OT  - Advanced adenomatous polyps
OT  - Black patients
OT  - Chemoprevention
COIS- The authors declare that they have no competing interests.
EDAT- 2021/10/19 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/10/18 05:27
PHST- 2021/04/12 00:00 [received]
PHST- 2021/09/27 00:00 [accepted]
PHST- 2021/10/18 05:27 [entrez]
PHST- 2021/10/19 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - 10.1186/s12876-021-01966-4 [pii]
AID - 1966 [pii]
AID - 10.1186/s12876-021-01966-4 [doi]
PST - epublish
SO  - BMC Gastroenterol. 2021 Oct 17;21(1):379. doi: 10.1186/s12876-021-01966-4.

PMID- 31997490
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20210611
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 27
IP  - 5
DP  - 2020 May
TI  - Higher early recurrence risk and potential benefit of dual antiplatelet therapy 
      for minor stroke with watershed infarction: subgroup analysis of CHANCE.
PG  - 800-808
LID - 10.1111/ene.14156 [doi]
AB  - BACKGROUND AND PURPOSE: The aim was to explore the risk of early stroke 
      recurrence within 3 months after watershed infarction and to investigate whether 
      early dual antiplatelet therapy is more effective in decreasing such risk. 
      METHODS: Patients enrolled in the Clopidogrel in High-risk Patients with Acute 
      Non-disabling Cerebrovascular Events (CHANCE) trial and who had acute infarction 
      on diffusion-weighted imaging were included in this subgroup analysis. All 
      magnetic resonance images were read centrally by two neurologists who were 
      blinded to the patients' baseline and outcome information. The primary outcome 
      was any stroke recurrence within 3 months. The hazard ratios were adjusted by 
      known predictors of stroke recurrence. RESULTS: Of the 1089 patients with 
      magnetic resonance imaging data enrolled in CHANCE, 834 (76.58%) patients had 
      acute infarcts on diffusion-weighted imaging. The median and range of duration 
      from randomization to stroke recurrence was 1.5 (1-6) days. Patients with 
      watershed infarction had higher risk of stroke recurrence than those without 
      (17.20% vs. 6.34%) within the first week after initial stroke; the hazard ratio 
      (95% confidence interval) was 2.799 (1.536-5.101) adjusted by age, sex, smoking, 
      body mass index, medical history, time to randomization, open-label aspirin dose 
      at first day, single or dual antiplatelet therapy, National Institutes of Health 
      Stroke Scale score at randomization, in-hospital treatment and white matter 
      lesions, P < 0.001. There was no interaction between antiplatelet therapy and the 
      presence of watershed infarction (P = 0.544). CONCLUSIONS: Minor stroke with 
      watershed infarction has high recurrent risk in the first week. Dual antiplatelet 
      therapy may be safely implemented, yet watershed infarction mechanisms of 
      hypoperfusion and emboli may not be addressed.
CI  - © 2020 European Academy of Neurology.
FAU - Pu, Y
AU  - Pu Y
AUID- ORCID: 0000-0002-9443-2706
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Liu, X
AU  - Liu X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wang, Y
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Meng, X
AU  - Meng X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Jing, J
AU  - Jing J
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Zou, X
AU  - Zou X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Pan, Y
AU  - Pan Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Wang, A
AU  - Wang A
AUID- ORCID: 0000-0003-4351-2877
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Zhao, X
AU  - Zhao X
AUID- ORCID: 0000-0002-8636-9540
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Johnston, S C
AU  - Johnston SC
AD  - Dell Medical School, University of Texas at Austin, TX, USA.
FAU - Wang, Y
AU  - Wang Y
AUID- ORCID: 0000-0001-9377-2867
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Atchaneeyasakul, K
AU  - Atchaneeyasakul K
AD  - UCLA Stroke Center, Los Angeles, CA, USA.
FAU - Liebeskind, D S
AU  - Liebeskind DS
AD  - UCLA Stroke Center, Los Angeles, CA, USA.
FAU - Liu, L
AU  - Liu L
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
CN  - CHANCE Investigators
LA  - eng
GR  - 2015BAI12B04/Ministry of Science and Technology of the People's Republic of 
      China/International
GR  - 2015BAI12B02/Ministry of Science and Technology of the People's Republic of 
      China/International
GR  - 2016YFC0901000/Ministry of Science and Technology of the People's Republic of 
      China/International
GR  - 2016YFC0901001/Ministry of Science and Technology of the People's Republic of 
      China/International
GR  - 2016YFC0901002/Ministry of Science and Technology of the People's Republic of 
      China/International
GR  - D151100002015001/Beijing Municipal Science and Technology 
      Commission/International
GR  - D151100002015002/Beijing Municipal Science and Technology 
      Commission/International
GR  - D151100002015003/Beijing Municipal Science and Technology 
      Commission/International
GR  - Z15110200390000/Beijing Municipal Science and Technology Commission/International
GR  - Z151100003915117/Beijing Municipal Science and Technology 
      Commission/International
GR  - 2016-1-2041/Beijing Municipal Commission of Health and Family 
      Planning/International
GR  - SML20150502/Beijing Municipal Commission of Health and Family 
      Planning/International
GR  - ,/International
GR  - Z161100004916104/Beijing Nova Program Projects/International
GR  - . 81870913/National Natural Science Foundation of China/International
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200303
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Infarction/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*therapeutic use
MH  - *Recurrence
MH  - Stroke/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - cerebral infarction
OT  - minor stroke
OT  - prognosis
OT  - watershed infarction
EDAT- 2020/01/31 06:00
MHDA- 2021/06/12 06:00
CRDT- 2020/01/31 06:00
PHST- 2019/06/22 00:00 [received]
PHST- 2020/01/17 00:00 [accepted]
PHST- 2020/01/31 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
PHST- 2020/01/31 06:00 [entrez]
AID - 10.1111/ene.14156 [doi]
PST - ppublish
SO  - Eur J Neurol. 2020 May;27(5):800-808. doi: 10.1111/ene.14156. Epub 2020 Mar 3.

PMID- 3094711
OWN - NLM
STAT- MEDLINE
DCOM- 19861205
LR  - 20190501
IS  - 0267-0623 (Print)
IS  - 0267-0623 (Linking)
VI  - 293
IP  - 6552
DP  - 1986 Oct 11
TI  - Effect of aspirin on pruritus.
PG  - 907
AB  - The effect of 900 mg aspirin on persistent itch from chronic dermatoses other 
      than urticaria (eight patients) and other causes (five patients) was measured 
      subjectively using a 10 cm line and objectively as nocturnal scratch using limb 
      meters. There was no change in itch or scratch and it is concluded that aspirin 
      neither affects itch centrally by a pain related mechanism nor affects itch 
      physiologically by cyclo-oxygenase inhibition in the skin.
FAU - Daly, B M
AU  - Daly BM
FAU - Shuster, S
AU  - Shuster S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Br Med J (Clin Res Ed)
JT  - British medical journal (Clinical research ed.)
JID - 8302911
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pruritus/*drug therapy/etiology
MH  - Skin Diseases/complications
PMC - PMC1341706
EDAT- 1986/10/11 00:00
MHDA- 1986/10/11 00:01
CRDT- 1986/10/11 00:00
PHST- 1986/10/11 00:00 [pubmed]
PHST- 1986/10/11 00:01 [medline]
PHST- 1986/10/11 00:00 [entrez]
AID - 10.1136/bmj.293.6552.907 [doi]
PST - ppublish
SO  - Br Med J (Clin Res Ed). 1986 Oct 11;293(6552):907. doi: 10.1136/bmj.293.6552.907.

PMID- 9065133
OWN - NLM
STAT- MEDLINE
DCOM- 19970317
LR  - 20220408
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 174
IP  - 5
DP  - 1996 May
TI  - Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with 
      heparin and low-dose aspirin is superior to low-dose aspirin alone.
PG  - 1584-9
AB  - OBJECTIVE: The purpose of this study was to compare the use of low-dose aspirin 
      alone with heparin and low-dose aspirin in the treatment of the antiphospholipid 
      antibody syndrome. STUDY DESIGN: A prospective, single-center trial included 50 
      patients who were alternately assigned to treatment. Each patient had at least 
      three consecutive spontaneous pregnancy losses, positive antiphospholipid 
      antibodies on two occasions, and a complete evaluation. Data were compared by 
      chi(2) analysis and Fisher's exact test. RESULTS: Viable infants were delivered 
      of 11 of 25 (44%) women treated with aspirin and 20 of 25 (80%) women treated 
      with heparin and aspirin (p < 0.05). There were no significant differences 
      between the low-dose aspirin and the heparin plus low-dose aspirin groups with 
      respect to gestational age at delivery (37.8 +/- 2.1 vs 37.2 +/- 3.4 weeks), 
      number of cesarean sections (18% vs 20%), or complications. CONCLUSION: Heparin 
      plus low-dose aspirin provides a significantly better pregnancy outcome than 
      low-dose aspirin alone does for antiphospholipid antibody-associated recurrent 
      pregnancy loss.
FAU - Kutteh, W H
AU  - Kutteh WH
AD  - Department of Obstetrics and Gynecology, University of Texas Southwestern Medical 
      Center at Dallas 75235-9032, USA.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*drug therapy/etiology/*immunology
MH  - Adult
MH  - Antiphospholipid Syndrome/complications/*drug therapy/*immunology
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy/*immunology
MH  - Pregnancy Outcome
MH  - Prospective Studies
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - S0002-9378(96)70610-5 [pii]
AID - 10.1016/s0002-9378(96)70610-5 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1996 May;174(5):1584-9. doi: 10.1016/s0002-9378(96)70610-5.

PMID- 5547756
OWN - NLM
STAT- MEDLINE
DCOM- 19710426
LR  - 20190511
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 41
IP  - 1
DP  - 1971 Jan
TI  - Factors influencing the inhibitory action of anti-inflammatory drugs on 
      carrageenin induced oedema.
PG  - 132-9
AB  - 1. In a series of experiments carried out over 2(1/2) years, the inflammatory 
      response of the rat hind paw to injected carrageenin was relatively constant, but 
      the anti-inflammatory activity of phenylbutazone was subject to wide variation.2. 
      Phenylbutazone, aspirin and indomethacin were all well absorbed after oral 
      administration, and the resultant plasma drug concentrations were closely similar 
      to those produced when the drugs were administered intraperitoneally.3. The 
      anti-inflammatory effect of the drugs on carrageenin oedema was variable and 
      poorly correlated with log dose and plasma concentration.4. There was a 
      pronounced and linearly correlated increase in the anti-inflammatory activity of 
      phenylbutazone with increasing ambient temperature in the range 5-30 degrees C.5. 
      Variations in relative humidity at constant temperature (20 degrees C) did not 
      influence the anti-oedema potency of phenylbutazone.6. For the precise evaluation 
      of anti-inflammatory activity in carrageenin oedema tests, it is concluded that 
      accurate control of temperature is essential.
FAU - Green, A Y
AU  - Green AY
FAU - Green, D
AU  - Green D
FAU - Murray, P A
AU  - Murray PA
FAU - Wilson, A B
AU  - Wilson AB
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 9000-07-1 (Carrageenan)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage/blood/metabolism
MH  - *Carrageenan
MH  - Edema/chemically induced/*drug therapy
MH  - Female
MH  - Hindlimb
MH  - Humidity
MH  - Indomethacin/*administration & dosage/blood/metabolism
MH  - Injections, Intraperitoneal
MH  - Intestinal Absorption
MH  - Phenylbutazone/*administration & dosage/blood/metabolism
MH  - Rats
MH  - Temperature
PMC - PMC1702749
EDAT- 1971/01/01 00:00
MHDA- 1971/01/01 00:01
CRDT- 1971/01/01 00:00
PHST- 1971/01/01 00:00 [pubmed]
PHST- 1971/01/01 00:01 [medline]
PHST- 1971/01/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1971.tb09943.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1971 Jan;41(1):132-9. doi: 10.1111/j.1476-5381.1971.tb09943.x.

PMID- 7906809
OWN - NLM
STAT- MEDLINE
DCOM- 19940328
LR  - 20170920
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 343
IP  - 8898
DP  - 1994 Mar 12
TI  - CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of 
      pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin 
      Study in Pregnancy) Collaborative Group.
PG  - 619-29
AB  - Pre-eclampsia is a common and serious complication of pregnancy that affects both 
      mother and child. Review of previous small trials of antiplatelet therapy, 
      particularly low-dose aspirin, suggested reductions of about three-quarters in 
      the incidence of pre-eclampsia and some avoidance of intrauterine growth 
      retardation (IUGR), but larger trials have not confirmed these results. In our 
      multicentre study 9364 women were randomly assigned 60 mg aspirin daily or 
      matching placebo. 74% were entered for prophylaxis of pre-eclampsia, 12% for 
      prophylaxis of IUGR, 12% for treatment of pre-eclampsia, and 3% for treatment of 
      IUGR. Overall, the use of aspirin was associated with a reduction of only 12% in 
      the incidence of proteinuric pre-eclampsia, which was not significant. Nor was 
      there any significant effect on the incidence of IUGR or of stillbirth and 
      neonatal death. Aspirin did, however, significantly reduce the likelihood of 
      preterm delivery (19.7% aspirin vs 22.2% control; absolute reduction of 2.5 [SD 
      0.9] per 100 women treated; 2p = 0.003). There was a significant trend (p = 
      0.004) towards progressively greater reductions in proteinuric pre-eclampsia the 
      more preterm the delivery. Aspirin was not associated with a significant increase 
      in placental haemorrhages or in bleeding during preparation for epidural 
      anaesthesia, but there was a slight increase in use of blood transfusion after 
      delivery. Low-dose aspirin was generally safe for the fetus and newborn infant, 
      with no evidence of an increased likelihood of bleeding. Our findings do not 
      support routine prophylactic or therapeutic administration of antiplatelet 
      therapy in pregnancy to all women at increased risk of pre-eclampsia or IUGR. 
      Low-dose aspirin may be justified in women judged to be especially liable to 
      early-onset pre-eclampsia severe enough to need very preterm delivery. In such 
      women it seems appropriate to start low-dose aspirin prophylactically early in 
      the second trimester.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 1994 Mar 12;343(8898):616-7. PMID: 7906806
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Birth Weight
MH  - Female
MH  - Fetal Death
MH  - Fetal Growth Retardation/drug therapy/*prevention & control
MH  - Humans
MH  - Infant Mortality
MH  - Infant, Newborn
MH  - Pre-Eclampsia/drug therapy/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Treatment Outcome
EDAT- 1994/03/12 00:00
MHDA- 1994/03/12 00:01
CRDT- 1994/03/12 00:00
PHST- 1994/03/12 00:00 [pubmed]
PHST- 1994/03/12 00:01 [medline]
PHST- 1994/03/12 00:00 [entrez]
AID - S0140-6736(94)92633-6 [pii]
PST - ppublish
SO  - Lancet. 1994 Mar 12;343(8898):619-29.

PMID- 22321277
OWN - NLM
STAT- MEDLINE
DCOM- 20150514
LR  - 20120210
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 39
IP  - 10
DP  - 2011 Oct
TI  - [Aspirin response and related factors in aged patients].
PG  - 925-8
AB  - OBJECTIVE: To explore clinical and laboratory factors associated aspirin 
      response, and the association between gastrointestinal bleeding and aspirin 
      response in aged patients. METHODS: A total of 136 patients aged 60 and over 
      [mean age (74.9 ± 7.0) years] with ischemic heart disease and at high risk for 
      ischemic heart disease were included. Arachidonic acid induced platelet 
      aggregation (AA-Ag) was measured before and at 7(th) day after taking aspirin 
      (100 mg/d). Patients were followed for 6 months and incidence of gastrointestinal 
      bleeding was obtained. RESULTS: Post-treatment AA-Ag was significantly reduced 
      compared to baseline (13.29% ± 5.52% vs. 73.20% ± 7.32%, P < 0.05). A 
      heterogeneous distributed post-treatment AA-Ag was observed (range 0.42% to 
      30.50%). Post-treatment AA-Ag was positively correlated with baseline AA-Ag (r = 
      0.493, P < 0.01). The level of post-treatment AA-Ag was significantly higher in 
      the fourth quartile group at baseline than in the others quartile groups at 
      baseline. Patients aged 80 years and over had significantly lower post-treatment 
      AA-Ag (10.25% ± 4.68%) compared with patients of 60 - 69 years (13.96% ± 5.20%) 
      and of 70 - 79 years (13.73% ± 5.48%, all P < 0.01). The incidence of patients in 
      the lowest quartile of post-treatment AA-Ag was significantly higher in patients 
      ≥ 80 years (38.24%) than in patients of 60 - 69 years (11.1%) and of 70 - 79 
      years (24.0%). Multiple variable analysis revealed post-treatment AA-Ag was 
      significantly influenced by baseline AA-Ag, ≥ 80 years old, diabetes mellitus and 
      acute coronary syndrome. We observed 4 (2.9%) mild gastrointestinal bleeding 
      during follow up. Post-treatment AA-Ag was in the lowest quartile in 3 patients 
      with mild gastrointestinal bleeding. CONCLUSIONS: Increased baseline platelet 
      reactivity as well as diabetes mellitus and acute coronary syndrome are 
      associated with low aspirin response in the aged patients. Aspirin response is 
      significantly higher in very old patients.
FAU - Feng, Xue-ru
AU  - Feng XR
AD  - Department of Geriatrics, Peking University First Hospital, Beijing 100034, 
      China.
FAU - Liu, Mei-lin
AU  - Liu ML
FAU - Liu, Fang
AU  - Liu F
FAU - Tian, Qing-ping
AU  - Tian QP
FAU - Fan, Yan
AU  - Fan Y
FAU - Liu, Qian-zhu
AU  - Liu QZ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Coronary Artery Disease/drug therapy
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Ischemia/drug therapy
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Platelet Function Tests
MH  - Ticlopidine
EDAT- 2012/02/11 06:00
MHDA- 2015/05/15 06:00
CRDT- 2012/02/11 06:00
PHST- 2012/02/11 06:00 [entrez]
PHST- 2012/02/11 06:00 [pubmed]
PHST- 2015/05/15 06:00 [medline]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Oct;39(10):925-8.

PMID- 6804150
OWN - NLM
STAT- MEDLINE
DCOM- 19820722
LR  - 20190511
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 31
IP  - 5
DP  - 1982 May
TI  - Interaction between valproic acid and aspirin in epileptic children: serum 
      protein binding and metabolic effects.
PG  - 642-9
AB  - In five of six epileptic children who were taking 18 to 49 mg/kg/day valproic 
      acid (VPA), the steady-state serum free fractions of VPA rose from 12% to 43% 
      when antipyretic doses of aspirin were also taken. Mean total VPA half-life 
      (t1/2) rose from 10.4 +/- 2.7 to 12.9 +/- 1.8 hr and mean free VPA t1/2 rose from 
      6.7 +/- to 2.1 to 8.9 +2- 3.0 hr when salicylate was present in the serum. The in 
      vitro albumin binding association constant (ka) for VPA was decreased by 
      salicylate, but the in vivo ka value was not affected. The 12-hr (trough) 
      concentrations of both free and total VPA were higher in the presence of serum 
      salicylate in five of six patients. Renal excretion of unchanged VPA decreased in 
      five of six patients, but the VPA carboxyl conjugate metabolite-excretion 
      patterns were not consistently affected. Salicylate appeared to displace VPA from 
      serum albumin in vivo, but the increased VPA t1/2 and changes in VPA elimination 
      patterns suggest that serum salicylate also altered VPA metabolism.
FAU - Orr, J M
AU  - Orr JM
FAU - Abbott, F S
AU  - Abbott FS
FAU - Farrell, K
AU  - Farrell K
FAU - Ferguson, S
AU  - Ferguson S
FAU - Sheppard, I
AU  - Sheppard I
FAU - Godolphin, W
AU  - Godolphin W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Blood Proteins)
RN  - 0 (Salicylates)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*metabolism/pharmacology
MH  - Blood Proteins/metabolism
MH  - Child
MH  - Child, Preschool
MH  - Drug Interactions
MH  - Epilepsy/*metabolism
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Protein Binding
MH  - Salicylates/blood
MH  - Valproic Acid/*blood
EDAT- 1982/05/01 00:00
MHDA- 1982/05/01 00:01
CRDT- 1982/05/01 00:00
PHST- 1982/05/01 00:00 [pubmed]
PHST- 1982/05/01 00:01 [medline]
PHST- 1982/05/01 00:00 [entrez]
AID - 0009-9236(82)90055-8 [pii]
AID - 10.1038/clpt.1982.89 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1982 May;31(5):642-9. doi: 10.1038/clpt.1982.89.

PMID- 15836656
OWN - NLM
STAT- MEDLINE
DCOM- 20050526
LR  - 20220331
IS  - 0954-6820 (Print)
IS  - 0954-6820 (Linking)
VI  - 257
IP  - 5
DP  - 2005 May
TI  - Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks 
      after its perioperative withdrawal versus bleeding risks with its continuation - 
      review and meta-analysis.
PG  - 399-414
AB  - OBJECTIVES: Low-dose aspirin given for secondary prevention of cardiovascular 
      disease is frequently withdrawn prior to surgical or diagnostic procedures to 
      reduce bleeding complications. This may expose patients to increased 
      cardiovascular morbidity and mortality. Aim of the study was to review and 
      quantify cardiovascular risks because of periprocedural aspirin withdrawal and 
      bleeding risks with the continuation of aspirin. METHODS: We screened MEDLINE 
      (January 1970-October 2004) with additional manual cross-referencing for clinical 
      studies, surveys on the opinions of doctors and guidelines. RESULTS: Studies 
      reporting the relative risk of acute cardiovascular events after aspirin 
      withdrawal when compared with its continuation were not found. However, 
      retrospective investigations revealed that aspirin withdrawal precedes up to 
      10.2% of acute cardiovascular syndromes. The time interval between 
      discontinuation and acute cerebral events was 14.3 +/- 11.3 days, 8.5 +/- 3.6 
      days for acute coronary syndromes, and 25.8 +/- 18.1 days for acute peripheral 
      arterial syndromes (P < 0.02 versus acute coronary syndromes). On aspirin-related 
      bleeding risks, we obtained 41 (12 observational retrospective, 19 observational 
      prospective, 10 randomized) studies, reporting on 49 590 patients (14 981 on 
      aspirin). Baseline frequency of bleeding complications varied between 0 (skin 
      lesion excision, cataract surgery) and 75% (transrectal prostate biopsy). Whilst 
      aspirin increased the rate of bleeding complications by factor 1.5 (median, 
      interquartile range: 1.0-2.5), it did not lead to a higher level of the severity 
      of bleeding complications (exception: intracranial surgery, and possibly 
      transurethral prostatectomy). Surveys amongst doctors on the management of this 
      problem demonstrate wide variations. Available guidelines are scarce and in part 
      contradictory. CONCLUSIONS: Only if low-dose aspirin may cause bleeding risks 
      with increased mortality or sequels comparable with the observed cardiovascular 
      risks after aspirin withdrawal, it should be discontinued prior to an intended 
      operation or procedure. Controlled clinical studies are urgently needed.
FAU - Burger, W
AU  - Burger W
AD  - Department of Interventional Cardiology, St Georg Hospital, Leipzig, Germany. 
      wolframburger@aol.com <wolframburger@aol.com>
FAU - Chemnitius, J-M
AU  - Chemnitius JM
FAU - Kneissl, G D
AU  - Kneissl GD
FAU - Rücker, G
AU  - Rücker G
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Evid Based Cardiovasc Med. 2005 Sep;9(3):234-6. PMID: 16380041
MH  - Acute Disease
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - *Blood Loss, Surgical
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Administration Schedule
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Preoperative Care
MH  - Randomized Controlled Trials as Topic
MH  - Risk
RF  - 74
EDAT- 2005/04/20 09:00
MHDA- 2005/05/27 09:00
CRDT- 2005/04/20 09:00
PHST- 2005/04/20 09:00 [pubmed]
PHST- 2005/05/27 09:00 [medline]
PHST- 2005/04/20 09:00 [entrez]
AID - JIM1477 [pii]
AID - 10.1111/j.1365-2796.2005.01477.x [doi]
PST - ppublish
SO  - J Intern Med. 2005 May;257(5):399-414. doi: 10.1111/j.1365-2796.2005.01477.x.

PMID- 3086889
OWN - NLM
STAT- MEDLINE
DCOM- 19860721
LR  - 20200930
IS  - 0037-9727 (Print)
IS  - 0037-9727 (Linking)
VI  - 182
IP  - 3
DP  - 1986 Jul
TI  - Slow intravenous administration of low dose aspirin inhibits both vascular and 
      platelet cyclooxygenase activity: an experimental study in the rat.
PG  - 287-90
AB  - Aspirin irreversibly inhibits cyclooxygenase, thus preventing thromboxane (Tx)A2 
      production in platelets and prostacyclin in vascular cells. While it is generally 
      accepted that the inhibitory effect of low dose aspirin is cumulative on platelet 
      cyclooxygenase, it is still a matter of debate whether a similar phenomenon also 
      occurs on vascular cyclooxygenase. We have measured in anesthetized rats the 
      inhibitory effect of two doses of aspirin (2.5 and 5.0 mg/kg), given 
      intravenously either as a bolus or as a continuous infusion (for 30 min), on 
      platelet TxB2 and 6-ketoprostaglandin F1 alpha generation by different vascular 
      segments. Aspirin significantly inhibited both platelet and vascular 
      cyclooxygenase independently of the rate of drug administration. The aspirin peak 
      plasma levels at the end of bolus injection was about 170 times higher than the 
      average level measured during the slow infusion (1.21 +/- 0.15 micrograms/ml). At 
      this concentration aspirin did not affect in vitro either platelet or vascular 
      cyclooxygenase activity. Thus the inhibitory effect of aspirin on both platelet 
      and vascular cyclooxygenase seems to be related to total exposure of the enzyme 
      to the drug rather than to the maximal drug concentration attainable in the 
      systemic circulation. These findings may be relevant to the current debate on 
      optimal conditions for the biochemical selectivity of aspirin as an 
      antithrombotic drug.
FAU - Gambino, M C
AU  - Gambino MC
FAU - Cerletti, C
AU  - Cerletti C
FAU - Marchi, S
AU  - Marchi S
FAU - Garattini, S
AU  - Garattini S
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Proc Soc Exp Biol Med
JT  - Proceedings of the Society for Experimental Biology and Medicine. Society for 
      Experimental Biology and Medicine (New York, N.Y.)
JID - 7505892
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/blood
MH  - Blood Platelets/*enzymology
MH  - Blood Vessels/*enzymology
MH  - *Cyclooxygenase Inhibitors
MH  - Epoprostenol/biosynthesis
MH  - Injections, Intravenous
MH  - Male
MH  - Rats
MH  - Thromboxane A2/biosynthesis
EDAT- 1986/07/01 00:00
MHDA- 1986/07/01 00:01
CRDT- 1986/07/01 00:00
PHST- 1986/07/01 00:00 [pubmed]
PHST- 1986/07/01 00:01 [medline]
PHST- 1986/07/01 00:00 [entrez]
AID - 10.3181/00379727-182-42340 [doi]
PST - ppublish
SO  - Proc Soc Exp Biol Med. 1986 Jul;182(3):287-90. doi: 10.3181/00379727-182-42340.

PMID- 32822002
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Linking)
VI  - 22
IP  - 10
DP  - 2020 Aug 21
TI  - Updates in Anti-anginal and Anti-ischemic Therapies for Acute Coronary Syndromes.
PG  - 126
LID - 10.1007/s11886-020-01370-6 [doi]
AB  - PURPOSE OF REVIEW: Acute coronary syndrome is a major health problem affecting 
      ~ 1.5 million individuals a year in the USA. We review the contemporary role of 
      anti-anginal and anti-ischemic therapies in the management of an individual 
      presenting with an acute coronary syndrome. RECENT FINDINGS: Early diagnosis and 
      appropriate evidence-based therapies significantly improve clinical outcomes in 
      acute coronary syndrome patients. Typically, acute coronary syndrome is 
      associated with rupture of an atherosclerotic plaque and either partial or 
      complete thrombotic occlusion of a coronary artery. Management of an acute 
      coronary syndrome is targeted towards this underlying pathophysiology. The last 
      few years have seen significant advances in anti-anginal and anti-ischemic 
      therapies in the management of patients with acute coronary syndrome. It is 
      important to have a team effort to target risk reduction measures and to 
      emphasize medication and dietary compliance. Long-term pharmacotherapy should 
      include aspirin, beta-blocker, DAPT (for at least 1 year), statins, and ACE 
      inhibitors and PCSK9 inhibitors if indicated.
FAU - Deoker, Abhizith
AU  - Deoker A
AD  - Department of Internal Medicine, Texas Tech University Health Sciences Center at 
      El Paso, 4800 Alberta Avenue, El Paso, TX, 79905, USA.
FAU - Lehker, Angelica
AU  - Lehker A
AD  - Department of Internal Medicine, Texas Tech University Health Sciences Center at 
      El Paso, 4800 Alberta Avenue, El Paso, TX, 79905, USA.
FAU - Mukherjee, Debabrata
AU  - Mukherjee D
AUID- ORCID: 0000-0002-5131-3694
AD  - Department of Internal Medicine, Texas Tech University Health Sciences Center at 
      El Paso, 4800 Alberta Avenue, El Paso, TX, 79905, USA. 
      debabrata.mukherjee@ttuhsc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200821
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 3.4.21.- (PCSK9 protein, human)
RN  - EC 3.4.21.- (Proprotein Convertase 9)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acute Coronary Syndrome/drug therapy
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Agents
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Proprotein Convertase 9
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Anti-anginal therapies
OT  - Anti-ischemic therapies
OT  - Anti-platelet therapies
OT  - Myocardial infarction
OT  - Outcomes
EDAT- 2020/08/22 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - 10.1007/s11886-020-01370-6 [pii]
AID - 10.1007/s11886-020-01370-6 [doi]
PST - epublish
SO  - Curr Cardiol Rep. 2020 Aug 21;22(10):126. doi: 10.1007/s11886-020-01370-6.

PMID- 20644468
OWN - NLM
STAT- MEDLINE
DCOM- 20101108
LR  - 20171116
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 25
IP  - 5
DP  - 2010 Sep
TI  - A practical approach to the metabolic syndrome: review of current concepts and 
      management.
PG  - 502-12
LID - 10.1097/HCO.0b013e32833cd474 [doi]
AB  - PURPOSE OF REVIEW: Novel research over the past 2 years has necessitated an 
      update of our 'ABCDE' approach to the metabolic syndrome. RECENT FINDINGS: 
      Clinical trials investigating the role of aspirin in primary prevention have led 
      to an adjustment in the indication for aspirin in metabolic syndrome patients at 
      intermediate risk of a cardiovascular event. There has been renewed enthusiasm 
      for the use of niacin as second-line treatment for atherogenic dyslipidemia, with 
      fibrates reserved for those with severe residual dyslipidemia. In light of the 
      noteworthy findings of the Justification for the Use of statins in Primary 
      Prevention: an Intervention Trial Evaluating Rosuvastatin trial, the 'C' category 
      representing 'cholesterol' has been expanded to include the use of 
      high-sensitivity C-reactive protein for guiding statin use and perhaps monitoring 
      statin therapy. Recent evidence confirms that diet and exercise continue to be 
      the cornerstone of any metabolic syndrome treatment strategy. SUMMARY: The 
      revised 'ABCDE' approach incorporates the most recent influential studies into a 
      simple yet thorough algorithm for management of the metabolic syndrome.
FAU - Tota-Maharaj, Rajesh
AU  - Tota-Maharaj R
AD  - Johns Hopkins Ciccarone Preventive Cardiology Center, Johns Hopkins University 
      School of Medicine, Baltimore, USA.
FAU - Defilippis, Andrew P
AU  - Defilippis AP
FAU - Blumenthal, Roger S
AU  - Blumenthal RS
FAU - Blaha, Michael J
AU  - Blaha MJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Diabetes Mellitus/prevention & control
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Metabolic Syndrome/*therapy
EDAT- 2010/07/21 06:00
MHDA- 2010/11/09 06:00
CRDT- 2010/07/21 06:00
PHST- 2010/07/21 06:00 [entrez]
PHST- 2010/07/21 06:00 [pubmed]
PHST- 2010/11/09 06:00 [medline]
AID - 10.1097/HCO.0b013e32833cd474 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2010 Sep;25(5):502-12. doi: 10.1097/HCO.0b013e32833cd474.

PMID- 8737461
OWN - NLM
STAT- MEDLINE
DCOM- 19961205
LR  - 20131121
IS  - 0253-9756 (Print)
IS  - 0253-9756 (Linking)
VI  - 17
IP  - 1
DP  - 1996 Jan
TI  - [Effects of aspirin and nifedipine alone or in combination on hemodynamics in 
      anesthetized dogs].
PG  - 72-4
AB  - AIM: To study the effects of the combination of aspirin (Asp) and nifedipine 
      (Nif) on hemodynamics in 8 anesthetized dogs. METHODS: Tension time index (TTI), 
      left ventricular work index (LVWI), mean arterial pressure (MAP), and total 
      peripheral vascular resistance (TPVR), femoral artery blood flow (FBF), 
      ventricular systolic pressure (LVSP), maximum of its first derivative 
      (dp/dt(max)), left ventricular end diastolic pressure (LVEDP) and heart rate (HR) 
      were recorded on polygraph and electromagnetic flowmeter. RESULTS: Asp 5, 10 
      mg.kg-1, i.v. exerted a significant effect on the hemodynamic indices, wheras Nif 
      15 micrograms.kg-1, i.v. decreased TTI, LVWI, MAP, and TRVR, increased FBF 
      distinctively, and slightly affected LVSP, dp/dt(max), LVEDP, and HR. The effects 
      of Asp in combination with Nif on hemodynamics were similar to those of Nif 
      alone. CONCLUSION: The improvement of cardiovascular function caused by Nif was 
      not affected by the presence of Asp.
FAU - Song, Y M
AU  - Song YM
AD  - Cardiovascular Research Laboratory, Baotou Medical College, China.
FAU - Li, Z X
AU  - Li ZX
FAU - Shi, S
AU  - Shi S
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Yao Li Xue Bao
JT  - Zhongguo yao li xue bao = Acta pharmacologica Sinica
JID - 8100330
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dogs
MH  - Drug Synergism
MH  - Female
MH  - Hemodynamics/*drug effects
MH  - Male
MH  - Nifedipine/*pharmacology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Vasodilator Agents/*pharmacology
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
PST - ppublish
SO  - Zhongguo Yao Li Xue Bao. 1996 Jan;17(1):72-4.

PMID- 28614821
OWN - NLM
STAT- MEDLINE
DCOM- 20180427
LR  - 20180427
IS  - 1423-0313 (Electronic)
IS  - 0031-7012 (Linking)
VI  - 100
IP  - 3-4
DP  - 2017
TI  - Thromboxane Formation Assay to Identify High On-Treatment Platelet Reactivity to 
      Aspirin.
PG  - 127-130
LID - 10.1159/000477303 [doi]
AB  - Platelet inhibition by aspirin is indispensable in the secondary prevention of 
      cardiovascular events. Nevertheless, impaired aspirin antiplatelet effects (high 
      on-treatment platelet reactivity [HTPR]) are frequent. This is associated with an 
      enhanced risk of cardiovascular events. The current gold standard to evaluate 
      platelet hyper-reactivity despite aspirin intake is the light-transmittance 
      aggregometry (LTA). However, pharmacologically, the most specific test is the 
      measurement of arachidonic acid (AA)-induced thromboxane (TX) B2 formation. 
      Currently, the optimal cut-off to define HTPR to aspirin by inhibition of TX 
      formation is not known. Therefore, in this pilot study, we aimed to calculate a 
      TX formation cut-off value to detect HTPR defined by the current gold standard 
      LTA. We measured platelet function in 2,507 samples. AA-induced TX formation by 
      ELISA and AA-induced LTA were used to measure aspirin antiplatelet effects. TX 
      formation correlated nonlinearly with the maximum of aggregation in the 
      AA-induced LTA (Spearman's rho R = 0.7396; 95% CI 0.7208-0.7573, p < 0.0001). 
      Receiver operating characteristic analysis and Youden's J statistics revealed 
      209.8 ng/mL as the optimal cut-off value to detect HTPR to aspirin with the TX 
      ELISA (area under the curve: 0.92, p < 0.0001, sensitivity of 82.7%, specificity 
      of 90.3%). In summary, TX formation ELISA is reliable in detecting HTPR to 
      aspirin. The calculated cut-off level needs to be tested in trials with clinical 
      end points.
CI  - © 2017 S. Karger AG, Basel.
FAU - Mohring, Annemarie
AU  - Mohring A
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Dusseldorf, Germany.
FAU - Piayda, Kerstin
AU  - Piayda K
FAU - Dannenberg, Lisa
AU  - Dannenberg L
FAU - Zako, Saif
AU  - Zako S
FAU - Schneider, Theresa
AU  - Schneider T
FAU - Bartkowski, Kirsten
AU  - Bartkowski K
FAU - Levkau, Bodo
AU  - Levkau B
FAU - Zeus, Tobias
AU  - Zeus T
FAU - Kelm, Malte
AU  - Kelm M
FAU - Hohlfeld, Thomas
AU  - Hohlfeld T
FAU - Polzin, Amin
AU  - Polzin A
LA  - eng
PT  - Journal Article
DEP - 20170615
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thromboxanes/*metabolism
OTO - NOTNLM
OT  - Aspirin
OT  - High on-treatment reactivity
OT  - Platelet activation
OT  - Platelet inhibition
OT  - Thromboxane
EDAT- 2017/06/15 06:00
MHDA- 2018/04/28 06:00
CRDT- 2017/06/15 06:00
PHST- 2017/04/20 00:00 [received]
PHST- 2017/04/28 00:00 [accepted]
PHST- 2017/06/15 06:00 [pubmed]
PHST- 2018/04/28 06:00 [medline]
PHST- 2017/06/15 06:00 [entrez]
AID - 000477303 [pii]
AID - 10.1159/000477303 [doi]
PST - ppublish
SO  - Pharmacology. 2017;100(3-4):127-130. doi: 10.1159/000477303. Epub 2017 Jun 15.

PMID- 28418881
OWN - NLM
STAT- MEDLINE
DCOM- 20180402
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 25
DP  - 2017 Jun 20
TI  - Aspirin as a potential modality for the chemoprevention of breast cancer: A 
      dose-response meta-analysis of cohort studies from 857,831 participants.
PG  - 40389-40401
LID - 10.18632/oncotarget.16315 [doi]
AB  - BACKGROUND: Previous meta-analyses on the relationship between aspirin use and 
      breast cancer risk have drawn inconsistent results. In addition, the threshold 
      effect of different doses, frequencies and durations of aspirin use in preventing 
      breast cancer have yet to be established. RESULTS: The search yielded 13 
      prospective cohort studies (N=857,831 participants) that reported an average of 
      7.6 cases/1,000 person-years of breast cancer during a follow-up period of from 
      4.4 to 14 years. With a random effects model, a borderline significant inverse 
      association was observed between overall aspirin use and breast cancer risk, with 
      a summarized RR = 0.94 (P = 0.051, 95% CI 0.87-1.01). The linear regression model 
      was a better fit for the dose-response relationship, which displayed a potential 
      relationship between the frequency of aspirin use and breast cancer risk (RR = 
      0.97, 0.95 and 0.90 for 5, 10 and 20 times/week aspirin use, respectively). It 
      was also a better fit for the duration of aspirin use and breast cancer risk (RR 
      = 0.86, 0.73 and 0.54 for 5, 10 and 20 years of aspirin use). METHODS: We 
      searched MEDLINE, EMBASE and CENTRAL databases through early October 2016 for 
      relevant prospective cohort studies of aspirin use and breast cancer risk. 
      Meta-analysis of relative risks (RR) estimates associated with aspirin intake 
      were presented by fixed or random effects models. The dose-response meta-analysis 
      was performed by linear trend regression and restricted cubic spline regression. 
      CONCLUSION: Our study confirmed a dose-response relationship between aspirin use 
      and breast cancer risk. For clinical prevention, long term (>5 years) consistent 
      use (2-7 times/week) of aspirin appears to be more effective in achieving a 
      protective effect against breast cancer.
FAU - Lu, Liming
AU  - Lu L
AD  - The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
FAU - Shi, Leiyu
AU  - Shi L
AD  - Department of Health Policy and Management, Bloomberg School of Public Health, 
      Johns Hopkins University, Baltimore, MD, USA.
FAU - Zeng, Jingchun
AU  - Zeng J
AD  - Guangzhou University of Chinese Medicine, Guangzhou, China.
FAU - Wen, Zehuai
AU  - Wen Z
AD  - The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
      Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
AD  - National Center for Design Measurement and Evaluation in Clinical Research, 
      Guangzhou University of Chinese Medicine, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Breast Neoplasms/*prevention & control
MH  - Chemoprevention/methods
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
PMC - PMC5522308
OTO - NOTNLM
OT  - aspirin
OT  - breast cancer
OT  - dose-response Meta-analysis
COIS- CONFLICTS OF INTERESTS The authors declare they have no competing interests.
EDAT- 2017/04/19 06:00
MHDA- 2018/04/03 06:00
CRDT- 2017/04/19 06:00
PHST- 2017/01/17 00:00 [received]
PHST- 2017/02/20 00:00 [accepted]
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2018/04/03 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
AID - 16315 [pii]
AID - 10.18632/oncotarget.16315 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Jun 20;8(25):40389-40401. doi: 10.18632/oncotarget.16315.

PMID- 37525078
OWN - NLM
STAT- MEDLINE
DCOM- 20230901
LR  - 20230906
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 30
IP  - 41
DP  - 2023 Sep
TI  - Remediation of water tainted with noxious aspirin and fluoride ion using 
      UiO-66-NH(2) loaded peanut shell.
PG  - 93877-93891
LID - 10.1007/s11356-023-28906-x [doi]
AB  - One green adsorbent, UiO-66-NH(2) modified peanut shell (c-PS-MOF), was prepared 
      in a green synthetic route for improving the capture level of aspirin (ASP) and 
      fluoride ion (F(-)). The adsorption properties of c-PS-MOF were evaluated by 
      batch experiments and its physicochemical properties were explored by various 
      characterization methods. The results showed that c-PS-MOF exhibited a wide range 
      of pH applications (ASP: 2-10; F(-): 3-12) and high salt resistance in the 
      capturing processes of ASP and F(-). The unit adsorption capacity of c-PS-MOF was 
      as high as 84.7 mg·g(-1) for ASP as pH = 3 and 11.2 mg·g(-1) for F(-) under 
      pH = 6 at 303 K from Langmuir model, respectively. When the solid-liquid ratio 
      was 2 g·L(-1), the content of ASP (C(0) = 100 mg·L(-1)) and F(-) 
      (C(0) = 20 mg·L(-1)) in solution can be reduced to 0.48 mg·L(-1) and 
      1.05 mg·L(-1) separately. The recycling of c-PS-MOF can be realized with 
      5 mmol·L(-1) NaOH as eluent. Analysis of simulated water samples showed that 
      c-PS-MOF could be used to remove ASP and F(-) from actual water. The c-PS-MOF is 
      promising to bind ASP and F(-) from rivers, lakes, etc.
CI  - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Zhang, Xiaoting
AU  - Zhang X
AD  - College of Chemistry, Zhengzhou University, No 100 of Ke Xue Road, Zhengzhou, 
      450001, People's Republic of China.
FAU - Han, Xiaoyu
AU  - Han X
AD  - College of Chemistry, Zhengzhou University, No 100 of Ke Xue Road, Zhengzhou, 
      450001, People's Republic of China.
FAU - Liu, Yang
AU  - Liu Y
AD  - College of Chemistry, Zhengzhou University, No 100 of Ke Xue Road, Zhengzhou, 
      450001, People's Republic of China.
FAU - Han, Runping
AU  - Han R
AUID- ORCID: 0000-0002-1585-4522
AD  - College of Chemistry, Zhengzhou University, No 100 of Ke Xue Road, Zhengzhou, 
      450001, People's Republic of China. rphan67@zzu.edu.cn.
FAU - Wang, Rong
AU  - Wang R
AD  - College of Chemistry, Zhengzhou University, No 100 of Ke Xue Road, Zhengzhou, 
      450001, People's Republic of China.
FAU - Qu, Lingbo
AU  - Qu L
AD  - College of Chemistry, Zhengzhou University, No 100 of Ke Xue Road, Zhengzhou, 
      450001, People's Republic of China.
LA  - eng
GR  - 2018YFD0401402-04/Key Technologies Research and Development Program/
GR  - 202101510005/Zhongyuan Scholars Foundation/
GR  - 42077389/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20230731
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 059QF0KO0R (Water)
RN  - Q80VPU408O (Fluorides)
RN  - 0 (UiO-66)
RN  - 0 (Water Pollutants, Chemical)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Water
MH  - Arachis
MH  - Fluorides
MH  - *Water Purification/methods
MH  - *Water Pollutants, Chemical/analysis
MH  - Adsorption
MH  - Aspirin/analysis
OTO - NOTNLM
OT  - Adsorption
OT  - Aspirin
OT  - Desorption
OT  - Fluoride ion
OT  - UiO-66-NH2 modified peanut shell
EDAT- 2023/08/01 01:08
MHDA- 2023/09/01 06:43
CRDT- 2023/07/31 23:34
PHST- 2023/04/23 00:00 [received]
PHST- 2023/07/17 00:00 [accepted]
PHST- 2023/09/01 06:43 [medline]
PHST- 2023/08/01 01:08 [pubmed]
PHST- 2023/07/31 23:34 [entrez]
AID - 10.1007/s11356-023-28906-x [pii]
AID - 10.1007/s11356-023-28906-x [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2023 Sep;30(41):93877-93891. doi: 
      10.1007/s11356-023-28906-x. Epub 2023 Jul 31.

PMID- 30684451
OWN - NLM
STAT- MEDLINE
DCOM- 20200120
LR  - 20200120
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 132
IP  - 7
DP  - 2019 Jul
TI  - Underutilization of Aspirin in Patients With Advanced Colorectal Polyps.
PG  - 884-885
LID - S0002-9343(19)30076-2 [pii]
LID - 10.1016/j.amjmed.2018.12.037 [doi]
AB  - BACKGROUND: Colorectal cancer is the third-most common cause of cancer deaths in 
      the United States, and advanced colorectal polyps are a major risk factor. 
      Although there are no large-scale individual trials designed a priori to test the 
      hypothesis, in meta-analyses of trials in primary prevention of cardiovascular 
      disease, aspirin reduces risk of colorectal cancer. The US Preventive Services 
      Task Force used a microsimulation model, including baseline risk factors, and 
      concluded that aspirin reduces risk of colorectal cancer by 40%. Their guidelines 
      suggest that without a specific contraindication, clinicians should routinely 
      prescribe aspirin to patients with advanced colorectal polyps. METHODS: Written 
      informed consent was obtained, and brief telephone interviews were conducted by 
      trained interviewers for 84 men and women with biopsy-proven advanced colorectal 
      polyps from 55 clinical practices. RESULTS: Of the 84, 39 (46.4%) were men. The 
      mean age was 66 with a range from 41 to 91 years. Among the 84, 36 (42.9%) 
      reported taking aspirin. CONCLUSIONS: These data suggest underutilization of 
      aspirin by patients with advanced colorectal polyps. These data pose major 
      challenges that require multifactorial approaches by clinicians and their 
      patients, which include therapeutic lifestyle changes, adjunctive drug therapies, 
      and screening. Lifestyle changes include treating overweight status and obesity 
      and engaging in regular physical activity; adjunctive drug therapies include 
      aspirin. These multifactorial approaches will be necessary to achieve the most 
      good for the most patients with regard to prevention, as well as, early diagnosis 
      and treatment of colorectal cancer in patients with advanced colorectal polyps.
CI  - Copyright © 2019. Published by Elsevier Inc.
FAU - Fiedler, Benjamin
AU  - Fiedler B
AD  - Cornell University College of Arts and Sciences, Ithaca, NY.
FAU - Fiedler, Lawrence
AU  - Fiedler L
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton.
FAU - DeDonno, Michael
AU  - DeDonno M
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton.
FAU - Anago, Kosi
AU  - Anago K
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton; 
      Boca Raton Regional Hospital, Fla.
FAU - de la Cruz, Leonie
AU  - de la Cruz L
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton.
FAU - Luck, George R
AU  - Luck GR
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton. 
      Electronic address: chenneke@health.fau.edu.
LA  - eng
PT  - Journal Article
DEP - 20190124
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Med. 2019 Jul;132(7):e629. PMID: 31400799
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Colonic Polyps/*drug therapy
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - Practice Patterns, Physicians'/*statistics & numerical data
OTO - NOTNLM
OT  - Advanced Colorectal Polyps
OT  - Aspirin
OT  - Underutilization
EDAT- 2019/01/27 06:00
MHDA- 2020/01/21 06:00
CRDT- 2019/01/27 06:00
PHST- 2018/12/22 00:00 [received]
PHST- 2018/12/23 00:00 [accepted]
PHST- 2019/01/27 06:00 [pubmed]
PHST- 2020/01/21 06:00 [medline]
PHST- 2019/01/27 06:00 [entrez]
AID - S0002-9343(19)30076-2 [pii]
AID - 10.1016/j.amjmed.2018.12.037 [doi]
PST - ppublish
SO  - Am J Med. 2019 Jul;132(7):884-885. doi: 10.1016/j.amjmed.2018.12.037. Epub 2019 
      Jan 24.

PMID- 12133028
OWN - NLM
STAT- MEDLINE
DCOM- 20020815
LR  - 20190709
IS  - 0002-8614 (Print)
IS  - 0002-8614 (Linking)
VI  - 50
IP  - 7
DP  - 2002 Jul
TI  - Interaction between aspirin and angiotensin-converting enzyme inhibitors: should 
      they be used together in older adults with heart failure?
PG  - 1293-6
AB  - PURPOSE: To determine whether the prostacyclin-inhibiting properties of aspirin 
      counteracts the bradykinin-induced prostacyclin-stimulating effects of 
      angiotensin-converting enzyme (ACE) inhibitors, thereby attenuating the 
      beneficial effects of ACE inhibitors in heart failure patients. BACKGROUND: Most 
      heart failure patients are older adults. Heart failure is the number one hospital 
      discharge diagnosis of older Americans. The renin-angiotensin system plays a 
      major role in the pathophysiology of heart failure, and ACE inhibitors play a 
      pivotal role in the management of heart failure. Large-scale double-blind 
      randomized trials have demonstrated the survival benefits of using ACE inhibitors 
      in patients with heart failure associated with left ventricular systolic 
      dysfunction. In addition to inhibiting the conversion of angiotensin I to 
      angiotensin II, ACE inhibitors also decrease the breakdown of bradykinin. 
      Bradykinin, a potent vasodilator, acts by stimulating formation of vasodilatory 
      prostaglandins such as prostacyclin, whereas aspirin or acetyl salicylic acid 
      inhibits the enzyme cyclooxygenase, which in turn decreases the production of the 
      prostaglandins. Coronary artery disease and hypertension are the two major 
      underlying causes of heart failure. Most heart failure patients are also on 
      aspirin. There is evidence that aspirin at a daily dose of 80 to 100 mg prevents 
      the synthesis of thromboxane A2 by platelets while relatively sparing the 
      synthesis of prostacyclin in the vascular endothelium. Aspirin at a daily dose of 
      325 mg has significant inhibitory effects on the vasodilatory prostacyclin 
      synthesis. Studies have demonstrated that, in heart failure patients, low-dose 
      aspirin has no adverse effect on hemodynamic, neurohumoral, or renal functions. 
      Whether the prostacyclin-inhibiting effects of aspirin attenuate some of the 
      beneficial effects of ACE inhibitors mediated by prostacyclin stimulation in 
      heart failure patients is currently unknown. METHODS: Data from large clinical 
      trials investigating the interaction between aspirin and ACE inhibitors were 
      analyzed to determine the effect of aspirin on the vasodilatory actions of ACE 
      inhibitors in heart failure patients, and the results were analyzed on the basis 
      of theoretical and laboratory findings. The studies included are the Studies of 
      Left Ventricular Dysfunction (SOLVD) (N=6,797), the Cooperative New Scandinavian 
      Enalapril Survival Study II (CONSENSUS II) (N=6,090), the Captopril and 
      Thrombolysis Study (CATS) (N=296), and another study involving 317 subjects. The 
      data from these clinical trials investigating the interaction between aspirin and 
      ACE inhibitors included 13,470 subjects. Most of the subjects received aspirin. 
      In the SOLVD study, subjects received aspirin or dipyridamole. Subjects were 
      followed up for an average of about 6 years. RESULTS: In the SOLVD study, 
      subjects were followed up for 41.1 months in the treatment trial and 37.4 months 
      in the prevention trial. Patients who received aspirin or dipyridamole at 
      baseline did not receive the survival benefits of enalapril, whereas patients who 
      received enalapril did not receive the survival benefits of aspirin. In a rather 
      small study of 317 subjects with left ventricular systolic dysfunction (ejection 
      fraction <35%) who were followed up for a relatively longer period of time (5.7 
      years), the favorable long-term prognosis of patients receiving aspirin was 
      independent of receipt of an ACE inhibitor. A retrospective subgroup analysis of 
      data from the CONSENSUS II study demonstrated that the 6-month mortality rate of 
      patients with acute myocardial infarction (MI) who received enalapril and aspirin 
      was higher than the combined mortality rates of patients receiving enalapril or 
      aspirin alone. This strong interaction between aspirin and the ACE inhibitor 
      enalapril suggests that the survival benefit of enalapril was significantly lower 
      in patients also taking aspirin than in those taking enalapril alone. This 
      interaction was not associated with other nonfatal major events. In the CATS 
      study, use of low-dose aspirin (80 or 100 mg) did not attenuate beneficial 
      effects of captopril (immediate and 1-year follow up) after acute MI. CONCLUSION: 
      There is a theoretical possibility that the negative interaction between ACE 
      inhibitors and aspirin may reduce the beneficial effects of ACE inhibitors in 
      patients with heart failure, but the information obtained from the existing 
      databases is limited by the retrospective nature of the analyses and does not 
      establish the association definitively. Double-blind randomized controlled trials 
      should be conducted to determine whether such a negative interaction indeed 
      exists.
FAU - Ahmed, Ali
AU  - Ahmed A
AD  - Division of Gerontology/Geriatric Medicine, Department of Medicine, School of 
      Medicine, Center for Aging, University of Alabama at Birmingham, 35294, USA. 
      aahmed@uab.edu
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/adverse effects/*therapeutic use
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Heart Failure/*drug therapy
MH  - Hemodynamics/drug effects
MH  - Humans
EDAT- 2002/07/23 10:00
MHDA- 2002/08/16 10:01
CRDT- 2002/07/23 10:00
PHST- 2002/07/23 10:00 [pubmed]
PHST- 2002/08/16 10:01 [medline]
PHST- 2002/07/23 10:00 [entrez]
AID - jgs50320 [pii]
AID - 10.1046/j.1532-5415.2002.50320.x [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2002 Jul;50(7):1293-6. doi: 10.1046/j.1532-5415.2002.50320.x.

PMID- 6499
OWN - NLM
STAT- MEDLINE
DCOM- 19760901
LR  - 20220310
IS  - 0002-8177 (Print)
IS  - 0002-8177 (Linking)
VI  - 93
IP  - 1
DP  - 1976 Jul
TI  - Aspirin-induced gastritis and gastrointestinal bleeding.
PG  - 111-7
AB  - Aspirin-induced gastritis and gastrointestinal hemorrhage were reviewed and 
      discussed on the basis of currently available literature. Acute hemorrhagic 
      gastritis occurs in from 50% to 70% of all patients taking aspirin, is not 
      directly related to dose size, and can be severe enough to cause death in a few 
      cases. No tolerance appears to ever develop. The mechanism that causes this 
      bleeding is not definite, but the back diffusion of H+ ions accross the gastric 
      barrier seems to bear primary responsibility, with physical erosion, prolonged 
      platelet bleeding, and the effect of low pH values also being possible 
      explanations. There appears to be less acid present in the stomach when bleeding 
      occurs, but this is a masking effect of the aspirin that causes increased 
      absorption of the H+ ions. Factors important in determining pharmaceutical 
      formulation are method of administration, particle size of the aspirin, duration 
      of contact between the drug and the mucosa, presence of buffers in the drug to 
      raise the gastric pH, dissolution rate of the drug in the stomach, and ionization 
      characteristics of the drug itself. Gastrointestinal blood loss caused by aspirin 
      can be minimized by administering the drug in one of these forms:--a dilute 
      solution of acetylsalicylate;--an intravenously injected solution;--a very 
      rapidly dissolving and rapidly absorbed tablet;--a solution with sufficiently 
      large amounts of antacid added;--a fine-grain, highly buffered aspirin 
      tablet;--an enteric-coated tablet that does not dissolve in the stomach; or--an 
      aspirin substitute such as acetaminophen.
FAU - Gartner, A H
AU  - Gartner AH
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Platelets/drug effects
MH  - Delayed-Action Preparations
MH  - Dose-Response Relationship, Drug
MH  - Epithelial Cells
MH  - Epithelium/drug effects
MH  - Gastric Mucosa/drug effects
MH  - Gastritis/*chemically induced
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Injections, Intravenous
MH  - Mucus/physiology
MH  - Particle Size
MH  - Platelet Aggregation/drug effects
MH  - Stomach/physiology
MH  - Tablets
MH  - Time Factors
EDAT- 1976/07/01 00:00
MHDA- 1976/07/01 00:01
CRDT- 1976/07/01 00:00
PHST- 1976/07/01 00:00 [pubmed]
PHST- 1976/07/01 00:01 [medline]
PHST- 1976/07/01 00:00 [entrez]
AID - S0002-8177(76)31038-1 [pii]
AID - 10.14219/jada.archive.1976.0591 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 1976 Jul;93(1):111-7. doi: 10.14219/jada.archive.1976.0591.

PMID- 19287328
OWN - NLM
STAT- MEDLINE
DCOM- 20090722
LR  - 20181201
IS  - 1524-4040 (Electronic)
IS  - 0148-396X (Linking)
VI  - 64
IP  - 5
DP  - 2009 May
TI  - Factors associated with aspirin resistance in patients premedicated with aspirin 
      and clopidogrel for endovascular neurosurgery.
PG  - 890-5; discussion 895-6
LID - 10.1227/01.NEU.0000341904.39691.2F [doi]
AB  - OBJECTIVE: Antiplatelet therapy is critical to endovascular neurosurgical 
      procedures. Some patients are aspirin-resistant nonresponders. We reviewed our 
      endovascular neurosurgery patients who were premedicated with aspirin and 
      clopidogrel and identified nonresponders to aspirin. Factors associated with 
      aspirin resistance were determined. METHODS: Consecutive endovascular 
      neurosurgery patients were identified who were treated by the senior author (BLH) 
      from December 2006 to October 2007 and who were premedicated with aspirin (325 
      mg) and clopidogrel (75 mg) for 7 days before the procedure. We retrospectively 
      reviewed values from the platelet function analyzer-100 test (Dade-Behring, 
      Deerfield, IL) from 1 day before the procedures. The following factors were 
      evaluated for association with aspirin drug resistance: age, sex, body mass 
      index, and smoking history; patients with hypertension, diabetes, coronary artery 
      disease/ peripheral vascular disease, or hypercholesterolemia; disease pathology 
      (aneurysm, intracranial stenosis, or extracranial stenosis); patients taking 
      statins, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin 
      receptor blockers, or antidepressants; and white blood cell count, hemoglobin, 
      hematocrit, and platelet levels. A stepwise logistic model selection was used to 
      select important factors and their interactions. RESULTS: Eighty-one consecutive 
      patients with the following interventions were included in the study: 35 aneurysm 
      coilings (43%), 21 stent-assisted aneurysm coilings (26%), 13 carotid stent and 
      angioplasties (16%), 7 intracranial stents and angioplasties (9%), and 5 
      extracranial vertebral artery stents and angioplasties (6%). Seventeen patients 
      (21%) were nonresponders to aspirin. After model selection, the only factor 
      associated with aspirin resistance was not taking an angiotensin-converting 
      enzyme inhibitor or angiotensin receptor blocker (P = 0.0348; odds ratio, 0.214; 
      95% confidence interval, 0.051-0.896). CONCLUSION: Twenty-one percent of patients 
      premedicated with aspirin and clopidogrel dual therapy for 7 days before 
      endovascular neurosurgical procedures were nonresponders to aspirin. Patients not 
      taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker 
      may be at higher risk for aspirin drug resistance.
FAU - Reavey-Cantwell, John F
AU  - Reavey-Cantwell JF
AD  - Department of Neurological Surgery, University of Florida, Gainesville, Florida 
      32610-0265, USA.
FAU - Fox, W Christopher
AU  - Fox WC
FAU - Reichwage, Brett D
AU  - Reichwage BD
FAU - Fautheree, Gregory L
AU  - Fautheree GL
FAU - Velat, Gregory J
AU  - Velat GJ
FAU - Whiting, Jobyna H
AU  - Whiting JH
FAU - Chi, Yueh-Yun
AU  - Chi YY
FAU - Hoh, Brian L
AU  - Hoh BL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aneurysm/*drug therapy/*surgery
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebral Revascularization/*methods
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2009/03/17 09:00
MHDA- 2009/07/23 09:00
CRDT- 2009/03/17 09:00
PHST- 2009/03/17 09:00 [entrez]
PHST- 2009/03/17 09:00 [pubmed]
PHST- 2009/07/23 09:00 [medline]
AID - 10.1227/01.NEU.0000341904.39691.2F [doi]
PST - ppublish
SO  - Neurosurgery. 2009 May;64(5):890-5; discussion 895-6. doi: 
      10.1227/01.NEU.0000341904.39691.2F.

PMID- 16154478
OWN - NLM
STAT- MEDLINE
DCOM- 20051020
LR  - 20131121
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 27
IP  - 7
DP  - 2005 Jul
TI  - Aspirin compared with acetaminophen in the treatment of fever and other symptoms 
      of upper respiratory tract infection in adults: a multicenter, randomized, 
      double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 
      6-hour dose-ranging study.
PG  - 993-1003
AB  - BACKGROUND: Aspirin (acetylsalicylic acid) and acetaminophen (paracetamol) are 
      frequently used to treat fever and other symptoms of upper respiratory tract 
      infection (URTI). Both are available over the counter for use at the standard 
      recommended doses of 500 and 1000 mg per single use. OBJECTIVE: This study 
      investigated the efficacy, safety profiles, and tolerability of aspirin 500 and 
      1000 mg and acetaminophen 500 and 1000 mg compared with placebo in adult patients 
      with acute febrile URTI of suspected viral origin. METHODS: This was a 
      multicenter, randomized, double-blind, double-dummy, placebo-controlled, 
      parallel-group trial conducted in Ukraine and Russia. Patients with URTI and 
      acute fever of > or =38.5 degrees C received a single dose of aspirin 500 or 1000 
      mg, acetaminophen 500 or 1000 mg, or matching placebo. Oral body temperature was 
      measured in the clinic at specified time points up to 6 hours after dosing. The 
      intensity of other symptoms of URTI was rated by patients at baseline and at 2, 
      4, and 6 hours after dosing (scale from 0 = none to 10 = severe). The primary 
      efficacy measure was the AUC for the change in orally measured body temperature 
      from the time of treatment (baseline) to 4 hours after dosing. Secondary outcome 
      measures included the change in body temperature from baseline to specified time 
      points between 0.5 and 6 hours after dosing, the difference between baseline and 
      the lowest measured body temperature, the time to the lowest measured body 
      temperature, and the intensity of other symptoms of URTI (ie, headache, sinus 
      sensitivity to percussion, sore throat, achiness, and feverish discomfort). 
      Tolerability was monitored by recording of adverse events. RESULTS: Three hundred 
      ninety-two patients were enrolled (78 in both aspirin groups, 79 in both 
      acetaminophen groups, 78 in the placebo group). Demographic and baseline 
      characteristics were comparable in the 5 groups; 51% of patients were male, with 
      a mean age of 37.4 years and a mean body weight of 74.3 kg. The AUC values for 
      the change in body temperature 0 to 4 hours after dosing were 3.18 (95% CI, 
      2.78-3.57) for aspirin 500 mg, 4.26 (95% CI, 3.84-4.68) for aspirin 1000 mg, 3.13 
      (95% CI, 2.77-3.49) for acetaminophen 500 mg, 4.11 (95% CI, 3.73-4.49) for 
      acetaminophen 1000 mg, and 0.76 (95% CI, 0.38-1.13) for placebo. In terms of the 
      primary efficacy variable, all active treatments were significantly superior to 
      placebo (P < 0.001, 1-sided t test), with no significant differences between 
      them. Reductions in body temperature were significantly greater with the 1000-mg 
      doses of both active treatments compared with the 500-mg doses (P< 0.001, 1-sided 
      t test). The mean maximum temperature reductions were 1.32 degrees C, 1.25 
      degrees C, 1.67 degrees C,1.71 degrees C, and 0.63 degrees C in the respective 
      treatment groups. Significant reductions were seen in the mean intensity of 
      headache, achiness, and feverish discomfort with all active treatments at most 
      time points (P < 0.001), but not in sinus sensitivity to percussion or sore 
      throat. All treatments were equally well tolerated, and no clinically significant 
      adverse events occurred. CONCLUSIONS: In this single-dose study, aspirin 500 and 
      1000 mg and acetaminophen 500 and 1000 mg were more effective against fever and 
      other symptoms of URTI than placebo. Both active treatments showed dose-related 
      efficacy, and there was no significant difference between equal doses of the 2 
      agents. Safety profiles and tolerability were also comparable between treatments.
FAU - Bachert, Claus
AU  - Bachert C
AD  - University of Ghent, Ghent, Belgium. claus.bachert@ugent.be
FAU - Chuchalin, Alexander G
AU  - Chuchalin AG
FAU - Eisebitt, Reinhard
AU  - Eisebitt R
FAU - Netayzhenko, Vasiliy Z
AU  - Netayzhenko VZ
FAU - Voelker, Michael
AU  - Voelker M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/adverse effects/*therapeutic use
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Fever/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiratory Tract Infections/*drug therapy/virology
EDAT- 2005/09/13 09:00
MHDA- 2005/10/21 09:00
CRDT- 2005/09/13 09:00
PHST- 2005/04/27 00:00 [accepted]
PHST- 2005/09/13 09:00 [pubmed]
PHST- 2005/10/21 09:00 [medline]
PHST- 2005/09/13 09:00 [entrez]
AID - S0149-2918(05)00095-0 [pii]
AID - 10.1016/j.clinthera.2005.06.002 [doi]
PST - ppublish
SO  - Clin Ther. 2005 Jul;27(7):993-1003. doi: 10.1016/j.clinthera.2005.06.002.

PMID- 32293031
OWN - NLM
STAT- MEDLINE
DCOM- 20200929
LR  - 20200929
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 150
IP  - 1
DP  - 2020 Jul
TI  - Low-dose aspirin improves endometrial receptivity in the midluteal phase in 
      unexplained recurrent pregnancy loss.
PG  - 77-82
LID - 10.1002/ijgo.13160 [doi]
AB  - OBJECTIVE: To evaluate differences in Doppler parameters and pregnancy outcomes, 
      if any, and to determine the predictive accuracy of such indices, as well as the 
      effects of low-dose aspirin (LDA) in unexplained recurrent pregnancy loss (URPL). 
      METHODS: An observational study was conducted at Ren Ji Hospital, Shanghai, 
      China, from May 2015 to December 2016. The endometrial thickness, and the 
      pulsatility index (PI), resistive index (RI), and systolic-to-diastolic ratio 
      (S/D) values of endometrial and uterine artery blood flow were collected. 
      Receiver operating characteristic (ROC) curve analysis was used to analyze data 
      from URPL patients (three or more first-trimester spontaneous abortions with 
      unknown etiology) and patients with normal fertility. A second ultrasonography 
      examination was performed in URPL patients who had received daily LDA for 
      2 months. RESULTS: There were 190 URPL patients and 35 control patients. 
      Endometrial thickness was significantly thinner in URPL patients than control 
      patients (P=0.005). The PI, RI, and S/D values for endometrial blood flow and the 
      mean PI, RI, and S/D values for uterine arteries were significantly higher in 
      URPL patients (P<0.001). The predictive accuracy of the indices mentioned above 
      were 0.660, 0.802, 0.852, 0.837, 0.784, 0.929, and 0.929, respectively. Following 
      LDA supplementation, URPL patients showed a significant reduction in resistance 
      to endometrial and uterine artery blood flow (P<0.001). CONCLUSION: URPL patients 
      had impaired uterine perfusion. Doppler parameters are valuable in predicting 
      women at high risk of URPL. LDA could be effective in improving endometrial 
      receptivity.
CI  - © 2020 International Federation of Gynecology and Obstetrics.
FAU - Wang, Tongfei
AU  - Wang T
AD  - Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, 
      Shanghai Jiao Tong University, Shanghai, China.
AD  - Obstetrics and Gynecology Department of Concord Hospital of the Fujian Medical 
      University, Fuzhou, China.
FAU - Kang, Xiaomin
AU  - Kang X
AD  - Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, 
      Shanghai Jiao Tong University, Shanghai, China.
FAU - Zhao, Aimin
AU  - Zhao A
AD  - Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, 
      Shanghai Jiao Tong University, Shanghai, China.
FAU - He, Liying
AU  - He L
AD  - Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, 
      Shanghai Jiao Tong University, Shanghai, China.
FAU - Liu, Zhilan
AU  - Liu Z
AD  - Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, 
      Shanghai Jiao Tong University, Shanghai, China.
FAU - Liu, Fangsun
AU  - Liu F
AD  - Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, 
      Shanghai Jiao Tong University, Shanghai, China.
LA  - eng
GR  - National Natural Science Foundation of China/
GR  - Key Discipline Project of Shanghai Municipal Commission of Health and Family 
      Planning/
PT  - Journal Article
PT  - Observational Study
DEP - 20200503
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*physiopathology/prevention & control
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Case-Control Studies
MH  - China
MH  - Endometrium/blood supply/diagnostic imaging/*drug effects
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - ROC Curve
MH  - Ultrasonography, Doppler
MH  - Uterine Artery/diagnostic imaging/drug effects
OTO - NOTNLM
OT  - Aspirin
OT  - Endometrial blood flow
OT  - Predictive accuracy
OT  - Unexplained recurrent spontaneous abortion
OT  - Uterine artery
EDAT- 2020/04/16 06:00
MHDA- 2020/09/30 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/09/02 00:00 [received]
PHST- 2019/12/31 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/09/30 06:00 [medline]
PHST- 2020/04/16 06:00 [entrez]
AID - 10.1002/ijgo.13160 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2020 Jul;150(1):77-82. doi: 10.1002/ijgo.13160. Epub 2020 
      May 3.

PMID- 23614860
OWN - NLM
STAT- MEDLINE
DCOM- 20130624
LR  - 20181202
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 157
IP  - 17
DP  - 2013
TI  - [Aspirin and cancer: evidence of a prophylactic effect].
PG  - A5189
AB  - Due to increased life expectancy, the number of new patients diagnosed with 
      cancer is also increasing; this requires effective and inexpensive strategies for 
      preventing cancer. The concept of chemoprevention involves taking medication to 
      reduce cancer risk. By re-assessing aspirin trials that were originally conducted 
      to determine its effect on cardiovascular disease, it appeared that aspirin was 
      associated with a reduction in the incidence of cancer as well as cancer-related 
      mortality. The vascular benefits and risks associated with aspirin are only 
      clinically relevant in the short term; its beneficial effects on cancer risk only 
      become apparent after three years. Aspirin probably has a preventive effect on 
      metastasis. These findings from randomised trials are consistent with results 
      from methodologically rigorous observational studies. Until now, primary 
      prevention in vascular disease has only proven to be cost-effective in certain 
      risk groups. In future cost-effectiveness analyses, the beneficial effect of 
      aspirin on cancer risk needs to be taken into account.
FAU - Algra, Annemijn M
AU  - Algra AM
AD  - Leids Universitair Medisch Centrum, Afd. Klinische Epidemiologie, Leiden, the 
      Netherlands. annechien.algra@clneuro.ox.ac.uk
FAU - Nortier, J W R Hans
AU  - Nortier JW
LA  - dut
PT  - Journal Article
PT  - Review
TT  - Acetylsalicylzuur en kanker: aanwijzingen voor een preventief effect.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Antineoplastic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticarcinogenic Agents/administration & dosage/economics
MH  - Antineoplastic Agents/administration & dosage/economics
MH  - Aspirin/*administration & dosage/economics
MH  - Cardiovascular Diseases/economics/epidemiology/prevention & control
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Incidence
MH  - Neoplasms/economics/epidemiology/*prevention & control
MH  - Primary Prevention
EDAT- 2013/04/26 06:00
MHDA- 2013/06/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/26 06:00 [entrez]
PHST- 2013/04/26 06:00 [pubmed]
PHST- 2013/06/26 06:00 [medline]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2013;157(17):A5189.

PMID- 18001625
OWN - NLM
STAT- MEDLINE
DCOM- 20080314
LR  - 20211020
IS  - 1523-3804 (Print)
IS  - 1523-3804 (Linking)
VI  - 9
IP  - 5
DP  - 2007 Nov
TI  - Aspirin in the treatment and prevention of cardiovascular disease: current 
      perspectives and future directions.
PG  - 409-16
AB  - In secondary prevention among male and female survivors of prior myocardial 
      infarction (MI), occlusive stroke, transient ischemic attack, and other high-risk 
      conditions, long-term use of aspirin confers very similar statistically 
      significant and clinically important reductions in MI, stroke, and cardiovascular 
      death. In men and women suffering acute MI or acute occlusive stroke, aspirin 
      confers similar benefits. In primary prevention, aspirin confers a statistically 
      significant and clinically important reduction in risk of a first MI, but the 
      data on stroke and cardiovascular disease death remain inconclusive, so aspirin 
      should be prescribed on an individual basis by the healthcare provider who weighs 
      this clear benefit against long-term side effects. Worldwide, aspirin used more 
      widely and appropriately would avoid many premature deaths in secondary 
      prevention, during acute MI, and during acute stroke, as well as many first MI in 
      primary prevention.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - PROFCHHMD@prodigy.net
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/epidemiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/drug therapy/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/drug therapy/prevention & control
RF  - 45
EDAT- 2007/11/16 09:00
MHDA- 2008/03/15 09:00
CRDT- 2007/11/16 09:00
PHST- 2007/11/16 09:00 [pubmed]
PHST- 2008/03/15 09:00 [medline]
PHST- 2007/11/16 09:00 [entrez]
AID - 10.1007/s11883-007-0053-0 [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2007 Nov;9(5):409-16. doi: 10.1007/s11883-007-0053-0.

PMID- 6782930
OWN - NLM
STAT- MEDLINE
DCOM- 19810528
LR  - 20201209
IS  - 0355-9521 (Print)
IS  - 0355-9521 (Linking)
VI  - 69
IP  - 6
DP  - 1980
TI  - Comparison of lysine acetylsalicylate and oxycodone in postoperative pain 
      following upper abdominal surgery.
PG  - 287-92
AB  - Intravenous lysine acetylsalicylate (LAS) and oxycodone were compared under 
      double-blind conditions for analgesia after upper abdominal surgery in sixty 
      patients anaesthetized by N2O--O2--halothane--relaxant technique. Either 125 
      mg/10 kg or 250 mg/10 kg LAS or 0.4 mg/10 kg or 0.8 mg/10 kg oxycodone was 
      randomly administered when the patients complained of moderate or severe 
      postoperative pain. When 30 min had elapsed following the injection of the test 
      drug, oxycodone was given in 4 mg increments on demand until adequate pain relief 
      was achieved. At 15 min postdrug, the lower dose of LAS offered significantly 
      less pain relief than all other test drugs. At 30 min, the effect of the higher 
      dose of LAS reached almost the analgesic level of the higher dose of oxycodone 
      but only the latter provided significantly (P less than 0.05) better analgesia 
      than the low dose of LAS. About 50% less additional narcotic supplementation was 
      demanded following higher doses of both drugs when compared to lower ones. LAS 
      250 mg/10 kg (c. 1.8 g/70 kg) was found approximately equipotent to oxycodone 0.8 
      mg/10 kg (c. 6 mg/70 kg). However, LAS had a slower onset of action. Sweating 
      seemed to occur more frequently after LAS than oxycodone, but significant changes 
      in respiratory rate or sedation following LAS-oxycodone combinations when 
      compared to oxycodone alone were not noted. The results show that for analgesia 
      after upper abdominal surgery, 1.8 g of LAS may be substituted for about 6 mg of 
      oxycodone.
FAU - Tammisto, T
AU  - Tammisto T
FAU - Tigerstedt, I
AU  - Tigerstedt I
FAU - Korttila, K
AU  - Korttila K
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Finland
TA  - Ann Chir Gynaecol
JT  - Annales chirurgiae et gynaecologiae
JID - 7609767
RN  - CD35PMG570 (Oxycodone)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Abdomen/surgery
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Clinical Trials as Topic
MH  - Codeine/*analogs & derivatives
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic 
      use
MH  - Male
MH  - Middle Aged
MH  - Oxycodone/administration & dosage/adverse effects/*therapeutic use
MH  - Pain, Postoperative/*drug therapy
MH  - Random Allocation
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Ann Chir Gynaecol. 1980;69(6):287-92.

PMID- 11715180
OWN - NLM
STAT- MEDLINE
DCOM- 20020206
LR  - 20191105
IS  - 0733-8651 (Print)
IS  - 0733-8651 (Linking)
VI  - 19
IP  - 4
DP  - 2001 Nov
TI  - Controversies in heart failure. Are beneficial effects of angiotensin-converting 
      enzyme inhibitors attenuated by aspirin in patients with heart failure?
PG  - 597-603
AB  - To whatever extent the improvement in symptoms and survival rendered by treatment 
      with ACE inhibitors is attributable to their effects on the circulation and the 
      kidneys, this benefit can be rescinded by concomitant administration of aspirin. 
      Although some useful prostaglandin-independent actions may persist, shutting down 
      the entire prostaglandin system and trading off a substantial portion of the 
      potential risk reduction with forfeit of salutary hemodynamic and renal effects 
      is a high price to pay just to suppress production of TXA2. In patients requiring 
      treatment for heart failure, if possible, aspirin should be avoided and the 
      integrity of prostaglandin metabolism respected; the severer the heart failure 
      the more compelling. There are other ways to inhibit platelet aggregation, some 
      equally effective or even better than aspirin. Orally active platelet 
      glycoprotein IIb/IIIa receptor antagonists, which may be more efficient than 
      aspirin, have been developed and are now in clinical testing. Ticlopidine and 
      clopidogrel, although more expensive than aspirin, are as easy to use and at 
      least as effective as aspirin. Finally, because patients with severer heart 
      failure are likely to be those with very low ejection fractions, these patients 
      are good candidates for oral anticoagulation even though this treatment requires 
      additional monitoring.
FAU - Hall, D
AU  - Hall D
AD  - Cardiac Outpatient Clinic, German Heart Center, Technical University of Munich, 
      Munich, Germany. hall@dhm.mhn.de
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cardiol Clin
JT  - Cardiology clinics
JID - 8300331
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Comorbidity
MH  - Coronary Disease/*drug therapy/epidemiology
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Drug Interactions
MH  - Heart Failure/*drug therapy/epidemiology
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Kidney/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 59
EDAT- 2001/11/22 10:00
MHDA- 2002/02/07 10:01
CRDT- 2001/11/22 10:00
PHST- 2001/11/22 10:00 [pubmed]
PHST- 2002/02/07 10:01 [medline]
PHST- 2001/11/22 10:00 [entrez]
AID - S0733-8651(05)70246-0 [pii]
AID - 10.1016/s0733-8651(05)70246-0 [doi]
PST - ppublish
SO  - Cardiol Clin. 2001 Nov;19(4):597-603. doi: 10.1016/s0733-8651(05)70246-0.

PMID- 34856618
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20221207
IS  - 1098-8785 (Electronic)
IS  - 0735-1631 (Linking)
VI  - 39
IP  - 4
DP  - 2022 Mar
TI  - Glycemic Control and Aspirin Resistance in Patients Taking Low-Dose Aspirin for 
      Pre-eclampsia Prevention.
PG  - 349-353
LID - 10.1055/s-0041-1740250 [doi]
AB  - OBJECTIVES: To assess the association between aspirin and glycemic control in 
      diabetic, pregnant patients, and the risk for aspirin resistance in those with 
      poor glycemic control across gestation taking low-dose aspirin (LDA) for 
      pre-eclampsia (PEC) prevention. STUDY DESIGN: We performed a secondary analysis 
      of samples collected during the Maternal-Fetal Medicine Units trial of LDA for 
      PEC prevention. A subset of insulin-controlled diabetic patient samples on 
      placebo or 60 mg aspirin daily were evaluated. Glycosylated hemoglobin was 
      measured at randomization, mid-second trimester, and third trimester time points. 
      Thromboxane B(2) (TXB(2)) measurements were previously assessed as part of the 
      original study. Primary outcome was the effect of LDA on glycosylated hemoglobin 
      levels compared with placebo across gestation. RESULTS: Levels of glycosylated 
      hemoglobin increased across gestation in the placebo group (2,067.7 
      [interquartile range, IQR: 1,624.6-2,713.5 µg/mL] vs. 2,461.9 [1,767.0-3,209.9 
      µg/mL] vs. 3,244.3 [2,691.5-4,187.0 µg/mL]; p < 0.01) compared with no difference 
      in levels of glycosylated hemoglobin across gestation in the LDA group (2,186.4 
      [IQR: 1,462.3-3,097.7 µg/mL] vs. 2,337.1 [1,327.7-5,932.6 µg/mL] vs. 2,532.9 
      [1,804.9-5,511.8 µg/mL]; p = 0.78). Higher levels of glycosylated hemoglobin were 
      associated with increased TXB(2) levels prior to randomization (r = 0.67, 
      p < 0.05). Incomplete TXB(2) was higher in pregnancies with increasing levels of 
      glycosylated hemoglobin compared with those with decreasing levels of 
      glycosylated hemoglobin across gestation (69.2 vs. 18.1%, p = 0.02). CONCLUSION: 
      LDA exposure may be beneficial to glycemic control in this patient population. 
      Additionally, poor glycemic control is associated with a higher level of TXB(2) 
      in diabetic pregnant patients on LDA. Higher doses of aspirin may be required in 
      these patients to prevent development of PEC. KEY POINTS: · Low-dose aspirin may 
      improve glycemic control.. · Poor glycemic control increases risk for aspirin 
      resistance.. · Higher doses of aspirin may be required for pre-eclampsia 
      prevention..
CI  - Thieme. All rights reserved.
FAU - Gee, Stephen E
AU  - Gee SE
AD  - Department of Obstetrics and Gynecology, The Ohio State University College of 
      Medicine, Columbus, Ohio.
FAU - Ma'ayeh, Marwan
AU  - Ma'ayeh M
AD  - Department of Obstetrics and Gynecology, The Ohio State University College of 
      Medicine, Columbus, Ohio.
FAU - Kniss, Douglas
AU  - Kniss D
AD  - Department of Obstetrics and Gynecology, The Ohio State University College of 
      Medicine, Columbus, Ohio.
FAU - Landon, Mark B
AU  - Landon MB
AD  - Department of Obstetrics and Gynecology, The Ohio State University College of 
      Medicine, Columbus, Ohio.
FAU - Gabbe, Steven G
AU  - Gabbe SG
AD  - Department of Obstetrics and Gynecology, The Ohio State University College of 
      Medicine, Columbus, Ohio.
FAU - Rood, Kara M
AU  - Rood KM
AD  - Department of Obstetrics and Gynecology, The Ohio State University College of 
      Medicine, Columbus, Ohio.
LA  - eng
PT  - Journal Article
DEP - 20211202
PL  - United States
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
RN  - 0 (Glycated Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Glycated Hemoglobin
MH  - Glycemic Control
MH  - Humans
MH  - *Pre-Eclampsia/epidemiology/prevention & control
MH  - Pregnancy
COIS- None declared.
EDAT- 2021/12/03 06:00
MHDA- 2022/05/03 06:00
CRDT- 2021/12/02 20:26
PHST- 2021/12/03 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
PHST- 2021/12/02 20:26 [entrez]
AID - 10.1055/s-0041-1740250 [doi]
PST - ppublish
SO  - Am J Perinatol. 2022 Mar;39(4):349-353. doi: 10.1055/s-0041-1740250. Epub 2021 
      Dec 2.

PMID- 35049195
OWN - NLM
STAT- MEDLINE
DCOM- 20220207
LR  - 20220716
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 48
DP  - 2021 Dec 3
TI  - Aspirin in the prevention of preeclampsia: A protocol for systematic review and 
      meta analysis.
PG  - e27916
LID - 10.1097/MD.0000000000027916 [doi]
LID - e27916
AB  - INTRODUCTION: Aspirin is widely used to prevent pregnancy related vascular 
      disorders such as preeclampsia (PE), intrauterine growth restriction and maternal 
      disorders. However, the indications for the use of aspirin during pregnancy is 
      currently controversial because the dosage of aspirin used and the sample sizes 
      in various studies differ considerably. Furthermore, women of African ancestry 
      are more likely to have higher rates of PE and more severe cases than those of 
      their Caucasian counterparts. Yet, there are very few studies in this population 
      group. Therefore, the aim of this review will be to determine the effect of 
      low-dose aspirin (LDA) for prevention of PE in women of African ancestry. METHODS 
      AND ANALYSIS: This is a protocol for a systematic review and meta-analysis of 
      published studies on the effect of LDA for prevention of PE. Relevant information 
      will be accessed from the following databases; PubMed, Cochrane Central Register 
      of Controlled Trials, Google Scholar, Google, EBSCO Host, and the Web of Science. 
      The studies will be mapped in 2 stages: stage 1 will map studies descriptively by 
      focus and method; stage 2 will involve additional inclusion criteria, quality 
      assessment and data extraction undertaken by 2 reviewers in parallel. Evidence 
      will be synthesized using relevant systematic research tools. Meta-analysis and 
      subgroup analysis will be conducted using RevMan whilst Stata 13 will be used for 
      meta-regressions. We will follow recommendations described in the preferred 
      reporting items for systematic reviews and meta-analyses statement and the 
      Cochrane Handbook for Intervention Reviews. DISCUSSION: The use of LDA as a 
      prophylactic treatment has been considered for the prevention of PE. However, 
      studies evaluating the use of LDA in women of African ancestry are few. 
      Therefore, with the increase in the prevalence of PE in the African population, 
      it is critical to further investigate the use of LDA in pregnant women of African 
      ancestry. ETHICS AND DISSEMINATION: The review and meta-analysis will not require 
      ethical approval and the findings will be published in peer-reviewed journals and 
      presented at local and international conferences. The findings of this review 
      will inform all stakeholders on current and future guidelines on the use of 
      aspirin in pregnancy, especially in populations of African ancestry. SYSTEMATIC 
      REVIEW REGISTRATION: International prospective Register of Systematic Reviews 
      (PROSERO) number: (CRD42020213213).
CI  - Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Mkhize, P Z
AU  - Mkhize PZ
AD  - Department of Obstetrics and Gynecology, School of Clinical Medicine, College of 
      Health Sciences, Nelson R Mandela School of Medicine, University of 
      KwaZulu-Natal, Durban, South Africa.
FAU - Phoswa, W N
AU  - Phoswa WN
AUID- ORCID: 0000-0002-7769-4528
AD  - Department of Life and Consumer Sciences, University of South Africa (UNISA), 
      Science Campus, Florida, Roodepoort, South Africa.
FAU - Khaliq, O P
AU  - Khaliq OP
AD  - Department of Obstetrics and Gynecology, School of Clinical Medicine, College of 
      Health Sciences, Nelson R Mandela School of Medicine, University of 
      KwaZulu-Natal, Durban, South Africa.
FAU - Dorsamy, V
AU  - Dorsamy V
AD  - School of Laboratory Medicine and Medical Sciences College of Health Sciences, 
      Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South 
      Africa.
FAU - Moodley, J
AU  - Moodley J
AD  - Department of Obstetrics and Gynecology, School of Clinical Medicine, College of 
      Health Sciences, Nelson R Mandela School of Medicine, University of 
      KwaZulu-Natal, Durban, South Africa.
LA  - eng
GR  - 113138/South African Agency for Science and Technology Advancement/
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC9191338
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2022/01/21 06:00
MHDA- 2022/02/08 06:00
CRDT- 2022/01/20 09:43
PHST- 2021/11/05 00:00 [received]
PHST- 2021/11/08 00:00 [accepted]
PHST- 2022/01/20 09:43 [entrez]
PHST- 2022/01/21 06:00 [pubmed]
PHST- 2022/02/08 06:00 [medline]
AID - 00005792-202112030-00031 [pii]
AID - MD-D-21-07361 [pii]
AID - 10.1097/MD.0000000000027916 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Dec 3;100(48):e27916. doi: 
      10.1097/MD.0000000000027916.

PMID- 31461231
OWN - NLM
STAT- MEDLINE
DCOM- 20190912
LR  - 20190912
IS  - 0038-3317 (Print)
IS  - 0038-3317 (Linking)
VI  - 72
IP  - 6
DP  - 2019 Jun
TI  - Management of Antiplatelet Agents in Patients with History of Coronary Artery 
      Disease in Various Medical Conditions.
PG  - 260-266
AB  - Antiplatelet agents are the mainstay of treatment for patients with acute 
      coronary syndrome (ACS) or stable ischemic heart disease (SIHD). The most 
      commonly used antiplatelet agents are aspirin and clopidogrel. Newer agents such 
      as ticagrelor are becoming more commonplace as new studies have shown more 
      cardiovascular benefits with these group of medications. The duration of use of 
      these agents in setting of stable disease versus ACS is variable. We have tried 
      to delineate the usage and duration of these agents in patients with the history 
      of ACS or SIHD in numerous medical conditions. We have delved into available 
      guidelines from American College of Cardiology/American Heart Association, 
      Society of Thoracic Surgeons, and American College of Gastroenterology for our 
      review article.
CI  - Copyright© South Dakota State Medical Association.
FAU - Shrestha, Anup
AU  - Shrestha A
AD  - Department of Internal Medicine, University of South Dakota Sanford School of 
      Medicine, Sioux Falls, South Dakota.
FAU - Wilson, Jeffrey
AU  - Wilson J
AD  - Cardiovascular Fellowship Program, University of South Dakota Sanford School of 
      Medicine, Sioux Falls, South Dakota.
FAU - Stys, Adam
AU  - Stys A
AD  - Cardiovascular Fellowship Program, University of South Dakota Sanford School of 
      Medicine, Sioux Falls, South Dakota.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - S D Med
JT  - South Dakota medicine : the journal of the South Dakota State Medical Association
JID - 101265265
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acute Coronary Syndrome
MH  - Aspirin/therapeutic use
MH  - *Coronary Artery Disease/drug therapy
MH  - Humans
MH  - *Myocardial Ischemia
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2019/08/29 06:00
MHDA- 2019/09/13 06:00
CRDT- 2019/08/29 06:00
PHST- 2019/08/29 06:00 [entrez]
PHST- 2019/08/29 06:00 [pubmed]
PHST- 2019/09/13 06:00 [medline]
PST - ppublish
SO  - S D Med. 2019 Jun;72(6):260-266.

PMID- 19537585
OWN - NLM
STAT- MEDLINE
DCOM- 20090914
LR  - 20181201
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 81
IP  - 5
DP  - 2009
TI  - [Difficulties in evaluating the efficacy of antiplatelet therapy in clinical 
      practice].
PG  - 41-7
AB  - AIM: To evaluate platelet activity changes in patients with coronary artery 
      disease (CAD) treated with aspirin, clopidogrel and combination of these drugs; 
      to estimate the rate of resistance of CAD patients to antiplatelet treatment. 
      MATERIAL AND METHODS: 199 patients with stable CAD were included in the study. Of 
      them, 83 were given aspirin, 46 received clopidogrel, 34--double antiplatelet 
      therapy (both aspirin and clopidogrel). The trial also studied an additional 
      group of 18 CAD patients on double antiplatelet therapy who had hemorrhages. The 
      control group consisted of 25 healthy volunteers. Platelet aggregation was 
      measured both by a mean size of aggregates (MSA) and light transmission (LTM, 
      Born method) using BIOLA platelet aggregation analyzer. A platelet shape, 
      leukocyte-platelet aggregates (LPA) and erythrocyte-platelet aggregates (EPA) in 
      the whole blood were studied using scanning electron microscopy. The levels of 
      IL-6 and sVCAM were also measured. RESULTS: It was found that 59.8% patients with 
      CAD had high platelet reactivity revealed in 94.9% of cases by measuring 
      spontaneous and induced by 0.1 mcM ADP platelet aggregation. LTM revealed 
      increased platelet reactivity only in 10.7% patients. Resistance to aspirin 
      correlated with the presence of LTA (r = 0.629, p = 0.0001) and the number of 
      large "reticulated" platelets (r = 0.334, p = 0.001). Low platelet reactivity was 
      associated with the presence of circulating EPA (r = -0.362, p = 0.008). 
      Administration of clopidogrel did not decrease platelet reactivity to normal 
      levels in 34.7% patients which correlated with the presence of LPA and EPA. In 
      83.3% patients with hemorrhages platelet aggregation, induced by 5.0 mcM, ADP was 
      dramatically decreased. CONCLUSION: Resistance to antiplatelet therapy is related 
      to platelet heterogeneity, the presence of inflammation and state of 
      erythrocytes. LT is capable to reveal only a part of patients resistant to 
      antiplatelet drugs. To fully identify these patients, it is necessary to register 
      spontaneous platelet aggregation and aggregation induced by low doses of ADP. 
      Redundant inhibition of platelet reactivity could be the cause of hemorrhagic 
      events.
FAU - Buriachkovskaia, L I
AU  - Buriachkovskaia LI
FAU - Uchitel', I A
AU  - Uchitel' IA
FAU - Sumarokov, A V
AU  - Sumarokov AV
FAU - Popov, E G
AU  - Popov EG
LA  - rus
PT  - Clinical Trial
PT  - Journal Article
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Chronic Disease
MH  - Clopidogrel
MH  - Data Interpretation, Statistical
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/blood/*drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Ticlopidine/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
MH  - Treatment Outcome
EDAT- 2009/06/23 09:00
MHDA- 2009/09/15 06:00
CRDT- 2009/06/23 09:00
PHST- 2009/06/23 09:00 [entrez]
PHST- 2009/06/23 09:00 [pubmed]
PHST- 2009/09/15 06:00 [medline]
PST - ppublish
SO  - Ter Arkh. 2009;81(5):41-7.

PMID- 1795526
OWN - NLM
STAT- MEDLINE
DCOM- 19920406
LR  - 20190828
IS  - 0378-8741 (Print)
IS  - 0378-8741 (Linking)
VI  - 34
IP  - 2-3
DP  - 1991 Sep
TI  - Radiation-protective and platelet aggregation inhibitory effects of five 
      traditional Chinese drugs and acetylsalicylic acid following high-dose 
      gamma-irradiation.
PG  - 215-9
AB  - High doses of 60Co radiation (4.0-8.0 Gy) in mice, rats and rabbits caused 
      increases in rate of platelet aggregation during the first 5 days after 
      irradiation. The inhibitory effects of the extracts of five Chinese drug plants 
      and acetylsalicylic acid on rate of platelet aggregation were observed in both in 
      vitro and in vivo tests, averaging 23-53% in vitro and 46-69% in vivo. 
      Antiradiation tests on mice vs. 7.5-8.0 Gy of gamma-radiation, using the plant 
      extracts and acetylsalicylic acid as protective agents, increased survival rates 
      by 8-50% for the plant extracts and 35% for acetylsalicylic acid.
FAU - Wang, H F
AU  - Wang HF
AD  - Institute of Radiation Medicine, Shanghai Medical University, People's Republic 
      of China.
FAU - Li, X D
AU  - Li XD
FAU - Chen, Y M
AU  - Chen YM
FAU - Yuan, L B
AU  - Yuan LB
FAU - Foye, W O
AU  - Foye WO
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Radiation-Protective Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Gamma Rays
MH  - Male
MH  - Mice
MH  - Platelet Aggregation/drug effects/*radiation effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rabbits
MH  - Radiation Injuries, Experimental/prevention & control
MH  - Radiation-Protective Agents/*pharmacology
MH  - Rats
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
AID - 0378-8741(91)90040-K [pii]
AID - 10.1016/0378-8741(91)90040-k [doi]
PST - ppublish
SO  - J Ethnopharmacol. 1991 Sep;34(2-3):215-9. doi: 10.1016/0378-8741(91)90040-k.

PMID- 8518865
OWN - NLM
STAT- MEDLINE
DCOM- 19930729
LR  - 20220331
IS  - 0007-1331 (Print)
IS  - 0007-1331 (Linking)
VI  - 71
IP  - 5
DP  - 1993 May
TI  - Aspirin and post-prostatectomy haemorrhage.
PG  - 574-6
AB  - Haemorrhage occasionally occurs following transurethral prostatectomy, and it may 
      be severe. In this study a relationship between severe haemorrhage and ingestion 
      of aspirin is documented. This is explicable in terms of the anti-aggregatory 
      affects of aspirin on platelets. There may also be a problem with other types of 
      non-steroidal anti-inflammatory agents. Surgery should be undertaken with caution 
      on patients taking these common medications.
FAU - Thurston, A V
AU  - Thurston AV
AD  - Urology Department, Royal East Sussex Hospital.
FAU - Briant, S L
AU  - Briant SL
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Urol
JT  - British journal of urology
JID - 15740090R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects
MH  - *Blood Loss, Surgical
MH  - Blood Transfusion
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Prostatectomy
MH  - Risk Factors
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
AID - 10.1111/j.1464-410x.1993.tb16027.x [doi]
PST - ppublish
SO  - Br J Urol. 1993 May;71(5):574-6. doi: 10.1111/j.1464-410x.1993.tb16027.x.

PMID- 23440682
OWN - NLM
STAT- MEDLINE
DCOM- 20130813
LR  - 20211021
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Print)
IS  - 1176-6344 (Linking)
VI  - 9
DP  - 2013
TI  - Comparative effect of clopidogrel plus aspirin and aspirin monotherapy on 
      hematological parameters using propensity score matching.
PG  - 65-70
LID - 10.2147/VHRM.S39351 [doi]
AB  - BACKGROUND: Clopidogrel and aspirin are antiplatelet agents that are recommended 
      to reduce the risk of recurrent stroke and other cardiovascular events. Dual 
      antiplatelet therapy with clopidogrel and aspirin has been shown to increase the 
      risk of hemorrhage, but the effects of the drugs on laboratory parameters have 
      not been well studied in real-world clinical settings. Therefore, we evaluated 
      and compared the effects of combination therapy with clopidogrel plus aspirin and 
      aspirin monotherapy on laboratory parameters. METHODS: We used data from the 
      Nihon University School of Medicine Clinical Data Warehouse obtained between 
      November 2004 and May 2011 to identify cohorts of new users (n = 130) of 
      clopidogrel (75 mg/day) plus aspirin (100 mg/day) and a propensity score matched 
      sample of new users (n = 130) of aspirin alone (100 mg/day). We used a 
      multivariate regression model to compare serum levels of creatinine, aspartate 
      aminotransferase, and alanine aminotransferase, as well as hematological 
      parameters including hemoglobin level, hematocrit, and white blood cell, red 
      blood cell, and platelet counts up to 2 months after the start of administration 
      of the study drugs. RESULTS: There were no significant differences for any 
      characteristics and baseline laboratory parameters between users of clopidogrel 
      plus aspirin and users of aspirin alone. Reductions in white blood cell and red 
      blood cell counts, hemoglobin levels, and hematocrit in users of clopidogrel plus 
      aspirin were significantly greater than those in users of aspirin alone. 
      CONCLUSION: Our findings suggest that adverse hematological effects may be 
      greater with combination clopidogrel plus aspirin therapy than with aspirin 
      monotherapy.
FAU - Hayasaka, Masatoshi
AU  - Hayasaka M
AD  - Department of Pharmacy, Nihon University Itabashi Hospital, Tokyo, Japan.
FAU - Takahashi, Yasuo
AU  - Takahashi Y
FAU - Nishida, Yayoi
AU  - Nishida Y
FAU - Yoshida, Yoshikazu
AU  - Yoshida Y
FAU - Hidaka, Shinji
AU  - Hidaka S
FAU - Asai, Satoshi
AU  - Asai S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20130218
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Hemoglobins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Erythrocyte Count
MH  - Female
MH  - Hematocrit
MH  - Hemoglobins
MH  - Humans
MH  - Leukocyte Count
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Count
MH  - Propensity Score
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Treatment Outcome
PMC - PMC3578669
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - aspirin
OT  - clopidogrel
OT  - laboratory parameter
OT  - propensity score matching
EDAT- 2013/02/27 06:00
MHDA- 2013/08/14 06:00
CRDT- 2013/02/27 06:00
PHST- 2013/02/27 06:00 [entrez]
PHST- 2013/02/27 06:00 [pubmed]
PHST- 2013/08/14 06:00 [medline]
AID - vhrm-9-065 [pii]
AID - 10.2147/VHRM.S39351 [doi]
PST - ppublish
SO  - Vasc Health Risk Manag. 2013;9:65-70. doi: 10.2147/VHRM.S39351. Epub 2013 Feb 18.

PMID- 20079219
OWN - NLM
STAT- MEDLINE
DCOM- 20100506
LR  - 20140226
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 48
IP  - 10
DP  - 2009 Oct
TI  - [The present status of the use of aspirin for secondary prevention of coronary 
      artery disease].
PG  - 809-13
AB  - OBJECTIVE: To examine the current status of the use of aspirin among outpatients 
      with established coronary heart disease (CHD) in China. METHODS: Sixty-four 
      hospitals across 31 provinces of China, including 32 secondary hospitals and 32 
      tertiary hospitals were selected for a baseline survey. Fifty outpatients with 
      history of acute coronary syndrome (ACS) were recruited consecutively in each 
      hospital. Information of these patients was collected and the situation of 
      aspirin use among the patients was analyzed. RESULTS: There totally 2781 CHD 
      outpatients were recruited with complete data. Mean age of the patients was 65 
      +/- 10. Sixty-nine percent of the patients was males and 31% was females. The 
      utilization rate of aspirin before this clinical visit was 83.6%. There were 
      significant difference among regions and hospitals. The utilization rate of 
      aspirin was 64.2% and 97.8% respectively in the two provinces with the lowest use 
      rate and the highest use rate. Use rates of aspirin in CHD outpatients varied 
      from 29.4% to 98%among 64 hospitals. The male CHD patients had higher use rate 
      than the female patients did (85.1% vs. 80.4%, P < 0.01). There also was notable 
      difference in prescribed dose of aspirin among regions and hospitals. An analysis 
      of multiple logistic regression model revealed that gender, age, monthly income, 
      history of PCI and onset time of the previous ACS event were independently 
      associated with the utilization status of aspirin in these outpatients. 
      CONCLUSIONS: The overall utilization rate of aspirin in CHD outpatients reached 
      to 83.6%, but remarkable differences in aspirin use existed among regions, 
      hospitals and patients with different characteristics in current clinical 
      practice in China.
FAU - Liu, Jun
AU  - Liu J
AD  - Department of Epidemiology, Capital University of Medical Science, Beijing 
      100029, China.
FAU - Zhao, Dong
AU  - Zhao D
FAU - Liu, Jing
AU  - Liu J
FAU - Sun, Jia-yi
AU  - Sun JY
FAU - Smith, Sidney C Jr
AU  - Smith SC Jr
CN  - Bridging the Gap on Coronary Heart Disease Seconday Prevention in China Project
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - China
MH  - Coronary Disease/drug therapy/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Secondary Prevention
EDAT- 2010/01/19 06:00
MHDA- 2010/05/07 06:00
CRDT- 2010/01/19 06:00
PHST- 2010/01/19 06:00 [entrez]
PHST- 2010/01/19 06:00 [pubmed]
PHST- 2010/05/07 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2009 Oct;48(10):809-13.

PMID- 19437335
OWN - NLM
STAT- MEDLINE
DCOM- 20090910
LR  - 20181201
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 20
IP  - 3
DP  - 2009 May
TI  - Effect of exercise on platelet activation during aspirin or clopidogrel intake in 
      healthy men.
PG  - 177-82
LID - 10.1080/09537100902795484 [doi]
AB  - Sudden strenuous exercise increases the risk of ischemic cardiac events in 
      patients with coronary artery disease. The exact mechanism behind this 
      observation is unknown, but platelet activation induced by exercise may be of 
      importance. We hypothesized that brief strenuous exercise would activate 
      platelets in healthy men, assessed by the Platelet Function Analyzer 100 and 
      light transmittance aggregometry. Nearly all participants exhibited increased 
      platelet reactivity after exercise measured by the Platelet Function Analyzer 
      100, whereas only minor changes were detected by light transmittance 
      aggregometry. A significant increase in plasma von Willebrand Factor was also 
      found in response to exercise. In conclusion, platelet activation occurs during 
      exercise in healthy individuals. This activation is not prevented by use of 
      aspirin or clopidogrel, and may partly be explained by an increase in plasma von 
      Willebrand Factor.
FAU - Hjorth Madsen, Esben
AU  - Hjorth Madsen E
AD  - Department of Clinical Biochemistry, Center for Cardiovascular Research, Aalborg 
      Hospital, Aarhus University Hospital, Aalborg, Denmark. ehmadsen@gmail.dk
FAU - Christiansen, Morten Krogh
AU  - Christiansen MK
FAU - Schmidt, Erik Berg
AU  - Schmidt EB
FAU - Poulsen, Tina Svenstrup
AU  - Poulsen TS
FAU - Kristensen, Søren Risom
AU  - Kristensen SR
LA  - eng
PT  - Journal Article
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (von Willebrand Factor)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - *Exercise
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Young Adult
MH  - von Willebrand Factor/metabolism
EDAT- 2009/05/14 09:00
MHDA- 2009/09/11 06:00
CRDT- 2009/05/14 09:00
PHST- 2009/05/14 09:00 [entrez]
PHST- 2009/05/14 09:00 [pubmed]
PHST- 2009/09/11 06:00 [medline]
AID - 911104034 [pii]
AID - 10.1080/09537100902795484 [doi]
PST - ppublish
SO  - Platelets. 2009 May;20(3):177-82. doi: 10.1080/09537100902795484.

PMID- 3760670
OWN - NLM
STAT- MEDLINE
DCOM- 19861030
LR  - 20180206
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 108
IP  - 4
DP  - 1986 Oct
TI  - Inhibition of glycation of albumin and hemoglobin by acetylation in vitro and in 
      vivo.
PG  - 286-93
AB  - Aspirin (acetylsalicylic acid or ASA) is known to inhibit glycosylation 
      (glycation) of albumin in vitro. The mechanism has been presumed to be 
      acetylation, but this has never been validated. The new affinity 
      aminophenylboronic acid procedure for determination of glycosylated albumin was 
      used to demonstrate inhibition of glycosylation by aspirin. ASA, but not 
      salicylic acid, inhibited glycation. The inhibition of glycation by equimolar 
      acetic anhydride was greater than that by ASA. Pretreatment of albumin with ASA 
      in the absence of glucose demonstrated that inhibition was extremely rapid, 
      occurring in a matter of minutes. However, the inhibition by ASA could not be 
      prevented by massive acceleration of glycation induced by borohydride reduction. 
      Glycation of hemoglobin was also inhibited by ASA, but the dose requirement was 
      considerably higher. Various analogues of ASA were evaluated for inhibition of 
      glycation. Only acetyl-5-ethylsalicylic acid was more effective than ASA in 
      inhibiting albumin glycation. None of these agents was more potent than ASA in 
      inhibiting glycation of hemoglobin. ASA was fed to diabetic rats in a long-term 
      experiment. Glycohemoglobin and glycoalbumin levels were decreased by ASA 
      administration. We conclude that ASA inhibits glycation by a very rapid 
      acetylation process. This process is apparently quite selective in terms of the 
      protein involved, presumably because of the local environment of affected lysine 
      groups. The phenomenon can be produced in vivo by administration of ASA.
FAU - Rendell, M
AU  - Rendell M
FAU - Nierenberg, J
AU  - Nierenberg J
FAU - Brannan, C
AU  - Brannan C
FAU - Valentine, J L
AU  - Valentine JL
FAU - Stephen, P M
AU  - Stephen PM
FAU - Dodds, S
AU  - Dodds S
FAU - Mercer, P
AU  - Mercer P
FAU - Smith, P K
AU  - Smith PK
FAU - Walder, J
AU  - Walder J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Blood Glucose)
RN  - 0 (Borohydrides)
RN  - 0 (Hemoglobins)
RN  - 0 (Serum Albumin)
RN  - 87L0B9CPPA (sodium borohydride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Blood Glucose/metabolism
MH  - Borohydrides/pharmacology
MH  - Diabetes Mellitus, Experimental/blood
MH  - Glycosylation
MH  - Hemoglobins/*metabolism
MH  - In Vitro Techniques
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Serum Albumin/*metabolism
EDAT- 1986/10/01 00:00
MHDA- 1986/10/01 00:01
CRDT- 1986/10/01 00:00
PHST- 1986/10/01 00:00 [pubmed]
PHST- 1986/10/01 00:01 [medline]
PHST- 1986/10/01 00:00 [entrez]
AID - 0022-2143(86)90167-8 [pii]
PST - ppublish
SO  - J Lab Clin Med. 1986 Oct;108(4):286-93.

PMID- 6623543
OWN - NLM
STAT- MEDLINE
DCOM- 19831123
LR  - 20190819
IS  - 0378-4274 (Print)
IS  - 0378-4274 (Linking)
VI  - 18
IP  - 1-2
DP  - 1983 Aug
TI  - Age-related susceptibility to aspirin-induced nephrotoxicity in female rats.
PG  - 167-70
AB  - The effect of puberty on aspirin-induced renal necrosis in female Sprague-Dawley 
      rats was observed. Rats aged 31 days were unaffected by aspirin administration, 
      but 55-day-old rats showed segmental cortical tubular necrosis after a single 
      dose of 1000 mg/kg of aspirin. Urinary gamma-glutamyl transpeptidase (gamma-GT) 
      and proteinuria were useful non-invasive indicators of these necrotic changes.
FAU - Owen, R A
AU  - Owen RA
FAU - Heywood, R
AU  - Heywood R
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Toxicol Lett
JT  - Toxicology letters
JID - 7709027
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Female
MH  - Kidney/*drug effects/pathology
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1983/08/01 00:00
MHDA- 1983/08/01 00:01
CRDT- 1983/08/01 00:00
PHST- 1983/08/01 00:00 [pubmed]
PHST- 1983/08/01 00:01 [medline]
PHST- 1983/08/01 00:00 [entrez]
AID - 0378-4274(83)90089-9 [pii]
AID - 10.1016/0378-4274(83)90089-9 [doi]
PST - ppublish
SO  - Toxicol Lett. 1983 Aug;18(1-2):167-70. doi: 10.1016/0378-4274(83)90089-9.

PMID- 26554558
OWN - NLM
STAT- MEDLINE
DCOM- 20160711
LR  - 20210109
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 16
DP  - 2015 Nov 10
TI  - Aspirin for Venous Ulcers: Randomised Trial (AVURT): study protocol for a 
      randomised controlled trial.
PG  - 513
LID - 10.1186/s13063-015-1039-9 [doi]
LID - 513
AB  - BACKGROUND: Venous leg ulcers (VLUs) are the commonest cause of leg ulceration, 
      affecting 1 in 100 adults. There is a significant health burden associated with 
      VLUs - it is estimated that the cost of treatment for 1 ulcer is up to £1300 per 
      year in the NHS. The mainstay of treatment is with graduated compression 
      bandaging; however, treatment is often prolonged and up to one quarter of venous 
      leg ulcers do not heal despite standard care. Two previous trials have suggested 
      that low-dose aspirin, as an adjunct to standard care, may hasten healing, but 
      these trials were small and of poor quality. Aspirin is an inexpensive, widely 
      used medication but its safety and efficacy in the treatment of VLUs remains to 
      be established. METHODS/DESIGN: AVURT is a phase II randomised double blind, 
      parallel-group, placebo-controlled efficacy trial. The primary objective is to 
      examine whether aspirin, in addition to standard care, is effective in patients 
      with chronic VLUs (i.e. over 6 weeks in duration or a history of VLU). Secondary 
      objectives include feasibility and safety of aspirin in this population. A target 
      of 100 participants, identified from community leg ulcer clinics and hospital 
      clinics, will be randomised to receive either 300 mg of aspirin once daily or 
      placebo. All participants will receive standard care with compression therapy. 
      The primary outcome will be time to healing of the reference ulcer. Follow-up 
      will occur for a maximum of 27 weeks. The primary analysis will use a Cox 
      proportional hazards model to compare time to healing using the principles of 
      intention-to-treat. Secondary outcomes will include ulcer size, pain evaluation, 
      compliance and adverse events. DISCUSSION: The AVURT trial will investigate the 
      efficacy and safety of aspirin as a treatment for VLU and will inform on the 
      feasibility of proceeding to a larger phase III study. This study will address 
      the paucity of information currently available regarding aspirin therapy to treat 
      VLU. TRIAL REGISTRATION: The study is registered on a public database with 
      clinicaltrials.gov ( NCT02333123 ; registered on 5 November 2014).
FAU - Tilbrook, Helen
AU  - Tilbrook H
AD  - Department of Health Sciences, York Trials Unit, University of York, York, UK. 
      helen.tilbrook@york.ac.uk.
FAU - Forsythe, Rachael O
AU  - Forsythe RO
AD  - St George's Vascular Institute, St George's Healthcare NHS Trust, Blackshaw Road, 
      London, SW17 0QT, UK. rachael.forsythe@ed.ac.uk.
FAU - Rolfe, Debbie
AU  - Rolfe D
AD  - St George's University of London, London, UK. drolfe@sgul.ac.uk.
FAU - Clark, Laura
AU  - Clark L
AD  - Department of Health Sciences, York Trials Unit, University of York, York, UK. 
      laura.clark@york.ac.uk.
FAU - Bland, Martin
AU  - Bland M
AD  - Department of Health Sciences, York Trials Unit, University of York, York, UK. 
      martin.bland@york.ac.uk.
FAU - Buckley, Hannah
AU  - Buckley H
AD  - Department of Health Sciences, York Trials Unit, University of York, York, UK. 
      hannah.buckley@york.ac.uk.
FAU - Chetter, Ian
AU  - Chetter I
AD  - Hull York Medical School, University of Hull, Kingston upon Hull, UK. 
      ian.chetter@hey.nhs.uk.
FAU - Cook, Liz
AU  - Cook L
AD  - Department of Health Sciences, York Trials Unit, University of York, York, UK. 
      liz.cook@york.ac.uk.
FAU - Dumville, Jo
AU  - Dumville J
AD  - School of Nursing, Midwifery and Social Work, University of Manchester, 
      Manchester, UK. jo.dumville@manchester.ac.uk.
FAU - Gabe, Rhian
AU  - Gabe R
AD  - Department of Health Sciences, York Trials Unit, University of York, York, UK. 
      rhian.gabe@york.ac.uk.
FAU - Harding, Keith
AU  - Harding K
AD  - Wound Healing Research Unit, Cardiff University, Cardiff, UK. hardingkg@cf.ac.uk.
FAU - Layton, Alison
AU  - Layton A
AD  - Harrogate and District NHS Foundation Trust, London, UK. 
      alison.layton@hdft.nhs.uk.
FAU - Lindsay, Ellie
AU  - Lindsay E
AD  - The Lindsay Leg Club Foundation, London, UK. ellie@legclubfoundation.com.
FAU - McDaid, Catriona
AU  - McDaid C
AD  - Department of Health Sciences, York Trials Unit, University of York, York, UK. 
      catriona.mcdaid@york.ac.uk.
FAU - Moffatt, Christine
AU  - Moffatt C
AD  - School of Health Sciences, University of Nottingham, Nottingham, UK. 
      christine.moffatt@nottingham.ac.uk.
FAU - Phillips, Ceri
AU  - Phillips C
AD  - Swansea Centre for Health Economics, Swansea University, Swansea, UK. 
      C.J.Phillips@swansea.ac.uk.
FAU - Stansby, Gerard
AU  - Stansby G
AD  - School of Surgical and Reproductive Sciences, Newcastle University, Newcastle 
      upon Tyne, UK. Gerard.Stansby@nuth.nhs.uk.
FAU - Vowden, Peter
AU  - Vowden P
AD  - University of Bradford, Bradford, UK. peter.vowden@mac.com.
FAU - Williams, Laurie
AU  - Williams L
AD  - St George's Vascular Institute, St George's Healthcare NHS Trust, Blackshaw Road, 
      London, SW17 0QT, UK. laurie.williams49@gmail.com.
FAU - Torgerson, David
AU  - Torgerson D
AD  - Department of Health Sciences, York Trials Unit, University of York, York, UK. 
      david.torgerson@york.ac.uk.
FAU - Hinchliffe, Robert J
AU  - Hinchliffe RJ
AD  - St George's Vascular Institute, St George's Healthcare NHS Trust, Blackshaw Road, 
      London, SW17 0QT, UK. rhinchli@sgul.ac.uk.
AD  - St George's University of London, London, UK. rhinchli@sgul.ac.uk.
LA  - eng
SI  - ClinicalTrials.gov/NCT02333123
GR  - HTA/13/87/08/DH_/Department of Health/United Kingdom
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20151110
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Clinical Protocols
MH  - Combined Modality Therapy
MH  - Compression Bandages
MH  - Double-Blind Method
MH  - England
MH  - Feasibility Studies
MH  - Humans
MH  - Intention to Treat Analysis
MH  - Proportional Hazards Models
MH  - Research Design
MH  - Time Factors
MH  - Treatment Outcome
MH  - Varicose Ulcer/diagnosis/*drug therapy
MH  - Wound Healing/*drug effects
PMC - PMC4641424
EDAT- 2015/11/12 06:00
MHDA- 2016/07/12 06:00
CRDT- 2015/11/12 06:00
PHST- 2015/08/11 00:00 [received]
PHST- 2015/10/29 00:00 [accepted]
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/07/12 06:00 [medline]
AID - 10.1186/s13063-015-1039-9 [pii]
AID - 1039 [pii]
AID - 10.1186/s13063-015-1039-9 [doi]
PST - epublish
SO  - Trials. 2015 Nov 10;16:513. doi: 10.1186/s13063-015-1039-9.

PMID- 36203169
OWN - NLM
STAT- MEDLINE
DCOM- 20221010
LR  - 20221011
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 23
IP  - 1
DP  - 2022 Oct 6
TI  - Examining evidence of time-dependent treatment effects: an illustration using 
      regression methods.
PG  - 857
LID - 10.1186/s13063-022-06803-x [doi]
LID - 857
AB  - BACKGROUND: For the design and analysis of clinical trials with time-to-event 
      outcomes, the Cox proportional hazards model and the logrank test have been the 
      cornerstone methods for many decades. Increasingly, the key assumption of 
      proportionality-or time-fixed effects-that underpins these methods has been 
      called into question. The availability of novel therapies with new mechanisms of 
      action and clinical trials of longer duration mean that non-proportional hazards 
      are now more frequently encountered. METHODS: We compared several 
      regression-based methods to model time-dependent treatment effects. For 
      illustration purposes, we used selected endpoints from a large, community-based 
      clinical trial of low dose daily aspirin in older persons. Relative and absolute 
      estimands were defined, and analyses were conducted in all participants. 
      Additional exploratory analyses were undertaken by selected subgroups of interest 
      using interaction terms in the regression models. DISCUSSION: In the trial with 
      median 4.7 years follow-up, we found evidence for non-proportionality and a 
      time-dependent treatment effect of aspirin on cancer mortality not previously 
      reported in trial findings. We also found some evidence of time-dependence to an 
      aspirin by age interaction for major adverse cardiovascular events. For other 
      endpoints, time-fixed treatment effect estimates were confirmed as appropriate. 
      CONCLUSIONS: The consideration of treatment effects using both absolute and 
      relative estimands enhanced clinical insights into potential dynamic treatment 
      effects. We recommend these analytical approaches as an adjunct to primary 
      analyses to fully explore findings from clinical trials.
CI  - © 2022. The Author(s).
FAU - Jachno, Kim M
AU  - Jachno KM
AUID- ORCID: 0000-0003-2550-9674
AD  - Public Health and Preventive Medicine, Monash University, Melbourne, Australia. 
      kim.jachno@monash.edu.
FAU - Heritier, Stephane
AU  - Heritier S
AD  - Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
FAU - Mahady, Suzanne
AU  - Mahady S
AD  - Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
FAU - Chan, Andrew
AU  - Chan A
AD  - Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, 
      Boston, MA, USA.
FAU - Tonkin, Andrew
AU  - Tonkin A
AD  - Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
FAU - Murray, Anne
AU  - Murray A
AD  - Berman Centre for Outcomes and Clinical Research, Hennepin Health Research 
      Institute, Minneapolis, MN, USA.
AD  - Division of Geriatrics, Department of Medicine, Hennepin County Medical Center 
      and University of Minnesota, Minneapolis, MN, USA.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
LA  - eng
GR  - U01AG029824/AG/NIA NIH HHS/United States
GR  - U19AG062682/CA/NCI NIH HHS/United States
GR  - 334047/National Health and Medical Research Council/
GR  - 1127060/National Health and Medical Research Institute/
GR  - 1171422/National Health and Medical Research Council/
GR  - R35 CA253185/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20221006
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aspirin/adverse effects
MH  - Humans
MH  - Proportional Hazards Models
MH  - Time Factors
PMC - PMC9535854
OTO - NOTNLM
OT  - Clinical trials
OT  - Flexible parametric modelling
OT  - Proportional hazards
OT  - Time-dependent effects
OT  - Treatment effect heterogeneity
COIS- The authors declare that they have no competing interests.
EDAT- 2022/10/07 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/10/06 23:44
PHST- 2021/10/26 00:00 [received]
PHST- 2022/09/29 00:00 [accepted]
PHST- 2022/10/06 23:44 [entrez]
PHST- 2022/10/07 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
AID - 10.1186/s13063-022-06803-x [pii]
AID - 6803 [pii]
AID - 10.1186/s13063-022-06803-x [doi]
PST - epublish
SO  - Trials. 2022 Oct 6;23(1):857. doi: 10.1186/s13063-022-06803-x.

PMID- 30532184
OWN - NLM
STAT- MEDLINE
DCOM- 20190506
LR  - 20200309
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 12
DP  - 2018
TI  - Low dose aspirin blocks breast cancer-induced cognitive impairment in mice.
PG  - e0208593
LID - 10.1371/journal.pone.0208593 [doi]
LID - e0208593
AB  - Cancer patients with non-central nervous system tumors often suffer from 
      cognitive impairment. While chemotherapy has long been attributed as the cause of 
      these memory, learning and concentration difficulties, we recently observed 
      cognitive impairment in cancer patients prior to treatment. This suggests the 
      cancer alone may be sufficient to induce cognitive impairment, however the 
      mechanisms are unknown. Here, we show that we can experimentally replicate the 
      clinical phenomenon of cancer-associated cognitive impairment and we identify 
      inflammation as a causal mechanism. We demonstrate that a peripheral tumor is 
      sufficient to induce memory loss. Using an othotopic mouse model of breast 
      cancer, we found that mice with 4T1.2 or EO771 mammary tumors had significantly 
      poorer memory than mice without tumors. Memory impairment was independent of 
      cancer-induced sickness behavior, which was only observed during the later stage 
      of cancer progression in mice with high metastatic burden. Tumor-secreted factors 
      were sufficient to induce memory impairment and pro-inflammatory cytokines were 
      elevated in the plasma of tumor-bearing mice. Oral treatment with low-dose 
      aspirin completely blocked tumor-induced memory impairment without affecting 
      tumor-induced sickness or tumor growth, demonstrating a causal role for 
      inflammation in cognitive impairment. These findings suggest that 
      anti-inflammatories may be a safe and readily translatable strategy that could be 
      used to prevent cancer-associated cognitive impairment in patients.
FAU - Walker, Adam K
AU  - Walker AK
AUID- ORCID: 0000-0003-3772-5745
AD  - Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash 
      University, Parkville, Victoria, Australia.
AD  - Neuroscience Research Australia, Randwick, New South Wales, Australia.
AD  - School of Psychiatry, University of New South Wales, Randwick, New South Wales, 
      Australia.
AD  - Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, 
      Victoria, Australia.
FAU - Chang, Aeson
AU  - Chang A
AD  - Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash 
      University, Parkville, Victoria, Australia.
FAU - Ziegler, Alexandra I
AU  - Ziegler AI
AD  - Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash 
      University, Parkville, Victoria, Australia.
FAU - Dhillon, Haryana M
AU  - Dhillon HM
AD  - Centre for Medical Psychology & Evidence-based Decision-Making, School of 
      Psychology, Faculty of Science, University of Sydney, Camperdown, New South 
      Wales, Australia.
FAU - Vardy, Janette L
AU  - Vardy JL
AD  - Concord Clinical School, Sydney Medical School, University of Sydney, Camperdown, 
      New South Wales, Australia.
AD  - Concord Cancer Centre, Concord Repatriation General Hospital, Concord, New South 
      Wales, Australia.
FAU - Sloan, Erica K
AU  - Sloan EK
AD  - Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash 
      University, Parkville, Victoria, Australia.
AD  - Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, 
      Victoria, Australia.
AD  - Cousins Center for PNI, UCLA Semel Institute, Jonsson Comprehensive Cancer 
      Center, and UCLA AIDS Institute, University of California Los Angeles, Los 
      Angeles, California, United states of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20181210
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cytokines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Behavior, Animal/drug effects
MH  - Cognitive Dysfunction/*prevention & control
MH  - Cytokines/blood
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Mammary Neoplasms, Animal/complications/*pathology
MH  - Memory/drug effects
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
PMC - PMC6287899
COIS- The authors have declared that no competing interests exist.
EDAT- 2018/12/12 06:00
MHDA- 2019/05/07 06:00
CRDT- 2018/12/12 06:00
PHST- 2018/03/04 00:00 [received]
PHST- 2018/11/20 00:00 [accepted]
PHST- 2018/12/12 06:00 [entrez]
PHST- 2018/12/12 06:00 [pubmed]
PHST- 2019/05/07 06:00 [medline]
AID - PONE-D-18-05885 [pii]
AID - 10.1371/journal.pone.0208593 [doi]
PST - epublish
SO  - PLoS One. 2018 Dec 10;13(12):e0208593. doi: 10.1371/journal.pone.0208593. 
      eCollection 2018.

PMID- 2611286
OWN - NLM
STAT- MEDLINE
DCOM- 19900226
LR  - 20131121
IS  - 0006-3029 (Print)
IS  - 0006-3029 (Linking)
VI  - 34
IP  - 5
DP  - 1989 Sep-Oct
TI  - [Luminescence, induced by UV-irradiation, of intact human skin].
PG  - 858-62
AB  - UV-C induced chemiluminescence of human skin was investigated in vivo by means of 
      an image-producing system using photon-counting camera and computer 
      PERICOLOR-1000. Luminescence after UV-C application is shown to decline 
      nonexponentially, the parameters of the decline depending on irradiation dose, 
      skin specimen and previous irradiations. If the same skin specimen is irradiated 
      second time 3-36 hours after the first irradiation, the luminescence decline time 
      increases from one-two minutes to more than half an hour. During the time when 
      the decline is slow the images produced by irradiation through the diaphragm do 
      not sustain distinct contours due to the luminescence of nonirradiated skin. The 
      luminescence is shown to be under the organisms' control and to diminish 
      significantly after the application of acetylsalicylic acid.
FAU - Lebedev, A V
AU  - Lebedev AV
FAU - Koreneva, L G
AU  - Koreneva LG
FAU - Lunin, E E
AU  - Lunin EE
FAU - Pasechnik, V I
AU  - Pasechnik VI
FAU - Zalogin, V N
AU  - Zalogin VN
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Indutsirovannaia UF-oblucheniem liuminestsentsiia intaktnoĭ kozhi cheloveka.
PL  - Russia (Federation)
TA  - Biofizika
JT  - Biofizika
JID - 0372666
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Humans
MH  - Kinetics
MH  - *Luminescence
MH  - Skin/drug effects/*radiation effects
MH  - *Ultraviolet Rays
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
PST - ppublish
SO  - Biofizika. 1989 Sep-Oct;34(5):858-62.

PMID- 3715801
OWN - NLM
STAT- MEDLINE
DCOM- 19860627
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 42
IP  - 2
DP  - 1986 Apr 15
TI  - Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin.
PG  - 215-23
AB  - We have examined the effects of dipyridamole on platelet aggregation in whole 
      blood both in vitro and after administration to man. The effects of dipyridamole 
      ex vivo were compared with those of aspirin and a combination of dipyridamole and 
      aspirin. In vitro dipyridamole was most effective as an inhibitor of platelet 
      aggregation induced by platelet activating factor (PAF) and low concentrations of 
      arachidonic acid (AA). Its inhibitory effect was always potentiated by adenosine 
      suggesting that its effect on aggregation may be via inhibition of adenosine 
      uptake into blood cells. Ex vivo, dipyridamole, aspirin and the combination of 
      these drugs inhibited the platelet aggregation induced by PAF and AA. Again, 
      adenosine increased the degree of inhibition. These results stress the importance 
      of measuring platelet aggregation in the natural whole blood environment for 
      detection of the inhibitory effects of dipyridamole and suggest a mode of action 
      for the drug.
FAU - Heptinstall, S
AU  - Heptinstall S
FAU - Fox, S
AU  - Fox S
FAU - Crawford, J
AU  - Crawford J
FAU - Hawkins, M
AU  - Hawkins M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Specimen Collection
MH  - Dipyridamole/*pharmacology
MH  - Drug Interactions
MH  - Humans
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Count
EDAT- 1986/04/15 00:00
MHDA- 1986/04/15 00:01
CRDT- 1986/04/15 00:00
PHST- 1986/04/15 00:00 [pubmed]
PHST- 1986/04/15 00:01 [medline]
PHST- 1986/04/15 00:00 [entrez]
AID - 10.1016/0049-3848(86)90297-5 [doi]
PST - ppublish
SO  - Thromb Res. 1986 Apr 15;42(2):215-23. doi: 10.1016/0049-3848(86)90297-5.

PMID- 6402412
OWN - NLM
STAT- MEDLINE
DCOM- 19830407
LR  - 20131121
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 84
IP  - 4
DP  - 1983 Apr
TI  - Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in 
      rat.
PG  - 756-61
AB  - Dose-response relationships between aspirin-induced cyclo-oxygenase inhibition 
      and gastric mucosal injury were studied in rats. Oral or parenteral aspirin, 25 
      mg/kg, inhibited prostaglandin generation by 87%-95% at 1, 3, and 6 h with no 
      lesion formation. Aspirin, 100 mg/kg, inhibited prostaglandin generation by 
      95%-98% at 1, 3, and 6 h, but lesions were observed only when aspirin was given 
      orally. Three-hour pretreatment with intraperitoneal aspirin, 12.5 mg/kg, did not 
      enhance the mucosal injury caused by 10 mM acidified taurocholate, although 
      prostaglandin generation was inhibited by 80%. Pretreatment with 25 mg/kg aspirin 
      inhibited prostaglandin generation by 89% and was associated with significant 
      mucosal injury by acidified taurocholate. We conclude that aspirin-induced 95% 
      inhibition of gastric mucosal cyclo-oxygenase is not, by itself, sufficient to 
      produce lesions and inhibition by greater than 80% is required to predispose the 
      gastric mucosa to injury by otherwise mild irritants.
FAU - Ligumsky, M
AU  - Ligumsky M
FAU - Golanska, E M
AU  - Golanska EM
FAU - Hansen, D G
AU  - Hansen DG
FAU - Kauffman, G L Jr
AU  - Kauffman GL Jr
LA  - eng
GR  - F05-TW0-2892-01/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 5E090O0G3Z (Taurocholic Acid)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - *Cyclooxygenase Inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Epoprostenol/biosynthesis
MH  - Gastric Mucosa/*drug effects/enzymology
MH  - Injections, Intraperitoneal
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Taurocholic Acid/pharmacology
EDAT- 1983/04/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - S0016508583000748 [pii]
PST - ppublish
SO  - Gastroenterology. 1983 Apr;84(4):756-61.

PMID- 23941821
OWN - NLM
STAT- MEDLINE
DCOM- 20140422
LR  - 20130920
IS  - 1421-9867 (Electronic)
IS  - 0012-2823 (Linking)
VI  - 88
IP  - 2
DP  - 2013
TI  - Association of gastric mucosal injury severity with platelet function and gastric 
      pH during low-dose aspirin treatment.
PG  - 79-86
LID - 10.1159/000353150 [doi]
AB  - INTRODUCTION: The antiplatelet effects of low-dose aspirin (LDA) vary between 
      individuals. Here, we investigated the relationship between the incidence of 
      LDA-induced mucosal injury, antiplatelet effects of LDA, and intragastric pH. 
      METHODS: We evaluated gastric injury severity and platelet function using the 
      VerifyNow® System before and after administration of 100 mg aspirin for 7 days to 
      18 young healthy subjects (study 1). We investigated whether injury was 
      correlated with platelet function and gastric juice pH in 45 patients with 
      cardiovascular disease administered LDA daily (study 2). RESULTS: In study 1, 
      platelet aggregation was attenuated by LDA to different degrees. Although 55.6% 
      of subjects (10/18) developed gastric injury of modified Lanza score (MLS) ≥ 3, 
      no significant difference in platelet function was detected between the mild (n = 
      8, MLS: 0-2) and severe injury groups (n = 10, MLS: 3-5). In study 2, the 
      severity of LDA-induced injury was associated with gastric juice pH, but not with 
      antiplatelet effects of LDA. DISCUSSION: In contrast to gastric juice pH, the 
      antiplatelet effect had no correlation with the severity of gastric mucosal 
      injury. Monitoring gastric acidity, rather than platelet function, may be useful 
      for predicting the risk of gastric injury during LDA treatment.
CI  - © 2013 S. Karger AG, Basel.
FAU - Nishino, Masafumi
AU  - Nishino M
AD  - First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, 
      Japan.
FAU - Sugimoto, Mitsushige
AU  - Sugimoto M
FAU - Uotani, Takahiro
AU  - Uotani T
FAU - Yamade, Mihoko
AU  - Yamade M
FAU - Sahara, Shu
AU  - Sahara S
FAU - Ichikawa, Hitomi
AU  - Ichikawa H
FAU - Sugimoto, Ken
AU  - Sugimoto K
FAU - Umemura, Kazuo
AU  - Umemura K
FAU - Watanabe, Hiroshi
AU  - Watanabe H
FAU - Miyajima, Hiroaki
AU  - Miyajima H
FAU - Furuta, Takahisa
AU  - Furuta T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130809
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Female
MH  - Gastric Mucosa/*drug effects/*injuries
MH  - Gastroscopy
MH  - Healthy Volunteers
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Platelet Function Tests
MH  - Stomach Diseases/*chemically induced
MH  - Young Adult
EDAT- 2013/08/15 06:00
MHDA- 2014/04/23 06:00
CRDT- 2013/08/15 06:00
PHST- 2013/02/25 00:00 [received]
PHST- 2013/05/15 00:00 [accepted]
PHST- 2013/08/15 06:00 [entrez]
PHST- 2013/08/15 06:00 [pubmed]
PHST- 2014/04/23 06:00 [medline]
AID - 000353150 [pii]
AID - 10.1159/000353150 [doi]
PST - ppublish
SO  - Digestion. 2013;88(2):79-86. doi: 10.1159/000353150. Epub 2013 Aug 9.

PMID- 22121249
OWN - NLM
STAT- MEDLINE
DCOM- 20120312
LR  - 20181201
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 88
IP  - 1035
DP  - 2012 Jan
TI  - Systematic review and meta-analysis of the effects of antipyretic medications on 
      mortality in Streptococcus pneumoniae infections.
PG  - 21-7
LID - 10.1136/postgradmedj-2011-130217 [doi]
AB  - AIM: To determine whether the use of antipyretic medications in the treatment of 
      Streptococcus pneumoniae infection affects mortality in humans or animal models. 
      DESIGN: A systematic search of Medline, Embase, and The Cochrane Register of 
      Controlled Trials was undertaken to identify in vivo animal experiments or 
      randomised, controlled trials in humans of antipyretic medication in S pneumoniae 
      infection which reported mortality data. Meta-analysis was by inverse variance 
      weighted method for odds ratios. SETTING: Antipyretics are recommended for the 
      symptomatic treatment of various diseases caused by S pneumoniae. However, there 
      is evidence that fever is a protective physiological response to infection, that 
      treating fever secondary to infection may be harmful, and that some strains of S 
      pneumoniae are temperature sensitive. MAIN OUTCOME MEASURES: Mortality associated 
      with antipyretic use in S pneumoniae infection. RESULTS: Four studies from two 
      publications met the inclusion criteria and investigated the use of aspirin in 
      animal models. The pooled estimate of mortality was an OR with aspirin treatment 
      of 1.97 (95% CI 1.22 to 3.19). There were no suitable human studies identified. 
      CONCLUSIONS: A twofold increased risk of mortality was found with aspirin 
      treatment in animal models of S pneumoniae infection. No relevant human studies 
      were identified. It is difficult to generalise from animal models to clinical 
      medicine, but based on these findings and the prevalence and severity of S 
      pneumoniae infections worldwide, future study of the effects of antipyretic 
      therapy in S pneumoniae infection in humans is recommended.
FAU - Jefferies, Sarah
AU  - Jefferies S
AD  - Medical Research Institute of New Zealand, Wellington, New Zealand. 
      sarah.jefferies@mrinz.ac.nz
FAU - Weatherall, Mark
AU  - Weatherall M
FAU - Young, Paul
AU  - Young P
FAU - Eyers, Sally
AU  - Eyers S
FAU - Beasley, Richard
AU  - Beasley R
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20111125
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - 0 (Antipyretics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antipyretics/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Body Temperature/*drug effects/immunology
MH  - Disease Models, Animal
MH  - Fever/*drug therapy/etiology
MH  - Humans
MH  - Pneumococcal Infections/drug therapy/*mortality
EDAT- 2011/11/29 06:00
MHDA- 2012/03/13 06:00
CRDT- 2011/11/29 06:00
PHST- 2011/11/29 06:00 [entrez]
PHST- 2011/11/29 06:00 [pubmed]
PHST- 2012/03/13 06:00 [medline]
AID - postgradmedj-2011-130217 [pii]
AID - 10.1136/postgradmedj-2011-130217 [doi]
PST - ppublish
SO  - Postgrad Med J. 2012 Jan;88(1035):21-7. doi: 10.1136/postgradmedj-2011-130217. 
      Epub 2011 Nov 25.

PMID- 3320388
OWN - NLM
STAT- MEDLINE
DCOM- 19880203
LR  - 20131121
IS  - 0741-5214 (Print)
IS  - 0741-5214 (Linking)
VI  - 6
IP  - 6
DP  - 1987 Dec
TI  - Platelet survival and serotonin content after placement of arterial prostheses in 
      dogs: effects of neointimal coverage and high- and low-dose aspirin.
PG  - 555-62
AB  - Because prosthetic neointima produces much less prostacyclin (PGI2) than arterial 
      intima and may be more susceptible to cyclooxygenase inhibition, aspirin 
      treatment might enhance surface thrombogenesis. To test this hypothesis, aortic 
      prostheses were placed in eight dogs and measurements of platelet survival and 
      platelet serotonin (5HT) were made under conditions of no treatment and treatment 
      with low-dose (2mg/kg) and high-dose (30 mg/kg) aspirin. These doses equally 
      suppressed platelet function. Measurements were performed preoperatively, 6 to 8 
      weeks postoperatively (when little neointima was present), and 28 to 32 weeks 
      postoperatively (neointima fully developed). Platelet survival and 5HT levels 
      were markedly reduced 6 to 8 weeks postoperatively and returned to normal at 28 
      to 32 weeks after implantation. At all times, low-dose aspirin improved platelet 
      survival and this effect was most apparent 6 to 8 weeks postoperatively. 
      Treatment with either aspirin dose decreased platelet 5HT levels at the 28 to 32 
      week postoperative period but not at other times. At recovery of prostheses, 90% 
      of the luminal surface was covered with endothelialized neointima. Neointimal 
      production of PGI2 was one half to one third that of aortic production. Despite 
      this, low- and high-dose aspirin equally suppressed PGI2 production from both 
      neointima and aorta. Furthermore, aspirin did not increase labeled platelet 
      uptake on neointima. We conclude that (1) aspirin treatment does not render 
      prosthetic neointima thrombogenic and (2) aspirin alters platelet survival and 
      5HT levels by mechanisms other than inhibition of platelet and neointima 
      cyclooxygenase.
FAU - Clagett, G P
AU  - Clagett GP
AD  - Department of Surgery, University of Texas Health Science Center, Dallas 
      75235-9031.
FAU - Hufnagel, H
AU  - Hufnagel H
FAU - Watkins, M T
AU  - Watkins MT
FAU - Sharefkin, J B
AU  - Sharefkin JB
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - 333DO1RDJY (Serotonin)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Platelets/*physiology
MH  - *Blood Vessel Prosthesis
MH  - Cell Survival/drug effects
MH  - Dogs
MH  - Endothelium, Vascular/drug effects/*physiology
MH  - Epoprostenol/biosynthesis
MH  - Graft Survival
MH  - Serotonin/*blood
EDAT- 1987/12/01 00:00
MHDA- 2001/09/06 10:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 2001/09/06 10:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
AID - S0741521487003148 [pii]
PST - ppublish
SO  - J Vasc Surg. 1987 Dec;6(6):555-62.

PMID- 24517849
OWN - NLM
STAT- MEDLINE
DCOM- 20160314
LR  - 20161125
IS  - 1521-0464 (Electronic)
IS  - 1071-7544 (Linking)
VI  - 22
IP  - 3
DP  - 2015 May
TI  - Polysaccharide arabinogalactan from larch Larix sibirica as carrier for molecules 
      of salicylic and acetylsalicylic acid: preparation, physicochemical and 
      pharmacological study.
PG  - 400-7
LID - 10.3109/10717544.2014.884655 [doi]
AB  - Inclusion complexes of salicylic acid (SA) and acetylsalicylic acid (aspirin, 
      ASA) with polysaccharide arabinogalactan (AG) from larch wood Larix sibirica and 
      Larix gmelinii were synthesized using mechanochemical technology. In the present 
      study, we have investigated physicochemical properties of the synthesized 
      complexes in solid state and in aqueous solutions as well as their 
      anti-aggregation and ulcerogenic activity. The evidence of the complexes 
      formation was obtained by nuclear magnetic resonance (NMR) relaxation technique. 
      It was shown that in aqueous solution the molecules of SA and ASA are in fast 
      exchange between the complex with AG macromolecules and solution. The stability 
      constant of aspirin complex was calculated. It was shown that mechanochemically 
      synthesized complexes are more stable when compared to the complex obtained by 
      mixing solutions of the components. Complexes of ASA show two-fold increase of 
      anti-platelet effect. It allows to reduce the dose of the antithrombotic drug and 
      its ulcerogenic activity. These results substantiate the possibility to design 
      new preparations on the basis of ASA with increased activity and safety.
FAU - Chistyachenko, Yulia S
AU  - Chistyachenko YS
AD  - Institute of Solid State Chemistry and Mechanochemistry , Novosibirsk , Russia .
FAU - Dushkin, Alexandr V
AU  - Dushkin AV
FAU - Polyakov, Nikolay E
AU  - Polyakov NE
FAU - Khvostov, Mikhail V
AU  - Khvostov MV
FAU - Tolstikova, Tatyana G
AU  - Tolstikova TG
FAU - Tolstikov, Genrikh A
AU  - Tolstikov GA
FAU - Lyakhov, Nikolay Z
AU  - Lyakhov NZ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140212
PL  - England
TA  - Drug Deliv
JT  - Drug delivery
JID - 9417471
RN  - 0 (Drug Carriers)
RN  - 0 (Galactans)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Solutions)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - SL4SX1O487 (arabinogalactan)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects/blood/pharmacology
MH  - Drug Carriers/*chemistry/isolation & purification
MH  - Galactans/*chemistry/isolation & purification
MH  - Larix/*chemistry
MH  - Male
MH  - Phase Transition
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/blood/pharmacology
MH  - Rats, Wistar
MH  - Salicylic Acid/administration & dosage/adverse effects/blood/pharmacology
MH  - Solubility
MH  - Solutions
MH  - Surface Properties
OTO - NOTNLM
OT  - Complexation
OT  - NMR
OT  - mechanical activation
OT  - platelet aggregation
OT  - solid dispersion
EDAT- 2014/02/13 06:00
MHDA- 2016/03/15 06:00
CRDT- 2014/02/13 06:00
PHST- 2014/02/13 06:00 [entrez]
PHST- 2014/02/13 06:00 [pubmed]
PHST- 2016/03/15 06:00 [medline]
AID - 10.3109/10717544.2014.884655 [doi]
PST - ppublish
SO  - Drug Deliv. 2015 May;22(3):400-7. doi: 10.3109/10717544.2014.884655. Epub 2014 
      Feb 12.

PMID- 16613770
OWN - NLM
STAT- MEDLINE
DCOM- 20060518
LR  - 20131121
IS  - 1302-8723 (Print)
IS  - 1302-8723 (Linking)
VI  - 6 Suppl 1
DP  - 2006 Apr
TI  - [Antiplatelet therapy in acute coronary syndromes without ST segment elevation].
PG  - 13-9
AB  - The pathophysiology of acute coronary syndromes involves plaque rupture or 
      fissure with platelet activation and aggregation. Antiplatelet therapy is a 
      cornerstone in the management of unstable angina and non-ST elevation myocardial 
      infarction. Three classes of antiplatelet drugs have been found useful in the 
      management of these patients: aspirin, thienopyridines and glycoprotein IIb/IIIa 
      antagonists. There is a great amount of interpatient variability in response to 
      these antiplatelet agents, and this variability may affect outcomes. It is needed 
      to prescribe appropriate antiplatelet therapies according to potential benefit in 
      reducing death and cardiovascular events vs the bleeding risks these agents 
      cause. Antiplatelet drugs are the subjects of continued intensive investigation.
FAU - Umman, Berrin
AU  - Umman B
AD  - Department of Cardiology, Istanbul Medical Faculty, Istanbul University, 
      Istanbul, Turkey. berrinumman@hotmail.com
LA  - tur
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - ST yükselmesiz akut koroner sendromlarda antitrombosit tedavi.
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/*drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
RF  - 40
EDAT- 2006/04/15 09:00
MHDA- 2006/05/19 09:00
CRDT- 2006/04/15 09:00
PHST- 2006/04/15 09:00 [pubmed]
PHST- 2006/05/19 09:00 [medline]
PHST- 2006/04/15 09:00 [entrez]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2006 Apr;6 Suppl 1:13-9.

PMID- 21501103
OWN - NLM
STAT- MEDLINE
DCOM- 20120105
LR  - 20131121
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 46
IP  - 7-8
DP  - 2011 Jul
TI  - Incidence of gastrointestinal bleeding in patients with cardiovascular disease: 
      buffered aspirin versus enteric-coated aspirin.
PG  - 803-9
LID - 10.3109/00365521.2011.568522 [doi]
AB  - OBJECTIVE: Aspirin-induced enteropathy is increasing, but whether the type of 
      aspirin affects the gastrointestinal (GI) bleeding, especially small intestine, 
      is unclear. The incidence of GI bleeding for buffered aspirin and enteric-coated 
      aspirin was evaluated in patients receiving long-term low-dose aspirin (LDA) for 
      cardiovascular (CV) diseases. METHODS: This retrospective cohort study assessed 
      overt GI bleeding, decreased hemoglobin levels suspecting small bowel blood loss, 
      and CV death in patients taking LDA for more than 1 year (LDA group) and in 
      patients not taking LDA (control group). The LDA group was divided into two 
      subgroups, patients taking either buffered aspirin (buffered subgroup) or 
      enteric-coated aspirin (enteric subgroup), and their outcomes were compared. 
      RESULTS: A total of 1402 patients (LDA group 701, control group 701; median 
      follow-up duration 1778 ± 747 days) were assessed. The incidences of overt GI 
      bleeding and decreased hemoglobin were 3.9% and 1.4% in LDA group, respectively, 
      significantly higher than the control group (p < 0.01; p < 0.01). In the LDA 
      group, 3% died during the follow-up period. Ten (3.7%) in the buffered subgroup 
      (n = 267) and 17 (3.9%) in the enteric subgroup (n = 434) developed GI bleeding 
      (p = 0.92). One (0.3%) in the buffered subgroup and nine (2%) in the enteric 
      subgroup developed decreased hemoglobin (p = 0.06, log-rank test). CONCLUSIONS: 
      The type of aspirin does not affect the incidence of overt GI bleeding and 
      decreased hemoglobin, but enteric-coated aspirin may be associated with an 
      increased incidence of decreased hemoglobin.
FAU - Hirata, Yoshikazu
AU  - Hirata Y
AD  - Department of Gastroenterology and Metabolism, Nagoya City University Graduate 
      School of Medical Sciences, Nagoya, Japan.
FAU - Kataoka, Hiromi
AU  - Kataoka H
FAU - Shimura, Takaya
AU  - Shimura T
FAU - Mizushima, Takashi
AU  - Mizushima T
FAU - Mizoshita, Tsutomu
AU  - Mizoshita T
FAU - Tanida, Satoshi
AU  - Tanida S
FAU - Kamiya, Takeshi
AU  - Kamiya T
FAU - Joh, Takashi
AU  - Joh T
LA  - eng
PT  - Journal Article
DEP - 20110419
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Buffers)
RN  - 0 (Hemoglobins)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Buffers
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Incidence
MH  - Kaplan-Meier Estimate
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Tablets, Enteric-Coated
EDAT- 2011/04/20 06:00
MHDA- 2012/01/06 06:00
CRDT- 2011/04/20 06:00
PHST- 2011/04/20 06:00 [entrez]
PHST- 2011/04/20 06:00 [pubmed]
PHST- 2012/01/06 06:00 [medline]
AID - 10.3109/00365521.2011.568522 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2011 Jul;46(7-8):803-9. doi: 10.3109/00365521.2011.568522. 
      Epub 2011 Apr 19.

PMID- 32521895
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 2241-6293 (Electronic)
IS  - 1107-0625 (Linking)
VI  - 25
IP  - 2
DP  - 2020 Mar-Apr
TI  - Effects of aspirin on hepatocellular carcinoma and its potential molecular 
      mechanism.
PG  - 981-986
AB  - PURPOSE: To explore the effects of aspirin (ASP) on the proliferation and 
      apoptosis of HepG2 hepatocellular carcinoma (HCC) cells via the Wnt/β-catenin 
      signaling pathway. METHODS: Human HCC cells were cultured and treated with ASP at 
      different concentrations. Cell proliferation was determined with cell counting 
      kit-8 (CCK-8) and colony formation, and the rate of apoptosis was measured by 
      flow cytometry. Western blotting (WB) and quantitative polymerase chain reaction 
      (qRT-PCR) assays were used to assess the changes in the expression levels of 
      related proteins. RESULTS: ASP showed a time-and concentration-depented 
      inhibitory effect on HepG2 cell proliferation. The number of colonies formed in 
      ASP-treated HCC cells was significantly lower than in control cells. For HCC 
      cells treated with ASP, the apoptosis rate enhanced with the increase of ASP 
      concentration. The expression levels of TCF4 and LEF1, key molecules of the 
      Wnt/β-catenin signaling pathway, were lowered in HCC cells treated with 4 mM ASP, 
      and the nuclear translocation of β-catenin was weakened. The β-catenin activator 
      exerted a negative influence on the anticancer effect of ASP. CONCLUSIONS: ASP 
      inhibits the proliferation and promotes the apoptosis of HCC cells through the 
      Wnt/β-catenin signaling pathway.
FAU - Yuan, Zhilu
AU  - Yuan Z
AD  - Department of General Surgery, the third People's Hospital of Liaocheng, 
      Liaocheng 252000, China.
FAU - Zhao, Jingfei
AU  - Zhao J
FAU - Wang, Zhengtang
AU  - Wang Z
FAU - Ren, Guoyan
AU  - Ren G
FAU - Zhang, Zhongbao
AU  - Zhang Z
FAU - Ma, Genshun
AU  - Ma G
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Carcinoma, Hepatocellular/*drug therapy/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Humans
MH  - Liver Neoplasms/*drug therapy/pathology
EDAT- 2020/06/12 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PST - ppublish
SO  - J BUON. 2020 Mar-Apr;25(2):981-986.

PMID- 2750673
OWN - NLM
STAT- MEDLINE
DCOM- 19890825
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 64
IP  - 4
DP  - 1989 Jul 18
TI  - Antithrombotic therapy in the primary prevention of acute myocardial infarction.
PG  - 29B-32B
AB  - The high factor VII coagulant (VIIc) activity in men at high risk of coronary 
      heart disease suggests that restoring normal hemostatic activity with appropriate 
      oral anticoagulants might constitute effective primary prevention. A pilot study 
      was therefore undertaken of a randomized, double-blind, placebo-controlled trial 
      of long-term, low-dose warfarin therapy. Middle-aged men at high risk (mean VIIc 
      120% of standard) but without clinical coronary heart disease or 
      contraindications to anticoagulants were randomized to warfarin or placebo. The 
      initial warfarin dose (2.5 mg/day) was increased at intervals to lower VIIc to 
      70% of standard and increase the prothrombin time international normalized ratio 
      to 1.6. The control participants received the same dose sequence of placebo. The 
      pilot study confirmed the feasibility of the design, the absence of any increased 
      risk of serious bleeding, and the high compliance and low withdrawal rate from 
      randomized treatment. Accordingly, a full-scale thrombosis prevention trial has 
      been launched, which, in addition to low-dose warfarin, includes a low-dose 
      aspirin regimen (75 mg/day) in a factorial design. The aim of this trial is to 
      produce a 30% reduction in coronary heart disease in 6,000 high-risk men aged 45 
      to 69 years. The men will receive either separate or combined therapy and will be 
      followed up for 5 years. Evidence so far indicates that the risk of bleeding in 
      those receiving combined therapy will be no higher than that in those taking 
      aspirin alone.
FAU - Miller, G J
AU  - Miller GJ
AD  - Medical Research Council Epidemiology and Medical Care Unit, Northwick Park 
      Hospital, Harrow, Middlesex, England.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Am J Cardiol 1990 Jun 1;65(20):1410
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Warfarin/*administration & dosage/adverse effects
EDAT- 1989/07/18 00:00
MHDA- 1989/07/18 00:01
CRDT- 1989/07/18 00:00
PHST- 1989/07/18 00:00 [pubmed]
PHST- 1989/07/18 00:01 [medline]
PHST- 1989/07/18 00:00 [entrez]
AID - S0002-9149(89)80007-4 [pii]
AID - 10.1016/s0002-9149(89)80007-4 [doi]
PST - ppublish
SO  - Am J Cardiol. 1989 Jul 18;64(4):29B-32B. doi: 10.1016/s0002-9149(89)80007-4.

PMID- 16397290
OWN - NLM
STAT- MEDLINE
DCOM- 20060629
LR  - 20141120
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 46
IP  - 1
DP  - 2006 Jan
TI  - Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using 
      chlorzoxazone as a probe.
PG  - 109-14
AB  - The authors evaluated the effect of high-dose aspirin at a therapeutic dose, 
      using chlorzoxazone as a probe for CYP2E1 enzyme activity. In a randomized, 
      open-label, 2-way crossover study, 10 healthy men were treated 3 times daily for 
      6 days with 1 g aspirin or placebo. On day 7, 1 dose of 400 mg chlorzoxazone was 
      administered orally. Plasma concentrations of chlorzoxazone and its metabolite, 
      6-hydroxychlorzoxazone, were measured. During the aspirin phase, the area under 
      the time-concentration curve (AUC) and peak plasma concentration of chlorzoxazone 
      were 95% (90% confidence interval [CI], 87%-103%) and 90% (90% CI, 80%-101%) of 
      the values during the placebo phase, respectively. High-dose aspirin did not 
      affect the oral clearance of chlorzoxazone significantly (90% CI, 98%-120%; P = 
      .24). The AUC ratio and plasma concentration ratios of 
      6-hydroxychlorzoxazone/chlorzoxazone were not changed significantly by high-dose 
      aspirin. High-dose aspirin at a therapeutic dose does not affect CYP2E1 activity 
      in humans.
FAU - Park, Ji-Young
AU  - Park JY
AD  - Department of Pharmacology, Gachon Medical School, 1198 Kuwol-dong, Namdong-gu, 
      Incheon 405-760, Korea.
FAU - Kim, Kyoung-Ah
AU  - Kim KA
FAU - Park, Pil-Whan
AU  - Park PW
FAU - Ha, Jong-Myung
AU  - Ha JM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 1750-45-4 (6-hydroxychlorzoxazone)
RN  - EC 1.14.13.- (Cytochrome P-450 CYP2E1)
RN  - H0DE420U8G (Chlorzoxazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chlorzoxazone/administration & dosage/*analogs & derivatives/pharmacokinetics
MH  - Cytochrome P-450 CYP2E1/*metabolism
MH  - Drug Administration Schedule
MH  - Humans
MH  - Korea
MH  - Liver/*drug effects/enzymology
MH  - Male
EDAT- 2006/01/07 09:00
MHDA- 2006/06/30 09:00
CRDT- 2006/01/07 09:00
PHST- 2006/01/07 09:00 [pubmed]
PHST- 2006/06/30 09:00 [medline]
PHST- 2006/01/07 09:00 [entrez]
AID - 46/1/109 [pii]
AID - 10.1177/0091270005282635 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2006 Jan;46(1):109-14. doi: 10.1177/0091270005282635.

PMID- 26753770
OWN - NLM
STAT- MEDLINE
DCOM- 20160613
LR  - 20181202
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Linking)
VI  - 18
IP  - 1
DP  - 2016 Jan
TI  - Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity.
PG  - 4
LID - 10.1007/s11883-015-0555-0 [doi]
AB  - Aspirin remains one of the most extensively studied cardiovascular medications in 
      the history of medicine. However, despite multiple, well-designed, large 
      randomized controlled trials evaluating the potential of aspirin to prevent 
      cardiovascular events in individuals without known cardiovascular disease (CVD), 
      the role of aspirin in primary prevention is currently unclear. The initial 
      aspirin trials included largely low-risk individuals with primary outcomes mostly 
      focused on myocardial infarction (MI) and stroke, and showed a significant 
      reduction in these CVD outcomes, especially MI. The more recently conducted 
      trials have focused on older, higher CVD risk populations with high rates of 
      lipid-lowering and antihypertensive medications use. These studies have used 
      broader CVD outcomes as their primary end points and have failed to show a 
      significant benefit of aspirin therapy in primary prevention. The exact reasons 
      for the lack of efficacy in these recent trials are unclear but may be related to 
      low rate of atherothrombotic events relative to other CVD events in the 
      populations studied. Four large randomized controlled trials are currently 
      underway which should provide some clarity in determining the optimal use of 
      aspirin in the primary prevention of CVD.
FAU - Miedema, Michael D
AU  - Miedema MD
AD  - Minneapolis Heart Institute, Minneapolis, MN, USA. mdm307@mail.harvard.edu.
AD  - Minneapolis Heart Institute Foundation, 920 E. 28th Street, Minneapolis, MN, 
      55414, USA. mdm307@mail.harvard.edu.
FAU - Huguelet, Joseph
AU  - Huguelet J
AD  - Abbott Northwestern Hospital, Minneapolis, MN, USA.
FAU - Virani, Salim S
AU  - Virani SS
AD  - Michael E. DeBakey Veterans Affairs Medical Center and Section of Cardiovascular 
      Research, Baylor College of Medicine, Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Primary Prevention
MH  - *Randomized Controlled Trials as Topic
MH  - Risk
MH  - Stroke/prevention & control
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Primary prevention
EDAT- 2016/01/13 06:00
MHDA- 2016/06/14 06:00
CRDT- 2016/01/13 06:00
PHST- 2016/01/13 06:00 [entrez]
PHST- 2016/01/13 06:00 [pubmed]
PHST- 2016/06/14 06:00 [medline]
AID - 10.1007/s11883-015-0555-0 [pii]
AID - 10.1007/s11883-015-0555-0 [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2016 Jan;18(1):4. doi: 10.1007/s11883-015-0555-0.

PMID- 23590878
OWN - NLM
STAT- MEDLINE
DCOM- 20140829
LR  - 20131118
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 19
IP  - 6
DP  - 2013 Nov-Dec
TI  - Prediction of antiplatelet effects of aspirin in vivo based on in vitro results.
PG  - 600-7
LID - 10.1177/1076029613484084 [doi]
AB  - The aim of this study was to establish a method to predict the antiplatelet 
      effects of aspirin in vivo based on in vitro results. Aspirin in 5 different 
      concentrations was added to the platelet-rich plasma samples, and the rates of 
      platelet aggregation induced by collagen were determined in vitro. In addition, 
      platelet aggregation and plasma drug concentration values were determined in vivo 
      before and after the administration of aspirin (162 mg). The 50% effective 
      concentration (EC50) values obtained from the in vivo and in vitro experiments 
      were shown to have relevance, because the EC50 ratio for each subject was the 
      same (0.23 ± 0.03). The actual and predicted values for the rate of inhibition of 
      platelet aggregation were well correlated (P < .0001, r = .95) when the predicted 
      rate was determined using the present method. Our results suggest that the 
      antiplatelet effects of aspirin can be predicted using blood samples obtained 
      before its administration.
FAU - Yokoyama, Haruko
AU  - Yokoyama H
AD  - 1School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, 
      Japan.
FAU - Ito, Naoko
AU  - Ito N
FAU - Soeda, Shinji
AU  - Soeda S
FAU - Ozaki, Masahiro
AU  - Ozaki M
FAU - Suzuki, Yuji
AU  - Suzuki Y
FAU - Watanabe, Masayuki
AU  - Watanabe M
FAU - Kashiwakura, Emiko
AU  - Kashiwakura E
FAU - Kawada, Tsutomu
AU  - Kawada T
FAU - Ikeda, Noriyuki
AU  - Ikeda N
FAU - Tokuoka, Kentaro
AU  - Tokuoka K
FAU - Kitagawa, Yasuhisa
AU  - Kitagawa Y
FAU - Yamada, Yasuhiko
AU  - Yamada Y
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/blood
MH  - Blood Platelets/cytology/*drug effects
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/blood
MH  - Platelet-Rich Plasma/drug effects
MH  - Predictive Value of Tests
OTO - NOTNLM
OT  - antiplatelet effect
OT  - aspirin
OT  - methodology
OT  - prediction
EDAT- 2013/04/18 06:00
MHDA- 2014/08/30 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/18 06:00 [entrez]
PHST- 2013/04/18 06:00 [pubmed]
PHST- 2014/08/30 06:00 [medline]
AID - 1076029613484084 [pii]
AID - 10.1177/1076029613484084 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2013 Nov-Dec;19(6):600-7. doi: 10.1177/1076029613484084. 
      Epub 2013 Apr 15.

PMID- 23268703
OWN - NLM
STAT- MEDLINE
DCOM- 20130627
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 14
IP  - 2
DP  - 2013 Feb
TI  - Ticagrelor: the first novel reversible P2Y(12) inhibitor.
PG  - 237-45
LID - 10.1517/14656566.2013.757303 [doi]
AB  - INTRODUCTION: Dual antiplatelet therapy is a standard of care for treating 
      patients with acute coronary syndrome (ACS). Combination therapy with aspirin and 
      one of the P2Y(12) inhibitors (clopidogrel, prasugrel, or most recently, 
      ticagrelor ) has been recommended by both ACC/AHA and ESC guidelines for ACS 
      patients. AREAS COVERED: Ticagrelor is the first generation of a new class of 
      reversible P2Y(12) inhibitors, recently added to updated ACC and ESC guidelines 
      for use in patients with ACS. The authors review the studies that evaluate the 
      pharmacokinetics, pharmacodynamics, clinical efficacy and safety of ticagrelor in 
      comparison to currently available antiplatelet agents. EXPERT OPINION: Ticagrelor 
      180 mg loading dose followed by 90 mg b.i.d. is significantly more efficacious 
      and, in general, as safe as clopidogrel in the treatment of all patients with an 
      ACS regardless of treatment strategy. In addition, besides aspirin compared to 
      placebo, it is the only pharmaceutical intervention shown to have a 
      cardiovascular mortality benefit within 1 year in a broad ACS population. Whether 
      this surprising benefit is realized in other populations is currently being 
      tested.
FAU - Htun, Wah Wah
AU  - Htun WW
AD  - Geisinger Medical Center, Department of Cardiology, Danville Pennsylvania, 100N 
      Academy Ave, MC 27-70, Danville, PA 17822, USA.
FAU - Steinhubl, Steven R
AU  - Steinhubl SR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20121227
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/physiopathology
MH  - Adenosine/administration & dosage/*analogs & derivatives/pharmacology/therapeutic 
      use
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Practice Guidelines as Topic
MH  - Purinergic P2Y Receptor Antagonists/administration & 
      dosage/pharmacology/therapeutic use
MH  - Ticagrelor
EDAT- 2012/12/28 06:00
MHDA- 2013/06/29 06:00
CRDT- 2012/12/28 06:00
PHST- 2012/12/28 06:00 [entrez]
PHST- 2012/12/28 06:00 [pubmed]
PHST- 2013/06/29 06:00 [medline]
AID - 10.1517/14656566.2013.757303 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2013 Feb;14(2):237-45. doi: 
      10.1517/14656566.2013.757303. Epub 2012 Dec 27.

PMID- 6842792
OWN - NLM
STAT- MEDLINE
DCOM- 19830617
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 249
IP  - 20
DP  - 1983 May 27
TI  - Airway constriction in normal humans produced by inhalation of leukotriene D. 
      Potency, time course, and effect of aspirin therapy.
PG  - 2814-7
AB  - Five normal human subjects inhaled aerosols generated from solutions of 
      leukotriene D (LTD) to determine the bronchoconstrictor potency and the time 
      course of airway obstruction produced by this constituent of slow-reacting 
      substance of anaphylaxis. The dose-effect and time-effect curves were compared 
      with curves similarly generated for the well-characterized airway constrictor 
      histamine. Leukotriene D was, on average, 5,900 times more potent than histamine 
      on a molar basis in producing an identical decrement in maximal expiratory flow 
      rate at 30% of control vital capacity above residual volume. In addition, 
      although LTD had a rapid onset of effect, similar to that of histamine, the 
      airway obstruction produced by LTD was longer lasting, thereby reflecting more 
      closely the response of asthmatic allergic individuals to antigen inhalation. The 
      response of these subjects to inhalation of LTD was not altered by ingestion of 
      aspirin, suggesting that the airway obstruction was not mediated by 
      cyclooxygenase products of arachidonic acid.
FAU - Weiss, J W
AU  - Weiss JW
FAU - Drazen, J M
AU  - Drazen JM
FAU - McFadden, E R Jr
AU  - McFadden ER Jr
FAU - Weller, P
AU  - Weller P
FAU - Corey, E J
AU  - Corey EJ
FAU - Lewis, R A
AU  - Lewis RA
FAU - Austen, K F
AU  - Austen KF
LA  - eng
GR  - AI-00399/AI/NIAID NIH HHS/United States
GR  - AI-07722/AI/NIAID NIH HHS/United States
GR  - AI-10356/AI/NIAID NIH HHS/United States
GR  - etc.
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Aerosols)
RN  - 0 (SRS-A)
RN  - 820484N8I3 (Histamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aerosols
MH  - Airway Obstruction/drug therapy
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Bronchi/*drug effects
MH  - Constriction, Pathologic
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Histamine/pharmacology
MH  - Humans
MH  - Male
MH  - SRS-A/administration & dosage/*pharmacology
MH  - Time Factors
MH  - Vital Capacity/drug effects
EDAT- 1983/05/27 00:00
MHDA- 2001/03/28 10:01
CRDT- 1983/05/27 00:00
PHST- 1983/05/27 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1983/05/27 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1983 May 27;249(20):2814-7.

PMID- 9569185
OWN - NLM
STAT- MEDLINE
DCOM- 19980713
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 79
IP  - 4
DP  - 1998 Apr
TI  - Titration of antiplatelet treatment in pregnant women at risk of preeclampsia.
PG  - 743-6
AB  - We recruited 111 patients who were considered to be at significantly increased 
      risk of preeclampsia on the basis of previous obstetric history or preexisting 
      medical disorders. All patients were treated with low dose aspirin (75 mg/day) 
      from the first occasion the patient attended the antenatal clinic, regardless of 
      gestational age. If the maternal mean platelet volume (MPV) increased 
      significantly (by > 0.8 fl) from the baseline, antiplatelet treatment was 
      increased. Five pregnancies were lost during the second trimester and 106 of the 
      treated patients had live infants. The incidence of neonatal death (3/106 
      infants) was much lower than in the previous pregnancies in these patients 
      (32/134 infants). Patients who were treated from the first trimester of pregnancy 
      (group A, 89 patients) did substantially better than those treated from the 
      second trimester (group B, 17 patients) as assessed by the incidence of 
      pre-eclampsia or intrauterine growth restriction (IUGR), gestational age and 
      birthweight at delivery. These data suggest that longitudinal monitoring of the 
      MPV may identify the women who could benefit from increased antiplatelet 
      treatment, and that antiplatelet treatment may be more effective when initiated 
      in the first trimester rather than later in pregnancy.
FAU - Sullivan, M H
AU  - Sullivan MH
AD  - Institute of Obstetrics and Gynaecology, Imperial College School of Medicine, 
      Hammersmith Hospital, London, UK. msulliva@rpms.ac.uk
FAU - Clark, N A
AU  - Clark NA
FAU - de Swiet, M
AU  - de Swiet M
FAU - Nelson-Piercy, C
AU  - Nelson-Piercy C
FAU - Elder, M G
AU  - Elder MG
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Spontaneous/epidemiology
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Birth Weight
MH  - Female
MH  - Fetal Death/epidemiology
MH  - Fetal Growth Retardation/epidemiology
MH  - Humans
MH  - Incidence
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Pregnancy Trimester, First
MH  - Pregnancy Trimester, Second
MH  - Recurrence
MH  - Risk
MH  - Risk Factors
EDAT- 1998/05/06 00:00
MHDA- 1998/05/06 00:01
CRDT- 1998/05/06 00:00
PHST- 1998/05/06 00:00 [pubmed]
PHST- 1998/05/06 00:01 [medline]
PHST- 1998/05/06 00:00 [entrez]
AID - 98040743 [pii]
PST - ppublish
SO  - Thromb Haemost. 1998 Apr;79(4):743-6.

PMID- 10226684
OWN - NLM
STAT- MEDLINE
DCOM- 19990701
LR  - 20191103
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 27
IP  - 3
DP  - 1999 May
TI  - Inhaled nitric oxide attenuates increased pulmonary artery pressure following 
      diaspirin crosslinked hemoglobin (DCLHB) administration.
PG  - 203-13
AB  - Intravenous administration of diaspirin crosslinked hemoglobin (DCLHb) can result 
      in elevated pulmonary and systemic arterial pressures in some mammalian species. 
      This study was designed to evaluate the ability of inhaled nitric oxide (INO) to 
      attenuate elevations in pulmonary artery pressure in a closed-chested swine 
      model. Yorkshire pigs received escalating doses of INO followed by escalating 
      doses of DCLHb or a single dose of DCLHb followed by escalating doses of INO. 
      Systemic and pulmonary arterial pressures were monitored continuously. 
      Significant elevations occurred in systemic and pulmonary arterial pressure 
      following a cumulative dose of 0.1 gm/kg DCLHb. A single dose of 0.3 gm/kg also 
      resulted in elevations of pulmonary and systemic arterial pressure. Inhaled 
      nitric oxide partially reversed the changes in pulmonary but not systemic 
      pressure. These results indicate that INO might be a therapeutic option for 
      humans who may experience increased pulmonary artery pressure following 
      administration of DCLHb.
FAU - Sefton, W
AU  - Sefton W
AD  - Department of Anesthesiology, Uniformed Services University of the Health 
      Sciences, Bethesda, Maryland 20814-4799, USA.
FAU - Pudimat, P
AU  - Pudimat P
FAU - Bina, S
AU  - Bina S
FAU - Lojeski, E
AU  - Lojeski E
FAU - Mongan, P
AU  - Mongan P
FAU - Muldoon, S
AU  - Muldoon S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Vasodilator Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Inhalation
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Gas Analysis
MH  - Blood Pressure/*drug effects
MH  - Blood Substitutes/pharmacology
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Methemoglobinemia/blood
MH  - Nitric Oxide/*pharmacology
MH  - Pulmonary Artery/*drug effects/physiology
MH  - Swine
MH  - Vasodilator Agents/*pharmacology
EDAT- 1999/05/05 00:00
MHDA- 1999/05/05 00:01
CRDT- 1999/05/05 00:00
PHST- 1999/05/05 00:00 [pubmed]
PHST- 1999/05/05 00:01 [medline]
PHST- 1999/05/05 00:00 [entrez]
AID - 10.3109/10731199909117694 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1999 May;27(3):203-13. doi: 
      10.3109/10731199909117694.

PMID- 9427730
OWN - NLM
STAT- MEDLINE
DCOM- 19980211
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 91
IP  - 2
DP  - 1998 Jan 15
TI  - Absence of immunogenicity of diaspirin cross-linked hemoglobin in humans.
PG  - 710-6
AB  - Diaspirin cross-linked hemoglobin (DCLHb) is an intramolecularly cross-linked 
      hemoglobin-based oxygen carrier being developed as a therapy for acute blood 
      loss. We report here the absence of immunogenicity of DCLHb in patients enrolled 
      in phase II and III clinical trials of DCLHb. Two very sensitive immunoassays, an 
      enzyme-linked immunosorbent assay (ELISA) and a Western blot assay, were 
      developed and validated for this assessment. The DCLHb-antibodies used in these 
      assays were raised in monkeys, had similar affinities for DCLHb and native human 
      hemoglobin (SFHb), and showed cross-reactivity for subunits of DCLHb and SFHb on 
      the Western blot, suggesting that these antibodies were elicited as a xenogenic 
      response to the protein. In the ELISA, the optical density of a patient sample 
      exposed to DCLHb-coated wells was compared with that of the patient sample 
      exposed to carbonate buffer-coated wells; an optical density ratio of 1.4 was 
      established for discriminating between a positive (reactive) or negative DCLHb 
      antibody response. To date, all of the more than 300 patient specimens 
      (preinfusion and postinfusion) from clinical trials have exhibited a ratio of 
      less than 1.4, confirming the lack of preexisting antibodies to DCLHb and clearly 
      showing the absence of DCLHb antibodies after exposure to this new biologic 
      entity. There has been no requirement for use of the confirmatory Western blot 
      assay. Taken together, the results from this study indicate DCLHb is not 
      immunogenic in humans at doses evaluated clinically.
FAU - Patel, M J
AU  - Patel MJ
AD  - Baxter Healthcare Corp, Round Lake, IL 60073-9799, USA.
FAU - Webb, E J
AU  - Webb EJ
FAU - Shelbourn, T E
AU  - Shelbourn TE
FAU - Mattia-Goldberg, C
AU  - Mattia-Goldberg C
FAU - George, A J
AU  - George AJ
FAU - Zhang, F
AU  - Zhang F
FAU - Moore, E G
AU  - Moore EG
FAU - Nelson, D J
AU  - Nelson DJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antibodies)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antibodies/*blood/immunology
MH  - Aspirin/*analogs & derivatives/immunology
MH  - Cross Reactions
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Haplorhini
MH  - Hemoglobins/*immunology
MH  - Humans
EDAT- 1998/01/15 00:00
MHDA- 1998/01/15 00:01
CRDT- 1998/01/15 00:00
PHST- 1998/01/15 00:00 [pubmed]
PHST- 1998/01/15 00:01 [medline]
PHST- 1998/01/15 00:00 [entrez]
AID - S0006-4971(20)54869-6 [pii]
PST - ppublish
SO  - Blood. 1998 Jan 15;91(2):710-6.

PMID- 6361788
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20201209
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 27 Suppl 1
DP  - 1983
TI  - Double-blind evaluation of suprofen and aspirin in the treatment of periodontal 
      pain.
PG  - 23-30
AB  - A double-blind, randomized, parallel group, placebo-controlled study was carried 
      out to compare the safety and efficacy of single doses of suprofen (200 mg and 
      400 mg) with aspirin (650 mg) and placebo in relieving pain. In patients with 
      pain resulting from periodontal surgery, a single dose of suprofen 200 or 400 mg 
      was significantly better than placebo in reducing pain intensity and providing 
      pain relief. The superiority of both doses of suprofen over placebo was 
      demonstrated in every parameter in which pain intensity or pain relief was 
      calculated. In addition, both doses of suprofen were better than, or at least 
      equivalent to, aspirin 650 mg in every efficacy measure including the patients' 
      overall acceptability of treatment.
FAU - Cooper, S A
AU  - Cooper SA
FAU - Wagenberg, B
AU  - Wagenberg B
FAU - Eskow, R
AU  - Eskow R
FAU - Zissu, J
AU  - Zissu J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Phenylpropionates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 988GU2F9PE (Suprofen)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Codeine/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Periodontal Diseases/*surgery
MH  - Phenylpropionates/*therapeutic use
MH  - Pregnancy
MH  - Suprofen/adverse effects/*therapeutic use
MH  - Time Factors
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1159/000137896 [doi]
PST - ppublish
SO  - Pharmacology. 1983;27 Suppl 1:23-30. doi: 10.1159/000137896.

PMID- 33231765
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
VI  - 20
IP  - 12
DP  - 2020 Nov 24
TI  - The Role of Aspirin for Preeclampsia Prevention in Women with Diabetes.
PG  - 76
LID - 10.1007/s11892-020-01365-1 [doi]
AB  - PURPOSE OF REVIEW: A diagnosis of type I or type 2 diabetes confers heightened 
      risk for virtually every obstetric and perinatal complication, with the incidence 
      of superimposed preeclampsia representing a particularly high-risk scenario. Over 
      the past three decades, studies have investigated the role of aspirin in 
      preeclampsia prevention, yielding some promising results for certain at-risk 
      groups, yet unconvincing evidence of benefit among women with pre-pregnancy 
      diabetes. The purpose of this review is to present the current evidence base for 
      aspirin use in pregnancy as a means of mitigating preeclampsia risk in the 
      setting of pregestational type I or type 2 diabetes. RECENT FINDINGS: 
      Meta-analysis data examining low-dose aspirin for preeclampsia prevention in 
      at-risk and low-risk women has demonstrated modest benefit, but subanalyses of 
      cohorts with diabetes have failed to demonstrate a beneficial effect. Evidence is 
      emerging that indicates a benefit only among women who initiate aspirin therapy 
      prior to 16 weeks' gestation, and uncertainty exists surrounding the effective 
      dose. In light of equipoise surrounding the potential role of aspirin for 
      prevention of preeclampsia in women with diabetes, current research is targeted 
      at determining clinical efficacy of aspirin in this high-risk obstetric 
      population.
FAU - Finnegan, Catherine
AU  - Finnegan C
AD  - Royal College of Surgeons in Ireland, Rotunda Hospital, Parnell Square, Dublin 1, 
      Ireland. catherinefinnegan@rcsi.ie.
FAU - Breathnach, Fionnuala M
AU  - Breathnach FM
AD  - Royal College of Surgeons in Ireland, Rotunda Hospital, Parnell Square, Dublin 1, 
      Ireland.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20201124
PL  - United States
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Diabetes Mellitus, Type 2
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors
MH  - *Pre-Eclampsia/epidemiology/prevention & control
MH  - Pregnancy
MH  - *Pregnancy in Diabetics
OTO - NOTNLM
OT  - Aspirin
OT  - Diabetes mellitus
OT  - Preeclampsia
OT  - Pregnancy
EDAT- 2020/11/25 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/11/24 12:12
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/11/24 12:12 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - 10.1007/s11892-020-01365-1 [pii]
AID - 10.1007/s11892-020-01365-1 [doi]
PST - epublish
SO  - Curr Diab Rep. 2020 Nov 24;20(12):76. doi: 10.1007/s11892-020-01365-1.

PMID- 32244293
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 10
IP  - 4
DP  - 2020 Mar 31
TI  - Aspirin: A Suicide Inhibitor of Carbonic Anhydrase II.
LID - 10.3390/biom10040527 [doi]
LID - 527
AB  - Carbonic anhydrase II (CAII) is a metalloenzyme that catalyzes the reversible 
      hydration/dehydration of CO(2)/HCO(3)(-). In addition, CAII is attributed to 
      other catalytic reactions, including esterase activity. Aspirin (acetyl-salicylic 
      acid), an everyday over-the-counter drug, has both ester and carboxylic acid 
      moieties. Recently, compounds with a carboxylic acid group have been shown to 
      inhibit CAII. Hence, we hypothesized that Aspirin could act as a substrate for 
      esterase activity, and the product salicylic acid (SA), an inhibitor of CAII. 
      Here, we present the crystal structure of CAII in complex with SA, a product of 
      CAII crystals pre-soaked with Aspirin, to 1.35Å resolution. In addition, we 
      provide kinetic data to support the observation that CAII converts Aspirin to its 
      deacetylated form, SA. This data may also explain the short half-life of Aspirin, 
      with CAII so abundant in blood, and that Aspirin could act as a suicide inhibitor 
      of CAII.
FAU - Andring, Jacob
AU  - Andring J
AUID- ORCID: 0000-0002-6632-6391
AD  - Department of Biochemistry and Molecular Biology, College of Medicine, University 
      of Florida, Gainesville, FL 32610, USA.
FAU - Combs, Jacob
AU  - Combs J
AUID- ORCID: 0000-0001-5657-4773
AD  - Department of Biochemistry and Molecular Biology, College of Medicine, University 
      of Florida, Gainesville, FL 32610, USA.
FAU - McKenna, Robert
AU  - McKenna R
AUID- ORCID: 0000-0002-2792-935X
AD  - Department of Biochemistry and Molecular Biology, College of Medicine, University 
      of Florida, Gainesville, FL 32610, USA.
LA  - eng
PT  - Journal Article
DEP - 20200331
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
RN  - 0 (Enzyme Inhibitors)
RN  - EC 4.2.1.- (Carbonic Anhydrase II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Carbonic Anhydrase II/*antagonists & inhibitors/chemistry
MH  - Catalytic Domain
MH  - Enzyme Inhibitors/*pharmacology
MH  - Kinetics
MH  - Models, Molecular
PMC - PMC7226357
OTO - NOTNLM
OT  - Aspirin
OT  - X-ray crystallography
OT  - carbonic anhydrase
OT  - esterase
OT  - salicylic acid
COIS- The authors declare no conflicts of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2020/04/05 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/04/05 06:00
PHST- 2020/03/14 00:00 [received]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - biom10040527 [pii]
AID - biomolecules-10-00527 [pii]
AID - 10.3390/biom10040527 [doi]
PST - epublish
SO  - Biomolecules. 2020 Mar 31;10(4):527. doi: 10.3390/biom10040527.

PMID- 3963025
OWN - NLM
STAT- MEDLINE
DCOM- 19860502
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 80
IP  - 3A
DP  - 1986 Mar 24
TI  - Effects of flurbiprofen and aspirin on the gastric and duodenal mucosa. An 
      endoscopic comparison.
PG  - 31-5
AB  - A single-blind, randomized endoscopic tolerance study was conducted to compare 
      daily doses of flurbiprofen (Ansaid, Upjohn) at 100, 150, and 200 mg per day with 
      2,600 mg of aspirin per day. Ten normal volunteers were enrolled in each of the 
      flurbiprofen groups, and five were enrolled in the aspirin group. Analysis of the 
      mean gastric mucosal injury scores obtained on day eight revealed statistically 
      significant lower mean scores (p = 0.05) in the 100-mg and 150-mg flurbiprofen 
      treatment groups when compared with the 200-mg flurbiprofen group and the aspirin 
      group. No significant differences were found between any of the treatment groups 
      in duodenal mucosal injury scores. Mean scores for gastric mucosal injury in the 
      three groups receiving flurbiprofen showed a definite dose relationship. The 
      aspirin-treated subjects had significantly decreased uric acid levels (p = 0.006) 
      and a significantly higher incidence of tinnitus (p = 0.04) compared with the 
      flurbiprofen treatment groups. There was a poor correlation between subjective 
      symptomatology and endoscopic pathologic findings.
FAU - Lanza, F L
AU  - Lanza FL
FAU - Royer, G L
AU  - Royer GL
FAU - Nelson, R S
AU  - Nelson RS
FAU - Seckman, C E
AU  - Seckman CE
FAU - Schwartz, J H
AU  - Schwartz JH
FAU - Rack, M F
AU  - Rack MF
FAU - Gernaat, C M
AU  - Gernaat CM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Duodenum/*drug effects
MH  - Endoscopy
MH  - Female
MH  - Flurbiprofen/adverse effects/*pharmacology
MH  - Gastric Mucosa/diagnostic imaging/*drug effects
MH  - Humans
MH  - Male
MH  - Propionates/*pharmacology
MH  - Radiography
EDAT- 1986/03/24 00:00
MHDA- 1986/03/24 00:01
CRDT- 1986/03/24 00:00
PHST- 1986/03/24 00:00 [pubmed]
PHST- 1986/03/24 00:01 [medline]
PHST- 1986/03/24 00:00 [entrez]
AID - 10.1016/0002-9343(86)90108-7 [doi]
PST - ppublish
SO  - Am J Med. 1986 Mar 24;80(3A):31-5. doi: 10.1016/0002-9343(86)90108-7.

PMID- 8428066
OWN - NLM
STAT- MEDLINE
DCOM- 19930310
LR  - 20131121
IS  - 0951-7383 (Print)
IS  - 0951-7383 (Linking)
VI  - 6
IP  - 1
DP  - 1993 Feb
TI  - Antiplatelet and anticoagulant therapy.
PG  - 55-9
AB  - Antiplatelet therapy is clearly indicated for long-term secondary prevention 
      after transient ischemic attack and ischemic stroke. In stroke-free patients with 
      atrial fibrillation, oral anticoagulants reduce the risk of stroke, and 
      antiplatelet agents may be a lower risk alternative. For the early treatment of 
      the acute phase of ischemic stroke, the role of antiplatelet and anticoagulant 
      therapy is unclear, but is being evaluated in large clinical trials.
FAU - Bower, S
AU  - Bower S
AD  - Department of Clinical Neurosciences, University of Edinburgh, Western General 
      Hospital, UK.
FAU - Sandercock, P
AU  - Sandercock P
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Neurol Neurosurg
JT  - Current opinion in neurology and neurosurgery
JID - 8809879
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Cerebrovascular Disorders/drug therapy
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/prevention & control
MH  - Male
MH  - Warfarin/administration & dosage/*therapeutic use
RF  - 24
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
PST - ppublish
SO  - Curr Opin Neurol Neurosurg. 1993 Feb;6(1):55-9.

PMID- 34563982
OWN - NLM
STAT- MEDLINE
DCOM- 20220118
LR  - 20220118
IS  - 2210-7797 (Electronic)
IS  - 2210-7789 (Linking)
VI  - 26
DP  - 2021 Dec
TI  - Low-dose aspirin increases 15-epi-lipoxins A(4) in pregnancies at high-risk for 
      developing preeclampsia.
PG  - 75-78
LID - S2210-7789(21)00518-3 [pii]
LID - 10.1016/j.preghy.2021.09.003 [doi]
AB  - BACKGROUND: LDA triggers biosynthesis of endogenous anti-inflammatory molecules, 
      aspirin-triggered 15-epi-lipoxin A(4) (15-epi-LXA(4)), which may counteract 
      inflammatory process of preeclampsia (PE), and play role in LDA's mechanism of 
      action in PE prevention in high-risk patients. OBJECTIVE: Investigate the effects 
      of daily LDA on levels of 15-epi-LXA(4) in pregnancies at high-risk for 
      developing PE. MATERIALS AND METHODS: Secondary analysis of multi-centered 
      randomized controlled trial investigating effects of daily LDA (60 mg) in 
      high-risk pregnancies. Maternal samples were drawn at three points: before LDA 
      initiation (13-26 weeks' gestation), 24-28 weeks' gestation (at least two weeks 
      after LDA) and 34-36 weeks' gestation. 15-epi-LXA(4) levels were measured by 
      ELISA. RESULTS: Analysis included 82 patients: 63 receiving daily LDA and 29 
      receiving daily placebo starting between 13 and 25 weeks gestation. Prior to 
      randomization, baseline 15-epi-LXA(4) levels were similar between both groups 
      (75.9 pg/mL [IQR; 63.8-114.0] vs 136.2 pg/mL [52.4-476.2]; p = 0.10). Patients 
      receiving daily LDA were noted to have significantly increased levels of 
      15-epi-LXA(4) after LDA administration (136.2 pg/mL [IQR; 52.4-476.2] vs 
      1758.2 pg/mL [905.4-6638.5]; p < 0.001). They also had higher 15-epi-LXA(4) 
      levels compared to those receiving placebo at 24-28 weeks' (50.3 [38.1-94.2] vs 
      1758.2 [905.4-6638.5]; p < 0.001 and 34-38 weeks' gestation (57.9 [41.9-76.7] vs 
      2310.3 pg/mL [656.9-10609.4]; p < 0.001). After LDA administration in the second 
      trimester, patients who developed PE had decrease in 15-epi-LXA(4) levels 
      compared to those without PE (942 pg/mL [348.3-1810.3] vs 1758.2 pg/mL 
      [905.4-6638.5]; p = 0.129). CONCLUSION: Daily LDA administration increases 
      15-epi-LXA(4) levels in high-risk pregnancies for PE. In LDA group, pregnancies 
      complicated by PE have lower levels of 15-epi-LXA(4) compared to pregnancies 
      without PE.
CI  - Published by Elsevier B.V.
FAU - Gonzalez-Brown, Veronica M
AU  - Gonzalez-Brown VM
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, San 
      Antonio Uniformed Services Health Science Consortium, Brooke Army Medical Center, 
      Ft Sam Houston, TX, United States. Electronic address: 
      veronica.m.gonzalez2.mil@mail.mil.
FAU - Ma'ayeh, Marwan
AU  - Ma'ayeh M
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The 
      Ohio State University College of Medicine, Columbus, OH, United States.
FAU - Kniss, Douglas A
AU  - Kniss DA
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The 
      Ohio State University College of Medicine, Columbus, OH, United States.
FAU - Cackovic, Michael
AU  - Cackovic M
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The 
      Ohio State University College of Medicine, Columbus, OH, United States.
FAU - Landon, Mark B
AU  - Landon MB
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The 
      Ohio State University College of Medicine, Columbus, OH, United States.
FAU - Rood, Kara M
AU  - Rood KM
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The 
      Ohio State University College of Medicine, Columbus, OH, United States.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20210915
PL  - Netherlands
TA  - Pregnancy Hypertens
JT  - Pregnancy hypertension
JID - 101552483
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Female
MH  - Humans
MH  - Lipoxins/biosynthesis/blood
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy, High-Risk
OTO - NOTNLM
OT  - Aspirin triggered lipoxins
OT  - Low dose aspirin
OT  - Preeclampsia
OT  - Pregnancy complications
EDAT- 2021/09/27 06:00
MHDA- 2022/01/19 06:00
CRDT- 2021/09/26 20:55
PHST- 2021/01/03 00:00 [received]
PHST- 2021/06/21 00:00 [revised]
PHST- 2021/09/09 00:00 [accepted]
PHST- 2021/09/27 06:00 [pubmed]
PHST- 2022/01/19 06:00 [medline]
PHST- 2021/09/26 20:55 [entrez]
AID - S2210-7789(21)00518-3 [pii]
AID - 10.1016/j.preghy.2021.09.003 [doi]
PST - ppublish
SO  - Pregnancy Hypertens. 2021 Dec;26:75-78. doi: 10.1016/j.preghy.2021.09.003. Epub 
      2021 Sep 15.

PMID- 8637071
OWN - NLM
STAT- MEDLINE
DCOM- 19960705
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 40
IP  - 2
DP  - 1996 Feb
TI  - Diaspirin cross-linked hemoglobin is efficacious in gut resuscitation as measured 
      by a GI tract optode.
PG  - 231-40; discussion 241
AB  - The objective of this study was to compare the efficacy of diaspirin cross-linked 
      hemoglobin (DCLHb) with that of standard resuscitative fluids in restoring 
      intestinal mucosal oxygenation and villous architecture after hemorrhage. Male 
      rats were bled to a base deficit of 5 +/- 2 nmol/l under propofol anesthesia and 
      monitored for 90 minutes postresuscitation with DCLHb, blood, lactated Ringer's 
      solution, albumin, or nothing (DNR) for mucosal oxygen tension (Pmo2) and 
      physiologic and laboratory parameters. Small intestinal histologic specimens were 
      obtained and scored independently by two investigators blinded to therapy on a 
      scale of 0 (normal) to 4 (worst). All treatments restored Pmo2; only DCLHb did so 
      without exceeding baseline values. For untreated rats (DNR), Pmo2 was not 
      restored. Normal mucosal architecture was maintained only in DCLHb-treated rats. 
      As Pmo2 increased, mucosal score improved. In a rat model of controlled 
      hemorrhage, Pmo2 changes measured by an optode correlated with gut histological 
      abnormalities. By these criteria, DCLHb is superior to crystalloid, colloid, and 
      blood in gut resuscitation.
FAU - Frankel, H L
AU  - Frankel HL
AD  - Department of Surgery, Uniformed Services University of the Health Sciences, 
      Bethesda, Maryland, USA.
FAU - Nguyen, H B
AU  - Nguyen HB
FAU - Shea-Donohue, T
AU  - Shea-Donohue T
FAU - Aiton, L A
AU  - Aiton LA
FAU - Ratigan, J
AU  - Ratigan J
FAU - Malcolm, D S
AU  - Malcolm DS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Pressure
MH  - *Fluid Therapy
MH  - Gastrointestinal Hemorrhage/pathology/*therapy
MH  - Hemoglobins/*therapeutic use
MH  - Intestinal Mucosa/metabolism/*pathology
MH  - Male
MH  - Oxygen/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Resuscitation/*methods
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - 10.1097/00005373-199602000-00010 [doi]
PST - ppublish
SO  - J Trauma. 1996 Feb;40(2):231-40; discussion 241. doi: 
      10.1097/00005373-199602000-00010.

PMID- 10519166
OWN - NLM
STAT- MEDLINE
DCOM- 19991124
LR  - 20191103
IS  - 1081-650X (Print)
IS  - 1081-650X (Linking)
VI  - 111
IP  - 5
DP  - 1999 Sep-Oct
TI  - Effects of cutaneous aspirin on the human stomach and duodenum.
PG  - 448-56
AB  - Oral aspirin blocks cyclooxygenase in platelets, lowering serum thromboxane 
      concentrations. Oral aspirin also blocks cyclooxygenase in the gastrointestinal 
      mucosa, lowering prostaglandin production and increasing the risk of 
      gastrointestinal ulceration and bleeding. Aspirin placed on the skin also 
      inhibits cyclooxygenase in platelets, but aspirin absorption through skin is 
      slow, which may minimize the gastrointestinal effects. Our objectives in this 
      study were 1) to compare the pharmacokinetic and pharmacodynamic effects of 
      cutaneous and oral aspirin in healthy volunteers and 2) to compare the effects of 
      cutaneous aspirin on gastroduodenal mucosal prostaglandin E2 and F2 alpha content 
      and on mucosal damage, using endoscopy. The bioavailability of cutaneous aspirin 
      was 4%-8% that of oral aspirin. Cutaneous aspirin (750 mg/day for 10 days) 
      significantly lowered serum thromboxane (by 85%) and gastric and duodenal 
      prostaglandins (by 49%-71%); placebo had no effect. Moreover, cutaneous aspirin, 
      but not placebo, resulted in significant gastric mucosal injury. These findings 
      demonstrate that even tiny amounts of aspirin in the blood (2 microM) have 
      inhibitory effects on prostaglandin production in the human stomach and duodenum 
      that result in gastric mucosal damage, even without direct exposure of the 
      stomach to aspirin.
FAU - Cryer, B
AU  - Cryer B
AD  - Medical Service, VA Medical Center, Dallas, TX 75216, USA.
FAU - Kliewer, D
AU  - Kliewer D
FAU - Sie, H
AU  - Sie H
FAU - McAllister, L
AU  - McAllister L
FAU - Feldman, M
AU  - Feldman M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Proc Assoc Am Physicians
JT  - Proceedings of the Association of American Physicians
JID - 9514310
RN  - 0 (Prostaglandins)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Cutaneous
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*administration & dosage/*adverse effects/pharmacokinetics
MH  - Duodenum/drug effects/injuries/metabolism
MH  - Female
MH  - Gastric Mucosa/*drug effects/*injuries/metabolism
MH  - Humans
MH  - Intestinal Mucosa/*drug effects/*injuries/metabolism
MH  - Male
MH  - Middle Aged
MH  - Prostaglandins/biosynthesis
MH  - Thromboxane B2/blood
EDAT- 1999/10/16 00:00
MHDA- 1999/10/16 00:01
CRDT- 1999/10/16 00:00
PHST- 1999/10/16 00:00 [pubmed]
PHST- 1999/10/16 00:01 [medline]
PHST- 1999/10/16 00:00 [entrez]
AID - 10.1111/paa.1999.111.5.448 [doi]
PST - ppublish
SO  - Proc Assoc Am Physicians. 1999 Sep-Oct;111(5):448-56. doi: 
      10.1111/paa.1999.111.5.448.

PMID- 15021994
OWN - NLM
STAT- MEDLINE
DCOM- 20040923
LR  - 20131121
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 93 Suppl 2
DP  - 2004
TI  - [Primary prevention of coronary heart disease with aspirin].
PG  - II33-6
AB  - According to the meta-analysis and the results of the two studies with the 
      highest power, aspirin is effective in primary prevention of coronary heart 
      disease. These beneficial effects, however, are at least partially outweighed by 
      unwanted effects-such as intense gastrointestinal bleeding and hemorrhagic 
      stroke. These side effects remain constant with increasing risk of coronary heart 
      disease, whereas the protective effects increase. If an annual risk of coronary 
      heart disease of < or = 0.6% exists, aspirin is normally not indicated; for a 
      risk of 0.7-1.4% the facts should be discussed with the patient. If a risk of > 
      or = 1.5% exists, aspirin should be given.
FAU - Kübler, W
AU  - Kübler W
AD  - Saarstr. 111, 69151 Neckargemünd, Germany.
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Primäre Prävention der koronaren Herzkrankheit mit Aspirin.
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/etiology/*prevention & control
MH  - Coronary Thrombosis/etiology/prevention & control
MH  - Female
MH  - Germany
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk
MH  - Treatment Outcome
EDAT- 2004/03/17 05:00
MHDA- 2004/09/24 05:00
CRDT- 2004/03/17 05:00
PHST- 2004/03/17 05:00 [pubmed]
PHST- 2004/09/24 05:00 [medline]
PHST- 2004/03/17 05:00 [entrez]
AID - 10.1007/s00392-004-1206-6 [doi]
PST - ppublish
SO  - Z Kardiol. 2004;93 Suppl 2:II33-6. doi: 10.1007/s00392-004-1206-6.

PMID- 504330
OWN - NLM
STAT- MEDLINE
DCOM- 19800128
LR  - 20181130
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 34
IP  - 7
DP  - 1979 Jul
TI  - A study of the in vitro diffusion kinetics of acetylsalicylic acid using the 
      Sartorius absorption simulator.
PG  - 410-3
AB  - A unidirectional transport condition is often assumed when studying the in vitro 
      diffusion of drugs. The present work describes a kinetic model that can be 
      applied to beyond the first diffusion period. Acetylsalicylic acid was chosen as 
      a model substance and its in vitro diffusion was studied using the Sartorius 
      absorption simulator. The results of the two kinetic models (unidirectional and 
      bidirectional) were in good agreement with each other. The curvature of the 
      corrected substance concentration in the artificial plasma versus time plot can 
      be used as a warning signal to detect passage beyond the first diffusion period.
FAU - Al-Janabi, I I
AU  - Al-Janabi II
FAU - Fikrat, H T
AU  - Fikrat HT
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Aspirin/*metabolism
MH  - Chemistry, Pharmaceutical
MH  - Diffusion
MH  - Gastric Mucosa/metabolism
MH  - Kinetics
MH  - Models, Biological
EDAT- 1979/07/01 00:00
MHDA- 1979/07/01 00:01
CRDT- 1979/07/01 00:00
PHST- 1979/07/01 00:00 [pubmed]
PHST- 1979/07/01 00:01 [medline]
PHST- 1979/07/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1979 Jul;34(7):410-3.

PMID- 22760763
OWN - NLM
STAT- MEDLINE
DCOM- 20130426
LR  - 20211021
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 35
IP  - 12
DP  - 2012 Dec
TI  - Statin and aspirin therapy for the prevention of cardiovascular events in 
      patients with type 2 diabetes mellitus.
PG  - 722-9
LID - 10.1002/clc.22032 [doi]
AB  - Patients with type 2 diabetes mellitus are at 2 to 4 times increased risk of 
      cardiovascular events compared with those without diabetes, both among patients 
      with multiple risk factors only and those with established atherothrombosis. In 
      this review, we provide recommendations for the use of statins and aspirin for 
      the prevention of cardiovascular events in high-risk patients with diabetes 
      mellitus.
CI  - © 2012 Wiley Periodicals, Inc.
FAU - Udell, Jacob A
AU  - Udell JA
AD  - TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and 
      Women's Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Scirica, Benjamin M
AU  - Scirica BM
FAU - Braunwald, Eugene
AU  - Braunwald E
FAU - Raz, Itamar
AU  - Raz I
FAU - Steg, Ph Gabriel
AU  - Steg PG
FAU - Davidson, Jaime
AU  - Davidson J
FAU - Hirshberg, Boaz
AU  - Hirshberg B
FAU - Bhatt, Deepak L
AU  - Bhatt DL
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120703
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Practice Guidelines as Topic
PMC - PMC6652724
EDAT- 2012/07/05 06:00
MHDA- 2013/04/27 06:00
CRDT- 2012/07/05 06:00
PHST- 2012/01/24 00:00 [received]
PHST- 2012/05/16 00:00 [revised]
PHST- 2012/07/05 06:00 [entrez]
PHST- 2012/07/05 06:00 [pubmed]
PHST- 2013/04/27 06:00 [medline]
AID - CLC22032 [pii]
AID - 10.1002/clc.22032 [doi]
PST - ppublish
SO  - Clin Cardiol. 2012 Dec;35(12):722-9. doi: 10.1002/clc.22032. Epub 2012 Jul 3.

PMID- 16886195
OWN - NLM
STAT- MEDLINE
DCOM- 20070104
LR  - 20161124
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 95
IP  - 11
DP  - 2006 Nov
TI  - Effect of pressure on molecular and ionic motions in ultraviscous 
      acetaminophen-aspirin mixture.
PG  - 2406-18
AB  - Effect of pressure and temperature on molecular motions and dc conductivity in 
      ultraviscous, 50 wt% acetaminophen-aspirin melt has been studied by dielectric 
      relaxation spectroscopy. The spectra obtained over the pressure range, 5-300 MPa 
      and temperature range, 295-320 K show a distribution of relaxation times greater 
      than found in pure acetaminophen. The equilibrium dielectric permittivity and 
      relaxation time, tau, of the melt increase with increase in pressure and decrease 
      in temperature and the dc conductivity, sigma(dc), decreases. The pressure and 
      temperature variation of the limiting high frequency permittivity shows 
      significant contribution from infrared polarization. The volumes of activation 
      for sigma(dc) and tau vary with both the pressure and temperature, indicating 
      that there is also a structural effect that determine sigma(dc). This effect 
      would add a non-linear term to the Debye-Stokes-Einstein equation for variation 
      of sigma(dc) with tau. The ultraviscous liquid remains stable with time, and with 
      change in temperature and pressure, suggesting that a more stable glassy state of 
      a pharmaceutical may be obtained by mixing a second component.
CI  - Copyright 2006 Wiley-Liss, Inc. and the American Pharmacists Association
FAU - Andersson, Ove
AU  - Andersson O
AD  - Department of Physics, Umeå University, S-901 87 Umeå, Sweden. 
      ove.andersson@physics.umu.se
FAU - Johari, G P
AU  - Johari GP
FAU - Shanker, R M
AU  - Shanker RM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Drug Combinations)
RN  - 0 (Ions)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*chemistry
MH  - Algorithms
MH  - Aspirin/*chemistry
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Crystallization
MH  - Drug Combinations
MH  - Drug Compounding
MH  - Drug Industry
MH  - Electric Conductivity
MH  - Ions
MH  - Pressure
MH  - Temperature
EDAT- 2006/08/04 09:00
MHDA- 2007/01/05 09:00
CRDT- 2006/08/04 09:00
PHST- 2006/08/04 09:00 [pubmed]
PHST- 2007/01/05 09:00 [medline]
PHST- 2006/08/04 09:00 [entrez]
AID - S0022-3549(16)32128-1 [pii]
AID - 10.1002/jps.20688 [doi]
PST - ppublish
SO  - J Pharm Sci. 2006 Nov;95(11):2406-18. doi: 10.1002/jps.20688.

PMID- 30816648
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20200831
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 163
DP  - 2019 Feb 22
TI  - [Elderly patients and atrial fibrillation: age alone should not be a 
      contra-indication for anticoagulant treatment].
LID - D2959 [pii]
AB  - A significant proportion of elderly patients are not properly treated with 
      anticoagulants. Here we describe the pros and cons of anticoagulant treatment in 
      elderly patients with atrial fibrillation, illustrated by two cases. We discuss 
      the sometimes difficult treatment decisions to be made in frail elderly patients, 
      especially after they have suffered bleeding complications. Aspirin is now 
      considered obsolete in the treatment of atrial fibrillation in the elderly.
FAU - Lucassen, Wim A M
AU  - Lucassen WAM
AD  - Amsterdam UMC, locatie AMC, afd. Huisartsgeneeskunde.
AD  - Contact: W.A.M. Lucassen (w.a.lucassen@amc.uva.nl).
FAU - van Peet, Petra G
AU  - van Peet PG
AD  - Leiden UMC, afd. Public Health en Huisartsgeneeskunde.
FAU - Himmelreich, Jelle C L
AU  - Himmelreich JCL
AD  - Amsterdam UMC, locatie AMC, afd. Huisartsgeneeskunde.
FAU - Uittenbogaart, Steven B
AU  - Uittenbogaart SB
AD  - Amsterdam UMC, locatie AMC, afd. Huisartsgeneeskunde.
LA  - dut
PT  - Case Reports
PT  - Journal Article
TT  - Ouderen en boezemfibrilleren.
DEP - 20190222
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Female
MH  - *Frail Elderly
MH  - Humans
MH  - Male
EDAT- 2019/03/01 06:00
MHDA- 2020/09/01 06:00
CRDT- 2019/03/01 06:00
PHST- 2019/03/01 06:00 [entrez]
PHST- 2019/03/01 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
AID - D2959 [pii]
PST - epublish
SO  - Ned Tijdschr Geneeskd. 2019 Feb 22;163:D2959.

PMID- 3906670
OWN - NLM
STAT- MEDLINE
DCOM- 19860102
LR  - 20191030
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 20
IP  - 2
DP  - 1985 Nov
TI  - Inhibition by aspirin of human arterial and venous prostacyclin synthesis.
PG  - 141-9
AB  - Prostacyclin (PGI2) synthesis by human mesenteric arteries and veins was measured 
      ex vivo in 62 patients who received either no medication or a single oral dose of 
      aspirin 40 mg, 75 mg or 300 mg approximately 24 hrs pre-operatively. Each dose of 
      aspirin caused a significant reduction in both arterial and venous PGI2 synthesis 
      compared with the untreated group. Arterial PGI2 synthesis did not differ 
      significantly from venous PGI2 synthesis whether assessed by sample weight or 
      sample area.
FAU - Hanley, S P
AU  - Hanley SP
FAU - Bevan, J
AU  - Bevan J
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins F)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - WJ72O6860W (prostaglandin F1)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Epoprostenol/*biosynthesis
MH  - Female
MH  - Humans
MH  - Male
MH  - Mesenteric Arteries/*metabolism
MH  - Mesenteric Veins/*metabolism
MH  - Middle Aged
MH  - Prostaglandin Antagonists/administration & dosage/*pharmacology
MH  - Prostaglandins F/biosynthesis
EDAT- 1985/11/01 00:00
MHDA- 1985/11/01 00:01
CRDT- 1985/11/01 00:00
PHST- 1985/11/01 00:00 [pubmed]
PHST- 1985/11/01 00:01 [medline]
PHST- 1985/11/01 00:00 [entrez]
AID - 10.1016/0262-1746(85)90005-8 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1985 Nov;20(2):141-9. doi: 
      10.1016/0262-1746(85)90005-8.

PMID- 34257805
OWN - NLM
STAT- MEDLINE
DCOM- 20220105
LR  - 20220105
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2021
DP  - 2021
TI  - The Protective Effect of Aspirin Eugenol Ester on Oxidative Stress to PC12 Cells 
      Stimulated with H(2)O(2) through Regulating PI3K/Akt Signal Pathway.
PG  - 5527475
LID - 10.1155/2021/5527475 [doi]
LID - 5527475
AB  - Aspirin eugenol ester (AEE) is a new pharmaceutical compound esterified by 
      aspirin and eugenol, which has anti-inflammatory, antioxidant, and other 
      pharmacological activities. This study is aimed at identifying the protective 
      effect of AEE against H(2)O(2)-induced apoptosis in rat adrenal pheochromocytoma 
      PC12 cells and the possible mechanisms. The results of cell viability assay 
      showed that AEE could increase the viability of PC12 cells stimulated by 
      H(2)O(2), while AEE alone had no significant effect on the viability of PC12 
      cells. Compared with the control group, the activities of superoxide dismutase 
      (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) were significantly 
      decreased, and the content of malondialdehyde (MDA) was significantly increased 
      in the H(2)O(2) group. By AEE pretreatment, the level of MDA was reduced and the 
      levels of SOD, CAT, and GSH-Px were increased in H(2)O(2)-stimulated PC12 cells. 
      In addition, AEE could reduce the apoptosis of PC12 cells induced by H(2)O(2) via 
      reducing superoxide anion, intracellular ROS, and mitochondrial ROS (mtROS) and 
      increasing the levels of mitochondrial membrane potential (ΔΨm). Furthermore, the 
      results of western blotting showed that compared with the control group, the 
      expression of p-PI3K, p-Akt, and Bcl-2 was significantly decreased, while the 
      expression of Caspase-3 and Bax was significantly increased in the H(2)O(2) 
      group. In the AEE group, AEE pretreatment could upregulate the expression of 
      p-PI3K, p-Akt, and Bcl-2 and downregulate the expression of Caspase-3 and Bax in 
      PC12 cells stimulated with H(2)O(2). The silencing of PI3K with shRNA and its 
      inhibitor-LY294002 could abrogate the protective effect of AEE in PC12 cells. 
      Therefore, AEE has a protective effect on H(2)O(2)-induced PC12 cells by 
      regulating the PI3K/Akt signal pathway to inhibit oxidative stress.
CI  - Copyright © 2021 Zhen-Dong Zhang et al.
FAU - Zhang, Zhen-Dong
AU  - Zhang ZD
AD  - Key Laboratory of New Animal Drug Project of Gansu Province, Key Laboratory of 
      Veterinary Pharmaceutical Development of Ministry of Agriculture and Rural 
      Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS, 
      Lanzhou 730050, China.
FAU - Yang, Ya-Jun
AU  - Yang YJ
AD  - Key Laboratory of New Animal Drug Project of Gansu Province, Key Laboratory of 
      Veterinary Pharmaceutical Development of Ministry of Agriculture and Rural 
      Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS, 
      Lanzhou 730050, China.
FAU - Liu, Xi-Wang
AU  - Liu XW
AD  - Key Laboratory of New Animal Drug Project of Gansu Province, Key Laboratory of 
      Veterinary Pharmaceutical Development of Ministry of Agriculture and Rural 
      Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS, 
      Lanzhou 730050, China.
FAU - Qin, Zhe
AU  - Qin Z
AD  - Key Laboratory of New Animal Drug Project of Gansu Province, Key Laboratory of 
      Veterinary Pharmaceutical Development of Ministry of Agriculture and Rural 
      Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS, 
      Lanzhou 730050, China.
FAU - Li, Shi-Hong
AU  - Li SH
AD  - Key Laboratory of New Animal Drug Project of Gansu Province, Key Laboratory of 
      Veterinary Pharmaceutical Development of Ministry of Agriculture and Rural 
      Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS, 
      Lanzhou 730050, China.
FAU - Bai, Li-Xia
AU  - Bai LX
AD  - Key Laboratory of New Animal Drug Project of Gansu Province, Key Laboratory of 
      Veterinary Pharmaceutical Development of Ministry of Agriculture and Rural 
      Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS, 
      Lanzhou 730050, China.
FAU - Li, Jian-Yong
AU  - Li JY
AUID- ORCID: 0000-0003-3317-0666
AD  - Key Laboratory of New Animal Drug Project of Gansu Province, Key Laboratory of 
      Veterinary Pharmaceutical Development of Ministry of Agriculture and Rural 
      Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS, 
      Lanzhou 730050, China.
LA  - eng
PT  - Journal Article
DEP - 20210624
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (Anti-Infective Agents, Local)
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Infective Agents, Local/pharmacology/*therapeutic use
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Eugenol/*analogs & derivatives/pharmacology/therapeutic use
MH  - Humans
MH  - Hydrogen Peroxide/pharmacology/*therapeutic use
MH  - Oxidative Stress/*drug effects
MH  - PC12 Cells
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Rats
MH  - Signal Transduction/*drug effects
MH  - Transfection
PMC - PMC8249132
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/15 06:00
MHDA- 2022/01/06 06:00
CRDT- 2021/07/14 07:04
PHST- 2021/01/20 00:00 [received]
PHST- 2021/05/28 00:00 [accepted]
PHST- 2021/07/14 07:04 [entrez]
PHST- 2021/07/15 06:00 [pubmed]
PHST- 2022/01/06 06:00 [medline]
AID - 10.1155/2021/5527475 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2021 Jun 24;2021:5527475. doi: 10.1155/2021/5527475. 
      eCollection 2021.

PMID- 6433636
OWN - NLM
STAT- MEDLINE
DCOM- 19841023
LR  - 20220408
IS  - 0001-5792 (Print)
IS  - 0001-5792 (Linking)
VI  - 72
IP  - 1
DP  - 1984
TI  - Treatment of sickle cell diseases with aspirin.
PG  - 61-4
AB  - The effects of long-term aspirin for the treatment of sickle cell disease were 
      compared with placebo in a double-blind trial completed by 29 patients. Each 
      patient was submitted to a 5-month period of treatment with aspirin (median dose 
      31 mg/kg/day) and an equivalent period with placebo. No clinical or laboratory 
      differences were observed between the two phases, including the frequency of 
      painful crises and infectious episodes, hemoglobin concentration, PCV, 
      reticulocytes, Hb F, bilirubin, irreversibly sickled cells, filterability of red 
      cell, sickling in vitro and hypoxia-induced potassium loss.
FAU - Zago, M A
AU  - Zago MA
FAU - Costa, F F
AU  - Costa FF
FAU - Ismael, S J
AU  - Ismael SJ
FAU - Tone, L G
AU  - Tone LG
FAU - Bottura, C
AU  - Bottura C
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anemia, Sickle Cell/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Placebos
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1159/000206360 [doi]
PST - ppublish
SO  - Acta Haematol. 1984;72(1):61-4. doi: 10.1159/000206360.

PMID- 26843729
OWN - NLM
STAT- MEDLINE
DCOM- 20180910
LR  - 20181113
IS  - 0350-199X (Print)
IS  - 1986-5961 (Electronic)
IS  - 0350-199X (Linking)
VI  - 69
IP  - 6
DP  - 2015 Dec
TI  - Does Early Post-operative Administration of Aspirin Influence the Risk of 
      Bleeding After Coronary Artery Bypass Graft Surgery? A Prospective Observational 
      Study.
PG  - 381-3
LID - 10.5455/medarh.2015.69.381-383 [doi]
AB  - BACKGROUND: Aspirin has a proven role in preventing thrombotic diseases. However, 
      given its anti-platelet activity, it is often assumed that its early 
      post-operative administration significantly increase the amount of post-operative 
      bleeding. AIM: The aim of this study was to determine whether early 
      post-operative administration of aspirin influence the risk of bleeding in 
      patients undergoing coronary artery bypass graft (CABG) surgery. METHODS: In a 
      prospective observational study, 100 consecutive patients undergoing first time 
      elective CABG surgery were include in the study. Patients received a low dose of 
      aspirin (75-150 mg per day) either 1 hours (the early aspirin group; n=43) or 6 
      hours after surgery (the late aspirin group; n=57). Total mediastinal blood 
      drainage, blood drainage after 6 hours, incidences of re-operation for the 
      control of bleeding and transfusion of red blood cells (RBCs) and blood products 
      were recorded and followed until chest tube removal. RESULTS: The groups were 
      found to be matched for the confounding variables and no significant differences 
      were found between post-aspirin bleeding (p=0.37), RBCs and blood product usage 
      (p=0.90) or incidences of re-operation for control of bleeding (p=1.00) between 
      the two groups. CONCLUSIONS: Early administration (1 hour after surgery) of 
      aspirin did not appear to increase the risk of post-operative bleeding in 
      patients undergoing CABG. Thereby, its early administration in such cases may be 
      considered. Although further well-designed randomized controlled trials to 
      confirm the safety and efficacy of early administration of aspirin after CABG 
      surgery are warranted.
FAU - Nouraei, Seyed Mahmood
AU  - Nouraei SM
AD  - Department of Cardiac Surgery, Faculty of Medicine, Mazandaran University of 
      Medical Sciences, Sari, Iran.
FAU - Gholipour Baradari, Afshin
AU  - Gholipour Baradari A
AD  - Department of Anesthesiology, Faculty of Medicine, Mazandaran University of 
      Medical Sciences, Sari, Iran.
FAU - Emami Zeydi, Amir
AU  - Emami Zeydi A
AD  - Student research Committee, School of Nursing and Midwifery, Mashhad University 
      of Medical Sciences, Mashhad, Iran.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - Bosnia and Herzegovina
TA  - Med Arch
JT  - Medical archives (Sarajevo, Bosnia and Herzegovina)
JID - 101635337
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Coronary Artery Bypass/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Postoperative Care/*adverse effects/methods
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC4720471
OTO - NOTNLM
OT  - Aspirin
OT  - Bleeding
OT  - CABG
OT  - Complication
COIS- CONFLICT OF INTEREST: NONE DECLARED.
EDAT- 2016/02/05 06:00
MHDA- 2016/02/05 06:01
CRDT- 2016/02/05 06:00
PHST- 2016/02/05 06:00 [entrez]
PHST- 2016/02/05 06:00 [pubmed]
PHST- 2016/02/05 06:01 [medline]
AID - MA-69-381 [pii]
AID - 10.5455/medarh.2015.69.381-383 [doi]
PST - ppublish
SO  - Med Arch. 2015 Dec;69(6):381-3. doi: 10.5455/medarh.2015.69.381-383.

PMID- 28965637
OWN - NLM
STAT- MEDLINE
DCOM- 20180523
LR  - 20180531
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 37
IP  - 4
DP  - 2017 Nov
TI  - Aspirin and Nonsteroidal Antiinflammatory Drugs Hypersensitivity and Management.
PG  - 727-749
LID - S0889-8561(17)30081-4 [pii]
LID - 10.1016/j.iac.2017.07.008 [doi]
AB  - Aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) are widely used in the 
      United States and throughout the world for a variety of indications. Several 
      unique hypersensitivity syndromes exist to this class of medications, making them 
      one of the common reasons for consultation to the allergist. The lack of any 
      laboratory-based diagnostic studies to assist in identifying the culprits in 
      these reactions make evaluation of aspirin and NSAID hypersensitivity 
      challenging. Identifying patients appropriate for oral challenge and/or 
      desensitization protocols is the standard pragmatic approach to this issue when 
      it arises.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Modena, Brian
AU  - Modena B
AD  - Division of Allergy, Asthma and Immunology, Scripps Clinic, 3811 Valley Centre 
      Drive, S99, San Diego, CA 92130, USA.
FAU - White, Andrew A
AU  - White AA
AD  - Division of Allergy, Asthma and Immunology, Scripps Clinic, 3811 Valley Centre 
      Drive, S99, San Diego, CA 92130, USA. Electronic address: 
      White.andrew@scrippshealth.org.
FAU - Woessner, Katharine M
AU  - Woessner KM
AD  - Division of Allergy, Asthma and Immunology, Scripps Clinic, 3811 Valley Centre 
      Drive, S99, San Diego, CA 92130, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170901
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Allergens)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Allergens/*immunology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*immunology/therapeutic use
MH  - Aspirin/*immunology/therapeutic use
MH  - Cyclooxygenase 2/metabolism
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/diagnosis/*therapy
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Urticaria/diagnosis/*therapy
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirin-exacerbated respiratory disease
OT  - Chronic spontaneous urticaria
OT  - Desensitization
OT  - Nonsteroidal antiinflammatory drugs
OT  - Oral challenge
EDAT- 2017/10/03 06:00
MHDA- 2018/05/24 06:00
CRDT- 2017/10/03 06:00
PHST- 2017/10/03 06:00 [entrez]
PHST- 2017/10/03 06:00 [pubmed]
PHST- 2018/05/24 06:00 [medline]
AID - S0889-8561(17)30081-4 [pii]
AID - 10.1016/j.iac.2017.07.008 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2017 Nov;37(4):727-749. doi: 
      10.1016/j.iac.2017.07.008. Epub 2017 Sep 1.

PMID- 35581629
OWN - NLM
STAT- MEDLINE
DCOM- 20220520
LR  - 20220716
IS  - 2050-6511 (Electronic)
IS  - 2050-6511 (Linking)
VI  - 23
IP  - 1
DP  - 2022 May 17
TI  - Aspirin versus placebo on estrogen levels in postmenopausal women: a double-blind 
      randomized controlled clinical trial.
PG  - 31
LID - 10.1186/s40360-022-00571-9 [doi]
LID - 31
AB  - BACKGROUND: Estrogen is involved in the pathogenesis of breast and gynecological 
      cancers. Regular use of aspirin reduces estrogen levels. The present study aimed 
      to evaluate the effect of aspirin on estrogen levels in postmenopausal women. 
      METHODS: This double-blind, placebo-controlled parallel-group trial was conducted 
      on postmenopausal women referred to an outpatient clinic at a women's hospital in 
      Tehran. Volunteers were randomly assigned to receive aspirin 100 mg/day or 
      placebo for 6 weeks. Estradiol, sex hormone-binding globulin (SHBG), and 
      testosterone levels at baseline and at the end of the intervention were measured 
      by ELISA. Data were analyzed using SPSS 20, Kolmogorov-Smirnov test, independent 
      samples t-test, and Mann-Whitney U test. RESULTS: Twenty-seven and 28 
      participants were finally analyzed in the aspirin and placebo groups, 
      respectively. There was no significant difference between the two groups in body 
      mass index (BMI), age, or menopausal years. There was a statistically significant 
      difference (p = 0.002) in the amount of  change in estradiol levels of the 
      intervention group (median=- 3.5 pg/ml) compared to the control group 
      (median=1.5 pg/ml). In contrast, there were no significant differences between 
      the two groups regarding testosterone and SHBG levels (p = 0.58, p = 0.32). 
      CONCLUSIONS: Since low doses of aspirin may decrease estradiol levels, it could 
      be considered a promising adjunctive therapeutic candidate in postmenopausal 
      women to decrease BC incidence. However, further studies with larger sample 
      sizes, measurements of estrogen levels and its related compounds in different 
      time points accompanied by long-term follow-ups are needed to better elucidate 
      the potential mechanisms by which nonsteroidal anti-inflammatory drugs (NSAIDs) 
      negatively affect breast cancer. TRIAL REGISTRATION: IRCT201012195397N1. Date of 
      first registration: 03/01/2011.
CI  - © 2022. The Author(s).
FAU - Oghazian, Mohammad Bagher
AU  - Oghazian MB
AD  - Department of Internal Medicine, Faculty of Medicine, North Khorasan University 
      of Medical Sciences, Bojnurd, Iran.
FAU - Shirzad, Nooshin
AU  - Shirzad N
AD  - Endocrinology and Metabolism Research Institute, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Ahadi, Mahdi
AU  - Ahadi M
AD  - Department of Clinical Pharmacy, School of Pharmacy, Zanjan University of Medical 
      Sciences, Zanjan, Iran.
FAU - Eivazi Adli, Shalaleh
AU  - Eivazi Adli S
AD  - School of Pharmacy and Pharmaceutical Sciences, Islamic Azad University of Tehran 
      Medical Sciences, Tehran, Iran.
FAU - Mollazadeh, Samaneh
AU  - Mollazadeh S
AD  - Natural Products and Medicinal Plants Research Center, North Khorasan University 
      of Medical Sciences, Bojnurd, Iran.
FAU - Radfar, Mania
AU  - Radfar M
AUID- ORCID: 0000-0001-9342-781X
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of 
      Medical Sciences, Tehran, Iran. mania_radfar@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20220517
PL  - England
TA  - BMC Pharmacol Toxicol
JT  - BMC pharmacology & toxicology
JID - 101590449
RN  - 0 (Estrogens)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Double-Blind Method
MH  - Estradiol
MH  - Estrogens
MH  - Female
MH  - Humans
MH  - Iran
MH  - *Postmenopause
MH  - Testosterone
PMC - PMC9116012
OTO - NOTNLM
OT  - Estradiol
OT  - Non-steroidal anti-inflammatory agents
OT  - Postmenopause
OT  - Sex hormone-binding globulin
OT  - Testosterone
COIS- The authors declare that they have no competing interests.
EDAT- 2022/05/18 06:00
MHDA- 2022/05/21 06:00
CRDT- 2022/05/17 23:41
PHST- 2021/10/21 00:00 [received]
PHST- 2022/05/13 00:00 [accepted]
PHST- 2022/05/17 23:41 [entrez]
PHST- 2022/05/18 06:00 [pubmed]
PHST- 2022/05/21 06:00 [medline]
AID - 10.1186/s40360-022-00571-9 [pii]
AID - 571 [pii]
AID - 10.1186/s40360-022-00571-9 [doi]
PST - epublish
SO  - BMC Pharmacol Toxicol. 2022 May 17;23(1):31. doi: 10.1186/s40360-022-00571-9.

PMID- 2398471
OWN - NLM
STAT- MEDLINE
DCOM- 19901018
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 79
IP  - 7
DP  - 1990 Jul
TI  - Nondestructive near-infrared analysis of intact tablets for determination of 
      degradation products.
PG  - 622-7
AB  - Near-infrared spectrometry was used in this study to examine intact aspirin 
      tablets in order to demonstrate the usefulness of the technique as a 
      nondestructive method of quality control. Unique sampling optics were used to 
      simultaneously illuminate the entire surface of the tablets, including the top, 
      bottom, and side. Changes in individual tablet spectra were correlated to (a) the 
      time that the tablets spent in a hydrator, (b) the mass of water absorbed by the 
      tablets, and (c) the mass of salicylic acid formed by base-catalyzed hydrolysis 
      of acetylsalicylic acid. A prediction equation for each of these three parameters 
      was constructed using near-infrared spectral reflectance values obtained from 
      intact tablets. Prediction errors were low for (a) the time that tablets spent in 
      the hydrator (+/- 19 h over a period of 168 h), (b) the mass of water absorbed 
      (+/- 0.04% of tablet mass), and (c) the mass of salicylic acid formed (+/- 0.04% 
      of tablet mass).
FAU - Drennen, J K
AU  - Drennen JK
AD  - Division of Pharmaceutics and Pharmaceutical Analysis, University of Kentucky 
      College of Pharmacy, Lexington 40536-0082.
FAU - Lodder, R A
AU  - Lodder RA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis
MH  - Chromatography, High Pressure Liquid
MH  - Mathematics
MH  - Salicylates/analysis
MH  - Salicylic Acid
MH  - Spectrophotometry, Infrared
MH  - Tablets/*analysis
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
AID - S0022-3549(15)48276-0 [pii]
AID - 10.1002/jps.2600790717 [doi]
PST - ppublish
SO  - J Pharm Sci. 1990 Jul;79(7):622-7. doi: 10.1002/jps.2600790717.

PMID- 392079
OWN - NLM
STAT- MEDLINE
DCOM- 19800327
LR  - 20181113
IS  - 0035-8797 (Print)
IS  - 0035-8797 (Linking)
VI  - 29
IP  - 204
DP  - 1979 Jul
TI  - A randomized controlled trial of aspirin in the prevention of early mortality in 
      myocardial infarction.
PG  - 413-6
AB  - A randomized controlled trial is reported in which a single dose of aspirin (300 
      mg) was given to patients with myocardial infarction on first contact with a 
      general practitioner. A total of 1,705 patients with confirmed infarction were 
      studied, and survival ascertained. There was no evidence of benefit from the 
      aspirin.
FAU - Elwood, P C
AU  - Elwood PC
FAU - Williams, W O
AU  - Williams WO
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J R Coll Gen Pract
JT  - The Journal of the Royal College of General Practitioners
JID - 7503107
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Random Allocation
MH  - Recurrence
PMC - PMC2159226
EDAT- 1979/07/01 00:00
MHDA- 1979/07/01 00:01
CRDT- 1979/07/01 00:00
PHST- 1979/07/01 00:00 [pubmed]
PHST- 1979/07/01 00:01 [medline]
PHST- 1979/07/01 00:00 [entrez]
PST - ppublish
SO  - J R Coll Gen Pract. 1979 Jul;29(204):413-6.

PMID- 3969898
OWN - NLM
STAT- MEDLINE
DCOM- 19850318
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 55
IP  - 5
DP  - 1985 Feb 15
TI  - Aspirin or dipyridamole individually prevent lipid accumulation in primate vein 
      bypass grafts.
PG  - 556-9
AB  - Although platelet inhibition with both aspirin and dipyridamole is widely 
      prescribed for patients with coronary artery bypass grafts, data are lacking to 
      prove that combined drug therapy has greater efficacy in preserving graft 
      integrity than either drug given independently. Thus, the ability of combined vs 
      single drug therapy to reduce cholesterol and apolipoprotein-B accumulation were 
      compared in autologous cephalic veins grafted into femoral arteries of 23 
      stump-tailed macaque monkeys. Ten monkeys were studied in 2 phases. They were 
      treated with aspirin (80 mg/day) during 1 phase and with dipyridamole (50 mg/day) 
      during the other phase. Five monkeys received aspirin plus dipyridamole in 
      combination and 8 received no medication and served as controls. When grafts were 
      removed 3 months after insertion cholesterol and apolipoprotein-B concentrations 
      in grafts were similar for groups treated with aspirin, with dipyridamole, and 
      with the drugs combined, and in each of the treated groups these concentrations 
      were significantly reduced compared with grafts from untreated control monkeys. 
      Cholesterol and apolipoprotein-B concentrations in grafts from the treated groups 
      were similar to concentrations in normal ungrafted veins, whereas cholesterol and 
      apolipoprotein-B levels in grafts from control monkeys were significantly greater 
      than those in ungrafted veins (250% and 925% of normal, respectively). Our 
      findings reaffirm the ameliorative effect of anti-platelet drugs in reducing the 
      accumulation of lipid in vein bypass grafts and indicate that the efficacy of 
      aspirin or dipyridamole given individually equals that of the combination of 
      these drugs in this subhuman primate model. The relation of the lipid-lowering 
      effect of these agents to their antithrombotic effect is uncertain.
FAU - Boerboom, L E
AU  - Boerboom LE
FAU - Olinger, G N
AU  - Olinger GN
FAU - Bonchek, L I
AU  - Bonchek LI
FAU - Gunay, I I
AU  - Gunay II
FAU - Kissebah, A H
AU  - Kissebah AH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Apolipoproteins B)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apolipoproteins B/metabolism
MH  - Arteriovenous Shunt, Surgical/*adverse effects
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cholesterol/metabolism
MH  - Dipyridamole/administration & dosage/*physiology
MH  - Drug Therapy, Combination
MH  - Femoral Artery/surgery
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - *Lipid Metabolism
MH  - Macaca
MH  - Veins/transplantation
EDAT- 1985/02/15 00:00
MHDA- 1985/02/15 00:01
CRDT- 1985/02/15 00:00
PHST- 1985/02/15 00:00 [pubmed]
PHST- 1985/02/15 00:01 [medline]
PHST- 1985/02/15 00:00 [entrez]
AID - 0002-9149(85)90246-2 [pii]
AID - 10.1016/0002-9149(85)90246-2 [doi]
PST - ppublish
SO  - Am J Cardiol. 1985 Feb 15;55(5):556-9. doi: 10.1016/0002-9149(85)90246-2.

PMID- 21933594
OWN - NLM
STAT- MEDLINE
DCOM- 20120427
LR  - 20161125
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 124
IP  - 16
DP  - 2011 Aug
TI  - Lysine acetylsalicylate ameliorates lung injury in rats acutely exposed to 
      paraquat.
PG  - 2496-501
AB  - BACKGROUND: Paraquat (PQ), an effective and widely used herbicide, has been 
      proven to be safe when appropriately applied to eliminate weeds. However, PQ 
      poisoning is an extremely frustrating clinical condition with a high mortality 
      and with a lack of effective treatments in humans. PQ mainly accumulates in the 
      lung, and the main molecular mechanism of PQ toxicity is based on redox cycling 
      and intracellular oxidative stress generation. The aim of this study was to 
      evaluate whether lysine acetylsalicylate (LAS) could protect the lung from the 
      damage of PQ poisoning and to study the mechanisms of protection. METHODS: A 
      model of PQ poisoning was established in 75 Sprague-Dawley rats by intragastric 
      administration of 50 mg/kg PQ, followed by treatment with 200 mg/kg of LAS. The 
      rats were randomly divided into sham, PQ, and PQ + LAS groups, with 25 in each 
      group. We assessed and compared the malonaldehyde (MDA) content, superoxide 
      dismutase activity (SOD), glutathion peroxidase (GSH-Px), and catalase (CAT) in 
      serum and lung and the hydroxyproline (HYP) content, pathological changes, 
      apoptosis and expression of Bcl-2/Bax protein in lung of rats on days 1, 3, 7, 14 
      and 21 after PQ poisoning and LAS treatment. RESULTS: Compared to the PQ group 
      rats, early treatment with LAS reduced the MDA and HYP contents, and increased 
      the SOD, GSH-Px, and CAT activities in the serum and lung on days 1, 3, 7, 14, 
      and 21 after PQ poisoning (all P < 0.05). After early LAS treatment, the 
      apoptotic rate and Bax expression of lung decreased, the Bcl-2 expression 
      increased, and the Bcl-2/Bax ratio increased, compared to the PQ group rats. 
      Furthermore, the pathological results of lungs revealed that after LAS treatment, 
      early manifestations of PQ poisoning, such as hemorrhage, edema and 
      inflammatory-cell infiltration, were improved to some degree, and collagen fibers 
      in the pulmonary interstitium were also obviously reduced. CONCLUSION: In this 
      rat model of PQ poisoning, LAS effectively ameliorated the lung injury induced by 
      PQ, possibly through antioxidation, anti-fibrosis, anti-apoptosis, and 
      anticoagulation.
FAU - Huang, Wei-Dong
AU  - Huang WD
AD  - Department of Emergency Medicine, First Affiliated Hospital, Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang 310003, China.
FAU - Wang, Jie-Zan
AU  - Wang JZ
FAU - Lu, Yuan-Qiang
AU  - Lu YQ
FAU - DI, Ya-Min
AU  - DI YM
FAU - Jiang, Jiu-Kun
AU  - Jiang JK
FAU - Zhang, Qin
AU  - Zhang Q
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Antioxidants)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.11.1.6 (Catalase)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - K3Z4F929H6 (Lysine)
RN  - PLG39H7695 (Paraquat)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Aspirin/*analogs & derivatives/standards/therapeutic use
MH  - Catalase/metabolism
MH  - Glutathione Peroxidase/metabolism
MH  - Lung/drug effects/metabolism
MH  - Lung Injury/*chemically induced/*drug therapy/metabolism
MH  - Lysine/*analogs & derivatives/standards/therapeutic use
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Paraquat/*toxicity
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Superoxide Dismutase/metabolism
EDAT- 2011/09/22 06:00
MHDA- 2012/04/28 06:00
CRDT- 2011/09/22 06:00
PHST- 2011/09/22 06:00 [entrez]
PHST- 2011/09/22 06:00 [pubmed]
PHST- 2012/04/28 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2011 Aug;124(16):2496-501.

PMID- 18491435
OWN - NLM
STAT- MEDLINE
DCOM- 20080707
LR  - 20190907
IS  - 0891-1150 (Print)
IS  - 0891-1150 (Linking)
VI  - 75
IP  - 4
DP  - 2008 Apr
TI  - Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy 
      with clopidogrel and aspirin?
PG  - 289-95
AB  - The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, 
      Management, and Avoidance (CHARISMA) study (N Engl J Med 2006; 354:1706-1717, J 
      Am Coil Cardiol 2007; 49:1982-1988) assessed the effect of dual antiplatelet 
      therapy with clopidogrel (Plavix) and aspirin in patients at risk of 
      atherothrombotic events. At a median of 28 months, the rate of the primary 
      efficacy end point (a composite of myocardial infarction, stroke, and death from 
      cardiovascular causes) was not significantly lower in the group receiving 
      clopidogrel plus aspirin than in the group receiving placebo plus aspirin. 
      However, one subgroup may have derived some benefit from the combination: those 
      at higher risk owing to a history of myocardial infarction, ischemic stroke, or 
      symptomatic peripheral arterial disease.
FAU - Bakhru, Mihir R
AU  - Bakhru MR
AD  - Department of Internal Medicine, Cleveland Clinic, Cleveland Clinic Foundation, 
      Cleveland, OH 44195, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cleve Clin J Med
JT  - Cleveland Clinic journal of medicine
JID - 8703441
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Thromboembolism/*drug therapy/prevention & control
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
RF  - 39
EDAT- 2008/05/22 09:00
MHDA- 2008/07/08 09:00
CRDT- 2008/05/22 09:00
PHST- 2008/05/22 09:00 [pubmed]
PHST- 2008/07/08 09:00 [medline]
PHST- 2008/05/22 09:00 [entrez]
AID - 10.3949/ccjm.75.4.289 [doi]
PST - ppublish
SO  - Cleve Clin J Med. 2008 Apr;75(4):289-95. doi: 10.3949/ccjm.75.4.289.

PMID- 6588541
OWN - NLM
STAT- MEDLINE
DCOM- 19840813
LR  - 20131121
IS  - 0085-5928 (Print)
IS  - 0085-5928 (Linking)
VI  - 92
DP  - 1984
TI  - Studies on the protective effect of deglycyrrhinised liquorice against aspirin 
      (ASA) and ASA plus bile acid-induced gastric mucosal damage, and ASA absorption 
      in rats.
PG  - 97-100
AB  - By per-oral intubation of the stomach, four groups of rats (n = 22) received ASA 
      64 mg/kg, alone or with taurodeoxycholic acid (TDC, 5 mM), DGL (2000 mg/kg) or 
      TDC plus DGL. At four hours the severity of bleeding was assessed by a lesion 
      scoring system and expressed as medians and quartiles. In a separate study two 
      groups of rats (n = 7) received ASA (128 mg/kg) or ASA plus DGL (2000 mg/kg) and 
      salicylate levels measured in serial tail blood samples at 20, 40, 60 and 80 
      minutes. Lesion scores were increased from 6(3;10) with ASA alone to 12(5;16) by 
      TDC (p less than 0.05) and reduced by DGL to 1(0;3.5) for ASA alone and 3.5(0;6) 
      for ASA plus TDC (p less than 0.0005 in both cases). In the second study a slight 
      reduction of ASA absorption was found only at 20 minutes with a median level of 
      0.9 mmol/l for the DGL treated rats and 1.2 mmol/l for the ASA alone group (p 
      less than 0.05). No differences were found at the other times. We have also 
      demonstrated that although DGL diminished ASA (128 mg/kg)-induced gastric mucosal 
      damage from 17(12;25) to 8(3;14) (p less than 0.005) when the two were given 
      together it did not do so significantly when DGL was given before ASA--15(20;22). 
      Intraperitoneal DGL reduced lesion scores from ASA (128 mg/kg) from 14(11;24) to 
      7(1;19) (p less than 0.03), thus indicating a systemic as well as a local effect 
      of the drug.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Russell, R I
AU  - Russell RI
FAU - Morgan, R J
AU  - Morgan RJ
FAU - Nelson, L M
AU  - Nelson LM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol Suppl
JT  - Scandinavian journal of gastroenterology. Supplement
JID - 0437034
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Plant Extracts)
RN  - 0 (deglycyrrhizinized liquorice)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*antagonists & inhibitors/metabolism
MH  - Bile Acids and Salts/*antagonists & inhibitors
MH  - Gastric Mucosa/*drug effects/metabolism
MH  - *Glycyrrhiza
MH  - Intestinal Absorption/drug effects
MH  - Male
MH  - Plant Extracts/*pharmacology
MH  - *Plants, Medicinal
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Time Factors
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol Suppl. 1984;92:97-100.

PMID- 12390062
OWN - NLM
STAT- MEDLINE
DCOM- 20021122
LR  - 20190813
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 162
IP  - 19
DP  - 2002 Oct 28
TI  - Evaluation of the benefits and risks of low-dose aspirin in the secondary 
      prevention of cardiovascular and cerebrovascular events.
PG  - 2197-202
AB  - BACKGROUND: In spite of the clear evidence of benefit of aspirin in the secondary 
      prevention of cerebrovascular and cardiovascular thrombotic events, its use in 
      patients at high risk due to a previous event remains suboptimal. A possible 
      explanation for this underuse is concern regarding the relative benefit in 
      relation to the potential risk for serious gastrointestinal events. OBJECTIVE: To 
      compare the benefit and gastrointestinal risk of aspirin use for the secondary 
      prevention of thromboembolic events. DESIGN: A meta-analysis was conducted using 
      6 trials (6300 patients) meeting the inclusion requirement of use of low-dose 
      aspirin (< or =325 mg/d) in approved secondary prevention indications. RESULTS: 
      Aspirin reduced all-cause mortality by 18%. In addition, aspirin use reduced the 
      number of strokes by 20%, myocardial infarctions by 30%, and other "vascular 
      events" by 30%. Alternately, patients who took aspirin were 2.5 times more likely 
      than those in the placebo group to have gastrointestinal tract bleeding. The 
      number needed to treat for aspirin to prevent 1 death from any cause of mortality 
      was 67, while 100 needed to be treated to detect 1 nonfatal gastrointestinal 
      tract bleeding. CONCLUSION: Aspirin use for the secondary prevention of 
      thromboembolic events has a favorable benefit-to-risk profile and should be 
      encouraged in those at high risk.
FAU - Weisman, Steven M
AU  - Weisman SM
AD  - 13 James St, Morristown, NJ 07960, USA. weisman@innovativescience.net
FAU - Graham, David Y
AU  - Graham DY
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Stroke/prevention & control
EDAT- 2002/10/24 04:00
MHDA- 2002/11/26 04:00
CRDT- 2002/10/24 04:00
PHST- 2002/10/24 04:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/10/24 04:00 [entrez]
AID - ioi10652 [pii]
AID - 10.1001/archinte.162.19.2197 [doi]
PST - ppublish
SO  - Arch Intern Med. 2002 Oct 28;162(19):2197-202. doi: 10.1001/archinte.162.19.2197.

PMID- 11704184
OWN - NLM
STAT- MEDLINE
DCOM- 20011205
LR  - 20190818
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 98
IP  - 5 Pt 1
DP  - 2001 Nov
TI  - Aspirin for the prevention of preeclampsia in women with abnormal uterine artery 
      Doppler: a meta-analysis.
PG  - 861-6
AB  - OBJECTIVE: To determine the effectiveness of aspirin to prevent preeclampsia in 
      women identified as high risk for preeclampsia by an abnormal second-trimester 
      uterine artery Doppler examination. DATA SOURCES: Searches were conducted in 
      MEDLINE, Embase, the Cochrane Controlled Trials Register, and Science Citation 
      Index for randomized trials published from 1966 to 2000, using the following 
      medical subject headings and key words: "aspirin," "antiplatelet*," "salicyl*," 
      "acetylsalicyl*," "platelet aggregation inhibitors," "ultrasonography," 
      "ultraso*," and "Doppler." STUDY SELECTION: We included all randomized trials 
      that evaluated the effectiveness of aspirin compared with placebo or no treatment 
      in women with an abnormal uterine artery Doppler and that reported clinically 
      relevant perinatal and maternal outcomes. Study selection, quality assessment, 
      and data extraction were performed in duplicate. TABULATION, INTEGRATION, AND 
      RESULTS: There were five relevant trials. Pooling of results from these trials 
      showed a significant benefit of aspirin in reducing preeclampsia (odds ratio [OR] 
      0.55, 95% confidence interval [CI] 0.32, 0.95). The baseline risk of preeclampsia 
      in women with abnormal uterine artery Doppler was 16%, and the number of women 
      needed to be treated with aspirin to prevent one case of preeclampsia was 16 (95% 
      CI 8, 316). Women on aspirin had babies who were on average 82 g heavier than 
      controls, but this result did not reach statistical significance (weighted mean 
      difference 81.5, 95% CI 40.27, 203.27). CONCLUSION: Uterine artery Doppler 
      assessment identifies high-risk women in whom aspirin therapy results in a 
      significant reduction in preeclampsia.
FAU - Coomarasamy, A
AU  - Coomarasamy A
AD  - Birmingham Women's Hospital, Birmingham, United Kingdom. arricoomar@hotmail.com
FAU - Papaioannou, S
AU  - Papaioannou S
FAU - Gee, H
AU  - Gee H
FAU - Khan, K S
AU  - Khan KS
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Ultrasonography, Doppler
MH  - *Ultrasonography, Prenatal
MH  - Uterus/*blood supply
EDAT- 2001/11/13 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/13 10:00
PHST- 2001/11/13 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/13 10:00 [entrez]
AID - S0029784401015691 [pii]
AID - 10.1016/s0029-7844(01)01569-1 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2001 Nov;98(5 Pt 1):861-6. doi: 10.1016/s0029-7844(01)01569-1.

PMID- 504965
OWN - NLM
STAT- MEDLINE
DCOM- 19800128
LR  - 20190907
IS  - 0036-553X (Print)
IS  - 0036-553X (Linking)
VI  - 23
IP  - 3
DP  - 1979 Sep
TI  - The effect of acetyl salicylic acid and dipyridamole on thromboembolic 
      complications in splenectomized patients with myelofibrosis.
PG  - 177-81
AB  - The effect of combined treatment with acetyl salicylic acid and dipyridamole on 
      thrombic phenomena was studied in splenectomized patients with an aggressive form 
      of myelofibrosis. 3 of these patients had thrombotic episodes, shortened platelet 
      survival and an abnormal platelet aggregation pattern. The treatment with 
      antiplatelet drugs resulted in a decreased platelet utilization as evidenced by 
      clinical improvement and an increasing platelet concentration.
FAU - Hansen, M S
AU  - Hansen MS
FAU - Christensen, B E
AU  - Christensen BE
FAU - Jønsson, V
AU  - Jønsson V
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Scand J Haematol
JT  - Scandinavian journal of haematology
JID - 0404507
RN  - 64ALC7F90C (Dipyridamole)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Platelets
MH  - Cell Survival/drug effects
MH  - Dipyridamole/*administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Plasminogen Activators/metabolism
MH  - Platelet Aggregation/drug effects
MH  - Primary Myelofibrosis/*drug therapy
MH  - *Splenectomy
MH  - Thromboembolism/complications/*drug therapy
EDAT- 1979/09/01 00:00
MHDA- 1979/09/01 00:01
CRDT- 1979/09/01 00:00
PHST- 1979/09/01 00:00 [pubmed]
PHST- 1979/09/01 00:01 [medline]
PHST- 1979/09/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1979.tb02689.x [doi]
PST - ppublish
SO  - Scand J Haematol. 1979 Sep;23(3):177-81. doi: 10.1111/j.1600-0609.1979.tb02689.x.

PMID- 8471399
OWN - NLM
STAT- MEDLINE
DCOM- 19930514
LR  - 20181113
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 35
IP  - 3
DP  - 1993 Mar
TI  - The differential effect of aspirin on human platelet activation in 
      aspirin-sensitive asthmatics and normal subjects.
PG  - 227-34
AB  - 1. The in vitro effect of aspirin on platelet aggregation and ATP release induced 
      by platelet activating factor (PAF), arachidonic acid (AA) and collagen (COL) was 
      assessed in 10 aspirin-sensitive (ASP+) asthmatic patients and 10 normal 
      subjects. 2. For PAF, but not AA or COL, both the baseline EC50 and minimum 
      concentration required to produce a maximum response for aggregation were 
      significantly increased in ASP+ asthmatics compared with normal subjects (P < 
      0.05). Maximum ATP released was greater in ASP+ patients for all agonists but the 
      difference was most significant for PAF (P < 0.025). 3. In ASP+ asthmatics COL 
      induced, but not AA induced, aggregation was less sensitive to inhibition by 
      aspirin compared with normals (P < 0.01). Similarly, analysis of the area under 
      the percent inhibition concentration-response curve showed aspirin to be less 
      effective in inhibiting platelet aggregation induced by PAF in ASP+ asthmatics 
      than in normal subjects (normal subjects: 155 +/- 11 mg% ml-1, ASP+ asthmatics: 
      115 +/- 19 mg% ml-1; P < 0.05). 4. Regression analysis showed a poor correlation 
      (r = 0.25, P < 0.4933) between the degree of aspirin induced inhibition of ATP 
      release and platelet aggregation induced by PAF in ASP+ asthmatics. 5. The 
      significant differences observed in platelet responses to PAF, COL and to aspirin 
      in ASP+ asthma patients further suggests an abnormality in platelet function 
      exists in this syndrome.
FAU - Taylor, M L
AU  - Taylor ML
AD  - Department of Medicine, University of Western Australia, Queen Elizabeth II 
      Medical Centre, Nedlands.
FAU - Stewart, G A
AU  - Stewart GA
FAU - Thompson, P J
AU  - Thompson PJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Platelet Activating Factor)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Triphosphate/metabolism
MH  - Adult
MH  - Analysis of Variance
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Asthma/*blood/etiology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Collagen/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/*blood/complications
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Platelet Activating Factor/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Regression Analysis
PMC - PMC1381567
EDAT- 1993/03/01 00:00
MHDA- 1993/03/01 00:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 1993/03/01 00:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
PST - ppublish
SO  - Br J Clin Pharmacol. 1993 Mar;35(3):227-34.

PMID- 2030210
OWN - NLM
STAT- MEDLINE
DCOM- 19910620
LR  - 20190515
IS  - 0001-4966 (Print)
IS  - 0001-4966 (Linking)
VI  - 89
IP  - 3
DP  - 1991 Mar
TI  - Modeling synchronization and suppression of spontaneous otoacoustic emissions 
      using Van der Pol oscillators: effects of aspirin administration.
PG  - 1201-12
AB  - Many of the aspects of the interaction of spontaneous otoacoustic emissions with 
      external tones (suppression and synchronization) can be qualitatively simulated 
      by the behavior of a single driven Van der Pol oscillator. Analytical and 
      numerical investigations of a model of spontaneous otoacoustic emissions based on 
      such an oscillator (with appropriate parametric changes in the nonlinear and 
      negative damping components) lead to predictions of the nature of the changes in 
      suppression and synchronization (frequency-locking) tuning curves when the levels 
      of spontaneous otoacoustic emissions are modified. Observations of the 
      suppression and synchronization of spontaneous otoacoustic emissions by external 
      tones of different frequencies and levels were obtained while the levels of 
      spontaneous emissions were altered by aspirin administration. Modeling an 
      emission as a single Van der Pol oscillator qualitatively accounts for: (1) the 
      reduction of the level of an external tone required to suppress the emission by a 
      decibel amount equivalent to the level reduction induced by aspirin 
      administration; (2) the broadening of the frequency-locking tuning curve of an 
      emission whose level is reduced; and (3) the pulling of the emission frequency by 
      an external tone. It does not account for: (1) the observed asymmetry in the 
      slopes of the external-tone suppression curves (more gradual for frequencies of 
      the suppressor tone higher, rather than lower, than that of the emission); and 
      (2) the frequency pushing of the emission by an external tone.
FAU - Long, G R
AU  - Long GR
AD  - Department of Audiology and Speech Sciences, Purdue University, West Lafayette, 
      Indiana 47907.
FAU - Tubis, A
AU  - Tubis A
FAU - Jones, K L
AU  - Jones KL
LA  - eng
GR  - DC 00307/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Acoust Soc Am
JT  - The Journal of the Acoustical Society of America
JID - 7503051
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acoustic Stimulation/*instrumentation
MH  - Acoustics
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Cochlea/drug effects/*physiology
MH  - Female
MH  - Humans
MH  - *Models, Biological
MH  - Oscillometry/instrumentation
EDAT- 1991/03/01 00:00
MHDA- 1991/03/01 00:01
CRDT- 1991/03/01 00:00
PHST- 1991/03/01 00:00 [pubmed]
PHST- 1991/03/01 00:01 [medline]
PHST- 1991/03/01 00:00 [entrez]
AID - 10.1121/1.400651 [doi]
PST - ppublish
SO  - J Acoust Soc Am. 1991 Mar;89(3):1201-12. doi: 10.1121/1.400651.

PMID- 6844122
OWN - NLM
STAT- MEDLINE
DCOM- 19830623
LR  - 20191111
IS  - 0167-6555 (Print)
IS  - 0167-6555 (Linking)
VI  - 5
IP  - 1
DP  - 1983 Feb 25
TI  - Plasma levels of acetylsalicylic acid and salicylic acid after oral ingestion of 
      plain and buffered acetylsalicylic acid in relation to bleeding time and 
      thrombocyte function.
PG  - 22-7
AB  - Buffered acetylsalicylic acid (Alka Seltzer, B-ASA) and plain aspirin (P-ASA) 
      tablets were compared as to their effects on bleeding time and platelet function 
      in eight healthy male volunteers. Two doses (500 and 1000 mg) of each preparation 
      were investigated in a cross-over design, each volunteer being his own control in 
      each dose group (n=4). Both preparations disturbed platelet aggregation to the 
      same extent. Bleeding time increased after both preparations, though 
      significantly more after the buffered preparation than after plain 
      acetylsalicylic acid, irrespective of the dosage. The 1000 mg dose prolonged 
      bleeding time significantly more than the 500 mg dose, irrespective of the 
      preparation. Kinetic analysis showed that B-ASA gave higher peak plasma levels of 
      acetylsalicylic acid (ASA) and accordingly salicylic acid peak levels were also 
      higher after the buffered preparation. It is concluded that B-ASA in 
      equi-analgesic doses prolongs bleeding time more than the plain preparation. 
      Since it is less agressive on the gastro-intestinal mucosa, its use may be 
      advantageous in situations where acetylsalicylic acid induced loss of platelet 
      aggregation is desired. However, the risk of prolonged bleeding--e.g. after tooth 
      extractions--is probably higher after the buffered preparation.
FAU - Proost, J H
AU  - Proost JH
FAU - Van Imhoff, G W
AU  - Van Imhoff GW
FAU - Wesseling, H
AU  - Wesseling H
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Pharm Weekbl Sci
JT  - Pharmaceutisch weekblad. Scientific edition
JID - 7907992
RN  - 0 (Buffers)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*blood/pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation/*drug effects
MH  - Blood Platelets/*drug effects
MH  - Buffers
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests
MH  - Salicylates/*blood
MH  - Salicylic Acid
EDAT- 1983/02/25 00:00
MHDA- 1983/02/25 00:01
CRDT- 1983/02/25 00:00
PHST- 1983/02/25 00:00 [pubmed]
PHST- 1983/02/25 00:01 [medline]
PHST- 1983/02/25 00:00 [entrez]
AID - 10.1007/BF01959647 [doi]
PST - ppublish
SO  - Pharm Weekbl Sci. 1983 Feb 25;5(1):22-7. doi: 10.1007/BF01959647.

PMID- 6500169
OWN - NLM
STAT- MEDLINE
DCOM- 19850110
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 12
IP  - 5
DP  - 1984
TI  - Comparative evaluation of antipyretic activity of ibuprofen and aspirin in 
      children with pyrexia of varied aetiology.
PG  - 292-7
AB  - The antipyretic activity of ibuprofen and aspirin was compared in sixteen 
      children with pyrexia due to upper respiratory tract infection and in twelve with 
      fever due to other causes. All 28 children received ibuprofen (7 mg/kg of 
      body-weight) and aspirin (15 mg/kg of body-weight) in a single dose on 2 
      consecutive days in a crossover manner. Rectal temperature was recorded prior to 
      and at regular intervals up to 8 hours after drug administration. Analysis of the 
      results indicate that ibuprofen and aspirin effectively lower temperature and the 
      two drugs are comparable in their antipyretic activity. In conclusion, 
      significant antipyretic activity, good tolerance profile and availability in 
      syrup form make ibuprofen a useful substitute for aspirin in children with fever.
FAU - Kandoth, P W
AU  - Kandoth PW
FAU - Joshi, M K
AU  - Joshi MK
FAU - Joshi, V R
AU  - Joshi VR
FAU - Satoskar, R S
AU  - Satoskar RS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Child, Preschool
MH  - Female
MH  - Fever/*drug therapy/etiology
MH  - Humans
MH  - Ibuprofen/*therapeutic use
MH  - Male
MH  - Respiratory Tract Infections/complications
MH  - Time Factors
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1177/030006058401200505 [doi]
PST - ppublish
SO  - J Int Med Res. 1984;12(5):292-7. doi: 10.1177/030006058401200505.

PMID- 3548985
OWN - NLM
STAT- MEDLINE
DCOM- 19870427
LR  - 20131121
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 9 Suppl C
DP  - 1986
TI  - Comparison of diflunisal and aspirin in long-term treatment of patients with 
      rheumatoid arthritis.
PG  - 37-46
AB  - A multicenter, open-label clinical trial evaluated the efficacy and tolerability 
      of diflunisal given twice daily and aspirin given four times daily in the 
      long-term treatment of patients with rheumatoid arthritis. Patients who 
      successfully completed a 12-week, double-blind, parallel study comparing 
      diflunisal (500 to 750 mg daily) with aspirin (2.6 to 3.9 gm daily) continued on 
      the same medication in a 40-week, open-label segment of the study. The dosage of 
      diflunisal could be increased to a maximum of 1 gm daily during the open-label 
      phase. Both regimens were effective during the 40-week study. Diflunisal was 
      better tolerated than aspirin as judged by the overall incidence of clinical 
      adverse experiences. Patients treated with diflunisal had significantly fewer 
      adverse experiences involving the digestive system and organs of special sense 
      than did those treated with aspirin.
FAU - Turner, R A
AU  - Turner RA
FAU - Shackleford, R W
AU  - Shackleford RW
FAU - Whipple, J P
AU  - Whipple JP
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Salicylates)
RN  - 7C546U4DEN (Diflunisal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*therapeutic use/toxicity
MH  - Clinical Trials as Topic
MH  - Diflunisal/*therapeutic use/toxicity
MH  - Double-Blind Method
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
MH  - Salicylates/*therapeutic use
MH  - Time Factors
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1986;9 Suppl C:37-46.

PMID- 24496978
OWN - NLM
STAT- MEDLINE
DCOM- 20150810
LR  - 20211021
IS  - 1436-2813 (Electronic)
IS  - 0941-1291 (Linking)
VI  - 44
IP  - 12
DP  - 2014 Dec
TI  - Feasibility of aspirin continuation during the perioperative period for pulmonary 
      resection in lung cancer patients: a retrospective study at a single institute in 
      Japan.
PG  - 2243-8
LID - 10.1007/s00595-014-0843-2 [doi]
AB  - PURPOSE: To evaluate the feasibility of aspirin continuation during the 
      perioperative period for pulmonary resection in lung cancer patients. METHODS: A 
      retrospective study was conducted in 46 patients who were taking aspirin and 
      underwent pulmonary resection. The indications for aspirin were generally a 
      cardiovascular or cerebrovascular comorbidity. Whether to continue or discontinue 
      aspirin was determined based on the severity of the cardiovascular or 
      cerebrovascular comorbidity, along with the patient's overall condition. The 
      intraoperative and postoperative outcomes were compared between patients 
      continuing and those discontinuing aspirin. RESULTS: Twenty patients continued 
      (group C) and 26 patients discontinued (group D) aspirin. The length of the 
      operation (226 ± 97 min in group C vs. 189 ± 90 min in group D), intraoperative 
      bleeding (234 ± 232 vs. 204 ± 367 g) and average pleural discharge on 
      postoperative days 1, 2 and 3 (331, 230 and 215 vs. 304, 210 and 174 ml/day) 
      showed no significant differences between the two groups. The postoperative 
      complication rates were also not significantly different between the two groups 
      [eight patients (40%) in group C vs. nine patients (35%) in group D]. 
      CONCLUSIONS: Continuous administration of aspirin during the perioperative period 
      for pulmonary resection in lung cancer patients appears to be clinically feasible 
      in the Japanese population.
FAU - Kanzaki, Ryu
AU  - Kanzaki R
AD  - Department of General Thoracic Surgery, Osaka University Graduate School of 
      Medicine, L5-2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan, 
      rkanzaki@tj8.so-net.ne.jp.
FAU - Inoue, Masayoshi
AU  - Inoue M
FAU - Minami, Masato
AU  - Minami M
FAU - Shintani, Yasushi
AU  - Shintani Y
FAU - Nakagiri, Tomoyuki
AU  - Nakagiri T
FAU - Funaki, Soichiro
AU  - Funaki S
FAU - Sawabata, Noriyoshi
AU  - Sawabata N
FAU - Okumura, Meinoshin
AU  - Okumura M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20140206
PL  - Japan
TA  - Surg Today
JT  - Surgery today
JID - 9204360
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases
MH  - Cerebrovascular Disorders
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Japan
MH  - Lung Neoplasms/*surgery
MH  - Male
MH  - Middle Aged
MH  - Perioperative Period
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - *Pneumonectomy
MH  - Prognosis
MH  - Retrospective Studies
MH  - Severity of Illness Index
EDAT- 2014/02/06 06:00
MHDA- 2015/08/11 06:00
CRDT- 2014/02/06 06:00
PHST- 2012/07/23 00:00 [received]
PHST- 2013/09/30 00:00 [accepted]
PHST- 2014/02/06 06:00 [entrez]
PHST- 2014/02/06 06:00 [pubmed]
PHST- 2015/08/11 06:00 [medline]
AID - 10.1007/s00595-014-0843-2 [doi]
PST - ppublish
SO  - Surg Today. 2014 Dec;44(12):2243-8. doi: 10.1007/s00595-014-0843-2. Epub 2014 Feb 
      6.

PMID- 19609060
OWN - NLM
STAT- MEDLINE
DCOM- 20091005
LR  - 20220408
IS  - 1347-8613 (Print)
IS  - 1347-8613 (Linking)
VI  - 110
IP  - 3
DP  - 2009 Jul
TI  - Analysis of the mechanism for the development of allergic skin inflammation and 
      the application for its treatment: aspirin modulation of IgE-dependent mast cell 
      activation: role of aspirin-induced exacerbation of immediate allergy.
PG  - 237-44
AB  - Aspirin (acetylsalicylic acid) is a well-known nonsteroidal anti-inflammatory 
      drug that can potentiate some acute allergies and causes adverse immunological 
      reactions collectively referred to as aspirin intolerance, a disorder that 
      induces urticaria, asthma, and anaphylaxis in response to oral administration of 
      the drug. Aspirin also potentiates some acute allergies such as food-dependent 
      exercise-induced anaphylaxis (FDEIA), a food allergy induced by physical 
      exercise. The anti-inflammatory actions as well as the adverse immunological 
      effects have been thought to be primarily due to inhibition of cyclooxygenase 
      activity. However, a growing body of evidence suggests that mechanisms unrelated 
      to inhibition of prostaglandin synthesis are involved. One key feature of aspirin 
      intolerance is the overproductions of cysteinyl leukotrienes (LTs), in which mast 
      cells have been implicated to play a role. In this review, we provide an overview 
      of our current knowledge about the regulatory mechanisms of LTC(4) secretion in 
      mast cells and its modulation by aspirin, with a special emphasis on the role of 
      Ca(2+) signals. We also introduced our recent findings that mast cells express 
      dihydropyridine-sensitive L-type Ca(2+) channels (LTCCs) and that Ca(2+) channels 
      of this kind mediate aspirin modulation of LTC(4) secretion in mast cells.
FAU - Suzuki, Yoshihiro
AU  - Suzuki Y
AD  - Division of Molecular Cell Immunology and Allergology, Nihon University Graduate 
      School of Medical Science, Japan. ysuzuki@med.nihon-u.ac.jp
FAU - Ra, Chisei
AU  - Ra C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Japan
TA  - J Pharmacol Sci
JT  - Journal of pharmacological sciences
JID - 101167001
RN  - 0 (Calcium Channels, L-Type)
RN  - 0 (Inflammation Mediators)
RN  - 2CU6TT9V48 (Leukotriene C4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/pharmacology
MH  - Calcium Channels, L-Type/*physiology
MH  - Dermatitis, Atopic/*etiology
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Inflammation Mediators/pharmacology
MH  - Leukotriene C4/*metabolism
MH  - Mast Cells/immunology/*metabolism
MH  - Models, Immunological
RF  - 25
EDAT- 2009/07/18 09:00
MHDA- 2009/10/06 06:00
CRDT- 2009/07/18 09:00
PHST- 2009/07/18 09:00 [entrez]
PHST- 2009/07/18 09:00 [pubmed]
PHST- 2009/10/06 06:00 [medline]
AID - JST.JSTAGE/jphs/08R32FM [pii]
AID - 10.1254/jphs.08r32fm [doi]
PST - ppublish
SO  - J Pharmacol Sci. 2009 Jul;110(3):237-44. doi: 10.1254/jphs.08r32fm.

PMID- 19300253
OWN - NLM
STAT- MEDLINE
DCOM- 20090805
LR  - 20211117
IS  - 1473-656X (Electronic)
IS  - 1040-872X (Print)
IS  - 1040-872X (Linking)
VI  - 21
IP  - 3
DP  - 2009 Jun
TI  - Effects of low-dose aspirin in in-vitro fertilization.
PG  - 275-8
LID - 10.1097/GCO.0b013e32832a0673 [doi]
AB  - PURPOSE OF REVIEW: In theory, use of aspirin in IVF is based on its 
      anti-inflammatory, vasodilatory, and platelet aggregation inhibition properties, 
      which improve blood flow to a woman's implantation site. It is hypothesized that 
      this effect on blood flow will improve success rates. RECENT FINDINGS: Clinical 
      studies investigating the use of low-dose aspirin (LDA) as an adjuvant therapy to 
      IVF have produced conflicting results. The conflicting results have come as a 
      consequence of the heterogeneous mixture of clinical trials with lack of adequate 
      power. Even after multiple meta-analyses, differing estimates of effect were 
      calculated as to whether aspirin should be used in conjunction with IVF. SUMMARY: 
      Conflicting results leave the question of the effects of LDA in IVF unanswered. 
      More trials are required for analysis to have adequate statistical power and 
      until then the data remain unclear. At this point, there are not enough data to 
      show that aspirin has a beneficial effect on the outcomes of IVF, but absence of 
      effect is not adequate grounds to overturn the current clinical practice for 
      those using LDA in efforts aimed at achieving success with IVF.
FAU - Schisterman, Enrique F
AU  - Schisterman EF
AD  - Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy 
      Shriver National Institute of Child Health and Human Development, Bethesda, 
      Maryland, USA. schistee@mail.nih.gov
FAU - Gaskins, Audrey J
AU  - Gaskins AJ
FAU - Whitcomb, Brian W
AU  - Whitcomb BW
LA  - eng
GR  - T32 DK007703/DK/NIDDK NIH HHS/United States
GR  - Z01 HD008795-01/ImNIH/Intramural NIH HHS/United States
GR  - Z01 HD008795-02/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Review
PL  - England
TA  - Curr Opin Obstet Gynecol
JT  - Current opinion in obstetrics & gynecology
JID - 9007264
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cyclooxygenase Inhibitors/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fertilization in Vitro/*methods
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pregnancy
PMC - PMC2736057
MID - NIHMS121736
EDAT- 2009/03/21 09:00
MHDA- 2009/08/06 09:00
CRDT- 2009/03/21 09:00
PHST- 2009/03/21 09:00 [entrez]
PHST- 2009/03/21 09:00 [pubmed]
PHST- 2009/08/06 09:00 [medline]
AID - 10.1097/GCO.0b013e32832a0673 [doi]
PST - ppublish
SO  - Curr Opin Obstet Gynecol. 2009 Jun;21(3):275-8. doi: 
      10.1097/GCO.0b013e32832a0673.

PMID- 30735979
OWN - NLM
STAT- MEDLINE
DCOM- 20200804
LR  - 20200804
IS  - 1878-0180 (Electronic)
IS  - 1878-0180 (Linking)
VI  - 92
DP  - 2019 Apr
TI  - Tough robust dual responsive nanocomposite hydrogel as controlled drug delivery 
      carrier of asprin.
PG  - 179-187
LID - S1751-6161(18)31251-7 [pii]
LID - 10.1016/j.jmbbm.2019.01.017 [doi]
AB  - Smart mechanical strong hydrogels have gained increasing attention in the last 
      decade. A novel tough robust biocompatible and dual pH- and temperature- 
      responsive poly (N-isopropylacrylamide)/clay (Laponite XLS)/gold nanoparticles 
      (Au-S-S NPs)/caboxymethyl chitosan (CMCTs) nanocomposite hydrogel was synthesized 
      by a facile one-pot in situ free radical polymerization, using clay and Au-S-S 
      NPs as the cross-linkers instead of toxic organic molecules. By tuning the 
      crucial factors, concentration of Au-S-S NPs, CMCTs and clay, the obtained 
      hydrogels exhibited the highest tensile stress of 535.5 kPa at the breaking 
      deformation of 1579.5%. Furthermore, these synthesized hydrogels were tough 
      enough and simultaneously owned a fast recoverability after unloaded in 15 min at 
      room temperature. Moreover, effects of the above factors on swelling and 
      swelling-shrinking behaviors of the prepared hydrogels were investigated in 
      detail. In addition, these designed hydrogels also possessed a controlled drug 
      release property of asprin by adjusting their inner crosslink density. Owing to 
      this property, they could be used as the potential drug delivery carriers in 
      future.
CI  - Copyright © 2019. Published by Elsevier Ltd.
FAU - Chen, Yang
AU  - Chen Y
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China.
FAU - Kang, Shuai
AU  - Kang S
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China.
FAU - Yu, Junrong
AU  - Yu J
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China. Electronic address: yjr@dhu.edu.cn.
FAU - Wang, Yan
AU  - Wang Y
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China.
FAU - Zhu, Jing
AU  - Zhu J
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China.
FAU - Hu, Zuming
AU  - Hu Z
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190130
PL  - Netherlands
TA  - J Mech Behav Biomed Mater
JT  - Journal of the mechanical behavior of biomedical materials
JID - 101322406
RN  - 0 (Drug Carriers)
RN  - 0 (Hydrogels)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Drug Carriers/*chemistry
MH  - Drug Liberation
MH  - Hydrogels/*chemistry
MH  - Mechanical Phenomena
MH  - Nanocomposites/*chemistry
OTO - NOTNLM
OT  - Biocompatible
OT  - Carboxymethyl chitosan
OT  - Drug delivery carriers
OT  - Hydrogel
OT  - Robust
EDAT- 2019/02/09 06:00
MHDA- 2020/08/05 06:00
CRDT- 2019/02/09 06:00
PHST- 2018/08/28 00:00 [received]
PHST- 2019/01/14 00:00 [revised]
PHST- 2019/01/17 00:00 [accepted]
PHST- 2019/02/09 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
PHST- 2019/02/09 06:00 [entrez]
AID - S1751-6161(18)31251-7 [pii]
AID - 10.1016/j.jmbbm.2019.01.017 [doi]
PST - ppublish
SO  - J Mech Behav Biomed Mater. 2019 Apr;92:179-187. doi: 10.1016/j.jmbbm.2019.01.017. 
      Epub 2019 Jan 30.

PMID- 31076895
OWN - NLM
STAT- MEDLINE
DCOM- 20200210
LR  - 20210109
IS  - 1435-5604 (Electronic)
IS  - 0914-8779 (Linking)
VI  - 37
IP  - 6
DP  - 2019 Nov
TI  - Local administration of aspirin with β-tricalcium 
      phosphate/poly-lactic-co-glycolic acid (β-TCP/PLGA) could enhance osteoporotic 
      bone regeneration.
PG  - 1026-1035
LID - 10.1007/s00774-019-01008-w [doi]
AB  - Composite materials β-tricalcium phosphate (β-TCP) and poly-lactic-co-glycolic 
      acid (PLGA) have achieved stable bone regeneration without cell transplantation 
      in previous studies. Recent research shows that aspirin (ASP) has great potential 
      in promoting bone regeneration. The objective of the present study was to 
      incorporate PLGA into β-TCP combined with a lower single-dose local 
      administration of ASP to enhance its in vivo biodegradation and bone tissue 
      growth. After the creation of a rodent critical-sized femoral metaphyseal bone 
      defect, PLGA -modified β-TCP (TP) was prepared by mixing sieved granules of β-TCP 
      and PLGA (50:50, v/v) for medical use, then TP with dripped 50 µg/0.1 ml and 
      100 µg/0.1 ml aspirin solution was implanted into the defect of OVX rats until 
      death at 8 weeks. The defected area in distal femurs of rats was harvested for 
      evaluation by histology, micro-CT, biomechanics and real time RT-PCR. The results 
      of our study show that a single-dose local administration of ASP combined with 
      the local usage of TP can increase the healing of defects in OVX rats. 
      Single-dose local administration of aspirin can improve the transcription of 
      genes involved in the regulation of bone formation and vascularization in the 
      defect area, and inhibits osteoclast activity. Furthermore, treatments with a 
      higher single-dose local administration of ASP and TP showed a stronger effect on 
      accelerating the local bone formation than while using a lower dose of ASP. The 
      results from our study demonstrate that the combination of a single-dose local 
      administration of ASP and β-TCP/PLGA had an additive effect on local bone 
      formation in osteoporosis rats, and bone regeneration by PLGA/β-TCP/ASP occured 
      in a dose-dependent manner.
FAU - Tao, Zhou-Shan
AU  - Tao ZS
AD  - Department of Trauma Orthopedics, The First Affiliated Hospital of Wannan Medical 
      College, Yijishan Hospital, No. 2, Zhe shan Xi Road, Wuhu, 241001, Anhui, 
      People's Republic of China.
FAU - Wu, Xing-Jing
AU  - Wu XJ
AD  - Department of Trauma Orthopedics, The First Affiliated Hospital of Wannan Medical 
      College, Yijishan Hospital, No. 2, Zhe shan Xi Road, Wuhu, 241001, Anhui, 
      People's Republic of China.
FAU - Zhou, Wan-Shu
AU  - Zhou WS
AD  - Department of Geriatrics, The Second Affiliated Hospital of Wannan Medical 
      College, No. 123, Kangfu Road, Wuhu, 241000, Anhui, People's Republic of China.
FAU - Wu, Xin-Ju
AU  - Wu XJ
AD  - Department of Trauma Orthopedics, The First Affiliated Hospital of Wannan Medical 
      College, Yijishan Hospital, No. 2, Zhe shan Xi Road, Wuhu, 241001, Anhui, 
      People's Republic of China.
FAU - Liao, Wei
AU  - Liao W
AD  - Department of Orthopedics, Children's Hospital of Nanjing Medical University, No. 
      8, Jiangdong South Road, Jianye District, Nanjing, People's Republic of China.
FAU - Yang, Min
AU  - Yang M
AD  - Department of Trauma Orthopedics, The First Affiliated Hospital of Wannan Medical 
      College, Yijishan Hospital, No. 2, Zhe shan Xi Road, Wuhu, 241001, Anhui, 
      People's Republic of China. tzs19900327@yeah.net.
FAU - Xu, Hong-Guang
AU  - Xu HG
AD  - Department of Trauma Orthopedics, The First Affiliated Hospital of Wannan Medical 
      College, Yijishan Hospital, No. 2, Zhe shan Xi Road, Wuhu, 241001, Anhui, 
      People's Republic of China. wnyxyyjsyy2437@126.com.
AD  - Department of Spinal Orthopedics, The First Affiliated Hospital of Wannan Medical 
      College, Yijishan Hospital, No. 2, Zhe shan Xi Road, Wuhu, 241001, Anhui, 
      People's Republic of China. wnyxyyjsyy2437@126.com.
FAU - Yang, Lei
AU  - Yang L
AD  - Department of Orthopaedics Surgery, The Second Affiliated Hospital and Yuying 
      Children's Hospital of Wenzhou Medical University, No. 109, Xueyuan West Road, 
      Lucheng District, Wenzhou, 325000, Zhejiang, People's Republic of China.
LA  - eng
GR  - KJ2017A266/University Natural Science Research Project of Anhui Province (CN)/
GR  - 81772348/National Natural Science Foundation of China/
GR  - 20191211/GaoFeng research project of the First Affiliated Hospital of Wannan 
      Medical College, Yijishan Hospital/
PT  - Journal Article
DEP - 20190510
PL  - Japan
TA  - J Bone Miner Metab
JT  - Journal of bone and mineral metabolism
JID - 9436705
RN  - 0 (Biomarkers)
RN  - 0 (Calcium Phosphates)
RN  - 0 (RNA, Messenger)
RN  - 0 (beta-tricalcium phosphate)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology/*therapeutic use
MH  - Biomarkers/metabolism
MH  - Biomechanical Phenomena
MH  - *Bone Regeneration/drug effects
MH  - Calcium Phosphates/*administration & dosage
MH  - Disease Models, Animal
MH  - Female
MH  - Femur/diagnostic imaging/drug effects
MH  - Neovascularization, Physiologic/drug effects
MH  - Osteogenesis/drug effects
MH  - Osteoporosis/diagnostic imaging/*drug therapy
MH  - Ovariectomy
MH  - Polylactic Acid-Polyglycolic Acid Copolymer/*administration & dosage
MH  - RNA, Messenger/genetics/metabolism
MH  - Rats, Sprague-Dawley
MH  - X-Ray Microtomography
OTO - NOTNLM
OT  - Aspirin
OT  - Osteoporotic bone defect
OT  - Poly-lactic-co-glycolic acid
OT  - Regeneration
OT  - β-Tricalcium phosphate
EDAT- 2019/05/12 06:00
MHDA- 2020/02/11 06:00
CRDT- 2019/05/12 06:00
PHST- 2018/12/24 00:00 [received]
PHST- 2019/04/22 00:00 [accepted]
PHST- 2019/05/12 06:00 [pubmed]
PHST- 2020/02/11 06:00 [medline]
PHST- 2019/05/12 06:00 [entrez]
AID - 10.1007/s00774-019-01008-w [pii]
AID - 10.1007/s00774-019-01008-w [doi]
PST - ppublish
SO  - J Bone Miner Metab. 2019 Nov;37(6):1026-1035. doi: 10.1007/s00774-019-01008-w. 
      Epub 2019 May 10.

PMID- 37280092
OWN - NLM
STAT- MEDLINE
DCOM- 20230719
LR  - 20230719
IS  - 1521-0103 (Electronic)
IS  - 0022-3565 (Linking)
VI  - 386
IP  - 2
DP  - 2023 Aug
TI  - Cyclooxygenase Inhibitors and Cancer: The Missing Pieces.
PG  - 181-189
LID - 10.1124/jpet.122.001631 [doi]
AB  - At 125, aspirin still represents the cornerstone of anti-platelet therapy for the 
      acute treatment and long-term prevention of atherothrombosis. The development of 
      a selective regimen of low-dose aspirin for the inhibition of platelet 
      thromboxane production was key to maximizing its antithrombotic efficacy and 
      minimizing its gastrointestinal toxicity. Based on about 50 observational 
      studies, published over the past 30 years, aspirin and other cyclooxygenase 
      inhibitors have been associated with a reduced risk of colorectal cancer, and 
      possibly other digestive tract cancers. The apparent chemopreventive effect of 
      aspirin has been confirmed in post-hoc analyses of randomized cardiovascular 
      trials and their meta-analyses. Moreover, prevention of sporadic colorectal 
      adenoma recurrence was demonstrated by randomized controlled trials of low-dose 
      aspirin and selective cyclooxygenase-2 inhibitors. A single placebo-controlled 
      randomized trial of aspirin has shown long-term colorectal cancer prevention in 
      patients with the Lynch syndrome. The sequential involvement of 
      thromboxane-dependent platelet activation and cyclooxygenase-2-driven 
      inflammatory response in the early stages of colorectal carcinogenesis may 
      explain these clinical benefits. The aim of this mini-review is to analyze the 
      existing evidence for a chemopreventive effect of aspirin and other 
      cyclooxygenase inhibitors and discuss the missing pieces of this mechanistic and 
      clinical puzzle. SIGNIFICANCE STATEMENT: Low-dose aspirin and other 
      cyclooxygenase inhibitors have been associated with a reduced risk of colorectal 
      cancer, and possibly other digestive tract cancers. The sequential involvement of 
      thromboxane-dependent platelet activation and cyclooxygenase-2-driven 
      inflammatory response in the early stages of colorectal carcinogenesis may 
      explain these clinical benefits. The aim of this mini-review is to analyze the 
      evidence for a chemopreventive effect of aspirin and other cyclooxygenase 
      inhibitors and discuss the missing pieces of this mechanistic and clinical 
      puzzle.
CI  - Copyright © 2023 by The American Society for Pharmacology and Experimental 
      Therapeutics.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy 
      carlo.patrono@unicatt.it.
LA  - eng
GR  - CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230606
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Thromboxanes)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - Cyclooxygenase 2
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cyclooxygenase 2 Inhibitors/pharmacology/therapeutic use
MH  - *Colorectal Neoplasms/drug therapy/prevention & control
MH  - *Gastrointestinal Neoplasms/drug therapy
MH  - Thromboxanes
MH  - Carcinogenesis
MH  - Cyclooxygenase 1
MH  - Platelet Aggregation Inhibitors
MH  - Randomized Controlled Trials as Topic
EDAT- 2023/06/07 01:07
MHDA- 2023/07/19 06:42
CRDT- 2023/06/06 21:22
PHST- 2022/12/16 00:00 [received]
PHST- 2023/05/17 00:00 [accepted]
PHST- 2023/07/19 06:42 [medline]
PHST- 2023/06/07 01:07 [pubmed]
PHST- 2023/06/06 21:22 [entrez]
AID - jpet.122.001631 [pii]
AID - 10.1124/jpet.122.001631 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2023 Aug;386(2):181-189. doi: 10.1124/jpet.122.001631. Epub 
      2023 Jun 6.

PMID- 11736865
OWN - NLM
STAT- MEDLINE
DCOM- 20020306
LR  - 20190513
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 52
IP  - 5
DP  - 2001 Nov
TI  - Association between aspirin and upper gastrointestinal complications: systematic 
      review of epidemiologic studies.
PG  - 563-71
AB  - AIMS: Because of the widespread use of aspirin for prevention of cardiovascular 
      diseases, side-effects associated with thromboprophylactic doses are of interest. 
      This study summarizes the relative risk (RR) for serious upper gastrointestinal 
      complications (UGIC) associated with aspirin exposure in general and with 
      specific aspirin doses and formulations in particular. METHODS: After a 
      systematic review, 17 original epidemiologic studies published between 1990 and 
      2001 were selected according to predefined criteria. Heterogeneity of effects was 
      explored. Pooled estimates were calculated according to different study 
      characteristics and patterns of aspirin use. RESULTS: The overall relative risk 
      of UGIC associated with aspirin use was 2.2 (95% confidence interval (CI): 2.1, 
      2.4) for cohort studies and nested case-control studies and 3.1 (95% CI: 2.8, 
      3.3) for non-nested case-control studies. Original studies found a dose-response 
      relationship between UGIC and aspirin, although the risk was still elevated for 
      doses lower or up to 300 mg day(-1). The summary RR was 2.6 (95% CI: 2.3, 2.9) 
      for plain, 5.3 (95% CI: 3.0, 9.2) for buffered, and 2.4 (95% CI: 1.9, 2.9) for 
      enteric-coated aspirin formulations. CONCLUSIONS: Aspirin was associated with 
      UGIC even when used at low doses or in buffered or enteric-coated formulations. 
      The latter findings may be partially explained by channeling of susceptible 
      patients to these formulations.
FAU - García Rodríguez, L A
AU  - García Rodríguez LA
AD  - Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain. 
      lagarcia@ceife.es
FAU - Hernández-Díaz, S
AU  - Hernández-Díaz S
FAU - de Abajo, F J
AU  - de Abajo FJ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Diseases/*chemically induced/epidemiology
MH  - Humans
MH  - Risk Assessment
PMC - PMC2014603
EDAT- 2001/12/12 10:00
MHDA- 2002/03/07 10:01
CRDT- 2001/12/12 10:00
PHST- 2001/12/12 10:00 [pubmed]
PHST- 2002/03/07 10:01 [medline]
PHST- 2001/12/12 10:00 [entrez]
AID - 1476 [pii]
AID - 10.1046/j.0306-5251.2001.01476.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2001 Nov;52(5):563-71. doi: 
      10.1046/j.0306-5251.2001.01476.x.

PMID- 7263462
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20131121
IS  - 0003-1488 (Print)
IS  - 0003-1488 (Linking)
VI  - 178
IP  - 6
DP  - 1981 Mar 15
TI  - Effect of aspirin on aqueous protein values in the dog.
PG  - 572-3
AB  - Aqueous protein concentration, degree of miosis, and intraocular pressure were 
      evaluated in dogs given aspirin, then subjected to aqueous paracentesis and 
      reverse cyclodialysis. Compared with control dogs, the dogs given aspirin had 
      less aqueous protein, but there was no difference in miosis or in intraocular 
      pressure. The practical application of this finding is that aspirin given prior 
      to intraocular surgery may be of value in minimizing the postoperative increase 
      in aqueous protein content.
FAU - Brightman, A H 2nd
AU  - Brightman AH 2nd
FAU - Helper, L C
AU  - Helper LC
FAU - Hoffman, W E
AU  - Hoffman WE
LA  - eng
GR  - 5-SO 7RR 05460-17/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Am Vet Med Assoc
JT  - Journal of the American Veterinary Medical Association
JID - 7503067
RN  - 0 (Blood Proteins)
RN  - 0 (Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aqueous Humor/*analysis
MH  - Aspirin/*pharmacology
MH  - Blood Proteins/analysis
MH  - Dogs/*surgery
MH  - Intraocular Pressure
MH  - *Ophthalmologic Surgical Procedures
MH  - Proteins/*analysis
EDAT- 1981/03/15 00:00
MHDA- 1981/03/15 00:01
CRDT- 1981/03/15 00:00
PHST- 1981/03/15 00:00 [pubmed]
PHST- 1981/03/15 00:01 [medline]
PHST- 1981/03/15 00:00 [entrez]
PST - ppublish
SO  - J Am Vet Med Assoc. 1981 Mar 15;178(6):572-3.

PMID- 3350330
OWN - NLM
STAT- MEDLINE
DCOM- 19880512
LR  - 20190824
IS  - 0306-3623 (Print)
IS  - 0306-3623 (Linking)
VI  - 19
IP  - 2
DP  - 1988
TI  - Effect of low-dose aspirin treatment on human platelet aggregation.
PG  - 195-9
AB  - 1. The effect of aspirin 50 mg/day during 28 days on human platelet aggregation 
      (PAG) induced by ADP and collagen has been studied in 12 healthy volunteers. 2. 
      The results show that aspirin treatment reduces both ADP and collagen-induced PAG 
      (P less than 0.01). 3. Maximal inhibition of PAG appears in the second week of 
      treatment for ADP-induced PAG (41.1%) and in the fourth week for collagen-induced 
      PAG (50.2%). No significant differences exist between the controls taken along 
      the treatment during the 28 days of the study. 4. The data suggest that the 
      low-dose of aspirin tested provides adequate PAG inhibition to be used in the 
      prophylaxis of thromboembolism patients, thus avoiding intolerances to higher 
      dosages.
FAU - Hevia, A
AU  - Hevia A
AD  - Departamento de Farmacología y Terapeútica, Facultad de Medicina, Hospital 
      Universitario, Sevilla, Spain.
FAU - Serrano, J S
AU  - Serrano JS
FAU - Gago, J
AU  - Gago J
FAU - Reche, A
AU  - Reche A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gen Pharmacol
JT  - General pharmacology
JID - 7602417
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Collagen/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 0306-3623(88)90060-2 [pii]
AID - 10.1016/0306-3623(88)90060-2 [doi]
PST - ppublish
SO  - Gen Pharmacol. 1988;19(2):195-9. doi: 10.1016/0306-3623(88)90060-2.

PMID- 34488373
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20210908
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 10
IP  - 8
DP  - 2021 Aug
TI  - Clinical efficacy of aspirin combination treatment in the treatment of coronary 
      heart disease and its effect on inflammatory factors: a systematic review and 
      meta-analysis.
PG  - 8858-8868
LID - 10.21037/apm-21-1648 [doi]
AB  - BACKGROUND: As the mainstay treatment for coronary heart disease (CHD), aspirin 
      alone is reported to be less effective than in combination when treating CHD. The 
      aim of this analysis was to systematically evaluate the efficacy and safety of 
      aspirin in combination with other drugs for the treatment of CHD, as well as its 
      effect on the levels of inflammatory factors. METHODS: Electronic databases were 
      searched from 2011 to 2021 and randomized controlled trials (RCTs) on aspirin in 
      CHD patients were included in our study. Data was statistically analyzed using 
      Stata 16.0 (StataCorp). RESULTS: A total of 13 RCTs were included, with a total 
      of 1,442 patients. Compared with control group (aspirin alone) group, the 
      response rate in the treatment group (aspirin in combination with other drugs) 
      was significantly improved [odds ratio (OR) =5.11; 95% confidence interval (CI): 
      3.56-7.35], while the incidence of adverse reactions was markedly decreased (OR 
      =0.36; 95% CI: 0.25-0.53). Before treatment, no significant differences were 
      identified in the levels of inflammatory factors between the groups The 
      inflammatory factors included C-reactive protein (CRP), interleukin-6 (IL-6), and 
      tumor necrosis factor-α (TNF-α). After treatment, CRP and TNF-α levels were 
      significantly lower in both groups compared with those before treatment. However, 
      there was no statistically significant difference in IL-6 levels after treatment 
      between the groups. DISCUSSION: Aspirin is effective in the treatment of CHD, 
      both alone and in combination. However, the latter has higher clinical efficacy 
      and safety, and can significantly reduce the level of inflammatory factors in CHD 
      patients.
FAU - Mao, Ping
AU  - Mao P
AD  - Department of Cardiovascular Diseases, Zhejiang Hospital, Hangzhou, China.
FAU - Liu, Xiaowei
AU  - Liu X
AD  - Department of Cardiovascular Diseases, Zhejiang Hospital, Hangzhou, China.
FAU - Weng, Yingzheng
AU  - Weng Y
AD  - Department of Cardiovascular Diseases, Zhejiang Hospital, Hangzhou, China.
FAU - Tang, Lijiang
AU  - Tang L
AD  - Department of Cardiovascular Diseases, Zhejiang Hospital, Hangzhou, China.
FAU - Tang, Yimin
AU  - Tang Y
AD  - Department of Cardiovascular Diseases, Zhejiang Hospital, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - C-Reactive Protein
MH  - *Coronary Disease/drug therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha
OTO - NOTNLM
OT  - Aspirin
OT  - clinical effect
OT  - coronary heart disease (CHD)
OT  - inflammatory factors
OT  - meta-analysis
EDAT- 2021/09/08 06:00
MHDA- 2021/09/09 06:00
CRDT- 2021/09/07 05:44
PHST- 2021/05/27 00:00 [received]
PHST- 2021/07/26 00:00 [accepted]
PHST- 2021/09/07 05:44 [entrez]
PHST- 2021/09/08 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
AID - 10.21037/apm-21-1648 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2021 Aug;10(8):8858-8868. doi: 10.21037/apm-21-1648.

PMID- 33571026
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1557-7708 (Electronic)
IS  - 1075-5535 (Print)
IS  - 1075-5535 (Linking)
VI  - 27
IP  - 4
DP  - 2021 Apr
TI  - Cost-Effectiveness Analysis of Ginkgolide Injection in the Treatment of Ischemic 
      Stroke Based on a Randomized Clinical Trial.
PG  - 331-341
LID - 10.1089/acm.2020.0455 [doi]
AB  - Objective: To evaluate the long-term cost-effectiveness of ginkgolide plus 
      aspirin compared with placebo plus aspirin treatment of ischemic stroke. 
      Background: Stroke is the leading cause of death and long-term disability in 
      China, with high incidence, high mortality, and heavy disease burden. In addition 
      to Western medicines, Chinese clinical guidelines for diagnosis and treatment of 
      acute ischemic stroke recommend application of Chinese patent medicines. 
      Ginkgolide injection is commonly used in the clinical treatment of stroke in 
      China to promote blood circulation and remove blood stasis. The economy of 
      ginkgolide injection needs to be evaluated. Methods: A Markov model was 
      constructed consisting of four disease states: no significant disability, 
      disability, stroke recurrence, and death. Therapeutic data were taken from the 
      Ginkgolide in Ischemic Stroke Patients with Large Artery Atherosclerosis (GISAA) 
      study. Utilities and transition probabilities were extracted from the literature. 
      Cost data were obtained from the China Health Statistics Yearbook and hospital 
      record survey. Expected costs and quality-adjusted life-years (QALYs) of 13 years 
      of cycles (calculated by average age of subjects and Chinese life expectancy) 
      were calculated through TreeAge Pro11 software. The willingness-to-pay (WTP) 
      threshold was set as the Chinese per capita Gross Domestic Product (GDP) in 2019, 
      CN¥70,892/QALY. The results were analyzed by single factor and probability 
      sensitivity analyses. Results: Ginkgolide plus aspirin had a higher expected 
      per-patient cost than placebo plus aspirin but a higher QALYs. Compared with 
      placebo plus aspirin, ginkgolide plus aspirin produced an incremental 
      cost-effectiveness ratio of CN¥14,866.06/QALY, which is below the WTP threshold. 
      Probabilistic sensitivity analysis suggested the acceptability of ginkgolide plus 
      aspirin was higher than that of placebo plus aspirin. Conclusions: The present 
      cost-effectiveness analysis showed that addition of ginkgolides to conventional 
      treatment is cost-effective at a threshold the Chinese per capita GDP.
FAU - Xiang, Yuliang
AU  - Xiang Y
AD  - Pharmaceutical Policy and Pharmacoeconomics Research Center, Sichuan University 
      West China School of Pharmacy, Chengdu, China.
FAU - Yang, Nan
AU  - Yang N
AD  - Pharmaceutical Policy and Pharmacoeconomics Research Center, Sichuan University 
      West China School of Pharmacy, Chengdu, China.
FAU - Guo, Zhaoting
AU  - Guo Z
AD  - Pharmaceutical Policy and Pharmacoeconomics Research Center, Sichuan University 
      West China School of Pharmacy, Chengdu, China.
FAU - Zhou, Li
AU  - Zhou L
AD  - Pharmaceutical Policy and Pharmacoeconomics Research Center, Sichuan University 
      West China School of Pharmacy, Chengdu, China.
FAU - Guo, Jeff Jianfei
AU  - Guo JJ
AD  - Division of Pharmacy Practice and Administrative Sciences, College of Pharmacy, 
      University of Cincinnati Medical Center, Cincinnati, OH, USA.
FAU - Hu, Ming
AU  - Hu M
AD  - Pharmaceutical Policy and Pharmacoeconomics Research Center, Sichuan University 
      West China School of Pharmacy, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20210210
PL  - United States
TA  - J Altern Complement Med
JT  - Journal of alternative and complementary medicine (New York, N.Y.)
JID - 9508124
RN  - 0 (Ginkgolides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/economics/therapeutic use
MH  - *Cost-Benefit Analysis
MH  - *Ginkgolides/economics/therapeutic use
MH  - Humans
MH  - *Ischemic Stroke/drug therapy/economics/mortality
MH  - Markov Chains
MH  - Prospective Studies
MH  - Quality-Adjusted Life Years
MH  - Randomized Controlled Trials as Topic
PMC - PMC8064937
OTO - NOTNLM
OT  - Markov model
OT  - cost-effectiveness analysis
OT  - ginkgolides
OT  - quality-adjusted life-years
OT  - stroke
COIS- There are no competing interests for any author.
EDAT- 2021/02/12 06:00
MHDA- 2021/05/04 06:00
CRDT- 2021/02/11 17:12
PHST- 2021/02/12 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PHST- 2021/02/11 17:12 [entrez]
AID - 10.1089/acm.2020.0455 [pii]
AID - 10.1089/acm.2020.0455 [doi]
PST - ppublish
SO  - J Altern Complement Med. 2021 Apr;27(4):331-341. doi: 10.1089/acm.2020.0455. Epub 
      2021 Feb 10.

PMID- 16647012
OWN - NLM
STAT- MEDLINE
DCOM- 20100105
LR  - 20131121
IS  - 1003-0603 (Print)
IS  - 1003-0603 (Linking)
VI  - 18
IP  - 4
DP  - 2006 Apr
TI  - [Aspirin resistance in patients taking small dose of aspirin].
PG  - 219-23
AB  - OBJECTIVE: To investigate the phenomenon and influencing factors of aspirin 
      resistance (AR) in patients taking small dose of aspirin. METHODS: Three hundred 
      and twenty-eight patients with stable cardiac and cerebral vascular diseases, 
      diabetes mellitus, et al taking aspirin 100 mg/d for > or =14 days, and then 
      their blood samples were collected for determination of optical platelet 
      aggregation index using arachidonic acid (AA) and adenosine diphosphate (ADP). AR 
      was defined as a state in which aggregation of > or =20% with AA and that > or 
      =70% with ADP was found. Aspirin semi-resistance (ASR) was defined as meeting one 
      of the above criteria. If both above criteria were not met, the condition was 
      defined as aspirin sensitive. The difference in clinical characteristics among 
      the groups and independent risk factors associated with AR and ASR were analyzed. 
      RESULTS: Of 328 patients, 4.9% were AR, 27.4% were ASR. Among AR+ASR group, 
      female, elderly, diabetic and hypertensive patients were predominant, but less 
      common in smokers. Logistic regression analysis showed that diabetes mellitus was 
      an independent risk factor of AR and ASR [odds ratio (OR)=0.953, 95% confidence 
      interval (CI) 0.323-0.876, P=0.013], and hypertension was independently 
      associated with AR and ASR (OR=0.610, 95%CI 0.376-0.991, P=0.046). The risk of AR 
      and ASR was increased in non-smokers (OR=2.231, 95%CI 1.182-4.210, P=0.013). 
      CONCLUSION: The incidence rate of AR in patients taking small dose of aspirin was 
      4.9%. Diabetes mellitus and hypertension are relative risk factors of AR and ASR. 
      The risk of AR and ASR in the no-smoking patients is increased.
FAU - Wang, Chun-bo
AU  - Wang CB
AD  - Cardiovascular Center, Beijing Tongren Hospital, Affiliated Hospital of Capital 
      University of Medicine Sciences, Beijing 100730, China. bzcat@263.net
FAU - Hu, Da-yi
AU  - Hu DY
FAU - Shi, Xu-bo
AU  - Shi XB
FAU - Zhu, Zheng-yan
AU  - Zhu ZY
FAU - Zhu, Jing-yan
AU  - Zhu JY
FAU - Yang, Jin-gang
AU  - Yang JG
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
JT  - Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo 
      weizhongbing jijiuyixue
JID - 9887521
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/blood/drug therapy
MH  - Cerebrovascular Disorders/blood/drug therapy
MH  - Dose-Response Relationship, Drug
MH  - *Drug Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Risk Factors
EDAT- 2006/05/02 09:00
MHDA- 2010/01/06 06:00
CRDT- 2006/05/02 09:00
PHST- 2006/05/02 09:00 [pubmed]
PHST- 2010/01/06 06:00 [medline]
PHST- 2006/05/02 09:00 [entrez]
PST - ppublish
SO  - Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006 Apr;18(4):219-23.

PMID- 14677790
OWN - NLM
STAT- MEDLINE
DCOM- 20040105
LR  - 20190917
IS  - 0731-3810 (Print)
IS  - 0731-3810 (Linking)
VI  - 41
IP  - 6
DP  - 2003
TI  - Randomized controlled trial of topical aspirin in the treatment of bee and wasp 
      stings.
PG  - 801-8
AB  - BACKGROUND: The New South Wales Poisons Information Centre (NSW PIC) has been 
      recommending the use of topical aspirin paste for bee and wasp stings since the 
      early 1980s. Anecdotal evidence from calls suggested it was effective in reducing 
      the swelling and duration of pain, but a literature search found no evidence to 
      support this. OBJECTIVE: The objective of this study was to assess the 
      effectiveness of advice given by a PIC to apply topical aspirin for the treatment 
      of bee and wasp stings. METHODS: Patients were recruited from callers to the NSW 
      PIC who reported a bee or wasp sting. They were randomly assigned, using a 2:1 
      ratio, to two different treatment advices: to apply an ice pack (control group), 
      or to apply an ice pack and topical aspirin paste (treatment group). Initial 
      follow-up was within 24-48 hours. Primary outcome was the presence of swelling at 
      12 hr. Secondary outcomes included the presence of pain at 12 hr, the presence of 
      itchiness, and duration of redness. RESULTS: There were 37 patients who received 
      treatment advice and 19 in the control group. Of the 37 patients advised to apply 
      aspirin, 21 (57%) had no swelling at 12 hr compared with 14 of the 19 (74%) 
      patients with ice alone (difference -17%; 95% CI: -47-12%; p = 0.26). Eighty-one 
      percent (30/37) of patients advised to apply aspirin had no pain at 12 hr 
      compared with (18/19) 95% of the others (-14%; 95% CI: -39-14%; p = 0.34). The 
      median duration of redness was 6 hr [interquartile range (IQR): 2-48 hr] in those 
      advised to apply aspirin paste compared with 2 hr (IQR: 0-10 hr) in those that 
      only applied ice (p = 0.04). CONCLUSIONS: Topical aspirin paste was not effective 
      in reducing the duration of swelling or pain in bee and wasp stings, and 
      significantly increased the duration of redness. Symptoms rapidly subsided with 
      ice alone as treatment.
FAU - Balit, Corrine R
AU  - Balit CR
AD  - NSW Poisons Information Centre, The Children's Hospital Westmead, Westmead, 
      Australia. corrinebalit@aol.com
FAU - Isbister, Geoffrey K
AU  - Isbister GK
FAU - Buckley, Nicholas A
AU  - Buckley NA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Toxicol Clin Toxicol
JT  - Journal of toxicology. Clinical toxicology
JID - 8213460
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Topical
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*therapeutic use
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Australia
MH  - *Bees
MH  - Child
MH  - Female
MH  - Humans
MH  - Insect Bites and Stings/*drug therapy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Poison Control Centers
MH  - Treatment Outcome
MH  - *Wasps
EDAT- 2003/12/18 05:00
MHDA- 2004/01/06 05:00
CRDT- 2003/12/18 05:00
PHST- 2003/12/18 05:00 [pubmed]
PHST- 2004/01/06 05:00 [medline]
PHST- 2003/12/18 05:00 [entrez]
AID - 10.1081/clt-120025345 [doi]
PST - ppublish
SO  - J Toxicol Clin Toxicol. 2003;41(6):801-8. doi: 10.1081/clt-120025345.

PMID- 17017929
OWN - NLM
STAT- MEDLINE
DCOM- 20061204
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 12
IP  - 26
DP  - 2006
TI  - Hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs 
      (NSAIDs).
PG  - 3347-58
AB  - Hypersensitivity to aspirin and other non steroidal anti-inflammatory drugs 
      (NSAIDs) manifesting in the airways (rhinosinusitis, polyps, asthma) or in the 
      skin (urticaria, angioedema) is the second most frequent untoward allergic 
      reaction to drugs. Various aspects of this syndrome, such as its clinical 
      features, the cell types and mediators involved, the role of underlying chronic 
      inflammatory processes, the patterns of cross-reactivity between NSAIDs, the 
      major role of sulfidoleukotrienes (LTC4) and of some other mediators such as 
      prostaglandin E2 (PGE2) and C5a are briefly reviewed. It has been assumed for a 
      long time that there were no reliable in vitro tests for that condition and that 
      diagnostic confirmation can only be ascertained by provocation challenge. This 
      appears no longer to be true, since several recent studies using a leukotriene 
      release test (CAST) or a basophil activation test (BAT) on blood basophils, or a 
      combination of both tests, yields positive results (70-75%) in a sizeable number 
      of clinically validated cases, with a high specificity (above 85%). The finding 
      in that syndrome of hyperreactive basophils suggests that the NSAID 
      hypersensitivity syndrome is due to the associated effect of several factors: 1) 
      Localized inflammatory processes causing a non specific cellular hyperreactivity; 
      2) An abnormal pharmacogenetic reaction to NSAIDs resulting in a hyperproduction 
      of LTC4 and other mediators by activated mast cells, basophils and eosinophils.
FAU - de Weck, A L
AU  - de Weck AL
AD  - Department of Allergology and Clinical Immunology, University Clinic of Navarra, 
      Apartado 4209, 31080 Pamplona, Spain.
FAU - Gamboa, P M
AU  - Gamboa PM
FAU - Esparza, R
AU  - Esparza R
FAU - Sanz, M L
AU  - Sanz ML
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacokinetics
MH  - Aspirin/*adverse effects/pharmacokinetics
MH  - Drug Hypersensitivity/*immunology/metabolism
MH  - Humans
RF  - 180
EDAT- 2006/10/05 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/10/05 09:00
PHST- 2006/10/05 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/10/05 09:00 [entrez]
AID - 10.2174/138161206778193971 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2006;12(26):3347-58. doi: 10.2174/138161206778193971.

PMID- 25660763
OWN - NLM
STAT- MEDLINE
DCOM- 20160211
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 13
IP  - 5
DP  - 2015 May
TI  - Aspirin therapy is associated with less compact fibrin networks and enhanced 
      fibrinolysis in patients with abdominal aortic aneurysm.
PG  - 795-801
LID - 10.1111/jth.12872 [doi]
AB  - OBJECTIVE: Thrombotic changes in fibrin networks contribute to increased 
      cardiovascular risk in patients with abdominal aortic aneurysm (AAA). Given that 
      aspirin modulates the fibrin network, we aimed to determine if aspirin therapy is 
      associated with changes in ex-vivo fibrin clot characteristics in AAA patients 
      and also conducted an exploratory analysis of 5-year mortality in these 
      individuals. METHODS: We recruited 145 male patients, divided into controls 
      (aortic diameter < 3 cm, n = 49), AAA not taking aspirin (AAA-Asp, n = 50) and 
      AAA on 75 mg day(-1) aspirin (AAA+Asp, n = 46), matched for aneurysm size. 
      Characteristics of clots made from plasma and plasma-purified fibrinogen were 
      investigated using turbidimetric analysis, permeation studies, and confocal and 
      electron microscopy. Plasma fibrinogen, D-dimer and inflammatory marker levels 
      were also measured. RESULTS: Maximum absorbance (MA) of plasma clots from 
      controls was lower than that of AAA patients not on aspirin (AAA-Asp) at 
      0.30 ± 0.01 and 0.38 ± 0.02 au, respectively (P = 0.002), whereas aspirin-treated 
      subjects had MA similar to controls (0.31 ± 0.02 P = 0.9). Plasma clot lysis time 
      displayed an identical pattern at 482 ± 15, 597 ± 24 and 517 ± 27 s for control, 
      AAA-Asp and AAA+Asp (P = 0.001 and P = 0.8). The lysis time of clots made from 
      purified fibrinogen of AAA-Asp was longer than that of AAA+Asp patients (756 ± 47 
      and 592 ± 52 s, respectively; P = 0.041). Permeation studies and confocal and 
      electron microscopy showed increased clot density in AAA-Asp compared with the 
      AAA+Asp group. Mortality in AAA-Asp and AAA+Asp was similar, despite increased 
      cardiovascular risk in the latter group, and both exhibited higher mortality than 
      controls. CONCLUSION: Aspirin improves fibrin clot characteristics in patients 
      with AAA, which may have important clinical implications.
CI  - © 2015 International Society on Thrombosis and Haemostasis.
FAU - Bailey, M A
AU  - Bailey MA
AD  - Division of Cardiovascular & Diabetes Research, School of Medicine, The Leeds 
      Institute of Cardiovascular & Metabolic Medicine, The University of Leeds, Leeds, 
      UK; The Leeds Vascular Institute, The Leeds General Infirmary, Leeds, UK.
FAU - Aggarwal, R
AU  - Aggarwal R
FAU - Bridge, K I
AU  - Bridge KI
FAU - Griffin, K J
AU  - Griffin KJ
FAU - Iqbal, F
AU  - Iqbal F
FAU - Phoenix, F
AU  - Phoenix F
FAU - Purdell-Lewis, J
AU  - Purdell-Lewis J
FAU - Thomas, T
AU  - Thomas T
FAU - Johnson, A B
AU  - Johnson AB
FAU - Ariëns, R A S
AU  - Ariëns RA
FAU - Scott, D J A
AU  - Scott DJ
FAU - Ajjan, R A
AU  - Ajjan RA
LA  - eng
GR  - FS/10/020/28242/BHF_/British Heart Foundation/United Kingdom
GR  - FS/12/26/29395/BHF_/British Heart Foundation/United Kingdom
GR  - PG/09/020/26305/BHF_/British Heart Foundation/United Kingdom
GR  - RG/13/3/30104/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150312
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 9001-31-4 (Fibrin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aortic Aneurysm, Abdominal/*complications
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Fibrin/*metabolism
MH  - *Fibrinolysis
MH  - Humans
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - abdominal aortic aneurysm
OT  - aspirin
OT  - blood coagulation
OT  - fibrin
OT  - fibrinolysis
OT  - thrombosis
EDAT- 2015/02/11 06:00
MHDA- 2016/02/13 06:00
CRDT- 2015/02/10 06:00
PHST- 2014/10/09 00:00 [received]
PHST- 2015/02/10 06:00 [entrez]
PHST- 2015/02/11 06:00 [pubmed]
PHST- 2016/02/13 06:00 [medline]
AID - S1538-7836(22)08975-9 [pii]
AID - 10.1111/jth.12872 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2015 May;13(5):795-801. doi: 10.1111/jth.12872. Epub 2015 Mar 
      12.

PMID- 8970819
OWN - NLM
STAT- MEDLINE
DCOM- 19970317
LR  - 20190822
IS  - 0378-5955 (Print)
IS  - 0378-5955 (Linking)
VI  - 99
IP  - 1-2
DP  - 1996 Sep 15
TI  - Effects of aspirin on human psychophysical tuning curves in forward and 
      simultaneous masking.
PG  - 110-8
AB  - Psychophysical tuning curves (PTCs) at 4 kHz were measured in forward and 
      simultaneous masking under two experimental conditions: 1 h after listeners had 
      ingested three 320 mg capsules of aspirin every 6 h for 3 days (3.84 g/day), and 
      after an identical schedule of placebo ingestion. Aspirin and placebo allocation 
      was double-blind. In addition to raising thresholds at several audiometric 
      frequencies, aspirin elevated the tips and reduced the slopes of the PTCs, 
      indicating a reduction in frequency selectivity. The aspirin-induced reduction in 
      PTC slopes did not differ significantly between forward and simultaneous masking, 
      nor did the overall reduction differ significantly between the low- and 
      high-frequency side. However, a separate analysis of the data obtained in 
      simultaneous masking indicated that the broadening in tuning caused by aspirin 
      was greatest on the high-frequency side of the PTC.
FAU - Beveridge, H A
AU  - Beveridge HA
AD  - Laboratory of Experimental Psychology, University of Sussex, Brighton, East 
      Sussex, UK.
FAU - Carlyon, R P
AU  - Carlyon RP
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Hear Res
JT  - Hearing research
JID - 7900445
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acoustic Stimulation
MH  - Administration, Oral
MH  - Adult
MH  - Analysis of Variance
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Auditory Threshold/*drug effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
EDAT- 1996/09/15 00:00
MHDA- 1996/09/15 00:01
CRDT- 1996/09/15 00:00
PHST- 1996/09/15 00:00 [pubmed]
PHST- 1996/09/15 00:01 [medline]
PHST- 1996/09/15 00:00 [entrez]
AID - S0378-5955(96)00091-3 [pii]
AID - 10.1016/s0378-5955(96)00091-3 [doi]
PST - ppublish
SO  - Hear Res. 1996 Sep 15;99(1-2):110-8. doi: 10.1016/s0378-5955(96)00091-3.

PMID- 3963028
OWN - NLM
STAT- MEDLINE
DCOM- 19860502
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 80
IP  - 3A
DP  - 1986 Mar 24
TI  - Flurbiprofen in the treatment of rheumatoid arthritis. A comparison with aspirin.
PG  - 89-95
AB  - This large-scale, double-blind study compared 200 mg per day of flurbiprofen 
      (Ansaid, Upjohn) with 4,000 mg per day of aspirin in 822 patients with definite 
      or classical rheumatoid arthritis who were evaluated for up to 52 weeks. Overall 
      response to therapy was similar in both groups. By the end of the study, however, 
      significantly more patients remained in the flurbiprofen (54 percent) than in the 
      aspirin group (40 percent). Significant differences were also found in the 
      incidence and severity of adverse reactions: 36 percent of flurbiprofen-treated 
      and 63 percent of aspirin-treated patients reported side effects. Severe adverse 
      reactions occurred in 6.7 percent of the flurbiprofen-treated patients compared 
      with 16.5 percent of the aspirin-treated patients. Withdrawals that were due at 
      least in part to adverse reactions were more than twice as frequent in the 
      aspirin group (21.4 percent) than in the flurbiprofen group (10.2 percent). 
      Laboratory data collected throughout the study showed no clinically significant 
      abnormalities in either group. This study suggests that flurbiprofen effectively 
      controls the pain and other symptoms of rheumatoid arthritis, and is superior in 
      safety to aspirin in the treatment of patients with acute and chronic disease.
FAU - Lomen, P L
AU  - Lomen PL
FAU - Turner, L F
AU  - Turner LF
FAU - Lamborn, K R
AU  - Lamborn KR
FAU - Brinn, E L
AU  - Brinn EL
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Evaluation
MH  - Female
MH  - Flurbiprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain/*drug therapy
MH  - Propionates/*therapeutic use
EDAT- 1986/03/24 00:00
MHDA- 1986/03/24 00:01
CRDT- 1986/03/24 00:00
PHST- 1986/03/24 00:00 [pubmed]
PHST- 1986/03/24 00:01 [medline]
PHST- 1986/03/24 00:00 [entrez]
AID - 10.1016/0002-9343(86)90120-8 [doi]
PST - ppublish
SO  - Am J Med. 1986 Mar 24;80(3A):89-95. doi: 10.1016/0002-9343(86)90120-8.

PMID- 22122763
OWN - NLM
STAT- MEDLINE
DCOM- 20120322
LR  - 20211021
IS  - 1532-1916 (Electronic)
IS  - 1521-6918 (Print)
IS  - 1521-6918 (Linking)
VI  - 25
IP  - 4-5
DP  - 2011 Aug
TI  - Aspirin for the prevention of colorectal cancer.
PG  - 461-72
LID - 10.1016/j.bpg.2011.10.015 [doi]
AB  - Over 600,000 people worldwide die of colorectal cancer (CRC) annually, 
      highlighting the importance of developing effective prevention strategies. Among 
      proposed chemopreventive interventions, aspirin is perhaps the agent with the 
      strongest body of evidence that supports wider spread use to significantly reduce 
      the population burden of CRC. Several epidemiological studies, four randomized 
      controlled trials (RCTs) of colorectal polyp recurrence, and RCTs in patients 
      with hereditary colorectal cancer syndromes, have shown that aspirin reduces 
      incidence of colorectal neoplasia. Recently, in a pooled analysis of five 
      cardiovascular-prevention RCTs linked to cancer outcomes, daily aspirin use at 
      any dose reduced the risk of CRC by 24% and of CRC-associated mortality by 35% 
      after a delay of 8-10 years. In an expanded meta-analysis of 8 
      cardiovascular-prevention RCTs, daily aspirin use at any dose was associated with 
      a 21% lower risk of all cancer death, including CRC, with benefit only apparent 
      after 5 years. In this review, we will summarize human studies of aspirin in CRC 
      prevention as well as discuss the safety profile and mechanism of aspirin in CRC 
      prevention.
CI  - Copyright © 2011 Elsevier Ltd. All rights reserved.
FAU - Garcia-Albeniz, X
AU  - Garcia-Albeniz X
AD  - Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave., 
      Boston, MA 02114, USA. xgarciad@hsph.harvard.edu
FAU - Chan, A T
AU  - Chan AT
LA  - eng
GR  - R01 CA137178/CA/NCI NIH HHS/United States
GR  - R01 CA137178-03/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Gastroenterol
JT  - Best practice & research. Clinical gastroenterology
JID - 101120605
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Anticarcinogenic Agents/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chemoprevention
MH  - Colorectal Neoplasms/*prevention & control
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Treatment Outcome
PMC - PMC3354696
MID - NIHMS339417
EDAT- 2011/11/30 06:00
MHDA- 2012/03/23 06:00
CRDT- 2011/11/30 06:00
PHST- 2011/10/27 00:00 [received]
PHST- 2011/10/27 00:00 [accepted]
PHST- 2011/11/30 06:00 [entrez]
PHST- 2011/11/30 06:00 [pubmed]
PHST- 2012/03/23 06:00 [medline]
AID - S1521-6918(11)00103-X [pii]
AID - 10.1016/j.bpg.2011.10.015 [doi]
PST - ppublish
SO  - Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):461-72. doi: 
      10.1016/j.bpg.2011.10.015.

PMID- 28159866
OWN - NLM
STAT- MEDLINE
DCOM- 20180129
LR  - 20220408
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 22
IP  - 2
DP  - 2017 Feb
TI  - Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer 
      Patients with Acute Myocardial Infarction.
PG  - 213-221
LID - 10.1634/theoncologist.2016-0110 [doi]
AB  - BACKGROUND: Patients with hematologic malignancies are at risk for severe 
      thrombocytopenia (sTP). The risk and benefit of aspirin are not known in 
      thrombocytopenic cancer patients experiencing acute myocardial infarction (AMI). 
      MATERIALS AND METHODS: Medical records of patients with hematologic malignancies 
      diagnosed with AMI at Memorial Sloan Kettering Cancer Center during 2005-2014 
      were reviewed. sTP was defined as a platelet count <50,000 cells per µL within 7 
      days of AMI. RESULTS: Of 118 patients with hematologic malignancies who had AMI, 
      58 (49%) had sTP. Twenty-five patients (43%) with sTP received aspirin as a 
      treatment for AMI. Compared with patients without sTP with AMI, patients with sTP 
      with AMI were less likely to receive aspirin (83% vs. 43%; p = .0001) and 
      thienopyridine treatment (27% vs. 3%; p = .0005). During median follow-up of 3.7 
      years after AMI, survival was lower in patients with sTP than in those with no 
      sTP (23% vs. 50% at 1 year; log rank p = .003). Patients with sTP who received 
      aspirin for AMI had improved survival compared with those who did not (92% vs. 
      70% at 7 days, 72% vs. 33% at 30 days, and 32% vs. 13% at 1 year; log rank 
      p = .008). In multivariate regression models, aspirin use was associated with 
      improved 30-day survival both in the overall patient cohort and in sTP patients. 
      No fatal bleeding events occurred. Major bleeding was not associated with sTP or 
      aspirin use. CONCLUSION: Treatment of AMI with aspirin in patients with 
      hematologic malignancies and sTP is associated with improved survival without 
      increase in major bleeding. The Oncologist 2017;22:213-221Implications for 
      Practice: In patients with hematologic malignancies and acute myocardial 
      infarction with severe thrombocytopenia (platelet count < 50,000 cells/µL), 
      guideline-recommended medical therapy is often withheld because of the fear of 
      major bleeding. In this study, aspirin therapy was associated with improved 
      survival without an increase in major bleeding in this high-risk patient cohort.
CI  - © AlphaMed Press 2017.
FAU - Feher, Attila
AU  - Feher A
AD  - Department of Medicine, Weill Cornell Medical College, New York, New York, USA 
      attila.feher@yale.edu.
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New 
      York, USA.
FAU - Kampaktsis, Polydoros N
AU  - Kampaktsis PN
AD  - Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New 
      York, USA.
FAU - Parameswaran, Rekha
AU  - Parameswaran R
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New 
      York, USA.
FAU - Stein, Eytan M
AU  - Stein EM
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New 
      York, USA.
FAU - Steingart, Richard
AU  - Steingart R
AD  - Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New 
      York, USA.
FAU - Gupta, Dipti
AU  - Gupta D
AD  - Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New 
      York, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170203
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*drug therapy/mortality
MH  - Neoplasms/*drug therapy/mortality
MH  - Survival Analysis
MH  - Thrombocytopenia/*drug therapy/mortality
PMC - PMC5330698
OTO - NOTNLM
OT  - Acute myocardial infarction
OT  - Aspirin
OT  - Cancer
OT  - Thrombocytopenia
COIS- Disclosures of potential conflicts of interest may be found at the end of this 
      article.
EDAT- 2017/02/06 06:00
MHDA- 2018/01/30 06:00
CRDT- 2017/02/05 06:00
PHST- 2016/07/13 00:00 [received]
PHST- 2016/10/06 00:00 [accepted]
PHST- 2017/02/06 06:00 [pubmed]
PHST- 2018/01/30 06:00 [medline]
PHST- 2017/02/05 06:00 [entrez]
AID - theoncologist.2016-0110 [pii]
AID - ONCO12013 [pii]
AID - 10.1634/theoncologist.2016-0110 [doi]
PST - ppublish
SO  - Oncologist. 2017 Feb;22(2):213-221. doi: 10.1634/theoncologist.2016-0110. Epub 
      2017 Feb 3.

PMID- 9337427
OWN - NLM
STAT- MEDLINE
DCOM- 19971205
LR  - 20190606
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 18
IP  - 5
DP  - 1997 Sep-Oct
TI  - Nasal provocation tests in the diagnosis of urticaria induced by acetylsalicylic 
      acid.
PG  - 319-22
AB  - Nasal provocation tests with lysine acetylsalicylic acid (ASA) have been used in 
      the diagnosis of ASA-induced asthma and rhinitis. To establish its possible role 
      in identifying aspirin sensitivity manifested by urticaria or angioedema, 18 
      patients suffering from chronic or acute recurring urticaria/angioedema (10 
      ASA-sensitive and 8 ASA-nonsensitive) were submitted to nasal provocation tests 
      with freshly prepared solutions of lysine ASA. Clinical response and variation of 
      nasal expiratory peak-flow were evaluated, classified according to previously 
      defined scores, and compared. The results showed a significant difference between 
      ASA-sensitive and ASA-nonsensitive patients, suggesting that this test can be an 
      important diagnostic tool for ASA-induced urticaria/angioedema.
FAU - Tomaz, E M
AU  - Tomaz EM
AD  - I Medical Clinic, University Hospital Santa Maria, Lisboa, Portugal.
FAU - Ferreira, M F
AU  - Ferreira MF
FAU - Spínola, M A
AU  - Spínola MA
FAU - Oliveira, M L
AU  - Oliveira ML
FAU - Clode, M H
AU  - Clode MH
FAU - Palma-Carlos, A G
AU  - Palma-Carlos AG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects/*analogs & derivatives
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - *Nasal Provocation Tests
MH  - Sensitivity and Specificity
MH  - Urticaria/chemically induced/*diagnosis
EDAT- 1997/10/24 00:00
MHDA- 1997/10/24 00:01
CRDT- 1997/10/24 00:00
PHST- 1997/10/24 00:00 [pubmed]
PHST- 1997/10/24 00:01 [medline]
PHST- 1997/10/24 00:00 [entrez]
AID - 10.2500/108854197778590515 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 1997 Sep-Oct;18(5):319-22. doi: 10.2500/108854197778590515.

PMID- 8124561
OWN - NLM
STAT- MEDLINE
DCOM- 19940414
LR  - 20220318
IS  - 0007-1226 (Print)
IS  - 0007-1226 (Linking)
VI  - 47
IP  - 1
DP  - 1994 Jan
TI  - The role of various antithrombotic agents in microvascular surgery.
PG  - 20-3
AB  - The ultimate goal in microvascular surgery is to achieve improved patency rates 
      while reducing complications of systemic antithrombotic agents. Using a described 
      model of microarterial thrombosis, the antithrombotic effects of oral aspirin 
      (ASA) were assessed in rats. ASA-treated animals (30 mg/kg orally) exhibited 
      significantly prolonged mean bleeding times 1 h and 24 h after dosing when 
      compared to controls (p < 0.01). Platelet aggregation profiles also displayed an 
      inhibition of platelet aggregation in the ASA group relative to controls. In the 
      thrombosis model, however, patency rates were significantly improved at 20 min, 
      but all vessels were thrombosed at 24 h.
FAU - Buckley, R C
AU  - Buckley RC
AD  - Department of Surgery, University of Mississippi Medical Center.
FAU - Davidson, S F
AU  - Davidson SF
FAU - Das, S K
AU  - Das SK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Plast Surg
JT  - British journal of plastic surgery
JID - 2984714R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anastomosis, Surgical
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Bleeding Time
MH  - Disease Models, Animal
MH  - Femoral Artery/*surgery/ultrastructure
MH  - Microscopy, Electron, Scanning
MH  - Microsurgery
MH  - Platelet Aggregation/drug effects
MH  - Postoperative Complications/*prevention & control
MH  - *Premedication
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thrombosis/pathology/*prevention & control
MH  - Time Factors
MH  - Vascular Patency/drug effects
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 0007-1226(94)90112-0 [pii]
AID - 10.1016/0007-1226(94)90112-0 [doi]
PST - ppublish
SO  - Br J Plast Surg. 1994 Jan;47(1):20-3. doi: 10.1016/0007-1226(94)90112-0.

PMID- 10384366
OWN - NLM
STAT- MEDLINE
DCOM- 19990723
LR  - 20191103
IS  - 1067-2516 (Print)
IS  - 1067-2516 (Linking)
VI  - 38
IP  - 3
DP  - 1999 May-Jun
TI  - Erythromelalgia: diagnosis and classification.
PG  - 238-41
AB  - Erythromelalgia is not a commonly recognized or diagnosed condition that affects 
      the lower extremities. The first reported case was in 1878, when Mitchell 
      suggested the term "erythromelalgia." This condition is characterized by a 
      burning sensation with erythema of the involved extremity. When the extremity is 
      lowered, or heat is applied, the pain is intensified. The application of cold or 
      elevation of the extremity will have the opposite effect of decreasing the pain. 
      Erythromelalgia is classified as primary or idiopathic if there is no 
      accompanying disease process. Secondary erythromelalgia is associated commonly 
      with myeloproliferative syndrome-related thrombocythemia, and is mostly evident 
      in adult onset of the condition. Treatment for adults with erythromelalgia 
      includes a single daily dose of aspirin, but children who have no associated 
      underlying disorder find little to no relief with acetylsalicylic acid.
FAU - Norton, J V
AU  - Norton JV
AD  - University Medical Center, Oak Lawn, IL 60453-2416, USA.
FAU - Zager, E
AU  - Zager E
FAU - Grady, J F
AU  - Grady JF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Foot Ankle Surg
JT  - The Journal of foot and ankle surgery : official publication of the American 
      College of Foot and Ankle Surgeons
JID - 9308427
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Erythromelalgia/classification/*diagnosis/etiology/therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
RF  - 12
EDAT- 1999/06/29 00:00
MHDA- 1999/06/29 00:01
CRDT- 1999/06/29 00:00
PHST- 1999/06/29 00:00 [pubmed]
PHST- 1999/06/29 00:01 [medline]
PHST- 1999/06/29 00:00 [entrez]
AID - S1067-2516(99)80060-X [pii]
AID - 10.1016/s1067-2516(99)80060-x [doi]
PST - ppublish
SO  - J Foot Ankle Surg. 1999 May-Jun;38(3):238-41. doi: 10.1016/s1067-2516(99)80060-x.

PMID- 25559436
OWN - NLM
STAT- MEDLINE
DCOM- 20150518
LR  - 20220311
IS  - 1530-0293 (Electronic)
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 43
IP  - 4
DP  - 2015 Apr
TI  - Prehospital aspirin use is associated with reduced risk of acute respiratory 
      distress syndrome in critically ill patients: a propensity-adjusted analysis.
PG  - 801-7
LID - 10.1097/CCM.0000000000000789 [doi]
AB  - OBJECTIVES: Platelet activation plays an active role in the pathogenesis of acute 
      respiratory distress syndrome. In our prior study of 575 patients at high risk 
      for acute respiratory distress syndrome, concurrent statin and aspirin use was 
      associated with reduced acute respiratory distress syndrome. However, the largest 
      study (n = 3,855) to date found no significant benefit of prehospital aspirin in 
      a lower-risk population when adjusted for the propensity for aspirin use. We 
      aimed to determine whether prehospital aspirin use is associated with decreased 
      acute respiratory distress syndrome in patients at high risk for acute 
      respiratory distress syndrome after adjusting for the propensity to receive 
      aspirin. DESIGN: Secondary analysis of patients enrolled prospectively in the 
      Validating Acute Lung Injury Markers for Diagnosis study. PATIENTS: A total of 
      1,149 critically ill patients (≥40 years old) admitted to the medical or surgical 
      ICUs of an academic tertiary care hospital including 575 previously reported 
      patients as well as additional patients who were enrolled after completion of the 
      prior statin and aspirin study. INTERVENTION: None. MEASUREMENTS AND RESULTS: Of 
      1,149 patients, 368 (32%) developed acute respiratory distress syndrome during 
      the first 4 ICU days and 287 (25%) patients had prehospital aspirin use. Patients 
      with prehospital aspirin had significantly lower prevalence of acute respiratory 
      distress syndrome (27% vs 34%; p=0.034). In a multivariable, propensity-adjusted 
      analysis including age, gender, race, sepsis, and Acute Physiology and Chronic 
      Health Evaluation score II, prehospital aspirin use was associated with a 
      decreased risk of acute respiratory distress syndrome (odds ratio, 0.66; 95% CI, 
      0.46-0.94) in the entire cohort and in a subgroup of 725 patients with sepsis 
      (odds ratio, 0.60; 95% CI, 0.41-0.90). CONCLUSIONS: In this selected cohort of 
      critically ill patients, prehospital aspirin use was independently associated 
      with a decreased risk of acute respiratory distress syndrome even after adjusting 
      for the propensity of prehospital aspirin use. These findings support the need 
      for prospective clinical trials to determine whether aspirin may be beneficial 
      for the prevention of clinical acute respiratory distress syndrome.
FAU - Chen, Wei
AU  - Chen W
AD  - 1Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt 
      University School of Medicine, Nashville, TN. 2Division of Pulmonary and Critical 
      Care Medicine, Chia-Yi Christian Hospital, Taiwan, Republic of China. 3Department 
      of Life Science, National Chung Hsing University, Taiwan, Republic of China. 
      4Department of Respiratory Therapy, China Medical University, Taiwan, Republic of 
      China. 5Section of Pulmonary and Critical Care Medicine, Louisiana State 
      University School of Medicine New Orleans, New Orleans, LA. 6Department of 
      Surgery, Vanderbilt University School of Medicine, Nashville, TN. 7Department of 
      Pathology, Microbiology, and Immunology, Vanderbilt University School of 
      Medicine, Nashville, TN.
FAU - Janz, David R
AU  - Janz DR
FAU - Bastarache, Julie A
AU  - Bastarache JA
FAU - May, Addison K
AU  - May AK
FAU - O'Neal, Hollis R Jr
AU  - O'Neal HR Jr
FAU - Bernard, Gordon R
AU  - Bernard GR
FAU - Ware, Lorraine B
AU  - Ware LB
LA  - eng
GR  - HL103836/HL/NHLBI NIH HHS/United States
GR  - HL112656-02/HL/NHLBI NIH HHS/United States
GR  - K24 HL103836/HL/NHLBI NIH HHS/United States
GR  - P01 GM015431/GM/NIGMS NIH HHS/United States
GR  - T32 HL087738/HL/NHLBI NIH HHS/United States
GR  - UL1 RR024975/RR/NCRR NIH HHS/United States
GR  - R21 HL112656/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Crit Care Med. 2015 Apr;43(4):916-7. PMID: 25768357
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Cohort Studies
MH  - *Critical Illness
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiratory Distress Syndrome/*prevention & control
PMC - PMC4359645
MID - NIHMS635472
COIS- Conflict of Interest: All authors declared no conflict of interest
EDAT- 2015/01/07 06:00
MHDA- 2015/05/20 06:00
CRDT- 2015/01/07 06:00
PHST- 2015/01/07 06:00 [entrez]
PHST- 2015/01/07 06:00 [pubmed]
PHST- 2015/05/20 06:00 [medline]
AID - 10.1097/CCM.0000000000000789 [doi]
PST - ppublish
SO  - Crit Care Med. 2015 Apr;43(4):801-7. doi: 10.1097/CCM.0000000000000789.

PMID- 7974569
OWN - NLM
STAT- MEDLINE
DCOM- 19941229
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 25
IP  - 12
DP  - 1994 Dec
TI  - Development of aspirin resistance in persons with previous ischemic stroke.
PG  - 2331-6
AB  - BACKGROUND AND PURPOSE: The ex vivo effect of aspirin (ASA) on platelet 
      aggregation, the platelet component of thrombosis, was studied at repeated 
      intervals in a cohort of patients taking aspirin for recurrent ischemic stroke 
      prevention to define the maintenance of efficacy over time. METHODS: We 
      administered increasing doses of aspirin (from 325 to 1300 mg/d) to patients with 
      previous ischemic stroke and determined the extent of inhibition of platelet 
      aggregation after 2 weeks and thereafter at approximately 6-month intervals. 
      RESULTS: Over 33 months, 306 patients had platelet aggregation studies performed 
      to define their initial response to ASA therapy. Of these, 228 had complete and 
      78 had partial inhibition of platelet aggregation at initial testing. To date, 
      119 of those who had complete inhibition and 52 who had partial inhibition have 
      undergone repeat testing at least once. At repeat testing 39 of the 119 (32.7%) 
      with complete inhibition at initial testing had lost part of the antiplatelet 
      effect of ASA and converted from complete to partial inhibition without change in 
      ASA dosage. Of the 52 with partial inhibition at initial testing, 35 achieved 
      complete inhibition either by ASA dosage escalation (in 325 mg/d increments) or 
      fluctuation of response at the same dosage, but 8 of those 35 (22.8%) had 
      reverted to partial inhibition when tested again. Overall, 8.2% of patients 
      ultimately exhibited ASA resistance to 1300 mg/d-8 of 52 (15.4%) with partial 
      inhibition and 6 of 119 (5.0%) with complete inhibition at initial testing. 
      CONCLUSIONS: The antiplatelet (and presumably the antithrombotic) effect of a 
      fixed dose of ASA is not constant over time in all individuals. The mechanisms by 
      which increased dosage requirement or ASA resistance develops and the clinical 
      significance of this development are currently undefined.
FAU - Helgason, C M
AU  - Helgason CM
AD  - University of Illinois at Chicago, Department of Neurology, IL.
FAU - Bolin, K M
AU  - Bolin KM
FAU - Hoff, J A
AU  - Hoff JA
FAU - Winkler, S R
AU  - Winkler SR
FAU - Mangat, A
AU  - Mangat A
FAU - Tortorice, K L
AU  - Tortorice KL
FAU - Brace, L D
AU  - Brace LD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/antagonists & inhibitors/pharmacology
MH  - Arachidonic Acid/antagonists & inhibitors/pharmacology
MH  - Aspirin/administration & dosage/blood/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Brain Ischemia/*prevention & control
MH  - Cerebrovascular Disorders/prevention & control
MH  - Cohort Studies
MH  - Collagen/antagonists & inhibitors/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance
MH  - Drug Tolerance
MH  - Epinephrine/antagonists & inhibitors/pharmacology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Intracranial Embolism and Thrombosis/prevention & control
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Recurrence
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
AID - 10.1161/01.str.25.12.2331 [doi]
PST - ppublish
SO  - Stroke. 1994 Dec;25(12):2331-6. doi: 10.1161/01.str.25.12.2331.

PMID- 20812493
OWN - NLM
STAT- MEDLINE
DCOM- 20100923
LR  - 20141120
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 149
IP  - 4
DP  - 2010 Apr
TI  - [A prospective study to evaluate the safety of minor cutaneous surgery during 
      aspirin treatment].
PG  - 219-21, 264, 263
AB  - BACKGROUND: Many patients undergoing cutaneous surgery are treated with aspirin 
      due to its proven advantages. Discontinuation of aspirin prior to surgery is 
      still controversial. We conducted a large-scale, prospective study to evaluate 
      the safety of dermatologic surgery in patients receiving aspirin. OBJECTIVES: The 
      authors' objectives were to evaluate the complication rate in patients undergoing 
      cutaneous surgery while treated with aspirin. METHODS: All patients operated on 
      solely by one plastic surgeon were included in the study. The study group 
      included all patients receiving aspirin during surgery, while the rest of the 
      patients comprised the control group. Demographic data, surgery type and 
      complication rate were collected. Complications were classified as major or minor 
      hematoma, wound infection and dehiscence. Statistical significance was calculated 
      using the Student's t-test and Chi test. RESULTS: During the study period 7259 
      patients underwent minor cutaneous surgery (without local flaps or skin grafts). 
      A group of 115 patients taking either Plavix (Clopidrogel) or Coumadin (Warfarin) 
      were excluded. The study group consisted of 1088 patients who were taking aspirin 
      regularly while 6056 patients comprised the control group. A statistically 
      significant change was found between the two groups regarding sex, age, 
      background chronic diseases and in the distribution of lesions across the body. 
      No significant change was found regarding the peri-operative complications. 
      CONCLUSIONS: In this large-scale prospective study, dermatologic surgery on 
      patients receiving aspirin was found to be safe, as no statistically different 
      complication rate was found between the study and the control groups. This 
      statement is further emphasized due to the significantly statistically older age, 
      chronic illness rate and the head and neck location of the lesions in the study 
      group.
FAU - Schein, Ophir
AU  - Schein O
AD  - Department of Plastic Surgery, Pigmented Lesions Service, Assaf Harofeh Medical 
      Center, Zerifin, Israel.
FAU - Wolf, Omer
AU  - Wolf O
FAU - Westreich, Moshe
AU  - Westreich M
FAU - Shalom, Avshalom
AU  - Shalom A
LA  - heb
PT  - English Abstract
PT  - Journal Article
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Minor Surgical Procedures/*standards
MH  - Prospective Studies
MH  - Skin Diseases/*surgery
MH  - Surgery, Plastic/*standards
EDAT- 2010/09/04 06:00
MHDA- 2010/09/24 06:00
CRDT- 2010/09/04 06:00
PHST- 2010/09/04 06:00 [entrez]
PHST- 2010/09/04 06:00 [pubmed]
PHST- 2010/09/24 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2010 Apr;149(4):219-21, 264, 263.

PMID- 3261930
OWN - NLM
STAT- MEDLINE
DCOM- 19881013
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 116
IP  - 3
DP  - 1988 Sep
TI  - Use of aspirin for prevention of cardiovascular disease--1981-82 to 1985-86: the 
      Minnesota Heart Survey.
PG  - 827-30
AB  - The efficacy of aspirin to prevent ischemic cardiovascular disease has received 
      considerable attention recently. To determine the prevalence of aspirin use for 
      cardiovascular disease prevention, the Minnesota Heart Survey examined 
      population-based samples of Twin Cities' adults in 1981 to 82 and 1985 to 86. 
      Over the 4-year period, reported use of aspirin for cardiovascular disease 
      prophylaxis increased from 0.6% to 2.4% in women (p less than 0.05) and from 1.7% 
      to 3.3% in men (p = 0.10). Prophylactic aspirin use was more common in older than 
      in younger adults, in whites than in blacks, in those with a history of 
      cardiovascular disease or hypercholesterolemia, and in health professionals and 
      nonsmokers. Some individuals were apparently taking aspirin for "primary" 
      prevention, although it has not yet been approved for that reason. Use of aspirin 
      for cardiovascular disease prevention has been increasing and is likely to 
      increase more rapidly over the next few years. This could favorably impact on 
      mortality rates of cardiovascular disease, but untoward side effects of aspirin 
      may be expected to increase as well.
FAU - Folsom, A R
AU  - Folsom AR
AD  - Division of Epidemiology, School of Public Health, University of Minnesota, 
      Minneapolis 55455.
FAU - Iso, H
AU  - Iso H
FAU - Sprafka, J M
AU  - Sprafka JM
FAU - Edlavitch, S A
AU  - Edlavitch SA
FAU - Luepker, R V
AU  - Luepker RV
LA  - eng
GR  - R01-HL-23727/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cross-Sectional Studies
MH  - Drug Utilization
MH  - Female
MH  - *Health Surveys
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Minnesota
MH  - Self Medication
EDAT- 1988/09/01 00:00
MHDA- 1988/09/01 00:01
CRDT- 1988/09/01 00:00
PHST- 1988/09/01 00:00 [pubmed]
PHST- 1988/09/01 00:01 [medline]
PHST- 1988/09/01 00:00 [entrez]
AID - 0002-8703(88)90344-4 [pii]
AID - 10.1016/0002-8703(88)90344-4 [doi]
PST - ppublish
SO  - Am Heart J. 1988 Sep;116(3):827-30. doi: 10.1016/0002-8703(88)90344-4.

PMID- 10796855
OWN - NLM
STAT- MEDLINE
DCOM- 20000706
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 2
DP  - 2000
TI  - Single dose oral aspirin for acute pain.
PG  - CD002067
AB  - BACKGROUND: Aspirin has been known to be an effective analgesic for many years 
      and is commonly used throughout the world for many different pain conditions. It 
      is important for both prescribers and patients to have the best possible 
      information about the efficacy and safety of analgesics, and this need is 
      reflected in patient surveys which show that postoperative pain is often poorly 
      managed. We also need to benchmark relative efficacy and safety of current 
      analgesics so that we can compare them with new analgesics. OBJECTIVES: To 
      quantitatively assess the analgesic efficacy and adverse effects of a single-dose 
      of aspirin in acute pain of moderate to severe intensity. SEARCH STRATEGY: 
      Randomised trials were identified by searching Medline (1966 to March 1998), 
      Embase (1980 to January 1998), the Cochrane Library (Issue 1,1998) and the Oxford 
      Pain Relief Database (1950 to 1994). SELECTION CRITERIA: The inclusion criteria 
      used were: full journal publication, postoperative pain or a mixture of 
      postoperative and acute trauma pain, oral administration, adult patients, 
      baseline pain of moderate to severe intensity, double-blind design, and random 
      allocation to treatment groups which compared aspirin with placebo. DATA 
      COLLECTION AND ANALYSIS: Summed pain relief or pain intensity difference over 
      four to six hours was extracted, and converted into dichotomous information 
      yielding the number of patients with at least 50% pain relief. This was then used 
      to calculate the relative benefit and the number-needed-to-treat (NNT) for one 
      patient to achieve at least 50% pain relief. MAIN RESULTS: Seventy-two randomised 
      single-dose trials met our inclusion criteria, with 3253 patients given aspirin, 
      and 3297 placebo. Significant benefit of aspirin over placebo was shown for 
      aspirin 600/650 mg, 1000 mg and 1200 mg, NNTs for at least 50% pain relief of 4.4 
      (4.0 to 4.9), 4.0 (3.2 to 5.4) and 2.4 (1.9 to 3.2) respectively. Single-dose 
      aspirin 600/650 mg produced significantly more drowsiness and gastric irritation 
      than placebo, with a number-needed-to-harm (NNH) of 28 (19 to 52) and 38 (22 to 
      174) respectively. Type of pain model, pain measurement, sample size, quality of 
      study design, and study duration had no significant impact on the results. 
      REVIEWER'S CONCLUSIONS: Aspirin is an effective analgesic for acute pain of 
      moderate to severe intensity with a clear dose-response. Drowsiness and gastric 
      irritation were seen as significant adverse effects even though the studies were 
      single-dose. The pain relief achieved with aspirin was very similar milligram for 
      milligram to that seen with paracetamol.
FAU - Edwards, J E
AU  - Edwards JE
AD  - Pain Research Unit, Nuffield Department of Anaesthetics, Churchill Hospital, Old 
      Road, Oxford, UK, OX3 7LJ. jayne.edwards@pru.ox.ac.uk
FAU - Oldman, A
AU  - Oldman A
FAU - Smith, L
AU  - Smith L
FAU - Collins, S L
AU  - Collins SL
FAU - Carroll, D
AU  - Carroll D
FAU - Wiffen, P J
AU  - Wiffen PJ
FAU - McQuay, H J
AU  - McQuay HJ
FAU - Moore, R A
AU  - Moore RA
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Analgesics, Non-Narcotic)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UIN - Cochrane Database Syst Rev. 2012;4:CD002067. PMID: 22513905
MH  - Acute Disease
MH  - Analgesics, Non-Narcotic/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Pain/*drug therapy
RF  - 72
EDAT- 2000/05/05 09:00
MHDA- 2000/07/08 11:00
CRDT- 2000/05/05 09:00
PHST- 2000/05/05 09:00 [pubmed]
PHST- 2000/07/08 11:00 [medline]
PHST- 2000/05/05 09:00 [entrez]
AID - CD002067 [pii]
AID - 10.1002/14651858.CD002067 [doi]
PST - ppublish
SO  - Cochrane Database Syst Rev. 2000;(2):CD002067. doi: 10.1002/14651858.CD002067.

PMID- 17244615
OWN - NLM
STAT- MEDLINE
DCOM- 20070510
LR  - 20220317
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 282
IP  - 13
DP  - 2007 Mar 30
TI  - Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, 
      anti-inflammatory properties, and enzymatic inactivation.
PG  - 9323-9334
LID - S0021-9258(19)33585-9 [pii]
LID - 10.1074/jbc.M609212200 [doi]
AB  - We recently uncovered two new families of potent docosahexaenoic acid-derived 
      mediators, termed D series resolvins (Rv; resolution phase interaction products) 
      and protectins. Here, we assign the stereochemistry of the conjugated double 
      bonds and chirality of alcohols present in resolvin D1 (RvD1) and its 
      aspirin-triggered 17R epimer (AT-RvD1) with compounds prepared by total organic 
      synthesis. In addition, docosahexaenoic acid was converted by a single 
      lipoxygenase in a "one-pot" reaction to RvD1 in vitro. The synthetic compounds 
      matched the physical and biological properties of those enzymatically generated. 
      RvD1 proved to be 7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic 
      acid, AT-RvD1 matched 7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic 
      acid, and they both stopped transendothelial migration of human neutrophils 
      (EC(50) approximately 30 nM). In murine peritonitis in vivo, RvD1 and AT-RvD1 
      proved equipotent (at nanogram dosages), limiting polymorphonuclear leukocyte 
      infiltration in a dose-dependent fashion. RvD1 was converted by eicosanoid 
      oxidoreductase to novel 8-oxo- and 17-oxo-RvD1 that gave dramatically reduced 
      bioactivity, whereas enzymatic conversion of AT-RvD1 was sharply reduced. These 
      results establish the complete stereochemistry and actions of RvD1 and AT-RvD1 as 
      well as demonstrate the stereoselective basis for their enzymatic inactivation. 
      RvD1 regulates human polymorphonuclear leukocyte transendothelial migration and 
      is anti-inflammatory. When its carbon 17S alcohol is enzymatically converted to 
      17-oxo-RvD1, it is essentially inactive, whereas the 17R alcohol configuration in 
      its aspirin-triggered form (AT-RvD1) resists rapid inactivation. These results 
      may contribute to the beneficial actions of aspirin and omega-3 fish oils in 
      humans.
FAU - Sun, Yee-Ping
AU  - Sun YP
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Boston, Massachusetts.
FAU - Oh, Sungwhan F
AU  - Oh SF
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Boston, Massachusetts.
FAU - Uddin, Jasim
AU  - Uddin J
AD  - Department of Chemistry, Loker Hydrocarbon Institute, University of Southern 
      California, Los Angeles, California 90089.
FAU - Yang, Rong
AU  - Yang R
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Boston, Massachusetts.
FAU - Gotlinger, Katherine
AU  - Gotlinger K
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Boston, Massachusetts; Department of Oral Medicine, Infection and Immunity, 
      Harvard School of Dental Medicine and Harvard Medical School, Boston, 
      Massachusetts 02115.
FAU - Campbell, Eric
AU  - Campbell E
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Boston, Massachusetts.
FAU - Colgan, Sean P
AU  - Colgan SP
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Boston, Massachusetts.
FAU - Petasis, Nicos A
AU  - Petasis NA
AD  - Department of Chemistry, Loker Hydrocarbon Institute, University of Southern 
      California, Los Angeles, California 90089.
FAU - Serhan, Charles N
AU  - Serhan CN
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Boston, Massachusetts; Department of Oral Medicine, Infection and Immunity, 
      Harvard School of Dental Medicine and Harvard Medical School, Boston, 
      Massachusetts 02115. Electronic address: cnserhan@zeus.bwh.harvard.edu.
LA  - eng
GR  - DK074448/DK/NIDDK NIH HHS/United States
GR  - P50-DE16191/DE/NIDCR NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20070123
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (resolvin D1)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry/*pharmacology
MH  - Aspirin/chemistry/*pharmacology
MH  - Cell Line
MH  - Cell Migration Inhibition
MH  - Docosahexaenoic Acids/chemical synthesis/*chemistry/*pharmacology
MH  - Enzyme Inhibitors/*chemistry/*pharmacology
MH  - Humans
MH  - Male
MH  - Mice
MH  - Neutrophil Infiltration/drug effects
MH  - Stereoisomerism
EDAT- 2007/01/25 09:00
MHDA- 2007/05/11 09:00
CRDT- 2007/01/25 09:00
PHST- 2007/01/25 09:00 [pubmed]
PHST- 2007/05/11 09:00 [medline]
PHST- 2007/01/25 09:00 [entrez]
AID - S0021-9258(19)33585-9 [pii]
AID - 10.1074/jbc.M609212200 [doi]
PST - ppublish
SO  - J Biol Chem. 2007 Mar 30;282(13):9323-9334. doi: 10.1074/jbc.M609212200. Epub 
      2007 Jan 23.

PMID- 35698818
OWN - NLM
STAT- MEDLINE
DCOM- 20221116
LR  - 20221116
IS  - 1748-5460 (Electronic)
IS  - 0022-2151 (Linking)
VI  - 136
IP  - 12
DP  - 2022 Dec
TI  - Decreased mortality in coronavirus disease 2019 associated mucormycosis with 
      aspirin use: a retrospective cohort study.
PG  - 1309-1313
LID - 10.1017/S0022215122001402 [doi]
AB  - OBJECTIVE: Rhino-orbito-cerebral mucormycosis is a rapidly progressive disease 
      with high mortality rates of about 60 per cent. The increasing incidence of 
      rhino-orbito-cerebral mucormycosis in coronavirus disease 2019 patients in India 
      and worldwide has become a matter of concern owing to the case fatality rate. 
      This study explored the use of low dose aspirin in decreasing the mortality rate 
      of coronavirus disease 2019 associated mucormycosis. METHOD: This was a 
      retrospective observational study. Patients suffering from post-coronavirus 
      disease 2019 mucormycosis were included in the study. Each patient was treated 
      with surgical debridement and systemic amphotericin B. Low dose aspirin was 
      added, and mortality rates were compared with the patients who did not receive 
      aspirin. RESULTS: The demographic data and rhino-orbito-cerebral mucormycosis 
      staging between the two groups were not significantly different. There was a 
      statistically significant difference in mortality outcomes between the two groups 
      (p = 0.029) and a 1.77 times higher risk of dying for patients not receiving 
      aspirin. Kaplan-Meier survival indicated that patients receiving aspirin had 
      better survival rates (p = 0.04). CONCLUSION: Low dose aspirin improves survival 
      rates in coronavirus disease 2019 associated mucormycosis.
FAU - Shaikh, Z
AU  - Shaikh Z
AUID- ORCID: 0000-0002-9475-3059
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Sarkar, S
AU  - Sarkar S
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Biswas, R
AU  - Biswas R
AD  - Department of Community and Family Medicine, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Adhikari, A
AU  - Adhikari A
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Hallur, V K
AU  - Hallur VK
AD  - Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, 
      India.
FAU - Parida, P K
AU  - Parida PK
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Preetam, C
AU  - Preetam C
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Pradhan, P
AU  - Pradhan P
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Samal, D K
AU  - Samal DK
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Nayak, A
AU  - Nayak A
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Chadaram, S
AU  - Chadaram S
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Das, K K
AU  - Das KK
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Chakraborty, S
AU  - Chakraborty S
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Sharma, P
AU  - Sharma P
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Veeti, A K
AU  - Veeti AK
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Karakkandy, V
AU  - Karakkandy V
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Mishra, A
AU  - Mishra A
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Mittal, Y
AU  - Mittal Y
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Chithambaram, K S
AU  - Chithambaram KS
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Swarup, A
AU  - Swarup A
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Chenniappan, S
AU  - Chenniappan S
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
FAU - Shah, A
AU  - Shah A
AD  - Department of ENT and Head and Neck Surgery, All India Institute of Medical 
      Sciences, Bhubaneswar, India.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220614
PL  - England
TA  - J Laryngol Otol
JT  - The Journal of laryngology and otology
JID - 8706896
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Antifungal Agents)
SB  - IM
MH  - Humans
MH  - *Mucormycosis/drug therapy
MH  - Retrospective Studies
MH  - *COVID-19
MH  - Aspirin/therapeutic use
MH  - *Orbital Diseases
MH  - Antifungal Agents/therapeutic use
MH  - Debridement
OTO - NOTNLM
OT  - Aspirin
OT  - COVID-19 Associated Mucormycosis
OT  - Mortality
EDAT- 2022/06/15 06:00
MHDA- 2022/11/18 06:00
CRDT- 2022/06/14 03:12
PHST- 2022/06/15 06:00 [pubmed]
PHST- 2022/11/18 06:00 [medline]
PHST- 2022/06/14 03:12 [entrez]
AID - S0022215122001402 [pii]
AID - 10.1017/S0022215122001402 [doi]
PST - ppublish
SO  - J Laryngol Otol. 2022 Dec;136(12):1309-1313. doi: 10.1017/S0022215122001402. Epub 
      2022 Jun 14.

PMID- 3798423
OWN - NLM
STAT- MEDLINE
DCOM- 19870219
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 44
IP  - 6
DP  - 1986 Dec 15
TI  - Sex-related differences in the effects of aspirin on the interaction of platelets 
      with subendothelium.
PG  - 837-47
AB  - Using the Baumgartner perfusion technique, marked sex-related differences in the 
      extent of platelet-subendothelium interaction and in the effect of aspirin (ASA) 
      have been observed. The administration of ASA (150 mg daily for 15 days) to two 
      groups of healthy volunteers, one composed of males and the other of females, 
      proved to block the generation of TXB2 in both cases. The basic pattern of 
      platelet subendothelium interaction, however, was found to be markedly different 
      in both groups studied. In men, aspirin treatment induced a significant reduction 
      in the percentage of platelet thrombi, whereas in women, post ASA values remained 
      at the same level as in control experiments. These results show that in the 
      Baumgartner perfusion system women display a less thrombogenic tendency than men 
      and that 150 mg of ASA administered daily are effective in reducing the extent of 
      platelet-subendothelium interaction in the male group but not in the female 
      group. These findings could explain the absence of benefit observed for women in 
      clinical trials with aspirin.
FAU - Escolar, G
AU  - Escolar G
FAU - Bastida, E
AU  - Bastida E
FAU - Garrido, M
AU  - Garrido M
FAU - Rodríguez-Gómez, J
AU  - Rodríguez-Gómez J
FAU - Castillo, R
AU  - Castillo R
FAU - Ordinas, A
AU  - Ordinas A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/cytology/drug effects/physiology
MH  - Blood Vessels/cytology/*physiology
MH  - Endothelium/drug effects/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/*drug effects
MH  - *Sex Factors
MH  - Thrombosis/prevention & control
MH  - Thromboxane A2/biosynthesis
EDAT- 1986/12/15 00:00
MHDA- 1986/12/15 00:01
CRDT- 1986/12/15 00:00
PHST- 1986/12/15 00:00 [pubmed]
PHST- 1986/12/15 00:01 [medline]
PHST- 1986/12/15 00:00 [entrez]
AID - 0049-3848(86)90029-0 [pii]
AID - 10.1016/0049-3848(86)90029-0 [doi]
PST - ppublish
SO  - Thromb Res. 1986 Dec 15;44(6):837-47. doi: 10.1016/0049-3848(86)90029-0.

PMID- 37525211
OWN - NLM
STAT- MEDLINE
DCOM- 20230802
LR  - 20230803
IS  - 1472-6831 (Electronic)
IS  - 1472-6831 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Jul 31
TI  - The effect of low-dose aspirin on aspirin triggered lipoxin, interleukin 1 beta, 
      and prostaglandin E2 levels in periapical fluid: a double-blind randomized 
      clinical trial.
PG  - 530
LID - 10.1186/s12903-023-03243-0 [doi]
LID - 530
AB  - BACKGROUND: The role of pro-resolving mediators in inflammation is a new concern 
      in research. The effect of low-dose aspirin on production of a special kind of 
      these mediators named aspirin triggered lipoxin (ATL) has been studied on 
      different tissues. This randomized clinical trial evaluated the effect of 
      low-dose aspirin on ATL and pro-inflammatory mediators' level in periapical fluid 
      of necrotic teeth with large lesions. METHODS: Twenty-four patients with necrotic 
      pulp and periapical lesion were randomly assigned to low-dose aspirin and placebo 
      groups. In the first appointment, canals were shaped up to F3 size and #40 K-file 
      and cleaned with 10 milliliters 2.5% sodium hypochlorite and 17% 
      Ethylenediaminetetraacetic acid. Periapical fluid was sampled by a paper cone. 
      The tooth was temporized without any intracanal medication. Tablets were 
      administered for 7 days, then the teeth were re-opened and the sampling were 
      repeated. Interleukin-1 beta (IL-1β), prostaglandin E2 (PGE2) and ATL were 
      analyzed by enzyme-linked immunosorbent assay. Data were analyzed with paired 
      t-test using SPSS statistical software, version 21 (α = 0.05). RESULTS: A 
      significant reduction in PGE2 and IL-1β was noted in the aspirin-treated group 
      while an increase in ATL was observed (P < 0.001). There was no significant 
      difference in the mediator scores before and after in the placebo-treated group 
      (P > 0.05). CONCLUSION: Low-dose aspirin can influence the inflammatory process 
      by reducing pro-inflammatory mediators such as PGE2 and IL-1β, as well as 
      increasing the pro-resolving mediators such as ATL. TRIAL REGISTRATION: 
      IRCT20191211045702N1.
CI  - © 2023. The Author(s).
FAU - Khoshbin, Elham
AU  - Khoshbin E
AD  - Department of Endodontics, Dental School, Hamadan University of Medical Sciences, 
      Hamadan, Iran.
FAU - Salehi, Razieh
AU  - Salehi R
AD  - Department of Endodontics, Dental School, Hamadan University of Medical Sciences, 
      Hamadan, Iran.
AD  - Department of Endodontics, School of dentistry, Qazvin University of Medical 
      Sciences, Qazvin, Iran.
FAU - Behroozi, Rooholah
AU  - Behroozi R
AD  - Department of Endodontics, Dental School, Hamadan University of Medical Sciences, 
      Hamadan, Iran.
FAU - Sadr, Soroush
AU  - Sadr S
AD  - Department of Endodontics, Dental School, Hamadan University of Medical Sciences, 
      Hamadan, Iran.
FAU - Zamani, Alireza
AU  - Zamani A
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Farhadian, Maryam
AU  - Farhadian M
AD  - Department of Biostatistics, School of Public Health, Hamadan University of 
      Medical Sciences, Hamadan, Iran.
FAU - Karkehabadi, Hamed
AU  - Karkehabadi H
AD  - Department of Endodontics, Dental School, Hamadan University of Medical Sciences, 
      Hamadan, Iran. hamed_karkehabadi@yahoo.com.
AD  - Department of Endodontics, Dental Research Center, Hamadan University of Medical 
      Sciences, Hamadan, Iran. hamed_karkehabadi@yahoo.com.
LA  - eng
SI  - IRCT/IRCT20191211045702N1
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20230731
PL  - England
TA  - BMC Oral Health
JT  - BMC oral health
JID - 101088684
RN  - R16CO5Y76E (Aspirin)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipoxins)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Inflammation Mediators)
SB  - IM
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - Dinoprostone
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - *Lipoxins/therapeutic use
MH  - Interleukin-1beta
MH  - Inflammation Mediators
PMC - PMC10388445
OTO - NOTNLM
OT  - Aspirin triggered lipoxin
OT  - Interleukin 1 beta
OT  - Low-dose aspirin
OT  - Prostaglandin E2
OT  - Specialized pro-resolving mediators
COIS- The authors declare that they have no competing interests in this section.
EDAT- 2023/08/01 01:08
MHDA- 2023/08/02 06:42
CRDT- 2023/07/31 23:43
PHST- 2023/04/14 00:00 [received]
PHST- 2023/07/19 00:00 [accepted]
PHST- 2023/08/02 06:42 [medline]
PHST- 2023/08/01 01:08 [pubmed]
PHST- 2023/07/31 23:43 [entrez]
AID - 10.1186/s12903-023-03243-0 [pii]
AID - 3243 [pii]
AID - 10.1186/s12903-023-03243-0 [doi]
PST - epublish
SO  - BMC Oral Health. 2023 Jul 31;23(1):530. doi: 10.1186/s12903-023-03243-0.

PMID- 12037691
OWN - NLM
STAT- MEDLINE
DCOM- 20020816
LR  - 20131121
IS  - 0950-9240 (Print)
IS  - 0950-9240 (Linking)
VI  - 16
IP  - 6
DP  - 2002 Jun
TI  - Clinical evidence of dose-dependent interaction between aspirin and 
      angiotensin-converting enzyme inhibitors.
PG  - 379-83
AB  - Since coronary artery and cerebrovascular diseases are the most common serious 
      complications of long standing hypertension, there is a great potential for 
      combining treatment with aspirin and angiotensin-converting enzyme inhibitors 
      (ACE-I). However, the data regarding interaction of aspirin and ACE-I in relation 
      to blood pressure control and survival benefits are controversial and 
      inconclusive. We presumed that the appearance of dry cough in some of the 
      patients following initiation of ACE-I treatment could be used as a marker for 
      the presence of their influence, whereas ACE-I cough attenuation after addition 
      of aspirin to treatment could be a sign of aspirin and ACE-I interaction on 
      clinical level. The present study was aimed to use ACE-I induced cough as a 
      clinical marker of ACE-I activity to determine whether dose-dependent aspirin and 
      ACE-I interaction does exist. In a cohort of 750 consecutive ACE-I treated 
      hypertensive and postinfarction outpatients we identified 78 (10.4%) non-smoking 
      ACE-I related coughers. Out of them, 31 (21 men, 10 women; mean age 61 +/- 0.9 
      years) agreed to take part in the study, which was aimed to compare two regimens 
      of combined ACE-I and aspirin treatment (self-matched control data): intermediate 
      (500 mg daily) vs low-dose aspirin (100 mg daily). On each visit the life 
      quality, cough severity (CS, 0-4) and frequency (CF, 0-10) scores were 
      registered. Low doses of aspirin demonstrated an excellent safety profile and did 
      not influence any life quality score and ACE-I induced cough. In contrast, 
      intermediate doses completely abolished cough in 17 patients and reduced coughing 
      in other 11 patients. Cough severity and cough frequency scores decreased, 
      respectively, from 2.7 +/- 1.1 to 0.7 +/- 1.2 (P < 0.001) and from 7.1 +/- 2.3 to 
      2.0 +/- 2.2 (P < 0.0001). Overall, the cough frequency score method alone could 
      identify a clear modification of cough in 26 (84%) patients, and cough severity 
      score method alone in 24 (77%). Using the combined frequency/severity score 
      method a modification of cough could be identified in 28 (90%) of the patients 
      receiving intermediate dose of aspirin. Aspirin did not influence heart rate and 
      blood pressure control either in hypertensives or in postinfarction patients. We 
      conclude that using ACE-I induced cough as a clinical marker of ACE-I activity 
      demonstrates that an interaction between ACE-I and aspirin at 500 mg/day does 
      exist. We did not find any evidence supporting the presence of a clinically 
      significant interaction between ACE-I and aspirin at 100 mg/day. Thus, combined 
      treatment by low dose aspirin and ACE-I seems to be both safe and useful.
FAU - Fisman, E Z
AU  - Fisman EZ
AD  - Cardiac Rehabilitation Institute, The Chaim Sheba Medical Center, Tel-Hashomer, 
      and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Grossman, E
AU  - Grossman E
FAU - Motro, M
AU  - Motro M
FAU - Tenenbaum, A
AU  - Tenenbaum A
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Hum Hypertens
JT  - Journal of human hypertension
JID - 8811625
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cough/chemically induced
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2002/05/31 10:00
MHDA- 2002/08/17 10:01
CRDT- 2002/05/31 10:00
PHST- 2002/05/31 10:00 [pubmed]
PHST- 2002/08/17 10:01 [medline]
PHST- 2002/05/31 10:00 [entrez]
AID - 10.1038/sj.jhh.1001406 [doi]
PST - ppublish
SO  - J Hum Hypertens. 2002 Jun;16(6):379-83. doi: 10.1038/sj.jhh.1001406.

PMID- 22148098
OWN - NLM
STAT- MEDLINE
DCOM- 20120612
LR  - 20221207
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 35
IP  - 2
DP  - 2012 Feb
TI  - High-dose aspirin is required to influence plasma fibrin network structure in 
      patients with type 1 diabetes.
PG  - 404-8
LID - 10.2337/dc11-1302 [doi]
AB  - OBJECTIVE: Patients with type 1 diabetes form a less permeable fibrin network, 
      which could contribute to their increased risk of cardiovascular disease (CVD). 
      Low-dose aspirin treatment is the standard in the management of CVD; however, the 
      effect seems reduced in patients with diabetes. We investigated the effects of 
      low- and high-dose aspirin treatment on fibrin network formation in patients with 
      type 1 diabetes (primary aim) and the possible interaction between the treatment 
      effects of aspirin on fibrin network permeability and glycemic control in these 
      patients (secondary aim). RESEARCH DESIGN AND METHODS: Forty-eight patients (24 
      subjects with good [HbA(1c) <7.4%] and 24 subjects with poor [HbA(1c) >8.4%] 
      glycemic control) were randomly assigned to treatment with 75 or 320 mg/day 
      aspirin during 4 weeks in a crossover fashion. A 4-week washout period separated 
      the treatment periods. The plasma fibrin network was assessed by determination of 
      the permeability coefficient (K(s)). RESULTS: Treatment with 75 mg aspirin did 
      not influence fibrin network permeability (K(s)). However, K(s) increased 
      significantly during treatment with 320 mg aspirin (P = 0.004), and a significant 
      treatment effect was seen compared with treatment with 75 mg aspirin (P = 0.009). 
      The increase in K(s) during high-dose aspirin treatment was significant in 
      patients with poor glycemic control (P = 0.02), whereas K(s) only tended to 
      increase in patients with good glycemic control (P = 0.06). CONCLUSIONS: A high 
      dose of aspirin is required to influence fibrin network permeability in patients 
      with type 1 diabetes. The observed lack of effect with low-dose aspirin may 
      contribute to aspirin treatment failure in diabetes.
FAU - Tehrani, Sara
AU  - Tehrani S
AD  - Division of Medicine, Department of Clinical Sciences, Danderyd Hospital, 
      Karolinska Institutet, Stockholm, Sweden. sara.tehrani@ds.se
FAU - Antovic, Aleksandra
AU  - Antovic A
FAU - Mobarrez, Fariborz
AU  - Mobarrez F
FAU - Mageed, Koteiba
AU  - Mageed K
FAU - Lins, Per-Eric
AU  - Lins PE
FAU - Adamson, Ulf
AU  - Adamson U
FAU - Wallén, Håkan N
AU  - Wallén HN
FAU - Jörneskog, Gun
AU  - Jörneskog G
LA  - eng
SI  - ClinicalTrials.gov/NCT01397513
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20111206
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Glycated Hemoglobin A)
RN  - 9001-31-4 (Fibrin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Chromatography, High Pressure Liquid
MH  - Diabetes Mellitus, Type 1/blood/drug therapy/*metabolism
MH  - Drug Administration Schedule
MH  - Female
MH  - Fibrin/*metabolism
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Male
PMC - PMC3263903
EDAT- 2011/12/08 06:00
MHDA- 2012/06/13 06:00
CRDT- 2011/12/08 06:00
PHST- 2011/12/08 06:00 [entrez]
PHST- 2011/12/08 06:00 [pubmed]
PHST- 2012/06/13 06:00 [medline]
AID - dc11-1302 [pii]
AID - 1302 [pii]
AID - 10.2337/dc11-1302 [doi]
PST - ppublish
SO  - Diabetes Care. 2012 Feb;35(2):404-8. doi: 10.2337/dc11-1302. Epub 2011 Dec 6.

PMID- 32847114
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 17
DP  - 2020 Aug 24
TI  - Resveratrol and Resveratrol-Aspirin Hybrid Compounds as Potent Intestinal 
      Anti-Inflammatory and Anti-Tumor Drugs.
LID - 10.3390/molecules25173849 [doi]
LID - 3849
AB  - Resveratrol (3,4,5-Trihydroxy-trans-stilbene) is a naturally occurring polyphenol 
      that exhibits beneficial pleiotropic health effects. It is one of the most 
      promising natural molecules in the prevention and treatment of chronic diseases 
      and autoimmune disorders. One of the key limitations in the clinical use of 
      resveratrol is its extensive metabolic processing to its glucuronides and 
      sulfates. It has been estimated that around 75% of this polyphenol is excreted 
      via feces and urine. To possibly alleviate the extensive metabolic processing and 
      improve bioavailability, we have added segments of acetylsalicylic acid to 
      resveratrol in an attempt to maintain the functional properties of both. We 
      initially characterized resveratrol-aspirin derivatives as products that can 
      inhibit cytochrome P450 Family 1 Subfamily A Member 1 (CYP1A1) activity, DNA 
      methyltransferase (DNMT) activity, and cyclooxygenase (COX) activity. In this 
      study, we provide a detailed analysis of how resveratrol and its aspirin 
      derivatives can inhibit nuclear factor kappa B (NFκB) activation, cytokine 
      production, the growth rate of cancer cells, and in vivo alleviate intestinal 
      inflammation and tumor growth. We identified resveratrol derivatives C3 and C11 
      as closely preserving resveratrol bioactivities of growth inhibition of cancer 
      cells, inhibition of NFκB activation, activation of sirtuin, and 5' adenosine 
      monophosphate-activated protein kinase (AMPK) activity. We speculate that the 
      aspirin derivatives of resveratrol would be more metabolically stable, resulting 
      in increased efficacy for treating immune disorders and as an anti-cancer agent.
FAU - Salla, Mohamed
AU  - Salla M
AD  - Department of Biochemistry, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
FAU - Pandya, Vrajesh
AU  - Pandya V
AD  - Department of Biochemistry, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
FAU - Bhullar, Khushwant S
AU  - Bhullar KS
AD  - Department of Pharmacology, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
FAU - Kerek, Evan
AU  - Kerek E
AUID- ORCID: 0000-0003-1019-4227
AD  - Department of Pharmacology, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
FAU - Wong, Yoke Fuan
AU  - Wong YF
AD  - Department of Pediatrics, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
FAU - Losch, Robyn
AU  - Losch R
AD  - Department of Biochemistry, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
FAU - Ou, Joe
AU  - Ou J
AD  - Department of Biochemistry, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
FAU - Aldawsari, Fahad S
AU  - Aldawsari FS
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, 113 
      Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
AD  - Saudi Food and Drug Authority Laboratories, 3292 Northern Ring Road, Riyadh 
      13312, Saudi Arabia.
FAU - Velazquez-Martinez, Carlos
AU  - Velazquez-Martinez C
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, 113 
      Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
FAU - Thiesen, Aducio
AU  - Thiesen A
AUID- ORCID: 0000-0001-6836-8619
AD  - Department of Laboratory Medicine and Pathology, Faculty of Medicine and 
      Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, 
      Canada.
FAU - Dyck, Jason R B
AU  - Dyck JRB
AD  - Department of Pharmacology, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
AD  - Department of Pediatrics, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
FAU - Hubbard, Basil P
AU  - Hubbard BP
AD  - Department of Pharmacology, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
FAU - Baksh, Shairaz
AU  - Baksh S
AD  - Department of Biochemistry, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
AD  - Department of Pediatrics, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
AD  - Departments of Oncology, Faculty of Medicine and Dentistry, University of 
      Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada.
AD  - Member, Cancer Research Institute of Northern Alberta and Women and Children's 
      Health Research Institute, Edmonton, AB T6G 2E1, Canada.
AD  - BioImmuno Designs, Inc., 4560 TEC Centre, 10230 Jasper Avenue, Edmonton, AB T5J 
      4P6, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200824
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Neoplasm Proteins)
RN  - Q369O8926L (Resveratrol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Antineoplastic Agents/*pharmacology
MH  - *Aspirin/analogs & derivatives/chemistry/pharmacology
MH  - Colonic Neoplasms/*drug therapy/enzymology/pathology
MH  - *Enzyme Inhibitors/chemistry/pharmacology
MH  - HCT116 Cells
MH  - Humans
MH  - Mice
MH  - Neoplasm Proteins/*antagonists & inhibitors/metabolism
MH  - *Resveratrol/analogs & derivatives/chemistry/pharmacology
PMC - PMC7503224
OTO - NOTNLM
OT  - AMPK
OT  - NFκB
OT  - cancer
OT  - inflammation
OT  - inflammatory bowel disease
OT  - resveratrol
OT  - sirtuin
COIS- The authors declare no conflict of interest.
EDAT- 2020/08/28 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/05/05 00:00 [received]
PHST- 2020/08/04 00:00 [revised]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - molecules25173849 [pii]
AID - molecules-25-03849 [pii]
AID - 10.3390/molecules25173849 [doi]
PST - epublish
SO  - Molecules. 2020 Aug 24;25(17):3849. doi: 10.3390/molecules25173849.

PMID- 8580747
OWN - NLM
STAT- MEDLINE
DCOM- 19960321
LR  - 20190920
IS  - 0942-8925 (Print)
IS  - 0942-8925 (Linking)
VI  - 20
IP  - 6
DP  - 1995 Nov-Dec
TI  - Drug-related segmental colitis: angiographic findings.
PG  - 529-30
AB  - We report a case of drug-related segmental colitis in a 70-year-old woman with no 
      thromboembolic risk factor. Mesenteric angiography showed multiple stenoses and 
      occlusions of the distal arterial circulation in the sigmoid and descending 
      colon. These observations support the hypothesis of an ischemic origin for this 
      type of colitis.
FAU - Morin, B
AU  - Morin B
AD  - Department of Radiology, Hôpital Notre-Dame, Montreal, Québec, Canada.
FAU - Oliva, V L
AU  - Oliva VL
FAU - Lalonde, L
AU  - Lalonde L
FAU - Panzini, B
AU  - Panzini B
FAU - Bourdon, F
AU  - Bourdon F
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Abdom Imaging
JT  - Abdominal imaging
JID - 9303672
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angiography
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Colitis, Ischemic/*chemically induced/diagnostic imaging
MH  - Drug Therapy, Combination
MH  - Estrogen Replacement Therapy/*adverse effects
MH  - Female
MH  - Humans
MH  - Mesenteric Arteries/diagnostic imaging
MH  - Osteoarthritis, Hip/*drug therapy
MH  - Recurrence
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 10.1007/BF01256705 [doi]
PST - ppublish
SO  - Abdom Imaging. 1995 Nov-Dec;20(6):529-30. doi: 10.1007/BF01256705.

PMID- 6787384
OWN - NLM
STAT- MEDLINE
DCOM- 19810820
LR  - 20161123
IS  - 0025-682X (Print)
IS  - 0025-682X (Linking)
VI  - 41
IP  - 2
DP  - 1981 Mar-Apr
TI  - [Valium-aspegic association. Its value in a remote medical unit (author's 
      transl)].
PG  - 215-7
AB  - An efficient narco-analgesia is given by the association of two drugs: -- 
      diazepam (Valium): a benzodiazepine with an anxiolytic and myoresolutive effect, 
      inducing sleep and giving amnesia; -- lysine acetylsalicylate (Aspegic) giving an 
      analgesia inferior to that of morphinomimetic drugs but not inducing respiratory 
      depression. These two drugs are given in an intravenous catheter. Their effects 
      last about 20 minutes - vomiting is rare. The authors report their experience of 
      50 cases and think that this technique is recommended in remote medical units for 
      moderately painful and short duration operations.
FAU - Cornen, L
AU  - Cornen L
FAU - Le Camus, J
AU  - Le Camus J
FAU - Debiane, S
AU  - Debiane S
FAU - Vitris, M
AU  - Vitris M
LA  - fre
PT  - Journal Article
TT  - L'association Valium-Aspegic. Intérêt en poste isolé.
PL  - France
TA  - Med Trop (Mars)
JT  - Medecine tropicale : revue du Corps de sante colonial
JID - 8710146
RN  - 0 (Anesthetics)
RN  - K3Z4F929H6 (Lysine)
RN  - Q3JTX2Q7TU (Diazepam)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anesthesia, Intravenous
MH  - Anesthetics/*administration & dosage
MH  - Aspirin/administration & dosage/*analogs & derivatives
MH  - Diazepam/*administration & dosage
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Preoperative Care
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
PST - ppublish
SO  - Med Trop (Mars). 1981 Mar-Apr;41(2):215-7.

PMID- 24861046
OWN - NLM
STAT- MEDLINE
DCOM- 20150206
LR  - 20140619
IS  - 1421-9867 (Electronic)
IS  - 0012-2823 (Linking)
VI  - 89
IP  - 3
DP  - 2014
TI  - Comparison of small-bowel mucosal injury between low-dose aspirin and non-aspirin 
      non-steroidal anti-inflammatory drugs: a capsule endoscopy study.
PG  - 225-31
LID - 10.1159/000358287 [doi]
AB  - BACKGROUND/AIMS: The differences in the severity of small-bowel toxicity induced 
      by aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) remain 
      unclear. This study aimed at clarifying these differences in small-bowel mucosal 
      injury by using capsule endoscopy (CE). METHODS: We retrospectively compared the 
      records of 78 and 40 obscure gastrointestinal bleeding patients receiving 
      low-dose aspirin (LDA) and non-aspirin NSAIDs, respectively. All patients were 
      found to have small-bowel mucosal injuries on CE. The two groups were compared 
      for the number of small-bowel mucosal injuries and CE scores on the basis of the 
      findings of CE. RESULTS: The mean numbers of reddened lesions in the LDA group 
      and non-aspirin NSAID group were 2.49 ± 3.15 and 1.65 ± 3.04; the mean numbers of 
      erosions/ulcers 1.56 ± 3.75 and 6.08 ± 10.4, and the mean CE scores 154 ± 294 and 
      520 ± 758, respectively. The mean number of reddened lesions was significantly 
      higher and the mean number of erosions/ulcers and CE scores significantly lower 
      in the LDA group than in the other non-aspirin NSAID group. CONCLUSION: 
      Small-bowel mucosal injuries were significantly milder in the LDA group than in 
      the non-aspirin NSAID group, though reddened lesions were more frequent in the 
      LDA group.
FAU - Watari, Ikue
AU  - Watari I
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Oka, Shiro
AU  - Oka S
FAU - Tanaka, Shinji
AU  - Tanaka S
FAU - Igawa, Atsushi
AU  - Igawa A
FAU - Nakano, Makoto
AU  - Nakano M
FAU - Aoyama, Taiki
AU  - Aoyama T
FAU - Yoshida, Shigeto
AU  - Yoshida S
FAU - Chayama, Kazuaki
AU  - Chayama K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20140522
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Capsule Endoscopy
MH  - Female
MH  - Humans
MH  - Intestinal Mucosa/*injuries/pathology
MH  - Intestine, Small/*injuries/pathology
MH  - Male
MH  - Middle Aged
EDAT- 2014/05/28 06:00
MHDA- 2015/02/07 06:00
CRDT- 2014/05/28 06:00
PHST- 2013/10/08 00:00 [received]
PHST- 2014/01/01 00:00 [accepted]
PHST- 2014/05/28 06:00 [entrez]
PHST- 2014/05/28 06:00 [pubmed]
PHST- 2015/02/07 06:00 [medline]
AID - 000358287 [pii]
AID - 10.1159/000358287 [doi]
PST - ppublish
SO  - Digestion. 2014;89(3):225-31. doi: 10.1159/000358287. Epub 2014 May 22.

PMID- 9753050
OWN - NLM
STAT- MEDLINE
DCOM- 19981117
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 102
IP  - 5
DP  - 1998 Sep
TI  - Low-dose aspirin does not lower in vivo platelet activation in healthy smokers.
PG  - 1229-31
AB  - Smoking causes atherosclerosis, and smokers have increased thromboxane (TXA2) 
      formation. As aspirin inhibits TXA2 production we speculated that smokers would 
      preferentially profit from inhibition of the TXA2 pathway by aspirin. Increased 
      expression of P-selectin, a constituent of the alpha-granules of platelets, and 
      increased levels of circulating (c)P-selectin in plasma are markers for platelet 
      activation. The aim of this study was to compare P-selectin expression on 
      platelets between smokers and nonsmokers, and to compare with placebo the effect 
      of 2 weeks administration of 100 mg/d aspirin on platelet activation in smokers. 
      Smokers exhibited higher P-selectin expression on platelets than non-smokers 
      (2.7+/-1.8% v 1.6+/-0.6%, P=0.018), thus confirming increased platelet 
      activation. Aspirin did not reduce platelet activation as demonstrated by 
      unchanged P-selectin expression on platelets and cP-selectin plasma levels.
FAU - Pernerstorfer, T
AU  - Pernerstorfer T
AD  - Department of Clinical Pharmacology, Clinical Institute of Medical and Chemical 
      Laboratory Diagnostics, Vienna, Austria.
FAU - Stohlawetz, P
AU  - Stohlawetz P
FAU - Stummvoll, G
AU  - Stummvoll G
FAU - Kapiotis, S
AU  - Kapiotis S
FAU - Szekeres, T
AU  - Szekeres T
FAU - Eichler, H G
AU  - Eichler HG
FAU - Jilma, B
AU  - Jilma B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/metabolism
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Humans
MH  - P-Selectin/metabolism
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Prospective Studies
MH  - Smoking/*blood
MH  - Thromboxanes/metabolism
EDAT- 1998/09/30 00:00
MHDA- 1998/09/30 00:01
CRDT- 1998/09/30 00:00
PHST- 1998/09/30 00:00 [pubmed]
PHST- 1998/09/30 00:01 [medline]
PHST- 1998/09/30 00:00 [entrez]
AID - 10.1046/j.1365-2141.1998.00883.x [doi]
PST - ppublish
SO  - Br J Haematol. 1998 Sep;102(5):1229-31. doi: 10.1046/j.1365-2141.1998.00883.x.

PMID- 14964343
OWN - NLM
STAT- MEDLINE
DCOM- 20040302
LR  - 20191108
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 20
IP  - 5
DP  - 2003 Sep-Oct
TI  - Acetylsalicylic acid tablets with glycine improve long-term tolerability in 
      antiplatelet drug therapy: results of a noninterventional trial.
PG  - 237-45
AB  - To determine the tolerability of a glycine (Gly)-containing acetylsalicylic acid 
      (ASA) preparation (Gly-ASA), investigators selected 1135 patients already 
      receiving longterm antiplatelet therapy for a noninterventional trial of Gly-ASA 
      50 to 300 mg daily. After an average treatment period of 42.6 days, tolerability 
      rating scores and the frequency of 5 gastrointestinal (GI) complaints were 
      compared with those reported for any previous treatment, including plain ASA. 
      After treatment with Gly-ASA, the mean percentage of patients without GI 
      complaints increased more than 2-fold, from 28.2% to 60.6%. Furthermore, the mean 
      percentage of patients reporting any GI symptoms as "always" present decreased 
      from 8.5% to 0.5%. Gly-ASA tolerability was rated "excellent" or "good" by 98% of 
      the patients. In 10 patients (0.9%), Gly-ASA treatment was terminated prematurely 
      due to GI intolerance (n=4) and nonmedication-related causes (n=6). With respect 
      to long-term treatment compliance, the improved tolerability profile observed 
      with this Gly-ASA preparation indicates an important advantage over 
      nonglycine-containing ASA alternatives.
FAU - Kusche, Werner
AU  - Kusche W
AD  - A. CRO Clinical Research Services GmbH, Wiesbaden, Germany.
FAU - Paxinos, Rafaela
AU  - Paxinos R
FAU - Haselmann, Jutta
AU  - Haselmann J
FAU - Schwantes, Ulrich
AU  - Schwantes U
FAU - Breddin, Hans Klaus
AU  - Breddin HK
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Child
MH  - *Drug Combinations
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced/*prevention & control
MH  - Glycine/*administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
EDAT- 2004/02/18 05:00
MHDA- 2004/03/03 05:00
CRDT- 2004/02/18 05:00
PHST- 2004/02/18 05:00 [pubmed]
PHST- 2004/03/03 05:00 [medline]
PHST- 2004/02/18 05:00 [entrez]
AID - 306 [pii]
AID - 10.1007/BF02849852 [doi]
PST - ppublish
SO  - Adv Ther. 2003 Sep-Oct;20(5):237-45. doi: 10.1007/BF02849852.

PMID- 9694243
OWN - NLM
STAT- MEDLINE
DCOM- 19981116
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 90
IP  - 5
DP  - 1998 Jun 1
TI  - Combination of two doses of acetyl salicylic acid: experimental study of arterial 
      thrombosis.
PG  - 215-21
AB  - The antithrombotic effect of high dose acetylsalicylic acid is well known, and 
      recently, in vitro studies hinted the potent thrombotic effect of ultra-low dose 
      of acetylsalicylic acid (<1mg/day) showing a significant decrease in bleeding 
      time. In this study, we investigated the effect of a combination between a high 
      and an ultra-low dosage (100 mg/kg+ 10(-30) mg/kg) on an arterial thrombosis 
      induced by a laser beam. We used an intravital microscopic technique, allowing to 
      evaluate (anti)-thromboembolic events at previously determined locations of 
      microvasculature. Thrombus formation was induced by argon-laser shot. The 
      instrumental test setup was completed with a video system, to select mesenteric 
      arterioles with the same diameter (between 15 and 25 microm). The changes in 
      platelet aggregability were determined by Cardinal and Flower method, and the 
      concentration of acetylsalicylic acid in the plasma was measured by high pressure 
      liquid chromatography. Antithrombotic effect of high dose (100 mg/kg) 
      acetylsalicylic acid was confirmed in all results obtained. Asa injected at 
      ultra-low dose (10(-30) mg/kg) had a potent thrombotic properties and decreased 
      significantly the bleeding time. The subcutaneous administration of the 
      combination of the two doses permitted to come back to the control values, and 
      the bleeding time was shortened compared to control group.
FAU - Belougne-Malfatti, E
AU  - Belougne-Malfatti E
AD  - Laboratoire d'Hématologie, Faculté de Pharmacie, Bordeaux, France.
FAU - Aguejouf, O
AU  - Aguejouf O
FAU - Doutremepuich, F
AU  - Doutremepuich F
FAU - Belon, P
AU  - Belon P
FAU - Doutremepuich, C
AU  - Doutremepuich C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Cutaneous
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Hemorrhage/chemically induced/prevention & control
MH  - Lasers
MH  - Male
MH  - Mesenteric Arteries/pathology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Rats
MH  - Rats, Wistar
MH  - Thrombosis/*drug therapy
EDAT- 1998/08/07 00:00
MHDA- 1998/08/07 00:01
CRDT- 1998/08/07 00:00
PHST- 1998/08/07 00:00 [pubmed]
PHST- 1998/08/07 00:01 [medline]
PHST- 1998/08/07 00:00 [entrez]
AID - S0049-3848(98)00051-6 [pii]
AID - 10.1016/s0049-3848(98)00051-6 [doi]
PST - ppublish
SO  - Thromb Res. 1998 Jun 1;90(5):215-21. doi: 10.1016/s0049-3848(98)00051-6.

PMID- 3536048
OWN - NLM
STAT- MEDLINE
DCOM- 19861224
LR  - 20131121
IS  - 0008-428X (Print)
IS  - 0008-428X (Linking)
VI  - 29
IP  - 6
DP  - 1986 Nov
TI  - Oral acetylsalicylic acid improves patency rates in small-vessel anastomoses.
PG  - 402-4
AB  - Because platelet aggregation is the critical step in vascular thrombosis, this 
      study investigated the possibility that acetylsalicylic acid given orally would 
      improve patency of anastomoses in small arteries. Under clean conditions, in male 
      Sprague-Dawley rats, the superficial femoral arteries were divided and 
      reanastomosed using the sleeve technique with 10-0 nylon suture. Fifty-one rats 
      received a full laboratory diet and acetylsalicylic acid in their drinking water 
      (1.08 mg/ml), before and after operation. A control group of 54 rats was matched 
      for weight, water intake and duration of vessel occlusion. Vessel patency was 
      assessed on postoperative day 7, at sacrifice, by dye angiography. In the 
      experimental group 7 (13.7%) anastomoses became occluded, compared with 20 
      (37.0%) in the control group (chi 2 = 5.99, df = 1, p less than 0.025). Serum 
      thromboxane B2 levels in five rats given acetylsalicylic acid orally (33.1 +/- 
      6.1 ng/ml) were significantly (p less than 0.001) lower than in five control rats 
      (86.6 +/- 49.1 ng/ml). The authors concluded that acetylsalicylic acid 
      administered in the drinking water to Sprague-Dawley rats improved the patency 
      rate of femoral artery anastomoses probably because of a reduction in platelet 
      aggregation. Orally administered acetylsalicylic acid may be of clinical benefit 
      to patients who undergo small-vessel anastomoses.
FAU - Thibert, M R
AU  - Thibert MR
FAU - Carroll, S E
AU  - Carroll SE
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can J Surg
JT  - Canadian journal of surgery. Journal canadien de chirurgie
JID - 0372715
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Femoral Artery/*surgery
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Postoperative Complications/*prevention & control
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Suture Techniques
MH  - Thrombosis/*prevention & control
MH  - Thromboxane A2/blood
MH  - Vascular Patency/drug effects
EDAT- 1986/11/01 00:00
MHDA- 1986/11/01 00:01
CRDT- 1986/11/01 00:00
PHST- 1986/11/01 00:00 [pubmed]
PHST- 1986/11/01 00:01 [medline]
PHST- 1986/11/01 00:00 [entrez]
PST - ppublish
SO  - Can J Surg. 1986 Nov;29(6):402-4.

PMID- 6337425
OWN - NLM
STAT- MEDLINE
DCOM- 19830311
LR  - 20161122
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 14
IP  - 1
DP  - 1983 Jan-Feb
TI  - Acetylsalicylic acid in the prevention of stroke in patients with reversible 
      cerebral ischemic attacks. A Danish cooperative study.
PG  - 15-22
AB  - Two hundred and three patients, 148 males and 55 females, who during the last 
      month before admission had experienced at least one reversible cerebral ischemic 
      attack of less than 72 hours duration, were randomly assigned to treatment with 
      either acetylsalicylic acid (ASA) 1000 mg daily (101 patients) or placebo (102 
      patients). The average follow-up period was 25 months. The two treatment groups 
      were comparable with respect to age, sex, associated diseases, risk factors, 
      number and duration of cerebral ischemic attacks. No statistically significant 
      differences were found between the treatment groups as to the primary end point: 
      stroke or death (ASA group 20.8%, placebo group 16.7%). Occurrence of transient 
      ischemic attacks during the treatment period was not reduced by ASA treatment, 
      whereas there was a trend suggesting fewer myocardial infarctions in the ASA 
      group (5.9%) than in the placebo group (13.7%). The difference, however, was not 
      statistically significant (p = 0.10). We were thus unable to demonstrate any 
      favorable influence of ASA 1000 mg daily in patients with reversible ischemic 
      attacks. This study does not, of course, prove that ASA treatment is ineffective 
      in stroke prevention.
FAU - Sorensen, P S
AU  - Sorensen PS
FAU - Pedersen, H
AU  - Pedersen H
FAU - Marquardsen, J
AU  - Marquardsen J
FAU - Petersson, H
AU  - Petersson H
FAU - Heltberg, A
AU  - Heltberg A
FAU - Simonsen, N
AU  - Simonsen N
FAU - Munck, O
AU  - Munck O
FAU - Andersen, L A
AU  - Andersen LA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/*drug therapy
MH  - Clinical Trials as Topic
MH  - Denmark
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Platelet Aggregation/drug effects
MH  - Random Allocation
MH  - Time Factors
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Stroke. 1983 Jan-Feb;14(1):15-22.

PMID- 34620790
OWN - NLM
STAT- MEDLINE
DCOM- 20211022
LR  - 20220628
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 36
IP  - 6
DP  - 2021 Nov 1
TI  - Review new concepts in pharmacotherapy for peripheral arterial disease.
PG  - 720-726
LID - 10.1097/HCO.0000000000000883 [doi]
AB  - PURPOSE OF REVIEW: To provide an overview of new concepts in the pharmacotherapy 
      of patients with peripheral artery disease (PAD). RECENT FINDINGS: Modern 
      therapeutic strategies for patients with PAD include specific symptom management 
      and multidisciplinary prevention of cardiovascular events. Low-dose rivaroxaban 
      in combination with aspirin improves outcomes compared with aspirin monotherapy 
      among patients with PAD. Other novel concepts include the use of bosentan, 
      vorapaxar or sildenafil among symptomatic patients with PAD. Likewise, 
      lipid-lowering therapy reduces the risk of major cardiovascular and limb events. 
      SUMMARY: Personalized management, identification of risk factors and 
      shared-decision making are crucial in improving the best medical therapy for 
      patients with PAD. Further studies are needed to assess the long-term safety and 
      efficacy of novel strategies in real-world patients.
CI  - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Kotalczyk, Agnieszka
AU  - Kotalczyk A
AD  - Liverpool Centre for Cardiovascular Science, University of Liverpool and 
      Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
AD  - Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical 
      University of Silesia, Silesian Centre for Heart Diseases, Zabrze, Poland.
FAU - Vallabhaneni, Srinivasa Rao
AU  - Vallabhaneni SR
AD  - Liverpool Centre for Cardiovascular Science, University of Liverpool and 
      Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
FAU - Lip, Gregory Y H
AU  - Lip GYH
AD  - Liverpool Centre for Cardiovascular Science, University of Liverpool and 
      Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
AD  - Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical 
      University of Silesia, Silesian Centre for Heart Diseases, Zabrze, Poland.
AD  - Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg 
      University, Aalborg, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Peripheral Arterial Disease/drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Rivaroxaban/therapeutic use
EDAT- 2021/10/09 06:00
MHDA- 2022/06/29 06:00
CRDT- 2021/10/08 06:12
PHST- 2021/10/08 06:12 [entrez]
PHST- 2021/10/09 06:00 [pubmed]
PHST- 2022/06/29 06:00 [medline]
AID - 00001573-202111000-00007 [pii]
AID - 10.1097/HCO.0000000000000883 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2021 Nov 1;36(6):720-726. doi: 10.1097/HCO.0000000000000883.

PMID- 6500384
OWN - NLM
STAT- MEDLINE
DCOM- 19850104
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 14
IP  - 4
DP  - 1984
TI  - The effects of high doses of aspirin and related benzoic acid derivatives on 
      arterial thrombosis in male rats.
PG  - 354-60
AB  - The antithrombotic effects of four compounds structurally related to aspirin 
      (acetylsalicylic acid, ASA) were examined in a rat model of arterial thrombosis 
      and compared to ASA. ASA had antithrombotic activity, but only at high doses (200 
      mg/kg), when carotid artery thrombosis was induced 15 min after intravenous drug 
      administration. Lower doses were associated with augmented thrombus formation in 
      some animals. 2-Propionyloxybenzoic acid, which has in vitro activities similar 
      to ASA, caused similar in vivo effects, but was antithrombotic at 100 mg/kg. 
      3-Propionyloxybenzoic acid, which augments platelet function in vitro, and 
      3-methylphthalide, which inhibits biphasic adenosine diphosphate-induced platelet 
      aggregation, had no statistically significant effects. 2-Acetoxybenzoic acid, 
      which is a weak platelet aggregation and prostaglandin biosynthesis inhibitor, 
      had antithrombotic activity at 100 and 200 mg/kg and was not associated with 
      augmented thrombosis at lower doses as found with ASA. The pattern of 
      antithrombotic activity of this series of compounds does not reflect in vitro 
      effects on prostaglandin biosynthesis and indicates alternative mechanisms of 
      antithrombotic activity.
FAU - Killackey, J J
AU  - Killackey JJ
FAU - Killackey, B A
AU  - Killackey BA
FAU - Philp, R B
AU  - Philp RB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Benzoates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Benzoates/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Structure-Activity Relationship
MH  - Thrombosis/*prevention & control
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1159/000215087 [doi]
PST - ppublish
SO  - Haemostasis. 1984;14(4):354-60. doi: 10.1159/000215087.

PMID- 3485119
OWN - NLM
STAT- MEDLINE
DCOM- 19860414
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 26
IP  - 2
DP  - 1986 Feb
TI  - Comparative efficacy study of chewable aspirin and acetaminophen in the 
      antipyresis of children.
PG  - 106-10
AB  - Aspirin and acetaminophen are the most widely used antipyretics in pediatrics. 
      Most clinicians believe the drugs to be equally effective, though clinical 
      opinion often suggests that aspirin is more effective at higher temperatures. 
      Fifty-nine outpatients (age range, 2-8 years), presenting with rectal 
      temperatures of 38.8 to 40.5 degrees C, were enrolled in this double-blind trial. 
      The children were stratified by weight and initial temperature. One dose of 
      chewable aspirin or acetaminophen (10-15 mg/kg based on current recommendations 
      for weight) was administered, and rectal temperatures were monitored for three 
      hours. Of the 59 patients enrolled, 46 successfully completed the protocol. Both 
      drugs significantly reduced temperatures in the groups studied. Age did not 
      influence the response of the children to the antipyretic effects of either drug. 
      Aspirin and acetaminophen appeared equally effective when initial temperatures 
      were between 38.8 and 39.9 degrees C. However, when the initial temperature was 
      between 40.0 and 40.5 degrees C, the duration of effect of acetaminophen was 
      shorter than that for aspirin. This suggests that therapeutic differences in the 
      antipyretic activities of aspirin and acetaminophen may exist at higher 
      temperatures.
FAU - Walker, P C
AU  - Walker PC
FAU - Helms, R A
AU  - Helms RA
FAU - Wall, H P
AU  - Wall HP
FAU - Jabbour, J T
AU  - Jabbour JT
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/blood/*pharmacology
MH  - *Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Body Temperature/drug effects
MH  - Child
MH  - Child, Preschool
MH  - Chromatography, High Pressure Liquid
MH  - Humans
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Time Factors
EDAT- 1986/02/01 00:00
MHDA- 1986/02/01 00:01
CRDT- 1986/02/01 00:00
PHST- 1986/02/01 00:00 [pubmed]
PHST- 1986/02/01 00:01 [medline]
PHST- 1986/02/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1986.tb02916.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1986 Feb;26(2):106-10. doi: 10.1002/j.1552-4604.1986.tb02916.x.

PMID- 3301151
OWN - NLM
STAT- MEDLINE
DCOM- 19870921
LR  - 20190510
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 42
IP  - 2
DP  - 1987 Aug
TI  - Pharmacokinetics of enteric-coated aspirin and inhibition of platelet thromboxane 
      A2 and vascular prostacyclin generation in humans.
PG  - 175-80
AB  - We evaluated whether an enteric-coated aspirin formulation showed a "presystemic" 
      component in its antiplatelet effect and if so would spare vascular 
      cyclooxygenase. In six healthy volunteers, 30 to 45 minutes after ingestion of 
      325 mg enteric-coated aspirin, platelet thromboxane A2 generation was inhibited 
      by about 20% before any drug could be detected in the peripheral venous blood. A 
      further decline in thromboxane A2 generation occurred with appearance of aspirin 
      in blood between 60 and 240 minutes. No presystemic component could be detected 
      after 325 mg aspirin tablets. Ten patients undergoing saphenectomy received 325 
      mg of either aspirin tablet or enteric-coated aspirin; 12 hours later platelet 
      thromboxane A2 and peripheral vascular prostacyclin generation were significantly 
      reduced by 98% and 58%, respectively. The effects of the two aspirin formulations 
      were not different. Aspirin formulations with "presystemic" component in their 
      antiplatelet effect may not necessarily result in sparing of peripheral vascular 
      cyclooxygenase.
FAU - Cerletti, C
AU  - Cerletti C
FAU - Marchi, S
AU  - Marchi S
FAU - Lauri, D
AU  - Lauri D
FAU - Domanin, M
AU  - Domanin M
FAU - Lorenzi, G
AU  - Lorenzi G
FAU - Urso, R
AU  - Urso R
FAU - Dejana, E
AU  - Dejana E
FAU - Latini, R
AU  - Latini R
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*metabolism
MH  - Blood Platelets/*drug effects
MH  - Epoprostenol/*antagonists & inhibitors
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Saphenous Vein/surgery
MH  - Tablets, Enteric-Coated
MH  - Thromboxane A2/*antagonists & inhibitors
MH  - Thromboxane B2/antagonists & inhibitors/blood
EDAT- 1987/08/01 00:00
MHDA- 1987/08/01 00:01
CRDT- 1987/08/01 00:00
PHST- 1987/08/01 00:00 [pubmed]
PHST- 1987/08/01 00:01 [medline]
PHST- 1987/08/01 00:00 [entrez]
AID - 0009-9236(87)90067-1 [pii]
AID - 10.1038/clpt.1987.128 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1987 Aug;42(2):175-80. doi: 10.1038/clpt.1987.128.

PMID- 8454370
OWN - NLM
STAT- MEDLINE
DCOM- 19930422
LR  - 20210526
IS  - 0019-9567 (Print)
IS  - 1098-5522 (Electronic)
IS  - 0019-9567 (Linking)
VI  - 61
IP  - 4
DP  - 1993 Apr
TI  - Reduction of bacterial titers by low-dose aspirin in experimental aortic valve 
      endocarditis.
PG  - 1593-5
AB  - Using a rabbit model of Staphylococcus aureus endocarditis, we studied the 
      effects of aspirin on the natural progression of this infection. Compared with 
      untreated animals, the aspirin-treated animals showed a 30% (P = 0.11) reduction 
      in the weight of the vegetations and an 84% (P = 0.03) reduction in the bacterial 
      titer of the vegetations.
FAU - Nicolau, D P
AU  - Nicolau DP
AD  - Department of Pharmacy, Hartford Hospital, Connecticut 06115.
FAU - Freeman, C D
AU  - Freeman CD
FAU - Nightingale, C H
AU  - Nightingale CH
FAU - Quintiliani, R
AU  - Quintiliani R
FAU - Coe, C J
AU  - Coe CJ
FAU - Maderazo, E G
AU  - Maderazo EG
FAU - Cooper, B W
AU  - Cooper BW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Infect Immun
JT  - Infection and immunity
JID - 0246127
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aortic Valve/microbiology
MH  - Aspirin/*therapeutic use
MH  - Bacterial Adhesion/drug effects
MH  - Endocarditis, Bacterial/*drug therapy
MH  - Rabbits
MH  - Staphylococcus aureus
PMC - PMC281409
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
AID - 10.1128/iai.61.4.1593-1595.1993 [doi]
PST - ppublish
SO  - Infect Immun. 1993 Apr;61(4):1593-5. doi: 10.1128/iai.61.4.1593-1595.1993.

PMID- 15986848
OWN - NLM
STAT- MEDLINE
DCOM- 20050726
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 50
IP  - 6
DP  - 2005 Jun
TI  - Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma 
      cells.
PG  - 1025-32
AB  - Various biochemical, clinical and epidemiological studies have shown that aspirin 
      (ASA) and other nonsteroidal anti-inflammatory drugs (NSAIDs) demonstrate 
      antineoplastic properties, particularly in the gastrointestinal tract, inhibiting 
      the proliferation of colorectal cancer cells. The mechanism of action may be 
      prostaglandin mediated through inhibition of the COX enzymatic system. This 
      includes two iso-enzymes, COX-I and COX-II, working in concert with the 
      activation of apoptosis, activation of immune surveillance, inhibition of 
      proliferation, and inhibition of carcinogen activation. 5-Fluorouracil (5-FU) has 
      demonstrated activity against colorectal cancer, leading to apoptosis of 
      neoplastic cells. We evaluated the effects of varying doses of ASA (0.5, 1, 1.5 
      mM), both as a single agent and in combination with 5-FU (50 microg) in HT-29, a 
      colon adenocarcinoma cell line. Proliferation assays showed that aspirin at a 
      concentration of 1 mM inhibits cell growth. Cells treated with ASA, both alone 
      and in combination with 5-FU, demonstrated apoptotic activity with the 
      up-regulation of Bax protein, which is consistent with 5-FU anticancer treatment. 
      Furthermore, there was synergistic cell death with ASA and 5-FU. DNA 
      fragmentation, TUNEL, and trypan blue exclusion methods indicated that a 
      combination of ASA and 5-FU induces apoptosis in cells in a time- and 
      concentration-dependent manner. This study serves to further elucidate the 
      mechanism of action of ASA, and ASA in combination with 5-FU, in colorectal 
      cancer as evidenced by its effect on the HT-29 cell line.
FAU - Ashktorab, Hassan
AU  - Ashktorab H
AD  - Department of Medicine, Division of Hematology/Oncology, Howard University Cancer 
      Center, Howard University, Washington, DC 20059, USA. hashktorab@howard.edu
FAU - Dawkins, Fitzroy W
AU  - Dawkins FW
FAU - Mohamed, Rihab
AU  - Mohamed R
FAU - Larbi, Daniel
AU  - Larbi D
FAU - Smoot, Duane T
AU  - Smoot DT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Antineoplastic Agents)
RN  - 0 (BAX protein, human)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (bcl-2-Associated X Protein)
RN  - R16CO5Y76E (Aspirin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adenocarcinoma/*drug therapy
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Apoptosis/*drug effects
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Colonic Neoplasms/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Fluorouracil/*pharmacology/therapeutic use
MH  - Humans
MH  - Proto-Oncogene Proteins c-bcl-2/drug effects
MH  - bcl-2-Associated X Protein
EDAT- 2005/07/01 09:00
MHDA- 2005/07/27 09:00
CRDT- 2005/07/01 09:00
PHST- 2005/07/01 09:00 [pubmed]
PHST- 2005/07/27 09:00 [medline]
PHST- 2005/07/01 09:00 [entrez]
AID - 10.1007/s10620-005-2698-2 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2005 Jun;50(6):1025-32. doi: 10.1007/s10620-005-2698-2.

PMID- 17094137
OWN - NLM
STAT- MEDLINE
DCOM- 20070720
LR  - 20131121
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 96
IP  - 6
DP  - 2007 Jun
TI  - Structure and release behavior of PMMA/silica composite drug delivery system.
PG  - 1518-26
AB  - The preparation, characterization, and in vitro release of aspirin from 
      polymethylmethacrylate (PMMA)/silica composites prepared via a sol-gel route are 
      reported. The in vitro drug release test revealed that the release rate of 
      aspirin in PBS increased with the silica content in the composites; on the 
      contrary, the increase of the content of 3-(trimethoxysilyl) propyl methacrylate 
      (MSMA), a coupling agent, decreased the drug release rate. The drug release 
      rate/composite structure relationship was studied using Fourier transform 
      infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and swelling 
      ratio (SR) measurement. The results indicated that the interface between polymer 
      matrix and inorganic fillers has significant influence on the drug release 
      behavior of the composite materials. In addition, models of mass transfer based 
      on Fickian diffusion law at constant temperature and pressure were employed to 
      analyze the results of the in vitro drug release experiments. The drug release 
      behaviors of the composite samples fitted well with the Fickian diffusion model. 
      The values of k, which is in direct proportion to drug release rate, increased 
      with the increasing content of silica while decreased with that of MSMA in the 
      composite samples.
FAU - Lin, Mei
AU  - Lin M
AD  - The Key Laboratory of Molecular Engineering of Polymers, Ministry of Education 
      and Department of Macromolecular Science, Fudan University, Shanghai 200433, 
      China.
FAU - Wang, Haitao
AU  - Wang H
FAU - Meng, Sheng
AU  - Meng S
FAU - Zhong, Wei
AU  - Zhong W
FAU - Li, Zhulai
AU  - Li Z
FAU - Cai, Rui
AU  - Cai R
FAU - Chen, Zhuo
AU  - Chen Z
FAU - Zhou, Xiaoyu
AU  - Zhou X
FAU - Du, Qiangguo
AU  - Du Q
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 7631-86-9 (Silicon Dioxide)
RN  - 9011-14-7 (Polymethyl Methacrylate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/chemistry
MH  - *Drug Delivery Systems
MH  - Kinetics
MH  - Microscopy, Electron, Scanning
MH  - Polymethyl Methacrylate/*administration & dosage/chemistry
MH  - Silicon Dioxide/*administration & dosage/chemistry
MH  - Solubility
MH  - Spectroscopy, Fourier Transform Infrared
EDAT- 2006/11/10 09:00
MHDA- 2007/07/21 09:00
CRDT- 2006/11/10 09:00
PHST- 2006/11/10 09:00 [pubmed]
PHST- 2007/07/21 09:00 [medline]
PHST- 2006/11/10 09:00 [entrez]
AID - S0022-3549(16)32280-8 [pii]
AID - 10.1002/jps.20809 [doi]
PST - ppublish
SO  - J Pharm Sci. 2007 Jun;96(6):1518-26. doi: 10.1002/jps.20809.

PMID- 3707309
OWN - NLM
STAT- MEDLINE
DCOM- 19860602
LR  - 20191022
IS  - 0344-8444 (Print)
IS  - 0344-8444 (Linking)
VI  - 105
IP  - 1
DP  - 1986
TI  - Effects of acetylsalicylic acid and naproxen on the mechanical properties of 
      intact femora in rats.
PG  - 5-10
AB  - The influence of acetylsalicylic acid (ASA) and naproxen on growing bones was 
      studied. Young male rats were used. The drugs were administered via gastric 
      gavage twice a day for 9 or 18 days. Drug doses giving serum concentrations 
      corresponding to ordinary anti-inflammatory steady-state levels in humans were 
      used. There was a drug-related influence on the strength of the growing femur. 
      After 9 days the ultimate bending moment of the distal femoral epiphyseal plate 
      and ultimate torsional moment and stress of the femoral diaphysis increased by 
      about 10% in the rats treated with 150 mg/kg/12 h of ASA as compared with 
      controls. After 18 days there were no differences. The ultimate metaphyseal 
      bending moment of the distal femur was not influenced after 9 days with this 
      dose, but was reduced by about 10% compared with controls after 18 days. Doses of 
      100 mg/kg/12 h of ASA and 20 mg/kg/12 h of naproxen did not change the bone 
      strength. The doses used were well tolerated and did not influence the bone 
      growth or body weight of the rats. A naproxen dose of 40 mg/kg/12 h was lethal; 
      rats that received this dose succumbed to jejunal perforations. The results 
      indicate that ASA influences the remodeling of normally growing bones.
FAU - Solheim, L F
AU  - Solheim LF
FAU - Rönningen, H
AU  - Rönningen H
FAU - Langeland, N
AU  - Langeland N
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arch Orthop Trauma Surg (1978)
JT  - Archives of orthopaedic and traumatic surgery. Archiv fur orthopadische und 
      Unfall-Chirurgie
JID - 7803037
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biomechanical Phenomena
MH  - Bone Development/*drug effects
MH  - Femur/*drug effects/growth & development/physiology
MH  - Male
MH  - Naproxen/administration & dosage/*pharmacology
MH  - Rats
MH  - Time Factors
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1007/BF00625652 [doi]
PST - ppublish
SO  - Arch Orthop Trauma Surg (1978). 1986;105(1):5-10. doi: 10.1007/BF00625652.

PMID- 2758104
OWN - NLM
STAT- MEDLINE
DCOM- 19890914
LR  - 20191022
IS  - 0142-2782 (Print)
IS  - 0142-2782 (Linking)
VI  - 10
IP  - 4
DP  - 1989 Jul-Aug
TI  - Pharmacokinetic interactions between arbaprostil and aspirin in humans.
PG  - 411-22
AB  - Arbaprostil is an orally active prostaglandin E2 analogue. It has been developed 
      as a drug to treat ulcers induced by non-steroidal anti-inflammatory drugs. In 
      this study, pharmacokinetic interactions between arbaprostil and aspirin were 
      examined in humans after chronic doses of both drugs. Subjects received either 
      arbaprostil (50 micrograms), aspirin (975 mg) or arbaprostil (50 micrograms) and 
      aspirin (975 mg) four times a day for 6 days and one dose on 7th day. Blood and 
      urine samples were collected after the last dose for 6 h. Pharmacokinetic 
      parameters of arbaprostil, aspirin, and salicylate were determined. 
      Coadministration of arbaprostil significantly lowered the area under curve (5.09 
      +/- 0.32 micrograms hml-1 vs 5.78 +/- 0.29 micrograms hml-1, mean +/- SE, p less 
      than 0.05) and time (0.45 +/- 0.07 h vs 0.70 +/- 0.12 h, p less than 0.05) to 
      reach maximal plasma concentration of aspirin (acetylsalicylate). The 
      pharmacokinetics of salicylate were not changed by arbaprostil, nor were the 
      pharmacokinetics of arbaprostil affected by aspirin. Coadministration of these 
      two drugs did not appear to potentiate the side-effects of either drug. The 
      results suggest that arbaprostil and aspirin may be administered together without 
      clinically significant changes in pharmacokinetics or adverse side-effects.
FAU - Hsyu, P H
AU  - Hsyu PH
AD  - Clinical Pharmacokinetics, Upjohn Company, Kalamazoo, MI 49007.
FAU - Cox, J W
AU  - Cox JW
FAU - Pullen, R H
AU  - Pullen RH
FAU - Gee, W L
AU  - Gee WL
FAU - Euler, A R
AU  - Euler AR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Biopharm Drug Dispos
JT  - Biopharmaceutics & drug disposition
JID - 7911226
RN  - 0 (Prostaglandins E, Synthetic)
RN  - 0 (Salicylates)
RN  - M6B59S6MEF (Arbaprostil)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arbaprostil/adverse effects/*pharmacokinetics/pharmacology
MH  - Aspirin/adverse effects/*pharmacokinetics/pharmacology
MH  - Drug Interactions
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Models, Biological
MH  - Prostaglandins E, Synthetic/*pharmacokinetics
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1989/07/01 00:00
MHDA- 1989/07/01 00:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 1989/07/01 00:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
AID - 10.1002/bdd.2510100408 [doi]
PST - ppublish
SO  - Biopharm Drug Dispos. 1989 Jul-Aug;10(4):411-22. doi: 10.1002/bdd.2510100408.

PMID- 31530511
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201008
IS  - 1018-9068 (Print)
IS  - 1018-9068 (Linking)
VI  - 30
IP  - 1
DP  - 2020
TI  - Statement of the Spanish Society of Allergology and Clinical Immunology on 
      Provocation Tests With Aspirin/Nonsteroidal Anti-inflammatory Drugs.
PG  - 1-13
LID - 10.18176/jiaci.0449 [doi]
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used throughout the 
      world. They are frequently involved in hypersensitivity reactions, which range 
      from local or mild reactions to systemic and severe reactions. Consequently, it 
      is necessary to perform an exhaustive study of patients in order to make an 
      accurate diagnosis, search for safe procedures in the case of severe reactions, 
      and identify alternative treatment options. Various guidelines and protocols 
      address the management of hypersensitivity to NSAIDs, although these vary widely 
      from country to country. The Committees of Asthma, Rhinoconjunctivitis, and Drug 
      Allergy of the Spanish Society of Allergy and Clinical Immunology (SEAIC) propose 
      the present position statement on available options for provocation testing with 
      aspirin/NSAIDs. This document is the fruit of an exhaustive review of current 
      evidence and is based on recent publications addressing the diagnosis of patients 
      with hypersensitivity to NSAIDs and on a consensus-oriented discussion among a 
      group of experts from the SEAIC. The main objective was to draft an easy-toread, 
      practical guideline for health care professionals in specialist areas who assess 
      and manage patients with suspected hypersensitivity to NSAIDs. Furthermore, 
      indications, contraindications, and procedures for oral, bronchial, and nasal 
      provocation tests with aspirin/NSAIDs have been updated.
FAU - Izquierdo-Domínguez, A
AU  - Izquierdo-Domínguez A
AD  - Allergy Service, Consorci Sanitari de Terrassa, Barcelona, Spain.
AD  - Allergy Unit, Clínica Diagonal, Barcelona, Spain.
FAU - Bobolea, I
AU  - Bobolea I
AD  - Allergy Section, Servei de Pneumologia i Al.lèrgia Respiratòria, Hospital Clínic, 
      Barcelona, Spain.
FAU - Doña, I
AU  - Doña I
AD  - Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
AD  - Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, 
      Málaga, Spain.
FAU - Campo, P
AU  - Campo P
AD  - Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
AD  - Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, 
      Málaga, Spain.
FAU - Segura, C
AU  - Segura C
AD  - UGC Alergología, Hospital Universitario Virgen Macarena, Sevilla, Spain.
FAU - Ortega, N
AU  - Ortega N
AD  - Allergy Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de 
      Gran Canaria, Spain.
FAU - González, R
AU  - González R
AD  - Allergy Service, Hospital Universitario de Canarias, Tenerife, Spain.
FAU - Delgado, J
AU  - Delgado J
AD  - UGC Alergología, Hospital Universitario Virgen Macarena, Sevilla, Spain.
FAU - Torres, M J
AU  - Torres MJ
AD  - Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
AD  - Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, 
      Málaga, Spain.
FAU - Dordal, M T
AU  - Dordal MT
AD  - Allergy Unit, Servei de Medicina Interna, Hospital Universitari de Bellvitge, 
      Barcelona, Spain.
CN  - SEAIC Rhinoconjunctivitis Committee
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190918
PL  - Spain
TA  - J Investig Allergol Clin Immunol
JT  - Journal of investigational allergology & clinical immunology
JID - 9107858
RN  - 0 (Allergens)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Allergens/*administration & dosage
MH  - Allergy and Immunology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Hypersensitivity/*diagnosis/therapy
MH  - Expert Testimony
MH  - Humans
MH  - Nasal Provocation Tests/*methods
MH  - Practice Guidelines as Topic
MH  - Spain
OTO - NOTNLM
OT  - AERD
OT  - Aspirin
OT  - Aspirin provocation test
OT  - NERD
OT  - NSAID
EDAT- 2019/09/19 06:00
MHDA- 2020/10/09 06:00
CRDT- 2019/09/19 06:00
PHST- 2019/09/19 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2019/09/19 06:00 [entrez]
AID - 10.18176/jiaci.0449 [doi]
PST - ppublish
SO  - J Investig Allergol Clin Immunol. 2020;30(1):1-13. doi: 10.18176/jiaci.0449. Epub 
      2019 Sep 18.

PMID- 6602401
OWN - NLM
STAT- MEDLINE
DCOM- 19830708
LR  - 20190727
IS  - 0041-008X (Print)
IS  - 0041-008X (Linking)
VI  - 68
IP  - 2
DP  - 1983 Apr
TI  - Prevention of the gastrotoxicity of aspirin and related drugs in rats by lithium 
      salts and sodium thiocyanate.
PG  - 323-7
AB  - Oral or parenteral administration of lithium salts considerably increased the 
      gastric fluid volume in rats, effectively preventing the hemorrhagic effects of 
      oral or parenteral aspirin and other nonsteroid anti-inflammatory drugs on the 
      gastric mucosa in cold-stressed and fasted animals and in fasted arthritic rats. 
      The doses of Li+ which were totally protective in normal rats, though active, 
      were much less protective in the arthritic animals. Thiocyanate salts reduced the 
      gastrotoxicity of these drugs only in normal (i.e., nonarthritic) rats.
FAU - Whitehouse, M W
AU  - Whitehouse MW
FAU - Rainsford, K D
AU  - Rainsford KD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Toxicol Appl Pharmacol
JT  - Toxicology and applied pharmacology
JID - 0416575
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Thiocyanates)
RN  - 5W0K9HKA05 (sodium thiocyanate)
RN  - 9FN79X2M3F (Lithium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/antagonists & inhibitors/toxicity
MH  - Aspirin/*antagonists & inhibitors/toxicity
MH  - Cold Temperature
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Lithium/*therapeutic use
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Thiocyanates/*therapeutic use
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 0041-008X(83)90016-9 [pii]
AID - 10.1016/0041-008x(83)90016-9 [doi]
PST - ppublish
SO  - Toxicol Appl Pharmacol. 1983 Apr;68(2):323-7. doi: 10.1016/0041-008x(83)90016-9.

PMID- 1150495
OWN - NLM
STAT- MEDLINE
DCOM- 19751105
LR  - 20131121
IS  - 0003-1488 (Print)
IS  - 0003-1488 (Linking)
VI  - 167
IP  - 1
DP  - 1975 Jul 1
TI  - Aspirin dosages for the dog.
PG  - 63-4
AB  - Aspirin dosages calculated from published pharmacokinetic data were tested in 3 
      male and 3 female Basset Hounds. Emesis occurred frequently after dosing at the 
      rate of 50 mg/kg of body weight, a dosage that would be required for a convenient 
      12-hour dosing interval. A dosage of 25 mg/kg every 12 hours avoided emesis but 
      did not maintain serum salicylate concentrations within the desired range of 10 
      to 30 mg/100 ml. A dosage of 25 mg/kg every 8 hours resulted in serum salicylate 
      concentrations varying from 12.5 to 17.8 mg/100 ml. It was concluded that a 
      maintenance dosage of 25 to 35 mg/kg every 8 hours in optimal for the dog, based 
      on extrapolation of data obtained in man.
FAU - Yeary, R A
AU  - Yeary RA
FAU - Brant, R J
AU  - Brant RJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Vet Med Assoc
JT  - Journal of the American Veterinary Medical Association
JID - 7503067
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage/toxicity
MH  - Dog Diseases/chemically induced
MH  - Dogs/*blood
MH  - Female
MH  - Male
MH  - Salicylates/blood
MH  - Time Factors
MH  - Vomiting/chemically induced/veterinary
EDAT- 1975/07/01 00:00
MHDA- 1975/07/01 00:01
CRDT- 1975/07/01 00:00
PHST- 1975/07/01 00:00 [pubmed]
PHST- 1975/07/01 00:01 [medline]
PHST- 1975/07/01 00:00 [entrez]
PST - ppublish
SO  - J Am Vet Med Assoc. 1975 Jul 1;167(1):63-4.

PMID- 7574219
OWN - NLM
STAT- MEDLINE
DCOM- 19951107
LR  - 20210503
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 123
IP  - 9
DP  - 1995 Nov 1
TI  - Lack of effect of aspirin in asymptomatic patients with carotid bruits and 
      substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group.
PG  - 649-55
AB  - OBJECTIVE: To determine the effectiveness of aspirin in preventing ischemic 
      events in patients with asymptomatic carotid stenosis. DESIGN: Double-blind, 
      placebo-controlled trial. SETTING: University-affiliated hospitals. PATIENTS: 372 
      neurologically asymptomatic patients with carotid stenosis of 50% or more in at 
      least one artery as determined by luminal diameter reduction on duplex 
      ultrasonography. INTERVENTION: Patients were randomly assigned to receive either 
      enteric coated aspirin, 325 mg/d, or identically appearing placebo. Duration of 
      therapy was 2.0 years for the aspirin recipients and 1.9 years for the placebo 
      recipients. OUTCOME MEASURES: Patients were scheduled for a clinical examination 
      every 6 months for assessment of the occurrence of any clinical event in the 
      composite end point, which consisted of transient ischemic attack, stroke, 
      myocardial infarction, unstable angina, or death. RESULTS: At baseline, the 188 
      patients receiving aspirin and the 184 patients receiving placebo had similar 
      demographic, ultrasonographic, and laboratory characteristics. The median 
      duration of follow-up was 2.3 years. The annual rate of all ischemic events and 
      death from any cause was 12.3% for the placebo group and 11.0% for the aspirin 
      group (P = 0.61). The Cox proportional hazards analysis yielded an adjusted 
      hazard ratio (aspirin-placebo) of 0.99 (95% CI, 0.67 to 1.46; P = 0.95). The 
      annual rates for vascular events only were 11% for the placebo group and 10.7% 
      for the aspirin group (P = 0.99). The multivariate analysis yielded a hazard 
      ratio of 1.08 (CI, 0.72 to 1.62; P = 0.71). CONCLUSION: Aspirin did not have a 
      significant long-term protective effect in asymptomatic patients with high-grade 
      (> or = 50%) carotid stenosis.
FAU - Côté, R
AU  - Côté R
AD  - Montreal General Hospital, Quebec, Canada.
FAU - Battista, R N
AU  - Battista RN
FAU - Abrahamowicz, M
AU  - Abrahamowicz M
FAU - Langlois, Y
AU  - Langlois Y
FAU - Bourque, F
AU  - Bourque F
FAU - Mackey, A
AU  - Mackey A
LA  - eng
PT  - Clinical Trial
PT  - Comment
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 1995 Nov 1;123(9):720-2. PMID: 7574228
CON - Ann Intern Med. 1995 Nov 1;123(9):720-2. PMID: 7574228
CIN - Ann Intern Med. 1995 Nov 1;123(9):723-5. PMID: 7574229
CON - Ann Intern Med. 1995 Nov 1;123(9):729. PMID: 7574232
CIN - Ann Intern Med. 1996 Sep 1;125(5):420; author reply 420-1. PMID: 8702096
CIN - Ann Intern Med. 1996 Sep 1;125(5):420; author reply 420-1. PMID: 8702097
CIN - Ann Intern Med. 1996 Sep 1;125(5):420-1. PMID: 8702098
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/*prevention & control
MH  - Carotid Arteries/*physiopathology
MH  - Carotid Stenosis/*drug therapy/physiopathology
MH  - Double-Blind Method
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Patient Compliance
MH  - Proportional Hazards Models
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 10.7326/0003-4819-123-9-199511010-00002 [doi]
PST - ppublish
SO  - Ann Intern Med. 1995 Nov 1;123(9):649-55. doi: 
      10.7326/0003-4819-123-9-199511010-00002.

PMID- 7181333
OWN - NLM
STAT- MEDLINE
DCOM- 19830214
LR  - 20131121
IS  - 0003-4886 (Print)
IS  - 0003-4886 (Linking)
VI  - 14
IP  - 11
DP  - 1982 Nov
TI  - Bilateral subconjunctival hemorrhage after acetylsalicylic acid overdose.
PG  - 1024-5
AB  - Isolated bilateral subconjunctival hemorrhages developed in an adult patient 
      after ingestion of a large amount (6.48 g) of aspirin. The time course and 
      bilateral pattern suggest a direct metabolic relationship between these two 
      events. Adverse ocular effect of aspirin previously described have not included 
      this finding. Treatment was supportive for the ingestion and was accompanied by 
      spontaneous clearing of the hemorrhage.
FAU - Black, R A
AU  - Black RA
FAU - Bensinger, R E
AU  - Bensinger RE
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Ophthalmol
JT  - Annals of ophthalmology
JID - 0210137
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*poisoning
MH  - Conjunctival Diseases/*chemically induced
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Suicide, Attempted
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
PST - ppublish
SO  - Ann Ophthalmol. 1982 Nov;14(11):1024-5.

PMID- 8147367
OWN - NLM
STAT- MEDLINE
DCOM- 19940505
LR  - 20131121
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 89
IP  - 4
DP  - 1994 Apr
TI  - Nonsteroidal anti-inflammatory drug-induced diaphragm disease arising in a 
      bypassed ileal segment.
PG  - 610-2
AB  - The formation of mucosal ileal diaphragms has been previously reported in 
      patients receiving nonsteroidal anti-inflammatory drugs over extended periods of 
      time. Whether this effect is the result of a local or systemic action by the 
      medication has remained unknown. We report the first known instance of diaphragm 
      disease arising in a segment of ileum that had been bypassed for many years and 
      therefore was not exposed normally to luminal contact with the drug. This case 
      supports at least a partial systemic mechanism in the production of the lesion.
FAU - Monihan, J M
AU  - Monihan JM
AD  - Department of Hepatic and Gastrointestinal Pathology, Armed Forces Institute of 
      Pathology, Washington, DC.
FAU - Hensley, S D Jr
AU  - Hensley SD Jr
FAU - Sobin, L H
AU  - Sobin LH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Constriction, Pathologic/chemically induced/pathology
MH  - Humans
MH  - Ileal Diseases/*chemically induced/pathology
MH  - Ileum/*pathology/surgery
MH  - Intestinal Mucosa/pathology
MH  - Jejunoileal Bypass
MH  - Low Back Pain/drug therapy
MH  - Male
MH  - Time Factors
EDAT- 1994/04/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
PST - ppublish
SO  - Am J Gastroenterol. 1994 Apr;89(4):610-2.

PMID- 2514478
OWN - NLM
STAT- MEDLINE
DCOM- 19900209
LR  - 20131121
IS  - 0165-6147 (Print)
IS  - 0165-6147 (Linking)
VI  - 10
IP  - 11
DP  - 1989 Nov
TI  - Aspirin and human platelets: from clinical trials to acetylation of 
      cyclooxygenase and back.
PG  - 453-8
AB  - Aspirin has been convincingly shown to reduce the incidence of vascular occlusive 
      events in a wide range of patients at risk of thrombotic complications. These 
      beneficial effects are currently linked to suppression of thromboxane 
      A2-dependent platelet aggregation. This in turn reflects permanent loss of the 
      cyclooxygenase activity of platelet prostaglandin G/H synthase, through 
      acetylation of Ser530. Progress in our understanding of the molecular mechanism 
      of action of aspirin and definition of the clinical pharmacology of its platelet 
      effects has been associated with a downward trend in its daily dosage. This has 
      been reduced by a factor of ten over the last decade, substantially reducing 
      gastrointestinal toxicity, while leaving antithrombotic efficacy virtually 
      unchanged. Carlo Patrono reviews the biochemical, pharmacological and clinical 
      data that form the basis of the present consensus and provide a rationale for 
      clinical trials of low-dose aspirin.
FAU - Patrono, C
AU  - Patrono C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - England
TA  - Trends Pharmacol Sci
JT  - Trends in pharmacological sciences
JID - 7906158
RN  - 0 (Fibrinolytic Agents)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Clinical Trials as Topic
MH  - Fibrinolytic Agents
MH  - Humans
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
RF  - 24
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
AID - S0165-6147(89)80010-0 [pii]
AID - 10.1016/S0165-6147(89)80010-0 [doi]
PST - ppublish
SO  - Trends Pharmacol Sci. 1989 Nov;10(11):453-8. doi: 10.1016/S0165-6147(89)80010-0.

PMID- 647162
OWN - NLM
STAT- MEDLINE
DCOM- 19780715
LR  - 20190509
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 63
IP  - 1
DP  - 1978 May
TI  - Role of platelets in aspirin-sensitive bronchoconstriction in the guinea-pig; 
      interactions with salicylic acid.
PG  - 35-42
AB  - 1 The bronchoconstriction caused in the guinea-pig by arachidonic acid (AA), 
      bradykinin, adenosine diphosphate (ADP) and adenosine triphosphate (ATP) was 
      correlated with effects on platelets. ATP and ADP produced a brief 
      thrombocytopenia and AA a more prolonged one. Bradykinin had no effect on 
      platelets.2 Aspirin inhibited bronchoconstriction and thrombocytopenia produced 
      by AA and part of the bronchoconstriction produced by ATP, but had no effect 
      against ADP. Thrombocytopenia produced by ADP and ATP was not affected by aspirin 
      or indomethacin.3 Platelet depletion by antiserum prevented bronchoconstriction 
      in response to ADP and to ATP, but not in response to bradykinin or to AA, 
      showing that platelets are not involved in aspirin-sensitive bronchoconstriction. 
      Infusions of ADP reduced bronchoconstriction and thrombocytopenia in response to 
      ADP itself and to ATP, but not to AA. Bronchoconstriction by ADP or ATP involves 
      an action on platelets. Only that due to ATP is partially dependent on the 
      activity of prostaglandin synthetase.4 ATP induced aggregation in vitro in 
      guinea-pig platelet-rich plasma (PRP). Rabbit PRP responded only when ATP was 
      first incubated with guinea-pig plasma. The aggregating compound formed was 
      probably ADP, since it was destroyed by apyrase. Its formation was not inhibited 
      by aspirin or indomethacin, indicating that aspirin inhibits ATP-induced 
      bronchoconstriction by a different mechanism.5 The aggregating effect of ATP on 
      guinea-pig platelets was inhibited by concentrations of apyrase that block 
      ADP-induced aggregation, and potentiated by lower concentrations of apyrase.6 
      Adenosine 5'-tetraphosphate did not aggregate platelets in vivo or in vitro. In 
      vitro aggregation occurred when apyrase was added, suggesting transformation into 
      ADP. Adenosine 5'-tetraphosphate and apyrase inhibited aggregation due to ADP, 
      but failed to affect that due to AA. This suggests that aggregation involving 
      products of prostaglandin synthesis does not require ADP.7 Salicylic acid did not 
      interfere with bronchoconstriction or aggregation due to AA, but prevented 
      inhibition by aspirin when the weight ratio, salicylic acid:aspirin was 4:1. 
      Salicyclic acid may be useful in studies of potential inhibitors of thromboxane 
      A2 synthesis and of thromboxane A2-dependent processes in vivo and in vitro.
FAU - Lefort, J
AU  - Lefort J
FAU - Vargaftig, B B
AU  - Vargaftig BB
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Arachidonic Acids)
RN  - 0 (Salicylates)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - EC 3.6.1.5 (Apyrase)
RN  - R16CO5Y76E (Aspirin)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adenosine Triphosphate/pharmacology
MH  - Animals
MH  - Apyrase/pharmacology
MH  - Arachidonic Acids/*antagonists & inhibitors
MH  - Aspirin/antagonists & inhibitors/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Bradykinin/pharmacology
MH  - Bronchi/*drug effects
MH  - Drug Synergism
MH  - Guinea Pigs
MH  - Platelet Aggregation/drug effects
MH  - Salicylates/*pharmacology
PMC - PMC1668291
EDAT- 1978/05/01 00:00
MHDA- 1978/05/01 00:01
CRDT- 1978/05/01 00:00
PHST- 1978/05/01 00:00 [pubmed]
PHST- 1978/05/01 00:01 [medline]
PHST- 1978/05/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1978.tb07771.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1978 May;63(1):35-42. doi: 10.1111/j.1476-5381.1978.tb07771.x.

PMID- 1087879
OWN - NLM
STAT- MEDLINE
DCOM- 19770321
LR  - 20131121
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 6 Suppl 1
DP  - 1976
TI  - Gastric damage by drugs and the role of the mucosal barrier.
PG  - Suppl 1:26-32
AB  - There are six drugs usually implicated in peptic ulceration and these are adrenal 
      corticosteroids, aspirin, phenylbutazone, indomethacin, ethanol and caffeine. The 
      types of data upon which these conclusions rest follows three lines of evidence. 
      First, the production of ulcers in experimental animals; all the drugs mentioned 
      above can produce experimental ulcers. Second, the cause and effect relationship 
      in man, i.e. epidemiological evidence; the epidemiological evidence is very weak 
      except for aspirin. Third, a mechanism suspected of participating in the 
      pathogenesis; the pathogenesis of drug ulceration is not fully understood but 
      aspirin may be the only one with a body of data to support its ulcerogenic 
      effect. The pathogenesis of peptic ulcer is usually considered in terms of the 
      equation, acid-pepsin versus mucosal resistance. Caffeine is a moderately strong 
      stimulus of acid secretion but corticosteroids, phenylbutazone, ethanol and 
      indomethacin are very weak stimulants or have no effect. Aspirin decreases acid 
      secretion...
FAU - Cooke, A R
AU  - Cooke AR
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 0 (Gastric Mucins)
RN  - 3K9958V90M (Ethanol)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/pharmacology
MH  - Dogs
MH  - Ethanol/adverse effects/pharmacology
MH  - Gastric Mucins
MH  - *Gastric Mucosa/metabolism
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Indomethacin/adverse effects
MH  - Prednisone/pharmacology
MH  - Sodium/metabolism
MH  - Stomach Ulcer/*chemically induced
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Aust N Z J Med. 1976;6 Suppl 1:Suppl 1:26-32.

PMID- 30261990
OWN - NLM
STAT- MEDLINE
DCOM- 20191002
LR  - 20221207
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 143
DP  - 2018 Oct
TI  - Aspirin desensitization in aspirin-exacerbated respiratory disease: New insights 
      into the molecular mechanisms.
PG  - 39-41
LID - S0954-6111(18)30275-0 [pii]
LID - 10.1016/j.rmed.2018.08.009 [doi]
AB  - BACKGROUND: Aspirin desensitization (AD) has been the only available modifying 
      treatment in aspirin-exacerbated respiratory disease (AERD). The mechanisms of AD 
      are nonetheless poorly understood. Though very effective, AD is limited by its 
      risks and side-effects. OBJECTIVE: Moving forward to the targeted biologicals 
      era, the aim of this study was to characterize the airway inflammatory response 
      to long-term AD, including TSLP dynamics, in order to assess potential new 
      targets in AERD. PATIENTS AND METHODS: Adult patients with aspirin 
      challenge-confirmed AERD underwent an oral AD followed by daily ingestion of 
      aspirin for at least 6 months. Clinical data and inflammatory biomarkers were 
      measured and compared, before and after AD. Induced sputum analyses were 
      performed at baseline, one and six months after AD (differential cell count and 
      levels of sputum supernatant leukotriene C4, prostaglandin D2 and E2, and TSLP). 
      RESULTS: AD was followed by significant clinical improvement, as quantified by 
      all monitored parameters. The good clinical outcomes of AD in our study are 
      supported by overall changes observed in the arachidonic acid metabolites 
      (decreased PGD2 over a constant LTC4/PGE2). TSLP increased (mean baseline 
      0.1 ± 0.03; 1 month 3.68 ± 7; 6 months 212.2 ± 44 pg/ml; p < 0.01). CONCLUSIONS: 
      Our findings suggest that new biologicals blocking TSLP might have a clinical 
      benefit in AERD, by cutting down the TSLP-induced PGD2 generation.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Bobolea, Irina
AU  - Bobolea I
AD  - Department of Pulmonology and Allergy, Hospital Clinic Barcelona- Institute for 
      Health Research (IdiBAPS), Spain. Electronic address: ibobolea@gmail.com.
FAU - Del Pozo, Victoria
AU  - Del Pozo V
AD  - Department of Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain; Spanish 
      Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES), 
      Spain.
FAU - Sanz, Veronica
AU  - Sanz V
AD  - Department of Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain; Spanish 
      Network of Centers for Biomedical Research on Respiratory Diseases (CIBERES), 
      Spain.
FAU - Cabañas, Rosario
AU  - Cabañas R
AD  - Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), 
      Madrid, Spain.
FAU - Fiandor, Ana
AU  - Fiandor A
AD  - Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), 
      Madrid, Spain.
FAU - Alfonso-Carrillo, Carolina
AU  - Alfonso-Carrillo C
AD  - Department of Otorhinolaryngology, Hospital La Paz Institute for Health Research 
      (IdiPAZ), Madrid, Spain.
FAU - Salcedo, María Ángeles
AU  - Salcedo MÁ
AD  - Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), 
      Madrid, Spain.
FAU - Heredia Revuelto, Rocío
AU  - Heredia Revuelto R
AD  - Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), 
      Madrid, Spain.
FAU - Quirce, Santiago
AU  - Quirce S
AD  - Spanish Network of Centers for Biomedical Research on Respiratory Diseases 
      (CIBERES), Spain; Department of Allergy, Hospital La Paz Institute for Health 
      Research (IdiPAZ), Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180823
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Cytokines)
RN  - R16CO5Y76E (Aspirin)
RN  - RXY07S6CZ2 (Prostaglandin D2)
RN  - GT0IL38SP4 (Thymic Stromal Lymphopoietin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects/*immunology
MH  - Asthma, Aspirin-Induced/*etiology/immunology/*therapy
MH  - Cytokines/antagonists & inhibitors/metabolism
MH  - Desensitization, Immunologic/*methods
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Prostaglandin D2/antagonists & inhibitors/metabolism
MH  - Young Adult
MH  - Thymic Stromal Lymphopoietin
OTO - NOTNLM
OT  - Aspirin desensitization
OT  - Aspirin desensitization mechanism
OT  - Aspirin-exacerbated respiratory disease
OT  - Asthma
OT  - Nasal polyps
OT  - TSLP
EDAT- 2018/09/29 06:00
MHDA- 2019/10/03 06:00
CRDT- 2018/09/29 06:00
PHST- 2018/03/29 00:00 [received]
PHST- 2018/08/17 00:00 [revised]
PHST- 2018/08/21 00:00 [accepted]
PHST- 2018/09/29 06:00 [entrez]
PHST- 2018/09/29 06:00 [pubmed]
PHST- 2019/10/03 06:00 [medline]
AID - S0954-6111(18)30275-0 [pii]
AID - 10.1016/j.rmed.2018.08.009 [doi]
PST - ppublish
SO  - Respir Med. 2018 Oct;143:39-41. doi: 10.1016/j.rmed.2018.08.009. Epub 2018 Aug 
      23.

PMID- 23460386
OWN - NLM
STAT- MEDLINE
DCOM- 20131029
LR  - 20211021
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Print)
IS  - 0944-1174 (Linking)
VI  - 48
IP  - 5
DP  - 2013 May
TI  - Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- 
      or low-dose aspirin-induced gastrointestinal injuries.
PG  - 559-73
LID - 10.1007/s00535-013-0771-8 [doi]
AB  - As the aging of the population advances, the use of nonsteroidal 
      anti-inflammatory drugs (NSAIDs) and/or low-dose aspirin (LDA) is increasing. 
      Their use is accompanied by a risk of serious complications, such as hemorrhage 
      or perforation of the gastrointestinal tract. Therefore, gastroprotective 
      strategies upon the prescription of NSAIDs/LDA are outlined in several guidelines 
      or recommendations. Because all NSAIDs including cyclooxygenase (COX)-2 
      inhibitors have cardiovascular (CV) toxicity, recent guidelines are based on not 
      only GI risks but also CV risks of NSAID users. Assessment of the adherence to 
      evidence-based guidelines or recommendations for the safe prescription of 
      NSAIDs/LDA in clinical practice is an important issue. Here, we summarize 
      randomized controlled trials (RCTs) on the preventive effects of antisecretory 
      drugs for NSAID- or LDA-induced peptic ulcers. Then, we describe preventive 
      strategies upon the prescription of NSAIDs/LDA outlined in several guidelines or 
      recommendations, and describe studies on adherence and outcomes of adherence to 
      these preventive strategies. Finally, we discuss strategies to increase the 
      adherence rate, and changing pattern of GI events associated with NSAIDs/LDA. In 
      Japan, the preventive strategies upon the prescription of NSAIDs/LDA are expected 
      to spread rapidly because the use of proton pump inhibitors for the prevention of 
      recurrence of NSAID- or LDA-induced peptic ulcers and the use of COX-2 for the 
      palliation of acute pain were recently approved under the national health 
      insurance system. Further studies on adherence to the preventive strategies and 
      the outcomes of adherence, which include both GI events and CV events, in the 
      Japanese population are required.
FAU - Fujita, Tsuyoshi
AU  - Fujita T
AD  - Department of Gastroenterology, Kobe University Graduate School of Medicine, 
      7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
FAU - Kutsumi, Hiromu
AU  - Kutsumi H
FAU - Sanuki, Tsuyoshi
AU  - Sanuki T
FAU - Hayakumo, Takanobu
AU  - Hayakumo T
FAU - Azuma, Takeshi
AU  - Azuma T
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130305
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Prescriptions/standards
MH  - Gastrointestinal Diseases/*chemically induced/*prevention & control
MH  - *Guideline Adherence
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
PMC - PMC3654181
EDAT- 2013/03/06 06:00
MHDA- 2013/10/30 06:00
CRDT- 2013/03/06 06:00
PHST- 2013/01/29 00:00 [received]
PHST- 2013/01/30 00:00 [accepted]
PHST- 2013/03/06 06:00 [entrez]
PHST- 2013/03/06 06:00 [pubmed]
PHST- 2013/10/30 06:00 [medline]
AID - 771 [pii]
AID - 10.1007/s00535-013-0771-8 [doi]
PST - ppublish
SO  - J Gastroenterol. 2013 May;48(5):559-73. doi: 10.1007/s00535-013-0771-8. Epub 2013 
      Mar 5.

PMID- 22782648
OWN - NLM
STAT- MEDLINE
DCOM- 20130422
LR  - 20211021
IS  - 1573-904X (Electronic)
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 29
IP  - 12
DP  - 2012 Dec
TI  - In vitro and in vivo metabolic studies of phospho-aspirin (MDC-22).
PG  - 3292-301
LID - 10.1007/s11095-012-0821-6 [doi]
AB  - PURPOSE: To investigate the metabolism of phospho-aspirin (PA, MDC-22), a novel 
      anti-cancer and anti-inflammatory agent. METHODS: The metabolism of PA was 
      studied in the liver and intestinal microsomes from mouse, rat and human. 
      RESULTS: PA is rapidly deacetylated to phospho-salicylic acid (PSA), which 
      undergoes regioselective oxidation to generate 3-OH-PSA and 5-OH-PSA. PSA also 
      can be hydrolyzed to give salicylic acid (SA), which can be further 
      glucuronidated. PA is far more stable in human liver or intestinal microsomes 
      compared to those from mouse or rat due to its slowest deacetylation in human 
      microsomes. Of the five major human cytochrome P450 (CYP) isoforms, CYP2C19 and 
      2D6 are the most active towards PSA. In contrast to PSA, conventional SA is not 
      appreciably oxidized by the CYPs and liver microsomes, indicating that PSA is a 
      preferred substrate of CYPs. Similarly, PA, in contrast to PSA, cannot be 
      directly oxidized by CYPs and liver microsomes, indicating that the acetyl group 
      of PA abrogates its oxidation by CYPs. CONCLUSIONS: Our findings establish the 
      metabolism of PA, reveal significant inter-species differences in its metabolic 
      transformations, and provide an insight into the role of CYPs in these processes.
FAU - Xie, Gang
AU  - Xie G
AD  - Stony Brook University, Division of Cancer Prevention, HSC, T17-080, Stony Brook, 
      New York 11794-8175, USA.
FAU - Wong, Chi C
AU  - Wong CC
FAU - Cheng, Ka-Wing
AU  - Cheng KW
FAU - Huang, Liqun
AU  - Huang L
FAU - Constantinides, Panayiotis P
AU  - Constantinides PP
FAU - Rigas, Basil
AU  - Rigas B
LA  - eng
GR  - R01 CA139454/CA/NCI NIH HHS/United States
GR  - S10 RR023680/RR/NCRR NIH HHS/United States
GR  - 5R01CA139454-03/CA/NCI NIH HHS/United States
GR  - 1S10 RR023680-1/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20120711
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Organophosphates)
RN  - 0 (phosphoaspirin)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism
MH  - Aspirin/*analogs & derivatives/metabolism
MH  - Cytochrome P-450 Enzyme System/metabolism
MH  - Humans
MH  - Intestinal Mucosa/*metabolism
MH  - Liver/*metabolism
MH  - Mice
MH  - Microsomes/*metabolism
MH  - Organophosphates/*metabolism
MH  - Oxidation-Reduction
MH  - Rats
PMC - PMC3602912
MID - NIHMS444478
EDAT- 2012/07/12 06:00
MHDA- 2013/04/23 06:00
CRDT- 2012/07/12 06:00
PHST- 2012/03/26 00:00 [received]
PHST- 2012/06/22 00:00 [accepted]
PHST- 2012/07/12 06:00 [entrez]
PHST- 2012/07/12 06:00 [pubmed]
PHST- 2013/04/23 06:00 [medline]
AID - 10.1007/s11095-012-0821-6 [doi]
PST - ppublish
SO  - Pharm Res. 2012 Dec;29(12):3292-301. doi: 10.1007/s11095-012-0821-6. Epub 2012 
      Jul 11.

PMID- 15360790
OWN - NLM
STAT- MEDLINE
DCOM- 20050607
LR  - 20131121
IS  - 0926-9630 (Print)
IS  - 0926-9630 (Linking)
VI  - 107
IP  - Pt 1
DP  - 2004
TI  - Effectiveness of an electronic medical record clinical quality alert prepared by 
      off-line data analysis.
PG  - 135-9
AB  - We tested whether off-line data analysis, instead of event monitoring, was a 
      viable method for initiating a clinical quality alert. A cohort of patients 
      eligible for an alert was identified by off-line data analysis and a flag was set 
      in their ambulatory Electronic Medical Records. One hundred clinicians were 
      randomly assigned either to a control group or to a group that received the alert 
      when viewing the electronic medical record of eligible patients. Primarily due to 
      actions of their clinicians, 315 of the 580 patients (54.3%) seen by alerted 
      clinicians were no longer eligible for the alert at the end of the one month 
      study, compared to 128 of the 496 patients (25.8%) seen by control clinicians 
      (p<.001). When not alerted, Allied Health clinicians were less likely than 
      physicians to prescribe aspirin, but they responded similarly to the alert. There 
      were no differences in response by specialty or gender of the clinician. Off-line 
      data analysis proved to be an effective method of initiating a clinical alert.
FAU - Krall, Michael A
AU  - Krall MA
AD  - Clinical Information Systems Department. Kaiser Permanente, 2850 NW Nicolai 
      Street, Portland, OR 97210, USA.
FAU - Traunweiser, Kati
AU  - Traunweiser K
FAU - Towery, William
AU  - Towery W
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ambulatory Care Information Systems
MH  - Aspirin/*therapeutic use
MH  - Computer Systems
MH  - Decision Making, Computer-Assisted
MH  - Female
MH  - Humans
MH  - Male
MH  - *Medical Records Systems, Computerized
MH  - *Reminder Systems
EDAT- 2004/09/14 05:00
MHDA- 2005/06/09 09:00
CRDT- 2004/09/14 05:00
PHST- 2004/09/14 05:00 [pubmed]
PHST- 2005/06/09 09:00 [medline]
PHST- 2004/09/14 05:00 [entrez]
AID - D040004082 [pii]
PST - ppublish
SO  - Stud Health Technol Inform. 2004;107(Pt 1):135-9.

PMID- 26239446
OWN - NLM
STAT- MEDLINE
DCOM- 20160629
LR  - 20150928
IS  - 1559-0291 (Electronic)
IS  - 0273-2289 (Linking)
VI  - 177
IP  - 3
DP  - 2015 Oct
TI  - Low-Transition-Temperature Mixtures (LTTMs) for Dissolving Proteins and for Drug 
      Formulation.
PG  - 753-8
LID - 10.1007/s12010-015-1777-x [doi]
AB  - Several diverse proteins are found to readily dissolve in neat 
      low-transition-temperature mixtures (LTTMs). They undergo no irreversible 
      denaturation in such unusual solvents, and the resistance of hen egg-white 
      lysozyme against thermoinactivation in LTTMs is greater than in aqueous solution 
      at extreme pHs. Separately, the water-sensitive drug aspirin is found to form 
      concentrated transparent LTTMs, where it is some 10-fold more stable against 
      cleavage than in water.
FAU - Su, Erzheng
AU  - Su E
AD  - Departments of Chemistry and Biological Engineering, Massachusetts Institute of 
      Technology, Cambridge, MA, 02139, USA. ezhsu@njfu.edu.cn.
AD  - Enzyme and Fermentation Technology Laboratory, College of Light Industry Science 
      and Engineering, Nanjing Forestry University, Nanjing, 210037, China. 
      ezhsu@njfu.edu.cn.
FAU - Klibanov, Alexander M
AU  - Klibanov AM
AD  - Departments of Chemistry and Biological Engineering, Massachusetts Institute of 
      Technology, Cambridge, MA, 02139, USA. klibanov@mit.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150804
PL  - United States
TA  - Appl Biochem Biotechnol
JT  - Applied biochemistry and biotechnology
JID - 8208561
RN  - 0 (Proteins)
RN  - 0 (Solvents)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry
MH  - Chemistry, Pharmaceutical/*methods
MH  - Hydrogen-Ion Concentration
MH  - Protein Denaturation
MH  - Proteins/*chemistry
MH  - Solvents/chemistry
MH  - *Transition Temperature
MH  - Water/chemistry
OTO - NOTNLM
OT  - Drug formulation
OT  - Low-transition-temperature mixtures
OT  - Protein solubility
OT  - Water-sensitive drugs
EDAT- 2015/08/05 06:00
MHDA- 2016/06/30 06:00
CRDT- 2015/08/05 06:00
PHST- 2015/05/09 00:00 [received]
PHST- 2015/07/21 00:00 [accepted]
PHST- 2015/08/05 06:00 [entrez]
PHST- 2015/08/05 06:00 [pubmed]
PHST- 2016/06/30 06:00 [medline]
AID - 10.1007/s12010-015-1777-x [pii]
AID - 10.1007/s12010-015-1777-x [doi]
PST - ppublish
SO  - Appl Biochem Biotechnol. 2015 Oct;177(3):753-8. doi: 10.1007/s12010-015-1777-x. 
      Epub 2015 Aug 4.

PMID- 15800839
OWN - NLM
STAT- MEDLINE
DCOM- 20050706
LR  - 20131121
IS  - 0044-4197 (Print)
IS  - 0044-4197 (Linking)
VI  - 127
IP  - 2
DP  - 2005 Apr
TI  - [Prevention of preeclampsia].
PG  - 83-90
AB  - Preeclampsia is accompanied by high fetal and maternal morbidity and mortality 
      and to a high degree responsible for preterm delivery. The pathophysiologic 
      mechanisms underlying this disease remain poorly understood. Accordingly, only 
      few causative or preventive therapeutical strategies are known. One such example 
      for a preventive strategy is the use of aspirin (ASA) which directly affects the 
      imbalance of vasodilative prostacycline and vasoconstrictive thromboxane. 
      Recently, some studies are indicating a preventive effect of vitamin C and E 
      substitution. In contrast, early antihypertensive therapy did not prevent later 
      progression of the disease. Furthermore, sodium restriction, calcium and 
      magnesium substitution, fish oil substitution, or steroid therapy are without any 
      effect regarding the later development of preeclampsia. It is of utmost 
      importance to further elucidate underlying pathophysiological mechanisms to 
      improve therapeutical and preventive strategies.
FAU - Fischer, T
AU  - Fischer T
AD  - Frauenklinik der Technischen Universität München, Klinikum rechts der Isar.
FAU - Pildner von Steinburg, S
AU  - Pildner von Steinburg S
FAU - Diedrich, F
AU  - Diedrich F
FAU - Neumaier-Wagner, P
AU  - Neumaier-Wagner P
FAU - Paepke, S
AU  - Paepke S
FAU - Jacobs, V R
AU  - Jacobs VR
FAU - Schneider, K T M
AU  - Schneider KT
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Prävention der Präeklampsie.
PL  - Germany
TA  - Zentralbl Gynakol
JT  - Zentralblatt fur Gynakologie
JID - 21820100R
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Diet, Sodium-Restricted
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
RF  - 86
EDAT- 2005/04/01 09:00
MHDA- 2005/07/07 09:00
CRDT- 2005/04/01 09:00
PHST- 2005/04/01 09:00 [pubmed]
PHST- 2005/07/07 09:00 [medline]
PHST- 2005/04/01 09:00 [entrez]
AID - 10.1055/s-2005-836321 [doi]
PST - ppublish
SO  - Zentralbl Gynakol. 2005 Apr;127(2):83-90. doi: 10.1055/s-2005-836321.

PMID- 3919746
OWN - NLM
STAT- MEDLINE
DCOM- 19850521
LR  - 20190515
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 57
IP  - 3
DP  - 1985 Mar
TI  - Comparison of infusions of morphine and lysine acetyl salicylate for the relief 
      of pain following thoracic surgery.
PG  - 259-63
AB  - A double-blind study comparing the effectiveness of a continuous infusion i.v. of 
      lysine acetyl salicylate (LAS) with an infusion of morphine for the treatment of 
      pain following pulmonary surgery is described. Mean pain scores in the two groups 
      were not significantly different at any stage during the 24-h period of study. 
      LAS was not associated with any significantly greater blood loss in the period 
      after operation. The incidence of drowsiness, nausea and vomiting, and the need 
      for antiemetic medication were similar in both groups.
FAU - Jones, R M
AU  - Jones RM
FAU - Cashman, J N
AU  - Cashman JN
FAU - Foster, J M
AU  - Foster JM
FAU - Wedley, J R
AU  - Wedley JR
FAU - Adams, A P
AU  - Adams AP
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Analgesics)
RN  - 76I7G6D29C (Morphine)
RN  - 8008-60-4 (Opium)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*analogs & derivatives/therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Lung/surgery
MH  - Lysine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Middle Aged
MH  - Morphine/adverse effects/*therapeutic use
MH  - Opium/therapeutic use
MH  - Pain, Postoperative/*drug therapy
MH  - Time Factors
EDAT- 1985/03/01 00:00
MHDA- 1985/03/01 00:01
CRDT- 1985/03/01 00:00
PHST- 1985/03/01 00:00 [pubmed]
PHST- 1985/03/01 00:01 [medline]
PHST- 1985/03/01 00:00 [entrez]
AID - S0007-0912(17)41454-1 [pii]
AID - 10.1093/bja/57.3.259 [doi]
PST - ppublish
SO  - Br J Anaesth. 1985 Mar;57(3):259-63. doi: 10.1093/bja/57.3.259.

PMID- 7802317
OWN - NLM
STAT- MEDLINE
DCOM- 19950125
LR  - 20151119
IS  - 0201-7563 (Print)
IS  - 0201-7563 (Linking)
IP  - 4
DP  - 1994 Jul-Aug
TI  - [Nonsteroid anti-inflammatory agents (acelysin) in postoperative analgesia and 
      intensive care].
PG  - 41-5
AB  - Efficacy of nonsteroid antiinflammatory drugs in the system of postoperative 
      intensive care of patients to relieve postoperative pain, reduce the aftereffects 
      of surgical injury to tissues, and thromboembolic complications is 
      pathogenetically validated. A high efficacy of water-soluble acetylsalicylic 
      acid, acelysin, in patients after extensive oncologic surgery is demonstrated. 
      Acelysin had a good analgesic effect without side effects and permitted reducing 
      the dose of opiates for postoperative analgesia by 3 times in comparison with the 
      control group. Acelysin infusion in the immediate postoperative period reliably 
      prevented thromboembolic complications and ruled out the necessity of resorting 
      to heparin. Acelysin is regarded as a special nonopiate component of 
      postoperative intensive care noticeably improving its efficacy.
FAU - Osipova, N A
AU  - Osipova NA
FAU - Beresnev, V A
AU  - Beresnev VA
FAU - Abuzarova, G R
AU  - Abuzarova GR
FAU - Loseva, N A
AU  - Loseva NA
FAU - Edeleva, N V
AU  - Edeleva NV
FAU - Novikova, O V
AU  - Novikova OV
LA  - rus
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Nesteroidnye protivovospalitel'nye preparaty (atselizin) v posleoperatsionnom 
      obezbolivanii i intensivnoĭ terapii.
PL  - Russia (Federation)
TA  - Anesteziol Reanimatol
JT  - Anesteziologiia i reanimatologiia
JID - 7705399
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 0 (acetylsalicylate, glycine, lysine drug combination)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Abdomen/surgery
MH  - Adult
MH  - Aged
MH  - Analgesics/administration & dosage/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Critical Care
MH  - Drug Combinations
MH  - Glycine/administration & dosage/*therapeutic use
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Thoracic Surgery
EDAT- 1994/07/01 00:00
MHDA- 1994/07/01 00:01
CRDT- 1994/07/01 00:00
PHST- 1994/07/01 00:00 [pubmed]
PHST- 1994/07/01 00:01 [medline]
PHST- 1994/07/01 00:00 [entrez]
PST - ppublish
SO  - Anesteziol Reanimatol. 1994 Jul-Aug;(4):41-5.

PMID- 32219391
OWN - NLM
STAT- MEDLINE
DCOM- 20220207
LR  - 20220207
IS  - 1536-4844 (Electronic)
IS  - 1078-0998 (Print)
IS  - 1078-0998 (Linking)
VI  - 27
IP  - 2
DP  - 2021 Jan 19
TI  - Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory 
      Bowel Disease.
PG  - 236-241
LID - 10.1093/ibd/izaa060 [doi]
AB  - BACKGROUND: Although several studies have associated the use of nonsteroidal 
      anti-inflammatory drugs with disease flares in patients with inflammatory bowel 
      disease (IBD), little is known about the impact of daily aspirin use on clinical 
      outcomes in patients with IBD. METHODS: We conducted a retrospective analysis of 
      a prospectively collected registry of patients with IBD from May 2008 to June 
      2015. Patients with any disease activity with daily aspirin use were matched 1:4 
      to controls by age, sex, disease, disease location, and presence of cardiac 
      comorbidity. Patients with at least 18 months of follow-up were included in the 
      final analysis. The primary outcomes of interest were having an IBD-related 
      hospitalization, IBD-related surgery, and requiring corticosteroids during the 
      follow-up period. RESULTS: A total of 764 patients with IBD were included in the 
      analysis, of which 174 patients were taking aspirin. There was no statistical 
      difference in age, gender, diagnosis (Crohn's disease vs ulcerative colitis), 
      disease duration, Charlson Comorbidity Index, smoking status, medication usage, 
      or baseline C-reactive protein between groups. After controlling for covariables 
      and length of follow-up in the entire population, aspirin use was not associated 
      with a risk of being hospitalized for an IBD-related complication (odds ratio 
      [OR], 1.46; P = 0.10), corticosteroid use (OR, 0.99; P = 0.70), or having an 
      IBD-related surgery (OR, 0.99; P = 0.96). CONCLUSION: In this single-center 
      analysis, aspirin use did not impact major clinical outcomes in patients with 
      IBD. Although the effect of aspirin use on mucosal inflammation was not directly 
      assessed in this study, these findings support the safety of daily aspirin use in 
      this population.
CI  - © 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All 
      rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
FAU - Patel, Parita
AU  - Patel P
AD  - Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago 
      Medical Center, Chicago, IL.
FAU - Gao, Guimin
AU  - Gao G
AD  - Department of Public Health Sciences, University of Chicago, Chicago, IL.
FAU - Gulotta, George
AU  - Gulotta G
AD  - Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago 
      Medical Center, Chicago, IL.
FAU - Dalal, Sushila
AU  - Dalal S
AD  - Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago 
      Medical Center, Chicago, IL.
FAU - Cohen, Russell D
AU  - Cohen RD
AD  - Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago 
      Medical Center, Chicago, IL.
FAU - Sakuraba, Atsushi
AU  - Sakuraba A
AD  - Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago 
      Medical Center, Chicago, IL.
FAU - Rubin, David T
AU  - Rubin DT
AD  - Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago 
      Medical Center, Chicago, IL.
FAU - Pekow, Joel
AU  - Pekow J
AD  - Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago 
      Medical Center, Chicago, IL.
LA  - eng
GR  - P30 DK042086/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Inflamm Bowel Dis
JT  - Inflammatory bowel diseases
JID - 9508162
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Inflamm Bowel Dis. 2020 Aug 20;26(9):e93. PMID: 32483592
CIN - Inflamm Bowel Dis. 2020 Aug 20;26(9):e94. PMID: 32483616
MH  - *Aspirin/adverse effects
MH  - *Colitis, Ulcerative/diagnosis
MH  - *Crohn Disease/diagnosis
MH  - Humans
MH  - Retrospective Studies
PMC - PMC7813746
OTO - NOTNLM
OT  - Crohn’s disease
OT  - aspirin
OT  - disease activity
OT  - ulcerative colitis
EDAT- 2020/03/29 06:00
MHDA- 2022/02/08 06:00
CRDT- 2020/03/29 06:00
PHST- 2019/12/11 00:00 [received]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2022/02/08 06:00 [medline]
PHST- 2020/03/29 06:00 [entrez]
AID - 5812729 [pii]
AID - izaa060 [pii]
AID - 10.1093/ibd/izaa060 [doi]
PST - ppublish
SO  - Inflamm Bowel Dis. 2021 Jan 19;27(2):236-241. doi: 10.1093/ibd/izaa060.

PMID- 30704653
OWN - NLM
STAT- MEDLINE
DCOM- 20190314
LR  - 20190314
IS  - 1558-299X (Electronic)
IS  - 0095-4543 (Linking)
VI  - 46
IP  - 1
DP  - 2019 Mar
TI  - Prescription of Aspirin and Statins in Primary Prevention.
PG  - 13-25
LID - S0095-4543(18)30092-7 [pii]
LID - 10.1016/j.pop.2018.10.004 [doi]
AB  - The increasing burden of cardiovascular disease worldwide, including the United 
      States, underscores the need for the more widespread use of adjunctive drug 
      therapies of proven net benefit in the primary prevention of cardiovascular 
      disease. These include aspirin to reduce mortality from cardiovascular disease, 
      statins to lower LDL-cholesterol levels, appropriate use of multiple 
      antihypertensive drug therapies to lower blood pressure, and aggressive 
      multifactorial management of diabetes. This article reviews randomized evidence 
      to provide guidance to primary care providers regarding the use of adjunctive 
      drug therapies.
CI  - Copyright © 2018 Elsevier Inc. All rights reserved.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, 
      FL, USA. Electronic address: profchhmd@prodigy.net.
FAU - Schuttenberg, Nicole
AU  - Schuttenberg N
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, 
      FL, USA.
FAU - Pfeffer, Marc A
AU  - Pfeffer MA
AD  - Division of Cardiovascular Medicine, The Harvard Medical School, Brigham and 
      Women's Hospital, 45 Francis Street, Boston, MA 02115, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Prim Care
JT  - Primary care
JID - 0430463
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Female
MH  - Healthy Lifestyle
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Male
MH  - Primary Prevention
MH  - Secondary Prevention
OTO - NOTNLM
OT  - Adjunctive drug therapies
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Metabolic syndrome
OT  - Statins
EDAT- 2019/02/02 06:00
MHDA- 2019/03/15 06:00
CRDT- 2019/02/02 06:00
PHST- 2019/02/02 06:00 [entrez]
PHST- 2019/02/02 06:00 [pubmed]
PHST- 2019/03/15 06:00 [medline]
AID - S0095-4543(18)30092-7 [pii]
AID - 10.1016/j.pop.2018.10.004 [doi]
PST - ppublish
SO  - Prim Care. 2019 Mar;46(1):13-25. doi: 10.1016/j.pop.2018.10.004.

PMID- 26334115
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1827-1618 (Electronic)
IS  - 0026-4725 (Linking)
VI  - 63
IP  - 6
DP  - 2015 Dec
TI  - Bleeding versus thrombosis: role of short DAPT in complex lesions.
PG  - 533-46
AB  - Therapy with dual antiplatelet agents, defined as the combination of a platelet 
      P2Y12 inhibitor and aspirin, is required to prevent thrombotic complications, 
      after percutaneous coronary intervention (PCI) with stent implantation. Usually 
      current guidelines recommend administration of dual antiplatelet therapy (DAPT) 
      following percutaneous revascularization with drug-eluting stent (DES) for a 
      period of at least 12 months or for 6 to 12 months in patients not at high risk. 
      Nevertheless, the treatment of stable/unstable coronary artery disease with DES 
      implantation increasing largely, the optimal duration of DAPT is still unclear. 
      The duration of DAPT after coronary stenting has been evaluated in recent 
      randomized studies with conflicting results. The administration of long period of 
      DAPT is a strategy to reduce thrombosis events but largely increase the 
      hemorrhagic ones. Otherwise, shorter DAPT period is protective about bleeds with 
      consequently increased ischemic events. In addition, as new DES carry a lower 
      risk of stent thrombosis (ST) compared with the first-generation DES and possibly 
      even bare-metal stents, a shift toward better protection from ST may have an 
      effect on the duration and the intensity of DAPT. Whether the duration of DAPT 
      should be shorter or longer than the currently recommended 6 to 12 months is 
      analyzed in this review, drawing on results from the most recent studies and 
      meta-analysis.
FAU - Calcagno, S
AU  - Calcagno S
AD  - Department of Cardiovascular Respiratory, Nephrologic, Anesthesiologic and 
      Geriatric Sciences, Umberto I Hospital, Sapienza University of Rome, Rome, Italy 
      - rino.sardella@uniroma1.it.
FAU - Lucisano, L
AU  - Lucisano L
FAU - Mancone, M
AU  - Mancone M
FAU - Cavallo, E
AU  - Cavallo E
FAU - Pennacchi, M
AU  - Pennacchi M
FAU - Stio, R E
AU  - Stio RE
FAU - Sardella, G
AU  - Sardella G
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150902
PL  - Italy
TA  - Minerva Cardioangiol
JT  - Minerva cardioangiologica
JID - 0400725
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Coronary Artery Disease/therapy
MH  - Drug Therapy, Combination
MH  - Drug-Eluting Stents/adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/adverse 
      effects/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Thrombosis/*prevention & control
EDAT- 2015/09/04 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/09/04 06:00
PHST- 2015/09/04 06:00 [entrez]
PHST- 2015/09/04 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - R05Y9999N00A150040 [pii]
PST - ppublish
SO  - Minerva Cardioangiol. 2015 Dec;63(6):533-46. Epub 2015 Sep 2.

PMID- 1999935
OWN - NLM
STAT- MEDLINE
DCOM- 19910409
LR  - 20131121
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 101
IP  - 3
DP  - 1991 Mar
TI  - Comparison of two levels of anticoagulant therapy in patients with substitute 
      heart valves.
PG  - 427-31
AB  - After cardiac valve replacement patients were blindly randomized into two groups, 
      both receiving aspirin (330 mg) and dipyridamole (75 mg) twice daily and the oral 
      anticoagulant acenocoumarol (Sintrom). An international normalized ratio of 2.0 
      to 2.99 was assigned to group A and 3.0 to 4.5 to group B; both groups were 
      subsequently analyzed for thromboembolic and hemorrhagic complications. Final 
      evaluation included 51 and 48 patients, respectively. The follow-up was 626 
      months for group A (12.3 months/patient) and 486 months for group B (10.1 
      months/patient). The frequency of thromboembolism was equal in both groups: one 
      transient ischemic attack in group A (a rate of 1.92/100 patient-years) and two 
      transient ischemic attacks in group B (a rate of 4.94/100 patient-years). There 
      was, however, a statistical difference in bleeding complications between the two 
      groups (p less than 0.02). Two patients bled in group A, a rate of 3.9% (3.8/100 
      patient-years), which represents an incidence of one episode each 25.6 years of 
      treatment; 10 patients bled in group B, a rate of 20.8% (24.7/100 patient-years) 
      representing an incidence of one episode each 4 years of treatment. We conclude 
      that an international normalized ratio of 2 to 3 is safer than a ratio of 3 to 
      4.5 and confers good protection from thromboembolism when oral anticoagulant 
      therapy is used conjointly with platelet function-inhibiting drugs in patients 
      with mechanical substitute heart valves.
FAU - Altman, R
AU  - Altman R
AD  - Fundacion Favaloro and Centro de Estudios Medicos y Bioquimicos Buenos Aires, 
      Argentina.
FAU - Rouvier, J
AU  - Rouvier J
FAU - Gurfinkel, E
AU  - Gurfinkel E
FAU - D'Ortencio, O
AU  - D'Ortencio O
FAU - Manzanel, R
AU  - Manzanel R
FAU - de La Fuente, L
AU  - de La Fuente L
FAU - Favaloro, R G
AU  - Favaloro RG
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 64ALC7F90C (Dipyridamole)
RN  - I6WP63U32H (Acenocoumarol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Thorac Cardiovasc Surg. 1991 Mar;101(3):557-9. PMID: 1999952
MH  - Acenocoumarol/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Dipyridamole/*administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Thromboembolism/*prevention & control
MH  - Time Factors
EDAT- 1991/03/01 00:00
MHDA- 1991/03/01 00:01
CRDT- 1991/03/01 00:00
PHST- 1991/03/01 00:00 [pubmed]
PHST- 1991/03/01 00:01 [medline]
PHST- 1991/03/01 00:00 [entrez]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1991 Mar;101(3):427-31.

PMID- 3361888
OWN - NLM
STAT- MEDLINE
DCOM- 19880608
LR  - 20190817
IS  - 0022-4804 (Print)
IS  - 0022-4804 (Linking)
VI  - 44
IP  - 4
DP  - 1988 Apr
TI  - Perioperative suppression of platelet adherence to small-diameter 
      polytetrafluoroethylene (PTFE) grafts.
PG  - 455-60
AB  - The perioperative effect of platelet antagonists on small-diameter 
      polytetrafluoroethylene (PTFE) grafts was evaluated in forty-six New Zealand 
      white male rabbits receiving either dipyridamole (DPM) 100 mg/kg/day (n = 10; 
      group 1), aspirin (ASA) 10 mg/kg/day (n = 10; group 2), a combination of ASA 10 
      mg/kg/day and DPM 10 mg/kg/day (n = 9; group 3) or 100 mg/kg/day (n = 10; group 
      4), or placebo (n = 7) as single daily doses. All regimens began 72 hr prior to 
      insertion of a 20 x 3-mm internal diameter PTFE interposition aortic graft. 
      Autologous indium-111 labeled platelets were injected immediately after 
      implantation. Graft and an equivalent segment of aorta were harvested after 48 
      hr. Graft platelet adherence index (GPAI) was calculated as the graft:reference 
      aorta ratio of emissions. The GPAI in the control group was 238 +/- 46 (mean +/- 
      SD). Single regimen antiplatelet agents in groups 1 and 2 reduced mean GPAI to 47 
      +/- 38 and 40 +/- 12, respectively. The combination regimen in group 3 lowered 
      mean GPAI to 43 +/- 8 and in group 4 to 21 +/- 7. Platelet uptake in PTFE grafts 
      at 48 hr is significantly lowered to 8.8 to 19.7% of control by perioperative 
      antiplatelet agents given as a single daily oral dose (P less than 0.001). ASA 
      alone and DPM alone provided similar suppression of platelet uptake, but 
      combination ASA + low dose or high dose DPM gave significantly greater (P less 
      than 0.001) suppression of early platelet deposition than the single agent 
      regimens. These results support perioperative administration of combination oral 
      antiplatelet agents as adjunctive therapy in small diameter prosthetic graft 
      implantation.
FAU - Fujitani, R M
AU  - Fujitani RM
AD  - Department of Surgery, Harbor-UCLA Medical Center, Torrance 90509.
FAU - Nordestgaard, A G
AU  - Nordestgaard AG
FAU - Marcus, C S
AU  - Marcus CS
FAU - Wilson, S E
AU  - Wilson SE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta/physiology
MH  - Aspirin/blood/*therapeutic use
MH  - *Blood Vessel Prosthesis
MH  - Dipyridamole/blood/*therapeutic use
MH  - Drug Combinations
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Polytetrafluoroethylene
MH  - *Preoperative Care
MH  - Regional Blood Flow
MH  - Thromboxane B2/blood
MH  - Vascular Patency
EDAT- 1988/04/01 00:00
MHDA- 1988/04/01 00:01
CRDT- 1988/04/01 00:00
PHST- 1988/04/01 00:00 [pubmed]
PHST- 1988/04/01 00:01 [medline]
PHST- 1988/04/01 00:00 [entrez]
AID - 0022-4804(88)90189-8 [pii]
AID - 10.1016/0022-4804(88)90189-8 [doi]
PST - ppublish
SO  - J Surg Res. 1988 Apr;44(4):455-60. doi: 10.1016/0022-4804(88)90189-8.

PMID- 34105097
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1672-0415 (Print)
IS  - 1672-0415 (Linking)
VI  - 27
IP  - 8
DP  - 2021 Aug
TI  - Effect of Weikang Capsule () on Aspirin-Related Gastric and Small Intestinal 
      Mucosal Injury.
PG  - 621-625
LID - 10.1007/s11655-021-3300-2 [doi]
AB  - OBJECTIVE: To investigate the effects of Weikang Capsule (, WKC) on 
      aspirin-related gastric and small intestinal mucosal injury by magnetically 
      controlled capsule endoscopy (MCCE). METHODS: Patients taking enteric-coated 
      aspirin aged 40-75 years were enrolled in Beijing Anzhen Hospital, Capital 
      Medical University from January 2019 to December 2019. The patients continued 
      taking aspirin Tablet (100 mg per day) and underwent MCCE before and after 
      1-month combined treatment with WKC (0.9 g per time orally, 3 times per day). The 
      gastrointestinal symptom score, gastric Lanza score, the duodenal, jejunal and 
      ileal mucosal injury scores were used to evaluate the gastrointestinal injury 
      before and after treatment. Adverse events including nausea, vomiting, abdominal 
      pain, abdominal distension, abdominal discomfort, dizziness, or headache during 
      MCCE and combined treatment were observed and recorded. RESULTS: Twenty-two 
      patients (male/female, 13/9) taking enteric-coated aspirin aged 59.5 ± 11.3 years 
      with a duration of aspirin use of 28.0 (1.0, 48.0) months were recruited. 
      Compared with pre-treatment, the gastrointestinal symptom rating scale scores, 
      gastric Lanza scores, and duodenal mucosal injury scores were significantly 
      reduced after 1-month WKC treatment (P<0.05), and jejunal and ileal mucosal 
      injury scores showed no obvious change. No adverse events occurred during the 
      trial. CONCLUSIONS: WKC can alleviate gastrointestinal symptoms, as well as 
      gastric and duodenal mucosal injuries, in patients taking enteric-coated aspirin; 
      it does not aggravate jejunal or ileal mucosal injury, which may be an effective 
      alternative for these patients (Clinical trial registry No. ChiCTR1900025451).
CI  - © 2021. The Chinese Journal of Integrated Traditional and Western Medicine Press 
      and Springer-Verlag GmbH Germany, part of Springer Nature.
FAU - Du, Lin
AU  - Du L
AD  - Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, 100029, China.
FAU - Gao, Feng
AU  - Gao F
AD  - Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, 100029, China.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, 100029, China. zhangjie4155@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20210608
PL  - China
TA  - Chin J Integr Med
JT  - Chinese journal of integrative medicine
JID - 101181180
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects
MH  - Capsule Endoscopy
MH  - Female
MH  - *Gastric Mucosa
MH  - Humans
MH  - *Intestinal Mucosa
MH  - Male
MH  - Middle Aged
MH  - Stomach
OTO - NOTNLM
OT  - Chinese medicine
OT  - Weikang Capsule
OT  - enteric-coated aspirin
OT  - gastric mucosal injury
OT  - magnetically controlled capsule endoscopy
OT  - small intestinal mucosal injury
EDAT- 2021/06/10 06:00
MHDA- 2021/11/09 06:00
CRDT- 2021/06/09 06:59
PHST- 2020/12/09 00:00 [accepted]
PHST- 2021/06/10 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
PHST- 2021/06/09 06:59 [entrez]
AID - 10.1007/s11655-021-3300-2 [pii]
AID - 10.1007/s11655-021-3300-2 [doi]
PST - ppublish
SO  - Chin J Integr Med. 2021 Aug;27(8):621-625. doi: 10.1007/s11655-021-3300-2. Epub 
      2021 Jun 8.

PMID- 33137710
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20220531
IS  - 2213-2317 (Electronic)
IS  - 2213-2317 (Linking)
VI  - 38
DP  - 2021 Jan
TI  - MZe786, a hydrogen sulfide-releasing aspirin prevents preeclampsia in heme 
      oxygenase-1 haplodeficient pregnancy under high soluble flt-1 environment.
PG  - 101768
LID - S2213-2317(20)30973-3 [pii]
LID - 10.1016/j.redox.2020.101768 [doi]
LID - 101768
AB  - Preeclampsia affects one in twelve of the 130 million pregnancies a year. The 
      lack of an effective therapeutic to prevent or treat it is responsible for an 
      annual global cost burden of 100 billion US dollars. Preeclampsia also affects 
      these women later in life as it is a recognised risk factor for cardiovascular 
      disease, stroke and vascular dementia. Our laboratory demonstrated that 
      preeclampsia is associated with high soluble fms-like tyrosine kinase 1 (sFlt-1) 
      and low heme oxygenase-1 (HO1/Hmox1) expression. Here we sought to determine the 
      therapeutic value of a novel H(2)S-releasing aspirin (MZe786) in HO-1 haploid 
      deficient (Hmox1(+/-)) pregnant mice in a high sFlt-1 environment. Pregnant 
      Hmox1(+/-) mice were injected with adenovirus encoding sFlt-1 or control virus at 
      gestation day E11.5. Subsequently, Hmox1(+/-) dams were treated daily with a 
      number of treatment regimens until E17.5, when maternal and fetal outcomes were 
      assessed. Here we show that HO-1 compromised mice in a high sFlt-1 environment 
      during pregnancy exhibit severe preeclampsia signs and a reduction in antioxidant 
      genes. MZe786 ameliorates preeclampsia by reducing hypertension and renal damage 
      possibly by stimulating antioxidant genes. MZe786 also improved fetal outcome in 
      comparison with aspirin alone and appears to be a better therapeutic agent at 
      preventing preeclampsia than aspirin alone.
CI  - Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Rezai, Homira
AU  - Rezai H
AD  - Mirzyme Therapeutics, Innovation Birmingham Campus, Faraday Wharf, Holt Street, 
      Birmingham, B7 4BB, United Kingdom; Aston Medical Research Institute, Aston 
      Medical School, Birmingham, United Kingdom.
FAU - Ahmad, Shakil
AU  - Ahmad S
AD  - Aston Medical Research Institute, Aston Medical School, Birmingham, United 
      Kingdom.
FAU - Alzahrani, Faisal A
AU  - Alzahrani FA
AD  - Mirzyme Therapeutics, Innovation Birmingham Campus, Faraday Wharf, Holt Street, 
      Birmingham, B7 4BB, United Kingdom; Department of Biochemistry, ESC Research 
      Unit, Faculty of Science, King Fahd Medical Research Center, King Abdulaziz 
      University, Jeddah, 21589, Saudi Arabia.
FAU - Sanchez-Aranguren, Lissette
AU  - Sanchez-Aranguren L
AD  - Mirzyme Therapeutics, Innovation Birmingham Campus, Faraday Wharf, Holt Street, 
      Birmingham, B7 4BB, United Kingdom; Aston Medical Research Institute, Aston 
      Medical School, Birmingham, United Kingdom.
FAU - Dias, Irundika Hk
AU  - Dias IH
AD  - Aston Medical Research Institute, Aston Medical School, Birmingham, United 
      Kingdom.
FAU - Agrawal, Swati
AU  - Agrawal S
AD  - Mirzyme Therapeutics, Innovation Birmingham Campus, Faraday Wharf, Holt Street, 
      Birmingham, B7 4BB, United Kingdom; Department of Maternal Fetal Medicine, Mt 
      Sinai Hospital, University of Toronto, Toronto, Canada.
FAU - Sparatore, Anna
AU  - Sparatore A
AD  - Department of Pharmaceutical Sciences, University of Milan, Milan, Italy.
FAU - Wang, Keqing
AU  - Wang K
AD  - Mirzyme Therapeutics, Innovation Birmingham Campus, Faraday Wharf, Holt Street, 
      Birmingham, B7 4BB, United Kingdom; Aston Medical Research Institute, Aston 
      Medical School, Birmingham, United Kingdom.
FAU - Ahmed, Asif
AU  - Ahmed A
AD  - Mirzyme Therapeutics, Innovation Birmingham Campus, Faraday Wharf, Holt Street, 
      Birmingham, B7 4BB, United Kingdom; Aston Medical Research Institute, Aston 
      Medical School, Birmingham, United Kingdom; Department of Biochemistry, ESC 
      Research Unit, Faculty of Science, King Fahd Medical Research Center, King 
      Abdulaziz University, Jeddah, 21589, Saudi Arabia; President's Office, University 
      of Southampton, University Road, Southampton, SO17 1BJ, UK. Electronic address: 
      asif.ahmed@mirzyme.com.
LA  - eng
GR  - G0700288/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201024
PL  - Netherlands
TA  - Redox Biol
JT  - Redox biology
JID - 101605639
RN  - 0 (Membrane Proteins)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - EC 1.14.14.18 (Hmox1 protein, mouse)
RN  - EC 2.7.10.1 (Flt1 protein, mouse)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/*therapeutic use
MH  - Female
MH  - *Heme Oxygenase-1/genetics
MH  - *Hydrogen Sulfide
MH  - Membrane Proteins
MH  - Mice
MH  - *Pre-Eclampsia/drug therapy/genetics
MH  - Pregnancy
MH  - Vascular Endothelial Growth Factor Receptor-1/genetics
PMC - PMC7610044
OTO - NOTNLM
OT  - Heme oxygenase-1
OT  - Hydrogen sulfide
OT  - Hypertension
OT  - Preeclampsia
OT  - sFlt-1
COIS- HR, SA, LSA, IHKD, FAA, SwA and AS declare they have no conflict of interest. AA 
      is the Executive Chairman and the majority shareholder in MirZyme Therapeutics. 
      AA and KW are inventors for the use of hydrogen sulphide compounds in the 
      treatment of preeclampsia (WO2014132083A2).
EDAT- 2020/11/03 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/02 20:20
PHST- 2020/08/20 00:00 [received]
PHST- 2020/10/01 00:00 [revised]
PHST- 2020/10/18 00:00 [accepted]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/11/02 20:20 [entrez]
AID - S2213-2317(20)30973-3 [pii]
AID - 101768 [pii]
AID - 10.1016/j.redox.2020.101768 [doi]
PST - ppublish
SO  - Redox Biol. 2021 Jan;38:101768. doi: 10.1016/j.redox.2020.101768. Epub 2020 Oct 
      24.

PMID- 6209513
OWN - NLM
STAT- MEDLINE
DCOM- 19841227
LR  - 20220317
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8411
DP  - 1984 Nov 10
TI  - High-dose intravenous gammaglobulin for Kawasaki disease.
PG  - 1055-8
AB  - The ability of high-dose intravenous gammaglobulin (IVGG) to prevent the coronary 
      artery lesion of Kawasaki disease has been studied in a multicentre controlled 
      trial of IVGG plus aspirin versus aspirin alone, aspirin being the conventional 
      treatment for Kawasaki disease. Patients were allocated at random to aspirin (45 
      cases) or IVGG (40 cases), there being no significant intergroup differences in 
      age, sex ratio, duration of disease until the start of treatment, or severity. 
      The development of coronary artery dilatation was monitored by two-dimensional 
      echocardiography. Within 29 days of the onset of the disease, this lesion had 
      developed in 19 cases (42%) in the aspirin group and in 6 cases (15%) in the IVGG 
      group. There were no new instances of this lesion: in the period 30-60 days 
      coronary artery dilatation persisted in 14 and 3 cases, respectively. In patients 
      found to have echocardiographic abnormalities selective coronary arteriography 
      was done 30-60 days after onset of Kawasaki disease and the lesion was confirmed 
      in 1 of the 6 cases in the IVGG group and in 11 of the 19 controls. High-dose 
      IVGG seems to reduce the frequency of coronary artery abnormalities in patients 
      with Kawasaki disease.
FAU - Furusho, K
AU  - Furusho K
FAU - Kamiya, T
AU  - Kamiya T
FAU - Nakano, H
AU  - Nakano H
FAU - Kiyosawa, N
AU  - Kiyosawa N
FAU - Shinomiya, K
AU  - Shinomiya K
FAU - Hayashidera, T
AU  - Hayashidera T
FAU - Tamura, T
AU  - Tamura T
FAU - Hirose, O
AU  - Hirose O
FAU - Manabe, Y
AU  - Manabe Y
FAU - Yokoyama, T
AU  - Yokoyama T
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (gamma-Globulins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Coronary Disease/prevention & control
MH  - Echocardiography
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infusions, Parenteral
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/physiopathology/*therapy
MH  - Random Allocation
MH  - gamma-Globulins/*administration & dosage/therapeutic use
EDAT- 1984/11/10 00:00
MHDA- 1984/11/10 00:01
CRDT- 1984/11/10 00:00
PHST- 1984/11/10 00:00 [pubmed]
PHST- 1984/11/10 00:01 [medline]
PHST- 1984/11/10 00:00 [entrez]
AID - S0140-6736(84)91504-6 [pii]
AID - 10.1016/s0140-6736(84)91504-6 [doi]
PST - ppublish
SO  - Lancet. 1984 Nov 10;2(8411):1055-8. doi: 10.1016/s0140-6736(84)91504-6.

PMID- 1514166
OWN - NLM
STAT- MEDLINE
DCOM- 19920929
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 68
IP  - 1
DP  - 1992 Jul 6
TI  - Extra-cranial bleeding and other symptoms due to low dose aspirin and low 
      intensity oral anticoagulation.
PG  - 1-6
AB  - Data from the early stages of the thrombosis prevention trial (TPT) have been 
      used to establish and quantify the risk of extracranial bleeding due to low dose 
      aspirin (75 mg) and low intensity oral anticoagulation with warfarin 
      (international normalised ratio, INR, 1.5) singly or in combination, in men aged 
      between 45 and 69 who are at high risk of ischaemic heart disease (IHD). The 
      design of the trial is factorial, the four treatments being combined low dose 
      aspirin and low intensity anticoagulation (WA), low intensity anticoagulation 
      alone (W), low dose aspirin alone (A) and double placebo treatment (P). The trial 
      is being carried out through the Medical Research Council's General Practice 
      Research Framework, with participating practices throughout the United Kingdom. 
      Results are based on the first 3,667 men entered. The risk of major 
      gastrointestinal bleeding due to active treatment is probably about 1 in 500 
      man-years of treatment, there currently being no difference between the three 
      active regimes (WA, W, A). Intermediate and minor bleeding episodes occur more 
      frequently with WA than with W or A on their own, the excess being mainly due to 
      minor nose bleeds and bruises. In turn, both W and A on their own cause more such 
      minor episodes than placebo treatment, P. There is no evidence that any of the 
      three active regimens increases the risk of peptic ulceration, nor do they 
      increase reports of indigestion. Aspirin increases reports of constipation and 
      reduces reports of blurred vision. Minor bleeding occurs less frequently in 
      smokers than in non-smokers but is not influenced by age. The antithrombotic 
      regimes used are feasible and acceptable.
FAU - Meade, T W
AU  - Meade TW
AD  - MRC Epidemiology and Medical Care Unit, Medical College of St Bartholomew's 
      Hospital, London, United Kingdom.
FAU - Roderick, P J
AU  - Roderick PJ
FAU - Brennan, P J
AU  - Brennan PJ
FAU - Wilkes, H C
AU  - Wilkes HC
FAU - Kelleher, C C
AU  - Kelleher CC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Coronary Disease/*prevention & control
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Thrombosis/*prevention & control
MH  - Warfarin/administration & dosage/*adverse effects
EDAT- 1992/07/06 00:00
MHDA- 1992/07/06 00:01
CRDT- 1992/07/06 00:00
PHST- 1992/07/06 00:00 [pubmed]
PHST- 1992/07/06 00:01 [medline]
PHST- 1992/07/06 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1992 Jul 6;68(1):1-6.

PMID- 6827479
OWN - NLM
STAT- MEDLINE
DCOM- 19830407
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 224
IP  - 3
DP  - 1983 Mar
TI  - Therapeutic and adjunctive applications of an imidazoline anti-inflammatory 
      agent.
PG  - 567-71
AB  - A unique combination of anti-inflammatory and antiulcerogenic activities is 
      described for 2-(2 methyl-4-chlorophenylamino)-2-imidazoline (CDMI). CDMI 
      administered i.p. produced a dose-related decrease in aspirin-induced ulcers 
      which persisted even in the presence of exogenously added HCI. The 
      carrageenin-edema reducing activities of i.p. CDMI and p.o. aspirin were 
      additive. When oral CDMI was combined with oral aspirin or oral indomethacin, the 
      combinations also resulted in additive anti-inflammatory activities (80 and 94% 
      vs. 52% for CDMI, 62% for aspirin and 71% for indomethacin alone). Moreover, 
      gastric ulcerogenicity was reduced by 92% when either aspirin or indomethacin was 
      combined with CDMI. These results indicate that CDMI and related compounds 
      deserve further study as adjuncts to increase the margin of safety of currently 
      used nonsteroidal anti-inflammatory agents. CDMI was also tested against a 
      developing acute inflammatory reaction. When administered at 2 hr post 
      carrageenin, CDMI was as effective as when it was administered 30 min before the 
      carrageenin. These results are discussed as a possible reflection of an action on 
      the lipoxygenase pathways of the arachidonic acid cascade that is not shared by 
      the classical nonsteroidal anti-inflammatory agents.
FAU - Holsapple, M P
AU  - Holsapple MP
FAU - Trizzino, J
AU  - Trizzino J
FAU - Nichols, D E
AU  - Nichols DE
FAU - Yim, G K
AU  - Yim GK
LA  - eng
GR  - RR0558613/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 4201-26-7 (2-(2-methyl-4-chlorophenylamino)-2-imidazoline)
RN  - 9000-07-1 (Carrageenan)
RN  - MN3L5RMN02 (Clonidine)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - *Anti-Ulcer Agents
MH  - Aspirin/antagonists & inhibitors/therapeutic use
MH  - Carrageenan
MH  - Clonidine/*analogs & derivatives/therapeutic use
MH  - Drug Therapy, Combination
MH  - Edema/drug therapy
MH  - Indomethacin/antagonists & inhibitors/therapeutic use
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach Ulcer/chemically induced/prevention & control
EDAT- 1983/03/01 00:00
MHDA- 1983/03/01 00:01
CRDT- 1983/03/01 00:00
PHST- 1983/03/01 00:00 [pubmed]
PHST- 1983/03/01 00:01 [medline]
PHST- 1983/03/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1983 Mar;224(3):567-71.

PMID- 10362655
OWN - NLM
STAT- MEDLINE
DCOM- 19990729
LR  - 20181218
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 276
IP  - 6
DP  - 1999 Jun
TI  - Effect of diaspirin cross-linked hemoglobin on normal and postischemic 
      microcirculation of the rat pancreas.
PG  - G1507-14
LID - 10.1152/ajpgi.1999.276.6.G1507 [doi]
AB  - Microcirculatory alterations with reduced nutritive supply to the pancreas could 
      be the cause of hyperamylasemia, which occurs in some patients receiving the 
      vasoactive oxygen carrier diaspirin cross-linked hemoglobin (DCLHb) in clinical 
      studies. Therefore, the effects of DCLHb on rat pancreas microcirculation were 
      evaluated. Anesthetized Sprague-Dawley rats received one of the following 
      treatments during baseline conditions (n = 7 rats/group): 10% hydroxyethyl starch 
      (HAES) (0.4 ml/kg), DCLHb (400 mg/kg), or DCLHb (1,400 mg/kg). After 1 h of 
      complete, reversible pancreatic ischemia, other animals received 10% HAES (0.4 
      ml/kg) or DCLHb (400 mg/kg) during the onset of reperfusion. The number of red 
      blood cell-perfused capillaries (functional capillary density, FCD) and the level 
      of leukocyte adherence in postcapillary venules in the pancreas were assessed by 
      means of intravital microscopy during 2 h after treatment. In the nonischemic 
      groups, FCD was 18% greater after DCLHb (1,400 mg/kg) than after 10% HAES 
      treatment without any increase in leukocyte adherence. In the 
      inschemia-reperfusion (I/R) 10% HAES group, FCD was significantly (P < 0.05) 
      lowered, leukocyte adherence enhanced, and mean arterial pressure (MAP) reduced 
      by 31% compared with nonischemic animals. DCLHb treatment in the I/R group 
      resulted in a slight increase in FCD, a significant (P < 0.05) reduction of 
      leukocyte adherence, and a complete restoration of MAP compared with the animals 
      of the I/R control group. Thus our data provide no evidence for a detrimental 
      effect on the pancreatic microcirculation or an enhanced risk of postischemic 
      pancreatitis by DCLHb.
FAU - von Dobschuetz, E
AU  - von Dobschuetz E
AD  - Institute for Surgical Research, Klinikum Grosshadern, Ludwig-Maximilians 
      University, D-81366 Munich, Germany. dobschuetzvon@stud.tu-muenchen.de
FAU - Hoffmann, T
AU  - Hoffmann T
FAU - Engelschalk, C
AU  - Engelschalk C
FAU - Messmer, K
AU  - Messmer K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cell Movement/drug effects
MH  - Granulocytes/pathology/physiology
MH  - Hemoglobins/*pharmacology
MH  - Ischemia/*physiopathology
MH  - Male
MH  - Microcirculation/drug effects
MH  - Pancreas/*blood supply/pathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reference Values
MH  - Reperfusion
EDAT- 1999/06/11 00:00
MHDA- 1999/06/11 00:01
CRDT- 1999/06/11 00:00
PHST- 1999/06/11 00:00 [pubmed]
PHST- 1999/06/11 00:01 [medline]
PHST- 1999/06/11 00:00 [entrez]
AID - 10.1152/ajpgi.1999.276.6.G1507 [doi]
PST - ppublish
SO  - Am J Physiol. 1999 Jun;276(6):G1507-14. doi: 10.1152/ajpgi.1999.276.6.G1507.

PMID- 18973893
OWN - NLM
STAT- MEDLINE
DCOM- 20090923
LR  - 20200816
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 92
IP  - 3
DP  - 2009 Sep
TI  - Low-dose aspirin in non-tubal IVF patients with previous failed conception: a 
      prospective randomized double-blind placebo-controlled trial.
PG  - 923-929
LID - S0015-0282(08)03282-2 [pii]
LID - 10.1016/j.fertnstert.2008.07.1759 [doi]
AB  - OBJECTIVE: To analyze whether the administration of low-dose aspirin during IVF 
      treatment improves the uterine blood flow and improves ongoing pregnancy rates 
      for non-tubal factor IVF patients with previous failed conception. DESIGN: 
      Prospective double-blind placebo-controlled trial. SETTING: University fertility 
      clinic. PATIENT(S): Non-tubal IVF patients with previous failed conception. 
      INTERVENTION(S): Daily 100 mg aspirin or placebo throughout an IVF treatment with 
      a long GnRH-agonist stimulation protocol. MAIN OUTCOME MEASURE(S): Ongoing 
      pregnancy rate, pulsatility index of the uterine artery. RESULT(S): Of 169 
      patients, 84 were assigned to aspirin treatment and 85 to placebo treatment. In 
      the aspirin group, 28 patients (35.4%) had an ongoing pregnancy, and in the 
      placebo group, 26 patients (31.0%) had an ongoing pregnancy. Multilevel analyses 
      showed that the pulsatility index of the uterine artery was not affected by 
      aspirin or placebo treatment. CONCLUSION(S): Low-dose aspirin administration 
      during IVF treatment does not improve pregnancy rates of non-tubal factor IVF 
      patients with previous failed conception, and it does not affect the arterial 
      uterine blood flow.
FAU - Lambers, Marieke J
AU  - Lambers MJ
AD  - Department of Obstetrics, Gynecology and Reproductive Medicine Free University 
      Medical Center, Amsterdam, The Netherlands. Electronic address: 
      mj.lambers@vumc.nl.
FAU - Hoozemans, Diederik A
AU  - Hoozemans DA
AD  - Department of Obstetrics, Gynecology and Reproductive Medicine Free University 
      Medical Center, Amsterdam, The Netherlands.
FAU - Schats, Roel
AU  - Schats R
AD  - Department of Obstetrics, Gynecology and Reproductive Medicine Free University 
      Medical Center, Amsterdam, The Netherlands.
FAU - Homburg, Roy
AU  - Homburg R
AD  - Department of Obstetrics, Gynecology and Reproductive Medicine Free University 
      Medical Center, Amsterdam, The Netherlands.
FAU - Lambalk, Cornelis B
AU  - Lambalk CB
AD  - Department of Obstetrics, Gynecology and Reproductive Medicine Free University 
      Medical Center, Amsterdam, The Netherlands.
FAU - Hompes, Peter G A
AU  - Hompes PGA
AD  - Department of Obstetrics, Gynecology and Reproductive Medicine Free University 
      Medical Center, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20081029
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arteries/drug effects/physiology
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Embryo Implantation
MH  - Female
MH  - Fertilization in Vitro/*methods
MH  - Humans
MH  - Infertility, Female/*drug therapy
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Prospective Studies
MH  - Regional Blood Flow/drug effects/physiology
MH  - Uterus/blood supply/drug effects
EDAT- 2008/11/01 09:00
MHDA- 2009/09/24 06:00
CRDT- 2008/11/01 09:00
PHST- 2008/05/20 00:00 [received]
PHST- 2008/07/15 00:00 [revised]
PHST- 2008/07/21 00:00 [accepted]
PHST- 2008/11/01 09:00 [pubmed]
PHST- 2009/09/24 06:00 [medline]
PHST- 2008/11/01 09:00 [entrez]
AID - S0015-0282(08)03282-2 [pii]
AID - 10.1016/j.fertnstert.2008.07.1759 [doi]
PST - ppublish
SO  - Fertil Steril. 2009 Sep;92(3):923-929. doi: 10.1016/j.fertnstert.2008.07.1759. 
      Epub 2008 Oct 29.

PMID- 7818584
OWN - NLM
STAT- MEDLINE
DCOM- 19950206
LR  - 20181212
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 44
IP  - 10
DP  - 1994 Oct
TI  - Synthesis and antiplatelet effects of the new antithrombotic agent aspalatone 
      with low ulcerogenicity.
PG  - 1122-6
AB  - A new compound, aspalatone (acetylsalicylic acid maltol ester), was synthesized 
      by esterification of acetylsalicylic acid (ASA) and maltol, an antioxidant, and 
      studied for its bleeding time prolongation effect in rats, for its antiplatelet 
      aggregation activity in vitro and ex vivo in rats, and for its antithrombotic 
      activity in vivo using the mouse thromboembolism test. Aspalatone treatment (15 
      mg/kg p.o.) for 10 days prolonged bleeding time by 57% (p < 0.005) in 
      Sprague-Dawley rats vs control, while ASA treatment (15 mg/kg p.o.) prolonged by 
      44%. At the low dose of 15 mg/kg p.o. at least 8 days of treatment were necessary 
      for aspalatone and ASA to prolong the bleeding time significantly. On the other 
      hand, salicylic acid maltol ester which lacks the acetyl group did not 
      significantly affect bleeding time at a dose of 15 mg/kg. Aspalatone produced a 
      potent inhibition of collagen-induced platelet aggregation in vitro with IC50 of 
      1.8 x 10(-4) mol/l, but, similar to ASA, did not significantly inhibit 
      ADP-induced aggregation. The ability of oral aspalatone to inhibit platelet 
      aggregation in rats ex vivo was compared with other reference antiplatelet drugs. 
      Relative potency was ASA > dipyridamole approximately equal to aspalatone > 
      ticlopidine. A single dose of aspalatone potently prevented death due to 
      collagen-induced platelet aggregation in mice in vivo with ED50 value of 32 mg/kg 
      p.o., but failed to prevent death due to ADP-induced platelet aggregation. When 
      given for 10 days, aspalatone prevented collagen-induced death by 90% (p < 0.001) 
      at 20 mg/kg, and this antithrombotic effect lasted after 4 days of wash-out 
      period.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Han, B H
AU  - Han BH
AD  - Natural Products Research Institute, Seoul National University, Korea.
FAU - Suh, D Y
AU  - Suh DY
FAU - Yang, H O
AU  - Yang HO
FAU - Park, Y H
AU  - Park YH
FAU - Kang, Y H
AU  - Kang YH
FAU - Kim, Y C
AU  - Kim YC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Antioxidants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - A233M007P0 (aspalatone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/antagonists & inhibitors/pharmacology
MH  - Animals
MH  - Antioxidants/pharmacology
MH  - Aspirin/*analogs & derivatives/chemical synthesis/pharmacology/toxicity
MH  - Bleeding Time
MH  - Collagen/antagonists & inhibitors/pharmacology
MH  - Fibrinolytic Agents/*chemical synthesis/pharmacology/toxicity
MH  - In Vitro Techniques
MH  - Lethal Dose 50
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*chemical synthesis/pharmacology/toxicity
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Stomach Ulcer/*chemically induced
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1994 Oct;44(10):1122-6.

PMID- 23257371
OWN - NLM
STAT- MEDLINE
DCOM- 20130715
LR  - 20140905
IS  - 1876-7605 (Electronic)
IS  - 1936-8798 (Linking)
VI  - 5
IP  - 12
DP  - 2012 Dec
TI  - Safety and efficacy of high- versus low-dose aspirin after primary percutaneous 
      coronary intervention in ST-segment elevation myocardial infarction: the 
      HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute 
      Myocardial Infarction) trial.
PG  - 1231-8
LID - S1936-8798(12)00987-9 [pii]
LID - 10.1016/j.jcin.2012.07.016 [doi]
AB  - OBJECTIVES: This study sought to examine the relationship between the aspirin 
      dose prescribed at hospital discharge and long-term outcomes after ST-segment 
      elevation myocardial infarction in patients treated with primary percutaneous 
      coronary intervention (PCI). BACKGROUND: Patients with ST-segment elevation 
      myocardial infarction who undergo primary PCI are prescribed maintenance aspirin 
      doses that vary between 75 and 325 mg daily. Whether the dose of aspirin affects 
      long-term patient outcomes is unknown. METHODS: We compared 3-year outcomes in 
      patients who were prescribed high-dose (>200 mg daily) versus low-dose (≤200 mg 
      daily) aspirin from the large-scale HORIZONS-AMI (Harmonizing Outcomes With 
      Revascularization and Stents in Acute Myocardial Infarction) trial. RESULTS: 
      Among 2,851 patients, 2,289 patients (80.3%) were discharged on low-dose aspirin 
      and 562 patients (19.7%) were discharged on high-dose aspirin. Patients 
      discharged on high-dose rather than low-dose aspirin were more likely to have a 
      history of hypertension, hyperlipidemia, family history of premature coronary 
      disease, prior treatment with PCI or coronary artery bypass surgery, and to be 
      enrolled in the United States. Patients discharged on high-dose aspirin had 
      higher 3-year rates of major adverse cardiovascular events, reinfarction, 
      ischemic target vessel revascularization, major bleeding, and stent thrombosis. 
      After multivariable analysis, discharge on high-dose aspirin was an independent 
      predictor of major bleeding (hazard ratio: 2.80; 95% confidence interval: 1.31 to 
      5.99; p = 0.008), but not of adverse ischemic events. CONCLUSIONS: In patients 
      with ST-segment elevation myocardial infarction undergoing primary PCI, discharge 
      on high-dose rather than low-dose aspirin may increase the rate of major bleeding 
      without providing additional ischemic benefit.
CI  - Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Yu, Jennifer
AU  - Yu J
AD  - Zena and Michael A. Weiner Cardiovascular Institute, Mount Sinai Medical Center, 
      New York, New York 10029, USA.
FAU - Mehran, Roxana
AU  - Mehran R
FAU - Dangas, George D
AU  - Dangas GD
FAU - Claessen, Bimmer E
AU  - Claessen BE
FAU - Baber, Usman
AU  - Baber U
FAU - Xu, Ke
AU  - Xu K
FAU - Parise, Helen
AU  - Parise H
FAU - Fahy, Martin
AU  - Fahy M
FAU - Lansky, Alexandra J
AU  - Lansky AJ
FAU - Witzenbichler, Bernhard
AU  - Witzenbichler B
FAU - Grines, Cindy L
AU  - Grines CL
FAU - Guagliumi, Giulio
AU  - Guagliumi G
FAU - Kornowski, Ran
AU  - Kornowski R
FAU - Wöhrle, Jochen
AU  - Wöhrle J
FAU - Dudek, Dariusz
AU  - Dudek D
FAU - Weisz, Giora
AU  - Weisz G
FAU - Stone, Gregg W
AU  - Stone GW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JACC Cardiovasc Interv
JT  - JACC. Cardiovascular interventions
JID - 101467004
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/physiopathology/*surgery
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Care
MH  - Prospective Studies
MH  - *Stents
EDAT- 2012/12/22 06:00
MHDA- 2013/07/17 06:00
CRDT- 2012/12/22 06:00
PHST- 2012/05/10 00:00 [received]
PHST- 2012/06/26 00:00 [revised]
PHST- 2012/07/04 00:00 [accepted]
PHST- 2012/12/22 06:00 [entrez]
PHST- 2012/12/22 06:00 [pubmed]
PHST- 2013/07/17 06:00 [medline]
AID - S1936-8798(12)00987-9 [pii]
AID - 10.1016/j.jcin.2012.07.016 [doi]
PST - ppublish
SO  - JACC Cardiovasc Interv. 2012 Dec;5(12):1231-8. doi: 10.1016/j.jcin.2012.07.016.

PMID- 21047145
OWN - NLM
STAT- MEDLINE
DCOM- 20110316
LR  - 20211020
IS  - 1179-1942 (Electronic)
IS  - 0114-5916 (Linking)
VI  - 34
IP  - 1
DP  - 2011 Jan 1
TI  - Effects of proton pump inhibitors on adverse gastrointestinal events in patients 
      receiving clopidogrel: systematic review and meta-analysis.
PG  - 47-57
LID - 10.2165/11584750-000000000-00000 [doi]
AB  - BACKGROUND: There has been recent concern regarding a possible adverse 
      interaction between clopidogrel and proton pump inhibitors (PPIs), coupled with 
      uncertainty as to whether PPIs genuinely help in reducing gastrointestinal (GI) 
      harm. OBJECTIVE: To perform a meta-analysis of GI outcomes in patients taking 
      clopidogrel, with and without concomitant PPI. METHODS: We searched MEDLINE, 
      EMBASE and the Cochrane Controlled Trials Register from inception to March 2010, 
      and checked conference abstracts for randomized and non-randomized studies that 
      reported on adverse GI events (haemorrhage, ulcer, perforation or obstruction) 
      with PPI exposure in patients taking clopidogrel. Relevant studies were 
      subcategorized according to the degree of aspirin (acetylsalicylic acid) 
      co-administration and nature of GI events, where available. We performed random 
      effects meta-analysis for risk of adverse GI events with PPI exposure in 
      clopidogrel-treated patients, and assessed heterogeneity using the I2 statistic. 
      RESULTS: Our review evaluated 71,277 participants in nine retrospective studies 
      and one randomized trial. Exposure to PPI for patients receiving dual 
      antiplatelet therapy (aspirin and clopidogrel in seven studies) was associated 
      with a significant reduction in adverse GI events, odds ratio (OR) 0.38 (95% CI 
      0.21, 0.68; p=0.001; I2=17%). There was significant heterogeneity in the analysis 
      of patients receiving clopidogrel monotherapy (two studies), and no definite 
      benefit was found. Restricting the analysis to studies specifically reporting 
      upper GI bleeds with any clopidogrel exposure yielded an OR of 0.31 (95% CI 0.19, 
      0.51; p<0.001; I2=27%) with associated PPI exposure. CONCLUSIONS: Use of PPIs is 
      associated with a reduction in adverse GI events (particularly haemorrhages) in 
      patients who are receiving dual antiplatelet therapy. Clinicians should carefully 
      weigh up the evidence for potential GI benefits against the uncertainties 
      surrounding any possible adverse cardiovascular impact of concomitant clopidogrel 
      PPI therapy.
FAU - Kwok, Chun Shing
AU  - Kwok CS
AD  - School of Medicine, Health Policy and Practice, University of East Anglia, 
      Norwich, UK.
FAU - Nijjar, Ramanpreet Singh
AU  - Nijjar RS
FAU - Loke, Yoon Kong
AU  - Loke YK
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Drug Saf. 2011 Feb 1;34(2):173; author reply 174. PMID: 21247223
MH  - Aspirin/administration & dosage/adverse effects/pharmacology
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Diseases/chemically induced/physiopathology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/pharmacology
MH  - Proton Pump Inhibitors/*adverse effects/pharmacology
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacology
EDAT- 2010/11/05 06:00
MHDA- 2011/03/17 06:00
CRDT- 2010/11/05 06:00
PHST- 2010/11/05 06:00 [entrez]
PHST- 2010/11/05 06:00 [pubmed]
PHST- 2011/03/17 06:00 [medline]
AID - 10.2165/11584750-000000000-00000 [doi]
PST - ppublish
SO  - Drug Saf. 2011 Jan 1;34(1):47-57. doi: 10.2165/11584750-000000000-00000.

PMID- 34854189
OWN - NLM
STAT- MEDLINE
DCOM- 20220915
LR  - 20220929
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 130
IP  - 4
DP  - 2022 Oct
TI  - Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot 
      inhibitors during bacille Calmette-Guérin?
PG  - 463-469
LID - 10.1111/bju.15665 [doi]
AB  - OBJECTIVE: To determine the impact of fibrin clot inhibitor (FCI) use on 
      oncological outcomes in a large contemporary cohort of patients with 
      non-muscle-invasive bladder cancer (NMIBC) treated with adequate bacille 
      Calmette-Guérin (BCG). PATIENTS AND METHODS: We performed an Institutional Review 
      Board-approved review of patients with NMIBC treated with adequate intravesical 
      BCG, at our institution between 2000 and 2018. FCI use at the time of BCG therapy 
      was recorded for each patient. Patients were stratified according to use of FCI 
      medication. Recurrence- and progression-free survival were analysed using 
      Kaplan-Meier methods and Cox proportional hazard models. RESULTS: Overall, 226 of 
      526 patients (43.0%) used a FCI: aspirin (205), clopidogrel (38), warfarin (18) 
      and novel oral anticoagulant (NOAC; seven). The use of FCIs did not adversely 
      affect either recurrence- or progression-free survival (P = 0.385 and P = 0.131, 
      respectively). These results did not change when the impact of aspirin, 
      clopidogrel or warfarin/NOAC use on recurrence and progression was evaluated 
      separately. On multivariate analysis, FCI use was neither associated with tumour 
      recurrence nor progression. CONCLUSION: The use of FCIs was not associated with 
      adverse oncological outcomes in a large contemporary cohort of patients receiving 
      adequate intravesical BCG for NMIBC. Based on these results, FCIs may be safely 
      continued during BCG immunotherapy.
CI  - © 2021 The Authors BJU International © 2021 BJU International.
FAU - Lobo, Niyati
AU  - Lobo N
AUID- ORCID: 0000-0002-6505-8399
AD  - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Hensley, Patrick J
AU  - Hensley PJ
AUID- ORCID: 0000-0002-8098-901X
AD  - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Bree, Kelly K
AU  - Bree KK
AD  - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Nogueras-Gonzalez, Graciela M
AU  - Nogueras-Gonzalez GM
AD  - Department of Biostatistics, University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Navai, Neema
AU  - Navai N
AD  - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Dinney, Colin P
AU  - Dinney CP
AD  - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Kamat, Ashish M
AU  - Kamat AM
AD  - Department of Urology, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20211213
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Anticoagulants)
RN  - 0 (BCG Vaccine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9001-31-4 (Fibrin)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adjuvants, Immunologic/therapeutic use
MH  - Administration, Intravesical
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - BCG Vaccine/therapeutic use
MH  - Clopidogrel/therapeutic use
MH  - Fibrin/therapeutic use
MH  - Humans
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - *Thrombosis
MH  - *Urinary Bladder Neoplasms/pathology
MH  - Warfarin/pharmacology/therapeutic use
OTO - NOTNLM
OT  - #BladderCancer
OT  - #Urology
OT  - #blcsm
OT  - #uroonc
OT  - aspirin
OT  - bacille Calmette-Guérin
OT  - bladder cancer
OT  - clopidogrel
OT  - fibrin clot inhibitor
OT  - novel oral anticoagulant
OT  - warfarin
EDAT- 2021/12/03 06:00
MHDA- 2022/09/16 06:00
CRDT- 2021/12/02 06:55
PHST- 2021/12/03 06:00 [pubmed]
PHST- 2022/09/16 06:00 [medline]
PHST- 2021/12/02 06:55 [entrez]
AID - 10.1111/bju.15665 [doi]
PST - ppublish
SO  - BJU Int. 2022 Oct;130(4):463-469. doi: 10.1111/bju.15665. Epub 2021 Dec 13.

PMID- 21801060
OWN - NLM
STAT- MEDLINE
DCOM- 20111118
LR  - 20131121
IS  - 1943-5681 (Electronic)
IS  - 0002-9645 (Linking)
VI  - 72
IP  - 8
DP  - 2011 Aug
TI  - Evaluation of effects of low-dose aspirin administration on urinary thromboxane 
      metabolites in healthy dogs.
PG  - 1038-45
LID - 10.2460/ajvr.72.8.1038 [doi]
AB  - OBJECTIVE: To evaluate markers of in vivo platelet function (urinary 
      11-dehydro-thromboxane B(2) [11-dehydroTXB(2)] and 2,3-dinorTXB(2)) and assess 
      their response to administration of 2 commonly used dosages of aspirin in healthy 
      dogs. ANIMALS: 20 healthy dogs. PROCEDURES: Urine was collected prior to aspirin 
      administration and on the morning following the last evening administration. 
      Twenty dogs received aspirin (1 mg/kg, PO, q 24 h) for 7 consecutive doses. After 
      a washout period of 5 months, 10 dogs received a single dose of aspirin (10 
      mg/kg, PO). Concentrations of urinary thromboxane metabolites 11-dehydroTXB(2) 
      and 2,3-dinorTXB(2) were measured via ELISA, and values were normalized to urine 
      creatinine concentration. RESULTS: Median baseline 11-dehydroTXB(2) 
      concentrations were 0.38 ng/mg of creatinine (range, 0.15 to 1.13 ng/mg). Mean ± 
      SD baseline 2 at a 3-dinorTXB(2) concentrations were 6.75 ± 2.77 ng/mg of 
      creatinine. Administration of aspirin at a dosage of 1 mg/kg, PO, every 24 hours 
      for 7 days did not significantly decrease urinary 11-dehydroTXB(2) concentration, 
      but administration of the single aspirin dose of 10 mg/kg did significantly 
      decrease 11-dehydroTXB(2) concentration by a median of 45.5% (range, 28.2% to 
      671%). Administration of the 1 mg/kg aspirin dosage significantly decreased 
      urinary 2,3-dinorTXB(2) concentration by a mean ± SD of 33.0 ± 23.7%. 
      Administration of the single aspirin dose of 10 mg/kg also significantly 
      decreased 2,3-dinorTXB(2) concentration by a mean ± SD of 46.7 ± 12.6%. 
      CONCLUSIONS AND CLINICAL RELEVANCE: Aspirin administration (1 mg/kg/d) may be 
      insufficient for reliable platelet inhibition in healthy dogs.
FAU - Hoh, Crystal M
AU  - Hoh CM
AD  - Department of Veterinary Clinical Medicine, College of Veterinary Medicine, 
      University of Illinois, Urbana, IL 61802, USA.
FAU - Smith, Stephanie A
AU  - Smith SA
FAU - McMichael, Maureen A
AU  - McMichael MA
FAU - Byron, Julie K
AU  - Byron JK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 63250-09-9 (2,3-dinor-thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dogs/*physiology
MH  - Enzyme-Linked Immunosorbent Assay/veterinary
MH  - Female
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Thromboxane B2/analogs & derivatives/metabolism/urine
EDAT- 2011/08/02 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/08/02 06:00
PHST- 2011/08/02 06:00 [entrez]
PHST- 2011/08/02 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 10.2460/ajvr.72.8.1038 [doi]
PST - ppublish
SO  - Am J Vet Res. 2011 Aug;72(8):1038-45. doi: 10.2460/ajvr.72.8.1038.

PMID- 8473644
OWN - NLM
STAT- MEDLINE
DCOM- 19930520
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 21
IP  - 6
DP  - 1993 May
TI  - Aspirin, but not heparin, suppresses the transient increase in thromboxane 
      biosynthesis associated with cardiac catheterization or coronary angioplasty.
PG  - 1377-81
AB  - OBJECTIVES: We sought to study the dose dependence of in vivo suppression by 
      aspirin of enhanced thromboxane biosynthesis in the setting of coronary 
      angioplasty and to evaluate the effects of heparin and aspirin during cardiac 
      catheterization. BACKGROUND: Percutaneous transluminal coronary angioplasty 
      induces a controlled injury of the intima of the diseased arterial segment, with 
      rapid deposition of platelets at the site of dilation. Thus, it provides a 
      clinical model of intracoronary platelet activation. METHODS: The urinary 
      excretion of a major enzymatic metabolite of thromboxane A2, 
      11-dehydro-thromboxane B2, was measured in 57 patients with stable coronary 
      artery disease undergoing cardiac catheterization (n = 28) or elective 
      single-vessel percutaneous transluminal coronary angioplasty (n = 29). Three 
      consecutive urine collections were obtained from all patients before during and 
      after either procedure. Patients undergoing catheterization were treated with the 
      following regimens: a) no aspirin for > or = 10 days and no heparin (n = 12); b) 
      no aspirin for > or = 10 days but heparin, 10,000 IU, at the time of 
      catheterization (n = 5); c) aspirin, 300 mg/day, for at least 5 days (n = 11). 
      Patients undergoing coronary angioplasty were randomly assigned to short-term 
      treatment with aspirin given as a) 75 mg/day for > or = 5 days before angioplasty 
      (n = 11); b) 300 mg/day for > or = 3 days before angioplasty (n = 9); or c) 300 
      mg/day for > or = 3 days before angioplasty followed by 1,000 mg during 
      angioplasty (n = 9). RESULTS: In patients undergoing catheterization, urinary 
      11-dehydro-thromboxane B2 excretion (pg/mg creatinine) increased from 563 +/- 481 
      (mean +/- SD) to 1,684 +/- 1,332 in the absence and from 620 +/- 191 to 1,588 +/- 
      597 in the presence of heparin. No increase was observed in the group receiving 
      aspirin (from 240 +/- 141 to 215 +/- 115). In patients undergoing coronary 
      angioplasty treated with aspirin, 75 mg/day, urinary 11-dehydro-thromboxane B2 
      averaged 180 +/- 112, 223 +/- 178 and 294 +/- 260, respectively, before, during 
      and after the procedure. At 300 mg/day, the corresponding values were 185 +/- 48, 
      217 +/- 70 and 197 +/- 93. In patients also receiving aspirin, 1,000 mg, during 
      angioplasty, 11-dehydro-thromboxane B2 averaged 151 +/- 66, 138 +/- 43 and 133 
      +/- 77, respectively. CONCLUSIONS: Enhanced thromboxane biosynthesis associated 
      with cardiac catheterization or coronary angioplasty can be largely suppressed by 
      low dose aspirin. This finding is consistent with the view that this alteration 
      reflects platelet activation.
FAU - Ciabattoni, G
AU  - Ciabattoni G
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.
FAU - Ujang, S
AU  - Ujang S
FAU - Sritara, P
AU  - Sritara P
FAU - Andreotti, F
AU  - Andreotti F
FAU - Davies, G
AU  - Davies G
FAU - Simonetti, B M
AU  - Simonetti BM
FAU - Patrono, C
AU  - Patrono C
FAU - Maseri, A
AU  - Maseri A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/*pharmacology
MH  - *Cardiac Catheterization
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Heparin/*pharmacology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Models, Cardiovascular
MH  - Platelet Activation/drug effects
MH  - Thromboxane A2/*biosynthesis
MH  - Thromboxane B2/analogs & derivatives/urine
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
AID - 0735-1097(93)90312-O [pii]
AID - 10.1016/0735-1097(93)90312-o [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1993 May;21(6):1377-81. doi: 10.1016/0735-1097(93)90312-o.

PMID- 5773090
OWN - NLM
STAT- MEDLINE
DCOM- 19690422
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 48
IP  - 3
DP  - 1969 Mar
TI  - Structural changes in human serum albumin induced by ingestion of acetylsalicylic 
      acid.
PG  - 536-42
AB  - Acetylsalicylic acid (aspirin) acetylates human serum albumin under physiologic 
      conditions in vitro. These investigations were done to determine whether this 
      phenomenon occurs in vivo and to delineate the site(s) of acetylation on the 
      albumin molecule. Albumin was reacted in vitro with aspirin labeled with 
      (14)carbon at the acetyl-1 or the carboxyl carbon. The altered albumin was 
      hydrolyzed with trypsin and peptide mapping performed. Albumin so treated 
      contains a unique peptide, designated "A," and shows diminution of two normal 
      peptides, designated "B" and "C." Peptide "A" is never seen in normal albumin. 
      Amino acid analyses indicate that peptide "A" equals the sum of peptides "B" and 
      "C." Furthermore all three peptides contain lysine but lack arginine. Thus 
      peptide "A" is formed by the acetylation of a lysine residue which is normally 
      susceptible to trypsin and yields peptides "B" and "C." Radioautography of the 
      peptide maps show most of the acetyl-1-(14)C activity in peptide "A." This 
      indicates that one of the lysine residues in this peptide is the preferential 
      site for the transacetylation reaction. Peptide "A," used as a marker for 
      acetylation, is found in albumin from patients who take aspirin but is not 
      demonstrable in albumin from one of these patients while she was taking sodium 
      salicylate. A transacetylation reaction between aspirin and human albumin occurs 
      in vivo and is similar to that observed in vitro.
FAU - Hawkins, D
AU  - Hawkins D
FAU - Pinckard, R N
AU  - Pinckard RN
FAU - Crawford, I P
AU  - Crawford IP
FAU - Farr, R S
AU  - Farr RS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Amino Acids)
RN  - 0 (Carbon Isotopes)
RN  - 0 (Serum Albumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acids/analysis
MH  - Aspirin/*pharmacology
MH  - Autoradiography
MH  - Carbon Isotopes
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Humans
MH  - In Vitro Techniques
MH  - Peptide Biosynthesis
MH  - Serum Albumin/*analysis/*metabolism
PMC - PMC535718
EDAT- 1969/03/01 00:00
MHDA- 1969/03/01 00:01
CRDT- 1969/03/01 00:00
PHST- 1969/03/01 00:00 [pubmed]
PHST- 1969/03/01 00:01 [medline]
PHST- 1969/03/01 00:00 [entrez]
AID - 10.1172/JCI106011 [doi]
PST - ppublish
SO  - J Clin Invest. 1969 Mar;48(3):536-42. doi: 10.1172/JCI106011.

PMID- 9010645
OWN - NLM
STAT- MEDLINE
DCOM- 19970401
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 53
IP  - 1
DP  - 1997 Jan
TI  - Gastric toxicity of antiplatelet therapy with low-dose aspirin.
PG  - 1-5
AB  - Low-dose aspirin is widely employed as antiplatelet therapy for cardiovascular 
      disorders. However, even in the dosages usually employed for that purpose (75 to 
      325 mg daily), the drug maintains its ability to damage the gastric mucosa by 
      inducing bleeding ulcers and/or erosions. Pharmacological protection is therefore 
      necessary. Specific long term studies with histamine H2 receptor antagonists or 
      sucralfate are lacking, but data from trials on the prevention of gastric damage 
      by other nonsteroidal anti-inflammatory drugs (NSAIDs) are discouraging. Recent 
      preliminary data suggest that misoprostol, in keeping with its ability to protect 
      both gastric and duodenal mucosa from long term NSAID treatment, seems to be 
      effective also against long term low-dose aspirin therapy in this setting.
FAU - Guslandi, M
AU  - Guslandi M
AD  - Gastroenterology Unit, S Raffaele Hospital, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects
RF  - 40
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.2165/00003495-199753010-00001 [doi]
PST - ppublish
SO  - Drugs. 1997 Jan;53(1):1-5. doi: 10.2165/00003495-199753010-00001.

PMID- 20855853
OWN - NLM
STAT- MEDLINE
DCOM- 20101008
LR  - 20131121
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 75
IP  - 12
DP  - 2010 Sep 21
TI  - Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of 
      headache.
PG  - 1098-103
LID - 10.1212/WNL.0b013e3181f39a11 [doi]
AB  - BACKGROUND: IV lysine acetylsalicylate (aspirin) has been shown to be effective 
      in the treatment of acute migraine attacks, but little is known about its 
      effectiveness and safety in patients hospitalized for management of severe 
      headache, typically arising from abrupt withdrawal of other acute attack 
      medications. METHODS: We present an audit of our use of IV aspirin in 168 
      patients in a tertiary referral setting. RESULTS: The findings demonstrate 
      subjective approval of this medication by the patients and objective improvements 
      in pain scores, a decrease of ≥3 points on a 10-point visual analog pain scale 
      being seen on >25% occasions on which the medication was administered. Further, 
      side effect rates were low (5.9%), with no serious adverse events. CONCLUSION: IV 
      aspirin is safe, effective, and useful in the inpatient management of headache.
FAU - Weatherall, M W
AU  - Weatherall MW
AD  - Headache Group, Department of Neurology, University of California, San Francisco, 
      1701 Divisadero St., San Francisco, CA 94115, USA.
FAU - Telzerow, A J
AU  - Telzerow AJ
FAU - Cittadini, E
AU  - Cittadini E
FAU - Kaube, H
AU  - Kaube H
FAU - Goadsby, P J
AU  - Goadsby PJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Neurology. 2011 Apr 5;76(14):1275; author reply 1275. PMID: 21464436
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Headache Disorders/chemically induced/*drug therapy
MH  - Humans
MH  - Infusions, Intravenous
MH  - Inpatients
MH  - Male
MH  - Medical Records
MH  - Middle Aged
MH  - Pain Measurement/*drug effects
MH  - Patient Selection
MH  - Treatment Outcome
EDAT- 2010/09/22 06:00
MHDA- 2010/10/12 06:00
CRDT- 2010/09/22 06:00
PHST- 2010/09/22 06:00 [entrez]
PHST- 2010/09/22 06:00 [pubmed]
PHST- 2010/10/12 06:00 [medline]
AID - 75/12/1098 [pii]
AID - 10.1212/WNL.0b013e3181f39a11 [doi]
PST - ppublish
SO  - Neurology. 2010 Sep 21;75(12):1098-103. doi: 10.1212/WNL.0b013e3181f39a11.

PMID- 17052745
OWN - NLM
STAT- MEDLINE
DCOM- 20070720
LR  - 20191210
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 120
IP  - 2
DP  - 2007
TI  - Using the Platelet Function Analyzer-100 for monitoring aspirin therapy.
PG  - 161-72
AB  - INTRODUCTION: The aim of the study was to evaluate the test characteristics of 
      the Platelet Function Analyzer-100 (PFA-100) in patients treated with aspirin. 
      METHODS AND RESULTS: The study consisted of two sub-studies. In study 1, 10 
      patients with ischemic heart disease (IHD) and 10 controls had platelet function 
      assessed by optical platelet aggregation and the PFA-100 method in two 5-week 
      periods. Patients with IHD were treated with aspirin 150 mg/day (first 5-week 
      period), and 300 mg/day (second 5-week period), whereas the controls only 
      received aspirin (150 mg/day) during the second 5-week period. From the results 
      of study 1, we found that a cut-off value for the PFA-100 collagen/epinephrine 
      cartridge <165 s identified patients not taking aspirin (sensitivity 0.91, 
      specificity 1.00). A good agreement between the PFA-100 method and optical 
      platelet aggregation was found. Within-subject variation for the PFA-100 
      collagen/epinephrine cartridge was +/-28%, as compared to +/-17% for the optical 
      platelet aggregation. Study 2 included 298 aspirin treated patients who were 
      admitted with symptoms suggestive of an acute myocardial infarction. Platelet 
      function was assessed in duplicate by the PFA-100 collagen/epinephrine cartridge, 
      and a 95% Limit of Agreement interval at [-65%, 65%] indicated a limited 
      precision. CONCLUSION: We defined a cut-off value below which patients not taking 
      aspirin can be identified. However, due to imprecision of the PFA-100 method 
      repeated duplicate assessment of the collagen/epinephrine Closure Time is 
      recommended.
FAU - Poulsen, Tina Svenstrup
AU  - Poulsen TS
AD  - Department of Cardiology, Odense University Hospital, Sdr. Boulevard 29, DK-5000 
      Odense C, Denmark. tina.poulsen@ouh.fyns-amt.dk
FAU - Mickley, Hans
AU  - Mickley H
FAU - Korsholm, Lars
AU  - Korsholm L
FAU - Licht, Peter Bjørn
AU  - Licht PB
FAU - Haghfelt, Torben
AU  - Haghfelt T
FAU - Jørgensen, Bo
AU  - Jørgensen B
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061018
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Case-Control Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/blood/drug therapy
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Function Tests/*instrumentation/statistics & numerical data
MH  - Reproducibility of Results
EDAT- 2006/10/21 09:00
MHDA- 2007/07/21 09:00
CRDT- 2006/10/21 09:00
PHST- 2005/09/25 00:00 [received]
PHST- 2006/08/13 00:00 [revised]
PHST- 2006/08/15 00:00 [accepted]
PHST- 2006/10/21 09:00 [pubmed]
PHST- 2007/07/21 09:00 [medline]
PHST- 2006/10/21 09:00 [entrez]
AID - S0049-3848(06)00272-6 [pii]
AID - 10.1016/j.thromres.2006.08.010 [doi]
PST - ppublish
SO  - Thromb Res. 2007;120(2):161-72. doi: 10.1016/j.thromres.2006.08.010. Epub 2006 
      Oct 18.

PMID- 28968454
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20190116
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 10
DP  - 2017
TI  - Reduction of intracerebral hemorrhage in hemodialysis patients after reducing 
      aspirin use: A quality-assurance observational study.
PG  - e0185847
LID - 10.1371/journal.pone.0185847 [doi]
LID - e0185847
AB  - There is so far no international consensus concerning the prescription of 
      antithrombotic agents in hemodialysis patients. It is not clear yet why they 
      cause more bleeding in some patients and are beneficial in others. We therefore 
      tried to find out what triggers bleeding in this population. This is an 
      observational before-and-after study that included all patients undergoing 
      hemodialysis in our center between 2005 and 2015. We divided the study into two 
      phases: phase one (125 patients) where aspirin was used without restrictions and 
      phase two (110 patients) where aspirin was avoided in severe hypertension and 
      primary prevention. We aimed to assess the differential occurrence of 
      intracerebral hemorrhage between the two phases and the cardiovascular mortality 
      of patients whether on aspirin or not. Bleeding events occurred in 12.8% of 
      patients in phase one and 13.6% in phase two (p = 0.85). Seven out of 125 
      patients (6%) in phase one experienced intracerebral hemorrhage and none in phase 
      two. Intracerebral hemorrhage was significantly increased in those with the 
      combination of aspirin and severe hypertension (p = 0.003). Aspirin and 
      acenocoumadin were significantly associated with total bleeding (OR = 3.81 and 
      4.85 with p = 0.005 and 0.001 respectively). Cardiovascular mortality did not 
      differ between phase one and two whether patients were on aspirin or not (p = 
      0.45 and 0.31 respectively). Minimizing aspirin use in hemodialysis patients with 
      severe hypertension reduced intracerebral bleeding without a significant 
      difference in cardiovascular mortality.
FAU - Aoun, Mabel
AU  - Aoun M
AUID- ORCID: 0000-0001-9893-5514
AD  - Department of Nephrology, Saint-Georges Hospital, Ajaltoun, Lebanon.
AD  - Department of Nephrology, Saint-Joseph University, Beirut, Lebanon.
FAU - Koubar, Sahar H
AU  - Koubar SH
AD  - Department of Internal Medicine, Division of Nephrology, American University of 
      Beirut Medical Center, Beirut, Lebanon.
FAU - Antoun, Leony
AU  - Antoun L
AD  - Department of Internal Medicine, Holy Spirit University, Kaslik, Lebanon.
FAU - Tamim, Hani
AU  - Tamim H
AD  - Biostatistics Unit, Clinical Research Institute, American University of Beirut 
      Medical Center, Beirut, Lebanon.
FAU - Makki, Maha
AU  - Makki M
AD  - Biostatistics Unit, Clinical Research Institute, American University of Beirut 
      Medical Center, Beirut, Lebanon.
FAU - Chelala, Dania
AU  - Chelala D
AD  - Department of Nephrology, Saint-Joseph University, Beirut, Lebanon.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20171002
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Cerebral Hemorrhage/*etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Quality Assurance, Health Care
MH  - *Renal Dialysis
PMC - PMC5624631
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2017/10/03 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/10/03 06:00
PHST- 2017/04/30 00:00 [received]
PHST- 2017/09/20 00:00 [accepted]
PHST- 2017/10/03 06:00 [entrez]
PHST- 2017/10/03 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - PONE-D-17-16596 [pii]
AID - 10.1371/journal.pone.0185847 [doi]
PST - epublish
SO  - PLoS One. 2017 Oct 2;12(10):e0185847. doi: 10.1371/journal.pone.0185847. 
      eCollection 2017.

PMID- 7942533
OWN - NLM
STAT- MEDLINE
DCOM- 19941026
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 74
IP  - 7
DP  - 1994 Oct 1
TI  - Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes 
      after ingestion in normal subjects.
PG  - 720-3
AB  - Aspirin interferes with platelet aggregation by inhibiting the metabolism of 
      arachidonic acid to thromboxane A2. Although both high- and low-dose aspirin 
      therapies are effective for secondary prophylaxis in patients with 
      atherosclerotic vascular disease, the acute response to low-dose aspirin therapy 
      is controversial. Eighteen volunteer subjects ingested 81, 162, or 324 mg of 
      aspirin in a longitudinal crossover study design. Initial doses were randomly 
      assigned and dosing intervals were separated by 2 weeks. Platelet aggregation in 
      response to 0.9 mM arachidonic acid was measured at baseline, 15, 30, 60, and 90 
      minutes after ingestion. Thromboxane B2 production was assayed on simultaneously 
      obtained samples after stimulation with arachidonic acid. The median inhibition 
      of aggregation was 97%, 97%, and 97% 15 minutes after ingestion of 81, 162, and 
      324 mg, respectively. Four subjects had < 20% inhibition 15 minutes after 
      ingesting 81 mg, but all 4 had > 90% inhibition after 30 minutes. Thromboxane B2 
      production declined by > 93% in all subjects at each dose. There was no 
      difference between doses in inhibition of thromboxane B2 production.
FAU - Dabaghi, S F
AU  - Dabaghi SF
AD  - Baylor College of Medicine, Houston, Texas 77030.
FAU - Kamat, S G
AU  - Kamat SG
FAU - Payne, J
AU  - Payne J
FAU - Marks, G F
AU  - Marks GF
FAU - Roberts, R
AU  - Roberts R
FAU - Schafer, A I
AU  - Schafer AI
FAU - Kleiman, N S
AU  - Kleiman NS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Cardiol. 1995 Sep 15;76(8):637-8. PMID: 7677099
MH  - Administration, Oral
MH  - Adult
MH  - Arachidonic Acid/metabolism/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane A2/biosynthesis
MH  - Thromboxane B2/biosynthesis
MH  - Time Factors
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 0002-9149(94)90317-4 [pii]
AID - 10.1016/0002-9149(94)90317-4 [doi]
PST - ppublish
SO  - Am J Cardiol. 1994 Oct 1;74(7):720-3. doi: 10.1016/0002-9149(94)90317-4.

PMID- 7022484
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20131121
IS  - 0308-051X (Print)
IS  - 0308-051X (Linking)
VI  - 2
IP  - 9
DP  - 1981
TI  - Sodium meclofenamate ('Meclomen') in the treatment of rheumatoid arthritis: a 
      double-blind comparison with aspirin and placebo.
PG  - 587-96
AB  - The therapeutic efficacy of sodium meclofenamate (300 mg per day) was compared 
      with that of aspirin (3.6 g per day) and placebo in 317 patients with active 
      rheumatoid arthritis. The 8-week double-blind treatment period was preceded by a 
      2-week washout period on aspirin. A smaller proportion of patients on sodium 
      meclofenamate (11%) withdrew for a lack of efficacy than did patients on aspirin 
      (18%) or placebo (40%). Analyses of measures of tenderness, total joint 
      involvement, duration of morning stiffness, and patient condition and global 
      improvement revealed that the therapeutic effectiveness of 300 mg sodium 
      meclofenamate daily and 3.6 g aspirin daily were equivalent and significantly 
      superior to that of placebo. The principal adverse reactions with sodium 
      meclofenamate were gastro-intestinal symptoms of which diarrhoea was the most 
      frequently reported. The rates of adverse reaction withdrawals were similar in 
      the three treatment groups. Sodium meclofenamate showed good control of disease 
      activity and was generally well tolerated in the treatment of rheumatoid 
      arthritis.
FAU - Willkens, R F
AU  - Willkens RF
FAU - Vreede, P
AU  - Vreede P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Pharmatherapeutica
JT  - Pharmatherapeutica
JID - 7606274
RN  - 0 (ortho-Aminobenzoates)
RN  - 48I5LU4ZWD (Meclofenamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Meclofenamic Acid/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - ortho-Aminobenzoates/*therapeutic use
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Pharmatherapeutica. 1981;2(9):587-96.

PMID- 7850677
OWN - NLM
STAT- MEDLINE
DCOM- 19950310
LR  - 20150901
IS  - 0578-1337 (Print)
IS  - 0578-1337 (Linking)
VI  - 54
IP  - 6
DP  - 1994 Dec
TI  - An experimental model of osteoarthritis in rabbit.
PG  - 377-81
AB  - BACKGROUND: From both a microscopic and a metabolic view, experimental animal 
      models are very important for study of the pathogenesis of osteoarthritis. A new, 
      different operative procedure was used in rabbit models, and the pathologic 
      findings were evaluated. METHODS: Twelve New Zealand white rabbits were divided 
      into six groups; eight were used as animal models and four, for drug efficacy 
      study. Transection of the anterior cruciate and medial collateral ligaments on 
      the left knee joint, and sham-operation were performed on the right knee joint. 
      Rabbits were sacrificed post surgery from 4, 6, 8 and 12 weeks. Eight parameters 
      from gross to microscopic findings were used in order to evaluate osteoarthritic 
      changes. Indomethacin and aspirin were chosen for the drug efficacy experiment; 
      the two rabbits of each group were sacrificed at the end of the sixth week 
      post-surgery. RESULTS: According to pathological findings, this operative 
      procedure can produce osteoarthritic changes, visible both microscopically and 
      macroscopically. There were osteoarthritic changes in the fourth week 
      post-surgery group and, obviously, in the eighth week; these persisted until 12th 
      weeks post-surgery. Neither indomethacin nor aspirin showed any effect in 
      preventing osteoarthritis progression. CONCLUSIONS: Transection of the anterior 
      cruciate and medial collateral ligament rabbit model can produce osteoarthritic 
      lesions in the knee joint. This model can be used for further biochemical and 
      metabolic studies.
FAU - Kuo, S Y
AU  - Kuo SY
AD  - Department of Medicine, Tri-Service General Hospital, National Defense Medical 
      Center, Taipei, Taiwan, R.O.C.
FAU - Chu, S J
AU  - Chu SJ
FAU - Hsu, C M
AU  - Hsu CM
FAU - Chen, C M
AU  - Chen CM
FAU - Chang, M L
AU  - Chang ML
FAU - Chang, D M
AU  - Chang DM
LA  - eng
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Zhonghua Yi Xue Za Zhi (Taipei)
JT  - Zhonghua yi xue za zhi = Chinese medical journal; Free China ed
JID - 0005327
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Disease Models, Animal
MH  - Indomethacin/therapeutic use
MH  - Male
MH  - Osteoarthritis/drug therapy/*pathology
MH  - Rabbits
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi (Taipei). 1994 Dec;54(6):377-81.

PMID- 19048536
OWN - NLM
STAT- MEDLINE
DCOM- 20090127
LR  - 20131121
IS  - 1576-6578 (Electronic)
IS  - 0210-0010 (Linking)
VI  - 47
IP  - 11
DP  - 2008 Dec 1-15
TI  - [Reye's syndrome. Description of a case focused on the patient's epileptic 
      seizures].
PG  - 571-4
AB  - INTRODUCTION: Reye's syndrome is an acute disease characterised by encephalopathy 
      and fatty degeneration of the liver that occurs almost exclusively in children. 
      It can cause the death of the patient in up to a third of all cases, generally 
      due to severe cerebral oedema. The aetiopathogenesis of this condition is 
      uncertain and is usually preceded by a viral infection, generally from the 
      influenza or varicella virus. Some studies have shown a strong epidemiological 
      association between the ingestion of acetylsalicylic acid (ASA) during the viral 
      infection and development of Reye's syndrome. CASE REPORT: We describe the case 
      of a 20-month-old female who developed Reye's syndrome within the context of a 
      viral infection and the ingestion of ASA. A hepatic biopsy study is appropriate 
      in this syndrome. The patient presented a non-convulsive status during the acute 
      phase and at one year developed Lennox-Gastaut syndrome. She died from pneumonia 
      at the age of 18 years. CONCLUSIONS: In all patients with clinical features that 
      suggest Reye's syndrome, inborn errors of metabolism that can mimic it must be 
      precluded. Although the incidence of this syndrome has gone down considerably in 
      recent years, it is important to keep it in mind as an early and aggressive 
      diagnosis and treatment of cerebral hypertension will reduce the mortality rate 
      and the sequelae.
FAU - Jiménez-Caballero, P E
AU  - Jiménez-Caballero PE
AD  - Servicio de Neurología, Hospital Virgen de la Salud, 45005 Toledo, España. 
      pjimenez1010j@yahoo.es
FAU - Montes-Gonzalo, M C
AU  - Montes-Gonzalo MC
FAU - Velázquez-Pérez, J M
AU  - Velázquez-Pérez JM
LA  - spa
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Síndrome de Reye. Descripción de un caso con especial interés en sus crisis 
      epilépticas.
PL  - Spain
TA  - Rev Neurol
JT  - Revista de neurologia
JID - 7706841
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/adverse effects/therapeutic use
MH  - Electroencephalography
MH  - *Epilepsy/complications/physiopathology
MH  - Fatal Outcome
MH  - Female
MH  - Humans
MH  - Infant
MH  - *Reye Syndrome/diagnosis/etiology/physiopathology
MH  - Virus Diseases/drug therapy
EDAT- 2008/12/03 09:00
MHDA- 2009/01/28 09:00
CRDT- 2008/12/03 09:00
PHST- 2008/12/03 09:00 [pubmed]
PHST- 2009/01/28 09:00 [medline]
PHST- 2008/12/03 09:00 [entrez]
AID - rn2008222 [pii]
PST - ppublish
SO  - Rev Neurol. 2008 Dec 1-15;47(11):571-4.

PMID- 9308744
OWN - NLM
STAT- MEDLINE
DCOM- 19980114
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 78
IP  - 3
DP  - 1997 Sep
TI  - Variable platelet response to low-dose ASA and the risk of limb deterioration in 
      patients submitted to peripheral arterial angioplasty.
PG  - 1003-7
AB  - A group of 100 patients with intermittent claudication (70 male, 30 female), 
      treated with I00 mg ASA per day, were followed over 18 months after elective 
      percutaneous balloon angioplasty. Platelet function was monitored over a period 
      of 12 months by corrected whole blood aggregometry (CWBA). Upon stimulation by 
      arachidonic acid (AA), adenosine diphosphate (ADP) and collagen, CWBA-results 
      were obtained by an electronic acquisition and evaluation system correcting for 
      hematocrit and platelet count of the blood sample. All patients showed a 
      completely inhibited platelet response to AA stimulation. Comparison of the 
      CWBA-results with clinical parameters revealed that reocclusions at the site of 
      angioplasty occurred exclusively in male patients for which CWBA failed to prove 
      an inhibition of aggregation upon both agonists, ADP and collagen, and for these 
      patients the risk of complication is at least 87% higher (p = 0.0093). Only 40% 
      of male patients show the expected effect of ASA on in vitro platelet aggregation 
      at any given point in time and CWBA is capable of predicting those male patients 
      which are at an elevated risk of reocclusion following peripheral angioplasty.
FAU - Mueller, M R
AU  - Mueller MR
AD  - University of Vienna, Department of Cardio-Thoracic Surgery, Austria. 
      michael-rolf.mueller@akh-wien.ac.at
FAU - Salat, A
AU  - Salat A
FAU - Stangl, P
AU  - Stangl P
FAU - Murabito, M
AU  - Murabito M
FAU - Pulaki, S
AU  - Pulaki S
FAU - Boehm, D
AU  - Boehm D
FAU - Koppensteiner, R
AU  - Koppensteiner R
FAU - Ergun, E
AU  - Ergun E
FAU - Mittlboeck, M
AU  - Mittlboeck M
FAU - Schreiner, W
AU  - Schreiner W
FAU - Losert, U
AU  - Losert U
FAU - Wolner, E
AU  - Wolner E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - *Angioplasty, Balloon
MH  - Arterial Occlusive Diseases/*therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Female
MH  - Humans
MH  - Intermittent Claudication/*therapy
MH  - Leg/*blood supply
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Risk Factors
MH  - Smoking
EDAT- 1997/10/06 00:00
MHDA- 1997/10/06 00:01
CRDT- 1997/10/06 00:00
PHST- 1997/10/06 00:00 [pubmed]
PHST- 1997/10/06 00:01 [medline]
PHST- 1997/10/06 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1997 Sep;78(3):1003-7.

PMID- 7931415
OWN - NLM
STAT- MEDLINE
DCOM- 19941110
LR  - 20190724
IS  - 0022-510X (Print)
IS  - 0022-510X (Linking)
VI  - 124
IP  - 1
DP  - 1994 Jun
TI  - Effects of viscosity and oxygen content on cerebral blood flow in ischemic and 
      normal rat brain.
PG  - 15-20
AB  - The mechanism of hemodilution-induced increases in cerebral blood flow (CBF) was 
      investigated. Hemodilution was achieved with a molecular hemoglobin solution 
      (DCLHb) and albumin which have similar viscosities but different oxygen carrying 
      capacities. Part A: CBF was assessed in rats after one of the following regimens: 
      (1) control-hematocrit not manipulated, (2) 30/Alb-hematocrit decreased to 30% 
      with albumin, (3) 30/DCLHb-hematocrit decreased to 30% with DCLHb, or (4) 
      16/Alb/DCLHb-hematocrit decreased to 30% with albumin and then 16% with DCLHb. 
      For viscosity matched groups (30/Alb and 30/DCLHb), CBF was greater in animals 
      with decreased oxygen content (30/Alb); while in oxygen content matched groups 
      (30/Alb and 16/Alb/DCLHb), CBF was greater in animals with decreased viscosity 
      (16/Alb/DCLHb) (p < 0.05). Part B: Middle cerebral artery occlusion was 
      performed, hemodilution achieved as in Part A, and CBF determined. For viscosity 
      matched groups (30/Alb and 30/DCLHb), CBF was less in rats with decreased oxygen 
      content (30/Alb); while in oxygen content matched groups (30/Alb and 
      16/Alb/DCLHb), CBF was greater in animals with decreased viscosity (16/Alb/DCLHb) 
      (p < 0.05). This data supports the premise, that in normal brain, both viscosity 
      and oxygen content effect CBF; while in ischemic brain, a decrease in viscosity 
      but not oxygen content increases CBF.
FAU - Cole, D J
AU  - Cole DJ
AD  - Department of Anesthesiology, Loma Linda University, CA 92354.
FAU - Drummond, J C
AU  - Drummond JC
FAU - Patel, P M
AU  - Patel PM
FAU - Marcantonio, S
AU  - Marcantonio S
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Hemoglobins)
RN  - 0 (Serum Albumin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Autoradiography
MH  - Blood Volume/physiology
MH  - Brain Chemistry/*physiology
MH  - Brain Ischemia/metabolism/*pathology
MH  - Cerebrovascular Circulation/*physiology
MH  - Hematocrit
MH  - Hemodilution
MH  - Hemoglobins/pharmacology
MH  - Male
MH  - Oxygen Consumption/*physiology
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Serum Albumin/pharmacology
MH  - Viscosity
EDAT- 1994/06/01 00:00
MHDA- 1994/06/01 00:01
CRDT- 1994/06/01 00:00
PHST- 1994/06/01 00:00 [pubmed]
PHST- 1994/06/01 00:01 [medline]
PHST- 1994/06/01 00:00 [entrez]
AID - 0022-510X(94)90004-3 [pii]
AID - 10.1016/0022-510x(94)90004-3 [doi]
PST - ppublish
SO  - J Neurol Sci. 1994 Jun;124(1):15-20. doi: 10.1016/0022-510x(94)90004-3.

PMID- 2808353
OWN - NLM
STAT- MEDLINE
DCOM- 19891127
LR  - 20210219
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 264
IP  - 30
DP  - 1989 Oct 25
TI  - Equilibrium oxygen binding to human hemoglobin cross-linked between the alpha 
      chains by bis(3,5-dibromosalicyl) fumarate.
PG  - 17824-33
AB  - Oxygen equilibrium curves of human hemoglobin Ao (HbAo) and human hemoglobin 
      cross-linked between the alpha chains (alpha alpha Hb) by bis(3,5-dibromosalicyl) 
      fumarate were measured as a function of pH and chloride or organic phosphate 
      concentration. Compared to HbAo, the oxygen affinity of alpha alpha Hb was lower, 
      cooperativity was maintained, although slightly reduced, and all heterotropic 
      effects were diminished. The major effect of alpha alpha-cross-linking appears to 
      be a reduction of the oxygen affinity of R-state hemoglobin under all conditions. 
      However, while the oxygen affinity of T-state alpha alpha Hb was slightly reduced 
      at physiologic chloride concentration and in the absence of organic phosphates, 
      KT was the same for both hemoglobins in the presence of 2,3-diphosphoglycerate 
      (or high salt) and higher for alpha alpha Hb in the presence of inositol 
      hexaphosphate. The reduced O2 affinity arises from smaller binding constants for 
      both T- and R-state alpha alpha Hb rather than through stabilization of the low 
      affinity conformation. All four Adair constants could be determined for alpha 
      alpha Hb under most conditions, but a3 could not be resolved for HbAo without 
      constraining a4, suggesting that the cross-link stabilizes triply ligated 
      intermediates of hemoglobin.
FAU - Vandegriff, K D
AU  - Vandegriff KD
AD  - Division of Blood Research, Letterman Army Institute of Research, Presidio of San 
      Francisco, California 94129-6800.
FAU - Medina, F
AU  - Medina F
FAU - Marini, M A
AU  - Marini MA
FAU - Winslow, R M
AU  - Winslow RM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Diphosphoglyceric Acids)
RN  - 0 (Macromolecular Substances)
RN  - 0 (Oxyhemoglobins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 138-81-8 (2,3-Diphosphoglycerate)
RN  - 7IGF0S7R8I (Phytic Acid)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2,3-Diphosphoglycerate
MH  - Allosteric Regulation
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cross-Linking Reagents/*pharmacology
MH  - Diphosphoglyceric Acids/pharmacology
MH  - Hemoglobin A/drug effects/*metabolism
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Macromolecular Substances
MH  - Mathematics
MH  - Models, Theoretical
MH  - Oxyhemoglobins/*metabolism
MH  - Phytic Acid/pharmacology
EDAT- 1989/10/25 00:00
MHDA- 1989/10/25 00:01
CRDT- 1989/10/25 00:00
PHST- 1989/10/25 00:00 [pubmed]
PHST- 1989/10/25 00:01 [medline]
PHST- 1989/10/25 00:00 [entrez]
AID - S0021-9258(19)84647-1 [pii]
PST - ppublish
SO  - J Biol Chem. 1989 Oct 25;264(30):17824-33.

PMID- 18835953
OWN - NLM
STAT- MEDLINE
DCOM- 20130103
LR  - 20211203
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 32
IP  - 1
DP  - 2009 Jan
TI  - A randomized trial of low-dose aspirin in the prevention of clinical type 2 
      diabetes in women.
PG  - 3-8
LID - 10.2337/dc08-1206 [doi]
AB  - OBJECTIVE: Subclinical inflammation is linked with the development of type 2 
      diabetes, and epidemiologic data suggest that this association may be stronger in 
      women. Although small clinical studies have shown a prominent hypoglycemic effect 
      of short-term high-dose aspirin, no randomized trials have directly evaluated the 
      efficacy of aspirin in diabetes prevention at doses acceptable for use in routine 
      clinical practice. We evaluated whether chronic low-dose aspirin prevents the 
      development of clinical diabetes among initially healthy American women. RESEARCH 
      DESIGN AND METHODS: Subjects were enrolled in the Women's Health Study, a 10-year 
      randomized double-blind, placebo-controlled trial of aspirin and vitamin E for 
      primary prevention of cardiovascular disease and cancer. Between 1992 and 1995, 
      38,716 women aged > or =45 years and free of clinical diabetes were randomly 
      assigned to either low-dose aspirin or placebo (median follow-up 10.2 years). 
      Documented clinical type 2 diabetes was prospectively evaluated throughout the 
      trial. RESULTS: Among women randomly assigned to receive aspirin (n = 19,326) or 
      placebo (n = 19,390), there was no statistically significant difference in the 
      incidence of type 2 diabetes. There were 849 cases of diabetes in the aspirin 
      group and 847 in the placebo group (rate ratio 1.01 [95% CI 0.91-1.11]). 
      Stratification by diabetes risk factors including age, BMI, family history of 
      diabetes, physical activity, A1C, and high-sensitivity C-reactive protein did not 
      support a modulating effect of these variables. Analyses accounting for treatment 
      duration and adherence similarly found no beneficial effects. CONCLUSIONS: These 
      data suggest that long-term low-dose aspirin does not prevent the development of 
      clinical type 2 diabetes in initially healthy women.
FAU - Pradhan, Aruna D
AU  - Pradhan AD
AD  - Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, Massachusetts, USA. apradhan@partners.org.
FAU - Cook, Nancy R
AU  - Cook NR
FAU - Manson, Joann E
AU  - Manson JE
FAU - Ridker, Paul M
AU  - Ridker PM
FAU - Buring, Julie E
AU  - Buring JE
LA  - eng
SI  - ClinicalTrials.gov/NCT00000479
GR  - R01 CA047988/CA/NCI NIH HHS/United States
GR  - R01 HL043851/HL/NHLBI NIH HHS/United States
GR  - CA-47988/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20081003
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Placebos)
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiotonic Agents/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Diabetes Mellitus, Type 2/epidemiology/*prevention & control
MH  - Ethnicity
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incidence
MH  - Middle Aged
MH  - Patient Compliance
MH  - Placebos
MH  - Primary Prevention
MH  - Racial Groups
MH  - Risk Assessment
MH  - Vitamin E/therapeutic use
PMC - PMC2606820
EDAT- 2008/10/07 09:00
MHDA- 2013/01/04 06:00
CRDT- 2008/10/07 09:00
PHST- 2008/10/07 09:00 [pubmed]
PHST- 2013/01/04 06:00 [medline]
PHST- 2008/10/07 09:00 [entrez]
AID - dc08-1206 [pii]
AID - 3213 [pii]
AID - 10.2337/dc08-1206 [doi]
PST - ppublish
SO  - Diabetes Care. 2009 Jan;32(1):3-8. doi: 10.2337/dc08-1206. Epub 2008 Oct 3.

PMID- 36676718
OWN - NLM
STAT- MEDLINE
DCOM- 20230124
LR  - 20230201
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 59
IP  - 1
DP  - 2022 Dec 31
TI  - Protective Effect of Irsogladine against Aspirin-Induced Mucosal Injury in Human 
      Induced Pluripotent Stem Cell-Derived Small Intestine.
LID - 10.3390/medicina59010092 [doi]
LID - 92
AB  - Background and Objectives: Acetylsalicylic acid (ASA) is widely used for 
      preventing cerebrovascular and cardiovascular diseases. Gastrointestinal (GI) 
      tract injury is one of the major complications of aspirin use, potentially 
      leading to severe GI bleeding. However, no drugs for preventing aspirin-induced 
      small intestinal injury have been developed. The aim of this study was to 
      establish a human experimental model for investigating aspirin-induced small 
      intestinal mucosal injury. In addition, we evaluated the protective effect of 
      Irsogladine against aspirin-induced small intestinal mucosal injury using human 
      induced pluripotent stem cell-derived 2D monolayer crypt-villus structural small 
      intestine (2D-hiPSC-SI). Materials and Methods: Human iPS cell-derived intestinal 
      organoids were seeded and cultured in Air-liquid interface. The permeability of 
      2D-hiPSC-SI was evaluated using Lucifer yellow. Changes in structure and mucosal 
      permeability of 2D-hiPSC-SI after addition of aspirin were confirmed over time, 
      and changes in intestinal epithelium-related markers were evaluated by real-time 
      qPCR and Immunofluorescence staining. The effect of Irsogladine on prevention of 
      aspirin mucosal injury was examined by adding Irsogladine to the culture medium. 
      Results: Cultured 2D-hiPSC-SI showed multi-lineage differentiation into small 
      intestinal epithelium comprised of absorptive cells, goblet cells, 
      enteroendocrine cells, and Paneth cells, which express CD10, MUC2, chromogranin 
      A, and lysozyme, respectively. RNA in situ hybridization revealed intestinal stem 
      cells that express Lgr5. ASA administration induced an increase in the mucosal 
      permeability of 2D-hiPSC-SI. ASA-injured 2D-hiPSC-SI showed decreased mRNA 
      expression of multi-lineage small intestinal cell markers as well as intestinal 
      stem cell marker Lgr5. Administration of Irsogladine on the basal side of the 
      2D-hiPSC-SI resulted in significant increases in Mki67 and Muc2 mRNA expression 
      by 2D-hiPSCs at 48 h compared with the control group. Administration of 400 µg/mL 
      Irsogladine to the ASA-induced small intestinal injury model resulting in 
      significantly decreased mucosal permeability of 2D-hiPSC-SI. In 
      immunofluorescence staining, Irsogladine significantly increased the fluorescence 
      intensity of MUC2 under normal conditions and administration of 400 µg/mL ASA. 
      Conclusions: we established a novel ASA-induced small intestinal injury model 
      using human iPSC-derived small intestine. Irsogladine maintains mucosal 
      permeability and goblet cell differentiation against ASA-induced small intestinal 
      injury.
FAU - Kanno, Takuya
AU  - Kanno T
AD  - Department of Gastroenterology and Metabolism, Nagoya City University Graduate 
      School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, 
      Japan.
FAU - Katano, Takahito
AU  - Katano T
AD  - Department of Gastroenterology and Metabolism, Nagoya City University Graduate 
      School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, 
      Japan.
FAU - Ogawa, Isamu
AU  - Ogawa I
AD  - Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, 
      Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan.
FAU - Iwao, Takahiro
AU  - Iwao T
AD  - Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, 
      Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan.
FAU - Matsunaga, Tamihide
AU  - Matsunaga T
AD  - Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, 
      Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan.
FAU - Kataoka, Hiromi
AU  - Kataoka H
AUID- ORCID: 0000-0001-9491-0723
AD  - Department of Gastroenterology and Metabolism, Nagoya City University Graduate 
      School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, 
      Japan.
LA  - eng
GR  - 22K08082/Grant-in-Aid for Scientific Research (C) in KAKENHI of Japan Society for 
      the Promotion of Science/
GR  - 20be0304203h0004/Grant-in-Aid from the Japan Agency for Medical Research and 
      Development/
GR  - 21be0304203h0005/Grant-in-Aid from the Japan Agency for Medical Research and 
      Development/
GR  - 22H02788/Japan Society for the Promotion of Science/
GR  - JOSE204001/THE HORI SCIENCE AND ARTS FOUNDATION/
PT  - Journal Article
DEP - 20221231
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - R16CO5Y76E (Aspirin)
RN  - QBX79NZC1D (irsogladine)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Humans
MH  - *Aspirin/adverse effects
MH  - *Induced Pluripotent Stem Cells
MH  - Intestine, Small/metabolism
MH  - RNA, Messenger/metabolism
PMC - PMC9863323
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - goblet cell
OT  - human induced pluripotent stem cell
OT  - intestinal injury
OT  - permeability
OT  - small intestine
COIS- All authors have no conflict of interest to disclose.
EDAT- 2023/01/22 06:00
MHDA- 2023/01/25 06:00
CRDT- 2023/01/21 01:37
PHST- 2022/11/09 00:00 [received]
PHST- 2022/12/23 00:00 [revised]
PHST- 2022/12/28 00:00 [accepted]
PHST- 2023/01/21 01:37 [entrez]
PHST- 2023/01/22 06:00 [pubmed]
PHST- 2023/01/25 06:00 [medline]
AID - medicina59010092 [pii]
AID - medicina-59-00092 [pii]
AID - 10.3390/medicina59010092 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2022 Dec 31;59(1):92. doi: 10.3390/medicina59010092.

PMID- 7994418
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Diaspirin crosslinked hemoglobin (DCLHb): bioanalytical studies in swine.
PG  - 917-22
AB  - These studies were a part of preclinical safety and efficacy studies of DCLHb. 
      Their purpose was to analyze the characteristics of DCLHb during circulation, and 
      the distribution of iron following the administration of DLCHb to swine. Swine 
      were dosed (2 g/kg) with 10 g/dL DCLHb, infused intravenously at a rate of 1 
      mL/kg/min. Blood samples were collected up to 48 hours post-infusion for 
      analysis. Tissue samples were obtained for iron determination. The data collected 
      showed that the concentration of DCLHb in the plasma gradually decreased, while 
      the concentration of methemoglobin remained low and essentially constant. The 
      oxygen binding characteristics and stability of the crosslink were preserved 
      following infusion, indicating that the DCLHb continued to function as an 
      effective oxygen carrier. Iron concentrations in the liver and kidneys increased 
      as expected, but plasma levels of iron did not saturate the iron binding capacity 
      of transferrin, inferring a controlled process for the release of iron.
FAU - Bush, S
AU  - Bush S
AD  - Blood Substitutes Program, Baxter Healthcare Corporation, Round Lake, Illinois 
      60073.
FAU - Marshall, T
AU  - Marshall T
FAU - Spicuzza, J
AU  - Spicuzza J
FAU - Nelson, D
AU  - Nelson D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - E1UOL152H7 (Iron)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacokinetics/toxicity
MH  - Blood Substitutes/administration & dosage/*pharmacokinetics/toxicity
MH  - Hemoglobins/administration & dosage/*pharmacokinetics/toxicity
MH  - Infusions, Intravenous
MH  - Iron/blood/metabolism
MH  - Kidney/metabolism
MH  - Liver/metabolism
MH  - Methemoglobinemia/etiology
MH  - Oxygen/blood/metabolism
MH  - Swine
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117930 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):917-22. doi: 
      10.3109/10731199409117930.

PMID- 32011647
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20210203
IS  - 2168-6114 (Electronic)
IS  - 2168-6106 (Print)
IS  - 2168-6106 (Linking)
VI  - 180
IP  - 3
DP  - 2020 Mar 1
TI  - Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism 
      Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and 
      Meta-analysis of Randomized Clinical Trials.
PG  - 376-384
LID - 10.1001/jamainternmed.2019.6108 [doi]
AB  - IMPORTANCE: Patients undergoing total hip replacement (THR) and total knee 
      replacement (TKR) receive venous thromboembolism (VTE) pharmacoprophylaxis. It is 
      unclear which anticoagulant is preferable. Observational data suggest aspirin 
      provides effective VTE prophylaxis. OBJECTIVE: To assess the effectiveness and 
      safety of aspirin for VTE prophylaxis after THR and TKR. DATA SOURCES: A 
      systematic review and meta-analysis was performed of randomized clinical trials 
      (RCTs), with no language restrictions, from inception to September 19, 2019, 
      using MEDLINE, Embase, Web of Science, Cochrane Library, and bibliographic 
      searches. The computer-based searches combined terms and combinations of keywords 
      related to the population (eg, hip replacement, knee replacement, hip 
      arthroplasty, and knee arthroplasty), drug intervention (eg, aspirin, heparin, 
      clexane, dabigatran, rivaroxaban, and warfarin), and outcome (eg, venous 
      thromboembolism, deep vein thrombosis, pulmonary embolism, and bleeding) in 
      humans. STUDY SELECTION: This study included RCTs assessing the effectiveness and 
      safety of aspirin for VTE prophylaxis compared with other anticoagulants in 
      adults undergoing THR and TKR. The RCTs with a placebo control group were 
      excluded. The searches and study selection were independently performed. DATA 
      EXTRACTION AND SYNTHESIS: This study followed PRISMA recommendations and used the 
      Cochrane Collaboration's risk of bias tool. Data were screened and extracted 
      independently by both reviewers. Study-specific relative risks (RRs) were 
      aggregated using random-effects models. Quality of evidence was assessed using 
      the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 
      approach. MAIN OUTCOMES AND MEASURES: The primary outcome was any postoperative 
      VTE (asymptomatic or symptomatic). Secondary outcomes were adverse events 
      associated with therapy, including bleeding. RESULTS: Of 437 identified articles, 
      13 RCTs were included (6060 participants; 3466 [57.2%] women; mean age, 63.0 
      years). The RR of VTE after THR and TKR was 1.12 (95% CI, 0.78-1.62) for aspirin 
      compared with other anticoagulants. Comparable findings were observed for deep 
      vein thrombosis (DVT) (RR, 1.04; 95% CI, 0.72-1.51) and pulmonary embolism (PE) 
      (RR, 1.01; 95% CI, 0.68-1.48). The risk of adverse events, including major 
      bleeding, wound hematoma, and wound infection, was not statistically 
      significantly different in patients receiving aspirin vs other anticoagulants. 
      When analyzing THRs and TKRs separately, there was no statistically significant 
      difference in the risk of VTE, DVT, and PE between aspirin and other 
      anticoagulants. Aspirin had a VTE risk not statistically significantly different 
      from low-molecular-weight heparin (RR, 0.76; 95% CI, 0.37-1.56) or rivaroxaban 
      (RR, 1.52; 95% CI, 0.56-4.12). The quality of the evidence ranged from low to 
      high. CONCLUSIONS AND RELEVANCE: In terms of clinical effectiveness and safety 
      profile, aspirin did not differ statistically significantly from other 
      anticoagulants used for VTE prophylaxis after THR and TKR. Future trials should 
      focus on noninferiority analysis of aspirin compared with alternative 
      anticoagulants and cost-effectiveness.
FAU - Matharu, Gulraj S
AU  - Matharu GS
AD  - Musculoskeletal Research Unit, Bristol Medical School, Southmead Hospital, 
      University of Bristol, Bristol, United Kingdom.
FAU - Kunutsor, Setor K
AU  - Kunutsor SK
AD  - Musculoskeletal Research Unit, Bristol Medical School, Southmead Hospital, 
      University of Bristol, Bristol, United Kingdom.
AD  - National Institute for Health Research Bristol Biomedical Research Centre, 
      Bristol, United Kingdom.
FAU - Judge, Andrew
AU  - Judge A
AD  - Musculoskeletal Research Unit, Bristol Medical School, Southmead Hospital, 
      University of Bristol, Bristol, United Kingdom.
AD  - National Institute for Health Research Bristol Biomedical Research Centre, 
      Bristol, United Kingdom.
FAU - Blom, Ashley W
AU  - Blom AW
AD  - Musculoskeletal Research Unit, Bristol Medical School, Southmead Hospital, 
      University of Bristol, Bristol, United Kingdom.
AD  - National Institute for Health Research Bristol Biomedical Research Centre, 
      Bristol, United Kingdom.
FAU - Whitehouse, Michael R
AU  - Whitehouse MR
AD  - Musculoskeletal Research Unit, Bristol Medical School, Southmead Hospital, 
      University of Bristol, Bristol, United Kingdom.
AD  - National Institute for Health Research Bristol Biomedical Research Centre, 
      Bristol, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - United States
TA  - JAMA Intern Med
JT  - JAMA internal medicine
JID - 101589534
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - MMW Fortschr Med. 2020 Mar;162(5):30. PMID: 32189271
MH  - Arthroplasty, Replacement, Hip/*adverse effects
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Postoperative Complications/*prevention & control
MH  - Treatment Outcome
MH  - Venous Thromboembolism/etiology/*prevention & control
PMC - PMC7042877
COIS- Conflict of Interest Disclosures: Dr Matharu reported receiving personal fees 
      from Leigh Day for medicolegal work. Dr Judge reported receiving personal fees 
      from Anthera Pharmaceuticals, Inc, Freshfields, Bruckhaus, and Deringer. Dr Blom 
      reported receiving grants from Stryker. Dr Whitehouse reported receiving grants 
      from the National Joint Registry, National Institute for Health Research (NIHR) 
      Bristol Biomedical Research Centre, NIHR, and Stryker and receiving teaching 
      support from Hearaeus and DePuy. No other disclosures were reported.
EDAT- 2020/02/06 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/02/04 06:00
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2020/02/04 06:00 [entrez]
AID - 2759736 [pii]
AID - ioi190102 [pii]
AID - 10.1001/jamainternmed.2019.6108 [doi]
PST - ppublish
SO  - JAMA Intern Med. 2020 Mar 1;180(3):376-384. doi: 10.1001/jamainternmed.2019.6108.

PMID- 29153543
OWN - NLM
STAT- MEDLINE
DCOM- 20180228
LR  - 20180228
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 105
IP  - 2
DP  - 2018 Feb
TI  - [Aspirin and colorectal cancer].
PG  - 171-180
LID - S0007-4551(17)30264-3 [pii]
LID - 10.1016/j.bulcan.2017.09.013 [doi]
AB  - Colorectal cancer is a worldwide public health problem. Aspirin has been 
      identified as a protective factor against the apparition of colorectal cancer. 
      There are several mechanisms about the actions by aspirin on colorectal 
      tumorogenesis. These are not perfectly known nowadays. On one hand, there are 
      direct mechanisms on colorectal mucosa, on the other hand there are indirect 
      mechanisms through platelet functions. Aspirin also plays a role by its 
      anti-inflammatory action and the stimulation of antitumor immunity. Several 
      studies show that long-term treatment with low-doses of aspirin decreases the 
      incidence of adenomas and colorectal cancers. In the United States, aspirin is 
      currently recommended for primary prevention of the risk of colorectal cancer in 
      all patients aged 50 to 59, with a 10-year risk of cardiovascular event greater 
      than 10 %. However, primary prevention with aspirin should not be a substitute 
      for screening in colorectal cancer. Furthermore, aspirin seems to be beneficial 
      when used in post-diagnosis of colorectal cancer. It could actually decrease the 
      risk of metastasis in case of a localized colorectal cancer, and increase the 
      survival in particular, concerning PIK3CA mutated tumors. The association of 
      aspirin with neoadjuvant treatment of colorectal cancer by radiochimiotherapy 
      seems to have beneficial effects. French prospective randomized study is 
      currently being conducted to investigate postoperative aspirin in colorectal 
      cancers with a PIK3CA mutation.
CI  - Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. 
      All rights reserved.
FAU - Grancher, Adrien
AU  - Grancher A
AD  - Normandie université, UNIROUEN, hôpital universitaire de Rouen, service 
      d'hépato-gastroenterologie, 76000 Rouen, France.
FAU - Michel, Pierre
AU  - Michel P
AD  - Normandie université, UNIROUEN, Inserm 1245, IRON group, hôpital universitaire de 
      Rouen, service d'hépato-gastroentérologie, 76000 Rouen, France. Electronic 
      address: Pierre.Michel@chu-rouen.fr.
FAU - Di Fiore, Frédéric
AU  - Di Fiore F
AD  - Normandie université, UNIROUEN, Inserm 1245, IRON group, hôpital universitaire de 
      Rouen, centre Henri-Becquerel, département d'oncolgie médicale, service 
      d'hépato-gastroentérologie, 76000 Rouen, France.
FAU - Sefrioui, David
AU  - Sefrioui D
AD  - Normandie université, UNIROUEN, Inserm 1245, IRON group, hôpital universitaire de 
      Rouen, service d'hépato-gastroentérologie, 76000 Rouen, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Aspirine et cancer colorectal.
DEP - 20171115
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/*prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Class I Phosphatidylinositol 3-Kinases/genetics
MH  - Colonic Neoplasms/prevention & control
MH  - Colorectal Neoplasms/drug therapy/genetics/pathology/*prevention & control
MH  - Dinoprostone/biosynthesis
MH  - Humans
MH  - Inflammation/complications
MH  - Mutation
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirine
OT  - Cancer colorectal
OT  - Colorectal cancer
OT  - Prevention
OT  - Prévention
EDAT- 2017/11/21 06:00
MHDA- 2018/03/01 06:00
CRDT- 2017/11/21 06:00
PHST- 2017/06/14 00:00 [received]
PHST- 2017/08/18 00:00 [revised]
PHST- 2017/09/08 00:00 [accepted]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2018/03/01 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - S0007-4551(17)30264-3 [pii]
AID - 10.1016/j.bulcan.2017.09.013 [doi]
PST - ppublish
SO  - Bull Cancer. 2018 Feb;105(2):171-180. doi: 10.1016/j.bulcan.2017.09.013. Epub 
      2017 Nov 15.

PMID- 21487091
OWN - NLM
STAT- MEDLINE
DCOM- 20110930
LR  - 20211020
IS  - 1941-7705 (Electronic)
IS  - 1941-7713 (Print)
IS  - 1941-7713 (Linking)
VI  - 4
IP  - 3
DP  - 2011 May
TI  - Individual and population benefits of daily aspirin therapy: a proposal for 
      personalizing national guidelines.
PG  - 268-75
LID - 10.1161/CIRCOUTCOMES.110.959239 [doi]
AB  - BACKGROUND: Clinical practice guidelines that help clinicians and patients to 
      understand the magnitude of expected individual risks and benefits would help 
      with patient-centered decision-making and prioritization of care. We assessed the 
      net benefit from taking daily aspirin to estimate the individual and public 
      health implications of a more individualized decision-making approach. METHODS 
      AND RESULTS: We used data from the National Health and Nutrition Examination 
      Survey representing all US persons aged 30 to 85 years with no history of 
      myocardial infarction and applied a Markov model based on randomized evidence and 
      published literature to estimate lifetime effects of aspirin treatment in 
      quality-adjusted life years (QALYs). We found that treatment benefit varies 
      greatly by an individual's cardiovascular disease (CVD) risk. Almost all adults 
      have fewer major clinical events on aspirin, but for most, events prevented would 
      be so rare that even a very small distaste for aspirin use would make treatment 
      inappropriate. With minimal dislike of aspirin use (disutility, 0.005 QALY per 
      year), only those with a 10-year cardiac event risk >6.1% would have a net 
      benefit. A disutility of 0.01 QALY moves this benefit cut point to 10.6%. 
      Multiple factors altered the absolute benefit of aspirin, but the strong 
      relationship between CVD risk and magnitude of benefit was robust. CONCLUSIONS: 
      The benefits of aspirin therapy depend substantially on an individual's risk of 
      CVD and adverse treatment effects. Understanding who benefits from aspirin use 
      and how much can help clinicians and patients to develop a more patient-centered 
      approach to preventive therapy.
FAU - Sussman, Jeremy B
AU  - Sussman JB
AD  - Department of Veterans Affairs, VA Health Service Research and Development Center 
      of Excellence, VA Ann Arbor Healthcare System, Ann Arbor, MI 48109, USA. 
      jeremysu@med.umich.edu
FAU - Vijan, Sandeep
AU  - Vijan S
FAU - Choi, HwaJung
AU  - Choi H
FAU - Hayward, Rodney A
AU  - Hayward RA
LA  - eng
GR  - P60 DK020572/DK/NIDDK NIH HHS/United States
GR  - R01 CA106782/CA/NCI NIH HHS/United States
GR  - P60 DK-20572/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20110412
PL  - United States
TA  - Circ Cardiovasc Qual Outcomes
JT  - Circulation. Cardiovascular quality and outcomes
JID - 101489148
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circ Cardiovasc Qual Outcomes. 2011 May;4(3):260-2. PMID: 21586722
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Decision Making
MH  - Female
MH  - *Health Planning Guidelines
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Participation
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Survival Rate
MH  - United States
PMC - PMC4039386
MID - NIHMS284215
EDAT- 2011/04/14 06:00
MHDA- 2011/10/01 06:00
CRDT- 2011/04/14 06:00
PHST- 2011/04/14 06:00 [entrez]
PHST- 2011/04/14 06:00 [pubmed]
PHST- 2011/10/01 06:00 [medline]
AID - CIRCOUTCOMES.110.959239 [pii]
AID - 10.1161/CIRCOUTCOMES.110.959239 [doi]
PST - ppublish
SO  - Circ Cardiovasc Qual Outcomes. 2011 May;4(3):268-75. doi: 
      10.1161/CIRCOUTCOMES.110.959239. Epub 2011 Apr 12.

PMID- 2396603
OWN - NLM
STAT- MEDLINE
DCOM- 19901005
LR  - 20190510
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 94
IP  - 3
DP  - 1990 Sep
TI  - The bleeding time response to aspirin. Identifying the hyperresponder.
PG  - 292-6
AB  - The authors measured the template bleeding time in 11 normal people before and 2, 
      4, 12, 24, and 48 hours after the subjects ingested a single dose of 74 mg of 
      aspirin (ASA). The entire experiment was repeated twice at two-week intervals, 
      with the dose of ASA increased to 325 mg and finally 3,900 mg. The mean increase 
      was maximal at 4 and 12 hours, regardless of the dose administered, with a return 
      to baseline by 48 hours. The authors then performed bleeding times in a 
      prospective randomized double-blinded fashion on an additional 39 subjects at 
      baseline and seven hours after they ingested either placebo or ASA 325 mg. The 
      mean baseline bleeding time was 5.2 minutes (SD +/- 1.4), with a mean 
      prolongation after ASA of 2.1 minutes (SD +/- 1.9). The authors identified 5 of 
      37 (14%) subjects as hyper-responders (HRs) using the criterion of a bleeding 
      time prolongation of greater than 5.9 minutes (greater than 2 SD beyond the mean 
      prolongation). Neither baseline bleeding time, threshold sensitivity of 
      collagen-induced platelet aggregation, nor other tests of hemostatic function 
      discriminated HRs from normals. The authors conclude that in subjects with normal 
      baseline bleeding times, a prolongation of greater than 5.9 minutes when measured 
      seven hours after the administration of a single dose of 325 mg of ASA can 
      discriminate HRs from normals.
FAU - Fiore, L D
AU  - Fiore LD
AD  - Boston Veterans Administration Medical Center, Massachusetts 02130.
FAU - Brophy, M T
AU  - Brophy MT
FAU - Lopez, A
AU  - Lopez A
FAU - Janson, P
AU  - Janson P
FAU - Deykin, D
AU  - Deykin D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - *Bleeding Time
MH  - Blood Coagulation Tests
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - *Platelet Function Tests
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
AID - 10.1093/ajcp/94.3.292 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1990 Sep;94(3):292-6. doi: 10.1093/ajcp/94.3.292.

PMID- 34993763
OWN - NLM
STAT- MEDLINE
DCOM- 20220530
LR  - 20220611
IS  - 2509-2723 (Electronic)
IS  - 2509-2715 (Print)
IS  - 2509-2723 (Linking)
VI  - 44
IP  - 2
DP  - 2022 Apr
TI  - Premorbid aspirin use is not associated with lower mortality in older inpatients 
      with SARS-CoV-2 pneumonia.
PG  - 573-583
LID - 10.1007/s11357-021-00499-8 [doi]
AB  - Platelet aggregation has been associated with COVID-19 pathogenesis. In older 
      patients hospitalized for SARS-CoV-2 pneumonia, we aimed to investigate the 
      association between aspirin use before admission and the risk of in-hospital 
      all-cause mortality. We performed a retrospective international cohort study in 
      five COVID-19 geriatric units in France and Switzerland. Among 1,357 consecutive 
      hospitalized patients aged 75 or older and testing positive for SARS-CoV-2, we 
      included 1,072 with radiologically confirmed pneumonia. To adjust for 
      confounders, a propensity score for treatment was created, and stabilized inverse 
      probability of treatment weighting (SIPTW) was applied. To assess the association 
      between aspirin use and in-hospital 30-day mortality, SIPTW-adjusted Kaplan-Meier 
      and Cox proportional hazards regression analyses were performed. Of the 1047 
      patients with SARS-CoV-2 pneumonia and median age 86 years, 301 (28.7%) were 
      taking aspirin treatment before admission. One hundred forty-seven (34.3%) 
      patients who had taken aspirin died in hospital within 1 month vs 118 patients 
      (30.7%) without aspirin. After SIPTW, aspirin treatment was not significantly 
      associated with lower mortality (adjusted hazard ratio: 1.10 [0.81-1.49], 
      P = .52). Moreover, patients on aspirin had a longer hospital stay and were more 
      frequently transferred to the intensive care unit. In a large multicenter cohort 
      of older inpatients with SARS-CoV-2 pneumonia, aspirin use before admission did 
      not appear to be associated with an improved prognosis.
CI  - © 2022. The Author(s), under exclusive licence to American Aging Association.
FAU - Sullerot, Coralie
AU  - Sullerot C
AD  - Department of Geriatric Internal Medicine, Dijon University Hospital, Dijon, 
      France.
FAU - Bouiller, Kevin
AU  - Bouiller K
AD  - Department of Infectious Diseases, Besançon University Hospital, Besançon, 
      France.
FAU - Laborde, Caroline
AU  - Laborde C
AD  - Department of Geriatric Internal Medicine, Nimes University Hospital, Nimes, 
      France.
FAU - Gilis, Marine
AU  - Gilis M
AD  - Department of Geriatrics, Besançon University Hospital, Besançon, France.
FAU - Fèvre, Amélie
AU  - Fèvre A
AD  - Department of Geriatric Internal Medicine, Nimes University Hospital, Nimes, 
      France.
FAU - Hacquin, Arthur
AU  - Hacquin A
AD  - Department of Geriatric Internal Medicine, Dijon University Hospital, Dijon, 
      France.
FAU - Manckoundia, Patrick
AU  - Manckoundia P
AD  - Department of Geriatric Internal Medicine, Dijon University Hospital, Dijon, 
      France.
FAU - Hoefler, Florence
AU  - Hoefler F
AD  - Department of Internal Medicine and Infectious Diseases, Troyes Hospital, Troyes, 
      France.
FAU - Bermejo, Messaline
AU  - Bermejo M
AD  - Department of Internal Medicine and Infectious Diseases, Troyes Hospital, Troyes, 
      France.
FAU - Mendes, Aline
AU  - Mendes A
AD  - Division of Geriatrics, Geneva University Hospitals, Geneva, Switzerland.
FAU - Serratrice, Christine
AU  - Serratrice C
AD  - Division of Internal Medicine for the Aged, Geneva University Hospitals, Geneva, 
      Switzerland.
FAU - Prendki, Virginie
AU  - Prendki V
AD  - Division of Internal Medicine for the Aged, Geneva University Hospitals, Geneva, 
      Switzerland.
AD  - Division of Infectious Diseases, Geneva University Hospitals, Geneva, 
      Switzerland.
FAU - Sanchez, Stéphane
AU  - Sanchez S
AD  - Department of Clinical Research, Troyes Hospital, Troyes, France.
FAU - Putot, Alain
AU  - Putot A
AUID- ORCID: 0000-0002-4408-554X
AD  - Department of Geriatric Internal Medicine, Dijon University Hospital, Dijon, 
      France. alain.putot@chu-dijon.fr.
AD  - Service de Médecine Interne Gériatrie, Hôpital de Champmaillot CHU, 21079, Dijon 
      Cedex, France. alain.putot@chu-dijon.fr.
CN  - ESGIE (European Society of Clinical Microbiology, European Society of Clinical 
      Microbiological and Infectious Diseases, Study Group for Infections in the 
      Elderly)
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20220107
PL  - Switzerland
TA  - Geroscience
JT  - GeroScience
JID - 101686284
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - *COVID-19
MH  - Cohort Studies
MH  - Humans
MH  - Inpatients
MH  - *Pneumonia
MH  - Retrospective Studies
MH  - SARS-CoV-2
PMC - PMC8736303
OTO - NOTNLM
OT  - Aged
OT  - Antiplatelet
OT  - Aspirin
OT  - COVID-19
OT  - Coronavirus
OT  - Mortality
OT  - Pneumonia
COIS- The authors declare no competing interests.
EDAT- 2022/01/08 06:00
MHDA- 2022/05/31 06:00
CRDT- 2022/01/07 06:43
PHST- 2021/09/21 00:00 [received]
PHST- 2021/12/13 00:00 [accepted]
PHST- 2022/01/08 06:00 [pubmed]
PHST- 2022/05/31 06:00 [medline]
PHST- 2022/01/07 06:43 [entrez]
AID - 10.1007/s11357-021-00499-8 [pii]
AID - 499 [pii]
AID - 10.1007/s11357-021-00499-8 [doi]
PST - ppublish
SO  - Geroscience. 2022 Apr;44(2):573-583. doi: 10.1007/s11357-021-00499-8. Epub 2022 
      Jan 7.

PMID- 19436018
OWN - NLM
STAT- MEDLINE
DCOM- 20090518
LR  - 20161017
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 301
IP  - 18
DP  - 2009 May 13
TI  - Aspirin for the prevention of cardiovascular events in patients with peripheral 
      artery disease: a meta-analysis of randomized trials.
PG  - 1909-19
LID - 10.1001/jama.2009.623 [doi]
AB  - CONTEXT: Randomized trials have shown that aspirin decreases the risk of 
      cardiovascular events in patients with symptomatic coronary and cerebrovascular 
      disease. Despite guideline recommendations for secondary prevention in peripheral 
      artery disease (PAD), the effect of aspirin in this population is not well 
      established. OBJECTIVE: To investigate the effect of aspirin on cardiovascular 
      event rates in patients with PAD. DATA SOURCES AND STUDY SELECTION: MEDLINE, the 
      Cochrane Central Register of Controlled Trials, EMBASE, Science Citation Index 
      (1966 to December 2008), and unpublished studies from the supplemental index of 
      the Antithrombotic Trialists' Collaboration. Eligible studies were prospective, 
      randomized controlled trials of aspirin therapy, with or without dipyridamole 
      that reported cardiovascular event rates. Eighteen trials involving 5269 
      individuals were identified. DATA EXTRACTION: Studies were reviewed to determine 
      the number of participants, mean follow-up, and the primary end point of 
      cardiovascular events (nonfatal myocardial infarction [MI], nonfatal stroke, and 
      cardiovascular death). Data on the secondary end points of all-cause mortality, 
      major bleeding, and the individual components of the primary outcome measure were 
      also abstracted. For the primary end point, the analysis had 88% power to detect 
      a 25% reduction and 70% power to detect a 20% reduction in cardiovascular events 
      in the aspirin group compared with the control group. DATA SYNTHESIS: Among 5269 
      participants, cardiovascular events were experienced by 251 (8.9%) of 2823 
      patients taking aspirin (alone or with dipyridamole) and by 269 (11.0%) of 2446 
      in the control group (pooled relative risk [RR], 0.88; 95% confidence interval 
      [CI], 0.76-1.04). Aspirin therapy was associated with a reduction in the 
      secondary outcome of nonfatal stroke (52 of 2823 vs 76 of 2446; RR, 0.66; 95% CI, 
      0.47-0.94) but was not associated with significant reductions in all-cause or 
      cardiovascular mortality, MI, or major bleeding. In the subset of 3019 
      participants taking aspirin alone vs control, aspirin was associated with a 
      nonsignificant reduction in cardiovascular events (125 of 1516 vs 144 of 1503; 
      RR, 0.75; 95% CI, 0.48-1.18), a significant reduction in nonfatal stroke (32 of 
      1516 vs 51 of 1503; RR, 0.64; 95% CI, 0.42-0.99), but no statistically 
      significant reductions in all-cause or cardiovascular mortality, MI, or major 
      bleeding. CONCLUSIONS: In patients with PAD, treatment with aspirin alone or with 
      dipyridamole resulted in a statistically nonsignificant decrease in the primary 
      end point of cardiovascular events and a significant reduction in nonfatal 
      stroke. Results for the primary end point may reflect limited statistical power. 
      Additional randomized controlled trials of aspirin therapy are needed to 
      establish the net benefit and bleeding risks in PAD.
FAU - Berger, Jeffrey S
AU  - Berger JS
AD  - Department of Medicine, Division of Cardiovascular Medicine, University of 
      Pennsylvania, Philadelphia, USA.
FAU - Krantz, Mori J
AU  - Krantz MJ
FAU - Kittelson, John M
AU  - Kittelson JM
FAU - Hiatt, William R
AU  - Hiatt WR
LA  - eng
GR  - 5K12HL83772-2/HL/NHLBI NIH HHS/United States
GR  - U01 HL079160/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2009 May 13;301(18):1927-8. PMID: 19436022
CIN - Ann Intern Med. 2009 Sep 15;151(6):JC3-5, JC3-4. PMID: 19755351
CIN - JAMA. 2009 Sep 16;302(11):1165; author reply 1165-6. PMID: 19755690
CIN - Expert Rev Cardiovasc Ther. 2009 Oct;7(10):1203-7. PMID: 19814663
CIN - Evid Based Med. 2009 Dec;14(6):172-3. PMID: 19949175
CIN - Praxis (Bern 1994). 2009 Nov 4;98(22):1315-6. PMID: 20029786
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Peripheral Vascular Diseases/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
EDAT- 2009/05/14 09:00
MHDA- 2009/05/19 09:00
CRDT- 2009/05/14 09:00
PHST- 2009/05/14 09:00 [entrez]
PHST- 2009/05/14 09:00 [pubmed]
PHST- 2009/05/19 09:00 [medline]
AID - 301/18/1909 [pii]
AID - 10.1001/jama.2009.623 [doi]
PST - ppublish
SO  - JAMA. 2009 May 13;301(18):1909-19. doi: 10.1001/jama.2009.623.

PMID- 12904140
OWN - NLM
STAT- MEDLINE
DCOM- 20030826
LR  - 20220409
IS  - 1474-0338 (Print)
IS  - 1474-0338 (Linking)
VI  - 1
IP  - 3
DP  - 2002 Sep
TI  - Treatment and prevention of aspirin-induced gastroduodenal ulcers and 
      gastrointestinal bleeding.
PG  - 245-52
AB  - Aspirin use is associated with gastroduodenal mucosal damage and increased risk 
      of upper gastrointestinal (GI) bleeding. Many aspirin users should receive 
      prophylactic treatment since they often have several risk factors for upper GI 
      complications. The best therapeutic approach for reducing GI toxicity in low-dose 
      aspirin users is still ill-defined as only a few studies have focused on this 
      problem. Omeprazole appears to be very effective in reducing both acute 
      gastroduodenal mucosal damage and upper GI bleeding in the high-risk patient 
      taking low-dose aspirin, but data with other anti-ulcer agents are lacking 
      (misoprostol) or inconsistent (ranitidine) at present. The role of Helicobacter 
      pylori is controversial in NSAID users, but there is now wide agreement that H. 
      pylori infection increases mucosal damage and the risk of upper GI bleeding in 
      low-dose aspirin users.
FAU - Lanas, Angel
AU  - Lanas A
AD  - Service of Gastroenterology, University Hospital Lozano Blesa, Zaragoza, Spain. 
      alanas@postaunizar.es
FAU - Ferrández, Angel
AU  - Ferrández A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/therapeutic use
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - *Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Hemorrhage/*chemically induced/prevention & control
MH  - Helicobacter pylori/*pathogenicity
MH  - Humans
MH  - Omeprazole/*therapeutic use
MH  - *Peptic Ulcer/chemically induced/drug therapy/prevention & control
MH  - Randomized Controlled Trials as Topic
RF  - 58
EDAT- 2003/08/09 05:00
MHDA- 2003/08/27 05:00
CRDT- 2003/08/09 05:00
PHST- 2003/08/09 05:00 [pubmed]
PHST- 2003/08/27 05:00 [medline]
PHST- 2003/08/09 05:00 [entrez]
AID - 10.1517/14740338.1.3.245 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2002 Sep;1(3):245-52. doi: 10.1517/14740338.1.3.245.

PMID- 1585379
OWN - NLM
STAT- MEDLINE
DCOM- 19920616
LR  - 20190818
IS  - 0300-483X (Print)
IS  - 0300-483X (Linking)
VI  - 72
IP  - 3
DP  - 1992
TI  - Action of allopurinol and aspirin on rat whole-embryo cultures.
PG  - 239-50
AB  - The effects of allopurinol (HPP) at concentrations ranging from 0.33-1.83 mM and 
      of aspirin (ASA) from 0.28-2.22 mM, were studied on the rat whole-embryo culture 
      system. Embryos were explanted at day 10 of gestation and cultured for 48 h, 
      either in the absence or in the presence of rat and human S9. HPP proved to be 
      potentially embryolethal and teratogenic without any S9, while it was 
      embryolethal with rat S9 and dysmorphogenic with human S9. ASA showed an 
      embryolethal and teratogenic potency without any S9 samples. These responses were 
      increased in the presence of rat S9, while ASA embryolethality was predominant 
      with human S9. These results obtained on rat embryos in culture suggest a 
      correlation between the species origin of the biotransforming system and the 
      known teratogenicity of HPP in sensitive animal models. However, ASA elicited 
      responses not in agreement with the known teratogenic response in rodents.
FAU - Spézia, F
AU  - Spézia F
AD  - Centre de Recherches Roussel UCLAF, Romainville, France.
FAU - Fournex, R
AU  - Fournex R
FAU - Vannier, B
AU  - Vannier B
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Toxicology
JT  - Toxicology
JID - 0361055
RN  - 0 (Teratogens)
RN  - 63CZ7GJN5I (Allopurinol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Allopurinol/pharmacokinetics/*toxicity
MH  - Animals
MH  - Aspirin/pharmacokinetics/*toxicity
MH  - Biotransformation
MH  - Culture Techniques
MH  - Embryo, Mammalian/drug effects
MH  - Humans
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Species Specificity
MH  - Teratogens/pharmacokinetics/*toxicity
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 0300-483X(92)90176-F [pii]
AID - 10.1016/0300-483x(92)90176-f [doi]
PST - ppublish
SO  - Toxicology. 1992;72(3):239-50. doi: 10.1016/0300-483x(92)90176-f.

PMID- 29442537
OWN - NLM
STAT- MEDLINE
DCOM- 20190417
LR  - 20190417
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 30
IP  - 3
DP  - 2019
TI  - Once- versus twice-daily aspirin treatment in patients with essential 
      thrombocytosis.
PG  - 322-328
LID - 10.1080/09537104.2018.1430356 [doi]
AB  - Insufficient platelet inhibition has been reported in up to 40% of 
      aspirin-treated patients, including patients with essential thrombocytosis. To 
      maintain sufficient platelet inhibition, a shorter dosing interval with aspirin 
      has been suggested. We aimed to investigate the antiplatelet effect of low-dose 
      aspirin given twice-daily compared to standard once-daily dosing in patients with 
      essential thrombocytosis. We included 22 patients, who were treated for 7 days 
      with standard once-daily aspirin (75 mg once-daily) followed by 7 days treatment 
      of twice-daily aspirin (37.5 mg twice-daily). The two regimens were separated by 
      14 days aspirin washout. Blood samples were obtained 1h and 24h/12h after the 
      last pill intake in each regimen. The effect of aspirin was evaluated by: (1) 
      platelet aggregation measured by whole blood impedance aggregometry (Multiplate® 
      Analyser) using arachidonic acid (ASPItest 0.5 mM) as agonist and (2) serum 
      thromboxane B(2) levels determined using an enzyme-linked immunosorbent assay. 
      The difference in platelet aggregation from 1h to the end of the dosing interval 
      (24h/12h) was used to compare the two regimens. We demonstrated a significantly 
      smaller difference in platelet aggregation in the twice-daily regimen compared to 
      the once-daily: mean of difference = 228 AU*min (95% confidence interval (CI): 
      92-363, p < 0.01). In addition, a significantly smaller difference in thromboxane 
      B(2) was demonstrated in the twice-daily regimen compared to the once-daily 
      regimen: mean of difference = 16.3 ng/mL (95% CI: 9.9-22.7, p < 0.01). In 
      conclusion, twice-daily dosing with low-dose aspirin provides a more consistent 
      platelet inhibition compared with standard once-daily dosing in patients with 
      essential thrombocytosis.
FAU - Larsen, Mads Lamm
AU  - Larsen ML
AUID- ORCID: 0000-0001-8670-0750
AD  - a Centre of Haemophilia and Thrombosis, Department of Clinical Biochemistry , 
      Aarhus University Hospital , Aarhus , Denmark.
AD  - b Department of Cardiology , Aarhus University Hospital , Aarhus , Denmark.
FAU - Pedersen, Oliver Heidmann
AU  - Pedersen OH
AUID- ORCID: 0000-0002-7437-270X
AD  - a Centre of Haemophilia and Thrombosis, Department of Clinical Biochemistry , 
      Aarhus University Hospital , Aarhus , Denmark.
AD  - b Department of Cardiology , Aarhus University Hospital , Aarhus , Denmark.
FAU - Hvas, Anne-Mette
AU  - Hvas AM
AD  - a Centre of Haemophilia and Thrombosis, Department of Clinical Biochemistry , 
      Aarhus University Hospital , Aarhus , Denmark.
AD  - d Department of Clinical Medicine, Faculty of Health , Aarhus University , Aarhus 
      , Denmark.
FAU - Niekerk, Peter Buur van Kooten
AU  - Niekerk PBVK
AD  - c Department of Hematology , Aarhus University Hospital , Aarhus , Denmark.
FAU - Bønløkke, Søren
AU  - Bønløkke S
AD  - c Department of Hematology , Aarhus University Hospital , Aarhus , Denmark.
FAU - Kristensen, Steen Dalby
AU  - Kristensen SD
AD  - b Department of Cardiology , Aarhus University Hospital , Aarhus , Denmark.
AD  - d Department of Clinical Medicine, Faculty of Health , Aarhus University , Aarhus 
      , Denmark.
FAU - Grove, Erik Lerkevang
AU  - Grove EL
AUID- ORCID: 0000-0002-1466-0865
AD  - b Department of Cardiology , Aarhus University Hospital , Aarhus , Denmark.
AD  - d Department of Clinical Medicine, Faculty of Health , Aarhus University , Aarhus 
      , Denmark.
LA  - eng
PT  - Journal Article
DEP - 20180214
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy/pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Thrombocythemia, Essential/*drug therapy/pathology
MH  - Time Factors
OTO - NOTNLM
OT  - Aspirin
OT  - essential thrombocythemia
OT  - platelet aggregation
OT  - platelet turnover
OT  - thrombocytosis
OT  - thromboxane b
EDAT- 2018/02/15 06:00
MHDA- 2019/04/18 06:00
CRDT- 2018/02/15 06:00
PHST- 2018/02/15 06:00 [pubmed]
PHST- 2019/04/18 06:00 [medline]
PHST- 2018/02/15 06:00 [entrez]
AID - 10.1080/09537104.2018.1430356 [doi]
PST - ppublish
SO  - Platelets. 2019;30(3):322-328. doi: 10.1080/09537104.2018.1430356. Epub 2018 Feb 
      14.

PMID- 11128344
OWN - NLM
STAT- MEDLINE
DCOM- 20010215
LR  - 20221207
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 23
IP  - 12
DP  - 2000 Dec
TI  - Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 
      diabetic patients with microalbuminuria.
PG  - 1742-5
AB  - OBJECTIVE: High-dose treatment with cyclooxygenase inhibitors reduces urinary 
      albumin excretion rate (AER) in type 1 diabetic patients with microalbuminuria 
      and macroalbuminuria. This effect may lead to an incorrect classification of 
      albuminuria (normo-, micro-, and macroalbuminuria) and jeopardize the monitoring 
      of antiproteinuric treatment (e.g., ACE inhibition). Whether similar difficulties 
      exist using low-dose acetylsalicylic acid (ASA), now widely recommended for 
      primary and secondary prevention of cardiovascular events in type 1 diabetic 
      patients with micro- and macroalbuminuria, remains to be elucidated. RESEARCH 
      DESIGN AND METHODS: We performed a randomized double-blind crossover trial in 17 
      type 1 diabetic patients with microalbuminuria (urinary AER 30-300 mg/24 h). 
      Patients were given ASA (150 mg/daily) for 4 weeks followed by placebo for 4 
      weeks with at least a 2-week washout period in random order. At the end of each 
      treatment period, AER (enzyme-linked immunosorbent assay), glomerular filtration 
      rate (GFR) (plasma clearance of 51Cr-EDTA), blood pressure (BP) (Hawksley), and 
      HbA1c (by high-performance liquid chromatography) were measured. Patients were 
      advised to follow a normal diabetes diet without sodium restriction and received 
      their usual antihypertensive treatment during the investigation. RESULTS: During 
      the study (ASA vs. placebo), urinary AER (geometric mean 64 [95% CI 39-105] vs. 
      59 [40-87] mg/24 h), GFR (mean 106 [93-118] vs. 104 [90-117] ml x min(-1) x 1.73 
      m(-2)), systolic BP (mean 130 [119-141] vs. 130 [119-142] mmHg), diastolic BP 
      (mean 71 [65-78] vs. 71 [64-78] mmHg), and HbA1c (mean 8.4% [8.0-9.0] vs. 8.5% 
      [8.1-9.0]) remained unchanged. CONCLUSIONS: Treatment with 150 mg ASA daily does 
      not have any impact on AER or GFR in type 1 diabetic patients with 
      microalbuminuria. Consequently, primary and secondary prevention of 
      cardiovascular events with low-dose ASA does not interfere with the 
      classification of AER or monitoring of antiproteinuric treatment in such 
      patients.
FAU - Hansen, H P
AU  - Hansen HP
AD  - Steno Diabetes Center, Copenhagen, Denmark.
FAU - Gaede, P H
AU  - Gaede PH
FAU - Jensen, B R
AU  - Jensen BR
FAU - Parving, H H
AU  - Parving HH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Albuminuria/*drug therapy
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Blood Pressure
MH  - Chromatography, High Pressure Liquid
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 1/*physiopathology/urine
MH  - Double-Blind Method
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Kidney/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Placebos
EDAT- 2000/12/29 11:00
MHDA- 2001/03/03 10:01
CRDT- 2000/12/29 11:00
PHST- 2000/12/29 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2000/12/29 11:00 [entrez]
AID - 10.2337/diacare.23.12.1742 [doi]
PST - ppublish
SO  - Diabetes Care. 2000 Dec;23(12):1742-5. doi: 10.2337/diacare.23.12.1742.

PMID- 10718778
OWN - NLM
STAT- MEDLINE
DCOM- 20000428
LR  - 20190513
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 49
IP  - 3
DP  - 2000 Mar
TI  - Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with 
      ticlopidine and aspirin.
PG  - 231-9
AB  - AIMS: The purpose of this clinical study was to evaluate the effects of a 
      ticlopidine/aspirin combination on the pharmacokinetics and pharmacodynamics of 
      sibrafiban and the tolerability of the combination therapy METHODS: Thirty-eight 
      healthy male volunteers were randomized to receive one of the following 
      treatments for 7 days: sibrafiban (n = 12), ticlopidine/aspirin (n = 12), or the 
      combination treatment sibrafiban/ticlopidine/aspirin (n = 14). Concentrations of 
      the active metabolite of sibrafiban, Ro 44-3888, in plasma and urine were 
      determined by column-switching liquid chromatography combined with tandem mass 
      spectrometry. The pharmacodynamics of sibrafiban and ticlopidine/aspirin were 
      examined by measuring the inhibition of ADP- or collagen-induced platelet 
      aggregation. RESULTS: The addition of ticlopidine/aspirin to sibrafiban did not 
      significantly alter the pharmacokinetic parameters of Ro 44-3888. the geometric 
      mean ratio for AUC(0,12h) was 110 (95% CI 0.82, 1.22). Separately, sibrafiban and 
      ticlopidine/aspirin inhibited ADP-and collagen-induced platelet aggregation and 
      the effects of the two treatments were additive. For example, the average 
      inhibition of ADP-induced platelet aggregation over 12 h was 42% in the 
      sibrafiban treated group, 55% in the ticlopidine/aspirin group and 69% in the 
      sibrafiban/ticlopidine group. The bleeding time was prolonged in the treatments 
      with ticlopidine/aspirin (8.1 min) and sibrafiban/ticlopidine/aspirin (8. 6 min) 
      compared with sibrafiban alone (3.5 min). CONCLUSIONS: This study shows a 
      significant pharmacodynamic interaction between sibrafiban and 
      ticlopidine/aspirin. Consequently, the simultaneous administration of sibrafiban 
      and ticlopidine/aspirin should be carefully monitored to ensure the patient's 
      coverage with an antiplatelet drug without exposure to an excessive bleeding 
      risk.
FAU - Wittke, B
AU  - Wittke B
AD  - Department of Clinical Pharmacology, F.Hoffmann-La Roche Ltd, Grenzacherstrasse 
      124, CH-4070 Basel, Switzerland. baerbel.wittke@roche.com
FAU - Ensor, H
AU  - Ensor H
FAU - Chung, J
AU  - Chung J
FAU - Birnböck, H
AU  - Birnböck H
FAU - Lausecker, B
AU  - Lausecker B
FAU - Ertel, S I
AU  - Ertel SI
FAU - MacKie, I J
AU  - MacKie IJ
FAU - Machin, S J
AU  - Machin SJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Oximes)
RN  - 0 (Piperidines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prodrugs)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - YUE443B0NF (sibrafiban)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/pharmacokinetics/pharmacology
MH  - Drug Interactions
MH  - Humans
MH  - Male
MH  - Oximes/adverse effects/*pharmacokinetics/pharmacology
MH  - Piperidines/adverse effects/*pharmacokinetics/pharmacology
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacokinetics/pharmacology
MH  - Prodrugs
MH  - Ticlopidine/adverse effects/pharmacokinetics/pharmacology
PMC - PMC2014917
EDAT- 2000/03/16 09:00
MHDA- 2000/05/08 09:00
CRDT- 2000/03/16 09:00
PHST- 2000/03/16 09:00 [pubmed]
PHST- 2000/05/08 09:00 [medline]
PHST- 2000/03/16 09:00 [entrez]
AID - bcp140 [pii]
AID - 10.1046/j.1365-2125.2000.049003231.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2000 Mar;49(3):231-9. doi: 
      10.1046/j.1365-2125.2000.049003231.x.

PMID- 21539676
OWN - NLM
STAT- MEDLINE
DCOM- 20120404
LR  - 20161020
IS  - 1442-2050 (Electronic)
IS  - 1120-8694 (Linking)
VI  - 24
IP  - 8
DP  - 2011 Nov
TI  - Meta-analysis: non-steroidal anti-inflammatory drug use and the risk of 
      esophageal squamous cell carcinoma.
PG  - 544-9
LID - 10.1111/j.1442-2050.2011.01198.x [doi]
AB  - The relationship between non-steroidal anti-inflammatory drug (NSAID) use and 
      esophageal squamous cell carcinoma (ESCC) has remained unclear. To evaluate the 
      relationship between NSAID use and risk of ESCC, we searched the MEDLINE, Biosis, 
      Web of Science and ISI proceedings databases up to September 2010, together with 
      a manual search of reference lists of relevant articles. Studies evaluating the 
      association between exposure to NSAIDs and risk of ESCC were included. The 
      analyses used random-effect or fixed-effect model based on homogeneity analysis. 
      Seven studies (six case-control studies and one nested case-control study) were 
      included in this meta-analysis. NSAID use was associated with a reduced risk of 
      ESCC (odds ratio = 0.58, 95% confidence interval = 0.47 to 0.72). Specific 
      analysis for aspirin and non-aspirin NSAIDs yielded similar results. There was a 
      protective association between NSAIDs and ESCC. This finding warrants more 
      prospective studies evaluating the relationship between NSAIDs and ESCC.
CI  - © 2011 Copyright the Authors. Journal compilation © 2011, Wiley Periodicals, Inc. 
      and the International Society for Diseases of the Esophagus.
FAU - Sun, Lei
AU  - Sun L
AD  - Department of Oncology, TongJi Hospital, TongJi Medical College, HuaZhong 
      University of Science and Technology; Wu Han, China.
FAU - Yu, Shiying
AU  - Yu S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20110503
PL  - United States
TA  - Dis Esophagus
JT  - Diseases of the esophagus : official journal of the International Society for 
      Diseases of the Esophagus
JID - 8809160
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Anticarcinogenic Agents/*pharmacology
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Carcinoma, Squamous Cell/*epidemiology/prevention & control
MH  - Esophageal Neoplasms/*epidemiology/prevention & control
MH  - Humans
MH  - Risk Factors
EDAT- 2011/05/05 06:00
MHDA- 2012/04/05 06:00
CRDT- 2011/05/05 06:00
PHST- 2011/05/05 06:00 [entrez]
PHST- 2011/05/05 06:00 [pubmed]
PHST- 2012/04/05 06:00 [medline]
AID - 10.1111/j.1442-2050.2011.01198.x [doi]
PST - ppublish
SO  - Dis Esophagus. 2011 Nov;24(8):544-9. doi: 10.1111/j.1442-2050.2011.01198.x. Epub 
      2011 May 3.

PMID- 24286218
OWN - NLM
STAT- MEDLINE
DCOM- 20140928
LR  - 20181202
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 39
IP  - 1
DP  - 2014 Feb
TI  - Clopidogrel cessation triggers aspirin rebound in patients with coronary stent.
PG  - 69-72
LID - 10.1111/jcpt.12111 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Premature discontinuation of clopidogrel in patients 
      undergoing percutaneous coronary intervention is a significant risk factor for 
      thrombotic adverse outcomes. However, recent studies indicate that even 
      discontinuation of long-term use of clopidogrel may be associated with multiple 
      adverse outcomes, that is, rebound phenomenon whose mechanism is not definitely 
      clear. The aim of the study was to examine the effect of clopidogrel withdrawal 
      in those on combined aspirin and clopidogrel therapy. METHODS: This prospective, 
      multicenter study enrolled 200 patients who underwent coronary stent implantation 
      and were on dual antiplatelet therapy (100 mg aspirin + 75 mg clopidogrel) 1 year 
      after the stent placement. In all patients, we measured the platelet aggregation, 
      by multiplate electrode aggregometry, using two agonists [adenosine diphosphate 
      with PGE1 (ADPHS) and arachidonic acid (ASPI)] two times: on the day of cessation 
      of clopidogrel and 90 days after clopidogrel was stopped. RESULTS AND DISCUSSION: 
      Following clopidogrel discontinuation, we registered an increase in ASPI values 
      (P < 0·001), linear correlation between changes in ASPI and ADPHS values 
      (P = 0·009) and significant difference in the values of ASPI first quartile of 
      ADPHS compared with the other three (P < 0·001, P = 0·016, P < 0·001, I vs. II, I 
      vs. III and I vs. IV quartile of ADPHS, respectively). WHAT IS NEW AND 
      CONCLUSION: Our findings show that cessation of clopidogrel causes loss of 
      antiplatelet synergism with aspirin, leading to a weakening of the response to 
      aspirin, which may be one explanation for the rebound after the clopidogrel 
      cessation.
CI  - © 2013 John Wiley & Sons Ltd.
FAU - Djukanovic, N
AU  - Djukanovic N
AD  - High Medical School Milutin Milankovic, Belgrade, Serbia.
FAU - Todorovic, Z
AU  - Todorovic Z
FAU - Obradovic, S
AU  - Obradovic S
FAU - Njegomirovic, S
AU  - Njegomirovic S
FAU - Zamaklar-Trifunovic, D
AU  - Zamaklar-Trifunovic D
FAU - Protić, D
AU  - Protić D
FAU - Ostojic, M
AU  - Ostojic M
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20131129
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Prospective Studies
MH  - Stents
MH  - Substance Withdrawal Syndrome/*etiology
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - aspirin rebound
OT  - clopidogrel cessation
EDAT- 2013/11/30 06:00
MHDA- 2014/10/01 06:00
CRDT- 2013/11/30 06:00
PHST- 2013/02/20 00:00 [received]
PHST- 2013/10/17 00:00 [accepted]
PHST- 2013/11/30 06:00 [entrez]
PHST- 2013/11/30 06:00 [pubmed]
PHST- 2014/10/01 06:00 [medline]
AID - 10.1111/jcpt.12111 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2014 Feb;39(1):69-72. doi: 10.1111/jcpt.12111. Epub 2013 Nov 
      29.

PMID- 16104622
OWN - NLM
STAT- MEDLINE
DCOM- 20051122
LR  - 20131121
IS  - 0003-3928 (Print)
IS  - 0003-3928 (Linking)
VI  - 54
IP  - 4
DP  - 2005 Aug
TI  - [Acute myocardial infarction complicating primary antiphospholipid syndrome after 
      aspirin and steroids withdrawal].
PG  - 212-5
AB  - A 24-year-old woman, with known antiphospholid antibodies (APS), presented with 
      an acute myocardial infarction (AMI) that occurred three months after delivery. 
      No risk factors for arteriosclerosis and no past history of arterial/venous 
      thrombosis were noted. During pregnancy, aspirin prophylaxis was prescribed and 
      followed by steroids after caesarian section. Steroids withdrawal was followed by 
      AMI. Immediate coronary angiography revealed thrombotic occlusion of the left 
      descending coronary artery; PTCA was successfully performed. She was discharged 
      with an antiplatelet and anticoagulant regimen. No recurrent coronary event 
      occurred during follow-up.
FAU - Wahbi, K
AU  - Wahbi K
AD  - Service de cardiologie, hôpital Cochin, université René-Descartes, 27, rue du 
      Faubourg-Saint-Jacques, 75014 Paris, France. karim.wahbi@cch.ap-hop-paris.fr
FAU - Salengro, E
AU  - Salengro E
FAU - Galicier, L
AU  - Galicier L
FAU - Guillevin, L
AU  - Guillevin L
FAU - Spaulding, C
AU  - Spaulding C
FAU - Weber, S
AU  - Weber S
FAU - Meune, C
AU  - Meune C
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Survenue d'un infarctus du myocarde après arrêt de l'aspirine et des corticoïdes 
      oraux chez une patiente présentant un syndrome des antiphospholipides.
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/*therapeutic use
MH  - Adult
MH  - Angioplasty, Balloon, Coronary
MH  - Antiphospholipid Syndrome/*complications
MH  - Aspirin/*therapeutic use
MH  - Coronary Thrombosis/*diagnosis/therapy
MH  - Female
MH  - Humans
MH  - Myocardial Infarction/complications/*diagnosis/therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/prevention & control
EDAT- 2005/08/18 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/08/18 09:00
PHST- 2005/08/18 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/08/18 09:00 [entrez]
AID - S0003-3928(05)00062-4 [pii]
AID - 10.1016/j.ancard.2005.05.019 [doi]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 2005 Aug;54(4):212-5. doi: 
      10.1016/j.ancard.2005.05.019.

PMID- 36443044
OWN - NLM
STAT- MEDLINE
DCOM- 20221130
LR  - 20230829
IS  - 1672-173X (Print)
IS  - 1672-173X (Linking)
VI  - 53
IP  - 6
DP  - 2022 Nov
TI  - [Latest Findings on Prediction and Prevention of Preeclampsia].
PG  - 1012-1015
LID - 10.12182/20221160509 [doi]
AB  - Preeclampsia, a progressive disease involving multiple systems, afflicts 
      pregnancy specifically. It contributes to severe maternal and perinatal morbidity 
      and mortality. It has been reported that preeclampsia initiates from a mismatch 
      between the utero-placental supply and demand, which subsequently triggers the 
      release of placental syncytiotrophoblast stress-derived factors and an imbalance 
      of proangiogenic/antiangiogenic factors, eventually causing maternal systemic 
      endothelial lesions and systemic inflammatory response. Currently, treatments 
      available for preeclampsia are very limited in number. Hence, prediction and 
      prevention carry special significance. Herein, we reviewed the current 
      understanding of preeclampsia, especially findings on the prediction and 
      prevention of preeclampsia published within the past 5 years. We discussed the 
      Fetal Medicine Foundation (FMF) screening model based on placental growth factor 
      (PlGF) and the effects of aspirin, calcium, exercise, and termination of 
      pregnancy in preventing preeclampsia. The efficacy and safety of other new 
      preventive measures still need further validation.
CI  - Copyright© by Editorial Board of Journal of Sichuan University (Medical 
      Sciences).
FAU - Ye, Yun-Zhen
AU  - Ye YZ
AD  - Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.
AD  - Shanghai Institute of Reproductive Endocrinology, Shanghai 200011, China.
FAU - Zhou, Qiong-Jie
AU  - Zhou QJ
AD  - Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.
AD  - Shanghai Institute of Reproductive Endocrinology, Shanghai 200011, China.
FAU - Xiao, Xi-Rong
AU  - Xiao XR
AD  - Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.
AD  - Shanghai Institute of Reproductive Endocrinology, Shanghai 200011, China.
FAU - Xiong, Yu
AU  - Xiong Y
AD  - Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.
AD  - Shanghai Institute of Reproductive Endocrinology, Shanghai 200011, China.
FAU - Li, Xiao-Tian
AU  - Li XT
AD  - Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.
AD  - Shanghai Institute of Reproductive Endocrinology, Shanghai 200011, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - China
TA  - Sichuan Da Xue Xue Bao Yi Xue Ban
JT  - Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical 
      science edition
JID - 101162609
RN  - 144589-93-5 (Placenta Growth Factor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Humans
MH  - Female
MH  - Placenta Growth Factor
MH  - *Pre-Eclampsia/diagnosis/prevention & control
MH  - Placenta
MH  - Trophoblasts
MH  - Aspirin/therapeutic use
PMC - PMC10408989
OTO - NOTNLM
OT  - Prediction
OT  - Preeclampsia
OT  - Prevention
COIS- 利益冲突　所有作者均声明不存在利益冲突
EDAT- 2022/11/29 06:00
MHDA- 2022/12/01 06:00
CRDT- 2022/11/28 21:43
PHST- 2022/11/28 21:43 [entrez]
PHST- 2022/11/29 06:00 [pubmed]
PHST- 2022/12/01 06:00 [medline]
AID - scdxxbyxb-53-6-1012 [pii]
AID - 10.12182/20221160509 [doi]
PST - ppublish
SO  - Sichuan Da Xue Xue Bao Yi Xue Ban. 2022 Nov;53(6):1012-1015. doi: 
      10.12182/20221160509.

PMID- 7602303
OWN - NLM
STAT- MEDLINE
DCOM- 19950810
LR  - 20131121
IS  - 0015-4148 (Print)
IS  - 0015-4148 (Linking)
VI  - 82
IP  - 5
DP  - 1995 May
TI  - Forty years of rheumatology in Florida.
PG  - 322-6
AB  - Changes in the practice of rheumatology in the past 40 years are detailed and 
      thoughts are expressed as to where further progress will be made in this 
      specialty. The author optimistically concludes that in the near future, both the 
      pain and disability of the arthritic patient may be markedly diminished, if not 
      completely abrogated.
FAU - Sales, L M
AU  - Sales LM
AD  - University of Florida College of Medicine, Gainesville, USA.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - J Fla Med Assoc
JT  - The Journal of the Florida Medical Association
JID - 7505604
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Organogold Compounds)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antirheumatic Agents/history
MH  - Arthritis/drug therapy/history
MH  - Aspirin/history
MH  - Florida
MH  - History, 20th Century
MH  - Humans
MH  - Organogold Compounds
MH  - Rheumatology/*history
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
PST - ppublish
SO  - J Fla Med Assoc. 1995 May;82(5):322-6.

PMID- 35011685
OWN - NLM
STAT- MEDLINE
DCOM- 20220330
LR  - 20220330
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Dec 30
TI  - Aspirin Inhibition of Group VI Phospholipase A2 Induces Synthetic Lethality in 
      AAM Pathway Down-Regulated Gingivobuccal Squamous Carcinoma.
LID - 10.3390/cells11010123 [doi]
LID - 123
AB  - BACKGROUND: To elucidate the role of iPLA2/PLA2G6 in gingivobuccal squamous cell 
      carcinoma (GB-SCC) and to ascertain the synthetic lethality-based chemoprevention 
      role of aspirin in arachidonic acid metabolism (AAM) pathway down-regulated 
      GB-SCC. METHODS: The in vitro efficacy of aspirin on GB-SCC cells (ITOC-03 and 
      ITOC-04) was assessed by cell proliferation, colony formation, apoptosis, cell 
      migration, cell cycle assay and RNA-seq, while inhibition of PLA2G6 and AAM 
      pathway components was affirmed by qPCR, Western blot and immunofluorescence 
      staining. The in vivo effect of aspirin was evaluated using NOD-SCID mice 
      xenografts and immunohistochemical analysis. RESULTS: We found that aspirin, 
      which has been reported to act through the COX pathway, is inhibiting PLA2G6, and 
      thereby the COX and LOX components of the AAM pathway. The findings were 
      validated using PLA2G6 siRNA and immunohistochemical marker panel. Moreover, a 
      pronounced effect in ITOC-04 cells and xenografts implied aspirin-induced 
      synthetic lethality in the AAM pathway down-regulated GB-SCC. CONCLUSIONS: This 
      study reveals that aspirin induces the anti-tumor effect by a previously 
      unrecognized mechanism of PLA2G6 inhibition. In addition, the effect of aspirin 
      is influenced by the baseline AAM pathway status and could guide precision 
      prevention clinical trials of AAM pathway inhibitors.
FAU - Pansare, Kshama
AU  - Pansare K
AD  - ICGC Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
FAU - Mohanty, Bhabani
AU  - Mohanty B
AD  - Small Animal Imaging Facility, Advanced Centre for Treatment, Research and 
      Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India.
FAU - Dhotre, Ranjeeta
AU  - Dhotre R
AD  - ICGC Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
FAU - Pettiwala, Aafrin M
AU  - Pettiwala AM
AD  - ICGC Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
FAU - Parab, Saili
AU  - Parab S
AD  - Biorepository, Advanced Centre for Treatment, Research and Education in Cancer, 
      Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India.
FAU - Gupta, Neha
AU  - Gupta N
AD  - ICGC Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
FAU - Gera, Poonam
AU  - Gera P
AD  - ICGC Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
AD  - Biorepository, Advanced Centre for Treatment, Research and Education in Cancer, 
      Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India.
FAU - Gardi, Nilesh
AU  - Gardi N
AD  - Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, 
      Mumbai 400012, India.
AD  - Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 
      400085, India.
FAU - Dugge, Rucha
AU  - Dugge R
AD  - ICGC Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
FAU - Sahu, Priyanka
AU  - Sahu P
AD  - ICGC Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
FAU - Alhans, Ruby
AU  - Alhans R
AD  - ICGC Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
FAU - Kowtal, Pradnya
AU  - Kowtal P
AD  - ICGC Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
AD  - Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 
      400085, India.
AD  - Sarin Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
FAU - Chaudhari, Pradip
AU  - Chaudhari P
AUID- ORCID: 0000-0002-6792-7658
AD  - Small Animal Imaging Facility, Advanced Centre for Treatment, Research and 
      Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India.
AD  - Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 
      400085, India.
FAU - Sarin, Rajiv
AU  - Sarin R
AD  - ICGC Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
AD  - Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 
      400085, India.
AD  - Sarin Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata 
      Memorial Centre, Kharghar, Navi Mumbai 410210, India.
LA  - eng
GR  - BT/MB/01/ICGC/2009/Department of Biotechnology/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211230
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 3.1.1.4 (Group VI Phospholipases A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Carcinoma, Squamous Cell/*drug therapy
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Disease Models, Animal
MH  - Down-Regulation
MH  - Gingival Neoplasms/*drug therapy
MH  - Group VI Phospholipases A2/*drug effects
MH  - Humans
MH  - Mice
MH  - Mice, SCID
MH  - Prognosis
MH  - Synthetic Lethal Mutations/*drug effects
MH  - Transfection
PMC - PMC8750243
OTO - NOTNLM
OT  - PLA2G6
OT  - arachidonic acid metabolism pathway
OT  - aspirin
OT  - gingivobuccal squamous cell carcinoma
OT  - phospholipase
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript; or in the decision to publish the results.
EDAT- 2022/01/12 06:00
MHDA- 2022/03/31 06:00
CRDT- 2022/01/11 01:15
PHST- 2021/11/18 00:00 [received]
PHST- 2021/12/20 00:00 [revised]
PHST- 2021/12/22 00:00 [accepted]
PHST- 2022/01/11 01:15 [entrez]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/03/31 06:00 [medline]
AID - cells11010123 [pii]
AID - cells-11-00123 [pii]
AID - 10.3390/cells11010123 [doi]
PST - epublish
SO  - Cells. 2021 Dec 30;11(1):123. doi: 10.3390/cells11010123.

PMID- 27322595
OWN - NLM
STAT- MEDLINE
DCOM- 20170616
LR  - 20180223
IS  - 2168-6114 (Electronic)
IS  - 2168-6106 (Linking)
VI  - 176
IP  - 8
DP  - 2016 Aug 1
TI  - Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: 
      Advances in Diagnosis and Treatment.
PG  - 1195-204
LID - 10.1001/jamainternmed.2016.2648 [doi]
AB  - IMPORTANCE: Clinical decision making regarding the appropriate use of aspirin for 
      the primary prevention of atherosclerotic cardiovascular disease (ASCVD) events 
      is complex, and requires an individualized benefit to risk assessment. OBJECTIVE: 
      To review advances in the individualized assessment for ASCVD and bleeding risk, 
      and to provide an update of the randomized clinical trial evidence that examined 
      the use of aspirin for primary prevention (primarily for ASCVD, and secondarily 
      for colorectal cancer). The recently released 2016 US Preventive Services Task 
      Force recommendations are discussed, as well as the role of ASCVD risk, age, sex, 
      and aspirin dose/formulation in clinical decision making. EVIDENCE REVIEW: We 
      performed a detailed review of peer-reviewed publications that were identified 
      through searches of MEDLINE and the Cochrane Database through 2016 using the 
      literature search terms "aspirin," "primary prevention," "cardiovascular 
      disease," "mortality," "cancer." Bibliographies from these references as well as 
      meta-analyses of these randomized clinical trials were also reviewed. FINDINGS: 
      Evidence from a total of 11 trials involving more than 118 000 patients is 
      available to guide clinical decision making for aspirin use in the primary 
      prevention of ASCVD. Clinicians should balance the benefit to risk ratio and the 
      individual's preferences, calculating the 10-year ASCVD risk and evaluating risk 
      factors for gastrointestinal bleeding, to facilitate a safer and more 
      personalized approach to appropriate selection of candidates for low-dose aspirin 
      (75 to 81 mg/d) for the primary prevention of ASCVD, with secondary 
      considerations for reducing colorectal cancer risk when taken for longer periods 
      (>10 years). Both the net ASCVD benefit and the bleeding risk of aspirin therapy 
      increased as the absolute ASCVD risk increased, but the net benefits generally 
      exceeded the risks at higher baseline ASCVD risk (≥10% ASCVD 10-year risk). The 
      Aspirin-Guide is a clinical decision making support tool (app for mobile devices) 
      with internal risk calculators to help clinicians with this dual assessment by 
      calculating the ASCVD risk and the bleeding risk in the individual patient, and 
      incorporating age- and sex-specific guidance based on randomized trial results. 
      CONCLUSIONS AND RELEVANCE: Balancing the benefit of ASCVD reduction with the risk 
      of bleeding from low-dose aspirin is difficult but essential for informed 
      decision making and achieving a net clinical benefit from aspirin for primary 
      prevention. This is facilitated by a free and readily available evidence-based 
      clinical decision support tool.
FAU - Mora, Samia
AU  - Mora S
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital and Harvard Medical School, Boston, Massachusetts2Cardiovascular 
      Division, Department of Medicine, Brigham and Women's Hospital and Harvard 
      Medical School, Boston, Massa.
FAU - Manson, JoAnn E
AU  - Manson JE
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital and Harvard Medical School, Boston, Massachusetts3Department of 
      Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
LA  - eng
GR  - R01 HL034594/HL/NHLBI NIH HHS/United States
GR  - R01 HL117861/HL/NHLBI NIH HHS/United States
GR  - R01 CA138962/CA/NCI NIH HHS/United States
GR  - HHSN268201100001C/WH/WHI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - JAMA Intern Med
JT  - JAMA internal medicine
JID - 101589534
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA Intern Med. 2017 Feb 1;177(2):291. PMID: 28166337
CIN - JAMA Intern Med. 2017 Feb 1;177(2):291-292. PMID: 28166350
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Chemoprevention
MH  - Colorectal Neoplasms/prevention & control
MH  - Evidence-Based Medicine
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Primary Prevention/*methods
EDAT- 2016/06/21 06:00
MHDA- 2017/06/18 06:00
CRDT- 2016/06/21 06:00
PHST- 2016/06/21 06:00 [entrez]
PHST- 2016/06/21 06:00 [pubmed]
PHST- 2017/06/18 06:00 [medline]
AID - 2528292 [pii]
AID - 10.1001/jamainternmed.2016.2648 [doi]
PST - ppublish
SO  - JAMA Intern Med. 2016 Aug 1;176(8):1195-204. doi: 
      10.1001/jamainternmed.2016.2648.

PMID- 7781459
OWN - NLM
STAT- MEDLINE
DCOM- 19950719
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 40
IP  - 6
DP  - 1995 Jun
TI  - Time course of mucosal cell proliferation following acute aspirin injury in rat 
      stomach.
PG  - 1351-6
AB  - The time course of replicating cell proliferation in the gastric fundic mucosa 
      following acute aspirin-induced injury was determined by BrdU labeling. Gastric 
      erosions were produced in adult rats by gastric gavage using aspirin (200 mg/kg) 
      suspended in 0.15 M HCl. Lesion scores indicated significant gross injury in the 
      aspirin-treated rats at all times measured (from 2 to 48 hr). BrdU labeling was 
      not elevated at 2 or 8 hr after gavage. A significant increase in labeling was 
      observed at 15 hr, reached a maximum at 16 hr, and declined with a slight, but 
      significant increase still present at 48 hr. Elevations in BrdU labeling were 
      uniform and seen in areas adjacent to and distant from the gross injury. The BrdU 
      labeling in the fasted control rats decreased during this same time period. The 
      height of the proliferative zone was not altered from control in the 
      aspirin-treated rats despite the marked differences in proliferation activity. 
      This study demonstrates the importance of the time course in the assessment of 
      mucosal cell proliferation following injury.
FAU - Ohning, G V
AU  - Ohning GV
AD  - Research Service, Department of Veteran Affairs, West Los Angeles Medical Center, 
      California, USA.
FAU - Guth, P H
AU  - Guth PH
LA  - eng
GR  - DK41301/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - G34N38R2N1 (Bromodeoxyuridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/administration & dosage/*toxicity
MH  - Bromodeoxyuridine
MH  - Cell Division/drug effects
MH  - Gastric Fundus
MH  - Gastric Mucosa/cytology/*drug effects/metabolism
MH  - Immunohistochemistry
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Time Factors
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
AID - 10.1007/BF02065550 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1995 Jun;40(6):1351-6. doi: 10.1007/BF02065550.

PMID- 3376161
OWN - NLM
STAT- MEDLINE
DCOM- 19880624
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 19
IP  - 6
DP  - 1988 Jun
TI  - Individual variation in platelet aggregability and serum thromboxane B2 
      concentrations after low-dose aspirin.
PG  - 700-3
AB  - The effects of low daily oral doses of aspirin (40 mg/day) on platelet 
      aggregability and serum thromboxane B2 concentrations were studied in 19 
      poststroke patients. Although platelet aggregation was reduced significantly 
      after 1 week, there was wide individual variation in the inhibition of platelet 
      function in spite of marked decreases of serum thromboxane B2 concentrations by 
      greater than 90% (from 224 +/- 58 to 8 +/- 8 ng/ml). There was no correlation 
      between collagen-induced platelet aggregability and serum thromboxane B2 
      concentration before aspirin administration in the range 100-350 ng/ml, but after 
      1 week of repeated administration of aspirin, there was a correlation between 
      platelet aggregability and serum thromboxane B2 concentrations of less than 25 
      ng/ml (r = 0.68, p less than 0.01). However, platelet inhibition was insufficient 
      even in some patients with markedly decreased thromboxane B2 concentrations (less 
      than 5 ng/ml). Our results suggest that individual variation of platelet 
      aggregability in response to low-dose aspirin may be due to variation not only in 
      the degree of inhibition of thromboxane A2 production but also in the relative 
      dependence of platelet aggregation on extra-arachidonic pathways.
FAU - Tohgi, H
AU  - Tohgi H
AD  - Department of Neurology, Iwate Medical University, Morioka City, Japan.
FAU - Tamura, K
AU  - Tamura K
FAU - Kimura, B
AU  - Kimura B
FAU - Kimura, M
AU  - Kimura M
FAU - Suzuki, H
AU  - Suzuki H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cerebrovascular Disorders/blood/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane B2/biosynthesis/*blood
EDAT- 1988/06/01 00:00
MHDA- 1988/06/01 00:01
CRDT- 1988/06/01 00:00
PHST- 1988/06/01 00:00 [pubmed]
PHST- 1988/06/01 00:01 [medline]
PHST- 1988/06/01 00:00 [entrez]
AID - 10.1161/01.str.19.6.700 [doi]
PST - ppublish
SO  - Stroke. 1988 Jun;19(6):700-3. doi: 10.1161/01.str.19.6.700.

PMID- 16092443
OWN - NLM
STAT- MEDLINE
DCOM- 20051020
LR  - 20131121
IS  - 0001-6837 (Print)
IS  - 0001-6837 (Linking)
VI  - 49
IP  - 4
DP  - 1992
TI  - Tensides from the group of propylene oxide and ethylene oxide copolymers. X. 
      Solubilization of acetylsalicylic acid by polyetherodiol micelles.
PG  - 93-8
AB  - The process of structural solubilization of acetylsalicylic acid in balanced 
      systems (weight-balanced) by micelles of Rokopols of 30p160 and 30p60 types and, 
      for comparison, by those of F-68 and F-108 Pluronics was investigated. The 
      determined viscosity and hydrodynamic parameters allowed for the calculation of 
      solubilizing activity of polyetherodiol micelles--n(s(A)). The results of the 
      investigation point at Rokopols as an excipient, which may help to obtain new 
      drug delivery systems.
FAU - Zgoda, M M
AU  - Zgoda MM
AD  - Department of Physical Chemistry, Institute of Chemistry, Faculty of Pharmacy, 
      Scholl of Medicine, 1 Muszyńskiego Str., 90-151 Lódź, Poland.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Poland
TA  - Acta Pol Pharm
JT  - Acta poloniae pharmaceutica
JID - 2985167R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Carriers)
RN  - 0 (Epoxy Compounds)
RN  - 0 (Ethers)
RN  - 0 (Micelles)
RN  - 0 (Polymers)
RN  - 0 (Surface-Active Agents)
RN  - JJH7GNN18P (Ethylene Oxide)
RN  - R16CO5Y76E (Aspirin)
RN  - Y4Y7NYD4BK (propylene oxide)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry
MH  - Aspirin/*chemistry/pharmacokinetics
MH  - Drug Carriers
MH  - Epoxy Compounds/chemistry
MH  - Ethers/*chemistry/pharmacokinetics
MH  - Ethylene Oxide/chemistry
MH  - *Micelles
MH  - Polymers/chemistry/pharmacokinetics
MH  - Solubility
MH  - Surface-Active Agents/*chemistry/pharmacokinetics
EDAT- 1992/01/01 00:00
MHDA- 2005/10/21 09:00
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 2005/10/21 09:00 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Pol Pharm. 1992;49(4):93-8.

PMID- 4599671
OWN - NLM
STAT- MEDLINE
DCOM- 19740828
LR  - 20181113
IS  - 0008-4409 (Print)
IS  - 0008-4409 (Linking)
VI  - 110
IP  - 12
DP  - 1974 Jun 22
TI  - Comparison of ibuprofen and acetylsalicylic acid in the treatment of rheumatoid 
      arthritis.
PG  - 1370-2
AB  - A double-blind crossover study of ibuprofen and acetylsalicylic acid was carried 
      out in 27 patients with rheumatoid arthritis. Patients were evaluated by joint 
      counts, grip-strength determination, erythrocyte sedimentation rate, and number 
      of acetaminophen tablets required in addition to the test drug, as well as by 
      various biochemical measurements. In the doses used ibuprofen and acetylsalicylic 
      acid appeared comparable in anti-inflammatory effect, but statistically fewer 
      side effects were observed during administration of ibuprofen.
FAU - Dornan, J
AU  - Dornan J
FAU - Reynolds, W J
AU  - Reynolds WJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Canada
TA  - Can Med Assoc J
JT  - Canadian Medical Association journal
JID - 0414110
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Phenylpropionates)
RN  - 268B43MJ25 (Uric Acid)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/metabolism
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Sedimentation
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Manometry
MH  - Phenylpropionates/*therapeutic use
MH  - Uric Acid/analysis
PMC - PMC1947619
EDAT- 1974/06/22 00:00
MHDA- 1974/06/22 00:01
CRDT- 1974/06/22 00:00
PHST- 1974/06/22 00:00 [pubmed]
PHST- 1974/06/22 00:01 [medline]
PHST- 1974/06/22 00:00 [entrez]
PST - ppublish
SO  - Can Med Assoc J. 1974 Jun 22;110(12):1370-2.

PMID- 8637072
OWN - NLM
STAT- MEDLINE
DCOM- 19960705
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 40
IP  - 2
DP  - 1996 Feb
TI  - Early resuscitation with low-volume PolyDCLHb is effective in the treatment of 
      shock induced by penetrating vascular injury.
PG  - 242-8
AB  - OBJECTIVE: To study the efficacy of an oxygen-carrying solution in early 
      resuscitation of hemorrhagic shock induced by penetrating vascular injury. 
      DESIGN: Experimental study with anesthetized rats. MATERIALS AND METHODS: Severe 
      hemorrhagic shock was induced by a 25-gauge needle puncture to the infrarenal 
      aorta. Forty animals were resuscitated 10 minutes after injury with either 
      lactated Ringer's solution (LR; 60 mL/kg), 7.5% hypertonic saline (HTS; 5 mL/kg), 
      or modified diaspirin cross-linked hemoglobin (PolyDCLHb; 5 or 20 mL/kg) or were 
      not resuscitated (NR) and followed for 6 hours. RESULTS: Total blood loss was 
      similar in all treatment groups. Mean arterial pressure was restored to baseline 
      values, base deficit was corrected to base excess, and venous oxygen saturation 
      improved with PolyDCLHb and more slowly with LR but persisted below baseline 
      values with HTS and NR. The 6-hour mortality rates were zero of eight (low-dose 
      PolyDCLHb), three of eight (high-dose PolyDCLHb), two of eight (LR), six of eight 
      (HTS), and six of eight (NR). CONCLUSION: Early resuscitation with low-volume 
      hemoglobin is effective in restoring tissue perfusion and improving survival in 
      uncontrolled hemorrhagic shock.
FAU - Leppäniemi, A
AU  - Leppäniemi A
AD  - Department of Surgery, Uniformed Services University of the Health Sciences, F. 
      Edward Hèbert School of Medicine, Bethesda, Maryland 20814-4799, USA.
FAU - Soltero, R
AU  - Soltero R
FAU - Burris, D
AU  - Burris D
FAU - Pikoulis, E
AU  - Pikoulis E
FAU - Ratigan, J
AU  - Ratigan J
FAU - Waasdorp, C
AU  - Waasdorp C
FAU - Hufnagel, H
AU  - Hufnagel H
FAU - Malcolm, D
AU  - Malcolm D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta/injuries
MH  - Arteries/*injuries
MH  - Aspirin/administration & dosage/*analogs & derivatives
MH  - Blood Pressure/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Fluid Therapy/methods
MH  - Hemoglobins/*administration & dosage
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Resuscitation/*methods
MH  - Shock, Hemorrhagic/etiology/*therapy
MH  - Wounds, Penetrating/*complications
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - 10.1097/00005373-199602000-00011 [doi]
PST - ppublish
SO  - J Trauma. 1996 Feb;40(2):242-8. doi: 10.1097/00005373-199602000-00011.

PMID- 8274164
OWN - NLM
STAT- MEDLINE
DCOM- 19940131
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 46
IP  - 12
DP  - 1993 Dec 14
TI  - Differential susceptibilities of the prosthetic heme of hemoglobin-based red cell 
      substitutes. Implications in the design of safer agents.
PG  - 2299-305
AB  - One approach to the development of an effective red cell substitute has been 
      chemical modification of human hemoglobin to optimize oxygen transport and plasma 
      half-life. Human hemoglobin A0 and two of these modified hemoglobins, one 
      prepared from the cross-linking of the alpha-chains at lysine residue 99 by 
      bis(3,5-dibromosalicyl)fumarate (Hb-DBBF) and the other by acylation of lysine 
      residue 82 of the beta-chain by mono-(3,5-dibromosalicyl)fumarate (Hb-FMDA), were 
      tested by HPLC for their susceptibility to oxidative damage caused by H2O2. Such 
      oxidative insult may occur during ischemia and reperfusion of tissues after 
      transfusion of red cell substitutes to patients with hypovolemic shock and 
      trauma. Hb-DBBF was extremely susceptible to damage of its heme and protein 
      moieties with stoichiometric amounts of H2O2, whereas Hb-FMDA was highly 
      resistant, even at 10-fold molar excess and at an acidic pH of 4.7. Hemoglobin A0 
      was of intermediate susceptibility, exhibiting alteration of heme and protein 
      moieties at acidic but not neutral pH. Since the degradation of heme can release 
      the potentially toxic agent iron, Hb-FMDA may be a more promising candidate than 
      Hb-DBBF for development as a red cell substitute. A similar approach may be used 
      to assess the susceptibility of other hemoglobin-based red cell substitutes to 
      oxidative damage in order to determine the molecular basis of heme and protein 
      alteration.
FAU - Osawa, Y
AU  - Osawa Y
AD  - Laboratory of Chemical Pharmacology, National Heart, Lung, and Blood Institute, 
      National Institutes of Health, Bethesda, MD 20892.
FAU - Darbyshire, J F
AU  - Darbyshire JF
FAU - Meyer, C A
AU  - Meyer CA
FAU - Alayash, A I
AU  - Alayash AI
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 42VZT0U6YR (Heme)
RN  - 93705-06-7 (mono(3,5-dibromosalicyl)fumarate)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Aspirin/analogs & derivatives/chemistry
MH  - Biological Transport
MH  - *Blood Substitutes
MH  - Cross-Linking Reagents
MH  - Drug Design
MH  - *Erythrocytes
MH  - Heme/*chemistry
MH  - Hemoglobins/*chemistry/drug effects/metabolism
MH  - Humans
MH  - Hydrogen Peroxide/pharmacology
MH  - Oxidation-Reduction
MH  - Oxygen/metabolism
EDAT- 1993/12/14 00:00
MHDA- 1993/12/14 00:01
CRDT- 1993/12/14 00:00
PHST- 1993/12/14 00:00 [pubmed]
PHST- 1993/12/14 00:01 [medline]
PHST- 1993/12/14 00:00 [entrez]
AID - 0006-2952(93)90621-3 [pii]
AID - 10.1016/0006-2952(93)90621-3 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1993 Dec 14;46(12):2299-305. doi: 
      10.1016/0006-2952(93)90621-3.

PMID- 12171603
OWN - NLM
STAT- MEDLINE
DCOM- 20020823
LR  - 20191106
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 2
DP  - 2002 Aug 9
TI  - Therapeutic utility of aspirin in the ApcMin/+ murine model of colon 
      carcinogenesis.
PG  - 19
AB  - BACKGROUND: In recent years it has become evident that nonsteroidal 
      anti-inflammatory drugs, in particular aspirin represent a potential class of 
      cancer chemotherapeutic agents. Despite the wealth of knowledge gained from 
      epidemiological, clinical and animal studies, the effectiveness of aspirin to 
      treat established gastrointestinal cancer has not been determined. The present 
      study examines the ability of aspirin to treat established polyposis in Min/+ 
      mice. METHODS: Min/+ mice with established polyposis were treated orally once 
      daily from 12-16 weeks of age with either drug vehicle or aspirin (25 mg/kg). 
      Upon completion of treatment, the number, location and size of intestinal tumours 
      was determined. Additional variables examined were the number of apoptotic cells 
      within tumours and COX activity. RESULTS: Administration of aspirin for 4 weeks 
      to Min/+ mice produce no effect on tumour number compared to vehicle-treated 
      Min/+ mice (65 +/- 8 vs. 63 +/- 9, respectively). In addition, aspirin had no 
      effect on tumour size or location. However, aspirin treatment produced a greater 
      than 2-fold (p<0.05) increase in the number of apoptotic positive cells within 
      tumours and significantly decreased hepatic PGE2 content. CONCLUSIONS: Aspirin 
      was found to have no effect on tumour number and size when administered to Min/+ 
      mice with established polyposis. The findings in the present study call in to 
      question the utility of aspirin as a stand-alone treatment for established GI 
      cancer. However, aspirin's ability to significantly promote apoptosis may render 
      it suitable for use in combinatorial chemotherapy.
FAU - Reuter, Brian K
AU  - Reuter BK
AD  - Center for Cardiovascular Sciences, Albany Medical College, New York 12208, USA. 
      ok_go@hotmail.com
FAU - Zhang, Xiao-Jing
AU  - Zhang XJ
FAU - Miller, Mark J S
AU  - Miller MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20020809
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenomatous Polyposis Coli/*drug therapy/enzymology/pathology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Apoptosis
MH  - Aspirin/*therapeutic use
MH  - Genes, APC
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
PMC - PMC122065
EDAT- 2002/08/13 10:00
MHDA- 2002/08/24 10:01
CRDT- 2002/08/13 10:00
PHST- 2002/04/02 00:00 [received]
PHST- 2002/08/09 00:00 [accepted]
PHST- 2002/08/13 10:00 [pubmed]
PHST- 2002/08/24 10:01 [medline]
PHST- 2002/08/13 10:00 [entrez]
AID - 1471-2407-2-19 [pii]
AID - 10.1186/1471-2407-2-19 [doi]
PST - epublish
SO  - BMC Cancer. 2002 Aug 9;2:19. doi: 10.1186/1471-2407-2-19.

PMID- 31230127
OWN - NLM
STAT- MEDLINE
DCOM- 20200212
LR  - 20200212
IS  - 1436-2813 (Electronic)
IS  - 0941-1291 (Print)
IS  - 0941-1291 (Linking)
VI  - 49
IP  - 11
DP  - 2019 Nov
TI  - Is laparoscopic colorectal surgery with continuation of antiplatelet therapy safe 
      without increasing bleeding complications?
PG  - 948-957
LID - 10.1007/s00595-019-01839-0 [doi]
AB  - PURPOSE: The number of patients on antiplatelet therapy (APT) who need surgery is 
      increasing; however, it is unclear whether APT should be continued for abdominal 
      surgery, particularly laparoscopic colorectal surgery. We investigated the safety 
      of continuing APT for patients undergoing laparoscopic colorectal surgery. 
      METHODS: We collected retrospective data from 529 patients who underwent 
      laparoscopic colorectal surgery at Hiroshima University between January, 2013 and 
      December, 2018. We analyzed information related to APT. Thirty-six pairs were 
      matched by the propensity score method between patients on APT (APT+) and those 
      not on APT (APT-). We compared the surgical outcomes of both groups. RESULTS: 
      Among 463 patients eligible for the study, 48 were on APT for cerebrovascular or 
      cardiovascular disease, and 36 continued to take aspirin. In the case-matched 
      comparison, the amount of intraoperative blood loss in the APT+ group was not 
      significantly higher than that in the APT- group, and the incidences of bleeding 
      complications, thromboembolic complications, and other complications were not 
      significantly different between the groups. CONCLUSION: In a case-matched 
      comparison, continuation of aspirin during laparoscopic colorectal surgery did 
      not increase perioperative complications. In laparoscopic colorectal surgery, 
      continuation of aspirin is an acceptable strategy for patients with 
      thromboembolic risk caused by interruption of APT.
FAU - Taguchi, Kazuhiro
AU  - Taguchi K
AD  - Department of Gastroenterological and Transplant Surgery, Graduate School of 
      Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, 
      Hiroshima, Hiroshima, 734-8551, Japan.
AD  - Institute for Clinical Research, National Hospital Organization, Kure Medical 
      Center and Chugoku Cancer Center, 3-1 Aoyamacho, Kure, Hiroshima, 737-0023, 
      Japan.
FAU - Shimomura, Manabu
AU  - Shimomura M
AD  - Department of Surgery, Hiroshima City Asa Citizens Hospital, 2-1-1 Kabeminami, 
      Asakita-ku, Hiroshima, 731-0293, Japan. manabus761215@gmail.com.
FAU - Egi, Hiroyuki
AU  - Egi H
AD  - Department of Gastroenterological and Transplant Surgery, Graduate School of 
      Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, 
      Hiroshima, Hiroshima, 734-8551, Japan.
FAU - Hattori, Minoru
AU  - Hattori M
AD  - Advanced Medical Skills Training Center, Institute of Biomedical and Health 
      Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, Hiroshima, Hiroshima, 
      734-8551, Japan.
FAU - Mukai, Shoichiro
AU  - Mukai S
AD  - Department of Gastroenterological and Transplant Surgery, Graduate School of 
      Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, 
      Hiroshima, Hiroshima, 734-8551, Japan.
FAU - Kochi, Masatoshi
AU  - Kochi M
AD  - Department of Gastroenterological and Transplant Surgery, Graduate School of 
      Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, 
      Hiroshima, Hiroshima, 734-8551, Japan.
FAU - Sada, Haruki
AU  - Sada H
AD  - Department of Gastroenterological and Transplant Surgery, Graduate School of 
      Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, 
      Hiroshima, Hiroshima, 734-8551, Japan.
FAU - Sumi, Yusuke
AU  - Sumi Y
AD  - Department of Gastroenterological and Transplant Surgery, Graduate School of 
      Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, 
      Hiroshima, Hiroshima, 734-8551, Japan.
FAU - Nakashima, Ikki
AU  - Nakashima I
AD  - Department of Gastroenterological and Transplant Surgery, Graduate School of 
      Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, 
      Hiroshima, Hiroshima, 734-8551, Japan.
FAU - Akabane, Shintaro
AU  - Akabane S
AD  - Department of Gastroenterological and Transplant Surgery, Graduate School of 
      Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, 
      Hiroshima, Hiroshima, 734-8551, Japan.
FAU - Sato, Koki
AU  - Sato K
AD  - Department of Gastroenterological and Transplant Surgery, Graduate School of 
      Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, 
      Hiroshima, Hiroshima, 734-8551, Japan.
FAU - Ohdan, Hideki
AU  - Ohdan H
AD  - Department of Gastroenterological and Transplant Surgery, Graduate School of 
      Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, 
      Hiroshima, Hiroshima, 734-8551, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190622
PL  - Japan
TA  - Surg Today
JT  - Surgery today
JID - 9204360
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Loss, Surgical/*statistics & numerical data
MH  - Digestive System Surgical Procedures/*methods
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Laparoscopy/*methods
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/*therapeutic use
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Safety
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC6800856
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - Laparoscopic colorectal surgery
OT  - Surgical outcome
COIS- We have no conflicts of interest to declare.
EDAT- 2019/06/24 06:00
MHDA- 2020/02/13 06:00
CRDT- 2019/06/24 06:00
PHST- 2019/02/18 00:00 [received]
PHST- 2019/05/31 00:00 [accepted]
PHST- 2019/06/24 06:00 [pubmed]
PHST- 2020/02/13 06:00 [medline]
PHST- 2019/06/24 06:00 [entrez]
AID - 10.1007/s00595-019-01839-0 [pii]
AID - 1839 [pii]
AID - 10.1007/s00595-019-01839-0 [doi]
PST - ppublish
SO  - Surg Today. 2019 Nov;49(11):948-957. doi: 10.1007/s00595-019-01839-0. Epub 2019 
      Jun 22.

PMID- 8359275
OWN - NLM
STAT- MEDLINE
DCOM- 19930930
LR  - 20190629
IS  - 0014-4754 (Print)
IS  - 0014-4754 (Linking)
VI  - 49
IP  - 8
DP  - 1993 Aug 15
TI  - Partition coefficients of drugs in bilayer lipid membranes.
PG  - 688-92
AB  - The oil/water partition coefficient of drugs is widely accepted as a key 
      parameter in drug design. The coefficients are usually determined using a bulk 
      octanol phase to represent the lipid. The physiologically and pharmacologically 
      relevant structure is, of course, the bilayer lipid membrane, but until now there 
      has been no convenient means of measuring the partition coefficients of small 
      molecules into a single bilayer. This paper demonstrates that the partition 
      coefficient may be calculated from the change in membrane refractive index which 
      occurs when a drug molecule partitions into the membrane. The refractive index is 
      determined by an integrated-optics technique ideally suited to an ultra-thin 
      structure such as a lipid bilayer.
FAU - Ramsden, J J
AU  - Ramsden JJ
AD  - Department of Biophysical Chemistry, Biozentrum, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Experientia
JT  - Experientia
JID - 0376547
RN  - 0 (Lipid Bilayers)
RN  - 0 (Phosphatidylcholines)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
RN  - TE895536Y5 (1-palmitoyl-2-oleoylphosphatidylcholine)
SB  - IM
MH  - Aspirin/chemistry
MH  - Caffeine/chemistry
MH  - Lipid Bilayers/*chemistry
MH  - Phosphatidylcholines/chemistry
MH  - Refractometry
MH  - Solubility
EDAT- 1993/08/15 00:00
MHDA- 1993/08/15 00:01
CRDT- 1993/08/15 00:00
PHST- 1993/08/15 00:00 [pubmed]
PHST- 1993/08/15 00:01 [medline]
PHST- 1993/08/15 00:00 [entrez]
AID - 10.1007/BF01923952 [doi]
PST - ppublish
SO  - Experientia. 1993 Aug 15;49(8):688-92. doi: 10.1007/BF01923952.

PMID- 28110287
OWN - NLM
STAT- MEDLINE
DCOM- 20171213
LR  - 20190202
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 7
IP  - 1
DP  - 2017 Jan 20
TI  - AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol.
PG  - e013636
LID - 10.1136/bmjopen-2016-013636 [doi]
LID - e013636
AB  - INTRODUCTION: Sepsis is a leading global cause of morbidity and mortality, and is 
      more common at the extremes of age. Moreover, the cost of in-hospital care for 
      elderly patients with sepsis is significant. There are indications from 
      experimental and observational studies that aspirin may reduce inflammation 
      associated with infection. This paper describes the rationale and design of the 
      AspiriN To Inhibit SEPSIS (ANTISEPSIS) trial, a substudy of ASPirin in Reducing 
      Events in the Elderly (ASPREE). ANTISEPSIS primarily aims to determine whether 
      low-dose aspirin reduces sepsis-related deaths in older people. Additionally, it 
      will assess whether low-dose aspirin reduces sepsis-related hospitalisations and 
      sepsis-related Intensive Care Unit (ICU) admissions. METHODS AND ANALYSIS: ASPREE 
      is a double-blinded, randomised, placebo-controlled primary prevention trial that 
      will determine whether daily low-dose aspirin extends disability-free longevity 
      in 19 000 healthy older people recruited in Australia and the USA. The ANTISEPSIS 
      substudy involves additional ASPREE trial data collection to assess the impact of 
      daily low-dose aspirin on sepsis-related events in the 16 703 ASPREE participants 
      aged 70 years and over, recruited in Australia. The intervention is a daily 
      100 mg dose of enteric-coated aspirin versus matching placebo, with 1:1 
      randomisation. The primary outcome for the ANTISEPSIS substudy is the incidence 
      of sepsis-related death in eligible patients. The incidence of sepsis-related 
      hospital and ICU admissions are secondary outcomes. ANTISEPSIS is to be conducted 
      between 2012 and 2018. DISCUSSION: This substudy will determine whether aspirin, 
      an inexpensive and accessible therapy, safely reduces sepsis-related deaths and 
      hospitalisations in older Australians. If shown to be the case, this would have 
      profound effects on the health of older Australians. TRIAL REGISTRATION NUMBER: 
      Pre-results, ACTRN12613000349741.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://www.bmj.com/company/products-services/rights-and-licensing/.
FAU - Eisen, Damon P
AU  - Eisen DP
AD  - Townsville Hospital and Health Service, Townsville, Queensland, Australia.
AD  - Division of Tropical Health and Medicine, College of Medicine and Dentistry, 
      James Cook University, Townsville, Queensland, Australia.
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Moore, Elizabeth M
AU  - Moore EM
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Leder, Karin
AU  - Leder K
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
AD  - Victorian Infectious Diseases Service at the Peter Doherty Institute, Royal 
      Melbourne Hospital, Melbourne, Victoria, Australia.
FAU - Lockery, Jessica
AU  - Lockery J
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - McBryde, Emma S
AU  - McBryde ES
AD  - Division of Tropical Health and Medicine, Australian Institute of Tropical Health 
      and Medicine, James Cook University, Townsville, Queensland, Australia.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Pilcher, David
AU  - Pilcher D
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
AD  - Department of Intensive Care, The Alfred Hospital,  Melbourne, Victoria, 
      Australia.
AD  - The Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcome 
      and Resource Evaluation (CORE), Melbourne, Victoria, Australia.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12613000349741
GR  - U01 AG029824/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20170120
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Antisepsis
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Australia
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Inflammation/mortality/*prevention & control
MH  - Intensive Care Units
MH  - Male
MH  - Research Design
MH  - Sepsis/*mortality
PMC - PMC5253551
COIS- Conflicts of Interest: None declared.
EDAT- 2017/01/23 06:00
MHDA- 2017/12/14 06:00
CRDT- 2017/01/23 06:00
PHST- 2017/01/23 06:00 [entrez]
PHST- 2017/01/23 06:00 [pubmed]
PHST- 2017/12/14 06:00 [medline]
AID - bmjopen-2016-013636 [pii]
AID - 10.1136/bmjopen-2016-013636 [doi]
PST - epublish
SO  - BMJ Open. 2017 Jan 20;7(1):e013636. doi: 10.1136/bmjopen-2016-013636.

PMID- 21626697
OWN - NLM
STAT- MEDLINE
DCOM- 20151005
LR  - 20191210
IS  - 1615-9314 (Electronic)
IS  - 1615-9306 (Linking)
VI  - 34
IP  - 16-17
DP  - 2011 Aug
TI  - Optimized mobile phase for CEC of acetylsalicylic acid and its impurities using a 
      methacrylate-based monolithic column.
PG  - 2284-92
LID - 10.1002/jssc.201100179 [doi]
AB  - In the past few years, monolithic methacrylate-based columns have attracted some 
      attention in separation science. The mobile-phase optimization on these columns 
      for drug analysis has not yet been thoroughly examined. This paper evaluates the 
      separation of acetylsalicylic acid and its impurities as a case study. First, the 
      best pH was determined as 2.3. Methacrylate-based phases can be employed at such 
      pH because they remain charged, necessary to generate electro-osmotic flow. Then, 
      a suitable solvent strength was determined. Trifluoroacetic acid (0.1%) was added 
      to the mobile phase to improve peak shapes. The optimal organic modifier 
      composition was then determined, using isoeluotropic mobile phases, based on the 
      theory of Snyder's solvent triangle. Quadratic models were built to predict the 
      retention of the compounds at all mobile-phase compositions within the triangle. 
      The predictions were tested and found appropriate. Eventually, a baseline 
      separation of acetylsalicylic acid and its impurities was not obtained. However, 
      it could be concluded that one can optimize the mobile phase on 
      methacrylate-based monolithic columns in CEC using Snyder's solvent triangle 
      approach.
CI  - Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Tanret, Indiana
AU  - Tanret I
AD  - Department of Analytical Chemistry and Pharmaceutical Technology, Center for 
      Pharmaceutical Research (CePhaR), Vrije Universiteit Brussel-VUB, Laarbeeklaan, 
      Brussels, Belgium.
FAU - Mangelings, Debby
AU  - Mangelings D
FAU - Vander Heyden, Yvan
AU  - Vander Heyden Y
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110527
PL  - Germany
TA  - J Sep Sci
JT  - Journal of separation science
JID - 101088554
RN  - 0 (Methacrylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Capillary Electrochromatography/instrumentation/*methods
MH  - Drug Contamination
MH  - Methacrylates/chemistry
OTO - NOTNLM
OT  - Acetylsalicylic acid and impurities
OT  - CEC
OT  - Methacrylate-based monoliths
OT  - Pharmaceutical analysis
EDAT- 2011/06/01 06:00
MHDA- 2015/10/06 06:00
CRDT- 2011/06/01 06:00
PHST- 2011/02/28 00:00 [received]
PHST- 2011/04/04 00:00 [revised]
PHST- 2011/04/04 00:00 [accepted]
PHST- 2011/06/01 06:00 [entrez]
PHST- 2011/06/01 06:00 [pubmed]
PHST- 2015/10/06 06:00 [medline]
AID - 10.1002/jssc.201100179 [doi]
PST - ppublish
SO  - J Sep Sci. 2011 Aug;34(16-17):2284-92. doi: 10.1002/jssc.201100179. Epub 2011 May 
      27.

PMID- 1818715
OWN - NLM
STAT- MEDLINE
DCOM- 19920723
LR  - 20131121
IS  - 1040-872X (Print)
IS  - 1040-872X (Linking)
VI  - 3
IP  - 6
DP  - 1991 Dec
TI  - Recent developments in pregnancy-induced hypertension.
PG  - 783-91
AB  - Pregnancy-induced hypertension (PIH) still remains an area in obstetrics of 
      active research and investigation. Despite widespread academic attention, the 
      cause of this disorder still remains unknown. The purpose of this paper is to 
      review the important contributions to the literature during the period of July, 
      1990 through June, 1991. Elucidation of the pathophysiology of PIH has been 
      enhanced by investigations of altered platelet calcium metabolism, the 
      renin-aldosterone-angiotensin system, and other potent vasopressors. Recent 
      reports of clinical management for eclampsia, liver rupture, HELLP syndrome, 
      severe PIH in the second trimester, severe hypertension, and magnesium toxicity 
      are presented.
FAU - Dildy, G A
AU  - Dildy GA
AD  - Utah Valley Regional Medical Center, Provo.
FAU - Clark, S L
AU  - Clark SL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Obstet Gynecol
JT  - Current opinion in obstetrics & gynecology
JID - 9007264
RN  - 0 (Anticonvulsants)
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticonvulsants/administration & dosage/therapeutic use
MH  - Antihypertensive Agents/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - *Hypertension/diagnosis/physiopathology/therapy
MH  - Pregnancy
MH  - *Pregnancy Complications, Cardiovascular/diagnosis/physiopathology/therapy
MH  - Prognosis
RF  - 29
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
PST - ppublish
SO  - Curr Opin Obstet Gynecol. 1991 Dec;3(6):783-91.

PMID- 2244178
OWN - NLM
STAT- MEDLINE
DCOM- 19910102
LR  - 20191029
IS  - 0085-591X (Print)
IS  - 0085-591X (Linking)
VI  - 201
DP  - 1990
TI  - Acetylsalicylic acid and the balance between prostacyclin and thromboxane A2.
PG  - 103-8
AB  - Arachidonic acid is metabolized in endothelial cells to antiaggregatory, 
      vasodilatory prostacyclin (PGI2), and in platelets to aggregatory, 
      vasoconstrictory thromboxane A2 (TxA2). The balance of these two prostanoids is 
      supposed to be involved with thrombogenesis and atherogenesis. Acetylsalicylic 
      acid (ASA) inhibits irreversibly the key enzyme of the synthesis of these 
      prostanoids, i.e. cyclo-oxygenase. Platelets do not synthetize new protein, but 
      endothelial cells do. Because of this, and certain pharmacokinetic 
      characteristics of ASA, it should be possible to shift the balance between PGI2 
      and TxA2 to the dominance of the former with the proper dose of this drug. 
      Altogether more than 50,000 subjects have volunteered for studies on the effect 
      of ASA in the primary or secondary prevention of myocardial infarction or 
      ischemic stroke. The results show that it is possible to reduce vascular attacks 
      by ASA. Furthermore, ASA has also found to prevent pre-eclampsia. Conclusions on 
      the effect of ASA on the PGI2/TxA2-balance are hampered by uncertainties 
      concerning the measurement PGI2 and TxA2 productions in vivo. It is, however, 
      evident that the doses of ASA used in most trials have been high enough to 
      inhibit partly also the production of PGI2. Whether smaller doses or less 
      frequent administration would be more efficient, remains to be studied.
FAU - Viinikka, L
AU  - Viinikka L
AD  - Children's Hospital, University of Helsinki, Finland.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Norway
TA  - Scand J Clin Lab Invest Suppl
JT  - Scandinavian journal of clinical and laboratory investigation. Supplementum
JID - 2984789R
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis/blood
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Administration Schedule
MH  - Epoprostenol/*blood
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/blood
MH  - Pregnancy
MH  - Thromboxane A2/*blood
RF  - 36
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.3109/00365519009085806 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest Suppl. 1990;201:103-8. doi: 10.3109/00365519009085806.

PMID- 955240
OWN - NLM
STAT- MEDLINE
DCOM- 19761101
LR  - 20190902
IS  - 0011-9075 (Print)
IS  - 0011-9075 (Linking)
VI  - 152 Suppl 1
DP  - 1976
TI  - Effect of bases and accelerants on the anti-inflammatory activity of topical 
      corticosteroids.
PG  - 81-9
AB  - The use of measurement of skin thickness in guinea pigs has been compared with 
      other techniques for assessment of topical applications. This method has provided 
      us with an accurate evaluation of the corticosteroid dose-response curve and the 
      effect of bases. The method has shown that non-steroid prostaglandin synthesis 
      inhibitors can also be demonstrated to possess topical anti-inflammatory 
      activity. As expected, indomethacin acts synergistically when formulated with 
      hydrocortisone. Contrary to our expectation, both salicylic acid and 
      acetylsalicylic acid show antagonism with hydrocortisone. This finding may be of 
      clinical significance. We have also found that a combination of salicylic acid 
      and indomethacin produces striking inflammatory changes in guinea pig skin which 
      points to interaction of these two drugs in the guinea pig. The relevance of this 
      phenomenon to both the mode of action of the two drugs and their use in clinical 
      practice remains to be elucidated, but preliminary tests suggest that similar 
      changes take place in human skin.
FAU - Sarkany, I
AU  - Sarkany I
FAU - Gaylarde, P M
AU  - Gaylarde PM
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Dermatologica
JT  - Dermatologica
JID - 0211607
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Anti-Inflammatory Agents/metabolism/*pharmacology
MH  - Aspirin/metabolism/pharmacology
MH  - Drug Interactions
MH  - Guinea Pigs
MH  - Hydrocortisone
MH  - Indomethacin/metabolism/pharmacology
MH  - Salicylates/metabolism/pharmacology
MH  - Skin/*drug effects/metabolism
MH  - Skinfold Thickness
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1159/000257868 [doi]
PST - ppublish
SO  - Dermatologica. 1976;152 Suppl 1:81-9. doi: 10.1159/000257868.

PMID- 1860198
OWN - NLM
STAT- MEDLINE
DCOM- 19910830
LR  - 20220408
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 84
IP  - 2
DP  - 1991 Aug
TI  - Stroke Prevention in Atrial Fibrillation Study. Final results.
PG  - 527-39
AB  - BACKGROUND: Atrial fibrillation in the absence of rheumatic valvular disease is 
      associated with a fivefold to sevenfold increased risk of ischemic stroke. 
      METHODS AND MAIN RESULTS: The Stroke Prevention in Atrial Fibrillation Study, a 
      multicenter, randomized trial, compared 325 mg/day aspirin (double-blind) or 
      warfarin with placebo for prevention of ischemic stroke and systemic embolism 
      (primary events), and included 1,330 inpatients and outpatients with constant or 
      intermittent atrial fibrillation. During a mean follow-up of 1.3 years, the rate 
      of primary events in patients assigned to placebo was 6.3% per year and was 
      reduced by 42% in those assigned to aspirin (3.6% per year; p = 0.02; 95% 
      confidence interval, 9-63%). In the subgroup of warfarin-eligible patients (most 
      less than 76 years old), warfarin dose-adjusted to prolong prothrombin time to 
      1.3-fold to 1.8-fold that of control reduced the risk of primary events by 67% 
      (warfarin versus placebo, 2.3% versus 7.4% per year; p = 0.01; 95% confidence 
      interval, 27-85%). Primary events or death were reduced 58% (p = 0.01) by 
      warfarin and 32% (p = 0.02) by aspirin. The risk of significant bleeding was 
      1.5%, 1.4%, and 1.6% per year in patients assigned to warfarin, aspirin, and 
      placebo, respectively. CONCLUSIONS: Aspirin and warfarin are both effective in 
      reducing ischemic stroke and systemic embolism in patients with atrial 
      fibrillation. Because warfarin-eligible patients composed a subset of all 
      aspirin-eligible patients, the magnitude of reduction in events by warfarin 
      versus aspirin cannot be compared. Too few events occurred in warfarin-eligible 
      patients to directly assess the relative benefit of aspirin compared with 
      warfarin, and the trial is continuing to address this issue. Patients with 
      nonrheumatic atrial fibrillation who can safely take either aspirin or warfarin 
      should receive prophylactic antithrombotic therapy to reduce the risk of stroke.
LA  - eng
GR  - R01-NS-24224/NS/NINDS NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 1991 Aug;84(2):933-5. PMID: 1860238
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*complications/drug therapy
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Embolism/prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
AID - 10.1161/01.cir.84.2.527 [doi]
PST - ppublish
SO  - Circulation. 1991 Aug;84(2):527-39. doi: 10.1161/01.cir.84.2.527.

PMID- 835940
OWN - NLM
STAT- MEDLINE
DCOM- 19770321
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 86
IP  - 2
DP  - 1977 Feb
TI  - Aspirin hepatotoxicity and disseminated intravascular coagulation.
PG  - 183-5
AB  - A 17-year-old girl with a clinical diagnosis of adult-type juvenile rheumatoid 
      arthritis developed a severe hepatotoxic reaction to 3.6 g of aspirin per day. 
      This was associated with a microangiopathic anemia and transient congestive 
      cardiac failure. She responded well to steroids, and when all laboratory test 
      findings were back to normal, she was "challenged" with five divided doses of 
      aspirin (total, 3.0 g). This produced a salicylate level of 9.1 g/dl and was 
      associated with an immediate deterioration in liver function test findings and a 
      return of microangiopathic blood features with elevation of fibrin split products 
      and a prolonged prothrombin time. These changes were again reversed by promptly 
      starting steroid therapy. This case suggests that disseminated intravascular 
      coagulation, and its rare association with hepatotoxicity, is a potentially fatal 
      side effect of aspirin therapy.
FAU - Sbarbaro, J A
AU  - Sbarbaro JA
FAU - Bennett, R M
AU  - Bennett RM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adolescent
MH  - Arthritis, Juvenile/drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Biopsy
MH  - Chemical and Drug Induced Liver Injury/*etiology
MH  - Disseminated Intravascular Coagulation/*chemically induced/drug therapy/pathology
MH  - Female
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Liver/drug effects/pathology
MH  - Liver Function Tests
MH  - Prednisone/therapeutic use
EDAT- 1977/02/01 00:00
MHDA- 1977/02/01 00:01
CRDT- 1977/02/01 00:00
PHST- 1977/02/01 00:00 [pubmed]
PHST- 1977/02/01 00:01 [medline]
PHST- 1977/02/01 00:00 [entrez]
AID - 10.7326/0003-4819-86-2-183 [doi]
PST - ppublish
SO  - Ann Intern Med. 1977 Feb;86(2):183-5. doi: 10.7326/0003-4819-86-2-183.

PMID- 10274573
OWN - NLM
STAT- MEDLINE
DCOM- 19851230
LR  - 20131121
IS  - 0098-6909 (Print)
IS  - 0098-6909 (Linking)
VI  - 20
IP  - 11
DP  - 1985 Nov
TI  - Drug utilization review: dipyridamole plus aspirin antiplatelet therapy.
PG  - 1175-7, 1180-1, 1185
AB  - To assess whether dipyridamole was being used appropriately in providing 
      antiplatelet therapy at the San Diego VAMC, a drug utilization review was 
      conducted. Concomitant aspirin therapy was required for dipyridamole to be 
      considered effective in the disease states reviewed. Seventy-three patients on 
      antiplatelet therapy were evaluated, using dosing criteria established through a 
      literature review. Our data indicated tht based on the criteria, only 11% of 
      patients received dipyridamole in appropriate doses; it was underdosed in 89% of 
      patients, and in 19% of patients, it was used when not indicated. In addition, 
      19% of patients did not receive concomitant aspirin therapy. Results suggest hat 
      dipyridamole is not used optimally in providing antiplatelet therapy to patients 
      in this institution.
FAU - Crisp, C B
AU  - Crisp CB
FAU - Garrard, E A
AU  - Garrard EA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hosp Formul
JT  - Hospital formulary
JID - 7508609
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*administration & dosage
MH  - Blood Platelets/drug effects
MH  - California
MH  - Dipyridamole/*administration & dosage
MH  - *Drug Utilization
MH  - Humans
EDAT- 1985/10/07 00:00
MHDA- 1985/10/07 00:01
CRDT- 1985/10/07 00:00
PHST- 1985/10/07 00:00 [pubmed]
PHST- 1985/10/07 00:01 [medline]
PHST- 1985/10/07 00:00 [entrez]
PST - ppublish
SO  - Hosp Formul. 1985 Nov;20(11):1175-7, 1180-1, 1185.

PMID- 10763206
OWN - NLM
STAT- MEDLINE
DCOM- 20000427
LR  - 20190826
IS  - 0248-8663 (Print)
IS  - 0248-8663 (Linking)
VI  - 21 Suppl 1
DP  - 2000 Mar
TI  - [Aspirin against cancer].
PG  - 60s-67s
AB  - PURPOSE: That aspirin as an anti-aggregative and anti-inflammatory compound might 
      prevent tumor spread is an old concept that is still not of clinical relevance. 
      To date, aspirin has been shown in several epidemiologic studies to be linked 
      with a reduction of colorectal cancer incidence, as well as the incidence of lung 
      and breast cancer. In this issue, we have summarized the mechanisms that support 
      this hypothesis, and we have analysed the main clinical studies. RESULTS: Only 
      case-control studies and most of the prospective cohort studies showed a 
      reduction of colorectal cancer incidence in regular aspirin users. Nevertheless, 
      the minimum effective doses of aspirin and the duration of therapy remain 
      unclear. To date, only one prospective randomized trial has evaluated the 
      influence of aspirin in the prevention of colorectal cancer. Despite the 
      inclusion of 22,000 subjects and a five-year follow-up, aspirin failed to show 
      any protection. The mechanism of the potential role of aspirin in preventing 
      cancer, primarily supposed to rely on the antiprostaglandin effect, is now under 
      debate. Few studies have evaluated the prevention of other cancers, such as 
      breast or lung cancers, by aspirin. Data remain too sparse to allow any 
      conclusion. CONCLUSION: The role of aspirin in the prevention of colorectal 
      cancer still needs further studies, such as a prospective randomized study, which 
      should be conducted in a high-risk population.
FAU - Mabro, M
AU  - Mabro M
AD  - Service de médecine interne et d'oncologie, hôpital Saint-Antoine, Paris, France.
FAU - de Gramont, A
AU  - de Gramont A
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - L'aspirine contre le cancer.
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Breast Neoplasms/prevention & control
MH  - Case-Control Studies
MH  - Clinical Trials as Topic
MH  - Cohort Studies
MH  - Colorectal Neoplasms/prevention & control
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Lung Neoplasms/prevention & control
MH  - Male
MH  - Neoplasms/drug therapy/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Prospective Studies
MH  - Time Factors
RF  - 72
EDAT- 2000/04/14 09:00
MHDA- 2000/04/29 09:00
CRDT- 2000/04/14 09:00
PHST- 2000/04/14 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/04/14 09:00 [entrez]
AID - S0248-8663(00)88726-3 [pii]
AID - 10.1016/s0248-8663(00)88726-3 [doi]
PST - ppublish
SO  - Rev Med Interne. 2000 Mar;21 Suppl 1:60s-67s. doi: 10.1016/s0248-8663(00)88726-3.

PMID- 12667121
OWN - NLM
STAT- MEDLINE
DCOM- 20030603
LR  - 20190916
IS  - 1465-6566 (Print)
IS  - 1465-6566 (Linking)
VI  - 4
IP  - 4
DP  - 2003 Apr
TI  - Warfarin and aspirin give more benefit than aspirin alone but also more bleeding 
      after myocardial infarction.
PG  - 587-90
AB  - The anticoagulant, warfarin, and the antiplatelet agent, aspirin, have been shown 
      to have similar benefits after myocardial infarction. As these agents have 
      different mechanisms of action, the beneficial effects of warfarin and aspirin 
      may be additive after myocardial infarction. In the Warfarin, Aspirin, 
      Reinfarction Study (WARIS II), the main outcome was a composite of death, 
      non-fatal reinfarction or thromboembolic stroke, whichever came first over 4 
      years. Compared to aspirin alone (160 mg/day), the risk reduction was 19% (p = 
      0.03) with warfarin alone (INR of 2.8 IU) and 29% (p = 0.001) with the 
      combination of aspirin and warfarin (aspirin, 75 mg/day; warfarin, INR of 2.2 
      IU). This difference in the first event with warfarin alone or the combination, 
      represented a reduction in reinfarction and thromboembolic stroke rather than 
      death. For reinfarction, compared to aspirin alone (117 of 1206), there was a 
      reduction with warfarin alone (90 of 1216) and a further reduction with the 
      combination (69 of 1208). For thromboembolic stroke, compared to aspirin (32 of 
      1206), there were similar reductions with warfarin and the combination. There 
      were more major and minor bleeding in the warfarin groups than the aspirin group, 
      with major bleeding occurring in 8, 33 and 28 patients taking aspirin, warfarin 
      and aspirin and warfarin, respectively. In conclusion, as compared with aspirin 
      alone, therapy with moderate-intensity warfarin combined with aspirin and 
      high-intensity warfarin alone, resulted in a reduced risk of reinfarction and 
      ischemic stroke but a higher risk of bleeding.
FAU - Doggrell, Sheila A
AU  - Doggrell SA
AD  - School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia. 
      s.doggrell@mailbox.uq.edu.au
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - International Normalized Ratio
MH  - Myocardial Infarction/*drug therapy/mortality
MH  - Norway
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2003/04/02 05:00
MHDA- 2003/06/05 05:00
CRDT- 2003/04/02 05:00
PHST- 2003/04/02 05:00 [pubmed]
PHST- 2003/06/05 05:00 [medline]
PHST- 2003/04/02 05:00 [entrez]
AID - 10.1517/14656566.4.4.587 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2003 Apr;4(4):587-90. doi: 10.1517/14656566.4.4.587.

PMID- 36286689
OWN - NLM
STAT- MEDLINE
DCOM- 20221028
LR  - 20221028
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 93
IP  - 12
DP  - 2021 Dec 15
TI  - [Antiplatelet drugs and COVID-19: use for prevention of arterial vascular 
      complications in different time periods of the disease].
PG  - 1562-1563
AB  - A Council of Experts was held in Moscow with the scientific and organizational 
      support of the National Medical Research Center for Therapy and Preventive 
      Medicine and the Russian Society for the Prevention of Noncommunicable Diseases. 
      Leading experts in various fields of medicine discussed the possibility of using 
      antiplatelet drugs as prevention of arterial vascular complications of COVID-19 
      in different time periods of the disease. The main outcome of the Council of 
      Experts was a resolution reflecting the general view of the scientific community 
      on the possibility of increasing the use of acetylsalicylic acid in patients with 
      coronavirus infection.
LA  - rus
PT  - English Abstract
PT  - Journal Article
DEP - 20211215
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - *COVID-19
MH  - Aspirin/therapeutic use
MH  - Arteries
MH  - Russia/epidemiology
EDAT- 2022/10/27 06:00
MHDA- 2022/10/29 06:00
CRDT- 2022/10/26 09:53
PHST- 2022/01/16 00:00 [received]
PHST- 2022/01/16 00:00 [accepted]
PHST- 2022/10/26 09:53 [entrez]
PHST- 2022/10/27 06:00 [pubmed]
PHST- 2022/10/29 06:00 [medline]
PST - epublish
SO  - Ter Arkh. 2021 Dec 15;93(12):1562-1563.

PMID- 22103069
OWN - NLM
STAT- MEDLINE
DCOM- 20111219
LR  - 20190715
IS  - 1533-4880 (Print)
IS  - 1533-4880 (Linking)
VI  - 11
IP  - 8
DP  - 2011 Aug
TI  - Bimodal mesoporous silicas functionalized with different level and species of the 
      amino groups for adsorption and controlled release of aspirin.
PG  - 6690-7
AB  - The synthesis of modified bimodal mesoporous materials (BMMs) with a small pore 
      size of around 2.9 nm and a large pore size of about 20 nm has been performed via 
      post-grafting methods. To study the application of functionalized BMMs in drug 
      delivery, loading and releasing profiles using aspirin as model drug were carried 
      out. XRD, SEM, TEM, N2 adsorption, FT-IR, 29Si-NMR, TG and UV-Vis spectroscopy 
      were used to characterize the related samples. The post-grafting modification was 
      performed through the weak chemical interaction or hydrogen bonding in between OH 
      groups of the mesopore surface and 3-aminopropyltriethoxysilane (N-TES) or 
      3-(2-aminoethylamino) propyItrimethoxysilane (NN-TES). The results showed that 
      N-TES groups with different amount and NN-TES groups were successfully 
      incorporated onto the mesopore surface. Subsequently, the controlled aspirin 
      delivery properties from the resulting modified BMMs were investigated in detail. 
      The aspirin adsorption experiments indicated that the adsorption capacities of 
      modified BMMs were improved with the increasing amount of N-TES groups, while the 
      NN-TES functionalized samples showed higher adsorption capacity than N-TES 
      modified samples with the same ratio of modification. The most reason is that the 
      interaction between the NN-TES groups and aspirin molecules is stronger than that 
      between the N-TES groups and aspirin molecules. The in vitro tests exhibited that 
      aspirin release behaviors mainly depended on the variation of the amount and 
      species of the functional groups in mesoporous carries. According to the 
      Korsmeyer-Peppas model, it is found that the kinetic release constant k reduced 
      with the increase amount of the amino groups on the mesopore surface of modified 
      BMMs, suggesting that the aspirin release rate from the pores of BMMs was 
      influenced directly by organic groups on the surface. The release exponent n of 
      all the situations were above 0.5, indicating the drug release mechanism followed 
      a non-Fickian model that was diffusion based. Therefore, this type of materials 
      described in this paper is of strong potential for the controlled drug release 
      applications.
FAU - Gao, Lin
AU  - Gao L
AD  - Department of Chemistry and Chemical Engineering, College of Environmental and 
      Energy Engineering, Beijing University of Technology, Beijing 100124, P. R. 
      China.
FAU - Sun, Jihong
AU  - Sun J
FAU - Li, Yuzhen
AU  - Li Y
FAU - Zhang, Li
AU  - Zhang L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Nanosci Nanotechnol
JT  - Journal of nanoscience and nanotechnology
JID - 101088195
RN  - 7631-86-9 (Silicon Dioxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Aspirin/*pharmacokinetics
MH  - Microscopy, Electron, Scanning
MH  - Microscopy, Electron, Transmission
MH  - Silicon Dioxide/*chemistry
MH  - Spectrophotometry, Ultraviolet
MH  - X-Ray Diffraction
EDAT- 2011/11/23 06:00
MHDA- 2011/12/20 06:00
CRDT- 2011/11/23 06:00
PHST- 2011/11/23 06:00 [entrez]
PHST- 2011/11/23 06:00 [pubmed]
PHST- 2011/12/20 06:00 [medline]
AID - 10.1166/jnn.2011.4237 [doi]
PST - ppublish
SO  - J Nanosci Nanotechnol. 2011 Aug;11(8):6690-7. doi: 10.1166/jnn.2011.4237.

PMID- 33779884
OWN - NLM
STAT- MEDLINE
DCOM- 20220426
LR  - 20220716
IS  - 1573-7322 (Electronic)
IS  - 1382-4147 (Print)
IS  - 1382-4147 (Linking)
VI  - 27
IP  - 3
DP  - 2022 May
TI  - Prognostic impact of antiplatelet therapy in Takotsubo syndrome: a systematic 
      review and meta-analysis of the literature.
PG  - 857-868
LID - 10.1007/s10741-021-10099-5 [doi]
AB  - While the most recent evidence suggests a lack of benefit, antithrombotic therapy 
      is still extensively prescribed in patients with Takotsubo syndrome (TTS). The 
      objective of this study was to determine whether patients with TTS benefit from 
      anti-aggregation, in terms of either short-term or long-term outcomes. A 
      systematic review and meta-analysis was conducted. A comprehensive search of the 
      literature included MEDLINE, Cochrane Library, Clinicaltrials.gov, EU Clinical 
      Trial Register, References, and contact with the authors. Methodological quality 
      assessment and data extraction were systematically performed. The review adhered 
      to the PRISMA framework guidelines. A total of 86 citations were identified, six 
      being eligible for inclusion, for a total of 1997 patients. One of them 
      considered both short-term and long-term outcomes. One reported outcomes during 
      the index event, while the remaining four focused on potential long-term 
      benefits. They were all retrospective cohort studies.Based on our data, the 
      long-term use of antiplatelet therapy (AT) led to a significantly higher 
      incidence of the composite outcome (OR: 1.54; 95% CI 1.09-2.17; p = 0.014) and 
      overall mortality (OR 1.72; 95% CI 1.07-2.77; p = 0.027). The analysis did not 
      show a statistically significant difference in TTS recurrences, stroke/TIA, and 
      MI or CAD worsening with AT compared with no anti-aggregation. The AT in this 
      settings did not show any clear benefit in improving the long-term outcomes, and 
      it may be even detrimental and it may be detrimental. These results warrant 
      further future research and the design of adequately powered randomized 
      controlled trials focusing on the impact of aspirin on the outcomes in patients 
      presenting with TTS.
CI  - © 2021. The Author(s).
FAU - Rizzetto, Francesca
AU  - Rizzetto F
AD  - Division of Cardiology, Department of Medicine, University of Verona, Verona, 
      Italy.
FAU - Lia, Micaela
AU  - Lia M
AD  - Division of Cardiology, Department of Medicine, University of Verona, Verona, 
      Italy.
FAU - Widmann, Maddalena
AU  - Widmann M
AD  - Division of Cardiology, Department of Medicine, University of Verona, Verona, 
      Italy.
FAU - Tavella, Domenico
AU  - Tavella D
AD  - Division of Cardiology, Department of Medicine, University of Verona, Verona, 
      Italy.
FAU - Zanolla, Luisa
AU  - Zanolla L
AD  - Division of Cardiology, Department of Medicine, University of Verona, Verona, 
      Italy.
FAU - Pighi, Michele
AU  - Pighi M
AD  - Division of Cardiology, Department of Medicine, University of Verona, Verona, 
      Italy. michele.pighi@univr.it.
FAU - Ferrero, Valeria
AU  - Ferrero V
AD  - Division of Cardiology, Department of Medicine, University of Verona, Verona, 
      Italy.
FAU - Ribichini, Flavio Luciano
AU  - Ribichini FL
AD  - Division of Cardiology, Department of Medicine, University of Verona, Verona, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20210329
PL  - United States
TA  - Heart Fail Rev
JT  - Heart failure reviews
JID - 9612481
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - Prognosis
MH  - Retrospective Studies
MH  - *Takotsubo Cardiomyopathy/drug therapy
PMC - PMC9033728
OTO - NOTNLM
OT  - Antiplatelet
OT  - Antithrombotic
OT  - Aspirin
OT  - Broken heart syndrome
OT  - Stress cardiomyopathy
OT  - Takotsubo
COIS- The authors declare no competing interests.
EDAT- 2021/03/30 06:00
MHDA- 2022/04/27 06:00
CRDT- 2021/03/29 13:40
PHST- 2021/03/17 00:00 [accepted]
PHST- 2021/03/30 06:00 [pubmed]
PHST- 2022/04/27 06:00 [medline]
PHST- 2021/03/29 13:40 [entrez]
AID - 10.1007/s10741-021-10099-5 [pii]
AID - 10099 [pii]
AID - 10.1007/s10741-021-10099-5 [doi]
PST - ppublish
SO  - Heart Fail Rev. 2022 May;27(3):857-868. doi: 10.1007/s10741-021-10099-5. Epub 
      2021 Mar 29.

PMID- 36967780
OWN - NLM
STAT- MEDLINE
DCOM- 20230328
LR  - 20230328
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Understanding the dosing-time-dependent antihypertensive effect of valsartan and 
      aspirin through mathematical modeling.
PG  - 1110459
LID - 10.3389/fendo.2023.1110459 [doi]
LID - 1110459
AB  - Chronopharmacology of arterial hypertension impacts the long-term cardiovascular 
      risk of hypertensive subjects. Therefore, clinical and computational studies have 
      proposed optimizing antihypertensive medications' dosing time (Ta). However, the 
      causes and mechanisms underlying the Ta-dependency antihypertensive effect have 
      not been elucidated. Here we propose using a Ta- dependent effect model to 
      understand and predict the antihypertensive effect of valsartan and aspirin 
      throughout the day in subjects with grade I or II essential hypertension. The 
      model based on physiological regulation mechanisms includes a periodic function 
      for each parameter that changes significantly after treatment. Circadian 
      variations of parameters depending on the dosing time allowed the determination 
      of regulation mechanisms dependent on the circadian rhythm that were most 
      relevant for the action of each drug. In the case of valsartan, it is the 
      regulation of vasodilation and systemic vascular resistance. In the case of 
      aspirin, the antithrombotic effect generates changes in the sensitivity of 
      systemic vascular resistance and heart rate to changes in physical activity. 
      Dosing time-dependent models predict a more significant effect on systemic 
      vascular resistance and blood pressure when administering valsartan or aspirin at 
      bedtime. However, circadian dependence on the regulation mechanisms showed 
      different sensitivity of their circadian parameters and shapes of functions, 
      presenting different phase shifts and amplitude. Therefore, different mechanisms 
      of action and pharmacokinetic properties of each drug can generate different 
      profiles of Ta-dependence of antihypertensive effect and optimal dosing times.
CI  - Copyright © 2023 Cortés-Ríos and Rodriguez-Fernandez.
FAU - Cortés-Ríos, Javiera
AU  - Cortés-Ríos J
AD  - Institute for Biological and Medical Engineering, Schools of Engineering, 
      Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, 
      Santiago, Chile.
FAU - Rodriguez-Fernandez, Maria
AU  - Rodriguez-Fernandez M
AD  - Institute for Biological and Medical Engineering, Schools of Engineering, 
      Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, 
      Santiago, Chile.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230308
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Antihypertensive Agents)
RN  - 80M03YXJ7I (Valsartan)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Tetrazoles)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Humans
MH  - *Antihypertensive Agents
MH  - Valsartan
MH  - Aspirin/therapeutic use
MH  - Tetrazoles/pharmacology
MH  - Valine/pharmacology/therapeutic use
MH  - *Hypertension/drug therapy
PMC - PMC10031009
OTO - NOTNLM
OT  - aspirin
OT  - blood pressure
OT  - chronopharmacology
OT  - circadian rhythm
OT  - hypertension
OT  - mathematical modeling
OT  - valsartan
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/28 06:00
MHDA- 2023/03/28 19:05
CRDT- 2023/03/27 03:16
PHST- 2022/11/28 00:00 [received]
PHST- 2023/02/08 00:00 [accepted]
PHST- 2023/03/28 19:05 [medline]
PHST- 2023/03/27 03:16 [entrez]
PHST- 2023/03/28 06:00 [pubmed]
AID - 10.3389/fendo.2023.1110459 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Mar 8;14:1110459. doi: 
      10.3389/fendo.2023.1110459. eCollection 2023.

PMID- 21175237
OWN - NLM
STAT- MEDLINE
DCOM- 20110330
LR  - 20211020
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 71
IP  - 1
DP  - 2011 Jan 1
TI  - Should prophylactic low-dose aspirin therapy be continued in peptic ulcer 
      bleeding?
PG  - 1-10
LID - 10.2165/11585320-000000000-00000 [doi]
AB  - Patients taking low-dose aspirin for cardiovascular prevention who develop an 
      acute peptic ulcer bleeding event represent a serious challenge in clinical 
      practice. Aspirin discontinuation is associated with increased risk of developing 
      a new cardiovascular event, but there is little evidence on the outcomes and best 
      management strategy in the setting of an acute ulcer bleeding event. In this 
      clinical scenario, it is common clinical practice to interrupt aspirin treatment 
      for various, sometimes long, periods of time. A recent study suggests that 
      patients with bleeding ulcers who keep taking aspirin after successful endoscopic 
      therapy followed by high-dose intravenous pantoprazole, bolus of 80 mg followed 
      by 8 mg/h for 3 days, have a small increase in the risk of rebleeding but a lower 
      overall and cardiovascular 30-day mortality rate than those who stop taking 
      aspirin treatment. Based on current, although limited, data, we propose that 
      these patients should undergo early endoscopic therapy to control bleeding 
      followed by a high-dose intravenous PPI, with early reintroduction of aspirin 
      treatment within a 5-day window after the last dose. However, in patients taking 
      aspirin for the primary prevention of cardiovascular events, it seems reasonable 
      to stop aspirin treatment, re-evaluate the indication and, if needed, reintroduce 
      aspirin after the risk of ulcer rebleeding decreases, usually after hospital 
      discharge. In the presence of an acute ulcer bleeding event soon after the 
      placement of coronary stents, the risk of stent thrombosis with removal of 
      antiplatelet therapy is very high. We believe that early therapeutic endoscopy 
      and a high-dose intravenous PPI is advisable in order to maintain patients on 
      dual antiplatelet therapy. Until more evidence becomes available, clinicians will 
      have to rely on actual data and the use of common sense to select the best option 
      for the patient.
FAU - Sostres, Carlos
AU  - Sostres C
AD  - IIS Aragón, Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano 
      Blesa, Zaragoza, Spain.
FAU - Lanas, Angel
AU  - Lanas A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Endoscopy, Gastrointestinal
MH  - Humans
MH  - Omeprazole/administration & dosage/therapeutic use
MH  - Peptic Ulcer Hemorrhage/*chemically induced/drug therapy/therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*adverse 
      effects/therapeutic use
MH  - Primary Prevention
MH  - Proton Pump Inhibitors/administration & dosage/therapeutic use
MH  - Risk
MH  - Risk Factors
EDAT- 2010/12/24 06:00
MHDA- 2011/03/31 06:00
CRDT- 2010/12/24 06:00
PHST- 2010/12/24 06:00 [entrez]
PHST- 2010/12/24 06:00 [pubmed]
PHST- 2011/03/31 06:00 [medline]
AID - 1 [pii]
AID - 10.2165/11585320-000000000-00000 [doi]
PST - ppublish
SO  - Drugs. 2011 Jan 1;71(1):1-10. doi: 10.2165/11585320-000000000-00000.

PMID- 2426590
OWN - NLM
STAT- MEDLINE
DCOM- 19860917
LR  - 20220318
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 315
IP  - 6
DP  - 1986 Aug 7
TI  - The treatment of Kawasaki syndrome with intravenous gamma globulin.
PG  - 341-7
AB  - We compared the efficacy of intravenous gamma globulin plus aspirin with that of 
      aspirin alone in reducing the frequency of coronary-artery abnormalities in 
      children with acute Kawasaki syndrome in a multicenter, randomized trial. 
      Children randomly assigned to the gamma globulin group received intravenous gamma 
      globulin, 400 mg per kilogram of body weight per day, for four consecutive days; 
      both treatment groups received aspirin, 100 mg per kilogram per day, through the 
      14th day of illness, then 3 to 5 mg per kilogram per day. Two-dimensional 
      echocardiograms were interpreted blindly and independently by two or more 
      readers. Two weeks after enrollment, coronary-artery abnormalities were present 
      in 18 of 78 children (23 percent) in the aspirin group, as compared with 6 of 75 
      (8 percent) in the gamma globulin group (P = 0.01). Seven weeks after enrollment, 
      abnormalities were present in 14 of 79 children (18 percent) in the aspirin group 
      and in 3 of 79 (4 percent) in the gamma globulin group (P = 0.005). No child had 
      serious adverse effects from receiving gamma globulin. We conclude that high-dose 
      intravenous gamma globulin is safe and effective in reducing the prevalence of 
      coronary-artery abnormalities when administered early in the course of Kawasaki 
      syndrome.
FAU - Newburger, J W
AU  - Newburger JW
FAU - Takahashi, M
AU  - Takahashi M
FAU - Burns, J C
AU  - Burns JC
FAU - Beiser, A S
AU  - Beiser AS
FAU - Chung, K J
AU  - Chung KJ
FAU - Duffy, C E
AU  - Duffy CE
FAU - Glode, M P
AU  - Glode MP
FAU - Mason, W H
AU  - Mason WH
FAU - Reddy, V
AU  - Reddy V
FAU - Sanders, S P
AU  - Sanders SP
AU  - et al.
LA  - eng
GR  - HL 34545/HL/NHLBI NIH HHS/United States
GR  - RR 2172/RR/NCRR NIH HHS/United States
GR  - RR 69/RR/NCRR NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (gamma-Globulins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aneurysm/prevention & control
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/drug therapy
MH  - Drug Therapy, Combination
MH  - Echocardiography
MH  - Female
MH  - Humans
MH  - Infant
MH  - Injections, Intravenous
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*therapy
MH  - Random Allocation
MH  - gamma-Globulins/*administration & dosage/adverse effects
EDAT- 1986/08/07 00:00
MHDA- 1986/08/07 00:01
CRDT- 1986/08/07 00:00
PHST- 1986/08/07 00:00 [pubmed]
PHST- 1986/08/07 00:01 [medline]
PHST- 1986/08/07 00:00 [entrez]
AID - 10.1056/NEJM198608073150601 [doi]
PST - ppublish
SO  - N Engl J Med. 1986 Aug 7;315(6):341-7. doi: 10.1056/NEJM198608073150601.

PMID- 32052203
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20210629
IS  - 1534-3111 (Electronic)
IS  - 1522-6417 (Print)
IS  - 1522-6417 (Linking)
VI  - 22
IP  - 2
DP  - 2020 Feb 12
TI  - Novel Interventions for the Prevention of Preeclampsia.
PG  - 17
LID - 10.1007/s11906-020-1026-8 [doi]
AB  - PURPOSE OF REVIEW: To review the rationale and biological plausibility and 
      discuss the current research on novel interventions for the prevention of 
      preeclampsia. RECENT FINDINGS: Preeclampsia affects up to 8% of pregnancies 
      worldwide and remains a major cause of maternal and neonatal morbidity and 
      mortality. Multiple medications have been investigated or repurposed as potential 
      effective interventions for preeclampsia prevention. Aspirin is currently the 
      only drug for which there is some evidence of benefit for preeclampsia 
      prevention, and its use is recommended by professional societies for pregnancies 
      at risk. Statins have shown promise for prevention of preeclampsia in animal 
      models and human pilot studies, without any trend or concerns for safety signals 
      or teratogenicity. The use of metformin has also gained popularity in 
      experimental studies, but observations from randomized clinical trials were not 
      consistent on its utility as a possible intervention for preeclampsia prevention. 
      While initial studies evaluating esomeprazole were promising, randomized trials 
      failed to show benefit. Contemporary research shows exciting new opportunities 
      for prophylactic treatment for preeclampsia, to prevent this debilitating and 
      life-threatening disease.
FAU - Ma'ayeh, Marwan
AU  - Ma'ayeh M
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, The 
      Ohio State University College of Medicine, 395 W 12th Avenue, Columbus, OH, 
      43210, USA. Marwan.Ma'ayeh@osumc.edu.
FAU - Rood, Kara M
AU  - Rood KM
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, The 
      Ohio State University College of Medicine, 395 W 12th Avenue, Columbus, OH, 
      43210, USA.
FAU - Kniss, Douglas
AU  - Kniss D
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, The 
      Ohio State University College of Medicine, 395 W 12th Avenue, Columbus, OH, 
      43210, USA.
FAU - Costantine, Maged M
AU  - Costantine MM
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, The 
      Ohio State University College of Medicine, 395 W 12th Avenue, Columbus, OH, 
      43210, USA.
LA  - eng
GR  - U54 HD047891/HD/NICHD NIH HHS/United States
GR  - UG1 HD027915/HD/NICHD NIH HHS/United States
GR  - UG3 HL140131/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200212
PL  - United States
TA  - Curr Hypertens Rep
JT  - Current hypertension reports
JID - 100888982
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - *Hypertension
MH  - *Pre-Eclampsia/prevention & control
MH  - Pregnancy
PMC - PMC8237364
MID - NIHMS1717595
OTO - NOTNLM
OT  - Aspirin
OT  - Esomeprazole
OT  - Metformin
OT  - Pravastatin
OT  - Preeclampsia
OT  - Pregnancy
COIS- Conflict of Interest: The authors declare no conflicts of interest relevant to 
      this manuscript
EDAT- 2020/02/14 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/02/14 06:00
PHST- 2020/02/14 06:00 [entrez]
PHST- 2020/02/14 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1007/s11906-020-1026-8 [pii]
AID - 10.1007/s11906-020-1026-8 [doi]
PST - epublish
SO  - Curr Hypertens Rep. 2020 Feb 12;22(2):17. doi: 10.1007/s11906-020-1026-8.

PMID- 8696691
OWN - NLM
STAT- MEDLINE
DCOM- 19960904
LR  - 20131121
IS  - 1210-7816 (Print)
IS  - 1210-7816 (Linking)
VI  - 45
IP  - 3
DP  - 1996 May
TI  - [Acetylsalicylic acid matrices for use in stomatology].
PG  - 123-4
AB  - In stomatological practice acetylsalicylic acid in the form of preparations 
      suitable for insertion into the created wound is used to alleviated pain after 
      extraction of teeth with good results. Such a preparation are also tablets 
      containing 85 mg of the above-mentioned drug with retarded release. They possess 
      the character of a hydrophilic matrix, which after administration softens and is 
      adapted to the shape of the wound. Tentative use in patients gave positive 
      experience.
FAU - Rabisková, M
AU  - Rabisková M
AD  - Ustav technologie lékŭ Farmaceutické fakulty Veterinární a farmaceutické 
      univerzity, Brno.
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Matrice s kyselinou acetylsalicylovou pro stomatologii.
PL  - Czech Republic
TA  - Ceska Slov Farm
JT  - Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske 
      farmaceuticke spolecnosti
JID - 9433765
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Drug Compounding
MH  - Humans
MH  - Pain, Postoperative/*drug therapy
MH  - Tablets
MH  - *Tooth Extraction
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
PST - ppublish
SO  - Ceska Slov Farm. 1996 May;45(3):123-4.

PMID- 2271076
OWN - NLM
STAT- MEDLINE
DCOM- 19910227
LR  - 20131121
IS  - 0014-827X (Print)
IS  - 0014-827X (Linking)
VI  - 45
IP  - 6
DP  - 1990 Jun
TI  - Determination of salicilic acid in saliva by high-performance liquid 
      chromatography.
PG  - 683-7
AB  - A sensitive reversed-phase HPLC method with fluorimetric detection was developed 
      for the determination of salicilic acid in saliva samples. The method, involving 
      a preliminary solid-phase extraction procedure, was found to be suitable for the 
      determination of salivary salicilic acid concentrations following the 
      administration of a single oral dose of some commercial acetylsalicilic acid 
      formulations.
FAU - Cavrini, V
AU  - Cavrini V
AD  - Dipartimento di Scienze Farmaceutiche, Università, Bologna, Italy.
FAU - Gatti, R
AU  - Gatti R
FAU - Di Pietra, A M
AU  - Di Pietra AM
LA  - eng
PT  - Journal Article
PL  - France
TA  - Farmaco
JT  - Farmaco (Societa chimica italiana : 1989)
JID - 8912641
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid
MH  - Humans
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Saliva/*chemistry
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
PST - ppublish
SO  - Farmaco. 1990 Jun;45(6):683-7.

PMID- 484098
OWN - NLM
STAT- MEDLINE
DCOM- 19791128
LR  - 20131121
IS  - 0044-4197 (Print)
IS  - 0044-4197 (Linking)
VI  - 101
IP  - 9
DP  - 1979
TI  - [Influence of na-salicylate on uterine motility in labour (author's transl)].
PG  - 592-4
AB  - A dosage of 10 mg/kg body weight Na-salicylate has no depressive effect on 
      uterine motility. The examination carried out intra partum in the condition of 
      normal uterine activity support our opinion that relatively high doses of 3--5 g 
      per day or the simultaneous administration of beta-adrenergical substances are 
      necessary to obtain an effective tocolysis.
FAU - Zanke, S
AU  - Zanke S
FAU - Seewald, H J
AU  - Seewald HJ
FAU - Michels, W
AU  - Michels W
FAU - Kunath, H
AU  - Kunath H
FAU - Voigt, R
AU  - Voigt R
FAU - Möller, R
AU  - Möller R
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Der Einfluss von Natriumsalizylat auf die Uterusmotilität sub partu.
PL  - Germany
TA  - Zentralbl Gynakol
JT  - Zentralblatt fur Gynakologie
JID - 21820100R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Humans
MH  - Labor, Obstetric/*drug effects
MH  - Pregnancy
MH  - Uterine Contraction/*drug effects
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Zentralbl Gynakol. 1979;101(9):592-4.

PMID- 33892182
OWN - NLM
STAT- MEDLINE
DCOM- 20211005
LR  - 20211005
IS  - 1701-2163 (Print)
IS  - 1701-2163 (Linking)
VI  - 43
IP  - 8
DP  - 2021 Aug
TI  - Aspirin for Endometrial Preparation in Patients Undergoing IVF: A Systematic 
      Review and Meta-analysis.
PG  - 984-992.e2
LID - S1701-2163(21)00309-1 [pii]
LID - 10.1016/j.jogc.2021.03.018 [doi]
AB  - OBJECTIVE: To investigate the effect of aspirin on IVF success rates when used as 
      an adjuvant treatment for endometrial preparation. DATA SOURCES: Relevant 
      publications were comprehensively selected from PubMed, MEDLINE, Embase, and the 
      Cochrane Central Register of Controlled Trials (CENTRAL) up to November 15, 2020. 
      STUDY SELECTION: Randomized controlled trials (RCTs) and retrospective cohort 
      studies that used aspirin as an adjuvant treatment for endometrial preparation 
      and reported subsequent pregnancy outcomes were included. Studies were excluded 
      if aspirin was used before and/or during ovarian stimulation. DATA EXTRACTION AND 
      SYNTHESIS: This systematic review and meta-analysis included a total of 7 
      studies. Risk of bias assessment was based on the methodology and categories 
      listed in the Cochrane Handbook for the RCTs and the Newcastle-Ottawa scale for 
      the retrospective studies. The primary outcome was live birth rate. Summary 
      measures were reported as odds ratios (ORs) with 95% confidence intervals (CIs). 
      There was significant evidence that aspirin for endometrial preparation improved 
      live birth rates (OR  1.52; 95% CI   1.15-2.00). No effect was noted for clinical 
      pregnancy rates (OR  1.37; 95% CI   1.00-1.87); however, aspirin was associated 
      with improved pregnancy rates in a subgroup analysis of patients receiving oocyte 
      donation (OR 2.53; 95% CI 1.30-4.92) and in the sensitivity analysis (OR 1.3; 95% 
      CI   1.02-1.66). No effect of aspirin was found for implantation or miscarriage 
      rates (OR 1.31; 95% CI  0.51-3.36 and OR 0.41; 95% CI  0.02-7.42, respectively). 
      CONCLUSION: These findings support a beneficial effect of aspirin for endometrial 
      preparation on IVF success rates, mainly live birth rates, outside the context of 
      ovarian stimulation. However, this evidence is based on poor quality data and 
      needs to be confirmed with high-quality RCTs.
CI  - Copyright © 2021 The Society of Obstetricians and Gynaecologists of Canada/La 
      Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. 
      All rights reserved.
FAU - Mourad, Ali
AU  - Mourad A
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of 
      Montréal, Montréal, QC; OVO Fertility Clinic, Montréal, QC.
FAU - Antaki, Roland
AU  - Antaki R
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of 
      Montréal, Montréal, QC; OVO Fertility Clinic, Montréal, QC. Electronic address: 
      r.antaki@cliniqueovo.com.
FAU - Jamal, Wael
AU  - Jamal W
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of 
      Montréal, Montréal, QC; OVO Fertility Clinic, Montréal, QC.
FAU - Albaini, Obey
AU  - Albaini O
AD  - Department of Research, Gilbert and Rose-Marie Chagouri School of Medicine, 
      Lebanese American University, Beirut, Lebanon.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20210421
PL  - Netherlands
TA  - J Obstet Gynaecol Can
JT  - Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et 
      gynecologie du Canada : JOGC
JID - 101126664
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abortion, Spontaneous
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Fertilization in Vitro
MH  - Humans
MH  - *Live Birth/epidemiology
MH  - Ovulation Induction
MH  - Pregnancy
MH  - Pregnancy Rate
OTO - NOTNLM
OT  - aspirin
OT  - embryo
OT  - endometrium
OT  - fertilization in vitro
OT  - live birth
OT  - pregnancy
EDAT- 2021/04/24 06:00
MHDA- 2021/10/06 06:00
CRDT- 2021/04/23 20:15
PHST- 2021/01/07 00:00 [received]
PHST- 2021/03/22 00:00 [revised]
PHST- 2021/03/23 00:00 [accepted]
PHST- 2021/04/24 06:00 [pubmed]
PHST- 2021/10/06 06:00 [medline]
PHST- 2021/04/23 20:15 [entrez]
AID - S1701-2163(21)00309-1 [pii]
AID - 10.1016/j.jogc.2021.03.018 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Can. 2021 Aug;43(8):984-992.e2. doi: 
      10.1016/j.jogc.2021.03.018. Epub 2021 Apr 21.

PMID- 28434157
OWN - NLM
STAT- MEDLINE
DCOM- 20180716
LR  - 20220129
IS  - 1573-7292 (Electronic)
IS  - 1389-9600 (Print)
IS  - 1389-9600 (Linking)
VI  - 16
IP  - 4
DP  - 2017 Oct
TI  - General practitioner attitudes towards prescribing aspirin to carriers of Lynch 
      Syndrome: findings from a national survey.
PG  - 509-516
LID - 10.1007/s10689-017-9986-9 [doi]
AB  - A dose non-inferiority study comparing 100 mg, 300 mg and 600 mg of aspirin for 
      cancer prevention among Lynch Syndrome carriers is underway (Colorectal 
      Adenoma/Carcinoma Prevention Programme trial 3, CaPP3). To guide implementation 
      of the findings, we investigated general practitioner (GP) attitudes towards 
      aspirin prescribing for Lynch Syndrome carriers. We surveyed 1007 UK GPs (9.6% 
      response rate). Using a within-subjects design, GPs read a statement on harms and 
      benefits of aspirin and indicated their willingness to prescribe aspirin at three 
      doses (100 mg, 300 mg, 600 mg). Approximately two-thirds (70.8%) of GPs had heard 
      of Lynch Syndrome or its associated names, and among those 46.7% were aware of 
      the cancer preventive effects of aspirin among carriers. Two-thirds (68.1%) of 
      GPs reported feeling comfortable discussing harms and benefits of aspirin with a 
      Lynch Syndrome patient. Willingness to prescribe was 91.3% at 100 mg, and 
      declined to 81.8% at 300 mg and 62.3% at 600 mg (p < 0.001). In multivariable 
      analyses, willingness to prescribe (600 mg) was higher among GPs ≥50 years (OR 
      1.46, 95% CI 1.03-2.07), more experienced GPs (OR 1.50, 95% CI 1.10-2.04), GPs 
      who were aware of the cancer preventive effects of aspirin (OR 1.58, 95% CI 
      1.20-2.09), and those who reported seeing a Lynch Syndrome patient in practice 
      (OR 1.44, 95% CI 1.01-2.05, p = 0.045). GPs report limited awareness of Lynch 
      Syndrome and the preventive effects of aspirin among carriers. To ensure the 
      optimal dose identified in the CaPP3 trial is readily available to patients, 
      prescribing guidance and strategies to educate GPs should be developed.
FAU - Smith, Samuel G
AU  - Smith SG
AD  - Leeds Institute of Health Sciences, University of Leeds, Floor 10, Worsley 
      Building, Leeds, LS2 9JT, UK. s.smith1@leeds.ac.uk.
AD  - Wolfson Institute of Preventive Medicine, Queen Mary University of London, 
      London, UK. s.smith1@leeds.ac.uk.
FAU - Foy, Robbie
AU  - Foy R
AD  - Leeds Institute of Health Sciences, University of Leeds, Floor 10, Worsley 
      Building, Leeds, LS2 9JT, UK.
FAU - McGowan, Jennifer
AU  - McGowan J
AD  - Institute of Epidemiology and Healthcare, University College London, London, UK.
FAU - Kobayashi, Lindsay C
AU  - Kobayashi LC
AD  - Harvard T. H. Chan School of Public Health, Center for Population and Development 
      Studies, Harvard University, Cambridge, MA, USA.
FAU - Burn, John
AU  - Burn J
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle, UK.
FAU - Brown, Karen
AU  - Brown K
AD  - Department of Cancer Studies, University of Leicester, Leicester, UK.
FAU - Side, Lucy
AU  - Side L
AD  - Institute for Women's Health, University College London, London, UK.
FAU - Cuzick, Jack
AU  - Cuzick J
AD  - Wolfson Institute of Preventive Medicine, Queen Mary University of London, 
      London, UK.
LA  - eng
GR  - 13101/CRUK_/Cancer Research UK/United Kingdom
GR  - C42785/A17965/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Fam Cancer
JT  - Familial cancer
JID - 100898211
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Attitude of Health Personnel
MH  - Colorectal Neoplasms, Hereditary Nonpolyposis/genetics/*prevention & control
MH  - Female
MH  - *General Practitioners
MH  - Health Care Surveys
MH  - Heterozygote
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - United Kingdom
PMC - PMC5603645
OTO - NOTNLM
OT  - Aspirin
OT  - Chemoprevention
OT  - Implementation
OT  - Lynch Syndrome
OT  - Prescribing
OT  - Preventive therapy
COIS- The authors declare that they have no conflict of interest.
EDAT- 2017/04/24 06:00
MHDA- 2018/07/17 06:00
CRDT- 2017/04/24 06:00
PHST- 2017/04/24 06:00 [pubmed]
PHST- 2018/07/17 06:00 [medline]
PHST- 2017/04/24 06:00 [entrez]
AID - 10.1007/s10689-017-9986-9 [pii]
AID - 9986 [pii]
AID - 10.1007/s10689-017-9986-9 [doi]
PST - ppublish
SO  - Fam Cancer. 2017 Oct;16(4):509-516. doi: 10.1007/s10689-017-9986-9.

PMID- 7065319
OWN - NLM
STAT- MEDLINE
DCOM- 19820527
LR  - 20190514
IS  - 0090-0036 (Print)
IS  - 1541-0048 (Electronic)
IS  - 0090-0036 (Linking)
VI  - 72
IP  - 4
DP  - 1982 Apr
TI  - Aspirin and myocardial infarction in young women.
PG  - 389-91
AB  - To assess whether aspirin reduces the risk of a first myocardial infarction (MI) 
      in young women, we evaluated data from a case-control study among women less than 
      50 years of age without a prior MI: 48 of 551 cases of MI and 67 of 896 hospital 
      controls had taken aspirin regularly for at least 12 weeks immediately before 
      admission. The relative risk estimate was 0.8 upon allowance for confounding 
      factors but it was not statistically significant (95 per cent confidence 
      interval, 0.5-1.4). These data alone do not provide evidence of protection by 
      aspirin against a first infarction in young women.
FAU - Rosenberg, L
AU  - Rosenberg L
FAU - Slone, D
AU  - Slone D
FAU - Shapiro, S
AU  - Shapiro S
FAU - Kaufman, D W
AU  - Kaufman DW
FAU - Miettinen, O S
AU  - Miettinen OS
FAU - Stolley, P D
AU  - Stolley PD
LA  - eng
GR  - 223-76-3016/PHS HHS/United States
GR  - N01-HD-6-2849/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Public Health
JT  - American journal of public health
JID - 1254074
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Preventive Medicine
MH  - Risk
PMC - PMC1649911
EDAT- 1982/04/01 00:00
MHDA- 1982/04/01 00:01
CRDT- 1982/04/01 00:00
PHST- 1982/04/01 00:00 [pubmed]
PHST- 1982/04/01 00:01 [medline]
PHST- 1982/04/01 00:00 [entrez]
AID - 10.2105/ajph.72.4.389 [doi]
PST - ppublish
SO  - Am J Public Health. 1982 Apr;72(4):389-91. doi: 10.2105/ajph.72.4.389.

PMID- 9122273
OWN - NLM
STAT- MEDLINE
DCOM- 19970422
LR  - 20131121
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 52
IP  - 2
DP  - 1997 Feb
TI  - Discrepancy among dissolution rates of commercial tables as a function of the 
      dissolution method. Part 7: Aspirin.
PG  - 145-9
AB  - The dissolution rate of fifteen batches of commercial aspirin tablets 
      manufactured by five leading pharmaceutical companies was determined by closed 
      and open dissolution systems. The most consistent results were those obtained by 
      the USP method. Inter-batch as well as inter-brand variations were found to be 
      more evidently detected and evaluated by adopting the USP and beaker methods, 
      respectively. The bioavailability of these products was assessed in human 
      subjects according to a cross-over design system. The following pharmacokinetic 
      parameters for the drug were computed, viz., maximum excretion rate, elimination 
      rate constant, half-life time, area under excretion rate versus time curve and 
      total amount of drug excreted during 24 h following administration of a single 
      oral dose. Based on the values of the correlation coefficient of the in vitro 
      results obtained by different methods with the in vivo results, the beaker method 
      appears to correlate best with the area under excretion rate versus time curve 
      and total amount of drug excreted. Thus, determination of the dissolution rate of 
      aspirin tablets by the beaker method can be considered as a reliable tool for 
      predicting the in vivo performance of the preparation.
FAU - Ammar, H A
AU  - Ammar HA
AD  - Department of Pharmaceutical Sciences, National Research Center, Dokki, Cairo, 
      Egypt.
FAU - el-Nahhas, S A
AU  - el-Nahhas SA
FAU - Emara, L H
AU  - Emara LH
FAU - Ghorab, M M
AU  - Ghorab MM
FAU - Salama, H A
AU  - Salama HA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analgesics, Non-Narcotic/*administration & dosage/*pharmacokinetics
MH  - Area Under Curve
MH  - Aspirin/*administration & dosage/*pharmacokinetics
MH  - Biological Availability
MH  - Chemistry, Pharmaceutical
MH  - Cross-Over Studies
MH  - Half-Life
MH  - Humans
MH  - Middle Aged
MH  - Solubility
MH  - Tablets
EDAT- 1997/02/01 00:00
MHDA- 1997/02/01 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1997/02/01 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1997 Feb;52(2):145-9.

PMID- 3318433
OWN - NLM
STAT- MEDLINE
DCOM- 19871223
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 83
IP  - 4B
DP  - 1987 Oct 30
TI  - Results of a six-month study comparing the safety and efficacy of nabumetone and 
      aspirin in the treatment of osteoarthritis.
PG  - 74-7
AB  - The safety and efficacy of nabumetone (1,000 mg at bedtime) were compared with 
      those of aspirin (900 mg four times daily) in the treatment of osteoarthritis in 
      adult patients in a private practice setting as part of a six-month, 
      double-blind, controlled, randomized, parallel group study. At screening, 
      baseline, and Days 7, 14, 28, 56, 112, and 168, efficacy was evaluated according 
      to independent assessments by the patients and the physician of overall 
      osteoarthritic activity and pain and by the physician's assessment with respect 
      to a defined activity. Of the 40 patients enrolled, 37 were evaluable for 
      efficacy (19 in the nabumetone group and 18 in the aspirin group). Demographic 
      parameters and diagnostic criteria for osteoarthritis were comparable between the 
      groups, although there was a preponderance of women in the nabumetone group. 
      Significant improvement from baseline in all five efficacy parameters was 
      observed in both groups. Safety was evaluated for all 20 enrolled patients in 
      each group. The percentage of aspirin-treated patients who withdrew from the 
      study due to adverse experiences was greater (60 percent versus 20 percent), as 
      was the number with at least one treatment-related adverse experience (19, or 95 
      percent, versus 11, or 55 percent). Treatment-related adverse experiences 
      described as moderate or severe were reported by 70 percent of the 
      aspirin-treated patients and by 35 percent of the nabumetone-treated patients. In 
      this study, nabumetone 1,000 mg at bedtime had an acceptable safety profile and 
      was as effective as aspirin 900 mg four times daily in the treatment of 
      osteoarthritis.
FAU - Mullen, B J
AU  - Mullen BJ
AD  - Polyclinic, Seattle, Washington 98122.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Butanones)
RN  - LW0TIW155Z (Nabumetone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Butanones/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nabumetone
MH  - Osteoarthritis/*drug therapy
MH  - Random Allocation
EDAT- 1987/10/30 00:00
MHDA- 1987/10/30 00:01
CRDT- 1987/10/30 00:00
PHST- 1987/10/30 00:00 [pubmed]
PHST- 1987/10/30 00:01 [medline]
PHST- 1987/10/30 00:00 [entrez]
AID - 0002-9343(87)90599-7 [pii]
AID - 10.1016/0002-9343(87)90599-7 [doi]
PST - ppublish
SO  - Am J Med. 1987 Oct 30;83(4B):74-7. doi: 10.1016/0002-9343(87)90599-7.

PMID- 9466476
OWN - NLM
STAT- MEDLINE
DCOM- 19980312
LR  - 20190914
IS  - 1073-2322 (Print)
IS  - 1073-2322 (Linking)
VI  - 9
IP  - 1
DP  - 1998 Jan
TI  - Dose-dependent effect of diaspirin cross-linked hemoglobin on regional blood 
      circulation of severely hemorrhaged rats.
PG  - 65-73
AB  - Diaspirin cross-linked hemoglobin (DCLHb), a hemoglobin-based blood substitute, 
      has been found to improve systemic hemodynamics, cutaneous oxygen tension, and 
      normalization of blood lactate levels and acid-base equilibrium after hemorrhage 
      in animals. The present study was conducted to determine the dose-dependent 
      effect of a 10% solution of DCLHb (20, 50, and 100% of shed blood volume; SBV) on 
      regional blood circulation in hemorrhaged rats. Hemorrhage was induced in 
      urethane-anesthetized rats by bleeding them at a rate of approximately .5 to 1 
      mL/min until a mean arterial pressure of 35-40 mmHg was achieved. This was 
      maintained for up to 90 min to reach a base deficit of more than -12 mmol/L. 
      Hemorrhage significantly decreased oxygen consumption, mean arterial pressure, 
      cardiac output, stroke volume, and regional blood circulation, but increased 
      total peripheral resistance. The vehicle Ringer's lactate (RL at 20% of SBV, 
      intravenously) did not produce any improvements in oxygen consumption, base 
      deficit, systemic hemodynamics, and regional blood circulation. DCLHb increased 
      oxygen consumption, decreased base deficit, and produced significant improvements 
      in systemic hemodynamics and regional blood flow in a dose-dependent manner. The 
      increase in blood flow was highly significant until 60 min, but was less marked 
      at 120 min, after resuscitation with DCLHb. Resuscitation with RL (300% of SBV) 
      significantly improved systemic and regional blood circulation. However, the 
      improvement was greater after resuscitation with DCLHb (50 or 100% of SBV) as 
      compared with RL at 300% SBV. DCLHb in the dose of 50% of SBV produced maximal 
      resuscitative effects, which were comparable to a DCLHb dose of 100% of SBV. The 
      effect of DCLHb at 50% of SBV on renal cortical blood perfusion, concentration of 
      moving red blood cells (CMBC), and blood velocity was also studied using laser 
      Doppler flowmetry. Hemorrhage produced a decrease in renal cortical blood 
      perfusion (85.3%), which was due to a decrease in the CMBC (61.0%) and their 
      velocity (64.2%). Resuscitation with the RL did not produce any improvement in 
      renal cortical perfusion. However, resuscitation with DCLHb significantly 
      increased renal cortical perfusion (364.7%) due to an increase in both CMBC 
      (123.4%) and their velocity (109.9%). It is concluded that DCLHb in a dose of 50% 
      of SBV produces maximal improvement in regional blood circulation of hemorrhaged 
      rats.
FAU - Gulati, A
AU  - Gulati A
AD  - Department of Pharmaceutics & Pharmacodynamics, The University of Illinois at 
      Chicago, Health Sciences Center 60612, USA.
FAU - Sen, A P
AU  - Sen AP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Shock
JT  - Shock (Augusta, Ga.)
JID - 9421564
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acid-Base Equilibrium/drug effects
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/*therapeutic use
MH  - Male
MH  - Microcirculation/drug effects
MH  - Oxygen Consumption/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Renal Circulation/drug effects
MH  - Shock, Hemorrhagic/*drug therapy
EDAT- 1998/02/18 00:00
MHDA- 1998/02/18 00:01
CRDT- 1998/02/18 00:00
PHST- 1998/02/18 00:00 [pubmed]
PHST- 1998/02/18 00:01 [medline]
PHST- 1998/02/18 00:00 [entrez]
AID - 10.1097/00024382-199801000-00010 [doi]
PST - ppublish
SO  - Shock. 1998 Jan;9(1):65-73. doi: 10.1097/00024382-199801000-00010.

PMID- 8644666
OWN - NLM
STAT- MEDLINE
DCOM- 19960716
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 77
IP  - 12
DP  - 1996 May 15
TI  - Intracoronary stenting without intravascular ultrasound guidance followed by 
      antiplatelet therapy with aspirin alone in selected patients.
PG  - 1105-7
AB  - One hundred selected patients with 103 lesions were treated with the deployment 
      of 117 Palmaz-Schatz stents without the use of intravascular ultrasound, followed 
      by antiplatelet therapy with aspirin alone. Angiographic and clinical follow-up 
      revealed 2 stent thromboses; 3 stents required redilation, and 3 patients 
      required intervention for disease progression elsewhere, suggesting that this 
      approach can be applied effectively in selected patients.
FAU - Roy, P R
AU  - Roy PR
AD  - Cardiac Catheterisation Laboratory, Department of Cardiology, St. Vincent's 
      Hospital, Darlinghurst, Sydney, Australia.
FAU - Lowe, H C
AU  - Lowe HC
FAU - Walker, B W
AU  - Walker BW
FAU - Baron, D W
AU  - Baron DW
FAU - Gavaghan, T P
AU  - Gavaghan TP
FAU - Morgan, J J
AU  - Morgan JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Combined Modality Therapy
MH  - Constriction, Pathologic
MH  - Coronary Angiography
MH  - Coronary Disease/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Stents
EDAT- 1996/05/15 00:00
MHDA- 1996/05/15 00:01
CRDT- 1996/05/15 00:00
PHST- 1996/05/15 00:00 [pubmed]
PHST- 1996/05/15 00:01 [medline]
PHST- 1996/05/15 00:00 [entrez]
AID - S0002914996001415 [pii]
AID - 10.1016/s0002-9149(96)00141-5 [doi]
PST - ppublish
SO  - Am J Cardiol. 1996 May 15;77(12):1105-7. doi: 10.1016/s0002-9149(96)00141-5.

PMID- 2718200
OWN - NLM
STAT- MEDLINE
DCOM- 19890612
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 20
IP  - 5
DP  - 1989 May
TI  - Effect of therapy on platelet activating factor-induced aggregation in acute 
      stroke.
PG  - 609-11
AB  - Platelet activating factor, a potent inducer of in vivo platelet activation and 
      thrombosis, has been shown to be excessively active in acute ischemic stroke 
      patients. Therefore, we studied the effect of aspirin/dipyridamole therapy in 
      inhibiting platelet activating factor-induced platelet activation in acute 
      ischemic stroke patients, 23 taking aspirin/dipyridamole and 21 untreated. 
      Aspirin/dipyridamole-treated patients failed to show suppression of platelet 
      activating factor-induced platelet aggregation even though collagen-induced 
      activation was inhibited, suggesting that platelet activating factor acts by 
      cyclooxygenase-independent mechanisms. Failure to suppress 
      cyclooxygenase-independent mechanisms of platelet activation may explain the 
      limited usefulness of current antiplatelet therapy, aspirin in particular, in 
      stroke prevention. The role of selective platelet activating factor antagonists 
      both in isolation and combined with aspirin needs to be investigated for their 
      usefulness in the treatment and prevention of ischemic stroke.
FAU - Joseph, R
AU  - Joseph R
AD  - Department of Neurology, Henry Ford Hospital, Detroit, Michigan 48202.
FAU - Welch, K M
AU  - Welch KM
FAU - D'Andrea, G
AU  - D'Andrea G
LA  - eng
GR  - NS 23393/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Activating Factor)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cerebrovascular Disorders/*blood/drug therapy
MH  - Dipyridamole/*pharmacology/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Activating Factor/*antagonists & inhibitors
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/therapeutic use
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
AID - 10.1161/01.str.20.5.609 [doi]
PST - ppublish
SO  - Stroke. 1989 May;20(5):609-11. doi: 10.1161/01.str.20.5.609.

PMID- 19718475
OWN - NLM
STAT- MEDLINE
DCOM- 20091125
LR  - 20151119
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 102
IP  - 3
DP  - 2009 Sep
TI  - Distribution of dipyridamole in blood components among post-stroke patients 
      treated with extended release formulation.
PG  - 538-43
LID - 10.1160/TH09-03-0158 [doi]
AB  - Extended release dipyridamole (ERD) is widely used in patients after ischaemic 
      stroke; however, the ability of this antithrombotic agent to be stored in 
      different blood cells has never been explored in post-stroke patients. We 
      hypothesised that since ERD is known to be highly lipophilic, the drug may be 
      present not only in plasma, but also accumulated in platelets, leukocytes, and 
      erythrocytes. Fifteen patients after documented ischaemic stroke were treated 
      with Aggrenox (ERD and low-dose aspirin combination) BID for 30 days, and 12 of 
      them completed the study. ERD concentrations in blood cells and platelet-poor 
      plasma were measured by spectrofluorimetry at Baseline, Day 14, and Day 30 after 
      the initiation of therapy. The background level of spectrofluorometry readings 
      differs slightly among the blood components (132-211 ng/ml) due to the 
      differences in the preparation of samples and cell isolation techniques. As 
      expected, two weeks of ERD therapy produced steady-state plasma concentration of 
      dipyridamole already at Day 14 (1,680 +/- 542 ng/ ml), followed by a slight not 
      significant decrease at one month (1,619 +/- 408 ng/ml). Two weeks of therapy was 
      sufficient to achieve a consistent dipyridamole accumulation in erythrocytes (361 
      +/- 43 ng/ml), but not in platelets (244 +/- 78 ng/ml), or leukocytes (275 +/- 49 
      ng/ml). In fact, white blood cells continued dipyridamole intake beyond 14 days 
      period, and this increase (398 +/- 66 ng/ml) was significant (p = 0.02) at 30 
      days. Treatment with ERD in post-stroke patients resulted not only in achievement 
      of therapeutic plasma dipyridamole concentrations, but also deposition of the 
      drug in erythrocytes and leukocytes, but not in platelets. If confirmed, these 
      data will affect our better understanding of dipyridamole pleiotropy, and may 
      explain long-term benefit of ERD formulation.
FAU - Serebruany, Victor
AU  - Serebruany V
AD  - HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD, USA. 
      Heartdrug@aol.com
FAU - Sabaeva, Elena
AU  - Sabaeva E
FAU - Booze, Christopher
AU  - Booze C
FAU - Atar, Oliver D
AU  - Atar OD
FAU - Eisert, Christian
AU  - Eisert C
FAU - Hanley, Dan
AU  - Hanley D
CN  - Aggrenox Compliance Task Force
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Blood Platelets/drug effects
MH  - Delayed-Action Preparations
MH  - Dipyridamole/*administration & dosage/*blood/pharmacokinetics/therapeutic use
MH  - Drug Combinations
MH  - Erythrocytes/drug effects
MH  - Female
MH  - Humans
MH  - Ischemia/drug therapy
MH  - Leukocytes/drug effects
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Spectrometry, Fluorescence/methods
MH  - Stroke/*drug therapy
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2009/09/01 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/09/01 09:00
PHST- 2009/09/01 09:00 [entrez]
PHST- 2009/09/01 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 09-03-0158 [pii]
AID - 10.1160/TH09-03-0158 [doi]
PST - ppublish
SO  - Thromb Haemost. 2009 Sep;102(3):538-43. doi: 10.1160/TH09-03-0158.

PMID- 29349896
OWN - NLM
STAT- MEDLINE
DCOM- 20180912
LR  - 20181201
IS  - 1365-2613 (Electronic)
IS  - 0959-9673 (Print)
IS  - 0959-9673 (Linking)
VI  - 98
IP  - 6
DP  - 2017 Dec
TI  - Treatment with low doses of aspirin during chronic phase of experimental Chagas' 
      disease increases oesophageal nitrergic neuronal subpopulation in mice.
PG  - 356-362
LID - 10.1111/iep.12259 [doi]
AB  - Patients with Chagas' disease may develop dysfunctions of oesophageal and colonic 
      motility resulting from the degeneration or loss of the myenteric neurons of the 
      enteric nervous system. Studies have shown that the use of aspirin, also known as 
      acetylsalicylic acid (ASA), influences the pathogenesis of the disease. However, 
      this remains controversial. The aim of this study was to evaluate the 
      consequences of treatment with low doses of aspirin during the chronic phase of 
      Chagas' disease on oesophageal function. Twenty male Swiss mice, 60 days of age, 
      were used. The animals were infected with Y strain of Trypanosoma cruzi, injected 
      intraperitoneally. Aspirin was given at a dose of 50 mg/kg to some of the 
      infected animals, from the 55th to 63rd day after inoculation on consecutive 
      days, and from the 65th to 75th day on alternate days. We investigated food 
      passage of time, wall structure and nitrergic neuronal population of the distal 
      oesophagus. Our data revealed that the use of low doses of aspirin in chronic 
      Chagas' disease caused an increase in the number of nitrergic neurons and 
      partially prevented hypertrophy of the oesophagus. In addition, the aspirin 
      administration impeded Chagas' diseases associated changes in intestinal transit 
      time. Thus treatment with aspirin in the chronic phase of Chagas' disease changes 
      the natural history of the disease and raises the possibility of using it as a 
      new therapeutic approach to the treatment of this aspect of Chagas' disease 
      pathology.
CI  - © 2018 The Authors. International Journal of Experimental Pathology © 2018 
      International Journal of Experimental Pathology.
FAU - Massocatto, Cristina Lorena
AU  - Massocatto CL
AUID- ORCID: 0000-0001-7251-1625
AD  - University Center Integrado, Campo Mourão, Paraná, Brazil.
FAU - Martins Moreira, Neide
AU  - Martins Moreira N
AD  - Department of Morphological Sciences, State University of Maringá, Maringá, 
      Paraná, Brazil.
FAU - Muniz, Eliane
AU  - Muniz E
AD  - Department of Morphological Sciences, State University of Maringá, Maringá, 
      Paraná, Brazil.
FAU - Marques de Araújo, Silvana
AU  - Marques de Araújo S
AD  - Department of Morphological Sciences, State University of Maringá, Maringá, 
      Paraná, Brazil.
FAU - Pinge-Filho, Phileno
AU  - Pinge-Filho P
AD  - Department of Pathological Sciences, State University of Londrina, Londrina, 
      Paraná, Brazil.
FAU - Rossi, Robson Marcelo
AU  - Rossi RM
AD  - Department of Statistics, State University of Maringá, Maringá, Paraná, Brazil.
FAU - de Almeida Araújo, Eduardo José
AU  - de Almeida Araújo EJ
AD  - Department of Histology, State University of Londrina, Londrina, Paraná, Brazil.
FAU - de Mello Gonçales Sant'ana, Débora
AU  - de Mello Gonçales Sant'ana D
AD  - Department of Morphological Sciences, State University of Maringá, Maringá, 
      Paraná, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20180119
PL  - England
TA  - Int J Exp Pathol
JT  - International journal of experimental pathology
JID - 9014042
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chagas Disease/*drug therapy/pathology
MH  - Chronic Disease
MH  - Colon/pathology
MH  - Disease Models, Animal
MH  - Esophagus/drug effects/*pathology
MH  - Male
MH  - Mice
MH  - Myenteric Plexus/drug effects/pathology
MH  - Neurons/*drug effects/pathology
PMC - PMC5826942
OTO - NOTNLM
OT  - American trypanosomiasis
OT  - acetylsalicylic acid
OT  - achalasia
OT  - enteric nervous system
OT  - myenteric neurons
EDAT- 2018/01/20 06:00
MHDA- 2018/09/13 06:00
CRDT- 2018/01/20 06:00
PHST- 2016/12/06 00:00 [received]
PHST- 2017/11/30 00:00 [accepted]
PHST- 2018/01/20 06:00 [pubmed]
PHST- 2018/09/13 06:00 [medline]
PHST- 2018/01/20 06:00 [entrez]
AID - IEP12259 [pii]
AID - 10.1111/iep.12259 [doi]
PST - ppublish
SO  - Int J Exp Pathol. 2017 Dec;98(6):356-362. doi: 10.1111/iep.12259. Epub 2018 Jan 
      19.

PMID- 27849653
OWN - NLM
STAT- MEDLINE
DCOM- 20180810
LR  - 20200220
IS  - 1531-6998 (Electronic)
IS  - 1068-9508 (Linking)
VI  - 25
IP  - 1
DP  - 2017 Feb
TI  - The role of aspirin desensitization in the management of aspirin-exacerbated 
      respiratory disease.
PG  - 30-34
LID - 10.1097/MOO.0000000000000331 [doi]
AB  - PURPOSE OF REVIEW: Aspirin-exacerbated respiratory disease (AERD) is a 
      progressive inflammatory disease of the upper and lower airways characterized by 
      marked eosinophilic nasal polyposis, asthma, and respiratory reactions to 
      medications that inhibit the cyclooxygenase pathway. Aspirin desensitization has 
      proven to be an effective tool in the management of this disease when used in a 
      multidisciplinary setting. The purpose of this article is to review the current 
      literature regarding AERD, aspirin desensitization, and share our opinion 
      regarding the most optimal multidisciplinary approach to these complex patients. 
      RECENT FINDINGS: Numerous studies, including randomized, double-blind, 
      placebo-controlled trials, have demonstrated the therapeutic effectiveness of 
      aspirin desensitization with significant improvement in number of sinus 
      infections per year, olfactory scores, nasal symptom scores, asthma symptom 
      scores, sinus operations, hospitalizations, emergency room visits, and oral 
      steroid use. Furthermore, the role of surgery is becoming increasingly important 
      for recalcitrant sinus disease with recent studies showing comprehensive surgery 
      as more beneficial to disease management. SUMMARY: Aspirin desensitization is an 
      effective therapeutic tool in the management of AERD. A multidisciplinary 
      approach is critical between the otorhinolaryngologist and allergist to provide 
      the most optimal care for this complex patient population.
FAU - Tajudeen, Bobby A
AU  - Tajudeen BA
AD  - aDepartment of Otorhinolaryngology - Head and Neck Surgery, Rush University 
      Medical Center, Chicago, Illinois, USA bDepartment of Otolaryngology - Head and 
      Neck Surgery, McGill University, Montreal, Quebec, Canada cDepartment of 
      Otorhinolaryngology - Head and Neck Surgery, The University of Pennsylvania, 
      Philadelphia, Pennsylvania, USA.
FAU - Schwartz, Joseph S
AU  - Schwartz JS
FAU - Bosso, John V
AU  - Bosso JV
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Otolaryngol Head Neck Surg
JT  - Current opinion in otolaryngology & head and neck surgery
JID - 9417024
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Desensitization, Immunologic/*methods
MH  - Disease Management
MH  - Female
MH  - Humans
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Respiratory Function Tests
MH  - Respiratory Tract Diseases/*etiology/physiopathology/*therapy
EDAT- 2016/11/17 06:00
MHDA- 2018/08/11 06:00
CRDT- 2016/11/17 06:00
PHST- 2016/11/17 06:00 [pubmed]
PHST- 2018/08/11 06:00 [medline]
PHST- 2016/11/17 06:00 [entrez]
AID - 10.1097/MOO.0000000000000331 [doi]
PST - ppublish
SO  - Curr Opin Otolaryngol Head Neck Surg. 2017 Feb;25(1):30-34. doi: 
      10.1097/MOO.0000000000000331.

PMID- 19293072
OWN - NLM
STAT- MEDLINE
DCOM- 20090408
LR  - 20190619
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 150
IP  - 6
DP  - 2009 Mar 17
TI  - Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services 
      Task Force recommendation statement.
PG  - 396-404
AB  - DESCRIPTION: Update of the 2002 U.S. Preventive Services Task Force (USPSTF) 
      recommendation about the use of aspirin for the prevention of coronary heart 
      disease. METHODS: Review of the literature since 2002, focusing on new evidence 
      on the benefits and harms of aspirin for the primary prevention of cardiovascular 
      disease, including myocardial infarction and stroke. The new evidence was 
      reviewed and synthesized according to sex. RECOMMENDATIONS: Encourage men age 45 
      to 79 years to use aspirin when the potential benefit of a reduction in 
      myocardial infarctions outweighs the potential harm of an increase in 
      gastrointestinal hemorrhage. (A recommendation) Encourage women age 55 to 79 
      years to use aspirin when the potential benefit of a reduction in ischemic 
      strokes outweighs the potential harm of an increase in gastrointestinal 
      hemorrhage. (A recommendation) Evidence is insufficient to assess the balance of 
      benefits and harms of aspirin for cardiovascular disease prevention in men and 
      women 80 years or older. (I statement) Do not encourage aspirin use for 
      cardiovascular disease prevention in women younger than 55 years and in men 
      younger than 45 years. (D recommendation).
CN  - US Preventive Services Task Force
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- Ann Intern Med. 2009 Mar 17;150(6):I-37. PMID: 19293068
CIN - Ann Intern Med. 2009 Mar 17;150(6):414-6. PMID: 19293075
CIN - Ann Intern Med. 2009 Oct 20;151(8):587-8; author reply 588. PMID: 19841461
CIN - Ann Intern Med. 2009 Oct 20;151(8):587; author reply 588. PMID: 19841462
CIN - Phys Sportsmed. 2010 Apr;38(1):158-61. PMID: 20424413
MH  - Age Factors
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/prevention & control
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cost of Illness
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention
MH  - Risk Assessment
FIR - Calonge, Ned
IR  - Calonge N
FIR - Petitti, Diana B
IR  - Petitti DB
FIR - DeWitt, Thomas G
IR  - DeWitt TG
FIR - Gordis, Leon
IR  - Gordis L
FIR - Gregory, Kimberly D
IR  - Gregory KD
FIR - Harris, Russell
IR  - Harris R
FIR - Isham, George
IR  - Isham G
FIR - LeFevre, Michael L
IR  - LeFevre ML
FIR - Loveland-Cherry, Carol
IR  - Loveland-Cherry C
FIR - Marion, Lucy N
IR  - Marion LN
FIR - Moyer, Virginia A
IR  - Moyer VA
FIR - Ockene, Judith K
IR  - Ockene JK
FIR - Sawaya, George F
IR  - Sawaya GF
FIR - Siu, Albert L
IR  - Siu AL
FIR - Teutsch, Steven M
IR  - Teutsch SM
FIR - Yawn, Barbara P
IR  - Yawn BP
EDAT- 2009/03/19 09:00
MHDA- 2009/04/09 09:00
CRDT- 2009/03/19 09:00
PHST- 2009/03/19 09:00 [entrez]
PHST- 2009/03/19 09:00 [pubmed]
PHST- 2009/04/09 09:00 [medline]
AID - 150/6/396 [pii]
AID - 10.7326/0003-4819-150-6-200903170-00008 [doi]
PST - ppublish
SO  - Ann Intern Med. 2009 Mar 17;150(6):396-404. doi: 
      10.7326/0003-4819-150-6-200903170-00008.

PMID- 7051035
OWN - NLM
STAT- MEDLINE
DCOM- 19821012
LR  - 20131121
IS  - 0361-7742 (Print)
IS  - 0361-7742 (Linking)
VI  - 89
DP  - 1982
TI  - Antithrombotic effects of drugs which suppress platelet function: their potential 
      in prevention growth of tumour cells.
PG  - 31-62
AB  - Four drugs that inhibit platelet function have been evaluated for their 
      antithrombotic effects in humans. These are aspirin, dipyridamole, 
      hydroxychloroquine and sulphinpyrazone. Aspirin has been shown to reduce the 
      number of transient ischemic attacks (TIA), stroke and death in patients with 
      multiple TIA. The reduction in TIA was greatest in males who were normotensive 
      and when there was an angiographically demonstrated lesion in the carotid artery 
      that accounted for the symptoms. Aspirin reduced venous thrombosis and non-fatal 
      and fatal pulmonary embolism in patients after surgery for fractured hip and 
      after elective hip replacement. There is evidence that the prophylactic effect of 
      aspirin may be greater in male patients. Aspirin reduced the frequency of 
      arteriovenous shunt thrombosis. Aspirin abolished symptoms in patients with 
      peripheral ischemia associated with thrombocytosis and spontaneous platelet 
      aggregation. There is no conclusive evidence at the present time that aspirin is 
      effective in patients with coronary artery artery disease. Dipyridamole in 
      combination with oral anticoagulants is effective in reducing the frequency of 
      systemic embolism in patients with prosthetic heart valve replacement but is 
      ineffective in patients with transient cerebral ischemic attacks or for the 
      prevention of venous thromboembolism. Hydroxychloroquine was effective in 
      reducing postoperative venous thrombosis in patients undergoing general 
      abdominothoracic surgery but the evidence that it was effective in patients 
      undergoing orthopaedic surgery is inconclusive. Sulphinpyrazone may be effective 
      in reducing the frequency of sudden cardiac deaths in patients in the first year 
      after myocardial infarction when it is started within 25 to 35 days after the 
      infarction. Sulphinpyrazone reduced the incidence of arteriovenous shunt 
      thrombosis in patients undergoing chronic hemodialysis and in combination with 
      anticoagulants, it reduced the frequency of recurrent venous thrombosis. There 
      have been no large scale trials of platelet suppressant drugs in clinical cancer 
      and successful treatment of thromboembolic disorders cannot be used to predict 
      success in the treatment of malignant disease.
FAU - Turpie, A G
AU  - Turpie AG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Prog Clin Biol Res
JT  - Progress in clinical and biological research
JID - 7605701
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects/*physiology
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cell Division/drug effects
MH  - Clinical Trials as Topic
MH  - Coronary Disease/drug therapy
MH  - Dipyridamole/pharmacology/*therapeutic use
MH  - Heart Diseases/drug therapy
MH  - Humans
MH  - Hydroxychloroquine/pharmacology/*therapeutic use
MH  - Neoplasms/*drug therapy
MH  - Sulfinpyrazone/therapeutic use
MH  - Thromboembolism/drug therapy
MH  - Thrombosis/*prevention & control
RF  - 133
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - Prog Clin Biol Res. 1982;89:31-62.

PMID- 22997999
OWN - NLM
STAT- MEDLINE
DCOM- 20121011
LR  - 20191112
IS  - 0001-5385 (Print)
IS  - 0001-5385 (Linking)
VI  - 67
IP  - 4
DP  - 2012 Aug
TI  - The prevalence and factors associated with aspirin resistance in patients 
      premedicated with aspirin.
PG  - 445-8
AB  - OBJECTIVE: Aspirin is a key drug used in treating patients with a high risk to 
      develop stroke, myocardial infarction and other cardiovascular events. However, a 
      considerable fraction of the patients develops aspirin resistance, which is a 
      multi-factorial process that can occur due to patient's non-compliance, improper 
      dosing, other co-morbidities or drug-drug interactions.This cross-sectional study 
      was carried out to determine the prevalence and factors associated with aspirin 
      resistance among Jordanians. METHODS: The study was performed on a sample of 418 
      adult patients who were taking aspirin as an antiplatelet agent. To determine 
      aspirin resistance, platelet function was assessed using a multiplate analyzer. 
      RESULTS: Data shows that about 18.7% (78) of the patients were aspirin resistant. 
      Aspirin resistance was associated with female gender (P < 0.05) and was higher 
      among diabetic subjects (P < 0.05). Statins use was correlated with improved 
      aspirin response (P < 0.05). No association was found between aspirin response 
      and: age, body mass index, education, smoking status, family history of 
      cardiovascular disease, aspirin dose and duration of aspirin use (P > 0.05). In 
      addition, aspirin resistance was not related to parameters such as HbA1c and 
      low-density lipoprotein (LDL), comorbidities including dyslipidaemia, and 
      hypertension, and concurrent use of other medications such as beta blockers, 
      angiotensin-converting enzyme inhibitors (ACEIs), calcium channel blockers 
      (CCBs), and proton pump inhibitors (PPIs) (P > 0.05). CONCLUSION: The incidence 
      of aspirin resistance is high in the Jordanian population. Aspirin resistance is 
      associated with female gender and diabetes. On the other hand, the use of statins 
      improves response to aspirin.
FAU - Al-Azzam, Sayer I
AU  - Al-Azzam SI
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of 
      Science and Technology, Irbid, Jordan. sayerazzam@yahoo.com
FAU - Alzoubi, Karem H
AU  - Alzoubi KH
FAU - Khabour, Omar
AU  - Khabour O
FAU - Alowidi, Abdallah
AU  - Alowidi A
FAU - Tawalbeh, Deniz
AU  - Tawalbeh D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Acta Cardiol
JT  - Acta cardiologica
JID - 0370570
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetic Angiopathies/prevention & control
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Prevalence
EDAT- 2012/09/25 06:00
MHDA- 2012/10/12 06:00
CRDT- 2012/09/25 06:00
PHST- 2012/09/25 06:00 [entrez]
PHST- 2012/09/25 06:00 [pubmed]
PHST- 2012/10/12 06:00 [medline]
AID - 10.1080/ac.67.4.2170686 [doi]
PST - ppublish
SO  - Acta Cardiol. 2012 Aug;67(4):445-8. doi: 10.1080/ac.67.4.2170686.

PMID- 3019744
OWN - NLM
STAT- MEDLINE
DCOM- 19861120
LR  - 20181130
IS  - 0232-7384 (Print)
IS  - 0232-7384 (Linking)
VI  - 87
IP  - 2
DP  - 1986 Jul
TI  - The role of cAMP and prostaglandins in gastric acid secretion after pentagastrin 
      administration.
PG  - 219-22
AB  - The role of cAMP and prostaglandins as specific intracellular effectors of 
      gastrin action at the level of the parietal cells has not been sufficiently 
      clarified. For this reason we studied the responses of the parietal cells to 
      stimulation with pentagastrin (6 micrograms/kg i.m.) during theophylline infusion 
      (which causes an increase in the intracellular cAMP) and during acetylsalicylic 
      acid infusion (which inhibits the prostaglandin synthesis) in 28 healthy 
      volunteers. Both theophylline and acetylsalicylic acid provoked a significant 
      increase of gastric acid secretion after pentagastrin. Our results suggest that: 
      1. an increase in intracellular cAMP may be the basis of the stimulatory effect 
      of gastrin on gastric acid secretion 2. a decrease in the synthesis of 
      prostaglandins may lead to a greater gastric acid response after pentagastrin.
FAU - Altomonte, L
AU  - Altomonte L
FAU - Palumbo, P
AU  - Palumbo P
FAU - Sommella, L
AU  - Sommella L
FAU - Zoli, A
AU  - Zoli A
FAU - Ghirlanda, G
AU  - Ghirlanda G
FAU - Manna, R
AU  - Manna R
FAU - Greco, A V
AU  - Greco AV
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Exp Clin Endocrinol
JT  - Experimental and clinical endocrinology
JID - 8302802
RN  - 0 (Prostaglandins)
RN  - C137DTR5RG (Theophylline)
RN  - E0399OZS9N (Cyclic AMP)
RN  - EF0NX91490 (Pentagastrin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cyclic AMP/*metabolism
MH  - Gastric Acid/drug effects/*metabolism
MH  - Humans
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Pentagastrin/*pharmacology
MH  - Prostaglandins/*metabolism
MH  - Theophylline/pharmacology
EDAT- 1986/07/01 00:00
MHDA- 1986/07/01 00:01
CRDT- 1986/07/01 00:00
PHST- 1986/07/01 00:00 [pubmed]
PHST- 1986/07/01 00:01 [medline]
PHST- 1986/07/01 00:00 [entrez]
AID - 10.1055/s-0029-1210548 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol. 1986 Jul;87(2):219-22. doi: 10.1055/s-0029-1210548.

PMID- 7252773
OWN - NLM
STAT- MEDLINE
DCOM- 19810915
LR  - 20190913
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 4
IP  - 3
DP  - 1981 Mar
TI  - Hypocalcemic effect of acetylsalicylic acid in rats.
PG  - 229-31
AB  - Oral administration of acetylsalicylic acid (ASA) at a dose of 200 mg/kg produced 
      a decrease in both total plasma calcium and plasma ionic calcium levels in rats. 
      The percent changes from controls in both total and ionic calcium were similar, 
      being approximately 13% at 3 hr after the administration. A significant (p less 
      than 0.01) decrease in plasma calcium level was also observed at 4 hr after oral 
      administration of salicylic acid at a dose level of 177 mg/kg. However, oral 
      administration of other non-steroidal anti-inflammatory agents such as 
      indomethacin failed to decrease plasma calcium levels in rats. The hypocalcemic 
      effect of ASA was recognized in parathyroidectomized rats, but neither in 
      thyroparathyroidectomized nor in thyroidectomized rats. Therefore, the data 
      suggested that the action of ASA might be mediated by stimulation of calcitonin 
      release, but not by inhibition of prostaglandin biosynthesis.
FAU - Ueno, K
AU  - Ueno K
FAU - Masumura, H
AU  - Masumura H
FAU - Kitagawa, H
AU  - Kitagawa H
FAU - Naminohira, S
AU  - Naminohira S
FAU - Saito, H
AU  - Saito H
FAU - Sakai, T
AU  - Sakai T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Phosphates)
RN  - 9007-12-9 (Calcitonin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*toxicity
MH  - Calcitonin/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Hypocalcemia/blood/*chemically induced
MH  - Male
MH  - Phosphates/blood
MH  - Rats
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
AID - 10.1248/bpb1978.4.229 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1981 Mar;4(3):229-31. doi: 10.1248/bpb1978.4.229.

PMID- 364260
OWN - NLM
STAT- MEDLINE
DCOM- 19790221
LR  - 20210313
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 2
IP  - 12
DP  - 1978 Dec 2
TI  - Salicylate sensitivity in children reported to respond to salicylate exclusion.
PG  - 570-2
AB  - Twelve children, aged six to 13 years, whose parents reported an improvement in 
      behavioural problems with use of the Feingold (K-P) diet for an average period of 
      12 months, were challenge-tested with 40 mg of acetylsalicylic acid in a 
      double-blind, cross-over trial with ascorbic acid as a placebo. The children were 
      tested within three hours of ingestion of either the experimental or placebo 
      tablet with a battery of psychological and neurological tests, and were rated by 
      a parent on an enlarged Conners' Parent-Teacher Questionnaire for four days after 
      the ingestion of the tablet. It was found that significance was reached in tests 
      of general cognitive capacity, line walking and the "finger-to-nose" tests, as 
      well as increased disturbance in sleep patterns in these children.
FAU - Fitzsimon, M
AU  - Fitzsimon M
FAU - Holborow, P
AU  - Holborow P
FAU - Berry, P
AU  - Berry P
FAU - Latham, S
AU  - Latham S
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Allergens)
RN  - 0 (Placebos)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Allergens/administration & dosage
MH  - Ascorbic Acid
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Child
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Hypersensitivity/diet therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hyperkinesis/*chemically induced/diet therapy
MH  - Male
MH  - Placebos
MH  - Surveys and Questionnaires
EDAT- 1978/12/02 00:00
MHDA- 1978/12/02 00:01
CRDT- 1978/12/02 00:00
PHST- 1978/12/02 00:00 [pubmed]
PHST- 1978/12/02 00:01 [medline]
PHST- 1978/12/02 00:00 [entrez]
AID - 10.5694/j.1326-5377.1978.tb131739.x [doi]
PST - ppublish
SO  - Med J Aust. 1978 Dec 2;2(12):570-2. doi: 10.5694/j.1326-5377.1978.tb131739.x.

PMID- 1413752
OWN - NLM
STAT- MEDLINE
DCOM- 19921112
LR  - 20181113
IS  - 0093-0415 (Print)
IS  - 0093-0415 (Linking)
VI  - 157
IP  - 1
DP  - 1992 Jul
TI  - Current management of diabetic retinopathy.
PG  - 67-70
AB  - Diabetic retinopathy progresses through three distinct stages. A rational 
      approach to management is based on an understanding of the pathophysiology of 
      each stage. Based on the results of national multicentered clinical trials of 
      laser photocoagulation and other treatments, advances in our understanding of the 
      pathogenesis and treatment can now make a dramatic impact on blindness in the 
      diabetic population: Panretinal laser photocoagulation treatment can reduce the 
      risk of vision loss from high-risk proliferative diabetic retinopathy by at least 
      50%. Laser photocoagulation treatment of clinically significant diabetic macular 
      edema can reduce the risk of vision loss by more than 50%. Vitrectomy can restore 
      useful vision to some patients with severe diabetic retinopathy and vitreous 
      hemorrhage with or without an accompanying traction retinal detachment. Diabetes 
      2000 is a new project sponsored by the American Academy of Ophthalmology, the 
      goal of which is to eliminate preventable blindness from diabetes by the year 
      2000. As its name implies, Diabetes 2000 will be a long-term project aimed at a 
      specific disease--diabetic retinopathy and its complications. It will provide the 
      latest research findings to ophthalmologists and primary care physicians as the 
      first priority, followed by the education of patients and the general public. 
      Recent advances and treatment guidelines for the medical and surgical treatment 
      of diabetic eye disease will be emphasized through the continuing education of 
      ophthalmologists, other physicians, and allied health professionals. In later 
      phases, educational programs for diabetic persons and the public will be 
      developed. Ultimately, improved access of diabetic patients to ophthalmologic 
      care and a close working relationship between ophthalmologists and primary care 
      physicians will ensure early detection of diabetic retinopathy and the timely 
      delivery of state-of-the-art treatments.
FAU - Ai, E
AU  - Ai E
AD  - Department of Ophthalmology, California Pacific Medical Center, San Francisco 
      94120.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - West J Med
JT  - The Western journal of medicine
JID - 0410504
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Diabetic Retinopathy/*therapy
MH  - Humans
MH  - Laser Coagulation
MH  - Middle Aged
MH  - United States
PMC - PMC1021914
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
PST - ppublish
SO  - West J Med. 1992 Jul;157(1):67-70.

PMID- 16967353
OWN - NLM
STAT- MEDLINE
DCOM- 20070227
LR  - 20150216
IS  - 0028-3843 (Print)
IS  - 0028-3843 (Linking)
VI  - 40
IP  - 4
DP  - 2006 Jul-Aug
TI  - [Aspirin resistance theory].
PG  - 313-9
AB  - Acetylsalicylic acid is an effective antiplatelet drug for primary and secondary 
      prevention of heart and brain vascular diseases. Analyses of trials including 
      patients with atherosclerosis proved that vascular ischaemic events have been 
      reduced by 25% and risk of vascular death has been reduced due to aspirin. The 
      increasing number of reports about aspirin resistance (the failure of the 
      compound to protect from an ischemic event despite regular intake of appropriate 
      doses) is alarming. The purpose of this review is to present current opinions and 
      results of investigations connected with this problem.
FAU - Porosińska, Aleksandra
AU  - Porosińska A
AD  - Katedra i Klinika Neurologii, Slaska Akademia Medyczna, ul. 3 Maja 13/15, 41-800 
      Zabrze. aleksandraporosinska@tlen.pl
FAU - Pierzchała, Krystyna
AU  - Pierzchała K
LA  - pol
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Koncepcje oporności na aspiryne.
PL  - Poland
TA  - Neurol Neurochir Pol
JT  - Neurologia i neurochirurgia polska
JID - 0101265
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/metabolism
MH  - Cerebrovascular Disorders/prevention & control
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/*pharmacology/therapeutic use
MH  - *Drug Resistance
MH  - Humans
MH  - Ischemic Attack, Transient/prevention & control
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
RF  - 59
EDAT- 2006/09/13 09:00
MHDA- 2007/02/28 09:00
CRDT- 2006/09/13 09:00
PHST- 2006/09/13 09:00 [pubmed]
PHST- 2007/02/28 09:00 [medline]
PHST- 2006/09/13 09:00 [entrez]
AID - 6532 [pii]
PST - ppublish
SO  - Neurol Neurochir Pol. 2006 Jul-Aug;40(4):313-9.

PMID- 1427066
OWN - NLM
STAT- MEDLINE
DCOM- 19921204
LR  - 20191028
IS  - 1046-9354 (Print)
IS  - 1046-9354 (Linking)
VI  - 13
IP  - 4
DP  - 1992 Jul-Aug
TI  - Management of aspirin-sensitive rhinosinusitis-asthma syndrome: what role for 
      aspirin desensitization?
PG  - 175-84
AB  - Although aspirin is only one of the triggers of asthma attacks in patients with 
      aspirin-sensitive rhinosinusitis asthma, aspirin sensitivity heralds severe and 
      protracted disease requiring comprehensive management of all components of the 
      syndrome. A review of the literature on the management of patients with 
      aspirin-sensitive rhinosinusitis-asthma allows for the establishment of 
      guidelines for conducting aspirin desensitization and evaluating the clinical 
      usefulness of this procedure.
FAU - Kowalski, M L
AU  - Kowalski ML
AD  - Department of Pulmonology and Allergy, Medical Academy, Lodz, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Allergy Proc
JT  - Allergy proceedings : the official journal of regional and state allergy 
      societies
JID - 8902396
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/therapy
MH  - Chronic Disease
MH  - *Desensitization, Immunologic
MH  - Humans
MH  - Rhinitis, Allergic, Perennial/*chemically induced/therapy
MH  - Sinusitis/*chemically induced/therapy
MH  - Syndrome
RF  - 93
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
AID - 10.2500/108854192778817202 [doi]
PST - ppublish
SO  - Allergy Proc. 1992 Jul-Aug;13(4):175-84. doi: 10.2500/108854192778817202.

PMID- 9296464
OWN - NLM
STAT- MEDLINE
DCOM- 19970930
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 80
IP  - 5A
DP  - 1997 Sep 4
TI  - Platelet activation and inhibition in unstable coronary syndromes.
PG  - 17E-20E
AB  - Platelet activation occurs episodically in unstable angina, as reflected by 
      enhanced thromboxane metabolite excretion, and most episodes can be suppressed by 
      low-dose aspirin. Biochemical evidence of platelet activation and 
      electrocardiographic evidence of myocardial ischemia are often temporally 
      dissociated, thus suggesting the likely involvement of different triggers. 
      Aspirin is effective in reducing the short-term and long-term risks of myocardial 
      infarction and death by 40-60%, in a dose-independent fashion consistent with the 
      saturability of platelet cyclo-oxygenase inhibition at low doses. Suppression of 
      platelet thromboxane synthesis by aspirin and the blockade of platelet adenosine 
      diphosphate receptors by ticlopidine or clopidogrel appear to have a similar 
      impact on limiting the risk of a thrombotic outcome of plaque fissuring, thereby 
      suggesting combined strategies for future studies.
FAU - Patrono, C
AU  - Patrono C
AD  - Center for Experimental Therapeutics and Department of Pharmacology, University 
      of Pennsylvania School of Medicine, Philadelphia 19104-6100, USA.
FAU - Renda, G
AU  - Renda G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/drug therapy/*physiopathology
MH  - Aspirin/pharmacology/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/drug therapy
MH  - *Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Thromboxane A2/metabolism
MH  - Ticlopidine/therapeutic use
RF  - 36
EDAT- 1997/09/20 00:00
MHDA- 1997/09/20 00:01
CRDT- 1997/09/20 00:00
PHST- 1997/09/20 00:00 [pubmed]
PHST- 1997/09/20 00:01 [medline]
PHST- 1997/09/20 00:00 [entrez]
AID - S0002-9149(97)00484-0 [pii]
AID - 10.1016/s0002-9149(97)00484-0 [doi]
PST - ppublish
SO  - Am J Cardiol. 1997 Sep 4;80(5A):17E-20E. doi: 10.1016/s0002-9149(97)00484-0.

PMID- 7486235
OWN - NLM
STAT- MEDLINE
DCOM- 19951218
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 46
IP  - 11
DP  - 1995 Nov
TI  - A randomized trial of E5510 versus aspirin in patients with transient ischemic 
      attacks. The Japanese E5510 TIA study-1 (JETS-1) Group.
PG  - 999-1008
AB  - In a randomized double-blind trial, the Study Group compared the efficacy of 
      E5510, a novel antiplatelet agent, and aspirin in preventing the recurrence of 
      transient ischemic attacks (TIA). In total, 227 patients who suffered from TIA in 
      the twelve weeks prior to the study were enrolled. They were randomly allocated 
      to three treatment groups, ie, 71 patients in the E5510 4 mg group, 77 patients 
      in the E5510 2 mg group, and 79 patients in the aspirin 324 mg group, and were 
      treated for twelve to twenty-four weeks. The incidence of recurrent TIA or stroke 
      was 21.5% in the aspirin group and was significantly lower in the E5510 groups, 
      being 8.5% in the 4 mg group (P < 0.05) and 11.7% in the 2 mg group (P < 0.05). 
      Adverse events were observed in 5 cases in the 4 mg group, in 8 cases in the 2 mg 
      group, and in 10 cases in the aspirin group, but none of them were serious. Since 
      safety was judged to be comparable among the three groups, E5510 appears to be an 
      antiplatelet agent for the treatment of TIA with a clinical benefit over aspirin.
FAU - Maruyama, S
AU  - Maruyama S
AD  - Department of Neurology, Neurological Institute, Tokyo Women's Medical College.
FAU - Uchiyama, S
AU  - Uchiyama S
FAU - Tohgi, H
AU  - Tohgi H
FAU - Hirai, S
AU  - Hirai S
FAU - Ikeda, Y
AU  - Ikeda Y
FAU - Shinohara, Y
AU  - Shinohara Y
FAU - Matsuda, T
AU  - Matsuda T
FAU - Fujishima, M
AU  - Fujishima M
FAU - Kameyama, M
AU  - Kameyama M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - XPV71VQL72 (Satigrel)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Fatty Acids, Monounsaturated/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Ischemic Attack, Transient/epidemiology/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Recurrence
MH  - Treatment Outcome
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 10.1177/000331979504601104 [doi]
PST - ppublish
SO  - Angiology. 1995 Nov;46(11):999-1008. doi: 10.1177/000331979504601104.

PMID- 17061171
OWN - NLM
STAT- MEDLINE
DCOM- 20070201
LR  - 20220317
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 23
IP  - 12
DP  - 2006 Dec
TI  - Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 
      3A4.
PG  - 2691-708
AB  - Antiplatelet therapy provided pivotal advances in the treatment of cardiovascular 
      disease. Aspirin and thienopyridine, clopidogrel, is currently the treatment of 
      choice in acute coronary syndromes and the prevention of thrombosis after 
      coronary stent implantation. Despite the efficacy of this dual antiplatelet 
      therapy in reduction of adverse coronary events in patients with acute coronary 
      syndromes, complications persist in a subgroup of these patients. Emerging causes 
      of aspirin and clopidogrel resistance may translate to increase risk for 
      recurrent myocardial infarction, stroke, or cardiac related mortality. However, 
      the mechanism of antiplatelet drug resistance remains incompletely characterized, 
      and a sensitive and specific assay of aspirin and clopidogrel effect that 
      reliably predicts treatment failure has not emerged. To date, evidence supporting 
      antiplatelet drug resistance are pharmacokinetic response variability, drug-drug 
      interaction through competitive inhibition a specific enzymatic pathway, genetic 
      variability, and variability in the induction of enzymatic pathway in metabolic 
      activation of prodrugs, like clopidogrel. Further investigation or guidelines are 
      needed to optimize antiplatelet treatment strategies to identify and treat 
      patients resistant to aspirin and/or clopidogrel.
FAU - Lau, Wei C
AU  - Lau WC
AD  - Medical Director Cardiovascular Center Operating Rooms, Cardiovascular 
      Anesthesiology, University of Michigan Health System, Ann Arbor, Michigan, USA. 
      weiclau@umich.edu
FAU - Gurbel, Paul A
AU  - Gurbel PA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20061024
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP3A43 protein, human)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aryl Hydrocarbon Hydroxylases/*metabolism
MH  - Aspirin/metabolism/pharmacology
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/metabolism/*pharmacology
MH  - Ticlopidine/analogs & derivatives/metabolism/pharmacology
RF  - 133
EDAT- 2006/10/25 09:00
MHDA- 2007/02/03 09:00
CRDT- 2006/10/25 09:00
PHST- 2006/05/17 00:00 [received]
PHST- 2006/06/06 00:00 [accepted]
PHST- 2006/10/25 09:00 [pubmed]
PHST- 2007/02/03 09:00 [medline]
PHST- 2006/10/25 09:00 [entrez]
AID - 10.1007/s11095-006-9084-4 [doi]
PST - ppublish
SO  - Pharm Res. 2006 Dec;23(12):2691-708. doi: 10.1007/s11095-006-9084-4. Epub 2006 
      Oct 24.

PMID- 19341823
OWN - NLM
STAT- MEDLINE
DCOM- 20091113
LR  - 20171116
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 9
IP  - 7-8
DP  - 2009 Jul
TI  - Comparative effects of aspirin and NO-releasing aspirins on differentiation, 
      maturation and function of human monocyte-derived dendritic cells in vitro.
PG  - 910-7
LID - 10.1016/j.intimp.2009.03.016 [doi]
AB  - Acetylsalicilyc acid (aspirin, ASA) is a well known anti-inflammatory drug with 
      immunomodulatory properties. NO-releasing aspirins (NO-ASA) are new compounds 
      with anti-inflammatory properties. We studied the effects of ASA and two NO-ASA 
      (NCX 4016 and NCX 4040) on human monocyte-derived dendritic cells (MoDC). 
      Immature MoDC were generated in vitro from monocytes in the presence of 
      recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and 
      interleukin (IL)-4. Mature MoDC were obtained by adding lipopolysaccharide (LPS) 
      in cultures of immature MoDC. As we found that ASA at 4-8 mM, NCX 4016 at 400-800 
      microM and NCX 4040 at 4-8 microM stimulated apoptosis of monocytes and immature 
      MoDC, sub-apoptotic concentrations of ASA (2 mM), NCX 4016 (200 microM) and NCX 
      4040 (2 microM) were used in experiments. Examined substances were added at the 
      beginning of MoDC cultivation. MoDC differentiated in the presence of examined 
      compounds had lower expression of HLA-DR, CD80, CD40 and CD54, decreased 
      allostimulatory activity and lower production of IL-12 p40. ASA and NCX 4016 
      decreased production of IL-10, whereas NCX 4040 had the opposite effect. ASA 
      inhibited the expression of CD1a and prevented downregulation of CD14, NCX 4016 
      stimulated the differentiation of CD1a+CD14+ and CD1a(-)CD14+ cells, whereas NCX 
      4040 decreased the proportion of CD1a+CD14(-) and increased the frequency of 
      CD1a+CD14+ cells, compared to control. Maturation, both in ASA and NO-ASA treated 
      MoDC was characterized by decreased allostimulatory activity, lower expression of 
      CD83, HLA-DR, costimulatory molecules and CD54 and decreased production of IL-10 
      and IL-12 p40. In conclusion, we confirmed that ASA impairs differentiation, 
      maturation and function of MoDC and found that NCX 4016 and NCX 4040 exerted 
      similar, but not identical effects at about 10- and 1000-fold lower 
      concentrations, respectively, compared to ASA.
FAU - Bufan, Biljana
AU  - Bufan B
AD  - Institute for Medical Research, Military Medical Academy, Belgrade, Serbia; 
      Department of Microbiology and Immunology, Faculty of Pharmacy, University of 
      Belgrade, Belgrade, Serbia. bbiljana@pharmacy.bg.ac.rs
FAU - Mojsilović, Slavko
AU  - Mojsilović S
FAU - Vucićević, Dragana
AU  - Vucićević D
FAU - Vucević, Dragana
AU  - Vucević D
FAU - Vasilijić, Sasa
AU  - Vasilijić S
FAU - Balint, Bela
AU  - Balint B
FAU - Colić, Miodrag
AU  - Colić M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20090331
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antigens, Differentiation)
RN  - 0 (Interleukin-12 Subunit p40)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NCX 4040)
RN  - 0 (Nitro Compounds)
RN  - 130068-27-8 (Interleukin-10)
RN  - 207137-56-2 (Interleukin-4)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Antigens, Differentiation/immunology/metabolism
MH  - Apoptosis/drug effects/immunology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cell Differentiation/drug effects/immunology
MH  - Cells, Cultured
MH  - Dendritic Cells/*drug effects/immunology/metabolism/pathology
MH  - Down-Regulation
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/immunology/metabolism
MH  - Humans
MH  - Interleukin-10/genetics/immunology/metabolism
MH  - Interleukin-12 Subunit p40/genetics/immunology/metabolism
MH  - Interleukin-4/immunology/metabolism
MH  - Lipopolysaccharides/metabolism
MH  - Lymphocyte Activation/drug effects
MH  - Monocytes/metabolism/pathology
MH  - Nitric Oxide/*metabolism
MH  - Nitro Compounds/*pharmacology
EDAT- 2009/04/04 09:00
MHDA- 2009/11/17 06:00
CRDT- 2009/04/04 09:00
PHST- 2008/09/27 00:00 [received]
PHST- 2009/03/07 00:00 [revised]
PHST- 2009/03/24 00:00 [accepted]
PHST- 2009/04/04 09:00 [entrez]
PHST- 2009/04/04 09:00 [pubmed]
PHST- 2009/11/17 06:00 [medline]
AID - S1567-5769(09)00122-2 [pii]
AID - 10.1016/j.intimp.2009.03.016 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2009 Jul;9(7-8):910-7. doi: 10.1016/j.intimp.2009.03.016. 
      Epub 2009 Mar 31.

PMID- 3688595
OWN - NLM
STAT- MEDLINE
DCOM- 19880104
LR  - 20190717
IS  - 0196-0644 (Print)
IS  - 0196-0644 (Linking)
VI  - 16
IP  - 12
DP  - 1987 Dec
TI  - Effectiveness of commercially available aqueous activated charcoal products.
PG  - 1340-3
AB  - A human research project was conducted to compare the relative effectiveness of 
      five commercially available aqueous activated charcoal products in 25-g 
      amounts--Acta-Char, Actidose-Aqua, Insta-Char, Liqui-Char, and Super-Char. Seven 
      healthy adult human fasting volunteers participated. The study was double-blinded 
      and subjects served as their own controls. Aspirin 2,592 mg was administered to 
      each subject in the control phase to establish baseline aspirin absorption as 
      measured by serial serum salicylate levels. During each of the five study phases 
      2,592 mg aspirin and a specific brand of activated charcoal were administered to 
      the subjects and serial serum salicylate levels were drawn. Aspirin absorption 
      was calculated using the trapezoidal rule for measuring the area under the 
      concentration-time curve. Total aspirin absorption was reduced as follows: 
      Super-Char, 57.76%; Actidose-Aqua, 50.42%; Insta-Char, 39.55%; Liqui-Char, 
      33.40%; and Acta-Char, 27.46%. Although there were large apparent differences in 
      the adsorptive capacities of the products, the only statistically significant 
      difference was between Super-Char and Acta-Char. The failure to show statistical 
      differences in the face of large apparent differences may have been a reflection 
      of type II beta error due to the small sample size. The most common factor 
      responsible for the apparent differences in the adsorptive capacities of the 
      products was most likely the surface area of the activated charcoals that were 
      used. The higher surface area products, Super-Char (3,150 m2/g) and Actidose-Aqua 
      (1,500 m2/g) prevented the absorption of aspirin more effectively than the other 
      three products that had surface areas of 950 m2/g.
FAU - Krenzelok, E P
AU  - Krenzelok EP
AD  - Pittsburgh Poison Center, Children's Hospital of Pittsburgh, Pennsylvania 15213.
FAU - Heller, M B
AU  - Heller MB
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Adult
MH  - Aspirin/*pharmacokinetics
MH  - Charcoal/*pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
AID - S0196-0644(87)80415-8 [pii]
AID - 10.1016/s0196-0644(87)80415-8 [doi]
PST - ppublish
SO  - Ann Emerg Med. 1987 Dec;16(12):1340-3. doi: 10.1016/s0196-0644(87)80415-8.

PMID- 16539994
OWN - NLM
STAT- MEDLINE
DCOM- 20060728
LR  - 20190922
IS  - 0213-9111 (Print)
IS  - 0213-9111 (Linking)
VI  - 20
IP  - 1
DP  - 2006 Jan-Feb
TI  - [Economic evaluation of the treatment with aspirin plus esomeprazole compared to 
      clopidogrel in gastrointestinal bleeding prevention].
PG  - 54-7
AB  - OBJECTIVE: To evaluate the use of aspirin plus esomeprazole vs. clopidogrel in 
      the prevention of gastrointestinal bleeding. METHODS: We performed a 
      cost-effectiveness analysis (two-branch decision tree: aspirin plus esomeprazole 
      or clopidogrel) of prevention of gastrointestinal bleeding over a 2-year period, 
      as well as sensitivity analyses. RESULTS: The total cost of aspirin plus 
      esomeprazole treatment (2,865 Euro/patient free of hemorrhage) was lower than 
      that of clopidogrel (2,965 Euro). Aspirin treatment was dominant. The combination 
      continued to be dominant in all sensitivity analyses. When esomeprazole 40 mg was 
      substituted by omeprazole 40 mg, the cost of combination therapy decreased to 
      1,934 Euro/prevented hemorrhage. CONCLUSIONS: The association of esomeprazole and 
      aspirin is more cost-effective than clopidogrel in preventing gastrointestinal 
      bleeding. Aspirin plus omeprazole was even more cost-effective.
FAU - Piñol, Carme
AU  - Piñol C
AD  - Unidad de Farmacoeconomía y Relaciones Institucionales, Departamento de 
      Investigación y Desarrollo, Química Farmacéutica Bayer, S.A., Barcelona, España. 
      carmen.pinol.cp@bayer.es
LA  - spa
PT  - Comparative Study
PT  - Journal Article
TT  - Evaluación económica del tratamiento con ácido acetilsalicílico más esomeprazol 
      comparado con clopidogrel en la prevención de la hemorragia gastrointestinal.
PL  - Spain
TA  - Gac Sanit
JT  - Gaceta sanitaria
JID - 8901623
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - KG60484QX9 (Omeprazole)
RN  - N3PA6559FT (Esomeprazole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gac Sanit. 2006 Jan-Feb;20(1):58. PMID: 16539995
MH  - Aspirin/adverse effects/*economics/*therapeutic use
MH  - Clopidogrel
MH  - Decision Trees
MH  - Drug Therapy, Combination
MH  - Esomeprazole
MH  - Gastrointestinal Hemorrhage/chemically induced/*economics/*prevention & control
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Omeprazole/*economics/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*economics/*therapeutic use
MH  - *Proton Pump Inhibitors
MH  - Ticlopidine/*analogs & derivatives/economics/therapeutic use
EDAT- 2006/03/17 09:00
MHDA- 2006/07/29 09:00
CRDT- 2006/03/17 09:00
PHST- 2006/03/17 09:00 [pubmed]
PHST- 2006/07/29 09:00 [medline]
PHST- 2006/03/17 09:00 [entrez]
AID - 13084128 [pii]
AID - 10.1157/13084128 [doi]
PST - ppublish
SO  - Gac Sanit. 2006 Jan-Feb;20(1):54-7. doi: 10.1157/13084128.

PMID- 35312246
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20220718
IS  - 1853-0605 (Electronic)
IS  - 0014-6722 (Print)
IS  - 0014-6722 (Linking)
VI  - 79
IP  - 1
DP  - 2022 Mar 7
TI  - [Assessment of a teleophthalmology program for the prevention of diabetes 
      blindness in a rural area of Argentina.].
PG  - 10-14
LID - 10.31053/1853.0605.v79.n1.35775 [doi]
AB  - INTRODUCTION: Teleophthalmology programs have become one of the main tools for 
      the early detection of diabetic retinopathy. Assessing the implementation of 
      these programs is essential to contextualize and understand their effectiveness 
      in different regions. The aim of this study was to evaluate the rate of annual 
      eye examination in people with diabetes before and after implementing a 
      teleophthalmology program in the province of La Pampa (Argentina). METHODS: A 
      before-and-after study design was performed, comparing the rate of eye 
      examination performed before and after starting with the Program. The analysis 
      was carried out with a random survey of people with diabetes. People from rural 
      and urban areas of the province were included. The program was implemented only 
      in the rural area, while the urban area has the traditional care system. RESULTS: 
      The annual eye examination rate carried out before and after the implementation 
      of the Program in rural areas improved from 39.3% to 78.6%. Being 22.9% higher 
      than in the urban area. CONCLUSION: The studied teleophthalmology program 
      achieved a significant increase in eye examinations. These kinds of programs are 
      essential to face blindness due to diabetes in the rural regions of Argentina.
CI  - Univesidad Nacional de Córdoba
FAU - Ortiz-Basso, Tomas
AU  - Ortiz-Basso T
AD  - Servicio de Oftalmología. Hospital italiano de Buenos Aires. 
      tomas.ortiz@hospitalitaliano.org.ar.
FAU - Gomez, Paula Verónica
AU  - Gomez PV
AD  - Hospital Comunitario Evita, Santa Rosa, La Pampa.. paulavgomez1975@gmail.com.
FAU - Boffelli, Analia
AU  - Boffelli A
AD  - Directora Centro de Salud Enfermera Nélida Maldonado, Santa Rosa, La Pampa. 
      aniboffelli@gmail.com.
FAU - Paladini, Ariel
AU  - Paladini A
AD  - Director Atención Primaria y Gestión Sanitaria, Ministerio de Salud de La Pampa. 
      aapaladini@gmail.com.
LA  - spa
PT  - Journal Article
TT  - Evaluación de un programa de teleoftalmología para prevención de la ceguera por 
      diabetes en una zona rural de la Argentina.
DEP - 20220307
PL  - Argentina
TA  - Rev Fac Cien Med Univ Nac Cordoba
JT  - Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)
JID - 8303003
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - Pregnancy, High-Risk
MH  - Risk Factors
PMC - PMC9004306
OTO - NOTNLM
OT  - preeclampsia
OT  - eclampsia
OT  - hypertension
OT  - pregnancy
OT  - aspirin
COIS- Conflicto de interés: Ninguno.
EDAT- 2022/03/22 06:00
MHDA- 2022/03/24 06:00
CRDT- 2022/03/21 12:47
PHST- 2021/12/07 00:00 [received]
PHST- 2022/02/07 00:00 [accepted]
PHST- 2022/03/21 12:47 [entrez]
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
AID - 35775 [pii]
AID - 10.31053/1853.0605.v79.n1.35775 [doi]
PST - epublish
SO  - Rev Fac Cien Med Univ Nac Cordoba. 2022 Mar 7;79(1):10-14. doi: 
      10.31053/1853.0605.v79.n1.35775.

PMID- 7528306
OWN - NLM
STAT- MEDLINE
DCOM- 19950125
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 24
IP  - 3
DP  - 1994 Sep
TI  - Thromboxane receptor antagonist BMS-180291, but not aspirin, reduces the severity 
      of pacing-induced ischemia in dogs.
PG  - 493-9
AB  - We determined the effect of thromboxane A2 (TXA2) prostaglandin endoperoxide (TP) 
      receptor antagonism, using BMS-180291 or aspirin, on the severity of 
      pacing-induced ischemia in anesthetized dogs. Thromboxane receptor antagonists 
      may not only have antithrombotic activity, but may also have direct 
      cardioprotective effects, unlike aspirin. Left anterior descending coronary 
      artery (LAD) stenosis was adjusted so that a significant (10-12 mV) ST segment 
      elevation was observed only when superimposed on atrial pacing. Each heart was 
      subjected to 5-min episodes of pacing-induced ischemia 10, 40, and 70 min after 
      initiation of BMS-180291 (1 mg/kg + 1 mg/kg/h) or vehicle. In the vehicle group, 
      ST segment elevation was reproducible at all pacing-induced ischemia episodes, 
      whereas BMS-180291 significantly reduced it by 30% at the later ischemia 
      episodes. This reduction in ST segment increase was not accompanied by 
      alterations in regional myocardial blood flow (RMBF) nor in hemodynamic status. 
      Aspirin in the same model [10 mg/kg intravenously (i.v.) given 10 min before 
      pacing-induced ischemia] did not significantly reduce ST segment elevation, 
      indicating a lack of protective effect in this model. Thromboxane receptor 
      blockade appears to protect myocardium subjected to pacing-induced ischemia, an 
      effect not produced by aspirin.
FAU - Grover, G J
AU  - Grover GJ
AD  - Department of Pharmacology, Bristol-Myers Squibb Pharmaceutical Research 
      Institute, Princeton, New Jersey 08543-4000.
FAU - Schumacher, W A
AU  - Schumacher WA
FAU - Ogletree, M L
AU  - Ogletree ML
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Oxazoles)
RN  - 0 (Propionates)
RN  - 0 (Receptors, Thromboxane)
RN  - E833KT807K (ifetroban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina Pectoris/drug therapy
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - *Bridged Bicyclo Compounds, Heterocyclic
MH  - Cardiac Pacing, Artificial
MH  - Coronary Circulation/drug effects
MH  - Disease Models, Animal
MH  - Dogs
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Injections, Intravenous
MH  - Male
MH  - Myocardial Ischemia/*drug therapy
MH  - Oxazoles/administration & dosage/blood/pharmacology/*therapeutic use
MH  - Propionates/administration & dosage/blood/pharmacology/*therapeutic use
MH  - Radioligand Assay
MH  - Receptors, Thromboxane/*antagonists & inhibitors
EDAT- 1994/09/01 00:00
MHDA- 1994/09/01 00:01
CRDT- 1994/09/01 00:00
PHST- 1994/09/01 00:00 [pubmed]
PHST- 1994/09/01 00:01 [medline]
PHST- 1994/09/01 00:00 [entrez]
AID - 10.1097/00005344-199409000-00019 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1994 Sep;24(3):493-9. doi: 
      10.1097/00005344-199409000-00019.

PMID- 27881565
OWN - NLM
STAT- MEDLINE
DCOM- 20170502
LR  - 20201215
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 135
IP  - 7
DP  - 2017 Feb 14
TI  - Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With 
      Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
PG  - 659-670
LID - 10.1161/CIRCULATIONAHA.116.025760 [doi]
AB  - BACKGROUND: The long-term efficacy and safety of low-dose aspirin for primary 
      prevention of cardiovascular events in patients with type 2 diabetes mellitus are 
      still inconclusive. METHODS: The JPAD trial (Japanese Primary Prevention of 
      Atherosclerosis With Aspirin for Diabetes) was a randomized, open-label, standard 
      care-controlled trial examining whether low-dose aspirin affected cardiovascular 
      events in 2539 Japanese patients with type 2 diabetes mellitus and without 
      preexisting cardiovascular disease. Patients were randomly allocated to receive 
      aspirin (81 or 100 mg daily; aspirin group) or no aspirin (no-aspirin group) in 
      the JPAD trial. After that trial ended in 2008, we followed up with the patients 
      until 2015, with no attempt to change the previously assigned therapy. Primary 
      end points were cardiovascular events, including sudden death, fatal or nonfatal 
      coronary artery disease, fatal or nonfatal stroke, and peripheral vascular 
      disease. For the safety analysis, hemorrhagic events, consisting of 
      gastrointestinal bleeding, hemorrhagic stroke, and bleeding from any other sites, 
      were also analyzed. The primary analysis was conducted for cardiovascular events 
      among patients who retained their original allocation (a per-protocol cohort). 
      Analyses on an intention-to-treat cohort were conducted for hemorrhagic events 
      and statistical sensitivity. RESULTS: The median follow-up period was 10.3 years; 
      1621 patients (64%) were followed up throughout the study; and 2160 patients 
      (85%) retained their original allocation. Low-dose aspirin did not reduce 
      cardiovascular events in the per-protocol cohort (hazard ratio, 1.14; 95% 
      confidence interval, 0.91-1.42). Multivariable Cox proportional hazard model 
      adjusted for age, sex, glycemic control, kidney function, smoking status, 
      hypertension, and dyslipidemia showed similar results (hazard ratio, 1.04; 95% 
      confidence interval, 0.83-1.30), with no heterogeneity of efficacy in subgroup 
      analyses stratified by each of these factors (all interaction P>0.05). 
      Sensitivity analyses on the intention-to-treat cohort yielded consistent results 
      (hazard ratio, 1.01; 95% confidence interval, 0.82-1.25). Gastrointestinal 
      bleeding occurred in 25 patients (2%) in the aspirin group and 12 (0.9%) in the 
      no-aspirin group (P=0.03), and the incidence of hemorrhagic stroke was not 
      different between groups. CONCLUSIONS: Low-dose aspirin did not affect the risk 
      for cardiovascular events but increased risk for gastrointestinal bleeding in 
      patients with type 2 diabetes mellitus in a primary prevention setting. CLINICAL 
      TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: 
      NCT00110448.
CI  - © 2016 American Heart Association, Inc.
FAU - Saito, Yoshihiko
AU  - Saito Y
AD  - From First Department of Internal Medicine (Y.S., S.O.) and Department of 
      Diabetology (S.O.), Nara Medical University, Kashihara, Japan; National Cerebral 
      and Cardiovascular Center, Suita, Osaka, Japan (H.O.); Department of 
      Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, 
      Cyuo-ku, Japan (H.S.); Department of Clinical Epidemiology, Hyogo College of 
      Medicine, Nishinomiya, Japan (M.S., T.M.); Nakayama Cardiovascular Clinic, 
      Amakusa, Kumamoto, Japan (M.N.); Department of Cardiology, Nara Prefecture 
      Western Medical Center, Sango-cho, Ikoma-gun, Japan (N.D.); Diabetes Center, 
      Jinnouchi Hospital, Chuo-ku, Kumamoto, Japan (H.J.); Department of Internal 
      Medicine, Shizuoka City Hospital, Japan (M.W.); and Medical Examination Center, 
      Takeda Hospital, Shimogyo- ku, Kyoto, Japan (I.M.). yssaito@naramed-u.ac.jp.
FAU - Okada, Sadanori
AU  - Okada S
AD  - From First Department of Internal Medicine (Y.S., S.O.) and Department of 
      Diabetology (S.O.), Nara Medical University, Kashihara, Japan; National Cerebral 
      and Cardiovascular Center, Suita, Osaka, Japan (H.O.); Department of 
      Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, 
      Cyuo-ku, Japan (H.S.); Department of Clinical Epidemiology, Hyogo College of 
      Medicine, Nishinomiya, Japan (M.S., T.M.); Nakayama Cardiovascular Clinic, 
      Amakusa, Kumamoto, Japan (M.N.); Department of Cardiology, Nara Prefecture 
      Western Medical Center, Sango-cho, Ikoma-gun, Japan (N.D.); Diabetes Center, 
      Jinnouchi Hospital, Chuo-ku, Kumamoto, Japan (H.J.); Department of Internal 
      Medicine, Shizuoka City Hospital, Japan (M.W.); and Medical Examination Center, 
      Takeda Hospital, Shimogyo- ku, Kyoto, Japan (I.M.).
FAU - Ogawa, Hisao
AU  - Ogawa H
AD  - From First Department of Internal Medicine (Y.S., S.O.) and Department of 
      Diabetology (S.O.), Nara Medical University, Kashihara, Japan; National Cerebral 
      and Cardiovascular Center, Suita, Osaka, Japan (H.O.); Department of 
      Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, 
      Cyuo-ku, Japan (H.S.); Department of Clinical Epidemiology, Hyogo College of 
      Medicine, Nishinomiya, Japan (M.S., T.M.); Nakayama Cardiovascular Clinic, 
      Amakusa, Kumamoto, Japan (M.N.); Department of Cardiology, Nara Prefecture 
      Western Medical Center, Sango-cho, Ikoma-gun, Japan (N.D.); Diabetes Center, 
      Jinnouchi Hospital, Chuo-ku, Kumamoto, Japan (H.J.); Department of Internal 
      Medicine, Shizuoka City Hospital, Japan (M.W.); and Medical Examination Center, 
      Takeda Hospital, Shimogyo- ku, Kyoto, Japan (I.M.).
FAU - Soejima, Hirofumi
AU  - Soejima H
AD  - From First Department of Internal Medicine (Y.S., S.O.) and Department of 
      Diabetology (S.O.), Nara Medical University, Kashihara, Japan; National Cerebral 
      and Cardiovascular Center, Suita, Osaka, Japan (H.O.); Department of 
      Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, 
      Cyuo-ku, Japan (H.S.); Department of Clinical Epidemiology, Hyogo College of 
      Medicine, Nishinomiya, Japan (M.S., T.M.); Nakayama Cardiovascular Clinic, 
      Amakusa, Kumamoto, Japan (M.N.); Department of Cardiology, Nara Prefecture 
      Western Medical Center, Sango-cho, Ikoma-gun, Japan (N.D.); Diabetes Center, 
      Jinnouchi Hospital, Chuo-ku, Kumamoto, Japan (H.J.); Department of Internal 
      Medicine, Shizuoka City Hospital, Japan (M.W.); and Medical Examination Center, 
      Takeda Hospital, Shimogyo- ku, Kyoto, Japan (I.M.).
FAU - Sakuma, Mio
AU  - Sakuma M
AD  - From First Department of Internal Medicine (Y.S., S.O.) and Department of 
      Diabetology (S.O.), Nara Medical University, Kashihara, Japan; National Cerebral 
      and Cardiovascular Center, Suita, Osaka, Japan (H.O.); Department of 
      Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, 
      Cyuo-ku, Japan (H.S.); Department of Clinical Epidemiology, Hyogo College of 
      Medicine, Nishinomiya, Japan (M.S., T.M.); Nakayama Cardiovascular Clinic, 
      Amakusa, Kumamoto, Japan (M.N.); Department of Cardiology, Nara Prefecture 
      Western Medical Center, Sango-cho, Ikoma-gun, Japan (N.D.); Diabetes Center, 
      Jinnouchi Hospital, Chuo-ku, Kumamoto, Japan (H.J.); Department of Internal 
      Medicine, Shizuoka City Hospital, Japan (M.W.); and Medical Examination Center, 
      Takeda Hospital, Shimogyo- ku, Kyoto, Japan (I.M.).
FAU - Nakayama, Masafumi
AU  - Nakayama M
AD  - From First Department of Internal Medicine (Y.S., S.O.) and Department of 
      Diabetology (S.O.), Nara Medical University, Kashihara, Japan; National Cerebral 
      and Cardiovascular Center, Suita, Osaka, Japan (H.O.); Department of 
      Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, 
      Cyuo-ku, Japan (H.S.); Department of Clinical Epidemiology, Hyogo College of 
      Medicine, Nishinomiya, Japan (M.S., T.M.); Nakayama Cardiovascular Clinic, 
      Amakusa, Kumamoto, Japan (M.N.); Department of Cardiology, Nara Prefecture 
      Western Medical Center, Sango-cho, Ikoma-gun, Japan (N.D.); Diabetes Center, 
      Jinnouchi Hospital, Chuo-ku, Kumamoto, Japan (H.J.); Department of Internal 
      Medicine, Shizuoka City Hospital, Japan (M.W.); and Medical Examination Center, 
      Takeda Hospital, Shimogyo- ku, Kyoto, Japan (I.M.).
FAU - Doi, Naofumi
AU  - Doi N
AD  - From First Department of Internal Medicine (Y.S., S.O.) and Department of 
      Diabetology (S.O.), Nara Medical University, Kashihara, Japan; National Cerebral 
      and Cardiovascular Center, Suita, Osaka, Japan (H.O.); Department of 
      Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, 
      Cyuo-ku, Japan (H.S.); Department of Clinical Epidemiology, Hyogo College of 
      Medicine, Nishinomiya, Japan (M.S., T.M.); Nakayama Cardiovascular Clinic, 
      Amakusa, Kumamoto, Japan (M.N.); Department of Cardiology, Nara Prefecture 
      Western Medical Center, Sango-cho, Ikoma-gun, Japan (N.D.); Diabetes Center, 
      Jinnouchi Hospital, Chuo-ku, Kumamoto, Japan (H.J.); Department of Internal 
      Medicine, Shizuoka City Hospital, Japan (M.W.); and Medical Examination Center, 
      Takeda Hospital, Shimogyo- ku, Kyoto, Japan (I.M.).
FAU - Jinnouchi, Hideaki
AU  - Jinnouchi H
AD  - From First Department of Internal Medicine (Y.S., S.O.) and Department of 
      Diabetology (S.O.), Nara Medical University, Kashihara, Japan; National Cerebral 
      and Cardiovascular Center, Suita, Osaka, Japan (H.O.); Department of 
      Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, 
      Cyuo-ku, Japan (H.S.); Department of Clinical Epidemiology, Hyogo College of 
      Medicine, Nishinomiya, Japan (M.S., T.M.); Nakayama Cardiovascular Clinic, 
      Amakusa, Kumamoto, Japan (M.N.); Department of Cardiology, Nara Prefecture 
      Western Medical Center, Sango-cho, Ikoma-gun, Japan (N.D.); Diabetes Center, 
      Jinnouchi Hospital, Chuo-ku, Kumamoto, Japan (H.J.); Department of Internal 
      Medicine, Shizuoka City Hospital, Japan (M.W.); and Medical Examination Center, 
      Takeda Hospital, Shimogyo- ku, Kyoto, Japan (I.M.).
FAU - Waki, Masako
AU  - Waki M
AD  - From First Department of Internal Medicine (Y.S., S.O.) and Department of 
      Diabetology (S.O.), Nara Medical University, Kashihara, Japan; National Cerebral 
      and Cardiovascular Center, Suita, Osaka, Japan (H.O.); Department of 
      Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, 
      Cyuo-ku, Japan (H.S.); Department of Clinical Epidemiology, Hyogo College of 
      Medicine, Nishinomiya, Japan (M.S., T.M.); Nakayama Cardiovascular Clinic, 
      Amakusa, Kumamoto, Japan (M.N.); Department of Cardiology, Nara Prefecture 
      Western Medical Center, Sango-cho, Ikoma-gun, Japan (N.D.); Diabetes Center, 
      Jinnouchi Hospital, Chuo-ku, Kumamoto, Japan (H.J.); Department of Internal 
      Medicine, Shizuoka City Hospital, Japan (M.W.); and Medical Examination Center, 
      Takeda Hospital, Shimogyo- ku, Kyoto, Japan (I.M.).
FAU - Masuda, Izuru
AU  - Masuda I
AD  - From First Department of Internal Medicine (Y.S., S.O.) and Department of 
      Diabetology (S.O.), Nara Medical University, Kashihara, Japan; National Cerebral 
      and Cardiovascular Center, Suita, Osaka, Japan (H.O.); Department of 
      Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, 
      Cyuo-ku, Japan (H.S.); Department of Clinical Epidemiology, Hyogo College of 
      Medicine, Nishinomiya, Japan (M.S., T.M.); Nakayama Cardiovascular Clinic, 
      Amakusa, Kumamoto, Japan (M.N.); Department of Cardiology, Nara Prefecture 
      Western Medical Center, Sango-cho, Ikoma-gun, Japan (N.D.); Diabetes Center, 
      Jinnouchi Hospital, Chuo-ku, Kumamoto, Japan (H.J.); Department of Internal 
      Medicine, Shizuoka City Hospital, Japan (M.W.); and Medical Examination Center, 
      Takeda Hospital, Shimogyo- ku, Kyoto, Japan (I.M.).
FAU - Morimoto, Takeshi
AU  - Morimoto T
AD  - From First Department of Internal Medicine (Y.S., S.O.) and Department of 
      Diabetology (S.O.), Nara Medical University, Kashihara, Japan; National Cerebral 
      and Cardiovascular Center, Suita, Osaka, Japan (H.O.); Department of 
      Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, 
      Cyuo-ku, Japan (H.S.); Department of Clinical Epidemiology, Hyogo College of 
      Medicine, Nishinomiya, Japan (M.S., T.M.); Nakayama Cardiovascular Clinic, 
      Amakusa, Kumamoto, Japan (M.N.); Department of Cardiology, Nara Prefecture 
      Western Medical Center, Sango-cho, Ikoma-gun, Japan (N.D.); Diabetes Center, 
      Jinnouchi Hospital, Chuo-ku, Kumamoto, Japan (H.J.); Department of Internal 
      Medicine, Shizuoka City Hospital, Japan (M.W.); and Medical Examination Center, 
      Takeda Hospital, Shimogyo- ku, Kyoto, Japan (I.M.).
CN  - JPAD Trial Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00110448
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20161115
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 2017 May 2;135(18):e1008-e1009. PMID: 28461421
CIN - Circulation. 2017 May 2;135(18):e1010-e1011. PMID: 28461422
CIN - Ann Transl Med. 2018 Jun;6(11):218. PMID: 30023381
CIN - Ann Transl Med. 2018 Jun;6(11):219. PMID: 30023382
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Diabetes Complications/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Risk Factors
MH  - Time Factors
OTO - NOTNLM
OT  - aspirin
OT  - diabetes mellitus
OT  - hemorrhage
OT  - primary prevention
EDAT- 2016/11/25 06:00
MHDA- 2017/05/04 06:00
CRDT- 2016/11/25 06:00
PHST- 2016/10/03 00:00 [received]
PHST- 2016/11/04 00:00 [accepted]
PHST- 2016/11/25 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
PHST- 2016/11/25 06:00 [entrez]
AID - CIRCULATIONAHA.116.025760 [pii]
AID - 10.1161/CIRCULATIONAHA.116.025760 [doi]
PST - ppublish
SO  - Circulation. 2017 Feb 14;135(7):659-670. doi: 10.1161/CIRCULATIONAHA.116.025760. 
      Epub 2016 Nov 15.

PMID- 32593779
OWN - NLM
STAT- MEDLINE
DCOM- 20210827
LR  - 20210827
IS  - 2468-7847 (Electronic)
IS  - 2468-7847 (Linking)
VI  - 49
IP  - 9
DP  - 2020 Nov
TI  - Aspirin for the prevention of placenta-mediated complications in pregnant women 
      with chronic hypertension.
PG  - 101845
LID - S2468-7847(20)30189-6 [pii]
LID - 10.1016/j.jogoh.2020.101845 [doi]
AB  - Chronic hypertension affects 1-5% of women of childbearing age. During pregnancy, 
      chronic hypertension is associated with an increased risk of vascular disease 
      such as superimposed preeclampsia (PE), intrauterine growth retardation (IUGR), 
      placental abruption, and preterm delivery. These serious and frequent 
      pathologies, specific to pregnancy, carry a particularly high risk of maternal 
      complications (HELLP syndrome, eclampsia, maternal death) and perinatal 
      complications (perinatal death, neurological disorders). To date, there is no 
      curative treatment of vascular complications of chronic hypertension during 
      pregnancy. The only effective treatment, once the complications are established, 
      is usually stopping the pregnancy and delivering the placenta. Some 
      recommendations suggest the use of low dose aspirin in the prevention of these 
      complications. Although the efficacy of low-dose aspirin is assumed in patients 
      with previous preeclampsia, few studies have evaluated its efficacy in patients 
      with chronic hypertension. Controlled prospective studies using very low doses of 
      aspirin (less than 100 mg) and started after 15 weeks of gestation do not seem 
      conclusive. The objective of this work is first to detail the complications of 
      chronic hypertension during pregnancy, then to analyze the studies which 
      evaluated the interest of low dose aspirin in prevention of the placental 
      vascular complications of the pregnancy in patients with chronic hypertension. We 
      also propose an update on the European and North American national 
      recommendations for the prevention of preeclampsia by low dose aspirin in the 
      high-risk population of patients with chronic hypertension. Finally we present 
      the CHASAP (Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy) trial 
      (NCT04356326), a multicentric prospective randomized double-blind superiority 
      trial, which will compare, in pregnant women with chronic hypertension, the 
      efficacy of low dose aspirin (150 mg/day) with a placebo, in the prevention of 
      maternal-fetal morbidity and mortality (preeclampsia, placental abruption, IUGR, 
      perinatal death, maternal death, and preterm delivery).
CI  - Copyright © 2020. Published by Elsevier Masson SAS.
FAU - Lecarpentier, E
AU  - Lecarpentier E
AD  - University Paris Est Créteil and CHI Créteil, Créteil, France; Department of 
      Obstetrics Gynecology and Reproductive Medicine, University Paris Est Créteil, 
      Centre Hospitalier Inter-Communal de Créteil, France.
FAU - Haddad, B
AU  - Haddad B
AD  - University Paris Est Créteil and CHI Créteil, Créteil, France; Department of 
      Obstetrics Gynecology and Reproductive Medicine, University Paris Est Créteil, 
      Centre Hospitalier Inter-Communal de Créteil, France. Electronic address: 
      Bassam.Haddad@chicreteil.fr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200625
PL  - France
TA  - J Gynecol Obstet Hum Reprod
JT  - Journal of gynecology obstetrics and human reproduction
JID - 101701588
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - France/epidemiology
MH  - Humans
MH  - Hypertension/*complications/epidemiology
MH  - Placenta
MH  - Pre-Eclampsia/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*drug therapy/epidemiology
MH  - Randomized Controlled Trials as Topic/methods
MH  - Risk Factors
OTO - NOTNLM
OT  - Chronic Hypertension Aspirin
OT  - Placenta-mediated complications
OT  - Preeclampsia
OT  - Pregnancy
EDAT- 2020/07/01 06:00
MHDA- 2021/08/28 06:00
CRDT- 2020/06/29 06:00
PHST- 2020/05/02 00:00 [received]
PHST- 2020/06/21 00:00 [revised]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/08/28 06:00 [medline]
PHST- 2020/06/29 06:00 [entrez]
AID - S2468-7847(20)30189-6 [pii]
AID - 10.1016/j.jogoh.2020.101845 [doi]
PST - ppublish
SO  - J Gynecol Obstet Hum Reprod. 2020 Nov;49(9):101845. doi: 
      10.1016/j.jogoh.2020.101845. Epub 2020 Jun 25.

PMID- 1154471
OWN - NLM
STAT- MEDLINE
DCOM- 19751106
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 6
IP  - 4
DP  - 1975 Jul-Aug
TI  - Endothelial cell ischemic injury: protective effect of heparin or aspirin 
      assessed by scanning electron microscopy.
PG  - 357-60
AB  - Scanning electron microscopic observations of the luminal surface of the rabbit 
      common carotid artery subjected to occlusion for 30 minutes or two hours revealed 
      crater-like and balloon-like defects in the endothelial surface. The frequency of 
      occurrence of these abnormalities was significantly decreased by pretreatment 
      with heparin or aspirin in doses considered to have antiplatelet aggregating 
      activity.
FAU - Gertz, D
AU  - Gertz D
FAU - Rennels, M L
AU  - Rennels ML
FAU - Nelson, E
AU  - Nelson E
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Carotid Arteries/pathology/*ultrastructure
MH  - Carotid Artery Diseases/pathology
MH  - Cerebrovascular Disorders/pathology
MH  - Endothelium/ultrastructure
MH  - Heparin/pharmacology/*therapeutic use
MH  - Ischemic Attack, Transient/*pathology
MH  - Microscopy, Electron, Scanning
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
MH  - Thromboembolism/prevention & control
MH  - Time Factors
EDAT- 1975/07/01 00:00
MHDA- 1975/07/01 00:01
CRDT- 1975/07/01 00:00
PHST- 1975/07/01 00:00 [pubmed]
PHST- 1975/07/01 00:01 [medline]
PHST- 1975/07/01 00:00 [entrez]
AID - 10.1161/01.str.6.4.357 [doi]
PST - ppublish
SO  - Stroke. 1975 Jul-Aug;6(4):357-60. doi: 10.1161/01.str.6.4.357.

PMID- 1124349
OWN - NLM
STAT- MEDLINE
DCOM- 19750707
LR  - 20131121
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 10
IP  - 2
DP  - 1975
TI  - Effects of carbenoxolone sodium and of aspirin on gastric mucosal potential 
      difference in normal subjects.
PG  - 161-4
AB  - The fall in potential difference (p.d.) across the gastric mucosa induced by 
      aspirin has been studied before and after administration of carbenoxolone sodium 
      in normal subjects. The subjects received 300 mg of carbenoxolone sodium daily 
      for 14 days. The mean percentage fall in p.d. measured 10 cm distal to the cardia 
      was unchanged.
FAU - Bennett, P N
AU  - Bennett PN
FAU - Frigo, G M
AU  - Frigo GM
FAU - Weerasinghe, W M
AU  - Weerasinghe WM
FAU - Lennard-Jones, J E
AU  - Lennard-Jones JE
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Succinates)
RN  - 0 (Triterpenes)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Action Potentials/*drug effects
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cardia/drug effects
MH  - Depression, Chemical
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/*drug effects
MH  - Glycyrrhiza
MH  - Humans
MH  - Male
MH  - Plants, Medicinal
MH  - Sodium/pharmacology
MH  - Stimulation, Chemical
MH  - Succinates/administration & dosage/pharmacology
MH  - Triterpenes/administration & dosage/*pharmacology
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol. 1975;10(2):161-4.

PMID- 26138568
OWN - NLM
STAT- MEDLINE
DCOM- 20160427
LR  - 20190923
IS  - 1875-5402 (Electronic)
IS  - 1386-2073 (Linking)
VI  - 18
IP  - 6
DP  - 2015
TI  - Prediction of Bioactive Compounds Using Computed NMR Chemical Shifts.
PG  - 562-76
AB  - NMR based chemical shifts are an important diagnostic parameter for structure 
      elucidation as they capture rich information related to conformational, 
      electronic and stereochemical arrangement of functional groups in a molecule 
      which is responsible for its activity towards any biological target. The present 
      work discusses the importance of computing NMR chemical shifts from molecular 
      structures. The NMR chemical shift data (experimental or computed) was used to 
      generate fingerprints in binary formats for mapping molecular fragments (as 
      descriptors) and correlating with the bioactivity classes. For this study, 
      chemical shift data derived binary fingerprints were computed for 149 classes and 
      4800 bioactive molecules. The sensitivity and selectivity of fingerprints in 
      discriminating molecules belonging to different therapeutic categories was 
      assessed using a LibSVM based classifier. An accuracy of 82% for proton and 94% 
      for carbon NMR fingerprints were obtained for anti-psoriatic and anti-psychotic 
      molecules demonstrating the effectiveness of this approach for virtual screening.
FAU - Karthikeyan, Muthukumarasamy
AU  - Karthikeyan M
AD  - Digital Information Resource Centre (DIRC) & Centre of Excellence in Scientific 
      Computing (CoESC) CSIR-National Chemical Laboratory Pune - 411008 India. 
      m.karthikeyan@ncl.res.in.
FAU - Rajamohanan, Pattuparambil Ramanpillai
AU  - Rajamohanan PR
FAU - Vyas, Renu
AU  - Vyas R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Comb Chem High Throughput Screen
JT  - Combinatorial chemistry & high throughput screening
JID - 9810948
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Small Molecule Libraries)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - *Datasets as Topic
MH  - *Drug Discovery
MH  - Hypoglycemic Agents/chemistry
MH  - *Magnetic Resonance Spectroscopy
MH  - Molecular Structure
MH  - Small Molecule Libraries/*chemistry
EDAT- 2015/07/04 06:00
MHDA- 2016/04/28 06:00
CRDT- 2015/07/04 06:00
PHST- 2014/02/13 00:00 [received]
PHST- 2014/04/01 00:00 [revised]
PHST- 2015/06/30 00:00 [accepted]
PHST- 2015/07/04 06:00 [entrez]
PHST- 2015/07/04 06:00 [pubmed]
PHST- 2016/04/28 06:00 [medline]
AID - CCHTS-EPUB-68536 [pii]
AID - 10.2174/1386207318666150703113312 [doi]
PST - ppublish
SO  - Comb Chem High Throughput Screen. 2015;18(6):562-76. doi: 
      10.2174/1386207318666150703113312.

PMID- 15471389
OWN - NLM
STAT- MEDLINE
DCOM- 20050620
LR  - 20181130
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 76
IP  - 8
DP  - 2004
TI  - [Dysaggregants effect of platelet aggregation in patients with non-ST segment 
      elevation acute coronary syndrome].
PG  - 18-22
AB  - AIM: To study efficacy of treating patients with acute coronary syndrome (ACS) 
      without ST segment elevation (STSE) with platelet dysaggregation drugs (aspirin, 
      cardiomagnil, clopidogrel). MATERIAL AND METHODS: 78 ACS without STSE were 
      randomized into five groups: group 1 patients (n = 17) received no dysaggregants; 
      patients of group 2 (n = 26) received aspirin in the dose 250 mg on the day of 
      admission and then 125 mg/day; group 3 was given cardiomagnil (150 mg on the day 
      of admission and then 75 mg/day, n = 17); group 4--clopidogrel 75 mg/day (n = 7); 
      group 5--combination of clopidogrel 75 mg/day with cardiomagnil 75 mg/day (n = 
      11). All the patients were administered fraxiparin 86 IU/kg sc each 12 hours for 
      5-8 days. RESULTS: Group 1 patients showed platelet hyperaggregation, platelet 
      aggregation decreased in groups 2, 3 and 4 (6 patients of group 1 were resistant 
      to aspirin). The highest antiaggregation effect was achieved in group 5. 
      CONCLUSION: Control over antiaggregation treatment in patients with ACS without 
      STSE by monitoring of platelet function open broad opportunities for selection of 
      effective individual therapy.
FAU - Poponina, T M
AU  - Poponina TM
FAU - Kapilevich, N A
AU  - Kapilevich NA
FAU - Kisteneva, I V
AU  - Kisteneva IV
FAU - Markov, V A
AU  - Markov VA
FAU - Novitskiĭ, V V
AU  - Novitskiĭ VV
LA  - rus
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Vlilanie dezagregantov na agregatsiiu trombotsitov u bol'nykh s ostrym koronarnym 
      sindromom bez pod'ema segmenta ST.
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Nadroparin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Clopidogrel
MH  - Coronary Disease/*drug therapy
MH  - Electrocardiography
MH  - Female
MH  - Humans
MH  - Male
MH  - Nadroparin/pharmacology/therapeutic use
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Syndrome
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2004/10/09 09:00
MHDA- 2005/06/21 09:00
CRDT- 2004/10/09 09:00
PHST- 2004/10/09 09:00 [pubmed]
PHST- 2005/06/21 09:00 [medline]
PHST- 2004/10/09 09:00 [entrez]
PST - ppublish
SO  - Ter Arkh. 2004;76(8):18-22.

PMID- 15735806
OWN - NLM
STAT- MEDLINE
DCOM- 20090915
LR  - 20181201
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 93
IP  - 3
DP  - 2005 Mar
TI  - Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet 
      thromboembolism and intimal thickening in mice.
PG  - 535-43
AB  - Clopidogrel plus aspirin is the treatment of choice for patients undergoing 
      percutaneous, coronary interventions with stenting, but it does not prevent 
      restenosis. NCX-4016, a nitric oxide-releasing aspirin (nitroaspirin), exerts a 
      wider range of antiplatelet actions compared to aspirin, superior antithrombotic 
      activity and reduces restenosis after arterial injury in animals. The aim of the 
      present study was to compare the combination of nitroaspirin plus clopidogrel 
      with aspirin plus clopidogrel in a model of platelet pulmonary thromboembolism, 
      bleeding and intimal thickening in mice. Drugs were administered orally for 5 
      days; the antithrombotic effects were evaluated against collagen plus 
      epinephrine-induced pulmonary thromboembolism, the haemorrhagic effects by tail 
      transection bleeding time and the effects on neointima proliferation by 
      histomorphology of photochemically injured femoral arteries. Lung platelet emboli 
      were reduced significantly and more effectively by nitroaspirin plus clopidogrel 
      (-56%, p<0.05 vs control) than by aspirin plus clopidogrel (-26%, p<0.05 vs 
      control). Ex vivo platelet aggregation was inhibited maximally by nitroaspirin 
      plus clopidogrel. Aspirin plus clopidogrel strikingly prolonged the bleeding time 
      while nitroaspirin plus clopidogrel induced a lesser prolongation. Nitroaspirin 
      plus clopidogrel significantly reduced intimal thickening of the femoral artery 
      while aspirin plus clopidogrel was ineffective. Nitroaspirin plus clopidogrel is 
      more effective and less prohaemorrhagic than aspirin plus clopidogrel in mice; 
      provided these data are confirmed in other animal models, nitroaspirin plus 
      clopidogrel may represent a new regimen to be tested in patients undergoing 
      coronary revascularization procedures.
FAU - Momi, Stefania
AU  - Momi S
AD  - Department of Internal Medicine, Section of Internal and Cardiovascular Medicine, 
      University of Perugia, Perugia, Italy.
FAU - Pitchford, Simon C
AU  - Pitchford SC
FAU - Alberti, Paolo F
AU  - Alberti PF
FAU - Minuz, Pietro
AU  - Minuz P
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Gresele, Paolo
AU  - Gresele P
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - EH04H13L6B (nitroaspirin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/*analogs & derivatives/pharmacology
MH  - Blood Coagulation Tests
MH  - Clopidogrel
MH  - Disease Models, Animal
MH  - Drug Therapy, Combination
MH  - Hemorrhage
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology
MH  - Pulmonary Embolism/prevention & control
MH  - Survival Rate
MH  - Thromboembolism/*drug therapy/mortality
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Tunica Intima/*drug effects/pathology
EDAT- 2005/03/01 09:00
MHDA- 2009/09/16 06:00
CRDT- 2005/03/01 09:00
PHST- 2005/03/01 09:00 [pubmed]
PHST- 2009/09/16 06:00 [medline]
PHST- 2005/03/01 09:00 [entrez]
AID - 05030535 [pii]
AID - 10.1160/TH04-07-0464 [doi]
PST - ppublish
SO  - Thromb Haemost. 2005 Mar;93(3):535-43. doi: 10.1160/TH04-07-0464.

PMID- 10703994
OWN - NLM
STAT- MEDLINE
DCOM- 20000313
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 21
IP  - 2
DP  - 1999 Nov
TI  - A comparative bioavailability study of different aspirin formulations using 
      on-line multidimensional chromatography.
PG  - 383-92
AB  - A multi-dimensional column chromatographic method employing UV spectrometric 
      detection was optimised and successfully used in a comparative bio-availability 
      study of aspirin obtained from different commercially available oral dosage 
      forms. Sample clean-up was achieved by on-line solid-phase extraction. In this 
      study, the bioavailability of aspirin was compared in plain aspirin tablets, 
      chewed tablets, effervescent tablets and Enteric-coated aspirin tablets. Blood 
      samples were taken at frequent intervals after single dosing in ten healthy 
      volunteers, the plasma samples were first treated with physostigmine sulphate to 
      minimise enzymatic hydrolysis of aspirin to salicylate. The results showed the 
      measured Tmax, Cmax, and AUC was significantly higher for soluble aspirin than 
      for the other formulations and the t1/2 was shorter. This indicates the rapid 
      absorption of aspirin from a soluble formulation compared with that from the 
      other formulations. These differences suggest that the soluble formulation could 
      be the aspirin of choice to treat patients suspected to be at high risk of 
      myocardial infarction. The method performs, in a single step, an efficient 
      extraction and clean-up of aspirin from human plasma. The calibration graph was 
      linear over the calibration range 0.2-12 microg ml(-1) plasma with a limit of 
      detection of 0.1 microg ml(-1). The intra- and inter-assay coefficients of 
      variation were less than 6% and the recoveries ranged from 86 to 98%. The 
      proposed method combines the advantages of being simple and selective in the 
      presence of other potential interfering drugs and is suitable for routine 
      analyses to obtain valuable information about the clinical effects of the drug 
      and its use in prevention treatments of acute myocardial infarction. The whole 
      procedure takes 7 min and is in agreement with other conventional methods.
FAU - Sagar, K A
AU  - Sagar KA
AD  - School of Chemical Sciences, Dublin City University, Ireland.
FAU - Smyth, M R
AU  - Smyth MR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 9U1VM840SP (Physostigmine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/blood/*pharmacokinetics/therapeutic use
MH  - Area Under Curve
MH  - Aspirin/blood/*pharmacokinetics/therapeutic use
MH  - Biological Availability
MH  - Chemistry, Pharmaceutical
MH  - Chromatography/instrumentation/*methods
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - Physostigmine
MH  - Regression Analysis
MH  - Solubility
MH  - Tablets
MH  - Tablets, Enteric-Coated
MH  - Time Factors
EDAT- 2000/03/07 09:00
MHDA- 2000/03/18 09:00
CRDT- 2000/03/07 09:00
PHST- 2000/03/07 09:00 [pubmed]
PHST- 2000/03/18 09:00 [medline]
PHST- 2000/03/07 09:00 [entrez]
AID - S0731-7085(99)00177-6 [pii]
AID - 10.1016/s0731-7085(99)00177-6 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1999 Nov;21(2):383-92. doi: 10.1016/s0731-7085(99)00177-6.

PMID- 25174713
OWN - NLM
STAT- MEDLINE
DCOM- 20150622
LR  - 20191113
IS  - 2212-4063 (Electronic)
IS  - 1871-529X (Linking)
VI  - 14
IP  - 3
DP  - 2014
TI  - Recent developments in antiplatelet therapy after percutaneus coronary 
      intervention.
PG  - 225-30
AB  - Antiplatelet therapy plays an important role in the treatment of patients 
      suffering from acute coronary syndrome (ACS) or undergoing percutaneous coronary 
      intervention (PCI) in order to prevent atherothrombotic events and restenosis or 
      ischemic reocclusion, respectively. Moreover, stent implantation is often 
      performed along with PCI to ensure that the arteries remain open. However, stent 
      thrombosis ST is a possible complication which can occur up to about one year 
      after the procedure. Therefore, it is standard to treat patients with a dual 
      antiplatelet regime whereby aspirin is combined with either clopidogrel, 
      prasugrel or ticagrelor. This review summarizes the characteristics of these 
      P2Y12 antagonists and evaluates the current and future clinical guidelines for 
      antiplatelet therapy in the setting of PCI with or without stenting.
FAU - Yildiz, Mustafa
AU  - Yildiz M
FAU - Yildiz, Banu Sahin
AU  - Yildiz BS
FAU - Gursoy, Mustafa Ozan
AU  - Gursoy MO
FAU - Akin, Ibrahim
AU  - Akin I
AD  - Cardiologist, Internal medicine Specialist and Physiologist, Department of 
      Cardiology, Istanbul University Cardiology Institute, Istanbul, Turkey. 
      mustafayilldiz@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Cardiovasc Hematol Disord Drug Targets
JT  - Cardiovascular & hematological disorders drug targets
JID - 101269160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/therapeutic use
MH  - Stents
MH  - Thrombosis/prevention & control
EDAT- 2014/09/02 06:00
MHDA- 2015/06/24 06:00
CRDT- 2014/09/02 06:00
PHST- 2014/02/22 00:00 [received]
PHST- 2014/04/28 00:00 [revised]
PHST- 2014/04/29 00:00 [accepted]
PHST- 2014/09/02 06:00 [entrez]
PHST- 2014/09/02 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - CHDDT-EPUB-61887 [pii]
AID - 10.2174/1871529x14666140823142031 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Disord Drug Targets. 2014;14(3):225-30. doi: 
      10.2174/1871529x14666140823142031.

PMID- 22948427
OWN - NLM
STAT- MEDLINE
DCOM- 20121203
LR  - 20191112
IS  - 2340-3527 (Electronic)
IS  - 1137-6627 (Linking)
VI  - 35
IP  - 2
DP  - 2012 May-Aug
TI  - [Aspirin in the primary prevention of colorectal cancer].
PG  - 261-7
AB  - Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) have been 
      associated with a reduction in the risk of developing adenomas and colorectal 
      cancer. The available scientific evidence justifies the need for more studies 
      that evaluate the protective effect of aspirin and other NSAIDs as a preventive 
      measure against cancer of the colon; define the minimum efficient dosage; the age 
      at which to begin treatment; the most convenient duration of the latter; and the 
      sub-populations for which the benefits of chemoprophylaxis outweigh possible 
      adverse effects.
FAU - Fernández Calderón, M
AU  - Fernández Calderón M
AD  - Departamento de Digestivo, Clínica Universidad de Navarra, Pamplona 31008, Spain. 
      mfdezcalderon@gmail.com
FAU - Betés Ibáñez, M T
AU  - Betés Ibáñez MT
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - La aspirina en la prevención primaria del cáncer colorrectal.
PL  - Spain
TA  - An Sist Sanit Navar
JT  - Anales del sistema sanitario de Navarra
JID - 9710381
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Colorectal Neoplasms/*prevention & control
MH  - Humans
MH  - Primary Prevention
EDAT- 2012/09/06 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/09/06 06:00
PHST- 2012/09/06 06:00 [entrez]
PHST- 2012/09/06 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.4321/s1137-66272012000200008 [doi]
PST - ppublish
SO  - An Sist Sanit Navar. 2012 May-Aug;35(2):261-7. doi: 
      10.4321/s1137-66272012000200008.

PMID- 1249539
OWN - NLM
STAT- MEDLINE
DCOM- 19760409
LR  - 20131121
IS  - 0094-3509 (Print)
IS  - 0094-3509 (Linking)
VI  - 3
IP  - 1
DP  - 1976 Feb
TI  - Fever in childhood.
PG  - 75-80
AB  - A clinical approach to the diagnosis of fever in childhood is presented. Fever 
      can be caused by a viral or bacterial infection, drug reaction, collagen disease, 
      neoplasm, central nervous disorder, blood diseases, or physiological changes. 
      Short-term fever is usually a viral infection but may be a bacterial infection. 
      Careful history and physical examination play the major role in making the 
      diagnosis, followed by appropriate studies: throat culture , urinalysis, blood 
      counts, x-rays, blood cultures, and specific tests. The latter are indicated for 
      the diagnosis of prolonged fevers, which also are usually caused by common 
      disorders. A high sedimentation rate is more likely to be associated with a 
      serious disorder and warrants immediate investigation. Treatment is symptomatic; 
      one should reserve specific treatment and/or antibiotics for specific illness.
FAU - Shrand, H
AU  - Shrand H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Fever/diagnosis/*etiology/therapy
MH  - Humans
EDAT- 1976/02/01 00:00
MHDA- 1976/02/01 00:01
CRDT- 1976/02/01 00:00
PHST- 1976/02/01 00:00 [pubmed]
PHST- 1976/02/01 00:01 [medline]
PHST- 1976/02/01 00:00 [entrez]
PST - ppublish
SO  - J Fam Pract. 1976 Feb;3(1):75-80.

PMID- 9562228
OWN - NLM
STAT- MEDLINE
DCOM- 19980723
LR  - 20131121
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 36
IP  - 3
DP  - 1998 Mar
TI  - Relative bioavailability of rapidly dispersing, plain, and microencapsuled 
      acetylsalicylic acid tablets after single dose administration.
PG  - 133-8
AB  - Extent and rate of absorption of acetylsalicylic acid (ASA) from rapidly 
      dispersing (Acesal Extra) and plain tablets (Acesal) relative to reference 1 
      (plain tablets, Aspirin) and from microcapsuled tablets (Micristin) relative to 
      comparable listed tablets (reference 2, Colfarit) were assessed in 2 single-dose 
      (0.5 g ASA), open, randomized, crossover studies with intervals of 14 days 
      between 2 periods. Both studies were performed in 24 male and female healthy 
      volunteers each (age 18-32 years, body weight 48-90 kg, body height 161-190 cm). 
      ASA and its metabolite salicylic acid (SA) were measured with an HPLC method 
      validated for ASA between 0.2 and 20 microg/ml and for SA between 0.4 and 40 
      microg/ml. The test tablets were considered bioequivalent with reference in 
      extent of absorption if the 90% confidence limits of the AUC0 to infinity ratio 
      were within the range of 0.80-1.25, and in rate of absorption if the confidence 
      limits of the Cmax/AUC0 to infinity ratios were within 0.70-1.43. RESULTS: 
      Geometric means and 90% confidence limits for the test/reference ratios of the 
      comparisons Acesal vs reference 1, Acesal Extra vs reference 1 and Micristin vs 
      reference 2 were 1.05 (0.97-1.13), 1.13 (1.05-1.22), 1.02 (0.92-1.14) for ASA 
      AUC0 to infinity and 1.02 (0.96-1.07), 1.05 (0.99-1.11), 0.98 (0.91-1.04) for SA 
      AUC0 to infinity, respectively. The results for Cmax/AUC of ASA were 1.16 
      (1.00-1.34), 1.72 (1.49-1.99), 0.83 (0.73-0.94) and of SA 1.02 (0.98-1.07), 1.07 
      (1.02-1.12), 0.93 (0.88-0.97). CONCLUSION: Acesal and Micristin were 
      bioequivalent with the respective references in both extent and rate of 
      absorption. Acesal Extra and reference 1 were bioequivalent with regard to extent 
      only. Acesal Extra was absorbed faster.
FAU - Siegmund, W
AU  - Siegmund W
AD  - Department of Pharmacology, Ernst Moritz Arndt University, Medical Faculty, 
      Germany.
FAU - Hoffmann, C
AU  - Hoffmann C
FAU - Zschiesche, M
AU  - Zschiesche M
FAU - Steinijans, V W
AU  - Steinijans VW
FAU - Sauter, R
AU  - Sauter R
FAU - Krüger, W D
AU  - Krüger WD
FAU - Diedrich, F
AU  - Diedrich F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Dosage Forms)
RN  - 0 (Drug Carriers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/blood/*pharmacokinetics
MH  - Area Under Curve
MH  - Aspirin/*administration & dosage/blood/*pharmacokinetics
MH  - Biological Availability
MH  - Cross-Over Studies
MH  - Dosage Forms
MH  - Drug Carriers
MH  - Drug Compounding
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Reference Values
MH  - Therapeutic Equivalency
EDAT- 1998/04/30 00:00
MHDA- 1998/04/30 00:01
CRDT- 1998/04/30 00:00
PHST- 1998/04/30 00:00 [pubmed]
PHST- 1998/04/30 00:01 [medline]
PHST- 1998/04/30 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 1998 Mar;36(3):133-8.

PMID- 2509391
OWN - NLM
STAT- MEDLINE
DCOM- 19891219
LR  - 20190903
IS  - 0301-1623 (Print)
IS  - 0301-1623 (Linking)
VI  - 21
IP  - 3
DP  - 1989
TI  - Lysine acetyl salicylic acid in acute renal pain.
PG  - 245-9
AB  - The effect of repeated doses of 1.8 g lysine acetyl salicylic acid (LAS) i.v. on 
      severe pain secondary to acute renal colic (ARC) was studied in 45 consecutive 
      patients. Clinically acceptable analgesia was obtained in 65% of the cases. No 
      additional pain relief was achieved with the combination of pethidine 100 mg i.v. 
      + metoclopramide 10 mg, i.m. (narcotics). Pain relief occurred within five 
      minutes in one third of the patients while in the rest within 30 minutes. 
      Significant reduction of systolic blood pressure (mean +/- S.D.) 23.8 +/- 19.5, 
      pulse rate (mean +/- S.D.) 19.5 +/- 10.1 and vomiting were noted in patients who 
      had pain relief. The incidence of nausea has increased after LAS administration. 
      No other side effects were observed. LAS might therefore be applied as a 
      first-hand alternative to narcotics for the treatment of ARC.
FAU - Youssef, H A
AU  - Youssef HA
AD  - Department of Surgery, Faculty of Medicine, Kuwait University, Safat.
FAU - Hanafi, A
AU  - Hanafi A
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
RN  - 0 (Analgesics)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*analogs & derivatives/therapeutic use
MH  - Colic/*drug therapy/etiology
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Kidney Diseases/*drug therapy/etiology
MH  - Lysine/adverse effects/therapeutic use
MH  - Male
MH  - Nausea/chemically induced/etiology
MH  - Ureteral Calculi/complications/surgery
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1007/BF02559733 [doi]
PST - ppublish
SO  - Int Urol Nephrol. 1989;21(3):245-9. doi: 10.1007/BF02559733.

PMID- 36175048
OWN - NLM
STAT- MEDLINE
DCOM- 20221003
LR  - 20230322
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 80
IP  - 14
DP  - 2022 Oct 4
TI  - Aspirin for Primary Prevention of Cardiovascular Events in Relation to 
      Lipoprotein(a) Genotypes.
PG  - 1287-1298
LID - S0735-1097(22)05720-5 [pii]
LID - 10.1016/j.jacc.2022.07.027 [doi]
AB  - BACKGROUND: The role of aspirin in reducing lipoprotein(a)-mediated 
      atherothrombotic events in primary prevention is not established. OBJECTIVES: 
      This study sought to assess whether low-dose aspirin benefits individuals with 
      elevated plasma lipoprotein(a)-associated genotypes in the setting of primary 
      prevention. METHODS: The study analyzed 12,815 genotyped individuals ≥70 years of 
      age of European ancestry and without prior cardiovascular disease events enrolled 
      in the ASPREE (ASPirin in Reducing Events in the Elderly) randomized controlled 
      trial of 100 mg/d aspirin. We defined lipoprotein(a)-associated genotypes using 
      rs3798220-C carrier status and quintiles of a lipoprotein(a) genomic risk score 
      (LPA-GRS). We tested for interaction between genotypes and aspirin allocation in 
      Cox proportional hazards models for incidence of major adverse cardiovascular 
      events (MACE) and clinically significant bleeding. We also examined associations 
      in the aspirin and placebo arms of the trial separately. RESULTS: During a median 
      4.7 years (IQR: 3.6-5.7 years) of follow-up, 435 MACE occurred, with an 
      interaction observed between rs3798220-C and aspirin allocation (P = 0.049). 
      rs3798220-C carrier status was associated with increased MACE risk in the placebo 
      group (HR: 1.90; 95% CI: 1.11-3.24) but not in the aspirin group (HR: 0.54; 
      95% CI: 0.17-1.70). High LPA-GRS (vs low) was associated with increased MACE risk 
      in the placebo group (HR: 1.70; 95% CI: 1.14-2.55), with risk attenuated in the 
      aspirin group (HR: 1.41; 95% CI: 0.90-2.23), but the interaction was not 
      statistically significant. In all participants, aspirin reduced MACE by 1.7 
      events per 1,000 person-years and increased clinically significant bleeding by 
      1.7 events per 1,000 person-years. However, in the rs3798220-C and high LPA-GRS 
      subgroups, aspirin reduced MACE by 11.4 and 3.3 events per 1,000 person-years 
      respectively, without significantly increased bleeding risk. CONCLUSIONS: Aspirin 
      may benefit older individuals with elevated lipoprotein(a) genotypes in primary 
      prevention.
CI  - Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Lacaze, Paul
AU  - Lacaze P
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia. 
      Electronic address: paul.lacaze@monash.edu.
FAU - Bakshi, Andrew
AU  - Bakshi A
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Riaz, Moeen
AU  - Riaz M
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Polekhina, Galina
AU  - Polekhina G
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Owen, Alice
AU  - Owen A
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Bhatia, Harpreet S
AU  - Bhatia HS
AD  - Division of Cardiovascular Medicine, Department of Medicine, University of 
      California San Diego, La Jolla, California, USA.
FAU - Natarajan, Pradeep
AU  - Natarajan P
AD  - Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, 
      Cambridge, Massachusetts, USA; Cardiology Division, Department of Medicine, 
      Massachusetts General Hospital, Boston, Massachusetts, USA; Cardiovascular 
      Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, 
      Massachusetts, USA.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Beilin, Lawrence
AU  - Beilin L
AD  - Medical School Royal Perth Hospital, University of Western Australia, Perth, 
      Western Australia, Australia.
FAU - Nicholls, Stephen J
AU  - Nicholls SJ
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Monash 
      Cardiovascular Research Centre, Victorian Heart Institute, Monash University, 
      Clayton, Victoria, Australia.
FAU - Watts, Gerald F
AU  - Watts GF
AD  - School of Medicine, Faculty of Health and Medical Sciences, University of Western 
      Australia, Perth, Western Australia, Australia; Lipid Disorders Clinic, 
      Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital, Victoria 
      Square, Perth, Western Australia, Australia.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Tonkin, Andrew M
AU  - Tonkin AM
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Tsimikas, Sotirios
AU  - Tsimikas S
AD  - Division of Cardiovascular Medicine, Department of Medicine, University of 
      California San Diego, La Jolla, California, USA.
LA  - eng
GR  - U19 AG062682/AG/NIA NIH HHS/United States
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - R01 HL127564/HL/NHLBI NIH HHS/United States
GR  - R01 HL142711/HL/NHLBI NIH HHS/United States
GR  - T32 HL079891/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Lipoprotein(a))
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2022 Oct 4;80(14):1299-1301. PMID: 36175049
EIN - J Am Coll Cardiol. 2022 Nov 15;80(20):1963. PMID: 36357094
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/epidemiology/genetics/prevention & control
MH  - Genotype
MH  - Humans
MH  - *Lipoprotein(a)/genetics
MH  - Primary Prevention
PMC - PMC10025998
MID - NIHMS1878686
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular disease
OT  - genetics
OT  - lipoprotein(a)
OT  - primary prevention
COIS- Funding Support and Author Disclosures The ASPREE Biobank is supported by a 
      Flagship cluster grant (including the Commonwealth Scientific and Industrial 
      Research Organisation, Monash University, Menzies Research Institute, Australian 
      National University, University of Melbourne), grants U01AG029824 and U19AG062682 
      from the National Institute on Aging and the National Cancer Institute at the 
      National Institutes of Health, by grants 334047 and 1127060 from the National 
      Health and Medical Research Council of Australia, and Monash University and the 
      Victorian Cancer Agency. Dr Lacaze is supported by a National Heart Foundation 
      Future Leader Fellowship (102604). Dr McNeil is supported by a National Health 
      and Medical Research Council Leadership Fellowship (IG1173690). Dr Bhatia is 
      partially supported by National Institutes of Health grant 5T32HL079891, as part 
      of the University of California San Diego Integrated Cardiovascular Epidemiology 
      Fellowship. Dr Natarajan is supported by grants from the National Heart, Lung, 
      and Blood Institute/National Institutes of Health (R01HL142711, R01HL127564). 
      Bayer AG provided low-dose aspirin and placebo tablets for the clinical trial but 
      had no other relationship with the work. Dr Riaz is a paid employee of Regeneron 
      Genetics Center, a Subsidiary of Regeneron Pharmaceuticals Inc. Dr Natarajan has 
      received investigator-initiated grants from Amgen, Apple, AstraZeneca, Boston 
      Scientific, and Novartis; has received personal fees from Apple, AstraZeneca, 
      Blackstone Life Sciences, Foresite Labs, Novartis, and Roche/Genentech; is a 
      co-founder of TenSixteen Bio; is a shareholder of geneXwell and TenSixteen Bio; 
      and has a spouse who is an employee of Vertex, all unrelated to the present work. 
      Dr Nicholls has received research support from AstraZeneca, Amgen, Anthera, CSL 
      Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and 
      Sanofi-Regeneron; and has served as a consultant for Amgen, Akcea, AstraZeneca, 
      Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, 
      Pfizer, Sanofi-Regeneron, and Novo Nordisk. Dr Tonkin has received research 
      support from Bayer for materials in ASPREE; and has received honoraria for 
      Advisory Board participation or lectures from Amgen, AstraZeneca, Boehringer 
      Ingelheim, and Pfizer. Dr Tsimikas is a co-inventor and has received royalties 
      from patents owned by the University of California-San Diego; is a co-founder of 
      and has an equity interest in Oxitope, LLC and its affiliates (Kleanthi 
      Diagnostics, LLC and Covicept Therapeutics, Inc); and has a dual appointment at 
      the University of California San Diego and Ionis Pharmaceuticals; although these 
      relationships have been identified for conflict-of-interest management based on 
      the overall scope of the project, the research findings included in this 
      particular publication may not necessarily relate to the interests of the 
      previous companies; the terms of this arrangement have been reviewed and approved 
      by the University of California San Diego in accordance with its 
      conflict-of-interest policies. All other authors have reported that they have no 
      relationships relevant to the contents of this paper to disclose.
EDAT- 2022/09/30 06:00
MHDA- 2022/10/04 06:00
PMCR- 2023/10/04
CRDT- 2022/09/29 21:02
PHST- 2022/05/05 00:00 [received]
PHST- 2022/06/23 00:00 [revised]
PHST- 2022/07/18 00:00 [accepted]
PHST- 2023/10/04 00:00 [pmc-release]
PHST- 2022/09/29 21:02 [entrez]
PHST- 2022/09/30 06:00 [pubmed]
PHST- 2022/10/04 06:00 [medline]
AID - S0735-1097(22)05720-5 [pii]
AID - 10.1016/j.jacc.2022.07.027 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2022 Oct 4;80(14):1287-1298. doi: 10.1016/j.jacc.2022.07.027.

PMID- 27599157
OWN - NLM
STAT- MEDLINE
DCOM- 20170901
LR  - 20220408
IS  - 1525-6065 (Electronic)
IS  - 1064-1955 (Linking)
VI  - 36
IP  - 1
DP  - 2017 Feb
TI  - Low-molecular-weight heparin and aspirin use in relation to pregnancy outcome in 
      women with systemic lupus erythematosus and antiphospholipid syndrome: A cohort 
      study.
PG  - 8-15
LID - 10.1080/10641955.2016.1217337 [doi]
AB  - OBJECTIVE: To relate anticoagulant use to pregnancy complications in women with 
      systemic lupus erythematosus (SLE) and primary antiphospholipid syndrome (APS). 
      METHODS: All ongoing pregnancies, 184, in two Dutch tertiary centers between 2000 
      and 2015. RESULTS: LMWH and aspirin was prescribed in 15/109 SLE women without 
      antiphospholipid antibodies (aPL), 5/14 with aPL, 11/13 with APS, 45/48 with 
      primary APS. Main complications in the four treatment groups (no anticoagulant 
      treatment, aspirin, LMWH, aspirin and LMWH) included hypertensive disorders of 
      pregnancy (9.4%, 23.3%, 50%, 18.4%, respectively, p = 0.12) and preterm birth 
      (16.7%, 34.3%, 75%, 36.8%, respectively, p < 0.001). CONCLUSION: Maternal and 
      perinatal complications occurred frequently, despite LMWH and aspirin use.
FAU - Abheiden, Carolien N H
AU  - Abheiden CN
AD  - a Department of Obstetrics and Gynaecology , VU University Medical Center , 
      Amsterdam , The Netherlands.
FAU - Blomjous, Birgit S
AU  - Blomjous BS
AD  - a Department of Obstetrics and Gynaecology , VU University Medical Center , 
      Amsterdam , The Netherlands.
AD  - b Department of Rheumatology , Amsterdam Rheumatology and Immunology Center, VU 
      University Medical Center , Amsterdam , The Netherlands.
FAU - Kroese, Sylvia J
AU  - Kroese SJ
AD  - c Department of Rheumatology , University Medical Center Utrecht , Utrecht , The 
      Netherlands.
FAU - Bultink, Irene E M
AU  - Bultink IE
AD  - b Department of Rheumatology , Amsterdam Rheumatology and Immunology Center, VU 
      University Medical Center , Amsterdam , The Netherlands.
FAU - Fritsch-Stork, Ruth D E
AU  - Fritsch-Stork RD
AD  - c Department of Rheumatology , University Medical Center Utrecht , Utrecht , The 
      Netherlands.
FAU - Lely, A Titia
AU  - Lely AT
AD  - d Department of Obstetrics and Gynaecology , University Medical Center Utrecht , 
      Utrecht , The Netherlands.
FAU - de Boer, Marjon A
AU  - de Boer MA
AD  - a Department of Obstetrics and Gynaecology , VU University Medical Center , 
      Amsterdam , The Netherlands.
FAU - de Vries, Johanna I P
AU  - de Vries JI
AD  - a Department of Obstetrics and Gynaecology , VU University Medical Center , 
      Amsterdam , The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20160906
PL  - England
TA  - Hypertens Pregnancy
JT  - Hypertension in pregnancy
JID - 9421297
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Antiphospholipid Syndrome/*drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Databases, Factual
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*adverse effects/therapeutic use
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/*chemically induced
MH  - Lupus Erythematosus, Systemic/*drug therapy
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Premature Birth/*chemically induced
OTO - NOTNLM
OT  - Antiphospholipid syndrome
OT  - aspirin
OT  - hypertensive disorders of pregnancy
OT  - low-molecular-weight heparin
OT  - systemic lupus erythematosus
EDAT- 2016/09/07 06:00
MHDA- 2017/09/02 06:00
CRDT- 2016/09/07 06:00
PHST- 2016/09/07 06:00 [pubmed]
PHST- 2017/09/02 06:00 [medline]
PHST- 2016/09/07 06:00 [entrez]
AID - 10.1080/10641955.2016.1217337 [doi]
PST - ppublish
SO  - Hypertens Pregnancy. 2017 Feb;36(1):8-15. doi: 10.1080/10641955.2016.1217337. 
      Epub 2016 Sep 6.

PMID- 22935833
OWN - NLM
STAT- MEDLINE
DCOM- 20130401
LR  - 20161021
IS  - 1138-3593 (Print)
IS  - 1138-3593 (Linking)
VI  - 38
IP  - 6
DP  - 2012 Sep
TI  - [Primary prevention with aspirin].
PG  - 366-76
LID - 10.1016/j.semerg.2012.01.006 [doi]
AB  - The benefit of acetylsalicylic acid and other antiplatelet drugs in secondary 
      prevention is well established, however it use in primary prevention continues to 
      be controversial. On the one hand, the benefit obtained is very near the 
      potential damage arising from its use (mainly gastrointestinal bleeding), and on 
      the other, the net benefit is less, given that its aim is to prevent the 
      occurrence of vascular events in situations with a lower baseline risk. 
      Antiplatelet treatment with aspirin in primary prevention has been evaluated in 
      clinical trials and several meta-analyses, comparing its efficacy with a placebo, 
      and with results noted for their heterogeneity. The mechanisms of action of 
      different antiplatelet drugs, as well as the existing evidence with aspirin in 
      primary prevention, the directions for its use by different Scientific Societies, 
      and the cost/benefit of the intervention are reviewed.
CI  - Copyright © 2010 Elsevier España, S.L. y SEMERGEN. All rights reserved.
FAU - Divisón, J A
AU  - Divisón JA
AD  - Centro de Salud de Casas Ibáñez, Albacete, España. jdivison@medynet.com
FAU - Galgo, A
AU  - Galgo A
FAU - Polo, J
AU  - Polo J
FAU - Durá, R
AU  - Durá R
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Prevención primaria con aspirina.
DEP - 20120510
PL  - Spain
TA  - Semergen
JT  - Semergen
JID - 9610769
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Trials as Topic
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - *Primary Prevention
EDAT- 2012/09/01 06:00
MHDA- 2013/04/02 06:00
CRDT- 2012/09/01 06:00
PHST- 2010/08/21 00:00 [received]
PHST- 2012/01/17 00:00 [revised]
PHST- 2012/01/17 00:00 [accepted]
PHST- 2012/09/01 06:00 [entrez]
PHST- 2012/09/01 06:00 [pubmed]
PHST- 2013/04/02 06:00 [medline]
AID - S1138-3593(12)00026-3 [pii]
AID - 10.1016/j.semerg.2012.01.006 [doi]
PST - ppublish
SO  - Semergen. 2012 Sep;38(6):366-76. doi: 10.1016/j.semerg.2012.01.006. Epub 2012 May 
      10.

PMID- 16741185
OWN - NLM
STAT- MEDLINE
DCOM- 20060718
LR  - 20191210
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 37
IP  - 7
DP  - 2006 Jul
TI  - Previous use of aspirin and baseline stroke severity: an analysis of 17,850 
      patients in the International Stroke Trial.
PG  - 1737-40
AB  - BACKGROUND AND PURPOSE: Some studies suggest that taking aspirin regularly at the 
      time of the onset of stroke reduces stroke severity. Other studies suggest the 
      converse (ie, that previous aspirin therapy is associated with greater stroke 
      severity). We sought to examine this question among the patients enrolled in the 
      International Stroke Trial (IST). METHODS: Analysis of the associations of 
      reported use of aspirin in the 3 days before randomization in IST with baseline 
      stroke severity (as assessed by stroke clinical syndrome, predicted outcome at 6 
      months, and observed outcome at 6 months). We adjusted analyses for confounding 
      factors. RESULTS: We excluded those patients who were first scanned after trial 
      entry and were found to have an intracerebral hemorrhage as the cause of the 
      stroke leading to randomization. We performed analyses for all treatment groups 
      combined. For the 17,850 patients with ischemic stroke, data at baseline and 
      follow-up were available for 100% and 99%, respectively. Among these patients, 
      3820 (21.4%) reported previous aspirin use. Previous aspirin use appeared, in 
      univariate analyses, to be associated with greater baseline stroke severity, more 
      severe stroke syndrome, and, in control subjects, worse observed outcome at 6 
      months. However, after adjustment, these associations were no longer significant. 
      CONCLUSIONS: In this large prospective and complete data set, we found no 
      evidence of any association of previous aspirin use with baseline stroke 
      severity. The analyses suggest that previously reported positive and negative 
      associations may well have been attributable to the play of chance in small 
      samples, confounding or other biases, rather than a biological effect of aspirin.
FAU - Ricci, Stefano
AU  - Ricci S
AD  - UOCD Neurologia e Ictus, USL 2, Centro di Salute, Via Cestellini, Perugia, Italy. 
      istitaly@unipg.it
FAU - Lewis, Steff
AU  - Lewis S
FAU - Sandercock, Peter
AU  - Sandercock P
CN  - IST Collaborative Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060601
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 2006 Nov;37(11):2660; author reply 2661. PMID: 16973927
CIN - Nat Clin Pract Neurol. 2007 Jan;3(1):12-3. PMID: 17205066
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Brain Ischemia/*prevention & control
MH  - Cerebral Infarction/diagnostic imaging
MH  - Cohort Studies
MH  - Confounding Factors, Epidemiologic
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Premedication
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Sample Size
MH  - Sampling Studies
MH  - Selection Bias
MH  - Severity of Illness Index
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
EDAT- 2006/06/03 09:00
MHDA- 2006/07/19 09:00
CRDT- 2006/06/03 09:00
PHST- 2006/06/03 09:00 [pubmed]
PHST- 2006/07/19 09:00 [medline]
PHST- 2006/06/03 09:00 [entrez]
AID - 01.STR.0000226740.29910.91 [pii]
AID - 10.1161/01.STR.0000226740.29910.91 [doi]
PST - ppublish
SO  - Stroke. 2006 Jul;37(7):1737-40. doi: 10.1161/01.STR.0000226740.29910.91. Epub 
      2006 Jun 1.

PMID- 16900307
OWN - NLM
STAT- MEDLINE
DCOM- 20070316
LR  - 20181113
IS  - 1861-0684 (Print)
IS  - 1861-0684 (Linking)
VI  - 95
IP  - 10
DP  - 2006 Oct
TI  - Aspirin resistance - does it clinically matter?
PG  - 505-10
AB  - A variable responsiveness to acetylsalicylic acid(ASA) is a clinical reality that 
      does not principally differ from variable responses to other kinds of drug 
      treatment in other therapeutic fields. Two questions arise: (i) is any resulting 
      "treatment failure"due to a pharmacological failure of the drug to act and (ii) 
      is any reduced antiplatelet activity to ASA related to the clinical outcome oft 
      he patient?Two major laboratory techniques are available to quantify platelet 
      variability to ASA ex vivo: Measurement of platelet function and measurement of 
      thromboxane formation. Both methods have limitations and did not yet result in a 
      generally accepted definition of a pharmacological ASA "resistance".A "true" 
      pharmacological resistance to ASA exists in selected groups of patients. However, 
      unless more information is available,results from in vitro assays of platelet 
      function should not be over-interpreted. More data from prospective trials are 
      required,predominantly by measuring serum thromboxane formation which is a 
      platelet-specific, ASA sensitive reaction. At this time,there is no reason to 
      change there commended daily maintenance dose of about 100 mg ASA without 
      particular requirements in patients who need coronary protection.
FAU - Schrör, Karsten
AU  - Schrör K
AD  - Institut für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum 
      Düsseldorf, Heinrich-Heine-Universität, Universitätsstr. 1, Geb. 22.21, 40225, 
      Düsseldorf, Germany. kschroer@uni-duesseldorf.de
FAU - Hohlfeld, T
AU  - Hohlfeld T
FAU - Weber, A-A
AU  - Weber AA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060816
PL  - Germany
TA  - Clin Res Cardiol
JT  - Clinical research in cardiology : official journal of the German Cardiac Society
JID - 101264123
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/physiology
MH  - Drug Resistance/*physiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Treatment Failure
RF  - 38
EDAT- 2006/08/11 09:00
MHDA- 2007/03/17 09:00
CRDT- 2006/08/11 09:00
PHST- 2005/10/11 00:00 [received]
PHST- 2006/06/16 00:00 [accepted]
PHST- 2006/08/11 09:00 [pubmed]
PHST- 2007/03/17 09:00 [medline]
PHST- 2006/08/11 09:00 [entrez]
AID - 10.1007/s00392-006-0424-5 [doi]
PST - ppublish
SO  - Clin Res Cardiol. 2006 Oct;95(10):505-10. doi: 10.1007/s00392-006-0424-5. Epub 
      2006 Aug 16.

PMID- 11074741
OWN - NLM
STAT- MEDLINE
DCOM- 20001227
LR  - 20190813
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 160
IP  - 20
DP  - 2000 Nov 13
TI  - An overview of the 4 randomized trials of aspirin therapy in the primary 
      prevention of vascular disease.
PG  - 3123-7
AB  - BACKGROUND: In the primary prevention of cardiovascular disease, in contrast to 
      the recommendations of the American College of Chest Physicians and the American 
      Heart Association, the US Food and Drug Administration recently stated that there 
      was insufficient evidence to judge whether aspirin therapy decreases the risk of 
      a first myocardial infarction. OBJECTIVE: To perform an overview of the 4 primary 
      prevention trials of aspirin therapy to obtain the most reliable estimates of the 
      effects of aspirin therapy on various vascular disease end points. METHODS AND 
      RESULTS: These 4 trials included more than 51,000 subjects and 2284 important 
      vascular events. Those assigned to aspirin therapy experienced significant 
      reductions of 32% (95% confidence interval [CI], 21%-41%) for nonfatal myocardial 
      infarction and 13% (95% CI, 5%-19%) for any important vascular event. There were 
      possible small but nonsignificant increases in risks of vascular disease-related 
      death (1%; 95% CI, -12% to 16%) and nonfatal stroke (8%; 95% CI, -12% to 33%). 
      When strokes were subdivided by type, there was no significant effect of aspirin 
      therapy on the risk of ischemic stroke, but, while based on small numbers, there 
      was a 1.7-fold apparent increase (95% CI, 6%-269%) in the risk of hemorrhagic 
      stroke, which did achieve statistical significance. CONCLUSIONS: For the primary 
      prevention of vascular disease, aspirin therapy confers significant beneficial 
      effects on first myocardial infarction and, as a result, on any important 
      vascular event; these effects are clinically important. Whether there is any 
      reduction in vascular disease-related death or stroke associated with treatment 
      remains unclear because of inadequate numbers of events in the primary prevention 
      trials completed to date. More data on hemorrhagic stroke are also needed. In 
      addition, randomized trial data, especially in women but also in men, are needed 
      to help to formulate a rational public health policy for individuals at usual 
      risk. Meanwhile, these data provide evidence for a significant benefit of aspirin 
      therapy in the primary prevention of myocardial infarction.
FAU - Hebert, P R
AU  - Hebert PR
AD  - Department of Internal Medicine, Yale University School of Medicine, 333 Cedar 
      St, New Haven, CT 06520, USA.
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
EDAT- 2000/11/14 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/14 11:00
PHST- 2000/11/14 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/14 11:00 [entrez]
AID - ioi90483 [pii]
AID - 10.1001/archinte.160.20.3123 [doi]
PST - ppublish
SO  - Arch Intern Med. 2000 Nov 13;160(20):3123-7. doi: 10.1001/archinte.160.20.3123.

PMID- 15180170
OWN - NLM
STAT- MEDLINE
DCOM- 20040702
LR  - 20190607
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 42
IP  - 2
DP  - 2004 Feb
TI  - Safety of AT-1015, a novel 5-HT2A antagonist, in combination with high-dose 
      aspirin: an open-label study.
PG  - 98-102
AB  - OBJECTIVE: To assess the safety of AT-1015 in combination with high-dose aspirin 
      (300 mg daily). Study subjects were 17 healthy male volunteers. METHODS: This was 
      an open-label, single-center study. Subjects received aspirin 300 mg once daily, 
      alone on days 1-4, and together with AT-1015 40 mg twice daily on days 5-11. A 
      follow-up assessment was performed on day 18. The primary outcome measure was 
      bleeding time; secondary outcome measures were vital signs, adverse events, 
      physical examinations, 12-lead electrocardiograms (ECG) and laboratory safety 
      tests. RESULTS: There was a significant increase in bleeding time between 
      screening and the end of the aspirin-only period (mean bleeding time 4.8 vs 7.6 
      min, p = 0.01), but there were no further significant increases during the 
      combination treatment period. The most common adverse events were dry mouth, 
      epistaxis, gingival bleeding and abdominal pain. All treatment-related adverse 
      events were mild in severity and no major bleeding episodes occurred. There were 
      no clinically significant changes in vital signs, physical examinations, 12-lead 
      ECGs or laboratory safety tests. CONCLUSIONS: AT-1015 was safe and well-tolerated 
      in healthy male volunteers when taken in combination with high-dose aspirin, and 
      did not significantly prolong bleeding time compared with aspirin alone.
FAU - Anderson, D
AU  - Anderson D
AD  - Ajinomoto Pharmaceuticals Europe Limited, Redhill, Surrey, UK.
FAU - Kato, N
AU  - Kato N
FAU - Onomichi, K
AU  - Onomichi K
FAU - Uchida, H
AU  - Uchida H
FAU - Shelley, S
AU  - Shelley S
FAU - Engert, D
AU  - Engert D
FAU - Ilgenfritz, J
AU  - Ilgenfritz J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Serotonin 5-HT2 Receptor Antagonists)
RN  - 0 (Serotonin Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Bleeding Time
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Electrocardiography
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - *Serotonin 5-HT2 Receptor Antagonists
MH  - Serotonin Antagonists/*administration & dosage/adverse effects
EDAT- 2004/06/08 05:00
MHDA- 2004/07/03 05:00
CRDT- 2004/06/08 05:00
PHST- 2004/06/08 05:00 [pubmed]
PHST- 2004/07/03 05:00 [medline]
PHST- 2004/06/08 05:00 [entrez]
AID - 10.5414/cpp42098 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2004 Feb;42(2):98-102. doi: 10.5414/cpp42098.

PMID- 36400665
OWN - NLM
STAT- MEDLINE
DCOM- 20230328
LR  - 20230720
IS  - 1878-3562 (Electronic)
IS  - 1590-8658 (Linking)
VI  - 55
IP  - 4
DP  - 2023 Apr
TI  - Using an algorithm to assess the rate and trend over time of inappropriate proton 
      pump inhibitors prescription upon hospital discharge.
PG  - 485-489
LID - S1590-8658(22)00751-4 [pii]
LID - 10.1016/j.dld.2022.10.018 [doi]
AB  - BACKGROUND: There is an increasing interest in inappropriate proton pump 
      inhibitors prescription (InPPIp), as defined by the National Institute for 
      Clinical Excellence (NICE) guidelines. AIMS: To evaluate the rate, trend over 
      time and factors associated with InPPIp upon discharge from internal medicine 
      departments. METHODS: We evaluated patients discharged from internal medicine 
      departments with a PPI prescription in 2014 and 2017 at an academic referral 
      center according to a developed algorithm. RESULTS: A total of 3,982 patients 
      were included (50.8% women, 74% ≥ 65 years). The rate of InPPIp was 44.3% (95% CI 
      42.8-45.9) for the entire cohort; 68.1% for subjects aged < 65 years and 36.0% 
      for those aged ≥ 65 years (p<0.001); 43.2% in 2014 and 45.6% in 2017 (p = 0.130). 
      In a decision-tree analysis, after the exclusion of 448 patients with 
      gastrointestinal indications, 89.4% (1,580/1,766) of all InPPIp cases were of 
      patients without dual antiplatelet treatment (DAPT) and 8.6% (151/1,766) were of 
      patients younger than 65 years, who were taking aspirin. CONCLUSIONS: The rate of 
      InPPIp is high, especially among patients not receiving DAPT and young patients 
      taking aspirin. Time trend analysis showed no improvement over time. Our 
      algorithm may serve as an automated quality measuring tool to reduce InPPIp.
CI  - Copyright © 2022 Editrice Gastroenterologica Italiana S.r.l. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Sneh-Arbib, Orly
AU  - Sneh-Arbib O
AD  - Division of Gastroenterology and liver disease, Talpiot, Clalit Health Services, 
      Jerusalem, Israel; School of Pharmacy, the faculty of medicine, Hebrew 
      University, Jerusalem, Israel. Electronic address: orlys2@clalit.org.il.
FAU - Ben-Shitrit, Shir
AU  - Ben-Shitrit S
AD  - Sackler School of Medicine, Tel-Aviv University, Israel; School of Pharmacy, the 
      faculty of medicine, Hebrew University, Jerusalem, Israel.
FAU - Weisman, Yaara Leibovici
AU  - Weisman YL
AD  - Sackler School of Medicine, Tel-Aviv University, Israel; School of Pharmacy, the 
      faculty of medicine, Hebrew University, Jerusalem, Israel.
FAU - Koshnir, Shiri
AU  - Koshnir S
AD  - Clalit Research Institute, Tel-Aviv, Israel; School of Pharmacy, the faculty of 
      medicine, Hebrew University, Jerusalem, Israel.
FAU - Levi, Zohar
AU  - Levi Z
AD  - Sackler School of Medicine, Tel-Aviv University, Israel; Division of 
      Gastroenterology, Rabin Medical Center, Petach-Tikva, Israel; School of Pharmacy, 
      the faculty of medicine, Hebrew University, Jerusalem, Israel.
FAU - Calivarysky, Bronya
AU  - Calivarysky B
AD  - Department of Pharmacy, Rabin Medical Center, Petach-Tikva, Israel; School of 
      Pharmacy, the faculty of medicine, Hebrew University, Jerusalem, Israel.
LA  - eng
PT  - Journal Article
DEP - 20221115
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - Female
MH  - Male
MH  - *Patient Discharge
MH  - *Proton Pump Inhibitors/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Hospitals
MH  - Prescriptions
MH  - Platelet Aggregation Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Accepted clinical indications
OT  - Inadequate use
OT  - Proton pump inhibitors
OT  - “Choosing wisely” principles
COIS- Conflict of interest None declared.
EDAT- 2022/11/19 06:00
MHDA- 2023/03/28 17:07
CRDT- 2022/11/18 22:05
PHST- 2022/08/07 00:00 [received]
PHST- 2022/10/15 00:00 [revised]
PHST- 2022/10/19 00:00 [accepted]
PHST- 2023/03/28 17:07 [medline]
PHST- 2022/11/19 06:00 [pubmed]
PHST- 2022/11/18 22:05 [entrez]
AID - S1590-8658(22)00751-4 [pii]
AID - 10.1016/j.dld.2022.10.018 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2023 Apr;55(4):485-489. doi: 10.1016/j.dld.2022.10.018. Epub 2022 
      Nov 15.

PMID- 14616672
OWN - NLM
STAT- MEDLINE
DCOM- 20040415
LR  - 20190911
IS  - 0307-7772 (Print)
IS  - 0307-7772 (Linking)
VI  - 28
IP  - 6
DP  - 2003 Dec
TI  - Subclinical aspirin sensitivity in subjects with nasal polyposis.
PG  - 539-44
AB  - It is unclear whether subclinical airway responses to aspirin occur in subjects 
      with nasal polyps and/or asthma without overt sensitivity. Sixty-three subjects 
      without known aspirin sensitivity (13 controls, 17 nasal polyps alone, 15 nasal 
      polyps and asthma and 18 asthma alone) inhaled increasing concentrations of 
      nebulized lysine aspirin. Forced expiratory volume in 1 s (FEV1), symptoms and 
      other potential markers of an airway response were measured. Four subjects (one 
      polyps alone, one asthma alone, two with both) had a positive response to lysine 
      aspirin predefined as symptoms plus a >10% fall in FEV1 from baseline. However, 
      there was no evidence of a general subclinical response in any of the subject 
      groups: mean (95% CI) change in FEV1; control 0.07 (-0.02,0.16) L, nasal polyps 
      alone -0.05 (-0.16,0.05) L, nasal polyps with asthma -0.03 (-0.10,0.04) L, asthma 
      alone -0.03 (-0.09,0.03) L. We concluded that in the absence of a suggestive 
      clinical history, only a small proportion of patients with nasal polyposis are 
      likely to be sensitive to aspirin. There is no evidence of general subclinical 
      sensitivity to aspirin in subjects with nasal polyps and no relevant history.
FAU - Killen, J W W
AU  - Killen JW
AD  - Departments of Respiratory Medicine and Otorhinolaryngology and Head and Neck 
      Surgery, Freeman Hospital, Newcastle upon Tyne, UK.
FAU - Wilson, J A
AU  - Wilson JA
FAU - Gibson, G J
AU  - Gibson GJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Otolaryngol Allied Sci
JT  - Clinical otolaryngology and allied sciences
JID - 7701793
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects/*analogs & derivatives
MH  - Asthma/*immunology
MH  - Drug Hypersensitivity/diagnosis
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/*adverse effects/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/*immunology
MH  - Nasal Provocation Tests
MH  - Nebulizers and Vaporizers
EDAT- 2003/11/18 05:00
MHDA- 2004/04/16 05:00
CRDT- 2003/11/18 05:00
PHST- 2003/11/18 05:00 [pubmed]
PHST- 2004/04/16 05:00 [medline]
PHST- 2003/11/18 05:00 [entrez]
AID - 772 [pii]
AID - 10.1046/j.1365-2273.2003.00772.x [doi]
PST - ppublish
SO  - Clin Otolaryngol Allied Sci. 2003 Dec;28(6):539-44. doi: 
      10.1046/j.1365-2273.2003.00772.x.

PMID- 32798081
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210521
IS  - 1873-5134 (Electronic)
IS  - 0738-3991 (Print)
IS  - 0738-3991 (Linking)
VI  - 104
IP  - 3
DP  - 2021 Mar
TI  - News coverage and online advertising effects on patient-led search for aspirin, 
      heart health, and stroke information and educational tool use.
PG  - 663-665
LID - S0738-3991(20)30405-5 [pii]
LID - 10.1016/j.pec.2020.08.004 [doi]
AB  - OBJECTIVE: Using indicators of campaign effort and relevant news stories, we 
      sought to predict two patterns of patient behavior regarding information about 
      aspirin and heart health: patient use of a campaign web tool to determine whether 
      they should talk with a physician about using aspirin and patient searches for 
      information about aspirin and the heart. METHODS: We used ARIMA modeling to 
      predict two time series as a function of independent variables. RESULTS: We found 
      significant prediction of time series in both models, but campaign expenditure 
      only predicted use of a campaign web tool whereas weekly news stories predicted 
      online searches regarding aspirin and the heart originating from Minnesota. 
      CONCLUSION: Patient information engagement is a function of information salience 
      at least in part. Campaign advertising expenditure can prompt audience use of 
      campaign tools but news coverage also operates as an important force on patient 
      search behavior. PRACTICE IMPLICATIONS: Health promotion professionals charged 
      with reaching patients with heart health and stroke prevention messages should 
      monitor news coverage as a potential complementary or rival force while at the 
      same time promoting campaign-related information online.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Southwell, Brian G
AU  - Southwell BG
AD  - Science in the Public Sphere Program, RTI International, Research Triangle Park, 
      NC, USA. Electronic address: bsouthwell@rti.org.
FAU - Eder, Milton
AU  - Eder M
AD  - School of Public Health, University of Minnesota, Minneapolis, MN, USA.
FAU - Finnegan, John
AU  - Finnegan J
AD  - School of Public Health, University of Minnesota, Minneapolis, MN, USA.
FAU - Luepker, Russell V
AU  - Luepker RV
AD  - School of Public Health, University of Minnesota, Minneapolis, MN, USA.
FAU - Duval, Sue
AU  - Duval S
AD  - School of Public Health, University of Minnesota, Minneapolis, MN, USA.
FAU - Russell, Carol
AU  - Russell C
AD  - Russell Herder, Minneapolis, MN, USA.
FAU - Graves, Robert N
AU  - Graves RN
AD  - Russell Herder, Minneapolis, MN, USA.
FAU - Namboodri, Adele
AU  - Namboodri A
AD  - Science in the Public Sphere Program, RTI International, Research Triangle Park, 
      NC, USA.
LA  - eng
GR  - R01 HL126041/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200806
PL  - Ireland
TA  - Patient Educ Couns
JT  - Patient education and counseling
JID - 8406280
RN  - R16CO5Y76E (Aspirin)
MH  - Advertising
MH  - Aspirin/adverse effects
MH  - Humans
MH  - Minnesota
MH  - *Stroke/prevention & control
MH  - *Tool Use Behavior
PMC - PMC7409926
MID - NIHMS1619985
EDAT- 2020/08/17 06:00
MHDA- 2021/05/22 06:00
CRDT- 2020/08/17 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/07/14 00:00 [revised]
PHST- 2020/08/01 00:00 [accepted]
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
PHST- 2020/08/17 06:00 [entrez]
AID - S0738-3991(20)30405-5 [pii]
AID - 10.1016/j.pec.2020.08.004 [doi]
PST - ppublish
SO  - Patient Educ Couns. 2021 Mar;104(3):663-665. doi: 10.1016/j.pec.2020.08.004. Epub 
      2020 Aug 6.

PMID- 30933424
OWN - NLM
STAT- MEDLINE
DCOM- 20200630
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 17
IP  - 6
DP  - 2019 Jun
TI  - Obesity is associated with impaired responsiveness to once-daily low-dose aspirin 
      and in vivo platelet activation.
PG  - 885-895
LID - 10.1111/jth.14445 [doi]
AB  - BACKGROUND: The prevalence and degree of obesity is rising worldwide, increases 
      cardiovascular risk, modifies body composition and organ function, and 
      potentially affects the pharmacokinetics and/or pharmacodynamics of drugs. 
      OBJECTIVES: To investigate the pharmacodynamics of once-daily low-dose aspirin in 
      healthy obese subjects, and to assess whether body weight (BW) and body mass 
      index (BMI) affect the pharmacology of aspirin. PATIENTS/METHODS: Otherwise 
      healthy, obese (BMI > 30 kg/m(2) ) subjects were studied before and after 
      3-4 weeks of 100-mg once-daily aspirin intake. Aspirin pharmacodynamics were 
      assessed according to serum thromboxane (TX) B(2) levels measured at 4 hours, 
      24 hours (i.e., posologic interval) and 48 hours after the last witnessed intake; 
      age-matched and sex-matched non-obese controls were included. A previously 
      calibrated pharmacokinetic/pharmacodynamic in silico model of aspirin was used to 
      fit serum TXB(2) data from obese subjects. At baseline, the major urinary TXA(2) 
      and prostacyclin metabolites, urinary isoprostane and plasma inflammatory 
      biomarkers were measured. RESULTS: In 16 obese subjects (aged 47 ± 11 years; BMI 
      of 39.4 ± 5.1 kg/m(2) ), residual serum TXB(2) values between 4 and 48 hours 
      after aspirin intake were increased 3- to 5-fold as compared with controls. At 
      24 hours, the residual serum TXB(2) level was log-linearly associated with body 
      size over a wide range of BMI and BW values, without any apparent threshold. The 
      in silico model predicted that reduced aspirin bioavailability would be inversely 
      related to body size and rescued by 200 mg of aspirin once daily or 85 mg twice 
      daily. Baseline urinary TXA(2) metabolite, isoprostane and plasma C-reactive 
      protein levels were significantly increased in obese subjects. CONCLUSIONS: 
      Obesity is associated with impaired aspirin responsiveness, largely because of 
      body size. Impaired inhibition of platelet activation by conventional low-dose 
      aspirin may affect antithrombotic efficacy.
CI  - © 2019 International Society on Thrombosis and Haemostasis.
FAU - Petrucci, Giovanna
AU  - Petrucci G
AD  - Istituto di Farmacologia, Università Cattolica, Rome, Italy.
AD  - Fondazione Policlinico Universitario IRCCS, A. Gemelli, Rome, Italy.
FAU - Zaccardi, Francesco
AU  - Zaccardi F
AD  - Leicester Diabetes Centre, Leicester General Hospital, Leicester, UK.
FAU - Giaretta, Alberto
AU  - Giaretta A
AD  - Department of Information Engineering, University of Padova, Padova, Italy.
FAU - Cavalca, Viviana
AU  - Cavalca V
AD  - Centro Cardiologico Monzino, IRCCS, Milano, Italy.
FAU - Capristo, Esmeralda
AU  - Capristo E
AD  - Fondazione Policlinico Universitario IRCCS, A. Gemelli, Rome, Italy.
AD  - Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, 
      Italy.
FAU - Cardillo, Carmine
AU  - Cardillo C
AD  - Fondazione Policlinico Universitario IRCCS, A. Gemelli, Rome, Italy.
AD  - Istituto di Patologia Medica, Università Cattolica del Sacro Cuore, Rome, Italy.
FAU - Pitocco, Dario
AU  - Pitocco D
AD  - Fondazione Policlinico Universitario IRCCS, A. Gemelli, Rome, Italy.
AD  - Diabetology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, 
      Italy.
FAU - Porro, Benedetta
AU  - Porro B
AD  - Centro Cardiologico Monzino, IRCCS, Milano, Italy.
FAU - Schinzari, Francesca
AU  - Schinzari F
AD  - Istituto di Patologia Medica, Università Cattolica del Sacro Cuore, Rome, Italy.
FAU - Toffolo, Gianna
AU  - Toffolo G
AD  - Department of Information Engineering, University of Padova, Padova, Italy.
FAU - Tremoli, Elena
AU  - Tremoli E
AD  - Centro Cardiologico Monzino, IRCCS, Milano, Italy.
FAU - Rocca, Bianca
AU  - Rocca B
AD  - Istituto di Farmacologia, Università Cattolica, Rome, Italy.
AD  - Fondazione Policlinico Universitario IRCCS, A. Gemelli, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190429
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Biomarkers)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacokinetics/pharmacology
MH  - Biological Availability
MH  - Biomarkers/blood
MH  - Body Mass Index
MH  - Body Weight
MH  - Case-Control Studies
MH  - Computer Simulation
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Models, Biological
MH  - Obesity/*blood/*drug therapy/pathology
MH  - Pilot Projects
MH  - Platelet Activation/*drug effects
MH  - Proof of Concept Study
MH  - Thromboxane A2/biosynthesis
MH  - Thromboxane B2/blood
OTO - NOTNLM
OT  - aspirin
OT  - body mass index
OT  - obesity
OT  - platelets
OT  - thromboxane A2
EDAT- 2019/04/02 06:00
MHDA- 2020/07/01 06:00
CRDT- 2019/04/02 06:00
PHST- 2019/02/20 00:00 [received]
PHST- 2019/03/28 00:00 [accepted]
PHST- 2019/04/02 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2019/04/02 06:00 [entrez]
AID - S1538-7836(22)04444-0 [pii]
AID - 10.1111/jth.14445 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2019 Jun;17(6):885-895. doi: 10.1111/jth.14445. Epub 2019 Apr 
      29.

PMID- 4093506
OWN - NLM
STAT- MEDLINE
DCOM- 19860331
LR  - 20191030
IS  - 0143-3180 (Print)
IS  - 0143-3180 (Linking)
VI  - 10
IP  - 4
DP  - 1985 Dec
TI  - Clinical-pharmacokinetic investigations of acetylsalicylic acid in cases of 
      imminent premature delivery.
PG  - 361-6
AB  - The pharmacokinetics of acetylsalicylic acid have been examined in a dose of 3.6 
      g per day (0.9 g every 6 h) for 4 days, and the effect of the drug in 25 
      gravidae, threatened by premature delivery, has also been studied. Salicylate in 
      maternal blood was higher than in amniotic fluid, umbilical cord and foetus at 
      birth. It is concluded that 9 h after a dose of 3.6 g acetylsalicylic acid, the 
      salicylate level in maternal blood was sufficient to reduce the number of uterine 
      spasms in most patients. No effect of the drug on blood coagulation in mother or 
      child was observed.
FAU - Jankowski, A
AU  - Jankowski A
FAU - Skublicki, S
AU  - Skublicki S
FAU - Wichliński, L M
AU  - Wichliński LM
FAU - Szymański, W
AU  - Szymański W
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Hosp Pharm
JT  - Journal of clinical and hospital pharmacy
JID - 8006505
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amniotic Fluid/metabolism
MH  - Aspirin/*metabolism/therapeutic use
MH  - Female
MH  - Fetal Blood/metabolism
MH  - Humans
MH  - Infant, Newborn
MH  - Kinetics
MH  - Obstetric Labor, Premature/*prevention & control
MH  - Placenta/metabolism
MH  - Pregnancy
MH  - Salicylates/urine
MH  - Salicylic Acid
MH  - Time Factors
EDAT- 1985/12/01 00:00
MHDA- 1985/12/01 00:01
CRDT- 1985/12/01 00:00
PHST- 1985/12/01 00:00 [pubmed]
PHST- 1985/12/01 00:01 [medline]
PHST- 1985/12/01 00:00 [entrez]
AID - 10.1111/j.1365-2710.1985.tb00934.x [doi]
PST - ppublish
SO  - J Clin Hosp Pharm. 1985 Dec;10(4):361-6. doi: 10.1111/j.1365-2710.1985.tb00934.x.

PMID- 150157
OWN - NLM
STAT- MEDLINE
DCOM- 19780925
LR  - 20131121
IS  - 0303-6464 (Print)
IS  - 0303-6464 (Linking)
VI  - 66
IP  - 1
DP  - 1977
TI  - [The effect of locally applied Grisaldone or choline salicylate gel on bone 
      healing after tooth extraction in animal experiments].
PG  - 14-20
AB  - Comparative histological and experimental animal studies of the effects upon bone 
      wound healing of topically applied choline salicylate gel and Grisaldon showed 
      that Grisaldon tends to hinder the course of reparation of bone, whereas choline 
      salicylate gel has no appreciable influence upon the time course of wound 
      healing. This essential difference is considered to be due predominantly to the 
      exactly opposite behavior shown by the two pharmaceutical preparations in regard 
      to their solubility in water. The difficultly watersoluble Grisaldon tends to 
      exert a longer-drawn-out irritant effect upon the tissue and can be detected in 
      alveoli even after twenty-eight days from administration thereof. By contrast, 
      choline salicylate gel, which is known to be readily soluble in water, will be 
      eliminated already after two days from administration thereof.
FAU - Cendelin, E
AU  - Cendelin E
FAU - Fröhlich, M
AU  - Fröhlich M
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Die Knochenheilung nach Zahnextraktion unter dem Einfluss von lokal appliziertem 
      Grisaldon bzw. Cholinsalizylat-Gel im Tierversuch.
PL  - Germany
TA  - Zahn Mund Kieferheilkd Zentralbl
JT  - Zahn-, Mund-, und Kieferheilkunde mit Zentralblatt
JID - 0434643
RN  - 0 (Salicylates)
RN  - N91BDP6H0X (Choline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Choline/administration & dosage/*therapeutic use
MH  - Rabbits
MH  - Salicylates/administration & dosage/*therapeutic use
MH  - Solubility
MH  - Tooth Extraction
MH  - Wound Healing/*drug effects
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Zahn Mund Kieferheilkd Zentralbl. 1977;66(1):14-20.

PMID- 7993983
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20191023
IS  - 0142-2782 (Print)
IS  - 0142-2782 (Linking)
VI  - 15
IP  - 6
DP  - 1994 Aug
TI  - The absence of a pharmacokinetic interaction between aspirin and the 
      angiotensin-converting enzyme inhibitor benazepril in healthy volunteers.
PG  - 451-61
AB  - Potential effects of the coadministration of single doses of aspirin (325 mg) and 
      of benazepril hydrochloride (20 mg) on the pharmacokinetics and the metabolism of 
      these two drugs were evaluated in 12 healthy subjects. Plasma concentration 
      profiles of benazepril, its active metabolite benazeprilat, and total salicylic 
      acid were determined together with urinary excretion of benazeprilat, salicylic 
      acid, salicyluric acid, and salicylate glucuronides. Almost superimposable plasma 
      profiles of benazepril, benazeprilat, and total salicylic acid were achieved with 
      the drugs given alone and concomitantly. The coadministration of benazepril 
      hydrochloride and aspirin did not modify the pharmacokinetics or the metabolism 
      of the two drugs.
FAU - Sioufi, A
AU  - Sioufi A
AD  - Laboratoires Ciba-Geigy, Biopharmaceutical Research Centre, Rueil-Malmaison, 
      France.
FAU - Pommier, F
AU  - Pommier F
FAU - Gauducheau, N
AU  - Gauducheau N
FAU - Godbillon, J
AU  - Godbillon J
FAU - Choi, L
AU  - Choi L
FAU - John, V
AU  - John V
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Biopharm Drug Dispos
JT  - Biopharmaceutics & drug disposition
JID - 7911226
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Benzazepines)
RN  - 0 (Hippurates)
RN  - 0 (Tablets)
RN  - 487-54-7 (salicylurate)
RN  - JRM708L703 (benazeprilat)
RN  - R16CO5Y76E (Aspirin)
RN  - UDM7Q7QWP8 (benazepril)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Angiotensin-Converting Enzyme Inhibitors/blood/*pharmacokinetics
MH  - Aspirin/blood/*pharmacokinetics/urine
MH  - Benzazepines/blood/*pharmacokinetics/urine
MH  - Chromatography, Gas
MH  - Drug Interactions
MH  - Hippurates/urine
MH  - Humans
MH  - Hydrolysis
MH  - Male
MH  - Quality Control
MH  - Reproducibility of Results
MH  - Tablets
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
AID - 10.1002/bdd.2510150603 [doi]
PST - ppublish
SO  - Biopharm Drug Dispos. 1994 Aug;15(6):451-61. doi: 10.1002/bdd.2510150603.

PMID- 29758501
OWN - NLM
STAT- MEDLINE
DCOM- 20180828
LR  - 20181202
IS  - 1879-1298 (Electronic)
IS  - 0045-6535 (Linking)
VI  - 206
DP  - 2018 Sep
TI  - Rolling-made gas diffusion electrode with carbon nanotube for electro-Fenton 
      degradation of acetylsalicylic acid.
PG  - 439-446
LID - S0045-6535(18)30869-5 [pii]
LID - 10.1016/j.chemosphere.2018.05.027 [doi]
AB  - H(2)O(2) production plays an important role in electro-Fenton process for 
      pharmaceutical and personal care products (PPCPs) degradation. In this work, 
      carbon nanotube (CNT) was attempted to make a gas diffusion electrode (GDE) by 
      rolling method to achieve a high H(2)O(2) production and current efficiency, and 
      it was further used as electro-Fenton cathode for the degradation of 
      acetylsalicylic acid (ASA) as one kind of PPCPs. The optimal amount of catalyst 
      layer was 0.15 g CNT and 93.75 μL PTFE, obtaining the production of H(2)O(2) of 
      805 mg L(-1) in 0.05 mM Na(2)SO(4) solution at 100 mA after 180 min. The 
      degradation of ASA by electro-Fenton on such a CNT-GDE cathode was studied, and 
      some important parameters such as current, pH as well as the dosage of Fe(2+) 
      were optimized. The degradation ratio of ASA could achieve almost 100% after 
      10 min and the TOC removal ratio was 62% at 1 h under the condition of 100 mA and 
      pH 3, showing a great potential for the treatment of PPCPs.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Yang, Huijia
AU  - Yang H
AD  - Key Laboratory of Pollution Process and Environmental Criteria, Ministry of 
      Education, College of Environmental Science and Engineering, Nankai University, 
      Tianjin 300350, China; Tianjin Key Laboratory of Urban Ecology Environmental 
      Remediation and Pollution Control, College of Environmental Science and 
      Engineering, Nankai University, Tianjin 300350, China; Tianjin Advanced Water 
      Treatment Technology International Joint Research Center, College of 
      Environmental Science and Engineering, Nankai University, Tianjin 300350, China.
FAU - Zhou, Minghua
AU  - Zhou M
AD  - Key Laboratory of Pollution Process and Environmental Criteria, Ministry of 
      Education, College of Environmental Science and Engineering, Nankai University, 
      Tianjin 300350, China; Tianjin Key Laboratory of Urban Ecology Environmental 
      Remediation and Pollution Control, College of Environmental Science and 
      Engineering, Nankai University, Tianjin 300350, China; Tianjin Advanced Water 
      Treatment Technology International Joint Research Center, College of 
      Environmental Science and Engineering, Nankai University, Tianjin 300350, China. 
      Electronic address: zhoumh@nankai.edu.cn.
FAU - Yang, Weilu
AU  - Yang W
AD  - Key Laboratory of Pollution Process and Environmental Criteria, Ministry of 
      Education, College of Environmental Science and Engineering, Nankai University, 
      Tianjin 300350, China; Tianjin Key Laboratory of Urban Ecology Environmental 
      Remediation and Pollution Control, College of Environmental Science and 
      Engineering, Nankai University, Tianjin 300350, China; Tianjin Advanced Water 
      Treatment Technology International Joint Research Center, College of 
      Environmental Science and Engineering, Nankai University, Tianjin 300350, China.
FAU - Ren, Gengbo
AU  - Ren G
AD  - Key Laboratory of Pollution Process and Environmental Criteria, Ministry of 
      Education, College of Environmental Science and Engineering, Nankai University, 
      Tianjin 300350, China; Tianjin Key Laboratory of Urban Ecology Environmental 
      Remediation and Pollution Control, College of Environmental Science and 
      Engineering, Nankai University, Tianjin 300350, China; Tianjin Advanced Water 
      Treatment Technology International Joint Research Center, College of 
      Environmental Science and Engineering, Nankai University, Tianjin 300350, China.
FAU - Ma, Liang
AU  - Ma L
AD  - Key Laboratory of Pollution Process and Environmental Criteria, Ministry of 
      Education, College of Environmental Science and Engineering, Nankai University, 
      Tianjin 300350, China; Tianjin Key Laboratory of Urban Ecology Environmental 
      Remediation and Pollution Control, College of Environmental Science and 
      Engineering, Nankai University, Tianjin 300350, China; Tianjin Advanced Water 
      Treatment Technology International Joint Research Center, College of 
      Environmental Science and Engineering, Nankai University, Tianjin 300350, China.
LA  - eng
PT  - Journal Article
DEP - 20180504
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - 0 (Nanotubes, Carbon)
RN  - 0 (Water Pollutants, Chemical)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Diffusion
MH  - Electrodes/*statistics & numerical data
MH  - Nanotubes, Carbon/*chemistry
MH  - Water Pollutants, Chemical/*chemistry
OTO - NOTNLM
OT  - Acetylsalicylic acid degradation
OT  - Carbon nanotube
OT  - Electro-Fenton
OT  - Gas diffusion electrode
OT  - H(2)O(2) generation
EDAT- 2018/05/15 06:00
MHDA- 2018/08/29 06:00
CRDT- 2018/05/15 06:00
PHST- 2018/01/14 00:00 [received]
PHST- 2018/04/19 00:00 [revised]
PHST- 2018/05/02 00:00 [accepted]
PHST- 2018/05/15 06:00 [pubmed]
PHST- 2018/08/29 06:00 [medline]
PHST- 2018/05/15 06:00 [entrez]
AID - S0045-6535(18)30869-5 [pii]
AID - 10.1016/j.chemosphere.2018.05.027 [doi]
PST - ppublish
SO  - Chemosphere. 2018 Sep;206:439-446. doi: 10.1016/j.chemosphere.2018.05.027. Epub 
      2018 May 4.

PMID- 7196241
OWN - NLM
STAT- MEDLINE
DCOM- 19810925
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 31
IP  - 6
DP  - 1981
TI  - Low dose of acetylsalicylic acid prolongs refractory periods in normal cat 
      myocardium.
PG  - 959-61
AB  - The effect of acetylsalicylic acid (ASA, Aspisol) upon diastolic threshold and 
      refractory period in normal myocardium was investigated in the experiments on 
      cats. It has been found that ASA given in a dose of 7 mg/kg i.v. significantly 
      prolongs refractory period up to 27.7% of initial value throughout 2 h or 
      observation. No significant changes in diastolic threshold were detected. Since 
      the prolongation of refractory period favours stabilisation of cardiac rhythm, 
      this effect of ASA may contribute to antiarrhythmic action of this drug observed 
      earlier by other authors.
FAU - Kwiatkowska-Patzer, B
AU  - Kwiatkowska-Patzer B
FAU - Herbaczyńska-Cedro, K
AU  - Herbaczyńska-Cedro K
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Cats
MH  - Female
MH  - Heart/*drug effects
MH  - Heart Rate/drug effects
MH  - Male
MH  - Time Factors
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1981;31(6):959-61.

PMID- 32091869
OWN - NLM
STAT- MEDLINE
DCOM- 20210127
LR  - 20210608
IS  - 1554-8937 (Electronic)
IS  - 1554-8929 (Linking)
VI  - 15
IP  - 5
DP  - 2020 May 15
TI  - Translation of Microbiota Short-Chain Fatty Acid Mechanisms Affords 
      Anti-infective Acyl-Salicylic Acid Derivatives.
PG  - 1141-1147
LID - 10.1021/acschembio.9b01009 [doi]
AB  - The discovery of specific microbiota metabolite mechanisms has begun to motivate 
      new therapeutic approaches. Inspired by our mechanistic studies of 
      microbiota-derived short chain fatty acid (SCFA) acylation of bacterial virulence 
      factors, here we explored covalent protein acylation therapeutics as potential 
      anti-infectives. For these studies, we focused on acetyl-salicylic acid, aspirin, 
      and discovered that SCFA analogues such as butyryl-salicylic acid showed 
      significantly improved anti-infective activity against Salmonella Typhimurium. 
      Structure-activity studies showed that the ester functionality of 
      butyryl-salicylic acid was crucial and associated with the acylation of key 
      bacterial virulence factors and metabolic enzymes, which are important for 
      Salmonella infection of host cells and bacterial growth. Beyond the Gram-negative 
      bacterial pathogens, butyryl-salicylic acid also showed better antibacterial 
      activity compared to aspirin against Clostridioides difficile, a clinically 
      challenging Gram-positive bacterial pathogen. Notably, coadministration of 
      butyryl-salicylic acid, but not aspirin, effectively attenuated Salmonella 
      pathogenesis in vivo. This study highlights how the analysis of microbiota 
      metabolite mechanisms may inspire the repurposing and development of new 
      anti-infective agents.
FAU - Yang, Xinglin
AU  - Yang X
AUID- ORCID: 0000-0002-1431-2836
AD  - Laboratory of Chemical Biology and Microbial Pathogenesis, The Rockefeller 
      University, New York, New York 10065, United States.
FAU - Forster, Emily R
AU  - Forster ER
AD  - Department of Molecular Biology and Microbiology, Tufts University School of 
      Medicine, Boston, Massachusetts 02111, United States.
AD  - Graduate School of Biomedical Sciences, Tufts University, Boston, Massachusetts 
      02111, United States.
FAU - Darabedian, Narek
AU  - Darabedian N
AD  - Department of Chemistry, University of Southern California, Los Angeles, 
      California 90089, United States.
FAU - Kim, Alexander T
AU  - Kim AT
AD  - Laboratory of Chemical Biology and Microbial Pathogenesis, The Rockefeller 
      University, New York, New York 10065, United States.
FAU - Pratt, Matthew R
AU  - Pratt MR
AUID- ORCID: 0000-0003-3205-5615
AD  - Department of Chemistry, University of Southern California, Los Angeles, 
      California 90089, United States.
FAU - Shen, Aimee
AU  - Shen A
AD  - Department of Molecular Biology and Microbiology, Tufts University School of 
      Medicine, Boston, Massachusetts 02111, United States.
FAU - Hang, Howard C
AU  - Hang HC
AUID- ORCID: 0000-0003-4053-5547
AD  - Laboratory of Chemical Biology and Microbial Pathogenesis, The Rockefeller 
      University, New York, New York 10065, United States.
LA  - eng
GR  - R01 GM108684/GM/NIGMS NIH HHS/United States
GR  - T32 GM007310/GM/NIGMS NIH HHS/United States
GR  - R01 GM087544/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200302
PL  - United States
TA  - ACS Chem Biol
JT  - ACS chemical biology
JID - 101282906
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Esters)
RN  - 0 (Fatty Acids, Volatile)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acylation
MH  - Anti-Infective Agents/*chemistry/pharmacology
MH  - Aspirin/chemistry/pharmacology
MH  - Clostridioides difficile/drug effects
MH  - Drug Therapy, Combination
MH  - Esters/chemistry
MH  - Fatty Acids, Volatile/*chemistry/pharmacology
MH  - Humans
MH  - Microbiota/*physiology
MH  - Salicylic Acid/*chemistry/pharmacology
MH  - Salmonella typhimurium/drug effects
MH  - Structure-Activity Relationship
EDAT- 2020/02/25 06:00
MHDA- 2021/01/28 06:00
CRDT- 2020/02/25 06:00
PHST- 2020/02/25 06:00 [pubmed]
PHST- 2021/01/28 06:00 [medline]
PHST- 2020/02/25 06:00 [entrez]
AID - 10.1021/acschembio.9b01009 [doi]
PST - ppublish
SO  - ACS Chem Biol. 2020 May 15;15(5):1141-1147. doi: 10.1021/acschembio.9b01009. Epub 
      2020 Mar 2.

PMID- 19148798
OWN - NLM
STAT- MEDLINE
DCOM- 20090312
LR  - 20211020
IS  - 0944-1174 (Print)
IS  - 0944-1174 (Linking)
VI  - 44 Suppl 19
DP  - 2009
TI  - Chemoprevention of colorectal cancer in Japan: a brief introduction to current 
      clinical trials.
PG  - 77-81
LID - 10.1007/s00535-008-2286-2 [doi]
AB  - The rapidly increasing incidence of colorectal cancer in Japan poses a great 
      challenge to researchers to develop preventive strategies against this disease. 
      Thus far, several clinical trials for this purpose have been planned in Japanese 
      subjects; some have been completed and documented while others are still ongoing. 
      Also, the Ministry of Health, Labour and Welfare of Japan recognizes the 
      significance of cancer prevention studies, especially against colorectal cancer, 
      including it as one of the pillars in the "Third Research Project on General 
      Strategies against Cancer" and funding several large-scale projects. Among them 
      are two chemoprevention studies currently being performed: in patients with 
      previous sporadic colorectal tumors (J-CAPP study) and in patients with familial 
      adenomatous polyposis (J-FAPP study II). Both are double-blind randomized 
      controlled trials with low-dose aspirin (100 mg/day), which is generally 
      considered to be safe for long-term use. This article outlines relevant past 
      clinical data and gives a brief introduction to these two studies.
FAU - Ishikawa, Hideki
AU  - Ishikawa H
AD  - Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University 
      of Medicine, 3-2-17 Imahashi, Chuo-ku, Osaka, 541-0042, Japan.
FAU - Nakamura, Tomiyo
AU  - Nakamura T
FAU - Kawano, Atsuko
AU  - Kawano A
FAU - Gondo, Nobuhisa
AU  - Gondo N
FAU - Sakai, Toshiyuki
AU  - Sakai T
LA  - eng
PT  - Journal Article
DEP - 20090116
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenomatous Polyposis Coli/drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Chemoprevention/methods
MH  - Colorectal Neoplasms/*prevention & control
MH  - Humans
MH  - Japan/epidemiology
MH  - Randomized Controlled Trials as Topic
EDAT- 2009/02/20 09:00
MHDA- 2009/03/13 09:00
CRDT- 2009/01/17 09:00
PHST- 2008/07/30 00:00 [received]
PHST- 2008/08/15 00:00 [accepted]
PHST- 2009/01/17 09:00 [entrez]
PHST- 2009/02/20 09:00 [pubmed]
PHST- 2009/03/13 09:00 [medline]
AID - 10.1007/s00535-008-2286-2 [doi]
PST - ppublish
SO  - J Gastroenterol. 2009;44 Suppl 19:77-81. doi: 10.1007/s00535-008-2286-2. Epub 
      2009 Jan 16.

PMID- 23639703
OWN - NLM
STAT- MEDLINE
DCOM- 20131118
LR  - 20131121
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 33
IP  - 2
DP  - 2013 May
TI  - Introduction: Szczeklik's contributions to our understanding of aspirin, NSAIDs, 
      asthma, and allergy.
PG  - 125-33
LID - S0889-8561(12)00112-9 [pii]
LID - 10.1016/j.iac.2012.10.001 [doi]
AB  - Andrew Szczeklik was born in 1938 and died on Feb 3rd, 2012. He was the most 
      influential expert in the field of aspirin and NSAID sensitivity reactions and 
      associated diseases in the world. This edition of NACAI is dedicated to Andrew. 
      In the introductory chapter, we elected to highlight his accomplishments as 
      reflected in his publications. Andrew published at least 503 articles including 
      many invited review articles. We present 20 of his most important publications 
      all of which contributed significantly to our understanding of these diseases.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Stevenson, Donald D
AU  - Stevenson DD
AD  - Division of Allergy and Immunology, Scripps Research Institute, Scripps Clinic, 
      San Diego, CA 92130, USA. dstevensonmd@gmail.com
FAU - Kowalski, Marek L
AU  - Kowalski ML
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
DEP - 20121127
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*history
MH  - Aspirin/adverse effects/*history
MH  - Asthma, Aspirin-Induced/*history/immunology
MH  - Drug Hypersensitivity/*history/immunology
MH  - History, 20th Century
MH  - Humans
PS  - Szczeklik A
FPS - Szczeklik, Andrew
EDAT- 2013/05/04 06:00
MHDA- 2013/11/19 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/05/04 06:00 [entrez]
PHST- 2013/05/04 06:00 [pubmed]
PHST- 2013/11/19 06:00 [medline]
AID - S0889-8561(12)00112-9 [pii]
AID - 10.1016/j.iac.2012.10.001 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2013 May;33(2):125-33. doi: 
      10.1016/j.iac.2012.10.001. Epub 2012 Nov 27.

PMID- 3428858
OWN - NLM
STAT- MEDLINE
DCOM- 19880302
LR  - 20131121
IS  - 0172-6390 (Print)
IS  - 0172-6390 (Linking)
VI  - 34
IP  - 6
DP  - 1987 Dec
TI  - Gastric mucosal cell loss caused by aspirin and alcohol.
PG  - 262-4
AB  - Gastric epithelial cell loss was studied in healthy volunteers before and after 
      intragastric instillation of four aspirin (ASA) formulations and three strengths 
      of alcohol. Each test solution was administered three times over a period of 
      three hours during one of the experiments. Three of the four aspirin formulations 
      significantly increased gastric epithelial cell loss. Microencapsulated aspirin 
      increased gastric epithelial cell loss significantly, but only after the third 
      dose. Alcohol, 10% (wine), increased cell loss to a similar extent as did 
      microencapsulated aspirin. Alcohol, 20% (campari), and 40% (whisky), 
      significantly enhanced cell loss to such a degree as was elicited by the two 
      strengths of soluble aspirin. Thus, gastric cell loss increased dose-dependently 
      after both aspirin and alcohol. The data suggest that, in man, gastric epithelial 
      cell damage caused by different aspirin formulations and alcohol concentrations 
      is reproducible and dose-dependent.
FAU - Hagel, H J
AU  - Hagel HJ
AD  - Department of Medicine, University of Erlangen-Nuremberg, FRG.
FAU - Melchner, M
AU  - Melchner M
FAU - Kachel, G
AU  - Kachel G
FAU - Ruppin, H
AU  - Ruppin H
FAU - Croft, D N
AU  - Croft DN
FAU - Domschke, W
AU  - Domschke W
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Hepatogastroenterology
JT  - Hepato-gastroenterology
JID - 8007849
RN  - 0 (Capsules)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Capsules
MH  - Dose-Response Relationship, Drug
MH  - Ethanol/*pharmacology
MH  - Female
MH  - Gastric Mucosa/*cytology/drug effects
MH  - Humans
MH  - Male
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
PST - ppublish
SO  - Hepatogastroenterology. 1987 Dec;34(6):262-4.

PMID- 7846108
OWN - NLM
STAT- MEDLINE
DCOM- 19950303
LR  - 20190913
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 51
IP  - 5
DP  - 1994 Nov
TI  - Salicylamide reverses the aspirin-antagonistic effect of salicylic acid on rat 
      platelet cyclooxygenase.
PG  - 363-7
AB  - The antagonistic effect of salicylic acid (SA), the major metabolite of aspirin, 
      on aspirin (ASA)-induced inhibition of cyclooxygenase has been recognized in vivo 
      and in vitro. Salicylamide is available with aspirin in some analgesic 
      preparations. Salicylamide shares important characteristics with salicylic acid 
      including the lack of effect on cyclooxygenase and platelet aggregation as well 
      as a close structural resemblance. This prompted us to study the interaction of 
      salicylamide with aspirin and/or SA on rat platelet and cyclooxygenase. Our 
      results showed that salicylamide has, unlike SA, no blocking effect on the 
      anticyclooxygenase effect of aspirin in vitro. Moreover, salicylamide could 
      dose-dependently prevent the aspirin-blocking effect of SA on platelet 
      cyclooxygenase. These results suggest that salicylamide and SA compete for a 
      receptor on cyclooxygenase different to that of aspirin. A functional model of 
      cyclooxygenase enzyme is proposed.
FAU - Rizk, M
AU  - Rizk M
AD  - Department of Pharmacology and Toxicology, University of Medicine and Dentistry 
      of New Jersey, New Jersey Medical School, Newark 07103.
FAU - Abdel-Rahman, M S
AU  - Abdel-Rahman MS
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Salicylamides)
RN  - 0 (Salicylates)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EM8BM710ZC (salicylamide)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*antagonists & inhibitors/pharmacology
MH  - Blood Platelets/*enzymology
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Male
MH  - Prostaglandin-Endoperoxide Synthases/*blood
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Salicylamides/*pharmacology
MH  - Salicylates/*pharmacology
MH  - Salicylic Acid
MH  - Thromboxane B2/biosynthesis
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
AID - 10.1016/0952-3278(94)90009-4 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 1994 Nov;51(5):363-7. doi: 
      10.1016/0952-3278(94)90009-4.

PMID- 21262427
OWN - NLM
STAT- MEDLINE
DCOM- 20110513
LR  - 20220317
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 127 Suppl 3
DP  - 2011 Feb
TI  - LMWH have no place in recurrent pregnancy loss: debate-against the motion.
PG  - S110-2
LID - 10.1016/S0049-3848(11)70029-9 [doi]
AB  - The SPIN and ALIFE intervention trials apparently support that LMWHs should not 
      be advocated in patients with idiopathic RPL. There are however some concerns. 
      Epidemiology implies that most of the included patients shared recurrent 
      regulatory embryonic losses associated with isolated cytogenetics defects, a 
      dominant good prognosis entity which doesn't have to be treated. The real PL 
      illness, idiopathic foetal loss with normal karyotypes, was a minority. Primary 
      and secondary RPL cases were included, whose prognostic, applied to non-sporadic 
      PLs, cannot be similar. Thrombophilic patients were a minority, despite existing 
      data suggesting a LMWH beneficial effect. LMWHs were associated with LDA, 
      previously suspected to be deleterious in PL patients with thrombophilia. The two 
      indubitably planned-to-be negative trials will positively contribute to limit 
      aberrant LMWH treatments in non-selected RPL women cared without comprehensive 
      clinical categorisation. This is not the real clinical target for LMWHs, which 
      still has to be fully investigated.
CI  - © 2011 Elsevier Ltd. All rights reserved.
FAU - Gris, Jean-Christophe R
AU  - Gris JC
AD  - Department of Haematology, University Hospital, Nîmes, France. 
      jean.christophe.gris@chu-nimes.fr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*chemically induced
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Embryo Loss/*drug therapy
MH  - Female
MH  - Fetus/drug effects
MH  - Heparin, Low-Molecular-Weight/*adverse effects/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Thrombophilia/drug therapy
EDAT- 2011/01/26 06:00
MHDA- 2011/05/14 06:00
CRDT- 2011/01/26 06:00
PHST- 2011/01/26 06:00 [entrez]
PHST- 2011/01/26 06:00 [pubmed]
PHST- 2011/05/14 06:00 [medline]
AID - S0049-3848(11)70029-9 [pii]
AID - 10.1016/S0049-3848(11)70029-9 [doi]
PST - ppublish
SO  - Thromb Res. 2011 Feb;127 Suppl 3:S110-2. doi: 10.1016/S0049-3848(11)70029-9.

PMID- 6791602
OWN - NLM
STAT- MEDLINE
DCOM- 19811014
LR  - 20161123
IS  - 0003-9780 (Print)
IS  - 0003-9780 (Linking)
VI  - 250
IP  - 2
DP  - 1981 Apr
TI  - Modification of convulsive behaviour and body temperature in mice by 
      intracerebroventricular administration of prostaglandins, arachidonic acid and 
      the soluble acetylsalicylic acid salt lysine acetylsalicylate.
PG  - 254-65
AB  - The effects of centrally injected prostaglandins (PGE1 and PGF2 alpha), 
      arachidonic acid and lysine acetylsalicylate were examined on the seizure 
      activity and temperature changes produced by pentylentetrazole (PTZ) and also on 
      maximal electroshock (MES) seizures. PGE1 antagonised both PTZ and MES seizures 
      whilst PGF2 alpha had the reverse effect. In addition both PGs alone produced 
      hyperthermia but attenuated PTZ hypothermia. Arachidonic acid protected against 
      PTZ--but potentiated MES--seizures whilst lysine acetylsalicylate augmented the 
      effects of both convulsive stimuli. Lysine acetylsalicylate and arachidonic acid 
      alone were transiently hyperthermic and also antagonised PTZ hypothermia though 
      the total net effect may have been due to a functional antagonism. It is 
      suggested from these findings that PGE1 has anticonvulsant effects whilst PGF2 
      alpha promotes seizures neither of these properties correlating with 
      thermoregulatory actions.
FAU - Climax, J
AU  - Climax J
FAU - Sewell, R D
AU  - Sewell RD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Belgium
TA  - Arch Int Pharmacodyn Ther
JT  - Archives internationales de pharmacodynamie et de therapie
JID - 0405353
RN  - 0 (Anticonvulsants)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Convulsants)
RN  - 0 (Prostaglandins E, Synthetic)
RN  - 0 (Prostaglandins F, Synthetic)
RN  - 0 (Prostaglandins, Synthetic)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Anticonvulsants
MH  - Arachidonic Acids/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Body Temperature/*drug effects
MH  - Convulsants
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
MH  - Mice
MH  - Prostaglandins E, Synthetic/pharmacology
MH  - Prostaglandins F, Synthetic/pharmacology
MH  - Prostaglandins, Synthetic/*pharmacology
MH  - Seizures/*drug therapy
EDAT- 1981/04/01 00:00
MHDA- 1981/04/01 00:01
CRDT- 1981/04/01 00:00
PHST- 1981/04/01 00:00 [pubmed]
PHST- 1981/04/01 00:01 [medline]
PHST- 1981/04/01 00:00 [entrez]
PST - ppublish
SO  - Arch Int Pharmacodyn Ther. 1981 Apr;250(2):254-65.

PMID- 35640703
OWN - NLM
STAT- MEDLINE
DCOM- 20221004
LR  - 20221102
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 227
IP  - 4
DP  - 2022 Oct
TI  - Toward the elimination of race-based medicine: replace race with racism as 
      preeclampsia risk factor.
PG  - 593-596
LID - S0002-9378(22)00413-6 [pii]
LID - 10.1016/j.ajog.2022.05.048 [doi]
AB  - Pregnancy-related morbidity and mortality continue to disproportionately affect 
      birthing people who identify as Black. The use of race-based risk factors in 
      medicine exacerbates racial health inequities by insinuating a false conflation 
      that fails to consider the underlying impact of racism. As we work toward health 
      equity, we must remove race as a risk factor in our guidelines to address 
      disparities due to racism. This includes the most recent US Preventive Services 
      Taskforce, American College of Obstetricians and Gynecologists, and Society for 
      Maternal-Fetal Medicine guidelines for aspirin prophylaxis in preeclampsia, where 
      the risk factor for "Black race" should be replaced with "anti-Black racism." In 
      this commentary, we reviewed the evidence that supports race as a sociopolitical 
      construct and the health impacts of racism. We presented a call to action to 
      remove racial determination in the guidelines for aspirin prophylaxis in 
      preeclampsia and more broadly in our practice of medicine.
CI  - Copyright © 2022 Elsevier Inc. All rights reserved.
FAU - Ukoha, Erinma P
AU  - Ukoha EP
AD  - Departments of Obstetrics, Gynecology, and Reproductive Sciences, University of 
      California, San Francisco, San Francisco, CA; Department of Obstetrics and 
      Gynecology, Columbia University Medical Center, New York, NY. Electronic address: 
      erinmapukoha@gmail.com.
FAU - Snavely, Michael E
AU  - Snavely ME
AD  - Family and Community Medicine, University of California, San Francisco, San 
      Francisco, CA.
FAU - Hahn, Monica U
AU  - Hahn MU
AD  - Departments of Obstetrics, Gynecology, and Reproductive Sciences, University of 
      California, San Francisco, San Francisco, CA; Family and Community Medicine, 
      University of California, San Francisco, San Francisco, CA.
FAU - Steinauer, Jody E
AU  - Steinauer JE
AD  - Departments of Obstetrics, Gynecology, and Reproductive Sciences, University of 
      California, San Francisco, San Francisco, CA.
FAU - Bryant, Allison S
AU  - Bryant AS
AD  - Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, 
      MA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220528
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/etiology/prevention & control
MH  - Pregnancy
MH  - *Racism
MH  - Risk Factors
OTO - NOTNLM
OT  - aspirin prophylaxis
OT  - health inequities
OT  - maternal morbidity and mortality
OT  - obstetrical outcomes
OT  - preeclampsia
OT  - race-based medicine
OT  - racism
EDAT- 2022/06/01 06:00
MHDA- 2022/10/05 06:00
CRDT- 2022/05/31 19:23
PHST- 2022/01/12 00:00 [received]
PHST- 2022/05/17 00:00 [revised]
PHST- 2022/05/23 00:00 [accepted]
PHST- 2022/06/01 06:00 [pubmed]
PHST- 2022/10/05 06:00 [medline]
PHST- 2022/05/31 19:23 [entrez]
AID - S0002-9378(22)00413-6 [pii]
AID - 10.1016/j.ajog.2022.05.048 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2022 Oct;227(4):593-596. doi: 10.1016/j.ajog.2022.05.048. 
      Epub 2022 May 28.

PMID- 32464310
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20211013
IS  - 1567-7257 (Electronic)
IS  - 1567-1348 (Linking)
VI  - 84
DP  - 2020 Oct
TI  - Anti-biofilm effect by the combined action of fluconazole and acetylsalicylic 
      acid against species of Candida parapsilosis complex.
PG  - 104378
LID - S1567-1348(20)30209-4 [pii]
LID - 10.1016/j.meegid.2020.104378 [doi]
AB  - The Candida parapsilosis complex has been associated with highly refractory 
      infections mainly due to the presence of biofilms. High glucose levels enable the 
      development of this virulence factor which can aggravate the clinical condition 
      of patients with diabetes mellitus, those using parenteral nutrition, with 
      invasive medical device, including others. Combined antifungal therapy, such as 
      azole and cyclooxygenase inhibitors, may be an alternative in such infections 
      since they modulate prostaglandin production favoring the adhesion and 
      development of biofilms. Thus, the present study aimed to evaluate the influence 
      of glucose supplementation in the formation and detection of Candida parapsilosis 
      complex biofilms and to treat them using fluconazole and a cyclooxygenase 
      inhibitor in combination. Protein spectra evaluation allowed the differentiation 
      between species from the complex (score > 2) in our studies. All isolates were 
      able to form active biofilms at different glucose concentrations. In addition, a 
      significant reduction in biofilm formation was observed when fluconazole and 
      acetylsalicylic acid were combined. The ultrastructural analysis presented 
      typical biofilm characteristics by species from the complex. These data support 
      new combined therapies for the treatment of fungal infections, especially with 
      those which are resistant and therapeutic failure is associated with virulence 
      factors.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Santos, Franz de Assis Graciano Dos
AU  - Santos FAGD
AD  - Departamento de Micologia, Universidade Federal de Pernambuco, Brazil.
FAU - Leite-Andrade, Melyna Chaves
AU  - Leite-Andrade MC
AD  - Departamento de Medicina Tropical, Universidade Federal de Pernambuco, Brazil.
FAU - Brandão, Ildnay de Sousa
AU  - Brandão IS
AD  - Departamento de Micologia, Universidade Federal de Pernambuco, Brazil.
FAU - Alves, Adryelle Idalina da Silva
AU  - Alves AIDS
AD  - Departamento de Medicina Tropical, Universidade Federal de Pernambuco, Brazil.
FAU - Buonafina, Maria Daniela Silva
AU  - Buonafina MDS
AD  - Departamento de Micologia, Universidade Federal de Pernambuco, Brazil.
FAU - Nunes, Michellangelo
AU  - Nunes M
AD  - Departamento de Micologia, Universidade Federal de Pernambuco, Brazil.
FAU - Araújo-Neto, Luiz Nascimento de
AU  - Araújo-Neto LN
AD  - Departamento de Micologia, Universidade Federal de Pernambuco, Brazil.
FAU - Freitas, Maria Audilene de
AU  - Freitas MA
AD  - Departamento de Micologia, Universidade Federal de Pernambuco, Brazil.
FAU - Brayner, Fábio André
AU  - Brayner FA
AD  - Laboratório de Imunopatologia Keizo Asami, Universidade Federal de Pernambuco, 
      Brazil.
FAU - Alves, Luiz Carlos
AU  - Alves LC
AD  - Laboratório de Imunopatologia Keizo Asami, Universidade Federal de Pernambuco, 
      Brazil.
FAU - Coutinho, Henrique Douglas Melo
AU  - Coutinho HDM
AD  - Departamento de Química Biológica, Universidade Regional do Cariri, Brazil. 
      Electronic address: hdouglas@zipmail.com.br.
FAU - Neves, Rejane Pereira
AU  - Neves RP
AD  - Departamento de Micologia, Universidade Federal de Pernambuco, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200526
PL  - Netherlands
TA  - Infect Genet Evol
JT  - Infection, genetics and evolution : journal of molecular epidemiology and 
      evolutionary genetics in infectious diseases
JID - 101084138
RN  - 0 (Antifungal Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 8VZV102JFY (Fluconazole)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antifungal Agents/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biofilms/*drug effects
MH  - Candida parapsilosis/*drug effects/physiology
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Fluconazole/administration & dosage/*pharmacology
MH  - Glucose/metabolism
MH  - Microbial Sensitivity Tests
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Biofilms
OT  - Candida parapsilosis complex
OT  - Fluconazole
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/05/29 06:00
MHDA- 2021/10/14 06:00
CRDT- 2020/05/29 06:00
PHST- 2019/09/06 00:00 [received]
PHST- 2020/02/29 00:00 [revised]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - S1567-1348(20)30209-4 [pii]
AID - 10.1016/j.meegid.2020.104378 [doi]
PST - ppublish
SO  - Infect Genet Evol. 2020 Oct;84:104378. doi: 10.1016/j.meegid.2020.104378. Epub 
      2020 May 26.

PMID- 10599950
OWN - NLM
STAT- MEDLINE
DCOM- 20000204
LR  - 20131121
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 37
IP  - 12
DP  - 1999 Dec
TI  - Inhibition of platelet aggregation after intake of acetylsalicylic acid detected 
      by a platelet function analyzer (PFA-100).
PG  - 584-8
AB  - OBJECTIVE: The aim of the investigation was to determine the inhibition of 
      platelet aggregation detected by the platelet function analyzer PFA-100 in 
      patients with coronary artery disease who routinely take 100 mg acetylsalicylic 
      acid once daily. METHOD: The PFA-100 (Dade International Inc., Miami, USA) is a 
      new device for in vitro measurement of platelet function in citrated whole blood. 
      The time needed to form a platelet plug occluding the aperture cut into a 
      collagen/epinephrine- or collagen/ADP-coated membrane is determined under high 
      shear conditions. Typically, acetylsalicylic acid-induced inhibition of platelet 
      aggregation is detected by prolonged closure time in collagen/epinephrine or and 
      normal values for collagen/ADP. Blood samples of 48 patients were investigated, 
      the control group consisted of 10 healthy volunteers without intake of 
      acetylsalicylic acid. The upper limits of normal values of the control group were 
      137 sec closure time for collagen/epinephrine and 150 sec for collagen/ADP (mean 
      + 2 SD). RESULTS: Statistical analysis (Wilcoxon test) did not show a significant 
      difference (p = 0.46) between the patient group (129 +/- 11 sec) and the control 
      group (92 +/- 7 sec) for collagen/epinephrine (mean +/- SEM). Only 31% of 
      patients had closure time values above those upper limits defined above. 
      CONCLUSION: The effect of 100 mg acetylsalicylic acid daily appears to be too 
      small and too variable to detect a sufficient inhibition of platelet aggregation 
      by the PFA-100 in all patients with coronary artery disease.
FAU - Feuring, M
AU  - Feuring M
AD  - Institute of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, 
      University of Heidelberg, Germany.
FAU - Haseroth, K
AU  - Haseroth K
FAU - Janson, C P
AU  - Janson CP
FAU - Falkenstein, E
AU  - Falkenstein E
FAU - Schmidt, B M
AU  - Schmidt BM
FAU - Wehling, M
AU  - Wehling M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Coronary Disease/blood/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Function Tests/methods
EDAT- 1999/12/22 00:00
MHDA- 1999/12/22 00:01
CRDT- 1999/12/22 00:00
PHST- 1999/12/22 00:00 [pubmed]
PHST- 1999/12/22 00:01 [medline]
PHST- 1999/12/22 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 1999 Dec;37(12):584-8.

PMID- 31490536
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20201231
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 2
IP  - 9
DP  - 2019 Sep 4
TI  - Assessment of the End Point Adjudication Process on the Results of the 
      Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: 
      A Secondary Analysis.
PG  - e1910769
LID - 10.1001/jamanetworkopen.2019.10769 [doi]
LID - e1910769
AB  - IMPORTANCE: Debate continues about the value of event adjudication in clinical 
      trials and whether independent centralized assessments improve reliability and 
      validity of study results in masked randomized trials compared with local, 
      investigator-assessed end points. OBJECTIVE: To assess the results of the 
      adjudicated end point process in the Platelet-Oriented Inhibition in New TIA and 
      Minor Ischemic Stroke (POINT) trial by comparing end points assessed by local 
      site investigators with centrally adjudicated end points. DESIGN, SETTING, AND 
      PARTICIPANTS: This is an ad hoc secondary analysis of a randomized, double-blind 
      clinical trial comparing safety and effectiveness of clopidogrel bisulphate plus 
      aspirin vs placebo plus aspirin. Patients received either 600 mg of clopidogrel 
      bisulphate on day 1, then 75 mg per day through day 90 plus 50 to 325 mg of 
      aspirin per day, or the same range of dosages of placebo plus aspirin. 
      Investigators reported all potential end points; independent masked adjudicators 
      were randomly assigned to review using definitions specified in the study 
      protocol. This was a multicenter study; 269 international sites in 10 countries 
      enrolled from May 28, 2010, to December 19, 2017. The study enrolled 4881 
      patients 18 years or older with transient ischemic attack or minor acute ischemic 
      stroke within 12 hours of symptom onset and followed for 90 days from 
      randomization; last follow-up was completed in March 2018. MAIN OUTCOMES AND 
      MEASURES: Independent adjudicators external to the study and masked to study 
      treatment assignment adjudicated 467 primary and secondary effectiveness outcomes 
      and major and minor bleeding events, including the primary composite end point, 
      which was the risk of a composite of major ischemic events at 90 days, defined as 
      ischemic stroke, myocardial infarction, or death from an ischemic vascular event. 
      The primary safety end point was major hemorrhage. All components of the primary 
      and safety outcomes were adjudicated. RESULTS: In this secondary analysis of an 
      international randomized clinical trial, a total of 269 sites worldwide 
      randomized 4881 patients (median age, 65.0 years; interquartile range, 55-74 
      years); 55.0% were male. The primary results have been published previously. The 
      hazard ratios for clopidogrel plus aspirin vs placebo plus aspirin for the 
      primary composite end point were 0.75 (95% CI, 0.59-0.95) for 
      adjudicator-assessed events and 0.76 (95% CI, 0.60-0.95) for 
      investigator-assessed events. Agreement between adjudicator and investigator 
      assessments was 90.7%. The hazard ratios for clopidogrel plus aspirin vs placebo 
      plus aspirin for the primary safety end point were 2.32 (95% CI, 1.10-4.87) for 
      adjudicator-assessed events and 2.58 (95% CI, 1.19-5.58) for 
      investigator-assessed events, with an agreement rate of 77.5%. CONCLUSIONS AND 
      RELEVANCE: Independent end point adjudication did not substantially alter 
      estimates of the primary treatment effectiveness in the POINT trial. TRIAL 
      REGISTRATION: ClinicalTrials.gov identifier: NCT00991029.
FAU - Farrant, Mary
AU  - Farrant M
AD  - University of California, San Francisco.
FAU - Easton, J Donald
AU  - Easton JD
AD  - University of California, San Francisco.
FAU - Adelman, Eric E
AU  - Adelman EE
AD  - Department of Neurology, University of Wisconsin School of Medicine and Public 
      Health, Madison.
FAU - Cucchiara, Brett L
AU  - Cucchiara BL
AD  - University of Pennsylvania, Philadelphia.
FAU - Barsan, William G
AU  - Barsan WG
AD  - Department of Emergency Medicine, University of Michigan, Ann Arbor.
FAU - Tillman, Holly J
AU  - Tillman HJ
AD  - Data Coordination Unit, Department of Public Health Sciences, Medical University 
      of South Carolina, Charleston.
FAU - Elm, Jordan J
AU  - Elm JJ
AD  - Data Coordination Unit, Department of Public Health Sciences, Medical University 
      of South Carolina, Charleston.
FAU - Kim, Anthony S
AU  - Kim AS
AD  - University of California, San Francisco.
FAU - Lindblad, Anne S
AU  - Lindblad AS
AD  - The Emmes Corporation, Rockville, Maryland.
FAU - Palesch, Yuko Y
AU  - Palesch YY
AD  - Data Coordination Unit, Department of Public Health Sciences, Medical University 
      of South Carolina, Charleston.
FAU - Zhao, Wenle
AU  - Zhao W
AD  - Data Coordination Unit, Department of Public Health Sciences, Medical University 
      of South Carolina, Charleston.
FAU - Pauls, Keith
AU  - Pauls K
AD  - Data Coordination Unit, Department of Public Health Sciences, Medical University 
      of South Carolina, Charleston.
FAU - Walsh, Kyle B
AU  - Walsh KB
AD  - Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio.
FAU - Martí-Fàbregas, Joan
AU  - Martí-Fàbregas J
AD  - Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
FAU - Bernstein, Richard A
AU  - Bernstein RA
AD  - Department of Neurology, Feinberg School of Medicine, Northwestern University, 
      Chicago, Illinois.
FAU - Johnston, S Claiborne
AU  - Johnston SC
AD  - Dean's Office, Dell Medical School, The University of Texas at Austin.
LA  - eng
SI  - ClinicalTrials.gov/NCT00991029
GR  - T32 NS047996/NS/NINDS NIH HHS/United States
GR  - U01 NS062835/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20190904
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Clopidogrel/pharmacology/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Endpoint Determination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Research Design
MH  - Secondary Prevention
MH  - Stroke/*drug therapy
MH  - Treatment Outcome
PMC - PMC6735409
COIS- Conflict of Interest Disclosures: Ms Farrant reported receiving research grant 
      support from the National Institutes of Health (NIH)/National Institute of 
      Neurological Disorders and Stroke (NINDS) for the Platelet-Oriented Inhibition in 
      New TIA and Minor Ischemic Stroke (POINT) trial and from AstraZeneca for 
      conducting the SOCRATES trial. Dr Easton reported receiving research grant 
      support from the NIH/NINDS as coprincipal investigator for the POINT trial; 
      receiving support from Boehringer Ingelheim as a consultant for the planning, 
      conduct, and publication of the results of the RE-SPECT ESUS trial; participating 
      in planning and conduct of the SOCRATES trial; that his institution received 
      research grant support from AstraZeneca; receiving nonfinancial support from 
      Sanofi; and serving as a consultant for Sanofi at an advisory board meeting. Dr 
      Adelman reported receiving research grant support from the NIH/NINDS for the 
      POINT trial, receiving funding as an adjudicator for the SOCRATES trial, 
      receiving salary support as the chair of the adjudications committee for the 
      POINT trial, receiving grants from the NIH, and receiving personal fees from the 
      University of California, San Francisco. Dr Cucchiara reported receiving research 
      grant support from the NIH/NINDS for the POINT trial, receiving funding as an 
      adjudicator for the SOCRATES trial, and receiving grants from the NINDS. Dr 
      Barsan reported receiving salary support from the NIH/NINDS for the POINT trial 
      and receiving salary support from the NIH/NINDS as principal investigator for the 
      Neurologic Emergencies Treatment Trials (NETT) network, as coinvestigator for the 
      SHINE trial, and as coinvestigator for the ESETT trial. Ms Tillman reported 
      receiving grants from the Medical University of South Carolina. Dr Elm reported 
      receiving research grant support from the NIH/NINDS for the POINT trial. Dr Kim 
      reported receiving research grant support from the NIH/NINDS as coprincipal 
      investigator for the POINT trial, support from Neuravi as a member of the data 
      and safety monitoring board for the ARISE-2 trial, and grants from SanBio. Dr 
      Lindblad reported serving as president and CEO of The Emmes Corporation (a 
      for-profit contract research organization) and receiving research grant support 
      from the NIH/NINDS for the POINT trial. Dr Palesch reported receiving grant 
      support from the NIH/NINDS for the POINT trial. Dr Zhao reported receiving salary 
      support from the NIH/NINDS for the POINT trial. Mr Pauls reported receiving 
      salary support from the NIH/NINDS for the POINT trial. Dr Walsh reported 
      receiving salary support from the NIH/NINDS for the POINT trial. Dr 
      Martí-Fàbregas reported receiving salary support from the NIH/NINDS for the POINT 
      trial. Dr Bernstein reported receiving salary support from the NIH/NINDS for the 
      POINT trial and receiving grants or personal fees from Boehringer Ingleheim, 
      Bristol-Myers Squibb, Medtronic, Pfizer, Abbott, AbbVie, and Amgen. Dr Johnston 
      reported receiving research grant support from the NIH/NINDS as principal 
      investigator for the POINT trial, serving as a consultant to AstraZeneca during 
      planning of the SOCRATES and THALES trials (his institution received research 
      support for their conduct), and receiving nonfinancial support from Sanofi and 
      AstraZeneca.
EDAT- 2019/09/07 06:00
MHDA- 2020/07/01 06:00
CRDT- 2019/09/07 06:00
PHST- 2019/09/07 06:00 [entrez]
PHST- 2019/09/07 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 2749447 [pii]
AID - zoi190421 [pii]
AID - 10.1001/jamanetworkopen.2019.10769 [doi]
PST - epublish
SO  - JAMA Netw Open. 2019 Sep 4;2(9):e1910769. doi: 
      10.1001/jamanetworkopen.2019.10769.

PMID- 1119447
OWN - NLM
STAT- MEDLINE
DCOM- 19750613
LR  - 20190509
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 63
IP  - 4
DP  - 1975 Apr
TI  - Spontaneous platelet aggregation. Occurrence in an asymptomatic individual.
PG  - 559-63
AB  - Spontaneous platelet aggregation in an asymptomatic individual is described. The 
      platelet-poor plasma of the subject greatly enhanced the response of normal 
      platelet-rich plasma to adenosine diphosphate. The spontaneous platelet 
      aggregation was easily inhibited by aspirin.
FAU - Kardinal, C G
AU  - Kardinal CG
FAU - Wegener, L T
AU  - Wegener LT
FAU - Anderson, L K
AU  - Anderson LK
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Aspirin/pharmacology
MH  - Depression, Chemical
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Platelet Adhesiveness
MH  - *Platelet Aggregation/drug effects
EDAT- 1975/04/01 00:00
MHDA- 1975/04/01 00:01
CRDT- 1975/04/01 00:00
PHST- 1975/04/01 00:00 [pubmed]
PHST- 1975/04/01 00:01 [medline]
PHST- 1975/04/01 00:00 [entrez]
AID - 10.1093/ajcp/63.4.559 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1975 Apr;63(4):559-63. doi: 10.1093/ajcp/63.4.559.

PMID- 23238666
OWN - NLM
STAT- MEDLINE
DCOM- 20131118
LR  - 20131121
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 109
IP  - 5
DP  - 2013 May
TI  - High on treatment platelet reactivity against aspirin by non-steroidal 
      anti-inflammatory drugs--pharmacological mechanisms and clinical relevance.
PG  - 825-33
LID - 10.1160/TH12-07-0532 [doi]
AB  - Inhibition of platelet function by aspirin results from irreversible inhibition 
      of platelet cyclooxygenase (COX)-1. While sufficient inhibition is obtained at 
      antiplatelet doses (75-325 mg/day) in most (≥95%) treated patients, the 
      antiplatelet effect of aspirin and subsequent cardiovascular risk reduction is 
      much less in clinical settings and disease-dependent. Several reasons for this 
      "high on treatment platelet reactivity" are known. This paper reviews the 
      evidence for an interaction between aspirin and other COX inhibitors, namely 
      non-steroidal anti-inflammatory drugs (NSAIDs). Numerous experimental studies 
      demonstrated a pharmacodynamic interaction between aspirin and NSAIDs. This 
      likely occurs within the hydrophobic substrate channel of platelet COX-1 and 
      might be explained by molecular competition between inhibitor drugs and substrate 
      (arachidonic acid) at overlapping binding sites. This interaction is found with 
      some compounds, notably ibuprofen and dipyrone (metamizole), but not with others, 
      such as diclofenac and acetaminophen (paracetamol). Hence, this interaction is 
      not a class effect of NSAIDs and/or non-steroidal analgesics but rather due to 
      specific structural requirements which still remain to be defined. In vivo 
      studies on healthy subjects and patients tend to confirm this type of interaction 
      as well as large differences between NSAIDs and non-steroidal analgesics, 
      respectively. These interactions may be clinically relevant and may increase the 
      cardiovascular risk in long-term treatment for primary and secondary 
      cardiovascular prevention in patients with chronic inflammation, such as 
      rheumatoid arthritis. These patients have an elevated risk for myocardial 
      infarctions and may require chronic antiplatelet treatment by aspirin in addition 
      to treatment of inflammatory pain.
FAU - Hohlfeld, T
AU  - Hohlfeld T
AD  - Institut für Pharmakologie und Klinische Pharmakologie, 
      Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, Düsseldorf, Germany. 
      hohlfeld@uni-duesseldorf.de
FAU - Saxena, A
AU  - Saxena A
FAU - Schrör, K
AU  - Schrör K
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20121213
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/chemistry/*therapeutic use
MH  - Cardiovascular Diseases/chemically induced
MH  - Cyclooxygenase Inhibitors/adverse effects/chemistry/*therapeutic use
MH  - Drug Interactions
MH  - Humans
MH  - Molecular Docking Simulation
MH  - Molecular Structure
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/chemistry/*therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Structure-Activity Relationship
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2012/12/15 06:00
MHDA- 2013/11/19 06:00
CRDT- 2012/12/15 06:00
PHST- 2012/07/31 00:00 [received]
PHST- 2012/11/13 00:00 [accepted]
PHST- 2012/12/15 06:00 [entrez]
PHST- 2012/12/15 06:00 [pubmed]
PHST- 2013/11/19 06:00 [medline]
AID - 12-07-0532 [pii]
AID - 10.1160/TH12-07-0532 [doi]
PST - ppublish
SO  - Thromb Haemost. 2013 May;109(5):825-33. doi: 10.1160/TH12-07-0532. Epub 2012 Dec 
      13.

PMID- 2182246
OWN - NLM
STAT- MEDLINE
DCOM- 19900524
LR  - 20190510
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 13
IP  - 3
DP  - 1990 Mar
TI  - Aspirin and dipyridamole and their limitations in the therapy of coronary artery 
      disease.
PG  - 165-70
AB  - We have reviewed some of the voluminous literature on the effects of aspirin 
      combined with dipyridamole on coronary thrombosis. There is clear evidence that 
      aspirin is partially effective in preventing platelet aggregation and subsequent 
      thrombosis in experimental constricted and damaged coronary arteries of dogs. 
      Clinical studies show a clear reduction in myocardial infarction in male human 
      subjects who are given aspirin as therapy for unstable angina, or as prophylaxis 
      in asymptomatic individuals. In many studies aspirin and dipyridamole have been 
      combined and are effective. We have not found dipyridamole to be effective in the 
      dog with coronary artery constriction and find no substantial evidence that it is 
      effective in preventing myocardial infarction in man. Until definitive studies 
      show that combining dipyridamole with aspirin is more effective than aspirin 
      alone, we do not recommend its use for prevention of coronary thrombosis.
FAU - Rowe, G G
AU  - Rowe GG
AD  - University of Wisconsin Hospital and Clinics, Department of Medicine, Madison 
      53792.
FAU - Folts, J D
AU  - Folts JD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Coronary Thrombosis/*drug therapy
MH  - Dipyridamole/*therapeutic use
MH  - Dogs
MH  - Drug Therapy, Combination
MH  - Humans
RF  - 80
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
AID - 10.1002/clc.4960130304 [doi]
PST - ppublish
SO  - Clin Cardiol. 1990 Mar;13(3):165-70. doi: 10.1002/clc.4960130304.

PMID- 15095704
OWN - NLM
STAT- MEDLINE
DCOM- 20040520
LR  - 20131121
IS  - 0035-3655 (Print)
IS  - 0035-3655 (Linking)
VI  - 123
IP  - 3
DP  - 2003 Mar
TI  - [Prevention of cardiovascular and degenerative diseases: I. Aspirin, statins, or 
      vitamins?].
PG  - 175-81
AB  - Coronary syndromes are induced by atherosclerosis which results from lipid 
      deposit as well as inflammatory cells in vascular walls triggered by oxidative 
      modification of LDL cholesterol. Treatment with antioxidant vitamins (vitamin C 
      and E) has no evident effect on coronary events whereas aspirin and statins 
      treatments result in a 25 to 30% reduced rate of fatal and non fatal myocardial 
      infarction in primary and in secondary prevention trials. Both drugs are highly 
      recommended in secondary prevention. In primary prevention they are useful and 
      cost effective if the estimated risk of coronary event is 1.5% per year or 
      higher. They are not cost-effective if this risk is 0.6% per year or less. With 
      aspirin there is a 1.5 fold increase of hemorrhagic stroke and a 2 fold increase 
      of gastrointestinal hemorrhage. Aspirin is less efficient in younger patients (< 
      50 years of age), in those with high blood pressure (> 145 mmHg) and those with 
      low serum hsCRP (< 1 mg/l.). Statins are well tolerated and they could reduce not 
      only C-V and global mortality but also the risk of stroke and of macular 
      degeneration. They could also delay the occurrence of diabetes and kidney 
      failure. Folate administration can lower elevated serum homocysteine level, which 
      is a risk factor for C-V and Alzheimer's disease. However the clinical benefit 
      resulting from folate treatment must still be demonstrated.
FAU - Martin-Du Pan, Rémy C
AU  - Martin-Du Pan RC
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Prévention des maladies cardio-vasculaires et dégénératives: I. Aspirines, 
      statines ou vitamines?
PL  - Switzerland
TA  - Rev Med Suisse Romande
JT  - Revue medicale de la Suisse romande
JID - 0421524
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Vitamins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticholesteremic Agents/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Neurodegenerative Diseases/*prevention & control
MH  - Vitamins/therapeutic use
RF  - 67
EDAT- 2004/04/21 05:00
MHDA- 2004/05/21 05:00
CRDT- 2004/04/21 05:00
PHST- 2004/04/21 05:00 [pubmed]
PHST- 2004/05/21 05:00 [medline]
PHST- 2004/04/21 05:00 [entrez]
PST - ppublish
SO  - Rev Med Suisse Romande. 2003 Mar;123(3):175-81.

PMID- 15773191
OWN - NLM
STAT- MEDLINE
DCOM- 20050719
LR  - 20131121
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 1
IP  - 1
DP  - 2005 Jan 5
TI  - [Widal triad (Asthma-Nasal polyposis-aspirin intolerance): an inflammatory 
      metabolism abnormality].
PG  - 15-8
AB  - Widal disease is characterized by symptomatic triad of aspirin intolerance, nasal 
      polyposis and asthma. This disease is closely linked to abnormalities of the 
      arachidonic acid metabolism. Partly of genetic origin, these anomalies are also 
      related to the immune system function and probably to age. These factors induce 
      an increase of cysleukotriene synthetase enzyme, and consequently an 
      overproduction of cysleukotrienes that have both proinflammatory and 
      bronchoconstrictive effects. In recent years, encouraging results were obtained 
      with anti-leukotrienes, especially when they are associated with topic 
      corticosteroids. Finally, numerous research that attempt to reach a better 
      understanding of arachidonic acid metabolism are underway, which enables us to 
      hope for future therapeutic advances.
FAU - Leimgruber, A
AU  - Leimgruber A
AD  - Service d'immunologie et d'allergie, CHUV, 1011 Lausanne. 
      annette.leimgruber@hospvd.ch
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - 2. La triade de Widal (asthme-polypose nasale-intolérance à l'aspirine): une 
      anomalie du métabolisme inflammatoire.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/complications/diagnosis/drug therapy/*immunology
MH  - Drug Hypersensitivity/complications/diagnosis/drug therapy/*immunology
MH  - Humans
MH  - Metabolic Diseases/complications/diagnosis/drug therapy/*immunology
MH  - Nasal Polyps/complications/diagnosis/drug therapy/*immunology
EDAT- 2005/03/19 09:00
MHDA- 2005/07/20 09:00
CRDT- 2005/03/19 09:00
PHST- 2005/03/19 09:00 [pubmed]
PHST- 2005/07/20 09:00 [medline]
PHST- 2005/03/19 09:00 [entrez]
PST - ppublish
SO  - Rev Med Suisse. 2005 Jan 5;1(1):15-8.

PMID- 6654189
OWN - NLM
STAT- MEDLINE
DCOM- 19840220
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 13
IP  - 5
DP  - 1983
TI  - Quantification of blood from skin bleeding time determinations: effects of fish 
      diet or acetylsalicylic acid.
PG  - 282-7
AB  - The Simplate II technique for measuring bleeding time was adapted to quantify the 
      volume of blood as a function of time and for determining how this parameter was 
      affected by either acetylsalicylic acid (ASA) or a dietary supplement of fish. 
      Both increased the bleeding time significantly. Irrespective of the final 
      bleeding time, the rate of blood loss increased for about the first 2 min and 
      then decreased almost linearly until bleeding stopped. This time course was not 
      affected by either ASA or the fish diet. The lack of effect by ASA suggests that 
      the initial increase in bleeding time, presumably due to reversal of 
      vasoconstriction, does not involve prostaglandin derivatives. After ASA the rate 
      of blood loss was significantly greater throughout, probably caused by 
      deceleration of platelet aggregation. During the fish diet, when bleeding time 
      was increased, there was no change in the rate of blood loss until the last 2-3 
      min during which bleeding continued at a very low rate. The results support the 
      conclusion that the delay in primary haemostasis produced by a fish diet is due 
      to a different mechanism than that produced by ASA.
FAU - Thorngren, M
AU  - Thorngren M
FAU - Shafi, S
AU  - Shafi S
FAU - Born, G V
AU  - Born GV
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - *Bleeding Time
MH  - Blood Volume
MH  - Fish Products
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Male
MH  - *Platelet Function Tests
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1159/000214765 [doi]
PST - ppublish
SO  - Haemostasis. 1983;13(5):282-7. doi: 10.1159/000214765.

PMID- 16370179
OWN - NLM
STAT- MEDLINE
DCOM- 20060106
LR  - 20191109
IS  - 1083-7450 (Print)
IS  - 1083-7450 (Linking)
VI  - 10
IP  - 4
DP  - 2005
TI  - Drug-excipient compatibility testing using a high-throughput approach and 
      statistical design.
PG  - 499-505
AB  - The aim of our research was to develop a miniaturized high throughput 
      drug-excipient compatibility test. Experiments were planned and evaluated using 
      statistical experimental design. Binary mixtures of a drug, acetylsalicylic acid, 
      or fluoxetine hydrochloride, and of excipients commonly used in solid dosage 
      forms were prepared at a ratio of approximately 1:100 in 96-well microtiter 
      plates. Samples were exposed to different temperature (40 degrees C/ 50 degrees 
      C) and humidity (10%/75%) for different time (1 week/4 weeks), and chemical drug 
      degradation was analyzed using a fast gradient high pressure liquid 
      chromatography (HPLC). Categorical statistical design was applied to identify the 
      effects and interactions of time, temperature, humidity, and excipient on drug 
      degradation. Acetylsalicylic acid was least stable in the presence of magnesium 
      stearate, dibasic calcium phosphate, or sodium starch glycolate. Fluoxetine 
      hydrochloride exhibited a marked degradation only with lactose. 
      Factor-interaction plots revealed that the relative humidity had the strongest 
      effect on the drug excipient blends tested. In conclusion, the developed 
      technique enables fast drug-excipient compatibility testing and identification of 
      interactions. Since only 0.1 mg of drug is needed per data point, fast rational 
      preselection of the pharmaceutical additives can be performed early in solid 
      dosage form development.
FAU - Wyttenbach, Nicole
AU  - Wyttenbach N
AD  - F. Hoffmann-La Roche Ltd., Pharmaceutical and Analytical R & D, Basel, 
      Switzerland. nicole.wyttenbach@roche.com
FAU - Birringer, Christian
AU  - Birringer C
FAU - Alsenz, Jochem
AU  - Alsenz J
FAU - Kuentz, Martin
AU  - Kuentz M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharm Dev Technol
JT  - Pharmaceutical development and technology
JID - 9610932
RN  - 0 (Excipients)
RN  - 0 (Pharmaceutical Preparations)
RN  - 01K63SUP8D (Fluoxetine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry/standards
MH  - Chromatography, High Pressure Liquid
MH  - Data Interpretation, Statistical
MH  - *Drug Compounding/methods/standards/statistics & numerical data
MH  - Drug Incompatibility
MH  - Drug Stability
MH  - Drug Storage
MH  - Excipients/*chemistry/standards
MH  - Fluoxetine/chemistry/standards
MH  - Hot Temperature
MH  - Humidity
MH  - Pharmaceutical Preparations/*chemistry/standards
MH  - Time Factors
EDAT- 2005/12/24 09:00
MHDA- 2006/01/07 09:00
CRDT- 2005/12/24 09:00
PHST- 2005/12/24 09:00 [pubmed]
PHST- 2006/01/07 09:00 [medline]
PHST- 2005/12/24 09:00 [entrez]
AID - 10.1080/10837450500299875 [doi]
PST - ppublish
SO  - Pharm Dev Technol. 2005;10(4):499-505. doi: 10.1080/10837450500299875.

PMID- 8848408
OWN - NLM
STAT- MEDLINE
DCOM- 19961022
LR  - 20181130
VI  - 95
IP  - 5
DP  - 1996 May
TI  - [Investigations concerning the effect of nabumetone on gastric mucosa].
PG  - 414-9
AB  - The investigations were carried out in 9 patients (6 women and 3 men) with 
      rheumatoid arthritis or degenerative joint disease. All subjects were given 1000 
      mg nabumetone (NA) in a single daily dose at the evening, during 21 days. Before 
      and after the therapeutic course, endoscopic examination of the upper digestive 
      tract was carried out. On day at the begin and on the 22nd day of the NA 
      treatment, the gastric transmucosal electric potential difference (PD) was 
      determined, in (a) standard condition, (b) after intragastric application of 1000 
      mg NA, and (c) after a similar application of 1000 mg of acetylsalicylic acid 
      (AAS). On the contrary to the effect caused by AAS (p < 0.001), NA did not result 
      any significant change of the PD (p > 0.05), neither after a single nor after 21 
      day-long application (the lowest PD value before the NA therapeutic course was 
      after a single NA dose -45.8 +/- 2.7 mV and after a single dose of AAS -40.4 +/- 
      2.45 mV; after the end of the NA therapy course the values were: after additional 
      NA dose -46.7 +/- 3.5 mV and after AAS -40.5 +/- 2.7 mV) Endoscopically, any 
      changes of the upper digestive tract mucosa which could be related to the NA 
      therapeutic course were not detected.
FAU - Gołab, T
AU  - Gołab T
AD  - IV Katedry i Kliniki Chorób Wewnetrznych Slaskiej Akademii Medycznej w Tychach.
FAU - Jonderko, G
AU  - Jonderko G
FAU - Straszecka, J
AU  - Straszecka J
FAU - Krzewiński, W
AU  - Krzewiński W
FAU - Kucharz, E J
AU  - Kucharz EJ
FAU - Klimczak-Gołab, L
AU  - Klimczak-Gołab L
LA  - pol
PT  - Journal Article
TT  - Badanie wpływu nabumetonu na śluzówke zoładka.
PL  - Poland
TA  - Pol Arch Med Wewn
JT  - Polskie Archiwum Medycyny Wewnetrznej
JID - 0401225
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Butanones)
RN  - LW0TIW155Z (Nabumetone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/pharmacology/therapeutic use
MH  - Butanones/*pharmacology/therapeutic use
MH  - Drug Administration Schedule
MH  - Female
MH  - Gastric Mucosa/*drug effects/physiology
MH  - Humans
MH  - Joint Diseases/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Nabumetone
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
PST - ppublish
SO  - Pol Arch Med Wewn. 1996 May;95(5):414-9.

PMID- 28762201
OWN - NLM
STAT- MEDLINE
DCOM- 20180917
LR  - 20181113
IS  - 1573-904X (Electronic)
IS  - 0724-8741 (Linking)
VI  - 34
IP  - 10
DP  - 2017 Oct
TI  - Scanning Electron Microscope Observations of Powder Sticking on Punches during a 
      Limited Number (N < 5) of Compactions of Acetylsalicylic Acid.
PG  - 2012-2024
LID - 10.1007/s11095-017-2186-3 [doi]
AB  - PURPOSE: To obtain quantitative information and mechanistic insight into the 
      problem of sticking of acetylsalicylic acid tablets on a metallic punch. METHODS: 
      Low voltage scanning electron microscopy was used to observe punch area coverage 
      and morphology of adhered powder on a flat punch used for a limited number of 
      compactions. RESULTS: Material accumulation in terms of area coverage of the 
      punch per compaction cycle was determined at two pressures over five compactions. 
      The distribution of the adhered material on the punch was non-uniform with more 
      material left on the center of the punch. The sizes of the adhered particles 
      range from 1 to 100 μm, with 50% of the punch surface coverage from particles of 
      an equivalent diameter > 30 μm. Three types of adhered particles were identified 
      after the first compaction: (a) fragments of initial particles with very high 
      aspect ratio, (b) nearly equiaxed fragments with multiple cracks, (c) heavily 
      deformed islands of low profile. Some preliminary ideas that explain these 
      observations are presented and discussed. CONCLUSIONS: The ability of SEM to 
      provide quantitative information on sticking from few compactions presents an 
      interesting possibility for a material sparing technique that provides insight on 
      the propensity of sticking.
FAU - Tsosie, Henrietta
AU  - Tsosie H
AD  - Materials Science and Engineering Department, Drexel University, 3141 Chestnut 
      St. LeBow 344, Philadelphia, Pennsylvania, 19104, USA.
FAU - Thomas, James
AU  - Thomas J
AD  - Materials Science and Engineering Department, Drexel University, 3141 Chestnut 
      St. LeBow 344, Philadelphia, Pennsylvania, 19104, USA.
FAU - Strong, John
AU  - Strong J
AD  - Global Pharmaceutical Sciences, AbbVie Inc., North Chicago, Illinois, 60064, USA.
FAU - Zavaliangos, Antonios
AU  - Zavaliangos A
AD  - Materials Science and Engineering Department, Drexel University, 3141 Chestnut 
      St. LeBow 344, Philadelphia, Pennsylvania, 19104, USA. azavalia@coe.drexel.edu.
LA  - eng
PT  - Journal Article
DEP - 20170731
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Powders)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adhesiveness
MH  - Aspirin/*chemistry
MH  - Drug Compounding/methods
MH  - Equipment Design/instrumentation
MH  - Microscopy, Electron, Scanning
MH  - Particle Size
MH  - Powders
MH  - Pressure
MH  - Surface Properties
MH  - Tablets
MH  - Technology, Pharmaceutical
MH  - Tensile Strength
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - scanning electron microscopy
OT  - sticking
EDAT- 2017/08/02 06:00
MHDA- 2018/09/18 06:00
CRDT- 2017/08/02 06:00
PHST- 2017/04/10 00:00 [received]
PHST- 2017/05/19 00:00 [accepted]
PHST- 2017/08/02 06:00 [pubmed]
PHST- 2018/09/18 06:00 [medline]
PHST- 2017/08/02 06:00 [entrez]
AID - 10.1007/s11095-017-2186-3 [pii]
AID - 10.1007/s11095-017-2186-3 [doi]
PST - ppublish
SO  - Pharm Res. 2017 Oct;34(10):2012-2024. doi: 10.1007/s11095-017-2186-3. Epub 2017 
      Jul 31.

PMID- 24291076
OWN - NLM
STAT- MEDLINE
DCOM- 20150930
LR  - 20140120
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 461
IP  - 1-2
DP  - 2014 Jan 30
TI  - Aspirin degradation in surface-charged TEMPO-oxidized mesoporous crystalline 
      nanocellulose.
PG  - 74-81
LID - S0378-5173(13)01026-0 [pii]
LID - 10.1016/j.ijpharm.2013.11.032 [doi]
AB  - TEMPO-mediated surface oxidation of mesoporous highly crystalline Cladophora 
      cellulose was used to introduce negative surface charges onto cellulose 
      nanofibrils without significantly altering other structural characteristics. This 
      enabled the investigation of the influence of mesoporous nanocellulose surface 
      charges on aspirin chemical stability to be conducted. The negative surface 
      charges (carboxylate content 0.44±0.01 mmol/g) introduced on the mesoporous 
      crystalline nanocellulose significantly accelerated aspirin degradation, compared 
      to the starting material which had significantly less surface charge (0.06±0.01 
      mmol/g). This effect followed from an increased aspirin amorphisation ability in 
      mesopores of the oxidized nanocellulose. These results highlight the importance 
      of surface charges in formulating nanocellulose for drug delivery.
CI  - Copyright © 2013 Elsevier B.V. All rights reserved.
FAU - Carlsson, Daniel O
AU  - Carlsson DO
AD  - Nanotechnology and Functional Materials, Department of Engineering Sciences, 
      Ångström Laboratory, Uppsala University, PO Box 534, SE-75121 Uppsala, Sweden.
FAU - Hua, Kai
AU  - Hua K
AD  - Nanotechnology and Functional Materials, Department of Engineering Sciences, 
      Ångström Laboratory, Uppsala University, PO Box 534, SE-75121 Uppsala, Sweden.
FAU - Forsgren, Johan
AU  - Forsgren J
AD  - Nanotechnology and Functional Materials, Department of Engineering Sciences, 
      Ångström Laboratory, Uppsala University, PO Box 534, SE-75121 Uppsala, Sweden. 
      Electronic address: johan.forsgren@angstrom.uu.se.
FAU - Mihranyan, Albert
AU  - Mihranyan A
AD  - Nanotechnology and Functional Materials, Department of Engineering Sciences, 
      Ångström Laboratory, Uppsala University, PO Box 534, SE-75121 Uppsala, Sweden. 
      Electronic address: albert.mihranyan@angstrom.uu.se.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131126
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Cyclic N-Oxides)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
RN  - VQN7359ICQ (TEMPO)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Cellulose/*chemistry
MH  - Chemistry, Pharmaceutical
MH  - Chlorophyta/chemistry
MH  - Crystallization
MH  - Cyclic N-Oxides/*chemistry
MH  - Drug Delivery Systems
MH  - Drug Stability
MH  - *Nanofibers
MH  - Oxidation-Reduction
MH  - Porosity
MH  - Surface Properties
OTO - NOTNLM
OT  - Chemical stability
OT  - Cladophora cellulose
OT  - Mesoporous materials
OT  - Nanocellulose
OT  - TEMPO-mediated oxidation
EDAT- 2013/12/03 06:00
MHDA- 2015/10/01 06:00
CRDT- 2013/12/03 06:00
PHST- 2013/08/14 00:00 [received]
PHST- 2013/11/11 00:00 [revised]
PHST- 2013/11/18 00:00 [accepted]
PHST- 2013/12/03 06:00 [entrez]
PHST- 2013/12/03 06:00 [pubmed]
PHST- 2015/10/01 06:00 [medline]
AID - S0378-5173(13)01026-0 [pii]
AID - 10.1016/j.ijpharm.2013.11.032 [doi]
PST - ppublish
SO  - Int J Pharm. 2014 Jan 30;461(1-2):74-81. doi: 10.1016/j.ijpharm.2013.11.032. Epub 
      2013 Nov 26.

PMID- 31494125
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20200622
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 222
IP  - 5
DP  - 2020 May
TI  - Does low-dose aspirin initiated before 11 weeks' gestation reduce the rate of 
      preeclampsia?
PG  - 437-450
LID - S0002-9378(19)31062-2 [pii]
LID - 10.1016/j.ajog.2019.08.047 [doi]
AB  - OBJECTIVE DATA: Preconception or early administration of low-dose aspirin might 
      improve endometrial growth, placental vascularization, and organogenesis. Most 
      studies have evaluated the potential benefit of preconception or early 
      administration of low-dose aspirin in women with a history of recurrent pregnancy 
      loss, women who have undergone in vitro fertilization, or women with 
      thrombophilia or antiphospholipid syndrome. These women are at an increased risk 
      of placenta-associated complications of pregnancy, including preeclampsia, 
      preterm delivery, and fetal growth restriction. STUDY OUTCOMES: We performed a 
      systematic review and meta-analysis to evaluate the effect of low-dose aspirin 
      initiated at <11 weeks' gestation on the risk of preeclampsia, gestational 
      hypertension, or any hypertensive disorder of pregnancy. Secondary outcomes 
      included preterm delivery at <37 weeks' gestation and fetal growth restriction. 
      STUDY APPRAISAL AND SYNTHESIS METHODS: We searched in MEDLINE via PubMed, EMBASE, 
      Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, and 
      the World Health Organization International Clinical Trials Registry Platform 
      from 1985 to November 2018. Entry criteria were randomized controlled trials 
      evaluating the effect of aspirin administered at <11 weeks' gestation in 
      preventing preeclampsia and/or hypertensive disorders in pregnancy or improving 
      pregnancy outcomes in women with recurrent miscarriage as compared with placebo 
      or no treatment and outcome data available or provided by authors for >85% of the 
      study population. Relative risks with 95% confidence intervals were calculated 
      for each study and pooled for global analysis as the effect measure. We assessed 
      statistical heterogeneity in each meta-analysis using the χ(2) statistics, I(2), 
      and Tau(2). Heterogeneity was considered substantial if an I(2) was greater than 
      50% and either the Tau(2) was greater than zero or there was a low P value 
      (<0.10) in the χ(2) test for heterogeneity. Random-effects meta-analysis, 
      weighted by the size of the studies, was performed to produce an overall summary 
      on aspirin effect for each outcome. Sensitivity analysis by sequential omission 
      of each individual study and by fixed-effects model was performed. Publication 
      bias was not assessed because of the small number of included studies. 
      Statistical analysis was performed using Stata release 14.0 (StataCorp). RESULTS: 
      The entry criteria were fulfilled by 8 randomized controlled trials on a combined 
      total of 1426 participants. Low-dose aspirin initiated at <11 weeks' gestation 
      was associated with a nonsignificant reduction in the risk of preeclampsia 
      (relative risk, 0.52; 95% confidence interval, 0.23-1.17, P = .115), gestational 
      hypertension (relative risk, 0.49; 95% confidence interval, 0.20-1.21; P = .121), 
      and any hypertensive disorder of pregnancy (relative risk, 0.59; 95% confidence 
      interval, 0.33-1.04, P = .067). Early administration of low-dose aspirin reduced 
      the risk of preterm delivery (relative risk, 0.52; 95% confidence interval, 
      0.27-0.97, P = .040) but had no impact on the risk of fetal growth restriction 
      (relative risk, 1.10; 95% confidence interval, 0.58-2.07, P = .775). Except for 
      preterm delivery and any hypertensive disorder of pregnancy, sensitivity analysis 
      demonstrated similar observations, therefore confirming the robustness of the 
      analysis. CONCLUSION: The administration of low-dose aspirin at <11 weeks' 
      gestation in women at high risk does not decrease the risk of preeclampsia, 
      gestational hypertension, any hypertensive disorder of pregnancy, and fetal 
      growth restriction. However, it might reduce the risk of preterm delivery. Larger 
      randomized controlled trials will be required to substantiate the findings.
CI  - Copyright © 2019. Published by Elsevier Inc.
FAU - Chaemsaithong, Piya
AU  - Chaemsaithong P
AD  - Department of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese 
      University of Hong Kong, Shatin, Hong Kong SAR.
FAU - Cuenca-Gomez, Diana
AU  - Cuenca-Gomez D
AD  - Department of Obstetrics and Gynecology, Hospital Universitario de Torrejón, 
      Torrejón de Ardoz, Madrid, Spain.
FAU - Plana, María N
AU  - Plana MN
AD  - Department of Preventive Medicine and Public Health, Hospital Universitario 
      Príncipe de Asturias, Alcalá de Henares, Madrid, Centro de Investigación 
      Biomédica en Red Epidemiology and Public Health, Madrid, Spain.
FAU - Gil, María M
AU  - Gil MM
AD  - Department of Obstetrics and Gynecology, Hospital Universitario de Torrejón, 
      Torrejón de Ardoz, Madrid, Spain; School of Health Sciences, Universidad 
      Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain.
FAU - Poon, Liona C
AU  - Poon LC
AD  - Department of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese 
      University of Hong Kong, Shatin, Hong Kong SAR.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20190905
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Pregnancy Trimester, First
MH  - Treatment Outcome
OTO - NOTNLM
OT  - abortion
OT  - antiphospholipid syndrome
OT  - antiplatelet
OT  - aspirin
OT  - early aspirin
OT  - fetal growth restriction
OT  - fixed effect
OT  - gestational hypertension
OT  - habitual abortion
OT  - hypertension
OT  - hypertensive disorder
OT  - intracytoplasmic sperm injection
OT  - in vitro fertilization
OT  - meta-analysis
OT  - miscarriage
OT  - platelet
OT  - preeclampsia
OT  - pregnancy
OT  - prepregnancy
OT  - preterm
OT  - preterm delivery
OT  - prevention
OT  - random effect
OT  - recurrent abortion
OT  - recurrent miscarriage
OT  - recurrent pregnancy loss
OT  - salicylic acid
OT  - sensitivity analysis
OT  - systematic review
OT  - thrombophilia
EDAT- 2019/09/09 06:00
MHDA- 2020/06/23 06:00
CRDT- 2019/09/09 06:00
PHST- 2019/07/16 00:00 [received]
PHST- 2019/08/23 00:00 [revised]
PHST- 2019/08/23 00:00 [accepted]
PHST- 2019/09/09 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
PHST- 2019/09/09 06:00 [entrez]
AID - S0002-9378(19)31062-2 [pii]
AID - 10.1016/j.ajog.2019.08.047 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2020 May;222(5):437-450. doi: 10.1016/j.ajog.2019.08.047. 
      Epub 2019 Sep 5.

PMID- 28950378
OWN - NLM
STAT- MEDLINE
DCOM- 20180622
LR  - 20181202
IS  - 1873-734X (Electronic)
IS  - 1010-7940 (Linking)
VI  - 52
IP  - 5
DP  - 2017 Nov 1
TI  - Stopping versus continuing acetylsalicylic acid before coronary artery bypass 
      surgery: A systematic review and meta-analysis of 14 randomized controlled trials 
      with 4499 patients.
PG  - 838-847
LID - 10.1093/ejcts/ezx293 [doi]
AB  - This study aimed to evaluate the efficacy and safety of continuing versus 
      stopping aspirin [acetylsalicylic acid (ASA)] preoperatively in patients 
      undergoing coronary artery bypass graft surgery. MEDLINE, EMBASE, 
      CENTRAL/Cochrane Controlled Trials Register (CCTR), ClinicalTrials.gov, 
      Scientific Electronic Library Online (SciELO), Literatura Latino Americana em 
      Ciências da Saúde (LILACS), Google Scholar and reference lists of relevant 
      articles were searched for randomized controlled trials that reported efficacy 
      outcomes of myocardial infarction and mortality, and safety outcomes of blood 
      loss, packed red blood cell transfusion and surgical re-exploration were compared 
      between groups. Fourteen studies fulfilled our eligibility criteria and included 
      a total of 4499 patients (2329 for 'continuing ASA' and 2170 for 'stopping ASA'). 
      In the pooled analysis, continuing aspirin therapy did not reduce the risk of 
      myocardial infarction [risk ratio 0.834, 95% confidence interval (CI) 
      0.688-1.010; P = 0.063] or operative mortality (risk ratio 1.384, 95% CI 
      0.727-2.636; P = 0.323). Preoperative ASA increased postoperative chest tube 
      drainage (mean difference 143 ml, 95% CI 39-248 ml; P = 0.007) and packed red 
      blood cell transfusion (mean difference 142 ml, 95% CI 55-228; P = 0.001) but did 
      not increase the risk of surgical re-exploration (risk ratio 1.316, 95% CI 
      0.910-1.905; P = 0.145). This meta-analysis found no statistically significant 
      difference regarding the risk of operative mortality and myocardial infarction 
      between the 'continuing ASA' and 'stopping ASA' strategies. On the other hand, 
      the mean volume of blood loss and packed red blood cell transfusion was higher in 
      the 'continuing ASA' group, but this finding did not translate into higher risk 
      of reoperation for bleeding.
CI  - © The Author 2017. Published by Oxford University Press on behalf of the European 
      Association for Cardio-Thoracic Surgery. All rights reserved.
FAU - Sá, Michel Pompeu Barros Oliveira
AU  - Sá MPBO
AD  - Division of Cardiovascular Surgery, Pronto Socorro Cardiológico de Pernambuco 
      (PROCAPE), Recife, Brazil.
AD  - University of Pernambuco (UPE), Recife, Brazil.
AD  - Nucleus of Postgraduate and Research in Health Sciences of Faculty of Medical 
      Sciences, Biological Sciences Instituite (FCM/ICB), Recife, Brazil.
FAU - Soares, Artur Freire
AU  - Soares AF
AD  - Division of Cardiovascular Surgery, Pronto Socorro Cardiológico de Pernambuco 
      (PROCAPE), Recife, Brazil.
AD  - University of Pernambuco (UPE), Recife, Brazil.
FAU - Miranda, Rodrigo Gusmão Albuquerque
AU  - Miranda RGA
AD  - Division of Cardiovascular Surgery, Pronto Socorro Cardiológico de Pernambuco 
      (PROCAPE), Recife, Brazil.
AD  - University of Pernambuco (UPE), Recife, Brazil.
FAU - Araújo, Mayara Lopes
AU  - Araújo ML
AD  - Division of Cardiovascular Surgery, Pronto Socorro Cardiológico de Pernambuco 
      (PROCAPE), Recife, Brazil.
AD  - University of Pernambuco (UPE), Recife, Brazil.
FAU - Menezes, Alexandre Motta
AU  - Menezes AM
AD  - Division of Cardiovascular Surgery, Pronto Socorro Cardiológico de Pernambuco 
      (PROCAPE), Recife, Brazil.
AD  - University of Pernambuco (UPE), Recife, Brazil.
FAU - Silva, Frederico Pires Vasconcelos
AU  - Silva FPV
AD  - Division of Cardiovascular Surgery, Pronto Socorro Cardiológico de Pernambuco 
      (PROCAPE), Recife, Brazil.
AD  - University of Pernambuco (UPE), Recife, Brazil.
FAU - Lima, Ricardo Carvalho
AU  - Lima RC
AD  - Division of Cardiovascular Surgery, Pronto Socorro Cardiológico de Pernambuco 
      (PROCAPE), Recife, Brazil.
AD  - University of Pernambuco (UPE), Recife, Brazil.
AD  - Nucleus of Postgraduate and Research in Health Sciences of Faculty of Medical 
      Sciences, Biological Sciences Instituite (FCM/ICB), Recife, Brazil.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - Germany
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European 
      Association for Cardio-thoracic Surgery
JID - 8804069
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur J Cardiothorac Surg. 2018 Jun 1;53(6):1294-1298. PMID: 29293912
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Coronary Artery Bypass/*mortality/*statistics & numerical data
MH  - Humans
MH  - Myocardial Infarction/epidemiology
MH  - Postoperative Hemorrhage/epidemiology/surgery
MH  - Randomized Controlled Trials as Topic
MH  - Reoperation/statistics & numerical data
OTO - NOTNLM
OT  - Aspirin
OT  - Coronary artery bypass
OT  - Meta-analysis
EDAT- 2017/09/28 06:00
MHDA- 2018/06/23 06:00
CRDT- 2017/09/27 06:00
PHST- 2017/02/07 00:00 [received]
PHST- 2017/07/19 00:00 [accepted]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2018/06/23 06:00 [medline]
PHST- 2017/09/27 06:00 [entrez]
AID - 4083518 [pii]
AID - 10.1093/ejcts/ezx293 [doi]
PST - ppublish
SO  - Eur J Cardiothorac Surg. 2017 Nov 1;52(5):838-847. doi: 10.1093/ejcts/ezx293.

PMID- 2121083
OWN - NLM
STAT- MEDLINE
DCOM- 19901120
LR  - 20181130
IS  - 0003-4886 (Print)
IS  - 0003-4886 (Linking)
VI  - 22
IP  - 8
DP  - 1990 Aug
TI  - Evaluation of combined systemic aspirin and cromolyn sodium in intractable vernal 
      catarrh.
PG  - 314-8
AB  - The steroids in vernal keratoconjunctivitis (VKC) are not always effective and 
      may result in glaucoma. Cromolyn sodium inhibits degranulation from mast cells, 
      thus preventing release of prostaglandins and the mediators of inflammation when 
      used topically. Aspirin, which blocks the production of inflammation-producing 
      prostaglandins in mast cells released in VKC, especially prostaglandin D2, was 
      used orally in 11 patients with intractable VKC of mixed type with limbal 
      predominance. The chi 2 test of combined therapy showed a significant improvement 
      in itching, lacrimation, and limbal edema (P less than .005) and improved 
      photophobia, palpebral lesions, and corneal staining (P less than .02) at six 
      weeks.
FAU - Chaudhary, K P
AU  - Chaudhary KP
AD  - Department of Ophthalmology, I. G. Medical College, Shimla, India.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Ophthalmol
JT  - Annals of ophthalmology
JID - 0210137
RN  - Q2WXR1I0PK (Cromolyn Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Chi-Square Distribution
MH  - Child
MH  - Conjunctivitis, Allergic/*drug therapy
MH  - Cromolyn Sodium/administration & dosage/*therapeutic use
MH  - Drug Evaluation
MH  - Drug Therapy, Combination
MH  - Edema/drug therapy
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Pruritus/drug therapy
MH  - Tears/drug effects/metabolism
EDAT- 1990/08/01 00:00
MHDA- 1990/08/01 00:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 1990/08/01 00:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
PST - ppublish
SO  - Ann Ophthalmol. 1990 Aug;22(8):314-8.

PMID- 16433444
OWN - NLM
STAT- MEDLINE
DCOM- 20060316
LR  - 20131121
IS  - 0001-4079 (Print)
IS  - 0001-4079 (Linking)
VI  - 189
IP  - 6
DP  - 2005 Jun
TI  - [New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); 
      diagnostic and therapeutic consequences].
PG  - 1201-18; discussion 1218-20
AB  - Hypersensitivity to aspirin usually takes the form of a clinical syndrome 
      combining chronic rhinitis, nasal polyposis and asthma attacks that are 
      exacerbated by aspirin or other non steroidal anti-inflammatory drugs (NSAIDs). 
      This syndrome, first described by Widal in 1922, is very frequent: it affects 
      nearly 15% of asthmatic patients and is usually associated with severe and 
      sometimes fatal asthma. In other instances, hypersensitivity to NSAIDs manifests 
      in the form of skin lesions, such as urticaria and angioedema. Until recently, 
      the pathophysiological mechanism of NSAID hypersensitivity was somewhat 
      mysterious. The fact that the main mediators involved are sulfidoleukotrienes 
      (LTC4, LTD4, LTE4) and that the drugs responsible all inhibit cyclooxygenase-1 
      (COX-1), pointed to a pharmacogenetic abnormality of arachidonic acid metabolism. 
      An immunopharmacological study of basophil activation (detected by flow 
      cytometry), sulfidoleukotriene production in the presence of NSAIDs in vitro, and 
      other related studies reviewed here have revealed that: a) basophils from 
      patients with the Widal syndrome are hyperactivated in a non specific manner, 
      probably related to chronic inflammation in the skin or airways; b) these 
      hyperactive basophils produce increased amounts of sulfidoleukotrienes but 
      decreased amounts of PGE2 when exposed to NSAIDs in vitro. These observations led 
      to the development of an in vitro diagnostic test which, in many cases, can 
      replace challenge tests. The pathogenic mechanism of the Widal syndrome now 
      appears to involve the combined effects of chronic inflammation (causing non 
      specific cellular hyper-reactivity, particularly of mast cells, basophils and 
      eosinophils) and a pharmacogenetic abnormality of arachidonic acid metabolism in 
      response to NSAIDs. This leads to sulfidoleukotriene overproduction and to a 
      decrease in the anti-inflammatory prostaglandin PGE2. This concept is compatible 
      with the onset and outcome of most cases of the Widal syndrome, and provides a 
      therapeutic rationale.
FAU - de Weck, Alain
AU  - de Weck A
AD  - Fondation Gerimmun, Beaumont 18, CH-1700, Fribourg, Suisse. alain.dew@bluewin.ch
FAU - Sanz, Maria Luisa
AU  - Sanz ML
FAU - Gamboa, Pedro
AU  - Gamboa P
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Nouvelles données pathophysiologiques sur l'hypersensibilité à l'aspirine 
      (syndrome de Widal); conséquences diagnostiques et thérapeutiques.
PL  - Netherlands
TA  - Bull Acad Natl Med
JT  - Bulletin de l'Academie nationale de medecine
JID - 7503383
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Asthma/chemically induced
MH  - Chronic Disease
MH  - Drug Hypersensitivity/*complications/*diagnosis
MH  - Female
MH  - Humans
MH  - Male
MH  - Nasal Polyps/chemically induced
MH  - Rhinitis/chemically induced
MH  - Syndrome
EDAT- 2006/01/26 09:00
MHDA- 2006/03/17 09:00
CRDT- 2006/01/26 09:00
PHST- 2006/01/26 09:00 [pubmed]
PHST- 2006/03/17 09:00 [medline]
PHST- 2006/01/26 09:00 [entrez]
PST - ppublish
SO  - Bull Acad Natl Med. 2005 Jun;189(6):1201-18; discussion 1218-20.

PMID- 8786689
OWN - NLM
STAT- MEDLINE
DCOM- 19960920
LR  - 20190701
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 58
IP  - 11
DP  - 1996
TI  - Effect of single and repeated doses of a new nitroderivative of acetylsalicylic 
      acid on platelet TXA2 production in rats.
PG  - PL207-10
AB  - The effects of a new ASA-nitroderivative compound, NCX 4016 (ASA-NO2), on 
      platelet TXA2 synthesis after single and repeated doses in the rat were 
      investigated. Compared to ASA, cumulative doses of ASA-NO2 showed similar 
      inhibitory effects on platelet TXA2 synthesis and significant increases in 
      nitrite/nitrate plasma concentrations 1 h after the last drug administration: 24 
      h later nitrite/nitrate plasma levels returned to the control values, while serum 
      TXA2 concentrations did not change. A time-course study after a single dose of 
      ASA-NO2 showed a significant inhibition of platelet TXA2 production also 24 h 
      after drug administration and a significant increase in nitrite/nitrate plasma 
      levels until 10 h.
FAU - Cuzzolin, L
AU  - Cuzzolin L
AD  - Institutes of Pharmacology and Internal Medicine, University of Verona, Italy.
FAU - Adami, A
AU  - Adami A
FAU - Degan, M
AU  - Degan M
FAU - Crivellente, F
AU  - Crivellente F
FAU - Bonapace, S
AU  - Bonapace S
FAU - Minuz, P
AU  - Minuz P
FAU - Benoni, G
AU  - Benoni G
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Nitrites)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Nitrites/blood
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thromboxane A2/*metabolism
MH  - Thromboxane B2/blood
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 0024320596000380 [pii]
AID - 10.1016/0024-3205(96)00038-0 [doi]
PST - ppublish
SO  - Life Sci. 1996;58(11):PL207-10. doi: 10.1016/0024-3205(96)00038-0.

PMID- 8419039
OWN - NLM
STAT- MEDLINE
DCOM- 19930211
LR  - 20221207
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 39
IP  - 1
DP  - 1993 Jan
TI  - Interference of carbamylated and acetylated hemoglobins in assays of 
      glycohemoglobin by HPLC, electrophoresis, affinity chromatography, and enzyme 
      immunoassay.
PG  - 138-42
AB  - In vitro-synthesized carbamylated and acetylated hemoglobins interfered in assays 
      of glycohemoglobin by HPLC and electrophoresis but had no effects on results 
      obtained by affinity chromatography and enzyme immunoassay. Correlations between 
      long-term serum urea concentrations and glycohemoglobin percentages revealed 
      that, in vivo, carbamylated hemoglobin equivalent to 0.063% of total hemoglobin 
      is formed for every 1 mmol/L of serum urea. The use of acetylsalicylate, either 
      chronically in small doses (200-300 mg/day) or for 1 week at 2000 mg/day, did not 
      cause significant interference from acetylhemoglobin, formed in vivo. We conclude 
      that interference from carbamylated hemoglobin explains only a small part of 
      existing discrepancies between results of glycohemoglobin assays in current use. 
      The interfering effect of acetylhemoglobin formed in vivo with acetyl-CoA as 
      substrate is as yet unknown.
FAU - Weykamp, C W
AU  - Weykamp CW
AD  - Department of Clinical Chemistry, Queen Beatrix Hospital, Winterswijk, The 
      Netherlands.
FAU - Penders, T J
AU  - Penders TJ
FAU - Siebelder, C W
AU  - Siebelder CW
FAU - Muskiet, F A
AU  - Muskiet FA
FAU - van der Slik, W
AU  - van der Slik W
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hemoglobins)
RN  - 0 (acetylated hemoglobin)
RN  - 60616-87-7 (hemoglobin A, carbamylated)
RN  - 8W8T17847W (Urea)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/blood/therapeutic use
MH  - Blood Glucose/analysis
MH  - *Chromatography
MH  - Chromatography, Affinity
MH  - Chromatography, High Pressure Liquid
MH  - *Electrophoresis
MH  - Glycated Hemoglobin/*analysis
MH  - Hemoglobin A/*analogs & derivatives
MH  - *Hemoglobins
MH  - Humans
MH  - *Immunoenzyme Techniques
MH  - Middle Aged
MH  - Quality Control
MH  - Urea/blood
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Chem. 1993 Jan;39(1):138-42.

PMID- 3075602
OWN - NLM
STAT- MEDLINE
DCOM- 19890818
LR  - 20131121
IS  - 0251-1649 (Print)
IS  - 0251-1649 (Linking)
VI  - 8
IP  - 6
DP  - 1988
TI  - Thermal, ventilatory, and gluco-regulatory responses during exercise following 
      short-term acetylsalicylic acid ingestion.
PG  - 477-83
AB  - Acetylsalicylic acid and exercise combined produce perturbations in thermal, 
      respiratory and carbohydrate metabolism. However, the therapeutic implications of 
      these therapies are antithrombotic and fibrinolytic respectively. In a 
      double-blind, counterbalanced cross-over design of eight men, salicylate 
      ingestion in combination with 60 min of moderate intensity exercise (50% VO2 max) 
      significantly increased respiratory rate and oxygen consumption (p less than 
      0.05) both at rest and during the exercise protocol. The effect of 
      acetylsalicylic acid ingestion on gluco-regulatory and counter-regulatory 
      hormones was not significant compared to the placebo. These data suggest a safe 
      prophylactic role for a combined short-term acetylsalicylic acid ingestion and 
      exercise therapy in the development of coronary artery disease when exercising in 
      a thermal neutral environment.
FAU - De Meersman, R E
AU  - De Meersman RE
AD  - Applied Physiology Laboratory, Teachers College, Columbia University, New York, 
      NY 10027.
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Int J Clin Pharmacol Res
JT  - International journal of clinical pharmacology research
JID - 8110183
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Placebos)
RN  - 9007-92-5 (Glucagon)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Glucose/*metabolism
MH  - Body Temperature Regulation/*drug effects
MH  - Double-Blind Method
MH  - Glucagon/blood
MH  - Humans
MH  - Insulin/blood
MH  - Male
MH  - *Physical Exertion
MH  - Placebos
MH  - Rectum
MH  - Respiration/*drug effects
MH  - Skin Temperature/drug effects
OID - NASA: 89307666
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Res. 1988;8(6):477-83.

PMID- 16185578
OWN - NLM
STAT- MEDLINE
DCOM- 20051207
LR  - 20191026
IS  - 0210-5705 (Print)
IS  - 0210-5705 (Linking)
VI  - 28
IP  - 8
DP  - 2005 Oct
TI  - [Active lower gastrointestinal bleeding due to appendiceal ulcer].
PG  - 445-6
AB  - We present a case of severe lower gastrointestinal bleeding due to appendiceal 
      ulcer associated with intake of enteric coated aspirin. Urgent colonoscopy 
      revealed the location and characteristics of the source of bleeding during the 
      acute episode, allowing effective treatment through simple appendicectomy to be 
      performed.
FAU - Rivera-Irigoín, R
AU  - Rivera-Irigoín R
AD  - Unidad de Aparato Digestivo, Hospital Costa del Sol, Marbella, Málaga, Spain. 
      robinrivera_i@hotmail.com
FAU - de Sola-Earle, C
AU  - de Sola-Earle C
FAU - Palma-Carazo, F
AU  - Palma-Carazo F
FAU - Montiel Quezel-Guerraz, N
AU  - Montiel Quezel-Guerraz N
FAU - Fernández-Moreno, N
AU  - Fernández-Moreno N
LA  - spa
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Hemorragia digestiva baja grave activa por úlcera apendicular.
PL  - Spain
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Appendectomy
MH  - *Appendix/pathology/surgery
MH  - Aspirin/administration & dosage/*adverse effects/pharmacokinetics
MH  - Cecal Diseases/chemically induced/*complications/diagnosis/surgery
MH  - Colonoscopy
MH  - Combined Modality Therapy
MH  - Erythrocyte Transfusion
MH  - Female
MH  - Gastrointestinal Hemorrhage/*etiology/surgery/therapy
MH  - Humans
MH  - Middle Aged
MH  - Rectum
MH  - Tablets, Enteric-Coated/adverse effects
MH  - Ulcer/chemically induced/*complications/diagnosis/surgery
EDAT- 2005/09/28 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/09/28 09:00
PHST- 2005/09/28 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/09/28 09:00 [entrez]
AID - 13078994 [pii]
AID - 10.1157/13078994 [doi]
PST - ppublish
SO  - Gastroenterol Hepatol. 2005 Oct;28(8):445-6. doi: 10.1157/13078994.

PMID- 3978484
OWN - NLM
STAT- MEDLINE
DCOM- 19850426
LR  - 20181113
IS  - 0008-4409 (Print)
IS  - 0008-4409 (Linking)
VI  - 132
IP  - 6
DP  - 1985 Mar 15
TI  - Evaluation of sponging to reduce body temperature in febrile children.
PG  - 641-2
AB  - A study was conducted to evaluate the efficacy of sponging as a way of reducing 
      body temperature in febrile children. Of 130 children 73 received antipyretic 
      medication and sponging and 57 received antipyretic medication alone. No 
      difference in temperature reduction was noted between the two groups. It is 
      therefore suggested that sponging be abandoned as a mode of temperature reduction 
      in febrile children whose increased temperature is due to an infectious process.
FAU - Newman, J
AU  - Newman J
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Med Assoc J
JT  - Canadian Medical Association journal
JID - 0414110
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Baths
MH  - Child, Preschool
MH  - Fever/drug therapy/*therapy
MH  - Humans
MH  - Infant
MH  - Male
PMC - PMC1345783
EDAT- 1985/03/15 00:00
MHDA- 1985/03/15 00:01
CRDT- 1985/03/15 00:00
PHST- 1985/03/15 00:00 [pubmed]
PHST- 1985/03/15 00:01 [medline]
PHST- 1985/03/15 00:00 [entrez]
PST - ppublish
SO  - Can Med Assoc J. 1985 Mar 15;132(6):641-2.

PMID- 6108727
OWN - NLM
STAT- MEDLINE
DCOM- 19810224
LR  - 20190821
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 35
IP  - 5
DP  - 1980 Jul
TI  - Inhibition by ketotifen of idiosyncratic reactions to aspirin.
PG  - 421-4
AB  - Ketotifen administered prior to aspirin offered protection against 
      bronchoconstriction in 13 of 14 patients with aspirin-sensitive asthma. In four 
      other subjects, suffering from urticaria/angioedema following ingestion of 
      aspirin-like drugs, pretreatment with ketotifen resulted in total prevention of 
      the adverse reactions. These results support the suggestion of a common 
      pathogenetic mechanism operating in two distinct clinical patterns of 
      idiosyncrasy to aspirin and other cyclo-oxygenase inhibitors. They also indicate 
      that ketotifen might find application in treatment of adverse reactions to 
      aspirin.
FAU - Szczeklik, A
AU  - Szczeklik A
FAU - Czerniawska-Mysik, G
AU  - Czerniawska-Mysik G
FAU - Serwonska, M
AU  - Serwonska M
FAU - Kuklinski, P
AU  - Kuklinski P
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Histamine H1 Antagonists)
RN  - 0 (Piperidines)
RN  - 0 (Placebos)
RN  - 0 (Thiophenes)
RN  - R16CO5Y76E (Aspirin)
RN  - X49220T18G (Ketotifen)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*antagonists & inhibitors
MH  - Asthma/chemically induced/*prevention & control
MH  - Bronchi/drug effects
MH  - Bronchial Spasm/drug therapy
MH  - Drug Hypersensitivity/drug therapy/prevention & control
MH  - Female
MH  - Histamine H1 Antagonists/pharmacology
MH  - Humans
MH  - Ketotifen
MH  - Male
MH  - Middle Aged
MH  - Piperidines/*pharmacology
MH  - Placebos
MH  - Thiophenes/*pharmacology
EDAT- 1980/07/01 00:00
MHDA- 1980/07/01 00:01
CRDT- 1980/07/01 00:00
PHST- 1980/07/01 00:00 [pubmed]
PHST- 1980/07/01 00:01 [medline]
PHST- 1980/07/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1980.tb01788.x [doi]
PST - ppublish
SO  - Allergy. 1980 Jul;35(5):421-4. doi: 10.1111/j.1398-9995.1980.tb01788.x.

PMID- 24556294
OWN - NLM
STAT- MEDLINE
DCOM- 20140501
LR  - 20211021
IS  - 1591-0199 (Print)
IS  - 1591-0199 (Electronic)
IS  - 1591-0199 (Linking)
VI  - 20
IP  - 1
DP  - 2014 Jan-Feb
TI  - Aspirin allergy desensitization in cerebrovascular disease. A report of two 
      cases, literature review and management guide for the neurointerventionalist.
PG  - 5-11
AB  - Aspirin (ASA) is the mainstay of treatment in cerebrovascular and systemic 
      vascular disease. ASA hypersensitivity can pose a challenge to achieving optimum 
      medical management prior to and after neurointerventional treatment. 
      Desensitization to ASA is well described in the allergy and cardiovascular 
      literature, but there are no similar discussions specific to neurointervention. 
      The purpose of our study was to describe our experience with ASA hypersensitivity 
      management and review the relevant literature. Two cases of patients with 
      symptomatic cerebrovascular disease requiring neurointervention who were 
      successfully desensitized to their ASA hypersensitivity prior to treatment are 
      described. The subsequent literature is reviewed. Several ASA desensitization 
      protocols exist and have been proven to successfully treat ASA hypersensitivity 
      and allow for ASA therapy to be safely initiated. We describe several previously 
      published protocols. ASA desensitization is a safe and simple way to manage ASA 
      hypersensitivity. We provide comprehensive management guidelines for the 
      neurointerventionalist engaging in ASA desensitization.
FAU - Zuckerman, Scott L
AU  - Zuckerman SL
AD  - Department of Neurosurgery, Vanderbilt University Medical Center; Nashville, TN, 
      USA - zuckerman.scott@gmail.com.
FAU - Seder, David B
AU  - Seder DB
AD  - Department of Neurosurgery, Vanderbilt University Medical Center; Nashville, TN, 
      USA.
FAU - Tsujiura, Crystiana
AU  - Tsujiura C
AD  - Department of Neurosurgery, Vanderbilt University Medical Center; Nashville, TN, 
      USA.
FAU - Cushing, Deborah
AU  - Cushing D
AD  - Department of Neurosurgery, Vanderbilt University Medical Center; Nashville, TN, 
      USA.
FAU - Gallup, Holly
AU  - Gallup H
AD  - Department of Neurosurgery, Vanderbilt University Medical Center; Nashville, TN, 
      USA.
FAU - Mocco, J
AU  - Mocco J
AD  - Department of Neurosurgery, Vanderbilt University Medical Center; Nashville, TN, 
      USA.
FAU - Hanel, Richard A
AU  - Hanel RA
AD  - Department of Neurosurgery, Vanderbilt University Medical Center; Nashville, TN, 
      USA.
FAU - Ecker, Robert D
AU  - Ecker RD
AD  - Department of Neurosurgery, Vanderbilt University Medical Center; Nashville, TN, 
      USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20140210
PL  - United States
TA  - Interv Neuroradiol
JT  - Interventional neuroradiology : journal of peritherapeutic neuroradiology, 
      surgical procedures and related neurosciences
JID - 9602695
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/*adverse effects/immunology
MH  - Asthma, Aspirin-Induced/*etiology/immunology/*prevention & control
MH  - Cerebrovascular Disorders/complications/*drug therapy/immunology
MH  - Desensitization, Immunologic/*methods
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/immunology
MH  - Treatment Outcome
PMC - PMC3971141
OTO - NOTNLM
OT  - allergy
OT  - aspirin
OT  - desensitization
OT  - intracranial atherosclerosis
OT  - sensitivity
EDAT- 2014/02/22 06:00
MHDA- 2014/05/03 06:00
CRDT- 2014/02/22 06:00
PHST- 2013/06/21 00:00 [received]
PHST- 2013/08/10 00:00 [accepted]
PHST- 2014/02/22 06:00 [entrez]
PHST- 2014/02/22 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - IN.v20.i1.p5 [pii]
AID - 10.15274/INR-2014-10002 [doi]
PST - ppublish
SO  - Interv Neuroradiol. 2014 Jan-Feb;20(1):5-11. doi: 10.15274/INR-2014-10002. Epub 
      2014 Feb 10.

PMID- 16841255
OWN - NLM
STAT- MEDLINE
DCOM- 20061219
LR  - 20220318
IS  - 0957-5243 (Print)
IS  - 0957-5243 (Linking)
VI  - 17
IP  - 7
DP  - 2006 Sep
TI  - Aspirin and cancer risk: an updated quantitative review to 2005.
PG  - 871-88
AB  - Aspirin has been associated to a reduced risk of colorectal, and possibly of a 
      few other common cancers. Epidemiological studies on aspirin and cancer risk 
      published up to December 2005 have been reviewed, and pooled relative risks (RR) 
      for several cancers have been provided. Besides a reduction in the risk of cancer 
      of the colorectum (RR = 0.71, 95% confidence interval, CI: 0.67-0.75), there is 
      evidence-although more limited, and mainly from case-control studies-that aspirin 
      has a favourable effect on cancers of the esophagus (RR = 0.72, 95% CI: 
      0.62-0.84), stomach (RR = 0.84, 95% CI: 0.76-0.93), breast (RR = 0.91, 95% CI: 
      0.88-0.95), ovary (RR = 0.89, 95% CI: 0.78-1.02) and lung (RR = 0.94, 95% CI: 
      0.89-1.00). The role of aspirin on other cancers, such as pancreatic, prostate, 
      bladder cancer, and non-Hodgkins' lymphomas is less clear, and an increase of 
      risk has been suggested for kidney cancer. For most cancer sites, however, 
      significant heterogeneity between studies, and particularly across study design, 
      was found, with a reduction in risk generally stronger in case-control than in 
      cohort studies. Further, notwithstanding the large amount of epidemiological 
      evidence, substantial uncertainties remain about the proper aspirin dose and 
      duration of treatment.
FAU - Bosetti, Cristina
AU  - Bosetti C
AD  - Istituto di Ricerche Farmacologiche Mario Negri, via Eritrea 62, 20157, Milan, 
      Italy. bosetti@marionegri.it
FAU - Gallus, Silvano
AU  - Gallus S
FAU - La Vecchia, Carlo
AU  - La Vecchia C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Neoplasms/epidemiology/*prevention & control
MH  - Risk Factors
RF  - 115
EDAT- 2006/07/15 09:00
MHDA- 2006/12/21 09:00
CRDT- 2006/07/15 09:00
PHST- 2005/08/03 00:00 [received]
PHST- 2006/04/11 00:00 [accepted]
PHST- 2006/07/15 09:00 [pubmed]
PHST- 2006/12/21 09:00 [medline]
PHST- 2006/07/15 09:00 [entrez]
AID - 10.1007/s10552-006-0033-7 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2006 Sep;17(7):871-88. doi: 10.1007/s10552-006-0033-7.

PMID- 34785236
OWN - NLM
STAT- MEDLINE
DCOM- 20220510
LR  - 20220711
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 161
IP  - 5
DP  - 2022 May
TI  - Aspirin as a Treatment for ARDS: A Randomized, Placebo-Controlled Clinical Trial.
PG  - 1275-1284
LID - S0012-3692(21)04289-6 [pii]
LID - 10.1016/j.chest.2021.11.006 [doi]
AB  - BACKGROUND: There is no pharmacologic treatment for ARDS. Platelets play an 
      important role in the pathophysiology of ARDS. Preclinical, observational, and 
      clinically relevant models of ARDS indicate aspirin as a potential therapeutic 
      option. RESEARCH QUESTION: Is enteral aspirin (75 mg, once daily) safe and 
      effective in improving surrogate outcomes in adult patients with ARDS? STUDY 
      DESIGN AND METHODS: This randomized, double-blind (patient and investigator), 
      allocation-concealed, placebo-controlled phase 2 trial was conducted in five UK 
      ICUs. Patients fulfilling the Berlin definition of ARDS were randomly assigned at 
      a 1:1 ratio to receive enteral aspirin (75 mg) or placebo, for a maximum of 
      14 days, using a computer-generated randomization schedule, with variable block 
      size, stratified by vasopressor requirement. The primary end point was 
      oxygenation index (OI) on day 7. Secondary outcomes included safety parameters 
      and other respiratory physiological markers. Analyses were by intention to treat. 
      RESULTS: The trial was stopped early, due to slow recruitment, after 49 of a 
      planned 60 patients were recruited. Twenty-four patients were allocated to 
      aspirin and 25 to placebo. There was no significant difference in day 7 OI 
      [aspirin group: unadjusted mean, 54.4 (SD 26.8); placebo group: 42.4 (SD 25); 
      mean difference, 12.0; 95% CI, -6.1 to 30.1; P = .19]. Aspirin did not 
      significantly impact the secondary outcomes. There was no difference in the 
      number of adverse events between the groups (13 in each; OR, 1.04; 95% CI, 
      0.56-1.94; P = .56). INTERPRETATION: Aspirin was well tolerated but did not 
      improve OI or other physiological outcomes; a larger trial is not feasible in its 
      current design. TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02326350; URL: 
      www. CLINICALTRIALS: gov.
CI  - Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.
FAU - Toner, Philip
AU  - Toner P
AD  - Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, 
      Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern 
      Ireland; Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, 
      Northern Ireland. Electronic address: philip.toner@belfasttrsut.hscni.net.
FAU - Boyle, Andrew J
AU  - Boyle AJ
AD  - Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, 
      Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern 
      Ireland; Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, 
      Northern Ireland.
FAU - McNamee, James J
AU  - McNamee JJ
AD  - Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, Northern 
      Ireland.
FAU - Callaghan, Kathryn
AU  - Callaghan K
AD  - Altnagelvin Area Hospital, Londonderry, Northern Ireland.
FAU - Nutt, Christopher
AU  - Nutt C
AD  - Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, Northern 
      Ireland.
FAU - Johnston, Paul
AU  - Johnston P
AD  - Antrim Area Hospital, Antrim, Northern Ireland.
FAU - Trinder, John
AU  - Trinder J
AD  - Ulster Hospital, Dundonald, Belfast, Northern Ireland.
FAU - McFarland, Margaret
AU  - McFarland M
AD  - Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, Northern 
      Ireland.
FAU - Verghis, Rejina
AU  - Verghis R
AD  - Northern Ireland Clinical Trial Unit, Royal Hospitals, Belfast, Northern Ireland.
FAU - McAuley, Daniel F
AU  - McAuley DF
AD  - Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, 
      Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern 
      Ireland; Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, 
      Northern Ireland.
FAU - O'Kane, Cecilia M
AU  - O'Kane CM
AD  - Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, 
      Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern 
      Ireland.
LA  - eng
SI  - ClinicalTrials.gov/NCT02326350
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20211114
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Chest. 2022 Jun;161(6):e391-e392. PMID: 35680322
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - *COVID-19
MH  - Double-Blind Method
MH  - Humans
MH  - Intensive Care Units
MH  - Respiration, Artificial
MH  - *Respiratory Distress Syndrome/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - ARDS
OT  - aspirin
OT  - clinical trial
OT  - critical care
OT  - placebo controlled
OT  - randomized control trial
EDAT- 2021/11/18 06:00
MHDA- 2022/05/11 06:00
CRDT- 2021/11/17 05:50
PHST- 2021/05/18 00:00 [received]
PHST- 2021/10/05 00:00 [revised]
PHST- 2021/11/02 00:00 [accepted]
PHST- 2021/11/18 06:00 [pubmed]
PHST- 2022/05/11 06:00 [medline]
PHST- 2021/11/17 05:50 [entrez]
AID - S0012-3692(21)04289-6 [pii]
AID - 10.1016/j.chest.2021.11.006 [doi]
PST - ppublish
SO  - Chest. 2022 May;161(5):1275-1284. doi: 10.1016/j.chest.2021.11.006. Epub 2021 Nov 
      14.

PMID- 23567078
OWN - NLM
STAT- MEDLINE
DCOM- 20140401
LR  - 20130715
IS  - 1873-6815 (Electronic)
IS  - 0531-5565 (Linking)
VI  - 48
IP  - 8
DP  - 2013 Aug
TI  - Chronic aspirin via dose-dependent and selective inhibition of cardiac proteasome 
      possibly contributed a potential risk to the ischemic heart.
PG  - 812-23
LID - S0531-5565(13)00098-3 [pii]
LID - 10.1016/j.exger.2013.03.012 [doi]
AB  - Impaired cardiac proteasome has been reported in ischemic heart and heart 
      failure. Recent data highlighted aspirin as an inhibitor of the 
      ubiquitin-proteasome system, however, it's unclear whether it affects cardiac 
      proteasome functions. Myocardial infarction (MI), sham or normal male SD rats 
      were injected intraperitoneally with high (300 mg/kg), low (5 mg/kg) aspirin or 
      saline (control) once a day for seven weeks. Parallel experiments were performed 
      in the hypoxia/reoxygenated human ventricular myocytes. Dose-related increases in 
      heart and ventricular weight, and impaired cardiac functions, were found more 
      exacerbated in the aspirin-treated MI rat hearts than the saline-treated MI 
      counterparts. The activity of 26S, 20S and 19S declined by about 30%, or the 20S 
      proteasome subunits β5, β2 and β1 decreased by 40%, 20% and 30%, respectively, in 
      the MI rats compared with the non-MI rats (P<0.05). Compared with the 
      saline-treated MI rats, 26S and 20S in high or low dose aspirin-treated MI rats 
      further decreased by 30% and 20%, β5 by 30% and 12%, and β1 by 40% and 30%, 
      respectively, and the lost activity was correlated with the compromised cardiac 
      functions or the decreased cell viability. The dose-related and selective 
      inhibition of 26S and 20S proteasome, or the 20S proteasome subunits β5 and β1 by 
      aspirin was comparable to their protein expressions in the MI rats and in the 
      cultured cells. The impaired cardiac proteasome, enhanced by chronic aspirin 
      treatment, attenuated the removal of oxidative and ubiquitinated proteins, and 
      chronic aspirin treatment via selective and dose-dependent inhibition of cardiac 
      proteasome possibly constituted a potential risk to ischemic heart.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Tan, Chunjiang
AU  - Tan C
AD  - Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese 
      Medicine, Fujian, China. tchunj@126.com
FAU - Chen, Wenlie
AU  - Chen W
FAU - Wu, Yanbin
AU  - Wu Y
FAU - Lin, Jiumao
AU  - Lin J
FAU - Lin, Ruhui
AU  - Lin R
FAU - Tan, Xuerui
AU  - Tan X
FAU - Chen, Songming
AU  - Chen S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130406
PL  - England
TA  - Exp Gerontol
JT  - Experimental gerontology
JID - 0047061
RN  - 0 (Proteasome Inhibitors)
RN  - EC 3.4.25.1 (Proteasome Endopeptidase Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects/pharmacology
MH  - Cell Survival/drug effects/physiology
MH  - Cells, Cultured
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Heart/physiopathology
MH  - Humans
MH  - Injections, Intraperitoneal
MH  - Male
MH  - Myocardial Infarction/physiopathology
MH  - Myocardial Ischemia/*epidemiology/*physiopathology
MH  - Myocytes, Cardiac/drug effects/physiology
MH  - Proteasome Endopeptidase Complex/drug effects/*physiology
MH  - Proteasome Inhibitors/administration & dosage/*adverse effects/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Risk Factors
OTO - NOTNLM
OT  - A potential risk
OT  - Aspirin
OT  - Cardiac proteasome
OT  - Ischemic rat heart
OT  - Selective inhibition
EDAT- 2013/04/10 06:00
MHDA- 2014/04/02 06:00
CRDT- 2013/04/10 06:00
PHST- 2012/10/16 00:00 [received]
PHST- 2013/03/13 00:00 [revised]
PHST- 2013/03/31 00:00 [accepted]
PHST- 2013/04/10 06:00 [entrez]
PHST- 2013/04/10 06:00 [pubmed]
PHST- 2014/04/02 06:00 [medline]
AID - S0531-5565(13)00098-3 [pii]
AID - 10.1016/j.exger.2013.03.012 [doi]
PST - ppublish
SO  - Exp Gerontol. 2013 Aug;48(8):812-23. doi: 10.1016/j.exger.2013.03.012. Epub 2013 
      Apr 6.

PMID- 26369682
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 21
IP  - 35
DP  - 2015
TI  - Epidemiology of Low Dose Aspirin Damage in the Lower Gastrointestinal Tract.
PG  - 5094-100
AB  - Low dose aspirin (ASA), commonly defined as the cardiovascular (CV) dose of 75 to 
      325 mg daily, is one of the most widely prescribed drugs in the world and the 
      cornerstone of therapy and prophylaxis for CV disease. However, the use of low 
      dose ASA is well known to be associated with an increased risk of different upper 
      and lower gastrointestinal (GI) complications, such as peptic ulceration and 
      bleeding. In the recent past, clinical research was mainly focused on ASA-related 
      injury of the upper GI tract. However, the introduction of new endoscopic 
      techniques, such as capsule endoscopy and balloon-assisted endoscopy for the 
      evaluation of small bowel lesions have resulted in an increasing interest among 
      gastroenterologists about the side effects of ASA on the large and small bowel. 
      Furthermore, it has been demonstrated that chronic use of low dose ASA results in 
      a variety of lesions in the lower GI tract, including multiple petechiae, 
      erosions, ulcers, diverticular bleeding and even circumferential ulcers with 
      stricture. The ideal treatment for small bowel injury in low dose ASA users would 
      be withdrawal of ASA, however, this withdrawal could increase the risk of 
      CV/cerebrovascular morbidity and mortality in high percentage of patients. 
      Therefore, several drugs have been evaluated to identify the best choice to 
      prevent or treat ASA-induced small bowel injury with different results. 
      Nevertheless, further specifically designed studies with more sample size are 
      needed to determine the best treatment for low dose ASA related GI injury.
FAU - Sostres, Carlos
AU  - Sostres C
FAU - Lanas, Angel
AU  - Lanas A
AD  - Division of Gastroenterology, Hospital Clínico Universitário Lozano Blesa, 
      c/Domingo Miral s/n, 5009, Zaragoza, Spain. carlossostres@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Endoscopy, Gastrointestinal/methods
MH  - Gastrointestinal Diseases/*chemically induced/epidemiology/prevention & control
MH  - Humans
MH  - Lower Gastrointestinal Tract/*drug effects/pathology
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
EDAT- 2015/09/16 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/06/19 00:00 [received]
PHST- 2015/09/14 00:00 [accepted]
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - CPD-EPUB-70385 [pii]
AID - 10.2174/1381612821666150915110204 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2015;21(35):5094-100. doi: 10.2174/1381612821666150915110204.

PMID- 15590881
OWN - NLM
STAT- MEDLINE
DCOM- 20050329
LR  - 20131121
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 39
IP  - 1
DP  - 2005 Jan
TI  - Analysis of aspirin-associated risks in healthy individuals.
PG  - 51-7
AB  - BACKGROUND: Aspirin therapy is widely accepted for patients with documented 
      cardiovascular disease, but there is a growing trend among healthy individuals to 
      use aspirin as primary prevention for both cardiovascular disease and cancer. 
      OBJECTIVE: To determine the impact of the complications of aspirin therapy on 
      quality-adjusted life-years (QALYs) in healthy individuals. METHODS: A 
      computer-based decision-analytic model was constructed. In this model, healthy 
      individuals taking aspirin were assumed to receive no advantages from the 
      aspirin, but were at risk of developing its associated complications. Individuals 
      took 325 mg of enteric-coated aspirin every day until death, discontinuing 
      therapy only if an aspirin-induced complication occurred. The analysis was 
      performed from a societal perspective, starting at age 50 years. Extensive 
      sensitivity analyses were performed. RESULTS: In the absence of any beneficial 
      effect, aspirin reduced QALYs by 0.03 per individual. Unadjusted life expectancy 
      was decreased by 0.04 years (2 wk). Lifetime aspirin use cost an average of 
      $460/healthy person. The total complication rate over a lifetime of aspirin 
      therapy was 6.79%, with a mortality rate of 0.18%. Alternatively stated, there 
      was one complication for every 15 individuals treated and one death for every 556 
      individuals treated. Extensive sensitivity analysis showed the range of results 
      possible when varying age, gender, length of follow-up, and other key parameters. 
      CONCLUSIONS: Assuming no benefits, aspirin therapy in healthy individuals leads 
      to a small reduction in QALYs at an overall low cost per person. However, 
      approximately 1 in 15 individuals will experience an aspirin-induced complication 
      and 1 in 556 individuals will die.
FAU - Hur, Chin
AU  - Hur C
AD  - Harvard Medical School, Institute for Technology Assessment and Gastrointestinal 
      Unit, Massachusetts General Hospital, Boston, MA 02114-4719, USA. 
      chur@mgh-ita.org
FAU - Simon, Lee S
AU  - Simon LS
FAU - Gazelle, G Scott
AU  - Gazelle GS
LA  - eng
PT  - Journal Article
DEP - 20041208
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/economics
MH  - Aspirin/*adverse effects/economics
MH  - Decision Support Techniques
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Models, Statistical
MH  - Monte Carlo Method
MH  - Quality-Adjusted Life Years
MH  - Risk Assessment
MH  - Sensitivity and Specificity
EDAT- 2004/12/14 09:00
MHDA- 2005/03/30 09:00
CRDT- 2004/12/14 09:00
PHST- 2004/12/14 09:00 [pubmed]
PHST- 2005/03/30 09:00 [medline]
PHST- 2004/12/14 09:00 [entrez]
AID - aph.1E115 [pii]
AID - 10.1345/aph.1E115 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2005 Jan;39(1):51-7. doi: 10.1345/aph.1E115. Epub 2004 Dec 8.

PMID- 26284848
OWN - NLM
STAT- MEDLINE
DCOM- 20160407
LR  - 20161125
IS  - 1520-510X (Electronic)
IS  - 0020-1669 (Linking)
VI  - 54
IP  - 19
DP  - 2015 Oct 5
TI  - Discussing endogenous NO(•)/HNO interconversion aided by phenolic drugs and 
      vitamins.
PG  - 9342-50
LID - 10.1021/acs.inorgchem.5b01347 [doi]
AB  - The reduction of NO(•) to HNO/NO(-) under biologically compatible conditions has 
      always been thought as unlikely, mostly because of the negative reduction 
      potential: E°(NO(•),H(+)/HNO) = -0.55 V vs NHE at physiological pH. Nonetheless, 
      during the past decade, several works hinted at the possible NO-to-HNO conversion 
      mediated by moderate biological reductants. Very recently, we have shown that the 
      reaction of NO(•) with ascorbate and aromatic alcohols occurs through a 
      proton-coupled nucleophilic attack (PCNA) of the alcohol to NO(•), yielding an 
      intermediate RO-N(H)O(•) species, which further decomposes to release HNO. For 
      the present work, we decided to inspect whether other common biological aromatic 
      alcohols obtained from foods, such as Vitamin E, or used as over-the-counter 
      drugs, like aspirin, are able to undergo the reaction. The positive results 
      suggest that the conversion of NO to HNO could occur far more commonly than 
      previously expected. Taking these as the starting point, we set to review our and 
      other groups' previous reports on the possible NO-to-HNO conversion mediated by 
      biological compounds including phenolic drugs and vitamins, as well as several 
      thiol-bearing compounds. Analysis of revised data prompted us to ask ourselves 
      the following key questions: What are the most likely physio/pathological 
      conditions for NO(•)-to-HNO conversion to take place? Which effects usually 
      attributed to NO(•) are indeed mediated by HNO? These inquiries are discussed in 
      the context of 2 decades of NO and HNO research.
FAU - Hamer, Mariana
AU  - Hamer M
AD  - Departamento de Química Analítica y Fisicoquímica, Facultad de Farmacia y 
      Bioquímica (IQUIFIB-CONICET), Universidad de Buenos Aires , Junin 956, Buenos 
      Aires, Argentina.
FAU - Suarez, Sebastian A
AU  - Suarez SA
AD  - Gerencia de Investigación y Aplicaciones, Centro Atómico Constituyentes, Comisión 
      Nacional de Energía Atómica , Buenos Aires, Argentina.
AD  - Departamento de Química Inorgánica, Analítica y Química Física, Facultad de 
      Ciencias Exactas y Naturales (INQUIMAE-CONICET), Universidad de Buenos Aires , 
      Ciudad Universitaria, Buenos Aires, Argentina.
FAU - Neuman, Nicolás I
AU  - Neuman NI
AD  - Departamento de Química Inorgánica, Analítica y Química Física, Facultad de 
      Ciencias Exactas y Naturales (INQUIMAE-CONICET), Universidad de Buenos Aires , 
      Ciudad Universitaria, Buenos Aires, Argentina.
AD  - Departamento de Física, Facultad de Bioquímica y Ciencias Biológicas, Universidad 
      Nacional del Litoral , Ciudad Universitaria, Paraje El Pozo, Santa Fe, Argentina.
FAU - Alvarez, Lucía
AU  - Alvarez L
AD  - Departamento de Química Inorgánica, Analítica y Química Física, Facultad de 
      Ciencias Exactas y Naturales (INQUIMAE-CONICET), Universidad de Buenos Aires , 
      Ciudad Universitaria, Buenos Aires, Argentina.
FAU - Muñoz, Martina
AU  - Muñoz M
AD  - Departamento de Química Inorgánica, Analítica y Química Física, Facultad de 
      Ciencias Exactas y Naturales (INQUIMAE-CONICET), Universidad de Buenos Aires , 
      Ciudad Universitaria, Buenos Aires, Argentina.
FAU - Marti, Marcelo A
AU  - Marti MA
AD  - Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, 
      Universidad de Buenos Aires , Ciudad Universitaria, Pab. II, Buenos Aires, 
      Argentina.
FAU - Doctorovich, Fabio
AU  - Doctorovich F
AD  - Departamento de Química Inorgánica, Analítica y Química Física, Facultad de 
      Ciencias Exactas y Naturales (INQUIMAE-CONICET), Universidad de Buenos Aires , 
      Ciudad Universitaria, Buenos Aires, Argentina.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150818
PL  - United States
TA  - Inorg Chem
JT  - Inorganic chemistry
JID - 0366543
RN  - 0 (Free Radicals)
RN  - 0 (Nitrogen Oxides)
RN  - 0 (Phenols)
RN  - 1406-18-4 (Vitamin E)
RN  - GFQ4MMS07W (nitroxyl)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Free Radicals/chemistry
MH  - Molecular Structure
MH  - Nitrogen Oxides/*chemistry
MH  - Phenols/*chemistry
MH  - Vitamin E/*chemistry
EDAT- 2015/08/19 06:00
MHDA- 2016/04/08 06:00
CRDT- 2015/08/19 06:00
PHST- 2015/08/19 06:00 [entrez]
PHST- 2015/08/19 06:00 [pubmed]
PHST- 2016/04/08 06:00 [medline]
AID - 10.1021/acs.inorgchem.5b01347 [doi]
PST - ppublish
SO  - Inorg Chem. 2015 Oct 5;54(19):9342-50. doi: 10.1021/acs.inorgchem.5b01347. Epub 
      2015 Aug 18.

PMID- 34377596
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Print)
IS  - 2162-4011 (Linking)
VI  - 10
IP  - 1
DP  - 2021
TI  - The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and 
      beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a 
      systematic review and meta-analysis.
PG  - 1957605
LID - 10.1080/2162402X.2021.1957605 [doi]
LID - 1957605
AB  - Immunotherapy shows promising therapeutic efficacy against various types of 
      cancer, but most fail to respond. Preclinical studies have suggested that 
      concomitant medications, such as statins, non-steroidal anti-inflammatory drugs 
      (NSAIDs), aspirin, metformin and beta-blockers, might affect clinical outcomes if 
      used with immune checkpoint inhibitors (ICIs), but their clinical roles are 
      conflicting. This meta-analysis investigates the effect of these concomitant 
      medications on outcomes in patients treated with ICIs. A search was conducted for 
      all reports published until 31 March 2021 in PubMed, Web of Science, Cochrane 
      Library, EMBASE and conference proceedings. Studies were included if they 
      investigated the association between the concomitant use of these medications and 
      progression-free survival (PFS) or overall survival (OS) during ICI treatment. A 
      total of 3331 patients from 13 eligible studies were included. Among them, five 
      articles on statins, six studies evaluating NSAIDs, five studies employing 
      low-dose aspirin, eight studies on metformin and four articles on beta-blockers 
      were included. The concomitant use of statins during ICI treatment was correlated 
      with improved OS and PFS. Low-dose aspirin was associated with better PFS instead 
      of OS. No significant association was demonstrated between the concurrent use of 
      NSAIDs, beta-blockers and metformin and OS or PFS. The concomitant use of statins 
      and low-dose aspirin during ICI treatment showed a positive impact on treatment 
      outcomes. The concurrent use of NSAIDs, beta-blockers and metformin is not 
      significantly associated with clinical benefits. The effect of these medications 
      in different cancer patients treated with ICI is needed to be further validated.
CI  - © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
FAU - Zhang, Yongchao
AU  - Zhang Y
AUID- ORCID: 0000-0003-0040-1034
AD  - Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, 
      China.
FAU - Chen, Hualei
AU  - Chen H
AD  - Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, 
      China.
FAU - Chen, Shanshan
AU  - Chen S
AD  - Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, 
      China.
FAU - Li, Zhen
AU  - Li Z
AD  - Emergency Department, Beijing Youan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Chen, Jinglong
AU  - Chen J
AD  - Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, 
      China.
FAU - Li, Wei
AU  - Li W
AUID- ORCID: 0000-0002-9991-7892
AD  - Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20210802
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Immune Checkpoint Inhibitors
MH  - *Metformin/therapeutic use
PMC - PMC8331004
OTO - NOTNLM
OT  - Immune checkpoint inhibitors
OT  - aspirin
OT  - meta-analysis
OT  - statin
COIS- Authors have no conflict of interest.
EDAT- 2021/08/12 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/08/11 06:40
PHST- 2021/08/11 06:40 [entrez]
PHST- 2021/08/12 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - 1957605 [pii]
AID - 10.1080/2162402X.2021.1957605 [doi]
PST - epublish
SO  - Oncoimmunology. 2021 Aug 2;10(1):1957605. doi: 10.1080/2162402X.2021.1957605. 
      eCollection 2021.

PMID- 7270337
OWN - NLM
STAT- MEDLINE
DCOM- 19811029
LR  - 20190825
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 10
IP  - 6
DP  - 1980 Dec
TI  - Actions of aspirin and dipyridamole on lymphocyte activation.
PG  - 509-12
AB  - The actions of aspirin and dipyridamole on lymphocyte activation in vitro have 
      been studied. Aspirin inhibits lymphocyte activation when measured by protein 
      synthesis or by 3H-thymidine incorporation at therapeutic concentration. 
      Dipyridamole also strongly inhibits 3H-thymidine incorporation, but is a less 
      potent inhibitor of protein synthesis at therapeutic concentrations. 
      Aspirin/dipyridamole combinations did not show synergism as inhibitors of 
      lymphocyte activation. It is concluded that these drugs has dissimilar actions on 
      the lymphocyte and that dipyridamole will not serve as an aspirin-sparing drug in 
      anti-inflammatory therapy.
FAU - Mobarok, A T
AU  - Mobarok AT
FAU - Morley, J
AU  - Morley J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9007-49-2 (DNA)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - DNA/biosynthesis
MH  - Dipyridamole/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Guinea Pigs
MH  - In Vitro Techniques
MH  - Lymphocyte Activation/*drug effects
MH  - Protein Biosynthesis
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
AID - 10.1007/BF02024153 [doi]
PST - ppublish
SO  - Agents Actions. 1980 Dec;10(6):509-12. doi: 10.1007/BF02024153.

PMID- 19426760
OWN - NLM
STAT- MEDLINE
DCOM- 20090914
LR  - 20181201
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 123
IP  - 2
DP  - 2009 Aug
TI  - Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a 
      look at the clinical and pharmacological evidence.
PG  - 178-86
LID - 10.1016/j.pharmthera.2009.03.019 [doi]
AB  - The importance of regular administration of antiplatelet drugs in patients 
      suffering from coronary artery disease stands on firm grounds, as large 
      meta-analyses have shown these therapies to drastically reduce the risk of death. 
      Although the current guidelines published jointly by the American Heart 
      Association, the American College of Cardiology, the Society for Cardiovascular 
      Angiography and Interventions, the American College of Surgeons and the American 
      Dental Association stress the hazards of premature discontinuation of 
      antiplatelet drugs, abrupt withdrawal remains widespread, with potentially 
      catastrophic consequences. In the limited state of knowledge on antiplatelet drug 
      withdrawal, an early sound of alarm has risen from early thromboembolic 
      complications reported after the interruption of treatment in patients who 
      require antiplatelet therapy for prevention of ischemic vascular disease. Acute 
      thrombotic complications are not immediate and usually follow interruption of 
      aspirin or clopidogrel therapy after a mean delay of 8-25 days, a time lapse 
      consistent with normal platelet turnover required to replace the platelet pool in 
      circulation and suggestive of a rebound phenomenon. This review article describes 
      the thrombotic risks associated with discontinuing antiplatelet therapy and the 
      bleeding risks associated with continuing these drugs. By integrating the current 
      understanding of the pharmacology of antiplatelet agents and the kinetics of 
      platelet function recovery, this article unveils the possibility of a 
      pharmacological rebound phenomenon which could lead to adverse ischemic events, 
      and supports the warning against premature discontinuation of antiplatelet drugs 
      issued in current guidelines.
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
AD  - Faculty of Pharmacy, Université de Montréal, C.P. 6128, Succursale Centre Ville, 
      Montréal, Québec H3C3J7, Canada.
FAU - Diodati, Jean G
AU  - Diodati JG
FAU - Pharand, Chantal
AU  - Pharand C
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090506
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Coronary Artery Disease/drug therapy
MH  - Drug Therapy, Combination
MH  - Hemorrhage/*etiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - *Withholding Treatment
RF  - 82
EDAT- 2009/05/12 09:00
MHDA- 2009/09/15 06:00
CRDT- 2009/05/12 09:00
PHST- 2009/03/20 00:00 [received]
PHST- 2009/03/20 00:00 [accepted]
PHST- 2009/05/12 09:00 [entrez]
PHST- 2009/05/12 09:00 [pubmed]
PHST- 2009/09/15 06:00 [medline]
AID - S0163-7258(09)00082-5 [pii]
AID - 10.1016/j.pharmthera.2009.03.019 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2009 Aug;123(2):178-86. doi: 10.1016/j.pharmthera.2009.03.019. 
      Epub 2009 May 6.

PMID- 16304418
OWN - NLM
STAT- MEDLINE
DCOM- 20091103
LR  - 20161021
IS  - 1520-4383 (Electronic)
IS  - 1520-4383 (Linking)
DP  - 2005
TI  - The cardiovascular pharmacology of COX-2 inhibition.
PG  - 445-51
AB  - Selective inhibitors of cyclooxygenase (COX)-2, the coxibs, were developed to 
      inhibit inflammatory prostaglandins derived from COX-2, while sparing 
      gastroprotective prostaglandins primarily formed by COX-1. However, COX-2-derived 
      prostaglandins mediate not only pain and inflammation but also affect vascular 
      function, the regulation of hemostasis/ thrombosis, and blood pressure control. 
      All coxibs depress COX-2-dependent prostacyclin (PGI(2)) biosynthesis without 
      effective suppression of platelet COX-1-derived thromboxane (Tx) A(2), unlike 
      aspirin or traditional nonsteroidal anti-inflammatory drugs, which inhibit both 
      COX-1 and COX-2. The actions of PGI(2) oppose mediators, which stimulate 
      platelets, elevate blood pressure, and accelerate atherogenesis, including 
      TxA(2). Indeed, structurally distinct inhibitors of COX-2 have increased the 
      likelihood of hypertension, myocardial infarction and stroke in controlled 
      clinical trials. The detection of these events in patients is related to the 
      duration of exposure and to their baseline risk of cardiovascular disease. Thus, 
      coxibs should be withheld from patients with preexisting cardiovascular risk 
      factors, and exposed patients at low cardiovascular baseline risk should be 
      monitored for changes in their risk factor profile, such as increases in arterial 
      blood pressure.
FAU - Fries, Susanne
AU  - Fries S
AD  - Institute for Translational Medicine and Therapeutics, University of Pennsylvania 
      School of Medicine, 809 Biomedical Research Building, 421 Curie Blvd., 
      Philadelphia, PA 19104-6084, USA.
FAU - Grosser, Tilo
AU  - Grosser T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hematology Am Soc Hematol Educ Program
JT  - Hematology. American Society of Hematology. Education Program
JID - 100890099
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Atherosclerosis/prevention & control
MH  - Blood Pressure/drug effects
MH  - Cardiovascular Diseases/chemically induced
MH  - Cyclooxygenase 1/drug effects/metabolism
MH  - Cyclooxygenase 2/drug effects/metabolism
MH  - Cyclooxygenase 2 Inhibitors/*pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Humans
MH  - Hypertension/prevention & control
MH  - Mice
EDAT- 2005/11/24 09:00
MHDA- 2009/11/05 06:00
CRDT- 2005/11/24 09:00
PHST- 2005/11/24 09:00 [pubmed]
PHST- 2009/11/05 06:00 [medline]
PHST- 2005/11/24 09:00 [entrez]
AID - 2005/1/445 [pii]
AID - 10.1182/asheducation-2005.1.445 [doi]
PST - ppublish
SO  - Hematology Am Soc Hematol Educ Program. 2005:445-51. doi: 
      10.1182/asheducation-2005.1.445.

PMID- 1324230
OWN - NLM
STAT- MEDLINE
DCOM- 19920924
LR  - 20161123
IS  - 0167-6865 (Print)
IS  - 0167-6865 (Linking)
VI  - 11
IP  - 3
DP  - 1992 Aug
TI  - Effects of combinations of a prostacyclin analogue (Cicaprost) with different 
      antithrombotic agents in a rat microcirculatory thrombosis model.
PG  - 277-86
AB  - The antithrombotic effects of the stable PGI2-analogue Cicaprost, acetylsalicylic 
      acid (Aspisol), the low molecular weight heparin CY 216 (Fraxiparin) and 
      Molsidomin (Corvaton) have been investigated alone and in combinations in a 
      thrombosis model in rats in which mesenteric venules with a diameter of 20-30 
      microns were injured by defined argon laser lesions. In this animal thrombosis 
      model all agents showed a significant and dose-dependent antithrombotic effect. A 
      strong additive effect was observed when Cicaprost was infused together with an 
      i.v. dose of 0.1 mg/kg Molsidomin. A similar additive effect was observed after 
      infusion of minimal effective doses of Cicaprost together with Fraxiparin. The 
      combination of Cicaprost and Aspisol did not have any additive effect. Our 
      results suggest that combinations of antithrombotic agents which show additive 
      effects in animal thrombosis model may lead to a more effective prophylaxis and 
      treatment of human venous or arterial thrombosis.
FAU - Giedrojc, J
AU  - Giedrojc J
AD  - Department of Angiology, University of Frankfurt/Main, Germany.
FAU - Breddin, H K
AU  - Breddin HK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Int J Microcirc Clin Exp
JT  - International journal of microcirculation, clinical and experimental
JID - 8400122
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - D46583G77X (Molsidomine)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - K3Z4F929H6 (Lysine)
RN  - NE94J8CAMD (cicaprost)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology/therapeutic 
      use
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Epoprostenol/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
MH  - Fibrinolytic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Lysine/administration & dosage/*analogs & derivatives/pharmacology/therapeutic 
      use
MH  - Male
MH  - Molsidomine/administration & dosage/pharmacology/*therapeutic use
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Thrombosis/*drug therapy
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
PST - ppublish
SO  - Int J Microcirc Clin Exp. 1992 Aug;11(3):277-86.

PMID- 351394
OWN - NLM
STAT- MEDLINE
DCOM- 19780828
LR  - 20170404
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 299
IP  - 2
DP  - 1978 Jul 13
TI  - A randomized trial of aspirin and sulfinpyrazone in threatened stroke.
PG  - 53-9
AB  - Five hundred and eighty-five patients with threatened stroke were followed in a 
      randomized clinical trial for an average of 26 months to determine whether 
      aspirin or sulfinpyrazone, singly or in combination, influence the subsequent 
      occurrence of continuing transient ischemic attacks, stroke or death. Eighty-five 
      subjects went on to stroke, and 42 died. Aspirin reduced the risk of continuing 
      ischemic attacks, stroke or death by 19 per cent (P less than 0.05) and also 
      reduced risk for the "harder," more important events of stroke or death by 31 
      percent (P less than 0.05), but this effect was sex-dependent: among men, the 
      risk reduction for stroke or death was 48 per cent (P less than 0.005), whereas 
      no significant trend was observed among women. For sulfinpyrazone, no risk 
      reduction of ischemic attacks was observed, and the 10 per cent risk reduction of 
      stroke or death was not statistically significant. No overall synergism or 
      antagonism was observed between the two drugs. We conclude that aspirin is an 
      efficacious drug for men with threatened stroke.
CN  - Canadian Cooperative Study Group
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Prognosis
MH  - Risk
MH  - Sex Factors
MH  - Sulfinpyrazone/administration & dosage/*therapeutic use
MH  - Time Factors
EDAT- 1978/07/13 00:00
MHDA- 1978/07/13 00:01
CRDT- 1978/07/13 00:00
PHST- 1978/07/13 00:00 [pubmed]
PHST- 1978/07/13 00:01 [medline]
PHST- 1978/07/13 00:00 [entrez]
AID - 10.1056/NEJM197807132990201 [doi]
PST - ppublish
SO  - N Engl J Med. 1978 Jul 13;299(2):53-9. doi: 10.1056/NEJM197807132990201.

PMID- 9281867
OWN - NLM
STAT- MEDLINE
DCOM- 19970917
LR  - 20181113
IS  - 0960-1643 (Print)
IS  - 0960-1643 (Linking)
VI  - 47
IP  - 420
DP  - 1997 Jul
TI  - Aspirin use in middle-aged men with cardiovascular disease: are opportunities 
      being missed?
PG  - 417-21
AB  - BACKGROUND: Since the 1980s, clinical trial evidence has supported aspirin use in 
      the secondary prevention of cardiovascular disease (CVD). AIM: To explore aspirin 
      use among British men with known CVD in a population-based study. METHOD: 
      Longitudinal study (British Regional Heart Study), in which subjects have been 
      followed up for cardiovascular morbidity and mortality since 1978-1980. Aspirin 
      use was assessed by questionnaires to study participants in November 1992 (Q92); 
      cardiovascular diagnoses are based on general practice notifications to October 
      1992. A total of 5751 men aged 52-73 years (87% of survivors) completed questions 
      on aspirin use. RESULTS: Overall, 547 men (9.5%) were taking aspirin daily, of 
      whom 321 (59%) had documented CVD. Among men with pre-existing disease, 153 out 
      of 345 (44%) men with myocardial infarction, 42 out of 109 (39%) with stroke, and 
      75 out of 247 (29%) with angina were taking aspirin daily. Among men with angina 
      (54% versus 26%) or myocardial infarction (59% versus 42%), those who had 
      undergone coronary artery bypass surgery (CABG) or angioplasty were more likely 
      to be receiving aspirin. Higher rates of aspirin use were also found in those 
      whose last major event occurred after January 1990 (47% versus 34%). There was no 
      association between aspirin use and social class or region of residence. 
      CONCLUSION: Despite strong evidence of its effectiveness, many patients with 
      established CVD were not receiving aspirin. Daily aspirin treatment was less 
      likely in men with less recent major CVD events and in those who had not received 
      invasive treatment.
FAU - McCallum, A K
AU  - McCallum AK
AD  - Department of Primary Care and Population Sciences, Royal Free Hospital School of 
      Medicine, London.
FAU - Whincup, P H
AU  - Whincup PH
FAU - Morris, R W
AU  - Morris RW
FAU - Thomson, A
AU  - Thomson A
FAU - Walker, M
AU  - Walker M
FAU - Ebrahim, S
AU  - Ebrahim S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of 
      General Practitioners
JID - 9005323
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br J Gen Pract. 1997 Nov;47(424):751. PMID: 9519534
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage
PMC - PMC1313050
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
PST - ppublish
SO  - Br J Gen Pract. 1997 Jul;47(420):417-21.

PMID- 12602712
OWN - NLM
STAT- MEDLINE
DCOM- 20030318
LR  - 20131121
IS  - 0038-4348 (Print)
IS  - 0038-4348 (Linking)
VI  - 96
IP  - 1
DP  - 2003 Jan
TI  - Reye's syndrome: down but not out.
PG  - 43-5
AB  - Reye's syndrome presents as acute central nervous system and liver dysfunction in 
      children. Its incidence has seen a sharp decline in parallel with the decline in 
      the use of aspirin in the pediatric age group. This report describes a patient 
      with Reye's syndrome and serves as a reminder for health professionals to 
      continue to discourage the use of aspirin for the treatment of viral infections.
FAU - Bhutta, Adnan T
AU  - Bhutta AT
AD  - Department of Pediatrics, University of Arkansas for Medical Sciences and 
      Arkansas Children's Hospital, Little Rock, AR 72202-3591, USA. 
      bhuttaadnant@uams.edu
FAU - Van Savell, H
AU  - Van Savell H
FAU - Schexnayder, Stephen M
AU  - Schexnayder SM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Child, Preschool
MH  - Diagnosis, Differential
MH  - Fatal Outcome
MH  - Fever/drug therapy
MH  - Humans
MH  - Male
MH  - Respiratory Tract Infections/drug therapy
MH  - Reye Syndrome/*chemically induced/*diagnosis
EDAT- 2003/02/27 04:00
MHDA- 2003/03/19 04:00
CRDT- 2003/02/27 04:00
PHST- 2003/02/27 04:00 [pubmed]
PHST- 2003/03/19 04:00 [medline]
PHST- 2003/02/27 04:00 [entrez]
AID - 10.1097/01.SMJ.0000047764.97329.1C [doi]
PST - ppublish
SO  - South Med J. 2003 Jan;96(1):43-5. doi: 10.1097/01.SMJ.0000047764.97329.1C.

PMID- 35471506
OWN - NLM
STAT- MEDLINE
DCOM- 20220428
LR  - 20220531
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 327
IP  - 16
DP  - 2022 Apr 26
TI  - Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated 
      Modeling Study for the US Preventive Services Task Force.
PG  - 1598-1607
LID - 10.1001/jama.2022.3385 [doi]
AB  - IMPORTANCE: The US Preventive Services Task Force (USPSTF) is updating its 2016 
      recommendation on the use of aspirin for the primary prevention of cardiovascular 
      disease (CVD) and colorectal cancer (CRC). OBJECTIVE: To provide updated 
      model-based estimates of the net balance in benefits and harms from routine use 
      of low-dose aspirin for primary prevention. DESIGN, SETTING, AND PARTICIPANTS: 
      Microsimulation modeling was used to estimate long-term benefits and harms for 
      hypothetical US cohorts of men and women aged 40 to 79 years with up to 20% 
      10-year risk for an atherosclerotic CVD event and without prior history of CVD or 
      elevated bleeding risks. EXPOSURES: Low-dose (≤100 mg/d) aspirin for lifetime 
      use, unless contraindicated by a bleeding event, and with stopping ages in 5-year 
      intervals from age 65 to 85 years. MAIN OUTCOMES AND MEASURES: Primary outcomes 
      were lifetime net benefits measured in quality-adjusted life-years (QALYs) and 
      life-years. Benefits included reduced nonfatal myocardial infarction and ischemic 
      stroke. Harms included increased nonfatal major gastrointestinal bleeding and 
      intracranial hemorrhage. Reduced CRC incidence was considered in sensitivity 
      analysis. RESULTS: Estimated lifetime net QALYs were positive for both men and 
      women at 5% or greater 10-year CVD risk when starting between ages 40 and 59 
      years and at 10% or greater 10-year CVD risk when starting between ages 60 and 69 
      years. These estimates ranged from 2.3 (95% CI, -2.7 to 7.4) to 66.2 (95% CI, 
      58.2 to 74.1) QALYs per 1000 persons. Lifetime net life-years were positive for 
      men at 5% or greater and women at 10% or greater 10-year CVD risk starting 
      aspirin at ages 40 to 49 years and for men at 7.5% or greater and women at 15% or 
      greater 10-year CVD risk at ages 50 to 59 years. These estimates ranged from 0.4 
      (95% CI, -6.1 to 6.9) to 52.4 (95% CI, 43.9 to 60.9) life-years per 1000 persons. 
      Lifetime net life-years were negative in most cases for persons starting aspirin 
      between ages 60 and 79 years, as were lifetime net QALYs for persons aged 70 to 
      79 years. Stopping aspirin between ages 65 and 85 years generally showed little 
      advantage compared with lifetime use. Sensitivity analyses showed lifetime net 
      benefits may be higher if aspirin reduced CRC incidence or CVD mortality and 
      lower if aspirin increased fatal major gastrointestinal bleeding or reduced 
      quality of life with routine use. CONCLUSIONS AND RELEVANCE: This microsimulation 
      study suggested that several population groups may benefit from taking aspirin 
      for the primary prevention of CVD, primarily in persons starting at younger ages 
      with higher 10-year CVD risk.
FAU - Dehmer, Steven P
AU  - Dehmer SP
AD  - HealthPartners Institute, Minneapolis, Minnesota.
FAU - O'Keefe, Lauren R
AU  - O'Keefe LR
AD  - HealthPartners Institute, Minneapolis, Minnesota.
FAU - Evans, Corinne V
AU  - Evans CV
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
FAU - Guirguis-Blake, Janelle M
AU  - Guirguis-Blake JM
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
AD  - Department of Family Medicine, University of Washington, Tacoma.
FAU - Perdue, Leslie A
AU  - Perdue LA
AD  - Kaiser Permanente Evidence-based Practice Center, Center for Health Research, 
      Kaiser Permanente, Portland, Oregon.
FAU - Maciosek, Michael V
AU  - Maciosek MV
AD  - HealthPartners Institute, Minneapolis, Minnesota.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Aspirin/adverse effects/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - *Colorectal Neoplasms/drug therapy/epidemiology/prevention & control
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention
MH  - Quality of Life
EDAT- 2022/04/27 06:00
MHDA- 2022/04/29 06:00
CRDT- 2022/04/26 12:52
PHST- 2022/04/26 12:52 [entrez]
PHST- 2022/04/27 06:00 [pubmed]
PHST- 2022/04/29 06:00 [medline]
AID - 2791400 [pii]
AID - 10.1001/jama.2022.3385 [doi]
PST - ppublish
SO  - JAMA. 2022 Apr 26;327(16):1598-1607. doi: 10.1001/jama.2022.3385.

PMID- 26394025
OWN - NLM
STAT- MEDLINE
DCOM- 20160314
LR  - 20181202
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 98
IP  - 4
DP  - 2015 Dec 15
TI  - NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing 
      hybrid has enhanced chemo-preventive properties compared to aspirin, is 
      gastrointestinal safe with all the classic therapeutic indications.
PG  - 564-72
LID - S0006-2952(15)00624-3 [pii]
LID - 10.1016/j.bcp.2015.09.014 [doi]
AB  - Aspirin is chemopreventive; however, side effects preclude its long-term use. 
      NOSH-aspirin (NBS-1120), a novel hybrid that releases nitric oxide and hydrogen 
      sulfide, was designed to be a safer alternative. Here we compare the 
      gastrointestinal safety, anti-inflammatory, analgesic, anti-pyretic, 
      anti-platelet, and chemopreventive properties of aspirin and NBS-1120 
      administered orally to rats at equimolar doses. Gastrointestinal safety: 6h 
      post-administration, the number and size of hemorrhagic lesions in stomachs were 
      counted; tissue samples were frozen for PGE2, SOD, and MDA determination. 
      Anti-inflammatory: 1h after drug administration, the volume of 
      carrageenan-induced rat paw edemas was measured for 5h. Anti-pyretic: fever was 
      induced by LPS (ip) an hour before administration of the test drugs, core body 
      temperature was measured hourly for 5h. Analgesic: time-dependent analgesic 
      effects were evaluated by carrageenan-induced hyperalgesia. Antiplatelet: 
      anti-aggregatory effects were studied on collagen-induced platelet aggregation of 
      human platelet-rich plasma. Chemoprevention: nude mice were gavaged daily for 25 
      days with vehicle, aspirin or NBS-1120. After one week, each mouse was inoculated 
      subcutaneously in the right flank with HT-29 human colon cancer cells. Both 
      agents reduced PGE2 levels in stomach tissue; however, NBS-1120 did not cause any 
      stomach ulcers, whereas aspirin caused significant bleeding. Lipid peroxidation 
      induced by aspirin was higher than that exerted by NBS-1120. SOD activity was 
      significantly inhibited by aspirin but increased by NBS-1120. Both agents showed 
      similar anti-inflammatory, analgesic, anti-pyretic, and anti-platelet activities. 
      Aspirin increased plasma TNFα more than NBS-1120-treated animals. NBS-1120 was 
      better than aspirin as a chemopreventive agent; it dose-dependently inhibited 
      tumor growth and tumor mass.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Kodela, Ravinder
AU  - Kodela R
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, NY, 
      United States.
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, NY, 
      United States.
FAU - Velázquez-Martínez, Carlos A
AU  - Velázquez-Martínez CA
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Canada.
FAU - Kashfi, Khosrow
AU  - Kashfi K
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, NY, 
      United States; Avicenna Pharmaceuticals Inc., New York, NY, United States. 
      Electronic address: kashfi@med.cuny.edu.
LA  - eng
GR  - R24 DA018055/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150921
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Disulfides)
RN  - 0 (Nitrates)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Chemoprevention/*methods
MH  - Disulfides/pharmacology/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/drug effects/*metabolism
MH  - Gastrointestinal Tract/drug effects/metabolism
MH  - HT29 Cells
MH  - Humans
MH  - Hydrogen Sulfide/*metabolism
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Nitrates/pharmacology/*therapeutic use
MH  - Nitric Oxide/*metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Xenograft Model Antitumor Assays/methods
PMC - PMC4656078
MID - NIHMS725165
OTO - NOTNLM
OT  - Aspirin
OT  - Chemopreventive
OT  - GI-sparing
OT  - Hydrogen sulfide
OT  - Nitric oxide
COIS- Conflict of interest The authors have nothing to disclose except for KK, who has 
      an equity position in Avicenna Pharmaceuticals, Inc. the supplier of NOSH-aspirin 
      used in these studies and to which NBS-1120 is licensed.
EDAT- 2015/09/24 06:00
MHDA- 2016/03/15 06:00
CRDT- 2015/09/23 06:00
PHST- 2015/08/24 00:00 [received]
PHST- 2015/09/17 00:00 [accepted]
PHST- 2015/09/23 06:00 [entrez]
PHST- 2015/09/24 06:00 [pubmed]
PHST- 2016/03/15 06:00 [medline]
AID - S0006-2952(15)00624-3 [pii]
AID - 10.1016/j.bcp.2015.09.014 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2015 Dec 15;98(4):564-72. doi: 10.1016/j.bcp.2015.09.014. Epub 
      2015 Sep 21.

PMID- 11766849
OWN - NLM
STAT- MEDLINE
DCOM- 20020123
LR  - 20181113
IS  - 0960-1643 (Print)
IS  - 0960-1643 (Linking)
VI  - 51
IP  - 473
DP  - 2001 Dec
TI  - Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of 
      cardiovascular disease.
PG  - 1001-3
AB  - Little is known about the contribution of over-the-counter (OTC) aspirin to 
      cardiovascular prophylaxis. To investigate this, a two-phase cross-sectional 
      study was carried out in nine general practices in North Staffordshire. In the 
      first phase, all patients with cardiovascular disease (CVD) were identified from 
      computer searches using morbidity registers and drug searches. The search also 
      identfied the subgroup receiving prescribed prophylactic aspirin. In the second 
      phase, a questionnaire was posted to all patients with CVD who were not on 
      prescribed aspirin to establish their current use of OTC aspirin. Overall, 69% of 
      the CVD group used aspirin, with 26% of aspirin being OTC. OTC aspirin use was 
      more common in those aged under 65 years, men, and the more affluent. Also, there 
      were significant differences in OTC aspirin use between the various practices. 
      This study shows that a considerable amount of aspirin is used OTC in those with 
      CVD. Its use is influenced by several factors that could be addressed when 
      considering attempts to improve the overall uptake of aspirin.
FAU - Bedson, J
AU  - Bedson J
AD  - Primary Care Sciences Research Centre, Keele University. bedsonj@aol.com
FAU - Whitehurst, T
AU  - Whitehurst T
FAU - Lewis, M
AU  - Lewis M
FAU - Croft, P
AU  - Croft P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of 
      General Practitioners
JID - 9005323
RN  - 0 (Nonprescription Drugs)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Nonprescription Drugs/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Sex Factors
MH  - Socioeconomic Factors
PMC - PMC1314169
EDAT- 2002/01/05 10:00
MHDA- 2002/01/24 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/01/24 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
PST - ppublish
SO  - Br J Gen Pract. 2001 Dec;51(473):1001-3.

PMID- 3318469
OWN - NLM
STAT- MEDLINE
DCOM- 19871218
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 157
IP  - 5
DP  - 1987 Nov
TI  - Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin 
      and dipyridamole.
PG  - 1230-5
AB  - In a controlled, nonrandomized trial a treatment group of 24 multigravid women 
      with a history of at least two previous pregnancies, all complicated by 
      idiopathic fetal growth retardation and placental infarction, received 1 to 1.6 
      mg/kg aspirin and 225 mg dipyridamole daily from 16 to 34 weeks' gestation in a 
      total of 30 pregnancies. The end-point measure of the study was birth weight 
      related to gestational age. Results obtained in the treatment group were compared 
      with those in 27 pregnancies of a control group of 24 multigravid women with a 
      similar history of recurrent fetal growth retardation who received comparable 
      antenatal care without low dose aspirin and dipyridamole. Fetal growth 
      retardation occurred in 61% of the control pregnancies and in only 13% of treated 
      pregnancies; severe fetal growth retardation was not observed in treated 
      pregnancies, but it occurred in 27% of the control group. In treated women, 
      platelet cyclo-oxygenase activity was suppressed to 5% to 10% of its pretreatment 
      level, but no effect on vascular prostacyclin production was demonstrated. 
      Treatment did not produce adverse effects in mothers or infants. Low-dose aspirin 
      and dipyridamole direct prostacyclin/thromboxane A2 balance in pregnancy to the 
      dominance of prostacyclin and may thus prevent idiopathic uteroplacental 
      insufficiency and fetal growth retardation in high-risk patients.
FAU - Wallenburg, H C
AU  - Wallenburg HC
AD  - Department of Obstetrics and Gynecology, Erasmus University Medical School, 
      Rotterdam, The Netherlands.
FAU - Rotmans, N
AU  - Rotmans N
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 57576-52-0 (Thromboxane A2)
RN  - 64ALC7F90C (Dipyridamole)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Obstet Gynecol. 1989 Mar;160(3):763-4. PMID: 2648844
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Birth Weight
MH  - Clinical Trials as Topic
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Epoprostenol/metabolism
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Humans
MH  - Infant, Newborn
MH  - Pregnancy
MH  - Recurrence
MH  - Thromboxane A2/antagonists & inhibitors
EDAT- 1987/11/01 00:00
MHDA- 1987/11/01 00:01
CRDT- 1987/11/01 00:00
PHST- 1987/11/01 00:00 [pubmed]
PHST- 1987/11/01 00:01 [medline]
PHST- 1987/11/01 00:00 [entrez]
AID - S0002-9378(87)80300-9 [pii]
AID - 10.1016/s0002-9378(87)80300-9 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1987 Nov;157(5):1230-5. doi: 10.1016/s0002-9378(87)80300-9.

PMID- 421338
OWN - NLM
STAT- MEDLINE
DCOM- 19790523
LR  - 20191021
IS  - 0009-9090 (Print)
IS  - 0009-9090 (Linking)
VI  - 9
IP  - 1
DP  - 1979 Jan
TI  - Oral acetylsalicylic acid (aspirin) challenge in asthmatic children.
PG  - 83-8
AB  - Thirty-two asthmatic children, mean age 9.6 years (range: 6-14 years), were 
      studied by oral challenge with acetylsalicylic acid (Aspirin), and their PEFR was 
      recorded at 30 min intervals for 3 hr. They had been asthmatic for a mean of 7.1 
      years. Other allergic symptoms (urticaria, rhinitis or atopic dermatitis), were 
      present in 81% of the patients, and a family history of atopy in 94%; the mean 
      blood eosinophilia was 590 cells per mm3. In three children aspirin induced a 
      fall in PEFR values less than 8% which was non-significant. In the group as a 
      whole there was an increase in the PEFR values of 13.9%, 150 min after aspirin 
      challenge. These values where subjected to statistical analysis 
      (Kolmogorov-Smirnov, Student's and Wilcoxon tests), which showed this increase to 
      be significant at a level of P = 0.001. Possible mechanisms involving 
      prostaglandin synthetase inhibition by aspirin are discussed as an explanation 
      for this increase.
FAU - Schuhl, J F
AU  - Schuhl JF
FAU - Pereyra, J G
AU  - Pereyra JG
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Allergy
JT  - Clinical allergy
JID - 0311172
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Peak Expiratory Flow Rate
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1111/j.1365-2222.1979.tb01526.x [doi]
PST - ppublish
SO  - Clin Allergy. 1979 Jan;9(1):83-8. doi: 10.1111/j.1365-2222.1979.tb01526.x.

PMID- 30582310
OWN - NLM
STAT- MEDLINE
DCOM- 20190502
LR  - 20190502
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 157
IP  - 12
DP  - 2018 Dec
TI  - [TREATMENT WITH DUAL ANTIPLATELET THERAPY FOR SECONDARY PREVENTION OF STROKE - 
      PROS AND CONS].
PG  - 773-778
AB  - The role of dual antiplatelet therapy combining aspirin and clopidogrel, is 
      controversial. There are two settings in which such treatment might be 
      considered: (a) patients presenting with a first ischemic event at high risk for 
      a recurrence; and (b) patients who experience a second ischemic event while being 
      treated with aspirin or clopidogrel monotherapy. In this paper we review the 
      literature dealing with secondary prevention of ischemic stroke, with an emphasis 
      on dual antiplatelet therapy. We examine international guidelines and present a 
      case study which illustrates the application of this information.
FAU - Sherban, Adi
AU  - Sherban A
AD  - Internal Medicine Department - Gimel.
FAU - Armon, Carmel
AU  - Armon C
AD  - Neurology Department, Assaf Harofeh Medical Center, Sackler Faculty of Medicine, 
      Tel-Aviv University.
FAU - Rapoport, Micha
AU  - Rapoport M
AD  - Internal Medicine Department - Gimel.
LA  - heb
PT  - Journal Article
PT  - Review
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - *Secondary Prevention
MH  - *Stroke/prevention & control
MH  - Ticlopidine
EDAT- 2018/12/26 06:00
MHDA- 2019/05/03 06:00
CRDT- 2018/12/25 06:00
PHST- 2018/12/25 06:00 [entrez]
PHST- 2018/12/26 06:00 [pubmed]
PHST- 2019/05/03 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2018 Dec;157(12):773-778.

PMID- 15753302
OWN - NLM
STAT- MEDLINE
DCOM- 20050509
LR  - 20220408
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 102
IP  - 11
DP  - 2005 Mar 15
TI  - Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes 
      tumor eradication by cancer vaccination.
PG  - 4185-90
AB  - Active suppression of tumor-specific T lymphocytes can limit the immune-mediated 
      destruction of cancer cells. Of the various strategies used by tumors to 
      counteract immune attacks, myeloid suppressors recruited by growing cancers are 
      particularly efficient, often resulting in the induction of systemic T lymphocyte 
      dysfunction. We have previously shown that the mechanism by which myeloid cells 
      from tumor-bearing hosts block immune defense strategies involves two enzymes 
      that metabolize L-arginine: arginase and nitric oxide (NO) synthase. NO-releasing 
      aspirin is a classic aspirin molecule covalently linked to a NO donor group. NO 
      aspirin does not possess direct antitumor activity. However, by interfering with 
      the inhibitory enzymatic activities of myeloid cells, orally administered NO 
      aspirin normalized the immune status of tumor-bearing hosts, increased the number 
      and function of tumor-antigen-specific T lymphocytes, and enhanced the preventive 
      and therapeutic effectiveness of the antitumor immunity elicited by cancer 
      vaccination. Because cancer vaccines and NO aspirin are currently being 
      investigated in independent phase I/II clinical trials, these findings offer a 
      rationale to combine these treatments in subjects with advanced neoplastic 
      diseases.
FAU - De Santo, Carmela
AU  - De Santo C
AD  - Department of Oncology and Surgical Sciences, Oncology Section, Padua University, 
      35128 Padua, Italy.
FAU - Serafini, Paolo
AU  - Serafini P
FAU - Marigo, Ilaria
AU  - Marigo I
FAU - Dolcetti, Luigi
AU  - Dolcetti L
FAU - Bolla, Manlio
AU  - Bolla M
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Melani, Cecilia
AU  - Melani C
FAU - Guiducci, Cristiana
AU  - Guiducci C
FAU - Colombo, Mario P
AU  - Colombo MP
FAU - Iezzi, Manuela
AU  - Iezzi M
FAU - Musiani, Piero
AU  - Musiani P
FAU - Zanovello, Paola
AU  - Zanovello P
FAU - Bronte, Vincenzo
AU  - Bronte V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050307
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Carrier Proteins)
RN  - 0 (Lipocalins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Tinagl1 protein, mouse)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Cancer Vaccines/*pharmacology
MH  - Carrier Proteins
MH  - Immune System Diseases/*drug therapy/immunology
MH  - Lipocalins
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Neoplasm Proteins
MH  - Neoplasms/*drug therapy/immunology/mortality
MH  - Nitric Oxide Synthase/metabolism
MH  - T-Lymphocytes/drug effects/immunology
MH  - Time Factors
PMC - PMC554823
EDAT- 2005/03/09 09:00
MHDA- 2005/05/10 09:00
CRDT- 2005/03/09 09:00
PHST- 2005/03/09 09:00 [pubmed]
PHST- 2005/05/10 09:00 [medline]
PHST- 2005/03/09 09:00 [entrez]
AID - 0409783102 [pii]
AID - 01024185 [pii]
AID - 10.1073/pnas.0409783102 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90. doi: 
      10.1073/pnas.0409783102. Epub 2005 Mar 7.

PMID- 27699648
OWN - NLM
STAT- MEDLINE
DCOM- 20180409
LR  - 20180409
IS  - 1179-1896 (Electronic)
IS  - 1175-5652 (Linking)
VI  - 15
IP  - 3
DP  - 2017 Jun
TI  - Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with 
      Atrial Fibrillation: An Australian Perspective.
PG  - 363-374
LID - 10.1007/s40258-016-0283-9 [doi]
AB  - OBJECTIVE: To determine the clinical and cost effectiveness of apixaban compared 
      to aspirin in the prevention of thromboembolic events for patients with atrial 
      fibrillation for whom vitamin K antagonist (VKA) therapy (warfarin) has been 
      considered unsuitable. METHODS: A previously published Markov model with yearly 
      cycles was updated. Information from the Apixaban Versus Acetylsalicylic acid to 
      prevent Stroke in Atrial Fibrillation (AVERROES) trial in combination with other 
      population data was used to simulate the costs and effects of apixaban compared 
      to aspirin over 10 years. The model comprised five health states. Costs from an 
      Australian healthcare perspective were estimated from published sources for the 
      year 2015. The main outcome of interest was number needed to treat (NNT), number 
      needed to harm (NNH), the incremental cost-effectiveness ratio (ICER) [cost per 
      quality-adjusted life-year (QALY) gained, and cost per year of life saved 
      (YoLS)]. Costs and benefits were discounted at 5.0 % per annum. RESULTS: For each 
      patient followed up over 10 years, NNT to prevent one additional event 
      (thromboembolic event, death) for apixaban compared to aspirin was 4.6 and 11.8, 
      respectively. NNH was 35.9 for non-fatal major bleeding. The model predicted that 
      compared to aspirin, apixaban would lead to 0.33 YoLS (discounted) and 0.29 QALYs 
      gained (discounted), at an incremental cost of AUD$1996 (discounted). This 
      resulted in ICERs of AUD$6011 per YoLS and AUD$6929 per QALY gained. In the 
      sensitivity analyses, ICERs were most sensitive to efficacy measures derived from 
      the AVERROES study, and time frame. CONCLUSION: Compared to aspirin, apixaban is 
      likely to be cost effective in preventing thromboembolic disease among VKA 
      unsuitable patients with atrial fibrillation.
FAU - Ademi, Zanfina
AU  - Ademi Z
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia. zanfina.ademi@unibas.ch.
AD  - Institute of Pharmaceutical Medicine (ECPM), University of Basel, 
      Klingelbergstrasse 61, 4056, Basel, Switzerland. zanfina.ademi@unibas.ch.
FAU - Pasupathi, Kumar
AU  - Pasupathi K
AD  - Optum, Sydney, Australia.
FAU - Liew, Danny
AU  - Liew D
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      VIC, Australia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - New Zealand
TA  - Appl Health Econ Health Policy
JT  - Applied health economics and health policy
JID - 101150314
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*economics/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy/economics
MH  - Australia
MH  - Cost-Benefit Analysis/statistics & numerical data
MH  - Female
MH  - Fibrinolytic Agents/*economics/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pyrazoles/*economics/*therapeutic use
MH  - Pyridones/*economics/*therapeutic use
EDAT- 2016/10/05 06:00
MHDA- 2018/04/10 06:00
CRDT- 2016/10/05 06:00
PHST- 2016/10/05 06:00 [pubmed]
PHST- 2018/04/10 06:00 [medline]
PHST- 2016/10/05 06:00 [entrez]
AID - 10.1007/s40258-016-0283-9 [pii]
AID - 10.1007/s40258-016-0283-9 [doi]
PST - ppublish
SO  - Appl Health Econ Health Policy. 2017 Jun;15(3):363-374. doi: 
      10.1007/s40258-016-0283-9.

PMID- 424843
OWN - NLM
STAT- MEDLINE
DCOM- 19790516
LR  - 20190702
IS  - 0038-4348 (Print)
IS  - 0038-4348 (Linking)
VI  - 72
IP  - 3
DP  - 1979 Mar
TI  - Hepatitis B presenting with tenosynovitis.
PG  - 375-6
AB  - A 31-year-old nurse's aide developed fever, malaise, migratory arthralgias, 
      arthritis, and severe tenosynovitis six weeks after pricking her finger with a 
      needle contaminated by blood from a patient having type B viral hepatitis. 
      Although disseminated Neisseria gonorrhoeae infection was the initial diagnosis, 
      her symptoms worsened on treatment with ampicillin. While the patient was on 
      aspirin therapy, her symptoms improved dramatically and eventually resolved as 
      she showed evidence, through laboratory findings, of an anicteric hepatitis B 
      infection. Evidently tenosynovitis can be part of the hepatitis B prodrome.
FAU - Greenberg, R N
AU  - Greenberg RN
FAU - Eversmeyer, W H
AU  - Eversmeyer WH
FAU - Sanders, C V
AU  - Sanders CV
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Hepatitis B/*complications
MH  - Humans
MH  - Tenosynovitis/drug therapy/*etiology
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
AID - 10.1097/00007611-197903000-00048 [doi]
PST - ppublish
SO  - South Med J. 1979 Mar;72(3):375-6. doi: 10.1097/00007611-197903000-00048.

PMID- 33268309
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20210630
IS  - 1701-2163 (Print)
IS  - 1701-2163 (Linking)
VI  - 43
IP  - 2
DP  - 2021 Feb
TI  - Family History of Hypertension, Cardiovascular Disease, or Diabetes and Risk of 
      Developing Preeclampsia: A Systematic Review.
PG  - 227-236.e19
LID - S1701-2163(20)30608-3 [pii]
LID - 10.1016/j.jogc.2020.08.010 [doi]
AB  - Preeclampsia is a severe pregnancy complication with high potential for adverse 
      effects on maternal and fetal health during the perinatal period. It is also 
      associated with an increased risk of maternal cardiovascular disease later in 
      life. Development of preeclampsia can be decreased by prescribing low-dose 
      aspirin to high-risk women. At present, maternal and pregnancy factors are used 
      to assess the risk of preeclampsia. One additional factor that could add to the 
      assessment of risk is a family history of hypertension, cardiovascular disease, 
      or diabetes, especially for nulliparous women who do not have a pregnancy history 
      to inform treatment decisions. Therefore, we conducted a systematic review to 
      assess the association between family history of the aforementioned conditions 
      and preeclampsia. Four databases including MEDLINE, EMBASE, the Cochrane Library, 
      and CINAHL/pre-CINAHL were searched for observational studies that examined a 
      family history of hypertension, cardiovascular disease, or diabetes in women with 
      preeclampsia and in a control population. Studies were evaluated for quality 
      using the Newcastle-Ottawa Scale. A total of 84 relevant studies were identified. 
      A meta-analysis was not conducted due to suspected heterogeneity in the included 
      studies. Most studies reported a positive association between a family history of 
      hypertension or cardiovascular disease and the development of preeclampsia. The 
      majority of studies examining family history of diabetes reported non-significant 
      associations. Overall, family history of hypertension or cardiovascular disease 
      is associated with a higher risk for developing preeclampsia and should be 
      considered when assessing women in the first trimester for low-dose aspirin.
CI  - Copyright © 2020. Published by Elsevier Inc.
FAU - Kay, Vanessa R
AU  - Kay VR
AD  - Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON. 
      Electronic address: 8vrk@queensu.ca.
FAU - Wedel, Naomi
AU  - Wedel N
AD  - Department of Obstetrics and Gynecology, Queen's University, Kingston, ON.
FAU - Smith, Graeme N
AU  - Smith GN
AD  - Department of Obstetrics and Gynecology, Queen's University, Kingston, ON.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20200825
PL  - Netherlands
TA  - J Obstet Gynaecol Can
JT  - Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et 
      gynecologie du Canada : JOGC
JID - 101126664
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/*genetics
MH  - Diabetes Mellitus, Type 1/complications/*genetics
MH  - Female
MH  - Humans
MH  - Hypertension/complications/*genetics
MH  - Pre-Eclampsia/genetics/*prevention & control
MH  - Pregnancy
MH  - Risk Factors
OTO - NOTNLM
OT  - cardiovascular disease
OT  - diabetes mellitus, type 2
OT  - hypertension
OT  - preeclampsia
OT  - risk factors
EDAT- 2020/12/04 06:00
MHDA- 2021/07/01 06:00
CRDT- 2020/12/03 05:33
PHST- 2020/06/25 00:00 [received]
PHST- 2020/07/31 00:00 [revised]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
PHST- 2020/12/03 05:33 [entrez]
AID - S1701-2163(20)30608-3 [pii]
AID - 10.1016/j.jogc.2020.08.010 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Can. 2021 Feb;43(2):227-236.e19. doi: 
      10.1016/j.jogc.2020.08.010. Epub 2020 Aug 25.

PMID- 7580359
OWN - NLM
STAT- MEDLINE
DCOM- 19951228
LR  - 20181130
IS  - 0730-2347 (Print)
IS  - 0730-2347 (Linking)
VI  - 22
IP  - 3
DP  - 1995
TI  - Limiting excessive postoperative blood transfusion after cardiac procedures. A 
      review.
PG  - 216-30
AB  - Analysis of blood product use after cardiac operations reveals that a few 
      patients (< or = 20%) consume the majority of blood products (> 80%). The risk 
      factors that predispose a minority of patients to excessive blood use include 
      patient-related factors, transfusion practices, drug-related causes, and 
      procedure-related factors. Multivariate studies suggest that patient age and red 
      blood cell volume are independent patient-related variables that predict 
      excessive blood product transfusion after cardiac procedures. Other factors 
      include preoperative aspirin ingestion, type of operation, over- or 
      underutilization of heparin during cardiopulmonary bypass, failure to correct 
      hypothermia after cardiopulmonary bypass, and physician overtransfusion. A survey 
      of the currently available blood conservation techniques reveals 5 that stand out 
      as reliable methods: 1) high-dose aprotinin therapy, 2) preoperative 
      erythropoietin therapy when time permits adequate dosage before operation, 3) 
      hemodilution by harvest of whole blood immediately before cardiopulmonary bypass, 
      4) autologous predonation of blood, and 5) salvage of oxygenator blood after 
      cardiopulmonary bypass. Other methods, such as the use of epsilon-aminocaproic 
      acid or desmopressin, cell saving devices, reinfusion of shed mediastinal blood, 
      and hemofiltration have been reported to be less reliable and may even be harmful 
      in some high-risk patients. Consideration of the available data allows 
      formulation of a 4-pronged plan for limiting excessive blood transfusion after 
      surgery: 1) recognize the causes of excessive transfusion, including the 
      importance of red blood cell volume, type of procedure being performed, 
      preoperative aspirin ingestion, etc.; 2) establish a quality management program, 
      including a survey of transfusion practices that emphasizes physician education 
      and availability of real-time laboratory testing to guide transfusion therapy; 3) 
      adopt a multimodal approach using institution-proven techniques; and 4) 
      continually reassess blood product use and analyze the cost-benefits of blood 
      conservation interventions.
FAU - Ferraris, V A
AU  - Ferraris VA
AD  - Division of Cardiothoracic Surgery, Albany Medical College, New York 12208, USA.
FAU - Ferraris, S P
AU  - Ferraris SP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Tex Heart Inst J
JT  - Texas Heart Institute journal
JID - 8214622
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - Blood Coagulation Tests
MH  - Blood Loss, Surgical/physiopathology/*prevention & control
MH  - Blood Transfusion/*statistics & numerical data
MH  - Cardiopulmonary Bypass
MH  - *Health Services Misuse
MH  - Heart Diseases/blood/*surgery
MH  - Humans
MH  - Postoperative Hemorrhage/etiology/*prevention & control
MH  - Risk Factors
PMC - PMC325257
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Tex Heart Inst J. 1995;22(3):216-30.

PMID- 32535924
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210401
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 151
IP  - 1
DP  - 2020 Oct
TI  - Meta-analysis of heparin combined with aspirin versus aspirin alone for 
      unexplained recurrent spontaneous abortion.
PG  - 23-32
LID - 10.1002/ijgo.13266 [doi]
AB  - BACKGROUND: Unexplained recurrent spontaneous abortion (URSA) frustrates women of 
      childbearing age profoundly, and effective therapies are particularly important. 
      OBJECTIVE: To compare the efficacy of heparin combined with aspirin and aspirin 
      alone for URSA. SEARCH STRATEGY: Electronic databases (PubMed, Medline, Web of 
      Science, Clinical key and Cochrane Library) were searched for relevant studies 
      from database inception to August 2019. SELECTION CRITERIA: Studies of women of 
      childbearing age with at least two consecutive abortions were included. DATA 
      COLLECTION AND ANALYSIS: Relevant items were extracted, tabulated, and subjected 
      to STATA for data analysis. Study women were divided into group A (taking heparin 
      plus aspirin) and group B (taking aspirin alone). The primary outcome was the 
      rate of live birth. MAIN RESULTS: Women from eight randomized controlled trials 
      were included: 493 in group A and 501 in group B. The number of live births was 
      significantly higher in group A (P=0.003). The result remained the same in 
      subgroup analysis by presence of antiphospholipid antibodies. Among women who had 
      a live birth, gestational age at delivery tended to be older in group B 
      (P=0.054). No differences in birthweight or intrauterine growth restriction were 
      observed. Adverse effects were sporadically reported. CONCLUSION: Among women 
      with URSA, heparin combined with aspirin increased the live birth rate as 
      compared with aspirin alone. There was a beneficial tendency of taking 
      aspirin-only to prolong gestation week.
CI  - © 2020 International Federation of Gynecology and Obstetrics.
FAU - Li, Jie
AU  - Li J
AD  - Department of Gynecology and Obstetrics, Tianjin Medical University General 
      Hospital, Tianjin, PR China.
FAU - Gao, Yue-Hua
AU  - Gao YH
AD  - Department of Gynecology and Obstetrics, Tianjin Medical University General 
      Hospital, Tianjin, PR China.
FAU - Xu, Lin
AU  - Xu L
AD  - Department of Gynecology and Obstetrics, Anyi People's hospital, Nanchang, PR 
      China.
FAU - Li, Zeng-Yan
AU  - Li ZY
AD  - Department of Gynecology and Obstetrics, Tianjin Medical University General 
      Hospital, Tianjin, PR China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200704
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*prevention & control
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Gestational Age
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Live Birth
MH  - Pregnancy
OTO - NOTNLM
OT  - Aspirin
OT  - Heparin combined with aspirin
OT  - Meta-analysis
OT  - Pregnancy failure
OT  - Repeated abortion
OT  - Repeated fetal loss
OT  - Treatment
OT  - Unexplained recurrent spontaneous abortion
EDAT- 2020/06/15 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/06/15 06:00
PHST- 2019/12/08 00:00 [received]
PHST- 2020/04/23 00:00 [revised]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
PHST- 2020/06/15 06:00 [entrez]
AID - 10.1002/ijgo.13266 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2020 Oct;151(1):23-32. doi: 10.1002/ijgo.13266. Epub 2020 
      Jul 4.

PMID- 30583437
OWN - NLM
STAT- MEDLINE
DCOM- 20190211
LR  - 20190215
IS  - 1873-7072 (Electronic)
IS  - 0308-8146 (Linking)
VI  - 278
DP  - 2019 Apr 25
TI  - Quantitative determination of carbasalate calcium derived metabolites, 
      acetylsalicylic acid and salicylic acid, in six animal foods using liquid-liquid 
      extraction method coupled with liquid chromatography-tandem mass spectrometry.
PG  - 744-750
LID - S0308-8146(18)32063-6 [pii]
LID - 10.1016/j.foodchem.2018.11.118 [doi]
AB  - This work describes a simple screening protocol for quantification of carbasalate 
      calcium derived metabolites, acetylsalicylic acid (ASA) and salicylic acid (SA), 
      in animal and aquatic food matrices using liquid chromatography-tandem mass 
      spectrometry (LC-MS/MS). The analytes were extracted from porcine muscle, milk, 
      egg, shrimp, eel, and flatfish using acetonitrile, with the addition of formic 
      acid as well as trifluoroacetic acid, followed by liquid-liquid purification with 
      saturated n-hexane. A reverse-phase analytical column was employed with a mobile 
      phase comprising (A) 1 mM ammonium acetate in distilled water and (B) methanol to 
      achieve the best chromatographic separation. Matrix-matched calibration curves 
      (R(2) ≥ 0.9817) were constructed using six concentrations of 5, 10, 20, 30, 40, 
      and 50 µg/kg in porcine muscle, milk, egg, shrimp, eel, and flatfish matrices. 
      The calculated limits of quantification (LOQ) were 10 and 7 µg/kg, for ASA and 
      SA, respectively. Recoveries of 67 to 102% with relative standard deviations 
      (RSDs) of ≤9.0% (intra-day and inter-day) were obtained for all matrices at four 
      spiking concentrations (5, 10, 20, and 50 µg/kg). The method was feasibly applied 
      for monitoring market samples. In conclusion, the developed method is versatile, 
      accurate, and precise for detecting and quantifying acetylsalicylic acid and 
      salicylic acid residues in animal-derived foods meant for human consumption.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Zheng, Weijia
AU  - Zheng W
AD  - Department of Veterinary Pharmacology and Toxicology, College of Veterinary 
      Medicine, Konkuk University, Seoul 143-701, Republic of Korea.
FAU - Yoo, Kyung-Hee
AU  - Yoo KH
AD  - Department of Veterinary Pharmacology and Toxicology, College of Veterinary 
      Medicine, Konkuk University, Seoul 143-701, Republic of Korea.
FAU - Abd El-Aty, A M
AU  - Abd El-Aty AM
AD  - Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, 
      12211 Giza, Egypt; Department of Medical Pharmacology, Medical Faculty, Ataturk 
      University, 25240 Erzurum, Turkey. Electronic address: abdelaty44@hotmail.com.
FAU - Park, Da-Hee
AU  - Park DH
AD  - Department of Veterinary Pharmacology and Toxicology, College of Veterinary 
      Medicine, Konkuk University, Seoul 143-701, Republic of Korea.
FAU - Choi, Jeong-Min
AU  - Choi JM
AD  - Department of Veterinary Pharmacology and Toxicology, College of Veterinary 
      Medicine, Konkuk University, Seoul 143-701, Republic of Korea.
FAU - Kim, Seong-Kwan
AU  - Kim SK
AD  - Department of Veterinary Pharmacology and Toxicology, College of Veterinary 
      Medicine, Konkuk University, Seoul 143-701, Republic of Korea.
FAU - Kang, Young-Sun
AU  - Kang YS
AD  - Department of Veterinary Pharmacology and Toxicology, College of Veterinary 
      Medicine, Konkuk University, Seoul 143-701, Republic of Korea; Department of 
      Biomedical Science and Technology, Konkuk University, Seoul 143-701, Republic of 
      Korea.
FAU - Zhang, Hongxia
AU  - Zhang H
AD  - State Key Laboratory of Biobased Material and Green Papermaking, College of Food 
      Science and Engineering, Qilu University of Technology, Shandong Academy of 
      Science, P.O. Box 250353, Jinan, Shandong, China.
FAU - Hacımüftüoğlu, Ahmet
AU  - Hacımüftüoğlu A
AD  - Department of Medical Pharmacology, Medical Faculty, Ataturk University, 25240 
      Erzurum, Turkey.
FAU - Bekhit, Alaa El-Din
AU  - Bekhit AE
AD  - Department of Food Science, University of Otago, PO Box 56, Dunedin, New Zealand.
FAU - Wang, Jing
AU  - Wang J
AD  - Key Laboratory of Agro-Product Quality and Safety, Institute of Quality Standard 
      and Testing Technology for Agro-Product, Chinese Academy of Agricultural 
      Sciences, 100081 Beijing, PR China.
FAU - Shim, Jae-Han
AU  - Shim JH
AD  - Natural Products Chemistry Laboratory, College of Agriculture and Life Sciences, 
      Chonnam National University, 300 Yongbong-dong, Buk-gu, Gwangju 500-757, Republic 
      of Korea.
FAU - Shin, Ho-Chul
AU  - Shin HC
AD  - Department of Veterinary Pharmacology and Toxicology, College of Veterinary 
      Medicine, Konkuk University, Seoul 143-701, Republic of Korea. Electronic 
      address: hshin@konkuk.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20181130
PL  - England
TA  - Food Chem
JT  - Food chemistry
JID - 7702639
RN  - 0 (Acetonitriles)
RN  - 8W8T17847W (Urea)
RN  - N667F17JP1 (carbaspirin calcium)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - Z072SB282N (acetonitrile)
SB  - IM
MH  - Acetonitriles/chemistry
MH  - Animal Feed/analysis
MH  - Animals
MH  - Aspirin/analogs & derivatives/*analysis/metabolism
MH  - Chromatography, Liquid/methods
MH  - Food Analysis/*methods
MH  - Food Contamination/analysis
MH  - Limit of Detection
MH  - Liquid-Liquid Extraction
MH  - Milk/chemistry
MH  - Red Meat/analysis
MH  - Salicylic Acid/*analysis/metabolism
MH  - Seafood/analysis
MH  - Swine
MH  - Tandem Mass Spectrometry/methods
MH  - Urea/analogs & derivatives/metabolism
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Animal-derived foods
OT  - Carbasalate calcium
OT  - Liquid chromatography-tandem mass spectrometry
OT  - Residue
OT  - Salicylic acid
EDAT- 2018/12/26 06:00
MHDA- 2019/02/12 06:00
CRDT- 2018/12/26 06:00
PHST- 2018/08/09 00:00 [received]
PHST- 2018/11/20 00:00 [revised]
PHST- 2018/11/21 00:00 [accepted]
PHST- 2018/12/26 06:00 [entrez]
PHST- 2018/12/26 06:00 [pubmed]
PHST- 2019/02/12 06:00 [medline]
AID - S0308-8146(18)32063-6 [pii]
AID - 10.1016/j.foodchem.2018.11.118 [doi]
PST - ppublish
SO  - Food Chem. 2019 Apr 25;278:744-750. doi: 10.1016/j.foodchem.2018.11.118. Epub 
      2018 Nov 30.

PMID- 11422094
OWN - NLM
STAT- MEDLINE
DCOM- 20010823
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 21
IP  - 2
DP  - 2001 Mar
TI  - A comparative study of oral acetylsalicyclic acid and metoprolol for the 
      prophylactic treatment of migraine. A randomized, controlled, double-blind, 
      parallel group phase III study.
PG  - 120-8
AB  - This study was a multinational, multicentre, double-blind, active controlled 
      phase III trial designed to investigate efficacy and safety of 300 mg 
      acetylsalicyclic acid (ASA) (n = 135) vs. 200 mg metoprolol (n = 135) in the 
      prophylaxis of migraine. In total 270 (51 male and 219 female) patients, aged 
      18-65 years, suffering between two and six migraine attacks per month were 
      recruited. The main objective was to show equivalence with respect to efficacy, 
      defined as a 50% reduction in the rate of migraine attacks. A run-in phase was 
      carried out with placebo for 4 weeks, followed by a 16-week drug phase. In both 
      treatment groups the median frequency of migraine attacks improved during the 
      study period, from three to two in the ASA group and from three to one in the 
      metoprolol group; 45.2% of all metoprolol patients were responders compared with 
      29.6% with ASA. Medication-related adverse events were less frequent in the ASA 
      group (37) than in the metoprolol group (73). The findings from this trial show 
      that metoprolol is superior to ASA for migraine prophylaxis but has more 
      side-effects. Acetylsalicylic acid is better tolerated than metoprolol. Using a 
      strict responder criterion ASA showed a responder rate comparable with the 
      placebo rate in the literature.
FAU - Diener, H C
AU  - Diener HC
AD  - Department of Neurology, University of Essen, Hufelandstr. 55, 45122 Essen, 
      Germany. h.diener@uni-essen.de
FAU - Hartung, E
AU  - Hartung E
FAU - Chrubasik, J
AU  - Chrubasik J
FAU - Evers, S
AU  - Evers S
FAU - Schoenen, J
AU  - Schoenen J
FAU - Eikermann, A
AU  - Eikermann A
FAU - Latta, G
AU  - Latta G
FAU - Hauke, W
AU  - Hauke W
CN  - Study Group
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - GEB06NHM23 (Metoprolol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Metoprolol/*administration & dosage/adverse effects
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Treatment Outcome
EDAT- 2001/06/26 10:00
MHDA- 2001/08/24 10:01
CRDT- 2001/06/26 10:00
PHST- 2001/06/26 10:00 [pubmed]
PHST- 2001/08/24 10:01 [medline]
PHST- 2001/06/26 10:00 [entrez]
AID - cha168 [pii]
AID - 10.1046/j.1468-2982.2001.00168.x [doi]
PST - ppublish
SO  - Cephalalgia. 2001 Mar;21(2):120-8. doi: 10.1046/j.1468-2982.2001.00168.x.

PMID- 11239227
OWN - NLM
STAT- MEDLINE
DCOM- 20010419
LR  - 20190727
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 41
IP  - 2
DP  - 2001 Feb
TI  - Effects of three Hb-based oxygen-carrying solutions on neutrophil activation in 
      vitro: quantitative measurement of the expression of adherence receptors.
PG  - 226-31
AB  - BACKGROUND: Hb-based oxygen carriers (HbOCs) are currently under investigation as 
      RBC substitutes. These solutions have vasoactive properties and may modify the 
      behavior of the RBC in vitro. The effects of these agents on other blood cells 
      have not been extensively investigated. The aim of this study was to evaluate the 
      potential effect(s) of three differently modified HbOCs on the activation of 
      PMNs. STUDY DESIGN AND METHODS: Whole blood from humans was incubated with Hb 
      dextran-benzene-tetracarboxylate, alphaalpha-Hb, or o-raffinose-poly-Hb for 15, 
      30, and 60 minutes. The expression of adherence receptors CD62L, CD18, and CD11b, 
      which reflects the activation state of the neutrophils, was assessed in vitro by 
      a direct immunofluorescence method using calibration beads measured by flow 
      cytometry. RESULTS: The observed expression of each of the three adherence 
      receptors for each solution at each time point was similar to that noted with the 
      RPMI control. Decreases in CD62L and increases in CD18 expression were noted at 
      15 minutes of incubation but, when those values were compared to the values 
      obtained with TNFalpha as the positive control of PMN activation, the profile of 
      expression of adherence receptors obtained with HbOC solutions did not conform to 
      the expected activation profile of PMNs. CONCLUSION: Hb solutions modified by a 
      variety of methods, as obtained and employed in this study, did not appear to 
      activate neutrophils in vitro.
FAU - Toussaint, M
AU  - Toussaint M
AD  - Department of Hematology and Physiology, Faculty of Pharmacy, Université de 
      Nancy, France. marie.toussaint@pharma.u-nancy.fr
FAU - Latger-Cannard, V
AU  - Latger-Cannard V
FAU - Caron, A
AU  - Caron A
FAU - Lecompte, T
AU  - Lecompte T
FAU - Stoltz, J F
AU  - Stoltz JF
FAU - Vigneron, C
AU  - Vigneron C
FAU - Menu, P
AU  - Menu P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Blood Substitutes)
RN  - 0 (Carrier Proteins)
RN  - 0 (Dextrans)
RN  - 0 (Hemoglobins)
RN  - 0 (Integrins)
RN  - 0 (O-raffinose cross-linked human hemoglobin)
RN  - 0 (Solutions)
RN  - 0 (hemoglobin-dextran 10-benzene-tetracarboxylate)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - N5O3QU595M (Raffinose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Blood Substitutes/*pharmacology
MH  - Carrier Proteins/*pharmacology
MH  - Dextrans/*pharmacology
MH  - Hemoglobins/*pharmacology
MH  - Humans
MH  - Integrins/biosynthesis
MH  - Leukocyte Count
MH  - Middle Aged
MH  - Neutrophil Activation/*drug effects
MH  - Raffinose/*analogs & derivatives/*pharmacology
MH  - Solutions/*pharmacology
MH  - Time Factors
EDAT- 2001/03/10 10:00
MHDA- 2001/04/21 10:01
CRDT- 2001/03/10 10:00
PHST- 2001/03/10 10:00 [pubmed]
PHST- 2001/04/21 10:01 [medline]
PHST- 2001/03/10 10:00 [entrez]
AID - 10.1046/j.1537-2995.2001.41020226.x [doi]
PST - ppublish
SO  - Transfusion. 2001 Feb;41(2):226-31. doi: 10.1046/j.1537-2995.2001.41020226.x.

PMID- 14512099
OWN - NLM
STAT- MEDLINE
DCOM- 20040824
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 477
IP  - 1
DP  - 2003 Sep 5
TI  - Nitric oxide-releasing aspirin inhibits vasoconstriction in perfused tail artery 
      of normotensive and spontaneously hypertensive rats.
PG  - 59-68
AB  - The aim of this study was to investigate the capacity of the 2-(acetyloxy)benzoic 
      acid 3-(nitrooxymethyl)phenyl ester (NCX 4016), a nitric oxide (NO)-releaser 
      derivative of aspirin, to decrease blood pressure in spontaneously hypertensive 
      rats (SHR) and to counteract the adrenergic vasoconstriction in perfused tail 
      artery of these animals. Oral treatment for 10 consecutive days with NCX 4016 
      (100 micromol/kg) in SHR and their genetic controls Wistar Kyoto (WKY) rats 
      resulted in a reduction of blood pressure in SHR but not in WKY rats. In SHR, the 
      NCX 4016 treatment increased the serum nitrite/nitrate and diminished the serum 
      thromboxane B2, whereas aspirin did not change blood pressure but abolished the 
      serum thromboxane B2. Perfused tail arteries excised from vehicle-treated SHR 
      exhibited a significant impairment of endothelium-dependent vasorelaxant 
      function. These vessels, prepared from SHR or WKY rats treated orally with NCX 
      4016 (10, 30 and 100 micromol/kg for 7 consecutive days), revealed a 
      dose-dependent decrease in vasoconstriction in response to transmural nerve 
      stimulation and norepinephrine, whereas aspirin was ineffective. Furthermore, in 
      tail arteries of both SHR and WKY rats treated orally with NCX 4016 (100 
      micromol/kg for 7 consecutive days), the cGMP increased significantly. In 
      conclusion, NCX 4016, by releasing NO and increasing cGMP in vascular tissue, 
      reduces sympathetic-mediated vasoconstriction in resistance vessels and lowers 
      blood pressure in SHR.
FAU - Rossoni, Giuseppe
AU  - Rossoni G
AD  - Department of Pharmacological Sciences, University of Milan, Milan, Italy. 
      giuseppe.rossoni@unimi.it
FAU - Manfredi, Barbara
AU  - Manfredi B
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Polvani, Gianluca
AU  - Polvani G
FAU - Berti, Ferruccio
AU  - Berti F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Nitrites)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EH04H13L6B (nitroaspirin)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteries/drug effects/metabolism/physiology
MH  - Aspirin/administration & dosage/analogs & derivatives/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Cyclic GMP/metabolism
MH  - Dose-Response Relationship, Drug
MH  - In Vitro Techniques
MH  - Nitrates/blood
MH  - Nitric Oxide Donors/*pharmacology
MH  - Nitrites/blood
MH  - Perfusion
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Rats, Inbred WKY
MH  - Tail/blood supply
MH  - Thromboxane B2/blood
MH  - Time Factors
MH  - Vasoconstriction/*drug effects
EDAT- 2003/09/27 05:00
MHDA- 2004/08/25 05:00
CRDT- 2003/09/27 05:00
PHST- 2003/09/27 05:00 [pubmed]
PHST- 2004/08/25 05:00 [medline]
PHST- 2003/09/27 05:00 [entrez]
AID - S0014299903021988 [pii]
AID - 10.1016/j.ejphar.2003.08.004 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2003 Sep 5;477(1):59-68. doi: 10.1016/j.ejphar.2003.08.004.

PMID- 9262298
OWN - NLM
STAT- MEDLINE
DCOM- 19970926
LR  - 20190512
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 12
IP  - 7
DP  - 1997 Jul
TI  - Low-dose aspirin in prevention of miscarriage in women with unexplained or 
      autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane 
      A2 production.
PG  - 1567-72
AB  - Early pregnancies in women with a history of recurrent spontaneous abortion (RSA) 
      are accompanied by a deficiency in vasodilatory and anti-aggregatory prostacyclin 
      (PGI2) and/or overproduction of its endogenous antagonist thromboxane A2 (TXA2). 
      We evaluated the effect of a low-dose aspirin (LDA) on PGI2 and TXA2 production 
      and on pregnancy outcome in RSA women with and without detectable anticardiolipin 
      antibodies (ACA). Of 82 RSA women studied, 66 became pregnant, and of them, 33 
      (six with elevated and 27 with normal ACA concentrations) were randomized to 
      receive LDA (50 mg/day) and 33 (six with elevated and 27 with normal ACA 
      concentrations) to receive placebo (PLA) from a mean of 6.6 days after the missed 
      period to delivery. Treatment with LDA inhibited platelet TXA2 production 
      similarly in RSA women with and without detectable ACA and with continuing 
      pregnancies (7.0 +/- 0.7 ng/ml, LDA group versus 254.5 +/- 37.8 ng/ml, PLA group, 
      mean +/- SEM, P < 0.0001) or miscarrying pregnancies (13.8 +/- 3.8 ng/ml compared 
      with 233.6 +/- 59.8 ng/ml, P < 0.0001 respectively). Furthermore, LDA decreased 
      urinary excretion of the TXA2 metabolite (2,3-dinor-TXB2) both in pregnancies 
      which went to term (6.1 +/- 0.6 ng/mmol creatinine, LDA group versus 19.3 +/- 3.0 
      ng/mmol creatinine, PLA group, P < 0.0001) or again ended in miscarriage (4.7 +/- 
      0.8 ng/mmol creatinine versus 17.3 +/- 4.4 ng/mmol creatinine, P < 0.0001 
      respectively), but did not affect the excretion of the prostacyclin metabolite 
      (2,3-dinor-6-keto-PGF1alpha). Early pregnancy ultrasound examination revealed a 
      living fetus in 58 women. Of these, seven in the LDA group (23.3%, four with 
      elevated and three with normal ACA concentrations) and five in the PLA group 
      (17.9%, two with elevated and three with normal ACA concentrations; not 
      significant) experienced a miscarriage. All infants were healthy, and the 
      frequency of growth retardation was similar in both groups (13.0%). One woman in 
      the LDA group (4.3%) and three women receiving PLA (13.0%) developed 
      pre-eclampsia (not significant). Therefore, although treatment with LDA caused a 
      desirable biochemical effect, it did not improve pregnancy outcome in RSA women 
      with or without detectable ACA.
FAU - Tulppala, M
AU  - Tulppala M
AD  - Department of Obstetrics and Gynaecology, University Central Hospital of 
      Helsinki, Finland.
FAU - Marttunen, M
AU  - Marttunen M
FAU - Söderstrom-Anttila, V
AU  - Söderstrom-Anttila V
FAU - Foudila, T
AU  - Foudila T
FAU - Ailus, K
AU  - Ailus K
FAU - Palosuo, T
AU  - Palosuo T
FAU - Ylikorkala, O
AU  - Ylikorkala O
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 63250-09-9 (2,3-dinor-thromboxane B2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*immunology/*prevention & control
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - *Autoimmune Diseases
MH  - Blood Platelets/metabolism
MH  - Epoprostenol/*biosynthesis
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Thromboxane A2/*biosynthesis
MH  - Thromboxane B2/analogs & derivatives/biosynthesis/urine
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - 10.1093/humrep/12.7.1567 [doi]
PST - ppublish
SO  - Hum Reprod. 1997 Jul;12(7):1567-72. doi: 10.1093/humrep/12.7.1567.

PMID- 25037988
OWN - NLM
STAT- MEDLINE
DCOM- 20150219
LR  - 20220331
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 384
IP  - 9954
DP  - 2014 Nov 1
TI  - Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation 
      (ARCTIC-Interruption): a randomised trial.
PG  - 1577-85
LID - S0140-6736(14)60612-7 [pii]
LID - 10.1016/S0140-6736(14)60612-7 [doi]
AB  - BACKGROUND: Optimum duration of dual antiplatelet treatment (DAPT) after coronary 
      stenting remains uncertain, with an unknown efficacy to safety ratio of extended 
      treatment leading to discrepancies between international guidelines and clinical 
      practice. We assessed whether DAPT continuation beyond 1 year after coronary 
      stenting is beneficial. METHODS: This analysis was a planned extension of the 
      previously published ARCTIC-Monitoring trial, in which we randomly allocated 2440 
      patients to a strategy of platelet function testing with antiplatelet treatment 
      adjustment or a conventional strategy after coronary stenting with drug-eluting 
      stent (DES). We recruited patients (aged 18 years or older) scheduled for planned 
      DES implantation at 38 centres in France. After 1 year of follow-up, patients 
      without contraindication to interruption of DAPT were eligible for a second 
      randomisation to this second phase of the study (ARCTIC-Interruption). Using a 
      computer-generated randomisation sequence (1:1; stratified by centre), we 
      allocated patients to a strategy of interruption of DAPT where the thienopyridine 
      was interrupted and single aspirin antiplatelet treatment was maintained 
      (interruption group) or a strategy of DAPT continuation for 6-18 months 
      (continuation group). The primary endpoint was the composite of death, myocardial 
      infarction, stent thrombosis, stroke, or urgent revascularisation, analysed by 
      intention to treat. This trial is registered with ClinicalTrials.gov, number 
      NCT00827411. FINDINGS: Between Jan 4, 2011, and March 3, 2012, 1259 eligible 
      patients were randomly allocated to treatment in ARCTIC-Interruption: 624 to the 
      interruption group and 635 to the continuation group. After a median follow-up of 
      17 months (IQR 15-18), the primary endpoint occurred in 27 (4%) patients in the 
      interruption group and 24 (4%) patients in the continuation group (hazard ratio 
      [HR] 1·17 [95% CI 0·68-2·03]; p=0·58). STEEPLE major bleeding events occurred 
      more often in the continuation group (seven [1%] patients) compared with the 
      interruption group (one [<0·5%] patient; HR 0·15 [0·02-1·20]; p=0·073). Major or 
      minor bleedings were also more common in the continuation group compared with the 
      interruption group (12 [2%] patients vs three [1%] patients; HR 0·26 [0·07-0·91]; 
      p=0·04). INTERPRETATION: Our finding suggests no apparent benefit but instead 
      harm with extension of DAPT beyond 1 year after stenting with DES when no event 
      has occurred within the first year after stenting. No conclusion can be drawn for 
      high-risk patients who could not be randomised. The consistency between findings 
      from all trials of such interruption suggests the need for a reappraisal of 
      guidelines for DAPT after coronary stenting towards shorter duration of 
      treatment. FUNDING: Allies in Cardiovascular Trials Initiatives and Organized 
      Networks (ACTION Study Group), Fondation de France, Sanofi-Aventis, Cordis, 
      Medtronic, Boston Scientific, Fondation SGAM.
CI  - Copyright © 2014 Elsevier Ltd. All rights reserved.
FAU - Collet, Jean-Philippe
AU  - Collet JP
AD  - ACTION Study Group, Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), 
      Université Paris 6, INSERM, Paris, France.
FAU - Silvain, Johanne
AU  - Silvain J
AD  - ACTION Study Group, Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), 
      Université Paris 6, INSERM, Paris, France.
FAU - Barthélémy, Olivier
AU  - Barthélémy O
AD  - ACTION Study Group, Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), 
      Université Paris 6, INSERM, Paris, France.
FAU - Rangé, Grégoire
AU  - Rangé G
AD  - Les Hôpitaux de Chartres, Le Coudray, France.
FAU - Cayla, Guillaume
AU  - Cayla G
AD  - ACTION Study Group, Cardiologie, CHU Carémeau, Nîmes, France.
FAU - Van Belle, Eric
AU  - Van Belle E
AD  - CHRU de Lille, Lille, France.
FAU - Cuisset, Thomas
AU  - Cuisset T
AD  - Département de Cardiologie, CHU La Timone, Marseille, France.
FAU - Elhadad, Simon
AU  - Elhadad S
AD  - Cardiologie, CH de Lagny-Marne-la-Vallée, Lagny-sur-Marne, France.
FAU - Schiele, François
AU  - Schiele F
AD  - CHU Jean Minjoz, Besançon, France.
FAU - Lhoest, Nicolas
AU  - Lhoest N
AD  - GH du Centre Alsace, France.
FAU - Ohlmann, Patrick
AU  - Ohlmann P
AD  - CHR Strasbourg, France.
FAU - Carrié, Didier
AU  - Carrié D
AD  - CHU Rangueil, Toulouse, France.
FAU - Rousseau, Hélène
AU  - Rousseau H
AD  - CHRU de Lille, Lille, France; ACTION Study Group, Unité de Recherche 
      Clinique-Hôpital Lariboisière (APHP), and Université Denis Diderot, Paris, 
      France.
FAU - Aubry, Pierre
AU  - Aubry P
AD  - Centre Hospitalier Bichat (APHP), Paris, France.
FAU - Monségu, Jacques
AU  - Monségu J
AD  - Institut Mutualiste Montsouris, Paris, France.
FAU - Sabouret, Pierre
AU  - Sabouret P
AD  - ACTION Study Group, Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), 
      Université Paris 6, INSERM, Paris, France.
FAU - O'Connor, Stephen A
AU  - O'Connor SA
AD  - ACTION Study Group, Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), 
      Université Paris 6, INSERM, Paris, France.
FAU - Abtan, Jérémie
AU  - Abtan J
AD  - ACTION Study Group, Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), 
      Université Paris 6, INSERM, Paris, France.
FAU - Kerneis, Mathieu
AU  - Kerneis M
AD  - ACTION Study Group, Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), 
      Université Paris 6, INSERM, Paris, France.
FAU - Saint-Etienne, Christophe
AU  - Saint-Etienne C
AD  - CHU Trousseau, Tours, France.
FAU - Beygui, Farzin
AU  - Beygui F
AD  - ACTION study Group, CHU Caen, France.
FAU - Vicaut, Eric
AU  - Vicaut E
AD  - ACTION Study Group, Unité de Recherche Clinique-Hôpital Lariboisière (APHP), and 
      Université Denis Diderot, Paris, France.
FAU - Montalescot, Gilles
AU  - Montalescot G
AD  - ACTION Study Group, Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), 
      Université Paris 6, INSERM, Paris, France. Electronic address: 
      gilles.montalescot@psl.aphp.fr.
CN  - ARCTIC investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00827411
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140715
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2014 Nov 1;384(9954):1553-5. PMID: 25037991
CIN - Nat Rev Cardiol. 2014 Oct;11(10):556. PMID: 25093435
CIN - Dtsch Med Wochenschr. 2015 Feb;140(4):234. PMID: 25704513
CIN - Lancet. 2015 Jan 24;385(9965):325-6. PMID: 25706844
CIN - Lancet. 2015 Jan 24;385(9965):326. PMID: 25706845
CIN - Lancet. 2015 Jan 24;385(9965):326. PMID: 25706846
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Coronary Artery Disease/*therapy
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Platelet Function Tests/methods
MH  - Prospective Studies
MH  - Pyridines/administration & dosage/adverse effects/therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2014/07/20 06:00
MHDA- 2015/02/20 06:00
CRDT- 2014/07/20 06:00
PHST- 2014/07/20 06:00 [entrez]
PHST- 2014/07/20 06:00 [pubmed]
PHST- 2015/02/20 06:00 [medline]
AID - S0140-6736(14)60612-7 [pii]
AID - 10.1016/S0140-6736(14)60612-7 [doi]
PST - ppublish
SO  - Lancet. 2014 Nov 1;384(9954):1577-85. doi: 10.1016/S0140-6736(14)60612-7. Epub 
      2014 Jul 15.

PMID- 14671242
OWN - NLM
STAT- MEDLINE
DCOM- 20040126
LR  - 20161122
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 35
IP  - 1
DP  - 2004 Jan
TI  - Antiplatelet effect of aspirin in patients with cerebrovascular disease.
PG  - 175-8
AB  - BACKGROUND AND PURPOSE: Aspirin is used commonly to prevent ischemic strokes and 
      other vascular events. Although aspirin is considered safe and effective, it has 
      limited efficacy with a relative risk reduction of 20% to 25% for ischemic 
      stroke. We sought to determine if aspirin as currently used is having its desired 
      antiplatelet effects. METHODS: We ascertained patients with cerebrovascular 
      disease who were taking only aspirin as an antiplatelet agent. Platelet function 
      was evaluated using a platelet function analyzer (PFA-100). PFA test results were 
      correlated with aspirin dose, formulation, and basic demographic factors. 
      RESULTS: We ascertained 129 patients, of whom 32% were taking an enteric-coated 
      aspirin preparation and 32% were taking low-dose (< or =162 mg/d) aspirin. For 
      the entire cohort, 37% of patients had normal PFA-100 results, indicating normal 
      platelet function. For the patients taking low-dose aspirin, 56% had normal PFAs 
      compared with 28% of those taking > or =325 mg/d of aspirin, while 65% of 
      patients taking enteric-coated aspirin had normal PFAs compared with 25% taking 
      an uncoated preparation (P<0.01 for both comparisons). Similar results were 
      obtained if PFA results were analyzed using mean closure times (low-dose aspirin, 
      183 sec; high-dose aspirin, 233 sec; enteric-coated, 173 sec; uncoated, 235 sec; 
      P<0.01 for comparisons). Older patients and women were less likely to have a 
      therapeutic response to aspirin, independent of aspirin dose or formulation. 
      CONCLUSIONS: A significant proportion of patients taking low-dose aspirin or 
      enteric-coated aspirin have normal platelet function as measured by the PFA-100 
      test. If these results correlate with clinical events, they have broad 
      implications in determining how aspirin is used and monitored.
FAU - Alberts, Mark J
AU  - Alberts MJ
AD  - Department of Neurology, Feinberg School of Medicine, Northwestern University 
      Medical School, Chicago, Ill 60611, USA. m-alberts@northwestern.edu
FAU - Bergman, Deborah L
AU  - Bergman DL
FAU - Molner, Elise
AU  - Molner E
FAU - Jovanovic, Borko D
AU  - Jovanovic BD
FAU - Ushiwata, Issei
AU  - Ushiwata I
FAU - Teruya, Jun
AU  - Teruya J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20031211
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 2004 Jun;35(6):e146-7; author reply e146-7. PMID: 15073394
CIN - Stroke. 2004 Jun;35(6):e144-5. PMID: 15073395
MH  - Age Factors
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Cerebrovascular Disorders/*drug therapy
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Inpatients
MH  - Ischemic Attack, Transient/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Outpatients
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Stroke/drug therapy
MH  - Tablets, Enteric-Coated/*pharmacology/therapeutic use
EDAT- 2003/12/13 05:00
MHDA- 2004/01/27 05:00
CRDT- 2003/12/13 05:00
PHST- 2003/12/13 05:00 [pubmed]
PHST- 2004/01/27 05:00 [medline]
PHST- 2003/12/13 05:00 [entrez]
AID - 01.STR.0000106763.46123.F6 [pii]
AID - 10.1161/01.STR.0000106763.46123.F6 [doi]
PST - ppublish
SO  - Stroke. 2004 Jan;35(1):175-8. doi: 10.1161/01.STR.0000106763.46123.F6. Epub 2003 
      Dec 11.

PMID- 32559114
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 17
IP  - 1
DP  - 2021 Jan
TI  - Mortality benefit in the COMPASS trial: is it related to superior statistical 
      power or better efficacy and safety?
PG  - 175-182
LID - 10.2217/fca-2020-0013 [doi]
AB  - Until recently, attempts to improve the benefit of aspirin by adding another 
      antithrombotic agent have not resulted in a mortality reduction in patients with 
      chronic symptomatic atherosclerosis. In this population, COMPASS is the only one 
      among six trials to show a significant mortality reduction, thereby providing 
      evidence of a clear net clinical benefit with the combination of low-dose 
      rivaroxaban plus aspirin. In this systematic review, we sought to determine 
      whether the mortality benefit of the combination arm in COMPASS is best explained 
      by greater statistical power or by a more favorable efficacy-safety profile than 
      the other regimens evaluated in patients with chronic symptomatic 
      atherosclerosis.
FAU - Shyamkumar, Krishnan
AU  - Shyamkumar K
AD  - Population Health Research Institute, Hamilton, ON L8L 2X2, Canada.
FAU - Hirsh, Jack
AU  - Hirsh J
AD  - Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.
FAU - Bhagirath, Vinai C
AU  - Bhagirath VC
AD  - Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.
AD  - Thrombosis & Atherosclerosis Research Institute, Hamilton, ON L8L 2X2, Canada.
FAU - Sinha, Smita
AU  - Sinha S
AD  - Population Health Research Institute, Hamilton, ON L8L 2X2, Canada.
AD  - University Hospitals Birmingham, Birmingham, UK.
FAU - Xu, Ke
AU  - Xu K
AD  - Population Health Research Institute, Hamilton, ON L8L 2X2, Canada.
AD  - Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, 
      Shanghai, China.
FAU - Ginsberg, Jeffrey S
AU  - Ginsberg JS
AD  - Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.
FAU - Díaz, Rafael
AU  - Díaz R
AD  - Estudios Clínicos Latinoamérica, Rosario, Argentina.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AD  - Population Health Research Institute, Hamilton, ON L8L 2X2, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.
AD  - Thrombosis & Atherosclerosis Research Institute, Hamilton, ON L8L 2X2, Canada.
FAU - Chan, Noel C
AU  - Chan NC
AD  - Population Health Research Institute, Hamilton, ON L8L 2X2, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.
AD  - Thrombosis & Atherosclerosis Research Institute, Hamilton, ON L8L 2X2, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200619
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Atherosclerosis/drug therapy
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Rivaroxaban
OTO - NOTNLM
OT  - anticoagulant
OT  - antiplatelet therapy
OT  - antithrombotic therapy
OT  - aspirin
OT  - atherosclerosis
OT  - low-dose rivaroxaban
OT  - mortality
OT  - myocardial infarction
OT  - stroke
EDAT- 2020/06/20 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.2217/fca-2020-0013 [doi]
PST - ppublish
SO  - Future Cardiol. 2021 Jan;17(1):175-182. doi: 10.2217/fca-2020-0013. Epub 2020 Jun 
      19.

PMID- 8419269
OWN - NLM
STAT- MEDLINE
DCOM- 19930211
LR  - 20131121
IS  - 0016-867X (Print)
IS  - 0016-867X (Linking)
VI  - 48
IP  - 1
DP  - 1993 Jan
TI  - The role of dipyridamole in the therapy of vascular disease.
PG  - 46, 51-3, 57-8
AB  - The antiplatelet agent dipyridamole is FDA-approved as an adjunct to warfarin for 
      the prevention of thromboembolism in patients receiving prosthetic heart values. 
      It is also prescribed in several other situations, although data supporting these 
      uses remain equivocal. Dipyridamole does not appear to be superior to aspirin 
      alone in the management of patients with cerebral or coronary artery disease nor 
      in maintaining the patency of autologous grafts. Its role in the management of 
      patients who fail aspirin or other antithrombotic therapy remains to be examined. 
      The drug may offer long-term advantages in the prevention of atherogenesis, but 
      this use also warrants future investigation.
FAU - Green, D
AU  - Green D
AD  - Rehabilitation Institute of Chicago, Northwestern University Medical School.
FAU - Miller, V
AU  - Miller V
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Geriatrics
JT  - Geriatrics
JID - 2985102R
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Coronary Artery Bypass
MH  - Dipyridamole/pharmacology/*therapeutic use
MH  - Graft Survival/*drug effects
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Recurrence
MH  - Vascular Diseases/*drug therapy
RF  - 39
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Geriatrics. 1993 Jan;48(1):46, 51-3, 57-8.

PMID- 17263358
OWN - NLM
STAT- MEDLINE
DCOM- 20070327
LR  - 20131121
IS  - 0003-2700 (Print)
IS  - 0003-2700 (Linking)
VI  - 79
IP  - 3
DP  - 2007 Feb 1
TI  - Grazing-angle fiber-optic fourier transform infrared reflection-absorption 
      spectroscopy for the in situ detection and quantification of two active 
      pharmaceutical ingredients on glass.
PG  - 1231-6
AB  - Fourier transform infrared reflection-absorption spectroscopy has been used with 
      a fiber-optic grazing-angle reflectance probe as a rapid, in situ method for 
      trace surface analysis of acetaminophen and aspirin at loadings of approximately 
      0-2 microg cm(-2) on glass. Partial least-squares multivariate regression permits 
      the loadings to be quantified, simultaneously, with root-mean-squared errors of 
      prediction of RMSEP approximately 0.1 microg cm(-2) for both compounds. The 
      detection limits are estimated to be LD approximately 0.2 microg cm(-2).
FAU - Perston, Benjamin B
AU  - Perston BB
AD  - Department of Chemistry, University of Canterbury, Christchurch, New Zealand.
FAU - Hamilton, Michelle L
AU  - Hamilton ML
FAU - Williamson, Bryce E
AU  - Williamson BE
FAU - Harland, Peter W
AU  - Harland PW
FAU - Thomson, Mary A
AU  - Thomson MA
FAU - Melling, Peter J
AU  - Melling PJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
RN  - 0 (Pharmaceutical Preparations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/analysis
MH  - Aspirin/analysis
MH  - Glass
MH  - Multivariate Analysis
MH  - Pharmaceutical Preparations/*analysis
MH  - Spectroscopy, Fourier Transform Infrared/*instrumentation/*methods
EDAT- 2007/02/01 09:00
MHDA- 2007/03/28 09:00
CRDT- 2007/02/01 09:00
PHST- 2007/02/01 09:00 [pubmed]
PHST- 2007/03/28 09:00 [medline]
PHST- 2007/02/01 09:00 [entrez]
AID - 10.1021/ac061660a [doi]
PST - ppublish
SO  - Anal Chem. 2007 Feb 1;79(3):1231-6. doi: 10.1021/ac061660a.

PMID- 15481570
OWN - NLM
STAT- MEDLINE
DCOM- 20041112
LR  - 20131121
IS  - 0028-2162 (Print)
IS  - 0028-2162 (Linking)
VI  - 148
IP  - 30
DP  - 2004 Jul 24
TI  - [Acetylsalicylic acid for the primary prevention of cardiovascular disease in 
      diabetic patients].
PG  - 1481-5
AB  - Large-scale trials have shown that primary prevention using acetylsalicylic acid 
      is useful in all patients with a cardiovascular risk exceeding 1.5% annually. In 
      these patients the benefits of prevention outweigh the risks of bleeding. Almost 
      all patients with diabetes mellitus are at high risk of developing cardiovascular 
      disease. Additionally, most diabetics have other cardiovascular risks besides 
      diabetes, providing further argument for prevention with acetylsalicylic acid. 
      Only very few prospective trials have confirmed that acetylsalicylic acid 
      treatment in patients with diabetes mellitus reduces their risk of cardiovascular 
      disease and myocardial infarction. Treatment with acetylsalicylic acid should be 
      considered in all patients with diabetes, especially in view of their decreased 
      survival after a cardiovascular event, myocardial infarction in particular. If 
      acetylsalicylic acid is contra-indicated treatment with clopidogrel is an 
      alternative.
FAU - de Lange, D W
AU  - de Lange DW
AD  - Universitair Medisch Centrum Utrecht, afd. Interne Geneeskunde, Heidelberglaan 
      100, 3584 CX Utrecht.
FAU - Fiets, W E
AU  - Fiets WE
FAU - Banga, J D
AU  - Banga JD
LA  - dut
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Acetylsalicylzuur bij patiëten met diabetes voor de primaire preventie van 
      cardiovasculaire aandoeningen.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ned Tijdschr Geneeskd. 2004 Oct 16;148(42):2097; author reply 2097-8. PMID: 
      15532335
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - *Diabetes Complications
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Primary Prevention
MH  - Risk Factors
RF  - 31
EDAT- 2004/10/16 09:00
MHDA- 2004/11/13 09:00
CRDT- 2004/10/16 09:00
PHST- 2004/10/16 09:00 [pubmed]
PHST- 2004/11/13 09:00 [medline]
PHST- 2004/10/16 09:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2004 Jul 24;148(30):1481-5.

PMID- 3903504
OWN - NLM
STAT- MEDLINE
DCOM- 19851216
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 313
IP  - 22
DP  - 1985 Nov 28
TI  - Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian 
      multicenter trial.
PG  - 1369-75
AB  - We performed a randomized, double-blind, placebo-controlled trial in 555 patients 
      with unstable angina who were hospitalized in coronary care units. Patients 
      received one of four possible treatment regimens: aspirin (325 mg four times 
      daily), sulfinpyrazone (200 mg four times daily), both, or neither. They were 
      entered into the trial within eight days of hospitalization and were treated and 
      followed for up to two years (mean, 18 months). The incidence of cardiac death 
      and nonfatal myocardial infarction, considered together, was 8.6 per cent in the 
      groups given aspirin and 17.0 per cent in the other groups, representing a risk 
      reduction with aspirin of 51 per cent (P = 0.008). The corresponding figures for 
      either cardiac death alone or death from any cause were 3.0 per cent in the 
      groups given aspirin and 11.7 per cent in the other groups, representing a risk 
      reduction of 71 per cent (P = 0.004). Analysis by intention to treat yielded 
      smaller risk reductions with aspirin of 30 per cent (P = 0.072), 56 per cent (P = 
      0.009), and 43 per cent (P = 0.035) for the outcomes of cardiac death or nonfatal 
      acute myocardial infarction, cardiac death alone, and all deaths, respectively. 
      There was no observed benefit of sulfinpyrazone for any outcome event, and there 
      was no evidence of an interaction between sulfinpyrazone and aspirin. Considered 
      together with the results of a previous clinical trial, these findings provide 
      strong evidence for a beneficial effect of aspirin in patients with unstable 
      angina.
FAU - Cairns, J A
AU  - Cairns JA
FAU - Gent, M
AU  - Gent M
FAU - Singer, J
AU  - Singer J
FAU - Finnie, K J
AU  - Finnie KJ
FAU - Froggatt, G M
AU  - Froggatt GM
FAU - Holder, D A
AU  - Holder DA
FAU - Jablonsky, G
AU  - Jablonsky G
FAU - Kostuk, W J
AU  - Kostuk WJ
FAU - Melendez, L J
AU  - Melendez LJ
FAU - Myers, M G
AU  - Myers MG
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Angina Pectoris/*drug therapy
MH  - Angina, Unstable/*drug therapy/mortality
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology
MH  - Patient Compliance
MH  - Random Allocation
MH  - Sulfinpyrazone/administration & dosage/adverse effects/*therapeutic use
EDAT- 1985/11/28 00:00
MHDA- 1985/11/28 00:01
CRDT- 1985/11/28 00:00
PHST- 1985/11/28 00:00 [pubmed]
PHST- 1985/11/28 00:01 [medline]
PHST- 1985/11/28 00:00 [entrez]
AID - 10.1056/NEJM198511283132201 [doi]
PST - ppublish
SO  - N Engl J Med. 1985 Nov 28;313(22):1369-75. doi: 10.1056/NEJM198511283132201.

PMID- 31474729
OWN - NLM
STAT- MEDLINE
DCOM- 20191024
LR  - 20191024
IS  - 1347-5223 (Electronic)
IS  - 0009-2363 (Linking)
VI  - 67
IP  - 9
DP  - 2019
TI  - Modification of Drug Crystallization by Cyclodextrins in Pre-formulation Study.
PG  - 915-920
LID - 10.1248/cpb.c18-00752 [doi]
AB  - Controlling drug crystallization is one of the important issues in 
      pre-formulation study. In recent years, advanced approaches including the use of 
      tailor-made additives have gathered considerable attention to control 
      crystallization behavior of drugs. This review focuses on the use of hydrophilic 
      cyclodextrins (CDs) as additives for controlling drug crystallization. CDs affect 
      the crystallization of drugs in solution and in solid state based on a host-guest 
      interaction. For example, 2,6-di-O-methyl-β-CD and 2-hydroxybutyl-β-CD suppressed 
      solution-mediated transition of drugs during crystallization by the host-guest 
      interaction; as a result, metastable forms selectively precipitated in solution. 
      The use of CDs in crystal engineering provided an opportunity for the detection 
      of a new polymorph by changing the crystallization pathway. It was also possible 
      to modify crystal morphology (i.e., crystal habit) by selective suppression of 
      crystal growth on a certain direction based on the host-gust interaction. For 
      solid formulation, stable amorphous drug/CDs complex under humid conditions was 
      prepared using two different CDs. An overview of some recent progress in the use 
      of CDs in crystal engineering and in amorphous formulation is described in this 
      review.
FAU - Iohara, Daisuke
AU  - Iohara D
AD  - Faculty of Pharmaceutical Sciences, Sojo University.
AD  - DDS Research Institute, Sojo University.
FAU - Anraku, Makoto
AU  - Anraku M
AD  - Faculty of Pharmaceutical Sciences, Sojo University.
AD  - DDS Research Institute, Sojo University.
FAU - Uekama, Kaneto
AU  - Uekama K
AD  - Faculty of Pharmaceutical Sciences, Sojo University.
FAU - Hirayama, Fumitoshi
AU  - Hirayama F
AD  - Faculty of Pharmaceutical Sciences, Sojo University.
AD  - DDS Research Institute, Sojo University.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (beta-Cyclodextrins)
RN  - QGC8W08I6I (Acetohexamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetohexamide/chemistry
MH  - Aspirin/chemistry
MH  - Crystallization
MH  - Drug Compounding
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Pharmaceutical Preparations/*chemistry
MH  - beta-Cyclodextrins/*chemistry
OTO - NOTNLM
OT  - amorphous
OT  - crystal habit
OT  - cyclodextrin (CD)
OT  - polymorph
OT  - solid state
OT  - solution-mediated transition
EDAT- 2019/09/03 06:00
MHDA- 2019/10/28 06:00
CRDT- 2019/09/03 06:00
PHST- 2019/09/03 06:00 [entrez]
PHST- 2019/09/03 06:00 [pubmed]
PHST- 2019/10/28 06:00 [medline]
AID - 10.1248/cpb.c18-00752 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 2019;67(9):915-920. doi: 10.1248/cpb.c18-00752.

PMID- 2594560
OWN - NLM
STAT- MEDLINE
DCOM- 19900125
LR  - 20161123
IS  - 0391-5387 (Print)
IS  - 0391-5387 (Linking)
VI  - 11
IP  - 3
DP  - 1989 May-Jun
TI  - [Benign intracranial hypertension during treatment with acetylsalicylic acid: 
      presentation of 2 cases in children].
PG  - 319-21
AB  - The authors report two cases of benign intracranial hypertension associated to 
      Aspirin therapy promptly regressed after withdrawal of the drug. This side effect 
      did never described and its pathogenetic mechanism is unknown.
FAU - Falcini, F
AU  - Falcini F
AD  - Dipartimento di Pediatria, Università degli Studi di Firenze, Italia.
FAU - Taccetti, G
AU  - Taccetti G
FAU - Montanelli, F
AU  - Montanelli F
FAU - Tafi, L
AU  - Tafi L
FAU - Volpi, M
AU  - Volpi M
LA  - ita
PT  - Case Reports
PT  - Journal Article
TT  - Ipertensione endocranica benigna in corso di terapia con acido acetilsalicilico: 
      segnalazione di due casi in età pediatrica.
PL  - Italy
TA  - Pediatr Med Chir
JT  - La Pediatria medica e chirurgica : Medical and surgical pediatrics
JID - 8100625
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Child
MH  - Humans
MH  - Male
MH  - Pseudotumor Cerebri/*chemically induced/diagnostic imaging
MH  - Radiography
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
PST - ppublish
SO  - Pediatr Med Chir. 1989 May-Jun;11(3):319-21.

PMID- 788748
OWN - NLM
STAT- MEDLINE
DCOM- 19770103
LR  - 20190509
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 3
IP  - 2
DP  - 1976 Apr
TI  - How double blind is double blind? And does it matter?
PG  - 331-2
AB  - In an apparently double blind crossover study, two experienced measurement 
      technicians were able to identify many of the treatment periods. They most often 
      correctly identified aspirin, a drug with prominent effects and side effects. It 
      is argued that in many circumstances it is better to use a blind observer who is 
      not concerned with the giving of treatment or the collection of side effects.
FAU - Huskisson, E C
AU  - Huskisson EC
FAU - Scott, J
AU  - Scott J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Evaluation/*methods
MH  - Humans
MH  - Placebos
MH  - Research Design
PMC - PMC1428878
EDAT- 1976/04/01 00:00
MHDA- 1976/04/01 00:01
CRDT- 1976/04/01 00:00
PHST- 1976/04/01 00:00 [pubmed]
PHST- 1976/04/01 00:01 [medline]
PHST- 1976/04/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1976.tb00612.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1976 Apr;3(2):331-2. doi: 
      10.1111/j.1365-2125.1976.tb00612.x.

PMID- 6726057
OWN - NLM
STAT- MEDLINE
DCOM- 19840629
LR  - 20131121
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 103
IP  - 6
DP  - 1984 Jun
TI  - Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug 
      interaction on platelet function.
PG  - 869-77
AB  - Salicylate can prevent the inhibitory effect of aspirin on platelet 
      cyclooxygenase activity. We investigated whether salicylate and aspirin interact 
      in platelets in humans at doses and plasma levels of clinical relevance. In our 
      first experiment in healthy volunteers, the lowest dose of intravenously 
      administered aspirin that suppressed arachidonate-induced platelet aggregation 
      and serum immunoreactive thromboxane B2 generation was 40 mg. In our second 
      experiment, volunteers given oral doses of sodium salicylate (250 or 1000 mg) had 
      peak plasma salicylate levels averaging 20 and 76 micrograms/ml, respectively. 
      Neither platelet aggregation or thromboxane B2 formation was modified by either 
      salicylate treatment. Forty minutes later, all six volunteers received 40 mg of 
      aspirin intravenously. Aspirin levels were not affected by previous salicylate 
      ingestion, but inhibition by aspirin of both platelet aggregation and thromboxane 
      B2 generation was significantly prevented by the higher salicylate dose. In our 
      last experiment, peak plasma levels of aspirin and salicylate were measured in 
      healthy volunteers after ingestion of either 320 mg of compressed or 800 mg of 
      enteric-coated aspirin. Salicylate levels averaged 19 and 51 micrograms/ml, 
      respectively, after the lower and higher doses of aspirin, whereas aspirin 
      averaged 3 micrograms/ml after either dose. Serum thromboxane B2 generation was 
      almost completely inhibited 1 hour after either aspirin dose.(ABSTRACT TRUNCATED 
      AT 250 WORDS)
FAU - Cerletti, C
AU  - Cerletti C
FAU - Bonati, M
AU  - Bonati M
FAU - del Maschio, A
AU  - del Maschio A
FAU - Galletti, F
AU  - Galletti F
FAU - Dejana, E
AU  - Dejana E
FAU - Tognoni, G
AU  - Tognoni G
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Salicylates)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Salicylates/blood
MH  - Sodium Salicylate/*pharmacology
MH  - Thromboxane B2/blood
MH  - Time Factors
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
PST - ppublish
SO  - J Lab Clin Med. 1984 Jun;103(6):869-77.

PMID- 35660296
OWN - NLM
STAT- MEDLINE
DCOM- 20220718
LR  - 20220916
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 80
IP  - 3
DP  - 2022 Jul 19
TI  - Association of Thromboxane Generation With Survival in Aspirin Users and 
      Nonusers.
PG  - 233-250
LID - S0735-1097(22)04928-2 [pii]
LID - 10.1016/j.jacc.2022.04.034 [doi]
AB  - BACKGROUND: Persistent systemic thromboxane generation, predominantly from 
      nonplatelet sources, in aspirin (ASA) users with cardiovascular disease (CVD) is 
      a mortality risk factor. OBJECTIVES: This study sought to determine the mortality 
      risk associated with systemic thromboxane generation in an unselected population 
      irrespective of ASA use. METHODS: Stable thromboxane B(2) metabolites (TXB(2)-M) 
      were measured by enzyme-linked immunosorbent assay in banked urine from 3,044 
      participants (mean age 66 ± 9 years, 53.8% women) in the Framingham Heart Study. 
      The association of TXB(2)-M to survival over a median observation period of 11.9 
      years (IQR: 10.6-12.7 years) was determined by multivariable modeling. RESULTS: 
      In 1,363 (44.8%) participants taking ASA at the index examination, median 
      TXB(2)-M were lower than in ASA nonusers (1,147 pg/mg creatinine vs 4,179 pg/mg 
      creatinine; P < 0.0001). TXB(2)-M were significantly associated with all-cause 
      and cardiovascular mortality irrespective of ASA use (HR: 1.96 and 2.41, 
      respectively; P < 0.0001 for both) for TXB(2)-M in the highest quartile based on 
      ASA use compared with lower quartiles, and remained significant after adjustment 
      for mortality risk factors for similarly aged individuals (HR: 1.49 and 1.82, 
      respectively; P ≤ 0.005 for both). In 2,353 participants without CVD, TXB(2)-M 
      were associated with cardiovascular mortality in ASA nonusers (adjusted HR: 3.04; 
      95% CI: 1.29-7.16) but not in ASA users, while ASA use was associated with 
      all-cause mortality in those with low (adjusted HR: 1.46; 95% CI: 1.14-1.87) but 
      not elevated TXB(2)-M. CONCLUSIONS: Systemic thromboxane generation is an 
      independent risk factor for all-cause and cardiovascular mortality irrespective 
      of ASA use, and its measurement may be useful for therapy modification, 
      particularly in those without CVD.
CI  - Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Rade, Jeffrey J
AU  - Rade JJ
AD  - University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA; 
      Johns Hopkins School of Medicine, Baltimore, Maryland, USA. Electronic address: 
      jeffrey.rade@umassmed.edu.
FAU - Barton, Bruce A
AU  - Barton BA
AD  - University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
FAU - Vasan, Ramachandran S
AU  - Vasan RS
AD  - Boston University School of Medicine, Boston, Massachusetts, USA.
FAU - Kronsberg, Shari S
AU  - Kronsberg SS
AD  - University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
FAU - Xanthakis, Vanessa
AU  - Xanthakis V
AD  - Boston University School of Medicine, Boston, Massachusetts, USA.
FAU - Keaney, John F Jr
AU  - Keaney JF Jr
AD  - University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA; 
      Boston University School of Medicine, Boston, Massachusetts, USA.
FAU - Hamburg, Naomi M
AU  - Hamburg NM
AD  - Boston University School of Medicine, Boston, Massachusetts, USA.
FAU - Kakouros, Nikolaos
AU  - Kakouros N
AD  - University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
FAU - Kickler, Thomas A
AU  - Kickler TA
AD  - Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
LA  - eng
PT  - Journal Article
DEP - 20220601
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2022 Jul 19;80(3):251-255. PMID: 35835497
MH  - Aged
MH  - *Aspirin/therapeutic use
MH  - *Cardiovascular Diseases
MH  - Creatinine
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Thromboxane B2
MH  - Thromboxanes/metabolism
OTO - NOTNLM
OT  - aspirin
OT  - isoprostane
OT  - mortality
OT  - platelets
OT  - thromboxane
COIS- Funding Support and Author Disclosures This study was supported by a grant from 
      American Heart Association (17GRNT3360007 to Dr Rade). The parent Framingham 
      Heart Study was supported by contracts NO1-HC-25195, HHSN268201500001I, and 
      75N92019D00031 from the National Heart, Lung, and Blood Institute. Dr Vasan is 
      supported in part by the Evans Medical Foundation and the Jay and Louis Coffman 
      Endowment from the Department of Medicine, Boston University School of Medicine. 
      The authors had sole control of the design of the study, collection, analyses, 
      and dissemination of the data. The authors have reported that they have no 
      relationships relevant to the contents of this paper to disclose.
EDAT- 2022/06/07 06:00
MHDA- 2022/07/19 06:00
CRDT- 2022/06/06 11:31
PHST- 2021/12/02 00:00 [received]
PHST- 2022/04/11 00:00 [revised]
PHST- 2022/04/12 00:00 [accepted]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/07/19 06:00 [medline]
PHST- 2022/06/06 11:31 [entrez]
AID - S0735-1097(22)04928-2 [pii]
AID - 10.1016/j.jacc.2022.04.034 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2022 Jul 19;80(3):233-250. doi: 10.1016/j.jacc.2022.04.034. 
      Epub 2022 Jun 1.

PMID- 14994847
OWN - NLM
STAT- MEDLINE
DCOM- 20040319
LR  - 20191108
IS  - 0733-8651 (Print)
IS  - 0733-8651 (Linking)
VI  - 22
IP  - 1
DP  - 2004 Feb
TI  - Anticoagulation for atrial fibrillation.
PG  - 47-62
AB  - For over two decades, valuable insights have been accumulated from epidemiologic 
      studies and randomized trials about the risks for and prevention of AF-related 
      stroke. AF substantially raises the risk of stroke, most likely through an 
      atrio-embolic mechanism. Warfarin and other members of its class of oral 
      anticoagulants targeted at an INR of 2.5 can abrogate the risk of stroke 
      attributable to AF effectively and fairly safely. High-quality management of 
      anticoagulation can be achieved in usual clinical care. These insights have 
      important implications for the care of individual patients and more generally for 
      public health. Future research is needed to specify the risk of stroke and 
      hemorrhage among patients with AF better, particularly among older individuals, 
      to optimize use of antithrombotic agents, and to define the role of recently 
      developed antithrombotic drugs and invasive nondrug approaches.
FAU - Fang, Margaret C
AU  - Fang MC
AD  - University of California, San Francisco, 533 Parnassus Avenue, Box 0131, San 
      Francisco, CA 94143, USA. mfang@medicine.ucsf.edu
FAU - Singer, Daniel E
AU  - Singer DE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cardiol Clin
JT  - Cardiology clinics
JID - 8300331
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/*prevention & control
MH  - Warfarin/administration & dosage/therapeutic use
RF  - 89
EDAT- 2004/03/05 05:00
MHDA- 2004/03/20 05:00
CRDT- 2004/03/05 05:00
PHST- 2004/03/05 05:00 [pubmed]
PHST- 2004/03/20 05:00 [medline]
PHST- 2004/03/05 05:00 [entrez]
AID - S0733-8651(03)00115-2 [pii]
AID - 10.1016/s0733-8651(03)00115-2 [doi]
PST - ppublish
SO  - Cardiol Clin. 2004 Feb;22(1):47-62. doi: 10.1016/s0733-8651(03)00115-2.

PMID- 31703028
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20200511
IS  - 1473-5849 (Electronic)
IS  - 0955-8810 (Linking)
VI  - 30
IP  - 8
DP  - 2019 Dec
TI  - Acetylsalicylic acid and its metabolite gentisic acid may act as adjunctive 
      agents in the treatment of psychiatric disorders.
PG  - 627-641
LID - 10.1097/FBP.0000000000000517 [doi]
AB  - Neuropsychiatric disorders place a very high burden on the global health and 
      economy. The efficacies of currently available drugs in the psychiatric 
      armamentarium are suboptimal and almost all of them target several 
      neurotransmitter pathways. But it is more and more recognized that the 
      neuroinflammation and associated oxidative pathways are important players in the 
      etiopathogenesis of psychiatric disorders. In parallel to this new concept, 
      recent investigations indicate that adjunction of acetylsalicylic acid (ASA) to 
      the orthodox psychiatric treatments augments therapeutic efficacy in bipolar 
      disorder and schizophrenia. Gentisic acid is a redox active quinonoid ASA 
      metabolite and an endogenously produced siderophore with much more potent 
      antioxidant effects than its parent compound. Moreover, it harbours molecular 
      features that provide its selective conversion to even more potent 
      anti-inflammatory quinonoid molecules within the inflammatory micromilieu. We 
      believe that ASA alone and its combination with gentisic acid should be studied 
      in animal models of psychiatric disorders to reveal their potential in regard to 
      the augmentation of currently available treatments. If several animal studies 
      prove their potential, clinical trials could easily be conducted, as both ASA and 
      gentisic acid have a relatively high biosafety and a long history of clinical 
      use.
FAU - Altinoz, Meric A
AU  - Altinoz MA
AD  - Department of Biochemistry, Acibadem University, Istanbul, Turkey.
AD  - Department of Psychiatry, Maastricht University, Holland, The Netherlands.
FAU - Ozpinar, Aysel
AU  - Ozpinar A
AD  - Department of Biochemistry, Acibadem University, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Behav Pharmacol
JT  - Behavioural pharmacology
JID - 9013016
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Gentisates)
RN  - R16CO5Y76E (Aspirin)
RN  - VP36V95O3T (2,5-dihydroxybenzoic acid)
SB  - IM
MH  - Anti-Inflammatory Agents
MH  - Antioxidants/therapeutic use
MH  - Aspirin/*metabolism/*pharmacology
MH  - Bipolar Disorder/drug therapy
MH  - Gentisates/metabolism/pharmacology
MH  - Humans
MH  - Inflammation/drug therapy/metabolism
MH  - Mental Disorders/*drug therapy
MH  - Oxidation-Reduction
MH  - Oxidative Stress/physiology
MH  - Schizophrenia/drug therapy
EDAT- 2019/11/09 06:00
MHDA- 2020/05/12 06:00
CRDT- 2019/11/09 06:00
PHST- 2019/11/09 06:00 [entrez]
PHST- 2019/11/09 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
AID - 00008877-201912000-00004 [pii]
AID - 10.1097/FBP.0000000000000517 [doi]
PST - ppublish
SO  - Behav Pharmacol. 2019 Dec;30(8):627-641. doi: 10.1097/FBP.0000000000000517.

PMID- 15198504
OWN - NLM
STAT- MEDLINE
DCOM- 20041014
LR  - 20181113
IS  - 1522-1059 (Electronic)
IS  - 1522-1059 (Linking)
VI  - 6
IP  - 1
DP  - 2004 Jan 26
TI  - Solvation and hydration characteristics of ibuprofen and acetylsalicylic acid.
PG  - E3
AB  - Ibuprofen and acetylsalicylic acid were studied by thermoanalytical methods: 
      sublimation calorimetry, solution calorimetry, and with respect to solubility. 
      Upon measuring the temperature dependences of the saturated vapor pressure, 
      enthalpies of sublimation, DeltaH(0) (sub), as well as the entropies of 
      sublimation, DeltaS(0) (sub), and their respective relative fractions in the 
      total process were calculated. The Gibbs energy of solvation in aliphatic 
      alcohols as well as the enthalpic and entropic fractions thereof were also 
      studied and compared with the respective properties of model substances and other 
      nonsteroidal antiinflammatory drugs (benzoic acid, diflunisal, flurbiprofen, 
      ketoprofen, and naproxen). In all cases, enthalpy was found to be the driving 
      force of the solvation process. Correlations were derived between Gibbs energy of 
      solvation in octanol, DeltaG(Oct) (solv), and the transfer Gibbs energy from 
      water to octanol, DeltaG(0) (tr). Influence of mutual octanol and water 
      solubilities on the driving force of partitioning is discussed. An 
      enthalpy-entropy-compensation effect in octanol was observed, and consequences of 
      deviation from the general trend are also discussed.
FAU - Perlovich, German L
AU  - Perlovich GL
AD  - University of Tromsø, Institute of Pharmacy, Breivika, N-9037 Tromsø, Norway.
FAU - Kurkov, Sergey V
AU  - Kurkov SV
FAU - Kinchin, Andrey N
AU  - Kinchin AN
FAU - Bauer-Brandl, Annette
AU  - Bauer-Brandl A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20040126
PL  - United States
TA  - AAPS PharmSci
JT  - AAPS pharmSci
JID - 100897065
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry/pharmacokinetics
MH  - Aspirin/*chemistry/pharmacokinetics
MH  - Drug Stability
MH  - Half-Life
MH  - Ibuprofen/*chemistry/pharmacokinetics
MH  - Solubility
MH  - Thermodynamics
MH  - Water/chemistry
PMC - PMC2750938
EDAT- 2004/06/17 05:00
MHDA- 2004/10/16 09:00
CRDT- 2004/06/17 05:00
PHST- 2004/06/17 05:00 [pubmed]
PHST- 2004/10/16 09:00 [medline]
PHST- 2004/06/17 05:00 [entrez]
AID - 61022 [pii]
AID - 10.1208/ps060103 [doi]
PST - epublish
SO  - AAPS PharmSci. 2004 Jan 26;6(1):E3. doi: 10.1208/ps060103.

PMID- 6818357
OWN - NLM
STAT- MEDLINE
DCOM- 19830317
LR  - 20190909
IS  - 0388-1350 (Print)
IS  - 0388-1350 (Linking)
VI  - 7
IP  - 3
DP  - 1982 Aug
TI  - Influence of maternal drug metabolism on the fetal toxicity induced by 
      acetylsalicylic acid.
PG  - 177-84
AB  - Investigations were performed to explore changes in fetal toxicity induced by 
      acetylsalicylic acid (ASA) in pregnant animals treated by various means for 
      maternal alterations. The fetotoxicity induced by ASA (500 mg/kg s.c.) was higher 
      in rats than in mice. In mice with low enzyme activity, those displaying a longer 
      sleeping time in pentobarbital-induced sleep, the ASA-fetotoxicity was higher 
      than that of mice with shorter sleeping time. In rats pretreated with 
      phenobarbital (0.05%), Zn (10 mg/l) and Cu (10 mg/l) in tap water and cysteine 
      (200 mg/kg s.c.), fetal toxicity of ASA was reduced, whereas it was enhanced in 
      rats pretreated with SKF-525A (200 mg/kg s.c.) and alpha-naphthyl acetic acid 
      (200 mg/kg p.o.) and in nephrectomized rats. The UDPGT activity in hepatic 9000 x 
      g supernate was higher in mice than in rats and the activity of mice was 
      increased by phenobarbital and Cu. This study indicates that ASA-induced 
      fetotoxicity can be positively modified by alterations in drug metabolizing 
      activity.
FAU - Saito, H
AU  - Saito H
FAU - Sakai, T
AU  - Sakai T
FAU - Ueno, K
AU  - Ueno K
FAU - Kitagawa, H
AU  - Kitagawa H
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Toxicol Sci
JT  - The Journal of toxicological sciences
JID - 7805798
RN  - 789U1901C5 (Copper)
RN  - EC 2.4.1.17 (Glucuronosyltransferase)
RN  - J41CSQ7QDS (Zinc)
RN  - R16CO5Y76E (Aspirin)
RN  - YQE403BP4D (Phenobarbital)
SB  - IM
MH  - Animals
MH  - Aspirin/metabolism/*toxicity
MH  - Copper/pharmacology
MH  - Female
MH  - Fetus/*drug effects
MH  - Glucuronosyltransferase/metabolism
MH  - Liver/enzymology
MH  - Male
MH  - *Maternal-Fetal Exchange
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Phenobarbital/pharmacology
MH  - Pregnancy
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Species Specificity
MH  - Zinc/pharmacology
EDAT- 1982/08/01 00:00
MHDA- 1982/08/01 00:01
CRDT- 1982/08/01 00:00
PHST- 1982/08/01 00:00 [pubmed]
PHST- 1982/08/01 00:01 [medline]
PHST- 1982/08/01 00:00 [entrez]
AID - 10.2131/jts.7.177 [doi]
PST - ppublish
SO  - J Toxicol Sci. 1982 Aug;7(3):177-84. doi: 10.2131/jts.7.177.

PMID- 23095368
OWN - NLM
STAT- MEDLINE
DCOM- 20130419
LR  - 20151119
IS  - 1423-0097 (Electronic)
IS  - 1018-2438 (Linking)
VI  - 160
IP  - 3
DP  - 2013
TI  - Acoustic rhinometry and aspirin nasal challenge in the diagnosis of 
      aspirin-intolerant asthma: clinical finding and safety aspects.
PG  - 307-12
LID - 10.1159/000341635 [doi]
AB  - BACKGROUND: The safety and utility of nasal provocation tests with lysine-aspirin 
      (L-ASA) in the diagnosis of aspirin-intolerant asthma (AIA) have previously been 
      described in a short series of patients. OBJECTIVES: To describe the clinical 
      features and safety of an L-ASA challenge test in patients with AIA. METHODS: We 
      evaluated 72 patients (79% women), with a mean ± SD age of 47.9 ± 14.5 years. All 
      patients were submitted to an L-ASA nasal provocation test (29 mg in each 
      nostril) under acoustic rhinometry (AcR) control. Symptom score (0-3), visual 
      analogical scale and nitric oxide determinations were performed at baseline and 
      at 15, 30, 60 and 90 min. A decrease in nasal volume of at least 25% was 
      considered a positive test. Nasal nitric oxide (nNO) and forced expiratory volume 
      in 1 s were measured. RESULTS: Nasal congestion and rhinorrhea represented 51 and 
      32%, respectively, of total symptoms. According to AcR data, the L-ASA challenge 
      test was positive in 20% of patients at 15 min, an additional 36% were positive 
      at 30 min, 18% at 60 min, and the remaining 26% at 90 min. nNO nasal values 
      decreased but did not reach statistical significance. No pulmonary or systemic 
      reactions were observed. CONCLUSIONS: Symptoms of nasal congestion associated 
      with the reduction in nasal volume measured by AcR are the most useful parameters 
      for establishing the diagnosis of AIA using the L-ASA nasal challenge. The method 
      is very well tolerated and can be safely used even in patients with severe 
      asthma.
CI  - Copyright © 2012 S. Karger AG, Basel.
FAU - Muñoz-Cano, R
AU  - Muñoz-Cano R
AD  - Unitat d'Allèrgia, Servei de Pneumologia i Al.lèrgia, Hospital Clinic, 
      Universitat de Barcelona, Barcelona, Spain. rmunoz@clinic.ub.es
FAU - Bartra, J
AU  - Bartra J
FAU - Sanchez-Lopez, J
AU  - Sanchez-Lopez J
FAU - Picado, C
AU  - Picado C
FAU - Bissinger, I
AU  - Bissinger I
FAU - Valero, A
AU  - Valero A
LA  - eng
PT  - Journal Article
DEP - 20121018
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Intranasal
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Asthma, Aspirin-Induced/*diagnosis
MH  - Feasibility Studies
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Immunization/methods
MH  - Male
MH  - Middle Aged
MH  - Nasal Obstruction/*diagnosis
MH  - Nitric Oxide/metabolism
MH  - Rhinometry, Acoustic/*methods
EDAT- 2012/10/26 06:00
MHDA- 2013/04/23 06:00
CRDT- 2012/10/26 06:00
PHST- 2011/12/05 00:00 [received]
PHST- 2012/07/06 00:00 [accepted]
PHST- 2012/10/26 06:00 [entrez]
PHST- 2012/10/26 06:00 [pubmed]
PHST- 2013/04/23 06:00 [medline]
AID - 000341635 [pii]
AID - 10.1159/000341635 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2013;160(3):307-12. doi: 10.1159/000341635. Epub 2012 
      Oct 18.

PMID- 923099
OWN - NLM
STAT- MEDLINE
DCOM- 19780127
LR  - 20191210
IS  - 0009-8981 (Print)
IS  - 0009-8981 (Linking)
VI  - 81
IP  - 3
DP  - 1977 Dec 15
TI  - Serum aspirin esterase activity in women with habitual aspirin intake.
PG  - 261-5
AB  - A method for the determination of aspirin esterase activity in serum is 
      described. Sera from 59 pregnant women who were habitual aspirin users were found 
      to have a mean enzyme activity value statistically lower than those of 68 
      non-pregnant women controls or of 12 pregnant women controls who were either 
      occasional users of the drug or were non-users. The distribution of enzyme 
      activity in the experimental group was also significantly different from that of 
      the control group. It is postulated that the low enzyme activity may further 
      aggravate the injurious effects of high intake of aspirin.
FAU - Gupta, J D
AU  - Gupta JD
FAU - Gupta, V
AU  - Gupta V
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.- (acetylsalicylic acid hydrolase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Aspirin/administration & dosage
MH  - Carboxylic Ester Hydrolases/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Methods
MH  - Pregnancy
MH  - Time Factors
EDAT- 1977/12/15 00:00
MHDA- 1977/12/15 00:01
CRDT- 1977/12/15 00:00
PHST- 1977/12/15 00:00 [pubmed]
PHST- 1977/12/15 00:01 [medline]
PHST- 1977/12/15 00:00 [entrez]
AID - 0009-8981(77)90057-2 [pii]
AID - 10.1016/0009-8981(77)90057-2 [doi]
PST - ppublish
SO  - Clin Chim Acta. 1977 Dec 15;81(3):261-5. doi: 10.1016/0009-8981(77)90057-2.

PMID- 28372885
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20220317
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 26
IP  - 8
DP  - 2017 Aug
TI  - The Cost Differential Between Warfarin Versus Aspirin Treatment After a Fontan 
      Procedure.
PG  - e44-e47
LID - S1443-9506(17)30086-0 [pii]
LID - 10.1016/j.hlc.2017.02.003 [doi]
AB  - BACKGROUND: The use of aspirin versus warfarin for treatment of patients after a 
      Fontan procedure remains contentious. Current preference-based models of 
      treatment across Australia and New Zealand show variation in care that is 
      unlikely to reflect patient differences and/or clinical risk. METHODS: We combine 
      data from the Australian and New Zealand Fontan Registry and a home INR 
      (International Normalised Ratio) monitoring program (HINRMP) from the Royal 
      Children's Hospital (RCH) Melbourne, to estimate the cost difference for Fontan 
      recipients receiving aspirin versus warfarin for 2015. We adopt a societal 
      perspective to costing which includes cost to the health system (e.g. medical 
      consults, pathology tests) and costs to patients and carers (e.g. travel and 
      time), but excludes costs of adverse events. Costs are presented in Australian 
      2015 dollars; any costs from previous years have been inflated using appropriate 
      rates from the Australian Bureau of Statistics. RESULTS: We find that warfarin 
      patients face additional costs of $825 per annum, with the majority ($584 or 71%) 
      of those borne by the patient or family. If aspirin is as clinically as effective 
      as warfarin, Fontan recipients could be enjoying far less costly, invasive and 
      time-consuming treatment. While achieving such clinical consensus can be 
      difficult, economics shows us that there are large costs associated with a 
      failure to achieve it.
CI  - Copyright © 2017. Published by Elsevier B.V.
FAU - Schilling, Chris
AU  - Schilling C
AD  - Centre for Health Policy, the University of Melbourne, Melbourne, Vic, Australia. 
      Electronic address: chris.schilling@unimelb.edu.au.
FAU - Dalziel, Kim
AU  - Dalziel K
AD  - Centre for Health Policy, the University of Melbourne, Melbourne, Vic, Australia.
FAU - Iyengar, Ajay J
AU  - Iyengar AJ
AD  - Cardiac Surgery Department, Royal Children's Hospital, Melbourne, Vic, Australia; 
      Department of Paediatrics, Faculty of Medicine, the University of Melbourne, 
      Melbourne, Vic, Australia; Murdoch Children's Research Institute, Melbourne, Vic, 
      Australia.
FAU - d'Udekem, Yves
AU  - d'Udekem Y
AD  - Cardiac Surgery Department, Royal Children's Hospital, Melbourne, Vic, Australia; 
      Department of Paediatrics, Faculty of Medicine, the University of Melbourne, 
      Melbourne, Vic, Australia; Murdoch Children's Research Institute, Melbourne, Vic, 
      Australia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170306
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*economics
MH  - Australia
MH  - Costs and Cost Analysis
MH  - Female
MH  - Fontan Procedure/*economics
MH  - Humans
MH  - International Normalized Ratio/*economics
MH  - Male
MH  - New Zealand
MH  - Registries
MH  - Warfarin/administration & dosage/*economics
OTO - NOTNLM
OT  - Congenital heart disease
OT  - Costs
OT  - Fontan
OT  - Warfarin
EDAT- 2017/04/05 06:00
MHDA- 2018/03/27 06:00
CRDT- 2017/04/05 06:00
PHST- 2015/07/06 00:00 [received]
PHST- 2017/01/23 00:00 [revised]
PHST- 2017/02/01 00:00 [accepted]
PHST- 2017/04/05 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
PHST- 2017/04/05 06:00 [entrez]
AID - S1443-9506(17)30086-0 [pii]
AID - 10.1016/j.hlc.2017.02.003 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2017 Aug;26(8):e44-e47. doi: 10.1016/j.hlc.2017.02.003. Epub 
      2017 Mar 6.

PMID- 25055737
OWN - NLM
STAT- MEDLINE
DCOM- 20151022
LR  - 20211021
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 4
DP  - 2014 Jul 24
TI  - Dermcidin isoform-2 induced nullification of the effect of acetyl salicylic acid 
      in platelet aggregation in acute myocardial infarction.
PG  - 5804
LID - 10.1038/srep05804 [doi]
LID - 5804
AB  - The aggregation of platelets on the plaque rupture site on the coronary artery is 
      reported to cause both acute coronary syndromes (ACS) and acute myocardial 
      infarction (AMI). While the inhibition of platelet aggregation by acetyl 
      salicylic acid was reported to produce beneficial effects in ACS, it failed to do 
      in AMI. The concentration of a stress induced protein (dermcidin isoform-2) was 
      much higher in AMI than that in ACS. Incubation of normal platelet rich plasma 
      (PRP) with dermcidin showed one high affinity (Kd = 40 nM) and one low affinity 
      binding sites (Kd = 333 nM). When normal PRP was incubated with 0.4 μM dermcidin, 
      the platelets became resistant to the inhibitory effect of aspirin similar to 
      that in the case of AMI. Incubation of PRP from AMI with dermcidin antibody 
      restored the sensitivity of the platelets to the aspirin effect. Incubation of 
      AMI PRP pretreated with 15 μM aspirin, a stimulator of the NO synthesis, resulted 
      in the increased production of NO in the platelets that removed the bound 
      dermcidin by 40% from the high affinity binding sites of AMI platelets. When the 
      same AMI PRP was retreated with 10 μM aspirin, the aggregation of platelets was 
      completely inhibited by NO synthesis.
FAU - Bank, Sarbashri
AU  - Bank S
AD  - 1] Sinha Institute of Medical Science and Technology, Kolkata [2] Department of 
      Biochemistry, Cell and Molecular Therapeutic Lab, OIST, Vidyasagar University, 
      Midnapur.
FAU - Jana, Pradipta
AU  - Jana P
AD  - Sinha Institute of Medical Science and Technology, Kolkata.
FAU - Maiti, Smarajit
AU  - Maiti S
AD  - Department of Biochemistry, Cell and Molecular Therapeutic Lab, OIST, Vidyasagar 
      University, Midnapur.
FAU - Guha, Santanu
AU  - Guha S
AD  - Department of Cardiology, Calcutta Medical College, Kolkata.
FAU - Sinha, A K
AU  - Sinha AK
AD  - Sinha Institute of Medical Science and Technology, Kolkata.
LA  - eng
PT  - Journal Article
DEP - 20140724
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Peptides)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Protein Isoforms)
RN  - 0 (dermcidin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*blood/drug therapy
MH  - Peptides/*physiology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet-Rich Plasma/drug effects
MH  - Protein Binding
MH  - Protein Isoforms/physiology
PMC - PMC4108914
EDAT- 2014/07/25 06:00
MHDA- 2015/10/23 06:00
CRDT- 2014/07/25 06:00
PHST- 2014/04/14 00:00 [received]
PHST- 2014/06/16 00:00 [accepted]
PHST- 2014/07/25 06:00 [entrez]
PHST- 2014/07/25 06:00 [pubmed]
PHST- 2015/10/23 06:00 [medline]
AID - srep05804 [pii]
AID - 10.1038/srep05804 [doi]
PST - epublish
SO  - Sci Rep. 2014 Jul 24;4:5804. doi: 10.1038/srep05804.

PMID- 18215590
OWN - NLM
STAT- MEDLINE
DCOM- 20080215
LR  - 20131121
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 155
IP  - 2
DP  - 2008 Feb
TI  - Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) Trial: rationale 
      and design.
PG  - 224-30
LID - 10.1016/j.ahj.2007.10.003 [doi]
AB  - BACKGROUND: Despite some concern that recent aspirin ingestion increases blood 
      loss after coronary artery surgery, there is some evidence that this may reduce 
      thrombotic complications. In contrast, antifibrinolytic drugs can reduce blood 
      loss in this setting, but there is concern that they may increase thrombotic 
      complications. Published guidelines are limited by a lack of large randomized 
      trials addressing the risks and benefits of each of these commonly used therapies 
      in cardiac surgery. The ATACAS Trial is a study comparing aspirin, tranexamic 
      acid, or both, with placebo in patients undergoing on-pump or off-pump coronary 
      artery surgery. METHODS: We discuss the rationale for conducting ATACAS, a 
      4600-patient, multicenter randomized trial in at-risk coronary artery surgery, 
      and the features of the ATACAS study design (objectives, end points, target 
      population, allocation, treatments, patient follow-up, and analysis). 
      CONCLUSIONS: The ATACAS Trial will be the largest study yet conducted to 
      ascertain the benefits and risks of aspirin and antifibrinolytic therapy in 
      coronary artery surgery. Results of the trial will guide the routine clinical 
      care of patients in this setting.
FAU - Myles, Paul S
AU  - Myles PS
AD  - Department of Anaesthesia and Perioperative Medicine, Alfred Hospital, Melbourne, 
      Victoria, Australia. p.myles@alfred.org.au
FAU - Smith, Julian
AU  - Smith J
FAU - Knight, John
AU  - Knight J
FAU - Cooper, D James
AU  - Cooper DJ
FAU - Silbert, Brendan
AU  - Silbert B
FAU - McNeil, John
AU  - McNeil J
FAU - Esmore, Donald S
AU  - Esmore DS
FAU - Buxton, Brian
AU  - Buxton B
FAU - Krum, Henry
AU  - Krum H
FAU - Forbes, Andrew
AU  - Forbes A
FAU - Tonkin, Andrew
AU  - Tonkin A
CN  - ATACAS Trial Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20071126
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Antifibrinolytic Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 6T84R30KC1 (Tranexamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antifibrinolytic Agents/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - *Epidemiologic Research Design
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Tranexamic Acid/adverse effects/*therapeutic use
EDAT- 2008/01/25 09:00
MHDA- 2008/02/19 09:00
CRDT- 2008/01/25 09:00
PHST- 2007/06/09 00:00 [received]
PHST- 2007/10/01 00:00 [accepted]
PHST- 2008/01/25 09:00 [pubmed]
PHST- 2008/02/19 09:00 [medline]
PHST- 2008/01/25 09:00 [entrez]
AID - S0002-8703(07)00782-X [pii]
AID - 10.1016/j.ahj.2007.10.003 [doi]
PST - ppublish
SO  - Am Heart J. 2008 Feb;155(2):224-30. doi: 10.1016/j.ahj.2007.10.003. Epub 2007 Nov 
      26.

PMID- 7270563
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20161123
IS  - 0002-9289 (Print)
IS  - 0002-9289 (Linking)
VI  - 38
IP  - 8
DP  - 1981 Aug
TI  - Salicylate hepatitis: a complication of the treatment of Kawasaki's disease.
PG  - 1171-2
AB  - A case of salicylate hepatitis in a seven-week-old boy with Kawasaki's disease, 
      mucocutaneous lymph node syndrome, is reported. The infant was admitted to the 
      hospital with fever and a diffuse maculopapular petechial rash. He was treated 
      with antibiotics for 72 hours for presumed septicemia. His condition deteriorated 
      and he developed mucous membrane lesions and edema in his hands and feet. When 
      the cultures of spinal fluid, blood, and urine were found to be negative, the 
      antimicrobial therapy was discontinued; however, the cyanosis of his extremities 
      progressed and gangrenous regions developed in his toe and finger pads. Oral 
      aspirin therapy was started at a dosage of 100 mg/kg/day, every six hours. After 
      five days, the rash, membrane lesions, and swelling in his hands and feet 
      resolved. The cyanosis regressed. Liver enzyme tests revealed mild elevations of 
      SGOT and LDH, and on the 12th hospital day these values peaked to a level 
      consistent with salicylate hepatitis. The aspirin therapy was discontinued and 
      within four days the liver function test results were normal. Aspirin therapy was 
      reinstituted at a single daily dose of 30 mg/kg with no recurrence of hepatitis. 
      The careful monitoring of liver function tests is recommended for children with 
      Kawasaki's disease receiving aspirin therapy to avoid salicylate-induced 
      hepatitis.
FAU - Bertino, J S Jr
AU  - Bertino JS Jr
FAU - Willis, E D
AU  - Willis ED
FAU - Reed, M D
AU  - Reed MD
FAU - Speck, W T
AU  - Speck WT
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Hosp Pharm
JT  - American journal of hospital pharmacy
JID - 0370474
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspartate Aminotransferases/blood
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Chemical and Drug Induced Liver Injury/*complications
MH  - Humans
MH  - L-Lactate Dehydrogenase/blood
MH  - Lymphatic Diseases/*complications
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*complications/drug therapy
MH  - Time Factors
EDAT- 1981/08/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1981/08/01 00:00
PHST- 1981/08/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1981/08/01 00:00 [entrez]
PST - ppublish
SO  - Am J Hosp Pharm. 1981 Aug;38(8):1171-2.

PMID- 7954760
OWN - NLM
STAT- MEDLINE
DCOM- 19941215
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 14
IP  - 4
DP  - 1994 Aug
TI  - Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment 
      of migraine: a multicentre double-blind placebo-controlled study.
PG  - 297-300
AB  - This multicentre, double-blind, randomized, placebo-controlled, parallel study 
      was designed to evaluate the efficacy of combined oral lysine acetylsalicylate 
      and metoclopramide (LAS-MCP) in the acute treatment of migraine attacks. A total 
      of 266 patients, 18-65 years old, with two to six attacks of migraine with or 
      without aura (IHS criteria) per month were included. The patients had to treat 
      two migraine attacks with LAS-MCP (1620 mg lysine acetylsalicylate--the 
      equivalent of 900 mg aspirin--combined with 10 mg metoclopramide) or placebo. The 
      main outcome measure was headache relief (reduction in headache severity from 
      grade 3 or 2--severe or moderate--to grade 1 or 0--mild or none) 2 h after 
      treatment. LAS-MCP was superior to placebo for headache relief (56% vs 28%) and 
      for the following secondary outcome measures: complete headache relief (18% vs 
      7%; p < 0.001), nausea (28% vs 44%; p < 0.001), vomiting (3% vs 11%; p = 0.001), 
      use of rescue medication (47% vs 68%; p < 0.001), global efficacy judged as good 
      or excellent (32% vs 14%; p < 0.001). The tolerability was considered as good in 
      94% of treated attacks in both groups. Combined oral lysine acetylsalicylate and 
      metoclopramide is an effective and well-tolerated acute treatment of migraine 
      attacks.
FAU - Chabriat, H
AU  - Chabriat H
AD  - Service de Neurologie, Hôpital Saint Antoine, Paris, France.
FAU - Joire, J E
AU  - Joire JE
FAU - Danchot, J
AU  - Danchot J
FAU - Grippon, P
AU  - Grippon P
FAU - Bousser, M G
AU  - Bousser MG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Analgesics)
RN  - K3Z4F929H6 (Lysine)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Analgesics/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic 
      use
MH  - Male
MH  - Metoclopramide/administration & dosage/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
AID - 10.1046/j.1468-2982.1994.1404297.x [doi]
PST - ppublish
SO  - Cephalalgia. 1994 Aug;14(4):297-300. doi: 10.1046/j.1468-2982.1994.1404297.x.

PMID- 30987481
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 34
IP  - 1
DP  - 2021 Jan
TI  - Practical approach to the prevention of preeclampsia: from screening to 
      pharmaceutical intervention.
PG  - 152-158
LID - 10.1080/14767058.2019.1588877 [doi]
AB  - Preeclampsia occurs in 3-8% of the pregnancies and is associated with a high rate 
      of morbi-mortality, both for mothers and the fetus. Screening and prevention of 
      patients at risk are the optimal way to reduce the morbi-mortality of this 
      disease. To set-up a preventive approach to preeclampsia (PE), one has to 
      identify using a screening strategy for the population at risk and propose them 
      an appropriate therapeutic intervention that would bear a favorable benefits/risk 
      ratio. While the classical method only considers epidemiological risk factors to 
      set up preventive measures, several authors have set-up complex multiparameter 
      algorithm to detect a population at risk of PE. The new pyramid of pregnancy care 
      integrates an early clinic allowing the assessment of biophysical and biochemical 
      markers combined with maternal factors. Such an approach can identify pregnancies 
      that are at high risk of PE and reduce its prevalence using low-aspirin regimen 
      initiated as early as possible in the population at risk.
FAU - Rafii Tabrizi, Arash
AU  - Rafii Tabrizi A
AUID- ORCID: 0000-0002-4122-5068
AD  - Weill Cornell Medicine in Qatar, Doha, Qatar.
AD  - Feto Maternal Centre, Doha, Qatar.
FAU - Ayoubi, Jean Marc
AU  - Ayoubi JM
AD  - Service De Gynécologie - Obstétrique et Médecine, de la reproduction, Hôpital 
      Foch, Suresnes, France.
FAU - Ahmed, Badreldeen
AU  - Ahmed B
AD  - Weill Cornell Medicine in Qatar, Doha, Qatar.
AD  - Feto Maternal Centre, Doha, Qatar.
LA  - eng
PT  - Journal Article
DEP - 20190415
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - 0 (Pharmaceutical Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Mass Screening
MH  - *Pharmaceutical Preparations
MH  - *Pre-Eclampsia/diagnosis/prevention & control
MH  - Pregnancy
MH  - Prenatal Care
OTO - NOTNLM
OT  - Pre-eclampsia
OT  - aspirin
OT  - prevention
OT  - screening
OT  - ultrasound
EDAT- 2019/04/17 06:00
MHDA- 2021/06/22 06:00
CRDT- 2019/04/17 06:00
PHST- 2019/04/17 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2019/04/17 06:00 [entrez]
AID - 10.1080/14767058.2019.1588877 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2021 Jan;34(1):152-158. doi: 
      10.1080/14767058.2019.1588877. Epub 2019 Apr 15.

PMID- 12360609
OWN - NLM
STAT- MEDLINE
DCOM- 20021212
LR  - 20181130
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 74
IP  - 8
DP  - 2002
TI  - [Effect of fluvastain and its combination with aspirin and trental on hemostasis 
      and microcirculation in atherosclerosis].
PG  - 9-12
AB  - AIM: To assess effects of fluvastatin monotherapy and combined therapy with 
      aspirin and trental on hemostasis and microcirculation in atherosclerosis. 
      MATERIAL AND METHODS: Hemostasis and microcirculation were studied in 68 patients 
      with coronary atherosclerosis and aortic atherosclerosis on fluvastatin 
      monotherapy and on combined therapy fluvastatin + aspirin + trental. RESULTS: 
      Hypolipidemic treatment with fluvastatin reduced thrombogenic blood potential due 
      to enhancement of plasmic fibrinolytic activity [the time of XII-a dependent 
      fibrinolysis decreased by 33% (p < 0.05)], decreased thrombinemia [blood level of 
      soluble fibrin-monomeric complexes fell by 44% (p < 0.05)] and reduced stimulated 
      platelet aggregation: by 18.2% in response to ADP (p < 0.05) and by 11% in 
      response to adrenalin (p < 0.05). CONCLUSION: Correction of lipid metabolism and 
      blood hypercoagulation improved microrheology. Combination of fluvastatin with 
      aspirin made platelet aggregation reduction in response to both inductors faster 
      and more stable, while combination of fluvastatin with trental contributed to 
      better results in microcirculation improvement.
FAU - Zhdanova, I V
AU  - Zhdanova IV
FAU - Tsvirenko, S V
AU  - Tsvirenko SV
FAU - Barats, S S
AU  - Barats SS
FAU - Smolenskaia, O G
AU  - Smolenskaia OG
FAU - Volkova, R F
AU  - Volkova RF
FAU - Serezhenko, T O
AU  - Serezhenko TO
LA  - rus
PT  - Journal Article
TT  - Vliianie fliuvastatina i ego sochetaniĭ s aspirinom i trentalom na gemostaz i 
      mikrotsirkuliatsiiu pri ateroskleroze.
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 0 (Indoles)
RN  - 4L066368AS (Fluvastatin)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticholesteremic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Arteriosclerosis/*drug therapy/physiopathology
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Fatty Acids, Monounsaturated/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Female
MH  - Fluvastatin
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Indoles/administration & dosage/pharmacology/*therapeutic use
MH  - Male
MH  - Microcirculation/*drug effects
MH  - Middle Aged
MH  - Pentoxifylline/administration & dosage/pharmacology/*therapeutic use
EDAT- 2002/10/04 04:00
MHDA- 2002/12/13 04:00
CRDT- 2002/10/04 04:00
PHST- 2002/10/04 04:00 [pubmed]
PHST- 2002/12/13 04:00 [medline]
PHST- 2002/10/04 04:00 [entrez]
PST - ppublish
SO  - Ter Arkh. 2002;74(8):9-12.

PMID- 6417815
OWN - NLM
STAT- MEDLINE
DCOM- 19840127
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 50
IP  - 3
DP  - 1983 Oct 31
TI  - The effect of two low doses of aspirin on whole blood thromboxane and 
      prostacyclin generation in healthy subjects.
PG  - 669-70
AB  - The effects of two low doses of aspirin (20 mg and 100 mg) on prostacyclin and 
      thromboxane formation during whole blood clotting were studied in 8 healthy 
      volunteers. A single 100 mg aspirin dose caused more than 90% reduction of both 
      serum TXB2 and 6-keto-PGF1 alpha; a single 20 mg dose of aspirin inhibited serum 
      TXB2 more than 6-keto-PGF1 alpha but effects on these two products could not be 
      completely dissociated. However, the effect of a single 20 mg aspirin dose on 
      serum TXB2, was of much longer duration than its inhibitory effect on PGI2 
      synthesis during whole blood clotting.
FAU - Davì, G
AU  - Davì G
FAU - Custro, N
AU  - Custro N
FAU - Novo, S
AU  - Novo S
FAU - Mattina, A
AU  - Mattina A
FAU - Strano, A
AU  - Strano A
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/*biosynthesis
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Coagulation
MH  - Cyclooxygenase Inhibitors
MH  - Epoprostenol/*biosynthesis
MH  - Female
MH  - Humans
MH  - Male
MH  - Thromboxane B2/*biosynthesis
MH  - Thromboxanes/*biosynthesis
MH  - Time Factors
EDAT- 1983/10/31 00:00
MHDA- 1983/10/31 00:01
CRDT- 1983/10/31 00:00
PHST- 1983/10/31 00:00 [pubmed]
PHST- 1983/10/31 00:01 [medline]
PHST- 1983/10/31 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1983 Oct 31;50(3):669-70.

PMID- 5454357
OWN - NLM
STAT- MEDLINE
DCOM- 19701017
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 3
IP  - 5722
DP  - 1970 Sep 5
TI  - Papillary necrosis in rats caused by aspirin and aspirin-containing mixtures.
PG  - 559-61
AB  - Nearly half the rats gavage-fed with aspirin and aspirin-containing mixtures 
      developed papillary necrosis in 20 weeks. This incidence is similar to that found 
      in rats on A.P.C. mixtures with high and low concentrations of 
      p-chloracetanilide, an impurity of phenacetin. Aspirin alone produced necrosis in 
      7 out of 19 rats (36.8%) whereas phenacetin in the same dose had failed to cause 
      any renal damage over six to nine months. If these results also apply to man they 
      suggest that aspirin and not phenacetin may be the major factor in analgesic 
      nephropathy in patients taking A.P.C. mixtures. An augmented clearance of aspirin 
      appeared to afford some protection to the medulla, and it is suggested that this 
      observation may have important clinical and epidemiological applications.
FAU - Nanra, R S
AU  - Nanra RS
FAU - Kincaid-Smith, P
AU  - Kincaid-Smith P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Acetanilides)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetanilides/toxicity
MH  - Animals
MH  - Aspirin/metabolism/*toxicity
MH  - Caffeine/administration & dosage
MH  - Female
MH  - Kidney/pathology
MH  - Kidney Papillary Necrosis/*chemically induced/pathology
MH  - Metabolic Clearance Rate
MH  - Phenacetin/toxicity
MH  - Rats
MH  - Water Deprivation
PMC - PMC1701568
EDAT- 1970/09/05 00:00
MHDA- 1970/09/05 00:01
CRDT- 1970/09/05 00:00
PHST- 1970/09/05 00:00 [pubmed]
PHST- 1970/09/05 00:01 [medline]
PHST- 1970/09/05 00:00 [entrez]
AID - 10.1136/bmj.3.5722.559 [doi]
PST - ppublish
SO  - Br Med J. 1970 Sep 5;3(5722):559-61. doi: 10.1136/bmj.3.5722.559.

PMID- 685578
OWN - NLM
STAT- MEDLINE
DCOM- 19781025
LR  - 20131121
IS  - 0044-4197 (Print)
IS  - 0044-4197 (Linking)
VI  - 100
IP  - 14
DP  - 1978
TI  - [Prevention of thromboembolism in surgical gynecology].
PG  - 946-53
AB  - It is reported on the prophylaxis of thromboembolic diseases with acetylsalicylic 
      acid (Micristin) in gynaecological surgery. The number of thromboembolic 
      complications clinically ascertained was diminished from 3,25% (without 
      Micristin) to 0,82% (with Micristin). Side effects were rarely observed, 
      laboratory control was not necessary, Low-dose-heparin-prophylaxis were executed 
      on contraindications and incompatibilities of Micristin. The perioperative use of 
      low doses of heparin combined with postoperative use of oral anticoagulants on 
      patients with increased risk of thromboembolism are discussed.
FAU - Räber, G
AU  - Räber G
FAU - Canzler, E
AU  - Canzler E
FAU - Lutze, G
AU  - Lutze G
FAU - Bauermeister, U
AU  - Bauermeister U
FAU - Kunze, M
AU  - Kunze M
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Zur Thromboembolieprophylaxe in der operativen Gynäkologie.
PL  - Germany
TA  - Zentralbl Gynakol
JT  - Zentralblatt fur Gynakologie
JID - 21820100R
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Hysterectomy
MH  - Postoperative Complications
MH  - Thromboembolism/*prevention & control
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
PST - ppublish
SO  - Zentralbl Gynakol. 1978;100(14):946-53.

PMID- 22610013
OWN - NLM
STAT- MEDLINE
DCOM- 20130801
LR  - 20211021
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Linking)
VI  - 270
IP  - 2
DP  - 2013 Feb
TI  - Sinonasal outcome under aspirin desensitization following functional endoscopic 
      sinus surgery in patients with aspirin triad.
PG  - 571-8
LID - 10.1007/s00405-012-2048-x [doi]
AB  - Recalcitrant forms of recurrent nasal polyposis are problematic for patients as 
      for rhinosurgeons. In aspirin-sensitive patients, aspirin desensitization is 
      supposed to prevent recurrence by targeting the metabolism of arachidonic acid. 
      Aspirin-sensitive patients (n = 65) following aspirin desensitization after 
      functional endoscopic sinus surgery (FESS) for recurrent nasal polyposis under 
      daily intake of 500-mg aspirin were compared to a post-FESS group (n = 81) of 
      aspirin-sensitive individuals using exclusively topical mometasone. Quality of 
      life (QoL) scores including sinonasal, pulmonal and general QoL items as well as 
      endoscopic endonasal examination findings were evaluated during the postoperative 
      follow-up period. After a follow-up period of minimum 18 months, a significant 
      improvement in nasal obstruction, rhinorrhea, post nasal drip, sense of smell, 
      facial pain, sleep quality and further general QoL items in desensitized patients 
      was found compared to aspirin-sensitive controls. Improvement in sinonasal 
      symptoms was evident, whereas the severity of asthmatic symptoms showed no 
      significant changes. Although the pathophysiology of aspirin sensitivity is still 
      not fully understood and the therapy is not sufficiently investigated, aspirin 
      desensitization seems to have a positive effect on QoL scores concerning 
      sinonasal symptoms and should be regarded as a possible postoperative treatment 
      modality for recurrent nasal polyposis in aspirin-sensitive individuals.
FAU - Havel, Miriam
AU  - Havel M
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Munich University 
      Hospital, Marchioninistrasse 15, 81377 Munich, Germany. 
      miriam.havel@med.uni-muenchen.de
FAU - Ertl, Lena
AU  - Ertl L
FAU - Braunschweig, Franziska
AU  - Braunschweig F
FAU - Markmann, Sabine
AU  - Markmann S
FAU - Leunig, Andreas
AU  - Leunig A
FAU - Gamarra, Fernando
AU  - Gamarra F
FAU - Kramer, Matthias F
AU  - Kramer MF
LA  - eng
PT  - Journal Article
DEP - 20120518
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*immunology
MH  - Asthma, Aspirin-Induced/*complications
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/diagnosis/etiology/*therapy
MH  - *Endoscopy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/immunology/*surgery
MH  - Quality of Life
MH  - Recurrence
MH  - Treatment Outcome
EDAT- 2012/05/23 06:00
MHDA- 2013/08/02 06:00
CRDT- 2012/05/22 06:00
PHST- 2012/03/13 00:00 [received]
PHST- 2012/05/02 00:00 [accepted]
PHST- 2012/05/22 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2013/08/02 06:00 [medline]
AID - 10.1007/s00405-012-2048-x [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2013 Feb;270(2):571-8. doi: 10.1007/s00405-012-2048-x. 
      Epub 2012 May 18.

PMID- 4010440
OWN - NLM
STAT- MEDLINE
DCOM- 19850807
LR  - 20190912
IS  - 0196-8092 (Print)
IS  - 0196-8092 (Linking)
VI  - 5
IP  - 3
DP  - 1985
TI  - Complete patency in thrombus-occluded arteries two weeks after laser 
      recanalization.
PG  - 291-6
AB  - The potential problem of rethrombosis after laser recanalization was studied in 
      16 thrombus-occluded canine femoral arteries. Balloon de-endothelialization and 
      thrombin-human blood injection produced adherent, completely occlusive thrombi 
      4.13 +/- 1.54 cm in length; laser exposure of the thrombi occurred at 18.35 +/- 
      22.1 hours. The argon laser catheter was introduced via a proximal arteriotomy 
      and a power of 3.83 +/- 0.58 W delivered for 411.3 +/- 296.87 seconds. Follow-up 
      period was 14 days. All arteries were patent immediately after and 14 days 
      following lasing, as demonstrated by angiography. There was no vessel 
      perforation. Seven of the dogs were maintained on aspirin and dipyridamole 4 days 
      before and throughout the study, but there were no differences in thrombus 
      length, laser power, or duration of laser exposure between these dogs and those 
      receiving no anti-platelet therapy. Control thrombosed arteries (without laser 
      energy application) showed no autolysis within 14 days in all dogs and up to 95 
      days in three dogs followed for this period of time. These data show that 
      rethrombosis of totally occluded, thrombosed arteries is not present up to 2 
      weeks later after laser recanalization, with or without the aid of anti-platelet 
      therapy.
FAU - Marco, J
AU  - Marco J
FAU - Silvernail, P J
AU  - Silvernail PJ
FAU - Fournial, G
AU  - Fournial G
FAU - Choy, D S
AU  - Choy DS
FAU - Fajadet, J
AU  - Fajadet J
FAU - Case, R B
AU  - Case RB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Lasers Surg Med
JT  - Lasers in surgery and medicine
JID - 8007168
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Dogs
MH  - Femoral Artery
MH  - *Laser Therapy
MH  - Thrombosis/drug therapy/*surgery
MH  - Time Factors
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1002/lsm.1900050311 [doi]
PST - ppublish
SO  - Lasers Surg Med. 1985;5(3):291-6. doi: 10.1002/lsm.1900050311.

PMID- 10826452
OWN - NLM
STAT- MEDLINE
DCOM- 20000606
LR  - 20190813
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 160
IP  - 10
DP  - 2000 May 22
TI  - Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme 
      inhibition in heart failure?
PG  - 1409-13
AB  - Ischemic heart disease is the most common underlying cause of congestive heart 
      failure, and thus aspirin (acetylsalicylic acid [ASA]) and angiotensin-converting 
      enzyme (ACE) inhibitors are commonly used together for treatment in this setting. 
      The issue of possible attenuation of the effect of ACE inhibitors by ASA has been 
      an area of intense debate. Currently, it is perceived that a significant part of 
      the beneficial effect of ACE inhibitors is related to augmentation of bradykinin 
      levels, which among other effects stimulate the release of prostacyclin. Aspirin, 
      on the other hand, inhibits the production of prostacyclin by blocking 
      cyclooxygenase. Prostaglandins play an important endogenous vasodilatory role and 
      counteract the enhanced peripheral vasoconstriction state in congestive heart 
      failure. Thus, the counteracting effect of ASA on the augmentation of 
      prostacyclin synthesis by ACE inhibitors could result in a potential reduction of 
      the beneficial effects of the ACE inhibitor's and could be of great importance. 
      This article reviews reports from large clinical trials pertaining to this issue 
      and relates their findings to the currently available theoretical bases for 
      support of the counteracting effect of ASA on augmentation of prostacyclin 
      synthesis by ACE inhibitors. The clinical implications of such an interaction are 
      discussed.
FAU - Stys, T
AU  - Stys T
AD  - Department of Medicine, State University of New York, Stony Brook, USA.
FAU - Lawson, W E
AU  - Lawson WE
FAU - Smaldone, G C
AU  - Smaldone GC
FAU - Stys, A
AU  - Stys A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/*adverse effects/therapeutic use
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Heart Failure/*drug therapy
MH  - Hemodynamics/drug effects
MH  - Humans
RF  - 45
EDAT- 2000/05/29 09:00
MHDA- 2000/06/10 09:00
CRDT- 2000/05/29 09:00
PHST- 2000/05/29 09:00 [pubmed]
PHST- 2000/06/10 09:00 [medline]
PHST- 2000/05/29 09:00 [entrez]
AID - 10.1001/archinte.160.10.1409 [doi]
PST - ppublish
SO  - Arch Intern Med. 2000 May 22;160(10):1409-13. doi: 10.1001/archinte.160.10.1409.

PMID- 26827923
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 501
IP  - 1-2
DP  - 2016 Mar 30
TI  - A method for grindability testing using the Scirocco disperser.
PG  - 65-74
LID - S0378-5173(16)30052-7 [pii]
LID - 10.1016/j.ijpharm.2016.01.052 [doi]
AB  - In the early stages of development of a new Active Pharmaceutical Ingredient 
      (API), insufficient material quantity is available for addressing processing 
      issues, and it is highly desirable to be able to assess processability issues 
      using the smallest possible powder sample quantity. A good example is milling of 
      new active pharmaceutical ingredients. For particle breakage that is sensitive to 
      strain rate, impact testing is the most appropriate method. However, there is no 
      commercially available single particle impact tester for fine particulate solids. 
      In contrast, dry powder dispersers, such as the Scirocco disperser of the Malvern 
      Mastersizer 2000, are widely available, and can be used for this purpose, 
      provided particle impact velocity is known. However, the distance within which 
      the particles can accelerate before impacting on the bend is very short and 
      different particle sizes accelerate to different velocities before impact. As the 
      breakage is proportional to the square of impact velocity, the interpretation of 
      breakage data is not straightforward and requires an analysis of particle 
      velocity as a function of size, density and shape. We report our work using an 
      integrated experimental and CFD modelling approach to evaluate the suitability of 
      this device as a grindability testing device, with the particle sizing being done 
      immediately following dispersion by laser diffraction. Aspirin, sucrose and 
      α-lactose monohydrate are tested using narrow sieve cuts in order to minimise 
      variations in impact velocity. The tests are carried out at eight different air 
      nozzle pressures. As intuitively expected, smaller particles accelerate faster 
      and impact the wall at a higher velocity compared to the larger particles. 
      However, for a given velocity the extent of breakage of larger particles is 
      larger. Using a numerical simulation based on CFD, the relationship between 
      impact velocity and particle size and density has been established assuming a 
      spherical shape, and using one-way coupling, as the particle concentration is 
      very low. Taking account of these dependencies, a clear unification of the change 
      in the specific surface area as a function of particle size, density and impact 
      velocity is observed, and the slope of the fitted line gives a measure of 
      grindability for each material. The trend of data obtained here matches the one 
      obtained by single particle impact testing. Hence aerodynamic dispersion of 
      solids by the Scirocco disperser can be used to evaluate the ease of grindability 
      of different materials.
CI  - Copyright © 2016 Elsevier B.V. All rights reserved.
FAU - Bonakdar, Tina
AU  - Bonakdar T
AD  - Institute of Particle Science and Engineering, University of Leeds, Leeds LS2 
      9JT, UK.
FAU - Ali, Muzammil
AU  - Ali M
AD  - Institute of Particle Science and Engineering, University of Leeds, Leeds LS2 
      9JT, UK.
FAU - Dogbe, Selasi
AU  - Dogbe S
AD  - Institute of Particle Science and Engineering, University of Leeds, Leeds LS2 
      9JT, UK.
FAU - Ghadiri, Mojtaba
AU  - Ghadiri M
AD  - Institute of Particle Science and Engineering, University of Leeds, Leeds LS2 
      9JT, UK. Electronic address: M.Ghadiri@leeds.ac.uk.
FAU - Tinke, Arjen
AU  - Tinke A
AD  - Janssen Research & Development, Department of Pharmaceutical Sciences-Particle & 
      Powder Characterization, Turnhoutseweg 30, B-2340 Beerse, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20160128
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Powders)
RN  - 57-50-1 (Sucrose)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Lactose/chemistry
MH  - Models, Theoretical
MH  - Particle Size
MH  - Powders/*chemistry
MH  - Sucrose/chemistry
MH  - Surface Properties
MH  - Technology, Pharmaceutical/*methods
OTO - NOTNLM
OT  - Aerodynamic dispersion
OT  - Breakage
OT  - Grindability
OT  - Impact
OT  - Milling
OT  - Pneumatic
OT  - Scirocco
EDAT- 2016/02/02 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/02/02 06:00
PHST- 2015/12/10 00:00 [received]
PHST- 2016/01/19 00:00 [revised]
PHST- 2016/01/20 00:00 [accepted]
PHST- 2016/02/02 06:00 [entrez]
PHST- 2016/02/02 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S0378-5173(16)30052-7 [pii]
AID - 10.1016/j.ijpharm.2016.01.052 [doi]
PST - ppublish
SO  - Int J Pharm. 2016 Mar 30;501(1-2):65-74. doi: 10.1016/j.ijpharm.2016.01.052. Epub 
      2016 Jan 28.

PMID- 92816
OWN - NLM
STAT- MEDLINE
DCOM- 19800228
LR  - 20190503
IS  - 0040-6376 (Print)
IS  - 1468-3296 (Electronic)
IS  - 0040-6376 (Linking)
VI  - 34
IP  - 5
DP  - 1979 Oct
TI  - Inhibition of idiosyncratic reactions to aspirin in asthmatic patients by 
      clemastine.
PG  - 654-7
AB  - An H1-receptor blocking antihistamine, clemastine, taken before aspirin gave 
      complete or partial protection against flushing, rhinorrhea, cough, and headache 
      in ten asthmatic patients with idiosyncrasy to aspirin. In five of the ten 
      patients aspirin-precipitated bronchoconstriction was also reduced or prevented 
      after pretreatment with clemastine. Thus histamine appears to play a part in the 
      production of most non-respiratory symptoms occurring after aspirin ingestion in 
      intolerant patients with asthma. Bronchial reactions might depend partly on 
      histamine and partly on the action of other spasmogens. It is suggested that 
      inhibition of prostaglandins of the E series by aspirin-like drugs plays a 
      crucial part in the release of histamine from tissue stores in aspirin-sensitive 
      asthmatic patients. Clemastine might be of use in the treatment of acute 
      reactions to aspirin.
FAU - Szczeklik, A
AU  - Szczeklik A
FAU - Serwonska, M
AU  - Serwonska M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Thorax
JT  - Thorax
JID - 0417353
RN  - 0 (Prostaglandins E)
RN  - 0 (Pyrrolidines)
RN  - 95QN29S1ID (Clemastine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/antagonists & inhibitors
MH  - Asthma/chemically induced/physiopathology/*prevention & control
MH  - Clemastine/*therapeutic use
MH  - Female
MH  - Histamine Release
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peak Expiratory Flow Rate
MH  - Prostaglandins E/metabolism
MH  - Pyrrolidines/*therapeutic use
PMC - PMC471141
EDAT- 1979/10/01 00:00
MHDA- 1979/10/01 00:01
CRDT- 1979/10/01 00:00
PHST- 1979/10/01 00:00 [pubmed]
PHST- 1979/10/01 00:01 [medline]
PHST- 1979/10/01 00:00 [entrez]
AID - 10.1136/thx.34.5.654 [doi]
PST - ppublish
SO  - Thorax. 1979 Oct;34(5):654-7. doi: 10.1136/thx.34.5.654.

PMID- 2393802
OWN - NLM
STAT- MEDLINE
DCOM- 19901011
LR  - 20220331
IS  - 0007-1331 (Print)
IS  - 0007-1331 (Linking)
VI  - 66
IP  - 1
DP  - 1990 Jul
TI  - Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin.
PG  - 85-7
AB  - Post-operative haemorrhagic complications following the ingestion of aspirin have 
      been reported after several types of surgery, most notably coronary artery bypass 
      surgery. In this study, aspirin ingestion also appeared to be a significant 
      aetiological factor in post-prostatectomy haemorrhage. This is explained in terms 
      of its inhibitory effect on platelet aggregation. A history of aspirin ingestion 
      should be carefully sought and its haemorrhagic implications considered prior to 
      prostatectomy.
FAU - Watson, C J
AU  - Watson CJ
AD  - Department of Urology, Addenbrooke's Hospital, Cambridge.
FAU - Deane, A M
AU  - Deane AM
FAU - Doyle, P T
AU  - Doyle PT
FAU - Bullock, K N
AU  - Bullock KN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Br J Urol
JT  - British journal of urology
JID - 15740090R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Blood Transfusion
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Postoperative Complications/*etiology
MH  - *Prostatectomy
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
AID - 10.1111/j.1464-410x.1990.tb14870.x [doi]
PST - ppublish
SO  - Br J Urol. 1990 Jul;66(1):85-7. doi: 10.1111/j.1464-410x.1990.tb14870.x.

PMID- 12011664
OWN - NLM
STAT- MEDLINE
DCOM- 20020927
LR  - 20190822
IS  - 0263-6352 (Print)
IS  - 0263-6352 (Linking)
VI  - 20
IP  - 5
DP  - 2002 May
TI  - Low-dose aspirin does not interfere with the blood pressure-lowering effects of 
      antihypertensive therapy.
PG  - 1015-22
AB  - BACKGROUND: It has been reported that aspirin (ASA) may interfere with the blood 
      pressure (BP)-lowering effect of various antihypertensive agents and attenuate 
      the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in 
      patients with congestive heart failure. METHODS AND RESULTS: Data from the 
      Hypertension Optimal Treatment (HOT) Study, in which 18 790 intensively treated 
      hypertensive patients were randomized to either ASA 75 mg daily or placebo for 
      3.8 years (with a 15% reduction in cardiovascular events and a 36% reduction in 
      myocardial infarction in ASA-treated patients), were reanalysed for the whole 
      group of patients and for various subgroups with particular attention to the 
      possible effects of ASA on BP and renal function. In ASA-treated and 
      placebo-treated patients: (1) systolic blood pressure (SBP) and diastolic blood 
      pressure (DBP) values achieved with antihypertensive treatment were 
      superimposable, with clinically irrelevant differences; (2) these superimposable 
      SBP and DBP were achieved with antihypertensive therapies, that were 
      quantitatively and qualitatively similar, and (3) changes in serum creatinine and 
      in estimated creatinine clearance and the number of patients developing renal 
      dysfunction were also similar. Furthermore, the cardiovascular benefits of ASA 
      were of the same magnitude in hypertensive patients receiving or not receiving 
      ACE-inhibitors. CONCLUSIONS: Even long-term, low-dose ASA does not interfere with 
      the BP-lowering effect of antihypertensive agents, including combinations with 
      ACE inhibitors, or with renal function. No negative interaction occurs between 
      ACE inhibition and the cardiovascular benefits of small dose of ASA. Our 
      conclusions cannot be extended to larger doses of ASA, or to patients with 
      congestive heart failure.
FAU - Zanchetti, Alberto
AU  - Zanchetti A
AD  - Centro di Fisiologia Clinica e Ipertensione, Università di Milano, Ospedale 
      Maggiore and Istituto Auxologico Italiano, Milano, Italy. 
      zanchett@mailserver.unimi.it
FAU - Hansson, Lennart
AU  - Hansson L
FAU - Leonetti, Gastone
AU  - Leonetti G
FAU - Rahn, Karl-Heinz
AU  - Rahn KH
FAU - Ruilope, Luis
AU  - Ruilope L
FAU - Warnold, Ingrid
AU  - Warnold I
FAU - Wedel, Hans
AU  - Wedel H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/*therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cardiovascular System/drug effects
MH  - Diastole
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Kidney/drug effects
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Systole
EDAT- 2002/05/16 10:00
MHDA- 2002/09/28 04:00
CRDT- 2002/05/16 10:00
PHST- 2002/05/16 10:00 [pubmed]
PHST- 2002/09/28 04:00 [medline]
PHST- 2002/05/16 10:00 [entrez]
AID - 10.1097/00004872-200205000-00038 [doi]
PST - ppublish
SO  - J Hypertens. 2002 May;20(5):1015-22. doi: 10.1097/00004872-200205000-00038.

PMID- 29407053
OWN - NLM
STAT- MEDLINE
DCOM- 20190109
LR  - 20190109
IS  - 1558-4410 (Electronic)
IS  - 0889-8529 (Linking)
VI  - 47
IP  - 1
DP  - 2018 Mar
TI  - Antiplatelet Therapy in Diabetes.
PG  - 223-235
LID - S0889-8529(17)30114-7 [pii]
LID - 10.1016/j.ecl.2017.10.009 [doi]
AB  - Cardiovascular disease (CVD) is a significant cause of morbidity and mortality 
      among patients with diabetes mellitus (DM). Increased platelet reactivity among 
      patients with DM contributes to disproportionately high levels of 
      atherothrombotic CVD. Consequently, there has been tremendous interest in 
      exploring the role of antiplatelet therapies in DM to reduce the development of 
      and frequency of future cardiovascular events.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Majithia, Arjun
AU  - Majithia A
AD  - Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, 41 
      Burlington Mall Road, Burlington, MA 01805, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Division of Cardiovascular Medicine, Brigham and Women's Hospital Heart and 
      Vascular Center and Harvard Medical School, 75 Francis Street, Boston, MA 02115, 
      USA. Electronic address: dlbhattmd@post.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171201
PL  - United States
TA  - Endocrinol Metab Clin North Am
JT  - Endocrinology and metabolism clinics of North America
JID - 8800104
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - *Cardiovascular Diseases/drug therapy/prevention & control
MH  - *Diabetes Complications/drug therapy/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - Antithrombotic therapy
OT  - Cardiovascular disease
OT  - Diabetes
OT  - Thrombosis
EDAT- 2018/02/07 06:00
MHDA- 2019/01/10 06:00
CRDT- 2018/02/07 06:00
PHST- 2018/02/07 06:00 [entrez]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2019/01/10 06:00 [medline]
AID - S0889-8529(17)30114-7 [pii]
AID - 10.1016/j.ecl.2017.10.009 [doi]
PST - ppublish
SO  - Endocrinol Metab Clin North Am. 2018 Mar;47(1):223-235. doi: 
      10.1016/j.ecl.2017.10.009. Epub 2017 Dec 1.

PMID- 3582487
OWN - NLM
STAT- MEDLINE
DCOM- 19870716
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 32
IP  - 2
DP  - 1987
TI  - In vitro and ex vivo effects of indobufen on red blood cell deformability.
PG  - 207-10
AB  - We have studied the effect of indobufen, a cyclo-oxygenase blocking agent which 
      has proved useful in patients with obstructive vascular disease, on red blood 
      cell (RBC) filterability in vitro and in a pilot study ex vivo. The addition of 
      indobufen in vitro to blood samples from 10 healthy volunteers did not 
      significantly modify RBC deformability. We evaluated the ex vivo effect of 
      indobufen (200 mg bd) in 14 patients with obstructive vascular disease. A 
      significant improvement in RBC deformability was noted on the 5th, 14th, and 28th 
      days of treatment, 2 h after the morning dose. Acetylsalicylic acid given to 6 
      similar patients had no effect suggesting that the positive haemorheological 
      effect of indobufen is probably not linked to its cyclooxygenase blocking effect.
FAU - Grasselli, S
AU  - Grasselli S
FAU - Guerciolini, R
AU  - Guerciolini R
FAU - Iadevaia, V
AU  - Iadevaia V
FAU - Parise, P
AU  - Parise P
FAU - Gresele, P
AU  - Gresele P
FAU - Nenci, G G
AU  - Nenci GG
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 6T9949G4LZ (indobufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Drug Interactions
MH  - Erythrocyte Deformability/*drug effects
MH  - Humans
MH  - In Vitro Techniques
MH  - Isoindoles
MH  - Phenylbutyrates/*pharmacology
MH  - Vascular Diseases/blood
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1007/BF00542198 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1987;32(2):207-10. doi: 10.1007/BF00542198.

PMID- 11274811
OWN - NLM
STAT- MEDLINE
DCOM- 20010517
LR  - 20190910
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 216
IP  - 1-2
DP  - 2001 Mar 23
TI  - Flow-through UV spectrophotometric sensor for determination of (acetyl)salicylic 
      acid in pharmaceutical preparations.
PG  - 95-104
AB  - The solid phase spectrophotometry technique, in which the absorbance of the 
      species of interest sorbed on a solid support is measured directly, was applied 
      to the determination of salicylic acid using flow injection-analysis. Salicylic 
      acid was determined by monitoring of its intrinsic absorbance at 297 nm sorbed on 
      Sephadex QAE A-25 resin placed in an appropriate flow-through cell. The method 
      proposed improves the selectivity compared with the corresponding solution-phase 
      method and the sensitivity is increased by a factor of 30 or more. The 
      flow-through sensor proposed allows working with several calibration lines simply 
      by varying the sample volume injected. Thus, linear dynamic ranges from 1 to 20 
      and from 2 to 40 microg ml(-1) can be obtained by using 1000 and 300 microl, 
      respectively, with detection limits being 0.064 and 0.135 microg ml(-1). Relative 
      Standard Deviations (RSDs) of 0.52 and 0.38%, and sampling frequencies of 18 and 
      25 h(-1), respectively, were also achieved. The sensor also allows the indirect 
      determination of acetylsalicylic acid previous hydrolysis on-line to salicylic 
      acid. For acetylsalicylic acid, a linear dynamic range from 5 to 120 microg 
      ml(-1) and 25 h(-1) of sampling frequency (300 microl of sample volume) were 
      obtained. The proposed flow-through sensor has been successfully applied to the 
      determination of both analytes in pharmaceutical preparations.
FAU - Ruiz-Medina, A
AU  - Ruiz-Medina A
AD  - Department of Physical and Analytical Chemistry, Faculty of Experimental 
      Sciences, University of Jaén, Jaén 23071, Spain.
FAU - Fernández-de Córdova, M L
AU  - Fernández-de Córdova ML
FAU - Ortega-Barrales, P
AU  - Ortega-Barrales P
FAU - Molina-Díaz, A
AU  - Molina-Díaz A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pharmaceutical Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis
MH  - Aspirin/*analysis
MH  - Flow Injection Analysis/*instrumentation
MH  - Hydrolysis
MH  - Pharmaceutical Preparations/*analysis
MH  - Spectrophotometry, Ultraviolet/*methods
EDAT- 2001/03/29 10:00
MHDA- 2001/05/18 10:01
CRDT- 2001/03/29 10:00
PHST- 2001/03/29 10:00 [pubmed]
PHST- 2001/05/18 10:01 [medline]
PHST- 2001/03/29 10:00 [entrez]
AID - S0378-5173(01)00569-5 [pii]
AID - 10.1016/s0378-5173(01)00569-5 [doi]
PST - ppublish
SO  - Int J Pharm. 2001 Mar 23;216(1-2):95-104. doi: 10.1016/s0378-5173(01)00569-5.

PMID- 25323536
OWN - NLM
STAT- MEDLINE
DCOM- 20150703
LR  - 20141031
IS  - 1521-3765 (Electronic)
IS  - 0947-6539 (Linking)
VI  - 20
IP  - 46
DP  - 2014 Nov 10
TI  - Simple synthetic receptors for aspirin.
PG  - 14991-5
LID - 10.1002/chem.201304808 [doi]
AB  - Shallow methylene-bridged cavitands appended with simple H-bond donor/acceptor 
      groups are shown to bind aspirin. The structural features needed in a synthetic 
      receptor for aspirin binding are defined.
CI  - © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Nguyen, Thanh V
AU  - Nguyen TV
AD  - Research School of Chemistry, Building 137, The Australian National University, 
      Canberra, ACT 2601 (Australia), Fax: (+61) 2 6125 8114.
FAU - Sherburn, Michael S
AU  - Sherburn MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141016
PL  - Germany
TA  - Chemistry
JT  - Chemistry (Weinheim an der Bergstrasse, Germany)
JID - 9513783
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Ethers, Cyclic)
RN  - 0 (Receptors, Artificial)
RN  - 0 (Resorcinols)
RN  - 0 (cavitand)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Binding Sites
MH  - Ethers, Cyclic/chemistry
MH  - Hydrogen Bonding
MH  - Models, Molecular
MH  - Receptors, Artificial/*chemistry
MH  - Resorcinols/chemistry
OTO - NOTNLM
OT  - aspirin
OT  - cavitands
OT  - host-guest systems
OT  - selective binding
OT  - synthetic receptors
EDAT- 2014/10/18 06:00
MHDA- 2015/07/04 06:00
CRDT- 2014/10/18 06:00
PHST- 2013/12/09 00:00 [received]
PHST- 2014/08/05 00:00 [revised]
PHST- 2014/10/18 06:00 [entrez]
PHST- 2014/10/18 06:00 [pubmed]
PHST- 2015/07/04 06:00 [medline]
AID - 10.1002/chem.201304808 [doi]
PST - ppublish
SO  - Chemistry. 2014 Nov 10;20(46):14991-5. doi: 10.1002/chem.201304808. Epub 2014 Oct 
      16.

PMID- 12638472
OWN - NLM
STAT- MEDLINE
DCOM- 20030505
LR  - 20131121
IS  - 0040-5930 (Print)
IS  - 0040-5930 (Linking)
VI  - 60
IP  - 1
DP  - 2003 Jan
TI  - [Antiaggregation: aspirin].
PG  - 15-8
AB  - Many randomized trials have shown aspirin as an effective antiplatelet drug for 
      the secondary prevention of cardiovascular events. The NNT (number needed to 
      treat) to prevent 1 vascular event is about 25. The NNH (number needed to harm) 
      inducing one cerebral bleeding is about 1'000, to provoke one severe 
      extracerebral bleeding about 100-200. The primary prevention can be recommended 
      only for high risk patients for cardiovascular events (annual risk of 1-1.5% or 
      more), calculated on the basis of the Framingham data, the Sheffield tables or in 
      analysis of U.S. Preventive Services Task Force. The mechanisms of action, 
      interactions and the "aspirin-resistance" are briefly discussed.
FAU - Eichenberger, A
AU  - Eichenberger A
AD  - Departement Innere Medizin, Kantonsspital Baden. adrian.eichenberger@ksb.ch
FAU - Pontiggia, L
AU  - Pontiggia L
FAU - Beer, J H
AU  - Beer JH
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Antiaggregation--Aspirin.
PL  - Switzerland
TA  - Ther Umsch
JT  - Therapeutische Umschau. Revue therapeutique
JID - 0407224
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Diabetes Complications
MH  - Diabetes Mellitus/drug therapy
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Time Factors
RF  - 12
EDAT- 2003/03/18 04:00
MHDA- 2003/05/06 05:00
CRDT- 2003/03/18 04:00
PHST- 2003/03/18 04:00 [pubmed]
PHST- 2003/05/06 05:00 [medline]
PHST- 2003/03/18 04:00 [entrez]
AID - 10.1024/0040-5930.60.1.15 [doi]
PST - ppublish
SO  - Ther Umsch. 2003 Jan;60(1):15-8. doi: 10.1024/0040-5930.60.1.15.

PMID- 27902474
OWN - NLM
STAT- MEDLINE
DCOM- 20180219
LR  - 20220321
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 3
DP  - 2017 Jan 17
TI  - Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: 
      A dose-response meta-analysis.
PG  - 4781-4795
LID - 10.18632/oncotarget.13591 [doi]
AB  - BACKGROUND: The association between non-steroidal anti-inflammatory drugs 
      (NSAIDs) and gastric cancer (GC) risk is controversial. The aim of this study is 
      to evaluate the chemopreventive effect of NSAIDs for GC. METHODS: A literature 
      search was performed for relevant studies using the PubMed and Embase database 
      (up to March 2016). Risk ratios (RRs) and 95% confidence intervals (CIs) were 
      used as the effect measures. The dose-response analysis and subgroup analysis 
      were also performed. RESULTS: Twenty-four studies were included. Our results 
      indicated that NSAIDs could reduce GC risk (any NSAIDs: RR=0.78, 96%CI=0.72-0.85; 
      aspirin: RR=0.70, 95%CI=0.62-0.80; non-aspirin NSAIDs: RR=0.86, 95%CI=0.80-0.94), 
      especially for non-cardia GC risk. Moreover, the dose-response analysis indicated 
      the risk of GC decreased by 11% and 5% for 2 years increment of any NSAIDs and 
      aspirin use, respectively. There were nonlinear relationships between the 
      frequency of any NSAIDs use and aspirin use and GC risk (P for 
      non-linearity<0.01), with a threshold effect of 5 times/week. A monotonically 
      decreasing trend was observed only for the frequency of less than 5 times/week. 
      CONCLUSIONS: Our results indicate that NSAIDs is inversely associated with GC 
      risk, especially for non-cardia GC risk. NSAIDs use may become a feasible 
      approach to prevent GC.
FAU - Huang, Xuan-Zhang
AU  - Huang XZ
AD  - Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and 
      Yuying Children's Hospital of Wenzhou Medical University, Wenzhou City 325027, 
      P.R. China.
FAU - Chen, You
AU  - Chen Y
AD  - The Wenzhou Dental Hospital, Wenzhou City 325027, P.R. China.
FAU - Wu, Jian
AU  - Wu J
AD  - Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and 
      Yuying Children's Hospital of Wenzhou Medical University, Wenzhou City 325027, 
      P.R. China.
FAU - Zhang, Xi
AU  - Zhang X
AD  - Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and 
      Yuying Children's Hospital of Wenzhou Medical University, Wenzhou City 325027, 
      P.R. China.
FAU - Wu, Cong-Cong
AU  - Wu CC
AD  - Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and 
      Yuying Children's Hospital of Wenzhou Medical University, Wenzhou City 325027, 
      P.R. China.
FAU - Zhang, Chao-Ying
AU  - Zhang CY
AD  - Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and 
      Yuying Children's Hospital of Wenzhou Medical University, Wenzhou City 325027, 
      P.R. China.
FAU - Sun, Shuang-Shuang
AU  - Sun SS
AD  - Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and 
      Yuying Children's Hospital of Wenzhou Medical University, Wenzhou City 325027, 
      P.R. China.
FAU - Chen, Wen-Jun
AU  - Chen WJ
AD  - Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and 
      Yuying Children's Hospital of Wenzhou Medical University, Wenzhou City 325027, 
      P.R. China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cardia/pathology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Odds Ratio
MH  - Stomach Neoplasms/pathology/*prevention & control
MH  - Treatment Outcome
PMC - PMC5354871
OTO - NOTNLM
OT  - aspirin
OT  - chemoprevention
OT  - gastric cancer
OT  - meta-analysis
OT  - non-steroidal anti-inflammatory drugs
COIS- CONFLICTS OF INTEREST All authors declare that they have no competing interests.
EDAT- 2016/12/03 06:00
MHDA- 2018/02/20 06:00
CRDT- 2016/12/01 06:00
PHST- 2016/07/25 00:00 [received]
PHST- 2016/11/14 00:00 [accepted]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2018/02/20 06:00 [medline]
PHST- 2016/12/01 06:00 [entrez]
AID - 13591 [pii]
AID - 10.18632/oncotarget.13591 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Jan 17;8(3):4781-4795. doi: 10.18632/oncotarget.13591.

PMID- 37364220
OWN - NLM
STAT- MEDLINE
DCOM- 20230628
LR  - 20230630
IS  - 2687-8941 (Electronic)
IS  - 2687-8941 (Linking)
VI  - 9
DP  - 2023 Jun
TI  - Operational Challenges of an Asia-Pacific Academic Oncology Clinical Trial.
PG  - e2300040
LID - 10.1200/GO.23.00040 [doi]
AB  - PURPOSE: The Asia-Pacific (APAC) region is a major focus for multinational 
      clinical trials, although its cultural, linguistic, economic, and regulatory 
      diversity pose significant challenges for trial conduct, particularly for 
      academic clinical trials. METHODS: We describe our experience running the 
      investigator-initiated phase III randomized, fully accrued, Aspirin for Dukes C 
      and high-risk Dukes B Colorectal cancer trial (ASCOLT, ClinicalTrials.gov 
      identifier: NCT00565708, N = 1,587), studying the benefit of aspirin in resected 
      high-risk colorectal cancer. ASCOLT opened in 2008 and is the first large 
      academic adjuvant trial fully conducted in the APAC region. Centrally coordinated 
      by the Trial Management Team at the National Cancer Centre Singapore, it has 
      involved 74 sites across 12 APAC countries/regions, including five middle-income 
      countries. RESULTS: Challenges encountered included regulatory complexity, 
      communication and logistical barriers, limited funding and resources, disparate 
      experience and infrastructure across sites, recruitment holds because of changes 
      in local laws, patient attrition, and disruptions caused by the COVID-19 
      pandemic. Over 100 contracts and 49 ethics board reviews were required, 
      contributing to a lengthy prestudy preparation time of 2 years and start-up times 
      of approximately 6 months per site. Some of the mitigating actions included 
      engaging local cooperative groups (eg, the Australasian Gastro-Intestinal Trials 
      Group in Australia and New Zealand) and seven contract research organizations to 
      manage sites, regular communication with the central team, transition to 
      electronic data management, and a centralized drug-dispensing system. CONCLUSION: 
      To ensure an efficient and patient-centered clinical trials environment in the 
      APAC region and sustained growth, we suggest coordinated approaches to harmonize 
      regulatory processes, APAC academic oncology trials consortia to streamline 
      processes and provide governance, and ongoing commitment from governments, 
      funding agents, and industry.
FAU - Day, Daphne
AU  - Day D
AUID- ORCID: 0000-0001-8262-2441
AD  - Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, 
      VIC, Australia.
AD  - Department of Oncology, Monash Health, Melbourne, VIC, Australia.
FAU - Toh, Han Chong
AU  - Toh HC
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Ali, Raghib
AU  - Ali R
AD  - Public Health Research Centre, New York University, Abu Dhabi, United Arab 
      Emirates.
FAU - Foo, Estelle Mei Jye
AU  - Foo EMJ
AUID- ORCID: 0000-0002-4957-3825
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Simes, John
AU  - Simes J
AD  - University of Sydney NHMRC Clinical Trials Centre, Sydney, NSW, Australia.
FAU - Chia, John Whay Kuang
AU  - Chia JWK
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Segelov, Eva
AU  - Segelov E
AUID- ORCID: 0000-0002-4410-6144
AD  - Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, 
      VIC, Australia.
AD  - Faculty of Medicine, University of Bern, Bern, Switzerland.
CN  - ASCOLT Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00565708
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JCO Glob Oncol
JT  - JCO global oncology
JID - 101760170
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *COVID-19
MH  - Pandemics
MH  - Asia/epidemiology
MH  - *Colorectal Neoplasms/therapy
MH  - Aspirin/therapeutic use
EDAT- 2023/06/26 19:07
MHDA- 2023/06/28 06:42
CRDT- 2023/06/26 16:03
PHST- 2023/06/28 06:42 [medline]
PHST- 2023/06/26 19:07 [pubmed]
PHST- 2023/06/26 16:03 [entrez]
AID - 10.1200/GO.23.00040 [doi]
PST - ppublish
SO  - JCO Glob Oncol. 2023 Jun;9:e2300040. doi: 10.1200/GO.23.00040.

PMID- 31027657
OWN - NLM
STAT- MEDLINE
DCOM- 20200131
LR  - 20200131
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 124
IP  - 1
DP  - 2019 Jul 1
TI  - Meta-Analysis of Acetylsalicylic Acid Desensitization in Patients With Acute 
      Coronary Syndrome.
PG  - 14-19
LID - S0002-9149(19)30412-6 [pii]
LID - 10.1016/j.amjcard.2019.03.047 [doi]
AB  - Acetylsalicylic acid (ASA) hypersensitivity represents a clinical challenge in 
      acute coronary syndrome (ACS) patients urgently requiring ASA for antiplatelet 
      therapy. ASA desensitization has been reported with successful outcomes in 
      cardiac patients. The aim of this review is to determine the safety and efficacy 
      of ASA desensitization therapy in ACS patients. A PubMed database search was 
      conducted for articles containing combinations of keywords, "aspirin 
      desensitization" or "aspirin hypersensitivity" and "acute coronary syndrome" 
      between January 1, 1990 and August 1, 2018. The primary end point was 
      desensitization protocol success. Secondary end points included hypersensitivity 
      adverse events and ASA discontinuation due to hypersensitivity adverse events at 
      follow-up. Fifteen reports consisting of 480 ACS patients with previous 
      hypersensitivity to ASA were included. The pooled desensitization success rate 
      was 98.3% (95% confidence interval: 97.2% to 99.5%). There was no statistical 
      difference in outcomes between protocols ≤ 2 hours and > 2 hours in duration 
      (96.3[92.3 to 100.3]% vs 97.2[94.6 to 99.8]%; p = 0.71). Protocols with > 6 dose 
      escalations were associated with higher success rates compared to those with ≤ 6 
      doses (99.2[97.9 to 100.4]% vs 95.4[93 to 97.8]%; p = 0.007). At follow-up 
      between 1 and 46 months (mode 12 months), zero hypersensitivity adverse events 
      were reported. Consequently, no ASA discontinuations were related to 
      hypersensitivity adverse events. In conclusion, ASA desensitization therapy is 
      safe and effective in patients with ACS. Protocols with > 6 dose escalations may 
      be optimal for ASA desensitization in ACS patients.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Chopra, Amitabh Madhukumar
AU  - Chopra AM
AD  - Self Employed, Chemical Engineer/Medical Researcher, Mumbai, Maharashtra, India. 
      Electronic address: Amitabh.m.chopra@gmail.com.
FAU - Díez-Villanueva, Pablo
AU  - Díez-Villanueva P
AD  - Department of Cardiology, University Hospital La Princesa, Madrid, Spain.
FAU - Córdoba-Soriano, Juan Gabriel
AU  - Córdoba-Soriano JG
AD  - Department of Cardiology, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Lee, Joe K T
AU  - Lee JKT
AD  - Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong 
      Kong.
FAU - Al-Ahmad, Mona
AU  - Al-Ahmad M
AD  - Department of Microbiology, Faculty of Medicine, Kuwait University, Safat, 
      Kuwait.
FAU - Ferraris, Victor A
AU  - Ferraris VA
AD  - Division of Cardiothoracic Surgery, Department of Surgery, University of 
      Kentucky, Lexington, Kentucky.
FAU - Mehta, Monik
AU  - Mehta M
AD  - Department of Cardiology, Artemis Hospital, Gurgaon, Haryana, India.
FAU - Kowalski, Marek L
AU  - Kowalski ML
AD  - Department of Immunology and Allergy, Medical University of Łódź, Łódź, Poland.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190410
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2019/04/28 06:00
MHDA- 2020/02/01 06:00
CRDT- 2019/04/28 06:00
PHST- 2019/01/31 00:00 [received]
PHST- 2019/03/07 00:00 [revised]
PHST- 2019/03/14 00:00 [accepted]
PHST- 2019/04/28 06:00 [pubmed]
PHST- 2020/02/01 06:00 [medline]
PHST- 2019/04/28 06:00 [entrez]
AID - S0002-9149(19)30412-6 [pii]
AID - 10.1016/j.amjcard.2019.03.047 [doi]
PST - ppublish
SO  - Am J Cardiol. 2019 Jul 1;124(1):14-19. doi: 10.1016/j.amjcard.2019.03.047. Epub 
      2019 Apr 10.

PMID- 962198
OWN - NLM
STAT- MEDLINE
DCOM- 19761101
LR  - 20131121
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 37
IP  - 3
DP  - 1976 Sep
TI  - Prolonged bleeding times after aspirin ingestion in patients with aspirin 
      idiosyncrasy.
PG  - 191-4
AB  - Measurements of the bleeding time after the ingestion of small doses of aspirin 
      in patients with aspirin idiosyncrasy demonstrate a marked prolongation compared 
      with control patients. Confirmation of this finding offers a clue to the 
      pathogenesis of this condition. Despite the prolonged bleeding time, 
      gastrointestinal haemorrhage is an uncommon event in patients with aspirin 
      idiosyncrasy.
FAU - Delaney, J C
AU  - Delaney JC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Blood Coagulation/*drug effects
MH  - Drug Hypersensitivity/blood/*etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1976/09/01 00:00
MHDA- 1976/09/01 00:01
CRDT- 1976/09/01 00:00
PHST- 1976/09/01 00:00 [pubmed]
PHST- 1976/09/01 00:01 [medline]
PHST- 1976/09/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1976 Sep;37(3):191-4.

PMID- 19407805
OWN - NLM
STAT- MEDLINE
DCOM- 20091005
LR  - 20131121
IS  - 1941-7225 (Electronic)
IS  - 0895-7061 (Linking)
VI  - 22
IP  - 8
DP  - 2009 Aug
TI  - Ambulatory blood pressure control with bedtime aspirin administration in subjects 
      with prehypertension.
PG  - 896-903
LID - 10.1038/ajh.2009.83 [doi]
AB  - BACKGROUND: Aspirin has been found to prevent angiotensin II-induced hypertension 
      and to induce nitric oxide (NO) release from vascular endothelium. Low-dose 
      aspirin has also been shown to reduce blood pressure (BP) when administered at 
      bedtime, as opposed to upon awakening, in untreated hypertensive patients and 
      high-risk pregnant women. Accordingly, we investigated the effects on ambulatory 
      BP of aspirin administered at different times of the day in prehypertension. 
      METHODS: We studied 244 subjects with prehypertension, 43.0 +/- 13.0 years of 
      age, randomly divided in three groups: nonpharmacological hygienic-dietary 
      recommendations; the same recommendations and aspirin (100 mg/day) on awakening; 
      or the same recommendations and aspirin at bedtime. BP was measured for 48 
      consecutive hours before and after 3 months of intervention. RESULTS: Ambulatory 
      BP was unchanged in subjects randomized to either nonpharmacological intervention 
      or aspirin on awakening. A significant ambulatory BP reduction was, however, 
      observed in the subjects who received aspirin at bedtime (decrease of 6/3 mm Hg 
      in the 24-h mean of systolic (SBP)/diastolic BP (DBP), respectively; P < 0.001), 
      without changes in heart rate (HR) from baseline. BP was homogeneously controlled 
      along the 24 h after bedtime aspirin administration (6/4 mm Hg reduction in 
      activity mean of SBP/DBP; 6/3 mm Hg reduction in sleep-time mean, respectively). 
      CONCLUSIONS: This prospective trial documents a significant effect on BP of low 
      dose aspirin only when ingested at bedtime by prehypertensive subjects. The timed 
      administration of low-dose aspirin could thus provide a valuable and 
      cost-effective approach for BP control in subjects at elevated risk of developing 
      hypertension.
FAU - Hermida, Ramón C
AU  - Hermida RC
AD  - Bioengineering and Chronobiology Laboratories, University of Vigo, Vigo, Spain. 
      rhermida@uvigo.es
FAU - Ayala, Diana E
AU  - Ayala DE
FAU - Mojón, Artemio
AU  - Mojón A
FAU - Fernández, José R
AU  - Fernández JR
LA  - eng
SI  - ClinicalTrials.gov/NCT00295542
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090430
PL  - United States
TA  - Am J Hypertens
JT  - American journal of hypertension
JID - 8803676
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Circadian Rhythm/physiology
MH  - Double-Blind Method
MH  - Endpoint Determination
MH  - Female
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Hypertension/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Motor Activity/physiology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*therapeutic use
MH  - Prospective Studies
MH  - Sleep/physiology
MH  - Time Factors
EDAT- 2009/05/02 09:00
MHDA- 2009/10/06 06:00
CRDT- 2009/05/02 09:00
PHST- 2009/05/02 09:00 [entrez]
PHST- 2009/05/02 09:00 [pubmed]
PHST- 2009/10/06 06:00 [medline]
AID - ajh200983 [pii]
AID - 10.1038/ajh.2009.83 [doi]
PST - ppublish
SO  - Am J Hypertens. 2009 Aug;22(8):896-903. doi: 10.1038/ajh.2009.83. Epub 2009 Apr 
      30.

PMID- 422089
OWN - NLM
STAT- MEDLINE
DCOM- 19790526
LR  - 20131121
IS  - 0015-8178 (Print)
IS  - 0015-8178 (Linking)
VI  - 97
IP  - 10
DP  - 1979 Mar 15
TI  - [Prevention of premature delivery with acetylsalicylic acid].
PG  - 463-6
AB  - In 52 cases acetylsalicylic acid was used to prevent labor when symptomatic 
      tocolysis with beta-adrenergic substances showed insufficient results. By 
      applying this method, 48 children were carried to full viability. Upon admission, 
      all pregnancies were below 36 weeks of gestation. Upon delivery, 15 were between 
      the 34th und 36th week, and 31 beyond the 36th week of gestation. We succeeded 
      fully in 32 cases, 15 incomplete cases were observed and 5 failures. In addition 
      to tocolysis, therapy with acetylsalicylic acid appears promising in preventing 
      premature delivery.
FAU - Babenerd, J
AU  - Babenerd J
FAU - Kyriakidis, K
AU  - Kyriakidis K
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Wehenhemmung durch Azetylsalizylsäure.
PL  - Germany
TA  - Fortschr Med
JT  - Fortschritte der Medizin
JID - 2984763R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Infant Mortality
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Obstetric Labor, Premature/*prevention & control
MH  - Pregnancy
MH  - Time Factors
EDAT- 1979/03/15 00:00
MHDA- 1979/03/15 00:01
CRDT- 1979/03/15 00:00
PHST- 1979/03/15 00:00 [pubmed]
PHST- 1979/03/15 00:01 [medline]
PHST- 1979/03/15 00:00 [entrez]
PST - ppublish
SO  - Fortschr Med. 1979 Mar 15;97(10):463-6.

PMID- 833724
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 66
IP  - 1
DP  - 1977 Jan
TI  - Effects of aspirin and acetaminophen on fetal and placental growth in rats.
PG  - 111-3
AB  - Aqueous suspensions of aspirin or acetaminophen (125 and 250 mg/kg/day) were 
      administered orally to pregnant Sprague-Dawley rats on Days 8-19 of gestation Day 
      20, each rat was sacrificed and the uterus was examined in situ. Each 
      fetal-placental unit was resected and examined. Fetuses from rats given 125 or 
      250 mg/kg/day of aspirin were shorter and weighed less than those obtained from 
      control rats. In animals receiving the higher dose of aspirin, the placentas were 
      smaller and the number of fetal resorptions was increased. Acetaminophen (250 
      mg/kg/day) did not affect fetal length or weight or the incidence of resorption. 
      Acetaminophen interfered less with the normal growth of the rat fetus and 
      placenta than did aspirin.
FAU - Lubawy, W C
AU  - Lubawy WC
FAU - Garrett, R J
AU  - Garrett RJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Body Weight/drug effects
MH  - Female
MH  - Fetus/*drug effects
MH  - Placenta/*drug effects
MH  - Pregnancy
MH  - Rats
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - S0022-3549(15)39116-4 [pii]
AID - 10.1002/jps.2600660129 [doi]
PST - ppublish
SO  - J Pharm Sci. 1977 Jan;66(1):111-3. doi: 10.1002/jps.2600660129.

PMID- 7770254
OWN - NLM
STAT- MEDLINE
DCOM- 19950705
LR  - 20190818
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 85
IP  - 6
DP  - 1995 Jun
TI  - Low-dose aspirin: lack of association with an increase in abruptio placentae or 
      perinatal mortality.
PG  - 1055-8
AB  - OBJECTIVE: To perform a meta-analysis determining the association of low-dose 
      aspirin treatment with subsequent abruptio placentae or perinatal mortality. DATA 
      SOURCES: Studies were identified and selected using the MEDLINE bibliographic 
      data base of entries from January 1985 through April 1994. In addition, a manual 
      search was performed using the references from all retrieved reports, review 
      articles, and chapters from textbooks. METHODS OF STUDY SELECTION: Three criteria 
      were used to select studies for inclusion: 1) Studies were designed as randomized 
      or double-blind clinical trials; 2) aspirin was administered in doses of less 
      than 200 mg/day; and 3) outcome data included the incidence of abruptio placentae 
      and perinatal mortality. Three studies did not report the occurrence of abruptio 
      placentae, but the authors of those papers answered written requests for such 
      data. A total of 11 studies met our inclusion criteria. DATA EXTRACTION AND 
      SYNTHESIS: We independently evaluated the study methods for each trial and 
      abstracted quantitative outcome data. For each outcome, relative risk, risk 
      differences, and 95% confidence intervals were calculated. The diagnosis of 
      abruptio placentae was taken as self-reported in each trial. No trial of low-dose 
      aspirin in pregnancy had predefined criteria for the diagnosis of abruptio 
      placentae, and abruption was not a primary outcome in any of the 11 trials. We 
      combined data from all studies and compared the data from the randomized trials 
      to those from the double-blind studies. CONCLUSION: We found no increased risk 
      for abruptio placentae or increased perinatal mortality in women taking low-dose 
      aspirin.
FAU - Hauth, J C
AU  - Hauth JC
AD  - Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 
      USA.
FAU - Goldenberg, R L
AU  - Goldenberg RL
FAU - Parker, C R Jr
AU  - Parker CR Jr
FAU - Cutter, G R
AU  - Cutter GR
FAU - Cliver, S P
AU  - Cliver SP
LA  - eng
GR  - 1 R01 HD24496-01/HD/NICHD NIH HHS/United States
GR  - 282-92-0055/PHS HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abruptio Placentae/chemically induced/*epidemiology
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Fetal Growth Retardation/prevention & control
MH  - Humans
MH  - Incidence
MH  - Infant, Newborn
MH  - Infant, Newborn, Diseases/chemically induced/*mortality
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
EDAT- 1995/06/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
AID - 002978449500042P [pii]
AID - 10.1016/0029-7844(95)00042-p [doi]
PST - ppublish
SO  - Obstet Gynecol. 1995 Jun;85(6):1055-8. doi: 10.1016/0029-7844(95)00042-p.

PMID- 12380142
OWN - NLM
STAT- MEDLINE
DCOM- 20021204
LR  - 20131121
IS  - 1438-3276 (Print)
IS  - 1438-3276 (Linking)
VI  - 144
IP  - 33-34
DP  - 2002 Aug 22
TI  - [Platelet aggregation inhibitor in general practice. Every 3rd infarct 
      prevented--reinfarction rate cut in half].
PG  - 38-41
AB  - Depending on their mode of action, pharmaceuticals with an antithrombocytic 
      effect are divided into five groups. In the doctor's office, acetylsalicylic acid 
      (ASA) and the thienopyridines, such a ticlopidine and clopidogrel predominate. 
      Acetylsalicylic acid should be considered for primary prevention in patients over 
      50 with a marked cardiovascular risk profile. In the secondary prophylaxis of 
      myocardial infarction, life-long ASA treatment continues to be the treatment of 
      choice. As an alternative, however, clopidogrel may be applied. A combination of 
      acetylsalicylic acid and clopidogrel is recommended for patients who have been 
      implanted with a stent. In patients with acute coronary syndrome, this regimen is 
      superior to monotherapy with acetylsalicylic acid. In comparison with 
      ticlopidine, clopidogrel has a more rapid onset of action, and has fewer side 
      effects. In patients with an acute coronary syndrome and an elevated risk 
      glycoprotein IIb/IIIa antagonists have proved highly effective.
FAU - Fliri, M
AU  - Fliri M
AD  - I. Medizinische Klinik, Klinikum Augsburg. mfliri@yahoo.de
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Thrombozytenaggregationshemmer in der Praxis. Jeder dritte Infarkt 
      verhütet--Reinfarktrate halbiert.
PL  - Germany
TA  - MMW Fortschr Med
JT  - MMW Fortschritte der Medizin
JID - 100893959
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/mortality/*prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/classification/*therapeutic use
MH  - Recurrence
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2002/10/17 04:00
MHDA- 2002/12/05 04:00
CRDT- 2002/10/17 04:00
PHST- 2002/10/17 04:00 [pubmed]
PHST- 2002/12/05 04:00 [medline]
PHST- 2002/10/17 04:00 [entrez]
PST - ppublish
SO  - MMW Fortschr Med. 2002 Aug 22;144(33-34):38-41.

PMID- 8135810
OWN - NLM
STAT- MEDLINE
DCOM- 19940421
LR  - 20171116
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 199
IP  - 2
DP  - 1994 Mar 15
TI  - The inhibition of sugar-induced structural alterations in collagen by aspirin and 
      other compounds.
PG  - 683-6
AB  - With age human collagen demonstrates, amongst other changes, reductions in 
      solubility, elasticity and permeability. Many of these changes have been 
      attributed to non-enzymic glycosylation (glycation)-a spontaneous addition of 
      sugar molecules to any protein with free amino groups. The resulting formation 
      and accumulation of Advanced Glycation End-products, some of which may be 
      cross-links, has been shown in both long- and short-lived proteins. We have shown 
      that glycation of human corneal and scleral collagen increases with age and that 
      this is accompanied by increases in cross-linking and collagen intermolecular 
      spacing. We have now investigated several compounds that have been used to 
      inhibit glycation, including aspirin, and have shown that all the inhibitors also 
      prevent the increase in intermolecular spacing caused by glycation.
FAU - Malik, N S
AU  - Malik NS
AD  - Biophysics Group, Open University, Boars Hill, Oxford, U.K.
FAU - Meek, K M
AU  - Meek KM
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Guanidines)
RN  - 7A314HQM0I (Pentetic Acid)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - SCQ4EZQ113 (pimagedine)
SB  - IM
MH  - Aspirin/antagonists & inhibitors/*pharmacology
MH  - Collagen/*chemistry/drug effects/metabolism
MH  - Cornea/metabolism
MH  - Elasticity
MH  - Glycation End Products, Advanced/analysis
MH  - Glycosylation
MH  - Guanidines/pharmacology
MH  - Humans
MH  - Kinetics
MH  - Middle Aged
MH  - Pentetic Acid/pharmacology
MH  - Permeability
MH  - Protein Conformation/*drug effects
MH  - Sclera/metabolism
MH  - Solubility
MH  - X-Ray Diffraction
EDAT- 1994/03/15 00:00
MHDA- 1994/03/15 00:01
CRDT- 1994/03/15 00:00
PHST- 1994/03/15 00:00 [pubmed]
PHST- 1994/03/15 00:01 [medline]
PHST- 1994/03/15 00:00 [entrez]
AID - S0006-291X(84)71282-4 [pii]
AID - 10.1006/bbrc.1994.1282 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1994 Mar 15;199(2):683-6. doi: 
      10.1006/bbrc.1994.1282.

PMID- 1705719
OWN - NLM
STAT- MEDLINE
DCOM- 19910408
LR  - 20181130
IS  - 0300-0729 (Print)
IS  - 0300-0729 (Linking)
VI  - 28
IP  - 4
DP  - 1990 Dec
TI  - ASA-induced release of histamine from nasal mucous membranes in analgesic 
      intolerance and polyposis nasi.
PG  - 231-8
AB  - Tissue samples from the polypous mucous membrane and the inferior nasal concha 
      were taken from 13 patients with polyposis nasi and from 12 other patients with 
      an additional intolerance to analgesics. The tissue of the inferior nasal concha 
      from patients without polyposis nasi served as a control. The relative histamine 
      content of the samples (in ng/mg dry weight) and the relative histamine release 
      (in %) after addition of acetylsalicylic acid (ASA) were determined. A 
      significantly higher relative histamine content in the tissue samples of polyp 
      patients without an intolerance to analgesics was seen in comparison to the other 
      two groups. The relative histamine release of both patient groups with nasal 
      polyposis was comparable. The control group exhibited both an increased 
      spontaneous release of histamine as well as a higher relative histamine release 
      from the tissue of the inferior nasal concha.
FAU - Hosemann, W G
AU  - Hosemann WG
AD  - Dept. of O.R.L., University of Erlangen-Nürnberg, Fed. Rep. of Germany.
FAU - Baenkler, H W
AU  - Baenkler HW
FAU - Günther, F
AU  - Günther F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - Rhinology
JT  - Rhinology
JID - 0347242
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/pharmacology
MH  - Drug Tolerance
MH  - Female
MH  - Histamine Release/*drug effects
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Nasal Mucosa/drug effects/*metabolism
MH  - Nasal Polyps/physiopathology/*surgery
MH  - Turbinates/drug effects/*surgery
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
PST - ppublish
SO  - Rhinology. 1990 Dec;28(4):231-8.

PMID- 7017488
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Evaluation of the therapeutic effects of broncaspin in chronic 
      bronchopneumopathies].
PG  - 379-86
AB  - A controlled single-blind clinical trial was made with Broncaspin, on original 
      synthetic molecule obtained by condensing acetylsalicylic acid and guaiacol, in a 
      comparison of its local and general tolerance, and antipyretic, antiexudative and 
      balsamic properties with those of dimethylaminophenazone guaiacolglycolate, a 
      well-known preparation, in two randomly composed groups of 15 patients with 
      chronic obstructive bronchial and lung diseases, using 1,2 g Broncaspin 
      suppositories and the commercial form of the other product twice a day for 14 
      consecutive days. Therapeutic assessment was based on the symptomatological, 
      spirometric and blood gas data.
FAU - Gunella, G
AU  - Gunella G
FAU - Galleri, C
AU  - Galleri C
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Valutazione degli effetti terapeutici del "Broncaspin" nei broncopneumopatici 
      cronici.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Drug Combinations)
RN  - 01704YP3MO (Aminopyrine)
RN  - 6JKA7MAH9C (Guaiacol)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Aminopyrine/*analogs & derivatives/therapeutic use
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Bronchial Diseases/*drug therapy
MH  - Clinical Trials as Topic
MH  - Drug Combinations
MH  - Drug Evaluation
MH  - Guaiacol/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Lung Diseases, Obstructive/*drug therapy
MH  - Respiration/drug effects
MH  - Spirometry
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):379-86.

PMID- 375849
OWN - NLM
STAT- MEDLINE
DCOM- 19790728
LR  - 20190503
IS  - 0003-4967 (Print)
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 38
IP  - 2
DP  - 1979 Apr
TI  - Diflunisal in osteoarthrosis of the hip and knee.
PG  - 148-51
AB  - Diflunisal (750 mg per day) has been compared with acetylsalicylic acid (ASA) 
      (3000 mg per day) in the treatment of osteoarthrosis of the hip and knee in a 
      double-blind, randomised, multicentre, outpatient study. Thirty-one patients 
      entered the diflunisal group and 29 the ASA group. The response of the 2 groups 
      was comparable, but the incidence of side effects was higher in the ASA group. At 
      the end of the 12-week period more patients in the diflunisal group chose to 
      remain in a further, open study.
FAU - Essigman, W K
AU  - Essigman WK
FAU - Chamberlain, M A
AU  - Chamberlain MA
FAU - Wright, V
AU  - Wright V
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Bone Diseases/*drug therapy
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Hip Joint
MH  - Humans
MH  - Joint Diseases/*drug therapy
MH  - Knee Joint
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
PMC - PMC1000340
EDAT- 1979/04/01 00:00
MHDA- 1979/04/01 00:01
CRDT- 1979/04/01 00:00
PHST- 1979/04/01 00:00 [pubmed]
PHST- 1979/04/01 00:01 [medline]
PHST- 1979/04/01 00:00 [entrez]
AID - 10.1136/ard.38.2.148 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 1979 Apr;38(2):148-51. doi: 10.1136/ard.38.2.148.

PMID- 968338
OWN - NLM
STAT- MEDLINE
DCOM- 19761201
LR  - 20191028
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - 15
IP  - 3
DP  - 1976 Aug
TI  - The effects of antacids on enteric-coated salicylate preparations.
PG  - 148-52
AB  - A volunteer study was undertaken in which the effect of the co-administration of 
      therapeutic doses of aluminium hydroxide and magnesium trisilicate on the 
      excretion of aspirin derived from enteric-coated preparations was studied. A 
      significant alteration in the pattern of salicylate excretion was seen, but the 
      mechanism of the interaction cannot be deduced from the present study. It was 
      concluded that the interaction was of potential therapeutic importance, and 
      further studies based on this pilot investigation have been initiated.
FAU - Strickland-Hodge, B
AU  - Strickland-Hodge B
FAU - Thomas, T R
AU  - Thomas TR
FAU - Gould, W A
AU  - Gould WA
FAU - Haslock, I
AU  - Haslock I
LA  - eng
PT  - Journal Article
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Antacids)
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antacids/administration & dosage/*pharmacology
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Dyspepsia/etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/administration & dosage/*pharmacology
MH  - *Tablets, Enteric-Coated
MH  - Time Factors
EDAT- 1976/08/01 00:00
MHDA- 1976/08/01 00:01
CRDT- 1976/08/01 00:00
PHST- 1976/08/01 00:00 [pubmed]
PHST- 1976/08/01 00:01 [medline]
PHST- 1976/08/01 00:00 [entrez]
AID - 10.1093/rheumatology/15.3.148 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1976 Aug;15(3):148-52. doi: 10.1093/rheumatology/15.3.148.

PMID- 27533057
OWN - NLM
STAT- MEDLINE
DCOM- 20180323
LR  - 20180323
IS  - 2055-6845 (Electronic)
VI  - 2
IP  - 1
DP  - 2016 Jan
TI  - Proton pump inhibitor use by aspirin-treated coronary artery disease patients is 
      not associated with increased risk of cardiovascular events.
PG  - 13-9
LID - 10.1093/ehjcvp/pvv036 [doi]
AB  - AIMS: Daily low-dose aspirin is recommended for prevention of cardiovascular 
      events in patients with coronary artery disease (CAD), and proton pump inhibitors 
      (PPIs) are recommended to prevent or treat aspirin-associated gastrointestinal 
      injury. Previous studies have reported contradictory findings regarding the risk 
      of major adverse cardiovascular events (MACE) in patients who use PPI with 
      aspirin therapy. We sought to examine associations between PPI use and MACE and 
      all-cause mortality in aspirin-treated CAD patients. METHODS AND RESULTS: Using 
      electronic medical record and healthcare claims data, we conducted a 
      retrospective population-based cohort study to examine patients 40 years or older 
      with a diagnosis of CAD and documented aspirin use. Patients taking clopidogrel 
      or other antiplatelet or anticoagulant agents were excluded. Risk of MACE and 
      all-cause mortality associated with PPI use vs. no PPI use was analysed by Cox 
      proportional hazards regression with standard covariate adjustment. Of the 2011 
      patients included in the study, 295 (14.7%) used a PPI. During a mean follow-up 
      of 3.1 years, 294 patients [63 PPI users (21.4%) and 231 PPI non-users (13.5%)] 
      experienced an MACE. In the adjusted model, the risk of MACE with PPI treatment 
      was no different than without PPI treatment [hazard ratio (HR) 1.32 (95% 
      confidence interval 0.8-2.4)]. Likewise, there was no difference between groups 
      for risk of all-cause mortality; 201 patients [47 PPI users (15.9%) and 154 PPI 
      non-users (9.0%)] died of any cause [HR 1.33 (0.9-1.9)]. Results were validated 
      by robust propensity score-matching methods (n = 574). CONCLUSIONS: No evidence 
      was found that PPI use is associated with increased risk of MACE or all-cause 
      mortality in aspirin-treated CAD patients.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved. © 
      The Author 2015. For permissions please email: journals.permissions@oup.com.
FAU - Fortuna, Laura A
AU  - Fortuna LA
AD  - HealthPartners Pharmacy Services, Minneapolis, MN, USA HealthPartners Pharmacy 
      Services, 8170 33rd Avenue South, MS 21111B, Bloomington, MN 55425, USA 
      laura.a.fortuna@healthpartners.com.
FAU - Pawloski, Pamala A
AU  - Pawloski PA
AD  - HealthPartners Pharmacy Services, Minneapolis, MN, USA HealthPartners Pharmacy 
      Services, 8170 33rd Avenue South, MS 21111B, Bloomington, MN 55425, USA 
      HealthPartners Institute for Education and Research, Minneapolis, MN, USA 
      HealthPartners Institute for Education and Research, 3311 Old Shakopee Avenue 
      South, MS 23301A, Bloomington, MN 55425, USA.
FAU - Parker, Emily D
AU  - Parker ED
AD  - HealthPartners Institute for Education and Research, Minneapolis, MN, USA 
      HealthPartners Institute for Education and Research, 3311 Old Shakopee Avenue 
      South, MS 23301A, Bloomington, MN 55425, USA.
FAU - Trower, Nicole K
AU  - Trower NK
AD  - HealthPartners Institute for Education and Research, Minneapolis, MN, USA 
      HealthPartners Institute for Education and Research, 3311 Old Shakopee Avenue 
      South, MS 23301A, Bloomington, MN 55425, USA.
FAU - Kottke, Thomas E
AU  - Kottke TE
AD  - HealthPartners Institute for Education and Research, Minneapolis, MN, USA 
      HealthPartners Institute for Education and Research, 3311 Old Shakopee Avenue 
      South, MS 23301A, Bloomington, MN 55425, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150907
PL  - England
TA  - Eur Heart J Cardiovasc Pharmacother
JT  - European heart journal. Cardiovascular pharmacotherapy
JID - 101669491
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J Cardiovasc Pharmacother. 2016 Jan;2(1):20-2. PMID: 27533058
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*chemically induced/*epidemiology/mortality
MH  - Cause of Death
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/*therapeutic use
MH  - Proton Pump Inhibitors/*adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - All-cause mortality
OT  - Aspirin therapy
OT  - Cardiovascular events
OT  - Coronary artery disease
OT  - Proton pump inhibitors
EDAT- 2016/08/18 06:00
MHDA- 2018/03/24 06:00
CRDT- 2016/08/18 06:00
PHST- 2015/06/30 00:00 [received]
PHST- 2015/09/01 00:00 [accepted]
PHST- 2016/08/18 06:00 [entrez]
PHST- 2016/08/18 06:00 [pubmed]
PHST- 2018/03/24 06:00 [medline]
AID - pvv036 [pii]
AID - 10.1093/ehjcvp/pvv036 [doi]
PST - ppublish
SO  - Eur Heart J Cardiovasc Pharmacother. 2016 Jan;2(1):13-9. doi: 
      10.1093/ehjcvp/pvv036. Epub 2015 Sep 7.

PMID- 22228745
OWN - NLM
STAT- MEDLINE
DCOM- 20120626
LR  - 20220310
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 35
IP  - 3
DP  - 2012 Mar
TI  - Potential implications of coronary artery calcium testing for guiding aspirin use 
      among asymptomatic individuals with diabetes.
PG  - 624-6
LID - 10.2337/dc11-1773 [doi]
AB  - OBJECTIVE: It is unclear whether coronary artery calcium (CAC) is effective for 
      risk stratifying patients with diabetes in whom treatment decisions are 
      uncertain. RESEARCH DESIGN AND METHODS: Of 44,052 asymptomatic individuals 
      referred for CAC testing, we studied 2,384 individuals with diabetes. Subjects 
      were followed for a mean of 5.6 ± 2.6 years for the end point of all-cause 
      mortality. RESULTS: There were 162 deaths (6.8%) in the population. CAC was a 
      strong predictor of mortality across age-groups (age <50, 50-59, ≥60), sex, and 
      risk factor burden (0 vs. ≥1 additional risk factor). In individuals without a 
      clear indication for aspirin per current guidelines, CAC stratified risk, 
      identifying patients above and below the 10% risk threshold of presumed aspirin 
      benefit. CONCLUSIONS: CAC can help risk stratify individuals with diabetes and 
      may aid in selection of patients who may benefit from therapies such as low-dose 
      aspirin for primary prevention.
FAU - Silverman, Michael Gordon
AU  - Silverman MG
AD  - Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, 
      Maryland, USA.
FAU - Blaha, Michael J
AU  - Blaha MJ
FAU - Budoff, Matthew J
AU  - Budoff MJ
FAU - Rivera, Juan J
AU  - Rivera JJ
FAU - Raggi, Paolo
AU  - Raggi P
FAU - Shaw, Leslee J
AU  - Shaw LJ
FAU - Berman, Daniel
AU  - Berman D
FAU - Callister, Tracy
AU  - Callister T
FAU - Rumberger, John A
AU  - Rumberger JA
FAU - Rana, Jamal S
AU  - Rana JS
FAU - Blumenthal, Roger S
AU  - Blumenthal RS
FAU - Nasir, Khurram
AU  - Nasir K
LA  - eng
PT  - Journal Article
DEP - 20120106
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Calcinosis/*diagnosis
MH  - Coronary Artery Disease/*diagnosis
MH  - Diabetes Mellitus/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
PMC - PMC3322717
EDAT- 2012/01/10 06:00
MHDA- 2012/06/27 06:00
CRDT- 2012/01/10 06:00
PHST- 2012/01/10 06:00 [entrez]
PHST- 2012/01/10 06:00 [pubmed]
PHST- 2012/06/27 06:00 [medline]
AID - dc11-1773 [pii]
AID - 1773 [pii]
AID - 10.2337/dc11-1773 [doi]
PST - ppublish
SO  - Diabetes Care. 2012 Mar;35(3):624-6. doi: 10.2337/dc11-1773. Epub 2012 Jan 6.

PMID- 17040212
OWN - NLM
STAT- MEDLINE
DCOM- 20070215
LR  - 20131121
IS  - 1742-7835 (Print)
IS  - 1742-7835 (Linking)
VI  - 99
IP  - 4
DP  - 2006 Oct
TI  - The established and emerging uses of aspirin.
PG  - 283-6
AB  - In this paper, summary narratives on the established and emerging uses of aspirin 
      are presented. On the former, aspirin is used to treat conditions such as 
      headache and also reduce the risks associated with cardiovascular disease and 
      also with pre-eclampsia. On the latter, aspirin might be taken more widely by 
      individuals over 50 years, used as a dietary supplement to possibly reduce cancer 
      risk and used post-transplant to improve organ survival. Aspirin will continue to 
      be an important therapeutic agent and to generate considerable interest among the 
      research community for the foreseeable future.
FAU - Morgan, Gareth
AU  - Morgan G
AD  - Welsh Aspirin Group, 41 Ffordd Beck, Gowerton, Swansea, Wales, UK. 
      morgan@fforrdbeck.fsnet.co.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Myocardial Infarction/complications/*drug therapy
RF  - 26
EDAT- 2006/10/17 09:00
MHDA- 2007/02/16 09:00
CRDT- 2006/10/17 09:00
PHST- 2006/10/17 09:00 [pubmed]
PHST- 2007/02/16 09:00 [medline]
PHST- 2006/10/17 09:00 [entrez]
AID - PTOpto_435 [pii]
AID - 10.1111/j.1742-7843.2006.pto_435.x [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2006 Oct;99(4):283-6. doi: 
      10.1111/j.1742-7843.2006.pto_435.x.

PMID- 24480279
OWN - NLM
STAT- MEDLINE
DCOM- 20140912
LR  - 20141212
IS  - 1943-3530 (Electronic)
IS  - 0003-7028 (Linking)
VI  - 68
IP  - 2
DP  - 2014
TI  - Mid-infrared, long wave infrared (4-12 μm) molecular emission signatures from 
      pharmaceuticals using laser-induced breakdown spectroscopy (LIBS).
PG  - 226-31
LID - 10.1366/13-07141 [doi]
AB  - In an effort to augment the atomic emission spectra of conventional laser-induced 
      breakdown spectroscopy (LIBS) and to provide an increase in selectivity, mid-wave 
      to long-wave infrared (IR), LIBS studies were performed on several organic 
      pharmaceuticals. Laser-induced breakdown spectroscopy signature molecular 
      emissions of target organic compounds are observed for the first time in the IR 
      fingerprint spectral region between 4-12 μm. The IR emission spectra of select 
      organic pharmaceuticals closely correlate with their respective standard Fourier 
      transform infrared spectra. Intact and/or fragment sample molecular species 
      evidently survive the LIBS event. The combination of atomic emission signatures 
      derived from conventional ultraviolet-visible-near-infrared LIBS with 
      fingerprints of intact molecular entities determined from IR LIBS promises to be 
      a powerful tool for chemical detection.
FAU - Yang, Clayton S-C
AU  - Yang CS
AD  - Battelle Eastern Science and Technology Center, Aberdeen, MD 21001 USA.
FAU - Brown, Ei E
AU  - Brown EE
FAU - Kumi-Barimah, Eric
AU  - Kumi-Barimah E
FAU - Hommerich, Uwe H
AU  - Hommerich UH
FAU - Jin, Feng
AU  - Jin F
FAU - Trivedi, Sudhir B
AU  - Trivedi SB
FAU - Samuels, Alan C
AU  - Samuels AC
FAU - Snyder, A Peter
AU  - Snyder AP
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Appl Spectrosc
JT  - Applied spectroscopy
JID - 0372406
RN  - 0 (Organic Chemicals)
RN  - 0 (Pharmaceutical Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Equipment Design
MH  - Lasers
MH  - Models, Chemical
MH  - Organic Chemicals/analysis/chemistry
MH  - Pharmaceutical Preparations/*analysis/*chemistry
MH  - Spectrophotometry, Infrared/instrumentation/*methods
EDAT- 2014/02/01 06:00
MHDA- 2014/09/13 06:00
CRDT- 2014/02/01 06:00
PHST- 2014/02/01 06:00 [entrez]
PHST- 2014/02/01 06:00 [pubmed]
PHST- 2014/09/13 06:00 [medline]
AID - 10.1366/13-07141 [doi]
PST - ppublish
SO  - Appl Spectrosc. 2014;68(2):226-31. doi: 10.1366/13-07141.

PMID- 28089180
OWN - NLM
STAT- MEDLINE
DCOM- 20170717
LR  - 20200108
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 69
IP  - 6
DP  - 2017 Feb 14
TI  - Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes 
      Mellitus.
PG  - 603-612
LID - S0735-1097(16)37323-5 [pii]
LID - 10.1016/j.jacc.2016.11.050 [doi]
AB  - BACKGROUND: A limitation of aspirin is that some patients, particularly those 
      with diabetes, may not have an optimal antiplatelet effect. OBJECTIVES: The goal 
      of this study was to determine if oral bioavailability mediates 
      nonresponsiveness. METHODS: The rate and extent of serum thromboxane generation 
      and aspirin pharmacokinetics were measured in 40 patients with diabetes in a 
      randomized, single-blind, triple-crossover study. Patients were exposed to three 
      325-mg aspirin formulations: plain aspirin, PL2200 (a modified-release 
      lipid-based aspirin), and a delayed-release enteric-coated (EC) aspirin. Onset of 
      antiplatelet activity was determined by the rate and extent of inhibition of 
      serum thromboxane B(2) (TXB(2)) generation. Aspirin nonresponsiveness was defined 
      as a level of residual serum TXB(2) associated with elevated thrombotic risk 
      (<99.0% inhibition or TXB(2) >3.1 ng/ml) within 72 h after 3 daily aspirin doses. 
      RESULTS: The rate of aspirin nonresponsiveness was 15.8%, 8.1%, and 52.8% for 
      plain aspirin, PL2200, and EC aspirin, respectively (p < 0.001 for both 
      comparisons vs. EC aspirin; p = 0.30 for comparison between plain aspirin and 
      PL2200). Similarly, 56% of EC aspirin-treated subjects had serum TXB(2) levels 
      >3.1 ng/ml, compared with 18% and 11% of subjects after administration of plain 
      aspirin and PL2200 (p < 0.0001). Compared with findings for plain aspirin and 
      PL2200, this high rate of nonresponsiveness with EC aspirin was associated with 
      lower exposure to acetylsalicylic acid (63% and 70% lower geometric mean maximum 
      plasma concentration [C(max)] and 77% and 82% lower AUC(0-t) [area under the 
      curve from time 0 to the last time measured]) and 66% and 72% lower maximum 
      decrease of TXB(2), with marked interindividual variability. CONCLUSIONS: A high 
      proportion of patients treated with EC aspirin failed to achieve complete 
      inhibition of TXB(2) generation due to incomplete absorption. Reduced 
      bioavailability may contribute to "aspirin resistance" in patients with diabetes. 
      (Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release 
      Aspirin in Diabetic Patients; NCT01515657).
CI  - Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical 
      School, Boston, Massachusetts. Electronic address: dlbhattmd@post.harvard.edu.
FAU - Grosser, Tilo
AU  - Grosser T
AD  - Institute for Translational Medicine and Therapeutics, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Dong, Jing-Fei
AU  - Dong JF
AD  - Hematology Division, Department of Medicine, University of Washington School of 
      Medicine, Seattle, Washington.
FAU - Logan, Douglas
AU  - Logan D
AD  - Veterans Administration Medical Center, Cincinnati, Ohio.
FAU - Jeske, Walter
AU  - Jeske W
AD  - Loyola University Chicago, Cardiovascular Research Institute, Maywood, Illinois.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - University of Florida College of Medicine, Jacksonville, Florida.
FAU - Frelinger, Andrew L 3rd
AU  - Frelinger AL 3rd
AD  - Center for Platelet Research Studies, Division of Hematology/Oncology, Boston 
      Children's Hospital, Dana Farber Cancer Institute, Harvard Medical School, 
      Boston, Massachusetts.
FAU - Lei, Lanyu
AU  - Lei L
AD  - Harvard Clinical Research Institute, Boston, Massachusetts.
FAU - Liang, Juan
AU  - Liang J
AD  - Medpace Inc., Cincinnati, Ohio.
FAU - Moore, Jason E
AU  - Moore JE
AD  - PLx Pharma Inc., Houston, Texas.
FAU - Cryer, Byron
AU  - Cryer B
AD  - University of Texas Southwestern and VA North Texas Health Care System, Dallas, 
      Texas.
FAU - Marathi, Upendra
AU  - Marathi U
AD  - PLx Pharma Inc., Houston, Texas.
LA  - eng
SI  - ClinicalTrials.gov/NCT01515657
GR  - R01 HL071895/HL/NHLBI NIH HHS/United States
GR  - R01 HL085769/HL/NHLBI NIH HHS/United States
GR  - R01 HL125957/HL/NHLBI NIH HHS/United States
GR  - U54 HL117798/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170111
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Dosage Forms)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2017 Feb 14;69(6):613-615. PMID: 28089179
CIN - J Am Coll Cardiol. 2017 Jun 13;69(23):2878-2879. PMID: 28595708
CIN - J Am Coll Cardiol. 2017 Jun 13;69(23):2879. PMID: 28595709
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Biological Availability
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*metabolism
MH  - Dosage Forms
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacokinetics
MH  - Single-Blind Method
MH  - Thromboxane B2/blood
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - enteric coating
OT  - pharmacodynamics
OT  - pharmacokinetics
OT  - platelet function
OT  - thromboxane
EDAT- 2017/01/17 06:00
MHDA- 2017/07/18 06:00
CRDT- 2017/01/17 06:00
PHST- 2016/09/05 00:00 [received]
PHST- 2016/10/24 00:00 [revised]
PHST- 2016/11/07 00:00 [accepted]
PHST- 2017/01/17 06:00 [pubmed]
PHST- 2017/07/18 06:00 [medline]
PHST- 2017/01/17 06:00 [entrez]
AID - S0735-1097(16)37323-5 [pii]
AID - 10.1016/j.jacc.2016.11.050 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2017 Feb 14;69(6):603-612. doi: 10.1016/j.jacc.2016.11.050. 
      Epub 2017 Jan 11.

PMID- 989289
OWN - NLM
STAT- MEDLINE
DCOM- 19761101
LR  - 20190902
IS  - 0340-5761 (Print)
IS  - 0340-5761 (Linking)
VI  - 35
IP  - 3
DP  - 1976 Jun 8
TI  - Inhibition of salicylate and lithium absorption in the human intestine by copper 
      sulfate.
PG  - 175-9
AB  - Copper sulfate, given orally in an emetic dose, decreased the absorption of 
      therapeutic doses of acetylsalicylic acid or lithium carbonate, more than was 
      expected judging from the recovery of salicylic acid in the vomit. Ten volunteers 
      participated.
FAU - Lindkaer-Jensen, S
AU  - Lindkaer-Jensen S
FAU - Nellemann-Sorensen, P
AU  - Nellemann-Sorensen P
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arch Toxicol
JT  - Archives of toxicology
JID - 0417615
RN  - 0 (Emetics)
RN  - 0 (Sulfates)
RN  - 789U1901C5 (Copper)
RN  - 9FN79X2M3F (Lithium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*metabolism/poisoning
MH  - Copper/*pharmacology/therapeutic use
MH  - *Emetics/therapeutic use
MH  - Humans
MH  - Intestinal Absorption/*drug effects
MH  - Lithium/*metabolism/poisoning
MH  - Poisoning/drug therapy
MH  - Sulfates/therapeutic use
EDAT- 1976/06/08 00:00
MHDA- 1976/06/08 00:01
CRDT- 1976/06/08 00:00
PHST- 1976/06/08 00:00 [pubmed]
PHST- 1976/06/08 00:01 [medline]
PHST- 1976/06/08 00:00 [entrez]
AID - 10.1007/BF00293564 [doi]
PST - ppublish
SO  - Arch Toxicol. 1976 Jun 8;35(3):175-9. doi: 10.1007/BF00293564.

PMID- 18314945
OWN - NLM
STAT- MEDLINE
DCOM- 20080611
LR  - 20220311
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 51
IP  - 6
DP  - 2008 Mar 27
TI  - Second-generation aspirin and indomethacin prodrugs possessing an 
      O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric 
      oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide 
      release studies.
PG  - 1954-61
LID - 10.1021/jm701450q [doi]
AB  - The carboxylic acid group of the anti-inflammatory (AI) drugs aspirin and 
      indomethacin was covalently linked to the 
      1-(2-carboxypyrrolidin-1-yl)diazen-1-ium-1,2-diolate ion via a one-carbon 
      methylene spacer to obtain two new hybrid prodrugs. The aspirin prodrug ( 23) was 
      a 2.2-fold more potent AI agent than aspirin, whereas the indomethacin prodrug ( 
      26) was about 1.6-fold less potent than indomethacin. Prodrugs 23 and 26 slowly 
      released nitric oxide (NO) upon dissolution in phosphate buffer at pH 7.4 (1.1 
      mol of NO/mol of compound after 43 h), but the rate and the extent of NO release 
      were higher (1.9 mol of NO/mol of compound in 3 min or less) when the compounds 
      were incubated in the presence of porcine liver esterase. In vivo ulcer index 
      (UI) studies showed that the aspirin prodrug 23 (UI = 0.7) and indomethacin 
      prodrug 26 (UI = 0) were substantially less ulcerogenic than the parent drugs 
      aspirin (UI = 51) and indomethacin (UI = 64).
FAU - Velázquez, Carlos A
AU  - Velázquez CA
AD  - Chemistry Section, Laboratory of Comparative Carcinogenesis and Basic Research 
      Program, SAIC-Frederick Inc., National Cancer Institute at Frederick, MD 21702, 
      USA.
FAU - Chen, Qiao-Hong
AU  - Chen QH
FAU - Citro, Michael L
AU  - Citro ML
FAU - Keefer, Larry K
AU  - Keefer LK
FAU - Knaus, Edward E
AU  - Knaus EE
LA  - eng
GR  - N01 CO 12400/CO/NCI NIH HHS/United States
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20080229
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Azo Compounds)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Prodrugs)
RN  - 0 (Pyrrolidines)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemical 
      synthesis/chemistry/*pharmacology
MH  - Aspirin/chemical synthesis/chemistry/*pharmacology
MH  - Azo Compounds/chemical synthesis/chemistry/*pharmacology
MH  - Carrageenan
MH  - Drug Design
MH  - Edema/chemically induced/drug therapy
MH  - Indomethacin/chemical synthesis/chemistry/*pharmacology
MH  - Molecular Structure
MH  - Nitric Oxide/*chemistry
MH  - Nitric Oxide Donors/chemical synthesis/chemistry/*pharmacology
MH  - Prodrugs/chemical synthesis/chemistry/*pharmacology
MH  - Pyrrolidines/chemical synthesis/chemistry/*pharmacology
MH  - Rats
MH  - Stomach Ulcer/chemically induced
EDAT- 2008/03/05 09:00
MHDA- 2008/06/12 09:00
CRDT- 2008/03/05 09:00
PHST- 2008/03/05 09:00 [pubmed]
PHST- 2008/06/12 09:00 [medline]
PHST- 2008/03/05 09:00 [entrez]
AID - 10.1021/jm701450q [doi]
PST - ppublish
SO  - J Med Chem. 2008 Mar 27;51(6):1954-61. doi: 10.1021/jm701450q. Epub 2008 Feb 29.

PMID- 1434725
OWN - NLM
STAT- MEDLINE
DCOM- 19921211
LR  - 20131121
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 104
IP  - 5
DP  - 1992 Nov
TI  - The effect of desmopressin acetate on postoperative hemorrhage in patients 
      receiving aspirin therapy before coronary artery bypass operations.
PG  - 1417-22
AB  - It has been suggested that desmopressin acetate has been effective in reducing 
      hemorrhage after coronary artery bypass grafting in patients receiving aspirin 
      before operation. We conducted a prospective, randomized, placebo-controlled, 
      double-blind trial to determine the effectiveness and safety of desmopressin in 
      these patients. Sixty-five patients pretreated with aspirin within 7 days before 
      their scheduled elective coronary artery bypass grafting were randomized to 
      receive desmopressin (0.3 micrograms/kg) or placebo after cessation of bypass and 
      reversal of heparin with protamine. The demographic characteristics and last dose 
      of aspirin were similar in both groups. There was a significant reduction in 
      postoperative blood loss noted between groups for both chest tube blood loss (833 
      +/- 311 ml for the 1-desamino-8-D-arginine vasopressin [desmopressin] group 
      versus 1176 +/- 674 ml for the placebo group; p = 0.016) and total blood loss 
      (1215 +/- 381 ml for the desmopressin group versus 1637 +/- 761 ml for the 
      placebo group; p = 0.0097). Despite the differences in blood loss between the two 
      groups, the red cell transfusions were not significantly different, but the use 
      of platelets was less in the desmopressin group and almost achieved statistical 
      significance (p = 0.053). Neither was there a difference in the occurrence of 
      thrombotic complications between groups. It appears that desmopressin in this 
      specific subgroup of patients receiving preoperative aspirin is effective as a 
      prophylactic agent for reduction of postsurgical hemorrhage.
FAU - Gratz, I
AU  - Gratz I
AD  - Department of Anesthesia, Medical College of Pennsylvania, Philadelphia 19129.
FAU - Koehler, J
AU  - Koehler J
FAU - Olsen, D
AU  - Olsen D
FAU - Afshar, M
AU  - Afshar M
FAU - DeCastro, N
AU  - DeCastro N
FAU - Spagna, P M
AU  - Spagna PM
FAU - Ablaza, S G
AU  - Ablaza SG
FAU - Larijani, G E
AU  - Larijani GE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Blood Coagulation Factors)
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Coagulation Factors/analysis
MH  - Cardiopulmonary Bypass/adverse effects
MH  - *Coronary Artery Bypass
MH  - Deamino Arginine Vasopressin/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/blood/*drug therapy/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Function Tests
MH  - Postoperative Complications/*drug therapy
MH  - Prospective Studies
MH  - Treatment Outcome
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1992 Nov;104(5):1417-22.

PMID- 113475
OWN - NLM
STAT- MEDLINE
DCOM- 19791129
LR  - 20151119
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 94
IP  - 4
DP  - 1979 Oct
TI  - In vivo platelet retention in human bleeding-time wounds. II. Effect of aspirin 
      ingestion.
PG  - 574-84
AB  - PRB was studied in normal human subjects before and after aspirin ingestion. 
      Aspirin ingestion resulted in a prolongation of individual bleeding times greater 
      than 2.4 min (greater than 2 S.D. beyond the group mean before aspirin) in 62.5% 
      of 48 paired studies. The relationship of platelets retained vs. time was linear 
      during the first 3 min of bleeding before and after aspirin. The mean PRB 
      decreased from 22.1 +/- 9.2 to 9.6 +/- 8.6 (p less than 0.001) after aspirin 
      ingestion. Subjects whose bleeding time was prolonged greater than 2.4 min had a 
      significantly higher mean PRB before aspirin and a significantly greater mean 
      decrease in PRB after aspirin than those whose bleeding time was prolonged less 
      than or equal to 2.4 min. Aspirin ingestion reduced the number of 
      EDTA-irreversible clumped platelets present in wound blood approximately 50% 
      during the second and third minute of bleeding, but large numbers of 
      EDTA-reversible platelet clumps were observed in wound blood before and after 
      aspirin. Although platelet retention was significantly decreased during the first 
      3 min of bleeding after aspirin, the percent of venous blood platelets present in 
      wound blood just prior to the arrest of hemorrhage was equal before and after 
      aspirin. These observations indicate that aspirin prolongs the bleeding time by 
      decreasing platelet clumping and slowing the rate of platelet thrombus formation 
      in severed blood vessels. The presence of platelet clumps in wound blood after 
      aspirin ingestion indicates that alternative mechanisms of platelet aggregation, 
      independent of the arachidonate pathway of prostaglandin synthesis, proceed in 
      vivo unaltered by aspirin.
FAU - Schwartz, B S
AU  - Schwartz BS
FAU - Leis, L A
AU  - Leis LA
FAU - Johnson, G J
AU  - Johnson GJ
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 9G34HU7RV0 (Edetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Blood Platelets/*cytology
MH  - Depression, Chemical
MH  - Edetic Acid
MH  - Humans
MH  - Leukocyte Count
MH  - Skin/injuries
MH  - Time Factors
EDAT- 1979/10/01 00:00
MHDA- 1979/10/01 00:01
CRDT- 1979/10/01 00:00
PHST- 1979/10/01 00:00 [pubmed]
PHST- 1979/10/01 00:01 [medline]
PHST- 1979/10/01 00:00 [entrez]
PST - ppublish
SO  - J Lab Clin Med. 1979 Oct;94(4):574-84.

PMID- 25873555
OWN - NLM
STAT- MEDLINE
DCOM- 20160322
LR  - 20200225
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 38
IP  - 6
DP  - 2015 Jun
TI  - Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention 
      in Clinical Practice.
PG  - 387-94
LID - 10.1002/clc.22394 [doi]
AB  - Emerging evidence suggesting the possibility that interventions able to prevent 
      cardiovascular disease (CVD) may also be effective in the prevention of cancer 
      have recently stimulated great interest in the medical community. In particular, 
      data from both experimental and observational studies have demonstrated that 
      aspirin may play a role in preventing different types of cancer. Although the use 
      of aspirin in the secondary prevention of CVD is well established, aspirin in 
      primary prevention is not systematically recommended because the absolute 
      cardiovascular event reduction is similar to the absolute excess in major 
      bleedings. By adding to its cardiovascular prevention benefits, the potential 
      beneficial effect of aspirin in reducing the incidence of mortality and cancer 
      could tip the balance between risks and benefits of aspirin therapy in primary 
      prevention in favor of the latter and broaden the indication for treatment with 
      aspirin in populations at average risk. Prospective and randomized studies are 
      currently investigating the effect of aspirin in prevention of both cancer and 
      CVD; however, clinical efforts at the individual level to promote the use of 
      aspirin in global (or total) primary prevention already could be made on the 
      basis of a balanced evaluation of the benefit/risk ratio.
CI  - © 2015 Wiley Periodicals, Inc.
FAU - Battistoni, Allegra
AU  - Battistoni A
AD  - Cardiology Department, Clinical and Molecular Medicine Department, Sapienza 
      University of Rome, Rome, Italy.
FAU - Mastromarino, Vittoria
AU  - Mastromarino V
AD  - Cardiology Department, Clinical and Molecular Medicine Department, Sapienza 
      University of Rome, Rome, Italy.
FAU - Volpe, Massimo
AU  - Volpe M
AD  - Cardiology Department, Clinical and Molecular Medicine Department, Sapienza 
      University of Rome, Rome, Italy.
AD  - IRCCS Neuromed (Volpe), Pozzilli, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150414
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Global Health
MH  - Humans
MH  - Neoplasms/drug therapy/*prevention & control
MH  - Primary Prevention/methods
PMC - PMC6711075
EDAT- 2015/04/16 06:00
MHDA- 2016/03/24 06:00
CRDT- 2015/04/16 06:00
PHST- 2014/11/19 00:00 [received]
PHST- 2015/01/15 00:00 [revised]
PHST- 2015/01/20 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2016/03/24 06:00 [medline]
AID - CLC22394 [pii]
AID - 10.1002/clc.22394 [doi]
PST - ppublish
SO  - Clin Cardiol. 2015 Jun;38(6):387-94. doi: 10.1002/clc.22394. Epub 2015 Apr 14.

PMID- 949085
OWN - NLM
STAT- MEDLINE
DCOM- 19761001
LR  - 20190627
IS  - 0002-9394 (Print)
IS  - 0002-9394 (Linking)
VI  - 82
IP  - 2
DP  - 1976 Aug
TI  - Experimental inhibition of prostaglandin-like inflammatory response after 
      cryotherapy.
PG  - 310-2
AB  - To determine the effect of aspirin as an inhibitor of the prostaglandin-induced 
      inflammatory reaction that follows cryotherapy, 12 rabbits were pretreated with 
      aspirin and 12 were controls. The aspirin-pretreated animals showed less 
      inflammatory reaction after cryotherapy and significantly less protein in the 
      aqueous humor than did the control animals (P less than .01). We believe that the 
      conjunctival hyperemia and chemosis, and the increase in protein concentrations 
      in the aqueous humor that follow cryotherapy, are prostaglandin-related, because 
      pretreatment with aspirin inhibited these phenomena.
FAU - Chavis, R M
AU  - Chavis RM
FAU - Vygantas, C M
AU  - Vygantas CM
FAU - Vygantas, A
AU  - Vygantas A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Anterior Chamber
MH  - Aspirin/*therapeutic use
MH  - Cryosurgery/adverse effects
MH  - Eye Diseases/etiology/prevention & control
MH  - Inflammation/etiology/prevention & control
MH  - Prostaglandin Antagonists
MH  - *Prostaglandins
MH  - Rabbits
EDAT- 1976/08/01 00:00
MHDA- 1976/08/01 00:01
CRDT- 1976/08/01 00:00
PHST- 1976/08/01 00:00 [pubmed]
PHST- 1976/08/01 00:01 [medline]
PHST- 1976/08/01 00:00 [entrez]
AID - 0002-9394(76)90439-6 [pii]
AID - 10.1016/0002-9394(76)90439-6 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 1976 Aug;82(2):310-2. doi: 10.1016/0002-9394(76)90439-6.

PMID- 6420164
OWN - NLM
STAT- MEDLINE
DCOM- 19840229
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 25
IP  - 6
DP  - 1983
TI  - Pharmacological interaction between nitroglycerin and aspirin after acute and 
      chronic aspirin treatment of healthy subjects.
PG  - 779-82
AB  - The interaction between nitroglycerin (NTG) and aspirin was investigated in 7 
      healthy subjects in order to test whether aspirin could block the haemodynamic 
      response to NTG; the doses used were NTG 0.8 mg, and aspirin 0.5 g for chronic 
      and 1 g for acute treatment. The plasma levels of NTG and various physiological 
      parameters (heart rate, diastolic arterial pressure, end diastolic diameter, and 
      end systolic diameter) were measured during the 30 minutes after the 
      administration of NTG. An increase in NTG Cmax and AUC was observed after both 
      aspirin treatment. The changes in physiological parameters produced by NTG were 
      enhanced by the two treatments, although the differences were not statistically 
      significant. The results indicate complex pharmacokinetic and pharmacodynamic 
      interactions between NTG and aspirin.
FAU - Rey, E
AU  - Rey E
FAU - El-Assaf, H D
AU  - El-Assaf HD
FAU - Richard, M O
AU  - Richard MO
FAU - Weber, S
AU  - Weber S
FAU - Bourdon, A
AU  - Bourdon A
FAU - Picard, G
AU  - Picard G
FAU - Olive, G
AU  - Olive G
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Chromatography, Gas
MH  - Drug Interactions
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Nitroglycerin/antagonists & inhibitors/*metabolism
MH  - Random Allocation
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1007/BF00542519 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1983;25(6):779-82. doi: 10.1007/BF00542519.

PMID- 27855711
OWN - NLM
STAT- MEDLINE
DCOM- 20170407
LR  - 20181113
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 15
IP  - 1
DP  - 2016 Nov 17
TI  - Lowering effects of aspirin eugenol ester on blood lipids in rats with high fat 
      diet.
PG  - 196
LID - 196
AB  - BACKGROUND: Aspirin and eugenol were esterified to synthesize aspirin eugenol 
      ester (AEE). As a pale yellow and odourless crystal, AEE reduced the 
      gastrointestinal damage of aspirin and vulnerability of eugenol. The study was 
      conducted to evaluate the preventive effects of AEE on blood lipids in rats with 
      high fat diet (HFD). METHODS: Suspensions of AEE and simvastatin were prepared in 
      5% carboxymethyl cellulose sodium (CMC-Na). In order to observe the intervention 
      effects, the drugs and HFD were administrated at the same time. Based on 
      individual weekly body weight (BW), AEE was intragastrically administrated at the 
      dosage of 18, 36 and 54 mg/kg. Simvastatin (10 mg/kg) and CMC-Na (20 mg/kg) were 
      used as control drug. After 6 weeks of administration, the changes of BW and 
      blood lipid indices including triglyceride (TG), low density lipoprotein (LDL), 
      high density lipoprotein (HDL) and total cholesterol (TCH) were determined in the 
      experiment. RESULTS: The rat blood lipids profile in model group was remarkably 
      different after feeding 6-weeks HFD. TG, TCH and LDL indexes in model group were 
      increased significantly compared with those in control group (p < 0.01). AEE at 
      the dosage of 54 mg/kg significantly decreased levels of TG, TCH and LDL 
      (p < 0.01), and slowed the rate of BW gain in comparison with model group 
      (p < 0.05). Moreover, high dose AEE showed better effects than simvastatin on 
      reducing TCH level and similar effects on TG, HDL and LDL. CONCLUSION: AEE could 
      remarkably reduce levels of TG, TCH and LDL in rats with high fat diet, and slow 
      the rate of body weight gain. It was conducted that AEE was a potential candidate 
      on reducing blood lipids level. The mechanism of action of AEE should be 
      investigated in further studies.
FAU - Karam, Isam
AU  - Karam I
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China.
FAU - Ma, Ning
AU  - Ma N
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China.
FAU - Liu, Xi-Wang
AU  - Liu XW
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China.
FAU - Kong, Xiao-Jun
AU  - Kong XJ
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China.
FAU - Zhao, Xiao-Le
AU  - Zhao XL
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China.
FAU - Yang, Ya-Jun
AU  - Yang YJ
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China. yangyue10224@163.com.
FAU - Li, Jian-Yong
AU  - Li JY
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China. lijy1971@163.com.
LA  - eng
PT  - Journal Article
DEP - 20161117
PL  - England
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Triglycerides)
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cholesterol/blood
MH  - Diet, High-Fat
MH  - Eugenol/*analogs & derivatives/pharmacology
MH  - Hyperlipidemias/*drug therapy
MH  - Hypolipidemic Agents/pharmacology
MH  - Male
MH  - Rats
MH  - Triglycerides/blood
PMC - PMC5114728
OTO - NOTNLM
OT  - Aspirin eugenol ester (AEE)
OT  - Blood lipids
OT  - Body weight
OT  - High fat diet
OT  - Rats
EDAT- 2016/11/20 06:00
MHDA- 2017/04/08 06:00
CRDT- 2016/11/19 06:00
PHST- 2016/09/04 00:00 [received]
PHST- 2016/11/10 00:00 [accepted]
PHST- 2016/11/19 06:00 [entrez]
PHST- 2016/11/20 06:00 [pubmed]
PHST- 2017/04/08 06:00 [medline]
AID - 10.1186/s12944-016-0369-2 [pii]
AID - 369 [pii]
AID - 10.1186/s12944-016-0369-2 [doi]
PST - epublish
SO  - Lipids Health Dis. 2016 Nov 17;15(1):196. doi: 10.1186/s12944-016-0369-2.

PMID- 1904163
OWN - NLM
STAT- MEDLINE
DCOM- 19910711
LR  - 20131121
IS  - 0035-2659 (Print)
IS  - 0035-2659 (Linking)
VI  - 58
IP  - 2
DP  - 1991 Feb
TI  - [Protective effect of misoprostol on the changes of transgastric potential 
      difference induced by aspirin in man].
PG  - 135-8
AB  - The measurement of transgastric electric potential difference (DDP) is an easy 
      and reproducible method for evaluation of the gastrotoxicity of aspirin. This 
      randomised crossover placebo-controlled trial in 12 healthy volunteers involved 
      study of the protective effect of misoprostol (Cytotec) against the fall in DDP 
      induced by a gram of aspirin. One day of treatment with misoprostol 200 
      micrograms morning and evening led to a statistically lower fall in DDP than with 
      the placebo: area under the curve 130 +/- 315 mV.min cf. 589 +/- 465 mV.min (p = 
      0.012), maximum variation 11.4 +/- 11.3 mV cf. 24.9 +/- 13.2 mV (p = 0.04). This 
      result independent of the antisecretory action of the compound, confirms the 
      protective effect of this prostaglandin analogue against the gastric damage 
      caused by aspirin.
FAU - Bergmann, J F
AU  - Bergmann JF
AD  - Clinique Thérapeutique (1), Hôpital Lariboisière, Paris.
FAU - Simoneau, G
AU  - Simoneau G
FAU - Naudin, R
AU  - Naudin R
FAU - Caulin, C
AU  - Caulin C
FAU - Segrestaa, J M
AU  - Segrestaa JM
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Etude chez l'homme de l'effet protecteur du misoprostol sur les variations de la 
      différence de potentiel transgastrique induites par l'aspirine.
PL  - France
TA  - Rev Rhum Mal Osteoartic
JT  - Revue du rhumatisme et des maladies osteo-articulaires
JID - 0407211
RN  - 0 (Anti-Ulcer Agents)
RN  - 0E43V0BB57 (Misoprostol)
RN  - F5TD010360 (Alprostadil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Alprostadil/*analogs & derivatives/pharmacology/therapeutic use
MH  - Anti-Ulcer Agents/*pharmacology/therapeutic use
MH  - Aspirin/*adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Gastric Mucosa/*drug effects/physiology
MH  - Humans
MH  - Male
MH  - Membrane Potentials/drug effects
MH  - Misoprostol
EDAT- 1991/02/01 00:00
MHDA- 1991/02/01 00:01
CRDT- 1991/02/01 00:00
PHST- 1991/02/01 00:00 [pubmed]
PHST- 1991/02/01 00:01 [medline]
PHST- 1991/02/01 00:00 [entrez]
PST - ppublish
SO  - Rev Rhum Mal Osteoartic. 1991 Feb;58(2):135-8.

PMID- 17221906
OWN - NLM
STAT- MEDLINE
DCOM- 20070605
LR  - 20191210
IS  - 0269-3879 (Print)
IS  - 0269-3879 (Linking)
VI  - 21
IP  - 3
DP  - 2007 Mar
TI  - Semi-micro column high-performance liquid chromatography with UV detection for 
      quantification of aspirin and salicylic acid and its application to patients' 
      sera administered with low-dose enteric-coated aspirin.
PG  - 221-4
AB  - A simultaneous determination of aspirin (ASA) and its metabolite, salicylic acid 
      (SA), in human serum by a semi-micro column HPLC-UV was developed. A relatively 
      small size of serum sample (100 microL) containing ASA and SA was cleaned up by a 
      simple solid phase extraction. A good separation of ASA and SA could be achieved 
      within 25 min using a semi-micro ODS column with an eluent of MeOH/0.7 mm 
      phosphoric acid solution (pH 2.5) = 50:50 (v/v). The calibration curves for ASA 
      and SA showed good linearity (r = 0.999) with the detection limits 114 and 38 
      ng/mL at a signal-to-noise ratio of 3, respectively. ASA and SA in patients' sera 
      administered with low-dose enteric-coated aspirin were determined, and the 
      concentration ranges obtained for ASA and SA were 1.2-2.2 and 0.5-57.3 microg/mL, 
      respectively.
FAU - Ohwaki, Yuichi
AU  - Ohwaki Y
AD  - Department of Clinical Pharmacy, Course of Pharmaceutical Sciences, Graduate 
      School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 
      852-8521, Japan.
FAU - Yamane, Tomoko
AU  - Yamane T
FAU - Ishimatsu, Takashi
AU  - Ishimatsu T
FAU - Wada, Mitsuhiro
AU  - Wada M
FAU - Nakashima, Kenichiro
AU  - Nakashima K
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - 0 (Indicators and Reagents)
RN  - 0 (Tablets, Enteric-Coated)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*blood
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Female
MH  - Humans
MH  - Indicators and Reagents
MH  - Male
MH  - Middle Aged
MH  - Salicylic Acid/*blood
MH  - Solid Phase Extraction/methods
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets, Enteric-Coated/administration & dosage
EDAT- 2007/01/16 09:00
MHDA- 2007/06/06 09:00
CRDT- 2007/01/16 09:00
PHST- 2007/01/16 09:00 [pubmed]
PHST- 2007/06/06 09:00 [medline]
PHST- 2007/01/16 09:00 [entrez]
AID - 10.1002/bmc.742 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2007 Mar;21(3):221-4. doi: 10.1002/bmc.742.

PMID- 9159625
OWN - NLM
STAT- MEDLINE
DCOM- 19970611
LR  - 20131121
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 113
IP  - 5
DP  - 1997 May
TI  - Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity 
      oral anticoagulation alone: a randomized trial in patients with mechanical 
      prosthetic heart valves.
PG  - 910-6
AB  - BACKGROUND: Mechanical heart valve replacement requires lifelong anticoagulant 
      treatment. Aspirin has proved useful in further reducing thromboembolic events 
      when added to oral anticoagulants. However, increased (gastrointestinal) bleeding 
      was observed at the doses previously tested for this combination in heart valve 
      prostheses. METHODS: We performed a prospective randomized trial to compare the 
      combination of low-intensity oral anticoagulants (international normalized ratio 
      2.5 to 3.5) plus aspirin (100 mg/day) (arm A) versus high-intensity oral 
      anticoagulants alone (arm B) (international normalized ratio 3.5 to 4.5). Arm A 
      included 258 patients and arm B 245 patients. The two groups were comparable for 
      all baseline characteristics. RESULTS: The outcomes of the study were embolism, 
      valve thrombosis, and major hemorrhage. The median follow-up was 23 months. The 
      two treatments offered similar antithrombotic protection. The incidence of 
      embolic episodes was 1.32 per 100 patient-years (95% confidence interval 0.53 to 
      2.7) for arm A and 1.48 per 100 patient-years (95% confidence interval 0.59 to 
      3.03) for arm B. Major hemorrhage occurred in 1.13 per 100 patient-years (95% 
      confidence interval 0.41 to 2.45) for arm A and 2.33 per 100 patient-years (95% 
      confidence interval 1.17 to 4.14) for arm B. Gastrointestinal bleeding was not 
      increased by this combined reduced dose of aspirin and coumarin.
FAU - Meschengieser, S S
AU  - Meschengieser SS
AD  - Departamento de Hemostasia y Trombosis, Instituto de Investigaciones 
      Hematólogicas Mariano R. Castex, Academia Nacional de Medicina, Buenos Aires, 
      Argentina.
FAU - Fondevila, C G
AU  - Fondevila CG
FAU - Frontroth, J
AU  - Frontroth J
FAU - Santarelli, M T
AU  - Santarelli MT
FAU - Lazzari, M A
AU  - Lazzari MA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Anticoagulants)
RN  - 0 (Coumarins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A4VZ22K1WT (coumarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coumarins/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastrointestinal Hemorrhage/etiology/prevention & control
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Thromboembolism/etiology/prevention & control
MH  - Time Factors
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - S0022-5223(97)70264-2 [pii]
AID - 10.1016/S0022-5223(97)70264-2 [doi]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1997 May;113(5):910-6. doi: 
      10.1016/S0022-5223(97)70264-2.

PMID- 10715254
OWN - NLM
STAT- MEDLINE
DCOM- 20000330
LR  - 20190623
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 101
IP  - 10
DP  - 2000 Mar 14
TI  - Aspirin use is low among United States outpatients with coronary artery disease.
PG  - 1097-101
AB  - BACKGROUND: The goal of the present study was to assess national trends and 
      patterns of aspirin use among outpatients with coronary artery disease. Although 
      there is strong evidence that the use of aspirin reduces the risk of death and 
      recurrent events in patients with coronary artery disease, current national 
      patterns of aspirin use are unknown. METHODS AND RESULTS: We used data from the 
      1980 to 1996 National Ambulatory Medical Care Surveys. These surveys provide a 
      nationally representative sample of physician activities during patient visits to 
      physician offices. We evaluated the report of aspirin as a new or continuing 
      medication in 10 942 visits to cardiologists and primary care physicians by 
      patients with coronary artery disease. We evaluated trends in the use of aspirin 
      for 1980 to 1996 and used logistic regression to identify independent predictors 
      of aspirin use for 1993 to 1996. Aspirin use in outpatient visits by persons with 
      coronary artery disease without reported contraindications increased from 5.0% in 
      1980 to 26.2% in 1996. Large increases occurred in the early 1990s. Independent 
      predictors of aspirin use in 1993 to 1996 were male patient gender (29% versus 
      21% for females), patient age of <80 years (28% versus 17% for age of >/=80 
      years), and presence of hyperlipidemia (45% versus 24% for patients without 
      hyperlipidemia; all comparisons P<0. 001). Cardiologists (37%) were more likely 
      to report aspirin use than were internists (20%), family physicians (18%), or 
      general practitioners (11%; P<0.001). These effects persisted after we controlled 
      for potential confounders with the use of logistic regression. CONCLUSIONS: 
      Although aspirin use in patients with coronary artery disease has increased 
      dramatically, it remains suboptimum. Low rates of aspirin use and variations in 
      use suggest a need to better translate clinical recommendations into practice.
FAU - Stafford, R S
AU  - Stafford RS
AD  - Institute for Health Policy and General Medicine Division, Massachusetts General 
      Hospital, Harvard Medical School, Boston, MA 02114, USA. rstafford@partners.org
LA  - eng
GR  - K08-HL-03548/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Drug Utilization/trends
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outpatients
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2000/03/15 00:00
MHDA- 2000/04/01 00:00
CRDT- 2000/03/15 00:00
PHST- 2000/03/15 00:00 [pubmed]
PHST- 2000/04/01 00:00 [medline]
PHST- 2000/03/15 00:00 [entrez]
AID - 10.1161/01.cir.101.10.1097 [doi]
PST - ppublish
SO  - Circulation. 2000 Mar 14;101(10):1097-101. doi: 10.1161/01.cir.101.10.1097.

PMID- 8885505
OWN - NLM
STAT- MEDLINE
DCOM- 19961205
LR  - 20131121
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 130
IP  - 12
DP  - 1996 Jun 16
TI  - [Use of aspirin for fever by Russian immigrant children].
PG  - 820-1, 879
AB  - This study describes the therapeutic drug approach in fever in Russian immigrant 
      children. 974 recent immigrants with their 208 children were under medical 
      treatment at 2 primary care clinics during 1991-1995. They came from 10 republics 
      of the Commonwealth of Independence States (CIS, formerly the Soviet Union). In 
      the CIS more than 3/4 of children aged 1-18 years had been given aspirin for 
      fever. Immigrants brought with them stocks of drugs and their children continued 
      to take them as they had in the CIS. This form of treatment is described in the 
      official CIS pharmacology book without any mention of potential danger. Use of 
      aspirin for fever may be an important factor in the severe hepatic injury and 
      encephalopathy seen in Reye's syndrome. Only after intervention of the family 
      physician did the immigrants stop this dangerous use of aspirin. During the study 
      Reye's syndrome was not seen. Since in Israel purchase of aspirin does not 
      require a physician's prescription, family physicians and pediatricians should be 
      aware of the potential deleterious effects of aspirin in fever among children.
FAU - Ben-Noun, L
AU  - Ben-Noun L
AD  - Dept. of Family Medicine, Faculty of Health Sciences, Ben-Gurion University of 
      the Negev, Beer Sheba.
LA  - heb
PT  - English Abstract
PT  - Journal Article
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Fever/*drug therapy
MH  - Hepatic Encephalopathy/prevention & control
MH  - Humans
MH  - Infant
MH  - Israel
MH  - Liver/pathology
MH  - Parents/*education
MH  - Physicians, Family
MH  - Professional-Family Relations
MH  - Reye Syndrome/prevention & control
MH  - Russia/ethnology
MH  - Socioeconomic Factors
EDAT- 1996/06/16 00:00
MHDA- 1996/06/16 00:01
CRDT- 1996/06/16 00:00
PHST- 1996/06/16 00:00 [pubmed]
PHST- 1996/06/16 00:01 [medline]
PHST- 1996/06/16 00:00 [entrez]
PST - ppublish
SO  - Harefuah. 1996 Jun 16;130(12):820-1, 879.

PMID- 21303400
OWN - NLM
STAT- MEDLINE
DCOM- 20110620
LR  - 20181201
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 33
IP  - 7
DP  - 2011 Apr
TI  - Review article: proton pump inhibitors with clopidogrel--evidence for and against 
      a clinically-important interaction.
PG  - 758-67
LID - 10.1111/j.1365-2036.2011.04585.x [doi]
AB  - BACKGROUND: The treatment of acute coronary syndromes involves a combination of 
      antiplatelet therapies. Proton pump inhibitors are frequently recommended for 
      patients receiving clopidogrel in addition to aspirin, to minimise the risk of 
      bleeding. Several studies have shown that proton pump inhibitors can affect the 
      platelet inhibitory effects of clopidogrel. However, the data on whether this has 
      an effect on clinical outcomes are conflicting and a definitive answer is still 
      awaited. AIM: To provide an overview of the evidence for the pharmacological 
      interaction between proton pump inhibitors and clopidogrel and to discuss whether 
      this interaction translates into adverse clinical outcomes. Despite recent 
      developments, clear consensus is lacking. METHODS: A search of the published 
      literature combined with the authors' knowledge of the field. RESULTS: There is 
      evidence to show that proton pump inhibitors can influence the pharmacodynamics 
      of clopidogrel, but the data suggesting clinical effects are weak and 
      conflicting. Supporting a clinically important interaction are four retrospective 
      studies including over 11,000 patients prescribed both clopidogrel and a proton 
      pump inhibitor. Evidence against a clinically important interaction is derived 
      from over 18,000 patients from seven studies, including the only prospective 
      trial to examine the potential interaction. Confounding variables are relevant 
      and prospective clinical evidence is lacking. CONCLUSIONS: Proton pump inhibitors 
      offer clear protection and the concern over clinically relevant interactions with 
      clopidogrel is biologically plausible, but not yet proven.
CI  - © 2011 Blackwell Publishing Ltd.
FAU - Disney, B R
AU  - Disney BR
AD  - Department of Gastroenterology, City Hospital, SWBH NHS Trust, Dudley Road, 
      Birmingham, UK.
FAU - Watson, R D S
AU  - Watson RD
FAU - Blann, A D
AU  - Blann AD
FAU - Lip, G Y H
AU  - Lip GY
FAU - Anderson, M R
AU  - Anderson MR
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110208
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Proton Pump Inhibitors/*pharmacology/therapeutic use
MH  - Risk
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2011/02/10 06:00
MHDA- 2011/06/21 06:00
CRDT- 2011/02/10 06:00
PHST- 2011/02/10 06:00 [entrez]
PHST- 2011/02/10 06:00 [pubmed]
PHST- 2011/06/21 06:00 [medline]
AID - 10.1111/j.1365-2036.2011.04585.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2011 Apr;33(7):758-67. doi: 
      10.1111/j.1365-2036.2011.04585.x. Epub 2011 Feb 8.

PMID- 22362558
OWN - NLM
STAT- MEDLINE
DCOM- 20121204
LR  - 20211021
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 33
IP  - 3
DP  - 2012 Apr
TI  - Persistent high on-treatment platelet reactivity in acute coronary syndrome.
PG  - 267-73
LID - 10.1007/s11239-012-0678-x [doi]
AB  - Persistent high on-treatment platelet reactivity in acute coronary syndrome (ACS) 
      patients managed with appropriate antiplatelet therapy has been correlated with 
      increased risk of cardiovascular events; however, the evolution of this 
      phenomenon overtime is not well known. We investigated platelet activity at a 
      three month follow-up after initial presentation with an ACS. We enrolled a total 
      of 124 patients in the study, 65 were diagnosed with ACS and 59 controls who 
      presented with non-cardiac chest pain for baseline comparisons. Of the enrolled 
      patients, we had 25 ACS patients return, in stable condition, three months after 
      their initial presentation for repeat platelet functional testing. Epinephrine 
      (EPI), adenosine diphosphate (ADP), and arachidonic acid induced platelet 
      aggregation were monitored at baseline with repeat measurement of EPI- and 
      ADP-stimulated aggregation at follow-up. In addition, P-selectin and PAC-1 
      expression were monitored at presentation and at a three month follow-up period. 
      ACS patients were maintained on aspirin therapy during the intervening period. At 
      the three month follow-up visit, ACS patients initiated on aspirin had no 
      significant percentage change in aggregation to submaximal concentrations of EPI 
      and ADP. They also had no significant percentage change in PAC-1 or P-selectin 
      expression. This study demonstrates persistent high on-treatment platelet 
      reactivity in ACS patients at a three month follow-up, which may place these 
      patients at increased risk of recurrent cardiovascular events.
FAU - Lynch, Donald R Jr
AU  - Lynch DR Jr
AD  - Department of Medicine, Johns Hopkins Medical Institute, Johns Hopkins Bayview 
      Medical Center, 4940 Eastern Avenue, 301 Building, Division of Cardiology, 
      Baltimore, MD 21224, USA.
FAU - Khan, Farooq H
AU  - Khan FH
FAU - Vaidya, Dhananjay
AU  - Vaidya D
FAU - Williams, Marlene S
AU  - Williams MS
LA  - eng
GR  - K23HL67066/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*blood/*drug therapy
MH  - Aged
MH  - Arachidonic Acid/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/drug effects/*physiology
MH  - Platelet Aggregation/drug effects/*physiology
MH  - Treatment Outcome
EDAT- 2012/03/01 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/02/25 06:00
PHST- 2012/02/25 06:00 [entrez]
PHST- 2012/03/01 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.1007/s11239-012-0678-x [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2012 Apr;33(3):267-73. doi: 10.1007/s11239-012-0678-x.

PMID- 22552812
OWN - NLM
STAT- MEDLINE
DCOM- 20120831
LR  - 20211021
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 41
IP  - 1
DP  - 2012 Jul
TI  - Nitric oxide-donating aspirin induces G2/M phase cell cycle arrest in human 
      cancer cells by regulating phase transition proteins.
PG  - 325-30
LID - 10.3892/ijo.2012.1455 [doi]
AB  - NO-aspirin (NO-ASA), consisting of aspirin and a nitric oxide-releasing group, is 
      safer than aspirin and effective in colon cancer prevention. Here, we examined 
      the mechanism of action of NO-ASA by focusing primarily on its effects on the 
      cell cycle. NO-ASA reduced the growth of several cell lines from colon, pancreas, 
      skin, cervix and breast cancer much more potently than aspirin, with 24-h IC(50) 
      values of 133-268 µM, while those of ASA were >1,000 µM. NO-ASA elevated the 
      intracellular levels of reactive oxygen species, generating a state of oxidative 
      stress. In all cell lines examined, NO-ASA induced cell cycle arrest in the 
      G(2)/M phase transition accompanied by altered expression of G(2)/M 
      transition-related proteins. In SW480 colon cancer cells NO-ASA modulated 
      proteins controlling this transition. Thus, it markedly increased the levels of 
      cyclin B1, decreased the expression of cyclin D1 and Cdc25C, and increased the 
      Thr14/Tyr15-phosphorylation of Cdk1 while leaving unchanged its protein levels. 
      These changes, including the G2/M arrest, were prevented by pretreating the cells 
      with the anti-oxidant N-acetyl-cysteine, indicating that redox signaling is 
      likely responsible for the cell cycle changes, a conclusion consistent with the 
      known redox regulation of these proteins. Collectively, these results confirm the 
      profound cytokinetic effect of NO-ASA and provide strong evidence that it 
      regulates cell cycle transitions through its ability to induce oxidative stress, 
      which activates redox signaling in the target cell.
FAU - Gao, Li
AU  - Gao L
AD  - Division of Cancer Prevention, Department of Medicine, Stony Brook University, 
      Stony Brook, NY 11794-8175, USA.
FAU - Williams, Jennie L
AU  - Williams JL
LA  - eng
GR  - K01 CA106604/CA/NCI NIH HHS/United States
GR  - R01 CA140487/CA/NCI NIH HHS/United States
GR  - K01CA106604/CA/NCI NIH HHS/United States
GR  - R01CA140487/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20120430
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - EC 2.4.2.30 (PARP1 protein, human)
RN  - EC 2.4.2.30 (Poly (ADP-Ribose) Polymerase-1)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
RN  - EC 3.4.22.- (CASP3 protein, human)
RN  - EC 3.4.22.- (Caspase 3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Caspase 3/metabolism
MH  - Cell Cycle Proteins/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - G2 Phase Cell Cycle Checkpoints/*drug effects
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Nitric Oxide Donors/*pharmacology
MH  - Oxidative Stress/drug effects
MH  - Poly (ADP-Ribose) Polymerase-1
MH  - Poly(ADP-ribose) Polymerases/metabolism
MH  - Reactive Oxygen Species/metabolism
PMC - PMC4430830
MID - NIHMS541638
EDAT- 2012/05/04 06:00
MHDA- 2012/09/01 06:00
CRDT- 2012/05/04 06:00
PHST- 2012/02/14 00:00 [received]
PHST- 2012/03/18 00:00 [accepted]
PHST- 2012/05/04 06:00 [entrez]
PHST- 2012/05/04 06:00 [pubmed]
PHST- 2012/09/01 06:00 [medline]
AID - 10.3892/ijo.2012.1455 [doi]
PST - ppublish
SO  - Int J Oncol. 2012 Jul;41(1):325-30. doi: 10.3892/ijo.2012.1455. Epub 2012 Apr 30.

PMID- 6386002
OWN - NLM
STAT- MEDLINE
DCOM- 19841109
LR  - 20190718
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 27
IP  - 10
DP  - 1984 Oct
TI  - Trial of platelet-inhibiting drug in scleroderma. Double-blind study with 
      dipyridamole and aspirin.
PG  - 1137-43
AB  - In a randomized, double-blind, controlled study, 28 patients with early 
      scleroderma received dipyridamole (225 mg/day) and aspirin (975 mg/day) or 
      placebo for 1-2 years. No significant clinical or objective laboratory 
      improvement was noted in either group. Platelet survival time, plasma renin 
      activity, and coagulation tests were not predictive of disease course. 
      Biomechanical and vascular tests of the hands correlated with clinical extent of 
      skin induration and presence of finger ulcers, respectively.
FAU - Beckett, V L
AU  - Beckett VL
FAU - Conn, D L
AU  - Conn DL
FAU - Fuster, V
AU  - Fuster V
FAU - Osmundson, P J
AU  - Osmundson PJ
FAU - Strong, C G
AU  - Strong CG
FAU - Chao, E Y
AU  - Chao EY
FAU - Chesebro, J H
AU  - Chesebro JH
FAU - O'Fallon, W M
AU  - O'Fallon WM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Biomechanical Phenomena
MH  - Blood Coagulation/drug effects
MH  - Blood Platelets/*drug effects
MH  - Clinical Trials as Topic
MH  - Dipyridamole/*administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Fingers/physiopathology
MH  - Humans
MH  - Movement
MH  - Scleroderma, Systemic/blood/*drug therapy/physiopathology
MH  - Skin/physiopathology
EDAT- 1984/10/01 00:00
MHDA- 1984/10/01 00:01
CRDT- 1984/10/01 00:00
PHST- 1984/10/01 00:00 [pubmed]
PHST- 1984/10/01 00:01 [medline]
PHST- 1984/10/01 00:00 [entrez]
AID - 10.1002/art.1780271009 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1984 Oct;27(10):1137-43. doi: 10.1002/art.1780271009.

PMID- 16298093
OWN - NLM
STAT- MEDLINE
DCOM- 20060518
LR  - 20220321
IS  - 0378-8741 (Print)
IS  - 0378-8741 (Linking)
VI  - 103
IP  - 2
DP  - 2006 Jan 16
TI  - Gastroprotective effect of cardamom, Elettaria cardamomum Maton. fruits in rats.
PG  - 149-53
AB  - Cardamom, the fruits of Elettaria cardamomum Maton. (Zingiberaceae) commonly 
      known as "Heel khurd" is used in Unani system of medicine to treat 
      gastrointestinal disorders. A crude methanolic extract (TM), essential oil (EO), 
      petroleum ether soluble (PS) and insoluble (PI) fractions of methanolic extract, 
      were studied in rats at doses of 100-500, 12.5-50, 12.5-150 and 450 mg/kg, 
      respectively for their ability to inhibit the gastric lesions induced by aspirin, 
      ethanol and pylorous ligature. In addition their effects on wall mucus and 
      gastric acid output were recorded. All fractions (TM, EO, PS, PI) significantly 
      inhibited gastric lesions induced by ethanol and aspirin but not those induced by 
      pylorus ligation. TM proved to be active reducing lesions by about 70% in the 
      EtOH-induced ulcer model at 500 mg/kg. The PS fraction reduced the lesions by 50% 
      at 50 and 100mg/kg (no dose response was observed) with similar effect than the 
      PI fraction at 450 mg/kg. In the aspirin-induced gastric ulcer, the best 
      gastroprotective effect was found in the PS fraction, which inhibited lesions by 
      nearly 100% at 12.5mg/kg. In our experimental conditions, the PS extract at doses 
      >or=12.5mg/kg proved to be more active than ranitidine at 50mg/kg.
FAU - Jamal, A
AU  - Jamal A
AD  - Department of Ilmul Advia, Faculty of Medicine (Unani), Jamia Hamdard, New 
      Delhi-110 062, India.
FAU - Javed, Kalim
AU  - Javed K
FAU - Aslam, M
AU  - Aslam M
FAU - Jafri, M A
AU  - Jafri MA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051117
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Plant Preparations)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aspirin/*antagonists & inhibitors/toxicity
MH  - Dose-Response Relationship, Drug
MH  - *Elettaria
MH  - Ethanol/*antagonists & inhibitors/toxicity
MH  - *Fruit
MH  - Gastric Mucosa/drug effects
MH  - *Phytotherapy
MH  - Plant Preparations/*therapeutic use
MH  - Rats
MH  - Stomach Ulcer/chemically induced/*prevention & control
EDAT- 2005/11/22 09:00
MHDA- 2006/05/19 09:00
CRDT- 2005/11/22 09:00
PHST- 2004/06/07 00:00 [received]
PHST- 2005/07/04 00:00 [revised]
PHST- 2005/07/19 00:00 [accepted]
PHST- 2005/11/22 09:00 [pubmed]
PHST- 2006/05/19 09:00 [medline]
PHST- 2005/11/22 09:00 [entrez]
AID - S0378-8741(05)00478-2 [pii]
AID - 10.1016/j.jep.2005.07.016 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2006 Jan 16;103(2):149-53. doi: 10.1016/j.jep.2005.07.016. Epub 
      2005 Nov 17.

PMID- 29393216
OWN - NLM
STAT- MEDLINE
DCOM- 20180507
LR  - 20180507
IS  - 1423-0097 (Electronic)
IS  - 1018-2438 (Linking)
VI  - 175
IP  - 4
DP  - 2018
TI  - Establishing a Safe Administration of ASA in Cardiovascular Patients with 
      Nonsteroidal Anti-Inflammatory Drug Hypersensitivity with Skin and/or Respiratory 
      Involvement.
PG  - 237-245
LID - 10.1159/000486415 [doi]
AB  - BACKGROUND: A history of nonsteroidal anti-inflammatory drug (NSAID) 
      hypersensitivity with cross-intolerance to several drugs is common in some 
      patients with coronary artery disease. We present a series of patients with acute 
      coronary syndrome undergoing ASA desensitization prior to a possible stent to 
      evaluate the short- and long-term efficacy and safety. The aim was to evaluate 
      the outcomes of an ASA desensitization protocol developed by our center based on 
      the guidelines proposed by the EAACI drug allergy expert recommendations. 
      METHODS: We developed a desensitization protocol that was based on both the 
      patient characteristics and onset of reaction after NSAIDs, including 
      premedication with a leukotriene antagonist and the H1-antagonist antihistamine. 
      The clinical entities were NSAID-induced urticaria and/or angioedema in the 
      absence of chronic spontaneous urticaria (NIUA) and NSAID-exacerbated respiratory 
      disease (NERD). RESULTS: A total of 23 patients were challenged or desensitized 
      with ASA: 19 NIUA and 4 NERD. All patients tolerated the protocol at the 
      different times of 30, 45, 90, and 120 min. The dosages of oral ASA that were 
      given included 10, 21, 41, 81, and 162 mg (cumulative dose 315 mg). One patient 
      reacted during the procedure and 1 during follow-up. Symptoms were limited to the 
      skin without manifestations in other organs. All patients tolerated the required 
      dose of ASA within 30-120 min. Those requiring urgent catheterization were 
      desensitized within 90 min. CONCLUSIONS: Our protocol addresses challenge or 
      desensitization with the contribution of a specialist allergist. It provides an 
      effective, dynamic, safe, and short administration of 81 mg or higher of ASA in 
      patients with a history of NSAID hypersensitivity with skin involvement.
CI  - © 2018 S. Karger AG, Basel.
FAU - Al-Ahmad, Mona
AU  - Al-Ahmad M
AD  - Microbiology Department, Faculty of Medicine, Kuwait University, Safat, Kuwait.
FAU - Rodriguez-Bouza, Tito
AU  - Rodriguez-Bouza T
AD  - Al-Rashed Allergy Center, Ministry of Health, Kuwait City, Kuwait.
FAU - Nurkic, Midhat
AU  - Nurkic M
AD  - Sabah Al Ahmed Cardiac Center, Ministry of Health, Kuwait City, Kuwait.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20180126
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/immunology/*therapeutic use
MH  - Aspirin/immunology/*therapeutic use
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*prevention & control
MH  - Female
MH  - Humans
MH  - Lung/drug effects
MH  - Male
MH  - Middle Aged
MH  - Skin/drug effects
OTO - NOTNLM
OT  - Challenge
OT  - Coronary angioplasty
OT  - Desensitization
OT  - High-risk patients
OT  - Nonsteroidal anti-inflammatory drugs
EDAT- 2018/02/03 06:00
MHDA- 2018/05/08 06:00
CRDT- 2018/02/03 06:00
PHST- 2017/05/11 00:00 [received]
PHST- 2017/12/18 00:00 [accepted]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/05/08 06:00 [medline]
PHST- 2018/02/03 06:00 [entrez]
AID - 000486415 [pii]
AID - 10.1159/000486415 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2018;175(4):237-245. doi: 10.1159/000486415. Epub 2018 
      Jan 26.

PMID- 30585539
OWN - NLM
STAT- MEDLINE
DCOM- 20191106
LR  - 20191106
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 24
IP  - 38
DP  - 2018
TI  - Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence.
PG  - 4511-4515
LID - 10.2174/1381612825666181226151959 [doi]
AB  - BACKGROUND: Peripheral artery disease is a common manifestation of systemic 
      atherosclerosis which strongly correlates to cardiovascular morbidity and 
      mortality. In addition, the progression of peripheral artery disease leads to an 
      increased risk of limb loss. In order to reduce these events, the benchmark of 
      treatment and research over the last years has been the antiplatelet therapy 
      which aims at inhibition of platelet aggregation. Over the last years, new 
      studies combining antiplatelet agents in different therapeutic schemes have been 
      proven efficacious. Unfortunately, patients remain still at high risk of CV 
      events. Novel Oral Anticoagulants have been introduced as alternatives to 
      warfarin, in the prevention and treatment of venous thromboembolism. The 
      rationale of using medication which acts on platelet activation and the 
      coagulation pathway of thrombosis has led investigators to examine the role of 
      Noac's in preventing CV events in patients with peripheral artery disease, stable 
      or unstable. METHODS: The aim of this study is to review the current evidence 
      with respect to recently published studies concerning the use of Novel 
      anticoagulants in peripheral artery disease. RESULTS: The Compass trial has shown 
      that a combination of rivaroxaban with traditional therapy may produce promising 
      results in reducing amputation rates, stroke, cardiac events, and mortality, 
      however, there are still safety issues with bleeding requiring acute care. The 
      ePAD study has provided us with insight concerning safety and efficacy after 
      peripheral angioplasty or stenting and actually the need for further research. 
      The Voyager Pad study, following the steps of Compass, is studying the effect and 
      safety of the addition of rivaroxaban to traditional therapy in the highest risk 
      population aka patients undergoing peripheral revascularization. The evidence 
      concerning patients with concomitant atrial fibrillation appears to be 
      insufficient, however, recent guidelines propose the use of novel oral 
      anticoagulants. CONCLUSION: For the time being, novel oral anticoagulants in 
      combination with aspirin may provide an alternative treatment in PAD, however, it 
      is deemed necessary to identify patient subgroups who will benefit the most.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Koutsoumpelis, A
AU  - Koutsoumpelis A
AD  - Department of Vascular Surgery, "Democritus" University of Thrace, University 
      Hospital of Alexandroupolis, Alexandroupolis, Greece.
FAU - Argyriou, C
AU  - Argyriou C
AD  - Department of Vascular Surgery, "Democritus" University of Thrace, University 
      Hospital of Alexandroupolis, Alexandroupolis, Greece.
FAU - Tasopoulou, K M
AU  - Tasopoulou KM
AD  - Department of Vascular Surgery, "Democritus" University of Thrace, University 
      Hospital of Alexandroupolis, Alexandroupolis, Greece.
FAU - Georgakarakos, E I
AU  - Georgakarakos EI
AD  - Department of Vascular Surgery, "Democritus" University of Thrace, University 
      Hospital of Alexandroupolis, Alexandroupolis, Greece.
FAU - Georgiadis, G S
AU  - Georgiadis GS
AD  - Department of Vascular Surgery, "Democritus" University of Thrace, University 
      Hospital of Alexandroupolis, Alexandroupolis, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Anticoagulants)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Clopidogrel/administration & dosage/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Peripheral Arterial Disease/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - CAD
OT  - PAD
OT  - antiplatelet
OT  - antithrombotic therapy
OT  - atrial fibrillation
OT  - oral anticoagulants
OT  - thrombosis.
EDAT- 2018/12/27 06:00
MHDA- 2019/11/07 06:00
CRDT- 2018/12/27 06:00
PHST- 2018/12/07 00:00 [received]
PHST- 2018/12/12 00:00 [revised]
PHST- 2018/12/20 00:00 [accepted]
PHST- 2018/12/27 06:00 [pubmed]
PHST- 2019/11/07 06:00 [medline]
PHST- 2018/12/27 06:00 [entrez]
AID - CPD-EPUB-95441 [pii]
AID - 10.2174/1381612825666181226151959 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2018;24(38):4511-4515. doi: 10.2174/1381612825666181226151959.

PMID- 15337503
OWN - NLM
STAT- MEDLINE
DCOM- 20050218
LR  - 20171116
IS  - 1056-8727 (Print)
IS  - 1056-8727 (Linking)
VI  - 18
IP  - 5
DP  - 2004 Sep-Oct
TI  - Aspirin rectifies calcium homeostasis, decreases reactive oxygen species, and 
      increases NO production in high glucose-exposed human endothelial cells.
PG  - 289-99
AB  - Aspirin's pharmacological action is mainly related to its property to inhibit 
      prostaglandin synthesis; apart from this, aspirin has some beneficial side 
      effects that are not completely understood, yet. Since aspirin possesses 
      antioxidant properties and antioxidants prevent high d-glucose enhanced 
      endothelial [Ca(2+)](i), we questioned whether aspirin also has an effect on this 
      process as well as on high-glucose-impaired nitric oxide (NO) production. For 
      these purposes, human endothelial cells (HECs) were cultured in normal 
      concentration (5 mM) glucose (NG) or high concentration (33 mM) glucose (HG) and 
      after confluence, exposed for 48 h to HG in the absence or presence of 1 mM 
      aspirin. Then, the [Ca(2+)](i) was measured fluorimetrically using fura-2, NO 
      production was determined by Griess reaction, superoxide anions (O(2)) was 
      evaluated by ferricytochrome c reduction, the intracellular reactive oxygen 
      species (ROS) were evaluated by fluorimetry, and the levels of protein kinase C 
      (PKC) by Western blot. The results showed that HECs exposed to HG displayed: (i) 
      increased [Ca(2+)](i); (ii) enhanced O(2) release; (iii) augmented level of 
      intracellular ROS; and (iv) PKC translocation to the membrane fraction. By 
      comparison, exposure to cells grown in HG to 1 mM aspirin resulted in: (i) a 
      reduction of histamine stimulated [Ca(2+)](i) release to control level and of 
      [Ca(2+)](i) entry by 30%; (ii) a twofold increase in NO production; (iii) a 
      decrease of O(2)(-) accumulation in both culture medium and cell homogenate (by 
      60.4% and 70%, respectively); (iv) a decline of ROS to the control levels; and 
      (v) a reduction of PKC translocation to the control levels. These data indicate 
      that aspirin corrects the high-glucose-induced changes in cellular Ca(2+) 
      homeostasis and NO production, via a mechanism involving the reduction of the 
      O(2)(-) levels possible by acting on PKC-induced NADPH activity.
FAU - Dragomir, Elena
AU  - Dragomir E
AD  - Institute of Cellular Biology and Pathology "Nicolae Simionescu", 8, BP Hasdeu 
      Street, PO Box 35-14, 79691 Bucharest, Romania.
FAU - Manduteanu, Ileana
AU  - Manduteanu I
FAU - Voinea, Manuela
AU  - Voinea M
FAU - Costache, Gabi
AU  - Costache G
FAU - Manea, Adrian
AU  - Manea A
FAU - Simionescu, Maya
AU  - Simionescu M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Reactive Oxygen Species)
RN  - 11062-77-4 (Superoxides)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.6.3.- (NADPH Oxidases)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Calcium/*metabolism
MH  - Cell Line, Transformed
MH  - Endothelial Cells/cytology/*drug effects/metabolism
MH  - Glucose/*pharmacology
MH  - Homeostasis/drug effects
MH  - Humans
MH  - NADPH Oxidases/metabolism
MH  - Nitric Oxide/*metabolism
MH  - Protein Kinase C/metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Superoxides/metabolism
EDAT- 2004/09/01 05:00
MHDA- 2005/02/19 09:00
CRDT- 2004/09/01 05:00
PHST- 2003/08/01 00:00 [received]
PHST- 2004/02/13 00:00 [revised]
PHST- 2004/03/05 00:00 [accepted]
PHST- 2004/09/01 05:00 [pubmed]
PHST- 2005/02/19 09:00 [medline]
PHST- 2004/09/01 05:00 [entrez]
AID - S1056872704000248 [pii]
AID - 10.1016/j.jdiacomp.2004.03.003 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2004 Sep-Oct;18(5):289-99. doi: 
      10.1016/j.jdiacomp.2004.03.003.

PMID- 37263611
OWN - NLM
STAT- MEDLINE
DCOM- 20230605
LR  - 20230627
IS  - 1541-8243 (Electronic)
IS  - 0038-4348 (Linking)
VI  - 116
IP  - 6
DP  - 2023 Jun
TI  - Comprehensive Review of Hypertensive Disorders Related to Pregnancy.
PG  - 482-489
LID - 10.14423/SMJ.0000000000001571 [doi]
AB  - Hypertensive disorder of pregnancy is a common complication during pregnancy that 
      affects approximately 10% of pregnancies and is responsible for nearly 14% of 
      maternal deaths worldwide. It affects the mother and the fetus simultaneously, 
      sometimes putting the health of the mother and the fetus at odds with each other. 
      It may present with only hypertension and proteinuria or with life-threatening 
      complications in the mother such as eclampsia; stroke; acute pulmonary edema; 
      acute renal failure; disseminated intravascular coagulation; placental abruption; 
      hemolysis, elevated liver enzymes, and low platelet syndrome; pregnancy loss; and 
      fetal growth restriction and prematurity resulting from the frequent need of 
      delivering preterm in the fetus. In this review, we aimed to describe 
      hypertensive disorders of pregnancy, mainly preeclampsia and chronic hypertension 
      in pregnancy, by discussing the pathophysiology, the central role of abnormal 
      placentation, the release of antiangiogenic factors in the circulation and 
      immunological factors, the clinical outcome in the mother and the fetus, and the 
      diagnostic criteria and principles of management of both the conditions. We also 
      discuss possible screening methods and prevention of preeclampsia using low-dose 
      aspirin and eclampsia prophylaxis.
FAU - Bangi, Eera Fatima
AU  - Bangi EF
AD  - From the Seth Gordhandas Sunderdas Medical College and King Edward Memorial 
      Hospital, Mumbai, India.
FAU - Yousuf, Muhammad Hamza
AU  - Yousuf MH
AD  - Dow University of Health Sciences, Karachi, Pakistan.
FAU - Upadhyay, Shubekshya
AU  - Upadhyay S
AD  - University of California, Berkeley.
FAU - Jain, Pranjal
AU  - Jain P
AD  - University of South Florida, Tampa.
FAU - Jain, Rohit
AU  - Jain R
AD  - Department of Internal Medicine, Penn State Milton S. Hershey Medical Center, 
      Hershey, Pennsylvania.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Infant, Newborn
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/etiology
MH  - *Eclampsia/diagnosis
MH  - *Hypertension, Pregnancy-Induced/diagnosis
MH  - Placenta
MH  - Aspirin/therapeutic use
EDAT- 2023/06/02 01:07
MHDA- 2023/06/05 06:42
CRDT- 2023/06/01 20:12
PHST- 2023/06/05 06:42 [medline]
PHST- 2023/06/02 01:07 [pubmed]
PHST- 2023/06/01 20:12 [entrez]
AID - SMJ_230358 [pii]
AID - 10.14423/SMJ.0000000000001571 [doi]
PST - ppublish
SO  - South Med J. 2023 Jun;116(6):482-489. doi: 10.14423/SMJ.0000000000001571.

PMID- 8854653
OWN - NLM
STAT- MEDLINE
DCOM- 19961107
LR  - 20190606
IS  - 1226-3303 (Print)
IS  - 2005-6648 (Electronic)
IS  - 1226-3303 (Linking)
VI  - 11
IP  - 2
DP  - 1996 Jun
TI  - Complete resolution of airway hyperresponsiveness in aspirin-sensitive asthmatic 
      patients.
PG  - 157-60
AB  - Appreciable numbers of aspirin-sensitive asthmatic patients have chronic 
      steroid-dependent severe asthmatic symptoms. We report four cases of 
      aspirin-sensitive asthmatics who had mild to severe asthmatic symptoms, whose 
      methacholine PC20 level ranged from 0.6 to 22 mg/ml at the first visit. The 
      aspirin sensitivity was confirmed by lysine-aspirin bronchoprovocation. After 
      anti-asthmatic medications and avoidance of salicylate-containing agents, airway 
      hyperresponsiveness and respiratory symptoms disappeared for two to 30 months. 
      These results suggest that early detection and careful avoidance of 
      salicylate-containing agents may have a beneficial effect resulting in the 
      resolution of airway hyperresponsiveness in aspirin-sensitive asthmatic patients.
FAU - Park, H S
AU  - Park HS
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Korean J Intern Med
JT  - The Korean journal of internal medicine
JID - 8712418
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Asthma/*physiopathology
MH  - Bronchoconstriction/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
PMC - PMC4532008
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
AID - kjim-11-2-157-10 [pii]
AID - 10.3904/kjim.1996.11.2.157 [doi]
PST - ppublish
SO  - Korean J Intern Med. 1996 Jun;11(2):157-60. doi: 10.3904/kjim.1996.11.2.157.

PMID- 9781831
OWN - NLM
STAT- MEDLINE
DCOM- 19981230
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 92
IP  - 1 Suppl 1
DP  - 1998 Sep 15
TI  - Prevention of myocardial infarction and stroke by aspirin: different mechanisms? 
      Different dosage?
PG  - S7-12
AB  - More than 50 randomized trials have documented the efficacy and safety of aspirin 
      as an antiplatelet agent and a cardiovascular drug. However, the optimal dose for 
      preventing coronary and cerebral thrombosis has long been a cause of debate. For 
      patients with ischaemic heart disease the range recommended for the prevention of 
      a secondary event, based on strong clinical evidence, is 75-160 mg aspirin/day. 
      For patients with cerebrovascular disease, recommendations range from 30-1300 
      mg/day. If these patients require a higher dose of aspirin it suggests that a 
      different mechanism of action is involved. This paper considers hypotheses and 
      reports the findings of recent clinical trials. The SALT study compared aspirin 
      with placebo in 1360 patients with TIA or minor ischaemic stroke. It showed an 
      18% reduction in the risk of stroke or death in patients receiving 75 mg 
      aspirin/day. Five other trials of 55,000 patients with ischaemic cerebrovascular 
      disease compared the protective effect of aspirin (range 30-300 mg/day) with 
      placebo, clopidogrel, or oral anticoagulants. Aspirin was better than placebo, 
      safer than oral anticoagulants, and no different from clopidogrel. The 
      implications of these findings are discussed. Mechanistic studies and randomized 
      clinical trials strongly suggest that the mechanism of action and dose 
      requirement of the antithrombotic effect of aspirin in patients with 
      cerebrovascular disease is the same as that for ischaemic heart disease.
FAU - Patrono, C
AU  - Patrono C
AD  - Department of Medicine and Aging, University of Chieti, G. D'Annunzio School of 
      Medicine, Italy. cpatrono@unich.it
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cerebrovascular Disorders/drug therapy/*prevention & control
MH  - Fibrinolytic Agents/administration & dosage/*pharmacology
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Myocardial Ischemia/drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Randomized Controlled Trials as Topic
RF  - 40
EDAT- 1998/10/22 00:00
MHDA- 1998/10/22 00:01
CRDT- 1998/10/22 00:00
PHST- 1998/10/22 00:00 [pubmed]
PHST- 1998/10/22 00:01 [medline]
PHST- 1998/10/22 00:00 [entrez]
AID - 10.1016/s0049-3848(98)00101-7 [doi]
PST - ppublish
SO  - Thromb Res. 1998 Sep 15;92(1 Suppl 1):S7-12. doi: 10.1016/s0049-3848(98)00101-7.

PMID- 8347440
OWN - NLM
STAT- MEDLINE
DCOM- 19930913
LR  - 20131121
IS  - 0007-0947 (Print)
IS  - 0007-0947 (Linking)
VI  - 47
IP  - 3
DP  - 1993 May-Jun
TI  - A survey of aspirin use in the pre-hospital treatment of suspected acute cardiac 
      chest pain.
PG  - 145-6
AB  - Recent large studies have demonstrated the value of early intervention with 
      aspirin and thrombolysis in myocardial infarction for patients reaching hospital 
      alive. Management of patients with suspected myocardial infarction prior to 
      hospitalisation is an important area of acute cardiac care. Guidelines for good 
      practice suggest the early administration of aspirin should be considered when an 
      infarct seems likely. We have found aspirin less commonly used than other 
      interventions prior to hospital admission in patients with suspected acute 
      cardiac pain.
FAU - Bland, R
AU  - Bland R
AD  - Royal Cornwall Hospitals, Truro.
FAU - Vaidya, K
AU  - Vaidya K
FAU - Deodhar, H
AU  - Deodhar H
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Clin Pract
JT  - The British journal of clinical practice
JID - 0372546
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angina Pectoris/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Chest Pain/etiology
MH  - Emergency Medical Services
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
PST - ppublish
SO  - Br J Clin Pract. 1993 May-Jun;47(3):145-6.

PMID- 18449815
OWN - NLM
STAT- MEDLINE
DCOM- 20080923
LR  - 20131121
IS  - 1748-2941 (Print)
IS  - 1748-2941 (Linking)
VI  - 10
IP  - 1
DP  - 2008
TI  - Antiplatelet effects of licking an aspirin tablet can be detected by 
      thrombelastography.
PG  - 62-3
LID - 10.1080/17482940701385203 [doi]
AB  - Aspirin is a cornerstone of treatment in cardiovascular disease. However, 
      individual responses vary and hyporesponsiveness has been associated with poor 
      outcomes following percutaneous intervention. Point of care assays for detecting 
      the effects of aspirin in individual patients would therefore be useful. 
      Thrombelastography has been shown to correlate with optical aggregation in the 
      assessment of antiplatelet therapies and is suitable for use as a point of care 
      assay. We demonstrate the ability of thrombelastography to detect the profound 
      effects of even the tiny doses of aspirin obtained by licking an aspirin tablet.
FAU - Hobson, A R
AU  - Hobson AR
AD  - Wessex Cardiac Unit, Southampton University Hospital, Southampton, UK.
FAU - Dawkins, K D
AU  - Dawkins KD
FAU - Curzen, N P
AU  - Curzen NP
LA  - eng
PT  - Letter
PL  - England
TA  - Acute Card Care
JT  - Acute cardiac care
JID - 101276603
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Blood Coagulation/*drug effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Thrombelastography/*drug effects
EDAT- 2008/05/02 09:00
MHDA- 2008/09/24 09:00
CRDT- 2008/05/02 09:00
PHST- 2008/05/02 09:00 [pubmed]
PHST- 2008/09/24 09:00 [medline]
PHST- 2008/05/02 09:00 [entrez]
AID - 792789497 [pii]
AID - 10.1080/17482940701385203 [doi]
PST - ppublish
SO  - Acute Card Care. 2008;10(1):62-3. doi: 10.1080/17482940701385203.

PMID- 23631222
OWN - NLM
STAT- MEDLINE
DCOM- 20130730
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 71
IP  - 2
DP  - 2013 Feb
TI  - [Antithrombotic drug and gastrointestinal injuries].
PG  - 365-8
AB  - Gastrointestinal injuries induced by anti-coagulant agents, especially low-dose 
      aspirin (LDA) increased. Concomitant usage of LDA and NSAIDs, LDA and 
      anti-coagulant are risk factor of upper gastrointestinal (UGI)-bleeding. Time of 
      UGI-bleeding occurred in early periods after starting of LDA and NSAIDs. H. 
      pylori infection and LDA interact synergic and negative synergic with reference 
      to gastric mucosal injury.
FAU - Kawai, Takashi
AU  - Kawai T
AD  - Endoscopic Center, Tokyo Medical University Hospital.
FAU - Fukuzawa, Mari
AU  - Fukuzawa M
FAU - Moriyasu, Fuminori
AU  - Moriyasu F
FAU - Yamashina, Akira
AU  - Yamashina A
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Fibrinolytic Agents/*adverse effects/therapeutic use
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Helicobacter Infections/*drug therapy
MH  - Humans
MH  - Risk Factors
EDAT- 2013/05/02 06:00
MHDA- 2013/07/31 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/05/02 06:00 [entrez]
PHST- 2013/05/02 06:00 [pubmed]
PHST- 2013/07/31 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2013 Feb;71(2):365-8.

PMID- 7109011
OWN - NLM
STAT- MEDLINE
DCOM- 19821021
LR  - 20190913
IS  - 0731-3810 (Print)
IS  - 0731-3810 (Linking)
VI  - 19
IP  - 2
DP  - 1982 Apr
TI  - In-vivo comparison of the adsorption capacity of "superactive charcoal" and 
      fructose with activated charcoal and fructose.
PG  - 219-24
AB  - This study was undertaken to assess the in-vivo capacity of two activated 
      charcoal products to adsorb aspirin after its ingestion by seven healthy 
      volunteers. The two products, Norit-A and Super-Sorb, were combined with fructose 
      solution and administered after the subjects ingested 975 mg of aspirin. Urinary 
      excretion of salicylates was measured during both charcoal administration phases 
      and after ingestion of aspirin alone in all subjects. Results showed 
      statistically significant differences in salicylate excretion between all phases. 
      Super-Sorb ("superactive charcoal") adsorbed almost twice (1.7) as much as 
      aspirin as the regular activated charcoal, Norit-A. Super-Sorb therefore has a 
      greater in-vivo adsorption capacity for aspirin and should be a more effective 
      antidote in poisonings with this drug.
FAU - Chung, D C
AU  - Chung DC
FAU - Murphy, J E
AU  - Murphy JE
FAU - Taylor, T W
AU  - Taylor TW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Toxicol Clin Toxicol
JT  - Journal of toxicology. Clinical toxicology
JID - 8213460
RN  - 0 (Adjuvants, Pharmaceutic)
RN  - 16291-96-6 (Charcoal)
RN  - 30237-26-4 (Fructose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adjuvants, Pharmaceutic
MH  - Adsorption
MH  - Adult
MH  - Aspirin/*urine
MH  - Charcoal/*metabolism
MH  - Female
MH  - Fructose
MH  - Humans
MH  - Male
EDAT- 1982/04/01 00:00
MHDA- 1982/04/01 00:01
CRDT- 1982/04/01 00:00
PHST- 1982/04/01 00:00 [pubmed]
PHST- 1982/04/01 00:01 [medline]
PHST- 1982/04/01 00:00 [entrez]
AID - 10.3109/15563658208990384 [doi]
PST - ppublish
SO  - J Toxicol Clin Toxicol. 1982 Apr;19(2):219-24. doi: 10.3109/15563658208990384.

PMID- 18552576
OWN - NLM
STAT- MEDLINE
DCOM- 20080725
LR  - 20140730
IS  - 0002-9629 (Print)
IS  - 0002-9629 (Linking)
VI  - 335
IP  - 6
DP  - 2008 Jun
TI  - Cryptogenic stroke in a patient with a PFO: a decision analysis.
PG  - 457-64
LID - 10.1097/MAJ.0b013e3181592278 [doi]
AB  - BACKGROUND: Octogenarian Israeli prime-minister Ariel Sharon recently sustained a 
      mild, reversible stroke. A patent foramen ovale (PFO) was detected and 
      anticoagulants were given pending PFO closure. A few days later, he sustained 
      major intracerebral hemorrhage and has since remained in vegetative state. The 
      events triggered serious criticism in the mass media, experts promoting one 
      management option over others. Because knowledge of outcome and hindsight bias 
      evaluation of appropriateness of care, we sought to systematically review the 
      clinical case. METHODS: We performed a formal decision analysis to identify the 
      preferred management between anticoagulation, antiplatelets, PFO closure, or no 
      treatment. Using the best evidence available, we built a decision tree. MAIN 
      OUTCOMES: recurrent stroke and treatment complications within 1 year. RESULTS: 
      Optimal decision was found to be critically sensitive to assumptions about 
      etiology, efficacy and safety of treatments, recurrence risk, and to small 
      changes in utilities. In multiway sensitivity analysis, when the risk of 
      recurrent stroke was <0.12 per year, no treatment was the best management. PFO 
      closure is dominant only when the risk of recurrent stroke is >0.12 per year 
      closure effectiveness is assumed to be <0.28. When closure effectiveness is >0.6, 
      it is inferior to anticoagulation and antiplatelet management. CONCLUSIONS: 
      Uncertainties precluded a clear-cut answer and choice was found to be a 
      "toss-up," often associated with much controversy. Use of novel therapies, such 
      as PFO closure, outside clinical trials will not reduce uncertainty about 
      efficacy.
FAU - Stern, Sagit
AU  - Stern S
AD  - Center for Clinical Quality and Safety, Hebrew University, Jerusalem, Israel.
FAU - Cohen, Matan J
AU  - Cohen MJ
FAU - Gilon, Dan
AU  - Gilon D
FAU - Leshno, Moshe
AU  - Leshno M
FAU - Brezis, Mayer
AU  - Brezis M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Cardiac Catheterization
MH  - *Decision Trees
MH  - Foramen Ovale, Patent/*complications/surgery
MH  - Humans
MH  - *Intracranial Hemorrhages/etiology/prevention & control
MH  - *Ischemic Attack, Transient/complications/drug therapy
MH  - *Models, Statistical
MH  - *Patient Care Management/statistics & numerical data
MH  - Practice Guidelines as Topic
MH  - Recurrence
EDAT- 2008/06/17 09:00
MHDA- 2008/07/26 09:00
CRDT- 2008/06/17 09:00
PHST- 2008/06/17 09:00 [pubmed]
PHST- 2008/07/26 09:00 [medline]
PHST- 2008/06/17 09:00 [entrez]
AID - S0002-9629(15)32280-1 [pii]
AID - 10.1097/MAJ.0b013e3181592278 [doi]
PST - ppublish
SO  - Am J Med Sci. 2008 Jun;335(6):457-64. doi: 10.1097/MAJ.0b013e3181592278.

PMID- 15508274
OWN - NLM
STAT- MEDLINE
DCOM- 20050127
LR  - 20191109
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 32
IP  - 3
DP  - 2004
TI  - Review of hemoglobin-induced myocardial lesions.
PG  - 353-74
AB  - Over 100 preclinical studies in several small and large animal species were 
      performed to evaluate the safety and efficacy of diaspirin cross-linked 
      hemoglobin (DCLHb; Baxter Healthcare Corp.) as an oxygen therapeutic. During the 
      preclinical evaluation of DCLHb, myocardial lesions were observed following the 
      administration of DCLHb to certain species. These lesions were characterized as 
      minimal to moderate, focal-to-multifocal myocardial degeneration and/or necrosis 
      that were scored using a severity scale of minimal to marked in relative 
      severity. The lesions were typically observed 24-48 h after single topload 
      infusions of DCLHb into rhesus monkeys or pigs at doses as low as 200 or 700 
      mg/kg, respectively. Dogs, sheep, and rats did not develop these lesions after 
      single-dose administrations of DCLHb. The left ventricular myocardium, typically 
      near the base of or including the papillary muscles, was the most severely 
      affected region, followed by the intraventricular septum and the right ventricle. 
      The left and right atria were usually not affected. In a study in rhesus monkeys, 
      morphometric analysis revealed that these lesions comprised less than 3% of the 
      total myocardium. Although increases in serum enzyme activities (AST, CK, LDH) 
      were observed after infusion of DCLHb, myocardial-related isoenzymes did not 
      increase. ECG analysis and echocardiography were not altered by these lesions, 
      and there was no observable adverse effect on myocardial function. Polymerization 
      of DCLHb reduced, but did not eliminate, the incidence and severity of the 
      lesions. However, infusion of hemoglobin solutions with reduced reaction rates 
      with nitric oxide (NO) resulted in a significant decrease in lesion incidence and 
      severity, while administration of L-NAME, an NO synthase inhibitor, resulted in 
      the appearance of lesions that were indistinguishable from those induced by 
      hemoglobin, suggesting that reduction in normal NO levels is an important 
      mechanistic factor. Overall, the presence of myocardial lesions represents a 
      histopathologic finding that must be considered during the preclinical testing 
      and development of new HBOCs.
FAU - Burhop, Kenneth
AU  - Burhop K
AD  - Baxter Healthcare Corporation, DF3-2W, One Baxter Parkway, Deerfield, Illinois 
      60015, USA. ken_burhop@baxter.com
FAU - Gordon, Donovan
AU  - Gordon D
FAU - Estep, Timothy
AU  - Estep T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Enzymes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/*adverse effects/*analogs & derivatives
MH  - Dogs
MH  - Drug Evaluation, Preclinical
MH  - Enzymes/blood
MH  - Haplorhini
MH  - Heart Atria/injuries/pathology
MH  - Heart Injuries/blood/*chemically induced
MH  - Heart Ventricles/injuries/*pathology
MH  - Hemoglobins/*administration & dosage/*adverse effects
MH  - Necrosis/chemically induced
MH  - Papillary Muscles/injuries/*pathology
MH  - Rats
MH  - Sheep
MH  - Swine
RF  - 22
EDAT- 2004/10/29 09:00
MHDA- 2005/01/28 09:00
CRDT- 2004/10/29 09:00
PHST- 2004/10/29 09:00 [pubmed]
PHST- 2005/01/28 09:00 [medline]
PHST- 2004/10/29 09:00 [entrez]
AID - 10.1081/bio-200027429 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 2004;32(3):353-74. doi: 
      10.1081/bio-200027429.

PMID- 2114414
OWN - NLM
STAT- MEDLINE
DCOM- 19900814
LR  - 20191022
IS  - 0269-4727 (Print)
IS  - 0269-4727 (Linking)
VI  - 15
IP  - 3
DP  - 1990 Jun
TI  - A double-blind crossover study to compare lysine acetyl salicylate (Aspergesic) 
      with ibuprofen in the treatment of rheumatoid arthritis.
PG  - 205-11
AB  - Lysine acetyl salicylate [1.8 g t.d.s. (Aspergesic 1,000 sachet)] has been 
      compared to 400-mg ibuprofen tablets t.d.s. in a randomized double-blind trial in 
      patients with rheumatoid arthritis using double-dummy technique. Both drugs 
      proved effective in relieving symptoms. Three patients experienced drug-related 
      side-effects with Aspergesic, and one patient with ibuprofen, that necessitated 
      early discontinuation of treatment. Aspergesic was associated with a greater 
      number of haemoglobin values falling below the normal range than ibuprofen. At 
      the end of the study, eight out of 10 patients who expressed a preference 
      selected Aspergesic for improving mobility whilst 15/24 selected Aspergesic for 
      improving pain.
FAU - Hill, J
AU  - Hill J
AD  - Clinical Pharmacology Unit, Royal Bath Hospital, Harrogate, U.K.
FAU - Bird, H A
AU  - Bird HA
FAU - Fenn, G C
AU  - Fenn GC
FAU - Lee, C E
AU  - Lee CE
FAU - Woodward, M
AU  - Woodward M
FAU - Wright, V
AU  - Wright V
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse 
      effects/pharmacokinetics/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Aspirin/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Ibuprofen/adverse effects/*therapeutic use
MH  - Lysine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Salicylates/blood
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2710.1990.tb00376.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 1990 Jun;15(3):205-11. doi: 
      10.1111/j.1365-2710.1990.tb00376.x.

PMID- 17393260
OWN - NLM
STAT- MEDLINE
DCOM- 20070919
LR  - 20181113
IS  - 0959-9851 (Print)
IS  - 0959-9851 (Linking)
VI  - 17
IP  - 2
DP  - 2007 Apr
TI  - The effects of acetylic salicylic acid on heart rate variability in healthy 
      subjects.
PG  - 115-7
AB  - In this placebo controlled double blind cross over study multiple daily dosing 
      with 500 mg acetylic salicylic acid did not influence heart rate variability in 
      16 healthy male volunteers aged 25 (22-28) years (median; range) to a relevant 
      extent (p > 0.05).
FAU - Siepmann, Martin
AU  - Siepmann M
AD  - Institute of Clinical Pharmacology, Medical Faculty, Technical University, 
      Fieldlerstrasse 27, Dresden, Germany. martin.siepmann@tu-dresden.de
FAU - Rauh, Robert
AU  - Rauh R
FAU - Spanos, Emmanouil
AU  - Spanos E
FAU - Dill, Oliver
AU  - Dill O
FAU - Mueck, Herbert
AU  - Mueck H
FAU - Mueck-Weymann, Michael
AU  - Mueck-Weymann M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20070328
PL  - Germany
TA  - Clin Auton Res
JT  - Clinical autonomic research : official journal of the Clinical Autonomic Research 
      Society
JID - 9106549
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - *Health
MH  - Heart Rate/*drug effects
MH  - Humans
MH  - Male
MH  - Physical Fitness
MH  - Respiration/drug effects
MH  - Rest
EDAT- 2007/03/30 09:00
MHDA- 2007/09/20 09:00
CRDT- 2007/03/30 09:00
PHST- 2006/12/28 00:00 [received]
PHST- 2007/02/23 00:00 [accepted]
PHST- 2007/03/30 09:00 [pubmed]
PHST- 2007/09/20 09:00 [medline]
PHST- 2007/03/30 09:00 [entrez]
AID - 10.1007/s10286-007-0408-1 [doi]
PST - ppublish
SO  - Clin Auton Res. 2007 Apr;17(2):115-7. doi: 10.1007/s10286-007-0408-1. Epub 2007 
      Mar 28.

PMID- 2082305
OWN - NLM
STAT- MEDLINE
DCOM- 19910509
LR  - 20131121
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 10
IP  - 6 ( Pt 2)
DP  - 1990
TI  - Comparison of long-term safety of ketorolac tromethamine and aspirin in the 
      treatment of chronic pain.
PG  - 106S-110S
AB  - A double-blind, randomized trail was conducted in 823 patients who required 
      long-term analgesic therapy for chronic pain such as that caused by 
      osteoarthritis, fibromyopathies or fibromyalgias, other nonarticular chronic soft 
      tissue pain syndromes, or headaches. The safety and analgesic efficacy of 
      ketorolac tromethamine 10 mg 4 times a day as needed was compared with that of 
      aspirin 650 mg 4 times a day as needed. The primary emphasis of this 52-week 
      study was on evaluating the safety of the drugs. Patients returned to the clinics 
      at 2, 5, 10, 15, 20, 28, 36, 44, and 52 weeks for assessments of safety and 
      efficacy. Both patients' and investigators' evaluations of overall efficacy and 
      safety favored ketorolac over aspirin. The probability of early withdrawal from 
      the study was significantly higher with aspirin than with ketorolac, primarily 
      because of lack of efficacy. Early withdrawal for safety-related reasons alone 
      was similar for those taking aspirin and ketorolac.
FAU - Rubin, P
AU  - Rubin P
AD  - Syntex Research, Institute of Clinical Medicine, Palo Alto, CA 94304.
FAU - Yee, J P
AU  - Yee JP
FAU - Ruoff, G
AU  - Ruoff G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 023C2WHX2V (Tromethamine)
RN  - 4EVE5946BQ (Ketorolac Tromethamine)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Chronic Disease
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Combinations
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Headache/chemically induced
MH  - Humans
MH  - Ketorolac Tromethamine
MH  - Male
MH  - Middle Aged
MH  - Pain/*drug therapy
MH  - Time Factors
MH  - Tolmetin/adverse effects/*analogs & derivatives/therapeutic use
MH  - Tromethamine/*adverse effects/therapeutic use
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - Pharmacotherapy. 1990;10(6 ( Pt 2)):106S-110S.

PMID- 35772341
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220809
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 104
DP  - 2022 Sep
TI  - A systematic review and meta-analysis for the primary prevention of high risk of 
      stroke by Nao-an capsules.
PG  - 154263
LID - S0944-7113(22)00342-7 [pii]
LID - 10.1016/j.phymed.2022.154263 [doi]
AB  - BACKGROUND: To date, Nao-an capsules are the only Chinese patent medicine 
      primarily prescribed for the primary prevention of stroke. PURPOSE: To evaluate 
      the efficacy and safety of Nao-an capsules in the primary prevention of stroke in 
      high-risk patients. STUDY DESIGN: A systematic review and meta-analysis of 
      randomized controlled trials. METHODS: We searched 7 electronic databases and 2 
      registries from inception to January 13, 2022 for relevant randomized controlled 
      trials. Two independent investigators selected trials, collected data, and judged 
      the risk of bias. We performed a meta-analysis using the Review Manager software. 
      RESULTS: Nine randomized controlled trials involving 14 744 patients at high risk 
      of stroke were included. Nao-an capsules reduced the risk of first stroke 
      compared with no intervention (risk ratio [RR] = 0.49, 95 % confidence interval 
      [CI] 0.29 to 0.82, p = 0.006) or aspirin (RR(50 mg qd) = 0.47, 95 % CI 0.25 to 
      0.91, p = 0.03; RR(100 mg qd) = 0.46, 95 % CI 0.22 to 0.99, p = 0.05), without 
      increased bleeding risks. The certainty of evidence was evaluated as moderate to 
      very low. CONCLUSION: In addition to controlling specific risk factors, Nao-an 
      capsules might provide additional preventive effects on first stroke with an 
      acceptable safety profile for populations at high risk of stroke. However, as 
      current evidence is too weak, a firm recommendation depends on further 
      confirmation from more studies with more rigorous methodology.
CI  - Copyright © 2022. Published by Elsevier GmbH.
FAU - Wang, Liuding
AU  - Wang L
AD  - Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, 
      China.
FAU - Fan, Xueming
AU  - Fan X
AD  - Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, 
      China.
FAU - Du, Wanqing
AU  - Du W
AD  - Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, 
      China.
FAU - Liang, Xiao
AU  - Liang X
AD  - Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, 
      China.
FAU - Chen, Yifan
AU  - Chen Y
AD  - Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, 
      China.
FAU - Shi, Jingzi
AU  - Shi J
AD  - Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, 
      China.
FAU - Sun, Linjuan
AU  - Sun L
AD  - Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, 
      China.
FAU - Shen, Wei
AU  - Shen W
AD  - Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, 
      China. Electronic address: 676665709@qq.com.
FAU - Zhang, Yunling
AU  - Zhang Y
AD  - Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, 
      China. Electronic address: yunlingzhang2004@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220615
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Primary Prevention
MH  - *Stroke/drug therapy/prevention & control
OTO - NOTNLM
OT  - Aspirin
OT  - Bleeding risks
OT  - Incidence of stroke
OT  - Stroke prevention
OT  - Traditional Chinese medicine
EDAT- 2022/07/01 06:00
MHDA- 2022/08/10 06:00
CRDT- 2022/06/30 18:26
PHST- 2022/04/10 00:00 [received]
PHST- 2022/06/05 00:00 [revised]
PHST- 2022/06/08 00:00 [accepted]
PHST- 2022/07/01 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2022/06/30 18:26 [entrez]
AID - S0944-7113(22)00342-7 [pii]
AID - 10.1016/j.phymed.2022.154263 [doi]
PST - ppublish
SO  - Phytomedicine. 2022 Sep;104:154263. doi: 10.1016/j.phymed.2022.154263. Epub 2022 
      Jun 15.

PMID- 4004853
OWN - NLM
STAT- MEDLINE
DCOM- 19850710
LR  - 20190612
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 128
IP  - 3
DP  - 1985 May 16
TI  - Acetylation of lens crystallins: a possible mechanism by which aspirin could 
      prevent cataract formation.
PG  - 1125-32
AB  - The calf eye lens homogenate incubated with [1-14C-acetyl] aspirin and separated 
      into HMW, alpha, beta H, beta L and gamma-crystallins by means of Sepharose 6B 
      and Bio-Gel P2 columns showed radioactivity in all the crystallins. In contrast, 
      no radioactivity was found in the crystallins when the lens homogenate was 
      incubated with [14C-carboxyl] aspirin. These experiments clearly indicated that 
      the eye lens crystallins are acetylated with aspirin. Furthermore, no decrease in 
      the radioactivity in the crystallins after exhaustive dialysis against 0.15M NaCl 
      suggests a covalent type of binding of acetyl moiety of aspirin to the lens 
      crystallins. The significant decrease in the free epsilon-amino groups of 
      aspirin-treated crystallins further suggests the probable sites of acetylation in 
      the crystallins. It may be concluded that acetylation of free epsilon-amino 
      groups of lens crystallins by aspirin may confer protection against crystallin 
      aggregation in cataractogenesis.
FAU - Rao, G N
AU  - Rao GN
FAU - Lardis, M P
AU  - Lardis MP
FAU - Cotlier, E
AU  - Cotlier E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Crystallins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Binding Sites
MH  - Cataract/*prevention & control
MH  - Cattle
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Crystallins/*metabolism
MH  - In Vitro Techniques
MH  - Lens, Crystalline/drug effects/metabolism
EDAT- 1985/05/16 00:00
MHDA- 1985/05/16 00:01
CRDT- 1985/05/16 00:00
PHST- 1985/05/16 00:00 [pubmed]
PHST- 1985/05/16 00:01 [medline]
PHST- 1985/05/16 00:00 [entrez]
AID - 0006-291X(85)91057-5 [pii]
AID - 10.1016/0006-291x(85)91057-5 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1985 May 16;128(3):1125-32. doi: 
      10.1016/0006-291x(85)91057-5.

PMID- 1290295
OWN - NLM
STAT- MEDLINE
DCOM- 19930325
LR  - 20131121
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 81 Suppl 4
DP  - 1992
TI  - [Clinical pharmacology of acetylsalicylic acid].
PG  - 171-5
AB  - The pharmacological actions of acetylsalicylic acid (ASA) are determined by two 
      compounds: ASA and salicylic acid. Salicylic acid is formed from its precursor 
      ASA within 15-20 min after oral application and is responsible for the 
      antiinflammatory, antipyretic, and analgetic activities of ASA. However, the 
      platelet inhibitory, i.e., the antithrombotic action of ASA is only due to this 
      compound itself and is caused by irreversible inhibition of the platelet 
      cyclooxygenase, i.e., inhibition of thromboxane A2 formation. The bioavailability 
      of plain ASA after oral administration amounts to 40-50% at therapeutic doses. 
      This is due to rapid deacetylation prior to reaching the systemic circulation. 
      This deacetylation accounts for a significant part of inhibition of platelet 
      cyclooxygenase within the portal circulation which is further enhanced by using 
      sustained-release preparations. Doses of 40-50 mg ASA per day are sufficient to 
      maintain complete blockade of platelet cyclooxygenase and this agrees well with 
      the established efficacy of 75 mg ASA/day in controlled clinical trials on 
      secondary prevention of myocardial infarction.
FAU - Schröder, H
AU  - Schröder H
AD  - Institut für Pharmakologie, Heinrich-Heine-Universität Düsseldorf.
FAU - Schrör, K
AU  - Schrör K
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Klinische Pharmakologie von Acetylsalizylsäure.
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Biological Availability
MH  - Coronary Artery Bypass
MH  - Dose-Response Relationship, Drug
MH  - Graft Occlusion, Vascular/blood
MH  - Humans
MH  - Myocardial Infarction/blood
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane A2/*antagonists & inhibitors
RF  - 34
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Kardiol. 1992;81 Suppl 4:171-5.

PMID- 33162259
OWN - NLM
STAT- MEDLINE
DCOM- 20210616
LR  - 20221207
IS  - 0736-4679 (Print)
IS  - 0736-4679 (Electronic)
IS  - 0736-4679 (Linking)
VI  - 60
IP  - 4
DP  - 2021 Apr
TI  - Multisystem Inflammatory Syndrome in Children.
PG  - 531-535
LID - S0736-4679(20)31053-2 [pii]
LID - 10.1016/j.jemermed.2020.10.009 [doi]
AB  - BACKGROUND: As the number of coronavirus disease 2019 (COVID-19) cases increases 
      globally, more cases of a rare COVID-19-associated disease process are being 
      identified in the pediatric population. This syndrome is referred to as 
      multisystem inflammatory syndrome in children (MIS-C). Clinical manifestations of 
      the syndrome vary and include one or a combination of the following: vasodilatory 
      shock, cardiogenic shock, Kawasaki-like disease, cytokine storming, coronary 
      artery dilatation, and aneurysms. CASE REPORT: This case report describes the 
      presentation, findings, workup, and treatment for a 9-year-old boy diagnosed with 
      MIS-C. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: It is important to 
      recognize MIS-C, as it shares many of the same features as other disease 
      processes, for example, Kawasaki disease and toxic shock syndrome, but has 
      different complications if left untreated.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Tabaac, Sydney
AU  - Tabaac S
AD  - Department of Emergency Medicine, Cooper University Hospital, Camden, New Jersey.
FAU - Kothari, Poonam
AU  - Kothari P
AD  - Department of Emergency Medicine, Cooper University Hospital, Camden, New Jersey.
FAU - Cassidy-Smith, Tara
AU  - Cassidy-Smith T
AD  - Department of Emergency Medicine, Cooper University Hospital, Camden, New Jersey.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20201105
PL  - United States
TA  - J Emerg Med
JT  - The Journal of emergency medicine
JID - 8412174
RN  - 0 (Immunoglobulins)
RN  - R16CO5Y76E (Aspirin)
RN  - pediatric multisystem inflammatory disease, COVID-19 related
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - COVID-19/*complications/diagnosis
MH  - Child
MH  - Humans
MH  - Immunoglobulins/administration & dosage/therapeutic use
MH  - Male
MH  - SARS-CoV-2
MH  - Systemic Inflammatory Response Syndrome/*diagnosis/drug therapy
MH  - COVID-19 Drug Treatment
PMC - PMC7962942
OTO - NOTNLM
OT  - COVID-19
OT  - Kawasaki disease
OT  - Kawasaki-like syndrome
OT  - MIS-C
OT  - SARS-CoV-2
OT  - coronavirus
OT  - infectious disease
OT  - multisystem inflammatory syndrome in children
EDAT- 2020/11/10 06:00
MHDA- 2021/06/17 06:00
CRDT- 2020/11/09 05:27
PHST- 2020/06/29 00:00 [received]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/10/04 00:00 [accepted]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/06/17 06:00 [medline]
PHST- 2020/11/09 05:27 [entrez]
AID - S0736-4679(20)31053-2 [pii]
AID - 10.1016/j.jemermed.2020.10.009 [doi]
PST - ppublish
SO  - J Emerg Med. 2021 Apr;60(4):531-535. doi: 10.1016/j.jemermed.2020.10.009. Epub 
      2020 Nov 5.

PMID- 26856059
OWN - NLM
STAT- MEDLINE
DCOM- 20160225
LR  - 20181023
IS  - 0039-4521 (Print)
IS  - 0039-4521 (Linking)
VI  - 58
IP  - 6
DP  - 2015 Nov-Dec
TI  - [The forensic chemical investigation of acetylsalicylic acid].
PG  - 37-43
LID - 10.17116/sudmed201558637-43 [doi]
AB  - The objective of the present study was to develop the universal approach to the 
      quantitative determination of acetylsalicylic acid in biological tissues and 
      fluids to be applied in the practice of forensic chemical expertise with the use 
      of thin-layer chromatography, gas chromatography and mass spectrometry, 
      low-pressure column chromatography, and spectrophotometry. A system of solvents 
      consisting of acetone and ethyl acetate (7:3) was proposed as a universal agent 
      for extracting acetylsalicylic acid from the cadaveric tissues and blood. It was 
      shown that acetylsalicylic acid and its principal metabolite, salicylic acid, can 
      be purified from the endogenous admixtures present in the biological materials by 
      column chromatography on silica gel L 40/100 mcm. Salicylic acid in extracts from 
      biological materials was identified and quantified with the use of thin-layer 
      chromatography, gas chromatography/mass spectrometry, and electronic 
      spectrophotometry. The method for forensic chemical investigation of 
      acetylsalicylic acid has been developed and applied in the analysis of the 
      material provided for expertise.
FAU - Shormanov, V K
AU  - Shormanov VK
AD  - Kursk State University, Kursk, Russia, 305041.
FAU - Chupak, V V
AU  - Chupak VV
AD  - Orel State University, Orel, Russia, 302028.
FAU - Pobedonstseva, M N
AU  - Pobedonstseva MN
AD  - Kursk State University, Kursk, Russia, 305041.
FAU - Maslov, S V
AU  - Maslov SV
AD  - Kursk Regional Bureau of Forensic Medical Expertise, Kursk, Russia, 305000.
FAU - Kibets, N A
AU  - Kibets NA
AD  - Kursk State University, Kursk, Russia, 305041.
FAU - Tikhopoeva, N N
AU  - Tikhopoeva NN
AD  - Kursk Regional Bureau of Forensic Medical Expertise, Kursk, Russia, 305000.
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Sud Med Ekspert
JT  - Sudebno-meditsinskaia ekspertiza
JID - 0404546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Solvents)
RN  - 1364PS73AF (Acetone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetone/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/pharmacology
MH  - *Aspirin/chemistry/pharmacology
MH  - Forensic Toxicology/methods
MH  - Humans
MH  - *Kidney/chemistry/pathology
MH  - *Liver/chemistry/pathology
MH  - Mass Spectrometry/methods
MH  - Organ Specificity
MH  - Reproducibility of Results
MH  - Solvents/pharmacology
MH  - Spectrophotometry/methods
MH  - *Stomach/chemistry/pathology
EDAT- 2016/02/10 06:00
MHDA- 2016/02/26 06:00
CRDT- 2016/02/10 06:00
PHST- 2016/02/10 06:00 [entrez]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
AID - 10.17116/sudmed201558637-43 [doi]
PST - ppublish
SO  - Sud Med Ekspert. 2015 Nov-Dec;58(6):37-43. doi: 10.17116/sudmed201558637-43.

PMID- 7192125
OWN - NLM
STAT- MEDLINE
DCOM- 19810129
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 30
IP  - 4A
DP  - 1980
TI  - Double blind cross-over trial comparing fenbufen and acetylsalicylic acid in 
      rheumatoid arthritis.
PG  - 735-9
AB  - 25 out-patients with active classical or definite adult-onset rheumatoid 
      arthritis were enrolled in a 4-week randomized, two-period double-blind 
      cross-over study comparing gamma-oxo(1,1'-biphenyl)-4-butanoic acid (fenbufen) 
      (1000 mg/d) and acetylsalicylic acid (ASA) (3600 mg/d). Only patients with 
      active, flaring disease, off antiinflammatory drugs, were admitted into this 
      study. Significant mean improvement from baseline was seen with both fenbufen and 
      ASA after two weeks of treatment. There were no statistically significant 
      differences between the degree of improvement from baseline between fenbufen and 
      ASA. However, there were significant differences in patient tolerance of the two 
      medications with more patients reporting adverse experiences with ASA than with 
      fenbufen. The differences between treatments were statistically significant for 
      side effects graded as moderate or severe with 6 patients experiencing 
      drug-related side effects on ASA compared to none on fenbufen.
FAU - Anderson, L G
AU  - Anderson LG
FAU - Bina, P R
AU  - Bina PR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Phenylbutyrates)
RN  - 0 (Propionates)
RN  - 9815R1WR9B (fenbufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Biphenyl Compounds/therapeutic use
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Phenylbutyrates
MH  - Propionates/*therapeutic use
MH  - Time Factors
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1980;30(4A):735-9.

PMID- 22633626
OWN - NLM
STAT- MEDLINE
DCOM- 20130328
LR  - 20141120
IS  - 1873-2828 (Electronic)
IS  - 1350-4177 (Linking)
VI  - 20
IP  - 1
DP  - 2013 Jan
TI  - Impact of process parameters in the generation of novel aspirin 
      nanoemulsions--comparative studies between ultrasound cavitation and 
      microfluidizer.
PG  - 485-97
LID - S1350-4177(12)00080-6 [pii]
LID - 10.1016/j.ultsonch.2012.04.005 [doi]
AB  - In the present investigation, the operating efficiency of a bench-top air-driven 
      microfluidizer has been compared to that of a bench-top high power ultrasound 
      horn in the production of pharmaceutical grade nanoemulsions using aspirin as a 
      model drug. The influence of important process variables as well as the 
      pre-homogenization and drug loading on the resultant mean droplet diameter and 
      size distribution of emulsion droplets was studied in an oil-in-water 
      nanoemulsion incorporated with a model drug aspirin. Results obtained show that 
      both the emulsification methods were capable of producing very fine nanoemulsions 
      containing aspirin with the minimum droplet size ranging from 150 to 170 nm. In 
      case of using the microfluidizer, it has been observed that the size of the 
      emulsion droplets obtained was almost independent of the applied 
      microfluidization pressure (200-600 bar) and the number of passes (up to 10 
      passes) while the pre-homogenization and drug loading had a marginal effect in 
      increasing the droplet size. Whereas, in the case of ultrasound emulsification, 
      the droplet size was generally decreased with an increase in sonication amplitude 
      (50-70%) and period of sonication but the resultant emulsion was found to be 
      dependent on the pre-homogenization and drug loading. The STEM microscopic 
      observations illustrated that the optimized formulations obtained using 
      ultrasound cavitation technique are comparable to microfluidized emulsions. These 
      comparative results demonstrated that ultrasound cavitation is a relatively 
      energy-efficient yet promising method of pharmaceutical nanoemulsions as compared 
      to microfluidizer although the means used to generate the nanoemulsions are 
      different.
CI  - Copyright © 2012 Elsevier B.V. All rights reserved.
FAU - Tang, Siah Ying
AU  - Tang SY
AD  - Department of Chemical and Environmental Engineering, Faculty of Engineering, The 
      University of Nottingham, Malaysia Campus, Jalan Broga, 43500 Semenyih, Malaysia.
FAU - Shridharan, Parthasarathy
AU  - Shridharan P
FAU - Sivakumar, Manickam
AU  - Sivakumar M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120503
PL  - Netherlands
TA  - Ultrason Sonochem
JT  - Ultrasonics sonochemistry
JID - 9433356
RN  - 0 (Emulsions)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Emulsions
MH  - Feasibility Studies
MH  - In Vitro Techniques
MH  - Microfluidics/*methods
MH  - Nanostructures/*chemistry
MH  - Nanotechnology/*methods
MH  - Pressure
MH  - Sonication/*methods
EDAT- 2012/05/29 06:00
MHDA- 2013/03/30 06:00
CRDT- 2012/05/29 06:00
PHST- 2011/12/09 00:00 [received]
PHST- 2012/04/10 00:00 [revised]
PHST- 2012/04/14 00:00 [accepted]
PHST- 2012/05/29 06:00 [entrez]
PHST- 2012/05/29 06:00 [pubmed]
PHST- 2013/03/30 06:00 [medline]
AID - S1350-4177(12)00080-6 [pii]
AID - 10.1016/j.ultsonch.2012.04.005 [doi]
PST - ppublish
SO  - Ultrason Sonochem. 2013 Jan;20(1):485-97. doi: 10.1016/j.ultsonch.2012.04.005. 
      Epub 2012 May 3.

PMID- 25753207
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20181113
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 80
IP  - 2
DP  - 2015 Aug
TI  - Evidence for a vasomotor cyclo-oxygenase dependent mechanism of sensitization at 
      the cutaneous level.
PG  - 185-92
LID - 10.1111/bcp.12623 [doi]
AB  - AIMS: Current-induced vasodilation (CIV) is an axon-reflex response observed 
      during monopolar current application such as iontophoresis. Cyclo-oxygenase 
      derivates (COD) participate in CIV and act as sensitizing agents at the anodal 
      level. Mechanisms involved during cathodal current application (CCA) are 
      partially unknown. In a randomized double-blind crossover trial, we tested in 16 
      healthy subjects (i) the influence of the inter-stimulation interval (I-I) by 
      comparing CIV following all-at-once 10 s CCA against 2 × 5 s CCA with intervals 
      ranging from15 s-16 min and (ii) the participation of COD in CIV using 1 g 
      aspirin or placebo intake. METHODS: Measurements were repeated 2 h and 14 days 
      after treatment. Laser Doppler flowmetry assessed cutaneous blood flow, reported 
      in multiples of baseline. RESULTS: Before treatment, peak vasodilation 10 min 
      after the last current application (CVCstim2 ) increased compared with baseline 
      whatever the I-I. Increase in CVCstim2 from baseline was greater for the 4 min 
      (9.4 (5.3, 10.9) times; median (1(st) percentile, 3(rd) percentile)) and higher 
      I-Is compared with all-at-once delivery (3.0 (2.1, 4.3) times, P < 0.05). The 
      response was similar after placebo but aspirin abolished this vasodilation 
      (increase by 1.2 (1.1, 1.3) times for all-at-once delivery and by 1.5 (1.3, 1.7) 
      ± 0.3 times for 4 min interval, 2 h after aspirin intake) that recovered after 14 
      days. CONCLUSIONS: This confirms the participation of COD in CIV with CCA and 
      their sensitizing action. This model can represent an attractive way to study the 
      axon-reflex and sensitizing function of COD in humans.
CI  - © 2015 The British Pharmacological Society.
FAU - Mahé, G
AU  - Mahé G
AD  - Biologie Neurovasculaire et Mitochondriale Intégrée (BNMI) - Unité mixte UMR CNRS 
      6214 / INSERM U 1083, Faculté de Médecine, Angers, France.
AD  - Laboratory of Vascular Investigations, University Hospital of Angers, France.
AD  - CHU Rennes, Imagerie cœur-vaisseaux, F-35033, Rennes, France.
AD  - INSERM, Clinical Investigation Center CIC 1414, F-34043, Rennes, France.
AD  - Université de Rennes 1, F-34043, Rennes, France.
FAU - Abraham, P
AU  - Abraham P
AD  - Biologie Neurovasculaire et Mitochondriale Intégrée (BNMI) - Unité mixte UMR CNRS 
      6214 / INSERM U 1083, Faculté de Médecine, Angers, France.
AD  - Laboratory of Vascular Investigations, University Hospital of Angers, France.
FAU - Humeau-Heurtier, A
AU  - Humeau-Heurtier A
AD  - LARIS - Laboratoire Angevin de Recherche en Ingénierie des Systèmes, Université 
      d'Angers, 62 avenue Notre-Dame du Lac, 49000, Angers, France.
FAU - Gascoin, L
AU  - Gascoin L
AD  - Laboratory of Vascular Investigations, University Hospital of Angers, France.
FAU - Lefthériotis, G
AU  - Lefthériotis G
AD  - Biologie Neurovasculaire et Mitochondriale Intégrée (BNMI) - Unité mixte UMR CNRS 
      6214 / INSERM U 1083, Faculté de Médecine, Angers, France.
AD  - Laboratory of Vascular Investigations, University Hospital of Angers, France.
FAU - Durand, S
AU  - Durand S
AUID- ORCID: 0000-0003-1268-1694
AD  - Université du Maine, EA 4334, Motricité, Interactions, Performance, LUNAM 
      Université, Le Mans, 72085, Cedex 9, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT01572961
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150526
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - *Iontophoresis/adverse effects/methods
MH  - Laser-Doppler Flowmetry
MH  - Male
MH  - Microcirculation
MH  - Prostaglandin-Endoperoxide Synthases/*physiology
MH  - Skin/*blood supply/drug effects/enzymology
MH  - *Skin Physiological Phenomena/drug effects
MH  - Skin Temperature
MH  - *Vasodilation/drug effects
MH  - Young Adult
PMC - PMC4541966
OTO - NOTNLM
OT  - blood flow
OT  - iontophoresis
OT  - laser Doppler flowmetry
OT  - prostaglandins
OT  - skin
EDAT- 2015/03/11 06:00
MHDA- 2016/04/19 06:00
CRDT- 2015/03/11 06:00
PHST- 2014/07/15 00:00 [received]
PHST- 2015/02/23 00:00 [revised]
PHST- 2015/03/03 00:00 [accepted]
PHST- 2015/03/11 06:00 [entrez]
PHST- 2015/03/11 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - 10.1111/bcp.12623 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2015 Aug;80(2):185-92. doi: 10.1111/bcp.12623. Epub 2015 May 
      26.

PMID- 12669971
OWN - NLM
STAT- MEDLINE
DCOM- 20040226
LR  - 20190818
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 20
IP  - 3
DP  - 2003 Mar
TI  - Thermodynamics of solutions I: benzoic acid and acetylsalicylic acid as models 
      for drug substances and the prediction of solubility.
PG  - 471-8
AB  - PURPOSE: To investigate the solution process of drug substances (exemplified by 
      benzoic acid. BA. and acetylsalicylic acid, ASA), particularly the interrelation 
      between enthalpic and entropic terms of Gibbs energy, in different solvents. To 
      develop an approach for the estimation of standard solution enthalpies based on a 
      self-consistent thermochemical scale. METHOD: Two independent methods, solubility 
      experiments (concentrations of saturated solutions) and solution calorimetry 
      (standard solution enthalpies) in aliphatic alcohols and individual organic 
      solvents were used. Correlation between the thermodynamic functions in various 
      solvents were analyzed by standard statistical methods. Multiple regression 
      analysis between delta Ho(sol) values and the parameters of the solvents was run 
      on the Koppel-Palm equation. RESULTS: Based on experimental data, a compensation 
      effect between thermodynamic functions was observed. Correlation was found 
      between delta Ho (sol) (BA) and delta Ho(sol) (ASA) [where the delta Ho(sol) 
      (BA)-values were used as a self-consistent thermochemical scale]. Furthermore, 
      delta Ho(sol) correlated with the Koppel-Palm basicity of the solvents. 
      CONCLUSION: The model based on solubility and solution experiments might be 
      useful for the prediction of solubility or solvation of drug substances in 
      different media. The regression equation based on the self-consistent 
      thermochemical scale makes it possible to approximate the ability to solvate a 
      drug substance in comparison with structure-relative substances.
FAU - Perlovichl, German L
AU  - Perlovichl GL
AD  - University of Tromsø, Institute of Pharmacy, Breivika, N-9037 Tromsø, Norway.
FAU - Bauer-Brandl, Annette
AU  - Bauer-Brandl A
LA  - eng
GR  - HS 58101/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Alcohols)
RN  - 0 (Solvents)
RN  - 8SKN0B0MIM (Benzoic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alcohols/chemistry
MH  - Aspirin/*chemistry
MH  - Benzoic Acid/*chemistry
MH  - Calorimetry, Differential Scanning
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Mathematics
MH  - Models, Chemical
MH  - Solubility
MH  - Solvents
MH  - Thermodynamics
EDAT- 2003/04/03 05:00
MHDA- 2004/02/27 05:00
CRDT- 2003/04/03 05:00
PHST- 2003/04/03 05:00 [pubmed]
PHST- 2004/02/27 05:00 [medline]
PHST- 2003/04/03 05:00 [entrez]
AID - 10.1023/a:1022624725495 [doi]
PST - ppublish
SO  - Pharm Res. 2003 Mar;20(3):471-8. doi: 10.1023/a:1022624725495.

PMID- 16102031
OWN - NLM
STAT- MEDLINE
DCOM- 20051207
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 3
IP  - 8
DP  - 2005 Aug
TI  - Aspirin resistance.
PG  - 1655-62
AB  - Treatment failures occur with any drug and aspirin is no exception. Evidence is 
      growing to indicate that there are subpopulations that do not respond to 
      antithrombotic action of aspirin. The term 'aspirin resistance' has been used to 
      describe a number of different phenomena, including inability of aspirin to: (i) 
      protect against cardiovascular events despite its regular intake; (ii) to affect 
      various laboratory tests, reflecting platelet activity. Research on aspirin 
      resistance yielded interesting results in clinical pharmacology and 
      pharmacogenetics. Future studies will show whether genotyping for polymorphisms 
      might be of value in everyday clinical use of aspirin. Present data indicate that 
      in survivors of recent myocardial infarction or unstable angina, patients 
      receiving coronary artery bypass grafts, as well as in subjects with 
      hypercholesterolemia, aspirin resistance has to be considered when implementing 
      antithrombotic therapy. However, in individual patients the available laboratory 
      tests are of no particular use to predict reliably the clinical outcome or to 
      guide in making therapeutic decision. Prospective clinical trials seem necessary 
      to reach such conclusions.
FAU - Szczeklik, A
AU  - Szczeklik A
AD  - Department of Medicine, Jagiellonian University School of Medicine, Cracow, 
      Poland. mmszczek@cyf-kr.edu.pl
FAU - Musiał, J
AU  - Musiał J
FAU - Undas, A
AU  - Undas A
FAU - Sanak, M
AU  - Sanak M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Membrane Glycoproteins)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Cardiovascular Diseases/chemically induced/drug therapy
MH  - Clinical Trials as Topic
MH  - *Drug Resistance
MH  - Genetic Variation
MH  - Genotype
MH  - Humans
MH  - Hypercholesterolemia
MH  - Models, Biological
MH  - Models, Genetic
MH  - Myocardial Infarction/pathology
MH  - Platelet Membrane Glycoproteins/genetics
MH  - Polymorphism, Genetic
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Time Factors
MH  - Treatment Outcome
RF  - 76
EDAT- 2005/08/17 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/08/17 09:00
PHST- 2005/08/17 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/08/17 09:00 [entrez]
AID - S1538-7836(22)16302-6 [pii]
AID - 10.1111/j.1538-7836.2005.01372.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2005 Aug;3(8):1655-62. doi: 10.1111/j.1538-7836.2005.01372.x.

PMID- 21434767
OWN - NLM
STAT- MEDLINE
DCOM- 20111115
LR  - 20160511
IS  - 1945-0257 (Electronic)
IS  - 1945-0257 (Linking)
VI  - 15
IP  - 7-8
DP  - 2011 Jul-Aug
TI  - The cyclooxygenase-1 C50T polymorphism is not associated with aspirin 
      responsiveness status in stable coronary artery disease in Tunisian patients.
PG  - 513-6
LID - 10.1089/gtmb.2010.0225 [doi]
AB  - In this study, we evaluate the relationships between aspirin nonresponsiveness 
      and the cyclooxygenase-1 (Cox-1) gene C50T polymorphism in stable coronary artery 
      disease (CAD) in Tunisian patients. One hundred twenty-five stable CAD patients 
      were included. The Cox-1 gene C50T polymorphism was determined by the polymerase 
      chain reaction/restriction fragment length polymorphism method. Aspirin response 
      was evaluated by measuring the collagen epinephrine closer time and the urinary 
      dehydro-thromboxane B2 excretion. According to the collagen epinephrine closer 
      time values, the frequency of the -50T allele was not significantly different in 
      bad responders when compared with good responders (36.8% vs. 15.7%; p=0.1). 
      Similarly, the presence of the -50T mutant allele was not statistically different 
      comparing bad and good responders according to the urinary 11-dehydro-thromboxane 
      B2 excretion concentration (60% vs. 40%; p=0.43). Our study did not demonstrate 
      any association between the Cox-1 gene C50T polymorphism and aspirin 
      nonresponsiveness status in stable CAD patients.
FAU - Chakroun, Tahar
AU  - Chakroun T
AD  - Regional Center of Blood Transfusion, Research Unit Platelet function Study 
      UR.06SP05, Farhat Hached University Hospital, Sousse, Tunisia. chakrount@voila.fr
FAU - Addad, Faouzi
AU  - Addad F
FAU - Yacoub, Saloua
AU  - Yacoub S
FAU - Abderrezak, Fatma
AU  - Abderrezak F
FAU - Gerotziafas, Gregoris T
AU  - Gerotziafas GT
FAU - Abdelkafi, Sadia
AU  - Abdelkafi S
FAU - Hassine, Mohssen
AU  - Hassine M
FAU - Gamra, Habib
AU  - Gamra H
FAU - Hatmi, Mohamed
AU  - Hatmi M
FAU - Elalamy, Ismail
AU  - Elalamy I
LA  - eng
PT  - Journal Article
DEP - 20110324
PL  - United States
TA  - Genet Test Mol Biomarkers
JT  - Genetic testing and molecular biomarkers
JID - 101494210
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Coronary Artery Disease/*drug therapy/genetics
MH  - Cyclooxygenase 1/*genetics
MH  - *Drug Resistance
MH  - Humans
MH  - Polymerase Chain Reaction
MH  - *Polymorphism, Genetic
MH  - Polymorphism, Restriction Fragment Length
MH  - Thromboxane B2/analogs & derivatives/urine
MH  - Tunisia
EDAT- 2011/03/26 06:00
MHDA- 2011/11/16 06:00
CRDT- 2011/03/26 06:00
PHST- 2011/03/26 06:00 [entrez]
PHST- 2011/03/26 06:00 [pubmed]
PHST- 2011/11/16 06:00 [medline]
AID - 10.1089/gtmb.2010.0225 [doi]
PST - ppublish
SO  - Genet Test Mol Biomarkers. 2011 Jul-Aug;15(7-8):513-6. doi: 
      10.1089/gtmb.2010.0225. Epub 2011 Mar 24.

PMID- 7102384
OWN - NLM
STAT- MEDLINE
DCOM- 19820924
LR  - 20190814
IS  - 0001-6268 (Print)
IS  - 0001-6268 (Linking)
VI  - 62
IP  - 3-4
DP  - 1982
TI  - Double-blind trial of aspirin in patient receiving tranexamic acid for 
      subarachnoid hemorrhage.
PG  - 195-202
AB  - Antifibrinolytic agents have been claimed to reduce the rebleed rate in patients 
      with subarachnoid haemorrhage from intracranial aneurysms. However, these agents 
      may in themselves increase the incidence of delayed cerebral ischaemia in these 
      patients. We have used aspirin in an attempt to reduce the incidence of this 
      complication. In a prospective, double-blind trial of aspirin against placebo, 53 
      patients with subarachnoid haemorrhage were all treated with the antifibrinolytic 
      agent tranexamic acid. Twenty-seven patients received aspirin and 26 patients 
      received placebo. The morbidity and mortality was similar in each group. A 
      further breakdown into patients who had their aneurysms clipped at craniotomy (21 
      patients) similarly failed to show a more favourable outcome in either group. It 
      is concluded that aspirin does not affect the outcome in patients with 
      subarachnoid haemorrhage treated with tranexamic acid.
FAU - Mendelow, A D
AU  - Mendelow AD
FAU - Stockdill, G
AU  - Stockdill G
FAU - Steers, A J
AU  - Steers AJ
FAU - Hayes, J
AU  - Hayes J
FAU - Gillingham, F J
AU  - Gillingham FJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Austria
TA  - Acta Neurochir (Wien)
JT  - Acta neurochirurgica
JID - 0151000
RN  - 6T84R30KC1 (Tranexamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiography
MH  - Aphasia/etiology
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Hemiplegia/etiology
MH  - Humans
MH  - Intracranial Aneurysm/complications
MH  - Male
MH  - Subarachnoid Hemorrhage/complications/*drug therapy/etiology
MH  - Tranexamic Acid/therapeutic use
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1007/BF01403624 [doi]
PST - ppublish
SO  - Acta Neurochir (Wien). 1982;62(3-4):195-202. doi: 10.1007/BF01403624.

PMID- 27937054
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 18
IP  - 1
DP  - 2017 Jan
TI  - Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery 
      disease.
PG  - 123-131
LID - 10.1080/14656566.2016.1269747 [doi]
AB  - Aspirin is indicated for primary and secondary prevention of cardiovascular 
      diseases (CVD) by major guidelines. However, its use may be associated with 
      gastrointestinal (GI) toxicities, including, but not limited to, GI bleeding. 
      This may lead to increased morbidity and mortality, as well as diminished 
      compliance, which again leads to increased risk of major cardiovascular events. 
      Modified formulations of aspirin often have comparable risks of GI toxicity 
      despite their dose or formulation and have had limited success to prevent GI 
      toxicities. Simultaneous treatment with Proton pump inhibitors (PPIs) has been 
      used successfully to prevent GI toxicities from aspirin. However, addition of an 
      extra medication may lead to lower compliance and hence ineffective or less than 
      optimal treatment. Areas covered: After a selective literature search, a brief 
      review of the available evidence regarding GI toxicity of aspirin and the 
      protective effects of PPIs was conducted. The concept of combination tablets, and 
      the available data about Aralez Pharmaceuticals' YOSPRALA (aspirin (81 mg or 
      325 mg) and omeprazole (40 mg) fixed dose combination tablet being evaluated for 
      secondary prevention of cardiovascular and cerebrovascular events in patients at 
      risk for GI complications of aspirin therapy) is also presented. Expert opinion: 
      The available evidence suggests that PPIs are the best option to prevent 
      aspirin-related GI toxicities, but compliance is low in people who are prescribed 
      both aspirin and PPI. Combination tablets containing both aspirin and a PPI may 
      be a good option for providing protection against GI toxicities in people who 
      require aspirin for secondary prevention of cardiovascular diseases.
FAU - Sharma, Tushar
AU  - Sharma T
AD  - a Department of Medicine , Sinai Hospital , Baltimore , MD , USA.
FAU - Bliden, Kevin
AU  - Bliden K
AD  - b Director of Cardiovascular Research , Inova Center for Thrombosis Research and 
      Drug Development, Inova Heart and Vascular Institute , Fairfax , VA , USA.
FAU - Chaudhary, Rahul
AU  - Chaudhary R
AD  - a Department of Medicine , Sinai Hospital , Baltimore , MD , USA.
FAU - Tantry, Udaya
AU  - Tantry U
AD  - b Director of Cardiovascular Research , Inova Center for Thrombosis Research and 
      Drug Development, Inova Heart and Vascular Institute , Fairfax , VA , USA.
FAU - Gurbel, Paul A
AU  - Gurbel PA
AD  - b Director of Cardiovascular Research , Inova Center for Thrombosis Research and 
      Drug Development, Inova Heart and Vascular Institute , Fairfax , VA , USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Coronary Artery Disease/*drug therapy
MH  - Gastrointestinal Diseases/prevention & control
MH  - Gastrointestinal Hemorrhage/prevention & control
MH  - Humans
MH  - Omeprazole/administration & dosage/*therapeutic use
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Secondary Prevention
OTO - NOTNLM
OT  - AXANUM
OT  - Aspirin
OT  - GI bleed
OT  - PA
OT  - YOSPRALA
OT  - cardiovascular event
OT  - combination tablets
OT  - gastrointestinal toxicity
OT  - proton pump inhibitors
EDAT- 2016/12/13 06:00
MHDA- 2017/03/11 06:00
CRDT- 2016/12/13 06:00
PHST- 2016/12/13 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
PHST- 2016/12/13 06:00 [entrez]
AID - 10.1080/14656566.2016.1269747 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2017 Jan;18(1):123-131. doi: 
      10.1080/14656566.2016.1269747.

PMID- 23094974
OWN - NLM
STAT- MEDLINE
DCOM- 20130923
LR  - 20131121
IS  - 1549-781X (Electronic)
IS  - 1040-8363 (Linking)
VI  - 49
IP  - 5-6
DP  - 2012 Sep-Dec
TI  - Overcoming aspirin treatment failure in diabetes.
PG  - 183-98
LID - 10.3109/10408363.2012.731377 [doi]
AB  - People with diabetes have an increased risk of life-threatening cardiovascular 
      disease compared to the general population. Furthermore, people with diabetes are 
      at greatly increased risk of not responding to standard anti-platelet therapy, 
      such as aspirin, for the prevention of atherothrombotic events. This phenomenon 
      is often referred to as treatment failure. Those who are at increased risk of 
      such events despite aspirin therapy can be prospectively identified by a variety 
      of laboratory measures of residual on-treatment platelet function, known as 
      aspirin resistance. However, there is little agreement among laboratories on the 
      approaches to these measurements, and insufficient data to guide the clinical 
      management of people with diabetes-associated aspirin resistance if it is 
      prospectively identified. This review provides a critical appraisal of the 
      different approaches to the detection and evidence of mechanisms which contribute 
      to this phenomenon, as well evidence for the potential effectiveness of different 
      clinical approaches to overcoming aspirin treatment failure in diabetes. 
      Potential mechanisms of aspirin resistance in diabetes include elevated platelet 
      turnover that results in an immature platelet fraction able to synthesise the 
      uninhibited therapeutic target of aspirin, cyclooxygenase-1 (COX-1); residual 
      thromboxane production by both COX-1-dependent and COX-1-independent pathways; 
      up-regulation of aspirin-insensitive pathways of platelet function, such as 
      adenosine diphosphate signalling; and increased underlying atherosclerotic 
      disease burden that results in elevated underlying platelet hyper-reactivity. 
      High on-aspirin platelet reactivity in diabetes may be related to glycemic 
      control. Potential approaches to treatment include controlling modifiable risk 
      factors to achieve effective glycemic control, guided increases in aspirin dose 
      or frequency of administration, or the use of additional antiplatelet therapies. 
      While evidence suggests that altering antiplatelet therapy, particularly by 
      increasing frequency of aspirin administration, can overcome incomplete 
      inhibition of thromboxane synthesis, no clinical studies to date have assessed 
      the effectiveness of these in preventing breakthrough atherothrombosis. While 
      some clinicians currently alter therapy on the basis of theoretical potential 
      benefit of these strategies following identification of aspirin resistance in the 
      laboratory, this is not yet supported by clinical evidence of a benefit, and 
      clear clinical guidelines for the management of aspirin resistance are lacking.
FAU - Linden, Matthew D
AU  - Linden MD
AD  - Centre for Microscopy, Characterisation and Analysis, University of Western 
      Australia , Perth, Australia. matthew.linden@uwa.edu.au
FAU - Tran, Huyen A
AU  - Tran HA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20121024
PL  - England
TA  - Crit Rev Clin Lab Sci
JT  - Critical reviews in clinical laboratory sciences
JID - 8914816
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cyclooxygenase 1/metabolism
MH  - Diabetes Mellitus/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Factors
MH  - Treatment Failure
EDAT- 2012/10/26 06:00
MHDA- 2013/09/24 06:00
CRDT- 2012/10/26 06:00
PHST- 2012/10/26 06:00 [entrez]
PHST- 2012/10/26 06:00 [pubmed]
PHST- 2013/09/24 06:00 [medline]
AID - 10.3109/10408363.2012.731377 [doi]
PST - ppublish
SO  - Crit Rev Clin Lab Sci. 2012 Sep-Dec;49(5-6):183-98. doi: 
      10.3109/10408363.2012.731377. Epub 2012 Oct 24.

PMID- 3720797
OWN - NLM
STAT- MEDLINE
DCOM- 19860808
LR  - 20181113
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 11
IP  - 1
DP  - 1986 Jan-Mar
TI  - Influence of caffeine on aspirin pharmacokinetics.
PG  - 71-6
AB  - The effects of caffeine on the pharmacokinetics and bioavailability of aspirin 
      were studied in 12 healthy adult male volunteers. The subjects received 650 mg of 
      aspirin or 650 mg of aspirin with 120 mg of caffeine citrate orally. It was found 
      that caffeine significantly increased the rate of appearance as well as the 
      maximum concentration of salicylate in the plasma by about 25% and 17%, 
      respectively. Moreover, area under the plasma concentration-time curve of 
      salicylate was significantly higher in the subjects given the drug combination as 
      compared to those given aspirin alone. There was no change in the plasma 
      half-life, volume of distribution and clearance of salicylate.
FAU - Yoovathaworn, K C
AU  - Yoovathaworn KC
FAU - Sriwatanakul, K
AU  - Sriwatanakul K
FAU - Thithapandha, A
AU  - Thithapandha A
LA  - eng
PT  - Journal Article
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*blood
MH  - Biological Availability
MH  - Caffeine/*pharmacology
MH  - Drug Interactions
MH  - Half-Life
MH  - Humans
MH  - Kinetics
MH  - Male
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1007/BF03189777 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 1986 Jan-Mar;11(1):71-6. doi: 10.1007/BF03189777.

PMID- 27566810
OWN - NLM
STAT- MEDLINE
DCOM- 20180801
LR  - 20180801
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 117 Suppl 2
DP  - 2016 Sep
TI  - New antiplatelet drugs and new oral anticoagulants.
PG  - ii74-ii84
LID - 10.1093/bja/aew214 [doi]
AB  - In our daily anaesthetic practice, we are confronted with an increasing number of 
      patients treated with either antiplatelet or anticoagulant agents. During the 
      last decade, changes have occurred that make the handling of antithrombotic 
      medication a challenging part of anaesthetic perioperative management. In this 
      review, the authors discuss the most important antiplatelet and anticoagulant 
      drugs, the perioperative management, the handling of bleeding complications, and 
      the interpretation of some laboratory analyses related to these agents.
CI  - © The Author 2016. Published by Oxford University Press on behalf of the British 
      Journal of Anaesthesia. All rights reserved. For Permissions, please email: 
      journals.permissions@oup.com.
FAU - Koenig-Oberhuber, V
AU  - Koenig-Oberhuber V
AD  - Division of Anaesthesiology, Intensive Care, Rescue and Pain Medicine, 
      Kantonsspital St Gallen, Rorschacherstrasse 95, 9000 St Gallen, Switzerland 
      Department of Anaesthesia, Kantonsspital Graubünden, Loëstrasse 170, 7000 Chur, 
      Switzerland.
FAU - Filipovic, M
AU  - Filipovic M
AD  - Division of Anaesthesiology, Intensive Care, Rescue and Pain Medicine, 
      Kantonsspital St Gallen, Rorschacherstrasse 95, 9000 St Gallen, Switzerland.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Drug Monitoring
MH  - Hemorrhage/drug therapy
MH  - Humans
MH  - Perioperative Care
MH  - Platelet Aggregation Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - anticoagulants and haemorrhage
OT  - antiplatelet agents
OT  - blood coagulation tests
EDAT- 2016/08/28 06:00
MHDA- 2018/08/02 06:00
CRDT- 2016/08/28 06:00
PHST- 2016/06/12 00:00 [accepted]
PHST- 2016/08/28 06:00 [entrez]
PHST- 2016/08/28 06:00 [pubmed]
PHST- 2018/08/02 06:00 [medline]
AID - S0007-0912(17)30147-2 [pii]
AID - 10.1093/bja/aew214 [doi]
PST - ppublish
SO  - Br J Anaesth. 2016 Sep;117 Suppl 2:ii74-ii84. doi: 10.1093/bja/aew214.

PMID- 3768508
OWN - NLM
STAT- MEDLINE
DCOM- 19861211
LR  - 20131121
IS  - 0365-9615 (Print)
IS  - 0365-9615 (Linking)
VI  - 102
IP  - 10
DP  - 1986 Oct
TI  - [Changes in the cyclic nucleotide level and the inhibition of human thrombocyte 
      aggregation in 3-hydroxypyridine exposure].
PG  - 432-4
AB  - The effect of six 3-oxypiridine derivatives (at a concentration of 10(-3) and 5 X 
      10(-3) M) on cyclic nucleotide level in human platelets and platelet aggregation 
      was studied. Five 3-oxypiridine derivatives were shown to depress platelet 
      aggregation, four of them causing the increase in cAMP platelet level. The 
      correlation between antiaggregation activity of 3-oxypiridine derivatives and 
      their ability to rise cyclic nucleotide level in human platelets is discussed.
FAU - Muranov, K O
AU  - Muranov KO
FAU - Polianskiĭ, N B
AU  - Polianskiĭ NB
FAU - Shvedova, A A
AU  - Shvedova AA
FAU - Kagan, V E
AU  - Kagan VE
FAU - Smirnov, L D
AU  - Smirnov LD
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Izmenenie urovnia tsiklicheskikh nukleotidov i tormozhenie agregatsii 
      trombotsitov cheloveka pri deĭstvii 3-oksipiridinov.
PL  - Russia (Federation)
TA  - Biull Eksp Biol Med
JT  - Biulleten' eksperimental'noi biologii i meditsiny
JID - 0370627
RN  - 0 (Nucleotides, Cyclic)
RN  - 0 (Pyridines)
RN  - 4KBE4P5B6S (3-hydroxypyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Depression, Chemical
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Nucleotides, Cyclic/*blood
MH  - Platelet Aggregation/*drug effects
MH  - Pyridines/*pharmacology
EDAT- 1986/10/01 00:00
MHDA- 1986/10/01 00:01
CRDT- 1986/10/01 00:00
PHST- 1986/10/01 00:00 [pubmed]
PHST- 1986/10/01 00:01 [medline]
PHST- 1986/10/01 00:00 [entrez]
PST - ppublish
SO  - Biull Eksp Biol Med. 1986 Oct;102(10):432-4.

PMID- 720236
OWN - NLM
STAT- MEDLINE
DCOM- 19790212
LR  - 20131121
IS  - 0012-0472 (Print)
IS  - 0012-0472 (Linking)
VI  - 103
IP  - 50
DP  - 1978 Dec 15
TI  - [Prevention of re-occlusion after recanalisation of occluded arteries by the 
      catheter method (author's transl)].
PG  - 1994-7
AB  - In a double-blind study, prevention of re-thrombosis was tested on 101 patients 
      in whom stenosis or segmental occlusion of a large artery of the lower limbs had 
      been successfully removed by the intraluminal catheter method. The combination of 
      75 mg dipyridamol and 330 mg acetylsalicylic acid, three times daily by mouth, 
      proved to be slightly more effective than acetylsalicylic acid alone at the same 
      dosage. In the group with the combined treatment 84% of the arteries remained 
      open, compared with 70% on acetylsalicylic acid alone.
FAU - Hess, H
AU  - Hess H
FAU - Müller-Fassbender, H
AU  - Müller-Fassbender H
FAU - Ingrisch, H
AU  - Ingrisch H
FAU - Mietaschk, A
AU  - Mietaschk A
LA  - ger
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Verhütung von Wiederverschlüssen nach Rekanalisation obliterierter Arterien mit 
      der Kathetermethode.
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/prevention & control/*surgery
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Recurrence
EDAT- 1978/12/15 00:00
MHDA- 1978/12/15 00:01
CRDT- 1978/12/15 00:00
PHST- 1978/12/15 00:00 [pubmed]
PHST- 1978/12/15 00:01 [medline]
PHST- 1978/12/15 00:00 [entrez]
AID - 10.1055/s-0028-1129383 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 1978 Dec 15;103(50):1994-7. doi: 10.1055/s-0028-1129383.

PMID- 36540065
OWN - NLM
STAT- MEDLINE
DCOM- 20221222
LR  - 20221222
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 2022
DP  - 2022
TI  - Long-Term Adherence and Persistence to Low-Dose Aspirin for the Prevention of 
      Cardiovascular Disease: A Population-Based Cohort Study.
PG  - 7786174
LID - 10.1155/2022/7786174 [doi]
LID - 7786174
AB  - METHODS: Using information from electronic health records in Germany and the 
      United Kingdom (UK) in a common data model, we followed adults with ≥2 low-dose 
      aspirin prescriptions (75-100 mg) during 2007-2018 for up to 10 years. Included 
      individuals had no low-dose aspirin prescriptions in the year before the 
      follow-up started (date of first low-dose aspirin prescription) and ≥12 months' 
      observation. Adherence was determined using the medication possession ratio 
      (MPR), and persistence was defined as continuous treatment disregarding gaps 
      between prescriptions of <60 days; analyses were undertaken according to 
      indication (primary/secondary CVD prevention). RESULTS: We identified 144,717 
      low-dose aspirin users from Germany and 190,907 from the UK. Among patients with 
      5-10 years' follow-up, median adherence among secondary CVD prevention users was 
      60% in Germany and 75% in the UK. Among primary prevention users, median 
      adherence was 50% for both countries. Persistence among secondary CVD prevention 
      users was 58.3% at 2 years, 47.0% at 5 years, 35.2% at 10 years (Germany), and 
      67.5% at 2 years, 58.0% at 5 years, and 46.8% at 10 years (UK). Among primary CVD 
      prevention users, persistence was 52.8% at 2 years, 41.6% at 5 years, 32.1% at 10 
      years (Germany), 56.3% at 2 years, 45.4% at 5 years, and 33.8% at 10 years (UK). 
      CONCLUSIONS: Long-term adherence and persistence to low-dose aspirin are 
      suboptimal; efforts for improvement could translate into a lower CVD burden in 
      the general population.
CI  - Copyright © 2022 Pareen Vora et al.
FAU - Vora, Pareen
AU  - Vora P
AUID- ORCID: 0000-0002-5822-2453
AD  - Integrated Evidence Generation, Bayer AG, Berlin, Germany.
FAU - Soriano-Gabarró, Montse
AU  - Soriano-Gabarró M
AUID- ORCID: 0000-0002-3825-0182
AD  - Integrated Evidence Generation, Bayer AG, Berlin, Germany.
FAU - Russell, Beth
AU  - Russell B
AUID- ORCID: 0000-0001-5640-8425
AD  - Comprehensive Cancer Centre, Kings College London, London, UK.
FAU - Morgan Stewart, Henry
AU  - Morgan Stewart H
AD  - IQVIA, Brighton, UK.
LA  - eng
PT  - Journal Article
DEP - 20221202
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Cardiovascular Diseases/prevention & control/drug therapy
MH  - Cohort Studies
MH  - Aspirin/therapeutic use
MH  - United Kingdom/epidemiology
MH  - Germany/epidemiology
MH  - Medication Adherence
PMC - PMC9734008
COIS- PV and MS-G are employees of Bayer AG, the funder of the study. BR received 
      consultancy fees from Bayer at the time of the study. HMS is an employee of 
      IQVIA, which received funding from Bayer to perform the data analysis.
EDAT- 2022/12/22 06:00
MHDA- 2022/12/23 06:00
CRDT- 2022/12/21 02:03
PHST- 2022/07/07 00:00 [received]
PHST- 2022/11/02 00:00 [revised]
PHST- 2022/11/03 00:00 [accepted]
PHST- 2022/12/21 02:03 [entrez]
PHST- 2022/12/22 06:00 [pubmed]
PHST- 2022/12/23 06:00 [medline]
AID - 10.1155/2022/7786174 [doi]
PST - epublish
SO  - Int J Clin Pract. 2022 Dec 2;2022:7786174. doi: 10.1155/2022/7786174. eCollection 
      2022.

PMID- 31700098
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20210110
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Nov 7
TI  - Gut Microbiota-Mediated Drug-Drug Interaction between Amoxicillin and Aspirin.
PG  - 16194
LID - 10.1038/s41598-019-52632-5 [doi]
LID - 16194
AB  - The effects of antibiotics on the intestinal flora can create potential drug-drug 
      interactions. The combination of amoxicillin and aspirin is high and there is a 
      high probability of interaction. We used 16S rRNA, incubation experiments and 
      liquid chromatography-tandem mass spectrometry to analyze rat biological samples 
      to characterize the effect of amoxicillin on the pharmacokinetics of aspirin 
      metabolites. We first discovered that amoxicillin reduced the species and number 
      of intestinal flora in rats, such as reducing the abundance of Helicobacter 
      pylori and Prevotella_copri. After 12, 24, and 36 hours of incubation, the 
      remaining amount of aspirin in the aspirin and amoxicillin treatment groups 
      decreased, and salicylic acid production increased, suggesting that aspirin is 
      metabolized by the intestinal flora, and the main metabolite is salicylic acid. 
      As the incubation time prolonged, the reduction of aspirin and the production of 
      salicylic acid in the amoxicillin treatment group were slower. It is indicated 
      that the metabolic activity of aspirin through the intestinal flora is slowed 
      down after administration of amoxicillin. The pharmacokinetic experiments showed 
      that after administration of amoxicillin, the area under the salicylic acid curve 
      increased by 91.38%, the peak concentration increased by 60.43%, and the 
      clearance rate decreased by 43.55%.The results demonstrated that amoxicillin 
      affected the pharmacokinetics of aspirin active metabolite salicylic acid by 
      slowing down the metabolic activity of intestinal flora on aspirin. The 
      interaction between amoxicillin and aspirin mediated by the intestinal flora may 
      affect the efficacy of aspirin and cause more significant adverse effects.
FAU - Zhang, Juanhong
AU  - Zhang J
AUID- ORCID: 0000-0001-8861-7336
AD  - Key Laboratory for Prevention and Remediation of Plateau Environmental Damage, 
      940th Hospital of Joint Logistics Support Force of CPLA, Lanzhou, 730050, China.
AD  - School of Pharmacy, Lanzhou University, Lanzhou, 730000, China.
FAU - Sun, Yuemei
AU  - Sun Y
AD  - Key Laboratory for Prevention and Remediation of Plateau Environmental Damage, 
      940th Hospital of Joint Logistics Support Force of CPLA, Lanzhou, 730050, China.
FAU - Wang, Rong
AU  - Wang R
AD  - Key Laboratory for Prevention and Remediation of Plateau Environmental Damage, 
      940th Hospital of Joint Logistics Support Force of CPLA, Lanzhou, 730050, China. 
      wangrong-69@163.com.
AD  - School of Pharmacy, Lanzhou University, Lanzhou, 730000, China. 
      wangrong-69@163.com.
FAU - Zhang, Junmin
AU  - Zhang J
AD  - School of Pharmacy, Lanzhou University, Lanzhou, 730000, China. 
      zhangjunmin@lzu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191107
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 804826J2HU (Amoxicillin)
RN  - R16CO5Y76E (Aspirin)
RN  - Prevotella copri
SB  - IM
MH  - *Amoxicillin/pharmacokinetics/pharmacology
MH  - Animals
MH  - *Aspirin/pharmacokinetics/pharmacology
MH  - Drug Interactions
MH  - Gastrointestinal Microbiome/*drug effects
MH  - Helicobacter pylori/*metabolism
MH  - Prevotella/*metabolism
MH  - Rats
MH  - Rats, Wistar
PMC - PMC6838174
COIS- The authors declare no competing interests.
EDAT- 2019/11/09 06:00
MHDA- 2020/10/28 06:00
CRDT- 2019/11/09 06:00
PHST- 2019/01/11 00:00 [received]
PHST- 2019/10/21 00:00 [accepted]
PHST- 2019/11/09 06:00 [entrez]
PHST- 2019/11/09 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
AID - 10.1038/s41598-019-52632-5 [pii]
AID - 52632 [pii]
AID - 10.1038/s41598-019-52632-5 [doi]
PST - epublish
SO  - Sci Rep. 2019 Nov 7;9(1):16194. doi: 10.1038/s41598-019-52632-5.

PMID- 24411092
OWN - NLM
STAT- MEDLINE
DCOM- 20140715
LR  - 20190318
IS  - 1873-3778 (Electronic)
IS  - 0021-9673 (Linking)
VI  - 1327
DP  - 2014 Jan 31
TI  - Ultra-fast determination of caffeine, dipyrone, and acetylsalicylic acid by 
      capillary electrophoresis with capacitively coupled contactless conductivity 
      detection and identification of degradation products.
PG  - 149-54
LID - S0021-9673(13)01929-8 [pii]
LID - 10.1016/j.chroma.2013.12.048 [doi]
AB  - Capillary electrophoresis with capacitively coupled contactless conductivity 
      detection (CE-C(4)D) was used for fast, simultaneous determination of dipyrone 
      (DIP), caffeine (CAF), and acetylsalicylic acid (ASA). In the same run and in 
      less than 1min, the degradation products from DIP and ASA were also detected. In 
      addition, the usage of the CE-C(4)D system allowed, for the first time, the 
      detection of methylamine as a degradation product of DIP. Capillary 
      electrophoresis with electrospray mass spectrometry experiments were carried out 
      in order to confirm the formation of methylamine. The limits of detection by 
      CE-C(4)D were 5, 5, and 6μmolL(-1) for CAF, DIP, and ASA, respectively. The 
      proposed method was applied to the analysis of these compounds in pharmaceutical 
      formulations with similar results to those achieved by HPLC (p<0.05).
CI  - Copyright © 2013 Elsevier B.V. All rights reserved.
FAU - Marra, Mariana Cardoso
AU  - Marra MC
AD  - Instituto de Química, Universidade Federal de Uberlândia, Av. João Naves de 
      Ávila, 2121 Uberlândia, MG, Brazil.
FAU - Cunha, Rafael Rodrigues
AU  - Cunha RR
AD  - Instituto de Química, Universidade Federal de Uberlândia, Av. João Naves de 
      Ávila, 2121 Uberlândia, MG, Brazil.
FAU - Vidal, Denis Tadeu Rajh
AU  - Vidal DT
AD  - Instituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes, 748 São 
      Paulo, SP, Brazil.
FAU - Munoz, Rodrigo Alejandro Abarza
AU  - Munoz RA
AD  - Instituto de Química, Universidade Federal de Uberlândia, Av. João Naves de 
      Ávila, 2121 Uberlândia, MG, Brazil.
FAU - do Lago, Claudimir Lucio
AU  - do Lago CL
AD  - Instituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes, 748 São 
      Paulo, SP, Brazil.
FAU - Richter, Eduardo Mathias
AU  - Richter EM
AD  - Instituto de Química, Universidade Federal de Uberlândia, Av. João Naves de 
      Ávila, 2121 Uberlândia, MG, Brazil. Electronic address: emrichter@iqufu.ufu.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131224
PL  - Netherlands
TA  - J Chromatogr A
JT  - Journal of chromatography. A
JID - 9318488
RN  - 0 (Methylamines)
RN  - 3G6A5W338E (Caffeine)
RN  - 6429L0L52Y (Dipyrone)
RN  - BSF23SJ79E (methylamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Chromatography, High Pressure Liquid
MH  - Dipyrone/*analysis
MH  - Electric Conductivity
MH  - Electrophoresis, Capillary/methods
MH  - Hydrolysis
MH  - Methylamines/analysis
OTO - NOTNLM
OT  - Aspirin
OT  - Capillary zone electrophoresis
OT  - Hydrolysis products
OT  - Mass spectroscopy
OT  - Metamizole
EDAT- 2014/01/15 06:00
MHDA- 2014/07/16 06:00
CRDT- 2014/01/14 06:00
PHST- 2013/10/04 00:00 [received]
PHST- 2013/12/05 00:00 [revised]
PHST- 2013/12/14 00:00 [accepted]
PHST- 2014/01/14 06:00 [entrez]
PHST- 2014/01/15 06:00 [pubmed]
PHST- 2014/07/16 06:00 [medline]
AID - S0021-9673(13)01929-8 [pii]
AID - 10.1016/j.chroma.2013.12.048 [doi]
PST - ppublish
SO  - J Chromatogr A. 2014 Jan 31;1327:149-54. doi: 10.1016/j.chroma.2013.12.048. Epub 
      2013 Dec 24.

PMID- 37119922
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20230713
IS  - 1539-7262 (Electronic)
IS  - 0022-2275 (Print)
IS  - 0022-2275 (Linking)
VI  - 64
IP  - 6
DP  - 2023 Jun
TI  - Bioactive lipid mediators in plasma are predictors of preeclampsia irrespective 
      of aspirin therapy.
PG  - 100377
LID - S0022-2275(23)00050-0 [pii]
LID - 10.1016/j.jlr.2023.100377 [doi]
LID - 100377
AB  - There are few early biomarkers to identify pregnancies at risk of preeclampsia 
      (PE) and abnormal placental function. In this cross-sectional study, we utilized 
      targeted ultra-performance liquid chromatography-ESI MS/MS and a linear 
      regression model to identify specific bioactive lipids that serve as early 
      predictors of PE. Plasma samples were collected from 57 pregnant women prior to 
      24-weeks of gestation with outcomes of either PE (n = 26) or uncomplicated term 
      pregnancies (n = 31), and the profiles of eicosanoids and sphingolipids were 
      evaluated. Significant differences were revealed in the eicosanoid, (±)11,12 
      DHET, as well as multiple classes of sphingolipids; ceramides, 
      ceramide-1-phosphate, sphingomyelin, and monohexosylceramides; all of which were 
      associated with the subsequent development of PE regardless of aspirin therapy. 
      Profiles of these bioactive lipids were found to vary based on self-designated 
      race. Additional analyses demonstrated that PE patients can be stratified based 
      on the lipid profile as to PE with a preterm birth linked to significant 
      differences in the levels of 12-HETE, 15-HETE, and resolvin D1. Furthermore, 
      subjects referred to a high-risk OB/GYN clinic had higher levels of 20-HETE, 
      arachidonic acid, and Resolvin D1 versus subjects recruited from a routine, 
      general OB/GYN clinic. Overall, this study shows that quantitative changes in 
      plasma bioactive lipids detected by ultra-performance liquid 
      chromatography-ESI-MS/MS can serve as an early predictor of PE and stratify 
      pregnant people for PE type and risk.
CI  - Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Stephenson, Daniel J
AU  - Stephenson DJ
AD  - Division of Hematology & Oncology, Department of Medicine, University of 
      Virginia, Charlottesville, VA, USA.
FAU - MacKnight, H Patrick
AU  - MacKnight HP
AD  - Division of Hematology & Oncology, Department of Medicine, University of 
      Virginia, Charlottesville, VA, USA.
FAU - Hoeferlin, L Alexis
AU  - Hoeferlin LA
AD  - Department of Biochemistry and Molecular Biology, Virginia Commonwealth 
      University (VCU), Richmond, VA, USA.
FAU - Washington, Sonya L
AU  - Washington SL
AD  - Department of Obstetrics and Gynecology, Virginia Commonwealth University, 
      Richmond, VA, USA.
FAU - Sawyers, Chelsea
AU  - Sawyers C
AD  - Virginia Institute for Psychiatric & Behavioral Genetics, Virginia Commonwealth 
      University School of Medicine, Richmond, VA, USA.
FAU - Archer, Kellie J
AU  - Archer KJ
AD  - Division of Biostatistics, The Ohio State University College of Public Health, 
      Columbus, OH, USA.
FAU - Strauss, Jerome F 3rd
AU  - Strauss JF 3rd
AD  - Department of Obstetrics and Gynecology, Virginia Commonwealth University, 
      Richmond, VA, USA.
FAU - Walsh, Scott W
AU  - Walsh SW
AD  - Department of Obstetrics and Gynecology, Virginia Commonwealth University, 
      Richmond, VA, USA. Electronic address: Scott.Walsh@vcuhealth.org.
FAU - Chalfant, Charles E
AU  - Chalfant CE
AD  - Division of Hematology & Oncology, Department of Medicine, University of 
      Virginia, Charlottesville, VA, USA; Department of Biochemistry and Molecular 
      Biology, Virginia Commonwealth University (VCU), Richmond, VA, USA; Department of 
      Cell Biology, University of Virginia, Charlottesville, VA, USA; Program in Cancer 
      Biology, University of Virginia Cancer Center, Charlottesville, VA, USA; Research 
      Service, Richmond Veterans Administration Medical Center, Richmond, VA, USA. 
      Electronic address: cechalfant@virginia.edu.
LA  - eng
GR  - U01 HD087198/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20230427
PL  - United States
TA  - J Lipid Res
JT  - Journal of lipid research
JID - 0376606
RN  - 0 (Sphingolipids)
RN  - 0 (Biomarkers)
RN  - 0 (Eicosanoids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - *Pre-Eclampsia
MH  - Tandem Mass Spectrometry
MH  - Placenta
MH  - Cross-Sectional Studies
MH  - *Premature Birth
MH  - Sphingolipids
MH  - Biomarkers
MH  - Eicosanoids
MH  - Aspirin/therapeutic use
PMC - PMC10230265
OTO - NOTNLM
OT  - aspirin
OT  - eicosanoids
OT  - pregnancy
OT  - sphingolipids
OT  - ultra-high performance liquid chromatography electrospray ionization-MS/MS
COIS- Conflict of interest All authors of this article declare that they have no 
      competing financial interests.
EDAT- 2023/04/30 00:42
MHDA- 2023/06/26 06:42
CRDT- 2023/04/29 19:25
PHST- 2022/11/16 00:00 [received]
PHST- 2023/04/13 00:00 [revised]
PHST- 2023/04/18 00:00 [accepted]
PHST- 2023/06/26 06:42 [medline]
PHST- 2023/04/30 00:42 [pubmed]
PHST- 2023/04/29 19:25 [entrez]
AID - S0022-2275(23)00050-0 [pii]
AID - 100377 [pii]
AID - 10.1016/j.jlr.2023.100377 [doi]
PST - ppublish
SO  - J Lipid Res. 2023 Jun;64(6):100377. doi: 10.1016/j.jlr.2023.100377. Epub 2023 Apr 
      27.

PMID- 29740435
OWN - NLM
STAT- MEDLINE
DCOM- 20190607
LR  - 20190607
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 9
DP  - 2018
TI  - A Beneficial Effect of Low-Dose Aspirin in a Murine Model of Active Tuberculosis.
PG  - 798
LID - 10.3389/fimmu.2018.00798 [doi]
LID - 798
AB  - An excessive, non-productive host-immune response is detrimental in active, 
      chronic tuberculosis (TB) disease as it typically leads to tissue damage. Given 
      their anti-inflammatory effect, non-steroidal anti-inflammatory drugs can 
      potentially attenuate excessive inflammation in active TB disease. As such, we 
      investigated the prophylactic and therapeutic effect of low-dose aspirin (LDA) 
      (3 mg/kg/day), either alone or in combination with common anti-TB treatment or 
      BCG vaccination, on disease outcome in an experimental murine model of active TB. 
      Survival rate, bacillary load (BL) in lungs, and lung pathology were measured. 
      The possible mechanism of action of LDA on the host's immune response was also 
      evaluated by measuring levels of CD5L/AIM, selected cytokines/chemokines and 
      other inflammatory markers in serum and lung tissue. LDA increased survival, had 
      anti-inflammatory effects, reduced lung pathology, and decreased bacillary load 
      in late-stage TB disease. Moreover, in combination with common anti-TB treatment, 
      LDA enhanced survival and reduced lung pathology. Results from the immunological 
      studies suggest the anti-inflammatory action of LDA at both a local and a 
      systemic level. Our results showed a systemic decrease in neutrophilic 
      recruitment, decreased levels of acute-phase reaction cytokines (IL-6, IL-1β, and 
      TNF-α) at late stage and a delay in the decrease in T cell response (in terms of 
      IFN-γ, IL-2, and IL-10 serum levels) that occurs during the course of 
      Mycobacterium tuberculosis infection. An anti-inflammatory milieu was detected in 
      the lung, with less neutrophil recruitment and lower levels of tissue factor. In 
      conclusion, LDA may be beneficial as an adjunct to standard anti-TB treatment in 
      the later stage of active TB by reducing excess, non-productive inflammation, 
      while enhancing Th1-cell responses for elimination of the bacilli.
FAU - Kroesen, Vera Marie
AU  - Kroesen VM
AD  - Experimental Tuberculosis Unit (UTE), Fundació Institut Germans Trias i Pujol 
      (IGTP), Universitat Autònoma de Barcelona (UAB), Badalona, Spain.
AD  - Carl-von-Ossietzky University Oldenburg, Oldenburg, Germany.
FAU - Rodríguez-Martínez, Paula
AU  - Rodríguez-Martínez P
AD  - Pathology Department, Hospital Universitari Germans Trias i Pujol (HUGTIP), 
      Universitat Autònoma de Barcelona (UAB), Badalona, Spain.
FAU - García, Eric
AU  - García E
AD  - Experimental Tuberculosis Unit (UTE), Fundació Institut Germans Trias i Pujol 
      (IGTP), Universitat Autònoma de Barcelona (UAB), Badalona, Spain.
FAU - Rosales, Yaiza
AU  - Rosales Y
AD  - Experimental Tuberculosis Unit (UTE), Fundació Institut Germans Trias i Pujol 
      (IGTP), Universitat Autònoma de Barcelona (UAB), Badalona, Spain.
FAU - Díaz, Jorge
AU  - Díaz J
AD  - Experimental Tuberculosis Unit (UTE), Fundació Institut Germans Trias i Pujol 
      (IGTP), Universitat Autònoma de Barcelona (UAB), Badalona, Spain.
FAU - Martín-Céspedes, Montse
AU  - Martín-Céspedes M
AD  - Pathology Department, Hospital Universitari Germans Trias i Pujol (HUGTIP), 
      Universitat Autònoma de Barcelona (UAB), Badalona, Spain.
FAU - Tapia, Gustavo
AU  - Tapia G
AD  - Pathology Department, Hospital Universitari Germans Trias i Pujol (HUGTIP), 
      Universitat Autònoma de Barcelona (UAB), Badalona, Spain.
FAU - Sarrias, Maria Rosa
AU  - Sarrias MR
AD  - Innate Immunity Group, Fundació Institut Germans Trias i Pujol (IGTP), Badalona, 
      Spain.
AD  - Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas 
      (CIBEREhD), Madrid, Spain.
FAU - Cardona, Pere-Joan
AU  - Cardona PJ
AD  - Experimental Tuberculosis Unit (UTE), Fundació Institut Germans Trias i Pujol 
      (IGTP), Universitat Autònoma de Barcelona (UAB), Badalona, Spain.
AD  - Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), 
      Madrid, Spain.
FAU - Vilaplana, Cristina
AU  - Vilaplana C
AD  - Experimental Tuberculosis Unit (UTE), Fundació Institut Germans Trias i Pujol 
      (IGTP), Universitat Autònoma de Barcelona (UAB), Badalona, Spain.
AD  - Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), 
      Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180423
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Disease Models, Animal
MH  - Mice
MH  - Tuberculosis/*pathology
PMC - PMC5924809
OTO - NOTNLM
OT  - Mycobacterium tuberculosis
OT  - aspirin
OT  - host-directed therapies
OT  - mouse model
OT  - non-steroidal anti-inflammatory drugs
OT  - tuberculosis
EDAT- 2018/05/10 06:00
MHDA- 2018/05/10 06:01
CRDT- 2018/05/10 06:00
PHST- 2018/02/07 00:00 [received]
PHST- 2018/04/03 00:00 [accepted]
PHST- 2018/05/10 06:00 [entrez]
PHST- 2018/05/10 06:00 [pubmed]
PHST- 2018/05/10 06:01 [medline]
AID - 10.3389/fimmu.2018.00798 [doi]
PST - epublish
SO  - Front Immunol. 2018 Apr 23;9:798. doi: 10.3389/fimmu.2018.00798. eCollection 
      2018.

PMID- 36342703
OWN - NLM
STAT- MEDLINE
DCOM- 20221207
LR  - 20230110
IS  - 2168-6114 (Electronic)
IS  - 2168-6106 (Print)
IS  - 2168-6106 (Linking)
VI  - 182
IP  - 12
DP  - 2022 Dec 1
TI  - Daily Low-Dose Aspirin and Risk of Serious Falls and Fractures in Healthy Older 
      People: A Substudy of the ASPREE Randomized Clinical Trial.
PG  - 1289-1297
LID - 10.1001/jamainternmed.2022.5028 [doi]
AB  - IMPORTANCE: Falls and fractures are frequent and deleterious to the health of 
      older people. Aspirin has been reported to reduce bone fragility and slow bone 
      loss. OBJECTIVE: To determine if daily low-dose aspirin (100 mg) reduces the risk 
      of fractures or serious falls (fall-related hospital presentations) in healthy 
      older men and women. DESIGN, SETTING, AND PARTICIPANTS: This substudy of a 
      double-blind, randomized, placebo-controlled trial studied older adult men and 
      women in 16 major sites across southeastern Australia. The ASPREE-FRACTURE 
      substudy was conducted as part of the Australian component of the ASPREE trial. 
      Between 2010 and 2014 healthy (free of cardiovascular disease, dementia or 
      physical disability), community-dwelling volunteers aged 70 years or older were 
      recruited to participate in the ASPREE trial. Potentially eligible participants 
      were identified by medical practitioners and trial personnel and were then sent a 
      letter of invitation to participate. Interested participants were screened for 
      suitability. Eligible participants with medical practitioner authorization and 
      adherent to a 4-week run-in medication trial were randomized. Data were analyzed 
      from October 17, 2019, to August 31, 2022. INTERVENTIONS: Participants in the 
      intervention group received a daily dose of oral 100 mg enteric-coated (low-dose) 
      aspirin. The control group received a daily identical enteric-coated placebo 
      tablet. MAIN OUTCOMES AND MEASURES: The primary outcome of ASPREE-FRACTURE was 
      the occurrence of any fracture. The secondary outcome was serious fall resulting 
      in hospital presentation. RESULTS: In total, 16 703 people with a median (IQR) 
      age of 74 (72-78) years were recruited, and 9179 (55.0%) were women. There were 
      8322 intervention participants and 8381 control participants included in the 
      primary and secondary outcome analysis of 2865 fractures and 1688 serious falls 
      over the median follow-up of 4.6 years. While there was no difference in the risk 
      of first fracture between the intervention and control participants (hazard 
      ratio, 0.97; 95% CI, 0.87-1.06; P = .50), aspirin was associated with a higher 
      risk of serious falls (total falls 884 vs 804; incidence rate ratio, 1.17; 95% 
      CI, 1.03-1.33; P = .01). Results remained unchanged in analyses that adjusted for 
      covariates known to influence fracture and fall risk. CONCLUSIONS AND RELEVANCE: 
      In this substudy of a randomized clinical trial, the failure of low-dose aspirin 
      to reduce the risk of fractures while increasing the risk of serious falls adds 
      to evidence that this agent provides little favorable benefit in a healthy, White 
      older adult population. TRIAL REGISTRATION: This substudy is registered with the 
      Australian New Zealand Clinical Trials Registry (ACTRN12615000347561).
FAU - Barker, Anna L
AU  - Barker AL
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
AD  - Silverchain Group, Melbourne, Victoria, Australia.
FAU - Morello, Renata
AU  - Morello R
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Thao, Le Thi Phuong
AU  - Thao LTP
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Seeman, Ego
AU  - Seeman E
AD  - Department of Endocrinology and Medicine, Austin Health, University of Melbourne, 
      Melbourne, Victoria, Australia.
FAU - Ward, Stephanie A
AU  - Ward SA
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
AD  - Centre for Healthy Brain Ageing, School of Psychiatry, University of New South 
      Wales, Sydney, New South Wales, Australia.
FAU - Sanders, Kerrie M
AU  - Sanders KM
AD  - Department of Medicine, Western Health, University of Melbourne, St Albans, 
      Victoria, Australia.
FAU - Cumming, Robert G
AU  - Cumming RG
AD  - School of Public Health, University of Sydney, Sydney, New South Wales, 
      Australia.
FAU - Pasco, Julie A
AU  - Pasco JA
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
AD  - Department of Medicine, Western Health, University of Melbourne, St Albans, 
      Victoria, Australia.
AD  - Deakin University, Institute for Mental and Physical Health and Clinical 
      Translation (IMPACT), Barwon Health, Geelong, Victoria, Australia.
FAU - Ebeling, Peter R
AU  - Ebeling PR
AD  - Department of Medicine, School of Clinical Sciences, Monash University, Clayton, 
      Victoria, Australia.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Khosla, Sundeep
AU  - Khosla S
AD  - Endocrine Research Unit, College of Medicine, Mayo Clinic, Rochester, Minnesota.
FAU - Hussain, Sultana Monira
AU  - Hussain SM
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
AD  - Department of Medical Education, Melbourne Medical School, University of 
      Melbourne, Melbourne, Victoria, Australia.
FAU - Ronaldson, Kathlyn
AU  - Ronaldson K
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Newman, Anne B
AU  - Newman AB
AD  - Center for Aging and Population Health, School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania.
FAU - Williamson, Jeff D
AU  - Williamson JD
AD  - Sticht Center on Aging and Alzheimer's Prevention, Section on Gerontology and 
      Geriatric Medicine, Department of Internal Medicine, Wake Forest School of 
      Medicine, Winston-Salem, North Carolina.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12615000347561
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U19 AG062682/AG/NIA NIH HHS/United States
GR  - P30 AG024827/AG/NIA NIH HHS/United States
GR  - P30 AG021332/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA Intern Med
JT  - JAMA internal medicine
JID - 101589534
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Male
MH  - Humans
MH  - Female
MH  - Aged
MH  - Australia/epidemiology
MH  - *Aspirin/therapeutic use
MH  - *Fractures, Bone/epidemiology/prevention & control
MH  - Independent Living
PMC - PMC9641595
COIS- Conflict of Interest Disclosures: Dr Barker reported grants from the National 
      Health and Medical Research Council of Australia (NHMRC) outside the submitted 
      work. Dr Ebeling reported grants from Amgen, Alexion, and Sanofi, and personal 
      fees from Amgen outside the submitted work. Dr Williamson reported grants from 
      the National Institutes of Health outside the submitted work. No other 
      disclosures were reported.
EDAT- 2022/11/08 06:00
MHDA- 2023/01/11 06:00
PMCR- 2023/11/07
CRDT- 2022/11/07 11:33
PHST- 2023/11/07 00:00 [pmc-release]
PHST- 2022/11/08 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2022/11/07 11:33 [entrez]
AID - 2797772 [pii]
AID - ioi220066 [pii]
AID - 10.1001/jamainternmed.2022.5028 [doi]
PST - ppublish
SO  - JAMA Intern Med. 2022 Dec 1;182(12):1289-1297. doi: 
      10.1001/jamainternmed.2022.5028.

PMID- 17408314
OWN - NLM
STAT- MEDLINE
DCOM- 20070524
LR  - 20181201
IS  - 1936-5764 (Electronic)
IS  - 0016-867X (Linking)
VI  - 62
IP  - 4
DP  - 2007 Apr
TI  - Antiplatelet therapy in the treatment of atherothrombotic disease: considering 
      the evidence.
PG  - 12-24
AB  - Aspirin should be used to treat patients with acute myocardial infarction (MI) 
      and continued indefinitely to reduce vascular death, nonfatal MI, and nonfatal 
      stroke. Clopidogrel added to aspirin is beneficial in the treatment of patients 
      with acute ST-elevation MI. Patients with unstable angina or non-ST-elevation MI 
      should be treated with aspirin plus clopidogrel for at least 9 months to reduce 
      the risk vascular death, nonfatal MI, and nonfatal stroke. Patients with prior MI 
      should be treated indefinitely with aspirin and with clopidogrel if aspirin is 
      contraindicated. Patients with ischemic stroke should be treated with either 
      aspirin or clopidogrel indefinitely. Extended-release dipyridamole plus low-dose 
      aspirin is more efficacious than low-dose aspirin but is associated with an 
      insignificant increase in nonfatal MI and vascular death than low-dose aspirin. 
      Clopidogrel is more effective than aspirin in reducing the risk of vascular 
      death, nonfatal MI, and nonfatal stroke in patients with peripheral arterial 
      disease.
FAU - Aronow, Wilbert S
AU  - Aronow WS
AD  - Department of Medicine, Division of Cardiology and Geriatrics, Westchester 
      Medical Center/New York Medical College, Valhalla, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Geriatrics
JT  - Geriatrics
JID - 2985102R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged, 80 and over
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/prevention & control/therapy
MH  - Clopidogrel
MH  - Comorbidity
MH  - Drug Therapy, Combination
MH  - *Evidence-Based Medicine
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Stroke/*drug therapy
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
RF  - 42
EDAT- 2007/04/06 09:00
MHDA- 2007/05/26 09:00
CRDT- 2007/04/06 09:00
PHST- 2007/04/06 09:00 [pubmed]
PHST- 2007/05/26 09:00 [medline]
PHST- 2007/04/06 09:00 [entrez]
PST - ppublish
SO  - Geriatrics. 2007 Apr;62(4):12-24.

PMID- 22621270
OWN - NLM
STAT- MEDLINE
DCOM- 20121030
LR  - 20211021
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 18
IP  - 22
DP  - 2012
TI  - Platelet-neutrophil interactions as a target for prevention and treatment of 
      transfusion-related acute lung injury.
PG  - 3260-6
AB  - Transfusion-related acute lung injury (TRALI) is a major cause of morbidity and 
      mortality in transfused hosts and like other causes of acute lung injury, there 
      is no effective pharmacologic treatment. The pathophysiology of TRALI is still 
      being defined, but neutrophils have a major role in the pathogenesis of both 
      human and experimental studies. Recently, MHC antibody-based experimental TRALI 
      models have revealed that platelets sequester in the lung microvasculature and 
      that platelet activation contributes to lung injury. Platelets, in general, have 
      been increasingly implicated as major contributors to acute inflammation and 
      injury in a variety of diseases. The role of platelets in TRALI may be through 
      critical interactions with neutrophils and therapeutically this could present a 
      target for pharmacologic intervention. Experimentally, aspirin pre-treatment of 
      mice before TRALI is protective from acute lung injury and mortality. Other 
      therapeutic interventions could include agents that uncouple neutrophils and 
      platelets or prevent aggregation and activation, however targeting platelet 
      activation in TRALI is complicated by the presence of bleeding as the indication 
      for many transfusions. In conclusion, experimental studies are elucidating the 
      role of platelets in acute lung injury and with this new understanding, clinical 
      trials of anti-platelet agents should be considered.
FAU - Caudrillier, Axelle
AU  - Caudrillier A
AD  - Cardiovascular Research Institute, University of California, San Francisco, San 
      Francisco, CA 94143-0130, USA.
FAU - Looney, Mark R
AU  - Looney MR
LA  - eng
GR  - K08 HL082742/HL/NHLBI NIH HHS/United States
GR  - R01 HL107386/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Lung Injury/etiology/prevention & control/*therapy
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/*metabolism
MH  - Blood Transfusion/methods
MH  - Drug Delivery Systems
MH  - Hemorrhage/epidemiology/therapy
MH  - Humans
MH  - Mice
MH  - Neutrophils/metabolism
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - *Transfusion Reaction
EDAT- 2012/05/25 06:00
MHDA- 2012/10/31 06:00
CRDT- 2012/05/25 06:00
PHST- 2012/01/09 00:00 [received]
PHST- 2012/01/31 00:00 [accepted]
PHST- 2012/05/25 06:00 [entrez]
PHST- 2012/05/25 06:00 [pubmed]
PHST- 2012/10/31 06:00 [medline]
AID - CPD-EPUB-20120522-4 [pii]
AID - 10.2174/1381612811209023260 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2012;18(22):3260-6. doi: 10.2174/1381612811209023260.

PMID- 7733002
OWN - NLM
STAT- MEDLINE
DCOM- 19950601
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 75
IP  - 14
DP  - 1995 May 1
TI  - Effect of aspirin on spontaneous contrast in the brachial veins of normal 
      subjects.
PG  - 924-8
AB  - Blood cell aggregates are thought to be the cause of spontaneous echo contrast 
      (SEC), although there is disagreement as to whether red cell or platelet 
      aggregates produce this effect. One way to differentiate between these 2 
      possibilities is to evaluate the effect of aspirin on SEC because aspirin would 
      not be expected to affect red cell aggregates. To eliminate the need to perform 
      repetitive transesophageal echocardiographic studies, and the possible effect of 
      the underlying disease process on SEC, the effect of aspirin on SEC in the 
      brachial vein was studied in normal volunteers using a single-blind, 
      before-and-after study design. Other factors known to affect blood echogenicity 
      including hematocrit, sedimentation rate, and the presence of platelet aggregates 
      by microscopy were also studied. The amount of SEC was quantitated by image 
      analysis and expressed as the aggregate score. The results in 10 volunteers 
      showed that all had SEC in brachial veins before aspirin, but there was no 
      significant day-to-day variation in the amount of SEC during the control period 
      (mean +/- SEM 104,248 +/- 23,088, 153,722 +/- 35,664, and 124,568 +/- 22,827 for 
      days 1, 3, and 5, respectively). A significant decrease in the aggregate score 
      occurred after 7 days of aspirin, 650 mg twice a day (51,690 vs 127,513, p = 
      0.002); this was accompanied by a striking decrement in the size of the largest 
      platelet aggregate found in venous blood. Aspirin caused no significant change in 
      the hematocrit or sedimentation rate. These results indicate that there is a 
      component of SEC that is aspirin-sensitive and is likely to represent platelet 
      aggregates.
FAU - Kearney, K
AU  - Kearney K
AD  - Division of Cardiology, University of Kentucky Medical Center, Lexington 
      40536-0084, USA.
FAU - Mahony, C
AU  - Mahony C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Axillary Vein/*diagnostic imaging
MH  - Blood/*diagnostic imaging
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Single-Blind Method
MH  - Ultrasonography
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
AID - S0002914999806882 [pii]
AID - 10.1016/s0002-9149(99)80688-2 [doi]
PST - ppublish
SO  - Am J Cardiol. 1995 May 1;75(14):924-8. doi: 10.1016/s0002-9149(99)80688-2.

PMID- 10914173
OWN - NLM
STAT- MEDLINE
DCOM- 20000906
LR  - 20131121
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 136
IP  - 2
DP  - 1999 Jan 15
TI  - [Ambulatory oral procedures in patients on low-dose aspirin].
PG  - 108-10, 175
AB  - Discontinuation of long-term, low-dose aspirin prior to ambulatory oral surgical 
      procedures was assessed in a blind, controlled prospective study. 50 patients on 
      low-dose aspirin who needed dental extractions, periodontal surgery, or other 
      ambulatory oral surgery were randomly divided into test and control groups. The 
      control patients stopped taking aspirin a week before operation, but in the test 
      group aspirin was continued. Before, during and after surgery bleeding time was 
      tested. Although bleeding time was significantly longer when aspirin was 
      continued, in both groups it was within normal limits. Intraoperative hemorrhage 
      was more frequent in those taking aspirin. Hemostasis control posed no problem 
      and there were no postoperative complications in either group. It is concluded 
      that discontinuing low-dose aspirin prior to elective oral surgery is not 
      justified.
FAU - Gaspar, R
AU  - Gaspar R
AD  - Dept. of Oral and Maxillofacial Surgery, Rambam Medical Center, Haifa.
FAU - Ardekian, L
AU  - Ardekian L
FAU - Brenner, B
AU  - Brenner B
FAU - Peled, M
AU  - Peled M
FAU - Laufer, D
AU  - Laufer D
LA  - heb
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Ambulatory Surgical Procedures
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Oral Surgical Procedures
MH  - Periodontal Diseases/surgery
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Tooth Extraction
EDAT- 2000/07/29 11:00
MHDA- 2000/09/09 11:01
CRDT- 2000/07/29 11:00
PHST- 2000/07/29 11:00 [pubmed]
PHST- 2000/09/09 11:01 [medline]
PHST- 2000/07/29 11:00 [entrez]
PST - ppublish
SO  - Harefuah. 1999 Jan 15;136(2):108-10, 175.

PMID- 34926688
OWN - NLM
STAT- MEDLINE
DCOM- 20220120
LR  - 20220120
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2021
DP  - 2021
TI  - Noncoding RNA Roles in Pharmacogenomic Responses to Aspirin: New Molecular 
      Mechanisms for an Old Drug.
PG  - 6830560
LID - 10.1155/2021/6830560 [doi]
LID - 6830560
AB  - Aspirin, as one of the most frequently prescribed drugs, can have therapeutic 
      effects on different conditions such as cardiovascular and metabolic disorders 
      and malignancies. The effects of this common cardiovascular drug are exerted 
      through different molecular and cellular pathways. Altered noncoding RNA (ncRNA) 
      expression profiles during aspirin treatments indicate a close relationship 
      between these regulatory molecules and aspirin effects through regulating gene 
      expressions. A better understanding of the molecular networks contributing to 
      aspirin efficacy would help optimize efficient therapies for this very popular 
      drug. This review is aimed at discussing and highlighting the identified 
      interactions between aspirin and ncRNAs and their targeting pathways and better 
      understanding pharmacogenetic responses to aspirin.
CI  - Copyright © 2021 Mohammad Amin Khazeei Tabari et al.
FAU - Khazeei Tabari, Mohammad Amin
AU  - Khazeei Tabari MA
AUID- ORCID: 0000-0001-6415-8403
AD  - Student Research Committee, Mazandaran University of Medical Sciences, Sari, 
      Iran.
AD  - USERN Office, Mazandaran University of Medical Sciences, Sari, Iran.
FAU - Mishan, Mohammad Amir
AU  - Mishan MA
AD  - Ocular Tissue Engineering Research Center, Research Institute for Ophthalmology 
      and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Moradi, Mona
AU  - Moradi M
AD  - Department of Clinical Biochemistry and Medical Genetics, Faculty of Medicine, 
      Molecular and Cell Biology Research Center, Mazandaran University of Medical 
      Sciences, Sari, Iran.
FAU - Khandan, Mohanna
AU  - Khandan M
AD  - Student Research Committee, Mazandaran University of Medical Sciences, Sari, 
      Iran.
AD  - USERN Office, Mazandaran University of Medical Sciences, Sari, Iran.
FAU - Khoshhal, Hooman
AU  - Khoshhal H
AD  - Student Research Committee, Mazandaran University of Medical Sciences, Sari, 
      Iran.
AD  - USERN Office, Mazandaran University of Medical Sciences, Sari, Iran.
FAU - Mahrooz, Abdolkarim
AU  - Mahrooz A
AD  - Department of Clinical Biochemistry and Medical Genetics, Faculty of Medicine, 
      Molecular and Cell Biology Research Center, Mazandaran University of Medical 
      Sciences, Sari, Iran.
FAU - Bagheri, Abouzar
AU  - Bagheri A
AUID- ORCID: 0000-0001-8040-5056
AD  - Department of Clinical Biochemistry and Medical Genetics, Faculty of Medicine, 
      Molecular and Cell Biology Research Center, Mazandaran University of Medical 
      Sciences, Sari, Iran.
AD  - Department of Clinical Biochemistry and Medical Genetics, Gastrointestinal Cancer 
      Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, 
      Sari, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211209
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Prescription Drugs)
RN  - 0 (RNA, Untranslated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cardiovascular Agents/pharmacology
MH  - Gene Expression/genetics
MH  - Humans
MH  - Pharmacogenetics/methods
MH  - Prescription Drugs/*pharmacology
MH  - RNA, Untranslated/*genetics
PMC - PMC8677408
COIS- All the authors declare that they have no competing interests.
EDAT- 2021/12/21 06:00
MHDA- 2022/01/21 06:00
CRDT- 2021/12/20 06:19
PHST- 2021/04/09 00:00 [received]
PHST- 2021/11/25 00:00 [accepted]
PHST- 2021/12/20 06:19 [entrez]
PHST- 2021/12/21 06:00 [pubmed]
PHST- 2022/01/21 06:00 [medline]
AID - 10.1155/2021/6830560 [doi]
PST - epublish
SO  - Biomed Res Int. 2021 Dec 9;2021:6830560. doi: 10.1155/2021/6830560. eCollection 
      2021.

PMID- 35469627
OWN - NLM
STAT- MEDLINE
DCOM- 20220427
LR  - 20220703
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 42
IP  - 2
DP  - 2022 May
TI  - Aspirin-Exacerbated Respiratory Disease: A Unique Case of Drug Hypersensitivity.
PG  - 421-432
LID - S0889-8561(21)00112-0 [pii]
LID - 10.1016/j.iac.2021.12.005 [doi]
AB  - This review of aspirin-exacerbated respiratory disease (AERD) describes the 
      clinical characteristics and pathophysiology of disease, highlighting its 
      similarities and unique differences in comparison to classic IgE mediated 
      hypersensitivity as well as AERD as a chronic disease. There is a specific focus 
      on the comparison of mediator production over time and the use of desensitization 
      in each diagnosis that serves to aid the clinician in differentiating aspirin 
      reactions in AERD from those related to true immediate hypersensitivity.
CI  - Copyright © 2021 Elsevier Inc. All rights reserved.
FAU - Corey, Kristen B
AU  - Corey KB
AD  - Division of Allergy, Pulmonary, and Critical Care Medicine, Department of 
      Medicine, Vanderbilt University Medical Center, 2611 West End Avenue, Suite 210, 
      Nashville, TN 37203, USA.
FAU - Cahill, Katherine N
AU  - Cahill KN
AD  - Division of Allergy, Pulmonary, and Critical Care Medicine, Department of 
      Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 450, 
      Room 418, Nashville, TN 32703, USA. Electronic address: 
      katherine.cahill@vumc.org.
LA  - eng
GR  - U01 AI155299/AI/NIAID NIH HHS/United States
GR  - U19 AI095227/AI/NIAID NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20220331
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Asthma, Aspirin-Induced/diagnosis/therapy
MH  - Humans
MH  - *Sinusitis
OTO - NOTNLM
OT  - Anaphylaxis
OT  - Aspirin
OT  - Aspirin-exacerbated respiratory disease
OT  - Desensitization
OT  - Eicosanoids
OT  - Mast cells
COIS- Disclosure K.N. Cahill has severed on scientific advisory boards for Teva, 
      GlaxoSmithKline, Blueprint Medicines, Regeneron, Genentech, Sanofi-Pasteur and 
      reports personal fees from Novartis, Third Harmonic Bio, Ribon Therapeutics, and 
      Verantos outside the submitted work and reports funding from NIHU01AI155299 and 
      U19AI095227. K.B. Corey has no disclosures to report.
EDAT- 2022/04/27 06:00
MHDA- 2022/04/28 06:00
CRDT- 2022/04/26 05:55
PHST- 2022/04/26 05:55 [entrez]
PHST- 2022/04/27 06:00 [pubmed]
PHST- 2022/04/28 06:00 [medline]
AID - S0889-8561(21)00112-0 [pii]
AID - 10.1016/j.iac.2021.12.005 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2022 May;42(2):421-432. doi: 
      10.1016/j.iac.2021.12.005. Epub 2022 Mar 31.

PMID- 8401941
OWN - NLM
STAT- MEDLINE
DCOM- 19931102
LR  - 20190512
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 109
IP  - 4
DP  - 1993 Aug
TI  - Different effects of aspirin on blood pressure of spontaneously hypertensive rats 
      (SHR) with high and spontaneously low levels of blood pressure.
PG  - 900-1
AB  - Spontaneously hypertensive rats (SHR) of the Okamoto strain with blood pressure 
      above 161 mmHg and SHR with blood pressure levels of less than 160 mmHg were 
      treated with oral doses of aspirin (100 mg kg-1) for three days. Whereas the 
      blood pressure of SHR with blood pressure above 161 mmHg was decreased by 
      aspirin, the blood pressure of SHR below 160 mmHg was increased by aspirin. The 
      extent and direction of blood pressure change by aspirin was strongly correlated 
      with the blood pressure of SHR before treatment (r = -0.88). The effect of 
      aspirin supports an important role for endogenous prostanoids in the regulation 
      of blood pressure of SHR.
FAU - Schirner, M
AU  - Schirner M
AD  - Institute of Pharmacology and Toxicology, Martin-Luther-University of Halle, 
      Germany.
FAU - Taube, C
AU  - Taube C
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Hypertension/physiopathology
MH  - Male
MH  - Prostaglandins/physiology
MH  - Rats
MH  - Rats, Inbred SHR
PMC - PMC2175725
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1993.tb13704.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1993 Aug;109(4):900-1. doi: 10.1111/j.1476-5381.1993.tb13704.x.

PMID- 16011873
OWN - NLM
STAT- MEDLINE
DCOM- 20060309
LR  - 20131121
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 231
IP  - 2
DP  - 2006 Jan 18
TI  - A study of the effect of salicylic acetic acid on a lymphocyte cell model of 
      cellular activation and proliferation.
PG  - 257-61
AB  - Salicylic acetic acid (SAA) is a drug that has formed part of the treatment of 
      many diseases for many years. Its anti-inflammatory activity is well known, but 
      recently its possible role in the interference in the oncogenesis mechanisms has 
      become apparent. With the aim of supporting these yet preliminary observations, 
      we studied the effect of salicylic acetic acid on a cellular activation and 
      proliferation model. We used lymphocytes obtained from peripheral blood, which 
      were later exposed to cellular activation and proliferation stimulus by the SEB 
      antigen. Lymphocyte activation was determined by direct immunoflourescence 
      through expression of the receptor IL-2 (CD25) alpha chain and proliferation 
      through the incorporation of tritiated thymidine to the DNA in synthesis together 
      with the determination of the cellular cycle by flow cytometry. We found that 
      both processes, activation and proliferation, are inhibited by increasing doses 
      of SAA.
FAU - Aguilar, Enrique Aranda
AU  - Aguilar EA
AD  - Medical Oncology Service, Reina Sofia University Hospital, Córdoba, Spain.
FAU - de la Haba-Rodríguez, Juan
AU  - de la Haba-Rodríguez J
FAU - Macho, Antonio
AU  - Macho A
FAU - Lucena, Concha
AU  - Lucena C
FAU - Gómez, Auxiliadora
AU  - Gómez A
FAU - Calzado, Marco
AU  - Calzado M
FAU - Muñoz, Eduardo
AU  - Muñoz E
LA  - eng
PT  - Journal Article
DEP - 20050711
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Enterotoxins)
RN  - 0 (Receptors, Interleukin-2)
RN  - 39424-53-8 (enterotoxin B, staphylococcal)
RN  - 9007-49-2 (DNA)
RN  - R16CO5Y76E (Aspirin)
RN  - VC2W18DGKR (Thymidine)
SB  - IM
MH  - Aspirin/chemistry/*pharmacology
MH  - Cell Cycle/drug effects
MH  - Cell Proliferation/*drug effects
MH  - Cells, Cultured
MH  - DNA/metabolism
MH  - Enterotoxins/pharmacology
MH  - Flow Cytometry
MH  - Fluorescent Antibody Technique, Direct
MH  - Humans
MH  - Lymphocyte Activation/*drug effects
MH  - Lymphocytes/drug effects
MH  - *Models, Biological
MH  - Receptors, Interleukin-2/metabolism
MH  - Thymidine/metabolism
EDAT- 2005/07/14 09:00
MHDA- 2006/03/10 09:00
CRDT- 2005/07/14 09:00
PHST- 2004/05/05 00:00 [received]
PHST- 2005/02/07 00:00 [accepted]
PHST- 2005/07/14 09:00 [pubmed]
PHST- 2006/03/10 09:00 [medline]
PHST- 2005/07/14 09:00 [entrez]
AID - S0304-3835(05)00169-2 [pii]
AID - 10.1016/j.canlet.2005.02.014 [doi]
PST - ppublish
SO  - Cancer Lett. 2006 Jan 18;231(2):257-61. doi: 10.1016/j.canlet.2005.02.014. Epub 
      2005 Jul 11.

PMID- 16611114
OWN - NLM
STAT- MEDLINE
DCOM- 20060612
LR  - 20190728
IS  - 1381-6128 (Print)
IS  - 1381-6128 (Linking)
VI  - 12
IP  - 10
DP  - 2006
TI  - Primary and secondary stroke prevention with antiplatelet drugs.
PG  - 1293-7
AB  - Aspirin is not effective in the primary prevention of stroke. Patients with TIA 
      or ischemic stroke carry a risk of recurrent stroke between 5 and 20% per year. 
      In patients with TIA or ischemic stroke of noncardiac origin antiplatelet drugs 
      are able to decrease the risk of stroke by 11-15% and the risk of stroke, MI and 
      vascular death by 15-22%. Aspirin is the most widely used drug. It is affordable 
      and effective. Low doses of 50-325 mg aspirin are as effective as high doses and 
      cause less gastrointestinal side effects. Severe bleeding complications are 
      dose-dependent. The combination of aspirin with slow release dipyridamole is 
      superior to aspirin alone for stroke prevention. Clopidgrel is superior to 
      aspirin in patients at high risk of recurrence. The combination of aspirin plus 
      clopidogrel is not more effective than clopidogrel alone but carries a higher 
      bleeding risk. None of the antiplatelet agents is able to reduce mortality.
FAU - Diener, Hans-Christoph
AU  - Diener HC
AD  - Department of Neurology, University of Essen, Hufelandstr. 55, D45122 Essen, 
      Germany. h.diener@uni-essen.de
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/etiology/*prevention & control
MH  - Treatment Failure
RF  - 43
EDAT- 2006/04/14 09:00
MHDA- 2006/06/13 09:00
CRDT- 2006/04/14 09:00
PHST- 2006/04/14 09:00 [pubmed]
PHST- 2006/06/13 09:00 [medline]
PHST- 2006/04/14 09:00 [entrez]
AID - 10.2174/138161206776361273 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2006;12(10):1293-7. doi: 10.2174/138161206776361273.

PMID- 6463857
OWN - NLM
STAT- MEDLINE
DCOM- 19840829
LR  - 20141120
IS  - 0039-6060 (Print)
IS  - 0039-6060 (Linking)
VI  - 96
IP  - 2
DP  - 1984 Aug
TI  - Effect of aspirin on epithelial cell membrane potentials of gastric fundic 
      mucosa.
PG  - 171-8
AB  - The effects of aspirin on epithelial cell membrane potentials of Necturus fundic 
      mucosa were examined by in vitro experiments according to intracellular 
      microelectrode techniques. Stable intracellular impalements were obtained with 15 
      to 50 M-ohm microelectrodes filled with 3M KCl. In neutral mucosal solutions (pH 
      7.0) aspirin (5.0 mM) resulted in a significant increase in apical cell membrane 
      potential (Vmc) from -36.7 +/- 1.5 mV to -43.3 +/- 2.3 mV (p less than 0.001) and 
      basolateral cell membrane potential (Vcs) from -42.7 +/- 1.8 mV to -50.6 +/- 2.4 
      (p less than 0.001). This hyperpolarization of the cell was associated with an 
      increase in transmucosal potential from -5.8 +/- 0.7 to -7.4 +/- 0.9 (p less than 
      0.05) and an increase in the ratio of apical to basolateral membrane resistances 
      from 5.1 +/- 1.2 to 8.8 +/- 1.9 (p less than 0.05). These changes were consistent 
      with an increase in potassium conductance induced by the salicylate anion. In 
      acidic mucosal solutions (pH 4.5) aspirin caused a reduction in Vmc and Vcs. This 
      hypopolarization of the cell membrane is consistent with acidification of the 
      epithelial cells. These observations support the proposed mechanisms of aspirin 
      injury: (1) back diffusion of H+ into the cells and (2) influx of the salicylate 
      anions into the cells, which may interfere with intracellular metabolism.
FAU - Cheung, L Y
AU  - Cheung LY
FAU - De, L
AU  - De L
FAU - Ashley, S W
AU  - Ashley SW
LA  - eng
GR  - AM07178-01/AM/NIADDK NIH HHS/United States
GR  - AM25998-05/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Electric Conductivity
MH  - Epithelium/drug effects
MH  - Gastric Fundus
MH  - Gastric Mucosa/*drug effects
MH  - Hydrogen-Ion Concentration
MH  - In Vitro Techniques
MH  - Membrane Potentials/drug effects
MH  - Necturus maculosus
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
PST - ppublish
SO  - Surgery. 1984 Aug;96(2):171-8.

PMID- 12666142
OWN - NLM
STAT- MEDLINE
DCOM- 20030421
LR  - 20151119
IS  - 0361-8609 (Print)
IS  - 0361-8609 (Linking)
VI  - 72
IP  - 4
DP  - 2003 Apr
TI  - Rapid platelet inhibition after a single capsule of Aggrenox: challenging a 
      conventional full-dose aspirin antiplatelet advantage?
PG  - 280-1
AB  - Aggrenox is a novel combination of 25 mg of aspirin with 200 mg of sustained 
      release dipyridamole. In a recent large trial (ESPS-2), Aggrenox was twice as 
      effective for secondary stroke prevention as either aspirin or dipyridamole 
      alone, suggesting superior platelet inhibition for combination therapy. We sought 
      to compare the time course of platelet inhibition with Aggrenox compared with 
      escalating doses of non-enteric coated aspirin. Data from 10 healthy volunteers 
      were analyzed. Fasting subjects sequentially ingested aspirin in the following 
      order: 325 mg, 81 mg, 25 mg, and then one pill of Aggrenox after a 3-week 
      interval for aspirin washout. Platelet function was assessed at baseline, 15, 30, 
      60, and 120 min post-medication with 5 microM epinephrine and 5 microM ADP using 
      conventional aggregometry. Aspirin provided significant (P < 0.01) reduction of 
      platelet aggregation at 15 min post 325 mg, 30 min post 81 mg, and unexpectedly 
      within 60 min after taking 25 mg of aspirin. A single pill of Aggrenox also 
      inhibited platelet aggregation within 1 hr after administration. Aspirin inhibits 
      platelets remarkably fast. Both Aggrenox and a matching dose of aspirin (25 mg) 
      exhibit significant antiplatelet properties within 60 min after ingestion. These 
      findings could be relevant for the optimal balance between the reduction of 
      vascular events via sufficient and rapid platelet inhibition and low risk of 
      bleeding complications associated with the Aggrenox therapy.
CI  - Copyright 2003 Wiley-Liss, Inc.
FAU - Serebruany, Victor L
AU  - Serebruany VL
AD  - Sinai Hospital, Johns Hopkins University, Baltimore, Maryland 21215, USA. 
      Heartdrug@aol.com
FAU - Malinin, Alex I
AU  - Malinin AI
FAU - Sane, David C
AU  - Sane DC
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Capsules)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Blood Platelets/drug effects
MH  - Capsules
MH  - Dipyridamole/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Function Tests
MH  - Risk Factors
MH  - Stroke/epidemiology/prevention & control
MH  - Time Factors
EDAT- 2003/04/01 05:00
MHDA- 2003/04/22 05:00
CRDT- 2003/04/01 05:00
PHST- 2003/04/01 05:00 [pubmed]
PHST- 2003/04/22 05:00 [medline]
PHST- 2003/04/01 05:00 [entrez]
AID - 10.1002/ajh.10290 [doi]
PST - ppublish
SO  - Am J Hematol. 2003 Apr;72(4):280-1. doi: 10.1002/ajh.10290.

PMID- 3707301
OWN - NLM
STAT- MEDLINE
DCOM- 19860602
LR  - 20191022
IS  - 0344-8444 (Print)
IS  - 0344-8444 (Linking)
VI  - 105
IP  - 1
DP  - 1986
TI  - Effects of acetylsalicylic acid and naproxen on the synthesis and mineralization 
      of collagen in the rat femur.
PG  - 1-4
AB  - The influence of acetylsalicylic acid (ASA) and naproxen on the biochemical 
      properties of intact growing femora in young male rats was studied. The 
      medication periods were 9 and 18 days. At an ASA dose of 150 mg/kg/12 h the rate 
      of collagen synthesis and the rate of mineral incorporation decreased and were 
      impaired by about 10% compared with controls after 18 days. The dry weights and 
      contents of collagen and calcium were not influenced after 9 days, but were 
      reduced by 4%-7% after 18 days. A higher solubility of collagen (7%) was also 
      found at the end of the study. In rats that received ASA at 100 mg/kg/12 h no 
      significant differences were observed. A naproxen dose of 20 mg/kg/12 h reduced 
      the rate of mineral deposition after 18 days, but had no other detectable effects 
      on bone. The results indicate that ASA inhibits bone formation.
FAU - Solheim, L F
AU  - Solheim LF
FAU - Rönningen, H
AU  - Rönningen H
FAU - Langeland, N
AU  - Langeland N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Arch Orthop Trauma Surg (1978)
JT  - Archives of orthopaedic and traumatic surgery. Archiv fur orthopadische und 
      Unfall-Chirurgie
JID - 7803037
RN  - 0 (Minerals)
RN  - 57Y76R9ATQ (Naproxen)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bone Development/*drug effects
MH  - Collagen/*biosynthesis
MH  - Femur/*metabolism
MH  - Male
MH  - Minerals/*metabolism
MH  - Naproxen/administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Solubility
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1007/BF00625651 [doi]
PST - ppublish
SO  - Arch Orthop Trauma Surg (1978). 1986;105(1):1-4. doi: 10.1007/BF00625651.

PMID- 18484780
OWN - NLM
STAT- MEDLINE
DCOM- 20081031
LR  - 20211020
IS  - 0114-5916 (Print)
IS  - 0114-5916 (Linking)
VI  - 31
IP  - 6
DP  - 2008
TI  - Safety of clopidogrel and aspirin for stroke prevention: implications of the 
      CHARISMA trial.
PG  - 449-58
AB  - Antiplatelet therapy is universally recommended for the prevention of recurrent 
      events in patients with noncardioembolic ischaemic stroke or transient ischaemic 
      attack (TIA), acute and chronic coronary artery disease, or peripheral arterial 
      disease. However, choosing which antiplatelet agents to use in these situations 
      remains controversial. The use of aspirin, aspirin plus extended-release 
      dipyridamole, or clopidogrel is recommended as initial therapy in patients with 
      noncardioembolic ischaemic stroke or TIA to reduce the risk of recurrent stroke 
      and other cardiovascular events. Based on the results of the MATCH trial, 
      combination therapy with aspirin plus clopidogrel is not recommended for patients 
      with ischaemic stroke or TIA due to the increased risk of haemorrhage. The 
      results of the CHARISMA trial support this recommendation; despite previous data 
      demonstrating a favourable benefit-risk profile of aspirin plus clopidogrel in 
      patients with acute coronary syndrome, this combination should not be used in 
      patients at high risk for atherothrombosis and those with previous stroke or TIA. 
      In these patients, the CHARISMA trial demonstrated a lack of significant clinical 
      efficacy and an increased risk of bleeding with clopidogrel plus aspirin compared 
      with aspirin alone. Further research is needed to assess the benefit-risk ratio 
      of clopidogrel plus aspirin in specific subpopulations of patients at high risk 
      for atherothrombotic events, and to determine the role of clopidogrel plus 
      aspirin in preventing cardioembolic stroke or early recurrent stroke after 
      symptomatic large-vessel atherostenosis. Recent and ongoing studies are seeking 
      to better define the roles of different antiplatelet regimens in preventing 
      recurrent stroke.
FAU - Ruland, Sean
AU  - Ruland S
AD  - Section of Cerebrovascular Disease and Neurologic Critical Care, Department of 
      Neurology and Rehabilitation, University of Illinois at Chicago, Chicago, 
      Illinois 60612, USA. sruland@uic.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/*therapeutic use
MH  - Stroke/*prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
RF  - 41
EDAT- 2008/05/20 09:00
MHDA- 2008/11/01 09:00
CRDT- 2008/05/20 09:00
PHST- 2008/05/20 09:00 [pubmed]
PHST- 2008/11/01 09:00 [medline]
PHST- 2008/05/20 09:00 [entrez]
AID - 3161 [pii]
AID - 10.2165/00002018-200831060-00001 [doi]
PST - ppublish
SO  - Drug Saf. 2008;31(6):449-58. doi: 10.2165/00002018-200831060-00001.

PMID- 11157651
OWN - NLM
STAT- MEDLINE
DCOM- 20010405
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 119
IP  - 1 Suppl
DP  - 2001 Jan
TI  - Antithrombotic therapy in patients with mechanical and biological prosthetic 
      heart valves.
PG  - 220S-227S
AB  - 1. Permanent therapy with oral anticoagulants offers the most consistent 
      protection in patients with mechanical heart valves. 2. Antiplatelet agents alone 
      do not consistently protect patients with mechanical prosthetic heart valves, 
      including patients in sinus rhythm with St. Jude Medical valves in the aortic 
      position. 3. Levels of oral anticoagulants that prolong the INR to 2.0 to 3.0 
      appear satisfactory for patients with St. Jude Medical bileaflet and 
      Medtronic-Hall tilting disk mechanical valves in the aortic position, provided 
      they are in sinus rhythm and the left atrium is not enlarged. Presumably, this is 
      also true for the CarboMedics bileaflet valve, based on the observation of no 
      clinically important difference in the rate of systemic embolism with this valve 
      and the St. Jude Medical bileaflet valve. 4. Levels of oral anticoagulants that 
      prolong the INR to 2.5 to 3.5 are satisfactory for tilting disk valves and 
      bileaflet prosthetic valves in the mitral position. 5. Experience in patients 
      with caged ball valves who had prothrombin time ratios reported in terms of the 
      INR is sparse, because few such valves have been inserted in recent years. The 
      number of surviving patients with caged ball valves continues to decrease. It has 
      been suggested that the most advantageous level of the INR in patients with caged 
      ball or caged disk valves should be as high as 4.0 to 4.9. However, others have 
      shown a high rate of major hemorrhage with an INR that is even somewhat lower, 
      3.0-4.5. The problem is self-limited, however, because few such valves are being 
      inserted. 6. In patients with mechanical heart valves, aspirin, in addition to 
      oral anticoagulants, has been shown to diminish the frequency of thromboemboli. 
      The risk of bleeding is somewhat increased if the INR is 2.0 to 3.0 or 2.5 to 
      3.5. However, if the INR is 3.0 to 4.5, the risk of bleeding becomes excessive 
      with aspirin. There are no investigations in which aspirin 80 mg/d in combination 
      with oral anticoagulants was evaluated. 7. Data are insufficient to recommend 
      dipyridamole over low doses of aspirin in combination with warfarin. Whether 
      dipyridamole plus aspirin is more effective than aspirin alone when used with 
      warfarin is undetermined. 8. Patients with bioprosthetic valves in the mitral 
      position as well as patients with bioprosthetic valves in the aortic position may 
      be at risk for thromboemboli during the first 3 months after operation. 9. Among 
      patients with bioprosthetic valves in the mitral position, oral anticoagulants at 
      an INR of 2.0 to 2.3 were as effective as an INR of 2.5 to 4.0 and were 
      associated with fewer bleeding complications during the first 3 months after 
      operation.10. Aspirin may reduce the long-term frequency of thromboembolism in 
      patients with bioprosthetic valves.
FAU - Stein, P D
AU  - Stein PD
AD  - St Joseph Mercy-Oakland Hospital, Pointia, MI 48341-2964, USA. 
      steinp@trinity-health.org
FAU - Alpert, J S
AU  - Alpert JS
FAU - Bussey, H I
AU  - Bussey HI
FAU - Dalen, J E
AU  - Dalen JE
FAU - Turpie, A G
AU  - Turpie AG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Chest 2001 Sep;120(3):1044
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Bioprosthesis
MH  - Child
MH  - Dipyridamole/therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - *Heart Valve Prosthesis
MH  - Humans
RF  - 58
EDAT- 2001/02/07 11:00
MHDA- 2001/04/06 10:01
CRDT- 2001/02/07 11:00
PHST- 2001/02/07 11:00 [pubmed]
PHST- 2001/04/06 10:01 [medline]
PHST- 2001/02/07 11:00 [entrez]
AID - S0012-3692(15)60789-9 [pii]
AID - 10.1378/chest.119.1_suppl.220s [doi]
PST - ppublish
SO  - Chest. 2001 Jan;119(1 Suppl):220S-227S. doi: 10.1378/chest.119.1_suppl.220s.

PMID- 26603742
OWN - NLM
STAT- MEDLINE
DCOM- 20161031
LR  - 20220321
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Print)
IS  - 0925-4692 (Linking)
VI  - 24
IP  - 1
DP  - 2016 Feb
TI  - Efficacy of disintegrating aspirin in two different models for acute 
      mild-to-moderate pain: sore throat pain and dental pain.
PG  - 43-51
LID - 10.1007/s10787-015-0253-0 [doi]
AB  - A recently developed fast-release aspirin tablet formulation has been evaluated 
      in two different pain models. The dental impaction pain model and the sore throat 
      pain model are widely used for assessing analgesia, including acute 
      mild-to-moderate pain. Both studies were double-blind, randomized, parallel group 
      and compared a single dose of 1000 mg aspirin with 1000 mg paracetamol and with 
      placebo and investigated the onset and overall time course of pain relief. Speed 
      of onset was measured by the double-stopwatch method for time to meaningful pain 
      relief and time to first perceptible pain relief. Pain intensity and pain relief 
      were rated subjectively over a 6-h (dental pain) and 2-h (sore throat pain) time 
      period. In both models fast-release aspirin and commercial paracetamol were 
      statistically significantly different from placebo for onset of action, summed 
      pain intensity differences and total pain relief. Meaningful pain relief was 
      achieved within a median of 42.3 and 42.9 min for aspirin and paracetamol, 
      respectively, in the dental pain model. The corresponding numbers in sore throat 
      pain were 48.0 and 40.4 min. All treatments in both studies were safe and well 
      tolerated. No serious adverse events were reported and no subject was 
      discontinued due to an adverse event. Overall the two studies clearly 
      demonstrated efficacy over placebo in the two pain models and a comparable 
      efficacy and safety profile between aspirin and an equivalent dose of paracetamol 
      under the conditions of acute dental pain and acute sore throat pain. Trial 
      registration These trials were registered with ClinicalTrials.gov, registration 
      number: NCT01420094, registration date: July 27, 2011 and registration number: 
      NCT01453400, registration date: October 13, 2011.
FAU - Voelker, M
AU  - Voelker M
AD  - Bayer HealthCare, Leverkusen, Germany. michael.voelker@bayer.com.
FAU - Schachtel, B P
AU  - Schachtel BP
AD  - Schachtel Research Company, Jupiter, FL, USA.
FAU - Cooper, S A
AU  - Cooper SA
AD  - Clinical Trial Consultant, Palm Beach Gardens, FL, USA.
FAU - Gatoulis, S C
AU  - Gatoulis SC
AD  - Bayer HealthCare, Whippany, NJ, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01420094
SI  - ClinicalTrials.gov/NCT01453400
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20151124
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/adverse effects/therapeutic use
MH  - Acute Pain/*drug therapy/etiology
MH  - Adolescent
MH  - Analgesics, Non-Narcotic/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain Measurement
MH  - Pharyngitis/*drug therapy
MH  - Time Factors
MH  - Tooth, Impacted/complications
MH  - Toothache/*drug therapy
MH  - Young Adult
PMC - PMC4740515
OTO - NOTNLM
OT  - Acetaminophen
OT  - Acetylsalicylic acid
OT  - Acute pain
OT  - Aspirin
OT  - Dental pain
OT  - Onset of action
OT  - Pain model
OT  - Paracetamol
OT  - Sore throat pain
OT  - Stopwatch
EDAT- 2015/11/26 06:00
MHDA- 2016/11/01 06:00
CRDT- 2015/11/26 06:00
PHST- 2015/07/24 00:00 [received]
PHST- 2015/10/28 00:00 [accepted]
PHST- 2015/11/26 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - 10.1007/s10787-015-0253-0 [pii]
AID - 253 [pii]
AID - 10.1007/s10787-015-0253-0 [doi]
PST - ppublish
SO  - Inflammopharmacology. 2016 Feb;24(1):43-51. doi: 10.1007/s10787-015-0253-0. Epub 
      2015 Nov 24.

PMID- 7831677
OWN - NLM
STAT- MEDLINE
DCOM- 19950217
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 75
IP  - 6
DP  - 1994 Sep 15
TI  - In vitro model to test the thrombogenicity of coronary stents.
PG  - 581-90
AB  - Thrombotic occlusion is a major complication limiting the application of stents 
      in coronary arteries. In an in vitro model we investigated the thrombogenicity of 
      different stent materials and several medical regimens to prevent thrombotic 
      occlusion. Experiments were conducted in a closed system of silicon tubing with 
      circulating citrated platelet rich plasma of healthy volunteers (n = 7) and of 
      patients (n = 7 for each condition). Patients were either treated with 
      phenprocoumon or with high or low dose heparin in combination with aspirin alone 
      (100 mg) or aspirin (990 mg) plus dipyridamole (225 mg). After placement of 
      tantalum wire stents into the system platelet aggregates were visible after 13.5 
      +/- 3.0 min, and occlusion occurred after 15.0 +/- 3.5 min. Similarly, with 
      implanted stainless steel stents aggregation was seen after 13.0 +/- 3.5 min and 
      thrombosis occurred after 14.5 +/- 3.5 min (p < 0.001 vs control without stent). 
      Microscopic examination revealed combined platelet fibrin thrombi occluding the 
      lumen. Platelet components predominately covered stent wires, particularly at 
      crossing points. In all experiments high-dose heparin prevented platelet 
      aggregate formation and stent occlusion independently of additional aspirin or 
      aspirin plus dipyridamole; perfusion time > 60 min (p < 0.001 vs no heparin). 
      Low-dose heparin could not prevent clotting. With aspirin alone aggregates were 
      visible after 16.0 +/- 4.0 min and clotting occurred after 23.0 +/- 5.0 min. In 
      combination with dipyridamole aggregates were visible after 15.5 +/- 5.0 min and 
      clotting after 21.0 +/- 4.0 min (NS vs aspirin alone). Phenprocoumon prevented 
      platelet aggregate formation and stent occlusion; perfusion time > 60 
      min.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Beythien, C
AU  - Beythien C
AD  - Department of Cardiology, University Hospital Eppendorf, Hamburg, Germany.
FAU - Terres, W
AU  - Terres W
FAU - Hamm, C W
AU  - Hamm CW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Biocompatible Materials)
RN  - 12597-68-1 (Stainless Steel)
RN  - 6424HBN274 (Tantalum)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - Q08SIO485D (Phenprocoumon)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/pharmacology/therapeutic use
MH  - Biocompatible Materials
MH  - Coronary Thrombosis/*etiology/prevention & control
MH  - *Coronary Vessels
MH  - Dipyridamole/blood/pharmacology/therapeutic use
MH  - Heparin/blood/pharmacology/therapeutic use
MH  - Humans
MH  - Male
MH  - Partial Thromboplastin Time
MH  - Phenprocoumon/blood/pharmacology/therapeutic use
MH  - *Platelet Aggregation/drug effects
MH  - Prothrombin Time
MH  - Stainless Steel
MH  - Stents/*adverse effects
MH  - Tantalum
EDAT- 1994/09/15 00:00
MHDA- 1994/09/15 00:01
CRDT- 1994/09/15 00:00
PHST- 1994/09/15 00:00 [pubmed]
PHST- 1994/09/15 00:01 [medline]
PHST- 1994/09/15 00:00 [entrez]
AID - 0049-3848(94)90170-8 [pii]
AID - 10.1016/0049-3848(94)90170-8 [doi]
PST - ppublish
SO  - Thromb Res. 1994 Sep 15;75(6):581-90. doi: 10.1016/0049-3848(94)90170-8.

PMID- 3775571
OWN - NLM
STAT- MEDLINE
DCOM- 19861208
LR  - 20140912
IS  - 0256-9574 (Print)
VI  - 70
IP  - 10
DP  - 1986 Nov 8
TI  - The effect of aspirin and anti-ulcer drugs on gastric mucosal prostaglandin E.
PG  - 594-7
AB  - The effect of single doses of aspirin, cimetidine, ranitidine, sucralfate, 
      dextran, colloidal bismuth subcitrate, carbenoxolone and antacid on gastric 
      mucosal prostaglandin E (PGE) content was studied in normal subjects. Endoscopic 
      gastric specimens were taken from the body and antrum before and 90 minutes after 
      drug ingestion and the PGE content was measured by radio-immunoassay. There was 
      more PGE in the antrum than in the body (4.02 +/- 3.09 v. 2.80 +/- 2.31 ng PGE/mg 
      protein; P less than 0.001). Aspirin, sucralfate and antacid reduced the amount 
      of PGE in the antral mucosa (2.85 +/- 0.54-1.44 +/- 0.44; P less than 0.001; 3.04 
      +/- 1.01-1.94 +/- 0.74; P less than 0.03; and 5.06 +/- 0.91-3.54 +/- 0.73; P less 
      than 0.006; ng PGE/mg protein respectively). None of the drugs had any effect on 
      the levels measured in the body mucosa.
FAU - Roost, R
AU  - Roost R
FAU - Wright, J P
AU  - Wright JP
FAU - Young, G O
AU  - Young GO
FAU - Lipshitz, E M
AU  - Lipshitz EM
FAU - Klaff, L
AU  - Klaff L
FAU - Isaacs, S
AU  - Isaacs S
FAU - Marks, I N
AU  - Marks IN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Prostaglandins E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Ulcer Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Gastric Mucosa/*analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostaglandins E/*analysis
EDAT- 1986/11/08 00:00
MHDA- 1986/11/08 00:01
CRDT- 1986/11/08 00:00
PHST- 1986/11/08 00:00 [pubmed]
PHST- 1986/11/08 00:01 [medline]
PHST- 1986/11/08 00:00 [entrez]
PST - ppublish
SO  - S Afr Med J. 1986 Nov 8;70(10):594-7.

PMID- 21532216
OWN - NLM
STAT- MEDLINE
DCOM- 20110830
LR  - 20190606
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 50
IP  - 9
DP  - 2011
TI  - Low-dose aspirin delays gastric healing after Helicobacter pylori eradication.
PG  - 951-9
AB  - BACKGROUND AND AIM: Helicobacter pylori (H. pylori) and aspirin are the major 
      causes of gastric injury, and eradication of H. pylori can restore mucosal injury 
      such as gastric ulcer. The aim of the present study was to investigate the 
      effects of low-dose aspirin on the healing process, determined by endoscopic 
      features, after H. pylori eradication. METHODS: From 2001 to 2008, 12,887 
      patients underwent endoscopic examination at our hospital. From these, 100 
      patients with and 100 patients without H. pylori infection were analyzed to 
      identify the endoscopic features characteristic of H. pylori-infected stomach. 
      Based on these characteristic features, we observed the healing process of 89 
      patients not taking low-dose aspirin and 12 patients taking low-dose aspirin for 
      6 months, 1 year, and 5 years, which was successful in eradicating H. pylori. 
      RESULTS: Diffuse redness (DR) of the fundic mucosa was the characteristic feature 
      of H. pylori-infected stomach, whereas reddish streaks (RS) on the greater 
      curvature of the antrum was the characteristic finding in non-infected stomach. 
      In the no aspirin group, DR faded by 6 months and new expression of RS was 
      observed 1 year after H. pylori eradication. In contrast, in the aspirin group, 
      both fading of DR and the expression of RS were observed 5 years after 
      eradication. CONCLUSION: Low-dose aspirin delayed the early phase of the healing 
      process in the gastric mucosa after H. pylori eradication.
FAU - Furukawa, Maiko
AU  - Furukawa M
AD  - Aoyama Hospital, Tokyo Women's Medical University, Japan.
FAU - Fujita, Mikiko
AU  - Fujita M
FAU - Takinishi, Akira
AU  - Takinishi A
FAU - Misaka, Ryoichi
AU  - Misaka R
FAU - Nagahara, Hikaru
AU  - Nagahara H
LA  - eng
PT  - Journal Article
DEP - 20110501
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Female
MH  - Gastric Mucosa/*drug effects/*injuries/microbiology
MH  - Gastritis/pathology
MH  - Gastroscopy
MH  - Helicobacter Infections/*pathology
MH  - *Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Time Factors
MH  - Wound Healing/drug effects
EDAT- 2011/05/03 06:00
MHDA- 2011/08/31 06:00
CRDT- 2011/05/03 06:00
PHST- 2011/05/03 06:00 [entrez]
PHST- 2011/05/03 06:00 [pubmed]
PHST- 2011/08/31 06:00 [medline]
AID - JST.JSTAGE/internalmedicine/50.4778 [pii]
AID - 10.2169/internalmedicine.50.4778 [doi]
PST - ppublish
SO  - Intern Med. 2011;50(9):951-9. doi: 10.2169/internalmedicine.50.4778. Epub 2011 
      May 1.

PMID- 6974544
OWN - NLM
STAT- MEDLINE
DCOM- 19811118
LR  - 20131121
IS  - 0003-9780 (Print)
IS  - 0003-9780 (Linking)
VI  - 251
IP  - 2
DP  - 1981 Jun
TI  - The anti-inflammatory, analgesic and antipyretic activities of non-narcotic 
      analgesic drug mixtures in rats.
PG  - 237-54
AB  - The effects of non-narcotic analgesics have been examined, separately and in 
      admixture, on carrageenan-induced hind paw oedema and on yeast-induced 
      hyperalgesia and hyperthermia in adult rats. The efficacy of the drugs was 
      evaluated using the kinetics of drug-receptor interaction. In addition, the 
      hypothesis was tested that the anti-inflammatory, analgesic and antipyretic 
      activities of the drug mixtures used equal the addition of the activities of the 
      individual drugs and could be predicted from their intrinsic activities and 
      affinities. Dose-dependent inhibition of paw oedema, hyperalgesia and 
      hyperthermia was observed after oral administration of acetylsalicylic acid 
      (aspirin), paracetamol, phenacetin (60, 125, 250 and 500 mg.kg--1), and caffeine 
      (12.5, 25, 50 and 100 mg.kf--1). Over the dose-ranges used, the anti-inflammatory 
      activities of paracetamol, phenacetin and caffeine tended to be smaller than that 
      of aspirin. The dose producing a semi-maximal effect for caffeine was lower than 
      that for aspirin which in turn was comparable to that for paracetamol or 
      phenacetin. The analgesic activities of phenacetin and caffeine were classified 
      as stronger than that of aspirin, whereas the efficacy of paracetamol was 
      similar. Paracetamol and aspirin were comparable as antipyretics. The antipyretic 
      activity of phenacetin was higher but that of caffeine was lower than that of 
      aspirin. For caffeine the dose producing a semi-maximal effect was lower than 
      that of aspirin. Within the dose-ranges used, low doses of mixtures of aspirin 
      with either paracetamol, phenacetin or caffeine exhibited anti-inflammatory, 
      analgesic and antipyretic activities which were not different from the activities 
      expected on the basis of addition. Incidentally, at some of the higher dose 
      levels potentiation of the activity of the drugs was found. Low doses of the 
      triple combinations: aspirin + paracetamol + caffeine and aspirin + phenacetin + 
      caffeine showed anti-inflammatory and antipyretic activities which were not 
      different from those expected on the basis of addition, but the activities 
      observed with higher doses of these combinations indicated potentiation. It is 
      concluded that, in the rat, the anti-inflammatory, analgesic and antipyretic 
      activities of dual and triple combinations of aspirin, paracetamol, phenacetin 
      and caffeine at least equal the activities expected on the basis of addition.
FAU - Seegers, A J
AU  - Seegers AJ
FAU - Jager, L P
AU  - Jager LP
FAU - Zandberg, P
AU  - Zandberg P
FAU - van Noordwijk, J
AU  - van Noordwijk J
LA  - eng
PT  - Journal Article
PL  - Belgium
TA  - Arch Int Pharmacodyn Ther
JT  - Archives internationales de pharmacodynamie et de therapie
JID - 0405353
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - *Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/pharmacology
MH  - Caffeine/pharmacology
MH  - Drug Combinations
MH  - Female
MH  - Phenacetin/pharmacology
MH  - Rats
MH  - Time Factors
EDAT- 1981/06/01 00:00
MHDA- 1981/06/01 00:01
CRDT- 1981/06/01 00:00
PHST- 1981/06/01 00:00 [pubmed]
PHST- 1981/06/01 00:01 [medline]
PHST- 1981/06/01 00:00 [entrez]
PST - ppublish
SO  - Arch Int Pharmacodyn Ther. 1981 Jun;251(2):237-54.

PMID- 18695083
OWN - NLM
STAT- MEDLINE
DCOM- 20080904
LR  - 20131121
IS  - 1538-3679 (Electronic)
IS  - 0003-9926 (Linking)
VI  - 168
IP  - 15
DP  - 2008 Aug 11
TI  - Cost-effectiveness of proton pump inhibitor cotherapy in patients taking 
      long-term, low-dose aspirin for secondary cardiovascular prevention.
PG  - 1684-90; discussion 1691
LID - 10.1001/archinte.168.15.1684 [doi]
AB  - BACKGROUND: Patients with coronary heart disease (CHD) require long-term therapy 
      with low-dose aspirin (ASA). Although these patients are at increased risk for 
      upper gastrointestinal bleeding (UGIB) and proton pump inhibitor (PPI) cotherapy 
      may reduce such risk, it is not known whether lifelong PPI cotherapy is 
      cost-effective. METHODS: A Markov model was developed to compare lifelong therapy 
      with ASA alone vs therapy with ASA plus PPI in patients with CHD who are at least 
      50 years old. Base-case assumptions were (1) starting age, 65 years (range, 50-80 
      years); (2) UGIB risk category, average risk (range, average to 8-fold increased 
      risk); (3) PPI effectiveness (66% (range, 25%-75%); and (4) annual PPI cost, $250 
      (range, $250-$1400). RESULTS: In the base-case analysis, ASA plus PPI resulted in 
      fewer lifetime UGIB events (3.1% vs 9.5%) and UGIB-related deaths (0.4% vs 1.4%). 
      At over-the-counter (OTC) PPI cost, ASA plus PPI was cost-effective, with an 
      incremental cost-effectiveness ratio (ICER) of $40,090 per life-year saved (LYS). 
      Varying PPI effectiveness from 75% to 25% resulted in ICERs of $35,315 to $94,578 
      per LYS. Varying the starting age of the cohort from 80 to 50 years resulted in 
      ICERs of $16,887 to $79,955 per LYS. At prescription PPI cost, the ICER for 
      average-risk patients was over $100,000 per LYS across all modeled age groups and 
      assumptions of PPI effectiveness, but the ICER for high-risk patients was $10,433 
      to $51,505 per LYS. CONCLUSIONS: At OTC cost, PPI cotherapy is cost-effective in 
      average-risk patients taking low-dose ASA for secondary prevention. At 
      prescription cost, cotherapy is cost-effective for high-risk patients only.
FAU - Saini, Sameer D
AU  - Saini SD
AD  - Department of Internal Medicine, University of Michigan Medical School, 3912 
      Taubman Center, Ann Arbor, MI 48109-0362, USA. sdsaini@umich.edu
FAU - Schoenfeld, Philip
AU  - Schoenfeld P
FAU - Fendrick, A Mark
AU  - Fendrick AM
FAU - Scheiman, James
AU  - Scheiman J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*economics/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Coronary Disease/drug therapy
MH  - Cost-Benefit Analysis
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Markov Chains
MH  - Middle Aged
MH  - Models, Economic
MH  - Platelet Aggregation Inhibitors/*economics/therapeutic use
MH  - Proton Pump Inhibitors/*economics/therapeutic use
MH  - Risk Assessment
EDAT- 2008/08/13 09:00
MHDA- 2008/09/05 09:00
CRDT- 2008/08/13 09:00
PHST- 2008/08/13 09:00 [pubmed]
PHST- 2008/09/05 09:00 [medline]
PHST- 2008/08/13 09:00 [entrez]
AID - 168/15/1684 [pii]
AID - 10.1001/archinte.168.15.1684 [doi]
PST - ppublish
SO  - Arch Intern Med. 2008 Aug 11;168(15):1684-90; discussion 1691. doi: 
      10.1001/archinte.168.15.1684.

PMID- 9341993
OWN - NLM
STAT- MEDLINE
DCOM- 19971105
LR  - 20191102
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 130
IP  - 3
DP  - 1997 Sep
TI  - Effects of diaspirin-cross-linked hemoglobin (DCLHb) on local tissue oxygen 
      tension in striated skin muscle: an efficacy study in the hamster.
PG  - 328-38
AB  - Using the dorsal skin fold chamber model in the hamster, we analyzed local tissue 
      partial oxygen pressure (PO2) in the striated skin muscle under nonischemic and 
      postischemic conditions with a Clark-type multiwire oxygen surface electrode. 
      Hypervolemic infusion (500 mg x kg(-1) I.V.) or isovolemic exchange transfusion 
      (3.3 gm x kg(-1) I.V.; hematocrit 30%) with diaspirin-cross-linked hemoglobin 
      (DCLHb) resulted in a slight decrease of the mean value of the local tissue PO2 
      (mm Hg) 1 hour after administration. Concomitantly, the frequency distribution 
      curves of local tissue PO2 values were found to be more narrow (fewer values > 25 
      mm Hg and < 10 mm Hg). Resuscitation from severe hemorrhagic shock (bleeding of 
      33 ml x kg(-1) at 0.4 ml x min(-1)) with autologous blood (AuB), Dx-60, or DCLHb 
      led to an increase of mean tissue PO2 values by 4.2-fold (p < 0.05 versus Dx-60), 
      1.9-fold, and 3.7-fold (p < 0.05 versus Dx-60), respectively, 2 hours after 
      resuscitation. The reduction of tissue hypoxia (0-5 mm Hg) was significant only 
      in the AuB- and DCLHb-treated animals. This study indicates that DCLHb 
      effectively reverses tissue hypoxia after resuscitation from severe hemorrhagic 
      shock by inducing a more homogeneous distribution of the local tissue PO2 levels.
FAU - Nolte, D
AU  - Nolte D
AD  - Institute for Surgical Research, Klinikum Grosshadern, 
      Ludwig-Maximilians-University of Munich, Germany.
FAU - Steinhauser, P
AU  - Steinhauser P
FAU - Pickelmann, S
AU  - Pickelmann S
FAU - Berger, S
AU  - Berger S
FAU - Härtl, R
AU  - Härtl R
FAU - Messmer, K
AU  - Messmer K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Substitutes/*pharmacology
MH  - Blood Volume
MH  - Cricetinae
MH  - Exchange Transfusion, Whole Blood
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Muscle, Skeletal/drug effects/*metabolism
MH  - Oximetry
MH  - Oxygen/*metabolism
MH  - Resuscitation
MH  - Shock, Hemorrhagic/drug therapy
MH  - Skin/drug effects/*metabolism
EDAT- 1997/10/28 00:00
MHDA- 1997/10/28 00:01
CRDT- 1997/10/28 00:00
PHST- 1997/10/28 00:00 [pubmed]
PHST- 1997/10/28 00:01 [medline]
PHST- 1997/10/28 00:00 [entrez]
AID - S0022-2143(97)90028-7 [pii]
AID - 10.1016/s0022-2143(97)90028-7 [doi]
PST - ppublish
SO  - J Lab Clin Med. 1997 Sep;130(3):328-38. doi: 10.1016/s0022-2143(97)90028-7.

PMID- 9191666
OWN - NLM
STAT- MEDLINE
DCOM- 19970710
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 42
IP  - 5
DP  - 1997 May
TI  - Pulmonary hypertension and systemic vasoconstriction may offset the benefits of 
      acellular hemoglobin blood substitutes.
PG  - 847-54; discussion 854-6
AB  - OBJECTIVE: We tested the hypothesis that the pharmacologic properties of a small 
      volume of alpha alpha-cross-linked hemoglobin (alpha alpha Hb) could effectively 
      resuscitate pigs subjected to hemorrhage. METHODS: Fourteen pigs hemorrhaged to a 
      mean arterial pressure (MAP) of 40 mm Hg for 60 minutes were treated with a 
      4-mL/kg 2-minute infusion of 10 g/dL alpha alpha Hb or 7 g/dL human serum 
      albumin, an oncotically matched control solution. RESULTS: The removal of blood 
      (17 +/- 1.5 mL/kg) caused the typical physiologic responses to hemorrhagic 
      hypovolemia. Infusion of alpha alpha Hb restored mean arterial pressure and 
      coronary perfusion pressure, but cardiac output and mixed venous O2 saturation 
      did not improve significantly. Pulmonary arterial pressure and pulmonary vascular 
      resistance increased markedly and were higher than baseline levels after alpha 
      alpha Hb. Infusion of human serum albumin produced only minor hemodynamic 
      changes. Brain blood flow did improve to baseline values after alpha alpha Hb, 
      but was the only tissue to do so. In the human serum albumin group, superior 
      mesenteric artery blood flow recovered to baseline values, whereas brain blood 
      flow did not. Blood flows to other tissues were similar in both groups. 
      CONCLUSION: Small-volume infusion of alpha alpha Hb restored mean arterial 
      pressure and brain blood flow, but pulmonary hypertension and low peripheral 
      perfusion may offset benefits for trauma patients.
FAU - de Figueiredo, L F
AU  - de Figueiredo LF
AD  - Department of Cardiopneumology, INCOR, FMUSP, Universidade de São Paulo, Brazil.
FAU - Mathru, M
AU  - Mathru M
FAU - Solanki, D
AU  - Solanki D
FAU - Macdonald, V W
AU  - Macdonald VW
FAU - Hess, J
AU  - Hess J
FAU - Kramer, G C
AU  - Kramer GC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Albumins)
RN  - 0 (Hemoglobins)
RN  - 0 (hemoglobin XL99alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Albumins/therapeutic use
MH  - Animals
MH  - Aspirin/adverse effects/*analogs & derivatives
MH  - Cerebrovascular Circulation/drug effects
MH  - Constriction, Pathologic/chemically induced
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Female
MH  - Hemoglobins/*adverse effects
MH  - Hypertension, Pulmonary/*chemically induced
MH  - Pulmonary Wedge Pressure/drug effects
MH  - Shock, Hemorrhagic/*therapy
MH  - Splanchnic Circulation/drug effects
MH  - Swine
MH  - Vascular Resistance/drug effects
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - 10.1097/00005373-199705000-00015 [doi]
PST - ppublish
SO  - J Trauma. 1997 May;42(5):847-54; discussion 854-6. doi: 
      10.1097/00005373-199705000-00015.

PMID- 7094984
OWN - NLM
STAT- MEDLINE
DCOM- 19820917
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 22
IP  - 2
DP  - 1982
TI  - Gastric potential difference as a model in clinical pharmacology: assessment of 
      gastric mucosal response to aspirin.
PG  - 147-51
AB  - Gastric potential difference in 16 healthy subjects (GPD) was measured on three 
      different days to assess baseline variability. The effect of three different 
      doses of aspirin on PD in 19 additional subjects was determined. Several new 
      parameters are suggested for better description of the GPD changes following 
      ingestion of known gastric irritants. From these parameters, a Reiz Index (RI) 
      was calculated as a single term representing the extent and severity of the GPD 
      response to aspirin. One-way Anova followed by Scheffe comparisons showed 
      significant differences between the mean RI values resulting from the 
      administration of aspirin 250, 500 and 1000 mg.
FAU - Laule, H
AU  - Laule H
FAU - Lücker, P W
AU  - Lücker PW
FAU - Altmayer, P
AU  - Altmayer P
FAU - Eldon, M A
AU  - Eldon MA
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 660YQ98I10 (Potassium Chloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Electrodes
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Membrane Potentials/drug effects
MH  - Potassium Chloride
MH  - Time Factors
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1007/BF00542460 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1982;22(2):147-51. doi: 10.1007/BF00542460.

PMID- 19352331
OWN - NLM
STAT- MEDLINE
DCOM- 20090706
LR  - 20211020
IS  - 1759-5010 (Electronic)
IS  - 1759-5002 (Linking)
VI  - 6
IP  - 4
DP  - 2009 Apr
TI  - Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements.
PG  - 273-82
LID - 10.1038/nrcardio.2009.10 [doi]
AB  - Antiplatelet drug therapy has become one of the cornerstones of treatment for 
      patients with cardiovascular disease. Large clinical trials have shown that 
      antiplatelet medications have important clinical benefits and prevent adverse 
      outcomes in patients with coronary artery disease. Recurrent adverse 
      cardiovascular events still occur in a substantial proportion of patients on 
      standard dual antiplatelet therapy, however, which has been attributed to 
      nonresponsiveness to this treatment. Both pharmacological and pharmacokinetic 
      mechanisms are involved in variability in responsiveness to antiplatelet agents, 
      and include drug bioavailability, medication noncompliance, drug-drug 
      interactions, cytochrome P450 activity, and genetic polymorphisms. Numerous 
      observational studies have consistently shown an association between antiplatelet 
      drug nonresponsiveness and adverse clinical outcomes. However, these studies are 
      limited by varying antiplatelet drug dosing regimens, heterogeneous laboratory 
      assessments for ex vivo platelet function, and wide interindividual variation in 
      platelet responses. Only within the last 2 years have randomized clinical trials 
      indicated that increased dosing with antiplatelet drugs could reduce adverse 
      clinical outcomes. Nonetheless, large clinical trials with standardized 
      laboratory methods and well-defined protocols are needed that will definitively 
      determine the association between antiplatelet drug nonresponsiveness and 
      clinical events, and establish therapeutic strategies to overcome blunted 
      antiplatelet effects.
FAU - Sweeny, Joseph M
AU  - Sweeny JM
AD  - Mount Sinai Medical Center, One Gustave L Levy Place, New York, NY 10029, USA.
FAU - Gorog, Diana A
AU  - Gorog DA
FAU - Fuster, Valentin
AU  - Fuster V
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Nat Rev Cardiol
JT  - Nature reviews. Cardiology
JID - 101500075
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Clopidogrel
MH  - Drug Interactions
MH  - *Drug Resistance
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Medication Adherence
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/pharmacokinetics/*therapeutic use
MH  - *Platelet Function Tests
MH  - Polymorphism, Genetic
MH  - Predictive Value of Tests
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacokinetics/therapeutic use
MH  - Treatment Failure
RF  - 89
EDAT- 2009/04/09 09:00
MHDA- 2009/07/07 09:00
CRDT- 2009/04/09 09:00
PHST- 2009/04/09 09:00 [entrez]
PHST- 2009/04/09 09:00 [pubmed]
PHST- 2009/07/07 09:00 [medline]
AID - nrcardio.2009.10 [pii]
AID - 10.1038/nrcardio.2009.10 [doi]
PST - ppublish
SO  - Nat Rev Cardiol. 2009 Apr;6(4):273-82. doi: 10.1038/nrcardio.2009.10.

PMID- 17350884
OWN - NLM
STAT- MEDLINE
DCOM- 20071219
LR  - 20191210
IS  - 1386-1425 (Print)
IS  - 1386-1425 (Linking)
VI  - 68
IP  - 2
DP  - 2007 Oct
TI  - Derivative-ratio spectrophotometric method for the determination of ternary 
      mixture of aspirin, paracetamol and salicylic acid.
PG  - 275-8
AB  - A derivative spectrophotometric method was developed for the assay of a ternary 
      mixture of aspirin (ASP), paracetamol (PAR) and salicylic acid (SAL). The method 
      is based on the use of the first and second derivatives of the ratio spectra and 
      measurement at zero-crossing wavelengths. The ratio spectra were obtained by 
      dividing the absorption spectrum of the mixture by that of one of the components. 
      The concentration of the other components are then determined from their 
      respective calibration curves treated similarly. The described method was applied 
      for the determination of these combinations in synthetic mixtures and dosage 
      forms. The results obtained were accurate and precise.
FAU - El-Yazbi, Fawzi A
AU  - El-Yazbi FA
AD  - Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Beirut Arab 
      University, Lebanon.
FAU - Hammud, Hassan H
AU  - Hammud HH
FAU - Assi, Sulaf A
AU  - Assi SA
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20061124
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Aspirin/*analysis
MH  - Drug Combinations
MH  - Salicylic Acid/*analysis
MH  - Spectrophotometry/*methods
MH  - Spectrophotometry, Ultraviolet/methods
EDAT- 2007/03/14 09:00
MHDA- 2007/12/20 09:00
CRDT- 2007/03/14 09:00
PHST- 2006/06/14 00:00 [received]
PHST- 2006/10/30 00:00 [revised]
PHST- 2006/11/17 00:00 [accepted]
PHST- 2007/03/14 09:00 [pubmed]
PHST- 2007/12/20 09:00 [medline]
PHST- 2007/03/14 09:00 [entrez]
AID - S1386-1425(06)00694-9 [pii]
AID - 10.1016/j.saa.2006.11.027 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2007 Oct;68(2):275-8. doi: 
      10.1016/j.saa.2006.11.027. Epub 2006 Nov 24.

PMID- 21386092
OWN - NLM
STAT- MEDLINE
DCOM- 20110818
LR  - 20131121
IS  - 1941-7632 (Electronic)
IS  - 1941-7640 (Linking)
VI  - 4
IP  - 2
DP  - 2011 Apr 1
TI  - Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes 
      mellitus patients with coronary artery disease.
PG  - 180-7
LID - 10.1161/CIRCINTERVENTIONS.110.960187 [doi]
AB  - BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have reduced 
      aspirin-induced pharmacodynamic effects. This may be attributed to increased 
      platelet turnover rates resulting in an increased proportion of 
      non-aspirin-inhibited platelets during the daily dosing interval. The hypothesis 
      of this study was that an increase in the frequency of drug administration [twice 
      daily (bid) versus once daily (od)] may provide more effective platelet 
      inhibition in T2DM patients. METHODS AND RESULTS: T2DM patients with stable 
      coronary artery disease were prospectively recruited. Patients modified their 
      aspirin regimen on a weekly basis according to the following scheme: 81 mg/od, 81 
      mg/bid, 162 mg/od, 162 mg/bid, and 325 mg/od. Pharmacodynamic assessments 
      included light-transmittance aggregometry after arachidonic acid, collagen and 
      adenosine diphosphate stimuli; VerifyNow-Aspirin assay; and serum thromboxane 
      B(2) (TXB(2)) levels. Twenty patients were analyzed. All patients were sensitive 
      and compliant to aspirin irrespective of dose, as assessed by arachidonic 
      acid-induced aggregation. When aspirin was administered once daily, there was no 
      significant effect on platelet reactivity by increasing the once-daily dosing 
      using aspirin-sensitive assays (collagen-induced aggregation and 
      VerifyNow-Aspirin). An increase in aspirin dose by means of a second daily 
      administration was associated with a significant reduction in platelet reactivity 
      assessed by collagen-induced aggregation and VerifyNow-Aspirin between 81 mg/od 
      and 81 mg/bid (P<0.05 for both assays) and between 81 mg/od and 162 mg/bid 
      (P<0.05 for both assays). There was no impact of aspirin dosing regimens on 
      adenosine diphosphate-induced aggregation. A dose-dependent effect of aspirin was 
      observed on serum TXB(2) levels (P=0.003). CONCLUSIONS: Aspirin dosing regimens 
      are associated with different pharmacodynamic effects in platelets from T2DM 
      patients and stable coronary artery disease, with a twice-daily, low-dose aspirin 
      administration resulting in greater platelet inhibition than once-daily 
      administration as assessed by aspirin-sensitive assays and a dose-dependent 
      effect on serum TXB(2) levels. The clinical implications of a modified aspirin 
      regimen tailored to T2DM patients warrant further investigation. CLINICAL TRIAL 
      REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01201785.
CI  - © 2011 American Heart Association, Inc.
FAU - Capodanno, Davide
AU  - Capodanno D
AD  - University of Florida College of Medicine-Jacksonville, Jacksonville, FL 32209, 
      USA.
FAU - Patel, Aasita
AU  - Patel A
FAU - Dharmashankar, Kodlipet
AU  - Dharmashankar K
FAU - Ferreiro, José Luis
AU  - Ferreiro JL
FAU - Ueno, Masafumi
AU  - Ueno M
FAU - Kodali, Murali
AU  - Kodali M
FAU - Tomasello, Salvatore D
AU  - Tomasello SD
FAU - Capranzano, Piera
AU  - Capranzano P
FAU - Seecheran, Naveen
AU  - Seecheran N
FAU - Darlington, Andrew
AU  - Darlington A
FAU - Tello-Montoliu, Antonio
AU  - Tello-Montoliu A
FAU - Desai, Bhaloo
AU  - Desai B
FAU - Bass, Theodore A
AU  - Bass TA
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
LA  - eng
SI  - ClinicalTrials.gov/NCT01201785
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110308
PL  - United States
TA  - Circ Cardiovasc Interv
JT  - Circulation. Cardiovascular interventions
JID - 101499602
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circ Cardiovasc Interv. 2011 Apr 1;4(2):118-20. PMID: 21505165
CIN - Circ Cardiovasc Interv. 2011 Aug;4(4):e31; author reply e32. PMID: 21846893
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Coronary Artery Disease/*drug therapy
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Angiopathies/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Prospective Studies
MH  - Thromboxane B2/blood
EDAT- 2011/03/10 06:00
MHDA- 2011/08/19 06:00
CRDT- 2011/03/10 06:00
PHST- 2011/03/10 06:00 [entrez]
PHST- 2011/03/10 06:00 [pubmed]
PHST- 2011/08/19 06:00 [medline]
AID - CIRCINTERVENTIONS.110.960187 [pii]
AID - 10.1161/CIRCINTERVENTIONS.110.960187 [doi]
PST - ppublish
SO  - Circ Cardiovasc Interv. 2011 Apr 1;4(2):180-7. doi: 
      10.1161/CIRCINTERVENTIONS.110.960187. Epub 2011 Mar 8.

PMID- 12787905
OWN - NLM
STAT- MEDLINE
DCOM- 20030922
LR  - 20191210
IS  - 0926-2040 (Print)
IS  - 0926-2040 (Linking)
VI  - 23
IP  - 4
DP  - 2003 Jun
TI  - Spin-lattice relaxation of 13CH3 groups in 13C-enriched aspirin after proton 
      saturation.
PG  - 224-42
AB  - We studied the spin-lattice relaxation of the 13C magnetisation, M(C), in 
      13C-enriched single crystal of aspirin (only methyl carbons enriched to 99%) at 
      the carbon resonance frequency of 54.5 MHz. After the carbon saturation the 
      recovery appears exponential except below 30K, where it is biexponential due to 
      the presence of the level crossing omega(t)=omega(C)+omega(H) (the symbols refer, 
      respectively, to the tunnel frequency and the carbon and proton resonance 
      frequencies in angular units). After the saturation of the proton magnetisation, 
      M(H), the description of the M(C) recovery needs three exponentials. The 
      evaluation of the time constants is easiest from the data in this case, since 
      M(C) varies with time in an initial growth-subsequent decrease (or an initial 
      decrease-subsequent growth depending on temperature) manner, instead of the 
      monotonous growth after the carbon saturation. Experimental data agree 
      semiquantitatively with the predictions of our recent model. According to the 
      model the relaxation of M(C) is coupled to M(H) and the tunnel energy TE at 
      temperatures below the minimum of the 13C relaxation time. Sufficiently above 
      this minimum M(C) is coupled to M(H) and the rotational polarization (but not to 
      TE) in agreement with experiment. Also the effect of torsional oscillations of a 
      methyl group on the magnitude of various 13C-related transition rates was 
      considered in detail. In aspirin the rates are reduced roughly by 10% and the 
      reduction should become larger in samples with a larger tunnel splitting. The 
      reduction also changes somewhat the angular dependence of these rates.
FAU - Kankaanpää, M
AU  - Kankaanpää M
AD  - Wihuri Physical Laboratory, Department of Physics, Turku University, Turku 
      Yliopisto, FIN-20014, Finland. mikko.kankaanpaa@utu.fi
FAU - Ylinen, E E
AU  - Ylinen EE
FAU - Punkkinen, M
AU  - Punkkinen M
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Validation Study
PL  - Netherlands
TA  - Solid State Nucl Magn Reson
JT  - Solid state nuclear magnetic resonance
JID - 9306181
RN  - 0 (Carbon Isotopes)
RN  - 0 (Protons)
RN  - 0 (Spin Labels)
RN  - 7440-44-0 (Carbon)
RN  - 7YNJ3PO35Z (Hydrogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Carbon/chemistry
MH  - Carbon Isotopes
MH  - Computer Simulation
MH  - Hydrogen/chemistry
MH  - Magnetic Resonance Spectroscopy/*methods
MH  - *Models, Molecular
MH  - Protons
MH  - Sensitivity and Specificity
MH  - Spin Labels
EDAT- 2003/06/06 05:00
MHDA- 2003/09/23 05:00
CRDT- 2003/06/06 05:00
PHST- 2003/06/06 05:00 [pubmed]
PHST- 2003/09/23 05:00 [medline]
PHST- 2003/06/06 05:00 [entrez]
AID - S0926-2040(03)00014-6 [pii]
AID - 10.1016/S0926-2040(03)00014-6 [doi]
PST - ppublish
SO  - Solid State Nucl Magn Reson. 2003 Jun;23(4):224-42. doi: 
      10.1016/S0926-2040(03)00014-6.

PMID- 12561950
OWN - NLM
STAT- MEDLINE
DCOM- 20030303
LR  - 20131121
IS  - 0019-5189 (Print)
IS  - 0019-5189 (Linking)
VI  - 38
IP  - 9
DP  - 2000 Sep
TI  - Effect of aspirin on blood-lipid interaction and lipid peroxidation phenomena in 
      relation to partition coefficient and biological activity.
PG  - 912-5
AB  - Considering the lipophilicity of aspirin (log P = -1.15), a significant 
      contributor to its action mechanism, interaction of the drug with the whole 
      lipids of goat blood have been investigated using phospholipid binding and lipid 
      peroxidation phenomena as the parameters under investigation. The lipid content 
      change along with the peroxidation induced by aspirin and its suppression with 
      ascorbic acid had been quantitatively measured. Significant loss in phospholipid 
      was observed after incubation of whole blood with aspirin in varying periods of 
      time. This may be ascribed to binding affinity of aspirin with lipid constituents 
      in blood, which may have potential role in its therapeutic effect. Lipid 
      peroxidation induction potential of aspirin caused significant extent of 
      peroxidation. Ascorbic acid, an antioxidant could significantly reduce aspirin 
      induced lipid peroxidation.
FAU - Saha, A
AU  - Saha A
AD  - Department of Chemical Technology, University Calcutta, 92, A P C Road, Calcutta 
      700 009, India.
FAU - De, A U
AU  - De AU
FAU - Sengupta, C
AU  - Sengupta C
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Exp Biol
JT  - Indian journal of experimental biology
JID - 0233411
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Fatty Acids)
RN  - 0 (Lipids)
RN  - 27YLU75U4W (Phosphorus)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Fatty Acids/blood
MH  - Goats
MH  - Lipid Peroxidation/*drug effects
MH  - Lipids/*blood
MH  - Phosphorus/analysis
EDAT- 2003/02/04 04:00
MHDA- 2003/03/04 04:00
CRDT- 2003/02/04 04:00
PHST- 2003/02/04 04:00 [pubmed]
PHST- 2003/03/04 04:00 [medline]
PHST- 2003/02/04 04:00 [entrez]
PST - ppublish
SO  - Indian J Exp Biol. 2000 Sep;38(9):912-5.

PMID- 31432979
OWN - NLM
STAT- MEDLINE
DCOM- 20200413
LR  - 20200413
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Print)
IS  - 0066-782X (Linking)
VI  - 113
IP  - 3
DP  - 2019
TI  - High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St 
      Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late 
      Phases.
PG  - 357-363
LID - 10.5935/abc.20190146 [doi]
AB  - BACKGROUND: High platelet reactivity (HPR) during therapy with acetylsalicylic 
      acid (ASA) is a poor prognostic factor in acute coronary syndromes (ACS). The 
      prevalence of HPR during ACS is greater than that reported in stable diseases. 
      However, it is unclear whether this prevalence of HPR is a transient phenomenon 
      or a characteristic of this high-risk population. OBJECTIVE: The main objective 
      is to compare the effects of ASA on platelet function in the initial and late 
      phases of ACS in a single population. Secondary objectives are: correlation 
      between the tests between themselves and the relationship between the tests and 
      the variation of the inflammatory markers (C-reactive protein and interleukin-6). 
      METHODS: Seventy patients with non-ST segment elevation (NSTE) ACS in use of 
      100-200 mg of ASA per day for at least 7 days were prospectively studied. 
      Platelet function was assessed in the first 48 hours and subsequently after 3 
      months using four methods: VerifyNow™ (VFN), whole blood platelet aggregation 
      (WBPA) with arachidonic acid (AA) and collagen as agonists, and platelet function 
      analyzer (PFA). The level of statistical significance considered was < 0.05. 
      RESULTS: According to the more specific methods (WBPA with AA and VFN), the 
      incidence of HPR was significantly higher in the early phase than in the late 
      phase: WBPA with AA: 31% versus 13%, p = 0.015; VFN: 32% versus 16%, p = 0.049. 
      The other methods tested, which were less specific for ASA, did not show 
      significant differences between phases. The correlation between the methods was 
      weak or moderate (r ranging from 0.3 to 0.5, p < 0.05), and there were no 
      significant associations between HPR and inflammatory markers. CONCLUSION: The 
      prevalence of HPR during AAS therapy, assessed by specific methods for 
      cyclooxygenase 1 (COX-1), is higher during the acute phase than in the late phase 
      of NSTE ACS.
FAU - Dracoulakis, Marianna Deway Andrade
AU  - Dracoulakis MDA
AUID- ORCID: 0000-0001-5521-5955
AD  - Hospital da Bahia - Instituto de Ensino e Pesquisa, Salvador, BA - Brazil.
FAU - Gurbel, Paul
AU  - Gurbel P
AD  - Sinai Hospital of Baltimore - Sinai Center for Thrombosis Research, Baltimore - 
      EUA.
FAU - Cattaneo, Marco
AU  - Cattaneo M
AD  - Universita Degli Studi Di Milano - Unita di Medicina III, Milão - Itália.
FAU - Martins, Herlon Saraiva
AU  - Martins HS
AD  - Universidade de São Paulo - Faculdade de Medicina Hospital das Clínicas, São 
      Paulo, SP - Brazil.
FAU - Nicolau, José Carlos
AU  - Nicolau JC
AUID- ORCID: 0000-0002-9680-3689
AD  - Universidade de São Paulo - Faculdade de Medicina Hospital das Clínicas, São 
      Paulo, SP - Brazil.
FAU - Kalil Filho, Roberto
AU  - Kalil Filho R
AD  - Universidade de São Paulo - Faculdade de Medicina Hospital das Clínicas, São 
      Paulo, SP - Brazil.
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20190815
PL  - Brazil
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arq Bras Cardiol. 2019 Oct 10;113(3):364-366. PMID: 31621775
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelet Disorders/drug therapy
MH  - Blood Platelets/*drug effects/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Non-ST Elevated Myocardial Infarction/physiopathology
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC6882399
COIS- Potential Conflict of Interest No potential conflict of interest relevant to this 
      article was reported.
EDAT- 2019/08/23 06:00
MHDA- 2020/04/14 06:00
CRDT- 2019/08/22 06:00
PHST- 2018/07/31 00:00 [received]
PHST- 2018/12/19 00:00 [accepted]
PHST- 2019/08/23 06:00 [pubmed]
PHST- 2020/04/14 06:00 [medline]
PHST- 2019/08/22 06:00 [entrez]
AID - S0066-782X2019005014103 [pii]
AID - 10.5935/abc.20190146 [doi]
PST - epublish
SO  - Arq Bras Cardiol. 2019 Aug 15;113(3):357-363. doi: 10.5935/abc.20190146. 
      eCollection 2019.

PMID- 25177792
OWN - NLM
STAT- MEDLINE
DCOM- 20141016
LR  - 20191113
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 54
IP  - 4
DP  - 2014
TI  - [Antiplatelet therapy in atherosclerosis of various localizations: acute and 
      stable States].
PG  - 96-108
AB  - We present in this review current data on specificities of efficacy and safety of 
      antiplatelet therapy in patients with atherosclerosis of various localizations. 
      Reduced priority of aspirin monotherapy in several clinical situations is shown. 
      Controversial issues of the use of dual antiplatelet therapy including its 
      application in patients with acute coronary syndrome are discussed. Novel groups 
      of antiplatelet agents as well as individual new drugs are also presented.
FAU - Koziolova, N A
AU  - Koziolova NA
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acute Coronary Syndrome/etiology/prevention & control
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Atherosclerosis/complications/drug therapy
MH  - Drug Therapy, Combination
MH  - Drug-Related Side Effects and Adverse Reactions/*prevention & control
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/classification/pharmacology/therapeutic use
MH  - Risk Adjustment
MH  - Ticlopidine/pharmacology/therapeutic use
MH  - Treatment Outcome
EDAT- 2014/09/02 06:00
MHDA- 2014/10/17 06:00
CRDT- 2014/09/02 06:00
PHST- 2014/09/02 06:00 [entrez]
PHST- 2014/09/02 06:00 [pubmed]
PHST- 2014/10/17 06:00 [medline]
AID - 10.18565/cardio.2014.4.96-108 [doi]
PST - ppublish
SO  - Kardiologiia. 2014;54(4):96-108. doi: 10.18565/cardio.2014.4.96-108.

PMID- 6991535
OWN - NLM
STAT- MEDLINE
DCOM- 19800815
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 20
IP  - 2-3
DP  - 1980 Feb-Mar
TI  - Pirprofen and aspirin in rheumatoid arthritis: a double-blind comparison study.
PG  - 145-50
AB  - A six-month, double-blind study was conducted to compare pirprofen (Rengasil), 
      800 mg per day, to aspirin, 3.6 Gm per day, in patients with active, definite, or 
      classical rheumatoid arthritis. Data from 33 patients, 17 in the pirprofen group 
      and 16 in the aspirin group, were analyzed for efficacy while data from 37 
      patients were analyzed for safety. In the pirprofen group, four of seven 
      variables analyzed were significantly improved over baseline at the terminal 
      visit; no statistically significant improvement was seen at the terminal visit in 
      the aspirin group, although statistically significant improvement was achieved at 
      a number of interim visits. Between-treatment comparisons indicated that 
      pirprofen was statistically superior to aspirin with respect to the number of 
      swollen joints at the terminal visit and average grip strength after six weeks of 
      treatment. There were no serious signs of toxicity in either treatment group.
FAU - Reid, R T
AU  - Reid RT
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyrroles)
RN  - R16CO5Y76E (Aspirin)
RN  - T7KN291890 (pirprofen)
SB  - IM
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Sedimentation
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenylpropionates/adverse effects/*therapeutic use
MH  - Pyrroles/adverse effects/therapeutic use
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1980.tb02536.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1980 Feb-Mar;20(2-3):145-50. doi: 
      10.1002/j.1552-4604.1980.tb02536.x.

PMID- 14686686
OWN - NLM
STAT- MEDLINE
DCOM- 20040415
LR  - 20190906
IS  - 0891-1150 (Print)
IS  - 0891-1150 (Linking)
VI  - 70
IP  - 12
DP  - 2003 Dec
TI  - Who should be taking aspirin to prevent coronary events?
PG  - 1076-80
AB  - The decision to prescribe aspirin to prevent a coronary event is not 
      straightforward, and requires physicians to balance the risk of a coronary event 
      with the risk of adverse events from aspirin. Although evidence-based medicine 
      shows the way, it does not answer all the questions, especially for patients at 
      intermediate risk.
FAU - Lauer, Michael S
AU  - Lauer MS
AD  - Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, 
      USA. lauerm@ccf.org
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cleve Clin J Med
JT  - Cleveland Clinic journal of medicine
JID - 8703441
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Algorithms
MH  - Aspirin/*therapeutic use
MH  - Contraindications
MH  - Coronary Disease/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Fitness
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2003/12/23 05:00
MHDA- 2004/04/16 05:00
CRDT- 2003/12/23 05:00
PHST- 2003/12/23 05:00 [pubmed]
PHST- 2004/04/16 05:00 [medline]
PHST- 2003/12/23 05:00 [entrez]
AID - 10.3949/ccjm.70.12.1076 [doi]
PST - ppublish
SO  - Cleve Clin J Med. 2003 Dec;70(12):1076-80. doi: 10.3949/ccjm.70.12.1076.

PMID- 5303551
OWN - NLM
STAT- MEDLINE
DCOM- 19690125
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 4
IP  - 5632
DP  - 1968 Dec 14
TI  - Alcohol, aspirin, and gastrointestinal bleeding.
PG  - 664-5
AB  - In 20 healthy male subjects faecal blood loss was measured by means of a 
      chromium-51-labelled red blood cell technique. Mean daily faecal blood loss 
      associated with unbuffered aspirin ingestion was significantly increased by 
      alcohol in the 13 subjects studied. In seven others alcohol alone did not cause 
      gastrointestinal bleeding. These findings suggest that alcohol may accentuate 
      gastrointestinal blood loss associated with unbuffered aspirin ingestion.
FAU - Goulston, K
AU  - Goulston K
FAU - Cooke, A R
AU  - Cooke AR
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Chromium Isotopes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Alcoholic Intoxication
MH  - Aspirin/*adverse effects
MH  - Chromium Isotopes
MH  - Feces/analysis
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
PMC - PMC1912769
EDAT- 1968/12/14 00:00
MHDA- 1968/12/14 00:01
CRDT- 1968/12/14 00:00
PHST- 1968/12/14 00:00 [pubmed]
PHST- 1968/12/14 00:01 [medline]
PHST- 1968/12/14 00:00 [entrez]
AID - 10.1136/bmj.4.5632.664 [doi]
PST - ppublish
SO  - Br Med J. 1968 Dec 14;4(5632):664-5. doi: 10.1136/bmj.4.5632.664.

PMID- 2459763
OWN - NLM
STAT- MEDLINE
DCOM- 19881123
LR  - 20160726
IS  - 0258-7661 (Print)
IS  - 0258-7661 (Linking)
VI  - 139
IP  - 5
DP  - 1988
TI  - [Value and limits of antiplatelet agents in cerebral ischemic pathology].
PG  - 11-25
AB  - The authors have reviewed the role of platelets in thromboembolic strokes, the 
      effects of usual antiplatelet drugs on haemostasis and the new approaches to the 
      prevention of thrombosis. Critical analysis of controlled clinical trials 
      indicates only aspirin use showed evidence of effectiveness in prevention of 
      transient ischemic attacks or minor strokes related to atherosclerosis.
FAU - Milandre, L
AU  - Milandre L
AD  - Clinique Neurologique, CHU Timone, Marseille.
FAU - Bonnefoi, B
AU  - Bonnefoi B
FAU - Aillaud, M F
AU  - Aillaud MF
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Intérêts et limites des agents antiplaquettaires en pathologie ischémique 
      cérébrale.
PL  - Switzerland
TA  - Schweiz Arch Neurol Psychiatr (1985)
JT  - Schweizer Archiv fur Neurologie und Psychiatrie (Zurich, Switzerland : 1985)
JID - 8503709
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Humans
MH  - Intracranial Embolism and Thrombosis/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 65
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Schweiz Arch Neurol Psychiatr (1985). 1988;139(5):11-25.

PMID- 9758259
OWN - NLM
STAT- MEDLINE
DCOM- 19981203
LR  - 20190816
IS  - 0301-2115 (Print)
IS  - 0301-2115 (Linking)
VI  - 80
IP  - 1
DP  - 1998 Sep
TI  - Low-molecular-weight heparin combined with aspirin in pregnant women with 
      thrombophilia and a history of preeclampsia or fetal growth restriction: a 
      preliminary study.
PG  - 49-54
AB  - OBJECTIVE: To assess the prevalence of haemostatic abnormalities in patients with 
      an obstetric history of preeclampsia and/or fetal growth restriction and 
      documented thrombophilia, and to evaluate the effects of low-molecular-weight 
      heparin (LMWH) and aspirin on pregnancy outcome. METHOD: A total of 276 patients 
      with a history of preeclampsia and/or fetal growth restriction were tested for 
      the presence of coagulation abnormalities and anticardiolipin antibodies (ACA). 
      Ninety patients with preeclampsia and 15 patients with isolated fetal growth 
      restriction had haemostatic abnormalities. Twenty-six patients with coagulation 
      abnormalities: protein S-deficiency, activated protein C (APC) resistance and/or 
      > or =15 ACA GPL and/or MPL had a subsequent pregnancy and were treated with 
      aspirin in combination with LMWH. Their pregnancy outcome was compared with all 
      patients having a subsequent pregnancy from the same cohort without 
      abnormalities, or <15 ACA GPL and/or MPL who received aspirin (n=19). RESULTS: In 
      subsequent pregnancies birth weight of babies born to patients with an 
      unequivocal coagulation abnormality (i.e., protein S-deficiency, APC resistance, 
      or ACA titres > or =15 GPL and/or MPL), were higher than in the group with no 
      disorders or <15 ACA GPL and/or MPL (P=0.019). CONCLUSIONS: In this preliminary 
      study, LMWH appears to have a favourable effect on the pregnancy outcome of women 
      with a history of preeclampsia and/or fetal growth restriction and documented 
      thrombophilia. Randomised trials are required.
FAU - Riyazi, N
AU  - Riyazi N
AD  - Department of Obstetrics and Gynecology, Free University Hospital, Amsterdam, The 
      Netherlands.
FAU - Leeda, M
AU  - Leeda M
FAU - de Vries, J I
AU  - de Vries JI
FAU - Huijgens, P C
AU  - Huijgens PC
FAU - van Geijn, H P
AU  - van Geijn HP
FAU - Dekker, G A
AU  - Dekker GA
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fetal Growth Retardation/*complications
MH  - Gestational Age
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Pre-Eclampsia/*complications/prevention & control
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - *Pregnancy Complications, Hematologic/drug therapy
MH  - Recurrence
MH  - Thrombophilia/*complications/drug therapy
EDAT- 1998/10/03 00:00
MHDA- 1998/10/03 00:01
CRDT- 1998/10/03 00:00
PHST- 1998/10/03 00:00 [pubmed]
PHST- 1998/10/03 00:01 [medline]
PHST- 1998/10/03 00:00 [entrez]
AID - S0301211598000839 [pii]
AID - 10.1016/s0301-2115(98)00083-9 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 1998 Sep;80(1):49-54. doi: 
      10.1016/s0301-2115(98)00083-9.

PMID- 32924644
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20220419
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 22
IP  - 1
DP  - 2021 Jan
TI  - Aspirin for primary prevention of cardiovascular disease: a review of recent 
      literature and updated guideline recommendations.
PG  - 83-91
LID - 10.1080/14656566.2020.1817389 [doi]
AB  - INTRODUCTION: Recent clinical trials evaluating the efficacy of aspirin in 
      primary prevention of atherosclerotic cardiovascular disease (ASCVD) have 
      suggested the risk of aspirin may outweigh its benefit in individuals once 
      thought to be candidates for aspirin therapy. These results led to the 
      publication of updated guideline recommendations in 2019 for aspirin use in 
      primary prevention of cardiovascular disease from the American College of 
      Cardiology (ACC) and American Heart Association (AHA). AREAS COVERED: Recent 
      clinical trials and guidelines relevant to aspirin for primary prevention of 
      ASCVD were identified using PubMed® (July 1, 2016 to April 1, 2019). Studies were 
      limited to randomized, controlled clinical trials. The most current clinical 
      practice guidelines were prioritized. EXPERT OPINION: Recent clinical trials 
      demonstrated an increased risk of bleeding associated with aspirin use, which 
      often outweighed cardiovascular risk reduction. In light of this new evidence, 
      the ACC/AHA guidelines recommend aspirin for primary prevention in patients 
      40-70 years of age at a high ASCVD risk and low bleeding risk, who are unable to 
      optimally control modifiable ASCVD risk factors.
FAU - Mogul, Amanda
AU  - Mogul A
AUID- ORCID: 0000-0001-9107-466X
AD  - Department of Pharmacy Practice, Binghamton University School of Pharmacy and 
      Pharmaceutical Sciences , Binghamton, NY, USA.
FAU - Leppien, Emily E
AU  - Leppien EE
AD  - Department of Pharmacy Practice, Binghamton University School of Pharmacy and 
      Pharmaceutical Sciences , Binghamton, NY, USA.
FAU - Laughlin, Elizabeth
AU  - Laughlin E
AD  - Department of Pharmacy Practice, Binghamton University School of Pharmacy and 
      Pharmaceutical Sciences , Binghamton, NY, USA.
FAU - Spinler, Sarah A
AU  - Spinler SA
AD  - Department of Pharmacy Practice, Binghamton University School of Pharmacy and 
      Pharmaceutical Sciences , Binghamton, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200914
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - American Heart Association
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Middle Aged
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Risk Reduction Behavior
MH  - United States
OTO - NOTNLM
OT  - Aspirin
OT  - cardiovascular disease
OT  - guidelines
OT  - myocardial infarction
OT  - primary prevention
OT  - stroke
EDAT- 2020/09/15 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/09/14 15:38
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/09/14 15:38 [entrez]
AID - 10.1080/14656566.2020.1817389 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2021 Jan;22(1):83-91. doi: 
      10.1080/14656566.2020.1817389. Epub 2020 Sep 14.

PMID- 25337618
OWN - NLM
STAT- MEDLINE
DCOM- 20151102
LR  - 20191027
IS  - 1522-7243 (Electronic)
IS  - 1522-7235 (Linking)
VI  - 29
IP  - 6
DP  - 2014 Sep
TI  - Flow-injection chemiluminescence determination of acetylsalicylic acid based on 
      its enhancing effect on the lucigenin–hydrogen peroxide system.
PG  - 684-8
AB  - A sensitive flow-injection chemiluminescence method for the determination of 
      acetylsalicylic acid is described. It is based on the enhanced chemiluminescent 
      emission of the alkaline lucigenin–H2O2 system by acetylsalicylic acid. The 
      difference in chemiluminescent intensity of alkaline lucigenin–H2O2 in the 
      presence of acetylsalicylic acid from that in the absence of acetylsalicylic acid 
      was linear at acetylsalicylic acid concentrations in the range of 0.0029–47.37 
      μg/mL, with detection and quantification limits of 0.0011 and 0.0029 μg/mL, 
      respectively. The correlation coefficient of the working curve was 0.9983. The 
      relative standard deviation (n = 10) for 25 μg/mL acetylsalicylic acid is 1.95%. 
      All experimental parameters were optimized. The method was successfully applied 
      to the determination of acetylsalicylic acid in pharmaceutical preparations. The 
      recovery results obtained by the method were satisfactory.
FAU - Wabaidur, S M
AU  - Wabaidur SM
FAU - Alam, S M
AU  - Alam SM
FAU - Alothmana, Z A
AU  - Alothmana ZA
FAU - Eldesokya, Gaber
AU  - Eldesokya G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Luminescence
JT  - Luminescence : the journal of biological and chemical luminescence
JID - 100889025
RN  - 0 (Acridines)
RN  - 2315-97-1 (10,10'-dimethyl-9,9'-biacridinium)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acridines/*chemistry
MH  - Aspirin/*analysis
MH  - *Flow Injection Analysis/instrumentation
MH  - Hydrogen Peroxide/*chemistry
MH  - Kinetics
MH  - *Luminescence
MH  - Molecular Structure
EDAT- 2014/10/23 06:00
MHDA- 2015/11/03 06:00
CRDT- 2014/10/23 06:00
PHST- 2014/10/23 06:00 [entrez]
PHST- 2014/10/23 06:00 [pubmed]
PHST- 2015/11/03 06:00 [medline]
AID - 10.1002/bio.2609 [doi]
PST - ppublish
SO  - Luminescence. 2014 Sep;29(6):684-8. doi: 10.1002/bio.2609.

PMID- 23023375
OWN - NLM
STAT- MEDLINE
DCOM- 20130129
LR  - 20141120
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
VI  - 32
IP  - 12
DP  - 2012 Dec
TI  - Hydrogen sulfide-releasing aspirin derivative ACS14 exerts strong antithrombotic 
      effects in vitro and in vivo.
PG  - 2884-91
LID - 10.1161/ATVBAHA.112.300627 [doi]
AB  - OBJECTIVE: Hydrogen sulfide (H(2)S)-releasing NSAIDs exert potent 
      anti-inflammatory effects beyond classical cyclooxygenase inhibition. Here, we 
      compared the platelet inhibitory effects of the H(2)S-releasing aspirin 
      derivative ACS14 with its mother compound aspirin to analyze additional effects 
      on platelets. METHODS AND RESULTS: In platelets of mice fed with ACS14 for 6 days 
      (50 mg/kg per day), not only arachidonic acid-induced platelet aggregation but 
      also ADP-dependent aggregation was decreased, an effect that was not observed 
      with an equimolar dose of aspirin (23 mg/kg per day). ACS14 led to a 
      significantly longer arterial occlusion time after light-dye-induced endothelial 
      injury as well as decreased thrombus formation after ferric chloride-induced 
      injury in the carotid artery. Bleeding time was not prolonged compared with 
      animals treated with equimolar doses of aspirin. In vitro, in human whole blood, 
      ACS14 (25-500 µmol/L) inhibited arachidonic acid-induced platelet aggregation, 
      but compared with aspirin additionally reduced thrombin receptor-activating 
      peptide-, ADP-, and collagen-dependent aggregation. In washed human platelets, 
      ACS14 (500 µmol/L) attenuated αIIbβ3 integrin activation and fibrinogen binding 
      and increased intracellular cAMP levels and cAMP-dependent vasodilator-stimulated 
      phosphoprotein (VASP) phosphorylation. CONCLUSIONS: The H(2)S-releasing aspirin 
      derivative ACS14 exerts strong antiaggregatory effects by impairing the 
      activation of the fibrinogen receptor by mechanisms involving increased 
      intracellular cyclic nucleotides. These additional antithrombotic properties 
      result in a more efficient inhibition of thrombus formation in vivo as achieved 
      with aspirin alone.
FAU - Pircher, Joachim
AU  - Pircher J
AD  - Medizinische Klinik und Poliklinik IV, Klinikum der LMU, München, Germany. 
      joachim.pircher@med.uni-muenchen.de
FAU - Fochler, Franziska
AU  - Fochler F
FAU - Czermak, Thomas
AU  - Czermak T
FAU - Mannell, Hanna
AU  - Mannell H
FAU - Kraemer, Bjoern F
AU  - Kraemer BF
FAU - Wörnle, Markus
AU  - Wörnle M
FAU - Sparatore, Anna
AU  - Sparatore A
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Pohl, Ulrich
AU  - Pohl U
FAU - Krötz, Florian
AU  - Krötz F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120927
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 0 (2-acetyloxybenzoic acid 4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl ester)
RN  - 0 (Disulfides)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Integrins)
RN  - E0399OZS9N (Cyclic AMP)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/*metabolism/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects/metabolism
MH  - Cyclic AMP/metabolism
MH  - Disulfides/pharmacology
MH  - Fibrinolytic Agents/*pharmacology
MH  - Humans
MH  - Hydrogen Sulfide/*metabolism
MH  - In Vitro Techniques
MH  - Integrins/drug effects/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Models, Animal
MH  - Platelet Activation/drug effects/physiology
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Prostaglandin-Endoperoxide Synthases/drug effects/metabolism
MH  - Thrombosis/metabolism/prevention & control
EDAT- 2012/10/02 06:00
MHDA- 2013/01/30 06:00
CRDT- 2012/10/02 06:00
PHST- 2012/10/02 06:00 [entrez]
PHST- 2012/10/02 06:00 [pubmed]
PHST- 2013/01/30 06:00 [medline]
AID - ATVBAHA.112.300627 [pii]
AID - 10.1161/ATVBAHA.112.300627 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2884-91. doi: 
      10.1161/ATVBAHA.112.300627. Epub 2012 Sep 27.

PMID- 36228639
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20230301
IS  - 2213-2619 (Electronic)
IS  - 2213-2600 (Print)
IS  - 2213-2600 (Linking)
VI  - 10
IP  - 12
DP  - 2022 Dec
TI  - Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, 
      factorial, randomised, controlled trial.
PG  - 1160-1168
LID - S2213-2600(22)00299-5 [pii]
LID - 10.1016/S2213-2600(22)00299-5 [doi]
AB  - BACKGROUND: The large number of patients worldwide infected with the SARS-CoV-2 
      virus has overwhelmed health-care systems globally. The Anti-Coronavirus 
      Therapies (ACT) outpatient trial aimed to evaluate anti-inflammatory therapy with 
      colchicine and antithrombotic therapy with aspirin for prevention of disease 
      progression in community patients with COVID-19. METHODS: The ACT outpatient, 
      open-label, 2 × 2 factorial, randomised, controlled trial, was done at 48 
      clinical sites in 11 countries. Patients in the community aged 30 years and older 
      with symptomatic, laboratory confirmed COVID-19 who were within 7 days of 
      diagnosis and at high risk of disease progression were randomly assigned (1:1) to 
      receive colchicine 0·6 mg twice daily for 3 days and then 0·6 mg once daily for 
      25 days versus usual care, and in a second (1:1) randomisation to receive aspirin 
      100 mg once daily for 28 days versus usual care. Investigators and patients were 
      not masked to treatment allocation. The primary outcome was assessed at 45 days 
      in the intention-to-treat population; for the colchicine randomisation it was 
      hospitalisation or death, and for the aspirin randomisation it was major 
      thrombosis, hospitalisation, or death. The ACT outpatient trial is registered at 
      ClinicalTrials.gov, NCT04324463 and is ongoing. FINDINGS: Between Aug 27, 2020, 
      and Feb 10, 2022, 3917 patients were randomly assigned to colchicine or control 
      and to aspirin or control; after excluding 36 patients due to administrative 
      reasons 3881 individuals were included in the analysis (n=1939 colchicine vs 
      n=1942 control; n=1945 aspirin vs 1936 control). Follow-up was more than 99% 
      complete. Overall event rates were 5 (0·1%) of 3881 for major thrombosis, 123 
      (3·2%) of 3881 for hospitalisation, and 23 (0·6%) of 3881 for death; 66 (3·4%) of 
      1939 patients allocated to colchicine and 65 (3·3%) of 1942 patients allocated to 
      control experienced hospitalisation or death (hazard ratio [HR] 1·02, 95% CI 
      0·72-1·43, p=0·93); and 59 (3·0%) of 1945 of patients allocated to aspirin and 73 
      (3·8%) of 1936 patients allocated to control experienced major thrombosis, 
      hospitalisation, or death (HR 0·80, 95% CI 0·57-1·13, p=0·21). Results for the 
      primary outcome were consistent in all prespecified subgroups, including 
      according to baseline vaccination status, timing of randomisation in relation to 
      onset of symptoms (post-hoc analysis), and timing of enrolment according to the 
      phase of the pandemic (post-hoc analysis). There were more serious adverse events 
      with colchicine than with control (34 patients [1·8%] of 1939 vs 27 [1·4%] of 
      1942) but none in either group that led to discontinuation of study 
      interventions. There was no increase in serious adverse events with aspirin 
      versus control (31 [1·6%] vs 31 [1·6%]) and none that led to discontinuation of 
      study interventions. INTERPRETATION: The results provide no support for the use 
      of colchicine or aspirin to prevent disease progression or death in outpatients 
      with COVID-19. FUNDING: Canadian Institutes for Health Research, Bayer, 
      Population Health Research Institute, Hamilton Health Sciences Research 
      Institute, and Thistledown Foundation. TRANSLATIONS: For the Portuguese, Russian 
      and Spanish translations of the abstract see Supplementary Materials section.
CI  - Copyright © 2022 Elsevier Ltd. All rights reserved.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Ontario, Canada; Department of Medicine, McMaster University, 
      Hamilton, ON, Canada. Electronic address: eikelbj@mcmaster.ca.
FAU - Jolly, Sanjit S
AU  - Jolly SS
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Ontario, Canada; Department of Medicine, McMaster University, 
      Hamilton, ON, Canada.
FAU - Belley-Cote, Emilie P
AU  - Belley-Cote EP
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Ontario, Canada; Department of Medicine, McMaster University, 
      Hamilton, ON, Canada.
FAU - Whitlock, Richard P
AU  - Whitlock RP
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Ontario, Canada; Department of Surgery, McMaster University, 
      Hamilton, ON, Canada.
FAU - Rangarajan, Sumathy
AU  - Rangarajan S
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Ontario, Canada.
FAU - Xu, Lizhen
AU  - Xu L
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Ontario, Canada.
FAU - Heenan, Laura
AU  - Heenan L
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Ontario, Canada.
FAU - Bangdiwala, Shrikant I
AU  - Bangdiwala SI
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Ontario, Canada; Department of Medicine, McMaster University, 
      Hamilton, ON, Canada.
FAU - Tarhuni, Wadea M
AU  - Tarhuni WM
AD  - Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; 
      Department of Medicine, Western University, Clinical Skills Building London, ON, 
      Canada; Windsor Cardiac Centre, Windsor, ON, Canada.
FAU - Hassany, Mohamed
AU  - Hassany M
AD  - National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
FAU - Kontsevaya, Anna
AU  - Kontsevaya A
AD  - National Medical Research Center for Therapy and Preventive Medicine, Moscow, 
      Russia.
FAU - Harper, William
AU  - Harper W
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
FAU - Sharma, Sanjib Kumar
AU  - Sharma SK
AD  - BP Koirala Institute of Health Sciences, Dharan, Nepal.
FAU - Lopez-Jaramillo, Patricio
AU  - Lopez-Jaramillo P
AD  - Masira Research Institute, Medical School, Universidad de Santander, Bucaramanga, 
      Colombia.
FAU - Dans, Antonio L
AU  - Dans AL
AD  - UP College of Medicine, University of the Philippines Manila, Manila, 
      Philippines.
FAU - Palileo-Villanueva, Lia M
AU  - Palileo-Villanueva LM
AD  - UP College of Medicine, University of the Philippines Manila, Manila, 
      Philippines.
FAU - Avezum, Alvaro
AU  - Avezum A
AD  - International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
FAU - Pais, Prem
AU  - Pais P
AD  - St John's Research Institute, Bangalore, India.
FAU - Xavier, Denis
AU  - Xavier D
AD  - St John's Medical College, St John's Research Institute, Bangalore, India.
FAU - Felix, Camilo
AU  - Felix C
AD  - Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Ecuador.
FAU - Yusufali, Afzalhussein
AU  - Yusufali A
AD  - Hatta Hospital, Dubai Medical College, Dubai Health Authority, Dubai, United Arab 
      Emirates.
FAU - Lopes, Renato D
AU  - Lopes RD
AD  - Division of Cardiology, Duke University Medical Center, Duke Clinical Research 
      Institute, NC, USA.
FAU - Berwanger, Otavio
AU  - Berwanger O
AD  - Hospital Israelita Albert Einstein, São Paulo, Brazil.
FAU - Ali, Zeeshan
AU  - Ali Z
AD  - Jinnah Sindh Medical University and Jinnah Postgraduate Medical Center, Karachi, 
      Pakistan.
FAU - Wasserman, Sean
AU  - Wasserman S
AD  - Wellcome Centre for Infectious Diseases Research in Africa, Institute for 
      Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, 
      South Africa; Division of Infectious Diseases and HIV Medicine, Groote Schuur 
      Hospital, University of Cape Town, Cape Town, South Africa.
FAU - Anand, Sonia S
AU  - Anand SS
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Ontario, Canada; Department of Medicine, McMaster University, 
      Hamilton, ON, Canada.
FAU - Bosch, Jackie
AU  - Bosch J
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Ontario, Canada; School of Rehabilitation Science, McMaster 
      University, Hamilton, ON, Canada.
FAU - Choudhri, Shurjeel
AU  - Choudhri S
AD  - Bayer, Medical & Scientific Affairs, Mississauga, ON, Canada.
FAU - Farkouh, Michael E
AU  - Farkouh ME
AD  - Peter Munk Cardiac Centre, University of Toronto, Toronto, ON, Canada.
FAU - Loeb, Mark
AU  - Loeb M
AD  - Departments of Pathology and Molecular Medicine and Health Evidence Methods, 
      Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
FAU - Yusuf, Salim
AU  - Yusuf S
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Ontario, Canada; Department of Medicine, McMaster University, 
      Hamilton, ON, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04324463
GR  - VR3-172627/CIHR/Canada
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20221010
PL  - England
TA  - Lancet Respir Med
JT  - The Lancet. Respiratory medicine
JID - 101605555
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
CIN - Lancet Respir Med. 2022 Dec;10(12):1106-1108. PMID: 36228642
CIN - Ann Intern Med. 2023 Feb;176(2):JC17. PMID: 36745891
MH  - Humans
MH  - Aspirin/therapeutic use
MH  - *COVID-19
MH  - SARS-CoV-2
MH  - Colchicine/therapeutic use
MH  - Treatment Outcome
MH  - Canada
MH  - *Thrombosis
MH  - Disease Progression
PMC - PMC9635862
COIS- Declaration of interests JWE reports grants or in-kind support from Astra-Zeneca, 
      Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Glaxo-Smith-Kline, Pfizer, 
      Janssen, and Sanofi-Aventis and honoraria from Astra-Zeneca, Bayer, 
      Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Eli-Lilly, 
      Glaxo-Smith-Kline, Merck, Pfizer, Janssen, Sanofi-Aventis, and Servier. SSJ 
      reports grant support from Boston Scientific and consulting fees from Medtronic 
      and Boston Scientific. EPB-C reports grant support from Bayer, Roche, BMS–Pfizer. 
      RPW reports grant support from Bayer, Roche, and BMS-Pfizer, grant and honorarium 
      from Boehringer-Ingelheim, and consultancy fees from Atricure and Phasebio. LMP-V 
      reports ACT study support from Unilab, RiteMed Phils, Philippine Council for 
      Health Research and Development, grant support from Wellcome Trust and Sanofi. AA 
      reports institutional grant support from Bayer and EMS, lecture fees from Bayer, 
      Sanofi-Aventis. DX reports ACT study funding from CIHR, grant support from PHRI, 
      Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Coco Cola India, Indian 
      Council of Medical Research, Pfizer, UK Medical Research Council, and Wellcome 
      Trust, speaker fees from Eli Lilly and Sanofi, meeting support from the Indian 
      Council of Medical Research, Eli Lilly, and Sanofi, and leadership roles in 
      SOCHARA and ISCR. RDL reports institutional grant support from Bristol Myers 
      Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi, consulting fees from 
      Bristol Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, Sanofi, Bayer, 
      Boehringer Ingelheim, Daiichi Sankyo, Merck, and Portola, honoraria from Pfizer 
      and meeting travel support from IQVIA. OB reports grant support from Astra 
      Zeneca, Bayer, Amgen, Novartis, Servier, and Pfizer. SW reports grant support 
      from NIH, honoraria from Pfizer, and safety monitoring committee of an AIDS 
      Clinical Trial. SSA reports grants from CIHR and PHAC, honoraria or consulting 
      fees from Bayer, Janssen Pharma, meeting support from Heart and Stroke Canada, 
      committee member at American Heart Association, Canadian Cardiovascular Society, 
      Heart and Stroke Canada. JB reports consulting fees from Bayer. SC reports ACT 
      study funding from Bayer, owns Bayer stock, is a board member of Canadian 
      Arrhythmia Network, is an institutional advisory board member at the Institute of 
      Circulatory and Respiratory Health, Canadian Institutes for Health Research. MEF 
      reports institutional grants from Amgen, Astra Zeneca, Novartis, and Novo Nordisk 
      and consulting fees from Otitopic. ML reports participation in vaccine advisory 
      boards for Medicago, Pfizer, Sanofi, and is on the data safety and monitoring 
      board for CanSino Biologics. SY reports institutional grant support from Bayer 
      and honoraria and travel costs for lectures from Bayer. SR, LX, LH, SIB, WMT, MH, 
      AK, WH, SKS, PL-J, ALD, PP, CF, AY, and ZA have no disclosures to report.
EDAT- 2022/10/14 06:00
MHDA- 2022/12/07 06:00
CRDT- 2022/10/13 19:02
PHST- 2022/06/30 00:00 [received]
PHST- 2022/07/28 00:00 [revised]
PHST- 2022/08/02 00:00 [accepted]
PHST- 2022/10/14 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/10/13 19:02 [entrez]
AID - S2213-2600(22)00299-5 [pii]
AID - 10.1016/S2213-2600(22)00299-5 [doi]
PST - ppublish
SO  - Lancet Respir Med. 2022 Dec;10(12):1160-1168. doi: 10.1016/S2213-2600(22)00299-5. 
      Epub 2022 Oct 10.

PMID- 10702699
OWN - NLM
STAT- MEDLINE
DCOM- 20000531
LR  - 20181130
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 29
IP  - 4
DP  - 1999
TI  - Effects of clopidogrel on platelet activation and coagulation of 
      non-anticoagulated rat blood under high shear stress.
PG  - 189-96
AB  - Clopidogrel is a new thienopyridine derivative similar to ticlopidine, which 
      inhibits adenosine diphosphate-induced platelet aggregation. The in vitro effects 
      of clopidogrel on shear-induced platelet activation and coagulation were assessed 
      after oral administration to rats, by subjecting non-anticoagulated blood to 
      haemostatometry. Clopidogrel significantly inhibited shear-induced platelet 
      activation and coagulation 2 h after administration at doses of 7.5 and 15 mg/kg. 
      Both ticlopidine (200 mg/kg) and aspirin (200 mg/kg) inhibited shear-induced 
      platelet activation, but not coagulation. The peak inhibition of plaetelet 
      activation by clopidogrel occurred 2 h after oral administration, but significant 
      inhibition persisted even after 24 h. These results suggest that clopidogrel 
      could be a more potent antithrombotic agent than ticlopidine or aspirin, and also 
      that ADP plays an important role in shear-induced platelet activation.
CI  - Copyright 2000 S. Karger AG, Basel
FAU - Taka, T
AU  - Taka T
AD  - Laboratory of Physiology, Faculty of Nutrition, Kobe Gakuin University, Kobe, 
      Japan.
FAU - Okano, E
AU  - Okano E
FAU - Seki, J
AU  - Seki J
FAU - Yamamoto, J
AU  - Yamamoto J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Clopidogrel
MH  - Hemostatic Techniques/instrumentation
MH  - Male
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Stress, Mechanical
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Time Factors
EDAT- 2000/03/07 09:00
MHDA- 2000/06/03 09:00
CRDT- 2000/03/07 09:00
PHST- 2000/03/07 09:00 [pubmed]
PHST- 2000/06/03 09:00 [medline]
PHST- 2000/03/07 09:00 [entrez]
AID - 22501 [pii]
AID - 10.1159/000022501 [doi]
PST - ppublish
SO  - Haemostasis. 1999;29(4):189-96. doi: 10.1159/000022501.

PMID- 12207011
OWN - NLM
STAT- MEDLINE
DCOM- 20021217
LR  - 20171116
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Linking)
VI  - 16
IP  - 12
DP  - 2002 Oct
TI  - NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against 
      apoptosis by modulating mitochondrial function.
PG  - 1645-7
AB  - We investigated the effect of a nitric oxide (NO)-releasing derivative of aspirin 
      (NCX-4016) on a mitochondria-dependent model of apoptosis in human umbilical 
      endothelial cells (HUVEC). Exposure of HUVEC to staurosporine caused a 
      progressive fall in mitochondrial membrane potential (DeltaPsi(m)) and apoptosis. 
      Exposure to an NO donor, 
      (z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate 
      (DETA-NO), caused an early (1-3h) hyperpolarization of DeltaPsi(m) and reduction 
      of apoptosis that was followed (at 4-8 h) by an accelerated collapse of 
      DeltaPsi(m) and cell death. In contrast, treatment with NCX-4016, but not with 
      aspirin or a non-NO-releasing analogue of NCX-4016, protected HUVEC against the 
      apoptotic actions of staurosporine for up to 8 h. Confocal microscopy 
      demonstrated that although NCX-4016 released NO in subcellular compartments, 
      DETA-NO caused a generalized increase in cytosolic fluorescence. Exposure to 
      DETA-NO resulted in a rapid and profound inhibition of cell respiration (78.3 +/- 
      6.4%), whereas NCX-4016 caused a less pronounced reduction in oxygen consumption 
      (43.5 +/- 5.3%). Staurosporine caused a time-dependent activation of proapoptotic 
      caspases. NCX-4016 prevented this activation, whereas DETA-NO failed to inhibit 
      caspase activity. In contrast to DETA-NO, NCX-4016 did not increase mitochondrial 
      oxidative stress. These data demonstrated that NCX-4016 conveys NO directly 
      inside endothelial cells and modulates mitochondrial function.
FAU - Fiorucci, Stefano
AU  - Fiorucci S
AD  - Dipartimento di Medicina Clinica e Sperimentale, Clinica di Gastroenterologia ed 
      Epatologia, Università degli Studi di Perugia, 06122 Perugia, Italy. 
      fiorucci@unipg.it
FAU - Mencarelli, Andrea
AU  - Mencarelli A
FAU - Mannucci, Roberta
AU  - Mannucci R
FAU - Distrutti, Eleonora
AU  - Distrutti E
FAU - Morelli, Antonio
AU  - Morelli A
FAU - del Soldato, Piero
AU  - del Soldato P
FAU - Moncada, Salvador
AU  - Moncada S
LA  - eng
PT  - Journal Article
DEP - 20020807
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - H88EPA0A3N (Staurosporine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Cell Survival/drug effects
MH  - Endothelium, Vascular/cytology/*drug effects/metabolism
MH  - Humans
MH  - Microscopy, Confocal
MH  - Mitochondria/*drug effects/physiology
MH  - Nitric Oxide/metabolism
MH  - Oxygen Consumption/drug effects
MH  - Staurosporine/pharmacology
MH  - Time Factors
EDAT- 2002/09/19 10:00
MHDA- 2002/12/18 04:00
CRDT- 2002/09/19 10:00
PHST- 2002/09/19 10:00 [pubmed]
PHST- 2002/12/18 04:00 [medline]
PHST- 2002/09/19 10:00 [entrez]
AID - 02-0297fje [pii]
AID - 10.1096/fj.02-0297fje [doi]
PST - ppublish
SO  - FASEB J. 2002 Oct;16(12):1645-7. doi: 10.1096/fj.02-0297fje. Epub 2002 Aug 7.

PMID- 7277327
OWN - NLM
STAT- MEDLINE
DCOM- 19811118
LR  - 20190724
IS  - 0022-4251 (Print)
IS  - 0022-4251 (Linking)
VI  - 63
IP  - 1
DP  - 1981 Sep
TI  - The action of anti-inflammatory drugs on the fertility of female rats with 
      intrauterine contraceptive devices.
PG  - 257-61
AB  - A silk thread (0-0) or a copper wire (0.18 mm diameter) was placed in the left 
      uterine horn of rats, at least 3 days before fertilization. The animals were 
      untreated or given daily injections of 3 mgh hydrocortisone or 30 mg aspirin 
      beginning the day after insertion of the IUD; 2 weeks after coitus, the animals 
      were killed. A longitudinal (less than or equal to 10 mm) silk thread and the 
      copper wire were effective IUDs regardless of treatment. With the short silk 
      thread (less than or equal to 2 mm), implantation occurred in all groups of rats 
      but a high failure rate was observed in hydrocortisone-treated rats (5/9 with 
      implantations). The no. of implantations/no. of corpora lutea (x 100) was much 
      higher (20.4%) in rats treated with aspirin and hydrocortisone than in untreated 
      animals (3.2%) (P less than 0.01). We conclude that the effectiveness of an IUD 
      can be altered by treatment with an anti-inflammatory substance.
FAU - Testart, J
AU  - Testart J
FAU - Gauthier, A
AU  - Gauthier A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Reprod Fertil
JT  - Journal of reproduction and fertility
JID - 0376367
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Embryo Implantation/drug effects
MH  - Female
MH  - Fertility/*drug effects
MH  - Hydrocortisone/*pharmacology
MH  - *Intrauterine Devices
MH  - Intrauterine Devices, Copper
MH  - Rats
EDAT- 1981/09/01 00:00
MHDA- 1981/09/01 00:01
CRDT- 1981/09/01 00:00
PHST- 1981/09/01 00:00 [pubmed]
PHST- 1981/09/01 00:01 [medline]
PHST- 1981/09/01 00:00 [entrez]
AID - 10.1530/jrf.0.0630257 [doi]
PST - ppublish
SO  - J Reprod Fertil. 1981 Sep;63(1):257-61. doi: 10.1530/jrf.0.0630257.

PMID- 11775396
OWN - NLM
STAT- MEDLINE
DCOM- 20020514
LR  - 20161020
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 22
IP  - 6
DP  - 2001 Nov-Dec
TI  - Aspirin treatment of patients with aspirin intolerance, asthma, and nasal polyps.
PG  - 377-82
AB  - Patients with the triad of aspirin (ASA) intolerance, asthma, and nasal polyps 
      present a clinical challenge for the allergist because their polyps generally are 
      refractory to traditional treatments and their asthmatic symptoms may become more 
      difficult to control with time. These patients can be desensitized and treated 
      with ASA with subsequent improvement in their nasal and respiratory symptoms. 
      This article describes one such individual and briefly reviews the literature 
      regarding this triad. The diagnosis of ASA intolerance, mechanistic studies, a 
      desensitization protocol, and new therapies are reviewed.
FAU - Feldweg, A M
AU  - Feldweg AM
AD  - Harvard Medical School, Department of Medicine, Division of Rheumatology, 
      Immunology, and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, 
      USA.
FAU - Horan, R F
AU  - Horan RF
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Cyclooxygenase Inhibitors/adverse effects/*therapeutic use
MH  - Drug Hypersensitivity/etiology
MH  - Female
MH  - Humans
MH  - Nasal Polyps/*drug therapy
MH  - Sinusitis/drug therapy
MH  - Treatment Outcome
RF  - 29
EDAT- 2002/01/05 10:00
MHDA- 2002/05/15 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/05/15 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
PST - ppublish
SO  - Allergy Asthma Proc. 2001 Nov-Dec;22(6):377-82.

PMID- 1184427
OWN - NLM
STAT- MEDLINE
DCOM- 19760129
LR  - 20131121
IS  - 0003-1488 (Print)
IS  - 0003-1488 (Linking)
VI  - 167
IP  - 10
DP  - 1975 Nov 15
TI  - Pharmacokinetics and dosage of aspirin in cattle.
PG  - 945-8
AB  - Sodium salicylate was given intravenously to clinically normal cows, and aspirin 
      (acetylsalicylic acid) was given orally to arthritic and clinically normal 
      cattle. Despite slow absorption (half-time of absorption, 2.91 hours) of orally 
      administered aspirin and rapid elimination (biologic half-life, 32 minutes) of 
      salicylates, oral dosage of 100 mg/kg every 12 hours maintained serum salicylate 
      concentration greater than 30 mug/ml, which was considered to be therapeutically 
      effective.
FAU - Gingerich, D A
AU  - Gingerich DA
FAU - Baggot, J D
AU  - Baggot JD
FAU - Yeary, R A
AU  - Yeary RA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Vet Med Assoc
JT  - Journal of the American Veterinary Medical Association
JID - 7503067
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Arthritis/drug therapy/veterinary
MH  - *Aspirin/administration & dosage/therapeutic use
MH  - Cattle/*metabolism
MH  - Cattle Diseases/drug therapy
MH  - Female
MH  - Hindlimb
MH  - Injections, Intravenous
MH  - Male
MH  - Salicylates/blood
MH  - Sodium Salicylate/administration & dosage
EDAT- 1975/11/15 00:00
MHDA- 1975/11/15 00:01
CRDT- 1975/11/15 00:00
PHST- 1975/11/15 00:00 [pubmed]
PHST- 1975/11/15 00:01 [medline]
PHST- 1975/11/15 00:00 [entrez]
PST - ppublish
SO  - J Am Vet Med Assoc. 1975 Nov 15;167(10):945-8.

PMID- 3332089
OWN - NLM
STAT- MEDLINE
DCOM- 19881123
LR  - 20191029
IS  - 0268-960X (Print)
IS  - 0268-960X (Linking)
VI  - 1
IP  - 1
DP  - 1987 Mar
TI  - Aspirin and other antiplatelet drugs in the prophylaxis of thrombosis.
PG  - 9-20
AB  - Aspirin is of proven value as an antithrombotic drug. In unstable angina it 
      reduces the risk of death and myocardial infarction by half. After a myocardial 
      infarction it reduces the risk of death by about 10% and of coronary incidence 
      (coronary death or definite myocardial infarction) by about 25%. These effects 
      appear to be additive with those of beta-blocking drugs. Aspirin also reduces the 
      risk of occlusion of aortocoronary saphenous vein grafts by about half. In 
      transient cerebral ischaemia, aspirin may reduce the risk of stroke and death by 
      50%. In most clinical trials to date the daily dose of aspirin ranges from 325 mg 
      to 1400 mg. Interest in very low doses of aspirin (less than 60 mg daily) is 
      considerable but has yet to be translated into proven clinical benefit. 
      Dipyridamole has not been shown to be effective as an antithrombotic when used 
      alone. Its antiplatelet action ex vivo may be enhanced by combination with 
      aspirin but clinical trials have shown relatively little advantage of the 
      combination over aspirin alone. Sulphinpyrazone has not become established as a 
      first line antithrombotic drug. Epoprostenol is useful in extracorporeal 
      circulations to prevent platelet consumption and possibly in severe inoperable 
      peripheral vascular disease.
FAU - Webster, J
AU  - Webster J
AD  - Department of Medicine and Therapeutics, University of Aberdeen.
FAU - Douglas, A S
AU  - Douglas AS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - England
TA  - Blood Rev
JT  - Blood reviews
JID - 8708558
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/*prevention & control
MH  - Coronary Thrombosis/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 74
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 0268-960X(87)90014-2 [pii]
AID - 10.1016/0268-960x(87)90014-2 [doi]
PST - ppublish
SO  - Blood Rev. 1987 Mar;1(1):9-20. doi: 10.1016/0268-960x(87)90014-2.

PMID- 27987244
OWN - NLM
STAT- MEDLINE
DCOM- 20180207
LR  - 20180309
IS  - 1524-475X (Electronic)
IS  - 1067-1927 (Linking)
VI  - 25
IP  - 1
DP  - 2017 Jan
TI  - Aspirin treatment for chronic wounds: Potential beneficial and inhibitory 
      effects.
PG  - 7-12
LID - 10.1111/wrr.12502 [doi]
AB  - Aspirin is a generally well-tolerated drug that is now widely used in aged 
      patients for its antithrombotic action. Aspirin works through several pathways to 
      reduce inflammation, fever and to alter platelet activity. The scientific 
      literature suggests that inhibition of the cyclooxygenase enzymes by aspirin or 
      other nonsteroidal anti-inflammatory drugs may be deleterious to normal wound 
      repair processes and result in healing inhibition. However, novel effects of 
      aspirin on other pathways that regulate inflammation and repair have been 
      reported more recently. These pathways, including inhibition of inflammatory 
      second messengers and transcription factor pathways and production of 
      anti-inflammatory, pro-resolution factors (lipoxins), provide a possible 
      explanation for beneficial effects of aspirin in chronic wound healing. There 
      have been limited studies to date that provide good evidence to support aspirin 
      use in chronic venous leg ulcers but this may change as we see results from 
      randomized trials that are currently being undertaken. In this article, we look 
      at possible effects that aspirin administration may have on venous leg ulcer 
      healing and the expanding knowledge of potential beneficial effects of aspirin 
      that operate via novel pathways. Though the literature suggests that aspirin 
      treatment and cyclooxygenase inhibition may have deleterious effects in normal 
      healing, it is possible that in chronic wounds that may be trapped in an 
      inflammatory state that aspirin treatment may result in beneficial outcomes.
CI  - © 2016 by the Wound Healing Society.
FAU - Darby, Ian Andrew
AU  - Darby IA
AD  - School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, 
      Australia.
FAU - Weller, Carolina Dragica
AU  - Weller CD
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170111
PL  - United States
TA  - Wound Repair Regen
JT  - Wound repair and regeneration : official publication of the Wound Healing Society 
      [and] the European Tissue Repair Society
JID - 9310939
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Chronic Disease/drug therapy
MH  - Cyclooxygenase Inhibitors/*pharmacology/therapeutic use
MH  - Disease Models, Animal
MH  - Humans
MH  - Varicose Ulcer/*drug therapy/metabolism
MH  - Wound Healing/*drug effects/physiology
EDAT- 2016/12/18 06:00
MHDA- 2018/02/08 06:00
CRDT- 2016/12/18 06:00
PHST- 2016/08/24 00:00 [received]
PHST- 2016/11/29 00:00 [accepted]
PHST- 2016/12/18 06:00 [pubmed]
PHST- 2018/02/08 06:00 [medline]
PHST- 2016/12/18 06:00 [entrez]
AID - 10.1111/wrr.12502 [doi]
PST - ppublish
SO  - Wound Repair Regen. 2017 Jan;25(1):7-12. doi: 10.1111/wrr.12502. Epub 2017 Jan 
      11.

PMID- 33990657
OWN - NLM
STAT- MEDLINE
DCOM- 20211029
LR  - 20211029
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 May 14
TI  - In-vitro and in-vivo metabolism of different aspirin formulations studied by a 
      validated liquid chromatography tandem mass spectrometry method.
PG  - 10370
LID - 10.1038/s41598-021-89671-w [doi]
LID - 10370
AB  - Low-dose aspirin (ASA) is used to prevent cardiovascular events. The most 
      commonly used formulation is enteric-coated ASA (EC-ASA) that may be absorbed 
      more slowly and less efficiently in some patients. To uncover these 
      "non-responders" patients, the availability of proper analytical methods is 
      pivotal in order to study the pharmacodynamics, the pharmacokinetics and the 
      metabolic fate of ASA. We validated a high-throughput, isocratic reversed-phase, 
      negative MRM, LC-MS/MS method useful for measuring circulating ASA and salicylic 
      acid (SA) in blood and plasma. ASA-d4 and SA-d4 were used as internal standards. 
      The method was applied to evaluate: (a) the "in vitro" ASA degradation by 
      esterases in whole blood and plasma, as a function of time and concentration; (b) 
      the "in vivo" kinetics of ASA and SA after 7 days of oral administration of 
      EC-ASA or plain-ASA (100 mg) in healthy volunteers (three men and three women, 
      37-63 years). Parameters of esterases activity were V(max) 6.5 ± 1.9 and K(m) 
      147.5 ± 64.4 in plasma, and V(max) 108.1 ± 20.8 and K(m) 803.2 ± 170.7 in whole 
      blood. After oral administration of the two formulations, t(max) varied between 3 
      and 6 h for EC-ASA and between 0.5 and 1.0 h for plain-ASA. Higher 
      between-subjects variability was seen after EC-ASA, and one subject had a delayed 
      absorption over eight hours. Plasma AUC was 725.5 (89.8-1222) for EC-ASA, and 
      823.1(624-1196) ng h/mL (median, 25-75% CI) for plain ASA. After the weekly 
      treatment, serum levels of TxB(2) were very low (< 10 ng/mL at 24 h from the drug 
      intake) in all the studied subjects, regardless of the formulation or the t(max). 
      This method proved to be suitable for studies on aspirin responsiveness.
FAU - Dei Cas, Michele
AU  - Dei Cas M
AUID- ORCID: 0000-0001-7359-8558
AD  - Laboratory of Clinical Chemistry and Mass Spectrometry, Department of Health 
      Sciences, Università degli Studi di Milano, ASST-Santi Paolo e Carlo, via di 
      Rudini' 8, 20142, Milan, Italy.
FAU - Rizzo, Jessica
AU  - Rizzo J
AD  - Laboratory of Clinical Chemistry and Mass Spectrometry, Department of Health 
      Sciences, Università degli Studi di Milano, ASST-Santi Paolo e Carlo, via di 
      Rudini' 8, 20142, Milan, Italy.
AD  - Laboratory of Hemostasis and Thrombosis, Department of Health Sciences, 
      Università degli Studi di Milano, Milan, Italy.
FAU - Scavone, Mariangela
AU  - Scavone M
AUID- ORCID: 0000-0002-8421-0210
AD  - Laboratory of Hemostasis and Thrombosis, Department of Health Sciences, 
      Università degli Studi di Milano, Milan, Italy.
FAU - Femia, Eti
AU  - Femia E
AUID- ORCID: 0000-0002-0858-9644
AD  - Laboratory of Hemostasis and Thrombosis, Department of Health Sciences, 
      Università degli Studi di Milano, Milan, Italy.
FAU - Podda, Gian Marco
AU  - Podda GM
AUID- ORCID: 0000-0002-1791-8905
AD  - Laboratory of Hemostasis and Thrombosis, Department of Health Sciences, 
      Università degli Studi di Milano, Milan, Italy.
AD  - Medicina III, ASST-Santi Paolo e Carlo, Milan, Italy.
FAU - Bossi, Elena
AU  - Bossi E
AD  - Laboratory of Hemostasis and Thrombosis, Department of Health Sciences, 
      Università degli Studi di Milano, Milan, Italy.
FAU - Bignotto, Monica
AU  - Bignotto M
AD  - Internal Medicine and Liver Unit, Department of Health Sciences, Universita' 
      degli Studi di Milano, Milan, Italy.
FAU - Caberlon, Sabrina
AU  - Caberlon S
AD  - Medicina III, ASST-Santi Paolo e Carlo, Milan, Italy.
FAU - Cattaneo, Marco
AU  - Cattaneo M
AUID- ORCID: 0000-0002-7343-4534
AD  - Laboratory of Hemostasis and Thrombosis, Department of Health Sciences, 
      Università degli Studi di Milano, Milan, Italy.
AD  - Medicina III, ASST-Santi Paolo e Carlo, Milan, Italy.
FAU - Paroni, Rita
AU  - Paroni R
AUID- ORCID: 0000-0002-3186-8860
AD  - Laboratory of Clinical Chemistry and Mass Spectrometry, Department of Health 
      Sciences, Università degli Studi di Milano, ASST-Santi Paolo e Carlo, via di 
      Rudini' 8, 20142, Milan, Italy. rita.paroni@unimi.it.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210514
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Tablets, Enteric-Coated)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Chromatography, High Pressure Liquid/methods
MH  - Female
MH  - Gastrointestinal Absorption
MH  - Healthy Volunteers
MH  - High-Throughput Screening Assays/*methods
MH  - Humans
MH  - Male
MH  - Metabolic Clearance Rate
MH  - Middle Aged
MH  - Salicylic Acid/blood/pharmacokinetics
MH  - Tablets, Enteric-Coated
MH  - Tandem Mass Spectrometry/methods
PMC - PMC8121850
COIS- The authors declare no competing interests.
EDAT- 2021/05/16 06:00
MHDA- 2021/10/30 06:00
CRDT- 2021/05/15 06:01
PHST- 2020/10/27 00:00 [received]
PHST- 2021/04/21 00:00 [accepted]
PHST- 2021/05/15 06:01 [entrez]
PHST- 2021/05/16 06:00 [pubmed]
PHST- 2021/10/30 06:00 [medline]
AID - 10.1038/s41598-021-89671-w [pii]
AID - 89671 [pii]
AID - 10.1038/s41598-021-89671-w [doi]
PST - epublish
SO  - Sci Rep. 2021 May 14;11(1):10370. doi: 10.1038/s41598-021-89671-w.

PMID- 6767450
OWN - NLM
STAT- MEDLINE
DCOM- 19800530
LR  - 20190514
IS  - 0003-4932 (Print)
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 191
IP  - 2
DP  - 1980 Feb
TI  - Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein 
      grafts.
PG  - 238-43
AB  - Release from platelets of a factor mitogenic for smooth muscle cells is a 
      postulated mechanism for the pathogenesis of vascular intimal hyperplasia. In 
      this study the effect of antiplatelet therapy was evaluated. Aspirin (165 mg 
      twice daily) and dipyridamole (25 mg twice daily) were administered to six rhesus 
      monkeys and six were given placebo only. Bilateral vein bypass grafts were placed 
      in the iliac arteries. In addition, to evaluate the relative contribution of 
      adventitial dissection and intimal injury, on one side the carotid artery and 
      femoral vein were stripped of adventitia and on the other side the intima of 
      these vessels were injured by the single passage of an inflated balloon tipped 
      catheter. Animals were killed after 16 weeks. In grafts relative luminal area was 
      determined by a photographic gravimetric method at three standard locations. 
      Femoral veins and carotid arteries were classified as histologically normal or as 
      exhibiting hyperplasia. All vessels with adventitial stripping were normal. All 
      vessels with intimal injury in the placebo group except one exhibited intimal 
      hyperplasia compared to the drug treated group in which over half were normal. 
      Relative intimal area was significantly less in grafts from drug treated animals 
      at all three locations and luminal area greater in two. These data suggest that 
      vascular intimal hyperplasia can be reduced by treatment with antiplatelet 
      agents.
FAU - McCann, R L
AU  - McCann RL
FAU - Hagen, P O
AU  - Hagen PO
FAU - Fuchs, J C
AU  - Fuchs JC
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Carotid Arteries/pathology/surgery
MH  - Dipyridamole/administration & dosage/*pharmacology
MH  - Femoral Vein/pathology/surgery
MH  - Haplorhini
MH  - Hyperplasia
MH  - Iliac Artery/surgery
MH  - Macaca mulatta
MH  - Male
MH  - Platelet Count
MH  - Transplantation, Autologous
MH  - Veins/drug effects/*transplantation
PMC - PMC1345615
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
AID - 10.1097/00000658-198002000-00018 [doi]
PST - ppublish
SO  - Ann Surg. 1980 Feb;191(2):238-43. doi: 10.1097/00000658-198002000-00018.

PMID- 12778080
OWN - NLM
STAT- MEDLINE
DCOM- 20030731
LR  - 20220317
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 88
IP  - 9
DP  - 2003 May 6
TI  - Age-related difference in susceptibility of Apc(Min/+) mice towards the 
      chemopreventive efficacy of dietary aspirin and curcumin.
PG  - 1480-3
AB  - The nonsteroidal anti-inflammatory drug aspirin and the spice curcumin retard 
      adenoma formation when administered long-term to Apc(Min/+) mice, a model of 
      human familial adenomatous polyposis coli. Both agents interfere with 
      cyclooxygenase activity. When aspirin is administered to Apc(Min/+) mice only 
      postweaning, but not before, it is inefficacious, while curcumin given 
      postweaning is active. Here the hypothesis was tested that dietary aspirin 
      (0.05%) or curcumin (0.2%) prevent or delay adenoma formation in offsprings when 
      administered to Apc(Min/+) mothers and up to the end of weaning, but not 
      afterwards. Whereas curcumin was without effect when administered in this way, 
      aspirin reduced numbers of intestinal adenomas by 21%. When aspirin given up to 
      the end of weaning was combined with curcumin administered from the end of 
      weaning for the rest of the animals' lifetime, intestinal adenoma numbers were 
      reduced by 38%. The combination was not superior to intervention postweaning with 
      curcumin alone. These results show that aspirin exerts chemopreventive activity 
      in the Apc(Min/+) mouse during tumour initiation/early promotion, while curcumin 
      is efficacious when given at a later stage of carcinogenic progression. Thus, the 
      results suggest that in this mouse model aspirin and curcumin act during 
      different 'windows' of neoplastic development.
FAU - Perkins, S
AU  - Perkins S
AD  - Cancer Biomarkers and Prevention Group, Department of Oncology, University of 
      Leicester, Leicester Royal Infirmary, Leicester LE2 7LX, UK.
FAU - Clarke, A R
AU  - Clarke AR
FAU - Steward, W
AU  - Steward W
FAU - Gescher, A
AU  - Gescher A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Anticarcinogenic Agents)
RN  - IT942ZTH98 (Curcumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/*prevention & control
MH  - Administration, Oral
MH  - Aging/*physiology
MH  - Animals
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Curcumin/*therapeutic use
MH  - Female
MH  - *Genes, APC
MH  - Genetic Predisposition to Disease/*genetics
MH  - Humans
MH  - Intestinal Neoplasms/*prevention & control
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
PMC - PMC2741037
EDAT- 2003/06/05 05:00
MHDA- 2003/08/02 05:00
CRDT- 2003/06/05 05:00
PHST- 2003/06/05 05:00 [pubmed]
PHST- 2003/08/02 05:00 [medline]
PHST- 2003/06/05 05:00 [entrez]
AID - 6600900 [pii]
AID - 10.1038/sj.bjc.6600900 [doi]
PST - ppublish
SO  - Br J Cancer. 2003 May 6;88(9):1480-3. doi: 10.1038/sj.bjc.6600900.

PMID- 19674078
OWN - NLM
STAT- MEDLINE
DCOM- 20100222
LR  - 20141120
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 39
IP  - 9
DP  - 2009 Sep
TI  - Postoperative development of aspirin resistance following coronary artery bypass.
PG  - 769-74
LID - 10.1111/j.1365-2362.2009.02175.x [doi]
AB  - BACKGROUND: Aspirin therapy is known to substantially reduce mortality and the 
      rate of ischaemic complications after coronary artery bypass grafting (CABG). 
      Rates of perioperative aspirin resistance cited in the literature are up to 50% 
      and could be influenced by extracorporeal circulation. Thus, aspirin resistance 
      after CABG may have a significant clinical relevance. MATERIALS AND METHODS: In 
      59 patients undergoing CABG (on-pump, off-pump and combined procedures) aspirin 
      resistance was investigated by arachidonic acid induced platelet aggregometry. 
      Clinical relevance was assessed with 12-month follow up. RESULTS: Two types of 
      resistance were observed: A preoperative resistance (despite oral aspirin or in 
      vitro addition) was present in 29% and a postoperative developing type was seen 
      in 49% resulting in only 22% of patients with a 'normal' reaction to aspirin. If 
      patients were already on oral aspirin at admission, the rate of resistance was 
      significantly reduced. Off-pump surgery or pump-times exceeding 120 min had no 
      significant impact on resistance. During the 12-month follow up (98.3%), there 
      were three deaths (one stroke, one intestinal ischaemia, one mediastinitis after 
      postoperative delirium) in patients with the perioperative resistance and none in 
      other patients (P = 0.345). In none of those patients who presented with 
      perioperative aspirin resistance, could this aspirin resistance be demonstrated 
      when tested again after 12 months? CONCLUSIONS: Aspirin resistance is a transient 
      phenomenon present in the majority of patients undergoing CABG. The three deaths 
      in the resistant group may - although not statistically significant - indicate 
      the possibility of a worse outcome for patients with aspirin resistance.
FAU - Kempfert, J
AU  - Kempfert J
AD  - Department of Cardiac Surgery, Heartcenter, University of Leipzig, Leipzig, 
      Germany. kempfert@web.de
FAU - Anger, K
AU  - Anger K
FAU - Rastan, A
AU  - Rastan A
FAU - Krabbes, S
AU  - Krabbes S
FAU - Lehmann, S
AU  - Lehmann S
FAU - Garbade, J
AU  - Garbade J
FAU - Sauer, M
AU  - Sauer M
FAU - Walther, T
AU  - Walther T
FAU - Dhein, S
AU  - Dhein S
FAU - Mohr, F W
AU  - Mohr FW
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*pharmacology
MH  - Coronary Artery Bypass/adverse effects/methods
MH  - Drug Administration Schedule
MH  - Drug Resistance/physiology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacology
MH  - Platelet Function Tests
MH  - Postoperative Period
MH  - Preoperative Care/methods
MH  - Risk Assessment
EDAT- 2009/08/14 09:00
MHDA- 2010/02/23 06:00
CRDT- 2009/08/14 09:00
PHST- 2009/08/14 09:00 [entrez]
PHST- 2009/08/14 09:00 [pubmed]
PHST- 2010/02/23 06:00 [medline]
AID - ECI2175 [pii]
AID - 10.1111/j.1365-2362.2009.02175.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2009 Sep;39(9):769-74. doi: 10.1111/j.1365-2362.2009.02175.x.

PMID- 94872
OWN - NLM
STAT- MEDLINE
DCOM- 19800815
LR  - 20131121
IS  - 0323-4347 (Print)
IS  - 0323-4347 (Linking)
VI  - 106
IP  - 5-6
DP  - 1979
TI  - [Prevention of cardiovascular complications in manifest arteriosclerosis by the 
      use of Micristine].
PG  - 804-9
AB  - A long-term clinical trial in micristin-treated patients suffering from organic 
      arterial circulatory disturbances is reported. Problems of therapy monitoring by 
      determination of the ASA level in plasma and of control of platelet aggregation 
      are discussed. Acute cardiovascular complications (myocardial infarction, stroke, 
      acute vascular occlusion, amputation and angiographically demonstrated 
      progression) were observed. The observation time did not suffice to establish 
      statistically significant differences between micristin therapy anticoagulant 
      treatment and basic cardiovascular therapy. The results are suggestive of a more 
      beneficial effect of anticoagulant treatment.
FAU - Heine, H
AU  - Heine H
FAU - Norden, C
AU  - Norden C
FAU - Heinemann, L
AU  - Heinemann L
FAU - Stepanauskas, M
AU  - Stepanauskas M
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Zur Prophylaxe kardiovaskulärer Komplikationen bei manifester Arteriosklerose mit 
      Micristin.
PL  - Germany
TA  - Folia Haematol Int Mag Klin Morphol Blutforsch
JT  - Folia haematologica (Leipzig, Germany : 1928)
JID - 0374615
RN  - 0 (Anticoagulants)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate
MH  - Anticoagulants/therapeutic use
MH  - Arteriosclerosis/*complications
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation/drug effects
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):804-9.

PMID- 19222626
OWN - NLM
STAT- MEDLINE
DCOM- 20090511
LR  - 20131121
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 63
IP  - 3
DP  - 2009 Mar
TI  - Responsiveness to aspirin in patients with unstable angina pectoris by whole 
      blood aggregometry.
PG  - 407-16
LID - 10.1111/j.1742-1241.2008.01976.x [doi]
AB  - AIMS: To evaluate aspirin responsiveness in patients with unstable angina 
      pectoris (UAP) by whole blood aggregometry. Another goal was to differentiate 
      aspirin-resistant patients into pharmacokinetic or pharmacodynamic type. METHODS: 
      We measured platelet aggregation by determining impedance values in 70 normal 
      volunteers and 104 UAP patients on aspirin (100 mg/day > or = 7 days) in four 
      inducing conditions [1 microg/ml collagen, 2 microg/ml collagen, 5 micromol/l 
      adenosine diphosphate (ADP) and 10 micromol/l ADP]. We calculated a cut-off value 
      based on data from normal volunteers to define aspirin responsiveness in cases. 
      Then, the correlation and agreement between the results in the four conditions 
      was analysed to choose a preferred inducing condition for identification of 
      aspirin resistance. Aliquots from all samples were incubated with 0.1 mmol/l 
      aspirin and measured again for aspirin-resistant classification. RESULTS: Aspirin 
      resistance was observed in 38 patients (36.5%), 51 patients (49.0%), 67 patients 
      (64.4%) and 67 patients (64.4%), respectively, for 1 microg/ml collagen, 2 
      microg/ml collagen, 5 micromol/l ADP and 10 micromol/l ADP among 104 patients. 
      Collagen at low concentration was suggested as a preferred agent for detecting 
      aspirin inhibitory effect according to the coefficient of sensitivity. After 
      incubation, only three among 38 aspirin-resistant patients showed normal platelet 
      aggregation and were classified into pharmacodynamic type. CONCLUSIONS: In the 
      presence of collagen at low concentration (1 microg/ml), the prevalence of 
      aspirin resistance is about 36.5% in UAP patients, and according to a 
      classification specific for resistant patients, most of the aspirin 'resistance' 
      is just because of pharmacokinetic issues.
FAU - Li, J B
AU  - Li JB
AD  - Institute of Cardiovascular Science, Xinqiao Hospital, Third Military Medical 
      University, Chongqing, China.
FAU - Dong, H M
AU  - Dong HM
FAU - Jian, Z
AU  - Jian Z
FAU - Wu, X J
AU  - Wu XJ
FAU - Zhao, X H
AU  - Zhao XH
FAU - Yu, S Y
AU  - Yu SY
FAU - Huang, L
AU  - Huang L
LA  - eng
PT  - Journal Article
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina, Unstable/blood/*drug therapy
MH  - Aspirin/*pharmacokinetics/therapeutic use
MH  - Drug Resistance/*physiology
MH  - Electric Impedance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacokinetics/therapeutic use
EDAT- 2009/02/19 09:00
MHDA- 2009/05/12 09:00
CRDT- 2009/02/19 09:00
PHST- 2009/02/19 09:00 [entrez]
PHST- 2009/02/19 09:00 [pubmed]
PHST- 2009/05/12 09:00 [medline]
AID - IJCP1976 [pii]
AID - 10.1111/j.1742-1241.2008.01976.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2009 Mar;63(3):407-16. doi: 10.1111/j.1742-1241.2008.01976.x.

PMID- 21453547
OWN - NLM
STAT- MEDLINE
DCOM- 20110909
LR  - 20220311
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 10
DP  - 2011 Apr 1
TI  - Aspirin effect on the incidence of major adverse cardiovascular events in 
      patients with diabetes mellitus: a systematic review and meta-analysis.
PG  - 25
LID - 10.1186/1475-2840-10-25 [doi]
AB  - BACKGROUND: Aspirin has been recommended for the prevention of major adverse 
      cardiovascular events (MACE, composite of non-fatal myocardial infarction, 
      non-fatal stroke, and cardiovascular death) in diabetic patients without previous 
      cardiovascular disease. However, recent meta-analyses have prompted re-evaluation 
      of this practice. The study objective was to evaluate the relative and absolute 
      benefits and harms of aspirin for the prevention of incident MACE in patients 
      with diabetes. METHODS: We performed a systematic review and meta-analysis on 
      seven studies (N=11,618) reporting on the use of aspirin for the primary 
      prevention of MACE in patients with diabetes. Two reviewers conducted a 
      systematic search of electronic databases (MEDLINE, EMBASE, the Cochrane Library, 
      and BIOSIS) and hand searched bibliographies and clinical trial registries. 
      Reviewers extracted data in duplicate, evaluated the quality of the trials, and 
      calculated pooled estimates. RESULTS: A total of 11,618 participants were 
      included in the analysis. The overall risk ratio (RR) for MACE was 0.91 (95% 
      confidence intervals, CI, 0.82-1.00) with little heterogeneity among trials (I2 
      0.0%). Secondary outcomes of interest included myocardial infarction (RR, 0.85; 
      95% CI, 0.66-1.10), stroke (RR, 0.84; 95% CI, 0.64-1.11), cardiovascular death 
      (RR, 0.95; 95% CI, 0.71-1.27), and all-cause mortality (RR, 0.95; 95% CI, 
      0.85-1.06). There were higher rates of hemorrhagic and gastrointestinal events. 
      In absolute terms, these relative risks indicate that for every 10,000 diabetic 
      patients treated with aspirin, 109 MACE may be prevented at the expense of 19 
      major bleeding events (with the caveat that the relative risk for the latter is 
      not statistically significant). CONCLUSIONS: The studies reviewed suggest that 
      aspirin reduces the risk of MACE in patients with diabetes without cardiovascular 
      disease, while also causing a trend toward higher rates of bleeding and 
      gastrointestinal complications. These findings and our absolute benefit and risk 
      calculations suggest that those with diabetes but without cardiovascular disease 
      lie somewhere between primary and secondary prevention patients on the spectrum 
      of benefit and risk. This underscores the importance of considering individual 
      risk in clinical decision making regarding aspirin in those with diabetes.
FAU - Butalia, Sonia
AU  - Butalia S
AD  - Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, 
      Alberta, Canada. sbutalia@ucalgary.ca
FAU - Leung, Alexander A
AU  - Leung AA
FAU - Ghali, William A
AU  - Ghali WA
FAU - Rabi, Doreen M
AU  - Rabi DM
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20110401
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Diabetes Complications/mortality/*prevention & control
MH  - Evidence-Based Medicine
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Patient Selection
MH  - *Primary Prevention
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC3098148
EDAT- 2011/04/02 06:00
MHDA- 2011/09/10 06:00
CRDT- 2011/04/02 06:00
PHST- 2011/03/08 00:00 [received]
PHST- 2011/04/01 00:00 [accepted]
PHST- 2011/04/02 06:00 [entrez]
PHST- 2011/04/02 06:00 [pubmed]
PHST- 2011/09/10 06:00 [medline]
AID - 1475-2840-10-25 [pii]
AID - 10.1186/1475-2840-10-25 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2011 Apr 1;10:25. doi: 10.1186/1475-2840-10-25.

PMID- 15824361
OWN - NLM
STAT- MEDLINE
DCOM- 20060210
LR  - 20131121
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 64
IP  - 7
DP  - 2005 Apr 12
TI  - A randomized controlled crossover trial of aspirin for fatigue in multiple 
      sclerosis.
PG  - 1267-9
AB  - Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are 
      limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or 
      placebo in a double-blind crossover study. Results favored ASA for the main 
      clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment 
      preference (p = 0.012). There were no significant adverse effects. The results 
      warrant further study and support a role for ASA-influenced mechanisms, perhaps 
      immunologic, in the generation of MS-related chronic fatigue.
FAU - Wingerchuk, D M
AU  - Wingerchuk DM
AD  - Department of Neurology Mayo Clinic, Scottsdale, AZ 85259, USA. 
      wingerchuk.dean@mayo.edu
FAU - Benarroch, E E
AU  - Benarroch EE
FAU - O'Brien, P C
AU  - O'Brien PC
FAU - Keegan, B M
AU  - Keegan BM
FAU - Lucchinetti, C F
AU  - Lucchinetti CF
FAU - Noseworthy, J H
AU  - Noseworthy JH
FAU - Weinshenker, B G
AU  - Weinshenker BG
FAU - Rodriguez, M
AU  - Rodriguez M
LA  - eng
GR  - NS-38468/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Neurology. 2005 Apr 12;64(7):1111-2. PMID: 15824329
MH  - Administration, Oral
MH  - Adult
MH  - Age Factors
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/blood
MH  - Aspirin/*administration & dosage/adverse effects/blood
MH  - Cross-Over Studies
MH  - Disease Progression
MH  - Double-Blind Method
MH  - Fatigue/*drug therapy/*immunology/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/*complications
MH  - Treatment Outcome
EDAT- 2005/04/13 09:00
MHDA- 2006/02/14 09:00
CRDT- 2005/04/13 09:00
PHST- 2005/04/13 09:00 [pubmed]
PHST- 2006/02/14 09:00 [medline]
PHST- 2005/04/13 09:00 [entrez]
AID - 64/7/1267 [pii]
AID - 10.1212/01.WNL.0000156803.23698.9A [doi]
PST - ppublish
SO  - Neurology. 2005 Apr 12;64(7):1267-9. doi: 10.1212/01.WNL.0000156803.23698.9A.

PMID- 2590603
OWN - NLM
STAT- MEDLINE
DCOM- 19900125
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 28
IP  - 4
DP  - 1989 Oct
TI  - Salicylate pharmacokinetics in patients with rheumatoid arthritis.
PG  - 449-61
AB  - 1. The pharmacokinetics of salicylic acid (SA) and its major metabolite 
      salicyluric acid (SU) were studied in nine patients with rheumatoid arthritis 
      following a 900 mg oral dose of acetylsalicylic acid and during 6 weeks of 
      chronic administration of enteric coated aspirin (3,900 mg day). Response to 
      therapy was also monitored. 2. The various pharmacokinetic parameters determined 
      in the study were similar to those observed in other single dose salicylate 
      studies amongst healthy volunteers but were not predictive of salicylate 
      concentration in the chronic dose study. 3. Plasma concentrations of SA (total 
      and unbound) were found to decline significantly over the 6 weeks and plasma SU 
      concentrations increased. 4. During the chronic dosing study, there was a 
      significant increase in the Vmax (total and unbound) for the formation of SU, 
      whilst the Km and SU clearance remained constant. Also, the elimination rate 
      constant (k) for salicylate was not significantly affected. 5. Therapeutic 
      response to salicylate therapy was not significantly affected by the decline in 
      SA concentrations.
FAU - Owen, S G
AU  - Owen SG
AD  - School of Pharmacy, University of Tasmania, Hobart, Australia.
FAU - Roberts, M S
AU  - Roberts MS
FAU - Friesen, W T
AU  - Friesen WT
FAU - Francis, H W
AU  - Francis HW
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arthritis, Rheumatoid/drug therapy/*metabolism
MH  - Aspirin/pharmacokinetics/therapeutic use
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Middle Aged
MH  - Salicylates/*pharmacokinetics/therapeutic use
PMC - PMC1379996
EDAT- 1989/10/01 00:00
MHDA- 1989/10/01 00:01
CRDT- 1989/10/01 00:00
PHST- 1989/10/01 00:00 [pubmed]
PHST- 1989/10/01 00:01 [medline]
PHST- 1989/10/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1989.tb03526.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1989 Oct;28(4):449-61. doi: 
      10.1111/j.1365-2125.1989.tb03526.x.

PMID- 37004474
OWN - NLM
STAT- MEDLINE
DCOM- 20230411
LR  - 20230425
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 371
DP  - 2023 Apr
TI  - Low-dose aspirin in the primary prevention of cardiovascular diseases: A 
      retrospective, propensity score matched study.
PG  - 54-60
LID - S0021-9150(23)00111-9 [pii]
LID - 10.1016/j.atherosclerosis.2023.03.009 [doi]
AB  - BACKGROUND AND AIMS: Although the guidelines have been revised recently, the 
      effect of aspirin for the primary prevention of cardiovascular disease (CVD) is 
      still controversial. Thus, we aimed to evaluate the effect of aspirin on primary 
      prevention in the real world. METHODS: Among the 4,266,268 participants without a 
      history of CVD or previous prescription of aspirin and other antiplatelet agents 
      who were screened between 2002 and 2008, 268,963 persons who were prescribed 
      low-dose aspirin (≤100 mg/day) over 90 days in 2002-2008 and 1,075,852 persons 
      who did not receive aspirin were selected after propensity score matching. A Cox 
      proportional-hazards model was used to evaluate the effect of low-dose aspirin on 
      the development of CVD and bleeding episodes. RESULTS: Aspirin showed a 
      protective effect on total CVD events (hazard ratio (HR); 0.737, 95% confidence 
      interval; 0.729-0.745). The protective effect of aspirin on total CVD events was 
      significant in men, women and even in young participants (<65 years). Aspirin had 
      a protective effect in participants with diabetes or hypertension against all 
      subcategories of CVD. The HR of bleeding risk was 1.4-1.5 in aspirin group. 
      CONCLUSIONS: Low-dose aspirin generally showed a protective effect against CVD 
      regardless of age, sex, and underlying comorbidities in the real world. Though, 
      the effect of aspirin was evident at a young age, the risk of bleeding was also 
      high (1.4-1.5 times), and thus, careful prescription is required.
CI  - Copyright © 2023 Elsevier B.V. All rights reserved.
FAU - Kim, Seong Pyo
AU  - Kim SP
AD  - Interdisciplinary Program of Medical Informatics, Seoul National University 
      College of Medicine, Seoul, Republic of Korea; Integrated Major in Innovative 
      Medical Science, Seoul National University Graduate School, Republic of Korea.
FAU - Ryu, Jiwon
AU  - Ryu J
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, Republic of Korea.
FAU - Kim, Su Hwan
AU  - Kim SH
AD  - Biomedical Research Institute, Seoul National University Hospital, Seoul, 
      Republic of Korea.
FAU - Yoon, Hyung-Jin
AU  - Yoon HJ
AD  - Medical Bigdata Research Center, Seoul National University College of Medicine, 
      Seoul, Republic of Korea. Electronic address: hjyoon@snu.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20230316
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Male
MH  - Humans
MH  - Female
MH  - *Cardiovascular Diseases/diagnosis/epidemiology/prevention & control
MH  - Retrospective Studies
MH  - Propensity Score
MH  - Primary Prevention
MH  - Aspirin/adverse effects
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Real world data
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/04/03 06:00
MHDA- 2023/04/11 06:42
CRDT- 2023/04/02 18:11
PHST- 2022/08/11 00:00 [received]
PHST- 2023/03/02 00:00 [revised]
PHST- 2023/03/14 00:00 [accepted]
PHST- 2023/04/11 06:42 [medline]
PHST- 2023/04/03 06:00 [pubmed]
PHST- 2023/04/02 18:11 [entrez]
AID - S0021-9150(23)00111-9 [pii]
AID - 10.1016/j.atherosclerosis.2023.03.009 [doi]
PST - ppublish
SO  - Atherosclerosis. 2023 Apr;371:54-60. doi: 10.1016/j.atherosclerosis.2023.03.009. 
      Epub 2023 Mar 16.

PMID- 36716303
OWN - NLM
STAT- MEDLINE
DCOM- 20230201
LR  - 20230313
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 18
IP  - 1
DP  - 2023
TI  - A randomized controlled trial to evaluate outcomes with Aggrenox in patients with 
      SARS-CoV-2 infection.
PG  - e0274243
LID - 10.1371/journal.pone.0274243 [doi]
LID - e0274243
AB  - BACKGROUND: Coronavirus disease 2019 (COVID-19) is an immunoinflammatory and 
      hypercoagulable state that contributes to respiratory distress, multi-organ 
      dysfunction, and mortality. Dipyridamole, by increasing extracellular adenosine, 
      has been postulated to be protective for COVID-19 patients through its 
      immunosuppressive, anti-inflammatory, anti-coagulant, vasodilatory, and 
      anti-viral actions. Likewise, low-dose aspirin has also demonstrated protective 
      effects for COVID-19 patients. This study evaluated the effect of these two drugs 
      formulated together as Aggrenox in hospitalized COVID-19 patients. METHODS: In an 
      open-label, single site randomized controlled trial (RCT), hospitalized COVID-19 
      patients were assigned to adjunctive Aggrenox (Dipyridamole ER 200mg/ Aspirin 
      25mg orally/enterally) with standard of care treatment compared to standard of 
      care treatment alone. Primary endpoint was illness severity according to changes 
      on the eight-point COVID ordinal scale, with levels of 1 to 8 where higher scores 
      represent worse illness. Secondary endpoints included all-cause mortality and 
      respiratory failure. Outcomes were measured through days 14, 28, and/or hospital 
      discharge. RESULTS: From October 1, 2020 to April 30, 2021, a total of 98 
      patients, who had a median [IQR] age of 57 [47, 62] years and were 53.1% (n = 52) 
      female, were randomized equally between study groups (n = 49 Aggrenox plus 
      standard of care versus n = 49 standard of care alone). No clinically significant 
      differences were found between those who received adjunctive Aggrenox and the 
      control group in terms of illness severity (COVID ordinal scale) at days 14 and 
      28. The overall mortality through day 28 was 6.1% (3 patients, n = 49) in the 
      Aggrenox group and 10.2% (5 patients, n = 49) in the control group (OR [95% CI]: 
      0.40 [0.04, 4.01], p = 0.44). Respiratory failure through day 28 occurred in 4 
      (8.3%, n = 48) patients in the Aggrenox group and 7 (14.6%, n = 48) patients in 
      the standard of care group (OR [95% CI]: 0.21 [0.02, 2.56], p = 0.22). A larger 
      decrease in the platelet count and blood glucose levels, and larger increase in 
      creatinine and sodium levels within the first 7 days of hospital admission were 
      each independent predictors of 28-day mortality (p < 0.05). CONCLUSION: In this 
      study of hospitalized patients with COVID-19, while the outcomes of COVID illness 
      severity, odds of mortality, and chance of respiratory failure were better in the 
      Aggrenox group compared to standard of care alone, the data did not reach 
      statistical significance to support the standard use of adjuvant Aggrenox in such 
      patients.
CI  - Copyright: © 2023 Singla et al. This is an open access article distributed under 
      the terms of the Creative Commons Attribution License, which permits unrestricted 
      use, distribution, and reproduction in any medium, provided the original author 
      and source are credited.
FAU - Singla, Amit
AU  - Singla A
AUID- ORCID: 0000-0002-4162-4691
AD  - Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, 
      New Jersey, United States of America.
FAU - Dadario, Nicholas B
AU  - Dadario NB
AD  - Department of Neurological Surgery, Rutgers Robert Wood Johnson Medical School, 
      New Brunswick, New Jersey, United States of America.
FAU - Singla, Ashima
AU  - Singla A
AD  - Department of OBGYN, Rutgers Robert Wood Johnson Medical School, New Brunswick, 
      New Jersey, United States of America.
FAU - Greenberg, Patricia
AU  - Greenberg P
AD  - Biostatistics and Epidemiology Services Center (RUBIES), Rutgers School of Public 
      Health, Rutgers University, Piscataway, New Jersey, United States of America.
FAU - Yan, Rachel
AU  - Yan R
AD  - Department of Neurological Surgery, Rutgers Robert Wood Johnson Medical School, 
      New Brunswick, New Jersey, United States of America.
FAU - Nanda, Anil
AU  - Nanda A
AD  - Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, 
      New Jersey, United States of America.
AD  - Department of Neurological Surgery, Rutgers Robert Wood Johnson Medical School, 
      New Brunswick, New Jersey, United States of America.
FAU - Boison, Detlev
AU  - Boison D
AD  - Department of Neurological Surgery, Rutgers Robert Wood Johnson Medical School, 
      New Brunswick, New Jersey, United States of America.
AD  - Brain Health Institute, Rutgers University, Piscataway, New Jersey, United States 
      of America.
FAU - Malhotra, Rakesh
AU  - Malhotra R
AD  - Department of Medicine, Division of Nephrology, UCSD, San Diego, California, 
      United States of America.
FAU - Patel, Sunil
AU  - Patel S
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, 
      United States of America.
FAU - Nipun, Suri
AU  - Nipun S
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, 
      United States of America.
FAU - Maninderpal, Kaur
AU  - Maninderpal K
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, 
      United States of America.
FAU - Castro, Dorothy
AU  - Castro D
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, 
      United States of America.
FAU - Bdiiwi, Sanaa
AU  - Bdiiwi S
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, 
      United States of America.
FAU - Boktor, Hala
AU  - Boktor H
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, 
      United States of America.
FAU - Kyi, Htay Htay
AU  - Kyi HH
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, 
      United States of America.
FAU - Sutherland, Anne
AU  - Sutherland A
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, 
      United States of America.
FAU - Patrawalla, Amee
AU  - Patrawalla A
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, 
      United States of America.
FAU - Ly, Kevin
AU  - Ly K
AD  - Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, 
      New Jersey, United States of America.
FAU - Xie, Yingda
AU  - Xie Y
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, 
      United States of America.
FAU - Sonig, Ashish
AU  - Sonig A
AD  - Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, 
      New Jersey, United States of America.
FAU - Khandelwal, Priyank
AU  - Khandelwal P
AD  - Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, 
      New Jersey, United States of America.
FAU - Liu, James
AU  - Liu J
AD  - Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, 
      New Jersey, United States of America.
FAU - Koziol, Joseph
AU  - Koziol J
AD  - Department of Neurological Surgery, Saint Barnabas Medical Center, Livingston, 
      New Jersey, United States of America.
FAU - Finkle, Diana
AU  - Finkle D
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, 
      United States of America.
FAU - Subanna, Sara
AU  - Subanna S
AUID- ORCID: 0000-0003-1222-9980
AD  - Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, 
      New Jersey, United States of America.
FAU - Libutti, Steven K
AU  - Libutti SK
AD  - Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, 
      New Jersey, United States of America.
LA  - eng
GR  - UL1 TR003017/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20230130
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Antiviral Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Humans
MH  - *COVID-19
MH  - Aspirin, Dipyridamole Drug Combination
MH  - SARS-CoV-2
MH  - Antiviral Agents/therapeutic use
MH  - Aspirin
MH  - Treatment Outcome
PMC - PMC9886260
COIS- The authors have declared that no competing interests exist.
EDAT- 2023/01/31 06:00
MHDA- 2023/02/02 06:00
CRDT- 2023/01/30 14:43
PHST- 2022/01/20 00:00 [received]
PHST- 2022/08/23 00:00 [accepted]
PHST- 2023/01/30 14:43 [entrez]
PHST- 2023/01/31 06:00 [pubmed]
PHST- 2023/02/02 06:00 [medline]
AID - PONE-D-22-00966 [pii]
AID - 10.1371/journal.pone.0274243 [doi]
PST - epublish
SO  - PLoS One. 2023 Jan 30;18(1):e0274243. doi: 10.1371/journal.pone.0274243. 
      eCollection 2023.

PMID- 6158420
OWN - NLM
STAT- MEDLINE
DCOM- 19801218
LR  - 20190721
IS  - 0013-4694 (Print)
IS  - 0013-4694 (Linking)
VI  - 49
IP  - 3-4
DP  - 1980 Aug
TI  - Aspirin and human sleep.
PG  - 409-13
AB  - Two groups of 8 females were given either 3 X 600 mg aspirin or placebo daily for 
      4 days, double blind. With aspirin, slow wave sleep was significantly decreased 
      and stage 2 sleep significantly increased. Aspirin also significantly disrupted 
      intra-subject night-to-night continuity of several sleep stages during drug and 
      recovery nights.
FAU - Horne, J A
AU  - Horne JA
FAU - Percival, J E
AU  - Percival JE
FAU - Traynor, J R
AU  - Traynor JR
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Electroencephalogr Clin Neurophysiol
JT  - Electroencephalography and clinical neurophysiology
JID - 0375035
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Double-Blind Method
MH  - Electroencephalography/*methods
MH  - Female
MH  - Humans
MH  - Sleep Stages/*drug effects
MH  - Sleep, REM/drug effects
EDAT- 1980/08/01 00:00
MHDA- 1980/08/01 00:01
CRDT- 1980/08/01 00:00
PHST- 1980/08/01 00:00 [pubmed]
PHST- 1980/08/01 00:01 [medline]
PHST- 1980/08/01 00:00 [entrez]
AID - 0013-4694(80)90238-2 [pii]
AID - 10.1016/0013-4694(80)90238-2 [doi]
PST - ppublish
SO  - Electroencephalogr Clin Neurophysiol. 1980 Aug;49(3-4):409-13. doi: 
      10.1016/0013-4694(80)90238-2.

PMID- 29362281
OWN - NLM
STAT- MEDLINE
DCOM- 20180622
LR  - 20180622
IS  - 0301-2603 (Print)
IS  - 0301-2603 (Linking)
VI  - 46
IP  - 1
DP  - 2018 Jan
TI  - [Takotsubo Cardiomyopathy and Neurogenic Pulmonary Edema Following Fibrinolytic 
      Therapy for Embolic Stroke:A Case Report].
PG  - 21-25
LID - 10.11477/mf.1436203669 [doi]
AB  - A 79-year-old man presented with left hemiparesis and disturbance of 
      consciousness. Brain magnetic resonance(MR)imaging revealed an infarction in the 
      right insular cortex. MR angiography showed a defect in the inferior trunk of the 
      right middle cerebral artery. The patient was treated with alteplase about 2.5 h 
      after onset. Immediately after the intravenous alteplase administration, the 
      hemiparesis improved. However, his respiratory condition unexpectedly worsened 10 
      h after onset. Chest radiography demonstrated an infiltrative shadow in both lung 
      fields. Transthoracic echocardiogram showed a dysfunction in the left ventricle 
      and no contraction at the apex of the heart, consistent with a type of 
      cardiomyopathy, known as takotsubo cardiomyopathy(TCM). Gradually, the patient's 
      respiratory and cardiac function improved. Here, we describe a very rare case of 
      TCM and neurogenic pulmonary edema(NPE)following an acute cerebral infarction, 
      which was treated with alteplase intravenous administration. TCM and NPE have a 
      poor prognosis, therefore diagnosis, management, and treatment in the acute phase 
      is required.
FAU - Kitagawa, Takehiro
AU  - Kitagawa T
AD  - Department of Neurosurgery, University of Occupational and Environmental Health.
FAU - Yamamoto, Junkoh
AU  - Yamamoto J
FAU - Kureshima, Makoto
AU  - Kureshima M
FAU - Maeda, Hitoshi
AU  - Maeda H
FAU - Nishizawa, Shigeru
AU  - Nishizawa S
LA  - jpn
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - No Shinkei Geka
JT  - No shinkei geka. Neurological surgery
JID - 0377015
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/therapeutic use
MH  - Fibrinolytic Agents/adverse effects/therapeutic use
MH  - Humans
MH  - Male
MH  - Pulmonary Edema/*diagnostic imaging/etiology
MH  - Stroke/*drug therapy
MH  - Takotsubo Cardiomyopathy/*diagnostic imaging/etiology
MH  - Thrombolytic Therapy/*adverse effects
EDAT- 2018/01/25 06:00
MHDA- 2018/06/23 06:00
CRDT- 2018/01/25 06:00
PHST- 2018/01/25 06:00 [entrez]
PHST- 2018/01/25 06:00 [pubmed]
PHST- 2018/06/23 06:00 [medline]
AID - 1436203669 [pii]
AID - 10.11477/mf.1436203669 [doi]
PST - ppublish
SO  - No Shinkei Geka. 2018 Jan;46(1):21-25. doi: 10.11477/mf.1436203669.

PMID- 10690130
OWN - NLM
STAT- MEDLINE
DCOM- 20000302
LR  - 20190515
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 83
IP  - 5
DP  - 1999 Nov
TI  - Haemodynamic effects of diaspirin crosslinked haemoglobin (DCLHb) given before 
      abdominal aortic aneurysm surgery.
PG  - 702-7
AB  - We studied 34 patients undergoing elective repair of an abdominal aortic aneurysm 
      under combined general anaesthesia and epidural block to evaluate the acute 
      effects of diaspirin crosslinked haemoglobin (DCLHb) 50, 100 and 200 mg kg-1 i.v. 
      Haemodynamic variables were measured continuously using pulmonary and radial 
      artery catheters, and oxygen delivery and consumption were calculated at regular 
      intervals. DCLHb was shown to be vasoactive, producing an increase in mean 
      arterial pressure of approximately 25% with each dose, with small decreases in 
      cardiac index and calculated oxygen delivery. These effects persisted beyond the 
      end of infusion and provided a degree of cardiovascular stability during the 
      operative procedure. The effects of DCLHb on oxygen consumption at these doses 
      were minimal.
FAU - Garrioch, M A
AU  - Garrioch MA
AD  - Department of Anaesthetics, Royal Infirmary, Edinburgh, UK.
FAU - McClure, J H
AU  - McClure JH
FAU - Wildsmith, J A
AU  - Wildsmith JA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aortic Aneurysm, Abdominal/*surgery
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Pressure/drug effects
MH  - Blood Substitutes/*pharmacology
MH  - Female
MH  - Heart Rate/drug effects
MH  - Hemodynamics/*drug effects
MH  - Hemoglobins/*pharmacology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/drug effects
MH  - Preoperative Care/*methods
MH  - Single-Blind Method
MH  - Vasoconstriction/drug effects
EDAT- 2000/02/26 09:00
MHDA- 2000/03/04 09:00
CRDT- 2000/02/26 09:00
PHST- 2000/02/26 09:00 [pubmed]
PHST- 2000/03/04 09:00 [medline]
PHST- 2000/02/26 09:00 [entrez]
AID - S0007-0912(17)38259-4 [pii]
AID - 10.1093/bja/83.5.702 [doi]
PST - ppublish
SO  - Br J Anaesth. 1999 Nov;83(5):702-7. doi: 10.1093/bja/83.5.702.

PMID- 8481583
OWN - NLM
STAT- MEDLINE
DCOM- 19930602
LR  - 20190905
IS  - 1051-0443 (Print)
IS  - 1051-0443 (Linking)
VI  - 4
IP  - 2
DP  - 1993 Mar-Apr
TI  - Bleeding due to needle biopsy: effect of venopirin in an animal model and 
      implications for humans.
PG  - 305-10
AB  - PURPOSE: This study was undertaken to address the effect of platelet dysfunction 
      on bleeding associated with percutaneous needle biopsy. MATERIALS AND METHODS: 
      With use of an established animal model, 199 biopsies were performed on the 
      livers of 13 anesthetized pigs (95 on control animals, 104 on venopirin-treated 
      animals). The needles used were 16-22-gauge Chiba type, 18-gauge Tru-Cut, and 
      18-gauge Menghini. The biopsies were performed under direct vision at laparotomy 
      with consistent technique. Blood loss was measured, and the results were 
      compared. Statistical analysis was performed with the Student t test and the 
      Turkey test, after logarithmic transformation of the data. RESULTS: A substantial 
      increase in blood loss resulting from the biopsy procedures was demonstrated in 
      the animals with platelet dysfunction. This was much greater than the effect of 
      either needle size or prothrombin time prolongation previously reported by the 
      authors. CONCLUSION: Platelet function may be an important factor in determining 
      the risk of bleeding due to percutaneous needle biopsy.
FAU - Gazelle, G S
AU  - Gazelle GS
AD  - Department of Radiology, Case Western Reserve University, Cleveland, Ohio.
FAU - Haaga, J R
AU  - Haaga JR
FAU - Rowland, D Y
AU  - Rowland DY
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Biopsy, Needle/*adverse effects
MH  - Blood Platelets/drug effects
MH  - Hemorrhage/blood/*etiology
MH  - Humans
MH  - Liver/*pathology
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Needles
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Swine
EDAT- 1993/03/01 00:00
MHDA- 1993/03/01 00:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 1993/03/01 00:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
AID - 10.1016/s1051-0443(93)71865-5 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 1993 Mar-Apr;4(2):305-10. doi: 
      10.1016/s1051-0443(93)71865-5.

PMID- 28629303
OWN - NLM
STAT- MEDLINE
DCOM- 20181001
LR  - 20181001
IS  - 1531-1937 (Electronic)
IS  - 0897-1900 (Linking)
VI  - 31
IP  - 3
DP  - 2018 Jun
TI  - Dual Antiplatelet Therapy Beyond One Year in Patients After Stent Placement: A 
      Review.
PG  - 335-341
LID - 10.1177/0897190017715560 [doi]
AB  - PURPOSE: To review the evidence on the safety and efficacy of the continued use 
      of dual antiplatelet therapy (DAPT) beyond 12 months after stent placement in 
      patients following an acute coronary syndrome (ACS) event. SUMMARY: Recently, the 
      American College of Cardiology (ACC) and the American Heart Association (AHA) 
      released a focused update on the duration of DAPT in patients with coronary 
      artery disease (CAD). The update makes new recommendations about the duration of 
      DAPT in light of recently performed studies investigating this topic. In regard 
      to patients after an ACS event, the update states it is reasonable to continue 
      DAPT beyond 1 year if these patients are not at a high risk of bleeding and had 
      no overt bleeding while on DAPT. Several trials have been released which aim to 
      provide information about the correct duration of DAPT after an ACS event. 
      CONCLUSION: Recent trials have shown a benefit of prolonged (beyond 12 months) 
      DAPT in preventing recurrent cardiovascular (CV) events in patients, mostly in 
      patients who have had a previous myocardial infarction (MI). These benefits must 
      be weighed with the elevated risks of bleeding.
FAU - Sumner, Jacob D
AU  - Sumner JD
AD  - 1 Research Medical Center, Kansas City, MO, USA.
FAU - Zinser, Brianna
AU  - Zinser B
AD  - 1 Research Medical Center, Kansas City, MO, USA.
FAU - Smith, Andrew
AU  - Smith A
AD  - 2 School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170620
PL  - United States
TA  - J Pharm Pract
JT  - Journal of pharmacy practice
JID - 8900945
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - Clinical Trials as Topic/methods
MH  - Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*adverse effects
MH  - Risk Factors
MH  - Stents/adverse effects/*trends
MH  - Time Factors
OTO - NOTNLM
OT  - cardiology
EDAT- 2017/06/21 06:00
MHDA- 2018/10/03 06:00
CRDT- 2017/06/21 06:00
PHST- 2017/06/21 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
PHST- 2017/06/21 06:00 [entrez]
AID - 10.1177/0897190017715560 [doi]
PST - ppublish
SO  - J Pharm Pract. 2018 Jun;31(3):335-341. doi: 10.1177/0897190017715560. Epub 2017 
      Jun 20.

PMID- 15562712
OWN - NLM
STAT- MEDLINE
DCOM- 20050809
LR  - 20131121
IS  - 1001-4454 (Print)
IS  - 1001-4454 (Linking)
VI  - 25
IP  - 11
DP  - 2002 Nov
TI  - [The clinical study on Dan Shao Tang in treating simple hematuria of masked 
      nephritis of deficiency of Yin with damp-heat symptom].
PG  - 842-4
AB  - OBJECTIVE: To explore the effect of Dan Shao Tang (DST) in treating simple 
      hematuria of masked nephritis of deficiency of Yin with damp-heat symptom. 
      METHODS: Sixty patients of simple hematuria of masked nephritis of deficiency of 
      Yin with damp-heat symptom were divided into two groups in random, 35 patients in 
      treatment group were treated with Dan Shao Tang and westen medicine, and 25 
      patients in control group were treated only with western medicine. The effect, 
      change of hematuria and immunity index of the two groups were observed three 
      months later. RESULTS: The total efficiency of treatment group (65.71%) is better 
      than that of control group (36%). Treatment group is obviously better than 
      control group on decreasing hematuria and improving immune function. CONCLUSION: 
      Dan Shao Tang is effective to treatment on simple hematuria of masked nephritis 
      of dificiency of Yin with damp-heat symptom effectively.
FAU - Wu, Xinlin
AU  - Wu X
AD  - Department of traditional Chinese Medicine of the First Affiliated Hospital of 
      Sun Yet-sen University, Guangzhou 510080.
FAU - Li, Junbiao
AU  - Li J
FAU - Mo, Suilin
AU  - Mo S
FAU - Shen, Weizeng
AU  - Shen W
LA  - chi
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhong Yao Cai
JT  - Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials
JID - 9426370
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Drug Combinations)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adjuvants, Immunologic/therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Dipyridamole/administration & dosage/therapeutic use
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Hematuria/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nephritis/*drug therapy
MH  - *Phytotherapy
MH  - Yin Deficiency/*drug therapy
EDAT- 2004/11/26 09:00
MHDA- 2005/08/10 09:00
CRDT- 2004/11/26 09:00
PHST- 2004/11/26 09:00 [pubmed]
PHST- 2005/08/10 09:00 [medline]
PHST- 2004/11/26 09:00 [entrez]
PST - ppublish
SO  - Zhong Yao Cai. 2002 Nov;25(11):842-4.

PMID- 9287258
OWN - NLM
STAT- MEDLINE
DCOM- 19970916
LR  - 20131121
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 51
IP  - 4
DP  - 1997 Jun
TI  - European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the 
      secondary prevention of stroke.
PG  - 205-8
AB  - In 1988, an optimal antiplatelet regimen for secondary stroke prevention remained 
      to be defined. We undertook a randomised, placebo-controlled, double-blind trial 
      to investigate the safely and efficacy of low-dose acetylsalicylic acid (ASA), 
      modified-release dipyridamole, and the two agents in combination. Patients with 
      prior stroke or transient ischaemic attack (TIA) were randomised to treatment 
      with ASA alone (50 mg daily), modified-release dipyridamole alone (400 mg daily), 
      the two agents in a combined formulation, or placebo. Primary endpoints were 
      stroke, death, and stroke or death. TIA and other vascular events were secondary 
      endpoints. Patients were followed on treatment for two years. We concluded that 
      dipyridamole, in a modified-release form, at a dose of 200 mg b.d. and ASA 25 mg 
      b.d., have been shown to be equally effective in the secondary prevention of 
      ischaemic stroke and TIA; that when co-prescribed, the protective effects are 
      additive, the combination being significantly more effective than each agent 
      prescribed singly; and that low-dose ASA does not eliminate the propensity for 
      induced bleeding.
FAU - Forbes, C D
AU  - Forbes CD
AD  - Ninewells Hospital and Medical School, Dundee, Scotland.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Disease-Free Survival
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Headache/chemically induced
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 1997/06/01 00:00
MHDA- 1997/06/01 00:01
CRDT- 1997/06/01 00:00
PHST- 1997/06/01 00:00 [pubmed]
PHST- 1997/06/01 00:01 [medline]
PHST- 1997/06/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pract. 1997 Jun;51(4):205-8.

PMID- 11446026
OWN - NLM
STAT- MEDLINE
DCOM- 20010712
LR  - 20131121
IS  - 0012-0472 (Print)
IS  - 0012-0472 (Linking)
VI  - 126
IP  - 24
DP  - 2001 Jun 15
TI  - [Decreased platelet aggregation during angiotensin-converting enzyme inhibitor 
      therapy. Results of a pilot study].
PG  - 707-11
AB  - BACKGROUND AND OBJECTIVE: Plaque rupture and subsequent thrombosis are key events 
      in the complication and progression of atherosclerotic disease. Recently, the 
      HOPE study showed a significant decrease in cardiovascular complications with the 
      angiotensin converting enzyme (ACE) inhibitor (ramipril). To assess the 
      therapeutic potential of this drug class, the present study evaluates the 
      coagulative activity in cardiovascular patients with ACE inhibitors and compares 
      these data with those of untreated patients and with those of patients taking 
      aspirin, resp. METHODS: Blood samples from 204 patients with coronary heart 
      disease and/or arterial hypertension were analyzed by whole-blood 
      lumi-aggregometry. Platelet aggregation was determined by the increase in 
      impedance across paired electrodes in response to the stimulatory agents collagen 
      and ADP, respectively. The data were correlated with the presence or absence of 
      ACE inhibitor and/or aspirin medication. Analogously, the coagulative potential 
      of beta-blockers, calcium antagonists, CSE-inhibitors and nitrates were studied. 
      RESULTS: As the central finding, study participants treated with ACE inhibitors 
      showed a decreased platelet aggregation compared to untreated control patients, 
      indicated by a significantly reduced increase in impedance. Platelet aggregation 
      induced by collagen decreased by 18% (p = 0.025), that induced by ADP by 39% (p = 
      0.039). With aspirin medication, the collagen-induced decrease amounted to 20% (p 
      = 0.020); no significant effect was seen by ADP stimulation. With combined intake 
      of ACE inhibitors and aspirin, collagen-induced platelet aggregation was found 
      markedly reduced. Platelet aggregation decreased by 26% (p = 0.003). 
      Beta-blockers, calcium antagonists, CSE inhibitors and nitrates did not reveal a 
      significant influence on platelet aggregation. CONCLUSIONS: ACE inhibition 
      decreases platelet aggregation, as detected and quantified by ex vivo whole-blood 
      aggregometry. Beyond known effects of this drug class, in particular on 
      endothelium and fibrinolysis, antithrombotic effects may explain the positive 
      influence on major clinical cardiovascular events.
FAU - Skowasch, D
AU  - Skowasch D
AD  - Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn.
FAU - Lentini, S
AU  - Lentini S
FAU - Andrié, R
AU  - Andrié R
FAU - Jabs, A
AU  - Jabs A
FAU - Bauriedel, G
AU  - Bauriedel G
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Verminderte Plättchenaggregation bei ACE-Hemmertherapie. Ergebnisse einer 
      Pilotstudie.
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Case-Control Studies
MH  - Coronary Disease/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Hypertension/blood/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
EDAT- 2001/07/12 10:00
MHDA- 2001/07/13 10:01
CRDT- 2001/07/12 10:00
PHST- 2001/07/12 10:00 [pubmed]
PHST- 2001/07/13 10:01 [medline]
PHST- 2001/07/12 10:00 [entrez]
AID - 10.1055/s-2001-15032 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2001 Jun 15;126(24):707-11. doi: 10.1055/s-2001-15032.

PMID- 19849660
OWN - NLM
STAT- MEDLINE
DCOM- 20100902
LR  - 20190907
IS  - 1873-4294 (Electronic)
IS  - 1568-0266 (Linking)
VI  - 9
IP  - 14
DP  - 2009
TI  - Antiplatelet treatment in ischemic stroke treatment.
PG  - 1298-316
AB  - Antiplatelets represent a diverse group of agents that share the ability to 
      reduce platelet activity through a variety of mechanisms. Antithrombotic agents 
      are effective in the secondary prevention of ischemic strokes. Most strokes are 
      caused by a sudden blockage of an artery in the brain (called an ischaemic 
      stroke) that is usually due to a blood clot. Immediate treatment with 
      antiplatelet drugs such as aspirin may prevent new clots from forming and hence 
      improve recovery after stroke. Several studies have evaluated the role of one 
      antiplatelet agent, aspirin, in reducing stroke severity. The International 
      Stroke Trial (IST) of 20,000 patients with acute stroke from other countries. In 
      this study there was a significant 14% proportional reduction in mortality during 
      the scheduled treatment period (343 [3.3%] deaths among aspirin-allocated 
      patients vs 398 [3.9%] deaths among placebo-allocated patients; 2p = 0.04). There 
      were significantly fewer recurrent ischaemic strokes in the aspirin-allocated 
      than in the placebo-allocated group (167 [1.6%] vs 215 [2.1%]; 2p = 0.01) but 
      slightly more haemorrhagic strokes (115 [1.1%] vs 93 [0.9%]. Few studies examined 
      the role of ticlopidin in acute stroke setting the results showed treatment with 
      ticlopidine improved the neurologic outcome. In the Examining the Safety of 
      Loading of Aspirin and Clopidogrel in Acute Ischemic Stroke and TIA (LOAD) study, 
      40 consecutive ischemic stroke patients were treated with 325 mg of aspirin and 
      375 mg of clopidogrel within 36 hours of symptom onset. Overall, 37.5% (n = 15) 
      of the patients had an improvement of 2 or more points on the NIHSS 24 hours 
      after antiplatelet administration. The antiplatelet efficacy of aspirin in 
      preventing secondary stroke was established by three studies conducted in the 
      late 1980s and early 1990s: the Swedish Aspirin Low-dose Trial (SALT) trials have 
      demonstrated that aspirin-even in doses as low as 30 mg/day-reduces secondary 
      stroke, MI, or vascular death in patients with. Clopidogrel and aspirin have been 
      used in combination in patients with diverse arterial vascular diseases However, 
      combinations of antithrombotic agents do not necessarily improve clinical 
      efficacy and are typically associated with increased toxicity.
FAU - Pinto, Antonio
AU  - Pinto A
AD  - Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli 
      Studi di Palermo, Palermo, Italy. pinto@unipa.it
FAU - Di Raimondo, Domenico
AU  - Di Raimondo D
FAU - Tuttolomondo, Antonino
AU  - Tuttolomondo A
FAU - Di Sciacca, Riccardo
AU  - Di Sciacca R
FAU - Arnao, Valentina
AU  - Arnao V
FAU - La Placa, Sergio
AU  - La Placa S
FAU - Milio, Glauco
AU  - Milio G
FAU - Miceli, Salvatore
AU  - Miceli S
FAU - Licata, Giuseppe
AU  - Licata G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Top Med Chem
JT  - Current topics in medicinal chemistry
JID - 101119673
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Stroke/*drug therapy
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
RF  - 96
EDAT- 2009/10/24 06:00
MHDA- 2010/09/03 06:00
CRDT- 2009/10/24 06:00
PHST- 2008/08/08 00:00 [received]
PHST- 2008/09/15 00:00 [accepted]
PHST- 2009/10/24 06:00 [entrez]
PHST- 2009/10/24 06:00 [pubmed]
PHST- 2010/09/03 06:00 [medline]
AID - CTMC-Abs-022-9-14 [pii]
AID - 10.2174/156802609789869664 [doi]
PST - ppublish
SO  - Curr Top Med Chem. 2009;9(14):1298-316. doi: 10.2174/156802609789869664.

PMID- 27105311
OWN - NLM
STAT- MEDLINE
DCOM- 20170328
LR  - 20170817
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 142
DP  - 2016 Jun
TI  - Multiple Electrode Aggregometry is an adequate method for aspirin response 
      testing in myeloproliferative neoplasms and differentiates the mechanisms of 
      aspirin resistance.
PG  - 26-32
LID - S0049-3848(16)30294-8 [pii]
LID - 10.1016/j.thromres.2016.04.006 [doi]
AB  - INTRODUCTION: In myeloproliferative neoplasms (MPN), aspirin reduces the 
      thrombotic risk. Nevertheless, aspirin resistance may be due to excessive 
      platelet production ("turnover" resistance). Aspirin resistance can also result 
      from a lack of effect of aspirin; this second component is called "intrinsic 
      resistance". Two biological tests are considered reference methods for the 
      assessment of aspirin resistance: TXB2 assay and Light Transmittance Aggregometry 
      (LTA) with arachidonic acid. MATERIALS & METHODS: We have compared a third 
      method, the Multiple Electrode Aggregometry (MEA), performed with arachidonic 
      acid on the Multiplate® analyzer, with both reference methods. Thirty-six 
      patients with MPN were assessed for aspirin resistance with all three techniques. 
      30 patients devoid of MPN were used as controls. RESULTS: The three methods were 
      statistically equivalent: LTA and TXB2 were comparable methods (ROC curve 
      AUC=0.844>0.7; LTA cutoff=67%). At this threshold, LTA had a sensitivity of 73% 
      and a specificity of 96%. MEA (without added aspirin) and TXB2 were also 
      comparable (ROC curve AUC=0.782; MEA cutoff=31U), but at this threshold, 11 
      patients (30%) were falsely positive with MEA. Last, MEA and LTA were comparable 
      (ROC curve AUC=0.888; MEA cutoff=56U), with a sensitivity of 90% and a 
      specificity of 84.6%. Besides, MEA gave an insight into the mechanism of aspirin 
      resistance (turnover and/or intrinsic). CONCLUSION: MEA is both rapid and 
      reliable as compared to reference methods. Clinical correlation with risk of 
      re-thrombosis should definitively validate this method and the best cutoff value.
CI  - Copyright © 2016 Elsevier Ltd. All rights reserved.
FAU - Gillet, Benjamin
AU  - Gillet B
AD  - Service d'Hématologie Biologique, CHRU de Brest, France.
FAU - Ianotto, Jean-Christophe
AU  - Ianotto JC
AD  - Service d'Hématologie Clinique, CHRU de Brest, France.
FAU - Mingant, Fanny
AU  - Mingant F
AD  - Service d'Hématologie Biologique, CHRU de Brest, France.
FAU - Didier, Romain
AU  - Didier R
AD  - Service de Cardiologie, CHRU de Brest, France.
FAU - Gilard, Martine
AU  - Gilard M
AD  - Service de Cardiologie, CHRU de Brest, France.
FAU - Ugo, Valérie
AU  - Ugo V
AD  - Service d'Hématologie Biologique, CHU d'Angers, France.
FAU - Lippert, Eric
AU  - Lippert E
AD  - Service d'Hématologie Biologique, CHRU de Brest, France. Electronic address: 
      eric.lippert@chu-brest.fr.
FAU - Galinat, Hubert
AU  - Galinat H
AD  - Service d'Hématologie Biologique, CHRU de Brest, France.
LA  - eng
PT  - Journal Article
DEP - 20160414
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/cytology/drug effects
MH  - Drug Resistance
MH  - Electrodes
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myeloproliferative Disorders/*complications
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests/methods
MH  - Thrombosis/*etiology/*prevention & control
MH  - Thromboxane B2/metabolism
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin resistance
OT  - Multiple Electrode Aggregometry
OT  - Myeloproliferative neoplasms
OT  - Thromboxane B2
OT  - Turnover resistance
EDAT- 2016/04/23 06:00
MHDA- 2017/03/30 06:00
CRDT- 2016/04/23 06:00
PHST- 2016/02/13 00:00 [received]
PHST- 2016/04/07 00:00 [revised]
PHST- 2016/04/09 00:00 [accepted]
PHST- 2016/04/23 06:00 [entrez]
PHST- 2016/04/23 06:00 [pubmed]
PHST- 2017/03/30 06:00 [medline]
AID - S0049-3848(16)30294-8 [pii]
AID - 10.1016/j.thromres.2016.04.006 [doi]
PST - ppublish
SO  - Thromb Res. 2016 Jun;142:26-32. doi: 10.1016/j.thromres.2016.04.006. Epub 2016 
      Apr 14.

PMID- 22305122
OWN - NLM
STAT- MEDLINE
DCOM- 20120625
LR  - 20171116
IS  - 1873-4367 (Electronic)
IS  - 0927-7765 (Linking)
VI  - 93
DP  - 2012 May 1
TI  - Protein based nanoparticles as platforms for aspirin delivery for ophthalmologic 
      applications.
PG  - 161-8
LID - 10.1016/j.colsurfb.2011.12.033 [doi]
AB  - Most conventional ophthalmic dosage forms, though simplistic are limited by poor 
      bioavailability in the posterior chamber of the eye. Application of 
      nanotechnology has the potential to overcome this problem. By varying aspirin 
      albumin ratios from 0.06 to 1.0, we obtained electrokinetically stable, 
      pharmacologically active albumin based aspirin nanoparticles of <200 nm diameter 
      with low polydispersity. In vitro release study showed nanoparticle formulation 
      can release aspirin at a sustained rate for prolonged duration (90% at 72 h) and 
      11% drug release in the posterior chamber over a period of 72 h under simulated 
      condition. Stability of the formulation was well maintained on storage for six 
      months and after reconstitution for 24 h. The formulation showed no hemolysis in 
      contrast to the high hemolysis due to the free drug. This study shows that 
      aspirin loaded albumin nanoparticles prepared by coacervation holds promise as a 
      formulation for topical delivery in diabetic retinopathy.
CI  - Copyright Â© 2012 Elsevier B.V. All rights reserved.
FAU - Das, Saikat
AU  - Das S
AD  - Department of Biosciences and BioEngineering, Indian Institute of Technology 
      Bombay, Bombay, India.
FAU - Bellare, Jayesh R
AU  - Bellare JR
FAU - Banerjee, Rinti
AU  - Banerjee R
LA  - eng
PT  - Journal Article
DEP - 20120103
PL  - Netherlands
TA  - Colloids Surf B Biointerfaces
JT  - Colloids and surfaces. B, Biointerfaces
JID - 9315133
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Carriers)
RN  - 0 (Ophthalmic Solutions)
RN  - 27432CM55Q (Serum Albumin, Bovine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry/pharmacology
MH  - Cattle
MH  - Delayed-Action Preparations/*chemistry/pharmacology
MH  - Drug Carriers/*chemistry/pharmacology
MH  - Drug Stability
MH  - Erythrocytes/drug effects
MH  - Hemolysis/drug effects
MH  - Humans
MH  - Kinetics
MH  - Microscopy, Electron, Transmission
MH  - Nanoparticles/*chemistry/ultrastructure
MH  - Ophthalmic Solutions/*chemistry/pharmacology
MH  - Particle Size
MH  - Serum Albumin, Bovine/*chemistry
MH  - Solubility
EDAT- 2012/02/07 06:00
MHDA- 2012/06/26 06:00
CRDT- 2012/02/07 06:00
PHST- 2011/09/20 00:00 [received]
PHST- 2011/12/27 00:00 [revised]
PHST- 2011/12/27 00:00 [accepted]
PHST- 2012/02/07 06:00 [entrez]
PHST- 2012/02/07 06:00 [pubmed]
PHST- 2012/06/26 06:00 [medline]
AID - S0927-7765(11)00774-0 [pii]
AID - 10.1016/j.colsurfb.2011.12.033 [doi]
PST - ppublish
SO  - Colloids Surf B Biointerfaces. 2012 May 1;93:161-8. doi: 
      10.1016/j.colsurfb.2011.12.033. Epub 2012 Jan 3.

PMID- 1804603
OWN - NLM
STAT- MEDLINE
DCOM- 19920506
LR  - 20131121
IS  - 0529-567X (Print)
IS  - 0529-567X (Linking)
VI  - 26
IP  - 6
DP  - 1991 Nov
TI  - [Low-dose aspirin preventing pregnancy induced hypertension].
PG  - 342-5, 387
AB  - A prospective randomized double-blind study was carried out in pregnant women 
      with risk of pregnancy induced hypertension (PIH). Low dose Aspirin (50 mg/day) 
      or placebo was given consecutively from the 28th weeks of gestation. The results 
      have shown that 8% of the pregnant women in the aspirin treatment group had 
      developed PIH, which was substantially lower than that in the control group (24%) 
      (P less than 0.05). The ratio of TXB2/6-keto-PGF1 alpha increased significantly 
      in the control group while it remained unchanged in treatment group. Increasing 
      plasma fibronectin (Fn) and decreasing AT-III level were seen in the control 
      group but no changes of these parameters in the treatment group. It was presumed 
      that low dose aspirin may have prophylactic effect on PIH. The mechanism of 
      aspirin may be the inhibition of TXA2 and Fn synthesis and decreased consumption 
      of AT-III.
FAU - Cheng, W W
AU  - Cheng WW
AD  - Shanghai Medical University Obstetrics and Gynecology Hospital.
FAU - Zhang, Z J
AU  - Zhang ZJ
LA  - chi
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Fu Chan Ke Za Zhi
JT  - Zhonghua fu chan ke za zhi
JID - 16210370R
RN  - 0 (Fibronectins)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Fibronectins
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy/*blood
MH  - Prospective Studies
MH  - Thromboxane B2/blood
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Fu Chan Ke Za Zhi. 1991 Nov;26(6):342-5, 387.

PMID- 366723
OWN - NLM
STAT- MEDLINE
DCOM- 19790324
LR  - 20191028
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - 17
IP  - 4
DP  - 1978 Nov
TI  - A clinical trial of diflunisal against aspirin in osteoarthritis.
PG  - 265-9
AB  - Thirty patients with osteoarthritis of knees or hips took part in a double-blind 
      randomized 12-week inter-group clinical trial of diflunisal 250 mg to 375 mg 
      twice daily against aspirin 500 mg to 750 mg four times daily using the 
      double-placebo technique. Changes were assessed in weight-bearing pain and night 
      pain, stiffness after rest, a specified activity, and overall judgements by 
      patient and physician, all graded on a five-point scale. Intermalleolar distance 
      or knee flexion were measured. Side-effects and safety tests were monitored. 
      Diflunisal produced statistically significant responses for all the criteria, 
      when numbers of patients better or worse after 12 weeks were compared using the 
      sign test. Neither the figures for aspirin alone, nor a comparison between the 
      two treatment groups, reached statistical significance. Side-effects and 
      especially dropouts were less on diflunisal. Nine patients on diflunisal but only 
      two on aspirin wanted to continue treatment beyond 12 weeks, though still 'blind' 
      when deciding this. Diflunisal may be a useful, less toxic and longer acting 
      alternative to aspirin in the management of osteoarthritis.
FAU - Grayson, M F
AU  - Grayson MF
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdomen
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dizziness/chemically induced
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Edema/chemically induced
MH  - Humans
MH  - Osteoarthritis/*drug therapy
MH  - Pain/chemically induced
MH  - Salicylates/adverse effects/*therapeutic use
MH  - Time Factors
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
AID - 10.1093/rheumatology/17.4.265 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1978 Nov;17(4):265-9. doi: 10.1093/rheumatology/17.4.265.

PMID- 36680667
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230314
IS  - 1573-3017 (Electronic)
IS  - 0963-9292 (Linking)
VI  - 32
IP  - 2
DP  - 2023 Mar
TI  - Assessment of ecotoxicity effects of aspirin on non-target organism (Daphnia 
      magna) via analysis of the responses of oxidative stress, DNA methylation-related 
      genes expressions and life traits changes.
PG  - 137-149
LID - 10.1007/s10646-023-02624-z [doi]
AB  - Aspirin (acetylsalicylic acid, ASA), a widely used non-steroidal 
      anti-inflammatory drug, was frequently detected in aquatic environments around 
      the world. However, information on the potential toxic effects of aspirin on 
      non-target aquatic invertebrates is limited. In the present study, we 
      investigated the effects of ASA on the transcriptional expressions of antioxidant 
      genes (Nrf2, Keap1, HO-1, GCLC, GPx, TRX, TrxR and Prx1) and DNA methylation 
      genes (DNMT1, DNMT3 and TET2) in Daphnia magna (D. magna)for 24, 48 and 96 h and 
      the changes of antioxidant enzymatic activity and GSH, MDA content for 48 h. The 
      effects of ASA on the life traits of D. magna were also addressed via a 21-days 
      chronic toxicity test. Results showed that the expressions of Nrf2 and its target 
      genes (HO-1, GPx and TrxR, GCLC, TRX and Prx1) were induced to different degrees 
      at 48 h and/or 96 h. The activity of antioxidant enzymes (SOD, CAT, GST and GPx) 
      and MDA content increased but GSH content decreased, indicating that ASA caused 
      oxidative stress in D. magna. ASA also changed the expression of DNA methylation 
      genes, such as DNMT and TET2, in D. magna. We speculated that ASA may affect the 
      antioxidant system responses through regulation of Nrf2/Keap1 signaling pathway, 
      and/or through indirectly influencing DNA methylation levels by DNMT and TET gene 
      expression, but the detailed mechanism needs further investigations. Chronic 
      exposure to ASA for 21 days caused inhibitions on the growth, reproduction and 
      behavior of D. magna (e.g., delaying days to the first brood and shortening the 
      body length). In summary, ASA significantly affected the antioxidant responses of 
      D. magna, and negatively disturbed its life traits in growth, development and 
      reproduction.
CI  - © 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Cuiping, He
AU  - Cuiping H
AD  - Department of Ecology, Jinan University, Guangzhou, 510632, China.
FAU - Na, Zhao
AU  - Na Z
AD  - Department of Ecology, Jinan University, Guangzhou, 510632, China.
FAU - Limei, Hu
AU  - Limei H
AD  - Department of Ecology, Jinan University, Guangzhou, 510632, China.
FAU - Tang, Tianli
AU  - Tang T
AD  - Department of Ecology, Jinan University, Guangzhou, 510632, China.
FAU - Yang, Yufeng
AU  - Yang Y
AD  - Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai), Guangzhou, 
      510632, China.
FAU - Xiangping, Nie
AU  - Xiangping N
AD  - Department of Ecology, Jinan University, Guangzhou, 510632, China. 
      txpnie@jnu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20230121
PL  - United States
TA  - Ecotoxicology
JT  - Ecotoxicology (London, England)
JID - 9885956
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Antioxidants)
RN  - 0 (Kelch-Like ECH-Associated Protein 1)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Water Pollutants, Chemical)
SB  - IM
MH  - Animals
MH  - *Aspirin/metabolism/pharmacology
MH  - Antioxidants/metabolism
MH  - Daphnia
MH  - Kelch-Like ECH-Associated Protein 1/genetics/metabolism
MH  - NF-E2-Related Factor 2/genetics/metabolism/pharmacology
MH  - DNA Methylation
MH  - Oxidative Stress
MH  - *Water Pollutants, Chemical/toxicity
OTO - NOTNLM
OT  - Antioxidant system
OT  - Aspirin
OT  - DNA methylation
OT  - Daphnia magna
OT  - Oxidative stress
EDAT- 2023/01/22 06:00
MHDA- 2023/03/15 06:00
CRDT- 2023/01/21 11:17
PHST- 2023/01/09 00:00 [accepted]
PHST- 2023/01/22 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2023/01/21 11:17 [entrez]
AID - 10.1007/s10646-023-02624-z [pii]
AID - 10.1007/s10646-023-02624-z [doi]
PST - ppublish
SO  - Ecotoxicology. 2023 Mar;32(2):137-149. doi: 10.1007/s10646-023-02624-z. Epub 2023 
      Jan 21.

PMID- 8143845
OWN - NLM
STAT- MEDLINE
DCOM- 19940503
LR  - 20190621
IS  - 0014-5793 (Print)
IS  - 0014-5793 (Linking)
VI  - 342
IP  - 1
DP  - 1994 Mar 28
TI  - Mutation of serine-516 in human prostaglandin G/H synthase-2 to methionine or 
      aspirin acetylation of this residue stimulates 15-R-HETE synthesis.
PG  - 33-7
AB  - Prostaglandin G/H synthase (PGHS) is a key enzyme in cellular prostaglandin (PG) 
      synthesis and is the target of non-steroidal anti-inflammatory agents. PGHS 
      occurs in two isoforms, termed PGHS-1 and PGHS-2. These isoforms differ in 
      several respects, including their enzymatic activity following acetylation by 
      aspirin. While PG synthesis by both isoforms is inhibited by aspirin, 
      15-R-hydroxyeicosatetraenoic acid (15-R-HETE) synthesis by PGHS-2, but not 
      PGHS-1, is stimulated by preincubation with aspirin. We have mutated the putative 
      aspirin acetylation site of hPGHS-2, and expressed the mutants in COS-7 cells 
      using recombinant vaccinia virus. Enzyme activity and inhibitor sensitivity 
      studies provide evidence that Ser516 is the aspirin acetylation site of human 
      PGHS-2 and that substitution of a methionine residue at this position can mimic 
      the effects of aspirin acetylation on enzyme activity.
FAU - Mancini, J A
AU  - Mancini JA
AD  - Department of Biochemistry and Molecular Biology, Merck Frosst Centre for 
      Therapeutic Research, Kirkland, Que., Canada.
FAU - O'Neill, G P
AU  - O'Neill GP
FAU - Bayly, C
AU  - Bayly C
FAU - Vickers, P J
AU  - Vickers PJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - FEBS Lett
JT  - FEBS letters
JID - 0155157
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - 0 (Prostaglandins)
RN  - 452VLY9402 (Serine)
RN  - 73945-47-8 (15-hydroxy-5,8,11,13-eicosatetraenoic acid)
RN  - AE28F7PNPL (Methionine)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Aspirin/*metabolism/pharmacology
MH  - Cell Line
MH  - Humans
MH  - Hydroxyeicosatetraenoic Acids/*biosynthesis
MH  - Methionine/chemistry
MH  - Microsomes/metabolism
MH  - Mutagenesis, Site-Directed
MH  - Prostaglandin-Endoperoxide Synthases/chemistry/genetics/*metabolism
MH  - Prostaglandins/biosynthesis
MH  - Serine/chemistry
EDAT- 1994/03/28 00:00
MHDA- 1994/03/28 00:01
CRDT- 1994/03/28 00:00
PHST- 1994/03/28 00:00 [pubmed]
PHST- 1994/03/28 00:01 [medline]
PHST- 1994/03/28 00:00 [entrez]
AID - 0014-5793(94)80579-2 [pii]
AID - 10.1016/0014-5793(94)80579-2 [doi]
PST - ppublish
SO  - FEBS Lett. 1994 Mar 28;342(1):33-7. doi: 10.1016/0014-5793(94)80579-2.

PMID- 368086
OWN - NLM
STAT- MEDLINE
DCOM- 19790428
LR  - 20190823
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 19
IP  - 1
DP  - 1979 Jan
TI  - Comparative efficacy of pirprofen and aspirin in rheumatoid arthritis.
PG  - 56-63
AB  - A six-month double-blind, randomized, parallel-design trial comparing pirprofen, 
      a new nonsteroidal antiinflammatory drug, with aspirin in patients with 
      rheumatoid arthritis is described. The dose of pirprofen, a phenylpropionic acid 
      derivative, was 600 mg per day; the dose of aspirin was 3600 mg per day. 
      Pirprofen was found to be as effective as aspirin in improving the modified 
      articular index, swelling joint index, grip strength, walking time, and duration 
      of morning stiffness. Fewer patients receiving pirprofen reported drug-related 
      side effects than those receiving aspirin, however, the difference was not 
      statistically significant (P less than 0.1). There was no significant difference 
      between groups in the incidence of positive stool guaiac tests (three of 17, 
      pirprofen; five of 18, aspirin). Pirprofen was found to be as safe and effective 
      as aspirin in the management of patients with rheumatoid arthritis.
FAU - Saykaly, R J
AU  - Saykaly RJ
FAU - Love, D W
AU  - Love DW
FAU - Simon, J A
AU  - Simon JA
FAU - DeGuzmann, R
AU  - DeGuzmann R
FAU - Gabovitch, E
AU  - Gabovitch E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyrroles)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Phenylpropionates/adverse effects/*therapeutic use
MH  - Pyrroles/adverse effects/therapeutic use
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1979.tb01617.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1979 Jan;19(1):56-63. doi: 10.1002/j.1552-4604.1979.tb01617.x.

PMID- 6143715
OWN - NLM
STAT- MEDLINE
DCOM- 19840620
LR  - 20131121
IS  - 0015-8178 (Print)
IS  - 0015-8178 (Linking)
VI  - 102
IP  - 12
DP  - 1984 Mar 29
TI  - [Interval therapy of migraine. Pharmacological bases].
PG  - 328-32
AB  - A quite heterogenous variety of drugs is used for the prophylactic treatment of 
      patients with severe migraine. These drugs may prove effective in preventing 
      migraine attacks due to two different pharmacological effects: a reduction of 
      platelets' aggregability and/or an effect on blood vessels tone. The latter 
      effect may be characterized by a decrease in reactivity, i.e. vasoconstriction as 
      well as an overshooting vasodilation is prevented. The vascular tone is 
      stabilized.
FAU - Ziegler, A
AU  - Ziegler A
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Intervalltherapie der Migräne. Pharmakologische Grundlagen.
PL  - Germany
TA  - Fortschr Med
JT  - Fortschritte der Medizin
JID - 2984763R
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Serotonin Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Vessels/physiology
MH  - Calcium Channel Blockers/pharmacology/therapeutic use
MH  - Cerebrovascular Circulation/drug effects
MH  - Humans
MH  - Microcirculation/drug effects
MH  - Migraine Disorders/*drug therapy/etiology
MH  - Models, Biological
MH  - Platelet Aggregation/drug effects
MH  - Serotonin Antagonists/pharmacology/therapeutic use
EDAT- 1984/03/29 00:00
MHDA- 1984/03/29 00:01
CRDT- 1984/03/29 00:00
PHST- 1984/03/29 00:00 [pubmed]
PHST- 1984/03/29 00:01 [medline]
PHST- 1984/03/29 00:00 [entrez]
PST - ppublish
SO  - Fortschr Med. 1984 Mar 29;102(12):328-32.

PMID- 11641591
OWN - NLM
STAT- MEDLINE
DCOM- 20020114
LR  - 20211008
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 12
IP  - 3
DP  - 2001
TI  - Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial 
      fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin 
      et Contraste Spontané; FFAACS).
PG  - 245-52
AB  - BACKGROUND: A combination of low-dose aspirin with anticoagulants may provide 
      better protection against thromboembolic events compared to anticoagulants alone 
      in high-risk patients with atrial fibrillation. OBJECTIVE: Evaluation of the 
      preventive efficacy against nonfatal thromboembolic events and vascular deaths of 
      the combination of the oral anticoagulant fluindione and aspirin (100 mg) in 
      patients with high-risk atrial fibrillation. METHODS: A multicenter, 
      placebo-controlled, double-blind, randomized trial was conducted at 49 
      investigating centers in France. Atrial fibrillation patients with a previous 
      thromboembolic event or older than 65 years and with either a history of 
      hypertension, a recent episode of heart failure or decreased left ventricular 
      function were included in the study. Patients were treated with fluindione plus 
      placebo (i.e. anticoagulant alone) or fluindione plus aspirin (i.e. combination 
      therapy), with an international normalized ratio target of between 2 and 2.6. The 
      combined primary endpoint was stroke (ischemic or hemorrhagic), myocardial 
      infarction, systemic arterial emboli or vascular death. The secondary endpoint 
      was the incidence of hemorrhagic complications. RESULTS: The 157 participants 
      (average age 74 years; 52% women; 42% with paroxysmal atrial fibrillation) were 
      followed for an average of 0.84 years. Three nonfatal thromboembolic events were 
      observed (1 in the anticoagulation group, 2 in the combination group) and 6 
      patients died (3 in the anticoagulation group, 3 in the combination group), none 
      of them from a thromboembolic complication. However, 3 deaths were secondary to 
      severe hemorrhagic complications (1 in the anticoagulation group, 2 in the 
      combination group). Nonfatal hemorrhagic complications occurred more often in the 
      combination group (n = 10, 13.1%) compared to the anticoagulation group (n = 1, 
      1.2%) (p = 0.003). CONCLUSION: The combination of aspirin with anticoagulant is 
      associated with increased bleeding in elderly atrial fibrillation patients. The 
      effect on thromboembolism and the overall balance of benefit to risk could not be 
      accurately assessed in this study due to the limited number of ischemic events.
CI  - Copyright 2001 S. Karger AG, Basel
FAU - Lechat, P
AU  - Lechat P
AD  - Pharmacology Department, Pitié-Salpêtrière Hospital, Paris, France. 
      philippe.lechat@ps1.ap-hop-paris.fr
FAU - Lardoux, H
AU  - Lardoux H
FAU - Mallet, A
AU  - Mallet A
FAU - Sanchez, P
AU  - Sanchez P
FAU - Derumeaux, G
AU  - Derumeaux G
FAU - Lecompte, T
AU  - Lecompte T
FAU - Maillard, L
AU  - Maillard L
FAU - Mas, J L
AU  - Mas JL
FAU - Mentre, F
AU  - Mentre F
FAU - Pousset, F
AU  - Pousset F
FAU - Lacomblez, L
AU  - Lacomblez L
FAU - Pisica, G
AU  - Pisica G
FAU - Solbes-Latourette, S
AU  - Solbes-Latourette S
FAU - Raynaud, P
AU  - Raynaud P
FAU - Chaumet-Riffaud, P
AU  - Chaumet-Riffaud P
CN  - FFAACS (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané) 
      Investigators
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Anticoagulants)
RN  - 0 (Drug Combinations)
RN  - 5M7Y6274ZE (Phenindione)
RN  - EQ35YMS20Q (fluindione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Phenindione/administration & dosage/adverse effects/*analogs & 
      derivatives/*therapeutic use
MH  - Risk Factors
MH  - Thromboembolism/prevention & control
MH  - Treatment Outcome
MH  - Vascular Diseases/mortality
EDAT- 2001/10/20 10:00
MHDA- 2002/01/15 10:01
CRDT- 2001/10/20 10:00
PHST- 2001/10/20 10:00 [pubmed]
PHST- 2002/01/15 10:01 [medline]
PHST- 2001/10/20 10:00 [entrez]
AID - 47711 [pii]
AID - 10.1159/000047711 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2001;12(3):245-52. doi: 10.1159/000047711.

PMID- 2167788
OWN - NLM
STAT- MEDLINE
DCOM- 19901003
LR  - 20190820
IS  - 0143-5221 (Print)
IS  - 0143-5221 (Linking)
VI  - 79
IP  - 1
DP  - 1990 Jul
TI  - Effect of aspirin infusions on platelet function in humans.
PG  - 37-42
AB  - 1. The inhibitory effects of aspirin on platelet function in vitro have been 
      shown to be both time (over 3 h) and concentration (1-10 mumol/l) dependent. 2. 
      To determine if these effects occurred in vivo, four volunteers received 
      intravenous infusions on four occasions, to give constant plasma aspirin 
      concentrations of 0, 1, 2 and 4 mumol/l over 3 h. Infusions were performed at 
      intervals of at least 2 weeks. 3. Before and during the infusions, blood was 
      taken for assay of aspirin concentrations, and measurements of platelet 
      aggregation in response to collagen, adenosine 5'-pyrophosphate and arachidonate. 
      Thromboxane generation after stimulated platelet aggregation and whole-blood 
      coagulation was also measured. 4. At each aspirin concentration, both platelet 
      aggregation and thromboxane generation in response to collagen and arachidonate 
      were inhibited progressively over the 3 h infusion period. Greatest inhibition 
      was seen during the 4 mumol/l infusion, which produced maximal or near-maximal 
      inhibition by the third hour. 5. Thromboxane generated during whole-blood 
      coagulation was similarly inhibited in both a time- and concentration-dependent 
      manner throughout all aspirin infusions. 6. The progressive nature of the 
      inhibition of platelet function with these low aspirin concentrations may be due 
      to either slow aspirin transport across the platelet membrane or delayed 
      interaction with cyclo-oxygenase.
FAU - Wilson, K M
AU  - Wilson KM
AD  - Department of Clinical and Experimental Pharmacology, University of Adelaide, 
      Australia.
FAU - Siebert, D M
AU  - Siebert DM
FAU - Duncan, E M
AU  - Duncan EM
FAU - Somogyi, A A
AU  - Somogyi AA
FAU - Lloyd, J V
AU  - Lloyd JV
FAU - Bochner, F
AU  - Bochner F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 0 (Arachidonic Acids)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/blood/*pharmacology
MH  - Collagen/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane A2/blood
MH  - Thromboxane B2/blood
MH  - Time Factors
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
AID - 10.1042/cs0790037 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 1990 Jul;79(1):37-42. doi: 10.1042/cs0790037.

PMID- 24215195
OWN - NLM
STAT- MEDLINE
DCOM- 20140623
LR  - 20131112
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 11
IP  - 12
DP  - 2013 Dec
TI  - Should we anticoagulate after bioprosthetic aortic valve replacement?
PG  - 1649-57
LID - 10.1586/14779072.2013.839216 [doi]
AB  - There is a lack of consensus as to the ideal antithrombotic strategy after 
      bioprosthetic aortic valve replacement. Herein, the authors review the literature 
      on this topic and find that most of the evidence is comprised of small 
      observational data, with a few prospective trials. The bulk of the evidence is in 
      favor of no anticoagulation after bioprosthetic aortic valve replacement in 
      patients at low risk of thromboembolism. Most studies suggest using only 
      antiplatelet therapy with the exception of two studies that advocate 
      anticoagulation. One study suggests that no antithrombotic therapy at all may be 
      safe. One study evaluated the question mechanistically, showing no increased 
      microembolic signals on transcranial Doppler in patients receiving aspirin 
      compared to patients who were anticoagulated. Based on the evidence presented, 
      the authors recommend using aspirin only after bioprosthetic aortic valve 
      replacement in patients at low risk of thromboembolism.
FAU - Al-Atassi, Talal
AU  - Al-Atassi T
AD  - Division of Cardiac Surgery, University of Ottawa, Heart Institute, 40 Ruskin 
      Street, Suite 3402, Ottawa, Ontario, K1Y 4W7, Canada.
FAU - Toeg, Hadi
AU  - Toeg H
FAU - Ruel, Marc
AU  - Ruel M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Aortic Valve/pathology/*surgery
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Bioprosthesis
MH  - Heart Valve Prosthesis
MH  - Heart Valve Prosthesis Implantation/*methods
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Risk Factors
MH  - Thromboembolism/etiology/*prevention & control
MH  - Ultrasonography, Doppler, Transcranial
EDAT- 2013/11/13 06:00
MHDA- 2014/06/24 06:00
CRDT- 2013/11/13 06:00
PHST- 2013/11/13 06:00 [entrez]
PHST- 2013/11/13 06:00 [pubmed]
PHST- 2014/06/24 06:00 [medline]
AID - 10.1586/14779072.2013.839216 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2013 Dec;11(12):1649-57. doi: 
      10.1586/14779072.2013.839216.

PMID- 24404131
OWN - NLM
STAT- MEDLINE
DCOM- 20140916
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 1
DP  - 2014
TI  - Microfluidic thrombosis under multiple shear rates and antiplatelet therapy 
      doses.
PG  - e82493
LID - 10.1371/journal.pone.0082493 [doi]
LID - e82493
AB  - The mainstay of treatment for thrombosis, the formation of occlusive platelet 
      aggregates that often lead to heart attack and stroke, is antiplatelet therapy. 
      Antiplatelet therapy dosing and resistance are poorly understood, leading to 
      potential incorrect and ineffective dosing. Shear rate is also suspected to play 
      a major role in thrombosis, but instrumentation to measure its influence has been 
      limited by flow conditions, agonist use, and non-systematic and/or 
      non-quantitative studies. In this work we measured occlusion times and thrombus 
      detachment for a range of initial shear rates (500, 1500, 4000, and 10000 s(-1)) 
      and therapy concentrations (0-2.4 µM for eptifibatide, 0-2 mM for 
      acetyl-salicylic acid (ASA), 3.5-40 Units/L for heparin) using a microfluidic 
      device. We also measured complete blood counts (CBC) and platelet activity using 
      whole blood impedance aggregometry. Effects of shear rate and dose were analyzed 
      using general linear models, logistic regressions, and Cox proportional hazards 
      models. Shear rates have significant effects on thrombosis/dose-response curves 
      for all tested therapies. ASA has little effect on high shear occlusion times, 
      even at very high doses (up to 20 times the recommended dose). Under ASA therapy, 
      thrombi formed at high shear rates were 4 times more prone to detachment compared 
      to those formed under control conditions. Eptifibatide reduced occlusion when 
      controlling for shear rate and its efficacy increased with dose concentration. In 
      contrast, the hazard of occlusion from ASA was several orders of magnitude higher 
      than that of eptifibatide. Our results show similar dose efficacy to our low 
      shear measurements using whole blood aggregometry. This quantitative and 
      statistically validated study of the effects of a wide range of shear rate and 
      antiplatelet therapy doses on occlusive thrombosis contributes to more accurate 
      understanding of thrombosis and to models for optimizing patient treatment.
FAU - Li, Melissa
AU  - Li M
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology, Atlanta, Georgia, United States of America.
FAU - Hotaling, Nathan A
AU  - Hotaling NA
AD  - Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of 
      Technology, Atlanta, Georgia, United States of America.
FAU - Ku, David N
AU  - Ku DN
AD  - George W. Woodruff Department of Mechanical Engineering, Georgia Institute of 
      Technology, Atlanta, Georgia, United States of America.
FAU - Forest, Craig R
AU  - Forest CR
AD  - George W. Woodruff Department of Mechanical Engineering, Georgia Institute of 
      Technology, Atlanta, Georgia, United States of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140103
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Coagulation Tests
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Microfluidic Analytical Techniques
MH  - Microfluidics/*methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Reproducibility of Results
MH  - Thrombosis/*blood/*drug therapy
PMC - PMC3880267
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/01/10 06:00
MHDA- 2014/09/17 06:00
CRDT- 2014/01/10 06:00
PHST- 2013/05/22 00:00 [received]
PHST- 2013/10/23 00:00 [accepted]
PHST- 2014/01/10 06:00 [entrez]
PHST- 2014/01/10 06:00 [pubmed]
PHST- 2014/09/17 06:00 [medline]
AID - PONE-D-13-21522 [pii]
AID - 10.1371/journal.pone.0082493 [doi]
PST - epublish
SO  - PLoS One. 2014 Jan 3;9(1):e82493. doi: 10.1371/journal.pone.0082493. eCollection 
      2014.

PMID- 14512126
OWN - NLM
STAT- MEDLINE
DCOM- 20040108
LR  - 20190922
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 25
IP  - 8
DP  - 2003 Aug
TI  - The role of clopidogrel in the management of acute coronary syndromes.
PG  - 2155-81
AB  - BACKGROUND: Despite significant advances in the management of coronary heart 
      disease, myocardial infarction (MI) is still associated with a mortality rate of 
      45%. Acetylsalicylic acid (ASA) has been the oral antiplatelet drug of choice 
      until recently. Thienopyridines such as clopidogrel have been shown to provide 
      significant benefits in the management of acute coronary syndromes (ACS), either 
      as an alternative to or in combination with ASA therapy. OBJECTIVE: The purpose 
      of this article was to review the available scientific literature evaluating the 
      use of clopidogrel in the management of ACS. METHODS: Relevant published data 
      were identified through searches of the English-language literature indexed on 
      MEDLINE and International Pharmaceutical Abstracts through April 2003. Search 
      terms included thienopyridines, platelet aggregation inhibitors, clopidogrel, 
      ticlopidine, acute coronary syndrome, myocardial infarction, and percutaneous 
      coronary intervention. Pertinent conference abstracts were also included. 
      RESULTS: The results of 3 large clinical trials-Clopidogrel in Unstable Angina to 
      Prevent Recurrent Events (CURE), Effect of Pretreatment with Clopidogrel and 
      Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous 
      Coronary Intervention (PCI-CURE), and Clopidogrel for the Reduction of Events 
      During Observation (CREDO)-support prolonged use of clopidogrel (up to 12 months) 
      in combination with ASA in patients with non-ST-segment elevation MI and patients 
      undergoing a percutaneous coronary intervention (PCI). A significant increase in 
      bleeding events was observed in the group that received clopidogrel plus ASA 
      compared with ASA alone in the CURE (major bleeding, P = 0.001; minor bleeding, P 
      < 0.001) and PCI-CURE (minor bleeding, P = 0.03) trials. Use of the combination 
      of clopidogrel and ASA with other antiplatelet and/or anticoagulant agents has 
      not been studied extensively. CONCLUSIONS: Use of the combination of clopidogrel 
      and ASA for up to 9 months is recommended for the medical management of 
      non-ST-segment elevation MI and after a PCI. The increased risk of bleeding must 
      be taken into account, and use of this combination with other agents that affect 
      bleeding risk should be considered carefully.
FAU - Wodlinger, Anna M
AU  - Wodlinger AM
AD  - Temple University School of Pharmacy, Philadelphia, Pennsylvania 19140, USA. 
      awodling@temple.edu
FAU - Pieper, John A
AU  - Pieper JA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Angina, Unstable/drug therapy
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Coronary Disease/*drug therapy
MH  - Cost-Benefit Analysis
MH  - Drug Interactions
MH  - Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Ticlopidine/adverse effects/*analogs & derivatives/pharmacology/*therapeutic use
RF  - 83
EDAT- 2003/09/27 05:00
MHDA- 2004/01/09 05:00
CRDT- 2003/09/27 05:00
PHST- 2003/09/27 05:00 [pubmed]
PHST- 2004/01/09 05:00 [medline]
PHST- 2003/09/27 05:00 [entrez]
AID - S0149291803802114 [pii]
AID - 10.1016/s0149-2918(03)80211-4 [doi]
PST - ppublish
SO  - Clin Ther. 2003 Aug;25(8):2155-81. doi: 10.1016/s0149-2918(03)80211-4.

PMID- 22480996
OWN - NLM
STAT- MEDLINE
DCOM- 20121107
LR  - 20221207
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 77
IP  - 2
DP  - 2012 Aug
TI  - Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung 
      cancer.
PG  - 246-51
LID - 10.1016/j.lungcan.2012.03.005 [doi]
AB  - There is evidence that aspirin and non-aspirin non-steroidal anti-inflammatory 
      drug (NSAID) have anti-carcinogenic properties, but their effect on lung cancer, 
      in particular in never-smokers, is unclear. Information on past or current use of 
      anti-inflammatory medication was obtained in 398 Chinese female primary lung 
      cancer cases and 814 controls in a hospital-based study in Singapore. 65% of 
      cases and 88% of controls were never-smokers. Controls were excluded if they had 
      been admitted for conditions associated with aspirin or NSAID use (n=174). 
      Regular aspirin use (twice a week or more, for a month or more) was associated 
      with a reduced risk of lung cancer (adjusted odds ratio [OR] 0.50, 95% confidence 
      intervals [95%CI] 0.31-0.81 in non-smokers; OR 0.38, 95%CI 0.16-0.93 in smokers). 
      Regular use of non-aspirin NSAID, paracetamol, steroid creams and steroid pills 
      was uncommon and no association with lung cancer was detected. Our results 
      suggest that aspirin consumption may reduce lung cancer risk in Asian women and 
      are consistent with current understanding of the role of cyclooxygenase in lung 
      carcinogenesis.
CI  - Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
FAU - Lim, Wei-Yen
AU  - Lim WY
AD  - Saw Swee Hock School of Public Health, National University of Singapore, MD3, 16 
      Medical Drive, Singapore 117597, Singapore. wei-yen lim@nuhs.edu.sg
FAU - Chuah, Khoon Leong
AU  - Chuah KL
FAU - Eng, Philip
AU  - Eng P
FAU - Leong, Swan Swan
AU  - Leong SS
FAU - Lim, Elaine
AU  - Lim E
FAU - Lim, Tow Keang
AU  - Lim TK
FAU - Ng, Alan
AU  - Ng A
FAU - Poh, Wee Teng
AU  - Poh WT
FAU - Tee, Augustine
AU  - Tee A
FAU - Teh, Ming
AU  - Teh M
FAU - Salim, Agus
AU  - Salim A
FAU - Seow, Adeline
AU  - Seow A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120403
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Asian People
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/epidemiology/*etiology
MH  - Middle Aged
MH  - Risk Assessment
MH  - Risk Factors
MH  - Singapore/epidemiology
MH  - Surveys and Questionnaires
EDAT- 2012/04/07 06:00
MHDA- 2012/11/08 06:00
CRDT- 2012/04/07 06:00
PHST- 2011/07/14 00:00 [received]
PHST- 2012/02/03 00:00 [revised]
PHST- 2012/03/10 00:00 [accepted]
PHST- 2012/04/07 06:00 [entrez]
PHST- 2012/04/07 06:00 [pubmed]
PHST- 2012/11/08 06:00 [medline]
AID - S0169-5002(12)00116-X [pii]
AID - 10.1016/j.lungcan.2012.03.005 [doi]
PST - ppublish
SO  - Lung Cancer. 2012 Aug;77(2):246-51. doi: 10.1016/j.lungcan.2012.03.005. Epub 2012 
      Apr 3.

PMID- 11781283
OWN - NLM
STAT- MEDLINE
DCOM- 20020208
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 122
IP  - 1
DP  - 2002 Jan
TI  - Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis.
PG  - 78-84
AB  - BACKGROUND & AIMS: The aim of the study is to compare the cost-effectiveness of 
      aspirin and colonoscopy in the prevention of colorectal cancer. METHODS: A Markov 
      process is used to follow a hypothetical cohort of 100,000 subjects aged 50 years 
      until death. Four strategies are compared: (1) no intervention, (2) colonoscopy 
      once per 10 years and every 3 years in subjects with polyps, (3) chemoprevention 
      with 325 mg of daily aspirin, and (4) combination of the second and third 
      strategies. The various strategies are compared calculating incremental 
      cost-effectiveness ratios (ICERs). RESULTS: The expected number of colorectal 
      cancers is 5904 per 100,000 subjects. Colonoscopy prevents 4428 colorectal 
      cancers and saves 7951 life-years at an ICER of $10,983 per life-year saved 
      compared with no intervention. Aspirin prevents 2952 colorectal cancers and saves 
      5301 life-years at an ICER of $47,249 per life-year saved compared with no 
      intervention. The cost of aspirin therapy plus management of aspirin-related 
      complications was reported to be $172 per year per patient. Varying the annual 
      aspirin-related costs between $50 and $200 results in ICER changes between $4617 
      and $57,080, with the 2 strategies breaking even at $70. Applying aspirin 
      chemoprevention plus colonoscopy screening concomitantly yields an ICER of 
      $227,607 per life-year saved compared with screening colonoscopy alone. 
      CONCLUSION: As compared with colonoscopy once per 10 years, the use of aspirin to 
      prevent colorectal cancer saves fewer lives at higher costs. The high 
      complication cost and the lower efficacy of aspirin render screening colonoscopy 
      a more cost-effective strategy to prevent colorectal cancer.
FAU - Suleiman, Saud
AU  - Suleiman S
AD  - Department of Veterans Affairs Medical Center, Albuquerque, New Mexico 87108, 
      USA.
FAU - Rex, Douglas K
AU  - Rex DK
FAU - Sonnenberg, Amnon
AU  - Sonnenberg A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 2002 Jan;122(1):230-3. PMID: 11781299
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/economics/*therapeutic use
MH  - Aspirin/economics/*therapeutic use
MH  - Colonoscopy
MH  - *Colorectal Neoplasms/drug therapy/economics/prevention & control
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Markov Chains
MH  - Middle Aged
EDAT- 2002/01/10 10:00
MHDA- 2002/02/09 10:01
CRDT- 2002/01/10 10:00
PHST- 2002/01/10 10:00 [pubmed]
PHST- 2002/02/09 10:01 [medline]
PHST- 2002/01/10 10:00 [entrez]
AID - S0016508502514438 [pii]
AID - 10.1053/gast.2002.29689 [doi]
PST - ppublish
SO  - Gastroenterology. 2002 Jan;122(1):78-84. doi: 10.1053/gast.2002.29689.

PMID- 31487647
OWN - NLM
STAT- MEDLINE
DCOM- 20200219
LR  - 20200219
IS  - 2210-7797 (Electronic)
IS  - 2210-7789 (Linking)
VI  - 17
DP  - 2019 Jul
TI  - Aspirin use during pregnancy and hypertensive disorders in women with various 
      risks.
PG  - 241-248
LID - S2210-7789(19)30099-6 [pii]
LID - 10.1016/j.preghy.2019.07.005 [doi]
AB  - BACKGROUND: It is still unclear how well aspirin performs in women with different 
      risks and how the timing of aspirin use influences its efficacy. This study was 
      to evaluate the association between timing of aspirin exposure and hypertensive 
      disorders in pregnant women with various risks in a prospective cohort. METHODS: 
      We used data from the Collaborative Perinatal Project, U.S., 1959-1976. Women 
      were grouped into high, moderate and low risks based on medical history. We 
      classified the timing of aspirin exposure into 4 weeks before the last menstrual 
      period, the first, second and third trimesters. RESULTS: A total of 50,579 
      pregnant women were included in our analysis with 6453, 18,552 and 25,574 women 
      at high, moderate and low risks, respectively. In high-risk women, aspirin use 
      for more than 7 days in the first trimester reduced the risks of preterm and term 
      preeclampsia/eclampsia by 42% (adjusted OR 0.58; 95% CI 0.36-0.94) and 24% 
      (adjusted OR 0.76; 95% CI 0.59-0.97), respectively; in moderate-risk women, 
      aspirin use for more than 7 days during the third trimester reduced the risks of 
      term preeclampsia/eclampsia and gestational hypertension by 37% (adjusted OR 
      0.63; 95% CI 0.50-0.79) and 27% (adjusted OR 0.73; 95% CI 0.62-0.86), 
      respectively. CONCLUSION: Aspirin use in pregnancy reduces the risks of maternal 
      hypertensive disorders. Early initiation of aspirin in high-risk women was 
      associated with lower incidence of preeclampsia/eclampsia. Meanwhile, the 
      protective effect of aspirin on term preeclampsia/eclampsia and gestational 
      hypertension may continue till late pregnancy.
CI  - Copyright © 2019. Published by Elsevier B.V.
FAU - Zhu, Jing
AU  - Zhu J
AD  - MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of 
      Obstetrics and Gynecology, Xinhua Hospital, Shanghai Jiao Tong University School 
      of Medicine, Shanghai, China.
FAU - Chen, Chang
AU  - Chen C
AD  - MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Jiao 
      Tong University School of Public Health, Shanghai, China.
FAU - Lu, Danni
AU  - Lu D
AD  - MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Jiao 
      Tong University School of Public Health, Shanghai, China.
FAU - Zhang, Jinwen
AU  - Zhang J
AD  - MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Jiao 
      Tong University School of Public Health, Shanghai, China.
FAU - Jing, Shiwen
AU  - Jing S
AD  - MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Jiao 
      Tong University School of Public Health, Shanghai, China.
FAU - Xie, Hehui
AU  - Xie H
AD  - School of Public Health, Hongqiao International Institute of Medicine, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Zhang, Jun
AU  - Zhang J
AD  - MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Jiao 
      Tong University School of Public Health, Shanghai, China. Electronic address: 
      zhangjun@xinhuamed.com.cn.
LA  - eng
PT  - Journal Article
DEP - 20190715
PL  - Netherlands
TA  - Pregnancy Hypertens
JT  - Pregnancy hypertension
JID - 101552483
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - China/epidemiology
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/epidemiology/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pre-Eclampsia/*epidemiology/prevention & control
MH  - Pregnancy
MH  - Pregnancy Trimesters
MH  - Prospective Studies
MH  - Risk Factors
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Gestational hypertension
OT  - Preeclampsia
OT  - Risk factors
EDAT- 2019/09/06 06:00
MHDA- 2020/02/20 06:00
CRDT- 2019/09/06 06:00
PHST- 2019/04/04 00:00 [received]
PHST- 2019/07/10 00:00 [revised]
PHST- 2019/07/14 00:00 [accepted]
PHST- 2019/09/06 06:00 [pubmed]
PHST- 2020/02/20 06:00 [medline]
PHST- 2019/09/06 06:00 [entrez]
AID - S2210-7789(19)30099-6 [pii]
AID - 10.1016/j.preghy.2019.07.005 [doi]
PST - ppublish
SO  - Pregnancy Hypertens. 2019 Jul;17:241-248. doi: 10.1016/j.preghy.2019.07.005. Epub 
      2019 Jul 15.

PMID- 27807733
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20181202
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Linking)
VI  - 18
IP  - 12
DP  - 2016 Dec
TI  - Aspirin Use in Women: Current Perspectives and Future Directions.
PG  - 74
AB  - PURPOSE OF REVIEW: This review examines the recent literature on the use of 
      low-dose aspirin (LDA) for primary and secondary prevention of cardiovascular 
      disease in women, use of LDA for pre-eclampsia prevention in pregnancy, and the 
      underutilization of aspirin therapy in women as compared to men. RECENT FINDINGS: 
      While men and women should not differ with respect to aspirin use for secondary 
      prevention, its role in primary prevention remains unclear for both sexes, with 
      particular uncertainty in women. Reflective of this are conflicting 
      recommendations in current guidelines for primary prevention and thus 
      investigations of primary prevention aspirin use are ongoing and will play an 
      important role in elucidating its efficacy. While there is significant 
      heterogeneity in studies to date of LDA for pre-eclampsia prevention, based on 
      recent meta-analyses suggesting promising results, guidelines now recommend 
      initiation in high risk women after the 12th week of gestation. Finally, studies 
      consistently reveal that aspirin therapy is underutilized in women as compared to 
      men, suggesting a need to better educate physicians and the general public about 
      its use in women. Further research is needed to better elucidate the role of 
      aspirin in women for primary prevention of cardiovascular disease and for 
      pre-eclampsia in high risk pregnant women. In addition, further investigation 
      into the factors that lead to the current underutilization of aspirin in women 
      are required in order to ensure that patients of both sexes are optimally 
      treated, with the goal of improving cardiovascular outcomes in all patients.
FAU - Sarma, Amy
AU  - Sarma A
AD  - Department of Cardiology, Massachusetts General Hospital, 55 Fruit Street, 
      Boston, MA, 02114, USA.
FAU - Scott, Nandita S
AU  - Scott NS
AD  - Department of Cardiology, Massachusetts General Hospital, 55 Fruit Street, 
      Boston, MA, 02114, USA. nsscott@mgh.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Primary Prevention
MH  - Risk Factors
MH  - Secondary Prevention
OTO - NOTNLM
OT  - Aspirin
OT  - Pre-eclampsia
OT  - Pregnancy
OT  - Prevention
OT  - Women
EDAT- 2016/11/04 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/11/04 06:00
PHST- 2016/11/04 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
PHST- 2016/11/04 06:00 [entrez]
AID - 10.1007/s11883-016-0630-1 [pii]
AID - 10.1007/s11883-016-0630-1 [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2016 Dec;18(12):74. doi: 10.1007/s11883-016-0630-1.

PMID- 30458652
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 33
IP  - 13
DP  - 2020 Jul
TI  - Prevention of preeclampsia in high-risk patients with low-molecular-weight 
      heparin: a meta-analysis.
PG  - 2202-2208
LID - 10.1080/14767058.2018.1543656 [doi]
AB  - Objective: To assess the secondary preventive effect of low-molecular-weight 
      heparin (LMWH) on pregnant women with prior early-onset or severe preeclampsia 
      (PE).Methods: A systematic literature search of several databases was conducted 
      for randomized controlled trials comparing LMWH with either aspirin or no 
      treatment in pregnant women at a high risk of placental-mediated pregnancy 
      complications (PMPCs). Odds ratios and associated 95% confidence intervals (CI) 
      and weighted mean differences and 95% CI were calculated.Results: Seven studies 
      including 1035 patients were evaluated. These studies showed a risk reduction in 
      composite PMPC outcome (relative risk (RR) 0.635 (95% CI: 0.436-0.925); p=.018), 
      PE (RR 0.522 (95% CI: 0.334-0.815); p=.004), a small-for-gestational-age neonate 
      (RR 0.622 (95% CI: 0.440-0.880); p=.007), and an increase in gestational length 
      (SMD 0.312 (95% CI: 0.017-0.607); p=.038) and neonatal weight (SMD 0.428 (95% CI: 
      0.066-0.791); p=.020).Conclusions: LMWH has a secondary preventive effect on 
      early or severe PE and improves neonatal outcomes. In the future, additional 
      large multicenter studies will need to focus on high-risk PE groups by more 
      accurate screening to obtain more information before clinical application.
FAU - Wang, Xiaoyi
AU  - Wang X
AD  - Internal Medicine Department, Beijing Obstetrics and Gynecology Hospital, Capital 
      Medical University, Beijing, China.
FAU - Gao, Hong
AU  - Gao H
AD  - Internal Medicine Department, Beijing Obstetrics and Gynecology Hospital, Capital 
      Medical University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20181120
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Birth Weight/drug effects
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/pharmacology
MH  - Humans
MH  - Placenta/drug effects
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - High-risk
OT  - LMWH
OT  - PMPC
OT  - meta-analysis
OT  - preeclampsia
EDAT- 2018/11/22 06:00
MHDA- 2021/02/27 06:00
CRDT- 2018/11/22 06:00
PHST- 2018/11/22 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2018/11/22 06:00 [entrez]
AID - 10.1080/14767058.2018.1543656 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2020 Jul;33(13):2202-2208. doi: 
      10.1080/14767058.2018.1543656. Epub 2018 Nov 20.

PMID- 26400105
OWN - NLM
STAT- MEDLINE
DCOM- 20160608
LR  - 20181113
IS  - 1477-0539 (Electronic)
IS  - 1477-0520 (Print)
IS  - 1477-0520 (Linking)
VI  - 13
IP  - 45
DP  - 2015 Dec 7
TI  - Towards aspirin-inspired self-immolating molecules which target the 
      cyclooxygenases.
PG  - 11078-86
LID - 10.1039/c5ob01805f [doi]
AB  - Cyclooxygenases (COXs) are enzymes that play a vital role in the inflammatory 
      cascade through the generation of prostaglandins. Their over-expression has been 
      implicated in numerous diseases. In particular, over-expression of COX-2 has been 
      shown to be a predictive biomarker for progression of pre-malignant lesions 
      towards invasive cancer in various tissues. This makes the early detection of 
      COX-2 expressing lesions of high clinical relevance. Herein we describe the 
      development of the first self-immolating trigger which targets COXs. We 
      incorporated our trigger design into 2 activatable fluorogenic probes and 
      demonstrated COX-specific activation in vitro. Experimental data revealed probe 
      activation was likely caused by solvent-exposed amino acids on the surface of the 
      COXs. Overall, the probes reported here mark the first step towards developing 
      self-immolating imaging/therapeutic agents targeted to specific COXs.
FAU - Drake, Christopher R
AU  - Drake CR
AD  - Department of Radiology and Biomedical Imaging, University of California San 
      Francisco, San Francisco, CA 94107, USA. chris.drake@ucsf.edu.
FAU - Estévez-Salmerón, Luis
AU  - Estévez-Salmerón L
FAU - Gascard, Philippe
AU  - Gascard P
FAU - Shen, Yang
AU  - Shen Y
FAU - Tlsty, Thea D
AU  - Tlsty TD
FAU - Jones, Ella F
AU  - Jones EF
LA  - eng
GR  - R01 CA135626/CA/NCI NIH HHS/United States
GR  - CA143803/CA/NCI NIH HHS/United States
GR  - CA58207/CA/NCI NIH HHS/United States
GR  - K12 GM081266/GM/NIGMS NIH HHS/United States
GR  - U54 CA143803/CA/NCI NIH HHS/United States
GR  - P01 CA107584/CA/NCI NIH HHS/United States
GR  - CA097214/CA/NCI NIH HHS/United States
GR  - P50 CA058207/CA/NCI NIH HHS/United States
GR  - R01 CA097214/CA/NCI NIH HHS/United States
GR  - K12GM081266/GM/NIGMS NIH HHS/United States
GR  - CA135626/CA/NCI NIH HHS/United States
GR  - CA107584/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20150924
PL  - England
TA  - Org Biomol Chem
JT  - Organic & biomolecular chemistry
JID - 101154995
RN  - 0 (Fluorescent Dyes)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*metabolism
MH  - Cell Line
MH  - Cyclooxygenase 1/analysis/*metabolism
MH  - Cyclooxygenase 2/analysis/*metabolism
MH  - Fluorescent Dyes/*chemistry/*metabolism
MH  - Humans
MH  - Mice
MH  - Models, Molecular
MH  - Optical Imaging
MH  - Sheep
MH  - Spectrometry, Fluorescence
MH  - Swine
PMC - PMC4644089
MID - NIHMS725858
EDAT- 2015/09/25 06:00
MHDA- 2016/06/09 06:00
CRDT- 2015/09/25 06:00
PHST- 2015/09/25 06:00 [entrez]
PHST- 2015/09/25 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - 10.1039/c5ob01805f [doi]
PST - ppublish
SO  - Org Biomol Chem. 2015 Dec 7;13(45):11078-86. doi: 10.1039/c5ob01805f. Epub 2015 
      Sep 24.

PMID- 1182343
OWN - NLM
STAT- MEDLINE
DCOM- 19760114
LR  - 20190509
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 55
IP  - 1
DP  - 1975 Sep
TI  - Meiosis: a prostaglandin response that is not inhibited by aspirin.
PG  - 157-9
AB  - Antidromic stimulation of the sensory nerve to the rabbit eye produces pupillary 
      meiosis, supposedly by release of prostaglandins into the aqueous humour. The 
      analogy between this phenomenon and neurogenic inflammation is drawn. It is shown 
      that aspirin and indomethacin, known blockers of prostaglandin synthesis and 
      release, fail to block the meiosis thus produced.
FAU - Dellow, P G
AU  - Dellow PG
FAU - Miles, T S
AU  - Miles TS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Miotics)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Electric Stimulation
MH  - Indomethacin/pharmacology
MH  - *Miotics
MH  - Prostaglandins/*physiology
MH  - Pupil/*drug effects/physiology
MH  - Rabbits
MH  - Time Factors
PMC - PMC1666705
EDAT- 1975/09/01 00:00
MHDA- 1975/09/01 00:01
CRDT- 1975/09/01 00:00
PHST- 1975/09/01 00:00 [pubmed]
PHST- 1975/09/01 00:01 [medline]
PHST- 1975/09/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1975.tb07624.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1975 Sep;55(1):157-9. doi: 10.1111/j.1476-5381.1975.tb07624.x.

PMID- 11113275
OWN - NLM
STAT- MEDLINE
DCOM- 20010301
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 100
IP  - 4
DP  - 2000 Nov 15
TI  - Time related neutralization of two doses acetyl salicylic acid.
PG  - 317-23
AB  - Aspirin has a well established role in the prevention of arterial thrombosis. 
      Discussion on the efficacy and safety of aspirin in the treatment and prophylaxis 
      of thrombosis has become an important issue. In fact, hemorrhage complications 
      are often associated with its use. On the other hand, previous studies showed 
      unexpected thrombotic potencies associated with the presence of this drug at 
      ultra low doses (ULD) in the circulation. In this study, we aimed to evaluate the 
      effect of aspirin at ULD, injected 1, 2, or 3 hours after the administration of 
      aspirin at 100 mg/kg, on hemostasis and bleeding in rats. We used an experimental 
      model of thrombosis induced by laser beams to evaluate these effects. Platelet 
      aggregation was determined by Cardinal and Flower method. Results from this 
      investigation demonstrate that the neutralizing effect of aspirin at ULD did not 
      operate significantly 1 hour after the injection of aspirin at 100 mg/kg. This 
      effect was observed 2 and 3 hours after. The use of aspirin at ULD to neutralize 
      the side effects of aspirin at high doses will reduce the hemorrhagic risk during 
      extra corporeal circulation. The therapeutic benefit and safety of aspirin 
      therapy in the treatment of cardiovascular diseases can be obtained.
FAU - Aguejouf, O
AU  - Aguejouf O
AD  - Laboratoire d'Hématologie, Faculté de Pharmacie, 146, Rue Léo-Saignat 33 076 
      Bordeaux Cedex, France.
FAU - Malfatti, E
AU  - Malfatti E
FAU - Belon, P
AU  - Belon P
FAU - Doutremepuich, C
AU  - Doutremepuich C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Bleeding Time
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical
MH  - Hemostasis/drug effects
MH  - Lasers/adverse effects
MH  - Male
MH  - Models, Animal
MH  - Platelet Aggregation/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Splanchnic Circulation
MH  - Thrombosis/*drug therapy/etiology/prevention & control
MH  - Time Factors
MH  - Vacuoles/pathology
EDAT- 2000/12/13 11:00
MHDA- 2001/03/07 10:01
CRDT- 2000/12/13 11:00
PHST- 2000/12/13 11:00 [pubmed]
PHST- 2001/03/07 10:01 [medline]
PHST- 2000/12/13 11:00 [entrez]
AID - S0049-3848(00)00336-4 [pii]
AID - 10.1016/s0049-3848(00)00336-4 [doi]
PST - ppublish
SO  - Thromb Res. 2000 Nov 15;100(4):317-23. doi: 10.1016/s0049-3848(00)00336-4.

PMID- 31388951
OWN - NLM
STAT- MEDLINE
DCOM- 20200116
LR  - 20200116
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 26
IP  - 28
DP  - 2019 Oct
TI  - Acetylsalicylic acid biosorption onto fungal-bacterial biofilm supported on 
      activated carbons: an investigation via batch and fixed-bed experiments.
PG  - 28962-28976
LID - 10.1007/s11356-019-06075-0 [doi]
AB  - This study reports on acetylsalicylic acid (ASA) biosorption onto 
      fungal-bacterial biofilm supported on two types of activated carbons (one 
      commercial type made of coconut fibers, CAC, and one other manufactured from 
      fruit rinds of Hymenaea stigonocarpa Mart., HYAC, which after biofilm 
      inoculation, they were named CAC-b and HYAC-b), via batch and fixed-bed 
      experiments. These materials were characterized by BET Specific Surface Area and 
      Scanning Electronic Microscopy (SEM). Biosorption onto HYAC-b was 57.2% higher 
      than HYAC. Despite presenting the highest biosorption capacity over time (q(t) = 
      85.4 ± 0.82 mg g(-1)), CAC-b had a lower increase in efficiency (32.4%) compared 
      to CAC. Kinetic data from the biosorption experiments responded well to the 
      pseudo-first-order model thus suggests the predominance of physisorption, while 
      without biofilm presence, there was a better agreement with the 
      pseudo-second-order model, suggesting chemisorption. The possible interaction 
      mechanism of ASA to biofilm was attributed to ionic forces between the drug in 
      anionic form and eventual presence of cationic by-products of the biologically 
      active surface metabolism. Biosorption equilibrium data responded better to the 
      Sips model and CAC-b presented the highest biosorption capacity (q(e) = 292.4 ± 
      2.01 mg g(-1)). A combination of faster volumetric flow rates, higher inlet 
      concentrations and shorter beds accelerated the breakthrough time of ASA 
      biosorption in the fixed-bed experiments. These operational conditions affected 
      C/C(o) ratio in the following magnitude order: volumetric flow rate < inlet 
      concentration < bed height. Breakthrough data responded better to the modified 
      dose-response model compared to Thomas and Yoon-Nelson models.
FAU - Bó, Luma Gomes
AU  - Bó LG
AD  - Chemistry Institute, University of Brasilia, Brasilia, 70910-900, Brazil.
FAU - Almeida, Rosane Mansan
AU  - Almeida RM
AD  - Biological Sciences Institute, University of Brasilia, Brasilia, 70910-900, 
      Brazil.
FAU - Cardoso, Carlos Magno Marques
AU  - Cardoso CMM
AD  - Biological Sciences Institute, University of Brasilia, Brasilia, 70910-900, 
      Brazil.
FAU - Zavarize, Danilo Gualberto
AU  - Zavarize DG
AUID- ORCID: 0000-0002-3897-4869
AD  - Department of Environmental Engineering, Federal University of Tocantins, Palmas, 
      77001-090, Brazil. profzavarize@outlook.com.
FAU - Brum, Sarah Silva
AU  - Brum SS
AD  - Chemistry Institute, University of Brasilia, Brasilia, 70910-900, Brazil.
FAU - Mendonça, Andressa Regina Vasques
AU  - Mendonça ARV
AD  - Chemistry Institute, University of Brasilia, Brasilia, 70910-900, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20190806
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Water Pollutants, Chemical)
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Aspirin/*chemistry
MH  - Bacteria/growth & development
MH  - Biofilms/*growth & development
MH  - Charcoal/*chemistry
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Water Pollutants, Chemical
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Activated carbon
OT  - Biofilm
OT  - Biosorption
EDAT- 2019/08/08 06:00
MHDA- 2020/01/17 06:00
CRDT- 2019/08/08 06:00
PHST- 2019/04/03 00:00 [received]
PHST- 2019/07/25 00:00 [accepted]
PHST- 2019/08/08 06:00 [pubmed]
PHST- 2020/01/17 06:00 [medline]
PHST- 2019/08/08 06:00 [entrez]
AID - 10.1007/s11356-019-06075-0 [pii]
AID - 10.1007/s11356-019-06075-0 [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2019 Oct;26(28):28962-28976. doi: 
      10.1007/s11356-019-06075-0. Epub 2019 Aug 6.

PMID- 27619938
OWN - NLM
STAT- MEDLINE
DCOM- 20170421
LR  - 20170817
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 70
IP  - 11
DP  - 2016 Nov
TI  - Compliance with USPSTF recommendations on aspirin for prevention of 
      cardiovascular disease in men.
PG  - 898-906
LID - 10.1111/ijcp.12869 [doi]
AB  - OBJECTIVE: In 2009, United States Preventive Services Taskforce (USPSTF) 
      recommends aspirin (ASA) for men aged 45-79 years when the benefit of coronary 
      artery disease (CAD) risk reduction outweighs the harm of gastrointestinal 
      haemorrhage. Our objective is to evaluate compliance with this USPSTF 
      recommendation. METHODS: This study is a cross-sectional study and 2011-2012 
      National Health and Nutrition Examination Survey (NHANES) dataset was used for 
      this study. Out of the available sample, 1155 (11.8%) had the inclusion criteria 
      (men aged 45-79 years, no prior history of CAD). The participants' 10-year 
      Framingham risk score for developing CAD was calculated to identify the people 
      who meet criteria to take aspirin. The population characteristics that influence 
      the physicians' decision to prescribe aspirin and the characteristics those 
      influence the participants' compliance with doctor's advice to take aspirin were 
      identified. RESULTS: Almost 91.5% qualified for aspirin intake. About 65% 
      (595/916) of them were not advised by their providers to take aspirin. Among the 
      321 who were prescribed aspirin, 30% (96/321) were non-compliant and 1.2% (4/321) 
      discontinued aspirin because of side effects. In the group that did not qualify 
      for aspirin, 37.6% (32/85) were inappropriately prescribed aspirin out of which 
      78.1% (25/32) were actually taking it. Younger age and lesser comorbidities were 
      significantly associated with under prescription by physicians (P < .001) and 
      lower compliance by participants (P < .001). CONCLUSIONS: In April 2016, USPSTF 
      updated the recommendations regarding benefits of aspirin. Our study evaluates 
      the factors that influenced the compliance with the 2009 recommendations. This 
      study highlights the challenges that the 2016 guidelines might have to face.
CI  - © 2016 John Wiley & Sons Ltd.
FAU - Malayala, Srikrishna Varun
AU  - Malayala SV
AD  - Department of Hospital Medicine, Jeanes Hospital, Temple University Health 
      System, Philadelphia, PA, USA.
FAU - Raza, Ambreen
AU  - Raza A
AD  - Department of Infectious Diseases, Cooper University, Camden, NJ, USA.
LA  - eng
PT  - Journal Article
DEP - 20160912
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cross-Sectional Studies
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Guideline Adherence
MH  - Humans
MH  - Inappropriate Prescribing/statistics & numerical data
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Nutrition Surveys
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Primary Prevention
MH  - Risk Assessment
MH  - Risk Factors
MH  - United States
EDAT- 2016/09/14 06:00
MHDA- 2017/04/22 06:00
CRDT- 2016/09/14 06:00
PHST- 2016/04/05 00:00 [received]
PHST- 2016/07/29 00:00 [accepted]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/04/22 06:00 [medline]
PHST- 2016/09/14 06:00 [entrez]
AID - 10.1111/ijcp.12869 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2016 Nov;70(11):898-906. doi: 10.1111/ijcp.12869. Epub 2016 Sep 
      12.

PMID- 9759636
OWN - NLM
STAT- MEDLINE
DCOM- 19981228
LR  - 20181201
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 80
IP  - 3
DP  - 1998 Sep
TI  - The antiaggregating and antithrombotic activity of clopidogrel is potentiated by 
      aspirin in several experimental models in the rabbit.
PG  - 512-8
AB  - It is unknown whether the addition of aspirin might increase both the efficacy 
      and the potency of clopidogrel, a potent and selective ADP blocker. For that 
      purpose, the efficacy of clopidogrel (1-20 mg/kg, p.o.) administered orally to 
      rabbits alone or in combination with aspirin (0.1-10 mg/kg, p.o.) was determined 
      in several experimental models. A potent synergistic effect of the 
      clopidogrel/aspirin association was demonstrated with regard to collagen-induced 
      platelet aggregation measured ex vivo. Similarly, aspirin potentiated the 
      antithrombotic activity of clopidogrel measured with regard to experimental 
      thrombosis induced by a silk thread or on stents placed in an arteriovenous 
      shunt, thrombus formation following electrical stimulation of the rabbit carotid 
      artery and with regard to 111In-labeled platelet deposition on a stent implanted 
      in an arteriovenous shunt or on the subendothelium following air drying injury of 
      the rabbit carotid artery. A similar potentiating effect of aspirin was obtained 
      with regard to myointimal proliferation (restenosis) in the femoral arteries of 
      atherosclerotic rabbits which occurred as a consequence of stent placement. The 
      clopidogrel/aspirin combination showed only additive-type effects on bleeding 
      time prolongation induced by ear transection in the rabbit, therefore showing 
      that combined inhibition of cyclooxygenase and ADP's effects provide a marked 
      enhanced antithrombotic efficacy. Such a combination may provide substantial 
      protection against platelet aggregation leading to thrombotic occlusion at sites 
      of endothelial injuries and coronary artery stenosis in humans.
FAU - Herbert, J M
AU  - Herbert JM
AD  - Sanofi Recherche, Haemobiology Research Department, Toulouse, France. 
      jean-marc.herbert@tls1.elfsanofi.fr
FAU - Dol, F
AU  - Dol F
FAU - Bernat, A
AU  - Bernat A
FAU - Falotico, R
AU  - Falotico R
FAU - Lalé, A
AU  - Lalé A
FAU - Savi, P
AU  - Savi P
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Constriction, Pathologic/drug therapy
MH  - Drug Synergism
MH  - Femoral Artery/*pathology
MH  - Fibrinolytic Agents/pharmacology/therapeutic use
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Rabbits
MH  - Thrombosis/*drug therapy
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 1998/10/06 00:00
MHDA- 1998/10/06 00:01
CRDT- 1998/10/06 00:00
PHST- 1998/10/06 00:00 [pubmed]
PHST- 1998/10/06 00:01 [medline]
PHST- 1998/10/06 00:00 [entrez]
AID - 98090512 [pii]
PST - ppublish
SO  - Thromb Haemost. 1998 Sep;80(3):512-8.

PMID- 1390504
OWN - NLM
STAT- MEDLINE
DCOM- 19921029
LR  - 20190501
IS  - 0007-1161 (Print)
IS  - 1468-2079 (Electronic)
IS  - 0007-1161 (Linking)
VI  - 76
IP  - 5
DP  - 1992 May
TI  - Does aspirin affect the rate of cataract formation? Cross-sectional results 
      during a randomised double-blind placebo controlled trial to prevent serious 
      vascular events. UK-TIA Study Group.
PG  - 259-61
AB  - A total of 2435 patients with transient ischaemic attack or minor ischaemic 
      stroke were entered into the UK-TIA aspirin trial and randomised to treatment 
      with aspirin 1200 mg/day, aspirin 300 mg/day, or placebo. At a single point in 
      time during the trial patients were examined ophthalmoscopically for evidence of 
      cataracts. The length of time that each patient had been participating in the 
      trial at the time of ophthalmic examination varied from 1 to 5 years. The 
      prevalence of cataracts was similar in patients allocated aspirin and patients 
      allocated placebo irrespective of the length of time that they had been in the 
      trial. These findings suggest that aspirin taken in a dose of 300 to 1200 mg 
      daily for a few years does not prevent cataracts.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Ophthalmol
JT  - The British journal of ophthalmology
JID - 0421041
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cataract/epidemiology/*prevention & control
MH  - Cross-Sectional Studies
MH  - Double-Blind Method
MH  - Humans
MH  - Prevalence
MH  - United Kingdom/epidemiology
PMC - PMC504250
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
AID - 10.1136/bjo.76.5.259 [doi]
PST - ppublish
SO  - Br J Ophthalmol. 1992 May;76(5):259-61. doi: 10.1136/bjo.76.5.259.

PMID- 34693854
OWN - NLM
STAT- MEDLINE
DCOM- 20220307
LR  - 20220430
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 57
IP  - 2
DP  - 2022 Feb
TI  - The effect of aspirin in patients with nonvaricose upper gastrointestinal 
      bleeding and risk factors analysis.
PG  - 149-153
LID - 10.1080/00365521.2021.1990396 [doi]
AB  - OBJECTIVE: This paper aims to explore the effect of aspirin on the in-hospital 
      mortality of patients with NVUGIB. METHODS: An observational study 
      retrospectively examined 1514 patients with NVUGIB based on a multi-center 
      database. RESULT: Our study reported a mortality rate of 4.8% in patients with 
      NVUGIB, with 163 patients had a history of aspirin. Among 163 patients with an 
      aspirin history, 76 patients (46.6%) continued to take aspirin in the hospital, 
      with an average duration of 0.66 days after bleeding. Subsequent multivariate 
      regression analysis showed heart rate (p <.001, OR = 0.978, 95%CI 0.969-0.987) 
      and albumin (p =.019, OR = 0.658, 95%CI 0.464-0.933) were independent factors for 
      aspirin-therapy after bleeding. Patients who received aspirin after NVUGIB 
      (log-rank = 3.968, p =.046) had better survival than those who did not, but it 
      was not an independent risk factor. The levels of albumin (p < .001, OR = 0.288, 
      95%CI 0.165-0.505) and INR (p =.013, OR = 1.166, 95%CI 1.033-1.316) and heart 
      rate (p =.005, OR = 1.017, 95%CI 1.005-1.029) were independent factors of 
      in-hospital mortality. CONCLUSIONS: The independent risk factors for in-hospital 
      mortality in patients with NVUGIB were albumin and INR and heart rate. The 
      history of aspirin and the aspirin therapy after the bleeding did not affect the 
      in-hospital mortality in patients with NVUGIB.
FAU - Peng, Ding
AU  - Peng D
AUID- ORCID: 0000-0003-3614-5538
AD  - Department of Gastroenterology, Xuanwu Hospital Capital Medical University, 
      Beijing, China.
FAU - Zhang, Mei
AU  - Zhang M
AD  - Department of Gastroenterology, Xuanwu Hospital Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20211023
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - *Gastrointestinal Hemorrhage/etiology
MH  - Hospital Mortality
MH  - Humans
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - NVUGIB
OT  - in-hospital mortality
EDAT- 2021/10/26 06:00
MHDA- 2022/03/08 06:00
CRDT- 2021/10/25 08:45
PHST- 2021/10/26 06:00 [pubmed]
PHST- 2022/03/08 06:00 [medline]
PHST- 2021/10/25 08:45 [entrez]
AID - 10.1080/00365521.2021.1990396 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2022 Feb;57(2):149-153. doi: 
      10.1080/00365521.2021.1990396. Epub 2021 Oct 23.

PMID- 25583304
OWN - NLM
STAT- MEDLINE
DCOM- 20160415
LR  - 20181113
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 16
IP  - 4
DP  - 2015 Aug
TI  - The effect of microcrystalline cellulose crystallinity on the hydrophilic 
      property of tablets and the hydrolysis of acetylsalicylic acid as active 
      pharmaceutical ingredient inside tablets.
PG  - 865-70
LID - 10.1208/s12249-014-0276-7 [doi]
AB  - The crystal structures of active pharmaceutical ingredients and excipients should 
      be strictly controlled because they influence pharmaceutical properties of 
      products which cause the change in the quality or the bioavailability of the 
      products. In this study, we investigated the effects of microcrystalline 
      cellulose (MCC) crystallinity on the hydrophilic properties of tablets and the 
      hydrolysis of active pharmaceutical ingredient, acetylsalicylic acid (ASA), 
      inside tablets by using tablets containing 20% MCC as an excipient. Different 
      levels of grinding were applied to MCC prior to tablet formulation, to 
      intentionally cause structural variation in the MCC. The water penetration and 
      moisture absorbability of the tablets increased with decreasing the crystallinity 
      of MCC through higher level of grinding. More importantly, the hydrolysis of ASA 
      inside tablets was also accelerated. These results indicate that the 
      crystallinity of MCC has crucial effects on the pharmaceutical properties of 
      tablets even when the tablets contain a relatively small amount of MCC. 
      Therefore, controlling the crystal structure of excipients is important for 
      controlling product qualities.
FAU - Awa, Kimie
AU  - Awa K
AD  - Analytical Research and Development Laboratories, Sumitomo Dainippon Pharma Co., 
      Ltd., Osaka, Japan, kimie-awa@ds-pharma.co.jp.
FAU - Shinzawa, Hideyuki
AU  - Shinzawa H
FAU - Ozaki, Yukihiro
AU  - Ozaki Y
LA  - eng
PT  - Journal Article
DEP - 20150114
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Excipients)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Tablets)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Cellulose/*chemistry
MH  - Crystallization
MH  - Excipients
MH  - Hydrolysis
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Pharmaceutical Preparations/*chemistry
MH  - *Tablets
MH  - Tomography, X-Ray Computed
PMC - PMC4508302
EDAT- 2015/01/15 06:00
MHDA- 2016/04/16 06:00
CRDT- 2015/01/14 06:00
PHST- 2014/08/08 00:00 [received]
PHST- 2014/12/16 00:00 [accepted]
PHST- 2015/01/14 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2016/04/16 06:00 [medline]
AID - 276 [pii]
AID - 10.1208/s12249-014-0276-7 [doi]
PST - ppublish
SO  - AAPS PharmSciTech. 2015 Aug;16(4):865-70. doi: 10.1208/s12249-014-0276-7. Epub 
      2015 Jan 14.

PMID- 27100934
OWN - NLM
STAT- MEDLINE
DCOM- 20170314
LR  - 20220330
IS  - 1360-046X (Electronic)
IS  - 0268-8697 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Oct
TI  - Subdural haematoma complicating shunting for normal pressure hydrocephalus in the 
      setting of concomitant antiplatelet medication - a report of 11 cases.
PG  - 567-70
LID - 10.3109/02688697.2016.1173196 [doi]
AB  - OBJECTIVE: To report on the occurrence and management of subdural haematoma after 
      shunt implantation for normal pressure hydrocephalus and to determine the risk of 
      recurrence in the setting of antiplatelet medication. METHODS: From a consecutive 
      series of 80 patients implanted with a cerebrospinal fluid shunt for normal 
      pressure hydrocephalus, records from 11 patients taking antiplatelet drugs, who 
      subsequently had surgery for subdural haematoma were extracted and 
      retrospectively reviewed. RESULTS: Patients were followed up for a mean of 1819 
      days after shunt implantation. Subdural haematomas occurred at a median of 335 
      days after shunt implantation - four ipsilateral, five contralateral and two 
      bilateral with respect to the ventricular catheter. Three patients had 
      reoperations done within a week without having resumed antiplatelet medication in 
      the interim. One of them had three further reoperations done before the subdural 
      collection disappeared. Only one patient had a late recurrence almost 11 years 
      after shunt implantation. CONCLUSIONS: Subdural haematoma in the setting of a 
      ventriculoperitoneal implantation for normal pressure hydrocephalus and 
      concomitant antiplatelet medication can be managed along usual lines. 
      Antiplatelet medication can be recommenced in due course with a low risk of 
      recurrence.
FAU - Birkeland, Peter
AU  - Birkeland P
AD  - a Department of Neurosurgery , Odense University Hospital , Odense , Denmark ;
FAU - Lauritsen, Jens
AU  - Lauritsen J
AD  - b Department of Orthopaedic Surgery , Odense University Hospital , Odense , 
      Denmark ;
AD  - c Institute of Clinical Research , University of Southern Denmark , Denmark.
FAU - Poulsen, Frantz Rom
AU  - Poulsen FR
AD  - a Department of Neurosurgery , Odense University Hospital , Odense , Denmark ;
AD  - c Institute of Clinical Research , University of Southern Denmark , Denmark.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20160421
PL  - England
TA  - Br J Neurosurg
JT  - British journal of neurosurgery
JID - 8800054
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Female
MH  - Hematoma, Subdural, Chronic/*complications/drug therapy
MH  - Humans
MH  - Hydrocephalus, Normal Pressure/*surgery
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*therapeutic use
MH  - Recurrence
MH  - Reoperation/statistics & numerical data
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Ventriculoperitoneal Shunt/*adverse effects
OTO - NOTNLM
OT  - Acute subdural haematoma
OT  - cerebrospinal fluid shunt
OT  - chronic subdural haematoma
OT  - normal pressure hydrocephalus
EDAT- 2016/04/22 06:00
MHDA- 2017/03/16 06:00
CRDT- 2016/04/22 06:00
PHST- 2016/04/22 06:00 [entrez]
PHST- 2016/04/22 06:00 [pubmed]
PHST- 2017/03/16 06:00 [medline]
AID - 10.3109/02688697.2016.1173196 [doi]
PST - ppublish
SO  - Br J Neurosurg. 2016 Oct;30(5):567-70. doi: 10.3109/02688697.2016.1173196. Epub 
      2016 Apr 21.

PMID- 11574796
OWN - NLM
STAT- MEDLINE
DCOM- 20011101
LR  - 20191210
IS  - 0196-0644 (Print)
IS  - 0196-0644 (Linking)
VI  - 38
IP  - 4
DP  - 2001 Oct
TI  - Monitoring a clinical trial conducted under the Food and Drug Administration 
      regulations allowing a waiver of prospective informed consent: the diaspirin 
      cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial.
PG  - 397-404
AB  - In 1996, the US Food and Drug Administration (FDA) enacted Rule 21 CFR section 
      50.24, which allows a narrow exception to the requirement for prospective 
      informed consent from human research subjects in clinical trials investigating 
      potentially beneficial therapies for acute, life-threatening conditions. The 
      first clinical trial to be conducted under this rule was sponsored by Baxter 
      Healthcare Corporation and approved by the FDA on November 21, 1996. This large, 
      multicenter, randomized clinical trial was designed to compare the addition of 
      diaspirin cross-linked hemoglobin (DCLHb) with standard care in the initial 
      resuscitation of adults experiencing severe, uncompensated, traumatic hemorrhagic 
      shock. Before the first planned interim analysis of the data, review of fatal 
      adverse events revealed an imbalance in mortality between the 2 treatment groups. 
      The Data Monitoring Committee (DMC) recommended suspension of patient enrollment 
      24 days later. Additional data collection and analyses confirmed the excess 
      number of deaths in patients treated with DCLHb but failed to reveal the cause of 
      these deaths. The trial was formally terminated after only 112 of the planned 850 
      patients had been enrolled. We review the events leading up to and the rationale 
      behind the DMC recommendations for suspension of patient enrollment and trial 
      termination. Although the DCLHb trial was unsuccessful in achieving its goals, 
      the monitoring process worked well. Emergency research was facilitated by DMC 
      oversight, and the interests of research subjects were protected by the actions 
      of the DMC.
FAU - Lewis, R J
AU  - Lewis RJ
AD  - Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, CA, UCLA 
      School of Medicine, Los Angeles, CA 90509, USA. roger@emedharbor.edu
FAU - Berry, D A
AU  - Berry DA
FAU - Cryer, H 3rd
AU  - Cryer H 3rd
FAU - Fost, N
AU  - Fost N
FAU - Krome, R
AU  - Krome R
FAU - Washington, G R
AU  - Washington GR
FAU - Houghton, J
AU  - Houghton J
FAU - Blue, J W
AU  - Blue JW
FAU - Bechhofer, R
AU  - Bechhofer R
FAU - Cook, T
AU  - Cook T
FAU - Fisher, M
AU  - Fisher M
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/analogs & derivatives/*antagonists & inhibitors
MH  - Critical Illness/*mortality/*therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Hemoglobins/*administration & dosage
MH  - Humans
MH  - *Informed Consent
MH  - Injury Severity Score
MH  - Male
MH  - Randomized Controlled Trials as Topic/*standards
MH  - Resuscitation/standards
MH  - Shock, Hemorrhagic/etiology/*mortality/*therapy
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - United States
MH  - United States Food and Drug Administration
MH  - Wounds and Injuries/*complications
EDAT- 2001/09/28 10:00
MHDA- 2001/11/03 10:01
CRDT- 2001/09/28 10:00
PHST- 2001/09/28 10:00 [pubmed]
PHST- 2001/11/03 10:01 [medline]
PHST- 2001/09/28 10:00 [entrez]
AID - S0196-0644(01)39086-8 [pii]
AID - 10.1067/mem.2001.118223 [doi]
PST - ppublish
SO  - Ann Emerg Med. 2001 Oct;38(4):397-404. doi: 10.1067/mem.2001.118223.

PMID- 28636893
OWN - NLM
STAT- MEDLINE
DCOM- 20180103
LR  - 20181202
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 528
IP  - 1-2
DP  - 2017 Aug 7
TI  - Controlled release from aspirin based linear biodegradable poly(anhydride esters) 
      for anti-inflammatory activity.
PG  - 732-740
LID - S0378-5173(17)30573-2 [pii]
LID - 10.1016/j.ijpharm.2017.06.065 [doi]
AB  - This work reports the synthesis of a novel, aspirin-loaded, linear poly 
      (anhydride ester) and provides mechanistic insights into the release of aspirin 
      from this polymer for anti-inflammatory activity. As compared to conventional 
      drug delivery systems that rely on diffusion based release, incorporation of 
      bioactives in the polymer backbone is challenging and high loading is difficult 
      to achieve. In the present study, we exploit the pentafunctional sugar alcohol 
      (xylitol) to provide sites for drug (aspirin) attachment at its non-terminal OH 
      groups. The terminal OH groups are polymerized with a diacid anhydride. The 
      hydrolysis of the anhydride and ester bonds under physiological conditions 
      release aspirin from the matrix. The resulting poly(anhydride ester) has high 
      drug loading (53%) and displays controlled release kinetics of aspirin. The 
      polymer releases 8.5 % and 20%, of the loaded drug in one and four weeks, 
      respectively and has a release rate constant of 0.0035h(-0.61). The release rate 
      is suitable for its use as an anti-inflammatory agent without being cytotoxic. 
      The polymer exhibits good cytocompatibility and anti-inflammatory properties and 
      may find applications as injectable or as an implantable bioactive material. The 
      physical insights into the release mechanism can provide development of other 
      drug loaded polymers.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - Dasgupta, Queeny
AU  - Dasgupta Q
AD  - Centre for Biosystems Science and Engineering, Indian Institute of Science, 
      Bangalore, 560012, India.
FAU - Movva, Sahitya
AU  - Movva S
AD  - Department of Chemical Engineering, Indian Institute of Science, Bangalore, 
      560012, India.
FAU - Chatterjee, Kaushik
AU  - Chatterjee K
AD  - Centre for Biosystems Science and Engineering, Indian Institute of Science, 
      Bangalore, 560012, India; Department of Materials Engineering, Indian Institute 
      of Science, Bangalore, 560012, India.
FAU - Madras, Giridhar
AU  - Madras G
AD  - Centre for Biosystems Science and Engineering, Indian Institute of Science, 
      Bangalore, 560012, India; Department of Chemical Engineering, Indian Institute of 
      Science, Bangalore, 560012, India. Electronic address: 
      giridhar@chemeng.iisc.ernet.in.
LA  - eng
PT  - Journal Article
DEP - 20170619
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Anhydrides)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Carriers)
RN  - 0 (Esters)
RN  - 0 (Polymers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anhydrides/*chemistry
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - *Delayed-Action Preparations
MH  - Drug Carriers/chemistry
MH  - Esters/*chemistry
MH  - Polymers
OTO - NOTNLM
OT  - Anti-inflammatory
OT  - Aspirin
OT  - Biodegradable polymers
OT  - Controlled release
OT  - Linear poly(anhydride ester)s
EDAT- 2017/06/22 06:00
MHDA- 2018/01/04 06:00
CRDT- 2017/06/22 06:00
PHST- 2017/04/12 00:00 [received]
PHST- 2017/06/13 00:00 [revised]
PHST- 2017/06/16 00:00 [accepted]
PHST- 2017/06/22 06:00 [pubmed]
PHST- 2018/01/04 06:00 [medline]
PHST- 2017/06/22 06:00 [entrez]
AID - S0378-5173(17)30573-2 [pii]
AID - 10.1016/j.ijpharm.2017.06.065 [doi]
PST - ppublish
SO  - Int J Pharm. 2017 Aug 7;528(1-2):732-740. doi: 10.1016/j.ijpharm.2017.06.065. 
      Epub 2017 Jun 19.

PMID- 19309245
OWN - NLM
STAT- MEDLINE
DCOM- 20090615
LR  - 20220309
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 8
IP  - 2
DP  - 2009 Mar
TI  - Antiplatelet therapy and coronary artery bypass graft surgery: perioperative 
      safety and efficacy.
PG  - 169-82
LID - 10.1517/14740330902797081 [doi]
AB  - BACKGROUND: Antiplatelet therapy is critical in the management of coronary artery 
      disease. For patients undergoing coronary artery bypass graft surgery (CABG), 
      controversy remains regarding the safety of preoperative antiplatelet therapy and 
      the optimal postoperative antiplatelet regimen to maintain graft patency and 
      reduce ischemic complications. OBJECTIVE: The goal of this systematic review is 
      to evaluate the risks and benefits of preoperative aspirin and clopidogrel 
      therapy, to identify the optimal timing and dose of aspirin following CABG, and 
      to assess the role of postoperative clopidogrel therapy. METHODS: A systematic 
      review was performed to retrieve relevant articles from the Medline database 
      published between 1978 and 2008. RESULTS: With respect to aspirin, the published 
      data suggest that it should be held for 7 - 10 days preoperatively in patients 
      undergoing elective CABG. However, in the current era of routine antifibrinolytic 
      therapy and the high prevalence of patients with extensive atherosclerotic 
      disease, this practice has been put into question. Clopidogrel should be held for 
      at least 5 days before CABG to avoid perioperative bleeding complications. 
      Following surgery, extensive evidence supports the use of aspirin, in doses of 
      100 - 325 mg daily, to be administered in 48 h postoperatively and continued 
      indefinitely. Less is known regarding the use of clopidogrel following CABG, 
      although it is now recommended as postoperative antiplatelet therapy in patients 
      with recent acute coronary syndromes. CONCLUSION: Despite > 30 years of 
      experience with antiplatelet agents during CABG, questions remain regarding their 
      perioperative safety and efficacy. The results of continuing randomized 
      controlled trials should further clarify the role of perioperative aspirin and 
      clopidogrel therapy and help redefine the modern antiplatelet management of 
      coronary artery bypass patients.
FAU - Kulik, Alexander
AU  - Kulik A
AD  - Cardiovascular Surgery Fellow Missouri Baptist Medical Center St Louis, Missouri, 
      USA.
FAU - Chan, Vincent
AU  - Chan V
FAU - Ruel, Marc
AU  - Ruel M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - *Coronary Artery Bypass
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Perioperative Care
MH  - *Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Postoperative Period
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
RF  - 113
EDAT- 2009/03/25 09:00
MHDA- 2009/06/16 09:00
CRDT- 2009/03/25 09:00
PHST- 2009/03/25 09:00 [entrez]
PHST- 2009/03/25 09:00 [pubmed]
PHST- 2009/06/16 09:00 [medline]
AID - 10.1517/14740330902797081 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2009 Mar;8(2):169-82. doi: 10.1517/14740330902797081.

PMID- 3336128
OWN - NLM
STAT- MEDLINE
DCOM- 19880220
LR  - 20190820
IS  - 0741-5214 (Print)
IS  - 0741-5214 (Linking)
VI  - 7
IP  - 1
DP  - 1988 Jan
TI  - Neoendothelialization of small-diameter polytetrafluoroethylene arterial grafts 
      is not delayed by aspirin and dipyridamole.
PG  - 93-8
AB  - The effect of aspirin and dipyridamole on neoendothelialization of 
      polytetrafluoroethylene (PTFE) was studied in the rabbit aortic graft model. 
      Forty-three New Zealand white rabbits were allocated to receive a combination of 
      aspirin 10 mg/kg/day and dipyridamole 10 mg/kg/day (n = 23) or placebo (n = 20). 
      Both regimens began 3 days before insertion of PTFE aortic grafts (10 mm long and 
      3 mm internal diameter). Serum thromboxane B2 concentration in the control group 
      averaged 254 +/- 22 ng/ml (+/- standard error of the mean) and 40 +/- 23 ng/ml in 
      the treatment group (p less than 0.001). Grafts and adjacent aorta were harvested 
      at 2 weeks (n = 4), 4 weeks (n = 9), 8 weeks (n = 13), and 12 weeks (n = 17) 
      after implantation. Morphologic techniques, including conventional light 
      microscopy, immunoperoxidase staining for endothelial factor VIII-related 
      antigen, and scanning electron microscopy (SEM) demonstrated that neointima was 
      composed of endothelial cells arising by ingrowth at anastomotic site and as 
      islands in the center of the graft. The percentage of graft neoendothelialization 
      was measured by SEM. At 2 weeks 18% +/- 2% of the PTFE surface was covered with 
      endothelium in the aspirin/dipyridamole group. The percentages of graft 
      neoendothelialization for the treatment and control groups at 4 weeks were 44% 
      +/- 13% (n = 5) and 46% +/- 10% (n = 4) (p = NS), respectively.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Nordestgaard, A G
AU  - Nordestgaard AG
AD  - Department of Surgery, Harbor-UCLA Medical Center, Torrance 90509.
FAU - Wilson, S E
AU  - Wilson SE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta, Thoracic
MH  - Aspirin/*pharmacology
MH  - *Blood Vessel Prosthesis
MH  - Dipyridamole/*pharmacology
MH  - Endothelium, Vascular/*drug effects
MH  - Male
MH  - Microscopy, Electron, Scanning
MH  - *Polytetrafluoroethylene
MH  - Rabbits
MH  - Wound Healing/drug effects
EDAT- 1988/01/01 00:00
MHDA- 2001/09/06 10:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 2001/09/06 10:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 0741-5214(88)90382-5 [pii]
AID - 10.1067/mva.1988.avs0070093 [doi]
PST - ppublish
SO  - J Vasc Surg. 1988 Jan;7(1):93-8. doi: 10.1067/mva.1988.avs0070093.

PMID- 8187688
OWN - NLM
STAT- MEDLINE
DCOM- 19940623
LR  - 20131121
IS  - 0733-8627 (Print)
IS  - 0733-8627 (Linking)
VI  - 12
IP  - 2
DP  - 1994 May
TI  - Concepts and controversies in salicylate toxicity.
PG  - 351-64
AB  - Despite efforts to minimize its occurrence, salicylate poisoning continues to 
      confound physicians and kill patients. The primary problems involve recognition 
      of salicylate poisoning and lack of aggressive early management. The use of 
      sodium bicarbonate and early hemodialysis should prevent mortality in most 
      patients.
FAU - Yip, L
AU  - Yip L
AD  - Department of Emergency Medicine, State University of New York at Syracuse.
FAU - Dart, R C
AU  - Dart RC
FAU - Gabow, P A
AU  - Gabow PA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Emerg Med Clin North Am
JT  - Emergency medicine clinics of North America
JID - 8219565
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*poisoning
MH  - Child
MH  - Chronic Disease
MH  - Decontamination/methods
MH  - Humans
MH  - Male
MH  - Poisoning/diagnosis/therapy
RF  - 73
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
PST - ppublish
SO  - Emerg Med Clin North Am. 1994 May;12(2):351-64.

PMID- 6998711
OWN - NLM
STAT- MEDLINE
DCOM- 19801218
LR  - 20190629
IS  - 0014-4754 (Print)
IS  - 0014-4754 (Linking)
VI  - 36
IP  - 10
DP  - 1980 Oct 15
TI  - Inactivation of yeast glucose-6-P dehydrogenase by aspirin.
PG  - 1149-50
AB  - Glucose-6-P dehydrogenase is irreversibly inactivated by treatment with Na salts 
      of aspirin. Kinetic data show that 1 molecule of aspirin reacts with each active 
      unit when the enzyme is inactivated. The rate of inactivation is enhanced with 
      increasing pH but is reduced in the presence of glucose-6-P or NADP+. Na 
      salicylate fails to inactivate the enzyme.
FAU - Han, P F
AU  - Han PF
FAU - Han, G Y
AU  - Han GY
FAU - McBay, H C
AU  - McBay HC
FAU - Johnson, J Jr
AU  - Johnson J Jr
LA  - eng
GR  - RR-8006/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Switzerland
TA  - Experientia
JT  - Experientia
JID - 0376547
RN  - 53-59-8 (NADP)
RN  - EC 1.1.1.49 (Glucosephosphate Dehydrogenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Glucosephosphate Dehydrogenase/*antagonists & inhibitors
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - NADP
MH  - Saccharomyces cerevisiae/*enzymology
EDAT- 1980/10/15 00:00
MHDA- 2001/03/28 10:01
CRDT- 1980/10/15 00:00
PHST- 1980/10/15 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1980/10/15 00:00 [entrez]
AID - 10.1007/BF01976092 [doi]
PST - ppublish
SO  - Experientia. 1980 Oct 15;36(10):1149-50. doi: 10.1007/BF01976092.

PMID- 34238511
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 2542-4513 (Print)
IS  - 2542-4513 (Linking)
VI  - 46
IP  - 4
DP  - 2021 Jul
TI  - Aspirin withdrawal: A risk factor for ischemic stroke severity.
PG  - 171-174
LID - S2542-4513(21)00078-X [pii]
LID - 10.1016/j.jdmv.2021.05.004 [doi]
AB  - INTRODUCTION: Acetylsalicylic acid (ASA) cessation, is suggestive of a rebound 
      phenomenon laying the ground for ischemic stroke (IS) re-occurrence but nothing 
      is known about its implication for IS severity (ISS). Thus, the aim of our study 
      is to examine whether or not aspirin withdrawal is a risk factor for ISS. 
      PATIENTS AND METHODS: This study, recruited patients having presented an IS in 
      the following 2 weeks of ASA withdrawal, matched with treatment free cases. ISS 
      was evaluated in all patients at admission using the National Institutes of 
      Health Stroke Scale (NIHSS) and the modified Rankin scale (mRS) at 3 months' 
      follow-up. FINDINGS: Fifty cases were included in this study and fifty, manually 
      matched, controls. ISS analysis found that the case group had a more severe 
      stroke at admission (mean NIHSS: 12.76 (±7.319) in cases vs 10.04 (±5.562) in 
      controls, P=0.039), with ASA discontinuation judged as a risk factor directly 
      related to ISS regardless of the underlying cardiovascular risk factors (using 
      the multivariate analysis). CONCLUSION: Our study's findings suggest that aspirin 
      interruption over a 15-days period could result in a more severe IS in the acute 
      phase. To our knowledge, no study has ever discussed this outcome, shedding the 
      light on the pressing need for larger studies with various withdrawal periods to 
      support these data.
CI  - Copyright © 2021 Elsevier Masson SAS. All rights reserved.
FAU - El Otmani, H
AU  - El Otmani H
AD  - Department of Neurology, Ibn Rochd Hospital, Hassan II University, Faculty of 
      Medicine and Pharmacy, rue Tarik Ibn Ziad, 20360 Casablanca, Morocco; Laboratory 
      of genetics and molecular pathology, Ibn Rochd Hospital, Hassan II University, 
      Faculty of Medicine and Pharmacy, rue Tarik Ibn Ziad, 20360 Casablanca, Morocco. 
      Electronic address: hichamotmani@yahoo.com.
FAU - Berrada, M
AU  - Berrada M
AD  - Department of Neurology, Ibn Rochd Hospital, Hassan II University, Faculty of 
      Medicine and Pharmacy, rue Tarik Ibn Ziad, 20360 Casablanca, Morocco.
FAU - Abdulhakeem, Z
AU  - Abdulhakeem Z
AD  - Department of Neurology, Ibn Rochd Hospital, Hassan II University, Faculty of 
      Medicine and Pharmacy, rue Tarik Ibn Ziad, 20360 Casablanca, Morocco.
FAU - Bellakhdar, S
AU  - Bellakhdar S
AD  - Department of Neurology, Ibn Rochd Hospital, Hassan II University, Faculty of 
      Medicine and Pharmacy, rue Tarik Ibn Ziad, 20360 Casablanca, Morocco.
FAU - El Moutawakil, B
AU  - El Moutawakil B
AD  - Department of Neurology, Ibn Rochd Hospital, Hassan II University, Faculty of 
      Medicine and Pharmacy, rue Tarik Ibn Ziad, 20360 Casablanca, Morocco; Laboratory 
      of genetics and molecular pathology, Ibn Rochd Hospital, Hassan II University, 
      Faculty of Medicine and Pharmacy, rue Tarik Ibn Ziad, 20360 Casablanca, Morocco.
FAU - Abdoh Rafai, M
AU  - Abdoh Rafai M
AD  - Department of Neurology, Ibn Rochd Hospital, Hassan II University, Faculty of 
      Medicine and Pharmacy, rue Tarik Ibn Ziad, 20360 Casablanca, Morocco; Research 
      Laboratory on diseases of the nervous system, neurosensory and disability, Hassan 
      II University, Faculty of Medicine and Pharmacy, rue Tarik Ibn Ziad, 20360 
      Casablanca, Morocco.
LA  - eng
PT  - Journal Article
DEP - 20210602
PL  - France
TA  - J Med Vasc
JT  - Journal de medecine vasculaire
JID - 101709200
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Brain Ischemia
MH  - Humans
MH  - *Ischemic Stroke
MH  - Risk Factors
MH  - *Stroke/etiology
OTO - NOTNLM
OT  - Aspirin withdrawal
OT  - Ischemic stroke severity
OT  - Modified Rankin scale
OT  - National Institutes of Health Stroke Scale
EDAT- 2021/07/10 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/07/09 05:52
PHST- 2021/04/06 00:00 [received]
PHST- 2021/05/09 00:00 [accepted]
PHST- 2021/07/09 05:52 [entrez]
PHST- 2021/07/10 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - S2542-4513(21)00078-X [pii]
AID - 10.1016/j.jdmv.2021.05.004 [doi]
PST - ppublish
SO  - J Med Vasc. 2021 Jul;46(4):171-174. doi: 10.1016/j.jdmv.2021.05.004. Epub 2021 
      Jun 2.

PMID- 975490
OWN - NLM
STAT- MEDLINE
DCOM- 19761230
LR  - 20191021
IS  - 0009-9090 (Print)
IS  - 0009-9090 (Linking)
VI  - 6
IP  - 5
DP  - 1976 Sep
TI  - Oral aspirin challenges in asthmatic patients: a study of plasma histamine.
PG  - 493-505
AB  - Under carefully controlled conditions, seven aspirin-intolerant asthmatic 
      patients were challenged with oral aspirin and experienced respiratory tract 
      reactions with a decline in forced expiratory volume in 1 sec (FEV1) ranging from 
      26 to 64%. Venous blood samples, which were collected during the challenges, 
      showed a rise in plasma histamine in all seven patients. The increase in plasma 
      histamine occurred at the onset of their respiratory reactions and those patients 
      with the most severe asthmatic responses were found to have the highest and most 
      prolonged levels of plasma histamine. The aspirin-intolerant asthmatic patients 
      were able to ingest Maalox or sodium salicylate without untoward effects, decline 
      in FEV1 values or changes in plasma histamine levels. Ten non-asthmatic 
      individuals and eight out of ten asthmatic control patients were able to ingest 
      aspirin without any reactions or changes in their plasma histamine levels. 
      However, two asthmatic control individuals, with severe asthma requiring 
      treatment with moderate dosages of corticosteroids, were found to have elevated 
      pre-challenge plasma histamine levels which increased during their ASA challenges 
      despite the absence of respiratory reactions or changes in FEV1 values. It is 
      possible that these two individuals were unsuspected aspirin-intolerant 
      asthmatics. These studies demonstrate that asthmatic reactions to 
      acetylsalicylates are associated with release of histamine into plasma in the 
      subgroup of asthmatic patients with the aspirin-intolerance syndrome. Such a 
      finding suggests that histamine may be one of the mediators of bronchospasm in 
      aspirin-induced asthma.
FAU - Stevenson, D D
AU  - Stevenson DD
FAU - Arroyave, C M
AU  - Arroyave CM
FAU - Bhat, K N
AU  - Bhat KN
FAU - Tan, E M
AU  - Tan EM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Clin Allergy
JT  - Clinical allergy
JID - 0311172
RN  - 820484N8I3 (Histamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*blood
MH  - Drug Hypersensitivity/*blood
MH  - Female
MH  - Forced Expiratory Volume
MH  - Histamine/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1976/09/01 00:00
MHDA- 1976/09/01 00:01
CRDT- 1976/09/01 00:00
PHST- 1976/09/01 00:00 [pubmed]
PHST- 1976/09/01 00:01 [medline]
PHST- 1976/09/01 00:00 [entrez]
AID - 10.1111/j.1365-2222.1976.tb01934.x [doi]
PST - ppublish
SO  - Clin Allergy. 1976 Sep;6(5):493-505. doi: 10.1111/j.1365-2222.1976.tb01934.x.

PMID- 7174153
OWN - NLM
STAT- MEDLINE
DCOM- 19830214
LR  - 20131121
IS  - 0174-4879 (Print)
IS  - 0174-4879 (Linking)
VI  - 20
IP  - 11
DP  - 1982 Nov
TI  - Effect of low estrogen combination oral contraceptive on metabolism of aspirin 
      and phenylbutazone.
PG  - 511-3
AB  - Plasma levels of aspirin and phenylbutazone were estimated before and during 
      administration of low estrogen combination type oral contraceptive for two 
      menstrual cycles in ten and seven female volunteers, respectively. Aspirin was 
      administered at doses of 300 and 600 mg, while phenylbutazone was administered at 
      a dose of 400 mg. Blood samples were collected at intervals of 1, 2, 4, 6, and 8 
      h for aspirin and 2, 4, 6, 8, 24, 48, 72, and 80 h for phenylbutazone. Plasma 
      levels, plasma half-life (t1/2), as well as area under curve (AUC) for aspirin 
      after use of oral contraceptive revealed lower values. Phenylbutazone levels were 
      not affected. Repeat studies of plasma t1/2 and AUC for aspirin after 
      discontinuation of oral contraceptive showed values similar to basal levels.
FAU - Gupta, K C
AU  - Gupta KC
FAU - Joshi, J V
AU  - Joshi JV
FAU - Hazari, K
AU  - Hazari K
FAU - Pohujani, S M
AU  - Pohujani SM
FAU - Satoskar, R S
AU  - Satoskar RS
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther Toxicol
JT  - International journal of clinical pharmacology, therapy, and toxicology
JID - 8003415
RN  - 0 (Contraceptives, Oral)
RN  - 0 (Contraceptives, Oral, Combined)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
RN  - T18F433X4S (Norethindrone)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*metabolism
MH  - Biotransformation
MH  - Contraceptives, Oral/*pharmacology
MH  - Contraceptives, Oral, Combined/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Ethinyl Estradiol/*pharmacology
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Norethindrone/*pharmacology
MH  - Phenylbutazone/blood/*metabolism
OID - PIP: 012721
OID - POP: 00116376
OAB - Plasma levels of aspirin and phenylbutazone were estimated before and during the 
      administration of low estrogen combination type oral contraceptive (OC) for 2 
      menstrual cycles in 10 and 7 female volunteers, respectively. Aspirin was 
      administered at doses of 300 and 600 mg.; phenylbutazone was administered at a 
      dose of 400 mg. Blood samples were collected at intervals of 1, 2, 4, 6, and 8 
      hours for aspirin and 2, 4, 6, 8, 24, 48, 72, and 80 hours for phenylbutazone. 
      Plasma levels, area under curve (AUC), and plasma half life (t1/2) of aspirin 
      were significantly lower during OC use as compared with predrug data. This was 
      applicable to both doses of aspirin. Plasma levels of phenylbutazone did not show 
      significant differences. Since there were significant alterations in plasma 
      levels of aspirin during OC use, the study was repeated after a drug free 
      interval of 3-5 months. A rise in plasma levels and t1/2 was observed after 
      discontinuation of OC. Tmax for aspirin was not consistently altered during OC 
      use, but the Pmax was reduced in all cases during OC use and was found to recover 
      in all the 7 subjects studied after discontinuation of OC. Salicylate levels in 5 
      women using OC for more than 2 years were similar to the levels before 
      administration of OC.
OABL- eng
OTO - PIP
OT  - *Clinical Research
OT  - *Contraception
OT  - Contraceptive Agents
OT  - *Contraceptive Agents, Female
OT  - Contraceptive Methods--pharmacodynamics
OT  - Contraceptive Methods--side effects
OT  - Family Planning
OT  - *Oral Contraceptives, Low-dose--pharmacodynamics
OT  - *Oral Contraceptives--side effects
OT  - Research Methodology
OT  - *Treatment--pharmacodynamics
GN  - PIP: TJ: INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY, THERAPY, AND TOXICOLOGY.
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther Toxicol. 1982 Nov;20(11):511-3.

PMID- 16687993
OWN - NLM
STAT- MEDLINE
DCOM- 20060629
LR  - 20221207
IS  - 0268-1315 (Print)
IS  - 0268-1315 (Linking)
VI  - 21
IP  - 4
DP  - 2006 Jul
TI  - Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the 
      chronic escape deficit model of depression.
PG  - 219-25
AB  - Evidence has accumulated suggesting that major depression is associated with 
      dysfunction of inflammatory mediators. Moreover, antidepressants show an 
      anti-inflammatory action possibly related to their clinical efficacy. An 
      improvement in psychiatric symptoms has been recently reported in patients 
      treated with anti-inflammatory drugs for other indications. These data imply that 
      inflammation may be involved in the pathogenesis of depression and that 
      anti-inflammatory drugs may be used as an adjunctive therapy. The aim of the 
      present study was to evaluate the behavioural effect of the co-administration of 
      acetylsalicylic acid (ASA, 45 mg/kg or 22.5 mg/kg) and fluoxetine (FLX, 5 mg/kg) 
      in the chronic escape deficit model of depression. The chronic escape deficit 
      model is based on the modified reactivity of rats to external stimuli induced by 
      exposure to unavoidable stress and allows evaluation of the capacity of a 
      treatment to revert the condition of escape deficit. In this model, FLX alone 
      needs to be administered for at least 3 weeks to revert this condition. Our 
      results show that combined treatment of fluoxetine and ASA completely reverted 
      the condition of escape deficit by as early as 7 days, the effect being already 
      partially present after 4 days. The effect was maintained after 14 and 21 days of 
      treatment. ASA alone was ineffective at any time tested and the effect of 
      fluoxetine was significant only at 21 days. These results, together with clinical 
      data from preliminary results, suggest that ASA might accelerate the onset of 
      action of selective serotonin reuptake inhibitor antidepressants.
FAU - Brunello, Nicoletta
AU  - Brunello N
AD  - Department of Biomedical Sciences, University of Modena and Reggio Emilia, Italy. 
      brunello.nicoletta@unimo.it
FAU - Alboni, Silvia
AU  - Alboni S
FAU - Capone, Giacomo
AU  - Capone G
FAU - Benatti, Cristina
AU  - Benatti C
FAU - Blom, Joan M C
AU  - Blom JM
FAU - Tascedda, Fabio
AU  - Tascedda F
FAU - Kriwin, Philippe
AU  - Kriwin P
FAU - Mendlewicz, Julien
AU  - Mendlewicz J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 01K63SUP8D (Fluoxetine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Antidepressive Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Depression/*drug therapy
MH  - Drug Synergism
MH  - Escape Reaction/*drug effects
MH  - Fluoxetine/administration & dosage/pharmacology/*therapeutic use
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Selective Serotonin Reuptake Inhibitors/administration & 
      dosage/pharmacology/therapeutic use
MH  - Time Factors
EDAT- 2006/05/12 09:00
MHDA- 2006/06/30 09:00
CRDT- 2006/05/12 09:00
PHST- 2006/05/12 09:00 [pubmed]
PHST- 2006/06/30 09:00 [medline]
PHST- 2006/05/12 09:00 [entrez]
AID - 00004850-200607000-00004 [pii]
AID - 10.1097/00004850-200607000-00004 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 2006 Jul;21(4):219-25. doi: 
      10.1097/00004850-200607000-00004.

PMID- 20608787
OWN - NLM
STAT- MEDLINE
DCOM- 20101022
LR  - 20171116
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 21
IP  - 5
DP  - 2010
TI  - Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation 
      in human endotoxemia.
PG  - 320-8
LID - 10.3109/09537101003735572 [doi]
AB  - Acetylsalicylic acid (ASA) prevents thromboembolic events by inhibiting platelet 
      function through blocking of cyclooxygenase type 1 (COX-1). A nitroderivate of 
      ASA, 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)-phenyl ester (NCX 4016) was 
      synthesized, which additionally acts through nitric oxide release. In various in 
      vitro and animal studies NCX 4016 exhibited antithrombotic and anti-platelet 
      properties. We used the standardized model of endotoxin infusion into human 
      volunteers to compare the effects of NCX 4016 and ASA on platelet function and 
      TF-induced coagulation activation. The trial consisted of two parts. In the first 
      part, 10 healthy male volunteers were included in a randomized, open cross-over 
      trial to find a NCX formulation with optimal tolerability and pharmacokinetic 
      data were obtained. The second part was a randomized, double blind placebo 
      controlled clinical trial consisting of 30 healthy male volunteers in three 
      parallel groups (n = 10 per group). Volunteers received either NCX 4016 (800 mg 
      b.i.d.), ASA (425 mg b.i.d.) or placebo for 7 days, before infusion of 2 ng/kg 
      endotoxin on day 8. ASA attenuated the endotoxin-induced platelet plug formation 
      (measured by PFA-100) significantly better than NCX 4016 and placebo (p < 0.004), 
      while there was no difference in soluble P-selectin or VWF-levels. Urine 
      11-dehydro-thromboxane B(2) levels were significantly lower in the ASA and NCX 
      4016 groups as compared to placebo (p < 0.05). Neither ASA nor NCX 4016 
      significantly changed prothrombin fragment(1 + 2), D-Dimer or tissue factor 
      (TF)-mRNA levels. In summary, NCX 4016 had no effect on VWF release, platelet 
      activation as measured by soluble P-selectin or TF gene expression. NCX 4016, at 
      the dose tested, unlike ASA, had no effect on platelet collagen/epinephrine 
      induced plug formation under high shear rates.
FAU - Derhaschnig, Ulla
AU  - Derhaschnig U
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
FAU - Schweeger-Exeli, Ingrid
AU  - Schweeger-Exeli I
FAU - Marsik, Claudia
AU  - Marsik C
FAU - Cardona, Francesco
AU  - Cardona F
FAU - Minuz, Pietro
AU  - Minuz P
FAU - Jilma, Bernd
AU  - Jilma B
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Endotoxins)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, 
      Non-Steroidal/pharmacokinetics/pharmacology/*therapeutic use
MH  - Aspirin/*analogs & derivatives/pharmacokinetics/pharmacology/*therapeutic use
MH  - Blood Coagulation/*drug effects
MH  - Blood Platelets/*drug effects/physiology
MH  - Double-Blind Method
MH  - Endotoxemia/*blood/chemically induced/*drug therapy/urine
MH  - Endotoxins/administration & dosage/antagonists & inhibitors
MH  - Humans
MH  - Male
MH  - Platelet Activation/drug effects
MH  - Thromboxane B2/pharmacology/urine
MH  - Young Adult
EDAT- 2010/07/09 06:00
MHDA- 2010/10/23 06:00
CRDT- 2010/07/09 06:00
PHST- 2010/07/09 06:00 [entrez]
PHST- 2010/07/09 06:00 [pubmed]
PHST- 2010/10/23 06:00 [medline]
AID - 10.3109/09537101003735572 [doi]
PST - ppublish
SO  - Platelets. 2010;21(5):320-8. doi: 10.3109/09537101003735572.

PMID- 9718466
OWN - NLM
STAT- MEDLINE
DCOM- 19981019
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 26
IP  - 3
DP  - 1998 Jun-Jul
TI  - Effects of nitrate and prophylactic aspirin on upper gastrointestinal bleeding: a 
      retrospective case-control study.
PG  - 120-8
AB  - Experimental studies suggest that nitric-oxide releasing drugs reduce 
      gastroduodenal damage induced by non-steroidal anti-inflammatory drugs, but it is 
      not known whether these agents have this effect in humans. The aim of the present 
      study was to evaluate the risk of upper gastrointestinal bleeding in patients who 
      receive aspirin and nitrates for vascular occlusive diseases. This was a 
      retrospective case-control study of 736 consecutive patients admitted with upper 
      gastrointestinal bleeding, compared with 1472 age- and sex-matched hospital 
      controls. Chronic low-dose aspirin regimens had been used by 12.6% of cases and 
      5.7% of controls, nitrates by 4.8% and 5.8%, and combined nitrates and low-dose 
      aspirin by 2.7% and 1.9%, respectively. Logistic regression analysis identified 
      low-dose aspirin use as an independent risk factor for gastrointestinal bleeding, 
      whereas nitrate use was found to be a protective factor. The combination of both 
      nitrate and low-dose aspirin was not associated with an increased risk of 
      bleeding.
FAU - Lanas, A
AU  - Lanas A
AD  - Service of Gastroenterology, University Hospital, Zaragoza, Spain.
FAU - Bajador, E
AU  - Bajador E
FAU - Serrano, P
AU  - Serrano P
FAU - Arroyo, M
AU  - Arroyo M
FAU - Fuentes, J
AU  - Fuentes J
FAU - Santolaria, S
AU  - Santolaria S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nitrates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Arterial Occlusive Diseases/drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nitrates/*adverse effects/therapeutic use
MH  - Retrospective Studies
EDAT- 1998/08/27 00:00
MHDA- 1998/08/27 00:01
CRDT- 1998/08/27 00:00
PHST- 1998/08/27 00:00 [pubmed]
PHST- 1998/08/27 00:01 [medline]
PHST- 1998/08/27 00:00 [entrez]
AID - 10.1177/030006059802600302 [doi]
PST - ppublish
SO  - J Int Med Res. 1998 Jun-Jul;26(3):120-8. doi: 10.1177/030006059802600302.

PMID- 7719445
OWN - NLM
STAT- MEDLINE
DCOM- 19950522
LR  - 20191031
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 23
IP  - 1
DP  - 1995
TI  - Resuscitation with Diaspirin Crosslinked Hemoglobin in a pig model of hemorrhagic 
      shock.
PG  - 39-61
AB  - The efficacy of Diaspirin Crosslinked Hemoglobin (DCLHb) as a resuscitative fluid 
      in hemorrhagic shock was compared to another colloid solution (human serum 
      albumin, HSA) and a crystalloid solution (Lactated Ringer's, LR). Hemorrhage (35 
      mL/kg) was followed by isovolemic exchange then volume replacement. This modeled 
      the clinical situation where resuscitative fluids are administered prior to 
      stopping the hemorrhage, the hemorrhage is stopped, then blood volume is 
      restored. Four combinations of resuscitative fluids were evaluated during 
      isovolemic exchange: volume replacement: DCLHb:LR, HSA:LR, HSA:HSA and LR:LR. All 
      doses were 10 mL/kg:35 mL/kg except LR:LR which was 10 mL/kg:125 mL/kg. Volume 
      replacement was followed by a stabilization period and reinfusion of shed blood 
      (35 mL/kg). MAP increased most rapidly using DCLHb (from 48 to 102 mmHg after 10 
      min of isovolemic exchange) and was maintained for at least 2 hours. Arterial 
      oxygen content and acid-base status were significantly improved after 
      resuscitation with DCLHb:LR vs. other resuscitative therapies. In conclusion, 
      DCLHb:LR was an effective resuscitative therapy in treatment of hemorrhagic 
      shock.
FAU - Dunlap, E
AU  - Dunlap E
AD  - Safety and Efficacy Assessment Center, Baxter Healthcare Corporation, Round Lake, 
      Illinois 60073, USA.
FAU - Farrell, L
AU  - Farrell L
FAU - Nigro, C
AU  - Nigro C
FAU - Estep, T
AU  - Estep T
FAU - Marchand, G
AU  - Marchand G
FAU - Burhop, K
AU  - Burhop K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Enzymes)
RN  - 0 (Hemoglobins)
RN  - 0 (Isotonic Solutions)
RN  - 0 (Serum Albumin)
RN  - 8026-10-6 (Ringer's Solution)
RN  - 8W8T17847W (Urea)
RN  - AYI8EX34EU (Creatinine)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Pressure Determination
MH  - Creatinine/blood
MH  - Enzymes/blood
MH  - Hematocrit
MH  - Hemoglobins/analysis/*therapeutic use
MH  - Isotonic Solutions/therapeutic use
MH  - Kidney Function Tests
MH  - Male
MH  - Orchiectomy
MH  - *Resuscitation
MH  - Ringer's Solution
MH  - Serum Albumin/therapeutic use
MH  - Shock, Hemorrhagic/*therapy
MH  - Swine
MH  - Time Factors
MH  - Urea/blood
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.3109/10731199509117667 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1995;23(1):39-61. doi: 
      10.3109/10731199509117667.

PMID- 7106166
OWN - NLM
STAT- MEDLINE
DCOM- 19821029
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 22
IP  - 4
DP  - 1982
TI  - Bioavailability of acetylsalicylic acid and salicylic acid from rapid-and 
      slow-release formulations, and in combination with dipyridamol.
PG  - 309-14
AB  - Acetylsalicylic acid (ASA) is a strong, irreversible inhibitor of platelet 
      aggregation, but loses this activity following first-pass deacetylation to 
      salicylic acid (SA). In order to compare the bioavailability of unchanged ASA 
      from rapid- and slow-release formulations, the single-dose concentration profiles 
      of ASA and SA were studied in healthy volunteers following intake of two 
      different rapid-release (conventional and effervescent tablets) and three 
      different slow-release (microencapsulated ASA in tablets and in capsules, and 
      enteric-coated tablets) formulations of ASA, and of one slow-release formulation 
      of sodium salicylate. Since anti-platelet therapy with ASA is often combined with 
      dipyridamol, the influence of this drug was also examined. The concentrations of 
      ASA and SA were measured by high-pressure liquid chromatography. While the 
      bioavailability of SA from the 5 ASA formulations was essentially equal and 
      similar to that of the salicylate formulation, the bioavailability and peak 
      concentrations of ASA appeared to be the much greater after rapid-release than 
      after slow-release formulations. Indeed, ASA was only rarely detected in systemic 
      blood following intake of slow-release ASA. Co-administered dipyridamol did not 
      significantly influence the kinetics of ASA or SA. It appears that rapid-release 
      formulations of ASA should be prefered in anti-platelet therapy, either alone or 
      in combination with dipyridamol.
FAU - Brantmark, B
AU  - Brantmark B
FAU - Wåhlin-Boll, E
AU  - Wåhlin-Boll E
FAU - Melander, A
AU  - Melander A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Salicylates)
RN  - 64ALC7F90C (Dipyridamole)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/metabolism
MH  - Biological Availability
MH  - Delayed-Action Preparations
MH  - Dipyridamole/*administration & dosage
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Salicylates/*administration & dosage/metabolism
MH  - Salicylic Acid
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1007/BF00548398 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1982;22(4):309-14. doi: 10.1007/BF00548398.

PMID- 6908869
OWN - NLM
STAT- MEDLINE
DCOM- 19810709
LR  - 20131121
IS  - 0016-5751 (Print)
IS  - 0016-5751 (Linking)
VI  - 41
IP  - 2
DP  - 1981 Feb
TI  - [Clinical study of the labour inhibiting effects an side effects of 
      acetylsalicylic acid (ASA) (author's transl)].
PG  - 96-100
AB  - In 37 pregnancy women preterm labour was inhibited with intravenous 
      administration of ASA. 20 patients (Group I) had a combined treatment of ASA and 
      Fenoterol. 7 pregnant women (Group II) without successful labour inhibition under 
      Fenoterol were treated with ASA subsequently. In a third group of 10 women we 
      administered ASA alone. The treatment was considered as successful if signs of 
      preterm labour stopped and pregnancy maintained for 7 days or more. In the first 
      group 16, in the second group all patients had been treated successfully. In 
      group III we succeeded in labour inhibiting for more than 7 days in 6 cases. An 
      initial loading dose of 5.5 to 7.0 mn/min ASA had been infused for 24 hours. If 
      preterm labour was stopped, the dosage had been reduced. In all patients dose 
      related but reversible symptoms of vertigo, tinnitus, headache and 
      hyperventilation were seen. Furthermore we found a non-dose-dependent 
      prolongation ( by 30% or normal) of bleeding time. In the fetus respectively the 
      newborn an affection by this ASA treatment could be excluded. We propose 
      inhibition of preterm labour by i.v. ASA administration in all pregnant women if 
      beta-mimetic drugs are not successful or an intolerance is diagnosed. 
      Contraindications for ASA therapy are mentioned.
FAU - Wolff, F
AU  - Wolff F
FAU - Berg, R
AU  - Berg R
FAU - Bolte, A
AU  - Bolte A
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Klinische Untersuchungen zur wehenhemmenden Wirkung der Azetylsalizylsäure (ASS) 
      und ihrer Nebenwirkungen.
PL  - Germany
TA  - Geburtshilfe Frauenheilkd
JT  - Geburtshilfe und Frauenheilkunde
JID - 0370732
RN  - 22M9P70OQ9 (Fenoterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Female
MH  - Fenoterol/therapeutic use
MH  - Headache/chemically induced
MH  - Humans
MH  - Hyperventilation/chemically induced
MH  - Obstetric Labor, Premature/*drug therapy
MH  - Pregnancy
MH  - Tinnitus/chemically induced
MH  - Vertigo/chemically induced
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
AID - 10.1055/s-2008-1036971 [doi]
PST - ppublish
SO  - Geburtshilfe Frauenheilkd. 1981 Feb;41(2):96-100. doi: 10.1055/s-2008-1036971.

PMID- 17053008
OWN - NLM
STAT- MEDLINE
DCOM- 20070207
LR  - 20220331
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 27
IP  - 22
DP  - 2006 Nov
TI  - A systematic review and meta-analysis on the hazards of discontinuing or not 
      adhering to aspirin among 50,279 patients at risk for coronary artery disease.
PG  - 2667-74
AB  - AIMS: The role of aspirin in patients with coronary artery disease (CAD) is well 
      established, yet patients happen to discontinue aspirin according to physician's 
      advice or unsupervised. We thus undertook a systematic review to appraise the 
      hazards inherent to aspirin withdrawal or non-compliance in subjects at risk for 
      or with CAD. METHODS AND RESULTS: Electronic databases were systematically 
      searched (updated January 2006). Study designs, patient characteristics, and 
      outcomes were abstracted. Pooled estimates for odds ratios (OR) were computed 
      according to random-effect methods. From the 612 screened studies, six were 
      selected (50,279 patients). One study (31,750 patients) focused on adherence to 
      aspirin therapy in the secondary prevention of CAD, two studies (2594) on aspirin 
      discontinuation in acute CAD, two studies (13,706) on adherence to aspirin 
      therapy before or shortly after coronary artery bypass grafting, and another 
      (2229) on aspirin discontinuation among patients undergoing drug-eluting 
      stenting. Overall, aspirin non-adherence/withdrawal was associated with 
      three-fold higher risk of major adverse cardiac events (OR=3.14 [1.75-5.61], 
      P=0.0001). This risk was magnified in patients with intracoronary stents, as 
      discontinuation of antiplatelet treatment was associated with an even higher risk 
      of adverse events (OR=89.78 [29.90-269.60]). CONCLUSION: Non-compliance or 
      withdrawal of aspirin treatment has ominous prognostic implication in subjects 
      with or at moderate-to-high risk for CAD. Aspirin discontinuation in such 
      patients should be advocated only when bleeding risk clearly overwhelms that of 
      atherothrombotic events.
FAU - Biondi-Zoccai, Giuseppe G L
AU  - Biondi-Zoccai GG
AD  - Interventional Cardiology, Division of Cardiology, University of Turin, corso 
      Bramante 88-90, 10126 Turin, Italy. gbiondizoccai@gmail.com
FAU - Lotrionte, Marzia
AU  - Lotrionte M
FAU - Agostoni, Pierfrancesco
AU  - Agostoni P
FAU - Abbate, Antonio
AU  - Abbate A
FAU - Fusaro, Massimiliano
AU  - Fusaro M
FAU - Burzotta, Francesco
AU  - Burzotta F
FAU - Testa, Luca
AU  - Testa L
FAU - Sheiban, Imad
AU  - Sheiban I
FAU - Sangiorgi, Giuseppe
AU  - Sangiorgi G
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20061019
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Factors
MH  - Treatment Refusal
RF  - 40
EDAT- 2006/10/21 09:00
MHDA- 2007/02/08 09:00
CRDT- 2006/10/21 09:00
PHST- 2006/10/21 09:00 [pubmed]
PHST- 2007/02/08 09:00 [medline]
PHST- 2006/10/21 09:00 [entrez]
AID - ehl334 [pii]
AID - 10.1093/eurheartj/ehl334 [doi]
PST - ppublish
SO  - Eur Heart J. 2006 Nov;27(22):2667-74. doi: 10.1093/eurheartj/ehl334. Epub 2006 
      Oct 19.

PMID- 7943744
OWN - NLM
STAT- MEDLINE
DCOM- 19941104
LR  - 20190821
IS  - 0003-2654 (Print)
IS  - 0003-2654 (Linking)
VI  - 119
IP  - 7
DP  - 1994 Jul
TI  - Spectrofluorimetry at zero angle: determination of salicylic acid in an 
      acetylsalicylic acid pharmaceutical formulation.
PG  - 1561-5
AB  - In this work, a solid-state spectrofluorimetric method for drug assays was 
      developed. In particular, we report the determination of salicylic acid (SA), as 
      a hydrolysis product, in solid pharmaceutical formulations containing 
      acetylsalicylic acid (ASA). Recently, we described a sensitive and accurate 
      fluorescence method that provided, through a mathematical application, the 
      simultaneous determination of ASA and SA. By means of the spectrofluorimetric 
      method reported herein it was possible to carry out the SA determination, without 
      any mathematical calculation and with a sensitivity 100 times that of our 
      previous method. The intra- and inter-day reproducibility of the 
      spectrofluorimetric method, expressed as the relative standard deviation, ranged 
      from 0.1 to 0.3%. The present method requires a fluorescence apparatus with the 
      excitation and detection systems in-line (zero angle). The detection system was 
      not sensitive to the excitation wavelength, but was highly sensitive to emission 
      wavelengths from 350 to 800 nm. The results obtained were compared with those of 
      our previous spectrofluorimetric method, together with those of a 
      high-performance liquid chromatography method and a US Pharmacopeia method. The 
      sensitivity of the method was of the order of 10(-8) g.
FAU - Villari, A
AU  - Villari A
AD  - Dipartimento Farmaco-Chimico Università di Messina, Italy.
FAU - Micali, N
AU  - Micali N
FAU - Fresta, M
AU  - Fresta M
FAU - Puglisi, G
AU  - Puglisi G
LA  - eng
PT  - Journal Article
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid
MH  - Drug Storage
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Spectrometry, Fluorescence
EDAT- 1994/07/01 00:00
MHDA- 1994/07/01 00:01
CRDT- 1994/07/01 00:00
PHST- 1994/07/01 00:00 [pubmed]
PHST- 1994/07/01 00:01 [medline]
PHST- 1994/07/01 00:00 [entrez]
AID - 10.1039/an9941901561 [doi]
PST - ppublish
SO  - Analyst. 1994 Jul;119(7):1561-5. doi: 10.1039/an9941901561.

PMID- 25917640
OWN - NLM
STAT- MEDLINE
DCOM- 20160222
LR  - 20161125
IS  - 1873-3441 (Electronic)
IS  - 0939-6411 (Linking)
VI  - 93
DP  - 2015 Jun
TI  - Near-infrared chemical imaging (NIR-CI) as a process monitoring solution for a 
      production line of roll compaction and tableting.
PG  - 293-302
LID - S0939-6411(15)00187-3 [pii]
LID - 10.1016/j.ejpb.2015.04.008 [doi]
AB  - In the present study the application of near-infrared chemical imaging (NIR-CI) 
      supported by chemometric modeling as non-destructive tool for monitoring and 
      assessing the roller compaction and tableting processes was investigated. Based 
      on preliminary risk-assessment, discussion with experts and current work from the 
      literature the critical process parameter (roll pressure and roll speed) and 
      critical quality attributes (ribbon porosity, granule size, amount of fines, 
      tablet tensile strength) were identified and a design space was established. Five 
      experimental runs with different process settings were carried out which revealed 
      intermediates (ribbons, granules) and final products (tablets) with different 
      properties. Principal component analysis (PCA) based model of NIR images was 
      applied to map the ribbon porosity distribution. The ribbon porosity distribution 
      gained from the PCA based NIR-CI was used to develop predictive models for 
      granule size fractions. Predictive methods with acceptable R(2) values could be 
      used to predict the granule particle size. Partial least squares regression 
      (PLS-R) based model of the NIR-CI was used to map and predict the chemical 
      distribution and content of active compound for both roller compacted ribbons and 
      corresponding tablets. In order to select the optimal process, setting the 
      standard deviation of tablet tensile strength and tablet weight for each tablet 
      batch was considered. Strong linear correlation between tablet tensile strength 
      and amount of fines and granule size was established, respectively. These 
      approaches are considered to have a potentially large impact on quality 
      monitoring and control of continuously operating manufacturing lines, such as 
      roller compaction and tableting processes.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Khorasani, Milad
AU  - Khorasani M
AD  - Department of Pharmacy, Faculty of Health and Medical Sciences, University of 
      Copenhagen, Denmark.
FAU - Amigo, José M
AU  - Amigo JM
AD  - Department of Food Science, Faculty of Science, University of Copenhagen, 
      Denmark.
FAU - Sun, Changquan Calvin
AU  - Sun CC
AD  - Department of Pharmaceutic, College of Pharmacy, University of Minnesota, USA.
FAU - Bertelsen, Poul
AU  - Bertelsen P
AD  - Takeda Pharma A/S, Roskilde, Denmark.
FAU - Rantanen, Jukka
AU  - Rantanen J
AD  - Department of Pharmacy, Faculty of Health and Medical Sciences, University of 
      Copenhagen, Denmark. Electronic address: jukka.rantanen@sund.ku.dk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150425
PL  - Netherlands
TA  - Eur J Pharm Biopharm
JT  - European journal of pharmaceutics and biopharmaceutics : official journal of 
      Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
JID - 9109778
RN  - 0 (Excipients)
RN  - 0 (Powders)
RN  - 0 (Tablets)
RN  - 9004-34-6 (Cellulose)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/standards
MH  - Cellulose/chemistry
MH  - Chemistry, Pharmaceutical
MH  - Excipients/chemistry
MH  - Least-Squares Analysis
MH  - *Models, Chemical
MH  - *Models, Statistical
MH  - Particle Size
MH  - Porosity
MH  - Powders
MH  - Principal Component Analysis
MH  - Quality Control
MH  - Spectroscopy, Near-Infrared/*methods/standards
MH  - Tablets
MH  - Technology, Pharmaceutical/*methods/standards
MH  - Tensile Strength
OTO - NOTNLM
OT  - Near-infrared chemical imaging
OT  - Partial least squares
OT  - Principal component analysis
OT  - Ribbon chemical map
OT  - Ribbon porosity map
OT  - Roll compaction/dry granulation
OT  - Tablet chemical map
EDAT- 2015/04/29 06:00
MHDA- 2016/02/24 06:00
CRDT- 2015/04/29 06:00
PHST- 2015/02/11 00:00 [received]
PHST- 2015/04/15 00:00 [revised]
PHST- 2015/04/17 00:00 [accepted]
PHST- 2015/04/29 06:00 [entrez]
PHST- 2015/04/29 06:00 [pubmed]
PHST- 2016/02/24 06:00 [medline]
AID - S0939-6411(15)00187-3 [pii]
AID - 10.1016/j.ejpb.2015.04.008 [doi]
PST - ppublish
SO  - Eur J Pharm Biopharm. 2015 Jun;93:293-302. doi: 10.1016/j.ejpb.2015.04.008. Epub 
      2015 Apr 25.

PMID- 7165392
OWN - NLM
STAT- MEDLINE
DCOM- 19830407
LR  - 20191031
IS  - 0170-9925 (Print)
IS  - 0170-9925 (Linking)
VI  - 233
IP  - 1
DP  - 1982
TI  - Perinatal pharmacokinetics of acetylsalicylic acid.
PG  - 15-22
AB  - Pregnant women were treated with infusions of acetylsalicylic acid (ASA). The 
      plasma concentrations of total salicylate or those of ASA and salicylic acid (SA) 
      were determined. The ASA steady state was reached after 2 h of infusion whereas 3 
      days seemed necessary to reach the steady state of SA. In a further study during 
      the late phase of cervical dilatation (12 min - 2 h before birth) healthy 
      pregnant women were given 1 g ASA as a single i.v. bolus injection. The resulting 
      plasma levels of ASA and SA in the mothers during delivery, the plasma 
      concentrations in umbilical cord blood and in blood obtained from the newborn 
      several hours after birth were measured. With increasing time the SA 
      concentrations in the umbilical cord blood plasma approached those of the 
      mothers. On the other hand, the umbilical cord blood concentrations of ASA did 
      not approach the maternal concentrations, probably because of the ASA esterase 
      activity at the placental barrier. The plasma concentrations in the newborn 
      indicated that the newborn is able to degrade ASA and to excrete SA. However, the 
      velocities are lower than the respective velocities in adults.
FAU - Wolff, F
AU  - Wolff F
FAU - Berg, R
AU  - Berg R
FAU - Bolte, A
AU  - Bolte A
FAU - Pütter, J
AU  - Pütter J
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arch Gynecol
JT  - Archives of gynecology
JID - 7901051
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/blood/*metabolism
MH  - Female
MH  - Fetal Blood/analysis
MH  - Humans
MH  - Infant, Newborn
MH  - Kinetics
MH  - Obstetric Labor, Premature/metabolism/prevention & control
MH  - Pregnancy
MH  - Salicylates/blood
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1007/BF02110674 [doi]
PST - ppublish
SO  - Arch Gynecol. 1982;233(1):15-22. doi: 10.1007/BF02110674.

PMID- 21223551
OWN - NLM
STAT- MEDLINE
DCOM- 20110503
LR  - 20211020
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 12
DP  - 2011 Jan 11
TI  - Accrual and drop out in a primary prevention randomised controlled trial: 
      qualitative study.
PG  - 7
LID - 10.1186/1745-6215-12-7 [doi]
AB  - BACKGROUND: Recruitment and retention of participants are critical to the success 
      of a randomised controlled trial. Gaining the views of potential trial 
      participants who decline to enter a trial and of trial participants who stop the 
      trial treatment is important and can help to improve study processes. Limited 
      research on these issues has been conducted on healthy individuals recruited for 
      prevention trials in the community. METHODS: Semi-structured interviews with 
      people who were eligible but had declined to participate in the Aspirin for 
      Asymptomatic Atherosclerosis (AAA) trial (N = 11), and AAA trial participants who 
      had stopped taking the trial medication (N = 11). A focus group with further 
      participants who had stopped taking the trial medication (N = 6). (Total 
      participants N = 28). RESULTS: Explanations for declining to participate could be 
      divided into two groups: the first group were characterised by a lack of 
      necessity to participate and a tendency to prioritise other largely mundane 
      problems. The second group's concern was with a high level of perceived risk from 
      participating.Explanations for stopping trial medication fell into four 
      categories: side effects attributed to the trial medication; starting on aspirin 
      or medication contraindicating to aspirin; experiencing an outcome event, and 
      changing one's mind. CONCLUSIONS: These results indicate that when planning 
      trials (especially in preventive medicine) particular attention should be given 
      to designing appropriate recruitment materials and processes that fully inform 
      potential recruits of the risks and benefits of participation. TRIAL 
      REGISTRATION: ISRCTN66587262.
FAU - Eborall, Helen C
AU  - Eborall HC
AD  - Department of Health Sciences, University of Leicester, UK. hce3@le.ac.uk
FAU - Stewart, Marlene C W
AU  - Stewart MC
FAU - Cunningham-Burley, Sarah
AU  - Cunningham-Burley S
FAU - Price, Jackie F
AU  - Price JF
FAU - Fowkes, F Gerry R
AU  - Fowkes FG
LA  - eng
SI  - ISRCTN/ISRCTN66587262
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110111
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Asymptomatic Diseases
MH  - Atherosclerosis/*drug therapy
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Female
MH  - Focus Groups
MH  - Health Behavior
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - Motivation
MH  - *Patient Dropouts
MH  - Patient Education as Topic
MH  - *Patient Selection
MH  - Primary Prevention/*methods
MH  - Qualitative Research
MH  - Risk Assessment
MH  - United Kingdom
PMC - PMC3024954
EDAT- 2011/01/13 06:00
MHDA- 2011/05/04 06:00
CRDT- 2011/01/13 06:00
PHST- 2010/04/20 00:00 [received]
PHST- 2011/01/11 00:00 [accepted]
PHST- 2011/01/13 06:00 [entrez]
PHST- 2011/01/13 06:00 [pubmed]
PHST- 2011/05/04 06:00 [medline]
AID - 1745-6215-12-7 [pii]
AID - 10.1186/1745-6215-12-7 [doi]
PST - epublish
SO  - Trials. 2011 Jan 11;12:7. doi: 10.1186/1745-6215-12-7.

PMID- 16164586
OWN - NLM
STAT- MEDLINE
DCOM- 20060124
LR  - 20191210
IS  - 1356-1294 (Print)
IS  - 1356-1294 (Linking)
VI  - 11
IP  - 5
DP  - 2005 Oct
TI  - Evaluating national guidelines for prevention of cardiovascular disease in 
      primary care.
PG  - 452-61
AB  - INTRODUCTION: National guidelines for prevention of cardiovascular disease make 
      different recommendations in relation to screening and treating patients with 
      aspirin, antihypertensive treatment and statins. The resource cost and health 
      implications of these differences are quantified in this paper. DATA SOURCES: 
      Guidelines were obtained from Australia, New Zealand, Canada, UK and USA. 
      Effectiveness data were obtained from published sources, costs and a model 
      population of 2000 patients from US sources. METHOD: The resource costs and 
      health effects of screening and treating a standard population of 2000 persons 
      were determined for each of the five national guidelines. Costs and effects were 
      calculated over a 5-year time horizon and cost-effectiveness determined cost per 
      cardiovascular event prevented. RESULTS: Cost per cardiovascular event prevented 
      is lowest in older patients and very high under 35. The New Zealand guidelines 
      are more cost-effective of the national guidelines, however, they would be more 
      effective if they incorporated US recommendations on the use of aspirin. Further 
      antihypertensive treatment is the least cost-effective of the interventions 
      considered. DISCUSSION: Cardiovascular disease prevention guidelines should focus 
      on older rather than younger patients. Treatment eligibility should be informed 
      more by risk than by individual risk factor status. Guidelines should put greater 
      emphasis on the use of aspirin and initial antihypertensive treatment than on 
      achieving blood pressure targets. CONCLUSION: In order to justify their 
      recommendations guidelines should quantify the resource implications in relation 
      to the health benefits.
FAU - Marshall, Tom
AU  - Marshall T
AD  - Department of Public Health & Epidemiology, University of Birmingham, Edgbaston, 
      Birmingham, UK. t.p.marshall@bham.ac.uk
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - J Eval Clin Pract
JT  - Journal of evaluation in clinical practice
JID - 9609066
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antihypertensive Agents/administration & dosage/economics
MH  - Aspirin/administration & dosage/economics
MH  - Australia
MH  - Canada
MH  - Cardiovascular Diseases/economics/*prevention & control/therapy
MH  - Cost-Benefit Analysis
MH  - Health Care Costs
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/economics
MH  - *Practice Guidelines as Topic
MH  - Primary Health Care
MH  - United Kingdom
MH  - United States
EDAT- 2005/09/17 09:00
MHDA- 2006/01/25 09:00
CRDT- 2005/09/17 09:00
PHST- 2005/09/17 09:00 [pubmed]
PHST- 2006/01/25 09:00 [medline]
PHST- 2005/09/17 09:00 [entrez]
AID - JEP557 [pii]
AID - 10.1111/j.1365-2753.2005.00557.x [doi]
PST - ppublish
SO  - J Eval Clin Pract. 2005 Oct;11(5):452-61. doi: 10.1111/j.1365-2753.2005.00557.x.

PMID- 12055585
OWN - NLM
STAT- MEDLINE
DCOM- 20020703
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 122
IP  - 7
DP  - 2002 Jun
TI  - Diet and colorectal cancer: an investigation of the lectin/galactose hypothesis.
PG  - 1784-92
AB  - BACKGROUND & AIMS: Mucosal expression of terminal unsubstituted galactose is 
      increased in colon cancer and precancer and allows interaction with mitogenic 
      galactose-binding lectins of dietary or microbial origin. This study tests the 
      hypothesis that galactose, which is variably plentiful in fruit and vegetable but 
      not cereal fibers, might prevent cancer by binding and inhibiting such lectins. 
      METHODS: Colorectal cancer cases (512) and controls (512) were matched for age, 
      sex, primary care practitioner, and postal code. A 160-item food-frequency 
      questionnaire was used to estimate their usual pre-illness (6 months previous) 
      diet, aspirin intake, and exercise. RESULTS: Neither cereal fiber nor fruit and 
      vegetable fiber were protective when assessed by univariate analysis, whereas 
      dietary fiber galactose content showed a dose-related protective effect (odds 
      ratio [OR] highest quartile/lowest quartile, 0.67; confidence interval [CI], 
      0.47-0.95) that remained protective when adjusted for energy, red meat, alcohol, 
      calcium, protein and fat intake, regular aspirin usage, and exercise. Intake of 
      nonlegume green vegetables, assessed because of the high lectin content of 
      legumes, was also protective (OR, 0.54; CI, 0.35-0.81), but this was not 
      independent of galactose. Protective effects of exercise and regular daily 
      aspirin consumption and harmful effects of high energy consumption and high red 
      meat intake were confirmed. CONCLUSIONS: The protective effect of fruit and 
      vegetable fibers may be related to their galactose content. This provides further 
      evidence that the association between diet and colon cancer is mediated via 
      specific food components and may explain the discrepant results of studies 
      addressing the protective effects of fiber.
FAU - Evans, Richard C
AU  - Evans RC
AD  - Department of Medicine, University of Liverpool, England.
FAU - Fear, Simon
AU  - Fear S
FAU - Ashby, Deborah
AU  - Ashby D
FAU - Hackett, Alan
AU  - Hackett A
FAU - Williams, Evelyn
AU  - Williams E
FAU - Van Der Vliet, Martine
AU  - Van Der Vliet M
FAU - Dunstan, Frank D J
AU  - Dunstan FD
FAU - Rhodes, Jonathan M
AU  - Rhodes JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Lectins)
RN  - R16CO5Y76E (Aspirin)
RN  - X2RN3Q8DNE (Galactose)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Case-Control Studies
MH  - Colorectal Neoplasms/etiology/*prevention & control
MH  - *Diet
MH  - Drug Administration Schedule
MH  - Energy Intake
MH  - Exercise
MH  - Female
MH  - Galactose/*pharmacology
MH  - Humans
MH  - Lectins/*pharmacology
MH  - Male
MH  - Meat
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Risk Factors
MH  - Surveys and Questionnaires
EDAT- 2002/06/11 10:00
MHDA- 2002/07/04 10:01
CRDT- 2002/06/11 10:00
PHST- 2002/06/11 10:00 [pubmed]
PHST- 2002/07/04 10:01 [medline]
PHST- 2002/06/11 10:00 [entrez]
AID - S0016508502000124 [pii]
AID - 10.1053/gast.2002.33659 [doi]
PST - ppublish
SO  - Gastroenterology. 2002 Jun;122(7):1784-92. doi: 10.1053/gast.2002.33659.

PMID- 2876664
OWN - NLM
STAT- MEDLINE
DCOM- 19861031
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 37
IP  - 10
DP  - 1986 Oct
TI  - Antiaggregative aspirin dosage at the affected vessel wall.
PG  - 695-701
AB  - The present study, using patients with Takayasu's disease (pulseless disease), 
      characterized by segmentally affected arterial lesions and stenotic conditions 
      with a nonspecific inflammatory morbid condition, was designed to assess whether 
      or not a low dose of aspirin can practically exert its preventive effect against 
      the aggregation of platelets that have just passed along a rough-surfaced 
      arterial wall. Twenty Japanese women with Takayasu's disease were selected under 
      the following criteria: A unilateral upper extremity was angiographically 
      confirmed to be affected with the disease, while the contralateral limb was 
      almost normal. Systolic blood pressure on the affected side was almost half that 
      on the nonaffected side. The patients showed neither a positive CRP nor an 
      accentuated ESR. In these patients, mean plasma levels of TXB2 and 3 microM 
      ADP-induced platelet aggregation in blood obtained from the affected side were 
      156.5 +/- 17.7 pg/ml, and 59.5 +/- 6.0%, respectively, which were significantly 
      high as compared with 104.5 +/- 17.6 and 41.7 +/- 8.8%, respectively, in samples 
      from the nonaffected side. Forty and eighty mg of aspirin per day administered to 
      two randomly composed groups, respectively, showed an improvement in platelet 
      aggregability and TXB2 levels on the nonaffected side. In the affected limbs, 
      though 80 mg/day led to significant decreases in TXB2 levels (108.0 +/- 7.8 
      pg/ml, p less than 0.05) and platelet aggregability (21.3 +/- 7.6%), the 40-mg 
      regimen showed no significant reductions (134.6 +/- 9.4 pg/ml, 35.6 +/- 17.1%). 
      Plasma levels of 6-keto PGF1 alpha revealed no differences between 40- and 80-mg 
      regimens, or between before and after treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Numano, F
AU  - Numano F
FAU - Maruyama, Y
AU  - Maruyama Y
FAU - Koyama, T
AU  - Koyama T
FAU - Numano, F
AU  - Numano F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aortic Arch Syndromes/*complications
MH  - Arm/*blood supply
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Random Allocation
MH  - Takayasu Arteritis/*complications
MH  - Thrombosis/etiology/*prevention & control
MH  - Thromboxane B2/blood
EDAT- 1986/10/01 00:00
MHDA- 1986/10/01 00:01
CRDT- 1986/10/01 00:00
PHST- 1986/10/01 00:00 [pubmed]
PHST- 1986/10/01 00:01 [medline]
PHST- 1986/10/01 00:00 [entrez]
AID - 10.1177/000331978603701001 [doi]
PST - ppublish
SO  - Angiology. 1986 Oct;37(10):695-701. doi: 10.1177/000331978603701001.

PMID- 36328927
OWN - NLM
STAT- MEDLINE
DCOM- 20221220
LR  - 20230131
IS  - 1878-4321 (Electronic)
IS  - 1049-3867 (Print)
IS  - 1049-3867 (Linking)
VI  - 33
IP  - 1
DP  - 2023 Jan-Feb
TI  - Content Analysis of Patient-Facing Information Related to Preeclampsia.
PG  - 77-86
LID - S1049-3867(22)00110-4 [pii]
LID - 10.1016/j.whi.2022.09.003 [doi]
AB  - BACKGROUND: Previous research has shown pregnant people are not knowledgeable 
      about preeclampsia, a significant cause of maternal morbidity and mortality. This 
      lack of knowledge may impact their ability to report symptoms, comply with 
      recommendations, and receive appropriate follow-up care. Pregnant people commonly 
      seek information from sources outside their treating clinician, including 
      pregnancy-specific books and online sources. We examined commonly used 
      preeclampsia information sources to evaluate whether pregnant people are 
      receiving up-to-date, guideline-based information. METHODS: We conducted a 
      content analysis of preeclampsia-related information in top-ranking websites and 
      bestselling pregnancy books. We used American College of Obstetricians and 
      Gynecologists preeclampsia guidelines to construct a codebook, which we used to 
      examine source content completeness and accuracy. For each source, we analyzed 
      information about preeclampsia diagnosis, patient-reported symptoms, risk 
      factors, prevention, treatment, and complications. RESULTS: Across 19 included 
      sources (13 websites and 6 books), we found substantial variation in completeness 
      and accuracy of preeclampsia information. We found high rates of mentions for 
      preeclampsia symptoms. Risk factors were more commonly included in online sources 
      than book sources. Most sources mentioned treatment options, including blood 
      pressure medication and giving birth; however, one-third of online sources 
      positively mentioned the nonrecommended treatment of bed rest. Prevention 
      methods, including prenatal aspirin for high-risk pregnancies, and long-term 
      complications of preeclampsia were infrequently mentioned. CONCLUSIONS: Varying 
      rates of accuracy in patient-facing preeclampsia information mean there is 
      substantial room for improvement in these sources. Ensuring pregnant people 
      receive current guideline-based information is critical for improving outcomes 
      and implementing shared decision-making.
CI  - Copyright © 2022 Jacobs Institute of Women's Health, George Washington 
      University. Published by Elsevier Inc. All rights reserved.
FAU - Geissler, Kimberley H
AU  - Geissler KH
AD  - Department of Health Promotion and Policy, University of Massachusetts School of 
      Public Health and Health Sciences, Amherst, Massachusetts. Electronic address: 
      kgeissler@umass.edu.
FAU - Evans, Valerie
AU  - Evans V
AD  - Department of Health Promotion and Policy, University of Massachusetts School of 
      Public Health and Health Sciences, Amherst, Massachusetts.
FAU - Cooper, Michael I
AU  - Cooper MI
AD  - Department of Health Promotion and Policy, University of Massachusetts School of 
      Public Health and Health Sciences, Amherst, Massachusetts; Tufts University 
      School of Medicine, Boston, Massachusetts.
FAU - Shaw, Susan J
AU  - Shaw SJ
AD  - Department of Health Promotion and Policy, University of Massachusetts School of 
      Public Health and Health Sciences, Amherst, Massachusetts.
FAU - Yarrington, Christina
AU  - Yarrington C
AD  - Boston Medical Center and Boston University School of Medicine, Boston, 
      Massachusetts.
FAU - Attanasio, Laura B
AU  - Attanasio LB
AD  - Department of Health Promotion and Policy, University of Massachusetts School of 
      Public Health and Health Sciences, Amherst, Massachusetts.
LA  - eng
GR  - R56 HL151636/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20221031
PL  - United States
TA  - Womens Health Issues
JT  - Women's health issues : official publication of the Jacobs Institute of Women's 
      Health
JID - 9101000
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Pregnancy
MH  - Humans
MH  - *Pre-Eclampsia/diagnosis/etiology
MH  - Aspirin/therapeutic use
MH  - Risk Factors
PMC - PMC9772133
MID - NIHMS1838995
COIS- Conflict of Interest Disclosures: The authors report no conflict of interest.
EDAT- 2022/11/04 06:00
MHDA- 2022/12/21 06:00
PMCR- 2024/01/01
CRDT- 2022/11/03 23:07
PHST- 2021/11/09 00:00 [received]
PHST- 2022/08/30 00:00 [revised]
PHST- 2022/09/21 00:00 [accepted]
PHST- 2024/01/01 00:00 [pmc-release]
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2022/12/21 06:00 [medline]
PHST- 2022/11/03 23:07 [entrez]
AID - S1049-3867(22)00110-4 [pii]
AID - 10.1016/j.whi.2022.09.003 [doi]
PST - ppublish
SO  - Womens Health Issues. 2023 Jan-Feb;33(1):77-86. doi: 10.1016/j.whi.2022.09.003. 
      Epub 2022 Oct 31.

PMID- 35674593
OWN - NLM
STAT- MEDLINE
DCOM- 20220610
LR  - 20220716
IS  - 2317-6385 (Electronic)
IS  - 1679-4508 (Print)
IS  - 1679-4508 (Linking)
VI  - 20
DP  - 2022
TI  - Low platelet reactivity in patients with myocardial infarction treated with 
      aspirin plus ticagrelor.
PG  - eAO7001
LID - S1679-45082022000100264 [pii]
LID - 10.31744/einstein_journal/2022AO7001 [doi]
LID - eAO7001
AB  - OBJECTIVE: Low platelet reactivity levels are associated with higher risk of 
      bleeding in patients receiving dual antiplatelet therapy relative to patients 
      with optimal platelet blockade. This study set out to evaluate the prevalence of 
      low platelet reactivity in patients with acute myocardial infarction treated with 
      ticagrelor and aspirin. METHODS: Patients admitted with acute myocardial 
      infarction who were already undergoing dual antiplatelet therapy with aspirin and 
      ticagrelor were enrolled. Blood samples were collected 1 hour before and 2 hours 
      after the maintenance dose of ticagrelor to investigate trough and the peak 
      effects of the drug respectively. Platelet reactivity was measured by three 
      methods: Multiplate®, PFA-100® with Innovance® PFA-P2Y cartridge and PFA-100® 
      with Collagen/ADP cartridge. Platelet reactivity was assessed in the presence of 
      peak levels of ticagrelor and defined according to previously validated cut-offs 
      for each method (<19 AUC, >299 seconds and >116 seconds respectively). The level 
      of significance was set at p<0.05. RESULTS: Fifty patients were enrolled (44% 
      with ST-elevation). Median duration of DAPT was 3 days (interquartile range, 2-5 
      days). On average, peak and trough platelet reactivity were markedly low and did 
      not differ between different methods. Low platelet reactivity was common, but 
      varied according to analytic method (PFA-100®/Innovance®PFA-P2Y: 86%; 
      Multiplate®: 74%; PFA-100®/Collagen/ADP: 48%; p<0.001). CONCLUSION: Low platelet 
      reactivity was very common in patients with acute myocardial infarction submitted 
      to dual antiplatelet therapy with ticagrelor and aspirin. Findings of this study 
      justify the investigation of less intensive platelet inhibition strategies aimed 
      at reducing the risk of bleeding in this population, such as lower dose regimens 
      or monotherapy with P2Y12 inhibitors.
FAU - Costa, Thiago Guarato Rodrigues
AU  - Costa TGR
AUID- ORCID: 0000-0002-7569-7290
AD  - Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
FAU - Katz, Marcelo
AU  - Katz M
AUID- ORCID: 0000-0003-1909-6607
AD  - Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
FAU - Lemos Neto, Pedro Alves
AU  - Lemos Neto PA
AUID- ORCID: 0000-0002-6782-750X
AD  - Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
FAU - Guerra, João Carlos de Campos
AU  - Guerra JCC
AUID- ORCID: 0000-0002-4156-529X
AD  - Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
FAU - Franken, Marcelo
AU  - Franken M
AUID- ORCID: 0000-0002-4286-8559
AD  - Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
FAU - Pesaro, Antonio Eduardo Pereira
AU  - Pesaro AEP
AUID- ORCID: 0000-0003-3133-4989
AD  - Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20220601
PL  - Brazil
TA  - Einstein (Sao Paulo)
JT  - Einstein (Sao Paulo, Brazil)
JID - 101281800
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/therapeutic use
MH  - *Aspirin/adverse effects/therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - *Myocardial Infarction/drug therapy
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Ticagrelor/adverse effects/therapeutic use
MH  - Treatment Outcome
PMC - PMC9165567
COIS- Conflict of interest: none.
EDAT- 2022/06/09 06:00
MHDA- 2022/06/11 06:00
CRDT- 2022/06/08 10:07
PHST- 2021/08/22 00:00 [received]
PHST- 2021/12/02 00:00 [accepted]
PHST- 2022/06/08 10:07 [entrez]
PHST- 2022/06/09 06:00 [pubmed]
PHST- 2022/06/11 06:00 [medline]
AID - S1679-45082022000100264 [pii]
AID - 10.31744/einstein_journal/2022AO7001 [doi]
PST - epublish
SO  - Einstein (Sao Paulo). 2022 Jun 1;20:eAO7001. doi: 
      10.31744/einstein_journal/2022AO7001. eCollection 2022.

PMID- 33865015
OWN - NLM
STAT- MEDLINE
DCOM- 20210811
LR  - 20210811
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 139
DP  - 2021 Jul
TI  - Aspirin facilitates trophoblast invasion and epithelial-mesenchymal transition by 
      regulating the miR-200-ZEB1 axis in preeclampsia.
PG  - 111591
LID - S0753-3322(21)00376-0 [pii]
LID - 10.1016/j.biopha.2021.111591 [doi]
AB  - Preeclampsia is a severe gestational hypertensive disorder that occurs after 20 
      weeks' of gestation. It involves several maternal systems, such as 
      cardiovascular, renal, coagulatory systems, and poses a major threat to the 
      maternal and fetal health. Recent clinical evidence showed that aspirin is an 
      effective preventative treatment for reducing the incidence of premature 
      preeclampsia among high-risk pregnant women, however, the mechanism of drug 
      action is not clear. miR-200 family has been shown to be associated with 
      preeclampsia and upregulated in the plasma and placenta of preeclamptic patients. 
      Here we revealed that miR-200 family inhibited trophoblast invasion and 
      epithelial-mesenchymal transition (EMT) process by stimulating epithelial marker 
      expression (E-cadherin and ZO-1) and repressing mesenchymal marker expression 
      (ZEB1 and TGFβ1). Similarly, EMT markers in the placenta of preeclamptic patients 
      showed higher E-cadherin and lower ZEB1 and TGF-β1 protein expression. Moreover, 
      aspirin was shown to suppress miR-200 family and these miR-200 family-mediated 
      cell functions, including cell invasion and EMT changes, were completely 
      reversed. In conclusion, this study demonstrates the effect of miR-200 family on 
      trophoblast invasion and EMT. For the first time, aspirin was shown to fully 
      reverse miR-200-mediated trophoblast biology and act through the network 
      signaling of TGF-β1/ZEB1/miR-200. These results provide a plausible mechanism 
      explaining aspirin's effect on preeclampsia prevention and a therapeutic target 
      for disease intervention.
CI  - Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Su, Mei-Tsz
AU  - Su MT
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan 
      704, Taiwan; Department of Obstetrics and Gynecology, Tainan Hospital, Ministry 
      of Health and Welfare, Tainan, Taiwan. Electronic address: 
      sumeitsz@mail.ncku.edu.tw.
FAU - Tsai, Pei-Yin
AU  - Tsai PY
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan 
      704, Taiwan.
FAU - Wang, Chia-Yih
AU  - Wang CY
AD  - Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung 
      University, Tainan, Taiwan; Institute of Basic Medical Sciences, College of 
      Medicine, National Cheng Kung University, Tainan, Taiwan.
FAU - Tsai, Hui-Ling
AU  - Tsai HL
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan 
      704, Taiwan.
FAU - Kuo, Pao-Lin
AU  - Kuo PL
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan 
      704, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20210414
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antigens, CD)
RN  - 0 (CDH1 protein, human)
RN  - 0 (Cadherins)
RN  - 0 (MIRN200 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (TGFB1 protein, human)
RN  - 0 (TJP1 protein, human)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (ZEB1 protein, human)
RN  - 0 (Zinc Finger E-box-Binding Homeobox 1)
RN  - 0 (Zonula Occludens-1 Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antigens, CD/metabolism
MH  - Aspirin/*pharmacology
MH  - Cadherins/metabolism
MH  - Cell Line
MH  - Cell Movement/drug effects
MH  - Cell Proliferation
MH  - Epithelial-Mesenchymal Transition/drug effects
MH  - Female
MH  - Humans
MH  - *MicroRNAs
MH  - Pre-Eclampsia/*genetics/*metabolism
MH  - Pregnancy
MH  - Transforming Growth Factor beta1/*metabolism
MH  - Trophoblasts/*drug effects/metabolism
MH  - Zinc Finger E-box-Binding Homeobox 1/*metabolism
MH  - Zonula Occludens-1 Protein/metabolism
OTO - NOTNLM
OT  - Aspirin
OT  - Epithelial-mesenchymal transition
OT  - MiR-200
OT  - Preeclampsia
OT  - Trophoblast invasion
EDAT- 2021/04/18 06:00
MHDA- 2021/08/12 06:00
CRDT- 2021/04/17 20:13
PHST- 2021/01/29 00:00 [received]
PHST- 2021/03/31 00:00 [revised]
PHST- 2021/04/02 00:00 [accepted]
PHST- 2021/04/18 06:00 [pubmed]
PHST- 2021/08/12 06:00 [medline]
PHST- 2021/04/17 20:13 [entrez]
AID - S0753-3322(21)00376-0 [pii]
AID - 10.1016/j.biopha.2021.111591 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2021 Jul;139:111591. doi: 10.1016/j.biopha.2021.111591. Epub 
      2021 Apr 14.

PMID- 35190417
OWN - NLM
STAT- MEDLINE
DCOM- 20220322
LR  - 20220322
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 12
IP  - 2
DP  - 2022 Feb 21
TI  - Off-label indications of aspirin in gynaecology and obstetrics outpatients at two 
      Chinese tertiary care hospitals: a retrospective cross-sectional study.
PG  - e050702
LID - 10.1136/bmjopen-2021-050702 [doi]
LID - e050702
AB  - OBJECTIVE: To investigate the prevalence of off-label aspirin indications and the 
      level of scientific support for off-label indications of aspirin in gynaecology 
      and obstetrics outpatients. DESIGN: A retrospective cross-sectional study. 
      SETTING: Two tertiary hospitals (a general hospital and a women and children's 
      specialised hospital) in Xiamen, a city located on the southeastern coast of 
      China. PARTICIPANTS: A total of 4257 prescriptions were included for 2091 female 
      patients aged >18 who visited the gynaecology and obstetrics outpatient clinics 
      and received aspirin treatment. OUTCOME MEASURES: The primary measure of this 
      study was the proportion of off-label indications and of off-label indications 
      supported by strong scientific evidence. Evidence from clinical guidelines and 
      Micromedex is shown using descriptive statements. On-label indications of drugs 
      in the same class as aspirin were also referred to for off-label aspirin use 
      without strong evidence support. RESULTS: All indications of aspirin on 
      outpatient prescriptions were determined as off-label use in this study. The most 
      frequent off-label indication was recurrent miscarriage (2244 prescriptions, 
      52.71%). Totally, 30.94% of the prescriptions were supported by strong evidence 
      for indications, including recurrent miscarriage with antiphospholipid syndrome 
      and prophylaxis for pre-eclampsia. No drugs in the same class as aspirin had 
      on-label indications for off-label aspirin use without strong evidence support. 
      CONCLUSIONS: This study demonstrated that all indications of aspirin used in 
      gynaecology and obstetrics outpatients at the two tertiary hospitals were 
      off-label and not always supported by strong evidence, implicating that 
      physicians should be cautious when issuing off-label prescriptions. More original 
      clinical research on off-label aspirin use is needed to provide reference for 
      routine clinical practice.
CI  - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Shen, Sijie
AU  - Shen S
AD  - Department of Pharmacy, The First Affiliated Hospital of Xiamen University, 
      Xiamen, Fujian, China.
FAU - Yang, Jianhui
AU  - Yang J
AUID- ORCID: 0000-0002-8710-1722
AD  - Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen 
      University, Xiamen, Fujian, China 814328154@qq.com.
FAU - Chen, Yao
AU  - Chen Y
AD  - Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen 
      University, Xiamen, Fujian, China.
FAU - Xie, Jingxian
AU  - Xie J
AD  - Department of Obstetrics, Women and Children's Hospital, School of Medicine, 
      Xiamen University, Xiamen, Fujian, China.
FAU - Huang, Yanni
AU  - Huang Y
AD  - Department of Gynaecology, Women and Children's Hospital, School of Medicine, 
      Xiamen University, Xiamen, Fujian, China.
FAU - Lin, Wubin
AU  - Lin W
AD  - Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen 
      University, Xiamen, Fujian, China.
FAU - Liao, Yufang
AU  - Liao Y
AD  - Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen 
      University, Xiamen, Fujian, China.
LA  - eng
PT  - Journal Article
DEP - 20220221
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Child
MH  - China
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Gynecology
MH  - Humans
MH  - *Obstetrics
MH  - Off-Label Use
MH  - Outpatients
MH  - Practice Patterns, Physicians'
MH  - Retrospective Studies
MH  - Tertiary Care Centers
PMC - PMC8860038
OTO - NOTNLM
OT  - gynaecology
OT  - health policy
OT  - obstetrics
COIS- Competing interests: None declared.
EDAT- 2022/02/23 06:00
MHDA- 2022/03/23 06:00
CRDT- 2022/02/22 06:06
PHST- 2022/02/22 06:06 [entrez]
PHST- 2022/02/23 06:00 [pubmed]
PHST- 2022/03/23 06:00 [medline]
AID - bmjopen-2021-050702 [pii]
AID - 10.1136/bmjopen-2021-050702 [doi]
PST - epublish
SO  - BMJ Open. 2022 Feb 21;12(2):e050702. doi: 10.1136/bmjopen-2021-050702.

PMID- 18093204
OWN - NLM
STAT- MEDLINE
DCOM- 20080214
LR  - 20131121
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Linking)
VI  - 34
IP  - 2
DP  - 2008 Feb
TI  - A meta-analysis of complications attributed to anticoagulation among patients 
      following cutaneous surgery.
PG  - 160-4; discussion 164-5
AB  - BACKGROUND: The frequency of postoperative bleeding and other complications in 
      anticoagulated patients undergoing cutaneous surgery has not been firmly 
      established and consensus on perioperative continuation of treatment is lacking. 
      OBJECTIVE: The objective was to ascertain the risk of postoperative complications 
      through meta-analysis of data pooled from previously published studies. METHODS: 
      A PubMed search (1966-2005) was performed to identify controlled studies 
      reporting bleeding and other complications among patients undergoing cutaneous 
      surgery who were taking anticoagulant medications. Emphasis was placed on 
      prescription anticoagulant medications (aspirin, NSAIDs, warfarin, clopidogrel) 
      and over-the-counter herbal agents with anticoagulant properties. RESULTS: A 
      total of six studies representing 1,373 patients met criteria for inclusion. 
      Among patients taking aspirin or warfarin, 1.3 and 5.7% experienced a severe 
      postoperative complication, respectively. Patients taking warfarin were nearly 
      seven times as likely to have a moderate-to-severe complication compared to 
      controls (OR, 6.69; 95% CI, 3.03-14.7), a statistically significant difference 
      (p<.001). Patients taking aspirin or NSAIDs were more than twice as likely to 
      have a moderate-to-severe complication compared to controls (OR, 2.0; 95% CI, 
      0.97-4.13), a strong trend toward statistical significance (p=.06). There were no 
      studies in the literature that examined the effects of combination anticoagulant 
      therapy or the effect of herbal agents on postoperative risk of bleeding. 
      CONCLUSION: The results of this meta-analysis suggest that while low, the risk of 
      bleeding among anticoagulated patients may be higher than baseline. Adequately 
      powered prospective studies are required to more carefully delineate the risk of 
      postoperative bleeding and other complications attributable to anticoagulation 
      therapy. Particular emphasis should be placed on examining the effect of 
      combination anticoagulant therapy as well as herbal agents with anticoagulant 
      properties on risk of bleeding after cutaneous surgery.
FAU - Lewis, Kevan G
AU  - Lewis KG
AD  - Department of Dermatology, Brown Medical School/Rhode Island Hospital, 
      Providence, Rhode Island 02903, USA.
FAU - Dufresne, Raymond G Jr
AU  - Dufresne RG Jr
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20071217
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*adverse effects
MH  - Aspirin/adverse effects/therapeutic use
MH  - Fibrinolytic Agents/*adverse effects/therapeutic use
MH  - Humans
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Skin Diseases/*surgery
MH  - Thrombosis/prevention & control
MH  - Warfarin/adverse effects/therapeutic use
RF  - 7
EDAT- 2007/12/21 09:00
MHDA- 2008/02/15 09:00
CRDT- 2007/12/21 09:00
PHST- 2007/12/21 09:00 [pubmed]
PHST- 2008/02/15 09:00 [medline]
PHST- 2007/12/21 09:00 [entrez]
AID - DSU34033 [pii]
AID - 10.1111/j.1524-4725.2007.34033.x [doi]
PST - ppublish
SO  - Dermatol Surg. 2008 Feb;34(2):160-4; discussion 164-5. doi: 
      10.1111/j.1524-4725.2007.34033.x. Epub 2007 Dec 17.

PMID- 10507957
OWN - NLM
STAT- MEDLINE
DCOM- 19990928
LR  - 20220409
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 131
IP  - 7
DP  - 1999 Oct 5
TI  - Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a 
      meta-analysis.
PG  - 492-501
AB  - PURPOSE: To characterize the efficacy and safety of anticoagulants and 
      antiplatelet agents for prevention of stroke in patients with atrial 
      fibrillation. DATA SOURCES: Randomized trials identified by using the search 
      strategy developed by the Cochrane Collaboration Stroke Review Group. STUDY 
      SELECTION: All published randomized trials testing antithrombotic agents to 
      prevent stroke in patients with atrial fibrillation. DATA EXTRACTION: Data on 
      interventions, number of participants, duration of exposure and occurrence of all 
      stroke (ischemic and hemorrhagic), major extracranial bleeding, and death were 
      extracted independently by two investigators. DATA SYNTHESIS: Sixteen trials 
      included a total of 9874 participants (mean follow-up, 1.7 years). Adjusted-dose 
      warfarin (six trials, 2900 participants) reduced stroke by 62% (95% CI, 48% to 
      72%); absolute risk reductions were 2.7% per year for primary prevention and 8.4% 
      per year for secondary prevention. Major extracranial bleeding was increased by 
      warfarin therapy (absolute risk increase, 0.3% per year). Aspirin (six trials, 
      3119 participants) reduced stroke by 22% (CI, 2% to 38%); absolute risk 
      reductions were 1.5% per year for primary prevention and 2.5% per year for 
      secondary prevention. Adjusted-dose warfarin (five trials, 2837 participants) was 
      more efficacious than aspirin (relative risk reduction, 36% [CI, 14% to 52%]). 
      Other randomized comparisons yielded inconclusive results. CONCLUSIONS: 
      Adjusted-dose warfarin and aspirin reduce stroke in patients with atrial 
      fibrillation, and warfarin is substantially more efficacious than aspirin. The 
      benefit of antithrombotic therapy was not offset by the occurrence of major 
      hemorrhage among participants in randomized trials. Judicious use of 
      antithrombotic therapy, tailored according to the inherent risk for stroke, 
      importantly reduces stroke in patients with atrial fibrillation.
FAU - Hart, R G
AU  - Hart RG
AD  - Department of Medicine (Neurology), University of Texas Health Science Center, 
      San Antonio 78284, USA.
FAU - Benavente, O
AU  - Benavente O
FAU - McBride, R
AU  - McBride R
FAU - Pearce, L A
AU  - Pearce LA
LA  - eng
GR  - R01 24224/PHS HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Anticoagulants)
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 1999 Oct 5;131(7):537-8. PMID: 10507965
CIN - Ann Intern Med. 2000 May 16;132(10):841-2. PMID: 10819710
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Placebos
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 1999/10/03 09:00
MHDA- 2000/09/08 11:01
CRDT- 1999/10/03 09:00
PHST- 1999/10/03 09:00 [pubmed]
PHST- 2000/09/08 11:01 [medline]
PHST- 1999/10/03 09:00 [entrez]
AID - 199910050-00003 [pii]
AID - 10.7326/0003-4819-131-7-199910050-00003 [doi]
PST - ppublish
SO  - Ann Intern Med. 1999 Oct 5;131(7):492-501. doi: 
      10.7326/0003-4819-131-7-199910050-00003.

PMID- 9322987
OWN - NLM
STAT- MEDLINE
DCOM- 19971016
LR  - 20190722
IS  - 0194-911X (Print)
IS  - 0194-911X (Linking)
VI  - 30
IP  - 3 Pt 2
DP  - 1997 Sep
TI  - Time-dependent effects of low-dose aspirin administration on blood pressure in 
      pregnant women.
PG  - 589-95
AB  - This study investigated the effects of low-dose acetylsalicylic acid (aspirin) on 
      blood pressure in pregnant women who were at risk of developing gestational 
      hypertension or preeclampsia and who received aspirin at different times of the 
      day according to their rest-activity cycle. A double-blind, randomized, 
      controlled trial was conducted in 100 pregnant women. Blood pressure for each 
      subject was automatically monitored for 2 days every 4 weeks from the day of 
      recruitment until delivery. Women were randomly assigned to one of six groups 
      according to treatment (placebo, 50 subjects or aspirin, 100 mg/d, starting at 12 
      to 16 weeks of gestation) and the time of treatment: on awakening (time 1), 8 
      hours after awakening (time 2), or before bedtime (time 3). Results indicated 
      that there was (1) no effect on blood pressure from placebo at any time (P>.212) 
      and (2) a highly statistically significant (P<.001) time-dependent effect on 
      blood pressure from aspirin. There was no effect of aspirin on blood pressure at 
      time 1 (compared with placebo), but the blood pressure reduction was highly 
      statistically significant after time 2 and, to a greater extent, after time 3 
      (mean reduction of 12 and 8 mm Hg in 24 hours for systolic and diastolic blood 
      pressure, respectively, at the time of delivery compared with placebo given at 
      the same time). These time-dependent effects of aspirin on blood pressure should 
      be taken into account for the optimization of long-term aspirin administration at 
      low doses for prevention of preeclampsia. In any meta-analysis of aspirin 
      effects, inquiries about the time when the subjects took the drug are indicated 
      and may account for discrepancies in the literature.
FAU - Hermida, R C
AU  - Hermida RC
AD  - ETSI Telecommunicación, Universidad de Vigo, Campus Universitario, Spain. 
      rhermida@tsc.uvigo.es
FAU - Ayala, D E
AU  - Ayala DE
FAU - Iglesias, M
AU  - Iglesias M
FAU - Mojón, A
AU  - Mojón A
FAU - Silva, I
AU  - Silva I
FAU - Ucieda, R
AU  - Ucieda R
FAU - Fernández, J R
AU  - Fernández JR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hypertension
JT  - Hypertension (Dallas, Tex. : 1979)
JID - 7906255
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy/*physiology
MH  - Time Factors
EDAT- 1997/10/10 00:00
MHDA- 1997/10/10 00:01
CRDT- 1997/10/10 00:00
PHST- 1997/10/10 00:00 [pubmed]
PHST- 1997/10/10 00:01 [medline]
PHST- 1997/10/10 00:00 [entrez]
AID - 10.1161/01.hyp.30.3.589 [doi]
PST - ppublish
SO  - Hypertension. 1997 Sep;30(3 Pt 2):589-95. doi: 10.1161/01.hyp.30.3.589.

PMID- 27251704
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20181202
IS  - 1534-3111 (Electronic)
IS  - 1522-6417 (Linking)
VI  - 18
IP  - 7
DP  - 2016 Jul
TI  - Aspirin vs Heparin for the Prevention of Preeclampsia.
PG  - 57
LID - 10.1007/s11906-016-0664-3 [doi]
AB  - Preeclampsia is a hypertensive disorder of pregnancy that remains a significant 
      cause of maternal morbidity and mortality worldwide. Preeclampsia can be resolved 
      by delivery, and most of the proposed preventive treatment approaches are based 
      on processes involved in placental development in early pregnancy. Yet, none of 
      these has been established in clinical practice. Low-dose aspirin is the most 
      promising candidate, nevertheless; while some individual randomized controlled 
      trials showed minimal or no statistically significant benefit, recent metanalyses 
      showed that early initiation before 16 weeks of gestation is associated with 
      prevention of early-onset preeclampsia and reduction in prevalence of perinatal 
      death or morbidity of pregnant women. Heparin could be an alternative 
      antithrombotic and anti-inflammatory median to prevent preeclampsia either alone 
      or in combination with aspirin; however, results are conflicting concerning 
      efficacy.
FAU - Katsi, Vasiliki
AU  - Katsi V
AD  - Department of Cardiology, Hippokration Hospital, Athens, Greece.
FAU - Kanellopoulou, Theoni
AU  - Kanellopoulou T
AD  - Blood Bank and Hemophilia Unit, Hippokration Hospital, 32, Dimarchiou str., 
      122-42 Aegaleo, Athens, Greece. theokanel@gmail.com.
FAU - Makris, Thomas
AU  - Makris T
AD  - Department of Cardiology, Helena Venizelou Hospital, Athens, Greece.
FAU - Nihoyannopoulos, Petros
AU  - Nihoyannopoulos P
AD  - Department of Cardiology, Hippokration Hospital, Athens, Greece.
FAU - Nomikou, Efrosyni
AU  - Nomikou E
AD  - Blood Bank and Hemophilia Unit, Hippokration Hospital, 32, Dimarchiou str., 
      122-42 Aegaleo, Athens, Greece.
FAU - Tousoulis, Dimitrios
AU  - Tousoulis D
AD  - First Cardiology Department, Athens University Medical School, Hippokration 
      Hospital, Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Hypertens Rep
JT  - Current hypertension reports
JID - 100888982
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Hypertension/drug therapy
MH  - Placenta Diseases
MH  - Pre-Eclampsia/physiopathology/*prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - Aspirin
OT  - Heparin
OT  - Hypertension
OT  - Placental disease
OT  - Preeclampsia
OT  - Pregnancy complications
EDAT- 2016/06/03 06:00
MHDA- 2017/08/09 06:00
CRDT- 2016/06/03 06:00
PHST- 2016/06/03 06:00 [entrez]
PHST- 2016/06/03 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
AID - 10.1007/s11906-016-0664-3 [pii]
AID - 10.1007/s11906-016-0664-3 [doi]
PST - ppublish
SO  - Curr Hypertens Rep. 2016 Jul;18(7):57. doi: 10.1007/s11906-016-0664-3.

PMID- 18277132
OWN - NLM
STAT- MEDLINE
DCOM- 20080520
LR  - 20131121
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 19
IP  - 2
DP  - 2008 Mar
TI  - Comparison of four laboratory methods to assess aspirin sensitivity.
PG  - 120-3
LID - 10.1097/MBC.0b013e3282f40dc2 [doi]
AB  - The purpose of this study was to compare the ability of four commercial platelet 
      function assays to detect aspirin response in normal individuals taking 81 or 325 
      mg aspirin in a single-dose response and then in a 7-day dosing regimen. We 
      employed the Chronolog 570VS whole-blood aggregometer with agonists 1.0 
      microgram/ml collagen and 0.5 mmol/l arachidonic acid, the PFA-100 
      epinephrine/collagen cartridge closure time, the Accumetrics Verify/Now 
      arachidonic acid cartridge, and the urine 11-dehydrothromboxane immunoassay 
      normalized to urine creatinine. Fifty normal individuals who met the inclusion 
      criteria were consented in the single-dose study. Blood and urine were collected 
      at baseline, and then each participant was given a 81 mg enteric-coated aspirin 
      tablet. Blood and urine were collected after 24 h. After a minimum of 14 days the 
      process was repeated with a 325 mg aspirin dose. Forty-five individuals were 
      enrolled in the 7-day study. Blood and urine were collected at baseline. Then 
      each participant was given an 81 mg dose of aspirin daily for 7 days. After 7 
      days, blood and urine specimens were obtained and tested. After a minimum washout 
      period of 14 days the process was repeated using a 7-day regimen of 325 mg 
      enteric-coated aspirin tablet. Student's t-test indicated statistical 
      significance between baseline and post responses in both dosing regimens (P < 
      0.05). Individuals were not consistently identified as aspirin responsive across 
      all platforms. All assays discriminated between platelet response and nonresponse 
      to aspirin at both dosages. It may be necessary to employ multiple assays to 
      detect individual platelet response.
FAU - McGlasson, David L
AU  - McGlasson DL
AD  - 59th Clinical, Research Division, Wilford Hall Medical Center, Lackland AFB, 
      Texas, USA. david.mcglasson@lackland.af.mil
FAU - Fritsma, George A
AU  - Fritsma GA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Blood Coagul Fibrinolysis. 2008 Dec;19(8):823-4. PMID: 19002051
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Bleeding Time/*methods
MH  - Blood Platelets/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Predictive Value of Tests
EDAT- 2008/02/16 09:00
MHDA- 2008/05/21 09:00
CRDT- 2008/02/16 09:00
PHST- 2008/02/16 09:00 [pubmed]
PHST- 2008/05/21 09:00 [medline]
PHST- 2008/02/16 09:00 [entrez]
AID - 00001721-200803000-00002 [pii]
AID - 10.1097/MBC.0b013e3282f40dc2 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2008 Mar;19(2):120-3. doi: 
      10.1097/MBC.0b013e3282f40dc2.

PMID- 21258676
OWN - NLM
STAT- MEDLINE
DCOM- 20110706
LR  - 20191210
IS  - 1364-5528 (Electronic)
IS  - 0003-2654 (Linking)
VI  - 136
IP  - 7
DP  - 2011 Apr 7
TI  - Spray desorption collection: an alternative to swabbing for pharmaceutical 
      cleaning validation.
PG  - 1298-301
LID - 10.1039/c0an00728e [doi]
AB  - Spray Desorption Collection (SDC) allows for much larger areas of surfaces to be 
      sampled compared to traditional swabbing techniques, providing a valuable 
      pre-concentration advantage. Closely related to desorption electrospray 
      ionization (DESI), analytes from the sample surface are collected onto a selected 
      collection surface, which in a second step can be analyzed directly. Here we 
      demonstrate the application of SDC as a large surface area sampling tool coupled 
      with paper spray MS (PS-MS) and demonstrate its capabilities for cleaning 
      validation of pharmaceutical equipment for both acidic and basic active 
      ingredients from an aluminium surface.
CI  - © The Royal Society of Chemistry 2011
FAU - Jain, Shashank
AU  - Jain S
AD  - Department of Chemistry, Western Michigan University, Kalamazoo, Michigan, USA.
FAU - Heiser, Amy
AU  - Heiser A
FAU - Venter, Andre R
AU  - Venter AR
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20110124
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - 0 (Pharmaceutical Preparations)
RN  - 7AJO3BO7QN (Loratadine)
RN  - CPD4NFA903 (Aluminum)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aluminum/chemistry
MH  - Aspirin/analysis
MH  - Loratadine/analysis
MH  - Pharmaceutical Preparations/*analysis
MH  - Spectrometry, Mass, Electrospray Ionization/instrumentation/*methods
EDAT- 2011/01/25 06:00
MHDA- 2011/07/08 06:00
CRDT- 2011/01/25 06:00
PHST- 2011/01/25 06:00 [entrez]
PHST- 2011/01/25 06:00 [pubmed]
PHST- 2011/07/08 06:00 [medline]
AID - 10.1039/c0an00728e [doi]
PST - ppublish
SO  - Analyst. 2011 Apr 7;136(7):1298-301. doi: 10.1039/c0an00728e. Epub 2011 Jan 24.

PMID- 18455891
OWN - NLM
STAT- MEDLINE
DCOM- 20080919
LR  - 20131121
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 359
IP  - 1-2
DP  - 2008 Jul 9
TI  - Microwave-assisted drying of pharmaceutical granules and its impact on drug 
      stability.
PG  - 53-62
LID - 10.1016/j.ijpharm.2008.03.018 [doi]
AB  - The advent of microwave technology has intensified the search for pharmaceuticals 
      amenable to microwave processing. This study investigated the influences of 
      powder load, diluent particle size and amount of granulating liquid employed on 
      the microwave-assisted drying and stability of acetylsalicylic acid (ASA)-loaded 
      granules in a single pot high shear processor. Powder load affected the profiles, 
      rate and extent of drying. Drying was more dependent on the size and structural 
      properties of granules rather than their surface areas as heat was generated 
      volumetrically. Increased granule size brought about by increasing the size of 
      diluent particles and amount of granulating liquid resulted in higher drying 
      rates. Drug stability was negatively correlated to the drying time of granules.
FAU - Loh, Z H
AU  - Loh ZH
AD  - Department of Pharmacy, Faculty of Science, 18 Science Drive 4, National 
      University of Singapore, Singapore 117543, Singapore.
FAU - Liew, C V
AU  - Liew CV
FAU - Lee, C C
AU  - Lee CC
FAU - Heng, P W S
AU  - Heng PW
LA  - eng
PT  - Journal Article
DEP - 20080322
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Excipients)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Chemistry, Pharmaceutical
MH  - Desiccation/*methods
MH  - Drug Stability
MH  - Excipients/*chemistry
MH  - *Microwaves
MH  - Particle Size
MH  - Technology, Pharmaceutical/methods
MH  - Time Factors
EDAT- 2008/05/06 09:00
MHDA- 2008/09/20 09:00
CRDT- 2008/05/06 09:00
PHST- 2007/11/07 00:00 [received]
PHST- 2008/02/04 00:00 [revised]
PHST- 2008/03/15 00:00 [accepted]
PHST- 2008/05/06 09:00 [pubmed]
PHST- 2008/09/20 09:00 [medline]
PHST- 2008/05/06 09:00 [entrez]
AID - S0378-5173(08)00226-3 [pii]
AID - 10.1016/j.ijpharm.2008.03.018 [doi]
PST - ppublish
SO  - Int J Pharm. 2008 Jul 9;359(1-2):53-62. doi: 10.1016/j.ijpharm.2008.03.018. Epub 
      2008 Mar 22.

PMID- 16601836
OWN - NLM
STAT- MEDLINE
DCOM- 20060622
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 95
IP  - 4
DP  - 2006 Apr
TI  - Dose- and time-dependent antiplatelet effects of aspirin.
PG  - 652-8
AB  - Aspirin is widely used, but dosages in different clinical situations and the 
      possible importance of "aspirin resistance" are debated. We performed an open 
      cross-over study comparing no treatment (baseline) with three aspirin dosage 
      regimens--37.5 mg/day for 10 days, 320 mg/day for 7 days, and, finally, a single 
      640 mg dose (cumulative dose 960 mg)--in 15 healthy male volunteers. Platelet 
      aggregability was assessed in whole blood (WB) and platelet rich plasma (PRP). 
      The urinary excretions of stable thromboxane (TxM) and prostacyclin (PGI-M) 
      metabolites, and bleeding time were also measured. Platelet COX inhibition was 
      nearly complete already at 37.5 mg aspirin daily, as evidenced by >98% 
      suppression of serum thromboxane B2 and almost abolished arachidonic acid (AA) 
      induced aggregation in PRP 2-6 h after dosing. Bleeding time was similarly 
      prolonged by all dosages of aspirin. Once daily dosing was associated with 
      considerable recovery of AA induced platelet aggregation in WB after 24 hours, 
      even after 960 mg aspirin. Collagen induced aggregation in WB with normal 
      extracellular calcium levels (hirudin anticoagulated) was inhibited <40% at all 
      dosages. TxM excretion was incompletely suppressed, and increased <24 hours after 
      the cumulative 960 mg dose. Aspirin treatment reduced PGI-M already at the lowest 
      dosage (by approximately 25%), but PGI-M excretion and platelet aggregability 
      were not correlated. Antiplatelet effects of aspirin are limited in WB with 
      normal calcium levels. Since recovery of COX-dependent platelet aggregation 
      occurred within 24 hours, once daily dosing of aspirin might be insufficient in 
      patients with increased platelet turnover.
FAU - Perneby, Christina
AU  - Perneby C
AD  - Department of Medicine, Clinical Pharmacology Unit, Karolinska University 
      Hospital (Solna), SE-171 76 Stockholm, Sweden.
FAU - Wallén, N Håkan
AU  - Wallén NH
FAU - Rooney, Cathy
AU  - Rooney C
FAU - Fitzgerald, Desmond
AU  - Fitzgerald D
FAU - Hjemdahl, Paul
AU  - Hjemdahl P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/*administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Epoprostenol/metabolism
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thromboxane B2/blood
MH  - Thromboxanes/metabolism
MH  - Time Factors
EDAT- 2006/04/08 09:00
MHDA- 2006/06/23 09:00
CRDT- 2006/04/08 09:00
PHST- 2006/04/08 09:00 [pubmed]
PHST- 2006/06/23 09:00 [medline]
PHST- 2006/04/08 09:00 [entrez]
AID - 06040652 [pii]
PST - ppublish
SO  - Thromb Haemost. 2006 Apr;95(4):652-8.

PMID- 2181674
OWN - NLM
STAT- MEDLINE
DCOM- 19900509
LR  - 20131121
IS  - 0049-0172 (Print)
IS  - 0049-0172 (Linking)
VI  - 19
IP  - 4 Suppl 2
DP  - 1990 Feb
TI  - Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of 
      salicylic acid in the treatment of rheumatoid arthritis?
PG  - 20-8
AB  - In a multicenter, double-blind, parallel-group study, 233 patients with classical 
      or definite RA who demonstrated disease flare during a prestudy washout period 
      were randomized to 12 weeks of treatment with either the nonacetylated 
      salicylate, salsalate (salicylsalicylic acid), or aspirin. Of the 150 patients 
      who completed the study, 83 received salsalate and 67 were treated with aspirin. 
      Doses of the two drugs were calculated to provide equal amounts of bioavailable 
      salicylic acid. The efficacy of salsalate and aspirin, as measured by all the 
      usual variables, was equivalent but aspirin-treated patients had a higher 
      incidence of severe gastrointestinal problems. Thus, this study demonstrated that 
      the acetyl group of aspirin does not enhance the anti-inflammatory efficacy of 
      salicylic acid in RA.
FAU - April, P
AU  - April P
AD  - Multicenter Salsalate/Aspirin Comparison Study Group St. Paul, MN.
FAU - Abeles, M
AU  - Abeles M
FAU - Baraf, H
AU  - Baraf H
FAU - Cohen, S
AU  - Cohen S
FAU - Curran, N
AU  - Curran N
FAU - Doucette, M
AU  - Doucette M
FAU - Ekholm, B
AU  - Ekholm B
FAU - Goldlust, B
AU  - Goldlust B
FAU - Knee, C M
AU  - Knee CM
FAU - Lee, E
AU  - Lee E
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Semin Arthritis Rheum
JT  - Seminars in arthritis and rheumatism
JID - 1306053
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Salicylates/administration & dosage/*therapeutic use
EDAT- 1990/02/01 00:00
MHDA- 1990/02/01 00:01
CRDT- 1990/02/01 00:00
PHST- 1990/02/01 00:00 [pubmed]
PHST- 1990/02/01 00:01 [medline]
PHST- 1990/02/01 00:00 [entrez]
PST - ppublish
SO  - Semin Arthritis Rheum. 1990 Feb;19(4 Suppl 2):20-8.

PMID- 23608356
OWN - NLM
STAT- MEDLINE
DCOM- 20140205
LR  - 20180505
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 46
IP  - 12
DP  - 2013 Aug
TI  - Low-dose acetylsalicylic acid therapy monitored with ultra high performance 
      liquid chromatography.
PG  - 988-992
LID - S0009-9120(13)00147-1 [pii]
LID - 10.1016/j.clinbiochem.2013.04.007 [doi]
AB  - OBJECTIVES: Assessment of compliance in patients on low-dose acetylsalicylic acid 
      (ASA) therapy is limited to interview, pill counting, witnessed ASA intake, and 
      measurement of thromboxane B2 levels. We validated a new, sensitive assay for 
      analyzing blood levels of ASA and the metabolite salicylic acid (SA). DESIGN AND 
      METHODS: Blood samples were withdrawn from 10 healthy volunteers and 50 patients 
      with stable coronary artery disease, before and after intake of 75 mg ASA. Plasma 
      was mixed with acetonitrile, and 2-methylbenzoic acid was added as internal 
      standard. After filtration, ASA and SA were quantified with ultra high 
      performance liquid chromatography (UHPLC). Separation was accomplished with an 
      isocratic flow of acetonitrile in phosphate buffer pH2.5, and a Zorbax RRHD C18 
      analytical column. Detection was achieved with wavelength photodiode array 
      detection set at 237 nm. RESULTS: The ASA- and SA-assay showed linearity 
      (r(2)>0.999) within the range of 0.2-200 μg/mL, and with detection limits of 170 
      ng/mL and 53 ng/mL. The intra- and inter-day imprecision for ASA and SA were 
      2.2-5.9%, 3.4-11.7% and 1.8-8.0%, 3.8-9.4%, respectively. Recovery was between 89 
      and 103% for both assays. More than 60 coadministered drugs were investigated for 
      interference, and only one drug interfered with the ASA-assay and none with the 
      SA-assay. ASA was measurable 1h after intake of 75 mg ASA, and SA was measurable 
      1 and 6h after ASA intake. CONCLUSION: We developed a fast and reliable UHPLC 
      assay with a high sensitivity and selectivity, suitable for monitoring of 
      compliance in patients treated with low-dose ASA.
CI  - Copyright © 2013 The Canadian Society of Clinical Chemists. Published by Elsevier 
      Inc. All rights reserved.
FAU - Rubak, Peter
AU  - Rubak P
AD  - Department of Clinical Biochemistry, Aarhus University Hospital, Denmark. 
      Electronic address: peterrubak@gmail.com.
FAU - Hardlei, Tore F
AU  - Hardlei TF
AD  - Department of Clinical Biochemistry, Aarhus University Hospital, Denmark.
FAU - Würtz, Morten
AU  - Würtz M
AD  - Department of Cardiology, Aarhus University Hospital, Denmark.
FAU - Kristensen, Steen D
AU  - Kristensen SD
AD  - Department of Cardiology, Aarhus University Hospital, Denmark.
FAU - Hvas, Anne-Mette
AU  - Hvas AM
AD  - Department of Clinical Biochemistry, Aarhus University Hospital, Denmark.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130419
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/*blood
MH  - Calibration
MH  - Case-Control Studies
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Coronary Artery Disease/blood/drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Limit of Detection
MH  - Male
MH  - Middle Aged
MH  - Reference Standards
OTO - NOTNLM
OT  - ASA
OT  - Acetylsalicylic acid
OT  - Aspirin
OT  - Compliance
OT  - HPLC
OT  - High pressure liquid chromatography
OT  - Liquid chromatography
OT  - SA
OT  - Salicylic acid
OT  - UHPLC
OT  - acetylsalicylic acid
OT  - high performance liquid chromatography
OT  - salicylic acid
OT  - ultra high performance liquid chromatography
EDAT- 2013/04/24 06:00
MHDA- 2014/02/06 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/11/05 00:00 [received]
PHST- 2013/03/12 00:00 [revised]
PHST- 2013/04/06 00:00 [accepted]
PHST- 2013/04/24 06:00 [entrez]
PHST- 2013/04/24 06:00 [pubmed]
PHST- 2014/02/06 06:00 [medline]
AID - S0009-9120(13)00147-1 [pii]
AID - 10.1016/j.clinbiochem.2013.04.007 [doi]
PST - ppublish
SO  - Clin Biochem. 2013 Aug;46(12):988-992. doi: 10.1016/j.clinbiochem.2013.04.007. 
      Epub 2013 Apr 19.

PMID- 6361789
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20201209
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 27 Suppl 1
DP  - 1983
TI  - Oral analgesic efficacy of suprofen compared to aspirin, aspirin plus codeine, 
      and placebo in patients with postoperative dental pain.
PG  - 31-40
AB  - The purpose of this study was to evaluate the analgesic efficacy and safety of 
      single oral doses of suprofen 200 and 400 mg, compared with aspirin 650 plus 
      codeine 60 mg, aspirin 650 mg, and placebo in the relief of moderate to severe 
      pain resulting from the surgical removal of impacted third molars. 157 patients 
      completed a randomized, double-blind, single-dose, stratified, parallel-groups 
      trial, and were observed for at least 4 h. Based upon each of the summary 
      efficacy measures, sum pain intensity difference (SPID), percent SPID, TOTPAR and 
      a global evaluation, all four active treatments were approximately equally 
      effective and all were statistically superior to placebo. In addition, suprofen 
      at both dose levels was significantly more effective than placebo beginning at 
      the 0.5-hour observation for mean pain intensity, whereas the two aspirin 
      treatments were not superior to placebo until the 1-hour observation. Side 
      effects were minimal; there was one in the suprofen 200 mg, three in the aspirin 
      650 mg, and one in the placebo treatment group. Thus, it appears that suprofen at 
      200 and 400 mg is a safe and effective oral analgesic for the relief of moderate 
      or severe postoperative dental pain, and it is possible that compared to aspirin 
      650 mg and aspirin 650 mg plus codeine 60 mg, it has a more rapid onset of 
      action.
FAU - Sunshine, A
AU  - Sunshine A
FAU - Marrero, I
AU  - Marrero I
FAU - Olson, N Z
AU  - Olson NZ
FAU - Laska, E M
AU  - Laska EM
FAU - McCormick, N
AU  - McCormick N
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Drug Combinations)
RN  - 0 (Phenylpropionates)
RN  - 0 (Placebos)
RN  - 988GU2F9PE (Suprofen)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Codeine/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - Placebos
MH  - Suprofen/adverse effects/*therapeutic use
MH  - *Tooth Extraction
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1159/000137897 [doi]
PST - ppublish
SO  - Pharmacology. 1983;27 Suppl 1:31-40. doi: 10.1159/000137897.

PMID- 2513995
OWN - NLM
STAT- MEDLINE
DCOM- 19900213
LR  - 20181113
IS  - 0028-7091 (Print)
IS  - 0028-7091 (Linking)
VI  - 65
IP  - 1
DP  - 1989 Jan
TI  - Biochemistry and pharmacology of cyclooxygenase inhibitors.
PG  - 5-15
AB  - Prostaglandins and leukotrienes are local hormones synthesized from essential 
      fatty acids by the cyclooxygenase and lipoxygenase systems. Many 
      anti-inflammatory drugs function by inhibiting prostaglandin production. 
      Acetylsalicylic acid irreversibly inhibits cyclooxygenase by acetylating a serine 
      residue in the active site. Aspirin selectively stimulates the proliferative 
      responses of T-lymphocytes in part by enhancing IL-2 production. Cells recover 
      from aspirin by synthesizing new cyclooxygenase, and many cells require EGF for 
      this. Corticosteroids block recovery from aspirin treatment by inhibiting 
      synthesis of cyclooxygenase. Cyclooxygenase and lipoxygenase inhibitors 
      frequently have opposing activities. More work on the integration of the 
      prostaglandin and the newly discovered leukotriene systems is needed.
FAU - Bailey, J M
AU  - Bailey JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Bull N Y Acad Med
JT  - Bulletin of the New York Academy of Medicine
JID - 7505398
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Eicosanoids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - *Cyclooxygenase Inhibitors
MH  - Eicosanoids/antagonists & inhibitors/*physiology
MH  - Humans
MH  - Immune System/physiology
PMC - PMC1807775
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Bull N Y Acad Med. 1989 Jan;65(1):5-15.

PMID- 7919067
OWN - NLM
STAT- MEDLINE
DCOM- 19941108
LR  - 20131213
IS  - 0840-6529 (Print)
IS  - 0840-6529 (Linking)
VI  - 6
IP  - 1
DP  - 1994
TI  - Aspirin in asymptomatic carotid disease.
PG  - 114-20
AB  - Medical management, particularly antithrombotic treatment with acetylsalicylic 
      acid (ASA) has not been rigorously assessed in the setting of asymptomatic 
      carotid disease. The risk of ischemic vascular events associated with this 
      condition is probably intermediate between the general population and patients 
      who have recently suffered from cerebral ischemic events. Unfortunately, there is 
      a paucity of reliable data regarding the efficacy of any antithrombotic regimen, 
      especially ASA, in the management of this condition. Furthermore, in assessing 
      the potential benefits of long-term use of ASA for prophylactic purposes in these 
      patients, one should also evaluate the side-effects and intolerance related to 
      its chronic use, as well as its potential complications especially from a 
      gastrointestinal perspective. Finally, we present the essential features of the 
      protocol for the Asymptomatic Cervical Bruit Study, which has two objectives: 
      first, to better characterize the natural history of patients with asymptomatic 
      carotid disease and second, to test the efficacy of ASA in the prevention of all 
      types of ischemic events in these patients. It is hoped that the results of this 
      study will provide more reliable data in order that firmer recommendations can be 
      made regarding the use of ASA in asymptomatic carotid disease.
FAU - Côté, R
AU  - Côté R
AD  - Montreal General Hospital, Quebec.
LA  - eng
LA  - fre
PT  - Journal Article
PT  - Review
PL  - Canada
TA  - Health Rep
JT  - Health reports
JID - 9012854
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Health Rep. 1994;6(1):111-3. PMID: 7919066
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/prevention & control
MH  - Carotid Artery Diseases/complications/*physiopathology
MH  - Carotid Stenosis/complications/physiopathology
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Humans
MH  - Risk Factors
MH  - Thrombolytic Therapy
RF  - 30
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Health Rep. 1994;6(1):114-20.

PMID- 20305990
OWN - NLM
STAT- MEDLINE
DCOM- 20100624
LR  - 20211020
IS  - 1537-744X (Electronic)
IS  - 2356-6140 (Print)
IS  - 1537-744X (Linking)
VI  - 10
DP  - 2010 Mar 16
TI  - Fever.
PG  - 490-503
LID - 10.1100/tsw.2010.50 [doi]
AB  - Measurement of body temperature remains one of the most common ways to assess 
      health. An increase in temperature above what is considered to be a normal value 
      is inevitably regarded as a sure sign of disease and referred to with one simple 
      word: fever. In this review, we summarize how research on fever allowed the 
      identification of the exogenous and endogenous molecules and pathways mediating 
      the fever response. We also show how temperature elevation is common to different 
      pathologies and how the molecular components of the fever-generation pathway 
      represent drug targets for antipyretics, such as acetylsalicylic acid, the first 
      "blockbuster drug". We also show how fever research provided new insights into 
      temperature and energy homeostasis, and into treatment of infection and 
      inflammation.
FAU - Bartfai, Tamas
AU  - Bartfai T
AD  - Molecular and Integrative Neurosciences Department, The Scripps Research 
      Institute, La Jolla, CA, USA. tbartfai@scripps.edu
FAU - Conti, Bruno
AU  - Conti B
LA  - eng
GR  - R01 MH074055/MH/NIMH NIH HHS/United States
GR  - 1 U01 NS063560-01/NS/NINDS NIH HHS/United States
GR  - R01 AG028040-03/AG/NIA NIH HHS/United States
GR  - AG028040/AG/NIA NIH HHS/United States
GR  - R01 AG028040-02/AG/NIA NIH HHS/United States
GR  - R01 AG028040/AG/NIA NIH HHS/United States
GR  - R01 AG028040-04/AG/NIA NIH HHS/United States
GR  - R01 AG028040-01A1/AG/NIA NIH HHS/United States
GR  - 5 R01 MH074055-03/MH/NIMH NIH HHS/United States
GR  - U01 NS063560/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20100316
PL  - United States
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Fever/drug therapy/etiology/physiopathology
MH  - Homeostasis
MH  - Humans
PMC - PMC2850202
MID - NIHMS188784
EDAT- 2010/03/23 06:00
MHDA- 2010/06/25 06:00
CRDT- 2010/03/23 06:00
PHST- 2010/03/23 06:00 [entrez]
PHST- 2010/03/23 06:00 [pubmed]
PHST- 2010/06/25 06:00 [medline]
AID - 636738 [pii]
AID - 10.1100/tsw.2010.50 [doi]
PST - epublish
SO  - ScientificWorldJournal. 2010 Mar 16;10:490-503. doi: 10.1100/tsw.2010.50.

PMID- 16079516
OWN - NLM
STAT- MEDLINE
DCOM- 20051014
LR  - 20190706
IS  - 0009-2363 (Print)
IS  - 0009-2363 (Linking)
VI  - 53
IP  - 8
DP  - 2005 Aug
TI  - Mathematical algorithms applied to the multi-linear regression functions for the 
      multicomponent determination of pharmaceutical dosage form containing 
      three-component mixtures.
PG  - 899-906
AB  - In the presence of closely overlapping spectra, the quantitative multiresolution 
      of ternary mixtures of three active compounds paracetamol (PAR), caffeine (CAF) 
      and acetylsalycilic acid (ASP) in tablets, without using pretreatment such as 
      separation step and graphical procedure of spectra was accomplished by the 
      multivariate spectral calibration models, tri-linear regression calibration 
      (TLRC), multi-linear regression calibration (MLRC) and Cramer's rule solution 
      (CRS) of three linear equation functions in the matrix form. In the first two 
      models, TLRC and MLRC are based on the use of the linear regression functions at 
      selected wavelength sets in the spectral region of 210-300 nm. In the case of CRS 
      model, A1(1) (1%, 1 cm) were used to obtain three linear equation functions and 
      this linear equation system was resolved by the Cramer's rule for the prediction 
      of PAR, CAF and ASP in samples. In the TLRC and CRS models, the selection of the 
      appropriate wavelength set was performed by the Kaiser's technique. The 
      algorithms of these mathematical calibration models were briefly described. The 
      validation of TLRC, MLRC and CRS models was carried out by analyzing various 
      synthetic ternary mixtures and by using the standard addition technique. These 
      three calibration approaches were applied to the analysis of the real 
      pharmaceutical tablets containing PAR, CAF and ASP. The obtained results were 
      statistically compared with each other by using experimental and statistical 
      tests. In the comparison of TLRC and MLRC models to the classical approach, CRS 
      technique, the successful assay results were observed for the quantitative 
      multiresolution of ternary mixture of the subject active compounds.
FAU - Dinç, Erdal
AU  - Dinç E
AD  - Department of Analytical Chemistry, Faculty of Pharmacy, University of Ankara, 
      06100 Tandoğan, Ankara, Turkey. dinc@pharmacy.ankara.edu.tr
FAU - Ozdemir, Abdil
AU  - Ozdemir A
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - 0 (Pharmaceutical Preparations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/chemistry
MH  - *Algorithms
MH  - Aspirin/chemistry
MH  - Caffeine/chemistry
MH  - Pharmaceutical Preparations/*chemistry
MH  - Regression Analysis
EDAT- 2005/08/05 09:00
MHDA- 2005/10/15 09:00
CRDT- 2005/08/05 09:00
PHST- 2005/08/05 09:00 [pubmed]
PHST- 2005/10/15 09:00 [medline]
PHST- 2005/08/05 09:00 [entrez]
AID - JST.JSTAGE/cpb/53.899 [pii]
AID - 10.1248/cpb.53.899 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 2005 Aug;53(8):899-906. doi: 10.1248/cpb.53.899.

PMID- 2126818
OWN - NLM
STAT- MEDLINE
DCOM- 19910327
LR  - 20161018
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 40
IP  - 4
DP  - 1990 Apr
TI  - Effect of chronic administration of aspirin, phenobarbitone and oxytetracycline 
      on the plasma levels of vitamin A in albino rats.
PG  - 89-90
AB  - Effect of chronic administration of aspirin, phenobarbitone and oxytetracycline 
      under therapeutic doses on the bioavailability of vitamin A was determined in 
      different groups of albino rats. The rats treated with phenobarbitone (group C) 
      showed significantly decreased vitamin A level in plasma whereas the other two 
      groups (B and D) treated with aspirin and oxytetracycline respectively did not 
      exhibit any significant difference as compared to control group (A).
FAU - Maqbool, T
AU  - Maqbool T
AD  - Department of Chemistry, University of Agriculture, Paisalabad.
FAU - Hashmi, A S
AU  - Hashmi AS
FAU - Shah, B H
AU  - Shah BH
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
RN  - 11103-57-4 (Vitamin A)
RN  - R16CO5Y76E (Aspirin)
RN  - X20I9EN955 (Oxytetracycline)
RN  - YQE403BP4D (Phenobarbital)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Female
MH  - Male
MH  - Oxytetracycline/administration & dosage/*pharmacology
MH  - Phenobarbital/administration & dosage/*pharmacology
MH  - Rats
MH  - Vitamin A/*blood
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
AID - 5414 [pii]
PST - ppublish
SO  - J Pak Med Assoc. 1990 Apr;40(4):89-90.

PMID- 9509896
OWN - NLM
STAT- MEDLINE
DCOM- 19980402
LR  - 20190914
IS  - 0165-6147 (Print)
IS  - 0165-6147 (Linking)
VI  - 19
IP  - 1
DP  - 1998 Jan
TI  - European Stroke Prevention Study-2 results: serendipitous demonstration of 
      neuroprotection induced by endogenous adenosine accumulation?
PG  - 14-6
AB  - In patients with prior stroke or transient ischaemic attack, anti-platelet 
      treatment with dipyridamole substantially reduced stroke recurrence, with a 
      beneficial effect comparable to and additive with that induced by aspirin (the 
      European Stroke Prevention Study-2). Eugenio Picano and Maria Abbracchio present 
      here a platelet-independent hypothesis, according to which cardiovascular and 
      neuroprotective actions achieved by dipyridamole through chronic elevation of 
      endogenous adenosine levels may have contributed to the therapeutic success of 
      this study.
FAU - Picano, E
AU  - Picano E
AD  - Italian National Research Council CNR, Institute of Clinical Physiology, Pisa, 
      Italy.
FAU - Abbracchio, M P
AU  - Abbracchio MP
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Trends Pharmacol Sci
JT  - Trends in pharmacological sciences
JID - 7906158
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - K72T3FS567 (Adenosine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine/*metabolism
MH  - Aspirin/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Blood-Brain Barrier
MH  - Cerebrovascular Disorders/metabolism/*prevention & control
MH  - Dipyridamole/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Neuroprotective Agents/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Placebos
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/pharmacokinetics/*therapeutic use
EDAT- 1998/03/24 00:00
MHDA- 1998/03/24 00:01
CRDT- 1998/03/24 00:00
PHST- 1998/03/24 00:00 [pubmed]
PHST- 1998/03/24 00:01 [medline]
PHST- 1998/03/24 00:00 [entrez]
AID - S0165-6147(97)01148-6 [pii]
AID - 10.1016/s0165-6147(97)01148-6 [doi]
PST - ppublish
SO  - Trends Pharmacol Sci. 1998 Jan;19(1):14-6. doi: 10.1016/s0165-6147(97)01148-6.

PMID- 3756063
OWN - NLM
STAT- MEDLINE
DCOM- 19861112
LR  - 20220421
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 22
IP  - 2
DP  - 1986 Aug
TI  - Influence of gender and oral contraceptive steroids on the metabolism of 
      salicylic acid and acetylsalicylic acid.
PG  - 135-42
AB  - Salicylic acid and acetylsalicylic acid (aspirin) disposition after an oral dose 
      of aspirin, 900 mg (equivalent to 689.7 mg of salicylic acid) was studied in 
      eight males, eight females and eight females receiving oral contraceptive 
      steroids (OCS). Salicylic acid clearance was 61% higher in males compared to the 
      control female group, an effect due largely to enhanced activity of the glycine 
      conjugation pathway (salicyluric acid formation) in males. Salicylic acid 
      clearance was 41% higher in OCS-users compared to the control female group due to 
      increases in both the glycine and glucuronic acid conjugation pathways in the 
      pill users. There was no difference in any salicylic acid disposition parameter 
      between males and OCS-users. Area under the plasma concentration-time curve (AUC) 
      and elimination half-life of aspirin was significantly greater and aspirin plasma 
      hydrolysis rate was significantly lower in both female groups compared to males. 
      There was no difference between OCS-users and the control female group in any of 
      these parameters. Aspirin AUC and elimination half-life were significantly 
      correlated with aspirin plasma hydrolysis rate. These data confirm the importance 
      of hormonal factors in the regulation of drug conjugation reactions in humans and 
      suggest that sex-related differences in salicylic acid and aspirin disposition 
      may be of clinical importance.
FAU - Miners, J O
AU  - Miners JO
FAU - Grgurinovich, N
AU  - Grgurinovich N
FAU - Whitehead, A G
AU  - Whitehead AG
FAU - Robson, R A
AU  - Robson RA
FAU - Birkett, D J
AU  - Birkett DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Blood Proteins)
RN  - 0 (Contraceptives, Oral, Hormonal)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*metabolism
MH  - Blood Proteins/metabolism
MH  - Contraceptives, Oral, Hormonal/*pharmacology
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Protein Binding
MH  - Salicylates/blood/*metabolism
MH  - Salicylic Acid
MH  - Sex Factors
PMC - PMC1401110
OID - PIP: 042136
OID - POP: 00175409
OAB - To characterize the influence of gender and oral contraceptives (OCs) on drugs 
      metabolized by conjugation reactions, salicylic metabolism was studied in 8 
      males, 8 females, and 8 additional females taking OCs. In addition, differences 
      in acetylsalicylic acid (aspirin) disposition were studied in these 3 groups of 
      subjects. Salicylic acid clearance was 61% higher in males than in female 
      controls due to enhanced activity of the glycine conjugation pathway (salicyluric 
      acid formation) in males. Salicylic acid clearance was 41% higher in OC users 
      than in female controls due to increases in both the glycine and glucuronic acid 
      conjugation pathways in the OC users. There were no differences in salicylic acid 
      disposition parameters between males and OC users. The area under the plasma 
      concentration time curve and the elimination half-life of aspirin were 
      significantly lower in both female groups compared to males, as was the aspirin 
      plasma hydrolysis rate. Overall, these data confirm the importance of hormonal 
      factors in the regulation of drug conjugation reactions in humans and suggest 
      that sex-related differences in salicylic acid and aspirin disposition may be of 
      clinical significance.
OABL- eng
OTO - PIP
OT  - Biology
OT  - *Clinical Research
OT  - *Contraception
OT  - Contraceptive Agents
OT  - *Contraceptive Agents, Female
OT  - Contraceptive Methods
OT  - Demographic Factors
OT  - *Drugs
OT  - *Family Planning
OT  - *Metabolic Effects
OT  - *Oral Contraceptives
OT  - Physiology
OT  - Population
OT  - *Population Characteristics
OT  - Research Methodology
OT  - *Sex Factors
OT  - *Steroid Metabolic Effects
OT  - Treatment
EDAT- 1986/08/01 00:00
MHDA- 1986/08/01 00:01
CRDT- 1986/08/01 00:00
PHST- 1986/08/01 00:00 [pubmed]
PHST- 1986/08/01 00:01 [medline]
PHST- 1986/08/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1986.tb05240.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1986 Aug;22(2):135-42. doi: 
      10.1111/j.1365-2125.1986.tb05240.x.

PMID- 350214
OWN - NLM
STAT- MEDLINE
DCOM- 19780715
LR  - 20190823
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 7
IP  - 6
DP  - 1977 Dec
TI  - The effects of enteric coating of aspirin tablets on occult gastrointestinal 
      blood loss.
PG  - 600-4
AB  - The effect of enteric coating of aspirin tablets on the gastrointestinal blood 
      loss associated with high dose aspirin therapy was investigated in 12 patients 
      with rheumatoid arthritis. Occult blood loss was measured after labelling the 
      patients' red blood cells with Cr51. Three salicylate preparations were used: 
      enteric coated tablets of aspirin ("Rhusal", G.P. Laboratories, 7 x 650 mg per 
      day), uncoated tablet cores of aspirin from the same batch (7 x 650 mg per day) 
      and enteric coated tablets of sodium salicylate (7 x 600 mg and 1 x 300 mg per 
      day). Daily blood loss during a salicylate-free period was (0.7 +/- 0.15 ml, mean 
      +/- SE). Blood loss was significantly increased during dosage with all three 
      salicylate preparations. Daily blood loss during dosage with the uncoated tablets 
      of aspirin (5.3 +/- 0.3 ml) was significantly greater than during dosage with the 
      enteric coated tablets of aspirin (2.3 +/- 0.3 ml) and enteric coated tablets of 
      sodium salicylate (2.1 +/- 0.4 ml). The bioavailability of the salicylate 
      preparations was studied in seven of the 12 patients. Mean plasma salicylate 
      concentration two hours after the second daily dose during dosage with the 
      enteric coated tablets of aspirin was 118 +/- 15 microgram/ml compared to 131 +/- 
      16 microgram/ml during dosage with the uncoated tablets. Urinary recoveries of 
      the daily dosage of aspirin in the two formulations were also similar.
FAU - Howe, G B
AU  - Howe GB
FAU - Champion, G D
AU  - Champion GD
FAU - Corrigan, A B
AU  - Corrigan AB
FAU - Hewson, J
AU  - Hewson J
FAU - Haski, A
AU  - Haski A
FAU - Day, R O
AU  - Day RO
FAU - Paull, P D
AU  - Paull PD
FAU - Graham, G G
AU  - Graham GG
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/metabolism
MH  - Biological Availability
MH  - Clinical Trials as Topic
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Occult Blood
MH  - Salicylates/administration & dosage/metabolism
MH  - Tablets, Enteric-Coated
EDAT- 1977/12/01 00:00
MHDA- 1977/12/01 00:01
CRDT- 1977/12/01 00:00
PHST- 1977/12/01 00:00 [pubmed]
PHST- 1977/12/01 00:01 [medline]
PHST- 1977/12/01 00:00 [entrez]
AID - 10.1111/j.1445-5994.1977.tb02315.x [doi]
PST - ppublish
SO  - Aust N Z J Med. 1977 Dec;7(6):600-4. doi: 10.1111/j.1445-5994.1977.tb02315.x.

PMID- 23516680
OWN - NLM
STAT- MEDLINE
DCOM- 20150102
LR  - 20211021
IS  - 1916-7237 (Electronic)
IS  - 0835-7900 (Print)
IS  - 0835-7900 (Linking)
VI  - 27
IP  - 3
DP  - 2013 Mar
TI  - Low-dose acetylsalicylic acid use and the risk of upper gastrointestinal 
      bleeding: a meta-analysis of randomized clinical trials and observational 
      studies.
PG  - 159-67
AB  - BACKGROUND: Low-dose acetylsalicylic acid (LDA, 75 mg/day to 325 mg/day) is 
      recommended for primary and secondary prevention of cardiovascular events, but 
      has been linked to an increased risk of upper gastrointestinal bleeding (UGIB). 
      OBJECTIVE: To analyze the magnitude of effect of LDA use on UGIB risk. METHODS: 
      The PubMed and Embase databases were searched for randomized controlled trials 
      (RCTs) reporting UGIB rates in individuals receiving LDA, and observational 
      studies of LDA use in patients with UGIB. Studies were pooled for analysis of 
      UGIB rates. RESULTS: Eighteen studies were included. Seven RCTs reported UGIB 
      rates in individuals randomly assigned to receive LDA (n=22,901) or placebo 
      (n=22,923). Ten case-control studies analyzed LDA use in patients with UGIB 
      (n=10,816) and controls without UGIB (n=30,519); one cohort study reported 207 
      UGIB cases treated with LDA only. All studies found LDA use to be associated with 
      an increased risk of UGIB. The mean number of extra UGIB cases associated with 
      LDA use in the RCTs was 1.2 per 1000 patients per year (95% CI 0.7 to 1.8). The 
      number needed to harm was 816 (95% CI 560 to 1500) for RCTs and 819 (95% CI 617 
      to 1119) for observational studies. Meta-analysis of RCT data showed that LDA use 
      was associated with a 50% increase in UGIB risk (OR 1.5 [95% CI 1.2 to 1.8]). 
      UGIB risk was most pronounced in observational studies (OR 3.1 [95% CI 2.5 to 
      3.7]). CONCLUSIONS: LDA use was associated with an increased risk of UGIB.
FAU - Valkhoff, Vera E
AU  - Valkhoff VE
FAU - Sturkenboom, Miriam C J M
AU  - Sturkenboom MC
FAU - Hill, Catherine
AU  - Hill C
FAU - Veldhuyzen van Zanten, Sander
AU  - Veldhuyzen van Zanten S
FAU - Kuipers, Ernst J
AU  - Kuipers EJ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Canada
TA  - Can J Gastroenterol
JT  - Canadian journal of gastroenterology = Journal canadien de gastroenterologie
JID - 8807867
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Duodenal Diseases/*chemically induced
MH  - Esophageal Diseases/*chemically induced
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk
MH  - Stomach Diseases/*chemically induced
PMC - PMC3732153
EDAT- 2013/03/22 06:00
MHDA- 2015/01/03 06:00
CRDT- 2013/03/22 06:00
PHST- 2013/03/22 06:00 [entrez]
PHST- 2013/03/22 06:00 [pubmed]
PHST- 2015/01/03 06:00 [medline]
AID - cjg27159 [pii]
AID - 10.1155/2013/596015 [doi]
PST - ppublish
SO  - Can J Gastroenterol. 2013 Mar;27(3):159-67. doi: 10.1155/2013/596015.

PMID- 27028617
OWN - NLM
STAT- MEDLINE
DCOM- 20171214
LR  - 20181113
IS  - 1179-1942 (Electronic)
IS  - 0114-5916 (Print)
IS  - 0114-5916 (Linking)
VI  - 39
IP  - 8
DP  - 2016 Aug
TI  - Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the 
      Secondary Prevention of Cardiovascular Disease.
PG  - 715-27
LID - 10.1007/s40264-016-0421-1 [doi]
AB  - Aspirin has been the cornerstone of therapy for the secondary prevention 
      treatment of patients with cardiovascular disease since landmark trials were 
      completed in the late 1970s and early 1980s that demonstrated the efficacy of 
      aspirin for reducing the risk of ischemic events. Notwithstanding the consistent 
      benefits demonstrated with aspirin for both acute and chronic cardiovascular 
      disease, there are a number of toxicities associated with aspirin that have been 
      showcased by recent long-term clinical trials that have included an aspirin 
      monotherapy arm. As an inhibitor of cyclooxygenase (COX), aspirin impairs gastric 
      mucosal protective mechanisms. Previous trials have shown that up to 15-20 % of 
      patients developed gastrointestinal symptoms with aspirin monotherapy, and 
      approximately 1 % of patients per year had a clinically significant bleeding 
      event, including 1 in 1000 patients who suffered an intracranial or fatal bleed. 
      These risks have been shown to be compounded for patients with acute coronary 
      syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI) who 
      are also treated with other antithrombotic agents during the acute 
      care/procedural period, as well as for an extended time period afterwards. Given 
      observations of substantial increases in bleeding rates from many prior long-term 
      clinical trials that have evaluated aspirin together with other oral platelet 
      inhibitors or oral anticoagulants, the focus of contemporary research has pivoted 
      towards tailored antithrombotic regimens that attempt to either shorten the 
      duration of exposure to aspirin or replace aspirin with an alternative 
      antithrombotic agent. While these shifts are occurring, the safety profile of 
      aspirin when used for the secondary prevention treatment of patients with 
      established cardiovascular disease deserves further consideration.
FAU - Fanaroff, Alexander C
AU  - Fanaroff AC
AD  - Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt 
      Street, Room 7035, Durham, NC, 27705, USA.
FAU - Roe, Matthew T
AU  - Roe MT
AD  - Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt 
      Street, Room 7035, Durham, NC, 27705, USA. matthew.roe@duke.edu.
LA  - eng
GR  - T32 HL069749/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/complications
MH  - Anticoagulants/administration & dosage
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Percutaneous Coronary Intervention/adverse effects/methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Secondary Prevention/methods
PMC - PMC5778440
MID - NIHMS934510
COIS- COMPLIANCE WITH ETHICAL STANDARDS Conflicts of interest: Alexander Fanaroff has 
      no conflicts of interest that are directly related to the content of this 
      manuscript. Matthew Roe reports receiving research funding from Eli Lilly, 
      Sanofi-Aventis, Daiichi Sanko, Janssen Pharmaceuticals, Ferring Pharmaceuticals, 
      American College of Cardiology, American Heart Association, and Familial 
      Hypercholesterolemia Foundation; and reports receiving consulting fees or 
      honoraria from PriMed, Astra Zeneca, Boehringer-Ingelheim, Merck, Amgen, 
      Myokardia, Eli Lilly, and Elsevier Publishers.
EDAT- 2016/03/31 06:00
MHDA- 2017/12/15 06:00
CRDT- 2016/03/31 06:00
PHST- 2016/03/31 06:00 [entrez]
PHST- 2016/03/31 06:00 [pubmed]
PHST- 2017/12/15 06:00 [medline]
AID - 10.1007/s40264-016-0421-1 [pii]
AID - 10.1007/s40264-016-0421-1 [doi]
PST - ppublish
SO  - Drug Saf. 2016 Aug;39(8):715-27. doi: 10.1007/s40264-016-0421-1.

PMID- 34376444
OWN - NLM
STAT- MEDLINE
DCOM- 20210813
LR  - 20210825
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 11
IP  - 8
DP  - 2021 Aug 10
TI  - Effect of aspirin in takotsubo syndrome: protocol of a systematic review and 
      meta-analysis.
PG  - e046727
LID - 10.1136/bmjopen-2020-046727 [doi]
LID - e046727
AB  - INTRODUCTION: Takotsubo syndrome (TTS) is a sudden reversible weakening of the 
      left ventricle function induced by severe stress and resembles many features as 
      acute coronary syndrome. Even though many guidelines had been published about 
      TTS, there is no consensus regarding the long-term treatment. Aspirin is one of 
      the most common prescribed medicines at discharge for patients with the intention 
      to reduce thrombus events and improve the overall prognosis. However, existing 
      studies yielded conflicting results concerning its effects. This study aims to 
      evaluate the impact of long-term maintenance treatment of aspirin in TTS and 
      provides insights in clinical management. METHODS AND ANALYSIS: After searching 
      through electronic databases (PubMed, Embase, Cochrane Library, Web of Science, 
      National Library of Medicine Gateway, CNKI, Wanfang and VIP), grey literatures, 
      conference abstract and trial registries for clinical studies investigating the 
      impact of aspirin on patients with TTS, a systemic review and meta-analysis will 
      be conducted. The search will be limited from inception of each database to 1 
      August 2020. The outcomes including all-cause death, TTS recurrence, stroke, 
      transient ischaemic attack or myocardial infarction at 30-day and 5-year 
      follow-up will be examined. Risk of bias will be assessed by Newcastle-Ottawa 
      quality assessment scale for observational studies and Cochrane Effective 
      Practice and Organization of Care evaluation tool for interventional studies. 
      Grading of Recommendations Assessment, Development and Evaluations method will be 
      applied to assess the quality of evidence. If available, the effects of aspirin 
      on the above outcomes for patients with TTS will be evaluated using random-effect 
      modelling with relative risk at 95% CIs. Subgroup analysis and sensitivity 
      analysis will also be performed when possible. ETHICS AND DISSEMINATION: Ethics 
      approval was not required due to the retrospective nature of the study. Results 
      of the review will be published in a peer-reviewed journal. PROSPERO REGISTRATION 
      NUMBER: CRD42020212729.
CI  - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lin, Jinhai
AU  - Lin J
AUID- ORCID: 0000-0003-0745-0904
AD  - The Second Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Wu, Bingxin
AU  - Wu B
AD  - The Second Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Lin, Luoqi
AU  - Lin L
AD  - The Second Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Ding, Yining
AU  - Ding Y
AD  - The Second Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Zhong, Biying
AU  - Zhong B
AUID- ORCID: 0000-0001-5307-1695
AD  - The Second Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Huang, Zhiwei
AU  - Huang Z
AD  - The Second Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Lin, Miaoyang
AU  - Lin M
AD  - The Second Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, China.
FAU - Xu, Dan-Ping
AU  - Xu DP
AUID- ORCID: 0000-0002-4900-0699
AD  - Department of Traditional Chinese Medicine, The Eighth Affiliated Hospital of Sun 
      Yat-sen University, Shenzhen, China xudanping@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20210810
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - *Ischemic Attack, Transient
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Retrospective Studies
MH  - *Stroke
MH  - Systematic Reviews as Topic
MH  - *Takotsubo Cardiomyopathy
PMC - PMC8356185
OTO - NOTNLM
OT  - cardiomyopathy
OT  - internal medicine
OT  - thromboembolism
COIS- Competing interests: None declared.
EDAT- 2021/08/12 06:00
MHDA- 2021/08/14 06:00
CRDT- 2021/08/11 05:45
PHST- 2021/08/11 05:45 [entrez]
PHST- 2021/08/12 06:00 [pubmed]
PHST- 2021/08/14 06:00 [medline]
AID - bmjopen-2020-046727 [pii]
AID - 10.1136/bmjopen-2020-046727 [doi]
PST - epublish
SO  - BMJ Open. 2021 Aug 10;11(8):e046727. doi: 10.1136/bmjopen-2020-046727.

PMID- 21936549
OWN - NLM
STAT- MEDLINE
DCOM- 20120214
LR  - 20131121
IS  - 1520-5827 (Electronic)
IS  - 0743-7463 (Linking)
VI  - 27
IP  - 20
DP  - 2011 Oct 18
TI  - Binding affinity of a small molecule to an amorphous polymer in a solvent. Part 
      2: preferential binding to local sites on a surface.
PG  - 12396-404
LID - 10.1021/la202593u [doi]
AB  - Crystallization, a separation and purification process, is commonly used to 
      produce a wide range of materials in various industries, and it usually begins 
      with heterogeneous nucleation on a foreign surface in industrial practice and 
      most other circumstances. Recent studies show that amorphous polymeric substrates 
      are useful in controlling crystallization and selectively producing 
      pharmaceutical polymorphs. In our previous publication, we investigated the 
      possible correlation of the binding affinity of one molecule to key binding sites 
      (local binding), and the possibility of using this binding affinity to guide the 
      selection of polymers promoting heterogeneous nucleation. The studied systems 
      were aspirin binding to four nonporous cross-linked polymers in ethanol-water 38 
      v% mixture. Cross-linked with divinylbenzene (DVB), these polymers were 
      poly(4-acryloylmorpholine) (PAM), poly(2-carboxyethyl acrylate) (PCEA), 
      poly(4-hydroxylbutyl acrylate) (PHBA), and polystyrene (PS). We discovered that 
      the trend of the magnitudes of the average free energies of binding to the best 
      sites is very similar to that of heterogeneous nucleation activities. This 
      Article aims to investigate whether or not local binding to key sites is the 
      important variable to describe heterogeneous nucleation as opposed to the 
      overall/average binding affinity of molecules to a surface, and to investigate 
      the possibility of using the overall binding affinity to guide the selection of 
      polymers. We used the polymer surfaces generated from our previous study to 
      calculate the overall binding affinity of aspirin molecules to the surface as 
      measured by the preferential interaction coefficients of aspirin (1 m) to these 
      polymers. We discovered that the trend of the average preferential interaction 
      coefficients does not correlate as well to that of heterogeneous nucleation 
      activities as the free energies of binding to the best sites. We also computed 
      the average numbers of aspirin molecules associated with the areas of the 
      surfaces' best binding sites and found that they correlate better to 
      heterogeneous nucleation activities than the average preferential interaction 
      coefficients. These results further support that local binding is indicative of 
      heterogeneous nucleation. Moreover, we found a weak trend of the distance order 
      parameters of the aspirin molecules to be similar that of heterogeneous 
      nucleation activities. Our results from the two-part study suggest the importance 
      of local binding to heterogeneous nucleation as well as the possibility of using 
      the binding affinity to the local area (the free energy of binding to the best 
      site and the number of nucleating molecules associated with the area of the best 
      binding site) and the distance order parameters to guide the selection of 
      polymers.
CI  - © 2011 American Chemical Society
FAU - Chunsrivirot, Surasak
AU  - Chunsrivirot S
AD  - Computational and Systems Biology, Massachusetts Institute of Technology, 
      Cambridge, Massachusetts 02139, USA.
FAU - Santiso, Erik
AU  - Santiso E
FAU - Trout, Bernhardt L
AU  - Trout BL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110921
PL  - United States
TA  - Langmuir
JT  - Langmuir : the ACS journal of surfaces and colloids
JID - 9882736
RN  - 0 (Polymers)
RN  - 0 (Powders)
RN  - 0 (Solvents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Binding Sites
MH  - Computer Simulation
MH  - Hydrogen Bonding
MH  - Models, Molecular
MH  - Molecular Structure
MH  - Polymers/*chemistry/metabolism
MH  - Porosity
MH  - Powders/*chemistry
MH  - Solvents/*chemistry
MH  - Thermodynamics
EDAT- 2011/09/23 06:00
MHDA- 2012/02/15 06:00
CRDT- 2011/09/23 06:00
PHST- 2011/09/23 06:00 [entrez]
PHST- 2011/09/23 06:00 [pubmed]
PHST- 2012/02/15 06:00 [medline]
AID - 10.1021/la202593u [doi]
PST - ppublish
SO  - Langmuir. 2011 Oct 18;27(20):12396-404. doi: 10.1021/la202593u. Epub 2011 Sep 21.

PMID- 3614840
OWN - NLM
STAT- MEDLINE
DCOM- 19870924
LR  - 20180216
IS  - 0030-3747 (Print)
IS  - 0030-3747 (Linking)
VI  - 19
IP  - 2
DP  - 1987
TI  - Effect of aspirin and vitamin E on phase separation in calf lens homogenate.
PG  - 65-71
AB  - Vitamin E (d-alpha-tocopherol) and aspirin were evaluated for their effects on 
      the phase separation temperature, Tc, of calf lens cytoplasm. Vitamin E and 
      aspirin were added to nuclear homogenate and the change in Tc was measured. 
      Aspirin had no measurable effect on Tc. Vitamin E lowered Tc at a rate of -22 
      degrees C M-1 l-1. The results suggest that the effects of aspirin on cataract 
      are unrelated to phase separation and that vitamin E may act on the phase 
      separation in precataractous lens cells.
FAU - Eccarius, S
AU  - Eccarius S
FAU - Clark, J I
AU  - Clark JI
LA  - eng
GR  - R01 EY004542/EY/NEI NIH HHS/United States
GR  - EY04542/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Switzerland
TA  - Ophthalmic Res
JT  - Ophthalmic research
JID - 0267442
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Body Temperature/drug effects
MH  - Cataract/prevention & control
MH  - Cattle
MH  - Lasers
MH  - Lens, Crystalline/*drug effects
MH  - Ophthalmology/instrumentation
MH  - Vitamin E/*pharmacology
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1159/000265475 [doi]
PST - ppublish
SO  - Ophthalmic Res. 1987;19(2):65-71. doi: 10.1159/000265475.

PMID- 32994449
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210929
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Sep 29
TI  - Aspirin administration might accelerate the subsidence of periprosthetic joint 
      infection.
PG  - 15967
LID - 10.1038/s41598-020-72731-y [doi]
LID - 15967
AB  - Since the past decade, aspirin, a popular anti-inflammatory drug, has been 
      increasingly studied for its potential antimicrobial and antibiofilm activity 
      with promising results, but studies were limited to in vitro and in vivo 
      investigations. Moreover, evidence concerning the beneficial effects of aspirin 
      on the treatment of biofilm-related infections in real-world population is 
      limited. Thus, this study aimed to investigate whether aspirin could promote 
      infection control for patients with periprosthetic joint infections (PJIs). A 
      single-center database was searched. Regular aspirin exposure was defined as a 
      prescription of aspirin for > 6 months before diagnosis of PJIs and consecutive 
      use during the PJI treatment course at a dose ≧ 100 mg/day. General data, 
      treatment modalities, and recurrence status were collected from medical records 
      by an independent orthopedic surgeon. From January 01, 2010, to February 17, 
      2019, 88 patients who met the PJI criteria were identified and included in this 
      study. Of these patients, 12 were taking aspirin regularly during the infectious 
      events. In the Cox proportional hazards model, multivariate analysis revealed 
      that the aspirin group demonstrated significant benefit via superior resolution 
      of PJIs (HR 2.200; 95% CI 1.018-4.757; p = 0.045). In this study, aspirin is 
      beneficial for infection resolution when combined with the current standard of 
      PJI treatment and conventional antibiotics in the management of PJIs.
FAU - Wei, Yi Ping
AU  - Wei YP
AD  - Department of Orthopaedics, Kaohsiung Veteran General Hospital, 386, Ta-Chung 1st 
      Rd, Kaohsiung, Taiwan, ROC.
FAU - Chien, Ju Chun
AU  - Chien JC
AD  - Department of Radiation Oncology, Kaohsiung Veteran General Hospital, Kaohsiung, 
      Taiwan, ROC.
FAU - Hsiang, Wei Hsin
AU  - Hsiang WH
AD  - Departement of Pharmacy, Tri-Service General Hospital Penghu Branch, Penghu, 
      Taiwan, ROC.
FAU - Yang, Shan Wei
AU  - Yang SW
AD  - Department of Orthopaedics, Kaohsiung Veteran General Hospital, 386, Ta-Chung 1st 
      Rd, Kaohsiung, Taiwan, ROC.
FAU - Chen, Chun Yu
AU  - Chen CY
AD  - Department of Orthopaedics, Kaohsiung Veteran General Hospital, 386, Ta-Chung 1st 
      Rd, Kaohsiung, Taiwan, ROC. iergy2000@gmail.com.
AD  - Department of Occupational Therapy, Shu-Zen Junior College of Medicine and 
      Management, Kaohsiung, Taiwan, ROC. iergy2000@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anti-Bacterial Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Bacterial Agents/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Case-Control Studies
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hip Prosthesis/*adverse effects/microbiology
MH  - Humans
MH  - Knee Prosthesis/*adverse effects/microbiology
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prosthesis-Related Infections/*drug therapy
MH  - Treatment Outcome
PMC - PMC7524723
COIS- The authors declare no competing interests.
EDAT- 2020/10/01 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/09/30 06:08
PHST- 2020/05/09 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/30 06:08 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.1038/s41598-020-72731-y [pii]
AID - 72731 [pii]
AID - 10.1038/s41598-020-72731-y [doi]
PST - epublish
SO  - Sci Rep. 2020 Sep 29;10(1):15967. doi: 10.1038/s41598-020-72731-y.

PMID- 8876550
OWN - NLM
STAT- MEDLINE
DCOM- 19961127
LR  - 20191210
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 98
IP  - 4
DP  - 1996 Oct
TI  - Aspirin desensitization treatment of aspirin-sensitive patients with 
      rhinosinusitis-asthma: long-term outcomes.
PG  - 751-8
AB  - BACKGROUND: Aspirin-sensitive patients with asthma experience continuous 
      inflammation of their nasal and sinus tissues, complicated by recurrent 
      sinusitis, which frequently leads to asthma attacks. Systemic corticosteroid 
      therapy and sinus or polyp surgery are currently required to control underlying 
      rhinosinusitis, and bursts of corticosteroids are used for asthma control. 
      OBJECTIVE: After aspirin desensitization therapy, objective measures of 
      respiratory disease activity, linked to the need for systemic corticosteroids and 
      sinus surgery, were studied to determine whether any changes occurred. METHODS: 
      Sixty-five aspirin-sensitive patients with asthma underwent aspirin challenge, 
      followed by aspirin desensitization and daily treatment with aspirin over 1 to 6 
      years (mean, 3.1 years). Clinical outcome measurements before aspirin 
      desensitization treatment and during follow-up were analyzed for the larger group 
      of 65 patients and subgroups (29 patients receiving therapy for 1 to 3 years and 
      36 patients receiving therapy for 3 to 6 years). RESULTS: In the larger group of 
      65 patients, there were significant reductions in numbers of sinus infections per 
      year (median, 6 to 2), hospitalizations for treatment of asthma per year (median, 
      0.2 to 0), improvement in olfaction (median, 0 to 2), and reduction in use of 
      systematic corticosteroids (mean, 10.2 to 2.5 mg) with p values less than 0.0001. 
      Numbers of sinus and polyp operations per year were significantly reduced 
      (median, 0.2 to 0; p = 0.004), and doses of nasal corticosteroids (in micrograms) 
      were significantly reduced (mean dose, 139 to 106 micrograms, p = 0.01). 
      Emergency department visits and use of inhaled corticosteroids were unchanged. 
      CONCLUSIONS: The results support a role for aspirin desensitization treatment of 
      aspirin-sensitive patients with rhinosinusitis-asthma.
FAU - Stevenson, D D
AU  - Stevenson DD
AD  - Division of Allergy, Asthma and Immunology, Scripps Clinic and Research 
      Foundation, La Jolla, CA 92037, USA.
FAU - Hankammer, M A
AU  - Hankammer MA
FAU - Mathison, D A
AU  - Mathison DA
FAU - Christiansen, S C
AU  - Christiansen SC
FAU - Simon, R A
AU  - Simon RA
LA  - eng
GR  - AI32834/AI/NIAID NIH HHS/United States
GR  - M01-RR00833/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/*immunology
MH  - Asthma/immunology/*prevention & control
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*therapy
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - Sinusitis/immunology/*prevention & control
MH  - Time Factors
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - S0091-6749(96)70123-9 [pii]
AID - 10.1016/s0091-6749(96)70123-9 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1996 Oct;98(4):751-8. doi: 10.1016/s0091-6749(96)70123-9.

PMID- 3755907
OWN - NLM
STAT- MEDLINE
DCOM- 19861002
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 35
IP  - 18
DP  - 1986 Sep 15
TI  - Low dose aspirin does not prevent fibrinolytic response to venous occlusion.
PG  - 3147-50
AB  - Interest in the antithrombotic potential of low-dose aspirin is based on its 
      ability to inhibit thromboxane (Tx)A2-related platelet function with concomitant 
      sparing of vascular prostacyclin (PGI2) production. The aim of this study was to 
      investigate the effect of low-dose aspirin (20 mg daily for 7 days) on the 
      increase in fibrinolytic activity in healthy volunteers after venous occlusion. 
      We also tested the effect of high-dose aspirin (650 mg X 2), of salicylate (569 
      mg X 2) and of indobufen (200 mg X 2), a new cyclo-oxygenase inhibitor unrelated 
      to salicylates. Low-dose aspirin reduced serum TxB2 generation by about 90% and 
      suppressed arachidonate-induced platelet aggregation. In contrast, fibrinolytic 
      activity, measured by the euglobulin lysis area and the euglobulin lysis time, 
      was not significantly affected. Both high-dose aspirin and indobufen 
      significantly inhibited TxB2 generation and the rise in fibrinolytic activity 
      induced by venous occlusion, without affecting the pre-occlusion values. 
      Salicylate did not significantly affect any parameter studied. Besides offering a 
      favorable solution to the "aspirin dilemma" related to the TxA2/PGI2 balance, 
      low-dose aspirin might leave intact the fibrinolytic capacity of the vessel wall.
FAU - de Gaetano, G
AU  - de Gaetano G
FAU - Carriero, M R
AU  - Carriero MR
FAU - Cerletti, C
AU  - Cerletti C
FAU - Mussoni, L
AU  - Mussoni L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 6T9949G4LZ (indobufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Analysis of Variance
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Fibrinolysis/*drug effects
MH  - Hematocrit
MH  - Humans
MH  - Isoindoles
MH  - Phenylbutyrates/administration & dosage/therapeutic use
MH  - Thrombosis/*drug therapy
MH  - Thromboxane B2/blood
EDAT- 1986/09/15 00:00
MHDA- 1986/09/15 00:01
CRDT- 1986/09/15 00:00
PHST- 1986/09/15 00:00 [pubmed]
PHST- 1986/09/15 00:01 [medline]
PHST- 1986/09/15 00:00 [entrez]
AID - 0006-2952(86)90400-4 [pii]
AID - 10.1016/0006-2952(86)90400-4 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1986 Sep 15;35(18):3147-50. doi: 10.1016/0006-2952(86)90400-4.

PMID- 3757722
OWN - NLM
STAT- MEDLINE
DCOM- 19861107
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 31
IP  - 10
DP  - 1986 Oct
TI  - Effects of oral agents on pancreatic duct permeability. A model of acute 
      alcoholic pancreatitis.
PG  - 1081-8
AB  - The main pancreatic duct can be made permeable to molecules of up to 20,000 
      daltons by oral pretreatment with aspirin and ethanol. Because pancreatic enzymes 
      have similar molecular weights, we hypothesized that activated pancreatic enzymes 
      would leak from a permeable duct and produce pancreatitis. Four groups of cats 
      were pretreated with either milk, aspirin, ethanol, or aspirin and ethanol for 48 
      hr. Then pancreatic juice (either activated by enterokinase or nonactivated) was 
      perfused along the duct from tail to duodenum. Twenty-four hours later the 
      animals were examined. Animals pretreated with aspirin, ethanol, or both, and in 
      which ducts were perfused with activated juice, developed acute edematous 
      pancreatitis. Animals that had perfusion with nonactivated enzymes had pancreases 
      indistinguishable from control animals. Morphological studies on ductal 
      permeability in animals pretreated with ethanol and aspirin showed electron-dense 
      material (believed to be dextran) between the basal plasma membrane and basal 
      lamina, and in the basal intercellular space.
FAU - Wedgwood, K R
AU  - Wedgwood KR
FAU - Adler, G
AU  - Adler G
FAU - Kern, H
AU  - Kern H
FAU - Reber, H A
AU  - Reber HA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Alcoholism/*complications
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cats
MH  - Cell Membrane Permeability/drug effects
MH  - Ethanol/*pharmacology
MH  - Pancreatic Ducts/*drug effects
MH  - Pancreatic Juice
MH  - Pancreatitis/*etiology
MH  - Perfusion
EDAT- 1986/10/01 00:00
MHDA- 1986/10/01 00:01
CRDT- 1986/10/01 00:00
PHST- 1986/10/01 00:00 [pubmed]
PHST- 1986/10/01 00:01 [medline]
PHST- 1986/10/01 00:00 [entrez]
AID - 10.1007/BF01300261 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1986 Oct;31(10):1081-8. doi: 10.1007/BF01300261.

PMID- 7573259
OWN - NLM
STAT- MEDLINE
DCOM- 19951026
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 173
IP  - 3 Pt 1
DP  - 1995 Sep
TI  - The angiotensin sensitivity test and low-dose aspirin are ineffective methods to 
      predict and prevent hypertensive disorders in nulliparous pregnancy.
PG  - 865-72
AB  - OBJECTIVE: Our purpose was to assess the efficiency of the angiotensin 
      sensitivity test as a predictive test for preeclampsia and the effectiveness of 
      low-dose aspirin to prevent preeclampsia when commenced at 28 weeks' gestation in 
      angiotensin II-sensitive women. STUDY DESIGN: A total of 495 healthy nulliparous 
      women underwent the angiotensin sensitivity test at 28 weeks' gestation. The 
      angiotensin II-sensitive women were randomized to 60 mg of aspirin or placebo as 
      a subset of a large multicenter, randomized, controlled trial of low-dose aspirin 
      therapy in pregnancy. Assessment of the efficiency of the angiotensin sensitivity 
      test and low-dose aspirin in pregnancy was performed after detailed review of 
      case notes after delivery. The Oxford definition of preeclampsia was used. This 
      includes women without proteinuria but requires blood pressure increments that 
      have been validated to bias the selection to primigravid women. RESULTS: Five 
      women had proteinuric preeclampsia in the angiotensin II-sensitive group 
      randomized to aspirin compared with none in the group randomized to placebo. 
      Overall, 11 (25%) of the women randomized to aspirin had preeclampsia compared 
      with four (11%) randomized to placebo (p < 0.05, not significant). The positive 
      and negative predictive values for the angiotensin sensitivity test were 19% and 
      87%, respectively. CONCLUSION: The angiotensin sensitivity test is not an 
      effective screening test for preeclampsia, and low-dose aspirin does not prevent 
      preeclampsia when commenced at 28 weeks' gestation in angiotensin II-sensitive 
      women.
FAU - Kyle, P M
AU  - Kyle PM
AD  - Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Oxford, United 
      Kingdom.
FAU - Buckley, D
AU  - Buckley D
FAU - Kissane, J
AU  - Kissane J
FAU - de Swiet, M
AU  - de Swiet M
FAU - Redman, C W
AU  - Redman CW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Placebos)
RN  - 11128-99-7 (Angiotensin II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angiotensin II
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Pressure
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Mass Screening/methods/statistics & numerical data
MH  - Parity
MH  - Placebos
MH  - Pre-Eclampsia/*diagnosis/physiopathology/*prevention & control
MH  - Pregnancy
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
AID - 0002-9378(95)90356-9 [pii]
AID - 10.1016/0002-9378(95)90356-9 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):865-72. doi: 
      10.1016/0002-9378(95)90356-9.

PMID- 12197849
OWN - NLM
STAT- MEDLINE
DCOM- 20030122
LR  - 20190901
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 16
IP  - 9
DP  - 2002 Sep
TI  - Effects of enteric-coated, low-dose aspirin on parameters of platelet function.
PG  - 1683-8
AB  - BACKGROUND: Aspirin is widely used as an anti-thrombotic drug; however, it has 
      been suggested that enteric-coated formulations of aspirin may be less 
      bioavailable and less effective as anti-thrombotic agents. AIM: To assess the 
      effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum 
      generated thromboxane B2 and platelet aggregation in healthy subjects. METHODS: 
      Twenty-four subjects participated in a double-blind, randomized, 
      placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each 
      of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or 
      matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 
      1 mm arachidonic acid and 1 microg/mL collagen as agonists) were measured 1-3 
      days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on 
      day 7. RESULTS: After seven daily doses of enteric-coated aspirin, the mean 
      percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 
      97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage 
      inhibition of arachidonic acid- and collagen-induced platelet aggregation was 
      97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with - 
      1.0% and 2.7%, respectively, after placebo. CONCLUSIONS: The anti-platelet 
      effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum 
      thromboxane B2 and platelet aggregation) are not adversely affected by enteric 
      coating.
FAU - Van Hecken, A
AU  - Van Hecken A
AD  - Center for Clinical Pharmacology, University Hospital Gasthuisberg, Leuven, 
      Belgium.
FAU - Juliano, M L
AU  - Juliano ML
FAU - Depré, M
AU  - Depré M
FAU - De Lepeleire, I
AU  - De Lepeleire I
FAU - Arnout, J
AU  - Arnout J
FAU - Dynder, A
AU  - Dynder A
FAU - Wildonger, L
AU  - Wildonger L
FAU - Petty, K J
AU  - Petty KJ
FAU - Gottesdiener, K
AU  - Gottesdiener K
FAU - De Hoon, J N
AU  - De Hoon JN
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Tablets, Enteric-Coated
MH  - Thromboxane B2/biosynthesis/blood
EDAT- 2002/08/29 10:00
MHDA- 2003/01/23 04:00
CRDT- 2002/08/29 10:00
PHST- 2002/08/29 10:00 [pubmed]
PHST- 2003/01/23 04:00 [medline]
PHST- 2002/08/29 10:00 [entrez]
AID - 1332 [pii]
AID - 10.1046/j.1365-2036.2002.01332.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2002 Sep;16(9):1683-8. doi: 
      10.1046/j.1365-2036.2002.01332.x.

PMID- 10807421
OWN - NLM
STAT- MEDLINE
DCOM- 20000623
LR  - 20190831
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 14 Suppl 1
DP  - 2000 Apr
TI  - Effects of growth factors on aspirin-induced inhibition of wound repair in a 
      rabbit gastric epithelial cell model.
PG  - 176-82
AB  - BACKGROUND: Aspirin is known to cause adverse effects, including gastric mucosal 
      injury, and to retard gastric wound healing. Growth factors including hepatocyte 
      growth factor (HGF), epidermal growth factor (EGF) and insulin-like growth 
      factor-I (IGF-I) have been shown to play an important role in the repair of 
      gastric mucosal injury. AIM: To employ the cultured gastric epithelial cell model 
      to elucidate the effects of aspirin, as well as several growth factors (HGF, EGF 
      and IGF-I), on gastric wound repair. METHODS: Isolated rabbit gastric epithelial 
      cells (92% mucous cells) were cultured in F-12 medium and formed a complete 
      monolayer cell sheet in 48 h. A wound with a cell-free area of constant size (2 
      mm2) was then created and the wound repair process was monitored by measuring 
      wound size every 12 h. Proliferating cells were detected by BrdU staining. 
      Effects of aspirin (8 mM), HGF (10 ng/mL), EGF (10 ng/mL) and IGF-I (30 ng/mL) 
      were assessed. RESULTS: Aspirin significantly retarded wound healing, but 
      simultaneous addition of growth factors significantly accelerated wound repair 
      compared with aspirin alone. Growth factors reversed the aspirin-induced 
      inhibition of cell proliferation. CONCLUSION: Growth factors, including HGF, EGF 
      and IGF-I, reversed the aspirin-induced inhibition of wound repair through their 
      cytoprotective effects on gastric epithelial cells.
FAU - Yoshizawa, T
AU  - Yoshizawa T
AD  - Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, 
      Japan.
FAU - Watanabe, S
AU  - Watanabe S
FAU - Hirose, M
AU  - Hirose M
FAU - Yamamoto, J
AU  - Yamamoto J
FAU - Osada, T
AU  - Osada T
FAU - Sato, K
AU  - Sato K
FAU - Oide, H
AU  - Oide H
FAU - Kitamura, T
AU  - Kitamura T
FAU - Takei, Y
AU  - Takei Y
FAU - Ogihara, T
AU  - Ogihara T
FAU - Miwa, H
AU  - Miwa H
FAU - Miyazaki, A
AU  - Miyazaki A
FAU - Sato, N
AU  - Sato N
LA  - eng
PT  - Journal Article
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology
MH  - Aspirin/*adverse effects/pharmacology
MH  - Cell Culture Techniques
MH  - Cell Division/drug effects
MH  - Cytoprotection
MH  - Epidermal Growth Factor/*pharmacology
MH  - Epithelial Cells/*physiology
MH  - Gastric Mucosa/*pathology
MH  - Hepatocyte Growth Factor/*pharmacology
MH  - Insulin-Like Growth Factor I/*pharmacology
MH  - Rabbits
EDAT- 2000/05/12 09:00
MHDA- 2000/07/06 11:00
CRDT- 2000/05/12 09:00
PHST- 2000/05/12 09:00 [pubmed]
PHST- 2000/07/06 11:00 [medline]
PHST- 2000/05/12 09:00 [entrez]
AID - 10.1046/j.1365-2036.2000.014s1176.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:176-82. doi: 
      10.1046/j.1365-2036.2000.014s1176.x.

PMID- 26363029
OWN - NLM
STAT- MEDLINE
DCOM- 20160725
LR  - 20190610
IS  - 1367-4811 (Electronic)
IS  - 1367-4803 (Print)
IS  - 1367-4803 (Linking)
VI  - 32
IP  - 1
DP  - 2016 Jan 1
TI  - An algorithm for automated layout of process description maps drawn in SBGN.
PG  - 77-84
LID - 10.1093/bioinformatics/btv516 [doi]
AB  - MOTIVATION: Evolving technology has increased the focus on genomics. The 
      combination of today's advanced techniques with decades of molecular biology 
      research has yielded huge amounts of pathway data. A standard, named the Systems 
      Biology Graphical Notation (SBGN), was recently introduced to allow scientists to 
      represent biological pathways in an unambiguous, easy-to-understand and efficient 
      manner. Although there are a number of automated layout algorithms for various 
      types of biological networks, currently none specialize on process description 
      (PD) maps as defined by SBGN. RESULTS: We propose a new automated layout 
      algorithm for PD maps drawn in SBGN. Our algorithm is based on a force-directed 
      automated layout algorithm called Compound Spring Embedder (CoSE). On top of the 
      existing force scheme, additional heuristics employing new types of forces and 
      movement rules are defined to address SBGN-specific rules. Our algorithm is the 
      only automatic layout algorithm that properly addresses all SBGN rules for 
      drawing PD maps, including placement of substrates and products of process nodes 
      on opposite sides, compact tiling of members of molecular complexes and 
      extensively making use of nested structures (compound nodes) to properly draw 
      cellular locations and molecular complex structures. As demonstrated 
      experimentally, the algorithm results in significant improvements over use of a 
      generic layout algorithm such as CoSE in addressing SBGN rules on top of commonly 
      accepted graph drawing criteria. AVAILABILITY AND IMPLEMENTATION: An 
      implementation of our algorithm in Java is available within ChiLay library 
      (https://github.com/iVis-at-Bilkent/chilay). CONTACT: ugur@cs.bilkent.edu.tr or 
      dogrusoz@cbio.mskcc.org SUPPLEMENTARY INFORMATION: Supplementary data are 
      available at Bioinformatics online.
CI  - © The Author 2015. Published by Oxford University Press.
FAU - Genc, Begum
AU  - Genc B
AD  - The Insight Centre for Data Analytics, University College Cork, Western Road, 
      Cork, Ireland, Computer Engineering Department, Faculty of Engineering, Bilkent 
      University, Ankara 06800, Turkey and.
FAU - Dogrusoz, Ugur
AU  - Dogrusoz U
AD  - Computer Engineering Department, Faculty of Engineering, Bilkent University, 
      Ankara 06800, Turkey and Sander Lab, Memorial Sloan-Kettering Cancer Center, 417 
      E68th St., New York, NY 10065, USA.
LA  - eng
GR  - U41 HG006623/HG/NHGRI NIH HHS/United States
GR  - P41GM103504/GM/NIGMS NIH HHS/United States
GR  - P41 GM103504/GM/NIGMS NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - U41HG006623/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150910
PL  - England
TA  - Bioinformatics
JT  - Bioinformatics (Oxford, England)
JID - 9808944
RN  - 8059-24-3 (Vitamin B 6)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Algorithms
MH  - Aspirin/pharmacology
MH  - Automation
MH  - Heuristics
MH  - Signal Transduction/drug effects
MH  - Systems Biology/*methods
MH  - Vitamin B 6/pharmacology
PMC - PMC4681988
EDAT- 2015/09/13 06:00
MHDA- 2016/07/28 06:00
CRDT- 2015/09/13 06:00
PHST- 2015/06/08 00:00 [received]
PHST- 2015/08/25 00:00 [accepted]
PHST- 2015/09/13 06:00 [entrez]
PHST- 2015/09/13 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - btv516 [pii]
AID - 10.1093/bioinformatics/btv516 [doi]
PST - ppublish
SO  - Bioinformatics. 2016 Jan 1;32(1):77-84. doi: 10.1093/bioinformatics/btv516. Epub 
      2015 Sep 10.

PMID- 22666816
OWN - NLM
STAT- MEDLINE
DCOM- 20121220
LR  - 20190823
IS  - 1678-4464 (Electronic)
IS  - 0102-311X (Linking)
VI  - 28
IP  - 6
DP  - 2012 Jun
TI  - [Aspirin use in cardiovascular disease prevention: a population-based study].
PG  - 1122-32
LID - S0102-311X2012000600011 [pii]
AB  - The objective of this study was to estimate the prevalence of aspirin use in 
      primary and secondary prevention of cardiovascular disease. A population-based 
      cross-sectional study was conducted in Pelotas, Rio Grande do Sul State, Brazil, 
      from January to May 2010. The study had two outcomes: 1) aspirin use in primary 
      prevention (individuals > 40 years of age with at least two risk factors: 
      hypertension, diabetes mellitus, and/or hyperlipidemia) and 2) aspirin use in 
      secondary prevention (history of stroke and/or angina/myocardial infarction). The 
      outcomes were analyzed based on demographic, socioeconomic, and lifestyle 
      variables. Prevalence of aspirin use was 24.8% for primary prevention and 34.3% 
      for secondary prevention. In primary prevention, aspirin use was more common in 
      non-whites and older individuals and among those with worse self-rated health. 
      For secondary prevention, aspirin use was more frequent among older and 
      higher-income individuals and former smokers. Prevalence of aspirin use was well 
      below recommended levels for prevention of cardiovascular diseases.
FAU - Vianna, Carolina Avila
AU  - Vianna CA
AD  - Programa de Pós-graduação em Epidemiologia, Universidade Federal de Pelotas, 
      Pelotas, Brasil. caruvianna@hotmail.com
FAU - González, David Alejandro
AU  - González DA
FAU - Matijasevich, Alicia
AU  - Matijasevich A
LA  - por
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Utilização de ácido acetilsalicílico (AAS) na prevenção de doenças 
      cardiovasculares: um estudo de base populacional.
PL  - Brazil
TA  - Cad Saude Publica
JT  - Cadernos de saude publica
JID - 8901573
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Brazil
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Socioeconomic Factors
EDAT- 2012/06/06 06:00
MHDA- 2012/12/21 06:00
CRDT- 2012/06/06 06:00
PHST- 2011/01/18 00:00 [received]
PHST- 2012/03/19 00:00 [accepted]
PHST- 2012/06/06 06:00 [entrez]
PHST- 2012/06/06 06:00 [pubmed]
PHST- 2012/12/21 06:00 [medline]
AID - S0102-311X2012000600011 [pii]
AID - 10.1590/s0102-311x2012000600011 [doi]
PST - ppublish
SO  - Cad Saude Publica. 2012 Jun;28(6):1122-32. doi: 10.1590/s0102-311x2012000600011.

PMID- 11007051
OWN - NLM
STAT- MEDLINE
DCOM- 20001010
LR  - 20190910
IS  - 0902-4441 (Print)
IS  - 0902-4441 (Linking)
VI  - 65
IP  - 3
DP  - 2000 Sep
TI  - Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies.
PG  - 165-9
AB  - OBJECTIVE: To evaluate treatment and outcome of 17 pregnancies in nine patients 
      with essential thrombocythaemia (ET) seen at our institution from 1988 to 1998. 
      METHODS: Treatment and outcome of 17 pregnancies in nine ET patients were 
      retrospectively analyzed. RESULTS: Seventeen pregnancies in nine patients with ET 
      resulted in 11 (65%) live births and ended in six (35%) spontaneous abortions. 
      Abortion could not be predicted from ET-associated complications before (p= 0.23) 
      or during (p = 0.39) pregnancy. Maternal complications occurred during six 
      pregnancies (35%): Three major bleedings in two patients with an acquired von 
      Willebrand disease and two minor bleedings in patients treated with low-dose 
      acetylsalicylic acid (ASA) were observed during pregnancy or at term; one patient 
      suffered from transient visual loss while pausing low-dose ASA. Platelet counts 
      prior to pregnancy were significantly higher as compared to the platelet nadir 
      observed during pregnancy (p = 0.0017). Postpartum clinical course was uneventful 
      in all patients. No specific treatment was given during 11 pregnancies. Six women 
      received low-dose ASA during pregnancy followed by low-molecular-weight heparin 
      until the end of the sixth week postpartum in five cases. This treatment was 
      correlated with a favourable outcome (live birth versus abortion) when compared 
      to no treatment (p=0.04). CONCLUSION: Pregnancy in ET can be complicated by first 
      trimester abortion and/or maternal haemorrhage. Our limited observation suggest a 
      positive impact of low-dose ASA during pregnancy followed by low-molecular-weight 
      heparin postpartum on pregnancy outcome in ET; nevertheless, confirmation by 
      prospective documentation is mandatory.
FAU - Bangerter, M
AU  - Bangerter M
AD  - Department of Medicine III, Haematology, Oncology, Clinical Immunology and 
      Infectious Diseases, University of Ulm, Germany.
FAU - Güthner, C
AU  - Güthner C
FAU - Beneke, H
AU  - Beneke H
FAU - Hildebrand, A
AU  - Hildebrand A
FAU - Grünewald, M
AU  - Grünewald M
FAU - Griesshammer, M
AU  - Griesshammer M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Spontaneous
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Female
MH  - Hemorrhage/chemically induced/etiology
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Platelet Count
MH  - Postpartum Period
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - *Pregnancy Outcome
MH  - Retrospective Studies
MH  - Thrombocythemia, Essential/blood/complications/*drug therapy
MH  - Uterine Hemorrhage/complications
MH  - von Willebrand Diseases/complications
EDAT- 2000/09/28 11:00
MHDA- 2000/10/14 11:01
CRDT- 2000/09/28 11:00
PHST- 2000/09/28 11:00 [pubmed]
PHST- 2000/10/14 11:01 [medline]
PHST- 2000/09/28 11:00 [entrez]
AID - 10.1034/j.1600-0609.2000.90214.x [doi]
PST - ppublish
SO  - Eur J Haematol. 2000 Sep;65(3):165-9. doi: 10.1034/j.1600-0609.2000.90214.x.

PMID- 1036963
OWN - NLM
STAT- MEDLINE
DCOM- 19770224
LR  - 20151119
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 26
IP  - 8
DP  - 1976
TI  - Experimental evaluation in man of analgesic effects.
PG  - 1616-7
AB  - A device operated by compression has been studied in order to define a method of 
      measuring analgesic effects. Three analgesics (metamizol, acetylsalicylic acid 
      and ketobemidone) and placebo have been tested in man to verify the adequacy of 
      this apparatus and its sensitivity.
FAU - Montanari, C
AU  - Montanari C
FAU - Sala, P
AU  - Sala P
FAU - Ferrari, P
AU  - Ferrari P
FAU - Gaetani, M
AU  - Gaetani M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Analgesics)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analgesics/*pharmacology
MH  - Aspirin/pharmacology
MH  - Dipyrone/pharmacology
MH  - Drug Evaluation/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1976;26(8):1616-7.

PMID- 12916918
OWN - NLM
STAT- MEDLINE
DCOM- 20031002
LR  - 20191210
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 4
IP  - 1
DP  - 2003
TI  - Artificial neural networks in the modeling and optimization of aspirin extended 
      release tablets with Eudragit L 100 as matrix substance.
PG  - E9
AB  - The purpose of the present study was to model the effects of the concentration of 
      Eudragit L 100 and compression pressure as the most important process and 
      formulation variables on the in vitro release profile of aspirin from matrix 
      tablets formulated with Eudragit L 100 as matrix substance and to optimize the 
      formulation by artificial neural network. As model formulations, 10 kinds of 
      aspirin matrix tablets were prepared. The amount of Eudragit L 100 and the 
      compression pressure were selected as causal factors. In vitro dissolution time 
      profiles at 4 different sampling times were chosen as responses. A set of release 
      parameters and causal factors were used as tutorial data for the generalized 
      regression neural network (GRNN) and analyzed using a computer. Observed results 
      of drug release studies indicate that drug release rates vary widely between 
      investigated formulations, with a range of 5 hours to more than 10 hours to 
      complete dissolution. The GRNN model was optimized. The root mean square value 
      for the trained network was 1.12%, which indicated that the optimal GRNN model 
      was reached. Applying the generalized distance function method, the optimal 
      tablet formulation predicted by GRNN was with 5% of Eudragit L 100 and tablet 
      hardness 60N. Calculated difference (f1 2.465) and similarity (f2 85.61) factors 
      indicate that there is no difference between predicted and experimentally 
      observed drug release profiles for the optimal formulation. This work illustrates 
      the potential for an artificial neural network, GRNN, to assist in development of 
      extended release dosage forms.
FAU - Ibrić, Svetlana
AU  - Ibrić S
AD  - Institute of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, 
      University of Belgrade, Serbia and Montenegro. ibric@beotel.yu
FAU - Jovanović, Milica
AU  - Jovanović M
FAU - Djurić, Zorica
AU  - Djurić Z
FAU - Parojcić, Jelena
AU  - Parojcić J
FAU - Petrović, Slobodan D
AU  - Petrović SD
FAU - Solomun, Ljiljana
AU  - Solomun L
FAU - Stupar, Biljana
AU  - Stupar B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Polymethacrylic Acids)
RN  - 0 (Tablets)
RN  - 25086-15-1 (methylmethacrylate-methacrylic acid copolymer)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Delayed-Action Preparations
MH  - Drug Design
MH  - *Neural Networks, Computer
MH  - Polymethacrylic Acids/*chemistry
MH  - Tablets
PMC - PMC2750305
EDAT- 2003/08/15 05:00
MHDA- 2003/10/03 05:00
CRDT- 2003/08/15 05:00
PHST- 2003/08/15 05:00 [pubmed]
PHST- 2003/10/03 05:00 [medline]
PHST- 2003/08/15 05:00 [entrez]
AID - 41062 [pii]
AID - 10.1208/pt040109 [doi]
PST - ppublish
SO  - AAPS PharmSciTech. 2003;4(1):E9. doi: 10.1208/pt040109.

PMID- 12379997
OWN - NLM
STAT- MEDLINE
DCOM- 20030103
LR  - 20131121
IS  - 0870-399X (Print)
IS  - 0870-399X (Linking)
VI  - 15
IP  - 3
DP  - 2002 May-Jun
TI  - [Acetylsalicylic acid and diabetes mellitus].
PG  - 199-202
AB  - The physiopathologic mechanisms underlying cardiovascular disease in diabetic 
      patients are briefly reviewed. The use of inhibitors of platelet aggregation is 
      discussed as being potentially valuable in the pharmacological prevention of this 
      condition. Acetylsalisylic acid turns out to be the reference within the 
      repertoire of currently available drugs since it has been extensively tested in 
      clinical trials. We conclude by discussing the recommendations of the American 
      Diabetes Association (ADA) concerning the primary and secondary prevention of 
      cardiovascular disease in diabetes mellitus.
FAU - Paiva, Sandra
AU  - Paiva S
AD  - Serviço de Endocrinologia, Diabetes e Metabolismo, Hospitais da Universidade de 
      Coimbra, Coimbra.
LA  - por
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Acido acetilsalicílico e diabetes mellitus.
PL  - Portugal
TA  - Acta Med Port
JT  - Acta medica portuguesa
JID - 7906803
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*etiology/physiopathology/*prevention & control
MH  - *Diabetes Complications
MH  - Diabetes Mellitus/physiopathology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 16
EDAT- 2002/10/17 04:00
MHDA- 2003/01/07 04:00
CRDT- 2002/10/17 04:00
PHST- 2002/10/17 04:00 [pubmed]
PHST- 2003/01/07 04:00 [medline]
PHST- 2002/10/17 04:00 [entrez]
PST - ppublish
SO  - Acta Med Port. 2002 May-Jun;15(3):199-202.

PMID- 1600455
OWN - NLM
STAT- MEDLINE
DCOM- 19920713
LR  - 20190503
IS  - 0306-3674 (Print)
IS  - 1473-0480 (Electronic)
IS  - 0306-3674 (Linking)
VI  - 26
IP  - 1
DP  - 1992 Mar
TI  - First-aid supplies for backpacking.
PG  - 48-50
AB  - A portable first-aid kit should be carried in the backpack of campers, hikers, 
      and anyone who expects to spend time in a remote and unoccupied area. That is the 
      recommendation found in lay texts dealing with medical care, in backpacking 
      books, as well as in articles appearing in popular magazines. It goes without 
      saying that it is far better to practise safety and prevention than to have to 
      use first aid. However, many times medical problems occur which no amount of 
      safety and forethought could have prevented. Information in this paper indicates 
      that hikers are generally well prepared for the health-related problems they 
      encounter. Hikers carry diverse supplies to meet health problems but there are 
      some basic supplies with which hikers start their long-distance sojourn. Those 
      supplies and their usage rates are discussed, as are attitudes toward using the 
      supplies.
FAU - Puretz, S L
AU  - Puretz SL
AD  - State University of New York, New Paltz 12561.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Sports Med
JT  - British journal of sports medicine
JID - 0432520
RN  - 0 (Sunscreening Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Attitude to Health
MH  - Emergencies
MH  - First Aid/*instrumentation
MH  - Humans
MH  - *Sports
MH  - Sunscreening Agents
MH  - Walking
PMC - PMC1478986
EDAT- 1992/03/01 00:00
MHDA- 1992/03/01 00:01
CRDT- 1992/03/01 00:00
PHST- 1992/03/01 00:00 [pubmed]
PHST- 1992/03/01 00:01 [medline]
PHST- 1992/03/01 00:00 [entrez]
AID - 10.1136/bjsm.26.1.48 [doi]
PST - ppublish
SO  - Br J Sports Med. 1992 Mar;26(1):48-50. doi: 10.1136/bjsm.26.1.48.

PMID- 30257119
OWN - NLM
STAT- MEDLINE
DCOM- 20190425
LR  - 20190425
IS  - 1747-4094 (Electronic)
IS  - 1747-4094 (Linking)
VI  - 11
IP  - 11
DP  - 2018 Nov
TI  - The prevention of venous thromboembolism recurrence in the elderly: a still open 
      issue.
PG  - 903-909
LID - 10.1080/17474086.2018.1526667 [doi]
AB  - Venous thromboembolism (VTE) is frequent in the elderly, with an unclear 
      recurrence risk. After the initial and early maintenance anticoagulant treatment, 
      the decision about its extension versus recurrences is difficult because of the 
      high risk of bleeding in this population. Areas covered: This paper analyzes 
      recent literature on VTE recurrence and risk of bleeding associated with extended 
      anticoagulation in elderly patients with VTE, focusing on available data 
      regarding efficacy and safety of old anticoagulant or recent direct oral 
      anticoagulant (DOACs). Expert commentary: The following are clinically important 
      and still unmet needs in elderly patients with VTE: the current real risks for 
      recurrence or for bleeding are still uncertain; the available clinical predictive 
      rules for recurrence are of less use; in general, the phase III trials on DOACs 
      proved less satisfactory in the elderly than in the general population; low dose 
      DOACs use for extended treatment seems promising and data on long periods of 
      therapy are needed; low dose aspirin does not seem an appropriate therapeutic 
      alternative to anticoagulants due to the high rate of bleeding in the elderly; 
      antithrombotic drugs, with low risk of bleeding should be assessed as alternative 
      therapeutic options for extended treatment in the elderly.
FAU - Palareti, Gualtiero
AU  - Palareti G
AD  - a Cardiovascular Medicine , University of Bologna , Bologna , Italy.
FAU - Poli, Daniela
AU  - Poli D
AD  - b Thrombosis Centre , Azienda Ospedaliero-Universitaria Careggi , Florence , 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180926
PL  - England
TA  - Expert Rev Hematol
JT  - Expert review of hematology
JID - 101485942
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Incidence
MH  - Prognosis
MH  - Recurrence
MH  - Risk Assessment
MH  - Treatment Outcome
MH  - Venous Thromboembolism/diagnosis/epidemiology/etiology/*prevention & control
MH  - Warfarin/administration & dosage/adverse effects/therapeutic use
OTO - NOTNLM
OT  - DOACs
OT  - Venous thromboembolism
OT  - anticoagulation
OT  - aspirin
OT  - bleeding complications
OT  - elderly
OT  - recurrent events
OT  - scores
OT  - vitamin K antagonists
EDAT- 2018/09/27 06:00
MHDA- 2019/04/26 06:00
CRDT- 2018/09/27 06:00
PHST- 2018/09/27 06:00 [pubmed]
PHST- 2019/04/26 06:00 [medline]
PHST- 2018/09/27 06:00 [entrez]
AID - 10.1080/17474086.2018.1526667 [doi]
PST - ppublish
SO  - Expert Rev Hematol. 2018 Nov;11(11):903-909. doi: 10.1080/17474086.2018.1526667. 
      Epub 2018 Sep 26.

PMID- 31976029
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20200625
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2019
DP  - 2019
TI  - Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in 
      Rats: Platelet Aggregation and Blood Clot.
PG  - 9084643
LID - 10.1155/2019/9084643 [doi]
LID - 9084643
AB  - We suggest that the stable gastric pentadecapeptide BPC 157 may rescue 
      thrombocyte function. We focused on the antithrombotic agent aspirin, 
      clopidogrel, and cilostazol application in rats; arachidonic acid, ADP, collagen, 
      and arachidonic acid/PGE1 platelet aggregation (aggregometry) and blood clot 
      viscoelastic properties (thromboelastometry); and the pentadecapeptide BPC 157. 
      Rats received intragastrically for three days once daily treatment with 
      antithrombotic agents-aspirin (10 mg/kg) or clopidogrel (10 mg/kg) or cilostazol 
      (10 mg/kg). Medication (BPC 157 (10 μg/kg) or an equal volume of saline 
      (5 ml/kg)) was given intragastrically, immediately after each antithrombotic 
      agent application. For multiple electrode aggregometry and modified rotational 
      thromboelastometry studies, blood sampling was at 2 h after last application. 
      Adenosine diphosphate (ADP test 6.5 μM), arachidonic acid (ASPI test 0.5 mM), a 
      combination of arachidonic acid and prostaglandin E1 (ASPI test 0.5 mM and 
      PGE1-test 30 nM), and collagen (COL test 3.2 μg/ml) were used as aggregation 
      agonists. Given with aspirin, clopidogrel, or cilostazol in rats, BPC 157 
      counteracted their inhibitory effects on aggregation activated by arachidonic 
      acid, ADP, collagen, and arachidonic acid/PGE1. Specifically, this includes 
      recovery of the aggregation induced by arachidonic acid (vs. aspirin, vs. 
      clopidogrel, and vs. cilostazol), arachidonic acid/PGE1 (vs. cilostazol), ADP 
      (vs. clopidogrel), or collagen (vs. clopidogrel). Contrarily, there is no effect 
      on the used tests (extrinsic/intrinsic hemostasis system, the fibrin part of the 
      clot) EXTEM, INTEM, and FIBTEM; clotting time; clot formation time; alpha-angle; 
      maximum clot firmness; lysis index after 30 minutes; and maximum lysis. In 
      conclusion, we revealed that BPC 157 largely rescues thrombocyte function.
CI  - Copyright © 2019 Sanja Konosic et al.
FAU - Konosic, Sanja
AU  - Konosic S
AD  - University Hospital Centre Zagreb, Zagreb, Croatia.
FAU - Petricevic, Mate
AU  - Petricevic M
AD  - University Hospital Centre Zagreb, Zagreb, Croatia.
FAU - Ivancan, Visnja
AU  - Ivancan V
AD  - University Hospital Centre Zagreb, Zagreb, Croatia.
FAU - Konosic, Lucija
AU  - Konosic L
AD  - University Hospital Centre Zagreb, Zagreb, Croatia.
FAU - Goluza, Eleonora
AU  - Goluza E
AD  - University Hospital Centre Zagreb, Zagreb, Croatia.
FAU - Krtalic, Branimir
AU  - Krtalic B
AD  - University Hospital Centre Zagreb, Zagreb, Croatia.
FAU - Drmic, Domagoj
AU  - Drmic D
AD  - Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, 
      Croatia.
FAU - Stupnisek, Mirjana
AU  - Stupnisek M
AD  - Department of Pharmacology, Faculty of Medicine, J.J. Strossmayer University of 
      Osijek, Osijek, Croatia.
FAU - Seiwerth, Sven
AU  - Seiwerth S
AD  - Department of Pathology, School of Medicine, University of Zagreb, Zagreb, 
      Croatia.
FAU - Sikiric, Predrag
AU  - Sikiric P
AUID- ORCID: 0000-0002-7952-2252
AD  - Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, 
      Croatia.
LA  - eng
PT  - Journal Article
DEP - 20191230
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Peptide Fragments)
RN  - 0 (Proteins)
RN  - 8ED8NXK95P (BPC 157)
RN  - A74586SNO7 (Clopidogrel)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology/therapeutic use
MH  - Cilostazol/*administration & dosage/pharmacology/therapeutic use
MH  - Clopidogrel/*administration & dosage/pharmacology/therapeutic use
MH  - Drug Administration Routes
MH  - Fibrinolytic Agents/pharmacology/therapeutic use
MH  - Male
MH  - Peptide Fragments/*administration & dosage/pharmacology/therapeutic use
MH  - Platelet Aggregation/*drug effects
MH  - Proteins/*administration & dosage/pharmacology/therapeutic use
MH  - Rats, Wistar
MH  - Stomach/*drug effects
MH  - Thrombelastography
MH  - Thrombosis/*drug therapy
PMC - PMC6955135
COIS- All authors declare that they have no conflict of interest.
EDAT- 2020/01/25 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/01/25 06:00
PHST- 2019/06/13 00:00 [received]
PHST- 2019/09/24 00:00 [revised]
PHST- 2019/12/11 00:00 [accepted]
PHST- 2020/01/25 06:00 [entrez]
PHST- 2020/01/25 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
AID - 10.1155/2019/9084643 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2019 Dec 30;2019:9084643. doi: 10.1155/2019/9084643. 
      eCollection 2019.

PMID- 22070887
OWN - NLM
STAT- MEDLINE
DCOM- 20120403
LR  - 20131121
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 78
IP  - 1
DP  - 2012 Jan
TI  - Aspirin may do wonders by the induction of immunological self-tolerance against 
      autoimmune atherosclerosis.
PG  - 171-3
LID - 10.1016/j.mehy.2011.10.019 [doi]
AB  - Induction of immune tolerance is one of the recent novel immunomodulatory 
      strategies to directly intervene the autoimmune-driven atherosclerosis. Aspirin 
      is a prototypic non-steroidal anti-inflammatory drug, which is now being regarded 
      as a life-saver in variety of atherosclerotic cardiovascular complications. 
      Considerable amount of data emerged during last few years clearly suggests that 
      aspirin can cause immunomodulation by several mechanisms, particularly, its 
      ability to induce tolerogenic dendritic cells (DCs) and to upregulate T 
      regulatory (Treg) cells is especially appealing with respect to induction of 
      immunological self-tolerance. Based on this fact, we hypothesize that aspirin, in 
      addition to its anti-inflammatory effect, may also specifically inhibit 
      autoimmune response in atherosclerosis by actively increasing CD4+CD25+FOXP3+Treg 
      cells as well as by inducing tolerogenic DCs which induce hyporesponsiveness in 
      responder naïve T cells. If proved to be correct, this hypothesis will provide an 
      opportunity to medical community with an already available aspirin-based 
      immunotherapeutic approach for inducing immune tolerance against atherosclerosis.
CI  - Copyright © 2011 Elsevier Ltd. All rights reserved.
FAU - Hussain, Muzammal
AU  - Hussain M
AD  - Department of Pharmacology & Toxicology, University of Veterinary and Animal 
      Sciences, Lahore, Pakistan.
FAU - Javeed, Aqeel
AU  - Javeed A
FAU - Ashraf, Muhammad
AU  - Ashraf M
FAU - Riaz, Amjad
AU  - Riaz A
FAU - Mushtaq, Muhammad Hassan
AU  - Mushtaq MH
LA  - eng
PT  - Journal Article
DEP - 20111108
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Atherosclerosis/*drug therapy/immunology
MH  - Autoimmune Diseases/*drug therapy
MH  - Dendritic Cells/immunology
MH  - Humans
MH  - Lymphocyte Activation/*drug effects
MH  - Self Tolerance/*drug effects
MH  - T-Lymphocytes, Regulatory/drug effects/immunology
EDAT- 2011/11/11 06:00
MHDA- 2012/04/04 06:00
CRDT- 2011/11/11 06:00
PHST- 2011/03/13 00:00 [received]
PHST- 2011/10/14 00:00 [accepted]
PHST- 2011/11/11 06:00 [entrez]
PHST- 2011/11/11 06:00 [pubmed]
PHST- 2012/04/04 06:00 [medline]
AID - S0306-9877(11)00533-0 [pii]
AID - 10.1016/j.mehy.2011.10.019 [doi]
PST - ppublish
SO  - Med Hypotheses. 2012 Jan;78(1):171-3. doi: 10.1016/j.mehy.2011.10.019. Epub 2011 
      Nov 8.

PMID- 14680440
OWN - NLM
STAT- MEDLINE
DCOM- 20040407
LR  - 20190917
IS  - 1465-6566 (Print)
IS  - 1465-6566 (Linking)
VI  - 5
IP  - 1
DP  - 2004 Jan
TI  - The role of aspirin in cardiovascular diseases--forgotten benefits?
PG  - 109-15
AB  - The increasing burden of cardiovascular diseases in developed, as well as 
      developing countries, underscores the need for the more widespread and 
      appropriate use of aspirin in secondary prevention of occlusive vascular events 
      during acute evolving myocardial infarction (MI) and in primary prevention. 
      Aspirin should be far more widely used in a wide range of patients who have 
      suffered a prior occlusive vascular event and in all patients suffering acute MI 
      or occlusive stroke. Finally, in primary prevention, aspirin should be considered 
      for individuals whose 10-year risks of a coronary event are > or = 10%, as an 
      adjunct not alternative to the management of other risk factors. The more 
      widespread and appropriate use of aspirin will avoid many premature deaths in 
      secondary prevention and MIs in primary prevention.
FAU - Williams, Adam
AU  - Williams A
AD  - University of Miami School of Medicine, Miami, FL, USA.
FAU - Hennekens, Charles H
AU  - Hennekens CH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/epidemiology/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/prevention & control
RF  - 43
EDAT- 2003/12/19 05:00
MHDA- 2004/04/08 05:00
CRDT- 2003/12/19 05:00
PHST- 2003/12/19 05:00 [pubmed]
PHST- 2004/04/08 05:00 [medline]
PHST- 2003/12/19 05:00 [entrez]
AID - 10.1517/14656566.5.1.109 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2004 Jan;5(1):109-15. doi: 10.1517/14656566.5.1.109.

PMID- 6361793
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20180214
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 27 Suppl 1
DP  - 1983
TI  - Multiple-dose comparison of suprofen, aspirin, and placebo in the treatment of 
      musculoskeletal pain.
PG  - 65-73
AB  - The effectiveness and safety of suprofen 200 mg, aspirin 650 mg, and placebo in 
      the treatment of moderate to severe pain were compared in a 72-hour 
      multiple-dose, double-blind, parallel, randomized study in 75 adults suffering 
      from musculoskeletal pain. Suprofen was superior to aspirin and placebo for pain 
      relief, total pain relief scores, pain severity, activity impairment, comparative 
      evaluation of activity impairment, and comparative evaluation of pain and sleep, 
      with differences achieving statistical significance for most parameters at the 
      24- to 72-hour evaluation points. 1 mild, transient side effect occurred in the 
      suprofen group, 3 in the placebo group, and 4 of moderate intensity in the 
      aspirin group. The effectiveness of multiple-dose treatment of musculoskeletal 
      pain with suprofen 200 mg is superior to that of aspirin and placebo.
FAU - Silberman, H M
AU  - Silberman HM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Phenylpropionates)
RN  - 0 (Placebos)
RN  - 988GU2F9PE (Suprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Bone Diseases/*drug therapy/physiopathology
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscular Diseases/*drug therapy/physiopathology
MH  - Pain/*drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - Placebos
MH  - Suprofen/adverse effects/*therapeutic use
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1159/000137901 [doi]
PST - ppublish
SO  - Pharmacology. 1983;27 Suppl 1:65-73. doi: 10.1159/000137901.

PMID- 11094489
OWN - NLM
STAT- MEDLINE
DCOM- 20010628
LR  - 20181130
IS  - 1364-8535 (Print)
IS  - 1466-609X (Electronic)
IS  - 1364-8535 (Linking)
VI  - 3
IP  - 5
DP  - 1999
TI  - Blood substitutes. Haemoglobin therapeutics in clinical practice.
PG  - R99-102
AB  - Early approaches to the development of oxygen carriers involved the use of 
      stroma-free hemoglobin solutions. These solutions did not require blood typing or 
      crossmatching and could be stored for long periods. In addition, a variety of 
      methods have been developed in chemically modifying and stabilizing the 
      hemoglobin molecule. Several hemoglobin therapeutics are now in clinical trials 
      as temporary alternatives to blood or as therapeutic agents for ischemia. The 
      various hemoglobin products under development are derived from three principal 
      sources: human, bovine and genetically engineered hemoglobin. Diaspirin 
      cross-linked hemoglobin (DCLHb), administered at doses ranging from approximately 
      20-1000 ml, has been investigated in a number of clinical trials in patients 
      undergoing orthopedic, abdominal aortic repair, major abdominal surgery, cardiac 
      surgery and in critically ill patients with septic shock. In several studies, 
      DCLHb was effective in avoiding the transfusion. However, Baxter Healthcare 
      Corporation (Chicago, Illinois, USA) stopped the development of DCLHb after two 
      unsuccessful trials in trauma patients. Bovine polymerized hemoglobin has also 
      been extensively studied. Several phase II and phase III trials have been 
      performed with this product in hemorrhagic surgery, cardiac surgery and vascular 
      surgery, but data have not yet been published. Hemoglobin therapeutics could 
      provide an important new option as an alternative to blood transfusion. 
      Furthermore, they may be able to provide an immediate on-site replacement for 
      traumatic blood loss, prevent global ischemia and organ failure, treat focal 
      ischemia, and provide effective hemodynamic support for septic shock-induced 
      hypotension.
FAU - Baron, J F
AU  - Baron JF
AD  - Hôpital Broussais, Paris, France. jfBaron.broussais@invivo.edu
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 19990928
PL  - England
TA  - Crit Care
JT  - Critical care (London, England)
JID - 9801902
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Crit Care. 1999;3(5):R91-2. PMID: 11094487
MH  - Animals
MH  - Aspirin/analogs & derivatives
MH  - *Blood Substitutes
MH  - Cattle
MH  - Critical Care
MH  - *Hemoglobins
MH  - Humans
MH  - Surgical Procedures, Operative
PMC - PMC137240
EDAT- 2000/11/30 11:00
MHDA- 2001/06/29 10:01
CRDT- 2000/11/30 11:00
PHST- 1999/08/16 00:00 [received]
PHST- 1999/09/06 00:00 [accepted]
PHST- 2000/11/30 11:00 [pubmed]
PHST- 2001/06/29 10:01 [medline]
PHST- 2000/11/30 11:00 [entrez]
AID - cc365 [pii]
AID - 10.1186/cc365 [doi]
PST - ppublish
SO  - Crit Care. 1999;3(5):R99-102. doi: 10.1186/cc365. Epub 1999 Sep 28.

PMID- 1518858
OWN - NLM
STAT- MEDLINE
DCOM- 19921007
LR  - 20190501
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 89
IP  - 17
DP  - 1992 Sep 1
TI  - Mechanism of C8 alkylation of guanine residues by activated arylamines: evidence 
      for initial adduct formation at the N7 position.
PG  - 8278-82
AB  - Aromatic amines are bioactivated to electrophilic compounds that react with DNA, 
      predominantly at the C8 position of guanine bases. This site is weakly 
      nucleophilic and it has been proposed that the C8 adduct is the final product 
      after initial N7-adduct formation. To consider this possibility, we reacted 
      several C8-substituted guanine derivatives with N-acetoxy-2-aminofluorene, 
      prepared in situ from 2-acetylsalicylic acid and N-hydroxy-2-aminofluorene. With 
      C8,N9-dimethylguanine, an adduct was isolated in good yield that was consistent, 
      by NMR and mass spectral characterization, with a structure involving carcinogen 
      substitution at the N7 position of guanine and linked through the 
      2-aminofluorenyl nitrogen--N-(C8,N9- dimethylguanin-N7-yl)-2-aminofluorene. This 
      adduct could be easily reduced with NaBH4, consistent with the proposed N7-adduct 
      structure. The same reaction was also carried out with C8-methylguanosine and 
      C8-methyldeoxyguanosine and similar adducts were isolated. In contrast, 
      C8-bromoguanosine reacted with N-acetoxy-2-aminofluorene to yield the 
      C8-substituted arylamine adduct N-(guanosin-C8-yl)-2-aminofluorene directly. 
      These products are uniquely consistent with a scheme in which C8-adduct formation 
      is preceded by an initial electrophilic substitution on the N7 atom, which is 
      postulated to be a general reaction for activated arylamines and heterocyclic 
      amines.
FAU - Humphreys, W G
AU  - Humphreys WG
AD  - Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, 
      TN 37232.
FAU - Kadlubar, F F
AU  - Kadlubar FF
FAU - Guengerich, F P
AU  - Guengerich FP
LA  - eng
GR  - CA44353/CA/NCI NIH HHS/United States
GR  - ES00267/ES/NIEHS NIH HHS/United States
GR  - ES05473/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Fluorenes)
RN  - 5Z93L87A1R (Guanine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Alkylation
MH  - Aspirin/chemistry
MH  - Chromatography, High Pressure Liquid
MH  - Fluorenes/*chemistry
MH  - Guanine/*chemistry
MH  - Magnetic Resonance Spectroscopy
MH  - Mass Spectrometry
PMC - PMC49901
EDAT- 1992/09/01 00:00
MHDA- 1992/09/01 00:01
CRDT- 1992/09/01 00:00
PHST- 1992/09/01 00:00 [pubmed]
PHST- 1992/09/01 00:01 [medline]
PHST- 1992/09/01 00:00 [entrez]
AID - 10.1073/pnas.89.17.8278 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8278-82. doi: 
      10.1073/pnas.89.17.8278.

PMID- 10220501
OWN - NLM
STAT- MEDLINE
DCOM- 19990607
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 116
IP  - 5
DP  - 1999 May
TI  - Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition 
      of ICE-like cysteine proteases in rats.
PG  - 1089-106
AB  - BACKGROUND & AIMS: Caspases, a class of cysteine proteases, modulate apoptosis. 
      Nitric oxide (NO)-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) are a 
      new class of NSAID derivatives with reduced gastrointestinal toxicity. The aim of 
      this study was to investigate whether cysteine endoproteases are involved in the 
      pathogenesis of NSAID gastropathy and are target for NO-aspirin (NCX-4016). 
      METHODS: Rats were treated orally with aspirin or equimolar doses of NCX-4016. 
      Caspase activities were measured by fluorometric assay. Apoptosis was quantified 
      by an enzyme-linked immunosorbent assay for histone-associated DNA, DNA ladder on 
      agarose gel, and terminal deoxynucleotidyl transferase-mediated deoxyuridine 
      triphosphate nick-end labeling assay. A primary culture of gastric chief cells 
      was used to investigate whether NCX-4016 modulates guanosine 3',5'-cyclic 
      monophosphate (cGMP)-dependent pathways. RESULTS: Short- and long-term (7 days) 
      aspirin administration resulted in a time- and dose-dependent gastric injury that 
      was associated with apoptosis and caspase up-regulation. Z-VAD.FMK, a pancaspase 
      inhibitor, and NO donors protected from acute damage induced by aspirin. NCX-4016 
      spared the gastric mucosa and caused caspase inactivation by S-nitrosylation. 
      Inhibition of tumor necrosis factor (TNF)-alpha release or activity by TAPI-2 or 
      anti-TNF-alpha receptor monoclonal antibodies protected against mucosal damage 
      and caspase activation. NCX-4016 protected gastric chief cells from toxicity 
      induced by TNF-alpha by activating cGMP-dependent pathways. CONCLUSIONS: Aspirin 
      administration leads to a TNF-alpha-dependent activation of gastric caspases. 
      NO-aspirin spares the gastric mucosa and inhibits caspase activity through 
      cGMP-dependent and -independent pathways.
FAU - Fiorucci, S
AU  - Fiorucci S
AD  - Sezione di Gastroenterologia ed Epatologia, Dipartimento di Medicina Clinica e 
      Sperimentale, Università degli Studi di Perugia, Perugia, Italy. Gastro1@unipg.it
FAU - Antonelli, E
AU  - Antonelli E
FAU - Santucci, L
AU  - Santucci L
FAU - Morelli, O
AU  - Morelli O
FAU - Miglietti, M
AU  - Miglietti M
FAU - Federici, B
AU  - Federici B
FAU - Mannucci, R
AU  - Mannucci R
FAU - Del Soldato, P
AU  - Del Soldato P
FAU - Morelli, A
AU  - Morelli A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Caspase Inhibitors)
RN  - 0 (Cysteine Proteinase Inhibitors)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Salicylates)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 169D1260KM (Nitroprusside)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 3.4.22.- (Caspases)
RN  - EH04H13L6B (nitroaspirin)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*pharmacology
MH  - Apoptosis
MH  - Aspirin/administration & dosage/adverse effects/*analogs & 
      derivatives/metabolism/pharmacology
MH  - Caspase Inhibitors
MH  - Caspases/*metabolism
MH  - Cyclic GMP/metabolism
MH  - Cysteine Proteinase Inhibitors/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/cytology/drug effects/enzymology/injuries
MH  - Humans
MH  - In Situ Nick-End Labeling
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Donors/pharmacology
MH  - Nitroprusside/pharmacology
MH  - Rats
MH  - Salicylates/blood
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/metabolism/pharmacology
MH  - U937 Cells
EDAT- 1999/04/30 00:00
MHDA- 1999/04/30 00:01
CRDT- 1999/04/30 00:00
PHST- 1999/04/30 00:00 [pubmed]
PHST- 1999/04/30 00:01 [medline]
PHST- 1999/04/30 00:00 [entrez]
AID - S0016508599004400 [pii]
AID - 10.1016/s0016-5085(99)70012-0 [doi]
PST - ppublish
SO  - Gastroenterology. 1999 May;116(5):1089-106. doi: 10.1016/s0016-5085(99)70012-0.

PMID- 2108852
OWN - NLM
STAT- MEDLINE
DCOM- 19900518
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 97
IP  - 4 Suppl
DP  - 1990 Apr
TI  - Role of aspirin with thrombolytic therapy in acute myocardial infarction.
PG  - 151S-155S
AB  - Thrombolytic therapy has been shown to limit infarct size, improve ventricular 
      function, and decrease mortality in suspected evolving myocardial infarction 
      (MI). Aspirin therapy also decreases mortality as well as stroke and reinfarction 
      in suspected evolving MI. The combined ability of both agents to lyse as well as 
      to prevent clots yields a greater benefit than either alone. The use of aspirin 
      with thrombolysis also protects against the increase in reinfarction observed 
      when thrombolytic therapy is given alone. While ongoing research is evaluating 
      the optimal thrombolytic agent as well as the possible role of heparin, it is 
      already clear that the use of aspirin with thrombolytic therapy will 
      significantly decrease reinfarction, stroke, and vascular mortality in suspected 
      evolving MI.
FAU - Hennekens, C H
AU  - Hennekens CH
AD  - Department of Medicine, Harvard Medical School, Boston.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Streptokinase)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Myocardial Infarction/*drug therapy/mortality
MH  - Randomized Controlled Trials as Topic
MH  - Streptokinase/therapeutic use
MH  - *Thrombolytic Therapy/adverse effects
MH  - Tissue Plasminogen Activator/therapeutic use
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
AID - S0012-3692(15)41154-7 [pii]
AID - 10.1378/chest.97.4_supplement.151s [doi]
PST - ppublish
SO  - Chest. 1990 Apr;97(4 Suppl):151S-155S. doi: 10.1378/chest.97.4_supplement.151s.

PMID- 456211
OWN - NLM
STAT- MEDLINE
DCOM- 19790925
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 24
IP  - 3
DP  - 1979 Mar
TI  - Nonsteroidal antiinflammatory drugs: effect on pyloric sphincter and 
      duodenogastric reflux.
PG  - 217-20
AB  - We have investigated the effect of nonsteroidal antiinflammatory drugs on canine 
      pyloric sphincter pressure, mucosal potential difference (PD), and duodenogastric 
      reflux in 5 dogs. Only intragastric aspirin at doses of 30 and 100 mg/kg caused a 
      significant (P less than 0.05) decrease in pyloric sphincter pressure, an 
      increase of duodenogastric reflux, and changed the mucosal PD. Neither 
      intravenous aspirin, intragastric phenylbutazone, or intrarectal indomethacin 
      produced these changes. The mechanism for the aspirin effect may be mediated by 
      local pathways related to changes in mucosal PD. We postulate that increased 
      duodenogastric reflux may be an aggravating factor for the gastric mucosal damage 
      caused by intragastric aspirin.
FAU - Pantoja, J L
AU  - Pantoja JL
FAU - Defilippi, C
AU  - Defilippi C
FAU - Valenzuela, J E
AU  - Valenzuela JE
FAU - Csendes, A
AU  - Csendes A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Anti-Inflammatory Agents)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Dogs
MH  - Duodenum/*drug effects/physiology
MH  - Electrophysiology
MH  - Gastric Mucosa/drug effects/physiology
MH  - Indomethacin/administration & dosage/pharmacology
MH  - Phenylbutazone/administration & dosage/pharmacology
MH  - Pressure
MH  - Pylorus/*drug effects/physiology
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
AID - 10.1007/BF01308433 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1979 Mar;24(3):217-20. doi: 10.1007/BF01308433.

PMID- 30690958
OWN - NLM
STAT- MEDLINE
DCOM- 20190828
LR  - 20190828
IS  - 2233-6869 (Electronic)
IS  - 1598-9992 (Linking)
VI  - 73
IP  - 1
DP  - 2019 Jan 25
TI  - [Acute Suppurative Appendicitis Diagnosed by Acute Lower Gastrointestinal 
      Hemorrhage].
PG  - 45-49
LID - 10.4166/kjg.2019.73.1.45 [doi]
AB  - A 49-year-old man visited the emergency room of Korea University Ansan Hospital 
      with hematochezia starting the day before the visit. Recently, he was on 
      anti-platelet medication due to hypertension. The patient had no definite 
      symptoms other than hematochezia. Digital rectal exam was positive and laboratory 
      tests showed severe anemia. Sigmoidoscopy was initiated and almost no fecal 
      material was observed in the intestinal tract, allowing insertion into the cecum. 
      Active bleeding from the appendiceal opening was noted. On abdominal CT, contrast 
      enhancement was observed at the tip of the appendix. Under suspicion of acute 
      appendicitis, we consulted with a surgeon. The patient underwent appendectomy 
      with partial cecal resection. Pathologic examination revealed a diagnosis of 
      appendix bleeding due to acute suppurative appendicitis. The patient had no 
      further bleeding after surgery and was discharged in a stable state. Careful 
      observation by the endoscopist is necessary for accurate diagnosis of lower 
      gastrointestinal hemorrhage. Appendiceal hemorrhage is very rarely reported, but 
      it has various pathophysiologies. CT scan is useful when appendiceal hemorrhage 
      is confirmed by endoscopic findings. Surgical treatment was needed in almost all 
      cases reported worldwide. If bleeding from the appendix is confirmed, surgical 
      treatment should be considered for both therapeutic and diagnostic purposes.
FAU - Kim, Dae-Ha
AU  - Kim DH
AD  - Division of Gastroenterology, Department of Internal Medicine, Korea University 
      Ansan Hospital, Ansan, Korea.
FAU - Lee, Ju Han
AU  - Lee JH
AD  - Department of Pathology, Korea University Ansan Hospital, Ansan, Korea.
FAU - Kim, Dongwoo
AU  - Kim D
AD  - Division of Gastroenterology, Department of Internal Medicine, Korea University 
      Ansan Hospital, Ansan, Korea.
FAU - Hwang, Suhyun
AU  - Hwang S
AD  - Division of Gastroenterology, Department of Internal Medicine, Korea University 
      Ansan Hospital, Ansan, Korea.
FAU - Kang, Kyuho
AU  - Kang K
AD  - Division of Gastroenterology, Department of Internal Medicine, Korea University 
      Ansan Hospital, Ansan, Korea.
FAU - Koo, Ja Seol
AU  - Koo JS
AD  - Division of Gastroenterology, Department of Internal Medicine, Korea University 
      Ansan Hospital, Ansan, Korea.
LA  - kor
PT  - Case Reports
PL  - Korea (South)
TA  - Korean J Gastroenterol
JT  - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JID - 101189416
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Appendectomy
MH  - Appendicitis/*diagnosis/etiology/surgery
MH  - Aspirin/administration & dosage/adverse effects
MH  - Colonoscopy
MH  - Gastrointestinal Hemorrhage/complications/*diagnosis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tomography, X-Ray Computed
OTO - NOTNLM
OT  - Appendectomya
OT  - Appendicitis
OT  - Appendix
OT  - Colonoscopy
OT  - Gastrointestinal hemorrhage
EDAT- 2019/01/29 06:00
MHDA- 2019/08/29 06:00
CRDT- 2019/01/29 06:00
PHST- 2018/03/01 00:00 [received]
PHST- 2015/06/21 00:00 [revised]
PHST- 2018/06/24 00:00 [accepted]
PHST- 2019/01/29 06:00 [entrez]
PHST- 2019/01/29 06:00 [pubmed]
PHST- 2019/08/29 06:00 [medline]
AID - kjg.2019.73.1.45 [pii]
AID - 10.4166/kjg.2019.73.1.45 [doi]
PST - ppublish
SO  - Korean J Gastroenterol. 2019 Jan 25;73(1):45-49. doi: 10.4166/kjg.2019.73.1.45.

PMID- 36595058
OWN - NLM
STAT- MEDLINE
DCOM- 20230501
LR  - 20230508
IS  - 0942-0940 (Electronic)
IS  - 0001-6268 (Linking)
VI  - 165
IP  - 5
DP  - 2023 May
TI  - Artificial cerebrospinal fluid restores aspirin-inhibited physiological 
      hemostasis through recovery of platelet aggregation function.
PG  - 1269-1276
LID - 10.1007/s00701-022-05471-9 [doi]
AB  - BACKGROUND: Optimal hemostasis provides safety and reliability during 
      neurosurgery which improves surgical outcomes. Previously, artificial 
      cerebrospinal fluid (aCSF) and its component sodium bicarbonate were found to 
      facilitate physiological hemostasis by amplifying platelet aggregation. This 
      study aimed to verify whether aCSF amplifies platelet-dependent hemostasis in the 
      presence of antiplatelet agents. METHODS: We prepared platelet-rich plasma (PRP) 
      or washed platelets using aspirin (acetylsalicylic acid, (ASA)) or normal saline 
      (NS). We evaluated samples treated with a commercially available aCSF solution or 
      NS for amplification of aggregation, activation of integrin αIIbβ3, 
      phosphatidylserine (PS) exposure, P-selectin (CD62P) expression, and formation of 
      microparticles (MPs). We assessed the effect of aCSF on in vivo hemostasis in the 
      presence of ASA by measuring the tail bleeding time in ASA-or NS-injected 
      C57BL/6 N mice. RESULTS: Compared with NS, aCSF amplified ASA-inhibited platelet 
      aggregation by recovering platelet activation including PS exposure, MP release, 
      CD62P expression, and integrin αIIbβ3 activation. When using washed platelets, 
      aCSF almost completely counteracted the inhibition of platelet aggregation by 
      ASA. Prolonged bleeding time from the amputated tail of ASA-injected mice was 
      significantly shortened by the treatment with aCSF compared to NS. Sodium 
      bicarbonate also directly amplified ASA-inhibited platelet aggregation. 
      CONCLUSIONS: aCSF and sodium bicarbonate facilitate physiological hemostasis 
      through the recovery of inhibited platelet aggregation even in the presence of 
      ASA. The utilization of aCSF in the operative field may be advantageous for 
      facilitating hemostasis in patients with impaired platelet function and 
      contribute to improving outcomes of neurosurgery.
CI  - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, 
      part of Springer Nature.
FAU - Suzuki, Ryosuke
AU  - Suzuki R
AD  - Department of Neurosurgery, Yokohama City University Graduate School of Medicine, 
      Yokohama, Kanagawa, Japan.
FAU - Kozuma, Yukinori
AU  - Kozuma Y
AD  - Department of Medical Technology, Faculty of Health Science, Kumamoto Health 
      Science University, Kumamoto, Kumamoto, Japan.
AD  - Division of Medical Sciences, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Ibaraki, Japan.
FAU - Inoue, Chisako
AU  - Inoue C
AD  - Division of Medical Sciences, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Ibaraki, Japan.
FAU - Tanabe, Kano
AU  - Tanabe K
AD  - Department of Medical Technology, Faculty of Health Science, Kumamoto Health 
      Science University, Kumamoto, Kumamoto, Japan.
FAU - Noboruo, Ippei
AU  - Noboruo I
AD  - Department of Medical Technology, Faculty of Health Science, Kumamoto Health 
      Science University, Kumamoto, Kumamoto, Japan.
FAU - Arao, Hohomi
AU  - Arao H
AD  - Department of Medical Technology, Faculty of Health Science, Kumamoto Health 
      Science University, Kumamoto, Kumamoto, Japan.
FAU - Kawaguchi, Tatsuya
AU  - Kawaguchi T
AD  - Department of Medical Technology, Faculty of Health Science, Kumamoto Health 
      Science University, Kumamoto, Kumamoto, Japan.
FAU - Shimizu, Nobuyuki
AU  - Shimizu N
AD  - Department of Neurosurgery, Yokohama City University Graduate School of Medicine, 
      Yokohama, Kanagawa, Japan.
FAU - Yamamoto, Tetsuya
AU  - Yamamoto T
AD  - Department of Neurosurgery, Yokohama City University Graduate School of Medicine, 
      Yokohama, Kanagawa, Japan. y_neuros@yokohama-cu.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230103
PL  - Austria
TA  - Acta Neurochir (Wien)
JT  - Acta neurochirurgica
JID - 0151000
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 8MDF5V39QO (Sodium Bicarbonate)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Aspirin/pharmacology/therapeutic use
MH  - *Platelet Aggregation/physiology
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/metabolism/pharmacology
MH  - Sodium Bicarbonate/metabolism/pharmacology
MH  - Reproducibility of Results
MH  - Mice, Inbred C57BL
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Hemostasis/physiology
MH  - Blood Platelets/metabolism
OTO - NOTNLM
OT  - Artificial cerebrospinal fluid
OT  - Aspirin
OT  - Hemostasis
OT  - Platelet aggregation
OT  - Recovery of function
OT  - Sodium bicarbonate
EDAT- 2023/01/04 06:00
MHDA- 2023/05/01 06:42
CRDT- 2023/01/03 11:16
PHST- 2022/11/05 00:00 [received]
PHST- 2022/12/21 00:00 [accepted]
PHST- 2023/05/01 06:42 [medline]
PHST- 2023/01/04 06:00 [pubmed]
PHST- 2023/01/03 11:16 [entrez]
AID - 10.1007/s00701-022-05471-9 [pii]
AID - 10.1007/s00701-022-05471-9 [doi]
PST - ppublish
SO  - Acta Neurochir (Wien). 2023 May;165(5):1269-1276. doi: 
      10.1007/s00701-022-05471-9. Epub 2023 Jan 3.

PMID- 11770244
OWN - NLM
STAT- MEDLINE
DCOM- 20020124
LR  - 20230315
IS  - 0019-5456 (Print)
IS  - 0019-5456 (Linking)
VI  - 68
IP  - 11
DP  - 2001 Nov
TI  - Fetal intracranial hemorrhage due to antenatal low dose aspirin intake.
PG  - 1071-2
AB  - Antenatal intake of low dose aspirin is advised for prevention of pregnancy 
      induced hypertension, intrauterine growth retardation and pre-term labour. 
      Aspirin has an anticoagulant effect due to its action on Cyclo-oxygenase and 
      vitamin K dependent coagulation factors. It can readily cross the placental 
      barrier and be a potential cause for bleeding tendency in the fetus. Fetal 
      intracranial hemorrhage, following low dose aspirin administration in a mother 
      and subsequent effect after delivery is being reported.
FAU - Sasidharan, C K
AU  - Sasidharan CK
AD  - Division of Neonatology, Dept. of Pediatrics, IMCH, Medical College, Calicut, 
      Kerala, India.
FAU - Kutty, P M
AU  - Kutty PM
FAU - Ajithkumar
AU  - Ajithkumar
FAU - Sajith, N
AU  - Sajith N
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Pediatr
JT  - Indian journal of pediatrics
JID - 0417442
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced/*diagnostic imaging
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cesarean Section
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant, Newborn
MH  - Intracranial Hemorrhages/*chemically induced/diagnostic imaging
MH  - Male
MH  - Maternal-Fetal Exchange/*drug effects
MH  - Pregnancy
MH  - Risk Assessment
MH  - Tomography, X-Ray Computed
MH  - *Ultrasonography, Prenatal
EDAT- 2002/01/05 10:00
MHDA- 2002/01/25 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/01/25 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
AID - 10.1007/BF02722359 [doi]
PST - ppublish
SO  - Indian J Pediatr. 2001 Nov;68(11):1071-2. doi: 10.1007/BF02722359.

PMID- 2455874
OWN - NLM
STAT- MEDLINE
DCOM- 19880818
LR  - 20190726
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 27
IP  - 5
DP  - 1988 May
TI  - Effect of aspirin on serotonin and met-enkephalin in brain: correlation with the 
      antinociceptive activity of the drug.
PG  - 499-505
AB  - Intravenous administration of acetyl salicylate of lysine, a soluble salt of 
      aspirin, reduced in rats the firing discharge of thalamic neurones, evoked by 
      noxious stimuli. Concomitantly, concentrations of 5-hydroxyindole acetic acid 
      increased, while those of met-enkephalin-like immuno-reactive derivatives were 
      decreased in several areas of the brain. Similar electrophysiological and 
      biochemical responses were obtained by administering tryptophan or 
      5-hydroxytryptophan plus carbidopa. The effect of aspirin on the evoked firing of 
      the thalamic neurones was counteracted by pretreating the animals with 
      metergoline. On the other hand, naloxone did not antagonize the inhibitory effect 
      of aspirin and 5-hydroxytryptophan on pain-induced neuronal excitation. These 
      data indicate that a serotonin-, but not a naloxone-sensitive opiate mechanism, 
      may be relevant for aspirin-mediated antinociception.
FAU - Groppetti, A
AU  - Groppetti A
AD  - Department of Pharmacology Emilio Trabucchi, University of Milan, Italy.
FAU - Braga, P C
AU  - Braga PC
FAU - Biella, G
AU  - Biella G
FAU - Parenti, M
AU  - Parenti M
FAU - Rusconi, L
AU  - Rusconi L
FAU - Mantegazza, P
AU  - Mantegazza P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Analgesics)
RN  - 333DO1RDJY (Serotonin)
RN  - 36B82AMQ7N (Naloxone)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - 58569-55-4 (Enkephalin, Methionine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesics
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Brain/drug effects/*metabolism
MH  - Enkephalin, Methionine/*metabolism
MH  - Evoked Potentials/drug effects
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Injections, Intravenous
MH  - Male
MH  - Naloxone/pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Serotonin/*metabolism
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
AID - 10.1016/0028-3908(88)90132-3 [doi]
PST - ppublish
SO  - Neuropharmacology. 1988 May;27(5):499-505. doi: 10.1016/0028-3908(88)90132-3.

PMID- 12777653
OWN - NLM
STAT- MEDLINE
DCOM- 20040909
LR  - 20171116
IS  - 1024-2708 (Print)
IS  - 1024-2708 (Linking)
VI  - 9
IP  - 3
DP  - 2003 Jun
TI  - Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong 
      Kong.
PG  - 179-85
AB  - OBJECTIVE: To measure the use, appropriateness, and safety of antithrombotic 
      therapy in Hong Kong Chinese patients with atrial fibrillation. DESIGN: 
      Retrospective review. SETTING: Regional hospital, Hong Kong. SUBJECTS AND 
      METHODS: Medical records of all patients with atrial fibrillation admitted to 
      acute internal medicine wards in April 2000 and between July and October 2001 
      were reviewed for details of antithrombotics given, results of international 
      normalised ratio monitoring for patients receiving warfarin, side-effects, and 
      additional risk factors for complications of atrial fibrillation. Statistical 
      analysis was undertaken to assess factors predictive of antithrombotic use. 
      RESULTS: A total of 207 patients with chronic atrial fibrillation were included 
      in the study. Of these, 44.0% of patients with non-valvular atrial fibrillation 
      without contra-indications for warfarin use were receiving warfarin, 34.1% were 
      receiving aspirin, and 22.0% were receiving no antithrombotic therapy. The 
      majority of patients (69.1%) were treated appropriately according to the American 
      College of Chest Physicians guidelines. The major side-effect rates for warfarin 
      and aspirin were 2.14% and 1.72% per patient-year, respectively, which were 
      comparable with western studies of usual clinical practice. The ischaemic stroke 
      rate for patients taking warfarin or aspirin were 1.40% and 6.02% per 
      patient-year, respectively. The median international normalised ratio was 1.96. 
      The median frequency of international normalised ratio measurement was 45.58 
      days. CONCLUSIONS: This study found that antithrombotic use in a Hong Kong 
      regional hospital for patients with atrial fibrillation was similar to that 
      reported from western institutions. Complication and stroke rates were also 
      comparable to the western data relating to usual clinical practice.
FAU - Leung, C S
AU  - Leung CS
AD  - Department of Medicine, Yan Chai Hospital, Tsuen Wan, Hong Kong.
FAU - Tam, K M
AU  - Tam KM
LA  - eng
PT  - Journal Article
PL  - China
TA  - Hong Kong Med J
JT  - Hong Kong medical journal = Xianggang yi xue za zhi
JID - 9512509
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Hong Kong Med J. 2003 Jun;9(3):157. PMID: 12777648
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Chronic Disease
MH  - Contraindications
MH  - Female
MH  - Hemorrhage/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Stroke/etiology
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2003/06/05 05:00
MHDA- 2004/09/10 05:00
CRDT- 2003/06/05 05:00
PHST- 2003/06/05 05:00 [pubmed]
PHST- 2004/09/10 05:00 [medline]
PHST- 2003/06/05 05:00 [entrez]
PST - ppublish
SO  - Hong Kong Med J. 2003 Jun;9(3):179-85.

PMID- 2933258
OWN - NLM
STAT- MEDLINE
DCOM- 19860116
LR  - 20180214
IS  - 0014-3022 (Print)
IS  - 0014-3022 (Linking)
VI  - 24
IP  - 6
DP  - 1985
TI  - Platelet behavior in patients with TIA: responsiveness to small doses of aspirin.
PG  - 426-32
AB  - To study platelet role in cerebrovascular disease, beta-thromboglobulin (beta-TG) 
      and platelet factor 4 (PF4) plasma levels, indices of in vivo platelet 
      activation, were assayed in a group of patients affected by cerebral ischemic 
      attack (transient ischemic attack; TIA). Determinations were carried out within 1 
      month from the ischemic event and following short-term (1 month) and long-term (1 
      year) daily administration of low doses (50 mg) of aspirin (ASA). After the 
      cerebral ischemic event, beta-TG and PF4 plasma levels were elevated. beta-TG and 
      PF4 plasma levels did not decrease after 1 month of treatment with ASA and 
      significantly increased in all the patients after 1 year. Such a trend can 
      perhaps be related to the natural course of the disease and associated with the 
      possible occurrence of collagen-induced platelet activation in cerebrovascular 
      patients. Data suggest that although platelet activation occurs in TIA-affected 
      patients, the high levels of beta-TG and PF4 may not be adequate parameters for 
      evaluation of TIA relapses and ASA efficacy.
FAU - D'Andrea, G
AU  - D'Andrea G
FAU - Toldo, M
AU  - Toldo M
FAU - Cananzi, A
AU  - Cananzi A
FAU - Cortelazzo, S
AU  - Cortelazzo S
FAU - Ferro-Milone, F
AU  - Ferro-Milone F
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Eur Neurol
JT  - European neurology
JID - 0150760
RN  - 0 (Benzilates)
RN  - 0 (beta-Thromboglobulin)
RN  - 37270-94-3 (Platelet Factor 4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Benzilates
MH  - Blood Platelets/*drug effects
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*blood/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Factor 4/analysis
MH  - Time Factors
MH  - beta-Thromboglobulin/analysis
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1159/000115837 [doi]
PST - ppublish
SO  - Eur Neurol. 1985;24(6):426-32. doi: 10.1159/000115837.

PMID- 20060448
OWN - NLM
STAT- MEDLINE
DCOM- 20100520
LR  - 20161125
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 388
IP  - 1-2
DP  - 2010 Mar 30
TI  - Novel multifunctional pharmaceutical excipients derived from microcrystalline 
      cellulose-starch microparticulate composites prepared by compatibilized reactive 
      polymer blending.
PG  - 159-67
LID - 10.1016/j.ijpharm.2009.12.056 [doi]
AB  - The choice of excipients remains a critical factor in pharmaceutical 
      formulations. Microcrystalline cellulose-maize starch composites (MCC-Mst) have 
      been prepared by mixing colloidal dispersions of microcrystalline cellulose (MCC) 
      with 10% (w/w) of chemically gelatinized maize starch (Mst) at controlled 
      temperature conditions for use as multifunctional excipients with direct 
      compression and enhanced disintegration abilities. The novel excipient was 
      evaluated for its direct compression and enhanced disintegrant properties and the 
      result compared with the properties of the individual components. Some of its 
      physicochemical and thermal properties were also determined together with effects 
      of freeze-thaw cycles of processing on the functional and physicochemical 
      properties. The scanning electron micrograph (SEM) shows that the particles of 
      the MCC-Mst were irregular in shape and multiparticulate with a marked degree of 
      asperity. The indirect assessment of the powder flow properties as determined by 
      Carr's compressibility index and angle of repose showed that the MCC-Mst 
      possesses better flow compared with MCC and Mst. MCC-Mst is moderately 
      hygroscopic and shows a Type III moisture sorption isotherm. The FT-IR spectra 
      and DSC thermograms of the composite were different from those of MCC and Mst. 
      The hardness of aspirin tablets was enhanced by incorporating MCC-Mst and MCC, 
      but was reduced by Mst. While the tablets prepared with MCC-Mst and Mst 
      disintegrated within 7min, aspirin compacts devoid of any excipient and those 
      prepared with MCC did not disintegrate even after 2h. Acetaminophen compacts 
      prepared with MCC and MCC-Mst showed similar compact hardness characteristics and 
      loading properties. The loading capacity of the different samples of the 
      composite decreased with increase in the freeze-thaw cycles. The loading capacity 
      of the different materials as assessed by their compact hardness efficiency can 
      be represented as follows (MCC>T0>T1>T4>T3>T2>Mst). Generally, the different 
      samples of MCC-Mst are characterized by physicochemical and functional properties 
      that are similar at different degrees to MCC and Mst.
CI  - Copyright (c) 2009 Elsevier B.V. All rights reserved.
FAU - Builders, Philip F
AU  - Builders PF
AD  - Department of Pharmaceutical Technology and Raw Materials Development, National 
      Institute for Pharmaceutical Research and Development, Abuja, Nigeria. 
      philsonsky@yahoo.com
FAU - Bonaventure, Agbo M
AU  - Bonaventure AM
FAU - Tiwalade, Adelakun
AU  - Tiwalade A
FAU - Okpako, Larry C
AU  - Okpako LC
FAU - Attama, Anthony A
AU  - Attama AA
LA  - eng
PT  - Journal Article
DEP - 20100108
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 9004-34-6 (Cellulose)
RN  - 9005-25-8 (Starch)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/chemistry
MH  - Aspirin/administration & dosage/chemistry
MH  - Calorimetry, Differential Scanning
MH  - Cellulose/*chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - Excipients/*chemistry
MH  - Freezing
MH  - Hardness
MH  - Microscopy, Electron, Scanning
MH  - Starch/*chemistry
MH  - Tablets
MH  - Temperature
MH  - Time Factors
MH  - Zea mays/chemistry
EDAT- 2010/01/12 06:00
MHDA- 2010/05/21 06:00
CRDT- 2010/01/12 06:00
PHST- 2009/10/15 00:00 [received]
PHST- 2009/12/22 00:00 [revised]
PHST- 2009/12/24 00:00 [accepted]
PHST- 2010/01/12 06:00 [entrez]
PHST- 2010/01/12 06:00 [pubmed]
PHST- 2010/05/21 06:00 [medline]
AID - S0378-5173(10)00009-8 [pii]
AID - 10.1016/j.ijpharm.2009.12.056 [doi]
PST - ppublish
SO  - Int J Pharm. 2010 Mar 30;388(1-2):159-67. doi: 10.1016/j.ijpharm.2009.12.056. 
      Epub 2010 Jan 8.

PMID- 11157646
OWN - NLM
STAT- MEDLINE
DCOM- 20010405
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 119
IP  - 1 Suppl
DP  - 2001 Jan
TI  - Use of antithrombotic agents during pregnancy.
PG  - 122S-131S
AB  - Anticoagulant therapy is indicated during pregnancy for the prevention and 
      treatment of VTE; for the prevention and treatment of systemic embolism in 
      patients with mechanical heart valves; and, often in combination with aspirin, 
      for the prevention of pregnancy loss in women with APLAs or thrombophilia and 
      previous pregnancy losses. Several questions concerning anticoagulant therapy 
      remain unanswered. It appears that LMWH will largely replace UFH. Oral 
      anticoagulants are fetopathic, but the true risks of the warfarin embryopathy and 
      CNS abnormalities remain unknown. There is considerable evidence that warfarin 
      embryopathy occurs only when oral anticoagulants are administered between the 
      sixth week and the 12th week of gestation and that oral anticoagulants may not be 
      fetopathic when administered in the first 6 weeks of gestation. Oral 
      anticoagulant therapy should be avoided in the weeks before delivery because of 
      the risk of serious perinatal bleeding caused by the trauma of delivery to the 
      anticoagulated fetus. The safety of aspirin during the first trimester of 
      pregnancy is still a subject of debate. There is a concern about the efficacy of 
      UFH in the prevention of arterial embolism in pregnant women with mechanical 
      heart valves. Finally, the optimum management of pregnant women with 
      thrombophilia (and prior pregnancy loss and/or prior VTE) is unknown, but trials 
      of anticoagulant therapy are ongoing. Because it is safe for the fetus, LMWH (or 
      UFH) is the anticoagulant of choice during pregnancy for situations in which its 
      efficacy is established. There is some doubt that heparin is effective for the 
      prevention of systemic embolism in patients with mechanical heart valves. Low 
      doses of heparin or poorly controlled heparin therapy are not effective in 
      preventing systemic embolism in patients with mechanical heart valves.
FAU - Ginsberg, J S
AU  - Ginsberg JS
AD  - McMaster Medical Center, Hamilton, Ontario, Canada.
FAU - Greer, I
AU  - Greer I
FAU - Hirsh, J
AU  - Hirsh J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Female
MH  - Fetus/drug effects
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*prevention & control
MH  - Pulmonary Embolism/*prevention & control
MH  - Risk Factors
MH  - Venous Thrombosis/*prevention & control
RF  - 80
EDAT- 2001/02/07 11:00
MHDA- 2001/04/06 10:01
CRDT- 2001/02/07 11:00
PHST- 2001/02/07 11:00 [pubmed]
PHST- 2001/04/06 10:01 [medline]
PHST- 2001/02/07 11:00 [entrez]
AID - S0012-3692(15)60784-X [pii]
AID - 10.1378/chest.119.1_suppl.122s [doi]
PST - ppublish
SO  - Chest. 2001 Jan;119(1 Suppl):122S-131S. doi: 10.1378/chest.119.1_suppl.122s.

PMID- 32058295
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1879-0593 (Electronic)
IS  - 1368-8375 (Linking)
VI  - 103
DP  - 2020 Apr
TI  - Regular aspirin intake and prognosis of TxN2-3M0 nasopharyngeal carcinoma: A 
      cohort study based on propensity score matching.
PG  - 104589
LID - S1368-8375(20)30025-7 [pii]
LID - 10.1016/j.oraloncology.2020.104589 [doi]
AB  - OBJECTIVES: Distant metastasis is the leading cause of death in patients with 
      N2-3 nasopharyngeal carcinoma (NPC). And aspirin is found to reduce metastasis 
      and improve prognosis in some other malignancies, such as colorectal cancer. This 
      study aimed to evaluate the clinical value of regular aspirin intake (RAI) in 
      N2-3 NPC treated with standard chemoradiotherapy. MATERIALS AND METHODS: Totally 
      2064 patients diagnosed with TxN2-3M0 NPC from Jan. 2008 to Dec. 2015 and treated 
      with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy were 
      involved. According to RAI, these patients were divided into 2 groups between 
      which a propensity score matching was made, with a ratio of 1:3 and a series of 
      clinical characteristics (age, gender, T stage, N stage and EBV DNA) as 
      covariates. Then survivals and acute toxicities were compared in the 464 matched 
      patients. RESULTS: RAI appeared to bring better overall (87.7% vs. 79.6%, 
      P = 0.031), metastasis-free (87.8% vs. 76.5%, P = 0.017) and disease-free (85.9% 
      vs. 75.5%, P = 0.033) survivals. It simultaneously increased total incidences of 
      myelosuppression (55.2% vs. 32.2%, P < 0.001), oral mucositis (60.3% vs. 38.2%, 
      P < 0.001), cervical dermatitis (60.3% vs. 38.5%, P < 0.001) and xerostomia 
      (49.1% vs. 33.3%, P = 0.002). But RAI failed to affect incidence of any grade 3/4 
      toxicity. CONCLUSIONS: Post-diagnosis RAI might be a tolerable approach to 
      control distant metastasis and provide survival benefit for N2-3 NPC in 
      combination with standard chemoradiotherapy.
CI  - Copyright © 2020. Published by Elsevier Ltd.
FAU - Chang, Hui
AU  - Chang H
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, Guangdong, China.
FAU - Tao, Ya-Lan
AU  - Tao YL
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, Guangdong, China.
FAU - Ye, Wei-Jun
AU  - Ye WJ
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, Guangdong, China.
FAU - Xiao, Wei-Wei
AU  - Xiao WW
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, Guangdong, China.
FAU - Xia, Yun-Fei
AU  - Xia YF
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, Guangdong, China.
FAU - Gao, Yuan-Hong
AU  - Gao YH
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, Guangdong, China. Electronic address: gaoyh1969@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200212
PL  - England
TA  - Oral Oncol
JT  - Oral oncology
JID - 9709118
RN  - 0 (Mitochondrial Proteins)
RN  - 0 (TXN2 protein, human)
RN  - 52500-60-4 (Thioredoxins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Child
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitochondrial Proteins/*adverse effects
MH  - Nasopharyngeal Carcinoma/*drug therapy/genetics
MH  - Prognosis
MH  - Propensity Score
MH  - Thioredoxins/*adverse effects
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - N2-3 disease
OT  - Nasopharyngeal carcinoma
OT  - Survival
OT  - Toxicities
COIS- Declaration of Competing Interest None declared.
EDAT- 2020/02/15 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/02/15 06:00
PHST- 2019/08/30 00:00 [received]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2020/02/15 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
PHST- 2020/02/15 06:00 [entrez]
AID - S1368-8375(20)30025-7 [pii]
AID - 10.1016/j.oraloncology.2020.104589 [doi]
PST - ppublish
SO  - Oral Oncol. 2020 Apr;103:104589. doi: 10.1016/j.oraloncology.2020.104589. Epub 
      2020 Feb 12.

PMID- 2507808
OWN - NLM
STAT- MEDLINE
DCOM- 19891031
LR  - 20170214
IS  - 1011-8942 (Print)
IS  - 1011-8942 (Linking)
VI  - 3
IP  - 1
DP  - 1989 Jun
TI  - Adjuvant therapy of aspirin and cromoglycate 2% eye drops in vernal 
      conjunctivitis.
PG  - 42-6
AB  - Thirty patients of vernal conjunctivitis were divided into two groups as 'A' and 
      'B'. A group received the aspirin and cromoglycate 2% eye drops and the B group 
      received cromoglycate eye drops. The results attained the group who received the 
      aspirin and cromoglycate shown encouraging results and the details discussed in 
      the full text.
FAU - Srinivas, C
AU  - Srinivas C
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Korean J Ophthalmol
JT  - Korean journal of ophthalmology : KJO
JID - 8804513
RN  - Q2WXR1I0PK (Cromolyn Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Conjunctivitis, Allergic/*drug therapy
MH  - Cromolyn Sodium/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Seasons
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
AID - 10.3341/kjo.1989.3.1.42 [doi]
PST - ppublish
SO  - Korean J Ophthalmol. 1989 Jun;3(1):42-6. doi: 10.3341/kjo.1989.3.1.42.

PMID- 8471545
OWN - NLM
STAT- MEDLINE
DCOM- 19930520
LR  - 20201209
IS  - 0937-9827 (Print)
IS  - 0937-9827 (Linking)
VI  - 105
IP  - 5
DP  - 1993
TI  - Abuse of codeine separated from over-the-counter drugs containing acetylsalicylic 
      acid and codeine.
PG  - 279-81
AB  - In Denmark a new trend concerning the abuse of codeine has been observed. Danish 
      drug abusers have discovered that codeine is easily separated from certain drugs 
      containing acetylsalicylic acid and codeine. When separated the codeine can be 
      used either orally or intravenously. Three different drugs combining 
      acetylsalicylic acid and codeine are available in Denmark, but codeine is only 
      easily separable from one of these. Applying the same procedure to the two other 
      drugs produces unpredictable or unfavourable ratios of codeine to acetylsalicylic 
      acid. In several countries, however, similar drugs combining acetylsalicylic acid 
      and codeine are available. It is not possible from a list of constituents to 
      predict how easily codeine can be separated from a particular drug. Therefore it 
      is strongly recommended that relevant drugs are tested at local forensic 
      laboratories. In case codeine is found to be very easily separated from a product 
      appropriate action should be taken.
FAU - Jensen, S
AU  - Jensen S
AD  - Department of Forensic Pathology, Aarhus University, Risskov, Denmark.
FAU - Hansen, A C
AU  - Hansen AC
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Legal Med
JT  - International journal of legal medicine
JID - 9101456
RN  - 0 (Drug Combinations)
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Codeine/*chemistry
MH  - Denmark
MH  - Drug Combinations
MH  - Humans
MH  - Nonprescription Drugs/*chemistry
MH  - *Substance Abuse Detection
MH  - Substance-Related Disorders/*etiology
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1007/BF01370385 [doi]
PST - ppublish
SO  - Int J Legal Med. 1993;105(5):279-81. doi: 10.1007/BF01370385.

PMID- 3823509
OWN - NLM
STAT- MEDLINE
DCOM- 19870414
LR  - 20131121
IS  - 0035-1040 (Print)
IS  - 0035-1040 (Linking)
VI  - 72
IP  - 7
DP  - 1986
TI  - [Subacute osteomyelitis in young children. Study of 17 cases].
PG  - 471-5
AB  - Subacute osteomyelitis is characterised by absence of symptoms of generalised 
      infection and a favourable prognosis. In the last 15 years, the authors have 
      observed 17 such cases in children, aged between 3 months and 4 years. Three were 
      situated in the epiphysis and 14 in the metaphyseal region. On three occasions, a 
      tarsal bone was involved and in five cases the lesion was in the spine. The 
      radiological signs were very characteristic and biological changes were minimal. 
      Exploration of the site of the infection was done on ten occasions, but only on 
      two were organisms found. Treatment was based on antibiotics active against 
      staphylococci and drugs inhibiting prostaglandins. Only one case was treated 
      surgically. Healing occurred eventually in all cases.
FAU - Rombouts, J J
AU  - Rombouts JJ
FAU - Delefortrie, G
AU  - Delefortrie G
FAU - Claus, D
AU  - Claus D
FAU - Vincent, A
AU  - Vincent A
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - L'ostéomyélite subaiguë chez le jeune enfant. Etude de 17 cas.
PL  - France
TA  - Rev Chir Orthop Reparatrice Appar Mot
JT  - Revue de chirurgie orthopedique et reparatrice de l'appareil moteur
JID - 1272427
RN  - 0 (Anti-Bacterial Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Infant
MH  - Osteomyelitis/*diagnosis/drug therapy
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Chir Orthop Reparatrice Appar Mot. 1986;72(7):471-5.

PMID- 6463916
OWN - NLM
STAT- MEDLINE
DCOM- 19840827
LR  - 20190503
IS  - 0040-6376 (Print)
IS  - 1468-3296 (Electronic)
IS  - 0040-6376 (Linking)
VI  - 39
IP  - 6
DP  - 1984 Jun
TI  - Intimal thickening in autogenous vein grafts in rabbits: influence of aspirin and 
      dipyridamole.
PG  - 457-61
AB  - The effects of three different platelet modifying regimens on the degree of 
      intimal thickening of autogenous vein grafts in rabbits were measured one month 
      after operation. Dipyridamole alone (2 mg/kg/6 h) had little effect on the 
      intimal thickness of these rabbits compared with that of controls (mean (1 SEM) 
      for treated animals: 72.0 (7.9) micron; controls: 63.6 (6.0) micron). High dose 
      acetylsalicylic acid (40 mg/kg/24 h) plus dipyridamole (2 mg/kg/6 h) increased 
      intimal thickening significantly (85.8 (6.0) v 63.6 (6.2) micron; p = 0.05, n = 
      17). Low dose acetylsalicylic acid (0.5 mg/kg/24 h) plus dipyridamole (2 mg/kg/6 
      h) also increased intimal thickening (79.0 (6.1) v 63.6 (6.0] micron but not to a 
      significant degree. It has previously been shown in vitro that acetylsalicylic 
      acid increases the area of an exposed subendothelial arterial surface covered by 
      platelets. Such an effect may explain our finding of increased intimal thickening 
      with high dose acetylsalicylic acid plus dipyridamole.
FAU - Murday, A J
AU  - Murday AJ
FAU - Gershlick, A H
AU  - Gershlick AH
FAU - Syndercombe-Court, Y D
AU  - Syndercombe-Court YD
FAU - Mills, P G
AU  - Mills PG
FAU - Lewis, C T
AU  - Lewis CT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Thorax
JT  - Thorax
JID - 0417353
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dipyridamole/*pharmacology
MH  - Jugular Veins/drug effects/pathology/*transplantation
MH  - Rabbits
PMC - PMC459830
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
AID - 10.1136/thx.39.6.457 [doi]
PST - ppublish
SO  - Thorax. 1984 Jun;39(6):457-61. doi: 10.1136/thx.39.6.457.

PMID- 11343821
OWN - NLM
STAT- MEDLINE
DCOM- 20010830
LR  - 20190701
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 304
IP  - 3
DP  - 2001 May 25
TI  - Low dose aspirin attenuates escape/avoidance behavior, but does not reduce 
      mechanical hyperalgesia in a rodent model of inflammatory pain.
PG  - 137-40
AB  - The present experiment examined the effect of aspirin on the escape/avoidance 
      behavioral response to a mechanical stimulus (476 mN von Frey monofilament) in 
      the place escape avoidance paradigm (PEAP) following subcutaneous administration 
      of carrageenan (CARR). Forty-one male Sprague-Dawley rats received subcutaneous 
      injection of CARR or saline in the left hindpaw and 3 1/2 h later were 
      administered aspirin (0, 50 or 150 mg/kg). Thirty minutes later, animals were 
      tested in the PEAP and then the mechanical paw withdrawal threshold was measured. 
      Compared with Saline vehicle-treated controls, all CARR-treated animals displayed 
      hyperalgesia, as reflected by enhanced responding to mechanical stimulation 
      applied to the CARR-injected paw. Mechanical hyperalgesia was significantly 
      reduced by the pre-treatment of 150 mg/kg, but not 50 mg/kg aspirin. In the PEAP, 
      CARR vehicle-treated animals avoided a preferred location of the test chamber 
      that was associated with mechanical stimulation of the hyperalgesic paw. The 
      shift from a preferred dark side of the chamber to the light side was attenuated 
      by pre-treatment with both doses of aspirin (50 and 150 mg/kg). The lack of 
      anti-hyperalgesia and avoidance behavior with 50 mg/kg aspirin suggests a 
      decrease in the aversive nature of mechanical stimulation of the afflicted paw. 
      It is suggested that the mechanisms underlying the affective/motivational 
      dimension of nociception (escape/avoidance) can be dissociated from the 
      processing of nociceptive information related to withdrawal responding.
FAU - LaBuda, C J
AU  - LaBuda CJ
AD  - Department of Psychology, Box 19528, University of Texas at Arlington, Arlington, 
      TX 76019, USA. cjlabuda@yahoo.com
FAU - Fuchs, P N
AU  - Fuchs PN
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Avoidance Learning/*drug effects
MH  - Carrageenan/administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Escape Reaction/*drug effects
MH  - Hindlimb
MH  - Hyperalgesia/*physiopathology
MH  - Inflammation/chemically induced/*physiopathology
MH  - Injections, Subcutaneous
MH  - Male
MH  - Pain/physiopathology
MH  - Physical Stimulation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reference Values
EDAT- 2001/05/10 10:00
MHDA- 2001/08/31 10:01
CRDT- 2001/05/10 10:00
PHST- 2001/05/10 10:00 [pubmed]
PHST- 2001/08/31 10:01 [medline]
PHST- 2001/05/10 10:00 [entrez]
AID - S0304394001017876 [pii]
AID - 10.1016/s0304-3940(01)01787-6 [doi]
PST - ppublish
SO  - Neurosci Lett. 2001 May 25;304(3):137-40. doi: 10.1016/s0304-3940(01)01787-6.

PMID- 8230008
OWN - NLM
STAT- MEDLINE
DCOM- 19931221
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 20
IP  - 8
DP  - 1993 Aug
TI  - Aspirin is not associated with more toxicity than other nonsteroidal 
      antiinflammatory drugs in patients with rheumatoid arthritis treated with 
      methotrexate.
PG  - 1297-302
AB  - OBJECTIVE: To compare the clinical and laboratory toxicities of aspirin vs 
      nonsteroidal antiinflammatory drugs (NSAID) in combination with low dose 
      methotrexate (MTX). METHODS: We retrospectively examined 34 patients with 
      rheumatoid arthritis (RA) who completed 12 months of a prospective MTX trial. 
      Analysis included descriptive and logistic regression. RESULTS: Twelve patients 
      took an average of 4.5 g aspirin daily; 22 patients took other NSAID at stable 
      doses. Limiting toxicity was not different between aspirin and NSAID treatment 
      groups, respectively, for stomatitis (33 vs 27%), gastrointestinal symptoms (25 
      vs 18%), hepatic (25 vs 27%), or other toxicity. However, using logistic 
      regression procedures, weight adjusted weekly MTX dose and prednisone dose 
      correlated with toxicity. CONCLUSION: While toxicity is common when aspirin or 
      NSAID are used with MTX to treat RA, there is no clinical difference between 
      aspirin and NSAID with respect to that toxicity during 12 months of therapy.
FAU - Rooney, T W
AU  - Rooney TW
AD  - Department of Medicine, University of Iowa, Iowa City 52242.
FAU - Furst, D E
AU  - Furst DE
FAU - Koehnke, R
AU  - Koehnke R
FAU - Burmeister, L
AU  - Burmeister L
LA  - eng
GR  - RR59/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Methotrexate/*therapeutic use
MH  - Middle Aged
MH  - Prednisone/therapeutic use
MH  - Retrospective Studies
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1993 Aug;20(8):1297-302.

PMID- 17901572
OWN - NLM
STAT- MEDLINE
DCOM- 20080512
LR  - 20200106
IS  - 1734-1140 (Print)
IS  - 1734-1140 (Linking)
VI  - 59
IP  - 4
DP  - 2007 Jul-Aug
TI  - Inhibition of NAD(P)H oxidase attenuates aggregation of platelets from high-risk 
      cardiac patients with aspirin resistance.
PG  - 428-36
AB  - Up to one-third of serious vascular events in high-risk patients is attributable 
      to a failure of aspirin (ASA) to suppress platelet aggregation. We hypothesized 
      that inhibition of NAD(P)H oxidase may inhibit aggregation of platelets from 
      ASA-resistant (ASA-R) patients. Thus, platelet-rich plasma was isolated from 
      ASA-sensitive (ASA-S) and ASA-R patients (aspirin resistance was defined as 
      higher than expected aggregation to collagen and epinephrine [> or = 40%] after 
      chronic oral treatment with 100 mg/day ASA). Aggregation to adenosine diphosphate 
      (ADP) (5 and 10 micromol/l), collagen (2 microg/ml) and epinephrine (10 
      micromol/l) in the absence and presence of the NAD(P)H oxidase inhibitors: 
      diphenylene iodonium (DPI) (1 micromol/l) and apocynin (3 x 10(-4) mol/l) was 
      measured by optical aggregometry. Maximal aggregation of ASA-R platelets to 
      collagen and epinephrine was significantly decreased by DPI and apocynin, whereas 
      they had no effect in ASA-S platelets. Maximal aggregation to ADP was unaffected 
      by NAD(P)H oxidase inhibition in either group. In ASA-R platelets both 
      NADPH-driven O2(.-) production (lucigenin chemiluminescence assay) and expression 
      of gp91phox and p67phox subunits of the NADPH oxidase (Western blotting) tended 
      to increase. Collectively, inhibition of NAD(P)H oxidase effectively suppressed 
      collagen and epinephrine-induced aggregation of platelets from ASA-R patients, 
      which may represent a novel pharmacological target for cardioprotection in 
      high-risk cardiac patients.
FAU - Stef, Gyorgyi
AU  - Stef G
AD  - State Hospital for Cardiology, Balatonfured 8230, Hungary.
FAU - Csiszar, Anna
AU  - Csiszar A
FAU - Ziangmin, Zhao
AU  - Ziangmin Z
FAU - Ferdinandy, Peter
AU  - Ferdinandy P
FAU - Ungvari, Zoltan
AU  - Ungvari Z
FAU - Veress, Gabor
AU  - Veress G
LA  - eng
GR  - HL-077256/HL/NHLBI NIH HHS/United States
GR  - HL-43023/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Acetophenones)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Onium Compounds)
RN  - 0 (Phosphoproteins)
RN  - 0 (neutrophil cytosol factor 67K)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 6HJ411TU98 (diphenyleneiodonium)
RN  - 9007-34-5 (Collagen)
RN  - B6J7B9UDTR (acetovanillone)
RN  - EC 1.6.3.- (CYBB protein, human)
RN  - EC 1.6.3.- (NADPH Oxidase 2)
RN  - EC 1.6.3.- (NADPH Oxidases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetophenones/pharmacology
MH  - Adenosine Diphosphate/pharmacology
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Blotting, Western
MH  - Collagen/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Enzyme Inhibitors/*pharmacology
MH  - Female
MH  - Heart Diseases/*blood/enzymology
MH  - Humans
MH  - Luminescent Measurements
MH  - Male
MH  - Membrane Glycoproteins/metabolism
MH  - Middle Aged
MH  - NADPH Oxidase 2
MH  - NADPH Oxidases/*antagonists & inhibitors/metabolism
MH  - Onium Compounds/pharmacology
MH  - Phosphoproteins/metabolism
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Function Tests/methods
MH  - Platelet-Rich Plasma/drug effects/metabolism
EDAT- 2007/09/29 09:00
MHDA- 2008/05/13 09:00
CRDT- 2007/09/29 09:00
PHST- 2007/03/01 00:00 [received]
PHST- 2007/08/06 00:00 [revised]
PHST- 2007/09/29 09:00 [pubmed]
PHST- 2008/05/13 09:00 [medline]
PHST- 2007/09/29 09:00 [entrez]
PST - ppublish
SO  - Pharmacol Rep. 2007 Jul-Aug;59(4):428-36.

PMID- 9649928
OWN - NLM
STAT- MEDLINE
DCOM- 19980917
LR  - 20191024
IS  - 0954-6928 (Print)
IS  - 0954-6928 (Linking)
VI  - 9
IP  - 4
DP  - 1998
TI  - Indobufen compared with aspirin and dipyridamole on graft patency after coronary 
      artery bypass surgery: results of a combined analysis.
PG  - 217-22
AB  - BACKGROUND: Two prospective, randomized, double-blind clinical trials, performed 
      in the UK and Italy, showed that indobufen, a reversible cyclo-oxygenase 
      inhibitor, is as effective as, and safer than, a combination of aspirin with 
      dipyridamole in preventing occlusion of saphenous vein coronary artery bypass 
      grafts (CABG) 1 year after surgery. OBJECTIVE: To obtain, in a larger patient 
      population, a more precise estimate of the possible differences in efficacy and 
      safety between the two treatments. METHODS: We performed a combined analysis of 
      the results of the two studies, based on the 1-year angiography data, on a total 
      of 934 patients with 2258 saphenous vein distal anastomoses. RESULTS: Patients in 
      the UK and Italy had similar baseline clinical characteristics. The analysis 
      confirmed that there were no significant differences between the two treatment 
      groups in the proportion of patients with one or more occluded grafts and in the 
      proportion of occluded distal anastomoses. The combined analysis showed that the 
      difference in response frequency (indobufen compared with aspirin and 
      dipyridamole) was close to 0: 2.0% (95% confidence interval (CI) -4.2 to 8.2) in 
      terms of patients, and 0.8% (95% CI -2.5 to 4.2) in terms of distal anastomoses. 
      The 1-year incidence of postoperative major cardiovascular events was not 
      statistically different between the treatment groups (19/694 indobufen compared 
      with 25/678 aspirin and dipyridamole). CONCLUSIONS: Two multicentre CABG studies 
      performed in different countries in patients with similar characteristics showed 
      similar results in terms of graft patency. On the basis of the combined analysis, 
      the two treatments can reasonably be considered to be equally effective in the 
      prevention of graft occlusion.
FAU - Cataldo, G
AU  - Cataldo G
AD  - Centro A. De Gasperis, Ospedale Niguarda Ca Granda, Università di Milano, Milan, 
      Italy.
FAU - Heiman, F
AU  - Heiman F
FAU - Lavezzari, M
AU  - Lavezzari M
FAU - Marubini, E
AU  - Marubini E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Coron Artery Dis
JT  - Coronary artery disease
JID - 9011445
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 6T9949G4LZ (indobufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Cyclooxygenase Inhibitors/adverse effects/*therapeutic use
MH  - Dipyridamole/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Graft Occlusion, Vascular/diagnostic imaging/*prevention & control
MH  - Humans
MH  - Isoindoles
MH  - Male
MH  - Middle Aged
MH  - Phenylbutyrates/adverse effects/*therapeutic use
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Radiography
MH  - Randomized Controlled Trials as Topic
EDAT- 1998/07/03 00:00
MHDA- 1998/07/03 00:01
CRDT- 1998/07/03 00:00
PHST- 1998/07/03 00:00 [pubmed]
PHST- 1998/07/03 00:01 [medline]
PHST- 1998/07/03 00:00 [entrez]
AID - 10.1097/00019501-199809040-00007 [doi]
PST - ppublish
SO  - Coron Artery Dis. 1998;9(4):217-22. doi: 10.1097/00019501-199809040-00007.

PMID- 18359332
OWN - NLM
STAT- MEDLINE
DCOM- 20080515
LR  - 20220330
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 101
IP  - 7
DP  - 2008 Apr 1
TI  - The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their 
      pharmacodynamic interaction with aspirin in healthy volunteers.
PG  - 1060-3
LID - 10.1016/j.amjcard.2007.11.054 [doi]
AB  - Patients with cardiovascular disease taking aspirin and some nonsteroidal 
      anti-inflammatory drugs (NSAIDs) appear to have increased vascular events. This 
      study was conducted to compare the ex vivo antiplatelet effects of 6 commonly 
      used NSAIDs and to determine whether these agents antagonize the effect of 
      aspirin. Platelet function was assessed by Platelet Function Analyzer 100 closure 
      time in normal subjects in a randomized, blinded, multiple-crossover study. 
      Platelet function was measured 12 hours after the administration of each NSAID. 
      The NSAID was then given 2 hours before aspirin 300 mg, and platelet function was 
      reassessed 24 hours later. At 12 hours after the administration of naproxen and 
      tiaprofenic acid, closure time was significantly prolonged, whereas the other 
      NSAIDs did not cause significant prolongations. Compared with placebo plus 
      aspirin, closure time was significantly reduced when ibuprofen, indomethacin, 
      naproxen, or tiaprofenic acid was given before aspirin. In conclusion, ibuprofen, 
      indomethacin, naproxen, and tiaprofenic acid all block the antiplatelet effect of 
      aspirin. Sulindac and celecoxib did not demonstrate any significant antiplatelet 
      effect or reduce the antiplatelet of aspirin and, therefore, of the NSAIDs 
      evaluated may be the drugs of choice for patients requiring aspirin and NSAIDs.
FAU - Gladding, Patrick A
AU  - Gladding PA
AD  - Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
FAU - Webster, Mark W I
AU  - Webster MW
FAU - Farrell, Helen B
AU  - Farrell HB
FAU - Zeng, Irene S L
AU  - Zeng IS
FAU - Park, Robert
AU  - Park R
FAU - Ruijne, Nicola
AU  - Ruijne N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080206
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics/therapeutic use
MH  - Aspirin/*pharmacokinetics/therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Cross-Over Studies
MH  - Double Bind Interaction
MH  - *Drug Antagonism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacokinetics/therapeutic use
MH  - Platelet Function Tests
MH  - Time Factors
EDAT- 2008/03/25 09:00
MHDA- 2008/05/16 09:00
CRDT- 2008/03/25 09:00
PHST- 2007/09/16 00:00 [received]
PHST- 2007/11/13 00:00 [revised]
PHST- 2007/11/13 00:00 [accepted]
PHST- 2008/03/25 09:00 [pubmed]
PHST- 2008/05/16 09:00 [medline]
PHST- 2008/03/25 09:00 [entrez]
AID - S0002-9149(07)02370-3 [pii]
AID - 10.1016/j.amjcard.2007.11.054 [doi]
PST - ppublish
SO  - Am J Cardiol. 2008 Apr 1;101(7):1060-3. doi: 10.1016/j.amjcard.2007.11.054. Epub 
      2008 Feb 6.

PMID- 22182587
OWN - NLM
STAT- MEDLINE
DCOM- 20120806
LR  - 20220317
IS  - 1748-5460 (Electronic)
IS  - 0022-2151 (Linking)
VI  - 126
IP  - 4
DP  - 2012 Apr
TI  - Antiplatelet therapy in ENT surgery: a review.
PG  - 331-6
LID - 10.1017/S0022215111003239 [doi]
AB  - INTRODUCTION: Antiplatelet agents such as aspirin and clopidogrel are 
      increasingly encountered in clinical practice. Otorhinolaryngological surgeons 
      are involved in the peri-operative decision of whether to continue treatment and 
      risk haemorrhage or to discontinue treatment and risk thrombosis. METHODS: 
      Literature relating to the risk of spontaneous or operative haemorrhage was 
      reviewed. The morbidity and mortality associated with cessation of agents was 
      evaluated. Published guidelines were also evaluated. A protocol for the 
      management of antiplatelet agents in the peri-operative period, with particular 
      reference to ENT operations, is presented. CONCLUSION: SIGNIFICANT morbidity and 
      mortality is associated with the premature cessation of antiplatelet agents. Data 
      from cardiac surgery suggest that operative blood loss only marginally increases 
      in patients on aspirin and clopidogrel. However, the management of antiplatelet 
      agents in the peri-operative period should be made after multidisciplinary 
      consultation.
FAU - Sylvester, D C
AU  - Sylvester DC
AD  - Department of Otolaryngology, York Hospital, UK. dsylvester@doctors.net.uk
FAU - Coatesworth, A P
AU  - Coatesworth AP
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20111219
PL  - England
TA  - J Laryngol Otol
JT  - The Journal of laryngology and otology
JID - 8706896
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects/pharmacology
MH  - Blood Loss, Surgical/prevention & control/*statistics & numerical data
MH  - Clopidogrel
MH  - Decision Making
MH  - Drug-Eluting Stents
MH  - Humans
MH  - *Otorhinolaryngologic Surgical Procedures
MH  - Perioperative Care/*methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/pharmacology
MH  - Risk Factors
MH  - Thrombosis/prevention & control
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacology
EDAT- 2011/12/21 06:00
MHDA- 2012/08/07 06:00
CRDT- 2011/12/21 06:00
PHST- 2011/12/21 06:00 [entrez]
PHST- 2011/12/21 06:00 [pubmed]
PHST- 2012/08/07 06:00 [medline]
AID - S0022215111003239 [pii]
AID - 10.1017/S0022215111003239 [doi]
PST - ppublish
SO  - J Laryngol Otol. 2012 Apr;126(4):331-6. doi: 10.1017/S0022215111003239. Epub 2011 
      Dec 19.

PMID- 19968611
OWN - NLM
STAT- MEDLINE
DCOM- 20100722
LR  - 20161125
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 45
IP  - 3
DP  - 2010 Mar
TI  - Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in 
      patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small 
      bowel damage.
PG  - 292-8
LID - 10.3109/00365520903453182 [doi]
AB  - OBJECTIVE: Low-dose enteric-coated aspirin is increasingly being used for 
      prevention of cardiovascular disease. The aim of this study was to evaluate 
      whether geranylgeranylacetone (GGA) could prevent aspirin-induced small bowel 
      injury. MATERIAL AND METHODS: This was a prospective, randomized, double-blind, 
      pilot study of GGA versus placebo in subjects taking low-dose enteric-coated 
      aspirin. Young healthy volunteers were enrolled and each received 100 mg of 
      enteric-coated aspirin per day plus either GGA (150 mg/day) or matching placebo 
      for 7 days. Video capsule endoscopy of the small bowel and the Gastrointestinal 
      Symptom Rating Scale (GSRS) questionnaire were performed before and after the 
      administration of aspirin. RESULTS: Twenty volunteers were evaluated. There was 
      no significant difference in the number of lesions in any category between those 
      receiving or not receiving GGA. Large erosions or ulcers were observed in 12 
      (60%; 95% confidence interval 36%- 80%) aspirin users. Mucosal breaks were most 
      frequently found in the latter half of the proximal small bowel. CONCLUSIONS: 
      Short-term administration of low-dose enteric-coated aspirin was associated with 
      visible small bowel damage in the majority of users. We could not prove that 
      aspirin-induced small bowel mucosal injury was prevented by GGA.
FAU - Shiotani, Akiko
AU  - Shiotani A
AD  - Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan. 
      shiotani@med.kawasaki-m.ac.jp
FAU - Haruma, Ken
AU  - Haruma K
FAU - Nishi, Ryuji
AU  - Nishi R
FAU - Fujita, Minoru
AU  - Fujita M
FAU - Kamada, Tomoari
AU  - Kamada T
FAU - Honda, Keisuke
AU  - Honda K
FAU - Kusunoki, Hiroaki
AU  - Kusunoki H
FAU - Hata, Jiro
AU  - Hata J
FAU - Graham, David Y
AU  - Graham DY
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Diterpenes)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
RN  - S8S8451A4O (geranylgeranylacetone)
SB  - IM
MH  - Adult
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Diterpenes/*administration & dosage
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Intestine, Small/drug effects
MH  - Male
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Tablets, Enteric-Coated/*adverse effects
MH  - Treatment Outcome
MH  - Ulcer/chemically induced/pathology
EDAT- 2009/12/09 06:00
MHDA- 2010/07/23 06:00
CRDT- 2009/12/09 06:00
PHST- 2009/12/09 06:00 [entrez]
PHST- 2009/12/09 06:00 [pubmed]
PHST- 2010/07/23 06:00 [medline]
AID - 10.3109/00365520903453182 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2010 Mar;45(3):292-8. doi: 10.3109/00365520903453182.

PMID- 2403864
OWN - NLM
STAT- MEDLINE
DCOM- 19900220
LR  - 20131121
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 81
IP  - 1 Suppl
DP  - 1990 Jan
TI  - Role of platelets and antiplatelet agents in cerebrovascular disease. Clues from 
      trials.
PG  - I20-1; discussion I22-3
AB  - Significant reductions in mortality and in the incidence of nonfatal strokes have 
      been shown in many trials of antiplatelet drugs, such as aspirin, in 
      cerebrovascular disease. The limitations of these trials must be considered; 
      however, if the trials are to provide useful information on the role of platelets 
      in thrombotic processes. Difficulties arise because of the variable composition 
      of emboli and the many possible causes of strokes. Some emboli are composed 
      mainly of platelets while others consist of atheromatous material. Strokes may 
      result from hemorrhage, hemodynamic disturbances, or lacunar infarction rather 
      than thromboembolism. Nonetheless, the results of clinical trials suggest that at 
      least some strokes can be prevented by antiplatelet drugs, thus implying that 
      platelets are involved in the underlying disease process.
FAU - Harrison, M J
AU  - Harrison MJ
AD  - Department of Neurological Studies, Middlesex Hospital Medical School, London, 
      UK.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*physiology
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - Circulation. 1990 Jan;81(1 Suppl):I20-1; discussion I22-3.

PMID- 7126358
OWN - NLM
STAT- MEDLINE
DCOM- 19821221
LR  - 20131121
IS  - 0037-8771 (Print)
IS  - 0037-8771 (Linking)
VI  - 58
IP  - 13
DP  - 1982 Jul 15
TI  - [In vitro effect of culture fluids from neoplastic tissues on platelet 
      aggregation. I. Human tumors of the gastrointestinal tract].
PG  - 847-53
AB  - The effects on platelet function of culture media from 7 human tumours of the 
      gastroenteric tract have been studied on platelet rich plasma obtained from 28 
      apparently normal subjects. Platelet aggregation was investigated according to 
      Born's method. Some of the culture media showed an aggregating activity on 
      platelets, while others did not; after dialysis, however, also the last ones 
      aggregated platelets. Furthermore all the media both before and after dialysis 
      were able to increase the platelet response to low doses of ADP (3 microM), and 
      these effects were inhibited by Aspirin (0,1 mM). These results suggest that the 
      tumours investigated release stimulating activities on platelet function and that 
      these interactions can be inhibited pharmacologically.
FAU - Pacchiarini, L
AU  - Pacchiarini L
FAU - Serra, L
AU  - Serra L
FAU - Grignani, G
AU  - Grignani G
FAU - Gamba, G
AU  - Gamba G
FAU - Gorini, M
AU  - Gorini M
LA  - ita
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Azione in vitro sull'aggregazione piastrinica dei liquidi di coltura di tessuti 
      neoplastici. I) Tumori umani del tratto gastroenterico.
PL  - Italy
TA  - Boll Soc Ital Biol Sper
JT  - Bollettino della Societa italiana di biologia sperimentale
JID - 7506962
RN  - 0 (Culture Media)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Culture Media/*pharmacology
MH  - Female
MH  - Gastrointestinal Neoplasms/*analysis
MH  - Humans
MH  - Male
MH  - *Platelet Aggregation
EDAT- 1982/07/15 00:00
MHDA- 1982/07/15 00:01
CRDT- 1982/07/15 00:00
PHST- 1982/07/15 00:00 [pubmed]
PHST- 1982/07/15 00:01 [medline]
PHST- 1982/07/15 00:00 [entrez]
PST - ppublish
SO  - Boll Soc Ital Biol Sper. 1982 Jul 15;58(13):847-53.

PMID- 35301133
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20220512
IS  - 1559-2030 (Electronic)
IS  - 1551-7144 (Linking)
VI  - 115
DP  - 2022 Apr
TI  - The challenges of data safety monitoring for a pragmatic study: Lessons from the 
      ADAPTABLE study.
PG  - 106732
LID - S1551-7144(22)00058-1 [pii]
LID - 10.1016/j.cct.2022.106732 [doi]
AB  - Data monitoring committees (DMCs) play a critical role in protecting the safety 
      of participants and integrity of clinical studies. While there are 
      well-established DMC guidelines for traditional, randomized controlled trials, 
      the clinical trial community is still in the search for best practices in data 
      and safety monitoring in pragmatic clinical trials. ADAPTABLE was a large, open 
      label, pragmatic, randomized controlled trial, harnessing real world data from 
      multiple sources and studying the comparative effectiveness of the two most 
      common dosages of aspirin in patients with atherosclerotic cardiovascular 
      disease. Specific issues arose in ADAPTABLE such as data quality, information 
      latency, and protocol adherence, and these issues were both expected and 
      unexpected features of the pragmatic study design. These issues imposed great 
      challenges to the DMC members who were tasked to make critical decisions during 
      the study. This article summarizes the unique experience of the ADAPTABLE DMC, 
      including the internal debates and concerns, the concerted efforts to accomplish 
      its mission, and the special contribution of the patient representatives. We also 
      offer recommendations on data and safety monitoring for future pragmatic trials.
CI  - Copyright © 2022. Published by Elsevier Inc.
FAU - Huang, Zhen
AU  - Huang Z
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, 
      USA. Electronic address: zhen.huang@duke.edu.
FAU - Rockhold, Frank W
AU  - Rockhold FW
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, 
      USA.
FAU - Jones, W Schuyler
AU  - Jones WS
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, 
      USA.
FAU - Hernandez, Adrian F
AU  - Hernandez AF
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, 
      USA.
FAU - McCall, Debbe
AU  - McCall D
AD  - Patient Partner/Advisor, Murrieta, CA, USA.
FAU - DeMets, David L
AU  - DeMets DL
AD  - University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
FAU - Hochman, Judith S
AU  - Hochman JS
AD  - New York University Grossman School of Medicine and NYU Langone Health, NY, New 
      York, USA.
FAU - Gersh, Bernard J
AU  - Gersh BJ
AD  - Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
FAU - Campos, Hugo
AU  - Campos H
AD  - Patient Partner/Advisor, Oakland, CA, USA.
FAU - Jacobs, Alice K
AU  - Jacobs AK
AD  - Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.
FAU - Yancy, Clyde W
AU  - Yancy CW
AD  - Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20220315
PL  - United States
TA  - Contemp Clin Trials
JT  - Contemporary clinical trials
JID - 101242342
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Atherosclerosis
MH  - *Clinical Trials Data Monitoring Committees
MH  - Data Accuracy
MH  - Humans
MH  - Research Design
OTO - NOTNLM
OT  - Data safety monitoring
OT  - Electronic health records
OT  - Pragmatic trial
EDAT- 2022/03/19 06:00
MHDA- 2022/04/20 06:00
CRDT- 2022/03/18 05:39
PHST- 2021/10/02 00:00 [received]
PHST- 2022/03/08 00:00 [revised]
PHST- 2022/03/09 00:00 [accepted]
PHST- 2022/03/19 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
PHST- 2022/03/18 05:39 [entrez]
AID - S1551-7144(22)00058-1 [pii]
AID - 10.1016/j.cct.2022.106732 [doi]
PST - ppublish
SO  - Contemp Clin Trials. 2022 Apr;115:106732. doi: 10.1016/j.cct.2022.106732. Epub 
      2022 Mar 15.

PMID- 31073532
OWN - NLM
STAT- MEDLINE
DCOM- 20190904
LR  - 20220410
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2019
DP  - 2019
TI  - Aspirin Exposure and Mortality Risk among Prostate Cancer Patients: A Systematic 
      Review and Meta-Analysis.
PG  - 9379602
LID - 10.1155/2019/9379602 [doi]
LID - 9379602
AB  - BACKGROUND: Prostate cancer (PCa) is the ninth most common cause of cancer death 
      globally. Many studies have investigated aspirin exposure and mortality risk 
      among PCa patients, returning inconsistent results. We conducted a comprehensive 
      meta-analysis to explore the association between aspirin exposure and mortality 
      risk among PCa patients and to investigate potential 
      dose/duration/frequency-response relationships. METHODS AND RESULTS: Studies 
      published from 1980 to 2018 of PubMed and EMBASE databases were searched. We 
      included 14 studies with 110,000 participants. Multivariate-adjusted odds ratios 
      (ORs) were pooled using random-effect models. Potential 
      dose/duration/frequency-response relationships were evaluated for aspirin 
      exposure and prostate cancer-specific mortality (PCSM) risk. We did not detect an 
      association between the highest aspirin exposure and mortality risk (PCSM of 
      prediagnostic aspirin exposure, OR: 0.96, 95% confidence interval [CI]: 0.87-1. 
      07, I(2)= 0%; PCSM of postdiagnostic aspirin exposure, OR:0.92, 95% CI: 
      0.77-1.10, I(2) = 56.9%; all-cause mortality [ACM] of prediagnostic aspirin 
      exposure, OR: 0.96, 95% CI: 0.88-1.04, I(2) = 9.4%; ACM of postdiagnostic aspirin 
      exposure, OR: 0.95, 95% CI: 0.73-1.23, I(2) = 88.9%). There was no significant 
      dose/frequency-response association observed for aspirin exposure and PCSM risk. 
      On duration-response analysis, we found that short-term postdiagnostic aspirin 
      exposure (shorter than 2.5 years) increased the risk of PCSM. CONCLUSIONS: Our 
      meta-analysis suggests that there is no association between aspirin exposure and 
      PCSM risk. Nor is there an association between the highest aspirin exposure and 
      ACM risk among PCa patients. More studies are needed for a further 
      dose/duration/frequency-response meta-analysis.
FAU - Fan, Lai Lai
AU  - Fan LL
AUID- ORCID: 0000-0003-2484-2109
AD  - Department of Urology, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, China.
FAU - Xie, Cheng Peng
AU  - Xie CP
AD  - Department of Urology, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, China.
FAU - Wu, Yi Ming
AU  - Wu YM
AUID- ORCID: 0000-0003-3514-2781
AD  - Department of Urology, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, China.
FAU - Gu, Xi Jie
AU  - Gu XJ
AD  - Department of Urology, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, China.
FAU - Chen, Ying He
AU  - Chen YH
AUID- ORCID: 0000-0001-9645-6851
AD  - Department of Urology, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, China.
FAU - Wang, Yi Jun
AU  - Wang YJ
AUID- ORCID: 0000-0003-2379-4336
AD  - Department of Urology, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190403
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cohort Studies
MH  - Follow-Up Studies
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Prostate/drug effects/pathology
MH  - Prostatic Neoplasms/*drug therapy/*mortality/pathology
MH  - Risk Factors
PMC - PMC6470443
EDAT- 2019/05/11 06:00
MHDA- 2019/09/05 06:00
CRDT- 2019/05/11 06:00
PHST- 2018/12/17 00:00 [received]
PHST- 2019/03/20 00:00 [accepted]
PHST- 2019/05/11 06:00 [entrez]
PHST- 2019/05/11 06:00 [pubmed]
PHST- 2019/09/05 06:00 [medline]
AID - 10.1155/2019/9379602 [doi]
PST - epublish
SO  - Biomed Res Int. 2019 Apr 3;2019:9379602. doi: 10.1155/2019/9379602. eCollection 
      2019.

PMID- 12403377
OWN - NLM
STAT- MEDLINE
DCOM- 20030130
LR  - 20170214
IS  - 0009-9228 (Print)
IS  - 0009-9228 (Linking)
VI  - 41
IP  - 8
DP  - 2002 Oct
TI  - Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in 
      the treatment of Kawasaki syndrome.
PG  - 597-601
AB  - The efficacy of intravenous immunoglobulin (IVIG) in the treatment of Kawasaki 
      syndrome (KS) has been unequivocally established, but questions remain concerning 
      the proper dose of adjunctive aspirin therapy in the treatment of KS. The medical 
      records of 72 children with KS were reviewed. All patients were treated with 
      IVIG; 21 received 400 mg/kg/dose on 4 consecutive days and 51 received 2 g/kg as 
      a single infusion. Seventy patients also received aspirin. Twenty-four of the 70 
      patients were started on high-dose aspirin (80-100 mg/kg/day) at the time of 
      diagnosis. High-dose aspirin was given for a mean (+/- SE) duration of 6.1+/-0.9 
      days, then switched to low-dose aspirin (3-5 mg/kg/day). Forty-six of the 70 
      patients were started on low-dose aspirin at the time of diagnosis and remained 
      on low-dose aspirin for the duration of treatment. Coronary artery abnormalities 
      were present at the time of diagnosis in 12 of 72 patients (17%), including 6 of 
      6 of patients (100%) with atypical KS and 6 of 66 patients (9%) with typical KS. 
      None of the remaining 60 patients developed coronary artery abnormalities after 
      treatment with IVIG and aspirin. The mean duration of fever after initiation of 
      therapy was 44+/-6 hours in patients treated with IVIG 400 mg/kg/dose on 4 
      consecutive days and 35+/-5 hours in patients treated with 2 g/kg as a single 
      infusion (p=0.3). The mean duration of fever after the initiation of therapy was 
      47+/-8 hours in patients treated with high-dose aspirin compared to 34+/-5 hours 
      in patients treated with low-dose aspirin (p=0.13). These preliminary results 
      indicate there is no benefit to high-dose aspirin compared to low-dose aspirin in 
      the treatment of children with KS.
FAU - Saulsbury, Frank T
AU  - Saulsbury FT
AD  - Division of Immunology and Rheumatology, Department of Pediatrics, University of 
      Virginia Health System, Charlottesville 2908, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Pediatr (Phila)
JT  - Clinical pediatrics
JID - 0372606
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Coronary Artery Disease/*complications
MH  - Coronary Vessel Anomalies/*complications
MH  - Fever
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Infant
MH  - Mucocutaneous Lymph Node Syndrome/*complications/*drug therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
EDAT- 2002/10/31 04:00
MHDA- 2003/01/31 04:00
CRDT- 2002/10/31 04:00
PHST- 2002/10/31 04:00 [pubmed]
PHST- 2003/01/31 04:00 [medline]
PHST- 2002/10/31 04:00 [entrez]
AID - 10.1177/000992280204100807 [doi]
PST - ppublish
SO  - Clin Pediatr (Phila). 2002 Oct;41(8):597-601. doi: 10.1177/000992280204100807.

PMID- 25676828
OWN - NLM
STAT- MEDLINE
DCOM- 20150921
LR  - 20181113
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Linking)
VI  - 17
IP  - 3
DP  - 2015 Mar
TI  - Preventing cardiovascular disease in patients with diabetes: use of aspirin for 
      primary prevention.
PG  - 566
LID - 10.1007/s11886-015-0566-z [doi]
AB  - Diabetics are at high risk for atherosclerotic cardiovascular disease (ASCVD) and 
      are considered a coronary heart disease risk equivalent. The utility of aspirin 
      in primary prevention of ASCVD in diabetic patients has been widely studied and 
      is still debated. Overall, the current evidence suggests a modest benefit for 
      reduction in ASCVD events with the greatest benefit among those with higher 
      baseline risk, but at the cost of increased risk of gastrointestinal bleeding. 
      Diabetic patients at higher risk (with 10-year ASCVD risk >10 %) are generally 
      recommended for aspirin therapy if bleeding risk is felt to be low. A 
      patient-provider discussion is recommended before prescribing aspirin therapy. 
      Novel markers such as coronary artery calcium scores and high-sensitivity 
      C-reactive protein may help refine ASCVD risk prediction and guide utility for 
      aspirin therapy. This article will review the literature for the most up-to-date 
      studies evaluating aspirin therapy for primary prevention of ASCVD in patients 
      with diabetes.
FAU - Desai, Dhaval
AU  - Desai D
AD  - Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, 21287, USA.
FAU - Ahmed, Haitham M
AU  - Ahmed HM
FAU - Michos, Erin D
AU  - Michos ED
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetic Angiopathies/*prevention & control
MH  - Evidence-Based Medicine/methods
MH  - Humans
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
EDAT- 2015/02/14 06:00
MHDA- 2015/09/22 06:00
CRDT- 2015/02/14 06:00
PHST- 2015/02/14 06:00 [entrez]
PHST- 2015/02/14 06:00 [pubmed]
PHST- 2015/09/22 06:00 [medline]
AID - 10.1007/s11886-015-0566-z [doi]
PST - ppublish
SO  - Curr Cardiol Rep. 2015 Mar;17(3):566. doi: 10.1007/s11886-015-0566-z.

PMID- 35485070
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20220502
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 122
IP  - 4
DP  - 2022
TI  - [COMPASS study results as a foundation for new treatment approach for 
      neurological patients. Opinion of the expert council of december 18, 2021].
PG  - 94-99
LID - 10.17116/jnevro202212204194 [doi]
AB  - The resolution of the Council of Experts devoted to the discussion of the 
      effectiveness of the use of a combination of rivaroxaban 2.5 mg 2 times a day and 
      acetylsalicylic acid 100 mg per day to prevent recurrent non-coronary ischemic 
      stroke results of the COMPASS study is presented. The advantages of this 
      combination and the safety of its use are considered. Recommendations for the 
      implementation of the results of the study in clinical practice are given.
FAU - Arutyunov, G P
AU  - Arutyunov GP
AUID- ORCID: 0000-0002-6645-2515
AD  - Pirogov Russian National Research Medical University, Moscow, Russia.
FAU - Amelin, A V
AU  - Amelin AV
AUID- ORCID: 0000-0001-6437-232X
AD  - Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia.
FAU - Voznyuk, I A
AU  - Voznyuk IA
AUID- ORCID: 0000-0002-0340-4110
AD  - Janelidze Scientific Research Institute of Ambulance, St. Petersburg, Russia.
FAU - Kulesh, A A
AU  - Kulesh AA
AUID- ORCID: 0000-0001-6061-8118
AD  - Wagner State Medical University, Perm, Russia.
FAU - Maximova, M Y
AU  - Maximova MY
AUID- ORCID: 0000-0002-7682-6672
AD  - Research Center of Neurology, Moscow, Russia.
FAU - Mkrtchyan, V R
AU  - Mkrtchyan VR
AUID- ORCID: 0000-0001-5289-2205
AD  - Scientific and Practical Psychoneurological Center n. a. Z.P. Solovyov, Moscow, 
      Russia.
FAU - Putilina, M V
AU  - Putilina MV
AUID- ORCID: 0000-0002-8655-8501
AD  - Pirogov Russian National Research Medical University, Moscow, Russia.
FAU - Sorokoumov, V A
AU  - Sorokoumov VA
AUID- ORCID: 0000-0001-7527-1882
AD  - Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia.
FAU - Fonyakin, A V
AU  - Fonyakin AV
AUID- ORCID: 0000-0001-5452-2152
AD  - Research Center of Neurology, Moscow, Russia.
FAU - Khasanova, D R
AU  - Khasanova DR
AUID- ORCID: 0000-0002-8825-2346
AD  - Kazan State Medical University, Kazan, Russia.
LA  - rus
PT  - Journal Article
TT  - Znachenie rezul'tatov issledovaniya COMPASS v izmenenii podkhodov k lecheniyu 
      patsientov nevrologicheskogo profilya. Zaklyuchenie soveta ekspertov ot 18 
      dekabrya 2021 g.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Rivaroxaban/therapeutic use
MH  - *Stroke/therapy
OTO - NOTNLM
OT  - COMPASS study
OT  - acetylsalicylic acid
OT  - atherothrombosis
OT  - ischemic stroke
OT  - prevention
OT  - rivaroxaban
EDAT- 2022/04/30 06:00
MHDA- 2022/05/03 06:00
CRDT- 2022/04/29 04:07
PHST- 2022/04/29 04:07 [entrez]
PHST- 2022/04/30 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
AID - 10.17116/jnevro202212204194 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(4):94-99. doi: 
      10.17116/jnevro202212204194.

PMID- 22560621
OWN - NLM
STAT- MEDLINE
DCOM- 20121011
LR  - 20131121
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 34
IP  - 6
DP  - 2012 Jun
TI  - Cost-effectiveness model of use of genetic testing as an aid in assessing the 
      likely benefit of aspirin therapy for primary prevention of cardiovascular 
      disease.
PG  - 1387-94
LID - 10.1016/j.clinthera.2012.04.004 [doi]
AB  - BACKGROUND: Aspirin use for the primary prevention of cardiovascular disease 
      (CVD) is controversial because of the need to balance the risk of major bleeding 
      events caused by aspirin with the benefit of CVD events prevented by aspirin. The 
      United States Preventive Services Task Force (USPSTF) proposed guidelines that 
      use CVD risk thresholds, based on the Framingham Risk Score, to identify patients 
      likely to benefit from aspirin use. Genetic information could be used to modify 
      this CVD risk assessment; for example, 2 variants of the LPA gene, which encodes 
      apolipoprotein(a), are associated with increased risk of CVD. OBJECTIVES: To 
      estimate the incremental cost-effectiveness of using genetic test results for 2 
      LPA variants to derive modified Framingham Risk Score estimates and to use these 
      estimates to identify patients likely to benefit from aspirin use according to 
      USPSTF guidelines for aspirin use in the primary prevention of CVD. METHODS: A 
      cost-effectiveness model of 1 million patients representative of the US 
      population was developed based on the association of 2 LPA variants (rs3798220 
      and rs10455872) with CVD. The cost of testing was estimated for patients whose 
      10-year CVD risk would exceed the USPSTF treatment threshold if they were to test 
      positive for the LPA variants. Patient utility estimates for myocardial 
      infarction and stroke, and cost estimates (using a 3.5% annual discount rate) for 
      myocardial infarction, stroke, and gastrointestinal bleeding events were based on 
      published estimates. RESULTS: Recommending aspirin to patients whose CVD risk 
      surpassed the risk threshold when LPA information was included in their risk 
      assessment would prevent an estimated 65 CVD events over 10 years. At a genetic 
      test cost of $150, the incremental cost-utility of testing for LPA variants is 
      estimated at $24,942 per quality-adjusted life-year. CONCLUSIONS: LPA genotyping 
      in the context of the aspirin use guidelines for primary prevention of CVD could 
      be cost-effective.
CI  - Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.
FAU - Shiffman, Dov
AU  - Shiffman D
AD  - Celera Corp., Alameda, California, USA.
FAU - Slawsky, Katherine
AU  - Slawsky K
FAU - Fusfeld, Lauren
AU  - Fusfeld L
FAU - Devlin, James J
AU  - Devlin JJ
FAU - Goss, Thomas F
AU  - Goss TF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120505
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - *Cost-Benefit Analysis
MH  - Female
MH  - Genetic Testing/*economics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Primary Prevention
EDAT- 2012/05/09 06:00
MHDA- 2012/10/12 06:00
CRDT- 2012/05/08 06:00
PHST- 2012/02/02 00:00 [received]
PHST- 2012/03/19 00:00 [revised]
PHST- 2012/04/06 00:00 [accepted]
PHST- 2012/05/08 06:00 [entrez]
PHST- 2012/05/09 06:00 [pubmed]
PHST- 2012/10/12 06:00 [medline]
AID - S0149-2918(12)00246-9 [pii]
AID - 10.1016/j.clinthera.2012.04.004 [doi]
PST - ppublish
SO  - Clin Ther. 2012 Jun;34(6):1387-94. doi: 10.1016/j.clinthera.2012.04.004. Epub 
      2012 May 5.

PMID- 15596642
OWN - NLM
STAT- MEDLINE
DCOM- 20050121
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 164
IP  - 22
DP  - 2004 Dec 13-27
TI  - Aspirin use among adults with diabetes: recent trends and emerging sex 
      disparities.
PG  - 2492-9
AB  - BACKGROUND: Despite high cardiovascular risk among adults with diabetes mellitus, 
      aspirin use has been low. METHODS: To assess recent self-reported regular aspirin 
      use among adults 35 years or older with diabetes, we used statewide telephone 
      surveys conducted in 7 states in 1997 and 20 states in 1999 and 2001 including 
      875, 3205, and 4272 subjects in 1997, 1999, and 2001, respectively. RESULTS: 
      Aspirin use increased from 37.5% in 1997 to 48.7% in 2001. In 2001, 74.2% (95% 
      confidence interval [CI], 70.9%-77.5%) of diabetic adults with cardiovascular 
      disease, but only 37.9% (95% CI, 35.1%-40.7%) of those without cardiovascular 
      disease, used aspirin regularly, including less than 40% with diagnosed 
      hypertension or hypercholesterolemia or who smoked. After adjusting for cardiac 
      risk factors and socioeconomic characteristics, among those without 
      cardiovascular disease, aspirin use was less common in women aged 35 to 49 years 
      (adjusted rate ratio [RR], 0.35; 95% CI, 0.24-0.51) and 50 to 64 years (RR, 0.69; 
      95% CI, 0.53-0.88) and in men aged 35 to 49 years (RR, 0.62; 95% CI, 0.43-0.85) 
      compared with men 65 years and older. For those with diagnosed cardiovascular 
      disease, aspirin use was lower among women (RR, 0.81 compared with men; 95% CI, 
      0.70-0.90) and adults younger than 50 years (RR compared with those >/=65 years, 
      0.81; 95% CI, 0.61-0.98). The disparity in aspirin use between men and women 
      appeared between 1997 and 2001. CONCLUSIONS: Aspirin use among adults with 
      diabetes has increased. However, many high-risk individuals, especially women and 
      those younger than 50 years, do not use this effective and inexpensive therapy.
FAU - Persell, Stephen D
AU  - Persell SD
AD  - Division of General Internal Medicine, Feinberg School of Medicine, Northwestern 
      University, Chicago, Ill, USA. spersell@nmff.org
FAU - Baker, David W
AU  - Baker DW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/complications
MH  - *Diabetes Mellitus
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Sex Factors
MH  - United States
EDAT- 2004/12/15 09:00
MHDA- 2005/01/22 09:00
CRDT- 2004/12/15 09:00
PHST- 2004/12/15 09:00 [pubmed]
PHST- 2005/01/22 09:00 [medline]
PHST- 2004/12/15 09:00 [entrez]
AID - 164/22/2492 [pii]
AID - 10.1001/archinte.164.22.2492 [doi]
PST - ppublish
SO  - Arch Intern Med. 2004 Dec 13-27;164(22):2492-9. doi: 
      10.1001/archinte.164.22.2492.

PMID- 12376516
OWN - NLM
STAT- MEDLINE
DCOM- 20021224
LR  - 20131121
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 11
IP  - 10 Pt 1
DP  - 2002 Oct
TI  - Aspirin use in relation to risk of prostate cancer.
PG  - 1108-11
AB  - Experimental studies have shown inhibitory effects of nonsteroidal 
      anti-inflammatory drugs on prostate cancer cell proliferation and reduction of 
      prostate cancer metastasis, suggesting their possible preventive role for 
      prostate cancer. We examined the association between regular aspirin use and the 
      risk of prostate cancer among participants in the Health Professionals Follow-up 
      Study, a prospective cohort of 47,882 United States men who were 40-75 years of 
      age and without a history of prostate cancer in 1986. Biennial self-administered 
      questionnaires were used to assess regular aspirin use from 1986 to 1996. We 
      confirmed and staged incident cases of prostate cancer according to medical 
      records and pathology reports. During 518,072 person-years of follow-up, 2,479 
      new cases of prostate cancer were ascertained. Of these, 608 were diagnosed as 
      advanced (extraprostatic) prostate cancer and 258 as metastatic prostate cancer. 
      We found no association between aspirin use and total prostate cancer. After 
      accounting for prostate-specific antigen examinations and other potentially 
      confounding variables, the relative risk of total prostate cancer for aspirin 
      users compared with nonusers was 1.05 (95% confidence interval, 0.96-1.14). For 
      metastatic prostate cancer, we observed a suggestive decrease in risk among men 
      reporting greater frequency of aspirin use. The multivariate relative risk of 
      metastatic prostate cancer among men using aspirin 22 or more days/month was 0.73 
      (95% confidence interval, 0.39-1.38) compared with nonusers. We noted no evidence 
      of a linear dose-response relationship (P for trend = 0.40). The results from 
      this cohort indicate that regular aspirin use is not likely to prevent the 
      incidence of total prostate cancer, but we cannot exclude a possible benefit of 
      frequent aspirin use on risk of developing metastatic prostate cancer.
FAU - Leitzmann, Michael F
AU  - Leitzmann MF
AD  - Department of Epidemiology, Harvard School of Public Health, Boston, 
      Massachusetts 02115, USA. michael.leitzmann@channing.harvard.edu
FAU - Stampfer, Meir J
AU  - Stampfer MJ
FAU - Ma, Jing
AU  - Ma J
FAU - Chan, June M
AU  - Chan JM
FAU - Colditz, Graham A
AU  - Colditz GA
FAU - Willett, Walter C
AU  - Willett WC
FAU - Giovannucci, Edward
AU  - Giovannucci E
LA  - eng
GR  - 5T32 CA09001-26/CA/NCI NIH HHS/United States
GR  - CA55075/CA/NCI NIH HHS/United States
GR  - HL35464/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Neoplasm Metastasis
MH  - Prostatic Neoplasms/epidemiology/pathology/*prevention & control
MH  - Risk Factors
EDAT- 2002/10/12 04:00
MHDA- 2002/12/27 04:00
CRDT- 2002/10/12 04:00
PHST- 2002/10/12 04:00 [pubmed]
PHST- 2002/12/27 04:00 [medline]
PHST- 2002/10/12 04:00 [entrez]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1108-11.

PMID- 32437818
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 1096-0295 (Electronic)
IS  - 0273-2300 (Linking)
VI  - 114
DP  - 2020 Jul
TI  - An interim internal Threshold of Toxicologic Concern (iTTC) for chemicals in 
      consumer products, with support from an automated assessment of ToxCast™ dose 
      response data.
PG  - 104656
LID - S0273-2300(20)30082-9 [pii]
LID - 10.1016/j.yrtph.2020.104656 [doi]
AB  - Additional non-animal methods are urgently needed to meet regulatory and animal 
      welfare goals. TTC is a broadly used risk assessment tool. TTC based on external 
      dose has limited utility for multi-route exposure and some types of structure 
      activity relationship assessments. An internal TTC (iTTC), where thresholds are 
      based on blood concentration, would extend the applicability of TTC. While work 
      is on-going to develop robust iTTC thresholds, we propose an interim conservative 
      iTTC. Specifically, an interim iTTC of 1 μM, supported by the published 
      experience of the pharmaceutical industry, a literature review of non-drug 
      chemical/receptor interactions, and analysis of ToxCast™ data. ToxCast™ data were 
      used to explore activity versus the 1 μM interim iTTC and recommendations for the 
      analysis and interpretation of HTS data. Test concentration-based points of 
      departure were classified to identify quality of fit to the Hill Model. We 
      identified, for exclusion from the approach, estrogen receptor and androgen 
      receptor targets as potent chemical/receptor interactions potentially associated 
      with low dose exposure to non-pharmaceutical active ingredients in addition to 
      the original TTC exclusions. With these exclusions, we conclude that a 1 μM 
      plasma concentration is unlikely to be associated with significant biological 
      effects from chemicals not intentionally designed for biological activity.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Blackburn, Karen L
AU  - Blackburn KL
AD  - The Procter & Gamble Company, Mason Business Center, 8700 Mason Montgomery Road, 
      Cincinnati, OH, 45040, United States.
FAU - Carr, Gregory
AU  - Carr G
AD  - The Procter & Gamble Company, Mason Business Center, 8700 Mason Montgomery Road, 
      Cincinnati, OH, 45040, United States.
FAU - Rose, Jane L
AU  - Rose JL
AD  - The Procter & Gamble Company, Mason Business Center, 8700 Mason Montgomery Road, 
      Cincinnati, OH, 45040, United States. Electronic address: rose.jl@pg.com.
FAU - Selman, Bastian G
AU  - Selman BG
AD  - The Procter & Gamble Company, Mason Business Center, 8700 Mason Montgomery Road, 
      Cincinnati, OH, 45040, United States.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - Netherlands
TA  - Regul Toxicol Pharmacol
JT  - Regulatory toxicology and pharmacology : RTP
JID - 8214983
RN  - 0 (Receptors, Androgen)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - Q40Q9N063P (Acetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetic Acid/*adverse effects/chemistry/metabolism
MH  - Animals
MH  - Aspirin/*adverse effects/chemistry/metabolism
MH  - *Automation
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Molecular Structure
MH  - No-Observed-Adverse-Effect Level
MH  - Receptors, Androgen/chemistry/*metabolism
MH  - Risk Assessment
MH  - Salicylic Acid/*adverse effects/chemistry/metabolism
MH  - Structure-Activity Relationship
OTO - NOTNLM
OT  - High throughput screening data analysis
OT  - Risk assessment
OT  - SAR
OT  - Structure activity relationships
OT  - TTC
OT  - Threshold of toxicological concern
OT  - ToxCast
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/05/22 06:00
MHDA- 2021/02/24 06:00
CRDT- 2020/05/22 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2020/03/04 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - S0273-2300(20)30082-9 [pii]
AID - 10.1016/j.yrtph.2020.104656 [doi]
PST - ppublish
SO  - Regul Toxicol Pharmacol. 2020 Jul;114:104656. doi: 10.1016/j.yrtph.2020.104656. 
      Epub 2020 May 11.

PMID- 2080923
OWN - NLM
STAT- MEDLINE
DCOM- 19910426
LR  - 20131121
IS  - 0158-5231 (Print)
IS  - 0158-5231 (Linking)
VI  - 21
IP  - 6
DP  - 1990 Sep
TI  - Effect of aspirin on the pressor activity of endothelin.
PG  - 1153-60
AB  - To examine the inhibition of prostaglandins to the pressor activity of 
      endothelin, hemodynamic changes of dogs pretreated with aspirin in response to 
      endothelin were compared with those of control. In control dogs, endothelin rose 
      blood pressure due to vasoconstriction, with a transient vasodilation in some 
      dogs in the initial phase. In dogs treated with aspirin, the initial vasodilation 
      and the subsequent vasoconstriction were also noted, but the zenith of the total 
      peripheral resistance was observed earlier, compared with control dogs. Thus, 
      prostaglandins do not appear to have a role in the initial vasodilatory action of 
      endothelin, but may modify the long lasting vasoconstriction in the late phase.
FAU - Otsuka, A
AU  - Otsuka A
AD  - Department of Geriatric Medicine, Osaka University Medical School, Japan.
FAU - Mikami, H
AU  - Mikami H
FAU - Tsunetoshi, T
AU  - Tsunetoshi T
FAU - Katahira, K
AU  - Katahira K
FAU - Kohara, K
AU  - Kohara K
FAU - Moriguchi, A
AU  - Moriguchi A
FAU - Nakamura, F
AU  - Nakamura F
FAU - Ogihara, T
AU  - Ogihara T
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Biochem Int
JT  - Biochemistry international
JID - 8100311
RN  - 0 (Endothelins)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Dogs
MH  - Drug Interactions
MH  - Endothelins/*pharmacology
MH  - Female
MH  - Male
MH  - Prostaglandins/physiology
MH  - Vascular Resistance/drug effects
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
PST - ppublish
SO  - Biochem Int. 1990 Sep;21(6):1153-60.

PMID- 9748494
OWN - NLM
STAT- MEDLINE
DCOM- 19981113
LR  - 20190610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1387
IP  - 1-2
DP  - 1998 Sep 8
TI  - Butyrylcholinesterase-catalysed hydrolysis of aspirin, a negatively charged 
      ester, and aspirin-related neutral esters.
PG  - 41-52
AB  - Although aspirin (acetylsalicylic acid) is negatively charged, it is hydrolysed 
      by butyrylcholinesterase (BuChE). Catalytic parameters were determined in 100 mM 
      Tris buffer, pH 7.4, in the presence and absence of metal cations. The presence 
      of Ca2+ or Mg2+ (<100 mM) in buffer did not change the Km, but accelerated the 
      rate of hydrolysis of aspirin by wild-type or D70G mutant BuChE by 5-fold. 
      Turnover numbers were of the order of 5000-12000 min-1 for the wild-type enzyme 
      and the D70G and D70K enzymes in 100 mM Tris, pH 7.4, containing 50 mM CaCl2 at 
      25 degreesC; Km values were 6 mM for wild-type, 16 mM for D70G and 38 mM for 
      D70K. People with 'atypical' BuChE have the D70G mutation. The apparent 
      inhibition seen at high aspirin concentration was not due to inhibition by excess 
      substrate but to spontaneous hydrolysis of aspirin, causing inhibition by 
      salicylate. The wild-type and D70G enzymes were competitively inhibited by 
      salicylic acid; the D70K enzyme showed a complex parabolic inhibition, suggesting 
      multiple binding. The effect of salicylate was substrate-dependent, the D70K 
      mutant being activated by salicylate with butyrylthiocholine as substrate. Km 
      value for wild-type enzyme was lower than for D70 mutants, suggesting that 
      residue 70 located at the rim of the active site gorge was not the major site for 
      the initial encounter aspirin-BuChE complex. On the other hand, the virtual 
      absence of affinity of the W82A mutant for aspirin indicated that W82 was the 
      major residue involved in formation of the Michaelis complex. Molecular modelling 
      of aspirin binding to BuChE indicated perpendicular interactions between the 
      aromatic rings of W82 and aspirin. Kinetic study of BuChE-catalysed hydrolysis of 
      different acetyl esters showed that the rate limiting step was acetylation. The 
      bimolecular rate constants for hydrolysis of aspirin by wild-type, D70G and D70K 
      enzymes were found to be close to 1x106 M-1 min-1. These results support the 
      contention that the electrostatic steering due to the negative electrostatic 
      field of the enzyme plays a role in substrate binding, but plays no role in the 
      catalytic steps, i.e. in the enzyme acetylation.
FAU - Masson, P
AU  - Masson P
AD  - Centre de Recherches du Service de Santé des Armées, Unité d'Enzymologie, 24 av. 
      des Maquis du Grésivaudan, B.P. 87, 38702 La Tronche Cedex, France.
FAU - Froment, M T
AU  - Froment MT
FAU - Fortier, P L
AU  - Fortier PL
FAU - Visicchio, J E
AU  - Visicchio JE
FAU - Bartels, C F
AU  - Bartels CF
FAU - Lockridge, O
AU  - Lockridge O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Esters)
RN  - 0 (Salicylates)
RN  - EC 3.1.1.8 (Butyrylcholinesterase)
RN  - I38ZP9992A (Magnesium)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Acetylation
MH  - Aspirin/analogs & derivatives/*metabolism
MH  - Binding Sites/physiology
MH  - Butyrylcholinesterase/genetics/*metabolism
MH  - Calcium/pharmacology
MH  - Enzyme Inhibitors/pharmacology
MH  - Esters/chemistry
MH  - Humans
MH  - Hydrolysis
MH  - Kinetics
MH  - Magnesium/pharmacology
MH  - Models, Molecular
MH  - Molecular Structure
MH  - Mutagenesis, Site-Directed/genetics
MH  - Salicylates/pharmacology
MH  - Static Electricity
EDAT- 1998/09/28 00:00
MHDA- 1998/09/28 00:01
CRDT- 1998/09/28 00:00
PHST- 1998/09/28 00:00 [pubmed]
PHST- 1998/09/28 00:01 [medline]
PHST- 1998/09/28 00:00 [entrez]
AID - S0167-4838(98)00104-6 [pii]
AID - 10.1016/s0167-4838(98)00104-6 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 1998 Sep 8;1387(1-2):41-52. doi: 
      10.1016/s0167-4838(98)00104-6.

PMID- 8509313
OWN - NLM
STAT- MEDLINE
DCOM- 19930715
LR  - 20190821
IS  - 0378-5955 (Print)
IS  - 0378-5955 (Linking)
VI  - 66
IP  - 2
DP  - 1993 Apr
TI  - Effects of aspirin on human auditory filters.
PG  - 233-44
AB  - Auditory filter shapes were measured in eight male volunteers with normal 
      hearing, using a notched-noise forward-masking paradigm and a signal frequency of 
      4 kHz. The measurements were made under three conditions: after listeners had 
      taken eight doses of three 320 mg aspirin tablets every six hours; after an 
      identical schedule of placebo ingestion; and one week after testing in the first 
      two conditions had been completed. Half of the listeners did the placebo 
      condition first, and half did the aspirin condition first. Aspirin and placebo 
      were administered double-blind, and testing took place approximately one hour 
      after the last dose. Filter shapes were significantly broader in the aspirin 
      condition than in the placebo and post-test conditions, indicating that even a 
      modest dose affects auditory frequency selectivity. Two-point measures of growth 
      of masking did not differ significantly between conditions.
FAU - Carlyon, R P
AU  - Carlyon RP
AD  - Laboratory of Experimental Psychology, University of Sussex, Brighton, UK.
FAU - Butt, M
AU  - Butt M
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Hear Res
JT  - Hearing research
JID - 7900445
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acoustic Stimulation
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Audiometry
MH  - Auditory Cortex/drug effects
MH  - Auditory Threshold/*drug effects
MH  - Double-Blind Method
MH  - Humans
MH  - Male
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
AID - 0378-5955(93)90143-O [pii]
AID - 10.1016/0378-5955(93)90143-o [doi]
PST - ppublish
SO  - Hear Res. 1993 Apr;66(2):233-44. doi: 10.1016/0378-5955(93)90143-o.

PMID- 8504628
OWN - NLM
STAT- MEDLINE
DCOM- 19930708
LR  - 20190821
IS  - 0143-5221 (Print)
IS  - 0143-5221 (Linking)
VI  - 84
IP  - 5
DP  - 1993 May
TI  - Rapid and selective inhibition of platelet aggregation and thromboxane formation 
      by intravenous low dose aspirin in man.
PG  - 517-24
AB  - 1. One of the major problems in the clinical use of low dose aspirin for the 
      prevention of vascular occlusion is that it takes about 3-5 days to become 
      effective, a time too long for patients with unstable angina or coronary 
      thrombolysis. Intravenous aspirin may be expected to exert a more rapid effect, 
      but its influence on endothelial prostacyclin synthesis is uncertain. 2. In a 
      single-blind, randomized, prospective study, we compared the effects of a single 
      intravenous low dose (50 mg) or high dose (500 mg) of aspirin or placebo infused 
      over a 60 min period on platelet aggregation, platelet thromboxane A2 production 
      and whole-body prostanoid synthesis in 10 healthy male subjects by gas 
      chromatography-tandem mass spectrometry. 3. Before the study, blood flow rates in 
      the basilic and subclavian veins were determined by sonographic colour velocity 
      imaging; the infusion rate for low dose aspirin was calculated to avoid 
      biologically effective plasma levels of aspirin in the systemic circulation. 4. 
      Platelet aggregation induced by 1 mmol/l arachidonic acid was similarly inhibited 
      by > 85% within 30 min after the start of the infusion of high dose or low dose 
      aspirin, respectively, and remained suppressed for 24 h. Platelet thromboxane A2 
      release declined gradually after low dose aspirin, reaching a minimum of 93% 
      inhibition after 60 min. High dose aspirin suppressed platelet thromboxane A2 
      release to below the detection limit after 10 min. 5. Urinary excretion of the 
      major urinary metabolite of thromboxane A2 (2,3-dinor-thromboxane B2) was equally 
      suppressed by both dosages of aspirin [no significant difference between high 
      dose (-83.2%) and low dose (-67.4%)].(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Böger, R H
AU  - Böger RH
AD  - Institute of Clinical Pharmacology, Hannover Medical School, F.R.G.
FAU - Bode-Böger, S M
AU  - Bode-Böger SM
FAU - Gutzki, F M
AU  - Gutzki FM
FAU - Tsikas, D
AU  - Tsikas D
FAU - Weskott, H P
AU  - Weskott HP
FAU - Frölich, J C
AU  - Frölich JC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prostaglandins)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Drug Administration Schedule
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Prospective Studies
MH  - Prostaglandins/urine
MH  - Single-Blind Method
MH  - Thromboxane A2/*biosynthesis
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
AID - 10.1042/cs0840517 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 1993 May;84(5):517-24. doi: 10.1042/cs0840517.

PMID- 3126155
OWN - NLM
STAT- MEDLINE
DCOM- 19880418
LR  - 20161123
IS  - 0251-1649 (Print)
IS  - 0251-1649 (Linking)
VI  - 7
IP  - 6
DP  - 1987
TI  - Clinical trial with muzolimine in healthy and hypertensive subjects: new vistas 
      on the drug action.
PG  - 455-61
AB  - The mechanism of muzolimine (3-amino-1-[3,4-dichloro-alpha-methyl-benzyl]-2 
      pyrazolin-5-one) action is still not completely defined. The identified site of 
      action is the Henle loop, similarly to furosemide which acts also by mediating 
      renal prostaglandin synthesis. The aim of the present study was to evaluate the 
      early effects of muzolimine (30 mg per os) on renal function and prostaglandin 
      urinary excretion in healthy controls and hypertensive subjects. Urinary flow 
      reached the peak values by the third hour after the drug and a diuretic effect 
      not directly dependent on glomerular filtration was observed, especially in 
      hypertensive patients. In these cases the diuresis increased also due to a low 
      glomerular filtration rate and tubular phenomena were more evident than in 
      controls: an increasing Na+ tubular excretion and a parallel decreasing % Na+ 
      reabsorption. Blood pressure was not significantly influenced by muzolimine in 
      healthy subjects, while it returned to normal values in the hypertensive group. A 
      cyclooxigenase inhibitor, lysine acetylsalicylate (1 g i.m.) administered 10 
      minutes after muzolimine, was not able to modify the parameters under 
      consideration. Therefore a mediation by prostaglandins on the diuretic and 
      antihypertensive effects of the drug under study may probably be excluded.
FAU - Bernardi, P
AU  - Bernardi P
AD  - Medical Clinic II, S. Orsola Hospital, Bologna, Italy.
FAU - Bastagli, L
AU  - Bastagli L
FAU - Cavazza, M
AU  - Cavazza M
FAU - Minelli, C
AU  - Minelli C
FAU - Ventura, C
AU  - Ventura C
FAU - Fontana, F
AU  - Fontana F
FAU - Danieli, A
AU  - Danieli A
FAU - Bartolini, G
AU  - Bartolini G
FAU - Tommasi, V
AU  - Tommasi V
FAU - Orlandi, M
AU  - Orlandi M
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int J Clin Pharmacol Res
JT  - International journal of clinical pharmacology research
JID - 8110183
RN  - 0 (Prostaglandins E)
RN  - 0 (Pyrazoles)
RN  - 07Z36289ZX (Muzolimine)
RN  - K3Z4F929H6 (Lysine)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aged
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Dinoprostone
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypertension/drug therapy/*metabolism
MH  - Lysine/analogs & derivatives/therapeutic use
MH  - Middle Aged
MH  - Muzolimine/*pharmacology/therapeutic use
MH  - Prostaglandins E/urine
MH  - Pyrazoles/*pharmacology
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Res. 1987;7(6):455-61.

PMID- 364364
OWN - NLM
STAT- MEDLINE
DCOM- 19790212
LR  - 20131121
IS  - 0147-7447 (Print)
IS  - 0147-7447 (Linking)
VI  - 1
IP  - 1
DP  - 1978 Jan-Feb
TI  - ASA-dipyridamole prophylaxis in elective total hip replacement.
PG  - 19-25
AB  - A prospective, double-blind clinical study was performed to evaluate the 
      combination of dipyridamole 225 mg/day and acetylsalicylic acid 1 gm/day 
      prophylaxis of postoperative venous thromboembolism in elective total hip 
      replacement. Patients were stratified according to age, and randomly assigned to 
      receive drug or placebo. All patients were followed with 125I-labeled fibrinogen 
      scanning for one week postoperatively, or until fully mobile. Venography was 
      performed in 79/132 patients; in 36 patients the venogram was obtained to confirm 
      a positive fibrinogen scan, in 43 patients an elective venogram was obtained on 
      the seventh postoperative day to evaluate the operated thigh (a blind area for 
      scanning). Thrombosis (by scan or venogram) was found in 17/68 (25%) in the 
      control group, and in 23/64 (36%) in the treated group. Overall incidence was 
      40/132 (30%). Correlation of scan with venography was 90%. There were no 
      clinically significant pulmonary emboli in either group. The combination of 
      acetylsalicylic acid (ASA) and dipyridamole as given in this study is not 
      effective prophylaxis in elective total hip replacement.
FAU - Silvergleid, A J
AU  - Silvergleid AJ
FAU - Bernstein, R
AU  - Bernstein R
FAU - Burton, D S
AU  - Burton DS
FAU - Tanner, J B
AU  - Tanner JB
FAU - Silverman, J F
AU  - Silverman JF
FAU - Schrier, S L
AU  - Schrier SL
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Orthopedics
JT  - Orthopedics
JID - 7806107
RN  - 0 (Placebos)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyridamole/*administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Hip Joint/*surgery
MH  - Humans
MH  - *Joint Prosthesis
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Postoperative Complications/etiology/*prevention & control
MH  - Thrombophlebitis/etiology/*prevention & control
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
PST - ppublish
SO  - Orthopedics. 1978 Jan-Feb;1(1):19-25.

PMID- 12403959
OWN - NLM
STAT- MEDLINE
DCOM- 20030103
LR  - 20171101
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 14
IP  - 3-4
DP  - 2002
TI  - Effect of increasing doses of aspirin on platelet aggregation among stroke 
      patients.
PG  - 252-5
AB  - BACKGROUND AND PURPOSE: Aspirin has been shown to reduce the risk of myocardial 
      infarction and stroke. Some investigators believe that low-dose aspirin inhibits 
      platelet aggregation to the same degree as high-dose aspirin. Our study aimed to 
      assess the effect of increasing doses of aspirin on the degree of platelet 
      aggregation induced by collagen and adenosine diphosphate (ADP) among stroke 
      patients. METHODS: Sixteen poststroke patients were prescribed aspirin at daily 
      doses of 40, 80, 160, 325, 650, and 1,300 mg, each dose to be taken for 14 days 
      (total duration 12 weeks). Platelet aggregation studies using 2 microgram/ml 
      collagen and 2 microM ADP were performed on platelet-rich plasma at baseline and 
      on the 14th day of each dose. RESULTS: Platelet aggregation studies using 2 
      microgram/ml collagen at the start of treatment and at the 14th day of each dose 
      revealed dose-dependent inhibition by aspirin starting at 40 mg/day, but was 
      optimal at 80- 160 mg/day. ADP-induced platelet aggregation inhibition appears to 
      be dose dependent up to 1,300 mg/day. CONCLUSION: Inhibition of collagen-induced 
      platelet aggregation by aspirin appears to be optimal at 80-160 mg/day, while 
      ADP-induced platelet aggregation inhibition by aspirin appears to be dose 
      dependent up to 1,300 mg/day in our poststroke patients, albeit to a less 
      remarkable degree at higher doses.
CI  - Copyright 2002 S. Karger AG, Basel
FAU - Gan, Robert
AU  - Gan R
AD  - Department of Neurosciences, College of Medicine and Philippine General Hospital, 
      University of the Philippines, Manila, Philippines. rgan@info.com.ph
FAU - Teleg, Rosalia A
AU  - Teleg RA
FAU - Florento, Leila
AU  - Florento L
FAU - Bitanga, Ester S
AU  - Bitanga ES
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Collagen/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Stroke/*blood/*drug therapy
EDAT- 2002/10/31 04:00
MHDA- 2003/01/07 04:00
CRDT- 2002/10/31 04:00
PHST- 2002/10/31 04:00 [pubmed]
PHST- 2003/01/07 04:00 [medline]
PHST- 2002/10/31 04:00 [entrez]
AID - 65685 [pii]
AID - 10.1159/000065685 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2002;14(3-4):252-5. doi: 10.1159/000065685.

PMID- 36302984
OWN - NLM
STAT- MEDLINE
DCOM- 20230818
LR  - 20230821
IS  - 1432-0711 (Electronic)
IS  - 0932-0067 (Linking)
VI  - 308
IP  - 4
DP  - 2023 Oct
TI  - Relationship between risk factor profile and prescription of low-dose aspirin for 
      preeclampsia prevention.
PG  - 1279-1286
LID - 10.1007/s00404-022-06773-0 [doi]
AB  - OBJECTIVE: The purpose of this study was to assess obstetrician-gynecologist 
      utilization of low-dose aspirin for women at increased risk for hypertensive 
      disorders of pregnancy using guidelines developed by the American College of 
      Obstetricians and Gynecologists and supported by the United States Preventive 
      Services Task Force. Further, the study evaluated prescribing practices in 
      relation to specific risk factor profiles to identify which women are at highest 
      risk of not receiving recommended therapy. METHODS: This was a retrospective 
      cohort study reviewed and approved by the local Institutional Review Board. 
      Electronic health records of women with singleton pregnancies who delivered 
      between February and August 2020 were reviewed to identify risk factors for 
      preeclampsia. Women were eligible for aspirin prophylaxis if they had at least 
      one "high" risk factor or multiple "moderate" risk factors, as defined by the 
      United States Preventive Services Task Force guidelines. Associations of interest 
      were addressed using Pearson Chi-squared tests and multinomial logistic 
      regression. RESULTS: 970 patients were included and 301 pregnant persons (31%) 
      met criteria for low-dose aspirin prophylaxis; of these, 92 (31%) were given this 
      recommendation. Those eligible for prophylaxis by presence of multiple "moderate" 
      risk factors alone are least likely (0-6%) to receive indicated aspirin 
      prophylaxis. CONCLUSIONS FOR PRACTICE: Low-dose aspirin is an underutilized tool 
      for preventing preeclampsia. Women with a combination of "moderate" risk factors 
      are most likely to not receive indicated aspirin prophylaxis. Efforts should be 
      made to encourage broader uptake of the recommendations for aspirin prophylaxis 
      among obstetrician-gynecologists. SIGNIFICANCE: What is already known on this 
      subject? Low-dose aspirin has been shown to reduce preeclampsia risk in pregnant 
      persons. This preventive measure has been recommended by most national and 
      international organizations including the American College of Obstetricians and 
      Gynecologists and the United States Preventive Services Task Force. Yet despite 
      widespread support of this recommendation, uptake is not universal among 
      obstetric care providers. What this study adds? This study identifies those who 
      are most likely to experience a missed opportunity for aspirin prophylaxis, thus 
      providing a suggestion for where provider education or other efforts to increase 
      adherence to this guideline may be most impactful.
CI  - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Phelps, Alexandra J D
AU  - Phelps AJD
AUID- ORCID: 0000-0002-6560-4249
AD  - Department of Obstetrics and Gynecology, Advocate Lutheran General Hospital, 1775 
      Dempster Street, 4 South, Park Ridge, IL, 60068, USA. ajdouglas731@gmail.com.
FAU - Holmgren, Calla
AU  - Holmgren C
AD  - Department of Obstetrics and Gynecology-Maternal-Fetal Medicine Division, 
      Advocate Lutheran General Hospital, Park Ridge, IL, USA.
LA  - eng
PT  - Journal Article
DEP - 20221027
PL  - Germany
TA  - Arch Gynecol Obstet
JT  - Archives of gynecology and obstetrics
JID - 8710213
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Humans
MH  - Female
MH  - United States
MH  - *Pre-Eclampsia/etiology
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - Aspirin/therapeutic use
MH  - Risk Factors
MH  - Prescriptions
OTO - NOTNLM
OT  - Low-dose aspirin
OT  - Preeclampsia
OT  - Prescriber practices
OT  - Prevention
EDAT- 2022/10/28 06:00
MHDA- 2023/08/18 06:42
CRDT- 2022/10/27 23:51
PHST- 2022/04/15 00:00 [received]
PHST- 2022/08/25 00:00 [accepted]
PHST- 2023/08/18 06:42 [medline]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/27 23:51 [entrez]
AID - 10.1007/s00404-022-06773-0 [pii]
AID - 10.1007/s00404-022-06773-0 [doi]
PST - ppublish
SO  - Arch Gynecol Obstet. 2023 Oct;308(4):1279-1286. doi: 10.1007/s00404-022-06773-0. 
      Epub 2022 Oct 27.

PMID- 25421783
OWN - NLM
STAT- MEDLINE
DCOM- 20150608
LR  - 20181202
IS  - 1573-7284 (Electronic)
IS  - 0393-2990 (Linking)
VI  - 30
IP  - 1
DP  - 2015 Jan
TI  - Prophylactic use of aspirin: systematic review of harms and approaches to 
      mitigation in the general population.
PG  - 5-18
LID - 10.1007/s10654-014-9971-7 [doi]
AB  - A careful assessment of benefits and harms is required to assess suitability of 
      aspirin as a prophylactic public health measure. However, comprehensive 
      population-level data on harms are lacking. We collected and synthesized age and 
      sex-specific data on harms relevant to aspirin use in average-risk individuals 
      aged 50 years or older. We conducted systematic literature searches to identify 
      baseline rates of gastrointestinal (GI) bleeding, peptic ulcer, major 
      extra-cranial bleeding, and case-fatality rates due to GI bleeding or peptic 
      ulcer in general population. The magnitude of aspirin-associated increase, the 
      prevalence and attributable risk of Helicobacter pylori infection on these events 
      in aspirin users was also assessed. Baseline rates of major extracranial bleeding 
      events and GI complications increase with age; an almost threefold to fourfold 
      increase is observed from age 50-54 to 70-74 years. Low or standard-dose aspirin 
      use increases GI bleeding events by 60% leading to an annual excess of 0.45 and 
      0.79 GI bleeding events per 1,000 women and men aged 50-54 years respectively. 
      5-10% of major GI complications are fatal; a clear age dependence--higher 
      fatality in older individuals, is seen. Eradication of H. pylori infection before 
      aspirin use could reduce the incidence of upper GI complications by 25-30%. GI 
      complications are increased by about 60% due to aspirin use but are fatal only in 
      a very small proportion of individuals younger than 70 years of age. Major 
      bleeding events that are comparable in severity to cancer or CVD, are infrequent. 
      Screening and eradication of H. pylori infection could substantially lower 
      aspirin-related GI harms.
FAU - Thorat, Mangesh A
AU  - Thorat MA
AD  - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen 
      Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK, 
      m.thorat@qmul.ac.uk.
FAU - Cuzick, Jack
AU  - Cuzick J
LA  - eng
GR  - British Heart Foundation/United Kingdom
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20141125
PL  - Netherlands
TA  - Eur J Epidemiol
JT  - European journal of epidemiology
JID - 8508062
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced/prevention & control
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Preventive Health Services
EDAT- 2014/11/26 06:00
MHDA- 2015/06/09 06:00
CRDT- 2014/11/26 06:00
PHST- 2014/03/26 00:00 [received]
PHST- 2014/10/30 00:00 [accepted]
PHST- 2014/11/26 06:00 [entrez]
PHST- 2014/11/26 06:00 [pubmed]
PHST- 2015/06/09 06:00 [medline]
AID - 10.1007/s10654-014-9971-7 [doi]
PST - ppublish
SO  - Eur J Epidemiol. 2015 Jan;30(1):5-18. doi: 10.1007/s10654-014-9971-7. Epub 2014 
      Nov 25.

PMID- 26369683
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20220409
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 21
IP  - 35
DP  - 2015
TI  - Aspirin Induced Adverse Effects on the Small and Large Intestine.
PG  - 5089-93
AB  - Aspirin is in many ways a non- steroidal anti-inflammatory drug (NSAID) 
      prototype. Similar to conventional NSAIDs the gastric side effects of aspirin are 
      well studied. However its potential adverse effects on the small and large 
      intestine are less well known and under- researched. Experimental studies support 
      a pathogenic pathway leading to NSAID enteropathy involving the topical effects 
      on the intestinal barrier (mucous layer, enterocytes) that lead to dysfunction 
      and increased intestinal permeability followed by increased exposure to luminal 
      triggers and acute inflammation. Although aspirin has a toxic effect in vitro, 
      enteral or parenteral administration in vivo, in animal models, did not result to 
      intestinal injury. In man, experimental studies have revealed changes in 
      intestinal permeability similar to conventional NSAIDs but of lesser magnitude. 
      The clinical implication of these changes though is not known. Population studies 
      have associated aspirin use with occult gastrointestinal bleeding from the small 
      or large bowel although the magnitude of this risk is difficult to estimate but 
      certainly small. Associations to colitis flare-ups have been made in case reports 
      and retrospective cohort studies but low dose aspirin appears safe. Complications 
      of diverticular disease may also be more frequent with aspirin use.
FAU - Pavlidis, Polychronis
AU  - Pavlidis P
FAU - Bjarnason, Ingvar
AU  - Bjarnason I
AD  - Department of Colorectal Surgery, King's College Hospital, London, SE5 9RS, UK. 
      Ingvar.bjarnason@kcl.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Intestinal Diseases/*chemically induced
MH  - Intestine, Large/drug effects/pathology
MH  - Intestine, Small/drug effects/pathology
MH  - Permeability
MH  - Species Specificity
EDAT- 2015/09/16 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/06/19 00:00 [received]
PHST- 2015/09/14 00:00 [accepted]
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - CPD-EPUB-70384 [pii]
AID - 10.2174/1381612821666150915110058 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2015;21(35):5089-93. doi: 10.2174/1381612821666150915110058.

PMID- 19222632
OWN - NLM
STAT- MEDLINE
DCOM- 20090511
LR  - 20131121
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 63
IP  - 3
DP  - 2009 Mar
TI  - Aspirin in cardiology--benefits and risks.
PG  - 468-77
LID - 10.1111/j.1742-1241.2008.01908.x [doi]
AB  - AIMS: To review the current knowledge of the benefits and risks of long-term 
      aspirin therapy for the prevention of cardiovascular disease. METHODS: Relevant 
      articles published in English between 1996 and 2006 were obtained from the 
      Current Contents Science Edition, EMBASE and MEDLINE databases. RESULTS: 
      Secondary aspirin prophylaxis is effective in reducing the risk of ischaemic 
      events in patients with cardiovascular disease. However, its utility in reducing 
      primary ischaemic events is more controversial; it appears to reduce the 
      incidence of ischaemic stroke, but increase the incidence of haemorrhagic stroke. 
      Aspirin therapy can also lead to an increased risk of gastrointestinal ulcers, 
      upper gastrointestinal bleeding and other haemorrhagic complications. Lower doses 
      of aspirin are associated with a reduced risk of gastrointestinal side effects 
      and are equally effective in reducing cardiovascular risk. Co-therapy with 
      non-steroidal anti-inflammatory drugs, clopidogrel or warfarin increases the risk 
      of gastrointestinal side effects, while co-therapy with proton pump inhibitors 
      reduces it. CONCLUSIONS: Both the benefits and risks need to be considered 
      carefully when prescribing aspirin, particularly in primary prevention. Patients 
      should be prescribed lower doses rather than higher doses of aspirin in line with 
      prescribing guidelines. Co-prescription of a proton pump inhibitors may be 
      necessary in patients at high risk for upper gastrointestinal complications.
FAU - Björklund, L
AU  - Björklund L
AD  - Pharmacy Program, Gothenburg University, Gothenburg, Sweden.
FAU - Wallander, M-A
AU  - Wallander MA
FAU - Johansson, S
AU  - Johansson S
FAU - Lesén, E
AU  - Lesén E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Aspirin/adverse effects/therapeutic use
MH  - Brain Ischemia/*prevention & control
MH  - Cerebral Hemorrhage/*chemically induced
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - *Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Time Factors
RF  - 91
EDAT- 2009/02/19 09:00
MHDA- 2009/05/12 09:00
CRDT- 2009/02/19 09:00
PHST- 2009/02/19 09:00 [entrez]
PHST- 2009/02/19 09:00 [pubmed]
PHST- 2009/05/12 09:00 [medline]
AID - IJCP1908 [pii]
AID - 10.1111/j.1742-1241.2008.01908.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2009 Mar;63(3):468-77. doi: 10.1111/j.1742-1241.2008.01908.x.

PMID- 18709479
OWN - NLM
STAT- MEDLINE
DCOM- 20081216
LR  - 20211020
IS  - 0944-1174 (Print)
IS  - 0944-1174 (Linking)
VI  - 43
IP  - 8
DP  - 2008
TI  - Low-dose aspirin-induced gastrointestinal diseases: past, present, and future.
PG  - 581-8
LID - 10.1007/s00535-008-2206-5 [doi]
AB  - Meta-analyses of randomized, placebo-controlled trials of low-dose aspirin 
      indicate that aspirin approximately doubles the risk of major GI bleeding 
      compared with placebo. The risk in Japanese may possibly be higher compared to 
      Western populations, although the evidence is still lacking and prospective 
      studies are required. Prior GI events, older age, and use of other injurious 
      medicines such as NSAIDs, anticoagulants, and corticosteroids seem to be factors 
      associated with an increased risk for upper GI bleeding among aspirin users. 
      Prospective studies are needed to identify specific risk factors for upper GI 
      bleeding in Japanese patients taking low-dose aspirin. There are many potential 
      gastroprotective drugs available in Japan, and studies are needed to assess the 
      relative effectiveness of various strategies including PPI use for the prevention 
      of aspirin-related upper GI ulcer complications and whether any of these other 
      agents also provide protection against small bowel or colonic damage. 
      Aspirin-induced enteropathy is now increasingly being recognized and is 
      presumably not uncommon, and the availability of new imaging techniques for the 
      small intestine and noninvasive tests such as fecal calprotectin should allow 
      rapid progress in this important area.
FAU - Shiotani, Akiko
AU  - Shiotani A
AD  - Department of Internal Medicine, Kawasaki Medical School, 577 Matsushima, 
      Kurashiki, 701-0192, Japan.
FAU - Kamada, Tomoari
AU  - Kamada T
FAU - Haruma, Ken
AU  - Haruma K
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20080817
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Diseases/*chemically induced/epidemiology
MH  - Global Health
MH  - Humans
MH  - Morbidity/trends
MH  - Risk Factors
RF  - 76
EDAT- 2008/08/19 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/08/19 09:00
PHST- 2008/04/11 00:00 [received]
PHST- 2008/04/13 00:00 [accepted]
PHST- 2008/08/19 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/08/19 09:00 [entrez]
AID - 10.1007/s00535-008-2206-5 [doi]
PST - ppublish
SO  - J Gastroenterol. 2008;43(8):581-8. doi: 10.1007/s00535-008-2206-5. Epub 2008 Aug 
      17.

PMID- 6430802
OWN - NLM
STAT- MEDLINE
DCOM- 19840831
LR  - 20200304
IS  - 0360-3997 (Print)
IS  - 0360-3997 (Linking)
VI  - 8
IP  - 2
DP  - 1984 Jun
TI  - Antiinflammatory properties of a hydroperoxide compound, structurally related to 
      acetylsalicylic acid.
PG  - 157-69
AB  - 3-Hydroperoxy-3-methylphthalide (3-HMP), a structural analog of acetylsalicylic 
      acid (ASA), was found to have some antiinflammatory properties which are distinct 
      from those of ASA. 3-HMP inhibits human platelet aggregation and ATP release in 
      response to low concentrations of collagen but is less effective than ASA. 3-HMP 
      inhibits prostaglandin and thromboxane production from exogenous [14C]arachidonic 
      acid by human platelet lysates in vitro and does so at lower concentrations than 
      ASA (3-HMP IC50 = 10 microM; ASA IC50 = 50 microM). 3-HMP is also more effective 
      than ASA as an inhibitor of prostacyclin-like activity production by rings of 
      rabbit aorta. Human polymorphonuclear (PMN) leukocyte [14C]arachidonic acid 
      metabolism is inhibited by 3-HMP but not ASA. In urethane-anesthetized rats, 
      3-HMP (10 mg/kg intravenously) is effective in inhibiting PMN leukocyte 
      accumulation in response to intrapleural carrageenan administration whereas ASA 
      is ineffective (100 mg/kg intravenously). This hydroperoxy analog of ASA has 
      antiinflammatory activity which may result from a combination of the ASA-like and 
      hydroperoxide-related pharmacological properties.
FAU - Killackey, J J
AU  - Killackey JJ
FAU - Killackey, B A
AU  - Killackey BA
FAU - Cerskus, I
AU  - Cerskus I
FAU - Philp, R B
AU  - Philp RB
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Inflammation
JT  - Inflammation
JID - 7600105
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Phthalic Acids)
RN  - 0 (Phthalic Anhydrides)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 90094-81-8 (3-hydroperoxy-3-methylphthalide)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Anti-Inflammatory Agents
MH  - Aorta/drug effects
MH  - Arachidonic Acid
MH  - Arachidonic Acids/blood
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Platelets/drug effects
MH  - Epoprostenol/biosynthesis
MH  - Humans
MH  - In Vitro Techniques
MH  - Neutrophils/drug effects
MH  - Phthalic Acids/*pharmacology
MH  - Phthalic Anhydrides/*pharmacology
MH  - Rabbits
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
AID - 10.1007/BF00916091 [doi]
PST - ppublish
SO  - Inflammation. 1984 Jun;8(2):157-69. doi: 10.1007/BF00916091.

PMID- 8692404
OWN - NLM
STAT- MEDLINE
DCOM- 19960829
LR  - 20131121
IS  - 0148-396X (Print)
IS  - 0148-396X (Linking)
VI  - 38
IP  - 4
DP  - 1996 Apr
TI  - Spontaneous resolution of a large spinal epidural hematoma: case report.
PG  - 816-8
AB  - Spontaneous spinal epidural hematoma is a rare condition that usually requires 
      surgical evacuation of the hematoma. We report a case of spontaneous spinal 
      epidural hematoma that was probably associated with aspirin intake. The initial 
      clinical signs and symptoms included sharp, left-sided neck pain and weakness of 
      the left arm. The initial magnetic resonance image showed a spinal epidural 
      hematoma extending from C2 to C6, with compression of the myelon. This case is 
      remarkable for dramatic clinical improvement within 12 hours and the magnetic 
      resonance imaging documentation of complete resolution within 3 days. For each 
      patient with a stable or improving neurological status, conservative management 
      monitored by magnetic resonance imaging might be the treatment of choice.
FAU - Wagner, S
AU  - Wagner S
AD  - Department of Neurology, University of Heidelberg, Germany.
FAU - Forsting, M
AU  - Forsting M
FAU - Hacke, W
AU  - Hacke W
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects
MH  - Hematoma, Epidural, Cranial/chemically induced/*diagnosis
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Neurologic Examination
MH  - Remission, Spontaneous
MH  - Spinal Cord/pathology
MH  - Spinal Cord Compression/chemically induced/*diagnosis
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
PST - ppublish
SO  - Neurosurgery. 1996 Apr;38(4):816-8.

PMID- 3548564
OWN - NLM
STAT- MEDLINE
DCOM- 19870410
LR  - 20131121
IS  - 0003-3928 (Print)
IS  - 0003-3928 (Linking)
VI  - 35
IP  - 10
DP  - 1986 Dec
TI  - [Anti-aggregating agents: for which patients?].
PG  - 623-7
AB  - Platelets are at the center of the phenomenon leading to thrombus formation; they 
      also occupy an important place in the process leading to the development of the 
      atheromatous plaque: these two actions justify the interest taken in 
      anti-platelets medications in cardiac pathology. In spite of the uncertainties 
      remaining about this very controverted subject, it seems that the prescription of 
      an anti-platelets medication is legitimate in all situations where there is a 
      danger of formation or extension of a thrombus. Within the scope of coronary 
      pathology, the most recent trials show a favorable action of anti-platelets 
      medications in unstable angina, aorto-coronary by-pass or the secondary 
      prevention of myocardial infarction. In addition, it is recommended to start the 
      treatment as quickly as possible before surgery, as far as cardiac surgery is 
      concerned. Finally, concerning the dispute about the optimal dose of aspirin, the 
      current tendency is to advocate a moderate dosage.
FAU - Nicolas, G
AU  - Nicolas G
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Les anti-agrégants: pour quels malades?
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/prevention & control
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Coronary Artery Bypass/adverse effects
MH  - Heart Valve Prosthesis/adverse effects
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation/*drug effects
MH  - Thromboembolism/etiology/*prevention & control
MH  - Thrombophlebitis/prevention & control
RF  - 27
EDAT- 1986/12/01 00:00
MHDA- 1986/12/01 00:01
CRDT- 1986/12/01 00:00
PHST- 1986/12/01 00:00 [pubmed]
PHST- 1986/12/01 00:01 [medline]
PHST- 1986/12/01 00:00 [entrez]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 1986 Dec;35(10):623-7.

PMID- 21061543
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - [Diagnosis and therapy of intestinal mucosal injury due to low-dose aspirin].
PG  - 2119-25
AB  - NSAIDs users have a significantly higher incidence of colonic lesions than 
      non-NSAIDs-users. Low-dose aspirin is widely used because it reduces the risk of 
      vascular events in patients with coronary and cerebrovascular disease. There has 
      been a substantial increase in prescriptions for low-dose aspirin in recent 
      years. Recent advances in diagnostic methods including video capsule endoscopy 
      and balloon endoscopy have enabled to observe the entire small intestine, and we 
      now recognize that prevalence of small intestinal lesions. Low-dose aspirin users 
      also have a significantly higher incidence of small and large intestinal lesions 
      than non-low-dose aspirin-users. It is necessary to be aware of not only 
      gastro-duodenal ulcers but also lower intestinal lesions with long-term use of 
      low-dose aspirin.
FAU - Osada, Taro
AU  - Osada T
AD  - Department of Gastroenterology, Juntendo University School of Medicine.
FAU - Shibuya, Tomoyoshi
AU  - Shibuya T
FAU - Watanabe, Sumio
AU  - Watanabe S
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Female
MH  - Humans
MH  - Intestinal Diseases/chemically induced/diagnosis/drug therapy
MH  - Intestinal Mucosa/*drug effects
MH  - Intestine, Large/*drug effects
MH  - Intestine, Small/*drug effects
MH  - Male
EDAT- 2010/11/11 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Nov;68(11):2119-25.

PMID- 23592503
OWN - NLM
STAT- MEDLINE
DCOM- 20130924
LR  - 20211021
IS  - 1530-8561 (Electronic)
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 59
IP  - 8
DP  - 2013 Aug
TI  - Microfluidic assay of platelet deposition on collagen by perfusion of whole blood 
      from healthy individuals taking aspirin.
PG  - 1195-204
LID - 10.1373/clinchem.2012.198101 [doi]
AB  - BACKGROUND: Microfluidic devices can create hemodynamic conditions for platelet 
      assays. We validated an 8-channel device in a study of interdonor response to 
      acetylsalicylic acid (ASA, aspirin) with whole blood from 28 healthy individuals. 
      METHODS: Platelet deposition was assessed before treatment or 24 h after 
      ingestion of 325 mg ASA. Whole blood (plus 100 μmol/L 
      H-d-Phe-Pro-Arg-chloromethylketone to inhibit thrombin) was further treated ex 
      vivo with ASA (0-500 μmol/L) and perfused over fibrillar collagen for 300 s at a 
      venous wall shear rate (200 s(-1)). RESULTS: Ex vivo ASA addition to blood drawn 
      before aspirin ingestion caused a reduction in platelet deposition [half-maximal 
      inhibitory concentration (IC50) approximately 10-20 μmol/L], especially between 
      150 and 300 s of perfusion, when secondary aggregation mediated by thromboxane 
      was expected. Twenty-seven of 28 individuals displayed smaller deposits (45% mean 
      reduction; range 10%-90%; P < 0.001) from blood obtained 24 h after ASA ingestion 
      (no ASA added ex vivo). In replicate tests, an R value to score secondary 
      aggregation [deposition rate from 150 to 300 s normalized by rate from 60 to 150 
      s] showed R < 1 in only 2 of 28 individuals without ASA ingestion, with R > 1 in 
      only 3 of 28 individuals after 500 μmol/L ASA addition ex vivo. At 24 h after ASA 
      ingestion, 21 of 28 individuals displayed poor secondary aggregation (R < 1) 
      without ex vivo ASA addition, whereas the 7 individuals with residual secondary 
      aggregation (R > 1) displayed insensitivity to ex vivo ASA addition. Platelet 
      deposition was not correlated with platelet count. Ex vivo ASA addition caused 
      similar inhibition at venous and arterial wall shear rates. CONCLUSIONS: 
      Microfluidic devices quantified platelet deposition after ingestion or ex vivo 
      addition of aspirin.
FAU - Li, Ruizhi
AU  - Li R
AD  - Institute for Medicine and Engineering, Department of Chemical and Biomolecular 
      Engineering, University of Pennsylvania, Philadelphia, PA 19104, USA
FAU - Fries, Susanne
AU  - Fries S
FAU - Li, Xuanwen
AU  - Li X
FAU - Grosser, Tilo
AU  - Grosser T
FAU - Diamond, Scott L
AU  - Diamond SL
LA  - eng
GR  - R01 HL-103419/HL/NHLBI NIH HHS/United States
GR  - R01 HL103419/HL/NHLBI NIH HHS/United States
GR  - U54 HL117798/HL/NHLBI NIH HHS/United States
GR  - UL1 TR000003/TR/NCATS NIH HHS/United States
GR  - UL1TR000003/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20130416
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 9007-34-5 (Collagen)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/physiology
MH  - *Collagen
MH  - Cyclooxygenase 1/metabolism
MH  - Female
MH  - Fluorescent Dyes
MH  - Humans
MH  - Male
MH  - Microfluidic Analytical Techniques/*instrumentation
MH  - Middle Aged
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Reference Values
MH  - Regional Blood Flow
MH  - Signal Transduction
MH  - Stress, Mechanical
MH  - Thromboxane A2/metabolism
MH  - Young Adult
PMC - PMC4119612
MID - NIHMS599914
COIS- Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript 
      submission, all authors completed the author disclosure form. Disclosures and/or 
      potential conflicts of interest:
EDAT- 2013/04/18 06:00
MHDA- 2013/09/26 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/18 06:00 [entrez]
PHST- 2013/04/18 06:00 [pubmed]
PHST- 2013/09/26 06:00 [medline]
AID - clinchem.2012.198101 [pii]
AID - 10.1373/clinchem.2012.198101 [doi]
PST - ppublish
SO  - Clin Chem. 2013 Aug;59(8):1195-204. doi: 10.1373/clinchem.2012.198101. Epub 2013 
      Apr 16.

PMID- 31916487
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 2309-4990 (Electronic)
IS  - 1022-5536 (Linking)
VI  - 28
IP  - 1
DP  - 2020 Jan-Apr
TI  - Effects of continuing use of aspirin on blood loss in patients who underwent 
      unilateral total knee arthroplasty.
PG  - 2309499019894390
LID - 10.1177/2309499019894390 [doi]
AB  - PURPOSE: Concerning the ongoing debate on the effects of continuing aspirin 
      therapy on blood loss in knee arthroplasty, we conducted a retrospective 
      investigation to test the hypothesis that continuation of aspirin prior total 
      knee arthroplasty (TKA) will not cause more blood loss. METHODS: From a database 
      of patients who underwent unilateral TKA between 2011 and 2016, we identified two 
      groups: the aspirin group (patients continued aspirin during perioperative 
      period) and the nonaspirin group (patients had no current or recent history of 
      aspirin usage). We extracted and compared patient demographic information, 
      comorbidity index, baseline serum hemoglobin (Hb), and creatinine level between 
      the two groups. We also compared our primary outcomes, including the total blood 
      loss, transfusion requirement, and length of hospitalization between the two 
      groups. A multivariate logistic regression for analyzing the risk factors of 
      requiring transfusion was performed. RESULTS: We found that apart from 
      preoperative serum creatinine level, there was no difference in the baseline Hb 
      level, perioperative change in Hb, total blood loss, or length of hospitalization 
      between the two groups. The percentage of transfusion utilization was also 
      comparable between the two groups. Our regression analysis shows that the risk of 
      requiring transfusion after TKA is not significantly associated with patients 
      taking aspirin therapy before operation. CONCLUSION: Patients who underwent TKA 
      with continuation of low-dose aspirin did not result in more blood loss. Current 
      blood loss management has provided sufficient reduction of blood loss to 
      accommodate aspirin therapy perioperatively. We suggest that it is safe to 
      continue aspirin prior to TKA.
FAU - Hang, Guanqi
AU  - Hang G
AUID- ORCID: 0000-0002-5660-6656
AD  - Department of Orthopaedic Surgery, Singapore General Hospital, Singapore.
FAU - Chen, Jerry Yongqiang
AU  - Chen JY
AD  - Department of Orthopaedic Surgery, Singapore General Hospital, Singapore.
FAU - Yew, Andy Khye Soon
AU  - Yew AKS
AUID- ORCID: 0000-0001-7299-2166
AD  - Department of Orthopaedic Surgery, Singapore General Hospital, Singapore.
FAU - Pang, Hee-Nee
AU  - Pang HN
AD  - Department of Orthopaedic Surgery, Singapore General Hospital, Singapore.
FAU - Jin, Darren Tay Keng
AU  - Jin DTK
AD  - Department of Orthopaedic Surgery, Singapore General Hospital, Singapore.
FAU - Chia, Shi-Lu
AU  - Chia SL
AD  - Department of Orthopaedic Surgery, Singapore General Hospital, Singapore.
FAU - Lo, Ngai Nung
AU  - Lo NN
AD  - Department of Orthopaedic Surgery, Singapore General Hospital, Singapore.
FAU - Yeo, Seng Jin
AU  - Yeo SJ
AD  - Department of Orthopaedic Surgery, Singapore General Hospital, Singapore.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Orthop Surg (Hong Kong)
JT  - Journal of orthopaedic surgery (Hong Kong)
JID - 9440382
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arthroplasty, Replacement, Knee/*methods
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Loss, Surgical/*statistics & numerical data
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis, Knee/*surgery
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Postoperative Hemorrhage/*epidemiology
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - aspirin
OT  - blood loss
OT  - orthopedics
OT  - total knee arthroplasty
EDAT- 2020/01/10 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/01/10 06:00
PHST- 2020/01/10 06:00 [entrez]
PHST- 2020/01/10 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1177/2309499019894390 [doi]
PST - ppublish
SO  - J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(1):2309499019894390. doi: 
      10.1177/2309499019894390.

PMID- 20864244
OWN - NLM
STAT- MEDLINE
DCOM- 20110614
LR  - 20131121
IS  - 1578-1267 (Electronic)
IS  - 0301-0546 (Linking)
VI  - 38
IP  - 6
DP  - 2010 Nov-Dec
TI  - Prognostic bases of asthma. Natural history?
PG  - 333-6
LID - 10.1016/j.aller.2010.07.002 [doi]
AB  - Different causes of asthma have been established. The most common cause is 
      conditioned to a genetic predisposition towards atopy (atopic asthma), although 
      other factors can also give rise to bronchial inflammation, such as over-exposure 
      to environmental irritants (occupational asthma), altered arachidonic acid 
      metabolism (aspirin-induced asthma) and also exercise - in which different 
      thermal and osmotic mechanisms are known to intervene. The prognosis of these 
      different variants of asthma depends on the severity of the condition; patient 
      age at onset of the disease; patient age at the time of diagnosis; the treatment 
      provided; and adherence to therapy. The concept of "natural history" refers to 
      the spontaneous evolution or course of the disease process in the absence of 
      pathogenic or etiological treatment, with the provision of only symptomatic 
      treatment. In order to gain increased certainty regarding the course of these 
      patients, the study groups must present similar baseline characteristics in terms 
      of the start and severity of the condition; the start of treatment; compliance; 
      and the clinical and functional control findings.
CI  - Copyright © 2010 SEICAP. Published by Elsevier Espana. All rights reserved.
FAU - Muñoz-López, F
AU  - Muñoz-López F
AD  - 5314fml@comb.cat
LA  - eng
PT  - Journal Article
DEP - 20100922
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Disease Progression
MH  - Environmental Exposure/*adverse effects
MH  - Exercise/physiology
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Hypersensitivity, 
      Immediate/*diagnosis/epidemiology/*etiology/physiopathology/therapy
MH  - Occupational Exposure/*adverse effects
MH  - Patient Compliance
MH  - Patient Selection
MH  - Prognosis
EDAT- 2010/09/25 06:00
MHDA- 2011/06/15 06:00
CRDT- 2010/09/25 06:00
PHST- 2010/07/29 00:00 [received]
PHST- 2010/07/30 00:00 [accepted]
PHST- 2010/09/25 06:00 [entrez]
PHST- 2010/09/25 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
AID - S0301-0546(10)00160-6 [pii]
AID - 10.1016/j.aller.2010.07.002 [doi]
PST - ppublish
SO  - Allergol Immunopathol (Madr). 2010 Nov-Dec;38(6):333-6. doi: 
      10.1016/j.aller.2010.07.002. Epub 2010 Sep 22.

PMID- 8748860
OWN - NLM
STAT- MEDLINE
DCOM- 19960930
LR  - 20190814
IS  - 0001-6268 (Print)
IS  - 0001-6268 (Linking)
VI  - 137
IP  - 1-2
DP  - 1995
TI  - Pathogenetic factors in chronic subdural haematoma and causes of recurrence after 
      drainage.
PG  - 6-14
AB  - The radiological aspect, pathology, treatment and results of 132 subdural 
      haematomas observed in 100 patients, are discussed. The majority of these cases 
      were characterized by a nonhomogenous CT scan picture, resulting from repeated 
      bleeding in a previous subdural haematoma evolving to chronicity, or in a 
      pre-existent subdural hygroma. Taking aspirin may have constituted a predisposing 
      factor in 16% of our patients, whilst coagulation disturbances, including 
      anticoagulant treatment, were observed in another 6%; ethylism was present in 
      11%. A traumatic origin was ascertained in 80% of the patients. The treatment 
      consisted of burr hole evacuation and drainage in 91.5% of the haematomas, 
      corresponding to 92% of the patients; it was eventually repeated once or twice in 
      some cases. In 6% of the patients, a subduro-peritoneal drainage had to be placed 
      ultimately and in 2%, a membranectomy had to be performed because the haematoma 
      had become nearly completely fibrous. The necessity for repeated evacuation and 
      eventual subduro-peritoneal drainage seems to depend mainly on a slow brain 
      re-expansion in some elderly people, who are actually more frequently referred. 
      Two patients died; one was deeply comatose and another in poor general condition. 
      Morbidity in the 96 remaining patients, 2 being lost to follow-up, was 11%: 5% 
      related to the haematoma or to the causal trauma, and 6% from other concomitant 
      neurological disease. The functional result was satisfactory in 85%.
FAU - Stroobandt, G
AU  - Stroobandt G
AD  - Department of Neurosurgery, Cliniques Universitaires St. Luc, Brussels, Belgium.
FAU - Fransen, P
AU  - Fransen P
FAU - Thauvoy, C
AU  - Thauvoy C
FAU - Menard, E
AU  - Menard E
LA  - eng
PT  - Journal Article
PL  - Austria
TA  - Acta Neurochir (Wien)
JT  - Acta neurochirurgica
JID - 0151000
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects
MH  - Chronic Disease
MH  - Drainage
MH  - Female
MH  - Hematoma, Subdural/etiology/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/etiology/*surgery
MH  - Recurrence
MH  - Reoperation
MH  - Risk Factors
MH  - Ventriculoperitoneal Shunt
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1007/BF02188772 [doi]
PST - ppublish
SO  - Acta Neurochir (Wien). 1995;137(1-2):6-14. doi: 10.1007/BF02188772.

PMID- 33513644
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 146
IP  - 3
DP  - 2021 Feb
TI  - [Antithrombotic therapy after peripheral revascularization].
PG  - 136-140
LID - 10.1055/a-1129-1999 [doi]
AB  - Patients with lower extremity arterial disease are at increased risk for 
      cardiovascular events. Antithrombotic therapy improves prognosis in these 
      patients especially after peripheral revascularization. After endovascular 
      revascularization duale anti-platelet therapy with Aspirin and Clopidogrel is 
      used for up to 3 months in most cases, although there is only little evidence for 
      this practice. Following peripheral bypass grafting most guidelines recommend 
      single anti-platelet therapy. In some patients, anticoagulation with Vitamin K 
      antagonists or dual anti-platelet therapy is indicated. But this practice is also 
      based on small studies. The Vascular Outcomes Study of ASA Along With Rivaroxaban 
      in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease 
      (VOYAGER PAD) study is the largest randomized trial concerning antithrombotic 
      therapy after peripheral revascularization. In total 6564 patients were included 
      after successful surgical or endovascular lower-extremity revascularization. 
      Rivaroxaban 2.5 mg twice daily plus Aspirin 100 mg reduced cardiac and peripheral 
      events compared with Aspirin 100 mg alone with increased risk for relevant but 
      not for critical bleeding complications. In addition to antithrombotic medication 
      risk factor management and regular follow-up examinations are important improve 
      long-term prognosis after peripheral revascularization.
CI  - Thieme. All rights reserved.
FAU - Espinola-Klein, Christine
AU  - Espinola-Klein C
AD  - Abteilung für Angiologie, Zentrum für Kardiologie/Kardiologie I, 
      Universitätsmedizin der Johannes-Gutenberg-Universität, Mainz.
LA  - ger
PT  - Journal Article
TT  - Antithrombotische Therapie nach peripherer Revaskularisation.
DEP - 20210129
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Fibrinolytic Agents)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - *Endovascular Procedures
MH  - *Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic use
MH  - Humans
MH  - Lower Extremity/blood supply
MH  - *Peripheral Arterial Disease/drug therapy/prevention & control/surgery
MH  - Randomized Controlled Trials as Topic
MH  - Rivaroxaban/administration & dosage/adverse effects/therapeutic use
COIS- Vortrags-/Beratertätigkeit und Unterstützung von Veranstaltungen: Amgen GmbH, 
      Bayer Health Care, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, 
      Leo Pharma, MSD Sharp & Dohme, Pfizer Pharma GmbH, Sanofi-Aventis GmbH.
EDAT- 2021/01/30 06:00
MHDA- 2021/09/21 06:00
CRDT- 2021/01/29 20:10
PHST- 2021/01/29 20:10 [entrez]
PHST- 2021/01/30 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
AID - 10.1055/a-1129-1999 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2021 Feb;146(3):136-140. doi: 10.1055/a-1129-1999. Epub 
      2021 Jan 29.

PMID- 32930782
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 105
IP  - 12
DP  - 2020 Dec 1
TI  - The 15-Epilipoxin-A4 Pathway with Prophylactic Aspirin in Preventing 
      Preeclampsia: A Longitudinal Cohort Study.
LID - dgaa642 [pii]
LID - 10.1210/clinem/dgaa642 [doi]
AB  - INTRODUCTION: The benefit of aspirin in preventing preeclampsia is increasingly 
      recognized; however, its mechanism of action remains unclear. Nonobstetric 
      studies have described an anti-inflammatory effect of aspirin through the 
      15-epilipoxin-A4 pathway (aspirin-triggered lipoxin [ATL]). However, the 
      anti-inflammatory mechanism of aspirin in the prevention of preeclampsia remains 
      unknown. OBJECTIVE/HYPOTHESIS: To examine (1) the difference in longitudinal 
      endogenous lipoxin-A4 (En-Lipoxin-A4) concentration in low-risk (LR) and 
      high-risk (HR) pregnancies, and (2) the effect of aspirin on endogenous ATL 
      concentration and the associated effect on cytokine profile of HR women. METHODS: 
      Plasma from 220 HR women was collected at 12, 16, 20, 24, 28, 32, and 36 weeks of 
      gestation. Adherence to aspirin was biochemically verified. Plasma En-Lipoxin-A4 
      and ATL concentrations were analyzed using liquid chromatography mass 
      spectrometry, and cytokines, interleukin (IL)-10, tumor necrosis factor-α, 
      interferon-γ, IL-8, and IL-1β, with the high-sensitivity multibead Luminex® 
      assay. RESULTS: HR women have up to 70% lower plasma concentration of 
      En-Lipoxin-A4 (P < 0.001) than LR women. HR women with adequate aspirin adherence 
      (HR-AA) (n = 82) had higher plasma concentration of ATL (P < .001), lower 
      concentration of IL-8 from 16 to 36 weeks of gestation (P < .001), and increased 
      IL-10 concentration from 16 to 28 weeks of gestation (P = .03) compared with 
      high-risk women who were not on aspirin (HR-NA). HR-AA who did not develop 
      preeclampsia had higher plasma En-lipoxin-A4 (P < .001), ATL (P = .02), and IL-10 
      concentrations (P < .001) with lower IL-8 concentration (P = .004) than HR women 
      who developed preeclampsia. DISCUSSION: Plasma concentration of En-Lipoxin-A4 is 
      lower in HR women than in LR controls. Adequate adherence with aspirin results in 
      an increase in ATL and IL-10 with reduced IL-8 plasma concentration. This study 
      suggests a potential anti-inflammatory role of aspirin through the ATL pathway 
      with prophylactic aspirin in HR pregnant women.
CI  - © The Author(s) 2020. Published by Oxford University Press on behalf of the 
      Endocrine Society. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Shanmugalingam, Renuka
AU  - Shanmugalingam R
AD  - Department of Renal Medicine, South Western Sydney Local Health District, NSW, 
      Australia.
AD  - School of Medicine, Western Sydney University, NSW, Australia.
AD  - Women's Health Initiative Translational Unit (WHITU), Ingham Institute For 
      Applied Medical Research and South Western Sydney Local Health District, NSW, 
      Australia.
AD  - Vascular Immunology Research Group, Heart Research Institute (HRI), Sydney, NSW, 
      Australia.
FAU - Wang, XiaoSuo
AU  - Wang X
AD  - Bosch Mass Spectrometry Faculty, University of Sydney, NSW, Australia.
AD  - Freedman Foundation Metabolomics Facility, Innovation Centre, Victor Chang 
      Cardiac Research Institute, NSW, Australia.
FAU - Motum, Penelope
AU  - Motum P
AD  - Women's Health Initiative Translational Unit (WHITU), Ingham Institute For 
      Applied Medical Research and South Western Sydney Local Health District, NSW, 
      Australia.
AD  - Department of Haematology, South Western Sydney Local Health District, NSW, 
      Australia.
FAU - Fulcher, Ian
AU  - Fulcher I
AD  - Department of Obstetrics and Gynaecology, South Western Sydney Local Health 
      District, NSW, Australia.
FAU - Lee, Gaksoo
AU  - Lee G
AD  - Women's Health Initiative Translational Unit (WHITU), Ingham Institute For 
      Applied Medical Research and South Western Sydney Local Health District, NSW, 
      Australia.
AD  - Department of Obstetrics and Gynaecology, South Western Sydney Local Health 
      District, NSW, Australia.
FAU - Kumar, Roshika
AU  - Kumar R
AD  - South Western Sydney Clinical School, University of New South Wales (UNSW), NSW, 
      Australia.
FAU - Hennessy, Annemarie
AU  - Hennessy A
AD  - Department of Renal Medicine, South Western Sydney Local Health District, NSW, 
      Australia.
AD  - School of Medicine, Western Sydney University, NSW, Australia.
AD  - Women's Health Initiative Translational Unit (WHITU), Ingham Institute For 
      Applied Medical Research and South Western Sydney Local Health District, NSW, 
      Australia.
AD  - Vascular Immunology Research Group, Heart Research Institute (HRI), Sydney, NSW, 
      Australia.
FAU - Makris, Angela
AU  - Makris A
AD  - Department of Renal Medicine, South Western Sydney Local Health District, NSW, 
      Australia.
AD  - School of Medicine, Western Sydney University, NSW, Australia.
AD  - Women's Health Initiative Translational Unit (WHITU), Ingham Institute For 
      Applied Medical Research and South Western Sydney Local Health District, NSW, 
      Australia.
AD  - Vascular Immunology Research Group, Heart Research Institute (HRI), Sydney, NSW, 
      Australia.
AD  - South Western Sydney Clinical School, University of New South Wales (UNSW), NSW, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Case-Control Studies
MH  - Chemoprevention/methods
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Lipoxins/blood/*metabolism
MH  - Longitudinal Studies
MH  - Metabolic Networks and Pathways/drug effects/physiology
MH  - Pre-Eclampsia/blood/metabolism/*prevention & control
MH  - Pregnancy
MH  - Pregnancy, High-Risk/drug effects/metabolism
OTO - NOTNLM
OT  - ATL
OT  - Aspirin
OT  - Lipoxin-A4
OT  - cytokines
OT  - preeclampsia
EDAT- 2020/09/16 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/09/15 12:14
PHST- 2020/04/09 00:00 [received]
PHST- 2020/09/11 00:00 [accepted]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2020/09/15 12:14 [entrez]
AID - 5905864 [pii]
AID - 10.1210/clinem/dgaa642 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2020 Dec 1;105(12):dgaa642. doi: 10.1210/clinem/dgaa642.

PMID- 321183
OWN - NLM
STAT- MEDLINE
DCOM- 19770520
LR  - 20190907
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 4
IP  - 7
DP  - 1977
TI  - Comparison of sulindac and aspirin in rheumatoid arthritis.
PG  - 485-91
AB  - Thirty-one out-patients with rheumatoid arthritis took part in a 10 week 
      double-blind comparison of sulindac 
      (cis-5-fluoro-2-methyl-1-[p-(methylsulphinyl)-benzylidene]-indene-3-acetic acid) 
      200 mg twice daily and aspirin 3.6 g daily, with a 2-week placebo control period. 
      Both drugs were superior to placebo. The incidence of side-effects was 
      approximately the same on the two drugs, but there was a higher drop-out rate due 
      to side-effects on aspirin.
FAU - Reynolds, P M
AU  - Reynolds PM
FAU - Rhymer, A R
AU  - Rhymer AR
FAU - MacLeod, M M
AU  - MacLeod MM
FAU - Buchanan, W W
AU  - Buchanan WW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Benzylidene Compounds)
RN  - 0 (Indenes)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Benzylidene Compounds/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Indenes/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Placebos
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1185/03007997709109337 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1977;4(7):485-91. doi: 10.1185/03007997709109337.

PMID- 8703797
OWN - NLM
STAT- MEDLINE
DCOM- 19960912
LR  - 20191101
IS  - 1062-0303 (Print)
IS  - 1062-0303 (Linking)
VI  - 14
IP  - 1
DP  - 1996 Mar
TI  - Erythromelalgia--a case study.
PG  - 18-20
AB  - Erythromelalgia is a rare syndrome characterized by pain, redness, and heat 
      involving the lower and, less frequently, the upper extremities. Symptoms occur 
      with local or environmental stimulation and may be mild for years or become 
      disablingly severe. A finding of relief with ice-water immersion helps 
      distinguish erythromelalgia from disorders such as causalgia and reflex 
      sympathetic dystrophy. Erythromelalgia may be classified in three ways: (1) 
      early-onset, (2) adult-onset aspirin-sensitive, and (3) adult-onset 
      non-aspirin-sensitive. Treatment options, which include medication, sympathetic 
      blocks, and surgery, are determined by classification.
FAU - Christensen, C R
AU  - Christensen CR
FAU - Stubbs, D H
AU  - Stubbs DH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Vasc Nurs
JT  - Journal of vascular nursing : official publication of the Society for Peripheral 
      Vascular Nursing
JID - 9014475
RN  - R16CO5Y76E (Aspirin)
MH  - Aged
MH  - Aspirin/adverse effects
MH  - *Erythromelalgia/classification/diagnosis/etiology/therapy
MH  - Humans
MH  - Male
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
AID - 10.1016/s1062-0303(96)80038-0 [doi]
PST - ppublish
SO  - J Vasc Nurs. 1996 Mar;14(1):18-20. doi: 10.1016/s1062-0303(96)80038-0.

PMID- 7341465
OWN - NLM
STAT- MEDLINE
DCOM- 19820719
LR  - 20131121
IS  - 0019-5499 (Print)
IS  - 0019-5499 (Linking)
VI  - 25
IP  - 4
DP  - 1981 Oct-Dec
TI  - A simple technique to measure paw volume in anti-inflammatory studies.
PG  - 361-4
AB  - A simple technique using common laboratory materials based on overflow-refill 
      principle is described. The technique provides a retrievable permanent record for 
      re-check, ease of single handed operation, and accurate and dependable 
      volume-measurements. The use of mercury and observer's bias have been completely 
      eliminated. Trustworthiness of the technique was confirmed by comparing the 
      estimated and known volume (0.3 to 2.4 ml) of different objects. Further 
      comparison of volume estimation of rat paw by this technique with that by another 
      method, showed the new method to be more accurate with coefficient of variation 
      of 8.98% as opposed to 15.60 % for the other methods.
FAU - Ignatius, J X
AU  - Ignatius JX
FAU - Tilloo, L D
AU  - Tilloo LD
FAU - Diwan, P V
AU  - Diwan PV
FAU - Kulkarni, D R
AU  - Kulkarni DR
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Physiol Pharmacol
JT  - Indian journal of physiology and pharmacology
JID - 0374707
RN  - 0 (Anti-Inflammatory Agents)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/therapeutic use
MH  - Carrageenan
MH  - Drug Evaluation, Preclinical/*methods
MH  - Edema/drug therapy/*pathology
MH  - Methods
MH  - Rats
EDAT- 1981/10/01 00:00
MHDA- 1981/10/01 00:01
CRDT- 1981/10/01 00:00
PHST- 1981/10/01 00:00 [pubmed]
PHST- 1981/10/01 00:01 [medline]
PHST- 1981/10/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Physiol Pharmacol. 1981 Oct-Dec;25(4):361-4.

PMID- 7195723
OWN - NLM
STAT- MEDLINE
DCOM- 19810820
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 31
IP  - 4
DP  - 1981
TI  - [A controlled clinical trial for testing the efficacy of the homeopathic drug 
      eupatorium perfoliatum D2 inthe treatment of common cold (author's transl)].
PG  - 732-6
AB  - 53 outpatients suffering from common cold (flu) were randomly assigned to either 
      a therapy with acetylsalicylic acid (ASA) or the homeopathic drug Eupatorium 
      perfoliatum D2 in a controlled clinical trial. The efficacy of the drugs was 
      assessed on day 1, 4 and 10 of the infection by symptom check lists and physical 
      examinations. Neither subjective complaints nor body temperature or laboratory 
      findings showed any significant differences between groups which was taken as 
      evidence that both drugs were equally effective.
FAU - Gassinger, C A
AU  - Gassinger CA
FAU - Wünstel, G
AU  - Wünstel G
FAU - Netter, P
AU  - Netter P
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Klinishe Prüfung zum Nachweis der therapeutischen Wirksamkeit des homöopathischen 
      Arzneimittels Eupatorium perfoliatum D 2 (Wasserhanf composite) bei der Diagnose 
      "Grippaler Infekt"1.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Eupatorium perfoliatum D2)
RN  - 0 (Plant Extracts)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Common Cold/*drug therapy
MH  - Eupatorium
MH  - *Homeopathy
MH  - Humans
MH  - Plant Extracts/*therapeutic use
MH  - *Plants, Medicinal
MH  - Time Factors
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1981;31(4):732-6.

PMID- 12564730
OWN - NLM
STAT- MEDLINE
DCOM- 20030521
LR  - 20220310
IS  - 0891-6640 (Print)
IS  - 0891-6640 (Linking)
VI  - 17
IP  - 1
DP  - 2003 Jan-Feb
TI  - Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and 
      long-term management with low-dose aspirin in 24 cases.
PG  - 73-83
AB  - Records of 127 cats with arterial thromboembolism (ATE) were reviewed. 
      Abyssinian, Birman, Ragdoll, and male cats were overrepresented. Tachypnea (91%), 
      hypothermia (66%), and absent limb motor function (66%) were common. Of 90 cats 
      with diagnostics performed, underlying diseases were hyperthyroidism (12), 
      cardiomyopathy (dilated [8], unclassified [33], hypertrophic obstructive [5], 
      hypertrophic [19]), neoplasia (6), other (4), and none (3). Common abnormalities 
      were left atrial enlargement (93%), congestive heart failure (CHF, 44%), and 
      arrhythmias (44%). Of cats without CHF, 89% were tachypneic. Common biochemical 
      abnormalities were hyperglycemia, azotemia, and abnormally high serum 
      concentrations of muscle enzymes. Of 87 cats treated for acute limb ATE, 39 (45%) 
      survived to be discharged. Significant differences were found between survivors 
      and nonsurvivors for temperature (P < .00001), heart rate (P = .038), serum 
      phosphorus concentration (P = .024), motor function (P = .008), and number of 
      limbs affected (P = .001). No significant difference was found between survivors 
      and nonsurvivors when compared by age, respiratory rate, other biochemical 
      analytes, or concurrent CHE A logistic regression model based on rectal 
      temperature predicted a 50% probability of survival at 98.9 degrees F (37.2 
      degrees C). Median survival time (MST) for discharged cats was 117 days. Eleven 
      cats had ATE recurrences, and 5 cats developed limb problems. Cats with CHF (MST: 
      77 days) had significantly shorter survival than cats without CHF (MST: 223 days; 
      P = .016). No significant difference was found in survival or recurrence rate 
      between cats receiving high-dose aspirin (> or = 40 mg/cat q72h) and cats 
      receiving low-dose aspirin (5 mg/cat q72h). Adverse effects were less frequent 
      and milder for the lower dosage.
FAU - Smith, Stephanie A
AU  - Smith SA
AD  - Department of Small Animal Clinical Sciences, University of Minnesota, St Paul, 
      MN 55108, USA.
FAU - Tobias, Anthony H
AU  - Tobias AH
FAU - Jacob, Kristin A
AU  - Jacob KA
FAU - Fine, Deborah M
AU  - Fine DM
FAU - Grumbles, Pamela L
AU  - Grumbles PL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Vet Intern Med
JT  - Journal of veterinary internal medicine
JID - 8708660
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Cat Diseases/diagnosis/*drug therapy/mortality/physiopathology
MH  - Cats
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Prognosis
MH  - Recurrence
MH  - Survival Analysis
MH  - Thromboembolism/*drug therapy/mortality/physiopathology/*veterinary
MH  - Time Factors
EDAT- 2003/02/05 04:00
MHDA- 2003/05/22 05:00
CRDT- 2003/02/05 04:00
PHST- 2003/02/05 04:00 [pubmed]
PHST- 2003/05/22 05:00 [medline]
PHST- 2003/02/05 04:00 [entrez]
AID - 10.1892/0891-6640(2003)017<0073:aticac>2.3.co;2 [doi]
PST - ppublish
SO  - J Vet Intern Med. 2003 Jan-Feb;17(1):73-83. doi: 
      10.1892/0891-6640(2003)017<0073:aticac>2.3.co;2.

PMID- 12916934
OWN - NLM
STAT- MEDLINE
DCOM- 20031118
LR  - 20181113
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 3
IP  - 3
DP  - 2002
TI  - Effect of magnesium stearate on the content uniformity of active ingredient in 
      pharmaceutical powder mixtures.
PG  - E19
AB  - The objective of this study was to determine the effect of magnesium stearate on 
      the physical stability of polydisperse powder mixtures. The effects of 
      concentration of magnesium stearate and the time of lubrication of mixtures with 
      magnesium stearate on the content uniformity of the active ingredient in the 
      mixtures were evaluated in a model mixture of lactose and aspirin. These effects 
      were compared in a random mixture of non-interacting components and a mixture 
      based on particle interaction. A statistical model that adequately described the 
      relationship between the factors examined and the response was generated. The 
      model indicated the presence of an interaction between magnesium stearate 
      concentration and lubrication time. At a given concentration of magnesium 
      stearate, there was a significant reduction in the content uniformity of aspirin 
      as the time of lubrication of the mixture with magnesium stearate was increased. 
      This effect was larger in mixtures based on particle interaction than in random 
      mixtures of non-interacting components.
FAU - Swaminathan, Vidya
AU  - Swaminathan V
AD  - Pfizer Global R&D Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA. 
      vidya_swaminathan@groton.pfizer.com
FAU - Kildsig, Dane O
AU  - Kildsig DO
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Powders)
RN  - 0 (Stearic Acids)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - Lactose/chemistry
MH  - Lubrication
MH  - Microspheres
MH  - Particle Size
MH  - Pharmaceutical Preparations/chemistry
MH  - Powders/chemistry
MH  - Stearic Acids/*chemistry/metabolism
MH  - Time Factors
PMC - PMC2784048
EDAT- 2003/08/15 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/08/15 05:00
PHST- 2003/08/15 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/08/15 05:00 [entrez]
AID - BF02830617 [pii]
AID - 10.1208/pt030319 [doi]
PST - ppublish
SO  - AAPS PharmSciTech. 2002;3(3):E19. doi: 10.1208/pt030319.

PMID- 19142049
OWN - NLM
STAT- MEDLINE
DCOM- 20090202
LR  - 20191210
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Linking)
VI  - 44
IP  - 12
DP  - 2008
TI  - [The impact of acute cerebral blood flow disturbances on platelet aggregation].
PG  - 922-8
AB  - OBJECTIVE: To determine the changes in platelet function, manifesting as 
      deviations of their aggregation intensity, in persons with acute ischemic stroke 
      and transient ischemic attacks, to evaluate the effect of aspirin on platelet 
      aggregation, dependent upon degree of cerebral blood flow disturbances and 
      patient's gender, and to compare these changes with those in healthy persons. 
      MATERIAL AND METHODS: We examined 50 patients aged 33 to 98 years (mean age, 
      63.7+/-2.1 years; 20 men and 30 women) with cerebral blood flow disturbances 
      during acute period (18 with transient ischemic attacks and 32 with ischemic 
      stroke). The diagnosis was confirmed by computer tomography and other clinical 
      examinations. Adenosine diphosphate-, epinephrine-, and collagen-induced platelet 
      aggregation was assessed in platelet-rich plasma. Twelve patients used aspirin at 
      prophylactic doses (100-150 mg/d), and 38 patients did not use. The control group 
      consisted of 25 healthy persons aged 31-64 years (mean age, 45.4+/-1.9 years; 17 
      men and 8 women). RESULTS: Increased platelet aggregation induced by all three 
      inducers was significantly more frequent in stroke group. Platelet reaction to 
      collagen was more expressed. Aspirin suppressed aggregation, but did not protect 
      against development of ischemic stroke. Higher activity of platelet function 
      during ischemic stroke was observed in platelets from men's plasma. CONCLUSIONS: 
      During acute period, platelet aggregation in platelet-rich plasma statistically 
      significantly increases in the stroke group, independently of the severity of the 
      disease. A part of patients, using recommended dose of prophylactic aspirin, 
      developed ischemic stroke. The effect of aspirin on platelets was more pronounced 
      in women than men.
FAU - Sabaliauskiene, Zita
AU  - Sabaliauskiene Z
AD  - Vilnius University Emergency Hospital, Siltnamiu 29, 04130 Vilnius, Lithuania. 
      z.sabaliauskiene@gmail.com
FAU - Grybauskas, Pranas
AU  - Grybauskas P
FAU - Gaigalaite, Virginija
AU  - Gaigalaite V
FAU - Ptasekas, Julius
AU  - Ptasekas J
LA  - lit
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
TT  - Uminiu smegenu kraujotakos sutrikimu itaka trombocitu agregacijos intensyvumui.
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Data Interpretation, Statistical
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*blood/diagnostic imaging/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - *Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Sex Factors
MH  - Stroke/*blood/diagnostic imaging/*prevention & control
MH  - Time Factors
MH  - Tomography, X-Ray Computed
EDAT- 2009/01/15 09:00
MHDA- 2009/02/03 09:00
CRDT- 2009/01/15 09:00
PHST- 2009/01/15 09:00 [entrez]
PHST- 2009/01/15 09:00 [pubmed]
PHST- 2009/02/03 09:00 [medline]
AID - 0812-02l [pii]
PST - ppublish
SO  - Medicina (Kaunas). 2008;44(12):922-8.

PMID- 31478782
OWN - NLM
STAT- MEDLINE
DCOM- 20191231
LR  - 20221207
IS  - 2000-6764 (Electronic)
IS  - 2000-6764 (Linking)
VI  - 53
IP  - 6
DP  - 2019 Dec
TI  - Venous thromboembolism in plastic surgery: the current state of evidence in risk 
      assessment and chemoprophylactic options.
PG  - 370-380
LID - 10.1080/2000656X.2019.1650057 [doi]
AB  - The application of venous thromboembolism (VTE) prophylaxis has been the topic of 
      intense debate in plastic surgery. The overall incidence of VTE is low in plastic 
      surgery patients as compared to other surgical subspecialties but may be higher 
      in the inpatient rather than outpatient plastic surgery populations. The Caprini 
      Risk Assessment Model is the most highly studied and validated tool to assess VTE 
      risk in plastic surgery patients. However, the Caprini model lacks 
      procedure-specific risk assessment and patient-specific risk factor calculations. 
      Due to these limitations, such as the low incidence and the heterogeneous nature 
      of the specialty, trials lacked the power to capture proof of benefit, except in 
      the highest-risk inpatient population. The emerging use of aspirin and novel oral 
      anticoagulants may provide an alternative, as noninferiority in terms of efficacy 
      and safety has been demonstrated in other fields. In this review, the authors 
      intend to summarize the current state of evidence for prevention and explore the 
      modalities available for prophylaxis, including novel oral anticoagulants.
FAU - Fan, Kenneth L
AU  - Fan KL
AD  - Department of Plastic and Reconstructive Surgery, MedStar Georgetown University 
      Hospital, Washington DC, USA.
FAU - Black, Cara K
AU  - Black CK
AD  - Department of Plastic and Reconstructive Surgery, MedStar Georgetown University 
      Hospital, Washington DC, USA.
FAU - Abbate, Olivia
AU  - Abbate O
AD  - Harvard Plastic Surgery, Brigham & Women's Hospital, Boston, MA, USA.
FAU - Lu, Karen
AU  - Lu K
AD  - University of Central Florida School of Medicine, Orlando, FL, USA.
FAU - Camden, Rachel C
AU  - Camden RC
AD  - Department of Plastic and Reconstructive Surgery, MedStar Georgetown University 
      Hospital, Washington DC, USA.
FAU - Evans, Karen K
AU  - Evans KK
AD  - Department of Plastic and Reconstructive Surgery, MedStar Georgetown University 
      Hospital, Washington DC, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190903
PL  - Sweden
TA  - J Plast Surg Hand Surg
JT  - Journal of plastic surgery and hand surgery
JID - 101534130
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Chemoprevention
MH  - Heparin, Low-Molecular-Weight/pharmacology/therapeutic use
MH  - Humans
MH  - Incidence
MH  - Postoperative Complications
MH  - Pyrazoles/pharmacology/therapeutic use
MH  - Pyridones/pharmacology/therapeutic use
MH  - Plastic Surgery Procedures/*adverse effects
MH  - *Risk Assessment
MH  - Rivaroxaban/pharmacology/therapeutic use
MH  - Venous Thromboembolism/*prevention & control
OTO - NOTNLM
OT  - Plastic surgery
OT  - aspirin
OT  - direct oral anticoagulants
OT  - low molecular weight heparin
OT  - risk assessment
OT  - venothromboembolism
EDAT- 2019/09/04 06:00
MHDA- 2020/01/01 06:00
CRDT- 2019/09/04 06:00
PHST- 2019/09/04 06:00 [pubmed]
PHST- 2020/01/01 06:00 [medline]
PHST- 2019/09/04 06:00 [entrez]
AID - 10.1080/2000656X.2019.1650057 [doi]
PST - ppublish
SO  - J Plast Surg Hand Surg. 2019 Dec;53(6):370-380. doi: 
      10.1080/2000656X.2019.1650057. Epub 2019 Sep 3.

PMID- 11010751
OWN - NLM
STAT- MEDLINE
DCOM- 20000922
LR  - 20131121
IS  - 1167-7422 (Print)
IS  - 1167-7422 (Linking)
VI  - 9
IP  - 47
DP  - 2000 Jun
TI  - Antiplatelet drugs in cardiovascular prevention: stroke prevention in patients 
      with thrombogenic heart disease.
PG  - 87-8
AB  - (1) In patients with atrial fibrillation and a moderate embolic risk, aspirin 
      reduces the risk of stroke and has a comparable risk-benefit ratio to oral 
      anticoagulants. (2) Oral anticoagulants are superior to aspirin in patients with 
      atrial fibrillation and a history of stroke. (3) In patients with a mechanical 
      valve prosthesis and a high embolic risk, the oral anticoagulant + aspirin 
      combination has a better risk-benefit ratio than oral anticoagulant alone.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Prescrire Int
JT  - Prescrire international
JID - 9439295
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Anticoagulants/therapeutic use
MH  - *Aspirin/administration & dosage/therapeutic use
MH  - Atrial Fibrillation
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Embolism/prevention & control
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Risk Factors
MH  - *Stroke/etiology/prevention & control
MH  - *Thrombosis/complications/drug therapy
MH  - Treatment Outcome
EDAT- 2000/09/30 11:00
MHDA- 2000/09/30 11:01
CRDT- 2000/09/30 11:00
PHST- 2000/09/30 11:00 [pubmed]
PHST- 2000/09/30 11:01 [medline]
PHST- 2000/09/30 11:00 [entrez]
PST - ppublish
SO  - Prescrire Int. 2000 Jun;9(47):87-8.

PMID- 36291709
OWN - NLM
STAT- MEDLINE
DCOM- 20221028
LR  - 20221222
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 12
IP  - 10
DP  - 2022 Oct 17
TI  - High-Intensity Exercise Training Improves Basal Platelet Prostacyclin Sensitivity 
      and Potentiates the Response to Dual Anti-Platelet Therapy in Postmenopausal 
      Women.
LID - 10.3390/biom12101501 [doi]
LID - 1501
AB  - The risk of thrombotic events dramatically increases with age and may be 
      accelerated in women by the cessation of endogenous estrogen production at 
      menopause. Patients at risk of thrombosis are prescribed dual anti-platelet 
      therapy (DAPT; aspirin and a P2Y(12) antagonist) and are encouraged to 
      participate in regular physical activity, as these modalities improve nitric 
      oxide and prostacyclin-mediated inhibition of platelet aggregation. METHODS: We 
      assessed prostacyclin sensitivity as well as basal platelet reactivity with and 
      without in vitro DAPT before and after an 8-week high-intensity exercise training 
      program in 13 healthy, sedentary postmenopausal women. The training intervention 
      consisted of three 1 h sessions per week. Isolated platelets were analyzed for 
      thromboxane A(2) receptor, thromboxane A(2) synthase, cyclooxygenase-1, and 
      prostacyclin receptor protein expression. Additionally, plasma 6-keto 
      prostaglandin F(1)(α) and thromboxane B(2) levels were determined. RESULTS: 
      Exercise training made platelets more sensitive to the inhibitory effects of 
      prostacyclin on thromboxane-, collagen-, and adenosine 5'-diphosphate 
      (ADP)-induced aggregation, as well as thrombin-receptor activator peptide 6- and 
      ADP-induced aggregation with DAPT. However, there was no change in protein 
      expression from isolated platelets or plasma thromboxane B(2) and prostacyclin 
      levels following training. CONCLUSION: Together, these findings emphasize the 
      importance of promoting physical activity as a tool for reducing thrombotic risk 
      in postmenopausal women and suggest that training status should be considered 
      when prescribing DAPT in this cohort.
FAU - Wickham, Kate A
AU  - Wickham KA
AUID- ORCID: 0000-0002-2702-6695
AD  - August Krogh Section for Human Physiology, Department of Nutrition, Exercise and 
      Sports, University of Copenhagen, 2100 Copenhagen, Denmark.
AD  - Environmental Ergonomics Lab, Department of Kinesiology, Brock University, St. 
      Catharines, ON L2S 3A1, Canada.
FAU - Nørregaard, Line B
AU  - Nørregaard LB
AD  - August Krogh Section for Human Physiology, Department of Nutrition, Exercise and 
      Sports, University of Copenhagen, 2100 Copenhagen, Denmark.
FAU - Lundberg Slingsby, Martina H
AU  - Lundberg Slingsby MH
AD  - August Krogh Section for Human Physiology, Department of Nutrition, Exercise and 
      Sports, University of Copenhagen, 2100 Copenhagen, Denmark.
FAU - Cheung, Stephen S
AU  - Cheung SS
AUID- ORCID: 0000-0002-6149-4978
AD  - Environmental Ergonomics Lab, Department of Kinesiology, Brock University, St. 
      Catharines, ON L2S 3A1, Canada.
FAU - Hellsten, Ylva
AU  - Hellsten Y
AD  - August Krogh Section for Human Physiology, Department of Nutrition, Exercise and 
      Sports, University of Copenhagen, 2100 Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221017
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
RN  - DCR9Z582X0 (Epoprostenol)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 3.4.21.5 (Thrombin)
RN  - 0 (Diphosphates)
RN  - 0 (Receptors, Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Thromboxanes)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 0 (Receptors, Thromboxane)
RN  - 0 (Estrogens)
RN  - K72T3FS567 (Adenosine)
RN  - 0 (Peptides)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Epoprostenol/pharmacology
MH  - Cyclooxygenase 1
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Dual Anti-Platelet Therapy
MH  - Nitric Oxide/pharmacology
MH  - Thrombin
MH  - Postmenopause
MH  - Diphosphates
MH  - Receptors, Epoprostenol
MH  - Aspirin/pharmacology/therapeutic use
MH  - Thromboxanes
MH  - Adenosine Diphosphate
MH  - Exercise
MH  - *Thrombosis
MH  - Receptors, Thromboxane
MH  - Estrogens
MH  - Adenosine
MH  - Peptides
PMC - PMC9599223
OTO - NOTNLM
OT  - coagulation
OT  - dual anti-platelet therapy
OT  - exercise
OT  - menopause
OT  - platelets
OT  - prostacyclin
OT  - thrombosis
COIS- The authors have no conflict of interest to declare.
EDAT- 2022/10/28 06:00
MHDA- 2022/10/29 06:00
CRDT- 2022/10/27 01:13
PHST- 2022/09/09 00:00 [received]
PHST- 2022/10/11 00:00 [revised]
PHST- 2022/10/12 00:00 [accepted]
PHST- 2022/10/27 01:13 [entrez]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/29 06:00 [medline]
AID - biom12101501 [pii]
AID - biomolecules-12-01501 [pii]
AID - 10.3390/biom12101501 [doi]
PST - epublish
SO  - Biomolecules. 2022 Oct 17;12(10):1501. doi: 10.3390/biom12101501.

PMID- 3230331
OWN - NLM
STAT- MEDLINE
DCOM- 19890414
LR  - 20191029
IS  - 0197-8357 (Print)
IS  - 0197-8357 (Linking)
VI  - 8
IP  - 6
DP  - 1988 Dec
TI  - Effect of indomethacin, aspirin, and acetaminophen on in vitro antiviral and 
      antiproliferative activities of recombinant human interferon-alpha 2a.
PG  - 727-33
AB  - The effects of indomethacin, aspirin, and acetaminophen on the antiviral and 
      antiproliferative activities of recombinant human interferon-alpha 2a (rIFN-alpha 
      2a) were studied in vitro. None of the drugs inhibited the antiviral activity of 
      rIFN-alpha 2a in human amnion FL cells against vesicular stomatitis virus, or 
      interfered with its antiproliferative activity against acute lymphoblastic 
      leukemia MOLT-4 cells or renal cell carcinoma NC 65 cells. Although, at high 
      concentrations, aspirin (1 mM) or indomethacin (0.1 mM) alone inhibited the cell 
      growth, rIFN-alpha 2a showed clear additive growth inhibition. It was concluded 
      that neither indomethacin, aspirin, nor acetaminophen directly inhibited the 
      antiviral and antiproliferative activities of rIFN-alpha 2a. The possible use of 
      these three drugs to reduce the adverse effects of rIFN-alpha 2a without spoiling 
      its profitable efficacy in clinical practice is suggested.
FAU - Takaoki, M
AU  - Takaoki M
AD  - Central Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan.
FAU - Yamashita, Y
AU  - Yamashita Y
FAU - Koike, K
AU  - Koike K
FAU - Matsuda, S
AU  - Matsuda S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Interferon Res
JT  - Journal of interferon research
JID - 8100396
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon Type I)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetaminophen/administration & dosage/*pharmacology
MH  - Animals
MH  - *Antiviral Agents
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cell Division/*drug effects
MH  - Cell Line
MH  - Drug Interactions
MH  - Humans
MH  - Indomethacin/administration & dosage/*pharmacology
MH  - Interferon Type I/*pharmacology
MH  - Interferon alpha-2
MH  - Interferon-alpha/*pharmacology
MH  - Mice
MH  - Recombinant Proteins
MH  - Tumor Cells, Cultured/drug effects
EDAT- 1988/12/01 00:00
MHDA- 1988/12/01 00:01
CRDT- 1988/12/01 00:00
PHST- 1988/12/01 00:00 [pubmed]
PHST- 1988/12/01 00:01 [medline]
PHST- 1988/12/01 00:00 [entrez]
AID - 10.1089/jir.1988.8.727 [doi]
PST - ppublish
SO  - J Interferon Res. 1988 Dec;8(6):727-33. doi: 10.1089/jir.1988.8.727.

PMID- 20335572
OWN - NLM
STAT- MEDLINE
DCOM- 20100504
LR  - 20220317
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 362
IP  - 17
DP  - 2010 Apr 29
TI  - Aspirin plus heparin or aspirin alone in women with recurrent miscarriage.
PG  - 1586-96
LID - 10.1056/NEJMoa1000641 [doi]
AB  - BACKGROUND: Aspirin and low-molecular-weight heparin are prescribed for women 
      with unexplained recurrent miscarriage, with the goal of improving the rate of 
      live births, but limited data from randomized, controlled trials are available to 
      support the use of these drugs. METHODS: In this randomized trial, we enrolled 
      364 women between the ages of 18 and 42 years who had a history of unexplained 
      recurrent miscarriage and were attempting to conceive or were less than 6 weeks 
      pregnant. We then randomly assigned them to receive daily 80 mg of aspirin plus 
      open-label subcutaneous nadroparin (at a dose of 2850 IU, starting as soon as a 
      viable pregnancy was demonstrated), 80 mg of aspirin alone, or placebo. The 
      primary outcome measure was the live-birth rate. Secondary outcomes included 
      rates of miscarriage, obstetrical complications, and maternal and fetal adverse 
      events. RESULTS: Live-birth rates did not differ significantly among the three 
      study groups. The proportions of women who gave birth to a live infant were 54.5% 
      in the group receiving aspirin plus nadroparin (combination-therapy group), 50.8% 
      in the aspirin-only group, and 57.0% in the placebo group (absolute difference in 
      live-birth rate: combination therapy vs. placebo, -2.6 percentage points; 95% 
      confidence interval [CI], -15.0 to 9.9; aspirin only vs. placebo, -6.2 percentage 
      points; 95% CI, -18.8 to 6.4). Among 299 women who became pregnant, the 
      live-birth rates were 69.1% in the combination-therapy group, 61.6% in the 
      aspirin-only group, and 67.0% in the placebo group (absolute difference in 
      live-birth rate: combination therapy vs. placebo, 2.1 percentage points; 95% CI, 
      -10.8 to 15.0; aspirin alone vs. placebo -5.4 percentage points; 95% CI, -18.6 to 
      7.8). An increased tendency to bruise and swelling or itching at the injection 
      site occurred significantly more frequently in the combination-therapy group than 
      in the other two study groups. CONCLUSIONS: Neither aspirin combined with 
      nadroparin nor aspirin alone improved the live-birth rate, as compared with 
      placebo, among women with unexplained recurrent miscarriage. (Current Controlled 
      Trials number, ISRCTN58496168.)
CI  - 2010 Massachusetts Medical Society
FAU - Kaandorp, Stef P
AU  - Kaandorp SP
AD  - Department of Obstetrics and Gynecology, Academic Medical Center, University of 
      Amsterdam, Amsterdam, The Netherlands.
FAU - Goddijn, Mariëtte
AU  - Goddijn M
FAU - van der Post, Joris A M
AU  - van der Post JA
FAU - Hutten, Barbara A
AU  - Hutten BA
FAU - Verhoeve, Harold R
AU  - Verhoeve HR
FAU - Hamulyák, Karly
AU  - Hamulyák K
FAU - Mol, Ben Willem
AU  - Mol BW
FAU - Folkeringa, Nienke
AU  - Folkeringa N
FAU - Nahuis, Marleen
AU  - Nahuis M
FAU - Papatsonis, Dimitri N M
AU  - Papatsonis DN
FAU - Büller, Harry R
AU  - Büller HR
FAU - van der Veen, Fulco
AU  - van der Veen F
FAU - Middeldorp, Saskia
AU  - Middeldorp S
LA  - eng
SI  - ISRCTN/ISRCTN58496168
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100324
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anticoagulants)
RN  - 0 (Nadroparin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2010 Apr 29;362(17):1630-1. PMID: 20335577
CIN - N Engl J Med. 2010 Aug 26;363(9):887; author reply 888. PMID: 20738192
CIN - N Engl J Med. 2010 Aug 26;363(9):887-8; author reply 888. PMID: 20799392
CIN - Ann Intern Med. 2010 Oct 19;153(8):JC4-7. PMID: 20956703
MH  - Abortion, Habitual/*prevention & control
MH  - Adult
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Contusions/chemically induced
MH  - Drug Therapy, Combination/adverse effects
MH  - Female
MH  - Humans
MH  - Live Birth
MH  - Nadroparin/adverse effects/*therapeutic use
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Pregnancy
MH  - Treatment Failure
MH  - Young Adult
EDAT- 2010/03/26 06:00
MHDA- 2010/05/05 06:00
CRDT- 2010/03/26 06:00
PHST- 2010/03/26 06:00 [entrez]
PHST- 2010/03/26 06:00 [pubmed]
PHST- 2010/05/05 06:00 [medline]
AID - NEJMoa1000641 [pii]
AID - 10.1056/NEJMoa1000641 [doi]
PST - ppublish
SO  - N Engl J Med. 2010 Apr 29;362(17):1586-96. doi: 10.1056/NEJMoa1000641. Epub 2010 
      Mar 24.

PMID- 16359516
OWN - NLM
STAT- MEDLINE
DCOM- 20060221
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 3
IP  - 12
DP  - 2005 Dec
TI  - Persistent production of platelet thromboxane A2 in patients chronically treated 
      with aspirin.
PG  - 2784-9
AB  - BACKGROUND: Patients treated with aspirin may have a reduced sensitivity to its 
      antiplatelet effect. The mechanism accounting for such a reduced sensitivity 
      might involve an impaired interaction of aspirin with cyclooxygenase-1 (COX)-1. 
      OBJECTIVE: We sought to investigate whether platelets from patients under chronic 
      treatment with aspirin still produce TxA2 and whether there is any relationship 
      between the eventual persistent TxA2 formation and platelet aggregation. Finally, 
      whether platelet-derived TxA2 can be inhibited by in vitro addition of aspirin. 
      METHODS: Collagen-induced platelet aggregation and thromboxane-A2 (TxA2) were 
      measured in 196 patients treated with aspirin (100-330 mg day(-1)) because of 
      previous vascular events or presence of risk factors of atherosclerosis. RESULTS: 
      Collagen-induced TxA2 production of the entire cohort was 128.7 +/- 21.6 pg 
      10(-8) cells, and was significantly correlated with platelet aggregation 
      (Spearman's correlation coefficient = 0.44; P < 0.0001). Patients in the highest 
      quartile of TxA2 showed higher platelet response to collagen (P < 0.0001) when 
      compared with those in the lowest quartile. In a subgroup of 96 patients, 
      platelets were treated in vitro with a TxA2 receptor antagonist (13-azaprostanoic 
      acid) or aspirin before stimulation with collagen. 13-APA acid significantly 
      inhibited platelet aggregation. Aspirin reduced (-72.9%) TxA2 production in 
      patients with TxA2 values above the median but it was ineffective in those with 
      TxA2 values below the median. CONCLUSION: In some patients chronically treated 
      with aspirin platelet production of TxA2 may persist and account for enhanced 
      platelet aggregation. Incomplete inhibition of COX-1 seems to be implicated in 
      persistent TxA2 production.
FAU - Pulcinelli, F M
AU  - Pulcinelli FM
AD  - Department of Experimental Medicine and Pathology, University La Sapienza, Roma 
      00161, Italy. fabio.pulcinelli@uniroma1.it
FAU - Riondino, S
AU  - Riondino S
FAU - Celestini, A
AU  - Celestini A
FAU - Pignatelli, P
AU  - Pignatelli P
FAU - Trifirò, E
AU  - Trifirò E
FAU - Di Renzo, L
AU  - Di Renzo L
FAU - Violi, F
AU  - Violi F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 57576-52-0 (Thromboxane A2)
RN  - 9007-34-5 (Collagen)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*metabolism
MH  - Cardiovascular Diseases/blood/drug therapy
MH  - Collagen
MH  - Cyclooxygenase 1/drug effects
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Thromboxane A2/antagonists & inhibitors/*biosynthesis/physiology
EDAT- 2005/12/20 09:00
MHDA- 2006/02/24 09:00
CRDT- 2005/12/20 09:00
PHST- 2005/12/20 09:00 [pubmed]
PHST- 2006/02/24 09:00 [medline]
PHST- 2005/12/20 09:00 [entrez]
AID - S1538-7836(22)16752-8 [pii]
AID - 10.1111/j.1538-7836.2005.01633.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2005 Dec;3(12):2784-9. doi: 10.1111/j.1538-7836.2005.01633.x.

PMID- 1675315
OWN - NLM
STAT- MEDLINE
DCOM- 19910717
LR  - 20190610
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 337
IP  - 8755
DP  - 1991 Jun 15
TI  - Prevention of fetal growth retardation with low-dose aspirin: findings of the 
      EPREDA trial.
PG  - 1427-31
AB  - The efficacy of low-dose aspirin in preventing fetal growth retardation was 
      tested in a randomised, placebo-controlled, double-blind trial. A secondary aim 
      was to find out whether dipyridamole improves the efficacy of aspirin. 323 women 
      at 15-18 weeks' amenorrhoea were selected at twenty-five participating centres on 
      the basis of fetal growth retardation and/or fetal death or abruptio placentae in 
      at least one previous pregnancy. They were randomly allocated to groups receiving 
      placebo, 150 mg/day aspirin, or 150 mg/day aspirin plus 225 mg/day dipyridamole, 
      for the remainder of the pregnancy. In the first phase of the trial all actively 
      treated patients (n = 156) were compared with the placebo group (n = 73). Mean 
      birthweight was significantly higher in the treated than in the placebo group 
      (2751 [SD 670] vs 2526 [848] g; difference 225 g [95% CI 129-321 g], p = 0.029) 
      and the frequency of fetal growth retardation in the placebo group was twice that 
      in the treated group (19 [26%] vs 20 [13%]; p less than 0.02). The frequencies of 
      stillbirth (4 [5%] vs 2 [1%]) and abruptio placentae (6 [8%] vs 7 [5%]) were also 
      higher in the placebo than in the treated group. The benefits of aspirin 
      treatment were greater in patients with two or more previous poor outcomes than 
      in those with only one. In the second analysis, of aspirin only (n = 127) vs 
      aspirin plus dipyridamole (n = 119), no significant differences were found. There 
      was no excess of maternal or neonatal side-effects in the aspirin-treated 
      patients.
FAU - Uzan, S
AU  - Uzan S
AD  - Service de Gynécologie-Obstétrique, INSERM U 149, Paris, France.
FAU - Beaufils, M
AU  - Beaufils M
FAU - Breart, G
AU  - Breart G
FAU - Bazin, B
AU  - Bazin B
FAU - Capitant, C
AU  - Capitant C
FAU - Paris, J
AU  - Paris J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Drug Combinations)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 1991 Aug 3;338(8762):324. PMID: 1677150
CIN - Lancet. 1991 Aug 31;338(8766):579. PMID: 1678840
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Birth Weight/*drug effects
MH  - Dipyridamole/*administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Combinations
MH  - Drug Evaluation
MH  - Drug Synergism
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Gestational Age
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Pregnancy
MH  - Proteinuria/prevention & control
MH  - Recurrence
EDAT- 1991/06/15 00:00
MHDA- 1991/06/15 00:01
CRDT- 1991/06/15 00:00
PHST- 1991/06/15 00:00 [pubmed]
PHST- 1991/06/15 00:01 [medline]
PHST- 1991/06/15 00:00 [entrez]
AID - 0140-6736(91)93124-R [pii]
AID - 10.1016/0140-6736(91)93124-r [doi]
PST - ppublish
SO  - Lancet. 1991 Jun 15;337(8755):1427-31. doi: 10.1016/0140-6736(91)93124-r.

PMID- 8328199
OWN - NLM
STAT- MEDLINE
DCOM- 19930809
LR  - 20131121
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 82 Suppl 2
DP  - 1993
TI  - Adjunctive therapy in thrombolysis for acute myocardial infarction.
PG  - 179-82
AB  - The value of prompt coronary reperfusion utilizing thrombolytic therapy during 
      acute myocardial infarction has been well established. However, new data 
      indicates that although rapid reperfusion is imperative, this positive effect 
      may, in fact, be partially or totally negated if patency is not sustained and 
      complete. The following manuscript discusses the role of adjunctive agents in 
      thrombolysis that are essential in preventing coronary reocclusion. It is this 
      important function that serves to prevent recurrent ischemia and reinfarction, 
      thereby improving resultant left ventricular function. This, in turn, should have 
      a positive effect on post-thrombolytic mortality. The data presented in this 
      paper supports high dose, titrated intravenous heparin and aspirin as required 
      adjunctive therapy to thrombolytic treatment in the setting of acute myocardial 
      infarction.
FAU - Bleich, S D
AU  - Bleich SD
AD  - Cardiovascular Specialists Research Group, Metairie, Louisiana.
FAU - Rolston, W A
AU  - Rolston WA
FAU - Tilton, G D
AU  - Tilton GD
FAU - Mailander, L
AU  - Mailander L
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Coronary Thrombosis/*drug therapy
MH  - Drug Therapy, Combination
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*therapy
MH  - *Thrombolytic Therapy
RF  - 16
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Kardiol. 1993;82 Suppl 2:179-82.

PMID- 1562587
OWN - NLM
STAT- MEDLINE
DCOM- 19920520
LR  - 20190609
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1120
IP  - 2
DP  - 1992 Apr 8
TI  - Glycation of human serum albumin: inhibition by Diclofenac.
PG  - 201-4
AB  - Glycation is a non-enzymatic modification of proteins by sugars, probably 
      responsible for the initiation of complications in diabetes patients and aging 
      individuals. Our in vitro experiments show an inhibition of sugar attachment in 
      the presence of Diclofenac. The levels of advanced glycation products, measured 
      as specific fluorescent groups, were also lowered due to Diclofenac. These 
      results were compared with inhibition by Aspirin (acetylsalicylic acid), a known 
      inhibitor of the glycation process. The protection by Diclofenac is based on a 
      non-covalent interaction of the drug with serum albumin. There is evidence that 
      Diclofenac specifically blocks at least one of the major glycation sites of human 
      serum albumin.
FAU - van Boekel, M A
AU  - van Boekel MA
AD  - Department of Biochemistry, University of Nijmegen, Netherlands.
FAU - van den Bergh, P J
AU  - van den Bergh PJ
FAU - Hoenders, H J
AU  - Hoenders HJ
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Glucosephosphates)
RN  - 0 (Serum Albumin)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 56-73-5 (Glucose-6-Phosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Binding, Competitive
MH  - Diclofenac/*chemistry
MH  - Glucose-6-Phosphate
MH  - Glucosephosphates/*chemistry
MH  - Humans
MH  - Protein Binding
MH  - Serum Albumin/*chemistry
MH  - Spectrometry, Fluorescence
EDAT- 1992/04/08 00:00
MHDA- 1992/04/08 00:01
CRDT- 1992/04/08 00:00
PHST- 1992/04/08 00:00 [pubmed]
PHST- 1992/04/08 00:01 [medline]
PHST- 1992/04/08 00:00 [entrez]
AID - 0167-4838(92)90270-N [pii]
AID - 10.1016/0167-4838(92)90270-n [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 1992 Apr 8;1120(2):201-4. doi: 
      10.1016/0167-4838(92)90270-n.

PMID- 11577831
OWN - NLM
STAT- MEDLINE
DCOM- 20020109
LR  - 20131121
IS  - 1129-471X (Print)
IS  - 1129-471X (Linking)
VI  - 2
IP  - 8
DP  - 2001 Aug
TI  - Aspirin and the prevention of ischemic heart disease. A Socratic dialogue between 
      a cardiologist, a clinical pharmacologist and an expert of blood platelets.
PG  - 582-8
AB  - The recent publication of the results of the "Progetto di Prevenzione Primaria" 
      by a large Italian group of researchers and general practitioners, prompts a 
      cardiologist, a clinical pharmacologist and a blood platelet expert to review - 
      using a Socratic dialogue style--the data on aspirin as a prototypal drug in the 
      prevention of ischemic heart disease. The distinction between primary and 
      secondary prevention seems to be rather artificial as it is based on past events 
      and not on the risk of future events. Although aspirin proved to be effective in 
      reducing both vascular mortality and non-fatal vascular events and is 
      inexpensive, it is still underused for prevention by many physicians. The major 
      indications on the beneficial effect of aspirin against ischemic heart disease 
      derive from large epidemiological trials and are valid for populations rather 
      than for single patients. Hopefully, biochemical markers such as C-reactive 
      protein or genetic polymorphism will help to establish the effects of aspirin in 
      more targeted groups or even in individuals.
FAU - de Gaetano, G
AU  - de Gaetano G
AD  - Center for High Technology Research and Education in Biomedical Sciences, 
      Catholic University of the Sacred Heart, Campobasso, Italy. degaetano@cotir.it
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Ital Heart J
JT  - Italian heart journal : official journal of the Italian Federation of Cardiology
JID - 100909716
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - C-Reactive Protein/analysis
MH  - Humans
MH  - Myocardial Ischemia/genetics/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Polymorphism, Genetic
EDAT- 2001/10/02 10:00
MHDA- 2002/01/10 10:01
CRDT- 2001/10/02 10:00
PHST- 2001/10/02 10:00 [pubmed]
PHST- 2002/01/10 10:01 [medline]
PHST- 2001/10/02 10:00 [entrez]
PST - ppublish
SO  - Ital Heart J. 2001 Aug;2(8):582-8.

PMID- 3061295
OWN - NLM
STAT- MEDLINE
DCOM- 19890131
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 159
IP  - 6
DP  - 1988 Dec
TI  - Low-dose aspirin inhibits thromboxane, but not prostacyclin, production by human 
      placental arteries.
PG  - 1381-4
AB  - Preeclampsia is associated with increased thromboxane and decreased prostacyclin 
      production by the placenta. Low-dose aspirin can selectively inhibit thromboxane 
      production in the adult circulation, but its effects on placental vascular 
      production of thromboxane and prostacyclin are incompletely understood. We 
      therefore studied the effects of low-dose aspirin on the production rates of 
      prostacyclin and thromboxane, with and without vasoconstricting doses of 
      angiotensin II, in human placental arteries. Chorionic plate arteries were 
      incubated and samples were assayed for thromboxane and prostacyclin by 
      radioimmunoassay of their stable metabolites. Production rates for prostacyclin 
      were similar in the control, aspirin, angiotensin II, and angiotensin II plus 
      aspirin groups. Mean (+/- SEM; n = 8) thromboxane production rates in the aspirin 
      (1.4 +/- 0.5 pg/mg/hr) and angiotensin II plus aspirin (2.9 +/- 0.6 pg/mg/hr) 
      groups were significantly lower (p less than 0.05) than values in the control 
      (8.6 +/- 2.7 pg/mg/hr) and angiotensin II (6.7 +/- 1.3 pg/mg/hr) groups. We 
      conclude that low-dose aspirin significantly decreases production of thromboxane 
      in placental arteries both with and without vasoconstricting doses of angiotensin 
      II.
FAU - Thorp, J A
AU  - Thorp JA
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, University of 
      Texas Medical School, Houston 77030.
FAU - Walsh, S W
AU  - Walsh SW
FAU - Brath, P C
AU  - Brath PC
LA  - eng
GR  - 2SO7 RR05745-15/RR/NCRR NIH HHS/United States
GR  - HD20973/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 11128-99-7 (Angiotensin II)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/biosynthesis
MH  - Angiotensin II/pharmacology
MH  - Arteries/metabolism
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Epoprostenol/*biosynthesis
MH  - Female
MH  - Humans
MH  - Placenta/*blood supply
MH  - Pregnancy
MH  - Thromboxane B2/*antagonists & inhibitors
EDAT- 1988/12/01 00:00
MHDA- 1988/12/01 00:01
CRDT- 1988/12/01 00:00
PHST- 1988/12/01 00:00 [pubmed]
PHST- 1988/12/01 00:01 [medline]
PHST- 1988/12/01 00:00 [entrez]
AID - 0002-9378(88)90560-1 [pii]
AID - 10.1016/0002-9378(88)90560-1 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1988 Dec;159(6):1381-4. doi: 10.1016/0002-9378(88)90560-1.

PMID- 3318428
OWN - NLM
STAT- MEDLINE
DCOM- 19871223
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 83
IP  - 4B
DP  - 1987 Oct 30
TI  - Long-term treatment of rheumatoid arthritis comparing nabumetone with aspirin.
PG  - 44-9
AB  - This report summarizes the results of a 17-investigator multicenter six-month 
      randomized double-blind parallel group study. The safety and efficacy of 
      nabumetone 1,000 mg taken at bedtime was compared with that of aspirin 900 mg 
      four times daily in the treatment of adult patients with active class II or III 
      classical or definite rheumatoid arthritis. Two hundred sixty-four patients were 
      entered into the study. Two hundred fifty-seven (126 nabumetone and 131 aspirin) 
      patients were evaluable for safety. Two hundred thirty-four (113 nabumetone and 
      121 aspirin) patients were evaluable for efficacy. There was significant 
      improvement in each of six clinical measurements of efficacy in both treatment 
      groups and little difference between groups. The somewhat greater improvement in 
      articular index and duration of morning stiffness in the nabumetone-treated group 
      did not reach statistical significance. There was an equal percentage of patient 
      withdrawal for lack of efficacy in each group. Overall, the rate of patient 
      withdrawal due to adverse experiences was greater (p = 0.01) for aspirin-treated 
      patients. These experiences were usually dispepsia, abdominal pain, and tinnitus. 
      It was concluded that nabumetone was an effective anti-inflammatory drug in the 
      treatment of rheumatoid arthritis with less toxicity than aspirin.
FAU - Bernhard, G C
AU  - Bernhard GC
AD  - Midwest Arthritis Treatment Center, Columbia Hospital, Milwaukee, Wisconsin 
      53211.
FAU - Appelrouth, D J
AU  - Appelrouth DJ
FAU - Bankhurst, A D
AU  - Bankhurst AD
FAU - Biundo, J
AU  - Biundo J
FAU - Bockow, B I
AU  - Bockow BI
FAU - Brobyn, R D
AU  - Brobyn RD
FAU - Brodsky, A L
AU  - Brodsky AL
FAU - Burch, F X
AU  - Burch FX
FAU - Chang, R W
AU  - Chang RW
FAU - Cohen, M H
AU  - Cohen MH
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Butanones)
RN  - LW0TIW155Z (Nabumetone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Butanones/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nabumetone
MH  - Random Allocation
EDAT- 1987/10/30 00:00
MHDA- 1987/10/30 00:01
CRDT- 1987/10/30 00:00
PHST- 1987/10/30 00:00 [pubmed]
PHST- 1987/10/30 00:01 [medline]
PHST- 1987/10/30 00:00 [entrez]
AID - 0002-9343(87)90593-6 [pii]
AID - 10.1016/0002-9343(87)90593-6 [doi]
PST - ppublish
SO  - Am J Med. 1987 Oct 30;83(4B):44-9. doi: 10.1016/0002-9343(87)90593-6.

PMID- 2711837
OWN - NLM
STAT- MEDLINE
DCOM- 19890605
LR  - 20131121
IS  - 0001-6659 (Print)
IS  - 0001-6659 (Linking)
VI  - 59
IP  - 1
DP  - 1989 Jan
TI  - [Formulation of effervescent tablets containing acetylsalicylic acid. III. 
      Investigation of the stability of the active principles of tablets].
PG  - 11-5
AB  - Parameters influencing the stability of active principles of effervescent tablets 
      containing acetylsalicylic acid were investigated. On the basis of factorial 
      experiment project the effects of contents of citric acid: sodium hydrogen 
      carbonate, polyvinylpyrrolidone and those of storing temperature of tablets and 
      humidity of atmosphere on decomposition of active principle were studied. High 
      performance liquid chromatographic method has been developed for simultaneous 
      determination of acetylsalicylic acid and salicylic acid. It has been established 
      that first of all storing circumstances effect the stability of preparation and 
      composition of tablets also significantly influences the decomposition of 
      acetylsalicylic acid.
FAU - Dévay, A
AU  - Dévay A
FAU - Kovács, P
AU  - Kovács P
FAU - Rácz, I
AU  - Rácz I
LA  - hun
PT  - English Abstract
PT  - Journal Article
TT  - Acetilszalicilsav tartalmú pezsgötabletta formulálása. III. A tabletták hatóanyag 
      stabilitásának vizsgálata.
PL  - Hungary
TA  - Acta Pharm Hung
JT  - Acta pharmaceutica Hungarica
JID - 0414322
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - Drug Stability
MH  - *Tablets
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Pharm Hung. 1989 Jan;59(1):11-5.

PMID- 6344629
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 74
IP  - 6A
DP  - 1983 Jun 14
TI  - Influence of aspirin on platelets and the bleeding time.
PG  - 72-8
AB  - Aspirin influences the bleeding time, presumably through the inhibition of 
      prostaglandin biosynthesis and the resultant platelet secretion reaction. This 
      can be measured by prolongation of the bleeding time and changes in platelet 
      function results. Despite these changes, bleeding is rarely a problem in patients 
      who have normal hemostatic mechanisms. To investigate this, we have studied the 
      technical variables associated with the determination of the bleeding time. Both 
      venostasis and direction of the incision play a major role in the bleeding time 
      prolongation induced by aspirin. When a bleeding time determination is performed 
      with vertical incision without venostasis, there is almost no detectable 
      prolongation of the bleeding time. These studies support our previous 
      observations that aspirin has a mild influence on primary hemostasis.
FAU - Mielke, C H Jr
AU  - Mielke CH Jr
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Tests/methods
MH  - Blood Platelets/*drug effects
MH  - Cell Adhesion/drug effects
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Platelet Aggregation/drug effects
RF  - 41
EDAT- 1983/06/14 00:00
MHDA- 2001/03/28 10:01
CRDT- 1983/06/14 00:00
PHST- 1983/06/14 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1983/06/14 00:00 [entrez]
AID - 0002-9343(83)90532-6 [pii]
AID - 10.1016/0002-9343(83)90532-6 [doi]
PST - ppublish
SO  - Am J Med. 1983 Jun 14;74(6A):72-8. doi: 10.1016/0002-9343(83)90532-6.

PMID- 15975467
OWN - NLM
STAT- MEDLINE
DCOM- 20050802
LR  - 20220317
IS  - 0886-3350 (Print)
IS  - 0886-3350 (Linking)
VI  - 31
IP  - 5
DP  - 2005 May
TI  - Perioperative use of warfarin and aspirin in cataract surgery by Canadian Society 
      of Cataract and Refractive Surgery members: survey.
PG  - 991-6
AB  - PURPOSE: To survey the members of the Canadian Society of Cataract and Refractive 
      Surgery (CSCRS) and identify their practices regarding the perioperative use of 
      warfarin and acetylsalicylic acid (aspirin) in cataract surgery. SETTING: Private 
      practice, Regina, Saskatchewan, Canada. METHODS: Members of the CSCRS were faxed 
      a questionnaire that examined their perioperative management of patients being 
      treated with warfarin and aspirin. RESULTS: Of the 110 eligible participants, 82 
      returned a completed questionnaire, representing a response rate of 74.5%. 
      Warfarin or aspirin was routinely stopped prior to cataract surgery by 25.6% of 
      the respondents. The majority of surgeons who discontinued these medications 
      reported doing so 3 to 7 days prior to surgery and resumed their use 1 to 2 days 
      postoperatively. Topical anesthesia and clear corneal incisions were preferred by 
      the higher volume surgeons. These surgeons were also less likely to discontinue 
      either warfarin or aspirin preoperatively. CONCLUSIONS: The majority of the 
      Canadian Society of Cataract and Refractive Surgery members do not stop either 
      warfarin or aspirin for cataract surgery during the perioperative period.
FAU - Ong-Tone, Lindsay
AU  - Ong-Tone L
AD  - University of Saskatchewan, Canada. longtone@accesscomm.ca
FAU - Paluck, Elan C
AU  - Paluck EC
FAU - Hart-Mitchell, Regan D
AU  - Hart-Mitchell RD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cataract Refract Surg
JT  - Journal of cataract and refractive surgery
JID - 8604171
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anesthesia, Local/methods
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Canada
MH  - *Cataract Extraction
MH  - Drug Utilization/statistics & numerical data
MH  - Female
MH  - Health Surveys
MH  - Humans
MH  - Male
MH  - Ophthalmology
MH  - Perioperative Care
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Societies, Medical/statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2005/06/25 09:00
MHDA- 2005/08/03 09:00
CRDT- 2005/06/25 09:00
PHST- 2004/09/29 00:00 [accepted]
PHST- 2005/06/25 09:00 [pubmed]
PHST- 2005/08/03 09:00 [medline]
PHST- 2005/06/25 09:00 [entrez]
AID - S0886-3350(04)01226-X [pii]
AID - 10.1016/j.jcrs.2004.09.058 [doi]
PST - ppublish
SO  - J Cataract Refract Surg. 2005 May;31(5):991-6. doi: 10.1016/j.jcrs.2004.09.058.

PMID- 841682
OWN - NLM
STAT- MEDLINE
DCOM- 19770425
LR  - 20190727
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 17
IP  - 1
DP  - 1977 Jan-Feb
TI  - Viability and function of platelets frozen at 2 to 3 C per minute with 4 or 5 per 
      cent DMSO and stored at -80 C for 8 months.
PG  - 8-15
AB  - Each of 15 healthy male volunteers was treated with 650 mg of aspirin 24 hours 
      before the autologous transfusion of one unit of freeze-preserved platelets. 
      Freeze-thaw-wash recovery values in vitro, viability and function in vivo, and 
      the bleeding time and platelet aggregation response were measured. The platelets 
      were frozen with 4 or 5 per cent dimethylsulfoxide (DMSO) at an overall rate of 2 
      to 3 C per minute and were stored at -80 C in a mechanical freezer for up to 
      eight months. They were washed by dilution/centrifugation. The mean recovery in 
      vitro of platelets frozen with 4 per cent DMSO was 76+/-16%; the value was 
      64+/-16% for platelets frozen with 5% DMSO. The mean in vivo 51Cr recovery of 
      autologous platelets frozen with 4% DMSO was 34+/-6%, and for platelets frozen 
      with 5% DMSO it was 33+/-7%. In both groups the platelet lifespan was normal. 
      There was a significant reduction in bleeding time after the transfusion of a 
      single unit of autologous platelets preserved with either 4 or 5% DMSO, but no 
      improvement in the aspirin-induced platelet aggregation pattern.
FAU - Spector, J I
AU  - Spector JI
FAU - Yarmala, J A
AU  - Yarmala JA
FAU - Marchionni, L D
AU  - Marchionni LD
FAU - Emerson, C P
AU  - Emerson CP
FAU - Valeri, C R
AU  - Valeri CR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - R16CO5Y76E (Aspirin)
RN  - YOW8V9698H (Dimethyl Sulfoxide)
SB  - IM
MH  - Aspirin/pharmacology
MH  - *Blood Platelets/metabolism
MH  - *Blood Preservation
MH  - Cell Survival
MH  - *Dimethyl Sulfoxide
MH  - *Freezing
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Transfusion
MH  - Time Factors
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1046/j.1537-2995.1977.17177128894.x [doi]
PST - ppublish
SO  - Transfusion. 1977 Jan-Feb;17(1):8-15. doi: 
      10.1046/j.1537-2995.1977.17177128894.x.

PMID- 27064677
OWN - NLM
STAT- MEDLINE
DCOM- 20170427
LR  - 20220409
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 164
IP  - 12
DP  - 2016 Jun 21
TI  - Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal 
      Cancer: U.S. Preventive Services Task Force Recommendation Statement.
PG  - 836-45
LID - 10.7326/M16-0577 [doi]
AB  - DESCRIPTION: Update of the 2009 USPSTF recommendation on aspirin use to prevent 
      cardiovascular disease (CVD) events and the 2007 recommendation on aspirin and 
      nonsteroidal anti-inflammatory drug use to prevent colorectal cancer (CRC). 
      METHODS: The USPSTF reviewed 5 additional studies of aspirin for the primary 
      prevention of CVD and several additional analyses of CRC follow-up data. The 
      USPSTF also relied on commissioned systematic reviews of all-cause mortality and 
      total cancer incidence and mortality and a comprehensive review of harms. The 
      USPSTF then used a microsimulation model to systematically estimate the balance 
      of benefits and harms. POPULATION: This recommendation applies to adults aged 40 
      years or older without known CVD and without increased bleeding risk. 
      RECOMMENDATIONS: The USPSTF recommends initiating low-dose aspirin use for the 
      primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or 
      greater 10-year CVD risk, are not at increased risk for bleeding, have a life 
      expectancy of at least 10 years, and are willing to take low-dose aspirin daily 
      for at least 10 years. (B recommendation) The decision to initiate low-dose 
      aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 69 
      years who have a 10% or greater 10-year CVD risk should be an individual one. 
      Persons who are not at increased risk for bleeding, have a life expectancy of at 
      least 10 years, and are willing to take low-dose aspirin daily for at least 10 
      years are more likely to benefit. Persons who place a higher value on the 
      potential benefits than the potential harms may choose to initiate low-dose 
      aspirin. (C recommendation) The current evidence is insufficient to assess the 
      balance of benefits and harms of initiating aspirin use for the primary 
      prevention of CVD and CRC in adults younger than 50 years. (I statement) The 
      current evidence is insufficient to assess the balance of benefits and harms of 
      initiating aspirin use for the primary prevention of CVD and CRC in adults aged 
      70 years or older. (I statement).
FAU - Bibbins-Domingo, Kirsten
AU  - Bibbins-Domingo K
CN  - U.S. Preventive Services Task Force
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
DEP - 20160412
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2016 Jun 21;164(12 ):846-7. PMID: 27064970
CIN - Am J Kidney Dis. 2017 Mar;69(3):337-340. PMID: 27889297
MH  - Adult
MH  - Anticarcinogenic Agents/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Colorectal Neoplasms/*prevention & control
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - *Primary Prevention
MH  - Risk Assessment
EDAT- 2016/04/12 06:00
MHDA- 2017/04/28 06:00
CRDT- 2016/04/12 06:00
PHST- 2016/04/12 06:00 [entrez]
PHST- 2016/04/12 06:00 [pubmed]
PHST- 2017/04/28 06:00 [medline]
AID - 2513179 [pii]
AID - 10.7326/M16-0577 [doi]
PST - ppublish
SO  - Ann Intern Med. 2016 Jun 21;164(12):836-45. doi: 10.7326/M16-0577. Epub 2016 Apr 
      12.

PMID- 10712
OWN - NLM
STAT- MEDLINE
DCOM- 19770103
LR  - 20191027
IS  - 0001-5148 (Print)
IS  - 0001-5148 (Linking)
VI  - 31
IP  - 5
DP  - 1976 Oct
TI  - Immunological mechanisms in aspirin hypersensitivity. Studies on the 
      immunogenicity of free aspirin.
PG  - 341-55
AB  - Anti-aspiryl antibodies were produced in rabbits and guinea pigs by inoculation 
      of aspirin incorporated in complete or incomplete Freund's adjuvant. These 
      antibodies were readily detected by passive haemagglutination using rabbit 
      erythrocytes incubated with aspirin at alkaline pH. Aspiryl conjugates with 
      ovalbumin, human gamma-globulin, bovine gamma-globulin and rabbit serum were also 
      prepared by incubating the proteins with aspirin at alkaline pH. Aspiryl 
      conjugates prepared by this technique behaved, immunologically, identically with 
      the conjugates prepared from aspirin chloride. By contrast, the molar absorbance 
      at 305 nm of the conjugates prepared from aspirin was about 25 times lower than 
      the molar absorbance of the conjugates prepared from aspirin chloride. Since the 
      absorbance of salicylic acid is about eight times greater than that of aspirin, 
      the conclusion is drawn that the aspiryl/salicylyl ratio is significantly higher 
      in the conjugates prepared by incubating proteins with aspirin at alkaline pH 
      than in the conjugates prepared from aspirin chloride. In parallel experiments, 
      salicylic acid did not induce formation of specific antibodies capable of 
      reacting with aspirin- or salicylic acid-treated red cells. Sera giving positive 
      passive haemagglutination with aspirin-treated erythrocytes did not react with 
      erythrocytes treated with salicylic acid or acetic anhydride.
FAU - Cîrstea, M
AU  - Cîrstea M
FAU - Suhaciu, G
AU  - Suhaciu G
FAU - Cîrje, M
AU  - Cîrje M
FAU - Ciontescu, L
AU  - Ciontescu L
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Acta Allergol
JT  - Acta allergologica
JID - 0370567
RN  - 0 (Anhydrides)
RN  - 0 (Antibodies)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anhydrides/pharmacology
MH  - Animals
MH  - Antibodies/analysis
MH  - Antibody Formation
MH  - Antibody Specificity
MH  - Aspirin/*immunology/pharmacology
MH  - Cell Membrane/immunology
MH  - Drug Hypersensitivity/*immunology
MH  - Erythrocytes/immunology
MH  - Female
MH  - Guinea Pigs
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Rabbits
MH  - Salicylates/immunology/pharmacology
MH  - Temperature
MH  - Time Factors
EDAT- 1976/10/01 00:00
MHDA- 1976/10/01 00:01
CRDT- 1976/10/01 00:00
PHST- 1976/10/01 00:00 [pubmed]
PHST- 1976/10/01 00:01 [medline]
PHST- 1976/10/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1976.tb01694.x [doi]
PST - ppublish
SO  - Acta Allergol. 1976 Oct;31(5):341-55. doi: 10.1111/j.1398-9995.1976.tb01694.x.

PMID- 24711050
OWN - NLM
STAT- MEDLINE
DCOM- 20140710
LR  - 20220410
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 160
IP  - 10
DP  - 2014 May 20
TI  - Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a 
      systematic evidence review for the U.S. Preventive Services Task Force.
PG  - 695-703
LID - 10.7326/M13-2844 [doi]
AB  - BACKGROUND: Preeclampsia is a leading cause of maternal and perinatal morbidity 
      and mortality. PURPOSE: To systematically review benefits and harms of low-dose 
      aspirin for preventing morbidity and mortality from preeclampsia. DATA SOURCES: 
      MEDLINE, Database of Abstracts of Reviews of Effects, PubMed, and Cochrane 
      Central Register of Controlled Trials (January 2006 to June 2013); previous 
      systematic reviews, clinical trial registries, and surveillance searches for 
      large studies (June 2013 to February 2014). STUDY SELECTION: Randomized, 
      controlled trials (RCTs) to assess benefits among women at high preeclampsia risk 
      and RCTs or large cohort studies of harms among women at any risk level. 
      English-language studies of fair or good quality were included. DATA EXTRACTION: 
      Dual quality assessment and abstraction of studies. DATA SYNTHESIS: Two large, 
      multisite RCTs and 13 smaller RCTs of high-risk women (8 good-quality) were 
      included, in addition to 6 RCTs and 2 observational studies of average-risk women 
      to assess harms (7 good-quality). Depending on baseline risk, aspirin use was 
      associated with absolute risk reductions of 2% to 5% for preeclampsia (relative 
      risk [RR], 0.76 [95% CI, 0.62 to 0.95]), 1% to 5% for intrauterine growth 
      restriction (RR, 0.80 [CI, 0.65 to 0.99]), and 2% to 4% for preterm birth (RR, 
      0.86 [CI, 0.76 to 0.98]). No significant perinatal or maternal harms were 
      identified, but rare harms could not be ruled out. Evidence on long-term outcomes 
      was sparse, but 18-month follow-up from the largest trial found no developmental 
      harms. LIMITATIONS: Benefits may have been overestimated due to small-study 
      effects. Predictive intervals were not statistically significant. Future studies 
      could shift findings toward the null. CONCLUSION: Daily low-dose aspirin 
      beginning as early as the second trimester prevented clinically important health 
      outcomes. No harms were identified, but long-term evidence was limited.
FAU - Henderson, Jillian T
AU  - Henderson JT
FAU - Whitlock, Evelyn P
AU  - Whitlock EP
FAU - O'Connor, Elizabeth
AU  - O'Connor E
FAU - Senger, Caitlyn A
AU  - Senger CA
FAU - Thompson, Jamie H
AU  - Thompson JH
FAU - Rowland, Maya G
AU  - Rowland MG
LA  - eng
GR  - HHS-290-2012-00015-I/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Evid Based Med. 2015 Feb;20(1):11. PMID: 25238770
CIN - Ann Intern Med. 2014 Oct 21;161(8):613. PMID: 25329210
CIN - Ann Intern Med. 2014 Oct 21;161(8):613-4. PMID: 25329211
CIN - Evid Based Nurs. 2015 Jul;18(3):71. PMID: 25743941
CIN - J Fam Pract. 2015 May;64(5):301-3. PMID: 26009747
MH  - Advisory Committees
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Fetal Growth Retardation/etiology/prevention & control
MH  - Humans
MH  - Pre-Eclampsia/*drug therapy/mortality
MH  - Pregnancy
MH  - Premature Birth/etiology/prevention & control
MH  - Randomized Controlled Trials as Topic
EDAT- 2014/04/09 06:00
MHDA- 2014/07/11 06:00
CRDT- 2014/04/09 06:00
PHST- 2014/04/09 06:00 [entrez]
PHST- 2014/04/09 06:00 [pubmed]
PHST- 2014/07/11 06:00 [medline]
AID - 1859300 [pii]
AID - 10.7326/M13-2844 [doi]
PST - ppublish
SO  - Ann Intern Med. 2014 May 20;160(10):695-703. doi: 10.7326/M13-2844.

PMID- 25590318
OWN - NLM
STAT- MEDLINE
DCOM- 20151014
LR  - 20150116
IS  - 1945-8932 (Electronic)
IS  - 1945-8932 (Linking)
VI  - 29
IP  - 1
DP  - 2015 Jan-Feb
TI  - State of the Art: Medical treatment of aspirin exacerbated respiratory disease 
      (AERD).
PG  - 41-3
LID - 10.2500/ajra.2015.29.4114 [doi]
AB  - Aspirin exacerbated respiratory disease (AERD) is characterized as adult onset 
      asthma, nasal polyps, chronic rhinosinusitis, and hypersensitivity to a 
      cyclooxygenase-1 (COX-1) inhibitor, viz aspirin or nonsteroidal antiinflammatory 
      drugs (NSAIDs). The method for diagnosing AERD is with aspirin challenge, and 
      treatment includes aspirin desensitization followed by continued daily aspirin. 
      Although oral challenge has been the mainstay in the United States, lysyl-aspirin 
      has been validated as a diagnostic tool for aspirin-sensitive asthma and will be 
      discussed further in this article. The challenges with aspirin therapy 
      surrounding endoscopy and perioperative aspirin therapy will be discussed. 
      Additionally, daily aspirin therapy is not for everyone. Aspirin is relatively 
      contraindicated in those with a history of gastrointestinal bleed and an absolute 
      contraindication in pregnancy. Aspirin desensitization and subsequent treatment 
      has been shown to be highly effective for AERD.
FAU - Ta, Von
AU  - Ta V
AD  - Scripps Clinic, La Jolla, California, USA.
FAU - Simon, Ronald
AU  - Simon R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Colonoscopy
MH  - Cyclooxygenase Inhibitors/therapeutic use
MH  - Desensitization, Immunologic
MH  - Humans
MH  - Respiratory Tract Diseases/*chemically induced/therapy
EDAT- 2015/01/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/01/16 06:00
PHST- 2015/01/16 06:00 [entrez]
PHST- 2015/01/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - 10.2500/ajra.2015.29.4114 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2015 Jan-Feb;29(1):41-3. doi: 10.2500/ajra.2015.29.4114.

PMID- 23038044
OWN - NLM
STAT- MEDLINE
DCOM- 20130827
LR  - 20221207
IS  - 1423-0003 (Electronic)
IS  - 0304-324X (Linking)
VI  - 59
IP  - 2
DP  - 2013
TI  - Frequency, risk factors, prognosis, and genetic polymorphism of the 
      cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with 
      cardiovascular disease.
PG  - 122-31
LID - 10.1159/000342489 [doi]
AB  - BACKGROUND: Cardiovascular disease (CVD) is an important cause of mortality in 
      elderly patients worldwide. Aspirin resistance has been well reported in CVD. 
      OBJECTIVE: The frequency, risk factors, prognosis, and genetic polymorphism of 
      the cyclooxygenase-1 (COX-1) gene for aspirin resistance have not been reported 
      in elderly patients with CVD. We therefore undertook this study to evaluate these 
      associations among elderly Chinese patients with CVD. METHODS: Four hundred 
      thirty-one elderly Chinese patients with CVD receiving daily aspirin therapy (≥75 
      mg) over 1 month were enrolled. Platelet aggregation was measured by light 
      transmission aggregometry (LTA) and thromboelastography platelet mapping assay 
      (TEG) using arachidonic acid (AA) as a stimulus. The median follow-up was 1.8 
      years. RESULTS: After the median follow-up, aspirin-resistant patients were at an 
      increased risk of the composite endpoint compared to nonresistant patients by 
      LTAAA + TEGAA (23.7 vs. 9.2%, p = 0.025). Additionally, Cox proportional hazards 
      regression modeling demonstrated that aspirin resistance and cerebrovascular 
      disease were associated with major adverse long-term outcomes (HR for aspirin 
      resistance = 2.31, 95% CI 1.11-4.81, p = 0.026). The variant G-allele of COX-1 
      rs1330344 (-1676 A/G) significantly increased the risk of aspirin resistance 
      defined by LTAAA + TEGAA (OR = 1.82, 95% CI 1.13- 2.92, p = 0.01). CONCLUSIONS: 
      Aspirin resistance, evaluated by LTAAA + TEGAA, is associated with an increased 
      risk of adverse clinical events in elderly Chinese patients with CVD. The variant 
      G-allele of COX-1 rs1330344 is significantly associated with aspirin resistance 
      defined by LTAAA + TEGAA.
CI  - Copyright © 2012 S. Karger AG, Basel.
FAU - Fan, Li
AU  - Fan L
AD  - Clinical Department of South Building, Chinese PLA General Hospital, Beijing, PR 
      China. calvin301@163.com
FAU - Cao, Jian
AU  - Cao J
FAU - Liu, Lin
AU  - Liu L
FAU - Li, Xiaoli
AU  - Li X
FAU - Hu, Guoliang
AU  - Hu G
FAU - Hu, Yixin
AU  - Hu Y
FAU - Zhu, Bingpo
AU  - Zhu B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120928
PL  - Switzerland
TA  - Gerontology
JT  - Gerontology
JID - 7601655
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Asian People/genetics
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - China
MH  - Cyclooxygenase 1/drug effects/*genetics
MH  - Drug Resistance/*genetics
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Odds Ratio
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Polymorphism, Single Nucleotide
MH  - Proportional Hazards Models
MH  - Thrombelastography
MH  - Treatment Outcome
EDAT- 2012/10/06 06:00
MHDA- 2013/08/28 06:00
CRDT- 2012/10/06 06:00
PHST- 2012/03/21 00:00 [received]
PHST- 2012/08/10 00:00 [accepted]
PHST- 2012/10/06 06:00 [entrez]
PHST- 2012/10/06 06:00 [pubmed]
PHST- 2013/08/28 06:00 [medline]
AID - 000342489 [pii]
AID - 10.1159/000342489 [doi]
PST - ppublish
SO  - Gerontology. 2013;59(2):122-31. doi: 10.1159/000342489. Epub 2012 Sep 28.

PMID- 3830391
OWN - NLM
STAT- MEDLINE
DCOM- 19860507
LR  - 20131121
IS  - 0749-0690 (Print)
IS  - 0749-0690 (Linking)
VI  - 1
IP  - 4
DP  - 1985 Nov
TI  - The use of antithrombotic therapy in the elderly.
PG  - 887-97
AB  - The elderly are predisposed to atherosclerosis and venous thrombosis, the 
      conditions for which anticoagulants are used. Anticoagulants can be used safely 
      in the elderly with little or no more risk of bleeding than exists in younger 
      patients. The prescribing physician must know the mechanism of drug action, be 
      attentive to potential side effects, and monitor drug activity adequately. The 
      authors emphasize the oral anticoagulants and heparin because, in general, their 
      use is associated with a greater degree of risk and more clearly defined benefits 
      than would apply for the antiplatelet agents.
FAU - Smith, T
AU  - Smith T
FAU - Viverette, F
AU  - Viverette F
FAU - Adelman, B
AU  - Adelman B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Geriatr Med
JT  - Clinics in geriatric medicine
JID - 8603766
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - *Hemostasis
MH  - Heparin/adverse effects/therapeutic use
MH  - Humans
MH  - Thromboembolism/*prevention & control
MH  - Warfarin/adverse effects/metabolism/therapeutic use
EDAT- 1985/11/01 00:00
MHDA- 1985/11/01 00:01
CRDT- 1985/11/01 00:00
PHST- 1985/11/01 00:00 [pubmed]
PHST- 1985/11/01 00:01 [medline]
PHST- 1985/11/01 00:00 [entrez]
PST - ppublish
SO  - Clin Geriatr Med. 1985 Nov;1(4):887-97.

PMID- 22273646
OWN - NLM
STAT- MEDLINE
DCOM- 20120514
LR  - 20220310
IS  - 1658-3175 (Electronic)
IS  - 0379-5284 (Linking)
VI  - 33
IP  - 1
DP  - 2012 Jan
TI  - Acetyl salicylic acid resistance in patients with chronic stable angina and the 
      correlation with coronary risk factors.
PG  - 39-43
AB  - OBJECTIVE: To evaluate acetyl salicylic acid (ASA) resistance in patients with 
      cardiovascular diseases and evaluate correlation with coronary risk factors. 
      METHODS: One hundred and twenty-four patients with stable coronary artery 
      diseases (CAD) were enrolled in this cross sectional study from the outpatient 
      clinic of the Department of Cardiology, Faculty of Medicine, Semnan University of 
      Medical Sciences, Semnan, Iran, between May 2008 and August 2008. All patients 
      had prior history of cardiovascular disease and were under treatment of 80 mg 
      daily ASA for at least 7 days. Aspirin resistance was measured by urinary 
      11-dehydro-thromboxane beta-concentrations with an enzyme immunoassay kit. 
      RESULTS: Approximately 49.2% patients were resistant to ASA, 15.3% borderline 
      response, and 35.5% were sensitive to ASA. Acetyl salicylic acid-resistant 
      patients were more likely to be smokers and older ages (63% versus 45.4%) (37.7% 
      less than 60 years, 53.7% between 60-69 years, and 63.3% aged ≥ 70 years). Other 
      variables such as gender, diabetes mellitus, hypertension, cholesterol, 
      triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and 
      hemoglobin levels were not significantly associated with aspirin resistance. 
      CONCLUSION: Acetyl salicylic acid resistance was present in a high number of 
      patients with chronic stable angina. Moreover, advanced age and smoking had a 
      direct influence on the aspirin resistance.
FAU - Eskandarian, Rahimeh
AU  - Eskandarian R
AD  - Department of Cardiology, Faculty of Medicine, Semnan University of Medical 
      Sciences, Semnan, Iran.
FAU - Darabian, Mohsen
AU  - Darabian M
FAU - Heshmatnia, Jalal
AU  - Heshmatnia J
FAU - Ghorbani, Raheb
AU  - Ghorbani R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Saudi Arabia
TA  - Saudi Med J
JT  - Saudi medical journal
JID - 7909441
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
EDAT- 2012/01/26 06:00
MHDA- 2012/05/15 06:00
CRDT- 2012/01/26 06:00
PHST- 2012/01/26 06:00 [entrez]
PHST- 2012/01/26 06:00 [pubmed]
PHST- 2012/05/15 06:00 [medline]
AID - 0' [pii]
PST - ppublish
SO  - Saudi Med J. 2012 Jan;33(1):39-43.

PMID- 3548088
OWN - NLM
STAT- MEDLINE
DCOM- 19870330
LR  - 20131121
IS  - 0043-5341 (Print)
IS  - 0043-5341 (Linking)
VI  - 136 Spec No
DP  - 1986
TI  - [Hemorheologic applications in vascular surgery].
PG  - 25-8
AB  - Possible vascular surgery interventions are reviewed in respect of the 
      supraaortic segment (carotis obstruction), in aortic aneurysm, and in the lower 
      extremities region (aorto-iliac/femoro-popliteal segment). The conservative 
      therapeutic measures in terms of pre-, per-, and postoperative reocclusion 
      prevention are discussed--also with a view to "surgically exhausted" cases--with 
      special focus on platelet antiaggregants (acetylsalicylic acid [ASA]), 
      hemorheological principles (hemodilution, pentoxifylline) and anticoagulation. In 
      an one year comparative reocclusion prevention study of ASA and pentoxifylline 
      (Trental 400) in patients with prosthetic bypass surgery in the femoro-popliteal 
      segment no difference was found in respect of the patency rate between the two 
      treatments, the hemorheological medication, however, proved significantly better 
      tolerable. It can be concluded that such conservative treatments can clearly 
      support the outcome of vascular surgery on the long run, with, indeed, control of 
      risk factors and activation of patients to physical therapy (walking exercise).
FAU - Raithel, D
AU  - Raithel D
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Hämorheologische Anwendungsmöglichkeiten in der Gefässchirurgie.
PL  - Austria
TA  - Wien Med Wochenschr
JT  - Wiener medizinische Wochenschrift (1946)
JID - 8708475
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Aortic Aneurysm/surgery
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Pentoxifylline/therapeutic use
MH  - Postoperative Complications/prevention & control
MH  - Rheology
MH  - *Vascular Surgical Procedures
RF  - 15
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Wien Med Wochenschr. 1986;136 Spec No:25-8.

PMID- 10718501
OWN - NLM
STAT- MEDLINE
DCOM- 20000407
LR  - 20191210
IS  - 1524-6094 (Print)
IS  - 1524-6094 (Linking)
VI  - 9
IP  - 1
DP  - 2000 Jan-Feb
TI  - Baseline characteristics of participants in the Women's Health Study.
PG  - 19-27
AB  - The Women's Health Study (WHS) is a randomized, double-blind, placebo-controlled 
      trial designed to evaluate the balance of benefits and risks of low-dose aspirin 
      and vitamin E in the primary prevention of cardiovascular disease and cancer in 
      women. A total of 39,876 female health professionals, age 45 years or older and 
      without a history of cardiovascular disease or cancer (other than nonmelanoma 
      skin cancer), were randomized in a 2x2 factorial design to one of four treatment 
      groups: active aspirin and vitamin E placebo, aspirin placebo and active vitamin 
      E, both active agents, or both placebos. The process of randomization was 
      successful, as evidenced by the equal distribution of a large number of baseline 
      demographic, lifestyle, and health history characteristics among the four 
      treatment groups. Similar distribution of known potential confounders, as well as 
      the large sample size, provides reassuring evidence that unmeasured or unknown 
      potential confounders are also equally distributed. As expected in a clinical 
      trial, the women in the study are healthier in some respects than the general 
      population, but they have very comparable rates of obesity, hypertension, and 
      elevated cholesterol. With adequate duration of treatment and follow-up, this 
      trial will provide important and relevant information on the balance of benefits 
      and risks of aspirin and vitamin E supplementation in the primary prevention of 
      cardiovascular disease and cancer in women.
FAU - Rexrode, K M
AU  - Rexrode KM
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, Massachusetts 02215, USA.
FAU - Lee, I M
AU  - Lee IM
FAU - Cook, N R
AU  - Cook NR
FAU - Hennekens, C H
AU  - Hennekens CH
FAU - Buring, J E
AU  - Buring JE
LA  - eng
GR  - CA-47988/CA/NCI NIH HHS/United States
GR  - HL-43851/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Womens Health Gend Based Med
JT  - Journal of women's health & gender-based medicine
JID - 100888719
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Confounding Factors, Epidemiologic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasms/epidemiology/*prevention & control
MH  - Vitamin E/administration & dosage/*therapeutic use
MH  - *Women's Health
EDAT- 2000/03/16 00:00
MHDA- 2000/03/16 00:01
CRDT- 2000/03/16 00:00
PHST- 2000/03/16 00:00 [pubmed]
PHST- 2000/03/16 00:01 [medline]
PHST- 2000/03/16 00:00 [entrez]
AID - 10.1089/152460900318911 [doi]
PST - ppublish
SO  - J Womens Health Gend Based Med. 2000 Jan-Feb;9(1):19-27. doi: 
      10.1089/152460900318911.

PMID- 33387203
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20220127
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 52
IP  - 2
DP  - 2021 Aug
TI  - Low molecular weight heparin and aspirin for prevention of deep vein 
      thrombosisafter orthopaedic surgery: a systematic review and meta-analysis.
PG  - 553-559
LID - 10.1007/s11239-020-02348-5 [doi]
AB  - To comprehensively evaluate the clinical effects of low molecular weight heparin 
      (LMWH) and aspirin for deep vein thrombosis (DVT) patients after orthopaedic 
      surgery. Studies comparing LMWH and aspirin were retrieved in multiple databases. 
      Review Manager 5.0 was adopted for meta-analysis, sensitivity analysis and bias 
      analysis. Finally, 4460 patients in 6 studies were included, and the eligibility 
      criteria were finally met. The meta-analysis suggested that there was significant 
      difference between LMWH and aspirin groups in DVT (RR = 0.58, 95%CI [0.39, 0.88], 
      P = 0.01; P for heterogeneity = 0.45, I(2) = 0%). Postoperative bleeding between 
      the two groups showed no difference (RR = 2.20, 95%CI [0.48, 10.09], P = 0.31; P 
      for heterogeneity = 0.79, I(2) = 0%) This study shows that LMWH is a more 
      effective therapy than aspirin for patients with DVT after orthopaedic surgery.
CI  - © 2021. Springer Science+Business Media, LLC, part of Springer Nature.
FAU - Chen, Bo
AU  - Chen B
AD  - Departments of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      China.
FAU - Hu, Nie
AU  - Hu N
AD  - Departments of Tumor Chemoradiotherapy, Zhongnan Hospital of Wuhan University, 
      Wuhan, Hubei, China. 276773040@qq.com.
AD  - Department of Tumor Chemoradiotherapy, Zhongnan Hospital of Wuhan University, No 
      169 Donghu Road, Wuchang District, Wuhan, 430071, Hubei, China. 276773040@qq.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210102
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Hemorrhage
MH  - Heparin
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - *Orthopedic Procedures/adverse effects
MH  - *Venous Thrombosis/prevention & control
OTO - NOTNLM
OT  - Aspirin
OT  - Deep venous thrombosis
OT  - Low molecular weight heparin
OT  - Orthopaedic surgery
EDAT- 2021/01/03 06:00
MHDA- 2022/01/28 06:00
CRDT- 2021/01/02 12:09
PHST- 2020/11/17 00:00 [accepted]
PHST- 2021/01/03 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
PHST- 2021/01/02 12:09 [entrez]
AID - 10.1007/s11239-020-02348-5 [pii]
AID - 10.1007/s11239-020-02348-5 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2021 Aug;52(2):553-559. doi: 10.1007/s11239-020-02348-5. 
      Epub 2021 Jan 2.

PMID- 7406934
OWN - NLM
STAT- MEDLINE
DCOM- 19801021
LR  - 20190718
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 23
IP  - 7
DP  - 1980 Jul
TI  - Evaluation of a continuing education program in rheumatoid arthritis.
PG  - 846-9
AB  - A continuing medical education (CME) program in rheumatoid arthritis was 
      implemented and evaluated in six community hospitals. It was targeted at primary 
      care physicians and utilized physicians identified by their peers as being 
      educationally influential for the dissemination of content knowledge. Although 
      inpatient and outpatient audits of physician records demonstrated little change 
      in three control communities, substantial improvement in the utilization of 
      diagnostic procedures and patient management was documented in the three 
      intervention communities utilizing the influential physicians. CME delivered 
      through community-based educationally influential physicians is an effective way 
      to change physician behavior in small communities with no prior ongoing 
      educational programs. This approach should improve the primary care given to 
      patients with rheumatoid arthritis and reduce the need for participation of 
      academic faculty in traditional CME programs.
FAU - Stross, J K
AU  - Stross JK
FAU - Bole, G G
AU  - Bole GG
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Adrenal Cortex Hormones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - *Arthritis, Rheumatoid/diagnosis
MH  - Aspirin/therapeutic use
MH  - *Education, Medical, Continuing
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Physical Therapy Modalities
MH  - Physician-Patient Relations
EDAT- 1980/07/01 00:00
MHDA- 1980/07/01 00:01
CRDT- 1980/07/01 00:00
PHST- 1980/07/01 00:00 [pubmed]
PHST- 1980/07/01 00:01 [medline]
PHST- 1980/07/01 00:00 [entrez]
AID - 10.1002/art.1780230711 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1980 Jul;23(7):846-9. doi: 10.1002/art.1780230711.

PMID- 7418706
OWN - NLM
STAT- MEDLINE
DCOM- 19801216
LR  - 20180214
IS  - 0014-312X (Print)
IS  - 0014-312X (Linking)
VI  - 12
IP  - 3
DP  - 1980
TI  - Trauma an acetylsalicylic acid-induced changes in hemostasis during liver 
      resection in the rat.
PG  - 186-98
AB  - The effect of acetylsalicylic acid and bilateral femoral crush fractures on 
      hemostasis after liver resection was studied in the rat. Serum salicylate levels 
      were dose-dependent and similar in traumatized and non-traumatized animals. 
      Bleeding time was significantly shortened and blood loss significantly decreased 
      after bilateral femoral crush fractures. Both these values were significantly 
      increased in salicylate pretreated animals compared to controls. Combination of 
      bilateral femoral crush fractures and administration of 0.7 mg/100 g b.w. 
      acetylsalicylic acid after bilateral femoral crush fractures increased blood loss 
      significantly. Normal APT times indicated that the intrinsic coagulation system 
      was not affected. ADP- and collagen-induced platelet aggregation was diminished 
      in all animals as compared to controls.
FAU - Bengmark, S
AU  - Bengmark S
FAU - Göransson, G
AU  - Göransson G
FAU - Zoucas, E
AU  - Zoucas E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Eur Surg Res
JT  - European surgical research. Europaische chirurgische Forschung. Recherches 
      chirurgicales europeennes
JID - 0174752
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation/*drug effects
MH  - Fractures, Bone/*physiopathology
MH  - Hemostasis/*drug effects
MH  - Leg
MH  - Liver/*surgery
MH  - Male
MH  - Rats
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1159/000128124 [doi]
PST - ppublish
SO  - Eur Surg Res. 1980;12(3):186-98. doi: 10.1159/000128124.

PMID- 3143707
OWN - NLM
STAT- MEDLINE
DCOM- 19890125
LR  - 20190820
IS  - 0378-5955 (Print)
IS  - 0378-5955 (Linking)
VI  - 36
IP  - 1
DP  - 1988 Oct
TI  - Acute effects of noradrenalin related vasoactive agents on the ototoxicity of 
      aspirin: an experimental study in the guinea pig.
PG  - 89-96
AB  - Aspirin is known to be ototoxic when administered at high doses. Its mode of 
      action is unknown but an alteration of the vascular function has been suspected. 
      To further document this hypothesis, acute effects of some vasoactive agents on 
      the ototoxicity of aspirin were tested in experiments on the guinea pig using 
      sensori-neural electrophysiological responses and morphometry of the vessels of 
      the stria and the spiral lamina. Electrophysiological measures showed no 
      modification of sensory responses but neural responses revealed clear changes 
      after administration of noradrenalin related agents, limited modifications after 
      a drug acting partly as a serotonin antagonist, and no change after a 
      dopaminergic agent. Morphometric studies showed no modification of the strial but 
      some effect on the spiral vessels. The results are compatible with the hypothesis 
      of a vascular involvement in the ototoxicity of aspirin and they point toward an 
      interaction with the noradrenergic sympathetic cochlear system in the spiral 
      lamina.
FAU - Cazals, Y
AU  - Cazals Y
AD  - Laboratoire d'Audiologie expérimentale, INSERM unité 229, Université Bordeaux II, 
      France.
FAU - Li, X Q
AU  - Li XQ
FAU - Aurousseau, C
AU  - Aurousseau C
FAU - Didier, A
AU  - Didier A
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Hear Res
JT  - Hearing research
JID - 7900445
RN  - 0 (Secologanin Tryptamine Alkaloids)
RN  - 0 (Vasodilator Agents)
RN  - 11032-41-0 (Dihydroergotoxine)
RN  - 2Y49VWD90Q (Yohimbine)
RN  - 42H8PQ0NMJ (Nafronyl)
RN  - 4QJL8OX71Z (raubasine)
RN  - 818U2PZ2EH (Metaraminol)
RN  - DO22K1PRDJ (Piribedil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/antagonists & inhibitors
MH  - Auditory Threshold/drug effects
MH  - Cochlea/*drug effects
MH  - Cochlear Microphonic Potentials/drug effects
MH  - Dihydroergotoxine/pharmacology
MH  - Guinea Pigs
MH  - Metaraminol/*pharmacology
MH  - Nafronyl/pharmacology
MH  - Piribedil/pharmacology
MH  - *Secologanin Tryptamine Alkaloids
MH  - Spiral Lamina/drug effects
MH  - Stria Vascularis/drug effects
MH  - Vasodilator Agents/*pharmacology
MH  - Yohimbine/pharmacology
EDAT- 1988/10/01 00:00
MHDA- 1988/10/01 00:01
CRDT- 1988/10/01 00:00
PHST- 1988/10/01 00:00 [pubmed]
PHST- 1988/10/01 00:01 [medline]
PHST- 1988/10/01 00:00 [entrez]
AID - 0378-5955(88)90139-6 [pii]
AID - 10.1016/0378-5955(88)90139-6 [doi]
PST - ppublish
SO  - Hear Res. 1988 Oct;36(1):89-96. doi: 10.1016/0378-5955(88)90139-6.

PMID- 2694764
OWN - NLM
STAT- MEDLINE
DCOM- 19900313
LR  - 20131121
IS  - 0326-6656 (Print)
IS  - 0326-6656 (Linking)
VI  - 39
IP  - 1
DP  - 1989
TI  - Clinical evaluation of acetylsalicylic acid to improve glycemia in type II 
      diabetic patients.
PG  - 9-13
AB  - The glycoregulation of 17 type II diabetics was observed to improve by 
      administering 1 g of acetylsalicylic acid three times per day, during a one-year 
      study. The subjects did not lose weight during the experimental period, but the 
      insulin daily requirement of 7 patients did decrease by 60%.
FAU - Mata-Segreda, J F
AU  - Mata-Segreda JF
AD  - School of Chemistry, University of Costa Rica, San José.
FAU - Fernández-Azofeifa, E
AU  - Fernández-Azofeifa E
FAU - Madrigal, X
AU  - Madrigal X
FAU - Morales, A C
AU  - Morales AC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Argentina
TA  - Acta Physiol Pharmacol Latinoam
JT  - Acta physiologica et pharmacologica latinoamericana : organo de la Asociacion 
      Latinoamericana de Ciencias Fisiologicas y de la Asociacion Latinoamericana de 
      Farmacologia
JID - 8409686
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Glucose/*analysis
MH  - Body Weight
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Female
MH  - Humans
MH  - Insulin/administration & dosage/*blood
MH  - Male
MH  - Middle Aged
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Physiol Pharmacol Latinoam. 1989;39(1):9-13.

PMID- 7736745
OWN - NLM
STAT- MEDLINE
DCOM- 19950607
LR  - 20190706
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 23
IP  - 5
DP  - 1995 May
TI  - Subcutaneous oxygen tension: a useful adjunct in assessment of perfusion status.
PG  - 867-73
AB  - OBJECTIVES: Using a new fluorescence-quenching optode which, unlike earlier 
      oximeters, neither consumes oxygen nor generates heat, we sought to determine the 
      effects of hemorrhage and resuscitation on subcutaneous PO2. Additionally, we 
      compared the effects of resuscitation with diaspirin crosslinked hemoglobin, an 
      oxygen-carrying solution, on subcutaneous PO2 to that of traditional 
      resuscitative fluids. We also compared mean arterial pressure and central venous 
      oxygen saturation, indirect indices of perfusion, to subcutaneous PO2, a direct 
      index of perfusion. DESIGN: Prospective trial, randomized for selection of 
      treatment regimen. SETTING: Shock-trauma laboratory of a medical university. 
      SUBJECTS: Male Sprague-Dawley rats, weighing 260 to 380 g. INTERVENTIONS: Rats 
      were bled 22 mL/kg and resuscitated, 1 min later, with either 66 mL/kg of 
      lactated Ringer's solution, 22 mL/kg of human serum albumin, 22 mL/kg of blood, 
      or 22 mL/kg of diaspirin crosslinked hemoglobin. A fifth group of animals was not 
      resuscitated after hemorrhage. Subcutaneous PO2 and mean arterial pressure were 
      monitored continuously throughout the experiment, while central venous oxygen 
      saturation was measured intermittently. MEASUREMENTS AND MAIN RESULTS: 
      Subcutaneous PO2 decreased in response to hemorrhage and, although it did 
      increase after resuscitation with each fluid, no treatment was able to restore 
      subcutaneous PO2 to baseline within 2 hrs postresuscitation. Subcutaneous PO2 
      continued to decrease after hemorrhage in the unresuscitated animals. In 
      contrast, mean arterial pressure was restored to baseline values in only blood- 
      and diaspirin crosslinked hemoglobin-treated animals, although this effect was 
      lost within 30 mins in the blood-treated group. Only blood restored the central 
      venous oxygen saturation to baseline values in the early postresuscitation 
      period. CONCLUSIONS: The fluorescence-quenching optode consistently followed 
      changes in subcutaneous PO2 during hemorrhage and after resuscitation. Diaspirin 
      crosslinked hemoglobin performed as well as blood in restoring peripheral 
      perfusion, as measured by subcutaneous PO2, while both of these fluids were 
      superior to either lactated Ringer's solution or albumin. Both whole blood and 
      diaspirin crosslinked hemoglobin restored mean arterial pressure to baseline, 
      although the effect of the latter was of a longer duration. The pressor effect of 
      the crosslinked hemoglobin did not affect peripheral perfusion, as reflected by 
      the values for subcutaneous PO2. Subcutaneous PO2 is a useful adjunct in 
      assessment of the adequacy of peripheral perfusion and may help redefine targets 
      for resuscitation.
FAU - Powell, C C
AU  - Powell CC
AD  - Department of Surgery, Uniformed Services University of the Health Sciences, 
      Bethesda, MD 20814, USA.
FAU - Schultz, S C
AU  - Schultz SC
FAU - Burris, D G
AU  - Burris DG
FAU - Drucker, W R
AU  - Drucker WR
FAU - Malcolm, D S
AU  - Malcolm DS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Blood Gas Monitoring, Transcutaneous/instrumentation/*methods
MH  - Evaluation Studies as Topic
MH  - Hemoglobins/therapeutic use
MH  - Hemorrhage/physiopathology/therapy
MH  - Male
MH  - Prospective Studies
MH  - Random Allocation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Resuscitation/methods
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
AID - 10.1097/00003246-199505000-00015 [doi]
PST - ppublish
SO  - Crit Care Med. 1995 May;23(5):867-73. doi: 10.1097/00003246-199505000-00015.

PMID- 2967433
OWN - NLM
STAT- MEDLINE
DCOM- 19880714
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 318
IP  - 26
DP  - 1988 Jun 30
TI  - Aspirin and dipyridamole in the prevention of restenosis after percutaneous 
      transluminal coronary angioplasty.
PG  - 1714-9
AB  - To examine the role of antiplatelet therapy in the prevention of arterial 
      restenosis after percutaneous transluminal coronary angioplasty (PTCA), we 
      conducted a randomized, double-blind, placebo-controlled study in 376 patients. 
      The active treatment consisted of an oral aspirin-dipyridamole combination (330 
      mg-75 mg) given three times daily, beginning 24 hours before PTCA. Eight hours 
      before PTCA, the oral dipyridamole was replaced with intravenous dipyridamole at 
      a dosage of 10 mg per hour for 24 hours, and oral aspirin was continued. Sixteen 
      hours after PTCA, the initial combination was reinstituted. Treatment was 
      continued in patients with a successfully dilated vessel until follow-up 
      angiography four to seven months after PTCA--or earlier, if symptoms dictated. Of 
      249 patients who underwent follow-up angiography, 37.7 percent of patients 
      receiving the active drug had restenosis in at least one segment, as compared 
      with 38.6 percent of patients taking placebo (P not significant). The number of 
      stenotic segments was virtually the same in the two groups. Among the 376 
      randomized patients, there were 16 periprocedural Q-wave myocardial 
      infarctions--13 in the placebo group and 3 in the active-drug group (6.9 percent 
      vs. 1.6 percent, P = 0.0113). Although the use of this antiplatelet regimen 
      before and after PTCA did not reduce the six-month rate of restenosis after 
      successful coronary angioplasty, it markedly reduced the incidence of transmural 
      myocardial infarction during or soon after PTCA. Thus, the short-term use of 
      antiplatelet agents in relation to PTCA can be recommended.
FAU - Schwartz, L
AU  - Schwartz L
AD  - Department of Cardiology, Montreal Heart Institute, Canada.
FAU - Bourassa, M G
AU  - Bourassa MG
FAU - Lespérance, J
AU  - Lespérance J
FAU - Aldridge, H E
AU  - Aldridge HE
FAU - Kazim, F
AU  - Kazim F
FAU - Salvatori, V A
AU  - Salvatori VA
FAU - Henderson, M
AU  - Henderson M
FAU - Bonan, R
AU  - Bonan R
FAU - David, P R
AU  - David PR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - *Angioplasty, Balloon
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Angiography
MH  - Coronary Disease/*prevention & control/therapy
MH  - Dipyridamole/*administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Random Allocation
MH  - Recurrence
EDAT- 1988/06/30 00:00
MHDA- 1988/06/30 00:01
CRDT- 1988/06/30 00:00
PHST- 1988/06/30 00:00 [pubmed]
PHST- 1988/06/30 00:01 [medline]
PHST- 1988/06/30 00:00 [entrez]
AID - 10.1056/NEJM198806303182603 [doi]
PST - ppublish
SO  - N Engl J Med. 1988 Jun 30;318(26):1714-9. doi: 10.1056/NEJM198806303182603.

PMID- 1962469
OWN - NLM
STAT- MEDLINE
DCOM- 19920109
LR  - 20150612
IS  - 0042-8450 (Print)
IS  - 0042-8450 (Linking)
VI  - 48
IP  - 4
DP  - 1991 Jul-Aug
TI  - [Determination of acetylsalicylic and salicylic acid in tablets using 
      high-performance liquid chromatography and a diode array detector].
PG  - 325-30
AB  - A fast and sensitive method of high-performance liquid chromatography (HPLC) for 
      determination of acetylsalicylic acid (ASA) and products of salicylic acid (SA) 
      hydrolysis in tablets has been elaborated. Extraction was done with the mixture 
      of methanol: formic acid (98:2 v/v) and separation of the components was achieved 
      by using the colon of Ultropac Lichrosorb RP-18, 10 um, 4 cm x 250 mm and diode 
      array detector. The mobile phase of methanol:water: :mol/1 H3PO4 (60:35:5) v/v, 
      pP = 2.6 and safe flow of 1 ml/min were used. Follow up of chromatographic 
      separation of ASA, SA and internal standard beta-naphtole (ITS) was performed at 
      the wave length of 290 microns. The threshold of ASA was 0.5 mg/ml and of SA 
      0.0025 mg/ml.
FAU - Nikolić, M
AU  - Nikolić M
AD  - Vojnomedicinska akademija, Institut za farmaciju, Zavod za preventivnu medicinu.
FAU - Petrović, D
AU  - Petrović D
LA  - srp
PT  - English Abstract
PT  - Journal Article
TT  - Odredivanje acetilsalicilne i salicilne kiseline u tabletama tecnom 
      hromatografijom pod visokim pritiskom sa diode array detektorom.
PL  - Serbia
TA  - Vojnosanit Pregl
JT  - Vojnosanitetski pregled
JID - 21530700R
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Spectrophotometry
MH  - Tablets
EDAT- 1991/07/01 00:00
MHDA- 1991/07/01 00:01
CRDT- 1991/07/01 00:00
PHST- 1991/07/01 00:00 [pubmed]
PHST- 1991/07/01 00:01 [medline]
PHST- 1991/07/01 00:00 [entrez]
PST - ppublish
SO  - Vojnosanit Pregl. 1991 Jul-Aug;48(4):325-30.

PMID- 7002357
OWN - NLM
STAT- MEDLINE
DCOM- 19810226
LR  - 20131121
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 62
IP  - 6 Pt 2
DP  - 1980 Dec
TI  - A randomized trial of aspirin and sulfinpyrazone in patients with threatened 
      stroke. Results and methodologic issues.
PG  - V97-105
AB  - In the Canadian Cooperative Study of aspirin and sulfinpyrazone in patients with 
      threatened stroke, there was no demonstrable benefit of sulfinpyrazone but there 
      was a significant overall risk reduction in stroke or death of 31% with aspirin 
      (p less than 0.05). This benefit of aspirin was restricted to males, in whom the 
      risk reduction in stroke or death was 48% (p less than 0.005). As with a 
      large-scale clinical trials, questions have been raised about the methodology of 
      the study, including the type of patient included, the choice of outcome 
      measures, the factorial design and the analysis of subgroups. In this report, the 
      design and principal results of the study are summarized and the above 
      methodologic concerns are discussed.
FAU - Gent, M
AU  - Gent M
FAU - Barnett, H J
AU  - Barnett HJ
FAU - Sackett, D L
AU  - Sackett DL
FAU - Taylor, D W
AU  - Taylor DW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Actuarial Analysis
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Canada
MH  - Cerebrovascular Disorders/diagnosis/*drug therapy
MH  - Clinical Trials as Topic
MH  - Death, Sudden
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/diagnosis
MH  - Male
MH  - Patient Compliance
MH  - Random Allocation
MH  - Risk
MH  - Sulfinpyrazone/adverse effects/*therapeutic use
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
PST - ppublish
SO  - Circulation. 1980 Dec;62(6 Pt 2):V97-105.

PMID- 1149486
OWN - NLM
STAT- MEDLINE
DCOM- 19751101
LR  - 20190907
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 3
IP  - 3
DP  - 1975
TI  - A comparison of a new analgesic, floctafenine, with dextropropoxyphene and 
      aspirin in post-operative pain.
PG  - 175-80
AB  - Seventy-seven patients took part in a double-blind crossover trial to compare the 
      effects of floctafenine, dextropropxyhene and aspirin in the relief of 
      post-operative pain. Pain levels were recorded at hourly intervals and pain 
      relief scores calculated. For Dose 1, the difference between the mean pain relief 
      score for patients receiving floctafenin (12.8) and that for patients receiving 
      dextropropoxyphen (6.2) was significant, (p smaller than 0.05) but the difference 
      between the mean score for aspirin (9.2) and that for dextropropoxyphene was not 
      significant. For Dose 2, there were no significant differences between the mean 
      pain relief scores for floctafenine (12.5), for aspirin (10.9) and for 
      dextropropoxyphene (13.2).
FAU - Lipton, S
AU  - Lipton S
FAU - Conway, M
AU  - Conway M
FAU - Akbar, F A
AU  - Akbar FA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Analgesics)
RN  - 0 (Quinolines)
RN  - 0 (ortho-Aminobenzoates)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analgesics/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Dextropropoxyphene/adverse effects/*therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Quinolines/adverse effects/*therapeutic use
MH  - ortho-Aminobenzoates/adverse effects/*therapeutic use
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 10.1185/03007997509113667 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1975;3(3):175-80. doi: 10.1185/03007997509113667.

PMID- 26895085
OWN - NLM
STAT- MEDLINE
DCOM- 20161031
LR  - 20220311
IS  - 1877-783X (Electronic)
IS  - 1877-7821 (Linking)
VI  - 41
DP  - 2016 Apr
TI  - Colorectal cancer prevention and intentions to use low-dose aspirin: A survey of 
      1000 U.S. adults aged 40-65.
PG  - 99-105
LID - S1877-7821(16)30008-X [pii]
LID - 10.1016/j.canep.2016.02.003 [doi]
AB  - OBJECTIVE: The Translating Research into Action (TRIA) study was initiated to 
      gather dissemination information on emerging cancer control recommendations. 
      Daily, low-dose aspirin has been identified as a promising means of preventing 
      colorectal cancer, and stakeholders are already calling for research to 
      facilitate dissemination. Thus, the current study sought to identify factors 
      related to intention to use aspirin for colorectal cancer prevention. METHODS: In 
      April 2014, U.S. adults aged 40-65 (N=1000) were recruited to participate in a 
      survey grounded in the health belief model. RESULTS: Older, Black males were more 
      likely to intend to use low-dose aspirin to prevent colorectal cancer. Smokers, 
      and those with a history of polyps, were also more receptive to initiating daily, 
      low-dose aspirin use. Five psychosocial factors were related to intention 
      including self-efficacy, response efficacy, perceived barriers, perceived 
      susceptibility to colorectal cancer, and cancer information overload. CONCLUSION: 
      Initial campaigns/interventions designed to increase daily, low-dose aspirin for 
      colorectal cancer prevention may be more effective if they target receptive 
      populations (older, Black males) using messages informed by the health belief 
      model.
CI  - Copyright © 2016. Published by Elsevier Ltd.
FAU - Jensen, Jakob D
AU  - Jensen JD
AD  - Department of Communication, University of Utah, United States; Huntsman Cancer 
      Institute, United States. Electronic address: jakob.jensen@utah.edu.
FAU - Holton, Avery E
AU  - Holton AE
AD  - Department of Communication, University of Utah, United States.
FAU - Krakow, Melinda
AU  - Krakow M
AD  - National Cancer Institute, United States.
FAU - Weaver, Jeremy
AU  - Weaver J
AD  - Department of Communication, University of Utah, United States.
FAU - Donovan, Erin
AU  - Donovan E
AD  - Department of Communication Studies, University of Texas - Austin, United States.
FAU - Tavtigian, Sean
AU  - Tavtigian S
AD  - Huntsman Cancer Institute, United States; Oncological Sciences, United States.
LA  - eng
PT  - Journal Article
DEP - 20160216
PL  - Netherlands
TA  - Cancer Epidemiol
JT  - Cancer epidemiology
JID - 101508793
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Colorectal Neoplasms/*prevention & control
MH  - Female
MH  - Humans
MH  - Intention
MH  - Male
MH  - Middle Aged
MH  - Surveys and Questionnaires
MH  - United States
OTO - NOTNLM
OT  - Colorectal cancer
OT  - Health belief model
OT  - Low-dose aspirin
OT  - Prevention
EDAT- 2016/02/20 06:00
MHDA- 2016/11/01 06:00
CRDT- 2016/02/20 06:00
PHST- 2015/06/17 00:00 [received]
PHST- 2016/02/06 00:00 [revised]
PHST- 2016/02/09 00:00 [accepted]
PHST- 2016/02/20 06:00 [entrez]
PHST- 2016/02/20 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - S1877-7821(16)30008-X [pii]
AID - 10.1016/j.canep.2016.02.003 [doi]
PST - ppublish
SO  - Cancer Epidemiol. 2016 Apr;41:99-105. doi: 10.1016/j.canep.2016.02.003. Epub 2016 
      Feb 16.

PMID- 6804991
OWN - NLM
STAT- MEDLINE
DCOM- 19820708
LR  - 20191031
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 8
IP  - 2
DP  - 1982 Feb
TI  - The effect of arachidonic acid on the aggregability of human platelet rich 
      plasma.
PG  - 133-9
AB  - Addition of arachidonic acid to human platelet rich plasma caused a reversible 
      aggregation, which was greatly decreased after aspirin ingestion. ADP induced a 
      greater aggregation, which was only slightly decreased after aspirin ingestion. 
      When PRP was incubated with arachidonic acid for 2 or 6 min before the addition 
      of ADP, the ADP-induced aggregation was greatly decreased. This decrease was not 
      changed by aspirin ingestion. The present study indicates that arachidonic acid 
      is metabolized in human platelets not only to aggregatory compounds but also to 
      anti-aggregatory compound(s). The formation of the latter compound is not 
      inhibited by aspirin.
FAU - Dahl, M L
AU  - Dahl ML
FAU - Puustinen, T
AU  - Puustinen T
FAU - Uotila, P
AU  - Uotila P
LA  - eng
GR  - ES-01684-20/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Arachidonic Acids)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Arachidonic Acid
MH  - Arachidonic Acids/*pharmacology
MH  - Aspirin/pharmacology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Time Factors
EDAT- 1982/02/01 00:00
MHDA- 1982/02/01 00:01
CRDT- 1982/02/01 00:00
PHST- 1982/02/01 00:00 [pubmed]
PHST- 1982/02/01 00:01 [medline]
PHST- 1982/02/01 00:00 [entrez]
AID - 10.1016/s0262-1746(82)80005-x [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1982 Feb;8(2):133-9. doi: 
      10.1016/s0262-1746(82)80005-x.

PMID- 608318
OWN - NLM
STAT- MEDLINE
DCOM- 19780508
LR  - 20131121
IS  - 0009-9309 (Print)
IS  - 0009-9309 (Linking)
VI  - 11
IP  - 5
DP  - 1977 Dec
TI  - Evaluation of a charcoal-sorbitol mixture as an antidote for oral aspirin 
      overdose.
PG  - 561-7
AB  - The preparation of charcoal in a 70% sorbitol solution results in a suspension 
      that is more palatable and less gritty than an aqueous slurry of charcoal. 
      Although the charcoal-sorbitol mixture may be slightly less effective in reducing 
      the extent of aspirin absorption compared with a charcoal slurry, it may prove to 
      be of particular value in those cases where acceptance of a charcoal slurry 
      presents a problem.
FAU - Mayersohn, M
AU  - Mayersohn M
FAU - Perrier, D
AU  - Perrier D
FAU - Picchioni, A L
AU  - Picchioni AL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Toxicol
JT  - Clinical toxicology
JID - 0205535
RN  - 0 (Antidotes)
RN  - 0 (Suspensions)
RN  - 16291-96-6 (Charcoal)
RN  - 506T60A25R (Sorbitol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antidotes/administration & dosage/*therapeutic use
MH  - Aspirin/metabolism/*poisoning
MH  - Charcoal/administration & dosage/pharmacology/*therapeutic use
MH  - Drug Evaluation
MH  - Humans
MH  - Intestinal Absorption/drug effects
MH  - Male
MH  - Sorbitol/administration & dosage/pharmacology/*therapeutic use
MH  - Suspensions
EDAT- 1977/12/01 00:00
MHDA- 1977/12/01 00:01
CRDT- 1977/12/01 00:00
PHST- 1977/12/01 00:00 [pubmed]
PHST- 1977/12/01 00:01 [medline]
PHST- 1977/12/01 00:00 [entrez]
AID - 10.3109/15563657708988220 [doi]
PST - ppublish
SO  - Clin Toxicol. 1977 Dec;11(5):561-7. doi: 10.3109/15563657708988220.

PMID- 25767068
OWN - NLM
STAT- MEDLINE
DCOM- 20160104
LR  - 20220310
IS  - 2212-4411 (Electronic)
VI  - 119
IP  - 5
DP  - 2015 May
TI  - Should aspirin be stopped before tooth extraction? A meta-analysis.
PG  - 522-30
LID - S2212-4403(15)00035-8 [pii]
LID - 10.1016/j.oooo.2015.01.004 [doi]
AB  - OBJECTIVE: To carry out a standard meta-analysis to determine if aspirin should 
      be stopped before tooth extraction. STUDY DESIGN: The PubMed, ScienceDirect, 
      EBSCOhost, and Science Citation Index databases were searched for studies 
      published up to September 30, 2014. Eligible studies were restricted to 
      randomized controlled trials (RCTs) and controlled, nonrandomized trials. 
      RESULTS: Three RCTs and seven controlled trials met the inclusion criteria 
      (covering 1752 patients: 529 on aspirin therapy and 1223 not on aspirin therapy). 
      The results showed that the risk of postoperative hemorrhage was significantly 
      higher in patients on aspirin therapy (relative risk [RR] = 2.46; 95% confidence 
      interval [CI]: 1.45-4.81) but that bleeding time (BT) was not significantly 
      different between the two groups (standardized mean difference [SMD] = 0.63; 95% 
      CI: -0.04 to 1.31). Sensitivity analyses showed that the results were unstable. 
      CONCLUSIONS: We could reach a conclusion that BT is prolonged or hemorrhage is 
      exacerbated by long-term use of aspirin. We recommend not stopping long-term 
      aspirin use before tooth extraction but enhancing hemostasis methods, if 
      necessary.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Zhao, Bingjie
AU  - Zhao B
AD  - College of Stomatology, Shandong University, Number 44, Wen Hua Xi Lu, Jinan 
      City, Shandong Province 250012, China; Shandong Provincial Key Laboratory of Oral 
      Biomedicine, Number 44, Wen Hua Xi Lu, Jinan City, Shandong Province 250012, 
      China.
FAU - Wang, Peihuan
AU  - Wang P
AD  - Department of Stomatology, Jinan Military General Hospital, Jinan City, Shandong 
      Province 250012, China.
FAU - Dong, Yabing
AU  - Dong Y
AD  - College of Stomatology, Shandong University, Number 44, Wen Hua Xi Lu, Jinan 
      City, Shandong Province 250012, China; Shandong Provincial Key Laboratory of Oral 
      Biomedicine, Number 44, Wen Hua Xi Lu, Jinan City, Shandong Province 250012, 
      China.
FAU - Zhu, Yong
AU  - Zhu Y
AD  - College of Stomatology, Shandong University, Number 44, Wen Hua Xi Lu, Jinan 
      City, Shandong Province 250012, China; Shandong Provincial Key Laboratory of Oral 
      Biomedicine, Number 44, Wen Hua Xi Lu, Jinan City, Shandong Province 250012, 
      China.
FAU - Zhao, Huaqiang
AU  - Zhao H
AD  - College of Stomatology, Shandong University, Number 44, Wen Hua Xi Lu, Jinan 
      City, Shandong Province 250012, China. Electronic address: Zhaohq@sdu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20150203
PL  - United States
TA  - Oral Surg Oral Med Oral Pathol Oral Radiol
JT  - Oral surgery, oral medicine, oral pathology and oral radiology
JID - 101576782
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Humans
MH  - Oral Hemorrhage/*etiology/*prevention & control
MH  - *Tooth Extraction
EDAT- 2015/03/15 06:00
MHDA- 2016/01/05 06:00
CRDT- 2015/03/14 06:00
PHST- 2014/10/24 00:00 [received]
PHST- 2014/11/25 00:00 [revised]
PHST- 2015/01/14 00:00 [accepted]
PHST- 2015/03/14 06:00 [entrez]
PHST- 2015/03/15 06:00 [pubmed]
PHST- 2016/01/05 06:00 [medline]
AID - S2212-4403(15)00035-8 [pii]
AID - 10.1016/j.oooo.2015.01.004 [doi]
PST - ppublish
SO  - Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 May;119(5):522-30. doi: 
      10.1016/j.oooo.2015.01.004. Epub 2015 Feb 3.

PMID- 512863
OWN - NLM
STAT- MEDLINE
DCOM- 19800215
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 68
IP  - 10
DP  - 1979 Oct
TI  - Dissolution behavior of commercial enteric-coated aspirin tablets.
PG  - 1290-2
AB  - Dissolution behavior was studied for four commercial batches of enteric-coated 
      aspirin tablets from two companies. The USP XIX dissolution procedure was 
      modified by including pretreatment in simulated gastric juice. The effects of 
      five pretreatment times were studied. Pretreated tablets yielded higher 
      dissolution profiles and fewer undissolved fractions than nonpretreated tablets. 
      Among pretreatments, 15 min was adequate and 60 min produced the highest 
      dissolution profiles. None of the pretreatments differed significantly from each 
      other. An F test and conducted on the data indicated that Product X was 
      significantly better than Product Y at the p=0.05 level. Batch C was ranked as 
      the best batch irrespective of pretreatment time, followed by Batch D. Batches A 
      and B were equal, although Batch A appeared to be better than B for the 60-min 
      pretreatment, as indicated by the lower t80% value.
FAU - Embil, K
AU  - Embil K
FAU - Torosian, G
AU  - Torosian G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - Solubility
MH  - Tablets, Enteric-Coated
MH  - Time Factors
EDAT- 1979/10/01 00:00
MHDA- 1979/10/01 00:01
CRDT- 1979/10/01 00:00
PHST- 1979/10/01 00:00 [pubmed]
PHST- 1979/10/01 00:01 [medline]
PHST- 1979/10/01 00:00 [entrez]
AID - S0022-3549(15)42887-4 [pii]
AID - 10.1002/jps.2600681024 [doi]
PST - ppublish
SO  - J Pharm Sci. 1979 Oct;68(10):1290-2. doi: 10.1002/jps.2600681024.

PMID- 28380176
OWN - NLM
STAT- MEDLINE
DCOM- 20170807
LR  - 20230301
IS  - 1806-9460 (Electronic)
IS  - 1516-3180 (Print)
IS  - 1516-3180 (Linking)
VI  - 135
IP  - 1
DP  - 2017 Jan-Feb
TI  - The effectiveness of aspirin for migraine prophylaxis: a systematic review.
PG  - 42-49
LID - S1516-31802017000100042 [pii]
LID - 10.1590/1516-3180.2016.0165050916 [doi]
AB  - CONTEXT AND OBJECTIVE: Many researchers have suggested that aspirin prevents 
      migraines. However, the evidence is unclear. The aim of this study was to analyze 
      the available evidence on the effect of aspirin as a migraine prophylactic. 
      DESIGN AND SETTING: Systematic review, conducted at the Pontifícia Universidade 
      Católica do Paraná, Brazil, and at the University of São Paulo, Brazil. METHODS: 
      We performed electronic searches in the databases of MEDLINE/PubMed, Embase, WEB 
      OF SCIENCE, the World Health Organization, CENTRAL and OpenGrey, and we also 
      searched manually for interventional studies published before April 2016 that 
      compared the effects of aspirin with a control, in adults. Two authors 
      independently extracted data on the publication, population recruited, 
      intervention (aspirin dosage, follow-up and combined treatment) and main outcomes 
      (frequency, severity and duration of migraine). We evaluated the quality of the 
      studies using the Cochrane risk-of-bias tool. RESULTS: Our search retrieved 1,098 
      references, of which 8 met the selection criteria for this systematic review. The 
      total population was 28,326 participants (18-64 years old); most (96%) were men. 
      The dosage varied from 50 to 650 mg/day across the studies. The risk of bias was 
      generally low or unclear. The only outcome for which most of the studies included 
      (6/8) reported a significant reduction was frequency of migraine, which was 
      reduced at an aspirin dosage of at least 325 mg/day. CONCLUSION: Aspirin can 
      reduce the frequency of migraines. However, the optimal dosage is unclear.
FAU - Baena, Cristina Pellegrino
AU  - Baena CP
AD  - MD, PhD. Professor, School of Medicine, Pontifícia Universidade Católica do 
      Paraná (PUCPR), Curitiba (PR), Brazil.
FAU - D'Amico, Raíssa Campos
AU  - D'Amico RC
AD  - Medical Student, School of Medicine, Pontifícia Universidade Católica do Paraná 
      (PUCPR), Curitiba (PR), Brazil.
FAU - Slongo, Helena
AU  - Slongo H
AD  - Medical Student, Faculdade Evangélica do Paraná (FEPAR), Curitiba (PR), Brazil.
FAU - Brunoni, André Russowsky
AU  - Brunoni AR
AD  - MD. Professor, Hospital Universitário (HU), Universidade de São Paulo (USP), and 
      Coordinator, Service of Interdisciplinary Neuromodulation (SIN), Laboratory of 
      Neurosciences (LIM-27), Department and Institute of Psychiatry, Universidade de 
      São Paulo (USP), São Paulo (SP), Brazil.
FAU - Goulart, Alessandra Carvalho
AU  - Goulart AC
AD  - MD. Epidemiologist, Hospital Universitário (HU), Universidade de São Paulo (USP), 
      São Paulo (SP), Brazil.
FAU - Benseñor, Isabela
AU  - Benseñor I
AD  - MD, PhD. Professor, Hospital Universitário (HU), Universidade de São Paulo (USP), 
      São Paulo (SP), Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - Brazil
TA  - Sao Paulo Med J
JT  - Sao Paulo medical journal = Revista paulista de medicina
JID - 100897261
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Male
MH  - Migraine Disorders/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage
PMC - PMC9969718
COIS- Conflict of interest: None
EDAT- 2017/04/06 06:00
MHDA- 2017/08/08 06:00
CRDT- 2017/04/06 06:00
PHST- 2016/09/05 00:00 [received]
PHST- 2016/09/14 00:00 [accepted]
PHST- 2017/04/06 06:00 [entrez]
PHST- 2017/04/06 06:00 [pubmed]
PHST- 2017/08/08 06:00 [medline]
AID - S1516-31802017000100042 [pii]
AID - 10.1590/1516-3180.2016.0165050916 [doi]
PST - ppublish
SO  - Sao Paulo Med J. 2017 Jan-Feb;135(1):42-49. doi: 
      10.1590/1516-3180.2016.0165050916.

PMID- 866810
OWN - NLM
STAT- MEDLINE
DCOM- 19770718
LR  - 20190823
IS  - 0034-5687 (Print)
IS  - 0034-5687 (Linking)
VI  - 29
IP  - 2
DP  - 1977 Apr
TI  - Role of prostaglandins in alveolar hypoxic vasoconstriction.
PG  - 151-62
AB  - The role of prostaglandins as mediators of alveolar hypoxic vasoconstriction was 
      investigated in dogs with the use of the prostaglandin synthesis inhibitors, 
      aspirin and indomethacin. Alveolar hypoxia was induced by inserting 
      double-lumened endotracheal tube into the carina and ventilating one lung with 
      nigrogen while maintaining normal systemic oxygenation with 100% O(2) ventilation 
      to the other lung. Relative perfusion to each lung was determined with 133Xenon 
      and external counters. Infusions up to 25 mg/kg of indomethacin and up to 250 
      mg/kg of aspirin did not block the shift in perfusion from the alveolar hypoxic 
      lung. In fact, the shift in perfusion from the alveolar hypoxic lung was slightly 
      augmented by aspirin (P = 0.03). Thus, no positive role was demonstrated in the 
      dog for prostaglandins in producing the vasoconstriction of alveolar hypoxia.
FAU - Hales, C A
AU  - Hales CA
FAU - Rouse, E
AU  - Rouse E
FAU - Buchwald, I A
AU  - Buchwald IA
FAU - Kazemi, H
AU  - Kazemi H
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Respir Physiol
JT  - Respiration physiology
JID - 0047142
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology
MH  - Blood Gas Analysis
MH  - Blood Pressure/drug effects
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Hypoxia/*physiopathology
MH  - Indomethacin/administration & dosage/pharmacology
MH  - Intubation, Intratracheal/methods
MH  - Prostaglandins/*physiology
MH  - Pulmonary Alveoli/*physiopathology
MH  - Pulmonary Circulation/drug effects
MH  - Pulmonary Ventilation/drug effects
MH  - Vascular Resistance/drug effects
MH  - Vasomotor System/*physiopathology
EDAT- 1977/04/01 00:00
MHDA- 1977/04/01 00:01
CRDT- 1977/04/01 00:00
PHST- 1977/04/01 00:00 [pubmed]
PHST- 1977/04/01 00:01 [medline]
PHST- 1977/04/01 00:00 [entrez]
AID - 10.1016/0034-5687(77)90088-3 [doi]
PST - ppublish
SO  - Respir Physiol. 1977 Apr;29(2):151-62. doi: 10.1016/0034-5687(77)90088-3.

PMID- 235394
OWN - NLM
STAT- MEDLINE
DCOM- 19750701
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 17
IP  - 1
DP  - 1975 Jan
TI  - Fetal acquisition and neonatal elimination of a large amount of salicylate. Study 
      of a neonate whose mother regularly took therapeutic doses of aspirin during 
      pregnancy.
PG  - 98-103
AB  - The purpose of this study was to determine the amount of salicylate acquired by a 
      newborn infant from a mother who took 6.5 gm of aspirin a day during her entire 
      pregnancy, and to characterize the kinetics of salicylate elimination by the 
      infant. This healthy female infant was born with a salicylic acid concentration 
      of 25 mg/100 ml plasma and 75 mg/kg body weight. The drug was eliminated during 
      the first 5 days of life, primarily in the form of salicyluric acid. Salicylate 
      elimination was relatively slower than in normal adults, but more rapid than in 
      newborn infants of mothers who had taken only one small dose of aspirin shortly 
      before delivery. The apparent in vivo KM and Vmax for salicylurate formation, on 
      a body weight basis, were at the adult level. The slower elimination of 
      salicylate (relative to adults) by the infant was due to immaturity of the 
      glucuronidation and renal excretory pathways.
FAU - Garrettson, L K
AU  - Garrettson LK
FAU - Procknal, J A
AU  - Procknal JA
FAU - Levy, G
AU  - Levy G
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis/drug therapy
MH  - Aspirin/*metabolism/therapeutic use
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Infant, Newborn
MH  - Kinetics
MH  - *Maternal-Fetal Exchange
MH  - Pregnancy
MH  - Salicylates/blood/*metabolism/urine
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 0009-9236(75)90170-8 [pii]
AID - 10.1002/cpt197517198 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1975 Jan;17(1):98-103. doi: 10.1002/cpt197517198.

PMID- 20870780
OWN - NLM
STAT- MEDLINE
DCOM- 20110506
LR  - 20131121
IS  - 1460-2393 (Electronic)
IS  - 1460-2393 (Linking)
VI  - 104
IP  - 2
DP  - 2011 Feb
TI  - Prevalence and independent factors for gastroduodenal ulcers/erosions in 
      asymptomatic patients taking low-dose aspirin and gastroprotective agents: the 
      OITA-GF study.
PG  - 133-9
LID - 10.1093/qjmed/hcq169 [doi]
AB  - BACKGROUND: Although it is well known that aspirin causes gastroduodenal mucosal 
      injury and that aspirin-induced gastroduodenal mucosal injury is often 
      asymptomatic, the prevalence and independent factors for gastroduodenal mucosal 
      injury have not been clarified in asymptomatic patients taking low-dose aspirin 
      and gastroprotective agents. AIM: To clarify the prevalence and independent 
      factors for gastroduodenal ulcers/erosions in asymptomatic patients taking 
      low-dose aspirin and gastroprotective agents. DESIGN: Prospective observational 
      study. METHODS: We performed endoscopy in 150 asymptomatic patients taking 
      low-dose aspirin and gastroprotective agents for at least 3 months. RESULTS: 
      Gastroduodenal ulcers/erosions were observed in 37.3% [ulcers (4.0%); erosions 
      (34.0%)]. Univariate logistic regression analyses showed that proton-pump 
      inhibitor (PPI) use was negatively associated with gastroduodenal ulcers/erosions 
      [odds ratio (OR) 0.35, 95% confidence interval (95% CI) 0.17-0.75, P=0.007]. A 
      multivariate logistic regression analysis selected PPI use as the only 
      independent factor for gastroduodenal ulcers/erosions (OR 0.35, 95% CI 0.14-0.86, 
      P=0.02). None of the 53 patients with PPI use had any gastroduodenal ulcers, and 
      11 with standard-dose PPI use tended to have a lower prevalence of gastroduodenal 
      erosions than 42 with low-dose PPI use (0% vs. 28.6%, P=0.052). CONCLUSION: 
      Gastroduodenal ulcers/erosions were observed in about one-third of asymptomatic 
      patients taking low-dose aspirin and gastroprotective agents, and PPI use was a 
      negative independent factor for gastroduodenal ulcers/erosions in those patients. 
      In addition, standard-dose PPI therapy might be more effective in the prevention 
      of aspirin-induced gastroduodenal mucosal injury than low-dose PPI therapy.
FAU - Tamura, A
AU  - Tamura A
AD  - Internal Medicine 2, Oita University, Idaigaoka 1-1, Hasama-machi, Yufu 879-5593, 
      Japan. akira@oita-u.ac.jp
FAU - Murakami, K
AU  - Murakami K
FAU - Kadota, J
AU  - Kadota J
CN  - OITA-GF Study Investigators
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20100924
PL  - England
TA  - QJM
JT  - QJM : monthly journal of the Association of Physicians
JID - 9438285
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Endoscopy, Gastrointestinal
MH  - Epidemiologic Methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*chemically induced/epidemiology/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Proton Pump Inhibitors/*therapeutic use
FIR - Goto, Y
IR  - Goto Y
FIR - Kawano, Y
IR  - Kawano Y
FIR - Naono, S
IR  - Naono S
FIR - Sato, T
IR  - Sato T
FIR - Kotoku, M
IR  - Kotoku M
FIR - Abe, T
IR  - Abe T
FIR - Watada, M
IR  - Watada M
FIR - Anan, J
IR  - Anan J
FIR - Tanahashi, J
IR  - Tanahashi J
FIR - Mizukami, K
IR  - Mizukami K
FIR - Yasaka, S
IR  - Yasaka S
FIR - Okimoto, T
IR  - Okimoto T
FIR - Kodama, M
IR  - Kodama M
FIR - Miyamoto, K
IR  - Miyamoto K
FIR - Watanabe, T
IR  - Watanabe T
FIR - Hino, M
IR  - Hino M
FIR - Shinozaki, K
IR  - Shinozaki K
FIR - Zaizen, H
IR  - Zaizen H
FIR - Hisamatsu, A
IR  - Hisamatsu A
FIR - Soma, W
IR  - Soma W
FIR - Nakagawa, Y
IR  - Nakagawa Y
FIR - Nakashima, H
IR  - Nakashima H
FIR - Okawara, H
IR  - Okawara H
FIR - Nagai, T
IR  - Nagai T
EDAT- 2010/09/28 06:00
MHDA- 2011/05/07 06:00
CRDT- 2010/09/28 06:00
PHST- 2010/09/28 06:00 [entrez]
PHST- 2010/09/28 06:00 [pubmed]
PHST- 2011/05/07 06:00 [medline]
AID - hcq169 [pii]
AID - 10.1093/qjmed/hcq169 [doi]
PST - ppublish
SO  - QJM. 2011 Feb;104(2):133-9. doi: 10.1093/qjmed/hcq169. Epub 2010 Sep 24.

PMID- 28072892
OWN - NLM
STAT- MEDLINE
DCOM- 20170727
LR  - 20170727
IS  - 1121-7138 (Print)
IS  - 1121-7138 (Linking)
VI  - 40
IP  - 2
DP  - 2017 Apr
TI  - Use of statins and aspirin to prevent cardiovascular disease among HIV-positive 
      patients. A survey among Italian HIV physicians.
PG  - 139-142
AB  - We conducted a survey among Italian HIV specialists to study the utilization of 
      statins and aspirin, administering a questionnaire aimed at investigating their 
      use, the use of guidelines and scores, and the management of interactions. The 
      answers were uniform in the different geographic areas. The majority directly 
      prescribe statins and 43% of them prescribe aspirin. The majority follows 
      guidelines and utilize scores to calculate the CV risk. Our survey demonstrates 
      the commitment and autonomy in prescribing statins and aspirin of Italian 
      physicians. There is a rationale to generate guidelines to overcome the 
      differences and limitations among current recommendations.
FAU - Maggi, Paolo
AU  - Maggi P
AD  - Clinica Malattie Infettive Policlinico, Bari.
FAU - De Socio, Giuseppe Vittorio
AU  - De Socio GV
AD  - Clinica Malattie Infettive, Azienda Ospedaliero-Universitaria di Perugia.
FAU - Cicalini, Stefania
AU  - Cicalini S
AD  - INMI L. Spallanzani, Roma.
FAU - D'Abbraccio, Maurizio
AU  - D'Abbraccio M
AD  - UOC. di Immunodeficienze e Malattie Infettive di Genere, P.O. "D. Cotugno" - AORN 
      Dei Colli, Napoli.
FAU - Dettorre, Gabriella
AU  - Dettorre G
AD  - Clinica Malattie Infettive. Policlinico Umberto I, Roma.
FAU - Di Biagio, Antonio
AU  - Di Biagio A
AD  - Clinica Malattie Infettive IRCCS AOU San Martino-IST, Genova.
FAU - Martinelli, Canio
AU  - Martinelli C
AD  - SOD Malattie Infettive e Tropicali AOU Careggi, Firenze.
FAU - Nunnari, Giuseppe
AU  - Nunnari G
AD  - Clinica Malattie Infettive Policlinico, Messina.
FAU - Rusconi, Stefano
AU  - Rusconi S
AD  - Divisione Clinicizzata AOU L. Sacco, Milano.
FAU - Sighinolfi, Laura
AU  - Sighinolfi L
AD  - U.O.Malattie Infettive AOU Ferrara.
FAU - Spagnuolo, Vincenzo
AU  - Spagnuolo V
AD  - Dipartimento Malattie Infettive Ospedale S. Raffaele, Milano.
FAU - Squillace, Nicola
AU  - Squillace N
AD  - Divisione Malattie Infettive AO S. Gerardo, Monza.
LA  - eng
PT  - Journal Article
DEP - 20170110
PL  - Italy
TA  - New Microbiol
JT  - The new microbiologica
JID - 9516291
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cardiovascular Diseases/*complications/*prevention & control
MH  - Data Collection
MH  - HIV Infections/*complications
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & 
      dosage/*pharmacology
MH  - Italy/epidemiology
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology
MH  - *Practice Patterns, Physicians'
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - HIV
OT  - Statins
EDAT- 2017/01/11 06:00
MHDA- 2017/07/28 06:00
CRDT- 2017/01/11 06:00
PHST- 2017/05/15 00:00 [received]
PHST- 2017/05/15 00:00 [accepted]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2017/07/28 06:00 [medline]
PHST- 2017/01/11 06:00 [entrez]
AID - 497M896 [pii]
PST - ppublish
SO  - New Microbiol. 2017 Apr;40(2):139-142. Epub 2017 Jan 10.

PMID- 3918838
OWN - NLM
STAT- MEDLINE
DCOM- 19850409
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 87
IP  - 3
DP  - 1985 Mar
TI  - Aspirin-sensitive asthma.
PG  - 386-91
AB  - Aspirin intolerance is particularly common in asthmatic patients who additionally 
      have chronic rhinitis and/or nasal polyps. These individuals differ in several 
      respects from patients who experience urticaria and/or angioedema after aspirin 
      administration, and differing mechanisms may be involved. Data regarding the 
      latter are indirect and incomplete, but suggest that ASA-sensitive asthma is most 
      likely to be related in some manner to the capacity of ASA to inhibit 
      cyclooxygenases, enhanced lipoxygenase metabolism perhaps playing a crucial role. 
      Current research employing ASA "desensitization" may help to elucidate these 
      enigmas.
FAU - Slepian, I K
AU  - Slepian IK
FAU - Mathews, K P
AU  - Mathews KP
FAU - McLean, J A
AU  - McLean JA
LA  - eng
GR  - 5M01-RR00042-22/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Arachidonic Acids)
RN  - 0 (Prostaglandin Antagonists)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/chemically induced/*immunology/metabolism
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/etiology/*metabolism
MH  - Humans
MH  - Prostaglandin Antagonists
RF  - 50
EDAT- 1985/03/01 00:00
MHDA- 1985/03/01 00:01
CRDT- 1985/03/01 00:00
PHST- 1985/03/01 00:00 [pubmed]
PHST- 1985/03/01 00:01 [medline]
PHST- 1985/03/01 00:00 [entrez]
AID - S0012-3692(15)40865-7 [pii]
AID - 10.1378/chest.87.3.386 [doi]
PST - ppublish
SO  - Chest. 1985 Mar;87(3):386-91. doi: 10.1378/chest.87.3.386.

PMID- 7377152
OWN - NLM
STAT- MEDLINE
DCOM- 19800722
LR  - 20190716
IS  - 0002-922X (Print)
IS  - 0002-922X (Linking)
VI  - 134
IP  - 5
DP  - 1980 May
TI  - Salicylate therapy in juvenile rheumatoid arthritis. Dose, serum level, and 
      toxicity.
PG  - 461-3
AB  - In a prospective study of aspirin therapy for 67 children with juvenile 
      rheumatoid arthritis, we have found that (1) doses greater than 100 mg/kg/day of 
      aspirin may be necessary to achieve therapeutic salicylate levels greater than 20 
      mg/dL; (2) no improvement in clinical remission rate is seen at salicylate levels 
      greater than 30 mg/dL; (3) clinical toxicity to aspirin is of relatively low 
      incidence (16%), and infrequently causes serious morbidity; (4) symptomatic SGOT 
      elevations are common in the first three months after onset of therapy; and (5) 
      these elevated SGOT levels generally return to normal despite continuation of 
      therapy.
FAU - Doughty, R A
AU  - Doughty RA
FAU - Giesecke, L
AU  - Giesecke L
FAU - Athreya, B
AU  - Athreya B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Dis Child
JT  - American journal of diseases of children (1960)
JID - 0370471
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Arthritis, Juvenile/blood/*drug therapy
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Infant
MH  - Prospective Studies
MH  - Salicylates/blood
EDAT- 1980/05/01 00:00
MHDA- 1980/05/01 00:01
CRDT- 1980/05/01 00:00
PHST- 1980/05/01 00:00 [pubmed]
PHST- 1980/05/01 00:01 [medline]
PHST- 1980/05/01 00:00 [entrez]
AID - 10.1001/archpedi.1980.02130170011005 [doi]
PST - ppublish
SO  - Am J Dis Child. 1980 May;134(5):461-3. doi: 10.1001/archpedi.1980.02130170011005.

PMID- 31755069
OWN - NLM
STAT- MEDLINE
DCOM- 20200513
LR  - 20200513
IS  - 1179-1969 (Electronic)
IS  - 1170-229X (Linking)
VI  - 37
IP  - 1
DP  - 2020 Jan
TI  - Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and 
      Cancer in the Elderly: A Population-Based Cohort Study in Korea.
PG  - 43-55
LID - 10.1007/s40266-019-00723-3 [doi]
AB  - INTRODUCTION: Aspirin is widely used to prevent cardiovascular diseases (CVDs). 
      However, the balance of its benefits and risks in the primary prevention of CVDs 
      and cancer is unclear, especially in elderly Asians. The present study aimed to 
      evaluate the efficacy of aspirin in the primary prevention of major adverse 
      cardiac and cerebrovascular events (MACCE), bleeding risk, and cancer in elderly 
      Koreans with cardiovascular (CV) risk factors. METHODS: This retrospective cohort 
      study used data from the Korean National Health Insurance Service-Senior cohort 
      database (2002-2015). Patients aged 60-90 years with hypertension, type 2 
      diabetes mellitus (T2DM), or dyslipidemia were identified. Aspirin users were 
      compared with non-users using propensity score matching at a 1:3 ratio. The 
      primary outcome was MACCE, a composite of CV mortality, myocardial infarction, 
      and ischemic stroke. The secondary outcomes were the components of MACCE, 
      all-cause mortality, angina pectoris, heart failure, the incidence and mortality 
      of cancer, and the risks of hemorrhagic stroke and gastrointestinal bleeding. 
      Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using a Cox 
      proportional hazard model. RESULTS: A total of 3366 aspirin users and 10,089 
      non-users were finally included in the study. During a mean follow-up of 
      7.8 years, the incidence of MACCE was 15.2% in aspirin users and 22.4% in 
      non-users. The risk of MACCE was significantly lower in aspirin users than in 
      non-users (HR 0.76; 95% CI 0.69-0.85), and this risk was significantly reduced in 
      patients using aspirin over 5 years (HR 0.52; 95% CI 0.46-0.60). Aspirin use was 
      associated with a 21% reduction in the risk of primary cancer (HR 0.79; 95% CI 
      0.70-0.88) and cancer-related mortality (HR 0.72; 95% CI 0.61-0.84). No 
      significant differences in bleeding risks were observed between the two groups. 
      CONCLUSION: Aspirin reduced the risks of MACCE and cancer without increasing the 
      bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia. 
      Moreover, the benefits of the long-term use of aspirin in reducing the risks of 
      MACCE were demonstrated. However, the decision of using aspirin for primary 
      prevention must be carefully made on an individual basis, while estimating the 
      benefit-risk balance of aspirin.
FAU - Jung, Minji
AU  - Jung M
AUID- ORCID: 0000-0002-5489-827X
AD  - Division of Clinical Pharmacy, College of Pharmacy, Ajou University, 206 
      Worldcup-ro Yeongtong-gu, Suwon, 16499, Republic of Korea.
FAU - Lee, Sukhyang
AU  - Lee S
AUID- ORCID: 0000-0002-8830-4353
AD  - Division of Clinical Pharmacy, College of Pharmacy, Ajou University, 206 
      Worldcup-ro Yeongtong-gu, Suwon, 16499, Republic of Korea. suklee@ajou.ac.kr.
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/prevention & control
MH  - Dyslipidemias/prevention & control
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Hypertension/prevention & control
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*prevention & control
MH  - Primary Prevention/*methods
MH  - Proportional Hazards Models
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Risk Assessment
EDAT- 2019/11/23 06:00
MHDA- 2020/05/14 06:00
CRDT- 2019/11/23 06:00
PHST- 2019/11/23 06:00 [pubmed]
PHST- 2020/05/14 06:00 [medline]
PHST- 2019/11/23 06:00 [entrez]
AID - 10.1007/s40266-019-00723-3 [pii]
AID - 10.1007/s40266-019-00723-3 [doi]
PST - ppublish
SO  - Drugs Aging. 2020 Jan;37(1):43-55. doi: 10.1007/s40266-019-00723-3.

PMID- 2657675
OWN - NLM
STAT- MEDLINE
DCOM- 19890629
LR  - 20190912
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 9
IP  - 2
DP  - 1989
TI  - An evaluation of flurbiprofen, aspirin, and placebo in postoperative oral surgery 
      pain.
PG  - 66-73
AB  - One hundred sixty-four outpatients with postoperative pain after the removal of 
      impacted third molars were randomly assigned on a double-blind basis, to receive 
      oral doses of flurbiprofen 25, 50, or 100 mg; aspirin 600 mg; or placebo. Using a 
      self-rating record, subjects rated their pain and its relief hourly for 8 hours 
      after medicating. Estimates of sum of pain differences (SPID), peak pain 
      intensity difference (PID), total relief, peak relief, and hours of 50% relief 
      were derived from these subjective reports. All active medications were 
      significantly superior to placebo. Analgesia was similar for flurbiprofen 25 mg 
      and aspirin 600 mg. Flurbiprofen 50 and 100 mg were significantly superior to 
      aspirin for every measure of analgesia except peak PID. There was a significant 
      dose-response regression between flurbiprofen 25 mg and both of the higher 
      dosages. Flurbiprofen 50 and 100 mg did not differ significantly, suggesting a 
      plateau in flurbiprofen's analgesia. The analgesic effect of flurbiprofen was 
      significant by hour 1 and persisted for 8 hours. The frequency of adverse effects 
      was similar for the active medications.
FAU - Forbes, J A
AU  - Forbes JA
AD  - Department of Psychiatry, Johns Hopkins University, School of Medicine, 
      Baltimore, Maryland.
FAU - Yorio, C C
AU  - Yorio CC
FAU - Selinger, L R
AU  - Selinger LR
FAU - Rosenmertz, S K
AU  - Rosenmertz SK
FAU - Beaver, W T
AU  - Beaver WT
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Flurbiprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Mouth/surgery
MH  - Pain, Postoperative/*drug therapy
MH  - Propionates/*therapeutic use
MH  - Random Allocation
MH  - Time Factors
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1002/j.1875-9114.1989.tb04105.x [doi]
PST - ppublish
SO  - Pharmacotherapy. 1989;9(2):66-73. doi: 10.1002/j.1875-9114.1989.tb04105.x.

PMID- 15740918
OWN - NLM
STAT- MEDLINE
DCOM- 20050809
LR  - 20131121
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 37
IP  - 3
DP  - 2005 Mar 9
TI  - Comparative study of the continuous wavelet transform, derivative and partial 
      least squares methods applied to the overlapping spectra for the simultaneous 
      quantitative resolution of ascorbic acid and acetylsalicylic acid in effervescent 
      tablets.
PG  - 569-75
AB  - The simultaneous spectrophotometric determination of ascorbic acid (AA) and 
      acetylsalicylic acid (ASA) in effervescent tablets in the presence of the 
      overlapping spectra was accomplished by the continuous wavelet transform (CWT), 
      derivative spectrophotometry (DS) and partial least squares (PLS) approaches 
      without using any chemical pre-treatment. CWT and DS calibration equations for AA 
      and ASA were obtained by measuring the CWT and DS amplitudes corresponding to 
      zero-crossing points of spectra obtained by plotting continuous wavelet 
      coefficients and first-derivative absorbance values versus the wavelengths, 
      respectively. The PLS calibration was constructed by using the concentration set 
      and its full absorbance data consisting of 850 points from 220 to 305 nm in the 
      range of 210-310 nm. These three methods were tested by analyzing the synthetic 
      mixtures of the above drugs and they were applied to the real samples containing 
      two commercial pharmaceutical preparations of subjected drugs. A comparative 
      study was carried out by using the experimental results obtained from three 
      analytical methodologies and precise and accurate results were obtained.
FAU - Dinç, Erdal
AU  - Dinç E
AD  - Department of Analytical Chemistry, Faculty of Pharmacy, Ankara University, 06100 
      Tandoğan, Ankara, Turkey. dinc@pharmacy.ankara.edu.tr
FAU - Ozdemir, Abdil
AU  - Ozdemir A
FAU - Baleanu, Dumitru
AU  - Baleanu D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20041222
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Tablets)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/*analysis
MH  - Aspirin/*analysis
MH  - Least-Squares Analysis
MH  - Spectrophotometry, Ultraviolet/methods/statistics & numerical data
MH  - Tablets
EDAT- 2005/03/03 09:00
MHDA- 2005/08/10 09:00
CRDT- 2005/03/03 09:00
PHST- 2004/08/01 00:00 [received]
PHST- 2004/11/09 00:00 [revised]
PHST- 2004/11/12 00:00 [accepted]
PHST- 2005/03/03 09:00 [pubmed]
PHST- 2005/08/10 09:00 [medline]
PHST- 2005/03/03 09:00 [entrez]
AID - S0731-7085(04)00601-6 [pii]
AID - 10.1016/j.jpba.2004.11.020 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2005 Mar 9;37(3):569-75. doi: 10.1016/j.jpba.2004.11.020. 
      Epub 2004 Dec 22.

PMID- 2178991
OWN - NLM
STAT- MEDLINE
DCOM- 19900424
LR  - 20190903
IS  - 0011-9075 (Print)
IS  - 0011-9075 (Linking)
VI  - 180
IP  - 2
DP  - 1990
TI  - Malignant atrophic papulosis: response to antiplatelet therapy.
PG  - 90-2
AB  - A patient with malignant atrophic papulosis (Degos' disease) is studied. Platelet 
      function studies showed abnormalities of increased adhesiveness and aggregation. 
      Treatment with dipyridamole and aspirin correlated with reversal of these 
      abnormalities and cessation of new lesion development. When treatment was 
      stopped, platelet function abnormalities and new skin lesions developed within 2 
      months. With reinstitution of therapy, the patient developed no new lesions in 
      the 5 months he was followed. This is the second report of platelet function 
      abnormality and apparent successful treatment with antiplatelet therapy in a 
      patient with Degos' disease.
FAU - Drucker, C R
AU  - Drucker CR
AD  - Baylor College of Medicine, Houston, Tex.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Switzerland
TA  - Dermatologica
JT  - Dermatologica
JID - 0211607
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Biopsy
MH  - Dipyridamole/*therapeutic use
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Skin Diseases, Vesiculobullous/*drug therapy/pathology
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1159/000247999 [doi]
PST - ppublish
SO  - Dermatologica. 1990;180(2):90-2. doi: 10.1159/000247999.

PMID- 9635120
OWN - NLM
STAT- MEDLINE
DCOM- 19980911
LR  - 20191102
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 26
IP  - 3
DP  - 1998 May
TI  - Influence of sepsis on the plasma elimination pharmacokinetics of diaspirin 
      crosslinked hemoglobin in rats.
PG  - 273-84
AB  - Septic shock is characterized by abnormalities in microcirculatory O2 delivery 
      (QO2) and profound tissue O2 debt. Administration of crosslinked hemoglobin may 
      be a means of augmenting the QO2 and tissue O2 availability. Sepsis is associated 
      with hemodynamic and metabolic alterations which may affect the pharmacokinetics 
      of crosslinked hemoglobin. The objective of this study was to determine the 
      effect of sepsis on the plasma elimination of diaspirin crosslinked hemoglobin 
      (DCLHb). Twenty-four hours after the induction of sepsis by cecal ligation and 
      perforation, septic (n = 9) and sham rats (n = 8) received an intravenous 
      infusion of 300 mg of DCLHb and arterial blood samples were taken at regular 
      intervals to determine free plasma hemoglobin concentration. DCLHb elimination in 
      septic and sham rats was consistent with first-order elimination kinetics. The 
      half life (t1/2) for septic rats was 4.2 +/- 0.7 h and was significantly shorter 
      than the t1/2 of non-septic rats (5.4 +/- 0.9 h). In all rats, free plasma 
      hemoglobin returned to basal levels by 24 hours after DCLHb administration. The 
      volume of distribution for DCLHb in the septic and non-septic rats was not 
      significantly different and suggests that DCLHb is not influenced by altered gut 
      permeability. Despite significant changes in some elimination parameters the 
      differences were small. Consequently, dosing regimens for this compound may not 
      need to be altered in sepsis.
FAU - d'Almeida, M S
AU  - d'Almeida MS
AD  - Department of Hematology, AC Burton Vascular Biology Laboratory, Victoria 
      Hospital Research Institute, London Health Sciences Centre, Ontario, Canada.
FAU - Sibbald, W J
AU  - Sibbald WJ
FAU - White, M
AU  - White M
FAU - Chin-Yee, I H
AU  - Chin-Yee IH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacokinetics
MH  - Blood Substitutes/*pharmacokinetics
MH  - Half-Life
MH  - Hemoglobins/*pharmacokinetics
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sepsis/*blood
EDAT- 1998/06/23 00:00
MHDA- 1998/06/23 00:01
CRDT- 1998/06/23 00:00
PHST- 1998/06/23 00:00 [pubmed]
PHST- 1998/06/23 00:01 [medline]
PHST- 1998/06/23 00:00 [entrez]
AID - 10.3109/10731199809117458 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1998 May;26(3):273-84. doi: 
      10.3109/10731199809117458.

PMID- 9431267
OWN - NLM
STAT- MEDLINE
DCOM- 19980203
LR  - 20190914
IS  - 0894-9115 (Print)
IS  - 0894-9115 (Linking)
VI  - 76
IP  - 6
DP  - 1997 Nov-Dec
TI  - Reduced skin hyperemia during tap water iontophoresis after intake of 
      acetylsalicylic acid.
PG  - 482-7
AB  - Skin microcirculation and skin temperature of 10 healthy subjects (6 men and 4 
      women, 20-44 yr of age) without any vascular diseases were registered when a 
      thermoindifferent tap water iontophoresis was applied. The aim of this controlled 
      study was to evaluate the development of skin hyperemia after the intake of 500 
      mg of acetylsalicylic acid (ASA). The measurement was conducted by laser-Doppler 
      flowmetry on the proximal forearm. The skin temperature was measured before and 
      after the treatment by an infrared thermometer. In all persons there was an 
      intense erythema on the side of the cathode and only a modest one on the side of 
      the anode. Without ASA preliminary treatment, the cutaneous flow showed an 
      increase of 106% at the anodal side and that of 834% at the cathodal side (P < 
      0.001). After ending tap water iontophoresis, the skin temperature increased more 
      on the cathode side than on the anode side (P < 0.001). After the intake of 500 
      mg ASA, the increase of the flow was 78% at the anode and 88% at the cathode. The 
      comparison of the skin microcirculation did not show any differences at the 
      anodal side when acetylsalicylic acid was taken before, but a strong suppression 
      of the galvanic erythema at the cathodal side was observed after the intake of 
      ASA. There is a direct influence of acetylsalicylic acid on the induction of the 
      neurogenic inflammation caused by a galvanic erythema. The intensity of the 
      induced erythema correlates with the analgesic effects of constant current 
      treatment. An attenuation of the electrotherapeutic analgesia is possible.
FAU - Berliner, M N
AU  - Berliner MN
AD  - Department of Rheumatology and Physical Medicine, University of Giessen, Bad 
      Nauheim, Germany.
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am J Phys Med Rehabil
JT  - American journal of physical medicine & rehabilitation
JID - 8803677
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Steroids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Female
MH  - Galvanic Skin Response
MH  - Humans
MH  - Hyperemia/*chemically induced
MH  - Iontophoresis/*methods
MH  - Laser-Doppler Flowmetry
MH  - Male
MH  - Microcirculation
MH  - Middle Aged
MH  - Skin/*blood supply
MH  - *Skin Temperature
MH  - Steroids
MH  - Thermography
MH  - Time Factors
EDAT- 1998/02/07 00:00
MHDA- 1998/02/07 00:01
CRDT- 1998/02/07 00:00
PHST- 1998/02/07 00:00 [pubmed]
PHST- 1998/02/07 00:01 [medline]
PHST- 1998/02/07 00:00 [entrez]
AID - 10.1097/00002060-199711000-00010 [doi]
PST - ppublish
SO  - Am J Phys Med Rehabil. 1997 Nov-Dec;76(6):482-7. doi: 
      10.1097/00002060-199711000-00010.

PMID- 1633323
OWN - NLM
STAT- MEDLINE
DCOM- 19920827
LR  - 20191028
IS  - 0940-5437 (Print)
IS  - 0940-5437 (Linking)
VI  - 22
IP  - 1
DP  - 1992
TI  - Bleeding time and antiplatelet agents in normal volunteers.
PG  - 58-61
AB  - Clinical trials have shown that antiplatelet agents are effective in the 
      prevention of thrombosis in arterial diseases and increase bleeding time. To 
      compare the effects of three such drugs [acetylsalicylic acid (ASA) at two dose 
      levels, ticlopidine and indobufen] on bleeding time, we performed a randomized 
      cross-over study on 12 normal subjects. All received the four treatments (ASA 300 
      mg daily and 500 mg twice daily, ticlopidine 250 mg twice daily and indobufen 200 
      mg twice daily, each for 6 days plus one dose on day 7) in a sequential manner 
      with a washout period of 15 days between the treatments. Bleeding time was 
      measured using a Surgicut device (Ortho, Milan, Italy) before treatment, 2 and 24 
      h after the first administration, and before and 2, 24, 48 and 72 h after the 
      last administration. ASA (at both doses) and indobufen quickly induced a 
      significant prolongation of bleeding time, but the effect of indobufen soon wore 
      off after the treatment was stopped, unlike that of ASA. In contrast, ticlopidine 
      treatment prolonged bleeding time only after the first 24 h, and after 7 days the 
      mean value was significantly higher than with ASA (both doses) and indobufen. 
      This significant difference in bleeding time between ticlopidine and the other 
      drugs was still present 48 h after the end of treatment.
FAU - Pogliani, E M
AU  - Pogliani EM
AD  - Department of Internal Medicine, S. Gerardo Hospital, Monza, Italy.
FAU - Fowst, C
AU  - Fowst C
FAU - Bregani, R
AU  - Bregani R
FAU - Corneo, G
AU  - Corneo G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int J Clin Lab Res
JT  - International journal of clinical & laboratory research
JID - 9206491
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 6T9949G4LZ (indobufen)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects
MH  - *Bleeding Time
MH  - Female
MH  - Humans
MH  - Isoindoles
MH  - Male
MH  - Phenylbutyrates/adverse effects/pharmacology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Reference Values
MH  - Ticlopidine/adverse effects/pharmacology
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1007/BF02591396 [doi]
PST - ppublish
SO  - Int J Clin Lab Res. 1992;22(1):58-61. doi: 10.1007/BF02591396.

PMID- 11253939
OWN - NLM
STAT- MEDLINE
DCOM- 20010531
LR  - 20191104
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 18
IP  - 2
DP  - 2001 Mar-Apr
TI  - Encapsulating aspirin into a surfactant-free ethyl cellulose microsphere using 
      non-toxic solvents by emulsion solvent-evaporation technique.
PG  - 223-36
AB  - Microencapsulation of aspirin in ethylcellulose was studied in a surfactant-free, 
      water-in-oil type of emulsification/solvent evaporation process using non-toxic 
      solvents. Ethanol was used as the dispersed phase and soybean oil as the 
      continuous phase. The recovered weight, particle size distribution, aspirin 
      loading efficiency, and the aspirin release rate of microspheres were analysed. 
      The addition of a small amount of non-solvent (water) prior to the emulsification 
      was found to have a significant impact on the microencapsulation process. Adding 
      non-solvent increases the recovered weight and the size of the microspheres. The 
      addition of non-solvent also markedly changes the microsphere characteristics, 
      resulting in a coarser surface and an increased release rate. Increasing the 
      emulsification evaporation temperature increases the size of the microsphere, but 
      reduces the recovered weight and loading efficiency. The release rate follows a 
      first-order kinetics and Higuchi matrix kinetics at low concentrations of 
      non-solvent, suggesting a monolithic system with aspirin uniformly distributed in 
      the microsphere.
FAU - Yang, C Y
AU  - Yang CY
AD  - Department of Chemical Engineering, National Cheng Kung University, Tainan, 
      Taiwan, Republic of China.
FAU - Tsay, S Y
AU  - Tsay SY
FAU - Tsiang, R C
AU  - Tsiang RC
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Emulsions)
RN  - 0 (Solvents)
RN  - 0 (Surface-Active Agents)
RN  - 3K9958V90M (Ethanol)
RN  - 7Z8S9VYZ4B (ethyl cellulose)
RN  - 8001-22-7 (Soybean Oil)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*chemistry
MH  - Aspirin/administration & dosage/*chemistry
MH  - Cellulose/analogs & derivatives
MH  - Chemistry, Pharmaceutical
MH  - Emulsions
MH  - Ethanol/chemistry
MH  - Hot Temperature
MH  - Kinetics
MH  - Microspheres
MH  - Solubility
MH  - Solvents
MH  - Soybean Oil/chemistry
MH  - Surface-Active Agents/chemistry
EDAT- 2001/03/20 10:00
MHDA- 2001/06/02 10:01
CRDT- 2001/03/20 10:00
PHST- 2001/03/20 10:00 [pubmed]
PHST- 2001/06/02 10:01 [medline]
PHST- 2001/03/20 10:00 [entrez]
AID - 10.1080/026520401750063937 [doi]
PST - ppublish
SO  - J Microencapsul. 2001 Mar-Apr;18(2):223-36. doi: 10.1080/026520401750063937.

PMID- 21249668
OWN - NLM
STAT- MEDLINE
DCOM- 20110228
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 1
DP  - 2011 Jan 19
TI  - Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular 
      disease.
PG  - CD005158
LID - 10.1002/14651858.CD005158.pub3 [doi]
AB  - BACKGROUND: Aspirin is the prophylactic antiplatelet drug of choice for people 
      with cardiovascular disease. Adding a second antiplatelet drug to aspirin may 
      produce additional benefit for those at high risk and those with established 
      cardiovascular disease. OBJECTIVES: To quantify the benefit and harm of adding 
      clopidogrel to standard long-term aspirin therapy for preventing cardiovascular 
      events in people at high risk of cardiovascular disease and those with 
      established cardiovascular disease. SEARCH STRATEGY: The searches have been 
      updated: CENTRAL (Issue 3 2009), MEDLINE (2002 to September 2009) and EMBASE 
      (2002 to September 2009). SELECTION CRITERIA: All randomized controlled trials 
      comparing long term use of aspirin plus clopidogrel with aspirin plus placebo or 
      aspirin alone in patients with coronary disease, ischemic cerebrovascular 
      disease, peripheral arterial disease, or at high risk of atherothrombotic disease 
      were included. DATA COLLECTION AND ANALYSIS: Data on mortality, non-fatal 
      myocardial infarction, non-fatal stroke, unstable angina, heart failure, 
      revascularizations, major and minor bleeding, and all adverse events were 
      collected. The overall treatment effect was estimated by the pooled odds ratio 
      (OR) with 95% confidence interval (CI) using a fixed-effect model 
      (Mantel-Haenszel). MAIN RESULTS: No new studies were identified from the updated 
      searches. A total of two RCTs were found: the CHARISMA and the CURE study. The 
      CURE study enrolled only patients with a recent non-ST segment elevation acute 
      coronary syndrome. The use of clopidogrel plus aspirin, compared with placebo 
      plus aspirin, was associated with a lower risk of cardiovascular events (OR: 
      0.87, 95% CI 0.81 to 0.94; P<0.01) and a higher risk of major bleeding (OR 1.34, 
      95% CI 1.14 to 1.57; P<0.01). Overall, we would expect 13 cardiovascular events 
      to be prevented for every 1000 patients treated with the combination, but 6 major 
      bleeds would be caused. In the CURE trial, for every 1000 people treated, 23 
      events would be avoided and 10 major bleeds would be caused. In the CHARISMA 
      trial, for every 1000 people treated, 5 cardiovascular events would be avoided 
      and 3 major bleeds would be caused. AUTHORS' CONCLUSIONS: The available evidence 
      demonstrates that the use of clopidogrel plus aspirin is associated with a 
      reduction in the risk of cardiovascular events and an increased risk of bleeding 
      compared with aspirin alone. Only in patients with acute non-ST coronary syndrome 
      benefits outweigh harms.
FAU - Squizzato, Alessandro
AU  - Squizzato A
AD  - Research Center on Thromboembolic Disorders and Antithrombotic Therapies, 
      Department of Clinical Medicine, University of Insubria, Medicina 1, viale Borri, 
      57, Varese, Italy, 21100.
FAU - Keller, Tymen
AU  - Keller T
FAU - Romualdi, Erica
AU  - Romualdi E
FAU - Middeldorp, Saskia
AU  - Middeldorp S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20110119
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2007;(3):CD005158. PMID: 17636787
UIN - Cochrane Database Syst Rev. 2017 Dec 14;12 :CD005158. PMID: 29240976
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clopidogrel
MH  - Drug Therapy, Combination/adverse effects/methods
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
EDAT- 2011/01/21 06:00
MHDA- 2011/03/01 06:00
CRDT- 2011/01/21 06:00
PHST- 2011/01/21 06:00 [entrez]
PHST- 2011/01/21 06:00 [pubmed]
PHST- 2011/03/01 06:00 [medline]
AID - 10.1002/14651858.CD005158.pub3 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2011 Jan 19;(1):CD005158. doi: 
      10.1002/14651858.CD005158.pub3.

PMID- 20946994
OWN - NLM
STAT- MEDLINE
DCOM- 20101101
LR  - 20161125
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 56
IP  - 17
DP  - 2010 Oct 19
TI  - Prior aspirin use and outcomes in acute coronary syndromes.
PG  - 1376-85
LID - 10.1016/j.jacc.2010.06.028 [doi]
AB  - OBJECTIVES: The purpose of this study was to determine whether patients taking 
      aspirin before an acute coronary syndrome (ACS) are at higher risk of recurrent 
      events or mortality. BACKGROUND: Controversy exists whether prior aspirin use is 
      an independent predictor of worse outcomes in patients who experience an ACS. 
      METHODS: We evaluated 66,443 ACS patients from a merged database of previous 
      Thrombolysis in Myocardial Infarction trials. We evaluated the differences in ACS 
      type, total mortality, and the composite end point of death, myocardial 
      infarction (MI), recurrent ischemia, or stroke between prior aspirin and nonprior 
      aspirin users. We used multivariate analysis to control for differences in 
      baseline characteristics. RESULTS: Prior aspirin users (n = 17,839) were older 
      (63 years vs. 59 years) and had more coronary risk factors and evidence of 
      coronary artery disease (MI, angina, prior intervention) than nonprior aspirin 
      users (n = 48,604) (all p < 0.0001). Prior aspirin use was associated with less 
      severe types of ACS at presentation (e.g., unstable angina > non-ST-segment 
      elevation MI > ST-segment elevation MI) than their nonaspirin user counterparts 
      (p < 0.0001). After multivariate analysis, there was no difference in total 
      mortality between prior aspirin users and nonaspirin users at day 30 (odds ratio 
      [OR]: 1.01; 95% confidence interval [CI]: 0.90 to 1.13) or by the last follow-up 
      visit (mean 328 days) (hazard ratio: 1.03; 95% CI: 0.95 to 1.11). Prior aspirin 
      use was modestly associated with recurrent MI (OR: 1.26; 95% CI: 1.12 to 1.43) 
      and the composite end point (OR: 1.16; 95% CI: 1.08 to 1.24). CONCLUSIONS: Prior 
      aspirin use was associated with more comorbidities and coronary disease and a 
      higher risk of recurrent MI, but not mortality. As such, it should best be 
      considered a marker of a patient population at high risk for recurrent adverse 
      events after ACS.
CI  - Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Rich, Jonathan D
AU  - Rich JD
AD  - Section of Cardiology, Department of Medicine, University of Chicago, Chicago, 
      Illinois, USA.
FAU - Cannon, Christopher P
AU  - Cannon CP
FAU - Murphy, Sabina A
AU  - Murphy SA
FAU - Qin, Jie
AU  - Qin J
FAU - Giugliano, Robert P
AU  - Giugliano RP
FAU - Braunwald, Eugene
AU  - Braunwald E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2011 Apr 19;57(16):1715; author reply 1715-6. PMID: 21492774
MH  - Acute Coronary Syndrome/diagnostic imaging/mortality/*physiopathology
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Coronary Angiography
MH  - Coronary Disease/therapy
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk Factors
MH  - Survival Rate
EDAT- 2010/10/16 06:00
MHDA- 2010/11/03 06:00
CRDT- 2010/10/16 06:00
PHST- 2009/09/03 00:00 [received]
PHST- 2010/04/28 00:00 [revised]
PHST- 2010/06/01 00:00 [accepted]
PHST- 2010/10/16 06:00 [entrez]
PHST- 2010/10/16 06:00 [pubmed]
PHST- 2010/11/03 06:00 [medline]
AID - S0735-1097(10)03452-2 [pii]
AID - 10.1016/j.jacc.2010.06.028 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2010 Oct 19;56(17):1376-85. doi: 10.1016/j.jacc.2010.06.028.

PMID- 636074
OWN - NLM
STAT- MEDLINE
DCOM- 19780524
LR  - 20131121
IS  - 0093-5387 (Print)
IS  - 0093-5387 (Linking)
VI  - 5
IP  - 1
DP  - 1978 Mar
TI  - Effects of hyperbaric helium-oxygen on the antipyretic actions of aspirin and 
      acetaminophen in rats.
PG  - 53-62
AB  - The effects of two antipyretics, aspirin and acetaminophen, were studied under 
      hyperbaric helium-oxygen conditions. Groups of yeast-fevered rats were given 
      three different doses of each antipyretic in 1-ATA air and 31-ATA helium-oxygen. 
      Neither agent was as effective an antipyretic in hyperbaric helium as it was in 
      1-ATA air. Responses to acetaminophen were reduced an average of 73%, and those 
      to the two lower doses of aspirin by 56%; the highest dose of aspirin (135 mg/kg) 
      caused a significant elevation of temperatures in the hyperbaric environment. A 
      similar increase in temperatures was observed in rats treated with 135 mg/kg of 
      aspirin and exposed to hot (30--31 degrees C) air at 1 ATA. It is concluded that 
      the decreased efficacy of antipyretics in hyperbaric helium environments is 
      caused by the high ambient temperatures maintained in helium (34--35 degrees C) 
      to compensate for the greater thermal conductivity of helium compared to 
      nitrogen, which may limit the heat-dissipating abilities of rats in the 
      hyperbaric environment.
FAU - Hart, J L
AU  - Hart JL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Undersea Biomed Res
JT  - Undersea biomedical research
JID - 0421514
RN  - 206GF3GB41 (Helium)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Atmospheric Pressure
MH  - Fever/drug therapy
MH  - Helium/*pharmacology
MH  - Hyperbaric Oxygenation
MH  - Oxygen/*pharmacology
MH  - Rats
OID - NASA: 78139728
EDAT- 1978/03/01 00:00
MHDA- 1978/03/01 00:01
CRDT- 1978/03/01 00:00
PHST- 1978/03/01 00:00 [pubmed]
PHST- 1978/03/01 00:01 [medline]
PHST- 1978/03/01 00:00 [entrez]
PST - ppublish
SO  - Undersea Biomed Res. 1978 Mar;5(1):53-62.

PMID- 21703023
OWN - NLM
STAT- MEDLINE
DCOM- 20130423
LR  - 20211020
IS  - 1748-5908 (Electronic)
IS  - 1748-5908 (Linking)
VI  - 6
DP  - 2011 Jun 26
TI  - Reconsidering low-dose aspirin therapy for cardiovascular disease: a study 
      protocol for physician and patient behavioral change.
PG  - 65
LID - 10.1186/1748-5908-6-65 [doi]
AB  - BACKGROUND: There are often disparities between current evidence and current 
      practice. Decreasing the gap between desired practice outcomes and observed 
      practice outcomes in the healthcare system is not always easy. Stopping 
      previously recommended or variably recommended interventions may be even harder 
      to achieve than increasing the use of a desired but under-performed activity. For 
      over a decade, aspirin has been prescribed for primary prevention of 
      cardiovascular disease and for patients with the coronary artery disease risk 
      equivalents; yet, there is no substantial evidence of an appropriate risk-benefit 
      ratio to support this practice. This paper describes the protocol of a randomized 
      trial being conducted in six primary care practices in the Denver metropolitan 
      area to examine the effectiveness of three interventional strategies to change 
      physician behavior regarding prescription of low-dose aspirin. METHODS: All 
      practices received academic detailing, one arm received clinician reminders to 
      reconsider aspirin, a second arm received both clinician and patient messages to 
      reconsider aspirin. The intervention will run for 15 to 18 months. Data collected 
      at baseline and for outcomes from an electronic health record will be used to 
      assess pre- and post-interventional prescribing, as well as to explore any 
      inappropriate decrease in aspirin use by patients with known cardiovascular 
      disease. DISCUSSION: This study was designed to investigate effective methods of 
      changing physician behavior to decrease the use of aspirin for primary 
      cardiovascular disease prevention. The results of this study will contribute to 
      the small pool of knowledge currently available on the topic of ceasing 
      previously supported practices. TRIAL REGISTRATION: ClinicalTrials.gov: 
      NCT01247454.
FAU - Folks, Brittany
AU  - Folks B
AD  - University of Colorado Denver, Department of Family Medicine, 12681 East 17th 
      Ave, Bldg. A01, Mail Stop 496, Aurora, CO 80045-0508, USA.
FAU - Leblanc, William G
AU  - Leblanc WG
FAU - Staton, Elizabeth W
AU  - Staton EW
FAU - Pace, Wilson D
AU  - Pace WD
LA  - eng
SI  - ClinicalTrials.gov/NCT01247454
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20110626
PL  - England
TA  - Implement Sci
JT  - Implementation science : IS
JID - 101258411
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Protocols
MH  - Colorado
MH  - Coronary Artery Disease/prevention & control
MH  - Decision Support Techniques
MH  - Education, Medical, Continuing/methods
MH  - Humans
MH  - Practice Patterns, Physicians'
PMC - PMC3141566
EDAT- 2011/06/28 06:00
MHDA- 2011/06/28 06:01
CRDT- 2011/06/28 06:00
PHST- 2010/11/23 00:00 [received]
PHST- 2011/06/26 00:00 [accepted]
PHST- 2011/06/28 06:00 [entrez]
PHST- 2011/06/28 06:00 [pubmed]
PHST- 2011/06/28 06:01 [medline]
AID - 1748-5908-6-65 [pii]
AID - 10.1186/1748-5908-6-65 [doi]
PST - epublish
SO  - Implement Sci. 2011 Jun 26;6:65. doi: 10.1186/1748-5908-6-65.

PMID- 30300709
OWN - NLM
STAT- MEDLINE
DCOM- 20190207
LR  - 20190215
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 552
IP  - 1-2
DP  - 2018 Dec 1
TI  - Analysis of pin milling of pharmaceutical materials.
PG  - 394-400
LID - S0378-5173(18)30726-9 [pii]
LID - 10.1016/j.ijpharm.2018.09.068 [doi]
AB  - Milling is an important process for tailoring the particle size distribution for 
      enhanced dissolution, content uniformity, tableting, etc., specially for active 
      pharmaceutical ingredients and excipient in pharmaceutical industries. Milling 
      performance of particulate solids depends on the equipment operating conditions 
      (geometry, process conditions and input energy etc.) as well as material 
      properties (particle size, shape, and mechanical properties, such as Young's 
      modulus, hardness and fracture toughness). In this work, a newly developed 
      approach to assess the breakability of pharmaceutical materials using an 
      aerodynamic dispersion method has been combined with the Discrete Element Method 
      (DEM) to simulate the dynamic behaviour of a number of pharmaceutical materials 
      in a pin mill. A sensitivity analysis is carried out addressing the effect of the 
      milling conditions (rotational speed of the mill and feed particle flow rate) and 
      feed properties on the milled products in terms of the shift in the specific 
      surface area of the milled particles. The outcome of the work is used as a method 
      to predict the breakage of the particles for the milling conditions where 
      chipping takes place.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Bonakdar, Tina
AU  - Bonakdar T
AD  - School of Chemical and Process Engineering, University of Leeds, Leeds LS2 9JT, 
      UK.
FAU - Ghadiri, Mojtaba
AU  - Ghadiri M
AD  - School of Chemical and Process Engineering, University of Leeds, Leeds LS2 9JT, 
      UK. Electronic address: M.Ghadiri@leeds.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20181006
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 362O9ITL9D (Acetaminophen)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/chemistry
MH  - Aspirin/chemistry
MH  - Lactose/chemistry
MH  - Particle Size
MH  - Surface Properties
MH  - Technology, Pharmaceutical/instrumentation/*methods
OTO - NOTNLM
OT  - Breakage
OT  - Impact
OT  - Milling
OT  - Picoline
OT  - Pin mill
EDAT- 2018/10/10 06:00
MHDA- 2019/02/08 06:00
CRDT- 2018/10/10 06:00
PHST- 2018/05/09 00:00 [received]
PHST- 2018/09/04 00:00 [revised]
PHST- 2018/09/27 00:00 [accepted]
PHST- 2018/10/10 06:00 [pubmed]
PHST- 2019/02/08 06:00 [medline]
PHST- 2018/10/10 06:00 [entrez]
AID - S0378-5173(18)30726-9 [pii]
AID - 10.1016/j.ijpharm.2018.09.068 [doi]
PST - ppublish
SO  - Int J Pharm. 2018 Dec 1;552(1-2):394-400. doi: 10.1016/j.ijpharm.2018.09.068. 
      Epub 2018 Oct 6.

PMID- 19765545
OWN - NLM
STAT- MEDLINE
DCOM- 20100119
LR  - 20151119
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
VI  - 79
IP  - 4
DP  - 2010 Feb 15
TI  - From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it 
      time to forget the humble aspirin and move ahead?
PG  - 525-34
LID - 10.1016/j.bcp.2009.09.015 [doi]
AB  - The study of the inflammatory response has seen a tremendous expansion over the 
      last 30 years. Advancements in technology and better knowledge of the 
      ethiopathogenesis of several inflammatory conditions have facilitated this 
      process allowing researchers to almost reach the core of problem. Thus, we now 
      know that inflammation can be manifested in many different ways depending on the 
      context that has elicited it. Viral and infectious, allergic and autoimmune, 
      carcinogenic and resolutive are just a few examples of how inflammation can 
      disguise itself. However, and most intriguingly, it appears that the more we try 
      to discover "an ideal target" and delineate borders for a specific class of 
      inflammatory conditions the more we find similarities, overlaps or often links 
      that we did not predict. These somehow disappointing findings have pushed 
      researchers towards a frantic search for new and more "reliable" targets. As 
      result, we have recently seen a surge of many novel mediators of inflammation. If 
      we just limit our focus to inflammatory cytokines, the main topic of this 
      commentary, the list seems never-ending: IL-15, IL-17, IL-18, IL-21, IL-22, 
      IL-23, IL-27 and IL-33. Are these cytokines destined to supersede prostaglandins 
      and other autacoids for their key role in inflammation? Are we going to see a 
      cheap and effective alternative to aspirin on the supermarket shelves in the next 
      few years? Here we summarize the most recent findings on the biological effects 
      of these new inflammatory cytokines and discuss how these discoveries might 
      influence our current view on therapeutic approaches to treat inflammation.
FAU - D'Acquisto, Fulvio
AU  - D'Acquisto F
AD  - The William Harvey Research Institute, Queen Mary University of London, Barts and 
      The London Medical School, Charterhouse Square, London EC1 M 6BQ, UK. 
      F.Dacquisto@qmul.ac.uk
FAU - Maione, Francesco
AU  - Maione F
FAU - Pederzoli-Ribeil, Magali
AU  - Pederzoli-Ribeil M
LA  - eng
GR  - PG/06/153/22042/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (IL33 protein, human)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-15)
RN  - 0 (Interleukin-33)
RN  - 0 (Interleukins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Drug Delivery Systems/methods/*trends
MH  - Humans
MH  - Inflammation/immunology/microbiology/pathology/virology
MH  - Inflammation Mediators/physiology/*therapeutic use
MH  - Interleukin-15/*physiology
MH  - Interleukin-33
MH  - Interleukins/*physiology
RF  - 130
EDAT- 2009/09/22 06:00
MHDA- 2010/01/20 06:00
CRDT- 2009/09/22 06:00
PHST- 2009/07/30 00:00 [received]
PHST- 2009/09/09 00:00 [revised]
PHST- 2009/09/10 00:00 [accepted]
PHST- 2009/09/22 06:00 [entrez]
PHST- 2009/09/22 06:00 [pubmed]
PHST- 2010/01/20 06:00 [medline]
AID - S0006-2952(09)00769-2 [pii]
AID - 10.1016/j.bcp.2009.09.015 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2010 Feb 15;79(4):525-34. doi: 10.1016/j.bcp.2009.09.015.

PMID- 12532202
OWN - NLM
STAT- MEDLINE
DCOM- 20030211
LR  - 20151119
IS  - 1221-4167 (Print)
IS  - 1221-4167 (Linking)
VI  - 11
IP  - 4
DP  - 2002 Dec
TI  - Salycylate--induced pancreatic injury in the cat: a preliminary study.
PG  - 309-12
AB  - The effect of intravenous aspirin on the exocrine pancreatic secretion was 
      investigated in a feline isolated pancreaticoduodenal preparation. The study 
      group received a 500 mg/kg bolus dose of aspirin intravenously. Duodenal washouts 
      were collected for six hours. The serum and perfusate aspirin content increased 
      significantly after aspirin administration (p = 0.01). However, the pH, 
      bicarbonate, sodium, potassium and calcium content in the duodenal outflow did 
      not show significant changes between 0 and 6 hours. A significant difference in 
      the perfusate calcium content was present between ASA treated and control cats 
      starting at the end of the first hour of the experiment (p=0.005). 
      Histopathological examination of the pancreas revealed marked erythrocyte 
      extravasation in the ASA treated animals. It is suggested that the ASA- related 
      increase in the calcium secretion of the pancreas should be regarded as an 
      indication of aspirin induced pancreatic damage.
FAU - Mentes, Ali
AU  - Mentes A
AD  - Department of Surgery, Aegean University Faculty of Medicine, Bornova, 35100 
      Yzmir, Turkey.
FAU - Batur, Y
AU  - Batur Y
FAU - Bayol, U
AU  - Bayol U
LA  - eng
PT  - Journal Article
PL  - Romania
TA  - Rom J Gastroenterol
JT  - Romanian journal of gastroenterology
JID - 9315667
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Biomarkers
MH  - Calcium/metabolism
MH  - Cats
MH  - Disease Models, Animal
MH  - Pancreatitis/*chemically induced/pathology/veterinary
EDAT- 2003/01/18 04:00
MHDA- 2003/02/13 04:00
CRDT- 2003/01/18 04:00
PHST- 2003/01/18 04:00 [pubmed]
PHST- 2003/02/13 04:00 [medline]
PHST- 2003/01/18 04:00 [entrez]
PST - ppublish
SO  - Rom J Gastroenterol. 2002 Dec;11(4):309-12.

PMID- 11793637
OWN - NLM
STAT- MEDLINE
DCOM- 20020611
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 35
IP  - 12
DP  - 2001 Dec
TI  - Combined aspirin/ACE inhibitor treatment for CHF.
PG  - 1653-8
AB  - OBJECTIVE: To review the literature evaluating the interaction between 
      angiotensin-converting enzyme (ACE) inhibitors and aspirin in patients with 
      congestive heart failure (CHF). DATA SOURCES: A literature search through MEDLINE 
      (1966-March 2001) and EMBASE (1966-March 2001) identified randomized, 
      double-blind, controlled trials evaluating the use of ACE inhibitors and aspirin 
      in patients with CHF. DATA SYNTHESIS: No prospective study has evaluated the 
      effects of aspirin and ACE inhibitors on clinical outcomes of patients with CHF. 
      All have been short-term studies evaluating the effects on hemodynamic parameters 
      only. CONCLUSIONS: While the potential for an interaction between ACE inhibitors 
      and aspirin exists, the results from ongoing prospective trials will help 
      determine the efficacy of using both agents in patients with CHF.
FAU - Olson, K L
AU  - Olson KL
AD  - University of Alberta, Edmonton, Alberta, Canada. karl.olson@kp.org
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Interactions
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
RF  - 20
EDAT- 2002/01/17 10:00
MHDA- 2002/06/12 10:01
CRDT- 2002/01/17 10:00
PHST- 2002/01/17 10:00 [pubmed]
PHST- 2002/06/12 10:01 [medline]
PHST- 2002/01/17 10:00 [entrez]
AID - 10.1345/aph.19296 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2001 Dec;35(12):1653-8. doi: 10.1345/aph.19296.

PMID- 11209540
OWN - NLM
STAT- MEDLINE
DCOM- 20010503
LR  - 20190515
IS  - 1058-0468 (Print)
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 17
IP  - 10
DP  - 2000 Nov
TI  - Low-dose aspirin does not increase implantation rates in patients undergoing 
      intracytoplasmic sperm injection: a prospective randomized study.
PG  - 586-90
AB  - PURPOSE: The aim was to evaluate the effect of aspirin on pregnancy and 
      implantation rates in an unselected group of patients undergoing intracytoplasmic 
      sperm injection (ICSI). METHODS: Two hundred and seventy-nine patients were 
      randomized to receive 80 mg of aspirin (n = 139) or no treatment (r = 136) 
      starting from the first day of controlled ovarian hyperstimulation. RESULTS: 
      Duration of stimulation, gonadotropin consumption, peak estradiol, number of 
      oocytes retrieved, fertilization rate, cleavage rate, and number of embryos 
      transferred were similar in the two groups. Implantation and clinical pregnancy 
      rates were 15.6% and 39.6% versus 15.1% and 43.4% in aspirin treated and 
      untreated groups, respectively (P > 0.05). CONCLUSIONS: Low-dose aspirin 
      administration does not improve implantation and pregnancy rates in an unselected 
      group of patients undergoing ICSI.
FAU - Urman, B
AU  - Urman B
AD  - Assisted Reproduction Unit, VKV American Hospital of Istanbul, Guzelbahce Sok No. 
      2, Nisantasi 80200, Istanbul, Turkey.
FAU - Mercan, R
AU  - Mercan R
FAU - Alatas, C
AU  - Alatas C
FAU - Balaban, B
AU  - Balaban B
FAU - Isiklar, A
AU  - Isiklar A
FAU - Nuhoglu, A
AU  - Nuhoglu A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aspirin/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Embryo Implantation/*drug effects
MH  - Female
MH  - Humans
MH  - Infertility, Male
MH  - Male
MH  - Pregnancy
MH  - *Pregnancy Outcome
MH  - Prospective Studies
MH  - *Sperm Injections, Intracytoplasmic
PMC - PMC3455451
EDAT- 2001/02/24 12:00
MHDA- 2001/05/05 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/05/05 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
AID - 227873 [pii]
AID - 10.1023/a:1026491426423 [doi]
PST - ppublish
SO  - J Assist Reprod Genet. 2000 Nov;17(10):586-90. doi: 10.1023/a:1026491426423.

PMID- 21506629
OWN - NLM
STAT- MEDLINE
DCOM- 20120105
LR  - 20131121
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 46
IP  - 7-8
DP  - 2011 Jul
TI  - Colonic mucosal lesions associated with low-dose aspirin: a case control study.
PG  - 810-7
LID - 10.3109/00365521.2011.574733 [doi]
AB  - OBJECTIVE: Low-dose aspirin (LDA) is widely used because it reduces the risk of 
      vascular events in patients with atherosclerosis. Recently, there has been a 
      substantial increase in prescriptions for LDA. We analyzed the risk of colonic 
      mucosal lesions associated with the long-term use of LDA. MATERIAL AND METHODS: 
      Among Japanese patients who underwent a colonoscopy between January 2004 and 
      December 2006, 199 colitis cases and 5764 non-colitis controls were identified 
      after excluding 749 patients based on study criteria. The history of LDA use was 
      compared between the cases and controls and the multivariate (age-, sex- and 
      underlying diseases-) adjusted odds ratio (OR) was estimated using a multiple 
      logistic regression model. RESULTS: The adjusted OR for colonic mucosal lesions 
      associated with LDA use versus non-use was 1.45 [95% confidence interval (CI), 
      0.87-2.42; p = 0.152]. In terms of gender differences, the OR for LDA-induced 
      colitis in females was significantly increased at 2.55 (95% CI, 1.31-4.94; p = 
      0.006) but was not significantly increased in males at 0.70 (95% CI, 0.34-1.45; p 
      = 0.334). CONCLUSIONS: In females, LDA increased the risk of colonic mucosal 
      lesions, suggesting that LDA may contribute to the pathogenesis of colonic 
      ulceration or colitis. Therefore, it is essential that prescribing physicians be 
      aware of the risk of LDA-induced colonic lesions.
FAU - Shibuya, Tomoyoshi
AU  - Shibuya T
AD  - Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, 
      Japan. tomoyosi@juntendo.ac.jp
FAU - Ohkusa, Toshifumi
AU  - Ohkusa T
FAU - Yokoyama, Tetsuji
AU  - Yokoyama T
FAU - Matsumoto, Kenshi
AU  - Matsumoto K
FAU - Beppu, Kazuko
AU  - Beppu K
FAU - Sakamoto, Naoto
AU  - Sakamoto N
FAU - Osada, Taro
AU  - Osada T
FAU - Nagahara, Akihito
AU  - Nagahara A
FAU - Otaka, Michiro
AU  - Otaka M
FAU - Ogihara, Tatsuo
AU  - Ogihara T
FAU - Watanabe, Sumio
AU  - Watanabe S
LA  - eng
PT  - Journal Article
DEP - 20110420
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Colitis/*chemically induced/*pathology
MH  - Colonoscopy
MH  - Female
MH  - Humans
MH  - Intestinal Mucosa/*pathology
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Retrospective Studies
MH  - Sex Factors
MH  - Time Factors
MH  - Young Adult
EDAT- 2011/04/22 06:00
MHDA- 2012/01/06 06:00
CRDT- 2011/04/22 06:00
PHST- 2011/04/22 06:00 [entrez]
PHST- 2011/04/22 06:00 [pubmed]
PHST- 2012/01/06 06:00 [medline]
AID - 10.3109/00365521.2011.574733 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2011 Jul;46(7-8):810-7. doi: 10.3109/00365521.2011.574733. 
      Epub 2011 Apr 20.

PMID- 21314637
OWN - NLM
STAT- MEDLINE
DCOM- 20120405
LR  - 20191027
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 9
IP  - 4
DP  - 2011 Jul 1
TI  - Platelet function and antiplatelet therapy in cardiovascular disease: 
      implications of genetic polymorphisms.
PG  - 479-89
AB  - Platelets play a crucial role in thrombosis, inflammation, immunity and 
      atherogenesis. Antiplatelet agents are widely used in patients with acute 
      coronary syndrome and other cardiovascular disorders. Aspirin and clopidogrel are 
      the most commonly prescribed antiplatelet agents, with a relatively safe profile 
      and efficiency in a variety of clinical conditions. Numerous prospective studies 
      have revealed variability of antiplatelet efficacy. The so called "antiplatelet 
      resistance" prompted a search for mechanisms implicated in poor responsiveness to 
      aspirin and clopidogrel therapy. In this regard, genetic polymorphisms in the 
      platelet receptor genes attracted considerable interest. Specific genetic 
      variants in platelet receptors such as the P2Y12, glycoprotein (GP) IIb/IIIa, 
      GPIa/IIa, GPIb/IX/V and the cytochrome P450 (CYP) family of genes are associated 
      with variable response to antiplatelet therapy and cardiovascular events. Genetic 
      polymorphisms and haplotypes that comprehensively capture the genetic information 
      encoded within the platelet receptor genes can, to some extent, predict response 
      to the antiplatelet drug better than any single genotype. Genotyping for multiple 
      receptor variants in patients on antiplatelet therapy, complemented by 
      standardized quantification of platelet function, can provide useful information 
      for future drug design studies and possibly for personalized antiplatelet therapy 
      and prevention of thrombotic events. Additional information is, however, needed 
      to evaluate the cost-effectiveness of complex genetic and platelet function 
      testing.
FAU - Shanker, Jayashree
AU  - Shanker J
AD  - Thrombosis Research Institute, Bommasandra Industrial Area, Anekal Taluk, 
      Bangalore, India. jayashreeshanker@triindia.org.in
FAU - Gasparyan, Armen Yuri
AU  - Gasparyan AY
FAU - Kitas, George D
AU  - Kitas GD
FAU - Kakkar, Vijay V
AU  - Kakkar VV
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/metabolism
MH  - Cardiovascular Diseases/*drug therapy/genetics/physiopathology
MH  - Clopidogrel
MH  - Genetic Variation
MH  - Genotype
MH  - Haplotypes
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Polymorphism, Genetic
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
EDAT- 2011/02/15 06:00
MHDA- 2012/04/06 06:00
CRDT- 2011/02/15 06:00
PHST- 2010/08/23 00:00 [received]
PHST- 2010/09/18 00:00 [revised]
PHST- 2010/09/21 00:00 [accepted]
PHST- 2011/02/15 06:00 [entrez]
PHST- 2011/02/15 06:00 [pubmed]
PHST- 2012/04/06 06:00 [medline]
AID - BSP/CVP/E-Pub/0000138 [pii]
AID - 10.2174/157016111796197224 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2011 Jul 1;9(4):479-89. doi: 10.2174/157016111796197224.

PMID- 6896115
OWN - NLM
STAT- MEDLINE
DCOM- 19820614
LR  - 20190825
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 11
IP  - 6-7
DP  - 1981 Dec
TI  - Leukotrienes C and D induce aspirin-sensitive bronchoconstriction in the 
      guinea-pig.
PG  - 574-6
AB  - Branchoconstriction in the guinea-pig due to leukotrienes C4 and D4 in vivo and 
      in vitro was suppressed by aspirin. Since contracting effects of putative 
      mediators of bronchial asthma should be refractory to inhibition of 
      cyclooxygenase, our results indicate that release of leukotrienes in the 
      guinea-pig does not alone account for anaphylactic bronchoconstriction.
FAU - Vargaftig, B B
AU  - Vargaftig BB
FAU - Lefort, J
AU  - Lefort J
FAU - Murphy, R C
AU  - Murphy RC
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (SRS-A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Airway Resistance/*drug effects
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bronchi/*drug effects
MH  - Guinea Pigs
MH  - In Vitro Techniques
MH  - Muscle Contraction/drug effects
MH  - Muscle, Smooth/drug effects
MH  - SRS-A/*pharmacology
EDAT- 1981/12/01 00:00
MHDA- 1981/12/01 00:01
CRDT- 1981/12/01 00:00
PHST- 1981/12/01 00:00 [pubmed]
PHST- 1981/12/01 00:01 [medline]
PHST- 1981/12/01 00:00 [entrez]
AID - 10.1007/BF01978747 [doi]
PST - ppublish
SO  - Agents Actions. 1981 Dec;11(6-7):574-6. doi: 10.1007/BF01978747.

PMID- 12391014
OWN - NLM
STAT- MEDLINE
DCOM- 20021119
LR  - 20221109
IS  - 0022-1007 (Print)
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Linking)
VI  - 196
IP  - 8
DP  - 2002 Oct 21
TI  - Resolvins: a family of bioactive products of omega-3 fatty acid transformation 
      circuits initiated by aspirin treatment that counter proinflammation signals.
PG  - 1025-37
AB  - Aspirin (ASA) is unique among current therapies because it acetylates 
      cyclooxygenase (COX)-2 enabling the biosynthesis of R-containing precursors of 
      endogenous antiinflammatory mediators. Here, we report that lipidomic analysis of 
      exudates obtained in the resolution phase from mice treated with ASA and 
      docosahexaenoic acid (DHA) (C22:6) produce a novel family of bioactive 
      17R-hydroxy-containing di- and tri-hydroxy-docosanoids termed resolvins. Murine 
      brain treated with aspirin produced endogenous 17R-hydroxydocosahexaenoic acid as 
      did human microglial cells. Human COX-2 converted DHA to 13-hydroxy-DHA that 
      switched with ASA to 17R-HDHA that also proved a major route in hypoxic 
      endothelial cells. Human neutrophils transformed COX-2-ASA-derived 
      17R-hydroxy-DHA into two sets of novel di- and trihydroxy products; one initiated 
      via oxygenation at carbon 7 and the other at carbon 4. These compounds inhibited 
      (IC(50) approximately 50 pM) microglial cell cytokine expression and in vivo 
      dermal inflammation and peritonitis at ng doses, reducing 40-80% leukocytic 
      exudates. These results indicate that exudates, vascular, leukocytes and neural 
      cells treated with aspirin convert DHA to novel 17R-hydroxy series of docosanoids 
      that are potent regulators. These biosynthetic pathways utilize omega-3 DHA and 
      EPA during multicellular events in resolution to produce a family of protective 
      compounds, i.e., resolvins, that enhance proresolution status.
FAU - Serhan, Charles N
AU  - Serhan CN
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital 
      and Harvard Medical School, Boston, MA 02115, USA. cnserhan@zeus.bwh.harvard.edu
FAU - Hong, Song
AU  - Hong S
FAU - Gronert, Karsten
AU  - Gronert K
FAU - Colgan, Sean P
AU  - Colgan SP
FAU - Devchand, Pallavi R
AU  - Devchand PR
FAU - Mirick, Gudrun
AU  - Mirick G
FAU - Moussignac, Rose-Laure
AU  - Moussignac RL
LA  - eng
GR  - GM38765/GM/NIGMS NIH HHS/United States
GR  - R01 GM038765/GM/NIGMS NIH HHS/United States
GR  - P01-DE13499/DE/NIDCR NIH HHS/United States
GR  - P01 DE013499/DE/NIDCR NIH HHS/United States
GR  - K01 DK060583-02/DK/NIDDK NIH HHS/United States
GR  - R37 GM038765/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (Biological Factors)
RN  - 0 (Fatty Acids, Omega-3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Biological Factors/*physiology
MH  - Fatty Acids, Omega-3/*pharmacology
MH  - Humans
MH  - Inflammation/*metabolism
MH  - Mice
MH  - Signal Transduction/*physiology
MH  - Tumor Cells, Cultured
PMC - PMC2194036
EDAT- 2002/10/23 04:00
MHDA- 2002/11/26 04:00
CRDT- 2002/10/23 04:00
PHST- 2002/10/23 04:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/10/23 04:00 [entrez]
AID - 20020760 [pii]
AID - 10.1084/jem.20020760 [doi]
PST - ppublish
SO  - J Exp Med. 2002 Oct 21;196(8):1025-37. doi: 10.1084/jem.20020760.

PMID- 2143235
OWN - NLM
STAT- MEDLINE
DCOM- 19900913
LR  - 20190820
IS  - 0741-5214 (Print)
IS  - 0741-5214 (Linking)
VI  - 12
IP  - 2
DP  - 1990 Aug
TI  - The effect of thromboxane receptor blockade versus thromboxane synthase 
      inhibition on canine arterial graft patency.
PG  - 119-25
AB  - This study compared the effects of a thromboxane synthase inhibitor, thromboxane 
      receptor antagonist, and cyclooxygenase inhibitor in a canine arterial graft 
      patency model. Fifty-six dogs were divided into a control (no treatment) and five 
      treatment groups: thromboxane synthase inhibitor (U63557A; 15 mg/kg/tid); 
      thromboxane receptor antagonist (SQ29548; 0.02 mg/kg/hr); high-dose aspirin (325 
      mg/day; low-dose aspirin (1 mg/kd/day; and aspirin plus dipyridamole (325 mg/day 
      aspirin; 3 mg/kg/day dipyridamole). Drugs were orally administered except for 
      thromboxane receptor antagonist, which was delivered intravenously by minosmotic 
      pumps. After 24 hours of drug treatment, bilateral femoral artery prosthetic 
      grafts (4 mm diameter x 7 cm; 1 polytetrafluoroethylene and 1 Dacron) were 
      implanted. Patency was determined after 1 week. Dogs were classified before 
      operation according to their epinephrine-enhanced arachidonate-stimulated 
      platelet aggregation response. Polytetrafluoroethylene and Dacron graft patency 
      rates were equivalent in all groups. Overall graft patency was significantly 
      improved from 42% (control) to 94% by both high-dose aspirin and thromboxane 
      receptor antagonist (p less than 0.001). Aspirin-dipyridamole also improved 
      patency (83%; p less than 0.01 versus control), whereas thromboxane synthase 
      inhibitor and low-dose aspirin were not effective. Baseline platelet aggregation 
      was not predictive of patency. The drugs that promoted graft patency in this 
      model either suppressed both thromboxane A2 and prostaglandin H2 formation 
      (high-dose aspirin) or blocked their combined platelet receptor (thromboxane 
      receptor antagonist). Thromboxane synthase inhibitor may be ineffective because 
      prostaglandin H2 production is allowed. These data suggest that activation of the 
      platelet thromboxane A2-prostaglandin H2 receptor is an essential event in early 
      arterial graft thrombosis.
FAU - Bech, F R
AU  - Bech FR
AD  - Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Hanover, NH 
      03756.
FAU - Cronenwett, J L
AU  - Cronenwett JL
FAU - McDaniel, M D
AU  - McDaniel MD
FAU - Ogletree, M L
AU  - Ogletree ML
FAU - Freeman, D H Jr
AU  - Freeman DH Jr
LA  - eng
GR  - HL-35102/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - 0 (Benzofurans)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Hydrazines)
RN  - 0 (Receptors, Prostaglandin)
RN  - 0 (Receptors, Thromboxane)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 88SD2J5ZNX (SQ 29548)
RN  - EC 5.3.99.5 (Thromboxane-A Synthase)
RN  - KX4D9BZA6X (furegrelate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - J Vasc Surg 1991 Feb;13(2):230
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Benzofurans/pharmacology/therapeutic use
MH  - Bridged Bicyclo Compounds, Heterocyclic
MH  - Dipyridamole/pharmacology/therapeutic use
MH  - Dogs
MH  - Fatty Acids, Unsaturated
MH  - Graft Occlusion, Vascular/drug therapy/*prevention & control
MH  - Hydrazines/pharmacology/therapeutic use
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Receptors, Prostaglandin/*drug effects
MH  - Receptors, Thromboxane
MH  - Thromboxane A2/antagonists & inhibitors
MH  - Thromboxane-A Synthase/*antagonists & inhibitors
MH  - Vascular Patency/*drug effects
EDAT- 1990/08/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
AID - 0741-5214(90)90099-V [pii]
AID - 10.1067/mva.1990.21703 [doi]
PST - ppublish
SO  - J Vasc Surg. 1990 Aug;12(2):119-25. doi: 10.1067/mva.1990.21703.

PMID- 6146681
OWN - NLM
STAT- MEDLINE
DCOM- 19840831
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 36
IP  - 6
DP  - 1984 Jun
TI  - Pretreatment with aspirin does not influence the pressor response to alpha 
      2-adrenoceptor agonists in conscious rabbits.
PG  - 417-8
AB  - It has proved relatively easy to demonstrate pressor responses mediated via alpha 
      2-adrenoceptors in-vivo and in whole blood perfused vascular beds, but not in 
      in-vitro work. The possibility that platelet alpha 2-adrenoceptor activation, 
      with subsequent release of vasoactive prostanoids, contributes to the pressor 
      response to alpha 2-adrenoceptor agonists was investigated. The pressor response 
      to the alpha 2-adrenoceptor agonist BHT 920 (Alefexole) was compared in rabbits 
      pretreated with distilled water or aspirin (3 X 200 mg kg-1 by gavage). Aspirin 
      pretreatment had no significant effect on responses to BHT 920; thus, prostanoid 
      formation does not appear to be an important mechanism contributing to 
      postsynaptic alpha 2-adrenoceptor activation.
FAU - Hannah, J A
AU  - Hannah JA
FAU - Hamilton, C A
AU  - Hamilton CA
FAU - Reid, J L
AU  - Reid JL
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Adrenergic alpha-Agonists)
RN  - 0 (Azepines)
RN  - 7AM2J46Z1Y (talipexole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic alpha-Agonists/*pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Azepines/pharmacology
MH  - Blood Pressure/*drug effects
MH  - Drug Interactions
MH  - Heart Rate/drug effects
MH  - Male
MH  - Rabbits
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1984.tb04415.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1984 Jun;36(6):417-8. doi: 10.1111/j.2042-7158.1984.tb04415.x.

PMID- 346049
OWN - NLM
STAT- MEDLINE
DCOM- 19780617
LR  - 20190704
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 38
IP  - 3
DP  - 1978 Mar
TI  - Lack of effect of prednisone administration on bleeding time and platelet 
      function of normal subjects.
PG  - 373-80
AB  - The effect of 80 mg prednisone given orally for 2 d on normal and post-aspirin 
      bleeding times and platelet function has been studied in a randomized, multiple 
      cross-over, double-blind controlled trial in 12 normal volunteers. Mean template 
      bleeding times were 6.6 min (placebo/placebo), 5.9 min (prednisone/placebo), 10.0 
      min (placebo/aspirin) and 8.7 min (prednisone/aspirin). The shortening after 
      prednisone administration was not statistically significant. Prednisone had no 
      effect on platelet glass bead retention nor on platelet aggregation by collagen, 
      adrenalin and adenosine diphosphate. Thus conventional clinical doses of 
      prednisone did not impair platelet function and did not enhance primary 
      haemostatis in normal subjects as measured by the bleeding time.
FAU - Thong, K L
AU  - Thong KL
FAU - Mant, M J
AU  - Mant MJ
FAU - Grace, M G
AU  - Grace MG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Prednisone/*pharmacology
MH  - Time Factors
EDAT- 1978/03/01 00:00
MHDA- 1978/03/01 00:01
CRDT- 1978/03/01 00:00
PHST- 1978/03/01 00:00 [pubmed]
PHST- 1978/03/01 00:01 [medline]
PHST- 1978/03/01 00:00 [entrez]
AID - 10.1111/j.1365-2141.1978.tb01057.x [doi]
PST - ppublish
SO  - Br J Haematol. 1978 Mar;38(3):373-80. doi: 10.1111/j.1365-2141.1978.tb01057.x.

PMID- 22122360
OWN - NLM
STAT- MEDLINE
DCOM- 20121010
LR  - 20211021
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 166
IP  - 3
DP  - 2012 Jun
TI  - Differential inhibition of tumour cell-induced platelet aggregation by the 
      nicotinate aspirin prodrug (ST0702) and aspirin.
PG  - 938-49
LID - 10.1111/j.1476-5381.2011.01794.x [doi]
AB  - BACKGROUND AND PURPOSE: Tumour cell-induced platelet aggregation (TCIPA) 
      facilitates cancer cell invasion, angiogenesis and the formation of metastatic 
      foci. TCIPA can be modulated by pharmacological inhibitors of MMP-2 and ADP; 
      however, the COX inhibitor aspirin did not prevent TCIPA. In this study, we have 
      tested the pharmacological effects of a new group of isosorbide-based aspirin 
      prodrugs on TCIPA. EXPERIMENTAL APPROACH: TCIPA was induced in human platelets by 
      mixing with human adenocarcinoma or fibrosarcoma cells under no flow and flow 
      conditions. The release of gelatinases and P-selectin expression during TCIPA 
      were studied by zymography and flow cytometry respectively. KEY RESULTS: Tumour 
      cells caused platelet aggregation. This aggregation resulted in the release of 
      MMP-2 and a significant up-regulation of P-selectin on platelets, indicative of 
      platelet activation. Pharmacological modulation of TCIPA revealed that ST0702, 
      one of the aspirin prodrugs, down-regulated TCIPA while aspirin was ineffective. 
      The deacetylated metabolite of ST0702, 5-nicotinate salicylate (ST0702 
      salicylate), down-regulated both ADP-stimulated platelet aggregation and TCIPA. 
      CONCLUSIONS AND IMPLICATIONS: Our results show that ST0702 was an effective 
      inhibitor of TCIPA in vitro. Its deacetylated metabolite may contribute to the 
      effects of ST0702 by inhibiting ADP-mediated TCIPA.
CI  - © 2011 The Authors. British Journal of Pharmacology © 2011 The British 
      Pharmacological Society.
FAU - Medina, Carlos
AU  - Medina C
AD  - School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, 
      Ireland. carlos.medina@tcd.ie
FAU - Harmon, Shona
AU  - Harmon S
FAU - Inkielewicz, Iwona
AU  - Inkielewicz I
FAU - Santos-Martinez, Maria Jose
AU  - Santos-Martinez MJ
FAU - Jones, Michael
AU  - Jones M
FAU - Cantwell, Paula
AU  - Cantwell P
FAU - Bazou, Despina
AU  - Bazou D
FAU - Ledwidge, Mark
AU  - Ledwidge M
FAU - Radomski, Marek W
AU  - Radomski MW
FAU - Gilmer, John F
AU  - Gilmer JF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Prodrugs)
RN  - 0 (isosorbide-5-nicotinate-2-aspirinate)
RN  - 2679MF687A (Niacin)
RN  - 9U1VM840SP (Physostigmine)
RN  - R16CO5Y76E (Aspirin)
RN  - WXR179L51S (Isosorbide)
SB  - IM
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Platelets/cytology/*drug effects
MH  - Cell Communication/*drug effects
MH  - Cell Line, Tumor
MH  - Chromatography, High Pressure Liquid
MH  - Drug Stability
MH  - Flow Cytometry
MH  - Humans
MH  - Isosorbide/*analogs & derivatives/pharmacology
MH  - Microscopy, Phase-Contrast
MH  - Niacin/*analogs & derivatives/pharmacology
MH  - Physostigmine/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Prodrugs/*pharmacology
PMC - PMC3417420
EDAT- 2011/11/30 06:00
MHDA- 2012/10/12 06:00
CRDT- 2011/11/30 06:00
PHST- 2011/11/30 06:00 [entrez]
PHST- 2011/11/30 06:00 [pubmed]
PHST- 2012/10/12 06:00 [medline]
AID - 10.1111/j.1476-5381.2011.01794.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 2012 Jun;166(3):938-49. doi: 10.1111/j.1476-5381.2011.01794.x.

PMID- 23786234
OWN - NLM
STAT- MEDLINE
DCOM- 20140213
LR  - 20130718
IS  - 1520-5126 (Electronic)
IS  - 0002-7863 (Linking)
VI  - 135
IP  - 28
DP  - 2013 Jul 17
TI  - A mechanistic hypothesis for the aspirin-induced switch in lipid mediator 
      production by cyclooxygenase-2.
PG  - 10404-10
LID - 10.1021/ja402870k [doi]
AB  - Cyclooxygenase (COX) carries out stereospecific oxygen addition to arachidonic 
      acid to generate prostaglandins, plus smaller amounts of 11- and 
      15-hydroxyeicosatetraenoic acids. For COX-2, the stereochemistry and relative 
      abundance of generated products is influenced by Ser530 acetylation following 
      aspirin treatment. The molecular bases of the high degree of stereospecificity 
      which characterizes COX-2-catalyzed oxygenations are not yet completely 
      understood, nor are the reasons behind the aspirin-induced shift in lipid 
      mediator production. A mechanistic hypothesis is proposed which identifies steric 
      shielding as the main determinant of oxygenation stereospecificity. This 
      hypothesis is supported by a computational model which accurately reproduces 
      experimental oxygenation patterns on both native and aspirin-inhibited COX-2.
FAU - Tosco, Paolo
AU  - Tosco P
AD  - Department of Drug Science and Technology, Via Pietro Giuria 9, 10125 Torino, 
      Italy. paolo.tosco@unito.it
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130705
PL  - United States
TA  - J Am Chem Soc
JT  - Journal of the American Chemical Society
JID - 7503056
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid/chemistry/*metabolism
MH  - Aspirin/chemistry/*pharmacology
MH  - Biocatalysis
MH  - Cyclooxygenase 2/chemistry/*metabolism
MH  - Cyclooxygenase 2 Inhibitors/chemistry/*pharmacology
MH  - Humans
MH  - Mice
MH  - Models, Molecular
MH  - Molecular Structure
MH  - Oxygen/chemistry/metabolism
MH  - Quantum Theory
MH  - Stereoisomerism
MH  - Structure-Activity Relationship
EDAT- 2013/06/22 06:00
MHDA- 2014/02/14 06:00
CRDT- 2013/06/22 06:00
PHST- 2013/06/22 06:00 [entrez]
PHST- 2013/06/22 06:00 [pubmed]
PHST- 2014/02/14 06:00 [medline]
AID - 10.1021/ja402870k [doi]
PST - ppublish
SO  - J Am Chem Soc. 2013 Jul 17;135(28):10404-10. doi: 10.1021/ja402870k. Epub 2013 
      Jul 5.

PMID- 8509232
OWN - NLM
STAT- MEDLINE
DCOM- 19930712
LR  - 20131121
IS  - 0251-1649 (Print)
IS  - 0251-1649 (Linking)
VI  - 13
IP  - 1
DP  - 1993
TI  - Pharmacokinetic and bacteriological study of cefadroxil-salicylate and 
      josamycin-salicylate drug regimens.
PG  - 11-20
AB  - Eye, nose, throat and bronchopulmonary infections are frequently associated with 
      inflammatory symptoms. This often leads the clinician to prescribe a combination 
      of an anti-inflammatory and an antibiotic. Cefadroxil and josamycin are among the 
      antibiotics most frequently used in these infections, and they are often combined 
      with acetylsalicylic acid in various pharmaceutical formulations. The study of 
      possible pharmacokinetic and bacteriological interactions was performed in 
      healthy volunteers who received in a crossover protocol each of the two 
      antibiotics, either alone or combined with acetylsalicylic acid or lysine 
      acetylsalicylate. No marked pharmacokinetic interaction was noted except an 
      increase in the AUC for plasma concentrations of cefadroxil when combined with a 
      salicylate. A greater uniformity of kinetic profiles was seen with cefadroxil 
      than with josamycin. Lastly, with the exception of one strain, the salicylates 
      did not alter the antibacterial activity of cefadroxil.
FAU - Dellamonica, P
AU  - Dellamonica P
AD  - University Hospital, Nice, France.
FAU - Garraffo, R
AU  - Garraffo R
FAU - Etesse-Carsenti, H
AU  - Etesse-Carsenti H
FAU - Bernard, E
AU  - Bernard E
FAU - Mondain, V
AU  - Mondain V
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int J Clin Pharmacol Res
JT  - International journal of clinical pharmacology research
JID - 8110183
RN  - 280111G160 (Cefadroxil)
RN  - HV13HFS217 (Josamycin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacokinetics/*pharmacology
MH  - Bacteria/*drug effects
MH  - Cefadroxil/*pharmacokinetics/*pharmacology
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Josamycin/*pharmacokinetics/*pharmacology
MH  - Male
MH  - Microbial Sensitivity Tests
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Res. 1993;13(1):11-20.

PMID- 1213133
OWN - NLM
STAT- MEDLINE
DCOM- 19760430
LR  - 20131121
IS  - 0014-8318 (Print)
IS  - 0014-8318 (Linking)
VI  - 38
IP  - 4
DP  - 1975 Jul-Aug
TI  - [Influence of sodium salicylate, acetylsalicylate, 2, 3-dihydroxybenzoic and 2, 
      3-diacetoxybenzoic acids on the blood coagulation system and the elimination of 
      heparin].
PG  - 445-9
AB  - Tests conducted on rabbits demonstrated that with a long-term enteral 
      introduction (in amounts of 200 mg/kg, twice a day for 10 days) of 
      2-3-diacetoxybenzoic acid, sodium salicylate and acetylsalicylic acid these 
      compounds depress the coagulation potential of the blood, 2-3-diacetoxybenzoic 
      acid displaying also a hypocoagulation action even with its single administration 
      in a dose of 400 mg/KJI. The said substances raise the level of the endogenous 
      blood heparin and reinforce the anticoagulative action of heparin, 
      2-3-dioxybenzoic acid lowers somewhat the concentration and the anticlotting 
      effect of heparin.
FAU - Ermakova, N V
AU  - Ermakova NV
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Vliianie natriia salitsilata, atsetilsalitsilovoĭ, 2-3-dioksibenzoĭnoĭ i 
      2-3-diatsetoksibenzoĭnoĭ kislot na sistemu svertyvaniia krovi i eliminatsiiu 
      geparina.
PL  - Russia (Federation)
TA  - Farmakol Toksikol
JT  - Farmakologiia i toksikologiia
JID - 16920420R
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Salicylates)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Heparin/*metabolism
MH  - Hydroxybenzoates/administration & dosage/*pharmacology
MH  - Rabbits
MH  - Salicylates/administration & dosage/*pharmacology
EDAT- 1975/07/01 00:00
MHDA- 1975/07/01 00:01
CRDT- 1975/07/01 00:00
PHST- 1975/07/01 00:00 [pubmed]
PHST- 1975/07/01 00:01 [medline]
PHST- 1975/07/01 00:00 [entrez]
PST - ppublish
SO  - Farmakol Toksikol. 1975 Jul-Aug;38(4):445-9.

PMID- 23602681
OWN - NLM
STAT- MEDLINE
DCOM- 20140102
LR  - 20181202
IS  - 1472-6491 (Electronic)
IS  - 1472-6483 (Linking)
VI  - 26
IP  - 6
DP  - 2013 Jun
TI  - Aspirin and heparin to improve live birth rate in IVF for unexplained 
      implantation failure?
PG  - 538-41
LID - S1472-6483(13)00133-8 [pii]
LID - 10.1016/j.rbmo.2013.03.007 [doi]
AB  - The data concerning use of aspirin and/or heparin in IVF failure patients is 
      reviewed. A number of methodological and biological problems are identified. A 
      strategy to achieve reliable conclusions is explained.
CI  - Copyright © 2013 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Clark, David A
AU  - Clark DA
AD  - Department of Medicine, Molecular Medicine and Pathology, Obstetrics and 
      Gynecology, McMaster University, Health Sciences Centre, 1280 Main St. West, 
      Hamilton, Ontario, Canada. clarkd@mcmaster.ca
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20130326
PL  - Netherlands
TA  - Reprod Biomed Online
JT  - Reproductive biomedicine online
JID - 101122473
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Reprod Biomed Online. 2013 Jun;26(6):586-94. PMID: 23518029
MH  - Aspirin/*administration & dosage
MH  - *Birth Rate
MH  - *Embryo Implantation
MH  - Female
MH  - *Fertilization in Vitro
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Male
MH  - Pregnancy
EDAT- 2013/04/23 06:00
MHDA- 2014/01/03 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/03/01 00:00 [received]
PHST- 2013/03/05 00:00 [accepted]
PHST- 2013/04/23 06:00 [entrez]
PHST- 2013/04/23 06:00 [pubmed]
PHST- 2014/01/03 06:00 [medline]
AID - S1472-6483(13)00133-8 [pii]
AID - 10.1016/j.rbmo.2013.03.007 [doi]
PST - ppublish
SO  - Reprod Biomed Online. 2013 Jun;26(6):538-41. doi: 10.1016/j.rbmo.2013.03.007. 
      Epub 2013 Mar 26.

PMID- 35485703
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20220820
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Print)
IS  - 1513-7368 (Linking)
VI  - 23
IP  - 4
DP  - 2022 Apr 1
TI  - Antiangiogenic Activity of Sweet Almond (Prunus dulcis) Oil Alone and in 
      Combination with Aspirin in both in vivo and in vitro Assays.
PG  - 1405-1413
LID - 90090 [pii]
LID - 10.31557/APJCP.2022.23.4.1405 [doi]
AB  - Objective: Angiogenesis is new blood vessels formations that are necessary for 
      certain physiological and pathologic conditions. Almond oil represents adjuvant 
      therapies for numerous health benefits; It has ability for prevent the formation 
      angiogenesis in tumour, due to its high concentration of unsaturated fatty acids, 
      polyphenols, flavonoids and other ingredients content. Aspirin is non-steroidal 
      ant-inflammatory drug; significantly reduce the angiogenesis of cancer. The aim 
      of the study is to investigate the role of Prunus dulcis oil alone and in 
      combination with aspirin, as an anti-angiogenic. Method: A sequential 
      concentrations ex-vivo rat aorta ring assay, investigate the anti-angiogenic 
      activity of Prunus dulcisoil in vivo. After three days of incubation, small holes 
      were created on the fine pinpoint. Acute toxicity study was evaluated after 
      administration of Prunus dulcis oil via intraperitoneal route. Results: the 
      obtained results displayed that the serial concentration dose-response has a 
      significant inhibition effect of blood vessels growth when compared to the 
      negative control (DMSO 1%), the dose depended percentage of inhibition, sweet 
      almond oil in combination with aspirin synergism effect to inhibition growth 
      blood vessels as anti-angiogenic activity. The zone of inhibition was been 
      measured as the mean of inhibition area of blood vessel on eggs in millimetre 
      (mm) ± standard deviation. Conclusion: Almond oil dose has inhibition effect on 
      cancer and can be used as (anti-angiogenesis), the activity of almond oil with 
      Aspirin synergism can significantly reduce blood vessel’s growth in rate aorta 
      ring and CAM assay.
FAU - Ali, Zainab K
AU  - Ali ZK
AD  - Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, 
      Iraq.
FAU - Sahib, Hayder B
AU  - Sahib HB
AD  - Department Pharmacology and Toxicology, College of Pharmacy, AL-Nahrain 
      University, Iraq.
LA  - eng
PT  - Journal Article
DEP - 20220401
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Angiogenesis Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiogenesis Inhibitors/pharmacology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Humans
MH  - Male
MH  - *Prunus dulcis
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Seeds
PMC - PMC9375604
OTO - NOTNLM
OT  - Anti-angiogenesis
OT  - CAM
OT  - aspirin
OT  - rate aorta ring
OT  - sweet almond oil
COIS- The authors declare that they have no competing interests.
EDAT- 2022/04/30 06:00
MHDA- 2022/05/03 06:00
CRDT- 2022/04/29 08:02
PHST- 2022/01/13 00:00 [received]
PHST- 2022/04/29 08:02 [entrez]
PHST- 2022/04/30 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
AID - 90090 [pii]
AID - 10.31557/APJCP.2022.23.4.1405 [doi]
PST - epublish
SO  - Asian Pac J Cancer Prev. 2022 Apr 1;23(4):1405-1413. doi: 
      10.31557/APJCP.2022.23.4.1405.

PMID- 29143196
OWN - NLM
STAT- MEDLINE
DCOM- 20180523
LR  - 20181113
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 63
IP  - 1
DP  - 2018 Jan
TI  - Effect of Low-Dose Aspirin on Chronic Acid Reflux Esophagitis in Rats.
PG  - 72-80
LID - 10.1007/s10620-017-4840-3 [doi]
AB  - BACKGROUND: Clinical role of low-dose aspirin (LDA) in pathogenesis of 
      gastroesophageal reflux disease is by far controversial. This can be attributed 
      to the paucity of basic research detailing the mechanism of LDA-induced 
      esophageal mucosal injury (EI) on underlying chronic acid reflux esophagitis 
      (RE). AIM: The aim of this study was to clarify the effect of LDA on chronic RE 
      in rats. METHODS: Esophagitis was induced in 8-week-old male Wistar rats by 
      ligating the border between forestomach and glandular portion with a 2-0 silk tie 
      and covering the duodenum with a small piece of 18-Fr Nélaton catheter. 
      Seventy-eight chronic RE rat models were divided into five treatment groups, 
      consisting of orally administered vehicle (controls), and aspirin doses of 2, 5, 
      50 or 100 mg/kg once daily for 28 days. EI was assessed by gross area of 
      macroscopic mucosal injury, severity grade of esophagitis and microscopic depth 
      of infiltration by inflammatory cells. RESULTS: Area of esophagitis in animals 
      with aspirin dose of 100 mg/kg/day showed a 36.5% increase compared with 
      controls, although it failed to achieve statistical significance (p = 0.812). 
      Additionally, the rate of severe EI was increased in animals with aspirin dose of 
      100 mg/kg/day as compared with controls (p < 0.05). The grade of severity 
      correlated with the depth of inflammation (r (s) = 0.492, p < 0.001). 
      CONCLUSIONS: Maximal dose aspirin (100 mg/kg/day) contributed in exacerbating 
      preexisting EI. LDA (2 and 5 mg/kg/day), on the other hand, did not affect 
      chronic RE in this model. LDA seems to be safe for use in patients with chronic 
      RE.
FAU - Masuda, Takahiro
AU  - Masuda T
AD  - Department of Surgery, The Jikei University School of Medicine, 3-25-8, 
      Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan. 04-1419-masuda@jikei.ac.jp.
FAU - Yano, Fumiaki
AU  - Yano F
AD  - Department of Surgery, The Jikei University School of Medicine, 3-25-8, 
      Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan.
FAU - Omura, Nobuo
AU  - Omura N
AD  - Department of Surgery, The Jikei University School of Medicine, 3-25-8, 
      Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan.
FAU - Tsuboi, Kazuto
AU  - Tsuboi K
AD  - Department of Surgery, The Jikei University School of Medicine, 3-25-8, 
      Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan.
FAU - Hoshino, Masato
AU  - Hoshino M
AD  - Department of Surgery, The Jikei University School of Medicine, 3-25-8, 
      Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan.
FAU - Yamamoto, Se Ryung
AU  - Yamamoto SR
AD  - Department of Surgery, The Jikei University School of Medicine, 3-25-8, 
      Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan.
FAU - Akimoto, Shunsuke
AU  - Akimoto S
AD  - Department of Surgery, The Jikei University School of Medicine, 3-25-8, 
      Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan.
FAU - Kashiwagi, Hideyuki
AU  - Kashiwagi H
AD  - Department of Surgery, The Jikei University School of Medicine, 3-25-8, 
      Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan.
FAU - Yanaga, Katsuhiko
AU  - Yanaga K
AD  - Department of Surgery, The Jikei University School of Medicine, 3-25-8, 
      Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171115
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Body Weight
MH  - Chronic Disease
MH  - Dose-Response Relationship, Drug
MH  - Esophagitis, Peptic/*pathology/surgery
MH  - Ligation
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Rats
MH  - Rats, Wistar
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Chronic acid reflux
OT  - GERD
OT  - Gastroesophageal reflux
OT  - Low-dose aspirin
OT  - Rat
EDAT- 2017/11/17 06:00
MHDA- 2018/05/24 06:00
CRDT- 2017/11/17 06:00
PHST- 2017/06/11 00:00 [received]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2018/05/24 06:00 [medline]
PHST- 2017/11/17 06:00 [entrez]
AID - 10.1007/s10620-017-4840-3 [pii]
AID - 10.1007/s10620-017-4840-3 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2018 Jan;63(1):72-80. doi: 10.1007/s10620-017-4840-3. Epub 2017 Nov 
      15.

PMID- 31982074
OWN - NLM
STAT- MEDLINE
DCOM- 20200213
LR  - 20210125
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 395
IP  - 10220
DP  - 2020 Jan 25
TI  - Low-dose aspirin for the prevention of preterm delivery in nulliparous women with 
      a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled 
      trial.
PG  - 285-293
LID - S0140-6736(19)32973-3 [pii]
LID - 10.1016/S0140-6736(19)32973-3 [doi]
AB  - BACKGROUND: Preterm birth remains a common cause of neonatal mortality, with a 
      disproportionately high burden in low-income and middle-income countries. 
      Meta-analyses of low-dose aspirin to prevent pre-eclampsia suggest that the 
      incidence of preterm birth might also be decreased, particularly if initiated 
      before 16 weeks of gestation. METHODS: ASPIRIN was a randomised, multicountry, 
      double-masked, placebo-controlled trial of low-dose aspirin (81 mg daily) 
      initiated between 6 weeks and 0 days of pregnancy, and 13 weeks and 6 days of 
      pregnancy, in nulliparous women with an ultrasound confirming gestational age and 
      a singleton viable pregnancy. Participants were enrolled at seven community sites 
      in six countries (two sites in India and one site each in the Democratic Republic 
      of the Congo, Guatemala, Kenya, Pakistan, and Zambia). Participants were randomly 
      assigned (1:1, stratified by site) to receive aspirin or placebo tablets of 
      identical appearance, via a sequence generated centrally by the data coordinating 
      centre at Research Triangle Institute International (Research Triangle Park, NC, 
      USA). Treatment was masked to research staff, health providers, and patients, and 
      continued until 36 weeks and 7 days of gestation or delivery. The primary outcome 
      of incidence of preterm birth, defined as the number of deliveries before 37 
      weeks' gestational age, was analysed in randomly assigned women with pregnancy 
      outcomes at or after 20 weeks, according to a modified intention-to-treat (mITT) 
      protocol. Analyses of our binary primary outcome involved a 
      Cochran-Mantel-Haenszel test stratified by site, and generalised linear models to 
      obtain relative risk (RR) estimates and associated confidence intervals. Serious 
      adverse events were assessed in all women who received at least one dose of drug 
      or placebo. This study is registered with ClinicalTrials.gov, NCT02409680, and 
      the Clinical Trial Registry-India, CTRI/2016/05/006970. FINDINGS: From March 23, 
      2016 to June 30, 2018, 14 361 women were screened for inclusion and 11 976 women 
      aged 14-40 years were randomly assigned to receive low-dose aspirin (5990 women) 
      or placebo (5986 women). 5780 women in the aspirin group and 5764 in the placebo 
      group were evaluable for the primary outcome. Preterm birth before 37 weeks 
      occurred in 668 (11·6%) of the women who took aspirin and 754 (13·1%) of those 
      who took placebo (RR 0·89 [95% CI 0·81 to 0·98], p=0·012). In women taking 
      aspirin, we also observed significant reductions in perinatal mortality (0·86 
      [0·73-1·00], p=0·048), fetal loss (infant death after 16 weeks' gestation and 
      before 7 days post partum; 0·86 [0·74-1·00], p=0·039), early preterm delivery 
      (<34 weeks; 0·75 [0·61-0·93], p=0·039), and the incidence of women who delivered 
      before 34 weeks with hypertensive disorders of pregnancy (0·38 [0·17-0·85], 
      p=0·015). Other adverse maternal and neonatal events were similar between the two 
      groups. INTERPRETATION: In populations of nulliparous women with singleton 
      pregnancies from low-income and middle-income countries, low-dose aspirin 
      initiated between 6 weeks and 0 days of gestation and 13 weeks and 6 days of 
      gestation resulted in a reduced incidence of preterm delivery before 37 weeks, 
      and reduced perinatal mortality. FUNDING: Eunice Kennedy Shriver National 
      Institute of Child Health and Human Development.
CI  - Copyright © 2020 Elsevier Ltd. All rights reserved.
FAU - Hoffman, Matthew K
AU  - Hoffman MK
AD  - Department of Obstetrics and Gynecology, Christiana Care, Newark, DE, USA. 
      Electronic address: mhoffman@christianacare.org.
FAU - Goudar, Shivaprasad S
AU  - Goudar SS
AD  - Jawaharlal Nehru Medical College, KLE University, Belgaum, India.
FAU - Kodkany, Bhalachandra S
AU  - Kodkany BS
AD  - Jawaharlal Nehru Medical College, KLE University, Belgaum, India.
FAU - Metgud, Mrityunjay
AU  - Metgud M
AD  - Jawaharlal Nehru Medical College, KLE University, Belgaum, India.
FAU - Somannavar, Manjunath
AU  - Somannavar M
AD  - Jawaharlal Nehru Medical College, KLE University, Belgaum, India.
FAU - Okitawutshu, Jean
AU  - Okitawutshu J
AD  - Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo.
FAU - Lokangaka, Adrien
AU  - Lokangaka A
AD  - Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo.
FAU - Tshefu, Antoinette
AU  - Tshefu A
AD  - Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo.
FAU - Bose, Carl L
AU  - Bose CL
AD  - University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
FAU - Mwapule, Abigail
AU  - Mwapule A
AD  - University Teaching Hospital, Lusaka, Zambia.
FAU - Mwenechanya, Musaku
AU  - Mwenechanya M
AD  - University Teaching Hospital, Lusaka, Zambia.
FAU - Chomba, Elwyn
AU  - Chomba E
AD  - University Teaching Hospital, Lusaka, Zambia.
FAU - Carlo, Waldemar A
AU  - Carlo WA
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Chicuy, Javier
AU  - Chicuy J
AD  - Instituto de Nutrición de Centro América y Panamá, Guatemala City, Guatemala.
FAU - Figueroa, Lester
AU  - Figueroa L
AD  - Instituto de Nutrición de Centro América y Panamá, Guatemala City, Guatemala.
FAU - Garces, Ana
AU  - Garces A
AD  - Instituto de Nutrición de Centro América y Panamá, Guatemala City, Guatemala.
FAU - Krebs, Nancy F
AU  - Krebs NF
AD  - University of Colorado Denver, Aurora, CO, USA.
FAU - Jessani, Saleem
AU  - Jessani S
AD  - Aga Khan University, Karachi, Pakistan.
FAU - Zehra, Farnaz
AU  - Zehra F
AD  - Aga Khan University, Karachi, Pakistan.
FAU - Saleem, Sarah
AU  - Saleem S
AD  - Aga Khan University, Karachi, Pakistan.
FAU - Goldenberg, Robert L
AU  - Goldenberg RL
AD  - Columbia University, New York, NY, USA.
FAU - Kurhe, Kunal
AU  - Kurhe K
AD  - Lata Medical Research Foundation, Nagpur, India.
FAU - Das, Prabir
AU  - Das P
AD  - Lata Medical Research Foundation, Nagpur, India.
FAU - Patel, Archana
AU  - Patel A
AD  - Lata Medical Research Foundation, Nagpur, India.
FAU - Hibberd, Patricia L
AU  - Hibberd PL
AD  - Boston University School of Public Health, Boston, MA, USA.
FAU - Achieng, Emmah
AU  - Achieng E
AD  - Department of Child Health and Paediatrics, Moi University School of Medicine, 
      Eldoret, Kenya.
FAU - Nyongesa, Paul
AU  - Nyongesa P
AD  - Department of Child Health and Paediatrics, Moi University School of Medicine, 
      Eldoret, Kenya.
FAU - Esamai, Fabian
AU  - Esamai F
AD  - Department of Child Health and Paediatrics, Moi University School of Medicine, 
      Eldoret, Kenya.
FAU - Liechty, Edward A
AU  - Liechty EA
AD  - School of Medicine, Indiana University, Indianapolis, IN, USA.
FAU - Goco, Norman
AU  - Goco N
AD  - RTI International, Research Triangle Park, NC, USA.
FAU - Hemingway-Foday, Jennifer
AU  - Hemingway-Foday J
AD  - RTI International, Research Triangle Park, NC, USA.
FAU - Moore, Janet
AU  - Moore J
AD  - RTI International, Research Triangle Park, NC, USA.
FAU - Nolen, Tracy L
AU  - Nolen TL
AD  - RTI International, Research Triangle Park, NC, USA.
FAU - McClure, Elizabeth M
AU  - McClure EM
AD  - RTI International, Research Triangle Park, NC, USA.
FAU - Koso-Thomas, Marion
AU  - Koso-Thomas M
AD  - Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD, USA.
FAU - Miodovnik, Menachem
AU  - Miodovnik M
AD  - Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD, USA.
FAU - Silver, R
AU  - Silver R
AD  - University of Utah, Salt Lake City, UT, USA.
FAU - Derman, Richard J
AU  - Derman RJ
AD  - Thomas Jefferson University, Philadelphia, PA, USA.
CN  - ASPIRIN Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT02409680
GR  - UG1 HD076461/HD/NICHD NIH HHS/United States
GR  - U24 HD092094/HD/NICHD NIH HHS/United States
GR  - U10 HD078438/HD/NICHD NIH HHS/United States
GR  - UG1 HD078439/HD/NICHD NIH HHS/United States
GR  - U10 HD076461/HD/NICHD NIH HHS/United States
GR  - U10 HD076465/HD/NICHD NIH HHS/United States
GR  - UG1 HD076465/HD/NICHD NIH HHS/United States
GR  - U10 HD078437/HD/NICHD NIH HHS/United States
GR  - UG1 HD078437/HD/NICHD NIH HHS/United States
GR  - UG1 HD078438/HD/NICHD NIH HHS/United States
GR  - UG1 HD076457/HD/NICHD NIH HHS/United States
GR  - U10 HD076457/HD/NICHD NIH HHS/United States
GR  - UG1 HD076474/HD/NICHD NIH HHS/United States
GR  - U10 HD076474/HD/NICHD NIH HHS/United States
GR  - U10 HD078439/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2020 Jan 25;395(10220):250-252. PMID: 31982051
EIN - Lancet. 2020 Mar 21;395(10228):e53. PMID: 32199490
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Pressure
MH  - Delivery, Obstetric/statistics & numerical data
MH  - Developing Countries
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*epidemiology/prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome/epidemiology
MH  - Premature Birth/*epidemiology/prevention & control
MH  - Young Adult
PMC - PMC7168353
MID - NIHMS1554091
COIS- Declaration of Interests: None of the authors have any interests to declare.
FIR - Achieng, Emmah
IR  - Achieng E
FIR - Bauserman, Melissa
IR  - Bauserman M
FIR - Bose, Carl
IR  - Bose C
FIR - Bucher, Sherri
IR  - Bucher S
FIR - Carlo, Waldemar
IR  - Carlo W
FIR - Charantimath, Umesh S
IR  - Charantimath US
FIR - Chicuy, Javier
IR  - Chicuy J
FIR - Chomba, Elwyn
IR  - Chomba E
FIR - Das, Prabir
IR  - Das P
FIR - Derman, Richard
IR  - Derman R
FIR - Esamai, Fabian
IR  - Esamai F
FIR - Figueroa, Lester
IR  - Figueroa L
FIR - Ganachari, M S
IR  - Ganachari MS
FIR - Garces, Ana
IR  - Garces A
FIR - Goco, Noman
IR  - Goco N
FIR - Goldenberg, Robert
IR  - Goldenberg R
FIR - Goudar, Shivaprasad
IR  - Goudar S
FIR - Hemingway-Foday, Jennifer
IR  - Hemingway-Foday J
FIR - Hibberd, Patricia
IR  - Hibberd P
FIR - Hoffman, Matthew
IR  - Hoffman M
FIR - Honnungar, Narayan V
IR  - Honnungar NV
FIR - Jessani, Saleem
IR  - Jessani S
FIR - Kavi, Avinash
IR  - Kavi A
FIR - Kodkany, Bhalachandra
IR  - Kodkany B
FIR - Koso-Thomas, Marion
IR  - Koso-Thomas M
FIR - Krebs, Nancy
IR  - Krebs N
FIR - Kumar Shashikanth, Yogesh
IR  - Kumar Shashikanth Y
FIR - Kurhe, Kunal
IR  - Kurhe K
FIR - Liechty, Edward
IR  - Liechty E
FIR - Lokangaka, Adrien
IR  - Lokangaka A
FIR - MacGuire, Emily
IR  - MacGuire E
FIR - Mallapur, Ashalata A
IR  - Mallapur AA
FIR - McClure, Elizabeth
IR  - McClure E
FIR - Metgud, Mrityunjay
IR  - Metgud M
FIR - Miodovnik, Menachem
IR  - Miodovnik M
FIR - Moore, Janet
IR  - Moore J
FIR - Mwapule, Abigail
IR  - Mwapule A
FIR - Mwenechanya, Musaku
IR  - Mwenechanya M
FIR - Naqvi, Farnaz
IR  - Naqvi F
FIR - Naqvi, Seemab
IR  - Naqvi S
FIR - Nathan, Robert
IR  - Nathan R
FIR - Nolen, Tracy
IR  - Nolen T
FIR - Nyongesa, Paul
IR  - Nyongesa P
FIR - Okitawutshu, Jean
IR  - Okitawutshu J
FIR - Parepalli, Suchita
IR  - Parepalli S
FIR - Patel, Archana
IR  - Patel A
FIR - Ramadurg, Umesh Y
IR  - Ramadurg UY
FIR - Saleem, Sarah
IR  - Saleem S
FIR - Silver, Robert
IR  - Silver R
FIR - Somannavar, Manjunath
IR  - Somannavar M
FIR - Soomro, Zahid
IR  - Soomro Z
FIR - Tshefu, Antoinette
IR  - Tshefu A
FIR - Vernekar, Sunil S
IR  - Vernekar SS
FIR - Wallace, Dennis
IR  - Wallace D
FIR - Zehra, Farnaz
IR  - Zehra F
EDAT- 2020/01/27 06:00
MHDA- 2020/02/14 06:00
CRDT- 2020/01/27 06:00
PHST- 2019/10/11 00:00 [received]
PHST- 2019/11/12 00:00 [revised]
PHST- 2019/11/14 00:00 [accepted]
PHST- 2020/01/27 06:00 [entrez]
PHST- 2020/01/27 06:00 [pubmed]
PHST- 2020/02/14 06:00 [medline]
AID - S0140-6736(19)32973-3 [pii]
AID - 10.1016/S0140-6736(19)32973-3 [doi]
PST - ppublish
SO  - Lancet. 2020 Jan 25;395(10220):285-293. doi: 10.1016/S0140-6736(19)32973-3.

PMID- 31936819
OWN - NLM
STAT- MEDLINE
DCOM- 20210312
LR  - 20210312
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jan 10
TI  - Exploring the Potential of Nitric Oxide and Hydrogen Sulfide (NOSH)-Releasing 
      Synthetic Compounds as Novel Priming Agents against Drought Stress in Medicago 
      sativa Plants.
LID - 10.3390/biom10010120 [doi]
LID - 120
AB  - Land plants are continuously exposed to multiple abiotic stress factors like 
      drought, heat, and salinity. Nitric oxide (NO) and hydrogen sulfide (H(2)S) are 
      two well-examined signaling molecules that act as priming agents, regulating the 
      response of plants to stressful conditions. Several chemical donors exist that 
      provide plants with NO and H(2)S separately. NOSH is a remarkable novel donor as 
      it can donate NO and H(2)S simultaneously to plants, while NOSH-aspirin 
      additionally provides the pharmaceutical molecule acetylsalicylic acid. The 
      current study aimed to investigate the potential synergistic effect of these 
      molecules in drought-stressed Medicago sativa L. plants by following a 
      pharmacological approach. Plants were initially pre-treated with both donors 
      (NOSH and NOSH-aspirin) via foliar spraying, and were then subsequently exposed 
      to a moderate water deficit while NO and H(2)S inhibitors (cPTIO and HA, 
      respectively) were also employed. Phenotypic and physiological data showed that 
      pre-treatment with NOSH synthetic compounds induced acclimation to subsequent 
      drought stress and improved the recovery following rewatering. This was 
      accompanied by modified reactive-oxygen and nitrogen-species signaling and 
      metabolism, as well as attenuation of cellular damage, as evidenced by altered 
      lipid peroxidation and proline accumulation levels. Furthermore, real-time 
      RT-qPCR analysis revealed the differential regulation of multiple defense-related 
      transcripts, including antioxidant enzymes. Overall, the present study proposed a 
      novel role for NOSH compounds as efficient plant priming agents against 
      environmental constraints through the coordinated regulation of multiple defense 
      components, thus opening new horizons in the field of chemical priming research 
      toward the use of target-selected compounds for stress tolerance enhancement.
FAU - Antoniou, Chrystalla
AU  - Antoniou C
AD  - Department of Agricultural Sciences, Biotechnology and Food Science, Cyprus 
      University of Technology, 3603 Lemesos, Cyprus.
FAU - Xenofontos, Rafaella
AU  - Xenofontos R
AD  - Department of Agricultural Sciences, Biotechnology and Food Science, Cyprus 
      University of Technology, 3603 Lemesos, Cyprus.
FAU - Chatzimichail, Giannis
AU  - Chatzimichail G
AD  - Department of Agricultural Sciences, Biotechnology and Food Science, Cyprus 
      University of Technology, 3603 Lemesos, Cyprus.
FAU - Christou, Anastasis
AU  - Christou A
AD  - Agricultural Research Institute, Ministry of Agriculture, Rural Development and 
      Natural Recourses, P.O. Box 22016, 1516 Nicosia, Cyprus.
FAU - Kashfi, Khosrow
AU  - Kashfi K
AD  - Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of 
      Biomedical Education, City University of New York School of Medicine, New York, 
      NY 10031, USA.
AD  - Graduate Program in Biology, City University of New York Graduate Center, New 
      York, NY 10016, USA.
FAU - Fotopoulos, Vasileios
AU  - Fotopoulos V
AD  - Department of Agricultural Sciences, Biotechnology and Food Science, Cyprus 
      University of Technology, 3603 Lemesos, Cyprus.
LA  - eng
GR  - EX032/Cyprus University of Technology/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200110
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
RN  - 0 (4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate)
RN  - 0 (Agrochemicals)
RN  - 0 (Disulfides)
RN  - 0 (Nitrates)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Acclimatization/drug effects
MH  - Agrochemicals/*metabolism
MH  - Aspirin/*analogs & derivatives/metabolism
MH  - Disulfides/*metabolism
MH  - Droughts
MH  - Hydrogen Sulfide/*metabolism
MH  - Medicago sativa/*drug effects/physiology
MH  - Nitrates/*metabolism
MH  - Nitric Oxide/*metabolism
MH  - Stress, Physiological/drug effects
PMC - PMC7023404
OTO - NOTNLM
OT  - alfalfa
OT  - antioxidants
OT  - aspirin
OT  - drought
OT  - hydrogen sulfide
OT  - nitric oxide
OT  - priming
OT  - proline
COIS- The authors declare no known competing financial interest or personal 
      relationships that could potentially influence the work reported in this paper.
EDAT- 2020/01/16 06:00
MHDA- 2021/03/13 06:00
CRDT- 2020/01/16 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2019/12/29 00:00 [revised]
PHST- 2020/01/02 00:00 [accepted]
PHST- 2020/01/16 06:00 [entrez]
PHST- 2020/01/16 06:00 [pubmed]
PHST- 2021/03/13 06:00 [medline]
AID - biom10010120 [pii]
AID - biomolecules-10-00120 [pii]
AID - 10.3390/biom10010120 [doi]
PST - epublish
SO  - Biomolecules. 2020 Jan 10;10(1):120. doi: 10.3390/biom10010120.

PMID- 30669908
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20211113
IS  - 1476-4954 (Electronic)
IS  - 1476-7058 (Print)
IS  - 1476-4954 (Linking)
VI  - 33
IP  - 17
DP  - 2020 Sep
TI  - Obstetricians' knowledge and practices regarding the management of preeclampsia.
PG  - 2970-2975
LID - 10.1080/14767058.2019.1566311 [doi]
AB  - Background: Preeclampsia affects over 4% of pregnancies in the United States. 
      Management of preeclampsia is dependent on the severity of the condition and can 
      range from expectant management to early delivery and inpatient observation. 
      After publication of the hypertension in Pregnancy Task Force guidelines in 2013, 
      little is known about their implementation and acceptance by practicing 
      obstetricians and maternal-fetal medicine (MFM) specialists.Objective: To 
      evaluate Obstetricians' knowledge and practices regarding the management of 
      preeclampsia.Methods: A prospective survey was administered to ob-gyns at three 
      different hospital systems in the Northeastern United States to assess practices 
      regarding preeclampsia management and prevention.Results: A total of 87 out of 
      130 providers completed and returned a questionnaire (66.9% response rate). 
      Providers with a subspecialty in MFM made up 44.3% of the sample. 90.7% of 
      respondents agreed that preeclampsia is a common diagnosis in their practice, 
      while 85% agreed that aspirin is useful for reducing a patient's risk of 
      preeclampsia. 68.8% of providers reported not administering magnesium sulfate in 
      labor to reduce seizure risk in patients with preeclampsia without severe 
      features. Only 5.8% of providers reported using a preeclampsia prediction 
      algorithm, all of whom were MFMs. Providers who specialized in MFM were more 
      likely to prescribe aspirin for preeclampsia prevention in patients with chronic 
      hypertension (26, 74.3% vs. 17, 39.5%, p = .002). MFM specialists were also more 
      likely to counsel patients with abnormal biomarkers on the risk of preeclampsia 
      (23, 69.7% vs. 15, 35.7%, p = .005).Conclusion: Efforts to inform practicing 
      ob-gyns about the best practices for preeclampsia management and prevention have 
      been largely successful, though there are still discrepancies between current 
      recommendations and practice. Differences between general OBGYNs and MFM 
      specialists were also significant with regards to practice. Given the 
      acknowledgement of how common diagnoses of preeclampsia are in respondents' 
      practices, better education and distribution of guidelines on management of 
      preeclampsia is needed.
FAU - Snead, Carrie M
AU  - Snead CM
AD  - American College of Obstetricians and Gynecologists, Washington, DC, USA.
FAU - Strassberg, Emmie
AU  - Strassberg E
AD  - Department of Obstetrics and Gynecology, Geisinger Medical Center, Danville,PA, 
      USA.
FAU - Overcash, Rachael
AU  - Overcash R
AD  - Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, 
      Washington, DC, USA.
FAU - Stark, Lauren
AU  - Stark L
AD  - American College of Obstetricians and Gynecologists, Washington, DC, USA.
FAU - Paglia, Michael J
AU  - Paglia MJ
AD  - Department of Obstetrics and Gynecology, Geisinger Medical Center, Danville,PA, 
      USA.
FAU - Schulkin, Jay
AU  - Schulkin J
AD  - American College of Obstetricians and Gynecologists, Washington, DC, USA.
FAU - Jelin, Angie
AU  - Jelin A
AD  - Department of Gynecology and Obstetrics, Johns Hopkins University Hospital, 
      Baltimore,MD, USA.
LA  - eng
GR  - K23 DK119949/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20190122
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Obstetrics
MH  - *Physicians
MH  - *Pre-Eclampsia/diagnosis/prevention & control
MH  - Pregnancy
MH  - Prospective Studies
MH  - United States
PMC - PMC8588994
MID - NIHMS1752466
OTO - NOTNLM
OT  - Aspirin
OT  - biomarkers
OT  - preeclampsia
COIS- Disclosure statement No potential conflict of interest was reported by the 
      authors.
EDAT- 2019/01/24 06:00
MHDA- 2021/06/22 06:00
CRDT- 2019/01/24 06:00
PHST- 2019/01/24 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2019/01/24 06:00 [entrez]
AID - 10.1080/14767058.2019.1566311 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2020 Sep;33(17):2970-2975. doi: 
      10.1080/14767058.2019.1566311. Epub 2019 Jan 22.

PMID- 10477035
OWN - NLM
STAT- MEDLINE
DCOM- 19991007
LR  - 20190915
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 61
IP  - 1
DP  - 1999 Jul
TI  - Plasma thromboxane and prostacyclin are linear related and increased in patients 
      presenting with acute myocardial infarction.
PG  - 7-11
AB  - The role of prostanoids in patients with ischemic heart disease including acute 
      myocardial infarction (AMI) has been recognized. However, there is very limited 
      knowledge of the baseline TXB2 and 6-keto-PGF1a plasma levels in patients with 
      AMI before therapy has been administered. We compared plasma levels of TXB2 and 
      6-keto-PGF1a by enzyme immunoassay in 18 AMI patients before thrombolysis, with 
      those of 13 healthy controls. Plasma levels of TXB2 (319.78+/-16.50 pg/ml) and 
      6-keto-PGF1a (536.72+/-56.71 pg/ml) were heterogeneous, but significantly higher 
      in the AMI patients than in controls (175.92+/-17.29 pg/ml and 192.08+/-26.11 
      pg/ml, respectively). In some patients, long-term aspirin therapy mildly inhibits 
      baseline prostanoid levels, however, limited data prevents us from further 
      speculations on this issue. Although, the contributions by prostanoids to the 
      pathogenesis of AMI have been well proposed, their plasma concentrations are not 
      uniformly elevated, and it is still unclear whether the resultant changes are 
      indicative of clinically meaningful effects.
FAU - Gurbel, P A
AU  - Gurbel PA
AD  - Sinai Hospital, Baltimore, MD 21215, USA.
FAU - Murugesan, S R
AU  - Murugesan SR
FAU - Lowry, D R
AU  - Lowry DR
FAU - Serebruany, V L
AU  - Serebruany VL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/*blood
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*blood
MH  - Reference Values
MH  - Thromboxane B2/*blood
EDAT- 1999/09/07 00:00
MHDA- 1999/09/07 00:01
CRDT- 1999/09/07 00:00
PHST- 1999/09/07 00:00 [pubmed]
PHST- 1999/09/07 00:01 [medline]
PHST- 1999/09/07 00:00 [entrez]
AID - S0952327899900649 [pii]
AID - 10.1054/plef.1999.0064 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 1999 Jul;61(1):7-11. doi: 
      10.1054/plef.1999.0064.

PMID- 1742514
OWN - NLM
STAT- MEDLINE
DCOM- 19920116
LR  - 20161123
IS  - 0392-0623 (Print)
IS  - 0392-0623 (Linking)
VI  - 23
IP  - 5
DP  - 1991 Jun
TI  - Protective effect of cyanidin (IdB 1027) against aspirin-induced fall in gastric 
      transmucosal potential difference in normal subjects.
PG  - 249-52
AB  - The effect of the natural flavonoid cyanidin (IdB 1027), 1200mg daily for 8 days, 
      on the fall in gastric transmucosal potential difference induced by a single dose 
      of aspirin (1000mg by nasogastric tube) was evaluated in 7 normal male 
      volunteers. As compared to pretreatment values, IdB 1027 caused a significant 
      reduction in both the percentage fall in transmucosal potential difference at the 
      time of peak aspirin effect (from 37 +/- 18% to 18 +/- 5%, p less than 0.05) and 
      the area under potential difference baseline (from 811 +/- 624 mvolt. min to 338 
      +/- 150 mvolt. min, p less than 0.05). These results provide evidence for a 
      protecting effect of IdB 1027 against aspirin-induced gastric mucosal damage in 
      man.
FAU - Barzaghi, N
AU  - Barzaghi N
AD  - Dipartimento di Medicina Interna e Terapia Medica, Università di Pavia, Italy.
FAU - Gatti, G
AU  - Gatti G
FAU - Crema, F
AU  - Crema F
FAU - Perucca, E
AU  - Perucca E
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Ital J Gastroenterol
JT  - The Italian journal of gastroenterology
JID - 8000544
RN  - 0 (Anthocyanins)
RN  - 0 (Benzopyrans)
RN  - 7732ZHU564 (cyanidin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Anthocyanins
MH  - Aspirin/*pharmacology
MH  - Benzopyrans/*pharmacology
MH  - Gastric Mucosa/*physiology
MH  - Humans
MH  - Male
MH  - Membrane Potentials/drug effects
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
PST - ppublish
SO  - Ital J Gastroenterol. 1991 Jun;23(5):249-52.

PMID- 17975886
OWN - NLM
STAT- MEDLINE
DCOM- 20080311
LR  - 20171116
IS  - 0893-228X (Print)
IS  - 0893-228X (Linking)
VI  - 20
IP  - 12
DP  - 2007 Dec
TI  - Quinone formation as a chemoprevention strategy for hybrid drugs: balancing 
      cytotoxicity and cytoprotection.
PG  - 1903-12
AB  - Cellular defense mechanisms that respond to damage from oxidative and 
      electrophilic stress, such as from quinones, represent a target for 
      chemopreventive agents. Drugs bioactivated to quinones have the potential to 
      activate antioxidant/electrophile responsive element (ARE) transcription of genes 
      for cytoprotective phase 2 enzymes such as NAD(P)H-dependent quinone 
      oxidoreductase (NQO1) but can also cause cellular damage. Two isomeric families 
      of compounds were prepared, including the NO-NSAIDs (NO-donating nonsteroidal 
      anti-inflammatory drugs) NCX 4040 and NCX 4016; one family was postulated to 
      release a quinone methide on esterase bioactivation. The study of reactivity and 
      GSH conjugation in model and cell systems confirmed the postulate. The 
      quinone-forming family, including NCX 4040 and conisogenic bromides and mesylate, 
      was rapidly bioactivated to a quinone, which gave activation of ARE and 
      consequent induction of NQO1 in liver cells. Although the control family, 
      including NCX 4016 and conisogenic bromides and mesylates, cannot form a quinone, 
      ARE activation and NQO1 induction were observed, compatible with slower SN2 
      reactions with thiol sensor proteins, and consequent ARE-luciferase and NQO1 
      induction. Using a Chemoprevention Index estimate, the quinone-forming compounds 
      suffered because of high cytoxicity and were more compatible with cancer therapy 
      than chemoprevention. In the Comet assay, NCX 4040 was highly genotoxic relative 
      to NCX 4016. There was no evidence that NO contributes to the observed biological 
      activity and no evidence that NCX 4040 is an NO donor, instead, rapidly releasing 
      NO3- and quinone. These results indicate a strategy for studying the quinone 
      biological activity and reinforce the therapeutic attributes of NO-ASA through 
      structural elements other than NO and ASA.
FAU - Dunlap, Tareisha
AU  - Dunlap T
AD  - Department of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, 
      University of Illinois at Chicago 60612, USA.
FAU - Chandrasena, R Esala P
AU  - Chandrasena RE
FAU - Wang, Zhiqiang
AU  - Wang Z
FAU - Sinha, Vaishali
AU  - Sinha V
FAU - Wang, Zhican
AU  - Wang Z
FAU - Thatcher, Gregory R J
AU  - Thatcher GR
LA  - eng
GR  - CA102590/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20071101
PL  - United States
TA  - Chem Res Toxicol
JT  - Chemical research in toxicology
JID - 8807448
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Benzoquinones)
RN  - 0 (NCX 4040)
RN  - 0 (Nitro Compounds)
RN  - 3T006GV98U (quinone)
RN  - EC 1.13.12.- (Luciferases)
RN  - EC 1.6.5.2 (NAD(P)H Dehydrogenase (Quinone))
RN  - EC 1.6.5.2 (Nqo1 protein, mouse)
RN  - EC 1.6.99.1 (NADPH Dehydrogenase)
RN  - EC 3.1.- (Esterases)
RN  - EH04H13L6B (nitroaspirin)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*metabolism/pharmacology
MH  - Aspirin/adverse effects/*analogs & derivatives/metabolism/pharmacology
MH  - Benzoquinones/*metabolism
MH  - Catalysis
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Chemoprevention
MH  - Cytoprotection
MH  - Esterases/metabolism
MH  - Glutathione/metabolism
MH  - *Liver/drug effects/enzymology/metabolism
MH  - Luciferases/genetics
MH  - Metabolic Detoxication, Phase II
MH  - Mice
MH  - Models, Biological
MH  - NAD(P)H Dehydrogenase (Quinone)
MH  - NADPH Dehydrogenase/biosynthesis/genetics
MH  - Nitro Compounds/adverse effects/*metabolism/pharmacology
MH  - Response Elements/genetics
MH  - Swine
EDAT- 2007/11/03 09:00
MHDA- 2008/03/12 09:00
CRDT- 2007/11/03 09:00
PHST- 2007/11/03 09:00 [pubmed]
PHST- 2008/03/12 09:00 [medline]
PHST- 2007/11/03 09:00 [entrez]
AID - 10.1021/tx7002257 [doi]
PST - ppublish
SO  - Chem Res Toxicol. 2007 Dec;20(12):1903-12. doi: 10.1021/tx7002257. Epub 2007 Nov 
      1.

PMID- 33010910
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1525-3198 (Electronic)
IS  - 0022-0302 (Linking)
VI  - 103
IP  - 12
DP  - 2020 Dec
TI  - Administration of acetylsalicylic acid after parturition in lactating dairy cows 
      under certified organic management: Part I. Milk yield, milk components, activity 
      patterns, fertility, and health.
PG  - 11697-11712
LID - S0022-0302(20)30765-7 [pii]
LID - 10.3168/jds.2020-18388 [doi]
AB  - Parturition is a natural process that gradually progresses from one stage to the 
      next. However, around 5% of dairy cows will experience dystocia, which is 
      considered to be a painful and stressful event. Studies have reported positive 
      effects on cow performance and welfare after treatment with nonsteroidal 
      anti-inflammatory drugs during the first postpartum days. The objectives were to 
      assess the effects of acetylsalicylic acid administration after calving on (1) 
      milk yield and components, (2) daily activity patterns, (3) reproductive 
      performance, and (4) health in lactating dairy cows under certified organic 
      management. Cows from 3 organic herds were enrolled. Within 12 h after 
      parturition, cows were blocked by parity and calving ease and randomly assigned 
      to 2 treatments: (1) aspirin (ASP; n = 278), in which cows received 4 consecutive 
      treatments every 12 h with acetylsalicylic acid (100 mg/kg; 2 boluses) or (2) 
      placebo (PLC, n = 285), in which cows received 4 treatments every 12 h with 
      gelatin capsules (2 capsules) filled with water. Daily milk yield for the first 
      30 d in milk (DIM) and monthly milk yield, fat, protein, and somatic cell count 
      (SCC) data from the first 5 Dairy Herd Improvement Association tests were 
      collected. Activity patterns were measured using activity data loggers in the 
      first 7 DIM. Clinical disease events (60 DIM) and fertility data were collected 
      from on-farm computer records. Statistical analysis was performed using the MIXED 
      (milk yield, components, and activity), LIFETEST (fertility), and GLIMMIX 
      (health) procedures of SAS (SAS Institute Inc., Cary, NC). Overall, ASP cows 
      produced 1.82 kg/d more milk than PLC cows during the first 30 DIM. 
      Interestingly, cows that experienced dystocia and received ASP produced 4.48 kg/d 
      more milk compared with cows in the PLC group that experienced dystocia. Cows 
      treated with ASP had lower somatic cell count during the first 5 Dairy Herd 
      Improvement Association tests. There were no differences in daily lying time, 
      lying bouts, and lying bout duration between the ASP and PLC groups. However, 
      cows in the ASP group had 587,64 steps/d more compared with PLC cows. In 
      addition, ASP cows tended to require fewer days (ASP = 113.76 ± 4.99 d; PLC = 
      125.36 ± 4.74 d) and needed fewer services (ASP = 1.86 ± 0.21 services; PLC = 
      2.19 ± 0.24 services) to become pregnant compared with PLC cows. There were no 
      differences in clinical disease events between treatments. Results from this 
      study suggest that treating cows with ASP after calving may help improve milk 
      yields and udder health, increase activity, and enhance fertility in dairy cattle 
      under certified organic management.
CI  - Copyright © 2020 American Dairy Science Association. Published by Elsevier Inc. 
      All rights reserved.
FAU - Barragan, A A
AU  - Barragan AA
AD  - Department of Veterinary Preventive Medicine, The Ohio State University, Columbus 
      43210.
FAU - Bauman, L
AU  - Bauman L
AD  - Department of Animal Sciences, The Ohio State University, Columbus 43210.
FAU - da Costa, L
AU  - da Costa L
AD  - Department of Veterinary Preventive Medicine, The Ohio State University, Columbus 
      43210.
FAU - Velez, J
AU  - Velez J
AD  - Aurora Organic Farms, Boulder, CO 80302.
FAU - Gonzalez, J D Rozo
AU  - Gonzalez JDR
AD  - Aurora Organic Farms, Boulder, CO 80302.
FAU - Schuenemann, G M
AU  - Schuenemann GM
AD  - Department of Veterinary Preventive Medicine, The Ohio State University, Columbus 
      43210.
FAU - Menichetti, B
AU  - Menichetti B
AD  - Department of Veterinary Preventive Medicine, The Ohio State University, Columbus 
      43210.
FAU - Piñeiro, J
AU  - Piñeiro J
AD  - Department of Veterinary Preventive Medicine, The Ohio State University, Columbus 
      43210.
FAU - Bas, S
AU  - Bas S
AD  - Department of Veterinary Preventive Medicine, The Ohio State University, Columbus 
      43210. Electronic address: s.bas@phytobiotics.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial, Veterinary
DEP - 20201001
PL  - United States
TA  - J Dairy Sci
JT  - Journal of dairy science
JID - 2985126R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Behavior, Animal/drug effects
MH  - Cattle
MH  - Cattle Diseases/prevention & control
MH  - Cell Count/veterinary
MH  - Drug Administration Schedule
MH  - Dystocia/prevention & control/veterinary
MH  - Female
MH  - Fertility
MH  - Lactation/*drug effects
MH  - Milk/*chemistry
MH  - Parity
MH  - Parturition
MH  - Postpartum Period
MH  - Pregnancy
MH  - Reproduction
OTO - NOTNLM
OT  - aspirin
OT  - behavior
OT  - calving
OT  - milk production
EDAT- 2020/10/05 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/10/04 20:20
PHST- 2020/02/18 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/10/05 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/10/04 20:20 [entrez]
AID - S0022-0302(20)30765-7 [pii]
AID - 10.3168/jds.2020-18388 [doi]
PST - ppublish
SO  - J Dairy Sci. 2020 Dec;103(12):11697-11712. doi: 10.3168/jds.2020-18388. Epub 2020 
      Oct 1.

PMID- 925893
OWN - NLM
STAT- MEDLINE
DCOM- 19780127
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 66
IP  - 10
DP  - 1977 Oct
TI  - Effect of aspirin on a subtoxic dose of 14C-acetaminophen in mice.
PG  - 1399-403
AB  - The interaction of 14C-acetaminophen, 150 mg/kg (20 muCi/kg), and aspirin, 200 
      mg/kg po, was studied in male mice. The radiolabel was rapidly absorbed from the 
      GI tract, achieving maximum blood levels 0.25 hr after oral dosing. Radioactivity 
      in the blood equilibrated rapidly with the tissues and was concentrated in the 
      liver and kidney. At 14 hr, most of the dose was eliminated in urine as the 
      glucuronide, cysteine, sulfate, free drug, and mercapturate. Pretreatment with 
      aspirin tended to reduce the rate and extent of acetaminophen absorption and 
      altered the percentage of the dose excreted in the urine as sulfate, 
      mercapturate, glucuronide, and cysteine. Interpretation of these data 
      toxicologically as an indication of the potentiation of either toxicity or 
      protection was not possible.
FAU - Whitehouse, L W
AU  - Whitehouse LW
FAU - Paul, C J
AU  - Paul CJ
FAU - Wong, L T
AU  - Wong LT
FAU - Thomas, B H
AU  - Thomas BH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 362O9ITL9D (Acetaminophen)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/blood/*metabolism/urine
MH  - Alanine Transaminase/blood
MH  - Animals
MH  - Aspartate Aminotransferases/blood
MH  - Aspirin/metabolism/*pharmacology
MH  - Chromatography, Gas
MH  - Chromatography, Thin Layer
MH  - Kinetics
MH  - Male
MH  - Mice
EDAT- 1977/10/01 00:00
MHDA- 1977/10/01 00:01
CRDT- 1977/10/01 00:00
PHST- 1977/10/01 00:00 [pubmed]
PHST- 1977/10/01 00:01 [medline]
PHST- 1977/10/01 00:00 [entrez]
AID - S0022-3549(15)39595-2 [pii]
AID - 10.1002/jps.2600661012 [doi]
PST - ppublish
SO  - J Pharm Sci. 1977 Oct;66(10):1399-403. doi: 10.1002/jps.2600661012.

PMID- 26959198
OWN - NLM
STAT- MEDLINE
DCOM- 20160808
LR  - 20210109
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 127
IP  - 4
DP  - 2016 Apr
TI  - Complications and Safety of Preconception Low-Dose Aspirin Among Women With Prior 
      Pregnancy Losses.
PG  - 689-698
LID - 10.1097/AOG.0000000000001301 [doi]
AB  - OBJECTIVE: To evaluate complications and safety of preconception low-dose aspirin 
      in 1,228 U.S. women (2007-2011). METHODS: Evaluation of the safety of low-dose 
      aspirin in the participants and their fetuses was a planned secondary analysis of 
      the Effects of Aspirin in Gestation and Reproduction trial, a multicenter, 
      block-randomized, double-blind, placebo-controlled trial investigating the effect 
      of low-dose aspirin on the incidence of live birth. Women aged 18-40 years with a 
      history of one to two pregnancy losses trying to conceive were randomized to 
      daily low-dose aspirin (81 mg, n=615) or placebo (n=613) and were followed for up 
      to six menstrual cycles or through gestation if they became pregnant. Emergency 
      care visits and possible aspirin-related symptoms were assessed at each study 
      follow-up using standardized safety interviews. In addition, complications for 
      both the participant and her fetus or neonate were captured prospectively using 
      case report forms, interviews conducted during pregnancy and postpartum, and 
      medical records. RESULTS: The proportion of women with at least one possible 
      aspirin-related symptom during the trial was similar between treatment arms (456 
      [74%] low-dose aspirin compared with 447 [73%] placebo, P=.65) as was the 
      proportion with at least one emergency care visit (104 [17%] low-dose aspirin 
      compared with 99 [16%] placebo, P=.76). Maternal complications were evenly 
      distributed by treatment arm with the exception of vaginal bleeding, which was 
      more commonly reported in the low-dose aspirin arm (22% compared with 17%, 
      P=.02). The distribution of fetal and neonatal complications-which included three 
      stillbirths, three neonatal deaths, and 10 neonates with birth defect(s)-was 
      similar between treatment arms. CONCLUSION: Although rare but serious 
      complications resulting from low-dose aspirin cannot be ruled out, preconception 
      low-dose aspirin appears to be well tolerated by women trying to conceive, women 
      who become pregnant, and by their fetuses and neonates.
FAU - Ahrens, Katherine A
AU  - Ahrens KA
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      Rockville, Maryland; the Department of Obstetrics and Gynecology, University of 
      Utah Health Sciences Center, Salt Lake City, Utah; the Department of Epidemiology 
      and Environmental Health, University at Buffalo, Buffalo, New York; the 
      Department of Statistics, University of Haifa, Mt. Carmel, Haifa, Israel; the 
      Department of Family, Community and Rural Health, Commonwealth Medical College, 
      Scranton, Pennsylvania; and the Department of Obstetrics and Gynecology, 
      University of Colorado, Aurora, Colorado.
FAU - Silver, Robert M
AU  - Silver RM
FAU - Mumford, Sunni L
AU  - Mumford SL
FAU - Sjaarda, Lindsey A
AU  - Sjaarda LA
FAU - Perkins, Neil J
AU  - Perkins NJ
FAU - Wactawski-Wende, Jean
AU  - Wactawski-Wende J
FAU - Galai, Noya
AU  - Galai N
FAU - Townsend, Janet M
AU  - Townsend JM
FAU - Lynch, Anne M
AU  - Lynch AM
FAU - Lesher, Laurie L
AU  - Lesher LL
FAU - Faraggi, David
AU  - Faraggi D
FAU - Zarek, Shvetha
AU  - Zarek S
FAU - Schisterman, Enrique F
AU  - Schisterman EF
LA  - eng
GR  - Z01 HD008795-01/Intramural NIH HHS/United States
GR  - HHSN267200603423/PHS HHS/United States
GR  - HHSN267200603424/PHS HHS/United States
GR  - HHSN267200603426/PHS HHS/United States
GR  - Z01 HD008795-02/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abortion, Habitual
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Pre-Eclampsia/prevention & control
MH  - *Preconception Care
MH  - Pregnancy
MH  - Pregnancy Complications/*chemically induced
MH  - Pregnancy Outcome
MH  - United States
MH  - Uterine Hemorrhage/chemically induced
MH  - Young Adult
PMC - PMC4805457
MID - NIHMS747620
COIS- Financial Disclosure The authors did not report any potential conflicts of 
      interest.
EDAT- 2016/03/10 06:00
MHDA- 2016/08/09 06:00
CRDT- 2016/03/10 06:00
PHST- 2016/03/10 06:00 [entrez]
PHST- 2016/03/10 06:00 [pubmed]
PHST- 2016/08/09 06:00 [medline]
AID - 00006250-201604000-00010 [pii]
AID - 10.1097/AOG.0000000000001301 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2016 Apr;127(4):689-698. doi: 10.1097/AOG.0000000000001301.

PMID- 15969319
OWN - NLM
STAT- MEDLINE
DCOM- 20050727
LR  - 20191109
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 60
IP  - 2
DP  - 2005 Mar-Apr
TI  - Bioequivalence assessment of two enteric-coated aspirin brands, Nu-Seals and 
      Loprin, after a single oral dose of 150 mg in healthy male adults.
PG  - 167-73
AB  - AIM: The bioequivalence of aspirin from two enteric-coated brands, Nu-seals and 
      Loprin, identified as the reference (R) and test (T) products, respectively, was 
      assessed. METHODS: A two-period randomised crossover design with a washout 
      interval of 15 days was used in this study. The study results were determined in 
      16 healthy volunteers, all males with ages ranging from 19-28 (23.33 +/- 3.74) 
      years and bodyweights of 52-92 (65.89 +/- 11.39) kg. After oral ingestion of 
      150mg of the either brand with 200 mL of water, serial blood samples were 
      obtained over a period of 24 hours. Plasma, harvested from blood was analysed for 
      the concentration of salicylic acid, a deacetylated metabolite of aspirin, by a 
      validated high performance liquid chromatography (HPLC) method. Pharmacokinetic 
      parameters were determined for both formulations by an interactive 
      computer-assisted PK II procedure. A general linear model for repeated measures 
      and 90% confidence intervals (CI) was employed to assess the sequence of 
      treatment effects and to exclude differences between the parameters due to the 
      product and period of administration, respectively. RESULTS: The observed 90% CI 
      ratios (Loprin/Nu-seals) for peak concentration, time to reach the peak and area 
      under the plasma-concentration time curve from zero to infinity of 1.03,1.08; 
      1.04,1.05 and 1.01,1.15, respectively, were within the bioequivalence range 
      (0.80,1.25) stipulated by the US Food and Drug Administration. CONCLUSION: On the 
      basis of the findings, the test (Loprin) and reference drug (Nu-seals) were 
      deemed bioequivalent.
FAU - Bukhari, Nadeem Irfan
AU  - Bukhari NI
AD  - School of Pharmacy, International Medical University (IMU), Kuala Lumpur, 
      Malaysia. nadeem_irfan@hotmail.com
FAU - Zafar, Azia
AU  - Zafar A
FAU - Shamsi, Waseem ur Rehman
AU  - Shamsi Wu
FAU - Bashir, Muhammad Amir
AU  - Bashir MA
FAU - Mirza, Ahmad Atif
AU  - Mirza AA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & 
      dosage/*pharmacokinetics
MH  - Aspirin/*administration & dosage/*pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Tablets, Enteric-Coated
MH  - Therapeutic Equivalency
EDAT- 2005/06/23 09:00
MHDA- 2005/07/28 09:00
CRDT- 2005/06/23 09:00
PHST- 2005/06/23 09:00 [pubmed]
PHST- 2005/07/28 09:00 [medline]
PHST- 2005/06/23 09:00 [entrez]
AID - S0040-5957(16)30281-5 [pii]
AID - 10.2515/therapie:2005021 [doi]
PST - ppublish
SO  - Therapie. 2005 Mar-Apr;60(2):167-73. doi: 10.2515/therapie:2005021.

PMID- 4022693
OWN - NLM
STAT- MEDLINE
DCOM- 19850829
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 76
IP  - 2
DP  - 1985 Aug
TI  - Reye syndrome associated with aspirin therapy for systemic lupus erythematosus.
PG  - 202-5
AB  - A 14-year-old girl in whom Reye syndrome developed during aspirin therapy for an 
      inflammatory disorder proven to be systemic lupus erythematosus is reported. This 
      case and similar cases of Reye syndrome in patients with juvenile rheumatoid 
      arthritis suggest that an etiologic relationship exists between salicylate 
      therapy and Reye syndrome in children with collagen vascular disorders.
FAU - Hansen, J R
AU  - Hansen JR
FAU - McCray, P B
AU  - McCray PB
FAU - Bale, J F Jr
AU  - Bale JF Jr
FAU - Corbett, A J
AU  - Corbett AJ
FAU - Flanders, D J
AU  - Flanders DJ
LA  - eng
GR  - KO7 NS 00805/NS/NINDS NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 7664-41-7 (Ammonia)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Ammonia/blood
MH  - Aspartate Aminotransferases/blood
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Biopsy, Needle
MH  - Electroencephalography
MH  - Female
MH  - Humans
MH  - Intracranial Pressure/drug effects
MH  - Liver/pathology
MH  - Lupus Erythematosus, Systemic/*drug therapy
MH  - Microscopy, Electron
MH  - Reye Syndrome/*chemically induced/pathology
EDAT- 1985/08/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1985/08/01 00:00
PHST- 1985/08/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1985/08/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1985 Aug;76(2):202-5.

PMID- 33449095
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 4
IP  - 1
DP  - 2021 Jan 4
TI  - Evaluation of Aspirin Use With Cancer Incidence and Survival Among Older Adults 
      in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
PG  - e2032072
LID - 10.1001/jamanetworkopen.2020.32072 [doi]
LID - e2032072
AB  - IMPORTANCE: Many studies have evaluated the long-term benefits of aspirin use; 
      however, the association of aspirin use with cancer incidence and survival in 
      older individuals remains uncertain. Additional population-based evidence of this 
      association is necessary to better understand any possible protective effects of 
      aspirin in older adults. OBJECTIVE: To investigate the association of aspirin use 
      with risk of developing new cancers and site-specific cancer-associated survival 
      in bladder, breast, esophageal, gastric, pancreatic, and uterine cancers. DESIGN, 
      SETTING, AND PARTICIPANTS: This cohort study used data from the Prostate, Lung, 
      Colorectal, and Ovarian Cancer Screening Trial. Participants were aged 65 years 
      or older at baseline (1993-2001) or reached age 65 during follow-up. Data 
      analysis was conducted from January to June 2020. MAIN OUTCOMES AND MEASURES: 
      Incidence of and survival from the investigated cancer types. Univariable and 
      multivariable hazard ratios (HRs) and 95% CIs were calculated using Cox 
      proportional hazards regression modeling, adjusting for covariates. Multivariable 
      models for incidence included time-varying covariates. RESULTS: A total of 
      139 896 individuals (mean [SD] age at baseline, 66.4 [2.4] years; 71 884 [51.4%] 
      women; 123 824 [88.5%] non-Hispanic White individuals) were included in the 
      analysis. During the study period, 32 580 incident cancers (1751 [5.4%] bladder, 
      4552 [14.0%] breast, 332 [1.0%] esophageal, 397 [1.2%] gastric, 878 [2.7%] 
      pancreatic, and 716 [2.2%] uterine cancers) were reported. Aspirin use was not 
      associated with incidence of any of the investigated cancer types among 
      individuals aged 65 years or older. Multivariable regression analysis 
      demonstrated that aspirin use at least 3 times/week was associated with increased 
      survival among patients with bladder (HR, 0.67; 95% CI, 0.51-0.88) and breast 
      (HR, 0.75; 95% CI, 0.59-0.96) cancers but not among those with esophageal, 
      gastric, pancreatic, or uterine cancer. A similar association of any aspirin use 
      with bladder (HR, 0.75; 95% CI, 0.58-0.98) and breast (HR, 0.79; 95% CI, 
      0.63-0.99) cancer survival was observed. CONCLUSIONS AND RELEVANCE: In the 
      current study, any aspirin use and aspirin use at least 3 times/week was 
      associated with improved bladder and breast cancer survival. Associations between 
      aspirin use and incidence of any of the investigated cancers or between aspirin 
      use and esophageal, gastric, pancreatic, or uterine cancer survival were not 
      observed.
FAU - Loomans-Kropp, Holli A
AU  - Loomans-Kropp HA
AD  - Cancer Prevention Fellowship Program, Division of Cancer Prevention, National 
      Cancer Institute, Rockville, Maryland.
AD  - Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, 
      National Cancer Institute, Rockville, Maryland.
FAU - Pinsky, Paul
AU  - Pinsky P
AD  - Early Detection Research Branch, Division of Cancer Prevention, National Cancer 
      Institute, Rockville, Maryland.
FAU - Umar, Asad
AU  - Umar A
AD  - Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, 
      National Cancer Institute, Rockville, Maryland.
LA  - eng
PT  - Journal Article
DEP - 20210104
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Neoplasms/*epidemiology/mortality/prevention & control
MH  - Risk Factors
MH  - Survival Analysis
PMC - PMC7811183
COIS- Conflict of Interest Disclosures: None reported.
EDAT- 2021/01/16 06:00
MHDA- 2021/03/16 06:00
CRDT- 2021/01/15 12:10
PHST- 2021/01/15 12:10 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - 2775219 [pii]
AID - zoi200992 [pii]
AID - 10.1001/jamanetworkopen.2020.32072 [doi]
PST - epublish
SO  - JAMA Netw Open. 2021 Jan 4;4(1):e2032072. doi: 
      10.1001/jamanetworkopen.2020.32072.

PMID- 22785245
OWN - NLM
STAT- MEDLINE
DCOM- 20130513
LR  - 20190606
IS  - 1347-7439 (Electronic)
IS  - 0916-7250 (Linking)
VI  - 74
IP  - 11
DP  - 2012 Nov
TI  - Lyophilized aspirin with trehalose may decrease the incidence of gastric injuries 
      in healthy dogs.
PG  - 1511-6
AB  - Trehalose has several novel anti-inflammatory and cell-protective functions. We 
      hypothesized that lyophilized aspirin/trehalose could decrease the severity of 
      aspirin-induced gastropathy. Thirteen dogs were assigned into aspirin, 
      lyophilized aspirin/trehalose, and control groups, and the gastric lesions were 
      assessed on gastroscopy with the modified Lanza scale. Another 6 dogs were used 
      to measure the plasma aspirin concentration by high-performance liquid 
      chromatography after aspirin or lyophilized aspirin/trehalose administration. The 
      results indicated that lyophilized aspirin/trehalose induced less gastric 
      ulceration than aspirin despite maintaining therapeutic concentrations of plasma 
      aspirin in both the groups. Lyophilized aspirin/trehalose might be a solution to 
      decrease aspirin-induced gastropathy.
FAU - Lin, Lee-Shuan
AU  - Lin LS
AD  - Department of Veterinary Surgery, Graduate School of Agriculture and Life 
      Science, The University of Tokyo, Tokyo, Japan.
FAU - Kayasuga, Yuko
AU  - Kayasuga Y
FAU - Shimohata, Nobuyuki
AU  - Shimohata N
FAU - Kamata, Hiroyuki
AU  - Kamata H
FAU - Suzuki, Shigeki
AU  - Suzuki S
FAU - Echigo, Ryosuke
AU  - Echigo R
FAU - Mochizuki, Manabu
AU  - Mochizuki M
FAU - Chung, Ung-Il
AU  - Chung UI
FAU - Sasaki, Nobuo
AU  - Sasaki N
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20120620
PL  - Japan
TA  - J Vet Med Sci
JT  - The Journal of veterinary medical science
JID - 9105360
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - B8WCK70T7I (Trehalose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse 
      effects/pharmacology
MH  - Aspirin/administration & dosage/*adverse effects/pharmacology
MH  - Chromatography, High Pressure Liquid/veterinary
MH  - Dog Diseases/*chemically induced/pathology/*prevention & control
MH  - Dogs
MH  - Female
MH  - Freeze Drying/*veterinary
MH  - Gastroscopy/veterinary
MH  - Male
MH  - Statistics, Nonparametric
MH  - Stomach Diseases/chemically induced/pathology/prevention & control/*veterinary
MH  - Trehalose/administration & dosage/*therapeutic use
EDAT- 2012/07/13 06:00
MHDA- 2013/05/15 06:00
CRDT- 2012/07/13 06:00
PHST- 2012/07/13 06:00 [entrez]
PHST- 2012/07/13 06:00 [pubmed]
PHST- 2013/05/15 06:00 [medline]
AID - DN/JST.JSTAGE/jvms/12-0109 [pii]
AID - 10.1292/jvms.12-0109 [doi]
PST - ppublish
SO  - J Vet Med Sci. 2012 Nov;74(11):1511-6. doi: 10.1292/jvms.12-0109. Epub 2012 Jun 
      20.

PMID- 16773199
OWN - NLM
STAT- MEDLINE
DCOM- 20070803
LR  - 20131121
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 29
IP  - 1
DP  - 2006 Jul
TI  - NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a 
      chemoprevention target (review).
PG  - 185-92
AB  - Pancreatic cancer is the most deadly of all gastrointestinal malignancies with 
      near zero five-year survival. This review summarizes our understanding of the 
      potentially important role of inflammation in cancer in general and pancreatic 
      cancer in particular. Nuclear factor kappaB (NF-kappaB), a mediator of 
      inflammatory responses, plays a significant role in carcinogenesis and is now 
      emerging as a link between inflammation and cancer. NF-kappaB is activated in 
      over two thirds of human pancreatic cancers; participates in early events of 
      pancreatic carcinogenesis through its interactions with signaling pathways; and 
      suppression of its activation restores pancreatic cell kinetics, mainly 
      normalizing the suppressed apoptosis of pancreatic cancer. NF-kappaB is an 
      excellent target for chemoprevention and its modulation for pancreatic cancer 
      prevention appears promising. The next few years will likely expand our 
      understanding of NF-kappaB biology; solidify NF-kappaB's role as a major link 
      between chronic inflammation and pancreatic carcinogenesis; and witness the 
      development of NF-kappaB-based approaches to pancreatic cancer prevention.
FAU - Zhang, Zhiquan
AU  - Zhang Z
AD  - Department of Medicine, Division of Cancer Prevention, SUNY at Stony Brook, Stony 
      Brook, NY 11794-5200, USA.
FAU - Rigas, Basil
AU  - Rigas B
LA  - eng
GR  - CA34527/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 
      4-(nitrooxy)butyl ester)
RN  - 0 (NF-kappa B)
RN  - 0 (Nitrates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/analogs & derivatives/pharmacology/therapeutic use
MH  - Cell Proliferation/drug effects
MH  - Cell Transformation, Neoplastic/drug effects/metabolism
MH  - Chemoprevention
MH  - Humans
MH  - Inflammation/*metabolism
MH  - NF-kappa B/antagonists & inhibitors/*metabolism
MH  - Nitrates/pharmacology/therapeutic use
MH  - Pancreatic Neoplasms/*metabolism/prevention & control
RF  - 89
EDAT- 2006/06/15 09:00
MHDA- 2007/08/04 09:00
CRDT- 2006/06/15 09:00
PHST- 2006/06/15 09:00 [pubmed]
PHST- 2007/08/04 09:00 [medline]
PHST- 2006/06/15 09:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2006 Jul;29(1):185-92.

PMID- 3329766
OWN - NLM
STAT- MEDLINE
DCOM- 19880623
LR  - 20170214
IS  - 0036-9330 (Print)
IS  - 0036-9330 (Linking)
VI  - 32
IP  - 6
DP  - 1987 Dec
TI  - Therapeutic potential of choline magnesium trisalicylate as an alternative to 
      aspirin for patients with bleeding tendencies.
PG  - 167-8
AB  - We have compared the effects of acetyl salicylic acid (ASA, aspirin) and choline 
      magnesium trisalicylate (CMT), a non-acetylated salicylate product, on platelet 
      aggregation in human whole blood ex-vivo. Using a whole blood platelet counter, 
      platelet aggregation was quantified by measuring the fall in the number of single 
      platelets at peak aggregation in response to collagen, arachidonic acid (AA), as 
      well as spontaneous aggregation. In double blind and random order, 12 healthy 
      volunteers received, on two separate occasions 10 days apart, a single oral dose 
      of 652 mg ASA or 655 mg CMT. Despite a comparable absorption of salicylic acid 
      from the two drugs, ingestion of ASA resulted in a marked inhibition of platelet 
      aggregation induced by collagen (p less than 0.005), AA (p less than 0.01) and 
      spontaneous aggregation (p less than 0.01), whereas such effects were not 
      observed after CMT ingestion. We suggest that CMT may have therapeutic potential 
      as an alternative to aspirin when inhibition of platelet aggregation can induce 
      bleeding complications.
FAU - Danesh, B J
AU  - Danesh BJ
AD  - Royal Infirmary, Glasgow.
FAU - Saniabadi, A R
AU  - Saniabadi AR
FAU - Russell, R I
AU  - Russell RI
FAU - Lowe, G D
AU  - Lowe GD
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Scotland
TA  - Scott Med J
JT  - Scottish medical journal
JID - 2983335R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - DJJ95FJP1H (choline magnesium trisalicylate)
RN  - N91BDP6H0X (Choline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Choline/*analogs & derivatives/pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Hemorrhage/*prevention & control
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors
MH  - Platelet Count/drug effects
MH  - Salicylates/pharmacology/*therapeutic use
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
AID - 10.1177/003693308703200603 [doi]
PST - ppublish
SO  - Scott Med J. 1987 Dec;32(6):167-8. doi: 10.1177/003693308703200603.

PMID- 11917725
OWN - NLM
STAT- MEDLINE
DCOM- 20020418
LR  - 20161124
IS  - 0368-2315 (Print)
IS  - 0150-9918 (Linking)
VI  - 30
IP  - 8
DP  - 2001 Dec
TI  - [Contribution of diagnostic ultrasonography in cases of repeated embryonic 
      implantation failure in fertilization in vitro].
PG  - 747-52
AB  - INTRODUCTION: To assess ultrasonic data in the context of repeated failure of 
      implantation in assisted reproduction medicine. MATERIALS AND METHODS: We 
      reviewed ultrasonic data (uterine score at follicular and luteal phase). The same 
      ultrasound exploration was repeated for two consecutive cycles to assess the 
      changes in abnormalities observed and compare findings in 16 patients with 
      repeated failure of implantation and in 14 controls. The controls were women who 
      became pregnant within the three months following the exploration. We then 
      introduced acetylsalicylic acid and prednisolone as first line treatment and 
      nitroglycerin as second line treatment to measure the effects induced in 14 
      pathological uterine scores. RESULTS: The score obtained under hormonal treatment 
      was representative of other cycles (r = 0.812, p < 0.0014). The score was 
      significantly lower and the luteal uterine artery pulsatility index was 
      significantly higher in the repeated failure group than in the control group (p < 
      0.0001 and p = 0.008 respectively). For the 14 patients, treatment improved the 
      uterine score in 8 with acetylsalicylic acid and prednisolone and in 4 with 
      nitroglycerin. Two patients did not respond to treatment. Concerning the effect 
      of therapy, of 14 patients, 8 had an improved uterine score with A + P, and with 
      T; 2 patients did not respond to any treatment. CONCLUSION: The uterine score and 
      luteal artery pulsatility index may be valuable tools for patients with 
      implantation failure who all do not respond to the same therapy.
FAU - Lédée-Bataille, N
AU  - Lédée-Bataille N
AD  - INSERM U131, Service de Gynécologie-Obstétrique et Médecine de la Reproduction, 
      Hôpital Antoine-Béclère, 92140 Clamart. Ledeenathalie@aol.com
FAU - Doumerc, S
AU  - Doumerc S
FAU - Olivennes, F
AU  - Olivennes F
FAU - Kadoch, J
AU  - Kadoch J
FAU - Chaouat, G
AU  - Chaouat G
FAU - Frydman, R
AU  - Frydman R
LA  - fre
PT  - Journal Article
TT  - Apport du diagnostic échographique en cas d'échecs répétés d'implantation 
      embryonnaire en fécondation in vitro.
PL  - France
TA  - J Gynecol Obstet Biol Reprod (Paris)
JT  - Journal de gynecologie, obstetrique et biologie de la reproduction
JID - 0322206
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteries
MH  - Aspirin/administration & dosage/therapeutic use
MH  - *Embryo Implantation
MH  - Embryo Transfer
MH  - Female
MH  - *Fertilization in Vitro
MH  - Humans
MH  - Luteal Phase
MH  - Nitroglycerin/administration & dosage/therapeutic use
MH  - Prednisolone/administration & dosage/therapeutic use
MH  - Pregnancy
MH  - Pulsatile Flow
MH  - Reproducibility of Results
MH  - Ultrasonography
MH  - Uterus/blood supply/*diagnostic imaging
EDAT- 2002/03/29 10:00
MHDA- 2002/04/19 10:01
CRDT- 2002/03/29 10:00
PHST- 2002/03/29 10:00 [pubmed]
PHST- 2002/04/19 10:01 [medline]
PHST- 2002/03/29 10:00 [entrez]
AID - MDOI-JGYN-12-2001-30-8-0368-2315-101019-ART3 [pii]
PST - ppublish
SO  - J Gynecol Obstet Biol Reprod (Paris). 2001 Dec;30(8):747-52.

PMID- 8705392
OWN - NLM
STAT- MEDLINE
DCOM- 19960909
LR  - 20190914
IS  - 1073-2322 (Print)
IS  - 1073-2322 (Linking)
VI  - 5
IP  - 2
DP  - 1996 Feb
TI  - The effects of diaspirin cross-linked hemoglobin in sepsis.
PG  - 141-8
AB  - We tested the hypothesis that diaspirin cross-linked hemoglobin (DCLHb; Baxter 
      Healthcare Corp.) would improve blood pressure, organ perfusion, and mortality 
      during sepsis. Rats were catheterized to assess general hemodynamics (protocol 1) 
      or regional blood flow (protocol 2). Sepsis was induced by intraperitoneal 
      introduction of a cecal slurry (100 mg/kg). In protocol 1, rats received either 
      100 or 250 mg/kg DCLHb, or albumin at 1, 2, or 4 h after sepsis induction. 
      Hemodynamics were recorded at these times and daily for 72 h. DCLHb increased 
      blood pressure, prevented 72 h leukocytosis, and reduced mortality, but the 
      timing of DCLHb administration was crucial. In protocol 2 only moribund septic 
      animals received 100 mg/kg DCLHb or iso-oncotic albumin i.v. Hemodynamics and 
      regional organ blood flows were measured at baseline, immediately before and 
      after treatment, and at 24 h. DCLHb immediately increased blood pressure with no 
      changes in cardiac output, heart rate, or regional perfusion. DCLHb increased 
      regional perfusion to vital areas at 24 h (compared to albumin group). 
      Distribution of cardiac output in albumin-treated rats was significantly skewed 
      toward skeletal muscle at a time when cardiac output was significantly lower as 
      compared with DCLHb treated animals. In conclusion, DCLHb safely elicited a 
      pressor response, and improved regional perfusion to selected tissues. However, 
      DCLHb benefits were best obtained when given within a specific time frame.
FAU - Mourelatos, M G
AU  - Mourelatos MG
AD  - Department of Surgery, University of Illinois at Chicago 60612, USA.
FAU - Enzer, N
AU  - Enzer N
FAU - Ferguson, J L
AU  - Ferguson JL
FAU - Rypins, E B
AU  - Rypins EB
FAU - Burhop, K E
AU  - Burhop KE
FAU - Law, W R
AU  - Law WR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Shock
JT  - Shock (Augusta, Ga.)
JID - 9421564
RN  - 0 (Albumins)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Albumins/administration & dosage
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Pressure/drug effects
MH  - Hemodynamics/*drug effects
MH  - Hemoglobins/*pharmacology
MH  - Infusions, Intravenous
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/drug effects
MH  - Shock, Septic/mortality/physiopathology/*therapy
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - 10.1097/00024382-199602000-00010 [doi]
PST - ppublish
SO  - Shock. 1996 Feb;5(2):141-8. doi: 10.1097/00024382-199602000-00010.

PMID- 19880273
OWN - NLM
STAT- MEDLINE
DCOM- 20100504
LR  - 20181201
IS  - 2213-0276 (Electronic)
IS  - 0755-4982 (Linking)
VI  - 39
IP  - 4
DP  - 2010 Apr
TI  - [Long-term use of oral antiplatelet therapy: from studies to practice].
PG  - 413-9
LID - 10.1016/j.lpm.2009.07.023 [doi]
AB  - Antiplatelet treatment (platelet aggregation inhibitors) is essential in 
      cardiovascular medicine today. Aspirin and, more recently, clopidogrel are among 
      the most important treatments of cardiovascular diseases. Although the 
      benefit/risk ratio is generally favorable as secondary prevention, and justifies 
      the treatment, it is less so in primary prevention and indeed, sometimes 
      difficult to establish. Although the combination of two treatments seems 
      attractive, it has been shown effective only for some indications. The principal 
      risk of an antiplatelet treatment that inhibits clotting is bleeding, and the 
      risk almost doubles when two treatments are combined. New platelet aggregation 
      inhibitors, undoubtedly more efficacious, but also more likely to induce 
      bleedings, will probably emerge.
CI  - (c) 2009 Elsevier Masson SAS. All rights reserved.
FAU - Helft, Gérard
AU  - Helft G
AD  - Service de cardiologie, Hôpital Pitié-Salpêtrière, Paris Cedex 13, F-75651, 
      France. gerard.helft@psl.aphp.fr
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Utilisation des anti-agrégants plaquettaires oraux au long cours: des études à la 
      pratique.
DEP - 20091031
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Drug Combinations)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/drug therapy/prevention & control
MH  - Clopidogrel
MH  - Drug Combinations
MH  - Fibrinolytic Agents/therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & 
      derivatives/therapeutic use
RF  - 15
EDAT- 2009/11/03 06:00
MHDA- 2010/05/05 06:00
CRDT- 2009/11/03 06:00
PHST- 2009/06/08 00:00 [received]
PHST- 2009/06/22 00:00 [revised]
PHST- 2009/07/20 00:00 [accepted]
PHST- 2009/11/03 06:00 [entrez]
PHST- 2009/11/03 06:00 [pubmed]
PHST- 2010/05/05 06:00 [medline]
AID - S0755-4982(09)00434-5 [pii]
AID - 10.1016/j.lpm.2009.07.023 [doi]
PST - ppublish
SO  - Presse Med. 2010 Apr;39(4):413-9. doi: 10.1016/j.lpm.2009.07.023. Epub 2009 Oct 
      31.

PMID- 4722040
OWN - NLM
STAT- MEDLINE
DCOM- 19731005
LR  - 20190511
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 47
IP  - 2
DP  - 1973 Feb
TI  - Delayed manifestation of ultraviolet reaction in the guinea-pig caused by 
      anti-inflammatory drugs.
PG  - 240-8
AB  - 1. Exposure of depilated skin of guinea-pig to ultraviolet (u.v.) light for 20 s 
      produces a prolonged inflammatory response.2. The erythaema becomes evident 
      within 15-30 min after the exposure and progressively increases in intensity 
      reaching its maximum by 4-6 hours. The erythaema persists over 24 hours.3. 
      Increase in vascular permeability is biphasic with an early short-lived rise 
      peaking at 0.5 h and a prolonged secondary response peaking at 9-12 h and lasting 
      over 48 hours.4. In presence of aspirin, phenylbutazone and indomethacin, 
      administered prior to u.v. exposure, the inflammatory reaction is partially 
      suppressed, depending upon the dose. The drugs are ineffective in aborting or 
      minimizing the response when given after the inflammation is established. 
      Corticosteroids fail to influence the u.v. inflammation in this test. The 
      significance of these findings is discussed.
FAU - Gupta, N
AU  - Gupta N
FAU - Levy, L
AU  - Levy L
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Anti-Inflammatory Agents)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Body Weight
MH  - Erythema/prevention & control
MH  - Guinea Pigs
MH  - Indomethacin/administration & dosage/pharmacology/therapeutic use
MH  - Permeability
MH  - Phenylbutazone/administration & dosage/pharmacology/therapeutic use
MH  - Prednisolone/administration & dosage/pharmacology/therapeutic use
MH  - Radiation Effects
MH  - Skin/drug effects/*radiation effects
MH  - Skin Absorption/drug effects/radiation effects
MH  - Time Factors
MH  - *Ultraviolet Rays
PMC - PMC1776544
EDAT- 1973/02/01 00:00
MHDA- 1973/02/01 00:01
CRDT- 1973/02/01 00:00
PHST- 1973/02/01 00:00 [pubmed]
PHST- 1973/02/01 00:01 [medline]
PHST- 1973/02/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1973.tb08321.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1973 Feb;47(2):240-8. doi: 10.1111/j.1476-5381.1973.tb08321.x.

PMID- 25734355
OWN - NLM
STAT- MEDLINE
DCOM- 20160630
LR  - 20220318
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 26
IP  - 8
DP  - 2015
TI  - Arachidonic acid-stimulated platelet tests: Identification of patients less 
      sensitive to aspirin treatment.
PG  - 783-7
LID - 10.3109/09537104.2014.1003291 [doi]
AB  - Serum thromboxane-B2 (TxB2), together with arachidonic acid (AA)-induced platelet 
      aggregation, are, at the moment, the most used tests to identify patients 
      displaying high on-aspirin treatment platelet reactivity (HAPR). Both tests are 
      specific for aspirin action on cyclooxygenase-1. While the correlation between 
      serum TxB2 assay and clinical outcome is established, data are conflicting with 
      regard to aspirin treatment and a possible association with AA-stimulated 
      platelet markers and clinical outcome. To understand such discrepancy, we 
      performed a retrospective study to compare both assays. We collected data from 
      132 patients receiving a daily dose of aspirin (100 mg/day) and data from 48 
      patients receiving aspirin on alternate days. All Patients who received a daily 
      dose of aspirin were studied for AA-induced platelet aggregation together with 
      serum TxB2 levels and AA-induced TxB2 formation was also studied in 71 patients 
      out of entire population. Consistent with recommendations in the literature, we 
      defined HAPR by setting a cut-off point at 3.1 ng/ml for serum levels of 
      thromboxane B2 and 20% for AA-induced platelet aggregation. According to this 
      cut-off point, we divided our overall population into two groups: (1) TxB2 < 3.1 
      ng/ml and (2) TxB2 > 3.1 ng/ml. We found low agreement between such tests to 
      identify patients displaying HAPR. Our results show that AA-induced platelet 
      aggregation >20% identify a smaller number of HAPR patients in comparison with 
      TxB2. A good correlation between serum TxB2 and arachidonic acid-induced TxB2 
      production was found (r = 0.76619).
FAU - Temperilli, Flavia
AU  - Temperilli F
AD  - a Department of Experimental Medicine , "Sapienza" University of Rome , Rome , 
      Italy.
FAU - Rina, Aldona
AU  - Rina A
AD  - a Department of Experimental Medicine , "Sapienza" University of Rome , Rome , 
      Italy.
FAU - Massimi, Isabella
AU  - Massimi I
AD  - a Department of Experimental Medicine , "Sapienza" University of Rome , Rome , 
      Italy.
FAU - Montemari, Anna Lisa
AU  - Montemari AL
AD  - a Department of Experimental Medicine , "Sapienza" University of Rome , Rome , 
      Italy.
FAU - Guarino, Maria Luisa
AU  - Guarino ML
AD  - a Department of Experimental Medicine , "Sapienza" University of Rome , Rome , 
      Italy.
FAU - Zicari, Alessandra
AU  - Zicari A
AD  - a Department of Experimental Medicine , "Sapienza" University of Rome , Rome , 
      Italy.
FAU - Pulcinelli, Fabio M
AU  - Pulcinelli FM
AD  - a Department of Experimental Medicine , "Sapienza" University of Rome , Rome , 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150303
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid/*pharmacology
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/*metabolism
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - *Platelet Function Tests
MH  - Retrospective Studies
MH  - Thromboxane B2/blood/metabolism
OTO - NOTNLM
OT  - Arachidonic acid
OT  - COX-1
OT  - aspirin
OT  - platelet aggregation
OT  - thromboxane B2
EDAT- 2015/03/04 06:00
MHDA- 2016/07/01 06:00
CRDT- 2015/03/04 06:00
PHST- 2015/03/04 06:00 [entrez]
PHST- 2015/03/04 06:00 [pubmed]
PHST- 2016/07/01 06:00 [medline]
AID - 10.3109/09537104.2014.1003291 [doi]
PST - ppublish
SO  - Platelets. 2015;26(8):783-7. doi: 10.3109/09537104.2014.1003291. Epub 2015 Mar 3.

PMID- 9531251
OWN - NLM
STAT- MEDLINE
DCOM- 19980408
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 97
IP  - 11
DP  - 1998 Mar 24
TI  - Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination 
      after stent implantation.
PG  - 1046-52
AB  - BACKGROUND: This study was performed to analyze the influence of either aspirin, 
      ticlopidine, or their combination on platelet activation and aggregation 
      parameters after stent implantation. METHODS AND RESULTS: Sixty-one patients with 
      successful implantation of a single Palmaz-Schatz stent in a native coronary 
      artery were randomly assigned to either group A (aspirin 300 mg/d+ticlopidine 
      2X250 mg/d), group B (ticlopidine 2X250 mg/d), or group C (aspirin 300 mg/d). 
      Platelet activation was evaluated on days 1, 7, and 14 by flow cytometry 
      measurement of expression of CD62p (p-selectin) and the binding of fibrinogen to 
      the platelet surface glycoprotein IIb/IIIa receptor. Platelet aggregation was 
      induced by addition of ADP or collagen. Differences between treatment groups were 
      compared by ANOVA. Between days 1 and 14, we observed a significant decrease in 
      collagen-induced platelet aggregation in group A (62.2+/-2.5% versus 
      36.9+/-3.1%), whereas an increase was seen in group B (58.3+/-2.5% versus 
      67.7+/-3.2%) and no change was seen in group C (P<.0001). The ADP-induced 
      aggregation declined significantly in group A (74.7+/-1.4% versus 55.3+/-2.6%), 
      whereas a delayed reduction was seen in group B (72.0+/-3.0% versus 52.6+/-4.2%) 
      and no change was seen in group C (P=.0017). The CD62p expression declined 
      significantly in groups A (68.2+/-2.7% versus 41.3+/-2.7%) and B (64.8+/-2.9% 
      versus 39.3+/-3.5%) but not in group C (P<.0001). Moreover, the fibrinogen 
      binding decreased significantly in group A (61.0+/-4.3% versus 36.3+/-4.2%) and 
      with delay in group B (58.3+/-2.2% versus 39.4+/-3.0%), whereas no alterations 
      were seen in group C (P=.012). CONCLUSIONS: Our results demonstrate synergistic 
      and accelerated platelet inhibitory effects of ticlopidine plus aspirin in 
      patients after stent implantation compared with a monotherapy with either 
      ticlopidine or aspirin alone.
FAU - Rupprecht, H J
AU  - Rupprecht HJ
AD  - Department of Medicine II, Johannes Gutenberg University, Mainz, Germany.
FAU - Darius, H
AU  - Darius H
FAU - Borkowski, U
AU  - Borkowski U
FAU - Voigtländer, T
AU  - Voigtländer T
FAU - Nowak, B
AU  - Nowak B
FAU - Genth, S
AU  - Genth S
FAU - Meyer, J
AU  - Meyer J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 9001-32-5 (Fibrinogen)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Coronary Disease/therapy
MH  - Drug Therapy, Combination
MH  - Fibrinogen/metabolism
MH  - Humans
MH  - P-Selectin/analysis
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/metabolism
MH  - *Stents
MH  - Ticlopidine/pharmacology/*therapeutic use
MH  - Time Factors
EDAT- 1998/04/08 00:00
MHDA- 1998/04/08 00:01
CRDT- 1998/04/08 00:00
PHST- 1998/04/08 00:00 [pubmed]
PHST- 1998/04/08 00:01 [medline]
PHST- 1998/04/08 00:00 [entrez]
AID - 10.1161/01.cir.97.11.1046 [doi]
PST - ppublish
SO  - Circulation. 1998 Mar 24;97(11):1046-52. doi: 10.1161/01.cir.97.11.1046.

PMID- 10694241
OWN - NLM
STAT- MEDLINE
DCOM- 20000424
LR  - 20181113
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 129
IP  - 2
DP  - 2000 Jan
TI  - A comparison of the anti-inflammatory and anti-nociceptive activity of 
      nitroaspirin and aspirin.
PG  - 343-50
AB  - 1. Nitroaspirin (2.5 - 50 mg kg(-1), i.p. or 2.5 - 100 mg kg(-1), p.o.) and 
      aspirin (2.5 - 100 mg kg(-1), i.p. or p.o.) exhibit anti-inflammatory activity in 
      the carrageenan-induced hindpaw oedema model in the rat. When administered i.p., 
      nitroaspirin was a more effective anti-oedema agent than aspirin particularly in 
      the 'early' phase (i.e. up to 60 min) of the response. The ED(50) values for 
      nitroaspirin and aspirin as inhibitors of the 'late' phase response (measured at 
      180 min) were 64.3 micromol kg(-1) and >555 micromol kg(-1), respectively. When 
      administered p.o., neither nitroaspirin nor aspirin exhibited significant 
      anti-inflammatory activity in the 'early' phase and were of similar potency in 
      the 'late' phase. Thus, at the highest dose used (100 mg kg(-1), 360 min) orally 
      administered nitroaspirin (aspirin in parenthesis) inhibited oedema formation by 
      46.9+/-1.6% (47.2+/-3.8%, both n=6, P<0.05). 2. Nitroaspirin and aspirin (25 - 
      200 mg kg(-1), p.o.) caused dose-related inhibition of the hyperalgesia to 
      mechanical stimulation following intraplantar injection of carrageenan in the 
      rat. ED(50) values were 365 micromol kg(-1) and 784 micromol kg(-1), 
      respectively. Neither drug influenced the threshold for mechanical stimulation in 
      the contralateral (i.e. untreated) hindpaw. 3. Nitroaspirin and aspirin (2.5 - 
      100 mg kg(-1), p.o.) caused dose-related inhibition of acetic acid induced 
      abdominal constrictions in the mouse (ED(50) values of 154.7 micromol kg(-1) and 
      242.8 micromol kg(-1), respectively). 4. Nitroaspirin and aspirin (>200 mg 
      kg(-1), p.o.) reduced the 'late' phase (but not the 'early' phase) of the 
      formalin-induced hindpaw licking assay in the mouse. Similarly, nitroaspirin and 
      aspirin (>50 mg kg(-1), p.o.) prolonged tail withdrawal latency following 
      application of a noxious heat stimulus in the mouse.
FAU - al-Swayeh, O A
AU  - al-Swayeh OA
AD  - Department of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.
FAU - Clifford, R H
AU  - Clifford RH
FAU - del Soldato, P
AU  - del Soldato P
FAU - Moore, P K
AU  - Moore PK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 1HG84L3525 (Formaldehyde)
RN  - 9000-07-1 (Carrageenan)
RN  - EH04H13L6B (nitroaspirin)
RN  - Q40Q9N063P (Acetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetic Acid
MH  - Analgesics, Non-Narcotic/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Carrageenan
MH  - Edema/chemically induced/prevention & control
MH  - Formaldehyde
MH  - Hyperalgesia/chemically induced/prevention & control
MH  - Male
MH  - Mice
MH  - Pain Measurement/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Reaction Time/drug effects
PMC - PMC1571848
EDAT- 2000/02/29 09:00
MHDA- 2000/04/29 09:00
CRDT- 2000/02/29 09:00
PHST- 2000/02/29 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/02/29 09:00 [entrez]
AID - 0703064 [pii]
AID - 10.1038/sj.bjp.0703064 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2000 Jan;129(2):343-50. doi: 10.1038/sj.bjp.0703064.

PMID- 30642844
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20221207
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
VI  - 28
IP  - 4
DP  - 2019 Apr
TI  - Aspirin Does Not Prevent Pancreatic Cancer in a Large Asian Cohort.
PG  - 826-828
LID - 10.1158/1055-9965.EPI-18-1325 [doi]
AB  - BACKGROUND: Evidence has suggested that aspirin reduces the incidence of several 
      cancers, but these benefits may not occur with pancreatic cancer. METHODS: A 
      12-year nationwide longitudinal cohort merged with the health checkup data was 
      divided into "exposure ascertainment period" and "outcome ascertainment period" 
      to avoid immortal time bias. The daily defined dose system was used to indicate 
      the drug exposure. RESULTS: We found no significant association between aspirin 
      use and incident pancreatic cancer based on HR. CONCLUSIONS: Aspirin does not 
      prevent pancreatic cancer. IMPACT: A large Asian cohort study with reliable 
      medication information affirms no impact of aspirin on pancreatic cancer 
      development.
CI  - ©2019 American Association for Cancer Research.
FAU - Kim, Min-Hyung
AU  - Kim MH
AUID- ORCID: 0000-0002-0072-2631
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul, South Korea.
AD  - Department of Family Medicine, Gil Medical Center, Gachon University College of 
      Medicine, Incheon, South Korea.
FAU - Park, Sang Min
AU  - Park SM
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul, South Korea.
AD  - Department of Family Medicine, Gil Medical Center, Gachon University College of 
      Medicine, Incheon, South Korea.
FAU - Yun, Young Ho
AU  - Yun YH
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul, South Korea.
AD  - Department of Family Medicine, Gil Medical Center, Gachon University College of 
      Medicine, Incheon, South Korea.
FAU - Hwang, In Cheol
AU  - Hwang IC
AUID- ORCID: 0000-0003-4677-5525
AD  - Department of Family Medicine, Gil Medical Center, Gachon University College of 
      Medicine, Incheon, South Korea. spfe0211@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20190114
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*metabolism
MH  - Asian People
MH  - Aspirin/administration & dosage/*metabolism
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Pancreatic Neoplasms/epidemiology/*prevention & control
EDAT- 2019/01/16 06:00
MHDA- 2020/06/04 06:00
CRDT- 2019/01/16 06:00
PHST- 2018/12/07 00:00 [received]
PHST- 2019/01/07 00:00 [revised]
PHST- 2019/01/10 00:00 [accepted]
PHST- 2019/01/16 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
PHST- 2019/01/16 06:00 [entrez]
AID - 1055-9965.EPI-18-1325 [pii]
AID - 10.1158/1055-9965.EPI-18-1325 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):826-828. doi: 
      10.1158/1055-9965.EPI-18-1325. Epub 2019 Jan 14.

PMID- 18615289
OWN - NLM
STAT- MEDLINE
DCOM- 20090326
LR  - 20191110
IS  - 1464-5246 (Electronic)
IS  - 0265-2048 (Linking)
VI  - 26
IP  - 2
DP  - 2009 Mar
TI  - Effect of alginate-pectin composition on drug release characteristics of 
      microcapsules.
PG  - 143-53
LID - 10.1080/02652040802211345 [doi]
AB  - Microencapsulation of model drug, acetylsalicylic acid into bio-based polymer, 
      alginate-pectin matrix has been undertaken in this work to characterize the 
      microcapsules based on their composition. Different proportions of the 
      alginate-pectin solutions prepared with drug were homogenized and atomized using 
      nitrogen gas into 1.0 M calcium chloride solution to form sol-gel microcapsules. 
      Drug loaded microcapsules were dried using microwave energy under vacuum at low 
      temperature. Average particle size of the microcapsules was found to be 90 
      micron. Scanning electron microscopy graphs and Fourier Transform Infrared 
      Spectroscopy analysis on the microcapsules confirm the presence of drug in the 
      polymer matrix. X-ray diffraction pattern showed that the microstructure was more 
      like an amorphous pattern. Drug release of the microcapsules was tested in three 
      different pH levels of 1.2, 7.4 and 8.2. Slow and controlled release of drug was 
      observed at all the pH levels. Increase in pectin increased the drug release and 
      also the release was more in acidic pH (1.2) as 75.6% for alginate: pectin-20:80.
FAU - Jaya, S
AU  - Jaya S
AD  - Faculty of Land and Food Systems, University of British Columbia, Vancouver, BC, 
      Canada. jayas@interchange.ubc.ca
FAU - Durance, T D
AU  - Durance TD
FAU - Wang, R
AU  - Wang R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Alginates)
RN  - 0 (Capsules)
RN  - 0 (Drug Carriers)
RN  - 0 (Hexuronic Acids)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Polymers)
RN  - 89NA02M4RX (Pectins)
RN  - 8A5D83Q4RW (Glucuronic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alginates/*chemistry
MH  - Aspirin/administration & dosage/chemistry
MH  - Capsules/*chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - Drug Carriers/chemistry
MH  - Drug Compounding/methods
MH  - *Drug Delivery Systems
MH  - Glucuronic Acid/chemistry
MH  - Hexuronic Acids/chemistry
MH  - Microscopy, Electron, Scanning
MH  - Microwaves
MH  - Pectins/*chemistry
MH  - Pharmaceutical Preparations
MH  - Polymers/chemistry
MH  - Solubility
MH  - Spectroscopy, Fourier Transform Infrared
MH  - X-Ray Diffraction
EDAT- 2008/07/11 09:00
MHDA- 2009/03/27 09:00
CRDT- 2008/07/11 09:00
PHST- 2008/07/11 09:00 [pubmed]
PHST- 2009/03/27 09:00 [medline]
PHST- 2008/07/11 09:00 [entrez]
AID - 794859966 [pii]
AID - 10.1080/02652040802211345 [doi]
PST - ppublish
SO  - J Microencapsul. 2009 Mar;26(2):143-53. doi: 10.1080/02652040802211345.

PMID- 21436383
OWN - NLM
STAT- MEDLINE
DCOM- 20110927
LR  - 20211020
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 4
IP  - 5
DP  - 2011 May
TI  - Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch 
      syndrome mouse model.
PG  - 684-93
LID - 10.1158/1940-6207.CAPR-10-0319 [doi]
AB  - Nonsteroidal anti-inflammatory drugs (NSAID) appear to be effective cancer 
      chemopreventives. Previous cellular studies showed that aspirin (acetylsalicylic 
      acid: ASA) and nitric oxide-donating ASA (NO-ASA) suppressed microsatellite 
      instability (MSI) in mismatch repair (MMR)-deficient cells linked to the common 
      cancer predisposition syndrome hereditary nonpolyposis colorectal cancer or Lynch 
      syndrome (LS/HNPCC), at doses 300- to 3,000-fold less than ASA. Using a mouse 
      model that develops MMR-deficient intestinal tumors that appear pathologically 
      identical to LS/HNPCC, we show that ASA (400 mg/kg) and low-dose NO-ASA (72 
      mg/kg) increased life span by 18% to 21%. We also note a trend where ASA 
      treatment resulted in intestinal tumors with reduced high MSI (H-MSI) and 
      increased low MSI (L-MSI) as defined by the Bethesda Criteria. Low-dose NO-ASA 
      had a minimal effect on MSI status. In contrast to previous studies, high-dose 
      NO-ASA (720/1,500 mg/kg) treatments increased tumor burden, decreased life span, 
      and exacerbated MSI uniquely in the LS/HNPCC mouse model. These results suggest 
      that MMR-deficient tissues/mice may be specifically sensitive to intrinsic 
      pharmacokinetic features of this drug. It is likely that long-term treatment with 
      ASA may represent a chemopreventive option for LS/HNPCC patients. Moreover, as 
      low-dose NO-ASA shows equivalent life span increase at 10-fold lower doses than 
      ASA, it may have the potential to significantly reduce the gastropathy associated 
      with long-term ASA treatment.
FAU - McIlhatton, Michael A
AU  - McIlhatton MA
AD  - Department of Molecular Virology, Immunology & Medical Genetics, Ohio State 
      University, Columbus, OH 43210, USA.
FAU - Tyler, Jessica
AU  - Tyler J
FAU - Kerepesi, Laura A
AU  - Kerepesi LA
FAU - Bocker-Edmonston, Tina
AU  - Bocker-Edmonston T
FAU - Kucherlapati, Melanie H
AU  - Kucherlapati MH
FAU - Edelmann, Winfried
AU  - Edelmann W
FAU - Kucherlapati, Raju
AU  - Kucherlapati R
FAU - Kopelovich, Levy
AU  - Kopelovich L
FAU - Fishel, Richard
AU  - Fishel R
LA  - eng
GR  - N01CN43302/CA/NCI NIH HHS/United States
GR  - R01 CA067007/CA/NCI NIH HHS/United States
GR  - CN43302/CN/NCI NIH HHS/United States
GR  - CA67007/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20110324
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*analogs & derivatives/*therapeutic use
MH  - Base Pair Mismatch/drug effects
MH  - Colorectal Neoplasms, Hereditary Nonpolyposis/*drug therapy
MH  - DNA Repair
MH  - *Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Longevity/*drug effects
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Microsatellite Instability
MH  - Nitric Oxide/*metabolism
MH  - Survival Rate
PMC - PMC3991477
MID - NIHMS279678
EDAT- 2011/03/26 06:00
MHDA- 2011/09/29 06:00
CRDT- 2011/03/26 06:00
PHST- 2011/03/26 06:00 [entrez]
PHST- 2011/03/26 06:00 [pubmed]
PHST- 2011/09/29 06:00 [medline]
AID - 1940-6207.CAPR-10-0319 [pii]
AID - 10.1158/1940-6207.CAPR-10-0319 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2011 May;4(5):684-93. doi: 
      10.1158/1940-6207.CAPR-10-0319. Epub 2011 Mar 24.

PMID- 2929496
OWN - NLM
STAT- MEDLINE
DCOM- 19890503
LR  - 20190510
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 91
IP  - 4
DP  - 1989 Apr
TI  - An in vitro bleeding time test.
PG  - 422-9
AB  - A new conical plastic device and method, the Platelet-Stat test, has been 
      developed to measure in vitro bleeding time. Ten milliliters of citrated blood, 
      collected by venipuncture, was used. The in vitro bleeding time test was 
      validated by several criteria. Eight volunteers tested had a mean bleeding time 
      of less than 1 minute. Different anticoagulants were evaluated, and the test 
      performed optimally with citrate. Within-run precision had a mean time of 39 +/- 
      6.7 seconds with a coefficient of variation of 17%. An aspirin study was done on 
      eight volunteers. Preaspirin in vitro bleeding time was less than 1 minute, 
      whereas postaspirin times were more than 7 minutes at 18-24 hours. This test is a 
      reproducible method of performing the bleeding time with greater precision than 
      the in vivo test.
FAU - Brubaker, D B
AU  - Brubaker DB
AD  - Department of Pathology, Harbor-UCLA Medical Center, Torrance 90509.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants
MH  - Aspirin/pharmacology
MH  - Bleeding Time
MH  - Female
MH  - Humans
MH  - Male
MH  - Microscopy, Electron
MH  - Platelet Aggregation
MH  - Platelet Function Tests/instrumentation/*methods
EDAT- 1989/04/01 00:00
MHDA- 1989/04/01 00:01
CRDT- 1989/04/01 00:00
PHST- 1989/04/01 00:00 [pubmed]
PHST- 1989/04/01 00:01 [medline]
PHST- 1989/04/01 00:00 [entrez]
AID - 10.1093/ajcp/91.4.422 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1989 Apr;91(4):422-9. doi: 10.1093/ajcp/91.4.422.

PMID- 23839768
OWN - NLM
STAT- MEDLINE
DCOM- 20131220
LR  - 20211021
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 2013
IP  - 7
DP  - 2013 Jul 9
TI  - Antiplatelet and anticoagulation for patients with prosthetic heart valves.
PG  - CD003464
LID - 10.1002/14651858.CD003464.pub2 [doi]
LID - CD003464
AB  - BACKGROUND: Patients with prosthetic heart valves are at increased risk for valve 
      thrombosis and arterial thromboembolism. Oral anticoagulation alone, or the 
      addition of antiplatelet drugs, has been used to minimise this risk. An important 
      issue is the effectiveness and safety of the latter strategy. OBJECTIVES: This is 
      an update of our previous review; the goal was to create a valid synthesis of all 
      available, methodologically sound data to further assess the safety and efficacy 
      of combined oral anticoagulant and antiplatelet therapy versus oral anticoagulant 
      monotherapy in patients with prosthetic heart valves. SEARCH METHODS: We updated 
      the previous searches from 2003 and 2010 on 16 January 2013 and searched the 
      Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library 
      (2012, Issue 12), MEDLINE (OVID, 1946 to January Week 1 2013), and EMBASE (OVID, 
      1980 to 2013 Week 02). We have also looked at reference lists of individual 
      reports, review articles, meta-analyses, and consensus statements. We included 
      reports published in any language or in abstract form. SELECTION CRITERIA: All 
      reports of randomised controlled trials comparing standard-dose oral 
      anticoagulation to standard-dose oral anticoagulation and antiplatelet therapy in 
      patients with one or more prosthetic heart valves. DATA COLLECTION AND ANALYSIS: 
      Two review authors independently performed the search strategy, assessed trials 
      for inclusion and study quality, and extracted data. We collected adverse effects 
      information from the trials. MAIN RESULTS: One new study has been identified and 
      included in this update. In total, 13 studies involving 4122 participants were 
      included in this review update. Years of publication ranged from 1971 to 2011. 
      Compared with anticoagulation alone, the addition of an antiplatelet agent 
      reduced the risk of thromboembolic events (odds ratio (OR) 0.43, 95% confidence 
      interval (CI) 0.32 to 0.59; P < 0.00001) and total mortality (OR 0.57, 95% CI 
      0.42 to 0.78; P = 0.0004). Aspirin and dipyridamole reduced these events 
      similarly. The risk of major bleeding was increased when antiplatelet agents were 
      added to oral anticoagulants (OR 1.58, 95% CI 1.14 to 2.18; P = 0.006).For major 
      bleeding, there was no evidence of heterogeneity between aspirin and dipyridamole 
      and in the comparison of trials performed before and after 1990, around the time 
      when anticoagulation standardisation with the international normalised ratio was 
      being implemented. A lower daily dose of aspirin (< 100 mg) may be associated 
      with a lower major bleeding risk than higher doses. AUTHORS' CONCLUSIONS: Adding 
      antiplatelet therapy, either dipyridamole or low-dose aspirin, to oral 
      anticoagulation decreases the risk of systemic embolism or death among patients 
      with prosthetic heart valves. The risk of major bleeding is increased with 
      antiplatelet therapy. These results apply to patients with mechanical prosthetic 
      valves or those with biological valves and indicators of high risk such as atrial 
      fibrillation or prior thromboembolic events. The effectiveness and safety of 
      low-dose aspirin (100 mg daily) appears to be similar to higher-dose aspirin and 
      dipyridamole. In general, the quality of the included trials tended to be low, 
      possibly reflecting the era when the majority of the trials were conducted (1970s 
      and 1980s when trial methodology was less advanced).
FAU - Massel, David R
AU  - Massel DR
AD  - Cardiology, London Health Sciences Centre, London, 
      Canada.david.massel@lhsc.on.ca.
FAU - Little, Stephen H
AU  - Little SH
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20130709
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2003;(4):CD003464. PMID: 14583979
MH  - Administration, Oral
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Dipyridamole/adverse effects/therapeutic use
MH  - Drug Therapy, Combination/methods
MH  - Heart Valve Prosthesis/*adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Thromboembolism/*prevention & control
PMC - PMC8094423
COIS- None known.
EDAT- 2013/07/11 06:00
MHDA- 2013/12/21 06:00
CRDT- 2013/07/11 06:00
PHST- 2013/07/11 06:00 [entrez]
PHST- 2013/07/11 06:00 [pubmed]
PHST- 2013/12/21 06:00 [medline]
AID - CD003464.pub2 [pii]
AID - 10.1002/14651858.CD003464.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2013 Jul 9;2013(7):CD003464. doi: 
      10.1002/14651858.CD003464.pub2.

PMID- 27055051
OWN - NLM
STAT- MEDLINE
DCOM- 20170210
LR  - 20181202
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 12
IP  - 6
DP  - 2016 Jun
TI  - The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
PG  - 615-32
LID - 10.1080/17425255.2016.1176141 [doi]
AB  - INTRODUCTION: As it is importance to understand the involvement of platelets in 
      the initiation and propagation of thrombosis, antiplatelet drugs have come to the 
      forefront of atherothrombotic disease treatment. Dual antiplatelet therapy of 
      aspirin plus clopidogrel has its benefits, but it also has its limitations with 
      regard to its pharmacologic properties and adverse effects. For these reasons, 
      within the last decade or so, the investigation of novel antiplatelet agents has 
      prospered. AREAS COVERED: In this review, we discuss the unique pharmacodynamic 
      properties of several antiplatelet drugs with their possible potential molecular 
      of mechanisms on inhibiting platelet aggregation. EXPERT OPINION: Considering 
      multiple synergetic pathways of platelet activation and their close interplay 
      with coagulation, the current treatment strategies are not only based on platelet 
      inhibition, they also rely on the attenuation of procoagulant activity, 
      inhibition of thrombin generation, and enhancement of clot dissolution. Current 
      guidelines recommend various antiplatelet agents in addition to aspirin for 
      patients with acute coronary syndromes. The advantages of these agents, as repute 
      mortality, may be associated with off-target effects of the drug. Hence, further 
      studies are required to facilitate the physician's choice of the most appropriate 
      antiplatelet agents for each patient for thrombosis treatment.
FAU - Jayakumar, Thanasekaran
AU  - Jayakumar T
AD  - a Graduate Institute of Medical Sciences, Taipei Medical University , Taipei , 
      Taiwan.
AD  - b Department of Pharmacology , Taipei Medical University , Taipei , Taiwan.
AD  - c College of Medicine, Taipei Medical University , Taipei , Taiwan.
FAU - Yang, Chih-Hao
AU  - Yang CH
AD  - b Department of Pharmacology , Taipei Medical University , Taipei , Taiwan.
FAU - Geraldine, Pitchairaj
AU  - Geraldine P
AD  - d Department of Animal Science , School of Life Sciences, Bharathidasan 
      University , Tiruchirappalli , India.
FAU - Yen, Ting-Lin
AU  - Yen TL
AD  - a Graduate Institute of Medical Sciences, Taipei Medical University , Taipei , 
      Taiwan.
FAU - Sheu, Joen-Rong
AU  - Sheu JR
AD  - a Graduate Institute of Medical Sciences, Taipei Medical University , Taipei , 
      Taiwan.
AD  - b Department of Pharmacology , Taipei Medical University , Taipei , Taiwan.
AD  - c College of Medicine, Taipei Medical University , Taipei , Taiwan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160426
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):521. PMID: 31037977
MH  - Acute Coronary Syndrome/drug therapy
MH  - Animals
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Blood Platelets/drug effects/metabolism
MH  - Clopidogrel
MH  - *Drug Design
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Thrombosis/*drug therapy
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & 
      derivatives/therapeutic use
OTO - NOTNLM
OT  - Antiplatelets
OT  - antithrombotic
OT  - multi-targets
OT  - pharmacodynamics
EDAT- 2016/04/08 06:00
MHDA- 2017/02/12 06:00
CRDT- 2016/04/08 06:00
PHST- 2016/04/08 06:00 [entrez]
PHST- 2016/04/08 06:00 [pubmed]
PHST- 2017/02/12 06:00 [medline]
AID - 10.1080/17425255.2016.1176141 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2016 Jun;12(6):615-32. doi: 
      10.1080/17425255.2016.1176141. Epub 2016 Apr 26.

PMID- 18941611
OWN - NLM
STAT- MEDLINE
DCOM- 20090109
LR  - 20181201
IS  - 0730-2347 (Print)
IS  - 1526-6702 (Electronic)
IS  - 0730-2347 (Linking)
VI  - 35
IP  - 3
DP  - 2008
TI  - Aspirin and clopidogrel response variability: review of the published literature.
PG  - 313-20
AB  - Antiplatelet resistance has been proposed as a possible mechanism to explain 
      recurrent cardiovascular events in patients who have coronary artery disease and 
      who are undergoing dual antiplatelet therapy. A comprehensive search on PubMed 
      was conducted for literature that was printed in the English language between 
      January 1996 and November 2007 on aspirin and clopidogrel resistance. Significant 
      traits for aspirin hyporesponsiveness were female sex, older age, and lower 
      levels of hemoglobin. Diabetes mellitus and elevated body mass index showed 
      trends toward a higher incidence of resistance in some aspirin trials but did not 
      reach statistical significance. Clopidogrel studies suggested that patients with 
      type-2 diabetes mellitus are more likely to manifest inadequate response to the 
      medication. Although 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
      inhibitors were initially suspected to decrease response to clopidogrel, later 
      studies refuted this possibility. Patients with a suboptimal response to aspirin 
      or clopidogrel seem to be at increased risk of recurrent cardiovascular events. 
      Large clinical trials with standardized laboratory methods and well-defined 
      protocols are needed to determine whether common features exist in patients with 
      suspected hyporesponsiveness to antiplatelet therapy, and to validate the 
      clinical relevance of response variability. A concise nonarbitrary definition of 
      physiologic "resistance" is needed, and investigators should identify patients as 
      having a variable response to antiplatelet therapy.
FAU - Ferguson, Angela D
AU  - Ferguson AD
AD  - Department of Medicine, Section of Cardiology, Baylor College of Medicine, 
      Houston, Texas 77030, USA.
FAU - Dokainish, Hisham
AU  - Dokainish H
FAU - Lakkis, Nasser
AU  - Lakkis N
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Tex Heart Inst J
JT  - Texas Heart Institute journal
JID - 8214622
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Coronary Artery Disease/*drug therapy
MH  - Drug Interactions
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Secondary Prevention
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
PMC - PMC2565550
OTO - NOTNLM
OT  - Aspirin/administration & dosage/therapeutic use
OT  - clopidogrel
OT  - combined modality therapy
OT  - coronary artery disease/drug therapy/prevention & control
OT  - dose-response relationship, drug
OT  - drug resistance
OT  - drug therapy, combination; platelet aggregation/drug effects
OT  - platelet aggregation inhibitors/administration & 
      dosage/pharmacokinetics/therapeutic use
OT  - platelet function tests/methods
OT  - predictive value of tests
OT  - randomized controlled trials as topic
OT  - up-regulation/drug effects
EDAT- 2008/10/23 09:00
MHDA- 2009/01/10 09:00
CRDT- 2008/10/23 09:00
PHST- 2008/10/23 09:00 [pubmed]
PHST- 2009/01/10 09:00 [medline]
PHST- 2008/10/23 09:00 [entrez]
AID - 0010801-200809000-00016 [pii]
PST - ppublish
SO  - Tex Heart Inst J. 2008;35(3):313-20.

PMID- 25630413
OWN - NLM
STAT- MEDLINE
DCOM- 20151009
LR  - 20150129
IS  - 1875-9114 (Electronic)
IS  - 0277-0008 (Linking)
VI  - 35
IP  - 1
DP  - 2015 Jan
TI  - Pharmacotherapy update of acute idiopathic pericarditis.
PG  - 99-111
LID - 10.1002/phar.1527 [doi]
AB  - Idiopathic (viral) pericarditis is the most common form of pericardial disease in 
      the Western world. Despite the combination of colchicine and nonsteroidal 
      antiinflammatory drugs (NSAIDs) plus aspirin (ASA), considered first-line 
      therapy, the incidence of recurrent pericarditis is ~20-30%. In addition, 
      secondary recurrence without optimal first-line therapy is ~50%. This is due to 
      the many clinical challenges, such as inappropriate NSAID/ASA duration of 
      therapy, the use of corticosteroid therapy, contraindications or intolerances to 
      therapy, adverse effects, and issues related to adherence. This review describes 
      contemporary pharmacotherapeutic management of idiopathic (viral) pericarditis, 
      with a particular emphasis on the role of colchicine. Emerging therapies and 
      management strategies, such as high-sensitivity C-reactive protein-guided therapy 
      and novel immunotherapies, are also reviewed. Ultimately, understanding 
      appropriate treatment will assist the clinician in helping decrease the risk of 
      recurrent, incessant, and refractory pericarditis.
CI  - © 2015 Pharmacotherapy Publications, Inc.
FAU - Schwier, Nicholas C
AU  - Schwier NC
AD  - Department of Pharmacy: Clinical and Administrative Sciences, University of 
      Oklahoma College of Pharmacy, Oklahoma City, Oklahoma; PGY-2 Cardiology Pharmacy 
      Resident, University of Pittsburgh Medical Center, University of Pittsburgh 
      School of Pharmacy, Pittsburgh, Pennsylvania.
FAU - Coons, James C
AU  - Coons JC
FAU - Rao, Shivdev K
AU  - Rao SK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Acute Disease
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - C-Reactive Protein/analysis/antagonists & inhibitors
MH  - Clinical Trials as Topic
MH  - Colchicine/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Immunotherapy/methods
MH  - Pericarditis/*drug therapy/immunology/virology
MH  - Recurrence
OTO - NOTNLM
OT  - ASA (Aspirin)
OT  - NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
OT  - colchicine
OT  - corticosteroids
OT  - hs-CRP (high sensitivity C-reactive protein)
OT  - immunotherapy
OT  - recurrence
EDAT- 2015/01/30 06:00
MHDA- 2015/10/10 06:00
CRDT- 2015/01/30 06:00
PHST- 2015/01/30 06:00 [entrez]
PHST- 2015/01/30 06:00 [pubmed]
PHST- 2015/10/10 06:00 [medline]
AID - 10.1002/phar.1527 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2015 Jan;35(1):99-111. doi: 10.1002/phar.1527.

PMID- 11152169
OWN - NLM
STAT- MEDLINE
DCOM- 20010118
LR  - 20211203
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 85
IP  - 6 Pt 1
DP  - 2000 Dec
TI  - Montelukast is only partially effective in inhibiting aspirin responses in 
      aspirin-sensitive asthmatics.
PG  - 477-82
AB  - BACKGROUND: Leukotrienes have been implicated as major mediators of ASA-induced 
      respiratory reactions. In several prior studies, pretreatment of ASA-sensitive 
      respiratory disease (ASRD) patients with leukotriene modifiers have sometimes 
      allowed subjects to tolerate previously established provoking doses of oral ASA 
      or inhalation ASA-lysine, without respiratory reactions. OBJECTIVE: The purpose 
      of this study was to examine whether ASA-provoked respiratory reactions would be 
      blocked or attenuated by pretreatment with a cystLT1 receptor antagonist, 
      montelukast, particularly if ASA doses were increased above their threshold 
      doses. METHODS: Baseline ASA oral challenges were performed. Eight to 12 days 
      later, following pretreatment with montelukast 10 mg daily, threshold and then 
      escalating doses of ASA were used during repeat oral ASA challenges. The 
      differences in responses between baseline and montelukast protected ASA oral 
      challenges were then compared. RESULTS: Nine of 10 patients, despite pretreatment 
      with montelukast, experienced at least naso-ocular reactions during their second 
      oral ASA challenges. In four of nine patients, asthmatic reactions also occurred. 
      In comparing baseline and montelukast protected ASA challenges, there were no 
      statistically significant differences in their responses. CONCLUSIONS: 
      Pretreatment with montelukast allowed only one patient to proceed through all 
      challenge doses of ASA without any reactions. The remaining nine patients enjoyed 
      only partial protection from respiratory reactions. Montelukast pretreatment was 
      generally not effective in altering upper airway reactions and only partly 
      effective in altering lower airway reactions.
FAU - Stevenson, D D
AU  - Stevenson DD
AD  - Division of Allergy, Asthma & Immunology, Scripps Clinic and The Scripps Research 
      Institute, La Jolla, California, USA.
FAU - Simon, R A
AU  - Simon RA
FAU - Mathison, D A
AU  - Mathison DA
FAU - Christiansen, S C
AU  - Christiansen SC
LA  - eng
GR  - M01RR00833/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Acetates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - MHM278SD3E (montelukast)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/prevention & control
MH  - Bronchial Spasm/prevention & control
MH  - Cyclopropanes
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Quinolines/*therapeutic use
MH  - Sulfides
EDAT- 2001/01/11 11:00
MHDA- 2001/02/28 10:01
CRDT- 2001/01/11 11:00
PHST- 2001/01/11 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2001/01/11 11:00 [entrez]
AID - S1081-1206(10)62575-6 [pii]
AID - 10.1016/S1081-1206(10)62575-6 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2000 Dec;85(6 Pt 1):477-82. doi: 
      10.1016/S1081-1206(10)62575-6.

PMID- 30710735
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20190415
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 235
DP  - 2019 May 10
TI  - Impact of the Chinese herbal medicines on dual antiplatelet therapy with 
      clopidogrel and aspirin: Pharmacokinetics and pharmacodynamics outcomes and 
      related mechanisms in rats.
PG  - 100-110
LID - S0378-8741(18)34077-7 [pii]
LID - 10.1016/j.jep.2019.01.040 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Dual antiplatelet therapy (DAPT) with aspirin 
      (ASA) and clopidogrel (CLP) has been consistently shown clinical effectiveness in 
      patients with coronary artery disease. According to the literature, four 
      traditional Chinese medicine (TCM) herbs effective for prevention cardiovascular 
      diseases, namely Radix Salvia Miltiorrhiza (Red sage root, Danshen), Radix 
      Pueraria Lobata (Kudzu root, Gegen), Radix Angelica Sinensis (Angelica root, 
      Danggui), and Rhizoma Ligusticum chuanxiong (Szehuan lovage rhizome, Chuanxiong), 
      are of high potential to be co-administered during DAPT. Since all these herbs 
      are blood vitalizing medicines and can promote blood circulation and eliminate 
      blood stasis, it was hypothesized that they may potentially alter the clinical 
      outcomes of DAPT with clopidogrel and aspirin. AIM OF STUDY: The current study is 
      proposed aiming to preliminarily evaluate the impact of these four commonly used 
      Chinese medicinal herbs on the pharmacokinetics and pharmacodynamics of the 
      combination therapy with clopidogrel and aspirin and its relevant outcomes and 
      mechanisms. MATERIALS AND METHODS: In order to mimic the standard dosing regimen 
      for DAPT in human, various Sprague-Dawley rats treatment groups were received a 
      bolus oral dose of DAPT on day 1 followed by DAPT for consecutive 13 days in 
      absence and presence of orally co-administered four TCM herbs (Danshen, Gegen, 
      Danggui and Chuanxiong) at their low and high doses. On day 14, serial blood 
      samples were collected after dosing to obtain the plasma concentrations of ASA, 
      CLP and their corresponding metabolites by LC/MS/MS. At the end of last blood 
      sampling point of each rat, about 4.5 ml of whole blood were collected to 
      estimate the prothrombin time from each treatment groups. After all the blood 
      sampling, the rats were sacrificed followed by collecting their livers for 
      evaluations of enzyme activities and expressions in the related liver microsome 
      preparations and stomach tissues for evaluations of their potential ulcer index. 
      In addition, gene expression and protein levels of related biomarkers (COX-1, 
      COX-2, P2Y12) in rat livers were measured by RT-PCR and Western blot, 
      respectively, and compared among different treatment groups. RESULTS: 
      Co-administration of Gegen and Danggui significantly altered the pharmacokinetics 
      of ASA and CLP in DAPT with increased systemic exposure of ASA and CLP 
      respectively. Although minimal impact on aspirin esterase activity for all 
      co-administered herbs, significant inhibition on rCyp2c11 and carboxylesterase 
      activities were observed for DAPT with Danshen, Gegen and Danggui co-treatment. 
      In addition, significantly longer PT were found in all DAPT treatment groups. 
      However, a trend of decrease in PT of DAPT in presence of Gegen, Danggui and 
      Chuanxiong was noticed. Nevertheless, all the treatments did not cause detectable 
      changes in COX and P2Y12 mRNA and protein expressions. CONCLUSION: Among the four 
      studied TCMs, it was demonstrated that co-administration of Gegen and Danggui 
      could lead to altered pharmacokinetics of DAPT with significant inhibition on 
      rCyp2c11 and carboxylesterase activities. Although Gegen, Danggui and Chuanxiong 
      might potentially offset the anticoagulant activity of DAPT, the overall 
      pharmacodynamics outcome was not considered to be harmful due to lack of risk in 
      bleeding, which warrant further verification for its clinical impact.
CI  - Copyright © 2019 Elsevier B.V. All rights reserved.
FAU - Xiao, Min
AU  - Xiao M
AD  - School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 
      Shatin, New Territories, Hong Kong Special Administrative Region. Electronic 
      address: shirleyxiao@cuhk.edu.hk.
FAU - Qian, Chenyu
AU  - Qian C
AD  - School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 
      Shatin, New Territories, Hong Kong Special Administrative Region. Electronic 
      address: scyqian@link.cuhk.edu.hk.
FAU - Luo, Xi
AU  - Luo X
AD  - School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 
      Shatin, New Territories, Hong Kong Special Administrative Region.
FAU - Yang, Mengbi
AU  - Yang M
AD  - School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 
      Shatin, New Territories, Hong Kong Special Administrative Region. Electronic 
      address: yangmengbi@cuhk.edu.hk.
FAU - Zhang, Yufeng
AU  - Zhang Y
AD  - School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 
      Shatin, New Territories, Hong Kong Special Administrative Region. Electronic 
      address: zhangyf@cuhk.edu.hk.
FAU - Wu, Cheyuen
AU  - Wu C
AD  - Department of Institute of Integrative Medicine, Faculty of Medicine, The Chinese 
      University of Hong Kong, Shatin, New Territories, Hong Kong Special 
      Administrative Region. Electronic address: justinwu@cuhk.edu.hk.
FAU - Mok, Chungtong
AU  - Mok C
AD  - Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese 
      University of Hong Kong, Shatin, New Territories, Hong Kong Special 
      Administrative Region. Electronic address: vctmok@cuhk.edu.hk.
FAU - Lee, Puiwai
AU  - Lee P
AD  - Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese 
      University of Hong Kong, Shatin, New Territories, Hong Kong Special 
      Administrative Region. Electronic address: alexpwlee@cuhk.edu.hk.
FAU - Zuo, Zhong
AU  - Zuo Z
AD  - School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 
      Shatin, New Territories, Hong Kong Special Administrative Region; State Key 
      Laboratory of Research on Bioactivities and Clinical Applications of Medicinal 
      Plants, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong 
      Special Administrative Region. Electronic address: joanzuo@cuhk.edu.hk.
LA  - eng
PT  - Journal Article
DEP - 20190130
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Biomarkers)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacokinetics/pharmacology
MH  - Biomarkers/metabolism
MH  - Blotting, Western
MH  - Chromatography, Liquid
MH  - Clopidogrel/*administration & dosage/pharmacokinetics/pharmacology
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/chemistry/*pharmacology
MH  - Gene Expression Regulation/drug effects
MH  - *Herb-Drug Interactions
MH  - Platelet Aggregation Inhibitors/*administration & 
      dosage/pharmacokinetics/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tandem Mass Spectrometry
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirin (PubChemCID: 2244)
OT  - Clopidogrel
OT  - Clopidogrel (PubChemCID: 60606)
OT  - Clopidogrel carboxylic acid (PubChemCID: 9861403)
OT  - Dual antiplatelet therapy
OT  - Herb-drug interactions
OT  - Pharmacodynamics
OT  - Pharmacokinetics
OT  - Salicylic acid (PubChemCID: 338)
OT  - Traditional Chinese medicine
EDAT- 2019/02/03 06:00
MHDA- 2019/04/16 06:00
CRDT- 2019/02/03 06:00
PHST- 2018/11/02 00:00 [received]
PHST- 2018/12/28 00:00 [revised]
PHST- 2019/01/29 00:00 [accepted]
PHST- 2019/02/03 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
PHST- 2019/02/03 06:00 [entrez]
AID - S0378-8741(18)34077-7 [pii]
AID - 10.1016/j.jep.2019.01.040 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2019 May 10;235:100-110. doi: 10.1016/j.jep.2019.01.040. Epub 
      2019 Jan 30.

PMID- 26315555
OWN - NLM
STAT- MEDLINE
DCOM- 20160823
LR  - 20181202
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
VI  - 24
IP  - 11
DP  - 2015 Nov
TI  - Aspirin use and risk of breast cancer: systematic review and meta-analysis of 
      observational studies.
PG  - 1645-55
LID - 10.1158/1055-9965.EPI-15-0452 [doi]
AB  - Previous studies concerning the association between aspirin use and breast cancer 
      risk yielded inconsistent results. We aimed to investigate the association by 
      meta-analysis. PubMed and EMBASE were searched for relevant studies. We 
      calculated the summary relative risks (RR) and 95% confidence intervals (CI) 
      using random-effects models. Seventeen cohort studies and 15 case-control studies 
      were included. The overall result showed that aspirin use decreased risk of 
      breast cancer (RR, 0.90; 95% CI, 0.85-0.95). However, there was evidence of 
      publication bias and heterogeneity and the association disappeared after 
      correction using the trim-and-fill method. When stratified by study design, a 
      significant benefit for aspirin users was only found in population-based and 
      hospital-based case-control studies but not in cohort or nest case-control 
      studies. Further subgroup analyses showed that aspirin use could decrease risk of 
      in situ breast tumors or hormone receptor-positive tumors and reduce risk of 
      breast cancer in postmenopausal women. Aspirin use may not affect overall risk of 
      breast cancer, but decrease risk of in situ breast tumors or hormone 
      receptor-positive tumors and reduce risk of breast cancer in postmenopausal 
      women. Considering between-study significant heterogeneity and publication bias, 
      confirmation in future studies is also essential.
CI  - ©2015 American Association for Cancer Research.
FAU - Zhong, Shanliang
AU  - Zhong S
AD  - Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to 
      Nanjing Medical University, Nanjing, China.
FAU - Chen, Lin
AU  - Chen L
AD  - Department of Oncology, Xuzhou Medical College, Xuzhou, China.
FAU - Zhang, Xiaohui
AU  - Zhang X
AD  - Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to 
      Nanjing Medical University, Nanjing, China.
FAU - Yu, Dandan
AU  - Yu D
AD  - Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing 
      Medical University, Nanjing, China.
FAU - Tang, Jinhai
AU  - Tang J
AD  - Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing 
      Medical University, Nanjing, China.
FAU - Zhao, Jianhua
AU  - Zhao J
AD  - Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to 
      Nanjing Medical University, Nanjing, China. seuzsl@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20150827
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Breast Neoplasms/*prevention & control
MH  - Female
MH  - Humans
MH  - Observational Studies as Topic
MH  - Risk
EDAT- 2015/09/01 06:00
MHDA- 2016/08/24 06:00
CRDT- 2015/08/29 06:00
PHST- 2015/05/04 00:00 [received]
PHST- 2015/08/04 00:00 [accepted]
PHST- 2015/08/29 06:00 [entrez]
PHST- 2015/09/01 06:00 [pubmed]
PHST- 2016/08/24 06:00 [medline]
AID - 1055-9965.EPI-15-0452 [pii]
AID - 10.1158/1055-9965.EPI-15-0452 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1645-55. doi: 
      10.1158/1055-9965.EPI-15-0452. Epub 2015 Aug 27.

PMID- 1427067
OWN - NLM
STAT- MEDLINE
DCOM- 19921204
LR  - 20191028
IS  - 1046-9354 (Print)
IS  - 1046-9354 (Linking)
VI  - 13
IP  - 4
DP  - 1992 Jul-Aug
TI  - Commentary: the American experience with aspirin desensitization for 
      aspirin-sensitive rhinosinusitis and asthma.
PG  - 185-92
AB  - The experience in the United States with aspirin sensitivity associated with 
      rhinosinusitis and asthma is generally in agreement with the European perspective 
      offered by Drs. Szczeklik and Kowalski, though our approach to challenging these 
      patients is slightly different. Most aspirin-sensitive patients no not have a 
      family history of aspirin sensitivity. Aspirin sensitivity is found in one third 
      of patients having nasal polyps, rhinosinusitis, and asthma, the remaining two 
      thirds of these patients having no adverse response to aspirin ingestion. In 85% 
      of asthmatics who give a history of aspirin-induced bronchospasm, oral aspirin 
      challenges are positive. Thus, a small group of patients have inappropriately 
      assigned aspirin-sensitive asthmatic (ASA) as the cause of a prior asthmatic 
      attack that in reality had been induced by an independent provoking factor.
FAU - Stevenson, D D
AU  - Stevenson DD
AD  - Scripps Clinic and Research Foundation, La Jolla, CA 92037.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Allergy Proc
JT  - Allergy proceedings : the official journal of regional and state allergy 
      societies
JID - 8902396
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/chemically induced/*prevention & control
MH  - *Desensitization, Immunologic
MH  - Evaluation Studies as Topic
MH  - Humans
MH  - Rhinitis, Allergic, Perennial/chemically induced/*prevention & control
MH  - Sinusitis/chemically induced/*prevention & control
MH  - United States
RF  - 17
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
AID - 10.2500/108854192778817167 [doi]
PST - ppublish
SO  - Allergy Proc. 1992 Jul-Aug;13(4):185-92. doi: 10.2500/108854192778817167.

PMID- 6859001
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20190913
IS  - 0195-7910 (Print)
IS  - 0195-7910 (Linking)
VI  - 4
IP  - 2
DP  - 1983 Jun
TI  - Intoxication by aspirin and alcohol in a child. A case of child abuse by medical 
      neglect.
PG  - 149-51
AB  - Investigation of child abuse deaths is often hindered by meager or unusual 
      autopsy findings. Circumstantial factors are crucial in such investigations for a 
      thorough understanding of the mechanism and manner of death. We present a case of 
      childhood poisoning from aspirin and alcohol to demonstrate the medical neglect 
      by the parents and the blatant discrepancies between the history provided by the 
      parents and the actual facts preceding the child's death.
FAU - Case, M E
AU  - Case ME
FAU - Short, C D
AU  - Short CD
FAU - Poklis, A
AU  - Poklis A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Forensic Med Pathol
JT  - The American journal of forensic medicine and pathology
JID - 8108948
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alcoholic Intoxication/*complications
MH  - Aspirin/*poisoning
MH  - *Child Abuse
MH  - Child, Preschool
MH  - Female
MH  - *Forensic Medicine
MH  - Humans
MH  - Male
EDAT- 1983/06/01 00:00
MHDA- 1983/06/01 00:01
CRDT- 1983/06/01 00:00
PHST- 1983/06/01 00:00 [pubmed]
PHST- 1983/06/01 00:01 [medline]
PHST- 1983/06/01 00:00 [entrez]
AID - 10.1097/00000433-198306000-00010 [doi]
PST - ppublish
SO  - Am J Forensic Med Pathol. 1983 Jun;4(2):149-51. doi: 
      10.1097/00000433-198306000-00010.

PMID- 25093998
OWN - NLM
STAT- MEDLINE
DCOM- 20150527
LR  - 20211021
IS  - 1365-2982 (Electronic)
IS  - 1350-1925 (Print)
IS  - 1350-1925 (Linking)
VI  - 26
IP  - 10
DP  - 2014 Oct
TI  - Effects of aspirin & simvastatin and aspirin, simvastatin, & lipoic acid on heme 
      oxygenase-1 in healthy human subjects.
PG  - 1437-42
LID - 10.1111/nmo.12404 [doi]
AB  - BACKGROUND: Heme oxygenase 1 (HO-1) degrades heme and protects against oxidative 
      stress. In vitro and animal models suggest that HO-1 is beneficial in several 
      diseases (e.g., postoperative ileus, gastroparesis, acute pancreatitis, and 
      colitis). However, the only drugs (i.e., hemin and heme arginate) which 
      pharmacologically upregulate HO-1 in humans are expensive and can only be 
      administered intravenously. Our aims were to compare the effects of placebo, 
      aspirin, and simvastatin alone, and with α-lipoic acid, on HO-1 protein 
      concentration and activity in humans. METHODS: This randomized, double-blind, 
      placebo-controlled study compared the effects of three oral regimens administered 
      for 7 days, i.e., placebo; aspirin (325 mg twice daily) and simvastatin (40 mg 
      twice daily); aspirin, simvastatin, and the sodium salt of R- α-lipoic acid 
      (NaRLA, 600 mg three times daily) on markers of HO-1 activation (i.e., plasma 
      HO-1 protein concentration and venous monocyte HO-1 protein activity) in 18 
      healthy subjects (14 females). Markers of HO-1 activation were evaluated at 
      baseline, days 2, and 7. KEY RESULTS: Baseline HO-1 protein concentrations and 
      activity were similar among the three groups. Compared to placebo, aspirin and 
      simvastatin combined, or together with NaRLA did not affect HO-1 protein 
      concentration or activity at 2 or 7 days. HO-1 protein concentrations and 
      activity were correlated on day 7 (r = 0.75, p = 0.0004) but not at baseline and 
      on day 2. CONCLUSIONS & INFERENCES: At therapeutic doses, aspirin, simvastatin, 
      and α-lipoic acid do not increase plasma HO-1 protein concentration or venous 
      monocyte HO-1 activity in healthy humans.
CI  - © 2014 John Wiley & Sons Ltd.
FAU - Bharucha, Adil E
AU  - Bharucha AE
AD  - Enteric Neurosciences Program, Division of Gastroenterology and Hepatology, Mayo 
      Clinic and Mayo Foundation, Rochester, MN, USA.
FAU - Choi, Kyoung Moo
AU  - Choi KM
FAU - Saw, Jessica J
AU  - Saw JJ
FAU - Gibbons, Simon J
AU  - Gibbons SJ
FAU - Farrugia, Gianrico F
AU  - Farrugia GF
FAU - Carlson, David A
AU  - Carlson DA
FAU - Zinsmeister, Alan R
AU  - Zinsmeister AR
LA  - eng
GR  - P01 DK068055/DK/NIDDK NIH HHS/United States
GR  - UL1 TR000135/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140729
PL  - England
TA  - Neurogastroenterol Motil
JT  - Neurogastroenterology and motility
JID - 9432572
RN  - 73Y7P0K73Y (Thioctic Acid)
RN  - AGG2FN16EV (Simvastatin)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Heme Oxygenase-1/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Simvastatin/administration & dosage/*pharmacology
MH  - Thioctic Acid/administration & dosage/*pharmacology
MH  - Young Adult
PMC - PMC4177447
MID - NIHMS611207
OTO - NOTNLM
OT  - HO-1
OT  - alpha lipoic acid
OT  - aspirin
OT  - heme oxygenase
OT  - humans
OT  - simvastatin
EDAT- 2014/08/06 06:00
MHDA- 2015/05/28 06:00
CRDT- 2014/08/06 06:00
PHST- 2014/04/20 00:00 [received]
PHST- 2014/06/27 00:00 [accepted]
PHST- 2014/08/06 06:00 [entrez]
PHST- 2014/08/06 06:00 [pubmed]
PHST- 2015/05/28 06:00 [medline]
AID - 10.1111/nmo.12404 [doi]
PST - ppublish
SO  - Neurogastroenterol Motil. 2014 Oct;26(10):1437-42. doi: 10.1111/nmo.12404. Epub 
      2014 Jul 29.

PMID- 32283542
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 12
IP  - 7
DP  - 2020 Apr 13
TI  - Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells 
      activation via the TLR4/NF-κB pathway.
PG  - 6058-6066
LID - 10.18632/aging.103002 [doi]
AB  - Hepatic fibrosis arises from a sustained wound-healing response to chronic liver 
      injury. Because the occurrence and development of hepatic fibrosis is always 
      associated with chronic inflammation, controlling inflammation within the liver 
      may be an effective means of controlling the development and progression of 
      hepatic fibrosis. Aspirin is a non-steroidal anti-inflammatory drug used to 
      relieve both inflammatory symptoms and pain. The results of our study showed that 
      aspirin significantly attenuated hepatic inflammation and fibrosis. Aspirin 
      effectively inhibited the activation and proliferation of hepatic stellate cells 
      (HSCs), which led to downregulation of inflammatory factors, including IL-6 and 
      TNF-α in those cells. Aspirin also downregulated expression of Toll-like 
      receptor-4 (TLR4) on HSCs, as well as its downstream mediators, MyD88 and NF-κB. 
      The results of our study demonstrate aspirin's potential to inhibit the 
      development of hepatic fibrosis and the molecular mechanism by which it acts. 
      They suggest aspirin may be an effective therapeutic agent for the treatment of 
      hepatic fibrosis.
FAU - Liu, Yan
AU  - Liu Y
AD  - The Fifth Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi 
      Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
AD  - Guangxi Key laboratory of Regenerative Medicine, Guangxi Medical University, 
      Nanning 530021, Guangxi Zhuang Autonomous Region, China.
AD  - Division of Spinal Surgery, The First Affiliated Hospital of Guangxi Medical 
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Nong, Li
AU  - Nong L
AD  - The Fifth Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi 
      Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Jia, Yuxian
AU  - Jia Y
AD  - The Fifth Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi 
      Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Tan, Aihua
AU  - Tan A
AD  - The Fifth Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi 
      Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Duan, Lixia
AU  - Duan L
AD  - The Fifth Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi 
      Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Lu, Yongkui
AU  - Lu Y
AD  - The Fifth Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi 
      Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Zhao, Jinmin
AU  - Zhao J
AD  - Guangxi Key laboratory of Regenerative Medicine, Guangxi Medical University, 
      Nanning 530021, Guangxi Zhuang Autonomous Region, China.
AD  - Division of Spinal Surgery, The First Affiliated Hospital of Guangxi Medical 
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200413
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (NF-kappa B)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/*pharmacology
MH  - Down-Regulation/drug effects
MH  - *Hepatic Stellate Cells/drug effects/metabolism
MH  - *Inflammation/drug therapy/metabolism
MH  - *Liver/metabolism/pathology
MH  - *Liver Cirrhosis/drug therapy/metabolism/pathology
MH  - NF-kappa B/metabolism
MH  - Rats
MH  - Toll-Like Receptor 4/metabolism
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/metabolism
PMC - PMC7185140
OTO - NOTNLM
OT  - aspirin
OT  - hepatic fibrosis
OT  - hepatic stellate cells
OT  - inflammation
COIS- CONFLICTS OF INTEREST: The authors declare that they have no conflicts of 
      interest.
EDAT- 2020/04/14 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/04/14 06:00
PHST- 2019/08/18 00:00 [received]
PHST- 2020/02/08 00:00 [accepted]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 103002 [pii]
AID - 10.18632/aging.103002 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2020 Apr 13;12(7):6058-6066. doi: 10.18632/aging.103002. Epub 
      2020 Apr 13.

PMID- 346292
OWN - NLM
STAT- MEDLINE
DCOM- 19780612
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 23
IP  - 5
DP  - 1978 May
TI  - Effect of aspirin on exercise-induced angina.
PG  - 505-10
AB  - Suspecting that platelet thromboemboli could play a role in the pathogenesis of 
      myocardial ischemia, we did a random-order, double-blind, crossover study of the 
      effect of the platelet aggregation inhibitor, aspirin, on treadmill 
      exercise-induced angina in 13 men with coronary artery disease. Although 
      collagen-induced platelet aggregation and the second phase of adenosine 
      diphosphate (ADP)-induced platelet aggregation were significantly decreased and 
      the rate of disaggregation of ADP-induced platelet aggregates was significantly 
      increased after 650 mg aspirin in buffered solution, there was no delay in onset 
      of exercise-induced angina, change in heart rate-blood pressure product at onset 
      of angina, or change in S-T segment depression at onset of angina. Regardless of 
      whether the patients had received placebo or aspirin on the preceding day, 
      treadmill exercise until angina was followed by no changes in platelet 
      aggregation or disaggregation, platelet count in blood or platelet-rich plasma, 
      or of the plasma concentration of nonesterified fatty acids.
FAU - Davis, J W
AU  - Davis JW
FAU - Lewis, H D Jr
AU  - Lewis HD Jr
FAU - Phillips, P E
AU  - Phillips PE
FAU - Schwegler, R A
AU  - Schwegler RA
FAU - Yue, K T
AU  - Yue KT
FAU - Hassanein, K R
AU  - Hassanein KR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Fatty Acids, Nonesterified)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Angina Pectoris/blood/*drug therapy/etiology
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Cell Count
MH  - Blood Platelets/drug effects
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Fatty Acids, Nonesterified/blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Platelet Aggregation/drug effects
EDAT- 1978/05/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1978/05/01 00:00
PHST- 1978/05/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1978/05/01 00:00 [entrez]
AID - 0009-9236(78)90182-0 [pii]
AID - 10.1002/cpt1978235505 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1978 May;23(5):505-10. doi: 10.1002/cpt1978235505.

PMID- 11252006
OWN - NLM
STAT- MEDLINE
DCOM- 20010524
LR  - 20220330
IS  - 0277-6715 (Print)
IS  - 0277-6715 (Linking)
VI  - 20
IP  - 6
DP  - 2001 Mar 30
TI  - A comparison of statistical methods for meta-analysis.
PG  - 825-40
AB  - Meta-analysis may be used to estimate an overall effect across a number of 
      similar studies. A number of statistical techniques are currently used to combine 
      individual study results. The simplest of these is based on a fixed effects 
      model, which assumes the true effect is the same for all studies. A random 
      effects model, however, allows the true effect to vary across studies, with the 
      mean true effect the parameter of interest. We consider three methods currently 
      used for estimation within the framework of a random effects model, and 
      illustrate them by applying each method to a collection of six studies on the 
      effect of aspirin after myocardial infarction. These methods are compared using 
      estimated coverage probabilities of confidence intervals for the overall effect. 
      The techniques considered all generally have coverages below the nominal level, 
      and in particular it is shown that the commonly used DerSimonian and Laird method 
      does not adequately reflect the error associated with parameter estimation, 
      especially when the number of studies is small.
CI  - Copyright 2001 John Wiley & Sons, Ltd.
FAU - Brockwell, S E
AU  - Brockwell SE
AD  - Department of Mathematics and Statistics, Richard Berry Building, The University 
      of Melbourne, Victoria 3010, Australia.
FAU - Gordon, I R
AU  - Gordon IR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Stat Med
JT  - Statistics in medicine
JID - 8215016
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/standards/therapeutic use
MH  - Aspirin/standards/therapeutic use
MH  - Clinical Trials as Topic
MH  - *Computer Simulation
MH  - Humans
MH  - Likelihood Functions
MH  - *Meta-Analysis as Topic
MH  - *Models, Biological
MH  - *Models, Statistical
MH  - Myocardial Infarction/drug therapy/prevention & control
EDAT- 2001/03/17 10:00
MHDA- 2001/05/26 10:01
CRDT- 2001/03/17 10:00
PHST- 2001/03/17 10:00 [pubmed]
PHST- 2001/05/26 10:01 [medline]
PHST- 2001/03/17 10:00 [entrez]
AID - 10.1002/sim.650 [doi]
PST - ppublish
SO  - Stat Med. 2001 Mar 30;20(6):825-40. doi: 10.1002/sim.650.

PMID- 7924753
OWN - NLM
STAT- MEDLINE
DCOM- 19941110
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 39
IP  - 10
DP  - 1994 Oct
TI  - Nonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer. At 
      what cost?
PG  - 2260-6
AB  - The objective was to provide a comparison of the known toxicities of nonsteroidal 
      antiinflammatory drugs (NSAIDS) and the likelihood of benefit from colorectal 
      cancer (CRC) chemoprevention attributed to them. Chemoprevention trials require 
      large numbers of subjects followed over many years and are therefore very 
      expensive and difficult. Hence, it is important that agents tested in these 
      trails have a realistic expectation of actual use in the population. Data sources 
      were published literature on the toxicity and CRC chemopreventive activity of 
      NSAIDS. Presently available NSAIDS, used at their usual therapeutic doses, have a 
      serious toxicity rate that quickly exceeds any benefit from CRC prevention. In 
      contrast, low-dose aspirin is worth evaluating, especially because of the 
      potential for simultaneous cardiovascular risk reduction. Possibly, low doses of 
      other NSAIDS may have benefit, but this remains unproven. Synthesis of other 
      NSAIDS, with less toxicity, is another approach towards making the 
      toxicity-benefit ratio more favorable for the use of these agents for CRC 
      prevention.
FAU - Trujillo, M A
AU  - Trujillo MA
AD  - Section of Gastroenterology, Tucson VA Medical Center, Arizona 85723.
FAU - Garewal, H S
AU  - Garewal HS
FAU - Sampliner, R E
AU  - Sampliner RE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Colorectal Neoplasms/epidemiology/*prevention & control
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Risk Assessment
RF  - 49
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 10.1007/BF02090382 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1994 Oct;39(10):2260-6. doi: 10.1007/BF02090382.

PMID- 23762987
OWN - NLM
STAT- MEDLINE
DCOM- 20130715
LR  - 20131121
IS  - 0869-2092 (Print)
IS  - 0869-2092 (Linking)
VI  - 76
IP  - 4
DP  - 2013
TI  - [Influence of hypoxen on acetylsalicylic acid efficiency in acute inflammation].
PG  - 32-5
AB  - Rats were treated by subplantar injections of 0.1 ml 1% carrageenan solution. In 
      3 hours, this led to the development of acute inflammatory reaction (swelling of 
      legs, neutrophilic leukocytosis, increased erythrocyte sedimentation rate, 
      activation of free-radical oxidation). Acetylsalicylic acid in a dose of 100 
      mg/kg reduced development of the inflammatory response. Hypoxen in a dose of 50 
      mg/kg potentiated the effect of acetylsalicylic acid. The injection of both 
      hypoxen and acetylsalicylic acid before the injection of carrageenan produced a 
      strong anti-inflammatory effect, which was manifested by a reliable decrease in 
      all monitored signs of inflammation.
FAU - Novikov, V E
AU  - Novikov VE
FAU - Iliuchin, S A
AU  - Iliuchin SA
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Eksp Klin Farmakol
JT  - Eksperimental'naia i klinicheskaia farmakologiia
JID - 9215981
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Phenyl Ethers)
RN  - 148465-31-0 (olifen)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Anti-Inflammatory Agents/*agonists/*pharmacology
MH  - Aspirin/*agonists/*pharmacology
MH  - Carrageenan/toxicity
MH  - Dose-Response Relationship, Drug
MH  - Drug Agonism
MH  - Inflammation/chemically induced/drug therapy/metabolism/pathology
MH  - Phenyl Ethers/*agonists/*pharmacology
MH  - Rats
MH  - Rats, Wistar
EDAT- 2013/06/15 06:00
MHDA- 2013/07/17 06:00
CRDT- 2013/06/15 06:00
PHST- 2013/06/15 06:00 [entrez]
PHST- 2013/06/15 06:00 [pubmed]
PHST- 2013/07/17 06:00 [medline]
PST - ppublish
SO  - Eksp Klin Farmakol. 2013;76(4):32-5.

PMID- 20174704
OWN - NLM
STAT- MEDLINE
DCOM- 20100512
LR  - 20131121
IS  - 1364-5528 (Electronic)
IS  - 0003-2654 (Linking)
VI  - 135
IP  - 3
DP  - 2010 Mar
TI  - Non-invasive monitoring of the mixing of pharmaceutical powders by broadband 
      acoustic emission.
PG  - 518-24
LID - 10.1039/b922446g [doi]
AB  - Broadband acoustic transducers, including an intrinsically safe device, were 
      assessed for non-invasive monitoring of aspirin, citric acid or Avicel mixing in 
      a bench scale convective blender. The frequency information content of the 
      acoustic emission (AE) spectra depends on the response characteristics of the 
      transducers, which vary depending on the design. As acoustic waves generated from 
      the impact of particles propagated through and around the glass mixing vessel, 
      comparable spectra were obtained from different locations on the glass. The 
      intensity of AE increased as the impeller speed, mass of powder or density of the 
      particles was increased. AE also increased with particle size, with a relatively 
      greater increase in intensity at lower frequencies. Mixing profiles were 
      generated in real time from the change in the integrated intensity over selected 
      frequency ranges on addition of aspirin to Avicel; the AE signal initially 
      increased and then came to a plateau as the mixture became homogeneous. The 
      average plateau signal was plotted against concentration for three different 
      particle size ranges of aspirin in Avicel; for aspirin concentrations <21% m/m 
      the increase in the AE was relatively small with no discernable effects of the 
      aspirin particle size; however, for >21% m/m aspirin, there was a proportionally 
      greater increase in AE, and particle size effects were more obvious. The study 
      has shown that AE is relatively easy to measure non-invasively during powder 
      mixing, but has poorer sensitivity than NIR spectrometry for detection of effects 
      caused by addition of secondary compounds, especially at smaller particle sizes.
FAU - Allan, Pamela
AU  - Allan P
AD  - WestCHEM, Department of Pure and Applied Chemistry and CPACT, University of 
      Strathclyde, 295 Cathedral Street, Glasgow, UK G1 1XL.
FAU - Bellamy, Luke J
AU  - Bellamy LJ
FAU - Nordon, Alison
AU  - Nordon A
FAU - Littlejohn, David
AU  - Littlejohn D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100114
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Powders)
RN  - 2968PHW8QP (Citric Acid)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acoustics/*instrumentation
MH  - Aspirin/chemistry
MH  - Cellulose/chemistry
MH  - Citric Acid/chemistry
MH  - Drug Compounding/instrumentation/*methods
MH  - Particle Size
MH  - Pharmaceutical Preparations/*chemistry
MH  - Powders
MH  - Spectroscopy, Near-Infrared
EDAT- 2010/02/23 06:00
MHDA- 2010/05/13 06:00
CRDT- 2010/02/23 06:00
PHST- 2010/02/23 06:00 [entrez]
PHST- 2010/02/23 06:00 [pubmed]
PHST- 2010/05/13 06:00 [medline]
AID - 10.1039/b922446g [doi]
PST - ppublish
SO  - Analyst. 2010 Mar;135(3):518-24. doi: 10.1039/b922446g. Epub 2010 Jan 14.

PMID- 18588374
OWN - NLM
STAT- MEDLINE
DCOM- 20090107
LR  - 20131121
IS  - 1029-2977 (Print)
IS  - 1029-2977 (Linking)
VI  - 11
IP  - 4
DP  - 2008 Jul
TI  - Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a 
      randomized clinical trial.
PG  - 418-22
AB  - BACKGROUND: Retinal vein occlusion is the second most common vascular disease of 
      retina after diabetic retinopathy, affecting 1.6% of the population above the age 
      of 40. The aim of this study was to compare the effect of dalteparin and aspirin 
      in patients with recent-onset branch retinal vein occlusion. METHODS: A 
      randomized clinical trial was conducted on patients with branch retinal vein 
      occlusion of less than 30 days' duration. Ophthalmic, systemic, and hematologic 
      evaluations were made. Visual acuity was measured with Early Treatment Diabetic 
      Retinopathy Study chart. Patients in the dalteparin group received subcutaneous 
      dalteparin 100 IU/kg twice daily for 10 days, then 100 IU/kg once daily for 
      another 10 days while the patients in the aspirin group were given aspirin 100 mg 
      daily throughout the study. RESULTS: Seventy-eight patients were enrolled, 37 in 
      the dalteparin and 41 in the aspirin group. The patients were followed for six 
      months. The visual outcomes of the two groups were compared. Although dalteparin 
      improved mean visual acuity slightly more than aspirin, no statistically 
      significant differences were found between the groups at one (P=0.37), two 
      (P=0.16), three (P=0.11), or six (P=0.13) months. Resolution of macular edema and 
      development of new vessels made no statistically significant difference between 
      the groups [(P=0.08) and (P=0.49), respectively]. CONCLUSION: In recent-onset 
      branch retinal vein occlusion, no significant difference was found in the final 
      visual acuity between the patients treated by dalteparin or aspirin. A further 
      study with larger sample size is recommended.
FAU - Farahvash, Mohammad-Sadegh
AU  - Farahvash MS
AD  - Department of Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Moradimogadam, Marzieh
AU  - Moradimogadam M
FAU - Farahvash, Mohammad-Mehdi
AU  - Farahvash MM
FAU - Mohammadzadeh, Shiva
AU  - Mohammadzadeh S
FAU - Mirshahi, Ahmad
AU  - Mirshahi A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Iran
TA  - Arch Iran Med
JT  - Archives of Iranian medicine
JID - 100889644
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Dalteparin/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retinal Vein Occlusion/*drug therapy
MH  - Time Factors
EDAT- 2008/07/01 09:00
MHDA- 2009/01/08 09:00
CRDT- 2008/07/01 09:00
PHST- 2008/07/01 09:00 [pubmed]
PHST- 2009/01/08 09:00 [medline]
PHST- 2008/07/01 09:00 [entrez]
AID - 0013 [pii]
PST - ppublish
SO  - Arch Iran Med. 2008 Jul;11(4):418-22.

PMID- 19427737
OWN - NLM
STAT- MEDLINE
DCOM- 20090922
LR  - 20131121
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 73
IP  - 3
DP  - 2009 Sep
TI  - A new strategy of treatment with low-dosage acetyl salicylic acid in patients 
      affected by central serous chorioretinopathy.
PG  - 435-7
LID - 10.1016/j.mehy.2009.03.036 [doi]
AB  - Central serous chorioretinopathy (CSCR) is an ocular disease characterized by 
      serous detachment of the neurosensory retina at the posterior pole, with or 
      without an associated retinal pigment epithelium (RPE) detachment. It is 
      associated with different systemic diseases although the pathogenesis is unknown. 
      Different therapies have been applied to treat CSCR with poor results. We 
      reviewed the literature and found that in all the diseases associated with CSCR 
      plasminogen activator inhibitor 1 (PAI-1) was increased. Acetyl salicylic acid 
      (Aspirin) is effective in lowering PAI-1 levels and platelets aggregation; as 
      such we decided to treat patients affected by CSCR with low dose Aspirin. From 
      January 2005 to December 2008 we enrolled 107 patients, 85 male and 22 female, 
      affected with active CSCR or the multifocal variant. Aspirin was administrated at 
      an oral dose of 100 mg. per day for a month and then 100 mg. every other day for 
      five months. After the first week of therapy and for the following three months 
      the visual acuity improved and remained stable to the end of the follow-up 
      (median follow-up 20 months). A recurrence of the disease interested the 6% of 
      the patients. In this study low-dose Aspirin was able to treat central serous 
      chorioretinopathy with a quick recovery of the visual acuity and a reduced number 
      of recurrences during the follow-up. Besides the effectiveness of the treatment 
      with Aspirin supports our observation regarding the role of impaired fibrinolysis 
      and increased platelets aggregation in the choriocapillaris as genesis of CSCR.
FAU - Caccavale, Antonio
AU  - Caccavale A
AD  - Department of Ophthalmology, Hospital C. Cantù, Abbiategrasso, Piazza Mussi, 1 
      20081 Abbiategrasso Milano, Italy. neureye@katamail.com
FAU - Imparato, Manuela
AU  - Imparato M
FAU - Romanazzi, Filippo
AU  - Romanazzi F
FAU - Negri, Angelo
AU  - Negri A
FAU - Porta, Alessandro
AU  - Porta A
FAU - Ferentini, Fabio
AU  - Ferentini F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
DEP - 20090508
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Choroidal Neovascularization/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Retinal Diseases/*drug therapy
MH  - Treatment Outcome
RF  - 39
EDAT- 2009/05/12 09:00
MHDA- 2009/09/23 06:00
CRDT- 2009/05/12 09:00
PHST- 2009/02/21 00:00 [received]
PHST- 2009/02/21 00:00 [revised]
PHST- 2009/03/04 00:00 [accepted]
PHST- 2009/05/12 09:00 [entrez]
PHST- 2009/05/12 09:00 [pubmed]
PHST- 2009/09/23 06:00 [medline]
AID - S0306-9877(09)00224-2 [pii]
AID - 10.1016/j.mehy.2009.03.036 [doi]
PST - ppublish
SO  - Med Hypotheses. 2009 Sep;73(3):435-7. doi: 10.1016/j.mehy.2009.03.036. Epub 2009 
      May 8.

PMID- 32357985
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1939-2869 (Electronic)
IS  - 0891-1150 (Linking)
VI  - 87
IP  - 5
DP  - 2020 May
TI  - Aspirin for primary prevention of atherosclerotic cardiovascular events.
PG  - 300-311
LID - 10.3949/ccjm.87a.19045 [doi]
AB  - Recent trials evaluated the impact of aspirin for primary prevention of 
      cardiovascular events in patients at intermediate risk, patients with diabetes, 
      and the elderly, and the results have been incorporated into the most recent 
      professional guidelines. For the most part, the role of aspirin in primary 
      prevention remains limited, albeit not adequately tested in those at higher risk.
CI  - Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
FAU - Schenone, Aldo L
AU  - Schenone AL
AD  - Non-Invasive Cardiovascular Imaging Department, Brigham and Women's Hospital, 
      Boston, MA.
FAU - Lincoff, A Michael
AU  - Lincoff AM
AD  - Department of Cardiovascular Medicine; Heart, Vascular, and Thoracic Institute; 
      Director, C5Research (Cleveland Clinic Coordinating Center for Clinical 
      Research); Director, Center for Clinical Research, Lerner Research Institute, 
      Cleveland Clinic; Professor of Medicine, Cleveland Clinic Lerner College of 
      Medicine of Case Western Reserve University, Cleveland, OH lincofa@ccf.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cleve Clin J Med
JT  - Cleveland Clinic journal of medicine
JID - 8703441
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Cleve Clin J Med. 2020 Jul 31;87(8):458. PMID: 32737041
MH  - Aspirin/*pharmacology
MH  - Atherosclerosis/*drug therapy
MH  - Cardiovascular Diseases/*prevention & control
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Primary Prevention/methods
EDAT- 2020/05/03 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - 87/5/300 [pii]
AID - 10.3949/ccjm.87a.19045 [doi]
PST - ppublish
SO  - Cleve Clin J Med. 2020 May;87(5):300-311. doi: 10.3949/ccjm.87a.19045.

PMID- 7670355
OWN - NLM
STAT- MEDLINE
DCOM- 19951018
LR  - 20161020
IS  - 1026-3470 (Print)
IS  - 1026-3470 (Linking)
IP  - 3
DP  - 1995 May-Jun
TI  - [Effect of heparin combined with aspirin upon intragastric administration on the 
      state of the insulin system in animals with alloxan diabetes].
PG  - 372-5
AB  - We studied the effect of heparin combined with aspirin on the development and 
      course of experimental alloxan-induced diabetes mellitus. This drug produced a 
      stable hypoglycemic action when it was regularly introduced intragastrically into 
      rats with developing or chronic diabetes.
FAU - Ul'ianov, A M
AU  - Ul'ianov AM
FAU - Tarasov, Iu A
AU  - Tarasov IuA
FAU - Liapina, L A
AU  - Liapina LA
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Vliianie preparata geparina v sochetanii s aspirinom pri ego vnutrizheludochnom 
      vvedenii na sostoianie insuliarnoĭ sistemy zhivotnykh pri alloksanovom diabete.
PL  - Russia (Federation)
TA  - Izv Akad Nauk Ser Biol
JT  - Izvestiia Akademii nauk. Seriia biologicheskaia
JID - 9300152
RN  - 0 (Blood Glucose)
RN  - 0 (Drug Combinations)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 6SW5YHA5NG (Alloxan)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alloxan
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Experimental/metabolism/*physiopathology
MH  - Drug Combinations
MH  - Heparin/administration & dosage/*pharmacology
MH  - Hypoglycemic Agents/administration & dosage/*pharmacology
MH  - Insulin/*metabolism
MH  - Male
MH  - Rats
MH  - Stomach
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
PST - ppublish
SO  - Izv Akad Nauk Ser Biol. 1995 May-Jun;(3):372-5.

PMID- 4071471
OWN - NLM
STAT- MEDLINE
DCOM- 19860122
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 40
IP  - 2
DP  - 1985 Oct 15
TI  - Effect of calcium dobesilate and its interaction with aspirin on thrombus 
      formation in vivo.
PG  - 215-26
AB  - The effect of calcium dobesilate (calcium dihydroxy-2,5 benzenesulphonate) on 
      thrombus formation in vivo was evaluated. Experimental thrombi were induced in a 
      venule of a hamster cheek pouch following iontophoresis of adenosine diphosphate 
      (ADP). Calcium dobesilate administered intraperitoneally as a single injection 
      inhibited thrombus formation in a time- and dose-dependent manner. Furthermore, 
      the combination of calcium dobesilate and aspirin resulted in the potentiation of 
      the inhibition of thrombus formation.
FAU - Michal, M
AU  - Michal M
FAU - Giessinger, N
AU  - Giessinger N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Benzenesulfonates)
RN  - 0 (Fibrinolytic Agents)
RN  - 5921X1560Q (Calcium Dobesilate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Benzenesulfonates/*pharmacology
MH  - Calcium Dobesilate/administration & dosage/*pharmacology/therapeutic use
MH  - Cricetinae
MH  - Drug Evaluation, Preclinical
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - *Fibrinolytic Agents
MH  - Male
MH  - Mesocricetus
MH  - Thrombophlebitis/*prevention & control
EDAT- 1985/10/15 00:00
MHDA- 1985/10/15 00:01
CRDT- 1985/10/15 00:00
PHST- 1985/10/15 00:00 [pubmed]
PHST- 1985/10/15 00:01 [medline]
PHST- 1985/10/15 00:00 [entrez]
AID - 10.1016/0049-3848(85)90332-9 [doi]
PST - ppublish
SO  - Thromb Res. 1985 Oct 15;40(2):215-26. doi: 10.1016/0049-3848(85)90332-9.

PMID- 35967416
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20220902
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Aspirin eugenol ester alleviates lipopolysaccharide-induced acute lung injury in 
      rats while stabilizing serum metabolites levels.
PG  - 939106
LID - 10.3389/fimmu.2022.939106 [doi]
LID - 939106
AB  - Aspirin eugenol ester (AEE) was a novel drug compound with aspirin and eugenol 
      esterified. AEE had various pharmacological activities, such as 
      anti-inflammatory, antipyretic, analgesic, anti-oxidative stress and so on. In 
      this study, it was aimed to investigate the effect of AEE on the acute lung 
      injury (ALI) induced by lipopolysaccharide (LPS) in rats. In vitro experiments 
      evaluated the protective effect of AEE on the LPS-induced A549 cells. The tumor 
      necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) were 
      measured in the cell supernatant. The Wistar rats were randomly divided into five 
      groups (n = 8): control group, model group (LPS group), LPS + AEE group (AEE, 54 
      mg·kg(-1)), LPS + AEE group (AEE, 108 mg·kg(-1)), LPS + AEE group (AEE, 216 
      mg·kg(-1)). The lung wet-to-dry weight (W/D) ratio and immune organ index were 
      calculated. WBCs were counted in bronchoalveolar lavage fluid (BALF) and total 
      protein concentration was measured. Hematoxylin-Eosin (HE) staining of lung 
      tissue was performed. Glutathione (GSH), glutathione peroxidase (GPx), catalase 
      (CAT), antioxidant superoxide dismutase (SOD), total antioxidant capacity 
      (T-AOC), lactate dehydrogenase (LDH), C-reactive protein (CRP), myeloperoxidase 
      (MPO), malondialdehyde (MDA), macrophage mobility inhibitory factor (MIF), TNF-α, 
      IL-6, and IL-1β activity were measured. The metabolomic analysis of rat serum was 
      performed by UPLC-QTOF-MS/MS. From the results, compared with LPS group, AEE 
      improved histopathological changes, reduced MDA, CRP, MPO, MDA, and MIF 
      production, decreased WBC count and total protein content in BALF, 
      pro-inflammatory cytokine levels, immune organ index and lung wet-dry weight 
      (W/D), increased antioxidant enzyme activity, in a dose-dependent manner. The 
      results of serum metabolomic analysis showed that the LPS-induced ALI caused 
      metabolic disorders and oxidative stress in rats, while AEE could ameliorate it 
      to some extent. Therefore, AEE could alleviate LPS-induced ALI in rats by 
      regulating abnormal inflammatory responses, slowing down oxidative stress, and 
      modulating energy metabolism.
CI  - Copyright © 2022 Tao, Zhang, Qin, Liu, Li, Bai, Ge, Li and Yang.
FAU - Tao, Qi
AU  - Tao Q
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture and Rural Affairs, Lanzhou 
      Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Zhang, Zhen-Dong
AU  - Zhang ZD
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture and Rural Affairs, Lanzhou 
      Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Qin, Zhe
AU  - Qin Z
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture and Rural Affairs, Lanzhou 
      Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Liu, Xi-Wang
AU  - Liu XW
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture and Rural Affairs, Lanzhou 
      Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Li, Shi-Hong
AU  - Li SH
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture and Rural Affairs, Lanzhou 
      Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Bai, Li-Xia
AU  - Bai LX
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture and Rural Affairs, Lanzhou 
      Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Ge, Wen-Bo
AU  - Ge WB
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture and Rural Affairs, Lanzhou 
      Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Li, Jian-Yong
AU  - Li JY
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture and Rural Affairs, Lanzhou 
      Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Yang, Ya-Jun
AU  - Yang YJ
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture and Rural Affairs, Lanzhou 
      Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220729
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antioxidants)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - A549 Cells/drug effects
MH  - *Acute Lung Injury/chemically induced/drug therapy/metabolism
MH  - Animals
MH  - *Antioxidants/pharmacology/therapeutic use
MH  - *Aspirin/analogs & derivatives/pharmacology/therapeutic use
MH  - *Eugenol/analogs & derivatives/pharmacology/therapeutic use
MH  - Humans
MH  - Interleukin-6/metabolism
MH  - Lipopolysaccharides/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Tandem Mass Spectrometry
MH  - Tumor Necrosis Factor-alpha/metabolism
PMC - PMC9372404
OTO - NOTNLM
OT  - acute lung injury
OT  - aspirin eugenol ester (AEE)
OT  - inflammation
OT  - metabolites
OT  - oxidative stress
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/16 06:00
MHDA- 2022/08/17 06:00
CRDT- 2022/08/15 03:57
PHST- 2022/05/08 00:00 [received]
PHST- 2022/07/06 00:00 [accepted]
PHST- 2022/08/15 03:57 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
AID - 10.3389/fimmu.2022.939106 [doi]
PST - epublish
SO  - Front Immunol. 2022 Jul 29;13:939106. doi: 10.3389/fimmu.2022.939106. eCollection 
      2022.

PMID- 23649680
OWN - NLM
STAT- MEDLINE
DCOM- 20130708
LR  - 20131121
IS  - 0888-5109 (Print)
IS  - 0888-5109 (Linking)
VI  - 28
IP  - 5
DP  - 2013 May
TI  - Use of electronic personal health records to identify patients at risk for 
      aspirin-induced gastrointestinal bleeding.
PG  - 313-8
LID - 10.4140/TCP.n.2013.313 [doi]
AB  - OBJECTIVE(S): The aim of this paper is to describe the utility of electronic 
      personal health records (ePHRs) to identify patients with potential risk factors 
      for aspirin-induced upper gastrointestinal bleeding (UGIB). SETTING: ER-Card, 
      LLC. a for-profit ePHR company located in Rhode Island from October 2008 to May 
      2010. PRACTICE DESCRIPTION: Clinical pharmacists reviewed the records of 615 
      patients enrolled in an ePHR service. Records included patient self-report of all 
      known medical conditions, current prescription medications, and self-care 
      therapies utilized. PRACTICE INNOVATION: Pharmacists reviewed ePHR profiles for 
      actual or potential medication-related problems. Patients taking low-dose aspirin 
      (81 mg-325 mg daily) were screened for known additional risk factors for 
      aspirin-induced UGIB. Patients identified were notified to contact their provider 
      for information and/or providers were contacted directly by pharmacists with 
      therapy recommendations. MAIN OUTCOME MEASURE(S): Number of patients at increased 
      risk for aspirin-induced UGIB as a result of concomitant medications. RESULTS: 
      Ninety-seven patients (16% of total records screened) with an average age of 72.1 
      years had risk factors for aspirin induced UGIB. In addition to daily aspirin 
      therapy patients reported regular use of nonsteroidal anti-inflammatory drugs or 
      cyclooxygenase-2 inhibitors (38%), other antiplatelet agents (22%), 
      anticoagulants (24%), corticosteroids (4%), or a combination of these medications 
      (12%). None of the patients included in this analysis reported use of prescribed 
      or overthe-counter gastroprotective therapy (such as proton-pump inhibitors or 
      histamine-2 receptor antagonists). CONCLUSION: Pharmacist screening of patient 
      self-reported health information as part of an ePHR service can result in the 
      detection of a significant number of patients at increased risk for 
      aspirin-induced UGIB.
FAU - Jackson, Anita N
AU  - Jackson AN
AD  - Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, 
      Kingston, RI, USA.
FAU - Kogut, Stephen
AU  - Kogut S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant 
      Pharmacists
JID - 9013983
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Electronic Health Records/*statistics & numerical data
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pharmaceutical Services/organization & administration
MH  - Pharmacists/organization & administration
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Professional Role
MH  - Risk Factors
MH  - Self Report
EDAT- 2013/05/08 06:00
MHDA- 2013/07/09 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/05/08 06:00 [entrez]
PHST- 2013/05/08 06:00 [pubmed]
PHST- 2013/07/09 06:00 [medline]
AID - K7375072416T7786 [pii]
AID - 10.4140/TCP.n.2013.313 [doi]
PST - ppublish
SO  - Consult Pharm. 2013 May;28(5):313-8. doi: 10.4140/TCP.n.2013.313.

PMID- 9716578
OWN - NLM
STAT- MEDLINE
DCOM- 19980910
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 92
IP  - 5
DP  - 1998 Sep 1
TI  - A double-blind randomized comparison of combined aspirin and ticlopidine therapy 
      versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in 
      humans.
PG  - 1518-25
AB  - No randomized study comparing the effect of combined ticlopidine and aspirin 
      therapy versus each drug alone in reducing poststenting thrombotic complications 
      has been performed. To compare these three antiplatelet regimens versus placebo, 
      we conducted a double-blind randomized study using an ex vivo model of 
      thrombosis. Sixteen healthy male volunteers were assigned to receive for 8 days 
      the following four regimens separated by a 1-month period: aspirin 325 mg/d, 
      ticlopidine 500 mg/d, aspirin 325 mg/d + ticlopidine 500 mg/d, and placebo. At 
      the end of each treatment period, native nonanticoagulated blood was drawn 
      directly from an antecubital vein over collagen- or tissue factor (TF)-coated 
      coverslips positioned in a parallel-plate perfusion chamber at an arterial wall 
      shear rate (2, 600 s-1 ) for 3 minutes. Thrombus, which formed on collagen in 
      volunteers treated by placebo, were rich in platelets and poor in fibrin. As 
      compared with placebo, aspirin and ticlopidine alone reduced platelet thrombus 
      formation by only 29% and 15%, respectively (P > .2). In contrast, platelet 
      thrombus formation was blocked by more than 90% in volunteers treated by aspirin 
      + ticlopidine (P < .01 v placebo or each treatment alone). Furthermore, the 
      effect of the drug combination therapy was significantly larger than the sum of 
      the two active treatments (P < .05). Thrombus, which formed on TF-coated 
      coverslips in volunteers treated by placebo, were rich in fibrin and platelets. 
      Neither of the three antiplatelet treatments significantly inhibited fibrin 
      deposition and platelet thrombus formation on this surface (P > .2). Thus, the 
      present study shows that combined aspirin and ticlopidine therapy dramatically 
      potentiates the antithrombotic effect of each drug alone, but that the 
      antithrombotic effect of the combined treatment depends on the nature of the 
      thrombogenic surface.
CI  - Copyright 1998 by The American Society of Hematology.
FAU - Bossavy, J P
AU  - Bossavy JP
AD  - Laboratoire de Recherche sur l'Hémostase et la Thrombose, Pavillon Lefèbvre, CHU 
      Purpan, Toulouse CEDEX, France.
FAU - Thalamas, C
AU  - Thalamas C
FAU - Sagnard, L
AU  - Sagnard L
FAU - Barret, A
AU  - Barret A
FAU - Sakariassen, K
AU  - Sakariassen K
FAU - Boneu, B
AU  - Boneu B
FAU - Cadroy, Y
AU  - Cadroy Y
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9007-34-5 (Collagen)
RN  - 9035-58-9 (Thromboplastin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arteries
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood
MH  - Blood Platelets/physiology
MH  - Collagen
MH  - Double-Blind Method
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Glass
MH  - Humans
MH  - Male
MH  - *Models, Biological
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Thromboplastin
MH  - Thrombosis/*prevention & control
MH  - Ticlopidine/*administration & dosage/therapeutic use
EDAT- 1998/08/26 00:00
MHDA- 1998/08/26 00:01
CRDT- 1998/08/26 00:00
PHST- 1998/08/26 00:00 [pubmed]
PHST- 1998/08/26 00:01 [medline]
PHST- 1998/08/26 00:00 [entrez]
AID - S0006-4971(20)74103-0 [pii]
PST - ppublish
SO  - Blood. 1998 Sep 1;92(5):1518-25.

PMID- 12806051
OWN - NLM
STAT- MEDLINE
DCOM- 20050729
LR  - 20180705
IS  - 1537-744X (Electronic)
IS  - 2356-6140 (Print)
IS  - 1537-744X (Linking)
VI  - 2
DP  - 2002 Jan 22
TI  - Lipid-derived mediators in endogenous anti-inflammation and resolution: lipoxins 
      and aspirin-triggered 15-epi-lipoxins.
PG  - 169-204
AB  - It is well appreciated that lipid-derived mediators play key roles in 
      inflammation and many other physiologic responses where multicellular processes 
      are involved. Among them, lipoxins (LX) and aspirin-triggered LX (ATL) evoke 
      actions of interest in a range of physiologic and pathophysiologic processes, and 
      these two series have emerged as founding members of the first class of 
      lipid/chemical mediators "switched on" in the resolution phase of an inflammatory 
      reaction. These unique compounds possess a trihydroxytetraene structure and are 
      both structurally and functionally distinct among the many groups of 
      lipid-derived bioactive mediators. LXA4 and 15-epi-LXA4 (a member of the ATL 
      series) display leukocyte-selective actions that enable them to serve as 
      endogenous "stop signals" in multicellular events in that they modulate 
      adherence, transmigration, and chemotaxis. Both LXA4 and 15-epi-LXA elicit these 
      responses via a G protein-coupled receptor (GPCR), termed ALXR, identified in 
      human and murine tissues. Among eicosanoids, ALXR is stereoselective for LXA4 
      (5S,6R,15S-trihydroxy-7,9,13- trans-11-cis-eicosatetraenoic acid). Its 
      aspirin-triggered 15 R epimer (15-epi-LXA4) and their bioactive stable analogs 
      act in the subnanomolar to nanomolar range in human cellular systems and murine 
      models of acute inflammation and reperfusion. ALXR also has the ability to 
      interact with a wide panel of small peptides that give different signaling 
      responses in vitro than LXA4 or its analogs, suggesting that ALXR is capable of 
      serving as a multirecognition receptor in immune responses. Characterization of 
      ALXR and development of metabolically stable LX and ATL analogs that are mimetics 
      rapidly advanced our appreciation of the mechanism of LX actions and the 
      potential utility of these counter-regulatory biocircuits in the quest to control 
      local inflammatory events. In this on-line update, LX and ATL biosynthesis and 
      the LXA4 specific receptor, termed ALXR, are reviewed with a focus on their roles 
      in inflammation and resolution with respect to pharmacology, molecular biology, 
      and signal transduction in several cell types and animal models investigated thus 
      far.
FAU - Serhan, Charles N
AU  - Serhan CN
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Harvard Medical School, Boston, Massachusetts 02115, USA. 
      cnserhan@zeus.bwh.harvard.edu
FAU - Chiang, Nan
AU  - Chiang N
LA  - eng
GR  - DK50305/DK/NIDDK NIH HHS/United States
GR  - GM38765/GM/NIGMS NIH HHS/United States
GR  - P01-DE13499/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
DEP - 20020122
PL  - United States
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Lipoxins)
RN  - 0 (Receptors, Lipoxin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*chemistry/*pharmacology
MH  - Aspirin/chemistry/*pharmacology
MH  - Humans
MH  - Inflammation Mediators/*chemistry/*pharmacology
MH  - Lipoxins/biosynthesis/*chemistry/metabolism/*pharmacology
MH  - Receptors, Lipoxin/chemistry/genetics/metabolism
MH  - Signal Transduction/drug effects
PMC - PMC6009744
EDAT- 2003/06/14 05:00
MHDA- 2005/07/30 09:00
CRDT- 2003/06/14 05:00
PHST- 2003/06/14 05:00 [pubmed]
PHST- 2005/07/30 09:00 [medline]
PHST- 2003/06/14 05:00 [entrez]
AID - 920986 [pii]
AID - 10.1100/tsw.2002.81 [doi]
PST - epublish
SO  - ScientificWorldJournal. 2002 Jan 22;2:169-204. doi: 10.1100/tsw.2002.81.

PMID- 26369688
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 21
IP  - 35
DP  - 2015
TI  - Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin.
PG  - 5049-55
AB  - Low-dose aspirin, commonly defined as 75-325 mg daily, is widely used for 
      cardiovascular (CV) protection. It reduced the risk of CV events and death in 
      patients with coronary and cerebrovascular diseases and has the advantages of 
      both low cost and long duration of antiplatelet action. However, low-dose aspirin 
      therapy is associated with upper gastrointestinal (GI) side effects, which range 
      from dyspepsia (point prevalence: 31%), gastroduodenal erosions (point 
      prevalence: 60%), endoscopic peptic ulcer (3-month incidence: 7%) to symptomatic 
      or complicated ulcers (annual incidence of upper GI bleeding: 0.6%; relative risk 
      of upper GI bleeding: 2.6). The important factors that increase the risk of 
      low-dose aspirin-related ulcer complications include a history of bleeding peptic 
      ulcer, prior peptic ulcer, age > 70 years, H pylori infection, and concomitant 
      drug therapy with non-steroidal anti-inflammatory drugs, other antiplatelet 
      agents (e.g., clopidogrel) or anticoagulants. The use of enteric-coated or 
      buffered preparations do not reduce the risk of upper GI complications. 
      Assessment of GI risk for patients is a crucial step in preventing complications 
      of antiplatelet agents. Patients with a high GI risk should prevent peptic ulcer 
      or ulcer complications by co-therapy with an antisecretory agent, especially 
      proton pump inhibitors. H pylori eradication is recommended for patients 
      requiring long-term low-dose aspirin therapy who have a prior history of peptic 
      ulcer or GI bleeding.
FAU - Hsu, Ping-I
AU  - Hsu PI
FAU - Tsai, Tzung-Jiun
AU  - Tsai TJ
AD  - Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans 
      General Hospital, 386 Ta Chung 1st Road, Kaohsiung 813, Taiwan. 
      tjtsai@vghks.gov.tw.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Diseases/*chemically induced/epidemiology/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk Factors
MH  - Upper Gastrointestinal Tract/drug effects/pathology
EDAT- 2015/09/16 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/06/19 00:00 [received]
PHST- 2015/09/14 00:00 [accepted]
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - CPD-EPUB-70379 [pii]
AID - 10.2174/1381612821666150915104800 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2015;21(35):5049-55. doi: 10.2174/1381612821666150915104800.

PMID- 24679062
OWN - NLM
STAT- MEDLINE
DCOM- 20140506
LR  - 20220321
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 370
IP  - 16
DP  - 2014 Apr 17
TI  - Aspirin in patients undergoing noncardiac surgery.
PG  - 1494-503
LID - 10.1056/NEJMoa1401105 [doi]
AB  - BACKGROUND: There is substantial variability in the perioperative administration 
      of aspirin in patients undergoing noncardiac surgery, both among patients who are 
      already on an aspirin regimen and among those who are not. METHODS: Using a 
      2-by-2 factorial trial design, we randomly assigned 10,010 patients who were 
      preparing to undergo noncardiac surgery and were at risk for vascular 
      complications to receive aspirin or placebo and clonidine or placebo. The results 
      of the aspirin trial are reported here. The patients were stratified according to 
      whether they had not been taking aspirin before the study (initiation stratum, 
      with 5628 patients) or they were already on an aspirin regimen (continuation 
      stratum, with 4382 patients). Patients started taking aspirin (at a dose of 200 
      mg) or placebo just before surgery and continued it daily (at a dose of 100 mg) 
      for 30 days in the initiation stratum and for 7 days in the continuation stratum, 
      after which patients resumed their regular aspirin regimen. The primary outcome 
      was a composite of death or nonfatal myocardial infarction at 30 days. RESULTS: 
      The primary outcome occurred in 351 of 4998 patients (7.0%) in the aspirin group 
      and in 355 of 5012 patients (7.1%) in the placebo group (hazard ratio in the 
      aspirin group, 0.99; 95% confidence interval [CI], 0.86 to 1.15; P=0.92). Major 
      bleeding was more common in the aspirin group than in the placebo group (230 
      patients [4.6%] vs. 188 patients [3.8%]; hazard ratio, 1.23; 95% CI, 1.01, to 
      1.49; P=0.04). The primary and secondary outcome results were similar in the two 
      aspirin strata. CONCLUSIONS: Administration of aspirin before surgery and 
      throughout the early postsurgical period had no significant effect on the rate of 
      a composite of death or nonfatal myocardial infarction but increased the risk of 
      major bleeding. (Funded by the Canadian Institutes of Health Research and others; 
      POISE-2 ClinicalTrials.gov number, NCT01082874.).
FAU - Devereaux, P J
AU  - Devereaux PJ
AD  - The authors' affiliations are listed in the Appendix.
FAU - Mrkobrada, Marko
AU  - Mrkobrada M
FAU - Sessler, Daniel I
AU  - Sessler DI
FAU - Leslie, Kate
AU  - Leslie K
FAU - Alonso-Coello, Pablo
AU  - Alonso-Coello P
FAU - Kurz, Andrea
AU  - Kurz A
FAU - Villar, Juan Carlos
AU  - Villar JC
FAU - Sigamani, Alben
AU  - Sigamani A
FAU - Biccard, Bruce M
AU  - Biccard BM
FAU - Meyhoff, Christian S
AU  - Meyhoff CS
FAU - Parlow, Joel L
AU  - Parlow JL
FAU - Guyatt, Gordon
AU  - Guyatt G
FAU - Robinson, Andrea
AU  - Robinson A
FAU - Garg, Amit X
AU  - Garg AX
FAU - Rodseth, Reitze N
AU  - Rodseth RN
FAU - Botto, Fernando
AU  - Botto F
FAU - Lurati Buse, Giovanna
AU  - Lurati Buse G
FAU - Xavier, Denis
AU  - Xavier D
FAU - Chan, Matthew T V
AU  - Chan MT
FAU - Tiboni, Maria
AU  - Tiboni M
FAU - Cook, Deborah
AU  - Cook D
FAU - Kumar, Priya A
AU  - Kumar PA
FAU - Forget, Patrice
AU  - Forget P
FAU - Malaga, German
AU  - Malaga G
FAU - Fleischmann, Edith
AU  - Fleischmann E
FAU - Amir, Mohammed
AU  - Amir M
FAU - Eikelboom, John
AU  - Eikelboom J
FAU - Mizera, Richard
AU  - Mizera R
FAU - Torres, David
AU  - Torres D
FAU - Wang, C Y
AU  - Wang CY
FAU - VanHelder, Tomas
AU  - VanHelder T
FAU - Paniagua, Pilar
AU  - Paniagua P
FAU - Berwanger, Otavio
AU  - Berwanger O
FAU - Srinathan, Sadeesh
AU  - Srinathan S
FAU - Graham, Michelle
AU  - Graham M
FAU - Pasin, Laura
AU  - Pasin L
FAU - Le Manach, Yannick
AU  - Le Manach Y
FAU - Gao, Peggy
AU  - Gao P
FAU - Pogue, Janice
AU  - Pogue J
FAU - Whitlock, Richard
AU  - Whitlock R
FAU - Lamy, André
AU  - Lamy A
FAU - Kearon, Clive
AU  - Kearon C
FAU - Baigent, Colin
AU  - Baigent C
FAU - Chow, Clara
AU  - Chow C
FAU - Pettit, Shirley
AU  - Pettit S
FAU - Chrolavicius, Susan
AU  - Chrolavicius S
FAU - Yusuf, Salim
AU  - Yusuf S
CN  - POISE-2 Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT01082874
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140331
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2014 Apr 17;370(16):1554-5. PMID: 24679063
CIN - Nat Rev Cardiol. 2014 Jun;11(6):314. PMID: 24736754
CIN - Anaesthesist. 2014 Jun;63(6):517-8. PMID: 24820358
CIN - Evid Based Med. 2014 Dec;19(6):224-5. PMID: 24985900
CIN - Semergen. 2014 Oct;40(7):395-6. PMID: 25092509
CIN - Ann Intern Med. 2014 Aug 19;161(4):JC5. PMID: 25133384
CIN - World Neurosurg. 2014 Dec;82(6):928-9. PMID: 25311980
CIN - Internist (Berl). 2014 Dec;55(12):1492-4. PMID: 25398476
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology/*prevention & control
MH  - Perioperative Care
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Surgical Procedures, Operative/*mortality
MH  - Treatment Failure
FIR - DeBeer, J
IR  - DeBeer J
FIR - Mizera, R
IR  - Mizera R
FIR - Patel, A
IR  - Patel A
FIR - VanHelder, T
IR  - VanHelder T
FIR - Cook, D
IR  - Cook D
FIR - Dechert, W
IR  - Dechert W
FIR - Jackson, P
IR  - Jackson P
FIR - Tiboni, M
IR  - Tiboni M
FIR - Allard, R
IR  - Allard R
FIR - Dumerton-Shore, D
IR  - Dumerton-Shore D
FIR - McCourt, J
IR  - McCourt J
FIR - Parlow, J L
IR  - Parlow JL
FIR - Jones, P M
IR  - Jones PM
FIR - Lavi, R
IR  - Lavi R
FIR - Lavi, S
IR  - Lavi S
FIR - Moor, R
IR  - Moor R
FIR - Dresser, G K
IR  - Dresser GK
FIR - Garg, A X
IR  - Garg AX
FIR - Gros, M L
IR  - Gros ML
FIR - Schumann, V C
IR  - Schumann VC
FIR - Baur, M
IR  - Baur M
FIR - MacDonald, C
IR  - MacDonald C
FIR - Wirzba, B
IR  - Wirzba B
FIR - Regalado, O
IR  - Regalado O
FIR - Srinathan, S K
IR  - Srinathan SK
FIR - Ong, D D
IR  - Ong DD
FIR - Todd, A
IR  - Todd A
FIR - Abbas, S
IR  - Abbas S
FIR - Beattie, W S
IR  - Beattie WS
FIR - Chan, V W S
IR  - Chan VW
FIR - Chin, K J
IR  - Chin KJ
FIR - Wijeysundera, D N
IR  - Wijeysundera DN
FIR - Graham, M M
IR  - Graham MM
FIR - Irwin, M
IR  - Irwin M
FIR - Jacka, M
IR  - Jacka M
FIR - El Beheiry, H
IR  - El Beheiry H
FIR - McMullen, S M
IR  - McMullen SM
FIR - MacDonald, P
IR  - MacDonald P
FIR - Akhtar, Z
IR  - Akhtar Z
FIR - Ayad, S
IR  - Ayad S
FIR - Buttar, M
IR  - Buttar M
FIR - Deroee, A
IR  - Deroee A
FIR - Eshraghi, Y
IR  - Eshraghi Y
FIR - Fergany, A
IR  - Fergany A
FIR - Finnigan, P
IR  - Finnigan P
FIR - Fu, A
IR  - Fu A
FIR - Grady, M
IR  - Grady M
FIR - Helper, S
IR  - Helper S
FIR - Hesler, B
IR  - Hesler B
FIR - Honar, H
IR  - Honar H
FIR - Hutcherson, M
IR  - Hutcherson M
FIR - Krebs, V
IR  - Krebs V
FIR - Kurz, A
IR  - Kurz A
FIR - Lee, J
IR  - Lee J
FIR - Malik, M
IR  - Malik M
FIR - Podolyak, A
IR  - Podolyak A
FIR - Salmasi, V
IR  - Salmasi V
FIR - Sessler, D I
IR  - Sessler DI
FIR - Arora, H
IR  - Arora H
FIR - Coombs, R F
IR  - Coombs RF
FIR - Kumar, P A
IR  - Kumar PA
FIR - Martinelli, S M
IR  - Martinelli SM
FIR - Bergese, S D
IR  - Bergese SD
FIR - Melibary, S B
IR  - Melibary SB
FIR - Uribe, A A
IR  - Uribe AA
FIR - Jordan, M
IR  - Jordan M
FIR - Miller, S A
IR  - Miller SA
FIR - Cata, J P
IR  - Cata JP
FIR - Nemergut, E C
IR  - Nemergut EC
FIR - Candiotti, K A
IR  - Candiotti KA
FIR - Memtsoudis, S G
IR  - Memtsoudis SG
FIR - McKay, R E
IR  - McKay RE
FIR - Montes, F R
IR  - Montes FR
FIR - Parra, G A
IR  - Parra GA
FIR - Rojas, M F
IR  - Rojas MF
FIR - Plata, R
IR  - Plata R
FIR - Vásquez, S M
IR  - Vásquez SM
FIR - Sarquis, T
IR  - Sarquis T
FIR - Haider, Z
IR  - Haider Z
FIR - Jane, N B
IR  - Jane NB
FIR - Lanjewar, P P
IR  - Lanjewar PP
FIR - Rahate, P V
IR  - Rahate PV
FIR - Mehra, B R
IR  - Mehra BR
FIR - Premendaran, B
IR  - Premendaran B
FIR - Abraham, V
IR  - Abraham V
FIR - George, P
IR  - George P
FIR - Kumar, P
IR  - Kumar P
FIR - Gaikwad, S B
IR  - Gaikwad SB
FIR - Mohan, N V S
IR  - Mohan NV
FIR - Sidhu, G
IR  - Sidhu G
FIR - Alvarez, J
IR  - Alvarez J
FIR - Gonzalez, R
IR  - Gonzalez R
FIR - Maestre, M
IR  - Maestre M
FIR - Popova, E
IR  - Popova E
FIR - Urrutia, G
IR  - Urrutia G
FIR - de Nadal, M
IR  - de Nadal M
FIR - González-Suárez, S
IR  - González-Suárez S
FIR - González-Tallada, A
IR  - González-Tallada A
FIR - Plou, P
IR  - Plou P
FIR - Mena, E Mata
IR  - Mena E
FIR - Riveira, C Fernandez
IR  - Riveira C
FIR - del Valle, S Garcia
IR  - del Valle S
FIR - Tena, B
IR  - Tena B
FIR - Lang, S A
IR  - Lang SA
FIR - Ludbrook, G L
IR  - Ludbrook GL
FIR - Painter, T W
IR  - Painter TW
FIR - Terblanche, N C
IR  - Terblanche NC
FIR - Osborne, C
IR  - Osborne C
FIR - Mahood, J R
IR  - Mahood JR
FIR - Leslie, K
IR  - Leslie K
FIR - Myles, P S
IR  - Myles PS
FIR - Sivalingam, P
IR  - Sivalingam P
FIR - Riedel, B
IR  - Riedel B
FIR - Elhalawani, I
IR  - Elhalawani I
FIR - Biccard, B M
IR  - Biccard BM
FIR - Drummond, L
IR  - Drummond L
FIR - Mugabi, A
IR  - Mugabi A
FIR - Naidoo, P
IR  - Naidoo P
FIR - Myburgh, A L
IR  - Myburgh AL
FIR - Porrill, O S
IR  - Porrill OS
FIR - Diedericks, B J S
IR  - Diedericks BJ
FIR - Turton, E W
IR  - Turton EW
FIR - Bøgeskov, M
IR  - Bøgeskov M
FIR - Dahl, R M
IR  - Dahl RM
FIR - Madsen, M V
IR  - Madsen MV
FIR - Søndergaard, E S
IR  - Søndergaard ES
FIR - Bauer, N E
IR  - Bauer NE
FIR - Martinsen, K R
IR  - Martinsen KR
FIR - Chan, M T V
IR  - Chan MT
FIR - Choi, G Y S
IR  - Choi GY
FIR - Gin, T
IR  - Gin T
FIR - Ng, S S M
IR  - Ng SS
FIR - Bidgoli, S J
IR  - Bidgoli SJ
FIR - Van der Linden, P J
IR  - Van der Linden PJ
FIR - De Kock, M
IR  - De Kock M
FIR - Forget, P
IR  - Forget P
FIR - Fleischmann, E
IR  - Fleischmann E
FIR - Kabon, B
IR  - Kabon B
FIR - Luf, F
IR  - Luf F
FIR - Radonic, M
IR  - Radonic M
FIR - Amir, M
IR  - Amir M
FIR - Ishtiaq, O
IR  - Ishtiaq O
FIR - Safdar, J
IR  - Safdar J
FIR - Acuna-Villaorduna, A
IR  - Acuna-Villaorduna A
FIR - Barrionuevo, P
IR  - Barrionuevo P
FIR - Castaneda-Guarderas, A
IR  - Castaneda-Guarderas A
FIR - Caballero, J A
IR  - Caballero JA
FIR - Lau, V E
IR  - Lau VE
FIR - Aphang-Lam, M R
IR  - Aphang-Lam MR
FIR - Lembo, R
IR  - Lembo R
FIR - Pasin, L
IR  - Pasin L
FIR - Gossetti, B
IR  - Gossetti B
FIR - Jara, X
IR  - Jara X
FIR - Leon, P
IR  - Leon P
FIR - Torres, D
IR  - Torres D
FIR - Ong, G S Y
IR  - Ong GS
FIR - Wang, C Y
IR  - Wang CY
FIR - Lee, H S
IR  - Lee HS
FIR - Seeberger, E E
IR  - Seeberger EE
FIR - Seeberger, M D
IR  - Seeberger MD
FIR - Alfonsi, P
IR  - Alfonsi P
FIR - Coriat, P
IR  - Coriat P
FIR - Piriou, V
IR  - Piriou V
FIR - Vizcaychipi, M P
IR  - Vizcaychipi MP
FIR - Rech, R L
IR  - Rech RL
FIR - Bergo, R R
IR  - Bergo RR
FIR - Walker, S
IR  - Walker S
FIR - Devereaux, P J
IR  - Devereaux PJ
FIR - Sessler, D I
IR  - Sessler DI
FIR - Kurz, A
IR  - Kurz A
FIR - Mrkobrada, M
IR  - Mrkobrada M
FIR - Lurati Buse, G
IR  - Lurati Buse G
FIR - Botto, F
IR  - Botto F
FIR - Rodseth, R
IR  - Rodseth R
FIR - Robinson, A
IR  - Robinson A
FIR - Guyatt, G
IR  - Guyatt G
FIR - LeManach, Y
IR  - LeManach Y
FIR - Pogue, J
IR  - Pogue J
FIR - Pettit, S
IR  - Pettit S
FIR - Chrolavicius, S
IR  - Chrolavicius S
FIR - Yusuf, S
IR  - Yusuf S
FIR - Botto, F
IR  - Botto F
FIR - Díaz, R
IR  - Díaz R
FIR - Leslie, K
IR  - Leslie K
FIR - Fleischmann, E
IR  - Fleischmann E
FIR - Forget, P
IR  - Forget P
FIR - Berwanger, O
IR  - Berwanger O
FIR - Devereaux, P J
IR  - Devereaux PJ
FIR - Mrkobrada, M
IR  - Mrkobrada M
FIR - Torres, D
IR  - Torres D
FIR - Villar, J C
IR  - Villar JC
FIR - Cortés, O L
IR  - Cortés OL
FIR - Meyhoff, C S
IR  - Meyhoff CS
FIR - Wetterslev, J
IR  - Wetterslev J
FIR - Alfonsi, P
IR  - Alfonsi P
FIR - Hoeft, A
IR  - Hoeft A
FIR - Wittmann, M
IR  - Wittmann M
FIR - Chan, M
IR  - Chan M
FIR - Sigamani, A
IR  - Sigamani A
FIR - Xavier, D
IR  - Xavier D
FIR - Landoni, G
IR  - Landoni G
FIR - Wang, C Y
IR  - Wang CY
FIR - Ishtiaq, O
IR  - Ishtiaq O
FIR - Malaga, G
IR  - Malaga G
FIR - Biccard, B M
IR  - Biccard BM
FIR - Alonso-Coello, P
IR  - Alonso-Coello P
FIR - Conen, D
IR  - Conen D
FIR - Balaji, P
IR  - Balaji P
FIR - Kurz, A
IR  - Kurz A
FIR - Robinson, A
IR  - Robinson A
FIR - Sovereign, T
IR  - Sovereign T
FIR - Blake, L
IR  - Blake L
FIR - Sephton, J
IR  - Sephton J
FIR - Serra, A
IR  - Serra A
FIR - Agrippa, C
IR  - Agrippa C
FIR - Lawrence, M
IR  - Lawrence M
FIR - Gao, P
IR  - Gao P
FIR - Pettit, S
IR  - Pettit S
FIR - Chrolavicius, S
IR  - Chrolavicius S
FIR - Leslie, K
IR  - Leslie K
FIR - Alonso-Coello, P
IR  - Alonso-Coello P
FIR - Biccard, B
IR  - Biccard B
FIR - Chan, M
IR  - Chan M
FIR - Meyhoff, C S
IR  - Meyhoff CS
FIR - Villar, J C
IR  - Villar JC
FIR - Xavier, D
IR  - Xavier D
FIR - Wang, C Y
IR  - Wang CY
FIR - Landoni, G
IR  - Landoni G
FIR - Berwanger, O
IR  - Berwanger O
FIR - Jacka, M
IR  - Jacka M
FIR - Malaga, G
IR  - Malaga G
FIR - Chow, C
IR  - Chow C
FIR - Gluud, C
IR  - Gluud C
FIR - Baigent, C
IR  - Baigent C
FIR - Karthikeyan, G
IR  - Karthikeyan G
FIR - Devereaux, P J
IR  - Devereaux PJ
FIR - Alfonsi, P
IR  - Alfonsi P
FIR - Alonso-Coello, P
IR  - Alonso-Coello P
FIR - Auerbach, A
IR  - Auerbach A
FIR - Baigent, C
IR  - Baigent C
FIR - Balaji, P
IR  - Balaji P
FIR - Beattie, S
IR  - Beattie S
FIR - Berwanger, O
IR  - Berwanger O
FIR - Biccard, B M
IR  - Biccard BM
FIR - Botto, F
IR  - Botto F
FIR - Buckley, N
IR  - Buckley N
FIR - Chan, M
IR  - Chan M
FIR - Chow, C
IR  - Chow C
FIR - Chrolavicius, S
IR  - Chrolavicius S
FIR - Conen, D
IR  - Conen D
FIR - Cook, D
IR  - Cook D
FIR - Douketis, J
IR  - Douketis J
FIR - Eikelboom, J
IR  - Eikelboom J
FIR - Forget, P
IR  - Forget P
FIR - Garg, A X
IR  - Garg AX
FIR - Gerstein, H
IR  - Gerstein H
FIR - Ghali, W
IR  - Ghali W
FIR - Graham, M
IR  - Graham M
FIR - Guyatt, G
IR  - Guyatt G
FIR - Hart, R
IR  - Hart R
FIR - Hill, M
IR  - Hill M
FIR - Hoeft, A
IR  - Hoeft A
FIR - Jacka, M
IR  - Jacka M
FIR - Karthikeyan, G
IR  - Karthikeyan G
FIR - Kearon, C
IR  - Kearon C
FIR - Kurz, A
IR  - Kurz A
FIR - Lamy, A
IR  - Lamy A
FIR - Landoni, G
IR  - Landoni G
FIR - LeManach, Y
IR  - LeManach Y
FIR - Leslie, K
IR  - Leslie K
FIR - Lurati Buse, G
IR  - Lurati Buse G
FIR - Malaga, G
IR  - Malaga G
FIR - McAlister, F
IR  - McAlister F
FIR - McAuley, D
IR  - McAuley D
FIR - Meyhoff, C S
IR  - Meyhoff CS
FIR - Miller, S
IR  - Miller S
FIR - Mrkobrada, M
IR  - Mrkobrada M
FIR - O'Donnell, M
IR  - O'Donnell M
FIR - Pais, P
IR  - Pais P
FIR - Parlow, J
IR  - Parlow J
FIR - Pogue, J
IR  - Pogue J
FIR - Robinson, A
IR  - Robinson A
FIR - Rodseth, R
IR  - Rodseth R
FIR - Schricker, T
IR  - Schricker T
FIR - Sessler, D
IR  - Sessler D
FIR - Simunovic, M
IR  - Simunovic M
FIR - Srinathan, S
IR  - Srinathan S
FIR - Teoh, K
IR  - Teoh K
FIR - Torres, D
IR  - Torres D
FIR - Urrutia, G
IR  - Urrutia G
FIR - Villar, J C
IR  - Villar JC
FIR - Walsh, M
IR  - Walsh M
FIR - Wang, C Y
IR  - Wang CY
FIR - Wetterslev, J
IR  - Wetterslev J
FIR - Whitlock, R
IR  - Whitlock R
FIR - Wijeysundera, D
IR  - Wijeysundera D
FIR - Xavier, D
IR  - Xavier D
FIR - Yang, H
IR  - Yang H
FIR - Yusuf, S
IR  - Yusuf S
FIR - Guyatt, G
IR  - Guyatt G
FIR - Botto, F
IR  - Botto F
FIR - Alonso-Coello, P
IR  - Alonso-Coello P
FIR - Alshalash, S
IR  - Alshalash S
FIR - Alvarez, J
IR  - Alvarez J
FIR - Bessissow, A
IR  - Bessissow A
FIR - Douketis, J
IR  - Douketis J
FIR - Duceppe, E
IR  - Duceppe E
FIR - Fleischmann, E
IR  - Fleischmann E
FIR - Hart, R
IR  - Hart R
FIR - Hill, M
IR  - Hill M
FIR - Khalid, Z
IR  - Khalid Z
FIR - Khan, J
IR  - Khan J
FIR - Kurz, A
IR  - Kurz A
FIR - Lauw, M
IR  - Lauw M
FIR - Le Manach, Y
IR  - Le Manach Y
FIR - Lurati Buse, G
IR  - Lurati Buse G
FIR - Martinsen, K
IR  - Martinsen K
FIR - Meyhoff, C S
IR  - Meyhoff CS
FIR - Mrkobrada, M
IR  - Mrkobrada M
FIR - Neary, J
IR  - Neary J
FIR - Oczkowski, W
IR  - Oczkowski W
FIR - O'Donnell, M
IR  - O'Donnell M
FIR - Paniagua, P
IR  - Paniagua P
FIR - Papina, M
IR  - Papina M
FIR - Pasin, L
IR  - Pasin L
FIR - Popova, E
IR  - Popova E
FIR - Rodseth, R
IR  - Rodseth R
FIR - Seeberger, M
IR  - Seeberger M
FIR - Tandon, V
IR  - Tandon V
FIR - Thomas, S
IR  - Thomas S
FIR - Tiboni, M
IR  - Tiboni M
FIR - Torres, D
IR  - Torres D
FIR - Wetterslev, J
IR  - Wetterslev J
FIR - Friedman, L
IR  - Friedman L
FIR - Cheng, D
IR  - Cheng D
FIR - Johnstone, D
IR  - Johnstone D
FIR - Lowenstein, E
IR  - Lowenstein E
FIR - Roberts, R
IR  - Roberts R
EDAT- 2014/04/01 06:00
MHDA- 2014/05/07 06:00
CRDT- 2014/04/01 06:00
PHST- 2014/04/01 06:00 [entrez]
PHST- 2014/04/01 06:00 [pubmed]
PHST- 2014/05/07 06:00 [medline]
AID - 10.1056/NEJMoa1401105 [doi]
PST - ppublish
SO  - N Engl J Med. 2014 Apr 17;370(16):1494-503. doi: 10.1056/NEJMoa1401105. Epub 2014 
      Mar 31.

PMID- 27449968
OWN - NLM
STAT- MEDLINE
DCOM- 20170517
LR  - 20181202
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 100
IP  - 5
DP  - 2016 Nov
TI  - The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin 
      Intake in Primary and Secondary Prevention of Cardiovascular Disease: A 
      Systematic Review.
PG  - 500-512
LID - 10.1002/cpt.438 [doi]
AB  - Enhancing the effectiveness of aspirin by tailoring administration regimens is an 
      important question among health professionals. We conducted a systematic review 
      to evaluate the evidence on the effects of different aspirin regimens in terms of 
      timing (chronotherapy) or frequency of dosing in the prevention of cardiovascular 
      disease. Only two out of the 28 included studies reported long-term 
      cardiovascular outcomes, highlighting an evidence gap that future research should 
      address. The remaining 26 studies used surrogate outcomes.
CI  - © 2016 American Society for Clinical Pharmacology and Therapeutics.
FAU - Bem, D
AU  - Bem D
AD  - Institute of Applied Health Research, College of Medical & Dental Sciences, 
      University of Birmingham, Edgbaston, Birmingham, UK.
FAU - Lordkipanidzé, M
AU  - Lordkipanidzé M
AD  - Montreal Heart Institute, Research Centre, Montréal, QC, Canada.
AD  - Université de Montreal, Faculté de pharmacie, Montreal, QC, Canada.
FAU - Hodgkinson, J
AU  - Hodgkinson J
AD  - Institute of Applied Health Research, College of Medical & Dental Sciences, 
      University of Birmingham, Edgbaston, Birmingham, UK.
FAU - Stevens, S
AU  - Stevens S
AD  - Institute of Applied Health Research, College of Medical & Dental Sciences, 
      University of Birmingham, Edgbaston, Birmingham, UK.
FAU - Bayliss, S
AU  - Bayliss S
AD  - Institute of Applied Health Research, College of Medical & Dental Sciences, 
      University of Birmingham, Edgbaston, Birmingham, UK.
FAU - Moore, D
AU  - Moore D
AD  - Institute of Applied Health Research, College of Medical & Dental Sciences, 
      University of Birmingham, Edgbaston, Birmingham, UK.
FAU - Fitzmaurice, D
AU  - Fitzmaurice D
AD  - Institute of Applied Health Research, College of Medical & Dental Sciences, 
      University of Birmingham, Edgbaston, Birmingham, UK. D.A.Fitzmaurice@bham.ac.uk.
FAU - Dretzke, J
AU  - Dretzke J
AD  - Institute of Applied Health Research, College of Medical & Dental Sciences, 
      University of Birmingham, Edgbaston, Birmingham, UK. j.dretzke@bham.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20160919
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*prevention & control
MH  - *Drug Administration Schedule
MH  - *Drug Chronotherapy
MH  - Humans
MH  - Primary Prevention/*methods
MH  - Secondary Prevention/*methods
EDAT- 2016/07/28 06:00
MHDA- 2017/05/18 06:00
CRDT- 2016/07/25 06:00
PHST- 2016/05/26 00:00 [received]
PHST- 2016/06/23 00:00 [revised]
PHST- 2016/07/15 00:00 [accepted]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/05/18 06:00 [medline]
PHST- 2016/07/25 06:00 [entrez]
AID - 10.1002/cpt.438 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2016 Nov;100(5):500-512. doi: 10.1002/cpt.438. Epub 2016 Sep 
      19.

PMID- 3177149
OWN - NLM
STAT- MEDLINE
DCOM- 19881101
LR  - 20131121
IS  - 0301-0546 (Print)
IS  - 0301-0546 (Linking)
VI  - 16
IP  - 3
DP  - 1988 May-Jun
TI  - Aspirin-induced asthma in children.
PG  - 145-9
AB  - Since Cooke first described bronchospasm induced by acetyl salicylic acid in 
      asthmatic patients in 1919, numerous studies have been done with the objective of 
      understanding the pathology, treatment and incidence of aspirin-induced asthma. 
      The incidence is difficult to establish but according to two recent studies, the 
      percentage in the infantile asthmatic population was estimated at 13% and 28%. 
      This prevalence is greater than that suspected at first and reveals the necessity 
      of reviewing this problem. In this study we present 4 pediatric patients, 2 
      atopics and 2 non-atopics affected with aspirin-induced asthma. A detailed 
      clinical history, oral provocation test to acetyl salicylic acid, other 
      non-steroid anti-inflammatory analgesics and additives was performed. The oral 
      provocation test with acetyl salicylic acid was positive in all 4 cases. The oral 
      provocation with non-steroid anti-inflammatory analgesics and other additives was 
      negative in 2 patients. In the remaining 2 patients, one demonstrated sensitivity 
      only to tartrazine and the other to tartrazine, red coccine, mefenamic acid and 
      benorylate. In conclusion, aspirin-induced asthma is not infrequent in infancy. 
      Therefore, it is important to bear it always in mind and to diagnose it through 
      oral provocation besides looking for possible cross reactions.
FAU - Botey, J
AU  - Botey J
AD  - Servicio de Alergia, Hospital Infantil de la Vall d'Hebron. Universidad Autonoma, 
      Barcelona, Spain.
FAU - Navarro, C
AU  - Navarro C
FAU - Marín, A
AU  - Marín A
FAU - Eseverri, J L
AU  - Eseverri JL
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Male
MH  - Skin Tests
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
PST - ppublish
SO  - Allergol Immunopathol (Madr). 1988 May-Jun;16(3):145-9.

PMID- 12146847
OWN - NLM
STAT- MEDLINE
DCOM- 20030102
LR  - 20211203
IS  - 0957-5243 (Print)
IS  - 0957-5243 (Linking)
VI  - 13
IP  - 5
DP  - 2002 Jun
TI  - Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the 
      US.
PG  - 427-34
AB  - OBJECTIVE: To examine the relationship between daily aspirin use and risk of 
      prostate cancer in a large, racially diverse cohort of men followed for up to 32 
      years. METHODS: The study population included 90,100 male subscribers to the 
      Kaiser Permanente Medical Care Program who had received one or more multiphasic 
      health checkups between 1964 and 1973. This general health checkup included a 
      self-completed questionnaire that requested men to record if they took more than 
      six aspirin almost every day during the previous year. Subjects were followed for 
      the development of prostate cancer using the local tumor registry. Cox regression 
      was used to estimate relative risks (RR) and 95% confidence intervals (CI). 
      RESULTS: A total of 2,574 men developed prostate cancer. Of these, 1617 had local 
      stage disease and 719 had either regional or distant disease at diagnosis. A 
      total of 2466 men (2.7%) reported taking more than six aspirin almost every day 
      during the past year at one or more health checkups. After adjusting for birth 
      year, education, race, and the number of health checkups. the relative risk of 
      prostate cancer associated with this amount of aspirin use was 0.76 (95% CI 
      0.60-0.98). Relative risks did not differ by race and were similar for both local 
      stage and regional or distant stage prostate cancer. CONCLUSION: Results from our 
      large, multiracial cohort study support a modest inverse relationship between 
      daily consumption of more than six aspirin and prostate cancer risk.
FAU - Habel, Laurel A
AU  - Habel LA
AD  - Division of Research, Kaiser Permanente Medical Care Program, Oakland, California 
      94611, USA. lah@dor.kaiser.org
FAU - Zhao, Wei
AU  - Zhao W
FAU - Stanford, Janet L
AU  - Stanford JL
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cohort Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/epidemiology/*prevention & control
MH  - *Racial Groups
MH  - Registries/*statistics & numerical data
MH  - Risk Factors
MH  - United States/epidemiology
EDAT- 2002/07/31 10:00
MHDA- 2003/01/03 04:00
CRDT- 2002/07/31 10:00
PHST- 2002/07/31 10:00 [pubmed]
PHST- 2003/01/03 04:00 [medline]
PHST- 2002/07/31 10:00 [entrez]
AID - 10.1023/a:1015788502099 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2002 Jun;13(5):427-34. doi: 10.1023/a:1015788502099.

PMID- 8072261
OWN - NLM
STAT- MEDLINE
DCOM- 19940927
LR  - 20220316
IS  - 0085-2538 (Print)
IS  - 0085-2538 (Linking)
VI  - 45
IP  - 5
DP  - 1994 May
TI  - Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, 
      double-blind study.
PG  - 1477-83
AB  - Hemodialysis (HD) vascular access thrombosis remains a major cause of morbidity, 
      accounting for 17.4% of all HD patient hospital admissions in 1986. We initiated 
      this prospective, randomized, double-blind, placebo-controlled, parallel group 
      study to examine if dipyridamole and/or aspirin decreased the rate of thrombosis 
      of expanded polytetrafluoroethylene (ePTFE) grafts in HD patients. Two patient 
      groups were studied: Type I--with a new ePTFE graft; and Type II--with 
      thrombectomy and/or revision of a previously placed ePTFE graft. One hundred and 
      seven patients were followed for 18 months or until the first thrombotic episode. 
      Actuarial analysis of Type I patients showed cumulative thrombosis rates (mean 
      +/- SEM) of 21 +/- 9% on dipyridamole alone, compared with 25 +/- 11% on 
      dipyridamole and aspirin combination, 42 +/- 13% on placebo, and 80 +/- 12% on 
      aspirin alone. The relative risk of thrombosis with dipyridamole was 0.35 (P = 
      0.02) and that for aspirin was 1.99 (P = 0.18). In Type II patients, the rate of 
      thrombosis was high in all study drug and placebo groups (overall 78% thrombosis) 
      and actuarial analysis was not carried out because of the small number of 
      patients enrolled. We conclude that dipyridamole is beneficial in patients with 
      new ePTFE grafts and that aspirin does not improve the risk of thrombosis in 
      ePTFE grafts. Neither dipyridamole nor aspirin has any beneficial effect in 
      patients with prior thrombosis of ePTFE grafts.
FAU - Sreedhara, R
AU  - Sreedhara R
AD  - Vanderbilt University Medical Center, Nashville, Tennessee.
FAU - Himmelfarb, J
AU  - Himmelfarb J
FAU - Lazarus, J M
AU  - Lazarus JM
FAU - Hakim, R M
AU  - Hakim RM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Vessel Prosthesis
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/*drug therapy/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polytetrafluoroethylene
MH  - Prospective Studies
MH  - Renal Dialysis/adverse effects
MH  - Thrombectomy
MH  - *Thrombolytic Therapy
MH  - Thrombosis/*drug therapy
MH  - Treatment Outcome
MH  - Vascular Patency
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
AID - S0085-2538(15)58473-1 [pii]
AID - 10.1038/ki.1994.192 [doi]
PST - ppublish
SO  - Kidney Int. 1994 May;45(5):1477-83. doi: 10.1038/ki.1994.192.

PMID- 1842215
OWN - NLM
STAT- MEDLINE
DCOM- 19911224
LR  - 20190703
IS  - 0003-2409 (Print)
IS  - 0003-2409 (Linking)
VI  - 46
IP  - 10
DP  - 1991 Oct
TI  - A comparison of azapropazone and aspirin for pain relief following dental 
      extractions.
PG  - 828-32
AB  - Eighty patients received one of three treatments after elective dental surgery 
      involving multiple extractions. Group A received aspirin 600 mg, group B 
      azapropazone 300 mg and group C azapropazone 600 mg. All drugs were administered 
      in a double-blind fashion. Quality of analgesia was unsatisfactory for all 
      treatments; over 30% of patients required supplementary analgesia with an opioid. 
      In addition there were a large number of withdrawals from the study. There were 
      no significant differences in analgesic efficacy between groups.
FAU - Garrioch, M A
AU  - Garrioch MA
AD  - University Department of Anaesthesia, Glasgow Royal Infirmary, Scotland.
FAU - Wardall, G J
AU  - Wardall GJ
FAU - Fitch, W
AU  - Fitch W
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Anaesthesia
JT  - Anaesthesia
JID - 0370524
RN  - 76I7G6D29C (Morphine)
RN  - K2VOT966ZI (Apazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Anaesthesia. 1992 Jun;47(6):540. PMID: 1616106
MH  - Adolescent
MH  - Adult
MH  - Apazone/adverse effects/blood/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Morphine/administration & dosage
MH  - Pain Measurement
MH  - Pain, Postoperative/*drug therapy
MH  - Tooth Extraction/*adverse effects
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
AID - 10.1111/j.1365-2044.1991.tb09594.x [doi]
PST - ppublish
SO  - Anaesthesia. 1991 Oct;46(10):828-32. doi: 10.1111/j.1365-2044.1991.tb09594.x.

PMID- 11434584
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190906
IS  - 0954-691X (Print)
IS  - 0954-691X (Linking)
VI  - 13
IP  - 6
DP  - 2001 Jun
TI  - Nonsteroidal anti-inflammatory drugs, low-dose aspirin, and potential ways of 
      reducing the risk of complications.
PG  - 623-6
AB  - Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an annual 
      incidence of 1-2% of gastrointestinal (GI) complications, which may be fatal in 
      some cases. Low-dose aspirin is also associated with an increased risk of upper 
      GI bleeding, but the increase is about three times lower than that found with 
      common NSAIDs. Misoprostol (600-800 microg/day) reduces the incidence of 
      complications in non-aspirin NSAID users. Co-therapy with antisecretory drugs 
      (proton pump inhibitors, PPIs) also reduces the risk of GI bleeding in high-risk 
      patients taking NSAIDs and/or low-dose aspirin. Another way of reducing the 
      incidence of GI complications is to use the highly selective cyclo-oxygenase 2 
      (COX-2) inhibitors. The GI safety of nitric oxide NSAIDs (NO-NSAIDs) has been 
      demonstrated extensively in experimental conditions and preliminary clinical 
      studies. Epidemiological studies have also shown that nitric oxide donor drugs 
      reduce the risk of upper GI bleeding, which might be important in patients 
      receiving low-dose aspirin.
FAU - Lanas, A
AU  - Lanas A
AD  - Service of Gastroenterology, University Hospital, Zaragoza, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clinical Trials as Topic
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced/*prevention & control
MH  - Humans
MH  - Male
MH  - Primary Prevention/*methods
MH  - Prognosis
MH  - Risk Assessment
MH  - Risk Factors
RF  - 31
EDAT- 2001/07/04 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/07/04 10:00
PHST- 2001/07/04 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/07/04 10:00 [entrez]
AID - 10.1097/00042737-200106000-00001 [doi]
PST - ppublish
SO  - Eur J Gastroenterol Hepatol. 2001 Jun;13(6):623-6. doi: 
      10.1097/00042737-200106000-00001.

PMID- 11159224
OWN - NLM
STAT- MEDLINE
DCOM- 20010308
LR  - 20190704
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 92
IP  - 2
DP  - 2001 Feb
TI  - The effects of diaspirin cross-linked hemoglobin on the tone of human saphenous 
      vein.
PG  - 324-8
AB  - Diaspirin cross-linked hemoglobin (DCL-Hb), when infused into animals, causes 
      vasoconstriction thought to be caused by nitric oxide (NO) binding by the 
      hemoglobin molecule. The purpose of this study was to ascertain whether DCL-Hb 
      causes vasoconstriction in human saphenous vein taken from patients undergoing 
      myocardial revascularization and whether NO scavenging is the mechanism. The 
      direct effect of DCL-Hb on saphenous vein tone was tested by adding increasing 
      concentrations (10(-8) to 10(-5)M) of the drug. In an additional series of 
      experiments, the influence of DCL-Hb on the dilator response to endothelial 
      dependent and independent vasodilators was tested. This was achieved by 
      attempting either to reverse the effects of acetylcholine, sodium nitroprusside, 
      or S-nitrosylglutathione with prior incubation with DCL-Hb or to inhibit the 
      dilator response in vessels preconstricted with 10(-6)M norepinephrine. There was 
      no effect of DCL-Hb alone on saphenous vein tone. DCL-Hb significantly reduced 
      vasodilatation with all vasodilators (P < 0.05). After maximal relaxation with 
      sodium nitroprusside and s-nitrosylglutathione, there was significant 
      vasoconstriction with DCL-Hb at concentrations larger than 10(-6)M, (P < 0.05). 
      The authors conclude that DCL-Hb does not constrict human saphenous vein but can 
      affect vessel tone by reversal of the effect of endogenously or exogenously 
      released NO.
FAU - Forrest, M R
AU  - Forrest MR
AD  - Department of Anaesthesia, Harefield and Royal Brompton NHS Trust, Harefield, 
      London, UK. mforrest50@hotmail.com
FAU - Chester, A H
AU  - Chester AH
FAU - Royston, D
AU  - Royston D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Nitroso Compounds)
RN  - 169D1260KM (Nitroprusside)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 57564-91-7 (S-Nitrosoglutathione)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - GAN16C9B8O (Glutathione)
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylcholine/pharmacology
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Blood Substitutes/*pharmacology
MH  - Glutathione/*analogs & derivatives/pharmacology
MH  - Hemoglobins/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Nitric Oxide/physiology
MH  - Nitroprusside/pharmacology
MH  - Nitroso Compounds/pharmacology
MH  - S-Nitrosoglutathione
MH  - Saphenous Vein/*drug effects/physiology
MH  - Vasoconstriction/*drug effects
EDAT- 2001/02/13 11:00
MHDA- 2001/03/10 10:01
CRDT- 2001/02/13 11:00
PHST- 2001/02/13 11:00 [pubmed]
PHST- 2001/03/10 10:01 [medline]
PHST- 2001/02/13 11:00 [entrez]
AID - 10.1097/00000539-200102000-00007 [doi]
PST - ppublish
SO  - Anesth Analg. 2001 Feb;92(2):324-8. doi: 10.1097/00000539-200102000-00007.

PMID- 7545822
OWN - NLM
STAT- MEDLINE
DCOM- 19951019
LR  - 20131121
IS  - 0033-2100 (Print)
IS  - 0033-2100 (Linking)
VI  - 49
IP  - 1-2
DP  - 1995
TI  - [Kawasaki disease].
PG  - 9-16
AB  - Kawasaki disease (KD), first described in Japan in 1967 by Dr. Tomisaku Kawasaki, 
      is an acute multi system vasculitis of infancy and early childhood characterised 
      by high fever, rash, conjunctivitis, inflammation of the mucous membranes, 
      erythematous induration of the hands and feet and cervical lymphadenopathy. 
      Synonyms for Kawasaki disease include "Kawasaki syndrome" and "mucocutaneous 
      lymph node syndrome" (MCLS, MLNS, MCLNS). Kawasaki disease was initially presumed 
      to occur only in Japan; but now this disease is known in the whole world. The 
      first cases in the United States were reported in Hawaii in 1976. In poland 5 
      cases were recognized, and first time described in 1981. The etiology of Kawasaki 
      disease remains unknown. Toxic, allergic and immunologic causes have been 
      suspected, but most investigators favor an infectious cause or an immune response 
      to an infectious agent. Among classes of microorganism suspected of causing 
      Kawasaki disease were bacteria, leptospires, fungi, rickettsiae and a number of 
      viruses. Recently, there has been considerable interest in the possibility, that 
      Kawasaki disease is caused by RETROVIRUSES. Although the disease is generally 
      benign and self-limited, about 20% of children develop coronary artery aneurysms. 
      In 5% of cases, giant aneurysm/more then 8 mm/develop, predisposing the patient 
      to acute coronary artery thrombosis, myocardial infarction and sudden death. This 
      is the most serious complication of KD. Other manifestations of hearth 
      involvement, include pericarditis, myocarditis, myocardial failure and mitral 
      regurgitation. Besides this many other clinical findings are commonly noted in 
      KD; such as: pneumonia, diarrhea, arthritis, aseptic meningitis, otitis media, 
      obstructive jaundice, hydrops of gallbladder and others.(ABSTRACT TRUNCATED AT 
      250 WORDS)
FAU - Gliwińska, E
AU  - Gliwińska E
AD  - Oddział Obserwacyjno-Zakaźny Centralnego Szpitala Klinicznego MSW.
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Choroba Kawasaki.
PL  - Poland
TA  - Przegl Epidemiol
JT  - Przeglad epidemiologiczny
JID - 0413725
RN  - 0 (gamma-Globulins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Infant
MH  - Injections, Intravenous
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/drug therapy/epidemiology
MH  - gamma-Globulins/administration & dosage/therapeutic use
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Przegl Epidemiol. 1995;49(1-2):9-16.

PMID- 22540524
OWN - NLM
STAT- MEDLINE
DCOM- 20130621
LR  - 20211021
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 13
DP  - 2012 Apr 27
TI  - Thrombelastographic haemostatic status and antiplatelet therapy after coronary 
      artery bypass surgery (TEG-CABG trial): assessing and monitoring the 
      antithrombotic effect of clopidogrel and aspirin versus aspirin alone in 
      hypercoagulable patients: study protocol for a randomized controlled trial.
PG  - 48
LID - 10.1186/1745-6215-13-48 [doi]
AB  - BACKGROUND: Hypercoagulability, assessed by the thrombelastography (TEG) assay, 
      has in several observational studies been associated with an increased risk of 
      post-procedural thromboembolic complications. We hypothesize that intensified 
      antiplatelet therapy with clopidogrel and aspirin, as compared to aspirin alone, 
      will improve saphenous vein graft patency in preoperatively TEG-Hypercoagulable 
      coronary artery bypass surgery (CABG) patients and reduce their risk for 
      thromboembolic complications and death postoperatively. METHODS/DESIGN: This is a 
      prospective randomized clinical trial, with an open-label design with blinded 
      evaluation of graft patency. TEG-Hypercoagulability is defined as a TEG maximum 
      amplitude above 69 mm. Two hundred and fifty TEG-Hypercoagulable patients will be 
      randomized to either an interventional group receiving clopidogrel 75 mg daily 
      for three months (after initial oral bolus of 300 mg) together with aspirin 75 mg 
      or a control group receiving aspirin 75 mg daily alone. Monitoring of 
      antiplatelet efficacy and on-treatment platelet reactivity to clopidogrel and 
      aspirin will be conducted with Multiplate aggregometry. Graft patency will be 
      assessed with Multislice computed tomography (MSCT) at three months after 
      surgery. CONCLUSIONS: The present trial is the first randomized clinical trial to 
      evaluate whether TEG-Hypercoagulable CABG patients will benefit from intensified 
      antiplatelet therapy after surgery. Monitoring of platelet inhibition from 
      instituted antithrombotic therapy will elucidate platelet resistance patterns 
      after CABG surgery. The results could be helpful in redefining how clinicians can 
      evaluate patients preoperatively for their postoperative thromboembolic risk and 
      tailor individualized postoperative antiplatelet therapy. TRIAL REGISTRATION: 
      Clinicaltrials.gov Identifier NCT01046942.
FAU - Rafiq, Sulman
AU  - Rafiq S
AD  - Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, 
      Copenhagen University Hospital, Copenhagen, Denmark. sulman_raf@hotmail.com
FAU - Johansson, Pär Ingemar
AU  - Johansson PI
FAU - Zacho, Mette
AU  - Zacho M
FAU - Stissing, Trine
AU  - Stissing T
FAU - Kofoed, Klaus
AU  - Kofoed K
FAU - Lilleør, Nikolaj Bang
AU  - Lilleør NB
FAU - Steinbrüchel, Daniel Andreas
AU  - Steinbrüchel DA
LA  - eng
SI  - ClinicalTrials.gov/NCT01046942
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20120427
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Protocols
MH  - Clopidogrel
MH  - Coronary Artery Bypass/*adverse effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - *Thrombelastography
MH  - Thromboembolism/*prevention & control
MH  - Thrombophilia/*drug therapy
MH  - Ticlopidine/administration & dosage/*analogs & derivatives
PMC - PMC3502390
EDAT- 2012/05/01 06:00
MHDA- 2013/06/25 06:00
CRDT- 2012/05/01 06:00
PHST- 2011/09/28 00:00 [received]
PHST- 2012/04/27 00:00 [accepted]
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2013/06/25 06:00 [medline]
AID - 1745-6215-13-48 [pii]
AID - 10.1186/1745-6215-13-48 [doi]
PST - epublish
SO  - Trials. 2012 Apr 27;13:48. doi: 10.1186/1745-6215-13-48.

PMID- 23817512
OWN - NLM
STAT- MEDLINE
DCOM- 20140210
LR  - 20130702
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Linking)
VI  - 22
IP  - 8
DP  - 2013 Jul
TI  - Aspirin resistance in systemic lupus erythematosus. A pilot study.
PG  - 835-8
LID - 10.1177/0961203313493487 [doi]
AB  - Systemic lupus erythematosus (SLE) patients are at increased risk of thrombosis 
      and cardiovascular diseases. Aspirin is an effective treatment option for these 
      patients. The aim of this study was to investigate the presence of aspirin 
      resistance in SLE patients. We studied aspirin resistance in 33 SLE patients and 
      nine healthy controls by using a Multiplate® impedance aggregometer (Dynabyte 
      GmbH, Munich, Germany). Twenty-six SLE patients were on regular aspirin 
      treatment. Aspirin resistance was found in five (19.2%) out of 26 patients who 
      were on aspirin treatment. When the tests were repeated by adding acetylsalicylic 
      acid in the medium, all of these patients became responsive to the aspirin. SLE 
      disease activity, body mass index, smoking status, and the presence of 
      anticardiolipin antibodies or positive lupus anticoagulant test results were no 
      different in patients with or without aspirin resistance. (p>0.05 for all). Our 
      results suggest that there may be a considerable number of SLE patients with 
      aspirin resistance.
FAU - Akdogan, A
AU  - Akdogan A
AD  - Division of Rheumatology, Department of Internal Medicine, Hacettepe University 
      Hospital, Turkey.
FAU - Kilic, L
AU  - Kilic L
FAU - Akman, U
AU  - Akman U
FAU - Dogan, I
AU  - Dogan I
FAU - Karadag, O
AU  - Karadag O
FAU - Bilgen, S A
AU  - Bilgen SA
FAU - Buyukasik, Y
AU  - Buyukasik Y
FAU - Kiraz, S
AU  - Kiraz S
FAU - Ertenli, I
AU  - Ertenli I
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antibodies, Anticardiolipin/blood
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Case-Control Studies
MH  - Drug Resistance
MH  - Electric Impedance
MH  - Female
MH  - Fibrinolytic Agents/pharmacology/*therapeutic use
MH  - Humans
MH  - Lupus Erythematosus, Systemic/complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Thrombosis/etiology/*prevention & control
MH  - Young Adult
OTO - NOTNLM
OT  - SLE
OT  - aspirin
OT  - aspirin resistance
EDAT- 2013/07/03 06:00
MHDA- 2014/02/11 06:00
CRDT- 2013/07/03 06:00
PHST- 2013/07/03 06:00 [entrez]
PHST- 2013/07/03 06:00 [pubmed]
PHST- 2014/02/11 06:00 [medline]
AID - 22/8/835 [pii]
AID - 10.1177/0961203313493487 [doi]
PST - ppublish
SO  - Lupus. 2013 Jul;22(8):835-8. doi: 10.1177/0961203313493487.

PMID- 11971828
OWN - NLM
STAT- MEDLINE
DCOM- 20020618
LR  - 20190503
IS  - 1472-0205 (Print)
IS  - 1472-0213 (Electronic)
IS  - 1472-0205 (Linking)
VI  - 19
IP  - 3
DP  - 2002 May
TI  - An evidence based flowchart to guide the management of acute salicylate (aspirin) 
      overdose.
PG  - 206-9
AB  - OBJECTIVE: To develop a flowchart to be used as a tool to guide clinicians step 
      by step through the management of salicylate poisoning. METHODS: A comprehensive 
      literature search was carried out. RESULTS: The evidence base was used to develop 
      a management flowchart that guides the clinician through the three main steps in 
      caring for the patient with salicylate poisoning: preventing further absorption, 
      assessing the severity of poisoning and, where appropriate, increasing 
      elimination. CONCLUSIONS: Salicylate poisoning can result in severe morbidity and 
      mortality and this flowchart provides an evidence based guideline that will guide 
      clinicians through the management of patients presenting to the emergency 
      department with salicylate poisoning.
FAU - Dargan, P I
AU  - Dargan PI
AD  - National Poisons Information Service, Guy's and St Thomas' NHS Trust, London, UK. 
      paul.dargan@gstt.sthames.nhs.uk
FAU - Wallace, C I
AU  - Wallace CI
FAU - Jones, A L
AU  - Jones AL
LA  - eng
PT  - Journal Article
PL  - England
TA  - Emerg Med J
JT  - Emergency medicine journal : EMJ
JID - 100963089
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Algorithms
MH  - Aspirin/*poisoning
MH  - Drug Overdose/therapy
MH  - Gastric Lavage
MH  - Humans
MH  - Intestinal Absorption
MH  - Renal Dialysis
PMC - PMC1725844
EDAT- 2002/04/25 10:00
MHDA- 2002/06/19 10:01
CRDT- 2002/04/25 10:00
PHST- 2002/04/25 10:00 [pubmed]
PHST- 2002/06/19 10:01 [medline]
PHST- 2002/04/25 10:00 [entrez]
AID - 10.1136/emj.19.3.206 [doi]
PST - ppublish
SO  - Emerg Med J. 2002 May;19(3):206-9. doi: 10.1136/emj.19.3.206.

PMID- 19519552
OWN - NLM
STAT- MEDLINE
DCOM- 20090914
LR  - 20191111
VI  - 4
IP  - 2
DP  - 2009 Jun
TI  - Platelet resistance to antiplatelet drugs.
PG  - 98-108
AB  - In patients with cardiovascular diseases, platelet aggregation plays an important 
      role in development of cardiovascular events and hence its inhibition is 
      important in prevention and treatment of these events. Antiplatelet therapy is 
      the cornerstone of treatment for patients with acute coronary syndrome and in 
      those who undergo percutaneous coronary intervention. Currently dual antiplatelet 
      therapy with aspirin and clopidogrel is the standard of care in such patients and 
      has been associated with improved cardiovascular outcomes. However, a significant 
      number of patients experience recurrent cardiovascular events despite being on 
      dual antiplatelet therapy. At present there is growing evidence that these events 
      may be associated with poor response to these antiplatelet drugs and has been 
      commonly called as antiplatelet drug resistance. The exact mechanisms leading to 
      antiplatelet drug resistance are not very well understood but are likely 
      multifactorial. Although the precise definition of antiplatelet drug resistance 
      is lacking, but there is sufficient evidence to support that persistence of 
      enhanced platelet reactivity persists despite use of aspirin and clopidogrel and 
      is associated with adverse cardiovascular outcomes. In this paper, we will review 
      the mechanisms, clinical relevance, methods to evaluate, controversies 
      surrounding the definition along with some recent patents and current and future 
      directions for management of antiplatelet drug resistance.
FAU - Kumar, Ashwani
AU  - Kumar A
AD  - Cardiac Catheterization Laboratory, Section of Cardiology, Jesse Brown VA Medical 
      Center, University of Illinois at Chicago, Illinois, USA.
FAU - Kao, John
AU  - Kao J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Recent Pat Cardiovasc Drug Discov
JT  - Recent patents on cardiovascular drug discovery
JID - 101263805
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary/adverse effects
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Clopidogrel
MH  - Coronary Artery Disease/drug therapy
MH  - *Drug Resistance, Multiple
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/therapeutic 
      use
MH  - Ticlopidine/administration & dosage/analogs & 
      derivatives/pharmacology/therapeutic use
RF  - 112
EDAT- 2009/06/13 09:00
MHDA- 2009/09/15 06:00
CRDT- 2009/06/13 09:00
PHST- 2009/06/13 09:00 [entrez]
PHST- 2009/06/13 09:00 [pubmed]
PHST- 2009/09/15 06:00 [medline]
AID - 10.2174/157489009788452959 [doi]
PST - ppublish
SO  - Recent Pat Cardiovasc Drug Discov. 2009 Jun;4(2):98-108. doi: 
      10.2174/157489009788452959.

PMID- 2516954
OWN - NLM
STAT- MEDLINE
DCOM- 19900413
LR  - 20131121
IS  - 0303-8173 (Print)
IS  - 0303-8173 (Linking)
VI  - 16
IP  - 5
DP  - 1989
TI  - [Clinical aspects of treatment and preventive treatment with thrombocyte 
      aggregation inhibitors in cerebrovascular diseases].
PG  - 114-8
AB  - Inhibitors of thrombocyte aggregation are generally accepted in the therapy and 
      prophylaxis of ischemic cerebrovascular disease. The frequency of re-infarction, 
      morbidity and mortality after TIA, PRIND and minor stroke is influenced 
      favourably. There are controversial opinions, however, about the usefulness for 
      patients suffering from completed strokes. In patients with progressive stroke, 
      cerebral embolism of cardiac source, or non-infective thrombosis of sinuses or 
      cerebral veins, inhibitors of thrombocyte aggregation are used if anticoagulation 
      therapy is not possible. Additionally, they are applied in cases of infective 
      thrombosis of sinuses or cerebral veins, after termination of anticoagulation 
      therapy, after cardiac valve replacement, and after surgical reconstructions of 
      craniocervical vessels. Acetylsalicylic acid is the clinically best examined 
      substance; its effect--especially in males--was proven by numerous prospective 
      trials. A combined treatment with dipyridamole, sulfinpyrazone or other drugs 
      seems to be unnecessary. A daily dose of not more than 300 to 325 mg 
      acetylsalicylic acid is recommended for prophylaxis after ischemic cerebral 
      events; in connection with that dose severe gastrointestinal side effects are 
      hardly to be expected. Whether even lower doses would yield the same prophylactic 
      effects will have to be clarified by further studies.
FAU - Kollegger, H
AU  - Kollegger H
AD  - Neurologischen Universitätsklinik, Wien.
FAU - Oder, W
AU  - Oder W
FAU - Zeiler, K
AU  - Zeiler K
FAU - Deecke, L
AU  - Deecke L
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Klinische Aspekte der Therapie bzw. Prophylaxe mit 
      Thrombozytenaggregationshemmern bei zerebrovaskulären Erkrankungen.
PL  - Austria
TA  - Acta Med Austriaca
JT  - Acta medica Austriaca
JID - 7501997
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Long-Term Care
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 40
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Med Austriaca. 1989;16(5):114-8.

PMID- 26110681
OWN - NLM
STAT- MEDLINE
DCOM- 20160318
LR  - 20150626
IS  - 1473-6322 (Electronic)
IS  - 1473-6322 (Linking)
VI  - 15
IP  - 4
DP  - 2015 Aug
TI  - Aspirin desensitization for cardiovascular disease.
PG  - 314-22
LID - 10.1097/ACI.0000000000000189 [doi]
AB  - PURPOSE OF REVIEW: The use of aspirin in coronary artery disease and address the 
      unmet need of aspirin therapy in patients with history of hypersensitivity 
      reactions to aspirin (acetylsalicylic acid; ASA) or other nonsteroidal 
      inflammatory drugs (NSAIDs). RECENT FINDINGS: Aspirin hypersensitivity is 
      reported in 1.5% of patients with cardiovascular disease. However, many of those 
      labeled as allergic to aspirin had experienced side-effects and could be safely 
      treated with aspirin. Those with true hypersensitivity reactions were often not 
      placed on appropriate antiplatelet therapy. A number of protocols of varying 
      complexity exist in the literature for aspirin desensitization. The focus of this 
      review is to identify the types of aspirin reactions that can occur and provide a 
      rational approach to oral aspirin challenge and desensitization. SUMMARY: In 
      summary, with rare exceptions, patients with a history of 'aspirin/NSAID allergy' 
      who need ASA for cardiovascular issues will be able to safely take aspirin either 
      after a graded challenge or desensitization providing a central role of the 
      allergist in the management of these patients.
FAU - Woessner, Katharine M
AU  - Woessner KM
AD  - Scripps Clinic Medical Group, San Diego, California, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Allergy Clin Immunol
JT  - Current opinion in allergy and clinical immunology
JID - 100936359
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - *Aspirin/adverse effects/therapeutic use
MH  - Coronary Artery Disease/complications/*drug therapy
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/complications/diagnosis/*therapy
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/adverse effects/therapeutic use
EDAT- 2015/06/26 06:00
MHDA- 2016/03/19 06:00
CRDT- 2015/06/26 06:00
PHST- 2015/06/26 06:00 [entrez]
PHST- 2015/06/26 06:00 [pubmed]
PHST- 2016/03/19 06:00 [medline]
AID - 00130832-201508000-00008 [pii]
AID - 10.1097/ACI.0000000000000189 [doi]
PST - ppublish
SO  - Curr Opin Allergy Clin Immunol. 2015 Aug;15(4):314-22. doi: 
      10.1097/ACI.0000000000000189.

PMID- 22724626
OWN - NLM
STAT- MEDLINE
DCOM- 20121019
LR  - 20181201
IS  - 1502-7686 (Electronic)
IS  - 0036-5513 (Linking)
VI  - 72
IP  - 4
DP  - 2012 Jul
TI  - Sequential ADP-stimulated light transmission and multiple electrode aggregometry 
      in patients taking aspirin and clopidogrel after non ST-elevation myocardial 
      infarction.
PG  - 318-25
LID - 10.3109/00365513.2012.666565 [doi]
AB  - BACKGROUND: Fast platelet function tests can identify weak clopidogrel 
      responders, but data on variability over time in clopidogrel responsiveness in 
      several clinical settings are lacking. We wanted to explore long-term variability 
      of multiple electrode aggregometry (MEA) measurements and the agreement between 
      MEA and light transmission aggregometry (LTA) in patients with non-ST elevation 
      myocardial infarction (NSTEMI) treated with aspirin and clopidogrel. METHODS: 
      Parallel MEA and LTA were performed at baseline and after 6 and 12 weeks in 31 
      patients treated with percutaneous coronary intervention after NSTEMI. Adenosine 
      diphosphate (ADP) concentrations 2 μM, 6.5 μM and 10 μM were used. Parallel 
      testings in both arterial and venous blood were performed at baseline. MEA and 
      LTA cut-off levels were applied to discriminate aggregation values suggesting 
      presence or absence of high platelet reactivity (HPR). RESULTS: Arterial and 
      venous MEA and LTA aggregation were similar. Within-subject variability in both 
      MEA and LTA aggregation throughout the study was moderate. According to MEA, 
      eight patients had HPR at baseline (MEA aggregation > 47 U). Defining > 47% as 
      the LTA aggregation HPR cut-off level, the same number of patients (eight) had 
      HPR according to LTA. Of the 93 MEA/LTA observations 81 (87.1%) gave the same HPR 
      classification. MEA vs. LTA agreement at baseline was slightly inferior to that 
      obtained after 12 weeks. CONCLUSIONS: MEA and LTA aggregation in arterial and 
      venous blood seem similar. Within-subject variability over time was moderate, and 
      the agreement between LTA and MEA was good, and stable in most patients.
FAU - Meen, Oystein
AU  - Meen O
AD  - Department of Medicine, Kongsberg Hospital, Vestre Viken HF, Norway.
FAU - Brosstad, Frank
AU  - Brosstad F
FAU - Liestøl, Knut
AU  - Liestøl K
FAU - Kunszt, Gabor
AU  - Kunszt G
FAU - Bendz, Bjørn
AU  - Bendz B
FAU - Wettergreen, Marianne
AU  - Wettergreen M
FAU - Schjelderup, Nina M
AU  - Schjelderup NM
FAU - Andreassen, Trine
AU  - Andreassen T
FAU - Erikssen, Gunnar
AU  - Erikssen G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests
MH  - Reproducibility of Results
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2012/06/26 06:00
MHDA- 2012/10/20 06:00
CRDT- 2012/06/26 06:00
PHST- 2012/06/26 06:00 [entrez]
PHST- 2012/06/26 06:00 [pubmed]
PHST- 2012/10/20 06:00 [medline]
AID - 10.3109/00365513.2012.666565 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2012 Jul;72(4):318-25. doi: 
      10.3109/00365513.2012.666565.

PMID- 19145733
OWN - NLM
STAT- MEDLINE
DCOM- 20090707
LR  - 20220408
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 28
IP  - 6
DP  - 2008 Sep 15
TI  - Low-dose aspirin reduces the gene expression of gastrokine-1 in the antral mucosa 
      of healthy subjects.
PG  - 782-8
AB  - BACKGROUND: Gastrokine 1 (GKN1), one of the most abundant transcripts in normal 
      stomach, is down-regulated by Helicobacter pylori infection. Aspirin (ASA), which 
      is often used for secondary prevention of cardiovascular events, can damage 
      gastric-duodenal mucosa within 1 or 2 h of ingestion. AIM: To study the gastric 
      mucosal expression of GKN1 during acute low-dose ASA consumption. METHODS: Ten H. 
      pylori-negative human volunteers took 100 mg ASA per day for 1 week, and 
      underwent multiple upper GI endoscopies. GKN1 expression was analysed in antral 
      and corpus mucosa by quantitative reverse-transcriptase polymerase chain 
      reaction, western blot and immunohistochemistry (IHC). Gastric mucosal damage was 
      detected endoscopically and histologically. RESULTS: Gastrokine 1 was similarly 
      expressed in both antral and corpus mucosa. The use of low-dose ASA led to a 
      significant decrease (3.07 a.u. vs. 0.23 a.u., P < 0.001) in antrum at day 7, 
      while GKN1 transcript levels in corpus mucosa were slightly elevated (twofold, P 
      < 0.005). Western blot and IHC confirmed these changes at the protein level. 
      Furthermore, IHC revealed a vesicular staining pattern in the cytoplasm for GKN1 
      that was confirmed by transfected human gastric adenocarcinoma cell line 
      expressing GKN1. CONCLUSION: Our data demonstrated that low-dose ASA 
      downregulates GKN1 expression specifically in antral mucosa.
FAU - Martin, G
AU  - Martin G
AD  - Department of Gastroenterology, Hepatology and Infectious Diseases, 
      Otto-von-Guericke University, Magdeburg, Germany.
FAU - Wex, T
AU  - Wex T
FAU - Treiber, G
AU  - Treiber G
FAU - Malfertheiner, P
AU  - Malfertheiner P
FAU - Nardone, G
AU  - Nardone G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (GKN1 protein, human)
RN  - 0 (Peptide Hormones)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blotting, Western
MH  - Down-Regulation
MH  - Gastric Mucosa/*chemistry/drug effects
MH  - Gene Expression/*drug effects
MH  - Humans
MH  - Peptide Hormones/*analysis/genetics
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Pyloric Antrum
MH  - Retrospective Studies
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Staining and Labeling
MH  - Time Factors
EDAT- 2009/01/16 09:00
MHDA- 2009/07/08 09:00
CRDT- 2009/01/16 09:00
PHST- 2009/01/16 09:00 [entrez]
PHST- 2009/01/16 09:00 [pubmed]
PHST- 2009/07/08 09:00 [medline]
AID - 10.1111/j.1365-2036.2008.03793.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2008 Sep 15;28(6):782-8. doi: 
      10.1111/j.1365-2036.2008.03793.x.

PMID- 8463897
OWN - NLM
STAT- MEDLINE
DCOM- 19930430
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 122
IP  - 4
DP  - 1993 Apr
TI  - Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome.
PG  - 538-42
AB  - OBJECTIVE: To determine the costs and clinical outcomes of three alternative 
      treatments of the acute phase of Kawasaki syndrome: aspirin alone; low doses of 
      intravenously administered immune globulin (IVIG-LD), 400 mg/kg per dose for 4 
      days; and high doses of intravenously administered immune globulin (IVIG-HD), 2.0 
      gm/kg for one dose. DESIGN: A model was developed that assumed the inclusion of 
      100 patients with acute Kawasaki syndrome in each treatment option. Costs were 
      valued by using the Chedoke-McMaster Corporate Cost Model in 1992 Canadian 
      dollars. Clinical outcome, based on the published literature, was measured by the 
      prevalence of coronary artery dilation at 7 weeks from the diagnosis of Kawasaki 
      syndrome. RESULTS: For every 100 patients with Kawasaki syndrome, the cost was 
      reduced by $323,400 when aspirin therapy alone was changed to IVIG-HD therapy and 
      14 cases of coronary artery dilation were thereby prevented. When IVIG-HD therapy 
      was compared with IVIG-LD therapy, the cost was reduced by $118,200 because two 
      cases of coronary artery aneurysm were prevented. This latter result was 
      sensitive to the duration of hospitalization, with IVIG-HD costing $8500 more for 
      every 100 patients than IVIG-LD when it was assumed that both groups were 
      hospitalized for 5 days, an unlikely occurrence. CONCLUSIONS: Treatment with 
      IVIG-HD for Kawasaki syndrome is preferred because it results in both lower costs 
      and lower rates of coronary artery dilation.
FAU - Klassen, T P
AU  - Klassen TP
AD  - Department of Pediatrics, University of Ottawa, Ontario, Canada.
FAU - Rowe, P C
AU  - Rowe PC
FAU - Gafni, A
AU  - Gafni A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/economics/therapeutic use
MH  - Child
MH  - Coronary Disease/prevention & control
MH  - Cost-Benefit Analysis
MH  - Costs and Cost Analysis
MH  - Economics
MH  - Humans
MH  - Immunoglobulins, Intravenous/*economics/*therapeutic use
MH  - Length of Stay/economics
MH  - Mucocutaneous Lymph Node Syndrome/*economics/*therapy
MH  - Treatment Outcome
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
AID - S0022-3476(05)83532-2 [pii]
AID - 10.1016/s0022-3476(05)83532-2 [doi]
PST - ppublish
SO  - J Pediatr. 1993 Apr;122(4):538-42. doi: 10.1016/s0022-3476(05)83532-2.

PMID- 1608405
OWN - NLM
STAT- MEDLINE
DCOM- 19920721
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 327
IP  - 3
DP  - 1992 Jul 16
TI  - Reactivation of unstable angina after the discontinuation of heparin.
PG  - 141-5
AB  - BACKGROUND: Heparin is an effective, widely used treatment for unstable angina. 
      Among patients enrolled in a double-blind, randomized, placebo-controlled trial 
      comparing intravenous heparin, aspirin, both treatments, and neither during the 
      acute phase of unstable angina, we encountered patients in whom unstable angina 
      was reactivated after heparin was discontinued. METHODS: The study population 
      included 403 of the original 479 patients in the trial who had completed six days 
      of blinded therapy without refractory angina or myocardial infarction. After the 
      discontinuation of therapy, clinical events, including reactivation of unstable 
      angina and myocardial infarction occurring within 96 hours after hospitalization, 
      were closely monitored. RESULTS: Early reactivation occurred in 14 of the 107 
      patients who received heparin alone, as compared with only 5 patients in each of 
      the other three study groups (P less than 0.01). These reactivations required 
      urgent intervention (thrombolysis, angioplasty, or coronary-bypass surgery) in 11 
      patients treated with heparin alone, but in only 2 patients in the other groups 
      combined (P less than 0.01). Four of the six patients who had a myocardial 
      infarction during a reactivation of their disease were in the heparin group. 
      Reactivations in this group occurred in a cluster a mean (+/- SD) of 9.5 +/- 5 
      hours after the discontinuation of the study drug but were randomly distributed 
      over the initial 96 hours in the other three groups. CONCLUSIONS: Although 
      heparin is beneficial in treating unstable angina, the disease process may be 
      reactivated within hours of the discontinuation of this drug. Concomitant therapy 
      with aspirin may prevent this withdrawal phenomenon.
FAU - Théroux, P
AU  - Théroux P
AD  - Montreal Heart Institute, QC, Canada.
FAU - Waters, D
AU  - Waters D
FAU - Lam, J
AU  - Lam J
FAU - Juneau, M
AU  - Juneau M
FAU - McCans, J
AU  - McCans J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 1992 Jul 16;327(3):192-4. PMID: 1608410
MH  - Acute Disease
MH  - Angina, Unstable/*drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/administration & dosage/*adverse effects/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy
MH  - Recurrence
MH  - Risk Factors
MH  - *Substance Withdrawal Syndrome
EDAT- 1992/07/16 00:00
MHDA- 1992/07/16 00:01
CRDT- 1992/07/16 00:00
PHST- 1992/07/16 00:00 [pubmed]
PHST- 1992/07/16 00:01 [medline]
PHST- 1992/07/16 00:00 [entrez]
AID - 10.1056/NEJM199207163270301 [doi]
PST - ppublish
SO  - N Engl J Med. 1992 Jul 16;327(3):141-5. doi: 10.1056/NEJM199207163270301.

PMID- 7389399
OWN - NLM
STAT- MEDLINE
DCOM- 19800928
LR  - 20131121
IS  - 0011-4162 (Print)
IS  - 0011-4162 (Linking)
VI  - 26
IP  - 1
DP  - 1980 Jul
TI  - Control of chronic erythema nodosum with naproxen.
PG  - 66-7
AB  - A patient with chronic erythema nodosum of two years' duration, who did not 
      respond to treatment with aspirin or with phenylbutazone therapy, had a dramatic 
      response and improvement when treated with naproxen.
FAU - Lehman, C W
AU  - Lehman CW
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 57Y76R9ATQ (Naproxen)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Chronic Disease
MH  - Erythema Nodosum/*drug therapy
MH  - Female
MH  - Humans
MH  - Naproxen/*therapeutic use
MH  - Phenylbutazone/therapeutic use
EDAT- 1980/07/01 00:00
MHDA- 1980/07/01 00:01
CRDT- 1980/07/01 00:00
PHST- 1980/07/01 00:00 [pubmed]
PHST- 1980/07/01 00:01 [medline]
PHST- 1980/07/01 00:00 [entrez]
PST - ppublish
SO  - Cutis. 1980 Jul;26(1):66-7.

PMID- 31872490
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210114
IS  - 1600-0897 (Electronic)
IS  - 1046-7408 (Linking)
VI  - 83
IP  - 4
DP  - 2020 Apr
TI  - Comparison of therapeutic interventions for recurrent pregnancy loss in 
      association with antiphospholipid syndrome: A systematic review and network 
      meta-analysis.
PG  - e13219
LID - 10.1111/aji.13219 [doi]
AB  - Antiphospholipid syndrome (APS) is one of the treatable causes for pregnant women 
      with recurrent pregnancy loss (RPL). This review compares the efficacy of a few 
      treatment interventions (low-dose aspirin (LDA), aspirin plus low molecular 
      weight heparin (LMWH), or unfractionated heparin (UFH)) in preventing 
      complications during pregnancy and miscarriages for women with RPL and APS, and 
      the potential differences in therapeutic effects of UFH and LMWH when combined 
      with aspirin. We searched randomized controlled trials (RCTs) in MEDLINE, EMBASE, 
      and the Cochrane Central Register of Controlled Trials and performed a systematic 
      review and a Bayesian network meta-analysis (NMA). Finally, we found aspirin 
      alone had a lower live birth rate compared to LMWH plus aspirin (OR = 0.37; 95% 
      CrI, 0.17, 0.71), and UFH plus aspirin showed a higher live birth rate than 
      aspirin alone (OR = 2.63; 95% CrI, 1.04, 5.39) in NMA, treating with UFH plus 
      aspirin or LMWH plus aspirin did not have difference on live birth. Furthermore, 
      LDA alone resulted in a lower birthweight compared to heparin plus aspirin, while 
      higher birthweight was found when compared UFH plus aspirin to LMWH plus aspirin 
      (MD = 895.40; 95% CrI, 817.40, 988.57) in NMA. Additionally, in women with RPL 
      and APS and without a prior thrombosis, heparin plus aspirin improved birthweight 
      but could not promote live birth rate compared to aspirin alone. In conclusion, 
      heparin plus aspirin is recommended for women with RPL and APS. Notably UFH plus 
      aspirin demonstrates the most significant therapeutic efficacy among these 
      interventions in improving birthweight.
CI  - © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Liu, Xiang
AU  - Liu X
AD  - Department of Gynecology and Obstetrics, West China Second University Hospital, 
      Sichuan University, Chengdu, China.
AD  - West China School of Medicine, Sichuan University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children 
      (Sichuan University), Ministry of Education, Chengdu, China.
FAU - Qiu, Yuxuan
AU  - Qiu Y
AD  - Department of Thyroid & Parathyroid Surgery, West China Hospital, Sichuan 
      University, Chengdu, China.
FAU - Yu, Esther Dawen
AU  - Yu ED
AD  - MOHH Holdings, Singapore City, Singapore.
FAU - Xiang, Shang
AU  - Xiang S
AD  - West China School of Medicine, Sichuan University, Chengdu, China.
FAU - Meng, Rui
AU  - Meng R
AD  - West China School of Medicine, Sichuan University, Chengdu, China.
FAU - Niu, Kai Fan
AU  - Niu KF
AD  - West China School of Medicine, Sichuan University, Chengdu, China.
FAU - Zhu, Huili
AU  - Zhu H
AUID- ORCID: 0000-0003-2369-0123
AD  - Department of Gynecology and Obstetrics, West China Second University Hospital, 
      Sichuan University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children 
      (Sichuan University), Ministry of Education, Chengdu, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200128
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Spontaneous/*drug therapy
MH  - Animals
MH  - Antiphospholipid Syndrome/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Live Birth
MH  - Pregnancy
MH  - Recurrence
OTO - NOTNLM
OT  - antiphospholipid syndrome
OT  - aspirin
OT  - birthweight
OT  - heparin
OT  - live birth rate
OT  - miscarriages
OT  - recurrent pregnancy loss
EDAT- 2019/12/25 06:00
MHDA- 2021/01/15 06:00
CRDT- 2019/12/25 06:00
PHST- 2019/10/06 00:00 [received]
PHST- 2019/12/10 00:00 [revised]
PHST- 2019/12/10 00:00 [accepted]
PHST- 2019/12/25 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
PHST- 2019/12/25 06:00 [entrez]
AID - 10.1111/aji.13219 [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 2020 Apr;83(4):e13219. doi: 10.1111/aji.13219. Epub 2020 Jan 
      28.

PMID- 382146
OWN - NLM
STAT- MEDLINE
DCOM- 19791024
LR  - 20190713
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 66
IP  - 3
DP  - 1979 Sep
TI  - Antiplatelet drugs in thromboembolism.
PG  - 119-23, 126-7
AB  - Evidence is mounting that three drugs that inhibit platelet function--aspirin, 
      dipyridamole, and sulfinpyrazine--have an antithrombotic effect in humans. 
      Particularly in men, aspirin is beneficial in controlling transient ischemic 
      attacks and stroke, and there is evidence that it may be effective in preventing 
      thrombotic and embolic complication of hip surgery. It abolishes symptoms in 
      peripheral ischemia associated with thrombocytosis and spontaneous platelet 
      aggregation and may prove effective in coronary artery disease. When combined 
      with oral anticoagulants, aspirin is more effective than oral anticoagulants 
      alone in preventing systemic embolism in patients with prosthetic heart valves. 
      Dipyridamole in combination with oral anticoagulants reduces the incidence of 
      systemic embolism after prosthetic heart valve replacement. Sulfinpyrazone 
      reduces the incidence of sudden death in the first year after myocardial 
      infarction, decreases the incidence of arteriovenous shunt thrombosis in patients 
      undergoing chronic hemodialysis, and when combined with anticoagulants, may be 
      effective in reducing the frequency of episodes in recurrent venous thrombosis.
FAU - Hirsh, J
AU  - Hirsh J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Anticoagulants)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Anticoagulants/administration & dosage
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Coronary Disease/prevention & control
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Sulfinpyrazone/administration & dosage/*therapeutic use
MH  - Thromboembolism/*prevention & control
MH  - Thrombophlebitis/prevention & control
RF  - 43
EDAT- 1979/09/01 00:00
MHDA- 1979/09/01 00:01
CRDT- 1979/09/01 00:00
PHST- 1979/09/01 00:00 [pubmed]
PHST- 1979/09/01 00:01 [medline]
PHST- 1979/09/01 00:00 [entrez]
AID - 10.1080/00325481.1979.11715250 [doi]
PST - ppublish
SO  - Postgrad Med. 1979 Sep;66(3):119-23, 126-7. doi: 10.1080/00325481.1979.11715250.

PMID- 681371
OWN - NLM
STAT- MEDLINE
DCOM- 19781027
LR  - 20131121
IS  - 0021-9304 (Print)
IS  - 0021-9304 (Linking)
VI  - 12
IP  - 4
DP  - 1978 Jul
TI  - Antiinflammatory activities of polymers of o-metacryloyloxybenzoic acid.
PG  - 525-30
AB  - Antiinflammatory activities of low- and high- molecular-weight polymers of 
      o-methacryloyloxybenzoic acid were compared with the antiinflammatory activity of 
      o-acetoxybenzoic (acetylsalicylic) acid in tests on hind-leg inflammations in 
      rats induced by injection of either Freund's adjuvant or aqueous suspension of 
      kaolin. The antiinflammatory activies of the orally administered polymers 
      cooresponded to 40-90% of the activity of o-acetoxybenzoic acid, and were not 
      substantially dependent on the degree of polymerization.
FAU - Grimová, J
AU  - Grimová J
FAU - Hrabák, F
AU  - Hrabák F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Biomed Mater Res
JT  - Journal of biomedical materials research
JID - 0112726
RN  - 0 (Acrylic Resins)
RN  - 0 (Polymethacrylic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acrylic Resins/*therapeutic use
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Inflammation/*drug therapy
MH  - Polymethacrylic Acids/*therapeutic use
MH  - Rats
EDAT- 1978/07/01 00:00
MHDA- 1978/07/01 00:01
CRDT- 1978/07/01 00:00
PHST- 1978/07/01 00:00 [pubmed]
PHST- 1978/07/01 00:01 [medline]
PHST- 1978/07/01 00:00 [entrez]
AID - 10.1002/jbm.820120407 [doi]
PST - ppublish
SO  - J Biomed Mater Res. 1978 Jul;12(4):525-30. doi: 10.1002/jbm.820120407.

PMID- 35026785
OWN - NLM
STAT- MEDLINE
DCOM- 20220701
LR  - 20230818
IS  - 1555-824X (Electronic)
IS  - 1062-8606 (Print)
IS  - 1062-8606 (Linking)
VI  - 37
IP  - 4
DP  - 2022 Jul-Aug 01
TI  - Implementation of an Electronic Health Record Integrated Clinical Pathway 
      Improves Adherence to COVID-19 Hospital Care Guidelines.
PG  - 335-341
LID - 10.1097/JMQ.0000000000000036 [doi]
AB  - BACKGROUND: During the COVID-19 pandemic, frequently changing guidelines 
      presented challenges to emergency department (ED) clinicians. The authors 
      implemented an electronic health record (EHR)-integrated clinical pathway that 
      could be accessed by clinicians within existing workflows when caring for 
      patients under investigation (PUI) for COVID-19. The objective was to examine the 
      association between clinical pathway utilization and adherence to institutional 
      best practice treatment recommendations for COVID-19. METHODS: The authors 
      conducted an observational analysis of all ED patients seen in a health system 
      inclusive of seven EDs between March 18, 2020, and April 20, 2021. They 
      implemented the pathway as an interactive flow chart that allowed clinicians to 
      place orders while viewing the most up-to-date institutional guidance. Primary 
      outcomes were proportion of admitted PUIs receiving dexamethasone and aspirin in 
      the ED, and secondary outcome was time to delivering treatment. RESULTS: A total 
      of 13 269 patients were admitted PUIs. The pathway was used by 40.6% of ED 
      clinicians. When clinicians used the pathway, patients were more likely to be 
      prescribed aspirin (OR, 7.15; 95% CI, 6.2-8.26) and dexamethasone (10.4; 
      8.85-12.2). For secondary outcomes, clinicians using the pathway had 
      statistically significant ( P < 0.0001) improvement in timeliness of ordering 
      medications and admission to the hospital. Aspirin, dexamethasone, and admission 
      order time were improved by 103.89, 94.34, and 121.94 minutes, respectively. 
      CONCLUSIONS: The use of an EHR-integrated clinical pathway improved clinician 
      adherence to changing COVID-19 treatment guidelines and timeliness to associated 
      medication administration. As pathways continue to be implemented, their effects 
      on improving patient outcomes and decreasing disparities in patient care should 
      be further examined.
CI  - Copyright © 2022 the American College of Medical Quality.
FAU - Sangal, Rohit B
AU  - Sangal RB
AD  - Department of Emergency Medicine, Yale University School of Medicine, New Haven, 
      CT.
FAU - Liu, Rachel B
AU  - Liu RB
AD  - Department of Emergency Medicine, Yale University School of Medicine, New Haven, 
      CT.
FAU - Cole, Kelsey O
AU  - Cole KO
AD  - Yale New Haven Hospital, New Haven, CT.
FAU - Rothenberg, Craig
AU  - Rothenberg C
AD  - Department of Emergency Medicine, Yale University School of Medicine, New Haven, 
      CT.
FAU - Ulrich, Andrew
AU  - Ulrich A
AD  - Department of Emergency Medicine, Yale University School of Medicine, New Haven, 
      CT.
FAU - Rhodes, Deborah
AU  - Rhodes D
AD  - Yale New Haven Hospital, New Haven, CT.
FAU - Venkatesh, Arjun K
AU  - Venkatesh AK
AD  - Department of Emergency Medicine, Yale University School of Medicine, New Haven, 
      CT.
AD  - Center for Outcomes Research, Yale University School of Medicine, New Haven, CT.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20220111
PL  - Netherlands
TA  - Am J Med Qual
JT  - American journal of medical quality : the official journal of the American 
      College of Medical Quality
JID - 9300756
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Critical Pathways
MH  - Dexamethasone/therapeutic use
MH  - *Electronic Health Records
MH  - Emergency Service, Hospital
MH  - Hospitals
MH  - Humans
MH  - Pandemics
MH  - *COVID-19 Drug Treatment
PMC - PMC9241559
EDAT- 2022/01/14 06:00
MHDA- 2022/07/02 06:00
CRDT- 2022/01/13 20:37
PHST- 2022/01/14 06:00 [pubmed]
PHST- 2022/07/02 06:00 [medline]
PHST- 2022/01/13 20:37 [entrez]
AID - 00008488-202207000-00008 [pii]
AID - 10.1097/JMQ.0000000000000036 [doi]
PST - ppublish
SO  - Am J Med Qual. 2022 Jul-Aug 01;37(4):335-341. doi: 10.1097/JMQ.0000000000000036. 
      Epub 2022 Jan 11.

PMID- 26739516
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20220408
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 104
DP  - 2016 Feb
TI  - Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and 
      their combinations: Results of a pharmacovigilance reporting system.
PG  - 108-14
LID - S1043-6618(15)30072-4 [pii]
LID - 10.1016/j.phrs.2015.12.026 [doi]
AB  - Gastrointestinal (GI) complications are one of the most limiting cause of use of 
      NSAIDs. Beyond others well defined factors, history of peptic ulcer, older age, 
      Helicobacter pylori infection and use of gastrotoxic drugs may affect their GI 
      safety profile. In particular, the risk of GI complications associated to the use 
      of antiplatelet drugs, especially low-dose acetylsalicylic acid (LDA) should 
      deserve much attention. However, only few studies have focused on the effect of 
      combination LDA/NSAIDs on the GI tract compared with the monotherapy and much 
      less studies assessed this effect with multiple NSAIDs use. We aimed to 
      characterize the GI safety profile of NSAIDs and LDA as monotherapy or their 
      combinations in real-life conditions by analysing spontaneous adverse drug 
      reactions (ADRs) reporting system in a Southern Italy. We used the case/non-case 
      method in the Italian Pharmacovigilance Network (RNF). Cases were reports of GI 
      events in the RNF between January 2007 and December 2011. Non-cases were all 
      other reports during the same period. The association between NSAID and suspected 
      GI ADRs was calculated using the reporting odds ratio (ROR) with 95% confidence 
      intervals as a measure of disproportionality while adjusting for age, and 
      concomitant use of antineoplastic agents or drugs for cardiovascular diseases. 
      Sub-analysis were performed within the NSAID class. Among the 2816 adverse drug 
      reactions recorded, we identified 374 (13.3%) cases of GI complications. Upper GI 
      complications were the most frequently reported type of events. The highest 
      associations were found for the combined use of NSAIDs and/or LDA, whilst the 
      lowest associations were for their respective monotherapy. Looking at individual 
      NSAIDs the highest association with GI events was observed for ketorolac exposure 
      followed by nimesulide, diclofenac, aspirin, ketoprofen, and ibuprofen. This 
      study highlights the primary role of the national spontaneous reporting system to 
      bring out potential signals, such as the inappropriate drug use pattern, which 
      however, have to be furtherly studied in-depth with ad hoc population-based 
      studies.
CI  - Copyright © 2016 Elsevier Ltd. All rights reserved.
FAU - Rafaniello, Concetta
AU  - Rafaniello C
AD  - Department of Experimental Medicine, Section of Pharmacology "L. Donatelli", 
      Second University of Naples, via de Crecchio 7, 80138 Naples, Italy. Electronic 
      address: concita.rafaniello@gmail.com.
FAU - Ferrajolo, Carmen
AU  - Ferrajolo C
AD  - Department of Experimental Medicine, Section of Pharmacology "L. Donatelli", 
      Second University of Naples, via de Crecchio 7, 80138 Naples, Italy. Electronic 
      address: carmenferrj@libero.it.
FAU - Sullo, Maria Giuseppa
AU  - Sullo MG
AD  - Department of Experimental Medicine, Section of Pharmacology "L. Donatelli", 
      Second University of Naples, via de Crecchio 7, 80138 Naples, Italy. Electronic 
      address: pina.sullo@libero.it.
FAU - Sessa, Maurizio
AU  - Sessa M
AD  - Department of Experimental Medicine, Section of Pharmacology "L. Donatelli", 
      Second University of Naples, via de Crecchio 7, 80138 Naples, Italy. Electronic 
      address: maurizio_sessa@hotmail.it.
FAU - Sportiello, Liberata
AU  - Sportiello L
AD  - Department of Experimental Medicine, Section of Pharmacology "L. Donatelli", 
      Second University of Naples, via de Crecchio 7, 80138 Naples, Italy. Electronic 
      address: liberata.sportiello@unina2.it.
FAU - Balzano, Antonio
AU  - Balzano A
AD  - Gastroenterology Dept., Cardarelli Hospital Naples, Via Antonio Cardarelli 9, 
      80131 Naples, Italy. Electronic address: balzano.antonio@hotmail.com.
FAU - Manguso, Francesco
AU  - Manguso F
AD  - Gastroenterology Unit, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131 
      Naples, Italy. Electronic address: manguso@alice.it.
FAU - Aiezza, Maria Luisa
AU  - Aiezza ML
AD  - Complex Operating Unit of Pharmacy, AORN A Cardarelli, Via Antonio Cardarelli, 9, 
      80131 Naples, Italy. Electronic address: marialuisa.aiezza@aocardarelli.it.
FAU - Rossi, Francesco
AU  - Rossi F
AD  - Department of Experimental Medicine, Section of Pharmacology "L. Donatelli", 
      Second University of Naples, via de Crecchio 7, 80138 Naples, Italy. Electronic 
      address: francesco.rossi@unina2.it.
FAU - Scarpignato, Carmelo
AU  - Scarpignato C
AD  - Clinical Pharmacology & Digestive Pathophysiology Unit, Department of Clinical & 
      Experimental Medicine, University of Parma, Via Volturno 39, 43100 Parma, Italy. 
      Electronic address: scarpi@tin.it.
FAU - Capuano, Annalisa
AU  - Capuano A
AD  - Department of Experimental Medicine, Section of Pharmacology "L. Donatelli", 
      Second University of Naples, via de Crecchio 7, 80138 Naples, Italy. Electronic 
      address: annalisa.capuano@unina2.it.
LA  - eng
PT  - Journal Article
DEP - 20151229
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Adverse Drug Reaction Reporting Systems
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Combinations
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Humans
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Pharmacovigilance
OTO - NOTNLM
OT  - Adverse drug reaction
OT  - Gastrointestinal complications
OT  - Non-steroidal antinflammatory drugs
EDAT- 2016/01/08 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/01/08 06:00
PHST- 2015/09/30 00:00 [received]
PHST- 2015/12/22 00:00 [revised]
PHST- 2015/12/22 00:00 [accepted]
PHST- 2016/01/08 06:00 [entrez]
PHST- 2016/01/08 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S1043-6618(15)30072-4 [pii]
AID - 10.1016/j.phrs.2015.12.026 [doi]
PST - ppublish
SO  - Pharmacol Res. 2016 Feb;104:108-14. doi: 10.1016/j.phrs.2015.12.026. Epub 2015 
      Dec 29.

PMID- 19878541
OWN - NLM
STAT- MEDLINE
DCOM- 20100524
LR  - 20211020
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 8
DP  - 2009 Oct 30
TI  - Lack of benefits for prevention of cardiovascular disease with aspirin therapy in 
      type 2 diabetic patients--a longitudinal observational study.
PG  - 57
LID - 10.1186/1475-2840-8-57 [doi]
AB  - BACKGROUND: The risk-benefit ratio of aspirin therapy in prevention of 
      cardiovascular disease (CVD) remains contentious, especially in type 2 diabetes. 
      This study examined the benefit and harm of low-dose aspirin (daily dose < 300 
      mg) in patients with type 2 diabetes. METHODS: This is a longitudinal 
      observational study with primary and secondary prevention cohorts based on 
      history of CVD at enrollment. We compared the occurrence of primary composite 
      (non-fatal myocardial infarction or stroke and vascular death) and secondary 
      endpoints (upper GI bleeding and haemorrhagic stroke) between aspirin users and 
      non-users between January 1995 and July 2005. RESULTS: Of the 6,454 patients 
      (mean follow-up: median [IQR]: 4.7 [4.4] years), usage of aspirin was 18% (n = 
      1,034) in the primary prevention cohort (n = 5731) and 81% (n = 585) in the 
      secondary prevention cohort (n = 723). After adjustment for covariates, in the 
      primary prevention cohort, aspirin use was associated with a hazard-ratio of 2.07 
      (95% CI: 1.66, 2.59, p < 0.001) for primary endpoint. There was no difference in 
      CVD event rate in the secondary prevention cohort. Overall, aspirin use was 
      associated with a hazard-ratio of 2.2 (1.53, 3.15, p < 0.001) of GI bleeding and 
      1.71 (1.00, 2.95, p = 0.051) of haemorrhagic stroke. The absolute risk of 
      aspirin-related GI bleeding was 10.7 events per 1,000 person-years of treatment. 
      CONCLUSION: In Chinese type 2 diabetic patients, low dose aspirin was associated 
      with a paradoxical increase in CVD risk in primary prevention and did not confer 
      benefits in secondary prevention. In addition, the risk of GI bleeding in aspirin 
      users was rather high.
FAU - Leung, Wilson Y
AU  - Leung WY
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong SAR, PR China. wilson_lg@hotmail.com
FAU - So, Wing-yee
AU  - So WY
FAU - Stewart, Derek
AU  - Stewart D
FAU - Lui, Augustine
AU  - Lui A
FAU - Tong, Peter C
AU  - Tong PC
FAU - Ko, Gary T
AU  - Ko GT
FAU - Kong, Alice P
AU  - Kong AP
FAU - Ma, Ronald C
AU  - Ma RC
FAU - Chan, Francis K
AU  - Chan FK
FAU - Yang, Xilin
AU  - Yang X
FAU - Chiang, Sau-chu
AU  - Chiang SC
FAU - Chan, Juliana C
AU  - Chan JC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20091030
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*etiology/*prevention & control
MH  - Cohort Studies
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention/methods
MH  - Registries
MH  - Risk Assessment
MH  - Risk Factors
MH  - Secondary Prevention/methods
PMC - PMC2777137
EDAT- 2009/11/03 06:00
MHDA- 2010/05/25 06:00
CRDT- 2009/11/03 06:00
PHST- 2009/04/21 00:00 [received]
PHST- 2009/10/30 00:00 [accepted]
PHST- 2009/11/03 06:00 [entrez]
PHST- 2009/11/03 06:00 [pubmed]
PHST- 2010/05/25 06:00 [medline]
AID - 1475-2840-8-57 [pii]
AID - 10.1186/1475-2840-8-57 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2009 Oct 30;8:57. doi: 10.1186/1475-2840-8-57.

PMID- 132024
OWN - NLM
STAT- MEDLINE
DCOM- 19760802
LR  - 20191027
IS  - 0084-5353 (Print)
IS  - 0084-5353 (Linking)
VI  - 86
IP  - 1
DP  - 1976 May 3
TI  - Platelet turnover in metastatic cancer and the effect of platelet aggregation 
      inhibitors.
PG  - 109-111
AB  - Patients with metastatic cancer have a permanent shortening of platelet survival 
      and increased platelet consumption. Acetylsalicylic acid or dipyridamole in doses 
      known to inhibit platelet aggregation, had no effect on platelet consumption.
FAU - Abrahamsen, A F
AU  - Abrahamsen AF
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Z Krebsforsch Klin Onkol Cancer Res Clin Oncol
JT  - Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and 
      clinical oncology
JID - 1276653
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Cell Survival/drug effects
MH  - Dipyridamole/pharmacology
MH  - Humans
MH  - Neoplasm Metastasis/*blood
MH  - Platelet Aggregation/*drug effects
EDAT- 1976/05/03 00:00
MHDA- 1976/05/03 00:01
CRDT- 1976/05/03 00:00
PHST- 1976/05/03 00:00 [pubmed]
PHST- 1976/05/03 00:01 [medline]
PHST- 1976/05/03 00:00 [entrez]
AID - 10.1007/BF00304941 [doi]
PST - ppublish
SO  - Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1976 May 3;86(1):109-111. doi: 
      10.1007/BF00304941.

PMID- 8112440
OWN - NLM
STAT- MEDLINE
DCOM- 19940328
LR  - 20161123
IS  - 0903-1936 (Print)
IS  - 0903-1936 (Linking)
VI  - 6
IP  - 10
DP  - 1993 Nov
TI  - Airway responsiveness to leukotriene C4 (LTC4), leukotriene E4 (LTE4) and 
      histamine in aspirin-sensitive asthmatic subjects.
PG  - 1468-73
AB  - We wanted to determine whether the airway response to inhaled leukotriene C4 
      (LTC4) is similar to inhaled leukotriene E4 (LTE4) in aspirin-sensitive asthma 
      and, therefore, determined airway responsiveness to histamine, LTC4 and LTE4 in 
      seven aspirin-sensitive subjects and 13 control asthmatic subjects, who were 
      tolerant of aspirin. The concentration of inhaled lysine-aspirin which produced a 
      15% fall in forced expiratory volume in one second (FEV1) (PC15) was determined 
      in aspirin-sensitive asthmatic subjects. The dose of histamine, LTC4 and LTE4 
      which produced a 35% fall in specific airways conductance (PD35sGaw) was 
      determined by linear interpolation from the log dose response curve. There was no 
      correlation between the PC15 for lysine-aspirin and the airway reactivity to 
      inhaled LTC4 or LTE4. There was no difference in airway response to histamine and 
      LTC4 between any of the groups of asthmatic subjects. There was a rank order of 
      potency LTC4 > LTE4 > histamine in both groups, with LTC4 approximately 1,000 
      fold more potent than histamine in both groups. Aspirin-sensitive asthmatic 
      subjects were significantly more responsive to LTE4 (p = 0.02) than 
      aspirin-tolerant asthmatic subjects. The relative responsiveness of LTE4 to 
      histamine (PD35 histamine/PD35 LTE4) was significantly greater in 
      aspirin-sensitive asthmatic subjects compared to aspirin-tolerant asthmatic 
      subjects (p = 0.05). There was no difference in relative responsiveness of LTC4 
      to histamine between aspirin-sensitive or aspirin-tolerant asthmatic subjects. We 
      conclude that the airways of aspirin-sensitive asthmatic subjects demonstrate a 
      selective hyperresponsiveness to LTE4, which is not observed for LTC4.
FAU - Christie, P E
AU  - Christie PE
AD  - Swiss Institute for Allergy and Asthma Research, Davos.
FAU - Schmitz-Schumann, M
AU  - Schmitz-Schumann M
FAU - Spur, B W
AU  - Spur BW
FAU - Lee, T H
AU  - Lee TH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - 2CU6TT9V48 (Leukotriene C4)
RN  - 75715-89-8 (Leukotriene E4)
RN  - 820484N8I3 (Histamine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*adverse effects/analogs & derivatives
MH  - Asthma/*physiopathology
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Histamine/*pharmacology
MH  - Humans
MH  - Leukotriene C4/*pharmacology
MH  - Leukotriene E4/*pharmacology
MH  - Lysine/adverse effects/analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Respiratory System/*drug effects
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PST - ppublish
SO  - Eur Respir J. 1993 Nov;6(10):1468-73.

PMID- 24684687
OWN - NLM
STAT- MEDLINE
DCOM- 20141215
LR  - 20181202
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 10
IP  - 5
DP  - 2014 May
TI  - Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic 
      rhinosinusitis with nasal polyposis.
PG  - 657-65
LID - 10.1586/1744666X.2014.901889 [doi]
AB  - Chronic rhinosinusitis patients with nasal polyps can be aspirin sensitive or 
      aspirin tolerant. The majority belong to the latter group. They tolerate intake 
      of aspirin or other non-steroidal anti-inflammatory drugs, whereas 
      aspirin-sensitive patients have an adverse reaction (asthma, rhinitis and/or 
      urticaria). Diagnosis of aspirin sensitivity is important for the patient, but is 
      rarely undertaken in routine ENT or respiratory medicine practice. Treatment of 
      nasal polyps is by a combination of medical therapy and surgery. Oral and topical 
      steroids form the mainstay of medical therapy, which is aimed at reducing 
      inflammation and symptom improvement. Surgery helps with polyps causing severe 
      nasal obstruction. Despite these therapies, recurrences are common in aspirin 
      sensitive patients. Any adjunctive therapy to prevent or prolong recurrence would 
      be welcome. One such possibility is topical nasal lysine-aspirin. This is an area 
      under current debate and this non-systematic review aims to provide evidence of 
      its use, to date, in aspirin sensitive and aspirin tolerant nasal polyp patients.
FAU - Parikh, Abhijeet
AU  - Parikh A
AD  - Imperial College Healthcare NHS Trust, St. Mary's Hospital, Praed Street, London 
      W2 1NY, UK.
FAU - Scadding, Glenis K
AU  - Scadding GK
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20140331
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Intranasal
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Chronic Disease
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Nasal Polyps/complications/*drug therapy
MH  - Rhinitis/complications/*drug therapy
MH  - Sinusitis/complications/*drug therapy
MH  - Treatment Outcome
EDAT- 2014/04/02 06:00
MHDA- 2014/12/17 06:00
CRDT- 2014/04/02 06:00
PHST- 2014/04/02 06:00 [entrez]
PHST- 2014/04/02 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
AID - 10.1586/1744666X.2014.901889 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2014 May;10(5):657-65. doi: 
      10.1586/1744666X.2014.901889. Epub 2014 Mar 31.

PMID- 30470579
OWN - NLM
STAT- MEDLINE
DCOM- 20191023
LR  - 20191023
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 40
IP  - 12
DP  - 2018 Dec
TI  - Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 
      12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China 
      Payer's Perspective.
PG  - 2125-2137
LID - S0149-2918(18)30513-7 [pii]
LID - 10.1016/j.clinthera.2018.10.018 [doi]
AB  - PURPOSE: Monotherapy with either aspirin or clopidogrel is recommended for 
      long-term use after discontinuation of dual-antiplatelet therapy (DAPT) for acute 
      coronary syndrome (ACS) management after percutaneous coronary intervention 
      (PCI). The present study is to evaluate the cost-effectiveness of clopidogrel 
      versus aspirin after 12-month DAPT for patients with ACS who underwent PCI in 
      China. METHODS: A 2-part model was developed to estimate the cost-effectiveness 
      of clopidogrel compared with aspirin. The short-term part was a decision tree 
      that included health states such as myocardial infarction (MI), stroke, MI and 
      stroke, cardiovascular death, and death from other causes with a treatment 
      horizon of 1 year (base case), 2 years or 3 years after 12-month DAPT. Major 
      bleeding was included. The long-term (lifetime) part was a Markov model that 
      included different health states such as MI, after MI, stroke, after stroke, and 
      death. Drug acquisition cost and other direct medical costs were based on pricing 
      records, literature, and expert panels. Clinical outcomes and utilities were 
      based on literature. The model output included incremental cost-effectiveness 
      ratio of quality-adjusted life-years (QALYs) and total costs per patient. Both 
      1-way sensitivity analysis and probabilistic sensitivity analysis (PSA) were 
      conducted. FINDINGS: In the base-case scenario, the total costs of the treatment 
      with clopidogrel and aspirin were ¥12,590 ($1849/€1590) and ¥10,642 
      ($1563/€1344), respectively; the total QALYs of the 2 patient populations were 
      9.7341 and 9.6894, respectively. The incremental cost-effectiveness ratio of 
      ¥43,593 ($6402/€5515) per QALY gained was lower than 3 times of gross domestic 
      product (GDP) per capita in China (¥161,940, $23,786/€20,449). Both 1-way 
      sensitivity analysis and PSA confirmed the robustness of the results. PSA results 
      indicated that clopidogrel was cost effective versus aspirin in 80.5% of the 
      simulations, considering >3 times the GDP per capita as the threshold. Results in 
      other scenarios (clopidogrel or aspirin for 2 or 3 years after 12-month DAPT) 
      also indicated that clopidogrel was more cost effective than aspirin for patients 
      with ACS after 12-month DAPT. IMPLICATIONS: Compared with aspirin monotherapy, 
      clopidogrel monotherapy for 1 year after 12-month DAPT was cost effective for 
      patients with ACS who underwent PCI in China. Furthermore, when the duration of 
      clopidogrel the monotherapy extended up to 3 years, clopidogrel was still cost 
      effective compared with aspirin. The study was limited by lack of high-quality 
      efficacy data among the Chinese population.
CI  - Copyright © 2018. Published by Elsevier Inc.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Shanghai Centennial Scientific, Shanghai, China.
FAU - Lin, Ziyi
AU  - Lin Z
AD  - Shanghai Centennial Scientific, Shanghai, China.
FAU - Yin, Hongjun
AU  - Yin H
AD  - Shanghai Centennial Scientific, Shanghai, China.
FAU - Liu, Jing
AU  - Liu J
AD  - Health Economic Research Institute, Sun Yat-sen University, Guangzhou, China.
FAU - Xuan, Jianwei
AU  - Xuan J
AD  - Health Economic Research Institute, Sun Yat-sen University, Guangzhou, China. 
      Electronic address: xuanjw3@mail.sysu.edu.cn.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181122
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/economics
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/economics/*therapeutic use
MH  - China
MH  - Clopidogrel/economics/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Decision Trees
MH  - Female
MH  - Humans
MH  - Insurance, Health, Reimbursement
MH  - Male
MH  - Markov Chains
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/economics/*therapeutic use
MH  - Quality-Adjusted Life Years
OTO - NOTNLM
OT  - aspirin
OT  - clopidogrel
OT  - cost-effectiveness
OT  - dual antiplatelet therapy
EDAT- 2018/11/25 06:00
MHDA- 2019/10/24 06:00
CRDT- 2018/11/25 06:00
PHST- 2018/07/20 00:00 [received]
PHST- 2018/09/25 00:00 [revised]
PHST- 2018/10/17 00:00 [accepted]
PHST- 2018/11/25 06:00 [pubmed]
PHST- 2019/10/24 06:00 [medline]
PHST- 2018/11/25 06:00 [entrez]
AID - S0149-2918(18)30513-7 [pii]
AID - 10.1016/j.clinthera.2018.10.018 [doi]
PST - ppublish
SO  - Clin Ther. 2018 Dec;40(12):2125-2137. doi: 10.1016/j.clinthera.2018.10.018. Epub 
      2018 Nov 22.

PMID- 2701053
OWN - NLM
STAT- MEDLINE
DCOM- 19900829
LR  - 20131121
IS  - 0213-1285 (Print)
IS  - 0213-1285 (Linking)
VI  - 5
IP  - 9
DP  - 1989 Nov
TI  - [Analgesia in dentistry].
PG  - 623-30
AB  - Antiinflamatories, antipiretics and analgesics of normal use with special 
      interest in the salicylates that we considered analgesics of first election, 
      excepting counter-indications are exposed. We expressed our conduct in the 
      handling of the pain with the different alternatives according to the cases, to 
      revitalise the use of aspirin in its different presentation forms, as an 
      effective analgesic.
FAU - Rubio Alonso, S
AU  - Rubio Alonso S
FAU - Burgos Sánchez Escribano, C
AU  - Burgos Sánchez Escribano C
FAU - Chaparro Heredia, A J
AU  - Chaparro Heredia AJ
LA  - spa
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Analgesia en odontologia.
PL  - Spain
TA  - Av Odontoestomatol
JT  - Avances en odontoestomatologia
JID - 8612453
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
MH  - Analgesics/pharmacokinetics/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics/*therapeutic use
MH  - Aspirin/pharmacokinetics/therapeutic use
MH  - Dental Care
MH  - Humans
MH  - Pain/drug therapy
RF  - 69
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
PST - ppublish
SO  - Av Odontoestomatol. 1989 Nov;5(9):623-30.

PMID- 27785736
OWN - NLM
STAT- MEDLINE
DCOM- 20170223
LR  - 20181202
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
VI  - 37
IP  - 2
DP  - 2017 Feb
TI  - Relationship between Adverse Gastric Reactions and the Timing of Enteric-Coated 
      Aspirin Administration.
PG  - 187-193
LID - 10.1007/s40261-016-0474-z [doi]
AB  - OBJECTIVE: This study aimed to elucidate the association between the adverse 
      gastric effects of enteric-coated aspirin and the timing of its administration. 
      METHODS: The study population comprised 572 patients (age range 45-84 years) 
      admitted to Huaiyin Hospital between August 2012 and October 2014. Patients were 
      administered a 100 mg enteric-coated aspirin tablet once daily: before a meal 
      (30 min before a meal), during a meal, after a meal (30 min after a meal), or 
      before sleep, and all patients were followed up for 6-9 months to observe for 
      adverse gastric reactions and other side effects. Gastroscopy was performed if 
      indicated by the patient's condition after obtaining due consent. In addition, 
      release tests for an enteric-coated aspirin tablet were conducted using the 
      chromatography method. RESULTS: Enteric-coated aspirin tablets released 
      completely, with a release rate of >99 % under 20-120 min at pH > 5.5. 
      Furthermore, the number of patients with recurring adverse stomach reactions was 
      significantly lower in the before-meal and before-sleep groups than that observed 
      in the during-meal and after-meal groups (p < 0.05). No significant between-group 
      differences were observed with respect to damage to other organs. Similarly, the 
      number of patients with gastric lesions was significantly lower in the 
      before-meal and before-sleep groups than that observed in the during-meal and 
      after-meal groups (p < 0.05). CONCLUSIONS: The optimal time for once-daily 
      administration of low-dose enteric-coated aspirin tablets was before a meal or 
      before sleep owing to the increase in pH level during and after meals.
FAU - Guo, Weijun
AU  - Guo W
AD  - Department of Cardiology, Huaiyin Hospital, No.38, Beijing West Road, Huaiyin 
      District, Huai'an, 223300, Jiangsu Province, China. hylucky289@163.com.
FAU - Lu, Wenlin
AU  - Lu W
AD  - Department of Cardiology, Huaiyin Hospital, No.38, Beijing West Road, Huaiyin 
      District, Huai'an, 223300, Jiangsu Province, China.
FAU - Xu, Yujun
AU  - Xu Y
AD  - Department of Cardiology, Huaiyin Hospital, No.38, Beijing West Road, Huaiyin 
      District, Huai'an, 223300, Jiangsu Province, China.
FAU - Wang, Liansheng
AU  - Wang L
AD  - Department of Cardiology, Jiangsu Province People's Hospital, Nanjing, China.
FAU - Wei, Qin
AU  - Wei Q
AD  - Department of Cardiology, Huaiyin Hospital, No.38, Beijing West Road, Huaiyin 
      District, Huai'an, 223300, Jiangsu Province, China.
FAU - Zhao, Qingyun
AU  - Zhao Q
AD  - Department of Cardiology, Huaiyin Hospital, No.38, Beijing West Road, Huaiyin 
      District, Huai'an, 223300, Jiangsu Province, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Algorithms
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Gastroscopy
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Stomach Diseases/*chemically induced
MH  - Tablets, Enteric-Coated
EDAT- 2016/10/28 06:00
MHDA- 2017/02/24 06:00
CRDT- 2016/10/28 06:00
PHST- 2016/10/28 06:00 [pubmed]
PHST- 2017/02/24 06:00 [medline]
PHST- 2016/10/28 06:00 [entrez]
AID - 10.1007/s40261-016-0474-z [pii]
AID - 10.1007/s40261-016-0474-z [doi]
PST - ppublish
SO  - Clin Drug Investig. 2017 Feb;37(2):187-193. doi: 10.1007/s40261-016-0474-z.

PMID- 16367896
OWN - NLM
STAT- MEDLINE
DCOM- 20060608
LR  - 20141120
IS  - 0001-6314 (Print)
IS  - 0001-6314 (Linking)
VI  - 113
IP  - 1
DP  - 2006 Jan
TI  - Aspirin resistance in secondary stroke prevention.
PG  - 31-5
AB  - BACKGROUND: We investigated the platelet function in stroke patients treated with 
      aspirin [acetylsalicylic acid (ASA)] for secondary stroke prevention during a 
      follow-up period of 1 year. METHODS: In this prospective study 291 patients with 
      first initiated aspirin therapy (300 mg/day) for secondary stroke prevention were 
      included. Platelet aggregation measurements were performed 24 h, 3, 6, and 12 
      months after starting medication. RESULTS: Twenty-one of 291 patients (7.2%) were 
      identified as primary ASA-non-responders (initial insufficient platelet 
      inhibition) and 4.1% as secondary ASA-non-responders (insufficient platelet 
      inhibition during follow-up). There were no significant differences between 
      ASA-responders and ASA-non-responders concerning age, gender, risk factors, and 
      stroke characteristics. CONCLUSION: Aspirin resistance in stroke patients is not 
      uncommon. The clinical usefulness of routine platelet function tests needs to be 
      proved by further trials.
FAU - Berrouschot, J
AU  - Berrouschot J
AD  - Department of Neurology, Municipal Hospital Altenburg, Altenburg, Germany. 
      berrouschot.kkh-altenburg@t-online.de
FAU - Schwetlick, B
AU  - Schwetlick B
FAU - von Twickel, G
AU  - von Twickel G
FAU - Fischer, C
AU  - Fischer C
FAU - Uhlemann, H
AU  - Uhlemann H
FAU - Siegemund, T
AU  - Siegemund T
FAU - Siegemund, A
AU  - Siegemund A
FAU - Roessler, A
AU  - Roessler A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - *Drug Resistance
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Selection
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Prospective Studies
MH  - Secondary Prevention
MH  - Stroke/drug therapy/*prevention & control
EDAT- 2005/12/22 09:00
MHDA- 2006/06/09 09:00
CRDT- 2005/12/22 09:00
PHST- 2005/12/22 09:00 [pubmed]
PHST- 2006/06/09 09:00 [medline]
PHST- 2005/12/22 09:00 [entrez]
AID - ANE419 [pii]
AID - 10.1111/j.1600-0404.2005.00419.x [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2006 Jan;113(1):31-5. doi: 10.1111/j.1600-0404.2005.00419.x.

PMID- 10438276
OWN - NLM
STAT- MEDLINE
DCOM- 19990805
LR  - 20180213
IS  - 0251-5350 (Print)
IS  - 0251-5350 (Linking)
VI  - 18
IP  - 3
DP  - 1999
TI  - Association of nonsteroidal anti-inflammatory drugs and aspirin with cognitive 
      performance in middle-aged adults.
PG  - 134-43
AB  - OBJECTIVES: To assess the cross-sectional association of regular use of 
      nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin with cognitive function 
      in 13,153 individuals, aged 48-67 years, participating in the Atherosclerosis 
      Risk in Communities (ARIC) Study. METHODS: Regular use of NSAIDs or aspirin was 
      analyzed in relation to the results of three cognitive tests, the Delayed Word 
      Recall Test, the WAIS-R Digit Symbol Subtest, and the Word Fluency Test. RESULTS: 
      After adjustment for covariates previously found to be associated with cognition 
      in this sample, we found a weak negative association between current use of 
      aspirin and poor Word Recall [OR = 0.84 (95% confidence interval: 0.68-1.04)] and 
      poor Word Fluency [OR = 0.85 (0.70-1.03)]. We found no association between 
      current use of aspirin and Digit Symbol score, nor did we find current NSAID use 
      to be significantly associated with any of the cognitive tests. CONCLUSIONS: This 
      study suggests a modest association, at best, between NSAIDs or aspirin and 
      better cognitive function.
FAU - Peacock, J M
AU  - Peacock JM
AD  - Division of Epidemiology, School of Public Health, University of Minnesota, 
      Minneapolis 55454-1015, USA.
FAU - Folsom, A R
AU  - Folsom AR
FAU - Knopman, D S
AU  - Knopman DS
FAU - Mosley, T H
AU  - Mosley TH
FAU - Goff, D C Jr
AU  - Goff DC Jr
FAU - Szklo, M
AU  - Szklo M
LA  - eng
GR  - N01-HC-55015/HC/NHLBI NIH HHS/United States
GR  - N01-HC-55016/HC/NHLBI NIH HHS/United States
GR  - N01-HC-55018/HC/NHLBI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Switzerland
TA  - Neuroepidemiology
JT  - Neuroepidemiology
JID - 8218700
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cognition/*drug effects
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Wechsler Scales
EDAT- 1999/08/07 10:00
MHDA- 2000/10/06 11:01
CRDT- 1999/08/07 10:00
PHST- 1999/08/07 10:00 [pubmed]
PHST- 2000/10/06 11:01 [medline]
PHST- 1999/08/07 10:00 [entrez]
AID - ned18134 [pii]
AID - 10.1159/000026205 [doi]
PST - ppublish
SO  - Neuroepidemiology. 1999;18(3):134-43. doi: 10.1159/000026205.

PMID- 35450493
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20220902
IS  - 1525-1489 (Electronic)
IS  - 0885-0666 (Print)
IS  - 0885-0666 (Linking)
VI  - 37
IP  - 9
DP  - 2022 Sep
TI  - Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A 
      Multicenter Propensity Score Matched Study.
PG  - 1238-1249
LID - 10.1177/08850666221093229 [doi]
AB  - BACKGROUND: Aspirin is widely used as a cardioprotective agent due to its 
      antiplatelet and anti-inflammatory properties. The literature has assessed and 
      evaluated its role in hospitalized COVID-19 patients. However, no data are 
      available regarding its role in COVID-19 critically ill patients. This study 
      aimed to evaluate the use of low-dose aspirin (81-100 mg) and its impact on 
      outcomes in critically ill patients with COVID-19. METHOD: A multicenter, 
      retrospective cohort study of all critically ill adult patients with confirmed 
      COVID-19 admitted to intensive care units (ICUs) between March 1, 2020, and March 
      31, 2021. Eligible patients were classified into two groups based on aspirin use 
      during ICU stay. The primary outcome was in-hospital mortality, and other 
      outcomes were considered secondary. Propensity score matching was used (1:1 
      ratio) based on the selected criteria. RESULTS: A total of 1033 patients were 
      eligible, and 352 patients were included after propensity score matching. The 
      in-hospital mortality (HR 0.73 [0.56, 0.97], p = 0.03) was lower in patients who 
      received aspirin during stay. Conversely, patients who received aspirin had a 
      higher odds of major bleeding than those in the control group (OR 2.92 [0.91, 
      9.36], p = 0.07); however, this was not statistically significant. Additionally, 
      subgroup analysis showed a possible mortality benefit for patients who used 
      aspirin therapy prior to hospitalization and continued during ICU stay (HR 0.72 
      [0.52, 1.01], p = 0.05), but not with the new initiation of aspirin (HR 1.22 
      [0.68, 2.20], p = 0.50). CONCLUSION: Continuation of aspirin therapy during ICU 
      stay in critically ill patients with COVID-19 who were receiving it prior to ICU 
      admission may have a mortality benefit; nevertheless, it may be associated with 
      an increased risk of significant bleeding. Appropriate evaluation for safety 
      versus benefits of utilizing aspirin therapy during ICU stay in COVID19 
      critically ill patients is highly recommended.
FAU - Al Harthi, Abdullah F
AU  - Al Harthi AF
AD  - Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi 
      Arabia.
AD  - College of Pharmacy, 48149King Saud bin Abdulaziz University for Health Sciences, 
      Riyadh, Saudi Arabia.
AD  - 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
FAU - Aljuhani, Ohoud
AU  - Aljuhani O
AD  - Department of Pharmacy Practice, Faculty of Pharmacy, 37848King Abdulaziz 
      University, Jeddah, Saudi Arabia.
AD  - Saudi Critical Care Pharmacy Research (SCAPE) Platform, Saudi Arabia.
FAU - Korayem, Ghazwa B
AU  - Korayem GB
AD  - Department of Pharmacy Practice, College of Pharmacy, 112893Princess Nourah Bint 
      Abdulrahman University, Riyadh, Saudi Arabia.
FAU - Altebainawi, Ali F
AU  - Altebainawi AF
AD  - Pharmaceutical Care Services, King Salman Specialist Hospital, Hail Health 
      Cluster, Ministry of Health, Hail, Saudi Arabia.
FAU - Alenezi, Raghdah S
AU  - Alenezi RS
AD  - College of Pharmacy, 48138University of Hail, Hail Saudi Arabia.
FAU - Al Harbi, Shmeylan
AU  - Al Harbi S
AD  - Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi 
      Arabia.
AD  - College of Pharmacy, 48149King Saud bin Abdulaziz University for Health Sciences, 
      Riyadh, Saudi Arabia.
AD  - 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
FAU - Gramish, Jawaher
AU  - Gramish J
AD  - Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi 
      Arabia.
AD  - College of Pharmacy, 48149King Saud bin Abdulaziz University for Health Sciences, 
      Riyadh, Saudi Arabia.
AD  - 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
FAU - Kensara, Raed
AU  - Kensara R
AD  - Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi 
      Arabia.
AD  - 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
FAU - Hafidh, Awattif
AU  - Hafidh A
AD  - Department of Pharmacy Practice, Faculty of Pharmacy, 37848King Abdulaziz 
      University, Jeddah, Saudi Arabia.
FAU - Al Enazi, Huda
AU  - Al Enazi H
AD  - Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi 
      Arabia.
AD  - 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
FAU - Alawad, Ahad
AU  - Alawad A
AD  - Department of Pharmacy Practice, College of Pharmacy, 112893Princess Nourah Bint 
      Abdulrahman University, Riyadh, Saudi Arabia.
FAU - Alotaibi, Rand
AU  - Alotaibi R
AD  - Department of Pharmacy Practice, College of Pharmacy, 112893Princess Nourah Bint 
      Abdulrahman University, Riyadh, Saudi Arabia.
FAU - Alshehri, Abdulaziz
AU  - Alshehri A
AD  - College of Pharmacy, 48149King Saud bin Abdulaziz University for Health Sciences, 
      Riyadh, Saudi Arabia.
FAU - Alhuthaili, Omar
AU  - Alhuthaili O
AD  - College of Pharmacy, 48149King Saud bin Abdulaziz University for Health Sciences, 
      Riyadh, Saudi Arabia.
FAU - Vishwakarma, Ramesh
AU  - Vishwakarma R
AD  - 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
FAU - Bin Saleh, Khalid
AU  - Bin Saleh K
AD  - Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi 
      Arabia.
AD  - College of Pharmacy, 48149King Saud bin Abdulaziz University for Health Sciences, 
      Riyadh, Saudi Arabia.
AD  - 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
FAU - Alsulaiman, Thamer
AU  - Alsulaiman T
AD  - Family Medicine Department, King Faisal Specialist Hospital & Research Center, 
      Riyadh, Saudi Arabia.
FAU - Alqahtani, Rahaf Ali
AU  - Alqahtani RA
AD  - Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi 
      Arabia.
AD  - 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
FAU - Hussain, Sajid
AU  - Hussain S
AD  - 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
AD  - Intensive Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi 
      Arabia.
FAU - Almazrou, Saja
AU  - Almazrou S
AD  - College of Pharmacy, 37850King Saud University, Riyadh, Saudi Arabia.
FAU - Al Sulaiman, Khalid
AU  - Al Sulaiman K
AUID- ORCID: 0000-0002-5547-2043
AD  - Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi 
      Arabia.
AD  - College of Pharmacy, 48149King Saud bin Abdulaziz University for Health Sciences, 
      Riyadh, Saudi Arabia.
AD  - 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
AD  - Saudi Critical Care Pharmacy Research (SCAPE) Platform, Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20220421
PL  - United States
TA  - J Intensive Care Med
JT  - Journal of intensive care medicine
JID - 8610344
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - *COVID-19
MH  - Critical Illness/therapy
MH  - Hemorrhage
MH  - Humans
MH  - Intensive Care Units
MH  - Propensity Score
MH  - Retrospective Studies
MH  - SARS-CoV-2
PMC - PMC9038962
OTO - NOTNLM
OT  - 30-day mortality
OT  - COVID-19
OT  - SARS-coV-2
OT  - aspirin
OT  - critically ill
OT  - in-hospital mortality
OT  - intensive care units (ICUs)
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2022/04/23 06:00
MHDA- 2022/08/24 06:00
CRDT- 2022/04/22 07:01
PHST- 2022/04/23 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
PHST- 2022/04/22 07:01 [entrez]
AID - 10.1177_08850666221093229 [pii]
AID - 10.1177/08850666221093229 [doi]
PST - ppublish
SO  - J Intensive Care Med. 2022 Sep;37(9):1238-1249. doi: 10.1177/08850666221093229. 
      Epub 2022 Apr 21.

PMID- 6973992
OWN - NLM
STAT- MEDLINE
DCOM- 19811014
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 31
IP  - 5a
DP  - 1981
TI  - Effects of fluproquazone on platelet aggregation in man.
PG  - 937-40
AB  - Turbidimetric investigations on platelets from healthy volunteers have shown 
      inhibitory effects of 4-(p-fluorophenyl)-1-isopropyl-7-methyl-2(1H)-quinazolinone 
      (fluproquazone) and acetylsalicylic acid (ASA) on both the extent and the 
      velocity of aggregation induced by collagen. The threshold concentration of 
      arachidonic acid needed to induce aggregation was also raised after fluproquazone 
      was given to the donors. Whereas the inhibitory effects of fluproquazone 
      disappear within 24 h, the qualitatively similar effects of ASA are much longer 
      lasting (72--96 h). There is no evidence for enhancement of the effects of 
      fluproquazone following four days of administration (100 mg t.i.d.).
FAU - Beveridge, T
AU  - Beveridge T
FAU - Crawford, M
AU  - Crawford M
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Quinazolines)
RN  - 0 (Quinazolinones)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - U4K85O58HD (fluproquazone)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/adverse effects/pharmacology
MH  - Collagen/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Quinazolines/adverse effects/*pharmacology
MH  - Quinazolinones
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1981;31(5a):937-40.

PMID- 25957056
OWN - NLM
STAT- MEDLINE
DCOM- 20160225
LR  - 20161125
IS  - 1941-7632 (Electronic)
IS  - 1941-7640 (Linking)
VI  - 8
IP  - 5
DP  - 2015 May
TI  - Impact of Intravenous Lysine Acetylsalicylate Versus Oral Aspirin on 
      Prasugrel-Inhibited Platelets: Results of a Prospective, Randomized, Crossover 
      Study (the ECCLIPSE Trial).
LID - e002281 [pii]
LID - 10.1161/CIRCINTERVENTIONS.114.002281 [doi]
AB  - BACKGROUND: Prasugrel and ticagrelor, new P2Y12-adenosine diphosphate receptor 
      antagonists, are associated with greater pharmacodynamic inhibition and reduction 
      of cardiovascular events compared with clopidogrel in patients with an acute 
      coronary syndrome. However, evidence is lacking about the effects of achieving 
      faster and stronger cyclooxygenase inhibition with intravenous lysine 
      acetylsalicylate (LA) compared with oral aspirin on prasugrel-inhibited 
      platelets. METHODS AND RESULTS: This was a prospective, randomized, 
      single-center, open, 2-period crossover platelet function study conducted in 30 
      healthy volunteers. Subjects were randomly assigned to receive a loading dose of 
      intravenous LA 450 mg plus oral prasugrel 60 mg or loading dose of aspirin 300 mg 
      plus prasugrel 60 mg orally in a crossover fashion after a 2-week washout period 
      between treatments. Platelet function was evaluated at baseline, 30 minutes, 1 h, 
      4 h, and 24 h using light transmission aggregometry and vasodilator-stimulated 
      phosphoprotein phosphorylation. The primary end point of the study, inhibition of 
      platelet aggregation after arachidonic acid 1.5 mmol/L at 30 minutes, was 
      significantly higher in subjects treated with LA compared with aspirin: 85.3% 
      versus 44.3%, respectively, P=0.003. This differential effect was observed at 1 
      hour (P=0.002) and 4 hours (P=0.048), but not at 24 hours. Subjects treated with 
      LA presented less variability and faster and greater inhibition of platelet 
      aggregation with arachidonic acid compared with aspirin. CONCLUSIONS: The 
      administration of intravenous LA resulted in a significant reduction of platelet 
      reactivity compared with oral aspirin on prasugrel-inhibited platelets. Loading 
      dose of LA achieves an earlier platelet inhibition and with less variability than 
      aspirin. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique 
      identifier: NCT02243137.
CI  - © 2015 American Heart Association, Inc.
FAU - Vivas, David
AU  - Vivas D
AD  - From the Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain. 
      dvivas@secardiologia.es.
FAU - Martín, Agustín
AU  - Martín A
AD  - From the Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.
FAU - Bernardo, Esther
AU  - Bernardo E
AD  - From the Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.
FAU - Ortega-Pozzi, María Aranzazu
AU  - Ortega-Pozzi MA
AD  - From the Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.
FAU - Tirado, Gabriela
AU  - Tirado G
AD  - From the Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.
FAU - Fernández, Cristina
AU  - Fernández C
AD  - From the Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.
FAU - Vilacosta, Isidre
AU  - Vilacosta I
AD  - From the Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.
FAU - Núñez-Gil, Iván
AU  - Núñez-Gil I
AD  - From the Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.
FAU - Macaya, Carlos
AU  - Macaya C
AD  - From the Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.
FAU - Fernández-Ortiz, Antonio
AU  - Fernández-Ortiz A
AD  - From the Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT02243137
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circ Cardiovasc Interv
JT  - Circulation. Cardiovascular interventions
JID - 101499602
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Intravenous
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/*analogs & derivatives
MH  - Blood Platelets/physiology
MH  - Cross-Over Studies
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Platelet Function Tests
MH  - Prasugrel Hydrochloride/*therapeutic use
MH  - Prospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - acute coronary syndrome
OT  - aspirin
OT  - lysine acetylsalicylate
OT  - platelet
EDAT- 2015/05/10 06:00
MHDA- 2016/02/26 06:00
CRDT- 2015/05/10 06:00
PHST- 2015/05/10 06:00 [entrez]
PHST- 2015/05/10 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
AID - CIRCINTERVENTIONS.114.002281 [pii]
AID - 10.1161/CIRCINTERVENTIONS.114.002281 [doi]
PST - ppublish
SO  - Circ Cardiovasc Interv. 2015 May;8(5):e002281. doi: 
      10.1161/CIRCINTERVENTIONS.114.002281.

PMID- 11816246
OWN - NLM
STAT- MEDLINE
DCOM- 20020712
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 36
IP  - 1
DP  - 2002 Jan
TI  - Risk of gastric injury with enteric- versus nonenteric-coated aspirin.
PG  - 163-6
AB  - OBJECTIVE: To evaluate through clinical trials the risk of various aspirin 
      preparations on the gastric mucosa. DATA SOURCES: Articles reporting clinical 
      research were accessed through MEDLINE (1980-November 1998). Key search terms 
      included enteric-coated aspirin, buffered aspirin, and gastrointestinal (GI) 
      bleeding. DATA SYNTHESIS: Aspirin products are known to cause GI bleeding. 
      Enteric-coated aspirin may provide an additional protective effect on gastric 
      mucosa compared with buffered aspirin. An evaluation of studies comparing various 
      aspirin preparations and the risk of gastric mucosal injury was conducted. 
      CONCLUSIONS: For long-term use, enteric-coated aspirin may provide a safer 
      alternative than buffered aspirin; however, further studies are necessary.
FAU - Banoob, Dalia W
AU  - Banoob DW
AD  - Pharmacy Department, Saint Joseph's Hospital, Tampa, FL, USA. 
      Dalia.Banoob@medmanagement.com
FAU - McCloskey, William W
AU  - McCloskey WW
FAU - Webster, William
AU  - Webster W
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Stomach Ulcer/*chemically induced/*epidemiology
MH  - Tablets, Enteric-Coated
RF  - 11
EDAT- 2002/01/31 10:00
MHDA- 2002/07/13 10:01
CRDT- 2002/01/31 10:00
PHST- 2002/01/31 10:00 [pubmed]
PHST- 2002/07/13 10:01 [medline]
PHST- 2002/01/31 10:00 [entrez]
AID - 10.1345/aph.18325 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2002 Jan;36(1):163-6. doi: 10.1345/aph.18325.

PMID- 1622907
OWN - NLM
STAT- MEDLINE
DCOM- 19920811
LR  - 20190719
IS  - 0306-5456 (Print)
IS  - 0306-5456 (Linking)
VI  - 99
IP  - 5
DP  - 1992 May
TI  - A randomized placebo-controlled study of the effect of low dose aspirin on 
      platelet reactivity and serum thromboxane B2 production in non-pregnant women, in 
      normal pregnancy, and in gestational hypertension.
PG  - 371-6
AB  - OBJECTIVE: To investigate the effect of 60 mg aspirin daily on platelet 
      reactivity and prostaglandin production in various groups of patients. Similar 
      regimens, which are thought to act through inhibition of platelet thromboxane 
      production, are currently undergoing clinical assessment for the prevention of 
      pre-eclampsia and intrauterine growth retardation. DESIGN: A prospective 
      randomized placebo controlled study. SETTING: University Hospital, Nottingham. 
      SUBJECTS: 12 non-pregnant female volunteers, 18 normal primigravidae before 16 
      weeks gestation and 16 pregnant women admitted with gestational hypertension (GH) 
      at a mean gestation of 38 weeks. INTERVENTIONS: In the non-pregnant women blood 
      samples were taken before and after a 10-day course of 60 mg aspirin daily. The 
      primigravidae had blood samples taken at 16 weeks and then they were randomized 
      to receive either 60 mg aspirin daily or a matched placebo. Further blood samples 
      were obtained at 28, 32 and 36 weeks. MAIN OUTCOME MEASURES: Changes in platelet 
      reactivity and release reaction, and serum thromboxane production, were estimated 
      in whole blood. RESULTS: 60 mg aspirin daily significantly inhibited 
      cyclo-oxygenase dependent platelet aggregation, release reaction and serum 
      thromboxane production in non-pregnant and pregnant women, and in women with GH 
      (P less than 0.01). When adrenaline was used as the aggregating agent, the 
      cyclo-oxygenase pathway was recruited in the increased reactivity seen in the 
      third trimester of normal pregnancy, and was sensitive to inhibition by low dose 
      aspirin. CONCLUSION: Low dose aspirin would appear to be an appropriate agent for 
      the inhibition of platelet reactivity associated with hypertensive pregnancy.
FAU - Louden, K A
AU  - Louden KA
AD  - Department of Obstetrics and Gynaecology, University Hospital, Nottingham, UK.
FAU - Broughton Pipkin, F
AU  - Broughton Pipkin F
FAU - Symonds, E M
AU  - Symonds EM
FAU - Tuohy, P
AU  - Tuohy P
FAU - O'Callaghan, C
AU  - O'Callaghan C
FAU - Heptinstall, S
AU  - Heptinstall S
FAU - Fox, S
AU  - Fox S
FAU - Mitchell, J R
AU  - Mitchell JR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Obstet Gynaecol
JT  - British journal of obstetrics and gynaecology
JID - 7503752
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Collagen/pharmacology
MH  - Female
MH  - Humans
MH  - Hypertension/*blood
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology
MH  - Pregnancy/*blood
MH  - Pregnancy Complications, Cardiovascular/*blood
MH  - Thromboxane B2/*metabolism
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
AID - 10.1111/j.1471-0528.1992.tb13751.x [doi]
PST - ppublish
SO  - Br J Obstet Gynaecol. 1992 May;99(5):371-6. doi: 
      10.1111/j.1471-0528.1992.tb13751.x.

PMID- 7533335
OWN - NLM
STAT- MEDLINE
DCOM- 19950331
LR  - 20171116
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 72
IP  - 4
DP  - 1994 Oct
TI  - Macroaggregation of platelets in plasma, as distinct from microaggregation in 
      whole blood (and plasma), as determined using optical aggregometry and platelet 
      counting respectively, is specifically impaired following cardiopulmonary bypass 
      in man.
PG  - 511-8
AB  - We determined changes in platelet aggregability following cardiopulmonary bypass, 
      using optical aggregometry to assess macroaggregation in platelet-rich plasma 
      (PRP), and platelet counting to assess microaggregation both in whole blood and 
      PRP. Hirudin was used as the anticoagulant to maintain normocalcaemia. 
      Microaggregation (%, median and interquartile range) in blood stirred with 
      collagen (0.6 micrograms/ml) was only marginally impaired following bypass (91 
      [88, 93] at 10 min postbypass v 95 (92, 96] prebypass; n = 22), whereas 
      macroaggregation (amplitude of response; cm) in PRP stirred with collagen (1.0 
      micrograms/ml) was markedly impaired (9.5 [8.0, 10.8], n = 41 v 13.4 [12.7, 
      14.3], n = 10; p < 0.0001). However, in PRP, despite impairment of 
      macroaggregation (9.1 [8.5, 10.1], n = 12), microaggregation was near-maximal (93 
      [91, 94]), as in whole blood stirred with collagen. In contrast, in 
      aspirin-treated patients (n = 14), both collagen-induced microaggregation in 
      whole blood (49 [47, 52]) and macroaggregation in PRP (5.1 [3.8, 6.6]) were more 
      markedly impaired, compared with control (both p < 0.001). Similarly, in PRP, 
      macroaggregation with ristocetin (1.5 mg/ml) was also impaired following bypass 
      (9.4 [7.2, 10.7], n = 38 v 12.4 [10.0, 13.4]; p < 0.0002, n = 20), but as found 
      with collagen, despite impairment of macroaggregation (7.2 [3.5, 10.9], n = 12), 
      microaggregation was again near-maximal (96 [93, 97]). The response to ristocetin 
      was more markedly impared after bypass in succinylated gelatin (Gelofusine) 
      treated patients (5.6 [2.8, 8.6], n = 17; p < 0.005 v control), whereas the 
      response to collagen was little different (9.3 v 9.5).(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Menys, V C
AU  - Menys VC
AD  - Department of Biological Sciences, Manchester Metropolitan University, UK.
FAU - Belcher, P R
AU  - Belcher PR
FAU - Noble, M I
AU  - Noble MI
FAU - Evans, R D
AU  - Evans RD
FAU - Drossos, G E
AU  - Drossos GE
FAU - Pillai, R
AU  - Pillai R
FAU - Westaby, S
AU  - Westaby S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Hirudins)
RN  - 0 (Recombinant Proteins)
RN  - 1404-55-3 (Ristocetin)
RN  - 9007-34-5 (Collagen)
RN  - 9087-70-1 (Aprotinin)
RN  - R16CO5Y76E (Aspirin)
RN  - U0JZ726775 (desirudin)
SB  - IM
MH  - Aprotinin/pharmacology
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood
MH  - Blood Loss, Surgical/physiopathology
MH  - Cardiopulmonary Bypass/*adverse effects
MH  - Collagen/pharmacology
MH  - Hirudins/analogs & derivatives/pharmacology
MH  - Humans
MH  - *Nephelometry and Turbidimetry
MH  - Plasma
MH  - Platelet Activation
MH  - *Platelet Aggregation/drug effects
MH  - *Platelet Count
MH  - *Platelet Function Tests
MH  - Recombinant Proteins/pharmacology
MH  - Ristocetin/pharmacology
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1994 Oct;72(4):511-8.

PMID- 21864660
OWN - NLM
STAT- MEDLINE
DCOM- 20120203
LR  - 20131121
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 419
IP  - 1-2
DP  - 2011 Oct 31
TI  - NMR imaging of chitosan and carboxymethyl starch tablets: swelling and hydration 
      of the polyelectrolyte complex.
PG  - 215-21
LID - 10.1016/j.ijpharm.2011.08.008 [doi]
AB  - The hydration and swelling properties of the tablets made of chitosan, 
      carboxymethyl starch, and a polyelectrolyte complex of these two polysaccharides 
      have been studied by NMR imaging. We studied the effect of pH and ionic strength 
      on the swelling of the tablets and on the diffusion of fluid into the tablets in 
      water and simulated physiological fluids. The pH value of the fluids exerts a 
      more significant effect than their ionic strengths on the swelling of the 
      tablets. The tablets are compared also with those made of cross-linked high 
      amylose starch. The formation of complex helps to keep the integrity of the 
      tablets in various media and render a slow and restricted swelling similar to 
      that of the tablets of the cross-linked high amylase starch, which is 
      significantly lower than the swelling of chitosan and of carboxymethyl starch. 
      The capacities to modulate the release rate of drugs in different media are 
      discussed by comparing the matrices and evaluating the preparation process of the 
      complex. A sustained release of less soluble drugs such as aspirin in 
      gastrointestinal fluids can be provided by the complex, due to the ionic 
      interaction and hydrogen bonding between the drug and the biopolymer complex.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Wang, Y J
AU  - Wang YJ
AD  - Département de Chimie, Université de Montréal, CP 6128, Succ. Centre-ville, 
      Montreal, QC, H3C 3J7, Canada.
FAU - Assaad, E
AU  - Assaad E
FAU - Ispas-Szabo, P
AU  - Ispas-Szabo P
FAU - Mateescu, M A
AU  - Mateescu MA
FAU - Zhu, X X
AU  - Zhu XX
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110812
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Carriers)
RN  - 0 (Tablets)
RN  - 059QF0KO0R (Water)
RN  - 9005-25-8 (Starch)
RN  - 9005-82-7 (Amylose)
RN  - 9012-76-4 (Chitosan)
RN  - 9057-06-1 (carboxymethyl starch)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amylose/chemistry
MH  - Aspirin/*administration & dosage/chemistry
MH  - Chitosan/*chemistry
MH  - Cross-Linking Reagents/chemistry
MH  - Delayed-Action Preparations
MH  - Drug Carriers/*chemistry
MH  - Gastric Juice/metabolism
MH  - Hydrogen Bonding
MH  - Hydrogen-Ion Concentration
MH  - Intestinal Secretions/metabolism
MH  - Magnetic Resonance Spectroscopy/methods
MH  - Osmolar Concentration
MH  - Solubility
MH  - Starch/*analogs & derivatives/chemistry
MH  - Tablets
MH  - Water/chemistry
EDAT- 2011/08/26 06:00
MHDA- 2012/02/04 06:00
CRDT- 2011/08/26 06:00
PHST- 2011/04/08 00:00 [received]
PHST- 2011/07/22 00:00 [revised]
PHST- 2011/08/07 00:00 [accepted]
PHST- 2011/08/26 06:00 [entrez]
PHST- 2011/08/26 06:00 [pubmed]
PHST- 2012/02/04 06:00 [medline]
AID - S0378-5173(11)00770-8 [pii]
AID - 10.1016/j.ijpharm.2011.08.008 [doi]
PST - ppublish
SO  - Int J Pharm. 2011 Oct 31;419(1-2):215-21. doi: 10.1016/j.ijpharm.2011.08.008. 
      Epub 2011 Aug 12.

PMID- 9769283
OWN - NLM
STAT- MEDLINE
DCOM- 19981113
LR  - 20181201
IS  - 1073-449X (Print)
IS  - 1073-449X (Linking)
VI  - 158
IP  - 4
DP  - 1998 Oct
TI  - Filtration of diaspirin crosslinked hemoglobin into lung and soft tissue lymph.
PG  - 1204-12
AB  - Diaspirin crosslinked hemoglobin (DCHb) is a new blood substitute manufactured 
      from human blood. To evaluate its microvascular filtration properties, we infused 
      DCLHb into unanesthetized sheep (10%, 20 ml/kg) and measured the flow and 
      composition of lung and soft tissue lymph. For comparison, we also infused human 
      serum albumin (HSA; 10%, 20 ml/kg). DCLHb raised systemic and pulmonary arterial 
      pressures from baseline values of 83 +/- 7 and 13 +/- 2 mm Hg, respectively, to 
      peak values of 113 +/- 9 and 26 +/- 3 mm Hg (p < 0.05 versus baseline). These 
      increases were significantly greater than those associated with HSA, which raised 
      systemic and pulmonary arterial pressures from baseline values of 86 +/- 4 and 13 
      +/- 2 mm Hg, respectively, to peak values of 97 +/- 3 and 21 +/- 7 mm Hg (p <= 
      0.05 versus baseline and versus DCLHb). These differences reflect the known 
      pressor properties of DCLHb. Accordingly, DCLHb raised lung and soft tissue lymph 
      flows to peak values of 12.2 +/- 3.8 and 1.6 +/- 0.7 ml/30 min, respectively, 
      while HSA raised lung and soft tissue lymph flows to peak values of 7.5 +/- 4.8 
      and 4.6 +/- 1.9 ml/30 min, respectively (p <= 0.05 versus DCLHb). The half-times 
      of DCLHb equilibration from plasma into lung and soft tissue lymph of 1. 0 +/- 
      0.3 and 2.1 +/- 1.1 h, respectively, were significantly faster than HSA 
      equilibration half-times of 3.1 +/- 0.2 and 3.8 +/- 0.9 h. Filtration differences 
      between DCLHb and HSA appear to be due to the pressor properties DCLHb.
FAU - Conhaim, R L
AU  - Conhaim RL
AD  - Department of Surgery, University of Wisconsin-Madison, and William S. Middleton 
      Memorial Veterans Hospital, Madison, Wisconsin, USA.
FAU - Cooler, S D
AU  - Cooler SD
FAU - McGrath, A M
AU  - McGrath AM
FAU - DeAngeles, D A
AU  - DeAngeles DA
FAU - Myers, G A
AU  - Myers GA
FAU - Harms, B A
AU  - Harms BA
LA  - eng
GR  - HL46236/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Serum Albumin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/chemistry/pharmacokinetics
MH  - Blood Pressure/drug effects
MH  - Blood Substitutes/administration & dosage/chemistry/*pharmacokinetics
MH  - Evaluation Studies as Topic
MH  - Half-Life
MH  - Hematocrit
MH  - Hemoglobins/administration & dosage/chemistry/*pharmacokinetics
MH  - Humans
MH  - Hydrostatic Pressure
MH  - Lung/*metabolism
MH  - Lymph/*metabolism
MH  - Microcirculation/metabolism
MH  - Osmotic Pressure
MH  - Pulmonary Artery
MH  - Pulmonary Wedge Pressure/drug effects
MH  - Serum Albumin/administration & dosage/chemistry/pharmacokinetics
MH  - Sheep
MH  - Tissue Distribution
EDAT- 1998/10/14 00:00
MHDA- 1998/10/14 00:01
CRDT- 1998/10/14 00:00
PHST- 1998/10/14 00:00 [pubmed]
PHST- 1998/10/14 00:01 [medline]
PHST- 1998/10/14 00:00 [entrez]
AID - 10.1164/ajrccm.158.4.9705042 [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 1998 Oct;158(4):1204-12. doi: 
      10.1164/ajrccm.158.4.9705042.

PMID- 4012150
OWN - NLM
STAT- MEDLINE
DCOM- 19850806
LR  - 20131121
IS  - 0035-3787 (Print)
IS  - 0035-3787 (Linking)
VI  - 141
IP  - 4
DP  - 1985
TI  - [Late hemorrhagic transformation of cerebellar infarction under anticoagulant 
      treatment].
PG  - 324-6
AB  - Anticoagulant treatment after cerebral infarcts is still debated due to the 
      imperfectly evaluated risk of hemorrhagic transformation. In the case reported 
      here the hemorrhage developed during anticoagulant treatment instituted 18 days 
      after the onset of the infarct. The role of previously administered aspirin is 
      discussed.
FAU - Masson, C
AU  - Masson C
FAU - Charlier, P
AU  - Charlier P
FAU - Masson, M
AU  - Masson M
FAU - Cambier, J
AU  - Cambier J
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Transformation hémorragique tardive d'un infarctus cérébelleux sous traitement 
      anticoagulant.
PL  - France
TA  - Rev Neurol (Paris)
JT  - Revue neurologique
JID - 2984779R
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cerebellum/*blood supply
MH  - Cerebral Hemorrhage/*etiology
MH  - Cerebral Infarction/*complications/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Time Factors
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Neurol (Paris). 1985;141(4):324-6.

PMID- 19124406
OWN - NLM
STAT- MEDLINE
DCOM- 20090202
LR  - 20131121
IS  - 1753-9447 (Print)
IS  - 1753-9447 (Linking)
VI  - 2
IP  - 1
DP  - 2008 Feb
TI  - Aspirin and Diabetes Mellitus: revisiting an old player.
PG  - 37-42
LID - 10.1177/1753944707088185 [doi]
AB  - Type 2 Diabetes Mellitus confers an excess risk of cardiovascular disease. The 
      mechanisms involved in the development of the disease are an active field of 
      research, and prompt the development of newer and safer therapeutics with 
      implications for cardiovascular disease. Currently there is increasing awareness 
      of the role of platelet dysfunction, low-grade chronic inflammation and 
      thrombogenesis in the pathophysiology of insulin resistance, T2DM, as well as 
      type 1 diabetes mellitus and cardiovascular disease. This new evolving knowledge 
      has allowed a better understanding of the role of aspirin, an old medication with 
      proven beneficial effects on patients with established cardiovascular disease. 
      The influence of salicylates on insulin resistance, glucose homeostasis, platelet 
      function and inflammatory pathways, in particular related to the activation of 
      the NFkappaB pathway, is a promising field of active research, and will help in 
      the management of both diabetes mellitus and atherosclerotic-related 
      cardiovascular disease.
FAU - Manrique, Camila
AU  - Manrique C
AD  - University of Missouri Columbia, Department of Internal Medicine, Endocrinology 
      and Diabetes Department, Harry S Truman VA Hospital, Columbia, MO, 1, Hospital 
      Drive, Columbia, MO 65211, USA.
FAU - Lastra, Guido
AU  - Lastra G
FAU - Palmer, John
AU  - Palmer J
FAU - Gardner, Michael
AU  - Gardner M
FAU - Sowers, James R
AU  - Sowers JR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Ther Adv Cardiovasc Dis
JT  - Therapeutic advances in cardiovascular disease
JID - 101316343
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Diabetic Angiopathies/*drug therapy
MH  - Humans
RF  - 45
EDAT- 2009/01/07 09:00
MHDA- 2009/02/03 09:00
CRDT- 2009/01/07 09:00
PHST- 2009/01/07 09:00 [entrez]
PHST- 2009/01/07 09:00 [pubmed]
PHST- 2009/02/03 09:00 [medline]
AID - 2/1/37 [pii]
AID - 10.1177/1753944707088185 [doi]
PST - ppublish
SO  - Ther Adv Cardiovasc Dis. 2008 Feb;2(1):37-42. doi: 10.1177/1753944707088185.

PMID- 3318434
OWN - NLM
STAT- MEDLINE
DCOM- 19871223
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 83
IP  - 4B
DP  - 1987 Oct 30
TI  - Comparison of the safety and efficacy of nabumetone and aspirin in the treatment 
      of osteoarthritis in adults.
PG  - 78-81
AB  - A six-month, multicenter, double-blind study compared the efficacy and safety of 
      two therapeutic regimens in 332 patients with osteoarthritis. The patients 
      received either 1,000 mg of nabumetone as a single bedtime dose or 900 mg of 
      aspirin in four divided doses. At the end of the study, patients in both 
      treatment groups showed significant improvement from baseline for all five 
      parameters; no statistically or clinically significant differences were observed 
      between the groups. The safety data did reveal clinically and statistically 
      significant differences between the groups. Aspirin-treated patients experienced 
      a greater frequency of withdrawal from the study because of adverse experiences 
      (34 percent versus 13 percent), a greater incidence of having at least one 
      treatment-related adverse experience (73 percent versus 52 percent), a greater 
      percentage of patients with at least one moderate or severe treatment-related 
      adverse experience (47 percent versus 22 percent), and a greater percentage of 
      patients with treatment-related adverse experiences affecting the 
      gastrointestinal system (43 percent versus 32 percent) or the inner ear (32 
      percent versus 10 percent). The results of this study demonstrated that 
      nabumetone, 1,000 mg at bedtime, is as efficacious as aspirin, 900 mg four times 
      daily, produces fewer adverse effects, and is indicated in the treatment of 
      osteoarthritis.
FAU - Appelrouth, D J
AU  - Appelrouth DJ
FAU - Baim, S
AU  - Baim S
FAU - Chang, R W
AU  - Chang RW
FAU - Cohen, M H
AU  - Cohen MH
FAU - Englund, D W
AU  - Englund DW
FAU - Germain, B F
AU  - Germain BF
FAU - Hartman, S S
AU  - Hartman SS
FAU - Jaffer, A
AU  - Jaffer A
FAU - Mullen, B J
AU  - Mullen BJ
FAU - Smith, F E
AU  - Smith FE
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Butanones)
RN  - LW0TIW155Z (Nabumetone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Butanones/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nabumetone
MH  - Osteoarthritis/*drug therapy
MH  - Patient Dropouts
MH  - Random Allocation
EDAT- 1987/10/30 00:00
MHDA- 1987/10/30 00:01
CRDT- 1987/10/30 00:00
PHST- 1987/10/30 00:00 [pubmed]
PHST- 1987/10/30 00:01 [medline]
PHST- 1987/10/30 00:00 [entrez]
AID - 0002-9343(87)90600-0 [pii]
AID - 10.1016/0002-9343(87)90600-0 [doi]
PST - ppublish
SO  - Am J Med. 1987 Oct 30;83(4B):78-81. doi: 10.1016/0002-9343(87)90600-0.

PMID- 33132228
OWN - NLM
STAT- MEDLINE
DCOM- 20211207
LR  - 20211214
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 84
IP  - 12
DP  - 2020 Nov 25
TI  - Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of 
      Undetermined Source　- Japanese Subanalysis of the RE-SPECT ESUS Randomized 
      Controlled Trial.
PG  - 2286-2295
LID - 10.1253/circj.CJ-20-0563 [doi]
AB  - BACKGROUND: The international Randomized, Double-Blind, Evaluation in Secondary 
      Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin 
      Inhibitor Dabigatran Etexilate versus Acetylsalicylic Acid in Patients with 
      Embolic Stroke of Undetermined Source (RE-SPECT ESUS) trial did not demonstrate 
      superiority of dabigatran over aspirin for reduction of recurrent strokes in 
      patients with embolic strokes of undetermined source (ESUS). Based on pre-defined 
      subanalyses, the safety and efficacy of dabigatran vs. aspirin in Japanese 
      patients was assessed.Methods and Results:ESUS patients were randomized to 
      receive either dabigatran (150 or 110 mg twice daily) or aspirin (100 mg once 
      daily). Of 5,390 patients randomized, 594 were Japanese. Most Japanese patients 
      (99.8%) underwent brain magnetic resonance imaging for trial screening, compared 
      to 76.8% of non-Japanese (P<0.0001). In the Japanese cohort, over a 19.4-month 
      median follow-up period, recurrent stroke as the primary outcome occurred in 
      20/294 patients (4.3%/year) in the dabigatran group and 38/300 (8.3%/year) in the 
      aspirin group (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.32-0.94). 
      Major bleeding occurred in 12 patients (2.5%/year) and 17 patients (3.5%/year), 
      respectively (HR, 0.72; 95% CI, 0.34-1.52). In contrast, in the non-Japanese 
      cohort, recurrent stroke occurred in 4.1%/year and 4.3%/year, respectively, 
      showing no apparent difference in recurrent stroke for dabigatran vs. aspirin 
      (HR, 0.91; 95% CI, 0.74-1.14). The P-interaction for treatment and region did not 
      reach statistical significance (P=0.09). CONCLUSIONS: Dabigatran was putatively 
      associated with a lower relative risk of recurrent stroke compared with aspirin 
      in Japanese ESUS patients.
FAU - Toyoda, Kazunori
AU  - Toyoda K
AD  - National Cerebral and Cardiovascular Center.
FAU - Uchiyama, Shinichiro
AU  - Uchiyama S
AD  - International University of Health and Welfare, Sanno Hospital and Sanno Medical 
      Center.
FAU - Hagihara, Yasushi
AU  - Hagihara Y
AD  - Rinku General Medical Center.
FAU - Kuwashiro, Takahiro
AU  - Kuwashiro T
AD  - National Hospital Organization, Kyushu Medical Center.
FAU - Mori, Takahisa
AU  - Mori T
AD  - Shonan Kamakura General Hospital.
FAU - Kamiyama, Kenji
AU  - Kamiyama K
AD  - Nakamura Memorial Hospital.
FAU - Urano, Yasuhisa
AU  - Urano Y
AD  - Nippon Boehringer Ingelheim Co, Ltd.
FAU - Taniguchi, Atsushi
AU  - Taniguchi A
AD  - Nippon Boehringer Ingelheim Co, Ltd.
FAU - Nozaki, Kenma
AU  - Nozaki K
AD  - Nippon Boehringer Ingelheim Co, Ltd.
FAU - Cronin, Lisa
AU  - Cronin L
AD  - Boehringer Ingelheim Ltd.
FAU - Grauer, Claudia
AU  - Grauer C
AD  - Boehringer Ingelheim Pharma GmbH & Co KG.
FAU - Brueckmann, Martina
AU  - Brueckmann M
AD  - Boehringer Ingelheim International GmbH.
AD  - Mannheim of the University of Heidelberg.
FAU - Diener, Hans-Christoph
AU  - Diener HC
AD  - University Duisburg-Essen and University Hospital Essen.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20201030
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - I0VM4M70GC (Dabigatran)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - *Dabigatran/therapeutic use
MH  - *Embolic Stroke/prevention & control
MH  - Humans
MH  - Japan
MH  - Secondary Prevention
MH  - Tomography, Emission-Computed, Single-Photon
OTO - NOTNLM
OT  - Anticoagulation
OT  - Aspirin
OT  - Dabigatran
OT  - Ischemic stroke
OT  - Stroke recurrence
EDAT- 2020/11/03 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/11/02 06:11
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/11/02 06:11 [entrez]
AID - 10.1253/circj.CJ-20-0563 [doi]
PST - ppublish
SO  - Circ J. 2020 Nov 25;84(12):2286-2295. doi: 10.1253/circj.CJ-20-0563. Epub 2020 
      Oct 30.

PMID- 11929349
OWN - NLM
STAT- MEDLINE
DCOM- 20020624
LR  - 20181113
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 20
IP  - 3
DP  - 2002
TI  - Economic evaluation of triflusal and aspirin in the treatment of acute myocardial 
      infarction.
PG  - 195-201
AB  - OBJECTIVE: To compare the costs to the Spanish healthcare system of 35 days' 
      treatment with triflusal (600 mg/day) and aspirin (300 mg/day) in patients with 
      confirmed acute myocardial infarction within 24 hours of onset of symptoms. 
      DESIGN: A cost minimisation analysis based on the results of the Triflusal in 
      Acute Myocardial Infarction study (TIM) was conducted. The hypothesis was that 
      despite a higher acquisition cost of triflusal, savings would result because of 
      differences in efficacy and safety outcome (non-fatal cerebrovascular event and 
      haemorrhagic events). Diagnostic Related Groups were used as a proxy for 
      determining hospital costs in Spain and the values were obtained from different 
      sources and refer to year 2000 costs. Only direct medical costs were considered 
      for the economic analysis. RESULTS: Although the acquisition cost of triflusal 
      was more expensive than that of aspirin, the cost of prevented events - non-fatal 
      ischaemic cerebrovascular events and cerebral haemorrhages - entirely compensated 
      for the cost of triflusal. The overall cost of treating patients with triflusal, 
      compared with aspirin, represented a net saving of 28.4% per patient treated. 
      CONCLUSION: Our study showed that triflusal is cost saving compared with aspirin 
      in the treatment of the acute phase of myocardial infarction.
FAU - Darbà, Josep
AU  - Darbà J
AD  - Department of Economy, University of Barcelona, Spain.
FAU - Izquierdo, Iñaki
AU  - Izquierdo I
FAU - Pontes, Caridad
AU  - Pontes C
FAU - Navas, Carlos
AU  - Navas C
FAU - Rovira, Joan
AU  - Rovira J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 1Z0YFI05OO (triflusal)
RN  - R16CO5Y76E (Aspirin)
MH  - Acute Disease
MH  - Aspirin/*economics/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Costs
MH  - Humans
MH  - Myocardial Infarction/*drug therapy/*economics
MH  - Platelet Aggregation Inhibitors/*economics/*therapeutic use
MH  - Recurrence
MH  - Salicylates/*economics/*therapeutic use
MH  - Spain
EDAT- 2002/04/04 10:00
MHDA- 2002/06/25 10:01
CRDT- 2002/04/04 10:00
PHST- 2002/04/04 10:00 [pubmed]
PHST- 2002/06/25 10:01 [medline]
PHST- 2002/04/04 10:00 [entrez]
AID - 200305 [pii]
AID - 10.2165/00019053-200220030-00005 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2002;20(3):195-201. doi: 10.2165/00019053-200220030-00005.

PMID- 27174764
OWN - NLM
STAT- MEDLINE
DCOM- 20181019
LR  - 20181019
IS  - 0002-5151 (Print)
IS  - 0002-5151 (Linking)
VI  - 63
IP  - 2
DP  - 2016 Apr-Jun
TI  - [Long-term efficacy of aspirin desensitization in aspirin-exacerbated respiratory 
      disease. Review of two clinical cases].
PG  - 207-12
AB  - BACKGROUND: The aspirin exacerbated respiratory disease (AERD) shows a prevalence 
      of 7% among asthmatics and increases to 14% in patients with difficult to control 
      asthma. Treatment includes the use of inhibitors of leukotriene receptor (), 
      intranasal steroids, polypectomy, asthma management according to the severity and 
      avoid taking nonsteroidal anti-inflammatory drugs (NSAIDs). In some patients it 
      is necessary desensitization protocol to it. CLINICAL CASES: Two patients 
      diagnosed with respiratory disease exacerbated by aspirin, with poor asthma 
      control and need for multiple polypectomies, despite optimal pharmacological 
      management, carrying out protocol desensitization to aspirin (AAS) successful, 
      now after 4 years of having carried out, they have adequate asthma control 
      without need for polypectomies with a maintenance dose of aspirin 150 mg/day.
FAU - Cambray-Gutiérrez, Julio César
AU  - Cambray-Gutiérrez JC
AD  - Servicio de Alergia e Inmunología Clínica, Hospital de Especialidades, Centro 
      Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de 
      México, Instituto Mexicano del Seguro Social, México. jcesar_963@hotmail.com.
FAU - García-Ramírez, Ulises Noel
AU  - García-Ramírez UN
FAU - Del Rivero-Hernández, Leonel Gerardo
AU  - Del Rivero-Hernández LG
FAU - Lozano-Martínez, Sean Alejandro
AU  - Lozano-Martínez SA
FAU - López-Pérez, Patricia
AU  - López-Pérez P
FAU - Chávez-García, Aurora
AU  - Chávez-García A
LA  - spa
PT  - Case Reports
PT  - Journal Article
TT  - Eficacia a largo plazo de la desensibilización a aspirina en enfermedad 
      respiratoria exacerbada por aspirina. Revisión de 2 casos clínicos.
PL  - Mexico
TA  - Rev Alerg Mex
JT  - Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
JID - 9438824
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - Asthma, Nasal Polyps, And Aspirin Intolerance
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/immunology
MH  - Aspirin/*administration & dosage/adverse effects/immunology
MH  - Asthma, Aspirin-Induced/immunology/*therapy
MH  - Desensitization, Immunologic/*methods
MH  - Humans
MH  - Maintenance Chemotherapy
MH  - Nasal Polyps/immunology/*surgery/therapy
OTO - NOTNLM
OT  - aspirin exacerbated respiratory disease
OT  - desensitization
EDAT- 2016/05/14 06:00
MHDA- 2018/10/20 06:00
CRDT- 2016/05/14 06:00
PHST- 2016/05/14 06:00 [entrez]
PHST- 2016/05/14 06:00 [pubmed]
PHST- 2018/10/20 06:00 [medline]
AID - 10.29262/ram.v63i2.151 [doi]
PST - ppublish
SO  - Rev Alerg Mex. 2016 Apr-Jun;63(2):207-12. doi: 10.29262/ram.v63i2.151.

PMID- 6687451
OWN - NLM
STAT- MEDLINE
DCOM- 19830415
LR  - 20190821
IS  - 0143-5221 (Print)
IS  - 0143-5221 (Linking)
VI  - 64
IP  - 4
DP  - 1983 Apr
TI  - Effect of aspirin on urinary excretion of 6-ketoprostaglandin F1 alpha.
PG  - 395-8
AB  - 1. We studied the effect of oral administration of acetylsalicylic acid (1200 
      mg/day for 3 days) on the urinary excretion of 6-ketoprostaglandin F1 alpha in 
      normal human subjects as an index of prostacyclin production in vivo. 2. The 
      concentrations and excretion rate in urine fell to 45% of pretreatment levels in 
      3 days, but returned to pretreatment values after 7 days. 3. These results 
      suggest that production of prostacyclin in vivo is only partially inhibited by 
      high doses of aspirin and that there are sites of production of prostacyclin 
      which are protected from inhibition by aspirin and which contribute to urinary 
      6-ketoprostaglandin F1 alpha. The measurement of 6-ketoprostaglandin F1 alpha in 
      urine may therefore be of only limited value as an index of the metabolism of 
      vascular tissue in vivo.
FAU - Jones, P B
AU  - Jones PB
FAU - Russell, R G
AU  - Russell RG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/*urine
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - Time Factors
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 10.1042/cs0640395 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 1983 Apr;64(4):395-8. doi: 10.1042/cs0640395.

PMID- 6972158
OWN - NLM
STAT- MEDLINE
DCOM- 19810720
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 47
IP  - 6
DP  - 1981 Jun
TI  - Reduction of thrombosis in canine coronary bypass vein grafts with dipyridamole 
      and aspirin.
PG  - 1248-54
AB  - The potential benefit of platelet inhibitor drugs in reducing early thrombosis of 
      coronary arterial vein bypass grafts was assessed in dogs. There were 26 control 
      dogs and 24 dogs treated with dipyridamole, 55 mg/day plus aspirin, 325 mg/day. 
      The dogs in both groups were killed at 2 hours and 1, 2, 3, 7 and 14 days after 
      operation. The grafts were perfused with fixative in vivo, harvested and examined 
      with light microscopy. Severe alterations of the graft wall were observed in the 
      dogs in both groups. The grafts in the control group had a high incidence rate of 
      thrombosis, which occurred early after the operation; those in the treated group 
      had a significantly reduced incidence of thrombosis (p = 0.025). Our study 
      indicates that a combined regimen of dipyridamole and aspirin is effective in 
      reducing early graft thrombosis in dogs.
FAU - Josa, M
AU  - Josa M
FAU - Lie, J T
AU  - Lie JT
FAU - Bianco, R L
AU  - Bianco RL
FAU - Kaye, M P
AU  - Kaye MP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/*therapeutic use
MH  - Dogs
MH  - Femoral Vein/transplantation
MH  - Thrombosis/*drug therapy/pathology
EDAT- 1981/06/01 00:00
MHDA- 1981/06/01 00:01
CRDT- 1981/06/01 00:00
PHST- 1981/06/01 00:00 [pubmed]
PHST- 1981/06/01 00:01 [medline]
PHST- 1981/06/01 00:00 [entrez]
AID - 0002-9149(81)90254-X [pii]
AID - 10.1016/0002-9149(81)90254-x [doi]
PST - ppublish
SO  - Am J Cardiol. 1981 Jun;47(6):1248-54. doi: 10.1016/0002-9149(81)90254-x.

PMID- 6484857
OWN - NLM
STAT- MEDLINE
DCOM- 19841109
LR  - 20131121
IS  - 0040-3709 (Print)
IS  - 0040-3709 (Linking)
VI  - 30
IP  - 1
DP  - 1984 Aug
TI  - Novel accessory skull bone in fetal rats after exposure to aspirin.
PG  - 95-8
AB  - Aspirin was administered by oral gavage to 25 gravid Sprague-Dawley rats on 
      gestation day 10, as a single dose of 500 mg/kg, in a concentration of 50 mg/ml. 
      The aspirin was suspended in a mixture of 0.5% w/v hydroxypropylmethylcellulose 
      (Methocel E-4M) and 0.1% w/v polysorbate 80 (Tween 80). A control group of 25 
      gravid rats was given 10 ml/kg/day of the suspending vehicle alone, by oral 
      gavage, on gestation days 6 through 15. C-sections were performed on gestation 
      day 20. Approximately two-thirds of the fetuses were processed for skeletal 
      examination with Alizarin Red S; the remaining fetuses were placed in Bouin's 
      solution. Examination of the fetal skeletal specimens from the aspirin-treated 
      group revealed a 20% fetal (43% litter) incidence of an accessory skull bone, 
      located between the nasal and frontal bones. This structure ranged in size from a 
      small, barely discernible, circular ossification site (less than 0.5 mm) to a 
      relatively large, bilobate bone (approximately 2 mm). This anomaly has not been 
      previously reported in fetal rats.
FAU - Mitala, J J
AU  - Mitala JJ
FAU - Boardman, J P
AU  - Boardman JP
FAU - Carrano, R A
AU  - Carrano RA
FAU - Iuliucci, J D
AU  - Iuliucci JD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Teratology
JT  - Teratology
JID - 0153257
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abnormalities, Drug-Induced
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Female
MH  - Gestational Age
MH  - Pregnancy
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Skull/*abnormalities
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 10.1002/tera.1420300113 [doi]
PST - ppublish
SO  - Teratology. 1984 Aug;30(1):95-8. doi: 10.1002/tera.1420300113.

PMID- 7923959
OWN - NLM
STAT- MEDLINE
DCOM- 19941108
LR  - 20131121
IS  - 0733-8635 (Print)
IS  - 0733-8635 (Linking)
VI  - 12
IP  - 3
DP  - 1994 Jul
TI  - Hints for hemostasis.
PG  - 601-6
AB  - As dermatologists perform more complex and extensive surgical procedures, 
      persistent bleeding and hematoma formation may be encountered more frequently. 
      Several hints for hemostasis are presented that will help dermatologists prevent 
      uncontrolled hemorrhage and manage bleeding complications. Employing these 
      techniques will ease patient and surgeon anxiety and help avoid unwanted surgical 
      complications.
FAU - Parker, R K
AU  - Parker RK
AD  - Department of Dermatology, University of Arkansas for Medical Sciences, Little 
      Rock.
FAU - Dinehart, S M
AU  - Dinehart SM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Dermatol Clin
JT  - Dermatologic clinics
JID - 8300886
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Blood Pressure
MH  - Electrocoagulation
MH  - Gelatin Sponge, Absorbable/therapeutic use
MH  - Hematoma/therapy
MH  - Hemostasis
MH  - Hemostasis, Surgical
MH  - *Hemostatic Techniques
MH  - Humans
RF  - 7
EDAT- 1994/07/01 00:00
MHDA- 1994/07/01 00:01
CRDT- 1994/07/01 00:00
PHST- 1994/07/01 00:00 [pubmed]
PHST- 1994/07/01 00:01 [medline]
PHST- 1994/07/01 00:00 [entrez]
PST - ppublish
SO  - Dermatol Clin. 1994 Jul;12(3):601-6.

PMID- 3698094
OWN - NLM
STAT- MEDLINE
DCOM- 19860616
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 6
IP  - 1
DP  - 1986 Mar
TI  - Chronic paroxysmal hemicrania: the first possible bilateral case.
PG  - 55-7
AB  - There are three headaches syndromes that are typically characterized by strictly 
      unilateral and always same-sided attacks: cluster headache, "cervicogenic" 
      headache, and chronic paroxysmal hemicrania (CPH). In rare cases, cluster 
      headache also occurs bilaterally; "cervicogenic" headaches probably as well. We 
      present a patient with a probable bilateral CPH. To our knowledge no such case 
      has previously been described.
FAU - Pöllmann, W
AU  - Pöllmann W
FAU - Pfaffenrath, V
AU  - Pfaffenrath V
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - Indomethacin/therapeutic use
MH  - Migraine Disorders/drug therapy/*physiopathology
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
AID - 10.1046/j.1468-2982.1986.0601055.x [doi]
PST - ppublish
SO  - Cephalalgia. 1986 Mar;6(1):55-7. doi: 10.1046/j.1468-2982.1986.0601055.x.

PMID- 8851260
OWN - NLM
STAT- MEDLINE
DCOM- 19961217
LR  - 20131121
IS  - 0301-1526 (Print)
IS  - 0301-1526 (Linking)
VI  - 25
IP  - 1
DP  - 1996
TI  - Oral anticoagulation alone or in combination with aspirin: risks and benefits.
PG  - 1-12
AB  - The combination of oral anticoagulants with antiplatelet agents has been 
      advocated as particularly efficient in prophylaxis of arterial thromboembolism. 
      The indications at issue are nonrheumatic chronic atrial fibrillation, mechanical 
      and biological heart valve prostheses, coronary artery disease, coronary stents 
      and peripheral arterial occlusive disease. However, such a combined prophylaxis 
      might also be associated with a higher bleeding risk. Clinical trials addressing 
      administration of coumarines with antiaggregants are rare and inhomogeneous. The 
      present article reviews the literature on oral anticoagulants combined with 
      aspirin in the prevention and treatment of arterial thromboembolism and draws a 
      comparison to oral anticoagulation alone and aspirin alone, respectively. It 
      clearly shows that this potentially dangerous combination should not be 
      recommended in most indications until specifically designed trials have addressed 
      its benefit-to-risk ratio.
FAU - Hafner, J
AU  - Hafner J
AD  - Department of Internal Medicine, University Hospital of Geneva.
FAU - de Moerloose, P
AU  - de Moerloose P
FAU - Bounameaux, H
AU  - Bounameaux H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Vasa
JT  - VASA. Zeitschrift fur Gefasskrankheiten
JID - 0317051
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Coagulation Tests
MH  - Cardiovascular Diseases/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Hemorrhage/blood/*chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk Factors
RF  - 75
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
PST - ppublish
SO  - Vasa. 1996;25(1):1-12.

PMID- 17955496
OWN - NLM
STAT- MEDLINE
DCOM- 20080410
LR  - 20131121
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 17
IP  - 2
DP  - 2008 Feb
TI  - Aspirin use and breast cancer risk: a meta-analysis and meta-regression of 
      observational studies from 2001 to 2005.
PG  - 115-24
AB  - PURPOSE: To examine the recent epidemiological studies on aspirin use and breast 
      cancer risk published from 2001 to 2005 within a meta-analysis, to investigate 
      reasons for heterogeneity between the individual studies and to analyse a 
      dose-response-relationship considering frequency and duration of use. METHODS: We 
      systematically searched for cohort-studies and case-control-studies from 
      2001-2005, which evaluated the association between aspirin and breast cancer 
      risk. We calculated a pooled estimate for the relative risk (RR) and investigated 
      reasons for heterogeneity between the individual studies and analysed a 
      dose-response-relationship using random effects mixed models. RESULTS: We 
      identified 10 studies which met the inclusion criteria. The combined estimate of 
      the RR was 0.75 (95%CI: 0.64, 0.88) using the random effects model. Heterogeneity 
      between the studies could not be explained by the covariates study-type and 
      study-population. The combination of frequency and duration of aspirin use 
      resulted in a significant dose-response-relationship between aspirin use and 
      breast cancer risk. Each additional pillyear reduced the breast cancer risk to 
      about 2%. CONCLUSION: Our meta-analysis supports the current evidence that 
      aspirin may reduce breast cancer risk. Moreover, a dose-response-relationship 
      seems to exist. However, results have to be interpreted carefully, as exposure 
      categories were defined very heterogeneously among the studies which weakens the 
      validity of the pooled estimates.
CI  - Copyright 2007 John Wiley & Sons, Ltd.
FAU - Mangiapane, Sandra
AU  - Mangiapane S
AD  - Technical University of Berlin, Department of Technology and Management, Berlin, 
      Germany. Sandra.mangiapane@tu-berlin.de
FAU - Blettner, Maria
AU  - Blettner M
FAU - Schlattmann, Peter
AU  - Schlattmann P
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Breast Neoplasms/epidemiology/*prevention & control
MH  - Controlled Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - *Models, Statistical
MH  - Regression Analysis
MH  - Reproducibility of Results
MH  - Risk
EDAT- 2007/10/24 09:00
MHDA- 2008/04/11 09:00
CRDT- 2007/10/24 09:00
PHST- 2007/10/24 09:00 [pubmed]
PHST- 2008/04/11 09:00 [medline]
PHST- 2007/10/24 09:00 [entrez]
AID - 10.1002/pds.1503 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):115-24. doi: 10.1002/pds.1503.

PMID- 8405169
OWN - NLM
STAT- MEDLINE
DCOM- 19931027
LR  - 20141120
IS  - 0014-4835 (Print)
IS  - 0014-4835 (Linking)
VI  - 57
IP  - 1
DP  - 1993 Jul
TI  - The reaction of bovine lens alpha A-crystallin with aspirin.
PG  - 29-35
AB  - Acetylation of the lysines of bovine lens alpha A-crystallin has been examined 
      after 0-48-hr incubations of whole alpha-crystallins in 100 mM aspirin. The alpha 
      A-crystallins were isolated after the incubation, proteolytically digested into 
      peptides which were separated by reversed phase HPLC and analysed by mass 
      spectrometry. For the reaction conditions used in this investigation, acetylated 
      lysyl residues were the principal products. The extent of acetylation was 
      quantified from the intensities of the peaks in the fast atom bombardment mass 
      spectra of the modified and unmodified peptides. The modified lysine containing 
      peptides demonstrated that all seven lysyl residues of alpha A-crystallin reacted 
      with aspirin; the extent of acetylation at each lysyl residue varied. Plots of 
      the extent of acetylation vs. time were used to calculate rate constants for the 
      reaction at each lysyl residue. The rate constant for the acetylation of Lys 166, 
      the most reactive, was about seven times greater than for Lys 88, the least 
      reactive. These rate constants were used to calculate the yield of predicted 
      products for the reaction of alpha-crystallin with therapeutic concentrations of 
      aspirin. Comparison of the yield of acetylated alpha-crystallin with the yield of 
      carbamylated alpha-crystallin that might occur due to renal failure indicates 
      that aspirin is not likely to be an effective inhibitor of cataract due to 
      carbamylation of lysyl residues.
FAU - Hasan, A
AU  - Hasan A
AD  - H.E.J. Research Institute of Chemistry, University of Karachi, Pakistan.
FAU - Smith, J B
AU  - Smith JB
FAU - Qin, W
AU  - Qin W
FAU - Smith, D L
AU  - Smith DL
LA  - eng
GR  - EY R01 07609/EY/NEI NIH HHS/United States
GR  - GM R01 40384/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 0 (Crystallins)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Amino Acid Sequence
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cattle
MH  - Chromatography, High Pressure Liquid
MH  - Crystallins/*drug effects
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Lysine/analysis
MH  - Mass Spectrometry
MH  - Molecular Sequence Data
MH  - Time Factors
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
AID - S0014-4835(83)71095-X [pii]
AID - 10.1006/exer.1993.1095 [doi]
PST - ppublish
SO  - Exp Eye Res. 1993 Jul;57(1):29-35. doi: 10.1006/exer.1993.1095.

PMID- 15173556
OWN - NLM
STAT- MEDLINE
DCOM- 20041006
LR  - 20131121
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 38
IP  - 7-8
DP  - 2004 Jul-Aug
TI  - Delayed salicylate toxicity at 35 hours without early manifestations following a 
      single salicylate ingestion.
PG  - 1186-8
AB  - OBJECTIVE: To report a case of delayed toxicity following a single ingestion of 
      aspirin, where the initial concentrations were nearly undetectable and the 
      patient was completely asymptomatic for the first 35 hours. CASE SUMMARY: A 
      14-year-old white female was evaluated after a single ingestion of 120 tablets of 
      aspirin 81 mg/tablet hours before arrival to the emergency department. She denied 
      nausea, abdominal pain, tinnitus, or shortness of breath. She received one dose 
      of activated charcoal. The first salicylate concentration (4 h after ingestion) 
      was 1 mg/dL. At 35 hours, the patient became symptomatic (dizziness, tinnitus, 
      epigastric discomfort). Her salicylate concentration at that time was 46 mg/dL. A 
      second dose of activated charcoal was administered, and intravenous bicarbonate 
      with potassium was started as a continuous infusion for 30 hours. DISCUSSION: 
      While delayed salicylate toxicity is well reported in the literature, no report 
      was found regarding concentrations increasing to toxicity 35 hours after 
      ingestion. The delayed aspirin absorption may be due to salicylate-induced 
      pylorospasm or the formation of pharmacobezoars. CONCLUSIONS: In cases with known 
      salicylate ingestion, it is important to follow salicylate concentrations every 4 
      hours until they are steadily decreasing according to a 4-hour half-life and the 
      patient shows no symptoms of salicylate intoxication.
FAU - Rivera, Wilfredo
AU  - Rivera W
AD  - Section of Toxicology, University of Texas Southwestern (UTSW) Emergency 
      Medicine, Dallas, TX 75390-8579, USA. wilfredo.rivera@utsouthwestern.edu
FAU - Kleinschmidt, Kurt C
AU  - Kleinschmidt KC
FAU - Velez, Larissa I
AU  - Velez LI
FAU - Shepherd, Greene
AU  - Shepherd G
FAU - Keyes, Daniel C
AU  - Keyes DC
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20040601
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Ann Pharmacother. 2006 May;40(5):999
MH  - Adolescent
MH  - Anti-Inflammatory Agents, Non-Steroidal/*blood/*poisoning
MH  - Aspirin/*blood/*poisoning
MH  - Drug Overdose
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Time Factors
EDAT- 2004/06/03 05:00
MHDA- 2004/10/07 09:00
CRDT- 2004/06/03 05:00
PHST- 2004/06/03 05:00 [pubmed]
PHST- 2004/10/07 09:00 [medline]
PHST- 2004/06/03 05:00 [entrez]
AID - aph.1D575 [pii]
AID - 10.1345/aph.1D575 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2004 Jul-Aug;38(7-8):1186-8. doi: 10.1345/aph.1D575. Epub 2004 
      Jun 1.

PMID- 9495304
OWN - NLM
STAT- MEDLINE
DCOM- 19980317
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 97
IP  - 7
DP  - 1998 Feb 24
TI  - Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: 
      comparison with heparin and aspirin.
PG  - 681-5
AB  - BACKGROUND: The presence of residual mural thrombus may predispose to recurrent 
      thrombotic events in acute coronary syndromes. The purpose of this study was to 
      evaluate the effects of antithrombotic and antiplatelet agents on a preformed, 
      fresh mural thrombus during growth of thrombus. METHODS AND RESULTS: A fresh 
      mural thrombus was formed by perfusing severely injured arterial wall with 
      porcine blood for 5 minutes at a shear rate of 1690 s(-1). Thrombus formation was 
      measured by morphometric analysis (mm2/mm). The average size of a mural thrombus 
      formed in 5 minutes was 0.14+/-0.03 mm2/mm. Progression of thrombus growth within 
      10 minutes triggered by the preformed thrombus was evaluated in pigs treated with 
      r-hirudin (1 mg/kg per hour i.v.) as a probe for thrombin, high-dose heparin (250 
      IU/kg per hour i.v.), moderate-dose heparin (100 IU/kg per hour), moderate-dose 
      heparin (100 IU/kg per hour) plus aspirin, aspirin alone (5 mg/kg i.v.), and 
      placebo. Hirudin was associated with a significant decrease (48%) of mural 
      thrombus area and significantly reduced growth of thrombus (0.07+/-0.01), even 
      compared with the highest dose of heparin (0.15+/-0.03), although at lower levels 
      of anticoagulation. Inhibition of growth of thrombus with heparin was dose 
      dependent, showing an inverse correlation of thrombus area with mean plasma 
      heparin concentrations (r=.77, P=.0001). Thrombus size was unchanged by aspirin 
      (0.29+/-0.07) compared with controls (0.28+/-0.07). CONCLUSIONS: Direct 
      inhibition of thrombin activity with r-hirudin completely inhibits growth of 
      thrombus, causes dissolution of a preexisting mural thrombus, and is more 
      effective at lower levels of anticoagulation than the highest dose of heparin at 
      shear rates typical of a moderate coronary stenosis.
FAU - Meyer, B J
AU  - Meyer BJ
AD  - Department of Medicine, University Hospital Inselspital, Bern, Switzerland. 
      bmeyer@insel.unibe.ch
FAU - Badimon, J J
AU  - Badimon JJ
FAU - Chesebro, J H
AU  - Chesebro JH
FAU - Fallon, J T
AU  - Fallon JT
FAU - Fuster, V
AU  - Fuster V
FAU - Badimon, L
AU  - Badimon L
LA  - eng
GR  - HL-38933/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hirudins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
RN  - U0JZ726775 (desirudin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Drug Evaluation, Preclinical
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/pharmacology/*therapeutic use
MH  - Heart Diseases/*drug therapy
MH  - Hematocrit
MH  - Heparin/administration & dosage/pharmacology/therapeutic use
MH  - Hirudin Therapy
MH  - Hirudins/*analogs & derivatives/pharmacology
MH  - Partial Thromboplastin Time
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Platelet Count/drug effects
MH  - Recombinant Proteins/pharmacology/therapeutic use
MH  - Swine
MH  - Thrombin/*antagonists & inhibitors
MH  - *Thrombolytic Therapy
MH  - Thrombosis/*drug therapy
EDAT- 1998/03/12 00:00
MHDA- 1998/03/12 00:01
CRDT- 1998/03/12 00:00
PHST- 1998/03/12 00:00 [pubmed]
PHST- 1998/03/12 00:01 [medline]
PHST- 1998/03/12 00:00 [entrez]
AID - 10.1161/01.cir.97.7.681 [doi]
PST - ppublish
SO  - Circulation. 1998 Feb 24;97(7):681-5. doi: 10.1161/01.cir.97.7.681.

PMID- 19033733
OWN - NLM
STAT- MEDLINE
DCOM- 20090511
LR  - 20191210
IS  - 1423-0097 (Electronic)
IS  - 1018-2438 (Linking)
VI  - 149
IP  - 1
DP  - 2009
TI  - Cellular allergen stimulation test with acetylsalicylic acid-lysine is not a 
      useful test to discriminate between asthmatic patients with and without 
      acetylsalicylic acid sensitivity.
PG  - 58-64
LID - 10.1159/000176307 [doi]
AB  - BACKGROUND: The aspirin provocation test, considered to be the gold standard in 
      the diagnosis of aspirin sensitivity, may be associated with severe adverse 
      reactions; thus, alternative procedures with a higher safety profile are highly 
      desirable. Although the cellular antigen stimulation test (CAST) has been 
      proposed to be such an alternative, there is limited information about its 
      clinical usefulness. OBJECTIVE: It was the aim of our study to evaluate the 
      clinical usefulness of CAST in the diagnosis of aspirin sensitivity. MATERIAL AND 
      METHODS: Patients with aspirin-sensitive asthma and/or nasal polyps (n = 40), 
      patients with aspirin-tolerant asthma and/or nasal polyps (n = 13) and healthy 
      volunteers (n = 26) were included. A 2-day, single-blind placebo-controlled oral 
      aspirin provocation test was performed. In vitro release of cysteinyl 
      leukotrienes (Cys-LTs) by peripheral blood leukocytes was measured after 
      stimulation with both stimulation buffer and lysine aspirin (2.5 mg/ml) by CAST. 
      RESULTS: Baseline Cys-LT levels were similar among the 3 groups. After lysine 
      aspirin stimulation, the net increase in Cys-LTs was significantly higher in 
      patients with aspirin sensitivity (median 91 pg/ml, interquartile range 22-206) 
      compared with aspirin-tolerant patients (20 pg/ml, range 0-46) and healthy 
      controls (23 pg/ml, range 0-71; p = 0.004). The assay had a sensitivity of 25%, a 
      specificity of 92.3%, and positive and negative predictive values of 28.7 and 
      90.7%, respectively. CONCLUSION: Although the leukocytes of patients with aspirin 
      sensitivity produce higher amounts of Cys-LTs as measured by CAST, the low 
      sensitivity and predictive values limit the clinical usefulness of this test in 
      the diagnosis of aspirin sensitivity.
CI  - 2008 S. Karger AG, Basel.
FAU - Bavbek, Sevim
AU  - Bavbek S
AD  - Department of Allergy, Ankara University, Turkey. bavbek@medicine.ankara.edu.tr
FAU - Dursun, A Berna
AU  - Dursun AB
FAU - Birben, Esra
AU  - Birben E
FAU - Kalayci, Omer
AU  - Kalayci O
FAU - Misirligil, Zeynep
AU  - Misirligil Z
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081126
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (Allergens)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Leukotrienes)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Allergens/adverse effects/immunology/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/immunology/*pharmacology
MH  - Aspirin/adverse effects/*analogs & derivatives/immunology/pharmacology
MH  - Asthma/complications/*diagnosis/immunology
MH  - Diagnosis, Differential
MH  - Drug Hypersensitivity/complications/*diagnosis/immunology
MH  - Female
MH  - Humans
MH  - Immunologic Tests
MH  - Leukocytes/*drug effects/immunology
MH  - Leukotrienes/*biosynthesis
MH  - Lysine/adverse effects/*analogs & derivatives/immunology/pharmacology
MH  - Male
MH  - Sensitivity and Specificity
EDAT- 2008/11/27 09:00
MHDA- 2009/05/12 09:00
CRDT- 2008/11/27 09:00
PHST- 2008/02/20 00:00 [received]
PHST- 2008/06/16 00:00 [accepted]
PHST- 2008/11/27 09:00 [pubmed]
PHST- 2009/05/12 09:00 [medline]
PHST- 2008/11/27 09:00 [entrez]
AID - 000176307 [pii]
AID - 10.1159/000176307 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2009;149(1):58-64. doi: 10.1159/000176307. Epub 2008 
      Nov 26.

PMID- 16613570
OWN - NLM
STAT- MEDLINE
DCOM- 20060728
LR  - 20191109
IS  - 1871-5281 (Print)
IS  - 1871-5281 (Linking)
VI  - 5
IP  - 2
DP  - 2006 Apr
TI  - Nitric oxide and inflammation.
PG  - 115-9
AB  - There are several pre-clinical studies on the involvement of NO in inflammation. 
      From this large amount of information it is clear that virtually every cell and 
      many immunological parameters are modulated by NO. Thus, the final outcome is 
      that NO cannot be rigidly classified as an anti-inflammatory or pro-inflammatory 
      molecule. This peculiar aspect of the pathophysiology of NO has hampered the 
      development of new drugs based on the concepts developed. Recent therapeutic 
      approach are targeted to increase endogenous NO by activating the gene and some 
      promising early data are available. At the present stage one of the most 
      promising approach in the inflammation field is represented by a new class of 
      NO-releasing compounds namely NO-NSAIDs that have recently enrolled in phase 2 
      clinical studies.
FAU - Cirino, Giuseppe
AU  - Cirino G
AD  - Department of Experimental Pharmacology, Università di Napoli-Federico II, 
      Napoli, Italy. cirino@unina.it
FAU - Distrutti, Eleonora
AU  - Distrutti E
FAU - Wallace, John L
AU  - Wallace JL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Inflamm Allergy Drug Targets
JT  - Inflammation & allergy drug targets
JID - 101266886
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Nitrates)
RN  - 0 (naproxen-n-butyl nitrate)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 57Y76R9ATQ (Naproxen)
RN  - EH04H13L6B (nitroaspirin)
RN  - F8Y1ZV5V9P (4-(nitroxy)butanoic acid 4-acetylaminophenyl ester)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analogs & derivatives/metabolism/therapeutic use
MH  - Animals
MH  - Anti-Inflammatory Agents/metabolism/*therapeutic use
MH  - Aspirin/*analogs & derivatives/metabolism/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Evaluation, Preclinical
MH  - Humans
MH  - Inflammation/*drug therapy/metabolism
MH  - Naproxen/*analogs & derivatives/metabolism/therapeutic use
MH  - Nitrates/metabolism/*therapeutic use
MH  - Nitric Oxide/metabolism/*therapeutic use
RF  - 23
EDAT- 2006/04/15 09:00
MHDA- 2006/07/29 09:00
CRDT- 2006/04/15 09:00
PHST- 2006/04/15 09:00 [pubmed]
PHST- 2006/07/29 09:00 [medline]
PHST- 2006/04/15 09:00 [entrez]
AID - 10.2174/187152806776383143 [doi]
PST - ppublish
SO  - Inflamm Allergy Drug Targets. 2006 Apr;5(2):115-9. doi: 
      10.2174/187152806776383143.

PMID- 33966411
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 10
IP  - 4
DP  - 2021 Apr
TI  - Effectiveness and safety of aspirin combined with letrozole in the treatment of 
      polycystic ovary syndrome: a systematic review and meta-analysis.
PG  - 4632-4641
LID - 10.21037/apm-21-606 [doi]
AB  - BACKGROUND: Meta-analysis was used to evaluate the efficacy and safety of aspirin 
      combined with letrozole in the treatment of polycystic ovary syndrome (PCOS). 
      METHODS: Through comprehensive searches of the China Knowledge Network (CNKI), 
      the VIP database (VIP), the Wanfang database, the China Biomedical Database 
      (CBM), PubMed, EMBASE, and the Cochrane Library, the clinical randomized 
      controlled trials (RCTs) published on aspirin combined with letrozole in the 
      treatment of PCOS were collected. According to the inclusion and exclusion 
      criteria, the included studies were screened and quality evaluated, and RevMan 
      5.3 software was used for meta-analysis. RESULTS: A total of 10 RCTs and 948 
      patients with PCOS were included. Meta-analysis results showed that compared with 
      letrozole monotherapy, aspirin combined with letrozole could significantly 
      increase the thickness of the endometrium [MD=1.98, 95% CI: 1.63-2.34, 
      P<0.00001], cervical mucus scores (MD =1.65, 95% CI: 1.32-1.98, P<0.00001), the 
      ovulation rate (OR=3.50, 95% CI: 2.08-5.91, P<0.00001), the number of mature 
      follicles (MD=0.65, 95% CI: 0.51-0.78, P<0.00001), and the pregnancy rate 
      (OR=3.06, 95% CI: 2.28-4.12, P<0.00001), and significantly reduced the abortion 
      rate (OR=0.20, 95% CI: 0.11-0.38, P<0.00001). There was no statistically 
      significant difference in the incidence of adverse reactions between the 2 groups 
      (OR=0.76, 95% CI: 0.44-1.32, P=0.33). CONCLUSIONS: Aspirin combined with 
      letrozole in the treatment of PCOS is safe and effective. Due to the limitations 
      in the number and quality of the included studies, further verification with 
      multi-center, large-sample, high-quality RCTs is still needed.
FAU - Yu, Qinjian
AU  - Yu Q
AD  - Department of Obstetrics and Gynecology, The Dingli Clinical College of Wenzhou 
      Medical University, Wenzhou, China.
FAU - Wang, Zhihui
AU  - Wang Z
AD  - Department of Obstetrics and Gynecology, The Dingli Clinical College of Wenzhou 
      Medical University, Wenzhou, China.
FAU - Su, Fangfang
AU  - Su F
AD  - Department of Obstetrics and Gynecology, The Dingli Clinical College of Wenzhou 
      Medical University, Wenzhou, China.
FAU - Wang, Mianmian
AU  - Wang M
AD  - Department of Obstetrics and Gynecology, The Dingli Clinical College of Wenzhou 
      Medical University, Wenzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 7LKK855W8I (Letrozole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - China
MH  - Female
MH  - Humans
MH  - Letrozole/therapeutic use
MH  - Ovulation Induction
MH  - *Polycystic Ovary Syndrome/drug therapy
MH  - Pregnancy
OTO - NOTNLM
OT  - Aspirin
OT  - letrozole
OT  - meta-analysis
OT  - polycystic ovary syndrome (PCOS)
EDAT- 2021/05/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/05/10 05:29
PHST- 2021/02/05 00:00 [received]
PHST- 2021/04/17 00:00 [accepted]
PHST- 2021/05/10 05:29 [entrez]
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.21037/apm-21-606 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2021 Apr;10(4):4632-4641. doi: 10.21037/apm-21-606.

PMID- 33389188
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1436-2813 (Electronic)
IS  - 0941-1291 (Linking)
VI  - 51
IP  - 6
DP  - 2021 Jun
TI  - Continuation of aspirin perioperatively for lung resection: a propensity matched 
      analysis.
PG  - 1054-1060
LID - 10.1007/s00595-020-02202-4 [doi]
AB  - PURPOSE: To clarify the safety and effectiveness of continuing aspirin during the 
      perioperative period of lung resection. METHODS: We analyzed, retrospectively, 
      consecutive patients who underwent lung resection between 2008 and 2017. To 
      investigate the safety of aspirin continuation, patients who continued taking 
      aspirin perioperatively (Group C) were matched to other patients (Group O), using 
      a propensity score, and bleeding outcomes were compared. To assess the effect of 
      aspirin interruption, Group C was matched to a group of patients whose aspirin 
      regimen was interrupted (Group I), and the postoperative complications related to 
      thromboembolism were compared. RESULTS: Among 3393 patients, 52 continued on 
      aspirin (Group C) perioperatively, whereas 184 had their aspirin discontinued 
      (Group I). Comparing the matched cohorts extracted from Group C and Group O 
      (n = 45), there were no significant differences in bleeding outcomes. Comparing 
      the matched cohorts extracted from Group C and Group I (n = 40), group C had 
      fewer postoperative complications related to thromboembolism (0% vs. 7.5%, 
      p = 0.039). CONCLUSION: Bleeding complications did not increase by continuing 
      aspirin, but thromboembolic complications increased when the aspirin regimen was 
      interrupted during the perioperative period of lung resection. Thus, in the 
      absence of a prohibitive bleeding risk, the continuation of aspirin during the 
      perioperative period of lung resection appears to be desirable.
FAU - Sakai, Takashi
AU  - Sakai T
AUID- ORCID: 0000-0003-2724-530X
AD  - Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, 
      Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
FAU - Aokage, Keiju
AU  - Aokage K
AD  - Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, 
      Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. kaokage@east.ncc.go.jp.
FAU - Katsumata, Shinya
AU  - Katsumata S
AD  - Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, 
      Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
FAU - Tane, Kenta
AU  - Tane K
AD  - Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, 
      Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
FAU - Miyoshi, Tomohiro
AU  - Miyoshi T
AD  - Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, 
      Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
FAU - Tsuboi, Masahiro
AU  - Tsuboi M
AD  - Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, 
      Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20210103
PL  - Japan
TA  - Surg Today
JT  - Surgery today
JID - 9204360
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Child
MH  - Female
MH  - Hemorrhage/epidemiology/etiology
MH  - Humans
MH  - Lung/*surgery
MH  - Male
MH  - Middle Aged
MH  - Perioperative Care
MH  - *Pneumonectomy
MH  - Postoperative Complications/epidemiology/*prevention & control
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Safety
MH  - Thromboembolism/epidemiology/*prevention & control
MH  - Treatment Outcome
MH  - Withholding Treatment
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Bleeding
OT  - Lung resection
OT  - Pulmonary disease
EDAT- 2021/01/04 06:00
MHDA- 2021/10/26 06:00
CRDT- 2021/01/03 20:38
PHST- 2020/09/15 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2021/01/04 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2021/01/03 20:38 [entrez]
AID - 10.1007/s00595-020-02202-4 [pii]
AID - 10.1007/s00595-020-02202-4 [doi]
PST - ppublish
SO  - Surg Today. 2021 Jun;51(6):1054-1060. doi: 10.1007/s00595-020-02202-4. Epub 2021 
      Jan 3.

PMID- 3413735
OWN - NLM
STAT- MEDLINE
DCOM- 19881012
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 51
IP  - 1
DP  - 1988 Jul 1
TI  - Epinephrine-induced reversal of aspirin effects on platelet deformability.
PG  - 35-44
AB  - The present study has evaluated the influence of epinephrine on the resistance of 
      platelets to aspiration into micropipettes, and the effect of epinephrine on the 
      altered deformability of aspirin treated platelets. Unlike other platelet 
      agonists previously studied, epinephrine stimulation did not alter platelet 
      deformability at a concentration capable of causing platelet aggregation. Aspirin 
      caused a dramatic decrease in the resistance of platelets to aspiration. 
      Pretreatment of platelets with epinephrine prevented aspirin from altering 
      platelet deformability, and exposure of platelets to epinephrine after treatment 
      with aspirin reversed the increased deformability produced by the drug. Blockade 
      of alpha-2 adrenergic receptors with yohimbine or clonidine prevented epinephrine 
      antagonism of the mechanical effects of aspirin. The studies provide further 
      evidence of the novel antagonism between epinephrine and aspirin on platelet 
      structure and function.
FAU - Smith, C M 2nd
AU  - Smith CM 2nd
AD  - Department of Pediatrics, University of Minnesota Health Sciences Center, 
      Minneapolis.
FAU - Burris, S M
AU  - Burris SM
FAU - Rao, G H
AU  - Rao GH
FAU - White, J G
AU  - White JG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Aspirin/*antagonists & inhibitors
MH  - Blood Platelets/*drug effects
MH  - Epinephrine/*pharmacology
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Stress, Mechanical
EDAT- 1988/07/01 00:00
MHDA- 1988/07/01 00:01
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 1988/07/01 00:01 [medline]
PHST- 1988/07/01 00:00 [entrez]
AID - 0049-3848(88)90280-0 [pii]
AID - 10.1016/0049-3848(88)90280-0 [doi]
PST - ppublish
SO  - Thromb Res. 1988 Jul 1;51(1):35-44. doi: 10.1016/0049-3848(88)90280-0.

PMID- 2187910
OWN - NLM
STAT- MEDLINE
DCOM- 19900627
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 30
IP  - 4
DP  - 1990 Apr
TI  - Clinical safety of flurbiprofen.
PG  - 342-51
AB  - Data from 58 premarketing studies of the nonsteroidal antiinflammatory drug 
      flurbiprofen were pooled for analyses of adverse drug reactions (ADRs). These 
      studies included 5602 patients treated with flurbiprofen (N = 4123), aspirin (N = 
      1033), or placebo (N = 446) for varying durations. Diagnoses included rheumatoid 
      arthritis, osteoarthritis, and other painful musculoskeletal conditions. In these 
      studies serious upper gastrointestinal ADRs occurred in flurbiprofen-treated 
      patients at less than one half the rate seen in aspirin-treated patients. The 
      incidence of serious urinary tract ADRs was lower with flurbiprofen than with 
      aspirin. The flurbiprofen group had no serious clinical ADRs related to the 
      hemic/lymphatic system. The most common laboratory abnormality was a decrease in 
      hematocrit, which occurred less often than in the aspirin group. We also 
      evaluated serious flurbiprofen-related ADRs in 4370 patients in a variety of 
      other studies and reviewed published reports of flurbiprofen clinical trials and 
      case reports. These reviews showed no additional, unanticipated patterns of 
      intolerance. These clinical safety data indicate that in the doses studied, 
      flurbiprofen is a well tolerated agent for patients requiring nonsteroidal 
      antiinflammatory drug therapy.
FAU - Brooks, C D
AU  - Brooks CD
AD  - Pharmaceutical Research Division, Upjohn Company, Kalamazoo, Michigan 49001.
FAU - Linet, O I
AU  - Linet OI
FAU - Schellenberg, D
AU  - Schellenberg D
FAU - Turner, L F
AU  - Turner LF
FAU - Defesche, C L
AU  - Defesche CL
FAU - Teoh, K W
AU  - Teoh KW
FAU - Johnson, J H
AU  - Johnson JH
FAU - Assenzo, J R
AU  - Assenzo JR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 5GRO578KLP (Flurbiprofen)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Digestive System/*drug effects
MH  - Female
MH  - Flurbiprofen/*adverse effects/therapeutic use
MH  - Hematocrit
MH  - Hemoglobin A/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Risk Factors
MH  - Urogenital System/*drug effects
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1990.tb03604.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1990 Apr;30(4):342-51. doi: 10.1002/j.1552-4604.1990.tb03604.x.

PMID- 11246553
OWN - NLM
STAT- MEDLINE
DCOM- 20010628
LR  - 20181130
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 85
IP  - 2
DP  - 2001 Feb
TI  - Time and dose dependent augmentation of inhibitory effects of abciximab by 
      aspirin.
PG  - 309-13
AB  - Aspirin and abciximab independently decrease the incidence of cardiac events. To 
      identify potential interactions, antiplatelet effects of abciximab were 
      characterized in blood from healthy subjects given aspirin. Platelet activation 
      was determined in whole blood with and without abciximab (2 microg/ml) added in 
      vitro. Flow cytometry was used to quantify fibrinogen binding (glycoprotein 
      IIb-IIIa activation). Binding of fluorochrome-labeled and 125I-labeled abciximab 
      was determined before and after exposure to aspirin. In blood from subjects given 
      aspirin for 5 days, abciximab-induced inhibition of the capacity to bind 
      fibrinogen in response to 1 microM ADP was greater when the daily dose had been 
      325 mg compared with 81 mg (% inhibition: no aspirin 53 +/- 6; 81 mg daily 62 +/- 
      5; 325 mg daily 69 +/- 6). The effect of 5 daily doses of aspirin was greater 
      than that of one. Larger single doses elicited larger effects (% inhibition 2 h 
      after 325 mg 59 +/- 6; 2 h after 650 mg 78 +/- 5). Neither salicylsalicylic acid 
      nor naproxen sodium potentiated the effect of abciximab. Exposure of platelets to 
      14C-acetylsalicylic acid led to acetylation of glycoprotein IIb and IIIa. Binding 
      of 125I-abciximab to platelets was increased after 30 and 60 min. Acetylation of 
      glycoprotein IIb-IIIa by aspirin augments inhibitory effects of abciximab in a 
      dose- and time-dependent manner by increasing binding of abciximab to platelets.
FAU - Schneider, D J
AU  - Schneider DJ
AD  - Department of Medicine, University of Vermont, Burlington 05446, USA. 
      djschnei@zoo.uvm.edu
FAU - Baumann, P Q
AU  - Baumann PQ
FAU - Holmes, M B
AU  - Holmes MB
FAU - Taatjes, D J
AU  - Taatjes DJ
FAU - Sobel, B E
AU  - Sobel BE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Carbon Radioisotopes)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - Acetylation
MH  - Antibodies, Monoclonal/pharmacokinetics/*pharmacology
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Carbon Radioisotopes
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Fibrinogen/metabolism
MH  - Humans
MH  - Immunoglobulin Fab Fragments/*pharmacology
MH  - Iodine Radioisotopes
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/pharmacology
MH  - Platelet Function Tests
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors/metabolism
MH  - Protein Binding/drug effects
MH  - Time Factors
EDAT- 2001/03/15 10:00
MHDA- 2001/06/29 10:01
CRDT- 2001/03/15 10:00
PHST- 2001/03/15 10:00 [pubmed]
PHST- 2001/06/29 10:01 [medline]
PHST- 2001/03/15 10:00 [entrez]
AID - 01020309 [pii]
PST - ppublish
SO  - Thromb Haemost. 2001 Feb;85(2):309-13.

PMID- 2112271
OWN - NLM
STAT- MEDLINE
DCOM- 19900711
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 58
IP  - 2
DP  - 1990 Apr 15
TI  - Effect of aspirin and dipyridamole treatment on prostacyclin production by human 
      veins.
PG  - 109-17
AB  - Patients admitted for surgical removal of varicose veins were treated in a 
      blinded manner for 48 hours prior to surgery with either placebo, low-dose 
      aspirin (25 mg twice daily), dipyridamole (150 mg twice daily) or both. Segments 
      of vein excised at surgery were incubated with or without sodium arachidonate and 
      subsequent prostacyclin (PGI2) production was measured without knowledge of 
      treatment given. During the first 5 minute period of incubation in the presence 
      of arachidonate, veins from dipyridamole-treated patients demonstrated increased 
      (by 75%) arachidonate-stimulated PGI2 production compared to placebo-treated 
      patients. By contrast, PGI2 production was reduced by 64% by aspirin treatment 
      and 67% by aspirin plus dipyridamole compared to placebo-treated patients (p = 
      less than 0.05). In unstimulated vein segments incubated in the absence of 
      arachidonate, spontaneous PGI2 production during the first 5 minute incubation 
      period was increased 32% following dipyridamole treatment but was unchanged 
      following aspirin treatment. By contrast, unstimulated (spontaneous) PGI2 
      production in patients treated with aspirin plus dipyridamole was reduced by 57% 
      (p = less than 0.05), compared to both placebo- and aspirin-treated patients, and 
      by 71% (p = less than 0.05) compared to dipyridamole-treated patients. With 
      repeated change of incubation medium, the ability of vein walls to produce PGI2 
      declined. This exhaustion was not prevented by drug treatment. However, drug 
      effects between patient treatment groups were consistent over successive 
      incubation periods. These results suggest that certain therapeutic benefits that 
      might be achieved by enhancement of PGI2 production from vascular endothelium 
      following dipyridamole treatment may be reduced by simultaneous aspirin 
      treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Costantini, V
AU  - Costantini V
AD  - Instituto di Semeiotica Medica, Università di Perugia, Italy.
FAU - Talpacci, A
AU  - Talpacci A
FAU - Cipolloni, S
AU  - Cipolloni S
FAU - Boschetti, E
AU  - Boschetti E
FAU - Bisacci, R
AU  - Bisacci R
FAU - Tristaino, B
AU  - Tristaino B
FAU - Nenci, G G
AU  - Nenci GG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 57576-52-0 (Thromboxane A2)
RN  - 64ALC7F90C (Dipyridamole)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Dipyridamole/administration & dosage/blood/*pharmacology
MH  - Double-Blind Method
MH  - Endothelium, Vascular/metabolism
MH  - Epoprostenol/*biosynthesis/blood
MH  - Humans
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Saphenous Vein/metabolism
MH  - Thromboxane A2/biosynthesis/blood
MH  - Varicose Veins/*surgery
EDAT- 1990/04/15 00:00
MHDA- 1990/04/15 00:01
CRDT- 1990/04/15 00:00
PHST- 1990/04/15 00:00 [pubmed]
PHST- 1990/04/15 00:01 [medline]
PHST- 1990/04/15 00:00 [entrez]
AID - 10.1016/0049-3848(90)90168-c [doi]
PST - ppublish
SO  - Thromb Res. 1990 Apr 15;58(2):109-17. doi: 10.1016/0049-3848(90)90168-c.

PMID- 3129553
OWN - NLM
STAT- MEDLINE
DCOM- 19880602
LR  - 20181130
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 245
IP  - 1
DP  - 1988 Apr
TI  - Selectivity of oral aspirin as an inhibitor of platelet vs. vascular 
      cyclooxygenase activity is reduced by portacaval shunt in rats.
PG  - 287-90
AB  - Oral aspirin can be extensively hydrolyzed to salicylate in the stomach and liver 
      before it enters the systemic circulation. "Presystemic" acetylation of platelets 
      may thus occur during aspirin absorption. This may result in concomitant sparing 
      of peripheral vascular cyclooxygenase mainly exposed to salicylate. We tested 
      whether the "biochemical selectivity" of p.o. aspirin as an inhibitor of platelet 
      rather than vascular cyclooxygenase was reduced by elimination of the 
      "first-pass" hepatic metabolism. A portacaval shunt was inserted in anesthetized 
      rats by connecting the portal vein to the inferior vena cava through a 
      heparinized polyethylene "Y" cannula. Sham-operated rats acted as controls. 
      Ninety minutes after recovery from anesthesia rats were given aspirin p.o. (10 
      mg/kg) and 45 min later serum thromboxane B2 and 6-keto-prostaglandin F1 alpha 
      formation by vascular rings was evaluated by radioimmunoassay. Serum thromboxane 
      B2 was almost suppressed completely in all animals; vascular 6-ketoprostaglandin 
      F1 alpha was reduced significantly (by 40-60% in aorta and vena cava) in rats 
      with the portacaval shunt but not in sham-operated animals. The results in rats 
      with the shunt were similar to those obtained previously after i.v. aspirin. 
      Fifteen minutes after aspirin, plasma levels of unmetabolized drug measured by 
      high-pressure liquid chromatography were significantly higher in rats with 
      portacaval shunt (0.56 +/- 0.16 micrograms/ml; n = 5) than in sham-operated 
      controls (0.16 +/- 0.02 micrograms/ml; n = 5). These findings support directly 
      the role of first-pass hepatic metabolism in the "biochemical selectivity" of 
      p.o. aspirin.
FAU - Gambino, M C
AU  - Gambino MC
AD  - Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.
FAU - Passaghe, S
AU  - Passaghe S
FAU - Chen, Z M
AU  - Chen ZM
FAU - Bucchi, F
AU  - Bucchi F
FAU - Gori, G
AU  - Gori G
FAU - Latini, R
AU  - Latini R
FAU - de Gaetano, G
AU  - de Gaetano G
FAU - Cerletti, C
AU  - Cerletti C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Salicylates)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Blood Platelets/drug effects/*enzymology
MH  - Blood Vessels/drug effects/*enzymology
MH  - *Cyclooxygenase Inhibitors
MH  - Gastric Mucosa/metabolism
MH  - Liver/metabolism
MH  - Male
MH  - *Portacaval Shunt, Surgical
MH  - Rats
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Thromboxane B2/blood
MH  - Time Factors
EDAT- 1988/04/01 00:00
MHDA- 1988/04/01 00:01
CRDT- 1988/04/01 00:00
PHST- 1988/04/01 00:00 [pubmed]
PHST- 1988/04/01 00:01 [medline]
PHST- 1988/04/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1988 Apr;245(1):287-90.

PMID- 6422734
OWN - NLM
STAT- MEDLINE
DCOM- 19840419
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 53
IP  - 7
DP  - 1984 Mar 15
TI  - Platelet adherence to bioprosthetic cardiac valves.
PG  - 945-9
AB  - Tissue from porcine aortic bioprosthetic valves (Hancock) and bovine pericardial 
      valves (Ionescu-Shiley) were incubated with platelets tagged with chromium-51. 
      There was a significantly decreased platelet-collagen adhesion reaction in both 
      porcine and bovine glutaraldehyde-treated valves compared with reactions in fresh 
      porcine aortic valve and fresh bovine pericardium (p less than 0.001). There was 
      no significant difference in the platelet-collagen reaction between porcine 
      aortic valve and bovine pericardium, whether treated with glutaraldehyde or in 
      the fresh state (p greater than 0.05). The addition of aspirin did not 
      significantly decrease the platelet-collagen reaction on glutaraldehyde-treated 
      or fresh valves (p greater than 0.05). Rinsing fresh valves in plasma appeared to 
      offer more protection against platelet adhesion than rinsing them in saline 
      solution (p less than 0.01). It is concluded that there is no difference in 
      platelet adherence to porcine aortic valve or bovine pericardium and that 
      glutaraldehyde, and perhaps plasma, offers a protective effect against platelet 
      adhesion.
FAU - Magilligan, D J Jr
AU  - Magilligan DJ Jr
FAU - Oyama, C
AU  - Oyama C
FAU - Klein, S
AU  - Klein S
FAU - Riddle, J M
AU  - Riddle JM
FAU - Smith, D
AU  - Smith D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - R16CO5Y76E (Aspirin)
RN  - T3C89M417N (Glutaral)
SB  - IM
MH  - Animals
MH  - Aortic Valve
MH  - Aspirin/pharmacology
MH  - *Bioprosthesis
MH  - Blood Platelets/drug effects
MH  - Cattle
MH  - Glutaral/pharmacology
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Microscopy, Electron
MH  - *Platelet Adhesiveness
MH  - Swine
EDAT- 1984/03/15 00:00
MHDA- 2001/03/28 10:01
CRDT- 1984/03/15 00:00
PHST- 1984/03/15 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1984/03/15 00:00 [entrez]
AID - 0002-9149(84)90530-7 [pii]
AID - 10.1016/0002-9149(84)90530-7 [doi]
PST - ppublish
SO  - Am J Cardiol. 1984 Mar 15;53(7):945-9. doi: 10.1016/0002-9149(84)90530-7.

PMID- 15230814
OWN - NLM
STAT- MEDLINE
DCOM- 20050210
LR  - 20131121
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 59
IP  - 8
DP  - 2004 Aug
TI  - Effect of inhalation aspirin challenge on exhaled nitric oxide in patients with 
      aspirin-inducible asthma.
PG  - 827-32
AB  - BACKGROUND: A complex relationship between arachidonic acid metabolites and 
      nitric oxide (NO) synthesis has been reported in asthma. The effects of inhaled 
      aspirin on fractional exhaled NO (FENO) in patients with aspirin-tolerant (ATA) 
      and aspirin-inducible (AIA) asthma compared with normal controls have been 
      investigated. METHODS: The FENO was measured baseline, after saline and 
      lysine-aspirin (L-ASA) bronchial challenge in 10 patients with ATA and in 10 
      patients with AIA [mean (PD(20)FEV(1) L-ASA): 14.7 +/- 12.7 mg], who had 
      comparable age and baseline FEV(1). Ten healthy subjects served as controls. 
      Sputum eosinophils were counted after saline and after L-ASA challenge in the two 
      groups of asthmatics. RESULTS: Asthmatic patients had baseline FENO significantly 
      higher than controls (29.7 +/- 6.8 vs 9.8 +/- 2.05 p.p.b. respectively, P < 
      0.0001). No difference was observed in methacholine PD(20)FEV(1) and baseline 
      FENO between ATA and AIA patients. After L-ASA inhalation, FENO increased 
      significantly only in patients with AIA, reaching the peak value 4 h after 
      bronchoconstriction (from 31.1 +/- 6 to 43 +/- 4.8 p.p.b., P < 0.001), while no 
      change was observed in patients with ATA and in controls. Sputum eosinophils 
      increased significantly after L-ASA inhalation only in patients with AIA (from 
      8.1 +/- 2.7 to 11.1 +/- 2.8%, P < 0.005) and there was a significant relationship 
      between the increase in sputum eosinophils and the increase in FENO after ASA 
      challenge. CONCLUSION: Exhaled NO may indicate eosinophilic airway inflammation 
      during ASA exposure in patients with ASA inducible asthma.
FAU - Rolla, G
AU  - Rolla G
AD  - Allergologia e Immunologia Cinica, Università di Torino and Ospedale Mauriziano 
      Umberto I di Torino, Largo Turati 62, 10128 Turin, Italy.
FAU - Di Emanuele, A
AU  - Di Emanuele A
FAU - Dutto, L
AU  - Dutto L
FAU - Marsico, P
AU  - Marsico P
FAU - Nebiolo, F
AU  - Nebiolo F
FAU - Corradi, F
AU  - Corradi F
FAU - Brussino, L
AU  - Brussino L
FAU - Bucca, C
AU  - Bucca C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/metabolism
MH  - *Breath Tests
MH  - Double-Blind Method
MH  - Eosinophils/physiology
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide/*metabolism
MH  - Sputum/cytology
EDAT- 2004/07/03 05:00
MHDA- 2005/02/11 09:00
CRDT- 2004/07/03 05:00
PHST- 2004/07/03 05:00 [pubmed]
PHST- 2005/02/11 09:00 [medline]
PHST- 2004/07/03 05:00 [entrez]
AID - ALL502 [pii]
AID - 10.1111/j.1398-9995.2004.00502.x [doi]
PST - ppublish
SO  - Allergy. 2004 Aug;59(8):827-32. doi: 10.1111/j.1398-9995.2004.00502.x.

PMID- 12133013
OWN - NLM
STAT- MEDLINE
DCOM- 20020815
LR  - 20190709
IS  - 0002-8614 (Print)
IS  - 0002-8614 (Linking)
VI  - 50
IP  - 7
DP  - 2002 Jul
TI  - Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on 
      health outcomes of very old patients with heart failure?
PG  - 1198-204
AB  - OBJECTIVES: Concomitant ischemic heart disease (IHD) is common in older 
      individuals with heart failure (HF). We estimated the effect of aspirin use on 
      the rate of mortality, morbidity, and decline in physical functioning in nursing 
      home residents with HF taking angiotensin-converting enzyme (ACE) inhibitors. 
      DESIGN: We conducted a retrospective cohort study using a nursing home database 
      linking resident information collected via the Minimum Data Set (MDS) with drug 
      utilization data. SETTING: Nursing homes in four states (1992-1995). 
      PARTICIPANTS: Of 49,779 residents with HF admitted to these homes, 12,703 
      residents were taking an ACE inhibitor; 2,046 of these took aspirin. 
      MEASUREMENTS: Medicare enrollment files provided the date of death, and we used 
      the Part A Medicare files to identify hospital admissions. The activity of daily 
      living scale from repeat MDS assessments allowed us to evaluate decline in 
      physical function. Cox proportional hazards models provided adjusted estimates of 
      the aspirin effect, with nonusers as the reference group. RESULTS: The overall 
      mortality rate, hospitalization rate,and rate of decline in physical function of 
      aspirin users were not different from those of nonusers (e.g., hospitalization 
      rate ratio = 0.99, 95% confidence interval = 0.92-1.07). This effect did not vary 
      by presence of concomitant IHD or by dose or type of ACE inhibitor. CONCLUSION: 
      In a cohort of older HF residents receiving ACE inhibitors in nursing homes, we 
      found that treatment with aspirin did not appear to affect outcomes negatively.
FAU - Lapane, Kate L
AU  - Lapane KL
AD  - Department of Community Health, Center for Gerontology and Health Care Research, 
      Brown University, Providence, Rhode Island 02912, USA. kate_lapane@brown.edu
FAU - Hume, Anne L
AU  - Hume AL
FAU - Barbour, Marilyn M
AU  - Barbour MM
FAU - Lipsitz, Lewis A
AU  - Lipsitz LA
LA  - eng
GR  - AG 17957-01/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Activities of Daily Living
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Heart Failure/complications/*drug therapy
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Myocardial Ischemia/*drug therapy/etiology
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2002/07/23 10:00
MHDA- 2002/08/16 10:01
CRDT- 2002/07/23 10:00
PHST- 2002/07/23 10:00 [pubmed]
PHST- 2002/08/16 10:01 [medline]
PHST- 2002/07/23 10:00 [entrez]
AID - jgs50305 [pii]
AID - 10.1046/j.1532-5415.2002.50305.x [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2002 Jul;50(7):1198-204. doi: 10.1046/j.1532-5415.2002.50305.x.

PMID- 14704234
OWN - NLM
STAT- MEDLINE
DCOM- 20040521
LR  - 20200930
IS  - 0363-6135 (Print)
IS  - 0363-6135 (Linking)
VI  - 286
IP  - 5
DP  - 2004 May
TI  - Disodium cromoglycate stabilizes mast cell degranulation while reducing the 
      number of hemoglobin-induced microvascular leaks in rat mesentery.
PG  - H1750-6
AB  - Blood substitutes, such as diaspirin cross-linked Hb (DBBF-Hb), have been 
      considered for use during blood transfusions. Unfortunately, bolus injection of 
      modified Hb has been shown to rapidly increase the leakage of microvessels to 
      plasma albumin. This effect may result from production of excess reactive oxygen 
      species (ROS) and could be linked to the observed increase in degranulated mast 
      cells (DMC). Disodium cromoglycate (cromolyn) stabilizes mast cells and therefore 
      might minimize the venular permeability in the rat mesentery. In 10 anesthetized 
      Sprague-Dawley rats, the mesenteric preparation was continuously suffused with 
      cromolyn while the microvasculature was filled with DBBF-Hb solution (10 mg/ml) 
      for 10 min. Six animals received cromolyn pretreatment [two intravascular 
      injections over 30 min (experiment A)] and four animals received pretreatment 
      with 2% HEPES-buffered saline (HBS)-BSA (experiment B). Two more animals were 
      pretreated with HBS-BSA without DBBF-Hb infusion but with cromolyn suffusion 
      (experiment C). Another set of experiments was performed on five animals without 
      cromolyn suffusion or any pretreatment but with DBBF-Hb infusion (experiment D). 
      All groups then received a 1-min perfusion of FITC-albumin, fixation for 60 min, 
      and microscopic examination. Experiments A and B demonstrated a significant 
      reduction in the number of venular leaks and DMC compared with experiment D, but 
      not in the area of venular leaks. These results suggest mast cell degranulation 
      is not a major contributor to microvascular leakage induced by DBBF-Hb.
FAU - Ginsburg, Maxwell I
AU  - Ginsburg MI
AD  - Department of Physiology, College of Medicine, University of Arizona, Tucson, 
      Arizona 85724-5051, USA.
FAU - Baldwin, Ann L
AU  - Baldwin AL
LA  - eng
PT  - Journal Article
DEP - 20040102
PL  - United States
TA  - Am J Physiol Heart Circ Physiol
JT  - American journal of physiology. Heart and circulatory physiology
JID - 100901228
RN  - 0 (Buffers)
RN  - 0 (Hemoglobins)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - Q2WXR1I0PK (Cromolyn Sodium)
RN  - R16CO5Y76E (Aspirin)
RN  - RWW266YE9I (HEPES)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Blood Vessels/cytology
MH  - Buffers
MH  - Capillary Permeability/*drug effects
MH  - Cell Degranulation/*drug effects
MH  - Cromolyn Sodium/*pharmacology
MH  - HEPES/pharmacology
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Mast Cells/cytology/*physiology
MH  - Microcirculation/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sodium Chloride/pharmacology
MH  - Splanchnic Circulation/*drug effects
EDAT- 2004/01/06 05:00
MHDA- 2004/05/22 05:00
CRDT- 2004/01/06 05:00
PHST- 2004/01/06 05:00 [pubmed]
PHST- 2004/05/22 05:00 [medline]
PHST- 2004/01/06 05:00 [entrez]
AID - 00605.2003 [pii]
AID - 10.1152/ajpheart.00605.2003 [doi]
PST - ppublish
SO  - Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1750-6. doi: 
      10.1152/ajpheart.00605.2003. Epub 2004 Jan 2.

PMID- 7093867
OWN - NLM
STAT- MEDLINE
DCOM- 19820917
LR  - 20181113
IS  - 0008-4409 (Print)
IS  - 0008-4409 (Linking)
VI  - 127
IP  - 4
DP  - 1982 Aug 15
TI  - Steady-state plasma levels of salicylate in patients with rheumatoid arthritis: 
      effects of dosing interval and tablet strength.
PG  - 283-6
AB  - Forty patients who were admitted to hospital with rheumatoid arthritis received a 
      total of 3.9 g/d of enteric-coated acetylsalicylic acid (ASA) (Entrophen) 
      according to one of four dosing schedules: group 1 (n = 13), three 325-mg tablets 
      four times daily; group 2 (n = 11), two 650-mg tablets three times daily; group 3 
      (n = 10), three 650-mg tablets twice daily; and group 4 (n = 6), two 975-mg 
      tablets twice daily. Five to seven days after the start of therapy, when 
      steady-state plasma salicylate levels had been achieved, 10 blood samples, 1 per 
      hour, were collected. Three healthy volunteers who received plain ASA formed a 
      control group. There was little fluctuation in the salicylate levels over the 
      sampling period, regardless of the dosing interval, and no significant difference 
      in the fluctuations between the five groups. Likewise, there was no significant 
      difference in the mean salicylate levels at each sampling time, regardless of the 
      dosing interval or tablet strength. These results suggest that different tablet 
      strengths of enteric-coated ASA and different dosing intervals produce comparable 
      plasma salicylate levels. Less frequent dosing may improve patient acceptance of 
      salicylate therapy in the treatment of arthritis.
FAU - Keystone, E C
AU  - Keystone EC
FAU - Paton, T W
AU  - Paton TW
FAU - Littlejohn, G
AU  - Littlejohn G
FAU - Verdejo, A
AU  - Verdejo A
FAU - Piper, S
AU  - Piper S
FAU - Wright, L A
AU  - Wright LA
FAU - Goldsmith, C H
AU  - Goldsmith CH
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Med Assoc J
JT  - Canadian Medical Association journal
JID - 0414110
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Aspirin/*administration & dosage/blood
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Tablets, Enteric-Coated
PMC - PMC1861881
EDAT- 1982/08/15 00:00
MHDA- 1982/08/15 00:01
CRDT- 1982/08/15 00:00
PHST- 1982/08/15 00:00 [pubmed]
PHST- 1982/08/15 00:01 [medline]
PHST- 1982/08/15 00:00 [entrez]
PST - ppublish
SO  - Can Med Assoc J. 1982 Aug 15;127(4):283-6.

PMID- 12227646
OWN - NLM
STAT- MEDLINE
DCOM- 20030605
LR  - 20191106
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 30
IP  - 4
DP  - 2002 Jul
TI  - Effect of diaspirin crosslinked hemoglobin (DCLHb HemAssist) during high blood 
      loss surgery on selected indices of organ function.
PG  - 259-83
AB  - BACKGROUND: The safety of the hemoglobin based oxygen carrier diaspirin 
      crosslinked hemoglobin (DCLHb) has been reported only in the low (50-200 mg/kg) 
      dose range [Przybelski. R.J.; Daily, E.K.; Kisicki, J.C.; Mattia-Goldberg, C.; 
      Bounds, M.J.; Colburn, W.A. Phase I study of the safety and pharmacologic effects 
      of diaspirin crosslinked hemoglobin solution. Crit. Care Med. 1996, 24 (12), 
      1993-2000, Bloomfield, E.; Rady, M.; Popovich, M.; Esfandiari, S.; Bedocs, N. The 
      use of diaspirin crosslinked hemoglobin (DCLHb 1996, 95, (3A), A220.]. We 
      conducted a randomized prospective open-label trial of DCLHb and packed red blood 
      cells (PRBCs) in high-blood loss surgical patients to show the effect of 750 ml 
      DCLHb (approximately 1000 mg/kg) on selected indices of organ function. METHOD: 
      After institutional approval, 24 patients scheduled to undergo elective 
      orthopedic or abdominal surgery, were randomized to receive either PRBCs or 10% 
      DCLHb within 12 hours after the start of surgery. Patients with renal 
      insufficiency, abnormal liver function, severe coronary artery disease (CAD) and 
      ASA physical status > or = IV were excluded. The anesthetic technique was left to 
      the judgment of the anesthesiologist. Autologous predonation and intraoperative 
      blood conservation techniques were utilized as appropriate. The indications for 
      blood transfusion were individualized on disease state, stage of surgery, and 
      plasma Hb concentration. Laboratory studies were obtained preoperatively and up 
      to 28 days postoperatively. Patients were observed daily for development of 
      jaundice, hematuria, nausea, vomiting, gastrointestinal discomfort, cardiac, 
      respiratory, and infectious complications. Organ effects were assessed with 
      urinalysis, creatinine clearance, electrocardiogram (ECG), and a panel of blood 
      and serum laboratory tests. RESULTS: The dose of DCLHb administered ranged from 
      680-1500 mg/kg (mean = 999 mg/kg). Estimated blood loss was 27 +/- 13 ml/kg and 
      31 +/- 15 ml/kg in the control and DCLHb groups, respectively. Fewer PRBCs (1.9 
      +/- 1.2 vs. 3.4 +/- 2.4 units. P = 0.06) were transfused to DCLHb patients on the 
      operative day although this difference was no longer apparent later on. In the 
      DCLHb group, 4/12 patients avoided any allogeneic PRBC transfusion vs. none in 
      the control group (P = 0.09). Systolic, diastolic and mean blood pressure 
      increased moderately after DCLHb for a period of 24-30 hours. There were no 
      occurrences of cardiac ischemia. myocardial infarction, stroke, or pulmonary 
      edema, by clinical or laboratory parameters up to the 28th postoperative day 
      (POD). Seven of 12 (58%) DCLHb patients had yellow skin discoloration vs. none in 
      the PRBC group (P < 0.01). Two of four non-urologic surgery patients developed 
      asymptomatic postoperative hemoglobinuria after DCLHb. Creatinine clearance was 
      unchanged postoperatively. Because of hemoglobin interference, bilirubin, 
      gamma-glutamyl transferase (GGT), and amylase could not be measured reliably on 
      POD1; on POD2. amylase was transiently elevated to 3 times ULN along with mild 
      elevations of bilirubin, transaminases and BUN. Mean total creatine phoshokinase 
      (CPK) peaked at 8 times the upper limit of normal (ULN) in the DCLHb group, 
      compared with less than twice ULN for controls. Three DCLHb patients had 
      prolonged ileus. Two of these patients had postoperative hyperamylasemia, one of 
      whom developed mild pancreatitis. DCLHb did not affect white blood cell count or 
      coagulation tests. CONCLUSION: Administration of approximately 1000 mg/kg DCLHb 
      was associated with transient arterial hypertension, gastrointestinal side 
      effects, laboratory abnormalities, yellow skin discoloration, and hemoglobinuria. 
      These observations point to opportunities for improvement in future synthetic 
      hemoglobin design.
FAU - Schubert, Armin
AU  - Schubert A
AD  - Department of General Anesthesiology, The Cleveland Clinic Foundation, OH 44195, 
      USA. Schubea@ccf.org
FAU - O'Hara, Jerome F Jr
AU  - O'Hara JF Jr
FAU - Przybelski, Robert J
AU  - Przybelski RJ
FAU - Tetzlaff, John E
AU  - Tetzlaff JE
FAU - Marks, Kenneth E
AU  - Marks KE
FAU - Mascha, Edward
AU  - Mascha E
FAU - Novick, Andrew C
AU  - Novick AC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*analogs & derivatives/*pharmacology
MH  - *Blood Loss, Surgical
MH  - Blood Substitutes/*administration & dosage/pharmacology
MH  - Digestive System/drug effects
MH  - Digestive System Surgical Procedures/adverse effects
MH  - Female
MH  - Hematologic Tests
MH  - Hemoglobins/administration & dosage/*pharmacology
MH  - Hemoglobinuria/chemically induced
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Jaundice/chemically induced
MH  - Kidney Function Tests
MH  - Liver Function Tests
MH  - Male
MH  - Middle Aged
MH  - Orthopedic Procedures/adverse effects
MH  - Perioperative Care
EDAT- 2002/09/14 10:00
MHDA- 2003/06/06 05:00
CRDT- 2002/09/14 10:00
PHST- 2002/09/14 10:00 [pubmed]
PHST- 2003/06/06 05:00 [medline]
PHST- 2002/09/14 10:00 [entrez]
AID - 10.1081/bio-120006118 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 2002 Jul;30(4):259-83. doi: 
      10.1081/bio-120006118.

PMID- 25518411
OWN - NLM
STAT- MEDLINE
DCOM- 20150120
LR  - 20220317
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 72
IP  - 9
DP  - 2014 Sep
TI  - [Aspirin treatment for patients with Kawasaki disease].
PG  - 1612-6
AB  - Aspirin was first used for patients with Kawasaki disease(KD) at 1970s. Favorable 
      outcomes of KD patients treated with aspirin were reported in 1970-80s and now it 
      is one of the standard therapeutic agents for KD. Its anti-inflammation effects 
      suppress vascular wall inflammation of KD at acute phase. In addition, its 
      antiplatelet effects heal endothelial dysfunction and prevent clot formation in 
      coronary arteries at sub-acute and convalescent phase. Long-term dosage for 
      patients with coronary artery aneurysms(CAA) is also important, however, there 
      are few evidences of risk-benefit assessment for its long-term use especially for 
      middle-aged and senior adults with KD and CAA.
FAU - Hamada, Hiromichi
AU  - Hamada H
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Inflammation/drug therapy
MH  - Mucocutaneous Lymph Node Syndrome/*drug therapy
EDAT- 2014/12/19 06:00
MHDA- 2015/01/21 06:00
CRDT- 2014/12/19 06:00
PHST- 2014/12/19 06:00 [entrez]
PHST- 2014/12/19 06:00 [pubmed]
PHST- 2015/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2014 Sep;72(9):1612-6.

PMID- 25206303
OWN - NLM
STAT- MEDLINE
DCOM- 20150515
LR  - 20211021
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 9
DP  - 2014
TI  - Promoting endothelial recovery and reducing neointimal hyperplasia using 
      sequential-like release of acetylsalicylic acid and paclitaxel-loaded 
      biodegradable stents.
PG  - 4117-33
LID - 10.2147/IJN.S67721 [doi]
AB  - INTRODUCTION: This work reports on the development of a biodegradable 
      dual-drug-eluting stent with sequential-like and sustainable drug-release of 
      anti-platelet acetylsalicylic acid and anti-smooth muscle cell (SMC) 
      proliferative paclitaxel. METHODS: To fabricate the biodegradable stents, 
      poly-L-lactide strips are first cut from a solvent-casted film. They are rolled 
      onto the surface of a metal pin to form spiral stents. The stents are then 
      consecutively covered by acetylsalicylic acid and paclitaxel-loaded 
      polylactide-polyglycolide nanofibers via electrospinning. RESULTS: Biodegradable 
      stents exhibit mechanical properties that are superior to those of metallic 
      stents. Biodegradable stents sequentially release high concentrations of 
      acetylsalicylic acid and paclitaxel for more than 30 and 60 days, respectively. 
      In vitro, the eluted drugs promote endothelial cell numbers on days 3 and 7, and 
      reduce the proliferation of SMCs in weeks 2, 4, and 8. The stents markedly 
      inhibit the adhesion of platelets on days 3, 7, and 14 relative to a 
      non-drug-eluting stent. In vivo, the implanted stent is intact, and no stent 
      thrombosis is observed in the stent-implanted vessels without the administration 
      of daily oral acetylsalicylic acid. Promotion of endothelial recovery and 
      inhibition of neointimal hyperplasia are also observed on the stented vessels. 
      CONCLUSION: The work demonstrates the efficiency and safety of the biodegradable 
      dual-drug-eluting stents with sequential and sustainable drug release to diseased 
      arteries.
FAU - Lee, Cheng-Hung
AU  - Lee CH
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital-Linkou, Tao-Yuan, Taiwan ; Department of Mechanical Engineering, Chang 
      Gung University, Tao-Yuan, Taiwan.
FAU - Yu, Chia-Ying
AU  - Yu CY
AD  - Department of Mechanical Engineering, Chang Gung University, Tao-Yuan, Taiwan.
FAU - Chang, Shang-Hung
AU  - Chang SH
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital-Linkou, Tao-Yuan, Taiwan.
FAU - Hung, Kuo-Chun
AU  - Hung KC
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital-Linkou, Tao-Yuan, Taiwan.
FAU - Liu, Shih-Jung
AU  - Liu SJ
AD  - Department of Mechanical Engineering, Chang Gung University, Tao-Yuan, Taiwan.
FAU - Wang, Chao-Jan
AU  - Wang CJ
AD  - Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, 
      Linkou, Tao-Yuan, Taiwan.
FAU - Hsu, Ming-Yi
AU  - Hsu MY
AD  - Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, 
      Linkou, Tao-Yuan, Taiwan.
FAU - Hsieh, I-Chang
AU  - Hsieh IC
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital-Linkou, Tao-Yuan, Taiwan.
FAU - Chen, Wei-Jan
AU  - Chen WJ
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital-Linkou, Tao-Yuan, Taiwan.
FAU - Ko, Yu-Shien
AU  - Ko YS
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital-Linkou, Tao-Yuan, Taiwan.
FAU - Wen, Ming-Shien
AU  - Wen MS
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital-Linkou, Tao-Yuan, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140827
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (Biocompatible Materials)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (Microfilament Proteins)
RN  - 0 (Polyesters)
RN  - 0 (calponin)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 459TN2L5F5 (poly(lactide))
RN  - P88XT4IS4D (Paclitaxel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Absorbable Implants
MH  - Animals
MH  - Aorta, Abdominal/metabolism/surgery
MH  - Aspirin/chemistry/*pharmacokinetics/*pharmacology
MH  - Biocompatible Materials
MH  - Calcium-Binding Proteins/metabolism
MH  - *Drug-Eluting Stents
MH  - Electrochemical Techniques
MH  - Hyperplasia
MH  - Lactic Acid/chemistry
MH  - Male
MH  - Microfilament Proteins/metabolism
MH  - Nanotechnology
MH  - Paclitaxel/chemistry/*pharmacokinetics/*pharmacology
MH  - Platelet Adhesiveness/drug effects
MH  - Polyesters/chemistry
MH  - Polyglycolic Acid/chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Rabbits
PMC - PMC4157626
OTO - NOTNLM
OT  - biodegradable drug-eluting stents
OT  - mechanical properties
OT  - poly-L-lactide
OT  - polylactide-polyglycolide
OT  - sequential-like and sustainable release
EDAT- 2014/09/11 06:00
MHDA- 2015/05/16 06:00
CRDT- 2014/09/11 06:00
PHST- 2014/09/11 06:00 [entrez]
PHST- 2014/09/11 06:00 [pubmed]
PHST- 2015/05/16 06:00 [medline]
AID - ijn-9-4117 [pii]
AID - 10.2147/IJN.S67721 [doi]
PST - epublish
SO  - Int J Nanomedicine. 2014 Aug 27;9:4117-33. doi: 10.2147/IJN.S67721. eCollection 
      2014.

PMID- 3098781
OWN - NLM
STAT- MEDLINE
DCOM- 19870219
LR  - 20190908
IS  - 0271-6798 (Print)
IS  - 0271-6798 (Linking)
VI  - 7
IP  - 1
DP  - 1987 Jan-Feb
TI  - Ectopic bone formation in children and adolescents with head injuries: its 
      management.
PG  - 83-90
AB  - During an 11-year prospective study at Kennedy Memorial Hospital for Children 
      (Brighton, MA), ectopic bone formation occurred in 22 of 145 children and 
      adolescents admitted in coma following head injury. Subsequent deformities and 
      limitation of motion were an impediment to rehabilitation in 15 of these 
      patients, who recovered from the coma. Several bone excision procedures, either 
      alone or in conjunction with other physical and/or pharmacological modes of 
      treatment, were followed by recurrence of ectopic bone until salicylates were 
      used. The latter eliminated or minimized recurrence of ectopic bone. The study 
      suggests a useful role for salicylates not only in preventing recurrence, but 
      also in minimizing the occurrence of ectopic bone formation in these patients.
FAU - Mital, M A
AU  - Mital MA
FAU - Garber, J E
AU  - Garber JE
FAU - Stinson, J T
AU  - Stinson JT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pediatr Orthop
JT  - Journal of pediatric orthopedics
JID - 8109053
RN  - 27YLU75U4W (Phosphorus)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - M2F465ROXU (Etidronic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alkaline Phosphatase/blood
MH  - Aspirin/adverse effects/therapeutic use
MH  - Child
MH  - Craniocerebral Trauma/*complications
MH  - Etidronic Acid/adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Ossification, Heterotopic/etiology/surgery/*therapy
MH  - Phosphorus/blood
MH  - Prospective Studies
MH  - Recurrence
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1097/01241398-198701000-00017 [doi]
PST - ppublish
SO  - J Pediatr Orthop. 1987 Jan-Feb;7(1):83-90. doi: 10.1097/01241398-198701000-00017.

PMID- 6819169
OWN - NLM
STAT- MEDLINE
DCOM- 19830407
LR  - 20161123
IS  - 0338-1684 (Print)
IS  - 0338-1684 (Linking)
VI  - 8
IP  - 4
DP  - 1982 Dec
TI  - Influence of acetylsalicylic acid on glucose turnover in normal man.
PG  - 279-82
AB  - This study was designed to evaluate the influence of intravenous infusion (72 mg 
      min-1) of lysine acetylsalicylate (LAS), an inhibitor of endogenous prostaglandin 
      synthesis, on glucose homeostasis in normal man. LAS infusion produced a 
      transient decrease of both hepatic glucose production (Ra, p less than 0.01) and 
      peripheral glucose uptake (Rd, p less than 0.01). Since Ra fell more than Rd, a 
      slight but significant decrease of plasma glucose concentration occurred. Glucose 
      metabolic clearance rate also showed a rapid, although transient, decrease after 
      the start of LAS infusion. Plasma insulin rose twofold in response to LAS, while 
      plasma glucagon remained unchanged. The failure of the glucose clearance to 
      increase as a consequence of the augmented insulin levels suggests that 
      salicylate compounds may cause a state of insulin resistance.
FAU - Giugliano, D
AU  - Giugliano D
FAU - Sacca, L
AU  - Sacca L
FAU - Scognamiglio, G
AU  - Scognamiglio G
FAU - Ungaro, B
AU  - Ungaro B
FAU - Torella, R
AU  - Torella R
LA  - eng
PT  - Journal Article
PL  - France
TA  - Diabete Metab
JT  - Diabete & metabolisme
JID - 7604157
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 9007-92-5 (Glucagon)
RN  - IY9XDZ35W2 (Glucose)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Glucose/analysis
MH  - Female
MH  - Glucagon/blood
MH  - Glucose/*metabolism
MH  - Humans
MH  - Insulin/blood
MH  - Kinetics
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
MH  - Middle Aged
EDAT- 1982/12/01 00:00
MHDA- 2000/03/11 09:00
CRDT- 1982/12/01 00:00
PHST- 1982/12/01 00:00 [pubmed]
PHST- 2000/03/11 09:00 [medline]
PHST- 1982/12/01 00:00 [entrez]
PST - ppublish
SO  - Diabete Metab. 1982 Dec;8(4):279-82.

PMID- 20214591
OWN - NLM
STAT- MEDLINE
DCOM- 20100528
LR  - 20191027
IS  - 1875-5453 (Electronic)
IS  - 1389-2002 (Linking)
VI  - 10
IP  - 9
DP  - 2009 Nov
TI  - Pharmacogenomics in aspirin intolerance.
PG  - 998-1008
AB  - Polymorphisms in drug-related enzymes and receptors are often strongly related to 
      altered drug response and to the risk of developing drug intolerance. Aspirin, 
      usually available as an over-the-counter drug, is one of the most used drugs 
      worldwide and is a common cause of drug intolerance events. Aspirin undergoes 
      polymorphic metabolism. Among the enzymes involved in aspirin biodisposition a 
      major role is played by the enzymes UDP-glucuronosyltransferase UGT1A6, 
      cytochrome P450 CYP2C9 and the xenobiotic/medium chain fatty acid:CoA ligase 
      ACSM2, although other UGTs and ACSMs enzymes may significantly contribute to 
      aspirin metabolism. UGT1A6, CYP2C9 and ACSM2 are polymorphic, as well as PTGS1 
      and PTGS2, the genes coding for the enzymes cyclo-oxygenases COX1 and COX2, 
      respectively. The present review analyzes the importance of genetic variations in 
      enzymes involved in the metabolism and in the effects of aspirin and common 
      polymorphisms related to aspirin intolerance, and it raises hypotheses on genetic 
      factors related to altered response to aspirin that require further 
      investigation. Major polymorphisms related to aspirin biodisposition are 
      rs2070959, rs1105879 and rs6759892 for the UGT1A6 gene, rs1133607 for the ACSM2 
      gene, and rs1799853, rs1057910, rs28371686, rs9332131 and rs28371685 for the 
      CYP2C9 gene. Regarding aspirin effects, major PGTS1 targets are rs3842787 and 
      rs5789 for European subjects, and rs3842789 and rs3842792 for African subjects. 
      For the PTGS2 gene nonsynonymous SNPs are likely to be of low relevance because 
      of the influence of transcriptional and posttranscriptional factors. Combined 
      studies for the above mentioned polymorphisms and those corresponding to other 
      genes related to aspirin intolerance will provide excellent tools to identify 
      individuals with a high risk to develop intolerance to aspirin.
FAU - Agúndez, José A G
AU  - Agúndez JA
AD  - Department of Pharmacology, Medical School University of Extremadura, Avda. de 
      Elvas s/n, Badajoz, Spain. jagundez@unex.es
FAU - Martínez, Carmen
AU  - Martínez C
FAU - Pérez-Sala, Dolores
AU  - Pérez-Sala D
FAU - Carballo, Miguel
AU  - Carballo M
FAU - Torres, María José
AU  - Torres MJ
FAU - García-Martín, Elena
AU  - García-Martín E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Curr Drug Metab
JT  - Current drug metabolism
JID - 100960533
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacokinetics
MH  - Aspirin/*adverse effects/pharmacokinetics
MH  - Biotransformation/genetics
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - *Pharmacogenetics
MH  - Phenotype
MH  - Polymorphism, Genetic
MH  - Risk Assessment
MH  - Risk Factors
RF  - 100
EDAT- 2010/03/11 06:00
MHDA- 2010/05/29 06:00
CRDT- 2010/03/11 06:00
PHST- 2010/03/11 06:00 [entrez]
PHST- 2010/03/11 06:00 [pubmed]
PHST- 2010/05/29 06:00 [medline]
AID - 10.2174/138920009790711814 [doi]
PST - ppublish
SO  - Curr Drug Metab. 2009 Nov;10(9):998-1008. doi: 10.2174/138920009790711814.

PMID- 31279757
OWN - NLM
STAT- MEDLINE
DCOM- 20200122
LR  - 20200122
IS  - 1878-8769 (Electronic)
IS  - 1878-8750 (Linking)
VI  - 129
DP  - 2019 Sep
TI  - Timing of Low-Dose Aspirin Discontinuation and the Influence on Clinical Outcome 
      of Patients Undergoing Surgery for Chronic Subdural Hematoma.
PG  - e695-e699
LID - S1878-8750(19)31529-3 [pii]
LID - 10.1016/j.wneu.2019.05.252 [doi]
AB  - BACKGROUND: An appropriate time (5-7 days) of discontinuation of low-dose 
      acetylsalicylic acid (ASA) in patients undergoing surgery for chronic subdural 
      hematoma (CSDH) is recommended. However, patient clinical deterioration often 
      does not allow to wait the recommended time for surgery. Clear guidelines 
      regarding the perioperative management of patients with ASA therapy are still 
      lacking. The aim of this study is to compare the surgical outcome, complications, 
      and mortality of patients suffering from CSDHs who underwent urgent surgery or 
      before and after 5 days of discontinuation of low-dose ASA. METHODS: A 
      retrospective 3-center study included patients treated for CSDH taking low-dose 
      ASA. Aspirin was discontinued on hospital admission. Based on the timing of 
      discontinuation, we classified patients in 3 groups: urgent (surgery at 
      admission), surgery within 5 days, and surgery 5 days after discontinuation. 
      Surgery consisted of minicraniotomy or burr holes. Variables analyzed were age, 
      comorbidities, modified Rankin Scale, complications, rebleedings, and mortality. 
      Outcome measures were acute rebleeding requiring surgery, recurrence, mortality, 
      complications, and clinical conditions. The χ(2) test and the Fisher exact test 
      were used to compare variables. Logistic regression analysis was used for 
      defining the impact on outcome measures. RESULTS: We enrolled 164 patients. After 
      aspirin discontinuation, patients underwent surgery: on admission (69 cases 
      [42.1%]), within 5 days (59 patients [36%]), and after 5 days (36 cases [22%]). 
      No correlation was observed between time of discontinuation and outcome measures, 
      including having a worse clinical outcome. CONCLUSIONS: Our data showed that the 
      time of discontinuation of ASA does not influence outcome.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Scerrati, Alba
AU  - Scerrati A
AD  - Neurosurgery Division, Department of Morphology, Surgery, and Experimental 
      Medicine, Ferrara University, Hospital S. Anna, Ferrara, Italy. Electronic 
      address: a.scerrati@gmail.com.
FAU - Germanò, Antonino
AU  - Germanò A
AD  - Neurosurgical Clinic, Department of Neurosciences, University of Messina, 
      Messina, Italy.
FAU - Trevisi, Gianluca
AU  - Trevisi G
AD  - Department of Neurosurgery, Chieti University G. D'Annunzio, Santo Spirito 
      Hospital, Pescara, Italy.
FAU - Visani, Jacopo
AU  - Visani J
AD  - Neurosurgery Division, Department of Morphology, Surgery, and Experimental 
      Medicine, Ferrara University, Hospital S. Anna, Ferrara, Italy.
FAU - Lofrese, Giorgio
AU  - Lofrese G
AD  - Neurosurgery Division, "M. Bufalini" Hospital, Cesena, Italy.
FAU - D'Angelo, Luca
AU  - D'Angelo L
AD  - Neurosurgery Division, Department of Morphology, Surgery, and Experimental 
      Medicine, Ferrara University, Hospital S. Anna, Ferrara, Italy.
FAU - Raffa, Giovanni
AU  - Raffa G
AD  - Neurosurgical Clinic, Department of Neurosciences, University of Messina, 
      Messina, Italy.
FAU - Fazzari, Elena
AU  - Fazzari E
AD  - Neurosurgical Clinic, Department of Neurosciences, University of Messina, 
      Messina, Italy.
FAU - Mangiola, Annunziato
AU  - Mangiola A
AD  - Department of Neurosurgery, Chieti University G. D'Annunzio, Santo Spirito 
      Hospital, Pescara, Italy.
FAU - Cavallo, Michele Alessandro
AU  - Cavallo MA
AD  - Neurosurgery Division, Department of Morphology, Surgery, and Experimental 
      Medicine, Ferrara University, Hospital S. Anna, Ferrara, Italy.
FAU - De Bonis, Pasquale
AU  - De Bonis P
AD  - Neurosurgery Division, Department of Morphology, Surgery, and Experimental 
      Medicine, Ferrara University, Hospital S. Anna, Ferrara, Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20190611
PL  - United States
TA  - World Neurosurg
JT  - World neurosurgery
JID - 101528275
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Hematoma, Subdural, Chronic/*surgery
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thrombosis/*prevention & control
MH  - Time Factors
MH  - Treatment Outcome
MH  - Withholding Treatment
OTO - NOTNLM
OT  - ASA discontinuation
OT  - CSDH
OT  - Chronic subdural hematoma
OT  - Clinical outcome
OT  - Low-dose ASA
OT  - Rebleeding
EDAT- 2019/07/08 06:00
MHDA- 2020/01/23 06:00
CRDT- 2019/07/08 06:00
PHST- 2019/04/19 00:00 [received]
PHST- 2019/05/29 00:00 [revised]
PHST- 2019/05/30 00:00 [accepted]
PHST- 2019/07/08 06:00 [pubmed]
PHST- 2020/01/23 06:00 [medline]
PHST- 2019/07/08 06:00 [entrez]
AID - S1878-8750(19)31529-3 [pii]
AID - 10.1016/j.wneu.2019.05.252 [doi]
PST - ppublish
SO  - World Neurosurg. 2019 Sep;129:e695-e699. doi: 10.1016/j.wneu.2019.05.252. Epub 
      2019 Jun 11.

PMID- 23035985
OWN - NLM
STAT- MEDLINE
DCOM- 20130516
LR  - 20211021
IS  - 1520-5010 (Electronic)
IS  - 0893-228X (Print)
IS  - 0893-228X (Linking)
VI  - 25
IP  - 12
DP  - 2012 Dec 17
TI  - Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs 
      masquerading as nitric oxide.
PG  - 2725-36
LID - 10.1021/tx3003609 [doi]
AB  - The promising therapeutic potential of the NO-donating hybrid aspirin prodrugs 
      (NO-ASA) includes induction of chemopreventive mechanisms and has been reported 
      in almost 100 publications. One example, NCX-4040 (pNO-ASA), is bioactivated by 
      esterase to a quinone methide (QM) electrophile. In cell cultures, pNO-ASA and 
      QM-donating X-ASA prodrugs that cannot release NO rapidly depleted intracellular 
      GSH and caused DNA damage; however, induction of Nrf2 signaling elicited cellular 
      defense mechanisms including upregulation of NAD(P)H:quinone oxidoreductase-1 
      (NQO1) and glutamate-cysteine ligase (GCL). In HepG2 cells, the "NO-specific" 
      4,5-diaminofluorescein reporter, DAF-DA, responded to NO-ASA and X-ASA, with 
      QM-induced oxidative stress masquerading as NO. LC-MS/MS analysis demonstrated 
      efficient alkylation of Cys residues of proteins including 
      glutathione-S-transferase-P1 (GST-P1) and Kelch-like ECH-associated protein 1 
      (Keap1). Evidence was obtained for alkylation of Keap1 Cys residues associated 
      with Nrf2 translocation to the nucleus, nuclear translocation of Nrf2, activation 
      of antioxidant response element (ARE), and upregulation of cytoprotective target 
      genes. At least in cell culture, pNO-ASA acts as a QM donor, bioactivated by 
      cellular esterase activity to release salicylates, NO(3)(-), and an electrophilic 
      QM. Finally, two novel aspirin prodrugs were synthesized, both potent activators 
      of ARE, designed to release only the QM and salicylates on bioactivation. Current 
      interest in electrophilic drugs acting via Nrf2 signaling suggests that 
      QM-donating hybrid drugs can be designed as informative chemical probes in drug 
      discovery.
FAU - Dunlap, Tareisha
AU  - Dunlap T
AD  - Department of Medicinal Chemistry & Pharmacognosy, University of Illinois College 
      of Pharmacy, 833 South Wood Street, Chicago, Illinois 60612, United States.
FAU - Piyankarage, Sujeewa C
AU  - Piyankarage SC
FAU - Wijewickrama, Gihani T
AU  - Wijewickrama GT
FAU - Abdul-Hay, Samer
AU  - Abdul-Hay S
FAU - Vanni, Michael
AU  - Vanni M
FAU - Litosh, Vladislav
AU  - Litosh V
FAU - Luo, Jia
AU  - Luo J
FAU - Thatcher, Gregory R J
AU  - Thatcher GR
LA  - eng
GR  - R01 CA102590/CA/NCI NIH HHS/United States
GR  - CA102590/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20121018
PL  - United States
TA  - Chem Res Toxicol
JT  - Chemical research in toxicology
JID - 8807448
RN  - 0 (Indolequinones)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (KEAP1 protein, human)
RN  - 0 (Kelch-Like ECH-Associated Protein 1)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - 0 (Prodrugs)
RN  - 138230-21-4 (quinone methide)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.6.5.2 (NAD(P)H Dehydrogenase (Quinone))
RN  - EC 1.6.5.2 (Nqo1 protein, mouse)
RN  - EC 2.5.1.18 (Glutathione S-Transferase pi)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Cell Line, Tumor
MH  - DNA Damage
MH  - Glutathione/metabolism
MH  - Glutathione S-Transferase pi/metabolism
MH  - Humans
MH  - Indolequinones/*metabolism
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Kelch-Like ECH-Associated Protein 1
MH  - Mice
MH  - NAD(P)H Dehydrogenase (Quinone)/metabolism
MH  - NF-E2-Related Factor 2/*metabolism
MH  - Nitric Oxide/metabolism
MH  - Prodrugs/*pharmacology
PMC - PMC3896098
MID - NIHMS416316
EDAT- 2012/10/06 06:00
MHDA- 2013/05/17 06:00
CRDT- 2012/10/06 06:00
PHST- 2012/10/06 06:00 [entrez]
PHST- 2012/10/06 06:00 [pubmed]
PHST- 2013/05/17 06:00 [medline]
AID - 10.1021/tx3003609 [doi]
PST - ppublish
SO  - Chem Res Toxicol. 2012 Dec 17;25(12):2725-36. doi: 10.1021/tx3003609. Epub 2012 
      Oct 18.

PMID- 2086198
OWN - NLM
STAT- MEDLINE
DCOM- 19910522
LR  - 20131121
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 18
IP  - 5
DP  - 1990 Oct
TI  - [Effects of the combination of aspirin and nifedipine on platelet aggregation and 
      thrombogenesis].
PG  - 301-3, 319
AB  - The effects of nifedipine (Nif), aspirin (ASA) and ASA + Nif on platelet 
      aggregation and generation of thrombosis were studied. Both ASA and Nif inhibited 
      rabbit platelet aggregation in vitro and rat platelet aggregation in vivo induced 
      by ADP, also prolonged the occlusion time of thrombosis induced electrically in 
      the carotid artery of the rat and reduced the death rate resulting from pulmonary 
      thrombosis induced by i.v collagen and epinephrine in mice. The above effects 
      were markedly increased when Nif and ASA were used in combination. All the above 
      effects were dose-dependent.
FAU - Dong, E
AU  - Dong E
AD  - Shi Shan Laboratory of Cardiovascular Research, Baotou Medical College.
FAU - Shi, S
AU  - Shi S
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Drug Synergism
MH  - Female
MH  - Male
MH  - Nifedipine/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rabbits
MH  - Rats
MH  - Thrombosis/*prevention & control
EDAT- 1990/10/01 00:00
MHDA- 1990/10/01 00:01
CRDT- 1990/10/01 00:00
PHST- 1990/10/01 00:00 [pubmed]
PHST- 1990/10/01 00:01 [medline]
PHST- 1990/10/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 1990 Oct;18(5):301-3, 319.

PMID- 7130497
OWN - NLM
STAT- MEDLINE
DCOM- 19821218
LR  - 20190709
IS  - 0190-9622 (Print)
IS  - 0190-9622 (Linking)
VI  - 7
IP  - 3
DP  - 1982 Sep
TI  - Antiplatelet therapy in atrophie blanche and livedo vasculitis.
PG  - 359-63
AB  - Seven patients with atrophie blanche or livedo vasculitis of the lower 
      extremities showed abnormal platelet functions in vitro. Six of seven showed 
      hyperaggregation with epinephrine and/or collagen, three showed increased 
      platelet adhesiveness, three showed increased platelet count, and one showed 
      increased microemboli. After treatment with dipyridamole and aspirin, all showed 
      return to normal platelet function. Clinical improvement occurred in all 
      patients, with significant alleviation of pain and decrease in new lesion 
      formation. Although enhanced healing of lesions seemed evident to physician and 
      patient, it was incomplete. In two patients, pain returned when dipyridamole and 
      aspirin were stopped, but the patients improved again when the medicines were 
      restarted. These preliminary findings indicate a possible beneficial effect of 
      antiplatelet therapy in atrophie blanche and livedo vasculitis. A double-blind 
      study is being undertaken to further study this effect.
FAU - Drucker, C R
AU  - Drucker CR
FAU - Duncan, W C
AU  - Duncan WC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Atrophy
MH  - Blood Platelets/*drug effects
MH  - Dipyridamole/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Function Tests
MH  - Skin Diseases/*drug therapy
MH  - Vasculitis/*drug therapy
EDAT- 1982/09/01 00:00
MHDA- 1982/09/01 00:01
CRDT- 1982/09/01 00:00
PHST- 1982/09/01 00:00 [pubmed]
PHST- 1982/09/01 00:01 [medline]
PHST- 1982/09/01 00:00 [entrez]
AID - S0190-9622(82)70123-9 [pii]
AID - 10.1016/s0190-9622(82)70123-9 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 1982 Sep;7(3):359-63. doi: 10.1016/s0190-9622(82)70123-9.

PMID- 2766902
OWN - NLM
STAT- MEDLINE
DCOM- 19890925
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 34
IP  - 9
DP  - 1989 Sep
TI  - Persistence of gastric ulcers caused by plain aspirin or nonsteroidal 
      antiinflammatory agents in patients treated with a combination of cimetidine, 
      antacids, and enteric-coated aspirin.
PG  - 1361-4
AB  - Twenty-three patients chronically ingesting plain aspirin or nonsteroidal 
      antiinflammatory drugs, who had endoscopically proven solitary or multiple 
      gastric ulcers, were treated for eight weeks with cimetidine and antacids. Plain 
      aspirin and nonsteroidal antiinflammatory drugs were discontinued in all 
      patients. Seven patients received enteric-coated aspirin throughout the treatment 
      phase and continuously for the entire study period (2.5-12 months). The remainder 
      of patients (N = 16) did not receive enteric-coated aspirin. An endoscopy was 
      performed to assess ulcer healing. None of seven patients receiving 
      enteric-coated aspirin had complete healing of their ulcer(s) while 15 of 16 
      patients not receiving enteric-coated aspirin demonstrated complete healing of 
      their ulcer(s) (P less than 0.001). An eight-week course of cimetidine and 
      antacids is ineffective in completely healing gastric ulcers caused by plain 
      aspirin or nonsteroidal antiinflammatory drugs while enteric-coated aspirin is 
      continued.
FAU - Jaszewski, R
AU  - Jaszewski R
AD  - Division of Gastroenterology, Veterans Administration Medical Center, Allen Park, 
      Michigan 48101.
FAU - Calzada, R
AU  - Calzada R
FAU - Dhar, R
AU  - Dhar R
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Antacids)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 80061L1WGD (Cimetidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antacids/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cimetidine/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/drug therapy
MH  - Prospective Studies
MH  - Stomach Ulcer/chemically induced/*drug therapy
MH  - Tablets, Enteric-Coated
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
AID - 10.1007/BF01538069 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1989 Sep;34(9):1361-4. doi: 10.1007/BF01538069.

PMID- 19678751
OWN - NLM
STAT- MEDLINE
DCOM- 20091127
LR  - 20131121
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 25
IP  - 10
DP  - 2009 Oct
TI  - Platelet inhibitory effects of OTC doses of naproxen sodium compared with 
      prescription dose naproxen sodium and low-dose aspirin.
PG  - 2471-7
LID - 10.1185/03007990903185706 [doi]
AB  - OBJECTIVES: Prescription dose naproxen has been reported to have an antiplatelet 
      effect similar to low-dose aspirin (ASA). This study evaluated the platelet 
      inhibitory effects of over-the-counter (OTC) doses of naproxen sodium (NAPSO) 
      compared to that of a prescription dose of NAPSO and to low-dose enteric-coated 
      aspirin (EC-ASA). RESEARCH DESIGN AND METHODS: This was a phase I, open-label, 
      randomized, placebo-controlled, two-way crossover, multi-dose, pharmacodynamic 
      trial conducted in healthy male and female volunteers (n = 48, mean age = 41.7 
      years). All subjects received 7 days of either prescription dose NAPSO (550 mg 
      twice daily), OTC doses of NAPSO (220 mg two or three times daily), or placebo 
      twice daily (period 1). After a minimum 6-day washout period, all subjects then 
      received 7 days of EC-ASA 81 mg once daily (period 2). All study medications were 
      taken by mouth. PRIMARY OUTCOME MEASURE: Inhibition of serum thromboxane B(2) 
      (TXB(2)), as a marker of platelet cyclooxygenase-1 (COX-1) inhibition, measured 
      24 h after the day 7 morning dose. This was measured after both period 1 and 
      period 2. RESULTS: After 7 days of treatment in period 1, mean inhibition of 
      TXB(2) was 47% for placebo and > or =98% for all doses of NAPSO. After 7 days of 
      EC-ASA 81 mg, mean inhibition of TXB(2) was > or = 97% (period 2). STUDY 
      LIMITATIONS: Out-patient study setting. CONCLUSIONS: These data suggest that OTC 
      doses of NAPSO (220 mg two or three times daily) have an antiplatelet effect 
      similar to EC-ASA 81 mg and to prescription dose NAPSO (550 mg twice daily).
FAU - Schiff, Michael
AU  - Schiff M
AD  - University of Colorado, Denver, CO, USA. lmschiff@aol.com
FAU - Hochberg, Marc C
AU  - Hochberg MC
FAU - Oldenhof, John
AU  - Oldenhof J
FAU - Brune, Kay
AU  - Brune K
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naproxen/*pharmacology/therapeutic use
MH  - *Nonprescription Drugs
MH  - Placebos
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Reference Values
MH  - Thromboxane B2/blood
EDAT- 2009/08/15 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/08/15 09:00
PHST- 2009/08/15 09:00 [entrez]
PHST- 2009/08/15 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 10.1185/03007990903185706 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2009 Oct;25(10):2471-7. doi: 10.1185/03007990903185706.

PMID- 1911573
OWN - NLM
STAT- MEDLINE
DCOM- 19911104
LR  - 20191028
IS  - 0894-1939 (Print)
IS  - 0894-1939 (Linking)
VI  - 4
IP  - 3
DP  - 1991
TI  - Modification of the thrombogenicity of a self-expanding vascular stent.
PG  - 269-78
AB  - When placed in the iliac arteries of normal healthy animals, the Wall-stent 
      self-expanding endovascular prosthesis exhibits minimal thrombogenicity, measured 
      by 111In-labeled platelet uptake. Preliminary clinical reports suggest a greater 
      thrombogenicity in diseased human arteries. When evaluated in an ex vivo shunt, 
      these stents exhibit significant thrombogenicity. The ex vivo shunt may therefore 
      provide a model to evaluate strategies to reduce thrombogenicity in the clinical 
      setting. Stents were released into shunts and the uptake of In111-labeled 
      platelets was measured by gamma imaging for 2 h at a flow rate of 100 mL/min. The 
      effect of systemic heparin, 100 U/kg, oral aspirin, 325 mg, and local application 
      of heparin-benzalkonium chloride complex were evaluated. At the end of each study 
      the stents were fixed in situ and evaluated with scanning electron microscopy 
      (SEM). Control stents exhibited a rapid, significant uptake of platelet 
      associated 111In activity, which reached a maximum in approximately 1 h. 
      Twenty-two percent of control stents occluded before 2 h. Aspirin reduced maximum 
      platelet uptake by 46%. Systemic heparin, with a clotting time greater than five 
      times control, reduced maximum platelet uptake by 86%. The benzalkonium-heparin 
      complex coating, with no increase in clotting time, reduced maximum platelet 
      uptake by 84%. No occlusions were observed with the anti-thrombotic regimes. SEM 
      evaluation of the stents supports the results of the isotope uptake studies.
FAU - Breckwoldt, W L
AU  - Breckwoldt WL
AD  - Department of Surgery, New England Medical Center, Boston, MA 02111.
FAU - Belkin, M
AU  - Belkin M
FAU - Gould, K
AU  - Gould K
FAU - Allen, M
AU  - Allen M
FAU - Connolly, R J
AU  - Connolly RJ
FAU - Termin, P
AU  - Termin P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Invest Surg
JT  - Journal of investigative surgery : the official journal of the Academy of 
      Surgical Research
JID - 8809255
RN  - 0 (Indium Radioisotopes)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Vessel Prosthesis/*adverse effects
MH  - Dogs
MH  - Female
MH  - Heparin/pharmacology
MH  - Indium Radioisotopes
MH  - Male
MH  - Microscopy, Electron, Scanning
MH  - *Stents
MH  - Thrombosis/*prevention & control
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.3109/08941939109141159 [doi]
PST - ppublish
SO  - J Invest Surg. 1991;4(3):269-78. doi: 10.3109/08941939109141159.

PMID- 2265681
OWN - NLM
STAT- MEDLINE
DCOM- 19910213
LR  - 20190816
IS  - 0014-4835 (Print)
IS  - 0014-4835 (Linking)
VI  - 51
IP  - 6
DP  - 1990 Dec
TI  - Effect of acetylation by aspirin on the thermodynamic stability of lens 
      crystallins.
PG  - 701-9
AB  - To assess the effect of aspirin on cataractogenesis, we compared the stability of 
      individual, native protein fractions alpha L, beta H, beta L, beta s, beta B2, 
      gamma-II, gamma-III and gamma-IV with that of their acetylated counterparts. The 
      conformational stabilities of native fractions beta B2 and beta s, which were not 
      reported earlier, were determined first from their thermal and a thermal 
      denaturation behaviour. Since alpha L, beta H and beta L fractions are 
      oligomeric, no thermodynamic analysis of these fractions was attempted. The 
      thermal stability of beta s and beta B2 is rather low; their melting temperature 
      (T1/2) range is 58-60 degrees C compared with 67-75 degrees C for the 
      gamma-crystallins. Furthermore, except for alpha L, which remains stable even at 
      100 degrees C, and beta B2, all crystallins aggregate at temperatures slightly 
      above T1/2. The Gibbs free energy of unfolding, delta GH2OD, calculated from 
      guanidine HCl (GdnHCl) denaturation, is surprising low (3-9 kcal mol-1) for all 
      crystallin fractions. The low values of delta GH2OD indicate that the structural 
      destabilization of these proteins, which may lead to cataract formation, could 
      result from a slight disturbance of a particular kind (sugar, UV light, 
      oxidation, and other factors). The overall effect of acetylation on the 
      individual crystallin fractions is mixed. The thermal stability of beta B2 
      increased, tended to decrease in the case of gamma-crystallins, but remained 
      virtually unchanged for other proteins. Delta GH2OD values of the native 
      crystallin fractions do not differ significantly from those of their acetylated 
      counterparts.
FAU - Sen, A C
AU  - Sen AC
AD  - Eye Research Institute, Boston, MA 02114.
FAU - Chakrabarti, B
AU  - Chakrabarti B
LA  - eng
GR  - EY04161/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 0 (Crystallins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cataract/etiology
MH  - Cattle
MH  - Circular Dichroism
MH  - Crystallins/*drug effects
MH  - Hot Temperature
MH  - Protein Conformation/drug effects
MH  - Protein Denaturation
MH  - Thermodynamics
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
AID - 10.1016/0014-4835(90)90055-y [doi]
PST - ppublish
SO  - Exp Eye Res. 1990 Dec;51(6):701-9. doi: 10.1016/0014-4835(90)90055-y.

PMID- 29869943
OWN - NLM
STAT- MEDLINE
DCOM- 20191114
LR  - 20191114
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 30
IP  - 5
DP  - 2019
TI  - The effects of aspirin and ticagrelor on Toll-like receptor (TLR)-mediated 
      platelet activation: results of a randomized, cross-over trial.
PG  - 599-607
LID - 10.1080/09537104.2018.1479520 [doi]
AB  - Platelet activation underlies the pathology of an acute myocardial infarction 
      (AMI), and dual antiplatelet therapy (DAPT) is administered post-AMI to limit 
      this activation. Platelets express Toll-like receptors (TLRs) 1, 2, and 4 and 
      become potently activated in response to TLR2/1 and TLR4 stimulation. However, it 
      is unknown whether antiplatelet agents can protect against platelet activation 
      via these TLR pathways. This study aimed to determine the extent to which 
      TLR-mediated platelet activation can be inhibited by currently used antiplatelet 
      agents. Ten healthy subjects were enrolled into a single-blinded randomized 
      cross-over trial. Subjects received either aspirin monotherapy or DAPT (aspirin 
      in combination with ticagrelor) for 1 week, were washed out, and crossed over to 
      the other drug regimen. Platelet activation was assessed in response to Pam3CSK4 
      (a TLR2/1 agonist) and lipopolysaccharide (LPS; a TLR4 agonist) at baseline and 
      after each antiplatelet drug regimen. Platelet-surface expression of CD62p and 
      PAC1 by flow cytometry was measured as markers of platelet activation. At 
      baseline, expression of CD62p and PAC1 increased significantly in response to 
      high-dose LPS and in a dose-dependent manner in response to Pam3CSK4. Aspirin 
      monotherapy did not inhibit platelet activation in response to any TLR agonist 
      tested. DAPT with aspirin and ticagrelor only modestly inhibited expression of 
      both activation markers in response to high doses of Pam3CSK4 and LPS. However, 
      incubation with these TLR agonists led to substantial platelet activation despite 
      treatment with these anti-platelet agents. Platelet-TLR2/1 and platelet-TLR4 
      represent intact on-treatment platelet activation pathways, which may contribute 
      to on-going platelet activation post-AMI.
FAU - Hally, Kathryn E
AU  - Hally KE
AD  - a School of Biological Sciences , Victoria University of Wellington , Wellington 
      , New Zealand.
AD  - b Wellington Cardiovascular Research Group , Wellington , New Zealand.
FAU - La Flamme, Anne C
AU  - La Flamme AC
AD  - a School of Biological Sciences , Victoria University of Wellington , Wellington 
      , New Zealand.
AD  - b Wellington Cardiovascular Research Group , Wellington , New Zealand.
FAU - Harding, Scott A
AU  - Harding SA
AD  - a School of Biological Sciences , Victoria University of Wellington , Wellington 
      , New Zealand.
AD  - b Wellington Cardiovascular Research Group , Wellington , New Zealand.
AD  - c Department of Cardiology , Wellington Hospital , Wellington , New Zealand.
FAU - Larsen, Peter D
AU  - Larsen PD
AD  - a School of Biological Sciences , Victoria University of Wellington , Wellington 
      , New Zealand.
AD  - b Wellington Cardiovascular Research Group , Wellington , New Zealand.
AD  - d Department of Surgery and Anaesthesia , University of Otago , Wellington , New 
      Zealand.
LA  - eng
PT  - Journal Article
DEP - 20180605
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Toll-Like Receptors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Biomarkers
MH  - Blood Platelets/*drug effects/*metabolism
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Signal Transduction
MH  - Ticagrelor/*pharmacology/therapeutic use
MH  - Toll-Like Receptors/*metabolism
OTO - NOTNLM
OT  - Antiplatelets
OT  - Toll-like receptors
OT  - antiplatelet therapy
OT  - aspirin
OT  - platelet activation
OT  - platelets
OT  - ticagrelor
EDAT- 2018/06/06 06:00
MHDA- 2019/11/15 06:00
CRDT- 2018/06/06 06:00
PHST- 2018/06/06 06:00 [pubmed]
PHST- 2019/11/15 06:00 [medline]
PHST- 2018/06/06 06:00 [entrez]
AID - 10.1080/09537104.2018.1479520 [doi]
PST - ppublish
SO  - Platelets. 2019;30(5):599-607. doi: 10.1080/09537104.2018.1479520. Epub 2018 Jun 
      5.

PMID- 22853771
OWN - NLM
STAT- MEDLINE
DCOM- 20121015
LR  - 20141120
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 156
IP  - 31
DP  - 2012
TI  - [A young man with recurrent chest pain].
PG  - A4850
AB  - BACKGROUND: Pericarditis is seen quite often in daily clinical practice. It is a 
      condition that is fairly easy to diagnose, but which frequently recurs. CASE 
      DESCRIPTION: A 23-year-old man suffered from recurring episodes of chest pain 
      which, following further investigation, appeared to be a result of pericarditis. 
      MRI revealed indications for acute exacerbation of chronic pericarditis. 
      Additional investigation showed no underlying cause for the pericarditis. After 
      long-term medication with calcium carbasalate and colchicine there was no 
      recurrence and the patient was able to function as before. CONCLUSION: Chest pain 
      in young people can be a symptom of pericarditis. This condition quite often 
      recurs, but in most patients no underlying cause is revealed. Adequate medication 
      with calcium carbasalate and colchicine reduces the chance of recurrence.
FAU - Steenmeijer, Rik
AU  - Steenmeijer R
AD  - Isala Klinieken, Afd. Cardiologie, Zwolle, the Netherlands.
FAU - Dambrink, Jan-Henk H E
AU  - Dambrink JH
FAU - Boomsma, Martijn F
AU  - Boomsma MF
LA  - dut
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Een jonge man met recidiverende pijn op de borst.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 8W8T17847W (Urea)
RN  - N667F17JP1 (carbaspirin calcium)
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Chest Pain/*diagnosis/drug therapy/epidemiology/etiology
MH  - Colchicine/therapeutic use
MH  - Diagnosis, Differential
MH  - Humans
MH  - Male
MH  - Pericarditis/*diagnosis/drug therapy/epidemiology/etiology
MH  - Secondary Prevention
MH  - Urea/analogs & derivatives/therapeutic use
MH  - Young Adult
EDAT- 2012/08/03 06:00
MHDA- 2012/10/16 06:00
CRDT- 2012/08/03 06:00
PHST- 2012/08/03 06:00 [entrez]
PHST- 2012/08/03 06:00 [pubmed]
PHST- 2012/10/16 06:00 [medline]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2012;156(31):A4850.

PMID- 14512697
OWN - NLM
STAT- MEDLINE
DCOM- 20040218
LR  - 20171101
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 69
IP  - 3
DP  - 2003 Nov
TI  - Inhibition of spinal reflexes by acetylsalicylate and metamizol (dipyrone) in 
      rats.
PG  - 123-6
AB  - The effects of acetylsalicylate and metamizol on spinal monosynaptic reflexes 
      were tested in spinal rats. Adult rats were anesthetized with ketamine, 
      artificially ventilated, and spinalized at the C1 level. A laminectomy was 
      performed in the lumbosacral region. Following electrical stimulation of the 
      sciatic nerve by single pulses, the reflex potentials were recorded from the 
      ipsilateral L5 ventral root. Acetylsalicylate was administered orally via 
      nasogastric tube and metamizol intramuscularly. Acetylsalicylate (50 and 100 
      mg/kg) and metamizol (15 mg/kg) significantly decreased the amplitude of the 
      reflex response (p < 0.05). But the 10-mg/kg metamizol dose did not significantly 
      decrease the amplitude of the reflex response. The cyclooxygenase products of 
      arachidonic acid may play an important role in regulating the reflex potential.
CI  - Copyright 2003 S. Karger AG, Basel
FAU - Genç, O
AU  - Genç O
AD  - Department of Physiology, Faculty of Medicine, Pamukkale University, TR-20020 
      Denizli, Turkey. ogenc@pamukkale.edu.tr
FAU - Turgut, S
AU  - Turgut S
FAU - Turgut, G
AU  - Turgut G
FAU - Kortunay, S
AU  - Kortunay S
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Decerebrate State
MH  - Dipyrone/administration & dosage/*pharmacology
MH  - Lumbosacral Region
MH  - Rats
MH  - Rats, Wistar
MH  - Reflex, Monosynaptic/*drug effects
MH  - Spinal Cord/*drug effects/physiology
EDAT- 2003/09/27 05:00
MHDA- 2004/02/19 05:00
CRDT- 2003/09/27 05:00
PHST- 2003/02/24 00:00 [received]
PHST- 2003/04/23 00:00 [accepted]
PHST- 2003/09/27 05:00 [pubmed]
PHST- 2004/02/19 05:00 [medline]
PHST- 2003/09/27 05:00 [entrez]
AID - 72663 [pii]
AID - 10.1159/000072663 [doi]
PST - ppublish
SO  - Pharmacology. 2003 Nov;69(3):123-6. doi: 10.1159/000072663.

PMID- 6395321
OWN - NLM
STAT- MEDLINE
DCOM- 19850225
LR  - 20190908
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 13
IP  - 4
DP  - 1984
TI  - Naproxen and acetylsalicylic acid in the treatment of pauciarticular and 
      polyarticular juvenile rheumatoid arthritis. Assessment of tolerance and efficacy 
      in a single-centre 24-week double-blind parallel study.
PG  - 342-50
AB  - Naproxen (NAP) (10 mg/kg/day) and acetylsalicylic acid (ASA) (75 mg/kg/day) were 
      compared in a 24-week randomized block, controlled, parallel, double-blind study 
      in 80 patients with pauciarticular or polyarticular juvenile rheumatoid 
      arthritis. Five NAP-treated compared with 20 ASA-treated patients stopped therapy 
      because of adverse reactions. Both drug regimens seemed to be therapeutically 
      effective. The outcome of the study indicated that ASA may have a slight 
      advantage over NAP with regard to efficacy. However, the changes in disease 
      activity measurements were similar in the two treatment groups.
FAU - Kvien, T K
AU  - Kvien TK
FAU - Høyeraal, H M
AU  - Høyeraal HM
FAU - Sandstad, B
AU  - Sandstad B
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Arthritis, Juvenile/*drug therapy/physiopathology
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Naproxen/adverse effects/*therapeutic use
MH  - Random Allocation
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.3109/03009748409111307 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 1984;13(4):342-50. doi: 10.3109/03009748409111307.

PMID- 1085534
OWN - NLM
STAT- MEDLINE
DCOM- 19761029
LR  - 20131121
IS  - 0044-2542 (Print)
IS  - 0044-2542 (Linking)
VI  - 31
IP  - 3
DP  - 1976 Feb 1
TI  - [The antithrombotic treatment and prevention of recurrence with acetylsalicylic 
      acid in myocardial infarct].
PG  - 61-5
AB  - A comparison of the therapy, especially of the long-term recidivation prophylaxis 
      of the myocardial infarction with acetyl salicylic acid and anticoagulants, on 
      the basis of 314 observations allows of the following opinions: By means of the 
      thrombocyte aggregation inhibitor acetyl salicylic acid an antithrombotic therapy 
      and recidivation prophylaxis of good value can be performed. The application of 
      acetyl salicylic acid is, concerning the course of the disease after the onset of 
      the infarction and the frequency of recidivation, adequate to the treatment with 
      classical anticoagulants. The practical performance of the long-term therapy with 
      acetyl salicylic acid is significantly simplified for physician and patient 
      compared with the application of anticoagulants. The daily dose lies uniformly at 
      1.5 g. There is no fear of acute haemorrhagic complications. As control only the 
      occasional establishment of the Hb-value as well as of the time of haemorrhage is 
      indicated. The only, however, very decisive disadvantage of the acetyl salicylic 
      acid, the bad compatibility for the stomach, is certainly not abolished with the 
      new drug "Micristin", but much diminished.
FAU - Heuchel, G
AU  - Heuchel G
FAU - Hässler, W
AU  - Hässler W
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Die antithrombotische Behandlung und Rezidivprophylaxe des Myokardinfarktes mit 
      Azetylsalizylsäure.
PL  - Germany
TA  - Z Gesamte Inn Med
JT  - Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete
JID - 21730470R
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Dogs
MH  - Drug Hypersensitivity
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/drug therapy/*prevention & control
MH  - Rabbits
MH  - Recurrence
MH  - Thrombosis/prevention & control
MH  - Urticaria/chemically induced
EDAT- 1976/02/01 00:00
MHDA- 1976/02/01 00:01
CRDT- 1976/02/01 00:00
PHST- 1976/02/01 00:00 [pubmed]
PHST- 1976/02/01 00:01 [medline]
PHST- 1976/02/01 00:00 [entrez]
PST - ppublish
SO  - Z Gesamte Inn Med. 1976 Feb 1;31(3):61-5.

PMID- 20008209
OWN - NLM
STAT- MEDLINE
DCOM- 20100315
LR  - 20181201
IS  - 1520-4383 (Electronic)
IS  - 1520-4383 (Linking)
DP  - 2009
TI  - Antiplatelet agents.
PG  - 267-72
LID - 10.1182/asheducation-2009.1.267 [doi]
AB  - The introduction of aspirin as an anti-thrombotic agent some 50 years ago has 
      changed the therapeutic approach in cardiovascular medicine. Since platelets play 
      a key role in the development of arterial thrombosis, antiplatelet drugs serve as 
      a cornerstone in the prevention and the treatment of these conditions. After many 
      years of a "monopoly" of aspirin, ADP receptor P2Y12 inhibitors were introduced 
      with a significant improvement in clinical outcome. Nowadays dual antiplatelet 
      therapy is the common practice for both acute events and secondary prevention in 
      selected groups of patients. Another revolution was the development of potent 
      inhibitors of the platelet integrin GPIIbIIIa, which significantly improved the 
      outcome of percutaneous interventions (PCI), in cardiology. The improved efficacy 
      of multiple-drug therapy is associated with an increased risk of bleeding, which 
      raises the issue of the dosing of these drugs. Recently, numerous studies have 
      reported a variable laboratory response to aspirin and clopidogrel, which 
      correlates with clinical outcome. Several mechanisms have been proposed to cause 
      this variable response, including genetic variability, disease burden and others. 
      A major obstacle in this field is the lack of a standardized method for testing 
      these responses, and thus some studies cannot be compared to others. Ongoing 
      studies are currently investigating the potential translation of these 
      observations into clinical practice. Such studies may lead to a change in the 
      paradigm of antiplatelet therapy, where individual dose adjustment may improve 
      efficacy and safety. Finally, a variety of new drugs are currently in different 
      stages of development, including new P2Y12 receptor inhibitors, thromboxane 
      receptor blockers, direct thrombin inhibitors and other signaling pathway 
      inhibitors including oral GPIIbIIIa inhibitors. Thus, antiplatelet therapy is 
      currently under intensive development toward multiple-drug therapy and 
      personal-dose adjustment, which may improve clinical outcome.
FAU - Varon, David
AU  - Varon D
AD  - Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, 
      Israel. dvaron@hadassah.org.il
FAU - Spectre, Galia
AU  - Spectre G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hematology Am Soc Hematol Educ Program
JT  - Hematology. American Society of Hematology. Education Program
JID - 100890099
RN  - 0 (P2RY12 protein, human)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Purinergic P2 Receptor Antagonists)
RN  - 0 (Receptors, Purinergic P2Y12)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Dose-Response Relationship, Drug
MH  - Drug Delivery Systems
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Forecasting
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - *Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/classification/pharmacology/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Practice Guidelines as Topic
MH  - Purinergic P2 Receptor Antagonists
MH  - Receptors, Purinergic P2Y12
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
RF  - 52
EDAT- 2009/12/17 06:00
MHDA- 2010/03/17 06:00
CRDT- 2009/12/17 06:00
PHST- 2009/12/17 06:00 [entrez]
PHST- 2009/12/17 06:00 [pubmed]
PHST- 2010/03/17 06:00 [medline]
AID - 2009/1/267 [pii]
AID - 10.1182/asheducation-2009.1.267 [doi]
PST - ppublish
SO  - Hematology Am Soc Hematol Educ Program. 2009:267-72. doi: 
      10.1182/asheducation-2009.1.267.

PMID- 36001989
OWN - NLM
STAT- MEDLINE
DCOM- 20230816
LR  - 20230816
IS  - 2058-1742 (Electronic)
IS  - 2058-1742 (Linking)
VI  - 9
IP  - 5
DP  - 2023 Aug 7
TI  - The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS 
      trial.
PG  - 502-510
LID - 10.1093/ehjqcco/qcac054 [doi]
AB  - AIMS: The Cardiovascular Outcomes for People Using Anticoagulation Strategies 
      (COMPASS) trial demonstrated that rivaroxaban 2.5 mg BID with aspirin 100 mg was 
      more effective than aspirin 100 mg daily alone for the prevention of 
      cardiovascular (CV) death, stroke, or myocardial infarction in patients with 
      stable coronary artery disease (CAD) or peripheral artery disease (PAD). We aimed 
      to examine the cost-effectiveness of rivaroxaban using patient-level data from 
      the COMPASS trial. METHODS AND RESULTS: We performed an in-trial analysis and 
      extrapolated our results for 33 years using a two-state Markov model with a 
      1-year cycle length. Hospitalization events, procedures, and study drugs were 
      documented for patients. We applied country-specific (Canada, France, and 
      Germany) direct healthcare system costs (in USD) to healthcare resources consumed 
      by patients. Average cost per patient during the trial (mean follow-up of 23 
      months), quality-adjusted life years (QALYs), and lifetime cost-effectiveness 
      were calculated. Costs of events and procedures were reduced with rivaroxaban 
      2.5 mg BID with aspirin. The addition of rivaroxaban 2.5 mg BID increased total 
      costs for the combination group. Over a lifetime horizon (in trial +33 years), 
      rivaroxaban plus aspirin was associated with 1.17 QALYs gained, yielding an 
      incremental cost-effectiveness ratio (ICER) of $3946/QALY, $9962/QALY, and 
      $10 264/QALY in Canada, France, and Germany, respectively. PAD and polyvascular 
      disease subgroups had lower ICERs. CONCLUSION: Rivaroxaban 2.5 mg twice daily 
      plus aspirin compared with aspirin alone reduces direct healthcare costs. After 
      acquisition costs of rivaroxaban, the lifetime cost-effectiveness of 2.5 mg twice 
      daily plus aspirin is highly cost-effective in Canada, France, and 
      Germany.(COMPASS ClinicalTrials.gov identifier: NCT01776424).
CI  - © The Author(s) 2022. Published by Oxford University Press on behalf of the 
      European Society of Cardiology.
FAU - Lamy, Andre
AU  - Lamy A
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
AD  - CADENCE Research Group, Hamilton Health Sciences, Hamilton, Ontario, Canada.
AD  - Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Eikelboom, John
AU  - Eikelboom J
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Tong, Wesley
AU  - Tong W
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
AD  - CADENCE Research Group, Hamilton Health Sciences, Hamilton, Ontario, Canada.
FAU - Yuan, Fei
AU  - Yuan F
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Bangdiwala, Shrikant I
AU  - Bangdiwala SI
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Bosch, Jackie
AU  - Bosch J
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Connolly, Stuart
AU  - Connolly S
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Lonn, Eva
AU  - Lonn E
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Dagenais, Gilles R
AU  - Dagenais GR
AD  - Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, 
      Québec, Canada.
FAU - Branch, Kelley R H
AU  - Branch KRH
AD  - University of Washington Medical Center, Seattle, WA, USA.
FAU - Wang, Wei-Jhih
AU  - Wang WJ
AD  - Comparative Health Outcomes, Policy and Economics Institute, School of Pharmacy, 
      University of Washington, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 
      Boston, MA, USA.
FAU - Probstfield, Jeff
AU  - Probstfield J
AD  - Division of Cardiology, University of Washinton, Seattle, WA, USA.
FAU - Ertl, Georg
AU  - Ertl G
AD  - Department of Medicine I, University of Würzburg, WürzburgGermany.
AD  - Comprehensive Heart Failure Center, University Hospital, Würzburg, Germany.
FAU - Störk, Stefan
AU  - Störk S
AD  - Department of Medicine I, University of Würzburg, WürzburgGermany.
AD  - Comprehensive Heart Failure Center, University Hospital, Würzburg, Germany.
FAU - Steg, P Gabriel
AU  - Steg PG
AD  - Department of Cardiology, Université Paris Diderot, Paris, France.
AD  - Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France.
FAU - Aboyans, Victor
AU  - Aboyans V
AD  - Department of Cardiology, Dupuytren University Hospital, and Inserm 1094 & IRD, 
      NET, Limoges University, Limoges, France.
FAU - Durand-Zaleski, Isabelle
AU  - Durand-Zaleski I
AD  - Assistance Publique Hôpitaux de Paris, URC Eco and Santé Publique, Hôpital Henri 
      Mondor, Créteil, France.
AD  - Health Economics Research Unit, Université Paris Est Créteil, Créteil, France.
AD  - INSERM ECEVE UMR 1123, ParisFrance.
FAU - Ryden, Lars
AU  - Ryden L
AD  - Cardiology Unit, Department of Medicine K2, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Yusuf, Salim
AU  - Yusuf S
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT01776424
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J Qual Care Clin Outcomes
JT  - European heart journal. Quality of care & clinical outcomes
JID - 101677796
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Factor Xa Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
SB  - IM
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Drug Therapy, Combination
MH  - Factor Xa Inhibitors/therapeutic use
MH  - *Peripheral Arterial Disease/drug therapy
MH  - Rivaroxaban/therapeutic use
OTO - NOTNLM
OT  - Anticoagulation
OT  - Coronary artery disease
OT  - Cost-effectiveness
OT  - Peripheral artery disease
EDAT- 2022/08/25 06:00
MHDA- 2023/08/08 06:42
CRDT- 2022/08/24 18:33
PHST- 2022/05/04 00:00 [received]
PHST- 2022/08/18 00:00 [accepted]
PHST- 2022/08/09 00:00 [revised]
PHST- 2023/08/08 06:42 [medline]
PHST- 2022/08/25 06:00 [pubmed]
PHST- 2022/08/24 18:33 [entrez]
AID - 6674756 [pii]
AID - 10.1093/ehjqcco/qcac054 [doi]
PST - ppublish
SO  - Eur Heart J Qual Care Clin Outcomes. 2023 Aug 7;9(5):502-510. doi: 
      10.1093/ehjqcco/qcac054.

PMID- 3559984
OWN - NLM
STAT- MEDLINE
DCOM- 19870427
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 240
IP  - 3
DP  - 1987 Mar
TI  - Failure of chronic aspirin treatment to inhibit urinary prostaglandin excretion 
      in spontaneously hypertensive rats: comparison with indomethacin and 
      flurbiprofen.
PG  - 916-21
AB  - The inability of chronic treatment with aspirin to cause sustained inhibition of 
      urinary prostaglandin (PG) excretion observed previously prompted us to compare 
      the effects of 9-day treatment of spontaneously hypertensive rats with aspirin, 
      200 mg/kg/day s.c., flurbiprofen, 2.5 mg/kg/b.i.d. s.c. and indomethacin, 2.5 
      mg/kg/b.i.d. s.c. on the excretion rate of radioimmunoassayable PGE2 and PGF2 
      alpha. Conversion of 1-[14C]arachidonic acid and the release of PGs from 
      endogenous substrate by the renal papilla were also examined. In vehicle-treated 
      control rats, PGF2 alpha excretion ranged from 32.2 +/- 6.2 (mean +/- S.E.M.) to 
      41.6 +/- 7.3 ng/6 h, and was 2- to 4-fold higher than that of PGE2. Within 6 h of 
      administration all three drugs reduced excretion of PGF2 alpha and PGE2 to less 
      than 20% and 35% of control rats, respectively. Thereafter, PGF2 alpha and PGE2 
      excretion in aspirin-treated rats returned to values similar to the 
      vehicle-treated group, whereas inhibition of PG excretion in indomethacin and 
      flurbiprofen groups was sustained. Urine volume was doubled by aspirin throughout 
      the study. In contrast, urine volume in flurbiprofen- and indomethacin-treated 
      rats was unaffected. Paradoxically, metabolism of 1-[14C]arachidonic acid to PGs 
      by renal papilla dissected on day 10, 2 to 4 h after the last drug dose, was 
      reduced markedly by aspirin as was the release of immunoreactive PGs but was 
      unaffected by flurbiprofen or indomethacin. The failure of long-term aspirin 
      treatment to inhibit urinary PG excretion and the disparity between in vivo and 
      ex vivo indices of PG release emphasize the need to verify their intended action 
      by measuring PGs in biological fluids.
FAU - Quilley, C P
AU  - Quilley CP
FAU - McGiff, J C
AU  - McGiff JC
FAU - Quilley, J
AU  - Quilley J
LA  - eng
GR  - 2 R01 HL 25394-07/HL/NHLBI NIH HHS/United States
GR  - P01 HL 34300/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Propionates)
RN  - 0 (Prostaglandins)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Drug Administration Schedule
MH  - Flurbiprofen/*pharmacology
MH  - Hypertension/*urine
MH  - Indomethacin/*pharmacology
MH  - Kidney/*drug effects/physiology/physiopathology
MH  - Male
MH  - Propionates/*pharmacology
MH  - Prostaglandins/*urine
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Rats, Inbred WKY
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1987 Mar;240(3):916-21.

PMID- 21145142
OWN - NLM
STAT- MEDLINE
DCOM- 20120201
LR  - 20161018
IS  - 1768-3122 (Electronic)
IS  - 0248-8663 (Linking)
VI  - 32
IP  - 11
DP  - 2011 Nov
TI  - [Narcolepsy associated with systemic lupus erythematosus].
PG  - e114-5
AB  - Many neurologic and psychiatric manifestations have been associated with systemic 
      lupus erythematosus. Narcolepsy, currently hypothesized as related to an 
      autoimmune process, has been rarely associated with systemic lupus erythematosus. 
      We report a 36-year-old woman who presented with narcolepsy and who subsequently 
      developed systemic lupus erythematosus. Excessive daytime sleepiness resolved 
      after the administration of four intravenous bolus of cyclophosphamide and 
      methylprednisolone followed by maintenance therapy with hydroxychloroquine, 
      aspirine and prednisone. Narcolepsy should be included in the neuropsychiatric 
      manifestations of systemic lupus erythematosus and it may have a parallel 
      clinical course to the activity of the lupus.
CI  - Copyright © 2010. Published by Elsevier SAS.
FAU - Haddad, F
AU  - Haddad F
AD  - Service de médecine interne, hôpital universitaire Hôtel-Dieu de France, 
      Ashrafieh, Beyrouth, Liban. prfghaddad@yahoo.com
FAU - Anouti, S
AU  - Anouti S
FAU - Maalouly, G
AU  - Maalouly G
FAU - Koussa, S
AU  - Koussa S
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Narcolepsie révélant un lupus érythémateux systémique.
DEP - 20101208
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage
MH  - Cyclophosphamide/administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Hydroxychloroquine/administration & dosage
MH  - Lupus Erythematosus, Systemic/*complications/diagnosis/drug therapy
MH  - Maintenance Chemotherapy
MH  - Methylprednisolone/administration & dosage
MH  - Narcolepsy/*complications/diagnosis/drug therapy
MH  - Prednisone/administration & dosage
EDAT- 2010/12/15 06:00
MHDA- 2012/02/02 06:00
CRDT- 2010/12/15 06:00
PHST- 2010/02/10 00:00 [received]
PHST- 2010/10/25 00:00 [accepted]
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2012/02/02 06:00 [medline]
AID - S0248-8663(10)01392-5 [pii]
AID - 10.1016/j.revmed.2010.10.352 [doi]
PST - ppublish
SO  - Rev Med Interne. 2011 Nov;32(11):e114-5. doi: 10.1016/j.revmed.2010.10.352. Epub 
      2010 Dec 8.

PMID- 11710598
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20190906
IS  - 0171-5216 (Print)
IS  - 0171-5216 (Linking)
VI  - 127
IP  - 11
DP  - 2001 Nov
TI  - Paradoxical effect of aspirin on the growth of C6 rat glioma and on time of 
      development of ENU-induced tumors of the nervous system.
PG  - 681-6
AB  - PURPOSE: Administration of acetylsalicylic acid (ASA), an inhibitor of the 
      synthesis of prostaglandins and thrombzoxanes, decreases the incidence of 
      colorectal cancer and other neoplasms and inhibits in vitro some tumor growth. We 
      studied the effect of various doses of ASA on the growth of C6 glioma implanted 
      in rats as well as the effect of chronic administration of ASA on time of 
      development and incidence of tumors of the central nervous system (CNS) induced 
      by prenatal exposure to ethylnitrosourea (ENU). METHODS: In a controlled study, 
      various doses of ASA, 12.5, 25, 50, 100, 200, 300, and 400 mg/kg per day, were 
      administered to Wistar rats in whom a subcutaneous C6 glioma had been 
      transplanted. Changes in tumor size, histologic characteristics, mitotic index, 
      cell proliferation, and vascular density were studied. In a parallel experiment, 
      we administered ASA (70 mg/kg per day) to rats who were prenatally exposed to 
      ENU; treatment started on day 50 of age, and continued until the end of the 
      experiment at day 400. The time of tumor development as well as incidence, 
      localization, and histological diagnosis were compared with matched controls. 
      RESULTS: A paradoxical effect of ASA administration was observed on the dynamics 
      of cell proliferation of C6 glioma. When high ASA doses were administered (200 or 
      400 mg/kg per day), tumor volume, cell proliferation, vascular density, and 
      mitotic index increased. In contrast, when low doses were administered (12.5 or 
      25 mg/kg per day) the tumor size diminished. In the second experiment, 
      localization and incidence of CNS tumors induced by ENU were similar in animals 
      treated with ASA and in controls; however, in rats treated with ASA the time of 
      tumor development was shortened. CONCLUSIONS: The growth-promoting effects of 
      high doses of ASA found in the present study in both transplanted and 
      chemically-induced brain tumors, might be due to the blockage of autocrine 
      inhibitory factors dependent on the cyclooxygenase pathway or by increased 
      vascular permeability and blood supply to the tumor due to inhibition of platelet 
      aggregation. In contrast, the inhibition of tumor growth obtained with low ASA 
      doses in transplanted glioma might be due to different mechanisms such as the 
      induction of apoptosis.
FAU - Arrieta, O
AU  - Arrieta O
AD  - Neuroimmunology Unit, Instituto Nacional de Neurologia y Neurocirugía and 
      Instituto de Investigaciones Biomédicas, Mexico City, Mexico. 
      ogar@servidor.unam.mx
FAU - Guevara, P
AU  - Guevara P
FAU - Reyes, S
AU  - Reyes S
FAU - Palencia, G
AU  - Palencia G
FAU - Rivera, E
AU  - Rivera E
FAU - Sotelo, J
AU  - Sotelo J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Alkylating Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Carcinogens)
RN  - P8M1T4190R (Ethylnitrosourea)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alkylating Agents
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Apoptosis
MH  - Aspirin/administration & dosage/*pharmacology
MH  - *Carcinogens
MH  - Cell Division
MH  - Central Nervous System Neoplasms/chemically induced/drug therapy
MH  - Dose-Response Relationship, Drug
MH  - *Ethylnitrosourea
MH  - Glioma/chemically induced/*drug therapy
MH  - Rats
MH  - Time Factors
MH  - Tumor Cells, Cultured
EDAT- 2001/11/17 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/17 10:00
PHST- 2001/11/17 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/17 10:00 [entrez]
AID - 10.1007/s004320100267 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2001 Nov;127(11):681-6. doi: 10.1007/s004320100267.

PMID- 36220422
OWN - NLM
STAT- MEDLINE
DCOM- 20221013
LR  - 20221013
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 68
IP  - 4
DP  - 2022 Fall
TI  - Acetylsalicylic acid in primary prevention of cardiovascular disease.
PG  - 240-245
AB  - Acetylsalicylic acid is an effective and widely accepted essential drug in the 
      secondary prevention of ischemic events. Its role in primary prevention has been 
      studied for several decades and still remains controversial. Initial studies 
      showed a reduction in both myocardial infarctions and ischemic strokes, without 
      affecting overall or cardiovascular mortality, but the enrolled subjects were not 
      treated with modern drugs and procedures in primary preventive care as they do 
      today. Recently published studies have also not shown a mortality benefit, but in 
      some sub-populations and groups of patients, the clinical benefit of aspirin 
      continues to outweigh the risks associated with its long-term use. This review 
      article will discuss the development of ASA in primary prevention, the results of 
      the latest studies of the year 2018 and their meta-analyses, current indications 
      for ASA treatment, as well as future perspectives.
FAU - Miklík, Roman
AU  - Miklík R
FAU - Jiravský, Otakar
AU  - Jiravský O
LA  - eng
PT  - Journal Article
PT  - Review
TT  - Kyselina acetylsalicylová v primární prevenci kardiovaskulárních onemocn&#283;ní.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - 0 (Drugs, Essential)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/drug therapy/prevention & control
MH  - *Drugs, Essential/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Primary Prevention
MH  - Secondary Prevention
MH  - *Stroke/prevention & control
OTO - NOTNLM
OT  - Aspirin
OT  - clinical benefit
OT  - ischemic risk
OT  - primary prevention
OT  - risk of bleeding
EDAT- 2022/10/12 06:00
MHDA- 2022/10/14 06:00
CRDT- 2022/10/11 21:45
PHST- 2022/10/11 21:45 [entrez]
PHST- 2022/10/12 06:00 [pubmed]
PHST- 2022/10/14 06:00 [medline]
AID - 131973 [pii]
PST - ppublish
SO  - Vnitr Lek. 2022 Fall;68(4):240-245.

PMID- 9682841
OWN - NLM
STAT- MEDLINE
DCOM- 19980930
LR  - 20190701
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 249
IP  - 2-3
DP  - 1998 Jun 19
TI  - Acetylsalicylate administered during simulated ischemia reduces the recovery of 
      neuronal function in the in vitro rabbit retina.
PG  - 159-62
AB  - Aspirin is widely used as an analgesic, in the secondary prevention of stroke, 
      and has recently been suggested to be a putative neuroprotective agent, yet 
      whether it acts directly on the central nervous system (CNS) is not yet 
      clarified. We therefore examined the effect of lysine acetylsalicylate (L-ASA, 
      4-2000 microM) on neuronal function under normal conditions and following 1 h of 
      ischemia using the in vitro rabbit retina preparation. L-ASA inhibited the 
      light-evoked compound action potentials, but not the electroretinogram, in a 
      concentration-dependent manner. In addition, L-ASA (2000 microM, but not 4, 40 or 
      200 microM) administered during ischemia, reduced the recovery of neuronal 
      function compared to control (untreated) retinas. L-ASA therefore inhibits CNS 
      neurotransmission, but not phototransduction, in a concentration-dependent 
      manner. In addition, high concentration L-ASA impairs the recovery of neuronal 
      function following an ischemic episode.
FAU - Maynard, K I
AU  - Maynard KI
AD  - Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, 
      Boston 02114, USA. Maynard@helix.mgh.harvard.edu
FAU - Arango, P M
AU  - Arango PM
FAU - Chen, D
AU  - Chen D
FAU - Ogilvy, C S
AU  - Ogilvy CS
LA  - eng
GR  - NS 01732/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Action Potentials
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Electroretinography
MH  - In Vitro Techniques
MH  - Ischemia/*physiopathology
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
MH  - Rabbits
MH  - Retina/drug effects/*physiology
MH  - Retinal Vessels
MH  - Time Factors
MH  - Vision, Ocular/drug effects/*physiology
EDAT- 1998/07/31 00:00
MHDA- 1998/07/31 00:01
CRDT- 1998/07/31 00:00
PHST- 1998/07/31 00:00 [pubmed]
PHST- 1998/07/31 00:01 [medline]
PHST- 1998/07/31 00:00 [entrez]
AID - S0304-3940(98)00416-9 [pii]
AID - 10.1016/s0304-3940(98)00416-9 [doi]
PST - ppublish
SO  - Neurosci Lett. 1998 Jun 19;249(2-3):159-62. doi: 10.1016/s0304-3940(98)00416-9.

PMID- 30502844
OWN - NLM
STAT- MEDLINE
DCOM- 20190507
LR  - 20210109
IS  - 1532-8686 (Electronic)
IS  - 0037-1963 (Linking)
VI  - 55
IP  - 4
DP  - 2018 Oct
TI  - Primary thromboembolic prevention in multiple myeloma patients: An exploratory 
      meta-analysis on aspirin use.
PG  - 182-184
LID - S0037-1963(17)30049-5 [pii]
LID - 10.1053/j.seminhematol.2017.08.002 [doi]
AB  - BACKGROUND: Multiple myeloma (MM) is a common hematological disorder, often 
      complicated by venous thromboembolism, especially during treatment with 
      immunomodulatory drugs. Acetylsalicylic acid (ASA) has been extensively used as 
      thromboprophylaxis but its rationale is unclear and the efficacy versus 
      low-molecular weight heparins (LMWH) is still matter of debate. European and 
      American guidelines suggest different approaches and the optimal antithrombotic 
      strategy is yet to be established. METHODS: We conducted an exploratory 
      metanalysis and a systematic review on studies comparing ASA versus other 
      interventions for thromboprophylaxis (no intervention or LMWH) in patients with 
      MM. RESULTS: Ten studies were included (2 randomized controlled trials, 6 
      longitudinal and 2 retrospective studies) with 1,964 participants (1,257 treated 
      with ASA, 640 with LMWH and 67 with no thromboprophylaxis). Patients treated with 
      ASA had a significantly lower risk of VTE compared to no intervention (OR=0.20; 
      95%CI: 0.07-0.61, p=0.005; I(2)=41%). The use of ASA was associated with a higher 
      VTE risk compared to LMWH in longitudinal studies (OR=2.60; 95%CI: 1.08-6.25; 
      p=0.03; I(2)=0%), however no differences have been showed in randomized 
      controlled trials. CONCLUSIONS: ASA demonstrated a good efficacy compared to no 
      intervention; data are insufficient to confirm superiority of LMWH over ASA as 
      thromboprophylaxis in MM patients. Large and well powered trials are warranted.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Zoppellaro, Giacomo
AU  - Zoppellaro G
AD  - Cardiology Clinic, Department of Cardiologic, Thoracic and Vascular Sciences, 
      University of Padua, Italy. Electronic address: giacomo.zoppellaro@unipd.it.
FAU - Veronese, Nicola
AU  - Veronese N
AD  - Department of Medicine, Geriatrics Section, University of Padua, Italy.
FAU - Granziera, Serena
AU  - Granziera S
AD  - Rehabilitation Ward, Villa Salus Hospital, Mestre, Italy.
FAU - Gobbi, Laura
AU  - Gobbi L
AD  - Department of Medicine, Geriatrics Section, University of Padua, Italy.
FAU - Stubbs, Brendon
AU  - Stubbs B
AD  - Department of Health Service and Population Research, King's College London, 
      London, UK.
FAU - Cohen, Alexander T
AU  - Cohen AT
AD  - Department of Haematological Medicine, Guy's and St. Thomas' NHS Foundation 
      Trust, London, UK.
LA  - eng
GR  - ICA-CL-2017-03-001/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20170812
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Humans
MH  - Multiple Myeloma/*complications/pathology
MH  - Retrospective Studies
MH  - Venous Thromboembolism/etiology/*prevention & control
OTO - NOTNLM
OT  - aspirin
OT  - low molecular weight heparins
OT  - multiple myeloma
OT  - thromboprophylaxis
OT  - venous thromboembolism
EDAT- 2018/12/07 06:00
MHDA- 2019/05/08 06:00
CRDT- 2018/12/04 06:00
PHST- 2017/04/21 00:00 [received]
PHST- 2017/07/18 00:00 [revised]
PHST- 2017/08/05 00:00 [accepted]
PHST- 2018/12/04 06:00 [entrez]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/05/08 06:00 [medline]
AID - S0037-1963(17)30049-5 [pii]
AID - 10.1053/j.seminhematol.2017.08.002 [doi]
PST - ppublish
SO  - Semin Hematol. 2018 Oct;55(4):182-184. doi: 10.1053/j.seminhematol.2017.08.002. 
      Epub 2017 Aug 12.

PMID- 11805391
OWN - NLM
STAT- MEDLINE
DCOM- 20020409
LR  - 20181130
IS  - 0014-312X (Print)
IS  - 0014-312X (Linking)
VI  - 33
IP  - 5-6
DP  - 2001 Sep-Dec
TI  - Diaspirin cross-linked hemoglobin fails to improve left ventricular diastolic 
      function after fluid resuscitation from hemorrhagic shock.
PG  - 318-26
AB  - In severe hemorrhagic shock, left ventricular (LV) diastolic dysfunction is an 
      early sign of cardiac failure due to compromised myocardial oxygenation. 
      Immediate fluid replacement or, in particular, administration of a 
      hemoglobin-based oxygen carrier (diaspirin cross-linked hemoglobin; DCLHb) 
      improves myocardial oxygenation; therefore, positive effects on LV diastolic 
      function could be expected. The effects of fluid resuscitation from severe 
      hemorrhagic shock with DCLHb were investigated in 20 anesthetized domestic pigs. 
      After generation of a critical left anterior descending coronary artery stenosis 
      (narrowing of the artery until disappearance of reactive hyperemia after a 
      10-second complete vessel occlusion), hemorrhagic shock (mean arterial blood 
      pressure 45 mm Hg) was induced within 15 min by controlled blood withdrawal and 
      maintained for 60 min. Fluid resuscitation consisted of replacement of the plasma 
      volume withdrawn during hemorrhage by infusion of either 10% DCLHb (DCLHb group, 
      n = 10) or 8% human serum albumin (HSA) oncotically matched to DCLHb (HSA group, 
      n = 10). After completion of resuscitation, an observation period of 60 min 
      elapsed. Measurements of central hemodynamics, myocardial oxygenation, and LV 
      diastolic function were performed at baseline, after induction of critical 
      coronary artery stenosis, after 60 min of hemorrhagic shock, immediately after 
      resuscitation, and 60 min later. While 5 out of 10 animals treated with HSA died 
      within the first 20 min after fluid resuscitation from acute LV pump failure, all 
      DCLHb-treated animals survived until the end of the protocol (p < 0.05). Despite 
      superior myocardial oxygenation due to augmentation of the arterial O(2) content 
      as well as of coronary perfusion pressure, no beneficial effects on LV diastolic 
      function were observed after infusion of DCLHb. Peak velocity of LV pressure 
      decrease (dp/dt(min)) did not reveal significant differences between the two 
      groups. Immediately after completion of fluid resuscitation with DCLHb, the time 
      constant of LV diastolic relaxation (tau) was prolonged when compared with 
      HSA-treated animals (p < 0.05), indicating retardation of early LV diastolic 
      relaxation. Our data suggest that DCLHb fails to improve LV diastolic function 
      after fluid resuscitation from severe hemorrhagic shock. However, positive 
      effects on myocardial perfusion and oxygenation result in a significant reduction 
      of the mortality of severe hemorrhagic shock.
CI  - Copyright 2001 S. Karger AG, Basel
FAU - Pape, A
AU  - Pape A
AD  - Clinic of Anaesthesiology, Ludwig Maximilians University, Munich, Germany. 
      andreas.page@helios.med.uni-muenchen.de
FAU - Kemming, G
AU  - Kemming G
FAU - Meisner, F
AU  - Meisner F
FAU - Kleen, M
AU  - Kleen M
FAU - Habler, O
AU  - Habler O
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Eur Surg Res
JT  - European surgical research. Europaische chirurgische Forschung. Recherches 
      chirurgicales europeennes
JID - 0174752
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Serum Albumin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - Coronary Stenosis/physiopathology
MH  - Diastole
MH  - Female
MH  - *Fluid Therapy
MH  - Hemoglobins/*therapeutic use
MH  - Humans
MH  - Male
MH  - *Resuscitation
MH  - Serum Albumin/therapeutic use
MH  - Shock, Hemorrhagic/*physiopathology/*therapy
MH  - Swine
MH  - Treatment Failure
MH  - Ventricular Function, Left/*drug effects
EDAT- 2002/01/24 10:00
MHDA- 2002/04/18 10:01
CRDT- 2002/01/24 10:00
PHST- 2002/01/24 10:00 [pubmed]
PHST- 2002/04/18 10:01 [medline]
PHST- 2002/01/24 10:00 [entrez]
AID - esr33318 [pii]
AID - 10.1159/000049725 [doi]
PST - ppublish
SO  - Eur Surg Res. 2001 Sep-Dec;33(5-6):318-26. doi: 10.1159/000049725.

PMID- 37146704
OWN - NLM
STAT- MEDLINE
DCOM- 20230724
LR  - 20230724
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 229
IP  - 2
DP  - 2023 Aug
TI  - Society for Maternal-Fetal Medicine Special Statement: Prophylactic low-dose 
      aspirin for preeclampsia prevention-quality metric and opportunities for quality 
      improvement.
PG  - B2-B9
LID - S0002-9378(23)00277-6 [pii]
LID - 10.1016/j.ajog.2023.04.039 [doi]
AB  - Prophylactic low-dose aspirin reduces the rates of preeclampsia, preterm birth, 
      fetal growth restriction, and perinatal death in patients with risk factors for 
      preeclampsia. Despite recommendations from the US Preventive Services Task Force, 
      the American College of Obstetricians and Gynecologists, and the Society for 
      Maternal-Fetal Medicine, low-dose aspirin use is reported in <50% of patients 
      with high-risk factors and <25% of patients with >1 moderate-risk factor. These 
      low use rates represent an important "quality gap" and demonstrate the need for 
      quality improvement activities. In this article, we outline the specifications 
      for a process metric to standardize the measurement of the rate of aspirin use. 
      Furthermore, we outline an approach to conducting a quality improvement project 
      to increase the use of aspirin by patients with risk factors for preeclampsia.
CI  - Copyright © 2023. Published by Elsevier Inc.
CN  - Society for Maternal-Fetal Medicine (SMFM). Electronic address: smfm@smfm.org
FAU - Combs, C Andrew
AU  - Combs CA
FAU - Kumar, Natasha R
AU  - Kumar NR
FAU - Morgan, Jamie L
AU  - Morgan JL
CN  - SMFM Patient Safety and Quality Committee
LA  - eng
PT  - Journal Article
DEP - 20230504
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - *Pre-Eclampsia/prevention & control/etiology
MH  - Perinatology
MH  - Quality Improvement
MH  - *Premature Birth/prevention & control
MH  - Aspirin/therapeutic use
OTO - NOTNLM
OT  - antiphospholipid syndrome
OT  - diabetes mellitus (pregestational)
OT  - fetal growth restriction
OT  - hypertension
OT  - kidney disease
OT  - multifetal pregnancy
OT  - preterm birth
OT  - risk factors
OT  - screening
OT  - systemic lupus erythematosus
EDAT- 2023/05/06 09:42
MHDA- 2023/07/24 06:42
CRDT- 2023/05/05 19:25
PHST- 2023/07/24 06:42 [medline]
PHST- 2023/05/06 09:42 [pubmed]
PHST- 2023/05/05 19:25 [entrez]
AID - S0002-9378(23)00277-6 [pii]
AID - 10.1016/j.ajog.2023.04.039 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2023 Aug;229(2):B2-B9. doi: 10.1016/j.ajog.2023.04.039. Epub 
      2023 May 4.

PMID- 21790788
OWN - NLM
STAT- MEDLINE
DCOM- 20120119
LR  - 20131121
IS  - 1540-8183 (Electronic)
IS  - 0896-4327 (Linking)
VI  - 24
IP  - 4
DP  - 2011 Aug
TI  - Low-dose versus high-dose aspirin after percutaneous coronary intervention: 
      analysis from the guthrie health off-label StenT (GHOST) registry.
PG  - 307-14
LID - 10.1111/j.1540-8183.2011.00627.x [doi]
AB  - BACKGROUND: The optimal dose of aspirin therapy after percutaneous coronary 
      intervention (PCI) remains unclear. We sought to compare the effectiveness and 
      safety of low and high doses of aspirin in preventing adverse outcomes after PCI. 
      METHODS: We studied 2,820 consecutive patients who underwent coronary stenting 
      for stable or unstable coronary artery disease (excluding cardiogenic shock) 
      discharged alive without any complications between 2001 and 2007. Patients were 
      categorized based on the discharge aspirin dose into low-dose (81 mg/day, N = 
      313) or high-dose (162-325 mg/day, N = 2,507) groups. The primary end-points 
      (adjusted using Cox Proportional Hazard and propensity scores) were major adverse 
      cardiovascular events (MACE; a composite of death, myocardial infarction [MI], 
      stent thrombosis [ST], or target vessel revascularization) and net adverse 
      clinical events (NACE; a composite of MACE and thrombolysis in myocardial 
      infarction [TIMI][major or minor] bleeding) at 1 year. RESULTS: In the low-dose 
      versus high-dose groups, MACE occurred in 8.6 versus 9.2% (log rank P = 0.71) and 
      NACE in 11 versus 10% (log rank P = 0.58). In multivariable analysis, low-dose 
      aspirin was not associated with worse outcomes (adjusted HR [95% CI] 0.74 
      [0.49-1.14] for MACE; 1.03 [0.71-1.50] for NACE). CONCLUSION: Low-dose aspirin, 
      as prescribed in this study of routine practice, was not associated with worse 
      outcomes compared to high-dose aspirin. (J Interven Cardiol 2011;24:307-314).
CI  - ©2011, Wiley Periodicals, Inc.
FAU - Harjai, Kishore J
AU  - Harjai KJ
AD  - Guthrie Clinic, Sayre, Pennsylvania William Beaumont Hospital, Royal Oak, 
      Michigan. harjai_kishore@guthrie.org
FAU - Shenoy, Chetan
AU  - Shenoy C
FAU - Orshaw, Pam
AU  - Orshaw P
FAU - Usmani, Samer
AU  - Usmani S
FAU - Singh, Maninder
AU  - Singh M
FAU - Boura, Judy
AU  - Boura J
FAU - Mehta, Rajendra H
AU  - Mehta RH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110725
PL  - United States
TA  - J Interv Cardiol
JT  - Journal of interventional cardiology
JID - 8907826
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cohort Studies
MH  - Coronary Artery Disease/*therapy
MH  - Delivery of Health Care, Integrated/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Complications/*prevention & control
MH  - Prospective Studies
MH  - Registries
MH  - Treatment Outcome
EDAT- 2011/07/28 06:00
MHDA- 2012/01/20 06:00
CRDT- 2011/07/28 06:00
PHST- 2011/07/28 06:00 [entrez]
PHST- 2011/07/28 06:00 [pubmed]
PHST- 2012/01/20 06:00 [medline]
AID - 10.1111/j.1540-8183.2011.00627.x [doi]
PST - ppublish
SO  - J Interv Cardiol. 2011 Aug;24(4):307-14. doi: 10.1111/j.1540-8183.2011.00627.x. 
      Epub 2011 Jul 25.

PMID- 37086835
OWN - NLM
STAT- MEDLINE
DCOM- 20230814
LR  - 20230814
IS  - 1916-7075 (Electronic)
IS  - 0828-282X (Linking)
VI  - 39
IP  - 8
DP  - 2023 Aug
TI  - Pericardial Diseases in Pregnancy.
PG  - 1067-1077
LID - S0828-282X(23)00311-2 [pii]
LID - 10.1016/j.cjca.2023.04.010 [doi]
AB  - Pericardial effusion is the most common manifestation of pericardial diseases 
      during pregnancy. This effusion is benign, mild, or moderate, well tolerated, 
      with spontaneous resolution after delivery; no specific treatment is required. 
      Acute pericarditis is the second most common condition, usually requiring medical 
      therapy during pregnancy. Cardiac tamponade and constrictive pericarditis are 
      rare in pregnancy. Pre-pregnancy counselling is essential in women of 
      childbearing age with recurrent pericarditis to plan pregnancy in a phase of 
      disease quiescence and to review therapy. High-dose aspirin or nonselective 
      nonsteroidal anti-inflammatory drugs, such as ibuprofen and indomethacin, can be 
      used up to the 20th week of gestation. Low-dose prednisone (2.5-10 mg/d) can be 
      administered throughout pregnancy. All of these medications, apart from high-dose 
      aspirin, may be used during lactation. Colchicine is compatible with pregnancy 
      and breastfeeding, and it can be continued throughout pregnancy to prevent 
      recurrences. Appropriate follow-up with a multidisciplinary team with experience 
      in the field is recommended throughout pregnancy to ensure good maternal and 
      fetal outcomes.
CI  - Copyright © 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All 
      rights reserved.
FAU - Serati, Lisa
AU  - Serati L
AD  - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy. 
      Electronic address: lisa.serati@unimi.it.
FAU - Mardigyan, Vartan
AU  - Mardigyan V
AD  - Department of Medicine, Jewish General Hospital, Montréal, Québec, Canada.
FAU - Dominioni, Costanza Caccia
AU  - Dominioni CC
AD  - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy.
FAU - Agozzino, Francesco
AU  - Agozzino F
AD  - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy.
FAU - Bizzi, Emanuele
AU  - Bizzi E
AD  - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy.
FAU - Trotta, Lucia
AU  - Trotta L
AD  - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy.
FAU - Nivuori, Mariangela
AU  - Nivuori M
AD  - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy.
FAU - Maestroni, Silvia
AU  - Maestroni S
AD  - Department of Internal Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy.
FAU - Negro, Enrica
AU  - Negro E
AD  - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy.
FAU - Imazio, Massimo
AU  - Imazio M
AD  - Cardiology, Cardiothoracic Department, University Hospital "Santa Maria della 
      Misericordia," Udine, Italy.
FAU - Brucato, Antonio
AU  - Brucato A
AD  - Department of Biomedical and Clinical Sciences, University of Milan, 
      Fatebenefratelli Hospital, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230420
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
SB  - IM
MH  - Pregnancy
MH  - Humans
MH  - Female
MH  - *Pericarditis/therapy/drug therapy
MH  - *Pericarditis, Constrictive
MH  - *Pericardial Effusion
MH  - Aspirin/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - *Cardiac Tamponade
EDAT- 2023/04/23 00:41
MHDA- 2023/08/14 06:42
CRDT- 2023/04/22 19:25
PHST- 2022/12/15 00:00 [received]
PHST- 2023/04/13 00:00 [revised]
PHST- 2023/04/14 00:00 [accepted]
PHST- 2023/08/14 06:42 [medline]
PHST- 2023/04/23 00:41 [pubmed]
PHST- 2023/04/22 19:25 [entrez]
AID - S0828-282X(23)00311-2 [pii]
AID - 10.1016/j.cjca.2023.04.010 [doi]
PST - ppublish
SO  - Can J Cardiol. 2023 Aug;39(8):1067-1077. doi: 10.1016/j.cjca.2023.04.010. Epub 
      2023 Apr 20.

PMID- 8958856
OWN - NLM
STAT- MEDLINE
DCOM- 19961231
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 25
IP  - 30
DP  - 1996 Oct 12
TI  - [Comparative trial of lysine acetylsalicylate and paracetamol on pain in daily 
      medical practice].
PG  - 1367-71
AB  - We performed a randomized double-blind controlled study in community medical 
      practice comparing lysine acetylsalicylate (LAS) and paracetamol (PAR). Both 
      drugs were given at the same dose (1 g, thrice daily) during two days; from the 
      third to the seventh day, the patients could freely take the same drug if 
      necessary. The analgesic effect of drugs was measured by two means: an analog 
      scale of pain during day 1 & 2 and the count of drugs units taken during days 3 
      to 7. The side effects were reported. We included 473 patients (167 men, 306 
      women) by means of a group of 54 general practitioners. 470 patients were 
      stratified according to the site of pain: head (n = 113), joints (n = 80), back 
      (n = 193), thorax (n = 11), teeth (n = 48), ENT (n = 25). The pain was either 
      acute (73%) or chronic (27%) and scored an average +/- SD of 76 +/- 12 mm on an 
      analog visual scale from 0 to 100 mm. Response was defined as a decrease of at 
      least 50% of the pain score. Before intake of active drugs, all patients were 
      given placebo. Only 14% responded. Under LAS or PAR, although the difference is 
      not statistically significant, the number of responders was slightly higher with 
      LAS than with PAR. Moreover, the study yields some interesting differences. 
      During day 1 and day 2, the patients of the LAS group had less pain than those of 
      the PAR group. This difference became statistically significant at D2 H12 (p < 
      0.05). LAS was significantly more effective than PAR in patients with back pain 
      (p < 0.01), and there was a trend in favor of LAS in dental and ENT pain, and for 
      intense pain. PAR never yielded better response levels than LAS. Among the 
      placebo-unresponsive patients, the amount of drug taken from day 3 to day 7 was 
      significantly lower in the LAS group than in the PAR group (p < 0.05). The side 
      effects were comparable in both groups. According to the investigators' point of 
      view both drugs were similarly well accepted by the patients (89.3% in LAS group, 
      94% in PAR group). The fact that LAS seems more effective than PAR in some kinds 
      of pain is to bring near to the anti-inflammatory action of LAS and to its better 
      bioavailability.
FAU - Cabane, J
AU  - Cabane J
AD  - Service de Médecine interne, Hôpital Saint-Antoine, Paris.
FAU - Festino, C
AU  - Festino C
FAU - Lablache Combier, B
AU  - Lablache Combier B
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Essai comparatif de l'acétylsalicylate de lysine et du paracétamol sur les 
      douleurs de pratique médicale courante.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acetaminophen/administration & dosage/*therapeutic use
MH  - Adult
MH  - Analgesics/administration & dosage/*therapeutic use
MH  - Analgesics, Non-Narcotic/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Double-Blind Method
MH  - Family Practice
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Placebos
EDAT- 1996/10/12 00:00
MHDA- 1996/10/12 00:01
CRDT- 1996/10/12 00:00
PHST- 1996/10/12 00:00 [pubmed]
PHST- 1996/10/12 00:01 [medline]
PHST- 1996/10/12 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1996 Oct 12;25(30):1367-71.

PMID- 20074228
OWN - NLM
STAT- MEDLINE
DCOM- 20100817
LR  - 20151113
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 17
IP  - 4
DP  - 2010 Apr
TI  - Efficacy of fixed combinations of acetylsalicyclic acid, acetaminophen and 
      caffeine in the treatment of idiopathic headache: a review.
PG  - 534-e25
LID - 10.1111/j.1468-1331.2009.02922.x [doi]
AB  - Headache is one of the most common reasons for patients to visit their general 
      practitioner. Most of these patients suffer from migraine, tension-type headache, 
      or a combination of the two; they tend to self-medicate using over the counter 
      combination headache preparations, particularly acetylsalicyclic acid (ASA) and 
      acetaminophen coformulated with caffeine, which is one of the most commonly used 
      combination analgesics in these patients worldwide. We reviewed studies on the 
      efficacy and safety of this combination. In the treatment of migraine and 
      tension-type headache, the combination of ASA, acetaminophen, and caffeine has 
      been shown to be more efficacious and superior to monotherapy with the single 
      substances of the combination. According to literature, there is no evidence for 
      higher prevalence of undesirable side-effects of combination analgesics in 
      comparison to monotherapy.
FAU - Anneken, K
AU  - Anneken K
AD  - Department of Neurology, Community Hospital of Dortmund, Dortmund, Germany.
FAU - Evers, S
AU  - Evers S
FAU - Husstedt, I W
AU  - Husstedt IW
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100113
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur J Neurol. 2010 Nov;17(11):e103-4. PMID: 20629725
MH  - Acetaminophen/administration & dosage/adverse effects/*therapeutic use
MH  - Analgesics, Non-Narcotic/administration & dosage/adverse effects/*therapeutic use
MH  - Animals
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Caffeine/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Combinations
MH  - Humans
MH  - Tension-Type Headache/*drug therapy
RF  - 55
EDAT- 2010/01/16 06:00
MHDA- 2010/08/18 06:00
CRDT- 2010/01/16 06:00
PHST- 2010/01/16 06:00 [entrez]
PHST- 2010/01/16 06:00 [pubmed]
PHST- 2010/08/18 06:00 [medline]
AID - ENE2922 [pii]
AID - 10.1111/j.1468-1331.2009.02922.x [doi]
PST - ppublish
SO  - Eur J Neurol. 2010 Apr;17(4):534-e25. doi: 10.1111/j.1468-1331.2009.02922.x. Epub 
      2010 Jan 13.

PMID- 12064188
OWN - NLM
STAT- MEDLINE
DCOM- 20030418
LR  - 20131121
IS  - 1129-4728 (Print)
IS  - 1129-4728 (Linking)
VI  - 3
IP  - 5
DP  - 2002 May
TI  - [Oral anticoagulants combined with aspirin in the prolonged treatment after acute 
      coronary syndrome].
PG  - 495-501
AB  - The incidence of death or myocardial infarction after acute coronary syndrome 
      (ACS) is still high despite the widespread use of aspirin. Oral anticoagulant 
      therapy (OAT) reducing thrombin activity has the potential to be beneficial when 
      administered alone or in combination with aspirin after ACS. Low-intensity OAT in 
      combination with aspirin is not superior to aspirin alone. Moderate-intensity OAT 
      in combination with aspirin is superior to aspirin alone in reducing death, 
      myocardial infarction or stroke after ACS. However, this regimen has higher rates 
      of both minor and major hemorrhages. The bleeding risk combined with the 
      difficulties of OAT management contributes to suboptimal compliance and has the 
      potential to mitigate the superior efficacy of combined regimens.
FAU - Di Pasquale, Giuseppe
AU  - Di Pasquale G
AD  - U.O. di Cardiologia, Azienda USL Bologna Nord, Ospedale di Bentivoglio, Via 
      Marconi, 35, 40010 Bentivoglio, BO. g.dipa@libero.it
FAU - Biancoli, Stefano
AU  - Biancoli S
FAU - Cerè, Elisabetta
AU  - Cerè E
FAU - Parlangeli, Riccardo
AU  - Parlangeli R
LA  - ita
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Associazione di anticoagulanti orali e aspirina in trattamento prolungato dopo 
      sindrome coronarica acuta.
PL  - Italy
TA  - Ital Heart J Suppl
JT  - Italian heart journal. Supplement : official journal of the Italian Federation of 
      Cardiology
JID - 101223651
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Administration, Oral
MH  - Anticoagulants/*administration & dosage
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Syndrome
MH  - Time Factors
RF  - 32
EDAT- 2002/06/18 10:00
MHDA- 2003/04/19 05:00
CRDT- 2002/06/18 10:00
PHST- 2002/06/18 10:00 [pubmed]
PHST- 2003/04/19 05:00 [medline]
PHST- 2002/06/18 10:00 [entrez]
PST - ppublish
SO  - Ital Heart J Suppl. 2002 May;3(5):495-501.

PMID- 2632449
OWN - NLM
STAT- MEDLINE
DCOM- 19900521
LR  - 20131121
IS  - 0301-4738 (Print)
IS  - 0301-4738 (Linking)
VI  - 37
IP  - 3
DP  - 1989 Jul-Sep
TI  - Systemic aspirin and systemic vitamin E in senile cataracts: cataract V.
PG  - 134-41
AB  - We undertook a prospective study in senile cataract patients using systemic 
      aspirin and systemic vitamin E. Vitamin E treated eyes did show less progression 
      of PSC opacities extent and less new nuclear opacities during the follow-up, but 
      overall vitamin E treated eyes did no better than the control group eyes. More 
      eyes in systemic aspirin treated group maintained the initial vision and loss of 
      vision in the aspirin group was also less marked. Aspirin also caused a 
      significant less mean increase in cortical opacity extent, nuclear/opacity and 
      density and PSC opacity extent and density as well as in ophthalmoscopically 
      graded opacity extent and density. We suggest that aspirin is a potential drug 
      which should be further evaluated in large double blind photodocumentated 
      studies. The present data does not justify the recommendation that aspirin be 
      prescribed for slowing down cataract progression. This must await large studies 
      and confirmation.
FAU - Sharma, Y R
AU  - Sharma YR
FAU - Vajpayee, R B
AU  - Vajpayee RB
FAU - Bhatnagar, R
AU  - Bhatnagar R
FAU - Mohan, M
AU  - Mohan M
FAU - Azad, R V
AU  - Azad RV
FAU - Kumar, M
AU  - Kumar M
FAU - Nath, R
AU  - Nath R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Ophthalmol
JT  - Indian journal of ophthalmology
JID - 0405376
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aging
MH  - Aspirin/*therapeutic use
MH  - Cataract/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Vitamin E/*therapeutic use
EDAT- 1989/07/01 00:00
MHDA- 1989/07/01 00:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 1989/07/01 00:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Ophthalmol. 1989 Jul-Sep;37(3):134-41.

PMID- 23696706
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20211021
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Print)
IS  - 1176-6344 (Linking)
VI  - 9
DP  - 2013
TI  - Esomeprazole and aspirin fixed combination for the prevention of cardiovascular 
      events.
PG  - 245-54
LID - 10.2147/VHRM.S44265 [doi]
AB  - Low dose aspirin therapy plays a fundamental role in both the primary and 
      secondary prevention of cardiovascular events. Although the evidence using low 
      dose aspirin for secondary prevention is well-established, the decision to use 
      aspirin for primary prevention is based on an evaluation of the patient's risk of 
      cardiovascular events compared to their risk of adverse events, such as bleeding. 
      In addition to the risk of bleeding associated with long term aspirin 
      administration, upper gastrointestinal side effects, such as dyspepsia often lead 
      to discontinuation of therapy, which places patients at an increased risk for 
      cardiovascular events. One option to mitigate adverse events and increase 
      adherence is the addition of esomeprazole to the medication regimen. This review 
      article provides an evaluation of the literature on the concomitant use of 
      aspirin and esomeprazole available through February 2013. The efficacy, safety, 
      tolerability, cost effectiveness, and patient quality of life of this regimen is 
      discussed. A summary of the pharmacokinetic and pharmacodynamic interactions 
      between aspirin and esomeprazole, as well as other commonly used cardiovascular 
      medications are also reviewed. The addition of esomeprazole to low dose aspirin 
      therapy in patients at high risk of developing gastric ulcers for the prevention 
      of cardiovascular disease, significantly reduced their risk of ulcer development. 
      Pharmacokinetic and pharmacodynamic studies suggested that esomeprazole did not 
      affect the pharmacokinetic parameters or the antiplatelet effects of aspirin. 
      Therefore, for those patients who are at a high risk of developing a 
      gastrointestinal ulcer, the benefit of adding esomeprazole likely outweighs the 
      risks of longer term proton pump inhibitor use, and the combination can be 
      recommended. Administering the two agents separately may also be more economical. 
      On the other hand, for those patients at lower risk of developing a 
      gastrointestinal ulcer, both the additional risk and cost make the inclusion of a 
      proton pump inhibitor unwarranted.
FAU - Sylvester, Katelyn W
AU  - Sylvester KW
AD  - Department of Pharmacy, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Cheng, Judy Wm
AU  - Cheng JW
FAU - Mehra, Mandeep R
AU  - Mehra MR
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130516
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - N3PA6559FT (Esomeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/economics/pharmacokinetics/*therapeutic use
MH  - Cardiovascular Diseases/economics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Drug Combinations
MH  - Drug Costs
MH  - Esomeprazole/adverse effects/economics/pharmacokinetics/*therapeutic use
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced/economics/*prevention & control
MH  - Humans
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/adverse 
      effects/economics/pharmacokinetics/*therapeutic use
MH  - Proton Pump Inhibitors/adverse effects/economics/pharmacokinetics/*therapeutic 
      use
MH  - Quality of Life
MH  - Risk Factors
MH  - Treatment Outcome
PMC - PMC3658534
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular event prevention
OT  - esomeprazole
OT  - proton pump inhibitors
EDAT- 2013/05/23 06:00
MHDA- 2013/10/18 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/23 06:00 [entrez]
PHST- 2013/05/23 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - vhrm-9-245 [pii]
AID - 10.2147/VHRM.S44265 [doi]
PST - ppublish
SO  - Vasc Health Risk Manag. 2013;9:245-54. doi: 10.2147/VHRM.S44265. Epub 2013 May 
      16.

PMID- 25869498
OWN - NLM
STAT- MEDLINE
DCOM- 20160212
LR  - 20220311
IS  - 1879-3649 (Electronic)
IS  - 1537-1891 (Linking)
VI  - 67-69
DP  - 2015 Apr-Jun
TI  - A brief review on high on-aspirin residual platelet reactivity.
PG  - 6-9
LID - S1537-1891(15)00068-3 [pii]
LID - 10.1016/j.vph.2015.03.018 [doi]
AB  - Although aspirin is effective in secondary prevention in coronary heart disease, 
      new thromboembolic events in patients on aspirin are frequently seen. In trials 
      on aspirin-treated patients, platelet function tests have revealed large 
      variability in platelet aggregation. This phenomenon has been named aspirin 
      resistance, aspirin non-responsiveness or high-on-aspirin residual platelet 
      reactivity. The mechanism of aspirin antiplatelet effect is due to the inhibition 
      of cyclooxygenase-1 enzyme in platelets. In some trials, almost all patients on 
      aspirin have a very low level of serum thromboxane B2, indicating that the 
      measured platelet reactivity in aspirin-treated patients might be due to platelet 
      activation via other pathways, such as ADP or thrombin. The prevalence of real 
      aspirin resistance seems to be very low, and probably the term "high-on-aspirin 
      residual platelet reactivity" should be preferred to describe this phenomenon.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Pettersen, A A
AU  - Pettersen AA
AD  - Center for Clinical Heart Research, Department of Cardiology, Oslo University 
      Hospital, Ullevaal, Norway; Department of Medicine, Vestre Viken HF, Ringerike 
      Hospital, Hønefoss, Norway. Electronic address: alfaage@online.no.
FAU - Arnesen, H
AU  - Arnesen H
AD  - Center for Clinical Heart Research, Department of Cardiology, Oslo University 
      Hospital, Ullevaal, Norway; Faculty of Medicine, University of Oslo, Oslo, 
      Norway.
FAU - Seljeflot, I
AU  - Seljeflot I
AD  - Center for Clinical Heart Research, Department of Cardiology, Oslo University 
      Hospital, Ullevaal, Norway; Faculty of Medicine, University of Oslo, Oslo, 
      Norway.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150411
PL  - United States
TA  - Vascul Pharmacol
JT  - Vascular pharmacology
JID - 101130615
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*pharmacology
MH  - Blood Platelets/drug effects/metabolism
MH  - Cardiovascular Diseases/blood/chemically induced/prevention & control
MH  - Endothelium, Vascular/drug effects/metabolism
MH  - Humans
MH  - Platelet Activation/*drug effects/physiology
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacology
MH  - Platelet Function Tests/methods
OTO - NOTNLM
OT  - Aspirin
OT  - Coronary artery disease
OT  - Cyclooxygenase
OT  - Platelet reactivity
OT  - Thromboxane
EDAT- 2015/04/15 06:00
MHDA- 2016/02/13 06:00
CRDT- 2015/04/15 06:00
PHST- 2015/02/24 00:00 [received]
PHST- 2015/03/17 00:00 [revised]
PHST- 2015/03/26 00:00 [accepted]
PHST- 2015/04/15 06:00 [entrez]
PHST- 2015/04/15 06:00 [pubmed]
PHST- 2016/02/13 06:00 [medline]
AID - S1537-1891(15)00068-3 [pii]
AID - 10.1016/j.vph.2015.03.018 [doi]
PST - ppublish
SO  - Vascul Pharmacol. 2015 Apr-Jun;67-69:6-9. doi: 10.1016/j.vph.2015.03.018. Epub 
      2015 Apr 11.

PMID- 31212398
OWN - NLM
STAT- MEDLINE
DCOM- 20191108
LR  - 20191108
IS  - 2208-7958 (Electronic)
VI  - 47
IP  - 12
DP  - 2018 Dec
TI  - Chemoprevention: A new concept for cancer prevention in primary care.
PG  - 825-828
LID - 10.31128/AJGP-07-18-4644 [doi]
AB  - BACKGROUND: Prevention of cancer in primary care has focused on modifying 
      behaviours associated with increased risk of cancer (primary prevention) or 
      increasing participation in national cancer screening programs (secondary 
      prevention). On the basis of metaanalyses of large prevention trials, a new 
      paradigm in primary prevention – chemoprevention – is beginning to enter the 
      realms of primary care for specific populations. OBJECTIVES: In this article, we 
      discuss two examples of cancer chemoprevention relevant to general practice: 
      low-dose aspirin for the prevention of colorectal cancer in people aged 50–70 
      years, and selective oestrogen receptor modulators (SERMs) for women at increased 
      risk of breast cancer. We present new expected frequency trees that show the 
      absolute benefits and harms of taking these medications in specific populations. 
      DISCUSSION: These expected frequency trees can serve as risk-communication aids 
      to support shared decision making and the implementation of new chemoprevention 
      guidelines in general practice.
FAU - Emery, Jon
AU  - Emery JD
AD  - MA, MBBCh, FRACGP, MRCGP, DPhil, Herman Professor of Primary Care Cancer 
      Research, Centre for Cancer Research and Department of General Practice, Faculty 
      of Medicine, Dentistry and Health Sciences, University of Melbourne, Vic. 
      jon.emery@unimelb.edu.au
FAU - Nguyen, Peter
AU  - Nguyen P
AD  - BBiomed(Hons) student, Centre for Cancer Research and Department of General 
      Practice, Faculty of Medicine, Dentistry and Health Sciences, University of 
      Melbourne, Vic
FAU - Minshall, Jesse
AU  - Minshall J
AD  - MD, BSc, medical intern, Western Health, Footscray, Vic
FAU - Cummings, Kara-Lynne
AU  - Cummings KL
AD  - BA, PC4 Project Officer, Centre for Cancer Research and Department of General 
      Practice, Faculty of Medicine, Dentistry and Health Sciences, University of 
      Melbourne, Vic
FAU - Walker, Jennifer
AU  - Walker J
AD  - BAppSci, MPH, PhD, Senior Research Fellow, Centre for Cancer Research and 
      Department of General Practice, Faculty of Medicine, Dentistry and Health 
      Sciences, University of Melbourne, Vic
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Aust J Gen Pract
JT  - Australian journal of general practice
JID - 101718099
RN  - 0 (Selective Estrogen Receptor Modulators)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Chemoprevention/*methods/trends
MH  - Humans
MH  - Neoplasms/*prevention & control
MH  - Primary Health Care/*trends
MH  - Selective Estrogen Receptor Modulators/therapeutic use
EDAT- 2019/06/20 06:00
MHDA- 2019/11/09 06:00
CRDT- 2019/06/19 06:00
PHST- 2019/06/19 06:00 [entrez]
PHST- 2019/06/20 06:00 [pubmed]
PHST- 2019/11/09 06:00 [medline]
AID - 10.31128/AJGP-07-18-4644 [doi]
PST - ppublish
SO  - Aust J Gen Pract. 2018 Dec;47(12):825-828. doi: 10.31128/AJGP-07-18-4644.

PMID- 35363182
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 7
DP  - 2022 Feb 18
TI  - Evaluation of efficacy and safety of aspirin combination treatment in treating 
      patients with coronary heart disease: A protocol for systematic review and 
      meta-analysis.
PG  - e28848
LID - 10.1097/MD.0000000000028848 [doi]
LID - e28848
AB  - BACKGROUND: Coronary heart disease (CHD) has a high incidence rate as a 
      cardiovascular condition, primarily affecting the elderly and middle-aged 
      individuals. CHD has debilitating effects on the standard of life of the elderly, 
      and affecting their physical and psychological health. Reportedly, using aspirin 
      alone is less effective as a first line of treatment for CHD. Therefore, this 
      systematic review and meta-analysis will synthesize evidence on the effectiveness 
      and safeness of aspirin combination treatment in treating patients with CHD. 
      METHODS: A comprehensive meta-analysis is to be performed to evaluate the 
      effectiveness and safety of aspirin combination treatment for CHD patients. A 
      search will be performed on PubMed, EMBASE, Cochrane Central, WanFang, and 
      Chinese National Knowledge Infrastructure till December 25, 2021 to identify 
      randomized controlled trials, assess all related studies on the aspirin 
      combination treatment in treating patients with CHD. In this systematic review, 
      we will adopt the second version of Cochrane risk of bias assessment tool to 
      assess the bias risk in all studies that fulfil the eligibility conditions. Two 
      authors will separately conduct the study selection process, risk of bias 
      assessment, and data extraction. Moreover, a random-effects meta-analysis will be 
      conducted to synthesize evidence for all outcomes. Provided there is sufficient 
      homogeneity among the studies, we will perform meta-analysis. I2 test will be 
      employed to assess the heterogeneity of the outcomes. OSF REGISTRATION NUMBER: 
      10.17605/OSF.IO/MDTCA.
CI  - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wang, Xueling
AU  - Wang X
AUID- ORCID: 0000-0002-7306-190
AD  - Department of Cardiovascular Medicine, Beijing Hospital of Integrated Traditional 
      Chinese and Western Medicine, Beijing, China.
FAU - Han, Lin
AU  - Han L
AD  - Department of Cardiology, Beijing Luhe Hospital, Capital Medical University, 
      Beijing, China.
FAU - Yang, Jiyuan
AU  - Yang J
AD  - Department of Cardiovascular Medicine, Beijing Hospital of Integrated Traditional 
      Chinese and Western Medicine, Beijing, China.
LA  - eng
GR  - 2016HDPMA15/Beijing Municipal Administration of Traditional Chinese Medicine/
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - *Coronary Disease/drug therapy
MH  - *Drugs, Chinese Herbal/adverse effects
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Systematic Reviews as Topic
PMC - PMC9281913
COIS- The authors have no conflicts of interests to disclose.
EDAT- 2022/04/02 06:00
MHDA- 2022/04/06 06:00
CRDT- 2022/04/01 12:21
PHST- 2022/01/22 00:00 [received]
PHST- 2022/01/28 00:00 [accepted]
PHST- 2022/04/01 12:21 [entrez]
PHST- 2022/04/02 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
AID - 00005792-202202180-00024 [pii]
AID - MD-D-22-00553 [pii]
AID - 10.1097/MD.0000000000028848 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Feb 18;101(7):e28848. doi: 
      10.1097/MD.0000000000028848.

PMID- 12885394
OWN - NLM
STAT- MEDLINE
DCOM- 20040428
LR  - 20191107
IS  - 0928-0987 (Print)
IS  - 0928-0987 (Linking)
VI  - 19
IP  - 4
DP  - 2003 Jul
TI  - Applications of a new device (spindle) for improved characterization of drug 
      release (dissolution) of pharmaceutical products.
PG  - 291-7
AB  - A crescent spindle (patent pending) is described which may be used in place of 
      the USP paddle component in USP dissolution apparatus 2. The new spindle is curve 
      shaped, corresponding to the bottom of a dissolution vessel, with attached 
      bristles to fill in the gap between the spindle and the surface of the vessel. 
      The geometry of the new spindle provides more efficient mixing than the USP 
      paddle and prevents accumulation of disintegrated material (no cone formation). 
      Using the new spindle, in comparison with the USP paddle, dissolution 
      characteristics of three drug products: 250 mg amoxicillin capsules, 15.6 g 
      acetylsalicylic acid (ASA) boluses and 200 mg carbamzepine tablets were 
      evaluated. The experimental conditions for dissolution testing with the two 
      stirring devices included; 900 ml of 0.05 M phosphate buffer, pH 6.8 with 50 rpm, 
      900 ml of 0.05 M acetate buffer, pH 4.5-ethanol (7:3) with 50 rpm, and water 
      containing 1% sodium lauryl sulphate with 75 rpm for amoxicillin capsules, ASA 
      boluses and carbamazepine tablets, respectively. Uncharacteristic of the test 
      products, which are fast release, the USP paddle provides significantly slower 
      drug release. For example, 90 min for <80% drug release vs. 10 min for >90% for 
      amoxicillin capsules and 6 h for 80% vs. 30 min for >90% for ASA boluses with USP 
      paddle vs. the new spindle. In case of the carbamazepine tablets, three products 
      which are bioequivalent and prescribed interchangeably, the USP paddle method 
      shows significantly different dissolution characteristics. However, with the new 
      device, all these products show similar drug release characteristics, a better 
      reflection of product release characteristics and in vivo drug release behaviour. 
      Compared with the USP paddle, the suggested device (spindle) provides improved 
      stirring and mixing which appears to provide more appropriate (biorelevant) 
      characterization of pharmaceutical products.
FAU - Qureshi, Saeed A
AU  - Qureshi SA
AD  - Health Products and Food Branch (PL 2202C1), Health Canada, Ottawa, Ontario K1A 
      0L2, Canada. saeed_qureshi@hc-sc.gc.ca
FAU - Shabnam, Javad
AU  - Shabnam J
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Capsules)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Solutions)
RN  - 0 (Tablets)
RN  - 33CM23913M (Carbamazepine)
RN  - 804826J2HU (Amoxicillin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amoxicillin/chemistry/pharmacokinetics
MH  - Aspirin/chemistry/pharmacokinetics
MH  - Capsules
MH  - Carbamazepine/chemistry/pharmacokinetics
MH  - *Chemistry, Pharmaceutical
MH  - Kinetics
MH  - Pharmaceutical Preparations/*chemistry
MH  - Solutions
MH  - Tablets
MH  - Time Factors
EDAT- 2003/07/30 05:00
MHDA- 2004/04/29 05:00
CRDT- 2003/07/30 05:00
PHST- 2003/07/30 05:00 [pubmed]
PHST- 2004/04/29 05:00 [medline]
PHST- 2003/07/30 05:00 [entrez]
AID - S0928098703001209 [pii]
AID - 10.1016/s0928-0987(03)00120-9 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2003 Jul;19(4):291-7. doi: 10.1016/s0928-0987(03)00120-9.

PMID- 11794538
OWN - NLM
STAT- MEDLINE
DCOM- 20020624
LR  - 20190916
IS  - 0253-6269 (Print)
IS  - 0253-6269 (Linking)
VI  - 24
IP  - 6
DP  - 2001 Dec
TI  - Effect of vehicles and enhancers on the in vitro skin penetration of aspalatone 
      and its enzymatic degradation across rat skins.
PG  - 572-7
AB  - The feasibility of skin penetration was studied for aspalatone (AM, 
      acetylsalicylic acid maltol ester), a novel antithrombotic agent. In this study, 
      hairless mouse dorsal skins were used as a model to select composition of vehicle 
      and AM. Based on measurements of solubility and partition coefficient, the 
      concentration of PG that showed the highest flux for AM across the hairless mouse 
      skin was found to be 40%. The cumulative amount permeated at 48 h, however, 
      appear inadequate, even when the PG concentration was employed. To identify a 
      suitable absorption enhancer and its optimal concentration for AM, a number of 
      absorption enhancers and a variety of concentration were screened for the 
      increase in transdermal flux of AM. Amongst these, linoleic acid (LOA) at the 
      concentration of 5% was found to have the largest enhancement factor (i.e., 132). 
      However, a further increase in AM flux was not found in the fatty acid 
      concentration greater than 5%, indicating the enhancement effect is in a 
      bell-shaped curve. In a study of the effect of AM concentration on the 
      permeation, there was no difference in the permeation rate between 0.5 and 1% for 
      AM, below its saturated concentration. At the donor concentration of 2%, over the 
      saturated condition, the flux of AM was markedly increased. A considerable 
      degradation of AM was found during permeation studies, and the extent was 
      correlated with protein concentrations in the epidermal and serosal extracts, and 
      skin homogenates. In rat dorsal skins, the protein concentration decreased in the 
      rank order of skin homogenate > serosal extract > epidermal extract. Estimated 
      first order degradation rate constants were 6.1 5 +/- 0.14, 0.57 +/- 0.02 and 
      0.011 +/- 0.004 h(-1) for skin homogenate, serosal extract and epidermal extract, 
      respectively. Therefore, it appeared that AM was hydrolyzed to some extent into 
      salicylmaltol by esterases in the dermal and subcutaneous tissues of skin. Taken 
      together, our data indicated that transdermal delivery of AM is feasible when the 
      combination of PG and LOA is used as a vehicle. However, since AM is not 
      metabolically stable, acceptable degradation inhibitors may be necessary to fully 
      realize the transdermal delivery of the drug.
FAU - Gwak, H S
AU  - Gwak HS
AD  - Laboratory of Pharmaceutics, College of Pharmacy, Dongduk Women's University, 
      Seoul, Korea.
FAU - Chun, I K
AU  - Chun IK
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Pharmaceutical Vehicles)
RN  - 9KJL21T0QJ (Linoleic Acid)
RN  - A233M007P0 (aspalatone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacokinetics
MH  - Fibrinolytic Agents/*pharmacokinetics
MH  - Linoleic Acid/pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Hairless
MH  - Pharmaceutical Vehicles
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Skin/*metabolism
MH  - *Skin Absorption
MH  - Species Specificity
EDAT- 2002/01/17 10:00
MHDA- 2002/06/25 10:01
CRDT- 2002/01/17 10:00
PHST- 2002/01/17 10:00 [pubmed]
PHST- 2002/06/25 10:01 [medline]
PHST- 2002/01/17 10:00 [entrez]
AID - 10.1007/BF02975168 [doi]
PST - ppublish
SO  - Arch Pharm Res. 2001 Dec;24(6):572-7. doi: 10.1007/BF02975168.

PMID- 8480641
OWN - NLM
STAT- MEDLINE
DCOM- 19930524
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 71
IP  - 13
DP  - 1993 May 15
TI  - Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris.
PG  - 1164-8
AB  - To evaluate the effects of aspirin on thrombin generation in patients with 
      unstable angina, plasma levels of thrombin-antithrombin III complex (TAT) as a 
      new marker of thrombin generation and of 11-dehydro-thromboxane B2 
      (11-dehydro-TXB2) as an indicator of platelet activation were measured in 18 
      patients with unstable angina, including 8 patients with prolonged rest angina (> 
      15 minutes). Aspirin DL-lysine (900 mg) was administered intravenously to 9 of 
      the 18 patients (aspirin group); the other 9 were not given aspirin during the 
      first 24 hours of hospitalization (non-aspirin group). Clinical characteristics, 
      angiographic features and medications other than aspirin were similar between the 
      2 groups. Levels of plasma TAT and 11-dehydro-TXB2 were significantly higher (p < 
      0.05) in patients with prolonged rest angina than in those without the condition 
      (n = 10). In 5 patients with prolonged rest angina who received aspirin, plasma 
      TAT levels (ng/ml) were significantly decreased (4.52 +/- 1.18 at baseline, 2.50 
      +/- 0.65 at 1 hour and 2.16 +/- 0.42 at 24 hours after aspirin administration, p 
      < 0.01) with a significant decrease in plasma 11-dehydro-TXB2 levels. However, 
      the reduction in TAT after aspirin administration was slight in patients without 
      prolonged rest angina (n = 4). In contrast, levels of plasma TAT and 
      11-dehydro-TXB2 in the non-aspirin group remained unchanged during the study 
      period. These results suggest that aspirin rapidly reduces thrombin generation 
      through inhibition of platelet activity in patients with unstable angina with 
      prolonged rest angina.
FAU - Yasu, T
AU  - Yasu T
AD  - Department of Medicine, National Cardiovascular Center, Osaka, Japan.
FAU - Oshima, S
AU  - Oshima S
FAU - Imanishi, M
AU  - Imanishi M
FAU - Nonogi, H
AU  - Nonogi H
FAU - Haze, K
AU  - Haze K
FAU - Kuramochi, M
AU  - Kuramochi M
FAU - Omae, T
AU  - Omae T
FAU - Hayashi, Y
AU  - Hayashi Y
FAU - Yamamoto, S
AU  - Yamamoto S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (antithrombin III-protease complex)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - 9000-94-6 (Antithrombin III)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - EC 3.4.21.5 (Thrombin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angina, Unstable/*blood/drug therapy
MH  - Antithrombin III/*analysis
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Peptide Hydrolases/*analysis
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Thrombin/biosynthesis
MH  - Thromboxane B2/*analogs & derivatives/blood
EDAT- 1993/05/15 00:00
MHDA- 1993/05/15 00:01
CRDT- 1993/05/15 00:00
PHST- 1993/05/15 00:00 [pubmed]
PHST- 1993/05/15 00:01 [medline]
PHST- 1993/05/15 00:00 [entrez]
AID - 0002-9149(93)90640-X [pii]
AID - 10.1016/0002-9149(93)90640-x [doi]
PST - ppublish
SO  - Am J Cardiol. 1993 May 15;71(13):1164-8. doi: 10.1016/0002-9149(93)90640-x.

PMID- 9716201
OWN - NLM
STAT- MEDLINE
DCOM- 19981116
LR  - 20190831
IS  - 0098-6569 (Print)
IS  - 0098-6569 (Linking)
VI  - 44
IP  - 4
DP  - 1998 Aug
TI  - Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation.
PG  - 387-91
AB  - Cilostazol inhibits intimal hyperplasia after stent implantation into canine 
      iliac arteries. To determine the antiproliferative effect of this agent, 
      cilostazol or aspirin was randomly given for 6 mo to 36 patients treated with 
      Palmaz-Schatz stent implantation. Initial success was obtained in 34 patients. 
      Repeat angiography was performed in 33 patients, and the complete angiographic 
      data were obtained in 22 lesions of the cilostazol group and in 21 lesions of the 
      aspirin group. The reference diameter and minimal luminal diameter were similar 
      in both groups before and immediately after stent implantation. At follow-up, 
      minimal luminal diameters were significantly greater in the cilostazol group than 
      in the aspirin group (P < 0.001). Late loss and loss index were significantly 
      smaller in the cilostazol group than in the aspirin group (P < 0.001). These 
      results suggest that cilostazol reduces angiographic late lumen loss and thereby 
      may reduce the incidence of restenosis after Palmaz-Schatz stent implantation.
FAU - Yamasaki, M
AU  - Yamasaki M
AD  - Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
FAU - Hara, K
AU  - Hara K
FAU - Ikari, Y
AU  - Ikari Y
FAU - Kobayashi, N
AU  - Kobayashi N
FAU - Kozuma, K
AU  - Kozuma K
FAU - Ohmoto, Y
AU  - Ohmoto Y
FAU - Oh-Hashi, Y
AU  - Oh-Hashi Y
FAU - Ako, J
AU  - Ako J
FAU - Nakajima, H
AU  - Nakajima H
FAU - Chiku, N
AU  - Chiku N
FAU - Saeki, F
AU  - Saeki F
FAU - Tamura, T
AU  - Tamura T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cathet Cardiovasc Diagn
JT  - Catheterization and cardiovascular diagnosis
JID - 7508512
RN  - 0 (Tetrazoles)
RN  - 0 (Vasodilator Agents)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Animals
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cilostazol
MH  - Coronary Angiography
MH  - Coronary Disease/diagnostic imaging/*therapy
MH  - Dogs
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Stents
MH  - Tetrazoles/*administration & dosage/adverse effects
MH  - Vascular Patency/*drug effects
MH  - Vasodilator Agents/*administration & dosage/adverse effects
EDAT- 1998/08/26 02:27
MHDA- 2000/06/20 09:00
CRDT- 1998/08/26 02:27
PHST- 1998/08/26 02:27 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1998/08/26 02:27 [entrez]
AID - 10.1002/(SICI)1097-0304(199808)44:4<387::AID-CCD4>3.0.CO;2-0 [pii]
AID - 10.1002/(sici)1097-0304(199808)44:4<387::aid-ccd4>3.0.co;2-0 [doi]
PST - ppublish
SO  - Cathet Cardiovasc Diagn. 1998 Aug;44(4):387-91. doi: 
      10.1002/(sici)1097-0304(199808)44:4<387::aid-ccd4>3.0.co;2-0.

PMID- 8584071
OWN - NLM
STAT- MEDLINE
DCOM- 19960315
LR  - 20131121
IS  - 0028-2804 (Print)
IS  - 0028-2804 (Linking)
VI  - 66
IP  - 12
DP  - 1995 Dec
TI  - [High dosage acetylsalicylic acid administration for prevention of acute cerebral 
      ischemia].
PG  - 886-9; discussion 885
AB  - 6 studies with a placebo-controlled, double blind, randomized protocol on the 
      effect of acetylsalicylic acid (ASA) in a dosage of higher than 100 mg/day have 
      been published. The preventive effect for TIA was obvious without a significant 
      difference between males and females. The effect on secondary cerebral ischemic 
      attacks after completed infarcts has not been sufficiently proven with the ASA. 
      The preventive effect for cerebral ischemic attacks in normals without preceding 
      strokes or TIA has not been shown.
FAU - Hartmann, A
AU  - Hartmann A
AD  - Neurologische Universitätsklinik, Bonn.
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Hochdosierte Acetylsalicylsäuregabe zur Prävention der akuten zerebralen 
      Ischämie.
PL  - Germany
TA  - Nervenarzt
JT  - Der Nervenarzt
JID - 0400773
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cerebral Infarction/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
RF  - 18
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
PST - ppublish
SO  - Nervenarzt. 1995 Dec;66(12):886-9; discussion 885.

PMID- 4022667
OWN - NLM
STAT- MEDLINE
DCOM- 19850919
LR  - 20190903
IS  - 0090-4481 (Print)
IS  - 0090-4481 (Linking)
VI  - 14
IP  - 7
DP  - 1985 Jul
TI  - Management of Reye's syndrome: need for early diagnosis and intravenous treatment 
      of stage I non-comatose cases.
PG  - 511, 514-5
AB  - Clinicians and nurses should obtain a history of antecedent illness occurring 
      within 2 weeks of the onset of vomiting. Ninety percent of school-age children 
      will give a history of an antecedent illness (varicella or influenza-like 
      respiratory illness) within 1 week of the onset of vomiting. The vomiting of 
      Reye's syndrome is usually persistent, lasting for 24 to 96 hours before the 
      onset of serious brain signs. We believe that any child with the history of flu 
      or chickenpox within 1 week of the onset of vomiting, which lasts for more than 
      12 hours, and is unusually severe or is associated with lethargy, should have an 
      SGPT (alanine aminotransferase). This laboratory measure is clearly elevated in 
      most cases of Reye's syndrome.
FAU - Partin, J C
AU  - Partin JC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatr Ann
JT  - Pediatric annals
JID - 0356657
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Chickenpox/drug therapy
MH  - Coma/etiology
MH  - Glucose/administration & dosage/*therapeutic use
MH  - Humans
MH  - Influenza, Human/drug therapy
MH  - Infusions, Parenteral
MH  - Reye Syndrome/complications/etiology/*therapy
EDAT- 1985/07/01 00:00
MHDA- 1985/07/01 00:01
CRDT- 1985/07/01 00:00
PHST- 1985/07/01 00:00 [pubmed]
PHST- 1985/07/01 00:01 [medline]
PHST- 1985/07/01 00:00 [entrez]
AID - 10.3928/0090-4481-19850701-10 [doi]
PST - ppublish
SO  - Pediatr Ann. 1985 Jul;14(7):511, 514-5. doi: 10.3928/0090-4481-19850701-10.

PMID- 3324618
OWN - NLM
STAT- MEDLINE
DCOM- 19880318
LR  - 20220318
IS  - 0001-6314 (Print)
IS  - 0001-6314 (Linking)
VI  - 76
IP  - 6
DP  - 1987 Dec
TI  - Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone 
      in the prevention of stroke in patients with reversible ischemic attacks.
PG  - 413-21
AB  - A total of 243 patients who had reversible ischemic attacks (RIA) were submitted 
      to clinical trial to determine whether dipyridamole (400 mg/day) (D) or aspirin 
      (100 mg/48 hours) + dipyridamole (300 mg/day) (ASA + D) would produce significant 
      reduction in the subsequent occurrence of RIA and completed stroke. One hundred 
      and fifteen were selected for Group ASA + D and 71 were treated with dipyridamole 
      only. The treatment groups were similar in relation to age, sex, risk factors, 
      duration and presumed vascular territory of RIA, incidence of alterations of 
      arterial supra-aortic trunks, cerebral infarct (CT scan), and platelet function. 
      Patients were followed for a mean time of 21 months. At the end of the study, 
      21.7% of the ASA + D group and 19.7% in the D group had suffered new episodes of 
      RIA or completed stroke (p = 0.88). Frequency of stroke (reversible ischemic 
      neurologic deficit or completed stroke) was 7.8% in the ASA + D patients and 9.8% 
      in the D patients (p = 0.83). Subgroup analysis did not show significant 
      differences either. It is concluded that ASA + D has no significantly greater 
      beneficial effect than that observed with D alone in the secondary prevention of 
      atherothrombotic cerebral ischemia. However, a statistical Type II error cannot 
      be excluded by the reduced number of recurrences.
FAU - Matías-Guiu, J
AU  - Matías-Guiu J
AD  - Department of Neurology, Hospital Vall D'Hebron, Barcelona, Spain.
FAU - Dávalos, A
AU  - Dávalos A
FAU - Picó, M
AU  - Picó M
FAU - Monasterio, J
AU  - Monasterio J
FAU - Vilaseca, J
AU  - Vilaseca J
FAU - Codina, A
AU  - Codina A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Brain Ischemia/*complications
MH  - Cerebrovascular Disorders/etiology/*prevention & control
MH  - Clinical Trials as Topic
MH  - Dipyridamole/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Risk Factors
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
AID - 10.1111/j.1600-0404.1987.tb03596.x [doi]
PST - ppublish
SO  - Acta Neurol Scand. 1987 Dec;76(6):413-21. doi: 
      10.1111/j.1600-0404.1987.tb03596.x.

PMID- 33657049
OWN - NLM
STAT- MEDLINE
DCOM- 20220201
LR  - 20220201
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 78
IP  - 2
DP  - 2021 Aug 1
TI  - Influence of Lipid Excipients on Platelet Function and the Pharmacodynamic 
      Effects of Aspirin.
PG  - 297-301
LID - 10.1097/FJC.0000000000000998 [doi]
AB  - The combination of pharmaceutical lipid excipients with aspirin in a novel liquid 
      oral formulation (Vazalore) limits gastrointestinal toxicity of aspirin. This 
      study was performed to determine whether the lipid excipients influence the 
      pharmacodynamic effects of aspirin and whether the excipients directly affect 
      platelet function. The pharmacodynamic effects of aspirin were assessed over a 
      range of concentrations designed to exert limited to maximal inhibition of 
      cyclooxygenase-1 (COX1) necessary for thromboxane A2 production. Platelet 
      aggregation induced by arachidonic acid and assessed with the use of light 
      transmission aggregometry was used as a direct measure of the inhibition of COX1 
      by aspirin. Flow cytometry was used to assess the direct effect of excipients on 
      platelet function. Twice the ratio of lipid excipient to aspirin used in the 
      formulation of the novel oral agent was used. Blood was taken from 20 healthy 
      subjects and anticoagulated with trisodium citrate (3.2%, 1:10 vol/vol). Aspirin 
      and excipients were added in vitro and incubated for 10 minutes before 
      performance of light transmission aggregometry and flow cytometry. The excipients 
      did not limit the pharmacodynamic effects of aspirin. When the extent of 
      inhibition of platelet aggregation was limited, the excipients tended to enhance 
      pharmacodynamic effects. The excipients did not activate platelets in the absence 
      of agonist and did not alter activation of platelets in response to adenosine 
      diphosphate, arachidonic acid, thrombin, or convulxin (a collagen mimetic). Lipid 
      excipients used in an oral formulation of aspirin do not impair the 
      pharmacodynamic effects of aspirin and do not alter platelet function.
CI  - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Schneider, David J
AU  - Schneider DJ
AD  - Departments of Medicine, Cardiovascular Research Institute, the University of 
      Vermont, Burlington, VT.
FAU - Taatjes-Sommer, Heidi S
AU  - Taatjes-Sommer HS
FAU - Prats, Jayne
AU  - Prats J
FAU - Deliargyris, Efthymios N
AU  - Deliargyris EN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Biomarkers)
RN  - 0 (Excipients)
RN  - 0 (Lipids)
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (SELP protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/chemistry/*pharmacology
MH  - Biomarkers/blood
MH  - Blood Platelets/*drug effects/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Compounding
MH  - Excipients/chemistry/*pharmacology
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Lipids/chemistry/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - P-Selectin/blood
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/chemistry/*pharmacology
MH  - Platelet Function Tests
COIS- E. N. Deliargyris and J. Prats are consultants to PLx Pharma, Inc. D. J. 
      Schneider was the principle investigator on a grant supporting this study. The 
      remaining author reports no conflicts of interest.
EDAT- 2021/03/04 06:00
MHDA- 2022/02/02 06:00
CRDT- 2021/03/03 17:10
PHST- 2020/12/01 00:00 [received]
PHST- 2021/02/04 00:00 [accepted]
PHST- 2021/03/04 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
PHST- 2021/03/03 17:10 [entrez]
AID - 00005344-900000000-98273 [pii]
AID - 10.1097/FJC.0000000000000998 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2021 Aug 1;78(2):297-301. doi: 
      10.1097/FJC.0000000000000998.

PMID- 15972451
OWN - NLM
STAT- MEDLINE
DCOM- 20051107
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 106
IP  - 8
DP  - 2005 Oct 15
TI  - In vivo aspirin supplementation inhibits nitric oxide consumption by human 
      platelets.
PG  - 2737-43
AB  - Antiplatelet therapies improve endothelial function in atherosclerosis, 
      suggesting that platelets regulate vascular nitric oxide (NO) bioactivity in 
      vivo. Herein, washed platelets consumed NO on activation in an aspirin-sensitive 
      manner, and aspirin enhanced platelet NO responses in vitro. To examine whether 
      in vivo aspirin can inhibit platelet NO consumption, a double-blind 
      placebo-controlled study was conducted. After a 2-week nonsteroidal 
      anti-inflammatory drug (NSAID)-free period, healthy men were randomly assigned 
      and administered aspirin (75 mg/d orally) or identical placebo for 14 days, then 
      crossed over to the opposite arm. Following in vivo aspirin, NO consumption by 
      platelets was inhibited 91%. Rate of onset and recovery following aspirin 
      withdrawal was consistent with cyclooxygenase 1 (COX-1) inhibition. In a small 
      substudy, NO consumption by platelets from postmenopausal women was faster in 
      hypercholesterolemics and less sensitive to aspirin (ie, 39% versus 76% 
      inhibition for hypercholesterolemics or normocholesterolemics, respectively). 
      However, 150 mg aspirin/day increased inhibition of NO consumption by platelets 
      of hypercholesterolemics to 80%. Comparisons of platelet COX-1 or -2 expression 
      and urinary 11-dehydro-thromboxane B2 excretion suggested that aspirin was less 
      able to block platelet activation in vivo in hypercholesterolemia. In conclusion, 
      aspirin inhibits NO consumption by platelets from healthy subjects, but its 
      beneficial effects on NO bioactivity may be compromised in some 
      hypercholesterolemic patients.
FAU - Williams, P Claire
AU  - Williams PC
AD  - Department of Medical Biochemistry and Immunology, University of Wales College of 
      Medicine, Heath Park, Cardiff, CF14 4XN, United Kingdom.
FAU - Coffey, Marcus J
AU  - Coffey MJ
FAU - Coles, Barbara
AU  - Coles B
FAU - Sanchez, Stephanie
AU  - Sanchez S
FAU - Morrow, Jason D
AU  - Morrow JD
FAU - Cockcroft, John R
AU  - Cockcroft JR
FAU - Lewis, Malcolm J
AU  - Lewis MJ
FAU - O'Donnell, Valerie B
AU  - O'Donnell VB
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20050621
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Isoenzymes)
RN  - 0 (Thromboxanes)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/cytology/*drug effects/*metabolism
MH  - Cyclic GMP/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Health
MH  - Humans
MH  - Isoenzymes/metabolism
MH  - Nitric Oxide/*metabolism
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Thromboxanes/urine
MH  - Time Factors
EDAT- 2005/06/24 09:00
MHDA- 2005/11/08 09:00
CRDT- 2005/06/24 09:00
PHST- 2005/06/24 09:00 [pubmed]
PHST- 2005/11/08 09:00 [medline]
PHST- 2005/06/24 09:00 [entrez]
AID - S0006-4971(20)69114-5 [pii]
AID - 10.1182/blood-2005-02-0664 [doi]
PST - ppublish
SO  - Blood. 2005 Oct 15;106(8):2737-43. doi: 10.1182/blood-2005-02-0664. Epub 2005 Jun 
      21.

PMID- 7560658
OWN - NLM
STAT- MEDLINE
DCOM- 19951109
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 96
IP  - 4
DP  - 1995 Oct
TI  - Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic 
      subjects.
PG  - 480-5
AB  - OBJECTIVE: Cross-sensitivity between aspirin and acetaminophen in 
      aspirin-sensitive asthmatic patients has been reported with frequencies ranging 
      from 0% to 29%. The relationship is dose-dependent for acetaminophen challenges, 
      ranging between 300 and 100 mg. METHODS: To determine the prevalence of 
      cross-sensitivity to high-dose acetaminophen, we performed single-blind 
      acetaminophen oral challenges with 1000 mg and 1500 mg in 50 aspirin-sensitive 
      asthmatic patients and in 20 non-aspirin-sensitive asthmatic control subjects. 
      RESULTS: Overall, 17 of 50 (34%) of aspirin-sensitive asthmatic patients reacted 
      to acetaminophen in doses of 1000 to 1500 mg (95% confidence interval: 20% to 
      49%). By contrast, none of the 20 non-aspirin-sensitive asthmatic patients 
      reacted to acetaminophen (95% confidence interval: 0% to 14%). This difference 
      was highly significant (p = 0.0013), supporting the hypothesis that 
      cross-sensitivity between aspirin and acetaminophen is unique in 
      aspirin-sensitive asthmatic patients. CONCLUSION: Although high-dose ( > 1000 mg) 
      acetaminophen cross-reactions with aspirin were significant with respect to 
      frequency (34%), such reactions included easily reversed bronchospasm in only 
      22%, and were generally mild. We recommended that high doses of acetaminophen 
      (1000 mg or greater) should be avoided in aspirin-sensitive asthmatic patients.
FAU - Settipane, R A
AU  - Settipane RA
AD  - Division of Allergy and Immunology, Scripps Clinic and Research Foundation, La 
      Jolla, CA 92037, USA.
FAU - Schrank, P J
AU  - Schrank PJ
FAU - Simon, R A
AU  - Simon RA
FAU - Mathison, D A
AU  - Mathison DA
FAU - Christiansen, S C
AU  - Christiansen SC
FAU - Stevenson, D D
AU  - Stevenson DD
LA  - eng
GR  - AI-10386/AI/NIAID NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Allergy Clin Immunol. 1996 Sep;98(3):713-4. PMID: 8828553
MH  - Acetaminophen/*immunology/pharmacology
MH  - Adult
MH  - Aged
MH  - Aspirin/*immunology/pharmacology
MH  - Asthma/complications/*immunology
MH  - Cross Reactions
MH  - Dose-Response Relationship, Immunologic
MH  - Drug Hypersensitivity/complications/epidemiology/*immunology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Prospective Studies
MH  - Single-Blind Method
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - S0091-6749(95)70290-3 [pii]
AID - 10.1016/s0091-6749(95)70290-3 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1995 Oct;96(4):480-5. doi: 10.1016/s0091-6749(95)70290-3.

PMID- 30978291
OWN - NLM
STAT- MEDLINE
DCOM- 20200316
LR  - 20220105
IS  - 1535-4970 (Electronic)
IS  - 1073-449X (Print)
IS  - 1073-449X (Linking)
VI  - 200
IP  - 6
DP  - 2019 Sep 15
TI  - Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory 
      Disease. A Prospective Trial.
PG  - 704-711
LID - 10.1164/rccm.201809-1755OC [doi]
AB  - Rationale: Daily high-dose aspirin therapy benefits many patients with 
      aspirin-exacerbated respiratory disease but provides no benefit for 
      aspirin-tolerant patients with asthma. Type 2 inflammation characterizes 
      aspirin-exacerbated respiratory disease.Objectives: To determine whether 
      high-dose aspirin therapy changes biomarkers of type 2 inflammation in 
      aspirin-exacerbated respiratory disease.Methods: Forty-two subjects with 
      aspirin-exacerbated respiratory disease underwent an aspirin desensitization and 
      were placed on high-dose aspirin (1,300 mg daily). Fifteen aspirin-tolerant 
      subjects with asthma were also placed on high-dose aspirin. Biologic specimens 
      and clinical parameters were collected at baseline and after 8 weeks on aspirin. 
      Urinary eicosanoids, plasma tryptase and cytokine levels, platelet-leukocyte 
      aggregates, and granulocyte transcripts were assessed.Measurements and Main 
      Results: Eight weeks of high-dose aspirin decreased nasal symptoms and urinary 
      prostaglandin E metabolite (P < 0.05) and increased urinary leukotriene E(4) 
      (P < 0.01) levels in subjects with aspirin-exacerbated respiratory disease, but 
      not in those with aspirin-tolerant asthma. Urinary prostaglandin D(2) and 
      thromboxane metabolites decreased in both groups. Only in subjects with 
      aspirin-exacerbated respiratory disease, exhaled nitric oxide (P < 0.05), plasma 
      tryptase (P < 0.01), and blood eosinophil (P < 0.01) and basophil (P < 0.01) 
      counts increased and plasma tryptase correlated with eosinophil counts (Pearson 
      r = 0.514; P < 0.01) on aspirin. After correction for eosinophil counts, 
      aspirin-induced changes in blood granulocyte transcripts did not differ between 
      groups. Aspirin had no effect on platelet-leukocyte aggregates, platelet 
      activation markers, or plasma cytokines in either group.Conclusions: High-dose 
      aspirin therapy for 8 weeks paradoxically increases markers of type 2 
      inflammation in subjects with aspirin-exacerbated respiratory disease, despite 
      reducing nasal symptoms. This effect of aspirin is unique to aspirin-exacerbated 
      respiratory disease and not observed in subjects with aspirin-tolerant asthma.
FAU - Cahill, Katherine N
AU  - Cahill KN
AUID- ORCID: 0000-0002-8549-1835
AD  - Division of Allergy, Pulmonary and Critical Care Medicine, Department of 
      Medicine, Vanderbilt University, Nashville, Tennessee.
FAU - Cui, Jing
AU  - Cui J
AD  - Division of Rheumatology, Immunology, and Allergy and.
AD  - Harvard Medical School, Boston, Massachusetts; and.
FAU - Kothari, Parul
AU  - Kothari P
AD  - Division of Rheumatology, Immunology, and Allergy and.
AD  - Harvard Medical School, Boston, Massachusetts; and.
FAU - Murphy, Katherine
AU  - Murphy K
AD  - Division of Rheumatology, Immunology, and Allergy and.
FAU - Raby, Benjamin A
AU  - Raby BA
AD  - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham 
      and Women's Hospital, Boston, Massachusetts.
AD  - Harvard Medical School, Boston, Massachusetts; and.
AD  - Channing Division of Network Biology, Boston, Massachusetts.
FAU - Singer, Joseph
AU  - Singer J
AD  - Division of Rheumatology, Immunology, and Allergy and.
FAU - Israel, Elliot
AU  - Israel E
AD  - Division of Rheumatology, Immunology, and Allergy and.
AD  - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham 
      and Women's Hospital, Boston, Massachusetts.
AD  - Harvard Medical School, Boston, Massachusetts; and.
FAU - Boyce, Joshua A
AU  - Boyce JA
AD  - Division of Rheumatology, Immunology, and Allergy and.
AD  - Harvard Medical School, Boston, Massachusetts; and.
FAU - Laidlaw, Tanya M
AU  - Laidlaw TM
AD  - Division of Rheumatology, Immunology, and Allergy and.
AD  - Harvard Medical School, Boston, Massachusetts; and.
LA  - eng
GR  - UL1 TR001102/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, Leukotriene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Respir Crit Care Med. 2019 Sep 15;200(6):651-652. PMID: 31026400
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Asthma, Aspirin-Induced/*drug therapy
MH  - Biomarkers/*urine
MH  - Drug Hypersensitivity/*complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Receptors, Leukotriene/*analysis
MH  - Respiratory Tract Infections/*chemically induced
PMC - PMC6775876
OTO - NOTNLM
OT  - aspirin-exacerbated respiratory disease
OT  - aspirin-tolerant asthma
OT  - cysteinyl leukotrienes
OT  - mast cell
OT  - type 2 inflammation
EDAT- 2019/04/13 06:00
MHDA- 2020/03/17 06:00
CRDT- 2019/04/13 06:00
PHST- 2019/04/13 06:00 [pubmed]
PHST- 2020/03/17 06:00 [medline]
PHST- 2019/04/13 06:00 [entrez]
AID - 10.1164/rccm.201809-1755OC [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 2019 Sep 15;200(6):704-711. doi: 
      10.1164/rccm.201809-1755OC.

PMID- 23678811
OWN - NLM
STAT- MEDLINE
DCOM- 20130829
LR  - 20131121
IS  - 1934-578X (Print)
IS  - 1555-9475 (Linking)
VI  - 8
IP  - 3
DP  - 2013 Mar
TI  - Evaluation of the in vivo anti-inflammatory and analgesic and in vitro 
      anti-cancer activities of curcumin and its derivatives.
PG  - 359-62
AB  - Curcumin, obtained from turmeric, has several biological properties to make it a 
      desirable template for drug development. A lipophilic derivative of curcumin, 
      diacetyl curcumin (DAC) and a hydrophilic derivative, diglutaryl curcumin (DGC) 
      were synthesized and their in vivo analgesic and anti-inflammatory activities 
      were compared with those of curcumin and aspirin. The in vitro anti-cancer 
      activities of curcumin and the two derivatives against three cell cancer lines 
      were compared with those against a non-cancerous cell line. The inhibitory 
      effects were comparable to each other and nearing that of curcumin while they 
      showed low inhibitory effect towards the non-cancerous cell line. The mouse tail 
      flick assay showed that curcumin, DAC and DGC increased latency time. DGC was 
      most effective as an analgesic, even more so than aspirin. The maximum percentage 
      effect (MPE) was highest with DGC at 3 hours. The carrageenan induced paw edema 
      model indicated anti-inflammatory activity of all three curcumin formulations. 
      The percentage inhibition of paw edema was maximum for DAC, followed by aspirin 
      and curcumin.
FAU - Jacob, James N
AU  - Jacob JN
AD  - Department of Medicinal Chemistry, Organomed Corporation, 11 Grandview St., Unit 
      8, Coventry, RI 02816, USA. Jacob@organomed.com
FAU - Badyal, Dinesh K
AU  - Badyal DK
FAU - Bala, Suman
AU  - Bala S
FAU - Toloue, Masoud
AU  - Toloue M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nat Prod Commun
JT  - Natural product communications
JID - 101477873
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - IT942ZTH98 (Curcumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/chemistry/*pharmacology/*therapeutic use
MH  - Animals
MH  - Anti-Inflammatory Agents/chemistry/*pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Curcumin/chemistry/*pharmacology/*therapeutic use
MH  - Edema/drug therapy
MH  - Humans
MH  - Mice
MH  - Rats
EDAT- 2013/05/18 06:00
MHDA- 2013/08/30 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/05/18 06:00 [entrez]
PHST- 2013/05/18 06:00 [pubmed]
PHST- 2013/08/30 06:00 [medline]
PST - ppublish
SO  - Nat Prod Commun. 2013 Mar;8(3):359-62.

PMID- 25555354
OWN - NLM
STAT- MEDLINE
DCOM- 20151228
LR  - 20220310
IS  - 1532-2823 (Electronic)
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 96
DP  - 2015 May
TI  - The effects of aspirin on platelet function and lysophosphatidic acids depend on 
      plasma concentrations of EPA and DHA.
PG  - 17-24
LID - S0952-3278(14)00207-5 [pii]
LID - 10.1016/j.plefa.2014.12.005 [doi]
AB  - Aspirin's prevention of cardiovascular disease (CVD) events in individuals with 
      type 2 diabetes mellitus is controversial. Eicosapentaenoic acid (EPA) and 
      docosahexaenoic acid (DHA) and aspirin all affect the cyclooxygenase enzyme. The 
      relationship between plasma EPA and DHA and aspirin's effects has not been 
      determined. Thirty adults with type 2 diabetes mellitus ingested aspirin (81 
      mg/day) for 7 days, then EPA+DHA (2.6g/day) for 28 days, then both for another 7 
      days. Lysophosphatidic acid (LPA) species and more classic platelet function 
      outcomes were determined. Plasma concentrations of total EPA+DHA were associated 
      with 7-day aspirin reduction effects on these outcomes in a "V"-shaped manner for 
      all 11 LPA species and ADP-induced platelet aggregation. This EPA+DHA 
      concentration was quite consistent for each of the LPA species and ADP. These 
      results support aspirin effects on lysolipid metabolism and platelet aggregation 
      depending on plasma EPA+DHA concentrations in individuals with a disturbed lipid 
      milieu.
CI  - Copyright © 2014 Elsevier Ltd. All rights reserved.
FAU - Block, Robert C
AU  - Block RC
AD  - Department of Public Health Sciences, University of Rochester, School of Medicine 
      and Dentistry, 265 Crittenden Boulevard, Box CU 420644, Rochester, NY 14642, USA. 
      Electronic address: robert_block@urmc.rochester.edu.
FAU - Abdolahi, Amir
AU  - Abdolahi A
AD  - Department of Public Health Sciences, University of Rochester, School of Medicine 
      and Dentistry, 265 Crittenden Boulevard, Box CU 420644, Rochester, NY 14642, USA.
FAU - Tu, Xin
AU  - Tu X
AD  - Department of Biostatistics and Computational Biology, University of Rochester, 
      School of Medicine and Dentistry, 265 Crittenden Boulevard, Box CU 420644, 
      Rochester, NY 14642 USA.
FAU - Georas, Steve N
AU  - Georas SN
AD  - Pulmonary and Critical Care Division, Department of Medicine, University of 
      Rochester, School of Medicine and Dentistry, Rochester, NY, USA.
FAU - Brenna, J Thomas
AU  - Brenna JT
AD  - Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.
FAU - Phipps, Richard P
AU  - Phipps RP
AD  - Department of Environmental Medicine, University of Rochester, School of Medicine 
      and Dentistry, Rochester, NY, USA.
FAU - Lawrence, Peter
AU  - Lawrence P
AD  - Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA.
FAU - Mousa, Shaker A
AU  - Mousa SA
AD  - Pharmaceutical Research Institute, Albany College of Pharmacy and Health 
      Sciences, Albany, NY, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01181882
GR  - R21ES023032/ES/NIEHS NIH HHS/United States
GR  - KL2RR024136/RR/NCRR NIH HHS/United States
GR  - R21 HL102582/HL/NHLBI NIH HHS/United States
GR  - P30 ES001247/ES/NIEHS NIH HHS/United States
GR  - UL1 TR000042/TR/NCATS NIH HHS/United States
GR  - R21 ES023032/ES/NIEHS NIH HHS/United States
GR  - R01HL071933/HL/NHLBI NIH HHS/United States
GR  - 5R21HL-102582-02/HL/NHLBI NIH HHS/United States
GR  - UL1 RR024160/RR/NCRR NIH HHS/United States
GR  - R01 HL071933/HL/NHLBI NIH HHS/United States
GR  - T32HL007937/HL/NHLBI NIH HHS/United States
GR  - KL2 RR024136/RR/NCRR NIH HHS/United States
GR  - T32 HL007937/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20141222
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Lysophospholipids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - PG6M3969SG (lysophosphatidic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Blood Platelets/*drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/metabolism
MH  - Docosahexaenoic Acids/*blood/pharmacology
MH  - Eicosapentaenoic Acid/*blood/pharmacology
MH  - Fatty Acids, Unsaturated/blood/pharmacology
MH  - Female
MH  - Humans
MH  - Lysophospholipids/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage
PMC - PMC4395522
MID - NIHMS651316
OTO - NOTNLM
OT  - Aspirin
OT  - Docosahexaenoic acid
OT  - Eicosapentaenoic acid
OT  - Lysophosphatidic acid
OT  - Lysophosphatidylcholine
OT  - Platelet function
EDAT- 2015/01/04 06:00
MHDA- 2015/12/29 06:00
CRDT- 2015/01/04 06:00
PHST- 2014/08/27 00:00 [received]
PHST- 2014/12/11 00:00 [revised]
PHST- 2014/12/14 00:00 [accepted]
PHST- 2015/01/04 06:00 [entrez]
PHST- 2015/01/04 06:00 [pubmed]
PHST- 2015/12/29 06:00 [medline]
AID - S0952-3278(14)00207-5 [pii]
AID - 10.1016/j.plefa.2014.12.005 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2015 May;96:17-24. doi: 
      10.1016/j.plefa.2014.12.005. Epub 2014 Dec 22.

PMID- 33819061
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 174
IP  - 4
DP  - 2021 Apr
TI  - In at-risk patients without CVD, polypill plus aspirin reduced a composite of 
      major CV events at 4.6 y.
PG  - JC41
LID - 10.7326/ACPJ202104200-041 [doi]
AB  - Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons 
      without cardiovascular disease. N Engl J Med. 2021;384:216-28. 33186492.
FAU - Tanner, Michael
AU  - Tanner M
AD  - NYU Grossman School of Medicine, New York, New York, USA (M.T.).
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20210406
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - N Engl J Med. 2021 Jan 21;384(3):216-228. PMID: 33186492
MH  - Angiotensin-Converting Enzyme Inhibitors
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/prevention & control
MH  - Drug Combinations
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors
MH  - Platelet Aggregation Inhibitors/adverse effects
OTO - NOTNLM
OT  - Adrenergic beta-antagonists
OT  - Angiotensin-converting enzyme inhibitors
OT  - Antihypertensive agents
OT  - Cardiovascular diseases
OT  - Hydroxymethylglutaryl-CoA reductase inhibitors
OT  - Platelet aggregation inhibitors
EDAT- 2021/04/06 06:00
MHDA- 2021/05/11 06:00
CRDT- 2021/04/05 17:09
PHST- 2021/04/06 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2021/04/05 17:09 [entrez]
AID - 10.7326/ACPJ202104200-041 [doi]
PST - ppublish
SO  - Ann Intern Med. 2021 Apr;174(4):JC41. doi: 10.7326/ACPJ202104200-041. Epub 2021 
      Apr 6.

PMID- 33961154
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Linking)
VI  - 23
IP  - 6
DP  - 2021 May 7
TI  - Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision 
      Making in the Face of Uncertainty.
PG  - 67
LID - 10.1007/s11886-021-01499-y [doi]
AB  - PURPOSE OF REVIEW: The utility of aspirin and statins for primary prevention of 
      atherosclerotic cardiovascular disease remains ambiguous in older adults. Current 
      guidelines and recent data are vague and inconclusive. This review seeks to 
      summarize the landscape of primary prevention of cardiovascular disease in older 
      adults and explore the role of shared decision making. RECENT FINDINGS: 
      Observational data suggest potential benefit of statin therapy in older adults. 
      Aspirin is presently not recommended for primary prevention based on evidence 
      from recent clinical trials. The implementation of shared decision making and 
      decision aids in routine clinical practice remains challenging but may rise in 
      coming years. Clinical trial data on the horizon may aid in solidifying guideline 
      therapy for statin use. However, in the face of uncertainty, shared decision 
      making between provider and patient should be utilized to determine whether 
      pharmacotherapy may benefit older adults. Decision aids are an effective tool to 
      guide this process.
FAU - Jhaveri, Amit
AU  - Jhaveri A
AD  - Department of Medicine, New York University Grossman School of Medicine, New 
      York, NY, USA.
FAU - Sibley, Rachel A
AU  - Sibley RA
AD  - Department of Medicine, New York University Grossman School of Medicine, New 
      York, NY, USA.
FAU - Spatz, Erica S
AU  - Spatz ES
AD  - Divison of Cardiovascular Medicine, Department of Medicine, Yale School of 
      Medicine, New Haven, CT, USA.
FAU - Dodson, John
AU  - Dodson J
AD  - Leon H. Charney Division of Cardiology, Department of Medicine, New York 
      University School of Medicine, 227 East 30th Street, TRB 851, New York, NY, 
      10016, USA. John.Dodson@nyumc.org.
AD  - Division of Healthcare Delivery Science, Department of Population Health, New 
      York University School of Medicine, New York, NY, USA. John.Dodson@nyumc.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210507
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Decision Making
MH  - Decision Making, Shared
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Primary Prevention
MH  - Uncertainty
OTO - NOTNLM
OT  - Aspirin
OT  - Decision aids
OT  - Older adults
OT  - Primary prevention
OT  - Shared decision making
OT  - Statin
EDAT- 2021/05/08 06:00
MHDA- 2021/05/21 06:00
CRDT- 2021/05/07 12:53
PHST- 2021/03/09 00:00 [accepted]
PHST- 2021/05/07 12:53 [entrez]
PHST- 2021/05/08 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
AID - 10.1007/s11886-021-01499-y [pii]
AID - 10.1007/s11886-021-01499-y [doi]
PST - epublish
SO  - Curr Cardiol Rep. 2021 May 7;23(6):67. doi: 10.1007/s11886-021-01499-y.

PMID- 15730113
OWN - NLM
STAT- MEDLINE
DCOM- 20050725
LR  - 20191109
IS  - 1544-3191 (Print)
IS  - 1086-5802 (Linking)
VI  - 45
IP  - 1
DP  - 2005 Jan-Feb
TI  - Community pharmacy Target Intervention Program to improve aspirin use in persons 
      with diabetes.
PG  - 17-22
AB  - OBJECTIVE: To identify the rate of aspirin or antiplatelet/anticoagulant use in 
      persons with diabetes presenting to community pharmacies and determine whether a 
      student pharmacist-driven Target Intervention Program (TIP) could increase the 
      number of eligible persons with diabetes receiving aspirin therapy in accordance 
      with American Diabetes Association (ADA) recommendations. DESIGN: Unblinded, 
      single intervention. SETTING: Eight Community Pharmacy Advanced Practice 
      Experience (CPAPE) sites in New York State. PARTICIPANTS: Persons having 
      prescriptions filled for diabetes medications or supplies who were not receiving 
      antiplatelet/anticoagulant medications. INTERVENTIONS: Assessment sheets were 
      completed by student pharmacists for eligible patients to determine 
      appropriateness for aspirin therapy. Recommendations for aspirin therapy were 
      faxed to physicians when indicated, and physicians responded via fax for aspirin 
      therapy implementation. The student pharmacists contacted patients, informed 
      patients of physician decisions, and provided appropriate counseling. MAIN 
      OUTCOME MEASURES: Number of persons with diabetes currently receiving aspirin or 
      antiplatelet/anticoagulant medications and the number initiated on aspirin as a 
      result of the TIP. RESULTS: A total of 436 persons with diabetes were identified. 
      Of those contacted, 322 agreed to participate and 31 declined; 228 were taking 
      aspirin or other antiplatelet/anticoagulant agents at baseline. Students 
      completed assessment sheets, which were forwarded to physicians, for 79 subjects 
      potentially eligible to receive aspirin therapy; 65 physician responses were 
      received (82% response rate). Aspirin therapy was initiated in 53 patients (67%). 
      CONCLUSION: The TIP enabled CPAPE students to increase aspirin use among eligible 
      persons with diabetes in accordance with ADA guidelines.
FAU - Haggerty, Stephanie A
AU  - Haggerty SA
AD  - Rite Aid Corporation, Glens Falls, NY, USA.
FAU - Cerulli, Jennifer
AU  - Cerulli J
FAU - Zeolla, Mario M
AU  - Zeolla MM
FAU - Cottrell, Jean S
AU  - Cottrell JS
FAU - Weck, Macary B
AU  - Weck MB
FAU - Faragon, John J
AU  - Faragon JJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Pharm Assoc (2003)
JT  - Journal of the American Pharmacists Association : JAPhA
JID - 101176252
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Community Pharmacy Services/*trends
MH  - Contraindications
MH  - Data Collection
MH  - Diabetes Mellitus/*drug therapy/epidemiology/physiopathology
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance/statistics & numerical data
MH  - Patient Education as Topic/methods
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - *Research Design
MH  - Students, Pharmacy
MH  - Voluntary Health Agencies/standards
EDAT- 2005/02/26 09:00
MHDA- 2005/07/26 09:00
CRDT- 2005/02/26 09:00
PHST- 2005/02/26 09:00 [pubmed]
PHST- 2005/07/26 09:00 [medline]
PHST- 2005/02/26 09:00 [entrez]
AID - S1544-3191(15)31732-5 [pii]
AID - 10.1331/1544345052843020 [doi]
PST - ppublish
SO  - J Am Pharm Assoc (2003). 2005 Jan-Feb;45(1):17-22. doi: 10.1331/1544345052843020.

PMID- 10535692
OWN - NLM
STAT- MEDLINE
DCOM- 19991104
LR  - 20181130
IS  - 0008-4212 (Print)
IS  - 0008-4212 (Linking)
VI  - 77
IP  - 3
DP  - 1999 Mar
TI  - Nonpeptide endothelin receptor antagonists attenuate the pressor effect of 
      diaspirin-crosslinked hemoglobin in rat.
PG  - 188-94
AB  - Endothelin 1 (ET-1) is a potent vasoactive and mitogenic peptide that is thought 
      to participate in the hemodynamic effects elicited by drugs that block the 
      biosynthesis and release of endothelium-derived nitric oxide (NO), such as NO 
      synthase inhibitors. Using the nonpeptide endothelin receptor antagonists 
      bosentan and LU-135252, we tested the hypothesis that endothelins contribute to 
      the pressor activity of diaspirin-crosslinked hemoglobin (DCLHb), a 
      hemoglobin-based oxygen carrier, whose pressor activity in mammals is attributed 
      primarily to a scavenging action towards NO. The NO synthase inhibitor 
      nitro-L-arginine methyl ester (L-NAME), ET-1, and noradrenaline (NA) were used as 
      reference drugs. Bosentan markedly reduced the pressor effects elicited by DCLHb, 
      L-NAME, and ET-1, but not those evoked by NA. LU-135252 attenuated the pressor 
      effect elicited by DCLHb and ET-1, but not that produced by L-NAME or NA. The 
      decreases in heart rate associated with the pressor effect of DCLHb and L-NAME 
      were reduced by LU-135252, whereas only those elicited by DCLHb were attenuated 
      by bosentan. In contrast with bosentan, LU-135252 caused a decrease in the 
      baseline blood pressure and heart rate. These results suggest that endothelins 
      may participate in the pressor activity of DCLHb. They suggest also that 
      nonpeptide endothelin receptor antagonists such as bosentan or LU-135252 may be 
      useful to counteract endothelin-mediated undesirable hemodynamic effects of drugs 
      that inhibit the activity of the NO system.
FAU - Rioux, F
AU  - Rioux F
AD  - Centre de recherche (Université Laval), Hôtel-Dieu de Québec, Canada.
FAU - Harvey, N
AU  - Harvey N
FAU - Moisan, S
AU  - Moisan S
FAU - Larivière, R
AU  - Larivière R
FAU - Lebel, M
AU  - Lebel M
FAU - Grose, J H
AU  - Grose JH
FAU - Burhop, K
AU  - Burhop K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Blood Substitutes)
RN  - 0 (Endothelin Receptor Antagonists)
RN  - 0 (Hemoglobins)
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 33JD57L6RW (darusentan)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - Q326023R30 (Bosentan)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Pressure/*drug effects
MH  - Blood Substitutes/*pharmacology
MH  - Bosentan
MH  - *Endothelin Receptor Antagonists
MH  - Heart Rate/drug effects
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - NG-Nitroarginine Methyl Ester/pharmacology
MH  - Nitric Oxide/physiology
MH  - Phenylpropionates/pharmacology
MH  - Pyrimidines/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sulfonamides/pharmacology
EDAT- 1999/10/27 00:00
MHDA- 1999/10/27 00:01
CRDT- 1999/10/27 00:00
PHST- 1999/10/27 00:00 [pubmed]
PHST- 1999/10/27 00:01 [medline]
PHST- 1999/10/27 00:00 [entrez]
PST - ppublish
SO  - Can J Physiol Pharmacol. 1999 Mar;77(3):188-94.

PMID- 7519946
OWN - NLM
STAT- MEDLINE
DCOM- 19940912
LR  - 20191031
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 1
DP  - 1994
TI  - Nitric oxide mediates the hypertensive response to a modified hemoglobin solution 
      (DCLHb) in rats.
PG  - 1-7
AB  - We investigated the effect of nitric oxide synthase inhibition with L-NAME, and 
      L-arginine (nitric oxide synthase substrate), on the hemodynamic response to a 
      modified hemoglobin solution (DCLHb). Rats were given one of the following 
      regimens (all groups hypervolemic except Control): Control-8.0 ml of donor blood 
      (isovolemic exchange); HV-8.0 ml of donor blood; DCLHb-8.0 ml of DCLHb; L-NAME-30 
      mg.kg-1 of L-NAME followed by 8.0 ml of DCLHb; or L-Arg-8.0 ml of DCLHb followed 
      by L-arginine (600 mg.kg-1). Mean arterial blood pressure (MABP) was continuously 
      recorded and the change compared to baseline and expressed as delta MABP. delta 
      MABP was greater in the HV and DCLHb groups versus the Control and L-NAME groups; 
      and was greater in the DCLHb group versus the HV group. delta MABP was not 
      different between the Control and L-NAME group. In the L-Arg group the initial 
      delta MABP (after DCLHb) was similar to the DCLHb group; however, after 
      L-arginine administration delta MABP was not different from the Control group. 
      This study supports a hypothesis that DCLHb effects an increase in MABP by a 
      nitric oxide related mechanism.
FAU - Katsuyama, S S
AU  - Katsuyama SS
AD  - School of Medicine, Department of Anesthesiology, Loma Linda University, 
      California 92354.
FAU - Cole, D J
AU  - Cole DJ
FAU - Drummond, J C
AU  - Drummond JC
FAU - Bradley, K
AU  - Bradley K
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Hemoglobins)
RN  - 0 (Solutions)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.4.- (Amino Acid Oxidoreductases)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Amino Acid Oxidoreductases/*antagonists & inhibitors
MH  - Animals
MH  - Arginine/*analogs & derivatives/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Hemodynamics/*drug effects
MH  - Hemoglobins/*pharmacology
MH  - Hypertension/chemically induced/*physiopathology
MH  - Male
MH  - NG-Nitroarginine Methyl Ester
MH  - Nitric Oxide/*physiology
MH  - Nitric Oxide Synthase
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Solutions
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117396 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(1):1-7. doi: 
      10.3109/10731199409117396.

PMID- 6288146
OWN - NLM
STAT- MEDLINE
DCOM- 19821203
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 60
IP  - 4
DP  - 1982 Oct
TI  - Evidence for interaction between platelet fibrinogen receptors.
PG  - 973-8
AB  - Previous analysis of fibrinogen binding to human aspirin-treated gel-filtered 
      platelets yielded upwardly concave Scatchard plots. To ascertain whether this was 
      due to the presence of independent heterogeneous receptor populations binding 
      fibrinogen with different affinities, the dissociation of purified 
      125I-fibrinogen from ADP-treated gel-filtered platelets was evaluated as a 
      function of receptor occupancy. Dissociation of bound labeled fibrinogen was 
      measured after 50-fold dilution with buffer containing O, 0.2, 0.8, and 2.0 mg/ml 
      unlabeled fibrinogen. Dissociation of labeled fibrinogen increased with 
      increasing receptor occupancy and was biphasic. With buffer alone, 76.0% +/- 5.8% 
      (SD) of labeled fibrinogen dissociated in 30 min, with an initial rate of 0.392 
      +/- 0.175 min-1; with 0.2 mg/ml fibrinogen, 83.7% +/- 3.9% dissociated, with an 
      initial rate of 0.589 +/- 0.044 min-1; with 0.8 mg/ml, 91.8% +/- 1.3% of the 
      labeled fibrinogen dissociated, with an initial rate of 0.910 +/- 0.028 min-1; 
      and with 2.0 mg/ml fibrinogen, 97.3% +/- 2.3% of label dissociated, with an 
      initial rate of 1.06 +/- 0.257 min-1 (n=5). The final rates of fibrinogen 
      dissociation were unaffected by unlabeled fibrinogen in the dilution buffer and 
      were not statistically different from the final dissociation rate of 0.015 +/- 
      0.10 min-1 observed following dilution with buffer alone. These results were 
      neither an artifact of aspirin treatment or gel filtration, as similar 
      observations were made using non-aspirin-treated washed platelets, nor were they 
      an artifact of the purified fibrinogen preparations, because binding studies 
      using whole plasma as the major source of fibrinogen also yielded upwardly 
      concave Scatchard plots. Since the data demonstrate that the initial rate and 
      extent of fibrinogen dissociation are dependent on fibrinogen receptor occupancy, 
      they suggest receptor interactions possibly resulting from receptor clustering or 
      crosslinking. Because the dissociation was biphasic, the results also suggest 
      some heterogeneity among platelet-fibrinogen interactions.
FAU - Peerschke, E I
AU  - Peerschke EI
LA  - eng
GR  - RR05736-08/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Platelet Membrane Glycoproteins)
RN  - 0 (Receptors, Cell Surface)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets/drug effects/*metabolism
MH  - Chromatography, Gel
MH  - Humans
MH  - Platelet Membrane Glycoproteins
MH  - Receptors, Cell Surface/*metabolism
EDAT- 1982/10/01 00:00
MHDA- 1982/10/01 00:01
CRDT- 1982/10/01 00:00
PHST- 1982/10/01 00:00 [pubmed]
PHST- 1982/10/01 00:01 [medline]
PHST- 1982/10/01 00:00 [entrez]
AID - S0006-4971(20)75956-2 [pii]
PST - ppublish
SO  - Blood. 1982 Oct;60(4):973-8.

PMID- 7082400
OWN - NLM
STAT- MEDLINE
DCOM- 19820722
LR  - 20190718
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 25
IP  - 5
DP  - 1982 May
TI  - Aspirin survival in human blood modulated by the concentration of erythrocytes.
PG  - 550-5
AB  - In vitro aspirin hydrolysis rates were measured in fresh human whole blood and in 
      its separate components. The half-life of aspirin in whole blood was relatively 
      rapid (mean 22.2 +/- 3.9 minutes) and exhibited a significant negative 
      correlation with hematocrit (r = -0.96). Hydrolysis of aspirin in buffer that 
      contained only washed red blood cells (40%) was significantly more rapid (mean 
      half-life 17.5 +/- 2.0 minutes) than that in whole blood. When aspirin was 
      incubated in solutions of washed red blood cells that contained human serum 
      albumin in various concentrations, the aspirin half-life was found to vary 
      directly with the concentration of albumin used; at normal levels of albumin, the 
      hydrolysis rate of aspirin approximated that measured in whole blood. The 
      presence of diisopropyl fluorophosphate in low concentrations (0.02-0.05 mM) 
      markedly inhibited the rate of aspirin hydrolysis in washed red blood cells and 
      whole blood. We conclude that enzymes(s) linked to the erythrocyte, probably 
      membrane-bound acetylcholinesterase, control the survival of aspirin in blood.
FAU - Costello, P B
AU  - Costello PB
FAU - Green, F A
AU  - Green FA
LA  - eng
GR  - HL 24009/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 12UHW9R67N (Isoflurophate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*blood
MH  - Erythrocyte Count
MH  - Erythrocytes/*physiology
MH  - Humans
MH  - Hydrolysis
MH  - In Vitro Techniques
MH  - Isoflurophate/pharmacology
MH  - Time Factors
EDAT- 1982/05/01 00:00
MHDA- 1982/05/01 00:01
CRDT- 1982/05/01 00:00
PHST- 1982/05/01 00:00 [pubmed]
PHST- 1982/05/01 00:01 [medline]
PHST- 1982/05/01 00:00 [entrez]
AID - 10.1002/art.1780250509 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1982 May;25(5):550-5. doi: 10.1002/art.1780250509.

PMID- 19707830
OWN - NLM
STAT- MEDLINE
DCOM- 20100406
LR  - 20131121
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 17
IP  - 1
DP  - 2010 Jan
TI  - Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery.
PG  - 31-9
LID - 10.1245/s10434-009-0671-6 [doi]
AB  - BACKGROUND: Consensus guidelines recommend prolonged thromboprophylaxis for up to 
      4 weeks after major abdominopelvic cancer operations. Several factors impede 
      widespread adoption of these guidelines. These include lack of awareness, cost, 
      increased bleeding complications, increased incidence of heparin-induced 
      thrombocytopenia, and poor patient compliance. METHODS: A cost-effectiveness 
      model was constructed comparing four potential strategies to postdischarge 
      thromboprophylaxis in surgical oncology patients: (1) low-molecular-weight 
      heparin (LMWH) once daily; (2) low-dose unfractionated heparin (LDUH) three times 
      daily; (3) oral aspirin once daily; or (4) no prolonged prophylaxis. 
      Probabilities and costs were estimated on the basis of published literature and 
      average Medicare reimbursement. The decision analysis was conducted from the 
      perspective of the health care system, with the primary end point being cost per 
      patient without venous thromboembolism (VTE). Sensitivity analyses tested the 
      robustness of the results. RESULTS: LDUH was most cost-effective, saving $154 per 
      patient without VTE compared with no prophylaxis. LMWH was not cost-effective, 
      incurring a cost of $230 per patient without VTE compared with no prophylaxis. 
      Aspirin was a viable alternative to LDUH, saving $123 compared with no 
      prophylaxis. When poor compliance was considered, aspirin became the dominant 
      strategy. Sensitivity analyses failed to show any instance where LMWH was 
      cost-effective. In terms of population costs, widespread use of LDUH after 
      discharge would save $30.3 million per year in the United States. CONCLUSIONS: 
      Although all chemical prophylaxis is effective in preventing VTE in the 
      outpatient setting after cancer surgery, either LDUH or aspirin are the most 
      cost-effective, depending on patient compliance.
FAU - Bradley, Ciarán T
AU  - Bradley CT
AD  - Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA. 
      cbradley@mcw.edu
FAU - Brasel, Karen J
AU  - Brasel KJ
FAU - Miller, Jessica Jane
AU  - Miller JJ
FAU - Pappas, Sam G
AU  - Pappas SG
LA  - eng
PT  - Journal Article
DEP - 20090826
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/economics/therapeutic use
MH  - Anticoagulants/*economics/therapeutic use
MH  - Aspirin/economics/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Heparin, Low-Molecular-Weight/economics/therapeutic use
MH  - Humans
MH  - Neoplasms/*surgery
MH  - Patient Compliance
MH  - Prognosis
MH  - Survival Rate
MH  - Venous Thromboembolism/*economics/prevention & control
EDAT- 2009/08/27 09:00
MHDA- 2010/04/07 06:00
CRDT- 2009/08/27 09:00
PHST- 2009/03/02 00:00 [received]
PHST- 2009/07/22 00:00 [accepted]
PHST- 2009/07/19 00:00 [revised]
PHST- 2009/08/27 09:00 [entrez]
PHST- 2009/08/27 09:00 [pubmed]
PHST- 2010/04/07 06:00 [medline]
AID - 10.1245/s10434-009-0671-6 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2010 Jan;17(1):31-9. doi: 10.1245/s10434-009-0671-6. Epub 2009 
      Aug 26.

PMID- 12208780
OWN - NLM
STAT- MEDLINE
DCOM- 20030220
LR  - 20181113
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 137
IP  - 2
DP  - 2002 Sep
TI  - NCX 4016, a nitric oxide-releasing aspirin, modulates adrenergic vasoconstriction 
      in the perfused rat tail artery.
PG  - 229-36
AB  - 1. The ability of the nitric oxide (NO)-releasing aspirin, NCX 4016, to control 
      vasoconstrictor responses induced by electrical field stimulation (TNS) or by 
      exogenous norepinephrine (NE) was investigated in perfused rat tail artery with 
      intact endothelium. 2. NCX 4016 (25, 50 and 100 microM) dose-dependently 
      antagonized the vasoconstriction caused by TNS (from 0.5 to 64 Hz) and by NE 
      (from 0.01 to 10 microM). The vasorelaxant activity of NCX 4016 (100 microM) in 
      NE-precontracted arteries was concomitant with a marked increase of tissue cyclic 
      GMP (4.9 fold, P<0.001) and was significantly antagonized by the inhibitors of 
      soluble guanylate cyclase, methylene blue and 
      1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one. 3. The effect of NCX 4016 was 
      endothelium NO-independent since, in preparations perfused with 
      N(G)-monomethyl-L-arginine (10 microM), this compound prevented the rise in basal 
      perfusion pressure and reversed the accentuation of vasoconstrictor responses 
      caused by NO synthase inhibition. 4. Aspirin-moiety released by NCX 4016 
      inhibited the 6-keto-PGF(1alpha) formation without interfering with the 
      vasorelaxant activity of NCX 4016, while aspirin (100 microM) was devoid of any 
      activity against vasoconstriction induced by both TNS and NE in perfused rat tail 
      artery. 5. NCX 4016 moderated adrenergic vasoconstriction in perfused rat tail 
      arteries by a direct donation of NO without involving the relaxant factors such 
      as PGI(2) and NO from endothelial cells. 6. The results obtained with NCX 4016 in 
      perfused rat tail artery bears some therapeutical potential in conditions 
      associated with vascular smooth muscle hyperreactivity to adrenergic stimulation.
FAU - Rossoni, Giuseppe
AU  - Rossoni G
AD  - Department of Pharmacological Sciences, University of Milan, Milan, Italy. 
      giuseppe.rossoni@unimi.it
FAU - Manfredi, Barbara
AU  - Manfredi B
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Berti, Ferruccio
AU  - Berti F
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 27JT06E6GR (omega-N-Methylarginine)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EH04H13L6B (nitroaspirin)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Animals
MH  - Arteries/drug effects/physiology
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Cyclic GMP/biosynthesis
MH  - Dose-Response Relationship, Drug
MH  - Electric Stimulation
MH  - Male
MH  - Nitric Oxide/physiology
MH  - Nitric Oxide Synthase/antagonists & inhibitors
MH  - Norepinephrine/*pharmacology
MH  - Perfusion
MH  - Rats
MH  - Rats, Wistar
MH  - Tail/blood supply
MH  - Vasoconstriction/*drug effects
MH  - omega-N-Methylarginine/pharmacology
PMC - PMC1573491
EDAT- 2002/09/05 10:00
MHDA- 2003/02/21 04:00
CRDT- 2002/09/05 10:00
PHST- 2002/09/05 10:00 [pubmed]
PHST- 2003/02/21 04:00 [medline]
PHST- 2002/09/05 10:00 [entrez]
AID - 0704869 [pii]
AID - 10.1038/sj.bjp.0704869 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2002 Sep;137(2):229-36. doi: 10.1038/sj.bjp.0704869.

PMID- 32394296
OWN - NLM
STAT- MEDLINE
DCOM- 20211005
LR  - 20211005
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jan
TI  - Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients.
PG  - 21-34
LID - 10.1007/s40256-020-00414-0 [doi]
AB  - Patients with coronary artery disease (CAD) presenting with acute coronary 
      syndrome or undergoing coronary stenting are indicated to treatment with dual 
      antiplatelet therapy (DAPT) combining aspirin with a P2Y12 receptor inhibitor. 
      The management of patients with CAD who present with a complex clinical profile 
      due to multiple comorbidities, and/or undergoing complex interventional 
      procedures, remains challenging as a high risk for both ischemic and bleeding 
      events is often present; hence, the risk-benefit balance on the optimal DAPT 
      duration is difficult to evaluate. The complexity of antiplatelet therapy in CAD 
      patients is due to the fact that this complexity embraces several aspects: the 
      coronary anatomy, the number of vascular districts at risk for atherothrombosis, 
      and patient comorbidities, including global frailty. Recent randomized and 
      epidemiological studies have highlighted subgroups that could benefit from 
      prolonged antithrombotic treatment, as well as frail patients, who may be better 
      suited to a shorter course of therapy. We provide an overview of the current 
      knowledge regarding treatment with DAPT, along with suggestions on its 
      management.
FAU - Sabouret, Pierre
AU  - Sabouret P
AUID- ORCID: 0000-0002-0243-3673
AD  - ACTION Group, Cardiology Department, Heart Institute, Pitié-Salpétrière Hospital, 
      Sorbonne University, 47-83 Bld de l'Hôpital, 75013, Paris, France. 
      cardiology.sabouret@gmail.com.
FAU - Savage, Michael P
AU  - Savage MP
AD  - Sidney Kimmel Medical College, Thomas Jefferson University Hospital, Thomas 
      Jefferson University, Philadelphia, PA, USA.
FAU - Fischman, David
AU  - Fischman D
AD  - Sidney Kimmel Medical College, Thomas Jefferson University Hospital, Thomas 
      Jefferson University, Philadelphia, PA, USA.
FAU - Costa, Francesco
AU  - Costa F
AD  - Department of Clinical and Experimental Medicine, Policlinic "G. Martino", 
      University of Messina, Messina, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy/epidemiology/surgery
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Multiple Chronic Conditions/epidemiology
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Sex Factors
EDAT- 2020/05/13 06:00
MHDA- 2021/10/06 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/10/06 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1007/s40256-020-00414-0 [pii]
AID - 10.1007/s40256-020-00414-0 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2021 Jan;21(1):21-34. doi: 10.1007/s40256-020-00414-0.

PMID- 20857911
OWN - NLM
STAT- MEDLINE
DCOM- 20101109
LR  - 20131121
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 53
IP  - 19
DP  - 2010 Oct 14
TI  - Synthesis and biological activities of transition metal complexes based on 
      acetylsalicylic acid as neo-anticancer agents.
PG  - 6889-98
LID - 10.1021/jm101019j [doi]
AB  - [(μ(4)-η(2))-(Prop-2-ynyl)-2-acetoxybenzoate]dicobalthexacarbonyl (Co-ASS), a 
      derivative of aspirin (ASS), demonstrated high growth-inhibitory potential 
      against various tumor cells with interference in the arachidonic acid cascade as 
      probable mode of action. The significance of the kind of metal and cluster was 
      verified in this structure-activity study: Co(2)(CO)(6) was respectively 
      exchanged by a tetrameric cobalt-, trimeric ruthenium-, or trimeric ironcarbonyl 
      cluster. Furthermore, the metal binding motif was changed from alkyne to 
      1,3-butadiene. Compounds were evaluated for growth inhibition, antiproliferative 
      effects, and apoptosis induction in breast (MCF-7, MDA-MB 231) and colon cancer 
      (HT-29) cell lines and for COX-1/2 inhibitory effects at isolated isoenzymes. 
      Additionally, the major COX metabolite prostaglandin E2 (PGE(2)) was quantified 
      in arachidonic acid-stimulated MDA-MB 231 breast tumor cells. It was demonstrated 
      that the metal cluster was of minor importance for effects on cellular activity 
      if an alkyne was used as ligand. Generally, no correlation existed between growth 
      inhibition and COX activity. Cellular growth inhibition and antiproliferative 
      activity at higher concentrations of the most active compounds Prop-ASS-Co(4) and 
      Prop-ASS-Ru(3) correlated well with apoptosis induction.
FAU - Rubner, Gerhard
AU  - Rubner G
AD  - Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Strasse 2 + 4, 
      14195 Berlin, Germany.
FAU - Bensdorf, Kerstin
AU  - Bensdorf K
FAU - Wellner, Anja
AU  - Wellner A
FAU - Kircher, Brigitte
AU  - Kircher B
FAU - Bergemann, Silke
AU  - Bergemann S
FAU - Ott, Ingo
AU  - Ott I
FAU - Gust, Ronald
AU  - Gust R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Alkynes)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Butadienes)
RN  - 0 (Coordination Complexes)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 3G0H8C9362 (Cobalt)
RN  - 7UI0TKC3U5 (Ruthenium)
RN  - E1UOL152H7 (Iron)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alkynes/chemical synthesis/pharmacology
MH  - Antineoplastic Agents/*chemical synthesis/chemistry/pharmacology
MH  - Apoptosis/drug effects
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*analogs & derivatives/*chemical synthesis/pharmacology
MH  - Butadienes/chemical synthesis/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - *Cobalt
MH  - Coordination Complexes/*chemical synthesis/pharmacology
MH  - Cyclooxygenase Inhibitors/*chemical synthesis/pharmacology
MH  - Dinoprostone/metabolism
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Iron
MH  - *Ruthenium
MH  - Stereoisomerism
MH  - Structure-Activity Relationship
EDAT- 2010/09/23 06:00
MHDA- 2010/11/10 06:00
CRDT- 2010/09/23 06:00
PHST- 2010/09/23 06:00 [entrez]
PHST- 2010/09/23 06:00 [pubmed]
PHST- 2010/11/10 06:00 [medline]
AID - 10.1021/jm101019j [doi]
PST - ppublish
SO  - J Med Chem. 2010 Oct 14;53(19):6889-98. doi: 10.1021/jm101019j.

PMID- 17037284
OWN - NLM
STAT- MEDLINE
DCOM- 20061214
LR  - 20131121
IS  - 0015-5616 (Print)
IS  - 0015-5616 (Linking)
VI  - 46
IP  - 1-2
DP  - 2005
TI  - [Disturbances in aggregability of red blood cells in essential hypertension].
PG  - 3-19
AB  - The study was performed to find the relationship between rheological properties 
      of erythrocytes and the effectiveness of antihypertensive therapy both in 
      patients suffering from essential hypertension as well as in spontaneously 
      hypertensive rats (SHR). Additionally, in patients receiving the same 
      antihypertensive therapy we evaluated the effect of aspirin at a low and high 
      dose on aggregation of erythrocytes. We found that in a consequence of uniformed 
      antihypertensive therapy which in patients lasted minimum one year and consisted 
      of one of ACE inhibitors (enalapril or perindopril or captopril), one of 
      beta-antagonists (metoprolol or bisoprolol) and diuretic agent (indapamid), while 
      SHR lasted 8 days and consisted of ACE inhibitor (chinapril), blood pressure 
      lowered and red blood cell rheology was significantly improved. For the first 
      time we observed that antihypertensive treatment which advantageously decreased 
      the aggregability of erythrocytes was diminished by a high dose of aspirin (300 
      mg/day).
FAU - Korbut, Renata A
AU  - Korbut RA
AD  - Katedra Farmakologii, Collegium Medicum Uniwersytetu Jagiellońskiego, Kraków. 
      mfkorbut@cyf-kr.edu.pl
FAU - Adamek-Guzik, Teresa
AU  - Adamek-Guzik T
LA  - pol
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Zaburzenia agregacji krwinek czerwonych w pierwotnym nadciśnieniu tetniczym.
PL  - Poland
TA  - Folia Med Cracov
JT  - Folia medica Cracoviensia
JID - 0374617
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Antihypertensive Agents/*administration & dosage
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Pressure/physiology
MH  - Dose-Response Relationship, Drug
MH  - Erythrocyte Aggregation/*drug effects
MH  - Erythrocyte Deformability/*drug effects
MH  - Female
MH  - Humans
MH  - Hypertension/blood/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Rats, Inbred WKY
EDAT- 2006/10/14 09:00
MHDA- 2006/12/15 09:00
CRDT- 2006/10/14 09:00
PHST- 2006/10/14 09:00 [pubmed]
PHST- 2006/12/15 09:00 [medline]
PHST- 2006/10/14 09:00 [entrez]
PST - ppublish
SO  - Folia Med Cracov. 2005;46(1-2):3-19.

PMID- 8062355
OWN - NLM
STAT- MEDLINE
DCOM- 19940922
LR  - 20201209
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 14
IP  - 2
DP  - 1994 Apr
TI  - Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination 
      versus aspirin 1000 mg and placebo in acute migraine attack.
PG  - 156-61
AB  - The purpose of this study was to compare the efficacy and tolerance of a single 
      dose of the acetaminophen 400 mg-codeine 25 mg combination (ACC) aspirin 1000 mg 
      (A) and a placebo (P) for the treatment of acute migraine attack. The study 
      design was randomized, multicentre, double-blind and double dummy with cross-over 
      on three periods. Of the 198 patients who had three attacks 29.8%, 52.3% and 
      49.7% had recorded the complete or almost complete disappearance of the pain at 2 
      h after P, A and ACC respectively. When compared with the placebo, the difference 
      was significant for the A and ACC. When complete disappearance of pain at 2 h was 
      used as a criterion, no significant difference was observed. These results 
      enabled the sensitivity of the evaluation criteria suggested for clinical trials 
      of migraine attack to be discussed.
FAU - Boureau, F
AU  - Boureau F
AD  - Centre d'Evaluation et de Traitement de la Douleur, Hôpital Saint-Antoine, Paris, 
      France.
FAU - Joubert, J M
AU  - Joubert JM
FAU - Lasserre, V
AU  - Lasserre V
FAU - Prum, B
AU  - Prum B
FAU - Delecoeuillerie, G
AU  - Delecoeuillerie G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Acetaminophen/adverse effects/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Codeine/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
AID - 10.1046/j.1468-2982.1994.1402156.x [doi]
PST - ppublish
SO  - Cephalalgia. 1994 Apr;14(2):156-61. doi: 10.1046/j.1468-2982.1994.1402156.x.

PMID- 1499936
OWN - NLM
STAT- MEDLINE
DCOM- 19920915
LR  - 20220419
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 103
IP  - 3
DP  - 1992 Sep
TI  - Objective evidence of aspirin use in both ulcer and nonulcer upper and lower 
      gastrointestinal bleeding.
PG  - 862-9
AB  - To obtain the best evidence for nonsteroidal anti-inflammatory drug (NSAID) use 
      in gastrointestinal (GI) bleeding, a detailed patient history was supplemented 
      with objective tests of aspirin use, i.e., high-performance liquid chromatography 
      of plasma and platelet cyclo-oxygenase inhibition, which detect aspirin intake 
      within 24 and 120 hours, respectively. Seventy-one patients consecutively 
      admitted for upper or lower GI bleeding and 138 age- and sex-matched controls 
      were studied. Five bleeders were excluded for confounding factors, e.g., 
      warfarin. Of the other 66 bleeders, 45 had upper GI bleeding (28 from peptic 
      ulcer, 14 from duodenal ulcer, and 14 from gastric ulcer) and 21 lower GI 
      bleeding. Evidence of current NSAID use (of which 89% was aspirin) was found in 
      80% of bleeders vs. 24.3% of controls (P less than 0.0001), for an odds ratio of 
      13.7 (95% confidence interval, 6.39-27.27). The cyclo-oxygenase test uncovered 
      21.5% more aspirin users than history alone. Severity of bleeding was not 
      different in acetylsalicylic acid users. The surprisingly high association of 
      current intake of NSAIDs, especially aspirin, with nonulcer GI bleeding including 
      colonic bleeding, changes the conventional view of the following hierarchy of the 
      risk: NSAID----peptic ulcer----bleeding to: NSAIDs----GI bleeding. This view has 
      important implications for current ulcer cotherapy prophylactic strategies, which 
      could fail to prevent greater than 50% of GI bleeding episodes.
FAU - Lanas, A
AU  - Lanas A
AD  - Division of Gastroenterology, University of Alabama, Birmingham.
FAU - Sekar, M C
AU  - Sekar MC
FAU - Hirschowitz, B I
AU  - Hirschowitz BI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/*adverse effects/blood
MH  - Blood Platelets/*enzymology
MH  - Cyclooxygenase Inhibitors
MH  - Gastrointestinal Hemorrhage/blood/*chemically induced
MH  - Humans
MH  - Intestinal Diseases/complications
MH  - Peptic Ulcer/complications
MH  - Prospective Studies
MH  - Prostaglandin-Endoperoxide Synthases/*blood
MH  - Severity of Illness Index
EDAT- 1992/09/01 00:00
MHDA- 1992/09/01 00:01
CRDT- 1992/09/01 00:00
PHST- 1992/09/01 00:00 [pubmed]
PHST- 1992/09/01 00:01 [medline]
PHST- 1992/09/01 00:00 [entrez]
AID - 0016-5085(92)90018-T [pii]
AID - 10.1016/0016-5085(92)90018-t [doi]
PST - ppublish
SO  - Gastroenterology. 1992 Sep;103(3):862-9. doi: 10.1016/0016-5085(92)90018-t.

PMID- 37478021
OWN - NLM
STAT- MEDLINE
DCOM- 20230724
LR  - 20230724
IS  - 1536-7355 (Electronic)
IS  - 1076-1608 (Linking)
VI  - 29
IP  - 5
DP  - 2023 Aug 1
TI  - Controversies in the Management of Antiphospholipid Syndrome.
PG  - e107-e112
LID - 10.1097/RHU.0000000000001961 [doi]
AB  - Strategies to prevent thrombosis in antiphospholipid antibody (aPL)-positive 
      patients are of the utmost importance. The risk of thrombosis in patients with 
      aPLs varies, depending on additional venous thrombosis and cardiovascular risk 
      factors, as well as associated comorbidities. Recurrent thrombosis despite 
      treatment with vitamin K antagonists is relatively common in daily practice. In 
      this context, the effectiveness of the new direct oral anticoagulants in 
      antiphospholipid syndrome is debated, as well as that of low-dose aspirin for 
      primary thromboprophylaxis. There is an urgent unmet need to recognize the 
      subgroup of patients that may benefit from low-dose aspirin use. Here we also 
      discuss different points of view on primary and secondary thrombosis preventions 
      in aPL-positive patients, which were presented as a debate during the 2021 PANLAR 
      Congress (Pan-American League of the Association of Rheumatology) and that was 
      organized by GESAF (Argentine Society of Rheumatology APS Study Group). It is the 
      intention of this article to provide a useful discussion to aid treatment 
      decision-making in daily clinical practice.
CI  - Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Porta, Sabrina V
AU  - Porta SV
AD  - From the Rheumatology Department, Carlos G. Durand Hospital, Buenos Aires, 
      Argentina.
FAU - de Andrade, Danieli Castro Oliveira
AU  - de Andrade DCO
AD  - Rheumatology Division, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, 
      Universidade de São Paulo, São Paulo, Brazil.
FAU - Erkan, Doruk
AU  - Erkan D
FAU - Gómez-Puerta, José A
AU  - Gómez-Puerta JA
AD  - Rheumatology Department, Hospital Clinic University of Barcelona, Barcelona, 
      Spain.
FAU - Jara, Luis J
AU  - Jara LJ
AD  - Rheumatology Division, Instituto Nacional de Rehabilitación "Luis Guillermo 
      Ibarra," Mexico City, Mexico.
FAU - Alba Moreyra, Paula
AU  - Alba Moreyra P
AD  - Unidad de Reumatología, Catedra de Semiología, Hospital Córdoba, FMC, Universidad 
      Nacional de Córdoba.
FAU - Pons-Estel, Guillermo J
AU  - Pons-Estel GJ
AD  - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, 
      Argentina.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Rheumatol
JT  - Journal of clinical rheumatology : practical reports on rheumatic & 
      musculoskeletal diseases
JID - 9518034
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Antiphospholipid Syndrome/complications/diagnosis/drug therapy
MH  - Anticoagulants/therapeutic use
MH  - *Venous Thromboembolism
MH  - *Thrombosis/etiology
MH  - Aspirin/therapeutic use
COIS- J.A.G.-P. received personal consultant fees from AbbVie, Amgen, AstraZeneca, BMS, 
      Galápagos, GSK, Janssen, Lilly, Novartis, Pfizer Sanofi, and Roche. G.J.P.-E. 
      received speaker fees, consultant fees, and grants from Pfizer, Janssen, GSK, 
      Sandoz, and Sanofi. The other authors have no conflicts of interest to declare. 
      This research received no external funding.
EDAT- 2023/07/21 19:10
MHDA- 2023/07/24 06:43
CRDT- 2023/07/21 12:53
PHST- 2023/07/24 06:43 [medline]
PHST- 2023/07/21 19:10 [pubmed]
PHST- 2023/07/21 12:53 [entrez]
AID - 00124743-202308000-00015 [pii]
AID - 10.1097/RHU.0000000000001961 [doi]
PST - ppublish
SO  - J Clin Rheumatol. 2023 Aug 1;29(5):e107-e112. doi: 10.1097/RHU.0000000000001961.

PMID- 8778820
OWN - NLM
STAT- MEDLINE
DCOM- 19960919
LR  - 20190726
IS  - 0031-9155 (Print)
IS  - 0031-9155 (Linking)
VI  - 41
IP  - 3
DP  - 1996 Mar
TI  - Calculation of van't Hoff enthalpy associated with aspirin-induced change in 
      liposomal membrane anisotropy.
PG  - 383-6
AB  - The lipid disordering effect of aspirin on the liposomal membrane of dipalmitoyl 
      phosphatidyl choline has recently been studied using the fluorescence 
      polarization method. From the anisotropy-temperature curve, we have calculated 
      here the associated change in van't Hoff enthalpy. Since the fluorescence 
      technique requires a very small amount of sample (10(-4) M), this method of 
      enthalpy calculation compares well and is advantageous over the standard 
      calorimetric methods.
FAU - De, S
AU  - De S
AD  - Department of Physics, Jadavpur University, Calcutta, India.
FAU - Ghosh, A K
AU  - Ghosh AK
FAU - Basu, R
AU  - Basu R
FAU - Nandy, P
AU  - Nandy P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Phys Med Biol
JT  - Physics in medicine and biology
JID - 0401220
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Liposomes)
RN  - 1720-32-7 (Diphenylhexatriene)
RN  - 2644-64-6 (1,2-Dipalmitoylphosphatidylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 1,2-Dipalmitoylphosphatidylcholine/chemistry
MH  - *Aspirin/chemistry
MH  - Biophysical Phenomena
MH  - Biophysics
MH  - Calorimetry
MH  - Diphenylhexatriene
MH  - Fluorescence Polarization
MH  - Fluorescent Dyes
MH  - *Liposomes/chemistry
MH  - Membrane Fluidity
MH  - Thermodynamics
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
AID - 10.1088/0031-9155/41/3/003 [doi]
PST - ppublish
SO  - Phys Med Biol. 1996 Mar;41(3):383-6. doi: 10.1088/0031-9155/41/3/003.

PMID- 22303820
OWN - NLM
STAT- MEDLINE
DCOM- 20121002
LR  - 20131121
IS  - 1931-843X (Electronic)
IS  - 1540-9996 (Linking)
VI  - 21
IP  - 4
DP  - 2012 Apr
TI  - Underuse of aspirin for primary and secondary prevention of cardiovascular 
      disease events in women.
PG  - 379-87
LID - 10.1089/jwh.2011.2990 [doi]
AB  - BACKGROUND: Evidence-based guidelines for use of aspirin to decrease 
      cardiovascular disease (CVD) events in women are well established. Despite this, 
      aspirin is underused in women. We examined self-reported aspirin use in women for 
      primary and secondary prevention of CVD events, correlates of use, and change in 
      use over time from 2004 to 2009. METHODS: Data from volunteer respondents 
      participating in a web-based CVD risk assessment tool at 127 US healthcare 
      centers were analyzed. Survey questions included information on CVD risk factors, 
      the presence or absence of any form of CVD, diabetes mellitus, and medication 
      usage, including daily aspirin. Logistic regression analyses identified factors 
      associated with aspirin intake. RESULTS: Of the 217,987 women respondents, 29,701 
      women were recommended to take aspirin based on the guidelines. We found, 
      however, that only 41% of women who meet criteria for primary prevention and 48% 
      of women who meet criteria for secondary prevention report that they take aspirin 
      on a daily basis. The main factors that favored aspirin use were a family history 
      of CVD or high cholesterol. Although aspirin use for secondary prevention did not 
      change between the years 2004 and 2009, there was a significant increase in 
      aspirin use for primary prevention. CONCLUSIONS: These findings confirm that the 
      majority of women for whom aspirin is recommended for primary and secondary 
      prevention of CVD were not following national guidelines. Educational programs 
      for clinicians and women aimed at promoting appropriate use of aspirin is one 
      measure that should improve CVD outcomes in women.
FAU - Rivera, Cathleen M
AU  - Rivera CM
AD  - Department of Internal Medicine, Scott and White Healthcare, Temple, Texas 76508, 
      USA. carivera@swmail.sw.org
FAU - Song, Juhee
AU  - Song J
FAU - Copeland, Laurel
AU  - Copeland L
FAU - Buirge, Chris
AU  - Buirge C
FAU - Ory, Marcia
AU  - Ory M
FAU - McNeal, Catherine J
AU  - McNeal CJ
LA  - eng
PT  - Journal Article
DEP - 20120203
PL  - United States
TA  - J Womens Health (Larchmt)
JT  - Journal of women's health (2002)
JID - 101159262
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Health Surveys
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - National Health Programs
MH  - Odds Ratio
MH  - Physician-Patient Relations
MH  - Risk Assessment
MH  - United States
EDAT- 2012/02/07 06:00
MHDA- 2012/10/04 06:00
CRDT- 2012/02/07 06:00
PHST- 2012/02/07 06:00 [entrez]
PHST- 2012/02/07 06:00 [pubmed]
PHST- 2012/10/04 06:00 [medline]
AID - 10.1089/jwh.2011.2990 [doi]
PST - ppublish
SO  - J Womens Health (Larchmt). 2012 Apr;21(4):379-87. doi: 10.1089/jwh.2011.2990. 
      Epub 2012 Feb 3.

PMID- 22981273
OWN - NLM
STAT- MEDLINE
DCOM- 20140609
LR  - 20181202
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
VI  - 22
IP  - 7
DP  - 2013 Oct
TI  - Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet 
      therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and 
      VerifyNow(®).
PG  - e84-92
LID - S1052-3057(12)00224-8 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2012.07.012 [doi]
AB  - BACKGROUND: The prevalence of ex vivo high on-treatment platelet reactivity 
      (HTPR) to commonly prescribed antiplatelet regimens after transient ischemic 
      attack (TIA) or ischemic stroke is uncertain. METHODS: Platelet function 
      inhibition was simultaneously assessed with modified light transmission 
      aggregometry (VerifyNow; Accumetrics Inc, San Diego, CA) and with a moderately 
      high shear stress platelet function analyzer (PFA-100; Siemens Medical Solutions 
      USA, Inc, Malvern, PA) in a pilot, cross-sectional study of TIA or ischemic 
      stroke patients. Patients were assessed on aspirin-dipyridamole combination 
      therapy (n = 51) or clopidogrel monotherapy (n = 25). RESULTS: On the VerifyNow, 
      HTPR on aspirin was identified in 4 of 51 patients (8%) on aspirin-dipyridamole 
      combination therapy (≥ 550 aspirin reaction units on the aspirin cartridge). 
      Eleven of 25 (44%) patients had HTPR on clopidogrel (≥ 194 P2Y12 reaction units 
      on the P2Y12 cartridge). On the PFA-100, 21 of 51 patients (41%) on 
      aspirin-dipyridamole combination therapy had HTPR on the collagen-epinephrine 
      (C-EPI) cartridge. Twenty-three of 25 patients (92%) on clopidogrel had HTPR on 
      the collagen-adenosine diphosphate (C-ADP) cartridge. The proportion of patients 
      with antiplatelet HTPR was lower on the VerifyNow than PFA-100 in patients on 
      both regimens (P < .001). CONCLUSIONS: The prevalence of ex vivo antiplatelet 
      HTPR after TIA or ischemic stroke is markedly influenced by the method used to 
      assess platelet reactivity. The PFA-100 C-ADP cartridge is not sensitive at 
      detecting the antiplatelet effects of clopidogrel ex vivo. Larger prospective 
      studies with the VerifyNow and with the PFA-100 C-EPI and recently released 
      Innovance PFA P2Y cartridges (Siemens Medical Solutions USA, Inc) in addition to 
      newer tests of platelet function are warranted to assess whether platelet 
      function monitoring predicts clinical outcome in ischemic cerebrovascular 
      disease.
CI  - Copyright © 2013 National Stroke Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Kinsella, Justin A
AU  - Kinsella JA
AD  - Department of Neurology, The Adelaide and Meath Hospital, incorporating the 
      National Children's Hospital, Trinity College Dublin, Ireland.
FAU - Tobin, W Oliver
AU  - Tobin WO
FAU - Cox, Dermot
AU  - Cox D
FAU - Coughlan, Tara
AU  - Coughlan T
FAU - Collins, Ronan
AU  - Collins R
FAU - O'Neill, Desmond
AU  - O'Neill D
FAU - Murphy, Raymond P
AU  - Murphy RP
FAU - McCabe, Dominick J H
AU  - McCabe DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120913
PL  - United States
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National 
      Stroke Association
JID - 9111633
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Blood Platelets/drug effects
MH  - Brain Ischemia/*drug therapy
MH  - Clopidogrel
MH  - Cross-Sectional Studies
MH  - Dipyridamole/pharmacology/therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Stroke/*drug therapy
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - PFA-100
OT  - VerifyNow
OT  - high on-treatment platelet reactivity
OT  - ischemic stroke
OT  - platelet function
OT  - transient ischemic attack
EDAT- 2012/09/18 06:00
MHDA- 2014/06/10 06:00
CRDT- 2012/09/18 06:00
PHST- 2012/01/10 00:00 [received]
PHST- 2012/07/12 00:00 [revised]
PHST- 2012/07/13 00:00 [accepted]
PHST- 2012/09/18 06:00 [entrez]
PHST- 2012/09/18 06:00 [pubmed]
PHST- 2014/06/10 06:00 [medline]
AID - S1052-3057(12)00224-8 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2012.07.012 [doi]
PST - ppublish
SO  - J Stroke Cerebrovasc Dis. 2013 Oct;22(7):e84-92. doi: 
      10.1016/j.jstrokecerebrovasdis.2012.07.012. Epub 2012 Sep 13.

PMID- 19884041
OWN - NLM
STAT- MEDLINE
DCOM- 20100416
LR  - 20131121
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 75
IP  - 1
DP  - 2010 Jan
TI  - Theoretical modeling of infrared spectra of the hydrogen and deuterium bond in 
      aspirin crystal.
PG  - 37-47
LID - 10.1016/j.saa.2009.09.029 [doi]
AB  - An extended quantum theoretical approach of the nu(X-H) IR lineshape of cyclic 
      dimers of weakly H-bonded species is proposed. We have extended a previous 
      approach [M.E.-A. Benmalti, P. Blaise, H.T. Flakus, O. Henri-Rousseau, Chem. 
      Phys. 320 (2006) 267] by accounting for the anharmonicity of the slow mode which 
      is described by a "Morse" potential in order to reproduce the polarized infrared 
      spectra of the hydrogen and deuterium bond in acetylsalicylic acid (aspirin) 
      crystals. From comparison of polarized IR spectra of isotopically neat and 
      isotopically diluted aspirin crystals it resulted that centrosymmetric aspirin 
      dimer was the bearer of the crystal main spectral properties. In this approach, 
      the adiabatic approximation is performed for each separate H-bond bridge of the 
      dimer and a strong non-adiabatic correction is introduced into the model via the 
      resonant exchange between the fast mode excited states of the two moieties. 
      Within the strong anharmonic coupling theory, according to which the X-H...Y 
      high-frequency mode is anharmonically coupled to the H-bond bridge, this model 
      incorporated the Davydov coupling between the excited states of the two moieties, 
      the quantum direct and indirect dampings and the anharmonicity for the H-bond 
      bridge. The spectral density is obtained within the linear response theory by 
      Fourier transform of the damped autocorrelation functions. The evaluated spectra 
      are in fairly good agreement with the experimental ones by using a minimum number 
      of independent parameters. The effect of deuteration has been well reproduced by 
      reducing simply the angular frequency of the fast mode and the anharmonic 
      coupling parameter.
CI  - Copyright 2009 Elsevier B.V. All rights reserved.
FAU - Ghalla, Houcine
AU  - Ghalla H
AD  - Laboratoire de Physique Quantique, Faculté des Sciences de Monastir, 5000 route 
      de Kairouan, Tunisia.
FAU - Rekik, Najeh
AU  - Rekik N
FAU - Michta, Anna
AU  - Michta A
FAU - Oujia, Brahim
AU  - Oujia B
FAU - Flakus, Henryk T
AU  - Flakus HT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091009
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 7YNJ3PO35Z (Hydrogen)
RN  - AR09D82C7G (Deuterium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Crystallization
MH  - Deuterium/*chemistry
MH  - Hydrogen/*chemistry
MH  - Mathematics
MH  - Models, Chemical
MH  - Models, Molecular
MH  - *Models, Theoretical
MH  - Spectrophotometry, Infrared/*methods
EDAT- 2009/11/04 06:00
MHDA- 2010/04/17 06:00
CRDT- 2009/11/04 06:00
PHST- 2009/05/15 00:00 [received]
PHST- 2009/09/06 00:00 [revised]
PHST- 2009/09/13 00:00 [accepted]
PHST- 2009/11/04 06:00 [entrez]
PHST- 2009/11/04 06:00 [pubmed]
PHST- 2010/04/17 06:00 [medline]
AID - S1386-1425(09)00466-1 [pii]
AID - 10.1016/j.saa.2009.09.029 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2010 Jan;75(1):37-47. doi: 
      10.1016/j.saa.2009.09.029. Epub 2009 Oct 9.

PMID- 3228050
OWN - NLM
STAT- MEDLINE
DCOM- 19890406
LR  - 20131121
IS  - 0301-0546 (Print)
IS  - 0301-0546 (Linking)
VI  - 16
IP  - 5
DP  - 1988 Sep-Oct
TI  - Aspirin "desensitization" in patients with aspirin-induced urticaria and 
      angioedema.
PG  - 305-8
AB  - The study was performed on 22 patients with sensitivity to aspirin which 
      manifested as urticaria and angioedema. Sensitivity to aspirin was established 
      based on the anamnesis of urticaria and angioedema occurring after ingestion of 
      aspirin and oral challenge tests with acetylsalicylic acid. At first, the 
      threshold dose of aspirin in all patients and additionally of indomethacin in 12 
      patients was established. Aspirin "desensitization" was induced by administering 
      increasing doses of acetylsalicylic acid every 24 hr until a good tolerance of 
      600 mg was obtained. The following day after the ingestion of 600 mg 
      acetylsalicylic acid, 12 patients received 50 mg indomethacin. A good tolerance 
      of 600 mg aspirin was achieved in all examined patients and 50 mg of indomethacin 
      was also well tolerated. The authors assume that mechanism of urticaria and 
      angioedema type of sensitivity to aspirin has the same pathogenic background as 
      aspirin-induced bronchoconstriction.
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
AD  - Department of Pneumonology and Allergology, Medical Academy of Lódź, Poland.
FAU - Roznlecki, J
AU  - Roznlecki J
FAU - Szmidt, M
AU  - Szmidt M
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Angioedema/chemically induced/*therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Asthma/chemically induced/complications
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/etiology/*therapy
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Hypersensitivity, Immediate/complications
MH  - Indomethacin/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Urticaria/chemically induced/*therapy
EDAT- 1988/09/01 00:00
MHDA- 1988/09/01 00:01
CRDT- 1988/09/01 00:00
PHST- 1988/09/01 00:00 [pubmed]
PHST- 1988/09/01 00:01 [medline]
PHST- 1988/09/01 00:00 [entrez]
PST - ppublish
SO  - Allergol Immunopathol (Madr). 1988 Sep-Oct;16(5):305-8.

PMID- 21615437
OWN - NLM
STAT- MEDLINE
DCOM- 20111207
LR  - 20131121
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 34
IP  - 2
DP  - 2011 Jul
TI  - Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor 
      co-therapy in patients using aspirin for secondary prevention.
PG  - 243-51
LID - 10.1111/j.1365-2036.2011.04707.x [doi]
AB  - BACKGROUND: Many patients with cardiovascular (CV) disease will stop aspirin 
      (ASA) because of ASA-related dyspepsia. Proton pump inhibitor (PPI) co-therapy 
      may reduce ASA-related dyspepsia, enhancing ASA adherence and improving CV 
      outcomes. AIM: To explore the impact of PPI co-therapy on CV outcomes in 
      long-term, low-dose ASA users. METHODS: We modified a previously published Markov 
      model to assess the long-term impact of PPI co-therapy on CV and upper 
      gastrointestinal bleeding (UGIB) outcomes among patients using ASA for secondary 
      CV prevention. UGIB events, recurrent myocardial infarctions (MIs) and 
      incremental cost-effectiveness ratios (ICERs) were measured. The perspective 
      taken was that of a long-term payer. RESULTS: Compared with ASA alone, ASA plus 
      PPI resulted in fewer lifetime UGIB events (3.4% vs. 7.2%) and increased ASA 
      adherence (74% vs. 71%). Increased ASA adherence resulted in fewer recurrent MIs 
      (26 fewer events per 10000 patients). On average, the ASA plus PPI strategy 
      resulted in 38 additional days of life per patient, with the majority of this 
      benefit (61%) because of a reduction in CV mortality (rather than UGIB-related 
      mortality). ASA plus PPI was also more costly than ASA alone, with an ICER of 
      $19000 per life-year saved. Results were sensitive to cost of PPI and impact of 
      PPI on ASA adherence. CONCLUSIONS: Proton pump inhibitor co-therapy has the 
      potential to impact not only GI, but also CV outcomes in patients with CV disease 
      using ASA and such co-therapy is likely to be cost-effective. Future studies 
      should better quantify the CV benefits of PPI co-therapy.
CI  - © 2011 Blackwell Publishing Ltd.
FAU - Saini, S D
AU  - Saini SD
AD  - Center for Clinical Management Research, Ann Arbor VA HSR&D Center of Excellence, 
      Ann Arbor, MI 48105, USA. sdsaini@umich.edu
FAU - Fendrick, A M
AU  - Fendrick AM
FAU - Scheiman, J M
AU  - Scheiman JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110525
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*economics/therapeutic use
MH  - Cardiovascular Diseases/economics/*prevention & control
MH  - Cohort Studies
MH  - Cost-Benefit Analysis
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Hemorrhage/*chemically induced/economics
MH  - Humans
MH  - Middle Aged
MH  - Models, Economic
MH  - Platelet Aggregation Inhibitors/*economics/therapeutic use
MH  - Proton Pump Inhibitors/*economics/therapeutic use
MH  - Secondary Prevention
EDAT- 2011/05/28 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/05/28 06:00
PHST- 2011/05/28 06:00 [entrez]
PHST- 2011/05/28 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 10.1111/j.1365-2036.2011.04707.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2011 Jul;34(2):243-51. doi: 
      10.1111/j.1365-2036.2011.04707.x. Epub 2011 May 25.

PMID- 1902404
OWN - NLM
STAT- MEDLINE
DCOM- 19910606
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 83
IP  - 5
DP  - 1991 May
TI  - A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 
      24 hours after recombinant tissue-type plasminogen activator for acute myocardial 
      infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
PG  - 1534-42
AB  - BACKGROUND: This study addressed the need for heparin administration to be 
      continued for more than 24 hours after coronary thrombolysis with recombinant 
      tissue-type plasminogen activator (rt-PA). METHODS AND RESULTS: A total of 241 
      patients with acute myocardial infarction were treated with 100 mg rt-PA and a 
      bolus of 5,000 units i.v. heparin followed by 1,000 units/hr i.v. heparin for 24 
      hours. At 24 hours, 202 patients were randomized to continue intravenous heparin 
      therapy (n = 99) in full dosage or to discontinue heparin therapy and begin an 
      oral antiplatelet regimen of aspirin (300 mg/day) and dipyridamole (300 mg/day) 
      (n = 103). On prospective recording, there were no differences in the pattern of 
      chest pain, reinfarction, or bleeding complications. Coronary angiography on 
      cardiac catheterization at 7-10 days showed no differences in patency of the 
      infarct-related artery. The proportion of patients with total occlusion (TIMI 
      grade 0-1) of the infarct-related artery was 18.9% in the heparin group and 19.8% 
      in the aspirin and dipyridamole group. In the patients with an incompletely 
      occluded infarct-related artery, the lumen was reduced by 69 +/- 2% of normal in 
      the heparin group and 67 +/- 2% in the aspirin and dipyridamole group. Left 
      ventricular function assessed on cardiac catheterization and radionuclide study 
      at day 2 and at 1 month showed no differences between the two groups. Left 
      ventricular ejection fraction on radionuclide ventriculography at 1 month was 
      52.4 +/- 1.2% in the heparin group and 51.9 +/- 1.2% in the aspirin and 
      dipyridamole group. CONCLUSIONS: We conclude that heparin therapy can be 
      discontinued 24 hours after rt-PA therapy and replaced with an oral antiplatelet 
      regimen without any adverse effects on chest pain, reinfarction, coronary 
      patency, or left ventricular function.
FAU - Thompson, P L
AU  - Thompson PL
AD  - Sir Charles Gairdner Hospital, Perth, Australia.
FAU - Aylward, P E
AU  - Aylward PE
FAU - Federman, J
AU  - Federman J
FAU - Giles, R W
AU  - Giles RW
FAU - Harris, P J
AU  - Harris PJ
FAU - Hodge, R L
AU  - Hodge RL
FAU - Nelson, G I
AU  - Nelson GI
FAU - Thomson, A
AU  - Thomson A
FAU - Tonkin, A M
AU  - Tonkin AM
FAU - Walsh, W F
AU  - Walsh WF
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anticoagulants)
RN  - 0 (Recombinant Proteins)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/*administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Dipyridamole/administration & dosage/therapeutic use
MH  - Female
MH  - Heparin/*administration & dosage/therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Recombinant Proteins
MH  - Tissue Plasminogen Activator/*therapeutic use
MH  - Vascular Patency/drug effects
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
AID - 10.1161/01.cir.83.5.1534 [doi]
PST - ppublish
SO  - Circulation. 1991 May;83(5):1534-42. doi: 10.1161/01.cir.83.5.1534.

PMID- 3012989
OWN - NLM
STAT- MEDLINE
DCOM- 19860701
LR  - 20131121
IS  - 0301-0546 (Print)
IS  - 0301-0546 (Linking)
VI  - 14
IP  - 2
DP  - 1986 Mar-Apr
TI  - Desensitization in aspirin-sensitive asthmatics.
PG  - 133-7
AB  - Tolerance to aspirin was induced in thirteen asthmatics with aspirin-intolerance. 
      Starting with the lowest aspirin doses eliciting bronchospasm, the dose of 
      aspirin was progressively increased up to a 1000 mg tolerance level. Tolerance 
      was rapidly achieved when initial threshold doses were greater than 150 mg. Daily 
      aspirin administration led to prolonged tolerance. Desensitization to aspirin may 
      be useful in aspirin-sensitive asthmatic patients who require antiinflammatory or 
      antithrombotic treatment.
FAU - Castillo, J A
AU  - Castillo JA
FAU - Picado, C
AU  - Picado C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins)
RN  - 0 (SRS-A)
RN  - 1HGW4DR56D (Leukotriene B4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Asthma/chemically induced/*therapy
MH  - Bronchial Spasm/chemically induced/physiopathology
MH  - *Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Leukotriene B4/physiology
MH  - Male
MH  - Prostaglandin Antagonists/adverse effects
MH  - Prostaglandins/physiology
MH  - SRS-A/physiology
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
PST - ppublish
SO  - Allergol Immunopathol (Madr). 1986 Mar-Apr;14(2):133-7.

PMID- 26596838
OWN - NLM
STAT- MEDLINE
DCOM- 20170206
LR  - 20210109
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 37
IP  - 5
DP  - 2016 May
TI  - Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification 
      of aspirin acetylated sites on recombinant p53.
PG  - 6007-16
LID - 10.1007/s13277-015-4438-3 [doi]
AB  - Aspirin's ability to inhibit cell proliferation and induce apoptosis in cancer 
      cell lines is considered to be an important mechanism for its anti-cancer 
      effects. We previously demonstrated that aspirin acetylated the tumor suppressor 
      protein p53 at lysine 382 in MDA-MB-231 human breast cancer cells. Here, we 
      extended these observations to human colon cancer cells, HCT 116 harboring wild 
      type p53, and HT-29 containing mutant p53. We demonstrate that aspirin induced 
      acetylation of p53 in both cell lines in a concentration-dependent manner. 
      Aspirin-acetylated p53 was localized to the nucleus. In both cell lines, aspirin 
      induced p21(CIP1). Aspirin also acetylated recombinant p53 (rp53) in vitro 
      suggesting that it occurs through a non-enzymatic chemical reaction. Mass 
      spectrometry analysis and immunoblotting identified 10 acetylated lysines on 
      rp53, and molecular modeling showed that all lysines targeted by aspirin are 
      surface exposed. Five of these lysines are localized to the DNA-binding domain, 
      four to the nuclear localization signal domain, and one to the C-terminal 
      regulatory domain. Our results suggest that aspirin's anti-cancer effect may 
      involve acetylation and activation of wild type and mutant p53 and induction of 
      target gene expression. This is the first report attempting to characterize p53 
      acetylation sites targeted by aspirin.
FAU - Ai, Guoqiang
AU  - Ai G
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Avera Health and 
      Sciences Center, South Dakota State University, Brookings, SD, USA.
FAU - Dachineni, Rakesh
AU  - Dachineni R
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Avera Health and 
      Sciences Center, South Dakota State University, Brookings, SD, USA.
FAU - Kumar, D Ramesh
AU  - Kumar DR
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Avera Health and 
      Sciences Center, South Dakota State University, Brookings, SD, USA.
FAU - Marimuthu, Srinivasan
AU  - Marimuthu S
AD  - Ayurveda Research Institute for Mother & Child Health Care, Poojapura, 
      Trivandrum, Kerala, India.
FAU - Alfonso, Lloyd F
AU  - Alfonso LF
AD  - School of Pharmacy, D'Youville College, 320 Porter Avenue, Buffalo, NY, 14201, 
      USA.
FAU - Bhat, G Jayarama
AU  - Bhat GJ
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Avera Health and 
      Sciences Center, South Dakota State University, Brookings, SD, USA. 
      Jayarama.gunaje@sdstate.edu.
LA  - eng
PT  - Journal Article
DEP - 20151123
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (Mutant Proteins)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation/drug effects
MH  - Aspirin/*pharmacology
MH  - Cell Line, Tumor
MH  - Cell Nucleus/metabolism
MH  - Colonic Neoplasms/genetics/*metabolism
MH  - Cyclin-Dependent Kinase Inhibitor p21/genetics/metabolism
MH  - HCT116 Cells
MH  - HT29 Cells
MH  - Humans
MH  - Lysine/metabolism
MH  - Mutant Proteins/chemistry/*metabolism
MH  - Protein Processing, Post-Translational
MH  - Protein Transport
MH  - Recombinant Proteins
MH  - Tumor Suppressor Protein p53/chemistry/genetics/*metabolism
OTO - NOTNLM
OT  - Acetylation
OT  - Anti-cancer effects
OT  - Apoptosis
OT  - Aspirin
OT  - p53
EDAT- 2015/11/26 06:00
MHDA- 2017/02/07 06:00
CRDT- 2015/11/25 06:00
PHST- 2015/10/29 00:00 [received]
PHST- 2015/11/12 00:00 [accepted]
PHST- 2015/11/25 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2017/02/07 06:00 [medline]
AID - 10.1007/s13277-015-4438-3 [pii]
AID - 10.1007/s13277-015-4438-3 [doi]
PST - ppublish
SO  - Tumour Biol. 2016 May;37(5):6007-16. doi: 10.1007/s13277-015-4438-3. Epub 2015 
      Nov 23.

PMID- 28285696
OWN - NLM
STAT- MEDLINE
DCOM- 20171227
LR  - 20180124
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 106
DP  - 2017 Apr
TI  - Effects of aspirin on small-cell lung cancer mortality and metastatic 
      presentation.
PG  - 67-69
LID - S0169-5002(17)30030-2 [pii]
LID - 10.1016/j.lungcan.2017.01.018 [doi]
AB  - Although meta-analysis data have shown that taking regular aspirin may reduce 
      lung cancer mortality, individual trial data results are conflicting, and the 
      data on the effects of aspirin on different histological subtypes of lung 
      tumours, in particular small-cell lung cancer, are sparse. We conducted a 
      prospective observational study of 313 patients with a new diagnosis of 
      small-cell lung cancer and recorded use of aspirin before and after tumour 
      diagnosis. Seventy-one (23%) patients were taking regular daily aspirin for more 
      than 2 years at the time of tumour diagnosis. We found that regular use of 
      aspirin had no effect on survival nor metastatic presentation compared to data 
      from small-cell lung cancer patients not taking aspirin. The lack of survival 
      benefit in patients with small-cell lung cancer taking long-term aspirin may be 
      due to the low expression of cyclooxygenase-2 in small-cell lung cancer tissue.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - Maddison, Paul
AU  - Maddison P
AD  - Department of Clinical Neurology, Queen's Medical Centre, Nottingham, NG7 2UH, 
      UK. Electronic address: paul.maddison@nhs.net.
LA  - eng
PT  - Journal Article
DEP - 20170204
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Cyclooxygenase 2/metabolism
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*diagnosis/drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis/drug therapy/pathology
MH  - Neoplasm Staging
MH  - Prospective Studies
MH  - Small Cell Lung Carcinoma/diagnosis/*drug therapy/*mortality
MH  - Survival Analysis
OTO - NOTNLM
OT  - Aspirin
OT  - Observational
OT  - Prospective
OT  - Small-cell lung cancer
OT  - Survival
EDAT- 2017/03/14 06:00
MHDA- 2017/12/28 06:00
CRDT- 2017/03/14 06:00
PHST- 2016/12/15 00:00 [received]
PHST- 2017/01/25 00:00 [revised]
PHST- 2017/01/29 00:00 [accepted]
PHST- 2017/03/14 06:00 [entrez]
PHST- 2017/03/14 06:00 [pubmed]
PHST- 2017/12/28 06:00 [medline]
AID - S0169-5002(17)30030-2 [pii]
AID - 10.1016/j.lungcan.2017.01.018 [doi]
PST - ppublish
SO  - Lung Cancer. 2017 Apr;106:67-69. doi: 10.1016/j.lungcan.2017.01.018. Epub 2017 
      Feb 4.

PMID- 18619179
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20181201
VI  - 118
IP  - 5
DP  - 2008 May
TI  - Antiplatelet treatment of cardiovascular disease: a translational research 
      perspective.
PG  - 289-97
AB  - Platelet mediated thrombosis is the primary cause of ischemic event occurrence in 
      patients with cardiovascular disease. The P2Y12 receptor plays a central role in 
      thrombus generation and is therefore a major target for pharmacologic therapy. 
      Although various clinical trials have demonstrated the efficacy of dual 
      antiplatelet therapy with aspirin and clopidogrel, recurrent ischemic events 
      occur in approximately 10% of patients with acute coronary artery syndromes. 
      Recent translational research studies have explored the various limitations of 
      dual antiplatelet therapy including wide response variability and resistance. The 
      association of ischemic event occurrence with high on-treatment platelet 
      reactivity to adenosine diphosphate has been reported in recent small studies 
      suggesting that the latter may be a quantifiable and modifiable risk factor. 
      Recent studies have identified a potential therapeutic target for P2Y12 
      inhibitors that may influence the future development of personalized antiplatelet 
      treatment strategies aimed at the reduction of ischemic event occurrence in high 
      risk patients. Finally, based on the current evidence platelet reactivity may 
      become a standard of care risk factor measured in all patients with 
      cardiovascular disease.
FAU - Gurbel, Paul A
AU  - Gurbel PA
AD  - Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 
      21215, USA. pgurbel@lifebridgehealth.org
FAU - Antonino, Mark J
AU  - Antonino MJ
FAU - Tantry, Udaya S
AU  - Tantry US
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Poland
TA  - Pol Arch Med Wewn
JT  - Polskie Archiwum Medycyny Wewnetrznej
JID - 0401225
RN  - 0 (P2RY12 protein, human)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Receptors, Purinergic P2)
RN  - 0 (Receptors, Purinergic P2Y12)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Coronary Thrombosis/*drug therapy
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Receptors, Purinergic P2/metabolism
MH  - Receptors, Purinergic P2Y12
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
RF  - 63
EDAT- 2008/07/16 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/07/16 09:00
PHST- 2008/07/16 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/16 09:00 [entrez]
PST - ppublish
SO  - Pol Arch Med Wewn. 2008 May;118(5):289-97.

PMID- 24990499
OWN - NLM
STAT- MEDLINE
DCOM- 20150221
LR  - 20190706
IS  - 1347-5223 (Electronic)
IS  - 0009-2363 (Linking)
VI  - 62
IP  - 7
DP  - 2014
TI  - Evaluation of the pharmaceutical characteristics of various enteric-coated 
      aspirin tablets under different storage conditions.
PG  - 617-26
AB  - The formulation characteristics of 6 brands of enteric-coated aspirin tablets 
      under unpackaged conditions at 40°C and 60°C for 4 weeks were analyzed. 
      Appearance, salicylic acid content, dissolution rates, and surface properties (by 
      Raman microscopy) were evaluated to determine stability data, taking into account 
      the clinical use of generic drugs. No change in appearance, decomposition, or 
      dissolution rates was observed in unpackaged aspirin tablets stored at 40°C for 4 
      weeks. However, when stored at 60°C, tablets of 5 of the 6 brands showed whiskers 
      on their surfaces along with an increase in salicylic acid content and a decrease 
      in dissolution rate. Results of Raman mapping on the surface and cross sectional 
      surface of the tablets with whiskers showed a salicylic acid peak associated with 
      storage at 60°C for 4 weeks. However, for tablets from 1 of the 6 brands, no 
      salicylic acid peaks were observed. For this tablet, Raman microscopy revealed 2 
      layers of film coating, and talc, which greatly affected the stability of the 
      acetylsalicylic acid, was found only in the outer layer film. These results 
      indicated that the protection of compatibility with talc is one of the important 
      factors in enhancement of aspirin tablet stability in this tablet. We concluded 
      that certification of the characteristics associated with stability and 
      formulation is essential for generic drugs, which are not required to undergo 
      stability testing under extreme storage conditions.
FAU - Abe, Toshihide
AU  - Abe T
AD  - Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, 
      The University of Tokyo.
FAU - Yanagihara, Yoshitsugu
AU  - Yanagihara Y
FAU - Uchino, Tomonobu
AU  - Uchino T
FAU - Oriyama, Toyohito
AU  - Oriyama T
FAU - Komatsu, Mamoru
AU  - Komatsu M
FAU - Nakajima, Katsuyoshi
AU  - Nakajima K
FAU - Suzuki, Hiroshi
AU  - Suzuki H
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - 0 (Tablets, Enteric-Coated)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Chemistry, Pharmaceutical
MH  - Drug Stability
MH  - Microscopy, Electron, Scanning
MH  - Salicylic Acid/analysis
MH  - Spectrum Analysis, Raman
MH  - Surface Properties
MH  - Tablets, Enteric-Coated/*chemistry
MH  - Temperature
MH  - Time Factors
EDAT- 2014/07/06 06:00
MHDA- 2015/02/24 06:00
CRDT- 2014/07/04 06:00
PHST- 2014/07/04 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2015/02/24 06:00 [medline]
AID - DN/JST.JSTAGE/cpb/c13-00580 [pii]
AID - 10.1248/cpb.c13-00580 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 2014;62(7):617-26. doi: 10.1248/cpb.c13-00580.

PMID- 28613225
OWN - NLM
STAT- MEDLINE
DCOM- 20180109
LR  - 20180109
IS  - 1539-2864 (Electronic)
IS  - 0275-004X (Linking)
VI  - 37
IP  - 9
DP  - 2017 Sep
TI  - MACULAR DEGENERATION AND ASPIRIN USE.
PG  - 1630-1635
LID - 10.1097/IAE.0000000000001475 [doi]
AB  - PURPOSE: To review current literature of the benefits that aspirin provides for 
      patients' cardiovascular health compared with the risk of AMD worsening. METHODS: 
      We performed a review and critically analyzed six cardiovascular and four 
      ophthalmological trials regarding risks and benefits of aspirin use. The 
      prospective randomized cardiovascular trials had a cumulative 167,580 while the 3 
      smaller ophthalmological data sets had a cumulative 12,015 subjects. RESULTS: The 
      reviewed meta-analysis literature demonstrated a statistically significant 32% 
      reduction in the risk of nonfatal stroke with regular aspirin users. The study 
      also documented that aspirin users decreased the risk of fatal vascular deaths by 
      15%. Of the three ophthalmological studies highlighting the adverse affects of 
      aspirin association with AMD, all suggested an exacerbation of AMD without 
      statistical significance and broad confidence bands. CONCLUSION: Overall, the 
      number, size, and quality of the cardiovascular studies recommending aspirin use 
      are far superior to the fewer, smaller and conflicting studies suggesting a 
      possible adverse effect of aspirin use in relation to AMD. The benefits of 
      aspirin usage include preserving the duration and quality of life by decreasing 
      stroke and heart attack risk. These benefits seem to far outweigh the theoretical 
      risks of possibly exacerbating wet AMD, which can be reasonably controlled with 
      anti-VEGF therapy.
FAU - Small, Kent W
AU  - Small KW
AD  - *Macula and Retina Institute, Los Angeles and Glendale, California and †Molecular 
      Insight Research Foundation, Los Angeles and Glendale, California.
FAU - Garabetian, Christine A
AU  - Garabetian CA
FAU - Shaya, Fadi S
AU  - Shaya FS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Retina
JT  - Retina (Philadelphia, Pa.)
JID - 8309919
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Fibrinolytic Agents/*adverse effects/therapeutic use
MH  - Humans
MH  - Macular Degeneration/*chemically induced
MH  - Meta-Analysis as Topic
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
EDAT- 2017/06/15 06:00
MHDA- 2018/01/10 06:00
CRDT- 2017/06/15 06:00
PHST- 2017/06/15 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
PHST- 2017/06/15 06:00 [entrez]
AID - 10.1097/IAE.0000000000001475 [doi]
PST - ppublish
SO  - Retina. 2017 Sep;37(9):1630-1635. doi: 10.1097/IAE.0000000000001475.

PMID- 34576324
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 18
DP  - 2021 Sep 21
TI  - Endothelium-Derived Hyperpolarizing Factor (EDHF) Mediates Acetylsalicylic Acid 
      (Aspirin) Vasodilation of Pregnant Rat Mesenteric Arteries.
LID - 10.3390/ijms221810162 [doi]
LID - 10162
AB  - Acetylsalicylic acid (aspirin) exhibits a broad range of activities, including 
      analgesic, antipyretic, and antiplatelet properties. Recent clinical studies also 
      recommend aspirin prophylaxis in women with a high risk of pre-eclampsia, a major 
      complication of pregnancy characterized by hypertension. We investigated the 
      effect of aspirin on mesenteric resistance arteries and found outdiscovered the 
      molecular mechanism underlying this action. Aspirin (10(-12)-10(-6) M) was tested 
      on pregnant rat mesenteric resistance arteries by a pressurized arteriography. 
      Aspirin was investigated in the presence of several inhibitors of: (a) nitric 
      oxide synthase (L-NAME 2 × 10(-4) M); (b) cyclooxygenase (Indomethacin, 10(-5) 
      M); (c) Ca(2+)-activated K(+) channels (Kca): small conductance (SKca, Apamin, 
      10(-7) M), intermediate conductance (IKca, TRAM34, 10(-5) M), and big conductance 
      (BKca, paxilline, 10(-5) M); and (d) endothelial-derived hyperpolarizing factor 
      (high KCl, 80 mM). Aspirin caused a concentration-dependent vasodilation. 
      Aspirin-vasodilation was abolished by removal of endothelium or by high KCl. 
      Furthermore, preincubation with either apamin plus TRAM-34 or paxillin 
      significantly attenuated aspirin vasodilation (p < 0.05). For the first time, we 
      showed that aspirin induced endothelium-dependent vasodilation in mesenteric 
      resistance arteries through the endothelial-derived hyperpolarizing factor (EDHF) 
      and calcium-activated potassium channels. By activating this molecular mechanism, 
      aspirin may lower peripheral vascular resistance and be beneficial in pregnancies 
      complicated by hypertension.
FAU - Helgadóttir, Helga
AU  - Helgadóttir H
AD  - Department of Biology, Ecology and Earth Sciences, University of Calabria, 
      Arcavacata di Rende, 87036 Cosenza, Italy.
AD  - Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, 107 
      Reykjavik, Iceland.
FAU - Tropea, Teresa
AU  - Tropea T
AD  - Department of Biology, Ecology and Earth Sciences, University of Calabria, 
      Arcavacata di Rende, 87036 Cosenza, Italy.
FAU - Gizurarson, Sveinbjörn
AU  - Gizurarson S
AUID- ORCID: 0000-0001-7824-9752
AD  - Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, 107 
      Reykjavik, Iceland.
FAU - Mandalà, Maurizio
AU  - Mandalà M
AUID- ORCID: 0000-0003-3736-0205
AD  - Department of Biology, Ecology and Earth Sciences, University of Calabria, 
      Arcavacata di Rende, 87036 Cosenza, Italy.
LA  - eng
GR  - 601852/Seventh Framework Programme/
GR  - 163369-051/Icelandic Research Fund/
PT  - Journal Article
DEP - 20210921
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Biological Factors)
RN  - 0 (endothelium-dependent hyperpolarization factor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Biological Factors/genetics/*metabolism
MH  - Mesenteric Arteries/*drug effects/*metabolism
MH  - Myocytes, Smooth Muscle/drug effects/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
PMC - PMC8471567
OTO - NOTNLM
OT  - calcium-activated potassium channels
OT  - endothelial cells
OT  - hypertension
OT  - pre-eclampsia
OT  - relaxation
OT  - smooth muscle cells
COIS- The authors declare no conflict of interest.
EDAT- 2021/09/29 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/09/28 01:19
PHST- 2021/08/30 00:00 [received]
PHST- 2021/09/14 00:00 [revised]
PHST- 2021/09/16 00:00 [accepted]
PHST- 2021/09/28 01:19 [entrez]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
AID - ijms221810162 [pii]
AID - ijms-22-10162 [pii]
AID - 10.3390/ijms221810162 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Sep 21;22(18):10162. doi: 10.3390/ijms221810162.

PMID- 11496277
OWN - NLM
STAT- MEDLINE
DCOM- 20011004
LR  - 20131121
IS  - 0741-5214 (Print)
IS  - 0741-5214 (Linking)
VI  - 34
IP  - 2
DP  - 2001 Aug
TI  - Cost-effectiveness of oral anticoagulants versus aspirin in patients after 
      infrainguinal bypass grafting surgery.
PG  - 254-62
AB  - PURPOSE: Several antithrombotic therapies are available for the treatment of 
      patients with peripheral vascular diseases. It is unknown how quality of life and 
      costs of treatment are influenced by different therapies. This study assessed the 
      cost-effectiveness of oral anticoagulants versus aspirin in patients after 
      infrainguinal bypass grafting surgery. METHODS: Clinical outcome events and 
      event-free survival were collected from 2650 patients in 77 centers who 
      participated in the Dutch Bypass Oral anticoagulants or Aspirin trial. 
      Approximately half the patients had critical ischemia; 60% received vein grafts, 
      and 20% had femorocrural bypass grafts. A model that was primarily driven by 
      clinical outcome events was used as a means of determining quality of life 
      (EuroQol EQ-5D) and costs for each patient. The main outcome measure was the 
      incremental health care costs in relation to the additional number of 
      quality-adjusted life years and the additional number of event-free years. 
      RESULTS: The mean costs during the 21 months of follow-up were epsilon 6875 per 
      patient in the oral anticoagulants group versus epsilon 7072 in the aspirin group 
      (difference, 197; 95% CI, -746 to 343). The event-free survival was 1.10 years in 
      the group treated with oral anticoagulants versus 1.09 years in the group treated 
      with aspirin (difference, 0.01; 95% CI, -0.07 to 0.08), whereas the corresponding 
      quality-adjusted life years were 1.06 and 1.05, respectively (difference, 0.01; 
      95% CI, -0.03 to 0.06). CONCLUSION: Health care costs, event-free survival, and 
      quality-adjusted life years in patients after infrainguinal bypass surgery were 
      not different in patients treated with aspirin and patients treated with oral 
      anticoagulants. The extra costs of monitoring patients treated with oral 
      anticoagulants were limited and play no role in the decision for treatment.
FAU - Oostenbrink, J B
AU  - Oostenbrink JB
AD  - Institute for Medical Technology Assessment, Erasmus University; the BOA Trial 
      Office, Julius Center for Patient-Oriented Research, and the Department of 
      Vascular Surgery, University Hospital; and the Department of Vascular Surgery, 
      Hospital Amstelveen.
FAU - Tangelder, M J
AU  - Tangelder MJ
FAU - Busschbach, J J
AU  - Busschbach JJ
FAU - van Hout, B A
AU  - van Hout BA
FAU - Buskens, E
AU  - Buskens E
FAU - Algra, A
AU  - Algra A
FAU - Lawson, J A
AU  - Lawson JA
FAU - Eikelboom, B C
AU  - Eikelboom BC
CN  - Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*administration & dosage/*economics
MH  - Aspirin/*administration & dosage/*economics
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Humans
MH  - Leg/blood supply/surgery
MH  - Male
MH  - Postoperative Complications/*prevention & control
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Vascular Surgical Procedures/*adverse effects
EDAT- 2001/08/10 10:00
MHDA- 2001/10/05 10:01
CRDT- 2001/08/10 10:00
PHST- 2001/08/10 10:00 [pubmed]
PHST- 2001/10/05 10:01 [medline]
PHST- 2001/08/10 10:00 [entrez]
AID - S0741-5214(01)87417-6 [pii]
AID - 10.1067/mva.2001.115961 [doi]
PST - ppublish
SO  - J Vasc Surg. 2001 Aug;34(2):254-62. doi: 10.1067/mva.2001.115961.

PMID- 3228043
OWN - NLM
STAT- MEDLINE
DCOM- 19890404
LR  - 20151119
IS  - 0301-0546 (Print)
IS  - 0301-0546 (Linking)
VI  - 16
IP  - 4
DP  - 1988 Jul-Aug
TI  - Serum neutrophil chemotactic activity (NCA) during aspirin-induced urticaria and 
      angioedema.
PG  - 231-6
AB  - In order to establish the role of mast cells in aspirin-induced urticaria and 
      angioedema, neutrophil chemotactic activity (NCA) in serum was assayed using the 
      method of Nelson before and after aspirin challenge. In 14 (82.4%) persons 
      sensitive to aspirin an increase in NCA during aspirin-induced urticaria and 
      angioedema was observed and in 9 of them (52.9%) it was considerable (index NCA 
      greater than or equal to 2.0). None of the 18 persons from the control group with 
      idiopathic urticaria and/or angioedema but without aspirin-sensitivity exhibit an 
      increase in NCA after aspirin challenge. The author assumes that mast cell 
      degranulation does occur in aspirin-induced urticaria and angioedema.
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
AD  - Department of Pneumonology and Allergology, Medical Academy of Lodz, Poland.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Angioedema/*chemically induced/immunology
MH  - Aspirin/*adverse effects/pharmacology
MH  - Chemotaxis, Leukocyte/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Mast Cells/immunology
MH  - Middle Aged
MH  - Neutrophils/immunology
MH  - Urticaria/*chemically induced/immunology
EDAT- 1988/07/01 00:00
MHDA- 1988/07/01 00:01
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 1988/07/01 00:01 [medline]
PHST- 1988/07/01 00:00 [entrez]
PST - ppublish
SO  - Allergol Immunopathol (Madr). 1988 Jul-Aug;16(4):231-6.

PMID- 3530585
OWN - NLM
STAT- MEDLINE
DCOM- 19861107
LR  - 20190510
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 40
IP  - 4
DP  - 1986 Oct
TI  - Renal safety of two analgesics used over the counter: ibuprofen and aspirin.
PG  - 373-7
AB  - The incidence of potentially serious drug-related elevations of BUN or serum 
      creatinine was examined among 1468 patients with rheumatoid arthritis or 
      osteoarthritis who took daily therapeutic doses of aspirin, ibuprofen, or 
      oxaprozin, an investigational nonsteroidal antiinflammatory drug (NSAID), in 
      multicenter clinical trials. Algorithms were developed to identify patients with 
      potentially important elevations of these renal laboratory parameters and to 
      assess the possible relation between these elevations and the study drugs. All 
      three drugs were associated with a low (4% to 6%) incidence of potentially 
      significant elevations in renal function parameters. Changes considered serious 
      occurred in only three (less than 1%) patients (one treated with oxaprozin and 
      two with ibuprofen), all of whom were receiving concomitant diuretic therapy. 
      None of the changes led to adverse clinical consequences. Thus despite recent 
      controversy regarding the renal safety of NSAIDs, all three drugs proved safe in 
      these studies, despite the fact that aspirin and ibuprofen were given in doses 
      equal to or higher than those used for over-the-counter indications.
FAU - Bonney, S L
AU  - Bonney SL
FAU - Northington, R S
AU  - Northington RS
FAU - Hedrich, D A
AU  - Hedrich DA
FAU - Walker, B R
AU  - Walker BR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Propionates)
RN  - AYI8EX34EU (Creatinine)
RN  - MHJ80W9LRB (Oxaprozin)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Urea Nitrogen
MH  - Clinical Trials as Topic
MH  - Creatinine/metabolism
MH  - Double-Blind Method
MH  - Humans
MH  - Ibuprofen/adverse effects/*therapeutic use
MH  - Kidney/*drug effects
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Oxaprozin
MH  - Propionates/therapeutic use
EDAT- 1986/10/01 00:00
MHDA- 1986/10/01 00:01
CRDT- 1986/10/01 00:00
PHST- 1986/10/01 00:00 [pubmed]
PHST- 1986/10/01 00:01 [medline]
PHST- 1986/10/01 00:00 [entrez]
AID - 0009-9236(86)90100-1 [pii]
AID - 10.1038/clpt.1986.193 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1986 Oct;40(4):373-7. doi: 10.1038/clpt.1986.193.

PMID- 319319
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20200304
IS  - 0024-4201 (Print)
IS  - 0024-4201 (Linking)
VI  - 12
IP  - 1
DP  - 1977 Jan
TI  - An intervention study-the aspirin myocardial infarction study.
PG  - 59-63
AB  - The Aspirin Myocaridal Infarction Study is a randomized, double-blind clinical 
      trial designed to study the potential value of aspirin in the reduction of 
      mortality in patients who have had a prior myocardial infarction. This trial is 
      based upon several previously published studies which suggest that aspirin may be 
      valuable iprevention of coronary thrombosis. The requirement of 4200 patients 
      dictates that the study must be multicenter, and good design requires that the 
      study be collaborative with cnetral monitoring and an elaborate committee 
      structure to insure uniformity and comparability.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Lipids
JT  - Lipids
JID - 0060450
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Research Design
MH  - United States
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1007/BF02532973 [doi]
PST - ppublish
SO  - Lipids. 1977 Jan;12(1):59-63. doi: 10.1007/BF02532973.

PMID- 529250
OWN - NLM
STAT- MEDLINE
DCOM- 19800417
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 6
IP  - 6
DP  - 1979 Nov-Dec
TI  - Hepatic abnormalities in adult onset Still's disease.
PG  - 673-9
AB  - Five patients with adult onset Still's disease are reported. Three had abnormal 
      liver function tests (LFT) prior to receiving salicylates. Liver biopsy in 1 of 
      these 3 and in another with normal LFT was abnormal. The elevated LFT returned to 
      normal with high dose salicylate therapy coincident with remission of disease 
      activity. It is proposed that hepatic abnormalities in Still's disease frequently 
      reflect the underlying disease and not salicylate hepatotoxicity (SH).
FAU - Esdaile, J M
AU  - Esdaile JM
FAU - Tannenbaum, H
AU  - Tannenbaum H
FAU - Lough, J
AU  - Lough J
FAU - Hawkins, D
AU  - Hawkins D
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Arthritis, Juvenile/*pathology
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Liver/pathology/*physiopathology
MH  - Liver Function Tests
MH  - Male
EDAT- 1979/11/01 00:00
MHDA- 1979/11/01 00:01
CRDT- 1979/11/01 00:00
PHST- 1979/11/01 00:00 [pubmed]
PHST- 1979/11/01 00:01 [medline]
PHST- 1979/11/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1979 Nov-Dec;6(6):673-9.

PMID- 17161547
OWN - NLM
STAT- MEDLINE
DCOM- 20070703
LR  - 20131121
IS  - 0306-9877 (Print)
IS  - 0306-9877 (Linking)
VI  - 68
IP  - 6
DP  - 2007
TI  - Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion 
      associated mortality in late-term hemoglobinopathies. Hypothesis and rationale.
PG  - 1342-7
AB  - Medroxyprogesterone acetate (MPA) - a safe depot contraceptive - is shown 
      previously to reduce painful crises of sickle cell anemia, which is parallel with 
      the recent findings showing progesterone induction of fetal hemoglobin genes. 
      This would be a way to reduce transfusions for late term thalassemia major and 
      sickle cell-disease cases with no chances left for a stem cell transplantation. 
      In these patients, transfusional hemosiderosis causes irreversible damage to many 
      organs despite the available iron-chelating agents. Pharmacological strategies 
      either target the conformal structure of the defective adult hemoglobin or aim to 
      activate fetal hemoglobin concentrations. The only concern on MPA may be its 
      thromboembolic risks, which may be uncoupled with agents acting both 
      anti-coagulant and inductive on the blood oxygen-carrying affinity. Such agents 
      could be valproic acid and aspirin. Valproic acid is being safely used to treat 
      epilepsy and its histone acetylating function may lead its induction of fetal 
      hemoglobin. Aspirin was shown to increase oxygen affinity of hemoglobin via 
      acetylating lysine residues and its general acetylating activity on proteins such 
      as histones makes it also an interesting candidate to activate fetal hemoglobin. 
      We propose that combining MPA with clinically available doses of valproic acid 
      and aspirin would be beneficial in terms of both reduced coagulation risks and 
      increased oxygen affinity to decrease the transfusions and to improve the 
      prognosis in late-phase hemoglobin disorders.
FAU - Altinoz, Meric A
AU  - Altinoz MA
AD  - Medical Biology and Genetics at Istanbul Medical School of Istanbul University, 
      Golden Horn (Halic) University, Istanbul, Turkey. maltinoz@gmail.com
FAU - Ozdilli, Kursat
AU  - Ozdilli K
FAU - Carin, Mahmut N
AU  - Carin MN
FAU - Gedikoglu, Gunduz
AU  - Gedikoglu G
LA  - eng
PT  - Journal Article
DEP - 20061211
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 614OI1Z5WI (Valproic Acid)
RN  - HSU1C9YRES (Medroxyprogesterone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Transfusion, Intrauterine/*mortality
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - *Hemoglobinopathies/complications/drug therapy/physiopathology
MH  - Humans
MH  - Medroxyprogesterone/pharmacology/*therapeutic use
MH  - *Models, Biological
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*drug therapy
MH  - Pregnancy Trimester, Third
MH  - Valproic Acid/pharmacology/*therapeutic use
EDAT- 2006/12/13 09:00
MHDA- 2007/07/04 09:00
CRDT- 2006/12/13 09:00
PHST- 2006/10/06 00:00 [received]
PHST- 2006/10/08 00:00 [accepted]
PHST- 2006/12/13 09:00 [pubmed]
PHST- 2007/07/04 09:00 [medline]
PHST- 2006/12/13 09:00 [entrez]
AID - S0306-9877(06)00776-6 [pii]
AID - 10.1016/j.mehy.2006.10.032 [doi]
PST - ppublish
SO  - Med Hypotheses. 2007;68(6):1342-7. doi: 10.1016/j.mehy.2006.10.032. Epub 2006 Dec 
      11.

PMID- 18297549
OWN - NLM
STAT- MEDLINE
DCOM- 20080811
LR  - 20211020
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 19
IP  - 2
DP  - 2008 Mar
TI  - Lack of reproducibility of assessment of aspirin responsiveness by optical 
      aggregometry and two platelet function tests.
PG  - 119-24
LID - 10.1080/09537100701771736 [doi]
AB  - The term aspirin-resistance describes the failure of aspirin to inhibit 
      thromboxane A(2) production. Many new tests have become available for potentially 
      measuring aspirin responses but some are non-specific and do not isolate COX-1 
      activity. We previously demonstrated that agreement between two tests (PFA-100 
      and VerifyNow-ASA) and light transmission aggregation (LTA) was no greater than 
      would be expected by chance. In this study we re-tested the same patients using 
      identical methods after 1 year to determine whether poor agreement might have 
      been due to assessment in the acute phase and whether the results of the 
      individual tests are consistent over time. Platelet function by all three tests 
      was re-tested in the 72 patients who were alive and still receiving low dose ASA 
      therapy one year after the first tests were performed. On re-testing the 
      prevalence of ASA non-responsiveness compared with baseline was 10% vs 17% by the 
      VerifyNow-ASA test, 25% vs 22% by the PFA-100(R), and 1% vs 5% by LTA. Agreement 
      between the tests at 1 year remained poor (kappas: 0.02-0.17) and only one 
      patient was identified as a non-responder by all three tests, in keeping with the 
      theoretical differences between the tests. Within test comparisons of baseline vs 
      1 year showed moderate agreement for the PFA-100(R) (kappa = 0.44, 95% CI 
      0.19-0.68, p = 0.0006), a fair agreement for VerifyNow-ASA (kappa = 0.34, 
      0.04-0.64, p = 0.12) and poor agreement for LTA (kappa = 0.14, -0.11 -0.39, p = 
      0.24 for ADP; kappa = 0.09, -0.21-0.39, p = 0.41 for arachidonic acid). Agreement 
      between the three tests in identifying aspirin non-responsiveness remained poor 
      in patients who had been taking aspirin for at least 1 year follow-up. 
      Reproducibility over time was no greater than chance for LTA and only moderate 
      for VerifyNow-ASA and PFA-100(R). Lack of consistency over time in identification 
      of apparently non-responsiveness individuals is likely to substantially undermine 
      any ability of these tests to predict risk of recurrent vascular events.
FAU - Harrison, Paul
AU  - Harrison P
AD  - Oxford Haemophilia and Thrombosis Centre, Oxford, UK. paul.harrison@ndm.ox.ac.uk
FAU - Segal, Helen
AU  - Segal H
FAU - Silver, Louise
AU  - Silver L
FAU - Syed, Anila
AU  - Syed A
FAU - Cuthbertson, Fiona C
AU  - Cuthbertson FC
FAU - Rothwell, Peter M
AU  - Rothwell PM
LA  - eng
GR  - G0500987/MRC_/Medical Research Council/United Kingdom
GR  - OSRP2/1006/DMT_/The Dunhill Medical Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Drug Resistance
MH  - Humans
MH  - Ischemic Attack, Transient/*blood/drug therapy
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests/methods
MH  - Reproducibility of Results
MH  - Stroke/*blood/drug therapy
EDAT- 2008/02/26 09:00
MHDA- 2008/08/12 09:00
CRDT- 2008/02/26 09:00
PHST- 2008/02/26 09:00 [pubmed]
PHST- 2008/08/12 09:00 [medline]
PHST- 2008/02/26 09:00 [entrez]
AID - 790789544 [pii]
AID - 10.1080/09537100701771736 [doi]
PST - ppublish
SO  - Platelets. 2008 Mar;19(2):119-24. doi: 10.1080/09537100701771736.

PMID- 7061727
OWN - NLM
STAT- MEDLINE
DCOM- 19820527
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 22
IP  - 1
DP  - 1982 Jan
TI  - Saline catharsis: effect on aspirin bioavailability in combination with activated 
      charcoal.
PG  - 59-64
AB  - The effect of a saline cathartic combined with activated charcoal or activated 
      charcoal alone on aspirin bioavailability was characterized in six healthy 
      volunteers. Using a random, Latin-square design, subjects were given 975 mg 
      aspirin followed by either water alone, 15 Gm activated charcoal (AC), or 15 Gm 
      activated charcoal plus 20 Gm sodium sulfate (AC + SS) separated by one week. 
      Both AC (44.16 +/- 16.85 microgram/ml) and AC + SS (58.61 +/- 10.63 microgram/ml) 
      decreased (P less than 0.001) the maximal plasma salicylate concentration (Cpmax) 
      compared to control (86.61 +/- 12.69 microgram/ml). Urinary salicylate recovery 
      was decreased (P less than 0.01) for AC (57.88 +/- 16.26 per cent) and AC + SS 
      (61.00 +/- 11.49 per cent) as compared to control (93.73 +/- 6.83 per cent), 
      while for area under the plasma concentration-time curve (AUC) only AC showed a 
      decrease (P less than 0.01) compared to control. Neither AC nor AC + SS differed 
      from each other for Cpmax, AUC, or cumulative urinary recovery. Our findings 
      indicate that the addition of sodium sulfate to activated charcoal has no added 
      effect on limiting aspirin adsorption relative to activated charcoal alone.
FAU - Sketris, I S
AU  - Sketris IS
FAU - Mowry, J B
AU  - Mowry JB
FAU - Czajka, P A
AU  - Czajka PA
FAU - Anderson, W H
AU  - Anderson WH
FAU - Stafford, D T
AU  - Stafford DT
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Cathartics)
RN  - 0 (Salicylates)
RN  - 0 (Sulfates)
RN  - 0YPR65R21J (sodium sulfate)
RN  - 16291-96-6 (Charcoal)
RN  - 9NEZ333N27 (Sodium)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/metabolism/*poisoning
MH  - Biological Availability
MH  - Cathartics/*therapeutic use
MH  - *Charcoal
MH  - Feces/analysis
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Kinetics
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Sodium/therapeutic use
MH  - Sulfates/*therapeutic use
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1982.tb05709.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1982 Jan;22(1):59-64. doi: 10.1002/j.1552-4604.1982.tb05709.x.

PMID- 29939889
OWN - NLM
STAT- MEDLINE
DCOM- 20190418
LR  - 20190418
IS  - 1473-5857 (Electronic)
IS  - 0268-1315 (Linking)
VI  - 33
IP  - 5
DP  - 2018 Sep
TI  - A review and study of aspirin utilization for the primary prevention of 
      cardiovascular events in a psychiatric population.
PG  - 274-281
LID - 10.1097/YIC.0000000000000228 [doi]
AB  - In April 2016, the US Preventive Service Task Force (USPSTF) updated the aspirin 
      guidelines for the primary prevention of cardiovascular disease (CVD) and 
      colorectal cancer. This review assesses the importance of appropriate use of 
      aspirin for the primary prevention of CVD and, specifically, how individuals with 
      psychiatric disorders may benefit from such use. This study examined how current 
      prescribing practices of aspirin in a state psychiatric hospital align with these 
      new guidelines and how inappropriate prescribing may jeopardize patient safety. A 
      retrospective chart review of 93 patients was performed to evaluate whether 
      aspirin therapy would be recommended for primary prevention of CVD based on the 
      new USPSTF guidelines. A secondary analysis of these data was performed using the 
      2009 USPSTF recommendations to strengthen the assumption that practitioners were 
      no longer using the old guidelines. Drug interactions between aspirin and 
      concurrently prescribed pharmacotherapy were classified based on of severity, and 
      the past events of bleeding were quantified. Based on the 2016 guidelines, 25 of 
      the 93 patients included in this study were identified as potential candidates 
      who would benefit from aspirin use for the primary prevention of CVD; of whom 22 
      (88%) were not prescribed aspirin. The remaining 68 patients did not meet the 
      criteria for aspirin use for primary prevention, although 11 (16.2%) of these 
      patients were taking low-dose aspirin. Based on the 2009 guidelines, 49 of the 93 
      patients included in our study would have been identified as potential candidates 
      who would benefit from the use of aspirin for the primary prevention of CVD; 41 
      (83.7%) of whom were not prescribed aspirin. The remaining 44 patients did not 
      meet the previous criteria for aspirin use for primary prevention, although six 
      (13.6%) of these individuals were taking low-dose aspirin daily. The results 
      above indicate a difference between prescribing practices of aspirin use for the 
      primary prevention of CVD. We identified a similar rate of underuse; however, 
      there was a slight increase in the appropriate prescribing according to the 2016 
      guidelines compared with the 2009 guidelines (88 vs. 83.7%, respectively). Also, 
      there was a higher incidence of unnecessary prescribing (overutilization) of 
      aspirin for the primary prevention of CVD in 2016 compared with 2009 despite the 
      more restrictive criteria (and smaller candidate pool) published in these newer 
      guidelines. There were 47 drug interactions identified when patients' aspirin and 
      concurrent medication regimens were reviewed for our entire sample population. 
      These interactions could potentially lead to an adverse drug reaction in the 
      future. Our safety analysis revealed that none of the patients who were 
      prescribed aspirin had any bleeding events while on therapy within the period of 
      this study. Inappropriate omission of aspirin (underutilization) was more 
      prevalent in our psychiatric institution than overutilization; however, the 
      overall percentage of both underuse and overuse were greater when patients were 
      evaluated according to the 2016 guidelines and then compared with the 2009 
      statistics. Overutilization did not pose a serious risk for those on aspirin 
      therapy in this sample, as there were no major episodes of bleeding. However, 
      future harm from aspirin still exists based on the significant number of major 
      and moderate potential drug interactions with aspirin and the increased risk of 
      decreased adherence to critical psychiatric medications due to increased pill 
      burden and regimen complexity. Our findings demonstrate that there is an 
      opportunity to educate prescribers on the updated 2016 USPSTF guidelines to 
      improve preventive care and patient safety, which include harm reduction by 
      initiating aspirin in those who are at a risk of cardiovascular events, 
      continuing aspirin in those who are currently receiving aspirin appropriately, 
      and discontinuing aspirin in those who are not considered to be at a high risk of 
      CVD and who may also be at a risk of experiencing an increased risk of bleeding.
FAU - Victor, Kaitlyn
AU  - Victor K
AD  - VA Western New York, Healthcare System, Buffalo, New York, USA.
FAU - Skelly, Megan
AU  - Skelly M
AD  - VA Western New York, Healthcare System, Buffalo, New York, USA.
FAU - Mulcahy, Kimberly
AU  - Mulcahy K
AD  - Buffalo Psychiatric Center, New York State Office of Mental Health.
AD  - Department of Psychiatry, State University of New York, University at Buffalo 
      School of Medicine, State University of New York.
FAU - Demler, Tammie Lee
AU  - Demler TL
AD  - Buffalo Psychiatric Center, New York State Office of Mental Health.
AD  - Department of Pharmacy Practice, University at Buffalo School of Pharmacy and 
      Pharmaceutical Sciences.
AD  - Department of Psychiatry, State University of New York, University at Buffalo 
      School of Medicine, State University of New York.
FAU - Trigoboff, Eileen
AU  - Trigoboff E
AD  - Buffalo Psychiatric Center, New York State Office of Mental Health.
AD  - Department of Pharmacy Practice, University at Buffalo School of Pharmacy and 
      Pharmaceutical Sciences.
AD  - Department of Psychiatry, State University of New York, University at Buffalo 
      School of Medicine, State University of New York.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*drug therapy/psychology
MH  - Humans
MH  - Mental Disorders/*complications/psychology
MH  - Middle Aged
MH  - Primary Prevention/methods
MH  - Retrospective Studies
EDAT- 2018/06/26 06:00
MHDA- 2019/04/19 06:00
CRDT- 2018/06/26 06:00
PHST- 2018/06/26 06:00 [pubmed]
PHST- 2019/04/19 06:00 [medline]
PHST- 2018/06/26 06:00 [entrez]
AID - 10.1097/YIC.0000000000000228 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 2018 Sep;33(5):274-281. doi: 
      10.1097/YIC.0000000000000228.

PMID- 18329202
OWN - NLM
STAT- MEDLINE
DCOM- 20080825
LR  - 20181201
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 357
IP  - 1-2
DP  - 2008 Jun 5
TI  - Controlled delivery of aspirin: effect of aspirin on polymer degradation and in 
      vitro release from PLGA based phase sensitive systems.
PG  - 119-25
LID - 10.1016/j.ijpharm.2008.01.053 [doi]
AB  - The objective of this study was to develop poly (d,l-lactide-co-glycolide) (PLGA) 
      based injectable phase sensitive in situ gel forming delivery system for 
      controlled delivery of aspirin, and to characterize the effect of drug/polymer 
      interaction on the in vitro release of aspirin and polymer degradation. Aspirin 
      was dissolved into PLGA solution in 1-methyl-2-pyrrolidone. Poly(ethylene 
      glycol)400 was used as plasticizer to reduce initial burst release. The solution 
      formulation was injected into aqueous release medium to form a gel depot. 
      Released samples were withdrawn periodically and assayed for aspirin content by 
      high performance liquid chromatography. The effect of aspirin on the degradation 
      of PLGA matrix was evaluated using Proton Nuclear Magnetic Resonance and Gel 
      Permeation Chromatography. PLGA based in situ gel forming formulations controlled 
      the in vitro release of aspirin for 7 days only. Analysis of PLGA matrix 
      residuals revealed that PLGA in aspirin loaded formulations exhibited a 
      significantly (p<0.05) faster degradation compared to blank formulations. These 
      findings suggest that aspirin causes an unusually faster degradation of PLGA. 
      Such faster degradation of PLGA has not been noticed for any other drugs reported 
      in the literature.
FAU - Tang, Yu
AU  - Tang Y
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Nursing, and Allied 
      Sciences, North Dakota State University, Fargo, ND 58105, USA.
FAU - Singh, Jagdish
AU  - Singh J
LA  - eng
PT  - Journal Article
DEP - 20080206
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Excipients)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & 
      dosage/*pharmacokinetics
MH  - Aspirin/*administration & dosage/*pharmacokinetics
MH  - Chemistry, Pharmaceutical
MH  - Chromatography, Gel
MH  - Delayed-Action Preparations
MH  - Drug Delivery Systems
MH  - Excipients
MH  - Lactic Acid/*chemistry
MH  - Magnetic Resonance Spectroscopy
MH  - Polyglycolic Acid/*chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
EDAT- 2008/03/11 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/03/11 09:00
PHST- 2007/08/01 00:00 [received]
PHST- 2008/01/22 00:00 [revised]
PHST- 2008/01/24 00:00 [accepted]
PHST- 2008/03/11 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/03/11 09:00 [entrez]
AID - S0378-5173(08)00101-4 [pii]
AID - 10.1016/j.ijpharm.2008.01.053 [doi]
PST - ppublish
SO  - Int J Pharm. 2008 Jun 5;357(1-2):119-25. doi: 10.1016/j.ijpharm.2008.01.053. Epub 
      2008 Feb 6.

PMID- 8627531
OWN - NLM
STAT- MEDLINE
DCOM- 19960627
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 277
IP  - 2
DP  - 1996 May
TI  - Transdermal modification of platelet function: an aspirin patch system results in 
      marked suppression of platelet cyclooxygenase.
PG  - 559-64
AB  - Aspirin inhibits platelet cyclooxygenase and prevents thromboxane A2 (TXA2) 
      production. Although it is an effective antithrombotic, even at a low doses 
      aspirin may induce gastrointestinal toxicity. We examined the feasibility of 
      delivering aspirin transdermally using two patch systems, one without (type A) 
      and one with (type B) the permeation enhancer limonene. Daily application of two 
      type A patches that had a total surface area of 100 cm2 and contained 84 mg/patch 
      resulted in 85% +/- 6% reduction in serum TXB2 in six male subjects by day 14. 
      Suppression of serum TXB2 was less marked in females (32% +/- 16%). Analysis of 
      the residual drug in the patch showed that each patch delivered 18 +/- 3 mg on 
      day 1 and 17 +/- 4 mg on day 14, with no difference between males and females. 
      Daily application of a single patch B that had a surface area of 50 cm2 and 
      contained 120 mg aspirin resulted in 60% +/- 11% suppression of serum TXB2 by day 
      14 in nine male subjects and 84% +/- 9% suppression by day 21. Analysis of the 
      applied patches showed that patch B delivered 33 +/- 3 mg of aspirin daily. 
      Plasma aspirin and salicylate were determined by gas chromatography, mass 
      spectrometry. No aspirin was detected, whereas plasma salicylate was 157 +/- 38 
      ng/ml and 133 +/- 20 ng/ml by day 14 with patch A and patch B, respectively. 
      Analysis of aspirin applied by patch to the skin in three subjects showed marked 
      hydrolysis to the inactive product, salicylic acid. Aspirin can be delivered 
      transdermally by patch in a dose that suppresses platelet cyclooxygenase. The 
      delivery rate is low reflecting hydrolysis of the drug in the skin. Delivery is 
      improved by the permeation enhancer limonene. This novel route of delivery may be 
      applicable to other antithrombotics and may limit the risk of gastrointestinal 
      toxicity.
FAU - McAdam, B
AU  - McAdam B
AD  - Centre for Cardiovascular Science, Royal College of Surgeons in Ireland, Dublin.
FAU - Keimowitz, R M
AU  - Keimowitz RM
FAU - Maher, M
AU  - Maher M
FAU - Fitzgerald, D J
AU  - Fitzgerald DJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Cutaneous
MH  - Adult
MH  - Aspirin/*administration & dosage/blood
MH  - Blood Platelets/*drug effects/enzymology
MH  - Cyclooxygenase Inhibitors/*administration & dosage
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Skin/drug effects/microbiology
MH  - Thromboxane B2/blood
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1996 May;277(2):559-64.

PMID- 3921440
OWN - NLM
STAT- MEDLINE
DCOM- 19850530
LR  - 20190829
IS  - 0015-5691 (Print)
IS  - 0015-5691 (Linking)
VI  - 85
IP  - 1
DP  - 1985 Jan
TI  - [The modes of anti-inflammatory and analgesic actions of aspirin and salicylic 
      acid].
PG  - 49-57
AB  - The modes of anti-inflammatory and analgesic actions of aspirin and salicylic 
      acid were investigated using some experimental animal models. Anti-inflammatory 
      potencies of aspirin were almost equal to those of sodium salicylate in the 
      carrageenin hind paw edema, the cotton pellet granuloma and the adjuvant 
      arthritis tests in rats. On the other hand, in the ultra-violet ray erythema and 
      the arachidonic acid erythema tests in guinea pigs, aspirin was more potent than 
      sodium salicylate. Aspirin and sodium salicylate exhibited almost the same 
      inhibitions of the rat hind paw edema induced by a mixture of carrageenin and 
      prostaglandin E1. These results suggest that inhibition of cyclo-oxygenase by 
      aspirin does not play any important roles for the prevention of the vascular 
      permeability increment and the granulation in the inflamed tissue. Aspirin may 
      exert its antiinflammatory activity mainly as salicylic acid which is not an 
      inhibitor of prostaglandins biosynthesis in vitro. Aspirin showed about 5 times 
      more potent analgesic action than sodium salicylate in the lameness test using 
      adjuvant arthritic rats. Analgesic potency of aspirin was decreased to the level 
      of sodium salicylate by injection of prostaglandin E2 into the inflamed rat paw 
      in the adjuvant-induced lameness test. On the other hand, analgesic potency of 
      sodium salicylate was not decreased by the same treatment. It is concluded that 
      aspirin has two analgesic effects on the inflammatory pain, one is inhibition of 
      prostaglandins biosynthesis by acetylation of cyclo-oxygenase and the other is an 
      action due to salicylic acid, but the action of salicylic acid was not totally 
      explained by the inhibition of prostaglandins synthetase.
FAU - Higuchi, S
AU  - Higuchi S
FAU - Osada, Y
AU  - Osada Y
FAU - Shioiri, Y
AU  - Shioiri Y
FAU - Tanaka, N
AU  - Tanaka N
FAU - Otomo, S
AU  - Otomo S
FAU - Aihara, H
AU  - Aihara H
LA  - jpn
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Yakurigaku Zasshi
JT  - Nihon yakurigaku zasshi. Folia pharmacologica Japonica
JID - 0420550
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cyclooxygenase Inhibitors
MH  - Disease Models, Animal
MH  - Female
MH  - Guinea Pigs
MH  - Inflammation/drug therapy
MH  - Male
MH  - Mice
MH  - Pain/drug therapy
MH  - Prostaglandins/biosynthesis
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Sodium Salicylate/*pharmacology/therapeutic use
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1254/fpj.85.49 [doi]
PST - ppublish
SO  - Nihon Yakurigaku Zasshi. 1985 Jan;85(1):49-57. doi: 10.1254/fpj.85.49.

PMID- 31887781
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 120
IP  - 2
DP  - 2020 Feb
TI  - Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to 
      Patients at High Cardiovascular Risk-A Review.
PG  - 199-206
LID - 10.1055/s-0039-3400294 [doi]
AB  - Current evidence supports the use of low-dose aspirin for secondary 
      cardiovascular prevention. By contrast, the benefit-to-risk ratio of aspirin use 
      in primary prevention is debated: three contemporary randomized control trials 
      have been conflicting, and meta-analyses have concluded for an unclear clinical 
      benefit, based on the consideration that the reduction in thromboembolic events 
      is counterbalanced by increased bleeding. The primary prevention setting is, 
      however, a heterogeneous mix of subjects at highly variable cardiovascular risk. 
      One possible explanation for the uncertainty of data interpretation is the 
      progressive reduction in risk of major adverse cardiovascular events (MACEs) in 
      primary prevention that has accompanied global education programs, leading 
      patients to smoke less, exercise more, and increasingly take lipid-lowering 
      therapies. Based on a meta-regression of the benefits and harm of aspirin therapy 
      in primary prevention as a function of the 10-year risk of MACE, we favor a 
      nuanced approach still, however, based on the evaluation of cardiovascular risk, 
      acknowledging differences between patients and emphasizing an individualized 
      assessment of both benefits and harm. After optimal control of cardiovascular 
      risk factors, and when patients are less than 70 years of age, clinicians should 
      assess the risk of MACE and base decision on such stratification, considering the 
      risk of bleeding and patient preferences. Clinicians would then advise the use of 
      aspirin in primary prevention patients at the highest risk of MACE who do not 
      have a prohibitive risk of bleeding, and in the majority of cases after 
      initiation of properly titrated statin therapy.
CI  - Georg Thieme Verlag KG Stuttgart · New York.
FAU - De Caterina, Raffaele
AU  - De Caterina R
AUID- ORCID: 0000-0003-1637-574X
AD  - Cardiovascular Division, Pisa University Hospital, University of Pisa, Pisa, 
      Italy.
FAU - Aimo, Alberto
AU  - Aimo A
AD  - Cardiovascular Division, Pisa University Hospital, University of Pisa, Pisa, 
      Italy.
FAU - Ridker, Paul M
AU  - Ridker PM
AD  - Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, Massachusetts, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191230
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiology/*methods/*standards
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cardiovascular System/drug effects
MH  - Diabetes Complications/drug therapy
MH  - Hemorrhage/prevention & control
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Odds Ratio
MH  - Practice Patterns, Physicians'
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment/methods
MH  - Risk Factors
MH  - Secondary Prevention
COIS- R.D.C. declares having received fees and honoraria from Bayer related to the 
      topic. A.A. and P.M.R. have no conflict of interest to disclose.
EDAT- 2019/12/31 06:00
MHDA- 2020/12/15 06:00
CRDT- 2019/12/31 06:00
PHST- 2019/12/31 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2019/12/31 06:00 [entrez]
AID - 10.1055/s-0039-3400294 [doi]
PST - ppublish
SO  - Thromb Haemost. 2020 Feb;120(2):199-206. doi: 10.1055/s-0039-3400294. Epub 2019 
      Dec 30.

PMID- 8717556
OWN - NLM
STAT- MEDLINE
DCOM- 19961129
LR  - 20220311
IS  - 0004-8666 (Print)
IS  - 0004-8666 (Linking)
VI  - 35
IP  - 4
DP  - 1995 Nov
TI  - Low dose aspirin for the treatment of fetal growth restriction: a randomized 
      controlled trial.
PG  - 370-4
AB  - The purpose of this study was to investigate the hypothesis that maternal 
      administration of 100mg aspirin each day will improve birth-weight and other 
      measures of neonatal size when given as a treatment to pregnancies complicated by 
      fetal growth restriction and umbilical-placental insufficiency. A randomized, 
      double-blind, placebo controlled study design was employed; 51 pregnant women 
      were enrolled. The entry criteria were a fetal abdominal circumference < 10th per 
      centile together with an umbilical artery Doppler systolic/diastolic ratio > 95th 
      per centile between 28 and 36 weeks' gestation. Compliance was assessed by serial 
      measurement of maternal serum thromboxane B2 levels. The mean gestational age at 
      enrolment was 32 weeks and at delivery was 36 weeks. There were no differences 
      between the 2 groups in gestational age at birth; birth-weight or birth-weight 
      ratio; circumferences of the head, chest or abdomen; skin fold thicknesses; or 
      neonatal morbidity. Low dose aspirin therapy did not alter Doppler 
      systolic/diastolic ratios. After 14 days therapy, mean thromboxane B2 levels fell 
      more than 80% from baseline values; 10.5% of women did not demonstrate 
      biochemical confirmation of aspirin ingestion, despite verbal confirmation of 
      compliance. We conclude that low dose aspirin therapy is not of benefit in the 
      treatment of pregnancies complicated by fetal growth restriction and 
      umbilical-placental insufficiency between 28 and 36 weeks' gestation.
FAU - Newnham, J P
AU  - Newnham JP
AD  - University Department of Obstetrics and Gynaecology, King Edward Memorial 
      Hospital for Women, Perth, Western Australia.
FAU - Godfrey, M
AU  - Godfrey M
FAU - Walters, B J
AU  - Walters BJ
FAU - Phillips, J
AU  - Phillips J
FAU - Evans, S F
AU  - Evans SF
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Aust N Z J Obstet Gynaecol
JT  - The Australian & New Zealand journal of obstetrics & gynaecology
JID - 0001027
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Birth Weight/drug effects
MH  - Double-Blind Method
MH  - Female
MH  - Fetal Growth Retardation/diagnostic imaging/*drug therapy
MH  - Humans
MH  - Placental Insufficiency/diagnostic imaging/*drug therapy
MH  - Pregnancy
MH  - Treatment Failure
MH  - Treatment Outcome
MH  - Ultrasonography, Prenatal
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 10.1111/j.1479-828x.1995.tb02144.x [doi]
PST - ppublish
SO  - Aust N Z J Obstet Gynaecol. 1995 Nov;35(4):370-4. doi: 
      10.1111/j.1479-828x.1995.tb02144.x.

PMID- 17434095
OWN - NLM
STAT- MEDLINE
DCOM- 20070508
LR  - 20221207
IS  - 1474-4422 (Print)
IS  - 1474-4465 (Electronic)
IS  - 1474-4422 (Linking)
VI  - 6
IP  - 5
DP  - 2007 May
TI  - Low-molecular-weight heparin compared with aspirin for the treatment of acute 
      ischaemic stroke in Asian patients with large artery occlusive disease: a 
      randomised study.
PG  - 407-13
AB  - BACKGROUND: Acute stroke patients with large artery occlusive disease (LAOD) have 
      a distinct pathophysiology and may respond differently to anticoagulation 
      treatments. We compared the efficacy of a low-molecular-weight heparin (LMWH), 
      nadroparin calcium, with aspirin in Asian acute stroke patients with LAOD. 
      METHODS: Acute ischaemic stroke patients with onset of symptoms less than 48 h 
      and LAOD (diagnosed by transcranial doppler imaging, carotid duplex scan, or 
      magnetic resonance angiography) were recruited. Patients were randomly assigned 
      to receive either subcutaneous nadroparin calcium 3800 anti-factor Xa IU/0.4 mL 
      twice daily or oral aspirin 160 mg daily for 10 days, and then all received 
      aspirin 80-300 mg once daily for 6 months. This study is registered at 
      www.strokecenter.org/trials (number 493). FINDINGS: Among 603 patients recruited, 
      353 (180 LMWH, 173 aspirin) had LAOD (300 had intracranial LAOD only, 42 had both 
      intracranial and extracranial disease, and 11 had extracranial disease only). The 
      proportion of patients with good outcomes at 6 months (Barthel index >or=85) was 
      73% in the LMWH group and 69% in the aspirin group (absolute risk reduction 4%; 
      95% CI -5 to 13). Analysis of prespecified secondary outcome measures showed a 
      benefit in outcome for LMWH versus aspirin on the modified Rankin scale 
      dichotomised at 0-1 (odds ratio 1.55, 95% CI 1.02-2.35). Haemorrhagic 
      transformation of infarct and severe adverse events were similar in both groups. 
      Post-hoc analyses of patients without LAOD, and all treated patients, showed 
      similar proportions with a good outcome in aspirin and LMWH groups (78%vs 79% and 
      73%vs 75%, respectively). INTERPRETATION: Overall, the results do not support a 
      significant benefit of LMWH over aspirin in patients with LAOD. The benefits 
      indicated in most outcome measures warrant further investigation into the use of 
      anticoagulation for acute stroke in patients with large artery atherosclerosis, 
      particularly in intracranial atherosclerosis.
FAU - Wong, Ka Sing
AU  - Wong KS
AD  - Department of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China. 
      ks-wong@cuhk.edu.hk
FAU - Chen, Christopher
AU  - Chen C
FAU - Ng, Ping Wing
AU  - Ng PW
FAU - Tsoi, Tak Hong
AU  - Tsoi TH
FAU - Li, Ho Lun
AU  - Li HL
FAU - Fong, Wing Chi
AU  - Fong WC
FAU - Yeung, Jonas
AU  - Yeung J
FAU - Wong, Chi Keung
AU  - Wong CK
FAU - Yip, Kin Keung
AU  - Yip KK
FAU - Gao, Hong
AU  - Gao H
FAU - Wong, Hwee Bee
AU  - Wong HB
CN  - FISS-tris Study Investigators
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet Neurol
JT  - The Lancet. Neurology
JID - 101139309
RN  - 0 (Anticoagulants)
RN  - 0 (Nadroparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet Neurol. 2007 May;6(5):381-2. PMID: 17434083
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Arterial Occlusive Diseases/*complications
MH  - *Asian People
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Brain Ischemia/*complications/ethnology
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Nadroparin/administration & dosage/adverse effects/*therapeutic use
MH  - Stroke/*drug therapy/ethnology/etiology
MH  - Treatment Outcome
PMC - PMC7185651
EDAT- 2007/04/17 09:00
MHDA- 2007/05/09 09:00
CRDT- 2007/04/17 09:00
PHST- 2007/04/17 09:00 [pubmed]
PHST- 2007/05/09 09:00 [medline]
PHST- 2007/04/17 09:00 [entrez]
AID - S1474-4422(07)70079-0 [pii]
AID - 10.1016/S1474-4422(07)70079-0 [doi]
PST - ppublish
SO  - Lancet Neurol. 2007 May;6(5):407-13. doi: 10.1016/S1474-4422(07)70079-0.

PMID- 33625688
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
VI  - 48
IP  - 3
DP  - 2021 Mar
TI  - Aspirin exacerbated respiratory disease (AERD): molecular and cellular diagnostic 
      & prognostic approaches.
PG  - 2703-2711
LID - 10.1007/s11033-021-06240-0 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is characterized by immune cells 
      dysfunction. This study aimed to investigate the molecular mechanisms involved in 
      AERD pathogenesis. Relevant literatures were identified by a PubMed search 
      (2005-2019) of english language papers using the terms "Aspirin-exacerbated 
      respiratory disease", "Allergic inflammation", "molecular mechanism" and 
      "mutation". According to the significant role of inflammation in AERD 
      development, ILC-2 is known as the most important cell in disease progression. 
      ILC-2 produces cytokines that induce allergic reactions and also cause lipid 
      mediators production, which activates mast cells and basophils, ultimately. 
      Finally, Monoclonal antibody and Aspirin desensitization in patients can be a 
      useful treatment strategy for prevention and treatment.
FAU - Hybar, Habib
AU  - Hybar H
AUID- ORCID: 0000-0002-9204-8698
AD  - Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical 
      Sciences, Ahvaz, Iran.
FAU - Saki, Najmaldin
AU  - Saki N
AUID- ORCID: 0000-0001-8494-5594
AD  - Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, 
      Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
FAU - Maleknia, Mohsen
AU  - Maleknia M
AUID- ORCID: 0000-0003-4559-6525
AD  - Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, 
      Ahvaz, Iran.
FAU - Moghaddasi, Mana
AU  - Moghaddasi M
AD  - Department of Biology, Payame Noor University (PUN), Tehran, Iran.
FAU - Bordbar, Armin
AU  - Bordbar A
AUID- ORCID: 0000-0001-5733-2602
AD  - Department of Cardiology, Musavi Hospital, School of Medicine, Zanjan University 
      of Medical Science, Zanjan, Iran.
FAU - Naghavi, Maliheh
AU  - Naghavi M
AUID- ORCID: 0000-0002-5177-5530
AD  - Department of Pathology, Vali-E-Asr Hospital, School of Medicine, Zanjan 
      University of Medical Science, Zanjan, Iran. naghavi@zums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210224
PL  - Netherlands
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects
MH  - *Disease Progression
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Polymorphism, Genetic
MH  - Prognosis
MH  - Respiratory Tract Diseases/*chemically 
      induced/*diagnosis/genetics/physiopathology
OTO - NOTNLM
OT  - Allergic inflammation
OT  - Aspirin-exacerbated respiratory disease
OT  - Molecular mechanism
OT  - Mutation
EDAT- 2021/02/25 06:00
MHDA- 2021/05/19 06:00
CRDT- 2021/02/24 12:14
PHST- 2020/12/15 00:00 [received]
PHST- 2021/02/16 00:00 [accepted]
PHST- 2021/02/25 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2021/02/24 12:14 [entrez]
AID - 10.1007/s11033-021-06240-0 [pii]
AID - 10.1007/s11033-021-06240-0 [doi]
PST - ppublish
SO  - Mol Biol Rep. 2021 Mar;48(3):2703-2711. doi: 10.1007/s11033-021-06240-0. Epub 
      2021 Feb 24.

PMID- 8811758
OWN - NLM
STAT- MEDLINE
DCOM- 19961024
LR  - 20190501
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 313
IP  - 7058
DP  - 1996 Sep 14
TI  - Clinical effects of anticoagulant therapy in suspected acute myocardial 
      infarction: systematic overview of randomised trials.
PG  - 652-9
AB  - OBJECTIVES: Most randomised trials of anticoagulant therapy for suspected acute 
      myocardial infarction have been small and, in some, aspirin and fibrinolytic 
      therapy were not used routinely. A systematic overview (meta-analysis) of their 
      results is needed, in particular to assess the clinical effects of adding heparin 
      to aspirin. DESIGN: Computer aided searches, scrutiny of reference lists, and 
      inquiry of investigators and companies were used to identify potentially eligible 
      studies. On central review, 26 studies were found to involve unconfounded 
      randomised comparisons of anticoagulant therapy versus control in suspected acute 
      myocardial infarction. Additional information on study design and outcome was 
      sought by correspondence with study investigators. SUBJECTS: Patients with 
      suspected acute myocardial infarction. INTERVENTIONS: No routine aspirin was used 
      among about 5000 patients in 21 trials (including half of one small trial) that 
      assessed heparin alone or heparin plus oral anticoagulants, and aspirin was used 
      routinely among 68,000 patients in six trials (including the other half of one 
      small trial) that assessed the addition of intravenous or high dose subcutaneous 
      heparin. MAIN OUTCOME MEASUREMENTS: Death, reinfarction, stroke, pulmonary 
      embolism, and major bleeds (average follow up of about 10 days). RESULTS: In the 
      absence of aspirin, anticoagulant therapy reduced mortality by 25% (SD 8%; 95% 
      confidence interval 10% to 38%; 2P = 0.002), representing 35 (11) fewer deaths 
      per 1000. There were also 10 (4) fewer strokes per 1000 (2P = 0.01), 19 (5) fewer 
      pulmonary emboli per 1000 (2P < 0.001), and non-significantly fewer 
      reinfarctions, with about 13 (5) extra major bleeds per 1000 (2P = 0.01). Similar 
      sized effects were seen with the different anticoagulant regimens studied. In the 
      presence of aspirin, however, heparin reduced mortality by only 6% (SD 3%; 0% to 
      10%; 2P = 0.03), representing just 5 (2) fewer deaths per 1000. There were 3 
      (1.3) fewer reinfarctions per 1000 (2P = 0.04) and 1 (0.5) fewer pulmonary emboli 
      per 1000 (2P = 0.01), but there was a small non-significant excess of stroke and 
      a definite excess of 3 (1) major bleeds per 1000 (2P < 0.0001). CONCLUSIONS: The 
      clinical evidence from randomised trials dose not justify the routine addition of 
      either intravenous or subcutaneous heparin to aspirin in the treatment of acute 
      myocardial infarction (irrespective of whether any type of fibrinolytic therapy 
      is used).
FAU - Collins, R
AU  - Collins R
AD  - BHF/MRC/ICRF Clinical Trial Service Unit, University of Oxford.
FAU - MacMahon, S
AU  - MacMahon S
FAU - Flather, M
AU  - Flather M
FAU - Baigent, C
AU  - Baigent C
FAU - Remvig, L
AU  - Remvig L
FAU - Mortensen, S
AU  - Mortensen S
FAU - Appleby, P
AU  - Appleby P
FAU - Godwin, J
AU  - Godwin J
FAU - Yusuf, S
AU  - Yusuf S
FAU - Peto, R
AU  - Peto R
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 1997 Jan 18;314(7075):222. PMID: 9022452
CIN - BMJ. 1997 Jan 18;314(7075):222; author reply 222-3. PMID: 9022453
CIN - BMJ. 1997 Jan 18;314(7075):223. PMID: 9022454
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cerebrovascular Disorders/prevention & control
MH  - Drug Therapy, Combination
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Pulmonary Embolism/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Survival Analysis
MH  - Treatment Outcome
PMC - PMC2351968
EDAT- 1996/09/14 00:00
MHDA- 1996/09/14 00:01
CRDT- 1996/09/14 00:00
PHST- 1996/09/14 00:00 [pubmed]
PHST- 1996/09/14 00:01 [medline]
PHST- 1996/09/14 00:00 [entrez]
AID - 10.1136/bmj.313.7058.652 [doi]
PST - ppublish
SO  - BMJ. 1996 Sep 14;313(7058):652-9. doi: 10.1136/bmj.313.7058.652.

PMID- 3105886
OWN - NLM
STAT- MEDLINE
DCOM- 19870527
LR  - 20161123
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 9
IP  - 2
DP  - 1987
TI  - Postoperative intravenous administration of lysine acetylsalicylate: effect on 
      pain relief and platelet function.
PG  - 159-66
AB  - The effects of lysine acetylsalicylate, a new injectable salicylate, on 
      postoperative pain relief and platelet function were studied in ten men who had 
      surgery for peptic ulcer. Four of five patients receiving lysine acetylsalicylate 
      had satisfactory pain relief. One patient required an additional injection of 15 
      mg of pentazocine. Of the five patients in the control group, an average (+/- SD) 
      dose of 90 +/- 23.7 mg of pentazocine was required to achieve adequate 
      postoperative pain relief. Lysine acetylsalicylate decreased platelet 
      aggregability but without resulting in hemorrhage. We concluded that this new 
      salicylate administered intravenously to patients in the postoperative period 
      provided adequate analgesia while allowing effective hemostasis despite its 
      inhibitory effect on platelet aggregation.
FAU - Hanaue, H
AU  - Hanaue H
FAU - Ogoshi, K
AU  - Ogoshi K
FAU - Makuuchi, H
AU  - Makuuchi H
FAU - Mitomi, T
AU  - Mitomi T
FAU - Kurosawa, T
AU  - Kurosawa T
FAU - Nemoto, A
AU  - Nemoto A
FAU - Kitano, Y
AU  - Kitano Y
FAU - Miyakawa, S
AU  - Miyakawa S
FAU - Yamoto, H
AU  - Yamoto H
FAU - Asagoe, T
AU  - Asagoe T
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*analogs & derivatives
MH  - Blood Coagulation/drug effects
MH  - Humans
MH  - Injections, Intravenous
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Count/drug effects
MH  - Random Allocation
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1987;9(2):159-66.

PMID- 27338841
OWN - NLM
STAT- MEDLINE
DCOM- 20170728
LR  - 20181202
IS  - 1557-900X (Electronic)
IS  - 0892-7790 (Linking)
VI  - 30
IP  - 9
DP  - 2016 Sep
TI  - The Impact of Perioperative Aspirin on Bleeding Complications Following Robotic 
      Partial Nephrectomy.
PG  - 997-1003
LID - 10.1089/end.2016.0290 [doi]
AB  - INTRODUCTION: Perioperative administration of aspirin for high-risk urologic 
      procedures is controversial. We evaluated whether continuation of perioperative 
      aspirin alters bleeding complications in patients who undergo robotic partial 
      nephrectomy (RPN). MATERIALS AND METHODS: Retrospective review identified 214 
      consecutive patients who underwent RPN at our institution from May 2012 to March 
      2015. Comparisons were performed between 49 patients continuing aspirin (81 mg), 
      34 patients holding aspirin for at least 7 days before surgery, and 131 patients 
      who had never taken aspirin. Overall bleeding complications included 
      postoperative hemoglobin drop of >3 g/dL during admission, postoperative blood 
      transfusion, or necessity for urgent selective angiographic embolization. 
      Multivariable logistic regression was performed to assess the independent 
      association between aspirin administration and bleeding complications. RESULTS: 
      Patients continuing aspirin were older and had higher Charlson Comorbidity Index 
      (CCI) compared with patients who held or never took aspirin (both p < 0.01). 
      Compared with those who held or never took aspirin, patients continuing aspirin 
      had similar rates of overall bleeding complications (27% vs 15% vs 14%, 
      p = 0.13), hemoglobin drop >3 g/dL (24% vs 15% vs 14%, p = 0.24), and 
      postoperative blood transfusion (4% vs 3% vs 2%, p = 0.43). There was a trend for 
      more frequent need for embolization in patients continuing aspirin (6% vs 3% vs 
      1%, p = 0.07). On multivariate analysis controlling for CCI and RENAL nephrometry 
      score, aspirin administration was not significantly associated with bleeding 
      complications. Continuation of aspirin was associated with higher overall 30-day 
      complications compared with the other groups (24% vs 12% vs 8%, p = 0.03). 
      CONCLUSIONS: Continuation of perioperative 81 mg aspirin for patients undergoing 
      RPN was not associated with significantly higher overall bleeding complications. 
      Patients continuing aspirin had increased comorbidities and overall 30-day 
      complications. While our data suggest that continuing perioperative aspirin is 
      safe in select patients, larger studies are needed to confirm these findings.
FAU - Packiam, Vignesh T
AU  - Packiam VT
AD  - Section of Urology, University of Chicago , Chicago, Illinois.
FAU - Nottingham, Charles U
AU  - Nottingham CU
AD  - Section of Urology, University of Chicago , Chicago, Illinois.
FAU - Cohen, Andrew J
AU  - Cohen AJ
AD  - Section of Urology, University of Chicago , Chicago, Illinois.
FAU - Pearce, Shane M
AU  - Pearce SM
AD  - Section of Urology, University of Chicago , Chicago, Illinois.
FAU - Shalhav, Arieh L
AU  - Shalhav AL
AD  - Section of Urology, University of Chicago , Chicago, Illinois.
FAU - Eggener, Scott E
AU  - Eggener SE
AD  - Section of Urology, University of Chicago , Chicago, Illinois.
LA  - eng
PT  - Journal Article
DEP - 20160715
PL  - United States
TA  - J Endourol
JT  - Journal of endourology
JID - 8807503
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Blood Transfusion/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*surgery
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Nephrectomy/adverse effects/*methods
MH  - Perioperative Care/methods
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Robotic Surgical Procedures/*methods
EDAT- 2016/06/25 06:00
MHDA- 2017/07/29 06:00
CRDT- 2016/06/25 06:00
PHST- 2016/06/25 06:00 [entrez]
PHST- 2016/06/25 06:00 [pubmed]
PHST- 2017/07/29 06:00 [medline]
AID - 10.1089/end.2016.0290 [doi]
PST - ppublish
SO  - J Endourol. 2016 Sep;30(9):997-1003. doi: 10.1089/end.2016.0290. Epub 2016 Jul 
      15.

PMID- 15780830
OWN - NLM
STAT- MEDLINE
DCOM- 20050721
LR  - 20131121
IS  - 1471-4892 (Print)
IS  - 1471-4892 (Linking)
VI  - 5
IP  - 2
DP  - 2005 Apr
TI  - Aspirin response and failure in diabetic patients with cardiovascular disease.
PG  - 190-7
AB  - Platelets are known to play a pivotal role not only in the formation of arterial 
      thrombosis but also in the progression of atherosclerotic disease. Recent data 
      suggest that these activities of platelets have become enhanced in patients with 
      type 2 diabetes, accounting for many of the cardiovascular complications. 
      Although aspirin is the most commonly used drug to regulate platelet function, 
      many patients do not receive the expected clinical benefit of this drug and do 
      not have the expected inhibition of platelet function, perhaps because of 
      platelet hyperactivity in diabetes. The data suggest that aspirin might be a less 
      than adequate antithrombotic for type 2 diabetes and that alternative therapies 
      (e.g. combinations with clopidogrel or new antithrombotic therapies) are required 
      to effectively manage the prevalent thrombotic complications associated with this 
      disease.
FAU - Yan, Yibing
AU  - Yan Y
AD  - Portola Pharmaceuticals Inc, 270 E. Grand Avenue, Suite 22, South San Francisco, 
      California 94080, USA.
FAU - Phillips, David R
AU  - Phillips DR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Pharmacol
JT  - Current opinion in pharmacology
JID - 100966133
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/blood/*therapeutic use
MH  - Cardiovascular Diseases/blood/complications/*drug therapy
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Diabetic Angiopathies/blood/complications/*drug therapy
MH  - Humans
RF  - 40
EDAT- 2005/03/23 09:00
MHDA- 2005/07/22 09:00
CRDT- 2005/03/23 09:00
PHST- 2005/03/23 09:00 [pubmed]
PHST- 2005/07/22 09:00 [medline]
PHST- 2005/03/23 09:00 [entrez]
AID - S1471-4892(05)00012-3 [pii]
AID - 10.1016/j.coph.2005.01.005 [doi]
PST - ppublish
SO  - Curr Opin Pharmacol. 2005 Apr;5(2):190-7. doi: 10.1016/j.coph.2005.01.005.

PMID- 343032
OWN - NLM
STAT- MEDLINE
DCOM- 19780426
LR  - 20190712
IS  - 0030-4220 (Print)
IS  - 0030-4220 (Linking)
VI  - 45
IP  - 2
DP  - 1978 Feb
TI  - Analgesic activity of ibuprofen (Motrin) in postoperative oral surgical pain.
PG  - 159-66
AB  - The effectiveness of 400 and 800 mg. of ibuprofen was compared to that of 650 mg. 
      of aspirin, 65 mg. of propoxyphene HCl, and placebo in 510 patients experiencing 
      pain subsequent to oral surgical procedures. In double-blind study, patients were 
      randomly assigned to one of five experimental groups and instructed to report the 
      intensity of pain (complete, partial, or none) over a 3-hour period of 
      evaluation. Ibuprofen, at both doses, was shown to be more effective for both 
      degree and duration of relief from pain.
FAU - Winter, L Jr
AU  - Winter L Jr
FAU - Bass, E
AU  - Bass E
FAU - Recant, B
AU  - Recant B
FAU - Cahaly, J F
AU  - Cahaly JF
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Oral Surg Oral Med Oral Pathol
JT  - Oral surgery, oral medicine, and oral pathology
JID - 0376406
RN  - 0 (Analgesics)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Analgesics
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Dextropropoxyphene/administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Ibuprofen/administration & dosage/*pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Mouth/*surgery
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
EDAT- 1978/02/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1978/02/01 00:00
PHST- 1978/02/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1978/02/01 00:00 [entrez]
AID - 10.1016/0030-4220(78)90079-8 [doi]
PST - ppublish
SO  - Oral Surg Oral Med Oral Pathol. 1978 Feb;45(2):159-66. doi: 
      10.1016/0030-4220(78)90079-8.

PMID- 3620271
OWN - NLM
STAT- MEDLINE
DCOM- 19870928
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 22 Suppl 2
IP  - Suppl 2
DP  - 1986
TI  - The effect of isoxicam-aspirin combinations on the polyurethane sponge 
      implantation model in the rat.
PG  - 125S-128S
AB  - 1 Anti-inflammatory effects of isoxicam alone and in combination with aspirin 
      were studied in rats using the polyurethane sponge implantation model of acute 
      inflammation. 2 Dose-response studies were performed to delineate a suppressive 
      (high) and non-suppressive (low) dose of isoxicam prior to studying these doses 
      in combination with aspirin. 3 The results indicate that a combination of aspirin 
      with isoxicam does not have an additive anti-inflammatory effect. 4 The 
      interference demonstrated by aspirin with the anti-inflammatory effects of other 
      NSAIDs such as indomethacin is also demonstrated with aspirin/isoxicam 
      combinations.
FAU - Garrett, R
AU  - Garrett R
FAU - Manthey, B
AU  - Manthey B
FAU - Vernon-Roberts, B
AU  - Vernon-Roberts B
FAU - Brooks, P M
AU  - Brooks PM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 0 (Polyurethanes)
RN  - 13T4O6VMAM (Piroxicam)
RN  - 8XU734C4NG (isoxicam)
RN  - 9009-54-5 (polyurethane foam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/*therapeutic use
MH  - Drug Combinations
MH  - Piroxicam/*analogs & derivatives/therapeutic use
MH  - Polyurethanes
MH  - Rats
MH  - Rats, Inbred Strains
PMC - PMC1400970
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1986.tb02993.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1986;22 Suppl 2(Suppl 2):125S-128S. doi: 
      10.1111/j.1365-2125.1986.tb02993.x.

PMID- 843622
OWN - NLM
STAT- MEDLINE
DCOM- 19770520
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 49
IP  - 4
DP  - 1977 Apr
TI  - Effect of aspirin on thrombogenesis and on production of experimental aortic 
      valvular Streptococcus viridans endocarditis in rabbits.
PG  - 645-50
AB  - Because thrombus formation at the site of endothelial injury has been thought to 
      be a critical step in the pathogenesis of bacterial endocarditis, the effect of 
      aspirin on experimental valvular thrombosis and bacterial endocarditis in rabbits 
      was evaluated. Aortic valvular injury and thrombosis were induced in 
      aspirin-treated and control rabbits with intracardiac catheters. A subsequent 
      inoculation of Streptococcus viridans resulted in the development of infective 
      endocarditis. Rabbits were sacrificed as early as 6 hr, and the effectiveness of 
      aspirin was determined by the weight of the sterile vegetations and the 
      quantitation of bacteria in the thrombotic vegetation. Aspirin, in levels in 
      excess of 50 mg/dl did not attenuate the evolution of infective endocarditis, 
      since the formation of sterile thrombotic vegetation and bacterial endocarditis 
      in aspirin-treated rabbits was similar to those in controls.
FAU - Levison, M E
AU  - Levison ME
FAU - Carrizosa, J
AU  - Carrizosa J
FAU - Tanphaichitra, D
AU  - Tanphaichitra D
FAU - Schick, P K
AU  - Schick PK
FAU - Rubin, W
AU  - Rubin W
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aortic Valve/drug effects
MH  - Aspirin/*pharmacology
MH  - Endocarditis, Bacterial/*prevention & control
MH  - Female
MH  - Rabbits
MH  - Streptococcus
MH  - Thrombosis/*chemically induced/pathology
EDAT- 1977/04/01 00:00
MHDA- 1977/04/01 00:01
CRDT- 1977/04/01 00:00
PHST- 1977/04/01 00:00 [pubmed]
PHST- 1977/04/01 00:01 [medline]
PHST- 1977/04/01 00:00 [entrez]
AID - S0006-4971(20)68036-3 [pii]
PST - ppublish
SO  - Blood. 1977 Apr;49(4):645-50.

PMID- 1151643
OWN - NLM
STAT- MEDLINE
DCOM- 19751030
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 64
IP  - 5
DP  - 1975 May
TI  - Comparison of analgesic effects of isosteric variations of salicylic acid and 
      aspirin (acetylasalicylic acid).
PG  - 760-3
AB  - A reliable and sensitive method was used to compare the analgesic activities of 
      salicylic acid and aspirin (acetylsalicylic acid) and several phenoxy substituted 
      isosteric pairs. Those isosteric compounds studied did not show analgesic 
      activity. The analgesic activity of aspirin was more than twofold greater than 
      that of salicylic acid.
FAU - Thompkins, L
AU  - Thompkins L
FAU - Lee, K H
AU  - Lee KH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Analgesics)
RN  - 0 (Benzoates)
RN  - 0 (Salicylates)
RN  - 0 (Sulfhydryl Compounds)
RN  - 0 (ortho-Aminobenzoates)
RN  - R16CO5Y76E (Aspirin)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - *Analgesics
MH  - Animals
MH  - Aspirin/*pharmacology/toxicity
MH  - Benzoates/pharmacology
MH  - Bradykinin/pharmacology
MH  - Isomerism
MH  - Lethal Dose 50
MH  - Male
MH  - Pain/chemically induced
MH  - Rats
MH  - Salicylates/*pharmacology/toxicity
MH  - Sulfhydryl Compounds/pharmacology
MH  - ortho-Aminobenzoates/pharmacology
EDAT- 1975/05/01 00:00
MHDA- 1975/05/01 00:01
CRDT- 1975/05/01 00:00
PHST- 1975/05/01 00:00 [pubmed]
PHST- 1975/05/01 00:01 [medline]
PHST- 1975/05/01 00:00 [entrez]
AID - S0022-3549(15)40162-5 [pii]
AID - 10.1002/jps.2600640506 [doi]
PST - ppublish
SO  - J Pharm Sci. 1975 May;64(5):760-3. doi: 10.1002/jps.2600640506.

PMID- 7423445
OWN - NLM
STAT- MEDLINE
DCOM- 19801218
LR  - 20191210
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 44
IP  - 1
DP  - 1980 Aug 29
TI  - Effects of 
      6-[p-(4-phenylacetylpiperazin-l-yl)-phenyl]-4,5-dihydro-3(2H)-pyridazinone (CCl 
      17810) and aspirin on experimental arterial thrombosis in rats.
PG  - 9-11
AB  - An experimental model for arterial thrombosis has been investigated in rats. A 
      loop of polythene tubing inserted in the left carotid artery induced thrombus 
      formation on the arterial wall at the points of contact with the tips of the 
      cannula. Sprague Dawley (CFY) rats were more susceptible to the thrombotic 
      stimulus than were Wistar (WAG) rats. Whole blood platelet adhesiveness measured 
      by a glass bead column method was higher in CFY rats than in WAG rats. 
      6-[p-(4-Phenylacetylpiperazin-1-yl)-phenyl]-4,5-dihydro-3(2H)-pyridazinone (CCI 
      17810) inhibited thrombus formation in CFY rats. Both the incidence of occlusion 
      of the cannulated artery and the mean thrombus weight were reduced by CCI 17810 
      in doses of 25, 50 or 100 mg/kg administered orally twice daily; the effects were 
      dose-related. The effects of aspirin depended on the dose administered. A high 
      dose (200 mg/kg) did not inhibit thrombus formation whereas a low dose (20 mg/kg) 
      reduced the incidence of occlusion and the mean thrombus weight. These results 
      are in accord with the differential effects of aspirin on platelet and blood 
      vessel wall cyclooxygenase.
FAU - Lecker, D
AU  - Lecker D
FAU - Kumar, A
AU  - Kumar A
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Pyridazines)
RN  - 76283-03-9 (CCI 17810)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arterial Occlusive Diseases/complications
MH  - Aspirin/*therapeutic use
MH  - Carotid Arteries/physiopathology
MH  - Male
MH  - Platelet Adhesiveness
MH  - Pyridazines
MH  - Rats
MH  - Thrombosis/complications/*prevention & control
EDAT- 1980/08/29 00:00
MHDA- 1980/08/29 00:01
CRDT- 1980/08/29 00:00
PHST- 1980/08/29 00:00 [pubmed]
PHST- 1980/08/29 00:01 [medline]
PHST- 1980/08/29 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1980 Aug 29;44(1):9-11.

PMID- 8451426
OWN - NLM
STAT- MEDLINE
DCOM- 19930414
LR  - 20161123
IS  - 0033-8419 (Print)
IS  - 0033-8419 (Linking)
VI  - 187
IP  - 1
DP  - 1993 Apr
TI  - Hemostatic protein polymer sheath: improvement in hemostasis at percutaneous 
      biopsy in the setting of platelet dysfunction.
PG  - 269-72
AB  - To study the effectiveness of the protein polymer sheath (PPS), a device intended 
      to limit hemorrhage caused by percutaneous biopsy, in the setting of platelet 
      dysfunction (which may be an important cause of such hemorrhage), percutaneous 
      biopsies were performed in eight anesthetized pigs: four control pigs and four 
      pigs treated with the experimental aspirinlike drug venopirin. These biopsies 
      were performed with (a) a cutting needle only, (b) the cutting needle equipped 
      with the PPS, and (c) the cutting needle equipped with a thrombin-coated PPS. 
      Needle configuration and biopsy site were randomized. Blood loss associated with 
      each needle configuration was measured and compared with that associated with the 
      other configurations. Venopirin caused a statistically significant increase in 
      blood loss with all needle configurations. The PPS significantly reduced blood 
      loss in both the control pigs and those treated with venopirin (P < .05); 
      thrombin coating was a statistically significant factor only in the 
      venopirin-treated pigs.
FAU - Gazelle, G S
AU  - Gazelle GS
AD  - Department of Radiology, Massachusetts General Hospital, Boston 02114.
FAU - Haaga, J R
AU  - Haaga JR
FAU - Halpern, E F
AU  - Halpern EF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Radiology
JT  - Radiology
JID - 0401260
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polymers)
RN  - 0 (Proteins)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Biopsy, Needle/adverse effects/*instrumentation
MH  - Blood Platelets/*drug effects/physiology
MH  - Hemorrhage/etiology
MH  - *Hemostasis
MH  - Liver/pathology
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Polymers
MH  - Proteins
MH  - Radiography, Interventional
MH  - Swine
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
AID - 10.1148/radiology.187.1.8451426 [doi]
PST - ppublish
SO  - Radiology. 1993 Apr;187(1):269-72. doi: 10.1148/radiology.187.1.8451426.

PMID- 3088690
OWN - NLM
STAT- MEDLINE
DCOM- 19860821
LR  - 20181130
IS  - 0181-1916 (Print)
IS  - 0181-1916 (Linking)
VI  - 26
IP  - 2B
DP  - 1986
TI  - [Effect of aspirin and nordihydroguaiaretic acid on the secretion of milk caseins 
      by the mammary epithelial cell].
PG  - 575-82
AB  - Phospholipase A2 and arachidonic acid mimic the stimulatory effect of prolactin 
      on casein exocytosis. We suggest that prolactin by activating phospholipase A2, 
      induces a release of arachidonic acid which is metabolized by a cyclooxygenase 
      pathway leading to prostaglandins, prostacyclins and thromboxanes, a lipoxygenase 
      pathway leading to hydroperoxides and leukotrienes and an epoxygenase pathway. 
      The effects of prolactin and of the major products of arachidonic acid metabolism 
      were studied by incubating mammary gland fragments of lactating rabbit and by 
      measuring neosynthesized caseins and prostaglandins F (PGF2 alpha) in the 
      incubation medium. Aspirin (10(-3) M) which strongly decreases PGF2 alpha 
      synthesis did not modify exocytosis or prolactin stimulation of exocytosis. 
      However, in some cases where prolactin did not stimulate exocytosis, aspirin 
      could restore this stimulation. Nor-dihydroguaiaretic acid (10 microM), an 
      inhibitor of lipoxygenases, increased PGF2 alpha synthesis in the presence of 
      prolactin. In parallel, this inhibitor increased casein exocytosis but inhibited 
      prolactin stimulation. These results are consistent with the action of 
      arachidonic acid metabolites in the regulation of casein exocytosis. We suggest a 
      dual control by the metabolites of the lipoxygenase and the cyclooxygenase 
      pathways.
FAU - Ollivier-Bousquet, M
AU  - Ollivier-Bousquet M
FAU - Lacroix, M C
AU  - Lacroix MC
LA  - fre
PT  - Journal Article
TT  - Effet de l'aspirine et de l'acide nordihydroguaiarétique sur la sécrétion des 
      caséines du lait par la cellule épithéliale mammaire.
PL  - France
TA  - Reprod Nutr Dev (1980)
JT  - Reproduction, nutrition, developpement
JID - 8005903
RN  - 0 (Caseins)
RN  - 0 (Catechols)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 0 (Prostaglandins F)
RN  - 7BO8G1BYQU (Masoprocol)
RN  - 9002-62-4 (Prolactin)
RN  - B7IN85G1HY (Dinoprost)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Caseins/*metabolism
MH  - Catechols/*pharmacology
MH  - Dinoprost
MH  - Epithelium/drug effects/metabolism
MH  - Exocytosis/drug effects
MH  - Female
MH  - Lactation
MH  - Lipoxygenase Inhibitors
MH  - Mammary Glands, Animal/drug effects/*metabolism
MH  - Masoprocol
MH  - Pregnancy
MH  - Prolactin/pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Prostaglandins F/biosynthesis
MH  - Rabbits
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Reprod Nutr Dev (1980). 1986;26(2B):575-82.

PMID- 23407637
OWN - NLM
STAT- MEDLINE
DCOM- 20130506
LR  - 20220408
IS  - 1535-1386 (Electronic)
IS  - 0021-9355 (Linking)
VI  - 95
IP  - 6
DP  - 2013 Mar 20
TI  - Effect of aspirin on bone healing in a rabbit ulnar osteotomy model.
PG  - 488-96
LID - 10.2106/JBJS.L.00462 [doi]
AB  - BACKGROUND: Aspirin is frequently prescribed following orthopaedic surgery. 
      Although there is substantial evidence that some nonsteroidal anti-inflammatory 
      drugs (NSAIDs) are associated with delayed bone healing, there have been few 
      studies of the effects of aspirin on bone healing and, to our knowledge, none on 
      the effects of physiologic dosages. METHODS: Following ulnar osteotomy, fifty-six 
      rabbits were administered a placebo (nine rabbits), indomethacin (nine rabbits 
      given 12.5 mg/kg daily), or aspirin at various doses and schedules (2.7 mg/kg 
      daily for ten rabbits, 10 mg/kg daily for nine rabbits, 50 mg/kg twice daily for 
      ten rabbits, and 100 mg/kg three times daily for nine rabbits). The aspirin doses 
      were chosen to span the clinical dosing range. The indomethacin group served as a 
      positive control and as a relative comparison with the effect of aspirin. 
      Radiographs were obtained every two weeks and the animals were killed at eight 
      weeks. Mechanical testing was performed on all rabbits except for six selected 
      for histological evaluation. RESULTS: Aspirin delayed bone healing, as 
      demonstrated radiographically and with mechanical testing, in a dose-dependent 
      fashion at salicylate levels equivalent to those resulting from typical human 
      dosing (low-dose aspirin). Receiver operating characteristic analysis 
      demonstrated a plasma salicylate threshold above 20.7 μg/mL predicting delayed 
      bone healing. This approximates a single human dose of 325 mg. Salicylate levels 
      above this threshold were associated with delayed bone healing similar to that 
      caused by indomethacin. Aspirin dosing frequency did not affect bone healing. 
      Mechanical testing was highly predictive of radiographic healing. The 
      interobserver reliability of radiographic assessment of healing at six and eight 
      weeks (kappa = 0.83 and 0.79, respectively) compared favorably with interobserver 
      reliability in previous studies assessing cortical bridging. CONCLUSIONS: In a 
      rabbit ulnar osteotomy model, aspirin delayed bone healing with a threshold 
      equivalent to a human dose of 325 mg.
FAU - Lack, William D
AU  - Lack WD
AD  - Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and 
      Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA. william-lack@uiowa.edu
FAU - Fredericks, Douglas
AU  - Fredericks D
FAU - Petersen, Emily
AU  - Petersen E
FAU - Donovan, Maureen
AU  - Donovan M
FAU - George, Maya
AU  - George M
FAU - Nepola, James
AU  - Nepola J
FAU - Smucker, Joseph
AU  - Smucker J
FAU - Femino, John E
AU  - Femino JE
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/pharmacokinetics/*pharmacology
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Biomechanical Phenomena
MH  - Bone Regeneration/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Indomethacin/administration & dosage/pharmacology
MH  - Observer Variation
MH  - *Osteotomy
MH  - ROC Curve
MH  - Rabbits
MH  - Radiography
MH  - Single-Blind Method
MH  - Ulna/diagnostic imaging/drug effects/physiology/*surgery
MH  - Wound Healing/*drug effects
EDAT- 2013/02/15 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/02/15 06:00
PHST- 2013/02/15 06:00 [entrez]
PHST- 2013/02/15 06:00 [pubmed]
PHST- 2013/05/07 06:00 [medline]
AID - 1566980 [pii]
AID - 10.2106/JBJS.L.00462 [doi]
PST - ppublish
SO  - J Bone Joint Surg Am. 2013 Mar 20;95(6):488-96. doi: 10.2106/JBJS.L.00462.

PMID- 29996660
OWN - NLM
STAT- MEDLINE
DCOM- 20200611
LR  - 20210109
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 24
IP  - 9_suppl
DP  - 2018 Dec
TI  - Associations Between PFA-Measured Aspirin Resistance, Platelet Count, Renal 
      Function, and Angiotensin Receptor Blockers.
PG  - 63S-68S
LID - 10.1177/1076029618786588 [doi]
AB  - Aspirin resistance is used to describe patients who are undergoing aspirin 
      therapy but fail for the inhibition of thromboxane biosynthesis in platelets. 
      Although the true mechanism is unclear, drug-drug interaction remains a possible 
      factor. The study aimed to determine whether there was association between 
      aspirin resistance and the concomitant cardiovascular medication. Using the 
      Platelet Function Analyzer-100 system, aspirin resistance was evaluated in 
      aspirin-treated patients from the outpatient department. The associations between 
      aspirin resistance and their concomitant common cardiovascular medication were 
      analyzed. Aspirin resistance was prevalent in 147 (17.7%) of 831 patients. 
      Concomitant angiotensin receptor blocker (ARB) treatment and low platelet count 
      were associated with aspirin response (P = .04, .02, respectively). Multivariate 
      logistic regression analysis results showed an association between aspirin 
      response and ARB therapy (adjusted odds ratio [OR] 1.48; 95% confidence interval, 
      CI: 1.08-2.18). And the association was blunted when platelet count was 
      considered (adjusted OR 1.43, 95% CI: 0.92-2.23). In ARB-treated patients, 
      increased creatinine and decreased hematocrit laboratory data increased the risk 
      of aspirin resistance (P = .02, .04, respectively), and the effect of platelet 
      count on aspirin resistance was diminished by ARB therapy. Concomitant ARB 
      treatment in aspirin-treated patients decreased the risk of aspirin resistance, 
      and the effect was dependent on low platelet count. In ARB-treated patients, 
      increased creatinine and decreased hematocrit data increased the risk of aspirin 
      resistance. In addition, the effect of platelet count on aspirin resistance was 
      diminished by ARB treatment.
FAU - Chen, Hung Yi
AU  - Chen HY
AD  - Division of Cardiology, Department of Medicine, Taipei City Hospital, Heping 
      Fuyou Branch, Taipei, Taiwan.
AD  - Institute of Public Health and Community Medicine Research Center, National 
      Yang-Ming University School of Medicine, Taipei, Taiwan.
FAU - Chou, Pesus
AU  - Chou P
AD  - Institute of Public Health and Community Medicine Research Center, National 
      Yang-Ming University School of Medicine, Taipei, Taiwan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20180711
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Angiotensin Receptor Antagonists/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - Platelet Count
PMC - PMC6714849
OTO - NOTNLM
OT  - PFA-100
OT  - angiotensin receptor blocker
OT  - aspirin resistance
OT  - platelet count
OT  - renal function
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2018/07/13 06:00
MHDA- 2020/06/12 06:00
CRDT- 2018/07/13 06:00
PHST- 2018/07/13 06:00 [pubmed]
PHST- 2020/06/12 06:00 [medline]
PHST- 2018/07/13 06:00 [entrez]
AID - 10.1177_1076029618786588 [pii]
AID - 10.1177/1076029618786588 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):63S-68S. doi: 
      10.1177/1076029618786588. Epub 2018 Jul 11.

PMID- 724344
OWN - NLM
STAT- MEDLINE
DCOM- 19790226
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 62
IP  - 5 Pt 2 Suppl
DP  - 1978 Nov
TI  - Comparative effects of aspirin and acetaminophen on hemostasis.
PG  - 926-9
AB  - Aspirin, even in small doses, has a profound and relatively long-lasting effect 
      on platelet function and hemostasis. This usually produces few clinical problems. 
      However, if a patient has an underlying hemostatic defect, undergoes surgery or 
      sustains an injury, or is a newborn, severe hemorrhage is a potential risk. 
      Aspirin is contraindicated in these clinical contexts. In contrast, acetaminophen 
      has no effect on the hemostatic mechanism unless massive overdose results in 
      hepatic necrosis with depression of synthesis of coagulation factors. 
      Acetaminophen can be used when indicated in clinical situations where the use of 
      aspirin may be potentially dangerous.
FAU - Pearson, H A
AU  - Pearson HA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood Cell Count
MH  - Blood Coagulation/drug effects
MH  - Blood Platelets/drug effects/physiology
MH  - Blood Vessels/drug effects
MH  - Hemostasis/*drug effects
MH  - Humans
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1978 Nov;62(5 Pt 2 Suppl):926-9.

PMID- 898184
OWN - NLM
STAT- MEDLINE
DCOM- 19771014
LR  - 20131121
IS  - 0039-8160 (Print)
IS  - 0039-8160 (Linking)
VI  - 7
IP  - 1-2
DP  - 1977
TI  - Effect of some antithrombogenic drugs on the polyethylene-Krebs solution 
      interface.
PG  - 7-11
AB  - The effects of some antithrombogenic drugs on the streaming potentials found in 
      the interface polyethylene-Krebs solutions were studied. Drugs such as 
      dypiramidol, heparin and apsirine were tested in different concentrations. The 
      variation of streaming potentials with the pressure gradient (fluid velocity) 
      were experimentally determined, surface charge densities and degrees of coverage 
      calculated. Surface charge densities were in the order of 4 X 10(-10) C/cm2, with 
      very low degrees of surface coverage.
FAU - Aragon, P J
AU  - Aragon PJ
FAU - Gottberg, C
AU  - Gottberg C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - TIT J Life Sci
JT  - T.-I.-T. journal of life sciences
JID - 1305601
RN  - 0 (Polyethylenes)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Aspirin/*pharmacology
MH  - Dipyridamole/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Heparin/*pharmacology
MH  - Humans
MH  - Membrane Potentials/*drug effects
MH  - *Models, Biological
MH  - *Polyethylenes
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - TIT J Life Sci. 1977;7(1-2):7-11.

PMID- 30074943
OWN - NLM
STAT- MEDLINE
DCOM- 20190508
LR  - 20190508
IS  - 1537-1948 (Electronic)
IS  - 0025-7079 (Print)
IS  - 0025-7079 (Linking)
VI  - 56 Suppl 10 Suppl 1
IP  - 10 Suppl 1
DP  - 2018 Oct
TI  - Exploring Meaningful Patient Engagement in ADAPTABLE (Aspirin Dosing: A 
      Patient-centric Trial Assessing Benefits and Long-term Effectiveness).
PG  - S11-S15
LID - 10.1097/MLR.0000000000000949 [doi]
AB  - BACKGROUND: Genuine patient engagement can improve research relevance, impact and 
      is required for studies using the National Patient-Centered Clinical Research 
      Network including major multicenter research projects. It is unclear, however, 
      how best to integrate patients into governance of such projects. METHODS: 
      ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and 
      Long-term Effectiveness) is the first major multicenter research project to be 
      conducted in National Patient-Centered Clinical Research Network. Here, we 
      provide a description of how we implemented patient engagement in ADAPTABLE thus 
      far, including a description of committee structures and composition, first-hand 
      patient testimonials, specific contributions, and lessons learned during the 
      planning and early implementation of ADAPTABLE. RESULTS: We recruited 1 patient 
      leader from 6 of the 7 enrolling networks to serve on a Patient Review Board for 
      ADAPTABLE, supported the Board with an experienced patient engagement team 
      including an "investigator-advocate" not otherwise involved in the trial, and 
      facilitated bidirectional communication between the Board and ADAPTABLE 
      Coordinating Center. The Board has reviewed and provided substantial input on the 
      informed consent procedure, recruitment materials, patient portal design, and 
      study policy including compensation of participants. Although it was "too late" 
      for some suggested modifications, most modifications suggested by the patient 
      leaders have been implemented, and they are enthusiastic about the study and 
      their role. The patient leaders also attend Steering and Executive Committee 
      calls; these experiences have been somewhat less productive. CONCLUSIONS: With 
      adequate support, a cadre of committed patient leaders can provide substantial 
      value to design and implementation of a major multicenter clinical trial.
FAU - Faulkner, Madelaine
AU  - Faulkner M
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, CA.
FAU - Alikhaani, Jacqueline
AU  - Alikhaani J
AD  - Duke Clinical Research Institute, Durham, NC.
FAU - Brown, Linda
AU  - Brown L
AD  - Duke Clinical Research Institute, Durham, NC.
FAU - Cruz, Henry
AU  - Cruz H
AD  - Duke Clinical Research Institute, Durham, NC.
FAU - Davidson, Desiree
AU  - Davidson D
AD  - Duke Clinical Research Institute, Durham, NC.
FAU - Gregoire, Ken
AU  - Gregoire K
AD  - Duke Clinical Research Institute, Durham, NC.
FAU - Berdan, Lisa
AU  - Berdan L
AD  - Duke Clinical Research Institute, Durham, NC.
FAU - Rorick, Ty
AU  - Rorick T
AD  - Duke Clinical Research Institute, Durham, NC.
FAU - Jones, W Schuyler
AU  - Jones WS
AD  - Duke Clinical Research Institute, Durham, NC.
FAU - Pletcher, Mark J
AU  - Pletcher MJ
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, CA.
AD  - Department of Medicine, Division of General Internal Medicine, University of 
      California, San Francisco, CA.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Med Care
JT  - Medical care
JID - 0230027
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cooperative Behavior
MH  - Humans
MH  - *Patient Outcome Assessment
MH  - Patient Participation/*statistics & numerical data
MH  - Patient-Centered Care/*organization & administration
MH  - Platelet Aggregation Inhibitors/*therapeutic use
PMC - PMC6143214
COIS- The authors declare no conflict of interest.
EDAT- 2018/08/04 06:00
MHDA- 2019/05/09 06:00
CRDT- 2018/08/04 06:00
PHST- 2018/08/04 06:00 [pubmed]
PHST- 2019/05/09 06:00 [medline]
PHST- 2018/08/04 06:00 [entrez]
AID - 10.1097/MLR.0000000000000949 [doi]
PST - ppublish
SO  - Med Care. 2018 Oct;56 Suppl 10 Suppl 1(10 Suppl 1):S11-S15. doi: 
      10.1097/MLR.0000000000000949.

PMID- 10187896
OWN - NLM
STAT- MEDLINE
DCOM- 19990423
LR  - 20220408
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 30
IP  - 4
DP  - 1999 Apr
TI  - Antiplatelet therapy in acute cerebral ischemia.
PG  - 887-93
AB  - BACKGROUND: Improved recognition of stroke signs and symptoms has paralleled the 
      development of pharmacological strategies that may be examined to reduce stroke 
      mortality and morbidity. Presently, tissue plasminogen activator is the only 
      therapy that significantly improves outcome in acute stroke, with no agent 
      demonstrating a significant reduction in mortality. SUMMARY OF REVIEW: 
      Antiplatelet agents are a heterogenous class of drugs that have been successfully 
      used for more than 2 decades in secondary stroke prevention. These agents include 
      aspirin, with or without dipyridamole, and more recently, the adenosine 
      antagonists ticlopidine and clopidogrel. However, studies of the use of 
      antiplatelet agents within 48 hours of the ictus have examined only aspirin. Only 
      1 study, the Multicentre Acute Stroke Trial-Italy (MAST-I), entered patients 
      within 6 hours of the ictus. These data suggest that an improvement in mortality 
      may be related to the speed of administration. No significant adverse events were 
      noted with early antiplatelet monotherapy. However, MAST-I did note a significant 
      increase in early mortality in patients receiving aspirin plus streptokinase, a 
      finding not adequately explained by an increase in the intracranial hemorrhage 
      rate. CONCLUSIONS: The use of antiplatelet therapy in acute stroke, clinical or 
      experimental, has only recently received attention. It is likely that the use of 
      antiplatelet agents for acute stroke therapy will be less restrictive than that 
      currently seen for thrombolytics. Future studies should include an examination of 
      those agents that have previously demonstrated efficacy in secondary stroke 
      prevention, most notably, aspirin. The recognition that all platelet stimuli 
      share a final common pathway that is dependent on the surface glycoprotein 
      IIb/IIIa (fibrinogen) receptor has resulted in the development of various agents 
      which block this receptor and are currently the focus for clinical trials. The 
      role of nitric oxide in stroke therapy will depend on minimizing the hypotensive 
      side effects of this agent. Stroke models are needed to provide preliminary data 
      on the efficacy of antiplatelet therapy, especially as relates to the interaction 
      of antiplatelet agents with thrombolytics.
FAU - Bednar, M M
AU  - Bednar MM
AD  - Division of Neurosurgery, University of Vermont, Burlington, VT 05405, 
      USA.mbednar@zoo.uvm.edu
FAU - Gross, C E
AU  - Gross CE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 1999 Oct;30(10):2245-6. PMID: 10513002
MH  - Acute Disease
MH  - Aspirin/*therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Cerebrovascular Disorders/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thrombolytic Therapy/*trends
RF  - 96
EDAT- 1999/04/03 03:15
MHDA- 2000/03/11 09:00
CRDT- 1999/04/03 03:15
PHST- 1999/04/03 03:15 [pubmed]
PHST- 2000/03/11 09:00 [medline]
PHST- 1999/04/03 03:15 [entrez]
AID - 10.1161/01.str.30.4.887 [doi]
PST - ppublish
SO  - Stroke. 1999 Apr;30(4):887-93. doi: 10.1161/01.str.30.4.887.

PMID- 21720139
OWN - NLM
STAT- MEDLINE
DCOM- 20120227
LR  - 20190724
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 131
IP  - 7
DP  - 2011
TI  - [Evaluation of the development of gastroduodenal lesions in patients treated with 
      low-dose aspirin or non-steroidal anti-inflammatory drugs].
PG  - 1085-94
AB  - Aspirin irreversibly inhibits the enzyme cyclooxygenase-1 and depresses the 
      production of thromboxane A(2), and also exerts antiplatelet effects. On the 
      other hand, it also depresses the production of prostaglandin E(2) (PGE(2)) and 
      induces gastroduodenal lesions, which are often seen in patients taking aspirin. 
      The aim of this study was to clarify the degree of gastroduodenal lesions induced 
      by low-dose aspirin. We investigated the incidence rate of such lesions induced 
      by aspirin and non-steroidal anti-inflammatory drugs (NSAIDs), and performed 
      theoretical evaluations in a retrospective study. The incidence rates of 
      gastroduodenal lesions in the low-dose aspirin (n=1103) and NSAIDs (n=1856) 
      groups were 2.54% and 0.27%, respectively, which was significantly greater in the 
      aspirin group. Furthermore, the calculated value of inhibition rate of gastric 
      PGE(2) was significantly correlated with the actual value after administration of 
      aspirin or NSAIDs (r=0.902, p<0.05), which suggested that the calculated value 
      reflected the actual value. The calculated value of aspirin (98.9%) was higher 
      than that of NSAIDs (3.67-70.8%) after administration of the drugs with the 
      standard doses. Our findings indicate that the incidence rate of gastroduodenal 
      lesions induced by low-dose aspirin was higher than that of those induced by 
      NSAIDs. Therefore, we were able to perform a theoretical evaluation of the 
      occurrence of gastroduodenal lesions.
FAU - Yaguchi, Takehiro
AU  - Yaguchi T
AD  - Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo 
      University of Pharmacy and Life Sciences, Tokyo, Japan.
FAU - Yokoyama, Haruko
AU  - Yokoyama H
FAU - Nakamura, Hironori
AU  - Nakamura H
FAU - Suzuki, Yuji
AU  - Suzuki Y
FAU - Tokuoka, Kentaro
AU  - Tokuoka K
FAU - Watanabe, Masayuki
AU  - Watanabe M
FAU - Kitagawa, Yasuhisa
AU  - Kitagawa Y
FAU - Yamada, Yasuhiko
AU  - Yamada Y
LA  - jpn
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse 
      effects/pharmacokinetics
MH  - Aspirin/administration & dosage/*adverse effects/pharmacokinetics
MH  - Cyclooxygenase Inhibitors
MH  - Dinoprostone/biosynthesis
MH  - Female
MH  - Gastric Mucosa/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*chemically induced/epidemiology
MH  - Platelet Aggregation Inhibitors
MH  - Time Factors
EDAT- 2011/07/02 06:00
MHDA- 2012/03/01 06:00
CRDT- 2011/07/02 06:00
PHST- 2011/07/02 06:00 [entrez]
PHST- 2011/07/02 06:00 [pubmed]
PHST- 2012/03/01 06:00 [medline]
AID - JST.JSTAGE/yakushi/131.1085 [pii]
AID - 10.1248/yakushi.131.1085 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2011;131(7):1085-94. doi: 10.1248/yakushi.131.1085.

PMID- 15768617
OWN - NLM
STAT- MEDLINE
DCOM- 20050405
LR  - 20181201
IS  - 0002-838X (Print)
IS  - 0002-838X (Linking)
VI  - 71
IP  - 5
DP  - 2005 Mar 1
TI  - Antiplatelet therapy and anticoagulation in patients with hypertension.
PG  - 897-9
AB  - BACKGROUND: Elevated systemic blood pressure results in high intravascular 
      pressure. The main complications, coronary heart disease, ischemic strokes, and 
      peripheral vascular disease, are related to thrombosis rather than hemorrhage. 
      Some complications related to elevated blood pressure, heart failure, and atrial 
      fibrillation are associated with stroke and thromboembolism. It seems plausible 
      that antithrombotic therapy may be particularly useful in preventing 
      thrombosis-related complications of elevated blood pressure. OBJECTIVES: To 
      conduct a systematic review of the role of antiplatelet therapy and 
      anticoagulation in patients with hypertension, including those with elevations in 
      systolic and diastolic blood pressure and those with isolated elevations of 
      systolic or diastolic blood pressure. The following hypotheses were addressed: 
      (1) antiplatelet agents reduce total deaths and major thrombotic events compared 
      with other active treatment or placebo; and (2) oral anticoagulants reduce total 
      deaths and major thromboembolic events compared with other active treatment or 
      placebo. SEARCH STRATEGY: The authors' studied reference lists of articles found 
      by searching electronic databases (MEDLINE, EMBASE, DARE) and abstracts from 
      national and international cardiovascular meetings. Relevant authors of these 
      studies were contacted to obtain further data. SELECTION CRITERIA: Randomized 
      controlled trials (RCTs) in patients with elevated blood pressure were included 
      if they were of at least three months' duration and compared antithrombotic 
      therapy with other active treatment or placebo. DATA COLLECTION AND ANALYSIS: 
      Data were independently collected and verified by two reviewers. Data from 
      different trials were pooled when appropriate. PRIMARY RESULTS: The Antiplatelet 
      Trialists' Collaboration meta-analysis of antiplatelet therapy for secondary 
      prevention in patients with elevated blood pressure reported a 4.1 percent 
      absolute reduction in vascular events compared with placebo. Data on the patients 
      with elevated blood pressure from the 29 individual trials were requested but 
      could not be obtained. Three additional trials met the inclusion criteria and 
      were included. Acetylsalicylic acid (ASA) did not reduce stroke or "all 
      cardiovascular events" compared with placebo in primary prevention patients with 
      elevated blood pressure and no prior cardiovascular disease. In one large trial 
      (the Hypertension Optimal Treatment trial), ASA taken for five years reduced 
      rates of myocardial infarction (MI) (absolute risk reduction, 0.5 percent; number 
      needed to treat [NNT], 200 for five years), increased rates of major hemorrhage 
      (absolute risk increase, 0.7 percent; NNT, 154), and did not reduce all-cause 
      mortality or cardiovascular mortality. In the Clopidogrel vs. Aspirin in Patients 
      at Risk of Ischemic Events trial, there was no significant difference between ASA 
      and clopidogrel for the composite end point of stroke, MI, or vascular death. In 
      two small trials, warfarin alone or in combination with ASA did not reduce rates 
      of stroke or coronary events. REVIEWERS' CONCLUSIONS: Antiplatelet therapy with 
      ASA cannot be recommended for primary prevention of vascular events in patients 
      with elevated blood pressure, because the magnitude of benefit--a reduction in 
      rates of MI--is negated by a harm of similar magnitude, an increase in rates of 
      major hemorrhage. Antiplatelet therapy is recommended for secondary prevention in 
      patients with elevated blood pressure because the magnitude of the absolute 
      benefit is many times greater. Warfarin therapy alone or in combination with 
      aspirin in patients with elevated blood pressure cannot be recommended because of 
      lack of demonstrated benefit. Glycoprotein IIb/IIIa inhibitors, as well as 
      ticlopidine and clopidogrel, have not been evaluated sufficiently in patients 
      with elevated blood pressure. Further trials of antithrombotic therapy with 
      complete documentation of all benefits and harms are needed in patients with 
      elevated blood pressure.
FAU - Griffin, Glenn
AU  - Griffin G
AD  - United Arab Emirates University, Faculty of Medicine and Health Sciences, Al Ain, 
      United Arab Emirates. griffing@uaeu.ac.ae
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Am Fam Physician
JT  - American family physician
JID - 1272646
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 6
EDAT- 2005/03/17 09:00
MHDA- 2005/04/06 09:00
CRDT- 2005/03/17 09:00
PHST- 2005/03/17 09:00 [pubmed]
PHST- 2005/04/06 09:00 [medline]
PHST- 2005/03/17 09:00 [entrez]
PST - ppublish
SO  - Am Fam Physician. 2005 Mar 1;71(5):897-9.

PMID- 22164910
OWN - NLM
STAT- MEDLINE
DCOM- 20111222
LR  - 20181201
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 150
IP  - 4
DP  - 2011 Apr
TI  - [Perioperative anti-platelet therapy management--protocol suggestion].
PG  - 327-32, 421, 420
AB  - BACKGROUND: Currently, dual antiplatelet treatment is conducted with aspirin and 
      clopidogrel. Preterm termination of combined treatment may cause morbidity and 
      mortality. In patients about to undergo surgery, antiplatelet treatment is 
      withheld before the operation to avoid perioperative excessive bleeding. As a 
      consequence, these patients are at high perioperative thromboembolic risk. AIM: A 
      perioperative antiplatelet management protocol developed by a dedicated committee 
      will be presented. This protocol guides the physician while preparing the patient 
      for surgery through three steps: (a) What is the indication for dual antiplatelet 
      treatment and what are the patient's thrombotic risk factors? (b) How severe is 
      the expected operative bleeding? (c) The combination of steps (a) and (b) leads 
      to a recommendation on whether to stop antiplatelet treatment, when and for how 
      long, or to continue antiplatelet treatment throughout the operation. In extreme 
      cases, the indication for antiplateLet treatment may be absolute (for example: 2 
      months after a drug eluting stent coronary implantation), but the expected 
      operative bleeding is very high and the operation cannot be deferred (e.g., 
      neurosurgery for growth removal). Such cases are referred to an expert consulting 
      committee. EXPECTED RESULTS: Many articles have pointed out the problems of 
      current perioperative antiplatelet management and call for change. A precise 
      assessment of the patient's indications, risk factors and perioperative bleeding, 
      as guided by the suggested protocol, will result in better antiplatelet 
      perioperative treatment, and will avoid both thromboembolic and bleeding risks.
FAU - Edry, Ruth
AU  - Edry R
AD  - Anesthesiology Department, Rambam Medical Center, Haifa, Israel. ruedry@gmail.com
FAU - Katz, Yeshayahu
AU  - Katz Y
LA  - heb
PT  - Journal Article
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Loss, Surgical/prevention & control
MH  - Clinical Protocols
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Perioperative Care/methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Risk Factors
MH  - Thromboembolism/etiology/*prevention & control
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
EDAT- 2011/12/15 06:00
MHDA- 2011/12/23 06:00
CRDT- 2011/12/15 06:00
PHST- 2011/12/15 06:00 [entrez]
PHST- 2011/12/15 06:00 [pubmed]
PHST- 2011/12/23 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2011 Apr;150(4):327-32, 421, 420.

PMID- 12901943
OWN - NLM
STAT- MEDLINE
DCOM- 20040106
LR  - 20220311
IS  - 1471-4892 (Print)
IS  - 1471-4892 (Linking)
VI  - 3
IP  - 4
DP  - 2003 Aug
TI  - Cyclooxygenase inhibitors: drugs for cancer prevention.
PG  - 352-61
AB  - Evidence that chronic intake of non-steroidal anti-inflammatory drugs, especially 
      aspirin, prevents cancer development continues to accumulate. The data are 
      particularly convincing for colorectal cancer; however, because of well-known 
      side effects, they cannot routinely be recommended for this purpose. An 
      appreciation of the mechanisms that underlie their anti-cancer effects might 
      permit the development of safer agents. Intensive investigation has led to the 
      characterization of several potential chemopreventive mechanisms of action of 
      these drugs. Antineoplastic actions could result from effects on overlapping 
      processes in the different cell-types that comprise tumors, such as epithelial 
      and stromal cells.
FAU - Shiff, Steven J
AU  - Shiff SJ
AD  - Diet and Nutrition in the Prevention of Chronic Diseases, Cancer Institute of New 
      Jersey, University of Medicine & Dentistry of NJ/Johnson Medical School, 195 
      Little Albany Street, New Brunswick, NJ 08903, USA. shiffst@umdnj.edu
FAU - Shivaprasad, Punitha
AU  - Shivaprasad P
FAU - Santini, Diana L
AU  - Santini DL
LA  - eng
GR  - P30 CA 72720/CA/NCI NIH HHS/United States
GR  - R01 CA 73298/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - England
TA  - Curr Opin Pharmacol
JT  - Current opinion in pharmacology
JID - 100966133
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiogenesis Inhibitors/pharmacology/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology/therapeutic 
      use
MH  - Anticarcinogenic Agents/pharmacology/*therapeutic use
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Colorectal Neoplasms/*prevention & control
MH  - Cyclooxygenase Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Humans
RF  - 76
EDAT- 2003/08/07 05:00
MHDA- 2004/01/07 05:00
CRDT- 2003/08/07 05:00
PHST- 2003/08/07 05:00 [pubmed]
PHST- 2004/01/07 05:00 [medline]
PHST- 2003/08/07 05:00 [entrez]
AID - S1471489203000870 [pii]
AID - 10.1016/s1471-4892(03)00087-0 [doi]
PST - ppublish
SO  - Curr Opin Pharmacol. 2003 Aug;3(4):352-61. doi: 10.1016/s1471-4892(03)00087-0.

PMID- 23566542
OWN - NLM
STAT- MEDLINE
DCOM- 20130913
LR  - 20131121
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 112
IP  - 2
DP  - 2013 Jul 15
TI  - Relation of aspirin response to age in patients with stable coronary artery 
      disease.
PG  - 212-6
LID - S0002-9149(13)00818-7 [pii]
LID - 10.1016/j.amjcard.2013.03.022 [doi]
AB  - Recent studies have suggested that clopidogrel response may vary significantly 
      with age. Limited data are available exploring the age dependency of ex vivo 
      aspirin response in young and old patients with stable coronary artery disease. 
      Patients with stable coronary artery disease (n = 583) who had been treated with 
      aspirin 75 to 325 mg/day for ≥1 week were recruited from a general cardiology 
      practice. The study cohort was divided into 2 groups: patients aged <75 years 
      (n = 438) and patients aged ≥75 years (n = 145). Aspirin response was determined 
      using the VerifyNow Aspirin Test, and resistance was defined as ≥500 or 550 
      aspirin reaction units (ARU). The independent predictive value of age on 
      VerifyNow score (as a continuous function) was determined using multivariate 
      linear regression, adjusted for gender, body mass index, and diabetes mellitus. 
      Younger and older patients had similar baseline clinical profiles, including 
      relative doses of aspirin therapy. The mean VerifyNow Aspirin Test score was 
      significantly higher in patients aged ≥75 years: 450 ± 54 versus 434 ± 53 ARU 
      (p = 0.0007). After accounting for the primary covariates, age remained a 
      predictor of VerifyNow score (p = 0.007). Aspirin resistance on the basis of the 
      500-ARU cutoff was higher in older patients (19% vs 11%, p = 0.009), but there 
      was no difference when the 550-ARU cutoff was used (7% vs 5%, p = 0.40). In 
      conclusion, aspirin response differs significantly by age in patients with stable 
      CAD.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Vaturi, Mordehay
AU  - Vaturi M
AD  - Department of Cardiology, Rabin Medical Center, Petah-Tikva and the Sackler 
      Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Vaduganathan, Muthiah
AU  - Vaduganathan M
FAU - Bental, Tamir
AU  - Bental T
FAU - Solodky, Alejandro
AU  - Solodky A
FAU - Kornowski, Ran
AU  - Kornowski R
FAU - Lev, Eli I
AU  - Lev EI
LA  - eng
PT  - Journal Article
DEP - 20130406
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2013/04/10 06:00
MHDA- 2013/09/14 06:00
CRDT- 2013/04/10 06:00
PHST- 2013/01/19 00:00 [received]
PHST- 2013/03/08 00:00 [revised]
PHST- 2013/03/08 00:00 [accepted]
PHST- 2013/04/10 06:00 [entrez]
PHST- 2013/04/10 06:00 [pubmed]
PHST- 2013/09/14 06:00 [medline]
AID - S0002-9149(13)00818-7 [pii]
AID - 10.1016/j.amjcard.2013.03.022 [doi]
PST - ppublish
SO  - Am J Cardiol. 2013 Jul 15;112(2):212-6. doi: 10.1016/j.amjcard.2013.03.022. Epub 
      2013 Apr 6.

PMID- 1036836
OWN - NLM
STAT- MEDLINE
DCOM- 19770216
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 36
IP  - 2
DP  - 1976 Nov 30
TI  - Platelet dysfunction in migraine: effect of self-medication with aspirin.
PG  - 319-24
AB  - Circulating microembolic index (CMI) was determined by drawing one blood sample 
      into EDTA-formalin and the other into DTA alone in patients with migraine and 
      compared with matched normal controls. Platelet aggregates, if any, are fixed in 
      EDTA-formalin but disaggregated by EDTA. Ratios of these two counts approximate 
      "unity" in normals and are proportionately less than unity, depending on the 
      number of platelet aggregates. 26 untreated migraineurs and 19 migraineurs with 
      history of self-medication with aspirin taken within 72 hours of the test, were 
      studied in headache-free intervals. Results were compared with those from 20 
      healthy, age and sex matched volunteers, without migraine, who were 
      medication-free for at least one week. Mean CMI in untreated migraineurs (0.77 
      +/- 0.03 SEM) was significantly lower than the mean in normal controls (0.94 +/- 
      0.02, p. less than 0.002). Migraineurs with self administration of aspirin had 
      mean CMI of 0.88 +/- 0.02, differing significantly from untreated migraineurs (p 
      less than 0.01) but not from normal controls (0.1 less than p less than 0.2). 
      Results suggest excessive platelet aggregation in migraineurs which tends to be 
      corrected by treatment with platelet inhibitors such as aspirin.
FAU - Deshmukh, S V
AU  - Deshmukh SV
FAU - Meyer, J S
AU  - Meyer JS
FAU - Mouche, R J
AU  - Mouche RJ
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Migraine Disorders/*blood/drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Self Medication
EDAT- 1976/11/30 00:00
MHDA- 1976/11/30 00:01
CRDT- 1976/11/30 00:00
PHST- 1976/11/30 00:00 [pubmed]
PHST- 1976/11/30 00:01 [medline]
PHST- 1976/11/30 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1976 Nov 30;36(2):319-24.

PMID- 2735989
OWN - NLM
STAT- MEDLINE
DCOM- 19890802
LR  - 20190828
IS  - 0735-6757 (Print)
IS  - 0735-6757 (Linking)
VI  - 7
IP  - 4
DP  - 1989 Jul
TI  - Salicylate-induced rhabdomyolysis.
PG  - 409-10
AB  - A 42-year-old woman was hospitalized with aspirin intoxication. The patient 
      developed massive skeletal muscle damage without any evidence of muscle 
      compression, hyperthermia, or other predisposing factors. The exact mechanism by 
      which salicylates cause muscle damage is unknown, but the muscle damage appears 
      to be the result of a direct toxic effect. This represents the first case of 
      isolated salicylate-induced rhabdomyolysis.
FAU - Leventhal, L J
AU  - Leventhal LJ
AD  - Department of Medicine, University of Pennsylvania School of Medicine, 
      Philadelphia 19104.
FAU - Kuritsky, L
AU  - Kuritsky L
FAU - Ginsburg, R
AU  - Ginsburg R
FAU - Bomalaski, J S
AU  - Bomalaski JS
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Emerg Med
JT  - The American journal of emergency medicine
JID - 8309942
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*poisoning
MH  - Female
MH  - Gastric Lavage
MH  - Humans
MH  - Renal Dialysis
MH  - Rhabdomyolysis/*chemically induced/therapy
MH  - Suicide, Attempted
EDAT- 1989/07/01 00:00
MHDA- 1989/07/01 00:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 1989/07/01 00:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
AID - 0735-6757(89)90049-1 [pii]
AID - 10.1016/0735-6757(89)90049-1 [doi]
PST - ppublish
SO  - Am J Emerg Med. 1989 Jul;7(4):409-10. doi: 10.1016/0735-6757(89)90049-1.

PMID- 3282386
OWN - NLM
STAT- MEDLINE
DCOM- 19880519
LR  - 20190912
IS  - 0195-5616 (Print)
IS  - 0195-5616 (Linking)
VI  - 18
IP  - 1
DP  - 1988 Jan
TI  - Drugs that alter the hemostatic mechanism.
PG  - 67-77
AB  - This article offers a brief review of antiplatelet drugs, anticoagulants, 
      fibrinolysins, and antifibrinolysins. Aspirin and heparin are discussed in 
      detail. Warfarin, streptokinase, urokinase, and tissue-type plasminogen activator 
      are also considered. Indications for use, mechanism of action, monitoring 
      therapy, and current investigational studies are discussed.
FAU - Rackear, D G
AU  - Rackear DG
AD  - University of California School of Veterinary Medicine, Davis.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Vet Clin North Am Small Anim Pract
JT  - The Veterinary clinics of North America. Small animal practice
JID - 7809942
RN  - 0 (Anticoagulants)
RN  - 0 (Antifibrinolytic Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/*pharmacology
MH  - Antifibrinolytic Agents/*pharmacology
MH  - Aspirin/pharmacology
MH  - Fibrinolytic Agents/*pharmacology
MH  - Hemostasis/*drug effects
MH  - Heparin/pharmacology
MH  - Platelet Aggregation Inhibitors/*pharmacology
RF  - 56
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - S0195-5616(88)50007-4 [pii]
AID - 10.1016/s0195-5616(88)50007-4 [doi]
PST - ppublish
SO  - Vet Clin North Am Small Anim Pract. 1988 Jan;18(1):67-77. doi: 
      10.1016/s0195-5616(88)50007-4.

PMID- 4037712
OWN - NLM
STAT- MEDLINE
DCOM- 19851004
LR  - 20131121
IS  - 0066-2070 (Print)
IS  - 0066-2070 (Linking)
VI  - 21
IP  - 2 Pt 2
DP  - 1985 May 28
TI  - [Value of oral primperan in the treatment of migraine].
PG  - 35-6
AB  - The association of Primperan with antimigrainous drugs, such as salicylates and 
      paracetamol, can reduce the duration of the migraine. The mechanism of this 
      action is studied: by accelerating the gastric emptying, which is delayed during 
      the migraine attack, Primperan enables the analgesics to reach their site of 
      absorption more rapidly and, consequently, to be more rapidly effective. The 
      activity of the oral administration of Primperan is demonstrated.
FAU - Girard, D
AU  - Girard D
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Apport du primpéran par voie orale au traitement de la migraine.
PL  - France
TA  - Ann Gastroenterol Hepatol (Paris)
JT  - Annales de gastroenterologie et d'hepatologie
JID - 0263111
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Gastric Emptying/drug effects
MH  - Humans
MH  - Metoclopramide/administration & dosage/pharmacology/*therapeutic use
MH  - Migraine Disorders/*drug therapy
EDAT- 1985/05/28 00:00
MHDA- 1985/05/28 00:01
CRDT- 1985/05/28 00:00
PHST- 1985/05/28 00:00 [pubmed]
PHST- 1985/05/28 00:01 [medline]
PHST- 1985/05/28 00:00 [entrez]
PST - ppublish
SO  - Ann Gastroenterol Hepatol (Paris). 1985 May 28;21(2 Pt 2):35-6.

PMID- 19100419
OWN - NLM
STAT- MEDLINE
DCOM- 20090225
LR  - 20131121
IS  - 0041-1345 (Print)
IS  - 0041-1345 (Linking)
VI  - 40
IP  - 10
DP  - 2008 Dec
TI  - Incidence of aspirin resistance and its relationship with cardiovascular risk 
      factors and graft function in renal transplant recipients.
PG  - 3485-8
LID - 10.1016/j.transproceed.2008.06.108 [doi]
AB  - BACKGROUND: Aspirin (ASA) is frequently used to prevent cardiovascular events and 
      improve renal graft function after renal transplantation. Clinical studies have 
      demonstrated that decreased responsiveness to ASA therapy is associated with an 
      increased risk of atherothrombotic events. However, no clinical trial to date has 
      evaluated the incidence and clinical importance of ASA resistance among renal 
      transplant recipients. AIM: To assess the incidence of ASA resistance and its 
      association with cardiovascular risk factors (CRF) and renal graft function after 
      renal transplantation. METHODS: We prospectively included 40 patients undergoing 
      living related donor renal transplantation using ASA (80 mg/d) in the study. ASA 
      resistance was defined using a platelet function analyzer (PFA-100). Glomerular 
      filtration rate (GFR) was measured by postoperative Tc-99m 
      diethylenetriaminepentaacetic acid renal scintigraphy. We investigated the 
      incidence of ASA resistance and its relationship to CRF and renal graft function. 
      RESULTS: ASA resistance was noted in 11 patients (27.5%). The demographic 
      characteristics of the patients were similar in both groups (P > .05). Compared 
      with patients in the ASA-sensitive group, patients in the ASA-resistant group 
      showed significantly higher total cholesterol, low-density lipoprotein 
      cholesterol, triglyceride, C-reactive protein, and fibrinogen levels and lower 
      GFRs (44 +/- 21 mL/min vs 63 +/- 26 mL/min, P = .03). The incidence of ASA 
      resistance was higher among patients with GFRs < 60 mL/min compared with those 
      with a GFR >or= 60 mL/min (10% vs 1%; P = .012). CONCLUSION: ASA resistance is 
      associated with higher lipid levels and inflammatory and thrombotic 
      cardiovascular risk factors and lower GFRs in renal transplant recipients.
FAU - Acikel, S
AU  - Acikel S
AD  - Ministry of Health Dişkapi Yildirim Beyazit Research and Educational Hospital, 
      Department of Cardiology, Ankara, Turkey. dr_acikel@yahoo.com
FAU - Yildirir, A
AU  - Yildirir A
FAU - Aydinalp, A
AU  - Aydinalp A
FAU - Demirtas, K
AU  - Demirtas K
FAU - Bal, U
AU  - Bal U
FAU - Kaynar, G
AU  - Kaynar G
FAU - Ozin, B
AU  - Ozin B
FAU - Karakayali, H
AU  - Karakayali H
FAU - Muderrisoglu, H
AU  - Muderrisoglu H
FAU - Haberal, M
AU  - Haberal M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Blood Platelets/drug effects/physiology
MH  - Cardiovascular Diseases/*epidemiology/prevention & control
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Kidney Transplantation/*physiology
MH  - Life Style
MH  - Male
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Prospective Studies
MH  - Risk Factors
MH  - Smoking/adverse effects
MH  - Young Adult
EDAT- 2008/12/23 09:00
MHDA- 2009/02/26 09:00
CRDT- 2008/12/23 09:00
PHST- 2007/11/04 00:00 [received]
PHST- 2008/05/01 00:00 [revised]
PHST- 2008/06/18 00:00 [accepted]
PHST- 2008/12/23 09:00 [entrez]
PHST- 2008/12/23 09:00 [pubmed]
PHST- 2009/02/26 09:00 [medline]
AID - S0041-1345(08)01217-7 [pii]
AID - 10.1016/j.transproceed.2008.06.108 [doi]
PST - ppublish
SO  - Transplant Proc. 2008 Dec;40(10):3485-8. doi: 10.1016/j.transproceed.2008.06.108.

PMID- 22027120
OWN - NLM
STAT- MEDLINE
DCOM- 20120803
LR  - 20131121
IS  - 1873-4324 (Electronic)
IS  - 0003-2670 (Linking)
VI  - 707
IP  - 1-2
DP  - 2011 Nov 30
TI  - Nanostructured conducting molecularly imprinted polymer for selective extraction 
      of salicylate from urine and serum samples by electrochemically controlled 
      solid-phase micro-extraction.
PG  - 62-8
LID - 10.1016/j.aca.2011.09.005 [doi]
AB  - Overoxidized polypyrrole (OPPy) films templated with salicylate (SA) have been 
      utilized as conducting molecular imprinted polymers (CMIPs) for potential-induced 
      selective solid-phase micro-extraction processes. Various important fabrication 
      factors for controlling the performance of the OPPy films have been investigated 
      using fluorescence spectrometry. Several key parameters such as applied potential 
      for uptake, release, pH of uptake and release solution were varied to achieve the 
      optimum micro-extraction procedure. The film template with SA exhibited excellent 
      selectivity over some interference. The calibration graphs were linear in the 
      ranges of 5×10(-8) to 5×10(-4) and 1.2×10(-6) to 5×10(-4)mol mL(-1) and the 
      detection limit was 4×10(-8) mol L(-1). The OPPy film as the solid-phase 
      micro-extraction absorbent has been applied for the selective clean-up and 
      quantification of trace amounts of SA from physiological samples. The results of 
      scanning electron microscopy (SEM) have confirmed the nano-structure morphologies 
      of the films.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Ameli, Akram
AU  - Ameli A
AD  - Department of Chemistry, Faculty of Science, Tarbiat Modares University, Tehran, 
      Iran.
FAU - Alizadeh, Naader
AU  - Alizadeh N
LA  - eng
PT  - Journal Article
DEP - 20110916
PL  - Netherlands
TA  - Anal Chim Acta
JT  - Analytica chimica acta
JID - 0370534
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/blood/urine
MH  - Cattle
MH  - Electrochemistry
MH  - Humans
MH  - Molecular Imprinting/*methods
MH  - Nanostructures/*chemistry
MH  - Salicylic Acid/administration & dosage/*blood/*urine
MH  - Solid Phase Extraction/*methods
EDAT- 2011/10/27 06:00
MHDA- 2012/08/04 06:00
CRDT- 2011/10/27 06:00
PHST- 2011/07/27 00:00 [received]
PHST- 2011/09/01 00:00 [revised]
PHST- 2011/09/07 00:00 [accepted]
PHST- 2011/10/27 06:00 [entrez]
PHST- 2011/10/27 06:00 [pubmed]
PHST- 2012/08/04 06:00 [medline]
AID - S0003-2670(11)01216-5 [pii]
AID - 10.1016/j.aca.2011.09.005 [doi]
PST - ppublish
SO  - Anal Chim Acta. 2011 Nov 30;707(1-2):62-8. doi: 10.1016/j.aca.2011.09.005. Epub 
      2011 Sep 16.

PMID- 6818974
OWN - NLM
STAT- MEDLINE
DCOM- 19830317
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 31
IP  - 24
DP  - 1982 Dec 15
TI  - Impairment of absorption of ascorbic acid following ingestion of aspirin in 
      guinea pigs.
PG  - 4035-8
AB  - A study was undertaken to investigate the interactions between aspirin and 
      ascorbic acid in guinea pigs. Animals received by gastric intubation either a 
      single dose of radiolabelled ascorbic acid alone or ascorbic acid with aspirin 
      and the exhalation of CO2 was monitored for 400 min following administration. 
      Animals receiving the vitamin only reached plasma peak levels within 90 min 
      following administration while coadministration of the vitamin with aspirin, not 
      only resulted in lower plasma peak levels, but also delayed their attainment 
      until after 160 min. The bioavailability of ascorbic acid during the first 400 
      min was reduced by half following simultaneous administration of aspirin. The 
      initial rate of exhalation of CO2 was decreased by 70% following coadministration 
      of aspirin. These observations indicate that aspirin impairs the gastrointestinal 
      absorption of ascorbic acid in guinea pigs, possibly by interfering with its 
      active transport.
FAU - Ioannides, C
AU  - Ioannides C
FAU - Stone, A N
AU  - Stone AN
FAU - Breacker, P J
AU  - Breacker PJ
FAU - Basu, T K
AU  - Basu TK
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 142M471B3J (Carbon Dioxide)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Ascorbic Acid/*metabolism
MH  - Aspirin/*pharmacology
MH  - Carbon Dioxide/metabolism
MH  - Drug Interactions
MH  - Guinea Pigs
MH  - Intestinal Absorption/*drug effects
MH  - Male
MH  - Respiration
EDAT- 1982/12/15 00:00
MHDA- 1982/12/15 00:01
CRDT- 1982/12/15 00:00
PHST- 1982/12/15 00:00 [pubmed]
PHST- 1982/12/15 00:01 [medline]
PHST- 1982/12/15 00:00 [entrez]
AID - 0006-2952(82)90652-9 [pii]
AID - 10.1016/0006-2952(82)90652-9 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1982 Dec 15;31(24):4035-8. doi: 10.1016/0006-2952(82)90652-9.

PMID- 27165086
OWN - NLM
STAT- MEDLINE
DCOM- 20171128
LR  - 20181113
IS  - 1753-4666 (Electronic)
IS  - 1753-4658 (Print)
IS  - 1753-4658 (Linking)
VI  - 10
IP  - 4
DP  - 2016 Aug
TI  - Aspirin use and the risk of bleeding complications after therapeutic 
      bronchoscopy.
PG  - 318-23
LID - 10.1177/1753465816646049 [doi]
AB  - BACKGROUND: Aspirin use has been shown to be safe for patients undergoing certain 
      diagnostic bronchoscopy procedures such as transbronchial biopsies and 
      endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration. However, 
      there are no studies documenting the safety of aspirin in patients undergoing 
      therapeutic bronchoscopy. The aim of this study is to evaluate whether aspirin 
      increases the risk of bleeding following therapeutic bronchoscopy. METHODS: This 
      was a retrospective study to determine if there was a higher risk of bleeding in 
      patients on aspirin undergoing therapeutic bronchoscopy compared with those not 
      on aspirin. Patient characteristics were reported by cohort using the mean, 
      median, and standard deviation for continuous variables, and using frequencies 
      and relative frequencies for categorical variables. RESULTS: Of the 108 patients 
      who had multimodality therapeutic bronchoscopy, 17 (15.7%) were taking aspirin 
      and 91 (84.3%) were not on aspirin. Patients in the aspirin group were older than 
      those in the no aspirin group (median age: 66 versus 60 years, p = 0.007). The 
      treatment modalities were similar in both groups except that more patients in the 
      no aspirin group were treated with argon plasma coagulation (APC) compared to the 
      aspirin group (60.4% versus 29.4%, p = 0.031). The estimated blood loss (EBL) 
      between the aspirin and no aspirin groups was not significantly different (mean: 
      6.0 versus 6.7 ml; median: 5.0 versus 5.0, p = 0.36). Overall, there was no 
      difference in complications between both groups. CONCLUSION: Aspirin use was not 
      associated with increased risk of bleeding or procedure-related complications 
      after therapeutic bronchoscopy.
CI  - © The Author(s), 2016.
FAU - Harris, Kassem
AU  - Harris K
AD  - Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14623, USA 
      kassem.harris@roswellpark.org.
FAU - Kebbe, Jad
AU  - Kebbe J
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine 
      University, Buffalo, State University of New York, Buffalo, NY, USA.
FAU - Modi, Kush
AU  - Modi K
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine 
      University, Buffalo, State University of New York, Buffalo, NY, USA.
FAU - Alraiyes, Abdul Hamid
AU  - Alraiyes AH
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine 
      University, Buffalo, State University of New York, Buffalo, NY, USA.
FAU - Kumar, Abhishek
AU  - Kumar A
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine 
      University, Buffalo, State University of New York, Buffalo, NY, USA.
FAU - Attwood, Kristopher
AU  - Attwood K
AD  - Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, 
      Buffalo, NY, USA.
FAU - Dhillon, Samjot S
AU  - Dhillon SS
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine 
      University, Buffalo, State University of New York, Buffalo, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20160510
PL  - England
TA  - Ther Adv Respir Dis
JT  - Therapeutic advances in respiratory disease
JID - 101316317
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Bronchoscopy/adverse effects/*methods
MH  - Female
MH  - Hemorrhage/*epidemiology/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Risk
PMC - PMC5933682
OTO - NOTNLM
OT  - aspirin
OT  - bleeding
OT  - therapeutic bronchoscopy
COIS- Conflict of interest statement: The author(s) declared the following potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: JK, KM, AK, KA and SSD have no personal or financial 
      disclosures and no conflict of interest. KH and AHA are consultants for Cook 
      Medical.
EDAT- 2016/05/12 06:00
MHDA- 2017/11/29 06:00
CRDT- 2016/05/12 06:00
PHST- 2016/05/12 06:00 [entrez]
PHST- 2016/05/12 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 1753465816646049 [pii]
AID - 10.1177_1753465816646049 [pii]
AID - 10.1177/1753465816646049 [doi]
PST - ppublish
SO  - Ther Adv Respir Dis. 2016 Aug;10(4):318-23. doi: 10.1177/1753465816646049. Epub 
      2016 May 10.

PMID- 21780891
OWN - NLM
STAT- MEDLINE
DCOM- 20111207
LR  - 20131121
IS  - 1747-4132 (Electronic)
IS  - 1747-4124 (Linking)
VI  - 5
IP  - 4
DP  - 2011 Aug
TI  - Reducing the risk of gastroduodenal ulcers with a fixed combination of 
      esomeprazole and low-dose acetyl salicylic acid.
PG  - 447-55
LID - 10.1586/egh.11.42 [doi]
AB  - Low-dose acetyl salicylic acid (ASA) for preventing cardiovascular and 
      cerebrovascular events is now one of the most frequently prescribed medications 
      in some Western countries. However, it is associated with significant morbidity 
      and mortality as a consequence of the development of gastric and duodenal ulcers 
      and their complications. Recent randomized controlled trials in patients who are 
      at moderately increased risk of ulcers have shown that the proton pump inhibitor 
      esomeprazole (the S-isomer of racemic omeprazole) reduces the gastroduodenal 
      ulcer incidence by approximately 70-85% and the gastrointestinal bleeding risk by 
      as much as 90%. Case-control studies also indicate that the risk of ulcer 
      bleeding is less in low-dose ASA users who concomitantly take a proton pump 
      inhibitor. This article reviews the pharmacology of the component agents and the 
      evidence for efficacy of the combination of esomeprazole and low-dose ASA.
FAU - Yeomans, Neville D
AU  - Yeomans ND
AD  - School of Medicine, University of Western Sydney, Locked Bag 1797, Penrith South, 
      NSW 2751, Australia. n.yeomans@uws.edu.au
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Gastroenterol Hepatol
JT  - Expert review of gastroenterology & hepatology
JID - 101278199
RN  - 0 (Anti-Ulcer Agents)
RN  - KG60484QX9 (Omeprazole)
RN  - N3PA6559FT (Esomeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Ulcer Agents/*administration & dosage/pharmacokinetics
MH  - Aspirin/*administration & dosage/adverse effects/pharmacokinetics
MH  - Cardiovascular Diseases/prevention & control
MH  - Cerebrovascular Disorders/prevention & control
MH  - Drug Therapy, Combination
MH  - Esomeprazole
MH  - Humans
MH  - Omeprazole/*administration & dosage/pharmacokinetics
MH  - Peptic Ulcer/*chemically induced/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Risk
EDAT- 2011/07/26 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/07/26 06:00
PHST- 2011/07/26 06:00 [entrez]
PHST- 2011/07/26 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 10.1586/egh.11.42 [doi]
PST - ppublish
SO  - Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):447-55. doi: 10.1586/egh.11.42.

PMID- 17245572
OWN - NLM
STAT- MEDLINE
DCOM- 20071105
LR  - 20181113
IS  - 0009-4722 (Print)
IS  - 0009-4722 (Linking)
VI  - 78
IP  - 2
DP  - 2007 Feb
TI  - [The use of antithrombotic drugs during various surgical procedures].
PG  - 119-20, 122-4
AB  - Neuraxial blockade has been shown to provide essential benefits in terms of 
      reduced perioperative morbidity and mortality. Case series from recent years 
      indicate that spinal epidural hematoma is more common than previously estimated, 
      with incidences of 1:200,000 in obstetric patients and as high as 1:3,600 in 
      female orthopedic patients. To lower this risk, societies worldwide have issued 
      guidelines establishing recommended time intervals between administration of 
      antithrombotic drugs and performance of neuraxial blockade. If adherence to these 
      intervals imposes a high risk of theomboembolic complications, neuraxial blockade 
      should be withheld in favor of continued antithrombotic therapy. In such patients 
      an alternative plan for postoperative pain management such as patient-controlled 
      intravenous analgesia or peripheral nerve blocks should be established. In 
      patients on continued acetylsalicylic acid therapy, neuraxial blockade may be 
      performed if thromboembolism prophylaxis is not administered concurrently.
FAU - Gogarten, W
AU  - Gogarten W
AD  - Klinik und Poliklinik für Anästhesiologie und operative Intensivmedizin, 48149 
      Münster. gogarten@anit.uni-muenster.de
FAU - Van Aken, H
AU  - Van Aken H
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Besonderheiten des Antithrombotikaeinsatzes bei verschiedenen chirurgischen 
      Eingriffen.
PL  - Germany
TA  - Chirurg
JT  - Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
JID - 16140410R
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesia, Patient-Controlled
MH  - *Anesthesia, Epidural
MH  - Anesthesia, Spinal
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Hematoma, Epidural, Spinal/epidemiology/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/drug therapy
MH  - Practice Guidelines as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
MH  - Spinal Puncture
MH  - *Surgical Procedures, Operative
MH  - Thromboembolism/prevention & control
MH  - Time Factors
RF  - 22
EDAT- 2007/01/25 09:00
MHDA- 2007/11/06 09:00
CRDT- 2007/01/25 09:00
PHST- 2007/01/25 09:00 [pubmed]
PHST- 2007/11/06 09:00 [medline]
PHST- 2007/01/25 09:00 [entrez]
AID - 10.1007/s00104-006-1291-3 [doi]
PST - ppublish
SO  - Chirurg. 2007 Feb;78(2):119-20, 122-4. doi: 10.1007/s00104-006-1291-3.

PMID- 24428091
OWN - NLM
STAT- MEDLINE
DCOM- 20140204
LR  - 20140116
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 96
IP  - 11
DP  - 2013 Nov
TI  - The prevalence of gastroduodenal mucosal injuries in aspirin users.
PG  - 1423-7
AB  - BACKGROUND: Aspirin is a widely used medication for primary and secondary 
      prevention of cardiovascular and cerebrovascular events. The gastrointestinal 
      risks of aspirin are well known, but the frequency of gastroduodenal mucosal 
      injuries in aspirin users in Thailand is currently unknown. OBJECTIVE: The 
      present study was performed to investigate the prevalence of gastroduodenal 
      mucosal injuries in asymptomatic aspirin users. MATERIAL AND METHOD: Asymptomatic 
      patients taking low doses ofaspirin without gastroprotective medication were 
      enrolled and underwent esophagogastroduodenoscopy RESULTS: One hundred four 
      patients were endoscoped. The prevalence of gastroduodenal mucosal injuries 
      (erosions or ulcer) was 63.5%. CONCLUSION: The prevalence of gastroduodenal 
      mucosal injuries was very high in asymptomatic aspirin users.
FAU - Thongbai, Thirada
AU  - Thongbai T
AD  - Department of Medicine, Bangkok Metropolitan Administration General Hospital, 
      Bangkok, Thailand. tthirada@yahoo.com
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asymptomatic Diseases
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Gastric Mucosa/*drug effects/*pathology
MH  - Humans
MH  - Intestinal Mucosa/*drug effects/*pathology
MH  - Male
MH  - Middle Aged
EDAT- 2014/01/17 06:00
MHDA- 2014/02/05 06:00
CRDT- 2014/01/17 06:00
PHST- 2014/01/17 06:00 [entrez]
PHST- 2014/01/17 06:00 [pubmed]
PHST- 2014/02/05 06:00 [medline]
PST - ppublish
SO  - J Med Assoc Thai. 2013 Nov;96(11):1423-7.

PMID- 20350286
OWN - NLM
STAT- MEDLINE
DCOM- 20101028
LR  - 20191111
IS  - 2212-4063 (Electronic)
IS  - 1871-529X (Linking)
VI  - 10
IP  - 2
DP  - 2010 Jun
TI  - Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals.
PG  - 103-10
AB  - Aspirin administration decreases the risk of vascular ischemic problems. However, 
      aspirin withdrawal may temporarily increase this risk. Previous studies reported 
      that high dilutions of aspirin might cause a pro-thrombotic effect. This paper 
      studies the effect of the lower end of the aspirin dose-response curve, its 
      possible mechanism and clinical implications. PROTOCOL: Wistar rats were 
      distributed into 100 groups of 10 rats each. Aspirin was injected at 100 mg/kg, 1 
      mg/kg and at several different aspirin dilutions along with cyclooxygenase (COX) 
      1 (SC-560), COX 2 (NS-398) or both selective inhibitors simultaneously using a 
      laser-induced thrombosis model. RESULTS: The higher doses of aspirin decreased 
      thrombosis. An opposite trend was observed with the lowest doses. SC-560 produced 
      an anti-thrombotic effect antagonized by the highest aspirin dilutions. NS-398 
      created a pro-thrombotic effect that was antagonized by aspirin at higher doses. 
      Simultaneous inhibition of COX 1 and 2 produced changes similar to COX 1 
      inhibition. CONCLUSION: COX 2 inhibition induced a pro-thrombotic effect that was 
      antagonized by aspirin at 1 mg/kg or 100 mg/kg. The administration of the lowest 
      aspirin doses induced a pro-thrombotic effect stronger than the antithrombotic 
      effect of COX 1 selective inhibition. The mechanism of this last pro-thrombotic 
      effect is induced by residual aspirin and is independent of COX 1 inhibition. 
      This study may explain the cause of the paradoxical thrombo-embolic complications 
      observed after aspirin discontinuation, an effect of residual aspirin rather than 
      a rebound effect, and highlights the importance of low doses of substances as a 
      barely studied source of side-effects.
FAU - Doutremepuich, Christian
AU  - Doutremepuich C
AD  - Laboratoire d'Hématologie, Université Victor Segalen, Bordeaux 2, Bordeaux, 
      France. christian.doutremepuich@heph.u-bordeaux2.fr
FAU - Aguejouf, Omar
AU  - Aguejouf O
FAU - Desplat, Vanessa
AU  - Desplat V
FAU - Eizayaga, Francisco X
AU  - Eizayaga FX
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Cardiovasc Hematol Disord Drug Targets
JT  - Cardiovascular & hematological disorders drug targets
JID - 101269160
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Nitrobenzenes)
RN  - 0 (Pyrazoles)
RN  - 0 (SC 560)
RN  - 0 (Sulfonamides)
RN  - 123653-11-2 (N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/*pharmacology/toxicity
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Male
MH  - Nitrobenzenes/pharmacology
MH  - Pyrazoles/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Substance Withdrawal Syndrome/blood/etiology
MH  - Sulfonamides/pharmacology
MH  - Thrombosis/*chemically induced/etiology/*prevention & control
EDAT- 2010/03/31 06:00
MHDA- 2010/10/29 06:00
CRDT- 2010/03/31 06:00
PHST- 2009/12/30 00:00 [received]
PHST- 2010/03/24 00:00 [accepted]
PHST- 2010/03/31 06:00 [entrez]
PHST- 2010/03/31 06:00 [pubmed]
PHST- 2010/10/29 06:00 [medline]
AID - BSP/CHDDT/E-Pub/00008 [pii]
AID - 10.2174/187152910791292510 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Disord Drug Targets. 2010 Jun;10(2):103-10. doi: 
      10.2174/187152910791292510.

PMID- 35937841
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220826
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Chronic histiocytic intervillositis (CHI): current treatments and perinatal 
      outcomes, a systematic review and a meta-analysis.
PG  - 945543
LID - 10.3389/fendo.2022.945543 [doi]
LID - 945543
AB  - BACKGROUND: Chronic histiocytic intervillositis (CHI) is a rare placental lesion 
      with a high recurrence rate and poor perinatal outcomes. There are currently 
      limited guidelines regarding the diagnosis of this condition in the index 
      pregnancy and treatment where recurrence is suspected. OBJECTIVE: The primary 
      objective of this systematic review and meta-analysis was to determine the 
      perinatal outcomes of pregnancies affected by chronic histiocytic intervillositis 
      and to what extent they can be improved with treatment. The secondary objective 
      was to assess the relationship between CHI lesion severity and pregnancy loss. 
      METHODS: A systematic search of Ovid Embase, Web of Science, Science Direct, 
      PubMed, Ovid Medline, Google Scholar and CINAHL was carried out. Case reports, 
      cohort, case-control and randomised controlled trials (RCT) detailing the 
      perinatal outcomes of CHI pregnancies, both treated and untreated, were included. 
      RESULTS: No RCTs were identified. However, in a review population of 659 
      pregnancies, with additional 7 in case reports, CHI treatments included aspirin, 
      prednisone, prednisolone, low molecular weight heparin (LMWH), hydroxychloroquine 
      and adalimumab. A descriptive synthesis of data found mixed results for 
      treatments in relation to live birth, miscarriage and fetal growth restriction 
      outcomes. Furthermore, quantitative synthesis of 38 pregnancies revealed a 
      non-significant improvement in live birth rate with CHI targeted treatment (OR 
      1.79 [95% CI 0.33-9.61] (p=0.50), while meta-analysis of CHI severity in line 
      with pregnancy loss, in a sample of 231 pregnancies, revealed lower odds of 
      pregnancy loss with less severe lesions (OR: 0.17 [0.03-0.80], p=0.03). 
      CONCLUSIONS: This systematic review and meta-analysis reinforce notions 
      surrounding the insufficient evidence for CHI treatment. It also strengthens 
      previous hypotheses detailing the positive association between CHI lesion 
      severity and odds of pregnancy loss. Aspirin, LMWH, prednisolone, 
      hydroxychloroquine and adalimumab are candidates with varying levels of weak to 
      moderate evidence supporting their use. Further prospective research is required 
      to obtain robust evidence pertaining to treatment safety and efficacy and optimal 
      drug regimes. SYSTEMATIC REVIEW REGISTRATION: [website], identifier 
      CRD42021237604.
CI  - Copyright © 2022 Moar, Simela, Nanda, Marnerides, Al-Adnani, Nelson-Piercy, 
      Nicolaides and Shangaris.
FAU - Moar, Laurel
AU  - Moar L
AD  - School of Life Course and Population Sciences, King's College London, London, 
      United Kingdom.
FAU - Simela, Chloe
AU  - Simela C
AD  - School of Life Course and Population Sciences, King's College London, London, 
      United Kingdom.
FAU - Nanda, Surabhi
AU  - Nanda S
AD  - School of Life Course and Population Sciences, King's College London, London, 
      United Kingdom.
AD  - Department of Women and Children, Guy's and St. Thomas' NHS Foundation Trust, 
      London, United Kingdom.
FAU - Marnerides, Andreas
AU  - Marnerides A
AD  - Department of Histopathology, St. Thomas Hospital, Westminster Bridge Road, 
      London, United Kingdom.
FAU - Al-Adnani, Mudher
AU  - Al-Adnani M
AD  - Department of Histopathology, St. Thomas Hospital, Westminster Bridge Road, 
      London, United Kingdom.
FAU - Nelson-Piercy, Catherine
AU  - Nelson-Piercy C
AD  - School of Life Course and Population Sciences, King's College London, London, 
      United Kingdom.
AD  - Department of Women and Children, Guy's and St. Thomas' NHS Foundation Trust, 
      London, United Kingdom.
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
AD  - School of Life Course and Population Sciences, King's College London, London, 
      United Kingdom.
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College London, 
      London, United Kingdom.
FAU - Shangaris, Panicos
AU  - Shangaris P
AD  - School of Life Course and Population Sciences, King's College London, London, 
      United Kingdom.
AD  - Department of Women and Children, Guy's and St. Thomas' NHS Foundation Trust, 
      London, United Kingdom.
AD  - Peter Gorer Department of Immunobiology, School of Immunology and Microbial 
      Sciences, Faculty of Life Sciences and Medicine, King's College London, London, 
      United Kingdom.
LA  - eng
GR  - DH_/Department of Health/United Kingdom
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20220722
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - FYS6T7F842 (Adalimumab)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abortion, Spontaneous
MH  - Adalimumab
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - *Hydroxychloroquine
MH  - Prednisolone
MH  - Pregnancy
PMC - PMC9355722
OTO - NOTNLM
OT  - CHI
OT  - intervillositis
OT  - recurrent miscarriage
OT  - small gestation age (SGA)
OT  - stillbirth
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/09 06:00
MHDA- 2022/08/10 06:00
CRDT- 2022/08/08 04:08
PHST- 2022/05/16 00:00 [received]
PHST- 2022/06/29 00:00 [accepted]
PHST- 2022/08/08 04:08 [entrez]
PHST- 2022/08/09 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
AID - 10.3389/fendo.2022.945543 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Jul 22;13:945543. doi: 
      10.3389/fendo.2022.945543. eCollection 2022.

PMID- 9525331
OWN - NLM
STAT- MEDLINE
DCOM- 19980514
LR  - 20190914
IS  - 1073-2322 (Print)
IS  - 1073-2322 (Linking)
VI  - 9
IP  - 3
DP  - 1998 Mar
TI  - Modulation of resuscitative effect of diaspirin cross-linked hemoglobin by L-NAME 
      in rats.
PG  - 223-30
AB  - Diaspirin Cross-linked Hemoglobin (DCLHb), a hemoglobin-based oxygen carrier, 
      improves regional blood circulation and systemic hemodynamics in normal and 
      hemorrhaged rats. The action of DCLHb is partly mediated by its scavenging effect 
      on nitric oxide. This study was undertaken to determine the effect of DCLHb on 
      nitric oxide mechanism in hemorrhagic conditions. We studied the modulation of 
      cardiovascular effects of DCLHb by a nitric oxide synthase inhibitor, 
      NG-nitro-L-arginine methyl ester (L-NAME) in hemorrhaged rats. The base deficit, 
      survival time, oxygen consumption, and blood circulation to the brain, heart, 
      gastrointestinal tract, and kidneys were determined in 1) DCLHb (100 mg/kg, 
      intravenously (i.v.), 2) L-NAME (2 mg/kg, i.v.), 3) L-NAME (2 mg/kg, i.v.) + 
      DCLHb (100 mg/kg, i.v.), and 4) L-arginine (100 mg/kg/h, i.v.) + DCLHb (100 
      mg/kg, i.v.) treated rats. Hemorrhage was induced in urethane-anesthetized male 
      rats by bleeding them at a rate of approximately .5 to 1 mL/min, until a mean 
      arterial pressure of 35-40 mmHg was achieved. This blood pressure was maintained 
      for 30 min. Sham-operated nonhemorrhaged rats survived for >300 min, whereas 
      hemorrhaged rats survived for only 85+/-31 min. Hemorrhage significantly 
      increased base deficit and decreased oxygen consumption. A significant decrease 
      in heart rate, mean arterial pressure, cardiac output, stroke volume, and in 
      blood flow to the gastrointestinal tract and kidneys was observed after 
      hemorrhage. Resuscitation with DCLHb produced a significant increase in survival 
      time, oxygen consumption, heart rate, mean arterial pressure, cardiac output, 
      total peripheral resistance, and blood flow to the brain, heart, and kidneys. In 
      contrast, resuscitation with L-NAME did not improve base deficit, survival time, 
      oxygen consumption, systemic hemodynamics, or regional blood flow. L-arginine 
      pretreatment did not affect DCLHb-induced resuscitation of hemorrhaged rats. 
      Furthermore, L-NAME (pretreated or co-administered) attenuated the resuscitative 
      effect of DCLHb. These data suggest that nitric oxide mechanism may not be the 
      only mechanism involved in the resuscitative effect of DCLHb.
FAU - Sen, A P
AU  - Sen AP
AD  - Department of Pharmaceutics & Pharmacodynamics, The University of Illinois at 
      Chicago, Health Sciences Center, 60612, USA.
FAU - Dong, Y
AU  - Dong Y
FAU - Saxena, P R
AU  - Saxena PR
FAU - Gulati, A
AU  - Gulati A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Shock
JT  - Shock (Augusta, Ga.)
JID - 9421564
RN  - 0 (Hemoglobins)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 94ZLA3W45F (Arginine)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Animals
MH  - Arginine/pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - NG-Nitroarginine Methyl Ester/*pharmacology
MH  - Nitric Oxide/*metabolism
MH  - Oxygen Consumption
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/drug effects
MH  - Resuscitation
MH  - Shock, Hemorrhagic/*drug therapy/metabolism
MH  - Time Factors
EDAT- 1998/04/03 00:00
MHDA- 1998/04/03 00:01
CRDT- 1998/04/03 00:00
PHST- 1998/04/03 00:00 [pubmed]
PHST- 1998/04/03 00:01 [medline]
PHST- 1998/04/03 00:00 [entrez]
AID - 10.1097/00024382-199803000-00011 [doi]
PST - ppublish
SO  - Shock. 1998 Mar;9(3):223-30. doi: 10.1097/00024382-199803000-00011.

PMID- 31283521
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20210706
IS  - 1018-9068 (Print)
IS  - 1018-9068 (Linking)
VI  - 30
IP  - 5
DP  - 2020
TI  - Safety and Efficacy of Aspirin Desensitization Combined With Long-Term Aspirin 
      Therapy in Aspirin-Exacerbated Respiratory Disease.
PG  - 327-333
LID - 10.18176/jiaci.0433 [doi]
AB  - OBJECTIVES: To assess the safety and efficacy of Aspirin desensitization combined 
      with long-term Aspirin therapy in patients with Aspirinexacerbated respiratory 
      disease (AERD). METHODS: We searched the PubMed, Ovid, Cochrane Library, and 
      Google Scholar databases from inception to October 2018 for articles in English. 
      We only included randomized controlled trials and parallel or cross-over studies 
      in which adults with AERD were randomly assigned to undergo Aspirin 
      desensitization and receive long-term Aspirin therapy or placebo. RESULTS: A 
      total of 869 citations were retrieved, and 6 studies met the criteria for 
      analysis. All studies indicated that nasal symptoms, asthma symptoms, or both 
      improved significantly after Aspirin desensitization. In addition, most studies 
      reported a decline in corticosteroid dosage (oral and inhaled). The 4 studies 
      that reported nasal polyps did not demonstrate a change in nasal polyps with 
      Aspirin therapy compared with placebo. The dropout rates in all studies reviewed 
      ranged from 5.8% to 55.7%, and the most common adverse events were 
      gastrointestinal symptoms. CONCLUSIONS: Clearly, Aspirin desensitization and 
      treatment are beneficial for AERD patients, with relief of nasal symptoms, 
      improvement in asthma control, decrease in daily corticosteroid use, and no fatal 
      adverse events. However, the long-term adverse effects of Aspirin desensitization 
      and optimal dosage of Aspirin merit further investigation.
FAU - Li, R
AU  - Li R
AD  - Department of General Medicine, West China Hospital of Sichuan University, 
      Chengdu, China.
FAU - Luo, F
AU  - Luo F
AD  - Department of Respiratory Medicine, West China Hospital of Sichuan University, 
      Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20190708
PL  - Spain
TA  - J Investig Allergol Clin Immunol
JT  - Journal of investigational allergology & clinical immunology
JID - 9107858
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma, Aspirin-Induced/diagnosis/*etiology/*therapy
MH  - *Desensitization, Immunologic/adverse effects/methods
MH  - Duration of Therapy
MH  - Endoscopy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/pathology
MH  - Symptom Assessment
MH  - Treatment Outcome
OTO - NOTNLM
OT  - AERD
OT  - Adverse events
OT  - Aspirin desensitization
OT  - Efficacy
EDAT- 2019/07/10 06:00
MHDA- 2021/07/07 06:00
CRDT- 2019/07/09 06:00
PHST- 2019/07/10 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2019/07/09 06:00 [entrez]
AID - 10.18176/jiaci.0433 [doi]
PST - ppublish
SO  - J Investig Allergol Clin Immunol. 2020;30(5):327-333. doi: 10.18176/jiaci.0433. 
      Epub 2019 Jul 8.

PMID- 287931
OWN - NLM
STAT- MEDLINE
DCOM- 19790927
LR  - 20131121
IS  - 0028-8446 (Print)
IS  - 0028-8446 (Linking)
VI  - 89
IP  - 631
DP  - 1979 Mar 14
TI  - Current trends in the treatment of rheumatoid arthritis in general practice.
PG  - 165-7
AB  - Questionnaires were sent to 180 randomly selected general medical practitioners 
      in the Auckland area, to determine the source of prescribing information and 
      current drug prescribing pattern in general practice, for the treatment of 
      rheumatoid arthritis. Medical journals were the main current source but 
      postgraduate seminars and lectures were the preferred source of prescribing 
      information. Aspirin remains the drug of first choice in the treatment of 
      rheumatoid arthritis and along with indomethacin, phenylbutazone and prednisone 
      (10 mg daily), considered to be more effective than the newer propionic acid 
      derivatives. Enteric coated aspirin was preferred in the patient with an active 
      peptic ulcer. Almost all of the replying doctors, endeavoured to give their 
      patients an explanation as to the underlying nature of their disease and 
      treatment, but had little confidence that they would comply with the therapeutic 
      instructions.
FAU - Lee, P
AU  - Lee P
FAU - Tan, L J
AU  - Tan LJ
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - N Z Med J
JT  - The New Zealand medical journal
JID - 0401067
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Drug Information Services
MH  - Drug Prescriptions
MH  - Family Practice
MH  - Humans
MH  - Patient Compliance
EDAT- 1979/03/14 00:00
MHDA- 1979/03/14 00:01
CRDT- 1979/03/14 00:00
PHST- 1979/03/14 00:00 [pubmed]
PHST- 1979/03/14 00:01 [medline]
PHST- 1979/03/14 00:00 [entrez]
PST - ppublish
SO  - N Z Med J. 1979 Mar 14;89(631):165-7.

PMID- 10379468
OWN - NLM
STAT- MEDLINE
DCOM- 19990810
LR  - 20131121
IS  - 1125-8055 (Print)
IS  - 1125-8055 (Linking)
VI  - 31 Suppl 1
DP  - 1999
TI  - Non-steroidal anti-inflammatory drugs and gastrointestinal bleeding.
PG  - S37-42
AB  - Non-steroidal anti-inflammatory drug use carries the risk of gastrointestinal 
      complications (1% over 6 months) which is increased by a factor of 4 to 5, 
      although strong differences are observed between different non-steroidal 
      anti-inflammatory drugs. This risk is present in both the upper and lower 
      gastrointestinal tract which indicates that non-steroidal anti-inflammatory drugs 
      induces bleeding from both peptic ulcer and non-peptic ulcer sources. Symptoms 
      are poor predictors of serious lesions and complications, which may occur without 
      previous symptoms. At present, risk factors for non-steroidal anti-inflammatory 
      drug-associated upper gastrointestinal bleeding are well defined and include 
      ulcer or complication history, age, high non-steroidal anti-inflammatory drug 
      dose, combination with corticosteroid and warfarin. Helicobacter pylori infection 
      is not considered a risk factor for complications in non-steroidal 
      anti-inflammatory drug users. There is a high prevalence of over-the-counter 
      non-steroidal anti-inflammatory drug (especially aspirin) use among those 
      presenting with gastrointestinal complications. Prophylactic aspirin regimens 
      increase the risk of gastrointestinal bleeding. The potential beneficial effect 
      of nitrate treatments (nitric oxide donors) in low dose aspirin users deserves 
      further study. The mechanisms involved in the induction of gastrointestinal 
      bleeding by non-steroidal anti-inflammatory drugs are poorly understood. Platelet 
      activity inhibition associated with an abnormal, but reversible, prolongation of 
      the bleeding time in susceptible individuals using aspirin might be a mechanism 
      affecting no more than a third of patients with gastrointestinal bleeding.
FAU - Lanas, A
AU  - Lanas A
AD  - Service of Gastroenterology, University Hospital, Zaragoza, Spain. 
      alanas@posta.unizar.es
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Ital J Gastroenterol Hepatol
JT  - Italian journal of gastroenterology and hepatology
JID - 9711056
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Peptic Ulcer/*chemically induced
MH  - Prognosis
MH  - Risk Assessment
MH  - Risk Factors
RF  - 46
EDAT- 1999/06/24 00:00
MHDA- 1999/06/24 00:01
CRDT- 1999/06/24 00:00
PHST- 1999/06/24 00:00 [pubmed]
PHST- 1999/06/24 00:01 [medline]
PHST- 1999/06/24 00:00 [entrez]
PST - ppublish
SO  - Ital J Gastroenterol Hepatol. 1999;31 Suppl 1:S37-42.

PMID- 8470984
OWN - NLM
STAT- MEDLINE
DCOM- 19930510
LR  - 20220408
IS  - 0003-9950 (Print)
IS  - 0003-9950 (Linking)
VI  - 111
IP  - 4
DP  - 1993 Apr
TI  - A prospective study of aspirin use and cataract extraction in women.
PG  - 503-8
AB  - We examined the association between aspirin use and the rates of cataract 
      extraction during 8 years of follow-up in a large prospective study of women, the 
      Nurses' Health Study. From 1980 to 1988, we documented 448 senile cataracts 
      diagnosed and extracted during 434,680 person-years of follow-up. While we 
      observed a modest positive association at the higher doses of aspirin use in the 
      age-adjusted analyses, no association was found after accounting for other 
      cataract risk factors (relative risk for > or = 20 years of use, 1.08; 95% 
      confidence interval, 0.84 to 1.39). Among women who consumed seven or more 
      tablets per week for 20 or more years, there was no suggestion of protection; if 
      anything, a nonsignificantly elevated risk was observed (relative risk, 1.31; 95% 
      confidence interval, 0.94 to 1.80). We observed no consistent difference in the 
      relationship between aspirin use and cataract when assessed by age. Overall, we 
      found no evidence to support the substantial reduction in risk of cataract among 
      aspirin users as reported in several previous studies.
FAU - Hankinson, S E
AU  - Hankinson SE
AD  - Department of Medicine, Channing Laboratory, Harvard Medical School, Brigham and 
      Women's Hospital, Boston, MA 02115.
FAU - Seddon, J M
AU  - Seddon JM
FAU - Colditz, G A
AU  - Colditz GA
FAU - Stampfer, M J
AU  - Stampfer MJ
FAU - Rosner, B
AU  - Rosner B
FAU - Speizer, F E
AU  - Speizer FE
FAU - Willett, W C
AU  - Willett WC
LA  - eng
GR  - 5T32 ES07069/ES/NIEHS NIH HHS/United States
GR  - CA 40356/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Ophthalmol
JT  - Archives of ophthalmology (Chicago, Ill. : 1960)
JID - 7706534
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cataract/etiology/*prevention & control
MH  - *Cataract Extraction/statistics & numerical data
MH  - Confidence Intervals
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Regression Analysis
MH  - Risk Factors
MH  - Surveys and Questionnaires
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
AID - 10.1001/archopht.1993.01090040095040 [doi]
PST - ppublish
SO  - Arch Ophthalmol. 1993 Apr;111(4):503-8. doi: 
      10.1001/archopht.1993.01090040095040.

PMID- 32221634
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 1433-0407 (Electronic)
IS  - 0028-2804 (Linking)
VI  - 91
IP  - 6
DP  - 2020 Jun
TI  - [Past and future of the ESUS concept].
PG  - 511-517
LID - 10.1007/s00115-020-00893-1 [doi]
AB  - Stroke has traditionally been classified according to the trial of ORG 10172 in 
      acute stroke treatment (TOAST) criteria; however, the concept of cryptogenic 
      stroke did not meet the operational criteria necessary to define patient 
      populations eligible for randomized studies. Therefore, the concept of embolic 
      stroke of undetermined etiology (ESUS) was developed. An underlying hypothesis 
      was that most strokes in patients with ESUS are caused by embolic events, hence, 
      anticoagulation may prevent secondary events. Therefore, two large randomized 
      trials were conducted comparing dabigatran or rivaroxaban with acetylsalicylic 
      acid. Both studies could not show superiority of the new oral anticoagulants 
      (NOAC) compared to aspirin; however, subgroup analyses showed that there is 
      a patient population that may benefit from oral anticoagulation.
FAU - Diener, Hans-Christoph
AU  - Diener HC
AD  - Institut für Medizinische Informatik, Biometrie und Epidemiologie (IMIBE), 
      Medizinische Fakultät der Universität Duisburg-Essen, Hufelandstraße 55, 45147, 
      Essen, Deutschland. hans.diener@uk-essen.de.
FAU - Endres, Matthias
AU  - Endres M
AD  - Klinik und Hochschulambulanz für Neurologie, Charite - Universitätsmedizin 
      Berlin, Berlin, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Vergangenheit und Zukunft des ESUS-Konzepts.
PL  - Germany
TA  - Nervenarzt
JT  - Der Nervenarzt
JID - 0400773
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - *Intracranial Embolism
MH  - Randomized Controlled Trials as Topic
MH  - *Stroke/diagnosis/therapy
OTO - NOTNLM
OT  - Anticoagulation
OT  - Aspirin
OT  - Bleeding complications
OT  - Embolic stroke of undetermined source
OT  - Stroke
EDAT- 2020/03/30 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
PHST- 2020/03/30 06:00 [entrez]
AID - 10.1007/s00115-020-00893-1 [pii]
AID - 10.1007/s00115-020-00893-1 [doi]
PST - ppublish
SO  - Nervenarzt. 2020 Jun;91(6):511-517. doi: 10.1007/s00115-020-00893-1.

PMID- 14584890
OWN - NLM
STAT- MEDLINE
DCOM- 20040602
LR  - 20220408
IS  - 0884-0431 (Print)
IS  - 0884-0431 (Linking)
VI  - 18
IP  - 10
DP  - 2003 Oct
TI  - Association between bone mineral density and the use of nonsteroidal 
      anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity.
PG  - 1795-802
AB  - BMD was examined in users of NSAIDs (by COX selectivity) and aspirin in the 
      Health ABC cohort (n = 2853). Significantly higher BMD was found in users of 
      relative COX-2 selective NSAIDs with aspirin (COX-2/ASA) compared with nonusers. 
      This suggests a role for COX-2/ASA in osteoporosis. INTRODUCTION: The purpose of 
      this study was to determine the relationship of nonsteroidal anti-inflammatory 
      drug (NSAID) use, by cyclo-oxygenase selectivity (COX), and aspirin use on bone 
      mineral density (BMD) in participants from the Health, Aging, and Body 
      Composition (Health ABC) population-based cohort. It is known that NSAIDs inhibit 
      the COX enzyme and decrease production of prostaglandins, which are involved in 
      regulation of bone turnover. COX has two isoforms, COX-1 and COX-2. Production of 
      prostaglandins associated with bone loss is primarily mediated through the COX-2 
      pathway. In addition, aspirin may have effects on bone independent of the 
      prostaglandin pathway. MATERIALS AND METHODS: NSAID (by COX selectivity) and 
      aspirin use and BMD were assessed in 2853 adults (49.5% women, 50.5% men: 43.1% 
      black, 56.9% white; mean age: 73.6 years) from the Health ABC cohort. For the 
      purposes of this analysis, relative COX-1 selective NSAIDs were defined as having 
      a ratio of COX-1 IC50 to COX-2 IC50 of > 1 in whole blood, and relative COX-2 
      selective NSAIDs were defined as having a ratio of COX-1 IC50 to COX-2 IC50 of < 
      1 in whole blood. Analysis of covariance was used to compare BMD across each 
      NSAID use and aspirin use category adjusting for age, race, gender, weight, 
      height, study site, calcium and vitamin D supplementation, Womac score, history 
      of rheumatoid arthritis, history of arthritis other than rheumatoid, and smoking 
      status. RESULTS: After adjustment for possible confounders, current use of 
      relative COX-2 selective NSAIDs with aspirin was associated with higher BMD at 
      the whole body (4.2%, 1.2-7.3 CI) and total hip (4.6%, 0.5-8.8 CI) by DXA and at 
      both trabecular (34.1%, 15.4-52.7 CI) and cortical spine (12.8%, 2.3-23.3 CI) by 
      quantitative computed tomography. CONCLUSIONS: Our data suggest that the 
      combination of relative COX-2 selective NSAIDs and aspirin is associated with 
      higher BMD at multiple skeletal sites in men and women.
FAU - Carbone, Laura D
AU  - Carbone LD
AD  - Department of Medicine, University of Tennessee Health Sciences Center, Memphis, 
      Tennessee 38163, USA. lcarbone@utmem.edu
FAU - Tylavsky, Frances A
AU  - Tylavsky FA
FAU - Cauley, Jane A
AU  - Cauley JA
FAU - Harris, Tamara B
AU  - Harris TB
FAU - Lang, Thomas F
AU  - Lang TF
FAU - Bauer, Douglas C
AU  - Bauer DC
FAU - Barrow, Karen D
AU  - Barrow KD
FAU - Kritchevsky, Stephen B
AU  - Kritchevsky SB
LA  - eng
GR  - K23AR02042-01A1/AR/NIAMS NIH HHS/United States
GR  - N01-AG-6-2101/AG/NIA NIH HHS/United States
GR  - N01-AG-6-2103/AG/NIA NIH HHS/United States
GR  - N01-AG-6-2106/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Bone Miner Res
JT  - Journal of bone and mineral research : the official journal of the American 
      Society for Bone and Mineral Research
JID - 8610640
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandins)
RN  - 0 (Protein Isoforms)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/metabolism/*pharmacology
MH  - Aspirin/metabolism/*pharmacology
MH  - Bone Density/*drug effects
MH  - Bone and Bones/*drug effects
MH  - Cohort Studies
MH  - Female
MH  - Hip/pathology
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Male
MH  - Middle Aged
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - Prostaglandins/metabolism
MH  - Protein Isoforms
MH  - Tomography, X-Ray Computed
EDAT- 2003/10/31 05:00
MHDA- 2004/06/03 05:00
CRDT- 2003/10/31 05:00
PHST- 2003/10/31 05:00 [pubmed]
PHST- 2004/06/03 05:00 [medline]
PHST- 2003/10/31 05:00 [entrez]
AID - 10.1359/jbmr.2003.18.10.1795 [doi]
PST - ppublish
SO  - J Bone Miner Res. 2003 Oct;18(10):1795-802. doi: 10.1359/jbmr.2003.18.10.1795.

PMID- 8678078
OWN - NLM
STAT- MEDLINE
DCOM- 19960809
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 100
IP  - 6
DP  - 1996 Jun
TI  - Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or 
      warfarin for cardiovascular disease.
PG  - 598-604
AB  - OBJECTIVE: To determine whether low-dose aspirin or warfarin induces fecal occult 
      blood loss. PATIENTS AND METHODS: A prospective, cross-over study, of 100 
      participants over 40 years of age in 1 of 3 groups, taking: (1) no aspirin or 
      warfarin, (2) daily aspirin (either 81 or 325 mg), or (3) warfarin, but no 
      aspirin. Stool samples were collected and analyzed for the presence of occult 
      blood using HemoQuant and Hemoccult II. After collection of baseline samples, 
      patients initially taking no aspirin (group 1) were asked to take regular aspirin 
      (325 mg daily) for 2 months. Patients initially taking aspirin 81 mg daily (group 
      2) were switched to 325 mg daily for 2 months, and vice versa. RESULTS: Patients 
      taking no aspirin had mean fecal blood of 0.68 +/- 0.05 mg hemoglobin/g stool, 
      which increased to 1.41 +/- 0.36 mg/g after taking 325 mg of aspirin daily (P = 
      0.02). In contrast, patients in group 2, taking 81 mg and 325 mg of aspirin, had 
      mean fecal blood of 0.82 +/- 0.08 mg/g (P = 0.57) and 1.04 +/- 0.23 mg/g (P = 
      0.13), respectively (comparisons with patients taking no aspirin). The mean blood 
      loss in patients taking warfarin was 0.51 +/- 0.04 mg/g (P = 0.55), and fecal 
      blood was not related to the degree of anticoagulation. There was no increase 
      over normal in the rate of Hemoccult II-positive stool tests with aspirin or 
      warfarin therapy. CONCLUSION: Aspirin, but not warfarin, caused a small but 
      clinically insignificant increase in occult fecal blood. The small blood loss in 
      patients taking aspirin or warfarin is unlikely to interfere with fecal occult 
      blood test. Therefore, positive fecal occult blood tests, in patients taking 
      either low-dose aspirin or warfarin, should be managed in the same fashion as 
      patients not taking these medications.
FAU - Greenberg, P D
AU  - Greenberg PD
AD  - San Francisco General Hospital, Department of Medicine, University of California 
      94110, USA.
FAU - Cello, J P
AU  - Cello JP
FAU - Rockey, D C
AU  - Rockey DC
LA  - eng
GR  - T32 DK-07002-20/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Med. 1996 Jun;100(6):596-7. PMID: 8678077
MH  - Analysis of Variance
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Chronic Disease
MH  - Cross-Over Studies
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Occult Blood
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Prospective Studies
MH  - Specimen Handling
MH  - Warfarin/*adverse effects/therapeutic use
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
AID - S0002934396000095 [pii]
AID - 10.1016/s0002-9343(96)00009-5 [doi]
PST - ppublish
SO  - Am J Med. 1996 Jun;100(6):598-604. doi: 10.1016/s0002-9343(96)00009-5.

PMID- 24927467
OWN - NLM
STAT- MEDLINE
DCOM- 20150212
LR  - 20140620
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 32
IP  - 2
DP  - 2014 Aug
TI  - Clinical evidence of the relationship between aspirin and breast cancer risk 
      (review).
PG  - 451
LID - 10.3892/or.2014.3270 [doi]
AB  - In the search for new therapeutic alternatives against cancer, either as a 
      preventive treatment or for advanced stages, it is common to appeal to well-known 
      drugs used for the treatment of other diseases that may interfere with the 
      metabolic pathways involved in carcinogenesis. Non-steroidal anti-inflammatory 
      drugs (NSAIDs) display anticancer activity through the inhibition of the COX-2 
      enzyme, triggering processes such as apoptosis, a reduction in proliferation and 
      inhibition of carcinogenesis. Breast cancer is a neoplasm with the highest 
      incidence and mortality rate among young women worldwide. Epidemiologic data have 
      shown that drugs such as NSAIDs, particularly aspirin, reduce the relative risk 
      of breast cancer. However, in the subgroup of responsive patients, dose, time and 
      frequency of use have not yet been established. Here, we review the reports 
      published during the last 10 years regarding the relationship between breast 
      cancer and aspirin.
FAU - Jacobo-Herrera, Nadia J
AU  - Jacobo-Herrera NJ
AD  - Unidad de Bioquímica, Instituto Nacional de Ciencias Médicas y Nutrición 
      'Salvador Zubirán', Tlalpan 14000, Mexico, D.F., Mexico.
FAU - Pérez-Plasencia, Carlos
AU  - Pérez-Plasencia C
AD  - Unidad de Biomedicina FES-Iztacala, Universidad Nacional Autónoma de México UNAM, 
      Tlalnepantla 54090, Mexico.
FAU - Camacho-Zavala, Elizabeth
AU  - Camacho-Zavala E
AD  - Unidad de Bioquímica, Instituto Nacional de Ciencias Médicas y Nutrición 
      'Salvador Zubirán', Tlalpan 14000, Mexico, D.F., Mexico.
FAU - González, Gabriela Figueroa
AU  - González GF
AD  - Unidad de Biomedicina FES-Iztacala, Universidad Nacional Autónoma de México UNAM, 
      Tlalnepantla 54090, Mexico.
FAU - Urrutia, Eduardo López
AU  - Urrutia EL
AD  - Laboratorio de Oncogenómica, Instituto Nacional de Cancerología, Tlalpan 14080, 
      Mexico, D.F., Mexico.
FAU - García-Castillo, Verónica
AU  - García-Castillo V
AD  - Unidad de Biomedicina FES-Iztacala, Universidad Nacional Autónoma de México UNAM, 
      Tlalnepantla 54090, Mexico.
FAU - Zentella-Dehesa, Alejandro
AU  - Zentella-Dehesa A
AD  - Unidad de Bioquímica, Instituto Nacional de Ciencias Médicas y Nutrición 
      'Salvador Zubirán', Tlalpan 14000, Mexico, D.F., Mexico.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140613
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*therapeutic use
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/epidemiology/*prevention & control
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase 2/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - PubMed
EDAT- 2014/06/14 06:00
MHDA- 2015/02/13 06:00
CRDT- 2014/06/14 06:00
PHST- 2014/03/21 00:00 [received]
PHST- 2014/05/15 00:00 [accepted]
PHST- 2014/06/14 06:00 [entrez]
PHST- 2014/06/14 06:00 [pubmed]
PHST- 2015/02/13 06:00 [medline]
AID - 10.3892/or.2014.3270 [doi]
PST - ppublish
SO  - Oncol Rep. 2014 Aug;32(2):451. doi: 10.3892/or.2014.3270. Epub 2014 Jun 13.

PMID- 14725573
OWN - NLM
STAT- MEDLINE
DCOM- 20040416
LR  - 20190901
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 19 Suppl 1
DP  - 2004 Feb
TI  - Review article: should NSAID/low-dose aspirin takers be tested routinely for H. 
      pylori infection and treated if positive? Implications for primary risk of ulcer 
      and ulcer relapse after initial healing.
PG  - 9-16
AB  - Helicobacter pylori infection and the use of nonsteroidal anti-inflammatory drugs 
      (NSAIDs) can each result in gastric or duodenal ulcer(s) and ulcer complications. 
      Together, H. pylori infection and NSAIDs account for approximately 90% of peptic 
      ulcer disease. In 2003, the results of studies suggest, and guidelines recommend, 
      the careful selection of anti-inflammatory drugs - NSAIDs or selective COX-2 
      inhibitors (coxibs) based upon patients gastrointestinal history and use of 
      aspirin therapy. Testing for, and cure of, H. pylori infection is recommended in 
      patients prior to the initiation of NSAID therapy and in those who are currently 
      receiving NSAIDs and have a history of dyspepsia, peptic ulcer or ulcer 
      complications. For patients who present with peptic ulcer bleeding but require 
      NSAIDs long-term, H. pylori eradication therapy should be considered, followed by 
      continuous proton pump inhibitor prophylaxis to prevent re-bleeding, regardless 
      of which kind of NSAID (nonselective NSAID /coxib) is being prescribed. Routine 
      testing for, and eradication of, H. pylori infection has not been recommended for 
      current takers of NSAIDs with no or low risk of complications. The management of 
      patients taking low-dose aspirin is complex, but eradication of H. pylori 
      infection alone in those with a past history of bleeding does not guarantee 
      complete protection and therefore a proton pump inhibitor should also be given. 
      The success of eradication therapy should always be confirmed, because of the 
      risk of ulcer recurrence and bleeding in H. pylori-infected patients who require 
      anti-inflammatory treatments.
FAU - Hunt, R H
AU  - Hunt RH
AD  - McMaster University Medical Centre, Hamilton, Ontario, Canada. huntr@mcmaster.ca
FAU - Bazzoli, F
AU  - Bazzoli F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Helicobacter Infections/*complications
MH  - *Helicobacter pylori
MH  - Humans
MH  - Peptic Ulcer/*etiology
MH  - Peptic Ulcer Hemorrhage/etiology
MH  - Recurrence
MH  - Risk Factors
MH  - Wound Healing
RF  - 46
EDAT- 2004/01/17 05:00
MHDA- 2004/04/17 05:00
CRDT- 2004/01/17 05:00
PHST- 2004/01/17 05:00 [pubmed]
PHST- 2004/04/17 05:00 [medline]
PHST- 2004/01/17 05:00 [entrez]
AID - 1830 [pii]
AID - 10.1111/j.0953-0673.2004.01830.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:9-16. doi: 
      10.1111/j.0953-0673.2004.01830.x.

PMID- 15282455
OWN - NLM
STAT- MEDLINE
DCOM- 20041026
LR  - 20131121
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 128
IP  - 2
DP  - 2004 Aug
TI  - Platelet activation and aggregation profile in prolonged external ventricular 
      support.
PG  - 197-202
AB  - BACKGROUND: Platelet function plays a major role in the understanding of 
      thromboembolic events in prolonged mechanical support. We studied the platelet 
      activation, platelet aggregation profile, and efficacy of aspirin in patients in 
      whom an external ventricular assist device had been implanted. PATIENTS AND 
      METHODS: Fifteen patients were studied prospectively up to 6 weeks after 
      implantation of the same type of ventricular assist device. Platelet function was 
      studied weekly before daily aspirin administration. Aspirin efficacy was tested 
      ex vivo by measuring platelet aggregation triggered by arachidonic acid. Flow 
      cytometry was used to quantify the spontaneous and induced (adenosine diphosphate 
      stimulation) expression of glycoproteins alphaIIbbeta3, Ibalpha, and CD62P on 
      platelet membranes. The plasma levels of von Willebrand factor (von Willebrand 
      factor activity and von Willebrand factor antigen) and fibrinogen were also 
      determined. RESULTS: Six of the 15 patients (26%) maintained an arachidonic 
      acid-induced platelet aggregation despite daily aspirin treatment (250 mg). CD62P 
      values remained increased during a 5-week postoperative period. Spontaneous 
      levels of glycoproteins alphaIIbbeta3 and Ibalpha on platelet membranes remained 
      within a normal range with a preserved reactivity. The plasma levels of 
      fibrinogen and von Willebrand factor remained increased during the entire study 
      period. CONCLUSION: In patients with an implanted external ventricular assist 
      device, the platelet activation profile displays a persistent activation with a 
      preserved reactivity associated with a persistent high inflammatory state and 
      endothelial activation.
FAU - Houël, Rémi
AU  - Houël R
AD  - Service de Chirurgie Cardiaque, Hôpital Henri Mondor, Créteil, France. 
      remihouel@hotmail.com
FAU - Mazoyer, Elisabeth
AU  - Mazoyer E
FAU - Boval, Bernadette
AU  - Boval B
FAU - Kirsch, Mathias
AU  - Kirsch M
FAU - Vermès, Emmanuelle
AU  - Vermès E
FAU - Drouet, Ludovic
AU  - Drouet L
FAU - Loisance, Daniel Y
AU  - Loisance DY
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - *Heart-Assist Devices
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Time Factors
EDAT- 2004/07/30 05:00
MHDA- 2004/10/27 09:00
CRDT- 2004/07/30 05:00
PHST- 2004/07/30 05:00 [pubmed]
PHST- 2004/10/27 09:00 [medline]
PHST- 2004/07/30 05:00 [entrez]
AID - S0022522303021159 [pii]
AID - 10.1016/j.jtcvs.2003.11.059 [doi]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 2004 Aug;128(2):197-202. doi: 
      10.1016/j.jtcvs.2003.11.059.

PMID- 6853927
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 71
IP  - 6
DP  - 1983 Jun
TI  - Aspirin-sensitive rhinosinusitis: the clinical syndrome and effects of aspirin 
      administration.
PG  - 580-7
AB  - Nineteen aspirin sensitive adult patients were identified who experienced 
      naso-ocular responses without associated bronchospasm during standardized oral 
      aspirin challenge. These 19 patients exhibited the characteristics of the aspirin 
      triad except asthma. These included hypertrophic rhinitis with or without 
      associated nasal polyps, abnormal sinus roentgenograms, nasal eosinophilia, 
      aspirin-provoked responses of the upper airway identical to those observed in 
      aspirin-sensitive asthmatics, capacity of the upper airway to be desensitized to 
      aspirin, and cross-reactivity and/or cross-desensitization of the upper airway to 
      indomethacin. Of the 17 patients who were treated with daily aspirin after 
      desensitization, 77% experienced improvement in their nasal symptoms.
FAU - Lumry, W R
AU  - Lumry WR
FAU - Curd, J G
AU  - Curd JG
FAU - Zeiger, R S
AU  - Zeiger RS
FAU - Pleskow, W W
AU  - Pleskow WW
FAU - Stevenson, D D
AU  - Stevenson DD
LA  - eng
GR  - AI 10386/AI/NIAID NIH HHS/United States
GR  - RR 00833/RR/NCRR NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/immunology
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/immunology
MH  - Female
MH  - Humans
MH  - Indomethacin/immunology
MH  - Male
MH  - Middle Aged
MH  - Rhinitis, Allergic, Perennial/*chemically induced/immunology
MH  - Sinusitis/*chemically induced/immunology
MH  - Skin Tests
EDAT- 1983/06/01 00:00
MHDA- 1983/06/01 00:01
CRDT- 1983/06/01 00:00
PHST- 1983/06/01 00:00 [pubmed]
PHST- 1983/06/01 00:01 [medline]
PHST- 1983/06/01 00:00 [entrez]
AID - 0091-6749(83)90440-2 [pii]
AID - 10.1016/0091-6749(83)90440-2 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1983 Jun;71(6):580-7. doi: 10.1016/0091-6749(83)90440-2.

PMID- 30055757
OWN - NLM
STAT- MEDLINE
DCOM- 20190808
LR  - 20190808
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
VI  - 356
IP  - 5
DP  - 2018 Nov
TI  - The Beat Goes On: The Story of Five Ageless Cardiac Drugs.
PG  - 441-450
LID - S0002-9629(18)30164-2 [pii]
LID - 10.1016/j.amjms.2018.04.011 [doi]
AB  - This article traces the history of 5 cardiac drugs-Aspirin, Atropine, Digitalis, 
      Nitroglycerine, and Quinidine-that have been in continuous use for centuries and 
      some for longer. Four of the 5 started life as botanicals and 4 have as also 
      served widely varied functions far removed from their current purposes. 
      Collectively, they have played a role in the history of royalty, religious 
      leaders, assassinations and military campaigns in addition to their place in 
      medical therapy. Their present clinical status has evolved from long-term 
      clinical observation without the need for controlled clinical trials, detailed 
      statistical analyses or FDA approvals. This review of their background 
      illustrates the varied means by which markedly different substances from widely 
      separated sources can come together to participate in the management of 
      circulatory disorders.
CI  - Copyright © 2018 Southern Society for Clinical Investigation. Published by 
      Elsevier Inc. All rights reserved.
FAU - Smulyan, Harold
AU  - Smulyan H
AD  - Department of Medicine, Upstate Medical University, State University of New York, 
      Syracuse, New York. Electronic address: smulyanh@upstate.edu.
LA  - eng
PT  - Editorial
PT  - Historical Article
DEP - 20180425
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Digitalis Glycosides)
RN  - 7C0697DR9I (Atropine)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - ITX08688JL (Quinidine)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*history/therapeutic use
MH  - Atropine/*history/therapeutic use
MH  - Cardiovascular Agents/*history/therapeutic use
MH  - Digitalis Glycosides/*history/therapeutic use
MH  - History, 15th Century
MH  - History, 16th Century
MH  - History, 17th Century
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - History, Ancient
MH  - History, Medieval
MH  - Humans
MH  - Nitroglycerin/*history/therapeutic use
MH  - Quinidine/*history/therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Atropine
OT  - Digitalis
OT  - Nitroglycerine
OT  - Quinidine
EDAT- 2018/07/30 06:00
MHDA- 2019/08/09 06:00
CRDT- 2018/07/30 06:00
PHST- 2017/12/05 00:00 [received]
PHST- 2018/03/29 00:00 [revised]
PHST- 2018/04/20 00:00 [accepted]
PHST- 2018/07/30 06:00 [pubmed]
PHST- 2019/08/09 06:00 [medline]
PHST- 2018/07/30 06:00 [entrez]
AID - S0002-9629(18)30164-2 [pii]
AID - 10.1016/j.amjms.2018.04.011 [doi]
PST - ppublish
SO  - Am J Med Sci. 2018 Nov;356(5):441-450. doi: 10.1016/j.amjms.2018.04.011. Epub 
      2018 Apr 25.

PMID- 6810667
OWN - NLM
STAT- MEDLINE
DCOM- 19821029
LR  - 20161123
IS  - 0300-8924 (Print)
IS  - 0300-8924 (Linking)
VI  - 3
IP  - 4
DP  - 1981
TI  - [Effect of prostaglandin-synthetase inhibitors on responses of segments of 
      coronary arteries to 4-methylesculetol and/or to angiotensin II].
PG  - 244-52
AB  - The aim of this work is to study the mechanism by which 4-methylesculetin (4-Me) 
      causes the relaxation or inhibits the angiotensin-2 (ATN2) induced contraction in 
      the smooth muscle. The effect of 4-Me, alone or associated with ascorbic acid, on 
      basal tone and ATN2 induced contraction of isolated coronary strips have been 
      studied. Experiments have been carried out in the presence of lysine 
      acetylsalicylate (LAS) and indomethacin (IN), specific inhibitors of 
      prostaglandin-synthetase. Both LAS and IN decreased, but did not abolish, the 
      4-Me induced relaxation and suppressed the depressive effect of 4-Me on the ATN2 
      dependent contraction. Therefore, it seems reasonable to conclude that the 4-Me 
      influence could be mediated by prostaglandins release in the smooth muscle.
FAU - Bettini, V
AU  - Bettini V
FAU - Calcagno, A
AU  - Calcagno A
FAU - Legrenzi, E
AU  - Legrenzi E
FAU - Mayellaro, F
AU  - Mayellaro F
FAU - Pilastro, G
AU  - Pilastro G
LA  - ita
PT  - Journal Article
TT  - Effetto di inibitori della PG-sintetasi sulle risposte di segmenti di arterie 
      coronarie al 4-metilesculetolo e/o all'angiotensina II.
PL  - Italy
TA  - Acta Vitaminol Enzymol
JT  - Acta vitaminologica et enzymologica
JID - 0135063
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Umbelliferones)
RN  - 11128-99-7 (Angiotensin II)
RN  - K3Z4F929H6 (Lysine)
RN  - KLF1HS0SXJ (Scopoletin)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Angiotensin II/*pharmacology
MH  - Animals
MH  - Ascorbic Acid/pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cattle
MH  - Coronary Vessels/*drug effects
MH  - *Cyclooxygenase Inhibitors
MH  - Enzyme Inhibitors/*pharmacology
MH  - Indomethacin/pharmacology
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Muscle, Smooth, Vascular/drug effects
MH  - Scopoletin/*pharmacology
MH  - Umbelliferones/*pharmacology
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Vitaminol Enzymol. 1981;3(4):244-52.

PMID- 16532425
OWN - NLM
STAT- MEDLINE
DCOM- 20060706
LR  - 20150127
IS  - 0899-823X (Print)
IS  - 0899-823X (Linking)
VI  - 27
IP  - 3
DP  - 2006 Mar
TI  - A new effect of acetylsalicylic acid? Significantly lower prevalence of nasal 
      carriage of Staphylococcus aureus among patients receiving orally administered 
      acetylsalicylic acid.
PG  - 318-9
AB  - We aimed to evaluate effect of acetylsalicylic acid on the prevalence of nasal 
      carriage of Staphylococcus aureus. Patients were orally administered a 
      prophylactic dose of acetylsalicylic acid and then were compared with control 
      subjects. The prevalence of nasal carriage of S. aureus was significantly lower 
      among patients who received acetylsalicylic acid than among the control subjects 
      (P<.001).
FAU - Karabay, Oguz
AU  - Karabay O
AD  - Department of Infectious Diseases and Clinical Microbiology, University of Abant 
      Izzet Baysal, Golkoy, Bolu, Turkey. drkarabay@yahoo.com
FAU - Arinc, Huseyin
AU  - Arinc H
FAU - Gunduz, Huseyin
AU  - Gunduz H
FAU - Tamer, Ali
AU  - Tamer A
FAU - Ozhan, Hakan
AU  - Ozhan H
FAU - Uyan, Cihangir
AU  - Uyan C
LA  - eng
PT  - Journal Article
DEP - 20060222
PL  - United States
TA  - Infect Control Hosp Epidemiol
JT  - Infection control and hospital epidemiology
JID - 8804099
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Carrier State/*prevention & control
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Nasal Cavity/microbiology
MH  - Prevalence
MH  - Staphylococcal Infections/epidemiology/*prevention & control
EDAT- 2006/03/15 09:00
MHDA- 2006/07/11 09:00
CRDT- 2006/03/15 09:00
PHST- 2005/01/04 00:00 [received]
PHST- 2005/01/10 00:00 [accepted]
PHST- 2006/03/15 09:00 [pubmed]
PHST- 2006/07/11 09:00 [medline]
PHST- 2006/03/15 09:00 [entrez]
AID - ICHE2004235 [pii]
AID - 10.1086/501541 [doi]
PST - ppublish
SO  - Infect Control Hosp Epidemiol. 2006 Mar;27(3):318-9. doi: 10.1086/501541. Epub 
      2006 Feb 22.

PMID- 6803194
OWN - NLM
STAT- MEDLINE
DCOM- 19820621
LR  - 20161123
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 73
IP  - 14
DP  - 1982 Apr 2
TI  - [Clinical and statistical study of 121 cases of acute myocardial infarct from 
      1976 to 1981 (month of April). Critical review].
PG  - 821-7
AB  - The authors realized a retrospective clinical-statistical study about 121 cases 
      of acute myocardial infarction (AMI), treated in the Department of general 
      medicine with a pharmacological association of Lysine 
      acetylsalicylate--Erythrityl tetranitrate--Papaverine hydrochloride, with the 
      purpose of obtaining a vasodilatation on coronary arteries and a platelet 
      antiaggregation, in the light of the new etiopathogenetic views about the 
      prolonged coronary spasm and the platelet aggregation, in some cases of 
      myocardial infarction with or without thrombosis. Obtained data are very 
      optimistic about incidence of left ventricular insufficiency and (of) 
      thromboembolisms, to they augur the sistematic adoption of this treatment of AMI, 
      especially as to the early antiaggregation therapy.
FAU - Carile, L
AU  - Carile L
FAU - Laquaglia, G A
AU  - Laquaglia GA
FAU - Martone, P
AU  - Martone P
FAU - Marchionni, F
AU  - Marchionni F
FAU - Di Falco, C
AU  - Di Falco C
LA  - ita
PT  - Journal Article
TT  - Studio clinico-statistico su 121 casi di infarto miocardico acuto (IMA) dal 1976 
      al 1981 (mese di aprile). Revisione critica.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 35X333P19D (Erythrityl Tetranitrate)
RN  - DAA13NKG2Q (Papaverine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Coronary Vessels/drug effects
MH  - Erythrityl Tetranitrate/*therapeutic use
MH  - Female
MH  - Heart Failure/prevention & control
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Papaverine/*therapeutic use
MH  - Platelet Aggregation/drug effects
MH  - Retrospective Studies
MH  - Thromboembolism/prevention & control
EDAT- 1982/04/02 00:00
MHDA- 1982/04/02 00:01
CRDT- 1982/04/02 00:00
PHST- 1982/04/02 00:00 [pubmed]
PHST- 1982/04/02 00:01 [medline]
PHST- 1982/04/02 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1982 Apr 2;73(14):821-7.

PMID- 10209351
OWN - NLM
STAT- MEDLINE
DCOM- 20000606
LR  - 20191103
IS  - 1351-5101 (Print)
IS  - 1351-5101 (Linking)
VI  - 6
IP  - 1
DP  - 1999 Jan
TI  - The effect of aspirin, ticlopidine and their low-dose combination on platelet 
      aggregability in acute ischemic stroke: a short duration follow-up study.
PG  - 57-61
AB  - We investigated the effects of aspirin (300 mg/d), ticlopidine (500 mg/d) and 
      their low-dose combination (aspirin 100 mg/d plus ticlopidine 250 mg/d) on the 
      platelet aggregability using the Wu and Hoak method. Each treatment group 
      consisted of 25 patients with acute ischemic stroke. Platelet aggregation ratios 
      (PAR) were measured on the 1(st) (before treatment), 10(th) and 90(th) days in 
      the treatment groups and compared with those of 25 control cases. On the first 
      day, comparison of PAR in each treatment group with the control was significant, 
      while the differences between treatment groups were not significant. On the 
      90(th) day, differences of PAR between aspirin and control were significant, but 
      differences between the other treatment groups and the control group were not 
      significant, indicating a lower anti-aggregant efficacy of aspirin. Our study 
      suggests that PAR determination can be used to assess the efficacy of 
      anti-aggregant drugs. Our crude observation also suggests a higher anti-aggregant 
      efficacy of ticlopidine, and aspirin plus ticlopidine, than aspirin. In addition, 
      proper doses of aspirin plus ticlopidine may be a good choice for the prevention 
      of ischemic stroke. Further studies are required to assess whether PAR 
      determination could be useful for assessing patients at risk of stroke, and for 
      drug selection for the prevention of stroke.
CI  - Copyright 1999 Lippincott Williams & Wilkins
FAU - Akyuz, A
AU  - Akyuz A
AD  - Cumhuriyet University, Faculty of Medicine, Department of Neurology, Sivas, 
      Turkey.
FAU - Bolayir, E
AU  - Bolayir E
FAU - Dener, S
AU  - Dener S
FAU - Topalkara, K
AU  - Topalkara K
FAU - Topaktas, S
AU  - Topaktas S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Stroke/*drug therapy
MH  - Ticlopidine/*administration & dosage/therapeutic use
MH  - Time Factors
EDAT- 1999/04/21 02:02
MHDA- 2000/06/10 09:00
CRDT- 1999/04/21 02:02
PHST- 1999/04/21 02:02 [pubmed]
PHST- 2000/06/10 09:00 [medline]
PHST- 1999/04/21 02:02 [entrez]
AID - NE060108 [pii]
AID - 10.1046/j.1468-1331.1999.610057.x [doi]
PST - ppublish
SO  - Eur J Neurol. 1999 Jan;6(1):57-61. doi: 10.1046/j.1468-1331.1999.610057.x.

PMID- 16642748
OWN - NLM
STAT- MEDLINE
DCOM- 20060607
LR  - 20190922
IS  - 0012-835X (Print)
IS  - 0012-835X (Linking)
VI  - 83
IP  - 1
DP  - 2006 Jan
TI  - Use and misuse of aspirin in rural Ethiopia.
PG  - 31-6
AB  - OBJECTIVES: To investigate ability to distinguish simple analgesics, to document 
      misconceptions about aspirin use, and to identify strategies to diminish 
      potentially harmful aspirin use in Ethiopia. DESIGN: Qualitative study (eight 
      focus group discussions) used to inform cross-sectional survey. SETTING: 
      Butajira, a small town in southern Ethiopia, and surrounding rural areas. 
      PARTICIPANTS: Purposively selected informants for focus groups; random sample of 
      urban and rural residents for cross-sectional survey. MAIN OUTCOME MEASURES: 
      Ability to distinguish aspirin from paracetamol; proportion using aspirin; 
      proportion aware of common risks of aspirin. RESULTS: Questionnaires were 
      completed by 204 of the 250 residents sampled (82% response). Three-quarters of 
      survey participants knew the difference between aspirin and paracetamol. Aspirin 
      was used by 7.3% of respondents, and was mainly taken for headache and fever. In 
      focus group discussions there was a suggestion that aspirin was considered 
      particularly useful for children. There was very low awareness of the risks of 
      using aspirin in children (2.5% unprompted, 18.6% prompted) or in people with 
      asthma (1% unprompted, 5.9% prompted). Aspirin is cheap and widely available in 
      urban and rural areas. CONCLUSION: Awareness of the risks of aspirin use by 
      children and in asthma is extremely low in this rural Ethiopian setting. 
      Medications are purchased with minimal packaging by a population with low 
      literacy. Drug dispensers and vendors must be trained to convey simple verbal 
      warnings about aspirin use.
FAU - Duncan, P
AU  - Duncan P
AD  - Division of Epidemiology and Public Health, University of Nottingham, City 
      Hospital, Hucknall Road, Nottingham NG5 1PB.
FAU - Aref-Adib, G
AU  - Aref-Adib G
FAU - Venn, A
AU  - Venn A
FAU - Britton, J
AU  - Britton J
FAU - Davey, G
AU  - Davey G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Kenya
TA  - East Afr Med J
JT  - East African medical journal
JID - 0372766
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Cross-Sectional Studies
MH  - Ethiopia
MH  - Female
MH  - Fever/drug therapy
MH  - Focus Groups
MH  - Headache/drug therapy
MH  - Health Care Surveys
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Education as Topic
MH  - Qualitative Research
MH  - Rural Health Services
MH  - Rural Population/*statistics & numerical data
MH  - Self Medication/statistics & numerical data
MH  - Surveys and Questionnaires
EDAT- 2006/04/29 09:00
MHDA- 2006/06/08 09:00
CRDT- 2006/04/29 09:00
PHST- 2006/04/29 09:00 [pubmed]
PHST- 2006/06/08 09:00 [medline]
PHST- 2006/04/29 09:00 [entrez]
AID - 10.4314/eamj.v83i1.9358 [doi]
PST - ppublish
SO  - East Afr Med J. 2006 Jan;83(1):31-6. doi: 10.4314/eamj.v83i1.9358.

PMID- 19923980
OWN - NLM
STAT- MEDLINE
DCOM- 20100322
LR  - 20131121
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 21
IP  - 1
DP  - 2010 Jan
TI  - Impact of genetic polymorphisms on platelet function and aspirin resistance.
PG  - 53-6
LID - 10.1097/MBC.0b013e328332ef66 [doi]
AB  - Genetic polymorphisms may affect platelets' responses to the antiplatelet 
      therapy. Our aim was to determine the role of genetic polymorphisms on aspirin 
      resistance in patients with coronary heart disease (CHD). A total of 126 
      consecutive patients (35-85 years old, 32% women) with chronic stable CHD was 
      enrolled in the study. Platelet function assays were realized by the platelet 
      function analyzer (PFA)-100 with collagen and epinephrine (Col/Epi) and collagen 
      and adenosine diphosphate (Col/ADP) cartridges. Aspirin resistance was defined as 
      having a closure time of less than 186 s with Col/Epi cartridges despite regular 
      aspirin therapy. Factor V, prothrombin, factor XIII, beta-fibrinogen, plasminogen 
      activator inhibitor I (PAI-1), glycoprotein IIIa, methylene tetrahydrofolate 
      reductase, ACE and ApoB gene polymorphisms were determined by three consecutive 
      steps: isolation and amplification of DNA and reverse hybridization. We 
      determined that 30 patients (23.8%) had aspirin resistance by the PFA-100. Mean 
      closure time measured with the Col/ADP cartridges was 74 +/- 12 s (51-104 s). Ten 
      of the 30 patients with aspirin resistance were women (33.3%). Genetic 
      polymorphisms were determined in 30 aspirin-resistant and 17 aspirin-sensitive 
      patients. No statistically significant relationship was determined between 
      aspirin resistance and the genetic panel. In our study we did not determine a 
      significant relationship between the aspirin resistance and factor V, 
      prothrombin, factor XIII, beta-fibrinogen, PAI-1, glycoprotein IIIa, methylene 
      tetrahydrofolate reductase, ACE and ApoB gene polymorphisms.
FAU - Pamukcu, Burak
AU  - Pamukcu B
AD  - Istanbul University, Istanbul Faculty of Medicine, Department of Cardiology, 
      Turkey. bpamukcu@istanbul.edu.tr
FAU - Oflaz, Huseyin
AU  - Oflaz H
FAU - Onur, Imran
AU  - Onur I
FAU - Hancer, Veysel
AU  - Hancer V
FAU - Yavuz, Selim
AU  - Yavuz S
FAU - Nisanci, Yilmaz
AU  - Nisanci Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Blood Proteins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Proteins/*genetics
MH  - Collagen/pharmacology
MH  - Drug Resistance/*genetics
MH  - Epinephrine/pharmacology
MH  - Female
MH  - *Genetic Association Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects/*genetics
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests/instrumentation
MH  - *Polymorphism, Genetic
MH  - Thrombophilia/blood/drug therapy
EDAT- 2009/11/20 06:00
MHDA- 2010/03/23 06:00
CRDT- 2009/11/20 06:00
PHST- 2009/11/20 06:00 [entrez]
PHST- 2009/11/20 06:00 [pubmed]
PHST- 2010/03/23 06:00 [medline]
AID - 10.1097/MBC.0b013e328332ef66 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2010 Jan;21(1):53-6. doi: 
      10.1097/MBC.0b013e328332ef66.

PMID- 15953514
OWN - NLM
STAT- MEDLINE
DCOM- 20060404
LR  - 20131121
IS  - 0378-5955 (Print)
IS  - 0378-5955 (Linking)
VI  - 205
IP  - 1-2
DP  - 2005 Jul
TI  - Effect of aspirin on phase gradient of 2F1-F2 distortion product otoacoustic 
      emissions.
PG  - 44-52
AB  - It is well known that aspirin consumption temporarily reduces overall otoacoustic 
      emission (OAE) amplitude in humans. However, little is known about changes in the 
      separate components of distortion product otoacoustic emissions (DPOAE), which 
      may be distinguished by examining phase gradients. The effects of aspirin on the 
      phase gradient of the DPOAE 2F1-F2 obtained with fixed frequency ratio sweeps 
      were studied longitudinally in a group of twelve subjects in whom a temporary 
      hearing loss was induced by aspirin consumption. DPOAE were recorded daily for 
      two days pre-aspirin consumption, during the three days of aspirin consumption 
      and two days afterwards. DP-grams were recorded over a restricted frequency range 
      centered on 2,3,4 and 6 kHz with the following stimulus levels: L1/L2 of 
      60/50-80/70 in 10-dB steps. The effects of aspirin on the phase gradients varied 
      between the subjects and across frequency: the general trend was that the phase 
      gradient became steeper across successive sessions for the higher frequencies, 
      while no significant effect was found at the lower frequencies. These results 
      suggest that aspirin may have more persistent effects on cochlear function than 
      are disclosed by measurements of hearing threshold level or DPOAE amplitude. 
      Particularly, DPOAE phase gradient appears to be increased by aspirin consumption 
      and has not recovered two days after cessation of aspirin intake, despite almost 
      complete recovery of DPOAE amplitude and hearing threshold levels. These findings 
      may suggest differential effects on the distortion and reflection mechanisms 
      considered to underlie DPOAE generation.
FAU - Parazzini, M
AU  - Parazzini M
AD  - Istituto di Ingegneria Biomedica ISIB, CNR, Milan, Piazza Leonardo da Vinci 32, 
      20133 Milano, Italy. marta.parazzini@polimit.it
FAU - Hall, A J
AU  - Hall AJ
FAU - Lutman, M E
AU  - Lutman ME
FAU - Kapadia, S
AU  - Kapadia S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Hear Res
JT  - Hearing research
JID - 7900445
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acoustic Stimulation
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/blood/*pharmacology
MH  - Aspirin/blood/*pharmacology
MH  - Cochlea/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Hair Cells, Auditory, Outer/drug effects
MH  - Hearing Loss/chemically induced
MH  - Humans
MH  - Male
MH  - Otoacoustic Emissions, Spontaneous/*drug effects/physiology
MH  - Reaction Time
EDAT- 2005/06/15 09:00
MHDA- 2006/04/06 09:00
CRDT- 2005/06/15 09:00
PHST- 2004/09/03 00:00 [received]
PHST- 2005/02/28 00:00 [accepted]
PHST- 2005/06/15 09:00 [pubmed]
PHST- 2006/04/06 09:00 [medline]
PHST- 2005/06/15 09:00 [entrez]
AID - S0378-5955(05)00056-0 [pii]
AID - 10.1016/j.heares.2005.02.010 [doi]
PST - ppublish
SO  - Hear Res. 2005 Jul;205(1-2):44-52. doi: 10.1016/j.heares.2005.02.010.

PMID- 8714150
OWN - NLM
STAT- MEDLINE
DCOM- 19961010
LR  - 20131121
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 103
DP  - 1996 Feb
TI  - The anti-inflammatory activity of some sulphonamides in albino rats.
PG  - 120-5
AB  - Clinically equivalent doses of dapsone, sulphasalasine and sulphamethizole in 
      albino rats showed significant (P < 0.05) anti-inflammatory activity in 
      carrageenan and cotton pellet induced inflammation. Their activity was comparable 
      to that of aspirin (200 mg/kg) and was confirmed by granuloma histology. Further, 
      these compounds also showed significant (P < 0.01) analgesic activity which was 
      comparable to that of aspirin. The ulcer index for sulphamethizole was comparable 
      to that of control animals, whereas dapsone and sulphasalazine showed significant 
      ulcerogenicity (P < 0.01). Other sulphonamides like sulphadiazine, 
      sulphanilamide, sulphamoxole and cotrimoxazole did not show significant 
      anti-inflammatory and analgesic activities.
FAU - Hiremath, S V
AU  - Hiremath SV
AD  - Department of Pharmacology, J.N. Medical College, Belgaum.
FAU - Gouripur, V V
AU  - Gouripur VV
FAU - Patil, P A
AU  - Patil PA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (Anti-Inflammatory Agents)
RN  - 25W8454H16 (Sulfamethizole)
RN  - 3XC8GUZ6CB (Sulfasalazine)
RN  - 8W5C518302 (Dapsone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/pharmacology
MH  - Dapsone/pharmacology
MH  - Female
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Sulfamethizole/pharmacology
MH  - Sulfasalazine/pharmacology
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Med Res. 1996 Feb;103:120-5.

PMID- 8669425
OWN - NLM
STAT- MEDLINE
DCOM- 19960808
LR  - 20190815
IS  - 0272-6386 (Print)
IS  - 0272-6386 (Linking)
VI  - 28
IP  - 1 Suppl 1
DP  - 1996 Jul
TI  - Does aspirin cause acute or chronic renal failure in experimental animals and in 
      humans?
PG  - S24-9
AB  - There are conflicting reports on the ability of aspirin as a single agent to 
      cause acute or chronic renal failure in experimental animals. Chronic 
      administration of aspirin alone over 18 to 68 weeks in doses of 120 to 500 
      mg/kg/d has been reported to cause renal papillary necrosis in rats. However, 
      some investigators have been unable to produce renal papillary necrosis in other 
      species or in rats given lower divided doses comparable to therapeutic doses used 
      in humans. In a variety of rat strains, aspirin administered as a single high 
      dose intravenously or by oral gavage produces acute tubular necrosis of proximal 
      tubules, rarely accompanied by renal papillary necrosis in susceptible strains. 
      Several human studies have addressed the chronic nephrotoxicity of aspirin alone 
      or relative risk of end-stage renal disease in association with aspirin use after 
      correction for other analgesics. With the exception of one case control study 
      demonstrating a low, but statistically significant risk of end-stage renal 
      disease in association with aspirin use, all other case control studies and 
      several prospective studies have been unable to identify a significant risk of 
      chronic renal failure in patients using aspirin alone in therapeutic doses. In 
      healthy adults, short-term aspirin administration in therapeutic doses has no 
      effect on creatinine clearance, urine volume, osmolar clearance, or sodium and 
      potassium excretion. However, in predisposed individuals with glomerulonephritis, 
      cirrhosis, and chronic renal insufficiency, and in children with congestive heart 
      failure, short-term aspirin use in therapeutic doses may precipitate reversible 
      acute renal failure. Acute aspirin intoxication (>300 mg/kg) frequently causes 
      acute renal failure and doses of 500 mg/kg may be lethal. Chronic salicylate 
      intoxication has been reported to cause reversible or irreversible acute renal 
      failure in association with a pseudosepsis syndrome.
FAU - D'Agati, V
AU  - D'Agati V
AD  - Department of Pathology, Columbia University College of Physicians and Surgeons, 
      New York, NY 10032, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Kidney Injury/*chemically induced
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Kidney Failure, Chronic/*chemically induced
RF  - 34
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
AID - S0272-6386(96)90565-X [pii]
AID - 10.1016/s0272-6386(96)90565-x [doi]
PST - ppublish
SO  - Am J Kidney Dis. 1996 Jul;28(1 Suppl 1):S24-9. doi: 
      10.1016/s0272-6386(96)90565-x.

PMID- 350473
OWN - NLM
STAT- MEDLINE
DCOM- 19780901
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 24
IP  - 1
DP  - 1978 Jul
TI  - Aspirin and aspirin-caffeine in postpartum pain relief.
PG  - 69-75
AB  - In two double-blind randomized, balanced, single oral dose studies with 140 
      women, a combination of 800 mg aspirin and 64 mg caffeine (aspirin-caffeine) was 
      compared to 650 mg aspirin and to placebo. In patients with moderate to severe 
      uterine or episiotomy pain, there was greater analgesic response with active 
      drugs when the initial pain intensity was more severe. In patients with severe 
      episiotomy pain, aspirin-caffeine was more effective than 650 mg aspirin (p less 
      than 0.05) at the second and third hours. There was no difference between 
      analgesic effects of aspirin and aspirin-caffeine in women with severe uterine 
      pain.
FAU - Jain, A K
AU  - Jain AK
FAU - McMahon, F G
AU  - McMahon FG
FAU - Ryan, J R
AU  - Ryan JR
FAU - Unger, D
AU  - Unger D
FAU - Richard, W
AU  - Richard W
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Drug Combinations)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Caffeine/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Drug Evaluation
MH  - Episiotomy/adverse effects
MH  - Female
MH  - Humans
MH  - Pain/*drug therapy/etiology
MH  - Pregnancy
MH  - Puerperal Disorders/*drug therapy
MH  - Uterine Diseases/drug therapy
EDAT- 1978/07/01 00:00
MHDA- 1978/07/01 00:01
CRDT- 1978/07/01 00:00
PHST- 1978/07/01 00:00 [pubmed]
PHST- 1978/07/01 00:01 [medline]
PHST- 1978/07/01 00:00 [entrez]
AID - 0009-9236(78)90050-4 [pii]
AID - 10.1002/cpt197824169 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1978 Jul;24(1):69-75. doi: 10.1002/cpt197824169.

PMID- 6878380
OWN - NLM
STAT- MEDLINE
DCOM- 19830920
LR  - 20151119
IS  - 0361-7742 (Print)
IS  - 0361-7742 (Linking)
VI  - 122
DP  - 1983
TI  - Modification of hemoglobin - tetrameric stabilization.
PG  - 41-9
AB  - Advantage has been taken of the unique affinity of DBBF for hemoglobin to 
      stabilize the T state and crosslink tetrameric hemoglobin. The oxygen affinity 
      has been further decreased by using PLP to produce a chemically unique molecule 
      with a P50 of 32 under physiologic conditions. Furthermore, the modification is 
      specific, requires only reagents that are commercially available or easily 
      synthesized, and can be prepared in large quantities with up to 80% yield. The 
      unique modified hemoglobin was purified by HPLC and the crosslink was found 
      between the beta chains. This derivative, pyridoxalated-fumarate hemoglobin, 
      sustained life in five rats that were 95% exchanged-transfused with the solution. 
      Preliminary in vivo tests support this derivative as a desirable 
      oxygen-transporting resuscitation fluid.
FAU - Tye, R W
AU  - Tye RW
FAU - Medina, F
AU  - Medina F
FAU - Bolin, R B
AU  - Bolin RB
FAU - Knopp, G L
AU  - Knopp GL
FAU - Irion, G S
AU  - Irion GS
FAU - McLaughlin, S K
AU  - McLaughlin SK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prog Clin Biol Res
JT  - Progress in clinical and biological research
JID - 7605701
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Aspirin/*analogs & derivatives
MH  - *Blood Substitutes
MH  - *Cross-Linking Reagents
MH  - Drug Stability
MH  - *Hemoglobins
MH  - Humans
MH  - Oxygen/blood
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Prog Clin Biol Res. 1983;122:41-9.

PMID- 7098376
OWN - NLM
STAT- MEDLINE
DCOM- 19820910
LR  - 20131121
IS  - 0300-8630 (Print)
IS  - 0300-8630 (Linking)
VI  - 194
IP  - 2
DP  - 1982 Mar
TI  - [Inhibition of platelet function in pediatric medicine (author's transl)].
PG  - 91-3
AB  - The postulated importance of platelets in the pathogenesis of thromboembolic 
      events has stimulated interest in drugs that inhibit platelet function. Clinical 
      trials of antiplatelet agents in the secondary prevention of myocardial 
      infarction and transient ischaemic attacks have so far been inconclusive. In 
      children antiplatelet drugs area used on the evidence of nothing but anecdote. 
      Optimum drug or combination of drugs and dosage are still controversial. Possible 
      fruitful applications of platelet modifying agents such as aspirin and 
      dipyridamole in paediatric nephrology and cardiology await further evaluation in 
      prospective trials.
FAU - Schmidt, B
AU  - Schmidt B
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Plättchenfunktionshemmung in der Kinderheilkunde.
PL  - Germany
TA  - Klin Padiatr
JT  - Klinische Padiatrie
JID - 0326144
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Child
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Glomerulonephritis/drug therapy
MH  - Graft Rejection
MH  - Heart Defects, Congenital/drug therapy
MH  - Heart Valve Prosthesis
MH  - Hemolytic-Uremic Syndrome/drug therapy
MH  - Humans
MH  - Mucocutaneous Lymph Node Syndrome/drug therapy
MH  - Renal Dialysis
MH  - Thrombosis/prevention & control
EDAT- 1982/03/01 00:00
MHDA- 1982/03/01 00:01
CRDT- 1982/03/01 00:00
PHST- 1982/03/01 00:00 [pubmed]
PHST- 1982/03/01 00:01 [medline]
PHST- 1982/03/01 00:00 [entrez]
AID - 10.1055/s-2008-1033780 [doi]
PST - ppublish
SO  - Klin Padiatr. 1982 Mar;194(2):91-3. doi: 10.1055/s-2008-1033780.

PMID- 11305980
OWN - NLM
STAT- MEDLINE
DCOM- 20010628
LR  - 20191104
IS  - 1523-3782 (Print)
IS  - 1523-3782 (Linking)
VI  - 3
IP  - 3
DP  - 2001 May
TI  - The angiotensin-converting enzyme inhibitor and aspirin interaction in congestive 
      heart failure: fear or reality?
PG  - 247-53
AB  - Angiotensin-converting enzyme (ACE) inhibitors have become the cornerstone of 
      therapy for congestive heart failure (CHF). Because ischemic heart disease is the 
      most common cause of CHF, aspirin is frequently given concomitantly with ACE 
      inhibitors in patients with CHF. Increased bradykinin levels, with the consequent 
      enhanced synthesis of vasodilatory prostaglandins, appear to mediate a 
      significant benefit of ACE inhibitor therapy in these patients. In contrast, 
      aspirin inhibits cyclooxygenase, and thereby suppresses prostaglandin production. 
      Thus, these counteracting effects on prostaglandins may result in antagonism 
      between ACE inhibitor and aspirin therapy in heart failure patients. Several 
      early reports questioned the safety of aspirin in CHF, and the potential 
      antagonistic interaction between ACE inhibitors and aspirin in patients with 
      heart failure has become the focus of both increasing research and intense 
      debate. This article briefly highlights the theoretic considerations underlying 
      this interaction, and reviews the available evidence for such an interaction from 
      clinical trials.
FAU - Moskowitz, R
AU  - Moskowitz R
AD  - Division of Cardiology, Montefiore Medical Center, 111 East 210th Street, Bronx, 
      New York 10467, USA. rmoskowi@montefiore.org
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Drug Interactions
MH  - Heart Failure/*drug therapy/mortality
MH  - Humans
RF  - 49
EDAT- 2001/04/18 10:00
MHDA- 2001/06/29 10:01
CRDT- 2001/04/18 10:00
PHST- 2001/04/18 10:00 [pubmed]
PHST- 2001/06/29 10:01 [medline]
PHST- 2001/04/18 10:00 [entrez]
AID - 10.1007/s11886-001-0030-0 [doi]
PST - ppublish
SO  - Curr Cardiol Rep. 2001 May;3(3):247-53. doi: 10.1007/s11886-001-0030-0.

PMID- 31339341
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 25
IP  - 1
DP  - 2020 Jan
TI  - Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French 
      Population.
PG  - 37-46
LID - 10.1177/1074248419865287 [doi]
AB  - BACKGROUND: Previous studies have shown that adherence to low-dose aspirin (LDA) 
      is suboptimal. However, these studies were based on an average measure of 
      adherence during follow-up, ignoring its dynamic process over time. We described 
      the trajectories of adherence to LDA treatment among the French population over 3 
      years of follow-up. METHODS: We identified a cohort of 11 793 new LDA users, aged 
      ≥50 years in 2010, by using the French national health-care database. Patients 
      included had at least 3 years of history in the database before study entry to 
      exclude prevalent aspirin users and to assess baseline comorbidities. They were 
      followed from the first date of LDA supply (the index date) until the first date 
      among death, exit from the database, or 3 years after the index date. Adherence 
      to LDA was assessed every 3 months by using the proportion of days covered (PDC) 
      and dichotomized with a cutoff of PDC of 0.8. We used group-based trajectory 
      modeling to identify trajectories of LDA adherence. Predictors of LDA adherence 
      trajectory membership were identified by multinomial logistics regression. 
      RESULTS: We identified 4 trajectories of adherence among new LDA users: the 
      not-adherents (4737 [40.2%]), the delayed not-adherents (gradual decrease in 
      adherence probability, 1601 [13.6%]), the delayed adherents (gradual increase in 
      adherence probability, 1137 [9.6%]), and the persistent adherents (4318 [36.6%]). 
      The probability of belonging to the not-adherent group was increased with female 
      sex, low socioeconomic status, and polymedication and was reduced with a 
      secondary indication for LDA use, such as diabetes, hypertension, and dementia, 
      at least 4 consultations in the previous year, or 1 hospitalization or a 
      cardiologist consultation in the 3 months before the index date. CONCLUSION: This 
      study provides a dynamic picture of adherence behaviors among new LDA users and 
      underlines the presence of critical trajectories that intervention could target 
      to improve adherence.
FAU - Ajrouche, Aya
AU  - Ajrouche A
AD  - Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital 
      Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information 
      Médicale, Centre de Pharmacoépidémiologie (Cephepi), INSERM, UMR 1123, ECEVE, 
      CIC-P 1421, Paris, France.
FAU - Estellat, Candice
AU  - Estellat C
AD  - Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital 
      Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information 
      Médicale, Centre de Pharmacoépidémiologie (Cephepi), INSERM, UMR 1123, ECEVE, 
      CIC-P 1421, Paris, France.
FAU - De Rycke, Yann
AU  - De Rycke Y
AD  - Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital 
      Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information 
      Médicale, Centre de Pharmacoépidémiologie (Cephepi), INSERM, UMR 1123, ECEVE, 
      CIC-P 1421, Paris, France.
FAU - Tubach, Florence
AU  - Tubach F
AD  - Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital 
      Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information 
      Médicale, Centre de Pharmacoépidémiologie (Cephepi), INSERM, UMR 1123, ECEVE, 
      CIC-P 1421, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190724
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Agents/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/diagnosis/mortality/*prevention & control
MH  - Comorbidity
MH  - Databases, Factual
MH  - Female
MH  - France/epidemiology
MH  - Health Knowledge, Attitudes, Practice
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - *Medication Adherence
MH  - Middle Aged
MH  - Primary Prevention
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Time Factors
OTO - NOTNLM
OT  - SNDS
OT  - adherence
OT  - aspirin
OT  - group-based trajectory modeling
OT  - pharmacoepidemiology
OT  - population-based study
EDAT- 2019/07/25 06:00
MHDA- 2020/09/15 06:00
CRDT- 2019/07/25 06:00
PHST- 2019/07/25 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2019/07/25 06:00 [entrez]
AID - 10.1177/1074248419865287 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2020 Jan;25(1):37-46. doi: 10.1177/1074248419865287. 
      Epub 2019 Jul 24.

PMID- 12653699
OWN - NLM
STAT- MEDLINE
DCOM- 20030519
LR  - 20190901
IS  - 0307-6938 (Print)
IS  - 0307-6938 (Linking)
VI  - 28
IP  - 2
DP  - 2003 Mar
TI  - Benign cutaneous Degos' disease.
PG  - 145-7
AB  - Malignant atrophic papulosis is a rare systemic vaso-occlusive disorder 
      characterized by thrombosis of vessels of the dermis, gastrointestinal tract, 
      central nervous system and, occasionally, other organs. Cutaneous lesions consist 
      of erythematous, dome-shaped papules that develop a central area of necrosis to 
      leave a porcelain-like scar. The most accepted theory of pathogenesis is based on 
      endothelial cell damage. There is no effective treatment of the disease. We 
      describe a 26-year-old man with Degos' disease, a diagnosis based on the clinical 
      and histologic pattern of skin lesions. The good response to antiplatelet therapy 
      and the absence of systemic involvement over 8 years' follow-up is noteworthy. We 
      believe that this case represents the benign form of the disease, typically 
      referred to as benign cutaneous Degos' disease.
FAU - Ojeda Cuchillero, R M
AU  - Ojeda Cuchillero RM
AD  - Department of Dermatology, Hospital Sagrado Corazón, Teaching Unit of University 
      of Barcelona, Barcelona, Spain. ireuamu@retemail.es
FAU - Sánchez Regaña, M
AU  - Sánchez Regaña M
FAU - Umbert Millet, P
AU  - Umbert Millet P
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Skin Diseases, Papulosquamous/drug therapy/*pathology
EDAT- 2003/03/26 05:00
MHDA- 2003/05/20 05:00
CRDT- 2003/03/26 05:00
PHST- 2003/03/26 05:00 [pubmed]
PHST- 2003/05/20 05:00 [medline]
PHST- 2003/03/26 05:00 [entrez]
AID - 1161 [pii]
AID - 10.1046/j.1365-2230.2003.01161.x [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2003 Mar;28(2):145-7. doi: 10.1046/j.1365-2230.2003.01161.x.

PMID- 2506587
OWN - NLM
STAT- MEDLINE
DCOM- 19891026
LR  - 20190818
IS  - 0031-8655 (Print)
IS  - 0031-8655 (Linking)
VI  - 50
IP  - 3
DP  - 1989 Sep
TI  - The microvascular effects of photodynamic therapy: evidence for a possible role 
      of cyclooxygenase products.
PG  - 419-23
AB  - Photodynamic therapy (PDT) of malignant tumours may involve the interruption of 
      tumor and peritumor microcirculation. We have studied the effect of light 
      activation of the photosensitizing drug dihematoporphyrin ether (DHE) on rat 
      subcutaneous arterioles and the modulation of these effects by cyclooxygenase 
      inhibitors indomethacin and acetyl salicylic acid (ASA). Animals received DHE 48 
      h prior to light activation and additionally either indomethacin, ASA or saline 3 
      h prior to treatment. Light activation (630 nm, 60 J/cm2) resulted in a 
      significant reduction to 62 +/- 2% SEM of initial blood flow. This effect was 
      inhibited by ASA (98 +/- 8% SEM) and indomethacin (87 +/- 8% SEM). Results from 
      the administration of various doses of both compounds indicate that this 
      inhibition is dose related. The data presented here show that PDT causes a 
      significant reduction in blood flow in normal arterioles and that this effect was 
      inhibited by ASA and indomethacin indicating that prostaglandins or thromboxane 
      A2 may play an important role in the microvascular response to PDT.
FAU - Reed, M W
AU  - Reed MW
FAU - Wieman, T J
AU  - Wieman TJ
FAU - Doak, K W
AU  - Doak KW
FAU - Pietsch, C G
AU  - Pietsch CG
FAU - Schuschke, D A
AU  - Schuschke DA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Photochem Photobiol
JT  - Photochemistry and photobiology
JID - 0376425
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Indomethacin/pharmacology
MH  - Male
MH  - *Microcirculation/drug effects
MH  - *Photochemotherapy
MH  - Prostaglandin-Endoperoxide Synthases/*physiology
MH  - Rats
MH  - Regional Blood Flow/drug effects
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
AID - 10.1111/j.1751-1097.1989.tb04179.x [doi]
PST - ppublish
SO  - Photochem Photobiol. 1989 Sep;50(3):419-23. doi: 
      10.1111/j.1751-1097.1989.tb04179.x.

PMID- 3122775
OWN - NLM
STAT- MEDLINE
DCOM- 19880323
LR  - 20131121
IS  - 1358-6173 (Print)
IS  - 1358-6173 (Linking)
VI  - 1
DP  - 1987
TI  - The potentiation of platelet aggregation by mechanical stimuli is inhibited by 
      ethanol in vitro.
PG  - 573-6
AB  - Previous work on inhibition by ethanol of human platelet aggregation suggested 
      that this was a consequence of inhibition of the activation of platelet membrane 
      phospholipase A2 (PLA2) which precedes aggregation. In these experiments, the 
      effect of ethanol in vitro on human gel-filtered platelets activated with A23187 
      or with collagen was studied at different levels of mechanical stimulus (stirring 
      rate) in the platelet aggregometer. The dose response curve obtained by varying 
      the concentration of aggregating agent at constant stirring rate was shifted to 
      the right in the parallel fashion by ethanol. A23187-induced aggregation was 
      inhibited to a greater extent than that due to collagen. When a stirring rate: 
      response curve for platelet aggregation was obtained at a constant concentration 
      of either chemical aggregating agent ethanol shifted the curve to the right in a 
      non-parallel fashion, its effect being greater at greater levels of mechanical 
      stimulus. The effects of acetylsalicylic acid, known to act at a step subsequent 
      to PLA2 activation, were completely unlike those of ethanol. The results are 
      consistent with an inhibitory effect of ethanol on activation of phospholipase A2 
      by mechanical stimuli which deform platelet membranes.
FAU - Fawcett, J
AU  - Fawcett J
AD  - Department of Pharmacology, Kings College, London, U.K.
FAU - Caberos, L P
AU  - Caberos LP
FAU - Littleton, J M
AU  - Littleton JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Alcohol Alcohol Suppl
JT  - Alcohol and alcoholism (Oxford, Oxfordshire). Supplement
JID - 8804836
RN  - 37H9VM9WZL (Calcimycin)
RN  - 3K9958V90M (Ethanol)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Calcimycin/pharmacology
MH  - Collagen/pharmacology
MH  - Ethanol/*pharmacology
MH  - Humans
MH  - Physical Stimulation
MH  - Platelet Aggregation/*drug effects
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Alcohol Alcohol Suppl. 1987;1:573-6.

PMID- 32086348
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Feb 20
TI  - Aspirin and fracture risk: a systematic review and exploratory meta-analysis of 
      observational studies.
PG  - e026876
LID - 10.1136/bmjopen-2018-026876 [doi]
LID - e026876
AB  - OBJECTIVES: This review provides insights into the potential for aspirin to 
      preserve bone mineral density (BMD) and reduce fracture risk, building knowledge 
      of the risk-benefit profile of aspirin. METHODS: We conducted a systematic review 
      and exploratory meta-analysis of observational studies. Electronic searches of 
      MEDLINE and Embase, and a manual search of bibliographies was undertaken for 
      studies published to 28 March 2018. Studies were included if: participants were 
      men or women aged ≥18 years; the exposure of interest was aspirin; and relative 
      risks, ORs and 95% CIs for the risk of fracture or difference (percentage or 
      absolute) in BMD (measured by dual energy X-ray absorptiometry) between aspirin 
      users and non-users were presented. Risk of bias was assessed using the Joanna 
      Briggs Institute Critical Appraisal Checklists for observational studies. Pooled 
      ORs for any fracture and standardised mean differences (SMDs) for BMD outcomes 
      were calculated using random-effects models. RESULTS: Twelve studies met the 
      inclusion criteria and were included in the meta-analysis. Aspirin use was 
      associated with a 17% lower odds for any fracture (OR 0.83, 95% CI 0.70 to 0.99; 
      I(2)=71%; six studies; n=511 390). Aspirin was associated with a higher total hip 
      BMD for women (SMD 0.03, 95% CI -0.02 to 0.07; I(2)=0%; three studies; n=9686) 
      and men (SMD 0.06, 95% CI -0.02 to 0.13, I(2)=0%; two studies; n=4137) although 
      these associations were not significant. Similar results were observed for lumbar 
      spine BMD in women (SMD 0.03, 95% CI -0.03 to 0.09; I(2)=34%; four studies; 
      n=11 330) and men (SMD 0.08; 95% CI -0.01 to 0.18; one study; n=432). 
      CONCLUSIONS: While the benefits of reduced fracture risk and higher BMD from 
      aspirin use may be modest for individuals, if confirmed in prospective controlled 
      trials, they may confer a large population benefit given the common use of 
      aspirin in older people.
CI  - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Barker, A L
AU  - Barker AL
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia anna.barker@monash.edu.
AD  - Member Health, Medibank Private, Melbourne, Victoria, Australia.
FAU - Soh, Sze-Ee
AU  - Soh SE
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
AD  - Department of Physiotherapy, Monash University, Melbourne, Victoria, Australia.
FAU - Sanders, Kerrie M
AU  - Sanders KM
AD  - Department of Medicine-Western Health, University of Melbourne Faculty of VCA and 
      MCM, Melbourne, Victoria, Australia.
AD  - Australian Institute for Musculoskeletal Science (AIMSS), The University of 
      Melbourne and Western Health, Melbourne, Victoria, Australia.
FAU - Pasco, Julie
AU  - Pasco J
AD  - Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, 
      Geelong, Victoria, Australia.
FAU - Khosla, Sundeep
AU  - Khosla S
AD  - Division of Endocrinology and Center on Aging, Rochester, Minnesota, USA.
FAU - Ebeling, Peter R
AU  - Ebeling PR
AD  - Bone and Muscle Health Research Group, School of Clinical Sciences at Monash 
      Health, Monash Medical Centre, Melbourne, Victoria, Australia.
FAU - Ward, Stephanie A
AU  - Ward SA
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Peeters, Geeske
AU  - Peeters G
AD  - Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland.
FAU - Talevski, Jason
AU  - Talevski J
AD  - Department of Medicine-Western Health, University of Melbourne Faculty of VCA and 
      MCM, Melbourne, Victoria, Australia.
AD  - Australian Institute for Musculoskeletal Science (AIMSS), The University of 
      Melbourne and Western Health, Melbourne, Victoria, Australia.
FAU - Cumming, Robert G
AU  - Cumming RG
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales, 
      Australia.
FAU - Seeman, Ego
AU  - Seeman E
AD  - Endocrinology and Medicine, Austin Health, Heidelberg, Victoria, Australia.
AD  - Mary McKillip Institute of Healthy Aging, Australian Catholic University, 
      Melbourne, Victoria, Australia.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200220
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Bone Density Conservation Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/*pharmacology
MH  - Bone Density/*drug effects
MH  - Bone Density Conservation Agents/pharmacology
MH  - Fractures, Bone/*prevention & control
MH  - Humans
MH  - Risk Assessment
PMC - PMC7044955
OTO - NOTNLM
OT  - ageing
OT  - fracture prevention
OT  - general population studies
OT  - osteoporosis
OT  - therapeutics (other)
COIS- Competing interests: ALB, KS, JP, SK, PE, SAW, RGC, ES and JJM are the members of 
      the investigator group for the ASPREE-Fracture substudy.
EDAT- 2020/02/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/02/23 06:00
PHST- 2020/02/23 06:00 [entrez]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2018-026876 [pii]
AID - 10.1136/bmjopen-2018-026876 [doi]
PST - epublish
SO  - BMJ Open. 2020 Feb 20;10(2):e026876. doi: 10.1136/bmjopen-2018-026876.

PMID- 35177216
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220308
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 226
IP  - 2S
DP  - 2022 Feb
TI  - When to give aspirin to prevent preeclampsia: application of Bayesian decision 
      theory.
PG  - S1120-S1125
LID - S0002-9378(21)01212-6 [pii]
LID - 10.1016/j.ajog.2021.10.038 [doi]
AB  - BACKGROUND: There is good evidence that first-trimester assessment of the risk 
      for preterm preeclampsia and treatment of the high-risk group with aspirin 
      reduces the incidence of preterm preeclampsia. Furthermore, there is evidence 
      that aspirin is associated with an increased risk of maternal and neonatal 
      hemorrhagic complications. Against this background, there are ongoing debates 
      whether aspirin should be recommended for all women or to a subpopulation of 
      women predicted to be at increased risk of developing preeclampsia. Moreover, if 
      a strategy of the prediction and prevention of preterm preeclampsia is to be 
      used, what method should be used for the prediction, and what risk cutoff should 
      be used to decide on who to treat? OBJECTIVE: This study aimed to compare the 
      policies of universal treatment, stratified treatment, and no treatment with 
      aspirin. STUDY DESIGN: Decisions about aspirin prophylaxis were considered from 
      the perspective of the Bayesian decision theory. Using this approach, the 
      treatment policies were evaluated for risks of preterm preeclampsia, effects of 
      aspirin, and trade-offs between the harms and benefits of the treatment. Evidence 
      on the risk of preterm preeclampsia was taken from the Screening programme for 
      pre-eclampsia study, which was a first-trimester screening study for the 
      prediction of preeclampsia. Evidence of the effect of aspirin was taken from the 
      Aspirin for Evidence-Based Preeclampsia Prevention trial, which was a trial of 
      aspirin vs placebo in the prevention of preterm preeclampsia. The trade-off 
      between the benefits and harms of aspirin was specified by addressing the 
      question, "What is the maximum number of women that should be treated to prevent 
      1 case of preterm preeclampsia?" The number can be considered as an exchange rate 
      between the harms and benefits of using aspirin to prevent preterm PE. Given the 
      uncertainty about the harms associated with aspirin, the treatment policies were 
      compared across a wide range of exchange rates. RESULTS: For exchange rates 
      between 10 and 1000 women treated with aspirin to prevent 1 case of preterm 
      preeclampsia, the net benefit achieved from the risk assessment and targeted 
      treatment of women at high risk of preterm preeclampsia was higher than that from 
      women with no treatment or women with universal treatment with aspirin. 
      CONCLUSION: Universal treatment with aspirin should be avoided. Risk-based 
      screening should be used, and the cutoff for taking aspirin should be determined 
      from the consideration of the trade-off between the benefits and harms and 
      detection, false-positive, and screen-positive rates.
CI  - Copyright © 2021. Published by Elsevier Inc.
FAU - Wright, David
AU  - Wright D
AD  - Institute of Health Research, University of Exeter Medical School, Exeter, United 
      Kingdom.
FAU - Wright, Alan
AU  - Wright A
AD  - Institute of Health Research, University of Exeter Medical School, Exeter, United 
      Kingdom.
FAU - Tan, Min Yi
AU  - Tan MY
AD  - Harris Birthright Research Centre for Fetal Medicine, Fetal Medicine Research 
      Institute, King's College Hospital, London, United Kingdom.
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
AD  - Harris Birthright Research Centre for Fetal Medicine, Fetal Medicine Research 
      Institute, King's College Hospital, London, United Kingdom. Electronic address: 
      kypros@fetalmedicine.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Video-Audio Media
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Bayes Theorem
MH  - Clinical Decision-Making
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - *Risk Assessment
OTO - NOTNLM
OT  - Aspirin for Evidence-Based Preeclampsia Prevention trial
OT  - Screening programme for pre-eclampsia study
OT  - aspirin
OT  - competing risks model
OT  - first-trimester screening
OT  - preeclampsia
EDAT- 2022/02/19 06:00
MHDA- 2022/03/09 06:00
CRDT- 2022/02/18 05:34
PHST- 2021/08/15 00:00 [received]
PHST- 2021/10/17 00:00 [revised]
PHST- 2021/10/20 00:00 [accepted]
PHST- 2022/02/18 05:34 [entrez]
PHST- 2022/02/19 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
AID - S0002-9378(21)01212-6 [pii]
AID - 10.1016/j.ajog.2021.10.038 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2022 Feb;226(2S):S1120-S1125. doi: 
      10.1016/j.ajog.2021.10.038.

PMID- 3103135
OWN - NLM
STAT- MEDLINE
DCOM- 19870406
LR  - 20190501
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 84
IP  - 5
DP  - 1987 Mar
TI  - Pharmacokinetics of aspirin and salicylate in relation to inhibition of 
      arachidonate cyclooxygenase and antiinflammatory activity.
PG  - 1417-20
AB  - Among the nonsteroid antiinflammatory drugs there is generally a close 
      correlation between the potency of their inhibition of arachidonate 
      cyclooxygenase, and thus prostaglandin production, and their antiinflammatory 
      activity. One anomaly in this generalization is that whereas aspirin and 
      salicylate are equipotent as antiinflammatory agents, salicylate is less active 
      than aspirin in inhibiting prostaglandin production in vitro. Using rats, we have 
      now measured the concentrations of aspirin and salicylate in plasma and in 
      inflammatory exudates after their oral administration and determined their 
      effects on thromboxane B2 production in clotting blood and prostaglandin (PG) E2 
      concentrations in the exudates. We have also investigated the effects of both 
      drugs, at concentrations achieved in the exudates, on PGE2 production by 
      nonproliferative explants of acutely inflamed tissues. Aspirin is rapidly 
      metabolized, resulting in peak concentrations of salicylate in the plasma and 
      exudate that exceeded peak concentrations of aspirin by 30- to 50-fold. 
      Furthermore, concentrations of aspirin rapidly declined, whereas high 
      concentrations of salicylate persisted in the plasma and in the exudate for up to 
      6 hr after a single administration of aspirin. Both drugs reduced PGE2 
      concentrations in inflammatory exudates by 50-70%, but aspirin was considerably 
      more potent than salicylate in inhibiting thromboxane B2 production in clotting 
      blood. The concentration of salicylate found in inflammatory exudates 6 hr after 
      the administration of aspirin was sufficient to reduce PGE2 production in 
      explants by more than 50%. We conclude that the antiinflammatory action of both 
      drugs depends on the inhibition of PGE2 synthesis by salicylate.
FAU - Higgs, G A
AU  - Higgs GA
FAU - Salmon, J A
AU  - Salmon JA
FAU - Henderson, B
AU  - Henderson B
FAU - Vane, J R
AU  - Vane JR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandins E)
RN  - 0 (Salicylates)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*pharmacology
MH  - *Cyclooxygenase Inhibitors
MH  - Inflammation/physiopathology
MH  - Kinetics
MH  - Male
MH  - Prostaglandins E/biosynthesis
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Salicylates/blood/*pharmacology
MH  - Thromboxane B2/biosynthesis
PMC - PMC304441
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 10.1073/pnas.84.5.1417 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1987 Mar;84(5):1417-20. doi: 10.1073/pnas.84.5.1417.

PMID- 1424642
OWN - NLM
STAT- MEDLINE
DCOM- 19921204
LR  - 20191028
IS  - 0792-5077 (Print)
IS  - 0792-5077 (Linking)
VI  - 10
IP  - 3
DP  - 1992
TI  - The effect of antacid on aspirin pharmacokinetics in healthy Thai volunteers.
PG  - 213-28
AB  - The effect of antacid on aspirin pharmacokinetics and bioavailability was 
      determined in 10 healthy adult male and female volunteers, aged 20-45 years old. 
      Each subject received 650 mg of aspirin orally after an overnight fast. The wash 
      out period was 14 days and then all subjects were given 650 mg of aspirin 10 
      minutes after antacid (aluminium hydroxide and magnesium hydroxide). Plasma 
      aspirin, salicylate and salicyluric acid levels were determined by a specific 
      high performance liquid chromatographic analysis. Individual plasma profiles were 
      analysed using compartmental and non-compartmental methods. The results show that 
      antacid affected the relative bioavailability of aspirin since the mean peak 
      concentration (Cmax) of aspirin was significantly higher when antacid was given. 
      However, the time to reach peak concentration (Tmax) and the area under the 
      plasma concentration-time curve (AUC) showed no significant difference between 
      the two treatments. It was, therefore, not possible to conclude that the 
      non-bioequivalence was caused by a difference in rate or amount of aspirin 
      absorption, or both. No significant difference was observed in Cmax, Tmax, AUC, 
      t1/2, Ka, Kel of salicylate and salicyluric acid. However, the rate of total 
      salicylate absorption was increased since the absorption rate constant (Ka) was 
      higher when antacid was given. This may provide a more rapid effect of the drug.
FAU - Itthipanichpong, C
AU  - Itthipanichpong C
AD  - Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, 
      Bangkok, Thailand.
FAU - Sirivongs, P
AU  - Sirivongs P
FAU - Wittayalertpunya, S
AU  - Wittayalertpunya S
FAU - Chaiyos, N
AU  - Chaiyos N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Drug Metabol Drug Interact
JT  - Drug metabolism and drug interactions
JID - 8904736
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 487-54-7 (salicylurate)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - NBZ3QY004S (Magnesium Hydroxide)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aluminum Hydroxide/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid
MH  - Drug Interactions
MH  - Female
MH  - Hippurates/blood
MH  - Humans
MH  - Magnesium Hydroxide/administration & dosage/*pharmacology
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Thailand
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1515/dmdi.1992.10.3.213 [doi]
PST - ppublish
SO  - Drug Metabol Drug Interact. 1992;10(3):213-28. doi: 10.1515/dmdi.1992.10.3.213.

PMID- 17067818
OWN - NLM
STAT- MEDLINE
DCOM- 20070419
LR  - 20141120
IS  - 1047-8477 (Print)
IS  - 1047-8477 (Linking)
VI  - 157
IP  - 2
DP  - 2007 Feb
TI  - Effect of human serum albumin on drug metabolism: structural evidence of esterase 
      activity of human serum albumin.
PG  - 348-55
AB  - Human serum albumin (HSA) is the most abundant plasma protein in the human body 
      with a plasma concentration of 0.6mM. HSA plays an important role in drug 
      transport and metabolism. Enzymatic activity of HSA on different substrates or 
      drugs has been studied and documented. The structural mechanism of this activity, 
      however, is unknown. In this study, we have determined the crystal structures of 
      HSA-myristate in a complex of aspirin and of salicylic acid, respectively. The 
      crystal structure of HSA-myristate-aspirin illustrates that aspirin transfers 
      acetyl group to Lys199 and is hydrolyzed into salicylic acid by HSA. The 
      hydrolysis product, salicylic acid, remains bound to HSA at a similar location, 
      but it shows a very different orientation when compared with the salicylic acid 
      in the HSA-myristate-salicylic acid ternary complex. These results not only 
      provide the structural evidence of esterase activity of HSA, and demonstrate the 
      conformational plasticity of HSA on drug binding, but also may provide structural 
      information for the modulation of HSA-drug interaction by computational approach 
      based on HSA-drug structure.
FAU - Yang, Feng
AU  - Yang F
AD  - State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the 
      Structure of Matter, 155 Yang Qiao Xi Lu, Fuzhou, Fujian 350002, People's 
      Republic of China.
FAU - Bian, Chuanbing
AU  - Bian C
FAU - Zhu, Lili
AU  - Zhu L
FAU - Zhao, Gengxiang
AU  - Zhao G
FAU - Huang, Zixiang
AU  - Huang Z
FAU - Huang, Mingdong
AU  - Huang M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060909
PL  - United States
TA  - J Struct Biol
JT  - Journal of structural biology
JID - 9011206
RN  - 0 (Salicylates)
RN  - 0 (Serum Albumin)
RN  - 0I3V7S25AW (Myristic Acid)
RN  - EC 3.1.- (Esterases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/chemistry
MH  - Crystallography
MH  - Esterases/*chemistry/metabolism/*physiology
MH  - Humans
MH  - *Inactivation, Metabolic
MH  - Models, Molecular
MH  - Myristic Acid/chemistry/metabolism
MH  - Protein Binding
MH  - Salicylates/chemistry/metabolism
MH  - Serum Albumin/*chemistry/metabolism/*physiology
EDAT- 2006/10/28 09:00
MHDA- 2007/04/20 09:00
CRDT- 2006/10/28 09:00
PHST- 2006/07/07 00:00 [received]
PHST- 2006/08/24 00:00 [revised]
PHST- 2006/08/25 00:00 [accepted]
PHST- 2006/10/28 09:00 [pubmed]
PHST- 2007/04/20 09:00 [medline]
PHST- 2006/10/28 09:00 [entrez]
AID - S1047-8477(06)00279-6 [pii]
AID - 10.1016/j.jsb.2006.08.015 [doi]
PST - ppublish
SO  - J Struct Biol. 2007 Feb;157(2):348-55. doi: 10.1016/j.jsb.2006.08.015. Epub 2006 
      Sep 9.

PMID- 32962804
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 135
DP  - 2020 Nov 15
TI  - Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following 
      Percutaneous Coronary Intervention.
PG  - 154-165
LID - S0002-9149(20)30858-4 [pii]
LID - 10.1016/j.amjcard.2020.07.061 [doi]
AB  - Dual antiplatelet therapy (DAPT) reduces ischemic and thrombotic events after 
      percutaneous coronary intervention (PCI). Initial reports of higher myocardial 
      infarction and mortality rates prompted guideline committees to choose 12-month 
      duration of DAPT after PCI. However, higher bleeding rates with DAPT remain a 
      major concern. Since these guidelines were published, there have been 
      improvements in stent design, deployment techniques, and antiplatelet therapies, 
      which have reduced ischemic events. To address bleeding concerns, trials were 
      performed to evaluate the effectiveness of short-duration DAPT. Two main 
      strategies were employed: (1) aspirin monotherapy after a short-duration DAPT, 
      and (2) P2Y12 inhibitor monotherapy after a short-duration DAPT. In this review, 
      we outline all the major trials on short-duration DAPT that have examined the 
      previously mentioned strategies and propose a new individualized treatment 
      algorithm for which monotherapy to choose or remove after PCI. In conclusion, 
      while removing the P2Y12 inhibitor after a short DAPT appears to be safe in the 
      low-risk population, removing aspirin and continuing the P2Y12 inhibitor as 
      monotherapy would be the preferred strategy in intermediate- to high-risk 
      patients to mitigate the bleeding risk.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Yerasi, Charan
AU  - Yerasi C
AD  - Section of Interventional Cardiology, MedStar Washington Hospital Center, 
      Washington, District of Columbia.
FAU - Case, Brian C
AU  - Case BC
AD  - Section of Interventional Cardiology, MedStar Washington Hospital Center, 
      Washington, District of Columbia.
FAU - Forrestal, Brian J
AU  - Forrestal BJ
AD  - Section of Interventional Cardiology, MedStar Washington Hospital Center, 
      Washington, District of Columbia.
FAU - Torguson, Rebecca
AU  - Torguson R
AD  - Section of Interventional Cardiology, MedStar Washington Hospital Center, 
      Washington, District of Columbia.
FAU - Weintraub, William S
AU  - Weintraub WS
AD  - Section of Interventional Cardiology, MedStar Washington Hospital Center, 
      Washington, District of Columbia.
FAU - Garcia-Garcia, Hector M
AU  - Garcia-Garcia HM
AD  - Section of Interventional Cardiology, MedStar Washington Hospital Center, 
      Washington, District of Columbia.
FAU - Waksman, Ron
AU  - Waksman R
AD  - Section of Interventional Cardiology, MedStar Washington Hospital Center, 
      Washington, District of Columbia. Electronic address: ron.waksman@medstar.net.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20200815
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dual Anti-Platelet Therapy/*methods
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Hemorrhage/chemically induced/*prevention & control
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Postoperative Complications/*prevention & control
MH  - Purinergic P2Y Receptor Antagonists/*administration & dosage
MH  - Time Factors
EDAT- 2020/09/24 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/23 06:03
PHST- 2020/06/02 00:00 [received]
PHST- 2020/07/24 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/23 06:03 [entrez]
AID - S0002-9149(20)30858-4 [pii]
AID - 10.1016/j.amjcard.2020.07.061 [doi]
PST - ppublish
SO  - Am J Cardiol. 2020 Nov 15;135:154-165. doi: 10.1016/j.amjcard.2020.07.061. Epub 
      2020 Aug 15.

PMID- 12639678
OWN - NLM
STAT- MEDLINE
DCOM- 20030625
LR  - 20190714
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 61
IP  - 3
DP  - 2003 Mar
TI  - Effect of castration on acetyl salicylic acid metabolism in rabbits.
PG  - 651-5
AB  - OBJECTIVES: The biotransformation of acetyl salicylic acid (ASA) differs within 
      species, and gender differences have been documented and attributed to the effect 
      of sex hormones. Castration remains a standard therapy for men with advanced 
      prostate cancer. We studied the effect of castration on the metabolism of ASA in 
      rabbits to find out whether the metabolism of ASA is adversely affected after 
      castration. METHODS: ASA in doses of 12.5, 25, and 50 mg/kg body weight was given 
      intravenously to male and female prepubertal and adult rabbits, castrated adult 
      male rabbits, and castrated male rabbits given testosterone (3 animals per 
      group). Blood samples were collected at 0, 10, 30, 60, 120, and 180 minutes. The 
      high-performance liquid chromatography method was used for the quantitation of 
      salicylic acid (SA) in serum. The percentage of SA not metabolized was determined 
      by comparing the serum level at 10 and 180 minutes for each group. RESULTS: At a 
      dose of 50 mg/kg in the adult rabbits, the mean +/- SD of SA in serum at 10 and 
      180 minutes was 146.54 +/- 29.54 microg/mL and 19.12 +/- 5.93 microg/mL for 
      males, 158.25 +/- 6.70 microg/mL and 33.24 +/- 2.78 microg/mL for females, 229.72 
      +/- 47.85 microg/mL and 44.33 +/- 5.64 microg/mL for castrated male rabbits, and 
      170.88 +/- 12.03 microg/mL and 68.1 +/- 37.54 microg/mL for castrated male 
      rabbits given testosterone, respectively. Also, at 180 minutes, the percentage of 
      SA not metabolized in adult male rabbits was 12.82% +/- 1.65% compared with 
      21.04% +/- 2.14% (P <0.01) in adult females, 19.53% +/- 1.73% (P <0.01) in 
      castrated adult male rabbits, and 38.95% +/- 19.48% (P <0.001) in castrated male 
      rabbits given testosterone. At all doses of ASA, the serum SA concentration in 
      male and female prepubertal rabbits was not significantly different for each time 
      point. CONCLUSIONS: These results indicate that male rabbits are able to 
      metabolize ASA faster than are females. After castration, this ability is 
      significantly decreased. If these experimental results are confirmed in humans, 
      men who are undergoing hormonal manipulation for advanced prostate cancer and who 
      require high-dose ASA, such as in the treatment of stroke or rheumatoid arthritis 
      or as an antioxidant, may need lower doses to reduce the possible toxic effects 
      of ASA.
FAU - Kehinde, E O
AU  - Kehinde EO
AD  - Department of Surgery, Kuwait University Faculty of Medicine, Sufat, Kuwait.
FAU - Eldeen, A Shihab
AU  - Eldeen AS
FAU - Ayesha, A
AU  - Ayesha A
FAU - Anim, J T
AU  - Anim JT
FAU - Memon, A
AU  - Memon A
FAU - Al-Sulaiman, S M
AU  - Al-Sulaiman SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Androgen Antagonists)
RN  - 3XMK78S47O (Testosterone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Androgen Antagonists/adverse effects/therapeutic use
MH  - Animals
MH  - Aspirin/blood/*metabolism/therapeutic use
MH  - Biotransformation/drug effects
MH  - *Castration
MH  - Chromatography, High Pressure Liquid
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Male
MH  - Ovary/metabolism
MH  - Prostatic Neoplasms/complications/drug therapy/metabolism
MH  - Rabbits
MH  - Sex Factors
MH  - Testis/metabolism
MH  - Testosterone/pharmacology
EDAT- 2003/03/18 04:00
MHDA- 2003/06/26 05:00
CRDT- 2003/03/18 04:00
PHST- 2003/03/18 04:00 [pubmed]
PHST- 2003/06/26 05:00 [medline]
PHST- 2003/03/18 04:00 [entrez]
AID - S0090429502022793 [pii]
AID - 10.1016/s0090-4295(02)02279-3 [doi]
PST - ppublish
SO  - Urology. 2003 Mar;61(3):651-5. doi: 10.1016/s0090-4295(02)02279-3.

PMID- 22209867
OWN - NLM
STAT- MEDLINE
DCOM- 20120413
LR  - 20211025
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
VI  - 83
IP  - 6
DP  - 2012 Mar 15
TI  - Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen 
      receptor negative breast cancer cells in vitro and in vivo.
PG  - 723-32
LID - 10.1016/j.bcp.2011.12.019 [doi]
AB  - Hormone-dependent estrogen receptor positive (ER+) breast cancers generally 
      respond well to anti-estrogen therapy. Unfortunately, hormone-independent 
      estrogen receptor negative (ER-) breast cancers are aggressive, respond poorly to 
      current treatments and have a poor prognosis. New approaches and targets are 
      needed for the prevention and treatment of ER- breast cancer. The NF-κB signaling 
      pathway is strongly implicated in ER- tumor genesis, constituting a possible 
      target for treatment. Hydrogen sulfide-releasing aspirin (HS-ASA), a novel and 
      safer derivative of aspirin, has shown promise as an anti-cancer agent. We 
      examined the growth inhibitory effect of HS-ASA via alterations in cell 
      proliferation, cell cycle phase transitions, and apoptosis, using MDA-MB-231 
      cells as a model of triple negative breast cancer. Tumor xenografts in mice, 
      representing human ER- breast cancer, were evaluated for reduction in tumor size, 
      followed by immunohistochemical analysis for proliferation, apoptosis and 
      expression of NF-κB. HS-ASA suppressed the growth of MDA-MB-231 cells by 
      induction of G(0)/G(1) arrest and apoptosis, down-regulation of NF-κB, reduction 
      of thioredoxin reductase activity, and increased levels reactive oxygen species. 
      Tumor xenografts in mice, were significantly reduced in volume and mass by HS-ASA 
      treatment. The decrease in tumor mass was associated with inhibition of cell 
      proliferation, induction of apoptosis and decrease in NF-κB levels in vivo. 
      HS-ASA has anti-cancer potential against ER- breast cancer and merits further 
      study.
CI  - Copyright © 2011 Elsevier Inc. All rights reserved.
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
AD  - Department of Physiology and Pharmacology, Sophie Davis School of Biomedical 
      Education, City University of New York Medical School, New York, NY 10031, United 
      States.
FAU - Kodela, Ravinder
AU  - Kodela R
FAU - Nath, Niharika
AU  - Nath N
FAU - Barsegian, Arpine
AU  - Barsegian A
FAU - Boring, Daniel
AU  - Boring D
FAU - Kashfi, Khosrow
AU  - Kashfi K
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20111224
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (4-(5-thioxo-5H-1,2-dithiol-3-yl)-phenyl 2-acetoxybenzoate)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (NF-kappa B)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Thiones)
RN  - EC 1.8.1.9 (Thioredoxin-Disulfide Reductase)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Breast Neoplasms/drug therapy/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Female
MH  - Humans
MH  - Hydrogen Sulfide/chemistry/*metabolism
MH  - Mice
MH  - NF-kappa B/*antagonists & inhibitors
MH  - Reactive Oxygen Species/metabolism
MH  - Receptors, Estrogen/genetics/*metabolism
MH  - Signal Transduction/drug effects
MH  - Thiones/chemistry/*pharmacology
MH  - Thioredoxin-Disulfide Reductase/metabolism
MH  - Xenograft Model Antitumor Assays
EDAT- 2012/01/03 06:00
MHDA- 2012/04/14 06:00
CRDT- 2012/01/03 06:00
PHST- 2011/09/14 00:00 [received]
PHST- 2011/12/09 00:00 [revised]
PHST- 2011/12/15 00:00 [accepted]
PHST- 2012/01/03 06:00 [entrez]
PHST- 2012/01/03 06:00 [pubmed]
PHST- 2012/04/14 06:00 [medline]
AID - S0006-2952(11)00935-X [pii]
AID - 10.1016/j.bcp.2011.12.019 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2012 Mar 15;83(6):723-32. doi: 10.1016/j.bcp.2011.12.019. Epub 
      2011 Dec 24.

PMID- 28025961
OWN - NLM
STAT- MEDLINE
DCOM- 20170726
LR  - 20170726
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 55
IP  - 6
DP  - 2017 Jun
TI  - Prevalence of aspirin resistance in patients with type II diabetes: a 
      descriptive-analytical study .
PG  - 493-497
LID - 10.5414/CP202637 [doi]
AB  - BACKGROUND: Aspirin resistance is one of the most important factors for arterial 
      thrombotic events in diabetic patients. This study aimed to evaluate aspirin 
      resistance in diabetic patients. METHODS: In this cross-sectional study, 
      180 patients who received 80 mg of aspirin daily for at least 10 days were 
      studied, and their urinary 11-DH-TXB2 was measured. Those with 
      11-dehydro-thromboxane B2 above 1,500 pg/mg creatinine were considered aspirin 
      resistant. Data with significance level of 5% were analyzed in SPSS-16. RESULTS: 
      The mean ± SD of patient age was 60.22 ± 9.59 years and 50% (n = 90) were male. 
      BMI was normal in 29.4% of the patients (n = 53), the others were overweight or 
      obese. Aspirin resistance was observed in 33 (18%) patients. The relationship 
      between aspirin resistance and gender, age, and BMI was not significant 
      (p > 0.05). CONCLUSIONS: There is a high prevalence of aspirin resistance in 
      diabetic patients and given that such patients are at risk of arterial thrombotic 
      events, evaluation of aspirin resistance is suggested for those at a high risk of 
      cardiovascular events or recurring events despite the use of aspirin. .
FAU - Eskandarian, Rahimeh
AU  - Eskandarian R
FAU - Razavi, Mohammadreza
AU  - Razavi M
FAU - Fattah, Abolfazal
AU  - Fattah A
FAU - Ghods, Kamran
AU  - Ghods K
FAU - Forozeshfard, Mohammad
AU  - Forozeshfard M
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Prevalence
EDAT- 2016/12/28 06:00
MHDA- 2017/07/27 06:00
CRDT- 2016/12/28 06:00
PHST- 2017/05/18 00:00 [accepted]
PHST- 2016/12/28 06:00 [pubmed]
PHST- 2017/07/27 06:00 [medline]
PHST- 2016/12/28 06:00 [entrez]
AID - 15072 [pii]
AID - 10.5414/CP202637 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2017 Jun;55(6):493-497. doi: 10.5414/CP202637.

PMID- 25218285
OWN - NLM
STAT- MEDLINE
DCOM- 20150302
LR  - 20211021
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 135
IP  - 1
DP  - 2015 Jan
TI  - Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
PG  - 245-52
LID - S0091-6749(14)01030-6 [pii]
LID - 10.1016/j.jaci.2014.07.031 [doi]
AB  - BACKGROUND: Aspirin desensitization followed by high-dose aspirin therapy is 
      routinely performed for patients with aspirin-exacerbated respiratory disease 
      (AERD). Little is known about the contributions of mediators other than cysteinyl 
      leukotrienes to aspirin reactions and to the therapeutic benefit of high-dose 
      aspirin therapy. OBJECTIVE: We investigated differences in urinary eicosanoid 
      metabolite levels and blood eosinophil counts in patients with AERD who tolerate 
      and those who fail aspirin desensitization and also in patients with AERD who 
      were successfully treated with high-dose aspirin therapy. METHODS: Twenty-nine 
      patients with AERD were stratified into those who tolerated aspirin 
      desensitization (group I) and those who did not (group II). Urine was analyzed 
      for eicosanoid metabolites at baseline, during aspirin reactions, and during 
      high-dose aspirin therapy. Blood was analyzed for cell differentials at baseline 
      and during aspirin therapy. RESULTS: Basal prostaglandin D2 metabolite (PGD-M; 
      13.6 ± 2.7 vs 7.0 ± 0.8 pmol/mg creatinine [Cr], P < .05) and thromboxane 
      metabolite (TX-M; 1.4 ± 0.3 vs 0.9 ± 0.1 pmol/mg Cr, P < .01) levels were higher 
      in group II than in group I. During aspirin reactions, PGD-M levels remained 
      unchanged, whereas TX-M levels (0.7 ± 0.1 pmol/mg Cr, P = .07) tended to decrease 
      in group I. In contrast, PGD-M levels increased dramatically in group II (61.3 ± 
      19.9 pmol/mg Cr, P < .05), whereas TX-M levels did not change. The decrease in 
      FEV1 inversely correlated with basal urinary levels of both leukotriene E4 and 
      PGD-M. Blood eosinophil and basophil levels increased and urinary PGD-M levels 
      (2.2 ± 0.8 pmol/mg Cr, P < .001) decreased on 2 months of high-dose aspirin 
      therapy in group I. CONCLUSION: Failure to tolerate aspirin desensitization in a 
      subset of patients with AERD is associated with prostaglandin D2 overproduction. 
      The increase in blood eosinophil and basophil counts during high-dose aspirin 
      therapy might reflect the functional consequences of decreased prostaglandin D2 
      release and the therapeutic benefit of aspirin.
CI  - Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Cahill, Katherine N
AU  - Cahill KN
AD  - Department of Medicine, Harvard Medical School, Boston, Mass; Division of 
      Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, 
      Mass; Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and 
      Women's Hospital, Boston, Mass.
FAU - Bensko, Jillian C
AU  - Bensko JC
AD  - Department of Medicine, Harvard Medical School, Boston, Mass; Division of 
      Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Mass.
FAU - Boyce, Joshua A
AU  - Boyce JA
AD  - Department of Medicine, Harvard Medical School, Boston, Mass; Division of 
      Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, 
      Mass; Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and 
      Women's Hospital, Boston, Mass.
FAU - Laidlaw, Tanya M
AU  - Laidlaw TM
AD  - Department of Medicine, Harvard Medical School, Boston, Mass; Division of 
      Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, 
      Mass; Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and 
      Women's Hospital, Boston, Mass. Electronic address: tlaidlaw@partners.org.
LA  - eng
GR  - U19 AI095219-01/AI/NIAID NIH HHS/United States
GR  - T32 AI007306/AI/NIAID NIH HHS/United States
GR  - U19 AI095219/AI/NIAID NIH HHS/United States
GR  - 5U19AI070412-06/AI/NIAID NIH HHS/United States
GR  - R01 AI078908/AI/NIAID NIH HHS/United States
GR  - K23 HL111113/HL/NHLBI NIH HHS/United States
GR  - AI007306-27/AI/NIAID NIH HHS/United States
GR  - R37 AI052353/AI/NIAID NIH HHS/United States
GR  - K23HL111113-02/HL/NHLBI NIH HHS/United States
GR  - R01 HL117945/HL/NHLBI NIH HHS/United States
GR  - 153556/153044/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140911
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Eicosanoids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/immunology
MH  - Basophils
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/etiology/immunology/therapy
MH  - Eicosanoids/*immunology/urine
MH  - Eosinophils
MH  - Female
MH  - Humans
MH  - Leukocyte Count
MH  - Male
MH  - Middle Aged
MH  - Respiratory Tract Diseases/*chemically induced/*immunology/urine
PMC - PMC4289104
MID - NIHMS616488
OTO - NOTNLM
OT  - Aspirin-exacerbated respiratory disease
OT  - Samter triad
OT  - aspirin desensitization
OT  - asthma
OT  - cysteinyl leukotrienes
OT  - eosinophils
OT  - nasal polyps
OT  - prostaglandin D(2)
OT  - thromboxane
OT  - urinary eicosanoids
EDAT- 2014/09/15 06:00
MHDA- 2015/03/03 06:00
CRDT- 2014/09/15 06:00
PHST- 2014/05/27 00:00 [received]
PHST- 2014/07/01 00:00 [revised]
PHST- 2014/07/15 00:00 [accepted]
PHST- 2014/09/15 06:00 [entrez]
PHST- 2014/09/15 06:00 [pubmed]
PHST- 2015/03/03 06:00 [medline]
AID - S0091-6749(14)01030-6 [pii]
AID - 10.1016/j.jaci.2014.07.031 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2015 Jan;135(1):245-52. doi: 10.1016/j.jaci.2014.07.031. 
      Epub 2014 Sep 11.

PMID- 21936548
OWN - NLM
STAT- MEDLINE
DCOM- 20120214
LR  - 20131121
IS  - 1520-5827 (Electronic)
IS  - 0743-7463 (Linking)
VI  - 27
IP  - 20
DP  - 2011 Oct 18
TI  - Binding affinity of a small molecule to an amorphous polymer in a solvent. Part 
      1: free energy of binding to a binding site.
PG  - 12381-95
LID - 10.1021/la201508m [doi]
AB  - Crystallization is commonly used in a separation and purification process in the 
      production of a wide range of materials in various industries. In industry, 
      crystallization usually starts with heterogeneous nucleation on a foreign 
      surface. The complicated mechanism of heterogeneous nucleation is not well 
      understood; however, we hypothesize that there might be a possible correlation 
      between binding affinity to a surface and enhancement of nucleation. Recent 
      studies show that amorphous polymers can be used to control crystallization, 
      selectively produce pharmaceutical polymorphs, and discover novel pharmaceutical 
      polymorphs. To investigate the possible correlation between the binding affinity 
      of one molecule to key binding sites (local binding) and heterogeneous nucleation 
      activity as well as the possibility of using this binding affinity to help guide 
      the selection of polymers that promote heterogeneous nucleation, we computed the 
      free energy of binding of aspirin to four nonporous cross-linked polymers in an 
      ethanol-water 38 v% mixture. These cross-linked polymers are 
      poly(4-acryloylmorpholine) (PAM), poly(2-carboxyethyl acrylate) (PCEA), 
      poly(4-hydroxylbutyl acrylate) (PHBA), and polystyrene (PS); all of them were 
      cross-linked with divinylbenzene (DVB). These systems were used because their 
      heterogeneous nucleation activities are available in literature, and the ranking 
      is PAM > PCEA > PHBA ≈ PS. We generated three independent surfaces for each 
      polymer and computed the free energy of binding of aspirin to the best binding 
      site that we found on each surface. The average free energies of binding to the 
      best sites of PAM, PCEA, PHBA, and PS are -20.4 ± 1.0, -16.7 ± 1.0, -14.4 ± 1.1, 
      and -13.6 ± 1.1 kcal/mol, respectively. We found that the trend of the magnitudes 
      of the average free energies of binding to the best sites is PAM > PCEA > PHBA ≈ 
      PS. This trend is very similar to that of heterogeneous nucleation activity. Our 
      results suggest the importance of the free energy of binding to key sites (local 
      binding) and the possibility of using this quantity to help guide the selection 
      of polymers that promote heterogeneous nucleation.
CI  - © 2011 American Chemical Society
FAU - Chunsrivirot, Surasak
AU  - Chunsrivirot S
AD  - Computational and Systems Biology, Massachusetts Institute of Technology, 
      Cambridge, Massachusetts 02139, USA.
FAU - Diao, Ying
AU  - Diao Y
FAU - Trout, Bernhardt L
AU  - Trout BL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110921
PL  - United States
TA  - Langmuir
JT  - Langmuir : the ACS journal of surfaces and colloids
JID - 9882736
RN  - 0 (Polymers)
RN  - 0 (Powders)
RN  - 0 (Solvents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Binding Sites
MH  - Computer Simulation
MH  - Molecular Structure
MH  - Polymers/*chemistry/metabolism
MH  - Porosity
MH  - Powders/*chemistry
MH  - Solvents/*chemistry
MH  - Thermodynamics
EDAT- 2011/09/23 06:00
MHDA- 2012/02/15 06:00
CRDT- 2011/09/23 06:00
PHST- 2011/09/23 06:00 [entrez]
PHST- 2011/09/23 06:00 [pubmed]
PHST- 2012/02/15 06:00 [medline]
AID - 10.1021/la201508m [doi]
PST - ppublish
SO  - Langmuir. 2011 Oct 18;27(20):12381-95. doi: 10.1021/la201508m. Epub 2011 Sep 21.

PMID- 32731776
OWN - NLM
STAT- MEDLINE
DCOM- 20220428
LR  - 20220428
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 35
IP  - 12
DP  - 2022 Jun
TI  - Effects of early aspirin therapy on utero-placental hemodynamics in patients at 
      risk of preeclampsia.
PG  - 2304-2310
LID - 10.1080/14767058.2020.1786048 [doi]
AB  - OBJECTIVES: To evaluate the effects of early aspirin therapy on the mean 
      pulsatility index of both uterine arteries (utA PI) at 1st and 2nd trimester in 
      women at risk of preeclampsia (PE). METHODS: Uterine artery (utA) blood flow 
      characteristics were obtained in 315 women, 73 women at risk for PE and early 
      aspirin treatment (group 1), 124 without specific risk factors and no aspirin 
      treatment (group 2) and 118 women with manifest PE (group 3). Mean utA PI of 
      group 1 and group 2 were compared within and between the groups at the 1st and 
      2nd trimester time points. Furthermore, values at 2nd trimester were compared 
      with those of group 3. Observed to expected mean utA PI ratio (O/E ratio) were 
      calculated for comparison between the groups. RESULTS: Mean utA PI of group 1 was 
      significantly higher in the 1st trimester compared to group 2 (1.74 vs. 1.47, 
      p = .0117). In the 2nd trimester mean PI decreased significantly in both groups 
      from 1.74 to 1.16 in group 1 and from 1.47 to 0.90 in group 2 (p < .0001). 
      Nevertheless, the difference between the groups was significantly higher in the 
      2nd trimester than in the 1st trimester (0.29 vs. 0.27, p < .001). Correction for 
      gestational age by analyzing mean utA O/E ratios showed a comparable pattern with 
      a significantly decrease in both groups (1.40 to 1.10 in group 1 and 1.18 to 0.78 
      in group 2, p < .0001), but a significant higher decrease in the 2nd trimester in 
      group 2 (0.31 vs.0.22, p < 0001).The prevalence of PE was 15.1% (11/73) in group 
      1 (4 early/7 late onset PE) and 4.7% (6/124) in group 2 (1 early/5 late onset). 
      Mean utA PI and O/E ratio obtained in the 2nd trimester were higher in all PE 
      cases with no significant difference between early and late onset PE (1.49/1.57 
      and 1.25/1.36 in group 1 and 0.80/0.97 and 0.77/0.99 in group 2). However, mean 
      utA PI and O/E ratio decreased in all cases without PE in both groups, whereas 
      mean utA PI was 1,37 and O/E-ratio was 1,29 in patients with manifest PE at 
      admission, with significantly higher values in early onset than in late onset PE 
      (1.45/1.31 vs. 1.07/1.02, p < .0001). CONCLUSIONS: Our results show that early 
      aspirin treatment leads to a decrease of elevated mean utA PI between 1st and 2nd 
      trimester in patients at elevated risk for PE which is inferior to the decrease 
      observed in women at standard risk for PE. While aspirin improves trophoblast 
      invasion during early second trimester, vascular resistance remains well above 
      average levels. Limited vascular remodeling capacity in the utero-placental 
      perfusion area seems to be the explanation why aspirin does not abrogate PE in 
      all women and has little effect on birth weight. Another explanation might be 
      that a dose of 100 mg aspirin was used as compared to the 150 mg which is 
      recommended today. Our findings underscore the need to study the effects of 
      intervention already during the early stages of trophoblast invasion in the first 
      trimester.
FAU - Malah, Nicole
AU  - Malah N
AD  - Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, 
      Switzerland.
FAU - Hofstaetter, Cornelia
AU  - Hofstaetter C
AD  - Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, 
      Switzerland.
FAU - Raio, Luigi
AU  - Raio L
AD  - Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, 
      Switzerland.
FAU - Surbek, Daniel
AU  - Surbek D
AD  - Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, 
      Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Placenta
MH  - *Pre-Eclampsia/epidemiology
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Pulsatile Flow/physiology
MH  - Ultrasonography, Prenatal
MH  - Uterine Artery/physiology
MH  - Vascular Resistance
OTO - NOTNLM
OT  - 1st and 2nd trimester
OT  - Uterine artery Doppler
OT  - early and late preeclampsia
OT  - early aspirin treatment
EDAT- 2020/08/01 06:00
MHDA- 2022/04/29 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2022/04/29 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - 10.1080/14767058.2020.1786048 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2022 Jun;35(12):2304-2310. doi: 
      10.1080/14767058.2020.1786048. Epub 2020 Jul 30.

PMID- 21316433
OWN - NLM
STAT- MEDLINE
DCOM- 20110804
LR  - 20131121
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 408
IP  - 1-2
DP  - 2011 Apr 15
TI  - Theoretical and experimental investigations into the delamination tendencies of 
      bilayer tablets.
PG  - 102-12
LID - 10.1016/j.ijpharm.2011.02.007 [doi]
AB  - Delamination is one major problem in the production of layered tablets, yet there 
      is little knowledge about the physical reasons for this to occur. The aim of this 
      work was to explore the theoretical influence of thermal stresses and strains 
      that can develop during tabletting and to devise an experimental method that can 
      be used to detect delamination tendencies in bilayered tablets. Theoretical 
      considerations have shown that thermal stresses due to development of heat during 
      powder compaction can result in delamination, and this effect is the more 
      pronounced the larger the Young's modulus for the individual layer materials is. 
      Elastic mismatch further enhances delamination tendencies. Experiments on mixed 
      powder beams showed that there is only limited adhesion between particle surfaces 
      of a model drug (acetylsalicylic acid) and model excipient (lactose monohydrate), 
      indicative of limited adhesion between similar interfaces in layered tablets. A 
      three-point bending test was developed to determine the far field stress 
      intensity factor for bilayered compacts. Under the test conditions employed, 
      lactose monohydrate behaved as a brittle material, whereas acetylsalicylic acid 
      demonstrated ductility, which resulted in considerable differences in the far 
      field stress intensity factor values, depending on whether the excipient or the 
      drug formed the downward facing layer during the bending test. Ductile phase 
      toughening was observed when the drug formed the downward facing layer, and hence 
      for bilayer tablets made from these two powders lactose monohydrate must form the 
      downward facing layer during the test. Using the correct test configuration the 
      far field stress intensity factor correctly predicted practically observed 
      delamination between the two material layers. Hence, the proposed fracture 
      mechanics approach could become a formulation tool in the development of 
      bilayered tablets.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Podczeck, Fridrun
AU  - Podczeck F
AD  - Dept. Mechanical Engineering, University College London, Torrington Place, London 
      WC1E7JE, United Kingdom. f.podczeck@ucl.ac.uk
LA  - eng
PT  - Journal Article
DEP - 20110221
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Powders)
RN  - 0 (Tablets)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - *Hot Temperature
MH  - Lactose/chemistry
MH  - *Models, Theoretical
MH  - Particle Size
MH  - Powders
MH  - *Stress, Mechanical
MH  - Tablets/*chemistry
MH  - Technology, Pharmaceutical/*methods
EDAT- 2011/02/15 06:00
MHDA- 2011/08/05 06:00
CRDT- 2011/02/15 06:00
PHST- 2010/12/17 00:00 [received]
PHST- 2011/02/01 00:00 [revised]
PHST- 2011/02/04 00:00 [accepted]
PHST- 2011/02/15 06:00 [entrez]
PHST- 2011/02/15 06:00 [pubmed]
PHST- 2011/08/05 06:00 [medline]
AID - S0378-5173(11)00123-2 [pii]
AID - 10.1016/j.ijpharm.2011.02.007 [doi]
PST - ppublish
SO  - Int J Pharm. 2011 Apr 15;408(1-2):102-12. doi: 10.1016/j.ijpharm.2011.02.007. 
      Epub 2011 Feb 21.

PMID- 3871786
OWN - NLM
STAT- MEDLINE
DCOM- 19850416
LR  - 20190829
IS  - 0021-9681 (Print)
IS  - 0021-9681 (Linking)
VI  - 38
IP  - 1
DP  - 1985
TI  - Aspirin and gastrointestinal haemorrhage: a methodologic assessment.
PG  - 101-11
AB  - The literature on the association between Aspirin (ASA) use and gastrointestinal 
      haemorrhage (GIH) has been reviewed. Thirteen control-studies were selected and 
      examined for (i) the type of design (ii) the choice of outcome measures, and 
      (iii) the adequacy of satisfying defined causation criteria and the influence of 
      sampling strategies on one of these criteria--strength of association. Of the 13 
      studies seven were large scale randomized control trials (RCTs) and six were 
      case-control studies. Among the outcome measures utilized in these studies and 
      currently available for the assessment of GIH, we found none were uniquely 
      satisfactory for use as a "gold standard". Furthermore, in none of these studies 
      was the particular chosen outcome measure sufficiently satisfactory to allow firm 
      conclusions on the issue of causation. None of the studies adequately met all the 
      defined causation criteria or adequately eliminated the potential biases in the 
      chosen sampling strategies. Thus the evidence that aspirin causes GIH fails to 
      stand up to critical evaluation. This, of course, does not mean that ASA does not 
      cause GIH. However, it is common practice for physicians to advise their patients 
      with a prior history of GIH and or gastrointestinal symptoms to refrain from ASA 
      use. This is probably sound advice in the setting where ASA is being used as a 
      casual or short term analgesic or anti-inflammatory agent. But in the context of 
      severe inflammatory joint disease when the use of ASA is clinically indicated, it 
      should not be withheld on the basis of the risk of GIH. There is a widespread 
      belief in medicine that by implication aspirin and other nonsteroidal anti 
      inflammatory drugs are a common cause of bleeding from the gastrointestinal 
      tract, yet it has been pointed out frequently [1-3] that the evidence to support 
      the belief is weak and circumstantial. Despite this the perceived association of 
      aspirin with gastrointestinal bleeding influences both pharmaceutical and 
      clinical practice and often hinders or prevents the prescription of 
      anti-inflammatory medication to patients with severe inflammatory joint disease. 
      It was felt that a proper critical appraisal of the evidence was essential. It is 
      unfortunate that the evidence most frequently cited implicating ASA as a cause of 
      GIH is almost entirely related to the casual use of the drug. Thus our 
      conclusions must be viewed with some caution in the patient group where this 
      knowledge would be of most importance, that is in patients with inflammatory 
      joint disease.
FAU - Belcon, M C
AU  - Belcon MC
FAU - Rooney, P J
AU  - Rooney PJ
FAU - Tugwell, P
AU  - Tugwell P
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Chronic Dis
JT  - Journal of chronic diseases
JID - 2985123R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Double-Blind Method
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Random Allocation
MH  - Research Design
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1016/0021-9681(85)90013-x [doi]
PST - ppublish
SO  - J Chronic Dis. 1985;38(1):101-11. doi: 10.1016/0021-9681(85)90013-x.

PMID- 6862593
OWN - NLM
STAT- MEDLINE
DCOM- 19830826
LR  - 20190920
IS  - 0360-3997 (Print)
IS  - 0360-3997 (Linking)
VI  - 7
IP  - 2
DP  - 1983 Jun
TI  - Aggregation of equine platelets by PAF (platelet-activating factor).
PG  - 197-203
AB  - Platelet-activating factor (PAF), a lipid released as a result of immediate 
      allergic reactions from basophils and mast cells as well as by a variety of other 
      cell types and stimuli, is one of the most potent platelet agonists and 
      hypotensive agents known. Equine platelets stimulated over a wide range of PAF 
      concentrations aggregated in a time- and dose-dependent manner. Maximum 
      aggregation was observed at concentrations of PAF as low as 3.58 x 10(-14) M with 
      platelet-rich plasma (PRP) and 3.58 x 10(-16) M with washed platelets. 
      Furthermore, the aggregation observed did not appear to be breed-dependent. 
      Finally, the platelet arachidonate pathway appeared to play no role in 
      PAF-induced aggregation as exogenous arachidonate did not enhance the reaction, 
      nor were equine platelets pretreated with 38 microM aspirin inhibited in their 
      response to PAF. This level of aspirin totally inhibited the equine platelet 
      aggregation response to arachidonate.
FAU - Suquet, C M
AU  - Suquet CM
FAU - Leid, R W
AU  - Leid RW
LA  - eng
GR  - 17913/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Inflammation
JT  - Inflammation
JID - 7600105
RN  - 0 (Platelet Activating Factor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*physiology
MH  - Cells, Cultured
MH  - Depression, Chemical
MH  - Horses
MH  - Platelet Activating Factor/*physiology
MH  - *Platelet Aggregation
EDAT- 1983/06/01 00:00
MHDA- 1983/06/01 00:01
CRDT- 1983/06/01 00:00
PHST- 1983/06/01 00:00 [pubmed]
PHST- 1983/06/01 00:01 [medline]
PHST- 1983/06/01 00:00 [entrez]
AID - 10.1007/BF00917823 [doi]
PST - ppublish
SO  - Inflammation. 1983 Jun;7(2):197-203. doi: 10.1007/BF00917823.

PMID- 22508148
OWN - NLM
STAT- MEDLINE
DCOM- 20121024
LR  - 20151119
IS  - 1572-0241 (Electronic)
IS  - 0002-9270 (Linking)
VI  - 107
IP  - 7
DP  - 2012 Jul
TI  - Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of 
      aspirin-related peptic ulcers.
PG  - 1022-9
LID - 10.1038/ajg.2012.87 [doi]
AB  - BACKGROUND: Aspirin-related peptic ulcers are a common disorder. However, whether 
      or not aspirin should be continued during treatment for aspirin-related ulcers 
      remains unclear. AIMS: To compare esomeprazole alone with esomeprazole plus 
      aspirin in the treatment of aspirin-related peptic ulcers and to investigate the 
      independent factors associated with the failure of ulcer healing. METHODS: From 
      January 2008 to July 2011, patients with aspirin-related peptic ulcers were 
      randomized to receive esomeprazole (40 mg per day) alone or esomeprazole (40 mg 
      per day) plus aspirin (100 mg per day) for 8 weeks. The subjects with 
      Helicobacter pylori infection were treated with standard triple therapy. 
      Follow-up endoscopy was carried out at the end of the 8th week. The primary end 
      point was the healing of peptic ulcers. RESULTS: In all, 178 patients (89 
      receiving esomeprazole alone and 89 receiving esomeprazole plus aspirin) were 
      enrolled and underwent follow-up endoscopy. The healing rate of ulcers by 
      modified intention-to-treat analysis was 82.5% (95% confidence interval (CI), 
      74.2-90.8%) among patients treated with esomeprazole alone and 81.5% (95% CI, 
      73.0-90.0%) among patients treated with esomeprazole plus aspirin (difference, 
      1.0%; 95% CI, -11.2 to 12.6%). The per-protocol analysis yielded similar results 
      (healing rate: 83.1% vs. 83.8%, respectively; difference, 0.7%; 95% CI, -11.2 to 
      12.6%). Multivariate analysis disclosed that use of steroids during treatment 
      (odds ratio: 5.6; 95% CI, 1.1-27.7%) was the only independent factor associated 
      with the failure of ulcer healing. CONCLUSIONS: The observed ulcer healing rates 
      were comparable in the esomeprazole and esomeprazole-plus-aspirin groups, but the 
      wide CIs do not rule out clinically meaningful differences of more than 10%.
FAU - Liu, Chun-Peng
AU  - Liu CP
AD  - Department of Internal Medicine, Kaohsiung Veterans General Hospital and National 
      Yang-Ming University, Kaohsiung, Taiwan, ROC.
FAU - Chen, Wen-Chi
AU  - Chen WC
FAU - Lai, Kwok-Hung
AU  - Lai KH
FAU - Mar, Guang-Yuan
AU  - Mar GY
FAU - Lin, Shyr-Yi
AU  - Lin SY
FAU - Ger, Luo-Ping
AU  - Ger LP
FAU - Hsu, Ping-I
AU  - Hsu PI
CN  - Formosa Acid-Related Disease (FARD) Study Group
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120417
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - N3PA6559FT (Esomeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Ulcer Agents/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Chi-Square Distribution
MH  - Drug Therapy, Combination
MH  - Esomeprazole/administration & dosage/*therapeutic use
MH  - Female
MH  - Helicobacter Infections/diagnosis
MH  - Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Peptic Ulcer/*chemically induced/*drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - Taiwan
MH  - Treatment Outcome
EDAT- 2012/04/18 06:00
MHDA- 2012/10/25 06:00
CRDT- 2012/04/18 06:00
PHST- 2012/04/18 06:00 [entrez]
PHST- 2012/04/18 06:00 [pubmed]
PHST- 2012/10/25 06:00 [medline]
AID - ajg201287 [pii]
AID - 10.1038/ajg.2012.87 [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2012 Jul;107(7):1022-9. doi: 10.1038/ajg.2012.87. Epub 2012 
      Apr 17.

PMID- 3730789
OWN - NLM
STAT- MEDLINE
DCOM- 19860925
LR  - 20190705
IS  - 0007-1323 (Print)
IS  - 0007-1323 (Linking)
VI  - 73
IP  - 7
DP  - 1986 Jul
TI  - Effect of the cyclo-oxygenase inhibitor indobufen on platelet accumulation in 
      prosthetic vascular grafts.
PG  - 563-5
AB  - An in vivo method of measuring thrombus deposition and pseudo-intimal thickening 
      in prosthetic arterial grafts in an animal model is described. The effect of 
      indobufen, a new cyclo-oxygenase inhibitor, was evaluated and compared to aspirin 
      plus dipyridamole and placebo in 24 greyhounds. Luminal platelet accumulation 
      expressed as thrombogenicity index was 0.33 +/- 0.07 in the placebo group. This 
      was significantly reduced to 0.14 +/- 0.01 by indobufen (P less than 0.05). The 
      reduction to 0.19 +/- 0.04 by aspirin plus dipyridamole failed to achieve 
      statistical significance. Pseudointimal thickness when measured 28 days after 
      implacement was significantly reduced to 21.4 +/- 10.6 per cent by indobufen (P 
      less than 0.01) and 29.4 +/- 10.6 per cent by aspirin plus dipyridamole (P less 
      than 0.02) compared to 75 +/- 10 per cent found in the placebo group. This 
      prosthetic graft model has considerable advantages in the evaluation of potential 
      platelet inhibitory drugs for use in vascular surgery.
FAU - Lane, I F
AU  - Lane IF
FAU - Irwin, J T
AU  - Irwin JT
FAU - Jennings, S A
AU  - Jennings SA
FAU - Poskitt, K R
AU  - Poskitt KR
FAU - Meek, A C
AU  - Meek AC
FAU - McCollum, C N
AU  - McCollum CN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 6T9949G4LZ (indobufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - *Blood Vessel Prosthesis
MH  - Dipyridamole/therapeutic use
MH  - Disease Models, Animal
MH  - Dogs
MH  - Drug Evaluation
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Isoindoles
MH  - Phenylbutyrates/*therapeutic use
MH  - Platelet Aggregation/*drug effects
EDAT- 1986/07/01 00:00
MHDA- 1986/07/01 00:01
CRDT- 1986/07/01 00:00
PHST- 1986/07/01 00:00 [pubmed]
PHST- 1986/07/01 00:01 [medline]
PHST- 1986/07/01 00:00 [entrez]
AID - 10.1002/bjs.1800730715 [doi]
PST - ppublish
SO  - Br J Surg. 1986 Jul;73(7):563-5. doi: 10.1002/bjs.1800730715.

PMID- 364762
OWN - NLM
STAT- MEDLINE
DCOM- 19790223
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 40
IP  - 1
DP  - 1978 Aug 31
TI  - The inhibitory effect of aspirin on human endothelial cells.
PG  - 103-10
AB  - Human endothelial cell monolayers prepared from umbilical veins have been 
      incubated with aspirin (1--2 mM) dissolved in Hepes modified solution and in 
      platelet-rich plasma. They have also been incubated with plasma prepared from 
      subjects before and after intake of aspirin giving a mean plasma concentration of 
      0.5 mM. The effects of the endothelial cells on ADP and collagen-induced platelet 
      aggregation and malondialdehyde production in platelet-rich plasma have been 
      tested. The endothelial cells had a spontaneous inhibitory effect on all three 
      parameters. This effect was abolished when the cells were incubated with aspirin 
      dissolved in MHS for 20 min and the increase in effect observed when 
      platelet-rich plasma was incubated with endothelial cells for a period of 30 min 
      was similarly inhibited when aspirin was dissolved in plasma or when plasma 
      prepared from subjects who had taken aspirin were used. Aspirin had no inhibitory 
      effect on prostacyclin (PGI2) with regard to the effect of PGI2 on platelets. On 
      the contrary, the two compounds had an additive inhibitory effect on platelet 
      aggregation induced by ADP and collagen. These findings should be considered with 
      regard to the use of aspirin as an antithrombotic agent.
FAU - Nordoy, A
AU  - Nordoy A
FAU - Svensson, B
AU  - Svensson B
FAU - Schroeder, C
AU  - Schroeder C
FAU - Hoak, J C
AU  - Hoak JC
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Endothelium/drug effects
MH  - Epoprostenol/pharmacology
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Umbilical Veins/*drug effects
EDAT- 1978/08/31 00:00
MHDA- 1978/08/31 00:01
CRDT- 1978/08/31 00:00
PHST- 1978/08/31 00:00 [pubmed]
PHST- 1978/08/31 00:01 [medline]
PHST- 1978/08/31 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1978 Aug 31;40(1):103-10.

PMID- 19595669
OWN - NLM
STAT- MEDLINE
DCOM- 20090820
LR  - 20131121
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 387
IP  - 2
DP  - 2009 Sep 18
TI  - Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in 
      human glioblastoma A172 cells.
PG  - 342-7
LID - 10.1016/j.bbrc.2009.07.022 [doi]
AB  - Aspirin has been reported to induce apoptosis in various cancer cell lines. 
      However, the apoptotic effects of aspirin on human brain tumor cells are not well 
      understood. Here, we have assessed the effect of aspirin on human gliobalstoma 
      cell line A172 and found that aspirin induced the apoptosis of A172 cells, as 
      determined by TUNEL assay, FACS analysis, and Hoechst staining. The underlying 
      mechanism of this effect consists of reduction in the level of phosphorylated 
      STAT3 (Tyr705), a transcription factor required for survival of A172 cells. 
      Moreover, the expression of STAT3 target genes such as Cyclin D1, XIAP, and Bcl-2 
      that are essential for cell growth and survival was apparently attenuated after 
      aspirin treatment. We also showed that the expression and secretion of 
      interleukin-6 (IL-6), leading to STAT3 phosphorylation, was inhibited by aspirin. 
      When administered exogenous IL-6 to aspirin-treated A172 cells, the 
      phosphorylation of STAT3 and cellular apoptosis were restrained compared to 
      aspirin only-treated cells. Taken together, our results indicate that aspirin 
      causes apoptosis via down-regulation of IL-6-dependent STAT3 signaling, 
      suggesting that aspirin could be therapeutically useful for a potential 
      anti-glioblastoma therapeutic approach.
FAU - Kim, Su-Ryun
AU  - Kim SR
AD  - Department of Molecular Biology, College of Natural Science, Pusan National 
      University, Busan 602-739, South Korea.
FAU - Bae, Moon-Kyoung
AU  - Bae MK
FAU - Kim, Jee-Young
AU  - Kim JY
FAU - Wee, Hee-Jun
AU  - Wee HJ
FAU - Yoo, Mie-Ae
AU  - Yoo MA
FAU - Bae, Soo-Kyung
AU  - Bae SK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090710
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interleukin-6)
RN  - 0 (STAT3 Transcription Factor)
RN  - 42HK56048U (Tyrosine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/antagonists & inhibitors/*pharmacology
MH  - *Apoptosis
MH  - Aspirin/antagonists & inhibitors/*pharmacology
MH  - Cell Line, Tumor
MH  - Glioblastoma/*metabolism
MH  - Humans
MH  - Interleukin-6/*antagonists & inhibitors/pharmacology
MH  - Phosphorylation/drug effects
MH  - STAT3 Transcription Factor/*antagonists & inhibitors
MH  - Signal Transduction/drug effects
MH  - Tyrosine/metabolism
EDAT- 2009/07/15 09:00
MHDA- 2009/08/21 09:00
CRDT- 2009/07/15 09:00
PHST- 2009/06/24 00:00 [received]
PHST- 2009/07/03 00:00 [accepted]
PHST- 2009/07/15 09:00 [entrez]
PHST- 2009/07/15 09:00 [pubmed]
PHST- 2009/08/21 09:00 [medline]
AID - S0006-291X(09)01355-2 [pii]
AID - 10.1016/j.bbrc.2009.07.022 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2009 Sep 18;387(2):342-7. doi: 
      10.1016/j.bbrc.2009.07.022. Epub 2009 Jul 10.

PMID- 11234849
OWN - NLM
STAT- MEDLINE
DCOM- 20010531
LR  - 20190729
IS  - 1060-3271 (Print)
IS  - 1060-3271 (Linking)
VI  - 84
IP  - 1
DP  - 2001 Jan-Feb
TI  - Simultaneous determination of ascorbic acid and acetylsalicylic acid in 
      pharmaceutical formulations.
PG  - 37-42
AB  - A direct, simple, and practical first-derivative spectrophotometric method is 
      described for simultaneous determination of ascorbic acid and acetylsalicylic 
      acid. The effects of the solvent, excipients, and spectral variables on the 
      analytical signal were investigated. The drugs were determined simultaneously 
      with a 0.01 M methanolic hydrochloric acid solution as the solvent, and the 
      signals were evaluated directly by using the zero-crossing method at 245.0 and 
      256.0 nm for acetylsalicylic acid and ascorbic acid, respectively. The method 
      allows the simultaneous determinations of acetylsalicylic acid and ascorbic acid 
      in the ranges of 6.6 x 10(-6) to 1.5 x 10(-4)M and 3.4 x 10(-6) to 2.0 x 10(-4)M, 
      respectively, with standard deviation of <2.0%. The proposed method was applied 
      to determinations of these drugs in tablets.
FAU - Toral, M I
AU  - Toral MI
AD  - University of Chile, Faculty of Sciences, Department of Chemistry, Santiago.
FAU - Lara, N
AU  - Lara N
FAU - Richter, P
AU  - Richter P
FAU - Tassara, A
AU  - Tassara A
FAU - Tapia, A E
AU  - Tapia AE
FAU - Rodriguez, C
AU  - Rodriguez C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J AOAC Int
JT  - Journal of AOAC International
JID - 9215446
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Solvents)
RN  - 0 (Tablets)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis
MH  - Ascorbic Acid/*analysis
MH  - Aspirin/*analysis
MH  - Calibration
MH  - Drug Combinations
MH  - Indicators and Reagents
MH  - Solvents
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets
EDAT- 2001/03/10 10:00
MHDA- 2001/06/02 10:01
CRDT- 2001/03/10 10:00
PHST- 2001/03/10 10:00 [pubmed]
PHST- 2001/06/02 10:01 [medline]
PHST- 2001/03/10 10:00 [entrez]
PST - ppublish
SO  - J AOAC Int. 2001 Jan-Feb;84(1):37-42.

PMID- 28213047
OWN - NLM
STAT- MEDLINE
DCOM- 20170803
LR  - 20181202
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 130
IP  - 7
DP  - 2017 Jul
TI  - The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence.
PG  - 826-832
LID - S0002-9343(17)30129-8 [pii]
LID - 10.1016/j.amjmed.2017.01.022 [doi]
AB  - BACKGROUND: Multiple studies have shown an association between aspirin treatment 
      and a reduction in newly diagnosed cancer. Conversely, there are conflicting 
      clinical and laboratory data on the effect of combined clopidogrel and aspirin 
      therapy on cancer incidence, including analyses suggesting an increased cancer 
      risk. No large-scale cohort study has been performed to address this issue in a 
      heterogeneous real-world scenario. We investigated the effect of clopidogrel and 
      aspirin on cancer incidence compared with aspirin alone and no antiplatelet 
      therapy. METHODS: A population-based historical cohort study of subjects aged ≥50 
      years covered by Clalit Health Services, an Israeli health maintenance 
      organization, was performed. Patients treated with the newer antiplatelet drugs, 
      prasugrel or ticagrelor, which, like clopidogrel, inhibit adenosine diphosphate 
      receptors, and those with prior cancer were excluded. Prescription records of 
      antiplatelet medication were retrieved. RESULTS: The cohort included 183,912 
      subjects diagnosed with 21,974 cancer cases based upon the International 
      Classification of Diseases, Ninth Revision. Dual aspirin and clopidogrel was 
      prescribed in 9.6%, while 49% received aspirin alone and 41% used neither. 
      Compared with nonusers, there was a lower risk of cancer in subjects exposed to 
      aspirin with (hazard ratio [HR] 0.46; 95% confidence interval [CI], 0.44-0.49) or 
      without clopidogrel (HR 0.54; 95% CI, 0.52-0.56), on long-term follow-up. 
      Combined treatment was associated with a lower cancer risk than the aspirin-only 
      group (HR 0.92; 95% CI, 0.86-0.97). CONCLUSIONS: Dual clopidogrel and aspirin 
      treatment is safe regarding the cancer risk. This study generates the hypothesis 
      that clopidogrel may reduce cancer incidence.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Leader, Avi
AU  - Leader A
AD  - Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin 
      Medical Center, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv 
      University, Israel.
FAU - Zelikson-Saporta, Ravit
AU  - Zelikson-Saporta R
AD  - Sackler School of Medicine, Tel Aviv University, Israel; Department of Medicine 
      A, Meir Medical Center, Kfar Saba, Israel.
FAU - Pereg, David
AU  - Pereg D
AD  - Sackler School of Medicine, Tel Aviv University, Israel; Department of 
      Cardiology, Meir Medical Center, Kfar Saba, Israel.
FAU - Spectre, Galia
AU  - Spectre G
AD  - Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin 
      Medical Center, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv 
      University, Israel.
FAU - Rozovski, Uri
AU  - Rozovski U
AD  - Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin 
      Medical Center, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv 
      University, Israel.
FAU - Raanani, Pia
AU  - Raanani P
AD  - Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin 
      Medical Center, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv 
      University, Israel.
FAU - Hermoni, Doron
AU  - Hermoni D
AD  - Sackler School of Medicine, Tel Aviv University, Israel; Department of Family 
      Medicine, Sharon-Shomron District, Clalit Health Services, Netanya, Israel.
FAU - Lishner, Michael
AU  - Lishner M
AD  - Sackler School of Medicine, Tel Aviv University, Israel; Department of Medicine 
      A, Meir Medical Center, Kfar Saba, Israel. Electronic address: 
      michael2@clalit.org.il.
LA  - eng
PT  - Journal Article
DEP - 20170214
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2017 Jul 18;167(2):JC10. PMID: 28715832
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*epidemiology
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Antiplatelet
OT  - Aspirin
OT  - Cancer
OT  - Clopidogrel
EDAT- 2017/02/19 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/02/19 06:00
PHST- 2016/08/29 00:00 [received]
PHST- 2016/10/27 00:00 [revised]
PHST- 2017/01/24 00:00 [accepted]
PHST- 2017/02/19 06:00 [pubmed]
PHST- 2017/08/05 06:00 [medline]
PHST- 2017/02/19 06:00 [entrez]
AID - S0002-9343(17)30129-8 [pii]
AID - 10.1016/j.amjmed.2017.01.022 [doi]
PST - ppublish
SO  - Am J Med. 2017 Jul;130(7):826-832. doi: 10.1016/j.amjmed.2017.01.022. Epub 2017 
      Feb 14.

PMID- 28410506
OWN - NLM
STAT- MEDLINE
DCOM- 20180312
LR  - 20180312
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 154
DP  - 2017 Jun
TI  - Inhibitory effect of Campomanesia xanthocarpa in platelet aggregation: Comparison 
      and synergism with acetylsalicylic acid.
PG  - 42-49
LID - S0049-3848(17)30246-3 [pii]
LID - 10.1016/j.thromres.2017.03.020 [doi]
AB  - BACKGROUND AND AIMS: Cardiovascular diseases of thrombotic origin are related to 
      high mortality and standard therapeutic agent used in this case is 
      acetylsalicylic acid (ASA), but serious adverse events may occur. However, recent 
      data has suggested the plant Campomanesia xanthocarpa has antiplatelet activity 
      and could be a viable alternative. In this study we investigated the effects of 
      the encapsulated powder of this plant in human platelet aggregation. METHODS: 23 
      healthy subjects were randomly divided into three groups: (1) ASA (100mg), (2) C. 
      xanthocarpa (1000mg) or (3) synergism (500mg of C. xanthocarpa plush 50mg of 
      ASA); daily for five days. Antiplatelet activity was determined by turbidimetric 
      method using ADP or arachidonic acid (AA) agonists before, 5 and 8days after 
      treatments. RESULTS: Treatment with C. xanthocarpa and synergism caused a 
      reduction of 8±13.5% and 12.5±5% in platelet aggregation induced by ADP after 
      5days of treatment, respectively, returning to basal levels after 8days. For AA 
      agonist, 5days of treatment with C. xanthocarpa, ASA or synergism caused a 
      reduction of 46±15%, 36±12% and 69.3±6% in platelet aggregation, respectively, 
      and first two groups returned to baseline values 8days after treatment ended. 
      Synergism group prolonged antiplatelet effect maintaining aggregation reduction 
      after 8days the end of treatment. CONCLUSION: C. xanthocarpa showed antiplatelet 
      action when stimulated by agonist AA, and contributed to the antiplatelet effect 
      when associated with ASA for both agonists, allowing dose reduction to 50mg.
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - Otero, Juliana Soares
AU  - Otero JS
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil.
FAU - Hirsch, Gabriela Elisa
AU  - Hirsch GE
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil.
FAU - Klafke, Jonatas Zeni
AU  - Klafke JZ
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil. Electronic address: jklafke@unicruz.edu.br.
FAU - Porto, Fernando Garcez
AU  - Porto FG
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil.
FAU - de Almeida, Amanda Spring
AU  - de Almeida AS
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil.
FAU - Nascimento, Sabrina
AU  - Nascimento S
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil.
FAU - Schmidt, Aline
AU  - Schmidt A
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil.
FAU - da Silva, Brenda
AU  - da Silva B
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil.
FAU - Pereira, Roberta Lelis Dias
AU  - Pereira RLD
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil.
FAU - Jaskulski, Mônica
AU  - Jaskulski M
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil.
FAU - Parisi, Mariana Migliorini
AU  - Parisi MM
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil.
FAU - Dos Santos Guarda, Naiara
AU  - Dos Santos Guarda N
AD  - Laboratório de Bioquímica Clínica, Departamento de Análises Clínicas e 
      Toxicológicas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, 
      97105-900 Santa Maria, RS, Brazil.
FAU - Moresco, Rafael Noal
AU  - Moresco RN
AD  - Laboratório de Bioquímica Clínica, Departamento de Análises Clínicas e 
      Toxicológicas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, 
      97105-900 Santa Maria, RS, Brazil.
FAU - Aita, Carlos Alberto Mayora
AU  - Aita CAM
AD  - Centro de Ciências Biológicas e da Saúde, Pontifícia Universidade Católica do 
      Paraná (PUC-PR), 80215-901 Curitiba, PR, Brazil.
FAU - Viecili, Paulo Ricardo Nazário
AU  - Viecili PRN
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Grupo Interdisciplinar de Saúde (GIS), Centro de 
      Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta (ICCA), 98005-096 
      Cruz Alta, RS, Brazil. Electronic address: vieciliprn@uol.com.br.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170323
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Plant Extracts)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/cytology/*drug effects
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Male
MH  - *Myrtaceae/chemistry
MH  - Plant Extracts/chemistry/pharmacology/*therapeutic use
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/chemistry/pharmacology/*therapeutic use
MH  - Platelet Function Tests
MH  - Young Adult
OTO - NOTNLM
OT  - Adenosine diphosphate
OT  - Arachidonic acid
OT  - Guavirova
OT  - Medicinal plants
OT  - Nitric oxide
EDAT- 2017/04/15 06:00
MHDA- 2018/03/13 06:00
CRDT- 2017/04/15 06:00
PHST- 2016/11/03 00:00 [received]
PHST- 2017/02/15 00:00 [revised]
PHST- 2017/03/21 00:00 [accepted]
PHST- 2017/04/15 06:00 [pubmed]
PHST- 2018/03/13 06:00 [medline]
PHST- 2017/04/15 06:00 [entrez]
AID - S0049-3848(17)30246-3 [pii]
AID - 10.1016/j.thromres.2017.03.020 [doi]
PST - ppublish
SO  - Thromb Res. 2017 Jun;154:42-49. doi: 10.1016/j.thromres.2017.03.020. Epub 2017 
      Mar 23.

PMID- 28673738
OWN - NLM
STAT- MEDLINE
DCOM- 20180503
LR  - 20180503
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 244
DP  - 2017 Oct 1
TI  - Chronic use of low-dose aspirin is not associated with lower bone mineral density 
      in the general population.
PG  - 298-302
LID - S0167-5273(17)32102-2 [pii]
LID - 10.1016/j.ijcard.2017.06.089 [doi]
AB  - BACKGROUND: Low-dose aspirin is the cornerstone of secondary prevention of 
      cardiovascular disease. Previous studies suggested that the use of aspirin is 
      associated with an increased fracture risk. However, there is uncertainty whether 
      this is due to an effect of aspirin on bone mineral density (BMD). METHODS: 
      Between 2008 and 2012, information on medication use and dual X-ray 
      absorptiometry measured vertebral and femoral BMD of 916 participants was 
      collected in the Netherland Epidemiology of Obesity study. The cross-sectional 
      association between chronic low-dose aspirin use and BMD was estimated using 
      linear regression, controlling for demography, body composition, comorbidity and 
      other medication use which could affect BMD. A subgroup analysis in 
      postmenopausal women (n=329) was conducted. RESULTS: After full adjustment, there 
      was no difference between aspirin users and non-users for vertebral BMD (adjusted 
      mean difference: 0.036 (95% CI -0.027 to 0.100) g/cm(2)) and femoral BMD 
      (adjusted mean difference: 0.001 (-0.067 to 0.069) g/cm(2)). Also in the subgroup 
      of postmenopausal women, aspirin use was not associated with lower vertebral 
      (adjusted mean difference: 0.069 (-0.046 to 0.184) g/cm(2)) or femoral BMD 
      (adjusted mean difference: -0.055 (-0.139;0.029) g/cm(2)). CONCLUSION: Chronic 
      use of low-dose aspirin is not associated with lower BMD in the general 
      population. The increased risk of fractures observed in aspirin users in previous 
      studies is therefore more likely to be the result of common causes of aspirin use 
      and fractures, but not of direct effects of aspirin on BMD.
CI  - Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.
FAU - Bonten, T N
AU  - Bonten TN
AD  - Department of Public Health & Primary Care, Leiden University Medical Center, 
      Leiden, The Netherlands; Department of Pulmonology, Leiden University Medical 
      Center, Leiden, The Netherlands. Electronic address: t.n.bonten@lumc.nl.
FAU - de Mutsert, R
AU  - de Mutsert R
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, The 
      Netherlands.
FAU - Rosendaal, F R
AU  - Rosendaal FR
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, The 
      Netherlands.
FAU - Jukema, J W
AU  - Jukema JW
AD  - Department of Cardiology, Leiden University Medical Center, Leiden, The 
      Netherlands.
FAU - van der Bom, J G
AU  - van der Bom JG
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, The 
      Netherlands; JJ van Rood Center for Clinical Transfusion Research, Sanquin 
      Research, Leiden, The Netherlands.
FAU - de Jongh, R T
AU  - de Jongh RT
AD  - Department of Internal Medicine, VU Medical Center, Amsterdam, The Netherlands.
FAU - den Heijer, M
AU  - den Heijer M
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, The 
      Netherlands; Department of Internal Medicine, VU Medical Center, Amsterdam, The 
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20170627
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorptiometry, Photon/trends
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Bone Density/*drug effects/physiology
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - Drug Administration Schedule
MH  - Female
MH  - Femur/*diagnostic imaging/drug effects
MH  - Fractures, Bone/chemically induced/diagnostic imaging/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Netherlands/epidemiology
MH  - *Population Surveillance
MH  - Spine/*diagnostic imaging/drug effects
OTO - NOTNLM
OT  - Aspirin
OT  - Bone mineral density
OT  - Cardiovascular disease
EDAT- 2017/07/05 06:00
MHDA- 2018/05/04 06:00
CRDT- 2017/07/05 06:00
PHST- 2017/04/03 00:00 [received]
PHST- 2017/06/01 00:00 [revised]
PHST- 2017/06/22 00:00 [accepted]
PHST- 2017/07/05 06:00 [pubmed]
PHST- 2018/05/04 06:00 [medline]
PHST- 2017/07/05 06:00 [entrez]
AID - S0167-5273(17)32102-2 [pii]
AID - 10.1016/j.ijcard.2017.06.089 [doi]
PST - ppublish
SO  - Int J Cardiol. 2017 Oct 1;244:298-302. doi: 10.1016/j.ijcard.2017.06.089. Epub 
      2017 Jun 27.

PMID- 30580558
OWN - NLM
STAT- MEDLINE
DCOM- 20191203
LR  - 20191203
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
VI  - 39
IP  - 1
DP  - 2019 Jan
TI  - Advances in Antithrombotic Therapy.
PG  - 7-12
LID - 10.1161/ATVBAHA.118.310960 [doi]
AB  - Thrombosis remains a major cause of morbidity and mortality. Consequently, 
      advances in antithrombotic therapy are needed to reduce the disease burden. This 
      article focuses on 2 such advances. First, the prevention of atherothrombosis in 
      patients with coronary or peripheral artery disease, which has been enhanced by 
      the finding that the combination of low-dose rivaroxaban plus aspirin is superior 
      to aspirin alone for prevention of recurrent ischemic events. However, this 
      benefit comes at the cost of increased bleeding albeit not fatal bleeding. To 
      overcome this problem, the second advance is the identification of factor XI as a 
      target for new anticoagulants that are potentially safer than those currently 
      available.
FAU - Weitz, Jeffrey I
AU  - Weitz JI
AD  - From the Thrombosis and Atherosclerosis Research Institute and Department of 
      Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Chan, Noel C
AU  - Chan NC
AD  - From the Thrombosis and Atherosclerosis Research Institute and Department of 
      Medicine, McMaster University, Hamilton, Ontario, Canada.
LA  - eng
GR  - FDN-159928/CAPMC/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 0 (Fibrinolytic Agents)
RN  - 9001-30-3 (Factor XII)
RN  - 9013-55-2 (Factor XI)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Factor XI/*antagonists & inhibitors/physiology
MH  - Factor XII/physiology
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Rivaroxaban/administration & dosage/therapeutic use
MH  - Thrombosis/etiology/*prevention & control
OTO - NOTNLM
OT  - anticoagulants
OT  - morbidity
OT  - mortality
OT  - myocardial infarction
OT  - stroke
OT  - thrombosis
EDAT- 2018/12/26 06:00
MHDA- 2019/12/04 06:00
CRDT- 2018/12/25 06:00
PHST- 2018/12/26 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2018/12/25 06:00 [entrez]
AID - 10.1161/ATVBAHA.118.310960 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):7-12. doi: 
      10.1161/ATVBAHA.118.310960.

PMID- 12425211
OWN - NLM
STAT- MEDLINE
DCOM- 20021212
LR  - 20131121
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 48
IP  - 8
DP  - 2002 Aug
TI  - [Acetylsalicylic acid (ASA)--is everything clear?].
PG  - 781-90
AB  - The authors summarize results of trials with acetysalicyl acid (ASA) in patients 
      with ischaemic heart disease and in particular with chronic cardiac failure. They 
      draw attention to the relatively frequent use this drug in common practice, 
      although so far not a single trial was completed which would prove the effect of 
      acetylsalicyl acid on long-term mortality. The authors discuss also possible 
      interactions of acetylsalicyl acid and ACE inhibitors which in retrospective 
      analyses indicate possible veakening of the ACE-I when administered concurrently 
      with ASA in cardiac failure. The authors mention also other antiaggregation 
      drugs, which similarly as ASA, significantly reduce the mortality in acute 
      coronary syndrome. Their long-term administration is however not associated with 
      further improvement of the diagnosis. Trials are mentioned which compare 
      antiaggregation and anticolagulation treatment in patients with ischaemic heart 
      disease. They analyze also the effect of dosage (benefit vs. risk). After ASA > 
      300 mg there are more frequent complications, and without a proved effect on 
      total mortality, while doses < or = 100 mg seem to be safer but there is evidence 
      that they are effective in reducing the total mortality of patients with IHD 
      and/or cardiac failure.
FAU - Spinar, J
AU  - Spinar J
AD  - II. interní klinika FN u sv. Anny a Lékarské fakulty MU, Brno.
FAU - Vítovec, J
AU  - Vítovec J
LA  - cze
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - ASA--je nám vse jasné?
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Vnitr Lek. 2002 Aug;48(8):695-7. PMID: 12425197
CIN - Vnitr Lek. 2002 Aug;48(8):698-700. PMID: 12425198
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Interactions
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 59
EDAT- 2002/11/12 04:00
MHDA- 2002/12/13 04:00
CRDT- 2002/11/12 04:00
PHST- 2002/11/12 04:00 [pubmed]
PHST- 2002/12/13 04:00 [medline]
PHST- 2002/11/12 04:00 [entrez]
PST - ppublish
SO  - Vnitr Lek. 2002 Aug;48(8):781-90.

PMID- 8737097
OWN - NLM
STAT- MEDLINE
DCOM- 19961209
LR  - 20190512
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 17
IP  - 5
DP  - 1996 May
TI  - Should all patients with atrial fibrillation receive warfarin? Evidence from 
      randomized clinical trials.
PG  - 674-81
AB  - Anticoagulants should be used more widely in patients with atrial fibrillation. 
      Legitimate concerns exist about the risk/benefit ratio in younger patients with 
      no risk factors and in patients over the age of 75 years. Use of lower doses of 
      anticoagulation (potential target range INR of 1.5-2.5) than used heretofore is 
      probably the solution to most of the problems associated with anticoagulation, 
      but conclusive proof of the efficacy of this strategy is needed. Although aspirin 
      may reduce the risk of stroke the effect may be no more than among patients with 
      a similar level of cardiovascular risk factors and in sinus rhythm. As such, 
      aspirin is a valid alternative for patients with atrial fibrillation at a low 
      risk of stroke but should not be used as an excuse to withhold anticoagulants in 
      patients at greater risk. Several larger studies investigating the effects of 
      different intensities of anticoagulation and the use of aspirin-warfarin 
      combinations are underway. Indeed SPAF-III, comparing a combination of low dose 
      warfarin and aspirin with formal anticoagulation has been stopped and reported in 
      March 1996. A summary of the results will appear in the July issue. 
      Identification of the minimum effective dose of warfarin and effective monitoring 
      systems remain a priority.
FAU - Cleland, J G
AU  - Cleland JG
AD  - Medical Research Council Clinical Research Initiative in Heart Failure, 
      University of Glasgow, Scotland, UK.
FAU - Cowburn, P J
AU  - Cowburn PJ
FAU - Falk, R H
AU  - Falk RH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Warfarin/*therapeutic use
RF  - 56
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.eurheartj.a014933 [doi]
PST - ppublish
SO  - Eur Heart J. 1996 May;17(5):674-81. doi: 
      10.1093/oxfordjournals.eurheartj.a014933.

PMID- 34871376
OWN - NLM
STAT- MEDLINE
DCOM- 20220329
LR  - 20220401
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 43
IP  - 10
DP  - 2022 Mar 7
TI  - Dual antithrombotic treatment in chronic coronary syndrome: European Society of 
      Cardiology criteria vs. CHADS-P2A2RC score.
PG  - 996-1004
LID - 10.1093/eurheartj/ehab785 [doi]
AB  - AIMS: According to the 2019 European Society of Cardiology (ESC) guidelines on 
      chronic coronary syndromes (CCS), adding a P2Y12 inhibitor or rivaroxaban to 
      aspirin should be considered in high-risk patients. We estimated the proportion 
      of patients eligible for treatment with the ESC criteria and examined if a 
      recently validated risk score (CHADS-P2A2RC) could improve risk prediction. 
      METHODS AND RESULTS: We included 61 338 CCS patients undergoing first-time 
      coronary angiography in Western Denmark (2003-16) and classified them according 
      to the ESC criteria and the CHADS-P2A2RC score. The ESC criteria identified 33.9% 
      as high risk, 53.3% as moderate risk, and 12.8% as low risk. The CHADS-P2A2RC 
      score identified 24.9% as high risk (≥4 points), 48.1% as moderate risk (2-3 
      points), and 27.0% as low risk (≤1 points). Major adverse cardiovascular events 
      per 100 person-years were 4.8 [95% confidence interval (CI) 4.6-5.0] in patients 
      considered high risk with both schemes, 2.1 (95% CI 2.0-2.2) in patients 
      considered high risk with the ESC but low-to-moderate risk with the CHADS-P2A2RC 
      criteria, 3.8 (95% CI 3.6-4.1) in patients considered low-to-moderate risk with 
      the ESC but high risk with the CHADS-P2A2RC criteria, and 1.5 (95% CI 1.5-1.6) in 
      patients considered low-to-moderate risk with both schemes. The CHADS-P2A2RC 
      score enabled correct downward risk reclassification of 5161 patients (8%) 
      without events, yielding an improved specificity of 9.7%, a loss of sensitivity 
      of 4.4%, and an overall net reclassification index of 0.053. CONCLUSION: Based on 
      the 2019 ESC guidelines, dual antithrombotic treatment should be considered in 
      one-third of CCS patients. The CHADS-P2A2RC score improved risk classification 
      and may particularly identify low-risk patients with limited benefit from 
      treatment.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved. © 
      The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.
FAU - Würtz, Morten
AU  - Würtz M
AUID- ORCID: 0000-0001-7150-7704
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 99, Aarhus 8200, Denmark.
FAU - Olesen, Kevin Kris Warnakula
AU  - Olesen KKW
AUID- ORCID: 0000-0002-0560-3615
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 99, Aarhus 8200, Denmark.
FAU - Mortensen, Martin Bødtker
AU  - Mortensen MB
AUID- ORCID: 0000-0003-2693-4154
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 99, Aarhus 8200, Denmark.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AUID- ORCID: 0000-0003-4126-1285
AD  - Population Health Research Institute, Hamilton Health Sciences 237 Barton Street 
      East Hamilton, ON L8L 2X2, Canada, and McMaster University, 1280 Main St W, 
      Hamilton, ON L8S 4L8, Canada.
FAU - Mohammad, Moman Aladdin
AU  - Mohammad MA
AUID- ORCID: 0000-0003-4242-9801
AD  - Department of Cardiology, Clinical Sciences, Skane University Hospital, 
      Entregatan 7, Lund 22185, Sweden.
FAU - Erlinge, David
AU  - Erlinge D
AD  - Department of Cardiology, Clinical Sciences, Skane University Hospital, 
      Entregatan 7, Lund 22185, Sweden.
FAU - Kristensen, Steen Dalby
AU  - Kristensen SD
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 99, Aarhus 8200, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health, Institute of Clinical 
      Medicine, Aarhus University, Palle Juul-Jensens Boulevard 82, Aarhus, Denmark.
FAU - Maeng, Michael
AU  - Maeng M
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens 
      Boulevard 99, Aarhus 8200, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2021 Dec 16;:. PMID: 34918038
MH  - Aspirin/therapeutic use
MH  - *Cardiology
MH  - *Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Risk Assessment
MH  - Risk Factors
MH  - Syndrome
OTO - NOTNLM
OT  - Aspirin
OT  - Chronic coronary syndrome
OT  - Coronary artery disease
OT  - Myocardial infarction
OT  - Platelet inhibitors
OT  - Rivaroxaban
EDAT- 2021/12/07 06:00
MHDA- 2022/03/30 06:00
CRDT- 2021/12/06 17:27
PHST- 2021/04/24 00:00 [received]
PHST- 2021/07/28 00:00 [revised]
PHST- 2021/10/29 00:00 [accepted]
PHST- 2021/12/07 06:00 [pubmed]
PHST- 2022/03/30 06:00 [medline]
PHST- 2021/12/06 17:27 [entrez]
AID - 6453845 [pii]
AID - 10.1093/eurheartj/ehab785 [doi]
PST - ppublish
SO  - Eur Heart J. 2022 Mar 7;43(10):996-1004. doi: 10.1093/eurheartj/ehab785.

PMID- 15951464
OWN - NLM
STAT- MEDLINE
DCOM- 20051103
LR  - 20191210
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 45
IP  - 7
DP  - 2005 Jul
TI  - The cardiovascular toxicity of selective and nonselective cyclooxygenase 
      inhibitors: comparisons, contrasts, and aspirin confounding.
PG  - 742-50
AB  - The premature suspension of the Alzheimer Disease Anti-inflammatory Prevention 
      (ADAPT) and the Adenoma Prevention with Celecoxib (APC) trials prompted intense 
      review of the cardiovascular safety profile of selective and nonselective 
      cyclooxygenase (COX) inhibitors. This article reviews the current state of 
      selective COX-2 inhibitors, discusses the mechanistic evidence underlying the 
      cardiovascular risk associated with selective COX-2 inhibition, outlines the 
      pharmacodynamics of aspirin effects on platelets and the interference of 
      propionic acid derivatives (ibuprofen and naproxen) with these effects, and poses 
      that aspirin confounding may have led to the erroneous conclusion of 
      naproxen-associated adverse cardiovascular outcomes in the ADAPT trial. Finally, 
      recommendations regarding selective COX-2 inhibitors and appropriate timing of 
      aspirin coadministration with traditional NSAIDs are proposed in relevance to 
      patient safety and future trial design.
FAU - Konstantinopoulos, Panagiotis A
AU  - Konstantinopoulos PA
AD  - SUNY Upstate Medical University, Syracuse, NY 13210, USA.
FAU - Lehmann, David F
AU  - Lehmann DF
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Membrane Proteins)
RN  - 0 (Propionates)
RN  - 57Y76R9ATQ (Naproxen)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - JHU490RVYR (propionic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/*chemically induced/epidemiology
MH  - Confounding Factors, Epidemiologic
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*adverse effects/therapeutic use
MH  - Humans
MH  - Membrane Proteins
MH  - Naproxen/adverse effects/therapeutic use
MH  - Propionates/therapeutic use
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - Randomized Controlled Trials as Topic
RF  - 51
EDAT- 2005/06/14 09:00
MHDA- 2005/11/04 09:00
CRDT- 2005/06/14 09:00
PHST- 2005/06/14 09:00 [pubmed]
PHST- 2005/11/04 09:00 [medline]
PHST- 2005/06/14 09:00 [entrez]
AID - 45/7/742 [pii]
AID - 10.1177/0091270005278202 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2005 Jul;45(7):742-50. doi: 10.1177/0091270005278202.

PMID- 12152253
OWN - NLM
STAT- MEDLINE
DCOM- 20020912
LR  - 20131121
IS  - 0033-2240 (Print)
IS  - 0033-2240 (Linking)
VI  - 59
IP  - 2
DP  - 2002
TI  - [The effect of acetylsalicylic acid on hypotensive action of enalapril in 
      hypertensive patients].
PG  - 76-8
AB  - The complex hypotensive action of angiotensin converting enzyme inhibitors (ACEI) 
      results not only from inhibition of converting not active angiotensin I to strong 
      vasoconstrictor-angiotensin II but also from diminution of inactivation of potent 
      vasodilator-bradykinin. Bradykinin promotes generation by endothelium such 
      substances as endothelium-derived hyperpolarizing factor, prostacyclin and nitric 
      oxide. Simultaneous therapy with acetylsalicylic acid, which inhibits synthesis 
      of prostanoids, and ACEI may block one of potent hypotensive mechanisms of ACEI. 
      This study indicates that concomitant therapy with 150 mg of aspirin per day does 
      not reduce hypotensive efficacy of enalapril.
FAU - Przewłocka-Kosmala, Monika
AU  - Przewłocka-Kosmala M
AD  - Katedra i Klinika Kardiologii, Akademii Medycznej we Wrocławiu. 
      kosmw@kard.am.wroc.pl
LA  - pol
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Wpływ kwasu acetylosalicylowego na skuteczność hipotensyjna enalaprilu u chorych 
      na pierwotne nadciśnienie tetnicze łagodne i umiarkowane.
PL  - Poland
TA  - Przegl Lek
JT  - Przeglad lekarski
JID - 19840720R
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antihypertensive Agents)
RN  - 69PN84IO1A (Enalapril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*pharmacology
MH  - Antihypertensive Agents/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Drug Therapy, Combination
MH  - Enalapril/administration & dosage/*pharmacology
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2002/08/03 10:00
MHDA- 2002/09/13 10:01
CRDT- 2002/08/03 10:00
PHST- 2002/08/03 10:00 [pubmed]
PHST- 2002/09/13 10:01 [medline]
PHST- 2002/08/03 10:00 [entrez]
PST - ppublish
SO  - Przegl Lek. 2002;59(2):76-8.

PMID- 11510359
OWN - NLM
STAT- MEDLINE
DCOM- 20020116
LR  - 20131121
IS  - 0201-7563 (Print)
IS  - 0201-7563 (Linking)
IP  - 3
DP  - 2001 May-Jun
TI  - [Effects of basic therapy of ischemic heart disease on vascular-platelet 
      hemostasis during myocardial revascularization].
PG  - 47-50
AB  - Effects of preoperative therapy of coronary diseases with calcium antagonists and 
      aspirin on vascular platelet hemostasis during aortocoronary shunting (ACS) have 
      been studied in order to evaluate the role of hemostasis disorders in the 
      pathogenesis of perioperative hemorrhagic complications. Therapy of coronary 
      disease with these drugs during preparation to ACS can involve changes in 
      platelet functional activity, depending on the individual sensitivity of 
      patients. Drug-induced thrombocytopathy can induce pathological hemorrhages in 
      the perioperative period of ACS.
FAU - Vorob'eva, N A
AU  - Vorob'eva NA
FAU - Nedashkovskiĭ, E V
AU  - Nedashkovskiĭ EV
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Vliianie bazisnoĭ terapii IBS na sostoianie sosudisto-trombotsitarnogo gemostaza 
      pri operatsii revaskuliarizatsii miokarda.
PL  - Russia (Federation)
TA  - Anesteziol Reanimatol
JT  - Anesteziologiia i reanimatologiia
JID - 7705399
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Calcium Channel Blockers/*pharmacology/therapeutic use
MH  - *Coronary Artery Bypass
MH  - Data Interpretation, Statistical
MH  - Female
MH  - Fibrinolytic Agents/*pharmacology/therapeutic use
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Intraoperative Complications/etiology
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*drug therapy/surgery
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Preoperative Care
EDAT- 2001/08/21 10:00
MHDA- 2002/01/17 10:01
CRDT- 2001/08/21 10:00
PHST- 2001/08/21 10:00 [pubmed]
PHST- 2002/01/17 10:01 [medline]
PHST- 2001/08/21 10:00 [entrez]
PST - ppublish
SO  - Anesteziol Reanimatol. 2001 May-Jun;(3):47-50.

PMID- 9649658
OWN - NLM
STAT- MEDLINE
DCOM- 19990119
LR  - 20131121
IS  - 1167-1122 (Print)
IS  - 1167-1122 (Linking)
VI  - 8
IP  - 4
DP  - 1998 Jun
TI  - Drug eruption due to Bufferin showing erythema exsudativum multiforme with a 
      photo-recall-like phenomenon.
PG  - 280-2
AB  - A 21-year-old woman who had been taking several kinds of analgesics to treat 
      dysmenorrhea developed episodic attacks of a purpuric macular eruption and a 
      burning sensation on unexposed areas of the upper chest and back where she had 
      sustained severe sunburn eight months earlier. Target-like lesions developed on 
      these areas after intake of Bufferin, a combination of aspirin and dialuminate. 
      After the eruptions had abated following systemic administration of a 
      corticosteroid agent, a challenge test was performed, using a quarter of a tablet 
      of Bufferin. The patient developed a temporary burning sensation and a 
      erythematous color on the previously sunburned skin. We diagnosed this case as a 
      drug eruption due to Bufferin showing erythema exsudativium multiforme with a 
      photo-recall-like phenomenon. In our case, skin tests would be useful to confirm 
      the causal drug.
FAU - Lee, S G
AU  - Lee SG
AD  - Department of Dermatology, Faculty of Medicine, Kyoto University, Kyoto, 6068507 
      Japan.
FAU - Matsuyoshi, N
AU  - Matsuyoshi N
FAU - Ohta, K
AU  - Ohta K
FAU - Horiguchi, Y
AU  - Horiguchi Y
FAU - Imamura, S
AU  - Imamura S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - France
TA  - Eur J Dermatol
JT  - European journal of dermatology : EJD
JID - 9206420
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Biopsy, Needle
MH  - Dermatitis, Photoallergic/diagnosis/*pathology
MH  - Diagnosis, Differential
MH  - Drug Eruptions/diagnosis/*etiology
MH  - Dysmenorrhea/drug therapy
MH  - Erythema Multiforme/*chemically induced/diagnosis/*pathology
MH  - Female
MH  - Humans
MH  - Skin Tests
EDAT- 1998/07/03 00:00
MHDA- 1998/07/03 00:01
CRDT- 1998/07/03 00:00
PHST- 1998/07/03 00:00 [pubmed]
PHST- 1998/07/03 00:01 [medline]
PHST- 1998/07/03 00:00 [entrez]
PST - ppublish
SO  - Eur J Dermatol. 1998 Jun;8(4):280-2.

PMID- 8529624
OWN - NLM
STAT- MEDLINE
DCOM- 19960129
LR  - 20191023
IS  - 0173-0835 (Print)
IS  - 0173-0835 (Linking)
VI  - 16
IP  - 8
DP  - 1995 Aug
TI  - Liposome capillary electrophoresis for analysis of interactions between lipid 
      bilayers and solutes.
PG  - 1519-23
AB  - Liposomes, which mimic biomembranes, were used as a pseudostationary phase in 
      capillary zone electrophoresis. The decrease in the mobility of an analyte owing 
      to the presence of liposomes reflected interaction between the analyte and the 
      liposomes. Equations were derived to calculate the specific capacity factor Ks 
      (the capacity factor, k', normalized to the liposome concentration 1 M) from the 
      migration times and to estimate the difference in free energy, delta(delta G0), 
      of the weak analyte/liposome interactions. The order of Ks values for the drugs 
      tested was aspirin < salicylic acid < warfarin << sulfasalazine. The peptide 
      TyrGlySerThrProGlyCysCys interacted more strongly with the liposomes (Ks = 10.1 
      M-1) than did TyrGlySerThrProGlySerSer (Ks = 9.1 M-1). These results were similar 
      to those obtained earlier by immobilized liposome chromatography.
FAU - Zhang, Y
AU  - Zhang Y
AD  - Department of Biochemistry, Uppsala University, Sweden.
FAU - Zhang, R
AU  - Zhang R
FAU - Hjertén, S
AU  - Hjertén S
FAU - Lundahl, P
AU  - Lundahl P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Electrophoresis
JT  - Electrophoresis
JID - 8204476
RN  - 0 (Lipid Bilayers)
RN  - 0 (Liposomes)
RN  - 0 (Peptides)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Salicylates)
RN  - 3XC8GUZ6CB (Sulfasalazine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Aspirin/analysis/chemistry
MH  - Electrophoresis, Capillary/*methods
MH  - Lipid Bilayers/*chemistry
MH  - *Liposomes
MH  - Molecular Sequence Data
MH  - Molecular Structure
MH  - Peptides/analysis/chemistry
MH  - Pharmaceutical Preparations/*analysis/*chemistry
MH  - Salicylates/analysis/chemistry
MH  - Salicylic Acid
MH  - Sulfasalazine/analysis/chemistry
MH  - Thermodynamics
MH  - Warfarin/analysis/chemistry
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
AID - 10.1002/elps.11501601251 [doi]
PST - ppublish
SO  - Electrophoresis. 1995 Aug;16(8):1519-23. doi: 10.1002/elps.11501601251.

PMID- 6436931
OWN - NLM
STAT- MEDLINE
DCOM- 19841205
LR  - 20180216
IS  - 0025-7931 (Print)
IS  - 0025-7931 (Linking)
VI  - 46
IP  - 1
DP  - 1984
TI  - Asthma relieved by acetylsalicylic acid and nonsteroid anti-inflammatory drugs.
PG  - 121-7
AB  - The authors report 2 typical asthmatic cases in whom the administration of 
      acetylsalicylic acid (ASA) and nonsteroid anti-inflammatory drugs (NSAID) 
      resulted in bronchodilatation. 500 mg of ASA were administered intravenously to 1 
      patient and the other was treated with ASA, indomethacin, noramidopyrine 
      intravenously and acetaminophen orally during a bronchospastic attack. FEV1 and 
      SRAW were measured before and after drug administration. The test was repeated 
      with placebo (physiological saline). FEV1 increased rapidly after ASA and NSAID 
      administration. Although the pathogenesis of asthma reversed by aspirin is not 
      entirely clear, the authors suggest an alteration of sensitivity of the 
      cyclo-oxygenase enzyme due to the inhibitory action of ASA and NSAID.
FAU - Resta, O
AU  - Resta O
FAU - Foschino-Barbaro, M P
AU  - Foschino-Barbaro MP
FAU - Carnimeo, N
AU  - Carnimeo N
FAU - Bavoso, P
AU  - Bavoso P
FAU - Picca, V
AU  - Picca V
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Respiration
JT  - Respiration; international review of thoracic diseases
JID - 0137356
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Prostaglandins)
RN  - 0 (Pyrazolones)
RN  - 6429L0L52Y (Dipyrone)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - NER31DE951 (noramidopyrine)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Anti-Inflammatory Agents/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Dipyrone/analogs & derivatives/therapeutic use
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Indomethacin/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Prostaglandins/metabolism
MH  - *Pyrazolones
MH  - Respiratory Function Tests
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1159/000194679 [doi]
PST - ppublish
SO  - Respiration. 1984;46(1):121-7. doi: 10.1159/000194679.

PMID- 18287865
OWN - NLM
STAT- MEDLINE
DCOM- 20080625
LR  - 20131121
IS  - 1473-5709 (Electronic)
IS  - 0959-8278 (Linking)
VI  - 17
IP  - 2
DP  - 2008 Apr
TI  - Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort 
      study.
PG  - 88-96
LID - 10.1097/CEJ.0b013e3282b6fd55 [doi]
AB  - Epidemiologic studies investigating the effects of nonsteroidal anti-inflammatory 
      drugs (NSAIDs) on breast cancer have yielded conflicting results. We examined the 
      association between use of aspirin and nonaspirin NSAIDs and breast cancer risk 
      among 28 695 women in the Danish Diet, Cancer and Health cohort. Information on 
      NSAID and paracetamol use was obtained from a self-administered questionnaire 
      completed at baseline (1993-1997) and updated through 2003 using a nationwide 
      prescription database. Detailed information on breast cancer incidence and tumour 
      characteristics was obtained from nationwide health registers. Cox proportional 
      hazards regression was used to compute incidence rate ratios (RRs) and 95% 
      confidence intervals (CIs). We identified 847 breast cancer cases over an average 
      follow-up period of 7.5 years. Any NSAID use at baseline was associated with an 
      increased incidence of breast cancer compared with nonuse (RR, 1.27; 95% CI, 
      1.10-1.45). A similar result was observed for any NSAID use in a combined 
      analysis of baseline and prescription data (1.34; 95% CI, 1.15-1.56). 
      Aspirin-only users experienced a slightly higher breast cancer incidence (RR, 
      1.38; 95% CI, 1.12-1.69) than exclusive users of nonaspirin NSAIDs (RR, 1.25; 95% 
      CI, 1.04-1.49). Introduction of a lag time of 1 year provided similar results. We 
      found no clear differences in risk estimates with frequency, recency or duration 
      of NSAID use, or by hormone receptor status of the breast tumours. Paracetamol 
      use was unrelated to breast cancer incidence. The increased breast cancer 
      incidence among NSAID users may reflect a noncausal association, but our study 
      provides no evidence of a chemopreventive effect of NSAIDs against breast cancer 
      over the durations studied.
FAU - Friis, Søren
AU  - Friis S
AD  - Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. 
      friis@cancer.dk
FAU - Thomassen, Lars
AU  - Thomassen L
FAU - Sørensen, Henrik T
AU  - Sørensen HT
FAU - Tjønneland, Anne
AU  - Tjønneland A
FAU - Overvad, Kim
AU  - Overvad K
FAU - Cronin-Fenton, Deirdre P
AU  - Cronin-Fenton DP
FAU - Vogel, Ulla
AU  - Vogel U
FAU - McLaughlin, Joseph K
AU  - McLaughlin JK
FAU - Blot, William J
AU  - Blot WJ
FAU - Olsen, Jørgen H
AU  - Olsen JH
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Eur J Cancer Prev
JT  - European journal of cancer prevention : the official journal of the European 
      Cancer Prevention Organisation (ECP)
JID - 9300837
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Breast Neoplasms/*epidemiology/prevention & control
MH  - Cohort Studies
MH  - Denmark/epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Risk Factors
EDAT- 2008/02/22 09:00
MHDA- 2008/06/26 09:00
CRDT- 2008/02/22 09:00
PHST- 2008/02/22 09:00 [pubmed]
PHST- 2008/06/26 09:00 [medline]
PHST- 2008/02/22 09:00 [entrez]
AID - 00008469-200804000-00004 [pii]
AID - 10.1097/CEJ.0b013e3282b6fd55 [doi]
PST - ppublish
SO  - Eur J Cancer Prev. 2008 Apr;17(2):88-96. doi: 10.1097/CEJ.0b013e3282b6fd55.

PMID- 27533449
OWN - NLM
STAT- MEDLINE
DCOM- 20180223
LR  - 20220321
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 40
DP  - 2016 Oct 4
TI  - Association of nonsteroidal anti-inflammatory drugs and aspirin use and the risk 
      of head and neck cancers: a meta-analysis of observational studies.
PG  - 65196-65207
LID - 10.18632/oncotarget.11239 [doi]
AB  - PURPOSE: Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, have 
      emerged as the potential chemopreventive agents for a number of cancer types, 
      however, previous studies of head and neck cancers (HNC) have yielded 
      inconclusive results. We performed a meta-analysis of observational studies to 
      quantitatively assess the association between NSAIDs use and the risk for HNC. 
      METHODS: We searched Pubmed, Embase, Google scholar, and Cochrane library for 
      relevant studies that were published in any language, from January 1980 to April 
      2016. We pooled the odds ratio (OR) from individual studies and performed 
      subgroup, heterogeneity, and publication bias analyses. RESULTS: A total of 
      eleven studies (eight case-control studies and three cohort studies), involving 
      370,000 participants and 10,673 HNC cases contributed to this meta-analysis. The 
      results of these studies suggested that neither use of overall NSAIDs (OR=0.95; 
      95% CI, 0.81-1.11), aspirin (OR=0.93; 95% CI, 0.79-1.10), nor nonsteroidal NSAIDs 
      (OR=0.92; 95% CI, 0.76-1.10) were associated with HNC risk. Similar nonsteroidal 
      results were observed when stratified by HNC sites, study design, sample size, 
      and varied adjustment factors. However, we found significant protective effect of 
      ibuprofen (OR=0.85; 95% CI, 0.72-0.99) and long-term aspirin use (≧5years) 
      (OR=0.75; 95% CI, 0.65-0.85) on HNC risk, with low heterogeneity and publication 
      bias. CONCLUSIONS: Our meta-analysis results do not support the hypothesis that 
      overall use of NSAIDs significant reduces the risk of HNC. Whereas, we cannot 
      rule out a modest reduction in HNC risk associated with ibuprofen and long-term 
      aspirin use.
FAU - Tang, Lanhua
AU  - Tang L
AD  - Department of Oncology, Xiangya Hospital of Central South University, Changsha, 
      China.
FAU - Hu, Huabin
AU  - Hu H
AD  - Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-Sen 
      University, Guangzhou, China.
FAU - Liu, Huai
AU  - Liu H
AD  - Department of Radiotherapy, Hunan Cancer Hospital and The Affiliated Cancer 
      Hospital of Xiangya School of Medicine, Central South University, Changsha, 
      China.
AD  - Key Laboratory of Translational Radiation Oncology, Changsha, China.
FAU - Jian, Chengzhu
AU  - Jian C
AD  - Department of Urology, The Second Xiangya Hospital of Central South University, 
      Changsha, China.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Radiotherapy, Hunan Cancer Hospital and The Affiliated Cancer 
      Hospital of Xiangya School of Medicine, Central South University, Changsha, 
      China.
AD  - Key Laboratory of Translational Radiation Oncology, Changsha, China.
FAU - Huang, Jin
AU  - Huang J
AD  - Department of Oncology, Xiangya Hospital of Central South University, Changsha, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Head and Neck Neoplasms/*epidemiology
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Observational Studies as Topic
MH  - Odds Ratio
PMC - PMC5323148
OTO - NOTNLM
OT  - aspirin
OT  - chemoprevention
OT  - head and neck cancer
OT  - meta-analysis
OT  - nonsteroidal anti-inflammatory drugs
COIS- CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.
EDAT- 2016/08/18 06:00
MHDA- 2018/02/24 06:00
CRDT- 2016/08/18 06:00
PHST- 2016/05/02 00:00 [received]
PHST- 2016/07/28 00:00 [accepted]
PHST- 2016/08/18 06:00 [pubmed]
PHST- 2018/02/24 06:00 [medline]
PHST- 2016/08/18 06:00 [entrez]
AID - 11239 [pii]
AID - 10.18632/oncotarget.11239 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Oct 4;7(40):65196-65207. doi: 10.18632/oncotarget.11239.

PMID- 27271700
OWN - NLM
STAT- MEDLINE
DCOM- 20170614
LR  - 20171105
IS  - 1522-2683 (Electronic)
IS  - 0173-0835 (Linking)
VI  - 37
IP  - 15-16
DP  - 2016 Aug
TI  - Thrombin generation assay in untreated whole human blood.
PG  - 2248-56
LID - 10.1002/elps.201600061 [doi]
AB  - Present coagulation assays fail to detect mild coagulation disorders, while 
      thrombin-generation (TG) assays solve this problem. However, most of them only 
      work with threated blood samples, which makes them labor intensive, time 
      consuming, unreliable, and expensive. We have developed a TG electrophoretic 
      assay that uses a thrombin specific charge-changing fluorescent peptide 
      substrate, electrophoretic separation, and requires a drop of blood. The limit of 
      detection of the assay was 1.97 nM in phosphate buffer saline and 6.82 nM in 
      citrated whole blood. The assay was used to determine the TG in whole blood from 
      healthy volunteers (n = 6, one aspirin user), over 30 min, after the blood was 
      drawn; the TG increased from a baseline level of 2 × 10(6) RFU to 1.2 × 10(13) 
      RFU. The lag time between the blood draw and initial burst of TG was 6 min for 
      the volunteers (n = 5) and 15 min for the aspirin user. Specificity of the assay 
      was evaluated by reacting our substrate with the heparinized blood samples and 
      other proteases. The TG electrophoretic assay was designed and tested in the 
      whole human blood, requiring no sample preparation, 5 μL of blood, 45 min, and it 
      detected differences in coagulation patterns between a volunteer taking aspirin 
      and non-aspirin users.
CI  - © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Modestino, Augusta
AU  - Modestino A
AD  - Department of Bioengineering, University of California San Diego, La Jolla, CA, 
      USA.
FAU - Tyndall, Matthew
AU  - Tyndall M
AD  - Department of Nanoengineering, University of California San Diego, La Jolla, CA, 
      USA.
FAU - Yu, Johnson
AU  - Yu J
AD  - Department of Nanoengineering, University of California San Diego, La Jolla, CA, 
      USA.
FAU - Lefkowitz, Roy B
AU  - Lefkowitz RB
AD  - Department of Bioengineering, University of California San Diego, La Jolla, CA, 
      USA.
FAU - Schmid-Schönbein, Geert W
AU  - Schmid-Schönbein GW
AD  - Department of Bioengineering, University of California San Diego, La Jolla, CA, 
      USA.
FAU - Heller, Michael J
AU  - Heller MJ
AD  - Department of Nanoengineering, University of California San Diego, La Jolla, CA, 
      USA.
AD  - Department of Bioengineering, University of California San Diego, La Jolla, CA, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Electrophoresis
JT  - Electrophoresis
JID - 8204476
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Coagulation Tests/*methods
MH  - Electrophoresis/*methods
MH  - Humans
MH  - Limit of Detection
MH  - Sensitivity and Specificity
MH  - Thrombin Time
OTO - NOTNLM
OT  - Charge-changing substrates
OT  - Electrophoresis
OT  - Protease
OT  - Thrombin
OT  - Whole-blood assay
EDAT- 2016/06/09 06:00
MHDA- 2017/06/15 06:00
CRDT- 2016/06/09 06:00
PHST- 2016/02/05 00:00 [received]
PHST- 2016/05/24 00:00 [revised]
PHST- 2016/05/25 00:00 [accepted]
PHST- 2016/06/09 06:00 [entrez]
PHST- 2016/06/09 06:00 [pubmed]
PHST- 2017/06/15 06:00 [medline]
AID - 10.1002/elps.201600061 [doi]
PST - ppublish
SO  - Electrophoresis. 2016 Aug;37(15-16):2248-56. doi: 10.1002/elps.201600061.

PMID- 24987696
OWN - NLM
STAT- MEDLINE
DCOM- 20150212
LR  - 20220331
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2014
DP  - 2014
TI  - Experimental and mathematical studies on the drug release properties of aspirin 
      loaded chitosan nanoparticles.
PG  - 613619
LID - 10.1155/2014/613619 [doi]
LID - 613619
AB  - The study of drug release dynamic is aiming at understanding the process that 
      drugs release in human body and its dynamic characteristics. It is of great 
      significance since these characteristics are closely related to the dose, dosage 
      form, and effect of the drugs. The Noyes-Whitney function is used to represent 
      how the solid material is dissolved into solution, and it is well used in study 
      of drug dynamic. In this research, aspirin (acetylsalicylic acid (ASA)) has been 
      encapsulated with different grades of chitosan (CS) varying in molecular weight 
      (Mw) for the purpose of controlled release. The encapsulation was accomplished by 
      ionic gelation technology based on assembly of positively charged chitosan and 
      negatively charged sodium tripolyphosphate (TPP). The encapsulation efficiency, 
      loading capacity, and drug release behavior of aspirin loaded chitosan 
      nanoparticles (CS-NPs) were studied. It was found that the concentration of TPP 
      and Aspirin, molecular weights of chitosan have important effect on the drug 
      release patterns from chitosan nanoparticles. The results for simulation studies 
      show that the Noyes-Whitney equation can be successfully used to interpret the 
      drug release characteristics reflected by our experimental data.
FAU - Shi, Yixiang
AU  - Shi Y
AUID- ORCID: 0000-0002-2138-1004
AD  - School of Chemistry and Chemical Engineering, Shanghai Jiaotong University, 800 
      Dongchuan Road, Shanghai 200240, China.
FAU - Wan, Ajun
AU  - Wan A
AD  - School of Chemistry and Chemical Engineering, Shanghai Jiaotong University, 800 
      Dongchuan Road, Shanghai 200240, China ; State Key Laboratory of Pollution 
      Control and Resources Reuse, College of Environmental Science and Engineering, 
      Tongji University, Shanghai, China.
FAU - Shi, Yifei
AU  - Shi Y
AD  - School of Life Sciences and Biotechnology, Shanghai Jiaotong University, 800 
      Dongchuan Road, Shanghai 200240, China.
FAU - Zhang, Yueyue
AU  - Zhang Y
AD  - School of Chemistry and Chemical Engineering, Shanghai Jiaotong University, 800 
      Dongchuan Road, Shanghai 200240, China.
FAU - Chen, Yupeng
AU  - Chen Y
AD  - School of Chemistry and Chemical Engineering, Shanghai Jiaotong University, 800 
      Dongchuan Road, Shanghai 200240, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140601
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - 9012-76-4 (Chitosan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Chitosan/*chemistry
MH  - Delayed-Action Preparations/chemistry
MH  - Humans
MH  - *Models, Chemical
MH  - Nanoparticles/*chemistry
PMC - PMC4058851
EDAT- 2014/07/06 06:00
MHDA- 2015/02/13 06:00
CRDT- 2014/07/03 06:00
PHST- 2014/02/28 00:00 [received]
PHST- 2014/05/14 00:00 [accepted]
PHST- 2014/07/03 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2015/02/13 06:00 [medline]
AID - 10.1155/2014/613619 [doi]
PST - ppublish
SO  - Biomed Res Int. 2014;2014:613619. doi: 10.1155/2014/613619. Epub 2014 Jun 1.

PMID- 9425618
OWN - NLM
STAT- MEDLINE
DCOM- 19980206
LR  - 20150831
IS  - 1043-6618 (Print)
IS  - 1043-6618 (Linking)
VI  - 36
IP  - 4
DP  - 1997 Oct
TI  - Comparative study of policosanol, aspirin and the combination therapy 
      policosanol-aspirin on platelet aggregation in healthy volunteers.
PG  - 293-7
AB  - A randomized, double-blind, placebo-controlled study was conducted in 43 healthy 
      volunteers to compare the effects of policosanol (20 mg day-1), aspirin (ASA) 
      (100 mg day-1) and combination therapy (policosanol 20 mg day-1 plus ASA 100 mg 
      day-1) on platelet aggregation. The healthy volunteers were randomly treated for 
      7 days. Both, platelet aggregation and coagulation time were measured at baseline 
      and after therapy. When policosanol was administered platelet aggregation induced 
      by ADP (37.3%), epinephrine (32.6%) and collagen (40.5%) were significantly 
      reduced. Meanwhile, aspirin significantly reduced platelet aggregation induced by 
      collagen (61.4%) and epinephrine (21.9%) but not ADP-induced aggregation. 
      Combined therapy significantly inhibited aggregation induced by all the agonists 
      reaching the highest reductions of platelet aggregation induced by collagen 
      (71.3%) and epinephrine (57.5%). Coagulation time did not change significantly in 
      any group. No subject withdrew from the trial. Four volunteers reported mild 
      adverse experiences during the study: three ASA-treated cases referred headache, 
      epigastralgia and nose bleeding, meanwhile one patient receiving combination 
      therapy reported gum bleeding. The present results demonstrate that policosanol 
      (20 mg day-1) is as effective as ASA (100 mg day-1). Moreover, combination 
      therapy shows some advantages compared with the respective monotherapies.
FAU - Arruzazabala, M L
AU  - Arruzazabala ML
AD  - Department of Pharmacology, Centre of Natural Products, CNIC, Habana, Cuba.
FAU - Valdés, S
AU  - Valdés S
FAU - Más, R
AU  - Más R
FAU - Carbajal, D
AU  - Carbajal D
FAU - Fernández, L
AU  - Fernández L
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Fatty Alcohols)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 142583-61-7 (policosanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Platelets/*drug effects
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Fatty Alcohols/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 1998/01/13 00:00
MHDA- 1998/01/13 00:01
CRDT- 1998/01/13 00:00
PHST- 1998/01/13 00:00 [pubmed]
PHST- 1998/01/13 00:01 [medline]
PHST- 1998/01/13 00:00 [entrez]
AID - S1043-6618(97)90201-2 [pii]
AID - 10.1006/phrs.1997.0201 [doi]
PST - ppublish
SO  - Pharmacol Res. 1997 Oct;36(4):293-7. doi: 10.1006/phrs.1997.0201.

PMID- 16298420
OWN - NLM
STAT- MEDLINE
DCOM- 20071212
LR  - 20131121
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 118
IP  - 4
DP  - 2006
TI  - Effects of different aspirin formulations on platelet aggregation times and on 
      plasma salicylate concentrations.
PG  - 529-34
AB  - BACKGROUND: Early aspirin treatment is widely used to inhibit platelet activity 
      and to reduce morbidity and mortality in patients presenting with an acute 
      myocardial infarction or a stroke. A number of different aspirin formulations 
      have been used for this purpose; however, a comparison of their effectiveness in 
      inhibiting early platelet aggregation has not been determined. METHODS: In this 
      study, we determined plasma salicylate concentrations and platelet inhibitory 
      activities at various times after ingestion of three commonly used aspirin 
      formulations: soluble aspirin (Alka-Seltzer), 325 mg, chewed baby aspirin, 324 
      mg, and whole compressed non-enteric coated aspirin, 324 mg. Twenty-four healthy 
      volunteers, 18-39 years of age, participated in the prospective single-blinded 
      triple-crossover study. Plasma salicylate concentrations and inhibition of 
      arachidonic acid-induced platelet aggregation were determined on post-dose blood 
      samples collected at 2.5, 5.0, 7.5, 10, 15, 20, 25, 30, and 40 min. All subjects 
      crossed over to the other two formulations with at least 2 weeks between 
      ingestions. RESULTS: The median platelet inhibition times for the chewed, 
      soluble, and whole aspirin formulations were 7.5, 7.5, and 10.0 min, 
      respectively. Soluble and chewed aspirin were found to inhibit platelet 
      aggregation faster than whole aspirin (p<0.001); however, there were no 
      significant differences in platelet aggregation times between the soluble and 
      chewed formulations (p<0.163). Inhibition of platelet aggregation was found to 
      occur at an average plasma salicylate concentration of 2.46 microg/mL, regardless 
      of method of ingestion. CONCLUSION: The results indicate that soluble and chewed 
      aspirin inhibit platelet aggregation in a shorter period of time than does whole 
      aspirin. The results suggest that chewing baby aspirin or taking soluble buffered 
      aspirin may be the preferred route of administration for early platelet 
      inhibition.
FAU - Schwertner, H A
AU  - Schwertner HA
AD  - Clinical Research, Wilford Hall Medical Center, Lackland, AFB, TX 78236-5300, 
      USA. harvey.schwertner@lackland.af.mil
FAU - McGlasson, D
AU  - McGlasson D
FAU - Christopher, M
AU  - Christopher M
FAU - Bush, A C
AU  - Bush AC
LA  - eng
PT  - Journal Article
DEP - 20051118
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Arachidonic Acid/antagonists & inhibitors/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cross-Over Studies
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Prospective Studies
MH  - Reference Values
MH  - Salicylates/*blood
MH  - Single-Blind Method
MH  - Solubility
MH  - Tablets, Enteric-Coated
MH  - Time Factors
EDAT- 2005/11/22 09:00
MHDA- 2007/12/13 09:00
CRDT- 2005/11/22 09:00
PHST- 2005/07/06 00:00 [received]
PHST- 2005/09/20 00:00 [revised]
PHST- 2005/10/03 00:00 [accepted]
PHST- 2005/11/22 09:00 [pubmed]
PHST- 2007/12/13 09:00 [medline]
PHST- 2005/11/22 09:00 [entrez]
AID - S0049-3848(05)00395-6 [pii]
AID - 10.1016/j.thromres.2005.10.001 [doi]
PST - ppublish
SO  - Thromb Res. 2006;118(4):529-34. doi: 10.1016/j.thromres.2005.10.001. Epub 2005 
      Nov 18.

PMID- 8101300
OWN - NLM
STAT- MEDLINE
DCOM- 19930817
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 342
IP  - 8866
DP  - 1993 Jul 31
TI  - Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a 
      comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral 
      anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology 
      Institute of The Netherlands.
PG  - 257-64
AB  - Aspirin, alone or in combination with dipyridamole, is known to prevent occlusion 
      of aortocoronary vein grafts. The benefit of dipyridamole in addition to aspirin 
      remains controversial, and the efficacy and safety of oral anticoagulants for 
      prevention of vein-graft occlusion have not been established. We assessed 
      one-year angiographic vein-graft patency after aortocoronary-bypass surgery in 
      948 patients assigned to receive aspirin, aspirin plus dipyridamole, or oral 
      anticoagulants in a prospective, randomised trial. The design was double-blind 
      and placebo-controlled for the aspirin groups, but open for oral anticoagulant 
      treatment. Dipyridamole (5 mg/kg per 24 h intravenously for 28 h, followed by 200 
      mg twice daily) and oral anticoagulants (desired prothrombin time range 2.8-4.8 
      international normalised ratio) were started before surgery, and aspirin (50 mg 
      per day) was started after surgery. Clinical outcome was assessed by the 
      incidence of myocardial infarction, thrombosis, major bleeding, or death. 
      Occlusion rate of distal anastomoses was 11% in the aspirin plus dipyridamole 
      group versus 15% in the aspirin group (relative risk 0.76, 95% CI 0.54-1.05) and 
      13% in the oral anticoagulants group. Clinical events occurred in 20.3% of 
      patients receiving aspirin plus dipyridamole compared with 13.9% of the aspirin 
      group (relative risk 1.46, 95% CI 1.02-2.08) and 16.9% of the oral anticoagulants 
      group. Our data provide no convincing evidence that addition of dipyridamole to 
      50 mg aspirin per day improves aortocoronary vein-graft patency. Moreover, there 
      is evidence that the combination increases the overall clinical-event rate. 
      Compared with aspirin, oral anticoagulants provided no benefit.
FAU - van der Meer, J
AU  - van der Meer J
AD  - Thoraxcentre, University Hospital, Groningen, Netherlands.
FAU - Hillege, H L
AU  - Hillege HL
FAU - Kootstra, G J
AU  - Kootstra GJ
FAU - Ascoop, C A
AU  - Ascoop CA
FAU - Mulder, B J
AU  - Mulder BJ
FAU - Pfisterer, M
AU  - Pfisterer M
FAU - van Gilst, W H
AU  - van Gilst WH
FAU - Lie, K I
AU  - Lie KI
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 64ALC7F90C (Dipyridamole)
RN  - I6WP63U32H (Acenocoumarol)
RN  - Q08SIO485D (Phenprocoumon)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 1994 Jan-Feb;120 Suppl 1:7
EIN - Lancet 1993 Sep 11;342(8872):690
CIN - Lancet. 1993 Sep 25;342(8874):806; author reply 807. PMID: 8103893
CIN - Lancet. 1993 Sep 25;342(8874):806-7. PMID: 8103894
MH  - Acenocoumarol/administration & dosage/*therapeutic use
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenprocoumon/administration & dosage/*therapeutic use
MH  - Treatment Outcome
MH  - Vascular Patency/drug effects
EDAT- 1993/07/31 00:00
MHDA- 1993/07/31 00:01
CRDT- 1993/07/31 00:00
PHST- 1993/07/31 00:00 [pubmed]
PHST- 1993/07/31 00:01 [medline]
PHST- 1993/07/31 00:00 [entrez]
AID - 0140-6736(93)91815-4 [pii]
AID - 10.1016/0140-6736(93)91815-4 [doi]
PST - ppublish
SO  - Lancet. 1993 Jul 31;342(8866):257-64. doi: 10.1016/0140-6736(93)91815-4.

PMID- 18287586
OWN - NLM
STAT- MEDLINE
DCOM- 20080527
LR  - 20131121
IS  - 1074-2484 (Print)
IS  - 1074-2484 (Linking)
VI  - 13
IP  - 1
DP  - 2008 Mar
TI  - Aspirin resistance: biological and clinical implications.
PG  - 5-12
LID - 10.1177/1074248407310869 [doi]
AB  - Cardiovascular events are the leading causes of mortality and morbidity in the 
      United States. This development has prompted the rise of aspirin therapy in the 
      prevention of atherothrombotic events. However, not all patients benefit to the 
      same extent from aspirin therapy and many continue experiencing atherothrombotic 
      complications. Researchers have labeled this phenomenon aspirin resistance, and 
      despite drawing much attention from both researchers and lay people the cause 
      remains unknown. Much needs to be clarified and standardized regarding the 
      phenomenon of aspirin resistance, including the prevalence, definition, 
      appropriate measurement methods, mechanisms, and, most important, linking low 
      response to aspirin with worsened clinical outcomes.
FAU - Tseeng, Stephanie
AU  - Tseeng S
AD  - Department of Cardiology, Chicago Medical School, VA Medical Center, North 
      Chicago, IL 60064, USA.
FAU - Arora, Rohit
AU  - Arora R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Atherosclerosis/prevention & control
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/physiopathology/*prevention & control
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thrombosis/prevention & control
RF  - 49
EDAT- 2008/02/22 09:00
MHDA- 2008/05/28 09:00
CRDT- 2008/02/22 09:00
PHST- 2008/02/22 09:00 [pubmed]
PHST- 2008/05/28 09:00 [medline]
PHST- 2008/02/22 09:00 [entrez]
AID - 13/1/5 [pii]
AID - 10.1177/1074248407310869 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2008 Mar;13(1):5-12. doi: 10.1177/1074248407310869.

PMID- 12523462
OWN - NLM
STAT- MEDLINE
DCOM- 20030416
LR  - 20190916
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 23
IP  - 1
DP  - 2003 Jan
TI  - Improving aspirin prophylaxis in a primary care diabetic population.
PG  - 73-9
AB  - STUDY OBJECTIVE: To evaluate and improve adherence to American Diabetes 
      Association guidelines for prophylactic aspirin therapy in ambulatory patients 
      with diabetes using a pharmacy-directed intervention. DESIGN: Unblinded, single 
      intervention. SETTING: Rural, primary care clinic. SUBJECTS: Eighty-five patients 
      with a diagnosis of diabetes mellitus. INTERVENTION: Patients with diabetes were 
      identified from database searches and routine clinic visits. Medical records were 
      screened for aspirin use, allergies, adverse events, and contraindications. 
      During routine clinic visits or structured telephone interviews, patients with 
      indications for aspirin therapy were advised to begin enteric-coated aspirin 81 
      mg/day A follow-up survey assessed adherence. MEASUREMENTS AND MAIN RESULTS: At 
      baseline, 28 (33%) of 85 patients were receiving aspirin therapy An additional 8 
      patients had contraindications to aspirin, and 2 patients had no indications for 
      aspirin therapy Aspirin was recommended to 27 patients during clinic 
      interventions and to 15 patients during telephone interventions. Two patients 
      declined the recommendation. At the completion of this intervention, 70 (82%) of 
      85 patients were receiving daily aspirin or had accepted the recommendation to 
      begin therapy. CONCLUSIONS: A pharmacy-directed intervention increased 
      prophylactic aspirin therapy in patients with diabetes from 33% of patients at 
      baseline to 82% at the end of the study The intervention, which has a simple, 
      patient-focused design, serves as a template for improving aspirin prophylaxis 
      among patients with diabetes in other ambulatory settings.
FAU - Faragon, John J
AU  - Faragon JJ
AD  - Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 
      12208, USA. faragonj@acp.edu
FAU - Waite, Nancy M
AU  - Waite NM
FAU - Hobson, Eric H
AU  - Hobson EH
FAU - Seoldo, Nathalie
AU  - Seoldo N
FAU - VanAmburgh, Jenny A
AU  - VanAmburgh JA
FAU - Migden, Hedy
AU  - Migden H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Data Collection
MH  - *Diabetes Complications
MH  - Drug Utilization/trends
MH  - Humans
MH  - *Patient Education as Topic
MH  - Physician-Patient Relations
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Health Care
EDAT- 2003/01/14 04:00
MHDA- 2003/04/17 05:00
CRDT- 2003/01/14 04:00
PHST- 2003/01/14 04:00 [pubmed]
PHST- 2003/04/17 05:00 [medline]
PHST- 2003/01/14 04:00 [entrez]
AID - 10.1592/phco.23.1.73.31923 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2003 Jan;23(1):73-9. doi: 10.1592/phco.23.1.73.31923.

PMID- 31349862
OWN - NLM
STAT- MEDLINE
DCOM- 20200205
LR  - 20210120
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 20
IP  - 1
DP  - 2019 Jul 26
TI  - Aspirin versus placebo for the treatment of venous leg ulcers-a phase II, pilot, 
      randomised trial (AVURT).
PG  - 459
LID - 10.1186/s13063-019-3480-7 [doi]
LID - 459
AB  - BACKGROUND: Venous leg ulcers (VLUs) can take many months to heal and 25% fail to 
      heal. The main treatment for venous leg ulcers is compression therapy and few 
      additional therapies exist. Two previous trials indicated that low-dose aspirin 
      may improve healing time, but these trials were insufficiently robust. METHODS: A 
      multi-centred, pilot, phase II, randomised, double blind, parallel-group, 
      placebo-controlled, efficacy trial (RCT) was conducted to determine: if aspirin 
      improves VLU healing time; the safety of aspirin in this population; treatment 
      compliance; and the feasibility of recruitment to a phase III trial. We recruited 
      patients from secondary care who were aged ≥ 18 years, had a chronic VLU and not 
      regularly taking aspirin. Participants were randomly assigned (1:1) to receive 
      300 mg of daily aspirin or placebo in addition to standard care, which consisted 
      of multi component compression therapy aiming to deliver 40 mmHg at the ankle 
      where possible. The randomisation list was stratified by ulcer size (≤ 5 cm(2) 
      or > 5 cm(2)). The primary endpoint was time to ulcer healing, which was defined 
      as 'complete epithelial healing in the absence of scab (eschar) with no dressing 
      required'. Safety outcomes were assessed in all participants who received at 
      least one dose of the study drug. RESULTS: Twenty-seven patients were recruited 
      from eight sites (target 100 patients). A short time-frame to recruit and a large 
      number of patients failing to meet the eligibility criteria were the main 
      barriers to recruitment. There was no evidence of a difference in time to healing 
      of the reference ulcer following adjustment for log ulcer area and duration 
      (hazard ratio 0.58, 95% confidence interval 0.18 to 1.85; p = 0.357). One 
      expected serious adverse event related to aspirin was recorded. A number of 
      options to improve recruitment were explored. CONCLUSIONS: There was no evidence 
      that aspirin was effective in expediting the healing of chronic VLUs. However, 
      the analysis was underpowered due to the low number of participants recruited. 
      The trial design would require substantial amendment in order to progress to a 
      phase III (effectiveness) trial. TRIAL REGISTRATION: Clinicaltrials.gov, 
      NCT02333123. Registered on 5 November 2014.
FAU - Helen, Tilbrook
AU  - Helen T
AUID- ORCID: 0000-0002-1312-5780
AD  - York Trials Unit, Department of Health Sciences, University of York, Heslington, 
      York, YO10 5DD, UK.
FAU - Liz, Cook
AU  - Liz C
AD  - York Trials Unit, Department of Health Sciences, University of York, Heslington, 
      York, YO10 5DD, UK.
FAU - Laura, Clark
AU  - Laura C
AD  - York Trials Unit, Department of Health Sciences, University of York, Heslington, 
      York, YO10 5DD, UK.
FAU - Illary, Sbizzera
AU  - Illary S
AD  - York Trials Unit, Department of Health Sciences, University of York, Heslington, 
      York, YO10 5DD, UK.
FAU - Martin, Bland
AU  - Martin B
AD  - Department of Health Sciences, University of York, Heslington, York, YO10 5DD, 
      UK.
FAU - Hannah, Buckley
AU  - Hannah B
AD  - Cancer Division, Clinical Trials Research Unit, Leeds Institute of Clinical 
      Trials Research, University of Leeds, Leeds, LS2 9JT, UK.
FAU - Ian, Chetter
AU  - Ian C
AD  - Academic Vascular Surgical Unit, Hull Royal Infirmary, Anlaby Road, Hull, HU3 
      2JZ, UK.
FAU - Jo, Dumville
AU  - Jo D
AD  - Division of Nursing, Midwifery and Social Work, School of Health Sciences, 
      Faculty of Biology, Medicine and Health, University of Manchester, Manchester 
      Academic Health Science Centre, Oxford Road, Manchester, M13 9PL, UK.
FAU - Chris, Fenner
AU  - Chris F
AD  - Orthopaedic Department, West Middlesex Hospital, Twickenham Road, Isleworth, 
      Middlesex, TW9 1UR, UK.
FAU - Rachael, Forsythe
AU  - Rachael F
AD  - Centre for Cardiovascular Science, University of Edinburgh, 49 Little France 
      Crescent, Edinburgh, EH16 4SB, UK.
FAU - Rhian, Gabe
AU  - Rhian G
AD  - Hull York Medical School & York Trials Unit, Department of Health Sciences, 
      University of York, Heslington, York, YO10 5DD, UK.
FAU - Keith, Harding
AU  - Keith H
AD  - Wound Healing, Cardiff University, School of Medicine, Heath Park, Cardiff, CF14 
      4XN, UK.
FAU - Alison, Layton
AU  - Alison L
AD  - Harrogate and District NHS Foundation Trust, Lancaster Park Road, Harrogate, HG2 
      7SX, UK.
FAU - Ellie, Lindsay
AU  - Ellie L
AD  - (Lay representative). The Lindsay Leg Club Foundation, PO Box 689, Ipswich, IP1 
      9BN, UK.
FAU - Catriona, Mc Daid
AU  - Catriona MD
AD  - York Trials Unit, Department of Health Sciences, University of York, Heslington, 
      York, YO10 5DD, UK.
FAU - Christine, Moffatt
AU  - Christine M
AD  - The University of Nottingham, School of Health Sciences, Derby Education Centre, 
      Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3DT, UK.
FAU - Debbie, Rolfe
AU  - Debbie R
AD  - Joint Research and Enterprise Office, St Georges University of London, Cranmer 
      Terrace, London, SW17 0RE, UK.
FAU - Gerard, Stansby
AU  - Gerard S
AD  - Freeman Hospital, Freeman Road, Newcastle upon Tyne, NE7 7DN, UK.
FAU - David, Torgerson
AU  - David T
AD  - York Trials Unit, Department of Health Sciences, University of York, Heslington, 
      York, YO10 5DD, UK.
FAU - Peter, Vowden
AU  - Peter V
AD  - Bradford Teaching Hospitals NHS Foundation Trust, Bradford Royal Infirmary, 
      Duckworth Lane, Bradford, West Yorkshire, BD9 6RJ, UK.
FAU - Laurie, Williams
AU  - Laurie W
AD  - (Lay representative). The Lindsay Leg Club Foundation, PO Box 689, Ipswich, IP1 
      9BN, UK.
FAU - Robert, Hinchliffe
AU  - Robert H
AD  - Bristol Centre for Surgical Research, Bristol NIHR Biomedical Research Centre, 
      University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK. 
      robert.hinchliffe@bristol.ac.uk.
LA  - eng
SI  - ClinicalTrials.gov/NCT02333123
GR  - 13/87/08/DH_/Department of Health/United Kingdom
GR  - 13/87/08/Health Technology Assessment Programme/
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20190726
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Agents/*administration & dosage/adverse effects
MH  - Compression Bandages
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Time Factors
MH  - Treatment Outcome
MH  - United Kingdom
MH  - Varicose Ulcer/diagnosis/*drug therapy
MH  - Wound Healing/*drug effects
PMC - PMC6660698
OTO - NOTNLM
OT  - Aspirin
OT  - Double-blind
OT  - Phase II
OT  - Pilot
OT  - Placebo
OT  - Randomised
OT  - Trial
OT  - Ulcer
OT  - Venous
OT  - Wound
COIS- C. Moffatt has received grant funding from three health science-based technology 
      companies. All others authors declare that they have no competing interests.
EDAT- 2019/07/28 06:00
MHDA- 2020/02/06 06:00
CRDT- 2019/07/28 06:00
PHST- 2017/12/19 00:00 [received]
PHST- 2019/05/29 00:00 [accepted]
PHST- 2019/07/28 06:00 [entrez]
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
AID - 10.1186/s13063-019-3480-7 [pii]
AID - 3480 [pii]
AID - 10.1186/s13063-019-3480-7 [doi]
PST - epublish
SO  - Trials. 2019 Jul 26;20(1):459. doi: 10.1186/s13063-019-3480-7.

PMID- 7027430
OWN - NLM
STAT- MEDLINE
DCOM- 19811222
LR  - 20190909
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 10
IP  - 3
DP  - 1981
TI  - Comparison of serum salicylate levels and gastro-intestinal blood loss between 
      salsalate (Disalcid)and other forms of salicylates.
PG  - 169-73
AB  - In a first stage the effect of a single dose of 3 g of salsalate on serum 
      salicylate level was compared with a single intake of 3 g of soluble or 
      enteric-coated acetylsalicylates in 12 healthy subjects. Salsalate seems to 
      resorb faster than the enteric-coated forms but more slowly than the soluble 
      forms of acetylsalicylate. However, in comparison with these latter forms, 
      salsalate activity is more protracted. In the second part of the study, 42 
      patients were admitted to a trial in which 3 to 5 g of salsalate was given daily 
      and in which serum salicylate levels and blood loss in stools were measured using 
      the method of labelling red blood cells with Cr51. The ideal dosage to obtain a 
      serum salicylate level of 20 mg/100 ml seems to lie between 3 and 4 g of 
      salsalate a day. Salsalate caused abnormal gastro-intestinal blood loss in only 2 
      of the 42 patients studied, which is significantly fewer compared with the 
      soluble, intravenous or enteric-coated forms of acetylsalicylates.
FAU - Mielants, H
AU  - Mielants H
FAU - Veys, E M
AU  - Veys EM
FAU - Verbruggen, G
AU  - Verbruggen G
FAU - Schelstraete
AU  - Schelstraete
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - V9MO595C9I (salicylsalicylic acid)
SB  - IM
MH  - Aspirin/*adverse effects/blood
MH  - Clinical Trials as Topic
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Salicylates/*adverse effects/blood
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.3109/03009748109095292 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 1981;10(3):169-73. doi: 10.3109/03009748109095292.

PMID- 11790072
OWN - NLM
STAT- MEDLINE
DCOM- 20020403
LR  - 20220408
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 136
IP  - 2
DP  - 2002 Jan 15
TI  - Aspirin for the primary prevention of cardiovascular events: a summary of the 
      evidence for the U.S. Preventive Services Task Force.
PG  - 161-72
AB  - BACKGROUND: The use of aspirin to prevent cardiovascular disease events in 
      patients without a history of cardiovascular disease is controversial. PURPOSE: 
      To examine the benefits and harms of aspirin chemoprevention. DATA SOURCES: 
      MEDLINE (1966 to May 2001). STUDY SELECTION: 1) Randomized trials at least 1 year 
      in duration that examined aspirin chemoprevention in patients without previously 
      known cardiovascular disease and 2) systematic reviews, recent trials, and 
      observational studies that examined rates of hemorrhagic strokes and 
      gastrointestinal bleeding secondary to aspirin use. DATA EXTRACTION: One reviewer 
      read and extracted data from each included article and constructed evidence 
      tables. A second reviewer checked the accuracy of the data extraction. 
      Discrepancies were resolved by consensus. DATA SYNTHESIS: Meta-analysis was 
      performed, and the quantitative results of the review were then used to model the 
      consequences of treating patients with different levels of baseline risk for 
      coronary heart disease. Five trials examined the effect of aspirin on 
      cardiovascular events in patients with no previous cardiovascular disease. For 
      patients similar to those enrolled in the trials, aspirin reduces the risk for 
      the combined end point of nonfatal myocardial infarction and fatal coronary heart 
      disease (summary odds ratio, 0.72 [95% CI, 0.60 to 0.87]). Aspirin increased the 
      risk for hemorrhagic strokes (summary odds ratio, 1.4 [CI, 0.9 to 2.0]) and major 
      gastrointestinal bleeding (summary odds ratio, 1.7 [CI, 1.4 to 2.1]). All-cause 
      mortality (summary odds ratio, 0.93 [CI, 0.84 to 1.02]) was not significantly 
      affected. For 1000 patients with a 5% risk for coronary heart disease events over 
      5 years, aspirin would prevent 6 to 20 myocardial infarctions but would cause 0 
      to 2 hemorrhagic strokes and 2 to 4 major gastrointestinal bleeding events. For 
      patients with a risk of 1% over 5 years, aspirin would prevent 1 to 4 myocardial 
      infarctions but would cause 0 to 2 hemorrhagic strokes and 2 to 4 major 
      gastrointestinal bleeding events. CONCLUSIONS: The net benefit of aspirin 
      increases with increasing cardiovascular risk. In the decision to use aspirin 
      chemoprevention, the patient's cardiovascular risk and relative utility for the 
      different clinical outcomes prevented or caused by aspirin use must be 
      considered.
FAU - Hayden, Michael
AU  - Hayden M
AD  - Division of General Medicine, Department of Medicine, 11C Ambulatory Care, 
      Veterans Administration Medical Center, USA.
FAU - Pignone, Michael
AU  - Pignone M
FAU - Phillips, Christopher
AU  - Phillips C
FAU - Mulrow, Cynthia
AU  - Mulrow C
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- Ann Intern Med. 2002 Jan 15;136(2):I55. PMID: 11928737
CIN - J Fam Pract. 2002 May;51(5):415. PMID: 12019044
CIN - ACP J Club. 2002 Jul-Aug;137(1):6. PMID: 12093205
CIN - Ann Intern Med. 2002 Oct 1;137(7):622-3. PMID: 12353960
CIN - Ann Intern Med. 2005 Jun 7;142(11):942-3. PMID: 15941704
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chemoprevention
MH  - Coronary Disease/epidemiology/*prevention & control
MH  - Evidence-Based Medicine
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention
MH  - Risk Factors
MH  - Stroke/chemically induced/prevention & control
MH  - United States/epidemiology
EDAT- 2002/01/16 10:00
MHDA- 2002/04/04 10:01
CRDT- 2002/01/16 10:00
PHST- 2002/01/16 10:00 [pubmed]
PHST- 2002/04/04 10:01 [medline]
PHST- 2002/01/16 10:00 [entrez]
AID - 200201150-00016 [pii]
AID - 10.7326/0003-4819-136-2-200201150-00016 [doi]
PST - ppublish
SO  - Ann Intern Med. 2002 Jan 15;136(2):161-72. doi: 
      10.7326/0003-4819-136-2-200201150-00016.

PMID- 21361438
OWN - NLM
STAT- MEDLINE
DCOM- 20110620
LR  - 20131121
IS  - 1520-8524 (Electronic)
IS  - 0001-4966 (Linking)
VI  - 129
IP  - 2
DP  - 2011 Feb
TI  - Effects of aspirin on distortion product fine structure: interpreted by the 
      two-source model for distortion product otoacoustic emissions generation.
PG  - 792-800
LID - 10.1121/1.3523308 [doi]
AB  - Distortion product otoacoustic emission (DPOAE) fine structure is due to the 
      interaction of two major components coming from different places in the cochlea. 
      One component is generated from the region of maximal overlap of the traveling 
      waves generated by the two primaries and is attributed to nonlinear distortion 
      (nonlinear component). The other component arises predominantly from the 
      tonotopic region of the distortion product and is attributed to linear coherent 
      reflection (reflection component). Aspirin (salicylate) ototoxicity can cause 
      reversible hearing loss and reduces otoacoustic emission generation in the 
      cochlea. The two components are expected to be affected differentially by 
      cochlear health. Changes in DPOAE fine structure were recorded longitudinally in 
      three subjects before, during, and after aspirin consumption. Full data sets were 
      analyzed for two subjects, but only partial data could be analyzed from the third 
      subject. Resulting changes in the two components of DPOAE fine structure revealed 
      variability among subjects and differential effects on the two components. For 
      low-intensity primaries, both components were reduced with the reflection 
      component being more vulnerable. For high-intensity primaries, the nonlinear 
      component showed little or no change, but the reflection component was always 
      reduced.
FAU - Rao, Aparna
AU  - Rao A
AD  - Department of Speech-Language-Hearing Sciences, University of Minnesota, 
      Minneapolis, Minnesota 55455, USA. raoxx098@umn.edu
FAU - Long, Glenis R
AU  - Long GR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Acoust Soc Am
JT  - The Journal of the Acoustical Society of America
JID - 7503051
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acoustic Stimulation
MH  - Adult
MH  - Aspirin/administration & dosage/*toxicity
MH  - Audiometry
MH  - Auditory Threshold
MH  - Cochlea/*drug effects/physiopathology
MH  - Fourier Analysis
MH  - Hearing Loss/*chemically induced/physiopathology
MH  - Humans
MH  - Least-Squares Analysis
MH  - *Models, Biological
MH  - Nonlinear Dynamics
MH  - Otoacoustic Emissions, Spontaneous/*drug effects
MH  - Reaction Time
MH  - Time Factors
MH  - Young Adult
EDAT- 2011/03/03 06:00
MHDA- 2011/06/21 06:00
CRDT- 2011/03/03 06:00
PHST- 2011/03/03 06:00 [entrez]
PHST- 2011/03/03 06:00 [pubmed]
PHST- 2011/06/21 06:00 [medline]
AID - 10.1121/1.3523308 [doi]
PST - ppublish
SO  - J Acoust Soc Am. 2011 Feb;129(2):792-800. doi: 10.1121/1.3523308.

PMID- 24689297
OWN - NLM
STAT- MEDLINE
DCOM- 20140527
LR  - 20140402
IS  - 1934-578X (Print)
IS  - 1555-9475 (Linking)
VI  - 9
IP  - 2
DP  - 2014 Feb
TI  - Biological studies of turmeric oil, part 3: anti-inflammatory and analgesic 
      properties of turmeric oil and fish oil in comparison with aspirin.
PG  - 225-8
AB  - Turmeric and fish oil have been gaining interest as food supplements because of 
      their beneficial properties. Turmeric oil contains sesquiterpenes and fish oil 
      has eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), possessing 
      anti-inflammatory activity. The present study is to evaluate and compare the 
      anti-inflammatory and analgesic properties of these two natural food products 
      with aspirin as a standard. The percent inhibition as a measure of paw edema for 
      turmeric oil and fish oil at 100 mg/kg was 76% and 31%, respectively, while the 
      percent inhibition by the combination of the two at 100 mg/kg was 62%, which was 
      the same as that of aspirin at the same dose. The inhibitory activity of fish oil 
      at 50 mg/kg was 86% and with an increase in dose the activity decreased. The 
      analgesic activity measured by the tail flick method showed optimum activities 
      for turmeric oil and fish oil at 60 and 90 minutes, respectively, whereas the 
      combination of the two decreased the analgesic activity. Thus the two common food 
      ingredients, oils from turmeric and fish, have desirable biochemical properties 
      to develop further their use as food and medicine.
FAU - Jacob, James N
AU  - Jacob JN
FAU - Badyal, Dinesh K
AU  - Badyal DK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Nat Prod Commun
JT  - Natural product communications
JID - 101477873
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Fish Oils)
RN  - 0 (Plant Oils)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - *Curcuma
MH  - Female
MH  - Fish Oils/*pharmacology
MH  - Male
MH  - Plant Oils/*pharmacology
MH  - Rats
EDAT- 2014/04/03 06:00
MHDA- 2014/05/28 06:00
CRDT- 2014/04/03 06:00
PHST- 2014/04/03 06:00 [entrez]
PHST- 2014/04/03 06:00 [pubmed]
PHST- 2014/05/28 06:00 [medline]
PST - ppublish
SO  - Nat Prod Commun. 2014 Feb;9(2):225-8.

PMID- 19155962
OWN - NLM
STAT- MEDLINE
DCOM- 20090312
LR  - 20131121
IS  - 1536-3694 (Electronic)
IS  - 0163-4356 (Linking)
VI  - 31
IP  - 1
DP  - 2009 Feb
TI  - Hearing loss in a woman on aspirin: the silent pharmacokinetic parameter.
PG  - 1-2
LID - 10.1097/FTD.0b013e3181951ed9 [doi]
AB  - A sudden hearing loss in a woman on aspirin has uncovered a frequently neglected 
      toxicological parameter.
FAU - Koren, Gideon
AU  - Koren G
AD  - From the Division of Clinical Pharmacology & Toxicology, The Hospital for Sick 
      Children, Toronto, Ontario, Canada. gkoren@sickkids.ca
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ther Drug Monit
JT  - Therapeutic drug monitoring
JID - 7909660
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/*blood/therapeutic use
MH  - Aspirin/*adverse effects/*blood/therapeutic use
MH  - Disease Progression
MH  - Female
MH  - Hearing Loss/*chemically induced
MH  - Humans
MH  - Lupus Erythematosus, Systemic/complications/drug therapy
MH  - Proteinuria/metabolism
MH  - Salicylates/blood
MH  - Tinnitus/etiology
EDAT- 2009/01/22 09:00
MHDA- 2009/03/13 09:00
CRDT- 2009/01/22 09:00
PHST- 2009/01/22 09:00 [entrez]
PHST- 2009/01/22 09:00 [pubmed]
PHST- 2009/03/13 09:00 [medline]
AID - 00007691-200902000-00001 [pii]
AID - 10.1097/FTD.0b013e3181951ed9 [doi]
PST - ppublish
SO  - Ther Drug Monit. 2009 Feb;31(1):1-2. doi: 10.1097/FTD.0b013e3181951ed9.

PMID- 29534696
OWN - NLM
STAT- MEDLINE
DCOM- 20180830
LR  - 20181114
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Mar 13
TI  - Associations between aspirin use and the risk of cancers: a meta-analysis of 
      observational studies.
PG  - 288
LID - 10.1186/s12885-018-4156-5 [doi]
LID - 288
AB  - BACKGROUND: Epidemiological studies have clarified the potential associations 
      between regular aspirin use and cancers. However, it remains controversial on 
      whether aspirin use decreases the risk of cancers risks. Therefore, we conducted 
      an updated meta-analysis to assess the associations between aspirin use and 
      cancers. METHODS: The PubMed, Embase, and Web of Science databases were 
      systematically searched up to March 2017 to identify relevant studies. Relative 
      risks (RRs) with 95% confidence intervals (CIs) were used to assess the strength 
      of associations. RESULTS: A total of 218 studies with 309 reports were eligible 
      for this meta-analysis. Aspirin use was associated with a significant decrease in 
      the risk of overall cancer (RR = 0.89, 95% CI: 0.87-0.91), and gastric 
      (RR = 0.75, 95% CI: 0.65-0.86), esophageal (RR = 0.75, 95% CI: 0.62-0.89), 
      colorectal (RR = 0.79, 95% CI: 0.74-0.85), pancreatic (RR = 0.80, 95% CI: 
      0.68-0.93), ovarian (RR = 0.89, 95% CI: 0.83-0.95), endometrial (RR = 0.92, 95% 
      CI: 0.85-0.99), breast (RR = 0.92, 95% CI: 0.88-0.96), and prostate (RR = 0.94, 
      95% CI: 0.90-0.99) cancers, as well as small intestine neuroendocrine tumors 
      (RR = 0.17, 95% CI: 0.05-0.58). CONCLUSIONS: These findings suggest that aspirin 
      use is associated with a reduced risk of gastric, esophageal, colorectal, 
      pancreatic, ovarian, endometrial, breast, and prostate cancers, and small 
      intestine neuroendocrine tumors.
FAU - Qiao, Yan
AU  - Qiao Y
AD  - Department of Social Medicine and Health Management, School of Public Health, 
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 
      430030, People's Republic of China.
FAU - Yang, Tingting
AU  - Yang T
AD  - Department of Nutriology, The People's Hospital of Henan Province, Zhengzhou, 
      Henan, 450003, People's Republic of China.
FAU - Gan, Yong
AU  - Gan Y
AD  - Department of Social Medicine and Health Management, School of Public Health, 
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 
      430030, People's Republic of China.
FAU - Li, Wenzhen
AU  - Li W
AD  - Department of Social Medicine and Health Management, School of Public Health, 
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 
      430030, People's Republic of China.
FAU - Wang, Chao
AU  - Wang C
AD  - Department of Social Medicine and Health Management, School of Public Health, 
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 
      430030, People's Republic of China.
FAU - Gong, Yanhong
AU  - Gong Y
AD  - Department of Social Medicine and Health Management, School of Public Health, 
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 
      430030, People's Republic of China. gongyanhong@hust.edu.cn.
FAU - Lu, Zuxun
AU  - Lu Z
AD  - Department of Social Medicine and Health Management, School of Public Health, 
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 
      430030, People's Republic of China. zuxunlu@yahoo.com.
LA  - eng
GR  - 2016YXMS215/Fundamental Research Funds for the Central Universities, Huazhong 
      University of Science and Technology , China/International
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20180313
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Neoplasms/epidemiology/*prevention & control
MH  - Observational Studies as Topic
MH  - Prognosis
MH  - Risk Assessment
PMC - PMC5851082
OTO - NOTNLM
OT  - Aspirin
OT  - Cancers
OT  - Meta-analysis
OT  - Observational studies
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable CONSENT FOR 
      PUBLICATION: Not applicable COMPETING INTERESTS: The authors declare that they 
      have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral 
      with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2018/03/15 06:00
MHDA- 2018/08/31 06:00
CRDT- 2018/03/15 06:00
PHST- 2017/09/28 00:00 [received]
PHST- 2018/02/20 00:00 [accepted]
PHST- 2018/03/15 06:00 [entrez]
PHST- 2018/03/15 06:00 [pubmed]
PHST- 2018/08/31 06:00 [medline]
AID - 10.1186/s12885-018-4156-5 [pii]
AID - 4156 [pii]
AID - 10.1186/s12885-018-4156-5 [doi]
PST - epublish
SO  - BMC Cancer. 2018 Mar 13;18(1):288. doi: 10.1186/s12885-018-4156-5.

PMID- 8591386
OWN - NLM
STAT- MEDLINE
DCOM- 19960401
LR  - 20150602
IS  - 1569-6332 (Print)
IS  - 1569-6332 (Linking)
VI  - 8 Pt 2
DP  - 1995
TI  - Numerical models for calculating the blood level of a drug with oral controlled 
      release forms.
PG  - 1127-31
AB  - Controlled release dosage forms offer advantages over conventional dosage forms 
      and a more constant and prolonged therapeutic effect. These new dosage forms are 
      tested by using in-vitro tests or in-vivo tests; however, a great problem appears 
      with the establishment of correlations between these tests. A new way of working 
      is able to resolve the problem. It consists of coupling either experiments or 
      models based on numerical analysis and computerization. In-vitro tests performed 
      at various pH are used to determine the kinetics of release and the parameters 
      characterizing diffusion or erosion. From the knowledge of the certain data (the 
      gastrointestinal tract-time history, the kinetics of release of the drug out of 
      the dosage form, the rate constants of absorption and elimination, and the 
      plasmatic volume), it is possible to obtain, by calculation, the kinetics of the 
      drug in the plasmatic volume, as well as other pieces of information. Not only is 
      the model able to predict the pharmacokinetics of a drug from a controlled 
      release dosage form, but it also optimizes the characteristics of the dosage 
      form. The validity of the model is successfully tested by comparing the blood 
      level of Theophylline, obtained either by in-vivo tests or calculation.
FAU - Vergnaud, J M
AU  - Vergnaud JM
AD  - Faculty of Sciences, University of St Etienne, 23 Dr. P. Michelon 42023 St 
      Edenne, France.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Medinfo
JT  - Medinfo. MEDINFO
JID - 7600347
RN  - 0 (Delayed-Action Preparations)
RN  - C137DTR5RG (Theophylline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/blood
MH  - Body Fluid Compartments
MH  - Delayed-Action Preparations/*pharmacokinetics
MH  - Diffusion
MH  - Humans
MH  - Mathematical Computing
MH  - *Models, Biological
MH  - Theophylline/administration & dosage/blood
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Medinfo. 1995;8 Pt 2:1127-31.

PMID- 6195676
OWN - NLM
STAT- MEDLINE
DCOM- 19831220
LR  - 20191031
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 12
IP  - 1
DP  - 1983 Sep
TI  - Possible prostacyclin-mediated vascular effect of angiotensin II in the isolated 
      perfused rat lung.
PG  - 77-83
AB  - Angiotensin I (A I) and angiotensin II (A II) when injected through the pulmonary 
      artery caused an increase in perfusion pressure (PP) of the isolated perfused rat 
      lung and a contraction when the venous outflow was superfused over rat ascending 
      colon (RC). Nicotine (N) when added to the perfusion medium caused a significant 
      increase in PP to A II without altering that to A I. Further addition of ZK 
      36374, a stable analog of prostacyclin (PGI2), to the medium prevented the 
      potentiating effect of N on the A II pressor response. Neither N nor ZK 36374 
      altered the superfused RC responses to A I and A II-injected venous effluent. 
      Lysine acetylsalicylate (ASA), however, caused a potentiation in the pressor 
      response to A I. The response of venous effluent superfused RC to A I was also 
      found to be potentiated by ASA. ASA failed to alter the responses to A II. These 
      results were taken as evidence that A II is a potent activator for the 
      biosynthesis of PGI2 in the pulmonary vascular bed. Moreover, PGI2 does not 
      affect angiotensin converting enzyme activity in the lung circulation while other 
      stable metabolites of arachidonic acid can inhibit the conversion of A I to A II.
FAU - Ercan, Z S
AU  - Ercan ZS
FAU - Zengil, H
AU  - Zengil H
FAU - Akar, F
AU  - Akar F
FAU - Türker, R K
AU  - Türker RK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 11128-99-7 (Angiotensin II)
RN  - 6M3C89ZY6R (Nicotine)
RN  - 9041-90-1 (Angiotensin I)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - JED5K35YGL (Iloprost)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Angiotensin I/pharmacology
MH  - Angiotensin II/*pharmacology
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Colon/drug effects
MH  - Epoprostenol/*pharmacology
MH  - Female
MH  - Iloprost
MH  - Lung/*drug effects
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Nicotine/*pharmacology
MH  - Pulmonary Circulation/*drug effects
MH  - Rats
EDAT- 1983/09/01 00:00
MHDA- 1983/09/01 00:01
CRDT- 1983/09/01 00:00
PHST- 1983/09/01 00:00 [pubmed]
PHST- 1983/09/01 00:01 [medline]
PHST- 1983/09/01 00:00 [entrez]
AID - 10.1016/0262-1746(83)90070-7 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1983 Sep;12(1):77-83. doi: 
      10.1016/0262-1746(83)90070-7.

PMID- 3555016
OWN - NLM
STAT- MEDLINE
DCOM- 19870605
LR  - 20190815
IS  - 0272-6386 (Print)
IS  - 0272-6386 (Linking)
VI  - 9
IP  - 5
DP  - 1987 May
TI  - Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis.
PG  - 417-21
AB  - A trial of antiplatelet therapy (slow-release aspirin and dipyridamole) in 
      mesangial IgA glomerulonephritis was conducted. Vitamin B was given to the 
      control group. Altogether, 38 patients were observed for a mean of 33.2 months. 
      Antiplatelet therapy did not favorably modify the course of mesangial IgA 
      glomerulonephritis. The rate of progression of the disease, measured by the slope 
      of reciprocals of serum creatinine v time plots, correlated significantly with 
      the severity of tissue damage as assessed by an arbitrary morphologic score from 
      renal biopsy specimens.
FAU - Chan, M K
AU  - Chan MK
FAU - Kwan, S Y
AU  - Kwan SY
FAU - Chan, K W
AU  - Chan KW
FAU - Yeung, C K
AU  - Yeung CK
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Immunoglobulin G)
RN  - 64ALC7F90C (Dipyridamole)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Clinical Trials as Topic
MH  - Creatinine/blood
MH  - Delayed-Action Preparations
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glomerular Mesangium
MH  - Glomerulonephritis, IGA/*drug therapy
MH  - Humans
MH  - Immunoglobulin G/analysis
MH  - Male
MH  - Random Allocation
EDAT- 1987/05/01 00:00
MHDA- 1987/05/01 00:01
CRDT- 1987/05/01 00:00
PHST- 1987/05/01 00:00 [pubmed]
PHST- 1987/05/01 00:01 [medline]
PHST- 1987/05/01 00:00 [entrez]
AID - S0272638687000416 [pii]
AID - 10.1016/s0272-6386(87)80145-2 [doi]
PST - ppublish
SO  - Am J Kidney Dis. 1987 May;9(5):417-21. doi: 10.1016/s0272-6386(87)80145-2.

PMID- 1602291
OWN - NLM
STAT- MEDLINE
DCOM- 19920710
LR  - 20190902
IS  - 0954-6820 (Print)
IS  - 0954-6820 (Linking)
VI  - 231
IP  - 5
DP  - 1992 May
TI  - Aspirin to prevent growth of vegetations and cerebral emboli in infective 
      endocarditis.
PG  - 543-6
AB  - The incidence of stroke on cranial computed tomography (CT) and change in 
      echocardiographic vegetation area was prospectively compared in a preliminary 
      observational study involving nine patients with infective endocarditis 
      randomized to either low-dose aspirin (75 mg d-1, Group I, n = 4) or no aspirin 
      (Group II, n = 5). Two symptomatic cerebral infarcts and one myocardial infarct 
      occurred in the controls, compared to no events in patients on aspirin during a 
      total observation period of 343 d (range 28-49 d). The mean vegetation area 
      decreased in the aspirin group (mean change = -0.24 cm2), compared to an increase 
      in controls (mean change = +0.35 cm2). The platelet half-life (normal range 5-6 
      d), which was measured using Indium-111 radiolabelling, tended to be lower in 
      Group II (4.6 +/- 0.2 vs. 3.9 +/- 0.5 d). No side-effects or complications 
      attributable to aspirin were observed. A possible role for adjunctive aspirin 
      therapy in the prevention of embolic complications in infective endocarditis is 
      suggested, and warrants further study.
FAU - Taha, T H
AU  - Taha TH
AD  - Department of Medicine (Clinical Cardiology), Hammersmith Hospital, London, UK.
FAU - Durrant, S S
AU  - Durrant SS
FAU - Mazeika, P K
AU  - Mazeika PK
FAU - Nihoyannopoulos, P
AU  - Nihoyannopoulos P
FAU - Oakley, C M
AU  - Oakley CM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Brain/diagnostic imaging
MH  - Echocardiography
MH  - Endocarditis, Bacterial/diagnosis/*drug therapy/microbiology
MH  - Female
MH  - Humans
MH  - Intracranial Embolism and Thrombosis/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Staphylococcus epidermidis/isolation & purification
MH  - Streptococcus/isolation & purification
MH  - Tomography, X-Ray Computed
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
AID - 10.1111/j.1365-2796.1992.tb00971.x [doi]
PST - ppublish
SO  - J Intern Med. 1992 May;231(5):543-6. doi: 10.1111/j.1365-2796.1992.tb00971.x.

PMID- 28838931
OWN - NLM
STAT- MEDLINE
DCOM- 20190603
LR  - 20190603
IS  - 2045-4368 (Electronic)
IS  - 2045-435X (Linking)
VI  - 9
IP  - 1
DP  - 2019 Mar
TI  - End-of-life prescribing of aspirin in patients with breast or colorectal cancer.
PG  - e6
LID - 10.1136/bmjspcare-2017-001370 [doi]
AB  - OBJECTIVES: The aim of this study was to evaluate the influence of an approaching 
      cancer death on end-of-life aspirin use, a frequently prescribed medication for 
      cardiovascular disease prevention. METHODS: This study was conducted using linked 
      cancer registry and prescribing data. Breast (n=1151) and colorectal (n=1859) 
      cancer decedents were matched to cancer survivors and the probability of either 
      initiating aspirin, or continuing established aspirin use, was estimated in 
      consecutive periods over the 5 years approaching a cancer-specific death 
      (decedents) or matched index date (survivors). RESULTS: Using the linked data 
      sets, we identified patients who died of their cancer (decedents) between 1 
      January 2001 and 31 December 2009. In the 5 years prior to death, we compared (1) 
      the probability of initiating aspirin use for the first time, and (2) the 
      probability of continuing aspirin use. In comparison to matched cancer survivors, 
      an approaching cancer death was not associated with a reduction in aspirin 
      initiation by breast or colorectal cancer decedents. However, the probability of 
      continuing established aspirin use declined considerably in the 24 months 
      approaching death and at the time of a death was significantly lower for breast 
      (risk difference (RD) -0.26, 95% CI -0.33 to -0.20) and colorectal (RD -0.38, 
      95% CI -0.46 to -0.30) cancer decedents versus matched survivors. CONCLUSION: A 
      significant proportion of patients discontinue their aspirin in the time 
      approaching a breast or colorectal cancer-specific death. The safety and benefits 
      of this are unclear and empirical data are needed to guide decisions about 
      aspirin use in the end of life.
CI  - © Article author(s) (or their employer(s) unless otherwise stated in the text of 
      the article) 2019. All rights reserved. No commercial use is permitted unless 
      otherwise expressly granted.
FAU - Murphy, Laura
AU  - Murphy L
AD  - Division of Population Health Science, Royal College of Surgeons in Ireland, 
      Dublin, Ireland.
FAU - Brown, Chris
AU  - Brown C
AD  - National Cancer Registry, Cork, Ireland.
FAU - Smith, Amelia
AU  - Smith A
AD  - Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, 
      Trinity College, University of Dublin, Dublin, Ireland.
FAU - Cranfield, Faith
AU  - Cranfield F
AD  - Saint Francis Hospice, Dublin, Ireland.
FAU - Sharp, Linda
AU  - Sharp L
AD  - Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
FAU - Visvanathan, Kala
AU  - Visvanathan K
AD  - Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins School of Medicine, 
      Baltimore, Maryland, USA.
AD  - Department of Epidemiology, Johns Hopkins University Bloomberg School of Public 
      Health, Baltimore, Maryland, USA.
FAU - Bennett, Kathleen
AU  - Bennett K
AD  - Division of Population Health Science, Royal College of Surgeons in Ireland, 
      Dublin, Ireland.
FAU - Barron, Thomas Ian
AU  - Barron TI
AD  - Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, 
      Trinity College, University of Dublin, Dublin, Ireland.
AD  - Department of Epidemiology, Johns Hopkins University Bloomberg School of Public 
      Health, Baltimore, Maryland, USA.
LA  - eng
PT  - Journal Article
DEP - 20170824
PL  - England
TA  - BMJ Support Palliat Care
JT  - BMJ supportive & palliative care
JID - 101565123
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - *Breast Neoplasms
MH  - Cancer Survivors
MH  - Cardiovascular Agents/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - *Colorectal Neoplasms
MH  - Female
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Terminal Care/*statistics & numerical data
OTO - NOTNLM
OT  - aspirin
OT  - breast cancer
OT  - colorectal cancer
OT  - end of life
COIS- Competing interests: LS held an unrestricted project grant from Sanofi-Aventis in 
      2011–2012 for research on survival from breast cancer. All remaining authors have 
      declared no competing interests.
EDAT- 2017/08/26 06:00
MHDA- 2019/06/04 06:00
CRDT- 2017/08/26 06:00
PHST- 2017/04/25 00:00 [received]
PHST- 2017/07/24 00:00 [revised]
PHST- 2017/07/26 00:00 [accepted]
PHST- 2017/08/26 06:00 [pubmed]
PHST- 2019/06/04 06:00 [medline]
PHST- 2017/08/26 06:00 [entrez]
AID - bmjspcare-2017-001370 [pii]
AID - 10.1136/bmjspcare-2017-001370 [doi]
PST - ppublish
SO  - BMJ Support Palliat Care. 2019 Mar;9(1):e6. doi: 10.1136/bmjspcare-2017-001370. 
      Epub 2017 Aug 24.

PMID- 20233202
OWN - NLM
STAT- MEDLINE
DCOM- 20100903
LR  - 20181113
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 69
IP  - 3
DP  - 2010 Mar
TI  - Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. 
      nonselective COX-2 inhibitors.
PG  - 303-6
LID - 10.1111/j.1365-2125.2009.03579.x [doi]
AB  - AIMS: Cyclooxygenase (COX)-2 inhibition has been reported to suppress the 
      biosynthesis of the gastroprotective lipoxygenase metabolite 15(R)-epi-lipoxin 
      A(4), also termed 'aspirin-triggered lipoxin' (ATL). We tested the hypothesis 
      that the co-administration of aspirin with either the selective COX-2 inhibitor 
      celecoxib or the nonselective COX inhibitor ibuprofen reduces ATL biosynthesis. 
      METHODS: We measured the urinary excretion of ATL in 24 patients with both 
      ischaemic heart disease and osteoarthritis, chronically treated with aspirin and 
      co-administered celecoxib 200 mg b.i.d., ibuprofen 600 mg t.i.d., or placebo for 
      7 days. RESULTS: Baseline ATL was comparable in the three groups. On days 1 and 
      7, 4 h after co-administration of celecoxib or ibuprofen, ATL levels did not show 
      significant variations (day 1: 0.24 +/- 0.33, 0.26 +/- 0.21 and 0.37 +/- 0.22 ng 
      mg(-1) creatinine, respectively; day 7: 0.21 +/- 0.13, 0.35 +/- 0.15 and 0.23 +/- 
      0.18 ng mg(-1) creatinine, respectively). CONCLUSIONS: Neither selective nor 
      nonselective COX-2 inhibition appreciably interferes with ATL biosynthesis, 
      suggesting that this mediator is not involved in exacerbating gastrotoxicity by 
      the association of aspirin with COX-2 inhibitors.
FAU - Renda, Giulia
AU  - Renda G
AD  - 'G. d'Annunzio' University, Chieti, Italy.
FAU - Zurro, Maria
AU  - Zurro M
FAU - Romano, Mario
AU  - Romano M
FAU - De Caterina, Raffaele
AU  - De Caterina R
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Lipoxins)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
EIN - Br J Clin Pharmacol. 2010 Aug;70(2):316
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Celecoxib
MH  - Cyclooxygenase 2 Inhibitors/*administration & dosage/pharmacology/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ibuprofen/administration & dosage
MH  - Lipoxins/*biosynthesis/metabolism/pharmacology
MH  - Middle Aged
MH  - Myocardial Ischemia/*drug therapy
MH  - Osteoarthritis/*drug therapy
MH  - Placebo Effect
MH  - Pyrazoles/administration & dosage
MH  - Sulfonamides/administration & dosage
PMC - PMC2829701
EDAT- 2010/03/18 06:00
MHDA- 2010/09/04 06:00
CRDT- 2010/03/18 06:00
PHST- 2010/03/18 06:00 [entrez]
PHST- 2010/03/18 06:00 [pubmed]
PHST- 2010/09/04 06:00 [medline]
AID - BCP3579 [pii]
AID - 10.1111/j.1365-2125.2009.03579.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2010 Mar;69(3):303-6. doi: 10.1111/j.1365-2125.2009.03579.x.

PMID- 10595862
OWN - NLM
STAT- MEDLINE
DCOM- 20000124
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 58
IP  - 5
DP  - 1999 Nov
TI  - Overview of pharmacological treatment of Kawasaki disease.
PG  - 813-22
AB  - Kawasaki disease has been researched for 32 years but its aetiology is still 
      unknown. Conventional therapy for the disease includes corticosteroids and 
      aspirin (acetylsalicylic acid) as anti-inflammatory and/or antithrombotic agents 
      but they have not been proven to prevent coronary artery aneurysms. Although a 
      high incidence of liver dysfunction in Japanese patients with Kawasaki disease 
      receiving high dose aspirin (> or =80 mg/kg/day) suggests racial differences in 
      salicylate sensitivity, the duration of fever in patients receiving high dose 
      aspirin is shorter than that in patients receiving moderate dosages (30 to 50 
      mg/kg/day). Furthermore, most corticosteroid-resistant patients were found to 
      develop coronary artery aneurysms, many of which were large. With the 
      clarification of the pathogenesis and clinical features of Kawasaki disease, 
      advances in its treatment have been achieved. The introduction of high-dose 
      intravenous gamma-globulin (IVGG) was an epoch in this field and IVGG is now a 
      standard therapy with the incidence of persistent coronary aneurysms 1.9% in 
      children with the disease receiving IVGG. Today, research is mainly directed 
      toward the treatment of IVGG-resistant patients. One to 3 days of pulsed doses of 
      methylprednisolone (30 mg/kg/day) or readministration of IVGG 1 g/kg (once to 
      several times) has been recommended for patients with IVGG-resistant Kawasaki 
      disease.
FAU - Onouchi, Z
AU  - Onouchi Z
AD  - Division of Paediatrics, Children's Research Hospital, Kyoto, Prefectural 
      University of Medicine, Japan.
FAU - Kawasaki, T
AU  - Kawasaki T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (gamma-Globulins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Heart Transplantation
MH  - Humans
MH  - Injections, Intravenous
MH  - Mucocutaneous Lymph Node Syndrome/drug therapy/*therapy
MH  - gamma-Globulins/administration & dosage/adverse effects/therapeutic use
RF  - 58
EDAT- 1999/12/14 00:00
MHDA- 1999/12/14 00:01
CRDT- 1999/12/14 00:00
PHST- 1999/12/14 00:00 [pubmed]
PHST- 1999/12/14 00:01 [medline]
PHST- 1999/12/14 00:00 [entrez]
AID - 10.2165/00003495-199958050-00004 [doi]
PST - ppublish
SO  - Drugs. 1999 Nov;58(5):813-22. doi: 10.2165/00003495-199958050-00004.

PMID- 16161940
OWN - NLM
STAT- MEDLINE
DCOM- 20051206
LR  - 20131121
IS  - 1426-9686 (Print)
IS  - 1426-9686 (Linking)
VI  - 18
IP  - 107
DP  - 2005 May
TI  - [Lipoxins--new view on old mediators carrying potent anti-inflammatory action].
PG  - 491-5
AB  - Lipoxins are the class of bioactive lipid mediators that carry potent 
      anti-inflammatory signals. They are generated in humans during cell-cell 
      interactions by one of at least three routes. Recently, aspirin was found to 
      influence one of them and to trigger formation of 15-epir-lipoxins that may 
      contribute to some of the beneficial action ascribed to aspirin. Lipoxins carry 
      unique counter-regulatory actions that promote resolution of inflammation via 
      multiple mechanisms, including inhibition of leukocyte recruitment and 
      activation, cytokine and chemokine release and biosynthesis of pro-inflammatory 
      lipid mediators. As lipoxins are likely to play physiologic role during 
      homeostatic response, they may be also associated with number of inflammatory 
      diseases. Thus, lipoxins and their stable analogues could provide novel 
      therapeutic approach to the treatment of inflammatory disorders. Here, we present 
      an overview of the recent knowledge about the biosynthesis and bioactions of 
      these anti-inflammatory lipid mediators.
FAU - Jarmakowska, Katarzyna
AU  - Jarmakowska K
AD  - Klinika Pneumonologii i Alergologii Instytutu Medycyny Wewnetrznej Uniwersytetu 
      Medycznego w Lodzi.
FAU - Kuna, Piotr
AU  - Kuna P
LA  - pol
PT  - Editorial
PT  - English Abstract
TT  - Lipoksyny--nowe światło na stare mediatory o silnym działaniu przeciwzapalnym.
PL  - Poland
TA  - Pol Merkur Lekarski
JT  - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
JID - 9705469
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Lipoxins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*metabolism
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Lipoxins/biosynthesis/*metabolism
EDAT- 2005/09/16 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/09/16 09:00
PHST- 2005/09/16 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/09/16 09:00 [entrez]
PST - ppublish
SO  - Pol Merkur Lekarski. 2005 May;18(107):491-5.

PMID- 8423906
OWN - NLM
STAT- MEDLINE
DCOM- 19930223
LR  - 20221207
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 43
IP  - 1
DP  - 1993 Jan
TI  - The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a 
      patient subgroup from the Ticlopidine Aspirin Stroke Study.
PG  - 27-31
AB  - We analyzed the efficacy of ticlopidine and aspirin in the non-white subgroup of 
      patients from the Ticlopidine Aspirin Stroke Study. In this double-blind, 
      randomized, multicenter study, patients received either ticlopidine 250 mg (312 
      non-white patients) or aspirin 650 mg (291 non-white patients) twice a day. The 
      1-year cumulative event rate per 100 patients for nonfatal stroke or death from 
      any cause was 5.5 for ticlopidine and 10.6 for aspirin--an apparent 48.1% 
      reduction in risk with ticlopidine relative to aspirin. The 1-year cumulative 
      event rate for fatal or non-fatal stroke was 3.7 for ticlopidine and 9.4 for 
      aspirin--an apparent 60.8% reduction in risk with ticlopidine relative to 
      aspirin. The cumulative event rates for both endpoints also were lower in 
      ticlopidine-treated patients after the 2nd and 3rd years. These reductions were 
      not significantly different between treatment groups, but were of the same order 
      of magnitude as previously found for the total series, which did attain 
      statistical significance (p = 0.048), and the frequency of adverse events was not 
      significantly different between the two treatment groups. Severe neutropenia, the 
      most serious adverse event associated with ticlopidine use, did not occur in 
      non-white patients. These results suggest that ticlopidine is superior to aspirin 
      for stroke prevention in non-whites.
FAU - Weisberg, L A
AU  - Weisberg LA
AD  - Department of Psychiatry and Neurology, Tulane Medical School, New Orleans, LA 
      70112.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/drug therapy
MH  - Cerebrovascular Disorders/ethnology/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neutropenia/chemically induced
MH  - *Racial Groups
MH  - Ticlopidine/adverse effects/*therapeutic use
MH  - White People
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1212/wnl.43.1_part_1.27 [doi]
PST - ppublish
SO  - Neurology. 1993 Jan;43(1):27-31. doi: 10.1212/wnl.43.1_part_1.27.

PMID- 27064573
OWN - NLM
STAT- MEDLINE
DCOM- 20170427
LR  - 20220321
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 164
IP  - 12
DP  - 2016 Jun 21
TI  - Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal 
      Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
PG  - 777-86
LID - 10.7326/M15-2129 [doi]
AB  - BACKGROUND: Evidence indicates that aspirin is effective for the primary 
      prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) but also 
      increases the risk for gastrointestinal (GI) and cerebral hemorrhages. OBJECTIVE: 
      To assess the net balance of benefits and harms from routine aspirin use across 
      clinically relevant age, sex, and CVD risk groups. DESIGN: Decision analysis 
      using a microsimulation model. DATA SOURCES: 3 systematic evidence reviews. 
      TARGET POPULATION: Men and women aged 40 to 79 years with a 10-year CVD risk of 
      20% or less, and no history of CVD and without elevated risk for GI or cerebral 
      hemorrhages that would contraindicate aspirin use. TIME HORIZON: Lifetime, 20 
      years, and 10 years. PERSPECTIVE: Clinical. INTERVENTION: Low-dose aspirin (≤100 
      mg/d). OUTCOME MEASURES: Primary outcomes are length and quality of life measured 
      in net life-years and quality-adjusted life-years. Benefits include reduced 
      nonfatal myocardial infarction, nonfatal ischemic stroke, fatal CVD, CRC 
      incidence, and CRC mortality. Harms include increased fatal and nonfatal GI 
      bleeding and hemorrhagic stroke. RESULTS OF BASE-CASE ANALYSIS: Lifetime net 
      quality-adjusted life-years are positive for most adults initiating aspirin at 
      ages 40 to 69 years, and life expectancy gains are expected for most men and 
      women initiating aspirin at ages 40 to 59 years and 60 to 69 years with higher 
      CVD risk. Harms may exceed benefits for persons starting aspirin in their 70s and 
      for many during the first 10 to 20 years of use. RESULTS OF SENSITIVITY ANALYSIS: 
      Results are most sensitive to the relative risk for hemorrhagic stroke and CVD 
      mortality but are affected by all relative risk estimates, baseline GI bleeding 
      incidence and case-fatality rates, and disutilities associated with aspirin use. 
      LIMITATIONS: Aspirin effects by age are uncertain. Stroke benefits are 
      conservatively estimated. Gastrointestinal bleeding incidence and case-fatality 
      rates account only for age and sex. CONCLUSION: Lifetime aspirin use for primary 
      prevention initiated at younger ages (40 to 69 years) and in persons with higher 
      CVD risk shows the greatest potential for positive net benefit. PRIMARY FUNDING 
      SOURCE: Agency for Healthcare Research and Quality.
FAU - Dehmer, Steven P
AU  - Dehmer SP
FAU - Maciosek, Michael V
AU  - Maciosek MV
FAU - Flottemesch, Thomas J
AU  - Flottemesch TJ
FAU - LaFrance, Amy B
AU  - LaFrance AB
FAU - Whitlock, Evelyn P
AU  - Whitlock EP
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20160412
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticarcinogenic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Colorectal Neoplasms/*prevention & control
MH  - *Decision Support Techniques
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Primary Prevention
MH  - Quality-Adjusted Life Years
MH  - Risk Assessment
MH  - Stroke/chemically induced
EDAT- 2016/04/12 06:00
MHDA- 2017/04/28 06:00
CRDT- 2016/04/12 06:00
PHST- 2016/04/12 06:00 [entrez]
PHST- 2016/04/12 06:00 [pubmed]
PHST- 2017/04/28 06:00 [medline]
AID - 2513178 [pii]
AID - 10.7326/M15-2129 [doi]
PST - ppublish
SO  - Ann Intern Med. 2016 Jun 21;164(12):777-86. doi: 10.7326/M15-2129. Epub 2016 Apr 
      12.

PMID- 29205497
OWN - NLM
STAT- MEDLINE
DCOM- 20180129
LR  - 20181202
IS  - 1540-8191 (Electronic)
IS  - 0886-0440 (Linking)
VI  - 32
IP  - 12
DP  - 2017 Dec
TI  - The use of preoperative aspirin in cardiac surgery: A systematic review and 
      meta-analysis.
PG  - 758-774
LID - 10.1111/jocs.13250 [doi]
AB  - BACKGROUND: Despite the fact that aspirin is of benefit to patients following 
      coronary artery bypass grafting (CABG), continuation or administration of 
      preoperative aspirin before CABG or any cardiac surgical procedure remains 
      controversial. Therefore, we performed a systematic review and meta-analysis to 
      assess the influence of preoperative aspirin administration on patients 
      undergoing cardiac surgery. MATERIALS AND METHODS: Medline database was searched 
      using OVID SP interface. Similar searches were performed separately in EMBASE, 
      PubMed, and Cochrane Central Registry of Controlled Trials. RESULTS: Twelve 
      randomized controlled trials and 28 observational studies met our inclusion 
      criteria and were included in the meta-analysis. The use of preoperative aspirin 
      in patients undergoing CABG at any dose is associated with reduced early 
      mortality as well as a reduced incidence of postoperative acute kidney injury 
      (AKI). Low-dose aspirin (≤160 mg/d) is associated with a decreased incidence of 
      perioperative myocardial infarction (MI). Administration of preoperative aspirin 
      at any dose in patients undergoing cardiac surgery increases postoperative 
      bleeding. Despite this effect of preoperative aspirin, it did not increase the 
      rates of surgical re-exploration due to excessive postoperative bleeding nor did 
      it increase the rates of packed red blood cell transfusions (PRBC) when 
      preoperative low-dose aspirin (≤160 mg/d) was administered. CONCLUSIONS: 
      Preoperative aspirin increases the risk for postoperative bleeding. However, this 
      did not result in an increased need for chest re-exploration and did not increase 
      the rates of PRBC transfusion when preoperative low-dose (≤160 mg/d) aspirin was 
      administered. Aspirin at any dose is associated with decreased mortality and AKI 
      and low-dose aspirin (≤160 mg/d) decreases the incidence of perioperative MI.
CI  - © 2017 Wiley Periodicals, Inc.
FAU - Aboul-Hassan, Sleiman Sebastian
AU  - Aboul-Hassan SS
AUID- ORCID: 0000-0003-4544-7466
AD  - Department of Cardiac Surgery, MEDINET Heart Center Ltd., Nowa Sol, Poland.
FAU - Stankowski, Tomasz
AU  - Stankowski T
AD  - Department of Cardiac Surgery, Sana-Heart Center Cottbus, Cottbus, Germany.
FAU - Marczak, Jakub
AU  - Marczak J
AD  - Department of Cardiac Surgery, MEDINET Heart Center Ltd., Nowa Sol, Poland.
AD  - Department of Cardiac Surgery, Wroclaw Medical University, Wroclaw, Poland.
FAU - Peksa, Maciej
AU  - Peksa M
AD  - Department of Cardiac Surgery, MEDINET Heart Center Ltd., Nowa Sol, Poland.
FAU - Nawotka, Marcin
AU  - Nawotka M
AD  - Department of Cardiac Surgery, MEDINET Heart Center Ltd., Nowa Sol, Poland.
FAU - Stanislawski, Ryszard
AU  - Stanislawski R
AD  - Department of Cardiac Surgery, MEDINET Heart Center Ltd., Nowa Sol, Poland.
FAU - Kryszkowski, Bartosz
AU  - Kryszkowski B
AD  - Department of General and Oncological Surgery, Hospital in Jelenia Gora, Jelenia 
      Gora, Poland.
FAU - Cichon, Romuald
AU  - Cichon R
AD  - Department of Cardiac Surgery, Warsaw Medical University, Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20171203
PL  - United States
TA  - J Card Surg
JT  - Journal of cardiac surgery
JID - 8908809
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - *Cardiac Surgical Procedures/mortality
MH  - Erythrocyte Transfusion
MH  - Humans
MH  - Models, Statistical
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Postoperative Complications/chemically induced/epidemiology/*prevention & control
MH  - Postoperative Hemorrhage/chemically induced/therapy
MH  - Preoperative Care/adverse effects/*methods
MH  - Reoperation
MH  - Treatment Outcome
OTO - NOTNLM
OT  - cardiac surgery
OT  - coronary artery disease
OT  - outcomes
OT  - preoperative aspirin
EDAT- 2017/12/06 06:00
MHDA- 2018/01/30 06:00
CRDT- 2017/12/06 06:00
PHST- 2017/12/06 06:00 [pubmed]
PHST- 2018/01/30 06:00 [medline]
PHST- 2017/12/06 06:00 [entrez]
AID - 10.1111/jocs.13250 [doi]
PST - ppublish
SO  - J Card Surg. 2017 Dec;32(12):758-774. doi: 10.1111/jocs.13250. Epub 2017 Dec 3.

PMID- 11166001
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 110
IP  - 1A
DP  - 2001 Jan 8
TI  - Aspirin: new cardiovascular uses for an old drug.
PG  - 62S-65S
AB  - Inhibition of TXA2-dependent platelet function by aspirin may lead to prevention 
      of thrombosis as well as to excess bleeding. The balance between the two depends 
      critically on the absolute thrombotic versus hemorrhagic risk of the patient. As 
      the risk of experiencing a major vascular event increases, so does the absolute 
      benefit of antiplatelet prophylaxis with aspirin [Figure-see text]. The 
      antithrombotic effect of aspirin does not appear to be dose related over a wide 
      range of daily doses (30 to 1,300 mg), an observation consistent with 
      saturability of platelet COX-1 inhibition by aspirin at very low doses. In 
      contrast, GI toxicity of the drug does appear to be dose related, consistent with 
      dose- and dosing interval-dependent inhibition of COX-1 activity in the nucleated 
      lining cells of the GI mucosa. Thus, aspirin once daily is recommended in all 
      clinical conditions where antiplatelet therapy is effective. Because of safety 
      considerations, physicians are encouraged to use the lowest dose of aspirin shown 
      effective in each clinical setting [Table-see text].
FAU - Patrono, C
AU  - Patrono C
AD  - Department of Medicine and Aging, University of Chieti G. D'Annunzio School of 
      Medicine, Chieti, Italy. cpatrono@unich.it
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cyclooxygenase Inhibitors/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
RF  - 17
EDAT- 2001/02/13 11:00
MHDA- 2001/04/03 10:01
CRDT- 2001/02/13 11:00
PHST- 2001/02/13 11:00 [pubmed]
PHST- 2001/04/03 10:01 [medline]
PHST- 2001/02/13 11:00 [entrez]
AID - S0002934300006458 [pii]
AID - 10.1016/s0002-9343(00)00645-8 [doi]
PST - ppublish
SO  - Am J Med. 2001 Jan 8;110(1A):62S-65S. doi: 10.1016/s0002-9343(00)00645-8.

PMID- 8451684
OWN - NLM
STAT- MEDLINE
DCOM- 19930412
LR  - 20140912
IS  - 0256-9574 (Print)
VI  - 83
IP  - 2
DP  - 1993 Feb
TI  - Abnormal peri-operative haemorrhage in asymptomatic patients is not predicted by 
      laboratory testing.
PG  - 106-8
AB  - The pre-operative identification of individuals at high risk of bleeding during 
      major elective surgery is obviously important. Extensive haemostatic screening 
      is, however, expensive and may be inappropriate in low-risk groups. Accordingly, 
      we undertook two studies to determine whether it could be justified in patients 
      without a history of abnormal bleeding. In the first of these, 45 of 159 patients 
      were excluded because of aspirin ingestion and a further 3 because of positive 
      bleeding history so that prothrombin time, activated partial thromboplastin time, 
      bleeding time and platelet count were measured in 111 asymptomatic patients about 
      to undergo major surgery. A single patient had mild thrombocytopenia, and 8 had a 
      prolonged partial thromboplastin time; none showed abnormal peri-operative 
      haemorrhage. In the second study, over a 4-month period, 49 patients out of 1,872 
      required larger peri-operative blood transfusions than anticipated; on 
      investigation, none of these patients was shown to have disturbances in 
      haemostatic mechanism, the transfusion having been indicated for technical 
      reasons. Patients undergoing elective surgery should be asked about medication 
      and previous bleeding and if they have no history thereof and a physical 
      examination is negative, pre-operative screening for coagulation defects would 
      appear to be unnecessary.
FAU - Macpherson, C R
AU  - Macpherson CR
AD  - Leukaemia Centre, Groote Schuur Hospital.
FAU - Jacobs, P
AU  - Jacobs P
FAU - Dent, D M
AU  - Dent DM
LA  - eng
PT  - Journal Article
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Blood Loss, Surgical/*prevention & control
MH  - *Hematologic Tests
MH  - Humans
MH  - *Preoperative Care
MH  - Risk Factors
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
PST - ppublish
SO  - S Afr Med J. 1993 Feb;83(2):106-8.

PMID- 32598600
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20200828
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 91
IP  - 12
DP  - 2019 Dec 15
TI  - [Do the patients with peripheral atherosclerosis need to a medical therapy before 
      the revascularization?].
PG  - 129-134
LID - 10.26442/00403660.2019.12.000498 [doi]
AB  - In the review article are provided the approaches to the therapy for improvement 
      of prognosis in patients with peripheral and multifocal atherosclerosis which are 
      available now; some limitations and a real situation are designated for the 
      antithrombotic therapy in this category of patients. According to the clinical 
      trial COMPASS the prospects of wide use of a combination of acetylsalicylic acid 
      and a rivaroxsaban of 2.5 mg 2 times a day in the patients with chronic coronary 
      heart disease and/or symptom peripheral atherosclerosis are designated.
FAU - Barbarash, O L
AU  - Barbarash OL
AD  - Research Institute for Complex Issues of Cardiovascular Diseases.
AD  - Kemerovo State Medical University.
FAU - Kashtalap, V V
AU  - Kashtalap VV
AD  - Research Institute for Complex Issues of Cardiovascular Diseases.
AD  - Kemerovo State Medical University.
LA  - rus
PT  - Journal Article
PT  - Review
DEP - 20191215
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Atherosclerosis/*drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Peripheral Arterial Disease/*drug therapy
MH  - Rivaroxaban/*therapeutic use
OTO - NOTNLM
OT  - antithrombotic therapy
OT  - chronic coronary heart disease
OT  - multifocal atherosclerosis
OT  - peripheral atherosclerosis
OT  - prognosis
OT  - rivaroxaban
EDAT- 2020/07/01 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
AID - 10.26442/00403660.2019.12.000498 [doi]
PST - epublish
SO  - Ter Arkh. 2019 Dec 15;91(12):129-134. doi: 10.26442/00403660.2019.12.000498.

PMID- 20223175
OWN - NLM
STAT- MEDLINE
DCOM- 20100729
LR  - 20190917
IS  - 1579-2242 (Electronic)
IS  - 0300-8932 (Linking)
VI  - 63 Suppl 1
DP  - 2010 Jan
TI  - [Progress in clinical cardiology: surface electrocardiography, cardiovascular 
      disease in women, and novel therapies].
PG  - 3-16
AB  - This review from the Clinical Cardiology and Outpatient Section of the Spanish 
      Society of Cardiology details recent progress in the field of clinical 
      cardiology. On this occasion, the emphasis is on advances in surface 
      electrocardiography and cardiovascular disease in women. In addition, the review 
      contains a brief overview of those major new developments in therapy that have 
      had the greatest impact on daily clinical practice and summarizes the activities 
      of the Clinical Cardiology and Outpatient Section.
FAU - Borrás, Xavier
AU  - Borrás X
AD  - Hospital de la Santa Creu i Sant Pau, Barcelona, España. xborras@santpau.cat
FAU - Murga, Nekane
AU  - Murga N
FAU - Fiol, Miquel
AU  - Fiol M
FAU - Pedreira, Milagros
AU  - Pedreira M
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Novedades en cardiología clínica: electrocardiografía de superficie, enfermedad 
      vascular y mujer y novedades terapéuticas.
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Therapy, Combination
MH  - Electrocardiography/*methods
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - Heart Diseases/*drug therapy
MH  - Humans
MH  - Sex Factors
RF  - 51
EDAT- 2010/03/27 06:00
MHDA- 2010/07/30 06:00
CRDT- 2010/03/13 06:00
PHST- 2010/03/13 06:00 [entrez]
PHST- 2010/03/27 06:00 [pubmed]
PHST- 2010/07/30 06:00 [medline]
AID - 13146748 [pii]
AID - 10.1016/s0300-8932(10)70136-6 [doi]
PST - ppublish
SO  - Rev Esp Cardiol. 2010 Jan;63 Suppl 1:3-16. doi: 10.1016/s0300-8932(10)70136-6.

PMID- 2358373
OWN - NLM
STAT- MEDLINE
DCOM- 19900801
LR  - 20190828
IS  - 0301-5564 (Print)
IS  - 0301-5564 (Linking)
VI  - 94
IP  - 2
DP  - 1990
TI  - The effects of acetylsalicylic acid on phosphoenolpyruvate carboxykinase activity 
      and acinar heterotopy in livers from juvenile and adult rats.
PG  - 149-53
AB  - Male and female juvenile as well as adult rats were treated with acetylsalicylic 
      acid in order to examine the effect of the drug on over-all activity and activity 
      distribution of phosphoenolpyruvate carboxykinase (PEPCK) in the liver acinus. 
      Upon administration of acetylsalicylic acid PEPCK activity increased in juvenile 
      males and adult females, but was reduced in juvenile females and adult males. The 
      periportal-perivenous activity gradient along the sinusoidal length, which is 
      flatter in untreated juvenile rats compared to the livers of adult rats, was 
      distinctly steepened by acetylsalicylic acid treatment. Acetylsalicylic acid did 
      not affect the gradient in adult rats.
FAU - Wimmer, M
AU  - Wimmer M
AD  - Anatomisches Institut der Universität Basel, Switzerland.
FAU - Luttringer, C
AU  - Luttringer C
FAU - Colombi, M
AU  - Colombi M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Histochemistry
JT  - Histochemistry
JID - 0411300
RN  - EC 4.1.1.32 (Phosphoenolpyruvate Carboxykinase (GTP))
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aging/*metabolism
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Liver/drug effects/*enzymology
MH  - Male
MH  - Phosphoenolpyruvate Carboxykinase (GTP)/*metabolism
MH  - Rats
MH  - Sex Factors
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1007/BF02440181 [doi]
PST - ppublish
SO  - Histochemistry. 1990;94(2):149-53. doi: 10.1007/BF02440181.

PMID- 2483710
OWN - NLM
STAT- MEDLINE
DCOM- 19900516
LR  - 20131121
IS  - 0323-4347 (Print)
IS  - 0323-4347 (Linking)
VI  - 116
IP  - 6
DP  - 1989
TI  - [Influencing the fibrinolytic activity by antithrombotics in patients with 
      atherosclerosis].
PG  - 907-13
AB  - In 106 atherosclerotic patients receiving an anticoagulant therapy and 91 
      patients receiving acetylsalicylic acid, fibrinogen and fibrin degradation 
      products were determined as well as euglobulin lysis before and after venous 
      occlusion. Platelet function data and thromboxane (TXB2) were also determined. 
      Since "moderate" anticoagulant therapy with thromboplastin time values 26-40% 
      results in deteriorated fibrinolysis data, anticoagulant therapy is strictly to 
      remain within the therapeutic range of 15-20% up to 25% thromboplastin time at 
      maximum. Treatment with acetylsalicylic acid proved useful on condition that the 
      required dose was determined individually. This type of treatment will then be 
      able to reduce the thromboxane level and positively influence the fibrinolytic 
      potential.
FAU - Norden, C
AU  - Norden C
AD  - Zentralinstitut für Herz-Kreislauf-Forschung, Akademie der Wissenschaften, DDR 
      Berlin-Buch.
FAU - Reimann, H
AU  - Reimann H
FAU - Grunow, G
AU  - Grunow G
FAU - Misselwitz, F
AU  - Misselwitz F
FAU - Taube, C
AU  - Taube C
FAU - Heine, H
AU  - Heine H
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Die Beeinflussung der Fibrinolysekapazität durch Antithrombotika bei Patienten 
      mit Arteriosklerose.
PL  - Germany
TA  - Folia Haematol Int Mag Klin Morphol Blutforsch
JT  - Folia haematologica (Leipzig, Germany : 1928)
JID - 0374615
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Arteriosclerosis/*drug therapy/physiopathology
MH  - Aspirin/*therapeutic use
MH  - Blood Coagulation Tests
MH  - Fibrinolysis
MH  - Humans
MH  - Platelet Function Tests
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Folia Haematol Int Mag Klin Morphol Blutforsch. 1989;116(6):907-13.

PMID- 7438381
OWN - NLM
STAT- MEDLINE
DCOM- 19810226
LR  - 20131121
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 62
IP  - 6 Pt 2
DP  - 1980 Dec
TI  - Aspirin and secondary mortality after myocardial infarction.
PG  - V53-8
AB  - Three randomized controlled trials of aspirin and secondary mortality have been 
      conducted in patients who had had a myocardial infarction. One trial was based on 
      1239 men followed for 1-2 years; the second was based on 1468 men and 257 women 
      followed for 1 year after infarction. Although the results are not statistically 
      significant in either trial, they are consistent with a reduction in mortality 
      during the year after infarction of about 24% and 17%. Detailed analyses, in 
      which allowance is made for small imbalances between the groups on aspirin and on 
      placebo, indicate that the estimate of benefit of 17% in one of the trials is 
      almost certainly an underestimation. The third trial, in which we analyzed only 
      very early mortality based on 2530 patients, did not show evidence of benefit 
      from aspirin given during the acute phase of infarction.
FAU - Elwood, P C
AU  - Elwood PC
FAU - Sweetnam, P M
AU  - Sweetnam PM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Hemoglobins)
RN  - 0 (Placebos)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Cholesterol/blood
MH  - Coronary Disease/mortality
MH  - Female
MH  - Hemoglobins
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/*mortality
MH  - Placebos
MH  - Smoking
MH  - Time Factors
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
PST - ppublish
SO  - Circulation. 1980 Dec;62(6 Pt 2):V53-8.

PMID- 312297
OWN - NLM
STAT- MEDLINE
DCOM- 19790716
LR  - 20190823
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 19
IP  - 4
DP  - 1979 Apr
TI  - Fecal blood loss and plasma salicylate study of salicylsalicylic acid and 
      aspirin.
PG  - 242-7
AB  - Using a placebo-controlled methodology, 20 healthy volunteers housed in a 
      clinical research facility for 23 days were studied for fecal blood loss and 
      plasma salicylate levels after taking salsalate (salicylsalicylic acid) or 
      aspirin. Daily dosages were 3000 mg salsalate or 3900 mg aspirin. Aspirin 
      produced statistically significant gastrointestinal blood loss over control 
      levels and over that produced by salsalate (P less than 0.01). Blood loss with 
      salsalate was not different than that with placebo. Despite the intentional 
      disparity of dosages between the two drugs, plasma salicylate levels were not 
      statistically different. Side effects occurred at about equal frequency with 
      either drug. Most prominent were headache and nausea. However, concomitant upper 
      respiratory infection in 12 subjects rendered interpretation difficult.
FAU - Cohen, A
AU  - Cohen A
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Placebos)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/metabolism
MH  - Chromium Radioisotopes
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Liver/enzymology
MH  - Male
MH  - Placebos
MH  - Salicylates/*adverse effects/*blood/metabolism
MH  - Time Factors
EDAT- 1979/04/01 00:00
MHDA- 1979/04/01 00:01
CRDT- 1979/04/01 00:00
PHST- 1979/04/01 00:00 [pubmed]
PHST- 1979/04/01 00:01 [medline]
PHST- 1979/04/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1979.tb01658.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1979 Apr;19(4):242-7. doi: 10.1002/j.1552-4604.1979.tb01658.x.

PMID- 2688988
OWN - NLM
STAT- MEDLINE
DCOM- 19900129
LR  - 20131121
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 80
IP  - 6 Suppl
DP  - 1989 Dec
TI  - Usefulness of calcium entry blockers during and after percutaneous transluminal 
      coronary artery angioplasty.
PG  - IV88-92
AB  - Calcium entry blockers can decrease myocardial ischemia and coronary spasm in 
      association with percutaneous transluminal coronary artery angioplasty (PTCA). 
      Restenosis after PTCA has not been shown to be statistically decreased by 
      nifedipine or diltiazem in patients who clinically did not have coronary spasm. 
      Patients who have evidence of coronary spasm before or at PTCA have a higher 
      incidence of restenosis after PTCA, but this is decreased by treatment with 
      calcium entry blockers. Most patients at Emory receive a calcium entry blocker 
      before and after PTCA while in the hospital. After discharge, long-term therapy 
      is given to select patients, especially those with any evidence of coronary 
      vasospasm or patients with incompletely revascularized, multivessel disease. All 
      patients receive aspirin before and long-term after PTCA. Some physicians give 
      calcium entry blockers to all patients after PTCA. There is a need for larger, 
      controlled clinical trials to evaluate the current use of calcium entry blockers 
      before, during, and after PTCA as well as other therapeutic agents to prevent 
      acute and chronic restenosis.
FAU - Schlant, R C
AU  - Schlant RC
AD  - Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 
      30303.
FAU - King, S B 3rd
AU  - King SB 3rd
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Calcium Channel Blockers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/therapeutic use
MH  - Calcium Channel Blockers/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/*therapy
MH  - Humans
MH  - Recurrence
RF  - 69
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
PST - ppublish
SO  - Circulation. 1989 Dec;80(6 Suppl):IV88-92.

PMID- 33067170
OWN - NLM
STAT- MEDLINE
DCOM- 20220225
LR  - 20220225
IS  - 2210-741X (Electronic)
IS  - 2210-7401 (Linking)
VI  - 45
IP  - 6
DP  - 2021 Nov
TI  - Influence of aspirin use on clinical outcomes of patients with hepatocellular 
      carcinoma: a meta-analysis.
PG  - 101545
LID - S2210-7401(20)30286-2 [pii]
LID - 10.1016/j.clinre.2020.09.006 [doi]
AB  - BACKGROUND: Aspirin use has been suggested to reduce cancer risk. However, 
      previous studies showed inconsistent results as for the association between 
      aspirin use and mortality in patients with hepatocellular carcinoma (HCC). The 
      aim of the study was to evaluate the influence of aspirin use on clinical 
      outcomes of patients with HCC in a meta-analysis. MATERIALS: Studies were 
      obtained via systematic search of PubMed, Cochrane's Library, and Embase 
      databases. A random-effect model, which incorporated the potential heterogeneity, 
      was used to pool the results. RESULTS: Six retrospective cohort studies including 
      18,855 HCC patients that underwent liver resection or transarterial 
      chemoembolization were included. Pooled results showed that compared to the 
      non-users, aspirin users of HCC had significantly reduced risk of HCC recurrence 
      (risk ratio [RR]: 0.74, 95% confidence interval [CI]: 0.59-0.93, p = 0.01; 
      I(2) = 34%) and all-cause mortality (RR: 0.59, 95% CI: 0.47-0.73, p < 0.001; 
      I(2) = 0%) after controlling of potential confounding factors. In addition, 
      pooled results showed that aspirin use was not associated with a significantly 
      increased risk of major bleeding events (RR: 1.42, 95% CI: 0.81-2.51, p = 0.22; 
      I(2) = 29%) in patients with HCC. CONCLUSIONS: Evidence from retrospective 
      studies suggests that aspirin use is associated with reduced recurrence and 
      all-cause mortality of HCC. These results should be validated in prospective 
      cohort studies and randomized controlled trials.
CI  - Copyright © 2020. Published by Elsevier Masson SAS.
FAU - Li, Xiaofei
AU  - Li X
AD  - Department of Infectious Diseases, Yiwu Central Hospital, Yiwu 322000, China. 
      Electronic address: metshep@sina.com.
FAU - Yu, Yuexiao
AU  - Yu Y
AD  - Department of Infectious Diseases, Yiwu Central Hospital, Yiwu 322000, China.
FAU - Liu, Liwen
AU  - Liu L
AD  - Department of Infectious Diseases, Yiwu Central Hospital, Yiwu 322000, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20201013
PL  - France
TA  - Clin Res Hepatol Gastroenterol
JT  - Clinics and research in hepatology and gastroenterology
JID - 101553659
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Humans
MH  - *Liver Neoplasms/drug therapy
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Hepatocellular carcinoma
OT  - Meta-analysis
OT  - Mortality
OT  - Recurrence
EDAT- 2020/10/18 06:00
MHDA- 2022/02/26 06:00
CRDT- 2020/10/17 05:24
PHST- 2020/08/16 00:00 [received]
PHST- 2020/09/10 00:00 [revised]
PHST- 2020/09/19 00:00 [accepted]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2022/02/26 06:00 [medline]
PHST- 2020/10/17 05:24 [entrez]
AID - S2210-7401(20)30286-2 [pii]
AID - 10.1016/j.clinre.2020.09.006 [doi]
PST - ppublish
SO  - Clin Res Hepatol Gastroenterol. 2021 Nov;45(6):101545. doi: 
      10.1016/j.clinre.2020.09.006. Epub 2020 Oct 13.

PMID- 22529913
OWN - NLM
STAT- MEDLINE
DCOM- 20121119
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 7
IP  - 4
DP  - 2012
TI  - Interaction of aspirin (acetylsalicylic acid) with lipid membranes.
PG  - e34357
LID - 10.1371/journal.pone.0034357 [doi]
LID - e34357
AB  - We studied the interaction of Aspirin (acetylsalicylic acid) with lipid membranes 
      using x-ray diffraction for bilayers containing up to 50 mol% of aspirin. From 2D 
      x-ray intensity maps that cover large areas of reciprocal space we determined the 
      position of the ASA molecules in the phospholipid bilayers and the molecular 
      arrangement of the molecules in the plane of the membranes. We present direct 
      experimental evidence that ASA molecules participate in saturated lipid bilayers 
      of DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) and preferably reside in 
      the head group region of the membrane. Up to 50 mol% ASA molecules can be 
      dissolved in this type of bilayer before the lateral membrane organization is 
      disturbed and the membranes are found to form an ordered, 2D crystal-like 
      structure. Furthermore, ASA and cholesterol were found to co-exist in saturated 
      lipid bilayers, with the ASA molecules residing in the head group region and the 
      cholesterol molecules participating in the hydrophobic membrane core.
FAU - Barrett, Matthew A
AU  - Barrett MA
AD  - Department of Physics and Astronomy, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Zheng, Songbo
AU  - Zheng S
FAU - Roshankar, Golnaz
AU  - Roshankar G
FAU - Alsop, Richard J
AU  - Alsop RJ
FAU - Belanger, Randy K R
AU  - Belanger RK
FAU - Huynh, Chris
AU  - Huynh C
FAU - Kučerka, Norbert
AU  - Kučerka N
FAU - Rheinstädter, Maikel C
AU  - Rheinstädter MC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120417
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Lipid Bilayers)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
RN  - U86ZGC74V5 (Dimyristoylphosphatidylcholine)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Cell Membrane/*chemistry
MH  - Cholesterol/chemistry
MH  - Dimyristoylphosphatidylcholine/chemistry
MH  - Electrons
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Lipid Bilayers/chemistry
MH  - X-Ray Diffraction
PMC - PMC3328472
COIS- Competing Interests: Silicon substrates for this project were partially provided 
      by ComDev. This does not alter the authors' adherence to all the PLoS ONE 
      policies on sharing data and materials.
EDAT- 2012/04/25 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/04/25 06:00
PHST- 2012/01/20 00:00 [received]
PHST- 2012/03/01 00:00 [accepted]
PHST- 2012/04/25 06:00 [entrez]
PHST- 2012/04/25 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - PONE-D-12-02044 [pii]
AID - 10.1371/journal.pone.0034357 [doi]
PST - ppublish
SO  - PLoS One. 2012;7(4):e34357. doi: 10.1371/journal.pone.0034357. Epub 2012 Apr 17.

PMID- 32061771
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20210602
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 176
DP  - 2020 Jun
TI  - NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft 
      mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.
PG  - 113857
LID - S0006-2952(20)30085-X [pii]
LID - 10.1016/j.bcp.2020.113857 [doi]
AB  - Pancreatic cancer has poor survival rates and largely ineffective therapies. 
      Aspirin is the prototypical anti-cancer agent but its long-term use is associated 
      with significant side effects. NOSH-aspirin belongs to a new class of 
      anti-inflammatory agents that were designed to be safer alternatives by releasing 
      nitric oxide and hydrogen sulfide. In this study we evaluated the effects of 
      NOSH-aspirin against pancreatic cancer using cell lines and a xenograft mouse 
      model. NOSH-aspirin inhibited growth of MIA PaCa-2 and BxPC-3 pancreatic cancer 
      cells with IC(50)s of 47 ± 5, and 57 ± 4 nM, respectively, while it did not 
      inhibit growth of a normal pancreatic epithelial cell line at these 
      concentrations. NOSH-aspirin inhibited cell proliferation, caused G(0)/G(1) phase 
      cycle arrest, leading to increased apoptosis. Treated cells displayed increases 
      in reactive oxygen species (ROS) and caspase-3 activity. In MIA PaCa-2 cell 
      xenografts, NOSH-aspirin significantly reduced tumor growth and tumor mass. 
      Growth inhibition was due to reduced proliferation (decreased PCNA expression) 
      and induction of apoptosis (increased TUNEL positive cells). Expressions of ROS, 
      iNOS, and mutated p53 were increased; while that of NF-κB and FoxM1 that were 
      high in vehicle-treated xenografts were significantly inhibited by NOSH-aspirin. 
      Taken together, these molecular events and signaling pathways contribute to 
      NOSH-aspirin mediated growth inhibition and apoptotic death of pancreatic cancer 
      cells in vitro and in vivo.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
AD  - Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of 
      Biomedical Education, City University of New York School of Medicine, New York, 
      NY, United States.
FAU - Kodela, Ravinder
AU  - Kodela R
AD  - Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of 
      Biomedical Education, City University of New York School of Medicine, New York, 
      NY, United States.
FAU - Santiago, Gabriela
AU  - Santiago G
AD  - Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of 
      Biomedical Education, City University of New York School of Medicine, New York, 
      NY, United States.
FAU - Le, Thuy Tien C
AU  - Le TTC
AD  - Department of Biological and Chemical Sciences, New York Institute of Technology, 
      NY 10023, United States.
FAU - Nath, Niharika
AU  - Nath N
AD  - Department of Biological and Chemical Sciences, New York Institute of Technology, 
      NY 10023, United States.
FAU - Kashfi, Khosrow
AU  - Kashfi K
AD  - Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of 
      Biomedical Education, City University of New York School of Medicine, New York, 
      NY, United States; Avicenna Pharmaceuticals Inc., New York NY, United States; 
      Graduate Program in Biology, City University of New York Graduate Center, New 
      York NY, United States. Electronic address: kashfi@med.cuny.edu.
LA  - eng
GR  - R24 DA018055/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200214
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate)
RN  - 0 (Disulfides)
RN  - 0 (Forkhead Box Protein M1)
RN  - 0 (NF-kappa B)
RN  - 0 (Nitrates)
RN  - 0 (Reactive Oxygen Species)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 3.4.22.- (Caspase 3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Caspase 3/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Disulfides/chemistry/*pharmacology
MH  - Forkhead Box Protein M1/metabolism
MH  - Male
MH  - Mice, Nude
MH  - Mice, SCID
MH  - NF-kappa B/metabolism
MH  - Nitrates/chemistry/*pharmacology
MH  - Nitric Oxide Synthase Type II/metabolism
MH  - Pancreatic Neoplasms/*drug therapy/metabolism/pathology
MH  - Reactive Oxygen Species/metabolism
MH  - Tumor Burden/drug effects
MH  - *Xenograft Model Antitumor Assays
PMC - PMC7263941
MID - NIHMS1561675
OTO - NOTNLM
OT  - Cell kinetics
OT  - Cell signaling
OT  - FoxM1
OT  - Hydrogen sulfide
OT  - NOSH-aspirin
OT  - Nitric oxide
OT  - Pancreatic cancer
OT  - Reactive oxygen species
OT  - p53
COIS- Declaration of Competing Interest The authors have nothing to disclose except for 
      KK, who has an equity position in Avicenna Pharmaceuticals, Inc. the supplier of 
      NOSH-aspirin used in these studies and to which NBS-1120 is licensed.
EDAT- 2020/02/18 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/02/17 06:00
PHST- 2019/12/03 00:00 [received]
PHST- 2020/02/11 00:00 [accepted]
PHST- 2020/02/18 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/02/17 06:00 [entrez]
AID - S0006-2952(20)30085-X [pii]
AID - 10.1016/j.bcp.2020.113857 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2020 Jun;176:113857. doi: 10.1016/j.bcp.2020.113857. Epub 2020 
      Feb 14.

PMID- 30504736
OWN - NLM
STAT- MEDLINE
DCOM- 20190531
LR  - 20230501
IS  - 2149-2271 (Electronic)
IS  - 2149-2263 (Print)
IS  - 2149-2263 (Linking)
VI  - 20
IP  - 6
DP  - 2018 Dec
TI  - Design and rationale for the ASSOS study: Appropriateness of aspirin use in 
      medical outpatients a multicenter and observational study.
PG  - 354-362
LID - 10.14744/AnatolJCardiol.2018.47587 [doi]
AB  - OBJECTIVE: The aim of this study was to describe the current status of aspirin 
      use and the demographic characteristics of patients on aspirin for primary and 
      secondary prevention of cardiovascular diseases. METHODS: The Appropriateness of 
      Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) 
      trial was a multicenter, cross-sectional, and observational study conducted in 
      Turkey. The study was planned to include 5000 patients from 14 cities in Turkey. 
      The data were collected at one visit, and the current clinical practice regarding 
      aspirin use was evaluated (ClinicalTrials.gov number NCT03387384). RESULTS: The 
      study enrolled all consecutive patients who were admitted to the outpatient 
      cardiology clinics from March 2018 until June 2018. Patients should be at least 
      18 years old, have signed written informed consent, and on aspirin (80-325 mg) 
      therapy within the last 30 days. Cardiologists from the hospital participates in 
      the study. Patients were divided into 2 categories according to presence or 
      absence of atherosclerotic cardiovascular disease, namely secondary prevention 
      group and primary prevention group, respectively. The appropriate use of aspirin 
      in the primary and secondary prevention groups was assessed according to the 
      European Society of Cardiology guidelines and US Preventive Services Task Force. 
      The patients' gastrointestinal bleeding risk factors and colorectal cancer risk 
      were evaluated. CONCLUSION: The ASSOS registry will be the most comprehensive and 
      largest study in Turkey evaluating the appropriateness of aspirin use. The 
      results of this study help understand the potential misuse of aspirin in a 
      real-world setting.
FAU - Çelik, Oğuzhan
AU  - Çelik O
AD  - Department of Cardiology, Faculty of Medicine, Muğla Sıtkı Koçman University; 
      Muğla-Turkey. droguzhancelik@hotmail.com.
FAU - Çil, Cem
AU  - Çil C
FAU - Özlek, Bülent
AU  - Özlek B
FAU - Özlek, Eda
AU  - Özlek E
FAU - Doğan, Volkan
AU  - Doğan V
FAU - Başaran, Özcan
AU  - Başaran Ö
FAU - Demirci, Erkan
AU  - Demirci E
FAU - Bekar, Lütfü
AU  - Bekar L
FAU - Kalçık, Macit
AU  - Kalçık M
FAU - Karaarslan, Osman
AU  - Karaarslan O
FAU - Yetim, Mücahit
AU  - Yetim M
FAU - Doğan, Tolga
AU  - Doğan T
FAU - Demir, Vahit
AU  - Demir V
FAU - Kalkan, Sedat
AU  - Kalkan S
FAU - Özkan, Buğra
AU  - Özkan B
FAU - Hidayet, Şıho
AU  - Hidayet Ş
FAU - Taylan, Gökay
AU  - Taylan G
FAU - Küçüksu, Zafer
AU  - Küçüksu Z
FAU - Çelik, Yunus
AU  - Çelik Y
FAU - Efe, Süleyman Çağan
AU  - Efe SÇ
FAU - Aslan, Onur
AU  - Aslan O
FAU - Biteker, Murat
AU  - Biteker M
LA  - eng
SI  - ClinicalTrials.gov/NCT03387384
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - Turkey
TA  - Anatol J Cardiol
JT  - Anatolian journal of cardiology
JID - 101652981
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Rev Med Pharmacol Sci. 2023 Jan;27(1):307-314. PMID: 36647878
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Atherosclerosis/drug therapy/*prevention & control
MH  - Cohort Studies
MH  - Colorectal Neoplasms/drug therapy/prevention & control
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Surveys/statistics & numerical data
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outpatients/*statistics & numerical data
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - *Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Registries/*statistics & numerical data
MH  - *Secondary Prevention
MH  - Turkey/epidemiology
MH  - Young Adult
PMC - PMC6287439
COIS- Conflict of interest: None declared.
EDAT- 2018/12/07 06:00
MHDA- 2019/06/01 06:00
CRDT- 2018/12/04 06:00
PHST- 2018/12/04 06:00 [entrez]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/06/01 06:00 [medline]
AID - AJC-20-354 [pii]
AID - 10.14744/AnatolJCardiol.2018.47587 [doi]
PST - ppublish
SO  - Anatol J Cardiol. 2018 Dec;20(6):354-362. doi: 
      10.14744/AnatolJCardiol.2018.47587.

PMID- 33962742
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 1532-8414 (Electronic)
IS  - 1071-9164 (Linking)
VI  - 27
IP  - 5
DP  - 2021 May
TI  - Association of Aspirin Treatment With Cardiac Allograft Vasculopathy Progression 
      and Adverse Outcomes After Heart Transplantation.
PG  - 542-551
LID - S1071-9164(21)00047-6 [pii]
LID - 10.1016/j.cardfail.2021.01.019 [doi]
AB  - BACKGROUND: Enhanced platelet reactivity may play a role in cardiac allograft 
      vasculopathy (CAV) progression. The use of antiplatelet agents after heart 
      transplantation (HT) has been inconsistent and although aspirin (ASA) is often a 
      part of the medication regimen after HT, limited evidence is available on its 
      benefit. METHODS AND RESULTS: CAV progression was assessed by measuring the 
      difference in plaque volume and plaque index between the last follow-up and the 
      baseline coronary intravascular ultrasound examination. Overall, 529 HT 
      recipients were retrospectively analyzed (337 had ≥2 intravascular ultrasound 
      studies). The progression in plaque volume (P = .007) and plaque index (P = .002) 
      was significantly attenuated among patients treated with early ASA (within the 
      first year after HT). Over a 6.7-year follow-up, all-cause mortality was lower 
      with early ASA compared with late or no ASA use (P < .001). No cardiac deaths 
      were observed in the early ASA group, and the risk of CAV-related graft 
      dysfunction was significantly lower in this group (P = .03). However, the 
      composite of all CAV-related events (cardiac death, CAV-related graft 
      dysfunction, or coronary angioplasty) was not significantly different between the 
      groups (P = .16). CONCLUSIONS: Early ASA use after HT may delay CAV progression 
      and decrease mortality and CAV-related graft dysfunction, but does not seem to 
      affect overall CAV-associated events.
CI  - Copyright © 2021 Elsevier Inc. All rights reserved.
FAU - Asleh, Rabea
AU  - Asleh R
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Heart 
      Institute, Faculty of Medicine, Hadassah-Hebrew University Medical Center, Hebrew 
      University, Jerusalem 90000, Israel. Electronic address: rasleh@gmail.com.
FAU - Briasoulis, Alexandros
AU  - Briasoulis A
AD  - Division of Cardiovascular Diseases, University of Iowa Hospitals and Clinics, 
      Iowa City, Iowa.
FAU - Smith, Byron
AU  - Smith B
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
FAU - Lopez, Camden
AU  - Lopez C
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
FAU - Alnsasra, Hilmi
AU  - Alnsasra H
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
FAU - Pereira, Naveen L
AU  - Pereira NL
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
FAU - Edwards, Brooks S
AU  - Edwards BS
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
FAU - Clavell, Alfredo L
AU  - Clavell AL
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
FAU - Stulak, John M
AU  - Stulak JM
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
FAU - Locker, Chaim
AU  - Locker C
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
FAU - Kremers, Walter K
AU  - Kremers WK
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
FAU - Daly, Richard C
AU  - Daly RC
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
FAU - Lerman, Amir
AU  - Lerman A
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
FAU - Kushwaha, Sudhir S
AU  - Kushwaha SS
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. 
      Electronic address: kushwaha.sudhir@mayo.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Allografts
MH  - Aspirin/therapeutic use
MH  - Coronary Angiography
MH  - *Coronary Artery Disease
MH  - *Heart Failure
MH  - *Heart Transplantation/adverse effects
MH  - Humans
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Cardiac allograft vasculopathy
OT  - aspirin
OT  - coronary intravascular ultrasound
OT  - heart transplantation
EDAT- 2021/05/09 06:00
MHDA- 2021/10/08 06:00
CRDT- 2021/05/08 06:13
PHST- 2020/09/06 00:00 [received]
PHST- 2021/01/21 00:00 [revised]
PHST- 2021/01/22 00:00 [accepted]
PHST- 2021/05/08 06:13 [entrez]
PHST- 2021/05/09 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
AID - S1071-9164(21)00047-6 [pii]
AID - 10.1016/j.cardfail.2021.01.019 [doi]
PST - ppublish
SO  - J Card Fail. 2021 May;27(5):542-551. doi: 10.1016/j.cardfail.2021.01.019.

PMID- 20830229
OWN - NLM
STAT- MEDLINE
DCOM- 20101105
LR  - 20220719
IS  - 1226-3303 (Print)
IS  - 2005-6648 (Electronic)
IS  - 1226-3303 (Linking)
VI  - 25
IP  - 3
DP  - 2010 Sep
TI  - Airway responsiveness to inhaled aspirin is influenced by airway 
      hyperresponsiveness in asthmatic patients.
PG  - 309-16
LID - 10.3904/kjim.2010.25.3.309 [doi]
AB  - BACKGROUND/AIMS: Many patients with aspirin-induced asthma have severe 
      methacholine airway hyperresponsiveness (AHR), suggesting a relationship between 
      aspirin and methacholine in airway response. This study was performed to 
      determine whether methacholine AHR affects the response of asthmatics to inhaled 
      aspirin. METHODS: The clinical records of 207 asthmatic patients who underwent 
      inhalation challenges with both aspirin and methacholine were reviewed 
      retrospectively. An oral aspirin challenge was performed in patients with a 
      negative inhalation response. The bronchial reactivity index (BRindex) was 
      calculated from the percent decrease in lung function divided by the last dose of 
      the stimulus. RESULTS: Forty-one (20.9%) and 14 (7.1%) patients showed a positive 
      response to aspirin following an inhalation and oral challenge, respectively. 
      Only 24.3 and 14.3% of the responders had a history of aspirin intolerance, 
      respectively. The methacholine BRindex was significantly higher in the inhalation 
      responders (1.46 ± 0.02) than in the oral responders (1.36 ± 0.03, p < 0.01) and 
      in non-responders (n = 141, 1.37 ± 0.01, p < 0.001). The aspirin BRindex was 
      significantly correlated with the methacholine BRindex (r = 0.270, p < 0.001). 
      Three of four patients who received the oral challenge, despite a positive 
      inhalation test, showed negative responses to the oral challenge. Two of these 
      patients had severe AHR. CONCLUSIONS: A considerable number of asthmatic patients 
      with no history of aspirin intolerance responded to the inhalation aspirin 
      challenge. The airway response to aspirin was significantly correlated with 
      methacholine-AHR, and a false-positive response to aspirin inhalation test seemed 
      to occur primarily in patients with severe AHR.
FAU - Kim, Sungsoo
AU  - Kim S
AD  - Department of Allergy, Chonnam National University Medical School and Research 
      Institute of Medical Sciences, Gwangju, Korea.
FAU - Choi, Inseon S
AU  - Choi IS
FAU - Kim, Yeon-Joo
AU  - Kim YJ
FAU - Kim, Chang-Seong
AU  - Kim CS
FAU - Han, Eui-Ryoung
AU  - Han ER
FAU - Park, Dong-Jin
AU  - Park DJ
FAU - Kim, Dae-Eun
AU  - Kim DE
LA  - eng
PT  - Journal Article
DEP - 20100831
PL  - Korea (South)
TA  - Korean J Intern Med
JT  - The Korean journal of internal medicine
JID - 8712418
RN  - 0W5ETF9M2K (Methacholine Chloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Asthma/*physiopathology
MH  - Asthma, Aspirin-Induced/etiology/physiopathology
MH  - Bronchial Hyperreactivity/physiopathology
MH  - Bronchial Provocation Tests
MH  - Drug Hypersensitivity/etiology/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Methacholine Chloride/*administration & dosage
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC2932945
OTO - NOTNLM
OT  - Asthma, aspirin-induced
OT  - Bronchial reactivity
OT  - Methacholine
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2010/09/11 06:00
MHDA- 2010/11/06 06:00
CRDT- 2010/09/11 06:00
PHST- 2010/01/20 00:00 [received]
PHST- 2010/02/25 00:00 [revised]
PHST- 2010/04/07 00:00 [accepted]
PHST- 2010/09/11 06:00 [entrez]
PHST- 2010/09/11 06:00 [pubmed]
PHST- 2010/11/06 06:00 [medline]
AID - 10.3904/kjim.2010.25.3.309 [doi]
PST - ppublish
SO  - Korean J Intern Med. 2010 Sep;25(3):309-16. doi: 10.3904/kjim.2010.25.3.309. Epub 
      2010 Aug 31.

PMID- 25353369
OWN - NLM
STAT- MEDLINE
DCOM- 20150916
LR  - 20151119
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 70
IP  - 2
DP  - 2015 Feb
TI  - Challenge-proven aspirin hypersensitivity in children with chronic spontaneous 
      urticaria.
PG  - 153-60
LID - 10.1111/all.12539 [doi]
AB  - BACKGROUND: Nonsteroidal anti-inflammatory drug (NSAID) exacerbated cutaneous 
      disease is defined as the exacerbation of wheals and/or angioedema in patients 
      with a history of chronic spontaneous urticaria (CSU). The objective of this 
      study was to define 'aspirin-hypersensitive' children and adolescents in a 
      clearly defined group of patients with CSU and to describe their clinical 
      features. METHODS: Eighty-one children with a history of CSU were enrolled over a 
      3-year period. The daily or almost daily (>4 days a week) presence of urticaria 
      was defined as 'chronic persistent urticaria' (CPU), while the presence of 
      urticaria for 2-4 days a week was defined as 'chronic recurrent urticaria' (CRU). 
      Single-blind, placebo-controlled provocation tests (SBPCPTs) with aspirin were 
      performed for children with CSU. RESULTS: Patients with CRU had a longer duration 
      of cutaneous symptoms [1.6 (0.5-4) vs 0.6 (0.3-1.5) years], and stress was less 
      frequently experienced as an eliciting factor in patients with CRU compared with 
      the patients with CPU (P < 0.016, P = 0.024, respectively). SBPCPTs with aspirin 
      revealed that 14 of 58 patients (24%) with CPU and one of 10 patients with CRU 
      (10%) were aspirin hypersensitive. Aspirin hypersensitivity rate was 26.5% in 
      patients <12 years of age. All of the 15 aspirin-hypersensitive patients (aged 
      between 6.6 and 17.4 years), except for three, experienced an unequivocal 
      angioedema of the lips as a positive reaction in SBPCPT. CONCLUSIONS: Nearly a 
      quarter of children and adolescents with CSU were hypersensitive to aspirin. For 
      children with chronic urticaria, determination of NSAID hypersensitivity in a 
      well-controlled clinical setting will help to avoid severe drug hypersensitivity 
      reactions.
CI  - © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Cavkaytar, Ozlem
AU  - Cavkaytar O
AD  - Department of Pediatric Allergy, School of Medicine, Hacettepe University, 
      Ankara, Turkey.
FAU - Arik Yilmaz, Ebru
AU  - Arik Yilmaz E
FAU - Buyuktiryaki, Betul
AU  - Buyuktiryaki B
FAU - Sekerel, Bulent E
AU  - Sekerel BE
FAU - Sackesen, Cansin
AU  - Sackesen C
FAU - Soyer, Ozge U
AU  - Soyer OU
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Angioedema/etiology
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Child
MH  - Chronic Disease
MH  - Comorbidity
MH  - Disease Progression
MH  - Drug Hypersensitivity/*diagnosis
MH  - Female
MH  - Humans
MH  - Immune Tolerance
MH  - Male
MH  - Prognosis
MH  - Urticaria/*chemically induced/*diagnosis
OTO - NOTNLM
OT  - aspirin
OT  - chronic urticaria
OT  - drug allergy
OT  - nonsteroidal anti-inflammatory drug
EDAT- 2014/10/30 06:00
MHDA- 2015/09/17 06:00
CRDT- 2014/10/30 06:00
PHST- 2014/10/23 00:00 [accepted]
PHST- 2014/10/30 06:00 [entrez]
PHST- 2014/10/30 06:00 [pubmed]
PHST- 2015/09/17 06:00 [medline]
AID - 10.1111/all.12539 [doi]
PST - ppublish
SO  - Allergy. 2015 Feb;70(2):153-60. doi: 10.1111/all.12539.

PMID- 28684123
OWN - NLM
STAT- MEDLINE
DCOM- 20180612
LR  - 20220311
IS  - 2174-2030 (Electronic)
IS  - 0870-2551 (Linking)
VI  - 36
IP  - 7-8
DP  - 2017 Jul-Aug
TI  - Aspirin and blood pressure: Effects when used alone or in combination with 
      antihypertensive drugs.
PG  - 551-567
LID - S0870-2551(17)30289-5 [pii]
LID - 10.1016/j.repc.2017.05.008 [doi]
AB  - Arterial hypertension is a major risk factor for cardiovascular and renal events. 
      Lowering blood pressure is thus an important strategy for reducing morbidity and 
      mortality. Since low-dose aspirin is a cornerstone in the prevention of adverse 
      cardiovascular outcomes, combined treatment with aspirin and antihypertensive 
      drugs is very common. However, the impact of aspirin therapy on blood pressure 
      control remains a subject of intense debate. Recent data suggest that the 
      cardioprotective action of aspirin extends beyond its well-known antithrombotic 
      effect. Aspirin has been shown to trigger the synthesis of specialized 
      pro-resolving lipid mediators from arachidonic acid and omega-3 fatty acids. 
      These novel anti-inflammatory and pro-resolving mediators actively stimulate the 
      resolution of inflammation and tissue regeneration. Additionally, they may 
      contribute to other protective effects on redox status and vascular reactivity 
      that have also been attributed to aspirin. Of note, aspirin has been shown to 
      improve vasodilation through cyclooxygenase-independent mechanisms. On the other 
      hand, higher aspirin doses have been reported to exert a negative impact on blood 
      pressure due to inhibition of cyclooxygenase-2 activity, which reduces renal 
      blood flow, glomerular filtration rate and sodium and water excretion. This 
      review aims to provide an overview of the effects of aspirin on blood pressure 
      and the underlying mechanisms, focusing on the interaction between aspirin and 
      antihypertensive drugs. Studies in both experimental and human hypertension are 
      presented.
CI  - Copyright © 2017 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier 
      España, S.L.U. All rights reserved.
FAU - Costa, Ana Catarina
AU  - Costa AC
AD  - Departamento de Biomedicina - Unidade de Farmacologia e Terapêutica, Faculdade de 
      Medicina da Universidade do Porto, Porto, Portugal.
FAU - Reina-Couto, Marta
AU  - Reina-Couto M
AD  - Departamento de Biomedicina - Unidade de Farmacologia e Terapêutica, Faculdade de 
      Medicina da Universidade do Porto, Porto, Portugal; MedInUP - Centro de 
      Investigação Farmacológica e Inovação Medicamentosa, Universidade do Porto, 
      Porto, Portugal; Departamento de Medicina Intensiva, Centro Hospitalar São João, 
      Porto, Portugal.
FAU - Albino-Teixeira, António
AU  - Albino-Teixeira A
AD  - Departamento de Biomedicina - Unidade de Farmacologia e Terapêutica, Faculdade de 
      Medicina da Universidade do Porto, Porto, Portugal; MedInUP - Centro de 
      Investigação Farmacológica e Inovação Medicamentosa, Universidade do Porto, 
      Porto, Portugal. Electronic address: albinote@med.up.pt.
FAU - Sousa, Teresa
AU  - Sousa T
AD  - Departamento de Biomedicina - Unidade de Farmacologia e Terapêutica, Faculdade de 
      Medicina da Universidade do Porto, Porto, Portugal; MedInUP - Centro de 
      Investigação Farmacológica e Inovação Medicamentosa, Universidade do Porto, 
      Porto, Portugal. Electronic address: tsousa@med.up.pt.
LA  - eng
LA  - por
PT  - Journal Article
PT  - Review
DEP - 20170703
PL  - Portugal
TA  - Rev Port Cardiol
JT  - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de 
      Cardiologia = Portuguese journal of cardiology : an official journal of the 
      Portuguese Society of Cardiology
JID - 8710716
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/pharmacology/*therapeutic use
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Drug Interactions
MH  - Fibrinolytic Agents/*pharmacology
MH  - Humans
MH  - Hypertension/*drug therapy
OTO - NOTNLM
OT  - Antihypertensive agents
OT  - Aspirin
OT  - Aspirina
OT  - Ações farmacológicas
OT  - Blood pressure
OT  - Fármacos anti-hipertensores
OT  - Hipertensão
OT  - Hypertension
OT  - Pharmacologic actions
OT  - Pressão arterial
EDAT- 2017/07/08 06:00
MHDA- 2018/06/13 06:00
CRDT- 2017/07/08 06:00
PHST- 2017/04/13 00:00 [received]
PHST- 2017/05/22 00:00 [accepted]
PHST- 2017/07/08 06:00 [pubmed]
PHST- 2018/06/13 06:00 [medline]
PHST- 2017/07/08 06:00 [entrez]
AID - S0870-2551(17)30289-5 [pii]
AID - 10.1016/j.repc.2017.05.008 [doi]
PST - ppublish
SO  - Rev Port Cardiol. 2017 Jul-Aug;36(7-8):551-567. doi: 10.1016/j.repc.2017.05.008. 
      Epub 2017 Jul 3.

PMID- 25499006
OWN - NLM
STAT- MEDLINE
DCOM- 20150814
LR  - 20181202
IS  - 1049-023X (Print)
IS  - 1049-023X (Linking)
VI  - 30
IP  - 1
DP  - 2015 Feb
TI  - Emergency Resuscitation of Patients Enrolled in the US Diaspirin Cross-linked 
      Hemoglobin (DCLHb) Clinical Efficacy Trial.
PG  - 54-61
LID - 10.1017/S1049023X14001174 [doi]
AB  - INTRODUCTION: Optimal emergent management of traumatic hemorrhagic shock patients 
      requires a better understanding of treatment provided in the 
      prehospital/Emergency Medical Services (EMS) and emergency department (ED) 
      settings. Hypothesis/Problem Described in this research are the initial clinical 
      status, airway management, fluid and blood infusions, and time course of 
      severely-injured hemorrhagic shock patients in the EMS and ED settings from the 
      diaspirin cross-linked hemoglobin (DCLHb) clinical trial. METHODS: Data were 
      analyzed from 17 US trauma centers gathered during a randomized, controlled, 
      single-blinded efficacy trial of a hemoglobin solution (DCLHb) as add-on therapy 
      versus standard therapy. RESULTS: Among the 98 randomized patients, the mean EMS 
      Glasgow Coma Scale (GCS) was 10.6 (SD = 5.0), the mean EMS revised trauma score 
      (RTS) was 6.3 (SD = 1.9), and the mean injury severity score (ISS) was 31 (SD = 
      17). Upon arrival to the ED, the GCS was 20% lower (7.8 (SD = 5.3) vs 9.7 (SD = 
      6.3)) and the RTS was 12% lower (5.3 (SD = 2.0) vs 6.0 (SD = 2.1)) than EMS 
      values in blunt trauma patients (P < .001). By ED disposition, 80% of patients 
      (78/98) were intubated. Rapid sequence intubation (RSI) was utilized in 77% 
      (60/78), most often utilizing succinylcholine (65%) and midazolam (50%). The mean 
      crystalloid volume infused was 4.2 L (SD = 3.4 L), 80% of which was infused 
      within the ED. Emergency department blood transfusion occurred in 62% of 
      patients, with an average transfused volume of 1.2 L (SD = 2.0 L). Blunt trauma 
      patients received 2.1 times more total fluids (7.4 L vs 3.5 L, < .001) and 2.4 
      times more blood (2.4 L vs 1.0 L, P < .001). The mean time of patients taken from 
      injury site to operating room (OR) was 113 minutes (SD = 87 minutes). Twenty-one 
      (30%) of the 70 patients taken to the OR from the ED were sent within 60 minutes 
      of the estimated injury time. Penetrating trauma patients were taken to the OR 
      52% sooner than blunt trauma patients (72 minutes vs 149 minutes, P < .001). 
      CONCLUSION: Both GCS and RTS decreased prior to ED arrival in blunt trauma 
      patients. Intubation was performed using RSI, and crystalloid infusion of three 
      times the estimated blood loss volume (L) and blood transfusion of the estimated 
      blood loss volume (L) were provided in the EMS and ED settings. Surgical 
      intervention for these trauma patients most often occurred more than one hour 
      from the time of injury. Penetrating trauma patients received surgical 
      intervention more rapidly than those with a blunt trauma mechanism.
FAU - Sloan, Edward P
AU  - Sloan EP
AD  - 1Department of Emergency Medicine,University of Illinois at 
      Chicago,Chicago,IllinoisUSA.
FAU - Koenigsberg, Max
AU  - Koenigsberg M
AD  - 2Advocate Illinois Masonic Medical Center,Chicago,IllinoisUSA.
FAU - Weir, W Brad
AU  - Weir WB
AD  - 3Carle Physician Group,Department of Emergency Medicine,University of Illinois 
      College of Medicine at Urbana-Champaign,Urbana-Champaign,IllinoisUSA.
FAU - Clark, James M
AU  - Clark JM
AD  - 4Rush Medical College,Rush University Medical Center,Chicago,IllinoisUSA.
FAU - O'Connor, Robert
AU  - O'Connor R
AD  - 5Department of Emergency Medicine,University of 
      Virginia,Charlottesville,VirginiaUSA.
FAU - Olinger, Michael
AU  - Olinger M
AD  - 6Department of Emergency Medicine,Indiana University,Indianapolis,IndianaUSA.
FAU - Cydulka, Rita
AU  - Cydulka R
AD  - 7Department of Emergency Medicine,Case Western Reserve 
      University,Cleveland,OhioUSA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20141215
PL  - United States
TA  - Prehosp Disaster Med
JT  - Prehospital and disaster medicine
JID - 8918173
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
MH  - Adult
MH  - Airway Management
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - Blood Transfusion/statistics & numerical data
MH  - Emergency Treatment
MH  - Female
MH  - Fluid Therapy/methods
MH  - Glasgow Coma Scale
MH  - Hemoglobins/*therapeutic use
MH  - Humans
MH  - Injury Severity Score
MH  - Male
MH  - Resuscitation/*methods
MH  - Shock, Hemorrhagic/*therapy
MH  - Single-Blind Method
MH  - Treatment Outcome
OTO - NOTNLM
OT  - DCLHb diaspirin cross-linked hemoglobin
OT  - ED emergency department
OT  - EMS Emergency Medical Services
OT  - ETI endotracheal intubation
OT  - GCS Glasgow Coma Scale
OT  - HR heart rate
OT  - ISS injury severity score
OT  - IV intravenous
OT  - MOI mechanism of injury
OT  - OR operating room
OT  - PRBC packed red blood cell
OT  - RR respiratory rate
OT  - RSI rapid sequence intubation
OT  - RTS revised trauma score
OT  - SBC systolic blood pressure
OT  - T-RTS triage revised trauma score
OT  - TBI traumatic brain injury
OT  - wounds and injuries
EDAT- 2014/12/17 06:00
MHDA- 2015/08/15 06:00
CRDT- 2014/12/16 06:00
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/08/15 06:00 [medline]
AID - S1049023X14001174 [pii]
AID - 10.1017/S1049023X14001174 [doi]
PST - ppublish
SO  - Prehosp Disaster Med. 2015 Feb;30(1):54-61. doi: 10.1017/S1049023X14001174. Epub 
      2014 Dec 15.

PMID- 1461865
OWN - NLM
STAT- MEDLINE
DCOM- 19930114
LR  - 20131121
IS  - 0032-5473 (Print)
IS  - 0032-5473 (Linking)
VI  - 68 Suppl 2
DP  - 1992
TI  - Why test antiplatelet therapy in acute ischaemic stroke and how can this be done?
PG  - S14-8; discussion S18-9
AB  - Stroke is a major public health problem, yet there is no treatment of proven 
      value for widespread use in the acute phase of the illness. This paper outlines 
      the rationale for using antiplatelet therapy in acute ischaemic stroke and why it 
      appears to be one of the most promising agents for testing in very large scale 
      clinical trials.
FAU - Lindley, R I
AU  - Lindley RI
AD  - Department of Clinical Neurosciences, University of Edinburgh, Western General 
      Hospital, UK.
FAU - Sandercock, P A
AU  - Sandercock PA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Clinical Trials as Topic
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Postgrad Med J. 1992;68 Suppl 2:S14-8; discussion S18-9.

PMID- 1361070
OWN - NLM
STAT- MEDLINE
DCOM- 19930112
LR  - 20131121
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 78
IP  - 1
DP  - 1992 Oct
TI  - Effect of aspirin on vascular tone and reactivity to vasoactive amines in the dog 
      lung.
PG  - 47-56
AB  - The effect of increasing blood levels of aspirin on pulmonary hemodynamics and 
      pressor response to vasoactive amines was examined in the isolated canine lung 
      lobe, blood perfused at constant flow. At steady state lobar vascular resistance 
      (LVR), lobes were challenged with either 250 micrograms serotonin (5-HT; n = 4), 
      5.0 mumol acetylcholine (ACh; n = 4) or 50 micrograms norepinephrine (NE; n = 4) 
      before and after blood aspirin concentration [ASA] was incrementally increased 
      from 17 to 3140 microM. LVR was partitioned into arterial (Ra) and venous (Rv) 
      segments by venous outflow occlusions 20 min after each ASA addition and at the 
      peak of the pressor response to each amine. ASA treatment was associated with a 
      dose-related 105% increase in LVR (P < 0.01) accounted for by a 154% increase in 
      Ra (P < 0.01) and a 70% increase in Rv (P < 0.01) at 3150 microM ASA (n = 12). In 
      spite of increased vascular tone, higher [ASA] also potentiated increases in both 
      pulmonary arterial pressure and LVR to both 5-HT and NE whereas only Ra increased 
      with ACh challenge. Thus, the increase in pulmonary vascular tone and reactivity 
      to vasoactive amines is positively correlated with blood aspirin levels in the 
      dog.
FAU - Hofman, W F
AU  - Hofman WF
AD  - Department of Physiology and Endocrinology, Medical College of Georgia, Augusta 
      30912.
FAU - Fravel, J
AU  - Fravel J
FAU - Ehrhart, I C
AU  - Ehrhart IC
LA  - eng
GR  - HL-40488/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - 0 (Neurotransmitter Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Pressure
MH  - Dogs
MH  - Hemodynamics/drug effects
MH  - Lung/*blood supply
MH  - Muscle, Smooth, Vascular/*drug effects
MH  - Neurotransmitter Agents/pharmacology
MH  - Perfusion
MH  - Vascular Resistance/*drug effects
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1992 Oct;78(1):47-56.

PMID- 23611162
OWN - NLM
STAT- MEDLINE
DCOM- 20131021
LR  - 20220331
IS  - 1557-9034 (Electronic)
IS  - 1092-6429 (Linking)
VI  - 23
IP  - 6
DP  - 2013 Jun
TI  - Continuous low-dose aspirin therapy in robotic-assisted laparoscopic radical 
      prostatectomy does not increase risk of surgical hemorrhage.
PG  - 500-5
LID - 10.1089/lap.2013.0013 [doi]
AB  - BACKGROUND: Withdrawal of oral antiplatelet therapy (OAT) is a major risk factor 
      for stent thrombosis, myocardial infarction, and cerebral strokes. In order to 
      minimize the risk for thrombotic complications, since 2007 robotic-assisted 
      laparoscopic radical prostatectomy (RARP) has taken place under continuous OAT 
      with aspirin at our institution. In this retrospective study we analyzed the risk 
      for perioperative bleeding and surgical outcome after RARP with OAT. PATIENTS AND 
      METHODS: All patients who underwent RARP with aspirin OAT at our institution 
      since 2007 were included in this analysis. The OAT group was compared with a 
      group that underwent RARP without OAT, which contained twice the number of 
      patients. Matching of the two groups was performed with regard to the tumor stage 
      and whether a lymph node dissection or nerve-sparing was performed. RESULTS: 
      Thirty-eight patients were assigned to the OAT group and 76 to the control group. 
      A difference in the decrease of postoperative hemoglobin concentration was not 
      detectable between the two groups (mean drop of 2.9±1.4 g/dL and 2.9±1.1 g/dL, 
      respectively; P=.93). RARP was completed in all OAT patients without conversion 
      to open surgery. Two of the 38 patients (5.3%) in the OAT group and none in the 
      control group required blood transfusions (P=.11). Equivalent rates of positive 
      surgical margins for pT2 tumors were detected (16% OAT versus 14% control group; 
      P=1.0). No adverse cardiovascular events occurred in either group during the 
      hospitalization. CONCLUSIONS: Continued perioperative OAT with aspirin in RARP is 
      safe, feasible, and not associated with increased blood loss.
FAU - Mortezavi, Ashkan
AU  - Mortezavi A
AD  - Department of Urology, University Hospital Zürich, Zürich, Switzerland.
FAU - Hermanns, Thomas
AU  - Hermanns T
FAU - Hefermehl, Lukas J
AU  - Hefermehl LJ
FAU - Spahn, Donat R
AU  - Spahn DR
FAU - Seifert, Burkhardt
AU  - Seifert B
FAU - Weber, Damian
AU  - Weber D
FAU - Brunnschweiler, Simone
AU  - Brunnschweiler S
FAU - Schmid, Daniel M
AU  - Schmid DM
FAU - Sulser, Tullio
AU  - Sulser T
FAU - Eberli, Daniel
AU  - Eberli D
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - United States
TA  - J Laparoendosc Adv Surg Tech A
JT  - Journal of laparoendoscopic & advanced surgical techniques. Part A
JID - 9706293
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Humans
MH  - *Laparoscopy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Postoperative Hemorrhage/*chemically induced/*epidemiology
MH  - Prostatectomy/*methods
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - *Robotics
MH  - Treatment Outcome
EDAT- 2013/04/25 06:00
MHDA- 2013/10/22 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/25 06:00 [entrez]
PHST- 2013/04/25 06:00 [pubmed]
PHST- 2013/10/22 06:00 [medline]
AID - 10.1089/lap.2013.0013 [doi]
PST - ppublish
SO  - J Laparoendosc Adv Surg Tech A. 2013 Jun;23(6):500-5. doi: 10.1089/lap.2013.0013. 
      Epub 2013 Apr 23.

PMID- 36181528
OWN - NLM
STAT- MEDLINE
DCOM- 20230308
LR  - 20230309
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Print)
IS  - 0937-4477 (Linking)
VI  - 280
IP  - 4
DP  - 2023 Apr
TI  - The pattern of epistaxis recurrence in patients taking prophylactic 
      acetylsalicylic acid (ASA) from a 10 year cohort.
PG  - 1723-1730
LID - 10.1007/s00405-022-07666-3 [doi]
AB  - OBJECTIVES: Epistaxis is the most common otolaryngological emergency and 
      one-third of epistaxis patients regularly take low-dose acetylsalicylic acid 
      (ASA) for the prevention of cardiovascular disease (CVD). The shift in 
      contemporary guidelines identifies little benefit of ASA intake in patients who 
      have not previously had an infarction. Existing evidence confirms ASA intake as a 
      factor for severe epistaxis, while the evidence concerning its impact on 
      recurrence is ambiguous. There are no available studies which justify the 
      administration of these drugs nor are there any studies correlating the effects 
      of these drugs to the SCORE2 CVD risk stratifying scale. STUDY DESIGN: A 
      retrospective analysis of all admitted epistaxis patients in a tertiary academic 
      hospital for the 10 year period 2011 to 2021. METHODS: Patient data were analysed 
      using the hospital information software. A recurrence was defined as an epistaxis 
      episode requiring hospital readmittance for at least one night. Patients taking 
      anticoagulants were excluded (N = 421). RESULTS: 444 patients were included: 246 
      were taking ASA and 198 were not (NoASA). ASA patients had more frequent 
      recurrence in general (p = 0.03), more recurrences per patient (p = 0.002), and 
      more changes in bleeding localisation (p = 0.04). Recurrence in the ASA group was 
      associated with lower haemoglobin values (HR 0.62, p < 0.0001), while surgery (HR 
      6.83, p < 0.0001) was associated with recurrence in the NoASA group. ASA patients 
      had a statistically significant (r 0.33, p = 0.032) correlation between the total 
      number of epistaxis recurrences and SCORE2. The indication for drug intake was 
      highly questionable in as much as 40% of ASA patients. Follow-up time was 
      5.27 years. CONCLUSIONS: Epistaxis patients taking prophylactic ASA are 
      significantly more burdened by recurrence, because they have more frequent 
      recurrences, a greater number of recurrences per patient, and more changes in 
      bleeding localisations when compared to control patients. The drug indication is 
      questionable in up to 40% of ASA patients, exposing them unnecessarily to 
      recurrence.
CI  - © 2022. The Author(s).
FAU - Stanković, Petar
AU  - Stanković P
AUID- ORCID: 0000-0002-0105-1489
AD  - Department of Otolaryngology, Head/Neck and Facial Plastic Surgery, Sana Kliniken 
      Leipziger Land, Borna, Germany.
FAU - Hoch, Stephan
AU  - Hoch S
AD  - Department of Otolaryngology, Head/Neck and Facial Plastic Surgery, 
      Philipps-University, Marburg, Germany.
FAU - Rudhart, Stefan
AU  - Rudhart S
AD  - Department of Otolaryngology, Head/Neck and Facial Plastic Surgery, 
      Philipps-University, Marburg, Germany.
FAU - Stojković, Stefan
AU  - Stojković S
AD  - Department of Cardiology, Medical University, Vienna, Austria.
FAU - Wilhelm, Thomas
AU  - Wilhelm T
AUID- ORCID: 0000-0003-1317-5224
AD  - Department of Otolaryngology, Head/Neck and Facial Plastic Surgery, Sana Kliniken 
      Leipziger Land, Borna, Germany. thomas.wilhelm@sana.de.
AD  - Medical Faculty, Philipps-University, Marburg, Germany. thomas.wilhelm@sana.de.
LA  - eng
PT  - Journal Article
DEP - 20221001
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Humans
MH  - *Aspirin/adverse effects
MH  - Retrospective Studies
MH  - Epistaxis
MH  - Anticoagulants
MH  - *Cardiovascular Diseases/prevention & control
MH  - Recurrence
PMC - PMC9988998
OTO - NOTNLM
OT  - ASA
OT  - Aspirin
OT  - Epistaxis
OT  - Recurrence
OT  - SCORE2
COIS- None declared.
EDAT- 2022/10/02 06:00
MHDA- 2023/03/09 06:00
CRDT- 2022/10/01 11:13
PHST- 2022/05/20 00:00 [received]
PHST- 2022/09/16 00:00 [accepted]
PHST- 2022/10/02 06:00 [pubmed]
PHST- 2023/03/09 06:00 [medline]
PHST- 2022/10/01 11:13 [entrez]
AID - 10.1007/s00405-022-07666-3 [pii]
AID - 7666 [pii]
AID - 10.1007/s00405-022-07666-3 [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2023 Apr;280(4):1723-1730. doi: 
      10.1007/s00405-022-07666-3. Epub 2022 Oct 1.

PMID- 8735820
OWN - NLM
STAT- MEDLINE
DCOM- 19961216
LR  - 20190914
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 7
IP  - 2
DP  - 1996 Mar
TI  - In vitro study of the anti-aggregating activity of two nitroderivatives of 
      acetylsalicylic acid.
PG  - 206-9
AB  - The antiplatelet activity of two new nitrocompounds, chemically related to 
      acetylsalicylic acid (NCX 4215 and NCX 4016), was studied in vitro to verify the 
      hypothetical dual action of these drugs. Both drugs, in a dose-dependent way, 
      inhibited arachidonic acid-induced platelet aggregation and thromboxane A2 
      production, measured as thromboxane B2 concentration in whole blood. These 
      effects are likely to be related to cyclo-oxygenase inhibition. NCX 4215 and NCX 
      4016 in a dose-dependent way inhibited also thrombin-induced aggregation of 
      platelets pretreated with acetylsalicylic acid. These inhibitory effects are 
      related to nitric oxide release and cGMP increase and significantly reversed by 
      oxyhaemoglobin and methylene blue. Either as a cyclo-oxygenase inhibitor or as a 
      nitric oxide donor, NCX 4016 proved to be significantly more potent than NCX 
      4215.
FAU - Lechi, C
AU  - Lechi C
AD  - Institute of Clinical Chemistry, University of Verona, Italy.
FAU - Gaino, S
AU  - Gaino S
FAU - Tommasoli, R
AU  - Tommasoli R
FAU - Zuliani, V
AU  - Zuliani V
FAU - Bonapace, S
AU  - Bonapace S
FAU - Fontana, L
AU  - Fontana L
FAU - Degan, M
AU  - Degan M
FAU - Lechi, A
AU  - Lechi A
FAU - Minuz, P
AU  - Minuz P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (NCX 4215)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 3.4.21.5 (Thrombin)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - In Vitro Techniques
MH  - Nitric Oxide/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thrombin/pharmacology
MH  - Thromboxane A2/metabolism
MH  - Thromboxane B2/metabolism
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
AID - 10.1097/00001721-199603000-00024 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 1996 Mar;7(2):206-9. doi: 
      10.1097/00001721-199603000-00024.

PMID- 32952164
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 1665-1731 (Electronic)
IS  - 1665-1731 (Linking)
VI  - 90
IP  - 3
DP  - 2020
TI  - Aspirin in primary prevention. Meta-analysis stratified by baseline 
      cardiovascular risk.
PG  - 293-299
LID - 10.24875/ACM.20000267 [doi]
AB  - INTRODUCCIÓN: La utilidad de la aspirina en la prevención primaria es todavía 
      objeto de controversia. Los avances médicos y la variabilidad del riesgo 
      cardiovascular podrían explicar la heterogeneidad de los estudios publicados, y 
      las poblaciones de alto riesgo tendrían mayor beneficio. OBJETIVO: Analizar los 
      efectos de la aspirina en pacientes sin antecedentes cardiovasculares y evaluar 
      los resultados de acuerdo con el riesgo cardiovascular de las poblaciones. 
      MÉTODOS: Se incluyeron estudios que evaluaron el uso de la aspirina en 
      comparación con placebo en la prevención primaria. Se analizó la combinación de 
      muerte cardiovascular, infarto agudo de miocardio (IAM) y accidente 
      cerebrovascular (ACV) isquémico. El punto final de seguridad fue la combinación 
      de ACV hemorrágico y sangrado mayor. Se clasificaron los estudios en riesgo bajo 
      y moderado/ alto, de acuerdo con el número de episodios en la rama de placebo. 
      RESULTADOS: Se evaluaron 13 estudios (n = 164,225), ocho de riesgo cardiovascular 
      bajo (n = 118,455) y cinco de moderado/alto (n = 45,770). Se observó una 
      reducción del punto final combinado en el grupo de aspirina (OR 0.90; IC 95%, 
      0.85-0.94), sin diferencias en mortalidad cardiovascular (OR 0.94; IC 95%, 
      0.86-1.04). No se identificaron diferencias entre los subgrupos de riesgo. Se 
      reconocieron mayores complicaciones hemorrágicas en el grupo de aspirina (OR 
      1.45; IC 95%, 1.32-1.60), sin diferencias entre los subgrupos de riesgo. 
      CONCLUSIÓN: La aspirina se relacionó con una leve disminución de IAM y ACV 
      isquémico en términos absolutos, sin diferencias en la mortalidad cardiovascular. 
      Esto, junto con el aumento de las complicaciones hemorrágicas, se traduce en una 
      ausencia de beneficio clínico neto. El riesgo cardiovascular basal de la 
      población no modificó los resultados. BACKGROUND: The usefulness of aspirin in 
      primary prevention continues to be the subject of debate. Medical advances and 
      the variability of cardiovascular risk could explain the heterogeneity of the 
      published studies. High risk populations would have greater benefit. OBJECTIVE: 
      Analyzing the effects of aspirin in patients without cardiovascular disease and 
      evaluating the results according to the cardiovascular risk of the populations. 
      METHODS: Studies evaluating aspirin versus placebo in primary prevention were 
      included. The primary endpoint was the combined cardiovascular death, acute 
      myocardial infarction (AMI) and ischemic stroke. The final safety point was the 
      combination of hemorrhagic stroke and major bleeding. The studies were classified 
      into low and moderate/high risk, according to the number of events in the placebo 
      arm. RESULTS: Thirteen studies were evaluated (n = 164,225), eight of low 
      cardiovascular risk (n = 118,455) and five of moderate/high risk (n = 45,770). 
      There was a reduction of the combined endpoint in the aspirin group (odds ratio 
      [OR] 0.90; 95% confidence interval [CI], 0.85-0.94), without differences in 
      cardiovascular mortality (OR 0.94; 95% CI, 0.86-1.04). No differences were 
      observed when comparing the risk subgroups. Greater hemorrhagic complications 
      were observed in the aspirin group (OR 1.45; 95% CI, 1.32-1.60), without 
      differences between the risk subgroups. CONCLUSION: Aspirin was associated with a 
      slight decrease in AMI and ischemic stroke in absolute terms, with no differences 
      in cardiovascular mortality. This accompanied by the increase in hemorrhagic 
      complications, results in an absence of net clinical benefit. The baseline 
      cardiovascular risk of the population did not affect the results.
CI  - Copyright: © 2020 Permanyer.
FAU - Masson, Gerardo
AU  - Masson G
AD  - Servicio de Cardiología, Instituto Cardiovascular San Isidro. Buenos Aires, 
      Argentina.
AD  - Consejo de Prevención y Epidemiología, Sociedad Argentina de Cardiología. Buenos 
      Aires, Argentina.
FAU - Lobo, Martín
AU  - Lobo M
AD  - Consejo de Prevención y Epidemiología, Sociedad Argentina de Cardiología. Buenos 
      Aires, Argentina.
FAU - Masson, Walter
AU  - Masson W
AD  - Consejo de Prevención y Epidemiología, Sociedad Argentina de Cardiología. Buenos 
      Aires, Argentina.
FAU - Molinero, Graciela
AU  - Molinero G
AD  - Consejo de Prevención y Epidemiología, Sociedad Argentina de Cardiología. Buenos 
      Aires, Argentina.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
TT  - Aspirina en la prevención primaria. Metaanálisis estratificado por riesgo 
      cardiovascular basal.
PL  - Mexico
TA  - Arch Cardiol Mex
JT  - Archivos de cardiologia de Mexico
JID - 101126728
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Heart Disease Risk Factors
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Ischemic Stroke/prevention & control
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Primary Prevention/methods
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirina
OT  - Cardiovascular prevention
OT  - Prevención cardiovascular
OT  - Prevención primaria
OT  - Primary prevention
EDAT- 2020/09/22 06:00
MHDA- 2021/08/04 06:00
CRDT- 2020/09/21 06:04
PHST- 2020/09/21 06:04 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
AID - j90/3/293 [pii]
AID - 10.24875/ACM.20000267 [doi]
PST - ppublish
SO  - Arch Cardiol Mex. 2020;90(3):293-299. doi: 10.24875/ACM.20000267.

PMID- 18167215
OWN - NLM
STAT- MEDLINE
DCOM- 20080205
LR  - 20131121
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 120
IP  - 24
DP  - 2007 Dec 20
TI  - Effect of external stents on prevention of intimal hyperplasia in a canine vein 
      graft model.
PG  - 2264-7
AB  - BACKGROUND: External stents have been used to reduce intimal hyperplasia of vein 
      grafts. The aim of the present study was to define the size of an external stent 
      appropriate for a particular graft by comparing vein grafts with different sizes 
      of external stents. METHODS: A series of paired trials was performed to compare 
      femoral vein grafts with different sizes of external stents, where 30 modeled 
      canines were equally divided into three groups: 6-mm external stent vs non-stent 
      control, 4-mm vs 6-mm external stent, and 4-mm vs 8-mm external stent. At day 3 
      after operation, color Doppler flow imaging (CDFI) was done to observe blood flow 
      in the lumen. Four weeks later, CDFI was re-checked and the veins were harvested, 
      stained and measured. RESULTS: All grafts were patent without formation of 
      thrombosis. External stents significantly reduced intimal thickness of the vein 
      grafts with a 6-mm external stent compared with the vein grafts without external 
      stents (P < 0.05). The vein grafts with the 4-mm external stent had similar 
      intimal, medial and adventitial thicknesses compared with those with the 6-mm 
      external stent and the 8-mm external stent. CONCLUSIONS: External stents can 
      reduce intimal hyperplasia of vein grafts. Stents of different diameters exert 
      the similar effect on prevention of intimal hyperplasia.
FAU - Zou, Rong-jiang
AU  - Zou RJ
AD  - Department of Cardiothoracic Surgery, Changhai Hospital, Second Military Medical 
      University, Shanghai 200433, China.
FAU - Zou, Liang-jian
AU  - Zou LJ
FAU - Huang, Sheng-dong
AU  - Huang SD
FAU - Wang, Yin
AU  - Wang Y
FAU - Han, Lin
AU  - Han L
FAU - Ji, Guang-yu
AU  - Ji GY
FAU - Xu, Zhi-yun
AU  - Xu ZY
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Dogs
MH  - Femoral Vein/*transplantation
MH  - Hyperplasia
MH  - *Stents
MH  - Tunica Intima/*pathology
MH  - Ultrasonography, Doppler, Color
EDAT- 2008/01/03 09:00
MHDA- 2008/02/06 09:00
CRDT- 2008/01/03 09:00
PHST- 2008/01/03 09:00 [pubmed]
PHST- 2008/02/06 09:00 [medline]
PHST- 2008/01/03 09:00 [entrez]
PST - ppublish
SO  - Chin Med J (Engl). 2007 Dec 20;120(24):2264-7.

PMID- 6241781
OWN - NLM
STAT- MEDLINE
DCOM- 19850523
LR  - 20131121
IS  - 0326-6656 (Print)
IS  - 0326-6656 (Linking)
VI  - 34
IP  - 3
DP  - 1984
TI  - Suppressive effect of acetylsalicylic acid on erythropoietin-responsive cells in 
      mice.
PG  - 229-34
AB  - The time-response curve for RBC-59Fe uptake following i.p. injections of 3 doses 
      of 5 mg of acetylsalicylic acid (ASA) at 4 hour interval into normal, 
      nonpolycythemic mice, shows a maximal depression (35% of normal) at 3 days after 
      ASA with return to almost normal values by 7 days. The effect is dose-related, 
      showing a plateau with doses of ASA above 5 mg/4 hr. The shape of the 
      time-response curve indicates that the more mature cells in the erythron are not 
      affected by ASA and that the major effect of the drug must be on earlier 
      erythroid cells. Administration of ASA prior to administration of erythropoietin 
      (Epo) into post-hypoxic polycythemic mice depresses the incorporation of 59Fe 
      into erythrocytes. The depression of radioiron uptake is similar when ASA is 
      given prior to or simultaneously with Epo. When ASA is given 24 hr after 
      injection of Epo, suppression is less marked. These results suggest a suppressive 
      effect of the drug on the erythropoietin-responsive cells (ERC).
FAU - Giglio, M J
AU  - Giglio MJ
FAU - Santoro, R C
AU  - Santoro RC
FAU - Bozzini, C E
AU  - Bozzini CE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Argentina
TA  - Acta Physiol Pharmacol Latinoam
JT  - Acta physiologica et pharmacologica latinoamericana : organo de la Asociacion 
      Latinoamericana de Ciencias Fisiologicas y de la Asociacion Latinoamericana de 
      Farmacologia
JID - 8409686
RN  - 0 (Iron Radioisotopes)
RN  - 11096-26-7 (Erythropoietin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/metabolism/*pharmacology
MH  - Binding Sites
MH  - Dose-Response Relationship, Drug
MH  - Erythrocytes/*drug effects/metabolism
MH  - Erythropoiesis/*drug effects
MH  - Erythropoietin/*pharmacology
MH  - Female
MH  - Hematocrit
MH  - Iron Radioisotopes/metabolism
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Polycythemia/blood/physiopathology
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Physiol Pharmacol Latinoam. 1984;34(3):229-34.

PMID- 23092002
OWN - NLM
STAT- MEDLINE
DCOM- 20121108
LR  - 20131121
IS  - 1764-1489 (Print)
IS  - 1764-1489 (Linking)
VI  - 44
IP  - 4
DP  - 2012 Aug
TI  - Aspirin challenge/desensitisation before coronary stenting in subjects with 
      history of hypersensitivity. A pragmatic approach.
PG  - 160-2
AB  - BACKGROUND: Aspirin hypersensitivity may represent a major problem in patients 
      with ischemic coronary disease who need a stenting procedure. In those patients, 
      clinically unsettled reasonably quick desensitisation procedures are needed. In 
      our study we attempted to select the most suitable procedure on the basis of 
      characteristics and severity of ASA hypersensitivity. METHODS: Thirty patients 
      with a history of mild reactions to anti-inflammatory doses of aspirin (> 325 mg) 
      were considered at low risk and underwent a tolerance test in 5 steps. Thirty-one 
      patients, with a history of severe reactions to anti-platelet doses of aspirin 0 
      mg) underwent a slow desensitisation in 12 steps, reaching a cumulative dose of 
      150 mg ASA in 220 minutes. RESULTS: In the first group, 29 patients tolerated the 
      challenge. One developed urticaria, thus underwent challenge/desensitisation and 
      achieved tolerance. In the second group, 3 patients did not tolerate the 
      procedure and had to discontinue. CONCLUSION. Our approach to aspirin 
      hypersensitivity in patients needing coronary stenting, based on a severity 
      stratification, allowed to achieve an effective tolerance to aspirin in the 
      majority of subject in a reasonable short time.
FAU - Cortellini, G
AU  - Cortellini G
AD  - Internal Medicine and Rheumatology Unit, Rimini Hospital, Rimini, Italy.
FAU - Testi, S
AU  - Testi S
FAU - Severino, M
AU  - Severino M
FAU - Chechi, T
AU  - Chechi T
FAU - Iorno, M L
AU  - Iorno ML
FAU - Santucci, A
AU  - Santucci A
FAU - Corvetta, A
AU  - Corvetta A
FAU - Piovaccari, G
AU  - Piovaccari G
FAU - Santarelli, A
AU  - Santarelli A
FAU - Franco, N
AU  - Franco N
FAU - Canonica, G W
AU  - Canonica GW
FAU - Passalacqua, G
AU  - Passalacqua G
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Ann Allergy Clin Immunol
JT  - European annals of allergy and clinical immunology
JID - 101466614
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/*adverse effects
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - *Stents
EDAT- 2012/10/25 06:00
MHDA- 2012/11/09 06:00
CRDT- 2012/10/25 06:00
PHST- 2012/10/25 06:00 [entrez]
PHST- 2012/10/25 06:00 [pubmed]
PHST- 2012/11/09 06:00 [medline]
PST - ppublish
SO  - Eur Ann Allergy Clin Immunol. 2012 Aug;44(4):160-2.

PMID- 19962464
OWN - NLM
STAT- MEDLINE
DCOM- 20100216
LR  - 20220331
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 104
IP  - 12
DP  - 2009 Dec 15
TI  - Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated 
      patients with acute myocardial infarction.
PG  - 1618-23
LID - 10.1016/j.amjcard.2009.07.039 [doi]
AB  - Inhibition of platelet thromboxane A(2) (TXA(2)) by aspirin is critical in 
      patients with acute myocardial infarction (AMI), but some patients have 
      persistent platelet TXA(2) production within 48 hours of the onset of AMI. 
      Statins are known to reduce TXA(2) in aspirin-free patients with 
      hypercholesterolemia. We hypothesized that treatment with aspirin plus 
      atorvastatin could reduce persistent TXA(2) synthesis and aspirin resistance in 
      patients with AMI. We evaluated platelet function in 184 aspirin-treated patients 
      within 48 hours of the onset of AMI. Patients were divided into group A (treated 
      with aspirin alone, n = 139) and group B (treated with aspirin plus atorvastatin, 
      n = 45). We studied collagen-induced platelet TXA(2) synthesis, serotonin 
      ((14)C-5HT) release and recruitment, and adenosine diphosphate-, arachidonic 
      acid-, and collagen-induced platelet aggregation. Persistent TXA(2) synthesis was 
      detected in 25% and 9% of groups A and B, respectively (p = 0.03). TXA(2), 
      arachidonic acid-aggregation, and collagen-induced responses were significantly 
      reduced in patients receiving dual treatment compared to those receiving aspirin 
      monotherapy. Atorvastatin did not modify platelet reactivity in patients with 
      efficiently blocked TXA(2) synthesis. These results strongly suggest a direct 
      effect of the statin on platelet eicosanoid synthesis. This was confirmed in 
      vitro by incubating washed aspirin-free and aspirin (1 muM)-treated platelets 
      from normal subjects with 1 to 20 microM atorvastatin. Atorvastatin in vitro 
      significantly reduced platelet TXA(2) synthesis and collagen-induced aggregation. 
      In conclusion, atorvastatin combined with aspirin early in the onset of the acute 
      event significantly reduced persistent TXA(2) and TXA(2)-dependent aspirin 
      resistance. This could contribute to the clinical benefit of atorvastatin in 
      patients with AMI.
FAU - Santos, M Teresa
AU  - Santos MT
AD  - Research Center, University Hospital La Fe, Valencia, Spain. santos_ter@gva.es
FAU - Fuset, M Paz
AU  - Fuset MP
FAU - Ruano, Miguel
AU  - Ruano M
FAU - Moscardó, Antonio
AU  - Moscardó A
FAU - Valles, Juana
AU  - Valles J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Heptanoic Acids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Pyrroles)
RN  - 57576-52-0 (Thromboxane A2)
RN  - A0JWA85V8F (Atorvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Atorvastatin
MH  - Blood Platelets/*drug effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heptanoic Acids/*pharmacology/therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy
MH  - Pyrroles/*pharmacology/therapeutic use
MH  - Thromboxane A2/*blood
MH  - Treatment Outcome
EDAT- 2009/12/08 06:00
MHDA- 2010/02/17 06:00
CRDT- 2009/12/08 06:00
PHST- 2009/05/28 00:00 [received]
PHST- 2009/07/26 00:00 [revised]
PHST- 2009/07/26 00:00 [accepted]
PHST- 2009/12/08 06:00 [entrez]
PHST- 2009/12/08 06:00 [pubmed]
PHST- 2010/02/17 06:00 [medline]
AID - S0002-9149(09)01470-2 [pii]
AID - 10.1016/j.amjcard.2009.07.039 [doi]
PST - ppublish
SO  - Am J Cardiol. 2009 Dec 15;104(12):1618-23. doi: 10.1016/j.amjcard.2009.07.039.

PMID- 23610452
OWN - NLM
STAT- MEDLINE
DCOM- 20141021
LR  - 20140220
IS  - 2047-4881 (Electronic)
IS  - 2047-4873 (Linking)
VI  - 21
IP  - 3
DP  - 2014 Mar
TI  - Review of guidelines on primary prevention of cardiovascular disease with 
      aspirin: how much evidence is needed to turn a tanker?
PG  - 354-65
LID - 10.1177/2047487312472077 [doi]
AB  - AIMS: There are numerous national and international guidelines on the use of 
      aspirin for the primary prevention of cardiovascular disease. Given the 
      uncertainties about aspirin in primary prevention, our aim was to compare the 
      recommendations and the reported evidence in guidelines for the treatment with 
      aspirin of subjects free of cardiovascular disease with or without diabetes. 
      METHODS AND RESULTS: Guidelines were retrieved through Medline and other 
      electronic databases and through a web-based search for guideline development 
      organizations. The content of the recommendations and the underlying evidence 
      were analysed with qualitative and bibliometric methods. In addition, we searched 
      for recent studies to assess whether they underscore the current recommendations. 
      We included 12 guidelines: six European, three North American, and one each from 
      New Zealand, Australia, and the World Health Organization. Recommendations differ 
      with regard to outcome (morbidity, mortality), time span (years of risk), cut-off 
      percentage between high and low risk, and the dose of aspirin. Most guidelines 
      are not in line with recent evidence, which show that aspirin is of uncertain net 
      value as the reduction in absolute risk for occlusive CV events needs to be 
      weighed against an increase in the risk of major bleeds. CONCLUSION: We found 
      conflicting recommendations in various guidelines about the use of aspirin for 
      the primary prevention of cardiovascular events, which reflect differences in 
      selection of the evidence and in the timing of publication. According to recent 
      evidence, in general, the use of aspirin seems no longer justifiable in primary 
      prevention in patients with or without diabetes.
FAU - Matthys, Frederik
AU  - Matthys F
AD  - Department of Cardiovascular Disease, University Hospital Ghent, Belgium.
FAU - De Backer, Tine
AU  - De Backer T
FAU - De Backer, Guy
AU  - De Backer G
FAU - Stichele, Robert Vander
AU  - Stichele RV
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20121220
PL  - England
TA  - Eur J Prev Cardiol
JT  - European journal of preventive cardiology
JID - 101564430
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiology/*standards
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Diabetes Mellitus/epidemiology
MH  - Evidence-Based Medicine/*standards
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Patient Selection
MH  - Practice Guidelines as Topic/*standards
MH  - Primary Prevention/*standards
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - cardiovascular prevention
OT  - evidence
OT  - guideline
OT  - primary prevention
OT  - review
EDAT- 2013/04/24 06:00
MHDA- 2014/10/22 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04/24 06:00 [entrez]
PHST- 2013/04/24 06:00 [pubmed]
PHST- 2014/10/22 06:00 [medline]
AID - 2047487312472077 [pii]
AID - 10.1177/2047487312472077 [doi]
PST - ppublish
SO  - Eur J Prev Cardiol. 2014 Mar;21(3):354-65. doi: 10.1177/2047487312472077. Epub 
      2012 Dec 20.

PMID- 30771282
OWN - NLM
STAT- MEDLINE
DCOM- 20191218
LR  - 20191218
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
VI  - 163
DP  - 2019 May
TI  - Characterization of aspirin esterase activity in health and disease: In vitro and 
      ex vivo studies.
PG  - 119-127
LID - S0006-2952(19)30052-8 [pii]
LID - 10.1016/j.bcp.2019.02.014 [doi]
AB  - Due to its ability to irreversibly inactivate platelet cyclooxygenase, low-dose 
      aspirin (ASA) is the most widely used antithrombotic agent. Although, studies in 
      specific types of patients with cardiovascular disease (CVD) have shown an 
      incomplete inhibition of platelet's cyclooxygenase, which may increase the 
      variability in drug response. Some aspects of ASA pharmacokinetics (PK) still 
      need further investigation. In this study, we aimed to characterise the 
      contribution of esterase enzymes to ASA hydrolysis in the peripheral blood and to 
      assess their activity in 36 healthy subjects (Ctrl) and 77 CVD patients. To this 
      aim, an in vitro assay testing esterase activity in parallel to a liquid 
      chromatography-tandem mass spectrometry method simultaneously detecting ASA and 
      its main metabolites salicylic (SA) and gentisic acids, have been developed. 
      Michaelis-Menten constant (Km) calculation, ASA esterase isoforms 
      characterisation, and ASA PK study were then achieved. The calculated Km 
      identified plasma esterases as the enzymes with the higher affinity for the 
      substrate compared to the RBC ones. Both rivastigmine and 4-bis-nitrophenyl 
      phosphate inhibited plasma esterase activities, suggesting that 
      acetylcholinesterase and carboxylesterase largely contribute to ASA hydrolysis. 
      The feasibility of the method here developed has been explored in Ctrl and CVD 
      patients. The effect of ASA treatment on enzyme activity was further evaluated on 
      an age, sex and BMI matched subgroup of patients and Ctrl (n = 10 for each 
      subgroup, on and off ASA). No overall variations were evidenced in both CVD and 
      Ctrl groups, even when the effect of ASA treatment was tested. This result 
      suggests the absence of any influence of disease state, drug treatments, and 
      comorbidities on plasma esterase and the inability of ASA intake to induce 
      esterase function. In conclusion, the method here developed allows a better 
      characterisation of ASA esterase activity and could be helpful to define the 
      PK-related determinants of ASA responsiveness in order to personalise regimen in 
      specific pathological conditions.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Porro, Benedetta
AU  - Porro B
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Di Minno, Alessandro
AU  - Di Minno A
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy. Electronic address: 
      alessandro.diminno@ccfm.it.
FAU - Rocca, Bianca
AU  - Rocca B
AD  - Istituto di Farmacologia, Università Cattolica, Rome, Italy.
FAU - Fiorelli, Susanna
AU  - Fiorelli S
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Eligini, Sonia
AU  - Eligini S
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Turnu, Linda
AU  - Turnu L
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Barbieri, Simone
AU  - Barbieri S
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Parolari, Alessandro
AU  - Parolari A
AD  - Department of Cardiac Surgery, IRCCS Policlinico S. Donato, Milan, Italy.
FAU - Tremoli, Elena
AU  - Tremoli E
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Cavalca, Viviana
AU  - Cavalca V
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190213
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 3.1.- (Esterases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*blood/pharmacology
MH  - Chromatography, Liquid/methods
MH  - Cyclooxygenase Inhibitors/*blood/pharmacology
MH  - Enzyme Activation/drug effects/physiology
MH  - Esterases/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Esterase
OT  - Liquid chromatography-tandem mass spectrometry
EDAT- 2019/02/17 06:00
MHDA- 2019/12/19 06:00
CRDT- 2019/02/17 06:00
PHST- 2018/11/06 00:00 [received]
PHST- 2019/02/11 00:00 [accepted]
PHST- 2019/02/17 06:00 [pubmed]
PHST- 2019/12/19 06:00 [medline]
PHST- 2019/02/17 06:00 [entrez]
AID - S0006-2952(19)30052-8 [pii]
AID - 10.1016/j.bcp.2019.02.014 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2019 May;163:119-127. doi: 10.1016/j.bcp.2019.02.014. Epub 
      2019 Feb 13.

PMID- 21435744
OWN - NLM
STAT- MEDLINE
DCOM- 20111103
LR  - 20131121
IS  - 0210-5705 (Print)
IS  - 0210-5705 (Linking)
VI  - 34
IP  - 5
DP  - 2011 May
TI  - [Aspirin in the prevention of colorectal cancer].
PG  - 337-45
LID - 10.1016/j.gastrohep.2011.01.004 [doi]
AB  - Colorectal adenomas are precursors of most colorectal cancers and are 
      consequently a surrogate endpoint for assessing the efficacy of chemopreventive 
      agents. Cyclooxygenase-2 (COX-2) levels have been found to be increased in a 
      significant number of colorectal carcinomas and adenomas. COX-2 overexpression is 
      linked to carcinogenesis due to increased production of prostaglandins, which 
      seem to play an important role in angiogenesis, cell proliferation and migration, 
      as well as in apoptosis. These data support the use of acetylsalicylic acid (AAS) 
      or aspirin, a COX-2 inhibitor, as an effective agent in colorectal cancer 
      prevention. Several cohort and case control studies have shown that regular use 
      of aspirin reduces the risk of colorectal cancer by approximately 50%. However, 
      randomized controlled trials of aspirin report discrepant results, although there 
      is an decrease in the relative risk of adenoma recurrence of approximately 17%. 
      To date, although there is compelling evidence that the use of aspirin protects 
      against adenoma and colorectal cancer, the optimal dose and duration of aspirin 
      required to obtain this effect remain to be defined. Probably, the longer the 
      treatment duration--even for more than 10 years--and possibly with higher doses, 
      the greater the protective effects of aspirin. Finally, these benefits need to be 
      considered in the context of all of the health effects of prolonged aspirin use, 
      both positive and negative.
CI  - Copyright © 2011 Elsevier España, S.L. All rights reserved.
FAU - Zubiaurre, Leire
AU  - Zubiaurre L
AD  - Servicio de Aparato Digestivo, Hospital de Mendaro, Mendaro, Guipúzcoa, España.
FAU - Bujanda Fernández de Pierola, Luis
AU  - Bujanda Fernández de Pierola L
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Aspirina en la prevención del cáncer colorrectal.
DEP - 20110323
PL  - Spain
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/*prevention & control
MH  - Aspirin/*therapeutic use
MH  - Colorectal Neoplasms/*prevention & control
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Humans
EDAT- 2011/03/26 06:00
MHDA- 2011/11/04 06:00
CRDT- 2011/03/26 06:00
PHST- 2011/01/04 00:00 [received]
PHST- 2011/01/15 00:00 [accepted]
PHST- 2011/03/26 06:00 [entrez]
PHST- 2011/03/26 06:00 [pubmed]
PHST- 2011/11/04 06:00 [medline]
AID - S0210-5705(11)00047-1 [pii]
AID - 10.1016/j.gastrohep.2011.01.004 [doi]
PST - ppublish
SO  - Gastroenterol Hepatol. 2011 May;34(5):337-45. doi: 
      10.1016/j.gastrohep.2011.01.004. Epub 2011 Mar 23.

PMID- 21725581
OWN - NLM
STAT- MEDLINE
DCOM- 20120110
LR  - 20131121
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 106
IP  - 3
DP  - 2011 Sep
TI  - Platelet reactivity is a stable and global phenomenon in aspirin-treated 
      cardiovascular patients.
PG  - 466-74
LID - 10.1160/TH11-04-0226 [doi]
AB  - In healthy subjects, platelet hyperreactivity is a global phenomenon--as opposed 
      to agonist-specific--and epinephrine-induced platelet aggregation (EPA) is a 
      reliable marker of this phenotype. Few data are available on platelet reactivity 
      and the relationship between EPA and aggregation induced by other agonists in 
      cardiovascular patients. It was the objective of this study to characterise 
      platelet reactivity in stable cardiovascular patients treated with aspirin and to 
      derive a composite index integrating several aggregation pathways, suitable for 
      selecting patients with extreme phenotypes for further proteomics analysis. 
      Platelet reactivity to agonists was assessed in 110 patients twice, two weeks 
      apart. Factorial analysis was used to determine whether the results obtained with 
      the different agonists could be summarised in a single composite index. EPA 
      correlated with the aggregation values obtained with each of the other agonists, 
      with correlation coefficients of 0.44 to 0.55 (p < 0.001). We constructed a 
      composite "platelet reactivity" index that included 60% of the information 
      provided by each agonist. The results obtained at the first patient visit were 
      consistent with those obtained at the second visit (r = 0.78, p<0.01). No 
      clinical or biological parameters correlated with the composite index. The 
      extreme phenotypes of six selected subjects were confirmed 12 months after the 
      second visit. In conclusion, platelet reactivity in aspirin-treated 
      cardiovascular patients is a global phenomenon that can be summarised by a 
      composite index based on the aggregation responses to various agonists and 
      integrating several activation pathways. This index is not dependent on clinical 
      or biological variables, suggesting that genetic factors regulate platelet 
      reactivity in these patients.
FAU - Zufferey, Anne
AU  - Zufferey A
AD  - Division of Angiology and Haemostasis, Geneva University Hospital and Faculty of 
      Medicine, Switzerland.
FAU - Reny, Jean-Luc
AU  - Reny JL
FAU - Combescure, Christophe
AU  - Combescure C
FAU - de Moerloose, Philippe
AU  - de Moerloose P
FAU - Sanchez, Jean-Charles
AU  - Sanchez JC
FAU - Fontana, Pierre
AU  - Fontana P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110704
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*drug therapy/pathology/physiopathology
MH  - Epinephrine/*metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Platelet Activation/drug effects
MH  - Platelet Function Tests
MH  - Practice Guidelines as Topic
MH  - Proteomics
MH  - Severity of Illness Index
EDAT- 2011/07/05 06:00
MHDA- 2012/01/11 06:00
CRDT- 2011/07/05 06:00
PHST- 2011/04/11 00:00 [received]
PHST- 2011/06/13 00:00 [accepted]
PHST- 2011/07/05 06:00 [entrez]
PHST- 2011/07/05 06:00 [pubmed]
PHST- 2012/01/11 06:00 [medline]
AID - 11-04-0226 [pii]
AID - 10.1160/TH11-04-0226 [doi]
PST - ppublish
SO  - Thromb Haemost. 2011 Sep;106(3):466-74. doi: 10.1160/TH11-04-0226. Epub 2011 Jul 
      4.

PMID- 31811419
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20200603
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 33
IP  - 6
DP  - 2019 Dec
TI  - Omitting aspirin in PCI patients: Myth or reality?
PG  - 711-724
LID - 10.1007/s10557-019-06916-7 [doi]
AB  - In the current era of percutaneous coronary intervention (PCI), with the use of 
      contemporary drug-eluting stents, refined techniques, and adjunctive 
      pharmacotherapy, the role of aspirin peri-PCI remains undisputable. Beyond the 
      initial period, dual antiplatelet therapy (DAPT) consisting of aspirin and a 
      P2Y(12) receptor inhibitor for 6 months in stable coronary artery disease and 12 
      months in acute coronary syndromes is the standard of care. However, concerns 
      regarding bleeding adverse events caused by aspirin have led to shortened DAPT 
      duration or even omission of aspirin. Aspirin free-strategies have been 
      increasingly encountered in several studies and showed a significant reduction in 
      bleeding events, without any sign of increased ischemic risk. Individualization 
      of DAPT duration particularly in high bleeding risk patients appears therefore 
      mandatory, making aspirin not necessary in several cases. Moreover, recent 
      randomized trials have shed light on how to treat PCI patients in the presence of 
      concomitant anticoagulant treatment with P2Y(12) monotherapy and excluding 
      aspirin. These aspirin-free strategies have been proved safer than the "older" 
      standard triple antithrombotic treatment, without compromising safety. Ongoing 
      studies may further dispel the myths and establish real facts regarding 
      post-PCI-tailored treatment with or without aspirin.
FAU - Alexopoulos, Dimitrios
AU  - Alexopoulos D
AD  - 2nd Department of Cardiology, Attikon University Hospital, National and 
      Kapodistrian University of Athens Medical School, Rimini 1, Chaidari, 12462, 
      Athens, Greece. dalex@med.uoa.gr.
FAU - Mpahara, Aikaterini
AU  - Mpahara A
AD  - 2nd Department of Cardiology, Attikon University Hospital, National and 
      Kapodistrian University of Athens Medical School, Rimini 1, Chaidari, 12462, 
      Athens, Greece.
FAU - Kassimis, George
AU  - Kassimis G
AD  - 2nd Department of Cardiology, Hippokration Hospital, Medical School, Aristotle 
      University of Thessaloniki, Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Decision-Making
MH  - Coronary Artery Disease/*therapy
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/adverse effects/*therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Anticoagulation
OT  - Aspirin
OT  - Dual antiplatelet therapy
OT  - Percutaneous coronary intervention
EDAT- 2019/12/08 06:00
MHDA- 2020/06/04 06:00
CRDT- 2019/12/08 06:00
PHST- 2019/12/08 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
PHST- 2019/12/08 06:00 [entrez]
AID - 10.1007/s10557-019-06916-7 [pii]
AID - 10.1007/s10557-019-06916-7 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2019 Dec;33(6):711-724. doi: 10.1007/s10557-019-06916-7.

PMID- 10638278
OWN - NLM
STAT- MEDLINE
DCOM- 20000229
LR  - 20131121
IS  - 0040-5930 (Print)
IS  - 0040-5930 (Linking)
VI  - 56
IP  - 12
DP  - 1999 Dec
TI  - [Aspirin].
PG  - 713-7
AB  - Acetylsalicylic acid (aspirin) was the first synthetized drug 100 years ago. 
      Whereas other drugs have disappeared a long time ago, aspirin has stood the test 
      of time and is one of the most important drugs at the turn of this century. 
      Initially it was used for its analgesic, antipyretic and antiphlogistic 
      properties. They are due to the acetylation of the cyclooxygenase and hence an 
      inhibition of prostaglandin synthesis. At higher doses aspirin inhibits 
      interleukin expression induced by nuclear factor-kappa B. Aspirin is the 
      prototype of nonsteroidal antiinflammatory drugs, which are currently challenged 
      by the development of specific inhibitors of cyclooxygenase isoform 2 (COX-2), 
      which must, however, first prove their efficacy and safety in clinical trials. 
      The inhibition of platelet aggregation by aspirin has only been recognized in the 
      second half of the century. It is due to an inhibition of thromboxane A2 
      synthesis because of an irreversible cyclooxygenase blockade in platelets. 
      Aspirin has been found to reduce the incidence and death rate of cardiovascular 
      and cerebrovascular events and is nowadays the cornerstone of any secondary 
      prevention in vascular diseases. Newer antiaggregatory agents such as 
      ticlopidine, clopidogrel or IIb/IIIa-blockers have been developed. Most often 
      they are used in conjunction with aspirin and their place has yet to be defined. 
      New modes of action of aspirin continue to be found. Recent examples are an 
      improvement of endothelial dysfunction or a reduced incidence of colorectal 
      cancers. It is therefore likely that aspirin will continue to be a very useful 
      and cheap drug for a very large population and will meet the interest of 
      researchers for many more decades.
FAU - Reinhart, W H
AU  - Reinhart WH
AD  - Medizinische Klinik, Kantonsspital Chur.
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspirin.
PL  - Switzerland
TA  - Ther Umsch
JT  - Therapeutische Umschau. Revue therapeutique
JID - 0407224
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/adverse effects/therapeutic use
MH  - Analgesics, Non-Narcotic/adverse effects/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
RF  - 30
EDAT- 2000/01/19 09:00
MHDA- 2000/03/04 09:00
CRDT- 2000/01/19 09:00
PHST- 2000/01/19 09:00 [pubmed]
PHST- 2000/03/04 09:00 [medline]
PHST- 2000/01/19 09:00 [entrez]
AID - 10.1024/0040-5930.56.12.713 [doi]
PST - ppublish
SO  - Ther Umsch. 1999 Dec;56(12):713-7. doi: 10.1024/0040-5930.56.12.713.

PMID- 15991122
OWN - NLM
STAT- MEDLINE
DCOM- 20051101
LR  - 20190911
IS  - 0883-5403 (Print)
IS  - 0883-5403 (Linking)
VI  - 20
IP  - 4 Suppl 2
DP  - 2005 Jun
TI  - Deep venous thrombosis prophylaxis: better living through chemistry--in 
      opposition.
PG  - 15-7
AB  - The best prophylactic regimens for thromboembolic disease continue to be debated 
      despite years of investigation. The surgeon must balance the clinical risks and 
      benefits. A decision depends on accurate data and our ability to balance the 
      risks of fatal pulmonary embolism (PE) to the risk of bleeding. The current risk 
      for fatal PE is 0.1% with most current prophylactic regimes. The risk of 
      perioperative bleeding increases 1.8% to 5.2% with low molecular weight heparins 
      or warfarin and generally is dose dependent. Most of the current prophylactic 
      recommendations are based on the presence or absence of deep venous thrombosis 
      (DVT). However, the correlation between the presence of a DVT and the risk of PE 
      is low and inconsistent. Therefore, DVT may not be an accurate surrogate marker 
      for the patient at risk after total joint surgery. Our experience with 2800 
      consecutive total knee arthroplasty patients, using aspirin as our principle 
      agent, shows a fatal PE risk of 0.1% and a low risk of bleeding. Therefore, our 
      current recommendation is aspirin.
FAU - Lotke, Paul A
AU  - Lotke PA
AD  - Department of Orthopedic Surgery, University of Pennsylvania, 3400 Spruce Street, 
      Philadelphia, PA 19104, USA.
FAU - Lonner, Jess H
AU  - Lonner JH
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - J Arthroplasty. 2005 Jun;20(4 Suppl 2):12-4. PMID: 15991121
MH  - Anticoagulants/therapeutic use
MH  - *Arthroplasty, Replacement
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Postoperative Complications/*prevention & control
MH  - Pulmonary Embolism/prevention & control
MH  - Venous Thrombosis/*prevention & control
EDAT- 2005/07/02 09:00
MHDA- 2005/11/03 09:00
CRDT- 2005/07/02 09:00
PHST- 2005/07/02 09:00 [pubmed]
PHST- 2005/11/03 09:00 [medline]
PHST- 2005/07/02 09:00 [entrez]
AID - S088354030500152X [pii]
AID - 10.1016/j.arth.2005.03.002 [doi]
PST - ppublish
SO  - J Arthroplasty. 2005 Jun;20(4 Suppl 2):15-7. doi: 10.1016/j.arth.2005.03.002.

PMID- 3677213
OWN - NLM
STAT- MEDLINE
DCOM- 19880121
LR  - 20191022
IS  - 0742-0528 (Print)
IS  - 0742-0528 (Linking)
VI  - 4
IP  - 1
DP  - 1987
TI  - Day and night aspirin-induced gastric mucosal damage and protection by ranitidine 
      in man.
PG  - 111-6
AB  - The severity of gastric mucosal injury produced by aspirin (ASA) was 
      endoscopically assessed during morning and evening studies in 10 healthy, male 
      volunteers. In a randomized, double-blind design, subjects received either ASA 
      (1300 mg) alone or ASA (1300 mg) plus Ranitidine (150 mg) or placebo tablets 
      during morning and evening studies. Each subject had 3 morning and 3 evening 
      studies. The severity of damage produced by ASA was assessed by counting the 
      number of punctate mucosal hemorrhages observed in the gastric antrum and 
      low-body. This study demonstrated (1) wide intersubject variability in the 
      severity of damage produced by ASA (range of 47-1030 lesions/subject in morning 
      studies), (2) significant protection against ASA-induced damage by Ranitidine and 
      (3) significantly greater damage produced by ASA in the morning compared to the 
      evening studies. Because evening acid secretory rates are higher and because 
      ASA-induced damage is believed to be acid-dependent, this last observation was 
      unexpected. It suggests mucosal resistance is higher in the evening and raises 
      the possibility that there may be circadian variation in gastric mucosal 
      resistance.
FAU - Moore, J G
AU  - Moore JG
AD  - Section of Gastroenterology, Salt Lake City VAMC, Utah 84148.
FAU - Goo, R H
AU  - Goo RH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Chronobiol Int
JT  - Chronobiology international
JID - 8501362
RN  - 884KT10YB7 (Ranitidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - *Circadian Rhythm
MH  - Gastric Acid/metabolism
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Male
MH  - Ranitidine/pharmacology
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1080/07420528709078514 [doi]
PST - ppublish
SO  - Chronobiol Int. 1987;4(1):111-6. doi: 10.1080/07420528709078514.

PMID- 29978783
OWN - NLM
STAT- MEDLINE
DCOM- 20190215
LR  - 20190215
IS  - 1000-503X (Print)
IS  - 1000-503X (Linking)
VI  - 40
IP  - 3
DP  - 2018 Jun 28
TI  - [Dynamical Analysis of the Inhibitory Effect of Aspirin and Clopidogrel on 
      Platelet Adhesion and Aggregation for Healthy People under Physiological Flow 
      Condition by Microfluidic Chip Technology].
PG  - 299-307
LID - 10.3881/j.issn.1000-503X.2018.03.001 [doi]
AB  - Objective To explore the inhibitory effect of aspirin and clopidogrel on platelet 
      adhesion and aggregation behaviors under the physiological flow condition using 
      microfluidic chip technology for health volunteers. Methods Peripheral venous 
      blood samples collected from twelve randomly recruited health volunteers were 
      treated with 20 μmol/L acetylsalicylic acid,50 μmol/L 
      2-methlthioadenosine-5'-monophosphate triethylammonium salt,and their 
      combination,respectively,with untreated blood samples being control group. The 
      blood samples were flowed through a microchannel modified with type I collagen 
      protein at a physiological relevant shear rate of 1000 s(-1) for 300 s,while the 
      fluorescent images of platelet aggregations were dynamic captured using a 
      microscope. Based on the images,the platelet coverage rates were calculated and 
      used as quantitative parameters for evaluating platelet adhesion and aggregation 
      behaviors. Results Under a flow condition of 1000 s(-1) shear rate,an expected in 
      vivo-like platelet adhesion and aggregation behaviors were observed at the 
      surfaces of collagen proteins for control blood samples. Aspirin alone or 
      clopidogrel alone suppressed platelet adhesion and aggregation at the later 
      period of flow(200-300 s),while the combination of aspirin and clopidogrel 
      reduced the adhesion numbers of platelets at the earlier stage of flow(≤150 s) 
      and compromised the stability of platelet aggregation at the later period of 
      flow(200-300 s). The combination showed synergistic effect in inhibiting platelet 
      aggregation. Furthermore,such inhibitory effect was heterogeneous among 12 
      volunteers. Conclusion This simple microfluidic technology can offer a new 
      technical platform for analyzing the inhibitory effect of antiplatelet drugs.
FAU - Chen, Jing
AU  - Chen J
AD  - Central Laboratory,Yongchuan Hospital,Chongqing Medical University,Chongqing 
      402160,China.
FAU - Ding, Ling
AU  - Ding L
AD  - Yongchuan Sub-center,Chongqing Blood Center,Chongqing 402160,China.
FAU - He, Cui
AU  - He C
AD  - Central Laboratory,Yongchuan Hospital,Chongqing Medical University,Chongqing 
      402160,China.
FAU - Chen, Dan
AU  - Chen D
AD  - Central Laboratory,Yongchuan Hospital,Chongqing Medical University,Chongqing 
      402160,China.
FAU - Deng, Su-Rong
AU  - Deng SR
AD  - Central Laboratory,Yongchuan Hospital,Chongqing Medical University,Chongqing 
      402160,China.
FAU - Gong, Fang
AU  - Gong F
AD  - Central Laboratory,Yongchuan Hospital,Chongqing Medical University,Chongqing 
      402160,China.
FAU - Li, Yuan
AU  - Li Y
AD  - Central Laboratory,Yongchuan Hospital,Chongqing Medical University,Chongqing 
      402160,China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao
JT  - Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
JID - 8006230
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Clopidogrel/*pharmacology
MH  - Humans
MH  - Microfluidics
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 2018/07/07 06:00
MHDA- 2019/02/16 06:00
CRDT- 2018/07/07 06:00
PHST- 2018/07/07 06:00 [entrez]
PHST- 2018/07/07 06:00 [pubmed]
PHST- 2019/02/16 06:00 [medline]
AID - 10.3881/j.issn.1000-503X.2018.03.001 [doi]
PST - ppublish
SO  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018 Jun 28;40(3):299-307. doi: 
      10.3881/j.issn.1000-503X.2018.03.001.

PMID- 941790
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20200108
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 6
IP  - 1-3
DP  - 1976 Feb
TI  - A novel relationship between plasma kininogen and rheumatoid.
PG  - 148-53
AB  - Plasma kininogen levels in the peripheral venous blood of untreated patients with 
      active rheumatoid disease was found to be more than twice the levels measured in 
      healthy normal individuals or in convalescing uncomplicated fracture patients. 
      Treatment with oral indomethacin or aspirin lowered the kininogen levels nearly 
      to normal. Sequential studies showed that the fall in kininogen was very rapid, 
      occurring within 1-2 hours of ingestion of drug, and was parallelled by reduction 
      in the clinical indices of inflammation. Control studies showed that the 
      kininogen changes were not due to changes in plasma volume or non-specific 
      changes in plasma protein concentration. Indomethacin treatment had no effect on 
      plasma kininogen levels in healthy volunteers. The significance of this finding 
      will be discussed.
FAU - Sharma, J N
AU  - Sharma JN
FAU - Zeitlin, I J
AU  - Zeitlin IJ
FAU - Brooks, P M
AU  - Brooks PM
FAU - Dick, W C
AU  - Dick WC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Blood Proteins)
RN  - 0 (Kininogens)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*blood
MH  - Aspirin/administration & dosage/pharmacology
MH  - Blood Proteins/analysis
MH  - Female
MH  - Humans
MH  - Indomethacin/administration & dosage/pharmacology
MH  - Kininogens/*blood
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Time Factors
EDAT- 1976/02/01 00:00
MHDA- 1976/02/01 00:01
CRDT- 1976/02/01 00:00
PHST- 1976/02/01 00:00 [pubmed]
PHST- 1976/02/01 00:01 [medline]
PHST- 1976/02/01 00:00 [entrez]
AID - 10.1007/BF01972199 [doi]
PST - ppublish
SO  - Agents Actions. 1976 Feb;6(1-3):148-53. doi: 10.1007/BF01972199.

PMID- 37614711
OWN - NLM
STAT- MEDLINE
DCOM- 20230825
LR  - 20230831
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Prediction and prevention of preeclampsia in women with preexisting diabetes: the 
      role of home blood pressure, physical activity, and aspirin.
PG  - 1166884
LID - 10.3389/fendo.2023.1166884 [doi]
LID - 1166884
AB  - Women with type 1 or type 2 (preexisting) diabetes are four times more likely to 
      develop preeclampsia compared with women without diabetes. Preeclampsia affects 
      9%-20% of pregnant women with type 1 diabetes and 7%-14% of pregnant women with 
      type 2 diabetes. The aim of this narrative review is to investigate the role of 
      blood pressure (BP) monitoring, physical activity, and prophylactic aspirin to 
      reduce the prevalence of preeclampsia and to improve pregnancy outcome in women 
      with preexisting diabetes. Home BP and office BP in early pregnancy are 
      positively associated with development of preeclampsia, and home BP and office BP 
      are comparable for the prediction of preeclampsia in women with preexisting 
      diabetes. However, home BP is lower than office BP, and the difference is greater 
      with increasing office BP. Daily physical activity is recommended during 
      pregnancy, and limiting sedentary behavior may be beneficial to prevent 
      preeclampsia. White coat hypertension in early pregnancy is not a clinically 
      benign condition but is associated with an elevated risk of developing 
      preeclampsia. This renders the current strategy of leaving white coat 
      hypertension untreated debatable. A beneficial preventive effect of initiating 
      low-dose aspirin (150 mg/day) for all in early pregnancy has not been 
      demonstrated in women with preexisting diabetes.
CI  - Copyright © 2023 Do, Vestgaard, Nørgaard, Damm, Mathiesen and Ringholm.
FAU - Do, Nicoline Callesen
AU  - Do NC
AD  - Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark.
AD  - Department of Endocrinology and Metabolism, Rigshospitalet, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
FAU - Vestgaard, Marianne
AU  - Vestgaard M
AD  - Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark.
AD  - Department of Endocrinology and Metabolism, Rigshospitalet, Copenhagen, Denmark.
FAU - Nørgaard, Sidse Kjærhus
AU  - Nørgaard SK
AD  - Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark.
AD  - Department of Endocrinology and Metabolism, Rigshospitalet, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
FAU - Damm, Peter
AU  - Damm P
AD  - Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
AD  - Department of Obstetrics, Rigshospitalet, Copenhagen, Denmark.
FAU - Mathiesen, Elisabeth R
AU  - Mathiesen ER
AD  - Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark.
AD  - Department of Endocrinology and Metabolism, Rigshospitalet, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
FAU - Ringholm, Lene
AU  - Ringholm L
AD  - Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark.
AD  - Department of Endocrinology and Metabolism, Rigshospitalet, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230808
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - *Pre-Eclampsia/epidemiology/prevention & control
MH  - Blood Pressure
MH  - Aspirin/therapeutic use
MH  - *Diabetes Mellitus, Type 2
MH  - *White Coat Hypertension
MH  - Exercise
PMC - PMC10443220
OTO - NOTNLM
OT  - aspirin
OT  - home blood pressure
OT  - hypertension
OT  - physical activity
OT  - preeclampsia
OT  - preexisting diabetes
OT  - pregnancy
OT  - sedentary behavior
COIS- SN, LR, and PD participated in clinical studies on the use of insulin in pregnant 
      women with preexisting diabetes in collaboration with Novo Nordisk. EM 
      participated in the clinical studies and has served as a consultant for Novo 
      Nordisk on studies focusing on insulin treatment in pregnant women. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2023/08/24 06:42
MHDA- 2023/08/25 06:42
CRDT- 2023/08/24 04:07
PHST- 2023/02/15 00:00 [received]
PHST- 2023/06/13 00:00 [accepted]
PHST- 2023/08/25 06:42 [medline]
PHST- 2023/08/24 06:42 [pubmed]
PHST- 2023/08/24 04:07 [entrez]
AID - 10.3389/fendo.2023.1166884 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Aug 8;14:1166884. doi: 
      10.3389/fendo.2023.1166884. eCollection 2023.

PMID- 758147
OWN - NLM
STAT- MEDLINE
DCOM- 19790126
LR  - 20131121
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 76
IP  - 1
DP  - 1979 Jan
TI  - Effect of aspirin and acid on human jejunal mucosa. An ultrastructural study.
PG  - 50-6
AB  - To determine the effects of aspirin and hydrochloric acid on human jejunal 
      mucosa, three obese patients with a small intestinal bypass that opened on the 
      abdominal wall as a mucous fistula were studied. An 80-mM solution of HCl, a 
      40-mM suspension of aspirin (equivalent to two tablets in a glass of water), and 
      a combination suspension of 40 mM aspirin plus 40 mM HCl damaged a mean +/- SE of 
      26 +/- 13% (P less than 0.05), 24 +/- 5% (P less than 0.05), and 29 +/- 5% (P 
      less than 0.05) of jejunal villi, respectively, 5 min after administration. By 60 
      min after instillation, considerable recovery had occurred. Scanning electron 
      microscopy revealed focal villous tip erosion and erythrocyte extrusion after all 
      test solutions. In conclusion, aspirin, 40 mM, physiologic concentration of 
      hydrochloric acid, and the combination of acid plus aspirin are each capable of 
      damaging human small intestinal mucosa on direct contact.
FAU - Ivey, K J
AU  - Ivey KJ
FAU - Baskin, W N
AU  - Baskin WN
FAU - Krause, W J
AU  - Krause WJ
FAU - Terry, B
AU  - Terry B
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Suspensions)
RN  - QTT17582CB (Hydrochloric Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*toxicity
MH  - Humans
MH  - Hydrochloric Acid/administration & dosage/*toxicity
MH  - Intestinal Diseases/*chemically induced/pathology
MH  - Intestinal Mucosa/*drug effects/pathology/ultrastructure
MH  - Intestine, Small/*drug effects/pathology/ultrastructure
MH  - Suspensions
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - S0016508579000184 [pii]
PST - ppublish
SO  - Gastroenterology. 1979 Jan;76(1):50-6.

PMID- 26589727
OWN - NLM
STAT- MEDLINE
DCOM- 20170413
LR  - 20170413
IS  - 2048-8734 (Electronic)
IS  - 2048-8726 (Linking)
VI  - 5
IP  - 7
DP  - 2016 Nov
TI  - Early aspirin desensitization in unstable patients with acute coronary syndrome: 
      Short and long-term efficacy and safety.
PG  - 41-50
LID - 10.1177/2048872615618509 [doi]
AB  - BACKGROUND: Aspirin hypersensitivity is not a rare condition among patients with 
      acute coronary syndrome. However, despite the publication of several successful 
      desensitization protocols, the procedure is not as widespread as expected. We 
      present a cohort of patients with acute coronary syndrome undergoing aspirin 
      desensitization to evaluate its short- and long-term efficacy and safety and to 
      reinforce data from previous studies. METHODS: Of 1306 patients admitted to our 
      Coronary Care Unit between February 2011 and February 2013, 24 (1.8%) had a 
      history of aspirin hypersensitivity. All 24 patients underwent an eight-dose 
      aspirin desensitization protocol (0.1, 0.3, 1, 3, 10, 25, 50 and 100 mg of 
      aspirin given by mouth every 15 minutes) after premedication with antihistamines 
      and corticosteroids or antileucotrienes. Previously prescribed β blockers and 
      angiotensin-converting enzyme inhibitors were not discontinued. All patients were 
      desensitized within 72 hours of admission. Those requiring urgent catheterization 
      (five patients with ST segment elevation myocardial infarction) were desensitized 
      within 12 hours of catheterization and the remainder before catheterization. 
      RESULTS: All patients were successfully desensitized and only one presented with 
      an urticarial reaction. The five patients with ST segment elevation myocardial 
      infarction were treated with abciximab until desensitization was complete. All 
      but one patient underwent catheterization and 20 underwent percutaneous coronary 
      intervention, most (66%) with the implantation of a bare metal stent. At 
      follow-up (a minimum of 6-24 months), only two patients had discontinued aspirin, 
      both due to gastrointestinal bleeding, and no hypersensitivy reaction had 
      occurred. CONCLUSIONS: Aspirin desensitization is effective and safe in unstable 
      patients with acute coronary syndrome in both the short and long term.
FAU - Córdoba-Soriano, Juan Gabriel
AU  - Córdoba-Soriano JG
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Corbí-Pascual, Miguel
AU  - Corbí-Pascual M
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - López-Neyra, Isabel
AU  - López-Neyra I
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Navarro-Cuartero, Javier
AU  - Navarro-Cuartero J
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Hidalgo-Olivares, Víctor
AU  - Hidalgo-Olivares V
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Barrionuevo-Sánchez, Maria Isabel
AU  - Barrionuevo-Sánchez MI
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Prieto-Mateos, Daniel
AU  - Prieto-Mateos D
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Gutiérrez-Díez, Antonio
AU  - Gutiérrez-Díez A
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Gallardo-López, Arsenio
AU  - Gallardo-López A
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Fuentes-Manso, Raquel
AU  - Fuentes-Manso R
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Gómez-Pérez, Alberto
AU  - Gómez-Pérez A
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Lafuente-Gormaz, Carlos
AU  - Lafuente-Gormaz C
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
FAU - Jiménez-Mazuecos, Jesús
AU  - Jiménez-Mazuecos J
AD  - Cardiology Department, Hospital General Universitario de Albacete, Albacete, 
      Spain.
LA  - eng
PT  - Journal Article
DEP - 20160922
PL  - England
TA  - Eur Heart J Acute Cardiovasc Care
JT  - European heart journal. Acute cardiovascular care
JID - 101591369
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/surgery
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Cardiac Catheterization
MH  - Desensitization, Immunologic/adverse effects/*methods
MH  - Drug Hypersensitivity/etiology/immunology/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin allergy
OT  - acute coronary syndrome
OT  - aspirin desensitization
OT  - coronary stenting
OT  - ischaemic heart disease
EDAT- 2015/11/22 06:00
MHDA- 2017/04/14 06:00
CRDT- 2015/11/22 06:00
PHST- 2015/11/22 06:00 [pubmed]
PHST- 2017/04/14 06:00 [medline]
PHST- 2015/11/22 06:00 [entrez]
AID - 2048872615618509 [pii]
AID - 10.1177/2048872615618509 [doi]
PST - ppublish
SO  - Eur Heart J Acute Cardiovasc Care. 2016 Nov;5(7):41-50. doi: 
      10.1177/2048872615618509. Epub 2016 Sep 22.

PMID- 16611202
OWN - NLM
STAT- MEDLINE
DCOM- 20061129
LR  - 20211027
IS  - 1742-7835 (Print)
IS  - 1742-7835 (Linking)
VI  - 98
IP  - 3
DP  - 2006 Mar
TI  - Is there an interaction between the cardiovascular protective effects of low-dose 
      aspirin and ibuprofen?
PG  - 275-80
AB  - Laboratory studies and studies in normal volunteers have suggested a possible 
      adverse interaction between aspirin and ibuprofen. It is thought that ibuprofen 
      prevents aspirin from gaining access to platelet cyclooxygenase. Following the 
      publication of these studies, a number of observational and other studies have 
      been published. We review these studies identified by structured searching of 
      Medline and Pubmed databases. We conclude that on the balance of probabilities 
      that ibuprofen is more likely to interact with aspirin than not. This interaction 
      is more likely in those who take ibuprofen chronically and is more important in 
      those at high cardiovascular risk. Thus, a reasonable strategy might be to advise 
      aspirin takers to avoid chronic ibuprofen.
FAU - MacDonald, Thomas M
AU  - MacDonald TM
AD  - Medicines Monitoring Unit (MEMO), Division of Medicine and Therapeutics, 
      Ninewells Hospital & Medical School, Dundee, Scotland, UK. 
      t.m.macdonald@dundee.ac.uk
FAU - Wei, Li
AU  - Wei L
LA  - eng
GR  - G106/1249/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Review
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Drug Interactions
MH  - Humans
MH  - Ibuprofen/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Secondary Prevention
RF  - 56
EDAT- 2006/04/14 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/04/14 09:00
PHST- 2006/04/14 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/04/14 09:00 [entrez]
AID - PTOpto_371 [pii]
AID - 10.1111/j.1742-7843.2006.pto_371.x [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):275-80. doi: 
      10.1111/j.1742-7843.2006.pto_371.x.

PMID- 29055792
OWN - NLM
STAT- MEDLINE
DCOM- 20180710
LR  - 20181126
IS  - 1872-7603 (Electronic)
IS  - 0165-0378 (Linking)
VI  - 124
DP  - 2017 Nov
TI  - The effect of acetyl salicylic acid (Aspirin) on trophoblast-endothelial 
      interaction in vitro.
PG  - 54-61
LID - S0165-0378(17)30160-2 [pii]
LID - 10.1016/j.jri.2017.10.044 [doi]
AB  - Early administration of low dose acetyl salicylic acid (Aspirin) in high risk 
      women reduces the risk of early onset preeclampsia. This study aims to 
      investigate the effect of aspirin on trophoblast integration and the its effect 
      on angiogenic and invasive pathways in an in-vitro model of preeclampsia. Red 
      fluorescent-labeled human uterine myometrial microvascular endothelial cells 
      (UtMVECs) were seeded on matrigel to form endothelial networks. Green 
      fluorescent-labeled trophoblastic HTR-8/SVneo cells were co-cultured with the 
      endothelial networks with/without TNF-a (0.5ng/mL) and/or aspirin (0.1mM) for 
      24h. Fluorescent images were captured and quantified by Image J to examine the 
      effects of TNF-a and aspirin on the trophoblast-endothelial integration. 
      Conditioned media were collected to measure free VEGF, PlGF and sFlt-1 by ELISA 
      and PGF1a by Enzyme immunoassay (EIA). Cells were retrieved to examine mRNA 
      expression of angiogenic factors (VEGF, PlGF and sFlt-1), invasion markers (MMP-2 
      and TIMP-1), endothelial cell activation markers (E-selectin and VCAM), eNOS and 
      cyclooxygenase (COX)-2 by quantitative PCR. Aspirin reversed the inhibitory 
      effect of TNF-a on trophoblast cell integration into endothelial cellular 
      networks. TNF-a increased PGF1a production (128±11%, p<0.05), whilst aspirin 
      reversed the TNF-a effect on PGF1a production (19±4%, p<0.01). TNF-a decreased 
      the mRNA expression of PlGF, eNOS, MMP-2 and TIMP-1, and stimulated COX2, 
      E-selectin and VCAM mRNA expression. Aspirin did not reverse the TNF-a effect on 
      these molecules. Aspirin improves trophoblast cell integration into endothelial 
      cellular networks by inhibiting the effect of TNF-a via PGI(2) with no 
      significant effect on antiangiogenic, invasive or endothelial activation markers.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - Xu, Bei
AU  - Xu B
AD  - Vascular Immunology Research Laboratory, The Heart Research Institute, University 
      of Sydney, Australia. Electronic address: bei.xu@hri.org.au.
FAU - Shanmugalingam, Renuka
AU  - Shanmugalingam R
AD  - Vascular Immunology Research Laboratory, The Heart Research Institute, University 
      of Sydney, Australia; School of Medicine, Western Sydney University, Sydney, 
      Australia; Renal Unit, Liverpool Hospital, Sydney, Australia.
FAU - Chau, Katrina
AU  - Chau K
AD  - Vascular Immunology Research Laboratory, The Heart Research Institute, University 
      of Sydney, Australia.
FAU - Pears, Suzanne
AU  - Pears S
AD  - Vascular Immunology Research Laboratory, The Heart Research Institute, University 
      of Sydney, Australia; School of Medicine, Western Sydney University, Sydney, 
      Australia.
FAU - Hennessy, Annemarie
AU  - Hennessy A
AD  - Vascular Immunology Research Laboratory, The Heart Research Institute, University 
      of Sydney, Australia; School of Medicine, Western Sydney University, Sydney, 
      Australia; Renal Unit, Liverpool Hospital, Sydney, Australia.
FAU - Makris, Angela
AU  - Makris A
AD  - Vascular Immunology Research Laboratory, The Heart Research Institute, University 
      of Sydney, Australia; School of Medicine, Western Sydney University, Sydney, 
      Australia; Renal Unit, Liverpool Hospital, Sydney, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171018
PL  - Ireland
TA  - J Reprod Immunol
JT  - Journal of reproductive immunology
JID - 8001906
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandins F)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - R16CO5Y76E (Aspirin)
RN  - WJ72O6860W (prostaglandin F1)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cell Communication
MH  - Cells, Cultured
MH  - Coculture Techniques
MH  - Endothelial Cells/drug effects/*physiology
MH  - Female
MH  - Humans
MH  - Microvessels/*pathology
MH  - Myometrium/*pathology
MH  - Pre-Eclampsia/*drug therapy
MH  - Pregnancy
MH  - Prostaglandins F/metabolism
MH  - Trophoblasts/drug effects/*physiology
MH  - Tumor Necrosis Factor-alpha/immunology
OTO - NOTNLM
OT  - Aspirin
OT  - Trophoblast-endothelial interaction
EDAT- 2017/10/23 06:00
MHDA- 2018/07/11 06:00
CRDT- 2017/10/23 06:00
PHST- 2017/07/12 00:00 [received]
PHST- 2017/09/28 00:00 [revised]
PHST- 2017/10/17 00:00 [accepted]
PHST- 2017/10/23 06:00 [pubmed]
PHST- 2018/07/11 06:00 [medline]
PHST- 2017/10/23 06:00 [entrez]
AID - S0165-0378(17)30160-2 [pii]
AID - 10.1016/j.jri.2017.10.044 [doi]
PST - ppublish
SO  - J Reprod Immunol. 2017 Nov;124:54-61. doi: 10.1016/j.jri.2017.10.044. Epub 2017 
      Oct 18.

PMID- 17618144
OWN - NLM
STAT- MEDLINE
DCOM- 20070926
LR  - 20220318
IS  - 1528-395X (Electronic)
IS  - 1079-2104 (Linking)
VI  - 104
IP  - 3
DP  - 2007 Sep
TI  - Aspirin and bleeding in dentistry: an update and recommendations.
PG  - 316-23
AB  - Aspirin use in the United States remains high because of its diverse and 
      beneficial activities. In adults at risk for cardiovascular thrombotic events, 
      low-dose aspirin is an excellent preventive agent; however, its antiplatelet 
      properties have contributed to a perceived increased risk for bleeding after 
      dental extractions. This article discusses recent evidence regarding the 
      thrombotic risks associated with discontinuing aspirin use in patients who take 
      aspirin daily and presents a new recommendation for continuing low-dose aspirin 
      during invasive dental procedures.
FAU - Brennan, Michael T
AU  - Brennan MT
AD  - Oral Medicine Residency Director, Department of Oral Medicine, Carolinas Medical 
      Center, Charlotte, NC, USA.
FAU - Wynn, Richard L
AU  - Wynn RL
FAU - Miller, Craig S
AU  - Miller CS
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20070706
PL  - United States
TA  - Oral Surg Oral Med Oral Pathol Oral Radiol Endod
JT  - Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
JID - 9508562
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/drug therapy
MH  - Dental Care/*methods
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Periodontal Index
MH  - Postoperative Hemorrhage/chemically induced
MH  - *Substance Withdrawal Syndrome
MH  - Thrombosis/prevention & control
RF  - 66
EDAT- 2007/07/10 09:00
MHDA- 2007/09/27 09:00
CRDT- 2007/07/10 09:00
PHST- 2007/02/02 00:00 [received]
PHST- 2007/03/07 00:00 [revised]
PHST- 2007/03/07 00:00 [accepted]
PHST- 2007/07/10 09:00 [pubmed]
PHST- 2007/09/27 09:00 [medline]
PHST- 2007/07/10 09:00 [entrez]
AID - S1079-2104(07)00229-6 [pii]
AID - 10.1016/j.tripleo.2007.03.003 [doi]
PST - ppublish
SO  - Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Sep;104(3):316-23. doi: 
      10.1016/j.tripleo.2007.03.003. Epub 2007 Jul 6.

PMID- 8199752
OWN - NLM
STAT- MEDLINE
DCOM- 19940705
LR  - 20131121
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 32
IP  - 1
DP  - 1994 Jan
TI  - Effects of nocloprost clathrate on absorption of acetylsalicylic acid.
PG  - 51-7
AB  - The cytoprotective prostaglandin E2 analog nocloprost clathrate (NOCLO) is tested 
      as a prophylactic for gastrointestinal lesions of NSAID. The effects of 400 
      micrograms NOCLO versus respective placebos with and without equivalent amounts 
      of beta-cyclodextrin on the pharmacokinetic behavior of acetylsalicylic acid 
      (ASA), given 30 min after NOCLO, were studied in two single-blind, parallel-group 
      trials. The trials were performed in 15 male healthy volunteers (age 21-25 years, 
      body weight 62-94 kg, body height 172-187 cm) with known N-acetylation and 
      debrisoquine type hydroxylation phenotype. ASA, salicylic acid (SA), and 
      salicyluric acid (SU) in plasma and SA and SU in urine were measured by HPLC. 
      NOCLO delayed the absorption of ASA (increased tmax, lower Cmax) significantly in 
      comparison with both placebos. AUC and clearance values were not changed by NOCLO 
      premedication. There were neither differences between the two placebo groups nor 
      between the two groups pretreated with NOCLO with regard to any pharmacokinetic 
      parameter. The changes in drug absorption are caused by the sum of those 
      cytoprotective effects of prostaglandin which are also determinants of drug 
      absorption.
FAU - Siegmund, W
AU  - Siegmund W
AD  - Department of Clinical Pharmacology, Medical Faculty, 
      Ernst-Moritz-Arndt-University, Greifswald, Germany.
FAU - Zschiesche, M
AU  - Zschiesche M
FAU - Franke, G
AU  - Franke G
FAU - Amon, I
AU  - Amon I
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Cyclodextrins)
RN  - 0 (Hippurates)
RN  - 0 (Prostaglandins F, Synthetic)
RN  - 0 (Salicylates)
RN  - 0 (Vasodilator Agents)
RN  - 0 (beta-Cyclodextrins)
RN  - 487-54-7 (salicylurate)
RN  - 7POM2OXT4Q (nocloprost)
RN  - JV039JZZ3A (betadex)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/blood/*metabolism/*pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Cyclodextrins/pharmacology
MH  - Drug Interactions
MH  - Hippurates/blood
MH  - Humans
MH  - Intestinal Absorption/drug effects
MH  - Male
MH  - Prostaglandins F, Synthetic/*pharmacology
MH  - Salicylates/urine
MH  - Salicylic Acid
MH  - Single-Blind Method
MH  - Vasodilator Agents/*pharmacology
MH  - *beta-Cyclodextrins
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 1994 Jan;32(1):51-7.

PMID- 8582983
OWN - NLM
STAT- MEDLINE
DCOM- 19960319
LR  - 20190512
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 10
IP  - 7
DP  - 1995 Jul
TI  - Prevention of post-surgical adhesion formation using aspirin in a rodent model: a 
      preliminary report.
PG  - 1797-800
AB  - Pelvic adhesions are one of the major factors which significantly and adversely 
      affect surgery outcome due to intra- and postoperative morbidity and reduce 
      future female fertility. Using a rodent model, we evaluated the efficacy of 
      aspirin, a non-steroidal anti-inflammatory drug, in the prevention of adhesion 
      formation. A total of 72 female Wistar rats received a standardized primary 
      traumatic lesion to the right uterine horn. They were randomly divided into eight 
      groups: group I (control) had no treatment and group II received a single 
      pre-operative 0.70 mg aspirin. All the succeeding groups (III-VIII) received 
      aspirin in doses of 0.35, 0.70, or 1.40 mg every 6 h for either 48 or 96 h in 
      addition to the pre-operative aspirin (0.70 mg). All animals were killed 4 weeks 
      later and adhesions were assessed using a modified adhesion scoring scale. The 
      lowest adhesion score was found in the group treated with 0.35 mg of aspirin for 
      96 h, and the highest was found among the groups treated with either 0.70 or 1.40 
      mg for 48-96 h respectively (P < 0.05). These results are in line with the 
      hypothesis that administration of a low dose of aspirin selectively inhibits the 
      production of thromboxane A2, whereas basal prostacyclin biosynthesis is 
      preserved. This phenomenon might contribute to reducing postoperative adhesion 
      formation in a rat model. Thus, future studies into the prevention of adhesion 
      formation may require the additional use of a non-steroidal anti-inflammatory 
      drug, for which aspirin deserves further attention, before extrapolation into 
      human therapy.
FAU - Golan, A
AU  - Golan A
AD  - Department of Obstetrics and Gynecology, Assaf Harofeh Medical Center (affiliated 
      with the Sackler Faculty of Medicine, Tel Aviv), Israel.
FAU - Maymon, R
AU  - Maymon R
FAU - Winograd, I
AU  - Winograd I
FAU - Bukovsky, I
AU  - Bukovsky I
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Hum Reprod 2001 Apr;16(4):805
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Postoperative Complications/*prevention & control
MH  - Rats
MH  - Rats, Wistar
MH  - Tissue Adhesions/prevention & control
MH  - Uterine Diseases/*prevention & control
MH  - Uterus/*surgery
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.humrep.a136177 [doi]
PST - ppublish
SO  - Hum Reprod. 1995 Jul;10(7):1797-800. doi: 10.1093/oxfordjournals.humrep.a136177.

PMID- 6363464
OWN - NLM
STAT- MEDLINE
DCOM- 19840314
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 23
IP  - 11-12
DP  - 1983 Nov-Dec
TI  - Long-term therapy for the pain of osteoarthritis: a comparison of zomepirac 
      sodium and aspirin.
PG  - 494-504
AB  - In this long-term, double-blind, multicenter study, efficacy and safety of 
      zomepirac sodium were compared with those of aspirin for treatment of the chronic 
      pain associated with osteoarthritis in 607 patients, 405 of whom received 
      zomepirac and 202 of whom received aspirin. Final evaluations during one year of 
      treatment showed zomepirac significantly more effective than aspirin for reducing 
      pain at rest (P = 0.02) and average pain (P = 0.04). Moreover, zomepirac was 
      rated better than aspirin in physician global evaluations of overall response to 
      therapy (P = 0.02) and patient evaluations of pain relief (P = 0.03). At the end 
      of the one-year study, patients were permitted to extend double-blind treatment 
      for an additional year. In final evaluations for patients who continued, 
      zomepirac was significantly better than aspirin for relief of pain on motion (P = 
      0.05) and also in patient global evaluations of therapeutic response (P = 0.02). 
      Side effect profiles during the first year of therapy were generally comparable 
      for zomepirac and aspirin. However, complaints related to the special senses, 
      especially tinnitus and hearing disturbances, were reported more frequently 
      during aspirin therapy, and urogenital side effects were more common during 
      zomepirac therapy. For both drug groups, the overall incidence of side effects 
      was lower in the second year than in the first. This is the first published study 
      to show a nonsteroidal antiinflammatory agent to be more effective than aspirin 
      for the long-term treatment of pain associated with osteoarthritis.
FAU - Honig, S
AU  - Honig S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Analgesics)
RN  - 0 (Pyrroles)
RN  - 822G987U9J (zomepirac)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*physiopathology
MH  - Pain/*drug therapy
MH  - Pyrroles/*therapeutic use
MH  - Tolmetin/adverse effects/analogs & derivatives/*therapeutic use
EDAT- 1983/11/01 00:00
MHDA- 1983/11/01 00:01
CRDT- 1983/11/01 00:00
PHST- 1983/11/01 00:00 [pubmed]
PHST- 1983/11/01 00:01 [medline]
PHST- 1983/11/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1983.tb01796.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1983 Nov-Dec;23(11-12):494-504. doi: 
      10.1002/j.1552-4604.1983.tb01796.x.

PMID- 24393755
OWN - NLM
STAT- MEDLINE
DCOM- 20140305
LR  - 20140107
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 126
IP  - 1
DP  - 2014 Jan
TI  - Aspirin and proton pump inhibitor combination therapy for prevention of 
      cardiovascular disease and Barrett's esophagus.
PG  - 87-96
LID - 10.3810/pgm.2014.01.2728 [doi]
AB  - Aspirin, used at low doses (75-325 mg daily), prevents aggregation of platelets 
      and is prescribed for patients as pharmacologic prevention of cardiovascular 
      disease. Despite the well-documented beneficial effects of aspirin, prolonged use 
      is associated with damage to the gastrointestinal (GI) mucosa in the upper and 
      lower GI tract. Patient risk of hemorrhage and peptic ulcer formation is 
      increased with older age, previous ulcer history, Helicobacter pylori infection, 
      and concomitant use of nonsteroidal anti-inflammatory drugs, corticosteroids, or 
      antithrombotic agents. As termination of aspirin therapy can precipitate a 
      cardiovascular event, patients at risk need co-therapy with gastroprotective 
      agents, such as proton pump inhibitors (PPIs), to reduce the GI side effects of 
      aspirin treatment. Fixed-dose combinations of low-dose aspirin and 
      gastroprotective agents have been designed to increase medication compliance, 
      improve clinical outcomes, and reduce the overall cost of therapy. Prolonged use 
      of PPIs may, however, lead to serious adverse effects or, in some cases, reduce 
      the cardioprotective effects of aspirin. Hence, physicians need to carefully 
      consider the benefits and risks associated with the condition of each patient to 
      optimize clinical outcomes of combination therapy. A growing body of clinical 
      evidence indicates that aspirin may decrease the risk of colorectal and other GI 
      cancers, as well as reduce progression from Barrett's esophagus (BE) to 
      esophageal adenocarcinoma. Furthermore, PPIs have recently been shown to reduce 
      neoplastic transformation in patients with BE. Thus, the use of a fixed-dose 
      aspirin/PPI combination could potentially provide chemopreventive benefit to 
      patients with BE, and, at the same time, treat the underlying gastroesophageal 
      reflux responsible for the condition.
FAU - Peura, David A
AU  - Peura DA
AD  - University of Virginia, Charlottesville, VA. DAP8V@hscmail.mcc.virginia.edu.
FAU - Wilcox, C Mel
AU  - Wilcox CM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Barrett Esophagus/*prevention & control
MH  - Cardiovascular Diseases/*prevention & control
MH  - Colorectal Neoplasms/prevention & control
MH  - Drug Combinations
MH  - Gastrointestinal Hemorrhage/*prevention & control
MH  - Humans
MH  - Medication Adherence
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Proton Pump Inhibitors/*administration & dosage/therapeutic use
MH  - Stomach Neoplasms/prevention & control
EDAT- 2014/01/08 06:00
MHDA- 2014/03/07 06:00
CRDT- 2014/01/08 06:00
PHST- 2014/01/08 06:00 [entrez]
PHST- 2014/01/08 06:00 [pubmed]
PHST- 2014/03/07 06:00 [medline]
AID - 10.3810/pgm.2014.01.2728 [doi]
PST - ppublish
SO  - Postgrad Med. 2014 Jan;126(1):87-96. doi: 10.3810/pgm.2014.01.2728.

PMID- 17488432
OWN - NLM
STAT- MEDLINE
DCOM- 20070710
LR  - 20181201
IS  - 0886-0440 (Print)
IS  - 0886-0440 (Linking)
VI  - 22
IP  - 3
DP  - 2007 May-Jun
TI  - Does the use of preoperative aspirin increase the risk of bleeding in patients 
      undergoing coronary artery bypass grafting surgery? Systematic review and 
      meta-analysis.
PG  - 247-56
AB  - BACKGROUND: The traditional recommendation has been to stop Aspirin seven to 10 
      days prior to coronary artery bypass surgery to reduce the potential risk of 
      bleeding. A few reports have shown that Aspirin did not increase the risk of 
      bleeding and may be beneficial to be continued until the time of surgery. The 
      objective of this review was to evaluate the effect of preoperative Aspirin on 
      bleeding in patients undergoing elective bypass surgery. METHODS: A meta-analysis 
      of 10 randomized and nonrandomized studies reporting comparisons between Aspirin 
      and control was undertaken. The primary outcome was the total amount of 
      postoperative chest tube drainage. Secondary outcomes were the number of units of 
      packed red blood cell transfusion, platelet transfusion, fresh frozen plasma 
      transfusion, and number of patients reexplored for bleeding. RESULTS: Ten 
      studies, involving 1748 patients, met the inclusion criteria for this review of 
      whom 913 were in the Aspirin group and 835 were in the control group. Pooling the 
      results of all studies showed a significant increase in blood loss and 
      transfusion of red blood cells and fresh frozen plasma in the Aspirin group (p < 
      0.05). There was no significant difference between the two groups in the rate of 
      platelet transfusion, or the incidence of reexploration (p > 0.05). Included 
      studies were heterogeneous and of low methodological quality. CONCLUSION: Aspirin 
      is associated with increased chest tube drainage and may be associated with a 
      greater requirement for blood products. High-quality prospective studies are 
      warranted to reassess the effect of Aspirin on important postoperative outcomes.
FAU - Alghamdi, Abdullah A
AU  - Alghamdi AA
AD  - Division of Cardiac and Vascular Surgery, Department of Surgery, University of 
      Toronto and Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 
      abdullah.alghamdi@utoronto.ca
FAU - Moussa, Fuad
AU  - Moussa F
FAU - Fremes, Stephen E
AU  - Fremes SE
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - J Card Surg
JT  - Journal of cardiac surgery
JID - 8908809
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BJU Int. 2014 Sep;114(3):318-9. PMID: 25156500
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Transfusion
MH  - Chest Tubes
MH  - Coronary Artery Bypass/*adverse effects
MH  - Coronary Artery Disease/drug therapy
MH  - Drainage
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Postoperative Hemorrhage/*chemically induced/etiology/therapy
MH  - Preoperative Care
MH  - Risk Factors
MH  - Thoracostomy
RF  - 50
EDAT- 2007/05/10 09:00
MHDA- 2007/07/11 09:00
CRDT- 2007/05/10 09:00
PHST- 2007/05/10 09:00 [pubmed]
PHST- 2007/07/11 09:00 [medline]
PHST- 2007/05/10 09:00 [entrez]
AID - JCS402 [pii]
AID - 10.1111/j.1540-8191.2007.00402.x [doi]
PST - ppublish
SO  - J Card Surg. 2007 May-Jun;22(3):247-56. doi: 10.1111/j.1540-8191.2007.00402.x.

PMID- 9074552
OWN - NLM
STAT- MEDLINE
DCOM- 19970410
LR  - 20161025
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 101
IP  - 3
DP  - 1997 Mar
TI  - Safer anticoagulant therapy after heart valve replacement. Recommendations for 
      less intense regimens.
PG  - 85-6, 89-90, 93-4
AB  - The use of anticoagulants in patients who undergo heart valve replacement greatly 
      reduces the rate of thromboembolism but increases the risk of bleeding. A number 
      of studies have been done to determine the efficacy of anticoagulation regimens 
      that are less intense than those considered standard. Dr Turpie reviews these and 
      lists the current recommendations of the American College of Chest Physicians.
FAU - Turpie, A G
AU  - Turpie AG
AD  - McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada. 
      turpiea@FHS.McMaster.CA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Drug Therapy, Combination
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Warfarin/therapeutic use
RF  - 20
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
AID - 10.3810/pgm.1997.03.182 [doi]
PST - ppublish
SO  - Postgrad Med. 1997 Mar;101(3):85-6, 89-90, 93-4. doi: 10.3810/pgm.1997.03.182.

PMID- 373167
OWN - NLM
STAT- MEDLINE
DCOM- 19790629
LR  - 20131121
IS  - 0302-4725 (Print)
IS  - 0302-4725 (Linking)
VI  - 29
IP  - 1
DP  - 1979 Jan
TI  - [New aspects of therapy for alveolitis with Grisaldon].
PG  - 45-8
AB  - In the GDR, Grisaldon has been used in alveolitis therapy since 1974. The results 
      from the bacteriological testing of this preparation and the diluting and rinsing 
      effects of saliva and blood on it arouse doubts about its antibacterial 
      efficiency. Thrombelastographic studies demonstrated the clotting-accelerating 
      and the marked fibrin-stabilizing effect of pure acetylsalicylic acid. In 
      contrast to other publications, it was stated that the p-hydroxybenzoic acid 
      propyl ester is absolutely indifferent. Histological studies on animals have 
      shown that Grisaldon is detectable in the alveolus as a foreign body even 28 days 
      after application, and that it decelerates wound healing.
FAU - Fröhlich, M
AU  - Fröhlich M
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Neue Aspekte zur Therapie der Alveolitis mit Grisaldon.
PL  - Germany
TA  - Stomatol DDR
JT  - Stomatologie der DDR
JID - 0421506
RN  - 0 (Benzoates)
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Benzoates/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Combinations
MH  - Drug Evaluation
MH  - Dry Socket/*drug therapy
MH  - Foreign-Body Reaction
MH  - Humans
MH  - Wound Healing/drug effects
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Stomatol DDR. 1979 Jan;29(1):45-8.

PMID- 6238183
OWN - NLM
STAT- MEDLINE
DCOM- 19841214
LR  - 20190821
IS  - 0741-5214 (Print)
IS  - 0741-5214 (Linking)
VI  - 1
IP  - 6
DP  - 1984 Nov
TI  - Aspirin therapy in small-caliber arterial prostheses: long-term experimental 
      observations.
PG  - 839-51
AB  - To study the therapeutic effects of 3 mg/kg aspirin given at the time of surgery 
      and postoperatively, Dacron carotid grafts with an internal diameter of 4 mm and 
      a length of 6 cm were implanted bilaterally in mongrel dogs. Sixteen control 
      grafts in eight subjects and 20 grafts in 10 subjects treated with aspirin were 
      followed by serial angiograms until consecutive studies showed stable patency 
      rates in both groups. Platelet aggregations, malondialdehyde production, serum 
      salicylate levels, and thromboxane A2 and prostacyclin secretion (measured as 
      thromboxane B2 and 6-keto-prostaglandin F1 alpha) were monitored prior to and 
      throughout the experiment. Surface mapping, indium-111 uptake, factor 
      VIII-related antigen staining, and scanning and transmission electron microscopy 
      were performed on the grafts at sacrifice. This study demonstrates a protective 
      effect on the early patency of small-caliber prostheses in the canine model with 
      daily oral aspirin administration. The degree and duration of this effect depends 
      on the preoperative baseline ratio of thromboxane to prostacyclin in each 
      subject.
FAU - Zammit, M
AU  - Zammit M
FAU - Kaplan, S
AU  - Kaplan S
FAU - Sauvage, L R
AU  - Sauvage LR
FAU - Marcoe, K F
AU  - Marcoe KF
FAU - Wu, H D
AU  - Wu HD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - 0 (Antigens)
RN  - 0 (Polyethylene Terephthalates)
RN  - 0 (von Willebrand Factor)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 9001-27-8 (Factor VIII)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Administration, Oral
MH  - Animals
MH  - Antigens/analysis
MH  - Aspirin/administration & dosage/blood/*therapeutic use
MH  - Blood Platelets/metabolism
MH  - *Blood Vessel Prosthesis/adverse effects
MH  - Dogs
MH  - Epoprostenol/metabolism
MH  - Factor VIII/analysis/immunology
MH  - Malondialdehyde/blood
MH  - Platelet Aggregation
MH  - Polyethylene Terephthalates
MH  - Thromboxane A2/metabolism
MH  - Thromboxane B2/blood
MH  - Time Factors
MH  - von Willebrand Factor
EDAT- 1984/11/01 00:00
MHDA- 2001/09/06 10:01
CRDT- 1984/11/01 00:00
PHST- 1984/11/01 00:00 [pubmed]
PHST- 2001/09/06 10:01 [medline]
PHST- 1984/11/01 00:00 [entrez]
AID - 0741-5214(84)90016-8 [pii]
AID - 10.1067/mva.1984.avs0010839 [doi]
PST - ppublish
SO  - J Vasc Surg. 1984 Nov;1(6):839-51. doi: 10.1067/mva.1984.avs0010839.

PMID- 1334228
OWN - NLM
STAT- MEDLINE
DCOM- 19930108
LR  - 20190818
IS  - 0300-8177 (Print)
IS  - 0300-8177 (Linking)
VI  - 114
IP  - 1-2
DP  - 1992 Sep 8
TI  - Aspirin, acetaminophen and proton transport through phospholipid bilayers and 
      mitochondrial membranes.
PG  - 3-8
AB  - Mechanisms of proton transport were investigated in planar phospholipid bilayer 
      membranes exposed to aspirin (acetylsalicylic acid), acetaminophen 
      (4-acetamidophenol), benzoic acid and three aspirin metabolites (salicylic acid, 
      gentisic acid and salicyluric acid). The objectives were to characterize the 
      conductances and permeabilities of these weak acids in lipid bilayer membranes 
      and then predict their effects on mitochondrial membranes. Of the compounds 
      tested only aspirin, benzoate and salicylate caused significant increases in 
      membrane conductance. The conductance was due mainly to proton current at low pH 
      and to weak acid anion current at neutral pH. Analysis of the concentration and 
      pH dependence suggests that these weak acids act as HA-2-type proton carriers 
      when pH approximately pK and as lipid soluble anions at neutral pH. Salicylate is 
      much more potent than aspirin and benzoate because salicylate contains an 
      internal hydrogen bond which delocalizes the negative charge and increases the 
      permeability of the anion. Model calculations for mitochondria suggest that 
      salicylate causes net H+ uptake by a cyclic process of HA influx and A- efflux. 
      This model can explain the salicylate-induced uncoupling and swelling observed in 
      isolated mitochondria. Since ingested aspirin breaks down rapidly to form 
      salicylate, these results may clarify the mechanisms of aspirin toxicity in 
      humans. The results may also help to explain why the ingestion of aspirin but not 
      acetaminophen is associated with Reye's syndrome, a disease characterized by 
      impaired energy metabolism and mitochondrial swelling.
FAU - Gutknecht, J
AU  - Gutknecht J
AD  - Department of Cell Biology, Duke University Medical Center, Beaufort, North 
      Carolina.
LA  - eng
GR  - GM 28844/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Mol Cell Biochem
JT  - Molecular and cellular biochemistry
JID - 0364456
RN  - 0 (Anions)
RN  - 0 (Lipid Bilayers)
RN  - 0 (Phospholipids)
RN  - 0 (Protons)
RN  - 0 (Salicylates)
RN  - 0 (Uncoupling Agents)
RN  - 362O9ITL9D (Acetaminophen)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Animals
MH  - Anions
MH  - Aspirin/*pharmacology/poisoning
MH  - Biological Transport/drug effects
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Intracellular Membranes/*drug effects
MH  - Lipid Bilayers/chemistry
MH  - Mitochondria/*drug effects
MH  - Oxidative Phosphorylation/drug effects
MH  - Permeability
MH  - Phospholipids/chemistry
MH  - *Protons
MH  - Reye Syndrome/physiopathology
MH  - Salicylates/pharmacology
MH  - Salicylic Acid
MH  - Uncoupling Agents
EDAT- 1992/09/08 00:00
MHDA- 1992/09/08 00:01
CRDT- 1992/09/08 00:00
PHST- 1992/09/08 00:00 [pubmed]
PHST- 1992/09/08 00:01 [medline]
PHST- 1992/09/08 00:00 [entrez]
AID - 10.1007/BF00240290 [doi]
PST - ppublish
SO  - Mol Cell Biochem. 1992 Sep 8;114(1-2):3-8. doi: 10.1007/BF00240290.

PMID- 11181942
OWN - NLM
STAT- MEDLINE
DCOM- 20010315
LR  - 20181130
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 296
IP  - 3
DP  - 2001 Mar
TI  - Effects of diaspirin cross-linked hemoglobin on motor function of the duodenum 
      and biliary system in the Australian brush-tailed possum in vivo.
PG  - 1067-73
AB  - Chemically altered hemoglobin-based oxygen carriers have been developed as 
      prototype blood substitutes. Such molecules may affect numerous biological 
      processes, since free hemoglobin scavenges nitric oxide (NO). Diaspirin 
      cross-linked hemoglobin (DCLHb) is a chemically cross-linked molecule, which has 
      a pressor effect on blood pressure, mainly mediated by NO scavenging. However, 
      the effects of DCLHb on the gastrointestinal and biliary motility have not been 
      reported. This study was conducted to investigate the effects of DCLHb on the 
      duodenal and biliary motility and determine if the underlying mechanism involves 
      a NO pathway. Blood pressure, duodenal, sphincter of Oddi and gallbladder 
      motility and trans-sphincteric flow were recorded in anesthetized Australian 
      Brush-tailed possums. The effects of intravenously administered DCLHb (10% 
      solution) or oncotically matched human serum albumin (HSA) solution on these 
      parameters were investigated. To determine the involvement of a NO-mediated 
      pathway in these effects, animals were pretreated with N(omega)-nitro-L-arginine 
      methyl ester (L-NAME) before DCLHb or HSA was given. DCLHb increased blood 
      pressure and duodenal contraction frequency and slowed trans-sphincteric flow 
      compared with the HSA control. The effects of DCLHb on blood pressure and 
      trans-sphincteric flow were immediate and transient, whereas the effect on 
      duodenal contraction frequency was delayed and long-lived. Pretreatment with 
      L-NAME alone increased blood pressure and duodenal contraction frequency and 
      slowed trans-sphincteric flow. DCLHb-induced changes were not evident in the 
      presence of L-NAME. These findings suggest that DCLHb affects duodenal and 
      trans-sphincteric flow predominantly by NO scavenging.
FAU - Konomi, H
AU  - Konomi H
AD  - Department of General and Digestive Surgery, Centre for Neuroscience, Flinders 
      University of South Australia, Adelaide, South Australia, Australia.
FAU - Woods, C M
AU  - Woods CM
FAU - Meedeniya, A C
AU  - Meedeniya AC
FAU - Giles, L C
AU  - Giles LC
FAU - Toouli, J
AU  - Toouli J
FAU - Saccone, G T
AU  - Saccone GT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Hemoglobins)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Duodenum/*drug effects/physiology
MH  - Female
MH  - Gallbladder/*drug effects/physiology
MH  - Gastrointestinal Motility/*drug effects
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Nitric Oxide/physiology
MH  - Opossums
MH  - Sphincter of Oddi/*drug effects/physiology
EDAT- 2001/02/22 11:00
MHDA- 2001/03/17 10:01
CRDT- 2001/02/22 11:00
PHST- 2001/02/22 11:00 [pubmed]
PHST- 2001/03/17 10:01 [medline]
PHST- 2001/02/22 11:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2001 Mar;296(3):1067-73.

PMID- 7913484
OWN - NLM
STAT- MEDLINE
DCOM- 19940816
LR  - 20181130
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 124
IP  - 1
DP  - 1994 Jul
TI  - Role of adrenergic mechanisms in the pressor effect of diaspirin cross-linked 
      hemoglobin.
PG  - 125-33
AB  - Diaspirin cross-linked hemoglobin (DCLHB; Baxter Healthcare Corp., Blood 
      Substitutes Division) is a promising hemoglobin-based oxygen-carrying 
      resuscitative solution. DCLHb (400 mg/kg, intravenously) produces an immediate 
      increase in blood pressure when administered to conscious or anesthetized rats. 
      To determine the role of the central nervous system and the peripheral vascular 
      system in the pressor effect of DCLHb, experiments were performed in 
      cervical-sectioned rats. Intravenous administration of DCLHb produced an increase 
      in blood pressure in cervical-sectioned animals (41.2 +/- 2.5 mm Hg), which was 
      similar to that observed in normal rats. To test whether the pressor effect was 
      due to release of catecholamines or other pressor substances from the adrenal 
      medulla, DCLHb was administered to bilateral adrenal demedullated rats. DCLHb was 
      found to produce a pressor effect in bilateral adrenal demedullated rats (42.0 
      +/- 6.4 mm Hg) that was similar to normal rats. To determine whether DCLHb alters 
      the responsiveness of peripheral vascular adrenoceptors, the effect of DCLHb 
      pretreatment on the blood pressure and heart rate responses of adrenergic 
      agonists was studied. DCLHb significantly potentiated (66.7%) the pressor 
      response to norepinephrine (0.5 to 2.0 microgram/kg, intravenously) but did not 
      affect the heart rate response to norepinephrine. Phenoxybenzamine completely 
      blocked the DCLHb-induced potentiation of the norepinephrine responses. 
      Phenylephrine produced a dose dependent (5 to 20 micrograms/kg, intravenously) 
      pressor and reflex bradycardic effect. DCLHb significantly potentiated the 
      pressor (40.6%) and bradycardiac (-22.8%) effect of phenylephrine, which were 
      completely blocked by prazosin.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Gulati, A
AU  - Gulati A
AD  - Department of Pharmaceutics and Pharmacodynamics (m/c 865), University of 
      Illinois at Chicago 60612.
FAU - Rebello, S
AU  - Rebello S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Hemoglobins)
RN  - 1WS297W6MV (Phenylephrine)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - MN3L5RMN02 (Clonidine)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Adrenal Medulla/physiology
MH  - Adrenalectomy
MH  - Adrenergic beta-Antagonists/pharmacology
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Pressure/*drug effects
MH  - Cardiovascular System/drug effects
MH  - Clonidine/pharmacology
MH  - Decerebrate State
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Norepinephrine/pharmacology
MH  - Phenylephrine/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reference Values
MH  - Sympathetic Nervous System/*physiology
EDAT- 1994/07/01 00:00
MHDA- 1994/07/01 00:01
CRDT- 1994/07/01 00:00
PHST- 1994/07/01 00:00 [pubmed]
PHST- 1994/07/01 00:01 [medline]
PHST- 1994/07/01 00:00 [entrez]
AID - 0022-2143(94)90164-3 [pii]
PST - ppublish
SO  - J Lab Clin Med. 1994 Jul;124(1):125-33.

PMID- 29976280
OWN - NLM
STAT- MEDLINE
DCOM- 20190819
LR  - 20190819
IS  - 1001-9294 (Print)
IS  - 1001-9294 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Jun 30
TI  - Effect of Red Ginseng Extract on the Pharmacokinetics of Aspirin Metabolite in 
      Sprague Dawley Rats.
PG  - 107-113
LID - 10.24920/11806 [doi]
AB  - Objective To investigate whether red ginseng extract can affect the 
      pharmacokinetics of aspirin in Sprague Dawley (SD) rats.Methods Totally, 12 male 
      SD rats were randomly and uniformly divided into the aspirin group (aspirin 10.42 
      mg·kg (-1)) and the combined group (red ginseng extraction 0.5 mg·g (-1) + 
      aspirin 10.42 mg·kg (-1)). After intragastric administration of drugs, blood 
      samples (0.5 ml once) were drawn from orbit at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 
      10 and 12 hours after dosing. Plasma concentration of salicylic acid (metabolite 
      of aspirin) was detected with ultraviolet-visible high performance liquid 
      chromatography (HPLC). The reliability of the procedure was verified with respect 
      to specificity, linearity, accuracy, precision, extraction recovery and matrix 
      effect, and stability. Pharmacokinetics of salicylic acid was evaluated by using 
      non-compartmental model. Results The method was proved to be validated. Compared 
      with the aspirin group, area under the curve (AUC (0-t)) and maximum 
      concentration of salicylic acid in rats of the combined group increased obviously 
      (P<0.01), while clearance rate (CL(z)/F) decreased clearly (P<0.05).Conclusion 
      The in vivo study showed that red ginseng extract can help the internal 
      absorption of aspirin, and delay the in vivo metabolism of aspirin.
FAU - Xue, Yu-Tao
AU  - Xue YT
AD  - Pharmaceutical Department, School of Chinese Materia Medica, Beijing University 
      of Chinese Medicine, Beijing 100029, China.
FAU - Tan, Ning
AU  - Tan N
AD  - Pharmaceutical Department, School of Chinese Materia Medica, Beijing University 
      of Chinese Medicine, Beijing 100029, China.
FAU - Yu, Gang-Yan
AU  - Yu GY
AD  - Pharmaceutical Department, School of Chinese Materia Medica, Beijing University 
      of Chinese Medicine, Beijing 100029, China.
FAU - Tan, Li
AU  - Tan L
AD  - Pharmaceutical Department, School of Chinese Materia Medica, Beijing University 
      of Chinese Medicine, Beijing 100029, China.
FAU - Lu, Yang
AU  - Lu Y
AD  - Pharmaceutical Department, School of Chinese Materia Medica, Beijing University 
      of Chinese Medicine, Beijing 100029, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med Sci J
JT  - Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
JID - 9112559
RN  - 0 (Drugs, Chinese Herbal)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
MH  - Animals
MH  - Aspirin/blood/*pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Drugs, Chinese Herbal/*pharmacokinetics/*pharmacology
MH  - Male
MH  - Panax/*chemistry
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reproducibility of Results
MH  - Salicylic Acid/blood
EDAT- 2018/07/07 06:00
MHDA- 2019/08/20 06:00
CRDT- 2018/07/07 06:00
PHST- 2018/07/07 06:00 [entrez]
PHST- 2018/07/07 06:00 [pubmed]
PHST- 2019/08/20 06:00 [medline]
AID - 10.24920/11806 [doi]
PST - ppublish
SO  - Chin Med Sci J. 2018 Jun 30;33(2):107-113. doi: 10.24920/11806.

PMID- 1533533
OWN - NLM
STAT- MEDLINE
DCOM- 19920610
LR  - 20200304
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 6
IP  - 1
DP  - 1992 Feb
TI  - Thromboxane synthase inhibitors and receptor antagonists.
PG  - 29-33
AB  - Platelet activation plays a major role in myocardial infarction and in 
      reocclusion following successful thrombolysis, as corroborated by several 
      clinical studies using aspirin. However, the overall reduction of new vascular 
      complications in patients with symptomatic arterial disease by aspirin was only 
      around 25%. Therefore, there is great interest in finding new means to inhibit 
      platelet activation more efficiently. One line of research has focused on ways to 
      interfere with the action of thromboxane A2 in a more selective way than aspirin 
      does. As such, the development of thromboxane synthase inhibitors, followed by 
      thromboxane receptor antagonists, raised hopes for a better treatment. However, 
      both classes of drugs have some drawbacks, which could be overcome by combining 
      them. This aim has led to the development of compounds that intrinsically possess 
      both activities. Ongoing research indicates that such a dual inhibitor may indeed 
      be more powerful than either aspirin or drugs with the single actions.
FAU - Vermylen, J
AU  - Vermylen J
AD  - Center for Thrombosis and Vascular Research, K.U. Leuven, Belgium.
FAU - Deckmyn, H
AU  - Deckmyn H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Receptors, Prostaglandin)
RN  - 0 (Receptors, Thromboxane)
RN  - 0 (Thromboxanes)
RN  - EC 5.3.99.5 (Thromboxane-A Synthase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Humans
MH  - Receptors, Prostaglandin/*drug effects
MH  - Receptors, Thromboxane
MH  - Thromboxane-A Synthase/*antagonists & inhibitors
MH  - Thromboxanes/*antagonists & inhibitors
RF  - 48
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
AID - 10.1007/BF00050914 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 1992 Feb;6(1):29-33. doi: 10.1007/BF00050914.

PMID- 15262298
OWN - NLM
STAT- MEDLINE
DCOM- 20040903
LR  - 20171116
IS  - 0889-8529 (Print)
IS  - 0889-8529 (Linking)
VI  - 33
IP  - 3
DP  - 2004 Sep
TI  - Management of metabolic syndrome: aspirin.
PG  - 577-93, vii
AB  - Cardiovascular disease (CVD), which includes myocardial infarction(MI), stroke, 
      and peripheral vascular disease, remains the leading cause of death in the United 
      States and in most developed countries. In the United States today, 25% of 
      patients have metabolic syndrome-including those who have had a prior occlusive 
      vascular disease event, those who are having an acute MI or ischemic stroke, and 
      finally, the largest segment of the population,namely those who have not yet 
      experienced a clinical CVD, but whose risks are substantial (10-year risk 10%). 
      This article reviews the totality of evidence for aspirin in the treatment and 
      prevention of CVD and emphasizes its importance as adjunctive therapy for 
      patients with metabolic syndrome.
FAU - Shields, T Matthew
AU  - Shields TM
AD  - Universidad Central del Caribe, Bayamón, Puerto Rico.
FAU - Hennekens, Charles H
AU  - Hennekens CH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Endocrinol Metab Clin North Am
JT  - Endocrinology and metabolism clinics of North America
JID - 8800104
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Metabolic Syndrome/*drug therapy
MH  - Stroke/prevention & control
RF  - 49
EDAT- 2004/07/21 05:00
MHDA- 2004/09/04 05:00
CRDT- 2004/07/21 05:00
PHST- 2004/07/21 05:00 [pubmed]
PHST- 2004/09/04 05:00 [medline]
PHST- 2004/07/21 05:00 [entrez]
AID - S0889852904000325 [pii]
AID - 10.1016/j.ecl.2004.03.015 [doi]
PST - ppublish
SO  - Endocrinol Metab Clin North Am. 2004 Sep;33(3):577-93, vii. doi: 
      10.1016/j.ecl.2004.03.015.

PMID- 3085277
OWN - NLM
STAT- MEDLINE
DCOM- 19860616
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 42
IP  - 1
DP  - 1986 Apr 1
TI  - Aspirin and venous occlusion: effects on blood fibrinolytic activity and 
      tissue-type plasminogen activator levels.
PG  - 73-82
AB  - The effects of oral aspirin (650 mg at 18 and 2 hours before testing) on the 
      response to 10 minute venous occlusion in normal young adults (8 men, 4 women) 
      was examined by fibrinolytic methods (euglobulin lysis, and radiofibrin assay of 
      whole blood and plasma activities) and immunoassay of plasma tissue-type 
      plasminogen activator (tPA). Aspirin had no effect on resting (pre-occlusion) 
      values for any of these. Resting plasma tPA levels were approximately 3-fold 
      greater in men than in women, with or without aspirin. Both before and after 
      aspirin, occlusion increased euglobulin lysis activity, plasma fibrinolytic 
      activity, and plasma tPA levels. In addition, there was an occlusion-related 
      increase in cellular phase activity, determined by radiofibrin assay, which was 
      similar, with and without aspirin, to the increase in plasma activity, indicating 
      the participation of blood cells in the response to occlusion. Mean whole blood 
      activity and cellular phase activity (whole blood less plasma activity) were 
      increased 1.8- and 1.5-fold, respectively, by venous occlusion. In all subjects, 
      the net effect of aspirin on occlusion-related increments in fibrinolytic 
      activity were decreases in whole blood and cellular phase responses (p less than 
      0.05), without significant effects on plasma or euglobulin lysis activity. In 
      contrast, aspirin treatment resulted in a 32% increase in mean individual 
      increments in plasma tPA concentration with occlusion, an effect predominant in 
      men. Aspirin interferes with the cellular phase fibrinolytic response to venous 
      occlusion, and results in increased, rather than decreased, mean 
      occlusion-induced increments in levels of plasma tissue activator, determined 
      immunochemically.
FAU - Hammouda, M W
AU  - Hammouda MW
FAU - Moroz, L A
AU  - Moroz LA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Serum Globulins)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Blood Cells/metabolism
MH  - Female
MH  - Fibrinolysis/*drug effects
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Plasma/metabolism
MH  - Serum Globulins/metabolism
MH  - Sex Factors
MH  - Sodium Salicylate/pharmacology
MH  - Tissue Plasminogen Activator/*blood
MH  - Tourniquets
MH  - Veins/physiology
EDAT- 1986/04/01 00:00
MHDA- 1986/04/01 00:01
CRDT- 1986/04/01 00:00
PHST- 1986/04/01 00:00 [pubmed]
PHST- 1986/04/01 00:01 [medline]
PHST- 1986/04/01 00:00 [entrez]
AID - 0049-3848(86)90198-2 [pii]
AID - 10.1016/0049-3848(86)90198-2 [doi]
PST - ppublish
SO  - Thromb Res. 1986 Apr 1;42(1):73-82. doi: 10.1016/0049-3848(86)90198-2.

PMID- 12635742
OWN - NLM
STAT- MEDLINE
DCOM- 20030506
LR  - 20200923
IS  - 0390-6663 (Print)
IS  - 0390-6663 (Linking)
VI  - 29
IP  - 4
DP  - 2002
TI  - Thromboprophylaxis throughout pregnancy in women with previous history of 
      recurrent miscarriages of unknown aetiology.
PG  - 267-70
AB  - The purpose of this prospective preliminary clinical study was to assess the 
      efficacy of thromboprophylaxis throughout pregnancy in women with a history of 
      unexplained first trimester recurrent miscarriages. From the 53 patients 
      originally assigned to the study 15 were excluded. The remaining 38 were treated 
      with low molecular weight heparin (LMWH-natroparine calcium 0.3 ml twice daily) 
      and low dose aspirin from the day the fetal heart motion was detected until the 
      37th week or earlier at the onset of premature labor. Among the patients treated 
      (n = 38) thrombophilia screening was positive in 16 patients and in the remaining 
      22 no causative factor was detected. The overall success rate (viable pregnancy > 
      or = 24 weeks) was 92.2% with no significant difference between patients with 
      positive or negative thrombophilia screening. The most significant complications 
      were: preeclampsia (21%), IUGR (26%), placenta abruptio (5.2%), injection site 
      haematoma (44%) and skin reaction (15.7%). No abnormal bleeding was observed 
      during vaginal or caesarean section. The results of this study suggest that 
      thromboprophylaxis during pregnancy, which has already been successfully tried in 
      patients with recurrent miscarriages with a causative factor, may be similarly 
      effective in patients with such a pregnancy complication but of unknown 
      aetiology.
FAU - Tzafettas, J
AU  - Tzafettas J
AD  - 3rd University Department of Obstetrics and Gynaecology, Hippokrateio Hospital of 
      Thessaloniki, Thessaloniki, Greece.
FAU - Mamopoulos, A
AU  - Mamopoulos A
FAU - Anapliotis, A
AU  - Anapliotis A
FAU - Loufopoulos, A
AU  - Loufopoulos A
FAU - Psarra, A
AU  - Psarra A
FAU - Klearchou, N
AU  - Klearchou N
FAU - Mamopoulos, M
AU  - Mamopoulos M
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Singapore
TA  - Clin Exp Obstet Gynecol
JT  - Clinical and experimental obstetrics & gynecology
JID - 7802110
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*prevention & control
MH  - Adult
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cohort Studies
MH  - Drug Administration Schedule
MH  - Female
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*prevention & control
MH  - Pregnancy Trimester, First
MH  - Prospective Studies
MH  - Thrombophilia/*prevention & control
MH  - Treatment Outcome
EDAT- 2003/03/15 04:00
MHDA- 2003/05/07 05:00
CRDT- 2003/03/15 04:00
PHST- 2003/03/15 04:00 [pubmed]
PHST- 2003/05/07 05:00 [medline]
PHST- 2003/03/15 04:00 [entrez]
PST - ppublish
SO  - Clin Exp Obstet Gynecol. 2002;29(4):267-70.

PMID- 32559792
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20230728
IS  - 1806-9339 (Electronic)
IS  - 0100-7203 (Print)
IS  - 0100-7203 (Linking)
VI  - 42
IP  - 7
DP  - 2020 Jul
TI  - Screening for Preeclampsia in the First Trimester and Aspirin Prophylaxis: Our 
      First Year.
PG  - 390-396
LID - 10.1055/s-0040-1712124 [doi]
AB  - OBJECTIVE:  Preeclampsia is a major cause of perinatal and maternal morbidity and 
      mortality. Our objective is to assess the performance of a combined screening 
      test for preeclampsia in the first trimester and the prophylactic use of low-dose 
      aspirin. METHODS:  Prospective study of all women attending our hospital for the 
      first-trimester screening of aneuploidies, between March 2017 and February 2018 
      (n = 1,297). The exclusion criteria were multiple pregnancy and major fetal 
      abnormalities. Preeclampsia screening was performed with an algorithm that 
      includes maternal characteristics, and biophysical and biochemical biomarkers. 
      High-risk was defined as a risk ≥ 1:50 of early-onset preeclampsia (before 34 
      weeks), in which cases low-dose aspirin (150 mg at night) was offered to these 
      women from screening until 36 weeks. RESULTS:  From the 1,272 enrolled 
      participants, the majority were Caucasian (1,051; 82.6%) and multiparous (658, 
      51.7%). Fifty patients (3.9%) screened high-risk for preeclampsia, and all 
      started a low-dose aspirin regimen, with good compliance (96%). Early-onset 
      preeclampsia was found in 3 pregnant women (0.24%), and total preeclampsia was 
      diagnosed in 25 (2.02%), compared with 28 (0.75%) cases of early preeclampsia 
      (p = 0.0099) and 98 (2.62%) of total preeclampsia (p = 0.2904) before the 
      implementation of screening. CONCLUSION:  There was a lower incidence of both, 
      early-onset and total preeclampsia, after the introduction of universal screening 
      and prophylactic use of low-dose aspirin. This reduction was statistically 
      significant in early-onset preeclampsia. The association of a first-trimester 
      combined screening model and aspirin prophylaxis appears to be useful in 
      predicting and reducing the incidence of early-onset preeclampsia, in a routine 
      care setting.
CI  - Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil.
FAU - Lourenço, Inês
AU  - Lourenço I
AUID- ORCID: 0000-0003-4630-829X
AD  - Department of Gynecology and Obstetrics, Hospital Beatriz Ângelo, Loures, 
      Portugal.
FAU - Gomes, Helena
AU  - Gomes H
AUID- ORCID: 0000-0001-5536-6796
AD  - Department of Gynecology and Obstetrics, Hospital Beatriz Ângelo, Loures, 
      Portugal.
FAU - Ribeiro, Joana
AU  - Ribeiro J
AUID- ORCID: 0000-0002-1237-3571
AD  - Department of Gynecology and Obstetrics, Hospital Beatriz Ângelo, Loures, 
      Portugal.
FAU - Caeiro, Filipa
AU  - Caeiro F
AUID- ORCID: 0000-0001-6024-9172
AD  - Department of Gynecology and Obstetrics, Hospital Beatriz Ângelo, Loures, 
      Portugal.
FAU - Rocha, Pedro
AU  - Rocha P
AUID- ORCID: 0000-0002-6834-9431
AD  - Department of Gynecology and Obstetrics, Hospital Beatriz Ângelo, Loures, 
      Portugal.
FAU - Francisco, Carla
AU  - Francisco C
AUID- ORCID: 0000-0002-4628-3064
AD  - Department of Gynecology and Obstetrics, Hospital Beatriz Ângelo, Loures, 
      Portugal.
LA  - eng
PT  - Journal Article
TT  - Rastreio de pré-eclâmpsia no primeiro trimestre e profilaxia com aspirina: O 
      nosso primeiro ano.
DEP - 20200619
PL  - Brazil
TA  - Rev Bras Ginecol Obstet
JT  - Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira 
      das Sociedades de Ginecologia e Obstetricia
JID - 9214757
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Incidence
MH  - *Mass Screening
MH  - Pre-Eclampsia/*diagnosis/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Pregnancy Trimester, First
MH  - *Pregnancy, High-Risk
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC10309226
COIS- The authors have no conflict of interests to declare.
EDAT- 2020/06/20 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 190288 [pii]
AID - 10.1055/s-0040-1712124 [doi]
PST - ppublish
SO  - Rev Bras Ginecol Obstet. 2020 Jul;42(7):390-396. doi: 10.1055/s-0040-1712124. 
      Epub 2020 Jun 19.

PMID- 27613165
OWN - NLM
STAT- MEDLINE
DCOM- 20170612
LR  - 20220408
IS  - 1432-1068 (Electronic)
IS  - 1633-8065 (Linking)
VI  - 26
IP  - 8
DP  - 2016 Dec
TI  - Comparison of preoperative continuation and discontinuation of aspirin in 
      patients undergoing total hip or knee arthroplasty.
PG  - 921-928
AB  - INTRODUCTION: Preoperative discontinuation of aspirin (acetylsalicylic acid) can 
      reduce bleeding risk but may increase the risk of perioperative cardiovascular 
      events. MATERIALS AND METHODS: We retrospectively assessed the impact of 
      preoperative continuation versus discontinuation of aspirin compared with a 
      control group in a cohort of 739 consecutive patients undergoing total hip (THA) 
      (n = 396) or knee arthroplasty (TKA) (n = 343) at a tertiary hospital. Bleeding 
      risk, local complications, orthopaedic outcome, and cardiac and cerebral 
      complications were assessed. RESULTS: Four hundred and sixty-five patients did 
      not receive antithrombotic or full-dose anticoagulant medication, 175 patients 
      were taking low-dose aspirin, 99 vitamin K antagonists, clopidogrel, or a 
      combination of these drugs. Of the patients taking aspirin, 139 discontinued and 
      36 continued aspirin. Blood loss and local bleeding complications were comparable 
      in these two groups. TKA patients who continued aspirin more frequently showed 
      marked knee swelling after 1 week than those discontinuing aspirin (35.1 vs. 
      81.3 %; p = 0.001). However, orthopaedic outcome did not differ significantly 
      between the two groups. There was a trend towards an increased risk of cardiac 
      complications in patients who discontinued aspirin (6.5 vs. 0.0 %; p = 0.107). 
      CONCLUSIONS: Continuation or discontinuation of aspirin did not show a 
      statistically significant difference in the risk of relevant perioperative 
      bleeding complications in our study. Continuation of aspirin was associated with 
      a transitory increase in knee swelling, but had no effect on orthopaedic outcome. 
      Continuation of aspirin may be associated with a favourable perioperative cardiac 
      outcome. Our data support perioperative continuation of aspirin intake in 
      patients undergoing THA or TKA.
FAU - Meier, Rahel
AU  - Meier R
AD  - Department of Handsurgery, Inselspital Bern, Freiburgstrasse 4, 3010, Bern, 
      Switzerland. rahel.meier@insel.ch.
FAU - Marthy, Regula
AU  - Marthy R
AD  - Departement of Internal Medicine, Kantonsspital Glarus, Burgstrasse 99, 8750, 
      Glarus, Switzerland. regula.marthy@ksgl.ch.
FAU - Saely, Christoph H
AU  - Saely CH
AD  - Department of Medicine and Cardiology, Landeskrankenhaus Feldkirch, Carinagasse 
      47, 6807, Feldkirch, Austria.
FAU - Kuster, Markus S
AU  - Kuster MS
AD  - Department of Orthopaedics and Traumatology, Royal Perth Hospital, 197 Wellington 
      Street, Perth, Western Australia, 6000, Australia.
FAU - Giesinger, Karlmeinrad
AU  - Giesinger K
AD  - Department of Orthopaedics and Tramatology, Kantonsspital St. Gallen, 
      Rorschacherstrass 95, 9007, St. Gallen, Switzerland.
FAU - Rickli, Hans
AU  - Rickli H
AD  - Department of Cardiology, Kantonsspital St. Gallen, Rorschachstrasse 95, 9007, 
      St. Gallen, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20160909
PL  - France
TA  - Eur J Orthop Surg Traumatol
JT  - European journal of orthopaedic surgery & traumatology : orthopedie traumatologie
JID - 9518037
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arthroplasty, Replacement, Knee/*adverse effects/methods
MH  - *Aspirin/administration & dosage/adverse effects
MH  - Blood Loss, Surgical/*prevention & control
MH  - Cardiovascular Diseases/prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Postoperative Hemorrhage/*prevention & control
MH  - Preoperative Care/*methods
MH  - Risk Adjustment/methods
MH  - Switzerland
MH  - Withholding Treatment
OTO - NOTNLM
OT  - Aspirin
OT  - Postoperative complications
OT  - Preoperative period
OT  - Total hip arthroplasty
OT  - Total knee arthroplasty
EDAT- 2016/09/11 06:00
MHDA- 2019/03/21 06:00
CRDT- 2016/09/11 06:00
PHST- 2016/05/18 00:00 [received]
PHST- 2016/07/30 00:00 [accepted]
PHST- 2016/09/11 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
PHST- 2016/09/11 06:00 [entrez]
AID - 10.1007/s00590-016-1830-7 [pii]
AID - 10.1007/s00590-016-1830-7 [doi]
PST - ppublish
SO  - Eur J Orthop Surg Traumatol. 2016 Dec;26(8):921-928. doi: 
      10.1007/s00590-016-1830-7. Epub 2016 Sep 9.

PMID- 31994315
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Apr
TI  - Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse 
      models of intestinal tumorigenesis.
PG  - 2535-2550
LID - 10.1002/cam4.2881 [doi]
AB  - Although early detection and treatment of colorectal cancer (CRC) have improved, 
      it remains a significant health-care problem with high morbidity and mortality. 
      Data indicate that long-term intake of low-dose aspirin reduces the risk of CRC; 
      however, the mechanisms underlying this chemopreventive effect are still unclear. 
      Different mouse models for inflammation-associated, sporadic, and hereditary CRC 
      were applied to assess the efficacy and mechanism of low-dose aspirin on tumor 
      prevention. An initial dosing study performed in healthy mice indicates that 
      aspirin at a dose of 25 mg/kg/d has a similar pharmacodynamic effect as low-dose 
      aspirin treatment in human subjects (100 mg/d). Chronic low-dose aspirin 
      treatment suppresses colitis-associated and to a lesser extent spontaneous 
      tumorigenesis in mice. Aspirin's antitumor effect is most pronounced in a 
      preventive approach when aspirin administration starts before the 
      tumor-initiating genotoxic event and continues for the duration of the 
      experiment. These effects are not associated with alterations in cell 
      proliferation, apoptosis, or activation of signaling pathways involved in CRC. 
      Aspirin-induced reduction in tumor burden is accompanied by inhibition of 
      thromboxane B(2) formation, indicating reduced platelet activation. Aspirin 
      treatment also results in decreased colonic prostaglandin E(2) formation and 
      tumor angiogenesis. With respect to colitis-triggered tumorigenesis, aspirin 
      administration is associated with a reduction in inflammatory activity in the 
      colon, as indicated by decreased levels of pro-inflammatory mediators, and 
      tumor-associated iNOS-positive macrophages. Our results suggest that low-dose 
      aspirin represents an effective antitumor agent in the context of colon 
      tumorigenesis primarily due to its well-established cyclooxygenase inhibition 
      effects.
CI  - © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Rohwer, Nadine
AU  - Rohwer N
AD  - Medical Department, Division of Hepatology and Gastroenterology, 
      Charite-Universitätsmedizin Berlin, Berlin, Germany.
AD  - Medical Department B, Divisions of Hepatology, Gastroenterology, Oncology, 
      Hematology, Rheumatology, Endocrinology and Diabetes, Brandenburg Medical School, 
      Ruppin General Hospital, Neuruppin, Germany.
AD  - Department of Molecular Toxicology, German Institute of Human Nutrition 
      Potsdam-Rehbruecke, Nuthetal, Germany.
FAU - Kühl, Anja A
AU  - Kühl AA
AD  - iPATH.Berlin-Immunopathology for Experimental Models, Charité-Universitätsmedizin 
      Berlin, Berlin, Germany.
FAU - Ostermann, Annika I
AU  - Ostermann AI
AD  - Chair of Food Chemistry, Faculty of Mathematics and Natural Sciences, University 
      of Wuppertal, Wuppertal, Germany.
FAU - Hartung, Nicole Marie
AU  - Hartung NM
AD  - Chair of Food Chemistry, Faculty of Mathematics and Natural Sciences, University 
      of Wuppertal, Wuppertal, Germany.
FAU - Schebb, Nils Helge
AU  - Schebb NH
AD  - Chair of Food Chemistry, Faculty of Mathematics and Natural Sciences, University 
      of Wuppertal, Wuppertal, Germany.
FAU - Zopf, Dieter
AU  - Zopf D
AD  - Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany.
FAU - McDonald, Fiona M
AU  - McDonald FM
AD  - Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany.
FAU - Weylandt, Karsten-H
AU  - Weylandt KH
AUID- ORCID: 0000-0002-5361-4327
AD  - Medical Department, Division of Hepatology and Gastroenterology, 
      Charite-Universitätsmedizin Berlin, Berlin, Germany.
AD  - Medical Department B, Divisions of Hepatology, Gastroenterology, Oncology, 
      Hematology, Rheumatology, Endocrinology and Diabetes, Brandenburg Medical School, 
      Ruppin General Hospital, Neuruppin, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200129
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Carcinogens)
RN  - 9042-14-2 (Dextran Sulfate)
RN  - MO0N1J0SEN (Azoxymethane)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Apoptosis
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Azoxymethane/toxicity
MH  - Carcinogens/toxicity
MH  - Cell Proliferation
MH  - Cell Transformation, Neoplastic/*drug effects/pathology
MH  - Colitis-Associated Neoplasms/chemically induced/*drug therapy/pathology
MH  - Colorectal Neoplasms/chemically induced/*drug therapy/pathology
MH  - Dextran Sulfate/toxicity
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Intestinal Neoplasms/chemically induced/*drug therapy/pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Tumor Cells, Cultured
PMC - PMC7131863
OTO - NOTNLM
OT  - aspirin
OT  - colorectal cancer
OT  - cyclooxygenase
OT  - tumor prevention
COIS- This preclinical study was supported by Bayer AG (Nadine Rohwer and Karsten‐H. 
      Weylandt). Dieter Zopf and Fiona M. McDonald are full‐time employees of Bayer AG. 
      The remaining authors disclose no conflicts.
EDAT- 2020/01/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/01/30 06:00
PHST- 2019/07/20 00:00 [received]
PHST- 2019/12/29 00:00 [revised]
PHST- 2020/01/13 00:00 [accepted]
PHST- 2020/01/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/01/30 06:00 [entrez]
AID - CAM42881 [pii]
AID - 10.1002/cam4.2881 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Apr;9(7):2535-2550. doi: 10.1002/cam4.2881. Epub 2020 Jan 29.

PMID- 23485835
OWN - NLM
STAT- MEDLINE
DCOM- 20130502
LR  - 20131121
IS  - 0301-1526 (Print)
IS  - 0301-1526 (Linking)
VI  - 42
IP  - 2
DP  - 2013 Mar
TI  - Is aspirin still the drug of choice for management of patients with peripheral 
      arterial disease?
PG  - 88-95
LID - 10.1024/0301-1526/a000251 [doi]
AB  - Antiplatelet drugs represent one of the basic options for management of patients 
      with different atherosclerotic diseases. Aspirin is the oldest and most often 
      prescribed antiplatelet drug. The efficacy of aspirin depends on the clinical 
      characteristics of the treated population and probably also on the type or 
      location of atherosclerotic disease. It seems that it is most effective in 
      coronary patients with clinically unstable disease, less effective in prevention 
      of cerebrovascular incidents, and its efficacy is uncertain in peripheral artery 
      disease (PAD) patients. One of the first meta-analyses (Antithrombotic Trialists' 
      Collaboration - ATC) indicated that antiplatelet drugs also significantly reduce 
      cardiovascular events in patients with PAD. However, only one third of the PAD 
      patients included were treated with aspirin, while the rest received other 
      anti-platelet drugs. The latest ATC meta-analysis of randomized control trials of 
      aspirin therapy involving patients with diabetes and PAD demonstrated no benefit 
      of aspirin in reducing cardiovascular events. Also in patients with preclinical 
      PAD (pathological ankle brachial index) aspirin did not result in a significant 
      reduction of vascular events. The new anti-platelet drugs prasugrel, ticagrelor 
      and picotamide seem to be more effective than aspirin in PAD patients, 
      particularly in diabetic patients with PAD. In conclusion, antiplatelet drugs are 
      effective in prevention of cardiovascular events in different atherosclerotic 
      diseases, including PAD. However, recent studies indicated that in PAD patients 
      aspirin is less effective than in coronary artery disease. New anti-platelet 
      drugs showed marginal superiority over aspirin without definite advantages. 
      Aspirin thus remains the first line of antiplatelet drug for secondary prevention 
      of cardiovascular events in PAD patients and clopidogrel as its effective 
      alternative. Further, new studies on PAD patients are necessary to better define 
      the role of anti-platelet agents in these patients and one of the promising ways 
      of access to anti-platelet treatment would be personalized anti-platelet therapy.
FAU - Poredos, Pavel
AU  - Poredos P
AD  - Department of Vascular Disease, University Medical Centre Ljubljana, Slovenia. 
      pavel.poredos@kclj.si
FAU - Jezovnik, Mateja K
AU  - Jezovnik MK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Vasa
JT  - VASA. Zeitschrift fur Gefasskrankheiten
JID - 0317051
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Disease Progression
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Peripheral Arterial Disease/complications/*drug therapy
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Secondary Prevention/*methods
MH  - Treatment Outcome
EDAT- 2013/03/15 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/03/15 06:00
PHST- 2013/03/15 06:00 [entrez]
PHST- 2013/03/15 06:00 [pubmed]
PHST- 2013/05/03 06:00 [medline]
AID - 21G2M787X2733882 [pii]
AID - 10.1024/0301-1526/a000251 [doi]
PST - ppublish
SO  - Vasa. 2013 Mar;42(2):88-95. doi: 10.1024/0301-1526/a000251.

PMID- 21828376
OWN - NLM
STAT- MEDLINE
DCOM- 20120713
LR  - 20200206
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 23
IP  - 4
DP  - 2012 Apr
TI  - Role of medical history and medication use in the aetiology of upper 
      aerodigestive tract cancers in Europe: the ARCAGE study.
PG  - 1053-60
LID - 10.1093/annonc/mdr335 [doi]
AB  - BACKGROUND: The study aimed to investigate the role of medical history (skin 
      warts, Candida albicans, herpetic lesions, heartburn, regurgitation) and 
      medication use (for heartburn; for regurgitation; aspirin) in the aetiology of 
      upper aerodigestive tract (UADT) cancer. METHODS: A multicentre (10 European 
      countries) case-control study [Alcohol-Related CAncers and GEnetic susceptibility 
      (ARCAGE) project]. RESULTS: There were 1779 cases of UADT cancer and 1993 
      controls. History of warts or C. albicans infection was associated with a reduced 
      risk [odds ratio (OR) 0.80, 95% confidence interval (CI) 0.68-0.94 and OR 0.73, 
      95% CI 0.60-0.89, respectively] but there was no association with herpetic 
      lesions, heartburn, regurgitation or medication for related symptoms. 
      Regurgitation was associated with an increased risk for cancer of the oesophagus 
      (OR 1.47, 95% CI 0.98-2.21). Regular aspirin use was not associated with risk of 
      UADT cancer overall but was associated with a reduced risk for cancer of 
      oesophagus (OR 0.51, 95% CI 0.28-0.96), hypopharynx (OR 0.53, 95% CI 0.28-1.02) 
      and larynx (OR 0.74, 95% CI 0.54-1.01). CONCLUSIONS: A history of some infections 
      appears to be a marker for decreased risk of UADT cancer. The role of medical 
      history and medication use varied by UADT subsites with aspirin use associated 
      with a decreased risk of oesophageal cancer and suggestive of a decreased risk of 
      hypopharyngeal and laryngeal cancers.
FAU - Macfarlane, T V
AU  - Macfarlane TV
AD  - School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK. 
      Tatiana.Macfarlane@abdn.ac.uk
FAU - Macfarlane, G J
AU  - Macfarlane GJ
FAU - Thakker, N S
AU  - Thakker NS
FAU - Benhamou, S
AU  - Benhamou S
FAU - Bouchardy, C
AU  - Bouchardy C
FAU - Ahrens, W
AU  - Ahrens W
FAU - Pohlabeln, H
AU  - Pohlabeln H
FAU - Lagiou, P
AU  - Lagiou P
FAU - Lagiou, A
AU  - Lagiou A
FAU - Castellsague, X
AU  - Castellsague X
FAU - Agudo, A
AU  - Agudo A
FAU - Slamova, A
AU  - Slamova A
FAU - Plzak, J
AU  - Plzak J
FAU - Merletti, F
AU  - Merletti F
FAU - Richiardi, L
AU  - Richiardi L
FAU - Talamini, R
AU  - Talamini R
FAU - Barzan, L
AU  - Barzan L
FAU - Kjaerheim, K
AU  - Kjaerheim K
FAU - Canova, C
AU  - Canova C
FAU - Simonato, L
AU  - Simonato L
FAU - Conway, D I
AU  - Conway DI
FAU - McKinney, P A
AU  - McKinney PA
FAU - Thomson, P
AU  - Thomson P
FAU - Sloan, P
AU  - Sloan P
FAU - Znaor, A
AU  - Znaor A
FAU - Healy, C M
AU  - Healy CM
FAU - McCartan, B E
AU  - McCartan BE
FAU - Marron, M
AU  - Marron M
FAU - Brennan, P
AU  - Brennan P
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20110809
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/therapeutic use
MH  - Candidiasis/complications
MH  - Carcinoma, Squamous Cell/*etiology
MH  - Case-Control Studies
MH  - Disease Susceptibility
MH  - Europe
MH  - Head and Neck Neoplasms/*etiology
MH  - Heartburn/complications
MH  - Herpesviridae Infections/complications
MH  - Humans
MH  - Laryngopharyngeal Reflux/complications
MH  - Middle Aged
MH  - Odds Ratio
MH  - Risk Factors
MH  - Warts/complications
MH  - Young Adult
EDAT- 2011/08/11 06:00
MHDA- 2012/07/14 06:00
CRDT- 2011/08/11 06:00
PHST- 2011/08/11 06:00 [entrez]
PHST- 2011/08/11 06:00 [pubmed]
PHST- 2012/07/14 06:00 [medline]
AID - S0923-7534(19)34643-5 [pii]
AID - 10.1093/annonc/mdr335 [doi]
PST - ppublish
SO  - Ann Oncol. 2012 Apr;23(4):1053-60. doi: 10.1093/annonc/mdr335. Epub 2011 Aug 9.

PMID- 24296111
OWN - NLM
STAT- MEDLINE
DCOM- 20140416
LR  - 20161125
IS  - 1879-1514 (Electronic)
IS  - 0166-445X (Linking)
VI  - 146
DP  - 2014 Jan
TI  - Lysine acetylsalicylate increases the safety of a paraquat formulation to 
      freshwater primary producers: a case study with the microalga Chlorella vulgaris.
PG  - 137-43
LID - S0166-445X(13)00304-4 [pii]
LID - 10.1016/j.aquatox.2013.10.034 [doi]
AB  - Large amounts of herbicides are presently used in the industrialized nations 
      worldwide, with an inexorable burden to the environment, especially to aquatic 
      ecosystems. Primary producers such as microalgae are of especial concern because 
      they are vital for the input of energy into the ecosystem and for the maintenance 
      of oxygen in water on which most of other marine life forms depend on. The 
      herbicide paraquat (PQ) is known to cause inhibition of photosynthesis and 
      irreversible damage to photosynthetic organisms through generation of reactive 
      oxygen species in a light-dependent manner. Previous studies have led to the 
      development of a new formulation of PQ containing lysine acetylsalicylate (LAS) 
      as an antidote, which was shown to prevent the mammalian toxicity of PQ, while 
      maintaining the herbicidal effect. However, the safety of this formulation to 
      primary producers in relation to commercially available PQ formulations has 
      hitherto not been established. Therefore, the aim of this study was to evaluate 
      the toxicity of the PQ+LAS formulation in comparison with the PQ, using Chlorella 
      vulgaris as a test organism. Effect criterion was the inhibition of microalgal 
      population growth. Following a 96 h exposure to increasing concentrations of PQ, 
      C. vulgaris growth was almost completely inhibited, an effect that was 
      significantly prevented by LAS at the proportion used in the formulation (PQ+LAS) 
      1:2 (mol/mol), while the highest protection was achieved at the proportion of 
      1:8. In conclusion, the present work demonstrated that the new formulation with 
      PQ+LAS has a reduced toxicity to C. vulgaris when compared to Gramoxone(®).
CI  - Copyright © 2013 Elsevier B.V. All rights reserved.
FAU - Baltazar, Maria Teresa
AU  - Baltazar MT
AD  - REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of 
      Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, 
      Portugal; IINFACTS-Institute of Research and Advanced Training in Health Sciences 
      and Technologies, Department of Sciences, Advanced Institute of Health 
      Sciences-North, CESPU, CRL, Rua Central de Gandra, 1317, 4585-116 Gandra, 
      Portugal. Electronic address: mteresabaltazar@gmail.com.
FAU - Dinis-Oliveira, Ricardo Jorge
AU  - Dinis-Oliveira RJ
AD  - REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of 
      Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, 
      Portugal; IINFACTS-Institute of Research and Advanced Training in Health Sciences 
      and Technologies, Department of Sciences, Advanced Institute of Health 
      Sciences-North, CESPU, CRL, Rua Central de Gandra, 1317, 4585-116 Gandra, 
      Portugal; Department of Legal Medicine and Forensic Sciences, Faculty of 
      Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 
      Porto, Portugal; CENCIFOR-Forensic Sciences Center, Largo da Sé Nova, 3000-213, 
      Coimbra, Portugal.
FAU - Martins, Alexandra
AU  - Martins A
AD  - CIIMAR Interdisciplinary Centre of Marine and Environmental Research, Laboratory 
      of Ecotoxicology and Ecology, Rua dos Bragas, 289, 4050-123 Porto, Portugal; 
      ICBAS-Institute of Biomedical Sciences of Abel Salazar, University of Porto, 
      Department of Populations Studies, Laboratory of Ecotoxicology, Rua Jorge Viterbo 
      Ferreira, 228, 4050-313 Porto, Portugal.
FAU - Bastos, Maria de Lourdes
AU  - Bastos Mde L
AD  - REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of 
      Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, 
      Portugal.
FAU - Duarte, José Alberto
AU  - Duarte JA
AD  - CIAFEL, Faculty of Sports, University of Porto, Rua Dr. Plácido Costa, 
      91-4200-450 Porto, Portugal.
FAU - Guilhermino, Lúcia
AU  - Guilhermino L
AD  - CIIMAR Interdisciplinary Centre of Marine and Environmental Research, Laboratory 
      of Ecotoxicology and Ecology, Rua dos Bragas, 289, 4050-123 Porto, Portugal; 
      ICBAS-Institute of Biomedical Sciences of Abel Salazar, University of Porto, 
      Department of Populations Studies, Laboratory of Ecotoxicology, Rua Jorge Viterbo 
      Ferreira, 228, 4050-313 Porto, Portugal.
FAU - Carvalho, Félix
AU  - Carvalho F
AD  - REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of 
      Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, 
      Portugal. Electronic address: felixdc@ff.up.pt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131107
PL  - Netherlands
TA  - Aquat Toxicol
JT  - Aquatic toxicology (Amsterdam, Netherlands)
JID - 8500246
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Water Pollutants, Chemical)
RN  - K3Z4F929H6 (Lysine)
RN  - PLG39H7695 (Paraquat)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Chlorella vulgaris/*drug effects
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Fresh Water
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Paraquat/*toxicity
MH  - Photosynthesis/drug effects
MH  - Reactive Oxygen Species/metabolism
MH  - Water Pollutants, Chemical/*toxicity
OTO - NOTNLM
OT  - Algae
OT  - Chlorella vulgaris.
OT  - Herbicides
OT  - Lysine acetylsalicylate
OT  - Paraquat
EDAT- 2013/12/04 06:00
MHDA- 2014/04/17 06:00
CRDT- 2013/12/04 06:00
PHST- 2013/08/09 00:00 [received]
PHST- 2013/10/07 00:00 [revised]
PHST- 2013/10/29 00:00 [accepted]
PHST- 2013/12/04 06:00 [entrez]
PHST- 2013/12/04 06:00 [pubmed]
PHST- 2014/04/17 06:00 [medline]
AID - S0166-445X(13)00304-4 [pii]
AID - 10.1016/j.aquatox.2013.10.034 [doi]
PST - ppublish
SO  - Aquat Toxicol. 2014 Jan;146:137-43. doi: 10.1016/j.aquatox.2013.10.034. Epub 2013 
      Nov 7.

PMID- 10235131
OWN - NLM
STAT- MEDLINE
DCOM- 19990526
LR  - 20191103
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 133
IP  - 5
DP  - 1999 May
TI  - Endothelin plays a role in contractions of isolated pig pulmonary vessels induced 
      by diaspirin cross-linked hemoglobin.
PG  - 478-87
AB  - The current studies were undertaken to investigate the role of endothelin-1 
      (ET-1) and its receptors in contractions of isolated pulmonary vessels of the pig 
      induced by diaspirin cross-linked hemoglobin (DCLHb). Second-order pulmonary 
      arteries (PAs) and veins (PVs) were isolated from pigs, cut into rings (4 to 5 
      mm), and mounted at optimal passive tension in 37 degrees C Krebs-filled tissue 
      baths bubbled with 95% O2/5% CO2. Isometric tension was recorded continuously. In 
      paired rings, concentration responses to ET-1 (10(-10) to 10(-7) mol/L), DCLHb 
      (10(-9) to 3x10(-6) mol/L), and N-nitro-L-arginine (LNA) (10(-6) to 5x10(-5) 
      mol/L) in the presence and absence of the ET(A) receptor antagonist BQ123 
      (3x10(-5) mol/L) were determined. PVs and PAs with intact endothelium and rings 
      from which the endothelium was removed (denuded) were pretreated with the ET(B) 
      receptor antagonist BQ788 to determine the contribution of ET(B) receptors to 
      ET-1, DCLHb, and LNA responses. ET-1, DCLHb, and LNA caused 
      concentration-dependent increases in tension in all vessels. In the presence of 
      BQ123, the 50% effective concentration (EC50) of ET-1 was significantly increased 
      (by 5-fold to 10-fold) in all vessels. DCLHb concentration responses were 
      significantly attenuated-in the PVs by 45% and in the PAs by 79%-during treatment 
      with BQ123. BQ123 attenuated LNA responses in PVs by 35% and in PAs by 87%. 
      Treatment with BQ788 had no effect on endothelium-intact PVs or PAs but 
      significantly increased ET-1 EC50 (log of the molar concentration) from 
      -9.0+/-0.22 to -7.8+/-0.05 in denuded PAs. The ET-1 EC50 was significantly 
      decreased in denuded PAs (-9.0+/-0.22) as compared with responses in 
      endothelium-intact PAs (-8.1+/-0.18). DCLHb concentration responses were 
      attenuated by 71% and LNA responses by 80% during antagonism with BQ788 in the 
      intact PAs only. These data demonstrate that ET-1 plays a role in DCLHb-induced 
      contractions in the PA and PV. The contributions of ET are mediated by both ET(A) 
      and ET(B) receptors in the PA but only by ET(A) receptors in the PV. These 
      results suggest that the vasoconstrictor actions of DCLHb, which have previously 
      been shown to depend on its interference with endothelium-generated NO, may also 
      involve ET. This may reflect the importance of the interaction of these two 
      endothelium-generated physiologic antagonists in the pulmonary circulation.
FAU - Ledvina, M A
AU  - Ledvina MA
AD  - The Uniformed Services University of the Health Sciences, Department of 
      Anesthesiology, Bethesda, Maryland 20814, USA.
FAU - Hart, J
AU  - Hart J
FAU - Bina, S
AU  - Bina S
FAU - Jing, M
AU  - Jing M
FAU - Muldoon, S
AU  - Muldoon S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Endothelin Receptor Antagonists)
RN  - 0 (Endothelin-1)
RN  - 0 (Glycopeptides)
RN  - 0 (Hemoglobins)
RN  - 0 (Oligopeptides)
RN  - 0 (Piperidines)
RN  - 0 (Receptor, Endothelin A)
RN  - 0 (Receptor, Endothelin B)
RN  - 0 (Vasoconstrictor Agents)
RN  - 2149-70-4 (Nitroarginine)
RN  - 44OLL8XEJ4 (BQ 788)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - T3G94E2LB1 (phosphoramidon)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Endothelin Receptor Antagonists
MH  - Endothelin-1/*pharmacology
MH  - Glycopeptides/pharmacology
MH  - Hemoglobins/*pharmacology
MH  - Isometric Contraction/drug effects
MH  - Muscle, Smooth, Vascular/*drug effects
MH  - Nitroarginine/pharmacology
MH  - Oligopeptides/pharmacology
MH  - Piperidines/pharmacology
MH  - Pulmonary Artery/*drug effects
MH  - Pulmonary Veins/*drug effects
MH  - Receptor, Endothelin A
MH  - Receptor, Endothelin B
MH  - Swine
MH  - Vasoconstrictor Agents/pharmacology
EDAT- 1999/05/11 00:00
MHDA- 1999/05/11 00:01
CRDT- 1999/05/11 00:00
PHST- 1999/05/11 00:00 [pubmed]
PHST- 1999/05/11 00:01 [medline]
PHST- 1999/05/11 00:00 [entrez]
AID - S0022-2143(99)90025-2 [pii]
AID - 10.1016/s0022-2143(99)90025-2 [doi]
PST - ppublish
SO  - J Lab Clin Med. 1999 May;133(5):478-87. doi: 10.1016/s0022-2143(99)90025-2.

PMID- 22038552
OWN - NLM
STAT- MEDLINE
DCOM- 20120619
LR  - 20181201
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
VI  - 47
IP  - 2
DP  - 2012 Feb
TI  - Association of gastric acid and mucus secretion level with low-dose 
      aspirin-induced gastropathy.
PG  - 150-8
LID - 10.1007/s00535-011-0478-7 [doi]
AB  - BACKGROUND: Low-dose aspirin is known to cause upper gastrointestinal 
      complications. The mechanism by which the aspirin disrupts gastric mucosal 
      integrity remains to be clarified. In this study we investigated the temporal 
      association of gastric secretory parameters (acid and mucus) with aspirin-induced 
      gastropathy. METHODS: In 42 long-term low-dose aspirin-takers and the same number 
      of sex- and age-matched controls, pentagastrin-stimulated gastric juice was 
      collected for 10 min during endoscopic examination. The collected gastric juice 
      was divided and half was submitted to analysis for gastric acid (mEq/10 min) and 
      the other half was analyzed for mucin (mg hexose/10 min) output. The grade of 
      gastric mucosal injury was assessed endoscopically according to the modified 
      Lanza score, and a score of more than 4 was defined as the presence of severe 
      gastropathy. RESULTS: While gastric acid secretion did not differ significantly 
      between aspirin-takers and controls, gastric mucus secretion, in terms of mucin 
      output, was significantly increased in aspirin-takers compared to controls (4.1 
      (SD 4.8) vs. 2.3 (1.4) mg hexose/10 min, P < 0.05). Consequently, the acid/mucin 
      ratio was significantly decreased in aspirin-takers compared to controls (1.2 
      (1.0) vs. 1.7 (1.4), P < 0.05). In the subanalysis of 25 aspirin-takers without 
      severe gastropathy, gastric mucus secretion was increased and the acid/mucus 
      ratio was decreased compared with controls, but there was no such association in 
      the remaining 17 aspirin-takers with severe gastropathy. CONCLUSION: Overall, 
      gastric mucus secretion is increased in aspirin-takers, suggesting a functional 
      adaptive response to long-term administration of the drug. However, it is 
      possible that the adaptive response is impaired in some aspirin takers, who might 
      be susceptible to severe upper gastrointestinal complication.
FAU - Iijima, Katsunori
AU  - Iijima K
AD  - Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 
      Seiryo-machi, Aobaku, Sendai, Miyagi 980-8574, Japan. kiijima@med.tohoku.ac.jp
FAU - Ara, Nobuyuki
AU  - Ara N
FAU - Abe, Yasuhiko
AU  - Abe Y
FAU - Koike, Tomoyuki
AU  - Koike T
FAU - Iwai, Wataru
AU  - Iwai W
FAU - Iwabuchi, Toshimitsu
AU  - Iwabuchi T
FAU - Ichikawa, Takafumi
AU  - Ichikawa T
FAU - Kamata, Yayoi
AU  - Kamata Y
FAU - Ishihara, Kazuhiko
AU  - Ishihara K
FAU - Shimosegawa, Tooru
AU  - Shimosegawa T
LA  - eng
PT  - Journal Article
DEP - 20111027
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Mucins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Female
MH  - Gastric Acid/*metabolism
MH  - Gastric Mucosa/*pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mucins/*metabolism
MH  - Prospective Studies
MH  - Stomach Diseases/*chemically induced/pathology
EDAT- 2011/11/01 06:00
MHDA- 2012/06/20 06:00
CRDT- 2011/11/01 06:00
PHST- 2011/07/06 00:00 [received]
PHST- 2011/08/21 00:00 [accepted]
PHST- 2011/11/01 06:00 [entrez]
PHST- 2011/11/01 06:00 [pubmed]
PHST- 2012/06/20 06:00 [medline]
AID - 10.1007/s00535-011-0478-7 [doi]
PST - ppublish
SO  - J Gastroenterol. 2012 Feb;47(2):150-8. doi: 10.1007/s00535-011-0478-7. Epub 2011 
      Oct 27.

PMID- 26117592
OWN - NLM
STAT- MEDLINE
DCOM- 20160830
LR  - 20150910
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 137
DP  - 2015 Oct
TI  - Aspirin Response Test role in platelet transfusion following intracerebral 
      hemorrhage.
PG  - 12-4
LID - S0303-8467(15)00230-9 [pii]
LID - 10.1016/j.clineuro.2015.06.007 [doi]
AB  - OBJECTIVES: Spontaneous intracerebral hemorrhage (ICH) results in high morbidity 
      and mortality. A target for therapy might be hematoma expansion, which occurs in 
      a significant proportion of patients, and can be exacerbated by antiplatelet 
      medications, such as aspirin. It is not clear whether platelet transfusion 
      neutralizes aspirin. The Aspirin Response Test (ART) is commonly ordered in this 
      patient population, but it is not clear whether the results of this test can help 
      select patients for transfusion of platelets. The aim of our study is to 
      investigate whether a selected group of ICH patients, those with reduced platelet 
      activity ("aspirin responders"), will benefit from platelet transfusion. 
      MATERIALS AND METHODS: This retrospective study included 63 patients who were 
      taking aspirin but no other antithrombotic medication prior to the ICH. For each 
      patient, we measured hematoma size by head CT on admission and compared with 
      follow-up head CT 1 day later. RESULTS: In the general cohort, 41% of transfused 
      patients and 29% of non-transfused patients had a hematoma expansion. In the 
      "aspirin responders" group, 46% of transfused patients and 22% of non-transfused 
      patients had an expansion. CONCLUSIONS: Our data suggest that platelet 
      transfusion following an ICH in "aspirin responders" does not reduce hematoma 
      expansion rates in those patients. A larger prospective study is needed.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Engel-Haber, Einat
AU  - Engel-Haber E
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic 
      address: einateng@post.tau.ac.il.
FAU - Horev, Anat
AU  - Horev A
AD  - University of Pittsburgh Medical Center, Department of Neurology, Pittsburgh, PA, 
      United States.
FAU - Chablani, Priyanka
AU  - Chablani P
AD  - Ohio State University College of Medicine, Columbus, OH, United States.
FAU - Bornstein, Natan M
AU  - Bornstein NM
AD  - Tel Aviv Sourasky Medical Center, Department of Neurology, Tel Aviv University, 
      Tel Aviv, Israel.
FAU - Jadhav, Ashutosh
AU  - Jadhav A
AD  - University of Pittsburgh Medical Center, Department of Neurology, Pittsburgh, PA, 
      United States.
FAU - Jovin, Tudor G
AU  - Jovin TG
AD  - University of Pittsburgh Medical Center, Department of Neurology, Pittsburgh, PA, 
      United States.
FAU - Reddy, Vivek
AU  - Reddy V
AD  - University of Pittsburgh Medical Center, Department of Neurology, Pittsburgh, PA, 
      United States.
FAU - Hammer, Maxim D
AU  - Hammer MD
AD  - University of Pittsburgh Medical Center, Department of Neurology, Pittsburgh, PA, 
      United States.
LA  - eng
PT  - Journal Article
DEP - 20150612
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cerebral Hemorrhage/*drug therapy/therapy
MH  - Female
MH  - Hematoma/diagnosis/*drug therapy/therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - *Platelet Transfusion/methods
MH  - Retrospective Studies
MH  - Tomography, X-Ray Computed/methods
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirin Response Test
OT  - Intracerebral hemorrhage
OT  - Platelet response test
OT  - Platelet transfusion
OT  - Platelets
OT  - Reduced platelet activity
EDAT- 2015/06/29 06:00
MHDA- 2016/08/31 06:00
CRDT- 2015/06/29 06:00
PHST- 2015/05/12 00:00 [received]
PHST- 2015/06/07 00:00 [revised]
PHST- 2015/06/10 00:00 [accepted]
PHST- 2015/06/29 06:00 [entrez]
PHST- 2015/06/29 06:00 [pubmed]
PHST- 2016/08/31 06:00 [medline]
AID - S0303-8467(15)00230-9 [pii]
AID - 10.1016/j.clineuro.2015.06.007 [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 2015 Oct;137:12-4. doi: 10.1016/j.clineuro.2015.06.007. 
      Epub 2015 Jun 12.

PMID- 9781832
OWN - NLM
STAT- MEDLINE
DCOM- 19981230
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 92
IP  - 1 Suppl 1
DP  - 1998 Sep 15
TI  - The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk 
      of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
PG  - S13-6
AB  - The role of aspirin in the secondary prevention of ischaemic events is being 
      challenged. CAPRIE, a blinded multicenter randomized trial of over 19,000 
      patients followed for 1-3 years, assessed the effect of clopidogrel in the 
      secondary prevention of major vascular events. Patients with a recent myocardial 
      infarction, stroke or peripheral arterial disease were randomized to treatment 
      with clopidogrel or aspirin. Clopidogrel was associated with a statistically 
      significant, overall 8.7%, relative reduction in the risk of ischaemic events, 
      but the direction and size of the effect was not homogeneous with respect to 
      three predefined clinical subgroups. Clopidogrel may be slightly better in 
      preventing major ischaemic events in high-risk patients, but the results of 
      CAPRIE suggest that there is room for doubt. It remains to be seen whether 
      treatment with clopidogrel is cost-effective compared with aspirin. However, 
      aspirin may still be of value in the early treatment of acute stroke. IST was a 
      20,000 patient, randomized, open-label study of aspirin plus heparin or neither 
      in patients with acute ischaemic stroke that should be treated in 48 hours. There 
      was a small but statistically nonsignificant reduction in mortality and 
      disability at 6 months for patients allocated to early treatment with aspirin 
      compared with those who were scheduled to avoid aspirin in the first 2 weeks 
      after the stroke. Similar results were seen in CAST, a double-blind trial of 
      aspirin vs. placebo in patients with suspected ischaemic stroke treated within 48 
      hours. A meta-analysis of the results of IST, CAST and MAST-I showed a 
      statistically significant effect of early aspirin treatment. The role of aspirin 
      in the treatment of acute stroke within 48 hours appears to be established.
FAU - Dippel, D W
AU  - Dippel DW
AD  - Department of Neurology, University Hospital Rotterdam, The Netherlands.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Meta-Analysis
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cerebrovascular Disorders/*drug therapy/prevention & control
MH  - Clopidogrel
MH  - Double-Blind Method
MH  - Humans
MH  - Ischemia/drug therapy
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Recurrence
MH  - Ticlopidine/analogs & derivatives/therapeutic use
EDAT- 1998/10/22 00:00
MHDA- 1998/10/22 00:01
CRDT- 1998/10/22 00:00
PHST- 1998/10/22 00:00 [pubmed]
PHST- 1998/10/22 00:01 [medline]
PHST- 1998/10/22 00:00 [entrez]
AID - 10.1016/s0049-3848(98)00102-9 [doi]
PST - ppublish
SO  - Thromb Res. 1998 Sep 15;92(1 Suppl 1):S13-6. doi: 10.1016/s0049-3848(98)00102-9.

PMID- 7912767
OWN - NLM
STAT- MEDLINE
DCOM- 19940804
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 344
IP  - 8916
DP  - 1994 Jul 16
TI  - Randomised trial of oral aspirin for chronic venous leg ulcers.
PG  - 164-5
AB  - The effect of oral aspirin on the healing rate of chronic venous leg ulcers was 
      compared with that of placebo in a double-blind randomised trial. 20 subjects 
      with chronic venous leg ulcers were randomised to daily enteric-coated aspirin 
      300 mg or placebo, and standardised compression bandaging. 4 months of treatment 
      achieved ulcer healing in 38% of the patients receiving aspirin compared with 0% 
      of those receiving placebo (p < 0.007). 52% of the aspirin-treated group showed 
      significant reduction in ulcer size compared with 26% of placebo recipients (p < 
      0.007). Reduction in ulcer surface area was significantly better in the 
      aspirin-treated group at 2 (p < 0.01) and 4 months (p < 0.002) compared with that 
      in the placebo group.
FAU - Layton, A M
AU  - Layton AM
AD  - Academic Unit of Dermatology, General Infirmary at Leeds, West Yorkshire, UK.
FAU - Ibbotson, S H
AU  - Ibbotson SH
FAU - Davies, J A
AU  - Davies JA
FAU - Goodfield, M J
AU  - Goodfield MJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 1994 Nov 26;344(8935):1512-3. PMID: 7832892
CIN - Lancet. 1994 Nov 26;344(8935):1513. PMID: 7968152
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Bandages
MH  - Chronic Disease
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Varicose Ulcer/*drug therapy/therapy
EDAT- 1994/07/16 00:00
MHDA- 1994/07/16 00:01
CRDT- 1994/07/16 00:00
PHST- 1994/07/16 00:00 [pubmed]
PHST- 1994/07/16 00:01 [medline]
PHST- 1994/07/16 00:00 [entrez]
AID - S0140-6736(94)92759-6 [pii]
AID - 10.1016/s0140-6736(94)92759-6 [doi]
PST - ppublish
SO  - Lancet. 1994 Jul 16;344(8916):164-5. doi: 10.1016/s0140-6736(94)92759-6.

PMID- 12049973
OWN - NLM
STAT- MEDLINE
DCOM- 20020716
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 28
IP  - 6
DP  - 2002 Jun 15
TI  - Accelerated dissolution testing for improved quality assurance.
PG  - 1081-9
AB  - In pharmaceutical production of controlled release tablets and capsules, a rapid 
      and automated at-line dissolution test for quality assurance of semi-products is 
      advantageous. For effective control of the production, the analysis should not 
      take more than about an hour, without loss of correlation to the ordinary (USP) 
      dissolution test of the final product. For almost a decade, the ACDRA apparatus 
      (ACcelerated Dissolution Rate Analysis) have been used for this purpose at 
      AstraZeneca Tablet Production Sweden (TPS). In this paper, we give examples on 
      different ways to accelerate the dissolution process. We use the USP dissolution 
      calibrator tablets of salicylic acid (non-disintegrating type) to illustrate the 
      strategy. We investigate the accelerated dissolution of the dissolution 
      calibrator tablets, and show how it can be correlated with the dissolution in the 
      ordinary USP-II equipment. The dissolution process was accelerated by variation 
      of temperature, solvent and stirring. For example, we show that by increasing the 
      temperature to 70 degrees C, changing the solvent to water, and increasing the 
      stirring, it is possible to accelerate the dissolution by a factor of 5, without 
      any loss of correlation to the dissolution process in the ordinary test.
FAU - Quist, Per Ola
AU  - Quist PO
AD  - Process Analytical Chemistry, Quality Control and Assurance, AstraZeneca Tablet 
      Production Sweden, Södertälje, Sweden. per-ola.quist@astrazeneca.com
FAU - Ostling, Göran
AU  - Ostling G
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - *Chemistry, Pharmaceutical
MH  - Equipment Design
MH  - *Quality Control
MH  - Technology, Pharmaceutical/*instrumentation/standards
EDAT- 2002/06/07 10:00
MHDA- 2002/07/18 10:01
CRDT- 2002/06/07 10:00
PHST- 2002/06/07 10:00 [pubmed]
PHST- 2002/07/18 10:01 [medline]
PHST- 2002/06/07 10:00 [entrez]
AID - S0731708502000481 [pii]
AID - 10.1016/s0731-7085(02)00048-1 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2002 Jun 15;28(6):1081-9. doi: 
      10.1016/s0731-7085(02)00048-1.

PMID- 12036006
OWN - NLM
STAT- MEDLINE
DCOM- 20021129
LR  - 20190706
IS  - 0009-2363 (Print)
IS  - 0009-2363 (Linking)
VI  - 50
IP  - 5
DP  - 2002 May
TI  - Characterization of physical state of mannitol after freeze-drying: effect of 
      acetylsalicylic acid as a second crystalline cosolute.
PG  - 567-70
AB  - Freeze-drying of mixed solutes is a preparative technique widely used in the 
      pharmaceutical industry. The presence of an amorphous form or changes in the 
      crystalline form can affect solid state stability. In this work, acetylsalicylic 
      acid (AAS) was chosen as a model drug, and was mixed with mannitol, a commonly 
      used bulking agent in formulation of tablets. Variations in the final 
      freeze-dried crystalline forms were found after changing the ratios of the two 
      co-solutes. Samples were analysed by powder X-ray diffractometry and differential 
      scanning calorimetry. A major amorphous form and a minor crystalline 
      delta-mannitol form were produced during the mannitol freeze-drying process. The 
      crystal form of mannitol in the two-component system depended on the AAS:mannitol 
      ratio. The AAS was mostly crystalline, regardless of the amount of mannitol 
      present. A major delta-mannitol and a minor amorphous form were obtained when AAS 
      was present in a high percentage (75% w/w). When AAS percentages of 50 and 25% 
      (w/w) were present during the drying process, the mannitol was found in a highly 
      crystalline form.
FAU - Torrado, Susana
AU  - Torrado S
AD  - Department of Pharmaceutical Technology, School of Pharmacy, Complutense 
      University, Madrid, Spain.
FAU - Torrado, Santiago
AU  - Torrado S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - 0 (Amides)
RN  - 0 (Powders)
RN  - 3OWL53L36A (Mannitol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amides/chemistry
MH  - Aspirin/*chemistry
MH  - Calorimetry, Differential Scanning
MH  - Crystallization
MH  - Freeze Drying
MH  - Hydrogen Bonding
MH  - Mannitol/*chemistry
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Powders
MH  - Thermodynamics
MH  - X-Ray Diffraction
EDAT- 2002/05/31 10:00
MHDA- 2002/11/30 04:00
CRDT- 2002/05/31 10:00
PHST- 2002/05/31 10:00 [pubmed]
PHST- 2002/11/30 04:00 [medline]
PHST- 2002/05/31 10:00 [entrez]
AID - 10.1248/cpb.50.567 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 2002 May;50(5):567-70. doi: 10.1248/cpb.50.567.

PMID- 3904436
OWN - NLM
STAT- MEDLINE
DCOM- 19851126
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 79
IP  - 4B
DP  - 1985 Oct 18
TI  - Evaluation of the safety of isoxicam.
PG  - 28-32
AB  - Data collected from more than 1,800 patients with rheumatoid arthritis or 
      degenerative joint disease in Phase 3 clinical studies of isoxicam (Maxicam) 
      indicated that the drug is well tolerated on both a short-term and a long-term 
      basis. The most common type of adverse reaction to all medications (isoxicam, 
      aspirin, and indomethacin) was gastrointestinal: 22.6 percent with isoxicam, at a 
      dosage greater than 200 mg per day; 14.2 percent with isoxicam at 200 mg per day; 
      31.6 percent with buffered aspirin at 3,600 to 4,800 mg per day; 24.6 percent 
      with indomethacin at 150 mg per day; and 7.2 percent with placebo. The incidence 
      of tinnitus and deafness was significantly greater with buffered aspirin than 
      with isoxicam, and the number of patients who had at least one episode of 
      dizziness, vertigo, or headache was significantly greater with indomethacin than 
      with isoxicam. In open-label, long-term studies, in which approximately 70 
      percent of the patients participated, the types and frequencies of adverse 
      effects were similar to those observed with isoxicam during the controlled 
      studies. The overall frequency of withdrawal for adverse reactions during the 
      long-term studies was 11.5 percent, similar to that during the controlled 
      studies. At the recommended dosage for isoxicam of 200 mg per day, the incidence 
      of gastrointestinal ulcers was 0.81 percent, well within the range expected among 
      arthritic patients receiving nonsteroidal anti-inflammatory drugs. From the data 
      collected in Phase 3 clinical studies, it may be concluded that isoxicam is 
      better tolerated than either aspirin or indomethacin and should not create 
      unusual problems in the short-term or long-term treatment of rheumatoid arthritis 
      or degenerative joint disease.
FAU - Burch, F X
AU  - Burch FX
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Thiazines)
RN  - 13T4O6VMAM (Piroxicam)
RN  - 8XU734C4NG (isoxicam)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aged
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Hip Joint
MH  - Humans
MH  - Indomethacin/*adverse effects/therapeutic use
MH  - Joint Diseases/drug therapy
MH  - Knee Joint
MH  - Middle Aged
MH  - *Piroxicam/*analogs & derivatives
MH  - Safety
MH  - Thiazines/*adverse effects/therapeutic use
EDAT- 1985/10/18 00:00
MHDA- 1985/10/18 00:01
CRDT- 1985/10/18 00:00
PHST- 1985/10/18 00:00 [pubmed]
PHST- 1985/10/18 00:01 [medline]
PHST- 1985/10/18 00:00 [entrez]
AID - 0002-9343(85)90178-0 [pii]
AID - 10.1016/0002-9343(85)90178-0 [doi]
PST - ppublish
SO  - Am J Med. 1985 Oct 18;79(4B):28-32. doi: 10.1016/0002-9343(85)90178-0.

PMID- 3054094
OWN - NLM
STAT- MEDLINE
DCOM- 19881220
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 15
IP  - 8
DP  - 1988 Aug
TI  - Two double blind trials of diclofenac sodium with aspirin and with naproxen in 
      the treatment of patients with rheumatoid arthritis.
PG  - 1205-11
AB  - In 2 multicenter, double blind studies, the efficacy and safety of diclofenac, 
      150 mg/day, were compared with those of aspirin, 3.6 g/day, in 194 patients with 
      rheumatoid arthritis (RA) in Study 1 and with those of naproxen, 1000 mg/day, in 
      223 patients with RA in Study 2. After single blind, placebo washout periods of 2 
      days to 2 weeks, patients entered 12-week treatment periods in each study. In 
      both studies, diclofenac, aspirin, and naproxen produced statistically 
      significant improvement (p less than or equal to 0.01) from baseline in all 
      primary efficacy variables at each assessment visit. There were no significant 
      differences between treatments. In both studies, significantly fewer (p less than 
      or equal to 0.05) patients receiving diclofenac experienced adverse effects 
      compared to the aspirin and naproxen groups. Significantly fewer (p less than 
      0.05) patients in the diclofenac group compared to the aspirin group discontinued 
      the trial due to side effects (primarily tinnitus and deafness). In Study 2, 
      fewer patients in the diclofenac group discontinued the trial due to adverse 
      effects than in the naproxen group. In conclusion, diclofenac, aspirin, and 
      naproxen demonstrated similar efficacy; however, diclofenac was significantly 
      better tolerated than either aspirin or naproxen.
FAU - Kolodny, A L
AU  - Kolodny AL
AD  - Franklin Square Hospital Medical Center, Baltimore, MD.
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 144O8QL0L1 (Diclofenac)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Diclofenac/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Middle Aged
MH  - Naproxen/adverse effects/*therapeutic use
MH  - Nervous System Diseases/chemically induced
MH  - Severity of Illness Index
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1988 Aug;15(8):1205-11.

PMID- 8988091
OWN - NLM
STAT- MEDLINE
DCOM- 19970121
LR  - 20181130
IS  - 0022-3085 (Print)
IS  - 0022-3085 (Linking)
VI  - 86
IP  - 1
DP  - 1997 Jan
TI  - Effect of hemodilution with diaspirin cross-linked hemoglobin on intracranial 
      pressure, cerebral perfusion pressure, and fluid requirements after head injury 
      and shock.
PG  - 131-8
AB  - Hemodilution has been shown to increase cerebral blood flow (CBF) and reduce 
      lesion volume in models of occlusive cerebral ischemia, but it has not been 
      evaluated in the setting of head trauma and shock in which ischemia is thought to 
      play a role in the evolution of secondary injury. In a porcine model of brain 
      injury and shock the authors compared hemodilution with diaspirin cross-linked 
      hemoglobin (DCLHb) to a standard resuscitation regimen using Ringer's lactate 
      solution and shed blood. After creation of a cryogenic brain injury followed by 
      hemorrhage, the animals received a bolus of either 4 ml/kg of Ringer's lactate 
      solution (Group 1, six animals) or DCLHb (Group 2, six animals), followed by 
      infusion of Ringer's lactate solution to restore mean arterial pressure (MAP) to 
      baseline. Group 1 received shed blood 1 hour after hemorrhage (R1) in the form of 
      packed red blood cells. Group 2 received shed blood only for an Hb count of less 
      than 5 g/dl. The animals were monitored for 24 hours. At R1, Group 2 had a 
      significantly greater cerebral perfusion pressure ([CPP] 88 +/- 5.7 vs. 68 +/- 
      2.4 mm Hg, p < 0.05). By 3 hours after hemorrhage (R3) Group 2 had a 
      significantly lower Hb concentration (8.5 +/- 0.4 vs. 12.1 +/- 0.3 g/dl, p < 
      0.05) and a significantly lower intracranial pressure ([ICP] 9 +/- 0.8 vs. 14 +/- 
      0.6 mm Hg, p < 0.05). The total 24-hour fluid requirement was significantly less 
      in Group 2 (10,654 +/- 505 ml vs. 15,542 +/- 1094 ml, p < 0.05) There was no 
      difference between the groups regarding levels of regional CBF in the injured 
      hemisphere. Cerebral O2 delivery was not significantly different between groups 
      at any time. Lesion volume as determined at postmortem examination was not 
      significantly different between the groups. The increased MAP and CPP and lower 
      ICP observed in the Group 2 animals indicate that hemodilution with DCLHb may be 
      beneficial in the treatment of head injury and shock.
FAU - Chappell, J E
AU  - Chappell JE
AD  - Department of Surgery, College of Medicine, University of Vermont, Burlington, 
      USA.
FAU - Shackford, S R
AU  - Shackford SR
FAU - McBride, W J
AU  - McBride WJ
LA  - eng
GR  - P20-NS 30324-03/NS/NINDS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Neurosurg
JT  - Journal of neurosurgery
JID - 0253357
RN  - 0 (Hemoglobins)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Body Water/chemistry
MH  - Cardiac Output/drug effects/physiology
MH  - Central Venous Pressure/drug effects
MH  - Cerebral Cortex/chemistry
MH  - Cerebral Hemorrhage/physiopathology
MH  - Cerebrovascular Circulation/*drug effects
MH  - Craniocerebral Trauma/physiopathology/*therapy
MH  - Female
MH  - Hemodilution
MH  - Hemoglobins/analysis/pharmacology/*therapeutic use
MH  - Intracranial Pressure/*drug effects
MH  - Male
MH  - Oxygen/metabolism
MH  - Shock/physiopathology/*therapy
MH  - Sodium Chloride/administration & dosage
MH  - Swine
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.3171/jns.1997.86.1.0131 [doi]
PST - ppublish
SO  - J Neurosurg. 1997 Jan;86(1):131-8. doi: 10.3171/jns.1997.86.1.0131.

PMID- 3552360
OWN - NLM
STAT- MEDLINE
DCOM- 19870622
LR  - 20190510
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 41
IP  - 5
DP  - 1987 May
TI  - Fluradoline and aspirin for orthopedic postoperative pain.
PG  - 531-6
AB  - Fluradoline (150 or 300 mg), a novel tricyclic with both antidepressant and 
      analgesic properties in animals, was compared with aspirin, 650 mg, and placebo 
      when given orally for postoperative orthopedic pain in a double-blind, 
      single-dose, parallel-group study. Analgesic measurements were made by two 
      trained nurse observers using standard verbal rating and visual analogue scales. 
      Aspirin was statistically superior to placebo on all analgesic measures, 
      demonstrating assay sensitivity. Fluradoline, 300 mg, was distinguished from 
      placebo and fluradoline, 150 mg, but not from aspirin, 650 mg. Overall, 
      fluradoline, 300 mg, was equivalent to aspirin, 650 mg. Fluradoline, 300 mg, 
      produced a significant elevation in mood score. Neither aspirin, 650 mg, nor 
      fluradoline caused untoward side effects, but fluradoline, 300 mg, increased 
      blood pressure.
FAU - McQuay, H J
AU  - McQuay HJ
FAU - Carroll, D
AU  - Carroll D
FAU - Poppleton, P
AU  - Poppleton P
FAU - Summerfield, R J
AU  - Summerfield RJ
FAU - Moore, R A
AU  - Moore RA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Dibenzoxazepines)
RN  - R16CO5Y76E (Aspirin)
RN  - WEP02A9K8C (fluradoline)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dibenzoxazepines/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Orthopedics
MH  - Pain, Postoperative/*drug therapy
EDAT- 1987/05/01 00:00
MHDA- 1987/05/01 00:01
CRDT- 1987/05/01 00:00
PHST- 1987/05/01 00:00 [pubmed]
PHST- 1987/05/01 00:01 [medline]
PHST- 1987/05/01 00:00 [entrez]
AID - 0009-9236(87)90022-1 [pii]
AID - 10.1038/clpt.1987.68 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1987 May;41(5):531-6. doi: 10.1038/clpt.1987.68.

PMID- 19250138
OWN - NLM
STAT- MEDLINE
DCOM- 20090611
LR  - 20131121
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 34
IP  - 2
DP  - 2009 Apr
TI  - Gastrointestinal tolerability of aspirin and the choice of over-the-counter 
      analgesia for short-lasting acute pain.
PG  - 177-86
LID - 10.1111/j.1365-2710.2008.00989.x [doi]
AB  - RATIONALE: For the management of common disorders producing short-lasting pain, 
      there is very good evidence of the efficacy of aspirin. Yet paracetamol is often 
      preferred, despite that evidence of its efficacy is much less sound. The reason 
      for this appears to be a concern over gastrointestinal (GI) toxicity. If this 
      concern is misplaced, so may be the preference for paracetamol, with the 
      consequence of widespread sub-optimal treatment. Our purpose in this analysis of 
      pooled individual patient data from clinical studies of aspirin is to adduce the 
      evidence that will show whether or not this is so, for the benefit of consumers 
      and health-care professionals who advise them. METHODS: The frequencies of all 
      and GI adverse events (AEs) and adverse drug reactions (ADRs) were calculated 
      from the pooled individual patient data of nine similar randomized, double-blind, 
      placebo controlled clinical trials of single-doses of aspirin 1000 mg in the 
      treatment of acute migraine attacks, episodic tension-type headache and dental 
      pain. Absolute differences between active and placebo AE and ADR rates, and 
      numbers-needed-to-harm (NNH), were calculated. RESULTS: Of 2852 patients included 
      in the analysis, 1581 were treated with aspirin and 1271 with placebo. Reported 
      AE rates were 14.9% and 11.1% amongst patients allocated to aspirin and placebo 
      respectively (NNH: 26), with the GI system most frequently affected (aspirin: 
      5.9%; placebo: 3.5%; NNH: 42). Reported ADR rates were much lower (aspirin: 6.3%; 
      placebo: 3.9%; NNH: 42), especially for the GI system (aspirin: 3.1%; placebo: 
      2.0%; NNH: 91). Most of the AEs and ADRs were mild or moderate, and none was 
      serious. CONCLUSIONS: The GI ADR differences between aspirin and placebo are not 
      great enough to support decision choices for short-lasting acute pain based on 
      tolerability: these are better based on efficacy.
FAU - Steiner, T J
AU  - Steiner TJ
AD  - Division of Neuroscience and Mental Health, Imperial College London, London, UK. 
      t.steiner@imperial.ac.uk
FAU - Voelker, M
AU  - Voelker M
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Clin Pharm Ther. 2009 Jun;34(3):247-8. PMID: 19646072
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/*therapeutic use
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Nonprescription Drugs
MH  - Pain/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Young Adult
RF  - 28
EDAT- 2009/03/03 09:00
MHDA- 2009/06/12 09:00
CRDT- 2009/03/03 09:00
PHST- 2009/03/03 09:00 [entrez]
PHST- 2009/03/03 09:00 [pubmed]
PHST- 2009/06/12 09:00 [medline]
AID - JCP989 [pii]
AID - 10.1111/j.1365-2710.2008.00989.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2009 Apr;34(2):177-86. doi: 10.1111/j.1365-2710.2008.00989.x.

PMID- 25867761
OWN - NLM
STAT- MEDLINE
DCOM- 20150921
LR  - 20230216
IS  - 1530-0307 (Electronic)
IS  - 0023-6837 (Linking)
VI  - 95
IP  - 7
DP  - 2015 Jul
TI  - Aspirin blocks growth of breast tumor cells and tumor-initiating cells and 
      induces reprogramming factors of mesenchymal to epithelial transition.
PG  - 702-17
LID - 10.1038/labinvest.2015.49 [doi]
AB  - Acetylsalicylic acid (ASA), also known as aspirin, a classic, nonsteroidal, 
      anti-inflammatory drug (NSAID), is widely used to relieve minor aches and pains 
      and to reduce fever. Epidemiological studies and other experimental studies 
      suggest that ASA use reduces the risk of different cancers including breast 
      cancer (BC) and may be used as a chemopreventive agent against BC and other 
      cancers. These studies have raised the tempting possibility that ASA could serve 
      as a preventive medicine for BC. However, lack of in-depth knowledge of the 
      mechanism of action of ASA reshapes the debate of risk and benefit of using ASA 
      in prevention of BC. Our studies, using in vitro and in vivo tumor xenograft 
      models, show a strong beneficial effect of ASA in the prevention of breast 
      carcinogenesis. We find that ASA not only prevents breast tumor cell growth in 
      vitro and tumor growth in nude mice xenograft model through the induction of 
      apoptosis, but also significantly reduces the self-renewal capacity and growth of 
      breast tumor-initiating cells (BTICs)/breast cancer stem cells (BCSCs) and delays 
      the formation of a palpable tumor. Moreover, ASA regulates other 
      pathophysiological events in breast carcinogenesis, such as reprogramming the 
      mesenchymal to epithelial transition (MET) and delaying in vitro migration in BC 
      cells. The tumor growth-inhibitory and reprogramming roles of ASA could be 
      mediated through inhibition of TGF-β/SMAD4 signaling pathway that is associated 
      with growth, motility, invasion, and metastasis in advanced BCs. Collectively, 
      ASA has a therapeutic or preventive potential by attacking possible target such 
      as TGF-β in breast carcinogenesis.
FAU - Maity, Gargi
AU  - Maity G
AD  - 1] Cancer Research Unit, VA Medical Center, Kansas City, MO, USA [2] Department 
      of Pathology, University of Kansas Medical Center, Kansas City, KS, USA.
FAU - De, Archana
AU  - De A
AD  - Cancer Research Unit, VA Medical Center, Kansas City, MO, USA.
FAU - Das, Amlan
AU  - Das A
AD  - 1] Cancer Research Unit, VA Medical Center, Kansas City, MO, USA [2] Department 
      of Pathology, University of Kansas Medical Center, Kansas City, KS, USA.
FAU - Banerjee, Snigdha
AU  - Banerjee S
AD  - 1] Cancer Research Unit, VA Medical Center, Kansas City, MO, USA [2] Division of 
      Hematology and Oncology, Department of Internal Medicine, University of Kansas 
      Medical Center, Kansas City, KS, USA.
FAU - Sarkar, Sandipto
AU  - Sarkar S
AD  - 1] Cancer Research Unit, VA Medical Center, Kansas City, MO, USA [2] Department 
      of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, 
      KS, USA.
FAU - Banerjee, Sushanta K
AU  - Banerjee SK
AD  - 1] Cancer Research Unit, VA Medical Center, Kansas City, MO, USA [2] Department 
      of Pathology, University of Kansas Medical Center, Kansas City, KS, USA [3] 
      Division of Hematology and Oncology, Department of Internal Medicine, University 
      of Kansas Medical Center, Kansas City, KS, USA [4] Department of Anatomy and Cell 
      Biology, University of Kansas Medical Center, Kansas City, KS, USA.
LA  - eng
GR  - I01 BX001989/BX/BLRD VA/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20150413
PL  - United States
TA  - Lab Invest
JT  - Laboratory investigation; a journal of technical methods and pathology
JID - 0376617
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Transforming Growth Factor beta)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenocarcinoma/*drug therapy
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Breast Neoplasms/*drug therapy
MH  - Cell Movement/drug effects
MH  - Cell Survival/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Epithelial-Mesenchymal Transition/*drug effects
MH  - Female
MH  - Humans
MH  - MCF-7 Cells
MH  - Mice, Nude
MH  - Transforming Growth Factor beta/metabolism
MH  - Xenograft Model Antitumor Assays
EDAT- 2015/04/14 06:00
MHDA- 2015/09/22 06:00
CRDT- 2015/04/14 06:00
PHST- 2014/11/05 00:00 [received]
PHST- 2015/02/10 00:00 [revised]
PHST- 2015/02/16 00:00 [accepted]
PHST- 2015/04/14 06:00 [entrez]
PHST- 2015/04/14 06:00 [pubmed]
PHST- 2015/09/22 06:00 [medline]
AID - S0023-6837(22)02315-7 [pii]
AID - 10.1038/labinvest.2015.49 [doi]
PST - ppublish
SO  - Lab Invest. 2015 Jul;95(7):702-17. doi: 10.1038/labinvest.2015.49. Epub 2015 Apr 
      13.

PMID- 7215405
OWN - NLM
STAT- MEDLINE
DCOM- 19810613
LR  - 20181130
IS  - 0014-312X (Print)
IS  - 0014-312X (Linking)
VI  - 12
IP  - 5
DP  - 1980
TI  - Effect of aspirin on gastric acid secretion in the rat.
PG  - 326-32
AB  - The effects of aspirin on gastric acid and sodium have been studied in a perfused 
      rat stomach preparation. In the pentagastrin-stimulated stomach, as intraluminal 
      aspirin concentration increased, there was a significant fall in acid output 
      together with a significant decrease in the loss of sodium from the gastric 
      lumen. It was concluded that these observations were due to a back-diffusion 
      effect resulting from disruption of the gastric mucosal barrier rather than 
      parietal cell inhibition
FAU - Galal, S
AU  - Galal S
FAU - Lewin, M R
AU  - Lewin MR
FAU - Clark, C G
AU  - Clark CG
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Eur Surg Res
JT  - European surgical research. Europaische chirurgische Forschung. Recherches 
      chirurgicales europeennes
JID - 0174752
RN  - 0 (Bile Acids and Salts)
RN  - 9NEZ333N27 (Sodium)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bile Acids and Salts/physiology
MH  - Diffusion
MH  - Female
MH  - Gastric Acid/*metabolism
MH  - Gastric Mucosa/drug effects
MH  - Glucose/pharmacology
MH  - Hydrogen-Ion Concentration
MH  - Rats
MH  - Sodium/physiology
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1159/000128138 [doi]
PST - ppublish
SO  - Eur Surg Res. 1980;12(5):326-32. doi: 10.1159/000128138.

PMID- 28936577
OWN - NLM
STAT- MEDLINE
DCOM- 20181003
LR  - 20190318
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 24
IP  - 33
DP  - 2017 Nov
TI  - Highly efficient electro-oxidation catalyst under ultra-low voltage for 
      degradation of aspirin.
PG  - 25881-25888
LID - 10.1007/s11356-017-0207-8 [doi]
AB  - A novel cryptomelane-Ir (cry-Ir) electrode is prepared for Ir to enter into the 
      cryptomelane (named as cry-Mn) structure and used for aspirin degradation. This 
      catalyst can efficiently reduce the Ir usage from 85 to 34%. Also, the onset 
      potential of cry-Ir is about 1.40 V and the over potential is about 0.34 V at 
      10 mA cm(-2), indicating that cry-Ir has an excellent oxygen evolution reaction 
      (OER) activity to produce oxidizing species and can decrease electrolytic voltage 
      during the electro-oxidation process. So, the electrical efficiency per log order 
      (EE/O) for cry-Ir electrode is only 5% of PbO(2) electrode, which is the best 
      electrode for organic degradation. Also, cry-Ir has large tunnel size which 
      favors insertion of aspirin molecule into cry-Ir structure and enhances the 
      contact between reactive intermediates and the contaminant. Using cry-Ir as 
      anode, 100% aspirin removal and 55% chemical oxygen demand (COD) removal could be 
      obtained at 4 V. We also compare cry-Ir electrode with IrO(2) and find that 
      IrO(2) anode can only eliminate 20% aspirin under the same condition. As a 
      result, cry-Ir is a promising anode material for organic pollutant degradation. 
      Graphical abstract Aspirin removal after 4h under different voltages. Aspirin 
      removal on IrO(2)/Ti-f and cry-Ir/Ti-f after 4h.
FAU - Kang, Xiaolei
AU  - Kang X
AD  - School of Resources and Environmental Engineering, State Environmental Protection 
      Key Laboratory of Environmental Risk Assessment and Control on Chemical Process, 
      East China University of Science and Technology, Shanghai, 200237, People's 
      Republic of China.
FAU - Sun, Wei
AU  - Sun W
AD  - School of Resources and Environmental Engineering, State Environmental Protection 
      Key Laboratory of Environmental Risk Assessment and Control on Chemical Process, 
      East China University of Science and Technology, Shanghai, 200237, People's 
      Republic of China.
FAU - Cao, Limei
AU  - Cao L
AD  - School of Resources and Environmental Engineering, State Environmental Protection 
      Key Laboratory of Environmental Risk Assessment and Control on Chemical Process, 
      East China University of Science and Technology, Shanghai, 200237, People's 
      Republic of China.
FAU - Yang, Ji
AU  - Yang J
AD  - School of Resources and Environmental Engineering, State Environmental Protection 
      Key Laboratory of Environmental Risk Assessment and Control on Chemical Process, 
      East China University of Science and Technology, Shanghai, 200237, People's 
      Republic of China. yangji@ecust.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20170922
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Manganese Compounds)
RN  - 0 (Minerals)
RN  - 0 (Oxides)
RN  - 0 (Water Pollutants, Chemical)
RN  - 12030-49-8 (iridium oxide)
RN  - 44448S9773 (Iridium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Catalysis
MH  - Electrochemical Techniques/*methods
MH  - Electrodes
MH  - Iridium/*chemistry
MH  - Manganese Compounds/*chemistry
MH  - Minerals/*chemistry
MH  - Oxidation-Reduction
MH  - Oxides/*chemistry
MH  - Water Pollutants, Chemical/*analysis
MH  - Water Purification/*methods
OTO - NOTNLM
OT  - Aspirin
OT  - Electrochemical oxidation
OT  - PPCPs
OT  - Tunnel structure
OT  - Wastewater treatment
EDAT- 2017/09/25 06:00
MHDA- 2018/10/04 06:00
CRDT- 2017/09/23 06:00
PHST- 2017/04/05 00:00 [received]
PHST- 2017/09/13 00:00 [accepted]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2018/10/04 06:00 [medline]
PHST- 2017/09/23 06:00 [entrez]
AID - 10.1007/s11356-017-0207-8 [pii]
AID - 10.1007/s11356-017-0207-8 [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2017 Nov;24(33):25881-25888. doi: 
      10.1007/s11356-017-0207-8. Epub 2017 Sep 22.

PMID- 11999816
OWN - NLM
STAT- MEDLINE
DCOM- 20020610
LR  - 20181130
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 84
IP  - 12
DP  - 2001 Dec
TI  - Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after 
      coronary stent implantation: 1 and 6-month follow-up.
PG  - 1701-7
AB  - BACKGROUND: Clopidogrel is a new thienopyridine derivative and has less serious 
      hematologic complications. We investigated the efficacy of clopidogrel plus 
      aspirin (CA) in stent thrombosis prevention compared with ticlopidine plus 
      aspirin (TA). METHOD AND RESULTS: Sixty-eight patients who underwent coronary 
      stenting were randomized into 2 groups: TA group, n = 31 and CA group, n = 37. At 
      1 month, there were 3 major bleeding complications, 2 in the CA group and 1 in 
      the TA group. Neither stent thrombosis nor hematologic events were found in both 
      groups. Two patients in the TA group died, 1 from sudden death and another from 
      tracheal stenosis. At 6 months, five patients developed in-stent restenosis, 4 in 
      the CA group and 1 in the TA group, p = NS. One patient in each group had acute 
      coronary syndrome. CONCLUSION: Clopidogrel plus aspirin is an effective coronary 
      stenting regimen comparable to ticlopidine plus aspirin.
FAU - Piamsomboon, C
AU  - Piamsomboon C
AD  - Department of Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand.
FAU - Laothavorn, P
AU  - Laothavorn P
FAU - Chatlaong, B
AU  - Chatlaong B
FAU - Saguanwong, S
AU  - Saguanwong S
FAU - Nasawadi, C
AU  - Nasawadi C
FAU - Tanprasert, P
AU  - Tanprasert P
FAU - Leelaprute, M
AU  - Leelaprute M
FAU - Intayakorn, U
AU  - Intayakorn U
FAU - Amornsak, N
AU  - Amornsak N
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Blood Vessel Prosthesis Implantation
MH  - Clopidogrel
MH  - Coronary Stenosis/*surgery
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - *Stents
MH  - Ticlopidine/administration & dosage/analogs & derivatives/*therapeutic use
MH  - Time Factors
EDAT- 2002/05/10 10:00
MHDA- 2002/06/11 10:01
CRDT- 2002/05/10 10:00
PHST- 2002/05/10 10:00 [pubmed]
PHST- 2002/06/11 10:01 [medline]
PHST- 2002/05/10 10:00 [entrez]
PST - ppublish
SO  - J Med Assoc Thai. 2001 Dec;84(12):1701-7.

PMID- 12586492
OWN - NLM
STAT- MEDLINE
DCOM- 20030502
LR  - 20220316
IS  - 0378-4320 (Print)
IS  - 0378-4320 (Linking)
VI  - 76
IP  - 3-4
DP  - 2003 Apr 15
TI  - Effects of acetylsalicylic acid and metamizol on hyaluronidase activity and sperm 
      characteristics in rams.
PG  - 195-204
AB  - The effects of acetylsalicylic acid and metamizol on hyaluronidase activity of 
      semen and sperm characteristics in rams were investigated. Acetylsalicylic acid 
      and metamizol at the doses of 75 and 50 mg/kg were administered to the rams, 
      respectively and then semen samples were taken at 1, 2, 4, 24, 48, 96, 120 and 
      144 h. The hyaluronidase activities of semen in rams treated with acetylsalicylic 
      acid and metamizol were determined to increase significantly (P<0.001) when 
      compared with control groups at all times. Additionally, the spermatozoa 
      motilities in both groups were measured to increase significantly (P<0.05) when 
      compared with control group. Furthermore, there were significant (P<0.01, <0.05) 
      decreases in the sperm concentrations and semen volumes of rams treated with 
      acetylsalicylic acid and metamizol at all times, respectively. In conclusion, 
      although the use of acetylsalicylic acid and metamizol cause an increase in the 
      hyaluronidase activities and spermatozoa motilities, these drugs decrease the 
      sperm concentrations and semen volumes along 6 days. For these reason, the use of 
      these drugs in breeding rams during ramming season is not suitable.
FAU - Tanyildizi, S
AU  - Tanyildizi S
AD  - Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Firat 
      University, 23119, Elazig, Turkey. stanyildizi@hotmail.com
FAU - Bozkurt, T
AU  - Bozkurt T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Anim Reprod Sci
JT  - Animal reproduction science
JID - 7807205
RN  - 6429L0L52Y (Dipyrone)
RN  - EC 3.2.1.35 (Hyaluronoglucosaminidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Breeding
MH  - Dipyrone/administration & dosage/*pharmacology
MH  - Hyaluronoglucosaminidase/*metabolism
MH  - Male
MH  - Semen/*drug effects/enzymology
MH  - Sheep/*physiology
MH  - Sperm Count
MH  - Sperm Motility/drug effects
MH  - Spermatozoa/*drug effects/physiology
EDAT- 2003/02/15 04:00
MHDA- 2003/05/03 05:00
CRDT- 2003/02/15 04:00
PHST- 2003/02/15 04:00 [pubmed]
PHST- 2003/05/03 05:00 [medline]
PHST- 2003/02/15 04:00 [entrez]
AID - S0378432003000022 [pii]
AID - 10.1016/s0378-4320(03)00002-2 [doi]
PST - ppublish
SO  - Anim Reprod Sci. 2003 Apr 15;76(3-4):195-204. doi: 10.1016/s0378-4320(03)00002-2.

PMID- 2090335
OWN - NLM
STAT- MEDLINE
DCOM- 19910605
LR  - 20161013
IS  - 0008-4182 (Print)
IS  - 0008-4182 (Linking)
VI  - 25
IP  - 7
DP  - 1990 Dec
TI  - Effect of antiplatelet drug therapy on the retinal vascular pattern in 
      experimental diabetes mellitus.
PG  - 329-32
AB  - We performed a study to evaluate the effect of acetylsalicylic acid (ASA) plus 
      dipyridamole on the retinal vascular pattern over 3 months in rats with 
      experimental diabetes mellitus. Rats treated with ASA alone showed a continuous 
      vascular bed and less tortuous vessels than untreated diabetic rats. Rats treated 
      with ASA plus dipyridamole showed a continuous vascular bed, scarce tortuous 
      vessels and vascular diameters similar to those in nondiabetic control rats. The 
      findings were related to aortic prostacyclin production: treatment with ASA alone 
      produced a reduction in prostacyclin production, whereas treatment with ASA plus 
      dipyridamole resulted in normal prostacyclin production. ASA alone or with 
      dipyridamole inhibited collagen-induced aggregation in whole blood by 57% 
      compared with the untreated diabetic rats.
FAU - de la Cruz, J P
AU  - de la Cruz JP
AD  - Department of Pharmacology and Therapeutics, School of Medicine, University of 
      Málaga, Spain.
FAU - Moreno, A
AU  - Moreno A
FAU - Sanchez de la Cuesta, F
AU  - Sanchez de la Cuesta F
FAU - García Campos, J
AU  - García Campos J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Can J Ophthalmol
JT  - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
JID - 0045312
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9007-34-5 (Collagen)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Collagen/pharmacology
MH  - Diabetes Mellitus, Experimental/*drug therapy
MH  - Diabetic Angiopathies/drug therapy
MH  - Dipyridamole/pharmacology/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Epoprostenol/metabolism
MH  - Male
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Retinal Vessels/*drug effects/pathology
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
PST - ppublish
SO  - Can J Ophthalmol. 1990 Dec;25(7):329-32.

PMID- 7478432
OWN - NLM
STAT- MEDLINE
DCOM- 19951205
LR  - 20180216
IS  - 0030-2414 (Print)
IS  - 0030-2414 (Linking)
VI  - 52
IP  - 6
DP  - 1995 Nov-Dec
TI  - Influence of acetylsalicylic acid and metabolites on DU-145 prostatic cancer cell 
      proliferation.
PG  - 465-9
AB  - Conflicting reports have been published on the anti-tumour activities of 
      acetylsalicylic acid in various cancers. Therefore, the effect of acetylsalicylic 
      acid and its major metabolites has been studied on human prostatic carcinoma 
      DU-145 cells. Investigations concentrated on the influence of acetylsalicylic 
      acid, salicylic acid and salicyluric acid, on cell proliferation, DNA- and 
      protein synthesis of DU-145 cells. DNA and protein synthesis determinations were 
      done in vitro by [3H]thymidine and [3H]glycine incorporation, respectively. No 
      effect on cell plating efficiency was observed, however proliferation studies 
      showed that acetylsalicylic acid and salicylic acid inhibited cell growth (10 mM, 
      100% inhibition). No significant effect on cell proliferation was ascertained 
      with salicyluric acid. Both DNA and protein synthesis were 40% inhibited by 0.1 
      mM acetylsalicylic acid. This study demonstrates that acetylsalicylic acid 
      exhibits a significant influence on cell growth of prostatic DU-145 cells. These 
      preliminary results may contribute to a better understanding of the anti-tumour 
      capabilities of acetylsalicylic acid.
FAU - Viljoen, T C
AU  - Viljoen TC
AD  - Department of Urology, HF Verwoerd Hospital, Pretoria, South Africa.
FAU - van Aswegen, C H
AU  - van Aswegen CH
FAU - du Plessis, D J
AU  - du Plessis DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism/*pharmacology
MH  - Cell Division/drug effects
MH  - Cell Survival/drug effects
MH  - DNA, Neoplasm/drug effects
MH  - Drug Screening Assays, Antitumor
MH  - Hippurates/pharmacology
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/*drug therapy/pathology
MH  - Salicylates/pharmacology
MH  - Salicylic Acid
MH  - Tumor Cells, Cultured
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 10.1159/000227512 [doi]
PST - ppublish
SO  - Oncology. 1995 Nov-Dec;52(6):465-9. doi: 10.1159/000227512.

PMID- 1806270
OWN - NLM
STAT- MEDLINE
DCOM- 19920514
LR  - 20131121
IS  - 0069-2328 (Print)
IS  - 0069-2328 (Linking)
VI  - 46
IP  - 12
DP  - 1991 Dec
TI  - [Analgesics and antipyretics in pediatrics].
PG  - 547-8
AB  - We compared the most usual analgetics-antipyretics in pediatric indications, 
      especially paracetamol and acetylosalicylic acid. We watched the effectivity and 
      side effects of both substances according to literature.
FAU - Hornová, J
AU  - Hornová J
AD  - L. Merckle Gesm. b.H., Víden.
FAU - Rettinger, H
AU  - Rettinger H
LA  - cze
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Analgetika-antipyretika v pediatrických indikacích.
PL  - Czech Republic
TA  - Cesk Pediatr
JT  - Ceskoslovenska pediatrie
JID - 0403576
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/therapeutic use
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Child
MH  - Humans
MH  - Phenacetin/therapeutic use
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
PST - ppublish
SO  - Cesk Pediatr. 1991 Dec;46(12):547-8.

PMID- 10342139
OWN - NLM
STAT- MEDLINE
DCOM- 19990706
LR  - 20131121
IS  - 0914-5087 (Print)
IS  - 0914-5087 (Linking)
VI  - 33 Suppl 1
DP  - 1999 Mar
TI  - [Frontiers in prevention of thromboembolism in nonvalvular atrial fibrillation].
PG  - 65-70
AB  - Atrial fibrillation, which has age-dependent exponentially rising high 
      prevalence, is now well known to frequently predispose to systemic 
      thromboembolism. In the past decade, several large-scale clinical randomized 
      trials for prevention of thromboembolism in nonrheumatic atrial fibrillation have 
      been performed for its primary and secondary preventions. The first five major 
      trials (AFASAK, BAATAF, SPAF-I, CAFA, SPINAF) for primary prevention of stroke 
      have demonstrated a significant risk reduction (68%) for stroke on oral 
      anticoagulation without any significant increase in major hemorrhage. On the 
      other hand, although AFASAK and SPAF I showed controversial results for 
      comparison of aspirin and control, the collaborative analysis revealed a 
      significant risk reduction (36%). In their analysis of risk factors for stroke, 
      prior stroke, diabetes mellitus, and hypertension have been stressed as high risk 
      factors. Recently, some additional trials have been done concerning secondary 
      prophylaxis, primary prevention in high risk patients, the optimal dose of 
      warfarin, the role of aspirin and so on. In EAFT, a secondary prevention trial, 
      warfarin has reduced (66%) stroke from 12%/yr to 4%/yr, while aspirin alone to 
      10%/yr. In SPAF III, it has been reported that adjusted-dose warfarin with target 
      INR2.0 to 3.0 is effective and safe in high risk patients. However, SPAF II 
      showed that warfarin was not useful in elder patients (75yr <) because of an 
      increase in hemorrhage. That may be why warfarin was still underused (40% >). 
      Anyway, it is of importance to think about the strategy for prevention on the 
      individual level of patients with atrial fibrillation, taking into consideration 
      echocardiographical and hematological data besides clinical risk factors.
FAU - Fukunami, M
AU  - Fukunami M
AD  - Department of Cardiology, Osaka Prefectural General Hospital.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Thromboembolism/*prevention & control
MH  - Warfarin/therapeutic use
RF  - 21
EDAT- 1999/05/26 00:00
MHDA- 1999/05/26 00:01
CRDT- 1999/05/26 00:00
PHST- 1999/05/26 00:00 [pubmed]
PHST- 1999/05/26 00:01 [medline]
PHST- 1999/05/26 00:00 [entrez]
PST - ppublish
SO  - J Cardiol. 1999 Mar;33 Suppl 1:65-70.

PMID- 21125740
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20131121
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 63
IP  - 3
DP  - 2010
TI  - [Resistance to aspirin in secondary stroke prevention. A pilot study].
PG  - 171-9
AB  - INTRODUCTION: The purpose of the study was to establish the frequency of aspirin 
      resistance in patients treated in the Department of Neurology in Zabrze with 
      diagnosed transient ischaemic attack (TIA) or ischaemic stroke who used aspirin 
      in the dose of 150 mg daily. MATERIAL AND METHODS: We examined 20 patients (14 
      female, 6 male), the mean age 66.8 +/- 11.1. The assessment of platelets' 
      function was performed by Platelet Function Analyzer-100 (PFA-100) and optical 
      aggregometry by Born. The examinations were done three times: in the acute phase, 
      after 6 +/- 1 months and after 12 +/- 1 months. RESULTS: In the successive exams 
      by PFA-100 following frequencies of aspirin resistance were observed: 0% (I), 
      37.5% (II), 23% (III). We found no correlation between results obtained by 
      PFA-100 and optical aggregometry. Also no correlation was observed between 
      aspirin resistance and age, sex, degree of motor incapability, total cholesterol, 
      LDL, HDL, triglycerides and other drugs. CONCLUSIONS: Some patients treated with 
      aspirin develop aspirin resistance. Sometimes the increase of aspirin dose 
      results in antiplatelet state again. No consistency between results of both 
      applied methods could be a consequence of heterogenity of the phenomenon of 
      aspirin resistace, and indicates that laboratory method should carefully be 
      chosen in purpose to monitoring antiplatelet therapy in prevention of vascular 
      diseases. This was a pilot study and it will be continued in purpose to increase 
      the examined group and prolong time of observation.
FAU - Łabuz-Roszak, Beata
AU  - Łabuz-Roszak B
AD  - Katedra i Klinika Neurologii w Zabrzu SUM w Katowicach. beatamaria.pl@hoga.pl
FAU - Pierzhała, Porosińska Aleksandra
AU  - Pierzhała PA
FAU - Trautsolt, Wanda
AU  - Trautsolt W
FAU - Kumor, Klaudiusz
AU  - Kumor K
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Oporność na kwas acetylosalicylowy stosowany w prewencji wtórnej udaru mózgu. 
      badanie pilotazowe.
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Drug Monitoring
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Secondary Prevention
MH  - Stroke/*prevention & control
EDAT- 2010/12/04 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/12/04 06:00
PHST- 2010/12/04 06:00 [entrez]
PHST- 2010/12/04 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Wiad Lek. 2010;63(3):171-9.

PMID- 7877232
OWN - NLM
STAT- MEDLINE
DCOM- 19950406
LR  - 20190821
IS  - 0741-5214 (Print)
IS  - 0741-5214 (Linking)
VI  - 21
IP  - 3
DP  - 1995 Mar
TI  - Inhibition of platelet deposition by combined hirulog and aspirin in a rat 
      carotid endarterectomy model.
PG  - 492-8
AB  - PURPOSE: Hirulog, a thrombin-specific inhibitor, has shown efficacy in reducing 
      arterial thrombosis in patients treated with aspirin who require angioplasty or 
      have unstable angina. In this study, the effect of hirulog on reducing deposition 
      of indium 111-labeled platelets was assessed in a surgical model of 
      aspirin-treated rats undergoing carotid endarterectomy. METHODS: Animals were 
      randomly assigned to one of five groups: control (no aspirin or hirulog); aspirin 
      alone (10 mg/kg); aspirin plus low-dose hirulog (0.2 mg/kg bolus followed by 0.5 
      mg/kg/hr); aspirin plus medium-dose hirulog (0.4 mg/kg bolus followed by 1.0 
      mg/kg/hr); or aspirin plus high-dose hirulog (0.6 mg/kg bolus followed by 1.5 
      mg/kg/hr). Hirulog was infused before surgery and continued until termination of 
      the experiment 30 minutes after endarterectomy. RESULTS: Platelet deposition in 
      rats receiving aspirin alone was reduced by 19% +/- 23% SE (p = 0.26) compared 
      with controls. Deposition in aspirin-treated groups receiving low-, medium-, and 
      high-dose hirulog decreased in a dose-dependent manner by 37% +/- 20% (p = 
      0.048), 44% +/- 19% (p = 0.061), and 56% +/- 13% (p = 0.022), respectively. As 
      the dose of hirulog was increased, the plasma hirulog levels and activated 
      partial thromboplastin time ratios (final:initial) also increased in a 
      dose-dependent manner. The mean plasma hirulog levels ranged from 0.74 +/- 0.08 
      micrograms/ml in the low-dose hirulog group to 2.55 +/- 0.08 micrograms/ml in the 
      high-dose hirulog group, and the corresponding activated partial thromboplastin 
      time ratios were 1.5 +/- 0.12 (p = 0.001) and 3.3 +/- 0.63 (p = 0.001). Bleeding 
      was easily controlled by local hemostatic measures for all experimental groups. 
      CONCLUSION: Hirulog causes significant decrease in 111In-labeled platelet 
      deposition in aspirin-treated rats subjected to microsurgical endarterectomy at 
      doses that allow surgical hemostasis to be easily established.
FAU - Hamelink, J K
AU  - Hamelink JK
AD  - Department of Hematology and Vascular Biology, Walter Reed Army Institute of 
      Research, Washington, D.C.
FAU - Tang, D B
AU  - Tang DB
FAU - Barr, C F
AU  - Barr CF
FAU - Jackson, M R
AU  - Jackson MR
FAU - Reid, T J
AU  - Reid TJ
FAU - Gomez, E R
AU  - Gomez ER
FAU - Alving, B M
AU  - Alving BM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - *Endarterectomy, Carotid
MH  - Hirudin Therapy
MH  - Hirudins/*analogs & derivatives/pharmacology
MH  - Male
MH  - Peptide Fragments/pharmacology/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Random Allocation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Recombinant Proteins/pharmacology/therapeutic use
MH  - Thrombin/*antagonists & inhibitors
MH  - Thrombosis/*prevention & control
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
AID - S0741-5214(95)70292-X [pii]
AID - 10.1016/s0741-5214(95)70292-x [doi]
PST - ppublish
SO  - J Vasc Surg. 1995 Mar;21(3):492-8. doi: 10.1016/s0741-5214(95)70292-x.

PMID- 6665757
OWN - NLM
STAT- MEDLINE
DCOM- 19840323
LR  - 20141120
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 50
IP  - 4
DP  - 1983 Dec 30
TI  - A sex difference in the effect of aspirin on "spontaneous" platelet aggregation 
      in whole blood.
PG  - 773-4
AB  - Platelet aggregation can be measured in whole blood by monitoring the fall in 
      single platelet count in an electronic platelet counter. The aggregation that 
      occurs when whole blood is stirred in a small cuvette ("spontaneous aggregation") 
      or upon the addition of collagen has been studied in citrated whole blood from 
      male and female volunteers. Aspirin 40 micrograms ml/l inhibited aggregation 
      induced by collagen in both sexes but spontaneous aggregation was only affected 
      by aspirin in males. These results may help explain the sex difference apparent 
      in the results of some clinical trials of aspirin as an antithrombotic agent.
FAU - Harrison, M J
AU  - Harrison MJ
FAU - Weisblatt, E
AU  - Weisblatt E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Collagen/antagonists & inhibitors
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Count
MH  - Sex Factors
EDAT- 1983/12/30 00:00
MHDA- 1983/12/30 00:01
CRDT- 1983/12/30 00:00
PHST- 1983/12/30 00:00 [pubmed]
PHST- 1983/12/30 00:01 [medline]
PHST- 1983/12/30 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1983 Dec 30;50(4):773-4.

PMID- 1271387
OWN - NLM
STAT- MEDLINE
DCOM- 19760802
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 3
IP  - 1
DP  - 1976 Mar
TI  - Bleeding, salicylates, and prolonged prothrombin time: three case reports and a 
      review of the literature.
PG  - 37-42
AB  - Fourteen cases of ASA induced hypoprothrombinemic bleeding, including three 
      patients reported by the authors, are reviewed. Predisposing factors toward 
      bleeding include malnutrition and malabsorption syndrome. Although the bleeding 
      is usually benign, it may be serious on occasion. The importance of this rarely 
      considered cause of ASA associated bleeding lies in the fact that it is readily 
      corrected with Vitamin K.
FAU - Goldsweig, H G
AU  - Goldsweig HG
FAU - Kapusta, M
AU  - Kapusta M
FAU - Schwartz, J
AU  - Schwartz J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Epistaxis/chemically induced
MH  - Female
MH  - Humans
MH  - Hypoprothrombinemias/*chemically induced/drug therapy
MH  - Malabsorption Syndromes/complications
MH  - Male
MH  - Middle Aged
MH  - Nutrition Disorders/complications
MH  - Vitamin K/therapeutic use
EDAT- 1976/03/01 00:00
MHDA- 1976/03/01 00:01
CRDT- 1976/03/01 00:00
PHST- 1976/03/01 00:00 [pubmed]
PHST- 1976/03/01 00:01 [medline]
PHST- 1976/03/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1976 Mar;3(1):37-42.

PMID- 21481826
OWN - NLM
STAT- MEDLINE
DCOM- 20110810
LR  - 20220321
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 107
IP  - 12
DP  - 2011 Jun 15
TI  - Meta-analysis of multiple primary prevention trials of cardiovascular events 
      using aspirin.
PG  - 1796-801
LID - 10.1016/j.amjcard.2011.02.325 [doi]
AB  - Several meta-analyses have focused on determination of the effectiveness of 
      aspirin (acetylsalicylic acid) in primary prevention of cardiovascular (CV) 
      events. Despite these data, the role of aspirin in primary prevention continues 
      to be investigated. Nine randomized trials have evaluated the benefits of aspirin 
      for the primary prevention of CV events: the British Doctors' Trial (BMD), the 
      Physicians' Health Study (PHS), the Thrombosis Prevention Trial (TPT), the 
      Hypertension Optimal Treatment (HOT) study, the Primary Prevention Project (PPP), 
      the Women's Health Study (WHS), the Aspirin for Asymptomatic Atherosclerosis 
      Trial (AAAT), the Prevention of Progression of Arterial Disease and Diabetes 
      (POPADAD) trial, and the Japanese Primary Prevention of Atherosclerosis With 
      Aspirin for Diabetes (JPAD) trial. The combined sample consists of about 90,000 
      subjects divided approximately evenly between those taking aspirin and subjects 
      not taking aspirin or taking placebo. A meta-analysis of these 9 trials assessed 
      6 CV end points: total coronary heart disease, nonfatal myocardial infarction 
      (MI), total CV events, stroke, CV mortality, and all-cause mortality. No 
      covariate adjustment was performed, and appropriate tests for treatment effect, 
      heterogeneity, and study size bias were applied. The meta-analysis suggested 
      superiority of aspirin for total CV events and nonfatal MI, (p <0.05 for each), 
      with nonsignificant results for decreased risk for stroke, CV mortality, and 
      all-cause mortality. There was no evidence of a statistical bias (p >0.05). In 
      conclusion, aspirin decreased the risk for CV events and nonfatal MI in this 
      large sample. Thus, primary prevention with aspirin decreased the risk for total 
      CV events and nonfatal MI, but there were no significant differences in the 
      incidences of stroke, CV mortality, all-cause mortality and total coronary heart 
      disease.
CI  - Copyright © 2011 Elsevier Inc. All rights reserved.
FAU - Bartolucci, Alfred A
AU  - Bartolucci AA
AD  - Department of Biostatistics, School of Public Health, University of Alabama at 
      Birmingham, Birmingham, Alabama, USA. abartolucci@ms.soph.uab.edu
FAU - Tendera, Michal
AU  - Tendera M
FAU - Howard, George
AU  - Howard G
LA  - eng
GR  - G9534799/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20110408
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Am J Cardiol. 2011 Aug 15;108(4):615
CIN - Am J Cardiol. 2011 Oct 15;108(8):1198-200. PMID: 21985953
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Reduction Behavior
EDAT- 2011/04/13 06:00
MHDA- 2011/08/11 06:00
CRDT- 2011/04/13 06:00
PHST- 2010/12/14 00:00 [received]
PHST- 2011/02/12 00:00 [revised]
PHST- 2011/02/12 00:00 [accepted]
PHST- 2011/04/13 06:00 [entrez]
PHST- 2011/04/13 06:00 [pubmed]
PHST- 2011/08/11 06:00 [medline]
AID - S0002-9149(11)01013-7 [pii]
AID - 10.1016/j.amjcard.2011.02.325 [doi]
PST - ppublish
SO  - Am J Cardiol. 2011 Jun 15;107(12):1796-801. doi: 10.1016/j.amjcard.2011.02.325. 
      Epub 2011 Apr 8.

PMID- 2086017
OWN - NLM
STAT- MEDLINE
DCOM- 19910523
LR  - 20140226
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 29
IP  - 8
DP  - 1990 Aug
TI  - [Drug modulation of thromboxane A2/prostacyclin balance and lipid peroxidation in 
      patients with coronary artery disease].
PG  - 476-8, 510-1
AB  - Sixty patients with coronary artery disease (CAD) were investigated in a 
      randomized, placebo-controlled study. Therapeutic dose of diltiazem markedly 
      inhibited the production of whole blood thromboxane A2(TXA2), but had no effect 
      on the production of prostacyclin(PGI2). Both aspirin 20mg/d and diltiazem plus 
      aspirin had marked inhibitive effects on both TXA2 and PGI2. The order of potency 
      of the three regimens in decreasing TXA2/PGI2 ratio was diltiazem plus aspirin 
      greater than diltiazem greater than aspirin. Diltiazem, aspirin and combination 
      of both all decreased significantly serum lipid peroxides level, but had no 
      effect on serum superoxide dismutase concentration. The results indicate that 
      both therapeutic dose of diltiazem and low-dose of aspirin may modulate TXA2/PGI2 
      balance and inhibit lipid peroxidation in CAD and that the combination of both 
      drugs may result in best therapeutic effect.
FAU - Zhao, X
AU  - Zhao X
AD  - Department of Cardiology, First Teaching Hospital, Third Military Medical 
      College, Chongqing.
FAU - Zhang, Y H
AU  - Zhang YH
FAU - Feng, H F
AU  - Feng HF
LA  - chi
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - EE92BBP03H (Diltiazem)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Coronary Disease/blood/*drug therapy
MH  - Diltiazem/administration & dosage/*therapeutic use
MH  - Epoprostenol/*blood
MH  - Female
MH  - Humans
MH  - Lipid Peroxidation
MH  - Male
MH  - Middle Aged
MH  - Superoxide Dismutase/blood
MH  - Thromboxane A2/*blood
EDAT- 1990/08/01 00:00
MHDA- 1990/08/01 00:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 1990/08/01 00:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 1990 Aug;29(8):476-8, 510-1.

PMID- 35351031
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20220405
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Mar 29
TI  - IVF/ICSI outcomes of euthyroid infertile women with thyroid autoimmunity: does 
      treatment with aspirin plus prednisone matter?
PG  - 263
LID - 10.1186/s12884-022-04532-2 [doi]
LID - 263
AB  - BACKGROUND: Thyroid autoimmunity (TAI) has been demonstrated to be associated 
      with adverse pregnancy including recurrent miscarriage, unexplained infertility, 
      and implantation failure. To settle with the fertility problem, prescribing 
      aspirin combined with prednisone (P + A) to women positive for anti-thyroid 
      antibodies is frequent in clinical practice, but the underlying effect remains 
      controversial. METHODS: A multicenter, retrospective study was conducted in three 
      reproductive centers from 2017 to 2020. A total of 494 euthyroid infertile women 
      were recruited who were positive for anti-thyroperoxidase and/or thyroglobulin 
      antibodies (TPOAb and TgAb, respectively) with thyroid-stimulating hormone (TSH) 
      levels ranging 0.35-4.0mIU/L and underwent their first in vitro fertilization and 
      embryo transfer (IVF-ET) cycle. Ultimately, 346 women were included of which 150 
      women were treated with prednisone (10 mg/d) and aspirin (100 mg/d). The 
      remaining 196 women were untreated (control group). Treatment started on the day 
      of embryo transfer and continued until clinical pregnancy was determined. 
      RESULTS: The clinical pregnancy rate was 57.5% vs. 63.5% in the control and 
      treated groups (P = 0.414) for first fresh embryo transfer cycles and 57.8% vs. 
      61.8% for frozen-thawed embryo transfer cycles (P = 0.606). In addition, the live 
      birth rate for the fresh embryo transfer was 49.6% vs. 47.3% in the control and 
      treated groups (P = 0.762). Logistic regression revealed that aspirin plus 
      prednisone did not improve the clinical pregnancy rate or miscarriage rate. 
      Furthermore, it was observed that low free triiodothyronine (FT3) was associated 
      with high miscarriage rates. CONCLUSIONS: Utilizing an adjuvant treatment of 
      P + A after the embryo transfer may not be necessary in euthyroid women with 
      thyroid autoimmunity undergoing their first IVF-ET, regardless of the embryo type 
      (fresh or frozen).
CI  - © 2022. The Author(s).
FAU - Zhou, Ping
AU  - Zhou P
AD  - Second Affiliated Hospital, School of Medicine, Zhejiang University, 310052, 
      Hangzhou, Zhejiang Province, P.R. China.
FAU - Yao, Qiuping
AU  - Yao Q
AD  - Second Affiliated Hospital, School of Medicine, Zhejiang University, 310052, 
      Hangzhou, Zhejiang Province, P.R. China.
AD  - Jiaxing Maternity and Child Health Care Hospital, Zhejiang Province, 314051, 
      Jiaxing, P.R. China.
FAU - Zhao, Qiaohang
AU  - Zhao Q
AD  - Second Affiliated Hospital, School of Medicine, Zhejiang University, 310052, 
      Hangzhou, Zhejiang Province, P.R. China.
FAU - Yang, Lihua
AU  - Yang L
AD  - Jinhua People's Hospital, 321000, Jinhua, Zhejiang Province, P.R. China.
FAU - Yu, Ya
AU  - Yu Y
AD  - Second Affiliated Hospital, School of Medicine, Zhejiang University, 310052, 
      Hangzhou, Zhejiang Province, P.R. China.
FAU - Xie, Jilai
AU  - Xie J
AD  - Second Affiliated Hospital, School of Medicine, Zhejiang University, 310052, 
      Hangzhou, Zhejiang Province, P.R. China.
FAU - Feng, Chun
AU  - Feng C
AD  - Second Affiliated Hospital, School of Medicine, Zhejiang University, 310052, 
      Hangzhou, Zhejiang Province, P.R. China.
FAU - Zhou, Liming
AU  - Zhou L
AD  - Ningbo Women and Children's Hospital, 315000, Ningbo, Zhejiang Province, P.R. 
      China. zhou.li.ming@163.com.
FAU - Jin, Min
AU  - Jin M
AD  - Second Affiliated Hospital, School of Medicine, Zhejiang University, 310052, 
      Hangzhou, Zhejiang Province, P.R. China. min_jin@zju.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20220329
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Autoimmunity
MH  - Female
MH  - Fertilization in Vitro
MH  - Humans
MH  - *Infertility, Female/therapy
MH  - Prednisone/therapeutic use
MH  - Pregnancy
MH  - Retrospective Studies
MH  - Sperm Injections, Intracytoplasmic
MH  - Thyroid Gland
PMC - PMC8966173
OTO - NOTNLM
OT  - Aspirin
OT  - Autoimmune
OT  - Prednisolone
OT  - Thyroiditis
OT  - fertilizationin vitro
COIS- The authors declare that there is no conflict of interest regarding the 
      publication of this article.
EDAT- 2022/03/31 06:00
MHDA- 2022/04/05 06:00
CRDT- 2022/03/30 05:36
PHST- 2021/11/11 00:00 [received]
PHST- 2022/03/02 00:00 [accepted]
PHST- 2022/03/30 05:36 [entrez]
PHST- 2022/03/31 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
AID - 10.1186/s12884-022-04532-2 [pii]
AID - 4532 [pii]
AID - 10.1186/s12884-022-04532-2 [doi]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2022 Mar 29;22(1):263. doi: 10.1186/s12884-022-04532-2.

PMID- 17436199
OWN - NLM
STAT- MEDLINE
DCOM- 20071206
LR  - 20131121
IS  - 0172-4622 (Print)
IS  - 0172-4622 (Linking)
VI  - 28
IP  - 9
DP  - 2007 Sep
TI  - Effect of aspirin and ibuprofen on GI permeability during exercise.
PG  - 722-6
AB  - This study was conducted to determine the effects of aspirin or ibuprofen on 
      gastrointestinal permeability when combined with exercise. Eight runners 
      completed three 60 min treadmill runs at 70 % VO(2max). For 24 hours prior to 
      each run, subjects ingested aspirin (2 x 325 mg), ibuprofen (2 x 200 mg), or 
      placebo capsules every 6 hours. Immediately before each run, a solution 
      containing 5 g sucrose, 5 g lactulose, and 2 g rhamnose was ingested. Urine 
      produced during each run, and for 4 h afterwards was collected. Urinary excretion 
      of sucrose is an indicator of gastroduodenal permeability. The excretion ratio of 
      lactulose-to-rhamnose assesses small intestinal permeability. Sucrose excretion 
      (%) was greater (p < 0.017) for aspirin (0.37 [0.2 - 0.97]) compared to placebo 
      (0.09 [0.05 - 0.30]) or ibuprofen (0.22 [0.1 - 0.39]) and sucrose excretion for 
      ibuprofen was greater than placebo. The lactulose-to-rhamnose ratio was greater 
      for aspirin (0.09 [0.08 - 0.30]) than placebo (0.065 [0.04 - 0.08]) however 
      ibuprofen (0.08 [0.06 - 0.19]) was not different from aspirin or placebo. These 
      results indicate that with prolonged running, gastroduodenal permeability is 
      increased if aspirin or ibuprofen is used prior to such exercise. Furthermore, 
      aspirin promotes greater gastroduodenal permeability and also increases small 
      intestinal permeability.
FAU - Lambert, G P
AU  - Lambert GP
AD  - Department of Exercise Science and Athletic Training, Creighton University, 
      Omaha, United States. plambert@creigton.edu
FAU - Boylan, M
AU  - Boylan M
FAU - Laventure, J-P
AU  - Laventure JP
FAU - Bull, A
AU  - Bull A
FAU - Lanspa, S
AU  - Lanspa S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070413
PL  - Germany
TA  - Int J Sports Med
JT  - International journal of sports medicine
JID - 8008349
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Gastrointestinal Tract/*drug effects
MH  - Humans
MH  - Ibuprofen/*pharmacology
MH  - Male
MH  - Oxygen Consumption
MH  - Permeability/*drug effects
MH  - Prospective Studies
MH  - Running/*physiology
MH  - Time Factors
EDAT- 2007/04/17 09:00
MHDA- 2007/12/07 09:00
CRDT- 2007/04/17 09:00
PHST- 2007/04/17 09:00 [pubmed]
PHST- 2007/12/07 09:00 [medline]
PHST- 2007/04/17 09:00 [entrez]
AID - 10.1055/s-2007-964891 [doi]
PST - ppublish
SO  - Int J Sports Med. 2007 Sep;28(9):722-6. doi: 10.1055/s-2007-964891. Epub 2007 Apr 
      13.

PMID- 32989963
OWN - NLM
STAT- MEDLINE
DCOM- 20210907
LR  - 20210907
IS  - 1827-1618 (Electronic)
IS  - 0026-4725 (Linking)
VI  - 68
IP  - 5
DP  - 2020 Oct
TI  - Dual antiplatelet therapy duration after percutaneous coronary intervention with 
      drug-eluting stents: how short can we go?
PG  - 436-450
LID - 10.23736/S0026-4725.20.05196-8 [doi]
AB  - Current guidelines recommend a duration of dual antiplatelet therapy (DAPT) with 
      aspirin and oral P2Y<inf>12</inf> receptor inhibitors following percutaneous 
      coronary intervention (PCI) with second-generation drug-eluting stents (DES) of 6 
      months for most patients with stable coronary disease and of 12 months for most 
      patients with acute coronary syndromes. Large evidence from randomised clinical 
      trials of shorter DAPT regimens after PCI with newer-generation DES is now 
      emerging in heterogenous patient population not selected on the basis of high 
      bleeding risk as well as in patients at high bleeding risk. The scope of this 
      review is to provide an update on the benefits and harms of these short DAPT 
      regimens and to discuss future directions in DAPT strategies after PCI with newer 
      generation DES.
FAU - Roccasalva, Fausto
AU  - Roccasalva F
AD  - Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, 
      IRCCS, Rozzano, Milan, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, 
      Italy.
FAU - Ferrante, Giuseppe
AU  - Ferrante G
AD  - Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, 
      IRCCS, Rozzano, Milan, Italy - giu.ferrante@hotmail.it.
AD  - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200929
PL  - Italy
TA  - Minerva Cardioangiol
JT  - Minerva cardioangiologica
JID - 0400725
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Coronary Artery Disease/therapy
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists
MH  - Treatment Outcome
EDAT- 2020/09/30 06:00
MHDA- 2021/09/08 06:00
CRDT- 2020/09/29 05:49
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/09/08 06:00 [medline]
PHST- 2020/09/29 05:49 [entrez]
AID - S0026-4725.20.05196-8 [pii]
AID - 10.23736/S0026-4725.20.05196-8 [doi]
PST - ppublish
SO  - Minerva Cardioangiol. 2020 Oct;68(5):436-450. doi: 
      10.23736/S0026-4725.20.05196-8. Epub 2020 Sep 29.

PMID- 21061529
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - [Differential diagnosis of gastric ulcer and gastric cancer in elderly patients].
PG  - 2036-9
AB  - Along with the growing elderly population, patients with gastric ulcers caused by 
      low-dose aspirin have increased. Gastric cancer is also common among the elderly 
      population, but is sometimes difficult to distinguish from gastric ulcers, 
      especially those stemming from aspirin use. To differentiate the diagnostic 
      symptoms of gastric ulcers and gastric cancers in elderly patients, we compared 
      the endoscopic findings of 198 subjects (92 benign ulcers and 106 cancers) aged 
      65 years and older. Despite their benign nature, aspirin-induced ulcers tended to 
      have more irregularity of the ulcer edge and heterogeneous formation of 
      regenerating epithelium than ulcer unrelated to aspirin. Asking about the use of 
      low-dose aspirin is therefore important when confronted with such lesions in 
      elderly patients.
FAU - Iwaya, Yugo
AU  - Iwaya Y
AD  - Department of Gastroenterology, Shinshu University School of Medicine.
FAU - Akamatsu, Taiji
AU  - Akamatsu T
FAU - Ito, Tetsuya
AU  - Ito T
FAU - Nagaya, Tadanobu
AU  - Nagaya T
FAU - Suga, Tomoaki
AU  - Suga T
FAU - Arakura, Norikazu
AU  - Arakura N
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects
MH  - Diagnosis, Differential
MH  - Humans
MH  - Stomach Neoplasms/*pathology
MH  - Stomach Ulcer/*pathology
EDAT- 2010/11/11 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Nov;68(11):2036-9.

PMID- 17180149
OWN - NLM
STAT- MEDLINE
DCOM- 20070116
LR  - 20131121
IS  - 1743-4300 (Electronic)
IS  - 1743-4297 (Linking)
VI  - 4
IP  - 1
DP  - 2007 Jan
TI  - Drug insight: aspirin resistance--fact or fashion?
PG  - 42-50
AB  - The term aspirin resistance has been used increasingly in clinical studies. The 
      aim of this Review is to analyze the origin of this term, to discuss the 
      biochemical, functional and clinical correlates of the phenomenon and to offer a 
      conceptual framework to redefine the major determinants of variability between 
      individuals in response to aspirin. Awareness needs to be increased of factors 
      that might interfere with the desired antiplatelet effect of aspirin, 
      particularly in terms of patients' adherence to treatment and avoidable drug 
      interactions with some traditional NSAIDs. Gaining such knowledge could result in 
      improved care of patients and might avoid the requesting of unnecessary platelet 
      function tests of unproven clinical significance.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - University of Rome La Sapienza, Ospedale Sant'Andrea, Via di Grottarossa 1035, 
      00189 Rome, Italy. cpatrono@unich.it
FAU - Rocca, Bianca
AU  - Rocca B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Nat Clin Pract Cardiovasc Med
JT  - Nature clinical practice. Cardiovascular medicine
JID - 101226507
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Nat Clin Pract Cardiovasc Med. 2007 Mar;4(3):E1; author reply E2. PMID: 17330121
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/metabolism
MH  - Cardiovascular Diseases/prevention & control
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/*pharmacology/therapeutic use
MH  - Drug Interactions
MH  - *Drug Resistance
MH  - Humans
MH  - Patient Compliance
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Practice Guidelines as Topic
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Treatment Outcome
RF  - 46
EDAT- 2006/12/21 09:00
MHDA- 2007/01/17 09:00
CRDT- 2006/12/21 09:00
PHST- 2006/03/30 00:00 [received]
PHST- 2006/10/03 00:00 [accepted]
PHST- 2006/12/21 09:00 [pubmed]
PHST- 2007/01/17 09:00 [medline]
PHST- 2006/12/21 09:00 [entrez]
AID - ncpcardio0728 [pii]
AID - 10.1038/ncpcardio0728 [doi]
PST - ppublish
SO  - Nat Clin Pract Cardiovasc Med. 2007 Jan;4(1):42-50. doi: 10.1038/ncpcardio0728.

PMID- 7625094
OWN - NLM
STAT- MEDLINE
DCOM- 19950831
LR  - 20131121
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 84
IP  - 5
DP  - 1995 May
TI  - [Prevention of reinfarction with 100 mg or 30 mg ASS daily?].
PG  - 335-43
AB  - The prevention of heart infarction with 100 mg aspirin is common practice in 
      Germany, in spite of the fact that it is based on only two small studies, the 
      results of which are not generalized. Over 14 years, several experimental and 
      clinical studies have shown that 20-30 mg aspirin/d for pharmacokinetic reason 
      selectively inhibit the thromboxane synthesis while the endogenous prostacyclin 
      synthesis remains intact. Prostacyclin plays an important cardioprotective role 
      for the ischemic heart, having antiplatelet and antifibrillatory effects, 
      potentiates the antiplatelet effect of the nitrovasodilators and nitric oxide, 
      and increases the release of adenosine. A superior preventive action and lower 
      side effects of 30 mg/d aspirin in direct comparison with higher doses was first 
      proved by the Cottbus reinfarction study. The 30 mg aspirin tablet per day ought 
      to replace the present prevention with higher doses.
FAU - Förster, W
AU  - Förster W
AD  - Instituts für Pharmakologie und Toxikologie, Martin-Luther-Universität 
      Halle-Wittenberg, Halle.
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Reinfarktprophylaxe mit 100 mg oder 30 mg ASS täglich?
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - DCR9Z582X0 (Epoprostenol)
RN  - EC 5.3.99.5 (Thromboxane-A Synthase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Z Kardiol. 1995 May;84(5):344-7. PMID: 7625095
CIN - Z Kardiol. 1995 Jun;84(6):496-8. PMID: 7653091
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Epoprostenol/blood
MH  - Humans
MH  - Myocardial Infarction/enzymology/*prevention & control
MH  - Platelet Aggregation/drug effects
MH  - Recurrence
MH  - Thromboxane-A Synthase/antagonists & inhibitors
RF  - 64
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
PST - ppublish
SO  - Z Kardiol. 1995 May;84(5):335-43.

PMID- 6112387
OWN - NLM
STAT- MEDLINE
DCOM- 19810723
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 8227
DP  - 1981 May 2
TI  - Differential inhibition by low-dose aspirin of human venous prostacyclin 
      synthesis and platelet thromboxane synthesis.
PG  - 969-71
AB  - The capacity of venous tissue for prostacyclin synthesis was determined in 68 
      patients undergoing surgery for removal of varicose veins. A single dose of 
      aspirin (81 mg or 300 mg) taken 14 h preoperatively strongly inhibited its 
      synthesis, and the effect of 300 mg was still evident 48 h after ingestion. A 
      single dose of 40 mg aspirin taken 14 h preoperatively had no effect on 
      prostacyclin synthesis. The capacity of blood platelets to synthesise thromboxane 
      (measured as malondialdehyde) was determined in volunteers before and at various 
      times after ingestion of 300 mg or 40 mg aspirin. Both doses had an inhibitory 
      effect that lasted for at least 96 h. The length of time for which the amount of 
      thromboxane synthesised was insufficient to support platelet aggregation and the 
      platelet release reaction depended on both the donor and the dose of aspirin. If 
      prostacyclin and thromboxane are important in the pathogenesis of thrombosis, 
      then doses of aspirin much lower than those used previously should be tested. The 
      long-lasting effect of 300 mg aspirin on both venous tissue and platelets 
      indicates that this dose is unlikely to produce a favourable 
      prostacyclin/thromboxane balance.
FAU - Hanley, S P
AU  - Hanley SP
FAU - Bevan, J
AU  - Bevan J
FAU - Cockbill, S R
AU  - Cockbill SR
FAU - Heptinstall, S
AU  - Heptinstall S
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Prostaglandins)
RN  - 0 (Thromboxanes)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/*metabolism
MH  - Depression, Chemical
MH  - Epoprostenol/*biosynthesis
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandins/*biosynthesis
MH  - Thromboxane A2/*biosynthesis
MH  - Thromboxanes/*biosynthesis
MH  - Veins/drug effects/*metabolism
EDAT- 1981/05/02 00:00
MHDA- 1981/05/02 00:01
CRDT- 1981/05/02 00:00
PHST- 1981/05/02 00:00 [pubmed]
PHST- 1981/05/02 00:01 [medline]
PHST- 1981/05/02 00:00 [entrez]
AID - S0140-6736(81)91733-5 [pii]
AID - 10.1016/s0140-6736(81)91733-5 [doi]
PST - ppublish
SO  - Lancet. 1981 May 2;1(8227):969-71. doi: 10.1016/s0140-6736(81)91733-5.

PMID- 18413689
OWN - NLM
STAT- MEDLINE
DCOM- 20080617
LR  - 20181201
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 42
IP  - 6
DP  - 2008 Jun
TI  - Single antiplatelet therapy for patients with previous gastrointestinal bleeds.
PG  - 836-40
LID - 10.1345/aph.1K566 [doi]
AB  - OBJECTIVE: To determine whether aspirin plus a proton pump inhibitor (PPI) is 
      preferable, from a gastrointestinal bleed (GIB) risk perspective, to clopidogrel 
      in patients who have experienced a GIB while on aspirin and who require single 
      antiplatelet therapy for secondary prevention of cardiovascular disease. DATA 
      SOURCES: A literature search was conducted using EMBASE (1980-January 2008), 
      PubMed (1966-January 2008), Google, and a manual search of the reference lists 
      using the search terms gastrointestinal bleed, gastrointestinal hemorrhage, 
      peptic ulcer hemorrhage, ASA, aspirin, Plavix, clopidogrel, and PPI. The search, 
      limited to human and English studies, yielded 110 returns. STUDY SELECTION AND 
      DATA EXTRACTION: Randomized trials that compared aspirin with clopidogrel, 
      involved patients who had previously experienced a GIB, and provided detailed 
      information on the type and dose of drugs used were included. Studies were 
      required to provide information on the recurrence of GIB. DATA SYNTHESIS: Two 
      randomized trials were reviewed to assess the safety of secondary prevention of 
      cardiovascular disease with respect to previous GIB. These noninferiority trials 
      compared aspirin plus a PPI with clopidogrel over 12 months following confirmed 
      healing of an aspirin-induced ulcer. In both trials, the majority of the GIB 
      recurrences were in the clopidogrel group (8.6% vs 0.7%; difference 7.9%; 95% CI 
      3.4 to 12.4; p = 0.001 and 13.6% vs 0%; difference 13.6%; 95% CI 6.3 to 20.9; p = 
      0.0019) and the difference in recurrence rates exceeded the a priori selected 
      upper boundary. CONCLUSIONS: Findings reported in the limited literature 
      available support that clopidogrel is not equivalent to the combination of 
      aspirin plus a PPI in the patient population studied. Aspirin plus a PPI would be 
      considered clinically superior and should be used in medically managed patients 
      who require single antiplatelet therapy but have had a prior GIB while on 
      aspirin. Further research regarding dual antiplatelet therapy and a PPI is 
      required.
FAU - Gellatly, Rochelle M
AU  - Gellatly RM
AD  - Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, 
      British Columbia, Canada.
FAU - Ackman, Margaret L
AU  - Ackman ML
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20080415
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
EDAT- 2008/04/17 09:00
MHDA- 2008/06/18 09:00
CRDT- 2008/04/17 09:00
PHST- 2008/04/17 09:00 [pubmed]
PHST- 2008/06/18 09:00 [medline]
PHST- 2008/04/17 09:00 [entrez]
AID - aph.1K566 [pii]
AID - 10.1345/aph.1K566 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2008 Jun;42(6):836-40. doi: 10.1345/aph.1K566. Epub 2008 Apr 
      15.

PMID- 24613793
OWN - NLM
STAT- MEDLINE
DCOM- 20150202
LR  - 20140521
IS  - 1096-0260 (Electronic)
IS  - 0091-7435 (Linking)
VI  - 63
DP  - 2014 Jun
TI  - Regular use of aspirin for cardiovascular disease prevention in Italy.
PG  - 48-51
LID - S0091-7435(14)00091-7 [pii]
LID - 10.1016/j.ypmed.2014.03.005 [doi]
AB  - OBJECTIVE: Only a few European studies focused on aspirin use in the general 
      population. We provide updated information on the prevalence and determinants of 
      regular aspirin use for the prevention of cardiovascular disease (CVD) in the 
      Italian adult population. METHOD: We used data from a survey conducted in Italy 
      in 2013, on a sample of 3000 individuals, representative of the general Italian 
      population aged ≥15years. RESULTS: Overall, 10.9% of Italians reported a regular 
      use of aspirin, 11.2% of men and 10.5% of women. Aspirin use significantly 
      increased with age. The highest prevalence of aspirin use was observed among the 
      elderly (30.3%), ex-smokers (22.6%), and in individuals with a diagnosis of 
      diabetes (52.0%), hypertension (42.6%) or hypercholesterolemia (38.6%). After 
      adjustment for several covariates, no significant heterogeneity in aspirin use 
      was observed according to education, body mass index, and physical activity. Only 
      1.2% of low CVD risk individuals regularly used aspirin versus 48.3% of 
      individuals with high CVD risk. CONCLUSION: About 3.4million high CVD risk 
      Italians do not regularly use aspirin for primary or secondary prevention. Thus, 
      more widespread preventive strategy is recommended for this population, once 
      individual benefits of regular aspirin use exceed harms.
CI  - Copyright © 2014 Elsevier Inc. All rights reserved.
FAU - Lugo, Alessandra
AU  - Lugo A
AD  - Department of Epidemiology, IRCCS - Istituto di Ricerche Farmacologiche "Mario 
      Negri", Milan, Italy; Department of Clinical Sciences and Community Health, 
      Università degli Studi di Milano, Milan, Italy.
FAU - Asciutto, Rosario
AU  - Asciutto R
AD  - Department of Sciences for the Health Promotion and Mother and Child Care "G. 
      D'Alessandro", Hygiene Section, University of Palermo, Palermo, Italy.
FAU - Bosetti, Cristina
AU  - Bosetti C
AD  - Department of Epidemiology, IRCCS - Istituto di Ricerche Farmacologiche "Mario 
      Negri", Milan, Italy.
FAU - Parazzini, Fabio
AU  - Parazzini F
AD  - Department of Clinical Sciences and Community Health, Università degli Studi di 
      Milano, Milan, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - La Vecchia, Carlo
AU  - La Vecchia C
AD  - Department of Clinical Sciences and Community Health, Università degli Studi di 
      Milano, Milan, Italy.
FAU - Gallus, Silvano
AU  - Gallus S
AD  - Department of Epidemiology, IRCCS - Istituto di Ricerche Farmacologiche "Mario 
      Negri", Milan, Italy. Electronic address: silvano.gallus@marionegri.it.
LA  - eng
PT  - Journal Article
DEP - 20140307
PL  - United States
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Agents/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Italy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular risk
OT  - Diabetes
OT  - Hypercholesterolemia
OT  - Hypertension
OT  - Italy
OT  - Prevention
EDAT- 2014/03/13 06:00
MHDA- 2015/02/03 06:00
CRDT- 2014/03/12 06:00
PHST- 2013/11/28 00:00 [received]
PHST- 2014/02/25 00:00 [revised]
PHST- 2014/03/03 00:00 [accepted]
PHST- 2014/03/12 06:00 [entrez]
PHST- 2014/03/13 06:00 [pubmed]
PHST- 2015/02/03 06:00 [medline]
AID - S0091-7435(14)00091-7 [pii]
AID - 10.1016/j.ypmed.2014.03.005 [doi]
PST - ppublish
SO  - Prev Med. 2014 Jun;63:48-51. doi: 10.1016/j.ypmed.2014.03.005. Epub 2014 Mar 7.

PMID- 12885284
OWN - NLM
STAT- MEDLINE
DCOM- 20030925
LR  - 20210623
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 179
IP  - 3
DP  - 2003 Aug 4
TI  - Aspirin for cardiovascular disease prevention.
PG  - 147-52
AB  - SECONDARY PREVENTION: Aspirin provides benefit in nearly all groups of patients 
      with clinical manifestations of coronary heart disease. This includes patients 
      with evolving acute myocardial infarction or after recovery from myocardial 
      infarction, with unstable or stable angina, and those who undergo coronary artery 
      bypass grafting or coronary angioplasty. Aspirin provides benefit in patients 
      with peripheral arterial disease. This includes patients with acute or previous 
      history of ischaemic stroke or transient ischaemic attack, those with lower limb 
      arterial insufficiency, and those who undergo grafting or angioplasty of 
      peripheral arterial vessels. PRIMARY PREVENTION: People without symptoms but at 
      increased risk of a coronary heart disease event (> 1% annual risk) may reduce 
      this risk by taking low-dose aspirin. However, the decision to take aspirin 
      requires detailed consideration of individual cardiovascular risk and the 
      potential benefit versus harm of treatment, particularly bleeding. Aspirin should 
      only be used to prevent a cardiovascular event in association with an overall 
      program of lifestyle measures including healthy eating, cessation of smoking, 
      control of blood pressure and regular physical activity. ASPIRIN FOR PREVENTION: 
      Prevention benefits of aspirin in heart disease can be achieved with doses as low 
      as 75-150 mg daily. Unwanted effects of aspirin include stomach upsets, 
      activation of peptic ulcers, an increased tendency to bruising, allergic 
      reactions and increased risk of major gastrointestinal and other bleeding, 
      including intracranial haemorrhage. In general, the risk of bleeding increases 
      with increasing dose of aspirin and when it is used in combination with 
      non-steroidal anti-inflammatory drugs or oral anticoagulants.
FAU - Hung, Joseph
AU  - Hung J
AD  - School of Medicine and Pharmacology, University of Western Australia, Sir Charles 
      Gairdner Hospital, Perth, WA. jhung@cyllene.uwa.edu.au
CN  - Medical Issues Committee of the National Heart Foundation of Australia
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Med J Aust. 2004 Jan 19;180(2):94; author reply 94. PMID: 14723595
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/drug therapy
MH  - Coronary Disease/drug therapy/*prevention & control
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Myocardial Infarction/drug therapy
MH  - Peripheral Vascular Diseases/drug therapy/*prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Stroke/drug therapy
MH  - Thromboembolism/prevention & control
EDAT- 2003/07/30 05:00
MHDA- 2003/09/26 05:00
CRDT- 2003/07/30 05:00
PHST- 2002/11/28 00:00 [received]
PHST- 2003/04/24 00:00 [accepted]
PHST- 2003/07/30 05:00 [pubmed]
PHST- 2003/09/26 05:00 [medline]
PHST- 2003/07/30 05:00 [entrez]
AID - hun10816_fm [pii]
AID - 10.5694/j.1326-5377.2003.tb05259.x [doi]
PST - ppublish
SO  - Med J Aust. 2003 Aug 4;179(3):147-52. doi: 10.5694/j.1326-5377.2003.tb05259.x.

PMID- 32270937
OWN - NLM
STAT- MEDLINE
DCOM- 20200413
LR  - 20200413
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 16
IP  - 689
DP  - 2020 Apr 8
TI  - [Widal's triad : clinical manifestations, pathophysiology and therapeutic 
      advances].
PG  - 694-697
AB  - NSAID-Exacerbated respiratory disease (also known as Samter's or Widal's triad, 
      aspirin-exacerbated respiratory disease) is characte- rized by asthma, nasal 
      polyposis and hypersensitivity to NSAIDs. The pathogenesis of this chronic 
      inflammation arises from an imbalance in arachidonic acid metabolism, leading to 
      an increase in pro- inflammatory cysteinyl-leukotrienes. The treatment is based 
      on drug management of asthma and polyps and, in advanced situations, surgical 
      management of polyposis. Monoclonal antibodies have shown promising results in 
      the further medical treatment of this entity.
FAU - Vandenberghe-Dürr, Sophie
AU  - Vandenberghe-Dürr S
AD  - Service d'immunologie et allergologie, HUG, 1211 Genève 14.
FAU - Landis, Basile Nicolas
AU  - Landis BN
AD  - Service d'ORL et chirurgie cervico-faciale, HUG, 1211 Genève 14.
FAU - Jandus, Peter
AU  - Jandus P
AD  - Service d'immunologie et allergologie, HUG, 1211 Genève 14.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Syndrome de Widal : manifestations cliniques, physiopathologie et avancées 
      thérapeutiques.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/immunology
MH  - Aspirin/adverse effects/immunology
MH  - *Asthma/chemically induced
MH  - *Drug Hypersensitivity
MH  - Humans
MH  - *Nasal Polyps/chemically induced
MH  - *Sinusitis/chemically induced
COIS- Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
EDAT- 2020/04/10 06:00
MHDA- 2020/04/14 06:00
CRDT- 2020/04/10 06:00
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/04/14 06:00 [medline]
AID - RMS0689-007 [pii]
PST - ppublish
SO  - Rev Med Suisse. 2020 Apr 8;16(689):694-697.

PMID- 11450321
OWN - NLM
STAT- MEDLINE
DCOM- 20011205
LR  - 20191105
IS  - 0749-0704 (Print)
IS  - 0749-0704 (Linking)
VI  - 17
IP  - 2
DP  - 2001 Apr
TI  - The use of antiplatelet agents in acute cardiac care.
PG  - 365-77, vii
AB  - Antiplatelet therapy with aspirin has long been established as standard therapy 
      in the management of conditions such as ST-elevation myocardial infarction and 
      the acute coronary syndromes (unstable angina and non-ST-elevation myocardial 
      infarction). Recently, several more potent platelet inhibitors have been 
      developed and tested in randomized clinical trials. This article reviews the 
      current state of the art of antiplatelet therapy.
FAU - Calvin, J E
AU  - Calvin JE
AD  - Department of Medicine, Cook County Hospital, Chicago, Illinois, USA. 
      jcalvin@rush.edu
FAU - Klein, L W
AU  - Klein LW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Crit Care Clin
JT  - Critical care clinics
JID - 8507720
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Coronary Disease/drug therapy
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
RF  - 44
EDAT- 2001/07/14 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/07/14 10:00
PHST- 2001/07/14 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/07/14 10:00 [entrez]
AID - S0749-0704(05)70172-X [pii]
AID - 10.1016/s0749-0704(05)70172-x [doi]
PST - ppublish
SO  - Crit Care Clin. 2001 Apr;17(2):365-77, vii. doi: 10.1016/s0749-0704(05)70172-x.

PMID- 6347232
OWN - NLM
STAT- MEDLINE
DCOM- 19830923
LR  - 20191023
IS  - 0007-0971 (Print)
IS  - 0007-0971 (Linking)
VI  - 77
IP  - 2
DP  - 1983 Apr
TI  - Asthma improved by aspirin-like drugs.
PG  - 153-8
AB  - In six adult patients with bronchial asthma aspirin in a single dose of 0.3-1.2 g 
      produced bronchodilatation with a marked improvement in both clinical symptoms 
      and pulmonary function tests. In these patients asthma was characterized by the 
      following traits: onset after a flu-like infection, perennial course, lack of 
      relation to specific allergenic exposures, negative skin tests with common 
      aeroallergens, and history of rhinorrhoea or sinusitis. Oral challenge with 12 
      nonsteroidal anti-inflammatory drugs performed in two patients showed that 
      bronchodilatation could be induced not only by aspirin but also by other drugs 
      which inhibit cyclo-oxygenase. This response to aspirin is rare and proper 
      diagnosis is of vital importance, since the same aspirin-like drugs which proved 
      effective in these patients may provoke dangerous bronchoconstriction in other 
      clinically indistinguishable patients with asthma.
FAU - Szczeklik, A
AU  - Szczeklik A
FAU - Nizankowska, E
AU  - Nizankowska E
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br J Dis Chest
JT  - British journal of diseases of the chest
JID - 7511123
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiratory Function Tests
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 10.1016/0007-0971(83)90021-9 [doi]
PST - ppublish
SO  - Br J Dis Chest. 1983 Apr;77(2):153-8. doi: 10.1016/0007-0971(83)90021-9.

PMID- 16570891
OWN - NLM
STAT- MEDLINE
DCOM- 20060502
LR  - 20161128
IS  - 0001-6462 (Print)
IS  - 0001-6462 (Linking)
VI  - 72
IP  - 1
DP  - 2006 Jan
TI  - The association between aspirin and blood loss in hip fracture patients.
PG  - 29-33
AB  - This is a cohort study involving 98 patients who presented to a regional 
      orthopaedic unit with a hip fracture. Blood loss was assessed by pre and post 
      operative haemoglobin concentrations, and transfusion requirements were used as 
      outcome measures. The influence of pre-operative aspirin use and fracture type 
      was analysed with respect to these outcome measures. Forty two percent of 
      patients were regular aspirin users, and were comparable to the non aspirin 
      group, apart from having a significantly greater prevalence of atherosclerotic 
      vascular disease. There was no significant difference between the aspirin and non 
      aspirin groups in terms of preoperative haemoglobin concentrations, perioperative 
      changes in haemoglobin levels and transfusion requirements. Fifty one percent of 
      patients had extracapsular hip fractures, and these patients were comparable in 
      terms of demographic characteristics, including aspirin use, to the group with 
      intracapsular hip fractures. The extracapsular hip fracture group were found to 
      have significantly increased peri-operative blood loss as measured by changes in 
      the haemoglobin level, and in transfusion requirements when analysed against the 
      intracapsular hip fracture group. We found that it is the fracture site, rather 
      than aspirin use pre-operatively, that is predictive of blood loss and 
      transfusion requirements in patients presenting with hip fractures.
FAU - Kennedy, Muiris T
AU  - Kennedy MT
AD  - Department of Orthopaedics, Merlin Park Hospital, Galway, Ireland. 
      mugrca@hotmail.com
FAU - Roche, Simon
AU  - Roche S
FAU - Fleming, Sean M
AU  - Fleming SM
FAU - Lenehan, Brian
AU  - Lenehan B
FAU - Curtin, William
AU  - Curtin W
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Belgium
TA  - Acta Orthop Belg
JT  - Acta orthopaedica Belgica
JID - 2985165R
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Bleeding Time
MH  - *Blood Loss, Surgical
MH  - Blood Transfusion/methods/*statistics & numerical data
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Female
MH  - Fracture Fixation, Internal/adverse effects/*methods
MH  - Hemoglobins/analysis
MH  - Hip Fractures/diagnostic imaging/*surgery
MH  - Humans
MH  - Injury Severity Score
MH  - Male
MH  - Middle Aged
MH  - Radiography
MH  - Reference Values
MH  - Risk Assessment
MH  - Treatment Outcome
EDAT- 2006/03/31 09:00
MHDA- 2006/05/04 09:00
CRDT- 2006/03/31 09:00
PHST- 2006/03/31 09:00 [pubmed]
PHST- 2006/05/04 09:00 [medline]
PHST- 2006/03/31 09:00 [entrez]
PST - ppublish
SO  - Acta Orthop Belg. 2006 Jan;72(1):29-33.

PMID- 10512596
OWN - NLM
STAT- MEDLINE
DCOM- 19991028
LR  - 20170214
IS  - 1358-863X (Print)
IS  - 1358-863X (Linking)
VI  - 4
IP  - 3
DP  - 1999
TI  - Platelets and stroke.
PG  - 165-72
AB  - Platelets are anucleate cells with little or no capacity for de novo protein 
      synthesis. Their potential haemostatic reactivity is established at or before 
      thrombopoiesis by their precursor cell, the bone marrow megakaryocyte. In some 
      pathologic conditions, the megakaryocyte-platelet-haemostatic axis (MPHA) becomes 
      perturbed, resulting in the formation of hyperfunctional platelets which may 
      contribute to the development of vascular disease or an acute thrombotic event 
      such as ischaemic stroke or myocardial infarction. Laboratory measurements of 
      platelet function have established that platelet reactivity is accentuated in 
      acute ischaemic stroke, particularly following cortical rather than lacunar 
      infarction. Whether accentuated platelet function is a cause or a consequence of 
      stroke is not yet clear, but it is likely that patients with certain risk factor 
      profiles have some degree of platelet activation preceding the stroke. Further 
      work into the MPHA is required to establish whether enhanced post-stroke platelet 
      reactivity can be referred to the megakaryocyte. The antiplatelet agents tested 
      to date are effective in secondary but not primary prevention of stroke. This 
      probably reflects the diverse pathophysiology of stroke: accentuated platelet 
      function is only likely to be a significant factor in cortical stroke.
FAU - Smith, N M
AU  - Smith NM
AD  - Department of Medicine, King's College School of Medicine and Dentistry, London, 
      UK.
FAU - Pathansali, R
AU  - Pathansali R
FAU - Bath, P M
AU  - Bath PM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Vasc Med
JT  - Vascular medicine (London, England)
JID - 9610930
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/*physiology
MH  - Clinical Trials as Topic
MH  - Hemostasis/drug effects/physiology
MH  - Humans
MH  - Megakaryocytes/drug effects/physiology
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Stroke/drug therapy/*physiopathology/prevention & control
RF  - 72
EDAT- 1999/10/08 00:00
MHDA- 1999/10/08 00:01
CRDT- 1999/10/08 00:00
PHST- 1999/10/08 00:00 [pubmed]
PHST- 1999/10/08 00:01 [medline]
PHST- 1999/10/08 00:00 [entrez]
AID - 10.1177/1358836X9900400307 [doi]
PST - ppublish
SO  - Vasc Med. 1999;4(3):165-72. doi: 10.1177/1358836X9900400307.

PMID- 3411052
OWN - NLM
STAT- MEDLINE
DCOM- 19881004
LR  - 20190515
IS  - 0001-4966 (Print)
IS  - 0001-4966 (Linking)
VI  - 84
IP  - 1
DP  - 1988 Jul
TI  - Partial dissociation of spontaneous otoacoustic emissions and distortion products 
      during aspirin use in humans.
PG  - 230-7
AB  - Otoacoustic emissions (OAEs) of two types--spontaneous and evoked distortion 
      products--were studied before, during, and following a period of aspirin use. As 
      previously reported, aspirin consumption uniformly reduced the spontaneous OAEs 
      (SOAEs) to unmeasurable or extremely low levels. Aspirin consumption also reduced 
      the amplitude of the evoked distortion products (EDPs) but did not eliminate them 
      entirely. The amplitude of the EDP and its change with aspirin consumption were 
      related to both the proximity of the EDP to the frequency of the SOAE and to the 
      level of the primaries producing the EDP. At low primary levels, even with the 
      SOAE absent (due to aspirin consumption, or suppression), EDPs near the SOAE 
      frequency were 10-20 dB higher than when they were 100 Hz away from the SOAE 
      frequency.
FAU - Wier, C C
AU  - Wier CC
AD  - Department of Speech Communication, University of Texas, Austin 78712.
FAU - Pasanen, E G
AU  - Pasanen EG
FAU - McFadden, D
AU  - McFadden D
LA  - eng
GR  - ES 03539/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Acoust Soc Am
JT  - The Journal of the Acoustical Society of America
JID - 7503051
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acoustic Stimulation
MH  - Aspirin/*pharmacology
MH  - Auditory Perception/*drug effects/physiology
MH  - Auditory Threshold/drug effects
MH  - Evoked Potentials, Auditory/drug effects
MH  - Humans
MH  - Male
EDAT- 1988/07/01 00:00
MHDA- 1988/07/01 00:01
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 1988/07/01 00:01 [medline]
PHST- 1988/07/01 00:00 [entrez]
AID - 10.1121/1.396970 [doi]
PST - ppublish
SO  - J Acoust Soc Am. 1988 Jul;84(1):230-7. doi: 10.1121/1.396970.

PMID- 7939909
OWN - NLM
STAT- MEDLINE
DCOM- 19941101
LR  - 20131121
IS  - 0038-4348 (Print)
IS  - 0038-4348 (Linking)
VI  - 87
IP  - 10
DP  - 1994 Oct
TI  - Massive bleeding from a Zenker's diverticulum: case report and review of the 
      literature.
PG  - 1003-4
AB  - Zenker's diverticulum is an unusual site of origin for clinically significant 
      upper gastrointestinal hemorrhage. Only three such cases have been previously 
      documented. We report a case of massive upper gastrointestinal bleeding from a 
      Zenker's diverticulum seen as hemoptysis and associated with chronic ingestion of 
      one aspirin tablet every other day. Because of the propensity for ingested 
      tablets to lodge in the diverticulum, caution is urged when prescribing 
      ulcerogenic agents in pill form to a patient with a known Zenker's diverticulum.
FAU - Kensing, K P
AU  - Kensing KP
AD  - Department of Gastroenterology, Scott & White Clinic, Temple, TX 76508.
FAU - White, J G
AU  - White JG
FAU - Korompai, F
AU  - Korompai F
FAU - Dyck, W P
AU  - Dyck WP
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects
MH  - Gastrointestinal Hemorrhage/*etiology
MH  - Humans
MH  - Male
MH  - Zenker Diverticulum/*complications
RF  - 7
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
PST - ppublish
SO  - South Med J. 1994 Oct;87(10):1003-4.

PMID- 28710312
OWN - NLM
STAT- MEDLINE
DCOM- 20180523
LR  - 20180523
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Linking)
VI  - 23
IP  - 20
DP  - 2017 Oct 15
TI  - Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase.
PG  - 6267-6278
LID - 10.1158/1078-0432.CCR-17-0242 [doi]
AB  - Purpose: Recent epidemiological and clinical studies have suggested the benefit 
      of aspirin for patients with cancer, which inspired increasing efforts to 
      demonstrate the anticancer ability of aspirin and reveal the molecular mechanisms 
      behind. Nevertheless, the anticancer activity and related mechanisms of aspirin 
      remain largely unknown. This study aimed to confirm this observation, and more 
      importantly, to investigate the potential target contributed to the anticancer of 
      aspirin.Experimental Design: A homogeneous time-resolved fluorescence (HTRF) 
      assay was used to examine the impact of aspirin on heparanase. Streptavidin 
      pull-down, surface plasmon resonance (SPR) assay, and molecular docking were 
      performed to identify heparanase as an aspirin-binding protein. Transwell, rat 
      aortic rings, and chicken chorioallantoic membrane model were used to evaluate 
      the antimetastasis and anti-angiogenesis effects of aspirin, and these phenotypes 
      were tested in a B16F10 metastatic model, MDA-MB-231 metastatic model, and 
      MDA-MB-435 xenograft model.Results: This study identified heparanase, an 
      oncogenic extracellular matrix enzyme involved in cancer metastasis and 
      angiogenesis, as a potential target of aspirin. We had discovered that aspirin 
      directly binds to Glu225 region of heparanase and inhibits the enzymatic 
      activity. Aspirin impeded tumor metastasis, angiogenesis, and growth in 
      heparanase-dependent manner.Conclusions: In summary, this study has illustrated 
      heparanase as a target of aspirin for the first time. It provides insights for a 
      better understanding of the mechanisms of aspirin in anticancer effects, and 
      offers a direction for the development of small-molecule inhibitors of 
      heparanase. Clin Cancer Res; 23(20); 6267-78. ©2017 AACR.
CI  - ©2017 American Association for Cancer Research.
FAU - Dai, Xiaoyang
AU  - Dai X
AD  - Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, 
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. 
      China.
AD  - Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of 
      Pharmaceutical Sciences, Zhejiang University, Hangzhou, P.R. China.
FAU - Yan, Juan
AU  - Yan J
AD  - Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, 
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. 
      China.
AD  - University of Chinese Academy of Sciences, Beijing, P.R. China.
FAU - Fu, Xuhong
AU  - Fu X
AD  - Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, 
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. 
      China.
FAU - Pan, Qiuming
AU  - Pan Q
AD  - Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, 
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. 
      China.
FAU - Sun, Danni
AU  - Sun D
AD  - Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, 
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. 
      China.
FAU - Xu, Yuan
AU  - Xu Y
AD  - Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China.
FAU - Wang, Jiang
AU  - Wang J
AD  - Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, 
      Chinese Academy of Sciences, Shanghai, P.R. China.
FAU - Nie, Litong
AU  - Nie L
AD  - The Chemical Proteomics Center, Shanghai Institute of Materia Medica, Chinese 
      Academy of Sciences, Shanghai, P.R. China.
FAU - Tong, Linjiang
AU  - Tong L
AD  - Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, 
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. 
      China.
FAU - Shen, Aijun
AU  - Shen A
AD  - Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, 
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. 
      China.
FAU - Zheng, Mingyue
AU  - Zheng M
AD  - Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai 
      Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China.
FAU - Huang, Min
AU  - Huang M
AD  - Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, 
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. 
      China.
FAU - Tan, Minjia
AU  - Tan M
AD  - The Chemical Proteomics Center, Shanghai Institute of Materia Medica, Chinese 
      Academy of Sciences, Shanghai, P.R. China.
FAU - Liu, Hong
AU  - Liu H
AD  - Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, 
      Chinese Academy of Sciences, Shanghai, P.R. China.
FAU - Huang, Xun
AU  - Huang X
AD  - Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, 
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. 
      China. mygeng@simm.ac.cn xhuang@simm.ac.cn jding@simm.ac.cn.
FAU - Ding, Jian
AU  - Ding J
AD  - Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, 
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. 
      China. mygeng@simm.ac.cn xhuang@simm.ac.cn jding@simm.ac.cn.
FAU - Geng, Meiyu
AU  - Geng M
AD  - Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, 
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. 
      China. mygeng@simm.ac.cn xhuang@simm.ac.cn jding@simm.ac.cn.
LA  - eng
PT  - Journal Article
DEP - 20170714
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - EC 3.2.1.- (heparanase)
RN  - EC 3.2.1.31 (Glucuronidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiogenesis Inhibitors/chemistry/*pharmacology
MH  - Animals
MH  - Antineoplastic Agents/chemistry/*pharmacology
MH  - Aspirin/chemistry/*pharmacology
MH  - Cell Line, Tumor
MH  - Chick Embryo
MH  - Disease Models, Animal
MH  - Enzyme Activation/drug effects
MH  - Glucuronidase/*antagonists & inhibitors/chemistry/metabolism
MH  - Humans
MH  - Mice
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Neoplasms/drug therapy/*metabolism/pathology
MH  - Neovascularization, Pathologic/drug therapy/*enzymology
MH  - Protein Binding
MH  - Structure-Activity Relationship
MH  - Xenograft Model Antitumor Assays
EDAT- 2017/07/16 06:00
MHDA- 2018/05/24 06:00
CRDT- 2017/07/16 06:00
PHST- 2017/01/26 00:00 [received]
PHST- 2017/05/26 00:00 [revised]
PHST- 2017/07/10 00:00 [accepted]
PHST- 2017/07/16 06:00 [pubmed]
PHST- 2018/05/24 06:00 [medline]
PHST- 2017/07/16 06:00 [entrez]
AID - 1078-0432.CCR-17-0242 [pii]
AID - 10.1158/1078-0432.CCR-17-0242 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2017 Oct 15;23(20):6267-6278. doi: 
      10.1158/1078-0432.CCR-17-0242. Epub 2017 Jul 14.

PMID- 18805846
OWN - NLM
STAT- MEDLINE
DCOM- 20100202
LR  - 20191210
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 15
IP  - 6
DP  - 2009 Dec
TI  - Utility of the PFA-100 instrument and the novel multiplate analyzer for the 
      assessment of aspirin and clopidogrel effects on platelet function in patients 
      with cardiovascular disease.
PG  - 652-9
LID - 10.1177/1076029608322547 [doi]
AB  - This study evaluated the utility of the PFA-100 and the Multiplate analyzer for 
      the assessment of aspirin and clopidogrel effects on platelet function in 
      patients with cardiovascular disease. Platelet function was determined with the 
      PFA-100 using collagen+epinephrine (CEPI) and collagen+adenosine-5'-diphosphate 
      (CADP) cartridges, and with whole blood impedance aggregometry using the 
      Multiplate ASPI and ADP+PG tests (aggregation triggered with arachidonic acid and 
      ADP+ prostaglandin E1, respectively). Four study groups were identified from the 
      154 patients enrolled: patients without antiplatelet therapy, patients with 100 
      mg aspirin daily but without clopidogrel treatment, patients with 75 mg 
      clopidogrel daily but without aspirin treatment, and patients with both 100 mg 
      aspirin daily plus 75 mg clopidogrel daily. It was found that the PFA-100 
      instrument is useful for detection of aspirin but not for detection of a 
      clopidogrel effect, while the Multiplate analyzer is useful for specific 
      detection of both aspirin and clopidogrel effects on platelet function.
FAU - Mueller, Thomas
AU  - Mueller T
AD  - Department of Laboratory Medicine, Konventhospital Barmherzige Brueder, Linz, 
      Austria. thomas.mueller@bs-lab.at
FAU - Dieplinger, Benjamin
AU  - Dieplinger B
FAU - Poelz, Werner
AU  - Poelz W
FAU - Haltmayer, Meinhard
AU  - Haltmayer M
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080919
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clopidogrel
MH  - Collagen
MH  - Electric Impedance
MH  - Epinephrine
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nephelometry and Turbidimetry
MH  - Platelet Activation/*drug effects
MH  - Platelet Function Tests/*instrumentation
MH  - Sensitivity and Specificity
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
EDAT- 2008/09/23 09:00
MHDA- 2010/02/03 06:00
CRDT- 2008/09/23 09:00
PHST- 2008/09/23 09:00 [pubmed]
PHST- 2010/02/03 06:00 [medline]
PHST- 2008/09/23 09:00 [entrez]
AID - 1076029608322547 [pii]
AID - 10.1177/1076029608322547 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2009 Dec;15(6):652-9. doi: 10.1177/1076029608322547. 
      Epub 2008 Sep 19.

PMID- 18181519
OWN - NLM
STAT- MEDLINE
DCOM- 20080207
LR  - 20170214
IS  - 0267-6591 (Print)
IS  - 0267-6591 (Linking)
VI  - 22
IP  - 4
DP  - 2007 Jul
TI  - Inhibition of thrombocyte aggregation during extracorporeal lung assist: a case 
      report.
PG  - 293-7
AB  - In extracorporeal lung assist, membrane oxygenators are used to improve gas 
      exchange. Accumulations on the membranes of coagulation end products can increase 
      resistance to blood flow and diffusion distance. Thus, functioning of the system 
      can be impaired and, in extreme cases, lead to malfunction which may necessitate 
      change out of the oxygenator. We describe a method that complements conventional 
      continuous heparinisation with the administration of acetylsalicylic acid to 
      inhibit thrombocyte aggregation.
FAU - Philipp, Alois
AU  - Philipp A
AD  - Department of Cardiothoracic Surgery, University Hospital of Regensburg, 
      Regensburg, Germany. Alois.Philipp@Klinik.uni-regensburg.de
FAU - Müller, Thomas
AU  - Müller T
FAU - Bein, Thomas
AU  - Bein T
FAU - Foltan, Maik
AU  - Foltan M
FAU - Schmid, Franz-Xaver
AU  - Schmid FX
FAU - Birnbaum, Dietrich
AU  - Birnbaum D
FAU - Schmid, Christof
AU  - Schmid C
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Perfusion
JT  - Perfusion
JID - 8700166
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - *Extracorporeal Membrane Oxygenation
MH  - Humans
MH  - Lung Diseases/*therapy
MH  - Oxygenators, Membrane
MH  - *Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/*administration & dosage
EDAT- 2008/01/10 09:00
MHDA- 2008/02/08 09:00
CRDT- 2008/01/10 09:00
PHST- 2008/01/10 09:00 [pubmed]
PHST- 2008/02/08 09:00 [medline]
PHST- 2008/01/10 09:00 [entrez]
AID - 10.1177/0267659107083244 [doi]
PST - ppublish
SO  - Perfusion. 2007 Jul;22(4):293-7. doi: 10.1177/0267659107083244.

PMID- 2835919
OWN - NLM
STAT- MEDLINE
DCOM- 19880617
LR  - 20181130
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 60
IP  - 5
DP  - 1988 May
TI  - Allergic rhinitis relieved by aspirin and other nonsteroidal antinflammatory 
      drugs.
PG  - 419-22
AB  - Aspirin and other non-steroidal antiinflammatory drugs (NSAIDS) are known to 
      cause urticaria and aggravate symptoms of bronchial asthma. This report describes 
      a patient with allergic rhinitis whose symptoms were improved after ingestion of 
      aspirin and the NSAIDS. The beneficial effect was confirmed by oral double-blind 
      challenges.
FAU - Kumar, P
AU  - Kumar P
AD  - Department of Medicine, Louisiana State University School of Medicine.
FAU - Bryan, C
AU  - Bryan C
FAU - Hwang, D
AU  - Hwang D
FAU - Kadowitz, P
AU  - Kadowitz P
FAU - Butcher, B
AU  - Butcher B
FAU - Leech, S H
AU  - Leech SH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Thromboxanes)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - E0399OZS9N (Cyclic AMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/pharmacology/*therapeutic use
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Cyclic AMP/biosynthesis
MH  - Double-Blind Method
MH  - Humans
MH  - Immunoglobulin E/analysis
MH  - Male
MH  - Nasal Mucosa/analysis/metabolism
MH  - Platelet Aggregation/drug effects
MH  - Rhinitis, Allergic, Perennial/*drug therapy
MH  - T-Lymphocytes, Regulatory/drug effects/physiology
MH  - Thromboxanes/analysis
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1988 May;60(5):419-22.

PMID- 18816492
OWN - NLM
STAT- MEDLINE
DCOM- 20090303
LR  - 20131121
IS  - 1469-0705 (Electronic)
IS  - 0960-7692 (Linking)
VI  - 32
IP  - 5
DP  - 2008 Oct
TI  - Low-dose aspirin reduces uteroplacental vascular impedance in early and mid 
      gestation in IVF and ICSI patients: a randomized, placebo-controlled double-blind 
      study.
PG  - 687-93
LID - 10.1002/uog.6215 [doi]
AB  - OBJECTIVE: To determine whether low-dose aspirin improves uteroplacental 
      hemodynamics in unselected in-vitro fertilization/intracytoplasmic sperm 
      injection (IVF/ICSI) subjects when medication is started concomitantly with 
      controlled ovarian hyperstimulation. METHODS: Thirty-seven pregnant women who had 
      undergone IVF/ICSI and had been randomized to receive 100 mg aspirin (n = 17) or 
      placebo (n = 20) daily, started concomitantly with controlled ovarian 
      hyperstimulation, were included in this study. Doppler ultrasound examination was 
      performed at 6, 10, 13 and 18 weeks' gestation. Uterine artery (UtA) pulsatility 
      index (PI) was calculated and bilateral UtA notching was noted. Subplacental 
      arcuate artery PI was obtained at 6 and 10 weeks' gestation. Umbilical artery 
      (UA) PI and mean velocity were calculated at 10, 13 and 18 weeks' gestation. In 
      the aspirin group there was one early pregnancy miscarriage, and one patient 
      discontinued the study medication owing to early pregnancy bleeding. A total of 
      15 women in the aspirin group and 20 women in the placebo group underwent the 
      complete ultrasound protocol. RESULTS: At 6 weeks' gestation, arcuate artery PI 
      and at 18 weeks' gestation, UtA PI were lower (P < 0.05) in the aspirin group 
      than in the placebo group. At 18 weeks' gestation, bilateral UtA notching tended 
      to be more common in the placebo group (40%) than in the aspirin group (13%) (P = 
      0.06). UA PI and mean velocity did not differ significantly between the groups. 
      CONCLUSION: Low-dose aspirin reduces uteroplacental vascular impedance in early 
      and mid pregnancy in unselected IVF/ICSI subjects when medication is started 
      concomitantly with controlled ovarian hyperstimulation.
FAU - Haapsamo, M
AU  - Haapsamo M
AD  - Department of Obstetrics and Gynecology, University of Oulu, Oulu, Finland. 
      mervi.haapsamo@oulu.fi
FAU - Martikainen, H
AU  - Martikainen H
FAU - Räsänen, J
AU  - Räsänen J
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ultrasound Obstet Gynecol
JT  - Ultrasound in obstetrics & gynecology : the official journal of the International 
      Society of Ultrasound in Obstetrics and Gynecology
JID - 9108340
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arteries/physiology
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - Blood Flow Velocity/physiology
MH  - Double-Blind Method
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/pharmacology
MH  - Humans
MH  - Male
MH  - Ovulation Induction/methods
MH  - Placenta/*blood supply
MH  - Pregnancy
MH  - Pregnancy Trimester, Second
MH  - Pulsatile Flow/physiology
MH  - Sperm Injections, Intracytoplasmic/methods
MH  - Uterus/*blood supply
EDAT- 2008/09/26 09:00
MHDA- 2009/03/04 09:00
CRDT- 2008/09/26 09:00
PHST- 2008/09/26 09:00 [pubmed]
PHST- 2009/03/04 09:00 [medline]
PHST- 2008/09/26 09:00 [entrez]
AID - 10.1002/uog.6215 [doi]
PST - ppublish
SO  - Ultrasound Obstet Gynecol. 2008 Oct;32(5):687-93. doi: 10.1002/uog.6215.

PMID- 29442006
OWN - NLM
STAT- MEDLINE
DCOM- 20180829
LR  - 20180829
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 73
IP  - 2
DP  - 2018 Feb 1
TI  - A time-scaled convolution approach to construct IVIVC for enteric-coated 
      acetylsalicylic acid tablets.
PG  - 67-69
LID - 10.1691/ph.2018.7136 [doi]
AB  - A scaled convolution-based in vitro-in vivo (IVIVC) model was constructed for two 
      enteric-coated acetylsalicylic acid tablet formulations. The in vitro data used 
      were the results of dissolution testing performed using three different 
      dissolution methods: the United States Pharmacopoeia (USP) method, a method 
      employing blank Fasted State Simulated Fluid (FaSSIF), and a new method developed 
      in house. The in vivo data were obtained from a pharmacokinetic study on human 
      subjects in the fasted state. When the new dissolution method results were used, 
      an average prediction error less than 10% and a maximum prediction error less 
      than 15% were obtained for the peak plasma concentration (Cmax) and area under 
      the curve (AUC) parameters, thus meeting the internal validation criteria of the 
      IVIVC guidance of the US Food and Drug Administration (FDA).
FAU - Al-Gousous, J
AU  - Al-Gousous J
FAU - Langguth, P
AU  - Langguth P
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacokinetics
MH  - Area Under Curve
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - Biological Availability
MH  - Chemistry, Pharmaceutical
MH  - Drug Compounding
MH  - Humans
MH  - *Models, Chemical
MH  - Solubility
MH  - *Tablets, Enteric-Coated
EDAT- 2018/02/15 06:00
MHDA- 2018/08/30 06:00
CRDT- 2018/02/15 06:00
PHST- 2018/02/15 06:00 [entrez]
PHST- 2018/02/15 06:00 [pubmed]
PHST- 2018/08/30 06:00 [medline]
AID - 10.1691/ph.2018.7136 [doi]
PST - ppublish
SO  - Pharmazie. 2018 Feb 1;73(2):67-69. doi: 10.1691/ph.2018.7136.

PMID- 36516169
OWN - NLM
STAT- MEDLINE
DCOM- 20221216
LR  - 20230112
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 12
DP  - 2022
TI  - Aspirin mediates protection from diabetic kidney disease by inducing ferroptosis 
      inhibition.
PG  - e0279010
LID - 10.1371/journal.pone.0279010 [doi]
LID - e0279010
AB  - Diabetic kidney disease (DKD) progression can be predicted by abnormalities in 
      the tubulointerstitial lining, and their treatment may be useful for preventing 
      the disease. DKD is a progressive disease that contributes to renal tubular cell 
      death, but its underlying mechanisms remain unclear. Ferroptosis is a novel term 
      linked to lipid hydroperoxidation, and it plays an important role in the 
      pathogenesis of DKD. Overexpression of cyclooxygenase-2 (COX2), an enzyme of the 
      proximal tubule, causes cellular redox damage in DKD. It remains unknown whether 
      COX2 exacerbates tubular damage by accelerating ferroptosis in the kidneys of 
      diabetic mice. HK-2 cells cultured in high glucose exhibited ferroptosis, which 
      was inhibited by ferroptosis inhibitors. Additionally, alterations in the sensors 
      of ferroptosis metabolism, such as glutathione peroxidase 4 (GPX4) activity, 
      lipid hydroperoxidation, reduced glutathione (GSH) levels and changes in 
      mitochondrial morphology, were observed in high glucose-cultured HK-2 cells. 
      Diabetic mice manifested tubular injury and deranged renal physiological indices, 
      which were mitigated by ferrostatin-1 (Fer-1). Importantly, these perturbations 
      were ameliorated by downregulating COX2. In addition, the increased COX2 was 
      observed to be elevated in the daibetic kindney. To explore the relevance of COX2 
      to ferroptosis, HK-2 cells that knocked down from COX2 exhibited decreased 
      ferroptosis sensitivity under high glucose conditions. In RSL-3-treated HK-2 
      cells, ferroptosis was improved by downregulating COX2 by treatment with aspirin, 
      which was confirmed in high glucose-cultured HK-2 cells. Furthermore, the 
      ferroptosis changes were also suppressed by decreasing COX2 in diabetic mice 
      treated with aspirin, which retarded DKD progression. In conclusion, our results 
      demonstrated that ferroptosis in renal tubular cells contributes to DKD 
      development and that diabetes-related ferroptosis was inhibited through the 
      downregulation of COX2 by aspirin, thus retarding the progression of DKD. Our 
      findings support a renoprotective mechanism by which aspirin inhibits COX2 
      activation, identify COX2 as a potential target of ferroptosis, and establish 
      that ferroptosis in renal tubular cells is an integral process in the 
      pathogenesis of DKD regulated by COX2 expression profiles.
CI  - Copyright: © 2022 Wu et al. This is an open access article distributed under the 
      terms of the Creative Commons Attribution License, which permits unrestricted 
      use, distribution, and reproduction in any medium, provided the original author 
      and source are credited.
FAU - Wu, Ziyu
AU  - Wu Z
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin, China.
AD  - Department of Geriatric Medicine, Fujian Provincial Hospital, Fujian Provincial 
      Center for Geriatrics, Fujian Provincial Key Laboratory of Geriatric Disease, The 
      Provincial Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, 
      China.
FAU - Li, Dan
AU  - Li D
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin, China.
FAU - Tian, Dingyuan
AU  - Tian D
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin, China.
FAU - Liu, Xuejun
AU  - Liu X
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin, China.
FAU - Wu, Zhongming
AU  - Wu Z
AUID- ORCID: 0000-0003-4133-9759
AD  - NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of 
      Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of 
      Endocrinology, Tianjin Medical University, Tianjin, China.
AD  - Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong 
      First Medical University, Jinan, Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221214
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - IY9XDZ35W2 (Glucose)
RN  - 0 (Lipids)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *Diabetic Nephropathies/drug therapy/prevention & control/etiology
MH  - *Ferroptosis
MH  - *Diabetes Mellitus, Experimental/complications/drug therapy/pathology
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cyclooxygenase 2
MH  - Cell Line
MH  - Glucose
MH  - Lipids
PMC - PMC9749971
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/12/15 06:00
MHDA- 2022/12/17 06:00
CRDT- 2022/12/14 13:43
PHST- 2021/12/21 00:00 [received]
PHST- 2022/11/29 00:00 [accepted]
PHST- 2022/12/14 13:43 [entrez]
PHST- 2022/12/15 06:00 [pubmed]
PHST- 2022/12/17 06:00 [medline]
AID - PONE-D-21-40203 [pii]
AID - 10.1371/journal.pone.0279010 [doi]
PST - epublish
SO  - PLoS One. 2022 Dec 14;17(12):e0279010. doi: 10.1371/journal.pone.0279010. 
      eCollection 2022.

PMID- 26010419
OWN - NLM
STAT- MEDLINE
DCOM- 20160609
LR  - 20180130
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
VI  - 33
IP  - 5
DP  - 2015 Oct
TI  - Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: 
      Meta-Analysis of Randomized Trials.
PG  - 253-63
LID - 10.1111/1755-5922.12137 [doi]
AB  - INTRODUCTION: The optimal duration of dual antiplatelet therapy (DAPT) after 
      drug-eluting stent implantation (DES) is not certain. The AHA/ACC guidelines 
      recommend 12 months of DAPT based on observational trials. Recently, several 
      large randomized controlled trials (RCT) suggested a noninferiority of shorter 
      duration of DAPT and other trials showed a benefit from extended duration of DAPT 
      after 12 months of DES implantation. METHODS: PubMed databases were searched for 
      RCTs comparing the continued use of DAPT to shorter duration of DAPT (aspirin 
      alone) for variable durations beyond 3 months of DES implantation. Our analysis 
      was limited to trials with clinical outcomes. Odds ratio (OR) and 95% confidence 
      intervals (CI) were calculated using fixed and random-effects models. Subgroup 
      analyses were performed for second generation DES and for trials comparing 
      12 months of DAPT vs. earlier interruption or longer duration of DAPT. RESULTS: 
      We identified 10 RCTs including 32,136 subjects randomized to continued use of 
      DAPT vs. aspirin alone for variable durations after 3 months of DES implantation. 
      There was no significant heterogeneity among studies (Q test P > 0.1). Compared 
      to shorter DAPT, longer DAPT resulted in a significant reduction in stent 
      thrombosis (0.3% vs. 0.7%, P < 0.01) and myocardial infarction (1.3% vs. 2%, 
      P < 0.01), and a significant increase in major bleeding (0.8% vs. 0.4%, 
      P < 0.01). There was no difference in cardiac deaths or stroke. All-cause deaths 
      were slightly lower with shorter DAPT compared to longer DAPT (OR 0.8, 95% CI 0.7 
      to 0.99, P = 0.04). A small number of subjects were included between 3 and 
      6 months after DES implantation. CONCLUSION: DAPT continued beyond 6 months after 
      second generation DES implantation decreases stent thrombosis and myocardial 
      infarction, but increases major bleeding and all-causes mortality compared to 
      shorter DAPT (aspirin alone). There was no difference in cardiac mortality or 
      stroke.
CI  - © 2015 John Wiley & Sons Ltd.
FAU - Abo-Salem, Elsayed
AU  - Abo-Salem E
AD  - Division of Cardiovascular Health and Disease, University of Cincinnati, 
      Cincinnati, OH, USA.
FAU - Alsidawi, Said
AU  - Alsidawi S
AD  - Division of Cardiovascular Health and Disease, University of Cincinnati, 
      Cincinnati, OH, USA.
FAU - Jamali, Hina
AU  - Jamali H
AD  - Division of Cardiovascular Health and Disease, University of Cincinnati, 
      Cincinnati, OH, USA.
FAU - Effat, Mohamed
AU  - Effat M
AD  - Division of Cardiovascular Health and Disease, University of Cincinnati, 
      Cincinnati, OH, USA.
FAU - Helmy, Tarek
AU  - Helmy T
AD  - Division of Cardiovascular Health and Disease, University of Cincinnati, 
      Cincinnati, OH, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - Confidence Intervals
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Odds Ratio
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Thrombosis/prevention & control
MH  - Time Factors
OTO - NOTNLM
OT  - Drug-eluting stents
OT  - Dual antiplatelet therapy
OT  - Stent thrombosis
EDAT- 2015/05/27 06:00
MHDA- 2016/06/10 06:00
CRDT- 2015/05/27 06:00
PHST- 2015/05/27 06:00 [entrez]
PHST- 2015/05/27 06:00 [pubmed]
PHST- 2016/06/10 06:00 [medline]
AID - 10.1111/1755-5922.12137 [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2015 Oct;33(5):253-63. doi: 10.1111/1755-5922.12137.

PMID- 25997576
OWN - NLM
STAT- MEDLINE
DCOM- 20160906
LR  - 20181202
IS  - 1873-3344 (Electronic)
IS  - 0162-0134 (Linking)
VI  - 150
DP  - 2015 Sep
TI  - Novel mixed metal Ag(I)-Sb(III)-metallotherapeutics of the NSAIDs, aspirin and 
      salicylic acid: Enhancement of their solubility and bioactivity by using the 
      surfactant CTAB.
PG  - 108-19
LID - S0162-0134(15)00108-7 [pii]
LID - 10.1016/j.jinorgbio.2015.04.014 [doi]
AB  - The already known Ag(I)-Sb(III) compound of the formula {Ag(Ph3Sb)3(NO3)} (1) and 
      two novel mixed metal Ag(I)-Sb(III) metallotherapeutics of the formulae 
      {Ag(Ph3Sb)3(SalH)}(2) and {Ag(Ph3Sb)3(Asp)}(3) (SalH2=salicylic acid, 
      AspH=aspirin or 2-acetylsalicylic acid and Ph3Sb=triphenyl antimony(III)) have 
      been synthesised and characterised by m.p., vibrational spectroscopy (mid-FT-IR), 
      (13)C-,(1)H-NMR, UV-visible (UV-vis) spectroscopic techniques, high resolution 
      mass spectroscopy (HRMS) and X-ray crystallography. Compounds 1,-3 were treated 
      with the surfactant cetyltrimethylammonium bromide (CTAB) in order to enhance 
      their solubility and as a consequence their bioactivity. The resulting micelles 
      a-c were characterised with X-ray powder diffraction (XRPD) analysis, X-ray 
      fluorescence (XRF) spectroscopy, Energy-dispersive X-ray spectroscopy (EDX), 
      conductivity, Thermal gravimetry-differential thermal analysis (TG-DTA), and 
      atomic absorption. Compounds 1-3 and the relevant micelles a-c were evaluated for 
      their in vitro cytotoxic activity against human cancer cell lines: MCF-7 (breast, 
      estrogen receptor (ER) positive), MDA-MB-231 (breast, ER negative) and MRC-5 
      (normal human fetal lung fibroblast cells) with sulforhodamine B (SRB) 
      colorimetric assay. The results show significant increase in the activity of 
      micelles compared to that of the initial compounds. Moreover, micelles exhibited 
      lower activity against normal cells than tumor cells. The binding affinity of a-c 
      towards the calf thymus (CT)-DNA, lipoxygenase (LOX) and glutathione (GSH) was 
      studied by the fluorescent emission light and UV-vis spectroscopy.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Gkaniatsou, E I
AU  - Gkaniatsou EI
AD  - Inorganic and Analytical Chemistry, Department of Chemistry, University of 
      Ioannina, 45110 Ioannina, Greece.
FAU - Banti, C N
AU  - Banti CN
AD  - Inorganic and Analytical Chemistry, Department of Chemistry, University of 
      Ioannina, 45110 Ioannina, Greece.
FAU - Kourkoumelis, N
AU  - Kourkoumelis N
AD  - Medical Physics Laboratory, Medical School, University of Ioannina, 45110 
      Ioannina, Greece. Electronic address: nkourkou@uoi.gr.
FAU - Skoulika, S
AU  - Skoulika S
AD  - Section of Physical Chemistry, Department of Chemistry, University of Ioannina, 
      Ioannina, Greece.
FAU - Manoli, M
AU  - Manoli M
AD  - Department of Chemistry, University of Cyprus, 1678 Nicosia, Cyprus.
FAU - Tasiopoulos, A J
AU  - Tasiopoulos AJ
AD  - Department of Chemistry, University of Cyprus, 1678 Nicosia, Cyprus.
FAU - Hadjikakou, S K
AU  - Hadjikakou SK
AD  - Inorganic and Analytical Chemistry, Department of Chemistry, University of 
      Ioannina, 45110 Ioannina, Greece. Electronic address: shadjika@uoi.gr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150501
PL  - United States
TA  - J Inorg Biochem
JT  - Journal of inorganic biochemistry
JID - 7905788
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cetrimonium Compounds)
RN  - 0 (Coordination Complexes)
RN  - 0 (Micelles)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Surface-Active Agents)
RN  - 3M4G523W1G (Silver)
RN  - 9IT35J3UV3 (Antimony)
RN  - 9KJL21T0QJ (Linoleic Acid)
RN  - EC 1.13.11.12 (Lipoxygenase)
RN  - GAN16C9B8O (Glutathione)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - Z7FF1XKL7A (Cetrimonium)
SB  - IM
MH  - Antimony/*chemistry
MH  - Antineoplastic Agents/chemical synthesis/chemistry/*pharmacology
MH  - Aspirin/chemical synthesis/chemistry/*pharmacology
MH  - Cetrimonium
MH  - Cetrimonium Compounds/chemistry
MH  - Coordination Complexes/chemical synthesis/chemistry/*pharmacology
MH  - Glutathione/chemistry
MH  - Humans
MH  - Kinetics
MH  - Linoleic Acid/chemistry
MH  - Lipoxygenase/metabolism
MH  - MCF-7 Cells
MH  - Micelles
MH  - Proton Magnetic Resonance Spectroscopy
MH  - Receptors, Estrogen/metabolism
MH  - Salicylic Acid/chemical synthesis/chemistry/*pharmacology
MH  - Silver/*chemistry
MH  - Solubility
MH  - Spectrometry, X-Ray Emission
MH  - Surface-Active Agents/chemistry
OTO - NOTNLM
OT  - Anti-inflammatory drugs
OT  - Bioinorganic chemistry
OT  - Cytotoxic activity
OT  - Micelles
OT  - Silver(I)-antimony(III) compounds
EDAT- 2015/05/23 06:00
MHDA- 2016/09/07 06:00
CRDT- 2015/05/23 06:00
PHST- 2015/02/09 00:00 [received]
PHST- 2015/04/17 00:00 [revised]
PHST- 2015/04/17 00:00 [accepted]
PHST- 2015/05/23 06:00 [entrez]
PHST- 2015/05/23 06:00 [pubmed]
PHST- 2016/09/07 06:00 [medline]
AID - S0162-0134(15)00108-7 [pii]
AID - 10.1016/j.jinorgbio.2015.04.014 [doi]
PST - ppublish
SO  - J Inorg Biochem. 2015 Sep;150:108-19. doi: 10.1016/j.jinorgbio.2015.04.014. Epub 
      2015 May 1.

PMID- 11413842
OWN - NLM
STAT- MEDLINE
DCOM- 20010705
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 30
IP  - 18
DP  - 2001 May 19
TI  - [Otorhinolaryngologic pain in the adult. A comparison of the analgesic efficacy 
      of lysine acetylsalicylate and paracetamol].
PG  - 885-91
AB  - OBJECTIVE: Unlike paracetamol, aspinin has anti-inflammatory properties which may 
      be helpful in relieving pain associated with inflammation. To confirm this 
      hypothesis, we performed a randomized, double-blind, double-dummy study to 
      compare the relative analgesic efficacy of lysine acetylsalicylate (LAS) and 
      paracetamol (PAR) in ENT pain in adults. PATIENTS AND METHODS: After initiation 
      of the treatment by a placebo (PLA), both drugs were given at the same dose (1 g 
      twice daily on D1 and 1 g three times daily on D2) for two days. From the third 
      day to the seventh day, the patients could freely take the same drug if 
      necessary. The analgesic effect was assessed by measuring the area under the 
      curve (AUC) of pain severity as scored by patients on a visual analogue scale. 
      The secondary efficacy criteria were the difference relative to the basal pain 
      score of the scores at each evaluation time (PID), the sum of these differences 
      (SPID), and the proportion of patients responding to the treatment (i.e. 
      experiencing a decrease of at least 50% in the pain score). RESULTS: A total of 
      312 patients, included by 30 French centres, were treated by LAS (n = 156) or PAR 
      (n = 156). Pain was related to an infection in 98% of the cases. Nine percent of 
      patients in each treatment group were responders to the PLA and were consequently 
      not included in the per protocol (PP) analysis but in the intent-to-treat (ITT) 
      analysis. During days 1 and 2, patients in the LAS group had less pain than those 
      of the PAR group, the difference becoming significant at Day 2 whatever the 
      population analysed, PP (p = 0.01) or ITT (p = 0.01). LAS also showed better 
      analgesic efficacy than PAR as assessed by measures of PID and SPID, the 
      difference being significant at several times of evaluation for PID, and on Day 2 
      for SPID evaluation in the PP (p = 0.01) and ITT analysis (p = 0.007). The 
      proportion of responders was significantly higher in the LAS group than in the 
      PAR group (70% versus 56%, p = 0.01). Safety was comparable between the treatment 
      groups. The overall efficacy judgement of investigators and patients was 
      significantly better for LAS than for PAR (p = 0.01 and p = 0.006 respectively, 
      at the Day 2 evaluation). CONCLUSION: In this study, LAS proved to be more 
      effective than PAR in the treatment of ENT-associated pain in adults. This is 
      probably related to the anti-inflammatory activity of LAS.
FAU - Cabane, J
AU  - Cabane J
AD  - Service de Médecine interne, Hôpital Saint-Antoine, 184, rue du Faubourg 
      Saint-Antoine, F75571 Paris. jean.cabane@sat.ap-hop-paris.fr
FAU - Bernard-Fernier, M F
AU  - Bernard-Fernier MF
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Douleurs oto-rhino-laryngologiques chez l'adulte. Comparaison de l'efficacité 
      antalgique de l'acétylsalicylate de lysine et du paracétamol.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acetaminophen/adverse effects/*therapeutic use
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*analogs & derivatives/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Lysine/adverse effects/*analogs & derivatives/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Otorhinolaryngologic Diseases/*drug therapy
MH  - Pain/*drug therapy/etiology
MH  - Pain Measurement
MH  - Treatment Outcome
EDAT- 2001/06/21 10:00
MHDA- 2001/07/06 10:01
CRDT- 2001/06/21 10:00
PHST- 2001/06/21 10:00 [pubmed]
PHST- 2001/07/06 10:01 [medline]
PHST- 2001/06/21 10:00 [entrez]
PST - ppublish
SO  - Presse Med. 2001 May 19;30(18):885-91.

PMID- 36059460
OWN - NLM
STAT- MEDLINE
DCOM- 20220908
LR  - 20220915
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Comparison of non-criteria antiphospholipid syndrome with definite 
      antiphospholipid syndrome: A systematic review.
PG  - 967178
LID - 10.3389/fimmu.2022.967178 [doi]
LID - 967178
AB  - OBJECTIVES: Patients with laboratory or clinical manifestations suggestive of 
      antiphospholipid syndrome (APS) but not fulfilling the classification criteria 
      constitute a clinical challenge. This study aims to compare non-criteria APS 
      (NC-APS) with definite APS in terms of clinical manifestations, therapies, and 
      outcomes. METHODS: A systematic review of observational studies comparing 
      definite and NC-APS was performed searching four electronic databases. Data on 
      clinical manifestations, therapies and clinical outcomes was extracted. RESULTS: 
      Sixteen studies, assessing a total of 3,798 participants, were included. Seven 
      out of 10 studies found no significant difference in the prevalence of arterial 
      or venous thrombosis between definite and NC-APS, with two studies on 
      seronegative APS also finding no difference in thrombosis recurrence. Seven out 
      of 12 studies found no significant difference in the prevalence of obstetric 
      manifestations between groups, with the remaining exhibiting conflicting results. 
      In 9 studies comparing treatment frequency in obstetric patients, all but one 
      described similar treatment frequency, with the percentage of NC-APS treated 
      during pregnancy ranging from 26% to 100%. In 10 studies comparing pregnancy 
      outcomes of NC-APS versus definite APS, 7 found similar successful 
      pregnancies/live births. Additionally, 5 studies described improvement of live 
      births in both groups with treatment, with three signalling aspirin monotherapy 
      as efficacious as combination therapy in NC-APS. CONCLUSION: This review hints at 
      an absence of marked differences in most evaluated parameters between definite 
      and NC-APS, emphasizing the value of a more active follow-up of these patients. 
      The low-quality available evidence highlights the need for well-defined NC-APS 
      populations in future studies. SYSTEMATIC REVIEW REGISTRATION: 
      https://www.crd.york.ac.uk/prospero, identifier CRD42020210674.
CI  - Copyright © 2022 Pires da Rosa, Ferreira, Sousa-Pinto, Rodríguez-Pintó, Brito, 
      Mota, Cervera and Espinosa.
FAU - Pires da Rosa, Gilberto
AU  - Pires da Rosa G
AD  - Department of Autoimmune Diseases, Hospital Clínic, Institut d'Investigacions 
      Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, 
      Spain.
AD  - Department of Dermatovenereology, Centro Hospitalar Universitário de São João, 
      Porto, Portugal.
AD  - Faculty of Medicine, University of Porto, Porto, Portugal.
FAU - Ferreira, Ester
AU  - Ferreira E
AD  - Faculty of Medicine, University of Porto, Porto, Portugal.
AD  - Department of Internal Medicine, Centro Hospitalar Universitário de São João, 
      Porto, Portugal.
FAU - Sousa-Pinto, Bernardo
AU  - Sousa-Pinto B
AD  - MEDCIDS - Department of Community Medicine, Information and Health Decision 
      Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.
AD  - CINTESIS - Center for Health Technology and Services Research, Porto, Portugal.
FAU - Rodríguez-Pintó, Ignasi
AU  - Rodríguez-Pintó I
AD  - Autoimmune Diseases Unit, Hospital Universitari Mútua de Terrassa, Terrassa, 
      Spain.
FAU - Brito, Iva
AU  - Brito I
AD  - Faculty of Medicine, University of Porto, Porto, Portugal.
AD  - Department of Rheumatology, Centro Hospitalar Universitário de São João, Porto, 
      Portugal.
FAU - Mota, Alberto
AU  - Mota A
AD  - Department of Dermatovenereology, Centro Hospitalar Universitário de São João, 
      Porto, Portugal.
AD  - Department of Medicine, Faculty of Medicine, University of Porto, Porto, 
      Portugal.
FAU - Cervera, Ricard
AU  - Cervera R
AD  - Department of Autoimmune Diseases, Hospital Clínic, Institut d'Investigacions 
      Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, 
      Spain.
FAU - Espinosa, Gerard
AU  - Espinosa G
AD  - Department of Autoimmune Diseases, Hospital Clínic, Institut d'Investigacions 
      Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, 
      Spain.
LA  - eng
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20220818
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Antiphospholipid Syndrome/diagnosis/epidemiology/therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - *Thrombosis
MH  - *Venous Thrombosis
PMC - PMC9434011
OTO - NOTNLM
OT  - antiphospholipid antibodies
OT  - antiphospholipid syndrome
OT  - clinical manifestations
OT  - low titre
OT  - non-criteria
OT  - probable
OT  - seronegative
OT  - treatment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/06 06:00
MHDA- 2022/09/09 06:00
CRDT- 2022/09/05 03:37
PHST- 2022/06/12 00:00 [received]
PHST- 2022/07/29 00:00 [accepted]
PHST- 2022/09/05 03:37 [entrez]
PHST- 2022/09/06 06:00 [pubmed]
PHST- 2022/09/09 06:00 [medline]
AID - 10.3389/fimmu.2022.967178 [doi]
PST - epublish
SO  - Front Immunol. 2022 Aug 18;13:967178. doi: 10.3389/fimmu.2022.967178. eCollection 
      2022.

PMID- 11858103
OWN - NLM
STAT- MEDLINE
DCOM- 20020524
LR  - 20131121
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 73
IP  - 12
DP  - 2001
TI  - [Comparative efficacy of tiklid and aspirin in patients with unstable angina].
PG  - 25-9
AB  - AIM: To evaluate effects of tiklid and aspirin on hemostasis, antithrombogenic 
      activity of vascular wall in patients with unstable angina (UA). MATERIAL AND 
      METHODS: An open randomized trial enrolled 30 UA patients given tiklid (n = 16) 
      or aspirin (n = 14). Hemostasis, platelet aggregation, antithrombogenic activity 
      of the vascular wall were examined on the treatment day 1 and 20. The response 
      was assessed by the number of anginal attacks, dose of nitroglycerine, data of 
      Holter monitoring. RESULTS: Tiklid was more effective than aspirin in UA patients 
      as it by the treatment day 20 lowered platelet aggregation more, higher elevated 
      anticoagulation potential of the blood and vessels, and stronger activated 
      fibrinolytic hemostasis. CONCLUSION: Compared to aspirin, tiklid is more potent 
      antiaggregant, has greater effect on antithrombogenic properties of the vascular 
      wall.
FAU - Rebrov, A P
AU  - Rebrov AP
FAU - Voskoboĭ, I V
AU  - Voskoboĭ IV
LA  - rus
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Sravnitel'noe izuchenie éffektivnosti tiklida i aspirina u bol'nykh nestabil'noĭ 
      stenokardieĭ.
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/blood/*drug therapy
MH  - Aspirin/metabolism/*therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Endothelium, Vascular/drug effects/metabolism
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prothrombin Time
MH  - Ticlopidine/*therapeutic use
EDAT- 2002/02/23 10:00
MHDA- 2002/05/25 10:01
CRDT- 2002/02/23 10:00
PHST- 2002/02/23 10:00 [pubmed]
PHST- 2002/05/25 10:01 [medline]
PHST- 2002/02/23 10:00 [entrez]
PST - ppublish
SO  - Ter Arkh. 2001;73(12):25-9.

PMID- 27846246
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20230906
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 11
DP  - 2016
TI  - Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal 
      Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No 
      Evidence of Increased Risk.
PG  - e0166166
LID - 10.1371/journal.pone.0166166 [doi]
LID - e0166166
AB  - BACKGROUND: Aspirin has been shown to lower the incidence and the mortality of 
      vascular disease and cancer but its wider adoption appears to be seriously 
      impeded by concerns about gastrointestinal (GI) bleeding. Unlike heart attacks, 
      stroke and cancer, GI bleeding is an acute event, usually followed by complete 
      recovery. We propose therefore that a more appropriate evaluation of the 
      risk-benefit balance would be based on fatal adverse events, rather than on the 
      incidence of bleeding. We therefore present a literature search and meta-analysis 
      to ascertain fatal events attributable to low-dose aspirin. METHODS: In a 
      systematic literature review we identified reports of randomised controlled 
      trials of aspirin in which both total GI bleeding events and bleeds that led to 
      death had been reported. Principal investigators of studies in which fatal events 
      had not been adequately described were contacted via email and asked for further 
      details. A meta-analyses was then performed to estimate the risk of fatal 
      gastrointestinal bleeding attributable to low-dose aspirin. RESULTS: Eleven 
      randomised trials were identified in the literature search. In these the relative 
      risk (RR) of 'major' incident GI bleeding in subjects who had been randomised to 
      low-dose aspirin was 1.55 (95% CI 1.33, 1.83), and the risk of a bleed 
      attributable to aspirin being fatal was 0.45 (95% CI 0.25, 0.80). In all the 
      subjects randomised to aspirin, compared with those randomised not to receive 
      aspirin, there was no significant increase in the risk of a fatal bleed (RR 0.77; 
      95% CI 0.41, 1.43). CONCLUSIONS: The majority of the adverse events caused by 
      aspirin are GI bleeds, and there appears to be no valid evidence that the overall 
      frequency of fatal GI bleeds is increased by aspirin. The substantive risk for 
      prophylactic aspirin is therefore cerebral haemorrhage which can be fatal or 
      severely disabling, with an estimated risk of one death and one disabling stroke 
      for every 1,000 people taking aspirin for ten years. These adverse effects of 
      aspirin should be weighed against the reductions in vascular disease and cancer.
FAU - Elwood, Peter C
AU  - Elwood PC
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
FAU - Morgan, Gareth
AU  - Morgan G
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
AD  - Hywel Dda University Health Board, Llanelli, United Kingdom.
FAU - Galante, Julieta
AU  - Galante J
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
AD  - Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom.
FAU - Chia, John W K
AU  - Chia JW
AD  - Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
FAU - Dolwani, Sunil
AU  - Dolwani S
AD  - Institute of Cancer & Genetics Cardiff University, Cardiff, United Kingdom.
FAU - Graziano, J Michael
AU  - Graziano JM
AD  - Harvard Medical School, Boston, MA, United States of America.
FAU - Kelson, Mark
AU  - Kelson M
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
FAU - Lanas, Angel
AU  - Lanas A
AD  - University Clinic Hospital, University of Zaragoza, IIS Aragón, CIBEReshd, 
      Zaragoza, Spain.
FAU - Longley, Marcus
AU  - Longley M
AD  - Welsh Institute for Health and Social Care, University of South Wales, Cardiff, 
      United Kingdom.
FAU - Phillips, Ceri J
AU  - Phillips CJ
AD  - Swansea Centre for Health Economics, Swansea University, Swansea, United Kingdom.
FAU - Pickering, Janet
AU  - Pickering J
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
FAU - Roberts, Stephen E
AU  - Roberts SE
AD  - Medical School, Swansea University, Swansea, United Kingdom.
FAU - Soon, Swee S
AU  - Soon SS
AD  - Department of Pharmacy, National University of Singapore, Singapore, Singapore.
FAU - Steward, Will
AU  - Steward W
AD  - Department of Cancer Studies, University of Leicester, Leicester, United Kingdom.
FAU - Morris, Delyth
AU  - Morris D
AD  - University Library Services, Cardiff University, Cardiff, United Kingdom.
FAU - Weightman, Alison L
AU  - Weightman AL
AD  - Cochrane Institute of Primary Care and Public Health, Cardiff University, 
      Cardiff, United Kingdom.
AD  - Specialist Unit for Review Evidence (SURE), Cardiff University, Cardiff, United 
      Kingdom.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20161115
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced/*epidemiology/pathology
MH  - Humans
MH  - Myocardial Infarction/complications/drug therapy
MH  - Neoplasms/complications/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/complications/drug therapy
PMC - PMC5113022
COIS- We have the following conflicts: PCE was an advisor to Bayer HealthCare and was 
      until recently a member of the Board of the International Aspirin Foundation. JMG 
      is a consultant to Bayer and the Chair of the executive committee for the ARRIVE 
      trial which is sponsored by Bayer. AL has participated in Advisory Boards 
      organized by Bayer Pharma AG. JWKC has previously participated in Advisory Boards 
      by Bayer AG. This does not alter our adherence to PLOS ONE policies on sharing 
      data and materials.
EDAT- 2016/11/16 06:00
MHDA- 2017/06/22 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/06/08 00:00 [received]
PHST- 2016/10/19 00:00 [accepted]
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - PONE-D-16-23093 [pii]
AID - 10.1371/journal.pone.0166166 [doi]
PST - epublish
SO  - PLoS One. 2016 Nov 15;11(11):e0166166. doi: 10.1371/journal.pone.0166166. 
      eCollection 2016.

PMID- 7908815
OWN - NLM
STAT- MEDLINE
DCOM- 19940519
LR  - 20170214
IS  - 0960-3271 (Print)
IS  - 0960-3271 (Linking)
VI  - 13
IP  - 2
DP  - 1994 Feb
TI  - Influence of protein malnutrition on teratogenicity of acetylsalicylic acid in 
      rats.
PG  - 83-8
AB  - The effect of protein malnutrition (PM) on the embryotoxicity and teratogenicity 
      of aspirin in rats has been studied. Protein malnourishment was produced from 
      Days 7 to 21 of gestation by limiting the casein content of the diet to 5% in 
      comparison to 20% for the normal animals. Six dose levels of aspirin (50-175 mg 
      kg-1) were administered p.o. from Days 8 to 11 of pregnancy. Aspirin from 75 mg 
      kg-1 d-1 induced growth retardation, embryolethality and teratogenicity, as shown 
      by external, skeletal and visceral malformations. All these effects were 
      potentiated by protein malnutrition.
FAU - Hamed, M R
AU  - Hamed MR
AD  - National Organization for Drug Control and Research, Cairo, Egypt.
FAU - al-Assy, Y S
AU  - al-Assy YS
FAU - Ezzeldin, E
AU  - Ezzeldin E
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Exp Toxicol
JT  - Human & experimental toxicology
JID - 9004560
RN  - 0 (Caseins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced/*etiology
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*toxicity
MH  - Body Weight/drug effects
MH  - Bone and Bones/drug effects
MH  - Caseins
MH  - Diet
MH  - Embryonic and Fetal Development/*drug effects
MH  - Female
MH  - Fetal Growth Retardation/*chemically induced
MH  - Gestational Age
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - Pregnancy Outcome
MH  - Protein-Energy Malnutrition/*complications
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
AID - 10.1177/096032719401300204 [doi]
PST - ppublish
SO  - Hum Exp Toxicol. 1994 Feb;13(2):83-8. doi: 10.1177/096032719401300204.

PMID- 34968866
OWN - NLM
STAT- MEDLINE
DCOM- 20220321
LR  - 20220321
IS  - 1476-5586 (Electronic)
IS  - 1522-8002 (Print)
IS  - 1476-5586 (Linking)
VI  - 24
IP  - 2
DP  - 2022 Feb
TI  - Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived 
      tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination 
      with irinotecan.
PG  - 133-144
LID - S1476-5586(21)00108-1 [pii]
LID - 10.1016/j.neo.2021.12.004 [doi]
AB  - Novel therapeutic strategies are needed in the fight against pancreatic cancer. 
      We have previously documented the chemopreventive effect of MDC-22 in preclinical 
      models of pancreatic cancer. In the present work, we examined the therapeutic 
      effects of MDC-22 in patient-derived tumor xenografts (PDTXs) and in 
      LSL-Kras(G12D/+,) LSL-Trp53(R172H/+,) Pdx1-Cre (KPC) genetically engineered mice, 
      two complementary and clinically relevant animal models of pancreatic cancer. In 
      addition, we evaluated whether MDC-22 could synergize with current 
      chemotherapeutic drugs used in the clinic. MDC-22 reduced the growth of various 
      human pancreatic cancer cell lines in a concentration-dependent manner. In vivo, 
      MDC-22 strongly reduced patient-derived pancreatic tumor xenograft growth by 50%, 
      and extended survival of LSL-Kras(G12D/+); LSL-Trp53(R172H/+); Pdx1-Cre (KPC) 
      mice by over a month (5.3 months versus 7.0 months). In both models, MDC-22 
      inhibited EGFR activation and its downstream signals, including ERK and FAK 
      phosphorylation. In human pancreatic cancer cell lines, MDC-22 enhanced the 
      growth inhibitory effect of irinotecan, and to a lesser degree those of 
      gemcitabine and nab-paclitaxel. Normal human pancreatic epithelial cells were 
      more resistant to the cytotoxic effects of, both, MDC-22 alone or in combination 
      with irinotecan, indicating selectivity. Furthermore, MDC-22 enhanced 
      irinotecan's effect on cell migration, in part, by inhibiting EGFR/FAK signaling. 
      Collectively, our results indicate that MDC-22 is an effective anticancer drug in 
      preclinical models of pancreatic cancer, and suggest that MDC-22 plus irinotecan 
      as drug combination strategy for pancreatic cancer treatment, which warrants 
      further evaluation.
CI  - Copyright © 2021. Published by Elsevier Inc.
FAU - Rodriguez Lanzi, Cecilia
AU  - Rodriguez Lanzi C
AD  - Department of Nutrition, University of California, Davis, One Shields Ave, Davis, 
      CA 95616, USA.
FAU - Wei, Ran
AU  - Wei R
AD  - Department of Tea Science, Zhejiang Agriculture and Forestry University, Hangzhou 
      311300, China; University of California, Davis Comprehensive Cancer Center, 
      Sacramento, CA 95817, USA.
FAU - Luo, Dingyuan
AU  - Luo D
AD  - Department of Nutrition, University of California, Davis, One Shields Ave, Davis, 
      CA 95616, USA; Department of Thyroid Surgery, Medical Research Center, Sun 
      Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China; 
      Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 
      University, Guangzhou 510120, China.
FAU - Mackenzie, Gerardo G
AU  - Mackenzie GG
AD  - Department of Nutrition, University of California, Davis, One Shields Ave, Davis, 
      CA 95616, USA; Department of Family, Population and Preventive Medicine, Stony 
      Brook University, Stony Brook, NY 11794-8175, USA; University of California, 
      Davis Comprehensive Cancer Center, Sacramento, CA 95817, USA. Electronic address: 
      ggmackenzie@ucdavis.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20211227
PL  - United States
TA  - Neoplasia
JT  - Neoplasia (New York, N.Y.)
JID - 100886622
RN  - 0 (Antineoplastic Agents)
RN  - 7673326042 (Irinotecan)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Disease Models, Animal
MH  - Drug Therapy, Combination
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Humans
MH  - Irinotecan/pharmacology
MH  - Mice
MH  - Pancreatic Neoplasms/drug therapy/pathology
MH  - Treatment Outcome
MH  - *Xenograft Model Antitumor Assays
PMC - PMC8717147
OTO - NOTNLM
OT  - EGFR
OT  - FAK
OT  - KPC
OT  - MDC-22
OT  - Pancreatic cancer
OT  - Phospho-Aspirin
OT  - irinotecan
COIS- Declaration of Competing Interest All authors declare no competing financial 
      interest.
EDAT- 2021/12/31 06:00
MHDA- 2022/03/22 06:00
CRDT- 2021/12/30 20:21
PHST- 2021/08/26 00:00 [received]
PHST- 2021/12/15 00:00 [revised]
PHST- 2021/12/17 00:00 [accepted]
PHST- 2021/12/31 06:00 [pubmed]
PHST- 2022/03/22 06:00 [medline]
PHST- 2021/12/30 20:21 [entrez]
AID - S1476-5586(21)00108-1 [pii]
AID - 10.1016/j.neo.2021.12.004 [doi]
PST - ppublish
SO  - Neoplasia. 2022 Feb;24(2):133-144. doi: 10.1016/j.neo.2021.12.004. Epub 2021 Dec 
      27.

PMID- 29439623
OWN - NLM
STAT- MEDLINE
DCOM- 20190423
LR  - 20190423
IS  - 1933-7205 (Electronic)
IS  - 1933-7191 (Linking)
VI  - 25
IP  - 12
DP  - 2018 Dec
TI  - Aspirin Ameliorates Preeclampsia Induced by a Peroxisome Proliferator-Activated 
      Receptor Antagonist.
PG  - 1655-1662
LID - 10.1177/1933719118756746 [doi]
AB  - Reduced expression of peroxisome proliferator-activated receptor γ (PPARγ) in the 
      placenta was found in women with severe preeclampsia. Aspirin is currently used 
      as the only recommended intervention in pregnancies for prevention of 
      preeclampsia. In this study, we aimed to investigate whether aspirin could 
      attenuate PPARγ inhibitor (T0070907)-induced preeclampsia and its impact on 
      expression of PPARγ. Sixty Sprague-Dawley rats were used and treated with 
      different doses of aspirin (0, 1, and 1.5 mg/kg) in presence or absence of PPARγ 
      antagonist, T0070907. We found that mean arterial blood pressure was 
      significantly reduced by aspirin treatment in T0070907-exposed rats. T0070907 
      exposure also led to significant decrease in fetal weight and increase in 
      placental weights. However, 1.5 mg/kg of aspirin reversed these effects of 
      T0070907. Additionally, aspirin also reversed T0070907-induced changes in the 
      levels of thromboxane B2, vascular endothelial growth factor, soluble fms-like 
      tyrosine kinase, and matrix metalloproteinase 2 in both maternal blood and 
      placental tissue. The increased messenger RNA and protein levels of Cox1 and Cox2 
      induced by T0070907 were markedly reduced by aspirin treatment. Importantly, 
      T0070907 repressed both transcriptional and translational levels of PPARγ, which 
      were reversed by aspirin. In conclusion, this study suggests that aspirin 
      prevented the occurrence of preeclampsia, which is possibly through enhancing 
      both transcriptional and translational levels of PPARγ.
FAU - Zhang, Chunhua
AU  - Zhang C
AD  - 1 Department of Obstetrics and Gynaecology, Shandong Provincial Hospital 
      Affiliated to Shandong University, Jinan, China.
FAU - Zhu, Yong
AU  - Zhu Y
AD  - 2 The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, 
      Jinan, China.
FAU - Shen, Yan
AU  - Shen Y
AD  - 3 Maternal and Child Health Care Center of Shandong Province, Jinan, China.
FAU - Zuo, Changting
AU  - Zuo C
AUID- ORCID: 0000-0003-0939-6569
AD  - 1 Department of Obstetrics and Gynaecology, Shandong Provincial Hospital 
      Affiliated to Shandong University, Jinan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180213
PL  - United States
TA  - Reprod Sci
JT  - Reproductive sciences (Thousand Oaks, Calif.)
JID - 101291249
RN  - 0 (Benzamides)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (PPAR gamma)
RN  - 0 (Pyridines)
RN  - 0 (T 0070907)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Reprod Sci. 2018 Dec;25(12):1605-1606. PMID: 30472937
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Benzamides
MH  - Blood Pressure/*drug effects
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Female
MH  - Gene Expression Regulation/drug effects
MH  - PPAR gamma/*antagonists & inhibitors/genetics/metabolism
MH  - Pre-Eclampsia/chemically induced/*drug therapy
MH  - Pregnancy
MH  - Pyridines
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Treatment Outcome
OTO - NOTNLM
OT  - T0070907
OT  - aspirin
OT  - cyclooxygenase (COX)
OT  - peroxisome proliferator-activated receptor γ (PPARγ)
OT  - preeclampsia
EDAT- 2018/02/15 06:00
MHDA- 2019/04/24 06:00
CRDT- 2018/02/15 06:00
PHST- 2018/02/15 06:00 [pubmed]
PHST- 2019/04/24 06:00 [medline]
PHST- 2018/02/15 06:00 [entrez]
AID - 10.1177/1933719118756746 [doi]
PST - ppublish
SO  - Reprod Sci. 2018 Dec;25(12):1655-1662. doi: 10.1177/1933719118756746. Epub 2018 
      Feb 13.

PMID- 932969
OWN - NLM
STAT- MEDLINE
DCOM- 19760901
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 65
IP  - 6
DP  - 1976 Jun
TI  - Contact angles and wetting of pharmaceutical powders.
PG  - 843-7
AB  - Contact angles of pharmaceutical powders were determined by the h-epsilon method, 
      which consists essentially of measuring the maximum height of a drop of liquid 
      fomed on a presaturated compact of the material. Determinations with aspirin as 
      the test material indicate that the measured value is independent of the particle 
      size of the powder and the porosity of the cake. The method was extended to 
      include determinations on mixed powder systems. The results show that the 
      hydrophobic material dominates with large particle-size powders; with small 
      particle sizes, a linear relationship between the cosine of the contact angle of 
      the mixed system and the proportion of the components is obtained. Results are 
      presented for a wide variety of materials of pharmaceutical interest.
FAU - Lerk, C F
AU  - Lerk CF
FAU - Schoonen, A J
AU  - Schoonen AJ
FAU - Fell, J T
AU  - Fell JT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Powders)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - Particle Size
MH  - *Powders
MH  - Surface Properties
MH  - Time Factors
EDAT- 1976/06/01 00:00
MHDA- 1976/06/01 00:01
CRDT- 1976/06/01 00:00
PHST- 1976/06/01 00:00 [pubmed]
PHST- 1976/06/01 00:01 [medline]
PHST- 1976/06/01 00:00 [entrez]
AID - S0022-3549(15)40823-8 [pii]
AID - 10.1002/jps.2600650611 [doi]
PST - ppublish
SO  - J Pharm Sci. 1976 Jun;65(6):843-7. doi: 10.1002/jps.2600650611.

PMID- 22561560
OWN - NLM
STAT- MEDLINE
DCOM- 20131114
LR  - 20131121
IS  - 1672-7347 (Print)
IS  - 1672-7347 (Linking)
VI  - 37
IP  - 4
DP  - 2012 Apr
TI  - [One case of adult Kawasaki disease].
PG  - 431-2
LID - 10.3969/j.issn.1672-7347.2012.04.020 [doi]
AB  - Kawasaki disease is far more frequent in children than in adults. The 
      pathogenesis of Kawasaki disease is unknown, but it involves changes to the 
      coronary artery and other diverse clinical manifestations. There are currently no 
      specific laboratory diagnostic indexes, and especially since the disease is rare 
      in adults, so it is extremely easy to misdiagnose or to overlook entirely. Our 
      retrospective analysis of an diagnosis of and treatment for Kawasaki disease in 
      an adult provides a guide to clinical doctors in terms of understanding Kawasaki 
      disease, early diagnosis of it, and improved prognosis.
FAU - Zhou, Yajuan
AU  - Zhou Y
AD  - Department of Paediatrics, Shengjing Hospital of China Medical University, 
      Shenyang 110004, China.
FAU - Sun, Lu
AU  - Sun L
FAU - Yu, Xianyi
AU  - Yu X
FAU - Yan, Zhihan
AU  - Yan Z
FAU - Huang, Fen
AU  - Huang F
LA  - chi
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhong Nan Da Xue Xue Bao Yi Xue Ban
JT  - Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. 
      Medical sciences
JID - 101230586
RN  - 0 (gamma-Globulins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/therapy
MH  - gamma-Globulins/therapeutic use
EDAT- 2012/05/09 06:00
MHDA- 2013/11/15 06:00
CRDT- 2012/05/08 06:00
PHST- 2012/05/08 06:00 [entrez]
PHST- 2012/05/09 06:00 [pubmed]
PHST- 2013/11/15 06:00 [medline]
AID - 10.3969/j.issn.1672-7347.2012.04.020 [doi]
PST - ppublish
SO  - Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012 Apr;37(4):431-2. doi: 
      10.3969/j.issn.1672-7347.2012.04.020.

PMID- 25380191
OWN - NLM
STAT- MEDLINE
DCOM- 20160426
LR  - 20211025
IS  - 1473-5709 (Electronic)
IS  - 0959-8278 (Linking)
VI  - 24
IP  - 5
DP  - 2015 Sep
TI  - Aspirin and NSAIDs for breast cancer chemoprevention.
PG  - 416-21
LID - 10.1097/CEJ.0000000000000098 [doi]
AB  - Novel treatment strategies are needed for breast cancer chemoprevention. 
      Tamoxifen is the only drug approved for the chemoprevention of estrogen 
      receptor-positive breast cancer. However, to date, no treatment exists for the 
      chemoprevention of estrogen receptor-negative breast cancer. NSAID use is 
      associated with a reduced risk of breast cancer. However, the biological 
      mechanisms underlying the effect of NSAID on breast cancer are not well defined. 
      NSAIDs inhibit cyclooxygenases, thus preventing the formation of prostaglandins, 
      prostacyclin, and thromboxane. NSAIDs also exert other biological effects, 
      including generation of reactive oxygen species and inhibition of nuclear 
      factor-κB-mediated signals. This review synthesizes the evidence on the 
      COX-2-independent mechanisms of action of aspirin, salicylates, and other NSAIDs 
      on breast cancer.
FAU - Yiannakopoulou, Eugenia Ch
AU  - Yiannakopoulou ECh
AD  - Department of Medical Laboratories, Faculty of Health and Caring Professions, 
      Technological Educational Institute of Athens, Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur J Cancer Prev
JT  - European journal of cancer prevention : the official journal of the European 
      Cancer Prevention Organisation (ECP)
JID - 9300837
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Breast Neoplasms/drug therapy/*prevention & control
MH  - Female
MH  - Humans
MH  - Prognosis
EDAT- 2014/11/08 06:00
MHDA- 2016/04/27 06:00
CRDT- 2014/11/08 06:00
PHST- 2014/11/08 06:00 [entrez]
PHST- 2014/11/08 06:00 [pubmed]
PHST- 2016/04/27 06:00 [medline]
AID - 10.1097/CEJ.0000000000000098 [doi]
PST - ppublish
SO  - Eur J Cancer Prev. 2015 Sep;24(5):416-21. doi: 10.1097/CEJ.0000000000000098.

PMID- 28070071
OWN - NLM
STAT- MEDLINE
DCOM- 20180618
LR  - 20180618
IS  - 1348-2246 (Electronic)
IS  - 0910-6340 (Linking)
VI  - 33
IP  - 1
DP  - 2017
TI  - Simultaneous Determination of Warfarin and Aspirin Contents in Biological Fluids 
      Using Excitation-Emission Matrix Fluorescence Coupled with a Second-order 
      Calibration Method.
PG  - 29-34
LID - 10.2116/analsci.33.29 [doi]
AB  - In the present work, a practical method that combines excitation-emission matrix 
      fluorescence with a second-order calibration method based on an alternating 
      trilinear decomposition (ATLD) algorithm was developed in order to simultaneously 
      and directly determine the contents of warfarin (WAR) and aspirin (ASA) in human 
      plasma and urine samples, even in the presence of unknown interferences. With the 
      pre-estimated component number of 4, the obtained average spiked recoveries were 
      105.4 ± 7.8 and 104.2 ± 8.3% for WAR, 96.5 ± 2.8 and 91.2 ± 2.3% for ASA in human 
      plasma and urine samples, respectively. Furthermore, the figures of merit were 
      calculated and also inter- and intra-day experiments were performed that proved 
      the proposed method is of great significance to the monitoring of clinical 
      administration and also being a simple sample pretreatment at low-cost.
FAU - Xiao, Rong
AU  - Xiao R
AD  - State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry 
      and Chemical Engineering, Hunan University.
FAU - Wu, Hai-Long
AU  - Wu HL
FAU - Hu, Yong
AU  - Hu Y
FAU - Yin, Xiao-Li
AU  - Yin XL
FAU - Gu, Hui-Wen
AU  - Gu HW
FAU - Liu, Zhi
AU  - Liu Z
FAU - Wang, Tong
AU  - Wang T
FAU - Sun, Xiao-Dong
AU  - Sun XD
FAU - Yu, Ru-Qin
AU  - Yu RQ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Anal Sci
JT  - Analytical sciences : the international journal of the Japan Society for 
      Analytical Chemistry
JID - 8511078
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Aspirin/*blood/*urine
MH  - Blood Chemical Analysis/*methods
MH  - Calibration
MH  - Humans
MH  - Spectrometry, Fluorescence
MH  - Time Factors
MH  - Urinalysis/*methods
MH  - Warfarin/*blood/*urine
EDAT- 2017/01/11 06:00
MHDA- 2018/06/19 06:00
CRDT- 2017/01/11 06:00
PHST- 2017/01/11 06:00 [entrez]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2018/06/19 06:00 [medline]
AID - 10.2116/analsci.33.29 [doi]
PST - ppublish
SO  - Anal Sci. 2017;33(1):29-34. doi: 10.2116/analsci.33.29.

PMID- 36694315
OWN - NLM
STAT- MEDLINE
DCOM- 20230829
LR  - 20230829
IS  - 1875-5453 (Electronic)
IS  - 1389-2002 (Linking)
VI  - 24
IP  - 3
DP  - 2023
TI  - Design and Construction of Carboxylesterase 2c Gene Knockout Rats by CRISPR/Cas9.
PG  - 190-199
LID - 10.2174/1389200224666230123140919 [doi]
AB  - BACKGROUND: Carboxylesterase 2 (CES2) is mainly distributed in the human liver 
      and gut, and plays an active role in the metabolic activation of many prodrugs 
      and lipid metabolism. Although CES2 is of great significance, there are still few 
      animal models related to CES2. OBJECTIVES: This research aims to construct Ces2c 
      gene knockout (KO) rats and further study the function of CES2. METHODS: 
      CRISPR/Cas9 gene editing technology was used to target and cleave the rat Ces2c 
      gene. Compensatory effects of major CES subtypes both in the liver and small 
      intestine of KO rats were detected at mRNA levels. Meanwhile, diltiazem and 
      aspirin were used as substrates to test the metabolic capacity of Ces2c in KO 
      rats. RESULTS: This Ces2c KO rat model showed normal growth and breeding without 
      off-target effects. The metabolic function of Ces2c KO rats was verified by the 
      metabolic study of CES2 substrates in vitro. The results showed that the 
      metabolic capacity of diltiazem in KO rats was weakened, while the metabolic 
      ability of aspirin did not change significantly. In addition, the serum 
      physiological indexes showed that the Ces2c deletion did not affect the liver 
      function of rats.. CONCLUSION: The Ces2c KO rat model was successfully 
      constructed by CRISPR/Cas9 system. This rat model can not only be used as an 
      important tool to study the drug metabolism mediated by CES2, but also as an 
      important animal model to study the physiological function of CES2.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Liu, Jie
AU  - Liu J
AD  - Changning Maternity and Infant Health Hospital and School of Life Sciences, 
      Shanghai Key Laboratory of Regulatory Biology, East China Normal University, 
      Shanghai, China.
FAU - Shang, Xuyang
AU  - Shang X
AD  - Changning Maternity and Infant Health Hospital and School of Life Sciences, 
      Shanghai Key Laboratory of Regulatory Biology, East China Normal University, 
      Shanghai, China.
FAU - Yao, Bingyi
AU  - Yao B
AD  - Changning Maternity and Infant Health Hospital and School of Life Sciences, 
      Shanghai Key Laboratory of Regulatory Biology, East China Normal University, 
      Shanghai, China.
FAU - Zhang, Yuanjin
AU  - Zhang Y
AD  - Changning Maternity and Infant Health Hospital and School of Life Sciences, 
      Shanghai Key Laboratory of Regulatory Biology, East China Normal University, 
      Shanghai, China.
FAU - Huang, Shengbo
AU  - Huang S
AD  - Changning Maternity and Infant Health Hospital and School of Life Sciences, 
      Shanghai Key Laboratory of Regulatory Biology, East China Normal University, 
      Shanghai, China.
FAU - Guo, Yuanqing
AU  - Guo Y
AD  - Changning Maternity and Infant Health Hospital and School of Life Sciences, 
      Shanghai Key Laboratory of Regulatory Biology, East China Normal University, 
      Shanghai, China.
FAU - Wang, Xin
AU  - Wang X
AUID- ORCID: 0000-0001-8079-8638
AD  - Changning Maternity and Infant Health Hospital and School of Life Sciences, 
      Shanghai Key Laboratory of Regulatory Biology, East China Normal University, 
      Shanghai, China.
LA  - eng
GR  - 011/East China Normal University/
GR  - 18430760400/Science and Technology Commission of Shanghai Municipality/
GR  - 2019CNECNUPI02/Shanghai Science and Technology Development Foundation/
GR  - 81773808/National Natural Science Foundation of China (NSFC)/
PT  - Journal Article
PL  - Netherlands
TA  - Curr Drug Metab
JT  - Current drug metabolism
JID - 100960533
RN  - EE92BBP03H (Diltiazem)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Rats
MH  - Humans
MH  - Animals
MH  - Gene Knockout Techniques
MH  - *CRISPR-Cas Systems
MH  - *Diltiazem/metabolism
MH  - Liver/metabolism
MH  - Aspirin/metabolism
OTO - NOTNLM
OT  - CRISPR associated protein 9
OT  - Carboxylesterase
OT  - gene knockout techniques
OT  - liver function
OT  - metabolism
OT  - rat model
EDAT- 2023/01/26 06:00
MHDA- 2023/08/29 12:42
CRDT- 2023/01/25 00:13
PHST- 2022/09/11 00:00 [received]
PHST- 2022/12/05 00:00 [revised]
PHST- 2023/01/04 00:00 [accepted]
PHST- 2023/08/29 12:42 [medline]
PHST- 2023/01/26 06:00 [pubmed]
PHST- 2023/01/25 00:13 [entrez]
AID - CDM-EPUB-129020 [pii]
AID - 10.2174/1389200224666230123140919 [doi]
PST - ppublish
SO  - Curr Drug Metab. 2023;24(3):190-199. doi: 10.2174/1389200224666230123140919.

PMID- 18729837
OWN - NLM
STAT- MEDLINE
DCOM- 20081031
LR  - 20170310
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 48
IP  - 6
DP  - 2008
TI  - [Peculiarities of hemostasis, metabolic activity of platelets, and rate of 
      aspirin resistance in patients with chronic heart failure after aorto-coronary 
      bypass surgery].
PG  - 51-6
AB  - Aim of the study was to investigate in dynamics peculiarities of hemostasis 
      including platelet aggregation and activity of NADP-dependent dehydrogenases in 
      platelets, as well as prevalence of resistance to aspirin in patients with 
      functional class II-III chronic heart failure (CHF). We determined parameters of 
      vascular thrombocytic and coagulative hemostasis, the state of intracellular 
      metabolism of platelets as assessed by activity of NADP-dependent dehydrogenases 
      in 46 men (age 45 - 72 years) with NYHA class II (n=16) and III (n=30) CHF before 
      and in 12 - 14 days after coronary artery bypass grafting (CABG). After CABG all 
      patients received aspirin (75 - 150 mg/day). Patients with ischemic CHF had 
      moderate activation of intravascular coagulation, endotheliosis, elevation of 
      fibrinogen and plasminogen levels. These processes were significantly augmented 
      after CABG and were most pronounced in class II CHF. At the background of therapy 
      with aspirin in 36 patients (78.3%) ADP and adrenaline induced platelet 
      aggregation was reduced 2 - 3 times. In 10 patients (21.7%) aggregation remained 
      at initial level or even increased what evidenced for resistance to aspirin. 
      Among patients with functional classes II and III CHF portion of resistant to 
      aspirin was 12.5 and 26.6%, respectively. In these patients most striking changes 
      in intracellular metabolism of platelets were revealed. These changes manifested 
      as derangements of energetic and plastic processes in the cell. Thus aspirin 
      resistant patients with CHF comprise a group with risk of development of 
      atherothrombosis of coronary arteries, arteriovenous grafts and arterial 
      conduits.
FAU - Grinshteĭn, Iu I
AU  - Grinshteĭn IuI
FAU - Savchenko, A A
AU  - Savchenko AA
FAU - Grinshteĭn, I Iu
AU  - Grinshteĭn IIu
FAU - Savchenko, E A
AU  - Savchenko EA
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/drug effects/*metabolism
MH  - Chronic Disease
MH  - Coronary Artery Bypass/*methods
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Follow-Up Studies
MH  - Heart Failure/*blood/drug therapy/surgery
MH  - Hemostasis/drug effects/*physiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Postoperative Period
MH  - Treatment Outcome
EDAT- 2008/08/30 09:00
MHDA- 2008/11/01 09:00
CRDT- 2008/08/30 09:00
PHST- 2008/08/30 09:00 [pubmed]
PHST- 2008/11/01 09:00 [medline]
PHST- 2008/08/30 09:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 2008;48(6):51-6.

PMID- 34730556
OWN - NLM
STAT- MEDLINE
DCOM- 20211105
LR  - 20211105
IS  - 2310-6972 (Print)
IS  - 2310-6905 (Linking)
VI  - 67
IP  - 5
DP  - 2021 Sep
TI  - [Integral tests of the hemostasis system in assessing the efficiency of 
      acetylsalicylic acid in patients with ischemic heart disease].
PG  - 427-433
LID - 10.18097/PBMC20216705427 [doi]
AB  - Despite the fact that acetylsalicylic acid (ASA) is the "gold" standard for the 
      prevention of cardiovascular complications in patients with coronary heart 
      disease (CAD), a number of patients still have risks of atherothrombosis. In the 
      present study, the antithrombotic effect of ASA in patients with CAD was assessed 
      in platelet-rich plasma (PRP) using integral tests of the hemostasis study: the 
      T-TAS system (Total Thrombus-formation Analysis System) and the thrombin 
      generation test (TGT). The study involved 34 patients with stable CAD (11 women, 
      23 men) and people (15 women, 18 men) in the control group. As a result of 
      assessing the activity of thrombus formation using the T-TAS system, a 
      significant decrease in the area under the curve (AUC10) was found in the group 
      with CAD patients compared with the control (135.6 [88.0-222.3] and 260.5 
      [217.3-301.9], respectively, p.
FAU - Melnichnikova, O S
AU  - Melnichnikova OS
AD  - V.A. Almazov National Medical Research Center, St.Petersburg, Russia.
FAU - Nazarova, I A
AU  - Nazarova IA
AD  - V.A. Almazov National Medical Research Center, St.Petersburg, Russia.
FAU - Sirotkina, O V
AU  - Sirotkina OV
AD  - V.A. Almazov National Medical Research Center, St.Petersburg, Russia; Petersburg 
      Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre 
      "Kurchatov Institute", St.Petersburg, Russia.
FAU - Panov, A V
AU  - Panov AV
AD  - V.A. Almazov National Medical Research Center, St.Petersburg, Russia.
FAU - Abesadze, I T
AU  - Abesadze IT
AD  - V.A. Almazov National Medical Research Center, St.Petersburg, Russia.
FAU - Alugishvili, M Z
AU  - Alugishvili MZ
AD  - V.A. Almazov National Medical Research Center, St.Petersburg, Russia.
FAU - Lokhovinina, N L
AU  - Lokhovinina NL
AD  - V.A. Almazov National Medical Research Center, St.Petersburg, Russia.
FAU - Vavilova, T V
AU  - Vavilova TV
AD  - V.A. Almazov National Medical Research Center, St.Petersburg, Russia.
LA  - rus
PT  - Journal Article
TT  - Integral'nye testy sistemy gemostaza v otsenke éffektivnosti atsetilsalitsilovoĭ 
      kisloty u bol'nykh ishemicheskoĭ bolezn'iu serdtsa.
PL  - Russia (Federation)
TA  - Biomed Khim
JT  - Biomeditsinskaia khimiia
JID - 101196966
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Hemostasis
MH  - Humans
MH  - Male
MH  - *Myocardial Ischemia/drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Thrombosis/drug therapy
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - thrombin generation
OT  - thrombus formation under flow conditions
EDAT- 2021/11/04 06:00
MHDA- 2021/11/06 06:00
CRDT- 2021/11/03 12:16
PHST- 2021/11/03 12:16 [entrez]
PHST- 2021/11/04 06:00 [pubmed]
PHST- 2021/11/06 06:00 [medline]
AID - 10.18097/PBMC20216705427 [doi]
PST - ppublish
SO  - Biomed Khim. 2021 Sep;67(5):427-433. doi: 10.18097/PBMC20216705427.

PMID- 3342798
OWN - NLM
STAT- MEDLINE
DCOM- 19880331
LR  - 20190828
IS  - 0301-5548 (Print)
IS  - 0301-5548 (Linking)
VI  - 57
IP  - 1
DP  - 1988
TI  - Physical versus pharmacological counter-measures. Studies on febrile rabbits.
PG  - 81-8
AB  - 128 experiments were carried out on febrile rabbits at air temperatures of 8, 18, 
      24 and 30 degrees C in order to analyze the thermoregulatory effects and 
      mechanisms of physical and/or pharmacological counter-measures. Fever was 
      achieved by injection of 0.1 micrograms Salmonella typhi endotoxin (LPS)/kg into 
      an ear vein. As the pharmacological counter-measure, injections of 
      acetylsalicylic acid (ASA) into an ear vein were chosen. For the physical 
      counter-measure, cooling thermodes (5 degrees C) were constructed for the 
      abdominal skin, for the ear and for the rectum. ASA injections had no effect on 
      the first fever maximum, even if applied 20 to 60 min before the LPS injection, 
      but eliminated the second fever maximum. Of course, the additional hyperthermia 
      observed at 30 degrees C ambient temperature could not be eliminated by the 
      injections. On the other hand, cooling procedures can obviously not affect the 
      pyrogen-induced temperature increase, but reduce the hyperthermic effect of a 
      higher ambient temperature. Rectal cooling was more effective than ear or 
      abdominal skin cooling. Abdominal cooling evoked an increase in metabolic heat 
      production. Application of combined physical and pharmacological counter-measures 
      achieved the strongest and quickest reduction of the second maximum, whereas the 
      first maximum was not affected, as in all other experiments. The study emphasizes 
      the necessity of taking into account the time course of the effector mechanisms 
      in order to discriminate between hyperthermic and febrile components of 
      temperature increase. In the initial phase cooling measures would evoke unwanted 
      regulatory responses of the effectors, whereas during the second febrile maximum 
      they would achieve a quicker reduction of core temperatures.(ABSTRACT TRUNCATED 
      AT 250 WORDS)
FAU - Wenzel, C
AU  - Wenzel C
AD  - Institut für Physiologie, Ruhr-Universität, Bochum, Federal Republic of Germany.
FAU - Werner, J
AU  - Werner J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Appl Physiol Occup Physiol
JT  - European journal of applied physiology and occupational physiology
JID - 0410266
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - *Body Temperature Regulation/drug effects
MH  - Cryotherapy
MH  - Fever/drug therapy/*physiopathology
MH  - Rabbits
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.1007/BF00691243 [doi]
PST - ppublish
SO  - Eur J Appl Physiol Occup Physiol. 1988;57(1):81-8. doi: 10.1007/BF00691243.

PMID- 9174558
OWN - NLM
STAT- MEDLINE
DCOM- 19970617
LR  - 20220408
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 349
IP  - 9065
DP  - 1997 May 31
TI  - The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous 
      heparin, both, or neither among 19435 patients with acute ischaemic stroke. 
      International Stroke Trial Collaborative Group.
PG  - 1569-81
AB  - BACKGROUND: Only a few small trials have compared antithrombotic therapy 
      (antiplatelet or anticoagulant agents) versus control in acute ischaemic stroke, 
      and none has been large enough to provide reliable evidence on safety or 
      efficacy. METHODS: The International Stroke Trial (IST) was a large, randomised, 
      open trial of up to 14 days of antithrombotic therapy started as soon as possible 
      after stroke onset. The aim was to provide reliable evidence on the safety and 
      efficacy of aspirin and of subcutaneous heparin. Half the patients were allocated 
      unfractionated heparin (5000 or 12,500 IU bd [twice daily]), and half were 
      allocated "avoid heparin"; and, in a factorial design, half were allocated 
      aspirin 300 mg daily and half "avoid aspirin". The primary outcomes were death 
      within 14 days and death or dependency at 6 months. 19,435 patients with 
      suspected acute ischaemic stroke entering 467 hospitals in 36 countries were 
      randomised within 48 hours of symptom onset. RESULTS: Among heparin-allocated 
      patients, there were non-significantly fewer deaths within 14 days (876 [9.0%] 
      heparin vs 905 [9.3%] no heparin), corresponding to 3 (SD 4) fewer deaths per 
      1000 patients. At 6 months the percentage dead or dependent was identical in both 
      groups (62.9%). Patients allocated to heparin had significantly fewer recurrent 
      ischaemic strokes within 14 days (2.9% vs 3.8%) but this was offset by a 
      similar-sized increase in haemorrhagic strokes (1.2% vs 0.4%), so the difference 
      in death or non-fatal recurrent stroke (11.7% vs 12.0%) was not significant. 
      Heparin was associated with a significant excess of 9 (SD 1) transfused or fatal 
      extracranial bleeds per 1000. Compared with 5000 IU bd heparin, 12,500 IU bd 
      heparin was associated with significantly more transfused or fatal extracranial 
      bleeds, more haemorrhagic strokes, and more deaths or non-fatal strokes within 14 
      days (12.6% vs 10.8%). Among aspirin-allocated patients there were 
      non-significantly fewer deaths within 14 days (872 [9.0%] vs 909 [9.4%]), 
      corresponding to 4 (SD 4) fewer deaths per 1000 patients. At 6 months there was a 
      non-significant trend towards a smaller percentage of the aspirin group being 
      dead or dependent (62.2% vs 63.5%, 2p = 0.07), a difference of 13 (SD 7) per 
      1000; after adjustment for baseline prognosis the benefit from aspirin was 
      significant (14 [SD 6] per 1000, 2p = 0.03). Aspirin-allocated patients had 
      significantly fewer recurrent ischaemic strokes within 14 days (2.8% vs 3.9%) 
      with no significant excess of haemorrhagic strokes (0.9% vs 0.8%), so the 
      reduction in death or non-fatal recurrent stroke with aspirin (11.3% vs 12.4%) 
      was significant. Aspirin was associated with a significant excess of 5 (SD 1) 
      transfused or fatal extracranial bleeds per 1000; in the absence of heparin the 
      excess was 2 (SD 1) and was not significant. There was no interaction between 
      aspirin and heparin in the main outcomes. INTERPRETATION: Neither heparin regimen 
      offered any clinical advantage at 6 months. The results suggest that if heparin 
      is given in routine clinical practice, the dose should not exceed 5000 IU 
      subcutaneously twice daily. For aspirin, the IST suggests a small but worthwhile 
      improvement at 6 months. Taking the IST together with the comparably large 
      Chinese Acute Stroke Trial, aspirin produces a small but real reduction of about 
      10 deaths or recurrent strokes per 1000 during the first few weeks. Both trials 
      suggest that aspirin should be started as soon as possible after the onset of 
      ischaemic stroke; previous trials have already shown that continuation of 
      low-dose aspirin gives protection in the longer term.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 1997 Nov-Dec;127(3):62
CIN - Lancet. 1997 May 31;349(9065):1563. PMID: 9174552
CIN - Lancet. 1997 Aug 9;350(9075):440; author reply 443-4. PMID: 9259671
CIN - Lancet. 1997 Aug 9;350(9075):440; author reply 443-4. PMID: 9259672
CIN - Lancet. 1997 Aug 9;350(9075):440-1; author reply 443-4. PMID: 9259673
CIN - Lancet. 1997 Aug 9;350(9075):441; author reply 443-4. PMID: 9259674
CIN - Lancet. 1997 Aug 9;350(9075):442-3; author reply 443-4. PMID: 9259676
CIN - Lancet. 1997 Aug 9;350(9075):443; author reply 443-4. PMID: 9259677
CIN - Lancet. 1997 Aug 9;350(9075):443; author reply 443-4. PMID: 9259678
CIN - Lancet. 1997 Aug 9;350(9075):441-2; author reply 443-4. PMID: 9289595
CIN - Lancet. 2001 Jan 20;357(9251):233-4. PMID: 11213128
CIN - Lancet. 2001 Mar 31;357(9261):1044-5. PMID: 11293624
MH  - Acute Disease
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cerebrovascular Disorders/*drug therapy/mortality
MH  - Clinical Protocols
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Infusions, Parenteral
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Recurrence
MH  - Treatment Outcome
EDAT- 1997/05/31 00:00
MHDA- 1997/05/31 00:01
CRDT- 1997/05/31 00:00
PHST- 1997/05/31 00:00 [pubmed]
PHST- 1997/05/31 00:01 [medline]
PHST- 1997/05/31 00:00 [entrez]
AID - S0140673697040117 [pii]
PST - ppublish
SO  - Lancet. 1997 May 31;349(9065):1569-81.

PMID- 2882626
OWN - NLM
STAT- MEDLINE
DCOM- 19870518
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 18
IP  - 2
DP  - 1987 Mar-Apr
TI  - High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative 
      Study.
PG  - 325-34
AB  - Within 3 weeks of the event, 505 patients with cerebral infarction, minor or 
      major stroke, were randomly assigned to treatment with acetylsalicylic acid (ASA) 
      1.5 g/day or placebo in a double-blind clinical trial with a follow-up of 2 years 
      in all patients. Primary events were considered to be recurrent stroke or death; 
      secondary events, myocardial infarction and transient ischemic attack. There was 
      no difference in stroke recurrence rate in the ASA and placebo groups (12 and 
      13%, respectively), nor was there any significant difference in the rate of 
      recurrent stroke or death, first event counted (23% in the ASA and 22% in the 
      placebo group). The risk of transient ischemic attack and myocardial infarction 
      was not reduced in the ASA group. In the present study there was no prophylactic 
      effect of high-dose ASA after cerebral infarction. A compilation of the major 
      trials of ASA after transient ischemic attack and cerebral infarction is 
      presented.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Cerebral Infarction/*drug therapy/mortality
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/complications/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/complications/prevention & control
MH  - Patient Compliance
MH  - Patient Dropouts
MH  - Recurrence
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 10.1161/01.str.18.2.325 [doi]
PST - ppublish
SO  - Stroke. 1987 Mar-Apr;18(2):325-34. doi: 10.1161/01.str.18.2.325.

PMID- 14746698
OWN - NLM
STAT- MEDLINE
DCOM- 20040325
LR  - 20190823
IS  - 0025-7753 (Print)
IS  - 0025-7753 (Linking)
VI  - 122
IP  - 3
DP  - 2004 Jan 31
TI  - [Acetylsalicylic acid consumption in patients with diabetes mellitus].
PG  - 96-8
AB  - BACKGROUND AND OBJECTIVE: Acetylsalicylic acid (ASA) has been recommended for 
      primary (PP) and secondary prevention (SP) of cardiovascular disease (CVD) in 
      diabetic patients. The consumption of ASA among Catalan diabetic people is 
      described here. SUBJECTS AND METHOD: We analyzed 1,718 questionnaires 
      administered to members of the Catalonia's Diabetic Association. ASA intake, 
      history of CVD and medical advice about the use of ASA were evaluated. RESULTS: 
      ASA was taken by 21% subjects (as PP in 14% and as SP in 53%). Medical advice had 
      been received in 23% (15% as PP and 56% as SP). CONCLUSIONS: ASA intake among 
      diabetic patients is low in both PP and SP. Physicians should recommend its use 
      to improve this situation.
FAU - Esmatjes, Enric
AU  - Esmatjes E
AD  - Societat Catalana de Diabetis. Barcelona. Spain. esmatjes@clinic.ub.es
FAU - Castell, Conxa
AU  - Castell C
FAU - Franch, Josep
AU  - Franch J
FAU - Puigoriol, Emma
AU  - Puigoriol E
FAU - Hernáez, Rubén
AU  - Hernáez R
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Consumo de ácido acetilsalicílico en pacientes con diabetes mellitus.
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Med Clin (Barc). 2004 Jan 31;122(3):101-3. PMID: 14746700
CIN - Med Clin (Barc). 2004 Jul 10;123(6):236; author reply 239. PMID: 15282080
CIN - Med Clin (Barc). 2004 Jul 10;123(6):237; author reply 239. PMID: 15282081
CIN - Med Clin (Barc). 2004 Jul 10;123(6):237; author reply 239. PMID: 15282082
CIN - Med Clin (Barc). 2004 Jul 10;123(6):237-8; author reply 239. PMID: 15282083
CIN - Med Clin (Barc). 2004 Jul 10;123(6):238-9; author reply 239. PMID: 15282084
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus/prevention & control
MH  - Diabetic Angiopathies/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2004/01/30 05:00
MHDA- 2004/03/26 05:00
CRDT- 2004/01/30 05:00
PHST- 2004/01/30 05:00 [pubmed]
PHST- 2004/03/26 05:00 [medline]
PHST- 2004/01/30 05:00 [entrez]
AID - S0025-7753(04)74155-X [pii]
AID - 10.1016/s0025-7753(04)74155-x [doi]
PST - ppublish
SO  - Med Clin (Barc). 2004 Jan 31;122(3):96-8. doi: 10.1016/s0025-7753(04)74155-x.

PMID- 34776464
OWN - NLM
STAT- MEDLINE
DCOM- 20211116
LR  - 20211229
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 60
IP  - 22
DP  - 2021
TI  - P2Y12 Inhibitors Exacerbate Low-dose Aspirin-induced Small Bowel Injury in Dual 
      Antiplatelet Therapy.
PG  - 3517-3523
LID - 10.2169/internalmedicine.7292-21 [doi]
AB  - Objective Antithrombotic drugs are being used increasingly frequently to prevent 
      cardiovascular diseases. Few studies have evaluated small bowel mucosal injury 
      induced by dual antiplatelet therapy (DAPT). The aim of the present study was to 
      evaluate small bowel mucosal injury induced by DAPT compared with other 
      antithrombotics using video capsule endoscopy (VCE). Methods The study included 
      chronic users of antithrombotics who underwent VCE for obscure gastrointestinal 
      bleeding between January 2007 and July 2018. We evaluated the instances of small 
      bowel injury classified into erosions and ulcers. Results Overall, 183 patients 
      (114 men and 69 women; mean age, 73.6 years old) were enrolled, and the study 
      groups comprised 49 patients taking low-dose aspirin (LDA) only, 50 taking 
      anticoagulants only, 37 being treated with DAPT, 33 on combined LDA and 
      anticoagulants, and 14 taking P2Y12 inhibitors. Small bowel erosions and ulcers 
      were most frequently observed in the DAPT group, with frequencies of 78.4% and 
      37.8%, respectively. Exacerbating factors of small bowel ulcers were DAPT [odds 
      ratio (OR) 3.0, 95% confidence interval (CI) 1.2-7.7] and age over 80 years old 
      (OR 2.4, 95% CI 1.1-5.4). Conclusion P2Y12 inhibitors seem to exacerbate 
      LDA-induced small bowel injury. Preventive strategies for small bowel injury 
      induced by LDA, especially DAPT, are urgently required.
FAU - Handa, Yukiko
AU  - Handa Y
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Japan.
FAU - Fukushima, Shinya
AU  - Fukushima S
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Japan.
FAU - Osawa, Motoyasu
AU  - Osawa M
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Japan.
FAU - Murao, Takahisa
AU  - Murao T
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Japan.
FAU - Handa, Osamu
AU  - Handa O
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Japan.
FAU - Matsumoto, Hiroshi
AU  - Matsumoto H
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Japan.
FAU - Umegaki, Eiji
AU  - Umegaki E
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Japan.
FAU - Shiotani, Akiko
AU  - Shiotani A
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Japan.
LA  - eng
PT  - Journal Article
DEP - 20211115
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects
MH  - *Capsule Endoscopy
MH  - Female
MH  - Humans
MH  - *Intestinal Diseases
MH  - Intestine, Small
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects
PMC - PMC8666225
OTO - NOTNLM
OT  - capsule endoscopy
OT  - dual antiplatelet therapy
OT  - low-dose aspirin
OT  - obscure gastrointestinal bleeding
OT  - small bowel injury
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2021/11/16 06:00
MHDA- 2021/11/17 06:00
CRDT- 2021/11/15 06:46
PHST- 2021/11/15 06:46 [entrez]
PHST- 2021/11/16 06:00 [pubmed]
PHST- 2021/11/17 06:00 [medline]
AID - 10.2169/internalmedicine.7292-21 [doi]
PST - ppublish
SO  - Intern Med. 2021;60(22):3517-3523. doi: 10.2169/internalmedicine.7292-21. Epub 
      2021 Nov 15.

PMID- 8481259
OWN - NLM
STAT- MEDLINE
DCOM- 19930601
LR  - 20190512
IS  - 1010-7940 (Print)
IS  - 1010-7940 (Linking)
VI  - 7
IP  - 4
DP  - 1993
TI  - Antiplatelet therapy in children with left-sided mechanical prostheses.
PG  - 211-5
AB  - Valve replacement in children has always been associated with a high mortality, 
      outgrowth of the prosthetic valve and difficulty in managing anticoagulation. 
      Between January 1985 and April 1991, 20 patients (14 males and 6 females) 
      underwent replacement of a left-sided cardiac valve. The median age at diagnosis 
      was 21.6 months (1 to 120 months) and the median age at surgery was 85 months (11 
      to 213 months). Six patients were under 4 years of age. The site of valve 
      replacement was aortic in 11 patients and left atrioventricular (AV) valve in 9 
      patients. The indications for aortic valve replacement were stenosis (6) and 
      incompetence (5). The left AV valve was replaced in three patients following 
      repair of AV septal defect, in one patient with corrected transposition of the 
      great arteries (LTGA), in one patient with severe dysplasia and insufficiency, 
      and in four patients for congenital mitral stenosis. A Bjork-Shiley prosthesis 
      was used in three mitral and one aortic position, all the other patients 
      receiving a St. Jude prosthesis: six mitral and ten aortic. All patients were 
      anticoagulated (warfarin) for 3 months post implantation and then switched to a 
      regimen of aspirin and persantine. There was no early or late death. Median 
      follow-up was 12.3 months (4 to 72 months). Total follow-up was 59 patient-years 
      or 708 months. There was one incident of thromboembolism (1.7%/patient-year) and 
      four instances of bleeding (6.8%/patient-year). There was no valve thrombosis. 
      Our regime of early warfarin followed by long-term antiplatelet therapy has been 
      associated with a low incidence of thromboembolism and no valve thrombosis.
FAU - LeBlanc, J G
AU  - LeBlanc JG
AD  - Department of Cardiovascular and Thoracic Surgery, University of British 
      Columbia, British Columbia's Children's Hospital, Vancouver, Canada.
FAU - Sett, S S
AU  - Sett SS
FAU - Vince, D J
AU  - Vince DJ
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European 
      Association for Cardio-thoracic Surgery
JID - 8804069
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aortic Valve/surgery
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Dipyridamole/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Valve Prosthesis
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Infant
MH  - Male
MH  - Mitral Valve/surgery
MH  - Patient Compliance
MH  - Postoperative Complications/*prevention & control
MH  - Retrospective Studies
MH  - Thromboembolism/*prevention & control
MH  - Time Factors
MH  - Warfarin/administration & dosage/adverse effects/*therapeutic use
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1016/1010-7940(93)90161-4 [doi]
PST - ppublish
SO  - Eur J Cardiothorac Surg. 1993;7(4):211-5. doi: 10.1016/1010-7940(93)90161-4.

PMID- 33268193
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 200
DP  - 2021 Jan
TI  - Relationship between aspirin use and subarachnoid hemorrhage: A systematic Review 
      and meta-analysis.
PG  - 106320
LID - S0303-8467(20)30663-6 [pii]
LID - 10.1016/j.clineuro.2020.106320 [doi]
AB  - BACKGROUND: Aspirin has been associated with a decreasing risk of subarachnoid 
      hemorrhage due to its anti-inflammatory mechanism of action and potential 
      protective properties against aneurysm growth. OBJECTIVE: To determine the 
      association between aneurysmal subarachnoid hemorrhage and aspirin use. METHODS: 
      A systematic review of the literature and a meta-analysis were performed across 
      the PubMed database. The following keywords were used: "aspirin, acetylsalicylic 
      acid, 2-acetyloxy-benzoic acid, ruptured intracranial aneurysm, aneurysmal 
      subarachnoid hemorrhage, spontaneous subarachnoid hemorrhage, intracerebral 
      hemorrhage, spontaneous aneurysmal hemorrhage, spontaneous intracerebral 
      bleeding". Studies that were performed with animals or analyzed patients with 
      traumatic brain injury were excluded. A total of five studies were included in 
      our meta-analysis, with a total of 19,222 patients evaluated. Statistical 
      analysis was performed to determine the association between the use of aspirin 
      and the risk of subarachnoid hemorrhage. RESULTS: Aspirin use reduce the risk of 
      subarachnoid hemorrhage (odds ratio [OR] 0.51, 95 % confidence interval [CI] 
      0.34-0.76). CONCLUSION: Although some previous studies suggested that aspirin may 
      potentially reduce the risk of subarachnoid hemorrhage, our meta-analysis found 
      an association between the reduction of risk of aneurysmal subarachnoid 
      hemorrhage.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Florez, William A
AU  - Florez WA
AD  - Latinoamerican Council of Neurocritical Care, Cartagena, Colombia; Faculty of 
      Health, Programa Medicina, Universidad Surcolombiana, Neiva, Huila, Colombia. 
      Electronic address: williamflorezmd@gmail.com.
FAU - García-Ballestas, Ezequiel
AU  - García-Ballestas E
AD  - Latinoamerican Council of Neurocritical Care, Cartagena, Colombia; Centro De 
      Investigaciones Biomédicas (CIB), Faculty of Medicine, University of Cartagena, 
      Cartagena, Colombia.
FAU - Maeda, Fernando
AU  - Maeda F
AD  - Department of Neurosurgery, University of Campinas (UNICAMP), Sao Paulo, Brazil.
FAU - Joaquim, Andrei
AU  - Joaquim A
AD  - Department of Neurosurgery, University of Campinas (UNICAMP), Sao Paulo, Brazil.
FAU - Pavlov, Orlin
AU  - Pavlov O
AD  - Departament of Neurosurgery, Klinikum Fulda gAG, Fulda, Germany.
FAU - Moscote-Salazar, Luis Rafael
AU  - Moscote-Salazar LR
AD  - Latinoamerican Council of Neurocritical Care, Cartagena, Colombia; Centro De 
      Investigaciones Biomédicas (CIB), Faculty of Medicine, University of Cartagena, 
      Cartagena, Colombia.
FAU - Tsimpas, Asterios
AU  - Tsimpas A
AD  - Section of Neurosurgery, Department of Surgery, Advocate Illinois Masonic Medical 
      Center, Chicago, IL, USA.
FAU - Martinez-Perez, Rafael
AU  - Martinez-Perez R
AD  - Department of Neurological Surgery, University of Colorado, Aurora, CO, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201019
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Case-Control Studies
MH  - Humans
MH  - Observational Studies as Topic/methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Subarachnoid Hemorrhage/chemically induced/*diagnostic imaging/*prevention & 
      control
OTO - NOTNLM
OT  - Aneurysmal subarachnoid hemorrhage
OT  - Aspirin
OT  - Cerebral aneurysm
OT  - Intracranial aneurysm
OT  - Intracrebral hemorrhage
EDAT- 2020/12/04 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/12/03 05:31
PHST- 2020/06/29 00:00 [received]
PHST- 2020/10/15 00:00 [revised]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/12/03 05:31 [entrez]
AID - S0303-8467(20)30663-6 [pii]
AID - 10.1016/j.clineuro.2020.106320 [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 2021 Jan;200:106320. doi: 10.1016/j.clineuro.2020.106320. 
      Epub 2020 Oct 19.

PMID- 24516128
OWN - NLM
STAT- MEDLINE
DCOM- 20140422
LR  - 20211021
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 111
IP  - 8
DP  - 2014 Feb 25
TI  - Resveratrol and aspirin eliminate tetraploid cells for anticancer 
      chemoprevention.
PG  - 3020-5
LID - 10.1073/pnas.1318440111 [doi]
AB  - Tetraploidy constitutes a genomically metastable state that can lead to 
      aneuploidy and genomic instability. Tetraploid cells are frequently found in 
      preneoplastic lesions, including intestinal cancers arising due to the 
      inactivation of the tumor suppressor adenomatous polyposis coli (APC). Using a 
      phenotypic screen, we identified resveratrol as an agent that selectively reduces 
      the fitness of tetraploid cells by slowing down their cell cycle progression and 
      by stimulating the intrinsic pathway of apoptosis. Selective killing of 
      tetraploid cells was observed for a series of additional agents that indirectly 
      or directly stimulate AMP-activated protein kinase (AMPK) including salicylate, 
      whose chemopreventive action has been established by epidemiological studies and 
      clinical trials. Both resveratrol and salicylate reduced the formation of 
      tetraploid or higher-order polyploid cells resulting from the culture of human 
      colon carcinoma cell lines or primary mouse epithelial cells lacking tumor 
      protein p53 (TP53, best known as p53) in the presence of antimitotic agents, as 
      determined by cytofluorometric and videomicroscopic assays. Moreover, oral 
      treatment with either resveratrol or aspirin, the prodrug of salicylate, 
      repressed the accumulation of tetraploid intestinal epithelial cells in the 
      Apc(Min/+) mouse model of colon cancer. Collectively, our results suggest that 
      the chemopreventive action of resveratrol and aspirin involves the elimination of 
      tetraploid cancer cell precursors.
FAU - Lissa, Delphine
AU  - Lissa D
AD  - Institut National de la Santé et de la Recherche Médicale (INSERM), U848, F-94805 
      Villejuif, France.
FAU - Senovilla, Laura
AU  - Senovilla L
FAU - Rello-Varona, Santiago
AU  - Rello-Varona S
FAU - Vitale, Ilio
AU  - Vitale I
FAU - Michaud, Mickaël
AU  - Michaud M
FAU - Pietrocola, Federico
AU  - Pietrocola F
FAU - Boilève, Alice
AU  - Boilève A
FAU - Obrist, Florine
AU  - Obrist F
FAU - Bordenave, Chloé
AU  - Bordenave C
FAU - Garcia, Pauline
AU  - Garcia P
FAU - Michels, Judith
AU  - Michels J
FAU - Jemaà, Mohamed
AU  - Jemaà M
FAU - Kepp, Oliver
AU  - Kepp O
FAU - Castedo, Maria
AU  - Castedo M
FAU - Kroemer, Guido
AU  - Kroemer G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140210
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Stilbenes)
RN  - Q369O8926L (Resveratrol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Nat Rev Clin Oncol. 2014 Apr;11(4):180. PMID: 24569449
MH  - Adenomatous Polyposis Coli/*prevention & control
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cell Death/*drug effects
MH  - Cell Line, Tumor
MH  - Epithelial Cells/chemistry/*drug effects
MH  - Flow Cytometry
MH  - Image Processing, Computer-Assisted
MH  - In Situ Hybridization, Fluorescence
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Microscopy, Video
MH  - Resveratrol
MH  - Stilbenes/pharmacology/*therapeutic use
MH  - *Tetraploidy
PMC - PMC3939868
COIS- The authors declare no conflict of interest.
EDAT- 2014/02/12 06:00
MHDA- 2014/04/23 06:00
CRDT- 2014/02/12 06:00
PHST- 2014/02/12 06:00 [entrez]
PHST- 2014/02/12 06:00 [pubmed]
PHST- 2014/04/23 06:00 [medline]
AID - 1318440111 [pii]
AID - 201318440 [pii]
AID - 10.1073/pnas.1318440111 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3020-5. doi: 
      10.1073/pnas.1318440111. Epub 2014 Feb 10.

PMID- 6486127
OWN - NLM
STAT- MEDLINE
DCOM- 19841101
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 77
IP  - 3A
DP  - 1984 Sep 10
TI  - Peripherally acting analgesics.
PG  - 17-26
AB  - The therapeutic effect of aspirin and the other nonsteroidal anti-inflammatory 
      drugs derives from the peripheral inhibition of prostaglandin synthetase. Aspirin 
      produces irreversible inhibition, whereas the inhibition triggered by the other 
      nonsteroidal anti-inflammatory drugs is reversible. Despite proved analgesic 
      efficacy, use of aspirin and the nonsteroidal anti-inflammatory drugs may be 
      accompanied by a wide range of side effects of a potentially serious nature. For 
      relief of pain, there appears to be no clear-cut superiority of one nonsteroidal 
      anti-inflammatory drug over another, and patients who fail to respond to one 
      class of nonsteroidal anti-inflammatory drugs may respond to a representative of 
      another class. As with aspirin, it is difficult to demonstrate the superiority of 
      higher doses of these agents over the lower doses. The side-effect profile of 
      non-narcotic analgesics favors acetaminophen, presumably because its inhibition 
      of prostaglandin synthetase occurs centrally. Acetaminophen does not appear to 
      have the same potential for toxicity that is seen with aspirin and other 
      nonsteroidal anti-inflammatory drugs. At dosages up to 4 g per day, acetaminophen 
      compares favorably in analgesic potency to aspirin and other nonsteroidal 
      anti-inflammatory drugs, and it should be considered the treatment of choice for 
      mild-to-moderate pain. Safe conditions for the analgesic use of nonsteroidal 
      anti-inflammatory drugs in children and pregnancy have not been established. 
      Because it is virtually free of side effects, acetaminophen may be the mild 
      analgesic of choice for the pregnant patient. It has been used safely for years 
      in children. Only a limited number of analgesic studies have been conducted in 
      children. The results of analgesic studies carried out in adults are generally 
      recognized as applicable to pain relief in children.
FAU - Amadio, P Jr
AU  - Amadio P Jr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 367589PJ2C (Mefenamic Acid)
RN  - 57Y76R9ATQ (Naproxen)
RN  - 7C546U4DEN (Diflunisal)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/adverse effects/pharmacology/therapeutic use
MH  - Analgesics/adverse effects/pharmacology/*therapeutic use
MH  - Anti-Inflammatory Agents/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Diflunisal/therapeutic use
MH  - Fenoprofen/therapeutic use
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Mefenamic Acid/adverse effects/therapeutic use
MH  - Naproxen/therapeutic use
MH  - Pain/*drug therapy
MH  - Primary Health Care
EDAT- 1984/09/10 00:00
MHDA- 2001/03/28 10:01
CRDT- 1984/09/10 00:00
PHST- 1984/09/10 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1984/09/10 00:00 [entrez]
AID - S0002-9343(84)80099-6 [pii]
AID - 10.1016/s0002-9343(84)80099-6 [doi]
PST - ppublish
SO  - Am J Med. 1984 Sep 10;77(3A):17-26. doi: 10.1016/s0002-9343(84)80099-6.

PMID- 28403216
OWN - NLM
STAT- MEDLINE
DCOM- 20170425
LR  - 20181202
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 4
DP  - 2017
TI  - Efficacy and safety of aspirin in patients with peripheral vascular disease: An 
      updated systematic review and meta-analysis of randomized controlled trials.
PG  - e0175283
LID - 10.1371/journal.pone.0175283 [doi]
LID - e0175283
AB  - BACKGROUND: Although considered a cornerstone therapy, the efficacy and safety of 
      aspirin for prevention of ischemic events in patients with peripheral vascular 
      disease (PVD) remains uncertain. Thus, we aimed to evaluate aspirin use in both 
      symptomatic and asymptomatic patients with PVD. METHODS: An electronic search of 
      databases was conducted from inception until January 2017 for all randomized 
      trials comparing aspirin with either placebo or control (no aspirin) in patients 
      with PVD. The primary efficacy outcome was all-cause mortality, and the primary 
      safety outcome was major bleeding. Other outcomes of interest were major adverse 
      cardiac and cerebrovascular events (MACCE), myocardial infarction (MI), stroke 
      and intracranial hemorrhage. Random-effects summary risk ratios (RR) were 
      calculated using Der-Simonian and Liard model. The quality of evidence was 
      assessed by GRADE tool and Cochrane risk of bias assessment tool. RESULTS: A 
      total of 6,560 patients from 11 trials were included. Only two trials were 
      considered to have low risk of bias. Compared with control, aspirin was 
      associated with similar incidence of all-cause mortality (RR = 0.93, 95% 
      confidence interval [CI] 0.8-1.1), MACCE (RR = 1.0, 95% CI 0.83-1.20), MI (RR = 
      0.91, 95% CI 0.67-1.23) and stroke (RR = 0.72, 95% CI 0.43-1.22), major bleeding 
      (RR = 1.59, 95% CI 0.96-2.62) and intracranial hemorrhage (RR = 1.38, 95% CI 
      0.59-3.21). CONCLUSIONS: Aspirin use in PVD might not be associated with improved 
      cardiovascular outcomes or worse bleeding outcomes. Larger randomized trials 
      assessing the efficacy and safety of aspirin in the contemporary era are 
      mandatory to confirm the current findings. Guideline recommendations regarding 
      the use of aspirin among patients with PVD need to be updated.
FAU - Mahmoud, Ahmed N
AU  - Mahmoud AN
AD  - Department of Medicine, University of Florida, Gainesville, FL, United States of 
      America.
FAU - Elgendy, Akram Y
AU  - Elgendy AY
AD  - Department of Medicine, University of Florida, Gainesville, FL, United States of 
      America.
FAU - Rambarat, Cecil
AU  - Rambarat C
AD  - Department of Medicine, University of Florida, Gainesville, FL, United States of 
      America.
FAU - Mahtta, Dhruv
AU  - Mahtta D
AD  - Department of Medicine, University of Florida, Gainesville, FL, United States of 
      America.
FAU - Elgendy, Islam Y
AU  - Elgendy IY
AD  - Department of Medicine, University of Florida, Gainesville, FL, United States of 
      America.
FAU - Bavry, Anthony A
AU  - Bavry AA
AUID- ORCID: 0000-0002-3545-370X
AD  - Department of Medicine, University of Florida, Gainesville, FL, United States of 
      America.
AD  - North Florida/South Georgia Veterans Health System, Gainesville, FL, United 
      States of America.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20170412
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Intracranial Hemorrhages/chemically induced
MH  - Myocardial Infarction/prevention & control
MH  - Peripheral Vascular Diseases/complications/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/prevention & control
MH  - Treatment Outcome
PMC - PMC5389721
COIS- Competing Interests: Dr. Bavry discloses the following relationship – Honorarium 
      from American College of Cardiology. This does not alter our adherence to PLOS 
      ONE policies on sharing data and materials. The other authors have no conflicts 
      of interest to declare.
EDAT- 2017/04/14 06:00
MHDA- 2017/04/26 06:00
CRDT- 2017/04/14 06:00
PHST- 2017/02/03 00:00 [received]
PHST- 2017/03/23 00:00 [accepted]
PHST- 2017/04/14 06:00 [entrez]
PHST- 2017/04/14 06:00 [pubmed]
PHST- 2017/04/26 06:00 [medline]
AID - PONE-D-17-04349 [pii]
AID - 10.1371/journal.pone.0175283 [doi]
PST - epublish
SO  - PLoS One. 2017 Apr 12;12(4):e0175283. doi: 10.1371/journal.pone.0175283. 
      eCollection 2017.

PMID- 30408229
OWN - NLM
STAT- MEDLINE
DCOM- 20190617
LR  - 20190617
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 34
IP  - 3
DP  - 2019 Mar
TI  - Helicobacter pylori and low-dose aspirin ulcer risk: A meta-analysis.
PG  - 517-525
LID - 10.1111/jgh.14539 [doi]
AB  - BACKGROUND AND AIM: Owing to wide-spread use, low-dose aspirin (LDA) produces a 
      substantial amount of peptic ulcer disease. Current guidelines are ambivalent 
      about the need for Helicobacter pylori eradication to protect against LDA ulcers. 
      This study aimed to determine, through meta-analysis, if (and by how much) 
      infection alters the baseline risk of peptic ulcers during LDA therapy. METHODS: 
      Literature screening was performed in MEDLINE and EMBASE from inception to May 
      2018. Original studies reporting prevalence or incidence of uncomplicated ulcers 
      in LDA users were included. Ulcer endpoints needed to be specified separately, 
      according to H. pylori infection status. Meta-analysis was performed in MIX 2.0 
      Pro. RESULTS: Ten cross-sectional studies and seven randomized controlled trials 
      were included (n = 5964). The pooled odds ratios with 95% confidence intervals 
      (CI) for the risk of LDA ulcers in H. pylori-positive versus H. pylori-negative 
      individuals were 1.68 (95%CI 1.40-2.02) and 1.65 (95%CI 1.29-2.08) under 
      fixed-effects and random-effects models, respectively. Heterogeneity among 
      studies was minimal (I(2)  = 26.9%). After adjusting for the protective effects 
      of antisecretory drugs, the odds ratios increased to 1.94 (95%CI 1.54-2.46). 
      CONCLUSION: This analysis suggests that H. pylori increases the risk of LDA 
      ulcers by almost 70% in a population where some were taking proton pump 
      inhibitors and/or other acid suppressants. Without antisecretory drugs, the risk 
      almost doubles. Clinically, these findings may support the use of a 
      test-and-treat approach to H. pylori in LDA users, particularly those already at 
      higher risk of developing peptic ulcers.
CI  - © 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & 
      Sons Australia, Ltd.
FAU - Sarri, Gino L
AU  - Sarri GL
AUID- ORCID: 0000-0001-7803-3169
AD  - Melbourne School of Medicine, University of Melbourne, Melbourne, Victoria, 
      Australia.
FAU - Grigg, Sam E
AU  - Grigg SE
AUID- ORCID: 0000-0002-6116-6595
AD  - Melbourne School of Medicine, University of Melbourne, Melbourne, Victoria, 
      Australia.
FAU - Yeomans, Neville D
AU  - Yeomans ND
AD  - Melbourne School of Medicine, University of Melbourne, Melbourne, Victoria, 
      Australia.
AD  - Office for Research, Austin Health, Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20181217
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Databases, Bibliographic
MH  - Gastritis/*complications/*microbiology
MH  - *Helicobacter Infections
MH  - Helicobacter pylori
MH  - Humans
MH  - Incidence
MH  - Peptic Ulcer/*chemically induced/epidemiology/*etiology/prevention & control
MH  - Prevalence
MH  - Risk
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - aspirin
OT  - peptic ulcer
EDAT- 2018/11/09 06:00
MHDA- 2019/06/18 06:00
CRDT- 2018/11/09 06:00
PHST- 2018/10/19 00:00 [received]
PHST- 2018/10/25 00:00 [revised]
PHST- 2018/10/30 00:00 [accepted]
PHST- 2018/11/09 06:00 [pubmed]
PHST- 2019/06/18 06:00 [medline]
PHST- 2018/11/09 06:00 [entrez]
AID - 10.1111/jgh.14539 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2019 Mar;34(3):517-525. doi: 10.1111/jgh.14539. Epub 
      2018 Dec 17.

PMID- 27063941
OWN - NLM
STAT- MEDLINE
DCOM- 20170320
LR  - 20170915
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 107
DP  - 2016 May
TI  - Role of thromboxane-dependent platelet activation in venous thrombosis: Aspirin 
      effects in mouse model.
PG  - 415-425
LID - S1043-6618(15)30238-3 [pii]
LID - 10.1016/j.phrs.2016.04.001 [doi]
AB  - Recent trials suggest that Aspirin (ASA) reduces the incidence of venous 
      thromboembolism in human. However, the molecular mechanisms underlying this 
      effect are still unclear. In this study we assessed the effects of ASA in venous 
      thrombosis mouse model induced by inferior vena cava (IVC) ligation and we 
      investigated the mechanisms responsible for this effect. ASA (3mg/kg daily for 2 
      days) treatment decreased the thrombus size, the amounts of tissue factor 
      activity in plasma microvesicles (TF-MP) and the levels of 2,3-dinor Thromboxane 
      B2 (TXB-M) in urine compared to control mice. Interestingly, the thrombus size 
      positively correlated with both TF-MP activity and TXB-M. In addition, positive 
      correlation was observed between TF-MP activity and TXB-M. A reduced number of 
      neutrophils and monocytes, and of TF-positive cells accompanied to a lower amount 
      of fibrin and neutrophil extracellular traps (NETs) were also found in thrombi of 
      ASA-treated mice. Similar results were obtained when mice were treated 24h before 
      IVC ligation with SQ29548 (1mg/kg), a selective thromboxane receptor antagonist. 
      In addition, transfusion of platelets in SQ29548 treated-mice excluded the 
      likelihood of a redundant role of platelet-TP receptor in this context. Finally, 
      incubation of macrophages and neutrophils with SQ29548 prevented TF activity 
      and/or NETs formation induced by supernatant of activated platelets or by IBOP, a 
      selective thromboxane analogue. In conclusion, ASA, suppressing TXA2, prevents 
      macrophages and neutrophils activation and markedly reduces thrombus size with a 
      mechanism most likely dependent of the inhibition of TF activity and NETs 
      formation. These results provide a new link between platelet-produced thromboxane 
      and the occurrence of venous thrombosis.
CI  - Copyright © 2016 Elsevier Ltd. All rights reserved.
FAU - Tarantino, Eva
AU  - Tarantino E
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Amadio, Patrizia
AU  - Amadio P
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Squellerio, Isabella
AU  - Squellerio I
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Porro, Benedetta
AU  - Porro B
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Sandrini, Leonardo
AU  - Sandrini L
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Turnu, Linda
AU  - Turnu L
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Cavalca, Viviana
AU  - Cavalca V
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy; Dipartimento di Scienze 
      Cliniche e di Comunità, University of Milan, Milan, Italy.
FAU - Tremoli, Elena
AU  - Tremoli E
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Barbieri, Silvia S
AU  - Barbieri SS
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy. Electronic address: 
      silvia.barbieri@ccfm.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160405
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - 9035-58-9 (Thromboplastin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/metabolism
MH  - Cell-Derived Microparticles
MH  - Disease Models, Animal
MH  - Male
MH  - Mice
MH  - Neutrophils/drug effects
MH  - Platelet Activation/*drug effects
MH  - *Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Thromboplastin/metabolism
MH  - Thromboxanes/*metabolism
MH  - Vena Cava, Inferior/surgery
MH  - Venous Thrombosis/*drug therapy/metabolism
OTO - NOTNLM
OT  - Aspirin
OT  - NETs
OT  - Thromboxane
OT  - Tissue factor
OT  - Venous thrombosis
EDAT- 2016/04/12 06:00
MHDA- 2017/03/21 06:00
CRDT- 2016/04/12 06:00
PHST- 2015/12/11 00:00 [received]
PHST- 2016/03/31 00:00 [revised]
PHST- 2016/04/02 00:00 [accepted]
PHST- 2016/04/12 06:00 [entrez]
PHST- 2016/04/12 06:00 [pubmed]
PHST- 2017/03/21 06:00 [medline]
AID - S1043-6618(15)30238-3 [pii]
AID - 10.1016/j.phrs.2016.04.001 [doi]
PST - ppublish
SO  - Pharmacol Res. 2016 May;107:415-425. doi: 10.1016/j.phrs.2016.04.001. Epub 2016 
      Apr 5.

PMID- 29444936
OWN - NLM
STAT- MEDLINE
DCOM- 20190627
LR  - 20210217
IS  - 1539-7262 (Electronic)
IS  - 0022-2275 (Print)
IS  - 0022-2275 (Linking)
VI  - 59
IP  - 5
DP  - 2018 May
TI  - Aspirin alone and combined with a statin suppresses eicosanoid formation in human 
      colon tissue.
PG  - 864-871
LID - 10.1194/jlr.M078725 [doi]
AB  - Eicosanoids, including prostaglandins (PGs) and thromboxanes, are broadly 
      bioactive lipid mediators and increase colon tumorigenesis possibly through 
      chronic inflammatory mechanisms. Epidemiological and experimental data suggest 
      that acetylsalicylic acid (ASA) helps prevent colorectal cancer (CRC), possibly 
      through cyclooxygenase (COX)-mediated suppression of eicosanoid, particularly 
      PGE(2), formation. Recent studies suggest that statins prevent CRC and improve 
      survival after diagnosis. We identified patients on ASA and/or statin treatment 
      undergoing routine colonoscopy and measured eicosanoid levels in colonic mucosa 
      with targeted metabolomics technology (LC-MS/MS). ASA-treated individuals (n = 
      27) had significantly lower tissue eicosanoid levels of most COX-derived 
      metabolites than untreated individuals (n = 31). In contrast, COX-derived lipid 
      metabolites tended to be higher in patients with statin treatment (n = 7) as 
      compared with those not receiving statins (n = 24). This effect was not 
      discernible in subjects treated with ASA and statins (n = 11): Individuals 
      treated with both drugs showed a pronounced suppression of COX-derived 
      eicosanoids in colon tissue, even compared with subjects treated with ASA alone. 
      Our data from a routine clinical setting support the hypothesis that ASA and 
      statins could inhibit CRC development via lipid mediator modification. Further 
      studies should directly investigate the effect of dual ASA and statin treatment 
      on colon tumorigenesis in humans.
CI  - Copyright © 2018 by the American Society for Biochemistry and Molecular Biology, 
      Inc.
FAU - Gottschall, Heike
AU  - Gottschall H
AUID- ORCID: 0000-0002-7334-2154
AD  - Department of Gastroenterology, Sana Klinikum Lichtenberg, Berlin, Germany.
FAU - Schmöcker, Christoph
AU  - Schmöcker C
AD  - Department of Gastroenterology, Sana Klinikum Lichtenberg, Berlin, Germany.
AD  - Medical Department, Division of Gastroenterology, Oncology, Hematology, 
      Rheumatology, and Diabetes, Ruppiner Kliniken, Brandenburg Medical School, 
      Neuruppin, Germany.
FAU - Hartmann, Dirk
AU  - Hartmann D
AD  - Department of Gastroenterology, Sana Klinikum Lichtenberg, Berlin, Germany.
FAU - Rohwer, Nadine
AU  - Rohwer N
AD  - Medical Department, Division of Hepatology and Gastroenterology, Campus 
      Virchow-Klinikum, Charité University Medicine, Berlin, Germany.
FAU - Rund, Katharina
AU  - Rund K
AD  - Institute for Food Toxicology, University for Veterinary Medicine Hannover, 
      Hannover, Germany.
FAU - Kutzner, Laura
AU  - Kutzner L
AD  - Institute for Food Toxicology, University for Veterinary Medicine Hannover, 
      Hannover, Germany.
FAU - Nolte, Fabian
AU  - Nolte F
AD  - Institute for Food Toxicology, University for Veterinary Medicine Hannover, 
      Hannover, Germany.
FAU - Ostermann, Annika I
AU  - Ostermann AI
AD  - Institute for Food Toxicology, University for Veterinary Medicine Hannover, 
      Hannover, Germany.
AD  - Chair of Food Chemistry, Faculty of Mathematics and Natural Sciences, University 
      of Wuppertal, Wuppertal, Germany.
FAU - Schebb, Nils Helge
AU  - Schebb NH
AD  - Institute for Food Toxicology, University for Veterinary Medicine Hannover, 
      Hannover, Germany.
AD  - Chair of Food Chemistry, Faculty of Mathematics and Natural Sciences, University 
      of Wuppertal, Wuppertal, Germany.
FAU - Weylandt, Karsten H
AU  - Weylandt KH
AD  - Medical Department, Division of Gastroenterology, Oncology, Hematology, 
      Rheumatology, and Diabetes, Ruppiner Kliniken, Brandenburg Medical School, 
      Neuruppin, Germany karsten.weylandt@mhb-fontane.de.
AD  - Medical Department, Division of Hepatology and Gastroenterology, Campus 
      Virchow-Klinikum, Charité University Medicine, Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180214
PL  - United States
TA  - J Lipid Res
JT  - Journal of lipid research
JID - 0376606
RN  - 0 (Eicosanoids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cohort Studies
MH  - Colon/*drug effects/*metabolism
MH  - Colonoscopy
MH  - Eicosanoids/analysis/*biosynthesis
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & 
      dosage/*pharmacology
MH  - Male
PMC - PMC5928440
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - arachidonic acid
OT  - colorectal cancer
OT  - cyclooxygenase
OT  - lipidomics
COIS- The authors declare no conflicts of interest.
EDAT- 2018/02/16 06:00
MHDA- 2019/06/30 06:00
CRDT- 2018/02/16 06:00
PHST- 2017/06/22 00:00 [received]
PHST- 2018/02/10 00:00 [revised]
PHST- 2018/02/16 06:00 [pubmed]
PHST- 2019/06/30 06:00 [medline]
PHST- 2018/02/16 06:00 [entrez]
AID - S0022-2275(20)33121-7 [pii]
AID - m078725 [pii]
AID - 10.1194/jlr.M078725 [doi]
PST - ppublish
SO  - J Lipid Res. 2018 May;59(5):864-871. doi: 10.1194/jlr.M078725. Epub 2018 Feb 14.

PMID- 36753345
OWN - NLM
STAT- MEDLINE
DCOM- 20230210
LR  - 20230210
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 19
IP  - 813
DP  - 2023 Feb 8
TI  - [Which anticoagulant or antiplatelet treatment for cancer patients with 
      thrombocytopenia ?].
PG  - 281-285
LID - 10.53738/REVMED.2023.19.813.281 [doi]
AB  - Cancer patients have an increased thrombotic risk of arterial and venous 
      thrombosis. Thrombocytopenia, particularly with anticoagulation, exposes the 
      patient to an increased risk of bleeding but does not reduce the risk of 
      recurrent thrombosis. When platelets are < 50 × 109/l, the strategy regarding 
      anticoagulation must be reassessed. Based on the thrombotic and bleeding risks as 
      well as the expected duration of thrombocytopenia, management options include 
      full-dose treatment with platelet transfusion, reduced-dose anticoagulation or 
      withholding antithrombotic therapy. Aspirin treatment appears to be a reasonable 
      choice for thrombocytopenic (> 30 × 109/l) patients with acute coronary syndrome. 
      This paper will review the guidelines on anticoagulation and antiplatelet therapy 
      in thrombocytopenic cancer patients.
FAU - Paoletti, Marco
AU  - Paoletti M
AD  - Service de médecine interne, HFR Fribourg, 1752 Villars-sur-Glâne.
FAU - Azizi, Mehdi Ahmad
AU  - Azizi MA
AD  - Service de médecine interne, HFR Fribourg, 1752 Villars-sur-Glâne.
FAU - Efthymiou, Anna
AU  - Efthymiou A
AD  - Service de médecine interne, HFR Fribourg, 1752 Villars-sur-Glâne.
AD  - Service d'hématologie, HFR Fribourg, 1752 Villars-sur-Glâne.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Quel anticoagulant ou antiagrégant chez le patient oncologique présentant une 
      thrombocytopénie ?
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Anticoagulants
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Thrombocytopenia/complications/drug therapy
MH  - Aspirin/therapeutic use
MH  - *Anemia
MH  - *Thrombosis/drug therapy
MH  - *Neoplasms/drug therapy
COIS- Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
EDAT- 2023/02/09 06:00
MHDA- 2023/02/11 06:00
CRDT- 2023/02/08 12:02
PHST- 2023/02/08 12:02 [entrez]
PHST- 2023/02/09 06:00 [pubmed]
PHST- 2023/02/11 06:00 [medline]
AID - RMS0813-006 [pii]
AID - 10.53738/REVMED.2023.19.813.281 [doi]
PST - ppublish
SO  - Rev Med Suisse. 2023 Feb 8;19(813):281-285. doi: 10.53738/REVMED.2023.19.813.281.

PMID- 3108321
OWN - NLM
STAT- MEDLINE
DCOM- 19870710
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 79
IP  - 6
DP  - 1987 Jun
TI  - Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet 
      cyclooxygenase inhibition.
PG  - 1788-97
AB  - We reported that aspirin (ASA) abnormally prolongs bleeding time (BT) in uremia. 
      The present study was designed to investigate whether the abnormally prolonged 
      post-ASA BT in uremia is due to different ASA pharmacokinetics and 
      bioavailability that might be a consequence of uremic condition, platelet 
      cyclooxygenase is peculiarly sensitive to ASA in uremia, and ASA affects primary 
      hemostasis in uremia by a mechanism independent of cyclooxygenase inhibition. Our 
      results showed that in patients with uremia, but not in normal subjects, ASA 
      markedly prolongs the BT. This effect is transient and depends on the presence of 
      ASA in the blood. The observed differences in ASA kinetic parameters are not an 
      explanation of the exaggerated effect of ASA on primary hemostasis in uremia. The 
      sensitivity of platelet cyclooxygenase to ASA inhibition is comparable in uremics 
      and in normal subjects. The temporal dissociation between ASA-induced 
      prolongation of BT and the effect on platelet thromboxane A2 generation suggests 
      that ASA inhibits platelet function in uremia by a mechanism distinct from 
      cyclooxygenase blocking. This possibility is strengthened by the observation that 
      ibuprofen at a dose that fully inhibits platelet cyclooxygenase activity does not 
      significantly prolong BT.
FAU - Gaspari, F
AU  - Gaspari F
FAU - Viganò, G
AU  - Viganò G
FAU - Orisio, S
AU  - Orisio S
FAU - Bonati, M
AU  - Bonati M
FAU - Livio, M
AU  - Livio M
FAU - Remuzzi, G
AU  - Remuzzi G
LA  - eng
GR  - 1 R01 HL-37491-01/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetylation
MH  - Adult
MH  - Aged
MH  - Aspirin/metabolism/*pharmacology
MH  - *Bleeding Time
MH  - Blood Platelets/*enzymology
MH  - *Cyclooxygenase Inhibitors
MH  - Female
MH  - Hemorrhagic Disorders/etiology
MH  - Humans
MH  - Ibuprofen/pharmacology
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - *Platelet Function Tests
MH  - Thromboxane A2/biosynthesis
MH  - Uremia/*blood/complications
PMC - PMC424522
EDAT- 1987/06/01 00:00
MHDA- 1987/06/01 00:01
CRDT- 1987/06/01 00:00
PHST- 1987/06/01 00:00 [pubmed]
PHST- 1987/06/01 00:01 [medline]
PHST- 1987/06/01 00:00 [entrez]
AID - 10.1172/JCI113020 [doi]
PST - ppublish
SO  - J Clin Invest. 1987 Jun;79(6):1788-97. doi: 10.1172/JCI113020.

PMID- 3929399
OWN - NLM
STAT- MEDLINE
DCOM- 19851021
LR  - 20140912
IS  - 0256-9574 (Print)
VI  - 68
IP  - 5
DP  - 1985 Aug 31
TI  - Long-term ultra-low-dose aspirin therapy and platelet function.
PG  - 307-9
AB  - The effect of ultra-low-dose aspirin on platelet aggregation and thromboxane B2 
      (TXB2) production was studied in two groups of normal subjects. Group 1 received 
      162 mg/d and group 2 received 20 mg/d for 4 weeks. For the first 2 weeks the 
      effects were similar in the two groups, namely inhibition of aggregation and 
      inhibition of TXB2 production. However, after 4 weeks there was significantly 
      less inhibition of platelet aggregation in those receiving 20 mg/d. Inhibition of 
      TXB2 production in the two groups was not significantly different. Two of 9 
      individuals receiving 20 mg/d showed an escape from the aspirin effect by the 4th 
      week. When 40 mg/d was given to these 2 individuals they again responded. A daily 
      dose of 20 mg aspirin is therefore too small to maintain adequate inhibition of 
      platelet function in normal subjects.
FAU - Chetty, N
AU  - Chetty N
FAU - Atkinson, P M
AU  - Atkinson PM
FAU - Bradlow, B A
AU  - Bradlow BA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - 0 (Arachidonic Acids)
RN  - 0 (Thromboxanes)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Arachidonic Acid
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Collagen/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane B2/*blood
MH  - Thromboxanes/*blood
MH  - Time Factors
EDAT- 1985/08/31 00:00
MHDA- 1985/08/31 00:01
CRDT- 1985/08/31 00:00
PHST- 1985/08/31 00:00 [pubmed]
PHST- 1985/08/31 00:01 [medline]
PHST- 1985/08/31 00:00 [entrez]
PST - ppublish
SO  - S Afr Med J. 1985 Aug 31;68(5):307-9.

PMID- 350495
OWN - NLM
STAT- MEDLINE
DCOM- 19780828
LR  - 20190907
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 5
IP  - 6
DP  - 1978
TI  - Oxaprozin versus aspirin in rheumatoid arthritis: a double-blind trial.
PG  - 433-8
AB  - A parallel double-blind trial was carried out over a 3-month period in 40 
      patients suffering from active rheumatoid arthritis to compare the 
      anti-inflammatory effectiveness and side-effects of treatment with oxaprozin and 
      aspirin. The results showed that 1200 mg oxaprozin daily had similar 
      anti-inflammatory properties to those of 3.9 g aspirin daily in rheumatoid 
      arthritis. Better results were produced with 1200 mg oxaproxin daily than with a 
      600 mg dosage level, suggesting that there is a close dose-response relationship. 
      The incidence of side-effects was similar with both drugs. Gastrointestinal 
      intolerance was more frequent and severe in the aspirin group, whereas rash and 
      headache were noted more often in patients receiving oxaprozin.
FAU - Jamar, R
AU  - Jamar R
FAU - Dequeker, J
AU  - Dequeker J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Oxazoles)
RN  - 0 (Propionates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxazoles/adverse effects/*therapeutic use
MH  - Propionates/adverse effects/*therapeutic use
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1185/03007997809111911 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1978;5(6):433-8. doi: 10.1185/03007997809111911.

PMID- 15338971
OWN - NLM
STAT- MEDLINE
DCOM- 20050623
LR  - 20131121
IS  - 0025-7680 (Print)
IS  - 0025-7680 (Linking)
VI  - 64
IP  - 4
DP  - 2004
TI  - [High doses of aspirin reduce natriuresis in hypertensive patients treated with 
      enalapril].
PG  - 301-5
AB  - Angiotensin converting enzyme inhibitors have been shown to be useful in the 
      treatment of essential hypertension while anti-platelet agents improve the 
      overall cardiovascular risk profile in this population. Our aim was to assess the 
      interaction of two different aspirin (ASA) doses--81 and 325 mg/day--with the 
      antihypertensive effect of enalapril as well as their impact upon the urinary 
      sodium excretion (Na(u)). A total of 22 patients between 35 and 65 years of age 
      were included in a prospective double blind trial with a partial cross-over 
      design. We excluded patients with secondary hypertension and recent use of 
      anti-inflammatory drugs. Patients were placed on enalapril and a low sodium 
      diet--<6 g of NaCl/day--and, sequentially, on two different doses of aspirin 
      separated by a 10 day wash out period. Blood pressure (BP) was measured at weekly 
      visits. Systolic, diastolic and mean BP levels decreased significantly in 
      enalapril-treated patients (p<0.01) and no difference was detected between the 
      two AAS dosages although a non-statistically significant difference towards 
      better BP control was observed when 81 mg of ASA was used. Na(u) was higher at 
      baseline when compared with the two periods under ASA (p<0.01) and Na(u) was 
      higher with 81 mg than with 325 mg. These results suggest that in essential 
      hypertensive individuals treated with enalapril and two ASA doses, low doses of 
      ASA are associated with better blood pressure control and higher natriuresis.
FAU - Di Gennaro, Federico P
AU  - Di Gennaro FP
AD  - Departamento de Medicina Interna, Centro de Educación Médica e Investigaciones 
      Clínicas Norberto Quirno, Buenos Aires, Argentina. fdigennaro@sinectis.com.ar
FAU - Cingolani, Oscar H
AU  - Cingolani OH
FAU - Abbate, Alejandro F
AU  - Abbate AF
FAU - Toblli, Jorge E
AU  - Toblli JE
FAU - Vilches, Antonio
AU  - Vilches A
LA  - spa
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Dosis elevadas de aspirina disminuyen la natriuresis en hipertensos tratados con 
      enalapril.
PL  - Argentina
TA  - Medicina (B Aires)
JT  - Medicina
JID - 0204271
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 69PN84IO1A (Enalapril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/antagonists & inhibitors/*therapeutic use
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Enalapril/antagonists & inhibitors/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Natriuresis/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Prospective Studies
EDAT- 2004/09/02 05:00
MHDA- 2005/06/24 09:00
CRDT- 2004/09/02 05:00
PHST- 2004/09/02 05:00 [pubmed]
PHST- 2005/06/24 09:00 [medline]
PHST- 2004/09/02 05:00 [entrez]
PST - ppublish
SO  - Medicina (B Aires). 2004;64(4):301-5.

PMID- 2899236
OWN - NLM
STAT- MEDLINE
DCOM- 19880825
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8605
DP  - 1988 Jul 30
TI  - Effects of intermittent treatment with aspirin on thromboxane and prostacyclin 
      formation in patients with acute myocardial infarction.
PG  - 245-7
AB  - Thromboxane and prostacyclin formation were monitored in twenty patients with 
      acute myocardial infarction. Ten received 500 mg acetylsalicylic acid (ASA) 
      orally starting 12 h after admission and then intermittently every third day for 
      one month; the other ten did not receive ASA or any other drug known to interfere 
      with the synthesis of prostanoids. In the ASA group thromboxane formation, 
      initially raised, fell rapidly and remained low. In the control group thromboxane 
      formation decreased very slowly and was not normal by the end of the study 
      period. Prostacyclin formation seemed identical in the two groups. Thus 
      intermittent ASA, in this dosage, efficiently inhibited the enhanced thromboxane 
      formation in acute myocardial infarction without interfering with prostacyclin 
      formation.
FAU - Rasmanis, G
AU  - Rasmanis G
AD  - Department of Medicine, Huddinge Hospital, Sweden.
FAU - Vesterqvist, O
AU  - Vesterqvist O
FAU - Gréen, K
AU  - Gréen K
FAU - Edhag, O
AU  - Edhag O
FAU - Henriksson, P
AU  - Henriksson P
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology/therapeutic use
MH  - Drug Administration Schedule
MH  - Epoprostenol/*biosynthesis/urine
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*metabolism/urine
MH  - Thromboxane A2/antagonists & inhibitors/*biosynthesis/urine
EDAT- 1988/07/30 00:00
MHDA- 1988/07/30 00:01
CRDT- 1988/07/30 00:00
PHST- 1988/07/30 00:00 [pubmed]
PHST- 1988/07/30 00:01 [medline]
PHST- 1988/07/30 00:00 [entrez]
AID - S0140-6736(88)92537-8 [pii]
AID - 10.1016/s0140-6736(88)92537-8 [doi]
PST - ppublish
SO  - Lancet. 1988 Jul 30;2(8605):245-7. doi: 10.1016/s0140-6736(88)92537-8.

PMID- 16525576
OWN - NLM
STAT- MEDLINE
DCOM- 20060427
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 95
IP  - 3
DP  - 2006 Mar
TI  - Biological efficacy of low against medium dose aspirin regimen after coronary 
      surgery: analysis of platelet function.
PG  - 476-82
AB  - The failure of aspirin to inhibit platelet function has been documented in 
      patients undergoing coronary artery bypass graft (CABG) surgery, but the causes 
      of "aspirin-resistance" remain uncertain. The aim of this study was to 
      investigate the efficacy of aspirin in patients undergoing CABG surgery receiving 
      either 100 mg or 325 mg of oral aspirin for 5-days. Platelet function was tested 
      the day before surgery and on day +1 and day +5, and evaluated by changes in 
      collagen-induced thromboxane-A2 (TxA2) release and platelet aggregation following 
      stimulation with collagen, ADP and epinephrine. In all patients, baseline 
      platelet aggregation was significantly inhibited by pre-incubation with in vitro 
      aspirin (150 micromol/l), with a mean reduction in TxA2-release of >or=95.5% 
      (82.3,99.1). After 5-days of oral aspirin, platelet aggregation was significantly 
      inhibited, and was not further inhibited by in vitro aspirin. Oral aspirin was 
      also associated with a >or=99.5% (97.8, 99.7) reduction in TxA2-release, and with 
      the reversal of the second-phase of ADP-induced aggregation which is 
      TxA2-dependent. In addition a single-dose of 325 mg aspirin on the first 
      post-operative morning may have a greater inhibitory effect on collagen-induced 
      aggregation than 100 mg aspirin. Western blot analysis provided no evidence for 
      the presence of COX-2 in platelets, while the up-regulation of p38-MAPK following 
      platelet-stimulation and surgery was seen. The inhibition of COX-2 (NS398) or 
      p38-MAPK (SB203580) activity did not affect platelet aggregation and TxA2-release 
      on day +5. In summary, there was no evidence for inherent or acquired 
      aspirin-resistance in this surgical population, or for the involvement of either 
      COX-2 or p38-MAPK.
FAU - Cornelissen, Jacqueline
AU  - Cornelissen J
AD  - Department of Clinical Pharmacology, Papworth Hospital NHS Trust, Cambridge, CB3 
      8RE, UK. jacqueline.cornelissen@papworth.nhs.uk
FAU - Kirtland, Stephen
AU  - Kirtland S
FAU - Lim, Eric
AU  - Lim E
FAU - Goddard, Martin
AU  - Goddard M
FAU - Bellm, Sarah
AU  - Bellm S
FAU - Sheridan, Kate
AU  - Sheridan K
FAU - Large, Stephen
AU  - Large S
FAU - Vuylsteke, Alain
AU  - Vuylsteke A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/*drug effects/metabolism
MH  - Collagen/pharmacology
MH  - Coronary Artery Bypass
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Thromboxane A2/metabolism
MH  - Time Factors
EDAT- 2006/03/10 09:00
MHDA- 2006/04/28 09:00
CRDT- 2006/03/10 09:00
PHST- 2006/03/10 09:00 [pubmed]
PHST- 2006/04/28 09:00 [medline]
PHST- 2006/03/10 09:00 [entrez]
AID - 06030476 [pii]
AID - 10.1160/TH05-10-0649 [doi]
PST - ppublish
SO  - Thromb Haemost. 2006 Mar;95(3):476-82. doi: 10.1160/TH05-10-0649.

PMID- 17593823
OWN - NLM
STAT- MEDLINE
DCOM- 20100602
LR  - 20151119
IS  - 1672-173X (Print)
IS  - 1672-173X (Linking)
VI  - 38
IP  - 3
DP  - 2007 Jun
TI  - [The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian 
      cancer].
PG  - 428-32
AB  - OBJECTIVE: To evaluate the effects of two commonly used non-steroidal 
      anti-inflammatory drugs (NSAIDs) Celecoxib and Aspirin on the SKOV3 cell growth, 
      apoptosis and neoplasm genesis of ovarian cancer in vitro and vivo. METHODS: The 
      proliferation of SKOV3 cells were determined by MTT assay, the apoptosis of cell 
      were measured by flow cytometry (FCM), and the cell morphologic changes were 
      observed under inverted phase contrast microscope. Xenografted nude mice models 
      of human ovarian cancer were established, and then randomly allocated to 
      treatment or control group, which was administered with either Celecoxib at the 
      dosage of 10, 25, 50 mg/kg or distilled water alone (control) orally daily for 56 
      d. The mice weight, tumor volume and drug side effects were detected. RESULTS: A 
      dose-dependent inhibition of proliferation of SKOV3 cell appeared after Celecoxib 
      or Aspirin administered for 24 h, and Celecoxib had more inhibiting efficiency to 
      cell growth than Aspirin did. The inhibitory concentration 50% (IC50) in this 
      assay for Celecoxib was 5X 10(-5) mol/L,whereas for Aspirin was 7X 10(-3) mol/L. 
      With cell morphology the "vacuole" presented in the cytoplasm. In contrast to the 
      control, the apoptotic rates (47. 1% and 15. 7%) of SKOV3 were increased after 
      treatment with Celecoxib (5 X 10(-5) mol/L) and Aspirin(7 X 10(-3) mol/L). In 
      nude mice, the average volume of tumor from control mice was (3. 283+/- 0. 432) 
      cm(3) as compared with (2. 457+/- 0. 224) cm(3), (2. 198+/- 0. 500) cm(3), (2. 
      017+/-0. 166) cm' from Celecoxib mice (10, 25, 50 mg/kg), P<0. 05, and the rates 
      of tumor growth inhibited by 3 Celecoxib dosages to SKOV3 cell burden mice were 
      25. 20%, 33. 00% and 38. 60%, in a dose-and time-dependent manner, and 
      histopathologic examinations of kidney, liver, stomach and bowel showed no 
      abnormality, with implying no untoward side effects. CONCLUSION: Both COX-2 
      specific inhibitor Celecoxib and non-selective inhibitor Aspirin can potentially 
      inhibit the tumor growth and induce apoptosis of SKOV3 cells, and the effect of 
      Celecoxib is more potential than that of Aspirin.
FAU - Wang, Hong-jing
AU  - Wang HJ
AD  - Department of Pathology, West China Second Hospital, Sichuan University, Chengdu 
      610041, China.
FAU - Peng, Zhi-lan
AU  - Peng ZL
FAU - Liu, Xiao-qing
AU  - Liu XQ
FAU - Yang, Kai-xuan
AU  - Yang KX
FAU - Lou, Jiang-yan
AU  - Lou JY
FAU - Luo, Feng-ming
AU  - Luo FM
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Sichuan Da Xue Xue Bao Yi Xue Ban
JT  - Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical 
      science edition
JID - 101162609
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology/therapeutic 
      use
MH  - Apoptosis/drug effects
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Celecoxib
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Female
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Ovarian Neoplasms/drug therapy/*pathology
MH  - Pyrazoles/adverse effects/pharmacology/therapeutic use
MH  - Sulfonamides/adverse effects/pharmacology/therapeutic use
MH  - Xenograft Model Antitumor Assays
EDAT- 2007/06/28 09:00
MHDA- 2010/06/03 06:00
CRDT- 2007/06/28 09:00
PHST- 2007/06/28 09:00 [pubmed]
PHST- 2010/06/03 06:00 [medline]
PHST- 2007/06/28 09:00 [entrez]
PST - ppublish
SO  - Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):428-32.

PMID- 10924892
OWN - NLM
STAT- MEDLINE
DCOM- 20000824
LR  - 20191104
IS  - 1056-8719 (Print)
IS  - 1056-8719 (Linking)
VI  - 42
IP  - 2
DP  - 1999 Oct
TI  - Effect of experimental spinal cord injury on salicylate bioavailability after 
      oral aspirin administration.
PG  - 93-7
AB  - The purpose of the present work was to study whether spinal cord injury (SCI) 
      alters salicylate bioavailability after oral aspirin administration. Female 
      Sprague-Dawley rats were subjected to SCI at the T8 level by two procedures, 
      contusion by the weight-drop method and severance by knife, and received a single 
      oral aspirin dose (15 mg/kg) 24 h after injury. Blood samples were drawn and 
      aspirin (ASA) and salicylic acid (SA) concentrations in whole blood were 
      determined at selected times over a period of 240 min. Both SCI procedures 
      produced similar alterations on salicylate bioavailability. ASA bioavailability 
      was not significantly changed by SCI. On the other hand, SA peak concentrations 
      were significantly reduced in 20% to 30%, compared with sham-lesioned controls. 
      The area under the SA concentration against time curve was decreased in 10% to 
      25%, although this difference did not reach statistical significance. Results 
      suggest that SCI at the T8 level decreases the rate, but not the extent, of 
      aspirin absorption from the gastrointestinal tract. SCI-induced alterations in 
      aspirin absorption appeared to be modest compared with those previously reported 
      for other analgesic agents, such as paracetamol (acetaminophen).
FAU - Fuentes-Lara, G
AU  - Fuentes-Lara G
AD  - Proyecto Camina A.C., Mexico.
FAU - Guízar-Sahagún, G
AU  - Guízar-Sahagún G
FAU - García-López, P
AU  - García-López P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharmacol Toxicol Methods
JT  - Journal of pharmacological and toxicological methods
JID - 9206091
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Biological Availability
MH  - Female
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Salicylates/*pharmacokinetics
MH  - Spinal Cord Injuries/*metabolism
EDAT- 2000/08/05 11:00
MHDA- 2000/08/29 11:01
CRDT- 2000/08/05 11:00
PHST- 2000/08/05 11:00 [pubmed]
PHST- 2000/08/29 11:01 [medline]
PHST- 2000/08/05 11:00 [entrez]
AID - S1056-8719(00)00048-4 [pii]
AID - 10.1016/s1056-8719(00)00048-4 [doi]
PST - ppublish
SO  - J Pharmacol Toxicol Methods. 1999 Oct;42(2):93-7. doi: 
      10.1016/s1056-8719(00)00048-4.

PMID- 1216936
OWN - NLM
STAT- MEDLINE
DCOM- 19760415
LR  - 20131121
IS  - 0044-2542 (Print)
IS  - 0044-2542 (Linking)
VI  - 30
IP  - 18
DP  - 1975 Sep 15
TI  - [Hemostasis suppression by a combination of heparin and acetylsalicylic acid].
PG  - 178-80
AB  - The effect of a combined application of acetylsalicylic acid and heparin on 
      haemostasis is examined on 7 healthy test persons. Apart from the change of the 
      plasmatic coagulation and the platelet function by the pharmaca a prolongation of 
      the bleeding time which is larger than the values of the individual application 
      can be established. In the in-vitro-experiment could be proved that the prolonged 
      bleeding time is based on the prevented by acetylsalicylic acid release of the 
      heparin neutralising factor 4 from the platelets. An improvement of the 
      therapeutic effect of heparin when at the same time acetylsalicylic acid is given 
      is discussed.
FAU - Wamhoff, D
AU  - Wamhoff D
FAU - Schmechel, H
AU  - Schmechel H
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Untersuchungen zur Hemmung der Blutstillungsvorgänge durch Kombination von 
      Heparin und Azetylsalizylsäure.
PL  - Germany
TA  - Z Gesamte Inn Med
JT  - Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete
JID - 21730470R
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Drug Therapy, Combination
MH  - Hemostasis/*drug effects
MH  - Heparin/*pharmacology
MH  - Humans
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
EDAT- 1975/09/15 00:00
MHDA- 1975/09/15 00:01
CRDT- 1975/09/15 00:00
PHST- 1975/09/15 00:00 [pubmed]
PHST- 1975/09/15 00:01 [medline]
PHST- 1975/09/15 00:00 [entrez]
PST - ppublish
SO  - Z Gesamte Inn Med. 1975 Sep 15;30(18):178-80.

PMID- 8167839
OWN - NLM
STAT- MEDLINE
DCOM- 19940602
LR  - 20191023
IS  - 1047-2797 (Print)
IS  - 1047-2797 (Linking)
VI  - 3
IP  - 5
DP  - 1993 Sep
TI  - Antiplatelet therapy and risk of stroke.
PG  - 568-70
AB  - Antiplatelet therapy, especially with aspirin, reduces the risks of occlusive 
      vascular disease, including ischemic stroke. In an overview of 25 trials of 
      antiplatelet therapy in patients with prior cardiovascular disease, antiplatelet 
      treatment reduced subsequent nonfatal stroke by 27% (P = 0.0001), nonfatal 
      myocardial infarction by 32% (P = 0.0001), and all vascular deaths by 15% (P = 
      0.0003), with no evidence that other antiplatelet agents were more effective than 
      aspirin, or that higher aspirin doses (900 to 1500 mg daily) were more effective 
      than 300 mg, the lowest daily dose tested. If begun during the acute phase of 
      myocardial infarction, aspirin reduces nonfatal stroke by 46% (P < 0.01) and 
      vascular deaths by 23% (P < 0.00001) after 5 weeks. In primary prevention, 
      currently available data are inconclusive regarding the effect of aspirin therapy 
      on stroke. However, any potential benefit on ischemic stroke must be weighed 
      against the possibility that aspirin could increase the risk of the less common, 
      but clinically more severe, strokes of hemorrhagic etiology.
FAU - Hennekens, C H
AU  - Hennekens CH
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, MA.
FAU - Jonas, M A
AU  - Jonas MA
FAU - Buring, J E
AU  - Buring JE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Epidemiol
JT  - Annals of epidemiology
JID - 9100013
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Factors
EDAT- 1993/09/01 00:00
MHDA- 1993/09/01 00:01
CRDT- 1993/09/01 00:00
PHST- 1993/09/01 00:00 [pubmed]
PHST- 1993/09/01 00:01 [medline]
PHST- 1993/09/01 00:00 [entrez]
AID - 1047-2797(93)90118-N [pii]
AID - 10.1016/1047-2797(93)90118-n [doi]
PST - ppublish
SO  - Ann Epidemiol. 1993 Sep;3(5):568-70. doi: 10.1016/1047-2797(93)90118-n.

PMID- 3724298
OWN - NLM
STAT- MEDLINE
DCOM- 19860730
LR  - 20151119
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 8
IP  - 4
DP  - 1986 Apr
TI  - In vitro teratogenicity of acetylsalicylic acid on rat embryos: studies with 
      various culture conditions.
PG  - 227-32
AB  - Rat embryos taken at day 9.5 of gestation were exposed in vitro to 
      acetylsalicylic acid (aspirin) using various culture conditions. It was observed 
      that embryos were sensitive to aspirin emulsified in olive oil at concentrations 
      greater than or equal to 150 micrograms/ml. Between 43% and 66% of the embryos 
      exhibited multiple malformations depending on the culture medium, 100% homologous 
      rat serum or Waymouth medium supplemented with 50% rat serum, respectively. At 
      concentrations greater than or equal to 400 micrograms/ml aspirin induced further 
      toxic effects on embryo growth and differentiation. When gelatin was used as the 
      drug-delivery system, aspirin at concentrations of greater than or equal to 150 
      micrograms/ml induced some malformations (mainly irregular somite shapes) in 57% 
      of the embryos cultured in Waymouth medium, but in only 13% of the embryos grown 
      in 100% serum. At concentrations which were greater than or equal to 400 
      micrograms/ml aspirin induced dysmorphogenic effects in all embryos, without any 
      concomittant toxicity.
FAU - Cicurel, L
AU  - Cicurel L
FAU - Schmid, B
AU  - Schmid B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - 0 (Culture Media)
RN  - 0 (Oils)
RN  - 0 (Olive Oil)
RN  - 0 (Pharmaceutical Vehicles)
RN  - 0 (Plant Oils)
RN  - 0 (Teratogens)
RN  - 9000-70-8 (Gelatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Culture Media
MH  - Embryo, Mammalian/drug effects
MH  - Gelatin
MH  - In Vitro Techniques
MH  - Oils
MH  - Olive Oil
MH  - Pharmaceutical Vehicles
MH  - *Plant Oils
MH  - Rats
MH  - *Teratogens
EDAT- 1986/04/01 00:00
MHDA- 1986/04/01 00:01
CRDT- 1986/04/01 00:00
PHST- 1986/04/01 00:00 [pubmed]
PHST- 1986/04/01 00:01 [medline]
PHST- 1986/04/01 00:00 [entrez]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 1986 Apr;8(4):227-32.

PMID- 6227296
OWN - NLM
STAT- MEDLINE
DCOM- 19831220
LR  - 20190514
IS  - 0003-4932 (Print)
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 198
IP  - 6
DP  - 1983 Dec
TI  - Aspirin and dipyridamole reduce platelet deposition on prosthetic 
      femoro-popliteal grafts in man.
PG  - 713-6
AB  - Platelet inhibitory drugs may be used in an attempt to reduce high failure rates 
      in small artery bypass using prosthetic grafts. We evaluated in patients the 
      effects of aspirin and dipyridamole (ASA/DPM) on radiolabelled platelet 
      accumulation on femoro-popliteal grafts of Dacron, polytetrafluorethylene and 
      saphenous vein. Forty-seven patients awaiting femoro-popliteal bypass received, 
      at random and double blind, either ASA/DPM or placebo capsules. On the seventh 
      postoperative day, the 42 remaining patients with patent grafts were injected 
      with autologous 111-Indium labelled platelets. Graft platelet accumulation was 
      expressed as the Thrombogenicity Index (TI), which was defined as the mean daily 
      rise in the ratio of radioactivity over the graft to that over the contralateral 
      thigh. ASA/DPM reduced mean (+/- s.e. mean) TI in Dacron grafts from 0.25 +/- 
      0.09 on placebo to 0.16 +/- 0.05 (p less than 0.05). Mean TI in 
      polytetrafluorethylene grafts was also significantly lower at 0.06 +/- 0.01 on 
      ASA/DPM compared to 0.16 +/- 0.03 on placebo. Vein grafts, however, accumulated 
      few, if any, labelled platelets and ASA/DPM had no further influence. ASA/DPM 
      reduces platelet accumulation in prosthetic femoro-popliteal grafts in man.
FAU - Goldman, M D
AU  - Goldman MD
FAU - Simpson, D
AU  - Simpson D
FAU - Hawker, R J
AU  - Hawker RJ
FAU - Norcott, H C
AU  - Norcott HC
FAU - McCollum, C N
AU  - McCollum CN
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 0 (Drug Combinations)
RN  - 0 (Polyethylene Terephthalates)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/blood/*surgery
MH  - Aspirin/administration & dosage/*pharmacology
MH  - *Blood Vessel Prosthesis
MH  - Clinical Trials as Topic
MH  - Dipyridamole/administration & dosage/*pharmacology
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Femoral Artery/*surgery
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Polyethylene Terephthalates
MH  - Polytetrafluoroethylene
MH  - Popliteal Artery/*surgery
MH  - Saphenous Vein/surgery
MH  - Thrombosis/prevention & control
PMC - PMC1353219
EDAT- 1983/12/01 00:00
MHDA- 1983/12/01 00:01
CRDT- 1983/12/01 00:00
PHST- 1983/12/01 00:00 [pubmed]
PHST- 1983/12/01 00:01 [medline]
PHST- 1983/12/01 00:00 [entrez]
AID - 10.1097/00000658-198312000-00008 [doi]
PST - ppublish
SO  - Ann Surg. 1983 Dec;198(6):713-6. doi: 10.1097/00000658-198312000-00008.

PMID- 12732586
OWN - NLM
STAT- MEDLINE
DCOM- 20030627
LR  - 20160726
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
VI  - 41
IP  - 6
DP  - 2003 Jun
TI  - Administration time-dependent effects of aspirin on blood pressure in untreated 
      hypertensive patients.
PG  - 1259-67
AB  - Previous studies on the potential influence of aspirin on blood pressure have not 
      taken into consideration the chronopharmacological effects of nonsteroidal 
      anti-inflammatory drugs. This pilot study investigates the effects of aspirin on 
      blood pressure in untreated hypertensive patients who received aspirin at 
      different times of the day according to their rest-activity cycle. We studied 100 
      untreated patients with mild hypertension (34 men and 66 women), 42.5+/-11.6 
      (mean+/-SD) years of age, randomly divided into 3 groups: nonpharmacological 
      hygienic-dietary recommendations; the same recommendations and aspirin (100 mg/d) 
      on awakening; or the same recommendations and aspirin before bedtime. Blood 
      pressure was measured every 20 minutes during the day and every 30 minutes at 
      night for 48 consecutive hours before and after 3 months of intervention. The 
      circadian pattern of blood pressure in each group was established by population 
      multiple-component analysis. After 3 months of nonpharmacological intervention, 
      there was a small, nonsignificant reduction of blood pressure (<1.1 mm Hg; 
      P>0.341). There was no change in blood pressure when aspirin was given on 
      awakening (P=0.229). A highly significant blood pressure reduction was, however, 
      observed in the patients who received aspirin before bedtime (decrease of 6 and 4 
      mm Hg in systolic and diastolic blood pressure, respectively; P<0.001). Results 
      indicate a statistically significant administration time-dependent effect of 
      low-dose aspirin on blood pressure in untreated patients with mild hypertension. 
      The influence of aspirin on blood pressure demonstrated in this study indicates 
      the need to quantify and control for aspirin effects in patients using this drug 
      in combination with antihypertensive medication.
FAU - Hermida, Ramón C
AU  - Hermida RC
AD  - Bioengineering and Chronobiology Laboratories, E.T.S.I. Telecomunicación, 
      University of Vigo, Vigo, Pontevedra 36200, Spain. rhermida@tsc.uvigo.es
FAU - Ayala, Diana E
AU  - Ayala DE
FAU - Calvo, Carlos
AU  - Calvo C
FAU - López, José E
AU  - López JE
FAU - Fernández, José R
AU  - Fernández JR
FAU - Mojón, Artemio
AU  - Mojón A
FAU - Domínguez, María J
AU  - Domínguez MJ
FAU - Covelo, Manuel
AU  - Covelo M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20030505
PL  - United States
TA  - Hypertension
JT  - Hypertension (Dallas, Tex. : 1979)
JID - 7906255
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Hypertension. 2004 Apr;43(4):e22-3; author reply e22-3. PMID: 14967832
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Blood Pressure Monitoring, Ambulatory
MH  - Circadian Rhythm
MH  - Demography
MH  - Diet
MH  - Drug Administration Schedule
MH  - Female
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Hygiene
MH  - Hypertension/blood/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Time Factors
EDAT- 2003/05/07 05:00
MHDA- 2003/06/28 05:00
CRDT- 2003/05/07 05:00
PHST- 2003/05/07 05:00 [pubmed]
PHST- 2003/06/28 05:00 [medline]
PHST- 2003/05/07 05:00 [entrez]
AID - 01.HYP.0000072335.73748.0D [pii]
AID - 10.1161/01.HYP.0000072335.73748.0D [doi]
PST - ppublish
SO  - Hypertension. 2003 Jun;41(6):1259-67. doi: 10.1161/01.HYP.0000072335.73748.0D. 
      Epub 2003 May 5.

PMID- 28583479
OWN - NLM
STAT- MEDLINE
DCOM- 20191025
LR  - 20191025
IS  - 2213-2201 (Electronic)
VI  - 6
IP  - 1
DP  - 2018 Jan-Feb
TI  - Smoking Cessation as a Possible Risk Factor for the Development of 
      Aspirin-Exacerbated Respiratory Disease in Smokers.
PG  - 116-125.e3
LID - S2213-2198(17)30351-3 [pii]
LID - 10.1016/j.jaip.2017.04.035 [doi]
AB  - BACKGROUND: The pathogenesis of aspirin-exacerbated respiratory disease (AERD) is 
      characterized by the low expression of cyclooxygenase-2 (COX-2) in airway 
      epithelia, which decreases the production of prostaglandin E(2) (PGE(2)). 
      Conversely, cigarette smoke stimulates COX-2 expression in airway epithelia. 
      Therefore, it was hypothesized that the development of AERD would be suppressed 
      by elevated PGE(2) levels in smokers, and smoking cessation might increase 
      susceptibility to AERD. OBJECTIVE: The objective of this study was to evaluate 
      the relationship between smoking and the risk of AERD development. METHODS: The 
      smoking status of patients with AERD (n = 114) was compared with 2 control groups 
      with aspirin-tolerant asthma (ATA), patients diagnosed by a systemic aspirin 
      provocation test (ATA-1, n = 83) and outpatients randomly selected from a 
      large-scale dataset (ATA-2, n = 914), as well as a healthy control group (HC, n = 
      2313). RESULTS: At the age of asthma onset, there was a low frequency of current 
      smokers (9.7%), but a high frequency of past smokers (20.2%) in the AERD group 
      compared with the ATA-1 (20.5% and 12.0% for current and past smokers, 
      respectively), ATA-2 (24.5% and 10.3%, respectively), and HC group (26.2% and 
      12.6%, respectively). After adjustment for confounding variables, AERD was 
      positively associated with smoking cessation between 1 and 4 years before disease 
      onset compared with the ATA-2 group (adjusted odds ratio [aOR] 4.63, 95% 
      confidence interval [CI]: 2.16-9.93) and the HC group (aOR 4.09, 95% CI: 
      2.07-8.05), implying that smoking cessation was followed by the development of 
      AERD. CONCLUSION: Smoking cessation may be a risk factor for the development of 
      AERD.
CI  - Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Hayashi, Hiroaki
AU  - Hayashi H
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara National 
      Hospital, Sagamihara, Kanagawa, Japan; Department of Respiratory Medicine, Nagoya 
      University Graduate School of Medicine, Nagoya, Japan.
FAU - Fukutomi, Yuma
AU  - Fukutomi Y
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara National 
      Hospital, Sagamihara, Kanagawa, Japan.
FAU - Mitsui, Chihiro
AU  - Mitsui C
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara National 
      Hospital, Sagamihara, Kanagawa, Japan.
FAU - Nakatani, Eiji
AU  - Nakatani E
AD  - Translational Research Informatics Center, Foundation for Biomedical Research and 
      Innovation, Kobe, Japan.
FAU - Watai, Kentaro
AU  - Watai K
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara National 
      Hospital, Sagamihara, Kanagawa, Japan; Department of Allergy and Clinical 
      Immunology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
FAU - Kamide, Yosuke
AU  - Kamide Y
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara National 
      Hospital, Sagamihara, Kanagawa, Japan.
FAU - Sekiya, Kiyoshi
AU  - Sekiya K
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara National 
      Hospital, Sagamihara, Kanagawa, Japan.
FAU - Tsuburai, Takahiro
AU  - Tsuburai T
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara National 
      Hospital, Sagamihara, Kanagawa, Japan.
FAU - Ito, Satoru
AU  - Ito S
AD  - Department of Respiratory Medicine, Nagoya University Graduate School of 
      Medicine, Nagoya, Japan.
FAU - Hasegawa, Yoshinori
AU  - Hasegawa Y
AD  - Department of Respiratory Medicine, Nagoya University Graduate School of 
      Medicine, Nagoya, Japan.
FAU - Taniguchi, Masami
AU  - Taniguchi M
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara National 
      Hospital, Sagamihara, Kanagawa, Japan. Electronic address: 
      m-taniguchi@sagamihara-hosp.gr.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170602
PL  - United States
TA  - J Allergy Clin Immunol Pract
JT  - The journal of allergy and clinical immunology. In practice
JID - 101597220
RN  - 0 (Allergens)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Allergens/*immunology
MH  - Aspirin/*immunology/therapeutic use
MH  - Asthma, Aspirin-Induced/*epidemiology
MH  - Cyclooxygenase 2/*metabolism
MH  - Dinoprostone/*metabolism
MH  - Disease Susceptibility
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiratory Mucosa/immunology/*metabolism
MH  - Risk Factors
MH  - Smokers
MH  - *Smoking Cessation
OTO - NOTNLM
OT  - Aspirin-exacerbated respiratory disease
OT  - Cyclooxygenase-2
OT  - Prostaglandin E(2)
OT  - Smoking
OT  - Smoking cessation
EDAT- 2017/06/07 06:00
MHDA- 2019/10/28 06:00
CRDT- 2017/06/07 06:00
PHST- 2016/09/02 00:00 [received]
PHST- 2017/03/24 00:00 [revised]
PHST- 2017/04/18 00:00 [accepted]
PHST- 2017/06/07 06:00 [pubmed]
PHST- 2019/10/28 06:00 [medline]
PHST- 2017/06/07 06:00 [entrez]
AID - S2213-2198(17)30351-3 [pii]
AID - 10.1016/j.jaip.2017.04.035 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol Pract. 2018 Jan-Feb;6(1):116-125.e3. doi: 
      10.1016/j.jaip.2017.04.035. Epub 2017 Jun 2.

PMID- 32654613
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 9
IP  - 14
DP  - 2020 Jul 21
TI  - Influence of Sex on Platelet Reactivity in Response to Aspirin.
PG  - e014726
LID - 10.1161/JAHA.119.014726 [doi]
LID - e014726
AB  - Background There are sex differences in the efficacy and safety of aspirin for 
      the prevention of myocardial infarction and stroke. Whether this is explained by 
      underlying differences in platelet reactivity and aspirin response remains poorly 
      understood. Methods and Results Healthy volunteers (n=378 208 women) and patients 
      with coronary artery disease or coronary artery disease risk factors (n=217 112 
      women) took aspirin for 4 weeks. Light transmittance aggregometry using 
      platelet-rich plasma was used to measure platelet reactivity in response to 
      epinephrine, collagen, and ADP at baseline, 3 hours after the first aspirin dose, 
      and after 4 weeks of daily aspirin therapy. A subset of patients underwent 
      pharmacokinetic and pharmacodynamic assessment with levels of salicylate and 
      cyclooxygenase-1-derived prostaglandin metabolites and light transmittance 
      aggregometry in response to arachidonic acid and after ex vivo exposure to 
      aspirin. At baseline, women had increased platelet aggregation in response to ADP 
      and collagen. Innate platelet response to aspirin, assessed with ex vivo aspirin 
      exposure of baseline platelets, did not differ by sex. Three hours after the 
      first oral aspirin dose, platelet aggregation was inhibited in women to a greater 
      degree in response to epinephrine and to a lesser degree with collagen. After 
      4 weeks of daily therapy, despite higher salicylate concentrations and greater 
      cyclooxygenase-1 inhibition, women exhibited an attenuation of platelet 
      inhibition in response to epinephrine and ADP. Conclusions We observed 
      agonist-dependent sex differences in platelet responses to aspirin. Despite 
      higher cyclooxygenase-1 inhibition, daily aspirin exposure resulted in a 
      paradoxical attenuation of platelet inhibition in response to epinephrine and ADP 
      over time in women but not in men.
FAU - Friede, Kevin A
AU  - Friede KA
AD  - Division of Cardiology Duke University Durham NC.
AD  - Center for Applied Genomics & Precision Medicine Duke University Durham NC.
FAU - Infeld, Margaret M
AU  - Infeld MM
AD  - Division of Cardiology Larner College of Medicine at the University of Vermont 
      Burlington VT.
FAU - Tan, Ru San
AU  - Tan RS
AD  - Department of Cardiology National Heart Centre Singapore.
FAU - Knickerbocker, Holly J
AU  - Knickerbocker HJ
AD  - Center for Applied Genomics & Precision Medicine Duke University Durham NC.
FAU - Myers, Rachel A
AU  - Myers RA
AD  - Center for Applied Genomics & Precision Medicine Duke University Durham NC.
FAU - Dubois, Laura G
AU  - Dubois LG
AD  - Center for Genomic and Computational Biology Duke University Durham NC.
FAU - Thompson, J Will
AU  - Thompson JW
AD  - Center for Genomic and Computational Biology Duke University Durham NC.
FAU - Kaddurah-Daouk, Rima
AU  - Kaddurah-Daouk R
AD  - Institute for Brain Sciences Duke University Durham NC.
FAU - Ginsburg, Geoffrey S
AU  - Ginsburg GS
AD  - Division of Cardiology Duke University Durham NC.
AD  - Center for Applied Genomics & Precision Medicine Duke University Durham NC.
FAU - Ortel, Thomas L
AU  - Ortel TL
AD  - Division of Hematology Duke University Durham NC.
FAU - Voora, Deepak
AU  - Voora D
AD  - Division of Cardiology Duke University Durham NC.
AD  - Center for Applied Genomics & Precision Medicine Duke University Durham NC.
LA  - eng
GR  - R01 HL118049/HL/NHLBI NIH HHS/United States
GR  - UL1 RR024128/RR/NCRR NIH HHS/United States
GR  - RC1 GM091083/GM/NIGMS NIH HHS/United States
GR  - U01 DD000014/DD/NCBDD CDC HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200711
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - *Sex Characteristics
MH  - Young Adult
PMC - PMC7660714
OTO - NOTNLM
OT  - aspirin
OT  - platelets
OT  - sex differences
EDAT- 2020/07/14 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - JAH35223 [pii]
AID - 10.1161/JAHA.119.014726 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2020 Jul 21;9(14):e014726. doi: 10.1161/JAHA.119.014726. Epub 
      2020 Jul 11.

PMID- 1148971
OWN - NLM
STAT- MEDLINE
DCOM- 19751106
LR  - 20181113
IS  - 0008-4409 (Print)
IS  - 0008-4409 (Linking)
VI  - 113
IP  - 1
DP  - 1975 Jul 12
TI  - A practical classification of untoward drug effects.
PG  - 32-4
AB  - All drug effects can be explained as results of complex interactions between the 
      drug, the patient and his condition, and additional extrinsic factors. On the 
      basis of these three "determinants", a practical classification of untoward drug 
      effects (UDE) is suggested. UDE lists using this classification would fulfill the 
      physician's informational needs better than the material with which he is 
      presently provided.
FAU - Gysling, E
AU  - Gysling E
FAU - Heisler, S
AU  - Heisler S
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Med Assoc J
JT  - Canadian Medical Association journal
JID - 0414110
RN  - 0 (Penicillins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Drug Hypersensitivity/etiology
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - Penicillins/adverse effects
MH  - Pharmacology
PMC - PMC1956317
EDAT- 1975/07/12 00:00
MHDA- 1975/07/12 00:01
CRDT- 1975/07/12 00:00
PHST- 1975/07/12 00:00 [pubmed]
PHST- 1975/07/12 00:01 [medline]
PHST- 1975/07/12 00:00 [entrez]
PST - ppublish
SO  - Can Med Assoc J. 1975 Jul 12;113(1):32-4.

PMID- 25401325
OWN - NLM
STAT- MEDLINE
DCOM- 20141223
LR  - 20220408
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 312
IP  - 23
DP  - 2014 Dec 17
TI  - Low-dose aspirin for primary prevention of cardiovascular events in Japanese 
      patients 60 years or older with atherosclerotic risk factors: a randomized 
      clinical trial.
PG  - 2510-20
LID - 10.1001/jama.2014.15690 [doi]
AB  - IMPORTANCE: Prevention of atherosclerotic cardiovascular diseases is an important 
      public health priority in Japan due to an aging population. OBJECTIVE: To 
      determine whether daily, low-dose aspirin reduces the incidence of cardiovascular 
      events in older Japanese patients with multiple atherosclerotic risk factors. 
      DESIGN, SETTING, AND PARTICIPANTS: The Japanese Primary Prevention Project (JPPP) 
      was a multicenter, open-label, randomized, parallel-group trial. Patients 
      (N = 14,464) were aged 60 to 85 years, presenting with hypertension, 
      dyslipidemia, or diabetes mellitus recruited by primary care physicians at 1007 
      clinics in Japan between March 2005 and June 2007, and were followed up for up to 
      6.5 years, with last follow-up in May 2012. A multidisciplinary expert panel 
      (blinded to treatment assignments) adjudicated study outcomes. INTERVENTIONS: 
      Patients were randomized 1:1 to enteric-coated aspirin 100 mg/d or no aspirin in 
      addition to ongoing medications. MAIN OUTCOMES AND MEASURES: Composite primary 
      outcome was death from cardiovascular causes (myocardial infarction, stroke, and 
      other cardiovascular causes), nonfatal stroke (ischemic or hemorrhagic, including 
      undefined cerebrovascular events), and nonfatal myocardial infarction. Secondary 
      outcomes included individual end points. RESULTS: The study was terminated early 
      by the data monitoring committee after a median follow-up of 5.02 years 
      (interquartile range, 4.55-5.33) based on likely futility. In both the aspirin 
      and no aspirin groups, 56 fatal events occurred. Patients with an occurrence of 
      nonfatal stroke totaled 114 in the aspirin group and 108 in the no aspirin group; 
      of nonfatal myocardial infarction, 20 in the aspirin group and 38 in the no 
      aspirin group; of undefined cerebrovascular events, 3 in the aspirin group and 5 
      in the no aspirin group. The 5-year cumulative primary outcome event rate was not 
      significantly different between the groups (2.77% [95% CI, 2.40%-3.20%] for 
      aspirin vs 2.96% [95% CI, 2.58%-3.40%] for no aspirin; hazard ratio [HR], 0.94 
      [95% CI, 0.77-1.15]; P = .54). Aspirin significantly reduced incidence of 
      nonfatal myocardial infarction (0.30 [95% CI, 0.19-0.47] for aspirin vs 0.58 [95% 
      CI, 0.42-0.81] for no aspirin; HR, 0.53 [95% CI, 0.31-0.91]; P = .02) and 
      transient ischemic attack (0.26 [95% CI, 0.16-0.42] for aspirin vs 0.49 [95% CI, 
      0.35-0.69] for no aspirin; HR, 0.57 [95% CI, 0.32-0.99]; P = .04), and 
      significantly increased the risk of extracranial hemorrhage requiring transfusion 
      or hospitalization (0.86 [95% CI, 0.67-1.11] for aspirin vs 0.51 [95% CI, 
      0.37-0.72] for no aspirin; HR, 1.85 [95% CI, 1.22-2.81]; P = .004). CONCLUSIONS 
      AND RELEVANCE: Once-daily, low-dose aspirin did not significantly reduce the risk 
      of the composite outcome of cardiovascular death, nonfatal stroke, and nonfatal 
      myocardial infarction among Japanese patients 60 years or older with 
      atherosclerotic risk factors. TRIAL REGISTRATION: clinicaltrials.gov Identifier: 
      NCT00225849.
FAU - Ikeda, Yasuo
AU  - Ikeda Y
AD  - Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, 
      Japan.
FAU - Shimada, Kazuyuki
AU  - Shimada K
AD  - Department of Cardiology, Shin-Oyama City Hospital, Tochigi, Japan.
FAU - Teramoto, Tamio
AU  - Teramoto T
AD  - Teikyo Academic Research Center, Teikyo University, Tokyo, Japan.
FAU - Uchiyama, Shinichiro
AU  - Uchiyama S
AD  - Clinical Research Center for Medicine, International University of Health and 
      Welfare, Tokyo, Japan.
FAU - Yamazaki, Tsutomu
AU  - Yamazaki T
AD  - Clinical Research Support Center, Center for Epidemiology and Preventive 
      Medicine, The University of Tokyo Hospital, Japan.
FAU - Oikawa, Shinichi
AU  - Oikawa S
AD  - Diabetes and Lifestyle Disease Center, Fukujuji Hospital, Tokyo, Japan.
FAU - Sugawara, Masahiro
AU  - Sugawara M
AD  - Department of Internal Medicine, Sugawara Medical Clinic, Tokyo, Japan.
FAU - Ando, Katsuyuki
AU  - Ando K
AD  - Department of Internal Medicine, Kitamura Memorial Clinic, Tokyo, Japan.
FAU - Murata, Mitsuru
AU  - Murata M
AD  - Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, 
      Japan.
FAU - Yokoyama, Kenji
AU  - Yokoyama K
AD  - Department of Hematology, Tokai University Hachioji Hospital, Tokyo, Japan.
FAU - Ishizuka, Naoki
AU  - Ishizuka N
AD  - Clinical Trial Department, Cancer Institute Hospital, Tokyo, Japan.
LA  - eng
SI  - ClinicalTrials.gov/NCT00225849
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2014 Dec 17;312(23):2503-4. PMID: 25402671
CIN - Nat Rev Cardiol. 2015 Jan;12(1):3. PMID: 25445143
CIN - Praxis (Bern 1994). 2015 Feb 11;104(4):205-6. PMID: 25669226
CIN - JAMA. 2015 Apr 14;313(14):1473. PMID: 25871676
CIN - JAMA. 2015 Apr 14;313(14):1473-4. PMID: 25871677
CIN - JAMA. 2015 Apr 14;313(14):1473. PMID: 25871678
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus
MH  - Double-Blind Method
MH  - Dyslipidemias/complications
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Hypertension/complications
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Primary Prevention
MH  - Risk Factors
MH  - Survival Analysis
EDAT- 2014/11/18 06:00
MHDA- 2014/12/24 06:00
CRDT- 2014/11/18 06:00
PHST- 2014/11/18 06:00 [entrez]
PHST- 2014/11/18 06:00 [pubmed]
PHST- 2014/12/24 06:00 [medline]
AID - 1936801 [pii]
AID - 10.1001/jama.2014.15690 [doi]
PST - ppublish
SO  - JAMA. 2014 Dec 17;312(23):2510-20. doi: 10.1001/jama.2014.15690.

PMID- 23607225
OWN - NLM
STAT- MEDLINE
DCOM- 20130508
LR  - 20181202
IS  - 0019-1442 (Print)
IS  - 0019-1442 (Linking)
VI  - 66
IP  - 1-2
DP  - 2013 Jan 30
TI  - Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. 
      Part II: Potential causes and laboratory tests.
PG  - 15-22
AB  - Recent meta-analyses have indicated that patients with vascular disease 
      demonstrated by laboratory tests to be aspirin or clopidogrel-resistant are at an 
      increased risk of major vascular events. The suggested mechanisms of aspirin 
      resistance include genetic polymorphism, alternative pathways of platelet 
      activation, aspirin-insensitive thromboxane biosynthesis, drug interactions, or a 
      low aspirin dose. Clopidogrel resistance is likely to develop as a result of a 
      decreased bioavailability of the active metabolite, due to genetic variation or 
      concomitant drug treatment. Additional work is required to improve and validate 
      laboratory tests of platelet function, so that they may become useful tools for 
      selection of the most appropriate antiplatelet therapy for an individual patient. 
      Improvements in antiplatelet treatment strategies in the future should lead to a 
      reduction in premature vascular events.
FAU - Vadász, Dávid
AU  - Vadász D
AD  - University of Szeged, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, 
      Neurology Department, Szeged, Hungary.
FAU - Sztriha, László K
AU  - Sztriha LK
FAU - Sas, Katalin
AU  - Sas K
FAU - Vécsei, László
AU  - Vécsei L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Hungary
TA  - Ideggyogy Sz
JT  - Ideggyogyaszati szemle
JID - 17510500R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biological Availability
MH  - Clopidogrel
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Platelet Function Tests
MH  - Polymorphism, Genetic
MH  - Sex Factors
MH  - Signal Transduction
MH  - Thromboxanes/biosynthesis
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
EDAT- 2013/04/24 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04/24 06:00 [entrez]
PHST- 2013/04/24 06:00 [pubmed]
PHST- 2013/05/09 06:00 [medline]
PST - ppublish
SO  - Ideggyogy Sz. 2013 Jan 30;66(1-2):15-22.

PMID- 21492991
OWN - NLM
STAT- MEDLINE
DCOM- 20120829
LR  - 20131121
IS  - 1578-1267 (Electronic)
IS  - 0301-0546 (Linking)
VI  - 40
IP  - 3
DP  - 2012 May-Jun
TI  - The values of nasal provocation test and basophil activation test in the 
      different patterns of ASA/NSAID hypersensitivity.
PG  - 156-63
LID - 10.1016/j.aller.2010.12.011 [doi]
AB  - BACKGROUND: The oral provocation test (OPT) is the current gold standard to 
      diagnose aspirin hypersensitivity syndrome although it is time-consuming and 
      contains some systemic risks. Other reliable methods with lower side effects and 
      shorter test duration are being investigated. OBJECTIVE: The purpose of this 
      study was to evaluate the efficacy of the nasal provocation test (NPT) and the 
      basophil activation test (BAT) in the diagnosis of different subtypes of aspirin 
      sensitivity. METHODS: Thirty aspirin sensitivity patients with cutaneous and 
      respiratory manifestations underwent NPT and BAT with lysine-ASA. NPT result was 
      interpreted as recommended in EAACI/GA2LEN guidelines and receiver operating 
      characteristic analysis of BAT was performed by using 15 NSAIDs tolerant 
      volunteers as a control group. RESULTS: NPT was positive in 60% (18/30) of 
      patients and BAT was positive in 76.7% (23/30) of patients. The incubation of 
      basophils with 0.31 mg/ml of lysine-aspirin and using 4.6% activated basophils 
      gives the best predictive values to diagnose aspirin sensitivity. The combination 
      of both tests yielded positive results in 80% and 93.3% of aspirin-induced 
      cutaneous and respiratory patterns. The agreement between NPT and BAT results was 
      63.3%. CONCLUSIONS: NPT and BAT are beneficial to detect patients with aspirin 
      sensitivity. The combination of both tests have additional diagnostic values; 
      less time-consuming than OPT and their complications are negligible. A reliable 
      alternative method with minimum side effects is needed to diagnose aspirin 
      sensitivity in suspected patients who have contraindications for OPT.
CI  - Copyright © 2010 SEICAP. Published by Elsevier Espana. All rights reserved.
FAU - Wismol, P
AU  - Wismol P
AD  - Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of 
      Medicine, Chulalongkorn University, Bangkok, Thailand.
FAU - Putivoranat, P
AU  - Putivoranat P
FAU - Buranapraditkun, S
AU  - Buranapraditkun S
FAU - Pinnobphun, P
AU  - Pinnobphun P
FAU - Ruxrungtham, K
AU  - Ruxrungtham K
FAU - Klaewsongkram, J
AU  - Klaewsongkram J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110413
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/immunology
MH  - Aspirin/adverse effects/immunology
MH  - Asthma, Aspirin-Induced/*diagnosis
MH  - *Basophil Degranulation Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Nasal Provocation Tests
MH  - Sensitivity and Specificity
MH  - Single-Blind Method
MH  - Young Adult
EDAT- 2011/04/16 06:00
MHDA- 2012/08/30 06:00
CRDT- 2011/04/16 06:00
PHST- 2010/11/10 00:00 [received]
PHST- 2010/12/22 00:00 [revised]
PHST- 2010/12/24 00:00 [accepted]
PHST- 2011/04/16 06:00 [entrez]
PHST- 2011/04/16 06:00 [pubmed]
PHST- 2012/08/30 06:00 [medline]
AID - S0301-0546(11)00117-0 [pii]
AID - 10.1016/j.aller.2010.12.011 [doi]
PST - ppublish
SO  - Allergol Immunopathol (Madr). 2012 May-Jun;40(3):156-63. doi: 
      10.1016/j.aller.2010.12.011. Epub 2011 Apr 13.

PMID- 15288138
OWN - NLM
STAT- MEDLINE
DCOM- 20041116
LR  - 20131121
IS  - 0730-725X (Print)
IS  - 0730-725X (Linking)
VI  - 22
IP  - 7
DP  - 2004 Sep
TI  - Investigation of microenvironmental factors influencing the longitudinal 
      relaxation times of drugs and other compounds.
PG  - 973-82
AB  - The aim of this study was to investigate the microenvironmental factors likely to 
      influence the longitudinal relaxation time of MR visible drugs or compounds in 
      vivo at 1.5 T. The relative influence that viscosity, albumin and paramagnetic 
      contrast agent concentrations have on the observed longitudinal relaxation times 
      of three 19F MR detectable drugs and compounds have been investigated. Our data 
      show that for 5-fluorouracil, flucloxacillin and tetrafluorosuccinic 
      acid-containing phantoms, the presence of albumin at normal physiological 
      concentrations will have relaxation effects of the same order of magnitude as 
      that of a commonly clinically administered contrast agent, gadolinium 
      diethylenetriamine pentaacetic acid. The contribution of viscosity is shown, in 
      the examples studied here, to be of minor importance, contributing less than 6.5% 
      to the observed relaxation effects. It is also demonstrated that in the presence 
      of competitive binding of other ligands for common binding sites on albumin, the 
      19F longitudinal relaxation time of 5-fluorouracil can increase by up to 340% 
      from its value in the absence of the competing ligand. The relevance of the 
      findings to in vivo studies is discussed.
FAU - Dzik-Jurasz, A S K
AU  - Dzik-Jurasz AS
AD  - Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of 
      Cancer Research, Sutton, Surrey, SM2 5PT. andrzej.s.dzik-jurasz@gsk.com
FAU - Leach, M O
AU  - Leach MO
FAU - Rowland, I J
AU  - Rowland IJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Magn Reson Imaging
JT  - Magnetic resonance imaging
JID - 8214883
RN  - 0 (Albumins)
RN  - 0 (Contrast Media)
RN  - 0 (Fluorocarbons)
RN  - 0 (Succinates)
RN  - 377-38-8 (perfluorosuccinic acid)
RN  - 43B2M34G2V (Floxacillin)
RN  - K2I13DR72L (Gadolinium DTPA)
RN  - R16CO5Y76E (Aspirin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Albumins/analysis
MH  - Aspirin/*analysis/chemistry
MH  - Contrast Media/*analysis/chemistry
MH  - Floxacillin/*analysis/chemistry
MH  - Fluorocarbons/*analysis/chemistry
MH  - Fluorouracil/*analysis/chemistry
MH  - Gadolinium DTPA/analysis
MH  - Magnetic Resonance Imaging/*methods
MH  - Phantoms, Imaging
MH  - Protein Binding
MH  - Succinates/*analysis/chemistry
MH  - Viscosity
EDAT- 2004/08/04 05:00
MHDA- 2004/11/17 09:00
CRDT- 2004/08/04 05:00
PHST- 2003/05/30 00:00 [received]
PHST- 2004/01/30 00:00 [accepted]
PHST- 2004/08/04 05:00 [pubmed]
PHST- 2004/11/17 09:00 [medline]
PHST- 2004/08/04 05:00 [entrez]
AID - S0730725X04001043 [pii]
AID - 10.1016/j.mri.2004.01.066 [doi]
PST - ppublish
SO  - Magn Reson Imaging. 2004 Sep;22(7):973-82. doi: 10.1016/j.mri.2004.01.066.

PMID- 2140251
OWN - NLM
STAT- MEDLINE
DCOM- 19900620
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 41
IP  - 4
DP  - 1990 Apr
TI  - Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid 
      following PTA.
PG  - 263-9
AB  - After primary successful PTA, 199 patients were randomized into one of three 
      treatment groups, namely, placebo or a combination of 75 mg dipyridamole with 
      either 330 mg (high dose) or 100 mg (low dose) acetylsalicylic acid (ASA) tid. 
      The duration of treatment was six months. Of the 199 patients admitted to the 
      study, 156 completed the six-month trial period. Not all patients had a second 
      angiogram, and in these cases clinical findings were used in the evaluation. 
      Evaluation of the combined angiographic and clinical results showed improvement 
      or no deterioration in 37% of patients in the placebo group compared with 49% in 
      the low-dose and 61% in the high-dose ASA groups respectively. The only 
      statistically significant difference observed was between the placebo group and 
      the group treated with dipyridamole and high-dose ASA (p = 0.01). This difference 
      remained statistically significant at p = 0.039 if only the angiographic findings 
      were considered for group comparison. It cannot, however, be concluded from this 
      study that 75 mg dipyridamole in combination with 100 mg ASA tid is more 
      effective in preventing reocclusion after PTA than in combination with 330 mg ASA 
      tid.
FAU - Heiss, H W
AU  - Heiss HW
AD  - Department of Internal Medicine III, University of Freiburg, West Germany.
FAU - Just, H
AU  - Just H
FAU - Middleton, D
AU  - Middleton D
FAU - Deichsel, G
AU  - Deichsel G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Fibrinolytic Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Angioplasty, Balloon
MH  - Arteriosclerosis Obliterans/*prevention & control
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Dipyridamole/*administration & dosage/pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Femoral Artery/diagnostic imaging
MH  - Fibrinolytic Agents/pharmacology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Popliteal Artery/diagnostic imaging
MH  - Radiography
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Vascular Patency/*drug effects
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
AID - 10.1177/000331979004100402 [doi]
PST - ppublish
SO  - Angiology. 1990 Apr;41(4):263-9. doi: 10.1177/000331979004100402.

PMID- 1233265
OWN - NLM
STAT- MEDLINE
DCOM- 19761201
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 9
IP  - 2-3
DP  - 1975 Dec 19
TI  - Interaction of indomethacin and acetylsalicylic acid as shown by the serum 
      concentrations of indomethacin and salicylate.
PG  - 199-207
AB  - A clinical-pharmacological study was performed to determine the effect of 
      acetylsalicylic acid upon the serum concentration of indomethacin. 14 rheumatic 
      patients were given indomethacin orally (25 mg X 4 for 4 days) and concurrently 
      acetylsalicylic acid 3.7 g orally (0.9 g X 3 and 1.0 g X 1 daily), and 21 
      rheumatic patients were given indomethacin rectally in the morning (100 mg X 1) 
      and concurrently acetylsalicylic acid 3.7 g orally (0.9 g X 3 and 1.0 g X 1 
      daily). On comparison with treatment with oral or rectal indomethacin alone, it 
      was found that peak serum concentrations of indomethacin were significantly 
      reduced (1% level), the times of the peaks were not shifted, and the areas 
      beneath the serum concentration curves of indomethacin were smaller, but 
      significantly so only if compared with rectal administration. In 12 rheumatic 
      patients given indomethacin by rectum in the evening (100 mg X 1) and 
      concurrently acetylsalicylic acid 3.7 g (0.9 g X 3 and 1.0 g X 1 daily), the 
      serum level of indomethacin on the following morning (after 11 h) did not differ 
      from that found after rectal treatment. A statistically but not biologically 
      significant difference was observed between the mean serum half-lives of 
      indomethacin given orally and rectally. For unknown reasons, concurrent doses of 
      acetylsalicylic acid and indomethacin made the mean serum half-life of 
      indomethacin longer than after its oral administration, but shorter than when the 
      same dose of indomethacin was given rectally. There was no difference between 
      serum levels of salicylate after oral administration of acetylsalicylic acid 
      alone or after a concurrent oral or rectal dose of indomethacin. The results have 
      been related to those reported previously, with respect to the interaction 
      between indomethacin and acetylsalicylic acid, the serum levels of indomethacin 
      after oral and rectal dosing, and the serum half-life of indomethacin based upon 
      a one- or two-compartment model. The clinical relevance of the study is 
      discussed.
FAU - Kaldestad, E
AU  - Kaldestad E
FAU - Hansen, T
AU  - Hansen T
FAU - Brath, H K
AU  - Brath HK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Salicylates)
RN  - 0 (Suppositories)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Indomethacin/administration & dosage/*blood
MH  - Male
MH  - Middle Aged
MH  - Salicylates/*blood
MH  - Suppositories
EDAT- 1975/12/19 00:00
MHDA- 1975/12/19 00:01
CRDT- 1975/12/19 00:00
PHST- 1975/12/19 00:00 [pubmed]
PHST- 1975/12/19 00:01 [medline]
PHST- 1975/12/19 00:00 [entrez]
AID - 10.1007/BF00614018 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):199-207. doi: 10.1007/BF00614018.

PMID- 2673619
OWN - NLM
STAT- MEDLINE
DCOM- 19891020
LR  - 20190510
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 46
IP  - 3
DP  - 1989 Sep
TI  - Whole-bowel irrigation versus activated charcoal in sorbitol for the ingestion of 
      modified-release pharmaceuticals.
PG  - 264-71
AB  - Overdose with modified-release pharmaceuticals is an increasing phenomenon. This 
      study examines whole-bowel irrigation as a potential decontamination strategy 
      after overdose with enteric-coated acetylsalicylic acid and compares it with 
      administration of activated charcoal in sorbitol, which is currently the 
      recommended intervention. A three-phase randomized crossover protocol was used in 
      10 adult volunteers. Each volunteer ingested nine 325 mg doses of enteric-coated 
      acetylsalicylic acid on three occasions, with at least 1 week between each 
      administration period. Serum samples were analyzed for salicylic acid 
      concentration by HPLC. Both interventions decreased peak salicylic acid 
      concentration, time-to-zero salicylic acid concentration, and AUC when compared 
      with control (p less than 0.01). Whole-bowel irrigation was superior to activated 
      charcoal in sorbitol by all three criteria (p less than 0.05). Adverse effects 
      were qualitatively and quantitatively greater during activated charcoal in 
      sorbitol, and the volunteers preferred whole-bowel irrigation over charcoal in 
      sorbitol. Our data suggest that whole-bowel irrigation should be considered for 
      overdose of other modified-release pharmaceuticals.
FAU - Kirshenbaum, L A
AU  - Kirshenbaum LA
AD  - Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, 
      Canada.
FAU - Mathews, S C
AU  - Mathews SC
FAU - Sitar, D S
AU  - Sitar DS
FAU - Tenenbein, M
AU  - Tenenbein M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Electrolytes)
RN  - 16291-96-6 (Charcoal)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 506T60A25R (Sorbitol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/blood
MH  - *Charcoal
MH  - Clinical Trials as Topic
MH  - Colon
MH  - Delayed-Action Preparations/*poisoning
MH  - Electrolytes/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Polyethylene Glycols
MH  - Random Allocation
MH  - Sorbitol
MH  - Surveys and Questionnaires
MH  - *Therapeutic Irrigation/methods
MH  - Time Factors
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
AID - 0009-9236(89)90462-1 [pii]
AID - 10.1038/clpt.1989.137 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1989 Sep;46(3):264-71. doi: 10.1038/clpt.1989.137.

PMID- 29090039
OWN - NLM
STAT- MEDLINE
DCOM- 20180719
LR  - 20181113
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2017
DP  - 2017
TI  - Platelet Carbonic Anhydrase II, a Forgotten Enzyme, May Be Responsible for 
      Aspirin Resistance.
PG  - 3132063
LID - 10.1155/2017/3132063 [doi]
LID - 3132063
AB  - BACKGROUND: Thromboembolic events constitute a major health problem, despite the 
      steadily expanding arsenal of antiplatelet drugs. Hence, there is still a need to 
      optimize the antiplatelet therapy. OBJECTIVES: The aim of our study was to verify 
      a hypothesis that there are no differences in platelet proteome between two 
      groups of healthy people representing different acetylsalicylic acid (aspirin) 
      responses as assessed by the liquid chromatography/mass spectrometry (LC/MS) 
      technique. PATIENTS/METHODS: A total of 61 healthy volunteers were recruited for 
      the study. Physical examination and blood collection were followed by 
      platelet-rich plasma aggregation assays and platelet separation for proteomic 
      LC/MS analysis. Arachidonic acid- (AA-) induced aggregation (in the presence of 
      aspirin) allowed to divide study participants into two groups aspirin-resistant 
      (AR) and aspirin-sensitive (AS) ones. Subsequently, platelet proteome was 
      compared in groups using the LC/MS analysis. RESULTS: The LC/MS analysis of 
      platelet proteome between groups revealed that out of all identified proteins, 
      the only discriminatory protein, affecting aspirin responsiveness, is platelet 
      carbonic anhydrase II (CA II). CONCLUSIONS: CA II is a platelet function 
      modulator and should be taken into consideration as a cardiovascular event risk 
      factor or therapeutic target.
FAU - Jakubowski, M
AU  - Jakubowski M
AD  - Department of Internal Medicine, Occupational Diseases and Hypertension, Wroclaw 
      Medical University, Wroclaw, Poland.
FAU - Dębski, J
AU  - Dębski J
AD  - Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warszawa, 
      Poland.
FAU - Szahidewicz-Krupska, E
AU  - Szahidewicz-Krupska E
AUID- ORCID: 0000-0002-4446-6991
AD  - Department of Internal Medicine, Occupational Diseases and Hypertension, Wroclaw 
      Medical University, Wroclaw, Poland.
FAU - Turek-Jakubowska, A
AU  - Turek-Jakubowska A
AD  - Department of Internal Medicine, Occupational Diseases and Hypertension, Wroclaw 
      Medical University, Wroclaw, Poland.
FAU - Gawryś, J
AU  - Gawryś J
AD  - Department of Internal Medicine, Occupational Diseases and Hypertension, Wroclaw 
      Medical University, Wroclaw, Poland.
FAU - Gawryś, K
AU  - Gawryś K
AD  - Department of Internal Medicine, Occupational Diseases and Hypertension, Wroclaw 
      Medical University, Wroclaw, Poland.
FAU - Skomro, R
AU  - Skomro R
AUID- ORCID: 0000-0002-9964-5305
AD  - Division of Respiratory, Critical Care and Sleep Medicine, Department of 
      Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
FAU - Derkacz, A
AU  - Derkacz A
AUID- ORCID: 0000-0002-9231-7392
AD  - Department of Internal Medicine, Occupational Diseases and Hypertension, Wroclaw 
      Medical University, Wroclaw, Poland.
FAU - Doroszko, A
AU  - Doroszko A
AUID- ORCID: 0000-0001-5472-028X
AD  - Department of Internal Medicine, Occupational Diseases and Hypertension, Wroclaw 
      Medical University, Wroclaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20170927
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - EC 4.2.1.- (Carbonic Anhydrase II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*enzymology
MH  - Carbonic Anhydrase II/*blood
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
PMC - PMC5635279
EDAT- 2017/11/02 06:00
MHDA- 2018/07/20 06:00
CRDT- 2017/11/02 06:00
PHST- 2017/06/22 00:00 [received]
PHST- 2017/08/22 00:00 [revised]
PHST- 2017/09/06 00:00 [accepted]
PHST- 2017/11/02 06:00 [entrez]
PHST- 2017/11/02 06:00 [pubmed]
PHST- 2018/07/20 06:00 [medline]
AID - 10.1155/2017/3132063 [doi]
PST - ppublish
SO  - Oxid Med Cell Longev. 2017;2017:3132063. doi: 10.1155/2017/3132063. Epub 2017 Sep 
      27.

PMID- 11154121
OWN - NLM
STAT- MEDLINE
DCOM- 20010531
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 84
IP  - 6
DP  - 2000 Dec
TI  - Effect of sodium arachidonate on thrombin generation through platelet 
      activation--inhibitory effect of aspirin.
PG  - 1109-12
AB  - BACKGROUND: Sodium arachidonate was used in this study to determine its capacity 
      to generate thrombin through platelet activation. Whether aspirin prevent this 
      effect was also investigated. METHODS AND RESULTS: Seventeen healthy volunteers 
      without and after 160 mg/day aspirin intake for 3-5 days were studied. Lag-time 
      and TG at basal condition and after platelet stimulation by sodium arachidonate 
      (AA) were measured in normal non-aspirinated as well as "in vivo" aspirinated 
      platelet rich plasma. (PRP). The lag-time was statistically significant shorter 
      in non-aspirinated PRP activated with AA compared with non-activated PRP. This 
      effect was inhibited by aspirin. In non-aspirinated PRP, there was an increase of 
      TG at 4 and 6 min. incubation when platelets were activated with AA but the 
      difference disappeared after 8 min. incubation, (84 +/- 71; 148 +/- 58 and 142 
      +/- 92 nmol/L respectively) compared with non-aspirinated. non-activated 
      platelets (16 +/- 23; 55 +/- 56 and 111 +/- 76 nmol/L at 4,6 and 8 min, p < 
      0.0001, p < 0.0001 and p = 0.292, respectively). The AUCo-->22 min were 520.6 +/- 
      545.5 in non-aspirinated, non-stimulated PRP and 808.9 +/- 617, in 
      non-aspirinated PRP activated with sodium arachidonate (p = 0.014). Aspirin 
      administered in vivo produced a decrease of TG in PRP activated with AA. 
      CONCLUSION: Platelet activated by AA trigged TG. This effect was inhibited by 
      aspirin and could be an additional beneficial effect of aspirin in the prevention 
      of thrombosis.
FAU - Altman, R
AU  - Altman R
AD  - Centro de Trombosis de Buenos Aires, Argentina. draltman@arnet.com.ar
FAU - Scazziota, A
AU  - Scazziota A
FAU - Rouvier, J
AU  - Rouvier J
FAU - Gonzalez, C
AU  - Gonzalez C
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 27YG812J1I (Arachidonic Acid)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arachidonic Acid/*pharmacology
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/pharmacology
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Thrombin/*agonists/antagonists & inhibitors/metabolism
EDAT- 2001/01/12 11:00
MHDA- 2001/06/02 10:01
CRDT- 2001/01/12 11:00
PHST- 2001/01/12 11:00 [pubmed]
PHST- 2001/06/02 10:01 [medline]
PHST- 2001/01/12 11:00 [entrez]
AID - 00121109 [pii]
PST - ppublish
SO  - Thromb Haemost. 2000 Dec;84(6):1109-12.

PMID- 3866409
OWN - NLM
STAT- MEDLINE
DCOM- 19860218
LR  - 20190903
IS  - 0163-4356 (Print)
IS  - 0163-4356 (Linking)
VI  - 7
IP  - 4
DP  - 1985
TI  - Effects of salsalate (nonacetylated salicylate) and aspirin on serum 
      prostaglandins in humans.
PG  - 435-8
AB  - Prostaglandin E2 (PGE2), thromboxane B2 (TXB2), and salicylic acid were measured 
      in blood samples from 10 healthy men after administration of antiinflammatory 
      doses of aspirin (3.9 g/day) or salsalate (3.0 g/day). Each medication was given 
      for 3 days, followed by an observation period of 13 days. Plasma salicylate 
      concentrations were slightly, but generally insignificantly, higher during 
      aspirin dosing, although both drugs produced salicylic acid levels in the 
      antiinflammatory range. Serum levels of PGE2 and TXB2, which reflected synthesis 
      of cyclo-oxygenase products by platelets, were minimally affected by salsalate 
      but profoundly suppressed by aspirin. When medication was discontinued, the 
      effects of salsalate on serum PGE2 and TXB2 were readily reversible within 36 h, 
      whereas the recovery from aspirin was still incomplete after 13 days of 
      observation. These results indicate that the two orally administered salicylates 
      have differential effects on prostaglandin synthesis in platelets and may also 
      differ in their therapeutic and adverse effects.
FAU - Morris, H G
AU  - Morris HG
FAU - Sherman, N A
AU  - Sherman NA
FAU - McQuain, C
AU  - McQuain C
FAU - Goldlust, M B
AU  - Goldlust MB
FAU - Chang, S F
AU  - Chang SF
FAU - Harrison, L I
AU  - Harrison LI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ther Drug Monit
JT  - Therapeutic drug monitoring
JID - 7909660
RN  - 0 (Prostaglandins E)
RN  - 0 (Salicylates)
RN  - 54397-85-2 (Thromboxane B2)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - V9MO595C9I (salicylsalicylic acid)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Dinoprostone
MH  - Humans
MH  - Male
MH  - Prostaglandins E/*blood
MH  - Salicylates/blood/*pharmacology
MH  - Thromboxane B2/blood
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1097/00007691-198512000-00012 [doi]
PST - ppublish
SO  - Ther Drug Monit. 1985;7(4):435-8. doi: 10.1097/00007691-198512000-00012.

PMID- 6707881
OWN - NLM
STAT- MEDLINE
DCOM- 19840504
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 73
IP  - 2
DP  - 1984 Feb
TI  - Stabilized normal-phase high-performance liquid chromatographic analysis of 
      aspirin and salicylic acid in solid pharmaceutical dosage forms.
PG  - 195-7
AB  - A simultaneous analysis of aspirin and nonaspirin salicylates in solid 
      pharmaceutical dosage forms is described. Two separate extraction procedures are 
      employed, one for plain aspirin tablets and one for tablets containing aspirin 
      plus buffers or antacids. The analyses of the extracted samples are accomplished 
      by a stabilized normal-phase high-performance liquid chromatographic (HPLC) 
      procedure. Prepared samples and standards are stable for up to 24 h, and the 
      methodology is suitable for an automated HPLC system.
FAU - Galante, R N
AU  - Galante RN
FAU - Visalli, A J
AU  - Visalli AJ
FAU - Grim, W M
AU  - Grim WM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Antacids)
RN  - 0 (Buffers)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antacids/analysis
MH  - Aspirin/*analysis
MH  - Buffers/analysis
MH  - Chromatography, High Pressure Liquid/methods
MH  - Drug Stability
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Tablets/analysis
EDAT- 1984/02/01 00:00
MHDA- 1984/02/01 00:01
CRDT- 1984/02/01 00:00
PHST- 1984/02/01 00:00 [pubmed]
PHST- 1984/02/01 00:01 [medline]
PHST- 1984/02/01 00:00 [entrez]
AID - S0022-3549(15)44964-0 [pii]
AID - 10.1002/jps.2600730212 [doi]
PST - ppublish
SO  - J Pharm Sci. 1984 Feb;73(2):195-7. doi: 10.1002/jps.2600730212.

PMID- 7060328
OWN - NLM
STAT- MEDLINE
DCOM- 19820527
LR  - 20190512
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 31
IP  - 4
DP  - 1982 Apr
TI  - Aspirin blocks nicotinic acid-induced flushing.
PG  - 478-82
AB  - Nicotinic acid flushing after placebo and 975-mg oral doses of aspirin was 
      assessed in 29 normal subjects over a range of nicotinic acid doses. Intensity of 
      flushing was assessed by the change in malar thermal circulation index (delta 
      MTCI). Aspirin pretreatment resulted in smaller delta MTCIs at the higher doses 
      of nicotinic acid. At the lower doses the change in the index after pretreatments 
      with both aspirin and placebo remained low, suggesting that very little flushing 
      was provoked by these doses. These results are compatible with the proposed 
      mediation by prostaglandins of the nicotinic acid-induced flush. According to the 
      delta MCTI method, flushing is quantitatively characterized as a nonquantal, 
      dose-response reaction of variable intensity.
FAU - Wilkin, J K
AU  - Wilkin JK
FAU - Wilkin, O
AU  - Wilkin O
FAU - Kapp, R
AU  - Kapp R
FAU - Donachie, R
AU  - Donachie R
FAU - Chernosky, M E
AU  - Chernosky ME
FAU - Buckner, J
AU  - Buckner J
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Nicotinic Acids)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Body Temperature/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Nicotinic Acids/*antagonists & inhibitors
MH  - Prostaglandins/physiology
MH  - Vasodilation/*drug effects
EDAT- 1982/04/01 00:00
MHDA- 1982/04/01 00:01
CRDT- 1982/04/01 00:00
PHST- 1982/04/01 00:00 [pubmed]
PHST- 1982/04/01 00:01 [medline]
PHST- 1982/04/01 00:00 [entrez]
AID - 0009-9236(82)90134-5 [pii]
AID - 10.1038/clpt.1982.63 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1982 Apr;31(4):478-82. doi: 10.1038/clpt.1982.63.

PMID- 12759515
OWN - NLM
STAT- MEDLINE
DCOM- 20040220
LR  - 20171101
IS  - 1424-8832 (Print)
IS  - 1424-8832 (Linking)
VI  - 32
IP  - 4
DP  - 2002 Jul-Aug
TI  - Effect of low-dose aspirin on the international normalized ratio variability in 
      patients with mechanical heart valve prostheses.
PG  - 155-7
AB  - An increased risk of bleeding is associated with a more intense oral 
      anticoagulation, a greater international normalized ratio (INR) variability and 
      the use of aspirin. We studied the INR variability of patients (n = 121) with 
      modern heart valves who had been prospectively randomized to receive 
      acenocoumarol at a targeted INR of 2.4-3.6 plus aspirin 100 mg/day or 
      acenocoumarol alone at the same dosage, to evaluate whether aspirin influences 
      variability and thus the risk of bleeding. Variability was similar in patients 
      with no events regardless of the use of aspirin. A statistically significantly 
      higher variability was observed in patients with bleeding events independently of 
      the use of aspirin. Nevertheless, the concomitant use of aspirin in patients with 
      a high variability should be monitored closely and thoroughly.
CI  - Copyright 2002 S. Karger AG, Basel
FAU - Casais, Patricia
AU  - Casais P
AD  - Hemostasis and Thrombosis Department, Institute of Hematological Research, 
      National Academy of Medicine, Buenos Aires, Argentina. 
      casais@hematologia.anm.edu.ar
FAU - Meschengieser, Susana S
AU  - Meschengieser SS
FAU - Sanchez Luceros, Analia G
AU  - Sanchez Luceros AG
FAU - Bermejo, Emilse I
AU  - Bermejo EI
FAU - Lazzari, Maria A
AU  - Lazzari MA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Pathophysiol Haemost Thromb
JT  - Pathophysiology of haemostasis and thrombosis
JID - 101142710
RN  - 0 (Anticoagulants)
RN  - I6WP63U32H (Acenocoumarol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acenocoumarol/administration & dosage/pharmacology
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Female
MH  - Heart Valve Prosthesis/*adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - International Normalized Ratio/*standards
MH  - Male
MH  - Middle Aged
MH  - Reproducibility of Results
MH  - Risk
MH  - Thrombosis/etiology/prevention & control
EDAT- 2003/05/22 05:00
MHDA- 2004/02/21 05:00
CRDT- 2003/05/22 05:00
PHST- 2002/03/08 00:00 [received]
PHST- 2002/09/02 00:00 [accepted]
PHST- 2003/05/22 05:00 [pubmed]
PHST- 2004/02/21 05:00 [medline]
PHST- 2003/05/22 05:00 [entrez]
AID - 70420 [pii]
AID - 10.1159/000070420 [doi]
PST - ppublish
SO  - Pathophysiol Haemost Thromb. 2002 Jul-Aug;32(4):155-7. doi: 10.1159/000070420.

PMID- 1185537
OWN - NLM
STAT- MEDLINE
DCOM- 19760202
LR  - 20201209
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 64
IP  - 10
DP  - 1975 Oct
TI  - GLC analysis of caffeine and codeine phosphate in pharmaceutical preparations.
PG  - 1686-7
AB  - A procedure for the determination of caffeine and codeine phosphate in 
      pharmaceutical preparations was developed. It depends upon a one-step extraction 
      followed by GLC analysis by the concentrated extract.
FAU - Stevens, M R
AU  - Stevens MR
AD  - Towne-Paulson & Co., Inc., Monrovia, CA 91016
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Aspirin/analysis
MH  - Caffeine/*analysis
MH  - Chromatography, Gas
MH  - Codeine/*analysis
MH  - Drug Combinations
MH  - Methods
MH  - Phenacetin/analysis
MH  - Tablets/analysis
EDAT- 1975/10/01 00:00
MHDA- 1975/10/01 00:01
CRDT- 1975/10/01 00:00
PHST- 1975/10/01 00:00 [pubmed]
PHST- 1975/10/01 00:01 [medline]
PHST- 1975/10/01 00:00 [entrez]
AID - S0022-3549(15)40417-4 [pii]
AID - 10.1002/jps.2600641022 [doi]
PST - ppublish
SO  - J Pharm Sci. 1975 Oct;64(10):1686-7. doi: 10.1002/jps.2600641022.

PMID- 22629768
OWN - NLM
STAT- MEDLINE
DCOM- 20120618
LR  - 20131121
IS  - 1682-8658 (Print)
IS  - 1682-8658 (Linking)
IP  - 9
DP  - 2011
TI  - [Oncogenesis humoral mechanisms regulation and NSAIDs ability in prevention of 
      tumors].
PG  - 3-10
AB  - The article observes modern data in mechanisms and pathways of carcinogenesis and 
      tumor progression and the role of oncogenes, cytokines, growth factors in this 
      process. The protective effects of aspirin and nonsteroidal anti-inflammatory 
      drugs (NSAIDs) for colorectal cancers in experimental and clinical studies are 
      also demonstrated in this review.
FAU - Kim, V A
AU  - Kim VA
FAU - Lazebnik, L V
AU  - Lazebnik LV
FAU - Drozdov, V N
AU  - Drozdov VN
LA  - rus
PT  - Editorial
PT  - English Abstract
PL  - Russia (Federation)
TA  - Eksp Klin Gastroenterol
JT  - Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical 
      gastroenterology
JID - 101144944
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cell Transformation, Neoplastic/*drug effects
MH  - Colorectal Neoplasms/*prevention & control
MH  - Humans
EDAT- 2011/01/01 00:00
MHDA- 2012/06/19 06:00
CRDT- 2012/05/29 06:00
PHST- 2012/05/29 06:00 [entrez]
PHST- 2011/01/01 00:00 [pubmed]
PHST- 2012/06/19 06:00 [medline]
PST - ppublish
SO  - Eksp Klin Gastroenterol. 2011;(9):3-10.

PMID- 22225857
OWN - NLM
STAT- MEDLINE
DCOM- 20130114
LR  - 20181201
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 129
IP  - 6
DP  - 2012 Jun
TI  - Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a 
      prospective observation study.
PG  - 760-4
LID - 10.1016/j.thromres.2011.12.019 [doi]
AB  - BACKGROUND: Thiazolidinediones (TZDs) are agonists of PPARγ and exert beneficial 
      metabolic effects in patients with diabetes. They may also affect platelet 
      function. OBJECTIVES: To characterize potential platelet inhibitory effect of 
      pioglitazone alone and in the presence of aspirin. METHODS: 20 normal and 20 
      diabetic subjects were enrolled in a prospective study. On day 1, a blood sample 
      was obtained at baseline and a second one after ingestion of 30mg of 
      pioglitazone. PRP was prepared and platelet aggregation and release were 
      evaluated using ADP, collagen and arachidonic acid as agonists. Subjects returned 
      at 6-9days later after ingesting a single 81mg dose of aspirin and a third blood 
      sample was obtained. The subjects then again ingested 30mg of pioglitazone and a 
      fourth and final blood sample was obtained. Platelet aggregation and release were 
      measured. PRP was incubated with thrombin to activate platelets, and the serum 
      was separated and assayed for thromboxane B2, TGFβ and CD40L RESULTS: 
      Pioglitazone alone did not affect aggregation with arachidonic acid. However, 
      following ingestion of both aspirin and pioglitazone aggregation was 
      significantly decreased compared to aspirin alone (P<0.0001). Pioglitazone also 
      potentiated aspirin-induced inhibition of ATP release using either arachidonic 
      acid or collagen. Following pioglitazone alone, TXB(2) release was 
      32,719±3,585pg/ml which was significantly reduced compared to baseline 
      (42,075±4,479, P=0.0004). Pioglitazone also potentiated the inhibition of TXB(2) 
      release by aspirin. CONCLUSION: Pioglitazone inhibits platelet function and 
      potentiates the inhibitory effects of aspirin.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Mongan, John
AU  - Mongan J
AD  - University of Rochester Medical Center, Department of Medicine - 
      Hematology/Oncology, Rochester, NY 14642, USA.
FAU - Mieszczanska, Hanna Z
AU  - Mieszczanska HZ
FAU - Smith, Brian H
AU  - Smith BH
FAU - Messing, Susan P
AU  - Messing SP
FAU - Phipps, Richard P
AU  - Phipps RP
FAU - Francis, Charles W
AU  - Francis CW
LA  - eng
SI  - ClinicalTrials.gov/NCT00861341
GR  - ES01247/ES/NIEHS NIH HHS/United States
GR  - R01 HL095467/HL/NHLBI NIH HHS/United States
GR  - RC1 HL100051/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120104
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - R16CO5Y76E (Aspirin)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Case-Control Studies
MH  - Diabetes Mellitus/*blood/*drug therapy
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Thiazolidinediones/administration & dosage/*pharmacology
EDAT- 2012/01/10 06:00
MHDA- 2013/01/15 06:00
CRDT- 2012/01/10 06:00
PHST- 2011/09/15 00:00 [received]
PHST- 2011/12/06 00:00 [revised]
PHST- 2011/12/11 00:00 [accepted]
PHST- 2012/01/10 06:00 [entrez]
PHST- 2012/01/10 06:00 [pubmed]
PHST- 2013/01/15 06:00 [medline]
AID - S0049-3848(11)00684-0 [pii]
AID - 10.1016/j.thromres.2011.12.019 [doi]
PST - ppublish
SO  - Thromb Res. 2012 Jun;129(6):760-4. doi: 10.1016/j.thromres.2011.12.019. Epub 2012 
      Jan 4.

PMID- 15212350
OWN - NLM
STAT- MEDLINE
DCOM- 20040826
LR  - 20220311
IS  - 0022-3492 (Print)
IS  - 0022-3492 (Linking)
VI  - 75
IP  - 5
DP  - 2004 May
TI  - The effect of aspirin intake on bleeding on probing in patients with gingivitis.
PG  - 679-84
AB  - BACKGROUND: Bleeding indices are used as a screen for periodontal disease 
      activity, a measure of disease prevalence, and a measure of effectiveness in 
      clinical trials. Bleeding on probing (BOP) is widely interpreted as a sign of 
      disease activity whereas its absence is interpreted as both a sign and predictor 
      of health. Aspirin use has become increasingly common in the prevention of 
      cerebrovascular and cardiovascular diseases. Because of its anti-platelet 
      activity, aspirin is a non-disease factor that has the potential to affect the 
      appearance of BOP. The hypothesis being tested is that short-term aspirin use in 
      doses of 81 mg and 325 mg will increase the number of bleeding sites in a 
      population with gingivitis. METHODS: Fifty-four subjects were screened initially, 
      those subjects with 20% to 30% whole mouth BOP were randomly assigned to one of 
      three arms: placebo group, 81 mg aspirin group, or 325 mg aspirin group. Before 
      and after exposure to the respective regimens, clinical parameters were measured 
      on all the teeth: the plaque index was recorded at four sites per tooth, and 
      probing depth and BOP were evaluated at six sites per tooth using an automated 
      pressure-sensitive probe. RESULTS: The data obtained in this clinical trial were 
      analyzed utilizing a linear regression analysis to control for confounding 
      variables. The primary measure of interest was BOP in patients clinically 
      demonstrating naturally occurring gingivitis. The results of this study indicate 
      that while controlling for age, gender, and plaque, "low dose" 81 mg and "regular 
      dose" 325 mg of aspirin demonstrated a statistically significant 5.30 (P = 0.001) 
      and 4.13 (P = 0.010) increase from baseline, respectively, in percent BOP. 
      CONCLUSION: Failure to consider the effects of aspirin on BOP could impair proper 
      diagnosis and treatment planning for clinicians and introduce a significant 
      confounding variable in research situations.
FAU - Royzman, Daniel
AU  - Royzman D
AD  - Department of Oral Medicine, Infection and Immunity, Harvard School of Dental 
      Medicine, Boston, MA 02115, USA.
FAU - Recio, Luisa
AU  - Recio L
FAU - Badovinac, Rachel L
AU  - Badovinac RL
FAU - Fiorellini, Joseph
AU  - Fiorellini J
FAU - Goodson, Max
AU  - Goodson M
FAU - Howell, Howard
AU  - Howell H
FAU - Karimbux, Nadeem
AU  - Karimbux N
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Periodontol
JT  - Journal of periodontology
JID - 8000345
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Confounding Factors, Epidemiologic
MH  - Dental Plaque Index
MH  - Female
MH  - Follow-Up Studies
MH  - Gingival Hemorrhage/*chemically induced
MH  - Gingivitis/*physiopathology
MH  - Humans
MH  - Linear Models
MH  - Male
MH  - Periodontal Index
MH  - Periodontal Pocket/classification
MH  - Periodontics/instrumentation
MH  - Placebos
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Sex Factors
EDAT- 2004/06/24 05:00
MHDA- 2004/08/27 05:00
CRDT- 2004/06/24 05:00
PHST- 2004/06/24 05:00 [pubmed]
PHST- 2004/08/27 05:00 [medline]
PHST- 2004/06/24 05:00 [entrez]
AID - 10.1902/jop.2004.75.5.679 [doi]
PST - ppublish
SO  - J Periodontol. 2004 May;75(5):679-84. doi: 10.1902/jop.2004.75.5.679.

PMID- 25360605
OWN - NLM
STAT- MEDLINE
DCOM- 20160101
LR  - 20220311
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 10
DP  - 2014
TI  - Aspirin for primary prevention of cardiovascular events: meta-analysis of 
      randomized controlled trials and subgroup analysis by sex and diabetes status.
PG  - e90286
LID - 10.1371/journal.pone.0090286 [doi]
LID - e90286
AB  - OBJECTIVE: To evaluate the benefits and harms of aspirin for the primary 
      prevention of CVD and determine whether the effects vary by sex and diabetes 
      status. METHODS: We searched Medline, Embase, and Cochrane databases for 
      randomized controlled trials comparing the effects of aspirin with placebo or 
      control in people with no pre-existing CVD. Two investigators independently 
      extracted data and assessed the study quality. Analyses were performed using 
      Stata version 12. RESULTS: Fourteen trials (107,686 participants) were eligible. 
      Aspirin was associated with reductions in major cardiovascular events (risk 
      ratio, 0.90; 95% confidence interval, 0.85-0.95), myocardial infarction (0.86; 
      0.75-0.93), ischemic stroke (0.86; 0.75-0.98) and all-cause mortality (0.94; 
      0.89-0.99). There were also increases in hemorrhagic stroke (1.34; 1.01-1.79) and 
      major bleeding (1.55; 1.35-1.78) with aspirin. The number needed to treat to 
      prevent 1 major cardiovascular event over a mean follow-up of 6.8 years was 284. 
      By comparison, the numbers needed to harm to cause 1 major bleeding is 299. In 
      subgroup analyses, pooled results demonstrated a reduction in myocardial 
      infarction among men (0.71; 0.59-0.85) and ischemic stroke among women (0.77; 
      0.63-0.93). Aspirin use was associated with a reduction (0.65; 0.51-0.82) in 
      myocardial infarction among diabetic men. In meta-regression analyses, the 
      results suggested that aspirin therapy might be associated with a decrease in 
      stroke among diabetic women and a decrease in MI among diabetic men and risk 
      reductions achieved with low doses (75 mg/day) were as large as those obtained 
      with higher doses (650 mg/day). CONCLUSIONS: The use of low-dose aspirin was 
      beneficial for primary prevention of CVD and the decision regarding an aspirin 
      regimen should be made on an individual patient basis. The effects of aspirin 
      therapy varied by sex and diabetes status. A clear benefit of aspirin in the 
      primary prevention of CVD in people with diabetes needs more trials.
FAU - Xie, Manling
AU  - Xie M
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science & Technology, Wuhan, China; Ministry of Education Key Laboratory of 
      Environment and Health, School of Public Health, Tongji Medical College, Huazhong 
      University of Science & Technology, Wuhan, China.
FAU - Shan, Zhilei
AU  - Shan Z
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science & Technology, Wuhan, China; Ministry of Education Key Laboratory of 
      Environment and Health, School of Public Health, Tongji Medical College, Huazhong 
      University of Science & Technology, Wuhan, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science & Technology, Wuhan, China; Ministry of Education Key Laboratory of 
      Environment and Health, School of Public Health, Tongji Medical College, Huazhong 
      University of Science & Technology, Wuhan, China.
FAU - Chen, Sijing
AU  - Chen S
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science & Technology, Wuhan, China; Ministry of Education Key Laboratory of 
      Environment and Health, School of Public Health, Tongji Medical College, Huazhong 
      University of Science & Technology, Wuhan, China.
FAU - Yang, Wei
AU  - Yang W
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science & Technology, Wuhan, China; Ministry of Education Key Laboratory of 
      Environment and Health, School of Public Health, Tongji Medical College, Huazhong 
      University of Science & Technology, Wuhan, China.
FAU - Bao, Wei
AU  - Bao W
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science & Technology, Wuhan, China; Ministry of Education Key Laboratory of 
      Environment and Health, School of Public Health, Tongji Medical College, Huazhong 
      University of Science & Technology, Wuhan, China.
FAU - Rong, Ying
AU  - Rong Y
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science & Technology, Wuhan, China; Ministry of Education Key Laboratory of 
      Environment and Health, School of Public Health, Tongji Medical College, Huazhong 
      University of Science & Technology, Wuhan, China.
FAU - Yu, Xuefeng
AU  - Yu X
AD  - Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, 
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 
      China.
FAU - Hu, Frank B
AU  - Hu FB
AD  - Department of Nutrition and Epidemiology, Harvard School of Public Health, 
      Boston, Massachusetts, United States of America.
FAU - Liu, Liegang
AU  - Liu L
AD  - Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition 
      and Safety, School of Public Health, Tongji Medical College, Huazhong University 
      of Science & Technology, Wuhan, China; Ministry of Education Key Laboratory of 
      Environment and Health, School of Public Health, Tongji Medical College, Huazhong 
      University of Science & Technology, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20141031
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/*prevention & control
MH  - Diabetes Mellitus/*pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Placebos
MH  - Publication Bias
MH  - *Randomized Controlled Trials as Topic
MH  - Regression Analysis
MH  - Treatment Outcome
PMC - PMC4215843
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/11/02 06:00
MHDA- 2016/01/02 06:00
CRDT- 2014/11/01 06:00
PHST- 2013/09/20 00:00 [received]
PHST- 2014/01/28 00:00 [accepted]
PHST- 2014/11/01 06:00 [entrez]
PHST- 2014/11/02 06:00 [pubmed]
PHST- 2016/01/02 06:00 [medline]
AID - PONE-D-13-38820 [pii]
AID - 10.1371/journal.pone.0090286 [doi]
PST - epublish
SO  - PLoS One. 2014 Oct 31;9(10):e90286. doi: 10.1371/journal.pone.0090286. 
      eCollection 2014.

PMID- 31252591
OWN - NLM
STAT- MEDLINE
DCOM- 20191210
LR  - 20200225
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 24
IP  - 13
DP  - 2019 Jun 27
TI  - UPLC-Q-TOF/MS-Based Plasma Metabolomics to Evaluate the Effects of Aspirin 
      Eugenol Ester on Blood Stasis in Rats.
LID - 10.3390/molecules24132380 [doi]
LID - 2380
AB  - Aspirin eugenol ester (AEE) is a novel compound that is formed from the 
      esterification of aspirin (acetylsalicylic acid (ASA)) and eugenol. This study 
      aimed to investigate the effects of AEE on blood stasis in rats and to 
      characterize the underlying mechanisms using a plasma metabolomic study. The 
      results indicate that AEE and ASA could modulate whole blood viscosity (WBV), 
      plasma viscosity (PV), blood coagulation parameters, platelet count, platelet 
      aggregation, lactate dehydrogenase (LDH), creatinine (CR) and the levels of 
      thromboxane A2 (TXA(2)) and 6-keto prostaglandin F1α (6-keto-PGF(1α)). The 
      metabolic profiles of the plasma samples from all groups were clearly separated 
      in the score plots. Nineteen potential metabolites were selected and identified, 
      and disordered levels of these metabolites could be regulated by AEE and ASA. 
      Pathway analysis showed that the mechanism of action of AEE on blood stasis might 
      be principally related to the metabolism of amino acid, fatty acid, energy and 
      glycerophospholipid. The above results indicate that AEE protected the rats 
      against blood stasis, and that this effect might have been caused by the 
      anticoagulation activity of AEE and its abilities to maintain a balance between 
      TXA(2) and PGI(2), reduce blood viscosity, inhibit platelet aggregation and 
      normalize the plasma metabolic profile.
FAU - Shen, Dongshuai
AU  - Shen D
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture; Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, China.
FAU - Ma, Ning
AU  - Ma N
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture; Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, China.
AD  - College of Veterinary Medicine, Agricultural University of Hebei, Baoding 071000, 
      China.
FAU - Yang, Yajun
AU  - Yang Y
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture; Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, China.
FAU - Liu, Xiwang
AU  - Liu X
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture; Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, China.
FAU - Qin, Zhe
AU  - Qin Z
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture; Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, China.
FAU - Li, Shihong
AU  - Li S
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture; Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, China.
FAU - Jiao, Zenghua
AU  - Jiao Z
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture; Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, China.
FAU - Kong, Xiaojun
AU  - Kong X
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture; Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, China.
FAU - Li, Jianyong
AU  - Li J
AUID- ORCID: 0000-0003-2154-830X
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture; Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou 730050, China. lijy1971@163.com.
LA  - eng
GR  - 31572573/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20190627
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Blood/*drug effects
MH  - Blood Chemical Analysis
MH  - Blood Coagulation/drug effects
MH  - Blood Viscosity/drug effects
MH  - Chromatography, High Pressure Liquid
MH  - Disease Models, Animal
MH  - Epoprostenol/blood
MH  - Eugenol/administration & dosage/*analogs & derivatives/pharmacology
MH  - Female
MH  - Hematologic Diseases/*drug therapy/metabolism
MH  - Metabolomics/*methods
MH  - Platelet Aggregation/drug effects
MH  - Rats
MH  - Thromboxane A2/blood
PMC - PMC6651160
OTO - NOTNLM
OT  - AEE
OT  - UPLC-Q-TOF/MS
OT  - aspirin
OT  - blood stasis
OT  - metabolomics
COIS- The authors declare no conflict of interest.
EDAT- 2019/06/30 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/06/30 06:00
PHST- 2019/06/01 00:00 [received]
PHST- 2019/06/23 00:00 [revised]
PHST- 2019/06/25 00:00 [accepted]
PHST- 2019/06/30 06:00 [entrez]
PHST- 2019/06/30 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
AID - molecules24132380 [pii]
AID - molecules-24-02380 [pii]
AID - 10.3390/molecules24132380 [doi]
PST - epublish
SO  - Molecules. 2019 Jun 27;24(13):2380. doi: 10.3390/molecules24132380.

PMID- 12189010
OWN - NLM
STAT- MEDLINE
DCOM- 20030711
LR  - 20161124
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 13
IP  - 5-6
DP  - 2002 Aug-Sep
TI  - Exercise and training effects on platelets in health and disease.
PG  - 261-6
AB  - In recent years the involvement of platelets dysfunction in atherogenesis and in 
      the clinical complications from atherosclerosis has become more recognised. 
      Systemic platelet-related thrombogenic factors have been shown to be involved in 
      the initiation and progression of atherogenesis and plaque growth. Over the last 
      two decades, interest has been heightened regarding the changes in platelet 
      aggregation and functions that are associated with exercise in normal subjects 
      and also patients, particularly those suffering from coronary artery disease. 
      Although exercise effects on platelet aggregation and function in healthy 
      individuals have been examined, the results reported have been conflicting, most 
      likely due to methodological problems in the measurements of platelet aggregation 
      and activation during and after exercise. However for patients suffering from 
      coronary heart disease, the balance of evidence available would strongly suggest 
      that platelet aggregation and function are increased with exercise. Several drugs 
      are known to affect platelets, the most studied among them is aspirin. The 
      evidence available would suggest that aspirin is ineffective in attenuating 
      enhanced platelet aggregation and activation induced by exercise. Although the 
      effects of physical training have been briefly investigated, available meagre 
      evidence suggests that exercise on a regular basis is associated with favourable 
      effects on platelets aggregation and activation in both men and women.
FAU - El-Sayed, Mahmoud S
AU  - El-Sayed MS
AD  - Faculty of Science, Liverpool John Moores University, Henry Cotton Campus, 
      Liverpool, UK. m.s.elsayed@livjm.ac.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Blood Platelets/*physiology
MH  - Cardiac Rehabilitation
MH  - Cardiovascular Diseases/blood/prevention & control
MH  - Exercise/*physiology
MH  - Humans
MH  - Physical Education and Training/*methods
MH  - Platelet Activation
RF  - 46
EDAT- 2002/08/22 10:00
MHDA- 2003/07/12 05:00
CRDT- 2002/08/22 10:00
PHST- 2002/08/22 10:00 [pubmed]
PHST- 2003/07/12 05:00 [medline]
PHST- 2002/08/22 10:00 [entrez]
AID - 10.1080/0953770021000007221 [doi]
PST - ppublish
SO  - Platelets. 2002 Aug-Sep;13(5-6):261-6. doi: 10.1080/0953770021000007221.

PMID- 26933848
OWN - NLM
STAT- MEDLINE
DCOM- 20160307
LR  - 20171018
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 374
IP  - 8
DP  - 2016 Feb 25
TI  - Stopping vs. Continuing Aspirin before Coronary Artery Surgery.
PG  - 728-37
LID - 10.1056/NEJMoa1507688 [doi]
AB  - BACKGROUND: Most patients with coronary artery disease receive aspirin for 
      primary or secondary prevention of myocardial infarction, stroke, and death. 
      Aspirin poses a risk of bleeding in patients undergoing surgery, but it is 
      unclear whether aspirin should be stopped before coronary artery surgery. 
      METHODS: We used a 2-by-2 factorial trial design to randomly assign patients who 
      were scheduled to undergo coronary artery surgery and were at risk for 
      perioperative complications to receive aspirin or placebo and tranexamic acid or 
      placebo. The results of the aspirin trial are reported here. Patients were 
      randomly assigned to receive 100 mg of aspirin or matched placebo preoperatively. 
      The primary outcome was a composite of death and thrombotic complications 
      (nonfatal myocardial infarction, stroke, pulmonary embolism, renal failure, or 
      bowel infarction) within 30 days after surgery. RESULTS: Among 5784 eligible 
      patients, 2100 were enrolled; 1047 were randomly assigned to receive aspirin and 
      1053 to receive placebo. A primary outcome event occurred in 202 patients in the 
      aspirin group (19.3%) and in 215 patients in the placebo group (20.4%) (relative 
      risk, 0.94; 95% confidence interval, 0.80 to 1.12; P=0.55). Major hemorrhage 
      leading to reoperation occurred in 1.8% of patients in the aspirin group and in 
      2.1% of patients in the placebo group (P=0.75), and cardiac tamponade occurred at 
      rates of 1.1% and 0.4%, respectively (P=0.08). CONCLUSIONS: Among patients 
      undergoing coronary artery surgery, the administration of preoperative aspirin 
      resulted in neither a lower risk of death or thrombotic complications nor a 
      higher risk of bleeding than that with placebo. (Funded by the Australian 
      National Health and Medical Research Council and others; Australia New Zealand 
      Clinical Trials Registry number, ACTRN12605000557639.).
FAU - Myles, Paul S
AU  - Myles PS
AD  - From the Alfred Hospital (P.S.M., D.J.C, S.M., S.W.) and Monash University 
      (P.S.M., J.A.S., A.F., D.J.C., S.M., J.M.), Melbourne, VIC, St. Vincent's 
      Hospital, Fitzroy, VIC (B.S.), and the Royal Adelaide Hospital, Adelaide, SA 
      (T.P.) - all in Australia; Plymouth Medical School, Devon, United Kingdom (M.J.); 
      and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, 
      QC, Canada (J.S.B).
FAU - Smith, Julian A
AU  - Smith JA
AD  - From the Alfred Hospital (P.S.M., D.J.C, S.M., S.W.) and Monash University 
      (P.S.M., J.A.S., A.F., D.J.C., S.M., J.M.), Melbourne, VIC, St. Vincent's 
      Hospital, Fitzroy, VIC (B.S.), and the Royal Adelaide Hospital, Adelaide, SA 
      (T.P.) - all in Australia; Plymouth Medical School, Devon, United Kingdom (M.J.); 
      and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, 
      QC, Canada (J.S.B).
FAU - Forbes, Andrew
AU  - Forbes A
AD  - From the Alfred Hospital (P.S.M., D.J.C, S.M., S.W.) and Monash University 
      (P.S.M., J.A.S., A.F., D.J.C., S.M., J.M.), Melbourne, VIC, St. Vincent's 
      Hospital, Fitzroy, VIC (B.S.), and the Royal Adelaide Hospital, Adelaide, SA 
      (T.P.) - all in Australia; Plymouth Medical School, Devon, United Kingdom (M.J.); 
      and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, 
      QC, Canada (J.S.B).
FAU - Silbert, Brendan
AU  - Silbert B
AD  - From the Alfred Hospital (P.S.M., D.J.C, S.M., S.W.) and Monash University 
      (P.S.M., J.A.S., A.F., D.J.C., S.M., J.M.), Melbourne, VIC, St. Vincent's 
      Hospital, Fitzroy, VIC (B.S.), and the Royal Adelaide Hospital, Adelaide, SA 
      (T.P.) - all in Australia; Plymouth Medical School, Devon, United Kingdom (M.J.); 
      and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, 
      QC, Canada (J.S.B).
FAU - Jayarajah, Mohandas
AU  - Jayarajah M
AD  - From the Alfred Hospital (P.S.M., D.J.C, S.M., S.W.) and Monash University 
      (P.S.M., J.A.S., A.F., D.J.C., S.M., J.M.), Melbourne, VIC, St. Vincent's 
      Hospital, Fitzroy, VIC (B.S.), and the Royal Adelaide Hospital, Adelaide, SA 
      (T.P.) - all in Australia; Plymouth Medical School, Devon, United Kingdom (M.J.); 
      and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, 
      QC, Canada (J.S.B).
FAU - Painter, Thomas
AU  - Painter T
AD  - From the Alfred Hospital (P.S.M., D.J.C, S.M., S.W.) and Monash University 
      (P.S.M., J.A.S., A.F., D.J.C., S.M., J.M.), Melbourne, VIC, St. Vincent's 
      Hospital, Fitzroy, VIC (B.S.), and the Royal Adelaide Hospital, Adelaide, SA 
      (T.P.) - all in Australia; Plymouth Medical School, Devon, United Kingdom (M.J.); 
      and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, 
      QC, Canada (J.S.B).
FAU - Cooper, D James
AU  - Cooper DJ
AD  - From the Alfred Hospital (P.S.M., D.J.C, S.M., S.W.) and Monash University 
      (P.S.M., J.A.S., A.F., D.J.C., S.M., J.M.), Melbourne, VIC, St. Vincent's 
      Hospital, Fitzroy, VIC (B.S.), and the Royal Adelaide Hospital, Adelaide, SA 
      (T.P.) - all in Australia; Plymouth Medical School, Devon, United Kingdom (M.J.); 
      and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, 
      QC, Canada (J.S.B).
FAU - Marasco, Silvana
AU  - Marasco S
AD  - From the Alfred Hospital (P.S.M., D.J.C, S.M., S.W.) and Monash University 
      (P.S.M., J.A.S., A.F., D.J.C., S.M., J.M.), Melbourne, VIC, St. Vincent's 
      Hospital, Fitzroy, VIC (B.S.), and the Royal Adelaide Hospital, Adelaide, SA 
      (T.P.) - all in Australia; Plymouth Medical School, Devon, United Kingdom (M.J.); 
      and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, 
      QC, Canada (J.S.B).
FAU - McNeil, John
AU  - McNeil J
AD  - From the Alfred Hospital (P.S.M., D.J.C, S.M., S.W.) and Monash University 
      (P.S.M., J.A.S., A.F., D.J.C., S.M., J.M.), Melbourne, VIC, St. Vincent's 
      Hospital, Fitzroy, VIC (B.S.), and the Royal Adelaide Hospital, Adelaide, SA 
      (T.P.) - all in Australia; Plymouth Medical School, Devon, United Kingdom (M.J.); 
      and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, 
      QC, Canada (J.S.B).
FAU - Bussières, Jean S
AU  - Bussières JS
AD  - From the Alfred Hospital (P.S.M., D.J.C, S.M., S.W.) and Monash University 
      (P.S.M., J.A.S., A.F., D.J.C., S.M., J.M.), Melbourne, VIC, St. Vincent's 
      Hospital, Fitzroy, VIC (B.S.), and the Royal Adelaide Hospital, Adelaide, SA 
      (T.P.) - all in Australia; Plymouth Medical School, Devon, United Kingdom (M.J.); 
      and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, 
      QC, Canada (J.S.B).
FAU - Wallace, Sophie
AU  - Wallace S
AD  - From the Alfred Hospital (P.S.M., D.J.C, S.M., S.W.) and Monash University 
      (P.S.M., J.A.S., A.F., D.J.C., S.M., J.M.), Melbourne, VIC, St. Vincent's 
      Hospital, Fitzroy, VIC (B.S.), and the Royal Adelaide Hospital, Adelaide, SA 
      (T.P.) - all in Australia; Plymouth Medical School, Devon, United Kingdom (M.J.); 
      and Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, 
      QC, Canada (J.S.B).
CN  - ATACAS Investigators of the ANZCA Clinical Trials Network
LA  - eng
SI  - ANZCTR/ACTRN12605000557639
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 2016;352:i1173. PMID: 26929303
CIN - Nat Rev Cardiol. 2016 Apr;13(4):182. PMID: 26961068
CIN - Anaesthesist. 2016 Sep;65(9):710-1. PMID: 27287403
CIN - N Engl J Med. 2016 Jul 7;375(1):91-2. PMID: 27406359
CIN - N Engl J Med. 2016 Jul 7;375(1):90-1. PMID: 27406360
CIN - N Engl J Med. 2016 Jul 7;375(1):91. PMID: 27406361
CIN - J Thorac Dis. 2016 Jul;8(7):E578-80. PMID: 27501008
CIN - J Thorac Dis. 2016 Jul;8(7):E599. PMID: 27501533
CIN - J Thorac Dis. 2016 Sep;8(9):2290-2291. PMID: 27746957
CIN - Ann Transl Med. 2016 Oct;4(Suppl 1):S26. PMID: 27867994
CIN - Ann Transl Med. 2016 Oct;4(Suppl 1):S34. PMID: 27868002
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Transfusion
MH  - *Coronary Artery Bypass/mortality
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Complications/*mortality
MH  - Postoperative Hemorrhage/*chemically induced
MH  - *Preoperative Care
MH  - Thrombosis/*prevention & control
FIR - Myles, P
IR  - Myles P
FIR - Wallace, S
IR  - Wallace S
FIR - Galagher, W
IR  - Galagher W
FIR - Farrington, C
IR  - Farrington C
FIR - Ditoro, A
IR  - Ditoro A
FIR - Peyton, P
IR  - Peyton P
FIR - Baulch, S
IR  - Baulch S
FIR - Sidiropoulos, S
IR  - Sidiropoulos S
FIR - Potgieter, D
IR  - Potgieter D
FIR - Baker, R
IR  - Baker R
FIR - Pesudovs, B
IR  - Pesudovs B
FIR - O'Loughlin, E
IR  - O'Loughlin E
FIR - Wells, J
IR  - Wells J
FIR - Lynch, K
IR  - Lynch K
FIR - Bolsin, S
IR  - Bolsin S
FIR - Osborne, C
IR  - Osborne C
FIR - Ives, K
IR  - Ives K
FIR - Smith, J
IR  - Smith J
FIR - Hulley, A
IR  - Hulley A
FIR - Christie-Taylor, G
IR  - Christie-Taylor G
FIR - Painter, T
IR  - Painter T
FIR - Lang, S
IR  - Lang S
FIR - Cokis, C
IR  - Cokis C
FIR - March, S
IR  - March S
FIR - Bannon, P
IR  - Bannon P
FIR - Wong, C
IR  - Wong C
FIR - Turner, L
IR  - Turner L
FIR - Jackson, A
IR  - Jackson A
FIR - Scott, D
IR  - Scott D
FIR - Silbert, B
IR  - Silbert B
FIR - Said, S
IR  - Said S
FIR - Bussières, J
IR  - Bussières J
FIR - Gagné, N
IR  - Gagné N
FIR - Lamy, A
IR  - Lamy A
FIR - Power, P
IR  - Power P
FIR - Chan, M
IR  - Chan M
FIR - Underwood, M
IR  - Underwood M
FIR - Mou, A
IR  - Mou A
FIR - Landoni, G
IR  - Landoni G
FIR - Lembo, R
IR  - Lembo R
FIR - McGuinness, S
IR  - McGuinness S
FIR - Parke, R
IR  - Parke R
FIR - Jayarajah, M
IR  - Jayarajah M
FIR - Alderton, J
IR  - Alderton J
FIR - Waugh, D
IR  - Waugh D
FIR - Platt, M
IR  - Platt M
FIR - Alston, Peter
IR  - Alston P
FIR - Pai, A
IR  - Pai A
FIR - Sevillano, A
IR  - Sevillano A
FIR - Saravanan, P
IR  - Saravanan P
FIR - Vasudevan, V
IR  - Vasudevan V
EDAT- 2016/03/05 06:00
MHDA- 2016/03/08 06:00
CRDT- 2016/03/03 06:00
PHST- 2016/03/03 06:00 [entrez]
PHST- 2016/03/05 06:00 [pubmed]
PHST- 2016/03/08 06:00 [medline]
AID - 10.1056/NEJMoa1507688 [doi]
PST - ppublish
SO  - N Engl J Med. 2016 Feb 25;374(8):728-37. doi: 10.1056/NEJMoa1507688.

PMID- 20170869
OWN - NLM
STAT- MEDLINE
DCOM- 20110602
LR  - 20140905
IS  - 1876-7605 (Electronic)
IS  - 1936-8798 (Linking)
VI  - 3
IP  - 2
DP  - 2010 Feb
TI  - Perioperative management of patients with drug-eluting stents.
PG  - 131-42
LID - 10.1016/j.jcin.2009.11.017 [doi]
AB  - Thrombosis of a drug-eluting stent (DES) is a catastrophic complication. The risk 
      of stent thrombosis (ST) is increased in the perioperative setting and is 
      strongly associated with the cessation of antiplatelet therapy. This article 
      reviews the perioperative management of patients with DES with a clinical focus 
      on the perioperative use of antiplatelet therapy. Cessation of dual antiplatelet 
      therapy is the single most significant predictor of perioperative ST. Available 
      data on perioperative management of patients with DES are limited, and 
      recommendations are therefore limited. To avoid ST with DES, aspirin and 
      thienopyridines should ideally be continued throughout surgery. In spite of the 
      increased risk of bleeding, this strategy is acceptable in many types of invasive 
      surgical procedures with no change in outcome. However, if the bleeding risk 
      outweighs the risk of ST, other potential strategies include treatment with 
      aspirin alone, "bridging therapy" with aspirin and a glycoprotein IIb/IIIa 
      inhibitor and/or heparin, and "bridging therapy" without aspirin. Novel 
      antiplatelet therapies are promising and potentially valuable in the 
      perioperative management of patients with DES. Maintaining dual antiplatelet 
      therapy is the mainstay of perioperative ST prevention. However, short-term 
      discontinuation of thienopyridines might be associated with relatively low risk 
      if aspirin therapy is maintained perioperatively.
CI  - Copyright (c) 2010 American College of Cardiology Foundation. Published by 
      Elsevier Inc. All rights reserved.
FAU - Abualsaud, Ali O
AU  - Abualsaud AO
AD  - Division of Cardiology, Royal Victoria Hospital/McGill University Health Centre, 
      Montreal, Quebec, Canada.
FAU - Eisenberg, Mark J
AU  - Eisenberg MJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - JACC Cardiovasc Interv
JT  - JACC. Cardiovascular interventions
JID - 101467004
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Coronary Restenosis/*drug therapy
MH  - Drug Therapy, Combination
MH  - Drug-Eluting Stents/*adverse effects
MH  - *Perioperative Care
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pyridines/therapeutic use
MH  - Risk Factors
RF  - 119
EDAT- 2010/02/23 06:00
MHDA- 2011/06/03 06:00
CRDT- 2010/02/23 06:00
PHST- 2009/08/27 00:00 [received]
PHST- 2009/11/17 00:00 [revised]
PHST- 2009/11/30 00:00 [accepted]
PHST- 2010/02/23 06:00 [entrez]
PHST- 2010/02/23 06:00 [pubmed]
PHST- 2011/06/03 06:00 [medline]
AID - S1936-8798(09)00872-3 [pii]
AID - 10.1016/j.jcin.2009.11.017 [doi]
PST - ppublish
SO  - JACC Cardiovasc Interv. 2010 Feb;3(2):131-42. doi: 10.1016/j.jcin.2009.11.017.

PMID- 7413998
OWN - NLM
STAT- MEDLINE
DCOM- 19801120
LR  - 20190825
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 20
IP  - 2
DP  - 1980 Aug
TI  - Evaluation of the role of the F prostaglandins in canine bile flow.
PG  - 373-82
AB  - Prostaglandin F2 alpha (PGF2 alpha) has been shown to be an effective stimulant 
      of hepatic bile flow producing a specific chloride rich bile. Subsequent 
      evaluation by radioimmunoassay has shown that prostaglandin F compounds are 
      present in relatively large amounts in canine hepatic bile. This study evaluates 
      the effect of PGF2 alpha administration and of prostaglandin synthetase 
      inhibition by aspirin and indomethacin on bile flow and radioimmunoassayable 
      prostaglandin F (iPGF) secretion. Chronic, canine bile fistula preparations were 
      utilized and the enterohepatic circulation was maintained by intravenous bile 
      salts. Bile volume and composition were evaluated by standard techniques as well 
      as bile PGF concentration by radioimmunoassay during bile salt infusion and 
      during bile salt and PGF2 alpha, aspirin and indomethacin infusion in varying 
      doses. Both aspirin and PGF2 alpha were potent stimulants of hepatic bile flow 
      with aspirin producing a chloride rich bile similar to that produced by PGF2 
      alpha. PGF2 alpha produced dose related increases in bile iPGF concentration and 
      output indicating that as the systemic concentration increases during infusion of 
      PGF2 alpha the lipid appears in bile. Aspirin in the highest dose administered, 
      decreased iPGF concentration in bile while output was unchanged. Indomethacin was 
      ineffectual in consistently altering bile flow or iPGF secretion. This study 
      demonstrates that iPGF is present in canine bile, that its concentration can be 
      altered by prostaglandin infusion while prostaglandin synthetase inhibition has 
      minimal effects on bile iPGF secretion.
FAU - Kaminski, D L
AU  - Kaminski DL
FAU - Deshpande, Y G
AU  - Deshpande YG
LA  - eng
GR  - AM 18779/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Prostaglandins F)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Bile/*physiology
MH  - Cholecystectomy
MH  - Dogs
MH  - Indomethacin/pharmacology
MH  - Liver/drug effects/*physiology
MH  - Prostaglandins F/*pharmacology/physiology
EDAT- 1980/08/01 00:00
MHDA- 1980/08/01 00:01
CRDT- 1980/08/01 00:00
PHST- 1980/08/01 00:00 [pubmed]
PHST- 1980/08/01 00:01 [medline]
PHST- 1980/08/01 00:00 [entrez]
AID - S0090-6980(80)80054-2 [pii]
AID - 10.1016/s0090-6980(80)80054-2 [doi]
PST - ppublish
SO  - Prostaglandins. 1980 Aug;20(2):373-82. doi: 10.1016/s0090-6980(80)80054-2.

PMID- 7608308
OWN - NLM
STAT- MEDLINE
DCOM- 19950815
LR  - 20220331
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 35
IP  - 3
DP  - 1995 Mar
TI  - Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic 
      hemostasis.
PG  - 209-19
AB  - Aspirin and nonaspirin nonsteroidal antiinflammatory drugs (NSAIDs) inhibit 
      platelet cyclooxygenase, thereby blocking the formation of thromboxane A2. These 
      drugs produce a systemic bleeding tendency by impairing thromboxane-dependent 
      platelet aggregation and consequently prolonging the bleeding time. Aspirin 
      exerts these effects by irreversibly blocking cyclooxygenase and, therefore, its 
      actions persist for the circulating lifetime of the platelet. Nonaspirin NSAIDs 
      inhibit cyclooxygenase reversibly and, therefore, the duration of their action 
      depends on specific drug dose, serum level, and half-life. The clinical risks of 
      bleeding with aspirin or nonaspirin NSAIDs are enhanced by the concomitant use of 
      alcohol or anticoagulants and by associated conditions, including advanced age, 
      liver disease, and other coexisting coagulopathies.
FAU - Schafer, A I
AU  - Schafer AI
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology
MH  - Aspirin/adverse effects/pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects/metabolism/physiology
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Hemorrhage/chemically induced
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Risk Factors
RF  - 141
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1995.tb04050.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1995 Mar;35(3):209-19. doi: 10.1002/j.1552-4604.1995.tb04050.x.

PMID- 3326678
OWN - NLM
STAT- MEDLINE
DCOM- 19880411
LR  - 20131121
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 9
IP  - 6
DP  - 1987
TI  - Comparison of meclofenamate sodium with buffered aspirin and placebo for the 
      relief of postoperative dental pain.
PG  - 594-601
AB  - The analgesic effect of meclofenamate sodium at two dose levels (100 mg and 200 
      mg) was compared with the effects of buffered aspirin (600 mg) and placebo in a 
      double-blind, randomized study of 105 dental outpatients with acute pain 
      following third-molar extraction. Meclofenamate sodium at either dose level was 
      significantly superior to both buffered aspirin and placebo, resulting in 
      significantly greater relief of pain. All four treatments were well tolerated, 
      and side effects were minimal. Meclofenamate sodium is a safe, highly effective 
      analgesic for the relief of acute pain.
FAU - Kempf, K K
AU  - Kempf KK
AD  - Walter Reed Army Medical Center, Washington, D.C.
FAU - Konzelman, J L
AU  - Konzelman JL
FAU - Schultz, R E
AU  - Schultz RE
FAU - Turner, J L
AU  - Turner JL
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Buffers)
RN  - 0 (ortho-Aminobenzoates)
RN  - 48I5LU4ZWD (Meclofenamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Buffers
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Meclofenamic Acid/administration & dosage/*therapeutic use
MH  - Middle Aged
MH  - Pain Measurement
MH  - Pain, Postoperative/*drug therapy
MH  - Tooth Extraction/*adverse effects
MH  - ortho-Aminobenzoates/*therapeutic use
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1987;9(6):594-601.

PMID- 6965646
OWN - NLM
STAT- MEDLINE
DCOM- 19800514
LR  - 20190722
IS  - 0016-5107 (Print)
IS  - 0016-5107 (Linking)
VI  - 26
IP  - 1
DP  - 1980 Feb
TI  - The prevalence of duodenal lesions in patients with rheumatic diseases on chronic 
      aspirin therapy.
PG  - 5-7
AB  - Peroral endoscopy was performed in 56 patients with rheumatic disease who had 
      been taking 8 or more aspirin tablets daily for more than 3 months yet who had no 
      major gastrointestinal symptoms or history of peptic ulcer disease. Duodenal 
      mucosal lesions were observed in 16 patients; 15 (27%) had erythema, 7 (13%) had 
      erosions, and 2 (4%) had ulcers. The prevalence of duodenal lesions was the same 
      in patients taking regular, buffered, or enteric-coated aspirin preparations. 
      Patients with duodenal lesions were more likely to have associated gastric 
      lesions.
FAU - Lockard, O O Jr
AU  - Lockard OO Jr
FAU - Ivey, K J
AU  - Ivey KJ
FAU - Butt, J H
AU  - Butt JH
FAU - Silvoso, G R
AU  - Silvoso GR
FAU - Sisk, C
AU  - Sisk C
FAU - Holt, S
AU  - Holt S
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastrointest Endosc
JT  - Gastrointestinal endoscopy
JID - 0010505
RN  - 0 (Buffers)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Buffers
MH  - Duodenal Diseases/*chemically induced/diagnosis/epidemiology
MH  - Duodenal Ulcer/chemically induced
MH  - Endoscopy
MH  - Erythema/chemically induced
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rheumatic Diseases/*drug therapy
MH  - Stomach Ulcer/chemically induced/epidemiology
MH  - Tablets, Enteric-Coated
EDAT- 1980/02/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
AID - S0016-5107(80)73248-0 [pii]
AID - 10.1016/s0016-5107(80)73248-0 [doi]
PST - ppublish
SO  - Gastrointest Endosc. 1980 Feb;26(1):5-7. doi: 10.1016/s0016-5107(80)73248-0.

PMID- 21155908
OWN - NLM
STAT- MEDLINE
DCOM- 20111013
LR  - 20131121
IS  - 1365-2222 (Electronic)
IS  - 0954-7894 (Linking)
VI  - 41
IP  - 1
DP  - 2011 Jan
TI  - Characteristics of subjects experiencing hypersensitivity to non-steroidal 
      anti-inflammatory drugs: patterns of response.
PG  - 86-95
LID - 10.1111/j.1365-2222.2010.03651.x [doi]
AB  - BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most 
      frequently involved groups of medicines in hypersensitivity drug reactions. Two 
      mechanisms can induce the reaction: immunological (sensitization) due to a 
      specific IgE or T cell response and pharmacological (cyclooxygenase inhibition). 
      The contribution of each of these mechanisms to the reactions is not well known. 
      OBJECTIVE: To analyse a large group of subjects with confirmed hypersensitivity 
      reactions to NSAIDs. METHODS: The drugs involved, the clinical entities induced 
      and the time interval between drug intake and appearance of the reaction were 
      studied. In cases where the diagnosis was not confirmed, a drug provocation test 
      was carried out. Atopy status was also assessed with prick test and total IgE in 
      serum. RESULTS: A total of 659 patients were finally considered to have had 
      hypersensitivity reactions to NSAIDs; 76% had cross-intolerance (CI) and 24% were 
      selective responders (SR). The most important drugs involved in CI were propionic 
      acid derivatives, in most cases ibuprofen, and in SR pyrazolones. In CI, the most 
      frequent clinical entity was urticaria and angio-oedema and to a lesser extent 
      airway involvement. The skin and airways were both involved in an important 
      proportion of cases. The most frequent entities in SR were urticaria and/or 
      angio-oedema followed by anaphylaxis. Atopy was significantly associated in the 
      CI group (P<0.005). CONCLUSION AND CLINICAL RELEVANCE: Cutaneous hypersensitivity 
      reactions by CI to NSAIDs are the most frequent entities induced by these 
      compounds. In addition to aspirin, other NSAIDs are taking on a predominant role. 
      Atopy can be a predisposing factor in patients with CI.
CI  - © 2010 Blackwell Publishing Ltd.
FAU - Doña, I
AU  - Doña I
AD  - Allergy Service, Carlos Haya Hospital (Pabellon C), Málaga, Spain.
FAU - Blanca-López, N
AU  - Blanca-López N
FAU - Cornejo-García, J A
AU  - Cornejo-García JA
FAU - Torres, M J
AU  - Torres MJ
FAU - Laguna, J J
AU  - Laguna JJ
FAU - Fernández, J
AU  - Fernández J
FAU - Rosado, A
AU  - Rosado A
FAU - Rondón, C
AU  - Rondón C
FAU - Campo, P
AU  - Campo P
FAU - Agúndez, J A
AU  - Agúndez JA
FAU - Blanca, M
AU  - Blanca M
FAU - Canto, G
AU  - Canto G
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse 
      effects/*immunology
MH  - Aspirin/administration & dosage/adverse effects/immunology
MH  - Asthma, Aspirin-Induced/etiology/immunology
MH  - Drug Hypersensitivity/etiology/*immunology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Young Adult
EDAT- 2010/12/16 06:00
MHDA- 2011/10/14 06:00
CRDT- 2010/12/16 06:00
PHST- 2010/12/16 06:00 [entrez]
PHST- 2010/12/16 06:00 [pubmed]
PHST- 2011/10/14 06:00 [medline]
AID - 10.1111/j.1365-2222.2010.03651.x [doi]
PST - ppublish
SO  - Clin Exp Allergy. 2011 Jan;41(1):86-95. doi: 10.1111/j.1365-2222.2010.03651.x.

PMID- 6774577
OWN - NLM
STAT- MEDLINE
DCOM- 19801125
LR  - 20180216
IS  - 0001-5792 (Print)
IS  - 0001-5792 (Linking)
VI  - 64
IP  - 1
DP  - 1980
TI  - Increased platelet aggregation induced by glucagon administration.
PG  - 6-11
AB  - The effect of 1 mg of intravenous glucagon on platelet aggregation has been 
      investigated in 12 normal subjects pre-treated with salicylate. All subjects 
      demonstrated the expected inhibition of collagen-induced secondary aggregation 
      but retained the normal adenosine diphosphate (ADP)-induced primary aggregation 
      phase 18 h after the salicylate therapy (600-1,200 mg). Subsequent administration 
      of glucagon caused a significant increase in the ADP-induced primary aggregation 
      phase in the 12 subjects. This data indicates that glucagon increases the 
      reactivity of platelets to ADP and may help to explain the common clinical 
      association of raised plasma glucagon, increased platelet aggregation and 
      vascular disease.
FAU - Proctor, S J
AU  - Proctor SJ
FAU - Davies, T F
AU  - Davies TF
FAU - Oxley, A
AU  - Oxley A
FAU - Jones, P
AU  - Jones P
FAU - Heath, A
AU  - Heath A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-92-5 (Glucagon)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Female
MH  - Glucagon/*pharmacology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1159/000207203 [doi]
PST - ppublish
SO  - Acta Haematol. 1980;64(1):6-11. doi: 10.1159/000207203.

PMID- 16907895
OWN - NLM
STAT- MEDLINE
DCOM- 20070306
LR  - 20191210
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 24
IP  - 4
DP  - 2006 Aug 15
TI  - Clinical outcome in upper gastrointestinal bleeding complicating low-dose aspirin 
      and antithrombotic drugs.
PG  - 633-6
AB  - BACKGROUND: The current risk stratification systems in upper gastrointestinal 
      bleeding do not correct for the intake of low-dose aspirin and other 
      antithrombotic drugs. AIM: To test the Blatchford scores in evaluating the 
      clinical outcome in bleeders using these drugs. METHODS: We calculated the 
      Blatchford scores in 510 bleeders, including 123 on low-dose aspirin, 44 on other 
      antithrombotic drugs, and 68 on non-steroidal anti-inflammatory drugs. RESULTS: 
      The median clinical scores distributed according to aetiological risk factors 
      were as follows: no risk factors, 5; non-steroidal anti-inflammatory drugs, 8; 
      aspirin, 7; other antithrombotics, 6; excess alcohol, 4; multiple risk factors, 
      7; (P = 0.003, Kruskal-Wallis test). Scores correlated positively with the 
      duration of admission in the entire group (r(s) = 0.285; P < 0.001) and in those 
      taking aspirin and antithrombotics (r(s) = 0.211; P = 0.029). The median scores 
      in patients requiring the blood transfusion were 10 in the entire group and 11 in 
      users of aspirin or antithrombotics, compared with 3 and 4, respectively, in 
      those not transfused (P < 0.001). CONCLUSIONS: The Blatchford scores are 
      significantly elevated in users of non-steroidal anti-inflammatory drugs, 
      low-dose aspirin, and other antithrombotic drugs. They correlate positively with 
      the duration of admission and the need for blood transfusion.
FAU - Taha, A S
AU  - Taha AS
AD  - Gastroenterology Unit, Crosshouse Hospital, Kilmarnock, Scotland, UK. 
      ali.taha1@btinternet.com
FAU - Angerson, W J
AU  - Angerson WJ
FAU - Knill-Jones, R P
AU  - Knill-Jones RP
FAU - Blatchford, O
AU  - Blatchford O
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*adverse effects
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk Factors
MH  - *Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2006/08/16 09:00
MHDA- 2007/03/07 09:00
CRDT- 2006/08/16 09:00
PHST- 2006/08/16 09:00 [pubmed]
PHST- 2007/03/07 09:00 [medline]
PHST- 2006/08/16 09:00 [entrez]
AID - APT3017 [pii]
AID - 10.1111/j.1365-2036.2006.03017.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2006 Aug 15;24(4):633-6. doi: 
      10.1111/j.1365-2036.2006.03017.x.

PMID- 6360786
OWN - NLM
STAT- MEDLINE
DCOM- 19840221
LR  - 20131121
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 86
IP  - 2
DP  - 1984 Feb
TI  - Prevention of acute aspirin-induced gastric mucosal injury by 15-R-15 methyl 
      prostaglandin E2: an endoscopic study.
PG  - 339-45
AB  - The deleterious effects of aspirin on gastric mucosa have been well documented in 
      experimental and clinical studies. Prostaglandins offer a potential method by 
      which this injury may be prevented. In these studies, we developed a single-dose 
      endoscopic assay system of aspirin-induced gastric mucosal injury in normal 
      volunteers. With this system, 27 of 30 volunteers (90%) demonstrated severe 
      mucosal injury after ingestion of aspirin. Subsequently, we evaluated whether 
      pretreatment with 15-R-15 methyl prostaglandin E2 prevented severe injury after 
      ingestion of aspirin. Following an initial dose-response study, a double-blind 
      crossover trial was performed using pretreatment with placebo or with 
      10-micrograms doses of 15-R-15 methyl prostaglandin E2 for 24 h before treatment 
      with aspirin. The results of this trial indicate that prostaglandin pretreatment 
      significantly prevented the occurrence of endoscopically visible severe gastric 
      mucosal injury after single-dose aspirin administration.
FAU - Gilbert, D A
AU  - Gilbert DA
FAU - Surawicz, C M
AU  - Surawicz CM
FAU - Silverstein, F E
AU  - Silverstein FE
FAU - Weinberg, C R
AU  - Weinberg CR
FAU - Saunders, D R
AU  - Saunders DR
FAU - Feld, A D
AU  - Feld AD
FAU - Sanford, R L
AU  - Sanford RL
FAU - Bergman, D
AU  - Bergman D
FAU - Washington, P
AU  - Washington P
LA  - eng
GR  - AM-16059/AM/NIADDK NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Prostaglandins E, Synthetic)
RN  - M6B59S6MEF (Arbaprostil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Arbaprostil/pharmacology/*therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Endoscopy
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Male
MH  - Prostaglandins E, Synthetic/*therapeutic use
EDAT- 1984/02/01 00:00
MHDA- 1984/02/01 00:01
CRDT- 1984/02/01 00:00
PHST- 1984/02/01 00:00 [pubmed]
PHST- 1984/02/01 00:01 [medline]
PHST- 1984/02/01 00:00 [entrez]
AID - S0016508584000263 [pii]
PST - ppublish
SO  - Gastroenterology. 1984 Feb;86(2):339-45.

PMID- 2588208
OWN - NLM
STAT- MEDLINE
DCOM- 19891227
LR  - 20190503
IS  - 0040-6376 (Print)
IS  - 1468-3296 (Electronic)
IS  - 0040-6376 (Linking)
VI  - 44
IP  - 9
DP  - 1989 Sep
TI  - Coronary artery bypass surgery: current practice in the United Kingdom.
PG  - 721-4
AB  - A survey of current clinical practice was carried out among the 84 consultant 
      cardiac surgeons currently performing coronary artery bypass surgery in the 
      United Kingdom. The 80 surgeons who returned the questionnaire performed an 
      estimated total of 17,100 coronary artery bypass graft operations in 1987, a mean 
      case load of 214 operations each. Sixty two of the 80 surgeons regarded the 
      internal mammary artery as the graft conduit of choice, and seven preferred the 
      saphenous vein. The internal mammary artery was used in 73% of bypass grafts to 
      the left anterior descending coronary artery but in only 4% of grafts to the 
      circumflex and right coronary systems. Contraindications to the use of the 
      internal mammary artery included advanced age of the patient (51 surgeons), 
      insufficient flow through the internal mammary artery (49), and endarterectomy 
      (35). Seventy four of the 80 surgeons considered intraoperative damage to the 
      saphenous vein to be a possible cause of vein graft failure, but there was no 
      agreement about how it should be reduced. All surgeons advocated pharmacological 
      measures to enhance graft patency. Dipyridamole and aspirin constituted the most 
      popular regimen (58 surgeons), though only 28 started dipyridamole 
      preoperatively. Warfarin was prescribed postoperatively on occasion by 22 
      surgeons, but 14 of these used it only after endarterectomy.
FAU - Angelini, G D
AU  - Angelini GD
AD  - Department of Cardiothoracic Surgery, University Hospital of Wales, Cardiff.
FAU - Bryan, A J
AU  - Bryan AJ
FAU - West, R R
AU  - West RR
FAU - Newby, A C
AU  - Newby AC
FAU - Breckenridge, I M
AU  - Breckenridge IM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Thorax
JT  - Thorax
JID - 0417353
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - Attitude of Health Personnel
MH  - Coronary Artery Bypass/*methods
MH  - Humans
MH  - Mammary Arteries
MH  - Middle Aged
MH  - Saphenous Vein
MH  - United Kingdom
MH  - Vascular Patency/drug effects
PMC - PMC462052
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
AID - 10.1136/thx.44.9.721 [doi]
PST - ppublish
SO  - Thorax. 1989 Sep;44(9):721-4. doi: 10.1136/thx.44.9.721.

PMID- 31699954
OWN - NLM
STAT- MEDLINE
DCOM- 20200415
LR  - 20200415
IS  - 0125-9326 (Print)
IS  - 0125-9326 (Linking)
VI  - 51
IP  - 3
DP  - 2019 Jul
TI  - Aspirin vs. P2Y12 Inhibitor Rivalry: Which One Can be Continued During 
      Gastrointestinal Bleeding.
PG  - 282-286
AB  - Dual antiplatelet therapy (DAPT) is the mainstay of secondary prevention 
      treatment for acute coronary syndrome (ACS) and ischemic stroke, especially after 
      coronary intervention. DAPT consists of aspirin and P2Y12 receptor inhibitor 
      (e.g. clopidogrel), and the use of DAPT has been increased over time. The most 
      serious and common adverse effect is gastrointestinal bleeding. Guidelines in 
      managing such condition are available among Gastroenterologist Societies and 
      Cardiologist Societies. Most guidelines are consistent with each other to 
      continue the use of aspirin while withholding P2Y12. However, European Society of 
      Cardiologist (ESC) guideline in 2017 recommends P2Y12 receptor inhibitor as the 
      preferred antiplatelet for patient with upper gastrointestinal bleeding. This 
      review will look on the guidelines and other supporting evidence for the 
      justification on the antiplatelet of choice.
FAU - Bestari, Muhammad Begawan
AU  - Bestari MB
AD  - Division of Gastroenterohepatology Department of Internal Medicine Faculty of 
      Medicine - University of Padjadjaran Hasan Sadikin General Hospital Bandung - 
      Indonesia. begawanb@yahoo.com.
FAU - Joewono, Ignatius R
AU  - Joewono IR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Indonesia
TA  - Acta Med Indones
JT  - Acta medica Indonesiana
JID - 7901042
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/prevention & control
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel/*adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Purinergic P2Y Receptor Antagonists/adverse effects/*therapeutic use
MH  - Secondary Prevention
MH  - Societies, Medical
MH  - Stroke/prevention & control
OTO - NOTNLM
OT  - aspirin
OT  - clopidogrel
OT  - dual anti platelet
OT  - gastrointestinal bleeding
EDAT- 2019/11/09 06:00
MHDA- 2020/04/16 06:00
CRDT- 2019/11/09 06:00
PHST- 2019/11/09 06:00 [entrez]
PHST- 2019/11/09 06:00 [pubmed]
PHST- 2020/04/16 06:00 [medline]
PST - ppublish
SO  - Acta Med Indones. 2019 Jul;51(3):282-286.

PMID- 936715
OWN - NLM
STAT- MEDLINE
DCOM- 19760901
LR  - 20131121
IS  - 0340-904X (Print)
IS  - 0340-904X (Linking)
VI  - 151
IP  - 4
DP  - 1976
TI  - Intolerance to aspirin: clinical and immunological studies.
PG  - 295-304
AB  - Skin-tests, patch-tests, Prausnitz-Küstner reactions, passive cutaneous 
      anaphylaxis in guinea pigs according to Ovary and lymphocyte proliferation tests 
      in vitro using thymidine 2-C14 have been carried out in 31 patients with aspirin 
      intolerance. Acetylsalicyclic acid, aspiryl-polylysine, lysine acetylsalicylate, 
      and sodium salicylate were used in these investigations. Collagen-induced 
      platelet aggregation according to BORN in the presence of aspirin was also 
      studied. An immunological mechanism was revealed in only a small percentage of 
      the patients studied, indicating in the remaining cases the possible role of 
      nonimmunological processes or the inadequacy of the test technique employed.
FAU - Patriarca, G
AU  - Patriarca G
FAU - Venuti, A
AU  - Venuti A
FAU - Schiavino, D
AU  - Schiavino D
FAU - Fais, G
AU  - Fais G
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Z Immunitatsforsch Immunobiol
JT  - Zeitschrift fur Immunitatsforschung. Immunobiology
JID - 7608602
RN  - 9007-49-2 (DNA)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*immunology/pharmacology
MH  - Asthma/immunology
MH  - Child
MH  - DNA/biosynthesis
MH  - *Drug Hypersensitivity
MH  - Female
MH  - Humans
MH  - Lysine
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/immunology
MH  - Oxidative Phosphorylation/drug effects
MH  - Oxygen Consumption/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Sodium Salicylate/immunology
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Immunitatsforsch Immunobiol. 1976;151(4):295-304.

PMID- 17539592
OWN - NLM
STAT- MEDLINE
DCOM- 20070706
LR  - 20131121
IS  - 0003-9225 (Print)
IS  - 0003-9225 (Linking)
VI  - 219
IP  - 3-4
DP  - 2007 Mar-Apr
TI  - [Suicide with acetylsalicylic acid].
PG  - 115-23
AB  - The authors report on a suicide of a 41-year-old man with acetylsalicylic acid. 
      According to his own statement the man had taken about 200 tablets of Aspirin (65 
      g acetylsalicylic acid) and initially showed no symptoms of intoxication. 4-5 
      hours after ingestion he vomited twice, but clear intoxication symptoms like 
      convulsions and cardiac arrhythmia occurred not earlier than 11 hours after 
      ingestion. Resuscitation by the emergency physician was not successful. The 
      chemical-toxicological analysis (HPLC-DAD) of blood samples taken in the hospital 
      approximately 12 h after ingestion showed salicylate in concentrations of 475 
      mg/L to 557 mg/L. The post-mortem concentrations of salicylate were within the 
      lethal-toxic range, i.e. 762 mg/L in heart blood and 215 mg/L in femoral blood. 
      All tested organs contained equally lethal salicylate levels (e.g. 503 mg/L in 
      the liver and 251 mg/L in the brain).
FAU - Wollersen, Heike
AU  - Wollersen H
AD  - Institut für Rechtsmedizin der Universität Bonn.
FAU - Preuss, Johanna
AU  - Preuss J
FAU - Thierauf, Annette
AU  - Thierauf A
FAU - Musshoff, Frank
AU  - Musshoff F
FAU - Madea, Burkhard
AU  - Madea B
LA  - ger
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Suizid durch Salicylat-Intoxikation.
PL  - Germany
TA  - Arch Kriminol
JT  - Archiv fur Kriminologie
JID - 0002256
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacokinetics/*poisoning
MH  - Autopsy/legislation & jurisprudence
MH  - Brain/pathology
MH  - Diagnosis, Differential
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/pathology
MH  - Humans
MH  - Intestinal Mucosa/pathology
MH  - Liver/pathology
MH  - Male
MH  - Poisoning
MH  - Substance Abuse Detection
MH  - Suicide/*legislation & jurisprudence
EDAT- 2007/06/02 09:00
MHDA- 2007/07/07 09:00
CRDT- 2007/06/02 09:00
PHST- 2007/06/02 09:00 [pubmed]
PHST- 2007/07/07 09:00 [medline]
PHST- 2007/06/02 09:00 [entrez]
PST - ppublish
SO  - Arch Kriminol. 2007 Mar-Apr;219(3-4):115-23.

PMID- 2266080
OWN - NLM
STAT- MEDLINE
DCOM- 19910211
LR  - 20131121
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 38
IP  - 9
DP  - 1990 Sep
TI  - Effects of commonly used non steroidal anti-inflammatory drugs on gastric mucosa. 
      A clinical, endoscopic and histopathological study.
PG  - 636-8
AB  - Non steroidal anti-inflammatory drugs (NSAIDS) are known to produce 
      gastro-intestinal lesions. In the present work we found that aspirin, 
      indomethacin and oxyphenbutazone caused gastric mucosal damage in 90.9%, 100% and 
      100% respectively, while ibuprofen and paracetamol caused damage in 33.3% and 
      37.5% of cases respectively. Thus the latter two drugs were much safer NSAIDs. 
      Furthermore we demonstrated that endoscopic monitoring of patients on NSAIDs is a 
      sensitive method for early detection of gastric mucosal damage. This monitoring 
      may be particularly valuable in high risk subjects on NSAIDs.
FAU - Misra, R
AU  - Misra R
AD  - King George's Medical College, Lucknow.
FAU - Pandey, H
AU  - Pandey H
FAU - Chandra, M
AU  - Chandra M
FAU - Chandra, M
AU  - Chandra M
FAU - Agarwal, P K
AU  - Agarwal PK
FAU - Pandeya, S N
AU  - Pandeya SN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/adverse effects/pharmacology
MH  - Drug Evaluation
MH  - Female
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastritis/*chemically induced/pathology
MH  - Gastroscopy
MH  - Humans
MH  - Hyperemia/chemically induced
MH  - Male
MH  - Middle Aged
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
PST - ppublish
SO  - J Assoc Physicians India. 1990 Sep;38(9):636-8.

PMID- 3236214
OWN - NLM
STAT- MEDLINE
DCOM- 19890511
LR  - 20190912
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 11
IP  - 8
DP  - 1988 Aug
TI  - Gastric emptying rates of drug preparations. I. Effects of size of dosage forms, 
      food and species on gastric emptying rates.
PG  - 563-70
AB  - The gastric emptying rates of oral dosage forms of different sizes were studied 
      in humans and beagle dogs measuring of marker drugs such as acetaminophen, 
      aspirin and pyridoxal phosphate in plasma or urine. The marker drugs, except 
      acetaminophen, were contained in enteric-coated granules or tablets which did not 
      dissolve in the stomach but dissolved rapidly in the upper intestine. The gastric 
      emptying rate of a dosage form of smaller size was faster than that of a larger 
      size. The gastric emptying rates of dosage forms with different sizes did not 
      correlate with each other inter-individually. The gastric emptying rates of 
      dosage forms of any size were delayed when drugs were administered after taking a 
      meal. The gastric emptying rates of dosage forms were extremely prolonged in 
      beagle dogs after drug administration postprandially, and this restricted the use 
      of beagle dogs as an animal model in bioavailability tests.
FAU - Kaniwa, N
AU  - Kaniwa N
AD  - Drugs Division, National Institute of Hygienic Sciences, Tokyo, Japan.
FAU - Aoyagi, N
AU  - Aoyagi N
FAU - Ogata, H
AU  - Ogata H
FAU - Ejima, A
AU  - Ejima A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Dosage Forms)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 5V5IOJ8338 (Pyridoxal Phosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*administration & dosage/pharmacokinetics
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - Biological Availability
MH  - Dogs
MH  - *Dosage Forms
MH  - *Eating
MH  - *Gastric Emptying
MH  - Humans
MH  - Particle Size
MH  - Pyridoxal Phosphate/administration & dosage
MH  - Tablets, Enteric-Coated
MH  - Time Factors
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
AID - 10.1248/bpb1978.11.563 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1988 Aug;11(8):563-70. doi: 10.1248/bpb1978.11.563.

PMID- 3190995
OWN - NLM
STAT- MEDLINE
DCOM- 19881228
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 26
IP  - 4
DP  - 1988 Oct
TI  - The effect of concurrent aspirin upon plasma concentrations of tenoxicam.
PG  - 455-62
AB  - 1. The effect of chronic, high-dose aspirin therapy upon the disposition of a 
      single dose and multiple doses of tenoxicam was examined in normal volunteers. 2. 
      Aspirin caused a 24% drop in the t1/2 (P less than 0.005), a 49% rise in the 
      volume of distribution (P less than 0.0003) and a 98% increase in the clearance 
      (P less than 0.0001) of tenoxicam after a single dose of the tenoxicam. 3. 
      Steady-state concentrations of tenoxicam decreased significantly from 10.4 +/- 
      1.5 to 4.5 +/- 1.6 micrograms ml-1 in the presence of chronic, high-dose aspirin 
      treatment. 4. Tenoxicam percentage free measured in plasma from a normal 
      volunteer was 0.56 +/- 0.05% over the tenoxicam concentration range 1-20 
      micrograms ml-1 and rose to 1.24 +/- 0.07% in the presence of aspirin 150 
      micrograms ml-1. 5. The effect of aspirin upon the disposition of tenoxicam was 
      consistent with a competitive protein binding interaction.
FAU - Day, R O
AU  - Day RO
AD  - Department of Clinical Pharmacology, St Vincent's Hospital, Sydney, N.S.W., 
      Australia.
FAU - Paull, P D
AU  - Paull PD
FAU - Lam, S
AU  - Lam S
FAU - Swanson, B R
AU  - Swanson BR
FAU - Williams, K M
AU  - Williams KM
FAU - Wade, D N
AU  - Wade DN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Salicylates)
RN  - 13T4O6VMAM (Piroxicam)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - Z1R9N0A399 (tenoxicam)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Piroxicam/administration & dosage/*analogs & derivatives/blood/pharmacokinetics
MH  - Protein Binding
MH  - Salicylates/blood
MH  - Salicylic Acid
PMC - PMC1386568
EDAT- 1988/10/01 00:00
MHDA- 1988/10/01 00:01
CRDT- 1988/10/01 00:00
PHST- 1988/10/01 00:00 [pubmed]
PHST- 1988/10/01 00:01 [medline]
PHST- 1988/10/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1988.tb03405.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1988 Oct;26(4):455-62. doi: 
      10.1111/j.1365-2125.1988.tb03405.x.

PMID- 6231190
OWN - NLM
STAT- MEDLINE
DCOM- 19840511
LR  - 20190722
IS  - 0014-4886 (Print)
IS  - 0014-4886 (Linking)
VI  - 84
IP  - 1
DP  - 1984 Apr
TI  - Possible role of central serotoninergic neurons in the development of dental pain 
      and aspirin-induced analgesia in the monkey.
PG  - 179-87
AB  - The effects of aspirin or 5-hydroxytryptamine (5-HT)-related drugs on the dental 
      pain induced by electrical stimulation of tooth pulp afferent fibers were 
      assessed in conscious monkeys. The electrical current required for producing jaw 
      opening is referred to as the pain threshold. Both systemic (25 to 75 mg/kg, 
      i.p.) or central (0.5 to 1.5 mg, third cerebral ventricle) administration of 
      aspirin produced analgesia in monkeys. In addition, activation of central 5-HT 
      receptors with central injection of either 5-HT or its precursor, 
      5-hydroxytryptophan, also produced analgesia. On the other hand, inhibition of 
      central 5-HT receptors with central administration of either cyproheptadine (a 
      blocking agent of 5-HT receptors), p-chlorophenylalanine (PCPA, an inhibitor of 
      5-HT synthesis) or 5,7-dihydroxytryptamine (5,7-DHT, a depletor of central 5-HT 
      nerve fibers) produced an enhancement in pain sensitivity (or a decrease in pain 
      threshold). Furthermore, the analgesia induced by aspirin was antagonized by 
      pretreatment of monkeys with either cyproheptadine, PCPA, or 5,7-DHT. The results 
      indicate that increases in the activity of central 5-HT neurons are associated 
      with reduced dental pain and enhanced aspirin-induced analgesia, whereas 
      decreases in the activity of those neurons correlate with dental hyperalgesia and 
      diminished aspirin-induced analgesia in monkeys.
FAU - Shyu, K W
AU  - Shyu KW
FAU - Lin, M T
AU  - Lin MT
FAU - Wu, T C
AU  - Wu TC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Exp Neurol
JT  - Experimental neurology
JID - 0370712
RN  - 0 (Serotonin Antagonists)
RN  - 2YHB6175DO (Cyproheptadine)
RN  - 31363-74-3 (5,7-Dihydroxytryptamine)
RN  - 333DO1RDJY (Serotonin)
RN  - R16CO5Y76E (Aspirin)
RN  - R5J7E3L9SP (Fenclonine)
SB  - IM
MH  - 5,7-Dihydroxytryptamine/pharmacology
MH  - Animals
MH  - Aspirin/*administration & dosage/antagonists & inhibitors
MH  - Cyproheptadine/pharmacology
MH  - Dental Pulp
MH  - Fenclonine/pharmacology
MH  - Macaca
MH  - Male
MH  - Pain/*drug therapy/metabolism
MH  - Serotonin/pharmacology
MH  - Serotonin Antagonists
MH  - Toothache/drug therapy
EDAT- 1984/04/01 00:00
MHDA- 1984/04/01 00:01
CRDT- 1984/04/01 00:00
PHST- 1984/04/01 00:00 [pubmed]
PHST- 1984/04/01 00:01 [medline]
PHST- 1984/04/01 00:00 [entrez]
AID - 0014-4886(84)90014-1 [pii]
AID - 10.1016/0014-4886(84)90014-1 [doi]
PST - ppublish
SO  - Exp Neurol. 1984 Apr;84(1):179-87. doi: 10.1016/0014-4886(84)90014-1.

PMID- 15019895
OWN - NLM
STAT- MEDLINE
DCOM- 20040406
LR  - 20191210
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 93
IP  - 6
DP  - 2004 Mar 15
TI  - Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and 
      aspirin on C-reactive protein levels in outpatients with heart failure.
PG  - 783-5
AB  - C-reactive protein (CRP) levels were measured in a cohort of 96 outpatients with 
      heart failure. Baseline angiotensin-converting enzyme inhibitor plus beta-blocker 
      use were associated with lower levels of CRP; no relation was found between CRP 
      levels and aspirin or statin use.
FAU - Joynt, Karen E
AU  - Joynt KE
AD  - Department of Medicine/Division of Cardiology, Duke University Medical Center, 
      Durham, North Carolina 27710, USA. oconn002@mc.duke.edu
FAU - Gattis, Wendy A
AU  - Gattis WA
FAU - Hasselblad, Vic
AU  - Hasselblad V
FAU - Fuzaylov, Sergey Y
AU  - Fuzaylov SY
FAU - Serebruany, Victor L
AU  - Serebruany VL
FAU - Gurbel, Paul A
AU  - Gurbel PA
FAU - Gaulden, Laura H
AU  - Gaulden LH
FAU - Felker, G Michael
AU  - Felker GM
FAU - Whellan, David J
AU  - Whellan DJ
FAU - O'Connor, Christopher M
AU  - O'Connor CM
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/administration & dosage/pharmacology/therapeutic use
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & 
      dosage/pharmacology/therapeutic use
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - C-Reactive Protein/*drug effects
MH  - Female
MH  - Heart Failure/blood/*drug therapy/epidemiology/*mortality
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & 
      dosage/pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - North Carolina/epidemiology
MH  - Pilot Projects
MH  - Prospective Studies
EDAT- 2004/03/17 05:00
MHDA- 2004/04/07 05:00
CRDT- 2004/03/17 05:00
PHST- 2003/08/04 00:00 [received]
PHST- 2003/12/02 00:00 [revised]
PHST- 2003/12/02 00:00 [accepted]
PHST- 2004/03/17 05:00 [pubmed]
PHST- 2004/04/07 05:00 [medline]
PHST- 2004/03/17 05:00 [entrez]
AID - S0002914903017302 [pii]
AID - 10.1016/j.amjcard.2003.12.010 [doi]
PST - ppublish
SO  - Am J Cardiol. 2004 Mar 15;93(6):783-5. doi: 10.1016/j.amjcard.2003.12.010.

PMID- 33618245
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 149
DP  - 2021 Apr
TI  - Aspirin and celecoxib may help to rectify a neurotransmission imbalance in 
      bipolar disorder.
PG  - 110536
LID - S0306-9877(21)00054-2 [pii]
LID - 10.1016/j.mehy.2021.110536 [doi]
AB  - BACKGROUND: Mood stabilizers with disparate chemical structures are approved for 
      treating bipolar disorder, but their mechanisms of action are not agreed on. 
      However, when administered to unanesthetized rats at clinically relevant doses, 
      they modulate neurotransmission involving arachidonic acid and brain activity of 
      COX-2, which oxidizes arachidonic acid within the arachidonic acid metabolic 
      cascade. HYPOTHESIS: Inhibiting COX-2 directly might enhance mood stabilizer 
      effects in bipolar disorder patients. OBSERVATIONS: This paper reviews randomized 
      controlled trials that showed that celecoxib, a selective COX-2 inhibitor, or 
      low-dose aspirin, which inhibits COX-1 and inhibits/acetylates COX-2, reduced 
      bipolar symptoms in patients on mood stabilizers. More convincing are two 
      population based pharmacoepidemiological studies that each demonstrated that 
      chronic low dose aspirin reduced bipolar severity markers in patients on mood 
      stabilizers. CONCLUSIONS: This clinical evidence is consistent with the 
      hypothesis that low-dose chronic aspirin and celecoxib, which can inhibit COX-2 
      and enter brain, can be repurposed in bipolar disorder to enhance mood stabilizer 
      effects on arachidonic acid metabolism and neurotransmission.
CI  - Published by Elsevier Ltd.
FAU - Rapoport, Stanley I
AU  - Rapoport SI
AD  - Laboratory on Molecular Signaling, National Institute on Alcohol Abuse and 
      Alcoholism, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 
      20892, United States. Electronic address: stanley.rapoport@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210213
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (Antimanic Agents)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antimanic Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Bipolar Disorder/drug therapy
MH  - Celecoxib/therapeutic use
MH  - Humans
MH  - Rats
MH  - Synaptic Transmission
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Arachidonic acid
OT  - Aspirin
OT  - Bipolar disorder
OT  - Brain
OT  - COX-2
OT  - Celecoxib
OT  - Cyclooxygenase
OT  - Imbalance
OT  - Mood stabilizer
OT  - Neurotransmission
OT  - Rat
EDAT- 2021/02/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/02/22 20:16
PHST- 2021/01/21 00:00 [received]
PHST- 2021/02/10 00:00 [accepted]
PHST- 2021/02/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2021/02/22 20:16 [entrez]
AID - S0306-9877(21)00054-2 [pii]
AID - 10.1016/j.mehy.2021.110536 [doi]
PST - ppublish
SO  - Med Hypotheses. 2021 Apr;149:110536. doi: 10.1016/j.mehy.2021.110536. Epub 2021 
      Feb 13.

PMID- 6581036
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 28
IP  - 12
DP  - 1983 Dec
TI  - Diflunisal protects human gastric mucosa against damage by indomethacin.
PG  - 1070-7
AB  - Mild irritants have been shown to protect the rat gastric mucosa from damage by 
      the subsequent administration of necrotizing agents. The purpose of this study 
      was to determine if a low concentration of a salicyclic acid analog (8 mM 
      diflunisal) was capable of protecting human gastric mucosa from the damage 
      induced by topical indomethacin. Healthy young volunteers were studied in three 
      separate experiments in which gastric transmucosal PD was used as an index of 
      mucosal integrity. In study I (10 subjects) 20 mM aspirin and 2 mM indomethacin 
      were shown to induce a significant (P less than 0.025) fall in PD of 15% and 10%, 
      respectively. In study II (10 subjects) 20 mM diflunisal was found to produce no 
      significant fall in PD nor any reduction in gastric juice PGE2. In study III (5 
      subjects) 8 mM diflunisal, given 15 min before 2 mM indomethacin, prevented the 
      fall in PD caused by indomethacin alone. These studies demonstrate that in 
      humans, 8 mM diflunisal protects the mucosa from injury induced by the subsequent 
      administration of a known damaging agent. It is possible that the mechanism of 
      this protection may be by stimulation of endogenous mucosal prostaglandins.
FAU - Cohen, M M
AU  - Cohen MM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Prostaglandins E)
RN  - 0 (Salicylates)
RN  - 7C546U4DEN (Diflunisal)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/antagonists & inhibitors
MH  - Diflunisal/*pharmacology
MH  - Dinoprostone
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Indomethacin/*adverse effects/antagonists & inhibitors
MH  - Male
MH  - Membrane Potentials/drug effects
MH  - Prostaglandins E/pharmacology
MH  - Salicylates/*pharmacology
EDAT- 1983/12/01 00:00
MHDA- 1983/12/01 00:01
CRDT- 1983/12/01 00:00
PHST- 1983/12/01 00:00 [pubmed]
PHST- 1983/12/01 00:01 [medline]
PHST- 1983/12/01 00:00 [entrez]
AID - 10.1007/BF01295804 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1983 Dec;28(12):1070-7. doi: 10.1007/BF01295804.

PMID- 30646422
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20200818
IS  - 1098-8785 (Electronic)
IS  - 0735-1631 (Linking)
VI  - 36
IP  - 13
DP  - 2019 Nov
TI  - Evaluation of the Effect of Low-Dose Aspirin on Biochemical and Biophysical 
      Biomarkers for Placental Disease in Low-Risk Pregnancy: Secondary Analysis of a 
      Multicenter RCT.
PG  - 1387-1393
LID - 10.1055/s-0038-1677476 [doi]
AB  - OBJECTIVE: To assess the effect of aspirin use in low-risk pregnancy on: (1) 
      pregnancy-associated plasma protein-A (PAPP-A) and placental-like growth factor 
      (PLGF); (2) urinary albumin-to-creatinine ratio (ACR) and blood pressure; (3) 
      fetal growth parameters; and (4) placental histopathology. STUDY DESIGN: This 
      secondary analysis from the T rial of low-dose aspirin with an E arly S creening 
      T est for preeclampsia and growth restriction randomized controlled trial was 
      based on low-risk nulliparous women randomized at 11 weeks to (1) aspirin 75 mg; 
      (2) no aspirin; and (3) aspirin based on the preeclampsia Fetal Medicine 
      Foundation screening test. At baseline, women underwent assessment of blood 
      pressure, PAPP-A, PLGF, and ACR, repeated 9 to 10 weeks postaspirin, in addition 
      to fetal growth assessment. Gross and histopathological placental analyses were 
      performed in line with Amsterdam criteria. RESULTS: A total of 445 subjects were 
      included (aspirin n = 163 [36.6%]; no aspirin n = 282 [63.4%]). Although the 
      fetal-to-placental weight ratio was significantly greater in the aspirin group 
      (7.5 [±1.3] vs. 7.3 [±1.4], p = 0.045), as was change in ultrasound assessed 
      estimated fetal weight from second to third trimesters (1,624.5 g [±235.1] vs. 
      1,606.2 [±189.4], p = 0.042), this was invalidated by the lack of a difference in 
      birth weight. Aspirin did not significantly impact on change in serum or urine 
      preeclampsia biomarkers, maternal blood pressure, or placental histopathology. 
      CONCLUSION: Aspirin use in low-risk pregnancy does not appear to impact on 
      preeclampsia biomarkers, fetal growth, or placental pathology.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Mone, Fionnuala
AU  - Mone F
AD  - UCD Perinatal Research Centre, School of Medicine, National Maternity Hospital, 
      University College Dublin, Dublin, Ireland.
FAU - Mulcahy, Cecilia
AU  - Mulcahy C
AD  - UCD Perinatal Research Centre, School of Medicine, National Maternity Hospital, 
      University College Dublin, Dublin, Ireland.
FAU - McParland, Peter
AU  - McParland P
AD  - UCD Perinatal Research Centre, School of Medicine, National Maternity Hospital, 
      University College Dublin, Dublin, Ireland.
FAU - Downey, Paul
AU  - Downey P
AD  - Department of Pathology and Laboratory Medicine, National Maternity Hospital, 
      Dublin, Ireland.
FAU - Culliton, Marie
AU  - Culliton M
AD  - Department of Pathology and Laboratory Medicine, National Maternity Hospital, 
      Dublin, Ireland.
FAU - Maguire, Orla C
AU  - Maguire OC
AD  - Department of Pathology and Laboratory Medicine, National Maternity Hospital, 
      Dublin, Ireland.
FAU - Mooney, Eoghan E
AU  - Mooney EE
AD  - Department of Pathology and Laboratory Medicine, National Maternity Hospital, 
      Dublin, Ireland.
FAU - Clarke, Philip
AU  - Clarke P
AD  - Department of Pathology and Laboratory Medicine, National Maternity Hospital, 
      Dublin, Ireland.
FAU - Fitzgerald, David
AU  - Fitzgerald D
AD  - Department of Pharmacy, National Maternity Hospital, Dublin, Ireland.
FAU - Tully, Elizabeth
AU  - Tully E
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - Malone, Fergal D
AU  - Malone FD
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin, Ireland.
FAU - McAuliffe, Fionnuala M
AU  - McAuliffe FM
AD  - UCD Perinatal Research Centre, School of Medicine, National Maternity Hospital, 
      University College Dublin, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190115
PL  - United States
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
RN  - 0 (Biomarkers)
RN  - 144589-93-5 (Placenta Growth Factor)
RN  - AYI8EX34EU (Creatinine)
RN  - EC 3.4.24.- (Pregnancy-Associated Plasma Protein-A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Albuminuria
MH  - Aspirin/administration & dosage/*pharmacology
MH  - *Biomarkers/blood/urine
MH  - Creatinine/urine
MH  - Female
MH  - Fetal Development/*drug effects
MH  - Humans
MH  - Placenta/pathology
MH  - Placenta Diseases/*diagnosis
MH  - Placenta Growth Factor/blood
MH  - Pre-Eclampsia/*diagnosis
MH  - Pregnancy
MH  - Pregnancy-Associated Plasma Protein-A/analysis
MH  - Ultrasonography, Prenatal
COIS- None declared.
EDAT- 2019/01/16 06:00
MHDA- 2020/08/19 06:00
CRDT- 2019/01/16 06:00
PHST- 2019/01/16 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
PHST- 2019/01/16 06:00 [entrez]
AID - 10.1055/s-0038-1677476 [doi]
PST - ppublish
SO  - Am J Perinatol. 2019 Nov;36(13):1387-1393. doi: 10.1055/s-0038-1677476. Epub 2019 
      Jan 15.

PMID- 35634882
OWN - NLM
STAT- MEDLINE
DCOM- 20220929
LR  - 20220929
IS  - 1364-6893 (Electronic)
IS  - 0144-3615 (Linking)
VI  - 42
IP  - 6
DP  - 2022 Aug
TI  - Short-term effects of first trimester low-dose aspirin therapy on uterine artery 
      flow in women at high risk for preeclampsia.
PG  - 1950-1955
LID - 10.1080/01443615.2022.2054688 [doi]
AB  - The aim of the study was to investigate the short-term effects of low-dose 
      aspirin treatment on uterine artery Doppler in pregnancies that were high-risk 
      for preeclampsia. This prospective observational study included 82 patients with 
      singleton pregnancies between 11-14 weeks of gestation. Uterine artery Doppler 
      measurements were obtained by transvaginal ultrasonography at the first prenatal 
      visit of women who started low-dose aspirin treatment due to the high risk of 
      preeclampsia and women who did not receive low-dose aspirin. Uterine artery 
      Doppler measurements of both groups were repeated 7-10 days after the first 
      examination. There was a significant decrease in the presence of uterine artery 
      diastolic notch in the low-dose aspirin group (p < .001). In both groups, the 
      mean uterine artery PI values between the two exams tended to decrease, but the 
      decrease in the control group was the only significant decrease (p = .014). The 
      changes in Doppler indices were more pronounced in the control group. Therefore, 
      they are much more likely to be related to the increase in gestational age than 
      with the use of aspirin. Although there was an improvement in uterine arteries of 
      Doppler measurements in high-risk women, they still had a high resistant flow 
      compared to women with normal pregnancies. IMPACT STATEMENTWhat is already known 
      on this subject? Pregnant women at high risk of preeclampsia have increased 
      uterine artery resistance. Low-dose aspirin therapy is the only strategy to 
      prevent the development of preeclampsia in these patients.What do the results of 
      this study add? Low-dose aspirin therapy may improve uterine perfusion in the 
      short term. After treatment, uterine artery resistance remains higher than in 
      normal pregnancies.What are the implications of these findings for clinical 
      practice and/or further research? Since baseline uterine blood flow and changes 
      throughout pregnancy can be very different depending on the risk of preeclampsia, 
      aspirin-treated or untreated groups may be used to evaluate the efficacy of 
      aspirin in future studies. For example, patients with 11 weeks and 13 weeks of 
      gestation can be divided into aspirin treated and control groups and efficacy of 
      starting the aspirin treatment at 11 weeks of gestation vs 13 weeks of gestation 
      can be evaluated.
FAU - Akalin, Emine Eda
AU  - Akalin EE
AUID- ORCID: 0000-0002-3593-5063
AD  - Department of Obstetrics and Gynaecology, Bahcesehir University School of 
      Medicine, Istanbul, Turkey.
FAU - Akalin, Munip
AU  - Akalin M
AUID- ORCID: 0000-0002-3737-7712
AD  - Department of Obstetrics and Gynaecology, University of Health Sciences Zeynep 
      Kamil Women's and Children's Disease Training and Research Hospital, Istanbul, 
      Turkey.
FAU - Ayvaci Tasan, Habibe
AU  - Ayvaci Tasan H
AUID- ORCID: 0000-0002-8517-0556
AD  - Department of Obstetrics and Gynaecology, University of Health Sciences Zeynep 
      Kamil Women's and Children's Disease Training and Research Hospital, Istanbul, 
      Turkey.
FAU - Koyuncu, Kazibe
AU  - Koyuncu K
AUID- ORCID: 0000-0001-9070-3962
AD  - Department of Obstetrics and Gynaecology, Kartal Dr. Lütfi Kırdar City Hospital, 
      Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220529
PL  - England
TA  - J Obstet Gynaecol
JT  - Journal of obstetrics and gynaecology : the journal of the Institute of 
      Obstetrics and Gynaecology
JID - 8309140
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/drug therapy/prevention & control
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Pregnancy Trimester, Second
MH  - Ultrasonography, Prenatal
MH  - *Uterine Artery/diagnostic imaging
OTO - NOTNLM
OT  - First trimester
OT  - low-dose aspirin
OT  - preeclampsia
OT  - uterine artery Doppler
EDAT- 2022/06/01 06:00
MHDA- 2022/09/30 06:00
CRDT- 2022/05/31 10:32
PHST- 2022/06/01 06:00 [pubmed]
PHST- 2022/09/30 06:00 [medline]
PHST- 2022/05/31 10:32 [entrez]
AID - 10.1080/01443615.2022.2054688 [doi]
PST - ppublish
SO  - J Obstet Gynaecol. 2022 Aug;42(6):1950-1955. doi: 10.1080/01443615.2022.2054688. 
      Epub 2022 May 29.

PMID- 8504499
OWN - NLM
STAT- MEDLINE
DCOM- 19930702
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 87
IP  - 6
DP  - 1993 Jun
TI  - Dose-dependent effect of aspirin on carotid atherosclerosis.
PG  - 1873-9
AB  - BACKGROUND: Antiplatelet treatment with aspirin is well established as secondary 
      prophylaxis after a transient ischemic attack or minor ischemic stroke, but the 
      effect of aspirin treatment on the course of carotid atherosclerosis is unknown. 
      We investigated the effect of aspirin on the initial stages of carotid 
      atherosclerosis. METHODS AND RESULTS: Patients were recruited from a prospective, 
      randomized, double-blind clinical trial to compare two doses of aspirin (900 mg 
      versus 50 mg daily) with regard to restenoses after lower limb angioplasty. Of 
      the 383 patients admitted to the angioplasty trial, 27 patients with 104 small 
      carotid atheroma (< 50% lumen narrowing) were examined at entry and after 1 year 
      of aspirin treatment with the use of a high-resolution ultrasound duplex system. 
      Disease progression and regression were defined by a change of maximal plaque 
      area (as measured by longitudinal ultrasound sections) of more than 2 SDs of the 
      method. The change in plaque area was significantly different for the treatment 
      groups: Average plaque size remained unchanged after treatment with 900 mg 
      aspirin daily but increased markedly after treatment with 50 mg aspirin daily (p 
      = 0.011). There were significantly more lesions in the 50-mg group showing 
      progression than in the 900-mg group (23 plaques [47%] versus 13 plaques [24%], p 
      = 0.025). Ultrasonic disappearance of a lesion was observed only in the 900-mg 
      group in nine cases (seven soft plaques and two ulcerative plaques, p = 0.018). 
      The six patients on 50 mg aspirin who continued smoking during the study showed 
      significantly more progression compared with the seven nonsmokers in the 50-mg 
      group (17 plaques [59%] versus six plaques [30%], p = 0.038). CONCLUSIONS: The 
      results of our study indicate that aspirin treatment slows carotid plaque growth 
      in a dose-dependent fashion, with a dose of 900 mg daily more efficient than 50 
      mg daily.
FAU - Ranke, C
AU  - Ranke C
AD  - Division of Angiology, Hannover Medical School, Germany.
FAU - Hecker, H
AU  - Hecker H
FAU - Creutzig, A
AU  - Creutzig A
FAU - Alexander, K
AU  - Alexander K
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Carotid Artery Diseases/diagnostic imaging/*drug therapy/epidemiology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Intracranial Arteriosclerosis/diagnostic imaging/*drug therapy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Ultrasonography
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - 10.1161/01.cir.87.6.1873 [doi]
PST - ppublish
SO  - Circulation. 1993 Jun;87(6):1873-9. doi: 10.1161/01.cir.87.6.1873.

PMID- 7449520
OWN - NLM
STAT- MEDLINE
DCOM- 19810327
LR  - 20161123
IS  - 0253-2662 (Print)
IS  - 0253-2662 (Linking)
VI  - 13
IP  - 1
DP  - 1980 Mar
TI  - [The value of serum salicylate determination in patients with rheumatoid 
      arthritis (author's transl)].
PG  - 27-32
AB  - Thirty-one patients with rheumatoid arthritis in the Veterans General Hospital 
      from July 1978 to June 1979 were treated with acetylsalicylic acid. The serum 
      salicylate level was determined twice a week. The dose of acetylsalicylic acid 
      was adjusted to keep the serum salicylate level around 15-30 mg%. All patients 
      were started with an initial dose of 65 mg/kg/day. The serum salicylate levels at 
      the 4th day varied greatly from 5.6 to 29.5 mg%. Tinnitus was noted in 24 
      patients. It occurred when the serum salicylate level reached 28.41 +/- 1.84 mg%. 
      Abnormal liver function was noted in 19.35% (6/31) patients during treatment. It 
      returned to normal after withdrawal of acetylsalicylic acid in 3 cases, after 
      decrease of the dosage in 2 cases and on the same dosage in 1 case. Patients with 
      positive FANA and RF were more prone to develop abnormal liver function during 
      treatment. Monitoring of serum salicylate level may decrease the incidence of 
      hepatic toxicity and maintain the dosage of acetylsalicylic acid in optimal 
      range.
FAU - Lan, J L
AU  - Lan JL
FAU - Wong, W
AU  - Wong W
FAU - Wang, W C
AU  - Wang WC
FAU - Wu, H S
AU  - Wu HS
FAU - Chen, H L
AU  - Chen HL
FAU - Han, S H
AU  - Han SH
LA  - chi
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi
JT  - Zhonghua Minguo wei sheng wu ji mian yi xue za zhi = Chinese journal of 
      microbiology and immunology
JID - 8008067
RN  - 0 (Salicylates)
RN  - 9009-79-4 (Rheumatoid Factor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chemical and Drug Induced Liver Injury
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rheumatoid Factor/analysis
MH  - Salicylates/*blood
MH  - Tinnitus/chemically induced
EDAT- 1980/03/01 00:00
MHDA- 1980/03/01 00:01
CRDT- 1980/03/01 00:00
PHST- 1980/03/01 00:00 [pubmed]
PHST- 1980/03/01 00:01 [medline]
PHST- 1980/03/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1980 Mar;13(1):27-32.

PMID- 21543340
OWN - NLM
STAT- MEDLINE
DCOM- 20110927
LR  - 20211020
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 4
IP  - 5
DP  - 2011 May
TI  - Aspirin and familial adenomatous polyposis: coming full circle.
PG  - 623-7
LID - 10.1158/1940-6207.CAPR-11-0157 [doi]
AB  - This perspective discusses the clinical trial reported by Burn and colleagues in 
      this issue of the journal (beginning on page 655), which assessed aspirin and 
      resistant starch for the prevention of colorectal adenomas in patients with 
      familial adenomatous polyposis (FAP). The findings are examined in the context of 
      previous clinical trials of aspirin in patients with sporadic adenomas and of 
      sulindac or celecoxib in patients with FAP. This newly reported work raises 
      important considerations of a role for aspirin in the clinical management of FAP 
      patients and adds to considerations of a role for aspirin in the chemoprevention 
      of colorectal cancer among broader populations.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Massachusetts General Hospital, Department of Medicine, Gastrointestinal Unit, 
      Boston, MA 02114, USA. achan@partners.org
LA  - eng
GR  - R01 CA137178/CA/NCI NIH HHS/United States
GR  - R01 CA137178-03/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Cancer Prev Res (Phila).
MH  - Adenomatous Polyposis Coli/*drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
PMC - PMC3097995
MID - NIHMS288201
COIS- Disclosure of Potential Conflicts of Interest The author has served as a 
      consultant to Bayer Healthcare.
EDAT- 2011/05/06 06:00
MHDA- 2011/09/29 06:00
CRDT- 2011/05/06 06:00
PHST- 2011/05/06 06:00 [entrez]
PHST- 2011/05/06 06:00 [pubmed]
PHST- 2011/09/29 06:00 [medline]
AID - 4/5/623 [pii]
AID - 10.1158/1940-6207.CAPR-11-0157 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2011 May;4(5):623-7. doi: 
      10.1158/1940-6207.CAPR-11-0157.

PMID- 19840560
OWN - NLM
STAT- MEDLINE
DCOM- 20091124
LR  - 20181201
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 104
IP  - 9
DP  - 2009 Nov 1
TI  - Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with 
      stable coronary heart disease.
PG  - 1189-93
LID - 10.1016/j.amjcard.2009.06.025 [doi]
AB  - This study sought to assess whether inadequate platelet responses to aspirin and 
      clopidogrel are distinct phenomena caused by different mechanisms or different 
      facets of the same phenomenon (i.e., general platelet hyperactivity). A total of 
      85 patients with stable coronary artery disease who were taking aspirin and 
      clopidogrel daily for > or =3 months were enrolled in the present study. Platelet 
      aggregation was measured by light transmission aggregometry (LTA) stimulated with 
      1.6 mM of arachidonic acid and 5, 10 and 20 microM of adenosine diphosphate, and 
      by the VerifyNow Aspirin and VerifyNow P2Y12 point-of-care assays. An inadequate 
      platelet response was defined as aggregation greater than or equal to the mean + 
      2 SDs. The prevalence of an inadequate platelet response varied greatly among the 
      assays. For aspirin, the prevalence was 2.4% using arachidonic acid-induced LTA 
      and 5.9% using the VerifyNow Aspirin assay. For clopidogrel, the prevalence 
      varied from 1.2% to 3.9% using adenosine diphosphate-induced LTA and was 2.4% 
      using the VerifyNow P2Y12 assay. The point-of-care assays did not select the same 
      patients as LTA. No subject was unresponsive to both aspirin and clopidogrel, 
      regardless of the assay used, suggesting that separate mechanisms govern platelet 
      unresponsiveness to aspirin and clopidogrel. In conclusion, an inadequate 
      platelet response to either aspirin or clopidogrel is rare, and the definition is 
      dependent on the platelet function assay used. Because no subject was found to be 
      unresponsive to both agents, the unresponsiveness is suspected to occur through 
      distinct mechanisms of platelet activation.
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
AD  - Université de Montréal, Québec, Canada.
FAU - Diodati, Jean G
AU  - Diodati JG
FAU - Schampaert, Erick
AU  - Schampaert E
FAU - Palisaitis, Donald A
AU  - Palisaitis DA
FAU - Pharand, Chantal
AU  - Pharand C
LA  - eng
PT  - Journal Article
DEP - 20090916
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Coronary Artery Disease/blood/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests/methods
MH  - Point-of-Care Systems
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2009/10/21 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/10/21 06:00
PHST- 2009/04/17 00:00 [received]
PHST- 2009/06/05 00:00 [revised]
PHST- 2009/06/05 00:00 [accepted]
PHST- 2009/10/21 06:00 [entrez]
PHST- 2009/10/21 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S0002-9149(09)01251-X [pii]
AID - 10.1016/j.amjcard.2009.06.025 [doi]
PST - ppublish
SO  - Am J Cardiol. 2009 Nov 1;104(9):1189-93. doi: 10.1016/j.amjcard.2009.06.025. Epub 
      2009 Sep 16.

PMID- 25771741
OWN - NLM
STAT- MEDLINE
DCOM- 20160912
LR  - 20181113
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 16
IP  - 6
DP  - 2015 Dec
TI  - A Reaction of Aspirin with Ferrous Gluconate.
PG  - 1495-9
LID - 10.1208/s12249-015-0316-y [doi]
AB  - A color reaction of aspirin with ferrous gluconate was studied by UV-Vis 
      spectrophotometry and HPLC-MS. It was found that the UV-Vis spectra of the two 
      drugs were different before and after they were mixed in water at about 0.3 M 
      (diluted by >20 times for analysis), indicating that a complexation reaction took 
      place. The drug-iron complex dissociated when the reacting solution was diluted 
      by 400 times. The by-products of the reaction identified by HPLC-MS were 
      salicylic acid, acetylated gluconic acid, salicylate-gluconic acid conjugate, and 
      an oxidized product of salicylic acid that was complexed with iron with a 
      molecular weight of 212. This reaction may be used as an important consideration 
      to optimize the dosing regime of the two drugs and to help explain some 
      pharmacological reactions between aspirin and biomolecules.
FAU - Zhang, Jian
AU  - Zhang J
AD  - Dr. J. Consulting, Atlanta, GA, 30341, USA. jzhang_mail04@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20150314
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Ferrous Compounds)
RN  - 0 (Gluconates)
RN  - 0 (Solutions)
RN  - E1UOL152H7 (Iron)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - R4R8J0Q44B (gluconic acid)
RN  - U1B11I423Z (ferrous gluconate)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Ferrous Compounds/*chemistry
MH  - Gluconates/chemistry
MH  - Iron/chemistry
MH  - Oxidation-Reduction
MH  - Salicylic Acid/chemistry
MH  - Solutions/chemistry
MH  - Spectrophotometry/methods
PMC - PMC4666253
OTO - NOTNLM
OT  - aspirin
OT  - ferrous gluconate
OT  - reaction
EDAT- 2015/03/17 06:00
MHDA- 2016/09/13 06:00
CRDT- 2015/03/17 06:00
PHST- 2015/02/09 00:00 [received]
PHST- 2015/03/03 00:00 [accepted]
PHST- 2015/03/17 06:00 [entrez]
PHST- 2015/03/17 06:00 [pubmed]
PHST- 2016/09/13 06:00 [medline]
AID - 10.1208/s12249-015-0316-y [pii]
AID - 316 [pii]
AID - 10.1208/s12249-015-0316-y [doi]
PST - ppublish
SO  - AAPS PharmSciTech. 2015 Dec;16(6):1495-9. doi: 10.1208/s12249-015-0316-y. Epub 
      2015 Mar 14.

PMID- 17168811
OWN - NLM
STAT- MEDLINE
DCOM- 20070124
LR  - 20190917
IS  - 1389-5575 (Print)
IS  - 1389-5575 (Linking)
VI  - 6
IP  - 12
DP  - 2006 Dec
TI  - Prothrombotic potential of NSAID in ischemic heart disease.
PG  - 1351-5
AB  - Non-steroidal anti-inflammatory drugs (NSAID) target the enzyme cyclooxygenase 
      (COX) thus affording relieve from pain, inflammation or fever. As COX-dependently 
      formed prostanoids not only mediate signals involved in inflammation and pain, 
      but also regulate important physiological cardiovascular functions, some NSAID 
      have recently been reported to be associated with arterial thrombosis or 
      hypertension. This is in contrast to the well-known antiplatelet effects of 
      low-dose aspirin, but in coherence with the specific effects of some NSAID on 
      prostanoid formation in the vasculature. A correlation between the intake of 
      selective inhibitors of the cyclooxygenase 2 (COX-2) isoform and atherothrombotic 
      events has recently been established. Large retrospective analyses of clinical 
      data have repeatedly shown this effect and in some cases have also observed 
      potential hazards for other, rather non-selective NSAID. This review evaluates 
      potential prothrombotic effects of NSAID in vascular ischemic disease in 
      comparison to low-dose aspirin and selective COX-2 inhibitors and discusses 
      pathophysiological backgrounds for such observations.
FAU - Krötz, Florian
AU  - Krötz F
AD  - Institute of Cardiology, Medical Policlinic, Ludwig-Maximilians-University, 
      Ziemssenstr.1, 80336 Munich, Germany. florian.kroetz@med.uni-muenchen.de
FAU - Hellwig, Nicole
AU  - Hellwig N
FAU - Schiele, Thomas M
AU  - Schiele TM
FAU - Klauss, Volker
AU  - Klauss V
FAU - Sohn, Hae-Young
AU  - Sohn HY
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Mini Rev Med Chem
JT  - Mini reviews in medicinal chemistry
JID - 101094212
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Cyclooxygenase Inhibitors/therapeutic use
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy
RF  - 86
EDAT- 2006/12/16 09:00
MHDA- 2007/01/25 09:00
CRDT- 2006/12/16 09:00
PHST- 2006/12/16 09:00 [pubmed]
PHST- 2007/01/25 09:00 [medline]
PHST- 2006/12/16 09:00 [entrez]
AID - 10.2174/138955706778993030 [doi]
PST - ppublish
SO  - Mini Rev Med Chem. 2006 Dec;6(12):1351-5. doi: 10.2174/138955706778993030.

PMID- 115671
OWN - NLM
STAT- MEDLINE
DCOM- 19800128
LR  - 20190827
IS  - 0013-7219 (Print)
IS  - 0013-7219 (Linking)
VI  - 26
IP  - 4
DP  - 1979 Aug
TI  - Potentiation by indomethacin of TRH-induced TSH secretion in the rat.
PG  - 465-70
AB  - We have studied the effect of two inhibitors of prostaglandin synthesis on the 
      basal and TRH-stimulated plasma TSH levels in the rat. Animals were injected sc 
      daily with indomethacin 3 mg/0.5 ml) or aspirin (16--30 mg/0.5 ml) for 3 days. 
      The plasma T4 and T3 were consistently lower in the indomethacin or aspirin 
      groups than in the controls, while the basal TSH levels did not change. 
      Indomethacin treatment significantly potentiated the TSH response to synthetic 
      TRH (20 ng. iv) in intact and thyroidectomized rats. The pituitary TSH content 
      was markedly increased by indomethacin, while hypothalamic TRH content did not 
      change. In contrast, aspirin inhibited the TSH response to TRH in intact rats, 
      when pituitary TSH content decreased significantly. No potentiation by aspirin of 
      TRH-stimulated TSH response in the thyroidectomized rats was observed. The 
      increased sensitivity of plasma TSH response to exogenous TRH in the indomethacin 
      group is presumably due to higher pituitary TSH content than in the controls. The 
      action of indomethacin appears to be mediated, at least in part, at the pituitary 
      level. In addition, there is a dissociation between the action of indomethacin 
      and the action of aspirin in the TSH response to TRH.
FAU - Tsuyusaki, K
AU  - Tsuyusaki K
FAU - Mori, M
AU  - Mori M
FAU - Tonooka, N
AU  - Tonooka N
FAU - Kabayashi, I
AU  - Kabayashi I
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Endocrinol Jpn
JT  - Endocrinologia japonica
JID - 0376546
RN  - 5Y5F15120W (Thyrotropin-Releasing Hormone)
RN  - 9002-71-5 (Thyrotropin)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Drug Synergism
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Rats
MH  - Thyroidectomy
MH  - Thyrotropin/*metabolism
MH  - Thyrotropin-Releasing Hormone/*pharmacology
EDAT- 1979/08/01 00:00
MHDA- 1979/08/01 00:01
CRDT- 1979/08/01 00:00
PHST- 1979/08/01 00:00 [pubmed]
PHST- 1979/08/01 00:01 [medline]
PHST- 1979/08/01 00:00 [entrez]
AID - 10.1507/endocrj1954.26.465 [doi]
PST - ppublish
SO  - Endocrinol Jpn. 1979 Aug;26(4):465-70. doi: 10.1507/endocrj1954.26.465.

PMID- 7863967
OWN - NLM
STAT- MEDLINE
DCOM- 19950323
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 75
IP  - 6
DP  - 1995 Feb 23
TI  - Combined use of aspirin and warfarin in primary prevention of ischemic heart 
      disease in men at high risk.
PG  - 23B-26B
AB  - The combination of aspirin and warfarin is likely to be more effective than 
      either agent alone in the prevention of ischemic heart disease (IHD), but its 
      practical value also crucially depends on a low incidence of serious bleeding. 
      The occurrence of bleeding of different degrees of severity is being established 
      in the Thrombosis Prevention Trial of primary prevention in men aged 45-69 years 
      at increased risk of IHD, in which 75 mg aspirin and warfarin dosed to an 
      international normalized ratio of 1.5 are used in a factorial design. The annual 
      risk of serious bleeding, i.e., requiring transfusion or surgery, may be about 1 
      in 500 for those on active treatment, whether this consists of both aspirin and 
      warfarin or either alone. Less serious degrees of bleeding are significantly 
      increased by the combination of aspirin and warfarin compared with either alone 
      and by either alone compared with placebo. The risk of serious bleeding is 
      probably acceptable if low dosages are used.
FAU - Meade, T W
AU  - Meade TW
AD  - MRC Epidemiology and Medical Care Unit, Wolfson Institute of Preventative 
      Medicine, Medical College, St. Bartholomew's Hospital, London, United Kingdom.
FAU - Miller, G J
AU  - Miller GJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/complications/*prevention & control
MH  - Risk Factors
MH  - Warfarin/*administration & dosage/adverse effects
EDAT- 1995/02/23 00:00
MHDA- 1995/02/23 00:01
CRDT- 1995/02/23 00:00
PHST- 1995/02/23 00:00 [pubmed]
PHST- 1995/02/23 00:01 [medline]
PHST- 1995/02/23 00:00 [entrez]
AID - 0002-9149(95)80006-E [pii]
AID - 10.1016/0002-9149(95)80006-e [doi]
PST - ppublish
SO  - Am J Cardiol. 1995 Feb 23;75(6):23B-26B. doi: 10.1016/0002-9149(95)80006-e.

PMID- 9090926
OWN - NLM
STAT- MEDLINE
DCOM- 19970515
LR  - 20131121
IS  - 0047-2166 (Print)
IS  - 0047-2166 (Linking)
VI  - 52
IP  - 1
DP  - 1997 Jan-Feb
TI  - Effect of particle shape of acetyl salicylic acid powders on gastric damages in 
      rats.
PG  - 1-6
AB  - In this study the correlation between particle shape of acetyl salicylic acid 
      (ASA) powders and gastric damage was studied. It is highly possible that 
      different pharmaceutical particulate systems having different shape factors, 
      cause different damages in contact with stomach walls. In this study five types 
      of ASA powders in the same size range with different shape factors were chosen. 
      From different shape factors, two important known as "elongation" and 
      "sphericity" were selected and by means of "image analyser" were quantitatively 
      calculated. The highest measured shape factor for elongation was 5.9 and for 
      sphericity was 3.7, and the smallest shape factor for elongation was 1.4 and for 
      sphericity was 1.4. For animal study, a suspension of each powder was orally 
      administered by feeding needle, and drug was entered into the stomaches of 
      fasting rats. After four hours, rats were killed and their stomaches were 
      observed. Maximum number of ulcers were produced by particles with corrugated 
      flat surfaces and the least damage was produced by particles with elongated 
      bodies. Therefore, the most important factor resulting highly intensive ulcers in 
      rat stomach, is flaky particles with corrugated shapes.
FAU - Zolfaghari, M E
AU  - Zolfaghari ME
AD  - Darou Pakhsh Pharmaceutical Research Center, Tehran, Iran.
FAU - Dhepour, A R
AU  - Dhepour AR
FAU - Mousavi, N
AU  - Mousavi N
LA  - eng
PT  - Journal Article
PL  - Belgium
TA  - J Pharm Belg
JT  - Journal de pharmacie de Belgique
JID - 0375351
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Gastric Mucosa/pathology
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Stomach Diseases/chemically induced/*pathology
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - J Pharm Belg. 1997 Jan-Feb;52(1):1-6.

PMID- 29521038
OWN - NLM
STAT- MEDLINE
DCOM- 20190627
LR  - 20190627
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 27
IP  - 1
DP  - 2018 Jan
TI  - The protective action of tocopherol and acetylsalicylic acid on the behavior of 
      rats treated with dioxins.
PG  - 5-14
LID - 10.17219/acem/67314 [doi]
AB  - BACKGROUND: Dioxins contribute to neurological disorders in humans and animals, 
      causing also neurological disorders in offspring during prenatal and postnatal 
      periods. These compounds significantly affect the development of the central 
      nervous system (CNS) structures, which results in behavioral changes. Tocopherol 
      (TCP) and acetylsalicylic acid (ASA) may provide protective measures to reduce 
      the inflammatory effects in the CNS associated with free radicals generated by 
      2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), thus contributing to the reduction of 
      the negative effects of dioxin. OBJECTIVES: The main objective of this study was 
      to determine the influence of dioxin on rats and their behavioral functions, and 
      to ascertain whether a combined administration of TCP and ASA to rats treated 
      with TCDD shows the possibility of potential protective effect on the functioning 
      of the CNS. MATERIAL AND METHODS: Experiments were performed on 75 female and 12 
      male Buffalo strain rats, which are offspring of females from particular study 
      groups. TCDD was used in the experiments, TCP and ASA were administered orally 
      every day for 3 weeks. Animals were subjected to behavioral testing: the tail and 
      swimming tests. RESULTS: During the observation of the offspring of both sexes 
      born to females exposed to TCDD, males did not demonstrate any attempt to swim, 
      whereas in females, the immobility time was significantly extended. Assessing the 
      response times from the tail test in the animals treated with dioxins in relation 
      to the control group, it was demonstrated that the response time was extended in 
      the 3rd measurement in both females and males. CONCLUSIONS: Dioxin is 
      characterized by neurotoxic effect causing behavioral disorders associated with 
      prolonged response times. The use of TCP after the administration of dioxins 
      causes a significant reduction and improvement of reflex response times. In 
      contrast, ASA reduces the reflex response times also in the offspring of females 
      exposed to TCDD and ASA.
FAU - Rosińczuk, Joanna
AU  - Rosińczuk J
AD  - Department of Nervous System Diseases, Wroclaw Medical University, Poland.
FAU - Dymarek, Robert
AU  - Dymarek R
AD  - Department of Nervous System Diseases, Wroclaw Medical University, Poland.
FAU - Całkosiński, Ireneusz
AU  - Całkosiński I
AD  - Independent Laboratory of Clinical Neurotoxicology and Environmental Diagnostics, 
      Wroclaw Medical University, Poland.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
RN  - 0 (Dioxins)
RN  - 0 (Polychlorinated Dibenzodioxins)
RN  - 0 (Protective Agents)
RN  - R0ZB2556P8 (Tocopherols)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Animals, Newborn/metabolism
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Behavior, Animal/*drug effects
MH  - Brain/drug effects
MH  - Central Nervous System/*drug effects
MH  - Dioxins/*adverse effects/therapeutic use
MH  - Female
MH  - Male
MH  - Polychlorinated Dibenzodioxins
MH  - Pregnancy
MH  - Prenatal Exposure Delayed Effects
MH  - Protective Agents/pharmacology
MH  - Rats
MH  - Tocopherols/administration & dosage/*pharmacology
OTO - NOTNLM
OT  - 2
OT  - 3
OT  - 7
OT  - 8-tetrachlorodibenzo-p-dioxin
OT  - acetylsalicylic acid
OT  - behavioral functions
OT  - central nervous system
OT  - tocopherol
EDAT- 2018/03/10 06:00
MHDA- 2019/06/30 06:00
CRDT- 2018/03/10 06:00
PHST- 2018/03/10 06:00 [entrez]
PHST- 2018/03/10 06:00 [pubmed]
PHST- 2019/06/30 06:00 [medline]
AID - 10.17219/acem/67314 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2018 Jan;27(1):5-14. doi: 10.17219/acem/67314.

PMID- 12575297
OWN - NLM
STAT- MEDLINE
DCOM- 20030711
LR  - 20131121
IS  - 1000-5625 (Print)
IS  - 1000-5625 (Linking)
VI  - 27
IP  - 3
DP  - 2002 Jun 28
TI  - [Effect of low-dosage aspirin combined with perindopril on prostacyclin, 
      thromboxone A2, and norepinephrine in rabbits' blood].
PG  - 224-6
AB  - OBJECTIVE: To explore the interaction of low-dosage aspirin combined with 
      angiotensin-converting enzyme (ACE) inhibitors by prostacyclin (PGI2), 
      thromboxone A2 (TXA2) and norepinephrine (NE)) levels in rabbits' blood. METHODS: 
      Forty healthy New Zealand rabbits were divided into four groups. Blood samples 
      were drawn from the rabbits' heart before and after a consecutive four-week. NE 
      was measured by high performance liquid chromatography, and PGI2 and TXA2 were 
      measured by radioimmunoassay. RESULTS: ACE inhibitors increased PGI2 levels (P < 
      0.05, P < 0.01); low-dosage aspirin suppressed TXA2 productions (P < 0.05, P < 
      0.01) after the four-week administration. Aspirin combined with ACE inhibitors 
      led to a significant increase in PGI2/TXA2(P < 0.01), together with a significant 
      decrease in NE levels in the rabbits' blood (P < 0.001). CONCLUSION: Neither 
      low-dosage aspirin nor ACE inhibitors influence NE levels alone. The ratio of 
      PGI2 to TXA2 increased, and NE levels decreased significantly during the 
      administration of aspirin combined with ACE inhibitors. The results suggest that 
      there is a synergis-action between low-dosage aspirin and ACE inhibitors due to 
      increased PGI2/TXA2 and decreased NE levels.
FAU - Zhuang, Han-ping
AU  - Zhuang HP
AD  - Department of Geriatrics, Xiangya Hospital, Central South University, Changsha 
      410008, China.
FAU - Li, Jing
AU  - Li J
FAU - Fang, Yun-xiang
AU  - Fang YX
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Hunan Yi Ke Da Xue Xue Bao
JT  - Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical 
      University
JID - 9424769
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W3ENH1CV (Norepinephrine)
RN  - Y5GMK36KGY (Perindopril)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*pharmacology
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Drug Synergism
MH  - Epoprostenol/*blood
MH  - Female
MH  - Male
MH  - Norepinephrine/*blood
MH  - Perindopril/*pharmacology
MH  - Rabbits
MH  - Thromboxane A2/*blood
EDAT- 2003/02/11 04:00
MHDA- 2003/07/12 05:00
CRDT- 2003/02/11 04:00
PHST- 2003/02/11 04:00 [pubmed]
PHST- 2003/07/12 05:00 [medline]
PHST- 2003/02/11 04:00 [entrez]
PST - ppublish
SO  - Hunan Yi Ke Da Xue Xue Bao. 2002 Jun 28;27(3):224-6.

PMID- 11073508
OWN - NLM
STAT- MEDLINE
DCOM- 20001214
LR  - 20220409
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 321
IP  - 7270
DP  - 2000 Nov 11
TI  - Risk of gastrointestinal haemorrhage with long term use of aspirin: 
      meta-analysis.
PG  - 1183-7
AB  - OBJECTIVES: To assess the incidence of gastrointestinal haemorrhage associated 
      with long term aspirin therapy and to determine the effect of dose reduction and 
      formulation on the incidence of such haemorrhage. DESIGN: Meta-analysis of 24 
      randomised controlled trials (almost 66 000 participants). INTERVENTION: Aspirin 
      compared with placebo or no treatment, for a minimum of one year. MAIN OUTCOME 
      MEASURES: Incidence of gastrointestinal haemorrhage. RESULTS: Gastrointestinal 
      haemorrhage occurred in 2.47% of patients taking aspirin compared with 1.42% 
      taking placebo (odds ratio 1.68; 95% confidence interval 1.51 to 1.88); the 
      number needed to harm was 106 (82 to 140) based on an average of 28 months' 
      therapy. At doses below 163 mg/day, gastrointestinal haemorrhage occurred in 
      2.30% of patients taking aspirin compared with 1.45% taking placebo (1.59; 1.40 
      to 1.81). Meta-regression showed no relation between gastrointestinal haemorrhage 
      and dose. For modified release formulations of aspirin the odds ratio was 1.93 
      (1.15 to 3.23). CONCLUSIONS: Long term therapy with aspirin is associated with a 
      significant increase in the incidence of gastrointestinal haemorrhage. No 
      evidence exists that reducing the dose or using modified release formulations 
      would reduce the incidence of gastrointestinal haemorrhage.
FAU - Derry, S
AU  - Derry S
AD  - Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, 
      Oxford OX2 6HE.
FAU - Loke, Y K
AU  - Loke YK
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 2000 Nov 11;321(7270):1170-1. PMID: 11073495
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cyclooxygenase Inhibitors/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Fibrinolytic Agents/administration & dosage/*adverse effects
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Long-Term Care
MH  - Odds Ratio
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
PMC - PMC27521
EDAT- 2000/11/10 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/10 11:00
PHST- 2000/11/10 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/10 11:00 [entrez]
AID - 10.1136/bmj.321.7270.1183 [doi]
PST - ppublish
SO  - BMJ. 2000 Nov 11;321(7270):1183-7. doi: 10.1136/bmj.321.7270.1183.

PMID- 2891837
OWN - NLM
STAT- MEDLINE
DCOM- 19880202
LR  - 20181130
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 243
IP  - 3
DP  - 1987 Dec
TI  - Prevention of aspirin-induced gastric mucosal injury by histamine H2 receptor 
      antagonists: a crossover endoscopic and intragastric pH study in the dog.
PG  - 1179-84
AB  - Histamine H2 receptor antagonists have been reported to protect the gastric 
      mucosa of animals and humans against aspirin-induced damage. It is unclear, 
      however, whether this protective effect can be observed at doses less than those 
      needed to markedly inhibit gastric acid secretion. We have developed a 
      single-dose endoscopic assay system of aspirin-induced gastric mucosal injury in 
      normal conscious dogs. In this model, severe gastric mucosal injury and a 
      decrease in the pH of the gastric luminal contents were consistently demonstrated 
      2 h after the oral administration of 100 mg/kg of aspirin. Pretreatment with 
      three histamine H2 receptor antagonists (cimetidine, ranitidine, BMY-25271), 
      prevented both of these effects in a dose-related manner. All three H2 receptor 
      antagonists reduced gastric mucosal injury only at doses that were greater than 
      those required to prevent the aspirin-induced decrease in gastric luminal pH or 
      to inhibit histamine-stimulated gastric acid secretion in Heidenhain pouch dogs. 
      Plasma levels of aspirin were not altered by histamine H2 receptor antagonism. 
      These results indicate that acid inhibition is an important component of the 
      mechanisms whereby histamine H2 receptor antagonists protect the gastric mucosa 
      from aspirin-induced damage in the dog.
FAU - Cavanagh, R L
AU  - Cavanagh RL
AD  - Department of Pharmacology, Bristol-Myers Company, Syracuse, New York.
FAU - Buyniski, J P
AU  - Buyniski JP
FAU - Schwartz, S E
AU  - Schwartz SE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*toxicity
MH  - Dogs
MH  - Female
MH  - Gastric Acid/metabolism
MH  - Gastric Acidity Determination
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastroscopy
MH  - Histamine H2 Antagonists/*pharmacology
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1987 Dec;243(3):1179-84.

PMID- 6188230
OWN - NLM
STAT- MEDLINE
DCOM- 19830505
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 28
IP  - 6
DP  - 1982 Dec 15
TI  - Experimental model of thrombus adherence to the vessel wall.
PG  - 749-56
AB  - Clot adherence to peritoneal cavity mesothelium was studied in rats in an attempt 
      to contribute to the problem of thrombus embolization. The adherence was 
      decreased by platelets and the active constituent was identified as adenosine 
      diphosphate which decreased the sticking of fibrin to cellular linings as well as 
      to artificial surfaces.
FAU - Hladovec, J
AU  - Hladovec J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9087-70-1 (Aprotinin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Animals
MH  - Aprotinin/pharmacology
MH  - Aspirin/pharmacology
MH  - Female
MH  - Hematocrit
MH  - Platelet Adhesiveness/drug effects
MH  - Rats
MH  - Thrombosis/*physiopathology
EDAT- 1982/12/15 00:00
MHDA- 1982/12/15 00:01
CRDT- 1982/12/15 00:00
PHST- 1982/12/15 00:00 [pubmed]
PHST- 1982/12/15 00:01 [medline]
PHST- 1982/12/15 00:00 [entrez]
AID - 0049-3848(82)90100-1 [pii]
AID - 10.1016/0049-3848(82)90100-1 [doi]
PST - ppublish
SO  - Thromb Res. 1982 Dec 15;28(6):749-56. doi: 10.1016/0049-3848(82)90100-1.

PMID- 31397009
OWN - NLM
STAT- MEDLINE
DCOM- 20200124
LR  - 20210110
IS  - 1939-1676 (Electronic)
IS  - 0891-6640 (Print)
IS  - 0891-6640 (Linking)
VI  - 33
IP  - 5
DP  - 2019 Sep
TI  - Clinical, clinicopathologic, and gastrointestinal changes from aspirin, 
      prednisone, or combination treatment in healthy research dogs: A double-blind 
      randomized trial.
PG  - 1977-1987
LID - 10.1111/jvim.15577 [doi]
AB  - BACKGROUND: Dogs with immune-mediated disease are often coadministered 
      glucocorticoids and aspirin, but ulcerogenic effects of current protocols are 
      unknown. OBJECTIVES: To compare gastrointestinal changes among dogs administered 
      aspirin, prednisone, and combination treatment. ANIMALS: Twenty-four healthy 
      research dogs. METHODS: Double-blinded, placebo-controlled randomized trial of 
      dogs administered placebo, aspirin (2 mg/kg q24h), prednisone (2 mg/kg q24h), or 
      combination treatment PO for 28 days. Clinical signs were recorded daily, with 
      laboratory work performed at baseline and day 28. Gastrointestinal mucosal 
      hemorrhages, erosions, and ulcers were numerated for endoscopic studies performed 
      on days 0, 14, and 28; endoscopic mucosal lesion scores were calculated. Results 
      were compared using mixed model repeated-measures analyses of variance and 
      generalized estimating equation proportional odds models. P < .05 was considered 
      significant. RESULTS: Gastric mucosal lesion scores differed by treatment-by-time 
      (F[6, 40] = 4.4, P = .002), treatment (F[3, 20] = 7.1, P = .002), and time (F[2, 
      40] = 18.9, P < .001). Post hoc analysis revealed increased scores in the aspirin 
      (day 14 only), prednisone, and prednisone/aspirin groups during treatment. Ulcers 
      were identified on 14 studies, representing 10 dogs. Dogs receiving prednisone 
      and prednisone/aspirin had 11.1 times (95% CI, 1.7-73.6) and 31.5 times (95% CI, 
      3.5-288.0) higher odds, respectively, of having endoscopic mucosal lesion scores 
      ≥4 than dogs receiving placebo (P ≤ .01). CONCLUSIONS AND CLINICAL IMPORTANCE: 
      Gastrointestinal bleeding occurs commonly in dogs administered aspirin, 
      prednisone, or prednisone/aspirin treatment, with higher lesion scores for dogs 
      receiving combination treatment. Even severe lesions are not accompanied by 
      clinical signs.
CI  - © 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley 
      Periodicals, Inc. on behalf of the American College of Veterinary Internal 
      Medicine.
FAU - Whittemore, Jacqueline C
AU  - Whittemore JC
AUID- ORCID: 0000-0003-2624-2262
AD  - The Department of Small Animal Clinical Sciences, University of Tennessee College 
      of Veterinary Medicine, Knoxville, Tennessee.
FAU - Mooney, Allison P
AU  - Mooney AP
AD  - The Department of Small Animal Clinical Sciences, University of Tennessee College 
      of Veterinary Medicine, Knoxville, Tennessee.
FAU - Price, Joshua M
AU  - Price JM
AD  - The Office of Information Technology, University of Tennessee College of 
      Veterinary Medicine, Knoxville, Tennessee.
FAU - Thomason, John
AU  - Thomason J
AUID- ORCID: 0000-0001-5678-8923
AD  - The Department of Clinical Sciences, College of Veterinary Medicine, Mississippi 
      State University, Starkville, Mississippi.
LA  - eng
GR  - University of Tennessee, Knoxville, Acree Research Chair of Medicine endowment./
PT  - Journal Article
PT  - Randomized Controlled Trial, Veterinary
DEP - 20190808
PL  - United States
TA  - J Vet Intern Med
JT  - Journal of veterinary internal medicine
JID - 8708660
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dogs
MH  - Double-Blind Method
MH  - Drug Therapy, Combination/*adverse effects
MH  - Female
MH  - Gastric Mucosa/drug effects/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced/*veterinary
MH  - Male
MH  - Prednisone/administration & dosage/*adverse effects
PMC - PMC6766539
OTO - NOTNLM
OT  - antiplatelet
OT  - corticosteroid
OT  - gastrointestinal bleeding
OT  - glucocorticoid
OT  - thromboprophylaxis
OT  - ulcer
COIS- The funder, University of Tennessee, Knoxville, through the Acree Research Chair 
      of Medicine endowment had no involvement in the design or performance of the 
      study, writing of the manuscript, or the decision to submit the manuscript for 
      publication.
EDAT- 2019/08/10 06:00
MHDA- 2020/01/25 06:00
CRDT- 2019/08/10 06:00
PHST- 2018/12/20 00:00 [received]
PHST- 2019/07/11 00:00 [accepted]
PHST- 2019/08/10 06:00 [pubmed]
PHST- 2020/01/25 06:00 [medline]
PHST- 2019/08/10 06:00 [entrez]
AID - JVIM15577 [pii]
AID - 10.1111/jvim.15577 [doi]
PST - ppublish
SO  - J Vet Intern Med. 2019 Sep;33(5):1977-1987. doi: 10.1111/jvim.15577. Epub 2019 
      Aug 8.

PMID- 27130815
OWN - NLM
STAT- MEDLINE
DCOM- 20170523
LR  - 20220330
IS  - 1528-0012 (Electronic)
IS  - 0016-5085 (Linking)
VI  - 151
IP  - 2
DP  - 2016 Aug
TI  - Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use 
      After Lower Gastrointestinal Hemorrhage.
PG  - 271-7
LID - S0016-5085(16)34298-6 [pii]
LID - 10.1053/j.gastro.2016.04.013 [doi]
AB  - BACKGROUND & AIMS: It is not clear whether use of low-dose aspirin should be 
      resumed after an episode of lower gastrointestinal (GI) bleeding. We assessed the 
      long-term risks of recurrent lower GI bleeding and serious cardiovascular 
      outcomes after aspirin-associated lower GI bleeding. METHODS: We performed a 
      retrospective study of patients diagnosed with lower GI bleeding (documented 
      melena or hematochezia and absence of upper GI bleeding) from January 1, 2000 
      through December 31, 2007 at the Prince of Wales Hospital in Hong Kong. Using the 
      hospital registry, we analyzed data from 295 patients on aspirin and determined 
      their outcomes during a 5-year period. Outcomes included recurrent lower GI 
      bleeding, serious cardiovascular events, and death from other causes, as 
      determined by an independent, blinded adjudication committee. Outcomes were 
      compared between patients assigned to the following groups based on cumulative 
      duration of aspirin use: <20% of the follow-up period (121 nonusers) vs ≥50% of 
      the observation period (174 aspirin users). RESULTS: Within 5 years, lower GI 
      bleeding recurred in 18.9% of aspirin users (95% confidence interval [CI], 
      13.3%-25.3%) vs 6.9% of nonusers (95% CI, 3.2%-12.5%; P = .007). However, serious 
      cardiovascular events occurred in 22.8% of aspirin users (95% CI, 16.6%-29.6%) vs 
      36.5% of nonusers (95% CI, 27.4%-45.6%; P = .017), and 8.2% of aspirin users died 
      from other causes (95% CI, 4.6%-13.2%) vs 26.7% of nonusers (95% CI, 18.7%-35.4%; 
      P = .001). Multivariable analysis showed that aspirin use was an independent 
      predictor of rebleeding, but protected against cardiovascular events and death. 
      CONCLUSIONS: Among aspirin users with a history of lower GI bleeding, 
      continuation of aspirin is associated with an increased risk of recurrent lower 
      GI bleeding, but reduced risk of serious cardiovascular events and death.
CI  - Copyright © 2016. Published by Elsevier Inc.
FAU - Chan, Francis K L
AU  - Chan FK
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong; State Key Laboratory of Digestive Disease, The Chinese University of 
      Hong Kong, Hong Kong. Electronic address: fklchan@cuhk.edu.hk.
FAU - Leung Ki, En-Ling
AU  - Leung Ki EL
AD  - La Tour Hospital, Geneva, Switzerland.
FAU - Wong, Grace L H
AU  - Wong GL
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong; State Key Laboratory of Digestive Disease, The Chinese University of 
      Hong Kong, Hong Kong.
FAU - Ching, Jessica Y L
AU  - Ching JY
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong.
FAU - Tse, Yee Kit
AU  - Tse YK
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong.
FAU - Au, Kim W L
AU  - Au KW
AD  - Department of Surgery, Institute of Digestive Disease, The Chinese University of 
      Hong Kong, Hong Kong.
FAU - Wu, Justin C Y
AU  - Wu JC
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong; State Key Laboratory of Digestive Disease, The Chinese University of 
      Hong Kong, Hong Kong.
FAU - Ng, Siew C
AU  - Ng SC
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong; State Key Laboratory of Digestive Disease, The Chinese University of 
      Hong Kong, Hong Kong.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160426
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 2016 Aug;151(2):222-5. PMID: 27374367
CIN - Gastroenterology. 2017 Feb;152(3):669-670. PMID: 28137515
CIN - Gastroenterology. 2017 Feb;152(3):670. PMID: 28137516
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*chemically induced
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Hong Kong
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Recurrence
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Complication
OT  - Intestine
EDAT- 2016/05/01 06:00
MHDA- 2017/05/24 06:00
CRDT- 2016/05/01 06:00
PHST- 2015/10/05 00:00 [received]
PHST- 2016/04/11 00:00 [revised]
PHST- 2016/04/17 00:00 [accepted]
PHST- 2016/05/01 06:00 [entrez]
PHST- 2016/05/01 06:00 [pubmed]
PHST- 2017/05/24 06:00 [medline]
AID - S0016-5085(16)34298-6 [pii]
AID - 10.1053/j.gastro.2016.04.013 [doi]
PST - ppublish
SO  - Gastroenterology. 2016 Aug;151(2):271-7. doi: 10.1053/j.gastro.2016.04.013. Epub 
      2016 Apr 26.

PMID- 34156663
OWN - NLM
STAT- MEDLINE
DCOM- 20220530
LR  - 20220831
IS  - 1863-4362 (Electronic)
IS  - 0021-1265 (Print)
IS  - 0021-1265 (Linking)
VI  - 191
IP  - 3
DP  - 2022 Jun
TI  - Appropriateness of aspirin prescribing for primary and secondary prevention of 
      cardiovascular disease in type 2 diabetes in different care settings.
PG  - 1185-1191
LID - 10.1007/s11845-021-02649-5 [doi]
AB  - BACKGROUND: Type 2 diabetes is associated with an increased cardiovascular risk. 
      Use of aspirin has been shown to be of benefit for secondary prevention of 
      cardiovascular disease in patients with type 2 diabetes; benefits in primary 
      prevention have not been clearly proven. AIMS: This study aims to (a) determine 
      if aspirin is prescribed appropriately in type 2 diabetes for primary or 
      secondary prevention of cardiovascular disease (CVD) and (b) evaluate whether 
      there are differences in aspirin prescribing according to where people receive 
      their care. DESIGN: Cross-sectional study METHODS: The medical records of 
      individuals with type 2 diabetes aged over 18 years and attending Elmwood Primary 
      Care Centre and Cork University Hospital Diabetes outpatient clinics (n = 400) 
      between February and August 2017 were reviewed. RESULTS: There were 90 
      individuals exclusively attending primary care and 310 persons attending shared 
      care. Overall, 49.0% (n = 196) of those were prescribed aspirin, of whom 42.3% 
      were using it for secondary prevention. Aspirin was used significantly more in 
      people attending shared care (p < 0.001). About 10.8% of individuals with 
      diabetes and CVD attending shared care met guidelines for, but were not 
      prescribed aspirin. CONCLUSION: A significant number of people with type 2 
      diabetes who should have been prescribed aspirin for secondary prevention were 
      not receiving it at the time of study assessment. In contrast, a substantial 
      proportion who did not meet criteria for aspirin use was prescribed it for 
      primary prevention.
CI  - © 2021. The Author(s).
FAU - Tan, Shi Ying
AU  - Tan SY
AD  - School of Medicine, University College Cork, College Road, Cork, Ireland.
FAU - Cronin, Heather
AU  - Cronin H
AD  - Department of Endocrinology and Diabetes, Cork University Hospital, Wilton, Cork, 
      Ireland.
FAU - Byrne, Stephen
AU  - Byrne S
AD  - School of Pharmacy, University College Cork, College Road, Cork, Ireland.
FAU - O'Donovan, Adrian
AU  - O'Donovan A
AD  - Elmwood Primary Care Centre, Frankfield, Douglas, Cork, Ireland.
FAU - Tuthill, Antoinette
AU  - Tuthill A
AUID- ORCID: 0000-0002-1460-517X
AD  - Department of Endocrinology and Diabetes, Cork University Hospital, Wilton, Cork, 
      Ireland. Antoinette.tuthill@hse.ie.
LA  - eng
PT  - Journal Article
DEP - 20210622
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ir J Med Sci. 2022 Aug;191(4):1667-1668. PMID: 34553329
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Humans
MH  - Middle Aged
MH  - Secondary Prevention
PMC - PMC9135889
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Diabetes mellitus
OT  - Primary prevention
COIS- The authors declare no competing interests.
EDAT- 2021/06/23 06:00
MHDA- 2022/05/31 06:00
CRDT- 2021/06/22 12:24
PHST- 2020/11/14 00:00 [received]
PHST- 2021/05/10 00:00 [accepted]
PHST- 2021/06/23 06:00 [pubmed]
PHST- 2022/05/31 06:00 [medline]
PHST- 2021/06/22 12:24 [entrez]
AID - 10.1007/s11845-021-02649-5 [pii]
AID - 2649 [pii]
AID - 10.1007/s11845-021-02649-5 [doi]
PST - ppublish
SO  - Ir J Med Sci. 2022 Jun;191(3):1185-1191. doi: 10.1007/s11845-021-02649-5. Epub 
      2021 Jun 22.

PMID- 35963596
OWN - NLM
STAT- MEDLINE
DCOM- 20220913
LR  - 20221011
IS  - 1532-2971 (Electronic)
IS  - 1090-0233 (Linking)
VI  - 287
DP  - 2022 Sep
TI  - Effectiveness of aspirin vs. clopidogrel in dogs with immune mediated haemolytic 
      anaemia evaluated by serial thromboelastography and platelet mapping.
PG  - 105882
LID - S1090-0233(22)00097-1 [pii]
LID - 10.1016/j.tvjl.2022.105882 [doi]
AB  - Most dogs with immune mediated haemolytic anaemia (IMHA) are hypercoagulable, as 
      measured by thromboelastography (TEG). Thromboelastography-platelet mapping 
      (TEG-PM) has been used to assess platelet function in human patients treated with 
      aspirin or clopidogrel. The aim of this study was to compare platelet thromboxane 
      A(2)-receptor inhibition (TXA(2-)RI) and platelet adenosine diphosphate 
      (ADP)-receptor inhibition (ADP-RI) as measured by TEG-PM in dogs with primary 
      IMHA receiving aspirin or clopidogrel to determine if TEG-PM might be useful to 
      monitor treatment. Eighteen client-owned dogs with IMHA were enroled in a 
      prospective double blinded study. Dogs were randomised to receive aspirin or 
      clopidogrel in addition to standard therapy. Thromboelastography was measured 
      before, and 1 and 4 days after commencing treatment. Thromboelastography-PM was 
      performed on days 1 and 4. Non-responders were defined as < 50 % platelet 
      thromboxane A(2)-receptor inhibition (TXA(2-)RI) in the aspirin group and < 50 % 
      platelet adenosine diphosphate (ADP)-receptor inhibition (ADP-RI) in the 
      clopidogrel group, on day 4. Mean platelet TXA(2)-RI and platelet ADP-RI were not 
      significantly different between groups at any timepoint (P > 0.05). The overall 
      mean percentage inhibition of TXA(2)-receptor was 25 % (aspirin 33 %, clopidogrel 
      15 %), and of ADP-receptor was 82 % (aspirin 83 %, clopidogrel 80 %). On day 4, 
      6/9 dogs (66 %) in the aspirin group and 2/8 dogs (25 %) in the clopidogrel group 
      were non-responders (P = 0.086). Two dogs defined as responders based on TEG-PM 
      developed thromboembolism. Overall, there was no significant difference in 
      efficacy between aspirin and clopidogrel based on measurement of receptor 
      inhibition using TEG-PM (P > 0.05), and routine TEG was not reliable for 
      monitoring treatment response in dogs with IMHA. In some dogs, there was a 
      discrepancy between TEG-PM results and clinical response. Further investigation 
      of TEG-PM use in dogs, including its usefulness to monitor treatment response and 
      adjust treatment in individual dogs and any effect of anaemia, is warranted.
CI  - Copyright © 2022 Elsevier Ltd. All rights reserved.
FAU - Griebsch, C
AU  - Griebsch C
AD  - Sydney School of Veterinary Science, Faculty of Science, University of Sydney, 
      Sydney, Australia. Electronic address: christine.griebsch@sydney.edu.au.
FAU - Hall, E
AU  - Hall E
AD  - Sydney School of Veterinary Science, Faculty of Science, University of Sydney, 
      Sydney, Australia.
FAU - Barrs, V R
AU  - Barrs VR
AD  - Sydney School of Veterinary Science, Faculty of Science, University of Sydney, 
      Sydney, Australia; Department of Veterinary Clinical Sciences, Jockey Club 
      College of Veterinary Medicine and Life Sciences, City University of Hong Kong, 
      Hong Kong, China.
LA  - eng
PT  - Journal Article
DEP - 20220811
PL  - England
TA  - Vet J
JT  - Veterinary journal (London, England : 1997)
JID - 9706281
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - *Anemia, Hemolytic, Autoimmune/veterinary
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets
MH  - Clopidogrel/pharmacology/therapeutic use
MH  - *Dog Diseases/chemically induced/drug therapy
MH  - Dogs
MH  - Humans
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Platelet Function Tests/methods/veterinary
MH  - Prospective Studies
MH  - Thrombelastography/veterinary
MH  - Thromboxanes/pharmacology
OTO - NOTNLM
OT  - Aspirin
OT  - Canine
OT  - Clopidogrel
OT  - IMHA
OT  - Thromboelastography-platelet mapping
COIS- Conflict of interest statement This study was funded by the Canine Research 
      Foundation (CRF). The CRF played no role in the study design nor in the 
      collection, analysis and interpretation of date, nor in the decision to submit 
      the manuscript for publication. None of the authors have any other financial or 
      personal relationships that could inappropriately influence or bias the content 
      of the paper.
EDAT- 2022/08/14 06:00
MHDA- 2022/09/14 06:00
CRDT- 2022/08/13 19:37
PHST- 2021/12/15 00:00 [received]
PHST- 2022/08/09 00:00 [revised]
PHST- 2022/08/09 00:00 [accepted]
PHST- 2022/08/14 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
PHST- 2022/08/13 19:37 [entrez]
AID - S1090-0233(22)00097-1 [pii]
AID - 10.1016/j.tvjl.2022.105882 [doi]
PST - ppublish
SO  - Vet J. 2022 Sep;287:105882. doi: 10.1016/j.tvjl.2022.105882. Epub 2022 Aug 11.

PMID- 35785535
OWN - NLM
STAT- MEDLINE
DCOM- 20220720
LR  - 20220923
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 175
IP  - 7
DP  - 2022 Jul
TI  - Aspirin use is associated with reduced risk for hepatocellular carcinoma.
PG  - JC83
LID - 10.7326/J22-0049 [doi]
AB  - Wang Y, Wang M, Liu C, et al. Aspirin use and the risk of hepatocellular 
      carcinoma: a meta-analysis. J Clin Gastroenterol. 2022. [Epub ahead of print.] 
      35316225.
FAU - Koretz, Ronald L
AU  - Koretz RL
AD  - Olive View-UCLA Medical Center, Sylmar, California, USA (R.L.K.).
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220705
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - J Clin Gastroenterol. 2022 Aug 1;56(7):e293-e302. PMID: 35316225
MH  - Aspirin/adverse effects
MH  - *Carcinoma, Hepatocellular/prevention & control
MH  - Humans
MH  - *Liver Neoplasms/prevention & control
EDAT- 2022/07/06 06:00
MHDA- 2022/07/22 06:00
CRDT- 2022/07/05 10:53
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/07/22 06:00 [medline]
PHST- 2022/07/05 10:53 [entrez]
AID - 10.7326/J22-0049 [doi]
PST - ppublish
SO  - Ann Intern Med. 2022 Jul;175(7):JC83. doi: 10.7326/J22-0049. Epub 2022 Jul 5.

PMID- 33410616
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 134
IP  - 2
DP  - 2021 Jan 5
TI  - Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous 
      thromboembolism prophylaxis following primary total hip arthroplasty: a 
      randomized controlled trial.
PG  - 164-172
LID - 10.1097/CM9.0000000000001305 [doi]
AB  - BACKGROUND: Aspirin has demonstrated safety and efficacy for venous 
      thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA); 
      however, inconsistent dose regimens have been reported in the literature. This 
      study aimed to evaluate and compare the safety and efficacy of 100 mg aspirin 
      twice daily with rivaroxaban in VTE prophylaxis following THA. METHODS: Patients 
      undergoing elective unilateral primary THA between January 2019 and January 2020 
      were prospectively enrolled in the study and randomly allocated to receive 5 
      weeks of VTE prophylaxis with either oral enteric-coated aspirin (100 mg twice 
      daily) or rivaroxaban (10 mg once daily). Medication safety and efficacy were 
      comprehensively evaluated through symptomatic VTE incidence, deep vein thrombosis 
      (DVT) on Doppler ultrasonography, total blood loss (TBL), laboratory bloodwork, 
      Harris hip score (HHS), post-operative recovery, and the incidence of other 
      complications. RESULTS: We included 70 patients in this study; 34 and 36 were 
      allocated to receive aspirin and rivaroxaban prophylaxis, respectively. No cases 
      of symptomatic VTE occurred in this study. The DVT rate on Doppler 
      ultrasonography in the aspirin group was not significantly different from that in 
      the rivaroxaban group (8.8% vs. 8.3%, χ2 = 0.01, P = 0.91), confirming the 
      non-inferiority of aspirin for DVT prophylaxis (χ2 = 2.29, P = 0.01). The 
      calculated TBL in the aspirin group (944.9 mL [658.5-1137.8 mL]) was similar to 
      that in the rivaroxaban group (978.3 mL [747.4-1740.6mL]) (χ2 = 1.55, P = 0.12). 
      However, there were no significant inter-group differences in HHS at 
      post-operative day (POD) 30 (Aspirin: 81.0 [78.8-83.0], Rivaroxaban: 81.0 
      [79.3-83.0], χ2 = 0.43, P = 0.67) and POD 90 (Aspirin: 90.0 [89.0-92.0], 
      Rivaroxaban: 91.5 [88.3-92.8], χ2 = 0.77, P = 0.44), the incidence of bleeding 
      events (2.9% vs. 8.3%, χ2 = 0.96, P = 0.33), or gastrointestinal complications 
      (2.9% vs. 5.6%, χ2 = 1.13, P = 0.29). CONCLUSION: In terms of safety and 
      efficacy, the prophylactic use of 100 mg aspirin twice daily was not 
      statistically different from that of rivaroxaban in preventing VTE and reducing 
      the risk of blood loss following elective primary THA. This supports the use of 
      aspirin chemoprophylaxis following THA as a less expensive and more widely 
      available option for future THAs. TRIAL REGISTRATION: Chictr.org, 
      ChiCTR18000202894; http://www.chictr.org.cn/showproj.aspx?proj=33284.
CI  - Copyright © 2020 The Chinese Medical Association, produced by Wolters Kluwer, 
      Inc. under the CC-BY-NC-ND license.
FAU - Ren, Yi
AU  - Ren Y
AD  - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking 
      Union Medical College, Beijing 100730, China.
FAU - Cao, Shi-Liang
AU  - Cao SL
AD  - Department of Orthopaedic Surgery, Peking University Third Hospital, Peking 
      University, Beijing 100191, China.
FAU - Li, Zeng
AU  - Li Z
AD  - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking 
      Union Medical College, Beijing 100730, China.
FAU - Luo, Tim
AU  - Luo T
AD  - Doctor of Medicine Program, University of Alberta, Edmonton, AB T6G 2R3, Canada.
FAU - Feng, Bin
AU  - Feng B
AD  - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking 
      Union Medical College, Beijing 100730, China.
FAU - Weng, Xi-Sheng
AU  - Weng XS
AD  - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking 
      Union Medical College, Beijing 100730, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210105
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Anticoagulants)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants
MH  - *Arthroplasty, Replacement, Hip/adverse effects
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Rivaroxaban/therapeutic use
MH  - *Venous Thromboembolism/prevention & control
PMC - PMC7817327
COIS- None.
EDAT- 2021/01/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/01/07 09:55
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2021/01/07 09:55 [entrez]
AID - 00029330-202101200-00005 [pii]
AID - CMJ-2020-2119 [pii]
AID - 10.1097/CM9.0000000000001305 [doi]
PST - epublish
SO  - Chin Med J (Engl). 2021 Jan 5;134(2):164-172. doi: 10.1097/CM9.0000000000001305.

PMID- 37062920
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20230515
IS  - 2162-3279 (Electronic)
VI  - 13
IP  - 5
DP  - 2023 May
TI  - Analysis of antiplatelet therapy adherence in patients with ischemic cerebral 
      stroke.
PG  - e2982
LID - 10.1002/brb3.2982 [doi]
LID - e2982
AB  - BACKGROUND: The related factors affecting the adherence of ischemic cerebral 
      stroke (ICS) patients to antiplatelet therapy have attracted much attention. 
      METHODS: Patients with ICS (confirmed by CT or MRI) were enrolled from January 
      2020 to July 2021. The demographic data were retrospectively investigated and 
      analyzed. The adherence calculation was as follows: Adherence = number of tablets 
      taken/number of tablets needed to be taken. Adherence < 100% was defined as 
      nonadherence. Severe nonadherence is defined as adherence ≤ 75%. RESULTS: A total 
      of 229 patients with ICS were enrolled. We found no significant difference in the 
      proportion of patients with nonadherence, while the proportion of severe 
      nonadherence in the aspirin group was significantly higher (p < .001). 
      Multivariable analysis indicated that medical insurance (odds ratio [OR] = 0.071, 
      p < .001) and regular exercise (OR = 0.438, p = .015) were independent factors 
      associated with adherence. In addition, only medical insurance (OR = 5.475, 
      p < .001) and aspirin treatment (OR = 0.228, p < .001) were independent risk 
      factors associated with severe nonadherence. We therefore constructed a nomogram 
      plot and a model as follows: Adherence risk score = 3 × medical insurance + 
      regular exercise. Patients were divided into low-risk and high-risk groups for 
      adherence based on the median model score. A total of 13.3% of patients in the 
      low-risk group were nonadherent patients compared with 53.4% in the high-risk 
      group (p < .001). Similarly, 8.4% of patients in the low-risk group had severe 
      nonadherence compared with 19.9% in the high-risk group (p = .022). Moreover, in 
      low-risk patients, no significant difference was observed. In patients with high 
      risk, aspirin-treated patients showed significantly decreased adherence compared 
      with the other two groups. CONCLUSION: Medical insurance and regular exercise 
      were independent factors for antiplatelet therapy adherence. For patients with 
      high model scores, timely intervention is necessary.
CI  - © 2023 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
FAU - Zhong, Jie
AU  - Zhong J
AUID- ORCID: 0000-0003-1220-5743
AD  - Department of Neurology, The First Affiliated Hospital, Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Gao, Yuguang
AU  - Gao Y
AD  - Department of Emergency, The First Affiliated Hospital, Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Huang, Deqing
AU  - Huang D
AD  - Department of Emergency, The First Affiliated Hospital, Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Hu, Yueqiang
AU  - Hu Y
AD  - Department of Neurology, The First Affiliated Hospital, Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - He, Qianchao
AU  - He Q
AD  - Department of Neurology, The First Affiliated Hospital, Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Diao, Limei
AU  - Diao L
AD  - Department of Neurology, The First Affiliated Hospital, Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Hu, Yuying
AU  - Hu Y
AD  - Department of Neurology, The First Affiliated Hospital, Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Chen, Wei
AU  - Chen W
AD  - Department of Neurology, The First Affiliated Hospital, Guangxi University of 
      Chinese Medicine, Nanning, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20230416
PL  - United States
TA  - Brain Behav
JT  - Brain and behavior
JID - 101570837
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - Aspirin/therapeutic use
MH  - *Stroke/drug therapy
MH  - *Ischemic Stroke
MH  - *Nervous System Diseases
MH  - Medication Adherence
PMC - PMC10175999
OTO - NOTNLM
OT  - adherence
OT  - aspirin
OT  - ischemic cerebral stroke
OT  - medical insurance
OT  - risk model
COIS- The authors declare no conflicts of interest.
EDAT- 2023/04/18 06:00
MHDA- 2023/05/15 11:42
CRDT- 2023/04/17 01:42
PHST- 2023/03/07 00:00 [revised]
PHST- 2022/12/07 00:00 [received]
PHST- 2023/03/14 00:00 [accepted]
PHST- 2023/05/15 11:42 [medline]
PHST- 2023/04/18 06:00 [pubmed]
PHST- 2023/04/17 01:42 [entrez]
AID - BRB32982 [pii]
AID - 10.1002/brb3.2982 [doi]
PST - ppublish
SO  - Brain Behav. 2023 May;13(5):e2982. doi: 10.1002/brb3.2982. Epub 2023 Apr 16.

PMID- 18954683
OWN - NLM
STAT- MEDLINE
DCOM- 20090122
LR  - 20131121
IS  - 0195-5616 (Print)
IS  - 0195-5616 (Linking)
VI  - 38
IP  - 6
DP  - 2008 Nov
TI  - An update on nonsteroidal anti-inflammatory drugs (NSAIDs) in small animals.
PG  - 1243-66, vi
LID - 10.1016/j.cvsm.2008.09.002 [doi]
AB  - There are several choices of nonsteroidal anti-inflammatory drugs (NSAIDs) for 
      treating dogs that have osteoarthritis. However, fewer drugs are available for 
      cats. Like people, there may be greater differences among individuals in their 
      response than there are differences among the drugs. In past practice, 
      veterinarians often selected aspirin or phenylbutazone as an initial drug, and 
      then progressed to off-label human drugs or other agents as an alternative. Now 
      we have the advantage of several approved NSAIDs for which there are excellent 
      published studies and US Food and Drug Administration or foreign approval to 
      guide clinical use and safe dosages.
FAU - Papich, Mark G
AU  - Papich MG
AD  - Department of Molecular Biomedical Sciences, North Carolina State University 
      College of Veterinary Medicine, 4700 Hillsborough Street, Raleigh, NC 27606, USA. 
      mark_papich@ncsu.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Vet Clin North Am Small Anim Pract
JT  - The Veterinary clinics of North America. Small animal practice
JID - 7809942
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cat Diseases/*drug therapy
MH  - Cats
MH  - Dog Diseases/*drug therapy
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Osteoarthritis/drug therapy/*veterinary
MH  - Phenylbutazone/adverse effects/therapeutic use
MH  - Species Specificity
RF  - 112
EDAT- 2008/10/29 09:00
MHDA- 2009/01/23 09:00
CRDT- 2008/10/29 09:00
PHST- 2008/10/29 09:00 [pubmed]
PHST- 2009/01/23 09:00 [medline]
PHST- 2008/10/29 09:00 [entrez]
AID - S0195-5616(08)00156-3 [pii]
AID - 10.1016/j.cvsm.2008.09.002 [doi]
PST - ppublish
SO  - Vet Clin North Am Small Anim Pract. 2008 Nov;38(6):1243-66, vi. doi: 
      10.1016/j.cvsm.2008.09.002.

PMID- 9221683
OWN - NLM
STAT- MEDLINE
DCOM- 19970711
LR  - 20131121
IS  - 0201-7563 (Print)
IS  - 0201-7563 (Linking)
IP  - 2
DP  - 1997 Mar-Apr
TI  - [Hyperbaric oxygenation and antiaggregants: effects on platelet function in 
      patients with ischemic heart disease].
PG  - 31-3
AB  - Platelet function (duration and percentage of aggregation and disaggregation) was 
      studied in 65 chronic coronary patients over the course of hyperbaric oxygenation 
      and antiaggregant therapy. A course of hyperbaric oxygenation (8 to 12 sessions 
      at absolute atmosphere of 1.3-1.6 for 40 min) had no proaggregant or 
      antiaggregant effects on the platelets in this category of patients. Aspirin in a 
      daily dose of 125 mg and pentoxifylline in a daily dose of 300 mg reliably 
      decreased the percentage of platelet aggregation and increased the share of 
      disaggregation. Hyperbaric oxygenation in the above mode did not change the 
      antiaggregant activity of these drugs.
FAU - Seriakov, V V
AU  - Seriakov VV
FAU - Feofanova, I D
AU  - Feofanova ID
LA  - rus
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Giperbaricheskaia oksigenatsiia i antiagregantnye preparaty: vliianie na 
      funktsional'noe sostoianie trombotsitov u bol'nykh ishemicheskoĭ bolezniu 
      serdtsa.
PL  - Russia (Federation)
TA  - Anesteziol Reanimatol
JT  - Anesteziologiia i reanimatologiia
JID - 7705399
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/*physiology
MH  - Coronary Disease/blood/drug therapy/*therapy
MH  - Female
MH  - Humans
MH  - *Hyperbaric Oxygenation
MH  - Male
MH  - Middle Aged
MH  - Pentoxifylline/pharmacology/therapeutic use
MH  - Phosphodiesterase Inhibitors/pharmacology/therapeutic use
MH  - *Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Time Factors
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
PST - ppublish
SO  - Anesteziol Reanimatol. 1997 Mar-Apr;(2):31-3.

PMID- 35985427
OWN - NLM
STAT- MEDLINE
DCOM- 20221005
LR  - 20221011
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 191
DP  - 2022 Sep
TI  - Questions and answers on the use of aspirin for primary prevention of 
      cardiovascular disease in diabetes.
PG  - 110043
LID - S0168-8227(22)00857-9 [pii]
LID - 10.1016/j.diabres.2022.110043 [doi]
AB  - Patients with diabetes have a prothrombotic state and a 2 to 4 times higher risk 
      of cardiovascular events than those without diabetes. Aspirin is the cornerstone 
      of treatment in patients withcardiovascular disease, irrespective of diabetes 
      status, being able to confer a 19% relative risk reduction per year in serious 
      vascular events compared with placebo at long-term follow-up (6.7% vs 8.2% per 
      year, p < 0.0001). Data regarding the benefit-risk ratio of aspirin prescribed to 
      patients with diabetes without established cardiovascular disease are less 
      convincing, especially when compared to other preventive strategies. Of note, in 
      primary prevention trials, aspirin allocation yielded a significant 12% 
      proportional reduction in serious vascular events, irrespective of diabetes 
      status, corresponding to a small annual absolute risk reduction (0.06% per year). 
      However, in everyday clinical practice aspirin is still largely prescribed by 
      both diabetologists and cardiologists. In this article, we provide eight 
      questions and answers corroborated by available evidence on the use of aspirin 
      for primary prevention of cardiovascular disease in diabetes.
CI  - Copyright © 2022 Elsevier B.V. All rights reserved.
FAU - Cavallari, Ilaria
AU  - Cavallari I
AD  - Department of Medicine, Unit of Cardiovascular Science, Campus Bio-Medico 
      University of Rome, Italy. Electronic address: i.cavallari@policlinicocampus.it.
FAU - Nobile, Edoardo
AU  - Nobile E
AD  - Department of Medicine, Unit of Cardiovascular Science, Campus Bio-Medico 
      University of Rome, Italy.
FAU - De Filippis, Aurelio
AU  - De Filippis A
AD  - Department of Medicine, Unit of Cardiovascular Science, Campus Bio-Medico 
      University of Rome, Italy.
FAU - Veneziano, Francesco
AU  - Veneziano F
AD  - Department of Medicine, Unit of Cardiovascular Science, Campus Bio-Medico 
      University of Rome, Italy.
FAU - Maddaloni, Ernesto
AU  - Maddaloni E
AD  - Department of Experimental Medicine, Sapienza University of Rome, Italy.
FAU - Ussia, Gian Paolo
AU  - Ussia GP
AD  - Department of Medicine, Unit of Cardiovascular Science, Campus Bio-Medico 
      University of Rome, Italy.
FAU - Grigioni, Francesco
AU  - Grigioni F
AD  - Department of Medicine, Unit of Cardiovascular Science, Campus Bio-Medico 
      University of Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220817
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - *Cardiovascular Diseases/prevention & control
MH  - *Diabetes Mellitus/drug therapy
MH  - Humans
MH  - Primary Prevention/methods
MH  - Risk Assessment
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Diabetes
OT  - Primary prevention
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/08/20 06:00
MHDA- 2022/10/06 06:00
CRDT- 2022/08/19 19:24
PHST- 2022/01/30 00:00 [received]
PHST- 2022/05/07 00:00 [revised]
PHST- 2022/08/11 00:00 [accepted]
PHST- 2022/08/20 06:00 [pubmed]
PHST- 2022/10/06 06:00 [medline]
PHST- 2022/08/19 19:24 [entrez]
AID - S0168-8227(22)00857-9 [pii]
AID - 10.1016/j.diabres.2022.110043 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2022 Sep;191:110043. doi: 10.1016/j.diabres.2022.110043. 
      Epub 2022 Aug 17.

PMID- 37684606
OWN - NLM
STAT- MEDLINE
DCOM- 20230911
LR  - 20230911
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Sep 8
TI  - Leveraging quality improvement to promote health equity: standardization of 
      prenatal aspirin recommendations.
PG  - 651
LID - 10.1186/s12884-023-05922-w [doi]
LID - 651
AB  - OBJECTIVE: Aspirin (ASA) is recommended for patients at elevated risk of 
      preeclampsia. Limited data exists on adherence to guidelines for ASA 
      prescription. This project evaluates the implementation of a standardized 
      approach to ASA prescription in an academic OB/Gyn practice. METHODS: We 
      implemented a quality improvement project to evaluate compliance with the United 
      States Preventative Services Task Force (USPSTF) recommendations for ASA to 
      prevent preeclampsia. Pre-intervention, we analyzed prescription adherence at 201 
      New Obstetric (NOB) visits. A multi-step intervention was then implemented at 199 
      NOB visits. Nurses utilized a checklist created from USPSTF guidelines to 
      identify high-risk patients, defined as having ≥1 high-risk factor or ≥2 
      moderate-risk factors. ASA orders were placed by physicians. A Plan-Do-Study-Act 
      (PDSA) cycle was performed, and changes implemented. Primary outcome was percent 
      of patients screened at RN intake visit (goal = 90%). Secondary outcomes were 
      percent of patients who screened positive that received the ASA recommendation 
      (goal = 80%) and percent screened and recommended by race. RESULTS: 
      Pre-intervention, 47% of patients met criteria for ASA and 28% received a 
      documented recommendation. Post-intervention, 99% were screened. Half (48%) met 
      criteria for an ASA recommendation and 79% received a recommendation 
      (p = < 0.001). Rates of appropriate recommendation did not differ by Black (80%) 
      vs. non-Black (79%) status (p = 0.25). Subsequent PDSA cycles for 12 months 
      neared 100% RN screening rates. Physicians correctly recommended ASA 80-100% of 
      the time. CONCLUSION: It is feasible, sustainable and equitable to standardize 
      screening and implementation of ASA to patients at high risk for preeclampsia. 
      Providers can easily reproduce our processes to improve delivery of equitable and 
      reliable preventative obstetric care.
CI  - © 2023. BioMed Central Ltd., part of Springer Nature.
FAU - Gross, Maya E
AU  - Gross ME
AD  - Department of Obstetrics and Gynecology, University of Wisconsin School of 
      Medicine and Public Health, Madison, WI, USA. maya.e.groos@gmail.com.
FAU - Godecker, Amy
AU  - Godecker A
AD  - Department of Obstetrics and Gynecology, University of Wisconsin School of 
      Medicine and Public Health, Madison, WI, USA.
FAU - Hughes, Ainsley
AU  - Hughes A
AD  - Department of Obstetrics and Gynecology, George Washington School of Medicine, 
      Washington, DC, USA.
FAU - Sampene, Katherine
AU  - Sampene K
AD  - Department of Obstetrics and Gynecology, University of Wisconsin School of 
      Medicine and Public Health, Madison, WI, USA.
LA  - eng
PT  - Journal Article
DEP - 20230908
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Vitamins)
SB  - IM
MH  - Female
MH  - Pregnancy
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - *Pre-Eclampsia/diagnosis/prevention & control
MH  - Health Promotion
MH  - Quality Improvement
MH  - Vitamins
MH  - Reference Standards
PMC - PMC10492279
OTO - NOTNLM
OT  - Aspirin
OT  - Implementation
OT  - Preeclampsia
OT  - Pregnancy
OT  - Quality improvement
COIS- The authors report no competing interest.
EDAT- 2023/09/09 10:41
MHDA- 2023/09/11 06:42
CRDT- 2023/09/08 23:40
PHST- 2023/03/26 00:00 [received]
PHST- 2023/08/14 00:00 [accepted]
PHST- 2023/09/11 06:42 [medline]
PHST- 2023/09/09 10:41 [pubmed]
PHST- 2023/09/08 23:40 [entrez]
AID - 10.1186/s12884-023-05922-w [pii]
AID - 5922 [pii]
AID - 10.1186/s12884-023-05922-w [doi]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2023 Sep 8;23(1):651. doi: 10.1186/s12884-023-05922-w.

PMID- 27079640
OWN - NLM
STAT- MEDLINE
DCOM- 20170308
LR  - 20170308
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 781
DP  - 2016 Jun 15
TI  - Reduced mucosal side-effects of acetylsalicylic acid after conjugation with 
      tris-hydroxymethyl-aminomethane. Synthesis and biological evaluation of a new 
      anti-inflammatory compound.
PG  - 181-9
LID - S0014-2999(16)30233-3 [pii]
LID - 10.1016/j.ejphar.2016.04.019 [doi]
AB  - Acetylsalicylic acid (ASA) causes adverse haemorrhagic reactions in the upper 
      gastrointestinal (GI) tract, and previous results have suggested that combination 
      therapy with 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris) could provide 
      protection in this scenario. Based on this hypothesis, our aim was to develop a 
      new compound from ASA and Tris precursors and to characterize the biological 
      effects of ASA-Tris and the derivatives ASA-bis- and 
      mono-hydroxymethyl-aminomethane (ASA-Bis, ASA-Mono, respectively) using in vivo 
      and in vitro test systems. ASA or ASA conjugates (0.55mmol/kg, each) were 
      administered intragastrically to Sprague-Dawley rats. Changes in the mucosal 
      structure and in the serosal microcirculation were detected by in vivo imaging 
      techniques, the plasma TNF-alpha, tissue xanthine oxidoreductase and 
      myeloperoxidase activities, and liver cytochrome c changes were also determined. 
      In two separate series, platelet aggregation and carrageenan arthritis-induced 
      inflammatory pain were measured in control, ASA and ASA-Tris-treated groups. 
      Severe mucosal injury and a significant decrease in serosal red blood cell 
      velocity developed in the ASA-treated group and an ~2-fold elevation in 
      proinflammatory mediator levels evolved. ASA-Tris did not cause bleeding, 
      microcirculatory dysfunction, mucosal injury or an elevation in proinflammatory 
      markers. The ASA-Mono and ASA-Bis conjugates did not cause macroscopic bleeding, 
      but the inflammatory activation was apparent. ASA-Tris did not influence the 
      cyclooxygenase-induced platelet aggregation significantly, but the inflammatory 
      pain was reduced as effectively as in the case of equimolar ASA doses. ASA-Tris 
      conjugation is an effective approach through which the GI side-effects of ASA are 
      controlled by decreasing the cytokine-mediated progression of pro-inflammatory 
      events.
CI  - Copyright © 2016 Elsevier B.V. All rights reserved.
FAU - Varga, Gabriella
AU  - Varga G
AD  - Institute of Surgical Research, Faculty of Medicine, University of Szeged, 
      H-6720, Szeged, Szőkefalvi-Nagy Béla u. 6, Hungary. Electronic address: 
      varga.gabriella.1@med.u-szeged.hu.
FAU - Lajkó, Norbert
AU  - Lajkó N
AD  - Institute of Surgical Research, Faculty of Medicine, University of Szeged, 
      H-6720, Szeged, Szőkefalvi-Nagy Béla u. 6, Hungary. Electronic address: 
      lajkonorbert91@gmail.com.
FAU - Ugocsai, Melinda
AU  - Ugocsai M
AD  - Institute of Surgical Research, Faculty of Medicine, University of Szeged, 
      H-6720, Szeged, Szőkefalvi-Nagy Béla u. 6, Hungary. Electronic address: 
      lindaugocsai@gmail.com.
FAU - Érces, Dániel
AU  - Érces D
AD  - Institute of Surgical Research, Faculty of Medicine, University of Szeged, 
      H-6720, Szeged, Szőkefalvi-Nagy Béla u. 6, Hungary. Electronic address: 
      erces.daniel@med.u-szeged.hu.
FAU - Horváth, Gyöngyi
AU  - Horváth G
AD  - Department of Physiology, Faculty of Medicine, University of Szeged, H-6720, 
      Szeged, Dóm tér 10, Hungary. Electronic address: horvath.gyongyi@med.u-szeged.hu.
FAU - Tóth, Gábor
AU  - Tóth G
AD  - Department of Medical Chemistry, Faculty of Medicine, University of Szeged, 
      H-6720, Szeged, Dóm tér 8, Hungary. Electronic address: 
      toth.gabor@med.u-szeged.hu.
FAU - Boros, Mihály
AU  - Boros M
AD  - Institute of Surgical Research, Faculty of Medicine, University of Szeged, 
      H-6720, Szeged, Szőkefalvi-Nagy Béla u. 6, Hungary. Electronic address: 
      boros.mihaly@med.u-szeged.hu.
FAU - Ghyczy, Miklós
AU  - Ghyczy M
AD  - Pax Forschung GmbH, Im Rapsfeld 23, 50933 Cologne, Germany. Electronic address: 
      ghyczy@t-online.de.
LA  - eng
PT  - Journal Article
DEP - 20160412
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Methylamines)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - BSF23SJ79E (methylamine)
RN  - EC 1.9.3.1 (Electron Transport Complex IV)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/chemical synthesis/*chemistry
MH  - Chemistry Techniques, Synthetic
MH  - Electron Transport Complex IV/metabolism
MH  - Gastric Mucosa/*drug effects/metabolism/pathology/physiopathology
MH  - Gastritis/chemically induced/metabolism/pathology/physiopathology
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Methylamines/*chemistry
MH  - Microcirculation/drug effects
MH  - Nociception/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Structure-Activity Relationship
OTO - NOTNLM
OT  - Aspirin
OT  - Cytokines
OT  - Gastritis
OT  - Inflammation
OT  - Microcirculation
OT  - Rat
EDAT- 2016/04/16 06:00
MHDA- 2017/03/09 06:00
CRDT- 2016/04/16 06:00
PHST- 2016/02/26 00:00 [received]
PHST- 2016/04/04 00:00 [revised]
PHST- 2016/04/11 00:00 [accepted]
PHST- 2016/04/16 06:00 [entrez]
PHST- 2016/04/16 06:00 [pubmed]
PHST- 2017/03/09 06:00 [medline]
AID - S0014-2999(16)30233-3 [pii]
AID - 10.1016/j.ejphar.2016.04.019 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2016 Jun 15;781:181-9. doi: 10.1016/j.ejphar.2016.04.019. Epub 
      2016 Apr 12.

PMID- 30972875
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20200817
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 26
IP  - 9
DP  - 2019 Sep
TI  - Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by 
      activated partial thromboplastin time.
PG  - 1168-e78
LID - 10.1111/ene.13961 [doi]
AB  - BACKGROUND AND PURPOSE: The efficacy of dual antiplatelet treatment may be 
      modified by many factors. The aim was to assess whether the effect of clopidogrel 
      plus aspirin versus aspirin alone on recurrent stroke would be affected by 
      admission activated partial thromboplastin time (aPTT). METHODS: Data were 
      derived from the Clopidogrel in High-Risk Patients with Acute Nondisabling 
      Cerebrovascular Events (CHANCE) trial. A total of 5074 patients were categorized 
      into three groups based on the aPTT distribution according to the 15th and 85th 
      percentile. The primary outcome was any stroke within 90 days. The interaction of 
      aPTT with antiplatelet therapy on stroke risk was assessed with a Cox 
      proportional hazards model with adjustment for covariates. RESULTS: In the high 
      aPTT group (defined as ≥35.9 s), stroke occurred in 6.7% of patients in the 
      clopidogrel-aspirin arm and 11.9% in the aspirin arm [adjusted hazard ratio (HR) 
      0.50; 95% confidence interval (CI) 0.29-0.85]. In the medium aPTT group 
      (24.6-35.8 s), stroke occurred in 7.7% of patients in the clopidogrel-aspirin arm 
      and 11.8% in the aspirin arm (adjusted HR 0.62; 95% CI 0.50-0.75). Furthermore, 
      in the low aPTT group (≤24.5 s), stroke occurred in 11.2% of patients in the 
      clopidogrel-aspirin arm and 9.9% in the aspirin arm (adjusted HR 1.07; 95% CI 
      0.65-1.62). The interaction P value of antiplatelet therapy with aPTT level at 
      the cut-point of approximately 25 s or below was significant (P < 0.05). 
      CONCLUSIONS: Dual antiplatelet therapy was superior to single antiplatelet 
      therapy in the high or medium aPTT group but not in the low aPTT group.
CI  - © 2019 EAN.
FAU - Xie, X
AU  - Xie X
AUID- ORCID: 0000-0001-8154-1957
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Wang, X
AU  - Wang X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Laskowitz, D T
AU  - Laskowitz DT
AD  - Department of Neurology, Duke University Medical Center, Durham, NC, USA.
FAU - Zhao, X
AU  - Zhao X
AUID- ORCID: 0000-0001-8345-5147
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Miao, Z
AU  - Miao Z
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
AD  - Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Liu, L
AU  - Liu L
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Li, H
AU  - Li H
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Meng, X
AU  - Meng X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Wang, Y
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Wang, Y
AU  - Wang Y
AUID- ORCID: 0000-0001-9377-2867
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
CN  - CHANCE investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00979589
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190509
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Brain Ischemia/*prevention & control
MH  - Clopidogrel/administration & dosage/*pharmacology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Outcome Assessment, Health Care
MH  - *Partial Thromboplastin Time
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Recurrence
MH  - Stroke/*prevention & control
OTO - NOTNLM
OT  - activated partial thromboplastin time
OT  - aspirin
OT  - clopidogrel
OT  - minor stroke
OT  - transient ischaemic attack
EDAT- 2019/04/12 06:00
MHDA- 2020/08/18 06:00
CRDT- 2019/04/12 06:00
PHST- 2018/06/23 00:00 [received]
PHST- 2019/04/03 00:00 [accepted]
PHST- 2019/04/12 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
PHST- 2019/04/12 06:00 [entrez]
AID - 10.1111/ene.13961 [doi]
PST - ppublish
SO  - Eur J Neurol. 2019 Sep;26(9):1168-e78. doi: 10.1111/ene.13961. Epub 2019 May 9.

PMID- 27503490
OWN - NLM
STAT- MEDLINE
DCOM- 20170629
LR  - 20220321
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Linking)
VI  - 27
IP  - 9
DP  - 2016 Sep
TI  - Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate 
      cancer risk: a nationwide study.
PG  - 1067-79
LID - 10.1007/s10552-016-0785-7 [doi]
AB  - PURPOSE: Increasing evidence suggests that aspirin use may protect against 
      prostate cancer. In a nationwide case-control study, using Danish high-quality 
      registry data, we evaluated the association between the use of low-dose aspirin 
      or other nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of prostate 
      cancer. METHODS: We identified 35,600 patients (cases) with histologically 
      verified prostate cancer during 2000-2012. Cases were matched to 177,992 
      population controls on age and residence by risk-set sampling. Aspirin and 
      nonaspirin NSAID exposure was defined by type, estimated dose, duration, and 
      consistency of use. We used conditional logistic regression to estimate odds 
      ratios (ORs), with 95 % confidence intervals (CIs), for prostate cancer 
      associated with low-dose aspirin (75-150 mg) or nonaspirin NSAID use, adjusted 
      for potential confounders. RESULTS: Use of low-dose aspirin was associated with 
      an OR for prostate cancer of 0.94 (95 % CI 0.91-0.97). Slightly lower ORs were 
      seen with increasing cumulative amount, duration, and consistency of low-dose 
      aspirin use (continuous use, ≥5 years: OR 0.89; 95 % CI 0.82-0.97; ≥10 years: OR 
      0.86; 95 % CI 0.70-1.06). Nonaspirin NSAID use was associated with a slightly 
      increased OR for prostate cancer (1.13; 95 % CI 1.10-1.15); however, this 
      association was confined to localized disease and did not vary materially with 
      amount, duration, or consistency of nonaspirin NSAID use. CONCLUSIONS: Our study 
      indicates that long-term, consistent low-dose aspirin use may provide modest 
      protection against prostate cancer. The slightly increased risk of only localized 
      prostate cancer with nonaspirin NSAID use suggests a noncausal explanation of the 
      observed association.
FAU - Skriver, Charlotte
AU  - Skriver C
AUID- ORCID: 0000-0003-0774-4259
AD  - Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 
      49, 2100, Copenhagen Ø, Denmark. skriver@cancer.dk.
FAU - Dehlendorff, Christian
AU  - Dehlendorff C
AD  - Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 
      49, 2100, Copenhagen Ø, Denmark.
FAU - Borre, Michael
AU  - Borre M
AD  - Department of Urology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 
      99, 8200, Aarhus N, Denmark.
FAU - Brasso, Klaus
AU  - Brasso K
AD  - Department of Urology, Copenhagen Prostate Cancer Center, Rigshospitalet, 
      Blegdamsvej 9, 2100, Copenhagen Ø, Denmark.
FAU - Sørensen, Henrik Toft
AU  - Sørensen HT
AD  - Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 
      43-45, 8200, Aarhus N, Denmark.
FAU - Hallas, Jesper
AU  - Hallas J
AD  - Clinical Pharmacology and Pharmacy, Department of Public Health, University of 
      Southern Denmark, J. B. Winsløws Vej 19, 5000, Odense C, Denmark.
FAU - Larsen, Signe Benzon
AU  - Larsen SB
AD  - Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 
      49, 2100, Copenhagen Ø, Denmark.
FAU - Tjønneland, Anne
AU  - Tjønneland A
AD  - Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 
      49, 2100, Copenhagen Ø, Denmark.
FAU - Friis, Søren
AU  - Friis S
AD  - Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 
      49, 2100, Copenhagen Ø, Denmark.
AD  - Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 
      43-45, 8200, Aarhus N, Denmark.
AD  - Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, 
      1014, Copenhagen K, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20160809
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Denmark/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/*epidemiology/*etiology
MH  - Registries
MH  - Risk
OTO - NOTNLM
OT  - Aspirin
OT  - Case–control study
OT  - Epidemiology
OT  - Nonsteroidal anti-inflammatory drugs
OT  - Prostate neoplasms
OT  - Risk
EDAT- 2016/08/10 06:00
MHDA- 2017/07/01 06:00
CRDT- 2016/08/10 06:00
PHST- 2016/02/09 00:00 [received]
PHST- 2016/07/09 00:00 [accepted]
PHST- 2016/08/10 06:00 [entrez]
PHST- 2016/08/10 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - 10.1007/s10552-016-0785-7 [pii]
AID - 10.1007/s10552-016-0785-7 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2016 Sep;27(9):1067-79. doi: 10.1007/s10552-016-0785-7. 
      Epub 2016 Aug 9.

PMID- 2252045
OWN - NLM
STAT- MEDLINE
DCOM- 19910114
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 89
IP  - 6
DP  - 1990 Dec
TI  - Aspirin in the primary prevention of angina pectoris in a randomized trial of 
      United States physicians.
PG  - 772-6
AB  - PURPOSE: The objective of this study was to examine the effect of low-dose 
      aspirin (325 mg on alternate days) on the primary prevention of angina pectoris 
      in the United States Physicians' Health Study. Despite a postulated role of 
      platelets in atherogenesis and myocardial ischemia, the effect of chronic 
      platelet inhibition on the development of clinical angina pectoris is unknown. 
      SUBJECTS AND METHODS: The Physicians' Health Study is a randomized, double-blind, 
      placebo-controlled trial among 22,071 male physicians aged 40 to 84 years, free 
      from previous myocardial infarction, stroke, and transient cerebral ischemia at 
      entry, and followed for an average of 60.2 months. The 21,738 physicians who were 
      also free from angina pectoris at baseline constituted the study population for 
      the present analyses. RESULTS: During 106,652 person-years of follow-up, 331 
      patients with confirmed angina pectoris were diagnosed, 194 of whom underwent a 
      coronary revascularization procedure (coronary artery bypass graft surgery or 
      coronary angioplasty). As compared to participants assigned placebo, the relative 
      risk of confirmed angina pectoris in the aspirin group was 1.10 (95% confidence 
      interval [CI], 0.88 to 1.38). For coronary revascularization, the relative risk 
      was 1.19 (95% CI, 0.88 to 1.59). After simultaneous control for other coronary 
      risk factors in a proportional-hazards model, these relative risks remained near 
      unity at 1.07 (95% CI, 0.84 to 1.36) and 1.11 (95% CI, 0.81 to 1.52), 
      respectively. When the risks of angina pectoris were examined according to year 
      of randomization in the trial, there was no pattern of increasing benefit with 
      longer duration of treatment. CONCLUSION: These randomized trial data indicate 
      that chronic platelet inhibition with low-dose aspirin for an average duration of 
      60.2 months does not reduce the incidence of angina pectoris.
FAU - Manson, J E
AU  - Manson JE
AD  - Channing Laboratory, Department of Medicine, Harvard Medical School.
FAU - Grobbee, D E
AU  - Grobbee DE
FAU - Stampfer, M J
AU  - Stampfer MJ
FAU - Taylor, J O
AU  - Taylor JO
FAU - Goldhaber, S Z
AU  - Goldhaber SZ
FAU - Gaziano, J M
AU  - Gaziano JM
FAU - Ridker, P M
AU  - Ridker PM
FAU - Buring, J E
AU  - Buring JE
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA-34944/CA/NCI NIH HHS/United States
GR  - HL-26490/HL/NHLBI NIH HHS/United States
GR  - HL-34595/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angina Pectoris/epidemiology/*prevention & control
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Physicians
MH  - Placebos
MH  - Primary Prevention
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Time Factors
MH  - United States/epidemiology
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
AID - 0002-9343(90)90220-8 [pii]
AID - 10.1016/0002-9343(90)90220-8 [doi]
PST - ppublish
SO  - Am J Med. 1990 Dec;89(6):772-6. doi: 10.1016/0002-9343(90)90220-8.

PMID- 9186127
OWN - NLM
STAT- MEDLINE
DCOM- 19970710
LR  - 20190627
IS  - 0002-9394 (Print)
IS  - 0002-9394 (Linking)
VI  - 123
IP  - 2
DP  - 1997 Feb
TI  - Aspirin therapy in nonarteritic anterior ischemic optic neuropathy.
PG  - 212-7
AB  - PURPOSE: To determine the benefit of aspirin in reducing the risk of nonarteritic 
      anterior ischemic optic neuropathy in the fellow eye following its occurrence in 
      the first eye. METHODS: A retrospective cohort study was conducted on 431 
      patients, 153 of whom were and 278 of whom were not prescribed aspirin following 
      the development of unilateral nonarteritic anterior ischemic optic neuropathy. 
      RESULTS: The 2-year cumulative probability of nonarteritic anterior ischemic 
      optic neuropathy in the fellow eye was 7% in the aspirin group and 15% in the 
      no-aspirin group, and 5-year cumulative probabilities were 17% and 20%, 
      respectively. Compared with the no-aspirin group, the rate ratio for nonarteritic 
      anterior ischemic optic neuropathy in the fellow eye in the aspirin-user group 
      was 0.43 (95% confidence interval, 0.19 to 0.92) over the first 2 years and 0.68 
      (95% confidence interval, 0.36 to 1.26) over the 5-year period. The overall 
      calculated 5-year risk was 19%; however, if none of the patients with incomplete 
      follow-up developed nonarteritic anterior ischemic optic neuropathy in the fellow 
      eye, then the 5-year risk would be about 12%. CONCLUSIONS: The 5-year risk of 
      nonarteritic anterior ischemic optic neuropathy occurring in the second eye is 
      far lower than that reported by previous studies. Our results suggest a possible 
      short-term but little or no long-term benefit to aspirin in reducing the risk of 
      nonarteritic anterior ischemic optic neuropathy in the fellow eye. However, this 
      finding must be viewed with caution because this study was not conducted 
      prospectively with a controlled protocol.
FAU - Beck, R W
AU  - Beck RW
AD  - Jaeh Center for Health Research, Tampa, Florida 33613, USA. beck@jach.com
FAU - Hayreh, S S
AU  - Hayreh SS
FAU - Podhajsky, P A
AU  - Podhajsky PA
FAU - Tan, E S
AU  - Tan ES
FAU - Moke, P S
AU  - Moke PS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cohort Studies
MH  - Humans
MH  - Optic Neuropathy, Ischemic/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 1997/02/01 00:00
MHDA- 1997/02/01 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1997/02/01 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
AID - S0002-9394(14)71038-4 [pii]
AID - 10.1016/s0002-9394(14)71038-4 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 1997 Feb;123(2):212-7. doi: 10.1016/s0002-9394(14)71038-4.

PMID- 23870608
OWN - NLM
STAT- MEDLINE
DCOM- 20140127
LR  - 20181202
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 35
IP  - 7
DP  - 2013 Jul
TI  - The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic 
      acid and clopidogrel compared with the concurrent administration of 
      acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, 
      open-label, 2-sequence, 2-period, single-dose crossover study.
PG  - 985-94
LID - S0149-2918(13)00267-1 [pii]
LID - 10.1016/j.clinthera.2013.05.015 [doi]
AB  - BACKGROUND: Dual antiplatelet therapy with clopidogrel plus acetylsalicylic acid 
      (ASA) is used for the treatment of acute coronary syndrome. A combined 
      formulation of ASA and clopidogrel has been developed to provide dosing 
      convenience and improve adherence. OBJECTIVE: This study was designed to compare 
      the pharmacokinetic properties and safety profile of a fixed-dose combination 
      formulation of ASA and clopidogrel with concurrent administration of each agent 
      in healthy male Korean volunteers. METHODS: This single-dose, randomized, 
      open-label, 2-period crossover study was conducted in 64 healthy Korean 
      volunteers. Equal numbers of eligible participants were randomly assigned to 
      receive either the fixed-dose combination of ASA 100 mg and clopidogrel 75 mg or 
      the free combination of each agent followed by a 7-day washout period and then 
      administration of the alternate formulation. Serial blood samples were collected 
      immediately before and after dosing for 24 hours. The safety profile was 
      evaluated by using adverse events (AEs), which were assessed by physical 
      examination, vital signs, ECGs, clinical laboratory tests, and interviews. The 2 
      formulations were considered to be bioequivalent if the 90% CIs for the 
      log-transformed C(max) and AUC(0-last) values were within the predetermined range 
      of 0.8 to 1.25. RESULTS: Sixty-four volunteers (mean [SD] age, 27.51 [8.15] 
      years; weight, 68.55 [7.86] kg; height, 173.80 [5.94] cm) were enrolled, and 63 
      completed the study. For ASA, the 90% CIs for the geometric mean ratios of C(max) 
      and AUC(0-last) were 0.9483 to 1.1717 and 0.9946 to 1.1020, respectively. For 
      salicylic acid, the 90% CIs were 0.9614 to 1.0396 for C(max) and 0.9778 to 1.0163 
      for AUC(0-last). For clopidogrel, the 90% CIs were 0.9809 to 1.2562 for C(max) 
      and 0.9674 to 1.2073 for AUC(0-last). Six of the 20 AEs reported were drug 
      related: decreased hemoglobin levels (n = 2), fever (n = 1), and headache (n = 1) 
      with the test formulation and increased alanine aminotransferase levels (n = 1) 
      and dyspepsia (n = 1) with the reference formulation. All of the drug-related AEs 
      were transient and mild in severity. CONCLUSIONS: The fixed-dose combination of 
      ASA and clopidogrel 100 mg/75 mg did not meet the regulatory criteria for 
      bioequivalence as defined by the Korea Food and Drug Administration. Both 
      formulations were well tolerated in these healthy male Korean subjects. 
      ClinicalTrials.gov Identifier: NCT01448330.
CI  - Copyright © 2013 Elsevier HS Journals, Inc. All rights reserved.
FAU - Jung, Jin Ah
AU  - Jung JA
AD  - Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, 
      Seoul, Korea.
FAU - Kim, Tae-Eun
AU  - Kim TE
FAU - Kim, Jung-Ryul
AU  - Kim JR
FAU - Kim, Min-Ji
AU  - Kim MJ
FAU - Huh, Wooseong
AU  - Huh W
FAU - Park, Kyung-Mi
AU  - Park KM
FAU - Lee, Soo-Youn
AU  - Lee SY
FAU - Ko, Jae-Wook
AU  - Ko JW
LA  - eng
SI  - ClinicalTrials.gov/NCT01448330
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Drug Combinations)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects/*pharmacokinetics
MH  - Clopidogrel
MH  - Cross-Over Studies
MH  - Drug Administration Schedule
MH  - Drug Combinations
MH  - Drug Therapy, Combination/adverse effects
MH  - Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacokinetics
MH  - Young Adult
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - clopidogrel
OT  - fixed-dose combination
OT  - healthy
OT  - pharmacokinetics
EDAT- 2013/07/23 06:00
MHDA- 2014/01/28 06:00
CRDT- 2013/07/23 06:00
PHST- 2013/02/15 00:00 [received]
PHST- 2013/05/07 00:00 [revised]
PHST- 2013/05/21 00:00 [accepted]
PHST- 2013/07/23 06:00 [entrez]
PHST- 2013/07/23 06:00 [pubmed]
PHST- 2014/01/28 06:00 [medline]
AID - S0149-2918(13)00267-1 [pii]
AID - 10.1016/j.clinthera.2013.05.015 [doi]
PST - ppublish
SO  - Clin Ther. 2013 Jul;35(7):985-94. doi: 10.1016/j.clinthera.2013.05.015.

PMID- 34643230
OWN - NLM
STAT- MEDLINE
DCOM- 20220304
LR  - 20221014
IS  - 1476-6256 (Electronic)
IS  - 0002-9262 (Print)
IS  - 0002-9262 (Linking)
VI  - 191
IP  - 2
DP  - 2022 Jan 24
TI  - The Role of the Natural Course in Causal Analysis.
PG  - 341-348
LID - 10.1093/aje/kwab248 [doi]
AB  - The average causal effect compares counterfactual outcomes if everyone had been 
      exposed versus if everyone had been unexposed, which can be an unrealistic 
      contrast. Alternatively, we can target effects that compare counterfactual 
      outcomes against the factual outcomes observed in the sample (i.e., we can 
      compare against the natural course). Here, we demonstrate how the natural course 
      can be estimated and used in causal analyses for model validation and effect 
      estimation. Our example is an analysis assessing the impact of taking aspirin on 
      pregnancy, 26 weeks after randomization, in the Effects of Aspirin in Gestation 
      and Reproduction trial (United States, 2006-2012). To validate our models, we 
      estimated the natural course using g-computation and then compared that against 
      the observed incidence of pregnancy. We observed good agreement between the 
      observed and model-based natural courses. We then estimated an effect that 
      compared the natural course against the scenario in which participants assigned 
      to aspirin always complied. If participants had always complied, there would have 
      been 5.0 (95% confidence interval: 2.2, 7.8) more pregnancies per 100 women than 
      was observed. It is good practice to estimate the natural course for model 
      validation when using parametric models, but whether one should estimate a 
      natural course contrast depends on the underlying research questions.
CI  - © The Author(s) 2021. Published by Oxford University Press on behalf of the Johns 
      Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Rudolph, Jacqueline E
AU  - Rudolph JE
FAU - Cartus, Abigail
AU  - Cartus A
FAU - Bodnar, Lisa M
AU  - Bodnar LM
FAU - Schisterman, Enrique F
AU  - Schisterman EF
FAU - Naimi, Ashley I
AU  - Naimi AI
LA  - eng
GR  - R01 HD093602/HD/NICHD NIH HHS/United States
GR  - R01 HD102313/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - Am J Epidemiol
JT  - American journal of epidemiology
JID - 7910653
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - *Causality
MH  - Female
MH  - Humans
MH  - *Models, Theoretical
MH  - Pregnancy
MH  - Pregnancy Complications/*epidemiology/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Reproducibility of Results
PMC - PMC8897990
OTO - NOTNLM
OT  - causal inference
OT  - g-computation
OT  - model validation
OT  - natural course
OT  - parametric model
EDAT- 2021/10/14 06:00
MHDA- 2022/03/05 06:00
CRDT- 2021/10/13 08:45
PHST- 2021/04/06 00:00 [received]
PHST- 2021/10/05 00:00 [accepted]
PHST- 2021/10/14 06:00 [pubmed]
PHST- 2022/03/05 06:00 [medline]
PHST- 2021/10/13 08:45 [entrez]
AID - 6395127 [pii]
AID - kwab248 [pii]
AID - 10.1093/aje/kwab248 [doi]
PST - ppublish
SO  - Am J Epidemiol. 2022 Jan 24;191(2):341-348. doi: 10.1093/aje/kwab248.

PMID- 12175738
OWN - NLM
STAT- MEDLINE
DCOM- 20021114
LR  - 20191210
IS  - 0168-3659 (Print)
IS  - 0168-3659 (Linking)
VI  - 82
IP  - 2-3
DP  - 2002 Aug 21
TI  - The application of generalized regression neural network in the modeling and 
      optimization of aspirin extended release tablets with Eudragit RS PO as matrix 
      substance.
PG  - 213-222
AB  - The objective of this work is to use a generalized regression neural network 
      (GRNN) in the design of extended-release aspirin tablets. As model formulations, 
      10 kinds of aspirin matrix tablets were prepared. Eudragit RS PO was used as 
      matrix substance. The amount of Eudragit RS PO and compression pressure were 
      selected as causal factors. In-vitro dissolution-time profiles at four different 
      sampling times, as well as coefficients n (release order) and log k (release 
      constant) from the Peppas equation were estimated as release parameters. A set of 
      release parameters and causal factors were used as tutorial data for the GRNN and 
      analyzing using a computer. A GRNN model was constructed. The optimized GRNN 
      model was used for prediction of formulation with desired in vitro drug release. 
      For two tested formulations there was very good agreement between the GRNN 
      predicted and observed in vitro profiles and estimated coefficients. Calculated 
      difference (f(1)) and similarity (f(2)) factors indicate that there is no 
      difference between predicted and experimental observed drug release profiles. 
      This work illustrates the potential for an artificial neural network, GRNN, to 
      assist in development of extended-release dosage forms. This method can be 
      employed to achieve a desired in vitro dissolution profile.
FAU - Ibrić, Svetlana
AU  - Ibrić S
AD  - Institute for Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, 
      Vojvode Stepe 450, 11221, Belgrade, Yugoslavia. ibric@beotel.yu
FAU - Jovanović, Milica
AU  - Jovanović M
FAU - Djurić, Zorica
AU  - Djurić Z
FAU - Parojcić, Jelena
AU  - Parojcić J
FAU - Solomun, Ljiljana
AU  - Solomun L
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Acrylic Resins)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Tablets)
RN  - 33434-24-1 (Eudragit RS)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acrylic Resins/*chemistry
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/*chemistry
MH  - Computer Simulation
MH  - Delayed-Action Preparations/chemistry
MH  - *Drug Compounding
MH  - *Models, Chemical
MH  - *Neural Networks, Computer
MH  - Research Design
MH  - Solubility
MH  - Tablets
EDAT- 2002/08/15 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/08/15 10:00
PHST- 2002/08/15 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/08/15 10:00 [entrez]
AID - S0168365902000445 [pii]
AID - 10.1016/s0168-3659(02)00044-5 [doi]
PST - ppublish
SO  - J Control Release. 2002 Aug 21;82(2-3):213-222. doi: 
      10.1016/s0168-3659(02)00044-5.

PMID- 29076760
OWN - NLM
STAT- MEDLINE
DCOM- 20190909
LR  - 20190909
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Linking)
VI  - 24
IP  - 11
DP  - 2018 Oct
TI  - Aspirin is an effective pretreatment for exercise in multiple sclerosis: A 
      double-blind randomized controlled pilot trial.
PG  - 1511-1513
LID - 10.1177/1352458517739138 [doi]
AB  - Exercise benefits multiple sclerosis (MS) patients, but exercise-induced 
      overheating is a deterrent for many. We conducted a double-blind crossover-design 
      placebo-controlled pilot of aspirin to increase time-to-exhaustion (TTE) and 
      reduce exercise-induced body temperature increase. A total of 12 patients 
      participated. At enrollment, 8 of 12 reported heat sensitivity during exercise. 
      After 650 mg of aspirin or placebo, participants performed lower body cycle 
      ergometer exercise test. TTE increased after aspirin compared to placebo: t(11) = 
      2.405, p = 0.035 (Cohen's d = 1.45). Body temperature increase after exercise 
      with acetylsalicylic acid (ASA) was reduced by 56% in heat-sensitive patients, 
      although limited power precluded statistical significance. Aspirin may represent 
      an effective pretreatment for exercise in MS.
FAU - Leavitt, Victoria M
AU  - Leavitt VM
AD  - Multiple Sclerosis Cognitive Neuroscience Laboratory, Department of Neurology, 
      Columbia University Medical Center, New York, NY, USA.
FAU - Blanchard, Adam R
AU  - Blanchard AR
AD  - Department of Rehabilitation and Regenerative Medicine, Columbia University 
      Medical Center, New York, NY, USA.
FAU - Guo, Chu-Yueh
AU  - Guo CY
AD  - Multiple Sclerosis Cognitive Neuroscience Laboratory, Department of Neurology, 
      Columbia University Medical Center, New York, NY, USA.
FAU - Gelernt, Eva
AU  - Gelernt E
AD  - Multiple Sclerosis Cognitive Neuroscience Laboratory, Department of Neurology, 
      Columbia University Medical Center, New York, NY, USA.
FAU - Sumowski, James F
AU  - Sumowski JF
AD  - Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 
      USA.
FAU - Stein, Joel
AU  - Stein J
AD  - Department of Rehabilitation and Regenerative Medicine, Columbia University 
      Medical Center, New York, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20171027
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
RN  - 0 (Antipyretics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antipyretics/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Body Temperature/*drug effects
MH  - Double-Blind Method
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Multiple Sclerosis, Relapsing-Remitting
MH  - Pilot Projects
OTO - NOTNLM
OT  - Multiple sclerosis
OT  - aspirin
OT  - body temperature
OT  - exercise
OT  - fatigue
EDAT- 2017/10/28 06:00
MHDA- 2019/09/10 06:00
CRDT- 2017/10/28 06:00
PHST- 2017/10/28 06:00 [pubmed]
PHST- 2019/09/10 06:00 [medline]
PHST- 2017/10/28 06:00 [entrez]
AID - 10.1177/1352458517739138 [doi]
PST - ppublish
SO  - Mult Scler. 2018 Oct;24(11):1511-1513. doi: 10.1177/1352458517739138. Epub 2017 
      Oct 27.

PMID- 35534443
OWN - NLM
STAT- MEDLINE
DCOM- 20220930
LR  - 20221005
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 57
IP  - 10
DP  - 2022 Oct
TI  - Lactobacillus complex capsules ameliorate aspirin-related small intestinal 
      mucosal injury: a prospective, randomized, controlled clinical trial.
PG  - 1195-1201
LID - 10.1080/00365521.2022.2073184 [doi]
AB  - OBJECTIVES: Aspirin can reduce cardiovascular disease risk; however, it can 
      increase the risk of gastrointestinal injury. Lactobacilli have some protective 
      effects; however, there are few studies on their effects on humans. This study 
      investigates the effects of Lactobacillus complex capsule treatment on the 
      aspirin-related small intestinal mucosal injury. METHODS: This single-center, 
      prospective, randomized controlled clinical trial included 69 patients using 
      enteric-coated aspirin for >1 month between May and December 2019. After baseline 
      magnetically controlled capsule endoscopy (MCCE), patients with aspirin-related 
      small intestinal mucosal injury were randomly assigned (1:1) to receive 
      enteric-coated aspirin and Lactobacillus complex capsules containing a 
      combination of Lactobacillus rhamnosus I, Lactobacillus rhamnosus II, and 
      Enterococcus faecium (probiotics group) or enteric-coated aspirin only (control 
      group) for 2 months. After treatment, the patient underwent MCCE again. The 
      primary outcome was the change in small intestinal mucosal injury scores from 
      baseline to post-intervention. RESULTS: Twenty-five patients in the probiotics 
      group and 28 in the control group completed the trial. The decrease in small 
      intestinal mucosal injury scores from baseline to post-intervention was 
      significantly greater in the probiotics group than that in the control group 
      (p < .001). The improvement rates of red spots and erosions in the probiotics 
      group were higher compared with the control group (p = .027 and .022, 
      respectively), and the improvement rate of small intestinal ulcers in the 
      probiotics group was 75.0%; however, there was no improvement in the control 
      group. CONCLUSION: Lactobacillus complex capsules can ameliorate aspirin-related 
      small intestinal mucosal injury.
FAU - Chen, Xue
AU  - Chen X
AUID- ORCID: 0000-0002-8798-1790
AD  - Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, China.
FAU - Gao, Feng
AU  - Gao F
AUID- ORCID: 0000-0001-6368-9771
AD  - Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, China.
FAU - Zhang, Jie
AU  - Zhang J
AUID- ORCID: 0000-0003-1587-503X
AD  - Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220509
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Capsule Endoscopy
MH  - Humans
MH  - Intestinal Mucosa
MH  - Intestine, Small
MH  - Lactobacillus
MH  - *Probiotics/therapeutic use
MH  - Prospective Studies
OTO - NOTNLM
OT  - Lactobacillus complex capsule
OT  - aspirin
OT  - injury
OT  - magnetically controlled capsule endoscopy
OT  - small intestine
EDAT- 2022/05/10 06:00
MHDA- 2022/10/01 06:00
CRDT- 2022/05/09 22:42
PHST- 2022/05/10 06:00 [pubmed]
PHST- 2022/10/01 06:00 [medline]
PHST- 2022/05/09 22:42 [entrez]
AID - 10.1080/00365521.2022.2073184 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2022 Oct;57(10):1195-1201. doi: 
      10.1080/00365521.2022.2073184. Epub 2022 May 9.

PMID- 2454026
OWN - NLM
STAT- MEDLINE
DCOM- 19880627
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 84
IP  - 5A
DP  - 1988 May 20
TI  - Impact of non-narcotic oral analgesics on pain management.
PG  - 3-15
AB  - Of the four categories of oral analgesics, three have been available since the 
      19th century. Although adequate doses of the more potent oral opioids such as 
      morphine and methadone are effective even in severe pain, the commonly used 
      "weak" narcotics such as codeine and propoxyphene are no more effective than 
      usual doses of aspirin or acetaminophen. Furthermore, the opioids produce 
      gastrointestinal and central nervous system adverse effects, and, during 
      long-term administration, tolerance may develop and there is a risk of drug 
      dependence. Aspirin and acetaminophen are the traditional agents of choice for 
      oral analgesic therapy; until 10 years ago, there were no single-entity, oral 
      analgesics--with the exception of large doses of oral narcotics--that were more 
      effective than usual doses of aspirin or acetaminophen. However, there is a 
      ceiling on the analgesic effect attainable with safe doses of these drugs, which 
      may in part be overcome through the use of the third category of oral analgesics, 
      combinations of aspirin or acetaminophen with oral opioids. The fourth category 
      of oral analgesics constitutes the most important recent development in pain 
      management with analgesic drugs: the newer peripherally acting, nonsteroidal 
      anti-inflammatory analgesics, some of which are clearly more efficacious than 
      aspirin or acetaminophen and compare favorably not only with full doses of 
      narcotic combination products but even, in some cases, with strong injectable 
      opioids. On repeated dosing, some nonsteroidal anti-inflammatory drugs are better 
      tolerated than aspirin and some have a much longer duration of analgesic effect 
      than aspirin or acetaminophen. Further study is needed to compare nonsteroidal 
      anti-inflammatory drugs among themselves and to determine their value in chronic 
      pain and in combination therapy.
FAU - Beaver, W T
AU  - Beaver WT
AD  - Department of Pharmacology, School of Medicine, Georgetown University, 
      Washington, D.C. 20007.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 0 (Narcotics)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/therapeutic use
MH  - Administration, Oral
MH  - Analgesics/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Biomechanical Phenomena
MH  - Drug Combinations
MH  - Humans
MH  - Narcotics/adverse effects/therapeutic use
MH  - *Palliative Care
RF  - 37
EDAT- 1988/05/20 00:00
MHDA- 1988/05/20 00:01
CRDT- 1988/05/20 00:00
PHST- 1988/05/20 00:00 [pubmed]
PHST- 1988/05/20 00:01 [medline]
PHST- 1988/05/20 00:00 [entrez]
AID - 0002-9343(88)90471-8 [pii]
AID - 10.1016/0002-9343(88)90471-8 [doi]
PST - ppublish
SO  - Am J Med. 1988 May 20;84(5A):3-15. doi: 10.1016/0002-9343(88)90471-8.

PMID- 11818533
OWN - NLM
STAT- MEDLINE
DCOM- 20020307
LR  - 20190108
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 99
IP  - 3
DP  - 2002 Feb 5
TI  - Efficacy and age-related effects of nitric oxide-releasing aspirin on 
      experimental restenosis.
PG  - 1689-94
AB  - Restenosis after percutaneous transluminal coronary angioplasty is caused by 
      neointimal hyperplasia, which involves impairment of nitric oxide (NO)-dependent 
      pathways, and may be further exacerbated by a concomitant aging process. We 
      compared the effects of NO-releasing-aspirin (NCX-4016) and aspirin (ASA) on 
      experimental restenosis in both adult and elderly rats. Moreover, to ascertain 
      the efficacy of NCX-4016 during vascular aging, we fully characterized the 
      release of bioactive NO by the drug. Sprague-Dawley rats aged 6 and 24 months 
      were treated with NO releasing-aspirin (55 mg/kg) or ASA (30 mg/kg) for 7 days 
      before and 21 days after standard carotid balloon injury. Histological 
      examination and immunohistochemical double-staining were used to evaluate 
      restenosis. Plasma nitrite and nitrate and S-nitrosothiols were determined by a 
      chemiluminescence-based assay. Electron spin resonance was used for determining 
      nitrosylhemoglobin. Treatment of aged rats with NCX-4016 was associated with 
      increased bioactive NO, compared with ASA. NO aspirin, but not ASA, reduced 
      experimental restenosis in old rats, an effect associated with reduced vascular 
      smooth muscle cell proliferation. NCX-4016, but not ASA, was well tolerated and 
      virtually devoid of gastric damage in either adult or old rats. Thus, impairment 
      of NO-dependent mechanisms may be involved in the development of restenosis in 
      old rats. We suggest that an NCX-4016 derivative could be an effective drug in 
      reducing restenosis, especially in the presence of aging and/or gastrointestinal 
      damage.
FAU - Napoli, Claudio
AU  - Napoli C
AD  - Department of Medicine, Federico II University of Naples, 80131 Naples, Italy.
FAU - Aldini, Giancarlo
AU  - Aldini G
FAU - Wallace, John L
AU  - Wallace JL
FAU - de Nigris, Filomena
AU  - de Nigris F
FAU - Maffei, Roberto
AU  - Maffei R
FAU - Abete, Pasquale
AU  - Abete P
FAU - Bonaduce, Domenico
AU  - Bonaduce D
FAU - Condorelli, Gianluigi
AU  - Condorelli G
FAU - Rengo, Franco
AU  - Rengo F
FAU - Sica, Vincenzo
AU  - Sica V
FAU - D'Armiento, Francesco P
AU  - D'Armiento FP
FAU - Mignogna, Chiara
AU  - Mignogna C
FAU - de Rosa, Gaetano
AU  - de Rosa G
FAU - Condorelli, Mario
AU  - Condorelli M
FAU - Lerman, Lilach O
AU  - Lerman LO
FAU - Ignarro, Louis J
AU  - Ignarro LJ
LA  - eng
GR  - R01 HL063282/HL/NHLBI NIH HHS/United States
GR  - HL-63282/HL/NHLBI NIH HHS/United States
GR  - R01 HL066999/HL/NHLBI NIH HHS/United States
GR  - HL-58433/HL/NHLBI NIH HHS/United States
GR  - HL-66999/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20020129
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hemoglobins)
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Nitrites)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aging
MH  - Angioplasty, Balloon, Coronary/adverse effects
MH  - Animals
MH  - Aspirin/analogs & derivatives/blood/*pharmacology
MH  - Coronary Restenosis/*prevention & control
MH  - Coronary Vessels/drug effects/pathology
MH  - Disease Models, Animal
MH  - Fibrinolytic Agents/*pharmacology
MH  - Hemoglobins/metabolism
MH  - Nitrates/blood
MH  - Nitric Oxide/*physiology
MH  - Nitric Oxide Donors/*pharmacology
MH  - Nitrites/blood
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Time Factors
MH  - Tunica Intima/drug effects/pathology
PMC - PMC122252
EDAT- 2002/01/31 10:00
MHDA- 2002/03/08 10:01
CRDT- 2002/01/31 10:00
PHST- 2002/01/31 10:00 [pubmed]
PHST- 2002/03/08 10:01 [medline]
PHST- 2002/01/31 10:00 [entrez]
AID - 022639399 [pii]
AID - 6393 [pii]
AID - 10.1073/pnas.022639399 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1689-94. doi: 10.1073/pnas.022639399. 
      Epub 2002 Jan 29.

PMID- 2881204
OWN - NLM
STAT- MEDLINE
DCOM- 19870330
LR  - 20190702
IS  - 0027-5107 (Print)
IS  - 0027-5107 (Linking)
VI  - 190
IP  - 2
DP  - 1987 Feb
TI  - Absence of mutagenic activity of benorylate, paracetamol and aspirin in the 
      Salmonella/mammalian microsome test.
PG  - 95-100
AB  - Benorylate and its two major hydrolysis products, paracetamol and aspirin were 
      examined for mutagenicity in the Salmonella/mammalian microsome screening test. 
      The compounds were tested in 6 strains of Salmonella typhimurium (TA1535, TA1537, 
      TA1538, TA100, TA97 and TA98) in the presence and absence of a rat-liver 
      microsome activation system. Benorylate did not show evidence of mutagenic 
      activity in the 6 strains tested with or without metabolic activation at 
      concentrations ranging from 0.006 to 3 mg per plate. Paracetamol and aspirin 
      likewise did not show any evidence of mutagenic activity at concentrations 
      ranging from 0.1 to 50 mg per plate for the former and 0.01 to 50 mg per plate 
      for the latter.
FAU - Jasiewicz, M L
AU  - Jasiewicz ML
FAU - Richardson, J C
AU  - Richardson JC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - Mutat Res
JT  - Mutation research
JID - 0400763
RN  - 0 (Salicylates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/metabolism/*pharmacology
MH  - Animals
MH  - Aspirin/metabolism/*pharmacology
MH  - Biotransformation
MH  - Male
MH  - Microsomes, Liver/metabolism
MH  - Mutagenicity Tests
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Salicylates/metabolism/*pharmacology
MH  - Salmonella typhimurium/*drug effects/genetics
EDAT- 1987/02/01 00:00
MHDA- 1987/02/01 00:01
CRDT- 1987/02/01 00:00
PHST- 1987/02/01 00:00 [pubmed]
PHST- 1987/02/01 00:01 [medline]
PHST- 1987/02/01 00:00 [entrez]
AID - 0165-7992(87)90038-8 [pii]
AID - 10.1016/0165-7992(87)90038-8 [doi]
PST - ppublish
SO  - Mutat Res. 1987 Feb;190(2):95-100. doi: 10.1016/0165-7992(87)90038-8.

PMID- 36200820
OWN - NLM
STAT- MEDLINE
DCOM- 20221010
LR  - 20221011
IS  - 1940-5480 (Electronic)
IS  - 1067-151X (Linking)
VI  - 30
IP  - 20
DP  - 2022 Oct 15
TI  - Randomized Trial of Postoperative Venous Thromboembolism Prophylactic Compliance: 
      Aspirin and Mobile Compression Pumps.
PG  - e1319-e1326
LID - 10.5435/JAAOS-D-21-01063 [doi]
AB  - BACKGROUND: Aspirin, as a routine venous thromboembolism (VTE) prophylaxis, is 
      approved along with pneumatic compression pumps by the American College of Chest 
      Physicians. We assessed compliance of aspirin and pump use after total joint 
      arthroplasty. METHODS: A randomized trial of aspirin alone or aspirin/mobile 
      compression pumps after total joint arthroplasty was performed. Aspirin and pump 
      compliance, VTE events, and satisfaction with pump use were collected. Compliance 
      was assessed through an internal device monitor and drug log book. Patients were 
      also contacted 90 days postoperatively for reported symptomatic VTEs. RESULTS: 
      Each group had 40 patients and greater than 94% compliance with aspirin use, with 
      no difference between groups (P = 0.55). Overall pump compliance during the first 
      14 days after hospital discharge was 51% (SD ± 33), which was significantly worse 
      than aspirin compliance at 99% (SD ± 4.1) (P < 0.0001). Only 10 patients were 
      compliant (>20 hr/d) with recommended pump use throughout the entire recommended 
      period. There was no notable association between aspirin compliance and VTE 
      within 90 days. There was no notable association between pump compliance and VTE 
      at 90 days. However, average pump use compliance was 20% in patients with VTE and 
      54% in patients without VTE within 90 days. With the numbers available in this 
      compliance study, there was no significant difference (P = 0.11). DISCUSSION: 
      Aspirin compliance was notably greater than pump compliance. In this study, we 
      found that pump compliance was not associated with lower VTE risk. In fact, no 
      increased risk was recognized in patients with an average pump usage of >50%. 
      Further study is warranted to define the duration of pump use required for 
      clinical significance. The recommended use of compression pumps should continue 
      to be examined.
CI  - Copyright © 2022 by the American Academy of Orthopaedic Surgeons.
FAU - Dietz, Matthew J
AU  - Dietz MJ
AUID- ORCID: 0000-0003-2468-9837
AD  - From the Department of Orthopaedics, West Virginia University School of Medicine, 
      Robert C. Byrd Health Sciences Center, Morgantown, WV (Dietz, Frye, Lindsey, 
      Murphy, and Klein), and MedStar Georgetown University Hospital/Washington 
      Hospital Center, Washington, DC (Moushmoush).
FAU - Moushmoush, Obadah
AU  - Moushmoush O
FAU - Frye, Benjamin M
AU  - Frye BM
FAU - Lindsey, Brock A
AU  - Lindsey BA
FAU - Murphy, T Ryan
AU  - Murphy TR
AUID- ORCID: 0000-0002-8686-9262
FAU - Klein, Adam E
AU  - Klein AE
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220629
PL  - United States
TA  - J Am Acad Orthop Surg
JT  - The Journal of the American Academy of Orthopaedic Surgeons
JID - 9417468
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - *Arthroplasty, Replacement, Hip/adverse effects
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Postoperative Period
MH  - *Venous Thromboembolism/etiology/prevention & control
EDAT- 2022/10/07 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/10/06 09:33
PHST- 2021/12/23 00:00 [received]
PHST- 2022/04/17 00:00 [accepted]
PHST- 2022/10/06 09:33 [entrez]
PHST- 2022/10/07 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
AID - 00124635-202210150-00013 [pii]
AID - 10.5435/JAAOS-D-21-01063 [doi]
PST - ppublish
SO  - J Am Acad Orthop Surg. 2022 Oct 15;30(20):e1319-e1326. doi: 
      10.5435/JAAOS-D-21-01063. Epub 2022 Jun 29.

PMID- 30719931
OWN - NLM
STAT- MEDLINE
DCOM- 20190808
LR  - 20190808
IS  - 1556-9535 (Electronic)
IS  - 1556-9527 (Linking)
VI  - 38
IP  - 2
DP  - 2019 Jun
TI  - The safety of intraocular usage of aspirin.
PG  - 201-205
LID - 10.1080/15569527.2019.1575391 [doi]
AB  - PURPOSE: To determine the effects of intravitreally injected aspirin on normal 
      ocular tissues. METHODS: Six eyes of 3 rabbits as a control group, 18 eyes of 9 
      albino rabbits which were injected aspirin intravitreally were studied. In the 
      control group, the same volume of balanced salt solution (BSS) as in drug groups 
      were injected. Clinical examination methods including biomicroscopy, indirect 
      ophthalmoscopy, and Schiotz tonometry, electrophysiological test including ERG, 
      and histopathological examination including light microscopy were used to 
      evaluate the ocular effects after drug injections. All the study tests were 
      performed before the injections and 1 week, 1 month, and 3 months after the 
      injections as well. RESULTS: No significant toxicity was determined after 
      injection in terms of the clinical examination methods in all eyes. Cataracts 
      were observed in 27.7% (5/18) of the eyes in the study group. All cataracts in 5 
      eyes disappeared at the end of three months. In tonometry, no value out of the 
      normal range of rabbits (17.5 ± 3.1 mmHg) was observed. No toxicity sign was 
      observed at electrophysiological and histopathological evaluations. CONCLUSION: 
      After intravitreal injection of aspirin, no significant toxicity sign was 
      observed other than a reversible cataract. Thus, intravitreal aspirin injections 
      may be an additional or alternative treatment option for several anterior or 
      posterior segment ocular diseases in addition to their topical utilization.
FAU - Dogan, Cezmi
AU  - Dogan C
AUID- ORCID: 0000-0002-6305-8176
AD  - a Department of Ophthalmology, Cerrahpaşa Medical Faculty , Istanbul University - 
      Cerrahpaşa , Istanbul , Turkey.
FAU - Yetik, Huseyin
AU  - Yetik H
AUID- ORCID: 0000-0002-4765-9529
AD  - a Department of Ophthalmology, Cerrahpaşa Medical Faculty , Istanbul University - 
      Cerrahpaşa , Istanbul , Turkey.
FAU - Arslan, Osman Sevki
AU  - Arslan OS
AD  - a Department of Ophthalmology, Cerrahpaşa Medical Faculty , Istanbul University - 
      Cerrahpaşa , Istanbul , Turkey.
FAU - Seymen, Hakki Oktay
AU  - Seymen HO
AUID- ORCID: 0000-0001-5096-747X
AD  - b Department of Physiology, Cerrahpaşa Medical Faculty , Istanbul University - 
      Cerrahpaşa , Istanbul , Turkey.
FAU - Suzer, Oner
AU  - Suzer O
AUID- ORCID: 0000-0003-4840-1316
AD  - c Department of Pharmacology, Cerrahpaşa Medical Faculty , Istanbul University - 
      Cerrahpaşa , Istanbul , Turkey.
FAU - Aydin, Ovgu
AU  - Aydin O
AD  - d Department of Pathology, Cerrahpaşa Medical Faculty , Istanbul University - 
      Cerrahpaşa , Istanbul , Turkey.
FAU - Mergen, Burak
AU  - Mergen B
AUID- ORCID: 0000-0002-8132-495X
AD  - a Department of Ophthalmology, Cerrahpaşa Medical Faculty , Istanbul University - 
      Cerrahpaşa , Istanbul , Turkey.
LA  - eng
PT  - Journal Article
DEP - 20190301
PL  - England
TA  - Cutan Ocul Toxicol
JT  - Cutaneous and ocular toxicology
JID - 101266892
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cataract/chemically induced/pathology
MH  - Cyclooxygenase Inhibitors/administration & dosage/*adverse effects
MH  - Electroretinography
MH  - Eye/*drug effects/pathology
MH  - Female
MH  - Intravitreal Injections
MH  - Male
MH  - Rabbits
OTO - NOTNLM
OT  - Aspirin
OT  - cataract
OT  - intravitreal injection
OT  - toxicity
EDAT- 2019/02/06 06:00
MHDA- 2019/08/09 06:00
CRDT- 2019/02/06 06:00
PHST- 2019/02/06 06:00 [pubmed]
PHST- 2019/08/09 06:00 [medline]
PHST- 2019/02/06 06:00 [entrez]
AID - 10.1080/15569527.2019.1575391 [doi]
PST - ppublish
SO  - Cutan Ocul Toxicol. 2019 Jun;38(2):201-205. doi: 10.1080/15569527.2019.1575391. 
      Epub 2019 Mar 1.

PMID- 28063965
OWN - NLM
STAT- MEDLINE
DCOM- 20170703
LR  - 20170703
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 100
DP  - 2017 Mar 30
TI  - A calix[4]arene derivative and its selective interaction with drugs (clofibric 
      acid, diclofenac and aspirin).
PG  - 1-8
LID - S0928-0987(16)30567-X [pii]
LID - 10.1016/j.ejps.2016.12.027 [doi]
AB  - The synthesis and characterisation of a partially substituted calix[4]arene, 
      namely, 5,11,17,23-tetra-tert-butyl,25,27-bis[aminoethoxy] 
      26,28-dihydroxycalix[4]arene are reported. Its interaction with commonly used 
      pharmaceuticals (clofibric acid, diclofenac and aspirin) was investigated by 
      spectroscopic ((1)H NMR and UV), electrochemical (conductance measurements) and 
      thermal (titration calorimetry) techniques. It is concluded on the basis of the 
      experimental work and molecular simulation studies that the receptor interacts 
      selectively with these drugs. Preliminary studies on the selective extraction of 
      these pharmaceuticals from water by the calix receptor are reported and the 
      potential for a carrier mediated sensor based on this ligand for 'on site' 
      monitoring of pharmaceuticals is discussed.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - Danil de Namor, Angela F
AU  - Danil de Namor AF
AD  - Laboratory of Thermochemistry, Department of Chemistry, University of Surrey, 
      Guildford, Surrey GU2 7XH, United Kingdom. Electronic address: 
      A.Danil-De-Namor@surrey.ac.uk.
FAU - Al Nuaim, Maan
AU  - Al Nuaim M
AD  - Laboratory of Thermochemistry, Department of Chemistry, University of Surrey, 
      Guildford, Surrey GU2 7XH, United Kingdom.
FAU - Villanueva Salas, Jose A
AU  - Villanueva Salas JA
AD  - Laboratory of Thermochemistry, Department of Chemistry, University of Surrey, 
      Guildford, Surrey GU2 7XH, United Kingdom.
FAU - Bryant, Sophie
AU  - Bryant S
AD  - Laboratory of Thermochemistry, Department of Chemistry, University of Surrey, 
      Guildford, Surrey GU2 7XH, United Kingdom.
FAU - Howlin, Brendan
AU  - Howlin B
AD  - Computational Research Group, Department of Chemistry, University of Surrey, 
      Guildford, Surrey GU2 7XH, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20170104
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Phenols)
RN  - 0 (calix(4)arene)
RN  - 130036-26-9 (Calixarenes)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 53PF01Q249 (Clofibric Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Calixarenes/*chemistry
MH  - Calorimetry
MH  - Clofibric Acid/*chemistry
MH  - Diclofenac/*chemistry
MH  - Electric Conductivity
MH  - Models, Molecular
MH  - Phenols/*chemistry
MH  - Proton Magnetic Resonance Spectroscopy
MH  - Spectrophotometry, Ultraviolet
MH  - Thermodynamics
OTO - NOTNLM
OT  - Aspirin
OT  - Calixarenes
OT  - Clofibric acid
OT  - Diclofenac
OT  - Pharmaceuticals
OT  - Thermodynamics
EDAT- 2017/01/09 06:00
MHDA- 2017/07/04 06:00
CRDT- 2017/01/09 06:00
PHST- 2016/09/30 00:00 [received]
PHST- 2016/12/22 00:00 [revised]
PHST- 2016/12/24 00:00 [accepted]
PHST- 2017/01/09 06:00 [pubmed]
PHST- 2017/07/04 06:00 [medline]
PHST- 2017/01/09 06:00 [entrez]
AID - S0928-0987(16)30567-X [pii]
AID - 10.1016/j.ejps.2016.12.027 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2017 Mar 30;100:1-8. doi: 10.1016/j.ejps.2016.12.027. Epub 2017 
      Jan 4.

PMID- 18302308
OWN - NLM
STAT- MEDLINE
DCOM- 20080417
LR  - 20181201
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 17
IP  - 4
DP  - 2008 Apr
TI  - Evidence for prolonged prescribing of aspirin-clopidogrel combination in Scottish 
      primary care.
PG  - 397-400
LID - 10.1002/pds.1561 [doi]
AB  - PURPOSE: To identify whether patients were prescribed the combination of 
      aspirin-clopidogrel in primary care after the generally recommended 12-month 
      period. METHODS: A population based cross-sectional study using data from 61 
      general practices (1st April 2003-31st March 2004). RESULTS: 691 patients (0.18% 
      of total population) were prescribed aspirin-clopidogrel in combination. 27.78% 
      of these patients had undergone coronary stenting or angioplasty and 34.30% were 
      prescribed this combination for more than 1 year. 96 (13.9%) patients had a 
      previous history of ischaemic stroke or transient ischaemic attack. CONCLUSIONS: 
      Patients were prescribed the combination of aspirin-clopidogrel beyond the 
      generally accepted 12-month period, which may lead to increased safety and cost 
      concerns.
FAU - Simpson, Colin R
AU  - Simpson CR
AD  - Department of General Practice & Primary Care, Foresterhill Health Centre, The 
      University of Aberdeen, UK.
FAU - Alford, Karen
AU  - Alford K
FAU - Williams, David
AU  - Williams D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Clopidogrel
MH  - Cross-Sectional Studies
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Population Surveillance/methods
MH  - Primary Health Care/*statistics & numerical data
MH  - Retrospective Studies
MH  - Scotland
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
EDAT- 2008/02/28 09:00
MHDA- 2008/04/18 09:00
CRDT- 2008/02/28 09:00
PHST- 2008/02/28 09:00 [pubmed]
PHST- 2008/04/18 09:00 [medline]
PHST- 2008/02/28 09:00 [entrez]
AID - 10.1002/pds.1561 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):397-400. doi: 10.1002/pds.1561.

PMID- 17546246
OWN - NLM
STAT- MEDLINE
DCOM- 20080731
LR  - 20190917
IS  - 0004-2730 (Print)
IS  - 0004-2730 (Linking)
VI  - 51
IP  - 3
DP  - 2007 Apr
TI  - [Low-dose aspirin in patients with diabete melitus: risks and benefits regarding 
      macro and microvascular complications].
PG  - 457-65
AB  - Aspirin is recommended as cardiovascular disease prevention in patients with 
      diabetes mellitus. Due to the increased risk of bleeding and because of the 
      hypothesis that there could be a worsening of microvascular complications related 
      to aspirin, there has been observed an important underutilization of the drug. 
      However, it is now known that aspirin is not associated with a deleterious effect 
      on diabetic retinopathy and there is evidence indicating that it also does not 
      affect renal function with usual doses (150 mg/d). On the other hand, higher 
      doses may prove necessary, since recent data suggest that diabetic patients 
      present the so called "aspirin resistance". The mechanisms of this resistance are 
      not yet fully understood, being probably related to an abnormal intrinsic 
      platelet activity. The employment of alternative antiplatelet strategies or the 
      administration of higher aspirin doses (150-300 mg/d) should be better evaluated 
      regarding effective cardiovascular disease prevention in diabetes as well as the 
      possible effects on microvascular complications.
FAU - Camargo, Eduardo G
AU  - Camargo EG
AD  - Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, Universidade 
      Federal do Rio Grande do Sul, Porto Alegre, RS.
FAU - Gross, Jorge Luiz
AU  - Gross JL
FAU - Weinert, Letícia S
AU  - Weinert LS
FAU - Lavinsky, Joel
AU  - Lavinsky J
FAU - Silveiro, Sandra P
AU  - Silveiro SP
LA  - por
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspirina em baixa dosagem em pacientes com diabete melito: riscos e benefícios em 
      relação às complicações macro e microvasculares.
PL  - Brazil
TA  - Arq Bras Endocrinol Metabol
JT  - Arquivos brasileiros de endocrinologia e metabologia
JID - 0403437
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus/*physiopathology
MH  - Diabetic Angiopathies/prevention & control
MH  - Diabetic Nephropathies/prevention & control
MH  - Diabetic Retinopathy/prevention & control
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Primary Prevention
RF  - 60
EDAT- 2007/06/05 09:00
MHDA- 2008/08/01 09:00
CRDT- 2007/06/05 09:00
PHST- 2006/06/02 00:00 [received]
PHST- 2006/11/02 00:00 [accepted]
PHST- 2007/06/05 09:00 [pubmed]
PHST- 2008/08/01 09:00 [medline]
PHST- 2007/06/05 09:00 [entrez]
AID - S0004-27302007000300015 [pii]
AID - 10.1590/s0004-27302007000300015 [doi]
PST - ppublish
SO  - Arq Bras Endocrinol Metabol. 2007 Apr;51(3):457-65. doi: 
      10.1590/s0004-27302007000300015.

PMID- 1484472
OWN - NLM
STAT- MEDLINE
DCOM- 19930212
LR  - 20170214
IS  - 0272-989X (Print)
IS  - 0272-989X (Linking)
VI  - 12
IP  - 4
DP  - 1992 Oct-Dec
TI  - Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision 
      analysis.
PG  - 239-49
AB  - The objective of the study was to determine the preferred treatment strategy for 
      elderly patients with chronic nonvalvular atrial fibrillation (CNVAF). A Markov 
      decision-analytic model was used to compare three treatment strategies for CNVAF: 
      1) warfarin; 2) aspirin; and 3) no treatment. Five-year quality-adjusted life 
      years (QALYs) were calculated for male and female cohorts aged 70 and 75 years. 
      In the baseline analysis (effectiveness of warfarin = 0.70, effectiveness of 
      aspirin = 0.45, utility of warfarin = 0.99, and utility of aspirin = 0.999) the 
      quality-adjusted survival rates for 70-year-old males were 4.03 QALYs on 
      warfarin, 4.02 QALYs on aspirin, and 3.95 QALYs on no treatment. Results were 
      similar for all age and sex cohorts. Sensitivity analyses revealed that the 
      results were very sensitive to the effectiveness of aspirin and the disutility of 
      warfarin. The authors conclude that the optimal strategy for the treatment of 
      CNVAF in elderly patients varies with the disutility assigned to warfarin therapy 
      and the effectiveness value for aspirin therapy.
FAU - Naglie, I G
AU  - Naglie IG
AD  - Division of General Internal Medicine, Geriatric Medicine, and Clinical 
      Epidemiology, Toronto Hospital, Ontario, Canada.
FAU - Detsky, A S
AU  - Detsky AS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Med Decis Making
JT  - Medical decision making : an international journal of the Society for Medical 
      Decision Making
JID - 8109073
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy/mortality
MH  - Chronic Disease
MH  - *Decision Support Techniques
MH  - Decision Trees
MH  - Female
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Sensitivity and Specificity
MH  - Survival Analysis
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 10.1177/0272989X9201200401 [doi]
PST - ppublish
SO  - Med Decis Making. 1992 Oct-Dec;12(4):239-49. doi: 10.1177/0272989X9201200401.

PMID- 20144559
OWN - NLM
STAT- MEDLINE
DCOM- 20110602
LR  - 20181201
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 19
IP  - 4
DP  - 2010 Apr
TI  - Serum thromboxane B2 compared to five other platelet function tests for the 
      evaluation of aspirin effect in stable cardiovascular disease.
PG  - 234-42
LID - 10.1016/j.hlc.2009.11.002 [doi]
AB  - BACKGROUND: To assess the role of serum thromboxane B(2) (TXB(2)) measurements 
      and the correlation between platelet function studies, in patients with stable 
      cardiovascular disease on aspirin or clopidogrel. METHODS: 76 patients (47 on 
      aspirin, 16 clopidogrel, 13 both) underwent assessment of TXB(2), whole blood 
      aggregometry (WBA) after stimulation with (i) arachidonic acid (0.5mM), (ii) ADP 
      (5 microM), (iii) collagen (1 and 5 microg/ml), PFA-100, and Cone and Plate 
      Analyzer. Clopidogrel patients were additionally assessed by the VerifyNow 
      System. RESULTS: TXB(2) values ranged between 0.2 and 56.2 ng/ml, with 
      significant separation between those taking aspirin, clopidogrel and controls 
      (0.45 ng/ml vs 6.85 ng/ml vs 12.97 ng/ml, p<0.001). There was moderate 
      correlation between WBA-AA and TXB(2) (r=0.487, p<0.001), PFA-100((R)) (r=0.599, 
      p<0.001), WBA-Col1 (r=0.424, p<0.001), WBA-Col1:5 (r=0.417, p<0.001), and between 
      TXB(2) and PFA-100((R)) (r=0.509, p<0.001). The prevalence of aspirin 
      non-responders for WBA-AA, TXB(2), PFA-100((R)), CPA and Coll1:5 was 13.1%, 8.2%, 
      14.8%, 9.7% and 16.4% respectively. Individual patients were not consistently 
      classified as aspirin non-responders in all tests. Those with inadequate aspirin 
      response on > or =3 tests had higher TXB(2) levels (mean 1.57+/-1.66, range 
      0.553-4.45 vs mean 0.45+/-0.18, range 0.23-1.50) (p=0.001). Clopidogrel 
      suppressed TXB(2) (p=0.02), WBA-AA (p<0.001), WBA-Col1 (p=0.012) and WBA-ADP 
      (p<0.001) compared to controls. TXB(2) in patients ingesting fish oil tablets was 
      lower compared to those without (0.4 ng/ml vs 0.52 ng/ml, p=0.004). Obesity was 
      associated with higher TXB(2) values (0.61 vs 0.41, p=0.01). CONCLUSION: Serum 
      TXB(2) measurements are a direct measure of the pharmacological effect of 
      aspirin, are easily performed and correlate with other measures of platelet 
      function. Serum TXB(2) measurements could be a useful sole measure of aspirin 
      non-response, and may be even more predictive when performed in tandem with a 
      global measure of platelet function. Aspirin and clopidogrel both suppressed 
      several platelet pathways.
CI  - Crown Copyright 2009. Published by Elsevier B.V. All rights reserved.
FAU - Kidson-Gerber, Giselle
AU  - Kidson-Gerber G
AD  - South Eastern Area Laboratory Services, Department of Haematology, Prince of 
      Wales Hospital, Sydney, Australia. 
      Giselle.Kidson-Gerber@sesiahs.health.nsw.gov.au
FAU - Weaver, James
AU  - Weaver J
FAU - Gemmell, Rosalie
AU  - Gemmell R
FAU - Prasan, Ananth M
AU  - Prasan AM
FAU - Chong, Beng Hock
AU  - Chong BH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100207
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
RN  - 0 (Fish Oils)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Cardiovascular Diseases/*drug therapy
MH  - Case-Control Studies
MH  - Clopidogrel
MH  - Female
MH  - Fish Oils
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors
MH  - Platelet Function Tests
MH  - Statistics as Topic
MH  - Statistics, Nonparametric
MH  - Surveys and Questionnaires
MH  - Thromboxane B2/*blood
MH  - Ticlopidine/analogs & derivatives/therapeutic use
EDAT- 2010/02/11 06:00
MHDA- 2011/06/03 06:00
CRDT- 2010/02/11 06:00
PHST- 2009/08/24 00:00 [received]
PHST- 2009/11/09 00:00 [revised]
PHST- 2009/11/11 00:00 [accepted]
PHST- 2010/02/11 06:00 [entrez]
PHST- 2010/02/11 06:00 [pubmed]
PHST- 2011/06/03 06:00 [medline]
AID - S1443-9506(09)01103-2 [pii]
AID - 10.1016/j.hlc.2009.11.002 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2010 Apr;19(4):234-42. doi: 10.1016/j.hlc.2009.11.002. Epub 2010 
      Feb 7.

PMID- 11535875
OWN - NLM
STAT- MEDLINE
DCOM- 20010927
LR  - 20191025
IS  - 0959-8278 (Print)
IS  - 0959-8278 (Linking)
VI  - 10
IP  - 4
DP  - 2001 Aug
TI  - APACC, a French prospective study on aspirin efficacy in reducing colorectal 
      adenoma recurrence: design and baseline findings.
PG  - 327-35
AB  - Colorectal cancer is the second most frequent cause of death from cancer in 
      western countries. Many lines of evidence suggest that non-steroidal 
      anti-inflammatory drugs (NSAIDs) may offer chemoprevention against colorectal 
      cancer. A multicentre, double-blind, randomized, controlled trial is underway to 
      determine the efficacy of regular aspirin intake (160 or 300 mg/day) in reducing 
      colorectal adenoma recurrence. We now report the baseline characteristics of 
      subjects enrolled into the trial. RESULTS: A total of 618 polyps were excised 
      from 274 patients at the baseline colonoscopy. Men had on average (+/-SD) 2.5 +/- 
      1.8 polyps per subject and women had 1.7 +/- 1.2. Ninety-one (33.7%) had three or 
      more adenomas and 183 (67.8%) had more than one adenoma measuring 10 mm or more 
      in diameter. The mean (+/-SD) age of the subjects was 57.7 (+/- 9.4) years. 
      Sixty-seven (24.9%) reported that they had previously had adenoma(s), 95 (35.2%) 
      reported a family history of colorectal cancer and 41 (15.2%) a family history of 
      colorectal adenomas. PERSPECTIVE: All subjects will undergo a one-year clearance 
      colonoscopy by February 2001. Clinical, molecular biological and dietary data 
      will enable us to investigate other factors influencing the recurrence of 
      adenomas in this group of high-risk subjects.
FAU - Benamouzig, R
AU  - Benamouzig R
AD  - Service de gastro-enterologie, Hôpital Avicenne, 125 rue de Stalingrad, 93009 
      Bobigny Cedex, France. robert.benamouzig@avc.ap-hop-paris.fr
FAU - Yoon, H
AU  - Yoon H
FAU - Little, J
AU  - Little J
FAU - Martin, A
AU  - Martin A
FAU - Couturier, D
AU  - Couturier D
FAU - Deyra, J
AU  - Deyra J
FAU - Coste, T
AU  - Coste T
FAU - Chaussade, S
AU  - Chaussade S
CN  - APACC Study Group. Association pour la Prevention par Aspirine du Cancer 
      Colorectal
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Cancer Prev
JT  - European journal of cancer prevention : the official journal of the European 
      Cancer Prevention Organisation (ECP)
JID - 9300837
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/pathology/*prevention & control
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Colonoscopy
MH  - Colorectal Neoplasms/pathology/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*prevention & control
MH  - Prospective Studies
MH  - Research Design
MH  - Risk Factors
EDAT- 2001/09/06 10:00
MHDA- 2001/09/28 10:01
CRDT- 2001/09/06 10:00
PHST- 2001/09/06 10:00 [pubmed]
PHST- 2001/09/28 10:01 [medline]
PHST- 2001/09/06 10:00 [entrez]
AID - 10.1097/00008469-200108000-00006 [doi]
PST - ppublish
SO  - Eur J Cancer Prev. 2001 Aug;10(4):327-35. doi: 10.1097/00008469-200108000-00006.

PMID- 35590161
OWN - NLM
STAT- MEDLINE
DCOM- 20220523
LR  - 20220608
IS  - 2666-6340 (Electronic)
IS  - 2666-6340 (Linking)
VI  - 2
IP  - 3
DP  - 2021 Mar 12
TI  - Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS 
      ushers in a new day in atherothrombotic risk reduction.
PG  - 233-242
LID - S2666-6340(20)30005-2 [pii]
LID - 10.1016/j.medj.2020.05.003 [doi]
AB  - Inhibiting thrombosis is a cornerstone of vascular protection. Antiplatelet 
      therapies, like aspirin and P2Y(12) inhibitors, are used to prevent thrombosis 
      and are widely endorsed in current clinical practice recommendations. Recent data 
      suggest that "dual anti-thrombotic pathway inhibition" targeting platelets and 
      coagulation may further reduce the residual atherosclerotic risk. This innovative 
      thesis was tested in the COMPASS (Cardiovascular Outcomes for People Using 
      Anticoagulation Strategies) trial, which demonstrated that a combination of 
      aspirin and low-dose rivaroxaban (2.5 mg twice daily) reduced cardiovascular 
      events (including mortality) in patients with stable coronary or peripheral 
      artery disease. Here we offer a bench-to-bedside synopsis of this important 
      translational advance for clinicians and scientists. We focus specifically on 
      patient subgroups that appear to derive the greatest absolute risk reduction, 
      including those with polyvascular disease, type 2 diabetes, heart failure, and 
      renal disease. In addition, we provide a practical algorithm to help clinicians 
      determine whether to switch their patients to dual anti-thrombotic pathway 
      inhibition.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Verma, Subodh
AU  - Verma S
AD  - Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's 
      Hospital, Unity Health Toronto, Toronto, ON, Canada; Department of Surgery, 
      University of Toronto, Toronto, ON, Canada. Electronic address: 
      subodh.verma@unityhealth.to.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada; Population 
      Health Research Institute, Hamilton, ON, Canada; Thrombosis and Atherosclerosis 
      Research Institute, Hamilton, ON, Canada.
FAU - Al-Omran, Mohammed
AU  - Al-Omran M
AD  - Department of Surgery, University of Toronto, Toronto, ON, Canada; Division of 
      Vascular Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Unity 
      Health Toronto, Toronto, ON, Canada.
FAU - Choi, Richard
AU  - Choi R
AD  - Division of Cardiology, St Joseph's Health Centre, Unity Health Toronto, Toronto, 
      ON, Canada.
FAU - Heffernan, Michael
AU  - Heffernan M
AD  - Division of Cardiology, Oakville-Trafalgar Memorial Hospital, Oakville, ON, 
      Canada.
FAU - Teoh, Hwee
AU  - Teoh H
AD  - Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's 
      Hospital, Unity Health Toronto, Toronto, ON, Canada; Division of Endocrinology 
      and Metabolism, Li Ka Shing Knowledge Institute of St Michael's Hospital, Unity 
      Health Toronto, Toronto, ON, Canada.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200704
PL  - United States
TA  - Med
JT  - Med (New York, N.Y.)
JID - 101769215
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Reduction Behavior
MH  - *Thrombosis/drug therapy
COIS- Declaration of interests S.V. holds a Tier 1 Canada Research Chair in 
      Cardiovascular Surgery and reports receiving research grants and/or speaking 
      honoraria from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, 
      Bristol-Myers Squibb, Eli Lilly, EOCI Pharmacomm, HLS Therapeutics, Janssen, 
      Merck, Novartis, Novo Nordisk, Sanofi, Sun Pharmaceuticals, and the Toronto 
      Knowledge Translation Working Group. He is the President of the Canadian Medical 
      and Surgical Knowledge Translation Research Group, a federally incorporated 
      not-for-profit physician organization. J.W.E. reports receiving honoraria and/or 
      research support from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, DSI, 
      Janssen, Pfizer, and Portola. R.C. reports receiving honoraria and/or research 
      support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS 
      Therapeutics, Novartis, Sanofi, Servier, and Bristol-Myers Squibb/Pfizer. M.H. 
      reports receiving honoraria and research support from AstraZeneca and Bayer. 
      D.L.B. reports the following: Advisory Board: Cardax, Cereno Scientific, Elsevier 
      Practice Update Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, 
      and Regado Biosciences; Board of Directors: Boston VA Research Institute, Society 
      of Cardiovascular Patient Care, and TobeSoft; Chair: American Heart Association 
      Quality Oversight Committee; Data Monitoring Committee: Baim Institute for 
      Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO 
      trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for 
      the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo 
      Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi 
      Sankyo), and Population Health Research Institute; honoraria: American College of 
      Cardiology (Senior Associate Editor, Clinical Trials and News, and American 
      College of Cardiology; Vice-Chair, ACC Accreditation Committee), Baim Institute 
      for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI 
      clinical trial steering committee funded by Boehringer Ingelheim, AEGIS-II 
      executive committee funded by CSL Behring), Belvoir Publications (Editor in 
      Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial 
      steering committees, including for the PRONOUNCE trial, funded by Ferring 
      Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), 
      Journal of the American College of Cardiology (Guest Editor; Associate Editor), 
      Medtelligence/ReachMD (CME steering committees), Level Ex, MJH Life Sciences, 
      Population Health Research Institute (for the COMPASS operations committee, 
      publications committee, steering committee, and USA national co-leader, funded by 
      Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s 
      Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), 
      WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), 
      NCDR-ACTION Registry Steering Committee (Chair), and VA CART Research and 
      Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, 
      Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, 
      Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest 
      Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, 
      Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, and The 
      Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A 
      Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston 
      Scientific, CSI, St. Jude Medical (now Abbott), and Svelte; Trustee: American 
      College of Cardiology; and Unfunded Research: FlowCo, Merck, Novo Nordisk, and 
      Takeda. All other authors indicate no relevant duality of interests to declare.
EDAT- 2021/03/12 00:00
MHDA- 2022/05/24 06:00
CRDT- 2022/05/19 23:41
PHST- 2020/05/02 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2022/05/19 23:41 [entrez]
PHST- 2021/03/12 00:00 [pubmed]
PHST- 2022/05/24 06:00 [medline]
AID - S2666-6340(20)30005-2 [pii]
AID - 10.1016/j.medj.2020.05.003 [doi]
PST - ppublish
SO  - Med. 2021 Mar 12;2(3):233-242. doi: 10.1016/j.medj.2020.05.003. Epub 2020 Jul 4.

PMID- 26642781
OWN - NLM
STAT- MEDLINE
DCOM- 20161222
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 22
IP  - 13
DP  - 2016
TI  - Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, 
      and Ticagrelor.
PG  - 1918-32
AB  - Antiplatelet drugs are the cornerstone of therapy in many cardiovascular 
      conditions. With the current success and increased use of transcatheter aortic 
      valve implantation (TAVI), the use of antiplatelet therapy is considered part of 
      the medical therapy for these patients. Clinicians caring for these patients need 
      to have a thorough understanding of the pharmacology, pharmacokinetics, 
      pharmacodynamic, and clinical efficacy and safety of commonly used antiplatelet 
      therapy. While aspirin therapy is widely used, dual antiplatelet therapy with 
      clopidogrel has become part of standard of care. Despite the extensive experience 
      with clopidogrel, there are limitations such as drug interactions, metabolism 
      genetic polymorphisms, and variability in the antiplatelet response. More 
      predictable and more potent antiplatelet agents, prasugrel and ticagrelor, have 
      demonstrated superior reductions in ischemic endpoints as part of dual 
      antiplatelet therapy compared to clopidogrel, but at the cost of more major 
      bleeding in patients with an acute coronary syndrome. Significant research needs 
      to be conducted in the setting of TAVI to help define the optimal antiplatelet 
      regimen.
FAU - Dobesh, Paul P
AU  - Dobesh PP
AD  - Professor of Pharmacy Practice, College of Pharmacy, University of Nebraska 
      Medical Center, Omaha, NE, 68198-6045, USA. pdobesh@unmc.edu.
FAU - Varnado, Sara
AU  - Varnado S
FAU - Doyle, Meagan
AU  - Doyle M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine/*analogs & derivatives/chemical synthesis/chemistry/therapeutic use
MH  - Aspirin/chemical synthesis/chemistry/*therapeutic use
MH  - Cardiovascular Diseases/*therapy
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Aggregation Inhibitors/chemical synthesis/chemistry/*therapeutic use
MH  - Prasugrel Hydrochloride/chemical synthesis/chemistry/*therapeutic use
MH  - Ticagrelor
MH  - Ticlopidine/*analogs & derivatives/chemical synthesis/chemistry/therapeutic use
MH  - Transcatheter Aortic Valve Replacement/*adverse effects
EDAT- 2015/12/09 06:00
MHDA- 2016/12/23 06:00
CRDT- 2015/12/09 06:00
PHST- 2015/10/19 00:00 [received]
PHST- 2015/12/07 00:00 [accepted]
PHST- 2015/12/09 06:00 [entrez]
PHST- 2015/12/09 06:00 [pubmed]
PHST- 2016/12/23 06:00 [medline]
AID - CPD-EPUB-72330 [pii]
AID - 10.2174/1381612822666151208120106 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2016;22(13):1918-32. doi: 10.2174/1381612822666151208120106.

PMID- 7140494
OWN - NLM
STAT- MEDLINE
DCOM- 19830127
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 27
IP  - 11
DP  - 1982 Nov
TI  - Resistance to medical therapy of gastric ulcers in rheumatic disease patients 
      taking aspirin. A double-blind study with cimetidine and follow-up.
PG  - 976-80
AB  - Little is known about healing or recurrence of aspirin-induced gastric ulcers if 
      aspirin intake is continued. A double-blind controlled study compared cimetidine 
      plus antacids as needed (prn) with placebo plus prn antacids in healing 
      aspirin-associated gastric ulcers during continued salicylate ingestion in 18 
      rheumatic disease patients over a 2-month period. Healing occurred in 44% of the 
      placebo and 56% of the cimetidine-treated patients (P greater than 0.05). 
      Subjects in both groups ingested potentially therapeutic doses of antacid. Ulcer 
      size had an effect on healing rate, irrespective of treatment. Ninety percent of 
      gastric ulcers less than 0.5 cm in diameter healed in 2 months but only 25% of 
      ulcers greater than 0.5 cm. Six of seven patients with unhealed ulcers at 2 
      months eventually healed medically at intervals of 6--26 months. Of 11 patients 
      managed medically and followed endoscopically for a mean of 15 months after 
      healing, only one had a recurrent ulcer. In conclusion, placebo and antacid 
      therapy were as effective as cimetidine and antacids in healing ulcers over a 
      2-month period. In spite of continued aspirin intake, most benign gastric ulcers 
      less than 0.5 cm in diameter heal medically in two months. Aspirin-induced ulcers 
      greater than or equal to 1 cm in diameter are relatively resistant to therapy but 
      can be healed with prolonged cimetidine and antacid treatment; once healed, 
      recurrence rate is low with prophylactic therapy even with continued aspirin 
      intake.
FAU - O'Laughlin, J C
AU  - O'Laughlin JC
FAU - Silvoso, G K
AU  - Silvoso GK
FAU - Ivey, K J
AU  - Ivey KJ
LA  - eng
GR  - RR00287-12/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Antacids)
RN  - 0 (Guanidines)
RN  - 0 (Placebos)
RN  - 80061L1WGD (Cimetidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antacids/*administration & dosage
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cimetidine/*administration & dosage
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Guanidines/*administration & dosage
MH  - Humans
MH  - Placebos
MH  - Prospective Studies
MH  - Rheumatic Heart Disease/drug therapy
MH  - Stomach Ulcer/chemically induced/*drug therapy
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
AID - 10.1007/BF01391742 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1982 Nov;27(11):976-80. doi: 10.1007/BF01391742.

PMID- 35976924
OWN - NLM
STAT- MEDLINE
DCOM- 20220819
LR  - 20220823
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 8
DP  - 2022
TI  - Physiologically based modelling of the antiplatelet effect of aspirin: A tool to 
      characterize drug responsiveness and inform precision dosing.
PG  - e0268905
LID - 10.1371/journal.pone.0268905 [doi]
LID - e0268905
AB  - A computational approach involving mathematical modeling and in silico 
      experiments was used to characterize the determinants of extent and duration of 
      platelet cyclooxygenase (COX)-1 inhibition by aspirin and design precision dosing 
      in patients with accelerated platelet turnover or reduced drug bioavailability. 
      To this purpose, a recently developed physiologically-based pharmacokinetics (PK) 
      and pharmacodynamics (PD) model of low-dose aspirin in regenerating platelets and 
      megakaryocytes, was used to predict the main features and determinants of 
      platelet COX-1 inhibition. The response to different aspirin regimens in healthy 
      subjects and in pathological conditions associated with alterations in aspirin PK 
      (i.e., severely obese subjects) or PD (i.e., essential thrombocytemya patients), 
      were simulated. A model sensitivity analysis was performed to identify the main 
      processes influencing COX-1 dynamics. In silico experiments and sensitivity 
      analyses indicated a major role for megakaryocytes and platelet turnover in 
      determining the extent and duration of COX-1 inhibition by once-daily, low-dose 
      aspirin. They also showed the superiority of reducing the dosing interval vs 
      increasing the once-daily dose in conditions of increased platelet turnover, 
      while suggested specific dose adjustments in conditions of possible reduction in 
      drug bioavailability. In conclusion, the consistency of our model-based findings 
      with experimental data from studies in healthy subjects and patients with 
      essential thrombocythemia supports the potential of our approach for describing 
      the determinants of platelet inhibition by aspirin and informing precision dosing 
      which may guide personalized antithrombotic therapy in different patient 
      populations, especially in those under-represented in clinical trials or in those 
      associated with poor feasibility.
FAU - Giaretta, Alberto
AU  - Giaretta A
AD  - Department of Information Engineering, University of Padova, Padova, Italy.
AD  - Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
FAU - Petrucci, Giovanna
AU  - Petrucci G
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.
FAU - Rocca, Bianca
AU  - Rocca B
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.
FAU - Toffolo, Gianna Maria
AU  - Toffolo GM
AD  - Department of Information Engineering, University of Padova, Padova, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220817
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Blood Platelets
MH  - Humans
MH  - Models, Theoretical
MH  - Obesity/drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Thrombocythemia, Essential/drug therapy
PMC - PMC9385056
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/08/18 06:00
MHDA- 2022/08/20 06:00
CRDT- 2022/08/17 13:43
PHST- 2021/10/25 00:00 [received]
PHST- 2022/05/11 00:00 [accepted]
PHST- 2022/08/17 13:43 [entrez]
PHST- 2022/08/18 06:00 [pubmed]
PHST- 2022/08/20 06:00 [medline]
AID - PONE-D-21-34163 [pii]
AID - 10.1371/journal.pone.0268905 [doi]
PST - epublish
SO  - PLoS One. 2022 Aug 17;17(8):e0268905. doi: 10.1371/journal.pone.0268905. 
      eCollection 2022.

PMID- 16531594
OWN - NLM
STAT- MEDLINE
DCOM- 20060524
LR  - 20181201
IS  - 1553-2712 (Electronic)
IS  - 1069-6563 (Linking)
VI  - 13
IP  - 4
DP  - 2006 Apr
TI  - A community intervention by firefighters to increase 911 calls and aspirin use 
      for chest pain.
PG  - 389-95
AB  - OBJECTIVES: To test the effectiveness of an intervention, delivered face-to-face 
      by local firefighters, designed to increase utilization of 911 and 
      self-administration of aspirin for seniors experiencing chest pain. METHODS: King 
      County, Washington was divided into 126 geographically distinct areas that were 
      randomized to intervention and control areas. A mailing list identified 
      households of seniors within these areas. More than 20,000 homes in the 
      intervention areas were contacted by local firefighters. Data on all 911 calls 
      for chest pain and self-administration of aspirin were collected from the medical 
      incident report form (MIRF). The unit of analysis was the area. Firefighters 
      delivered a heart attack survival kit (that included an aspirin) and counseled 
      participants on the importance of aspirin and 911 use for chest pain. Main 
      outcome measures were 911 calls for chest pain and aspirin ingestion for a chest 
      pain event, obtained from the MIRFs that are collected by emergency medical 
      services personnel for 2 years after the intervention. RESULTS: There were 
      significantly more calls (16%) among seniors on the mailing list in the 
      intervention than control areas in the first year after the intervention. Among 
      the seniors who were not on the mailing list, there was little difference in the 
      intervention and control areas. The results were somewhat sensitive to the 
      analytical model used and to an outlier in the treatment group. CONCLUSIONS: A 
      community-based firefighter intervention can be effective in increasing 
      appropriate response to symptoms of a heart attack among elders.
FAU - Meischke, Hendrika
AU  - Meischke H
AD  - Department of Health Services, University of Washington, Seattle, WA 98195, USA. 
      hendrika@u.washington.edu
FAU - Diehr, Paula
AU  - Diehr P
FAU - Rowe, Sharon
AU  - Rowe S
FAU - Cagle, Anthony
AU  - Cagle A
FAU - Eisenberg, Mickey
AU  - Eisenberg M
LA  - eng
GR  - R01 HL63136-04/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20060310
PL  - United States
TA  - Acad Emerg Med
JT  - Academic emergency medicine : official journal of the Society for Academic 
      Emergency Medicine
JID - 9418450
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - *Chest Pain
MH  - Emergency Medical Service Communication Systems/*statistics & numerical data
MH  - Emergency Medical Services
MH  - Fires
MH  - *Health Education
MH  - Humans
MH  - Myocardial Infarction/therapy
MH  - Regression Analysis
MH  - Washington
EDAT- 2006/03/15 09:00
MHDA- 2006/05/25 09:00
CRDT- 2006/03/15 09:00
PHST- 2006/03/15 09:00 [pubmed]
PHST- 2006/05/25 09:00 [medline]
PHST- 2006/03/15 09:00 [entrez]
AID - j.aem.2005.10.021 [pii]
AID - 10.1197/j.aem.2005.10.021 [doi]
PST - ppublish
SO  - Acad Emerg Med. 2006 Apr;13(4):389-95. doi: 10.1197/j.aem.2005.10.021. Epub 2006 
      Mar 10.

PMID- 2497545
OWN - NLM
STAT- MEDLINE
DCOM- 19890616
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 53
IP  - 3
DP  - 1989 Feb 1
TI  - Response of thromboxane B2, malondialdehyde and platelet sensitivity to 3 weeks 
      low-dose aspirin (ASA) in healthy volunteers.
PG  - 261-9
AB  - To examine the effects of low-dose aspirin thromboxane B2 (TXB2), malondialdehyde 
      (MDA) and platelet sensitivity to prostaglandin I2 (PGI2) have been measured in a 
      total of 18 healthy volunteers. They were randomly assigned to 3 groups, 6 
      volunteers each, receiving either 1, 10 or 20 mg ASA orally a day for 3 weeks in 
      a double-blind fashion. In order to assess the time course of ASA-induced 
      changes, blood was drawn before, 1 hour and 2, 3, 5, 7, 9, 12, 14, 16 and 21 days 
      after the first drug-intake. Serum-TXB2 was depressed time- and dose-dependently, 
      after 1 mg daily to about 60%, after 10 mg to about 30%, after 20 mg to about 5% 
      of controls. MDA-formation and conversion of exogenously added arachidonic acid 
      (AA) to TXB2 also dropped significantly, (p less than 0.01), the extent depending 
      on the ASA-dosage administered. The drop in MDA- and TXB2-values in the 3 groups 
      correlated with r = 0.98, 0.94, 0.98, respectively. The platelet sensitivity 
      during 20 and 10 mg ASA-administration did not change at all, whereas a 
      significant increase (p less than 0.01) in platelet sensitivity during treatment 
      with 1 mg ASA was observed.
FAU - Sinzinger, H
AU  - Sinzinger H
AD  - Atherosclerosis Research Group (ASF), Vienna, Austria.
FAU - Virgolini, I
AU  - Virgolini I
FAU - Peskar, B A
AU  - Peskar BA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Arachidonic Acids)
RN  - 0 (Malonates)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 54397-85-2 (Thromboxane B2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid
MH  - Arachidonic Acids/blood
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Epoprostenol/pharmacology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Malonates/*blood
MH  - Malondialdehyde/*blood
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane B2/*blood
EDAT- 1989/02/01 00:00
MHDA- 1989/02/01 00:01
CRDT- 1989/02/01 00:00
PHST- 1989/02/01 00:00 [pubmed]
PHST- 1989/02/01 00:01 [medline]
PHST- 1989/02/01 00:00 [entrez]
AID - 0049-3848(89)90101-1 [pii]
AID - 10.1016/0049-3848(89)90101-1 [doi]
PST - ppublish
SO  - Thromb Res. 1989 Feb 1;53(3):261-9. doi: 10.1016/0049-3848(89)90101-1.

PMID- 16924685
OWN - NLM
STAT- MEDLINE
DCOM- 20070305
LR  - 20141120
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 95
IP  - 12
DP  - 2006 Dec
TI  - Towards an understanding of the structurally based potential for mechanically 
      activated disordering of small molecule organic crystals.
PG  - 2645-56
AB  - The potential for various small molecule organic crystals to undergo complete 
      mechanically induced disordering is investigated. A model is proposed, which 
      considers changes in free energy required for lattice incorporation of a critical 
      dislocation density. Application requires knowledge of a few physical properties, 
      namely the elastic shear modulus, Burgers vector magnitude, molar volume, melting 
      temperature, and heat of fusion. The model was tested using seven compounds; 
      acetaminophen, aspirin, gamma-indomethacin, salicylamide, sucrose, and two 
      proprietary drug compounds, PFZ1 and PFZ2. Crystalline solids were subjected to 
      high shear, controlled temperature comminution for various durations, after which 
      the samples were examined using powder X-ray diffraction (PXRD) and differential 
      scanning calorimetry (DSC). The results verified that acetaminophen, aspirin, and 
      salicylamide, which were suggested by the model to be resistant to complete 
      mechanical disordering, remained fully crystalline, even after 5 h of milling. 
      Sucrose and gamma-indomethacin were both predicted to be susceptible to 
      amorphization, which was confirmed by physical characterization. Single, 3-h 
      grinding experiments were performed on two proprietary compounds, PFZ1 and PFZ2. 
      The model indicated that each should be resistant to complete disordering, a 
      trend held by PFZ1. Evidence of partial disordering of PFZ2 was unexpected and is 
      discussed with respect to possible temperature effects.
CI  - (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association
FAU - Wildfong, Peter L D
AU  - Wildfong PL
AD  - Department of Pharmaceutical Sciences, Duquesne University, Mylan School of 
      Pharmacy, 600 Forbes Av., Pittsburgh, Pennsylvania 15282, USA. wildfongp@duq.edu
FAU - Hancock, Bruno C
AU  - Hancock BC
FAU - Moore, Michael D
AU  - Moore MD
FAU - Morris, Kenneth R
AU  - Morris KR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Powders)
RN  - 0 (Salicylamides)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 57-50-1 (Sucrose)
RN  - EM8BM710ZC (salicylamide)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetaminophen/chemistry
MH  - Aspirin/chemistry
MH  - Calorimetry, Differential Scanning
MH  - Crystallization
MH  - Indomethacin/chemistry
MH  - *Models, Chemical
MH  - Powders
MH  - Salicylamides/chemistry
MH  - Stress, Mechanical
MH  - Sucrose/chemistry
MH  - X-Ray Diffraction
EDAT- 2006/08/23 09:00
MHDA- 2007/03/06 09:00
CRDT- 2006/08/23 09:00
PHST- 2006/08/23 09:00 [pubmed]
PHST- 2007/03/06 09:00 [medline]
PHST- 2006/08/23 09:00 [entrez]
AID - S0022-3549(16)37302-6 [pii]
AID - 10.1002/jps.20672 [doi]
PST - ppublish
SO  - J Pharm Sci. 2006 Dec;95(12):2645-56. doi: 10.1002/jps.20672.

PMID- 10722949
OWN - NLM
STAT- MEDLINE
DCOM- 20000523
LR  - 20220331
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 198
IP  - 1
DP  - 2000 Mar 30
TI  - Improved kinetic parameter estimation in pH-profile data treatment.
PG  - 39-49
AB  - Statistical problems in temperature stability parameter estimation have been the 
      subject of many papers whereas statistics in, pH-profile parameter estimation 
      have focused little attention. However, the conventional two step method used in 
      data treatment in both cases leads to identical statistical problems. The aim of 
      this study is then to introduce a method that improves statistics in pH-profile 
      parameter estimation. A one step non-linear method that takes into account the 
      errors in drug content determination is proposed. A mathematical relationship 
      between drug content C, pH and time t is tested. The proposed method allows the 
      estimation of the specific kinetic constants and the dissociation constant 
      (pK(a)) in a single run. The most likely experimental initial drug contents 
      C(0j),. where j is the index of a given experiment, are also determined. This 
      approach that takes into account all relevant experimental information for the 
      estimation of kinetic parameters is more rigorous from a statistical viewpoint 
      than the classical two step methods. Kinetic data from acetylsalicylic acid (ASA) 
      hydrolysis was used for the tests.
FAU - Some, I T
AU  - Some IT
AD  - Laboratoire de Chimie bioanalytique, de Toxicologie et de Chimie physique 
      appliquée, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la 
      Plaine, CP 205/1 Boulevard du Triomphe, B-1050, Brussels, Belgium.
FAU - Bogaerts, P
AU  - Bogaerts P
FAU - Hanus, R
AU  - Hanus R
FAU - Hanocq, M
AU  - Hanocq M
FAU - Dubois, J
AU  - Dubois J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Aspirin/chemistry
MH  - Chromatography, High Pressure Liquid
MH  - Costs and Cost Analysis
MH  - Data Interpretation, Statistical
MH  - *Drug Stability
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Markov Chains
MH  - Nonlinear Dynamics
EDAT- 2000/03/21 09:00
MHDA- 2000/06/08 09:00
CRDT- 2000/03/21 09:00
PHST- 2000/03/21 09:00 [pubmed]
PHST- 2000/06/08 09:00 [medline]
PHST- 2000/03/21 09:00 [entrez]
AID - S0378-5173(99)00404-4 [pii]
AID - 10.1016/s0378-5173(99)00404-4 [doi]
PST - ppublish
SO  - Int J Pharm. 2000 Mar 30;198(1):39-49. doi: 10.1016/s0378-5173(99)00404-4.

PMID- 10701943
OWN - NLM
STAT- MEDLINE
DCOM- 20000308
LR  - 20220331
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 21
IP  - 4
DP  - 1999 Dec
TI  - Interaction of substituted phenoxazine chemosensitizers with bovine serum 
      albumin.
PG  - 775-85
AB  - The binding of 10-[3'-[N-bis(hydroxyethyl)amino]propyl]phenoxazine [BPP], 
      10-[3'-[N-bis(hydroxyethyl)amino]propyl]-2-chlorophenoxazine [BPCP], 
      10-[3'-[N-bis-(hydroxyethyl)amino]propyl]-2-trifluoromethylphenoxazin e [BPFP], 
      10-(3'-N-pyrrolidino propyl)-2-chlorophenoxazine [PPCP] or 
      10-(3'-N-pyrrolidinopropyl)-2-trifluoromethylphenoxazine [PPFP] to bovine serum 
      albumin (BSA) has been measured by gel filtration and equilibrium dialysis 
      methods. The binding of these modulators to bovine serum albumin based on 
      dialysis experiments has been characterized by the following parameters: 
      percentage (beta) of bound drug, the association constant 'K1', the apparent 
      binding constant 'k' and the free energy deltaFdegrees. The binding of 
      phenoxazine derivatives to bovine serum albumin is correlated with their 
      octanol-water partition coefficient, log10P. In addition, the displacing activity 
      of hydroxyzine and acetylsalicylic acid on the binding of phenoxazines to albumin 
      has been studied. The results of the displacing experiments showed that the 
      phenoxazine benzene rings and the tertiary amines attached to the side chain of 
      the phenoxazine moiety are bound to a hydrophobic area on the albumin molecule.
FAU - Channu, B C
AU  - Channu BC
AD  - Department of Studies in Chemistry, University of Mysore, Manasagangotri, India.
FAU - Kalpana, H N
AU  - Kalpana HN
FAU - Eregowda, G B
AU  - Eregowda GB
FAU - Dass, C
AU  - Dass C
FAU - Houghton, P J
AU  - Houghton PJ
FAU - Thimmaiah, K N
AU  - Thimmaiah KN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Oxazines)
RN  - 27432CM55Q (Serum Albumin, Bovine)
RN  - 30S50YM8OG (Hydroxyzine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Binding Sites
MH  - Binding, Competitive
MH  - Chromatography, Gel
MH  - Dialysis
MH  - Drug Interactions
MH  - Drug Resistance, Multiple
MH  - Hydroxyzine/chemistry
MH  - Oxazines/*chemistry
MH  - Serum Albumin, Bovine/*chemistry
EDAT- 2000/03/04 09:00
MHDA- 2000/03/11 09:00
CRDT- 2000/03/04 09:00
PHST- 2000/03/04 09:00 [pubmed]
PHST- 2000/03/11 09:00 [medline]
PHST- 2000/03/04 09:00 [entrez]
AID - S0731-7085(99)00187-9 [pii]
AID - 10.1016/s0731-7085(99)00187-9 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1999 Dec;21(4):775-85. doi: 10.1016/s0731-7085(99)00187-9.

PMID- 8714491
OWN - NLM
STAT- MEDLINE
DCOM- 19961023
LR  - 20131121
IS  - 0210-0010 (Print)
IS  - 0210-0010 (Linking)
VI  - 24
IP  - 126
DP  - 1996 Feb
TI  - [Antiaggregant treatment for cerebral ischemia: ticlopidine versus aspirin].
PG  - 214-8
AB  - INTRODUCTION: There at present exists marked controversy as to the possible 
      greater efficacy of ticlopidine as opposed to aspirin in brain ischaemia 
      secondary prophylaxis. In our study we compare the efficacy and safety of 
      antiaggregant treatment with ticlopidine as opposed to aspirin in a group of 310 
      patients admitted to the 'Hospital Mutua de Terrassa' between the years 1990 and 
      1994. RESULTS: In the group of patients treated with ticlopidine we found a 
      larger number of new cerebrovascular incidents (p = 0.02) and peripheral vascular 
      incidents (p = 0.01). New cerebrovascular incidents were more frequent in males 
      (p = 0.03), in those patients with substantiated infarct (p = 0.02) and in 
      patients with ischaemia in the carotidal region (p = 0.04). On the other hand, 
      the group of patients treated with ticlopidine presented more secondary effects 
      than the group treated with aspirin at the digestive (p < 0.001) and haematologic 
      (p < 0.001) levels. The most frequent digestive secondary effects were diarrhoea 
      (p < 0.001) and hepatopathy (p = 0.02); abnormalities in the leucocyte count were 
      more frequent in patients treated with ticlopidine (p < 0.001), neutropenia being 
      found in 0.8% of cases. CONCLUSION: In the patients we studied ticlopidine was 
      less efficacious than aspirin in the secondary prophylaxis of new vascular 
      incidents (both cerebrovascular and peripheral vascular) and also presented a 
      greater incidence of secondary (digestive and haematological) effects.
FAU - Rey, A
AU  - Rey A
AD  - Servicio de Neurología, Unidad de Vigilancia intensiva, Barcelona.
FAU - Aguilar, M
AU  - Aguilar M
FAU - Bonaventura, I
AU  - Bonaventura I
FAU - Martínez, I
AU  - Martínez I
FAU - Quintana, S
AU  - Quintana S
LA  - spa
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Tratamiento antiagregante en la isquemia cerebral: ticlopidina frente aspirina.
PL  - Spain
TA  - Rev Neurol
JT  - Revista de neurologia
JID - 7706841
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Brain Ischemia/*drug therapy/physiopathology/prevention & control
MH  - Carotid Arteries/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - Ticlopidine/administration & dosage/*therapeutic use
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
PST - ppublish
SO  - Rev Neurol. 1996 Feb;24(126):214-8.

PMID- 8437779
OWN - NLM
STAT- MEDLINE
DCOM- 19930322
LR  - 20131121
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 81
IP  - 3
DP  - 1993 Mar
TI  - Production of prostacyclin and thromboxane in lupus pregnancies: effect of small 
      dose of aspirin.
PG  - 327-31
AB  - OBJECTIVES: To find out whether the tendency toward poor outcome in lupus 
      pregnancies could be explained by changes in prostacyclin/thromboxane production, 
      to relate these changes to the presence of antiphospholipid antibodies, and to 
      study the potential benefits of low-dose aspirin. METHODS: We followed the 
      urinary output of prostacyclin metabolites (6-keto-prostaglandin [PG]F1 alpha, 
      2,3-dinor-6-keto-PGF1 alpha) and thromboxane metabolites (thromboxane B2, 
      2,3-dinor-thromboxane B2) using high-pressure liquid chromatography followed by 
      radioimmunoassay. We studied 14 pregnant women with systemic lupus erythematosus 
      (SLE), of whom six had detectable antiphospholipid antibodies. The patients were 
      randomized by a computerized program to receive either 50 mg aspirin daily (six 
      women) or placebo (eight women). Nine healthy pregnant women served as controls. 
      RESULTS: The production of prostacyclin was normal in early pregnancy in SLE 
      patients but was reduced during late gestation in those without antiphospholipid 
      antibodies. The production of thromboxane was increased in SLE patients compared 
      with controls, and this increase was highest (two-to threefold rise) when 
      antiphospholipid antibodies were detectable. Aspirin eliminated thromboxane 
      dominance without affecting prostacyclin production. CONCLUSION: These data 
      suggest that the presence of antiphospholipid antibodies in SLE patients may 
      trigger thromboxane dominance, possibly contributing to the adverse outcome of 
      these pregnancies. This thromboxane dominance can be eliminated with aspirin.
FAU - Kaaja, R
AU  - Kaaja R
AD  - Department I of Obstetrics and Gynecology, University Central Hospital of 
      Helsinki, Finland.
FAU - Julkunen, H
AU  - Julkunen H
FAU - Viinikka, L
AU  - Viinikka L
FAU - Ylikorkala, O
AU  - Ylikorkala O
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Thromboxanes)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antibodies, Antiphospholipid/*analysis
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Chromatography, High Pressure Liquid
MH  - Epoprostenol/*biosynthesis
MH  - Female
MH  - Humans
MH  - Lupus Erythematosus, Systemic/immunology/*metabolism
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy/immunology/metabolism
MH  - Pregnancy Outcome
MH  - Radioimmunoassay
MH  - Thromboxanes/*biosynthesis
EDAT- 1993/03/01 00:00
MHDA- 1993/03/01 00:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 1993/03/01 00:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
PST - ppublish
SO  - Obstet Gynecol. 1993 Mar;81(3):327-31.

PMID- 1304414
OWN - NLM
STAT- MEDLINE
DCOM- 19930708
LR  - 20180215
IS  - 0008-6312 (Print)
IS  - 0008-6312 (Linking)
VI  - 81
IP  - 6
DP  - 1992
TI  - Combined effect of captopril and aspirin in renal hemodynamics in elderly 
      patients with congestive heart failure.
PG  - 334-9
AB  - Captopril and aspirin have been claimed to adversely affect renal function. This 
      study was designed to evaluate the safety of concomitant administration of both 
      drugs in patients with moderate to severe congestive heart failure (CHF). The 
      study group consisted of 10 patients with a mean age of 77.6 +/- 4.4 years and a 
      mean New York Heart Association functional class of 2.6 +/- 0.5. Captopril was 
      administered in a rapidly escalating dose regimen over a 4-day period to a 
      maximum dose of 75 mg/day. Aspirin 0.25 g/day was added from day 5 on. Renal 
      plasma flow (RPF) was measured by iodohippurate scan and the creatinine clearance 
      test (Ccr) was used as an index of glomerular filtration rate (GFR). Both Ccr and 
      RPF remained unchanged throughout the study period; 48.9 +/- 16; 48.2 +/- 16.5; 
      49.4 +/- 16, and 222 +/- 67, 241 +/- 97, 237 +/- 88 ml/min, for days 0, 4, 9, 
      respectively. Only 1 patient developed a significant decrease in Ccr following 
      the administration of captopril. This patient had a further decrease when aspirin 
      was added. The decrease in Ccr was accompanied by a marked reduction in 
      filtration fraction and in mean arterial pressure. Our data suggest that the 
      administration of aspirin to elderly patients with moderate CHF treated with 
      captopril is relatively safe and is not associated with further deterioration in 
      renal function.
FAU - Schwartz, D
AU  - Schwartz D
AD  - Department of Medicine T, Ichilov Hospital, Tel-Aviv Sourasky Medical Center, 
      Israel.
FAU - Kornowski, R
AU  - Kornowski R
FAU - Lehrman, H
AU  - Lehrman H
FAU - Averbuch, M
AU  - Averbuch M
FAU - Pines, A
AU  - Pines A
FAU - Greenland, M
AU  - Greenland M
FAU - Finkelstein, A
AU  - Finkelstein A
FAU - Levo, Y
AU  - Levo Y
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
RN  - 0 (Electrolytes)
RN  - 9G64RSX1XD (Captopril)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Flow Velocity/drug effects
MH  - Captopril/administration & dosage/*adverse effects
MH  - Creatinine/blood
MH  - Drug Therapy, Combination
MH  - Electrolytes/blood
MH  - Female
MH  - Heart Failure/*drug therapy
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Kidney/*blood supply
MH  - Kidney Function Tests
MH  - Male
MH  - Myocardial Ischemia/drug therapy
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1159/000175826 [doi]
PST - ppublish
SO  - Cardiology. 1992;81(6):334-9. doi: 10.1159/000175826.

PMID- 21515026
OWN - NLM
STAT- MEDLINE
DCOM- 20110816
LR  - 20161209
IS  - 2213-0276 (Electronic)
IS  - 0755-4982 (Linking)
VI  - 40
IP  - 6
DP  - 2011 Jun
TI  - [Cardiopulmonary resuscitation, new recommendations].
PG  - 639-43
LID - 10.1016/j.lpm.2011.01.028 [doi]
AB  - A procedure for telephone CPR must be started since the call centres do the 
      diagnosis of cardiac arrest. All the rescuers, trained or not, have to realize 
      quality chest compressions (depths 5 in 6cm, rhythm from 100 to 120 per minute) 
      to the victims of cardiac arrest. Chest compressions must be interrupted only 
      briefly in case of indispensable specific interventions. The trained rescuers 
      have to realize insufflations during the CPR, with a ratio 
      compression-ventilation of 30/2. The development of AE programs is encouraged. A 
      more important deployment of AED is necessary in public places and residential 
      areas. The use of the acetylsalicylic acid by witnesses, in case of cardiac 
      arrest, is authorized with or without the assistance of the medical dispatcher of 
      the EMS. The administration of medicines by endotracheal tube is not any more 
      recommended. If the intravenous access cannot be used, it is the intra-osseous, 
      which would be privileged. In case of children cardiac arrest, the 
      non-professional rescuer have to use a ratio of 30 compressions for two 
      ventilations if he is alone and 15/2 if they are working in team. All the 
      citizens, and all the healthcare providers, should be trained in CPR and to keep 
      their skills should follow all three to six months refresher courses to upgrade 
      their knowledge.
CI  - Copyright © 2011. Published by Elsevier Masson SAS.
FAU - Cassan, Pascal
AU  - Cassan P
AD  - Croix-Rouge française, 98, rue Didot, 75014 Paris, France. 
      pascal.cassan@croix-rouge.fr
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Réanimation cardiopulmonaire : nouvelles recommandations.
DEP - 20110422
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Advanced Cardiac Life Support/methods/standards
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cardiopulmonary Resuscitation/education/methods/*standards
MH  - Chest Wall Oscillation/methods
MH  - Child
MH  - Defibrillators/supply & distribution
MH  - Emergency Medical Services/methods/standards
MH  - First Aid/methods/standards
MH  - Humans
MH  - *Practice Guidelines as Topic
EDAT- 2011/04/26 06:00
MHDA- 2011/08/17 06:00
CRDT- 2011/04/26 06:00
PHST- 2011/01/07 00:00 [received]
PHST- 2011/01/14 00:00 [accepted]
PHST- 2011/04/26 06:00 [entrez]
PHST- 2011/04/26 06:00 [pubmed]
PHST- 2011/08/17 06:00 [medline]
AID - S0755-4982(11)00143-6 [pii]
AID - 10.1016/j.lpm.2011.01.028 [doi]
PST - ppublish
SO  - Presse Med. 2011 Jun;40(6):639-43. doi: 10.1016/j.lpm.2011.01.028. Epub 2011 Apr 
      22.

PMID- 6971045
OWN - NLM
STAT- MEDLINE
DCOM- 19810513
LR  - 20200304
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 10
IP  - 5
DP  - 1980 Nov
TI  - Anti-inflammatory/anti-pyretic salicylic acid esters with low gastric ulcerogenic 
      activity.
PG  - 451-6
AB  - The methyl and some other esters of acetylsalicylic and salicylic acids and their 
      derivatives were found to have much lower gastric ulcerogenic activity (when 
      assayed in the stress-sensitized rat) compared with their corresponding acids. 
      There was little or no loss in therapeutic potencies of these salicylate esters 
      as determined by assessment of anti-inflammatory activity (against the 
      carrageenan-induced oedema) and antipyretic activity (against yeast-induced fever 
      in rats. The methyl ester of acetylsalicylic acid (=AME) was almost devoid of 
      gastric irritancy/ulcerogenicity (as observed with acetylsalicylic acid) when 
      given orally to pigs for 10 days. AME had appreciable anti-inflammatory activity 
      in the adjuvant-arthritis model and at high doses (200 mg/kg t.i.d.) was without 
      the lethal effects seen with acetylsalicylic acid. Moreover, no toxic effects 
      were seen after long-term administration of 100-1000 mg/kg/day AME for 3-4 
      months. The results provide further evidence for the hypothesis that the 
      carboxylic acid moiety of salicylates is a major factor in the gastric 
      ulcerogenic activity of these drugs. The methyl esters of these salicylates may 
      be considered as models for the development of pro-drugs and in some cases may be 
      therapeutic alternatives to acetylsalicylic acid or salicylate.
FAU - Rainsford, K D
AU  - Rainsford KD
FAU - Whitehouse, M W
AU  - Whitehouse MW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*toxicity
MH  - Anti-Inflammatory Agents, Non-Steroidal/*toxicity
MH  - Aspirin/*analogs & derivatives/toxicity
MH  - Drug Evaluation, Preclinical
MH  - Female
MH  - Male
MH  - Rats
MH  - Salicylates/*toxicity
MH  - Stomach Ulcer/*chemically induced
MH  - Structure-Activity Relationship
MH  - Swine
EDAT- 1980/11/01 00:00
MHDA- 1980/11/01 00:01
CRDT- 1980/11/01 00:00
PHST- 1980/11/01 00:00 [pubmed]
PHST- 1980/11/01 00:01 [medline]
PHST- 1980/11/01 00:00 [entrez]
AID - 10.1007/BF01968046 [doi]
PST - ppublish
SO  - Agents Actions. 1980 Nov;10(5):451-6. doi: 10.1007/BF01968046.

PMID- 15342146
OWN - NLM
STAT- MEDLINE
DCOM- 20041122
LR  - 20131121
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 368
IP  - 1
DP  - 2004 Sep 16
TI  - Spinal cholinergic involvement after treatment with aspirin and paracetamol in 
      rats.
PG  - 116-20
AB  - Aspirin and paracetamol have been shown to suppress non-inflammatory pain 
      conditions like thermal, visceral and mechanical pain in mice and rats. The 
      non-inflammatory antinociception appears to be mediated by central receptor 
      mechanisms, such as the cholinergic system. In this study, we tested the 
      hypothesis that the non-inflammatory antinociception of aspirin and paracetamol 
      could be mediated by an increase of intraspinal acetylcholine release. 
      Microdialysis probes were placed intraspinally in anesthetized rats for 
      acetylcholine sampling. Subcutaneously administered aspirin 100 and 300 mg/kg 
      increased, while paracetamol 300 mg/kg decreased intraspinal acetylcholine 
      release. Intraspinal drug administration did not affect acetylcholine release. 
      Our results suggest that an increased intraspinal acetylcholine release could be 
      involved in part of the non-inflammatory pain suppression by aspirin, but not by 
      paracetamol.
FAU - Abelson, Klas S P
AU  - Abelson KS
AD  - Department of Neuroscience, Division of Comparative Medicine, Biomedical Center, 
      Uppsala University, P.O. Box 572, S-751 23 Uppsala, Sweden. 
      klas.abelson@fysiologi.uu.se
FAU - Kommalage, Mahinda
AU  - Kommalage M
FAU - Höglund, A Urban
AU  - Höglund AU
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Acetylcholine/pharmacology
MH  - Analgesics, Non-Narcotic/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Body Temperature/drug effects
MH  - Injections, Subcutaneous
MH  - Male
MH  - Microdialysis
MH  - Pain/physiopathology
MH  - Parasympathetic Nervous System/*physiology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Spinal Cord/*physiology
EDAT- 2004/09/03 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/09/03 05:00
PHST- 2004/06/07 00:00 [received]
PHST- 2004/06/28 00:00 [revised]
PHST- 2004/06/29 00:00 [accepted]
PHST- 2004/09/03 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/09/03 05:00 [entrez]
AID - S0304-3940(04)00824-9 [pii]
AID - 10.1016/j.neulet.2004.06.070 [doi]
PST - ppublish
SO  - Neurosci Lett. 2004 Sep 16;368(1):116-20. doi: 10.1016/j.neulet.2004.06.070.

PMID- 8269785
OWN - NLM
STAT- MEDLINE
DCOM- 19940202
LR  - 20140226
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 32
IP  - 8
DP  - 1993 Aug
TI  - [The effect of low dose aspirin on the platelet function in patients with acute 
      myocardial infarction].
PG  - 542-4
AB  - To assess the appropriate dose of aspirin in the treatment of patients with acute 
      myocardial infarction (AMI), 60 cases of AMI were randomized into 2 groups, 30 
      cases each; one with conventional therapy, another with conventional therapy 
      combined with daily oral aspirin 100mg. The second group was further divided into 
      subgroup I with serum peak CK < 1000 U/L and subgroup II with serum peak CK > 
      1000U/L. The parameters of platelet function including plasma TXB2, 
      TXB2/6-keto-PGF1 alpha, platelet aggregation induced by 5-HT and epinephrine were 
      studied on different days for 3 weeks. The results revealed that there was a 
      successful inhibition of platelet function as assessed by significant decrease of 
      plasma TXB2 and TXB2/6-keto-PGF1 alpha ratio and inhibition of platelet 
      aggregation in the subgroup I, but little effect on subgroup II. It is shown that 
      in the treatment of AMI, a daily dose of 100mg of aspirin is insufficient for 
      severe cases, and according to the observation in ISIS-2 study, a daily dose of 
      aspirin around 160mg may be appropriate.
FAU - Jin, L
AU  - Jin L
AD  - Peking Union Medical College Hospital, Beijing.
FAU - Xu, S H
AU  - Xu SH
FAU - Yan, X W
AU  - Yan XW
LA  - chi
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/blood/*drug therapy
MH  - Platelet Function Tests
MH  - Thromboxane B2/blood
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 1993 Aug;32(8):542-4.

PMID- 2400216
OWN - NLM
STAT- MEDLINE
DCOM- 19901018
LR  - 20190501
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Print)
IS  - 0003-9888 (Linking)
VI  - 65
IP  - 8
DP  - 1990 Aug
TI  - Trends in the incidence of Reye's syndrome and the use of aspirin.
PG  - 826-9
AB  - In 1986 there was a public warning in the United Kingdom about a link between the 
      consumption of aspirin and Reye's syndrome. To find out if the use of aspirin and 
      paracetamol in children had altered, and whether the incidence of Reye's syndrome 
      had changed since a previous study, parents were interviewed in Belfast and 
      London, and the British Reye's Syndrome Surveillance System data were reviewed. 
      Children with febrile illnesses were 17 times more likely to have received 
      aspirin before admission to hospital in 1985/6 compared with 1988/9. Only 21 
      Belfast parents (40%) and 13 London parents (27%) had heard of Reye's syndrome 
      and only 12 in Belfast (23%) and seven in London (15%) knew of its association 
      with aspirin, suggesting a continuing need for public education. Cases of Reye's 
      syndrome declined both in numbers (from a peak of 79 in 1983/4 to 19 in 1988/9) 
      and in median age. Of the 418 reported cases, the diagnosis was subsequently 
      revised in 89, most often (in 31 of 89, 36%) to 'inborn errors of metabolism'.
FAU - Porter, J D
AU  - Porter JD
AD  - Public Health Laboratory Service Communicable Disease Surveillance Centre, 
      London.
FAU - Robinson, P H
AU  - Robinson PH
FAU - Glasgow, J F
AU  - Glasgow JF
FAU - Banks, J H
AU  - Banks JH
FAU - Hall, S M
AU  - Hall SM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Fever/drug therapy
MH  - Humans
MH  - Incidence
MH  - Infant
MH  - Male
MH  - Reye Syndrome/*chemically induced/epidemiology/ethnology
MH  - Social Class
MH  - United Kingdom/epidemiology/ethnology
PMC - PMC1792465
EDAT- 1990/08/01 00:00
MHDA- 1990/08/01 00:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 1990/08/01 00:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
AID - 10.1136/adc.65.8.826 [doi]
PST - ppublish
SO  - Arch Dis Child. 1990 Aug;65(8):826-9. doi: 10.1136/adc.65.8.826.

PMID- 18844728
OWN - NLM
STAT- MEDLINE
DCOM- 20090522
LR  - 20131121
IS  - 1472-8206 (Electronic)
IS  - 0767-3981 (Linking)
VI  - 22
IP  - 5
DP  - 2008 Oct
TI  - Which parameters differ in very old patients with chronic atrial fibrillation 
      treated by anticoagulant or aspirin? Antithrombotic treatment of atrial 
      fibrillation in the elderly.
PG  - 569-74
LID - 10.1111/j.1472-8206.2008.00629.x [doi]
AB  - The objective was to determine the main parameters taken into account for the 
      decision of antithrombotic treatment of atrial fibrillation (AF) by vitamin K 
      antagonist or aspirin. This was a prospective clinical study of four clinical 
      services of geriatric medicine. Two hundred and nine inpatients, 84.7 +/- 7 years 
      (women 60.8%), with chronic AF were included. The patients were distributed into 
      two groups (anticoagulant or aspirin) according to medical decision. All the 
      decision criteria for treatment were recorded: cardiopathy, conditions of life, 
      clinical examination (nutrition and autonomy, mini-mental state examination 
      (MMSE), walking evaluation, comorbidity), subjective evaluation of risk of falls 
      and glomerular filtration rate. The thromboembolic risk and the bleeding risk, 
      evaluated subjectively for each patient, were compared with two scores of 
      thrombo-embolic risk and bleeding risk. The evolution of the patients was 
      recorded after 3 months. Student's t-test and chi-squared tests were used for 
      statistical analysis. One hundred and two patients (48.8%) received anticoagulant 
      and 107 patients received aspirin. Patients in the aspirin group were 
      significantly older (86.5 +/- 6.5 vs. 82.9 +/- 7.1 years), with more frequent 
      social isolation, higher systolic blood pressure, and had more important 
      subjective bleeding risk and risk of falls. Patients in the anticoagulant group 
      had significantly more valvulopathies and a more important subjective 
      thromboembolic risk. Thrombo-phlebitis antecedents, dementia, denutrition and 
      walking alterations were only slightly more frequent in patients in the aspirin 
      group. Physicians underestimated thromboembolic risk (one-third of patients) and 
      they overestimated bleeding risk (half of the patients). After 3 months, the two 
      groups did not significantly differ for death, bleeding or ischaemic events. In 
      common practice, the decision of antithrombotic treatment for AF should take into 
      account not only cardiovascular but also geriatric criteria.
FAU - Doucet, Jean
AU  - Doucet J
AD  - Service de Médecine Interne Gériatrique, Centre Hospitalo-Universitaire de Rouen, 
      Rouen University Hospital, Rouen F-76031, France. jean.doucet@chu-rouen.fr
FAU - Gréboval-Furstenfeld, Emmanuelle
AU  - Gréboval-Furstenfeld E
FAU - Tavildari, Alain
AU  - Tavildari A
FAU - M'bello, Luc
AU  - M'bello L
FAU - Delaunay, Olympe
AU  - Delaunay O
FAU - Pesqué, Thierry
AU  - Pesqué T
FAU - Moirot, P
AU  - Moirot P
FAU - Mouton-Schleifer, Dominique
AU  - Mouton-Schleifer D
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/pharmacokinetics/*therapeutic use
MH  - Aspirin/pharmacokinetics/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy/metabolism
MH  - Chronic Disease
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Risk Factors
MH  - Vitamin K/antagonists & inhibitors
EDAT- 2008/10/11 09:00
MHDA- 2009/05/23 09:00
CRDT- 2008/10/11 09:00
PHST- 2008/10/11 09:00 [pubmed]
PHST- 2009/05/23 09:00 [medline]
PHST- 2008/10/11 09:00 [entrez]
AID - FCP629 [pii]
AID - 10.1111/j.1472-8206.2008.00629.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2008 Oct;22(5):569-74. doi: 
      10.1111/j.1472-8206.2008.00629.x.

PMID- 11468015
OWN - NLM
STAT- MEDLINE
DCOM- 20011213
LR  - 20191025
IS  - 0767-3981 (Print)
IS  - 0767-3981 (Linking)
VI  - 15
IP  - 1
DP  - 2001 Feb
TI  - Endoscopic evaluation of the gastrotolerance of short-term antalgic treatment 
      with low dose k-diclofenac: a comparison of ibuprofen and aspirin.
PG  - 61-3
AB  - In a short-term gastro-duodenal endoscopic study in 12 healthy volunteers, the 
      gastrotoxicity was not different after intake of diclofenac-K 12.5 mg (0.33) or 
      ibuprofen 200 mg (0.42, P=0.66) but significantly higher after aspirin 500 mg 
      (2.67, P=0.002).
FAU - Mahé, I
AU  - Mahé I
AD  - Unité de Recherches Thérapeutiques, Hôpital Lariboisière, 2 rue Ambroise Paré, 
      75010 Paris, France.
FAU - Mouly, S
AU  - Mouly S
FAU - Mahé, E
AU  - Mahé E
FAU - Diemer, M
AU  - Diemer M
FAU - Knellwolf, A L
AU  - Knellwolf AL
FAU - Simoneau, G
AU  - Simoneau G
FAU - Caulin, C
AU  - Caulin C
FAU - Bergmann, J F
AU  - Bergmann JF
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Diclofenac/*administration & dosage/adverse effects/therapeutic use
MH  - Duodenum/drug effects
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Humans
MH  - Ibuprofen/*administration & dosage/adverse effects/therapeutic use
MH  - Male
MH  - Pain/drug therapy
MH  - Single-Blind Method
MH  - Stomach/drug effects
EDAT- 2001/07/27 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/07/27 10:00
PHST- 2001/07/27 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/07/27 10:00 [entrez]
AID - fcp004 [pii]
AID - 10.1046/j.1472-8206.2001.00004.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2001 Feb;15(1):61-3. doi: 
      10.1046/j.1472-8206.2001.00004.x.

PMID- 3887210
OWN - NLM
STAT- MEDLINE
DCOM- 19850530
LR  - 20190514
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 35
IP  - 5
DP  - 1985 May
TI  - Does platelet antiaggregant therapy lessen the severity of stroke?
PG  - 632-6
AB  - Data from the Aspirin in Transient Ischemic Attack (AITIA) study, an ongoing 
      study of two platelet antiaggregant drugs, and other published therapeutic trials 
      were reviewed to determine whether the severity of stroke is reduced in patients 
      taking platelet antiaggregants. Data from three of four studies suggest that 
      strokes in treated patients are less severe than those in untreated patients. 
      Further studies evaluating platelet antiaggregant therapy should include 
      assessment of the severity as well as the incidence of stroke.
FAU - Grotta, J C
AU  - Grotta JC
FAU - Lemak, N A
AU  - Lemak NA
FAU - Gary, H
AU  - Gary H
FAU - Fields, W S
AU  - Fields WS
FAU - Vital, D
AU  - Vital D
LA  - eng
GR  - HL-14340-03/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cerebrovascular Disorders/epidemiology/physiopathology/*prevention & control
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/physiopathology
MH  - Platelet Aggregation/*drug effects
MH  - Prospective Studies
MH  - Random Allocation
MH  - Sulfinpyrazone/pharmacology/*therapeutic use
RF  - 36
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
AID - 10.1212/wnl.35.5.632 [doi]
PST - ppublish
SO  - Neurology. 1985 May;35(5):632-6. doi: 10.1212/wnl.35.5.632.

PMID- 8948068
OWN - NLM
STAT- MEDLINE
DCOM- 19970305
LR  - 20131121
IS  - 0145-6296 (Print)
IS  - 0145-6296 (Linking)
VI  - 38
IP  - 6
DP  - 1996 Dec
TI  - Measurement of serum acetylsalicylic acid in a porcine model of aspirin overdose.
PG  - 409-12
AB  - Although the pharmacokinetics of acetylsalicylic acid (ASA) absorption and 
      metabolism in therapeutic doses are well described, there is little information 
      for overdose. A porcine model was developed to study ASA pharmacokinetics in 
      overdose and to establish the feasibility of using area-under-the-curve (AUC) for 
      serum ASA vs time rather than salicylate vs time as an indirect method of 
      quantifying total drug absorption. Such a model could be useful in comparing the 
      effectiveness of different methods of gastrointestinal decontamination in 
      poisoning. The hydrolysis of ASA to salicylate, known to be a first-order process 
      in therapeutic doses, was confirmed to remain first-order at high serum 
      concentrations using iv aspirin in 2 pigs. Five simulated overdoses were then 
      carried out in 4 pigs using 500 mg ASA/kg administered enterally as intact 
      tablets. Serial determinations of both serum ASA and salicylate concentration 
      were carried out over 72 h. Plots of ASA concentration vs time for each of the 
      trials revealed delayed, multiple and erratic peaks consistent with a bolus 
      effect from sudden dissolution of aspirin concretions, suggesting our model 
      accurately simulates human overdose. Despite the variable peaks, the AUC of ASA 
      concentration vs time for the 5 trials revealed a coefficient of variation of 
      only 13%, compared with 27% for salicylate concentration vs time AUC. This 
      suggests that serial measurements of serum ASA in a porcine ASA overdose model 
      can be used to measure total drug absorption and thereby compare the 
      effectiveness of different methods of gastrointestinal decontamination.
FAU - Eppler, J
AU  - Eppler J
AD  - Department of Emergency Medicine, Kelowna General Hospital, BC, Canada.
FAU - Johnson, D
AU  - Johnson D
FAU - Verjee, Z
AU  - Verjee Z
FAU - Giesbrecht, E
AU  - Giesbrecht E
FAU - Ito, S
AU  - Ito S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Vet Hum Toxicol
JT  - Veterinary and human toxicology
JID - 7704194
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*blood/pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Cyclooxygenase Inhibitors/administration & dosage/*blood/pharmacokinetics
MH  - Dose-Response Relationship, Drug
MH  - Drug Overdose/veterinary
MH  - Feasibility Studies
MH  - Hydrolysis
MH  - Injections, Intravenous/veterinary
MH  - Intestinal Absorption
MH  - Swine
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
PST - ppublish
SO  - Vet Hum Toxicol. 1996 Dec;38(6):409-12.

PMID- 33752228
OWN - NLM
STAT- MEDLINE
DCOM- 20210909
LR  - 20210909
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 70
IP  - 1 suppl [i]
DP  - 2021 Jan-Feb
TI  - An Update on Aspirin for Cardioprevention: Implications for Patient Care.
PG  - S1-S10
LID - 10.12788/jfp.0143 [doi]
AB  - The goal of this activity is to increase awareness among healthcare providers 
      about the role of aspirin in the primary and secondary prevention of 
      cardiovascular disease.
FAU - Cannon, Christopher P
AU  - Cannon CP
AD  - Harvard Medical School, Cardiovascular Innovation, Cardiovascular Division, 
      Brigham and Women's Faulkner Hospital, Boston, MA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention/*methods
MH  - Secondary Prevention/*methods
MH  - Stroke/prevention & control
EDAT- 2021/03/23 06:00
MHDA- 2021/09/10 06:00
CRDT- 2021/03/22 20:29
PHST- 2021/03/22 20:29 [entrez]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/09/10 06:00 [medline]
AID - 10.12788/jfp.0143 [doi]
PST - ppublish
SO  - J Fam Pract. 2021 Jan-Feb;70(1 suppl [i]):S1-S10. doi: 10.12788/jfp.0143.

PMID- 8202972
OWN - NLM
STAT- MEDLINE
DCOM- 19940701
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 25
IP  - 6
DP  - 1994 Jun
TI  - Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.
PG  - 1149-56
AB  - BACKGROUND: Ticlopidine, an antiplatelet agent, when compared with aspirin has 
      been found to reduce the risk of stroke in high-risk patients, ie, those with 
      recent transient ischemic attack, reversible ischemic neurological deficit, 
      amaurosis fugax, or minor stroke. Its cost-effectiveness in such use, however, is 
      unknown. METHODS: We developed a model of primary stroke prevention in which a 
      hypothetical cohort of 100 high-risk men and women 65 years of age was assumed to 
      receive either ticlopidine (500 mg daily) or aspirin (1300 mg daily). Using 
      published data, we estimated lifetime incidence of stroke, life expectancy 
      (unadjusted and adjusted for changes in quality of life), and lifetime medical 
      care costs associated with each therapy. RESULTS: Patients who receive 
      ticlopidine would experience two fewer initial strokes per hundred than those 
      treated with aspirin. Life expectancy would be extended by approximately one-half 
      month, and lifetime medical care costs (discounted at 5%) would increase by about 
      $2300. The cost-effectiveness of ticlopidine, compared with aspirin, is estimated 
      to range from $31,200 to $55,500 per quality-adjusted life-year gained as the 
      utility of life after nonfatal stroke is assumed to vary from 0.75 to 0.95. 
      CONCLUSIONS: Ticlopidine therapy to prevent stroke in high-risk patients is 
      cost-effective by current standards of medical practice.
FAU - Oster, G
AU  - Oster G
AD  - Policy Analysis Inc., Brookline, MA 02146.
FAU - Huse, D M
AU  - Huse DM
FAU - Lacey, M J
AU  - Lacey MJ
FAU - Epstein, A M
AU  - Epstein AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 1994 Jun;25(6):1097-8. PMID: 8202963
MH  - Aged
MH  - Aspirin/adverse effects/economics/therapeutic use
MH  - Cerebrovascular Disorders/economics/*prevention & control/therapy
MH  - Cohort Studies
MH  - Cost-Benefit Analysis
MH  - Decision Support Techniques
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Hemorrhage/etiology
MH  - Health Care Costs
MH  - Humans
MH  - Incidence
MH  - Ischemic Attack, Transient/complications
MH  - Life Expectancy
MH  - Male
MH  - Neutropenia/etiology
MH  - Quality of Life
MH  - Risk Factors
MH  - Survival Rate
MH  - Ticlopidine/adverse effects/*economics/*therapeutic use
EDAT- 1994/06/01 00:00
MHDA- 1994/06/01 00:01
CRDT- 1994/06/01 00:00
PHST- 1994/06/01 00:00 [pubmed]
PHST- 1994/06/01 00:01 [medline]
PHST- 1994/06/01 00:00 [entrez]
AID - 10.1161/01.str.25.6.1149 [doi]
PST - ppublish
SO  - Stroke. 1994 Jun;25(6):1149-56. doi: 10.1161/01.str.25.6.1149.

PMID- 876669
OWN - NLM
STAT- MEDLINE
DCOM- 19770825
LR  - 20210111
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 3
IP  - 2
DP  - 1977 Apr
TI  - On the sensitivity of the tourniquet pain test.
PG  - 105-110
LID - 10.1016/0304-3959(77)90073-2 [doi]
AB  - Twenty-four chronic pain patients were given, on each of 4 successive days, oral 
      doses of 60 mg morphine, 60 mg codeine, 600 mg aspirin and placebo, using a 
      double-blind counterbalanced design. Two hours after ingestion, subjective pain 
      estimates and tourniquet pain scores were obtained. Variability of the tourniquet 
      pain scores was too great for differences in response to the analgesics to be 
      significant. However, differences in pain estimates were also too small to 
      discriminate among the drugs, and the lack of sensitivity may be a function of 
      pain chronicity. The tourniquet techniques will continue to be useful until there 
      is a purely objective measure of the severity of clinical pain.
FAU - Sternbach, Richard A
AU  - Sternbach RA
AD  - Pain Unit, Veterans Administration Hospital, San Diego, Calif. 92161, U.S.A.
FAU - Deems, Lydia M
AU  - Deems LM
FAU - Timmermans, Gretchen
AU  - Timmermans G
FAU - Huey, Leighton Y
AU  - Huey LY
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - 0 (Placebos)
RN  - 76I7G6D29C (Morphine)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Codeine/pharmacology
MH  - Humans
MH  - Male
MH  - Morphine/pharmacology
MH  - *Pain
MH  - Placebos
MH  - *Tourniquets
EDAT- 1977/04/01 00:00
MHDA- 1977/04/01 00:01
CRDT- 1977/04/01 00:00
PHST- 1977/04/01 00:00 [pubmed]
PHST- 1977/04/01 00:01 [medline]
PHST- 1977/04/01 00:00 [entrez]
AID - 00006396-197704000-00002 [pii]
AID - 10.1016/0304-3959(77)90073-2 [doi]
PST - ppublish
SO  - Pain. 1977 Apr;3(2):105-110. doi: 10.1016/0304-3959(77)90073-2.

PMID- 27161240
OWN - NLM
STAT- MEDLINE
DCOM- 20160909
LR  - 20220318
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 898
DP  - 2016
TI  - Remodeling of Calcium Entry Pathways in Cancer.
PG  - 449-66
LID - 10.1007/978-3-319-26974-0_19 [doi]
AB  - Ca(2+) entry pathways play important roles in control of many cellular functions, 
      including long-term proliferation, migration and cell death. In recent years, it 
      is becoming increasingly clear that, in some types of tumors, remodeling of 
      Ca(2+) entry pathways could contribute to cancer hallmarks such as excessive 
      proliferation, cell migration and invasion as well as resistance to cell death or 
      survival. In this chapter we briefly review findings related to remodeling of 
      Ca(2+) entry pathways in cancer with emphasis on the mechanisms that contribute 
      to increased store-operated Ca(2+) entry (SOCE) and store-operated currents 
      (SOCs) in colorectal cancer cells. Finally, since SOCE appears critically 
      involved in colon tumorogenesis, the inhibition of SOCE by aspirin and other 
      NSAIDs and its possible contribution to colon cancer chemoprevention is reviewed.
FAU - Villalobos, Carlos
AU  - Villalobos C
AD  - Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y 
      Consejo Superior de Investigaciones Científicas (CSIC), C/Sanz y Forés 3, 47003, 
      Valladolid, Spain. carlosv@ibgm.uva.es.
FAU - Sobradillo, Diego
AU  - Sobradillo D
AD  - Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y 
      Consejo Superior de Investigaciones Científicas (CSIC), C/Sanz y Forés 3, 47003, 
      Valladolid, Spain.
FAU - Hernández-Morales, Miriam
AU  - Hernández-Morales M
AD  - Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y 
      Consejo Superior de Investigaciones Científicas (CSIC), C/Sanz y Forés 3, 47003, 
      Valladolid, Spain.
FAU - Núñez, Lucía
AU  - Núñez L
AD  - Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y 
      Consejo Superior de Investigaciones Científicas (CSIC), C/Sanz y Forés 3, 47003, 
      Valladolid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/pharmacology
MH  - Calcium/*metabolism
MH  - Homeostasis
MH  - Humans
MH  - Ion Transport
MH  - Neoplasms/*metabolism/prevention & control
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer
OT  - Colorectal cancer
OT  - NSAID
OT  - Store-operated Ca2+ entry
EDAT- 2016/05/11 06:00
MHDA- 2016/09/10 06:00
CRDT- 2016/05/11 06:00
PHST- 2016/05/11 06:00 [entrez]
PHST- 2016/05/11 06:00 [pubmed]
PHST- 2016/09/10 06:00 [medline]
AID - 10.1007/978-3-319-26974-0_19 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2016;898:449-66. doi: 10.1007/978-3-319-26974-0_19.

PMID- 11966501
OWN - NLM
STAT- MEDLINE
DCOM- 20020910
LR  - 20220309
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 16
IP  - 5
DP  - 2002 May
TI  - Does withholding aspirin for one week reduce the risk of post-sphincterotomy 
      bleeding?
PG  - 929-36
AB  - BACKGROUND: Complications of endoscopic sphincterotomy are closely related to the 
      endoscopic technique. To date, there have been no studies to indicate that 
      aspirin increases the risk of bleeding after endoscopic sphincterotomy. AIM: To 
      compare the incidence of post-sphincterotomy bleeding in patients with and 
      without prior aspirin therapy. METHODS: Eight hundred and four patients were 
      recruited into this retrospective study: 124 patients continued to take aspirin 
      until the day of sphincterotomy (Group 1), 116 patients had their aspirin 
      discontinued for 1 week before sphincterotomy (Group 2) and 564 patients had 
      never taken aspirin (Group 3). The primary outcome analysed was the incidence of 
      post-sphincterotomy bleeding. RESULTS: Sixty-seven patients (8.3%) developed 
      post-sphincterotomy bleeding. The incidences of post-sphincterotomy bleeding in 
      Groups 1, 2 and 3 were 9.7%, 9.5% and 3.9%, respectively. Group 1 showed 
      significantly increased post-sphincterotomy bleeding when compared with Group 3 
      (P=0.01), and the risk was also significantly increased when Group 2 was compared 
      with Group 3 (P=0.01). However, there was no significant difference in 
      post-sphincterotomy bleeding between Groups 1 and 2 (P=0.96). CONCLUSIONS: 
      Aspirin therapy increased the risk of post-sphincterotomy bleeding. Withholding 
      aspirin for 1 week before endoscopic sphincterotomy did not seem to decrease the 
      risk of post-sphincterotomy bleeding.
FAU - Hui, C-K
AU  - Hui CK
AD  - Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, 
      China.
FAU - Lai, K-C
AU  - Lai KC
FAU - Yuen, M-F
AU  - Yuen MF
FAU - Wong, W-M
AU  - Wong WM
FAU - Lam, S-K
AU  - Lam SK
FAU - Lai, C-L
AU  - Lai CL
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Postoperative Complications
MH  - Postoperative Hemorrhage/*chemically induced/prevention & control
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Sphincterotomy, Endoscopic
EDAT- 2002/04/23 10:00
MHDA- 2002/09/11 10:01
CRDT- 2002/04/23 10:00
PHST- 2002/04/23 10:00 [pubmed]
PHST- 2002/09/11 10:01 [medline]
PHST- 2002/04/23 10:00 [entrez]
AID - 1251 [pii]
AID - 10.1046/j.1365-2036.2002.01251.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2002 May;16(5):929-36. doi: 
      10.1046/j.1365-2036.2002.01251.x.

PMID- 2989503
OWN - NLM
STAT- MEDLINE
DCOM- 19850820
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 234
IP  - 1
DP  - 1985 Jul
TI  - Inhibition by metoprolol of the antihypertensive effect of aspirin in young rats.
PG  - 166-71
AB  - A group of 21-day-old, spontaneous hypertensive rats (SHR) received either 
      aspirin (75-100 mg/kg), metoprolol (1.0-1.5 mg/kg) or both in their drinking 
      water for 56 days. Controls received plain water. Groups of normotensive 
      Wistar-Kyoto rats (WKY) received the same drug treatment as did the SHR. Blood 
      pressure, heart rate and body weight were determined weekly, and water 
      consumption was monitored on a daily basis. Renal prostaglandin (PG) activities 
      were determined in a separate group of rats at 7 and at 56 days on each protocol. 
      Blood pressures in the SHRs remained in the range of the WKY during 56 days of 
      treatment with aspirin or metoprolol, but increased to hypertensive levels after 
      exposure to plain water. Blood pressures in the WKY receiving aspirin or 
      metoprolol were also lower than those receiving plain water, but the 
      antihypertensive effect was somewhat slower in onset. The antihypertensive 
      effects of aspirin and of metoprolol were lost in the SHR but not in the WKY when 
      both drugs were given simultaneously in the drinking water. In comparison to rats 
      receiving plain water, renal PG activity (PGF1 alpha and PGF2 alpha) was lower in 
      rats receiving aspirin, metoprolol or both together. The mechanism for the 
      antihypertensive effect of aspirin in the young SHR may be related to a decline 
      in renal PG content, or to the release of other hormones controlling water and 
      electrolyte balance. Reports that the cyclooxygenase inhibitors, such as aspirin, 
      can block the antihypertensive effect of the beta adrenoceptor antagonists is 
      confirmed in chronic studies using the SHR model.(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Tuttle, R S
AU  - Tuttle RS
FAU - Banziger, V
AU  - Banziger V
FAU - Patel, S
AU  - Patel S
FAU - Northrup, N
AU  - Northrup N
LA  - eng
GR  - RR03367-01/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandins)
RN  - 0 (Receptors, Adrenergic, beta)
RN  - GEB06NHM23 (Metoprolol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Animals
MH  - Antihypertensive Agents/*antagonists & inhibitors/pharmacology
MH  - Aspirin/*antagonists & inhibitors/pharmacology
MH  - Blood Pressure/drug effects
MH  - Cyclooxygenase Inhibitors
MH  - Drinking/drug effects
MH  - Heart Rate/drug effects
MH  - Kidney/analysis
MH  - Male
MH  - Metoprolol/*pharmacology
MH  - Prostaglandins/analysis
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Rats, Inbred WKY
MH  - Receptors, Adrenergic, beta/drug effects
EDAT- 1985/07/01 00:00
MHDA- 1985/07/01 00:01
CRDT- 1985/07/01 00:00
PHST- 1985/07/01 00:00 [pubmed]
PHST- 1985/07/01 00:01 [medline]
PHST- 1985/07/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1985 Jul;234(1):166-71.

PMID- 24085627
OWN - NLM
STAT- MEDLINE
DCOM- 20150909
LR  - 20140702
IS  - 1976-3786 (Electronic)
IS  - 0253-6269 (Linking)
VI  - 37
IP  - 7
DP  - 2014 Jul
TI  - Comparative evaluation of gastroulcerogenic potential of nitrogen isoforms of 
      salicyl alcohol and aspirin in rats: biochemical and histological study.
PG  - 916-26
LID - 10.1007/s12272-013-0245-9 [doi]
AB  - The aim of the current study was to explore in vivo any relative 
      gastroulcerogenic prospective propensity of newly synthesized nitrogen containing 
      derivatives of salicyl alcohol; compound (I) [1-(2-hydroxybenzyl)piperidinium 
      chloride], compound (II) [4-carbamoyl-1-(2-hydroxybenzyl)piperidinium chloride] 
      and aspirin in albino rats. The experimental groups received the following oral 
      treatments daily for 6 days: group I saline control; group II, standard (aspirin) 
      treatment group [150 mg/kg of body weight]; group III, test (compound I) 
      treatment group [100, 150 mg/kg]; group IV, test (compound II) treatment group 
      [100, 150 mg/kg]. The results showed that in the case of the aspirin treated 
      group and compound (I) [150 mg/kg], there was a significant increase in gastric 
      volume, free acidity, total acidity, ulcer score and a decrease in gastric pH. 
      Furthermore, histopathological examination of gastric mucosa of these treated 
      groups revealed detectable morphological changes. Utilizing the same protocol, 
      synthetic compound (I) [100 mg/kg] and (II) [100, 150 mg/kg] exhibited no 
      statistically significant ulcerogenic or cytotoxic properties. A cyclooxygenase 
      (COX) selectivity test indicated the preferential inhibition of COX-I and COX-II 
      enzymes by compounds (I) and (II). This study therefore indicates that these 
      synthetic compounds may possess reduced ulcerogenic potential and could be a 
      functional substitute to aspirin.
FAU - Ali, Gowhar
AU  - Ali G
AD  - Department of Pharmacy, University of Peshawar, Peshawar, 25120, Pakistan, 
      gohar.pharmacist@gmail.com.
FAU - Subhan, Fazal
AU  - Subhan F
FAU - Islam, Nazar Ul
AU  - Islam NU
FAU - Ullah, Nasir
AU  - Ullah N
FAU - Shahid, Muhammad
AU  - Shahid M
FAU - Ullah, Sami
AU  - Ullah S
FAU - Ullah, Ihsan
AU  - Ullah I
FAU - Shah, Rehmat
AU  - Shah R
FAU - Khan, Ikhtiar
AU  - Khan I
FAU - Sewell, Robert D E
AU  - Sewell RD
FAU - Abbas, Ghulam
AU  - Abbas G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131002
PL  - Korea (South)
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
RN  - 0 (Benzyl Alcohols)
RN  - FA1N0842KB (salicyl alcohol)
RN  - N762921K75 (Nitrogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry/*toxicity
MH  - Benzyl Alcohols/chemistry/*toxicity
MH  - Drug Evaluation, Preclinical/methods
MH  - Female
MH  - Gastric Mucosa/drug effects/pathology
MH  - Male
MH  - Nitrogen/chemistry/*toxicity
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Stomach Ulcer/*chemically induced/*pathology
EDAT- 2013/10/03 06:00
MHDA- 2015/09/10 06:00
CRDT- 2013/10/03 06:00
PHST- 2013/05/18 00:00 [received]
PHST- 2013/09/13 00:00 [accepted]
PHST- 2013/10/03 06:00 [entrez]
PHST- 2013/10/03 06:00 [pubmed]
PHST- 2015/09/10 06:00 [medline]
AID - 10.1007/s12272-013-0245-9 [doi]
PST - ppublish
SO  - Arch Pharm Res. 2014 Jul;37(7):916-26. doi: 10.1007/s12272-013-0245-9. Epub 2013 
      Oct 2.

PMID- 23895681
OWN - NLM
STAT- MEDLINE
DCOM- 20140409
LR  - 20211025
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 20
IP  - 33
DP  - 2013
TI  - Aspirin: a potential therapeutic approach in pancreatic cancer.
PG  - 4153-62
AB  - Inflammation has become a research hotspot in solid tumours and has been 
      confirmed as a key factor in tumour development through the interactions of 
      inflammatory mediators with gene expression, cell proliferation, and apoptosis. 
      Pancreatic cancer (PC) is one of the most aggressive and deadliest forms of 
      gastrointestinal cancer. A large case-control study found that aspirin, an 
      anti-inflammatory drug, was associated with a decreased risk of PC. Moreover, 
      aspirin has been shown to have inhibitory effects on PC in both in vitro and in 
      vivo studies. However, the clinical data analysis has not been similarly 
      promising. Results from genetic and pharmacological studies suggest that the 
      anti-tumour effects of aspirin are mediated, at least in part, through the 
      inhibition of COXs. Furtermore, other results suggest that the chemopreventive 
      and therapeutic effects of aspirin are also mediated through COX-independent 
      mechanisms. The COX-dependent and COX-independent mechanisms will be described in 
      this review. In addition, we will discuss future research directions on the risks 
      and benefits of the use of aspirin to treat PC and the potential 
      cellular/molecular.
FAU - Shen, Xin
AU  - Shen X
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical 
      College, Xi'an Jiaotong University, 277 West Yanta Road, Xi'an 710061, Shaanxi, 
      China. qyma56@mail.xjtu.edu.cn.
FAU - Han, Liang
AU  - Han L
FAU - Ma, Zhenhua
AU  - Ma Z
FAU - Chen, Chao
AU  - Chen C
FAU - Duan, Wanxing
AU  - Duan W
FAU - Yu, Shuo
AU  - Yu S
FAU - Li, Pei
AU  - Li P
FAU - Zhang, Lun
AU  - Zhang L
FAU - Li, Wei
AU  - Li W
FAU - Xu, Qinhong
AU  - Xu Q
FAU - Ma, Qingyong
AU  - Ma Q
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Disease Models, Animal
MH  - Humans
MH  - Inflammation/drug therapy
MH  - Pancreatic Neoplasms/metabolism/pathology/*prevention & control
EDAT- 2013/07/31 06:00
MHDA- 2014/04/10 06:00
CRDT- 2013/07/31 06:00
PHST- 2013/01/29 00:00 [received]
PHST- 2013/03/20 00:00 [revised]
PHST- 2013/04/01 00:00 [accepted]
PHST- 2013/07/31 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2014/04/10 06:00 [medline]
AID - CMC-EPUB-54485 [pii]
AID - 10.2174/09298673113209990196 [doi]
PST - ppublish
SO  - Curr Med Chem. 2013;20(33):4153-62. doi: 10.2174/09298673113209990196.

PMID- 19187982
OWN - NLM
STAT- MEDLINE
DCOM- 20090722
LR  - 20191210
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 133
IP  - 1
DP  - 2009 Mar 20
TI  - Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary 
      syndromes: when does the risk outweigh the benefit?
PG  - 8-17
LID - 10.1016/j.ijcard.2008.12.202 [doi]
AB  - Most guidelines recommend indefinite use of aspirin in patients at increased 
      atherothrombotic risk. Dual antiplatelet therapy (aspirin/clopidogrel) is 
      significantly more effective than aspirin monotherapy in reducing cardiovascular 
      risk in a number of patient populations. As a result, dual therapy is recommended 
      in many patient groups, including those with acute coronary syndromes and those 
      who have undergone percutaneous coronary intervention. The recommended duration 
      of clopidogrel/aspirin treatment is generally less than one year and, in some 
      cases, as little as one month. However, there is evidence from a range of patient 
      populations that more prolonged clopidogrel/aspirin therapy may be more effective 
      than short-term treatment in reducing cardiovascular risk in some patients. The 
      effects of discontinuing clopidogrel after an event-free period of one year 
      require examination in clinical trials. Trial data are also needed to guide 
      management of patients in whom early antiplatelet withdrawal is being considered 
      (e.g. those who require non-cardiac surgery). This review discusses the benefits 
      and risks of long-term dual antiplatelet therapy in a range of clinical 
      situations.
FAU - Collet, Jean-Philippe
AU  - Collet JP
AD  - Inserm 856 and Institut de Cardiologie, Pitié-Salpêtrière University Hospital, 
      Paris, France. jean-philippe.collet@psl.aphp.fr
FAU - Montalescot, Gilles
AU  - Montalescot G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20090201
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
RF  - 56
EDAT- 2009/02/04 09:00
MHDA- 2009/07/23 09:00
CRDT- 2009/02/04 09:00
PHST- 2008/09/25 00:00 [received]
PHST- 2008/12/13 00:00 [revised]
PHST- 2008/12/24 00:00 [accepted]
PHST- 2009/02/04 09:00 [entrez]
PHST- 2009/02/04 09:00 [pubmed]
PHST- 2009/07/23 09:00 [medline]
AID - S0167-5273(09)00013-8 [pii]
AID - 10.1016/j.ijcard.2008.12.202 [doi]
PST - ppublish
SO  - Int J Cardiol. 2009 Mar 20;133(1):8-17. doi: 10.1016/j.ijcard.2008.12.202. Epub 
      2009 Feb 1.

PMID- 18174450
OWN - NLM
STAT- MEDLINE
DCOM- 20080317
LR  - 20131121
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
VI  - 28
IP  - 3
DP  - 2008 Mar
TI  - Aspirin: promise and resistance in the new millennium.
PG  - s25-32
LID - 10.1161/ATVBAHA.107.160481 [doi]
AB  - Although conceived at the end of the 19th century, aspirin remains the gold 
      standard of antiplatelet therapy. Approximately 100 randomized clinical trials 
      have established its efficacy and safety in the prevention of myocardial 
      infarction, ischemic stroke, and vascular death among high-risk patients treated 
      for a few weeks, at one end of the spectrum, and in low-risk subjects treated up 
      to 10 years at the other. Despite this wealth of data, several issues continue to 
      be debated concerning the use of aspirin as an antiplatelet agent, and novel 
      opportunities appear on the horizon for this 110-year-old drug. These issues 
      include: (1) the optimal dose for cardiovascular prophylaxis; (2) the uncertain 
      threshold of cardiovascular risk for its use in primary prevention; (3) the 
      apparent gender-related difference in its cardioprotective effects; (4) the 
      increasingly popular theme of aspirin "resistance"; (5) the opportunities of 
      chemoprevention in colorectal cancer; and (6) the renewed interest in aspirin as 
      an analgesic agent in osteoarthritic patients at high cardiovascular risk. The 
      aim of this review is to address these issues by integrating our current 
      understanding of the molecular mechanism of action of the drug with the results 
      of clinical trials and epidemiological studies of aspirin as an antiplatelet 
      drug.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. 
      carlo.patrono@rm.unicatt.it
FAU - Rocca, Bianca
AU  - Rocca B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20080103
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/mortality/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Utilization/trends
MH  - Education, Medical, Continuing
MH  - Female
MH  - Forecasting
MH  - Humans
MH  - Male
MH  - Maximum Tolerated Dose
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Stroke/prevention & control
MH  - Survival Analysis
RF  - 78
EDAT- 2008/01/05 09:00
MHDA- 2008/03/18 09:00
CRDT- 2008/01/05 09:00
PHST- 2008/01/05 09:00 [pubmed]
PHST- 2008/03/18 09:00 [medline]
PHST- 2008/01/05 09:00 [entrez]
AID - ATVBAHA.107.160481 [pii]
AID - 10.1161/ATVBAHA.107.160481 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s25-32. doi: 
      10.1161/ATVBAHA.107.160481. Epub 2008 Jan 3.

PMID- 18086929
OWN - NLM
STAT- MEDLINE
DCOM- 20080125
LR  - 20131121
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 117
IP  - 2
DP  - 2008 Jan 15
TI  - Initial aspirin dose and outcome among ST-elevation myocardial infarction 
      patients treated with fibrinolytic therapy.
PG  - 192-9
AB  - BACKGROUND: Although treatment with immediate aspirin reduces morbidity and 
      mortality in ST-elevation myocardial infarction, the optimal dose is unclear. We 
      therefore compared the acute mortality and bleeding risks associated with the 
      initial use of 162 versus 325 mg aspirin in fibrinolytic-treated ST-elevation 
      myocardial infarction patients. METHODS AND RESULTS: Using combined data from the 
      Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded 
      Coronary Arteries (GUSTO I) and Global Use of Strategies to Open Occluded 
      Coronary Arteries (GUSTO III) trials (n=48 422 ST-elevation myocardial infarction 
      patients), we compared the association between initial aspirin dose of 162 versus 
      325 mg and 24-hour and 7-day mortality, as well as rates of in-hospital 
      moderate/severe bleeding. Results were adjusted for previously identified 
      mortality and bleeding risk factors. Overall, 24.4% of patients (n=11 828) 
      received an initial aspirin dose of 325 mg, and 75.6% (n=36 594) received 162 mg. 
      The 24-hour mortality rates were 2.9% versus 2.8% (P=0.894) for those receiving 
      an initial aspirin dose of 325 versus 162 mg. Mortality rates at 7 and 30 days 
      were 5.2% versus 4.9% (P=0.118) and 7.1% versus 6.5% (P=0.017) among patients 
      receiving the 325 versus 162 mg aspirin. After adjustment, aspirin dose was not 
      associated with 24-hour (odds ratio [OR], 1.01; 95% CI, 0.82 to 1.25), 7-day (OR, 
      1.00; 95% CI, 0.87 to 1.17), or 30-day (OR, 0.99; 95% CI, 0.87 to 1.12) mortality 
      rates. No significant difference was noted for myocardial infarction or the 
      composite of death or myocardial infarction between groups. In-hospital 
      moderate/severe bleeding occurred in 9.3% of those treated with 325 mg versus 
      12.2% among those receiving 162 mg (P<0.001). After adjustment, 325 mg was 
      associated with a significant increase in moderate/severe bleeding (OR, 1.14; 95% 
      CI, 1.05 to 1.24; P=0.003). CONCLUSIONS: These data suggest that an initial dose 
      of 162 mg aspirin may be as effective as and perhaps safer than 325 mg for the 
      acute treatment of ST-elevation myocardial infarction.
FAU - Berger, Jeffrey S
AU  - Berger JS
AD  - Duke Clinical Research Institute, Durham, NC, USA. berge026@mc.duke.edu
FAU - Stebbins, Amanda
AU  - Stebbins A
FAU - Granger, Christopher B
AU  - Granger CB
FAU - Ohman, Eric M
AU  - Ohman EM
FAU - Armstrong, Paul W
AU  - Armstrong PW
FAU - Van de Werf, Frans
AU  - Van de Werf F
FAU - White, Harvey D
AU  - White HD
FAU - Simes, R John
AU  - Simes RJ
FAU - Harrington, Robert A
AU  - Harrington RA
FAU - Califf, Robert M
AU  - Califf RM
FAU - Peterson, Eric D
AU  - Peterson ED
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20071217
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/toxicity
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/complications/*drug therapy/mortality
MH  - Odds Ratio
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Thrombolytic Therapy/*methods
MH  - Treatment Outcome
EDAT- 2007/12/19 09:00
MHDA- 2008/01/26 09:00
CRDT- 2007/12/19 09:00
PHST- 2007/12/19 09:00 [pubmed]
PHST- 2008/01/26 09:00 [medline]
PHST- 2007/12/19 09:00 [entrez]
AID - CIRCULATIONAHA.107.729558 [pii]
AID - 10.1161/CIRCULATIONAHA.107.729558 [doi]
PST - ppublish
SO  - Circulation. 2008 Jan 15;117(2):192-9. doi: 10.1161/CIRCULATIONAHA.107.729558. 
      Epub 2007 Dec 17.

PMID- 18268496
OWN - NLM
STAT- MEDLINE
DCOM- 20080506
LR  - 20211020
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 98
IP  - 5
DP  - 2008 Mar 11
TI  - Low-dose aspirin and breast cancer risk: results by tumour characteristics from a 
      randomised trial.
PG  - 989-91
LID - 10.1038/sj.bjc.6604240 [doi]
AB  - The Women's Health Study trial previously reported no overall effect of low-dose 
      aspirin (100 mg every other day) on invasive breast cancer over an average of 10 
      years of treatment. The present subgroup analyses further show no effects by 
      tumour characteristics at diagnosis, suggesting that low-dose aspirin has no 
      preventive effect on breast cancer.
FAU - Zhang, S M
AU  - Zhang SM
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, Boston, MA 02215, USA. 
      shumin.zhang@channing.harvard.edu
FAU - Cook, N R
AU  - Cook NR
FAU - Manson, J E
AU  - Manson JE
FAU - Lee, I-M
AU  - Lee IM
FAU - Buring, J E
AU  - Buring JE
LA  - eng
GR  - R01 CA047988/CA/NCI NIH HHS/United States
GR  - R01 HL043851/HL/NHLBI NIH HHS/United States
GR  - CA-47988/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20080212
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Breast Neoplasms/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Risk
PMC - PMC2266841
EDAT- 2008/02/13 09:00
MHDA- 2008/05/07 09:00
CRDT- 2008/02/13 09:00
PHST- 2008/02/13 09:00 [pubmed]
PHST- 2008/05/07 09:00 [medline]
PHST- 2008/02/13 09:00 [entrez]
AID - 6604240 [pii]
AID - 10.1038/sj.bjc.6604240 [doi]
PST - ppublish
SO  - Br J Cancer. 2008 Mar 11;98(5):989-91. doi: 10.1038/sj.bjc.6604240. Epub 2008 Feb 
      12.

PMID- 28903849
OWN - NLM
STAT- MEDLINE
DCOM- 20180330
LR  - 20220321
IS  - 1681-7168 (Electronic)
IS  - 1022-386X (Linking)
VI  - 27
IP  - 8
DP  - 2017 Aug
TI  - Acute Complete Adult-onset Kawasaki Disease in a Middle-Aged Woman.
PG  - 517-519
AB  - A 55-year-old Chinese lady was diagnosed with acute complete Kawasaki disease 
      (KD) in January 2015. To our knowledge, this patient was the first described 
      woman who was over 50 years and fulfilled all the characteristics of acute 
      complete KD. The patient had a striking result on the 26th day since this disease 
      onset after the initiation of treatment of immunoglobulin (IG) and aspirin; and 
      did not have any complications up to now. The purpose of this case report was to 
      raise the awareness of KD in the middle-aged persons and the therapeutic 
      schedules, as there is no valid therapeutic therapeutic for adults with KD.
FAU - Chen, Jiu
AU  - Chen J
AD  - Department of Traditional Chinese Medicine, The First Affiliated Hospital, 
      College of Medicine, Zhejiang University, China.
FAU - Li, Youdi
AU  - Li Y
AD  - Department of Traditional Chinese Medicine, The First Affiliated Hospital, 
      College of Medicine, Zhejiang University, China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Pakistan
TA  - J Coll Physicians Surg Pak
JT  - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
JID - 9606447
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age of Onset
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Middle Aged
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis
MH  - Treatment Outcome
EDAT- 2017/09/15 06:00
MHDA- 2018/03/31 06:00
CRDT- 2017/09/15 06:00
PHST- 2015/12/26 00:00 [received]
PHST- 2017/02/11 00:00 [accepted]
PHST- 2017/09/15 06:00 [entrez]
PHST- 2017/09/15 06:00 [pubmed]
PHST- 2018/03/31 06:00 [medline]
AID - 040579197 [pii]
PST - ppublish
SO  - J Coll Physicians Surg Pak. 2017 Aug;27(8):517-519.

PMID- 22330155
OWN - NLM
STAT- MEDLINE
DCOM- 20120703
LR  - 20131121
IS  - 0210-5705 (Print)
IS  - 0210-5705 (Linking)
VI  - 34 Suppl 2
DP  - 2011 Oct
TI  - [Advances in gastrointestinal disorders associated with non-steroidal 
      antiinflammatory agents and aspirin].
PG  - 36-42
LID - 10.1016/S0210-5705(11)70019-X [doi]
AB  - Patients with gastrointestinal (GI) risk factors who require non-steroidal 
      antiinflammatory drugs (NSAIDs) or aspirin must receive gastropreventive 
      therapies. According to some recent surveys, the low prescription rates of these 
      therapies reported some years ago are progressively improving in several European 
      countries, which should be accompanied by a subsequent decrease in the frequency 
      of hospitalizations due to complications of the upper GI tract, but not of those 
      located in the lower GI tract. The most recent data confirm that celecoxib has a 
      better GI safety profile both in the upper and lower GI tract than traditional 
      NSAIDs. The NSAID most frequently involved in admissions for GI complications is 
      aspirin and consequently at-risk patients receiving this drug should also receive 
      antisecretory agents. Cotherapy consisting of proton pump inhibitors with double 
      antiplatelet therapy is highly frequent in Spain, which has been associated with 
      a low incidence of upper GI bleeding, and a growing incidence of patients with 
      lower GI bleeding usually due to pre-existing vascular lesions. Another 
      therapeutic tool that has been proposed to reduce the occurrence of upper GI 
      bleeding in patients taking aspirin is Helicobacter pylori eradication therapy. 
      The most recent data show that eradication of H. pylori infection in patients 
      with a previous peptic ulcer bleeding episode who continue to take aspirin 
      reduces the recurrence rate of this complication to levels observed in patients 
      without a history of ulcer bleeding history who take aspirin for cardiovascular 
      disease.
CI  - Copyright © 2011 Elsevier España S.L. All rights reserved.
FAU - Lanas, Angel
AU  - Lanas A
AD  - Servicio de Aparato Digestivo, Hospital Clínico Universitario, Universidad de 
      Zaragoza, IIS Aragón, Zaragoza, España. alanas@unizar.es
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Avances en patología gastrointestinal asociada a antiinflamatorios no esteroideos 
      y ácido acetilsalicílico.
PL  - Spain
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Humans
EDAT- 2012/02/15 06:00
MHDA- 2012/07/04 06:00
CRDT- 2012/02/15 06:00
PHST- 2012/02/15 06:00 [entrez]
PHST- 2012/02/15 06:00 [pubmed]
PHST- 2012/07/04 06:00 [medline]
AID - S0210-5705(11)70019-X [pii]
AID - 10.1016/S0210-5705(11)70019-X [doi]
PST - ppublish
SO  - Gastroenterol Hepatol. 2011 Oct;34 Suppl 2:36-42. doi: 
      10.1016/S0210-5705(11)70019-X.

PMID- 32138560
OWN - NLM
STAT- MEDLINE
DCOM- 20220210
LR  - 20220501
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 35
IP  - 5
DP  - 2022 Mar
TI  - Effects of maternal aspirin treatment on hemodynamically significant patent 
      ductus arteriosus in preterm infants - pilot study.
PG  - 958-963
LID - 10.1080/14767058.2020.1736028 [doi]
AB  - AIM: To assess the burden of hemodynamically significant patent ductus arteriosus 
      (hs-PDA) in preterm infants exposed to aspirin in utero. METHODS: We 
      retrospectively reviewed the medical records of 21 preterm infants <34 weeks 
      whose mothers were treated with aspirin during gestation, and were screened for 
      patent ductus arteriosus due to severe respiratory distress syndrome and the need 
      for positive pressure ventilation. These infants were compared to 42 preterm 
      infants born without exposure to aspirin in utero. RESULTS: We found 
      significantly lower frequency of hs-PDA and higher rate of successful 
      pharmacological PDA closure after single course of ibuprofen treatment along with 
      significantly lower cumulative doses of ibuprofen in the study group. 
      Furthermore, PDA closure was achieved significantly earlier in the study group 
      (day 4 versus 11, p = .02). CONCLUSION: Aspirin treatment during pregnancy seemed 
      to reduce the incidence of hs-PDA in preterm infant and to increase infant 
      responsiveness to postnatal medical treatment of PDA.
FAU - Fridman, Elena
AU  - Fridman E
AD  - Department of Neonatology, Assuta Medical Center, Ashdod, Israel.
AD  - Be'er Sheva School of Medicine, Ben Gurion University of the Negev, Beersheba, 
      Israel.
FAU - Mangel, Laurence
AU  - Mangel L
AD  - Department of Neonatology, Lis Maternity Hospital, Tel Aviv Sourasky Medical 
      Center, Tel Aviv, Israel.
FAU - Mandel, Dror
AU  - Mandel D
AD  - Department of Neonatology, Lis Maternity Hospital, Tel Aviv Sourasky Medical 
      Center, Tel Aviv, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Beer, Gil
AU  - Beer G
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
AD  - Pediatric Cardiology Unit, Dana-Dwek Children Hospital, Tel Aviv Sourasky Medical 
      Centre, Tel Aviv, Israel.
FAU - Kapusta, Livia
AU  - Kapusta L
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
AD  - Pediatric Cardiology Unit, Dana-Dwek Children Hospital, Tel Aviv Sourasky Medical 
      Centre, Tel Aviv, Israel.
AD  - Department of Pediatric Cardiology, Radboud University Medical Centre, Amalia 
      Children's Hospital, Nijmegen, The Netherlands.
FAU - Marom, Ronella
AU  - Marom R
AD  - Department of Neonatology, Lis Maternity Hospital, Tel Aviv Sourasky Medical 
      Center, Tel Aviv, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
LA  - eng
PT  - Journal Article
DEP - 20200306
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Ductus Arteriosus, Patent/drug therapy
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Infant
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Pilot Projects
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Aspirin antenatal treatment
OT  - PDA closure
OT  - hemodynamically significant patent ductus arteriosus
OT  - patent ductus arteriosus
OT  - preterm infant
EDAT- 2020/03/07 06:00
MHDA- 2022/02/11 06:00
CRDT- 2020/03/07 06:00
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2022/02/11 06:00 [medline]
PHST- 2020/03/07 06:00 [entrez]
AID - 10.1080/14767058.2020.1736028 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2022 Mar;35(5):958-963. doi: 
      10.1080/14767058.2020.1736028. Epub 2020 Mar 6.

PMID- 17893001
OWN - NLM
STAT- MEDLINE
DCOM- 20071106
LR  - 20181201
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 154
IP  - 4
DP  - 2007 Oct
TI  - Dual antiplatelet agent failure: a new syndrome or clinical nonentity?
PG  - 732-5
AB  - BACKGROUND: Aspirin resistance is a well-documented laboratory finding, but the 
      effects of clinical aspirin (ASA) failure on patients with acute coronary 
      syndrome (ACS) have been debated. Likewise, there is recognition of clopidogrel 
      resistance, but the clinical effects of clopidogrel failure are not well 
      understood. We sought to determine the 6-month outcomes of patients who developed 
      an ACS while on ASA or dual antiplatelet agents. METHODS: Of all patients 
      admitted to the University of Michigan, Ann Arbor, between 1999 and 2005 with a 
      diagnosis of ACS, 6-month follow-up data were available for 3126. The cohort was 
      divided into 3 groups based on medication history: no prior antiplatelet agent, 
      ASA only, and ASA with clopidogrel (or ticlopidine). Primary end point was the 
      rate of death, myocardial infarction, and stroke, or composite major adverse 
      cardiac events (MACEs) at 6 months. RESULTS: Aside from a lower rate of 
      myocardial infarction in patients without any prior antiplatelet agent use, there 
      were no significant differences in 6-month stroke, death, or MACE between the 3 
      medication cohorts. In the propensity-adjusted model, whereas dual antiplatelet 
      status was not an independent predictor of 6-month mortality or MACE, there was a 
      trend toward lower 6-month death rates for patients with prior ASA use (odds 
      ratio 0.72, 95% CI 0.51-1.04, P = .08). CONCLUSIONS: Patients who "fail" 
      antiplatelet therapy do not have overall worse prognosis. Our data do not support 
      ASA or dual antiplatelet agent failure as a distinct clinical entity.
FAU - Barnes, Geoffrey D
AU  - Barnes GD
AD  - University of Michigan Cardiovascular Center, Ann Arbor, MI, USA.
FAU - Li, Jin
AU  - Li J
FAU - Kline-Rogers, Eva
AU  - Kline-Rogers E
FAU - Vedre, Ameeth
AU  - Vedre A
FAU - Armstrong, David F
AU  - Armstrong DF
FAU - Froehlich, James B
AU  - Froehlich JB
FAU - Eagle, Kim A
AU  - Eagle KA
FAU - Gurm, Hitinder S
AU  - Gurm HS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Prognosis
MH  - Recurrence
MH  - Syndrome
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Treatment Outcome
EDAT- 2007/09/26 09:00
MHDA- 2007/11/07 09:00
CRDT- 2007/09/26 09:00
PHST- 2007/03/16 00:00 [received]
PHST- 2007/06/17 00:00 [accepted]
PHST- 2007/09/26 09:00 [pubmed]
PHST- 2007/11/07 09:00 [medline]
PHST- 2007/09/26 09:00 [entrez]
AID - S0002-8703(07)00514-5 [pii]
AID - 10.1016/j.ahj.2007.06.014 [doi]
PST - ppublish
SO  - Am Heart J. 2007 Oct;154(4):732-5. doi: 10.1016/j.ahj.2007.06.014.

PMID- 19385948
OWN - NLM
STAT- MEDLINE
DCOM- 20100107
LR  - 20161125
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 64
IP  - 12
DP  - 2009 Dec
TI  - Lipoxin A4 generation is decreased in aspirin-sensitive patients in 
      lysine-aspirin nasal challenge in vivo model.
PG  - 1746-52
LID - 10.1111/j.1398-9995.2009.02047.x [doi]
AB  - BACKGROUND: Lipoxins represent a group of lipoxygenase derived eicosanoids which, 
      in contrast to leukotrienes, are potent anti-inflammatory mediators. The aim of 
      our study was to determine lipoxin A(4) (LXA(4)) and leukotriene C(4) (LTC(4)) 
      levels in nasal lavages after intranasal challenge with aspirin in aspirin 
      intolerant (AIA) in comparison to aspirin tolerant (ATA) asthmatics and after 
      allergen challenge in patients suffering from allergic rhinitis. METHODS: Twelve 
      AIA, 8 ATA and 20 allergic patients were challenged with placebo, 16 mg of 
      lysine-aspirin (Lys-ASA) or allergen (grasses). Nasal lavages were collected and 
      eicosanoids' levels were determined using ELISA. RESULTS: Clinically positive 
      Lys-ASA challenge in AIA resulted in influx of leukocytes (eosinophils and 
      basophils) to nasal secretions and increase of LTC(4) to 106.82 pg/ml (P < 0.05 
      vs baseline (26.58 pg/ml)) on first hour after the challenge. We did not observe 
      any differences in LTC(4) level before and after ASA challenge in ATA. In AIA 
      group the mean level of LXA(4) was 43 +/- 21.5 pg/ml after placebo and decreased 
      in 2 h after Lys-ASA challenge (29 +/- 17 pg/ml, P = 0.015). We found an increase 
      in LXA(4) in ATA after ASA provocation as compared to placebo (33 +/- 16 pg/ml vs 
      52 +/- 31 pg/ml, P = 0.046). In atopic patients baseline level of LXA(4) was 
      33.49 +/- 16.95 pg/ml with no difference after the clinically positive allergen 
      challenge (36.22 +/- 13.26 pg/ml, P = 0.23). CONCLUSIONS: Results of our study 
      confirm that AIA have diminished LXs' biosynthesis capacities in vivo after ASA 
      challenge. Taking into consideration anti-inflammatory properties of lipoxins 
      this phenomenon may be partially responsible for the development of chronic 
      inflammation in AIA patients.
FAU - Kupczyk, M
AU  - Kupczyk M
AD  - Department of Internal Medicine, Medical University of Lodz, Lodz, Poland.
FAU - Antczak, A
AU  - Antczak A
FAU - Kuprys-Lipinska, I
AU  - Kuprys-Lipinska I
FAU - Kuna, P
AU  - Kuna P
LA  - eng
PT  - Journal Article
DEP - 20090406
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Allergens)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - 2CU6TT9V48 (Leukotriene C4)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Allergens/administration & dosage
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/administration & dosage/*analogs & derivatives/*immunology
MH  - Case-Control Studies
MH  - Drug Tolerance/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Inflammation/etiology
MH  - Leukotriene C4/analysis/biosynthesis
MH  - Lipoxins/analysis/*biosynthesis
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Middle Aged
MH  - Nasal Provocation Tests/*adverse effects/methods
MH  - Poaceae/immunology
EDAT- 2009/04/24 09:00
MHDA- 2010/01/08 06:00
CRDT- 2009/04/24 09:00
PHST- 2009/04/24 09:00 [entrez]
PHST- 2009/04/24 09:00 [pubmed]
PHST- 2010/01/08 06:00 [medline]
AID - ALL2047 [pii]
AID - 10.1111/j.1398-9995.2009.02047.x [doi]
PST - ppublish
SO  - Allergy. 2009 Dec;64(12):1746-52. doi: 10.1111/j.1398-9995.2009.02047.x. Epub 
      2009 Apr 6.

PMID- 29511170
OWN - NLM
STAT- MEDLINE
DCOM- 20180820
LR  - 20181114
IS  - 2222-1751 (Electronic)
IS  - 2222-1751 (Linking)
VI  - 7
IP  - 1
DP  - 2018 Mar 7
TI  - Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for 
      the treatment of influenza in hospitalized patients.
PG  - 21
LID - 10.1038/s41426-018-0023-3 [doi]
LID - 21
AB  - Influenza has been a long-running health problem and novel antiviral drugs are 
      urgently needed. In pre-clinical studies, we demonstrated broad antiviral 
      activity of D, L-lysine-acetylsalicylate glycine (LASAG) against influenza virus 
      (IV) in cell culture and protection against lethal challenge in mice. LASAG is a 
      compound with a new antiviral mode of action. It inhibits the NF-κB signal 
      transduction module that is essential for IV replication. Our goal was to 
      determine whether aerosolized LASAG would also show a therapeutic benefit in 
      hospitalized patients suffering from severe influenza. The primary endpoint was 
      time to alleviation of clinical influenza symptoms. The primary analysis was 
      based on the modified intention-to-treat (MITT) population. This included all 
      patients with confirmed influenza virus infection who received at least one 
      treatment. The per protocol (PP) analysis set included all subjects from the MITT 
      population who underwent at least 13 inhalations. In the MITT group, 48 (41.7%) 
      participants (29 LASAG; 19 placebo) had severe influenza. The mean time to 
      symptom alleviation was 56.2 h in the placebo group and 43.0 h in the LASAG 
      group. The PP set consisted of 41 patients (24 LASAG; 17 placebo). The mean time 
      to symptom alleviation in the LASAG group (38.3 h; P = 0.0365) was lower than 
      that in the placebo group (56.2 h). In conclusion, LASAG improved the time to 
      alleviation of influenza symptoms in hospitalized patients. The present phase II 
      proof-of-concept (PoC) study demonstrates that targeting an intra-cellular 
      signaling pathway using aerosolized LASAG improves the time to symptom 
      alleviation compared to standard treatment.
FAU - Scheuch, Gerhard
AU  - Scheuch G
AD  - Bio-Inhalation GmbH, 35285, Gemuenden/Wohra, Hessen, Germany.
FAU - Canisius, Sebastian
AU  - Canisius S
AUID- ORCID: 0000-0002-2639-1180
AD  - Ventaleon GmbH, 35285, Gemuenden/Wohra, Hessen, Germany.
FAU - Nocker, Karlheinz
AU  - Nocker K
AD  - Ventaleon GmbH, 35285, Gemuenden/Wohra, Hessen, Germany.
FAU - Hofmann, Thomas
AU  - Hofmann T
AD  - Aumapharma LLC, Doylestown, PA, 18901, USA.
FAU - Naumann, Rolf
AU  - Naumann R
AD  - Ventaleon GmbH, 35285, Gemuenden/Wohra, Hessen, Germany.
FAU - Pleschka, Stephan
AU  - Pleschka S
AD  - Institute of Medical Virology, Justus Liebig University Giessen, 35392, Giessen, 
      Hessen, Germany.
FAU - Ludwig, Stephan
AU  - Ludwig S
AD  - Institute of Virology (IVM), Westfaelische Wilhelms-University Muenster, 48149, 
      Muenster, North Rhine-Westphalia, Germany.
FAU - Welte, Tobias
AU  - Welte T
AD  - Pneumology Clinic, Medical University Hannover, 30625, Hannover, Lower Saxony, 
      Germany.
FAU - Planz, Oliver
AU  - Planz O
AD  - Interfaculty Institute for Cell Biology, Department of Immunology, Eberhard Karls 
      Tuebingen University, 72076, Tuebingen, Baden-Württemberg, Germany. 
      oliver.planz@uni-tuebingen.de.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20180307
PL  - United States
TA  - Emerg Microbes Infect
JT  - Emerging microbes & infections
JID - 101594885
RN  - 0 (Antiviral Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (acetylsalicylate, glycine, lysine drug combination)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Antiviral Agents/*administration & dosage/chemistry
MH  - Aspirin/administration & dosage/*analogs & derivatives/chemistry
MH  - Drug Combinations
MH  - Female
MH  - Glycine/*administration & dosage/chemistry
MH  - Hospitalization
MH  - Humans
MH  - Influenza A Virus, H1N1 Subtype/drug effects/physiology
MH  - Influenza, Human/*drug therapy/virology
MH  - Lysine/administration & dosage/*analogs & derivatives/chemistry
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Middle Aged
MH  - Patients
PMC - PMC5841227
COIS- Declaration of interests GS reports personal fees from 
      Activaero/Vectura/Ventaleon GmbH, during the conduct of the study and personal 
      fees outside the submitted work. GS, RN, SC, KN, OP, SP, SL are shareholders from 
      Activaero/Vectura. KN, RN report personal fees from Ventaleon GmbH outside the 
      submitted work. OP reports grants from Activaero/Vectura/Ventaleon GmbH, during 
      the conduct of the study; also grants from Atriva Therapeutics GmbH and 
      Activaero/Ventaleon GmbH outside the submitted work. RN, SC, OP, SL, SP are 
      shareholders from Atriva Therapeutics GmbH outside the submitted work. TH was, at 
      the time of the study, a consultant to Activaero/Vectura/Ventaleon GmbH. TW 
      reports personal fees and others outside the submitted work (GSK). In addition, 
      SL, SP, OP have a patent 8313751 and a patent EP20090701974 both issued to 
      Ventaleon GmbH. GS has an issued patent WO 2009/089822 A2.
EDAT- 2018/03/08 06:00
MHDA- 2018/08/21 06:00
CRDT- 2018/03/08 06:00
PHST- 2017/07/07 00:00 [received]
PHST- 2017/12/23 00:00 [accepted]
PHST- 2017/09/18 00:00 [revised]
PHST- 2018/03/08 06:00 [entrez]
PHST- 2018/03/08 06:00 [pubmed]
PHST- 2018/08/21 06:00 [medline]
AID - 10.1038/s41426-018-0023-3 [pii]
AID - 23 [pii]
AID - 10.1038/s41426-018-0023-3 [doi]
PST - epublish
SO  - Emerg Microbes Infect. 2018 Mar 7;7(1):21. doi: 10.1038/s41426-018-0023-3.

PMID- 26466698
OWN - NLM
STAT- MEDLINE
DCOM- 20160602
LR  - 20181202
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 54
IP  - 20
DP  - 2015
TI  - Hemoptysis due to aspirin treatment alternative to warfarin therapy in a patient 
      with atrial fibrillation.
PG  - 2615-8
LID - 10.2169/internalmedicine.54.4695 [doi]
AB  - An 80-year-old female with a history of hypertension and atrial fibrillation had 
      been receiving warfarin anticoagulant therapy and had stably maintained an 
      international normalized ratio (INR) within the 2.0-3.0 range. Due to dental 
      extractions, she was prescribed aspirin (100 mg/day) as an alternative therapy to 
      warfarin. Three days later, the patient complained of hemoptysis without obvious 
      inducement and the INR was 3.51. The aspirin was immediately discontinued and 
      intravenous vitamin K was administered. Hemoptysis did not reappear and the INR 
      returned to the normal limits. According to the Drug Interaction Probability 
      Scale, a causal relationship between aspirin and warfarin and an increased INR 
      value is possible.
FAU - Song, Wei
AU  - Song W
AD  - Respiratory Department, the First Affiliated Hospital with Nanjing Medical 
      University, China.
FAU - Cao, Jia
AU  - Cao J
FAU - Xu, Yazhou
AU  - Xu Y
FAU - Han, Zhonglin
AU  - Han Z
FAU - Wen, Hao
AU  - Wen H
FAU - Cui, Xuefan
AU  - Cui X
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151015
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged, 80 and over
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Drug Interactions
MH  - Female
MH  - Hemoptysis/*chemically induced/drug therapy
MH  - Humans
MH  - International Normalized Ratio
MH  - Tooth Extraction
MH  - Vitamin K/therapeutic use
MH  - Warfarin/*administration & dosage/therapeutic use
EDAT- 2015/10/16 06:00
MHDA- 2016/06/03 06:00
CRDT- 2015/10/16 06:00
PHST- 2015/10/16 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/06/03 06:00 [medline]
AID - 10.2169/internalmedicine.54.4695 [doi]
PST - ppublish
SO  - Intern Med. 2015;54(20):2615-8. doi: 10.2169/internalmedicine.54.4695. Epub 2015 
      Oct 15.

PMID- 7097918
OWN - NLM
STAT- MEDLINE
DCOM- 19820910
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 248
IP  - 6
DP  - 1982 Aug 13
TI  - Reye's syndrome and medication use.
PG  - 687-91
AB  - Ninety-seven Reye's syndrome (RS) cases in Ohio children with onsets from 
      December 1978 through March 1980 were studied for medication use during their 
      pre-RS illness. They were matched with 156 control subjects for age, race, sex, 
      geographic location, time, and type of illness. Only the use of aspirin was 
      reported by significantly more cases (97%, 94/97) than controls (71%, 110/156) 
      during the pre-RS matched illness. Using a multiple logistic model to control for 
      the presence of fever, headache, and sore throat statistically, the difference in 
      aspirin use remained significant. Conversely, fewer cases (16%) took medications 
      containing acetaminophen than controls (33%). In 87% of the cases receiving 
      aspirin, their maximum daily dosage did not exceed recommended levels, but their 
      doses were higher than those of controls receiving aspirin. No relationship was 
      found between dosage and stage of RS encephalopathy.
FAU - Halpin, T J
AU  - Halpin TJ
FAU - Holtzhauer, F J
AU  - Holtzhauer FJ
FAU - Campbell, R J
AU  - Campbell RJ
FAU - Hall, L J
AU  - Hall LJ
FAU - Correa-Villaseñor, A
AU  - Correa-Villaseñor A
FAU - Lanese, R
AU  - Lanese R
FAU - Rice, J
AU  - Rice J
FAU - Hurwitz, E S
AU  - Hurwitz ES
LA  - eng
GR  - 200-78-0824/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Infant
MH  - Influenza, Human/drug therapy
MH  - Male
MH  - Ohio
MH  - Reye Syndrome/diagnosis/epidemiology/*etiology
MH  - Seasons
MH  - Virus Diseases/complications
EDAT- 1982/08/13 00:00
MHDA- 1982/08/13 00:01
CRDT- 1982/08/13 00:00
PHST- 1982/08/13 00:00 [pubmed]
PHST- 1982/08/13 00:01 [medline]
PHST- 1982/08/13 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1982 Aug 13;248(6):687-91.

PMID- 19422469
OWN - NLM
STAT- MEDLINE
DCOM- 20091109
LR  - 20161018
IS  - 0891-6640 (Print)
IS  - 0891-6640 (Linking)
VI  - 23
IP  - 3
DP  - 2009 May-Jun
TI  - Effects of prednisone alone or prednisone with ultralow-dose aspirin on the 
      gastroduodenal mucosa of healthy dogs.
PG  - 482-7
LID - 10.1111/j.1939-1676.2009.0312.x [doi]
AB  - BACKGROUND: The coadministration of prednisone and ultralow-dose aspirin has been 
      recommended for the management of various diseases, but the safety of this 
      combination in dogs has not been studied. HYPOTHESES: The gastroduodenal lesions 
      associated with prednisone and ultralow-dose aspirin administration will be 
      similar to those caused by prednisone alone, but both treatments will result in 
      more severe lesions than placebo. ANIMALS: Eighteen healthy adult purpose-bred 
      dogs. METHODS: Randomized, blinded, placebo-controlled study of 3 treatment 
      groups for 27 days: placebo, prednisone, and prednisone and aspirin. 
      Gastroduodenoscopy was performed before and on days 5, 14, and 27 of treatment 
      and mucosal lesions scores were assigned. Mucosal lesion scores were compared by 
      a Kruskal-Wallis test. Clinical signs were compared by the Friedman's chi-square 
      test (significance at P < .05). RESULTS: There were no significant differences in 
      the gastroduodenal lesion scores among groups, or within groups at any time 
      during the study. Significantly more dog-days of diarrhea occurred in the 
      prednisone and aspirin group during treatment, compared with baseline. No 
      significant differences in clinical signs were found among any of the groups. 
      CONCLUSION: The concurrent use of prednisone and ultralow-dose aspirin did not 
      increase the severity of gastroduodenal lesions compared with prednisone or 
      placebo. Coadministration of prednisone and ultralow-dose aspirin increases the 
      frequency of mild, self-limiting diarrhea in some dogs.
FAU - Heather Graham, A
AU  - Heather Graham A
AD  - Department of Small Animal Clinical Sciences, CR Roberts Professor Small Animal 
      Medicine, Virginia-Maryland Regional College of Veterinary Medicine, Virginia 
      Tech, Blacksburg, VA 24061, USA. heath06@vt.edu
FAU - Leib, Michael S
AU  - Leib MS
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090421
PL  - United States
TA  - J Vet Intern Med
JT  - Journal of veterinary internal medicine
JID - 8708660
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Dogs
MH  - Female
MH  - Gastric Mucosa/drug effects/pathology
MH  - Gastrointestinal Diseases/chemically induced/pathology/*veterinary
MH  - Intestinal Mucosa/drug effects/pathology
MH  - Male
MH  - Prednisone/*administration & dosage/*adverse effects
EDAT- 2009/05/09 09:00
MHDA- 2009/11/10 06:00
CRDT- 2009/05/09 09:00
PHST- 2009/05/09 09:00 [entrez]
PHST- 2009/05/09 09:00 [pubmed]
PHST- 2009/11/10 06:00 [medline]
AID - JVIM312 [pii]
AID - 10.1111/j.1939-1676.2009.0312.x [doi]
PST - ppublish
SO  - J Vet Intern Med. 2009 May-Jun;23(3):482-7. doi: 10.1111/j.1939-1676.2009.0312.x. 
      Epub 2009 Apr 21.

PMID- 11300428
OWN - NLM
STAT- MEDLINE
DCOM- 20010426
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 37
IP  - 5
DP  - 2001 Apr
TI  - Aspirin inhibits the acute venodilator response to furosemide in patients with 
      chronic heart failure.
PG  - 1234-8
AB  - OBJECTIVES: We sought to determine the effect of aspirin on the venodilator 
      effect of furosemide in patients with chronic heart failure (CHF) BACKGROUND: 
      Furosemide has an acute venodilator effect preceding its diuretic action, which 
      is blocked by nonsteroidal anti-inflammatory, drugs. The ability of therapeutic 
      doses of aspirin to block this effect of furosemide in patients with CHF has not 
      been studied. For comparison, the venodilator response to nitroglycerin (NTG) was 
      also studied. METHODS: Eleven patients with CHF were randomized to receive 
      placebo, aspirin at 75 mg/day or aspirin at 300 mg/day for 14 days in a 
      double-blind, crossover study. The effect of these pretreatments on the change in 
      forearm venous capacitance (FVC) after 20 mg of intravenous furosemide was 
      measured over 20 min by using venous occlusion plethysmography. In a second 
      study, the effect of 400 microg of sublingual NTG on FVC was documented in 11 
      similar patients (nine participated in the first study). RESULTS: Mean arterial 
      pressure, heart rate and forearm blood flow did not change in response to 
      furosemide. After placebo pretreatment, furosemide caused an increase in FVC of 
      2.2% (95% confidence interval [CI] -0.9% to 5.2%; mean response over 20 min). By 
      comparison, FVC fell by -1.1% (95% CI -4.2% to 1.9%) after pretreatment with 
      aspirin at 75 mg/day, and by -3.7% (95% CI -6.8% to -0.7%) after aspirin at 300 
      mg/day (p = 0.020). In the second study, NTG increased FVC by 2.1% (95% CI -1.6% 
      to 5.8%) (p = 0.95 vs. furosemide). CONCLUSIONS: In patients with CHF, 
      venodilation occurs within minutes of the administration of intravenous dose of 
      furosemide. Our observation that aspirin inhibits this effect further questions 
      the use of aspirin in patients with CHF.
FAU - Jhund, P S
AU  - Jhund PS
AD  - Clinical Research Initiative in Heart Failure, University of Glasgow, United 
      Kingdom.
FAU - Davie, A P
AU  - Davie AP
FAU - McMurray, J J
AU  - McMurray JJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Chronic Disease
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Forearm/blood supply
MH  - Furosemide/administration & dosage/*antagonists & inhibitors
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Nitroglycerin/administration & dosage
MH  - Plethysmography
MH  - Vasodilation/*drug effects
MH  - Veins/drug effects
EDAT- 2001/04/13 10:00
MHDA- 2001/05/01 10:01
CRDT- 2001/04/13 10:00
PHST- 2001/04/13 10:00 [pubmed]
PHST- 2001/05/01 10:01 [medline]
PHST- 2001/04/13 10:00 [entrez]
AID - S0735-1097(01)01169-X [pii]
AID - 10.1016/s0735-1097(01)01169-x [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2001 Apr;37(5):1234-8. doi: 10.1016/s0735-1097(01)01169-x.

PMID- 30776996
OWN - NLM
STAT- MEDLINE
DCOM- 20191125
LR  - 20191125
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 50
IP  - 3
DP  - 2019 Mar
TI  - Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.
PG  - 675-682
LID - 10.1161/STROKEAHA.118.022675 [doi]
AB  - Background and Purpose- Recurrent ischemia risk is high in the acute period after 
      cerebral ischemic events. Effects of antiplatelet agents may vary by time to 
      loading dose (TLD). We explored the risk of recurrent events and safety and 
      efficacy of ticagrelor versus aspirin in relation to TLD. Methods- We randomized 
      13 199 patients with noncardioembolic, nonsevere ischemic stroke, or high-risk 
      transient ischemic attack to 90-day ticagrelor or aspirin treatment within 24 
      hours of symptom onset. For this analysis, 13 126 patients were categorized by 
      TLD as <12 hours or ≥12 hours from start of index event. The primary end point 
      was the composite of stroke, myocardial infarction, or death within 90 days. 
      Major bleeding was the primary safety end point. Results- TLD was <12 hours in 
      4403 (33.5%) and ≥12 hours in 8723 (66.5%). The Kaplan-Meier% for the primary end 
      point for all patients with TLD<12 hours was 7.5% versus 6.9% in TLD≥12 hours. 
      Among patients with TLD<12 hours, the primary end point occurred in 147/2196 
      (6.8%) randomized to ticagrelor and in 184/2207 (8.3%) randomized to aspirin 
      (hazard ratio, 0.79; 95% CI, 0.64-0.98; P=0.036). Among patients with TLD≥12 
      hours, the primary end point occurred in 6.7% patients randomized to ticagrelor 
      versus 7.0% to aspirin (hazard ratio, 0.95; 95% CI, 0.81-1.12; P=0.55). There was 
      no significant treatment-by-TLD interaction. Major bleeding rates were comparable 
      on ticagrelor and aspirin, regardless of TLD. Conclusions- The event rate for the 
      primary end point was higher in patients treated early (<12 hours) versus later 
      (≥12 hours). In this exploratory analysis, a larger numerical difference in the 
      primary end point was observed among patients on ticagrelor than on aspirin when 
      TLD was <12 hours compared with ≥12 hours, although the interaction terms for 
      treatment-by-TLD were not significant. For major bleeding, no relation to TLD was 
      observed. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . 
      Unique identifier: NCT01994720.
FAU - Molina, Carlos A
AU  - Molina CA
AD  - From the Stroke Unit, Hospital Vall d'Hebron, Barcelona, Spain (C.A.M.).
FAU - Johnston, S Claiborne
AU  - Johnston SC
AD  - Dean's Office, Dell Medical School, University of Texas, Austin (S.C.J.).
FAU - Ladenvall, Per
AU  - Ladenvall P
AD  - Global Medicines Development, AstraZeneca, Gothenburg, Sweden (P.L., H.D., P.H., 
      M.K.).
FAU - Amarenco, Pierre
AU  - Amarenco P
AD  - Department of Neurology and Stroke Center, Bichat University Hospital and 
      Paris-Diderot, Sorbonne University, France (P.A.).
FAU - Albers, Gregory W
AU  - Albers GW
AD  - Stanford Stroke Center, Stanford University, Palo Alto, CA (G.W.A.).
FAU - Denison, Hans
AU  - Denison H
AD  - Global Medicines Development, AstraZeneca, Gothenburg, Sweden (P.L., H.D., P.H., 
      M.K.).
FAU - Easton, J Donald
AU  - Easton JD
AD  - Department of Neurology, University of California, San Francisco (J.D.E.).
FAU - Evans, Scott R
AU  - Evans SR
AD  - Department of Biostatistics, Harvard University, Boston, MA (S.R.E.).
FAU - Held, Peter
AU  - Held P
AD  - Global Medicines Development, AstraZeneca, Gothenburg, Sweden (P.L., H.D., P.H., 
      M.K.).
FAU - Knutsson, Mikael
AU  - Knutsson M
AD  - Global Medicines Development, AstraZeneca, Gothenburg, Sweden (P.L., H.D., P.H., 
      M.K.).
FAU - Minematsu, Kazuo
AU  - Minematsu K
AD  - Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular 
      Center, Suita, Osaka, Japan (K.M.).
FAU - Röther, Joachim
AU  - Röther J
AD  - Department of Neurology, Asklepios Klinik Altona, Hamburg, Germany (J.R.).
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Department of Neurology, Tiantan Hospital, Beijing, China (Y.W.).
FAU - Wong, K S Lawrence
AU  - Wong KSL
AD  - Department of Medicine & Therapeutics, The Chinese University of Hong Kong 
      (K.S.L.W.).
CN  - SOCRATES Steering Committee and Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT01994720
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Stroke. 2019 Apr;50(4):e118. PMID: 30908157
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects/*therapeutic use
MH  - Endpoint Determination
MH  - Female
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/*therapeutic use
MH  - Recurrence
MH  - Risk
MH  - Stroke/*drug therapy
MH  - Ticagrelor/*administration & dosage/adverse effects/*therapeutic use
MH  - Time-to-Treatment
OTO - NOTNLM
OT  - aspirin
OT  - myocardial infarction
OT  - platelet aggregation inhibitors
OT  - risk
OT  - ticagrelor
EDAT- 2019/02/20 06:00
MHDA- 2019/11/26 06:00
CRDT- 2019/02/20 06:00
PHST- 2019/02/20 06:00 [pubmed]
PHST- 2019/11/26 06:00 [medline]
PHST- 2019/02/20 06:00 [entrez]
AID - 10.1161/STROKEAHA.118.022675 [doi]
PST - ppublish
SO  - Stroke. 2019 Mar;50(3):675-682. doi: 10.1161/STROKEAHA.118.022675.

PMID- 11231774
OWN - NLM
STAT- MEDLINE
DCOM- 20010405
LR  - 20190704
IS  - 0003-9950 (Print)
IS  - 0003-9950 (Linking)
VI  - 119
IP  - 3
DP  - 2001 Mar
TI  - Aspirin use and risk of cataract in posttrial follow-up of Physicians' Health 
      Study I.
PG  - 405-12
AB  - BACKGROUND: In Physicians' Health Study I, randomized trial results indicated no 
      major beneficial effect of 5 years of low-dose aspirin treatment on total 
      cataract (relative risk [RR], 0.94; 95% confidence interval [CI], 0.79-1.13) or 
      cataract extraction (RR, 0.81; 95% CI, 0.65-1.01) during the period of treatment. 
      OBJECTIVE: To examine the effect of assigned aspirin treatment and posttrial, 
      self-selected aspirin use on the risk of age-related cataract over the 15 years 
      of follow-up of Physicians' Health Study I. METHODS: Participants were 20 968 US 
      male physicians enrolled in Physicians' Health Study I who did not report 
      cataract at baseline. At 7 years, after termination of the randomized aspirin 
      component of the trial, self-selected aspirin use was computed from annual 
      questionnaires. The main outcome measures were age-related cataract and 
      extraction of age-related cataract, defined as an incident, age-related lens 
      opacity responsible for a reduction in best-corrected visual acuity to 20/30 or 
      worse based on self-report confirmed by medical record review. RESULTS: During a 
      median of 14.9 years of follow-up, there were 2081 cataracts and 1198 cataract 
      extractions. Overall, the age- and beta carotene-adjusted RR of cataract in men 
      assigned to aspirin compared with those assigned to placebo was 1.09 (95% CI, 
      1.00-1.18). For cataract extraction, the RR was 1.09 (95% CI, 0.98-1.22). During 
      a median posttrial follow-up of 7.9 years, a total of 1225 incident cataracts and 
      635 cataract extractions were documented. The multivariate RR of cataract in men 
      who reported using aspirin frequently (>/=180 days per year) at 7 years compared 
      with nonusers (0-13 days per year) was 1.20 (95% CI, 1.03-1.40). For cataract 
      extraction, the multivariate RR was 1.22 (95% CI, 0.98-1.51). Results for 
      diagnosis and extraction of cataract subtypes were similar. CONCLUSIONS: Analyses 
      based on randomized aspirin assignment indicated no long-term benefit of 5 years 
      of low-dose aspirin treatment on total cataract or cataract extraction. 
      Posttrial, observational data also indicated no decreased risk of cataract in 
      aspirin users and suggested a small increased risk of cataract in aspirin users. 
      Further randomized trial data to investigate the effect of longer term treatment 
      with low-dose aspirin are being collected as part of the ongoing Women's Health 
      Study, a randomized trial of low-dose aspirin and vitamin E among 39 876 
      apparently healthy, postmenopausal US female health professionals.
FAU - Christen, W G
AU  - Christen WG
AD  - Division of Preventive Medicine, Department of Medicine, Harvard Medical School 
      and Brigham and Women's Hospital, Boston, MA 02215-1204, USA.
FAU - Ajani, U A
AU  - Ajani UA
FAU - Schaumberg, D A
AU  - Schaumberg DA
FAU - Glynn, R J
AU  - Glynn RJ
FAU - Manson, J E
AU  - Manson JE
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - K23 EY000365-04/EY/NEI NIH HHS/United States
GR  - K23 EY000365-05/EY/NEI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Arch Ophthalmol
JT  - Archives of ophthalmology (Chicago, Ill. : 1960)
JID - 7706534
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Ophthalmol. 2001 Oct;119(10):1562-3. PMID: 11594971
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cataract/chemically induced/*epidemiology
MH  - Cataract Extraction/statistics & numerical data
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Health Status
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physicians
MH  - Risk
MH  - United States/epidemiology
MH  - Visual Acuity
EDAT- 2001/03/20 10:00
MHDA- 2001/04/06 10:01
CRDT- 2001/03/20 10:00
PHST- 2001/03/20 10:00 [pubmed]
PHST- 2001/04/06 10:01 [medline]
PHST- 2001/03/20 10:00 [entrez]
AID - eeb00009 [pii]
AID - 10.1001/archopht.119.3.405 [doi]
PST - ppublish
SO  - Arch Ophthalmol. 2001 Mar;119(3):405-12. doi: 10.1001/archopht.119.3.405.

PMID- 11228592
OWN - NLM
STAT- MEDLINE
DCOM- 20041115
LR  - 20191027
IS  - 1472-6904 (Electronic)
IS  - 1472-6904 (Linking)
VI  - 1
DP  - 2001
TI  - Risk of upper gastrointestinal bleeding and perforation associated with low-dose 
      aspirin as plain and enteric-coated formulations.
PG  - 1
AB  - BACKGROUND: The use of low-dose aspirin has been reported to be associated with 
      an increased risk of upper gastrointestinal complications (UGIC). The coating of 
      aspirin has been proposed as an approach to reduce such a risk. To test this 
      hypothesis, we carried out a population based case-control study. METHODS: We 
      identified incident cases of UGIC (bleeding or perforation) aged 40 to 79 years 
      between April 1993 to October 1998 registered in the General Practice Research 
      Database. Controls were selected randomly from the source population. Adjusted 
      estimates of relative risk (RR) associated with current use of aspirin as 
      compared to non use were computed using unconditional logistic regression. 
      RESULTS: We identified 2,105 cases of UGIC and selected 11,500 controls. Among 
      them, 287 (13.6%) cases and 837 (7.3%) controls were exposed to aspirin, 
      resulting in an adjusted RR of 2.0 (1.7-2.3). No clear dose-effect was found 
      within the range of 75-300 mg. The RR associated with enteric-coated formulations 
      (2.3, 1.6-3.2) was similar to the one of plain aspirin (1.9, 1.6-2.3), and no 
      difference was observed depending on the site. The first two months of treatment 
      was the period of greater risk (RR= 4.5, 2.9-7.1). The concomitant use of aspirin 
      with high-dose NSAIDs greatly increased the risk of UGIC (13.3, 8.5-20.9) while 
      no interaction was apparent with low-medium doses (2.2, 1.0-4.6). CONCLUSIONS: 
      Low-dose aspirin increases by twofold the risk of UGIC in the general population 
      and its coating does not modify the effect. Concomitant use of low-dose aspirin 
      and NSAIDs at high doses put patients at a specially high risk of UGIC.
FAU - de Abajo, F J
AU  - de Abajo FJ
AD  - División de Farmacoepidemiología y Farmacovigilancia, Agencia Española del 
      Medicamento, Madrid, Spain. fabajo@agemed.es
FAU - García Rodríguez, L A
AU  - García Rodríguez LA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20010213
PL  - England
TA  - BMC Clin Pharmacol
JT  - BMC clinical pharmacology
JID - 101088667
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Chemistry, Pharmaceutical
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
PMC - PMC32172
EDAT- 2001/03/03 10:00
MHDA- 2004/11/16 09:00
CRDT- 2001/03/03 10:00
PHST- 2000/11/29 00:00 [received]
PHST- 2001/02/13 00:00 [accepted]
PHST- 2001/03/03 10:00 [pubmed]
PHST- 2004/11/16 09:00 [medline]
PHST- 2001/03/03 10:00 [entrez]
AID - 1472-6904-1-1 [pii]
AID - 10.1186/1472-6904-1-1 [doi]
PST - ppublish
SO  - BMC Clin Pharmacol. 2001;1:1. doi: 10.1186/1472-6904-1-1. Epub 2001 Feb 13.

PMID- 8413387
OWN - NLM
STAT- MEDLINE
DCOM- 19931026
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 329
IP  - 17
DP  - 1993 Oct 21
TI  - Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant 
      women. The National Institute of Child Health and Human Development Network of 
      Maternal-Fetal Medicine Units.
PG  - 1213-8
AB  - BACKGROUND: Although low-dose aspirin has been reported to reduce the incidence 
      of preeclampsia among women at high risk for this complication, its efficacy and 
      safety in healthy, nulliparous pregnant women are not known. METHODS: We studied 
      3135 normotensive nulliparous women who were 13 to 26 weeks pregnant to determine 
      whether treatment with aspirin reduced the incidence of preeclampsia. Of this 
      group, 1570 women received 60 mg of aspirin per day and 1565 received placebo for 
      the remainder of their pregnancies. We also evaluated the effect of aspirin on 
      maternal and neonatal morbidity. RESULTS: Of the original group of 3135 women, 
      2985 (95 percent) were followed throughout pregnancy and the immediate 
      puerperium. The incidence of preeclampsia was lower in the aspirin group (69 of 
      1485 women [4.6 percent]) than in the placebo group (94 of 1500 women [6.3 
      percent]) (relative risk, 0.7; 95 percent confidence interval, 0.6 to 1.0; P = 
      0.05), whereas the incidence of gestational hypertension was 6.7 and 5.9 percent, 
      respectively. There were no significant differences in the infants' birth weight 
      or in the incidence of fetal growth retardation, postpartum hemorrhage, or 
      neonatal bleeding problems between the two groups. Subgroup analysis showed that 
      preeclampsia occurred primarily in women whose initial systolic blood pressure 
      was 120 to 134 mm Hg (incidence among such women, 5.6 percent in the aspirin 
      group vs. 11.9 percent in the placebo group; P = 0.01). The incidence of abruptio 
      placentae was greater among the women who received aspirin (11 women, vs. 2 in 
      the placebo group; P = 0.01). CONCLUSIONS: Low-dose aspirin decreases the 
      incidence of preeclampsia among nulliparous women, primarily through its effect 
      in those who have elevated systolic blood pressure initially. This treatment does 
      not decrease perinatal morbidity but increases the risk of abruptio placentae.
FAU - Sibai, B M
AU  - Sibai BM
FAU - Caritis, S N
AU  - Caritis SN
FAU - Thom, E
AU  - Thom E
FAU - Klebanoff, M
AU  - Klebanoff M
FAU - McNellis, D
AU  - McNellis D
FAU - Rocco, L
AU  - Rocco L
FAU - Paul, R H
AU  - Paul RH
FAU - Romero, R
AU  - Romero R
FAU - Witter, F
AU  - Witter F
FAU - Rosen, M
AU  - Rosen M
AU  - et al.
LA  - eng
GR  - HD 21366/HD/NICHD NIH HHS/United States
GR  - HD 21410/HD/NICHD NIH HHS/United States
GR  - HD 21434/HD/NICHD NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 1994 Mar 17;330(11):794-5. PMID: 8107757
CIN - N Engl J Med. 1993 Oct 21;329(17):1265-6. PMID: 8413395
MH  - Abruptio Placentae/chemically induced
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Incidence
MH  - Parity
MH  - Patient Compliance
MH  - Pre-Eclampsia/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/epidemiology
MH  - Pregnancy Outcome
MH  - Risk Factors
MH  - Single-Blind Method
EDAT- 1993/10/21 00:00
MHDA- 1993/10/21 00:01
CRDT- 1993/10/21 00:00
PHST- 1993/10/21 00:00 [pubmed]
PHST- 1993/10/21 00:01 [medline]
PHST- 1993/10/21 00:00 [entrez]
AID - 10.1056/NEJM199310213291701 [doi]
PST - ppublish
SO  - N Engl J Med. 1993 Oct 21;329(17):1213-8. doi: 10.1056/NEJM199310213291701.

PMID- 30724102
OWN - NLM
STAT- MEDLINE
DCOM- 20200414
LR  - 20200414
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 53
IP  - 7
DP  - 2019 Jul
TI  - Evaluating the Effect of a Patient Decision Aid for Atrial Fibrillation Stroke 
      Prevention Therapy.
PG  - 665-674
LID - 10.1177/1060028019828420 [doi]
AB  - BACKGROUND: Stroke prevention therapy decisions for patients with atrial 
      fibrillation (AF) are complex and require trade-offs, but few validated patient 
      decision aids (PDAs) are available to facilitate shared decision making. 
      OBJECTIVE: To evaluate the effects of a novel PDA on decision-making parameters 
      for AF patients choosing stroke prevention therapy. METHODS: We developed an 
      evidence-based individualized online AF PDA for stroke prevention therapy and 
      evaluated it in a prospective observational pilot study. The primary outcome was 
      decisional conflict. Secondary outcomes were knowledge, usability/acceptability, 
      patient preferences, effects on therapy choices, and participant feedback. 
      RESULTS: 37 participants completed the PDA. The PDA could be completed 
      independently and was well accepted. It significantly decreased the mean 
      decisional conflict score ( P < 0.001) and all its subscales and increased 
      participant AF knowledge ( P = 0.02). 76% of participants indicated that their 
      individualized therapy attribute ranking was congruent with their values. The 
      PDA-generated best-match therapy was chosen by 70% of participants in decision 1 
      (no therapy, aspirin, or oral anticoagulant), and 17% for decision 2 (choice of 
      anticoagulant). Among AF patients, 60% chose a different drug than that currently 
      prescribed to them. Conclusion and Relevance: Our PDA was effective for reducing 
      decisional conflict, increasing patient knowledge, eliciting patients' values, 
      and presenting therapy options that aligned with patients' values and 
      preferences. Using the PDA revealed that many patients have therapy preferences 
      different from their currently prescribed treatment. The PDA is a practical and 
      potentially valuable tool to facilitate decision making about stroke prevention 
      therapy for AF.
FAU - Loewen, Peter S
AU  - Loewen PS
AUID- ORCID: 0000-0001-7160-6438
AD  - 1 The University of British Columbia, Vancouver, BC, Canada.
FAU - Bansback, Nick
AU  - Bansback N
AD  - 1 The University of British Columbia, Vancouver, BC, Canada.
AD  - 2 Providence Health Research Institute, Vancouver, BC, Canada.
FAU - Hicklin, James
AU  - Hicklin J
AD  - 1 The University of British Columbia, Vancouver, BC, Canada.
FAU - Andrade, Jason G
AU  - Andrade JG
AD  - 3 Vancouver General Hospital, Vancouver, BC, Canada.
FAU - Kapanen, Anita I
AU  - Kapanen AI
AD  - 1 The University of British Columbia, Vancouver, BC, Canada.
FAU - Kwan, Leanne
AU  - Kwan L
AD  - 4 Royal Columbian Hospital, New Westminster, BC, Canada.
FAU - Lynd, Larry D
AU  - Lynd LD
AD  - 1 The University of British Columbia, Vancouver, BC, Canada.
AD  - 2 Providence Health Research Institute, Vancouver, BC, Canada.
FAU - McClean, Alison
AU  - McClean A
AD  - 1 The University of British Columbia, Vancouver, BC, Canada.
FAU - MacGillivray, Jenny
AU  - MacGillivray J
AD  - 3 Vancouver General Hospital, Vancouver, BC, Canada.
FAU - Salmasi, Shahrzad
AU  - Salmasi S
AUID- ORCID: 0000-0003-1330-3388
AD  - 1 The University of British Columbia, Vancouver, BC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20190206
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - British Columbia
MH  - *Decision Making
MH  - Decision Support Techniques
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Participation
MH  - Patient Preference
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Stroke/*prevention & control
OTO - NOTNLM
OT  - anticoagulation
OT  - atrial fibrillation
OT  - bleeding
OT  - patient decision aid
OT  - shared decision making
OT  - stroke prevention
EDAT- 2019/02/07 06:00
MHDA- 2020/04/15 06:00
CRDT- 2019/02/07 06:00
PHST- 2019/02/07 06:00 [pubmed]
PHST- 2020/04/15 06:00 [medline]
PHST- 2019/02/07 06:00 [entrez]
AID - 10.1177/1060028019828420 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2019 Jul;53(7):665-674. doi: 10.1177/1060028019828420. Epub 
      2019 Feb 6.

PMID- 7017497
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Clinical trials of a new preparation in chronic bronchopneumopathies].
PG  - 451-8
AB  - The new preparation Broncaspin (guacetisal) has been experimented in the form of 
      1.2 g suppositories and 5% suspension, in 40 patients suffering from chronic 
      bronchopneumopathy at acute phase. The drug exerted a marked therapeutic action 
      in objective and subjective symptomatology in 87.5% of cases. The action was 
      manifold in relation to the typical expectorant fluidifying, bronchiole 
      disobstructing and anti-inflammatory characteristics of the drug. Tolerance was 
      always excellent.
FAU - Zuccali, G
AU  - Zuccali G
FAU - Gherson, G
AU  - Gherson G
FAU - Parenti, M
AU  - Parenti M
LA  - ita
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Sperimentazione clinica di un nuovo preparato nelle broncopneumopatie croniche.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Asthma/drug therapy
MH  - Bronchitis/*drug therapy
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Cough/drug therapy
MH  - Female
MH  - Humans
MH  - Lung Diseases, Obstructive/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Emphysema/drug therapy
MH  - Respiration/drug effects
MH  - Silicosis/drug therapy
MH  - Tracheitis/drug therapy
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):451-8.

PMID- 27337929
OWN - NLM
STAT- MEDLINE
DCOM- 20170110
LR  - 20200325
IS  - 1000-1182 (Print)
IS  - 2618-0456 (Electronic)
IS  - 1000-1182 (Linking)
VI  - 34
IP  - 2
DP  - 2016 Apr
TI  - [Effects of aspirin on dendritic cells in the inflammatory microenvironment of 
      rabbit buccal VX-2 squamous cell carcinoma].
PG  - 178-82
AB  - OBJECTIVE: To explore the effects of aspirin and inflammation on the maturation 
      and function of dendritic cells (DC) on the supernatant of VX-2 squamous cell 
      carcinoma. METHODS: The rabbit buccal VX-2 squamous cell carcinoma models with 
      inflammation were established by tumor particle implantation, mechanical trauma, 
      and high sugar diet. The rabbits were divided into three groups. For the 
      experimental group (rabbit buccal VX-2 squamous cell carcinoma with local 
      inflammation), aspirin were given by gavage for three consecutive days. For the 
      control group (rabbit buccal VX-2 squamous cell carcinoma with local 
      inflammation), normal saline was given by gavage for three consecutive days. For 
      the blank group (tumor without inflammation), normal saline was given by gavage 
      for three consecutive days. Each tumor specimens were collected in three days and 
      made into tissue homogenate. The supernatant was collected after centrifugation. 
      Normal rabbit peripheral blood mononuclear cells were separated and co-cultured 
      with different states of supernatant. The expression of DC surface markers CD83, 
      CD86, and human leukocyte antigen-DR (HLA-DR) were detected by flow cytometry. 
      The state of function of DC was tested by mixed lymphocyte reaction. RESULTS: The 
      positive rate of CD83, CD86, and HLA-DR of the experimental and control groups 
      were both lower than that of the blank group (P<0.05). In addition, the ability 
      to stimulate T cell proliferation of the experimental and control groups were 
      weaker than that of the blank group (P<0.05). No significant difference was 
      observed between the experi- and HLADR of DC. The short-term administration of 
      aspirin is not conducive to the phenoty and function of DC in a rabbit mental and 
      control groups (P>0.05). CONCLUSION: Inflammation may inhibit the function and 
      expression of CD83, CD86, buccal VX-2 squamous cell carcinoma inflammatory 
      environment
FAU - Chen, Zhihong
AU  - Chen Z
FAU - Huang, Guilin
AU  - Huang G
FAU - Zhang, Nini
AU  - Zhang N
FAU - Yi, Jie
AU  - Yi J
FAU - Yao, Li
AU  - Yao L
FAU - Zhang, Lin
AU  - Zhang L
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Hua Xi Kou Qiang Yi Xue Za Zhi
JT  - Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal 
      of stomatology
JID - 9422648
RN  - 0 (Organothiophosphorus Compounds)
RN  - 9A4381183B (VX)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Carcinoma, Squamous Cell
MH  - Coculture Techniques
MH  - Dendritic Cells/*drug effects
MH  - Flow Cytometry
MH  - Humans
MH  - Inflammation
MH  - *Leukocytes, Mononuclear
MH  - Organothiophosphorus Compounds
MH  - Rabbits
PMC - PMC7029969
EDAT- 2016/06/25 06:00
MHDA- 2017/01/11 06:00
CRDT- 2016/06/25 06:00
PHST- 2016/06/25 06:00 [entrez]
PHST- 2016/06/25 06:00 [pubmed]
PHST- 2017/01/11 06:00 [medline]
AID - wcjs-34-02-178 [pii]
AID - 10.7518/hxkq.2016.02.015 [doi]
PST - ppublish
SO  - Hua Xi Kou Qiang Yi Xue Za Zhi. 2016 Apr;34(2):178-82. doi: 
      10.7518/hxkq.2016.02.015.

PMID- 1537105
OWN - NLM
STAT- MEDLINE
DCOM- 19920327
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 85
IP  - 3
DP  - 1992 Mar
TI  - High-dose aspirin inhibits shear-induced platelet reaction involving thrombin 
      generation.
PG  - 1077-82
AB  - BACKGROUND: A unifying concept of explaining all pharmacological actions of 
      aspirin by the irreversible blockage of the enzyme cyclooxygenase and therefore 
      the inhibition of prostaglandin biosynthesis has left many unanswered questions. 
      METHODS AND RESULTS: Two hundred ninety-four patients taking 75 mg/day aspirin 
      were tested 3 months after coronary artery bypass surgery. Platelet thromboxane 
      formation (whole blood aggregation to arachidonate) was completely prevented in 
      80% of patients. Compared with matched healthy controls (n = 95), a significant 
      platelet hyperreactivity was observed in patients (p less than 0.0001 versus less 
      than 0.002). Ninety patients were advised to increase their daily dose of aspirin 
      from 75 mg to 300 mg. Platelet reactivity retested 1 month after increasing the 
      dose has significantly decreased (p = 0.0008; less than 0.0001), whereas it 
      remained unchanged in those patients (n = 84) who continued with the same dose 
      regimens. In normal subjects, ingestion of a single 600-mg aspirin significantly 
      inhibited shear-induced platelet reaction. CONCLUSIONS: It is concluded that 
      aspirin does affect the platelet response to shear forces, but this requires 
      higher dosage (greater than 300 mg/day), suggesting a mechanism probably 
      different from that of interference with thromboxane formation.
FAU - Ratnatunga, C P
AU  - Ratnatunga CP
AD  - Department of Cardiothroracic Surgery, St. Bartholomew's Hospital Medical School, 
      London.
FAU - Edmondson, S F
AU  - Edmondson SF
FAU - Rees, G M
AU  - Rees GM
FAU - Kovacs, I B
AU  - Kovacs IB
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Coronary Artery Bypass
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Thrombin/*biosynthesis
MH  - Thrombosis/*prevention & control
MH  - Thromboxanes/biosynthesis
EDAT- 1992/03/01 00:00
MHDA- 1992/03/01 00:01
CRDT- 1992/03/01 00:00
PHST- 1992/03/01 00:00 [pubmed]
PHST- 1992/03/01 00:01 [medline]
PHST- 1992/03/01 00:00 [entrez]
AID - 10.1161/01.cir.85.3.1077 [doi]
PST - ppublish
SO  - Circulation. 1992 Mar;85(3):1077-82. doi: 10.1161/01.cir.85.3.1077.

PMID- 10573278
OWN - NLM
STAT- MEDLINE
DCOM- 19991207
LR  - 20190701
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 282
IP  - 19
DP  - 1999 Nov 17
TI  - Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic 
      hemorrhagic shock: a randomized controlled efficacy trial.
PG  - 1857-64
AB  - CONTEXT: Severe, uncompensated, traumatic hemorrhagic shock causes significant 
      morbidity and mortality, but resuscitation with an oxygen-carrying fluid might 
      improve patient outcomes. OBJECTIVE: To determine if the infusion of up to 1000 
      mL of diaspirin cross-linked hemoglobin (DCLHb) during the initial hospital 
      resuscitation could reduce 28-day mortality in traumatic hemorrhagic shock 
      patients. DESIGN AND SETTING: Multicenter, randomized, controlled, single-blinded 
      efficacy trial conducted between February 1997 and January 1998 at 18 US trauma 
      centers selected for their high volume of critically injured trauma patients, but 
      1 did not enroll patients. PATIENTS: A total of 112 patients with traumatic 
      hemorrhagic shock and unstable vital signs or a critical base deficit, who had a 
      mean (SD) patient age of 39 (20) years. Of the infused patients, 79% were male 
      and 56% were white. An exception to informed consent was used when necessary. 
      INTERVENTION: All patients were to be infused with 500 mL of DCLHb or saline 
      solution. Critically ill patients who still met entry criteria could have 
      received up to an additional 500 mL during the 1-hour infusion period. MAIN 
      OUTCOME MEASURES: Twenty-eight day mortality, 28-day morbidity, 48-hour 
      mortality, and 24-hour lactate levels. RESULTS: Of the 112 patients, 98 (88%) 
      were infused with DCLHb or saline solution. At 28 days, 24 (46%) of the 52 
      patients infused with DCLHb died, and 8 (17%) of the 46 patients infused with the 
      saline solution died (P = .003). At 48 hours, 20 (38%) of the 52 patients infused 
      with DCLHb died and 7 (15%) of the 46 patients infused with the saline solution 
      died (P = .01). The 28-day morbidity rate, as measured by the multiple organ 
      dysfunction score, was 72% higher in the DCLHb group (P = .03). There was no 
      difference in adverse event rates or the 24-hour lactate levels. CONCLUSIONS: 
      Mortality was higher for patients treated with DCLHb. Although further analysis 
      should investigate whether the mortality difference was solely due to a direct 
      treatment effect or to other factors, DCLHb does not appear to be an effective 
      resuscitation fluid.
FAU - Sloan, E P
AU  - Sloan EP
AD  - Department of Emergency Medicine, University of Illinois at Chicago, 60612, USA. 
      edsloan@uic.edu
FAU - Koenigsberg, M
AU  - Koenigsberg M
FAU - Gens, D
AU  - Gens D
FAU - Cipolle, M
AU  - Cipolle M
FAU - Runge, J
AU  - Runge J
FAU - Mallory, M N
AU  - Mallory MN
FAU - Rodman, G Jr
AU  - Rodman G Jr
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - Female
MH  - *Fluid Therapy
MH  - Hemoglobins/*therapeutic use
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multiple Organ Failure/etiology
MH  - Shock, Hemorrhagic/complications/*drug therapy
MH  - Single-Blind Method
MH  - Sodium Chloride
MH  - Statistics, Nonparametric
MH  - Survival Analysis
MH  - Trauma Severity Indices
EDAT- 1999/11/26 09:00
MHDA- 2001/03/28 10:01
CRDT- 1999/11/26 09:00
PHST- 1999/11/26 09:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1999/11/26 09:00 [entrez]
AID - joc91232 [pii]
AID - 10.1001/jama.282.19.1857 [doi]
PST - ppublish
SO  - JAMA. 1999 Nov 17;282(19):1857-64. doi: 10.1001/jama.282.19.1857.

PMID- 24831762
OWN - NLM
STAT- MEDLINE
DCOM- 20150413
LR  - 20140516
IS  - 1827-1618 (Electronic)
IS  - 0026-4725 (Linking)
VI  - 62
IP  - 3
DP  - 2014 Jun
TI  - Current developments in dual antiplatelet therapy after stenting.
PG  - 261-76
AB  - Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and an inhibitor of 
      the adenosine diphosphate platelet receptor P2Y12 has been shown to reduce the 
      risk of stent thrombosis (ST), myocardial infarction and cardiac death after 
      percutaneous coronary intervention (PCI) with bare-metal stents (BMS) and 
      drug-eluting stents (DES). However, while there is consensus on 1-month DAPT 
      after BMS, the optimal duration and the risk-benefit ratio of DAPT duration after 
      DES implantation remains controversial. Controversy surrounding this issue is 
      demonstrated by differences in guideline recommendations for DAPT duration after 
      PCI with DES. For example, while the ACC/AHA recommends a minimum of 12 months, 
      ESC guidelines recommend at least 6 months of DAPT. Recent reports suggest that 6 
      months of DAPT after second-generation DES implantation might be safe compared 
      with longer durations. Large randomized controlled trials powered to examine ST 
      and bleeding events are currently ongoing and will shed novel insight on 
      unresolved concerns and inform medical practice in the foreseeable future. In the 
      present review, we critically and comprehensively examine the current level of 
      evidence regarding the optimal duration of DAPT after PCI with DES and illustrate 
      new and future perspectives surrounding this rapidly changing field.
FAU - Giacoppo, D
AU  - Giacoppo D
AD  - Cardiology Department, Mount Sinai Hospital, New York, NY, USA - rmehran@crf.org.
FAU - Baber, U
AU  - Baber U
FAU - Mehran, R
AU  - Mehran R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Minerva Cardioangiol
JT  - Minerva cardioangiologica
JID - 0400725
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stents
MH  - Time Factors
EDAT- 2014/05/17 06:00
MHDA- 2015/04/14 06:00
CRDT- 2014/05/17 06:00
PHST- 2014/05/17 06:00 [entrez]
PHST- 2014/05/17 06:00 [pubmed]
PHST- 2015/04/14 06:00 [medline]
AID - R05Y2014N03A0261 [pii]
PST - ppublish
SO  - Minerva Cardioangiol. 2014 Jun;62(3):261-76.

PMID- 9823936
OWN - NLM
STAT- MEDLINE
DCOM- 19981203
LR  - 20191102
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 132
IP  - 5
DP  - 1998 Nov
TI  - Low-volume resuscitation with a hemoglobin-based oxygen carrier after hemorrhage 
      improves gut microvascular oxygenation in swine.
PG  - 421-31
AB  - Using palladium-porphyrin quenching of phosphorescence, we investigated the 
      influence of diaspirin cross-linked hemoglobin (DCLHb) on gut microvascular 
      oxygen pressure (microPO2) in anesthetized pigs. Values of gut microPO2 were 
      studied in correlation with regional intestinal as well as global metabolic and 
      circulatory parameters. A controlled hemorrhagic shock (blood withdrawal of 40 
      mL/kg) was followed by resuscitation with either a combination of lactated 
      Ringer's solution (75 mL/kg) and modified gelatin (15 mL/kg)(lactR/Gel) or 10% 
      DCLHb (5 mL/kg). After resuscitation, gut microPO2 was similarly improved in the 
      lactR/Gel group (from 25 +/- 10 mm Hg to 53 +/- 8 mm Hg) and the DCLHb group 
      (from 23 +/- 9 mm Hg to 46 +/- 6 mm Hg), which was associated with increased gut 
      oxygen delivery. However, the improvement after resuscitation with DCLHb was 
      sustained for longer periods of time (75 vs 30 min). Mesenteric venous PO2 was 
      increased after resuscitation with lactated Ringer's solution and modified 
      gelatin but not with DCLHb, which was associated with an increased gut oxygen 
      consumption in the latter group. We conclude that measurement of microPO2 by the 
      palladium-porphyrin phosphorescence technique revealed DCLHb to be an effective 
      carrier of oxygen to the microcirculation of the gut. Also, this effect can be 
      achieved with a lower volume than is currently used in resuscitation procedures.
FAU - van Iterson, M
AU  - van Iterson M
AD  - Department of Anesthesiology, Academic Medical Centre, University of Amsterdam, 
      The Netherlands.
FAU - Sinaasappel, M
AU  - Sinaasappel M
FAU - Burhop, K
AU  - Burhop K
FAU - Trouwborst, A
AU  - Trouwborst A
FAU - Ince, C
AU  - Ince C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - Disease Models, Animal
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/*therapeutic use
MH  - Ileum/*blood supply/drug effects
MH  - Microcirculation
MH  - Oxygen/*blood
MH  - Oxygen Consumption/*physiology
MH  - Partial Pressure
MH  - Resuscitation/methods
MH  - Shock, Hemorrhagic/blood/*therapy
MH  - Swine
EDAT- 1998/11/21 00:00
MHDA- 1998/11/21 00:01
CRDT- 1998/11/21 00:00
PHST- 1998/11/21 00:00 [pubmed]
PHST- 1998/11/21 00:01 [medline]
PHST- 1998/11/21 00:00 [entrez]
AID - S0022-2143(98)90113-5 [pii]
AID - 10.1016/s0022-2143(98)90113-5 [doi]
PST - ppublish
SO  - J Lab Clin Med. 1998 Nov;132(5):421-31. doi: 10.1016/s0022-2143(98)90113-5.

PMID- 9532989
OWN - NLM
STAT- MEDLINE
DCOM- 19980424
LR  - 20190719
IS  - 0306-5456 (Print)
IS  - 0306-5456 (Linking)
VI  - 105
IP  - 3
DP  - 1998 Mar
TI  - A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica 
      Low Dose Aspirin Study Group.
PG  - 293-9
AB  - OBJECTIVE: To investigate whether low dose aspirin medication given to 
      primiparous women provides benefit in preventing pre-eclampsia or intrauterine 
      growth retardation. DESIGN: Randomised double-blind controlled trial of low dose 
      aspirin and placebo in pregnancy. POPULATION: Residents of the parishes of 
      Kingston and St Andrew, Jamaica; 6275 primiparae enrolled between 12 and 32 weeks 
      of gestation. MAIN OUTCOME MEASURES: Hypertensive disorders of pregnancy 
      (including pre-eclampsia and eclampsia), preterm delivery, and low birthweight. 
      In addition, to assess whether enrollment early, rather than late had more 
      beneficial effect. Possible adverse effects on the woman and her infant were 
      monitored. RESULTS: Of enrolled primiparae, 97% were followed throughout 
      pregnancy. There were no differences between those on aspirin and those on 
      placebo in the development of hypertensive disorders (e.g. for a rise in 
      diastolic pressure of 25 mmHg the odds ratio [OR] was 1.02 [95% CI 0.86-1.21]; 
      for proteinuric pre-eclampsia OR 1.15 [95% CI 0.92-1.44]; eclampsia OR 0.82 [95% 
      CI 0.44-1.53]); except for oedema which was significantly less prevalent in those 
      on aspirin (OR 0.85 [95% CI 0.75-0.96]). Women on aspirin were no significantly 
      less likely to deliver preterm (OR 0.93 [95% CI 0.79-1.09]) or have a larger 
      fetus (mean birthweight difference 18 g [95% CI -9 to 45]). They were, however, 
      significantly more likely to suffer from bleeding disorders antenatally, 
      intrapartum and postpartum; for postpartum haemorrhage OR 1.40 (95% CI 
      1.13-1.73). CONCLUSIONS: This trial shows that low dose aspirin has no consistent 
      beneficial effect in primiparae.
FAU - Golding, J
AU  - Golding J
AD  - Tropical Metabolism Research Unit, Kingston, Jamaica.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Obstet Gynaecol
JT  - British journal of obstetrics and gynaecology
JID - 7503752
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br J Obstet Gynaecol. 1999 Feb;106(2):180. PMID: 10426687
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Birth Weight
MH  - Double-Blind Method
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Follow-Up Studies
MH  - Humans
MH  - Jamaica
MH  - *Parity
MH  - Patient Compliance
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Pregnancy Trimester, First
MH  - Pregnancy Trimester, Second
EDAT- 1998/04/09 00:00
MHDA- 1998/04/09 00:01
CRDT- 1998/04/09 00:00
PHST- 1998/04/09 00:00 [pubmed]
PHST- 1998/04/09 00:01 [medline]
PHST- 1998/04/09 00:00 [entrez]
AID - 10.1111/j.1471-0528.1998.tb10089.x [doi]
PST - ppublish
SO  - Br J Obstet Gynaecol. 1998 Mar;105(3):293-9. doi: 
      10.1111/j.1471-0528.1998.tb10089.x.

PMID- 581339
OWN - NLM
STAT- MEDLINE
DCOM- 19781227
LR  - 20131121
IS  - 0003-9985 (Print)
IS  - 0003-9985 (Linking)
VI  - 102
IP  - 10
DP  - 1978 Oct
TI  - Experimental meningococcal septicemia. Effect of aspirin therapy.
PG  - 515-7
AB  - In previous studies we have presented morphological evidence that the terminal 
      shock-like phase of fatal meningococcemia is caused by the occlusion of the 
      pulmonary microcirculation with thrombi composed of platelets, leukocytes, and 
      fibrin. We have also shown that in experimental meningococcemia, pretreatment of 
      rabbits with heparin sodium prevents fibrin formation but does not influence the 
      cellular pulmonary thrombi and does not prolong survival. If our theory is 
      correct, drugs that inhibit platelet aggregation and leukocyte adhesion in 
      rabbits should prolong life. The present experiment demonstrates that 
      pretreatment with a small dose of aspirin doubles the survival time without 
      altering the mortality.
FAU - Dalldorf, F G
AU  - Dalldorf FG
FAU - Jennette, J C
AU  - Jennette JC
FAU - Upton, G W
AU  - Upton GW
FAU - Tullar, J C
AU  - Tullar JC
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 9001-31-4 (Fibrin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Female
MH  - Fibrin/metabolism
MH  - Kidney Glomerulus/metabolism
MH  - Kidney Tubular Necrosis, Acute/etiology
MH  - Lung/pathology
MH  - Meningococcal Infections/complications/*mortality/pathology
MH  - Rabbits
MH  - Sepsis/complications/*mortality/pathology
MH  - Shock, Septic/pathology
EDAT- 1978/10/01 00:00
MHDA- 1978/10/01 00:01
CRDT- 1978/10/01 00:00
PHST- 1978/10/01 00:00 [pubmed]
PHST- 1978/10/01 00:01 [medline]
PHST- 1978/10/01 00:00 [entrez]
PST - ppublish
SO  - Arch Pathol Lab Med. 1978 Oct;102(10):515-7.

PMID- 35438083
OWN - NLM
STAT- MEDLINE
DCOM- 20220701
LR  - 20220701
IS  - 1473-5725 (Electronic)
IS  - 1359-5237 (Linking)
VI  - 27
IP  - 4
DP  - 2022 Aug 1
TI  - Validation of the EDAN SA-10 ambulatory blood pressure monitor in general 
      population according to the Association for the Advancement of Medical 
      Instrumentation/European Society of Hypertension/International Organization for 
      Standardization Universal Standard.
PG  - 276-279
LID - 10.1097/MBP.0000000000000600 [doi]
AB  - OBJECTIVE: To evaluate the accuracy of the EDAN SA-10 oscillometric upper-arm 
      professional office ambulatory blood pressure (BP) monitor in general population 
      according to the Association for the Advancement of Medical Instrumentation 
      (AAMI)/European Society of Hypertension (ESH)/International Organization for 
      Standardization (ISO) Universal Standard (ISO 81060-2:2018). METHODS: Subjects 
      were recruited according to the AAMI/ESH/ISO Universal Standard using the same 
      arm sequential BP measurement method. Four cuffs of the test device were used for 
      arm circumference 16-21.5 cm (extra small), 20.5-28 cm (small), 27-35 cm 
      (medium), and 34-43 cm (large). RESULTS: A total of 105 subjects were recruited, 
      and 97 subjects were included in the final analysis. For validation criterion 1, 
      the mean ± SD of the differences between the test device and reference BP 
      readings was -0.59 ± 4.04/-1.79 ± 4.39 mmHg (systolic/diastolic). For criterion 
      2, the SD of the averaged BP differences between the test device and reference BP 
      per subject was 3.10/3.80 mmHg (systolic/diastolic). CONCLUSION: The EDAN SA-10 
      upper-arm ambulatory BP monitor has passed all the requirements of the 
      AAMI/ESH/ISO Universal Standard (ISO 81060-2:2018) in general population and can 
      be recommended for clinical use.
CI  - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Wang, Bing
AU  - Wang B
AD  - Department of Neurology, Rocket Force Characteristic Medical Center, Beijing.
AD  - Department of Health Services, Fourth Military Medical University, Xi'an, China.
FAU - Liu, Kui
AU  - Liu K
AD  - Department of Health Services, Fourth Military Medical University, Xi'an, China.
FAU - Li, Linyi
AU  - Li L
AD  - Department of Health Services, Fourth Military Medical University, Xi'an, China.
FAU - Yin, Shimin
AU  - Yin S
AD  - Department of Neurology, Rocket Force Characteristic Medical Center, Beijing.
FAU - Ren, Jie
AU  - Ren J
AD  - Department of Health Services, Fourth Military Medical University, Xi'an, China.
LA  - eng
PT  - Journal Article
DEP - 20220418
PL  - England
TA  - Blood Press Monit
JT  - Blood pressure monitoring
JID - 9606438
RN  - 7194-12-9 (Edan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives
MH  - Blood Pressure
MH  - Blood Pressure Determination
MH  - Blood Pressure Monitoring, Ambulatory
MH  - *Blood Pressure Monitors
MH  - Humans
MH  - *Hypertension/diagnosis
MH  - Reference Standards
EDAT- 2022/04/20 06:00
MHDA- 2022/07/02 06:00
CRDT- 2022/04/19 08:40
PHST- 2022/04/20 06:00 [pubmed]
PHST- 2022/07/02 06:00 [medline]
PHST- 2022/04/19 08:40 [entrez]
AID - 00126097-990000000-00004 [pii]
AID - 10.1097/MBP.0000000000000600 [doi]
PST - ppublish
SO  - Blood Press Monit. 2022 Aug 1;27(4):276-279. doi: 10.1097/MBP.0000000000000600. 
      Epub 2022 Apr 18.

PMID- 28124651
OWN - NLM
STAT- MEDLINE
DCOM- 20170421
LR  - 20210112
IS  - 1945-8932 (Electronic)
IS  - 1945-8924 (Print)
IS  - 1945-8932 (Linking)
VI  - 30
IP  - 6
DP  - 2016 Nov 1
TI  - Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and 
      considerations for the future.
PG  - 407-413
LID - 10.2500/ajra.2016.30.4370 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is a late onset condition 
      characterized by the Samter triad (aspirin sensitivity [as well as sensitivity to 
      any nonselective cyclooxygenase inhibitor], nasal polyps, asthma) and additional 
      features, including eosinophilic chronic rhinosinusitis, hypereosinophilia, 
      anosmia, frequent absence of atopy, and, intolerance to ingestion of red wine and 
      other alcoholic beverages. The diagnosis is rare, and, because of this, it is 
      also often missed by physicians. However, it is highly overexpressed in patients 
      with severe asthma (and severe chronic rhinosinusitis with nasal polyps), which 
      makes its recognition essential. For this review, we considered mechanisms 
      involved in the pathogenesis of this disease and discussed the clinical symptoms 
      of AERD. We also discussed the role of aspirin desensitization in the treatment 
      of AERD. Also, we considered medications (e.g, leukotriene modifiers) and 
      surgical interventions that have a role in the treatment of AERD.
FAU - Kennedy, Joshua L
AU  - Kennedy JL
AD  - Department of Pediatrics, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas, USA.
FAU - Stoner, Ashley N
AU  - Stoner AN
FAU - Borish, Larry
AU  - Borish L
LA  - eng
GR  - UL1 TR000039/TR/NCATS NIH HHS/United States
GR  - T32 AI007496/AI/NIAID NIH HHS/United States
GR  - R56 AI120055/AI/NIAID NIH HHS/United States
GR  - KL2 TR000063/TR/NCATS NIH HHS/United States
GR  - U01 AI100799/AI/NIAID NIH HHS/United States
GR  - K08 AI121345/AI/NIAID NIH HHS/United States
GR  - P20 GM103625/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Leukotrienes)
RN  - R16CO5Y76E (Aspirin)
RN  - YZI5105V0L (Ketorolac)
SB  - IM
MH  - Animals
MH  - Anti-Allergic Agents/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Asthma/diagnosis/epidemiology/*therapy
MH  - Desensitization, Immunologic/*methods
MH  - Diagnosis, Differential
MH  - Drug Hypersensitivity/diagnosis/epidemiology/*therapy
MH  - Humans
MH  - Ketorolac/*adverse effects/therapeutic use
MH  - Leukotrienes/metabolism
MH  - Prevalence
MH  - United States
PMC - PMC5108840
EDAT- 2017/01/27 06:00
MHDA- 2017/04/22 06:00
CRDT- 2017/01/27 06:00
PHST- 2017/01/27 06:00 [entrez]
PHST- 2017/01/27 06:00 [pubmed]
PHST- 2017/04/22 06:00 [medline]
AID - AJRA064-16 [pii]
AID - 10.2500/ajra.2016.30.4370 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2016 Nov 1;30(6):407-413. doi: 10.2500/ajra.2016.30.4370.

PMID- 28056332
OWN - NLM
STAT- MEDLINE
DCOM- 20170605
LR  - 20220330
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 56
IP  - 1
DP  - 2017 Jan 1
TI  - [Aspirin use in patients with atherosclerotic cardiovascular disease: the 2016 
      Chinese expert consensus statement].
PG  - 68-80
LID - 10.3760/cma.j.issn.0578-1426.2017.01.020 [doi]
AB  - Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and 
      has the largest disease burden in China. Aspirin is the most promising agent for 
      the prevention of ASCVD in such a large population for its easy availability and 
      relative effectiveness, although its use in primary prevention is still a subject 
      of debate. The joint task force has reviewed the current evidence of aspirin use 
      in healthy population and in patients with stable coronary artery disease, acute 
      coronary syndrome, transient ischemic attack, stroke and peripheral artery 
      disease. The consensus statement provides a practical algorithm for identifying 
      those at a high 10-year ASCVD risk, with more than or equal to 10%, who may 
      benefit from aspirin use. Recommendations for aspirin use in primary and 
      secondary prevention of ASCVD in Chinese, as well as its safety and "resistance" 
      issues, are also stated.
CN  - Geriatrics Branch of Chinese Medical Association
CN  - Editorial Board of Chinese Journal of Internal Medicine
CN  - Editorial Board of Chinese Journal of Geriatrics
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atherosclerosis/*prevention & control
MH  - Case-Control Studies
MH  - China
MH  - Consensus
MH  - Coronary Disease
MH  - Humans
MH  - Ischemic Attack, Transient/prevention & control
MH  - Peripheral Arterial Disease
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Secondary Prevention/*methods/*statistics & numerical data
MH  - Stroke/drug therapy/prevention & control
MH  - Treatment Outcome
EDAT- 2017/01/06 06:00
MHDA- 2017/06/06 06:00
CRDT- 2017/01/06 06:00
PHST- 2017/01/06 06:00 [entrez]
PHST- 2017/01/06 06:00 [pubmed]
PHST- 2017/06/06 06:00 [medline]
AID - 10.3760/cma.j.issn.0578-1426.2017.01.020 [doi]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2017 Jan 1;56(1):68-80. doi: 
      10.3760/cma.j.issn.0578-1426.2017.01.020.

PMID- 11837557
OWN - NLM
STAT- MEDLINE
DCOM- 20020823
LR  - 20190916
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 22
IP  - 2
DP  - 2002 Feb
TI  - Hemorrhagic complications of enoxaparin and aspirin in patients with kidney 
      transplants.
PG  - 184-7
AB  - STUDY OBJECTIVE: To evaluate the frequency of early posttransplant hemorrhagic 
      complications in patients with kidney and kidney-pancreas transplants who 
      received thromboprophylaxis with enoxaparin and aspirin. DESIGN: Retrospective 
      chart review. SETTING: University-based tertiary care center. PATIENTS: Thirteen 
      patients who had received enoxaparin within 10 days of kidney or kidney-pancreas 
      transplantation. INTERVENTION: Medical records were reviewed, and data from 
      patients who had received low-dose aspirin 81 mg once/day and enoxaparin within 
      10 days of transplantation were collected. MEASUREMENTS AND MAIN RESULTS: Major 
      bleeding events were defined as intracranial or retroperitoneal bleeding, or a 
      decrease in hemoglobin of greater than 2 g/dl that was confirmed on repeat 
      evaluation. Nine (69%) of the 13 patients had confirmed major bleeding events and 
      required blood transfusions. Six of the nine patients had elevated serum 
      creatinine levels. CONCLUSION: The combination of enoxaparin and low-dose aspirin 
      early after kidney or kidney-pancreas transplantation was associated with a high 
      frequency of hemorrhagic events. Further evaluation is needed to determine the 
      safety of enoxaparin in combination with aspirin after transplantation.
FAU - Shullo, Michael A
AU  - Shullo MA
AD  - Department of Pharmacy and Therapeutics, School of Pharmacy, University of 
      Pittsburgh, Pennsylvania 15213, USA.
FAU - Rose, Meredith L
AU  - Rose ML
FAU - Vivas, Carlos
AU  - Vivas C
FAU - Jordan, Mark L
AU  - Jordan ML
FAU - Scantlebury, Velma P
AU  - Scantlebury VP
FAU - Jain, Ashok
AU  - Jain A
FAU - Corry, Robert J
AU  - Corry RJ
FAU - Fung, John J
AU  - Fung JJ
FAU - McCauley, Jerry
AU  - McCauley J
FAU - Johnston, James
AU  - Johnston J
FAU - Shapiro, Ron
AU  - Shapiro R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Enoxaparin/*adverse effects/therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*adverse effects/therapeutic use
MH  - Hemoglobins/analysis
MH  - Humans
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - Pancreas Transplantation
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Retrospective Studies
EDAT- 2002/02/12 10:00
MHDA- 2002/08/24 10:01
CRDT- 2002/02/12 10:00
PHST- 2002/02/12 10:00 [pubmed]
PHST- 2002/08/24 10:01 [medline]
PHST- 2002/02/12 10:00 [entrez]
AID - 10.1592/phco.22.3.184.33541 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2002 Feb;22(2):184-7. doi: 10.1592/phco.22.3.184.33541.

PMID- 26155946
OWN - NLM
STAT- MEDLINE
DCOM- 20151124
LR  - 20150721
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 16
IP  - 12
DP  - 2015
TI  - Aspirin and heparin in pregnancy.
PG  - 1793-803
LID - 10.1517/14656566.2015.1066335 [doi]
AB  - INTRODUCTION: A pro-coagulant state during pregnancy can be involved in the 
      occurrence of gestational vascular complications (GVCs) and venous 
      thromboembolism (VTE). AREAS COVERED: Antithrombotic drugs are used to prevent 
      GVCs and VTE. Aspirin is not efficacious to prevent recurrences in women with 
      previous early loss, while it can prevent pre-eclampsia in some groups of women. 
      Heparins are not effective in the prevention of early recurrent loss and there is 
      uncertainty about their efficacy in women carrying inherited thrombophilias. They 
      could be efficacious in the prevention of GVCs in carriers of inherited 
      thrombophilias, as GVCs have heterogeneous causes, and future studies have to 
      focus on more homogeneous groups of patients. Not enough data are available 
      regarding prophylaxis with heparins to prevent pregnancy-related VTE, but an 
      accurate risk stratification of women during pregnancy and puerperium is crucial 
      for administering prophylaxis in moderate-/high-risk women. Aspirin does not 
      improve live births after assisted reproductive technologies, while heparins 
      increase the number of clinical pregnancies and live births. EXPERT OPINION: 
      Aspirin is efficacious in the prevention of GVCs in women at risk for 
      pre-eclampsia and in those with antiphospholipid antibodies syndrome. Heparins 
      could give benefit to women at risk for GVCs and/or pregnancy-related VTE.
FAU - Grandone, Elvira
AU  - Grandone E
AD  - Unita' di Aterosclerosi e Trombosi, I.R.C.C.S. 'Casa Sollievo della Sofferenza' , 
      S. Giovanni Rotondo (FOGGIA) , Italy +39 0 882 416 286 ; +39 0 882 416 273 ; 
      e.grandone@operapadrepio.it.
FAU - Villani, Michela
AU  - Villani M
FAU - Tiscia, Giovanni L
AU  - Tiscia GL
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150709
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - Thrombophilia, hereditary
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Heparin/adverse effects/*therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Reproductive Techniques, Assisted
MH  - Risk
MH  - Thrombophilia/*drug therapy
MH  - Vascular Diseases/*drug therapy/prevention & control
MH  - Venous Thromboembolism/prevention & control
OTO - NOTNLM
OT  - aspirin
OT  - gestational vascular complications
OT  - heparin
OT  - venous thromboembolism
EDAT- 2015/07/15 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/07/10 06:00
PHST- 2015/07/10 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1517/14656566.2015.1066335 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2015;16(12):1793-803. doi: 
      10.1517/14656566.2015.1066335. Epub 2015 Jul 9.

PMID- 17044808
OWN - NLM
STAT- MEDLINE
DCOM- 20070108
LR  - 20191110
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 5
IP  - 6
DP  - 2006 Nov
TI  - The safety and efficacy of aspirin and clopidogrel as a combination treatment in 
      patients with coronary heart disease.
PG  - 815-26
AB  - The use of aspirin and clopidogrel in combination has become part of the standard 
      clinical care of patients with coronary artery disease. The use of this 
      combination provides significant benefits compared with the use of aspirin alone 
      in patients with acute coronary syndromes, and in patients treated with 
      percutaneous coronary intervention with stent placement (both bare metal and 
      drug-eluting stents). Clinical trials have demonstrated significant efficacy of 
      this dual therapy; however, there is the potential for significant bleeding 
      complications from the synergistic antiplatelet effects. In total, it appears 
      that when there is vessel injury (mechanical from perctutaneous coronary 
      intervention or a ruptured plaque), dual antiplatelet therapy with aspirin and 
      clopidogrel results in improved outcomes, albeit with a small but significant 
      inherent risk of increased bleeding.
FAU - Cooke, Glen E
AU  - Cooke GE
AD  - Assistant Professor of Medicine, The Ohio State University, The Davis Heart and 
      Lung Research Institute and Division of Cardiovascular Medicine, Department of 
      Internal Medicine, College of Medicine, Columbus, OH, USA. glen.cooke@osumc.edu
FAU - Goldschmidt-Clermont, Pascal J
AU  - Goldschmidt-Clermont PJ
LA  - eng
GR  - K23 HL004483/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Coronary Disease/*drug therapy/epidemiology/prevention & control
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/*therapeutic use
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
RF  - 82
EDAT- 2006/10/19 09:00
MHDA- 2007/01/09 09:00
CRDT- 2006/10/19 09:00
PHST- 2006/10/19 09:00 [pubmed]
PHST- 2007/01/09 09:00 [medline]
PHST- 2006/10/19 09:00 [entrez]
AID - 10.1517/14740338.5.6.815 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2006 Nov;5(6):815-26. doi: 10.1517/14740338.5.6.815.

PMID- 12723746
OWN - NLM
STAT- MEDLINE
DCOM- 20030604
LR  - 20161124
IS  - 1368-504X (Print)
IS  - 1368-504X (Linking)
IP  - 135
DP  - 2003 Apr
TI  - Population impact of strategies designed to reduce peptic ulcer risks associated 
      with NSAID use.
PG  - 38-42
AB  - The risk of ulcer complications rises steeply with dose for aspirin and other 
      non-steroidal anti-inflammatory drugs (NSAIDs) but estimates of the overall 
      incidence of bleeding ulcer are unreliable. Drug utilisation data, 
      epidemiological data on the frequency of bleeding ulcer and death, and the 
      relative risks associated with different NSAIDs, indicate that the number of 
      cases of bleeding ulcer attributable to NSAIDs in the United Kingdom is 
      approximately 2,400. Substitution of ibuprofen at a dose of 2.4 g/day for all 
      other NSAIDs would reduce the number of events attributable to NSAIDs from 2,431 
      to 695 annually. At a dose of 1200 mg/day, substituting ibuprofen or another safe 
      NSAID would be likely to reduce events to zero. Similarly, substitution of 
      ibuprofen 2.4 g/day for all other NSAIDs would reduce attributable ulcer 
      mortality to 80. The total number of excess cases attributable to aspirin is 753 
      annually. If prophylactic aspirin was prescribed solely at a dose of 75 mg/day, 
      the number of cases would fall to 445 annually and the number of related deaths 
      from 87 to 51 annually. NSAIDs and aspirin account for approximately one-third 
      and previous ulcer for about one-fifth of the overall risk of bleeding ulcer and 
      its complications.
FAU - Langman, Michael
AU  - Langman M
AD  - University of Birmingham, Birmingham, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Int J Clin Pract Suppl
JT  - International journal of clinical practice. Supplement
JID - 9712380
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Humans
MH  - Incidence
MH  - Peptic Ulcer Hemorrhage/*chemically induced/epidemiology
MH  - Risk Factors
MH  - United Kingdom/epidemiology
RF  - 7
EDAT- 2003/05/02 05:00
MHDA- 2003/06/05 05:00
CRDT- 2003/05/02 05:00
PHST- 2003/05/02 05:00 [pubmed]
PHST- 2003/06/05 05:00 [medline]
PHST- 2003/05/02 05:00 [entrez]
PST - ppublish
SO  - Int J Clin Pract Suppl. 2003 Apr;(135):38-42.

PMID- 8646257
OWN - NLM
STAT- MEDLINE
DCOM- 19960725
LR  - 20140603
VI  - 20
IP  - 2
DP  - 1996 Feb
TI  - Post-prandial thermogenesis with ephedrine, caffeine and aspirin in lean, 
      pre-disposed obese and obese women.
PG  - 91-7
AB  - OBJECTIVE: To determine whether or not aspirin further potentiates the greater 
      post-prandial thermogenesis induced by ephedrine with caffeine. DESIGN: 
      Determination of the acute metabolic rate response to the following treatments: 
      1050 kJ liquid meal (M); meal plus ephedrine (30 mg) and caffeine (100 mg) (MEC) 
      or meal plus ephedrine, caffeine and aspirin (300 mg) (MECA). SUBJECTS: Lean, 
      pre-disposed obese and obese women (n = 10 each group). MEASUREMENTS: Pre- and 
      post-treatment metabolic rate determinations via indirect calorimetry. 
      Post-treatment measurements made at 20 min intervals for a total of 160 min. 
      RESULTS: In all groups, metabolic rate increased significantly more following the 
      MEC or MECA, compared to the meal only (p < 0.05). The obese group had a 
      significantly greater absolute increase in metabolic rate following the MECA and 
      MEC compared to both the lean and pre-disposed obese groups (p < 0.05). Metabolic 
      rate remained elevated at the end of the 160 min following all treatments. 
      CONCLUSION: Aspirin does not further potentiate the acute thermic effect of 
      ephedrine and caffeine with a meal. However, the full thermogenic response was 
      not measured and longer duration studies are necessary to confirm these results.
FAU - Horton, T J
AU  - Horton TJ
AD  - Department of Nutrition and Dietetics, King's College, University of London, 
      Kensington, UK.
FAU - Geissler, C A
AU  - Geissler CA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Obes Relat Metab Disord
JT  - International journal of obesity and related metabolic disorders : journal of the 
      International Association for the Study of Obesity
JID - 9313169
RN  - 3G6A5W338E (Caffeine)
RN  - GN83C131XS (Ephedrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Basal Metabolism
MH  - Body Constitution
MH  - Body Mass Index
MH  - Body Temperature Regulation/*drug effects
MH  - Caffeine/administration & dosage/*pharmacology
MH  - Calorimetry, Indirect
MH  - Ephedrine/administration & dosage/*pharmacology
MH  - Female
MH  - *Food
MH  - Humans
MH  - Kinetics
MH  - Obesity/*metabolism
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
PST - ppublish
SO  - Int J Obes Relat Metab Disord. 1996 Feb;20(2):91-7.

PMID- 19522741
OWN - NLM
STAT- MEDLINE
DCOM- 20091230
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 7
IP  - 8
DP  - 2009 Aug
TI  - Aspirin reduces the prothrombotic activity of C-reactive protein.
PG  - 1393-400
LID - 10.1111/j.1538-7836.2009.03511.x [doi]
AB  - AIM: C-reactive protein (CRP) is a risk marker and a potential modulator of 
      vascular disease. Previous studies support a prothrombotic activity of CRP, with 
      impaired thromboregulation. The present study examined the antithrombotic effect 
      of aspirin in mice transgenic for human CRP (CRPtg mice). Mechanistic 
      investigations further elucidated the effect of CRP on prostanoid metabolism in 
      vivo and in vitro. METHODS AND RESULTS: Administration of aspirin (30 mg kg(-1) 
      day(-1)) to CRPtg mice slowed the accelerated thrombosis after photochemical 
      injury to the carotid (99 +/- 32 vs. 45 +/- 24 min and 75 +/- 23 vs. 82 +/- 26 
      min in wild-type mice vs. CRPtg mice, without and following aspirin treatment, 
      respectively). Vascular injury modulated the expression of key pathways in 
      prostanoid metabolism differently in CRPtg mice and wild-type mice. Suppression 
      of cyclo-oxygenase 2 (COX-2)-derived metabolism with suppression of prostaglandin 
      I2 (PGI2) synthase and PGI2 metabolism was recorded in the injured artery with 
      increased thromboxane receptor expression. Aspirin therapy reduced the difference 
      in PGI2 biosynthesis between CRPtg mice and wild-type mice. In vitro studies in 
      human-derived cells further supported these findings. Incubation of human 
      umbilical vein endothelial cells (HUVECs) with human recombinant CRP (5 microg 
      mL(-1)) suppressed PGI2 synthase expression and significantly increased 
      thromboxane receptor levels. Incubation of smooth muscle cells with CRP did not 
      affect prostanoid expression. CONCLUSIONS: CRP modulates prostanoid metabolism to 
      favor vascular occlusion. Elevated CRP levels might predispose to the 
      cardiovascular hazard conferred by selective COX-2 inhibitors, and the risk 
      mediated by CRP may be limited by aspirin.
FAU - Grad, E
AU  - Grad E
AD  - Heart Research Centre, Hadassah Hebrew University Medical Centre, Jerusalem, 
      Israel.
FAU - Golomb, M
AU  - Golomb M
FAU - Koroukhov, N
AU  - Koroukhov N
FAU - Lawson, J A
AU  - Lawson JA
FAU - Lotan, C
AU  - Lotan C
FAU - Fitzgerald, G A
AU  - Fitzgerald GA
FAU - Danenberg, H D
AU  - Danenberg HD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090609
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Receptors, Thromboxane)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - EC 5.3.- (Intramolecular Oxidoreductases)
RN  - EC 5.3.99.4 (prostacyclin synthetase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - C-Reactive Protein/*pharmacology
MH  - Cells, Cultured
MH  - Cytochrome P-450 Enzyme System/analysis
MH  - Drug Interactions
MH  - Endothelium, Vascular/cytology
MH  - Epoprostenol/*metabolism
MH  - Humans
MH  - Intramolecular Oxidoreductases/analysis
MH  - Mice
MH  - Mice, Transgenic
MH  - Receptors, Thromboxane/analysis
MH  - Thrombosis/*chemically induced/*drug therapy/prevention & control
EDAT- 2009/06/16 09:00
MHDA- 2009/12/31 06:00
CRDT- 2009/06/16 09:00
PHST- 2009/06/16 09:00 [entrez]
PHST- 2009/06/16 09:00 [pubmed]
PHST- 2009/12/31 06:00 [medline]
AID - S1538-7836(22)17301-0 [pii]
AID - 10.1111/j.1538-7836.2009.03511.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2009 Aug;7(8):1393-400. doi: 10.1111/j.1538-7836.2009.03511.x. 
      Epub 2009 Jun 9.

PMID- 11300432
OWN - NLM
STAT- MEDLINE
DCOM- 20010426
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 37
IP  - 5
DP  - 2001 Apr
TI  - Ticlopidine versus aspirin after myocardial infarction (STAMI) trial.
PG  - 1259-65
AB  - OBJECTIVES: We sought to compare the efficacy of aspirin and ticlopidine in 
      survivors of acute myocardial infarction (AMI) treated with thrombolysis. 
      BACKGROUND: The role of ticlopidine in secondary prevention after AMI has not yet 
      been explored. METHODS: Of 4,696 patients with AMI treated with thrombolysis who 
      were screened, 261 died in the hospital (5.6%) and 1,470 were enrolled in this 
      randomized, double-blind, multicenter trial and allocated to treatment with 
      either aspirin (160 mg/day) or ticlopidine (500 mg/day). The most frequent 
      reasons for exclusion were refusal to give informed consent, planned myocardial 
      revascularization, risk of noncompliance with study procedures, need for 
      anticoagulant therapy and contraindications to the study treatments. The primary 
      end point was the first occurrence of any of the following events during the 
      six-month follow-up: fatal and nonfatal AMI, fatal and nonfatal stroke, angina 
      with objective evidence of myocardial ischemia, vascular death or death due to 
      any other cause. RESULTS: The primary end point was recorded in 59 (8.0%) of the 
      736 aspirin-treated and 59 (8.0%) of the 734 ticlopidine-treated patients (p = 
      0.966). Vascular death was the first event in five patients taking aspirin and in 
      six patients taking ticlopidine (0.7% vs. 0.8%; p = NS); nonfatal AMI in 18 and 8 
      (2.4% vs. 1.1%; p = 0.049); nonfatal stroke in 3 and 4 (0.4% vs. 0.5%; p = NS); 
      and angina in 33 and 40 (4.5% vs. 5.4%; p = NS), respectively. The frequency of 
      adverse reactions was not significantly different between the two groups. 
      CONCLUSIONS: No difference was found between the ticlopidine and aspirin groups 
      in the rate of the primary combined end point of death, recurrent AMI, stroke and 
      angina.
FAU - Scrutinio, D
AU  - Scrutinio D
AD  - Division of Cardiology, S. Maugeri Foundation, IRCCS, Institute of 
      Rehabilitation, Cassano Murge, Bari, Italy. dscrutinio@fsm.it
FAU - Cimminiello, C
AU  - Cimminiello C
FAU - Marubini, E
AU  - Marubini E
FAU - Pitzalis, M V
AU  - Pitzalis MV
FAU - Di Biase, M
AU  - Di Biase M
FAU - Rizzon, P
AU  - Rizzon P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cause of Death
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/mortality
MH  - Recurrence
MH  - Survival Rate
MH  - *Thrombolytic Therapy
MH  - Ticlopidine/adverse effects/*therapeutic use
EDAT- 2001/04/13 10:00
MHDA- 2001/05/01 10:01
CRDT- 2001/04/13 10:00
PHST- 2001/04/13 10:00 [pubmed]
PHST- 2001/05/01 10:01 [medline]
PHST- 2001/04/13 10:00 [entrez]
AID - S0735109701011640 [pii]
AID - 10.1016/s0735-1097(01)01164-0 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2001 Apr;37(5):1259-65. doi: 10.1016/s0735-1097(01)01164-0.

PMID- 8193093
OWN - NLM
STAT- MEDLINE
DCOM- 19940628
LR  - 20190719
IS  - 0306-5456 (Print)
IS  - 0306-5456 (Linking)
VI  - 101
IP  - 3
DP  - 1994 Mar
TI  - Neonatal platelet reactivity and serum thromboxane B2 production in whole blood: 
      the effect of maternal low dose aspirin.
PG  - 203-8
AB  - OBJECTIVES: Concern has been expressed about possible neonatal side effects after 
      the use of maternal anti-platelet agents in pregnancy, particularly low dose 
      aspirin treatment. We have studied neonatal platelet behaviour using whole blood 
      techniques, and assessed the neonatal effect of the maternal ingestion of 60 mg 
      aspirin daily. DESIGN: Cross sectional and randomised, double-blind, 
      placebo-controlled. SETTING: University hospital. SUBJECTS: 1. Eight normal 
      women, studied before conception, and their infants. 2. Twenty-four infants whose 
      mothers had been randomised to receive either 60 mg aspirin daily, or placebo, in 
      double-blind fashion. METHODS: The Clay Adams Ultra Flo 100 whole blood single 
      platelet counter was employed to measure platelet aggregation in response to 
      various agonists. The platelet release reaction was also measured in whole blood, 
      and serum thromboxane B2 (TxB2) production was measured by radio-immunoassay. 
      Umbilical cord blood samples were obtained at delivery. RESULTS: 1. Neonatal 
      platelet aggregation induced by adrenaline, ADP and platelet activating factor 
      was reduced in comparison with their mothers (P < 0.01), whereas the neonatal 
      platelet release reaction was reduced when stimulated by collagen and U46619 (a 
      thromboxane mimetic) (P < 0.01). Serum TxB2 production was similar in mothers and 
      babies. 2. Neonatal platelet aggregation, release reaction and serum TxB2 
      production were not significantly reduced in infants exposed to maternal aspirin 
      in comparison with those neonates exposed to maternal placebo. This is in 
      contrast to the effect on maternal platelets. CONCLUSIONS: Although only a small 
      number of patients were studied, we interpret this as a relative sparing of 
      neonatal platelet reactivity due to the presystemic action of low dose aspirin.
FAU - Louden, K A
AU  - Louden KA
AD  - Department of Obstetrics & Gynaecology, Queens Medical Centre, Nottingham, UK.
FAU - Broughton Pipkin, F
AU  - Broughton Pipkin F
FAU - Heptinstall, S
AU  - Heptinstall S
FAU - Fox, S C
AU  - Fox SC
FAU - Tuohy, P
AU  - Tuohy P
FAU - O'Callaghan, C
AU  - O'Callaghan C
FAU - Mitchell, J R
AU  - Mitchell JR
FAU - Symonds, E M
AU  - Symonds EM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Obstet Gynaecol
JT  - British journal of obstetrics and gynaecology
JID - 7503752
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br J Obstet Gynaecol. 1994 Nov;101(11):1023. PMID: 7864999
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Fetal Blood
MH  - Humans
MH  - Hypertension/blood/prevention & control
MH  - In Vitro Techniques
MH  - Infant, Newborn
MH  - Platelet Aggregation/*drug effects
MH  - Pre-Eclampsia/blood/prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/metabolism/prevention & control
MH  - Thromboxane B2/*blood
EDAT- 1994/03/01 00:00
MHDA- 1994/03/01 00:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 1994/03/01 00:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
AID - 10.1111/j.1471-0528.1994.tb13110.x [doi]
PST - ppublish
SO  - Br J Obstet Gynaecol. 1994 Mar;101(3):203-8. doi: 
      10.1111/j.1471-0528.1994.tb13110.x.

PMID- 1127641
OWN - NLM
STAT- MEDLINE
DCOM- 19750808
LR  - 20190724
IS  - 0022-4251 (Print)
IS  - 0022-4251 (Linking)
VI  - 43
IP  - 1
DP  - 1975 Apr
TI  - Inhibition by aspirin and indomethacin of uterine hypertrophy induced by an IUD.
PG  - 77-81
AB  - An IUD inserted into one uterine horn caused an increase in its weight when this 
      was compared with that of the contralateral control horn in rats. Such an 
      increase could be partly prevented by treating the animals with indomethacin and 
      aspirin. It is suggested that the IUD-induced increase in weight is at least in 
      part mediated by release of prostaglandins.
FAU - Chaudhuri, G
AU  - Chaudhuri G
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Reprod Fertil
JT  - Journal of reproduction and fertility
JID - 0376367
RN  - 48I5LU4ZWD (Meclofenamic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Castration
MH  - Fallopian Tubes
MH  - Female
MH  - Hydrocortisone/therapeutic use
MH  - Hypertrophy/etiology/prevention & control
MH  - Indomethacin/pharmacology/*therapeutic use
MH  - Intrauterine Devices/*adverse effects
MH  - Meclofenamic Acid/therapeutic use
MH  - Organ Size/drug effects
MH  - Ovary/physiology
MH  - Rats
MH  - Sutures
MH  - Uterine Diseases/*etiology/prevention & control
MH  - Uterus/drug effects
EDAT- 1975/04/01 00:00
MHDA- 1975/04/01 00:01
CRDT- 1975/04/01 00:00
PHST- 1975/04/01 00:00 [pubmed]
PHST- 1975/04/01 00:01 [medline]
PHST- 1975/04/01 00:00 [entrez]
AID - 10.1530/jrf.0.0430077 [doi]
PST - ppublish
SO  - J Reprod Fertil. 1975 Apr;43(1):77-81. doi: 10.1530/jrf.0.0430077.

PMID- 29132159
OWN - NLM
STAT- MEDLINE
DCOM- 20181231
LR  - 20181231
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 168
IP  - 4
DP  - 2018 Feb 20
TI  - Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing 
      Noncardiac Surgery.
PG  - 237-244
LID - 10.7326/M17-2341 [doi]
AB  - BACKGROUND: Uncertainty remains about the effects of aspirin in patients with 
      prior percutaneous coronary intervention (PCI) having noncardiac surgery. 
      OBJECTIVE: To evaluate benefits and harms of perioperative aspirin in patients 
      with prior PCI. DESIGN: Nonprespecified subgroup analysis of a multicenter 
      factorial trial. Computerized Internet randomization was done between 2010 and 
      2013. Patients, clinicians, data collectors, and outcome adjudicators were 
      blinded to treatment assignment. (ClinicalTrials.gov: NCT01082874). SETTING: 135 
      centers in 23 countries. PATIENTS: Adults aged 45 years or older who had or were 
      at risk for atherosclerotic disease and were having noncardiac surgery. 
      Exclusions were placement of a bare-metal stent within 6 weeks, placement of a 
      drug-eluting stent within 1 year, or receipt of nonstudy aspirin within 72 hours 
      before surgery. INTERVENTION: Aspirin therapy (overall trial, n = 4998; subgroup, 
      n = 234) or placebo (overall trial, n = 5012; subgroup, n = 236) initiated within 
      4 hours before surgery and continued throughout the perioperative period. Of the 
      470 subgroup patients, 99.9% completed follow-up. MEASUREMENTS: The 30-day 
      primary outcome was death or nonfatal myocardial infarction; bleeding was a 
      secondary outcome. RESULTS: In patients with prior PCI, aspirin reduced the risk 
      for the primary outcome (absolute risk reduction, 5.5% [95% CI, 0.4% to 10.5%]; 
      hazard ratio [HR], 0.50 [CI, 0.26 to 0.95]; P for interaction = 0.036) and for 
      myocardial infarction (absolute risk reduction, 5.9% [CI, 1.0% to 10.8%]; HR, 
      0.44 [CI, 0.22 to 0.87]; P for interaction = 0.021). The effect on the composite 
      of major and life-threatening bleeding in patients with prior PCI was uncertain 
      (absolute risk increase, 1.3% [CI, -2.6% to 5.2%]). In the overall population, 
      aspirin increased the risk for major bleeding (absolute risk increase, 0.8% [CI, 
      0.1% to 1.6%]; HR, 1.22 [CI, 1.01 to 1.48]; P for interaction = 0.50). 
      LIMITATION: Nonprespecified subgroup analysis with small sample. CONCLUSION: 
      Perioperative aspirin may be more likely to benefit rather than harm patients 
      with prior PCI. PRIMARY FUNDING SOURCE: Canadian Institutes of Health Research.
FAU - Graham, Michelle M
AU  - Graham MM
AD  - University of Alberta and Mazankowski Alberta Heart Institute, Edmonton, Alberta, 
      Canada (M.M.G.).
FAU - Sessler, Daniel I
AU  - Sessler DI
AD  - Cleveland Clinic, Cleveland, Ohio (D.I.S.).
FAU - Parlow, Joel L
AU  - Parlow JL
AD  - Queen's University, Kingston, Ontario, Canada (J.L.P.).
FAU - Biccard, Bruce M
AU  - Biccard BM
AD  - Groote Schuur Hospital and University of Cape Town, Western Cape, South Africa 
      (B.M.B.).
FAU - Guyatt, Gordon
AU  - Guyatt G
AD  - Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada 
      (G.G., D.J.C., V.T., A.L., R.W., Y.L., P.G., S.Y., P.D.).
FAU - Leslie, Kate
AU  - Leslie K
AD  - Royal Melbourne Hospital, Melbourne Medical School, University of Melbourne, and 
      Monash University, Melbourne, Victoria, Australia (K.L.).
FAU - Chan, Matthew T V
AU  - Chan MTV
AD  - The Chinese University of Hong Kong, Hong Kong, China (M.T.C.).
FAU - Meyhoff, Christian S
AU  - Meyhoff CS
AD  - Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, 
      Denmark (C.S.M.).
FAU - Xavier, Denis
AU  - Xavier D
AD  - St. John's Medical College and Research Institute, Bangalore, India (D.X.).
FAU - Sigamani, Alben
AU  - Sigamani A
AD  - Narayana Hrudayalaya, Bangalore, India (A.S.).
FAU - Kumar, Priya A
AU  - Kumar PA
AD  - University of North Carolina, Chapel Hill, North Carolina (P.A.K.).
FAU - Mrkobrada, Marko
AU  - Mrkobrada M
AD  - Schulich School of Medicine & Dentistry at Western University, London, Ontario, 
      Canada (M.M.).
FAU - Cook, Deborah J
AU  - Cook DJ
AD  - Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada 
      (G.G., D.J.C., V.T., A.L., R.W., Y.L., P.G., S.Y., P.D.).
FAU - Tandon, Vikas
AU  - Tandon V
AD  - Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada 
      (G.G., D.J.C., V.T., A.L., R.W., Y.L., P.G., S.Y., P.D.).
FAU - Alvarez-Garcia, Jesus
AU  - Alvarez-Garcia J
AD  - Sant Pau Hospital and Biomedical Research Institute, Autonomous University of 
      Barcelona, Research Center of Cardiovascular Diseases (CIBERCV), Barcelona, Spain 
      (J.A.).
FAU - Villar, Juan Carlos
AU  - Villar JC
AD  - Fundación Cardioinfantil Instituto de Cardiología, Bogotá, Colombia, and 
      Department of Medicine, Universidad Autónoma de Bucaramanga, Santander, Colombia 
      (J.C.V.).
FAU - Painter, Thomas W
AU  - Painter TW
AD  - University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia (T.W.P.).
FAU - Landoni, Giovanni
AU  - Landoni G
AD  - IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, 
      Milan, Italy (G.L.).
FAU - Fleischmann, Edith
AU  - Fleischmann E
AD  - Medical University of Vienna, Vienna, Austria (E.F.).
FAU - Lamy, Andre
AU  - Lamy A
AD  - Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada 
      (G.G., D.J.C., V.T., A.L., R.W., Y.L., P.G., S.Y., P.D.).
FAU - Whitlock, Richard
AU  - Whitlock R
AD  - Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada 
      (G.G., D.J.C., V.T., A.L., R.W., Y.L., P.G., S.Y., P.D.).
FAU - Le Manach, Yannick
AU  - Le Manach Y
AD  - Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada 
      (G.G., D.J.C., V.T., A.L., R.W., Y.L., P.G., S.Y., P.D.).
FAU - Aphang-Lam, Meylin
AU  - Aphang-Lam M
AD  - Hospital Arzobispo Loayza, Universidad Peruana Cayetano Heredia, Lima, Peru 
      (M.A.).
FAU - Cata, Juan P
AU  - Cata JP
AD  - The University of Texas MD Anderson Cancer Center, Houston, Texas (J.P.C.).
FAU - Gao, Peggy
AU  - Gao P
AD  - Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada 
      (G.G., D.J.C., V.T., A.L., R.W., Y.L., P.G., S.Y., P.D.).
FAU - Terblanche, Nicolaas C S
AU  - Terblanche NCS
AD  - Royal Hobart Hospital and University of Tasmania, Hobart, Tasmania, Australia 
      (N.C.T.).
FAU - Ramana, Pamidimukkala V
AU  - Ramana PV
AD  - CARE Hospitals, Maharanipeta, Visakhapatnam, India (P.V.R.).
FAU - Jamieson, Kim A
AU  - Jamieson KA
AD  - Auckland City Hospital, Auckland, New Zealand (K.A.J.).
FAU - Bessissow, Amal
AU  - Bessissow A
AD  - McGill University Health Centre, Montréal, Québec, Canada (A.B.).
FAU - Mendoza, Gabriela R
AU  - Mendoza GR
AD  - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina (G.R.M.).
FAU - Ramirez, Silvia
AU  - Ramirez S
AD  - Hospital Universitario Fundación Hospital Alcorcon, Madrid, Spain (S.R.).
FAU - Diemunsch, Pierre A
AU  - Diemunsch PA
AD  - Centre Hospitalier Universitaire de Hautepierre, Strasbourg, France (P.A.D.).
FAU - Yusuf, Salim
AU  - Yusuf S
AD  - Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada 
      (G.G., D.J.C., V.T., A.L., R.W., Y.L., P.G., S.Y., P.D.).
FAU - Devereaux, P J
AU  - Devereaux PJ
AD  - Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada 
      (G.G., D.J.C., V.T., A.L., R.W., Y.L., P.G., S.Y., P.D.).
LA  - eng
SI  - ClinicalTrials.gov/NCT01082874
GR  - CIHR/Canada
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20171114
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - MN3L5RMN02 (Clonidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2018 Feb 20;168(4):289-290. PMID: 29132156
MH  - Aged
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Biomarkers/blood
MH  - Clonidine/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Postoperative Complications/chemically induced/prevention & control
MH  - *Surgical Procedures, Operative
MH  - Treatment Outcome
EDAT- 2017/11/14 06:00
MHDA- 2019/01/01 06:00
CRDT- 2017/11/14 06:00
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2019/01/01 06:00 [medline]
PHST- 2017/11/14 06:00 [entrez]
AID - 2663288 [pii]
AID - 10.7326/M17-2341 [doi]
PST - ppublish
SO  - Ann Intern Med. 2018 Feb 20;168(4):237-244. doi: 10.7326/M17-2341. Epub 2017 Nov 
      14.

PMID- 18574281
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20170602
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 133
IP  - 6 Suppl
DP  - 2008 Jun
TI  - Antithrombotic therapy in neonates and children: American College of Chest 
      Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
PG  - 887S-968S
LID - S0012-3692(08)60133-6 [pii]
LID - 10.1378/chest.08-0762 [doi]
AB  - This chapter about antithrombotic therapy in neonates and children is part of the 
      Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians 
      Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 
      recommendations are strong and indicate that the benefits do, or do not, outweigh 
      risks, burden, and costs, and Grade 2 suggests that individual patient values may 
      lead to different choices (for a full understanding of the grading, see Guyatt et 
      al in this supplement, pages 123S-131S). In this chapter, many recommendations 
      are based on extrapolation of adult data, and the reader is referred to the 
      appropriate chapters relating to guidelines for adult populations. Within this 
      chapter, the majority of recommendations are separate for neonates and children, 
      reflecting the significant differences in epidemiology of thrombosis and safety 
      and efficacy of therapy in these two populations. Among the key recommendations 
      in this chapter are the following: In children with first episode of venous 
      thromboembolism (VTE), we recommend anticoagulant therapy with either 
      unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) [Grade 1B]. 
      Dosing of IV UFH should prolong the activated partial thromboplastin time (aPTT) 
      to a range that corresponds to an anti-factor Xa assay (anti-FXa) level of 0.35 
      to 0.7 U/mL, whereas LMWH should achieve an anti-FXa level of 0.5 to 1.0 U/mL 4 h 
      after an injection for twice-daily dosing. In neonates with first VTE, we suggest 
      either anticoagulation or supportive care with radiologic monitoring and 
      subsequent anticoagulation if extension of the thrombosis occurs during 
      supportive care (Grade 2C). We recommend against the use of routine systemic 
      thromboprophylaxis for children with central venous lines (Grade 1B). For 
      children with cerebral sinovenous thrombosis (CSVT) without significant 
      intracranial hemorrhage (ICH), we recommend anticoagulation initially with UFH, 
      or LMWH and subsequently with LMWH or vitamin K antagonists (VKAs) for a minimum 
      of 3 months (Grade 1B). For children with non-sickle-cell disease-related acute 
      arterial ischemic stroke (AIS), we recommend UFH or LMWH or aspirin (1 to 5 
      mg/kg/d) as initial therapy until dissection and embolic causes have been 
      excluded (Grade 1B). For neonates with a first AIS, in the absence of a 
      documented ongoing cardioembolic source, we recommend against anticoagulation or 
      aspirin therapy (Grade 1B).
FAU - Monagle, Paul
AU  - Monagle P
AD  - From the Haematology Department, The Royal Children's Hospital and Department of 
      Pathology, The University of Melbourne, Melbourne, VIC, Australia. Electronic 
      address: paul.monagle@rch.org.au.
FAU - Chalmers, Elizabeth
AU  - Chalmers E
AD  - Consultant Pediatric Hematologist, Royal Hospital for Sick Children, Glasgow, UK.
FAU - Chan, Anthony
AU  - Chan A
AD  - Henderson Research Centre, Hamilton, ON, Canada.
FAU - deVeber, Gabrielle
AU  - deVeber G
AD  - Division of Neurology, Hospital for Sick Children, Toronto, ON, Canada.
FAU - Kirkham, Fenella
AU  - Kirkham F
AD  - Neurosciences Unit, Institute of Child Health, London, UK.
FAU - Massicotte, Patricia
AU  - Massicotte P
AD  - Department of Pediatrics, Stollery Children's Hospital, Edmonton, AB, Canada.
FAU - Michelson, Alan D
AU  - Michelson AD
AD  - Center for Platelet Function Studies, University of Massachusetts Medical School, 
      Worcester, MA.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Child
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Infant, Newborn
MH  - Partial Thromboplastin Time
MH  - Risk Assessment
MH  - Risk Factors
MH  - Venous Thrombosis/*drug therapy
MH  - Vitamin K/antagonists & inhibitors
EDAT- 2008/07/24 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/07/24 09:00
PHST- 2008/07/24 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/24 09:00 [entrez]
AID - S0012-3692(08)60133-6 [pii]
AID - 10.1378/chest.08-0762 [doi]
PST - ppublish
SO  - Chest. 2008 Jun;133(6 Suppl):887S-968S. doi: 10.1378/chest.08-0762.

PMID- 15178495
OWN - NLM
STAT- MEDLINE
DCOM- 20040809
LR  - 20181130
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 116
IP  - 12
DP  - 2004 Jun 15
TI  - Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a 
      cost-effectiveness analysis.
PG  - 797-806
AB  - PURPOSE: Clopidogrel is more effective than aspirin in preventing recurrent 
      vascular events, but concerns about its cost-effectiveness have limited its use. 
      We evaluated the cost-effectiveness of clopidogrel and aspirin as secondary 
      prevention in patients with a prior myocardial infarction, a prior stroke, or 
      peripheral arterial disease. METHODS: We constructed Markov models assuming a 
      societal perspective, and based analyses on the lifetime treatment of a 
      63-year-old patient facing event probabilities derived from the Clopidogrel 
      versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial as the base 
      case. Outcome measures included costs, life expectancy in quality-adjusted 
      life-years (QALYs), incremental cost-effectiveness ratios, and events averted. 
      RESULTS: In patients with peripheral arterial disease, clopidogrel increased life 
      expectancy by 0.55 QALYs at an incremental cost-effectiveness ratio of $25,100 
      per QALY, as compared with aspirin. In poststroke patients, clopidogrel increased 
      life expectancy by 0.17 QALYs at a cost of $31,200 per QALY. Aspirin was both 
      less expensive and more effective than clopidogrel in post-myocardial infarction 
      patients. In probabilistic sensitivity analyses, our evaluation for patients with 
      peripheral vascular disease was robust. Evaluations of stroke and myocardial 
      infarction patients were sensitive predominantly to the cost and efficacy of 
      clopidogrel, with aspirin therapy more effective and less expensive in 153 of 
      1000 simulations (15.3%) in poststroke patients and clopidogrel more effective in 
      119 of 1000 simulations (11.9%) in the myocardial infarction sample. CONCLUSION: 
      Clopidogrel provides a substantial increase in quality-adjusted life expectancy 
      at a cost that is within traditional societal limits for patients with either 
      peripheral arterial disease or a recent stroke. Current evidence does not support 
      increased efficacy with clopidogrel relative to aspirin in patients following 
      myocardial infarction.
FAU - Schleinitz, Mark D
AU  - Schleinitz MD
AD  - Department of Medicine (JPW), Stanford University, Palo Alto, California, USA. 
      Mark_Schleinitz@Brown.edu
FAU - Weiss, J Peter
AU  - Weiss JP
FAU - Owens, Douglas K
AU  - Owens DK
LA  - eng
GR  - HD43447/HD/NICHD NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Med. 2004 Jun 15;116(12):850-2. PMID: 15178502
CIN - Am J Med. 2005 Feb;118(2):198-9; author reply 199. PMID: 15694909
CIN - Am J Med. 2005 Feb;118(2):199-200; author reply 200. PMID: 15694910
MH  - Aspirin/*economics/*therapeutic use
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Fibrinolytic Agents/*economics/*therapeutic use
MH  - Humans
MH  - Markov Chains
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*economics/*therapeutic use
MH  - Sensitivity and Specificity
MH  - Ticlopidine/*analogs & derivatives/*economics/*therapeutic use
MH  - Vascular Diseases/*prevention & control
EDAT- 2004/06/05 05:00
MHDA- 2004/08/10 05:00
CRDT- 2004/06/05 05:00
PHST- 2002/12/11 00:00 [received]
PHST- 2004/01/07 00:00 [accepted]
PHST- 2004/06/05 05:00 [pubmed]
PHST- 2004/08/10 05:00 [medline]
PHST- 2004/06/05 05:00 [entrez]
AID - S0002934304001445 [pii]
AID - 10.1016/j.amjmed.2004.01.014 [doi]
PST - ppublish
SO  - Am J Med. 2004 Jun 15;116(12):797-806. doi: 10.1016/j.amjmed.2004.01.014.

PMID- 12860580
OWN - NLM
STAT- MEDLINE
DCOM- 20030805
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 163
IP  - 13
DP  - 2003 Jul 14
TI  - Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in 
      patients with heart failure: a dose-related adverse effect of aspirin.
PG  - 1574-9
AB  - BACKGROUND: It is debated whether in patients with chronic heart failure (CHF), 
      aspirin may contrast the clinical benefits of angiotensin-converting enzyme 
      inhibitors (ACEIs). Two major unresolved issues in patients with CHF are whether 
      these agents together can affect mortality and whether the interaction is related 
      with the dose of aspirin. We aimed at exploring these possibilities. METHODS: We 
      evaluated more than 4000 hospitalizations with a principal discharge diagnosis of 
      CHF from January 10, 1990, to December 31, 1999. The final analysis was 
      restricted to 344 patients taking ACEIs who satisfied the selection criteria, in 
      whom reliable information was available concerning drug therapy during follow-up. 
      In these patients, treatment included no aspirin in 235 (group 1), a low dose (< 
      or =160 mg) in 45 (group 2), and a high dose (> or = 325 mg) in 64 (group 3). 
      RESULTS: During a mean follow-up of 37.6 months, there were 84 (36%) deaths in 
      group 1, 15 (33%) in group 2, and 35 (55%) in group 3. By the Kaplan-Meier 
      approach, survival was similar in groups 1 and 2, and significantly (P =.009) 
      worse in group 3 compared with groups 1 and 2. After adjusting for potential 
      confounding factors (including treatment, cause of heart disease, age, smoking, 
      and diabetes mellitus), a time-dependent multivariate Cox proportional hazards 
      regression analysis showed that the combination of high-dose aspirin with an ACEI 
      was independently associated with the risk of death (hazard ratio, 1.03; P =.01) 
      and that the combination of low-dose aspirin with an ACEI was not (hazard ratio, 
      1.02; P =.18). CONCLUSION: These results support the possibility that in some 
      patients with CHF who are taking an ACEI, a dose-related effect of aspirin may 
      adversely affect survival.
FAU - Guazzi, Marco
AU  - Guazzi M
AD  - Istituto di Cardiologia, Università degli Studi di Milano, Milan, Italy. 
      maurizio.guazzi@unimi.it
FAU - Brambilla, Roberto
AU  - Brambilla R
FAU - Reina, Giuseppe
AU  - Reina G
FAU - Tumminello, Gabriele
AU  - Tumminello G
FAU - Guazzi, Maurizio D
AU  - Guazzi MD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Chi-Square Distribution
MH  - Chronic Disease
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*drug therapy/*mortality
MH  - Humans
MH  - Italy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Survival Analysis
EDAT- 2003/07/16 05:00
MHDA- 2003/08/06 05:00
CRDT- 2003/07/16 05:00
PHST- 2003/07/16 05:00 [pubmed]
PHST- 2003/08/06 05:00 [medline]
PHST- 2003/07/16 05:00 [entrez]
AID - 163/13/1574 [pii]
AID - 10.1001/archinte.163.13.1574 [doi]
PST - ppublish
SO  - Arch Intern Med. 2003 Jul 14;163(13):1574-9. doi: 10.1001/archinte.163.13.1574.

PMID- 20098039
OWN - NLM
STAT- MEDLINE
DCOM- 20100427
LR  - 20171116
IS  - 1016-5169 (Print)
IS  - 1016-5169 (Linking)
VI  - 37
IP  - 7
DP  - 2009 Oct
TI  - The prevalence of aspirin resistance in patients with metabolic syndrome.
PG  - 461-6
AB  - OBJECTIVES: Aspirin is recommended for primary prevention in patients with 
      metabolic syndrome (MetS). In this study, we evaluated aspirin resistance in MetS 
      patients. STUDY DESIGN: The study included 32 patients (23 males, 9 females; mean 
      age 60.7+/-11.4 years) with the diagnosis of MetS, according to the criteria of 
      the International Diabetes Federation. Aspirin resistance was determined by the 
      PFA-100 analysis (Platelet Function Analyzer). The results were compared with a 
      control group of 30 patients (16 males, 14 females; mean age 61.6+/-7.3 years) 
      without MetS. All the patients were taking aspirin at the time of the PFA-100 
      analysis. RESULTS: Overall, 21 patients (33.9%) were aspirin nonresponders. The 
      prevalence of aspirin resistance was 46.9% in the MetS group, and 20% in the 
      control group. The difference between the two groups was statistically 
      significant (p=0.033). Compared to aspirin responders, fasting blood glucose 
      level was higher (102.0+/-14.6 mg/dl vs. 95.3+/-9.9 mg/dl; p=0.036) and waist 
      circumference tended to be greater in nonresponders (97.4+/-14.1 cm vs. 
      89.7+/-15.0 cm; p=0.053). Multivariate logistic regression analysis showed that 
      MetS (OR 0.28, 95% CI 0.09-0.88; p=0.029), fasting blood glucose (OR 0.95, 95% CI 
      0.91-0.99; p=0.045), uric acid (OR 0.46, 95% CI 0.28-0.76; p=0.002), 
      gamma-glutamyl transferase (OR 1.04, 95% CI 1.00-1.08; p=0.043), high-sensitivity 
      C-reactive protein (OR 1.07, 95% CI 1.01-1.12; p=0.015) levels and platelet count 
      (OR 0.99, 95% CI 0.98-0.99; p=0.034) significantly affected aspirin resistance. 
      CONCLUSION: Our results show that a significant proportion of MetS patients will 
      not benefit from aspirin use due to high aspirin resistance.
FAU - Cağirci, Göksel
AU  - Cağirci G
AD  - Department of Cardiology, Dişkapi Yildirim Beyazit Training and Research 
      Hospital, Ankara, Turkey.
FAU - Ozdemir, Ozcan
AU  - Ozdemir O
FAU - Geyik, Bilal
AU  - Geyik B
FAU - Cay, Serkan
AU  - Cay S
FAU - Oztürk, Sezgin
AU  - Oztürk S
FAU - Aras, Dursun
AU  - Aras D
FAU - Topaloğlu, Serkan
AU  - Topaloğlu S
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Turk Kardiyol Dern Ars
JT  - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
JID - 9426239
RN  - 0 (Biomarkers, Pharmacological)
RN  - 0 (Blood Glucose)
RN  - 0 (Triglycerides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Biomarkers, Pharmacological/analysis
MH  - Blood Glucose/analysis
MH  - Blood Pressure
MH  - Body Mass Index
MH  - Coronary Disease/epidemiology
MH  - Diastole
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolic Syndrome/blood/complications/*physiopathology/prevention & control
MH  - Middle Aged
MH  - Primary Prevention
MH  - Systole
MH  - Triglycerides/blood
EDAT- 2010/01/26 06:00
MHDA- 2010/04/28 06:00
CRDT- 2010/01/26 06:00
PHST- 2010/01/26 06:00 [entrez]
PHST- 2010/01/26 06:00 [pubmed]
PHST- 2010/04/28 06:00 [medline]
PST - ppublish
SO  - Turk Kardiyol Dern Ars. 2009 Oct;37(7):461-6.

PMID- 21061521
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - [New guideline for peptic ulcer treatment, attention to low-dose aspirin].
PG  - 1987-92
AB  - The guideline for peptic ulcer treatment was reported in 2009. In the guideline, 
      eight clinical questions were chosen for peptic ulcers associated with use of 
      low-dose aspirin. Five questions out of them were related to the clinical 
      behavior, and three were the treatment of peptic ulcers in patients taking 
      low-dose aspirin. The statements were made for these questions according to EBM 
      respectively. In the statements, the grade of recommendation, the evidence level 
      of literatures and the application to Japanese medical insurance were mentioned.
FAU - Yoshino, Junji
AU  - Yoshino J
AD  - Department of Internal Medicine, Banbuntane-Hotokukai Hospital, Fujita Health 
      University, School of Medicine.
FAU - Kosaka, Toshihito
AU  - Kosaka T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cyclooxygenase 2 Inhibitors/adverse effects
MH  - Humans
MH  - Peptic Ulcer/*chemically induced/therapy
MH  - Practice Guidelines as Topic
EDAT- 2010/11/11 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Nov;68(11):1987-92.

PMID- 7356892
OWN - NLM
STAT- MEDLINE
DCOM- 19800530
LR  - 20190512
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 9
IP  - 1
DP  - 1980 Jan
TI  - Metabolism of salicylate during chronic aspirin therapy.
PG  - 41-5
AB  - 1. The effects of chronic administration of aspirin in therapeutic doses (3.9 
      g/day) on plasma and salivary salicylate levels were studied in eight subjects. 
      2. The urinary excretion profile for free salicylic acid and metabolites of 
      salicylate were examined. 3. Plasma and salivary salicylate levels declined 
      significantly after peak levels were achieved between days 3 and 10. 4. The 
      decline in plasma and salivary salicylate levels may be due to an induction of a 
      metabolic pathway such as salicylurate formation (Furst, Gupta & Paulus, 1977). 
      Only the mean fraction of salicylate excreted as salicylurate appears to increase 
      with time during the present study, although the change was not significant 
      statistically. 5. The decline in plasma and salivary salicylate levels during 
      chronic therapy may lead to an apparent 'tolerance' of some rheumatoid patients 
      to aspirin.
FAU - Rumble, R H
AU  - Rumble RH
FAU - Brooks, P M
AU  - Brooks PM
FAU - Roberts, M S
AU  - Roberts MS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/*metabolism/therapeutic use
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Salicylates/blood/*metabolism/urine
MH  - Saliva/metabolism
MH  - Time Factors
PMC - PMC1429927
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1980.tb04794.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1980 Jan;9(1):41-5. doi: 10.1111/j.1365-2125.1980.tb04794.x.

PMID- 27984533
OWN - NLM
STAT- MEDLINE
DCOM- 20180220
LR  - 20201209
IS  - 1540-0514 (Electronic)
IS  - 1073-2322 (Print)
IS  - 1073-2322 (Linking)
VI  - 47
IP  - 1
DP  - 2017 Jan
TI  - Prevention or Treatment of Ards With Aspirin: A Review of Preclinical Models and 
      Meta-Analysis of Clinical Studies.
PG  - 13-21
AB  - BACKGROUND: The acute respiratory distress syndrome (ARDS) is a life-threating 
      disorder that contributes significantly to critical illness. No specific 
      pharmacological interventions directed at lung injury itself have proven 
      effective in improving outcome of patients with ARDS. Platelet activation was 
      identified as a key component in ARDS pathophysiology and may provide an 
      opportunity for preventive and therapeutic strategies. We hypothesize that use of 
      acetyl salicylic acid (ASA) may prevent and/or attenuate lung injury. METHODS: We 
      conducted a systematic review of preclinical studies and meta-analysis of 
      clinical studies investigating the efficacy of ASA in the setting of lung injury. 
      Medline, embase, and cochrane databases were searched. RESULTS: The literature 
      search yielded 1,314 unique articles. Fifteen preclinical studies and eight 
      clinical studies fulfilled the in- and exclusion criteria. In the animal studies, 
      the overall effect of ASA was positive, e.g., ASA improved survival and 
      attenuated inflammation and pulmonary edema. Mechanisms of actions involved, 
      among others, are interference with the neutrophil-platelets interaction, 
      reduction of leukotrienes, neutrophil extracellular traps, and prostaglandins. 
      High-dose ASA may be the drug of choice. A meta-analysis of three clinical 
      studies showed an association between ASA use and a reduced incidence of ARDS (OR 
      0.59, 95% CI 0.36-0.98), albeit with substantial between-study heterogeneity. All 
      studies had their own shortcomings in methodological quality. CONCLUSION: This 
      systematic review of preclinical studies and meta-analysis of clinical studies 
      suggests a beneficial role for ASA in ARDS prevention and treatment. However, the 
      currently available data is insufficient to justify an indication for ASA in 
      ARDS. The body of literature does support further studies in humans. We suggest 
      clinical trials in which the mechanisms of action of ASA in lung injury models 
      are being evaluated to guide optimal timing and dose, before prospective 
      randomized trials.
FAU - Panka, Bernardo Amisa
AU  - Panka BA
AD  - *Department of Intensive Care Medicine, VU University Medical Centre, Amsterdam, 
      The Netherlands †Department of Intensive Care Medicine, s' Lands Hospitaal 
      Paramaribo, Paramaribo, Suriname ‡Research VUmc Intensive Care (REVIVE) and 
      Institute for Cardiovascular Research (ICAR-VU), Amsterdam, The Netherlands 
      §Department of Medicine, University of California, San Francisco; San Francisco, 
      California.
FAU - de Grooth, Harm-Jan
AU  - de Grooth HJ
FAU - Spoelstra-de Man, Angélique Maria Elisabeth
AU  - Spoelstra-de Man AM
FAU - Looney, Mark R
AU  - Looney MR
FAU - Tuinman, Pieter-Roel
AU  - Tuinman PR
LA  - eng
GR  - R01 HL107386/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Shock
JT  - Shock (Augusta, Ga.)
JID - 9421564
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Respiratory Distress Syndrome/*drug therapy/metabolism/*prevention & control
PMC - PMC5175412
MID - NIHMS813804
EDAT- 2016/12/17 06:00
MHDA- 2018/02/21 06:00
CRDT- 2016/12/17 06:00
PHST- 2016/12/17 06:00 [entrez]
PHST- 2016/12/17 06:00 [pubmed]
PHST- 2018/02/21 06:00 [medline]
AID - 00024382-201701000-00003 [pii]
AID - 10.1097/SHK.0000000000000745 [doi]
PST - ppublish
SO  - Shock. 2017 Jan;47(1):13-21. doi: 10.1097/SHK.0000000000000745.

PMID- 8116304
OWN - NLM
STAT- MEDLINE
DCOM- 19940331
LR  - 20131121
IS  - 0043-5325 (Print)
IS  - 0043-5325 (Linking)
VI  - 105
IP  - 24
DP  - 1993
TI  - [Acetylsalicylic acid in pregnancy].
PG  - 697-703
AB  - Preeclampsia is characterized by a functional imbalance between vascular 
      prostacyclin and thromboxane A2 production. Studies have demonstrated that the 
      increase in thromboxane A2 can be corrected by administration of low-dose aspirin 
      without causing a further decrease in prostacyclin production. Low-dose aspirin 
      during pregnancy appears to be safe for both mother and child. Furthermore, 
      clinical trials have demonstrated that it is effective in reducing the incidence 
      of preeclampsia and/or intrauterine growth retardation in selected high-risk 
      women. The use of aspirin in the treatment of existing preeclampsia and in the 
      prevention of premature labor is not recommended. With regard to recurrent 
      spontaneous abortion, further studies are warranted to evaluate its efficacy.
FAU - Karas, H
AU  - Karas H
AD  - I. Universitäts-Frauenklinik, Wien.
FAU - Egarter, C
AU  - Egarter C
FAU - Husslein, P
AU  - Husslein P
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Acetylsalicylsäure in der Schwangerschaft.
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Epoprostenol/physiology
MH  - Female
MH  - Fetal Growth Retardation/*drug therapy/physiopathology
MH  - Humans
MH  - Infant, Newborn
MH  - Obstetric Labor, Premature/prevention & control
MH  - Pre-Eclampsia/*drug therapy/physiopathology
MH  - Pregnancy
MH  - Thromboxane A2/physiology
RF  - 62
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Wien Klin Wochenschr. 1993;105(24):697-703.

PMID- 6113615
OWN - NLM
STAT- MEDLINE
DCOM- 19810810
LR  - 20191031
IS  - 0161-4630 (Print)
IS  - 0161-4630 (Linking)
VI  - 6
IP  - 2
DP  - 1981 Feb
TI  - Lipoxygenase pathway and hydroperoxy acids: possible relevance to aspirin-induced 
      asthma and hyperirritability of airways in asthmatics.
PG  - 249-56
AB  - The precise mechanisms(s) responsible for airway hyperreactivity to spasmogenic 
      agents (for example, cholinergic stimulants, alpha-adrenergic agonists, 
      histamine, PGF2 alpha and several other nonspecific stimuli) in asthmatics is not 
      known. Substantial evidence exists fo the mediator, as well as modulatory, roles 
      of the products of arachidonic acid metabolism operating via the cyclo-oxygenase 
      pathway in the pathophysiology of lung diseases. Aspirin and other inhibitors of 
      cyclo-oxygenase induce severe bronchospasm and asthmatic attacks in a significant 
      population of asthmatic patients. This adverse effect of aspirin is often 
      attributed to inhibition of the synthesis and release of defensive "modulatory" 
      endogenous prostaglandins (PGD and PGI2?) in the lungs. Thus, removal of their 
      "negative feedback" mechanism on the allergic release of chemical mediators 
      (e.g., histamine and SRS-A: leukotriene C and D) from lung mast cells could lead 
      to an enhancement of the release of mediators and severity of asthmatic attacks. 
      In addition to these mechanisms, recent work suggests the diversion of 
      arachidonic acid (AA) metabolism via the lipoxygenase pathway (especially after 
      cyclo-oxygenase inhibition by aspirin and indomethacin), thereby leading to the 
      formation of a new class of biologically active lipids: hydroperoxy acids (HPETE 
      and HETE), leukotrienes (LTA, B, C, D, E) and SRS or SRS-A (LTC, LTD). The 
      inherent or drug (aspirin)-induced deficiency or blockade of cyclo-oxygenases(s) 
      and/or peroxidases in the lungs (and/or other body tissues, including leukocytes) 
      leading to diversion of AA into the formation and accumulation of SRS 
      (leukotrienes), especially in sensitive individuals, could explain the mechanism 
      of aspirin-induced asthma, and probably the generalized syndrome of 
      aspirin-tolerance. Furthermore, the hydroperoxy acids, leukotrienes, (SRS) may 
      also sensitize receptors for other mediators and common nonspecific irritants, 
      and/or induce airway contractions directly. Collectively, these mechanisms could 
      account for airway hyperreactivity in asthma.
FAU - Chand, N
AU  - Chand N
FAU - Altura, B M
AU  - Altura BM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins Med
JT  - Prostaglandins and medicine
JID - 7810330
RN  - 0 (Arachidonic Acids)
RN  - 0 (Autacoids)
RN  - 0 (Leukotrienes)
RN  - 0 (Lipid Peroxides)
RN  - 0 (Peroxides)
RN  - 59985-28-3 (12-Hydroxy-5,8,10,14-eicosatetraenoic Acid)
RN  - 67675-14-3 (15-hydroperoxy-5,8,11,13-eicosatetraenoic acid)
RN  - EC 1.13.11.12 (Lipoxygenase)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/adverse effects/*pharmacology
MH  - Asthma/chemically induced/*metabolism
MH  - Autacoids/metabolism
MH  - Humans
MH  - *Leukotrienes
MH  - *Lipid Peroxides
MH  - Lipoxygenase/metabolism
MH  - Peroxides/metabolism
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
AID - 10.1016/0161-4630(81)90097-5 [doi]
PST - ppublish
SO  - Prostaglandins Med. 1981 Feb;6(2):249-56. doi: 10.1016/0161-4630(81)90097-5.

PMID- 35595172
OWN - NLM
STAT- MEDLINE
DCOM- 20220907
LR  - 20220907
IS  - 1944-7922 (Electronic)
IS  - 1060-3271 (Linking)
VI  - 105
IP  - 5
DP  - 2022 Sep 6
TI  - Micelle-Incorporated Liquid Chromatography in the Light of Green Chemistry: An 
      Application for the Quality Control Analysis of Anti-Platelet Fixed-Dose 
      Combinations.
PG  - 1228-1233
LID - 10.1093/jaoacint/qsac046 [doi]
AB  - BACKGROUND: Oral anti-platelet agents are the cornerstone of the treatment of 
      multiple cardiovascular diseases and in the long-term prevention of their 
      recurrence. OBJECTIVE: In the present work, we report a method based on micellar 
      liquid chromatography coupled with ultraviolet detection (MLC/UV), for the 
      simultaneous quantification of combined anti-platelet therapy namely, clopidogrel 
      bisulfate (CPS), aspirin (ASP), together with salicylic acid (SA), in their 
      pharmaceutical dosage form. METHODS: The incorporation of 0.1M polyoxyethylene 23 
      lauryl ether (Brij-35) as a surfactant into the mobile phase improved 
      solute-mobile phase interaction allowing for minimal organic solvent utilization, 
      enhanced resolution, and rapid analysis (7 min). Furthermore, we performed a 
      comprehensive evaluation of the environmental impact caused by our procedures 
      versus previously reported analytical procedures applied in the determination of 
      CPS and ASP. The evaluation was made using the Eco-scale tool. RESULTS: The 
      results of the developed method indicated the superiority of our procedures in 
      terms of greenness without compromising the quality of performance 
      characteristics. The method was linear in the range of 1-100 µg/mL with limits of 
      detection of 0.28, 0.32, and 0.29 µg/mL for CPS, ASP, and SA, respectively. The 
      developed method can also be utilized to test the purity and the stability of ASP 
      in pharmaceutical formulations through monitoring SA as its main degradation 
      product. CONCLUSION: The MLC/UV method was successfully applied to the 
      quantitative analysis of CPS, ASP together with SA-as a main degradation product 
      of ASP-in their pharmaceutical dosage form. HIGHLIGHTS: The developed method was 
      successfully applied for the determination of clopidogrel bisulfate (CPS), 
      aspirin (ASP), together with salicylic acid (SA), in their pharmaceutical dosage 
      form.
CI  - © The Author(s) 2022. Published by Oxford University Press on behalf of AOAC 
      INTERNATIONAL. All rights reserved. For permissions, please email: 
      journals.permissions@oup.com.
FAU - Elsonbaty, Ahmed
AU  - Elsonbaty A
AUID- ORCID: 0000-0003-0836-2375
AD  - Egyptian Russian University, Faculty of Pharmacy, Department of Analytical 
      Chemistry, Cairo, Egypt.
FAU - Hassan, Wafaa S
AU  - Hassan WS
AD  - Zagazig University, Faculty of Pharmacy, Department of Analytical Chemistry, 
      Zagazig, Egypt.
FAU - Eissa, Maya S
AU  - Eissa MS
AD  - Egyptian Russian University, Faculty of Pharmacy, Department of Analytical 
      Chemistry, Cairo, Egypt.
FAU - Abdulwahab, Sara
AU  - Abdulwahab S
AUID- ORCID: 0000-0003-2536-5412
AD  - Zagazig University, Faculty of Pharmacy, Department of Analytical Chemistry, 
      Zagazig, Egypt.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J AOAC Int
JT  - Journal of AOAC International
JID - 9215446
RN  - 0 (Micelles)
RN  - A74586SNO7 (Clopidogrel)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis
MH  - Chromatography, High Pressure Liquid/methods
MH  - Chromatography, Liquid
MH  - Clopidogrel
MH  - *Micelles
MH  - Quality Control
MH  - Reproducibility of Results
MH  - *Salicylic Acid/analysis
EDAT- 2022/05/21 06:00
MHDA- 2022/09/08 06:00
CRDT- 2022/05/20 19:34
PHST- 2021/11/11 00:00 [received]
PHST- 2022/03/04 00:00 [revised]
PHST- 2022/04/01 00:00 [accepted]
PHST- 2022/05/21 06:00 [pubmed]
PHST- 2022/09/08 06:00 [medline]
PHST- 2022/05/20 19:34 [entrez]
AID - 6589898 [pii]
AID - 10.1093/jaoacint/qsac046 [doi]
PST - ppublish
SO  - J AOAC Int. 2022 Sep 6;105(5):1228-1233. doi: 10.1093/jaoacint/qsac046.

PMID- 15292011
OWN - NLM
STAT- MEDLINE
DCOM- 20040903
LR  - 20131121
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 104
IP  - 2
DP  - 2004 Aug
TI  - Effects of low-molecular-weight and unfractionated heparin on trophoblast 
      function.
PG  - 354-61
AB  - OBJECTIVE: Unfractionated and low-molecular-weight heparin and low-dose aspirin 
      are used for the prevention of pregnancy loss in pregnant women with 
      thrombophilia. We investigated the effect of these drugs on in vitro models of 
      human extravillous trophoblast motility and differentiation. METHODS: Chorion 
      from term placentas was digested and extravillous trophoblast isolated. 
      Extravillous trophoblast formed giant multinuclear cells that were counted after 
      24, 36, and 48 hours of culture. This model was then used to investigate the 
      effect of unfractionated, low-molecular-weight heparin and aspirin on in vitro 
      extravillous trophoblast differentiation at both therapeutic and supratherapeutic 
      doses. In addition, the effect of unfractionated and low-molecular-weight heparin 
      on hepatocyte growth factor-stimulated SGHPL-4 cell (extravillous trophoblast 
      cell line) motility was determined by time-lapse microscopy. RESULTS: At 
      therapeutic doses unfractionated heparin promoted extravillous trophoblast 
      differentiation. However, low-molecular-weight heparin inhibited giant 
      multinuclear cells formation. At supratherapeutic doses, both 
      low-molecular-weight and unfractionated heparin promoted extravillous trophoblast 
      differentiation. Low-dose aspirin had minimal effects on the extravillous 
      trophoblast differentiation. Both unfractionated and low-molecular-weight heparin 
      inhibited hepatocyte growth factor-stimulated extravillous trophoblast motility 
      at supratherapeutic doses. At a therapeutic dose of 0.25 IU/mL, only 
      unfractionated heparin inhibited hepatocyte growth factor-stimulated motility, 
      whereas low-molecular-weight heparin had no effect. CONCLUSION: Our data suggest 
      that unfractionated and low-molecular-weight heparin have differing effects on 
      trophoblast differentiation and motility at therapeutic doses. This finding may 
      be one of many factors that contribute to the clinical scenario.
FAU - Quenby, Siobhan
AU  - Quenby S
AD  - Department of Obstetrics and Gynaecology, University of Liverpool, Liverpool, 
      United Kingdom. squenby@liv.ac.uk
FAU - Mountfield, Steve
AU  - Mountfield S
FAU - Cartwright, Judith E
AU  - Cartwright JE
FAU - Whitley, Guy St J
AU  - Whitley GS
FAU - Vince, Gill
AU  - Vince G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Cell Line/drug effects/physiology
MH  - Cell Movement/drug effects/physiology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*pharmacology
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*prevention & control
MH  - Thrombophilia/*prevention & control
MH  - Trophoblasts/*drug effects/physiology
EDAT- 2004/08/05 05:00
MHDA- 2004/09/04 05:00
CRDT- 2004/08/05 05:00
PHST- 2004/08/05 05:00 [pubmed]
PHST- 2004/09/04 05:00 [medline]
PHST- 2004/08/05 05:00 [entrez]
AID - 104/2/354 [pii]
AID - 10.1097/01.AOG.0000128902.84876.d4 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2004 Aug;104(2):354-61. doi: 10.1097/01.AOG.0000128902.84876.d4.

PMID- 28082800
OWN - NLM
STAT- MEDLINE
DCOM- 20170606
LR  - 20220330
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 22
IP  - 48
DP  - 2016 Dec 28
TI  - Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing 
      risks and benefits.
PG  - 10477-10481
LID - 10.3748/wjg.v22.i48.10477 [doi]
AB  - Proton pump inhibitors (PPIs) represent a milestone in the treatment of 
      acid-related diseases, and are the mainstay in preventing upper gastrointestinal 
      bleeding in high-risk patients treated with nonsteroidal anti-inflammatory drugs 
      (NSAIDs) or low-dose aspirin. However, this beneficial effect does not extend to 
      the lower gastrointestinal tract. PPIs do not prevent NSAID or aspirin-associated 
      lower gastrointestinal bleeding (LGB). PPIs may increase both small bowel injury 
      related to NSAIDs and low-dose aspirin treatment and the risk of LGB. Recent 
      studies suggested that altering intestinal microbiota by PPIs may be involved in 
      the pathogenesis of NSAID-enteropathy. An increase in LGB hospitalization rates 
      may occur more frequently in older patients with more comorbidities and are 
      associated with high hospital resource utilization, longer hospitalization, and 
      increased mortality. Preventive strategies for NSAID and aspirin-associated 
      gastrointestinal bleeding should be directed toward preventing both upper and 
      lower gastrointestinal damage. Future research should be directed toward 
      identifying patients at low-risk for gastrointestinal events associated with the 
      use of NSAIDs or aspirin to avoid inappropriate PPI prescribing. Alternatively, 
      the efficacy of new pharmacologic strategies should be evaluated in high-risk 
      groups, with the aim of reducing the risk of both upper and lower 
      gastrointestinal bleeding in these patients.
FAU - Lué, Alberto
AU  - Lué A
AD  - Alberto Lué, Angel Lanas, Digestive Diseases Service, University Clinic Hospital 
      Lozano Blesa, Avenida San Juan Bosco, 50009 Zaragoza, Spain.
FAU - Lanas, Angel
AU  - Lanas A
AD  - Alberto Lué, Angel Lanas, Digestive Diseases Service, University Clinic Hospital 
      Lozano Blesa, Avenida San Juan Bosco, 50009 Zaragoza, Spain.
LA  - eng
PT  - Editorial
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Gastrointestinal Microbiome/drug effects
MH  - Humans
MH  - Inappropriate Prescribing/prevention & control
MH  - Lower Gastrointestinal Tract/drug effects
MH  - Probiotics/*therapeutic use
MH  - Proton Pump Inhibitors/*adverse effects/*therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Upper Gastrointestinal Tract/drug effects
PMC - PMC5192259
OTO - NOTNLM
OT  - Lower gastrointestinal bleeding
OT  - Nonsteroidal anti-inflammatory drugs
OT  - Proton pump inhibitor
OT  - Small bowel
COIS- Conflict-of-interest statement: Lué A and Lanas A declare no conflict of interest 
      related to this publication.
EDAT- 2017/01/14 06:00
MHDA- 2017/06/07 06:00
CRDT- 2017/01/14 06:00
PHST- 2016/08/27 00:00 [received]
PHST- 2016/09/28 00:00 [revised]
PHST- 2016/11/12 00:00 [accepted]
PHST- 2017/01/14 06:00 [entrez]
PHST- 2017/01/14 06:00 [pubmed]
PHST- 2017/06/07 06:00 [medline]
AID - 10.3748/wjg.v22.i48.10477 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2016 Dec 28;22(48):10477-10481. doi: 
      10.3748/wjg.v22.i48.10477.

PMID- 94871
OWN - NLM
STAT- MEDLINE
DCOM- 19800815
LR  - 20131121
IS  - 0323-4347 (Print)
IS  - 0323-4347 (Linking)
VI  - 106
IP  - 5-6
DP  - 1979
TI  - [Prevention of reinfarction with acetylsalicylic acid].
PG  - 797-803
AB  - A report is presented on the prospective trial for prophylaxis of myocardial 
      reinfarction by means of acetylsalicyclic acid. For the first time it was 
      organized on the basis of population. 1,340 patients were treated with 
      acetylsalicylic acid or placebo respectively for 22 months on an average. There 
      were 24 cases of reinfarction in the group of treatment and 51 in the placebo 
      group. The difference is significant.
FAU - Vogel, G
AU  - Vogel G
FAU - Fischer, C
AU  - Fischer C
FAU - Huyke, R
AU  - Huyke R
LA  - ger
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Reinfarktprophylaxe mit Azetylsalizylsäure.
PL  - Germany
TA  - Folia Haematol Int Mag Klin Morphol Blutforsch
JT  - Folia haematologica (Leipzig, Germany : 1928)
JID - 0374615
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Placebos
MH  - Prospective Studies
MH  - Recurrence
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):797-803.

PMID- 26289078
OWN - NLM
STAT- MEDLINE
DCOM- 20160405
LR  - 20181113
IS  - 1746-6148 (Electronic)
IS  - 1746-6148 (Linking)
VI  - 11
DP  - 2015 Aug 20
TI  - Regulation effect of Aspirin Eugenol Ester on blood lipids in Wistar rats with 
      hyperlipidemia.
PG  - 217
LID - 10.1186/s12917-015-0523-5 [doi]
LID - 217
AB  - BACKGROUND: Aspirin eugenol ester (AEE) is a promising drug candidate for 
      treatment of inflammation, pain and fever and prevention of cardiovascular 
      diseases with less side effects. The experiment will be conducted to investigate 
      the efficacy of AEE on curing hyperlipidemia in Wistar rats. The rats were fed 
      with high fat diet (HFD) for 8 weeks to induce hyperlipidemia. RESULTS: Compared 
      with the model group, the results showed that AEE at 54 mg/kg dosage could 
      significantly decrease the hyperlipidemia indexes including triglyceride (TG), 
      low density lipoprotein (LDL) and total cholesterol (TCH) (p < 0.01), increase 
      high density lipoprotein (HDL) (p < 0.05) for five weeks drug administration. 
      Meanwhile, simvastatin had same effect on hyperlipidemia indexes such as TG, LDL, 
      TC, but no significant increase in HDL. CONCLUSION: AEE was effective against 
      hyperlipidemia and had better anti-hyperlipidemic effect than its component, 
      acetylsalicylic acid (Aspirin, ASA), eugenol and integration of ASA and eugenol. 
      Under the experimental circumstance, the optimal dose of AEE to cure 
      hyperlipidemia is 54 mg/kg for five weeks in Wistar rats.
FAU - Karam, Isam
AU  - Karam I
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China. isamkarm@yahoo.com.
FAU - Ma, Ning
AU  - Ma N
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China. maning9618@163.com.
FAU - Liu, Xi-Wang
AU  - Liu XW
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China. xiwangliu@126.com.
FAU - Li, Shi-Hong
AU  - Li SH
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China. lzlishihong@163.com.
FAU - Kong, Xiao-Jun
AU  - Kong XJ
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China. kongxj009@163.com.
FAU - Li, Jian-Yong
AU  - Li JY
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China. lijy1971@163.com.
FAU - Yang, Ya-Jun
AU  - Yang YJ
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of CAAS, No.335, jiangouyan, qilihe 
      district, Lanzhou, 730050, China. yangyue10224@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150820
PL  - England
TA  - BMC Vet Res
JT  - BMC veterinary research
JID - 101249759
RN  - 0 (Dietary Fats)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - AGG2FN16EV (Simvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Dietary Fats/*adverse effects
MH  - Eugenol/*analogs & derivatives/pharmacology
MH  - Hyperlipidemias/chemically induced/*drug therapy
MH  - Hypolipidemic Agents/therapeutic use
MH  - Male
MH  - Random Allocation
MH  - Rats
MH  - Simvastatin/therapeutic use
PMC - PMC4546030
EDAT- 2015/08/21 06:00
MHDA- 2016/04/06 06:00
CRDT- 2015/08/21 06:00
PHST- 2015/05/07 00:00 [received]
PHST- 2015/07/31 00:00 [accepted]
PHST- 2015/08/21 06:00 [entrez]
PHST- 2015/08/21 06:00 [pubmed]
PHST- 2016/04/06 06:00 [medline]
AID - 10.1186/s12917-015-0523-5 [pii]
AID - 523 [pii]
AID - 10.1186/s12917-015-0523-5 [doi]
PST - epublish
SO  - BMC Vet Res. 2015 Aug 20;11:217. doi: 10.1186/s12917-015-0523-5.

PMID- 24161074
OWN - NLM
STAT- MEDLINE
DCOM- 20140430
LR  - 20151119
IS  - 0301-0430 (Print)
IS  - 0301-0430 (Linking)
VI  - 81
IP  - 1
DP  - 2014 Jan
TI  - Cost-effectiveness of antiplatelet therapy to prolong primary patency of 
      hemodialysis graft.
PG  - 38-51
LID - 10.5414/CN108100 [doi]
AB  - INTRODUCTION: The Dialysis Access Consortium (DAC) study group previously 
      reported that treatment with extended-release dipyridamole plus aspirin (DASA) 
      resulted in a significant but clinically modest improvement in primary unassisted 
      arteriovenous graft (AVG) patency. Utilizing DAC published data, the objective of 
      this study is to evaluate the cost effectiveness of antiplatelet interventions 
      aimed at preventing loss of primary AVG patency in hemodialysis (HD) patients. 
      METHODS: We performed a cost-utility analysis, using a decision analysis tree 
      model with a 12-month time horizon and a third party payer perspective. 
      Interventions included DASA with and without concurrent aspirin, aspirin alone, 
      and no prophylaxis. The modeled population was defined as adult (≥ 18 years of 
      age) end-stage renal disease (ESRD) patients who had undergone placement of a new 
      AVG in the United States. The outcomes were costs, quality-adjusted life-years 
      (QALY), incremental cost-effectiveness ratios, and net monetary benefit. 
      Probabilities were based upon published studies performed by the DAC Study Group 
      while costs of medications and procedures were drawn from public sources. 
      Utilities of health states were derived from published reports and the Short Form 
      6D (SF-6D) instrument. RESULTS: Aspirin alone is the most cost effective strategy 
      for AVG pharmacologic prophylaxis, as compared to no prophylaxis or DASA with or 
      without concurrent aspirin. The results are robust on multiple scenario analyses 
      using both deterministic and Monte Carlo probabilistic sensitivity analyses. 
      Accounting for both costs and QALY, using aspirin alone to prevent AVG thrombosis 
      can potentially reduce healthcare costs by $24,679,412 per year compared to no 
      aspirin use, at a willingness-to-pay of $50,000/ QALY. CONCLUSIONS: Aspirin 
      monotherapy compared favorably to other strategies based on cost per QALY. Our 
      findings support the use of aspirin prophylaxis in HD patients with a new AVG who 
      do not have a contraindication to aspirin.
FAU - Nee, Robert
AU  - Nee R
FAU - Parker, Austin L
AU  - Parker AL
FAU - Little, Dustin J
AU  - Little DJ
FAU - Yuan, Christina M
AU  - Yuan CM
FAU - Himmelfarb, Jonathan
AU  - Himmelfarb J
FAU - Lowe, Stephen R
AU  - Lowe SR
FAU - Abbott, Kevin C
AU  - Abbott KC
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Clin Nephrol
JT  - Clinical nephrology
JID - 0364441
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arteriovenous Shunt, Surgical
MH  - Aspirin/therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Cost-Benefit Analysis
MH  - Dipyridamole/therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Monte Carlo Method
MH  - Platelet Aggregation Inhibitors/economics/*therapeutic use
MH  - Quality-Adjusted Life Years
MH  - *Renal Dialysis/adverse effects/economics
EDAT- 2013/10/29 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/10/29 06:00
PHST- 2013/12/19 00:00 [accepted]
PHST- 2013/10/29 06:00 [entrez]
PHST- 2013/10/29 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - 11038 [pii]
AID - 10.5414/CN108100 [doi]
PST - ppublish
SO  - Clin Nephrol. 2014 Jan;81(1):38-51. doi: 10.5414/CN108100.

PMID- 3489445
OWN - NLM
STAT- MEDLINE
DCOM- 19861007
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 42
IP  - 3
DP  - 1986 Sep
TI  - Improved patency of the aortocoronary bypass by antithrombotic drugs.
PG  - 312-4
AB  - A total of 1,017 bypasses were performed in 442 patients operated on in our 
      department between January 1, 1981, and May 30, 1984. The overall early 
      postoperative graft patency rate in our hospital was 91.5%. About 10% of the 
      grafts had a flow rate of 40 ml/min or less, measured intraoperatively, and most 
      occluded grafts were in this group. This article presents our experience with 
      low-flow bypasses whose patency rates we attempted to improve. Patients with 
      aortocoronary bypasses (ACBs) and with intraoperative blood flow rates of 40 
      ml/min or less were divided into two groups. The treated group was given, from 
      day 0 onward, a 500-mg dose of acetylsalicylic acid twice a day and a 75-mg dose 
      of dipyridamole three times a day. The control group was given no medication. 
      Control coronary arteriography was performed at one month and then at one year 
      after the operation. One month postoperatively, 34 out of 41 ACBs in the treated 
      group were patent; in the control group, only 17 out of 37 were patent (p less 
      than .001). One year after the operation, 24 out of 37 ACBs in the treated group 
      were patent, whereas in the control group only 8 out of 38 ACBs were patent (p 
      less than .001). We conclude that antiplatelet drugs have a beneficial effect on 
      the short-term and long-term patency of ACBs.
FAU - Pirk, J
AU  - Pirk J
FAU - Vojácek, J
AU  - Vojácek J
FAU - Kovác, J
AU  - Kovác J
FAU - Fabián, J
AU  - Fabián J
FAU - Firt, P
AU  - Firt P
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Coronary Circulation/*drug effects
MH  - Dipyridamole/*therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Random Allocation
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
AID - S0003-4975(10)62742-7 [pii]
AID - 10.1016/s0003-4975(10)62742-7 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1986 Sep;42(3):312-4. doi: 10.1016/s0003-4975(10)62742-7.

PMID- 17676891
OWN - NLM
STAT- MEDLINE
DCOM- 20071108
LR  - 20131121
IS  - 1520-6106 (Print)
IS  - 1520-5207 (Linking)
VI  - 111
IP  - 34
DP  - 2007 Aug 30
TI  - A linear scaling study of solvent-solute interaction energy of drug molecules in 
      aqua solution.
PG  - 10320-8
AB  - Solvent-solute interaction energies for three well-known drug molecules in water 
      solution are computed at the Hartree-Fock and B3LYP density functional theory 
      levels using a linear scaling technique, which allows one to explicitly include 
      in the model water molecules up to 14 A away from the solute molecule. The 
      dependence of calculated interaction energies on the amount of included solvent 
      has been examined. It is found that it is necessary to account for water 
      molecules within an 8 A radius around the drug molecule to reach the saturated 
      solvent interaction level. Effects of electron correlation and basis set on 
      solvent-solute interaction energies are discussed.
FAU - Bondesson, Laban
AU  - Bondesson L
AD  - Department of Theoretical Chemistry, Royal Institute of Technology, SE-10691 
      Stockholm, Sweden.
FAU - Rudberg, Elias
AU  - Rudberg E
FAU - Luo, Yi
AU  - Luo Y
FAU - Sałek, Paweł
AU  - Sałek P
LA  - eng
PT  - Journal Article
DEP - 20070804
PL  - United States
TA  - J Phys Chem B
JT  - The journal of physical chemistry. B
JID - 101157530
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Solvents)
RN  - 059QF0KO0R (Water)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/chemistry
MH  - Caffeine/chemistry
MH  - Electrons
MH  - Ibuprofen/chemistry
MH  - *Mathematical Computing
MH  - Pharmaceutical Preparations/*chemistry
MH  - Solvents/*chemistry
MH  - Thermodynamics
MH  - Water/*chemistry
EDAT- 2007/08/07 09:00
MHDA- 2007/11/09 09:00
CRDT- 2007/08/07 09:00
PHST- 2007/08/07 09:00 [pubmed]
PHST- 2007/11/09 09:00 [medline]
PHST- 2007/08/07 09:00 [entrez]
AID - 10.1021/jp072621l [doi]
PST - ppublish
SO  - J Phys Chem B. 2007 Aug 30;111(34):10320-8. doi: 10.1021/jp072621l. Epub 2007 Aug 
      4.

PMID- 3677676
OWN - NLM
STAT- MEDLINE
DCOM- 19880120
LR  - 20190824
IS  - 0010-7824 (Print)
IS  - 0010-7824 (Linking)
VI  - 36
IP  - 3
DP  - 1987 Sep
TI  - The effect of acetylsalicylic acid on menstrual blood loss in women with IUDs.
PG  - 295-303
AB  - Fifty-three volunteer women using Copper T 220C IUDs, complaining of increased 
      menstrual bleeding, received per os 1 g, three times a day, of acetylsalicylic 
      acid, for 5 days, during their menstrual periods. Menstrual bleeding for each 
      patient was measured at least once before treatment. Bleeding estimates were also 
      performed from the second to the fifth treatment cycle. From the 53 women 
      admitted to the study, only 13 subjects (24.7%) had pre-treatment menstrual 
      bleeding of more than 80 ml; 40 subjects had less than 80 ml. The group with 
      hypermenorrhea had slightly decreased (not significant) the amount of menstrual 
      blood loss with acetylsalicylic acid intake. On the other hand, 67.1% of women 
      with bleeding less than 80 ml observed a significant increase in menstrual blood 
      loss.
FAU - Pedrón, N
AU  - Pedrón N
AD  - Laboratorio de Biología Molecular, Instituto Mexicano del Seguro Social (IMSS), 
      México.
FAU - Lozano, M
AU  - Lozano M
FAU - Gallegos, A J
AU  - Gallegos AJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Contraception
JT  - Contraception
JID - 0234361
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Humans
MH  - *Intrauterine Devices, Copper
MH  - Menorrhagia/chemically induced
MH  - Menstruation/*drug effects
EDAT- 1987/09/01 00:00
MHDA- 1987/09/01 00:01
CRDT- 1987/09/01 00:00
PHST- 1987/09/01 00:00 [pubmed]
PHST- 1987/09/01 00:01 [medline]
PHST- 1987/09/01 00:00 [entrez]
AID - 0010-7824(87)90099-0 [pii]
AID - 10.1016/0010-7824(87)90099-0 [doi]
PST - ppublish
SO  - Contraception. 1987 Sep;36(3):295-303. doi: 10.1016/0010-7824(87)90099-0.

PMID- 7303042
OWN - NLM
STAT- MEDLINE
DCOM- 19820109
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 12
IP  - 5
DP  - 1981 Sep-Oct
TI  - Treatment program and comparison between anticoagulants and platelet aggregation 
      inhibitors after transient ischemic attack.
PG  - 578-80
AB  - Transient cerebral ischemic attacks (TIA) are an important warning symptom of 
      threatening stroke from cerebral infarction (CI). A local treatment program aimed 
      at identifying as many individuals with TIA as possible and treating them in a 
      uniform manner is desirable. Platelet aggregation inhibitors with a combination 
      of acetylsalicylic acid and dipyridamole (ASA + DP) has been compared with 
      anticoagulants (AC). The average length of treatment was 24 months and all 
      patients received the treatment for at least 6 months. Sixty patients received AC 
      and 65 ASA + DP. Four patients in the ASA + DP group (6 percent) and 2 in the AC 
      group (3.3 percent) sustained cerebral infarction. These figures are essentially 
      lower than the expected incidence of 15--20 percent.
FAU - Burén, A
AU  - Burén A
FAU - Ygge, J
AU  - Ygge J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Anticoagulants)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
EDAT- 1981/09/01 00:00
MHDA- 1981/09/01 00:01
CRDT- 1981/09/01 00:00
PHST- 1981/09/01 00:00 [pubmed]
PHST- 1981/09/01 00:01 [medline]
PHST- 1981/09/01 00:00 [entrez]
AID - 10.1161/01.str.12.5.578 [doi]
PST - ppublish
SO  - Stroke. 1981 Sep-Oct;12(5):578-80. doi: 10.1161/01.str.12.5.578.

PMID- 3228537
OWN - NLM
STAT- MEDLINE
DCOM- 19890418
LR  - 20131121
IS  - 0890-5096 (Print)
IS  - 0890-5096 (Linking)
VI  - 2
IP  - 1
DP  - 1988 Jan
TI  - Patency and intimal hyperplasia: the effect of aspirin on small arterial 
      anastomosis.
PG  - 50-6
AB  - This experiment evaluated the effect of aspirin (ASA) on the patency and 
      development of intimal hyperplasia in autologous, small caliber, arterial 
      end-to-side anastomosis. Twenty-eight adult female rabbits had their distal left 
      external iliac artery transposed and anastomosed to the right proximal external 
      iliac artery. Fourteen rabbits received ASA 40 mg by gavage twice in the 24 hours 
      preceding the operation and 5 times a week postoperatively (experimental) and 14 
      rabbits received no ASA therapy (control). Plasma salicylate levels range from 25 
      to 36 micrograms per milliliter in experimental animals. Patency of the 
      reconstruction was assessed by Doppler examination each month, confirmed by 
      autopsy and calculated by life table analysis. Five cross sections of each patent 
      anastomosis harvested at six and nine months were examined by light microscopy. A 
      total of seven thromboses occurred in the control group versus two occlusions in 
      the experimental group. Four of the thromboses in the control group occurred less 
      than seven days after the reconstruction, whereas no such events occurred in the 
      experimental group. Patency by actuarial methods at nine months was 45.5% versus 
      81.8% (p less than .05) in control and experimental groups, respectively. This 
      improvement occurred in spite of similar values for intimal thickness and 
      lumen-to-basement membrane ratios in both control and experimental groups. We 
      conclude that aspirin significantly improves the nine month patency rate of small 
      autologous end-to-side anastomosis, and its effect is most noticeable in the 
      early postoperative period.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Quiñones-Baldrich, W J
AU  - Quiñones-Baldrich WJ
AD  - Department of Surgery, UCLA Medical Center.
FAU - Ziomek, S
AU  - Ziomek S
FAU - Henderson, T
AU  - Henderson T
FAU - Moore, W S
AU  - Moore WS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - Netherlands
TA  - Ann Vasc Surg
JT  - Annals of vascular surgery
JID - 8703941
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anastomosis, Surgical
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Hyperplasia
MH  - Iliac Artery/*pathology/surgery
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
MH  - Vascular Patency/*drug effects
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - S0890-5096(06)60777-2 [pii]
AID - 10.1016/S0890-5096(06)60777-2 [doi]
PST - ppublish
SO  - Ann Vasc Surg. 1988 Jan;2(1):50-6. doi: 10.1016/S0890-5096(06)60777-2.

PMID- 5687585
OWN - NLM
STAT- MEDLINE
DCOM- 19681220
LR  - 20190511
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 34
IP  - 2
DP  - 1968 Oct
TI  - A device for measuring the threshold of pain in man.
PG  - 251-8
AB  - 1. A device operated by hand has been constructed for the controlled compression 
      of the soft tissue in front of the Achilles tendon.2. The sensitivity of the 
      device was sufficient to demonstrate the analgesic action of 0.3 g aspirin.
FAU - Burn, G P
AU  - Burn GP
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - *Achilles Tendon
MH  - Analgesia
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Methods
MH  - *Pain/drug therapy
MH  - Pharmacology/*instrumentation
PMC - PMC1703330
EDAT- 1968/10/01 00:00
MHDA- 1968/10/01 00:01
CRDT- 1968/10/01 00:00
PHST- 1968/10/01 00:00 [pubmed]
PHST- 1968/10/01 00:01 [medline]
PHST- 1968/10/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1968.tb07048.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1968 Oct;34(2):251-8. doi: 10.1111/j.1476-5381.1968.tb07048.x.

PMID- 10537230
OWN - NLM
STAT- MEDLINE
DCOM- 19991104
LR  - 20131121
IS  - 0008-4212 (Print)
IS  - 0008-4212 (Linking)
VI  - 77
IP  - 6
DP  - 1999 Jun
TI  - Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability 
      after oral asprin administration in the rat.
PG  - 441-6
AB  - The bioavailabilities of aspirin (acetylsalicylic acid) and of salicylic acid 
      were studied in male Wistar rats after acute and chronic administration of a 
      Capsicum annuum extract, containing 100 mg of capsaicin per gram. With a single 
      administration of 100 mg/kg of the extract, aspirin blood levels remained 
      unchanged, but salicylic acid bioavailability was reduced in 44% compared with 
      control animals. With a single administration of 300 mg/kg of the extract, 
      aspirin blood levels were undetectable while salicylic acid bioavailability was 
      reduced in 59%. Chronic administration once daily for 4 weeks of 100 and 300 
      mg/kg of the extract resulted in undetectable aspirin blood levels, while 
      salicylic acid bioavailability was reduced in 63 and 76%, respectively, compared 
      with controls. Results show that Capsicum ingestion reduces oral drug 
      bioavailability, likely as a result of the gastrointestinal effects of capsaicin.
FAU - Cruz, L
AU  - Cruz L
AD  - Area Farmacéutica, Facultad de Estudios Superiores Zaragoza, Universidad Nacional 
      Autónoma de México, Iztapalapa, México DF.
FAU - Castañeda-Hernández, G
AU  - Castañeda-Hernández G
FAU - Navarrete, A
AU  - Navarrete A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Plant Extracts)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Biological Availability
MH  - *Capsicum
MH  - Male
MH  - Plant Extracts/pharmacology
MH  - *Plants, Medicinal
MH  - Rats
MH  - Rats, Wistar
MH  - Salicylic Acid/*pharmacokinetics
EDAT- 1999/10/28 00:00
MHDA- 1999/10/28 00:01
CRDT- 1999/10/28 00:00
PHST- 1999/10/28 00:00 [pubmed]
PHST- 1999/10/28 00:01 [medline]
PHST- 1999/10/28 00:00 [entrez]
PST - ppublish
SO  - Can J Physiol Pharmacol. 1999 Jun;77(6):441-6.

PMID- 2976211
OWN - NLM
STAT- MEDLINE
DCOM- 19890405
LR  - 20131121
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 60
IP  - 8
DP  - 1988
TI  - [Advantages and shortcomings of platelet antiaggregants in the treatment of 
      myocardial infarction].
PG  - 59-63
AB  - The authors compared the action of small doses of aspirin (100-200 mg/day) and 
      ticlopidine (500 mg/day) in multimodality therapy of acute myocardial infarction. 
      Rapid normalization of aggregation time and disaggregation percentage, a sharp 
      decrease in spontaneous aggregation before adding ADP were noted on the first 5 
      days of ticlopidine therapy. Platelet aggregation indices returned to normal 3-4 
      days earlier in the use of ticlopidine versus aspirin. However ticlopidine 
      administration over 7 days was characterized by more frequent episodes of G. I. 
      tract hemorrhages of short duration. There were also some data on the toxic 
      effect of the drug on hepatocytes. More allergic reactions were observed in 
      comparison with the group of patients on aspirin therapy. In order to achieve an 
      optimal antiaggregation effect and to reduce the number of ticlopidine-related 
      side effects short-term courses of ticlopidine with subsequent administration of 
      aspirin at small doses were recommended.
FAU - Nechaev, D D
AU  - Nechaev DD
FAU - Bochko, I I
AU  - Bochko II
FAU - Martynov, I V
AU  - Martynov IV
FAU - Kuz'mina, L F
AU  - Kuz'mina LF
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Preimushchestva i nedostatki antiagregantov pri lechenii infarkta miokarda.
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Eruptions/etiology
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Infarction/blood/*drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors
MH  - Ticlopidine/adverse effects/*therapeutic use
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Ter Arkh. 1988;60(8):59-63.

PMID- 16204910
OWN - NLM
STAT- MEDLINE
DCOM- 20060818
LR  - 20191126
IS  - 0254-8860 (Print)
IS  - 0254-8860 (Linking)
VI  - 24
IP  - 4
DP  - 2005 Jul-Aug
TI  - Gastrointestinal bleed after leeching in a patient on aspirin therapy.
PG  - 170
AB  - Leeches ( Hirudo medicinalis ) have been used in health care for their property 
      of bloodletting. Bleed occurring from the site of leech attachment has been well 
      documented. We report a 50-year-old man who was on aspirin therapy for coronary 
      artery disease, and presented with GI bleed after leech treatment for his knee 
      pain.
FAU - Kumar, Naveen
AU  - Kumar N
AD  - Department of Medicine, Dayanand Medical College and Hospital, Ludhiana, India.
FAU - Mohindra, Rajat
AU  - Mohindra R
FAU - Mohan, Bishav
AU  - Mohan B
FAU - Wander, G S
AU  - Wander GS
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - India
TA  - Indian J Gastroenterol
JT  - Indian journal of gastroenterology : official journal of the Indian Society of 
      Gastroenterology
JID - 8409436
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Gastrointestinal Hemorrhage/*etiology
MH  - Humans
MH  - Leeching/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects
EDAT- 2005/10/06 09:00
MHDA- 2006/08/19 09:00
CRDT- 2005/10/06 09:00
PHST- 2005/10/06 09:00 [pubmed]
PHST- 2006/08/19 09:00 [medline]
PHST- 2005/10/06 09:00 [entrez]
PST - ppublish
SO  - Indian J Gastroenterol. 2005 Jul-Aug;24(4):170.

PMID- 19597002
OWN - NLM
STAT- MEDLINE
DCOM- 20090806
LR  - 20220317
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
VI  - 183
IP  - 3
DP  - 2009 Aug 1
TI  - Effects of low-dose aspirin on acute inflammatory responses in humans.
PG  - 2089-96
LID - 10.4049/jimmunol.0900477 [doi]
AB  - Aspirin is a unique nonsteroidal anti-inflammatory drug; at high doses 
      (aspirin(high), 1g), it is anti-inflammatory stemming from the inhibition of 
      cyclooxygenase and proinflammatory signaling pathways including NF-kappaB, but is 
      cardioprotective at lower doses (aspirin(low), 75 mg). The latter arises from the 
      inhibition of thromboxane (Tx) B(2), a prothrombotic eicosanoid also implicated 
      in polymorphonuclear leukocyte trafficking. As a result, aspirin(low) is widely 
      used as a primary and secondary preventative against vascular disease. Despite 
      this and its ability to synthesize proresolution 15-epi-lipoxin A(4) it is not 
      known whether aspirin(low) is anti-inflammatory in humans. To address this, we 
      generated skin blisters by topically applying cantharidin on the forearm of 
      healthy male volunteers, causing an acute inflammatory response including dermal 
      edema formation and leukocyte trafficking. Although not affecting blister fluid 
      volume, aspirin(low) (75 mg, oral, once daily/10 days) reduced polymorphonuclear 
      leukocyte and macrophage accumulation independent of NF-kappaB-regulated gene 
      expression and inhibition of conventional prostanoids. However, aspirin(low) 
      triggered 15-epi-lipoxin A(4) synthesis and up-regulated its receptor (FPRL1, 
      ALX). From complimentary in vitro experiments, we propose that 15-epi-lipoxin 
      A(4) exerts its protective effects by triggering antiadhesive NO, thereby 
      dampening leukocyte/endothelial cell interaction and subsequent extravascular 
      leukocyte migration. Since similar findings were obtained from murine 
      zymosan-induced peritonitis, we suggest that aspirin(low) possesses the ability 
      to inhibit mammalian innate immune-mediated responses. This highlights 
      15-epi-lipoxin A(4) as a novel anti-inflammatory working through a defined 
      receptor and suggests that mimicking its mode of action represents a new approach 
      to treating inflammation-driven diseases.
FAU - Morris, Thea
AU  - Morris T
AD  - Division of Medicine, University College London, Centre for Clinical Pharmacology 
      and Therapeutics, London, United Kingdom.
FAU - Stables, Melanie
AU  - Stables M
FAU - Hobbs, Adrian
AU  - Hobbs A
FAU - de Souza, Patricia
AU  - de Souza P
FAU - Colville-Nash, Paul
AU  - Colville-Nash P
FAU - Warner, Tim
AU  - Warner T
FAU - Newson, Justine
AU  - Newson J
FAU - Bellingan, Geoffrey
AU  - Bellingan G
FAU - Gilroy, Derek W
AU  - Gilroy DW
LA  - eng
GR  - 087520/WT_/Wellcome Trust/United Kingdom
GR  - G0500017/MRC_/Medical Research Council/United Kingdom
GR  - DH_/Department of Health/United Kingdom
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090713
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (FPR2 protein, human)
RN  - 0 (Lipoxins)
RN  - 0 (Receptors, Formyl Peptide)
RN  - 0 (Receptors, Lipoxin)
RN  - 0 (lipoxin A4)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - IGL471WQ8P (Cantharidin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blister/chemically induced
MH  - Cantharidin
MH  - Cell Adhesion/drug effects
MH  - Chemotaxis, Leukocyte/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Lipoxins/*biosynthesis
MH  - Macrophages
MH  - Male
MH  - Nitric Oxide/biosynthesis
MH  - Receptors, Formyl Peptide/biosynthesis
MH  - Receptors, Lipoxin/biosynthesis
MH  - Up-Regulation/drug effects
EDAT- 2009/07/15 09:00
MHDA- 2009/08/07 09:00
CRDT- 2009/07/15 09:00
PHST- 2009/07/15 09:00 [entrez]
PHST- 2009/07/15 09:00 [pubmed]
PHST- 2009/08/07 09:00 [medline]
AID - jimmunol.0900477 [pii]
AID - 10.4049/jimmunol.0900477 [doi]
PST - ppublish
SO  - J Immunol. 2009 Aug 1;183(3):2089-96. doi: 10.4049/jimmunol.0900477. Epub 2009 
      Jul 13.

PMID- 22699516
OWN - NLM
STAT- MEDLINE
DCOM- 20121029
LR  - 20211203
IS  - 1573-7284 (Electronic)
IS  - 0393-2990 (Print)
IS  - 0393-2990 (Linking)
VI  - 27
IP  - 6
DP  - 2012 Jun
TI  - Aspirin in the primary prevention of cardiovascular disease in the Women's Health 
      Study: effect of noncompliance.
PG  - 431-8
LID - 10.1007/s10654-012-9702-x [doi]
AB  - Randomized evidence for aspirin in the primary prevention of cardiovascular 
      disease (CVD) among women is limited and suggests at most a modest effect for 
      total CVD. Lack of compliance, however, can null-bias estimated effects. We used 
      marginal structural models (MSMs) to estimate the etiologic effect of continuous 
      aspirin use on CVD events among 39,876 apparently healthy female health 
      professionals aged 45 years and older in the Women's Health Study, a randomized 
      trial of 100 mg aspirin every other day versus placebo. As-treated analyses and 
      MSMs controlled for time-varying determinants of aspirin use and CVD. Predictors 
      of aspirin use differed by randomized group and prior use and included medical 
      history, CVD risk factors, and intermediate CVD events. Previously reported 
      intent-to-treat analyses found small non-significant effects of aspirin on total 
      CVD (hazard ratio (HR) = 0.91, 95 % confidence interval (CI) = 0.81-1.03) and CVD 
      mortality (HR = 0.95, 95 % CI = 0.74-1.22). As-treated analyses were similar for 
      total CVD with a slight reduction in CVD mortality (HR = 0.88, 95 % CI = 
      0.67-1.16). MSMs, which adjusted for non-compliance, were similar for total CVD 
      (HR = 0.93; 95 % CI: 0.81, 1.07) but suggested lower CVD mortality with aspirin 
      use (HR = 0.76; 95 % CI: 0.54, 1.08). Adjusting for non-compliance had little 
      impact on the estimated effect of aspirin on total CVD, but strengthened the 
      effect on CVD mortality. These results support a limited effect of low-dose 
      aspirin on total CVD in women, but potential benefit for CVD mortality.
FAU - Cook, Nancy R
AU  - Cook NR
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical 
      School, Boston, MA, USA. ncook@rics.bwh.harvard.edu
FAU - Cole, Stephen R
AU  - Cole SR
FAU - Buring, Julie E
AU  - Buring JE
LA  - eng
GR  - R01 HL043851/HL/NHLBI NIH HHS/United States
GR  - R21 HL084609/HL/NHLBI NIH HHS/United States
GR  - HL-84609/HL/NHLBI NIH HHS/United States
GR  - R01 CA047988/CA/NCI NIH HHS/United States
GR  - CA-47988/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20120615
PL  - Netherlands
TA  - Eur J Epidemiol
JT  - European journal of epidemiology
JID - 8508062
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Anticoagulants/*adverse effects
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Body Mass Index
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Comorbidity
MH  - Female
MH  - Health Behavior
MH  - Humans
MH  - Medication Adherence/*statistics & numerical data
MH  - Middle Aged
MH  - Primary Prevention/*methods
MH  - Racial Groups
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Risk Factors
PMC - PMC3383873
MID - NIHMS381509
EDAT- 2012/06/16 06:00
MHDA- 2012/10/30 06:00
CRDT- 2012/06/16 06:00
PHST- 2012/03/19 00:00 [received]
PHST- 2012/05/25 00:00 [accepted]
PHST- 2012/06/16 06:00 [entrez]
PHST- 2012/06/16 06:00 [pubmed]
PHST- 2012/10/30 06:00 [medline]
AID - 10.1007/s10654-012-9702-x [doi]
PST - ppublish
SO  - Eur J Epidemiol. 2012 Jun;27(6):431-8. doi: 10.1007/s10654-012-9702-x. Epub 2012 
      Jun 15.

PMID- 33871623
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1944-7922 (Electronic)
IS  - 1060-3271 (Linking)
VI  - 104
IP  - 5
DP  - 2021 Sep 27
TI  - DoE and Risk-Based DMAIC Principle for Implementation of Enhanced Analytical 
      Quality by Design Approach to Multipurpose-Chromatography Method for Simultaneous 
      Estimation of Multiple Fixed-Dose Combination Products of Aspirin.
PG  - 1430-1441
LID - 10.1093/jaoacint/qsab058 [doi]
AB  - BACKGROUND: Numerous RP-HPLC and HPTLC methods have been reported for estimation 
      of fixed-dose combination (FDC) products of aspirin with anti-hypertensive and 
      anti-lipidemic drugs. Each FDC of aspirin needs separate and dedicated 
      chromatographic conditions for analyses. No chromatographic method has been 
      reported for simultaneous estimation of FDC products of aspirin using a single 
      chromatography condition. OBJECTIVE: A multipurpose HPTLC method was developed 
      for simultaneous estimation of some FDC products of aspirin using an enhanced 
      analytical quality-by-design approach based on a design of experiment (DoE) and 
      risk-based define, measure, analyse, improve and control (DMAIC) principle to 
      save solvent, cost, and time of analysis. METHOD: The risk-based DMAIC process 
      was carried out with identification of potential method risk parameters and their 
      assessment using risk priority number (RPN) ranking and filtering. The DoE-based 
      DMAIC process was carried out by the implementation of fractional factorial and 
      full factorial design. RESULTS: The mobile phase composition and volume of 
      modifier were found to be critical method risk parameters for resolution of all 
      peaks. The developed method was found to be validated, and assay results of all 
      FDC products of aspirin were found to be in good agreement with their respective 
      labelled claim. CONCLUSIONS: The developed method is found to be solvent, cost, 
      and time saving and also fulfilled the analytical requirements of many reported 
      chromatography methods. Hence, the developed method is a multipurpose 
      chromatography for analysis of FDC products of aspirin. HIGHLIGHTS: DoE and 
      risk-based DMAIC principle to development of the multipurpose-chromatography 
      method. The developed method was applied for the estimation of eight different 
      FDC products of aspirin.
CI  - © AOAC INTERNATIONAL 2021. All rights reserved. For permissions, please email: 
      journals.permissions@oup.com.
FAU - Prajapati, Pintu B
AU  - Prajapati PB
AUID- ORCID: 0000-0002-5282-2087
AD  - Uka Tarsadia University, Maliba Pharmacy College, Department of Quality 
      Assurance, Bardoli-Mahuva Road, Tarsadi, Mahuva, Surat-394 350, Gujarat, India.
FAU - Jayswal, Kajal V
AU  - Jayswal KV
AD  - Uka Tarsadia University, Maliba Pharmacy College, Department of Quality 
      Assurance, Bardoli-Mahuva Road, Tarsadi, Mahuva, Surat-394 350, Gujarat, India.
FAU - Shah, Shailesh A
AU  - Shah SA
AD  - Uka Tarsadia University, Maliba Pharmacy College, Department of Quality 
      Assurance, Bardoli-Mahuva Road, Tarsadi, Mahuva, Surat-394 350, Gujarat, India.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J AOAC Int
JT  - Journal of AOAC International
JID - 9215446
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - Chromatography, High Pressure Liquid
MH  - *Chromatography, Reverse-Phase
MH  - Research Design
EDAT- 2021/04/20 06:00
MHDA- 2021/09/30 06:00
CRDT- 2021/04/19 12:23
PHST- 2021/01/02 00:00 [received]
PHST- 2021/03/02 00:00 [revised]
PHST- 2021/04/01 00:00 [accepted]
PHST- 2021/04/20 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2021/04/19 12:23 [entrez]
AID - 6237904 [pii]
AID - 10.1093/jaoacint/qsab058 [doi]
PST - ppublish
SO  - J AOAC Int. 2021 Sep 27;104(5):1430-1441. doi: 10.1093/jaoacint/qsab058.

PMID- 22122406
OWN - NLM
STAT- MEDLINE
DCOM- 20121113
LR  - 20131121
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 37
IP  - 4
DP  - 2012 Aug
TI  - Prediction of time-dependent interaction of aspirin with ibuprofen using a 
      pharmacokinetic/pharmacodynamic model.
PG  - 469-74
LID - 10.1111/j.1365-2710.2011.01313.x [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Low-dose aspirin is widely used for prevention of 
      thrombosis, but combined use of aspirin with non-steroidal anti-inflammatory 
      drugs (NSAIDs), such as ibuprofen, reduces the antiplatelet effect of aspirin. 
      However, there has been no report describing the effects of the timing of the 
      ibuprofen dose on the degree of interaction between low-dose aspirin and 
      ibuprofen. The purpose of this study was to predict the time-course of the 
      antiplatelet effect of low-dose aspirin when ibuprofen is administered as a 
      single dose or repeatedly in combination with aspirin at various time intervals. 
      METHODS: We simulated ex vivo platelet aggregation using a previously developed 
      pharmacokinetic (PK)/pharmacodynamic (PD) model. RESULTS AND DISCUSSION: The 
      antiplatelet effect of low-dose aspirin (81 mg) was predicted to be markedly 
      reduced when ibuprofen (200 mg; the usual prescribed dose in Japan) was 
      administered 1 h or less after aspirin, but not when it was administered more 
      than 2 h after the administration of aspirin. Moreover, the administration of 
      ibuprofen up to 12 h before aspirin completely abrogated the antiplatelet effect 
      of aspirin. When ibuprofen (200 mg) was administered three times daily for 3 days 
      (day 1 to day 3) on a background of continuous low-dose aspirin (81 mg) once 
      daily, 2 h after aspirin, no reduction in the antiplatelet effect of aspirin was 
      predicted on day 1, but a reduction is predicted from day 2, with no return to 
      the initial level until more than 3 days after discontinuation of ibuprofen. A 
      marked reduction in the antiplatelet effect of aspirin was also seen on the same 
      schedule when the dosage of ibuprofen was 150 mg, which is the dose used in 
      over-the-counter (OTC) preparations. WHAT IS NEW AND CONCLUSION: This study 
      indicates that the antiplatelet effect of low-dose aspirin can be markedly 
      reduced with combined use of ibuprofen, depending on the timing of 
      co-administration. As even the lower OTC dose of ibuprofen (150 mg) was enough to 
      affect the antiplatelet effect of aspirin, health professionals should take into 
      account patients' use of OTC ibuprofen when prescribing low-dose aspirin.
CI  - © 2011 Blackwell Publishing Ltd.
FAU - Awa, K
AU  - Awa K
AD  - Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, 
      Japan.
FAU - Satoh, H
AU  - Satoh H
FAU - Hori, S
AU  - Hori S
FAU - Sawada, Y
AU  - Sawada Y
LA  - eng
PT  - Journal Article
DEP - 20111128
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacokinetics/pharmacology
MH  - Computer Simulation
MH  - Cyclooxygenase Inhibitors/administration & dosage/pharmacokinetics/pharmacology
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Humans
MH  - Ibuprofen/*administration & dosage/pharmacokinetics/pharmacology
MH  - Japan
MH  - *Models, Biological
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/pharmacokinetics/pharmacology
MH  - Time Factors
EDAT- 2011/11/30 06:00
MHDA- 2012/11/14 06:00
CRDT- 2011/11/30 06:00
PHST- 2011/11/30 06:00 [entrez]
PHST- 2011/11/30 06:00 [pubmed]
PHST- 2012/11/14 06:00 [medline]
AID - 10.1111/j.1365-2710.2011.01313.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2012 Aug;37(4):469-74. doi: 10.1111/j.1365-2710.2011.01313.x. 
      Epub 2011 Nov 28.

PMID- 26069253
OWN - NLM
STAT- MEDLINE
DCOM- 20150918
LR  - 20200220
IS  - 0032-5791 (Print)
IS  - 0032-5791 (Linking)
VI  - 94
IP  - 8
DP  - 2015 Aug
TI  - Improving appearance and microbiologic quality of broiler carcasses with an 
      allostatic modulator.
PG  - 1957-63
LID - 10.3382/ps/pev144 [doi]
AB  - An important priority of poultry producers is to guarantee animal welfare during 
      animal production; however, broilers are exposed to unavoidable chronic stress 
      (also known as allostasis) when they are captured, caged, and transported to the 
      processing plant. This antemortem management causes allostatic load, animal 
      injuries, and poor carcass quality. The aim of the present study was to evaluate 
      the effects of an allostatic modulator (AM) on antemortem stress by measuring the 
      appearance and microbiological quality of broiler carcasses. The AM consisted of 
      a liquid formula containing ascorbic acid, acetyl salicylic acid, and 
      electrolytes, administered orally 48 h before shipment to the processing plant. A 
      total of 600 chickens (49-days-old) were used under a factorial arrangement 2 × 2 
      × 2 [2 commercial hybrid lines, 2 feed withdrawal programs (10 and 16 h), and 2 
      water treatments (control and AM)]. Each treatment included 25 chickens per pen 
      and was carried out in triplicate. The broilers were shipped, slaughtered, and 
      processed in a commercial processing plant where carcass defects (bruises and 
      broken bones caused by antemortem management), crop pH, and carcass bacterial 
      counts were evaluated in all experimental groups. Broilers under AM treatment 
      showed a reduction in carcass defects (P = 0.015), crop pH (P = 0.0001), 
      coliforms counts (P = 0.014), and total aerobic mesophilic bacteria (P = 0.0001) 
      when compared to the control treatment. The present study indicates that the AM 
      can be used to improve carcass quality in broilers. Our study provides a novel 
      and economic alternative to reduce the allostatic load in broilers.
CI  - © 2015 Poultry Science Association Inc.
FAU - Rubio-García, M E
AU  - Rubio-García ME
AD  - Center for Teaching, Research, and Poultry Extension (CEIEPAv), School of 
      Veterinary Medicine, National Autonomous University of Mexico, FMVZ-UNAM, México, 
      D.F. C.P. 13209.
FAU - Rubio-Lozano, M S
AU  - Rubio-Lozano MS
AD  - Center for Teaching and Research in Production and Animal Health, FMVZ-UNAM, 
      México, D.F. C.P. 04510.
FAU - Ponce-Alquicira, E
AU  - Ponce-Alquicira E
AD  - Medicine and Poultry Husbandry Department, FMVZ-UNAM. México City, México, D.F. 
      C.P. 04510.
FAU - Rosario-Cortes, C
AU  - Rosario-Cortes C
AD  - Biotechnology Department, Autonomous Metropolitan University, Iztapalapa, México 
      City, México, D.F. C.P. 09340.
FAU - Nava, G M
AU  - Nava GM
AD  - Department of Research and Graduate Studies in Food Science, School of Chemistry, 
      University Autonomous of Queretaro, México, C.P. 04510.
FAU - Castañeda-Serrano, M P
AU  - Castañeda-Serrano MP
AD  - Center for Teaching, Research, and Poultry Extension (CEIEPAv), School of 
      Veterinary Medicine, National Autonomous University of Mexico, FMVZ-UNAM, México, 
      D.F. C.P. 13209 pilarcs@unam.mx.
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150611
PL  - England
TA  - Poult Sci
JT  - Poultry science
JID - 0401150
RN  - 0 (Drinking Water)
RN  - 0 (Electrolytes)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Allostasis
MH  - Animals
MH  - Ascorbic Acid/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chickens/microbiology
MH  - Drinking Water
MH  - Electrolytes/administration & dosage/*pharmacology
MH  - Female
MH  - *Food Microbiology
MH  - Male
MH  - Meat/*microbiology
MH  - Stress, Physiological/*drug effects
OTO - NOTNLM
OT  - allostatic load
OT  - broilers
OT  - carcass quality
OT  - stress
OT  - welfare
EDAT- 2015/06/13 06:00
MHDA- 2015/09/19 06:00
CRDT- 2015/06/13 06:00
PHST- 2015/04/20 00:00 [accepted]
PHST- 2015/06/13 06:00 [entrez]
PHST- 2015/06/13 06:00 [pubmed]
PHST- 2015/09/19 06:00 [medline]
AID - S0032-5791(19)32226-6 [pii]
AID - 10.3382/ps/pev144 [doi]
PST - ppublish
SO  - Poult Sci. 2015 Aug;94(8):1957-63. doi: 10.3382/ps/pev144. Epub 2015 Jun 11.

PMID- 11199481
OWN - NLM
STAT- MEDLINE
DCOM- 20010712
LR  - 20191025
IS  - 0340-2096 (Print)
IS  - 0340-2096 (Linking)
VI  - 29
IP  - 6
DP  - 2000 Dec
TI  - Teratogenicity of edoferon kappa A, a molecule derived from salicylate, in 
      cultured rat embryos: differences from salicylate and interaction with free 
      oxygen radical scavenging enzymes.
PG  - 363-70
AB  - The effect of edoferon kappa A (E-KA), a non-specific immunomodulatory and 
      anti-neoplastic chemical substance derived from the methyl form of salicylate 
      (acetyl salicylic acid; ASA), on mammalian embryos was studied and compared to 
      the effects of ASA. Rat embryos were cultured in vitro from 9.5 days of gestation 
      for 48 h. E-KA (0.1-12.8 mg/ml) and ASA (0.1-0.6 mg/ml) were added to the whole 
      rat serum. To investigate the interaction of these molecules with antioxidant 
      agents, the lowest effective concentrations of E-KA (0.6 mg/ml) and ASA (0.3 
      mg/ml) for all parameters were added to the culture media in the presence of 
      superoxide dismutase (SOD) (30 U/ml) or glutathione (0.5 mumol/ml). The growth 
      and development of embryos was compared and each embryo was evaluated for the 
      presence of any malformations. E-KA and ASA decreased growth and development in a 
      concentration-responsive manner. There was also a concentration-related increase 
      in overall dysmorphology (haematoma in the yolk sac and neural system, open 
      neural tube, abnormal tail torsion and the absence of fore limb bud). There were 
      no statistically significant differences between the control and embryos grown in 
      the presence of 0.1-0.4 mg/ml E-KA, although the effects of ASA started at a 
      concentration of 0.2 mg/ml. Embryos showed significant growth retardation in all 
      scoring criteria and severe malformations when 0.5-3.2 mg/ml E-KA and 0.3-0.6 
      mg/ml ASA were added. When SOD was added, there was a significant decrease in the 
      incidence of malformations and growth and developmental parameters were increased 
      but this decrease never reached the control level. We concluded that E-KA has 
      direct toxic effects on the developing embryo but at much higher concentrations 
      than ASA, and the teratogenic effects of these molecules might be related to free 
      oxygen radicals.
FAU - Karabulut, A K
AU  - Karabulut AK
AD  - Department of Anatomy, Faculty of Medicine, Selcuk University, Konya 42080, 
      Turkey. akkarabulut@yahoo.com
FAU - Ulger, H
AU  - Ulger H
FAU - Pratten, M
AU  - Pratten M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Anat Histol Embryol
JT  - Anatomia, histologia, embryologia
JID - 7704218
RN  - 0 (Antioxidants)
RN  - 0 (Free Radical Scavengers)
RN  - 0 (Teratogens)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Aspirin/chemistry/*toxicity
MH  - Culture Techniques
MH  - Dose-Response Relationship, Drug
MH  - Embryonic and Fetal Development/*drug effects
MH  - Female
MH  - Free Radical Scavengers/*metabolism
MH  - Male
MH  - Pregnancy
MH  - Rats
MH  - Rats, Wistar
MH  - Superoxide Dismutase/*metabolism
MH  - Teratogens/chemistry/metabolism/*toxicity
EDAT- 2001/02/24 12:00
MHDA- 2001/07/13 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/07/13 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
AID - 10.1046/j.1439-0264.2000.00287.x [doi]
PST - ppublish
SO  - Anat Histol Embryol. 2000 Dec;29(6):363-70. doi: 
      10.1046/j.1439-0264.2000.00287.x.

PMID- 37078457
OWN - NLM
STAT- MEDLINE
DCOM- 20230421
LR  - 20230427
IS  - 2051-817X (Electronic)
IS  - 2051-817X (Linking)
VI  - 11
IP  - 8
DP  - 2023 Apr
TI  - Influence of aspirin on aging skeletal muscle: Insights from a cross-sectional 
      cohort of septuagenarians.
PG  - e15669
LID - 10.14814/phy2.15669 [doi]
LID - e15669
AB  - Aspirin is one of the most commonly consumed cyclooxygenase (COX)-inhibitors and 
      anti-inflammatory drugs and has been shown to block COX-produced regulators of 
      inflammation and aging skeletal muscle size. We used propensity score matching to 
      compare skeletal muscle characteristics of individuals from the Health ABC study 
      that did not consume aspirin or any other COX-inhibiting drugs (non-consumers, 
      n = 497, 74 ± 3 year, 168 ± 9 cm, 75.1 ± 13.8 kg, 33.1 ± 7.4% body fat, 37% 
      women, 34% black) to those that consumed aspirin daily (and not any other 
      COX-inhibiting drugs) and for at least 1 year (aspirin consumers, n = 515, 
      74 ± 3 year, 168 ± 9 cm, 76.2 ± 13.6 kg, 33.8 ± 7.1% body fat, 39% women, 30% 
      black, average aspirin consumption: 6 year). Subjects were matched (p > 0.05) 
      based on age, height, weight, % body fat, sex, and race (propensity scores: 
      0.33 ± 0.09 vs. 0.33 ± 0.09, p > 0.05). There was no difference between 
      non-consumers and aspirin consumers for computed tomography-determined muscle 
      size of the quadriceps (103.5 ± 0.9 vs. 104.9 ± 0.8 cm(2) , p > 0.05) or 
      hamstrings (54.6 ± 0.5 vs. 54.9 ± 0.5 cm(2) , p > 0.05), or quadriceps muscle 
      strength (111.1 ± 2.0 vs. 111.7 ± 2.0 Nm, p > 0.05). However, muscle attenuation 
      (i.e., density) was higher in the aspirin consumers in the quadriceps (40.9 ± 0.3 
      vs. 44.4 ± 0.3 Hounsfield unit [HU], p < 0.05) and hamstrings (27.7 ± 0.4 vs. 
      33.2 ± 0.4 HU, p < 0.05). These cross sectional data suggest that chronic aspirin 
      consumption does not influence age-related skeletal muscle atrophy, but does 
      influence skeletal muscle composition in septuagenarians. Prospective 
      longitudinal investigations remain necessary to better understand the influence 
      of chronic COX regulation on aging skeletal muscle health.
CI  - © 2023 The Authors. Physiological Reports published by Wiley Periodicals LLC on 
      behalf of The Physiological Society and the American Physiological Society.
FAU - Fountain, William A
AU  - Fountain WA
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana, United 
      States.
FAU - Naruse, Masatoshi
AU  - Naruse M
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana, United 
      States.
FAU - Finch, W Holmes
AU  - Finch WH
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana, United 
      States.
FAU - Claiborne, Alex
AU  - Claiborne A
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana, United 
      States.
FAU - Trappe, Scott W
AU  - Trappe SW
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana, United 
      States.
FAU - Trappe, Todd A
AU  - Trappe TA
AUID- ORCID: 0000-0002-0609-5632
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana, United 
      States.
LA  - eng
GR  - R01-AG028050/AG/NIA NIH HHS/United States
GR  - R01-NR012459/NR/NINR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - Physiol Rep
JT  - Physiological reports
JID - 101607800
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Cyclooxygenase Inhibitors)
SB  - IM
MH  - Humans
MH  - Female
MH  - Male
MH  - *Aspirin/pharmacology
MH  - Cross-Sectional Studies
MH  - Prospective Studies
MH  - *Muscle, Skeletal/physiology
MH  - Aging/physiology
MH  - Cyclooxygenase Inhibitors/pharmacology
PMC - PMC10116541
OTO - NOTNLM
OT  - COX inhibitor
OT  - aging
OT  - aspirin
OT  - inflammation
OT  - skeletal muscle
COIS- No conflicts of interest, financial or otherwise, are declared by the authors.
EDAT- 2023/04/20 13:41
MHDA- 2023/04/21 06:41
CRDT- 2023/04/20 06:42
PHST- 2023/03/25 00:00 [revised]
PHST- 2023/03/05 00:00 [received]
PHST- 2023/03/27 00:00 [accepted]
PHST- 2023/04/21 06:41 [medline]
PHST- 2023/04/20 13:41 [pubmed]
PHST- 2023/04/20 06:42 [entrez]
AID - PHY215669 [pii]
AID - 10.14814/phy2.15669 [doi]
PST - ppublish
SO  - Physiol Rep. 2023 Apr;11(8):e15669. doi: 10.14814/phy2.15669.

PMID- 8267487
OWN - NLM
STAT- MEDLINE
DCOM- 19940125
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 154
IP  - 1
DP  - 1994 Jan 10
TI  - The benefits of aspirin in acute myocardial infarction. Still a well-kept secret 
      in the United States.
PG  - 37-9
AB  - Acute myocardial infarction (MI) remains far and away the leading cause of death 
      in the United States, and is responsible for approximately 500,000 annual 
      fatalities. However, mortality due to MI has declined substantially in recent 
      decades, owing to advances in treatment as well as prevention. Low-dose aspirin 
      as well as thrombolytic therapy given during acute evolving MI each decrease 
      mortality by about one quarter. Both therapies remain underutilized in the United 
      States. Aspirin can be given to virtually all patients, has a far more favorable 
      safety profile than thrombolysis, and confers a comparable benefit at a small 
      fraction of the cost of thrombolytic agents. The more widespread use of aspirin 
      in acute MI is one of the most important and timely clinical challenges in the 
      United States.
FAU - Hennekens, C H
AU  - Hennekens CH
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, Mass.
FAU - Jonas, M A
AU  - Jonas MA
FAU - Buring, J E
AU  - Buring JE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Humans
MH  - Myocardial Infarction/*drug therapy/prevention & control
MH  - Thrombolytic Therapy
MH  - United States
RF  - 16
EDAT- 1994/01/10 00:00
MHDA- 1994/01/10 00:01
CRDT- 1994/01/10 00:00
PHST- 1994/01/10 00:00 [pubmed]
PHST- 1994/01/10 00:01 [medline]
PHST- 1994/01/10 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1994 Jan 10;154(1):37-9.

PMID- 33774952
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 1819-2718 (Electronic)
IS  - 1025-9589 (Linking)
VI  - 33
IP  - 1
DP  - 2021 Jan-Mar
TI  - Mitigative Effects Of Nigella Sativa On The Histology Of Kidneys Against 
      Aspirin-Induced Toxicity.
PG  - 39-43
AB  - BACKGROUND: Aspirin is one of the popular, economical, easily accessible and 
      commonly used drugs all over the world. Injudicious use of this over-the-counter 
      available drug is a common cause of nephrotoxicity. The aim of the present study 
      is to assess the protective effects of Nigella Sativa (NS) on the histology of 
      kidneys against aspirin-induced toxicity. It was an experimental study that 
      included comparative analysis of control and experimental groups, conducted in 
      the department of Anatomy, University of Health Sciences, Lahore, from October 
      2016 to December 2016. METHODS: The study included thirty-two female albino rats 
      which were equally distributed into 4 groups. Group A was run as control and 
      given single oral dose of 1% methyl-cellulose (10mg/100gm body weight of rat). 
      Group B and C were treated with a single oral dose of aspirin (1000mg/kg body 
      weight) dissolved in 1% methyl-cellulose (10mg/100gm body weight). Group C 
      animals were left untreated for 7 days. Group D was pre-treated on day 1 with 
      oral dose of Nigella Sativa (NS) extract (250mg/kg body weight) followed one hour 
      later by a single oral dose of aspirin (1000mg/kg body weight), subsequently NS 
      extract was administered till day 7. Rats of group B were euthanized and 
      dissected on 2nd day of experiment while those of groups A, C and D on 8th day. 
      Kidneys were dissected out, weighed and fixed in 10% formalin. 5μm thick sections 
      were yielded after tissue processing and stained with haematoxylin, eosin (H&E 
      staining) and periodic acid Schiff's reagent (PAS staining). Histological 
      parameters of distal convoluted tubules (DCT) were observed. RESULTS: All 
      histological parameters were normal in group A. Group B showed marked increase in 
      epithelial necrosis, intraluminal protein casts and broken basement membranes of 
      distal convoluted tubules. Group C showed no self-recovery. Statistically 
      significant improvement was observed in the histology of distal convoluted 
      tubules with treatment of Nigella Sativa extract in aspirin-ingested rats in 
      group D. CONCLUSIONS: Nigella Sativa extract has shown protective effects on 
      kidneys against aspirin-induced damage as shown by improvement in the 
      histological parameters of distal convoluted tubules.
FAU - Asif, Sania
AU  - Asif S
AD  - 1Department of Anatomy, King Edward Medical University, Lahore, Pakistan.
FAU - Toor, Rabia Sajjad
AU  - Toor RS
AD  - 2Department of Anatomy, Sahara Medical College, Narowal, Pakistan.
FAU - Amna, Sitwat
AU  - Amna S
AD  - Department of Anatomy, Allama Iqbal Medical College, Lahore, Pakistan.
FAU - Haider, Areeba
AU  - Haider A
AD  - 1Department of Anatomy, King Edward Medical University, Lahore, Pakistan.
FAU - Khan, Sarah
AU  - Khan S
AD  - 1Department of Anatomy, King Edward Medical University, Lahore, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Ayub Med Coll Abbottabad
JT  - Journal of Ayub Medical College, Abbottabad : JAMC
JID - 8910750
RN  - 0 (Plant Extracts)
RN  - 0 (Protective Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Female
MH  - *Kidney/drug effects/pathology
MH  - *Nigella sativa
MH  - Plant Extracts/*pharmacology
MH  - Protective Agents/*pharmacology
MH  - Rats
OTO - NOTNLM
OT  - Distal convoluted tubules; Methyl-cellulose
OT  - Kidneys; Nigella Sativa; Aspirin
EDAT- 2021/03/29 06:00
MHDA- 2021/06/03 06:00
CRDT- 2021/03/28 21:18
PHST- 2021/03/28 21:18 [entrez]
PHST- 2021/03/29 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
AID - xxxxxxxxxxxx [pii]
PST - ppublish
SO  - J Ayub Med Coll Abbottabad. 2021 Jan-Mar;33(1):39-43.

PMID- 32479906
OWN - NLM
STAT- MEDLINE
DCOM- 20210909
LR  - 20210909
IS  - 1878-5832 (Electronic)
IS  - 1359-6446 (Linking)
VI  - 25
IP  - 8
DP  - 2020 Aug
TI  - Prophylactic aspirin for preventing pre-eclampsia and its complications: An 
      overview of meta-analyses.
PG  - 1487-1501
LID - S1359-6446(20)30202-6 [pii]
LID - 10.1016/j.drudis.2020.05.011 [doi]
AB  - Benefits of aspirin administration on pre-eclampsia and IUGR depend on the 
      gestational age and dose of aspirin administration. Meta-analyses show that, to 
      prevent preterm labor, aspirin could be administrated even after 16 weeks of 
      gestational age.
CI  - Copyright © 2020 Elsevier Ltd. All rights reserved.
FAU - Ghazanfarpour, Masumeh
AU  - Ghazanfarpour M
AD  - Nursing Research Center, Kerman University of Medical Sciences, Kerman, Iran.
FAU - Sathyapalan, Thozhukat
AU  - Sathyapalan T
AD  - Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical 
      School, University of Hull, Hull, UK.
FAU - Banach, Maciej
AU  - Banach M
AD  - Department of Hypertension, WAM University Hospital in Lodz, Medical University 
      of Lodz, Zeromskiego 113, Lodz, Poland; Polish Mother's Memorial Hospital 
      Research Institute (PMMHRI), Lodz, Poland.
FAU - Jamialahmadi, Tannaz
AU  - Jamialahmadi T
AD  - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad 9177948564, Iran; Department of Food 
      Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran; 
      Department of Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Sahebkar, Amirhossein
AU  - Sahebkar A
AD  - Halal Research Center of IRI, FDA, Tehran, Iran; Biotechnology Research Center, 
      Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, 
      Mashhad, Iran; Neurogenic Inflammation Research Center, Mashhad University of 
      Medical Sciences, Mashhad, Iran. Electronic address: sahebkara@mums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200529
PL  - England
TA  - Drug Discov Today
JT  - Drug discovery today
JID - 9604391
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abruptio Placentae/chemically induced
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Female
MH  - Fetal Growth Retardation/etiology/prevention & control
MH  - Hemorrhage/chemically induced/drug therapy
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/drug therapy
MH  - Meta-Analysis as Topic
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
EDAT- 2020/06/02 06:00
MHDA- 2021/09/10 06:00
CRDT- 2020/06/02 06:00
PHST- 2019/07/10 00:00 [received]
PHST- 2020/05/03 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2021/09/10 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - S1359-6446(20)30202-6 [pii]
AID - 10.1016/j.drudis.2020.05.011 [doi]
PST - ppublish
SO  - Drug Discov Today. 2020 Aug;25(8):1487-1501. doi: 10.1016/j.drudis.2020.05.011. 
      Epub 2020 May 29.

PMID- 25389076
OWN - NLM
STAT- MEDLINE
DCOM- 20150120
LR  - 20141202
IS  - 1365-2168 (Electronic)
IS  - 0007-1323 (Linking)
VI  - 102
IP  - 1
DP  - 2015 Jan
TI  - Cohort study of corticosteroid use and risk of hospital admission for 
      diverticular disease.
PG  - 119-24
LID - 10.1002/bjs.9686 [doi]
AB  - BACKGROUND: Medication has been suggested as a potential risk factor for 
      diverticular disease. The objective of this study was to investigate the 
      association between the intake of corticosteroids, indometacin or aspirin and 
      diverticular disease. METHOD: This was a prospective population-based cohort 
      study of middle-aged women in the Swedish Mammography Cohort. Use of 
      corticosteroids (oral or inhaled), indometacin or aspirin in 1997 was determined 
      from questionnaires. Cases of diverticular disease were identified from the 
      Swedish national registers until the end of 2010. The relative risk (RR) of 
      diverticular disease requiring hospital admission according to the use of 
      medication was estimated using Cox proportional hazards models, adjusted for age, 
      body mass index, physical activity, fibre intake, diabetes, hypertension, 
      alcohol, smoking and education. RESULTS: A total of 36 586 middle-aged women in 
      the Swedish Mammography Cohort were included, of whom 674 (1.8 per cent) were 
      hospitalized with diverticular disease at least once. Some 7.2 per cent of women 
      reported intake of oral corticosteroids and 8.5 per cent use of inhaled 
      corticosteroids. In multivariable analysis, women who reported oral 
      corticosteroid intake had a 37 per cent (RR 1.37, 95 per cent c.i. 1.06 to 1.78; 
      P = 0.012) increased risk of diverticular disease compared with those who 
      reported no intake at all. Use of inhaled corticosteroids was associated with an 
      even more pronounced increase in risk of 71 per cent (RR 1.71, 1.36 to 2.14; 
      P < 0.001). There was a significant dose-response relationship, with the risk 
      increasing with longer duration of inhaled corticosteroids (P for trend < 0.001). 
      Use of indometacin (2.5 per cent of women) or aspirin (44.2 per cent) did not 
      influence the risk. CONCLUSION: There was a significant relationship between 
      corticosteroids (especially inhaled) and diverticular disease requiring hospital 
      admission.
CI  - © 2014 BJS Society Ltd. Published by John Wiley & Sons Ltd.
FAU - Hjern, F
AU  - Hjern F
AD  - Division of Surgery, Department of Clinical Sciences, Danderyd University 
      Hospital, Stockholm, Sweden.
FAU - Mahmood, M W
AU  - Mahmood MW
FAU - Abraham-Nordling, M
AU  - Abraham-Nordling M
FAU - Wolk, A
AU  - Wolk A
FAU - Håkansson, N
AU  - Håkansson N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141112
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
RN  - 0 (Adrenal Cortex Hormones)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Inhalation
MH  - Administration, Oral
MH  - Adrenal Cortex Hormones/administration & dosage/*adverse effects
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cohort Studies
MH  - Diverticulum, Colon/*chemically induced
MH  - Female
MH  - Hospitalization/*statistics & numerical data
MH  - Humans
MH  - Indomethacin/administration & dosage/*adverse effects
MH  - Risk Factors
EDAT- 2014/11/13 06:00
MHDA- 2015/01/21 06:00
CRDT- 2014/11/13 06:00
PHST- 2014/05/30 00:00 [received]
PHST- 2014/09/28 00:00 [revised]
PHST- 2014/09/29 00:00 [accepted]
PHST- 2014/11/13 06:00 [entrez]
PHST- 2014/11/13 06:00 [pubmed]
PHST- 2015/01/21 06:00 [medline]
AID - 10.1002/bjs.9686 [doi]
PST - ppublish
SO  - Br J Surg. 2015 Jan;102(1):119-24. doi: 10.1002/bjs.9686. Epub 2014 Nov 12.

PMID- 34988752
OWN - NLM
STAT- MEDLINE
DCOM- 20220315
LR  - 20230402
IS  - 1438-1435 (Electronic)
IS  - 1070-3004 (Print)
IS  - 1070-3004 (Linking)
VI  - 29
IP  - 2
DP  - 2022 Apr
TI  - Increased relative risk of delayed hemorrhage in patients taking 
      anticoagulant/antiplatelet medications with concurrent aspirin therapy: 
      implications for clinical practice based on 3-year retrospective analysis in a 
      large health system.
PG  - 353-358
LID - 10.1007/s10140-021-02003-3 [doi]
AB  - PURPOSE: The incidence of delayed posttraumatic intracranial hemorrhage (DH) in 
      patients on anticoagulant (AC) and antiplatelet (AP) medications, especially with 
      concurrent aspirin therapy, is not well established, with studies reporting 
      disparate results with between 1-10% risk of DH and 0-3% mortality. The purpose 
      of this 3-year retrospective study is to evaluate the true risk of DH in patients 
      on AP/AC medications with or without concurrent aspirin therapy. METHODS: One 
      thousand forty-six patients taking AP and AC medications presenting to network 
      emergency departments with head trauma who had repeat CT to evaluate for DH were 
      included in the study. Repeat examinations were typically performed within 24 h 
      (average follow-up time was 21 h and 99% were within 3 days). Mean time to DH was 
      20 h. All positive studies were reviewed by two board-certified 
      neuroradiologists. Patients were excluded from the study if hemorrhage was 
      retrospectively identified on the initial examination. Cases were reclassified as 
      negative if hemorrhage on the follow-up examination was thought to be not present 
      or artifactual. Cases were considered positive if the initial examination was 
      negative and the follow-up examination demonstrated new hemorrhage. RESULTS: 
      Overall, there was 1.91% incidence (20 patients) of DH and 0.3% overall mortality 
      (3 patients). The group of patients taking warfarin or AP agents demonstrated a 
      significantly higher rate of DH (3.2% compared to 0.9%) and higher mortality 
      (0.9% compared to 0.0%) compared to the DOAC group (p < 0.01). The risk of DH in 
      patients taking AC or AP agents with aspirin (13/20 cases) was significantly 
      higher (RR 3.8, p < 0.01) than that of patients taking AC or AP alone (7/20 
      cases). CONCLUSION: The risk of DH was significantly higher in patients taking 
      aspirin in addition to AC/AP medications. Repeat imaging should be obtained for 
      trauma patients taking AC/AP agents with concurrent aspirin. The rate of DH was 
      also significantly higher in patients taking warfarin or AP agents when compared 
      to patients taking DOACs. Repeat examination should be strongly considered on 
      patients taking warfarin or AP agents without aspirin. Given the relatively low 
      risk of DH in patients taking DOACs alone, repeat imaging could be reserved for 
      patients with external signs of trauma or dangerous mechanism of injury.
CI  - © 2021. American Society of Emergency Radiology.
FAU - Chang, Warren
AU  - Chang W
AUID- ORCID: 0000-0003-1308-5077
AD  - Imaging Institute, Allegheny Health Network, 320 E. North Ave, Pittsburgh, PA, 
      15206, USA. warren.chang@ahn.org.
FAU - Yin, Danielle
AU  - Yin D
AD  - Imaging Institute, Allegheny Health Network, 320 E. North Ave, Pittsburgh, PA, 
      15206, USA.
FAU - Li, Charles
AU  - Li C
AD  - Imaging Institute, Allegheny Health Network, 320 E. North Ave, Pittsburgh, PA, 
      15206, USA.
FAU - Weston, Brian
AU  - Weston B
AD  - Imaging Institute, Allegheny Health Network, 320 E. North Ave, Pittsburgh, PA, 
      15206, USA.
FAU - Sohn, Albert
AU  - Sohn A
AD  - Imaging Institute, Allegheny Health Network, 320 E. North Ave, Pittsburgh, PA, 
      15206, USA.
FAU - Wanamaker, Christian
AU  - Wanamaker C
AD  - Imaging Institute, Allegheny Health Network, 320 E. North Ave, Pittsburgh, PA, 
      15206, USA.
FAU - Kulzer, Matthew
AU  - Kulzer M
AD  - Imaging Institute, Allegheny Health Network, 320 E. North Ave, Pittsburgh, PA, 
      15206, USA.
FAU - Tragon, Tyson
AU  - Tragon T
AD  - Imaging Institute, Allegheny Health Network, 320 E. North Ave, Pittsburgh, PA, 
      15206, USA.
FAU - Spearman, Michael
AU  - Spearman M
AD  - Imaging Institute, Allegheny Health Network, 320 E. North Ave, Pittsburgh, PA, 
      15206, USA.
FAU - Eisenmenger, Laura
AU  - Eisenmenger L
AD  - School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
FAU - Goldberg, Michael
AU  - Goldberg M
AD  - Imaging Institute, Allegheny Health Network, 320 E. North Ave, Pittsburgh, PA, 
      15206, USA.
LA  - eng
GR  - UL1 TR002373/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20220106
PL  - United States
TA  - Emerg Radiol
JT  - Emergency radiology
JID - 9431227
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anticoagulants/adverse effects
MH  - *Aspirin/adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Retrospective Studies
MH  - Risk
PMC - PMC8917980
MID - NIHMS1766236
OTO - NOTNLM
OT  - Anticoagulation
OT  - Antiplatelet
OT  - Aspirin
OT  - Computational tomography
OT  - Cost-effectiveness
OT  - Delayed hemorrhage
OT  - Emergency department
OT  - Intracranial hemorrhage
OT  - Trauma
COIS- There are no conflicts of interest to disclose from any of the authors.
EDAT- 2022/01/07 06:00
MHDA- 2022/03/16 06:00
CRDT- 2022/01/06 06:13
PHST- 2021/09/21 00:00 [received]
PHST- 2021/11/22 00:00 [accepted]
PHST- 2022/01/07 06:00 [pubmed]
PHST- 2022/03/16 06:00 [medline]
PHST- 2022/01/06 06:13 [entrez]
AID - 10.1007/s10140-021-02003-3 [pii]
AID - 10.1007/s10140-021-02003-3 [doi]
PST - ppublish
SO  - Emerg Radiol. 2022 Apr;29(2):353-358. doi: 10.1007/s10140-021-02003-3. Epub 2022 
      Jan 6.

PMID- 36361664
OWN - NLM
STAT- MEDLINE
DCOM- 20230330
LR  - 20230330
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 21
DP  - 2022 Oct 25
TI  - Synthesis of Tropine-Based Functionalized Acidic Ionic Liquids and Catalysis of 
      Esterification.
LID - 10.3390/ijms232112877 [doi]
LID - 12877
AB  - Some traditional acidic ionic liquids (AILs) have shown great catalytic potential 
      in esterification; meanwhile, the design and application of more new AILs are 
      expected at present.Tropine-based functionalized acidic ionic liquids (FAILs) 
      were synthesized to realize esterification catalysis for the first time; with 
      aspirin synthesis as the template reaction, key influences on the substrate 
      conversion and product yield of the synthesis, such as IL type, ratio of 
      salicylic acid to acetic anhydride, temperature, reaction time and amount of IL, 
      were investigated. The new tropine-based FAILs exhibited excellent performance in 
      catalytic synthesis of aspirin with 88.7% yield and 90.8% selectivity. Multiple 
      recovery and re-usage of N-(3-propanesulfonic acid) tropine is the cation, and 
      p-toluenesulfonic acid is the anion. ([Trps][OTs]) shows satisfactory results. 
      When [Trps][OTs] was used to catalyze different esterification reactions, it also 
      showed good results. The above studies proved that ionic liquid [Trps][OTs] could 
      serve as an ideal green solvent for esterification reaction, which serves as a 
      suitable substitute for current catalysts.
FAU - Ni, Hongfei
AU  - Ni H
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
FAU - Zhang, Yiwei
AU  - Zhang Y
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
FAU - Zong, Chuhong
AU  - Zong C
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
FAU - Hou, Zhengbo
AU  - Hou Z
AD  - College of Chemical Engineering, Sichuan University, Chengdu 610065, China.
FAU - Song, Hang
AU  - Song H
AD  - College of Chemical Engineering, Sichuan University, Chengdu 610065, China.
FAU - Chen, Yong
AU  - Chen Y
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
FAU - Liu, Xuesong
AU  - Liu X
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
FAU - Xu, Tengfei
AU  - Xu T
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
FAU - Luo, Yingjie
AU  - Luo Y
AD  - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
LA  - eng
GR  - 81373284/Shun Yao/
PT  - Journal Article
DEP - 20221025
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Acids)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Ionic Liquids)
RN  - 7YXR19M72Y (tropine)
SB  - IM
MH  - Acids
MH  - Aspirin
MH  - Catalysis
MH  - Esterification
MH  - *Ionic Liquids
PMC - PMC9656471
OTO - NOTNLM
OT  - aspirin
OT  - catalyst
OT  - esterification
OT  - ionic liquids
OT  - tropine
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2022/11/12 06:00
MHDA- 2022/11/15 06:00
CRDT- 2022/11/11 01:24
PHST- 2022/09/16 00:00 [received]
PHST- 2022/10/21 00:00 [revised]
PHST- 2022/10/23 00:00 [accepted]
PHST- 2022/11/11 01:24 [entrez]
PHST- 2022/11/12 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
AID - ijms232112877 [pii]
AID - ijms-23-12877 [pii]
AID - 10.3390/ijms232112877 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Oct 25;23(21):12877. doi: 10.3390/ijms232112877.

PMID- 29291490
OWN - NLM
STAT- MEDLINE
DCOM- 20181102
LR  - 20181102
IS  - 1095-8630 (Electronic)
IS  - 0301-4797 (Linking)
VI  - 209
DP  - 2018 Mar 1
TI  - Application of as-synthesised MCM-41 and MCM-41 wrapped with reduced graphene 
      oxide/graphene oxide in the remediation of acetaminophen and aspirin from aqueous 
      system.
PG  - 205-215
LID - S0301-4797(17)31215-X [pii]
LID - 10.1016/j.jenvman.2017.12.037 [doi]
AB  - In this study, ASM41 (as-synthesised MCM-41), MCM-41, MCM-41 encapsulated with 
      graphene oxide (MCM-41-GO) and reduced graphene oxide (MCM-41-G) were fabricated 
      and utilized in the remediation of acetaminophen and aspirin from water. A 
      surfactant template (cetyltrimethylammonium bromide) was added to ASM41 to make 
      it more hydrophobic and its effects on the remediation of acetaminophen and 
      aspirin from wastewater was studied. To further improve the adsorption capacity 
      of the adsorbent, MCM-41 was encapsulated with GO and G which also aided in easy 
      separation of the adsorbent from the aqueous solution. Comparative studies of the 
      adsorption of acetaminophen and aspirin on all four adsorbents were investigated. 
      Batch adsorption studies of acetaminophen and aspirin were carried out to 
      determine the effects of pH, initial concentration, time and adsorbent dose. 
      Adsorption mechanism was through EDA, π-π interactions, and hydrophobic effects. 
      Data from sorption kinetics showed ASM41 had the highest q(m) value for aspirin 
      (909.1 mg/g) and MCM-41-G had the highest q(m) value for acetaminophen 
      (555.6 mg/g). The significant adsorption by ASM41 can be attributed to increased 
      hydrophobicity due to the retention of the surfactant template. Thermodynamic 
      studies revealed the adsorption process as spontaneous and exothermic. Desorption 
      studies revealed that adsorbents could be regenerated and reused for adsorption.
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - Akpotu, Samson O
AU  - Akpotu SO
AD  - School of Chemistry and Physics, University of KwaZulu-Natal, Westville Campus, 
      Durban, 4000, South Africa.
FAU - Moodley, Brenda
AU  - Moodley B
AD  - School of Chemistry and Physics, University of KwaZulu-Natal, Westville Campus, 
      Durban, 4000, South Africa. Electronic address: moodleyb3@ukzn.ac.za.
LA  - eng
PT  - Journal Article
DEP - 20180104
PL  - England
TA  - J Environ Manage
JT  - Journal of environmental management
JID - 0401664
RN  - 0 (MCM-41)
RN  - 0 (Oxides)
RN  - 0 (Water Pollutants, Chemical)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - 7782-42-5 (Graphite)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*isolation & purification
MH  - Adsorption
MH  - Aspirin/*isolation & purification
MH  - Graphite
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Oxides
MH  - Silicon Dioxide
MH  - Water Pollutants, Chemical/*isolation & purification
MH  - *Water Purification
OTO - NOTNLM
OT  - Adsorption
OT  - As-synthesised
OT  - Graphene oxide
OT  - MCM-41
OT  - Pharmaceuticals
OT  - Reduced graphene
EDAT- 2018/01/02 06:00
MHDA- 2018/11/06 06:00
CRDT- 2018/01/02 06:00
PHST- 2017/10/16 00:00 [received]
PHST- 2017/12/11 00:00 [revised]
PHST- 2017/12/16 00:00 [accepted]
PHST- 2018/01/02 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
PHST- 2018/01/02 06:00 [entrez]
AID - S0301-4797(17)31215-X [pii]
AID - 10.1016/j.jenvman.2017.12.037 [doi]
PST - ppublish
SO  - J Environ Manage. 2018 Mar 1;209:205-215. doi: 10.1016/j.jenvman.2017.12.037. 
      Epub 2018 Jan 4.

PMID- 33794285
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20220531
IS  - 1095-8541 (Electronic)
IS  - 0022-5193 (Linking)
VI  - 522
DP  - 2021 Aug 7
TI  - Effect of pharmacodynamical interaction between nutlin-3a and aspirin in the 
      activation of p53.
PG  - 110696
LID - S0022-5193(21)00118-1 [pii]
LID - 10.1016/j.jtbi.2021.110696 [doi]
AB  - BACKGROUND AND OBJECTIVE: p53, an anti-tumour protein, is significantly 
      inactivated in most tumours. A small molecule of nutlin-3a is used to activate 
      its function by repressing (Mouse double minute 2 homolog) Mdm2 protein which 
      inhibits its activity. In cancer patients, a high risk of drug-drug interactions 
      (DDIs) is observed owing to their multi-dosing prescriptions, which may lead them 
      to harmful effects. In the presented work, we have aimed to investigate the 
      effect of pharmacodynamical interaction between two anti-cancer drugs, nutlin-3a 
      and aspirin in the activation of p53 protein. METHODS: We have adapted control 
      system techniques and designed a Proportional-Integral-Derivative (PID) 
      controller. This controller is used to activate p53 protein. A drug interaction 
      parameter is used to incorporate the effect of both drugs. Extensive simulation 
      is performed using two different doses of aspirin, i.e. a low and a high dose of 
      aspirin. RESULTS: The result shows no harmful effects of pharmacodynamical 
      interaction when a low dose is administered along with nutlin-3a. When a high 
      dose of aspirin is administered it acts as input disturbance and leads to 
      undesirable over-expression of p53 protein. This can further harm other growth 
      cells, thus inducing harmful effects. A comparative analysis is also tabulated 
      with different dosing regimens which shows that a combination of nutlin-3a and a 
      low dose of aspirin provides better results than a high dose of aspirin. 
      CONCLUSION: Overall, the work provides an insight to the activation of p53 
      protein in cancer patients under the presence of pharmacodynamical interaction 
      and might contribute to the effective management of cancer patients.
CI  - Copyright © 2021 Elsevier Ltd. All rights reserved.
FAU - Awan, Muhammad Suleman
AU  - Awan MS
AD  - Department of Electrical Engineering, National University of Sciences and 
      Technology, Islamabad, Pakistan. Electronic address: msawan17@ee.ceme.edu.pk.
FAU - Aslam, Maria
AU  - Aslam M
AD  - Department of Electrical Engineering, National University of Sciences and 
      Technology, Islamabad, Pakistan.
FAU - Liaquat, Muwahida
AU  - Liaquat M
AD  - Department of Electrical Engineering, National University of Sciences and 
      Technology, Islamabad, Pakistan. Electronic address: muwahida@ee.ceme.edu.pk.
FAU - Bhatti, A I
AU  - Bhatti AI
AD  - CASPR, Department of Electronic Engineering, Capital University of Science and 
      Technology, Islamabad, Pakistan.
FAU - Liaquat, Afrose
AU  - Liaquat A
AD  - Department of Biochemistry, Shifa College of Medicine, Shifa Tamer-e-Millat 
      University, Islamabad, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20210329
PL  - England
TA  - J Theor Biol
JT  - Journal of theoretical biology
JID - 0376342
RN  - 0 (Imidazoles)
RN  - 0 (Piperazines)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 53IA0V845C (nutlin 3)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis
MH  - *Aspirin/pharmacology
MH  - Cell Line, Tumor
MH  - Humans
MH  - *Imidazoles/pharmacology
MH  - *Piperazines/pharmacology
MH  - Proto-Oncogene Proteins c-mdm2/metabolism
MH  - *Tumor Suppressor Protein p53
OTO - NOTNLM
OT  - DDIs
OT  - Mdm2 protein
OT  - PID
OT  - Pharmacodynamical interaction
OT  - p53 protein
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/04/02 06:00
MHDA- 2021/07/06 06:00
CRDT- 2021/04/01 20:10
PHST- 2020/08/12 00:00 [received]
PHST- 2021/02/22 00:00 [revised]
PHST- 2021/03/19 00:00 [accepted]
PHST- 2021/04/02 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2021/04/01 20:10 [entrez]
AID - S0022-5193(21)00118-1 [pii]
AID - 10.1016/j.jtbi.2021.110696 [doi]
PST - ppublish
SO  - J Theor Biol. 2021 Aug 7;522:110696. doi: 10.1016/j.jtbi.2021.110696. Epub 2021 
      Mar 29.

PMID- 7096668
OWN - NLM
STAT- MEDLINE
DCOM- 19820924
LR  - 20180414
IS  - 0190-9622 (Print)
IS  - 0190-9622 (Linking)
VI  - 6
IP  - 6
DP  - 1982 Jun
TI  - Atrophie blanche. Report of two patients treated with aspirin and dipyridamole.
PG  - 1048-53
AB  - Atrophie blanche was originally attributed to syphilis or tuberculosis, but 
      recent investigators have generally implicated a localized cutaneous vasculitis. 
      In an attempt to inhibit the occlusive vascular changes believed responsible for 
      the cutaneous lesions, drugs such as phenformin and ethylestrenol, which 
      increased the blood fibrinolytic activity, were used with favorable results. When 
      phenformin was taken off the market, the use of drugs that act by preventing 
      platelet aggregation was suggested by encouraging results in the management of 
      other occlusive vascular disorders such as coronary artery disease and stroke. 
      Excellent results are reported in two cases of atrophie blanche treated with two 
      anti-platelet-aggregating medications, aspirin and dipyridamole (Persantine). It 
      is imperative that low doses of aspirin be used, since high doses have the effect 
      of increasing the thrombotic tendency by preventing prostacyclin formation.
FAU - Kern, A B
AU  - Kern AB
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Atrophy/drug therapy
MH  - Dipyridamole/*therapeutic use
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Skin/*blood supply/pathology
MH  - Vasculitis/*drug therapy
EDAT- 1982/06/01 00:00
MHDA- 1982/06/01 00:01
CRDT- 1982/06/01 00:00
PHST- 1982/06/01 00:00 [pubmed]
PHST- 1982/06/01 00:01 [medline]
PHST- 1982/06/01 00:00 [entrez]
AID - S0190-9622(82)70089-1 [pii]
PST - ppublish
SO  - J Am Acad Dermatol. 1982 Jun;6(6):1048-53.

PMID- 12107984
OWN - NLM
STAT- MEDLINE
DCOM- 20020909
LR  - 20170306
VI  - 107
IP  - 3
DP  - 2002 Mar
TI  - [Tolerability of Asacard--controlled-release aspirin and aspirin-induced asthma].
PG  - 249-56
AB  - Asacard is a microcapsulated, controlled-release form of acetylsalicylic acid, 
      which delivers very low but constant amount of the drug directly into the 
      intestine. The dose 162.5 mg Asacard, used in prevention of cardiovascular 
      diseases, is thus sufficient to block platelets in the portal vein from 
      synthesizing thromboxane but not high enough to enter the systemic circulation 
      and block the formulation of prostacyclin and other prostaglandins. It is 
      generally accepted that in aspirin-induced asthma (AIA) the bronchospasm is 
      provoked by inhibition of prostaglandin synthesis with overproduction of 
      cysteinyl leukotrienes. The aim of our study was to verify the hypothesis if 
      Asacard, as a form of aspirin, which theoretically does not block prostacycline 
      synthesis in systematic circulation, would be well tolerated by patients with 
      AIA. We thus studied in an open study the tolerability of three single, 
      increasing doses of Asacard in 10 patients with confirmed by oral challenge test 
      aspirin intolerance (4 males, 6 females, mean age 40 years). Initially, the 
      patients received 40 mg of Asacard and FEV1 and clinical symptoms were assessed 
      every 30 minutes for 8 hours. A positive reaction was defined as a > or = 20% 
      decline in FEV1 from baseline. Patients with negative reaction received 75 mg 
      Asacard 7 days later. In absence of the reaction, the last dose 162.5 mg was 
      administered a week later. In 5 out of 10 patients studied, Asacard given at 
      single doses up to 162.5 mg was tolerated well. In the remaining 5, it provoked 
      bronchospasm, a fall in FEV1 > or = 20% and other extrabronchial symptoms of 
      aspirin intolerance. No correlation was found between the doses of regular 
      aspirin, which provoked a fall in FEV1 > or = 20% during baseline oral 
      provocation test and Asacard doses. In conclusion, any form of aspirin, even 
      controlled-release, should not be prescribed for patients with AIA, because it 
      may provoke symptoms of intolerance to this drug.
FAU - Bochenek, Grazyna
AU  - Bochenek G
AD  - II Katedra Chorób Wewnetrznych Collegium Medicum UJ w Krakowie.
FAU - Swierczyńska, Monika
AU  - Swierczyńska M
FAU - Nizankowska-Mogilnicka, Ewa
AU  - Nizankowska-Mogilnicka E
FAU - Vivet, Phillippe
AU  - Vivet P
FAU - Gicquel, Michel
AU  - Gicquel M
FAU - Szczeklik, Andrzej
AU  - Szczeklik A
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Tolerancja Asacardu--aspiryny o kontrolowanym uwalnianiu w astmie aspirynowej.
PL  - Poland
TA  - Pol Arch Med Wewn
JT  - Polskie Archiwum Medycyny Wewnetrznej
JID - 0401225
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/prevention & control
MH  - Cardiovascular Diseases/drug therapy/prevention & control
MH  - Delayed-Action Preparations
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2002/07/11 10:00
MHDA- 2002/09/11 10:01
CRDT- 2002/07/11 10:00
PHST- 2002/07/11 10:00 [pubmed]
PHST- 2002/09/11 10:01 [medline]
PHST- 2002/07/11 10:00 [entrez]
PST - ppublish
SO  - Pol Arch Med Wewn. 2002 Mar;107(3):249-56.

PMID- 26970125
OWN - NLM
STAT- MEDLINE
DCOM- 20160719
LR  - 20170727
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 43
IP  - 1
DP  - 2016 Feb
TI  - Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention.
PG  - 65-77
LID - S0093-7754(15)00175-X [pii]
LID - 10.1053/j.seminoncol.2015.09.010 [doi]
AB  - Various clinical and epidemiologic studies show that nonsteroidal 
      anti-inflammatory drugs (NSAIDs), including aspirin and cyclooxygenase inhibitors 
      (COXIBs) help prevent cancer. Since eicosanoid metabolism is the main inhibitory 
      targets of these drugs the resulting molecular and biological impact is generally 
      accepted. As our knowledge base and technology progress we are learning that 
      additional targets may be involved. This review attempts to summarize these new 
      developments in the field.
CI  - Published by Elsevier Inc.
FAU - Umar, Asad
AU  - Umar A
AD  - Division of Cancer Prevention, National Cancer Institute, National Institutes of 
      Health, Bethesda, MD, USA. Electronic address: umara@mail.nih.gov.
FAU - Steele, Vernon E
AU  - Steele VE
AD  - Division of Cancer Prevention, National Cancer Institute, National Institutes of 
      Health, Bethesda, MD, USA.
FAU - Menter, David G
AU  - Menter DG
AD  - The University of Texas MD Anderson Cancer Center, Division of Cancer Prevention 
      and Population Sciences, Houston, TX, USA.
FAU - Hawk, Ernest T
AU  - Hawk ET
AD  - The University of Texas MD Anderson Cancer Center, Division of Cancer Prevention 
      and Population Sciences, Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150910
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Eicosanoids)
RN  - IY9XDZ35W2 (Glucose)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism/*pharmacology/therapeutic use
MH  - Aspirin/metabolism/*pharmacology/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Chemoprevention
MH  - Cyclooxygenase Inhibitors/metabolism/*pharmacology/therapeutic use
MH  - Dinoprostone/*metabolism
MH  - Eicosanoids/antagonists & inhibitors/metabolism
MH  - Glucose/metabolism
MH  - Humans
MH  - Immunity, Cellular/drug effects
MH  - Inflammation/metabolism
MH  - Neoplasms/immunology/*prevention & control
MH  - Signal Transduction/drug effects
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer prevention
OT  - Inflammation
OT  - Non-steroidal anti-inflammatory drugs (NSAID)
EDAT- 2016/03/13 06:00
MHDA- 2016/07/20 06:00
CRDT- 2016/03/13 06:00
PHST- 2016/03/13 06:00 [entrez]
PHST- 2016/03/13 06:00 [pubmed]
PHST- 2016/07/20 06:00 [medline]
AID - S0093-7754(15)00175-X [pii]
AID - 10.1053/j.seminoncol.2015.09.010 [doi]
PST - ppublish
SO  - Semin Oncol. 2016 Feb;43(1):65-77. doi: 10.1053/j.seminoncol.2015.09.010. Epub 
      2015 Sep 10.

PMID- 7414107
OWN - NLM
STAT- MEDLINE
DCOM- 19801124
LR  - 20180216
IS  - 0025-7931 (Print)
IS  - 0025-7931 (Linking)
VI  - 39
IP  - 5
DP  - 1980
TI  - Is tartrazine-induced asthma related to inhibition of prostaglandin biosynthesis?
PG  - 276-82
AB  - Since it has been suggested that aspirin-induced asthma is due to inhibition of 
      prostaglandin (PG) biosynthesis, the present investigation was undertaken to 
      determine whether tartrazine would display a similar profile. Use was made of the 
      exquisite sensitivity of blood platelets, both in humans and in rats, to 
      aggregating substances generated from arachidonic acid during PG biosynthesis and 
      of the ability of aspirin to inhibit aggregation and generation of those 
      substances. Failure to affect aggregation by arachidonic acid as well as the 
      accompanying formation of thromboxane A2, demonstrates that neither tartrazine 
      nor its metabolite sulfanilic acid inhibit platelet PG synthesis. It seems 
      unlikely that tartrazine-induced asthma results from inhibition of PG 
      biosynthesis.
FAU - Vargaftig, B B
AU  - Vargaftig BB
FAU - Bessot, J C
AU  - Bessot JC
FAU - Pauli, G
AU  - Pauli G
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Respiration
JT  - Respiration; international review of thoracic diseases
JID - 0137356
RN  - 0 (Azo Compounds)
RN  - 0 (Prostaglandins)
RN  - 0 (Sulfanilic Acids)
RN  - 57576-52-0 (Thromboxane A2)
RN  - I753WB2F1M (Tartrazine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/pharmacology
MH  - Asthma/chemically induced/*metabolism
MH  - Azo Compounds/*pharmacology
MH  - Blood Platelets/physiology
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandins/*biosynthesis
MH  - Sulfanilic Acids/pharmacology
MH  - Tartrazine/adverse effects/*pharmacology
MH  - Thromboxane A2/biosynthesis
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1159/000194228 [doi]
PST - ppublish
SO  - Respiration. 1980;39(5):276-82. doi: 10.1159/000194228.

PMID- 31722438
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 177
IP  - 5
DP  - 2020 Mar
TI  - The Second Gaddum Lecture: its origins and outcomes.
PG  - 969-977
LID - 10.1111/bph.14928 [doi]
AB  - Fifty years ago, the BJP published the Second Gaddum Lecture, given by John Vane 
      to the British Pharmacological Society. This article assesses the origins of the 
      experiments described in the Lecture, linking them directly to Gaddum's use of 
      bioassay, a defining feature of pharmacology. The outcomes of those experiments 
      are also assessed, tracking those results that have survived the past five 
      decades. Two of the major advances in cardiovascular medicine, the ACE 
      inhibitors, as anti-hypertensives, and low-dose aspirin, to prevent thrombosis 
      were initiated by the work in this Lecture. Physiologically significant outcomes 
      include a new non-respiratory function of the lung, based on the metabolism of 
      endogenous vasoactive substrates in the pulmonary circulation and the recognition 
      of the endothelium as a highly interactive component of blood vessels. The 
      present state of the art in pharmacology, physiology and medicine owes much to 
      the work described in the Second Gaddum Lecture.
CI  - © 2019 The British Pharmacological Society.
FAU - Bakhle, Y S
AU  - Bakhle YS
AD  - NHLI, Imperial College London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200205
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angiotensin-Converting Enzyme Inhibitors
MH  - *Aspirin
MH  - Endothelium
MH  - Lung
PMC - PMC7042101
COIS- The authors declare no conflicts of interest.
EDAT- 2019/11/14 06:00
MHDA- 2021/06/22 06:00
CRDT- 2019/11/14 06:00
PHST- 2019/08/28 00:00 [received]
PHST- 2019/10/03 00:00 [revised]
PHST- 2019/10/07 00:00 [accepted]
PHST- 2019/11/14 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2019/11/14 06:00 [entrez]
AID - BPH14928 [pii]
AID - 10.1111/bph.14928 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2020 Mar;177(5):969-977. doi: 10.1111/bph.14928. Epub 2020 Feb 5.

PMID- 8528459
OWN - NLM
STAT- MEDLINE
DCOM- 19960131
LR  - 20190815
IS  - 0953-816X (Print)
IS  - 0953-816X (Linking)
VI  - 7
IP  - 9
DP  - 1995 Sep 1
TI  - Anti-nociception induced by systemic or PAG-microinjected lysine-acetylsalicylate 
      in rats. Effects on tail-flick related activity of medullary off- and on-cells.
PG  - 1857-65
AB  - Previous experiments using metamizol have shown that this non-steroidal 
      anti-inflammatory drug (NSAID) produces a central anti-nociceptive effect 
      probably through neural substrates that also support the analgesic effects of 
      opiates, such as the periaqueductal grey matter (PAG) and the off- and on-cells 
      of the rostral ventromedial medulla (RVM). Off- and on-cells have been postulated 
      to respectively inhibit and facilitate nociceptive transmission, since the 
      heat-elicited tail flick reflex (TF) occurs only after off-cells have decreased 
      (pause), and on-cells, have increased (burst) their activity. The aim of the 
      present study was to examine whether the effect of metamizol upon TF and off- and 
      on-cells responses could be generalized to other NSAIDs such as, in this case, 
      lysine-acetylsalicylate (LASA). Fifty-nine off- and on-cells of the RVM were 
      recorded in lightly anaesthetized rats. Systemic administration (200 and 300 
      mg/kg) or PAG microinjection (30, 50 and 100 micrograms) of LASA caused 
      retardation of the heat-elicited off-cell pause, on-cell burst and the 
      corresponding TF. Neuronal responses and TF retained their mutual time 
      relationship but shifted simultaneously toward longer latencies. This 
      anti-nociceptive effect of LASA was dose-dependent, present 5 min after 
      administration and reached a maximum in 30 min for both administration methods. 
      These data confirm that analgesics typically defined as peripherally-acting, such 
      as metamizol and LASA in this study, may also have an anti-nociceptive effect by 
      acting directly upon PAG, and suggest that this central effect involves the RVM 
      off- and on-cells.
FAU - Tortorici, V
AU  - Tortorici V
AD  - Centro de Biofísica y Bioquímica, Instituto Venezolano de Investigaciones 
      Científicas (IVIC), Caracas, Venezuela.
FAU - Vanegas, H
AU  - Vanegas H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Eur J Neurosci
JT  - The European journal of neuroscience
JID - 8918110
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 6429L0L52Y (Dipyrone)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Action Potentials/drug effects
MH  - Analgesics/administration & dosage/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Behavior, Animal/drug effects
MH  - Dipyrone/pharmacology
MH  - Injections, Intravenous
MH  - Lysine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Male
MH  - Medulla Oblongata/anatomy & histology/*cytology/*physiology
MH  - Microinjections
MH  - Neurons/drug effects/*physiology
MH  - Pain Measurement/drug effects
MH  - Periaqueductal Gray/anatomy & histology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tail
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
AID - 10.1111/j.1460-9568.1995.tb00706.x [doi]
PST - ppublish
SO  - Eur J Neurosci. 1995 Sep 1;7(9):1857-65. doi: 10.1111/j.1460-9568.1995.tb00706.x.

PMID- 30244614
OWN - NLM
STAT- MEDLINE
DCOM- 20190403
LR  - 20190403
IS  - 1744-7631 (Electronic)
IS  - 1472-8222 (Linking)
VI  - 22
IP  - 11
DP  - 2018 Nov
TI  - The effect of aspirin on antibiotic susceptibility.
PG  - 967-972
LID - 10.1080/14728222.2018.1527314 [doi]
AB  - Aspirin (acetylsalicylic acid, ASA) is often co-administered during the treatment 
      of infections. Salicylic acid (SAL), the active metabolite of ASA, has 
      significant effects on bacteria that might improve or (more likely) compromise 
      the effectiveness of antibiotics. Areas covered: In this review, we summarize the 
      interactions between SAL and antibiotics, and describe the underlying mechanisms 
      involved. Expert opinion: In an era of rapidly increasing antibiotic resistance 
      and lack of new antibiotic development, it is important to explore ways to 
      optimize the effectiveness of antimicrobial treatment. This includes a better 
      understanding of the interactions between commonly co-administered drugs. SAL 
      might compromise the effectiveness of antibiotic treatment by inducing phenotypic 
      resistance in bacteria. It can induce phenotypic resistance by up- or 
      downregulating outer membrane proteins or efflux pumps, by upregulating 
      antibiotic targets and by inducing enzymes with degrading activity. Moreover, SAL 
      can increase the frequency of mutations leading to antibiotic resistance.
FAU - Zimmermann, Petra
AU  - Zimmermann P
AUID- ORCID: 0000-0002-2388-4318
AD  - a Department of Paediatrics , The University of Melbourne , Parkville , 
      Australia.
AD  - b Infectious Diseases & Microbiology Research Group , Murdoch Children's Research 
      Institute , Parkville , Australia.
AD  - c Infectious Diseases Unit , The Royal Children's Hospital Melbourne , Parkville 
      , Australia.
AD  - d Infectious Diseases Unit , University of Basel Children's Hospital , Basel , 
      Switzerland.
FAU - Curtis, Nigel
AU  - Curtis N
AUID- ORCID: 0000-0003-3446-4594
AD  - a Department of Paediatrics , The University of Melbourne , Parkville , 
      Australia.
AD  - b Infectious Diseases & Microbiology Research Group , Murdoch Children's Research 
      Institute , Parkville , Australia.
AD  - c Infectious Diseases Unit , The Royal Children's Hospital Melbourne , Parkville 
      , Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20181013
PL  - England
TA  - Expert Opin Ther Targets
JT  - Expert opinion on therapeutic targets
JID - 101127833
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Bacterial Agents/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*metabolism
MH  - Bacteria/drug effects
MH  - Drug Interactions
MH  - Drug Resistance, Bacterial/drug effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/metabolism
MH  - Salicylic Acid/metabolism/*pharmacology
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - antibacterial
OT  - antibiotics
OT  - efflux pump
OT  - outer membrane porin
OT  - salicylic acid
EDAT- 2018/09/25 06:00
MHDA- 2019/04/04 06:00
CRDT- 2018/09/25 06:00
PHST- 2018/09/25 06:00 [pubmed]
PHST- 2019/04/04 06:00 [medline]
PHST- 2018/09/25 06:00 [entrez]
AID - 10.1080/14728222.2018.1527314 [doi]
PST - ppublish
SO  - Expert Opin Ther Targets. 2018 Nov;22(11):967-972. doi: 
      10.1080/14728222.2018.1527314. Epub 2018 Oct 13.

PMID- 26478300
OWN - NLM
STAT- MEDLINE
DCOM- 20160801
LR  - 20151019
IS  - 1873-0191 (Electronic)
IS  - 0928-4931 (Linking)
VI  - 58
DP  - 2016 Jan 1
TI  - Sustained release of hydrophilic drug from polyphosphazenes/poly(methyl 
      methacrylate) based microspheres and their degradation study.
PG  - 169-79
LID - S0928-4931(15)30265-4 [pii]
LID - 10.1016/j.msec.2015.08.010 [doi]
AB  - Drug delivery system is referred as an approach to deliver the therapeutic agents 
      to the target site safely in order to achieve the maximum therapeutic effects. In 
      this perspective, synthesis of three new polyphosphazenes and their blend 
      fabrication system with poly(methyl methacrylate) is described and characterized 
      with (1)H NMR, (31)P NMR, GPC and DSC. Furthermore, these novel blends were used 
      to fabricate microspheres and evaluated for sustain release of hydrophilic drug 
      (aspirin as model drug). Microspheres of the two blends showed excellent 
      encapsulation efficacy (about 93%), controlled burst release (2.3% to 7.93%) and 
      exhibited sustain in vitro drug release (13.44% to 32.77%) up to 218 h. At 
      physiological conditions, the surface degradation of microspheres and diffusion 
      process controlled the drug release sustainability. Furthermore, it was found 
      that the degree of porosity was increased with degradation and the resulting 
      porous network was responsible for water retention inside the microspheres. The 
      percentage water retention was found to be interrelated with degradation time and 
      percentage drug release.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Akram, Muhammad
AU  - Akram M
AD  - State Key Laboratory of Chemical Engineering, College of Chemical and Biological 
      Engineering, Zhejiang University, Hangzhou 310027, China.
FAU - Yu, Haojie
AU  - Yu H
AD  - State Key Laboratory of Chemical Engineering, College of Chemical and Biological 
      Engineering, Zhejiang University, Hangzhou 310027, China. Electronic address: 
      hjyu@zju.edu.cn.
FAU - Wang, Li
AU  - Wang L
AD  - State Key Laboratory of Chemical Engineering, College of Chemical and Biological 
      Engineering, Zhejiang University, Hangzhou 310027, China. Electronic address: 
      opl_wl@zju.edu.cn.
FAU - Khalid, Hamad
AU  - Khalid H
AD  - State Key Laboratory of Chemical Engineering, College of Chemical and Biological 
      Engineering, Zhejiang University, Hangzhou 310027, China.
FAU - Abbasi, Nasir M
AU  - Abbasi NM
AD  - State Key Laboratory of Chemical Engineering, College of Chemical and Biological 
      Engineering, Zhejiang University, Hangzhou 310027, China.
FAU - Zain-ul-Abdin
AU  - Zain-ul-Abdin
AD  - State Key Laboratory of Chemical Engineering, College of Chemical and Biological 
      Engineering, Zhejiang University, Hangzhou 310027, China.
FAU - Chen, Yongsheng
AU  - Chen Y
AD  - State Key Laboratory of Chemical Engineering, College of Chemical and Biological 
      Engineering, Zhejiang University, Hangzhou 310027, China.
FAU - Ren, Fujie
AU  - Ren F
AD  - State Key Laboratory of Chemical Engineering, College of Chemical and Biological 
      Engineering, Zhejiang University, Hangzhou 310027, China.
FAU - Saleem, Muhammad
AU  - Saleem M
AD  - State Key Laboratory of Chemical Engineering, College of Chemical and Biological 
      Engineering, Zhejiang University, Hangzhou 310027, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150812
PL  - Netherlands
TA  - Mater Sci Eng C Mater Biol Appl
JT  - Materials science & engineering. C, Materials for biological applications
JID - 101484109
RN  - 0 (Drug Carriers)
RN  - 0 (Organophosphorus Compounds)
RN  - 0 (Polymers)
RN  - 0 (poly(phosphazene))
RN  - 9011-14-7 (Polymethyl Methacrylate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/metabolism
MH  - Calorimetry, Differential Scanning
MH  - Drug Carriers/chemical synthesis/*chemistry
MH  - Drug Liberation
MH  - Hydrophobic and Hydrophilic Interactions
MH  - *Microspheres
MH  - Organophosphorus Compounds/chemical synthesis/*chemistry
MH  - Particle Size
MH  - Polymers/chemical synthesis/*chemistry
MH  - Polymethyl Methacrylate/chemical synthesis/*chemistry
MH  - Porosity
MH  - Temperature
OTO - NOTNLM
OT  - Blends
OT  - Drug release behavior
OT  - Hydrolytic degradation
OT  - Microspheres
OT  - Polyphosphazenes
EDAT- 2015/10/20 06:00
MHDA- 2016/08/02 06:00
CRDT- 2015/10/20 06:00
PHST- 2015/03/25 00:00 [received]
PHST- 2015/06/15 00:00 [revised]
PHST- 2015/08/10 00:00 [accepted]
PHST- 2015/10/20 06:00 [entrez]
PHST- 2015/10/20 06:00 [pubmed]
PHST- 2016/08/02 06:00 [medline]
AID - S0928-4931(15)30265-4 [pii]
AID - 10.1016/j.msec.2015.08.010 [doi]
PST - ppublish
SO  - Mater Sci Eng C Mater Biol Appl. 2016 Jan 1;58:169-79. doi: 
      10.1016/j.msec.2015.08.010. Epub 2015 Aug 12.

PMID- 26094902
OWN - NLM
STAT- MEDLINE
DCOM- 20160506
LR  - 20211025
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 12
IP  - 3
DP  - 2015 Sep
TI  - Synergistic apoptosis-inducing effect of aspirin and isosorbide mononitrate on 
      human colon cancer cells.
PG  - 4750-4758
LID - 10.3892/mmr.2015.3963 [doi]
AB  - Aspirin and isosorbide mononitrate (ISMN) are two commonly used drugs, which are 
      clinically applied for the treatment of inflammatory and cardiovascular diseases, 
      respectively. Recently, aspirin has attracted interest due to its potential 
      application for the treatment of cancer, particularly colon cancer. NO-aspirin, 
      an aspirin derivative containing a covalently bound NO-donating moiety, has been 
      proven to be an effective anti‑tumor agent with apoptosis-inducing ability. In 
      the present study, ISMN was used as an NO donor and its synergic effect with 
      aspirin was assessed in human colon cancer cells. In vitro, an MTT assay 
      demonstrated that ISMN had a synergistic effect on the growth inhibitory effects 
      of aspirin on HCT116 and SW620 colon cancer cells, while the growth of EA.hy926 
      normal endothelial cells was unaffected. This synergistic anti‑tumor effect was 
      further validated in vivo using nude mouse HCT116 cell xenograft model. 
      Observation of nuclear morphology, Annexin V-fluorescein isothiocyanate/propidium 
      iodide double staining and a caspase-3 activity assay suggested that the 
      combination of the two drugs induced apoptosis in HCT116 cells. Furthermore, the 
      molecular mechanisms of the apoptotic effect of the drugs was assessed using an 
      NO release assay, reverse transcription quantitative polymerase chain reaction 
      analysis, western blot analysis and a luciferase reporter assay. It was certified 
      that the increase in the amount of NO release, the decrease in the luciferase 
      promoter activity and the expression of cyclin D1 and c-myc in HCT116 cells were 
      affected by aspirin and ISMN in a synergistic manner. In conclusion, the present 
      study was the first, to the best of our knowledge, to report on the synergistic 
      apoptosis-inducing effects of aspirin and ISMN in human colon cancer cells, which 
      were mediated via Wnt and NO signaling pathways. The results of the present study 
      will facilitate the development of future therapeutic strategies.
FAU - Wang, Xiaodong
AU  - Wang X
AD  - Shenzhen Engineering Laboratory of Synthetic Biology, School of Medicine, 
      Shenzhen University, Shenzhen, Guangdong 518060, P.R. China.
FAU - Diao, Yuwen
AU  - Diao Y
AD  - Shenzhen Engineering Laboratory of Synthetic Biology, School of Medicine, 
      Shenzhen University, Shenzhen, Guangdong 518060, P.R. China.
FAU - Liu, Yu
AU  - Liu Y
AD  - Shenzhen Engineering Laboratory of Synthetic Biology, School of Medicine, 
      Shenzhen University, Shenzhen, Guangdong 518060, P.R. China.
FAU - Gao, Ningning
AU  - Gao N
AD  - Shenzhen Engineering Laboratory of Synthetic Biology, School of Medicine, 
      Shenzhen University, Shenzhen, Guangdong 518060, P.R. China.
FAU - Gao, Dong
AU  - Gao D
AD  - Shenzhen Engineering Laboratory of Synthetic Biology, School of Medicine, 
      Shenzhen University, Shenzhen, Guangdong 518060, P.R. China.
FAU - Wan, Yanyan
AU  - Wan Y
AD  - Shenzhen Engineering Laboratory of Synthetic Biology, School of Medicine, 
      Shenzhen University, Shenzhen, Guangdong 518060, P.R. China.
FAU - Zhong, Jingjing
AU  - Zhong J
AD  - Shenzhen Engineering Laboratory of Synthetic Biology, School of Medicine, 
      Shenzhen University, Shenzhen, Guangdong 518060, P.R. China.
FAU - Jin, Guangyi
AU  - Jin G
AD  - Shenzhen Engineering Laboratory of Synthetic Biology, School of Medicine, 
      Shenzhen University, Shenzhen, Guangdong 518060, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150618
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Antineoplastic Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - IA7306519N (Isosorbide Dinitrate)
RN  - LX1OH63030 (isosorbide-5-mononitrate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Apoptosis/*drug effects
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Colonic Neoplasms/*drug therapy/pathology
MH  - Drug Synergism
MH  - Female
MH  - HCT116 Cells
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Isosorbide Dinitrate/*analogs & derivatives/pharmacology/therapeutic use
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Nitric Oxide/metabolism
MH  - Xenograft Model Antitumor Assays
EDAT- 2015/06/23 06:00
MHDA- 2016/05/07 06:00
CRDT- 2015/06/23 06:00
PHST- 2014/09/29 00:00 [received]
PHST- 2015/05/27 00:00 [accepted]
PHST- 2015/06/23 06:00 [entrez]
PHST- 2015/06/23 06:00 [pubmed]
PHST- 2016/05/07 06:00 [medline]
AID - 10.3892/mmr.2015.3963 [doi]
PST - ppublish
SO  - Mol Med Rep. 2015 Sep;12(3):4750-4758. doi: 10.3892/mmr.2015.3963. Epub 2015 Jun 
      18.

PMID- 12533193
OWN - NLM
STAT- MEDLINE
DCOM- 20040325
LR  - 20191210
IS  - 0885-4513 (Print)
IS  - 0885-4513 (Linking)
VI  - 37
IP  - Pt 3
DP  - 2003 Jun
TI  - Bifunctional constructs of aspirin and ibuprofen (non-steroidal anti-inflammatory 
      drugs; NSAIDs) that express antibacterial and alkylation activities.
PG  - 273-82
AB  - Ibuprofen and aspirin are two common non-steroidal anti-inflammatory drugs 
      (NSAIDs). Both NSAIDs have a carbonyl carbon [-C(O)-], which was utilized to 
      attach a nitrogen mustard (N-mustard) ester group or a tripeptide group. The 
      tripeptide consisted of a L-Gly-D-Ala-D-Ala sequence, where D-Ala-D-Ala is the 
      reactive site for antibacterial activity and L-Gly serves as a linker to the 
      NSAID carrier drug. The aspirin tripeptide and N-mustard show significant 
      antibacterial activity at >or=5.0 x 10(-5) M against penicillin-susceptible or 
      -resistant Escherichia coli. The partition coefficients (log Kow)log P of aspirin 
      and ibuprofen tripeptide drugs were -1.05 and 2.23, respectively. The NSAIDs 
      served as carrier drugs of the N-mustard group which expressed alkylation 
      activity directed towards the nucleophilic primary amine of p -chloroaniline. 
      Hydrolysis of the N-mustard agents yielded the parent structure of aspirin (or 
      ibuprofen) and an N-mustard moiety, 2-[bis(2-chloroethyl)amino]ethanol. The (log 
      Kow)log P for the N-mustard structures of aspirin and ibuprofen were 2.61 and 
      5.63, respectively. The (log Kow)log P value of 
      2-[bis(2-chloroethyl)amino]ethanol was 0.56. Fluorescamine was utilized to 
      determine unreacted p -chloroaniline at known time intervals, which permitted 
      calculation of rate constants and rate equations. The aspirin N-mustard agent 
      expressed strong antibacterial activity against a penicillin-resistant bacteria 
      and first-order alkylation kinetics. The ibuprofen N-mustard and 
      2-[bis(2-chloroethyl)amino]ethanol followed second-order alkylation kinetics. All 
      N-mustard and tripeptide compounds showed zero violations of the Rule of 5. 
      Values of TPSA (molecular polar surface area), C log P and molecular dipoles were 
      calculated.
FAU - Bartzatt, Ronald
AU  - Bartzatt R
AD  - University of Nebraska, College of Arts & Sciences, Chemistry Department, Durham 
      Science Center, 6001 Dodge Street, Omaha, NE 68182, USA. 
      bartzatt@mail.unomaha.edu
FAU - Cirillo, Suat L G
AU  - Cirillo SL
FAU - Cirillo, Jeffrey D
AU  - Cirillo JD
FAU - Donigan, Laura
AU  - Donigan L
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Validation Study
PL  - United States
TA  - Biotechnol Appl Biochem
JT  - Biotechnology and applied biochemistry
JID - 8609465
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Drug Combinations)
RN  - 0 (Nitrogen Mustard Compounds)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis/chemistry/pharmacology
MH  - Antineoplastic Agents, Alkylating/chemical synthesis/*chemistry/*pharmacology
MH  - Aspirin/chemical synthesis/*chemistry/*pharmacology
MH  - Cell Division/drug effects
MH  - Cross-Linking Reagents/chemical synthesis/chemistry/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Drug Delivery Systems/methods
MH  - Escherichia coli/cytology/*drug effects
MH  - Ibuprofen/chemical synthesis/*chemistry/*pharmacology
MH  - Nitrogen Mustard Compounds/chemical synthesis/*chemistry/*pharmacology
EDAT- 2003/01/21 04:00
MHDA- 2004/03/26 05:00
CRDT- 2003/01/21 04:00
PHST- 2003/01/17 00:00 [accepted]
PHST- 2003/01/14 00:00 [revised]
PHST- 2002/11/05 00:00 [received]
PHST- 2003/01/21 04:00 [pubmed]
PHST- 2004/03/26 05:00 [medline]
PHST- 2003/01/21 04:00 [entrez]
AID - BA20020108 [pii]
AID - 10.1042/BA20020108 [doi]
PST - ppublish
SO  - Biotechnol Appl Biochem. 2003 Jun;37(Pt 3):273-82. doi: 10.1042/BA20020108.

PMID- 31580039
OWN - NLM
STAT- MEDLINE
DCOM- 20200624
LR  - 20200624
IS  - 1827-1839 (Electronic)
IS  - 0392-9590 (Linking)
VI  - 38
IP  - 6
DP  - 2019 Dec
TI  - Aspirin for prevention of venous thromboembolism in recipients of major 
      lower-limb orthopedic surgery: a systematic review of Level I evidence.
PG  - 429-442
LID - 10.23736/S0392-9590.19.04086-0 [doi]
AB  - INTRODUCTION: Major lower-limb orthopedic surgery recipients are at increased 
      risk of venous thromboembolism (VTE). The optimal strategy for preventing VTE is 
      a topic of ongoing debate. The use of aspirin has been implicated in reducing VTE 
      events and is potentially advantageous compared to other agents in respect to 
      cost, access, route of administration and reduced adverse effects such as 
      bleeding. EVIDENCE ACQUISITION: A systematic search for Level I evidence 
      (systematic reviews and meta-analyses of randomised-controlled trials) was 
      performed in April 2019 to evaluate the use of aspirin for primary and secondary 
      VTE prophylaxis compared to alternative chemical and mechanical strategies. This 
      search encompassed three electronic databases (Pubmed, Embase and the Cochrane 
      Database of Systematic Reviews). All references of included studies were screened 
      for additional studies. Data was compiled and compared to the recommendations and 
      guidelines published by major institutions. Included studies were appraised with 
      the aid of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
      (PRISMA) checklist. EVIDENCE SYNTHESIS: In total, 21 studies were included. 
      Interventions and outcomes identified were heterogeneous across studies. Most 
      statistical tests applied found no difference between aspirin and other 
      interventions in regards to deep vein thrombosis, pulmonary embolism, bleeding 
      and mortality outcomes. CONCLUSIONS: Aspirin may be a viable alternative to 
      established thromboprophylactic regimes for primary prevention of VTE, however in 
      the setting of secondary prevention it is generally less efficacious. Future 
      studies should have clearly identified and comparable outcome measures, with 
      direct comparisons and assessment of intervention combination, dosing and 
      treatment duration.
FAU - Seagrave, Kurt G
AU  - Seagrave KG
AD  - The University of Sydney, Westmead Clinical School, Sydney, Australia - 
      kurtseagrave.au@gmail.com.
FAU - Fletcher, John P
AU  - Fletcher JP
AD  - The University of Sydney, Westmead Clinical School, Sydney, Australia.
AD  - Westmead Research Centre for Evaluation of Surgical Outcomes, Department of 
      Surgery, Westmead Hospital, Sydney, Australia.
FAU - Hitos, Kerry
AU  - Hitos K
AD  - The University of Sydney, Westmead Clinical School, Sydney, Australia.
AD  - Westmead Research Centre for Evaluation of Surgical Outcomes, Department of 
      Surgery, Westmead Hospital, Sydney, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190930
PL  - Italy
TA  - Int Angiol
JT  - International angiology : a journal of the International Union of Angiology
JID - 8402693
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Evidence-Based Medicine
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Lower Extremity/surgery
MH  - Orthopedic Procedures/*methods
MH  - Practice Guidelines as Topic
MH  - Primary Prevention
MH  - Pulmonary Embolism/chemically induced
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Societies, Medical
MH  - United States
MH  - Venous Thromboembolism/etiology/mortality/*prevention & control
EDAT- 2019/10/04 06:00
MHDA- 2020/06/25 06:00
CRDT- 2019/10/04 06:00
PHST- 2019/10/04 06:00 [pubmed]
PHST- 2020/06/25 06:00 [medline]
PHST- 2019/10/04 06:00 [entrez]
AID - S0392-9590.19.04086-0 [pii]
AID - 10.23736/S0392-9590.19.04086-0 [doi]
PST - ppublish
SO  - Int Angiol. 2019 Dec;38(6):429-442. doi: 10.23736/S0392-9590.19.04086-0. Epub 
      2019 Sep 30.

PMID- 18560039
OWN - NLM
STAT- MEDLINE
DCOM- 20080917
LR  - 20161124
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 158
DP  - 2008 May
TI  - Study of non-opioid analgesics tolerance in young and adult rats.
PG  - 40-4
AB  - It was demonstrated that systemic injections of metamizol and 
      lysine-acetylsalicylate (LASA) induce inhibition of tail-flick reflex and 
      hot-plate responses and their repeated administration leads to the development of 
      tolerance. However, it has not been established whether these effects can be 
      elicited by other non-steroidal anti-inflammatory drugs (NSAIDs). In this study 
      the authors used other commonly applied analgesics--analgine, ketorolac, xefocam, 
      which are the representatives of the three diverse groups of NSAIDs. In 
      particular, analgine is a derivative of pirozolon, while ketorolac belongs to 
      indoles and xefocam to amoxicams. The authors decided to examine and compare 
      tolerance to analgine, ketorolac and xefocam in groups of young and adult rats. 
      The experiments were carried out on experimental and control rats with saline by 
      the model of tail-flick reflex to the stimulation of focusing light. Latency 
      increase of this reflex indicates the degree of antinociception. The present 
      study has revealed that systemic, intraperitoneal injections of NSAIDs (analgine, 
      ketorolac and xefocam), the equivalent to maximal analgesic doses for humans, 
      induces antinociception in awake rats of young and adult ages and when 
      administered repeatedly, induce tolerance to these drugs and cross-tolerance to 
      morphine. This is in line with results of earlier experiments, in which metamizol 
      or LASA were given intravenously or microinjected into the periaqueductal gray 
      matter. More importantly, the study indicate that the repeated administration of 
      these non-opioid analgesics induces a decrease in antinociceptive effectiveness 
      reminiscent of that induced by opiates. Moreover, the present results 
      paradoxically suggest that analgine, ketorolac and xefocam tolerance is related 
      to the endogenous opioid system. Taken together the present and previous findings 
      the authors support the notion that the contribution of the CNS, particularly of 
      the downstream pain-control system, to the tolerance effects of NSAIDs involve 
      endogenous opioidergic mechanisms.
FAU - Tsiklauri, N
AU  - Tsiklauri N
AD  - Department of Neurophysiology, Beritashvili Institute of Physiology, Tbilisi, 
      Georgia.
FAU - Gurtskaia, G
AU  - Gurtskaia G
FAU - Tsagareli, M
AU  - Tsagareli M
LA  - eng
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 13T4O6VMAM (Piroxicam)
RN  - 6429L0L52Y (Dipyrone)
RN  - 76I7G6D29C (Morphine)
RN  - ER09126G7A (lornoxicam)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - YZI5105V0L (Ketorolac)
SB  - IM
MH  - Age Factors
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Dipyrone/*pharmacology
MH  - *Drug Tolerance
MH  - Ketorolac/*pharmacology
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Morphine/pharmacology
MH  - Nociceptors/*drug effects
MH  - Piroxicam/*analogs & derivatives/pharmacology
MH  - Rats
MH  - Time Factors
EDAT- 2008/06/19 09:00
MHDA- 2008/09/18 09:00
CRDT- 2008/06/19 09:00
PHST- 2008/06/19 09:00 [pubmed]
PHST- 2008/09/18 09:00 [medline]
PHST- 2008/06/19 09:00 [entrez]
PST - ppublish
SO  - Georgian Med News. 2008 May;(158):40-4.

PMID- 18361314
OWN - NLM
STAT- MEDLINE
DCOM- 20080522
LR  - 20131121
IS  - 1426-9686 (Print)
IS  - 1426-9686 (Linking)
VI  - 23
IP  - 137
DP  - 2007 Nov
TI  - [Effect of the acetylosalicyd acid (ASA) and ticlopidine therapy on clinical 
      condition and parameters of blood platelets in patients with peripheral arterial 
      occlusive disease (PAOD)].
PG  - 335-9
AB  - Hyperreactivity of platelets is one of the agents promoting atherosclerosis and 
      its organ complications THE AIM: To assess antiplatelet therapy with 
      acetylsalicylic acid (ASA) and ticlopidine on clinical condition and chosen 
      parameters of blood platelet activity and reactivity in patients with PAOD. 
      MATERIAL AND METHODS: Twenty eight patients, aged 40-65 years, were enrolled to 
      the study after clinically and echographically established diagnosis. The 
      patients were randomly divided into two groups: 13 were treated with ASA 300 mg 
      daily and 15 with ticlopidine 2 x 250 mg daily. The therapy lasted two months. 
      Clinical stress tests were done on moving track according to thB modified Bruce's 
      protocol and blood platelets activity parameters on flow-cytometer. Percentage of 
      spontaneous platelet aggregates, microplatelets and platelets expressing CD62P, 
      Cd42b and CD41 were tested. RESULTS: Supplementation therapy with ASA or 
      ticlopidine to the standard therapy with pentoxyphylline resulted in a marked 
      increase in the distance of claudication evaluated subjectively and objectively 
      on moving track and revealed silent myocardial ischemia in 4 PAOD patients. In 
      platelet activation tests, both at rest and after the stress test, independently 
      of the antiplatelet agent used, we observed significant drop in the percentage of 
      platelet aggregates and symptoms of vWF receptor activation. No effect of the 
      therapy on CD62P expression, reflecting platelet release reaction and CD41 
      expression (the fragment of receptor for fibrynogen) were noted. CONCLUSIONS: 
      Both antiplatelet drugs have beneficial effect on clinical condition of PAOD 
      patients and the effect may results from their anti-aggregative and anti-adhesive 
      properties.
FAU - Leo, Wojciech
AU  - Leo W
AD  - Szpital im. M. Pirogowa w Łodzi, Oddzial Kardiologii i Pracownia Diagnostyki 
      Kardiologicznej.
FAU - Westrych, Renata
AU  - Westrych R
FAU - Bissinger, Andrzej
AU  - Bissinger A
FAU - Okraszewski, Jerzy
AU  - Okraszewski J
FAU - Baj, Zbigniew
AU  - Baj Z
LA  - pol
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Ocena wpływu terapii kwasem acetylosalicylowym i tiklopidyna na stan kliniczny 
      oraz parametry płytek krwi u chorych na miazdzyce zarostowa kończyn dolnych 
      (arteriosclerosis obliterans).
PL  - Poland
TA  - Pol Merkur Lekarski
JT  - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
JID - 9705469
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arteriosclerosis Obliterans/diagnosis/*drug therapy
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Ticlopidine/*administration & dosage/therapeutic use
MH  - Treatment Outcome
EDAT- 2008/03/26 09:00
MHDA- 2008/05/23 09:00
CRDT- 2008/03/26 09:00
PHST- 2008/03/26 09:00 [pubmed]
PHST- 2008/05/23 09:00 [medline]
PHST- 2008/03/26 09:00 [entrez]
PST - ppublish
SO  - Pol Merkur Lekarski. 2007 Nov;23(137):335-9.

PMID- 15006717
OWN - NLM
STAT- MEDLINE
DCOM- 20040510
LR  - 20131121
IS  - 1474-0338 (Print)
IS  - 1474-0338 (Linking)
VI  - 3
IP  - 2
DP  - 2004 Mar
TI  - The safety of antithrombotic therapy during pregnancy.
PG  - 113-8
AB  - A number of clinical conditions can require the use of antithrombotic drugs 
      during pregnancy. These mainly include prevention of venous thromboembolism (VTE) 
      and fetal complications in high-risk patients, treatment of VTE and prevention of 
      arterial emboli in patients with mechanical heart valve prostheses. However, 
      there are several problems when using antithrombotic drugs during pregnancy. 
      Warfarin, as well as the other coumarin compounds, crosses the placenta and has 
      the potential to cause both bleeding in the fetus and teratogenicity, therefore 
      its use is not recommended during the first trimester and during the perinatal 
      period. Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) do 
      not cross the placenta and are safe for the fetus, but long-term treatment with 
      UFH is problematic because of its inconvenient administration, the need to 
      monitor anticoagulant activity and because of its potential side effects, such as 
      heparin-induced thrombocytopenia and osteoporosis. LMWH is the drug of choice in 
      the prevention and treatment of VTE during pregnancy because of its practical 
      advantages over UFH and because of a lower risk of side effects. Patients with 
      mechanical heart valve prostheses represent a major clinical challenge. Warfarin, 
      the drug of choice in non-pregnant women, can be administered between the 12th 
      and 36th week. Full-dose UFH is recommended in the first trimester and after week 
      36. The use of LMWH as an alternative to UFH is still a matter of debate, because 
      inadequate data are available.
FAU - Ageno, Walter
AU  - Ageno W
AD  - Department of Internal Medicine, UO Medicina I, Ospedale di Circolo, Varese, 
      Italy. agewal@yahoo.com
FAU - Crotti, Stefania
AU  - Crotti S
FAU - Turpie, Alexander G G
AU  - Turpie AG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/therapeutic use
MH  - Heparin, Low-Molecular-Weight/*adverse effects/therapeutic use
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*prevention & control
MH  - Venous Thrombosis/*prevention & control
RF  - 33
EDAT- 2004/03/10 05:00
MHDA- 2004/05/11 05:00
CRDT- 2004/03/10 05:00
PHST- 2004/03/10 05:00 [pubmed]
PHST- 2004/05/11 05:00 [medline]
PHST- 2004/03/10 05:00 [entrez]
AID - 10.1517/eods.3.2.113.27343 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2004 Mar;3(2):113-8. doi: 10.1517/eods.3.2.113.27343.

PMID- 9931189
OWN - NLM
STAT- MEDLINE
DCOM- 19990322
LR  - 20171213
IS  - 8750-7587 (Print)
IS  - 0161-7567 (Linking)
VI  - 86
IP  - 2
DP  - 1999 Feb
TI  - Cardiovascular and hemorheological effects of three modified human hemoglobin 
      solutions in hemodiluted rabbits.
PG  - 541-8
AB  - The cardiovascular effects of human albumin (Alb) and three human hemoglobin (Hb) 
      solutions, dextran-benzene-tetracarboxylate Hb, alphaalpha-crosslinked Hb, and 
      o-raffinose-polymerized Hb were compared in anesthetized rabbits undergoing acute 
      isovolemic hemodilution with Hct reduction from 41.4 +/- 2.7 to 28.8 +/- 1.6%. 
      The impact of the vasoconstricting properties of Hb was examined by measuring 
      heart rate (HR), mean arterial pressure (MAP), abdominal aortic, and femoral 
      arterial blood flow, vascular resistance (VR), and aortic distension during the 
      first 3 h after hemodilution. The impact of the hemorheological parameters was 
      assessed by measurements of hemodiluted blood viscosity. In contrast to Alb, the 
      Hb solutions elicited an immediate increase in MAP (20-38%). The effects of Alb 
      and Hb solutions on HR, as well as on aortic and femoral arterial blood flow, 
      were similar. VR decreased with Alb (20-28%) and increased with all three Hb 
      solutions (30-90%), but the MAP and VR rising trends were different with each Hb 
      solution. Aortic distension decreased in Hb groups compared with the Alb group 
      for the first 60 min. The viscosity of hemodiluted blood was similar for all 
      groups at high shear rates but was dependent on the viscosity of the solutions at 
      low shear rates. We conclude that the vasoconstriction elicited by the Hb 
      solutions overrides the vasodilation associated with viscosity changes due to 
      hemodilution and would be the major factor responsible to the cardiovascular 
      changes.
FAU - Caron, A
AU  - Caron A
AD  - Department of Hematology and Physiology, School of Pharmacy, University Henri 
      Poincaré- Nancy 1, 54001 Nancy cedex, France. caron@pharma.u-nancy.fr
FAU - Menu, P
AU  - Menu P
FAU - Faivre-Fiorina, B
AU  - Faivre-Fiorina B
FAU - Labrude, P
AU  - Labrude P
FAU - Alayash, A I
AU  - Alayash AI
FAU - Vigneron, C
AU  - Vigneron C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Appl Physiol (1985)
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
RN  - 0 (Albumins)
RN  - 0 (Blood Substitutes)
RN  - 0 (Dextrans)
RN  - 0 (Hemoglobins)
RN  - 0 (O-raffinose cross-linked human hemoglobin)
RN  - 0 (Solutions)
RN  - 0 (hemoglobin XL99alpha)
RN  - 0 (hemoglobin-dextran 10-benzene-tetracarboxylate)
RN  - N5O3QU595M (Raffinose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Albumins/pharmacology
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Blood Pressure/drug effects
MH  - Blood Substitutes/*pharmacology
MH  - Blood Viscosity/*drug effects
MH  - Dextrans/pharmacology
MH  - Heart Rate/drug effects
MH  - *Hemodilution
MH  - Hemodynamics/*drug effects
MH  - Hemoglobins/*pharmacology
MH  - Humans
MH  - Male
MH  - Rabbits
MH  - Raffinose/analogs & derivatives/pharmacology
MH  - Rheology
MH  - Solutions
MH  - Vascular Resistance/drug effects
EDAT- 1999/02/04 00:00
MHDA- 1999/02/04 00:01
CRDT- 1999/02/04 00:00
PHST- 1999/02/04 00:00 [pubmed]
PHST- 1999/02/04 00:01 [medline]
PHST- 1999/02/04 00:00 [entrez]
AID - 10.1152/jappl.1999.86.2.541 [doi]
PST - ppublish
SO  - J Appl Physiol (1985). 1999 Feb;86(2):541-8. doi: 10.1152/jappl.1999.86.2.541.

PMID- 7687725
OWN - NLM
STAT- MEDLINE
DCOM- 19930820
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 21
IP  - 6
DP  - 1993 Jun
TI  - Acetylsalicylic acid, at high concentrations, inhibits vascular smooth muscle 
      cell proliferation.
PG  - 973-6
AB  - The growth of human smooth muscle cells in culture is inhibited by 
      acetylsalicylic acid (ASA). In comparison to control, the proliferation of cells 
      treated with 270 mg/L lysinmono(acetylsalicylate)/30 mg/L glycine was inhibited 
      by 50-90% under different culture conditions. Cell numbers per well (control vs. 
      treated) were as follows: (a) 470,500 +/- 55,890 vs. 24,750 +/- 4,030 (p < 0.002) 
      after 6 days in the presence of 10% fetal calf serum (FCS), (b) 160,500 +/- 9,920 
      vs. 74,000 (p < 0.001) after 8 days in the presence of 10% human serum; and (c) 
      387,000 +/- 29,420 vs. 35,250 +/- 1,110 (p < 0.001) after 8 days in the presence 
      of 5% FCS. Significant inhibition of growth by lysinmono(acetylsalicylate) at 90 
      mg/L was noted only for cultures grown with 10% FCS. Lower concentrations of this 
      drug were ineffective under all culture conditions. Higher dosages of ASA, which 
      would prevent not only platelet aggregation but also smooth muscle cell growth, 
      may therefore be indicated in therapy of patients who undergo percutaneous 
      transluminal coronary angioplasty (PTCA) or coronary artery transplantation.
FAU - Bernhardt, J
AU  - Bernhardt J
AD  - Department of Research, Basel University Hospitals, Switzerland.
FAU - Rogalla, K
AU  - Rogalla K
FAU - Lüscher, T F
AU  - Lüscher TF
FAU - Bühler, F R
AU  - Bühler FR
FAU - Resink, T J
AU  - Resink TJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Phosphatidylinositols)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cell Division/drug effects
MH  - Cell Survival/drug effects
MH  - Humans
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Muscle, Smooth, Vascular/*cytology/drug effects/metabolism
MH  - Phosphatidylinositols/metabolism
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - 10.1097/00005344-199306000-00019 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1993 Jun;21(6):973-6. doi: 
      10.1097/00005344-199306000-00019.

PMID- 12435257
OWN - NLM
STAT- MEDLINE
DCOM- 20021126
LR  - 20220408
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 288
IP  - 19
DP  - 2002 Nov 20
TI  - Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual 
      patient meta-analysis.
PG  - 2441-8
AB  - CONTEXT: Patients with nonvalvular atrial fibrillation (AF) have an increased 
      risk of stroke and other vascular events. OBJECTIVE: To compare the risk of 
      vascular and bleeding events in patients with nonvalvular AF treated with vitamin 
      K -inhibiting oral anticoagulants or acetylsalicylic acid (aspirin). DESIGN: 
      Pooled analysis of patient-level data from 6 published, randomized clinical 
      trials. PATIENTS: A total of 4052 patients with AF randomly assigned to receive 
      therapeutic doses of oral anticoagulant or aspirin with or without low-dose oral 
      anticoagulants. MAIN OUTCOME MEASURES: Ischemic and hemorrhagic stroke, other 
      cardiovascular events, all-cause death, and major bleeding events. Person-year 
      incidence rates were calculated to provide crude comparisons. Relative efficacy 
      was assessed using proportional hazards modeling stratified by study. The 
      variation of the oral anticoagulant's relative effect by pertinent patient 
      factors was explored with interaction terms. All analyses were conducted using 
      the intention-to-treat principle. RESULTS: Patients receiving oral anticoagulant 
      and aspirin were balanced for important prognostic factors. There was no 
      significant heterogeneity between trials in the relative efficacy of oral 
      anticoagulant vs aspirin for any outcome. Patients receiving oral anticoagulant 
      were significantly less likely to experience any stroke (2.4 vs 4.5 events per 
      100 patient-years; hazard ratio [HR], 0.55; 95% confidence interval [CI], 
      0.43-0.71), ischemic stroke (HR, 0.48; 95% CI, 0.37-0.63), or cardiovascular 
      events (HR, 0.71; 95% CI, 0.59-0.85) but were more likely to experience major 
      bleeding (2.2 vs 1.3 events per 100 patient-years; HR, 1.71; 95% CI, 1.21-2.41). 
      The reduction in ischemic stroke risk was similar in patients with paroxysmal AF 
      (1.5 vs 4.7 events per 100 patient-years; HR, 0.32; 95% CI, 0.16-0.61; P<.001). 
      Treating 1000 patients with AF for 1 year with oral anticoagulant rather than 
      aspirin would prevent 23 ischemic strokes while causing 9 additional major 
      bleeds. Overall all-cause survival did not differ but appeared to improve for 
      oral anticoagulant patients 3 years after therapy was started. CONCLUSIONS: 
      Compared with aspirin, oral anticoagulant significantly decreases the risk of all 
      strokes, ischemic strokes, and cardiovascular events for patients with 
      nonvalvular chronic or paroxysmal AF but modestly increases the absolute risk of 
      major bleeding. The balance of benefits and risks varies by patient subgroup.
FAU - van Walraven, Carl
AU  - van Walraven C
AD  - Clinical Epidemiology Unit, Ottawa Health Research Institute, F-6, Ottawa 
      Hospital, Civic Campus, 1053 Carling Ave, Ottawa, Ontario, Canada K1Y 4E9. 
      carlv@ohri.ca
FAU - Hart, Robert G
AU  - Hart RG
FAU - Singer, Daniel E
AU  - Singer DE
FAU - Laupacis, Andreas
AU  - Laupacis A
FAU - Connolly, Stuart
AU  - Connolly S
FAU - Petersen, Palle
AU  - Petersen P
FAU - Koudstaal, Peter J
AU  - Koudstaal PJ
FAU - Chang, Yuchiao
AU  - Chang Y
FAU - Hellemons, Beppie
AU  - Hellemons B
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Drug Therapy, Combination
MH  - Hemorrhage/epidemiology/etiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Proportional Hazards Models
MH  - Randomized Controlled Trials as Topic
MH  - Risk
MH  - Stroke/epidemiology/prevention & control
MH  - Survival Analysis
MH  - Thrombosis/etiology/*prevention & control
EDAT- 2002/11/19 04:00
MHDA- 2002/11/28 04:00
CRDT- 2002/11/19 04:00
PHST- 2002/11/19 04:00 [pubmed]
PHST- 2002/11/28 04:00 [medline]
PHST- 2002/11/19 04:00 [entrez]
AID - jcc20007 [pii]
AID - 10.1001/jama.288.19.2441 [doi]
PST - ppublish
SO  - JAMA. 2002 Nov 20;288(19):2441-8. doi: 10.1001/jama.288.19.2441.

PMID- 497917
OWN - NLM
STAT- MEDLINE
DCOM- 19800128
LR  - 20131121
IS  - 0008-428X (Print)
IS  - 0008-428X (Linking)
VI  - 22
IP  - 5
DP  - 1979 Sep
TI  - Aspirin prophylaxis of venous thromboembolic disease following fracture of the 
      upper femur.
PG  - 468-72
AB  - In a prospective study of 51 patients with fractures of the femoral neck, aspirin 
      was used as a prophylactic measure against thromboembolic disease. Thrombi were 
      detected by cuff impedence plethysmography, Doppler ultrasonography and ascending 
      venography. Thrombi were identified in 20 (39.2%) of the patients. There was no 
      significant difference between the frequency with which thrombi occurred in men 
      and in women. Blood salicylate values were the same for patients who had and who 
      did not have thrombi. There were no instances of pulmonary embolism. The 
      frequency of deep vein thrombosis was comparable to that in a previous series of 
      untreated patients from the same centre. It appears from this study that in these 
      cases prophylaxis against venous thromboembolism using aspirin in a dosage of 600 
      mg bid is ineffective.
FAU - Channon, G M
AU  - Channon GM
FAU - Wiley, A M
AU  - Wiley AM
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can J Surg
JT  - Canadian journal of surgery. Journal canadien de chirurgie
JID - 0372715
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Femoral Neck Fractures/*complications/surgery
MH  - Hip Fractures/*complications/surgery
MH  - Hip Prosthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Sex Ratio
MH  - Thrombophlebitis/diagnosis/etiology/*prevention & control
EDAT- 1979/09/01 00:00
MHDA- 1979/09/01 00:01
CRDT- 1979/09/01 00:00
PHST- 1979/09/01 00:00 [pubmed]
PHST- 1979/09/01 00:01 [medline]
PHST- 1979/09/01 00:00 [entrez]
PST - ppublish
SO  - Can J Surg. 1979 Sep;22(5):468-72.

PMID- 33463124
OWN - NLM
STAT- MEDLINE
DCOM- 20210930
LR  - 20210930
IS  - 1735-5249 (Electronic)
IS  - 1735-1502 (Linking)
VI  - 19
IP  - 5
DP  - 2020 Oct 18
TI  - A Case of Linear IgA Bullous Dermatosis Induced by Aspirin Therapy.
PG  - 550-554
LID - 10.18502/ijaai.v19i5.4473 [doi]
AB  - Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disease that 
      may be triggered by some diseases and medications. For the latter one, 
      non-steroidal anti-inflammatory drugs (NSAIDs) have been identified as one of the 
      potential causative agents to develop LABD. Here, a rare case of drug-induced 
      LABD is introduced. A 13-month-old Iranian boy presented with a history of 
      generalized blisters, displaying the classic "string of pearls" sign who was 
      eventually diagnosed as a case of LABD. In his admission, he was diagnosed whit 
      Mucocutaneous lymph node syndrome and treated with aspirin.  Some features like 
      appearing the characteristic lesions one week following the administration of 
      aspirin, rapid clearance of lesions after the withdrawal of the drug, and 
      reappearance of new lesions after readministration of aspirin were highly 
      suggestive of aspirin-induced LABD. To establish the diagnosis, we used the 
      "Naranjo probability score" which determined the probable causative role of 
      aspirin. The diagnosis was confirmed by showing the positive IgA deposition in 
      the basement membrane zone in a direct immunofluorescence study of the skin 
      biopsy. The child was treated with dapsone with dramatical response to the drug.
FAU - Nabavi, Mohammad
AU  - Nabavi M
AD  - Department of Allergy and Clinical Immunology, Iran University of Medical 
      Sciences, Tehran, Iran. mnabavi44@yahoo.com.
FAU - Rezaeifar, Afshin
AU  - Rezaeifar A
AD  - Department of Allergy and Clinical Immunology, Iran University of Medical 
      Sciences, Tehran, Iran. rezaeifar.a@iums.ac.ir.
FAU - Sadeghinia, Ali
AU  - Sadeghinia A
AD  - Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, 
      Tehran, Iran. sadeghinia2000@yahoo.com.
FAU - Arshi, Saba
AU  - Arshi S
AD  - Department of Allergy and Clinical Immunology, Iran University of Medical 
      Sciences, Tehran, Iran. sabaarshi@yahoo.com.
FAU - Bahrami, Sima
AU  - Bahrami S
AD  - Department of Allergy and Clinical Immunology, Iran University of Medical 
      Sciences, Tehran, Iran. simabahrami.ped@yahoo.com.
FAU - Bemanian, Mohammad Hassan
AU  - Bemanian MH
AD  - Department of Allergy and Clinical Immunology, Iran University of Medical 
      Sciences, Tehran, Iran. mhbemanian@yahoo.com.
FAU - Fallahpour, Morteza
AU  - Fallahpour M
AD  - Department of Allergy and Clinical Immunology, Iran University of Medical 
      Sciences, Tehran, Iran. fallahpour.morteza@yahoo.com.
FAU - Shokri, Sima
AU  - Shokri S
AD  - Department of Allergy and Clinical Immunology, Iran University of Medical 
      Sciences, Tehran, Iran. Dr.shokri.83@gmail.com.
FAU - Vakilazad, Zahra
AU  - Vakilazad Z
AD  - Department of Allergy and Clinical Immunology, Iran University of Medical 
      Sciences, Tehran, Iran. Rezaeifar.a@iums.ac.ir.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20201018
PL  - Iran
TA  - Iran J Allergy Asthma Immunol
JT  - Iranian journal of allergy, asthma, and immunology
JID - 101146178
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunoglobulin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/*immunology
MH  - Aspirin/*adverse effects/*immunology
MH  - Humans
MH  - Immunoglobulin A/*immunology
MH  - Infant
MH  - Iran
MH  - Linear IgA Bullous Dermatosis/*chemically induced/*immunology
MH  - Male
OTO - NOTNLM
OT  - Aspirin
OT  - Dapsone
OT  - Linear IgA bullous dermatosis
OT  - Mucocutaneous lymph node syndrome
EDAT- 2021/01/20 06:00
MHDA- 2021/10/01 06:00
CRDT- 2021/01/19 07:08
PHST- 2019/12/16 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2021/01/19 07:08 [entrez]
PHST- 2021/01/20 06:00 [pubmed]
PHST- 2021/10/01 06:00 [medline]
AID - 10.18502/ijaai.v19i5.4473 [doi]
PST - epublish
SO  - Iran J Allergy Asthma Immunol. 2020 Oct 18;19(5):550-554. doi: 
      10.18502/ijaai.v19i5.4473.

PMID- 20405964
OWN - NLM
STAT- MEDLINE
DCOM- 20100810
LR  - 20131121
IS  - 1520-510X (Electronic)
IS  - 0020-1669 (Linking)
VI  - 49
IP  - 10
DP  - 2010 May 17
TI  - Terbium-macrocycle complexes as chemical sensors: detection of an aspirin 
      metabolite in urine using a salicylurate-specific receptor site.
PG  - 4643-7
LID - 10.1021/ic1003066 [doi]
AB  - Salicylurate (SU) is the major metabolite in urine of acetylsalicylic acid 
      (aspirin) and can be used as a metric to monitor aspirin pharmacokinetics and as 
      an indicator of appendicitis, anemia, and liver disease. Detection in urine and 
      plasma currently requires solvent extraction or other sample handling prior to 
      analysis. We present a simple method to quantify SU in urine via chelation to a 
      terbium binary complex with the macrocycle 
      1,4,7,10-tetraazacyclododecane-1,7-bisacetate (DO2A). Binding of SU to form the 
      [Tb(DO2A)(SU)](-) ternary complex triggers intense luminescence under UV 
      excitation due to an absorbance-energy transfer-emission mechanism. Here we 
      report characterization of the [Tb(DO2A)(SU)](-) ternary complex and application 
      of this sensitized lanthanide luminescence method to quantify SU in urine samples 
      following a low-dose aspirin regimen.
FAU - Esplin, Taran L
AU  - Esplin TL
AD  - Planetary Science Section, Jet Propulsion Laboratory, California Institute of 
      Technology, 4800 Oak Grove Drive, Pasadena, California 91109, USA.
FAU - Cable, Morgan L
AU  - Cable ML
FAU - Gray, Harry B
AU  - Gray HB
FAU - Ponce, Adrian
AU  - Ponce A
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Inorg Chem
JT  - Inorganic chemistry
JID - 0366543
RN  - 0 (Hippurates)
RN  - 0 (Macrocyclic Compounds)
RN  - 0 (Organometallic Compounds)
RN  - 06SSF7P179 (Terbium)
RN  - 487-54-7 (salicylurate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*metabolism
MH  - Calibration
MH  - Chemistry Techniques, Analytical/economics/*instrumentation
MH  - Hippurates/*chemistry/metabolism/*urine
MH  - Humans
MH  - Luminescent Measurements
MH  - Macrocyclic Compounds/*chemistry
MH  - Organometallic Compounds/chemical synthesis/*chemistry
MH  - Terbium/*chemistry
MH  - Time Factors
MH  - Urinalysis
EDAT- 2010/04/22 06:00
MHDA- 2010/08/11 06:00
CRDT- 2010/04/22 06:00
PHST- 2010/04/22 06:00 [entrez]
PHST- 2010/04/22 06:00 [pubmed]
PHST- 2010/08/11 06:00 [medline]
AID - 10.1021/ic1003066 [doi]
PST - ppublish
SO  - Inorg Chem. 2010 May 17;49(10):4643-7. doi: 10.1021/ic1003066.

PMID- 21636235
OWN - NLM
STAT- MEDLINE
DCOM- 20111123
LR  - 20161125
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 56
IP  - 2
DP  - 2011 Sep 10
TI  - Content uniformity studies in tablets by NIR-CI.
PG  - 408-12
LID - 10.1016/j.jpba.2011.04.018 [doi]
AB  - Near infrared chemical imaging (NIR-CI) is attracting growing interest in 
      pharmaceutical analysis by virtue of its ability to provide a wealth of 
      information from a single sample. Among others, NIR-CI has enabled the 
      determination of the quantitative composition and distribution of acetylsalicylic 
      (ASA) from the analysis of commercial tablets. In this work, we analyzed ASA 
      commercial tablets of four different brands purchased at local chemists. The 
      nominal ASA concentration for the brands was calculated from the nominal content 
      and averaged weight of tablets. The tablets were found to span an ASA 
      concentration range of 71-82%, and to differ in size and composition between 
      brands. The API content and its homogeneity distribution were determined by 
      applying quantitative algorithm to global hyperspectral image of ten tablets. 
      Multivariate curve resolution-alternating least squares (MCR-ALS) is used to 
      quantify each pixel in the images to obtain appropriate concentration maps. No 
      prior calibration or reference data were needed for quantitation and results are 
      close to the nominal content used as reference. Application to an image for 10 
      tablets and an individual tablet quantitation of the API allowed us to obtain the 
      Accepted Value (AV) as defined by the European Pharmacopoeia. We conclude that 
      all brands meet the pharmacopoeia specifications.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Cruz, J
AU  - Cruz J
AD  - Unitat de Química Analítica, Facultat de Ciencies, Universitat Autònoma de 
      Barcelona, 08193 Bellaterra, Barcelona, Spain.
FAU - Blanco, M
AU  - Blanco M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110427
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - 9004-34-6 (Cellulose)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis/standards
MH  - Aspirin/*analysis/standards
MH  - Calibration
MH  - Cellulose/analysis
MH  - Chemistry, Pharmaceutical
MH  - Excipients/analysis
MH  - Image Processing, Computer-Assisted
MH  - Least-Squares Analysis
MH  - Quality Control
MH  - Software
MH  - *Spectroscopy, Near-Infrared/standards
MH  - Tablets
MH  - Technology, Pharmaceutical/*methods/standards
EDAT- 2011/06/04 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/06/04 06:00
PHST- 2010/12/23 00:00 [received]
PHST- 2011/04/14 00:00 [revised]
PHST- 2011/04/18 00:00 [accepted]
PHST- 2011/06/04 06:00 [entrez]
PHST- 2011/06/04 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - S0731-7085(11)00229-9 [pii]
AID - 10.1016/j.jpba.2011.04.018 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2011 Sep 10;56(2):408-12. doi: 10.1016/j.jpba.2011.04.018. 
      Epub 2011 Apr 27.

PMID- 17900834
OWN - NLM
STAT- MEDLINE
DCOM- 20080311
LR  - 20131121
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 349
IP  - 1-2
DP  - 2008 Feb 12
TI  - Preparation of ionic-crosslinked chitosan-based gel beads and effect of reaction 
      conditions on drug release behaviors.
PG  - 180-7
AB  - Drug-loaded chitosan (CS) beads were prepared under simple and mild condition 
      using trisodium citrate as ionic crosslinker. The beads were further coated with 
      poly(methacrylic acid) (PMAA) by dipping the beads in PMAA aqueous solution. The 
      surface and cross-section morphology of these beads were observed by scanning 
      electron microscopy and the observation showed that the coating beads had 
      core-shell structure. In vitro release of model drug from these beads obtained 
      under different reaction conditions was investigated in buffer medium (pH 1.8). 
      The results showed that the rapid drug release was restrained by PMAA coating and 
      the optimum conditions for preparing CS-based drug-loaded beads were decided 
      through the effect of reaction conditions on the drug release behaviors. In 
      addition, the drug release mechanism of CS-based drug-loaded beads was analyzed 
      by Peppa's potential equation. According to this study, the ionic-crosslinked CS 
      beads coated by PMAA could serve as suitable candidate for drug site-specific 
      carrier in stomach.
FAU - Chen, Shilan
AU  - Chen S
AD  - Department of Chemistry and State Key Laboratory of Applied Organic Chemistry, 
      Lanzhou University, Lanzhou 730000, PR China.
FAU - Liu, Mingzhu
AU  - Liu M
FAU - Jin, Shuping
AU  - Jin S
FAU - Wang, Bin
AU  - Wang B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070825
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Citrates)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Gels)
RN  - 0 (Polymethacrylic Acids)
RN  - 0 (trisodium citrate)
RN  - 25087-26-7 (polymethacrylic acid)
RN  - 9012-76-4 (Chitosan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/chemistry
MH  - Aspirin/administration & dosage/chemistry
MH  - Chemistry, Pharmaceutical
MH  - Chitosan/*chemistry
MH  - Citrates/chemistry
MH  - Cross-Linking Reagents
MH  - Delayed-Action Preparations
MH  - Freeze Drying
MH  - Gels
MH  - Hydrogen-Ion Concentration
MH  - Microscopy, Electron, Scanning
MH  - Particle Size
MH  - Polymethacrylic Acids/chemistry
EDAT- 2007/09/29 09:00
MHDA- 2008/03/12 09:00
CRDT- 2007/09/29 09:00
PHST- 2007/01/31 00:00 [received]
PHST- 2007/06/04 00:00 [revised]
PHST- 2007/08/11 00:00 [accepted]
PHST- 2007/09/29 09:00 [pubmed]
PHST- 2008/03/12 09:00 [medline]
PHST- 2007/09/29 09:00 [entrez]
AID - S0378-5173(07)00691-6 [pii]
AID - 10.1016/j.ijpharm.2007.08.029 [doi]
PST - ppublish
SO  - Int J Pharm. 2008 Feb 12;349(1-2):180-7. doi: 10.1016/j.ijpharm.2007.08.029. Epub 
      2007 Aug 25.

PMID- 12877570
OWN - NLM
STAT- MEDLINE
DCOM- 20040323
LR  - 20181113
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 28
IP  - 2
DP  - 2003 Apr-Jun
TI  - Comparative pharmacokinetics of salicylate in camels, sheep and goats.
PG  - 125-8
AB  - This study compared some pharmacokinetic parameters of DL-lysine-acetyl 
      salicylate administered intravenously (i.v.) and intramuscularly (i.m.) at a dose 
      of 20 mg/kg in camels, sheep and goats. The data was analyzed using a 
      non-compartmental model. In camels, sheep and goats given the drug i.v., the t1/2 
      values were 43.1, 31.2 and 27.3; the clearance (Cl) values were 203.7, 261.1, and 
      280.4 ml/h/kg, while the area under the curve (AUC) were 100.1, 106.9 and 110.5 
      mg.h/L, respectively. In camels, sheep and goats given the drug by the i.m. route 
      the mean peak plasma concentration (Cmax) were 0.94, 1.44 and 1.74 mg/ml, and the 
      time to reach Cmax (tmax) were 2.94, 2.57 and 2.43h, respectively. The t1/2 
      values were 48.9, 38.2 and 36.0 min; the clearance (Cl) values were 261.3, 297.4 
      and 306.4 ml/h/kg, while the area under the curve (AUC) were 101.6, 117.3 and 
      123.7 mg.h/L, respectively. The drug bioavailability (F) in camels, sheep and 
      goats were 71.3, 78.4 and 79.4% respectively. These findings suggest that the 
      rate of absorption and elimination of the salicylate is slower in camels than in 
      sheep and goats.
FAU - Ali, B H
AU  - Ali BH
AD  - Department of Veterinary Medicine, King Saud University, Al Gaseem branch, 
      Buraydah, Saudi Arabia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacokinetics
MH  - Camelus/*metabolism
MH  - Cross-Over Studies
MH  - Goats/*metabolism
MH  - Lysine/*analogs & derivatives/*pharmacokinetics
MH  - Male
MH  - Sheep/*metabolism
MH  - Species Specificity
EDAT- 2003/07/25 05:00
MHDA- 2004/03/24 05:00
CRDT- 2003/07/25 05:00
PHST- 2003/07/25 05:00 [pubmed]
PHST- 2004/03/24 05:00 [medline]
PHST- 2003/07/25 05:00 [entrez]
AID - 10.1007/BF03190500 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 2003 Apr-Jun;28(2):125-8. doi: 
      10.1007/BF03190500.

PMID- 1147509
OWN - NLM
STAT- MEDLINE
DCOM- 19751008
LR  - 20131121
IS  - 0003-4886 (Print)
IS  - 0003-4886 (Linking)
VI  - 7
IP  - 6
DP  - 1975 Jun
TI  - Conjunctival temperature: a measure of ocular decongestant and anti-inflammatory 
      activity.
PG  - 819-24
AB  - A new experimental method is presented that permits objective evaluation of 
      ocular decongestant and anti-inflammatory activity following systemic or local 
      administration of drugs to the rabbit eye inflamed with mustard oil. The 
      inflammation produced by mustard oil is characterized by conjunctival hyperemia 
      and chemosis and is measured by the conjunctival sac temperature. Although a 2% 
      suspension of acetylsalicylic acid (0.1 ml) applied topically to the eye did not 
      markedly reduce conjunctival temperature compared to the control eye, oral 
      administration of 300 mg/kg showed a significant reduction throughout the 
      duration of the experiment. In addition to the anti-inflammatory agent, 
      acetylsalicylic acid, the antihistaminic, antazoline phosphate 0.5% and a 
      vasoconstrictor or decongestant, naphazoline hydrochloride 0.05% were applied 
      individually and in combination (Vasocon-A) locally in the conjunctival sac. Both 
      antazoline phosphate and naphazoline hydrochloride reduced congestion and 
      conjunctival sac temperature while the combination reflected the action of the 
      individual ingredients. The palliative effect of antazoline phosphate indicates 
      that this drug administered topically readily antagonizes histamine in the 
      inflamed eye. There was no corneal anesthesia after instillation of Vasocon-A 
      into the rabbit eye. Antazoline hydrochloride administered in up to 8 times the 
      concentration in Vasocon-A did not induce corneal anesthesia which could be 
      readily obtained with tetracaine hydrochloride.
FAU - Salem, H
AU  - Salem H
FAU - Dunn, B J
AU  - Dunn BJ
FAU - Loux, J J
AU  - Loux JJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Ophthalmol
JT  - Annals of ophthalmology
JID - 0210137
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Imidazoles)
RN  - DHA8014SS1 (Antazoline)
RN  - H231GF11BV (Naphazoline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Administration, Topical
MH  - Animals
MH  - Antazoline/*therapeutic use
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Body Temperature/drug effects
MH  - *Conjunctiva/physiology
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Drug Therapy, Combination
MH  - Edema/chemically induced/drug therapy
MH  - Eye Diseases/chemically induced/*drug therapy
MH  - Hyperemia/chemically induced/drug therapy
MH  - Imidazoles/*therapeutic use
MH  - Male
MH  - Mustard Plant
MH  - Naphazoline/*therapeutic use
MH  - Plants, Medicinal
MH  - Rabbits
EDAT- 1975/06/01 00:00
MHDA- 1975/06/01 00:01
CRDT- 1975/06/01 00:00
PHST- 1975/06/01 00:00 [pubmed]
PHST- 1975/06/01 00:01 [medline]
PHST- 1975/06/01 00:00 [entrez]
PST - ppublish
SO  - Ann Ophthalmol. 1975 Jun;7(6):819-24.

PMID- 525834
OWN - NLM
STAT- MEDLINE
DCOM- 19800324
LR  - 20131121
IS  - 0003-3014 (Print)
IS  - 0003-3014 (Linking)
VI  - 36
IP  - 7-8
DP  - 1979
TI  - [Antiplatelet drugs (author's transl)].
PG  - 283-7
AB  - Acetyl salicylic acid, sulfinpyrazone, dipyridamole, hydroxychloroquine, 
      ticlopidine, clofibrate, nicergoline are the most used antiplatelet drugs. A. S. 
      A. and sulfinpyrazone have been tested in several large scale clinical trials. A. 
      S. A. seems beneficial in the prevention of cerebral ischemia for patients, 
      specially men who have previously had a transient cerebral ischemic attack. 
      Sulfinpyrazone appears to be effective in reducing cardiac deaths during the 
      first year after myocardial infarction.
FAU - Dechavanne, M
AU  - Dechavanne M
FAU - Follea, G
AU  - Follea G
FAU - Trzeciak, M C
AU  - Trzeciak MC
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Les inhibiteurs des fonctions plaquettaires ou anti-agrégants.
PL  - France
TA  - Anesth Analg (Paris)
JT  - Anesthesie, analgesie, reanimation
JID - 0404017
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 64ALC7F90C (Dipyridamole)
RN  - HPN91K7FU3 (Clofibrate)
RN  - JCV8365FWN (Nicergoline)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Clofibrate/pharmacology
MH  - Dipyridamole/pharmacology
MH  - Female
MH  - Humans
MH  - Hydroxychloroquine/pharmacology
MH  - Ischemic Attack, Transient/prevention & control
MH  - Male
MH  - Myocardial Infarction/drug therapy
MH  - Nicergoline/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Sulfinpyrazone/pharmacology/therapeutic use
MH  - Thrombosis/*prevention & control
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Anesth Analg (Paris). 1979;36(7-8):283-7.

PMID- 910388
OWN - NLM
STAT- MEDLINE
DCOM- 19771130
LR  - 20191028
IS  - 0066-0078 (Print)
IS  - 0066-0078 (Linking)
VI  - 23
DP  - 1977
TI  - Treatment of severe drug overdosage with charcoal hemoperfusion.
PG  - 599-605
AB  - Mortality from severe poisoning remains excessively high in patients managed 
      conservatively. In this report, charcoal hemoperfusion was used as a therapeutic 
      aid to active drug removal in 10 patients (9 of whom were in Grade IV coma) 
      intoxicated with a variety of drugs and a further 3 patients poisoned with the 
      highly lethal herbicide, paraquat. All 10 patients who ingested drugs recovered. 
      One of the 3 patients ingesting paraquat survived. The hemoperfusion treatments 
      were associated with demonstrated drug removal. Complications associated with 
      hemoperfusion were minor. Decreases in platelet levels were observed but were not 
      accompanied by clinically important bleeding. The technique of hemoperfusion is 
      simple and provides a therapeutic aid in the care of the severely poisoned 
      patient.
FAU - Gelfand, M C
AU  - Gelfand MC
FAU - Winchester, J F
AU  - Winchester JF
FAU - Knepshield, J H
AU  - Knepshield JH
FAU - Hanson, K M
AU  - Hanson KM
FAU - Cohan, S L
AU  - Cohan SL
FAU - Strauch, B S
AU  - Strauch BS
FAU - Geoly, K L
AU  - Geoly KL
FAU - Kennedy, A C
AU  - Kennedy AC
FAU - Schreiner, G E
AU  - Schreiner GE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Trans Am Soc Artif Intern Organs
JT  - Transactions - American Society for Artificial Internal Organs
JID - 7506088
RN  - 0 (Barbiturates)
RN  - 16291-96-6 (Charcoal)
RN  - C8I4BVN78E (Glutethimide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/blood/poisoning
MH  - Barbiturates/blood/poisoning
MH  - Charcoal
MH  - Female
MH  - Glutethimide/blood/poisoning
MH  - *Hemoperfusion
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Poisoning/*therapy
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1097/00002480-197700230-00160 [doi]
PST - ppublish
SO  - Trans Am Soc Artif Intern Organs. 1977;23:599-605. doi: 
      10.1097/00002480-197700230-00160.

PMID- 25248816
OWN - NLM
STAT- MEDLINE
DCOM- 20160222
LR  - 20220317
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 21
IP  - 5
DP  - 2015 Jul
TI  - Clopidogrel plus aspirin prevents early neurologic deterioration and improves 
      6-month outcome in patients with acute large artery atherosclerosis stroke.
PG  - 453-61
LID - 10.1177/1076029614551823 [doi]
AB  - AIMS: To evaluate the effects of treatments with clopidogrel plus aspirin (dual 
      therapy) on early neurological deterioration (END) and outcomes at 6 months in 
      patients with acute large artery atherosclerosis (LAA) stroke. METHODS: A total 
      of 574 patients with LAA stroke were randomly assigned to receive either dual 
      therapy or aspirin alone (monotherapy). The primary outcome was END. Secondary 
      outcomes included recurrent ischemic stroke (RIS) and outcomes at 6 months. 
      RESULTS: The prevalence of END and RIS was lower in patients on dual therapy than 
      in those on monotherapy during the 30 days. At 6 months, dual therapy improved 
      outcomes among older patients and those with symptomatic stenosis in the 
      posterior circulation and basilar artery. CONCLUSION: Clopidogrel plus aspirin is 
      superior to aspirin alone for reducing END and RIS within 30 days and improves 
      outcomes in certain subgroups at 6 months.
CI  - © The Author(s) 2014.
FAU - Wang, Chun
AU  - Wang C
AD  - Department of Neurology, People's Hospital of Deyang City, Deyang, China.
FAU - Yi, Xingyang
AU  - Yi X
AD  - Department of Neurology, People's Hospital of Deyang City, Deyang, China 
      yixingyang64@126.com.
FAU - Zhang, Biao
AU  - Zhang B
AD  - Department of Neurology, People's Hospital of Deyang City, Deyang, China.
FAU - Liao, Duanxiu
AU  - Liao D
AD  - Department of Neurology, People's Hospital of Deyang City, Deyang, China.
FAU - Lin, Jing
AU  - Lin J
AD  - Department of Neurology, Third Affiliated Hospital of Wenzhou Medical College, 
      Wenzhou, China.
FAU - Chi, Lifen
AU  - Chi L
AD  - Department of Neurology, Third Affiliated Hospital of Wenzhou Medical College, 
      Wenzhou, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20140923
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Atherosclerosis/*drug therapy
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Nervous System Diseases/*prevention & control
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Stroke/*drug therapy
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - acute ischemic stroke
OT  - dual antiplatelet therapy
OT  - early neurological deterioration
OT  - monoantiplatelet therapy
EDAT- 2014/09/25 06:00
MHDA- 2016/02/24 06:00
CRDT- 2014/09/25 06:00
PHST- 2014/09/25 06:00 [entrez]
PHST- 2014/09/25 06:00 [pubmed]
PHST- 2016/02/24 06:00 [medline]
AID - 1076029614551823 [pii]
AID - 10.1177/1076029614551823 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2015 Jul;21(5):453-61. doi: 10.1177/1076029614551823. 
      Epub 2014 Sep 23.

PMID- 15481331
OWN - NLM
STAT- MEDLINE
DCOM- 20050310
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 49
IP  - 9
DP  - 2004 Sep
TI  - Aspirin-induced mucosal cell death in human gastric cells: evidence supporting an 
      apoptotic mechanism.
PG  - 1518-25
AB  - This study was undertaken to define the role that apoptosis may play in inducing 
      cellular injury and death in gastric mucosa exposed to aspirin. Apoptosis was 
      characterized by DNA gel electrophoresis, terminal deoxynucleotidyl transferase 
      dUTP nick-end labeling assay, and DNA-histone-associated complex formation. A 
      human gastric cell line (AGS) was exposed to physiologic concentrations (3 to 50 
      mM) of aspirin. Both time- and concentration-dependent effects on apoptosis were 
      noted, which were effectively prevented by the caspase inhibitor z-VAD-fmk. 
      Accordingly, the role of caspases in aspirin-induced apoptosis was also 
      evaluated. Early activation of caspase-8 and caspase-9 was demonstrated, 
      indicating a role for both receptor and mitochondrial pathways, respectively, in 
      the apoptotic process. Corresponding activation of effector caspases-3, -6, and 
      -7 was also evident, as was cleavage of PARP. We conclude that physiologically 
      relevant concentrations of aspirin induces apoptosis in human gastric cells 
      through a caspase-mediated mechanism.
FAU - Power, Jacinda J
AU  - Power JJ
AD  - Department of Surgery, Medical College of Virginia Campus of Virginia 
      Commonwealth University, Richmond, Virginia 23298, USA.
FAU - Dennis, Miranda S
AU  - Dennis MS
FAU - Redlak, Maria J
AU  - Redlak MJ
FAU - Miller, Thomas A
AU  - Miller TA
LA  - eng
GR  - DK25838/DK/NIDDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (DNA, Neoplasm)
RN  - EC 3.4.22.- (Caspases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/*drug effects/physiology
MH  - Aspirin/*adverse effects/*pharmacology
MH  - Blotting, Western
MH  - Caspases/analysis/*metabolism
MH  - Cell Survival/drug effects
MH  - DNA, Neoplasm/analysis
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/cytology/*drug effects
MH  - Humans
MH  - Sensitivity and Specificity
MH  - Stomach Neoplasms/*pathology
MH  - Tumor Cells, Cultured
EDAT- 2004/10/16 09:00
MHDA- 2005/03/11 09:00
CRDT- 2004/10/16 09:00
PHST- 2004/10/16 09:00 [pubmed]
PHST- 2005/03/11 09:00 [medline]
PHST- 2004/10/16 09:00 [entrez]
AID - 10.1023/b:ddas.0000042258.41480.30 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2004 Sep;49(9):1518-25. doi: 10.1023/b:ddas.0000042258.41480.30.

PMID- 8620177
OWN - NLM
STAT- MEDLINE
DCOM- 19960620
LR  - 20131121
IS  - 0867-7077 (Print)
IS  - 0867-7077 (Linking)
VI  - 63
IP  - 9-10
DP  - 1995
TI  - [The influence of misoprostol on post-aspirin bronchoconstriction in patients 
      with aspirin sensitive asthma].
PG  - 544-52
AB  - It is believed that aspirin (ASA) and other nonsteroidal antiinflammatory drugs 
      elicit dysponea in ASA sensitive asthmatics by blocking the cyclooxygenase. It is 
      unclear whether this bronchospasm is due to shunting of arachidonic acid into the 
      lipooxygenase pathway or removal of cyclooxygenase product which prevent 
      bronchospasm. Diminished tissue concentration of PGE may cause 
      bronchoconstriction. PGE play also modulatory function to mast call decreasing 
      the release of mediators of anaphylaxis. There are some evidences concerning the 
      mast cell degranulation in postaspirin reaction in ASA sensitive asthmatics. The 
      authors investigated the influence of synthetic analogue of PGE1--misoprostol 
      (Cototec, Searle) on the postaspirin bronchoconstriction in seven ASA sensitive 
      asthmatics aged 33-62. Aspirin threshold doses ranged from 10 to 150 mg. 
      Postaspirin bronchoconstriction begun usually within 1-2 hrs after digestion of 
      ASA and 200 micrograms were additionally given 2 h later. Seven days later 
      misoprostol (400 micrograms) was administered together with previously determined 
      dose of ASA. One the other day the bronchodilating effect of misoprostol alone 
      was examined. In all but one patients we observed the protective influence of 
      misoprostol on ASA induced bronchoconstriction. Max. fall in FEV1 in % after ASA 
      in each of the patients was 40, 25, 24, 33, 47 and 54, and after ASA with 
      misoprostol, respectively 10, 9, 4, (+8), 10, (+2) and 45. Misoprostol given 
      together with ASA attenuated aspirin-induced bronchoconstriction reaching 
      statistical significance at 3 and 3.5 h, and also diminished extrapulmonary 
      symptoms. The authors discuss the possible mechanism of protective influence of 
      misoprostol.
FAU - Szmidt, M
AU  - Szmidt M
AD  - II Kliniki Gruźlicy i Chorób Płuc w Lodzi.
FAU - Wasiak, W
AU  - Wasiak W
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Wpływ misoprostolu na poaspirynowe zwezenie oskrzeli chorych na astme z 
      nadwrazliwościa na aspiryne.
PL  - Poland
TA  - Pneumonol Alergol Pol
JT  - Pneumonologia i alergologia polska
JID - 9302892
RN  - 0 (Bronchodilator Agents)
RN  - 0E43V0BB57 (Misoprostol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/antagonists & inhibitors
MH  - Asthma/chemically induced/*drug therapy
MH  - Bronchoconstriction/drug effects
MH  - Bronchodilator Agents/*pharmacology/therapeutic use
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Misoprostol/*pharmacology/therapeutic use
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Pneumonol Alergol Pol. 1995;63(9-10):544-52.

PMID- 1972487
OWN - NLM
STAT- MEDLINE
DCOM- 19900726
LR  - 20190610
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 335
IP  - 8705
DP  - 1990 Jun 30
TI  - Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced 
      hypertension.
PG  - 1552-5
AB  - Screening of 1226 nulliparous women by means of doppler uteroplacental 
      flow-velocity waveforms in early pregnancy identified 148 (12%) as being at high 
      risk of pregnancy-induced hypertension. After exclusions and refusals, 100 women 
      were randomly allocated to groups receiving either low-dose aspirin (75 mg daily; 
      48 patients) or identical placebo (52 patients) for the remainder of the 
      pregnancy. The difference between the aspirin and placebo groups in the frequency 
      of pregnancy-induced hypertension (13% vs 25%) did not achieve significance, but 
      there were significant differences in the frequencies of proteinuric hypertension 
      (2% vs 19%) and hypertension occurring before 37 weeks' gestation (0% vs 17%). 
      Fewer aspirin-treated than placebo-treated women had low birthweight babies (15% 
      vs 25%), but this difference was not significant. The only perinatal death in the 
      aspirin group followed a cord accident during labour, whereas the 3 perinatal 
      deaths in the placebo group were all due to severe hypertensive disease. No 
      maternal or neonatal side-effects were observed in either group.
FAU - McParland, P
AU  - McParland P
AD  - Department of Obstetrics and Gynaecology, St George's Hospital Medical School, 
      London, UK.
FAU - Pearce, J M
AU  - Pearce JM
FAU - Chamberlain, G V
AU  - Chamberlain GV
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Tablets)
RN  - 0 (Thromboxanes)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Drug Administration Schedule
MH  - Drug Evaluation
MH  - Epoprostenol/antagonists & inhibitors
MH  - Female
MH  - Humans
MH  - Hypertension/*prevention & control
MH  - Infant, Low Birth Weight
MH  - Infant, Newborn
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*prevention & control
MH  - Pregnancy Trimester, Second
MH  - Proteinuria/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Tablets
MH  - Thromboxanes/antagonists & inhibitors
MH  - *Ultrasonography
EDAT- 1990/06/30 00:00
MHDA- 1990/06/30 00:01
CRDT- 1990/06/30 00:00
PHST- 1990/06/30 00:00 [pubmed]
PHST- 1990/06/30 00:01 [medline]
PHST- 1990/06/30 00:00 [entrez]
AID - 0140-6736(90)91377-M [pii]
AID - 10.1016/0140-6736(90)91377-m [doi]
PST - ppublish
SO  - Lancet. 1990 Jun 30;335(8705):1552-5. doi: 10.1016/0140-6736(90)91377-m.

PMID- 25163307
OWN - NLM
STAT- MEDLINE
DCOM- 20141017
LR  - 20140828
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 72
IP  - 7
DP  - 2014 Jul
TI  - [Historical and future perspective of antithrombotic agents].
PG  - 1193-7
AB  - Antithrombotic agents including antiplatelet and anticoagulant ones are effective 
      in prevention of thrombotic diseases such as myocardial infarction, ischemic 
      stroke, and venous thrombosis. Aspirin is the most commonly used antiplatelet 
      agent, which has strong evidence to prevent cardiovascular death in patients with 
      acute myocardial infarction. Clopidogrel is also commonly used antiplatelet 
      agents, which is now known to block P2Y12 ADP receptor. New generation of P2Y12 
      ADP antagonists including prasugrel and ticagrelor are available, but only in 
      patients with acute coronary syndrome. We have used warfarin for more than 50 
      years. Warfarin is a potent anticoagulant agent to prevent functional completion 
      of vitamin K dependent coagulant factors. New generation of oral anticoagulants 
      were developed, but some were shown not to strong enough in prevention of 
      thrombotic complication in patients with artificial valve. All antithrombotic 
      agents have limitations. Most important limitation is to increase the incidence 
      of serious bleeding complication. Future progress of our understanding for the 
      mechanisms of the onset of thrombotic diseases is essentially important to 
      develop better antithrombotic agents.
FAU - Goto, Shinya
AU  - Goto S
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thrombosis/*drug therapy
MH  - Treatment Outcome
MH  - Warfarin/*therapeutic use
EDAT- 2014/08/29 06:00
MHDA- 2014/10/18 06:00
CRDT- 2014/08/29 06:00
PHST- 2014/08/29 06:00 [entrez]
PHST- 2014/08/29 06:00 [pubmed]
PHST- 2014/10/18 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2014 Jul;72(7):1193-7.

PMID- 12403957
OWN - NLM
STAT- MEDLINE
DCOM- 20030103
LR  - 20171101
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 14
IP  - 3-4
DP  - 2002
TI  - Effects of dipyridamole and aspirin on shear-induced platelet aggregation in 
      whole blood and platelet-rich plasma.
PG  - 234-8
AB  - BACKGROUND: Shear-induced platelet aggregation (SIPA) is an important mechanism 
      of thrombosis at arterial bifurcations or stenotic lesions. METHODS: We 
      investigated the in vitro effects of dipyridamole (DP) and acetylsalicyclic acid 
      (ASA) on SIPA in whole blood and platelet-rich plasma (PRP). RESULTS: In whole 
      blood, DP 20 microM significantly inhibited SIPA, while DP 5 microM or ASA 5 or 
      20 microM did not. SIPA in whole blood was, however, significantly inhibited by 
      the combination of 5 or 20 microM of DP and ASA. SIPA in PRP was not inhibited by 
      any concentration of DP or ASA, alone or in combination. CONCLUSIONS: These 
      results suggest that DP has an effect on red blood cells and that ASA enhances 
      the inhibitory effect of DP on SIPA in whole blood. These effects may be related 
      to the additive effect of combination therapy with DP and ASA on stroke 
      prevention.
CI  - Copyright 2002 S. Karger AG, Basel
FAU - Nakamura, T
AU  - Nakamura T
AD  - Department of Neurology, Neurological Institute, Tokyo Women's Medical 
      University, Tokyo, Japan. tnakamur@nij.twmu.ac.jp
FAU - Uchiyama, S
AU  - Uchiyama S
FAU - Yamazaki, M
AU  - Yamazaki M
FAU - Iwata, M
AU  - Iwata M
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 94ZLA3W45F (Arginine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arginine/pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood/drug effects
MH  - Dipyridamole/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Stress, Mechanical
EDAT- 2002/10/31 04:00
MHDA- 2003/01/07 04:00
CRDT- 2002/10/31 04:00
PHST- 2002/10/31 04:00 [pubmed]
PHST- 2003/01/07 04:00 [medline]
PHST- 2002/10/31 04:00 [entrez]
AID - 65669 [pii]
AID - 10.1159/000065669 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2002;14(3-4):234-8. doi: 10.1159/000065669.

PMID- 25366148
OWN - NLM
STAT- MEDLINE
DCOM- 20150703
LR  - 20220310
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 60
IP  - 4
DP  - 2015 Apr
TI  - Low-Dose Aspirin and Non-steroidal Anti-inflammatory Drugs Increase the Risk of 
      Bleeding in Patients with Gastroduodenal Ulcer.
PG  - 1010-5
LID - 10.1007/s10620-014-3415-9 [doi]
AB  - BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs), low-dose aspirin 
      (LDA), non-aspirin antiplatelet medications (APs), and anticoagulant medications 
      (ACs) increase the risk of gastrointestinal bleeding. AIM: To examine whether 
      NSAIDs, LDA, APs, and ACs use is associated with bleeding from gastroduodenal 
      ulcers. METHODS: This was a case-control study of patients with endoscopically 
      verified gastroduodenal ulcer diagnosed at our institution from 2004 to 2011. 
      Among 1,611 patients, we identified those who required endoscopic hemostasis for 
      bleeding ulcers as cases. Age-matched, sex-matched, and Helicobacter pylori 
      status-matched patients who did not require therapeutic interventions served as 
      controls. Use of NSAIDs, LDA, APs, and ACs within 2 weeks prior to the endoscopy 
      was compared between cases and controls, and effects on ulcer bleeding were 
      calculated. RESULTS: We recruited 341 cases and 668 controls. The site and number 
      of ulcers were not different between groups. Multivariate analyses revealed that 
      LDA and NSAIDs, individually, were associated with the increase in the risk of 
      bleeding (OR 1.80 and 95 % CI 1.18-2.75 for LDA; 1.35 and 1.01-1.80 for NSAIDs). 
      In addition, a combination of LDA and NSAIDs or LDA and APs contributed more 
      profoundly to the bleeding (OR 3.59 and 95 % CI 1.19-10.81 for LDA/NSAIDs; OR 
      6.70 and 95 % CI 1.83-24.50 for LDA/APs). However, ACs, alone or in combination, 
      were not associated with bleeding ulcers. CONCLUSIONS: Both LDA and NSAIDs are 
      risk factors for upper GI bleeding in patients with gastroduodenal ulcer, while 
      ACs are unrelated to the increased risk. The risk of bleeding with LDA may 
      increase with simultaneous use of APs.
FAU - Kawasaki, Keisuke
AU  - Kawasaki K
AD  - Division of Gastroenterology, Department of Internal Medicine, Iwate Medical 
      University, 19-1, Uchimaru, Morioka, 020-8505, Japan, kkeisuke@iwate-med.ac.jp.
FAU - Kurahara, Koichi
AU  - Kurahara K
FAU - Yanai, Shunichi
AU  - Yanai S
FAU - Kochi, Shuji
AU  - Kochi S
FAU - Fuchigami, Tadahiko
AU  - Fuchigami T
FAU - Matsumoto, Takayuki
AU  - Matsumoto T
LA  - eng
PT  - Journal Article
DEP - 20141101
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Anticoagulants/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*complications
MH  - Platelet Aggregation Inhibitors/*adverse effects
EDAT- 2014/11/05 06:00
MHDA- 2015/07/04 06:00
CRDT- 2014/11/05 06:00
PHST- 2014/09/24 00:00 [received]
PHST- 2014/10/24 00:00 [accepted]
PHST- 2014/11/05 06:00 [entrez]
PHST- 2014/11/05 06:00 [pubmed]
PHST- 2015/07/04 06:00 [medline]
AID - 10.1007/s10620-014-3415-9 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2015 Apr;60(4):1010-5. doi: 10.1007/s10620-014-3415-9. Epub 2014 Nov 
      1.

PMID- 16599001
OWN - NLM
STAT- MEDLINE
DCOM- 20060418
LR  - 20220316
IS  - 0003-9896 (Print)
IS  - 0003-9896 (Linking)
VI  - 59
IP  - 11
DP  - 2004 Nov
TI  - The effect of alcohol, tobacco, and aspirin consumption on seminal quality among 
      healthy young men.
PG  - 548-52
AB  - In this study, the authors examined the effects of alcohol, tobacco, and drug use 
      on plasma testosterone and seminal parameters (in accordance with the World 
      Health Organization's standards) in healthy Argentine medical students (n = 34). 
      Some alterations in seminal parameters were detected in 19 (56%) subjects. 
      Alcohol and tobacco use were correlated significantly, p = 0.005; subjects who 
      used these substances exhibited a nonsignificant reduction in sperm 
      concentration, motility, viability, and normal morphology. There was a 
      significant decrease in sperm motility among students who used moderate amounts 
      of aspirin (i.e., > or = 500 mg/wk). The authors concluded that alcohol, tobacco, 
      and aspirin use could have had detrimental effects on seminal parameters and that 
      men who wish to procreate should be warned of such effects. Doses, exposure time, 
      and interactions with other variables deserve additional study.
FAU - Stutz, Graciela
AU  - Stutz G
AD  - Institute of Physiology, Medical School, National University of Córdoba, 
      Argentina. gstutz42@hotmail.com
FAU - Zamudio, Javier
AU  - Zamudio J
FAU - Santillán, Maria Emilia
AU  - Santillán ME
FAU - Vincenti, Laura
AU  - Vincenti L
FAU - de Cuneo, Marta Fiol
AU  - de Cuneo MF
FAU - Ruiz, Rubin Daniel
AU  - Ruiz RD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Environ Health
JT  - Archives of environmental health
JID - 0212627
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 3XMK78S47O (Testosterone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Alcohol Drinking/*adverse effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Humans
MH  - Infertility, Male/etiology
MH  - Male
MH  - Smoking/*adverse effects
MH  - *Sperm Count
MH  - *Sperm Motility
MH  - Students, Medical
MH  - Testosterone/blood
EDAT- 2006/04/08 09:00
MHDA- 2006/04/19 09:00
CRDT- 2006/04/08 09:00
PHST- 2006/04/08 09:00 [pubmed]
PHST- 2006/04/19 09:00 [medline]
PHST- 2006/04/08 09:00 [entrez]
AID - 10.1080/00039890409603432 [doi]
PST - ppublish
SO  - Arch Environ Health. 2004 Nov;59(11):548-52. doi: 10.1080/00039890409603432.

PMID- 6232035
OWN - NLM
STAT- MEDLINE
DCOM- 19840607
LR  - 20190511
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 35
IP  - 5
DP  - 1984 May
TI  - Etodolac, aspirin, and gastrointestinal microbleeding.
PG  - 716-21
AB  - The effects of etodolac, a new nonsteroidal anti-inflammatory drug, on 
      gastrointestinal (GI) microbleeding were quantitatively assessed in two studies 
      in healthy adult men. The first was a two-group, open-label, parallel comparison 
      of etodolac, 600 mg/day, aspirin, 2600 mg/day, and placebo in 20 subjects; the 
      second was a four-group, double-blind, parallel comparison of etodolac, 600, 800, 
      and 1200 mg/day, aspirin, 2600 mg/day, and placebo in 41 subjects. Subjects in 
      both studies received a single-blind placebo on days 1 through 7, either etodolac 
      or aspirin on days 8 through 14, and a single-blind placebo on days 15 through 
      19. GI blood loss (milliliters per day) was estimated by the radiolabeled (51Cr) 
      erythrocyte method and was based on daily radioactivity counts of stool specimens 
      and regression-estimated daily blood radioactivity. Etodolac, 600 mg/day, induced 
      no significant GI blood loss at any time during the experiments, nor was there 
      significant blood loss after 800 and 1200 mg/day in experiment 2. Blood loss was 
      noted after aspirin in both.
FAU - Arnold, J D
AU  - Arnold JD
FAU - Mullane, J F
AU  - Mullane JF
FAU - Hayden, D M
AU  - Hayden DM
FAU - March, L
AU  - March L
FAU - Hart, K
AU  - Hart K
FAU - Perdomo, C A
AU  - Perdomo CA
FAU - Fencik, M
AU  - Fencik M
FAU - Berger, A E
AU  - Berger AE
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Acetates)
RN  - 2M36281008 (Etodolac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/*pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation
MH  - Etodolac
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Occult Blood
MH  - Random Allocation
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
AID - 10.1038/clpt.1984.100 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1984 May;35(5):716-21. doi: 10.1038/clpt.1984.100.

PMID- 8735826
OWN - NLM
STAT- MEDLINE
DCOM- 19961216
LR  - 20190914
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 7
IP  - 2
DP  - 1996 Mar
TI  - High shear-induced platelet activation and inactivation: the importance of 
      methodology.
PG  - 228-32
AB  - High shear platelet activation may be conveniently studied by forcing blood 
      through a fine filter in the filterometer. To achieve haemostasis in vivo 
      platelets are activated. When haemostasis is achieved, inactivation must follow. 
      In the filterometer, activation occurs with filter blocking (first phase) and 
      after 100s inactivation ('rebleeding') may occur (second phase). We report the 
      effect of different pressures, temperatures, incubation times, anticoagulants and 
      aspirin in this system. Most 'rebleeding' occurred in citrate, followed by native 
      blood, r-hirudin and low-molecular-weight heparin. Unfractionated heparin 
      inhibited 'rebleeding' whereas aspirin potentiated it. These and other findings 
      are technically and clinically relevant and contribute to an understanding of the 
      mechanisms involved in 'rebleeding' and hence perhaps in thrombogenesis.
FAU - O'Brien, J R
AU  - O'Brien JR
AD  - Haematology Research Department, St Mary's Hospital, Portsmouth, UK.
FAU - Etherington, M D
AU  - Etherington MD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Anticoagulants)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Anticoagulants/pharmacology
MH  - Aspirin/pharmacology
MH  - Hemorheology
MH  - Hot Temperature
MH  - Humans
MH  - *Platelet Activation
MH  - Platelet Function Tests/*methods
MH  - Pressure
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
AID - 10.1097/00001721-199603000-00030 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 1996 Mar;7(2):228-32. doi: 
      10.1097/00001721-199603000-00030.

PMID- 34326051
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210820
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 11
IP  - 7
DP  - 2021 Jul 29
TI  - Impact of aspirin use on clinical outcomes in patients with vasospastic angina: a 
      systematic review and meta-analysis.
PG  - e048719
LID - 10.1136/bmjopen-2021-048719 [doi]
LID - e048719
AB  - OBJECTIVES: The use of aspirin to prevent cardiovascular disease in vasospastic 
      angina (VSA) patients without significant stenosis has yet to be investigated. 
      This study aimed to investigate the efficacy of aspirin use among VSA patients. 
      DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Web of Science 
      and Cochrane Central Register of Controlled Trials were searched for relevant 
      information prior to October 2020. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: 
      Aspirin use versus no aspirin use (placebo or no treatment) among VSA patients 
      without significant stenosis. DATA EXTRACTION AND SYNTHESIS: Two investigators 
      extracted the study data. ORs and 95% CIs were calculated and graphed as forest 
      plots. The Newcastle-Ottawa Quality Assessment Scale tool and Begg's funnel plot 
      were used to assess risk of bias. RESULTS: Four propensity-matched cohorts, one 
      retrospective analysis and one prospective multicentre cohort, in total 
      comprising 3661 patients (aspirin use group, n=1695; no aspirin use group, 
      n=1966) were included in this meta-analysis. Aspirin use and the incidence of 
      major cardiovascular adverse events with follow-up of 1-5 years were not 
      significantly correlated (combined OR=0.90, 95% CI: 0.55 to 1.68, p=0.829, 
      I(2)=82.2%; subgroup analysis: OR=1.09, 95% CI: 0.81 to 1.47, I(2)=0%). No 
      significant difference was found between aspirin use and the incidence of 
      myocardial infarction (OR=0.62, 95% CI: 0.09 to 4.36, p=0.615, I(2)=73.8%) or 
      cardiac death (OR=1.73, 95% CI: 0.61 to 4.94, p=0.444, I(2)=0%) during follow-up. 
      CONCLUSION: Aspirin use may not reduce the risk of future cardiovascular events 
      in VSA patients without significant stenosis. PROSPERO REGISTRATION NUMBER: 
      CRD42020214891.
CI  - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lin, Yaowang
AU  - Lin Y
AUID- ORCID: 0000-0002-4075-4259
AD  - Department of Cardiology, Shenzhen Cardiovascular Minimally Invasive Medical 
      Engineering Technology Research and Development Center, Shenzhen People's 
      Hospital, Second Clinical Medical College of Jinan University, First affiliated 
      Hospital of South University of Science and Technology, Shenzhen, China.
FAU - Chen, Yang
AU  - Chen Y
AD  - School of Pharmacy, Guangdong Medical University, Dongguan 523808, Guangdong, 
      China.
FAU - Yuan, Jie
AU  - Yuan J
AD  - Department of Cardiology, Shenzhen Cardiovascular Minimally Invasive Medical 
      Engineering Technology Research and Development Center, Shenzhen People's 
      Hospital, Second Clinical Medical College of Jinan University, First affiliated 
      Hospital of South University of Science and Technology, Shenzhen, China.
FAU - Qin, Haiyan
AU  - Qin H
AUID- ORCID: 0000-0002-1057-4003
AD  - Department of Health Management, Shenzhen People's Hospital, Second Clinical 
      Medical College of Jinan University, First affiliated Hospital of South 
      University of Science and Technology, Shenzhen, China.
FAU - Dong, Shaohong
AU  - Dong S
AD  - Department of Cardiology, Shenzhen Cardiovascular Minimally Invasive Medical 
      Engineering Technology Research and Development Center, Shenzhen People's 
      Hospital, Second Clinical Medical College of Jinan University, First affiliated 
      Hospital of South University of Science and Technology, Shenzhen, China 
      xnkdsh@yeah.net szchenqiuling@126.com.
FAU - Chen, Qiuling
AU  - Chen Q
AUID- ORCID: 0000-0003-0565-8082
AD  - Department of Pharmacy, Shenzhen People's Hospital, Second Clinical Medical 
      College of Jinan University, First affiliated Hospital of South University of 
      Science and Technology, Shenzhen, China xnkdsh@yeah.net szchenqiuling@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20210729
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Coronary Vasospasm/drug therapy/prevention & control
MH  - Humans
MH  - *Myocardial Infarction
MH  - Prospective Studies
MH  - Retrospective Studies
PMC - PMC8323370
OTO - NOTNLM
OT  - coronary heart disease
OT  - myocardial infarction
OT  - vascular medicine
COIS- Competing interests: None declared.
EDAT- 2021/07/31 06:00
MHDA- 2021/08/05 06:00
CRDT- 2021/07/30 05:48
PHST- 2021/07/30 05:48 [entrez]
PHST- 2021/07/31 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
AID - bmjopen-2021-048719 [pii]
AID - 10.1136/bmjopen-2021-048719 [doi]
PST - epublish
SO  - BMJ Open. 2021 Jul 29;11(7):e048719. doi: 10.1136/bmjopen-2021-048719.

PMID- 24254886
OWN - NLM
STAT- MEDLINE
DCOM- 20140930
LR  - 20140122
IS  - 1941-7705 (Electronic)
IS  - 1941-7713 (Linking)
VI  - 7
IP  - 1
DP  - 2014 Jan
TI  - Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary 
      cardiovascular prevention: a population-based, nested case-control study.
PG  - 70-7
LID - 10.1161/CIRCOUTCOMES.113.000494 [doi]
AB  - BACKGROUND: The benefit-risk profile of low-dose aspirin in primary prevention of 
      cardiovascular disease is unclear. We sought to quantify upper gastrointestinal 
      bleeding (UGIB) risk associated with low-dose aspirin in secondary versus primary 
      prevention patients. METHODS AND RESULTS: We performed a population-based nested 
      case-control study using The Health Improvement Network (THIN) Database between 
      2000 and 2007. We identified 2049 cases of UGIB and 20,000 controls, 
      frequency-matched to the cases on age, sex, and calendar year, who were 
      subdivided into primary (without previous cardiovascular disease) and secondary 
      (with previous cardiovascular disease) prevention populations. We estimated the 
      relative risk of UGIB associated with the use of low-dose aspirin by multivariate 
      logistic regression. The UGIB risk in patients taking low-dose aspirin relative 
      to nonusers was significantly higher in the primary (adjusted relative risk, 
      1.90; 95% confidence interval, 1.59-2.26) than in the secondary (relative risk, 
      1.40; 95% confidence interval, 1.14-1.72; P value for the difference=0.0014) 
      prevention cohort. However, as the baseline risk of UGIB was lower in the primary 
      than in the secondary prevention cohort, numbers needed to harm per 1 year of 
      low-dose aspirin use were 601 and 391 for primary and secondary prevention, 
      respectively. CONCLUSIONS: The relative risk of UGIB in patients taking low-dose 
      aspirin is higher when used for primary than for secondary cardiovascular disease 
      prevention, but this difference is more than compensated by the lower baseline 
      risk in the primary prevention population. Such estimates are important for an 
      assessment of the net clinical benefit in primary prevention.
FAU - Lin, Kueiyu Joshua
AU  - Lin KJ
AD  - Department of Epidemiology, Harvard School of Public Health, Boston, MA.
FAU - De Caterina, Raffaele
AU  - De Caterina R
FAU - García Rodríguez, Luis A
AU  - García Rodríguez LA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131119
PL  - United States
TA  - Circ Cardiovasc Qual Outcomes
JT  - Circulation. Cardiovascular quality and outcomes
JID - 101489148
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Case-Control Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Hemorrhage/*epidemiology/etiology
MH  - Humans
MH  - Incidence
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - *Primary Prevention
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Secondary Prevention
MH  - Treatment Outcome
OTO - NOTNLM
OT  - angina unstable
OT  - aspirin
OT  - myocardial infarction
OT  - peripheral arterial disease
EDAT- 2013/11/21 06:00
MHDA- 2014/10/01 06:00
CRDT- 2013/11/21 06:00
PHST- 2013/11/21 06:00 [entrez]
PHST- 2013/11/21 06:00 [pubmed]
PHST- 2014/10/01 06:00 [medline]
AID - CIRCOUTCOMES.113.000494 [pii]
AID - 10.1161/CIRCOUTCOMES.113.000494 [doi]
PST - ppublish
SO  - Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):70-7. doi: 
      10.1161/CIRCOUTCOMES.113.000494. Epub 2013 Nov 19.

PMID- 37218252
OWN - NLM
STAT- MEDLINE
DCOM- 20230524
LR  - 20230524
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 73
IP  - 5
DP  - 2023 May
TI  - The Diabetic Platelets.
PG  - 1130-1133
LID - 10.47391/JPMA.23-34 [doi]
AB  - This communication describes the platelet morphology and physiology noted in 
      persons with diabetes and its complications. It reviews the effects of glucose 
      lowering drugs on platelet function, and summarizes the role of anti-platelet 
      drugs in diabetes management.
FAU - Verma, Suneet Kumar
AU  - Verma SK
AD  - Department of Internal Medicine, Alchemist Hospital, Panchkula, India; Sparsh 
      Clinic, Panchkula.
FAU - Kalra, Sanjay
AU  - Kalra S
AD  - Department of Endocrinology, Bharti Hospital, Karnal, India; University Center 
      for Research & Development, Chandigarh University, Mohali, India.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
RN  - R16CO5Y76E (Aspirin)
RN  - IY9XDZ35W2 (Glucose)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - Aspirin/pharmacology
MH  - Platelet Aggregation
MH  - Blood Platelets
MH  - *Diabetes Mellitus/drug therapy
MH  - Glucose/pharmacology
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Diabetes Mellitus, Type 2/complications
OTO - NOTNLM
OT  - Anaemia, aspirin, aspirin resistance, blood, dengue, haematology, hyperglycaemia, 
      platelet.
EDAT- 2023/05/23 06:42
MHDA- 2023/05/24 06:42
CRDT- 2023/05/23 03:40
PHST- 2023/05/24 06:42 [medline]
PHST- 2023/05/23 06:42 [pubmed]
PHST- 2023/05/23 03:40 [entrez]
AID - 12038 [pii]
AID - 10.47391/JPMA.23-34 [doi]
PST - ppublish
SO  - J Pak Med Assoc. 2023 May;73(5):1130-1133. doi: 10.47391/JPMA.23-34.

PMID- 7354422
OWN - NLM
STAT- MEDLINE
DCOM- 19800417
LR  - 20201209
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 69
IP  - 1
DP  - 1980 Jan
TI  - Simultaneous quantitation of acetaminophen, aspirin, caffeine, codeine phosphate, 
      phenacetin, and salicylamide by high-pressure liquid chromatography.
PG  - 110-3
AB  - A method for the simultaneous quantitation of acetaminophen, aspirin, caffeine, 
      codeine phosphate, phenacetin, and salicylamide was developed. The method is 
      based on reversed-phase high-pressure liquid chromatography with a mobile phase 
      buffered with phosphate (pH 2.3). The procedure not only separated these six 
      active ingredients but also salicylic acid, the major decomposition product of 
      aspirin. The method gave excellent results for three commercial products and a 
      synthetic mixture containing four active ingredients. Lowering the pH increased 
      the retention time of some weak acids and decreased that of some weak bases. Only 
      these changes in the retention times made the separation possible.
FAU - Das Gupta, V
AU  - Das Gupta V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylamides)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Chromatography, High Pressure Liquid
MH  - Codeine/*analysis
MH  - Phenacetin/*analysis
MH  - Salicylamides/*analysis
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - S0022-3549(15)43019-9 [pii]
AID - 10.1002/jps.2600690136 [doi]
PST - ppublish
SO  - J Pharm Sci. 1980 Jan;69(1):110-3. doi: 10.1002/jps.2600690136.

PMID- 17903525
OWN - NLM
STAT- MEDLINE
DCOM- 20071108
LR  - 20171116
IS  - 1097-685X (Electronic)
IS  - 0022-5223 (Linking)
VI  - 134
IP  - 4
DP  - 2007 Oct
TI  - Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig 
      model of saphenous vein-carotid artery interposition grafting: a comparison with 
      aspirin and morpholinosydnonimine (SIN-1).
PG  - 1033-9
AB  - OBJECTIVE: Despite its proven value in reducing thrombotic complications in 
      patients undergoing coronary artery bypass graft surgery, aspirin does not reduce 
      the incidence of late vein graft failure. It was suggested, therefore, that 
      co-administration of nitric oxide with aspirin may compensate for these 
      limitations. A drug class that fulfills this pharmacologic criterion is nitric 
      oxide-donating aspirin (NCX 4016). METHODS: The effect of administration of the 
      aspirin-nitric oxide adduct, NCX 4016, compared with those of aspirin alone and 
      the nitric oxide donor, morpholinosydnonimine, alone (once daily for 1 month) on 
      thickening of saphenous vein-carotid artery interposition grafts was 
      investigated. RESULTS: NCX 4016, at 10 mg, 30 mg, and 60 mg x kg(-1) x d(-1), 
      inhibited neointimal thickness and area in porcine vein grafts. Aspirin alone (60 
      mg x kg(-1) x d(-1)) and morpholinosydnonimine alone (1 mg x kg(-1) x d(-1)), 
      also inhibited neointimal thickness and neointimal area, although they were less 
      potent than NCX 4016. At 30 mg x kg(-1) x d(-1), aspirin had no effect. Compared 
      with untreated controls, NCX 4016 had little effect on medial thickness or area 
      at 10 mg/kg or 30 mg x kg(-1) x d(-1) but had a significant effect at 60 mg x 
      kg(-1) x d(-1). Aspirin alone and morpholinosydnonimine alone also inhibited 
      medial thickness and area. NCX 4016 at 60 mg x kg(-1) x d(-1) and aspirin at 60 
      mg x kg(-1) x d(-1) increased luminal area. CONCLUSIONS: The range of properties 
      displayed by NCX 4016 (inhibition of neointima formation, gastroprotection, 
      antithrombotic and antiatherogenic effects) renders them potentially useful in 
      treating both early and late vein graft failure and indicates that a clinical 
      study on this novel drug class in patients undergoing coronary bypass grafting is 
      warranted.
FAU - Wan, Song
AU  - Wan S
AD  - Department of Surgery, Prince of Wales Hospital, Chinese University of Hong Kong, 
      Hong Kong, China.
FAU - Shukla, Nilima
AU  - Shukla N
FAU - Angelini, Gianni D
AU  - Angelini GD
FAU - Yim, Anthony P C
AU  - Yim AP
FAU - Johnson, Jason L
AU  - Johnson JL
FAU - Jeremy, Jamie Y
AU  - Jeremy JY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Nitric Oxide Donors)
RN  - 5O5U71P6VQ (linsidomine)
RN  - D46583G77X (Molsidomine)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Analysis of Variance
MH  - Anastomosis, Surgical
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Carotid Arteries/drug effects/pathology/*transplantation
MH  - Dose-Response Relationship, Drug
MH  - Graft Occlusion, Vascular/prevention & control
MH  - Male
MH  - Molsidomine/*analogs & derivatives/pharmacology
MH  - Nitric Oxide Donors/*pharmacology
MH  - Saphenous Vein/drug effects/pathology/*transplantation
MH  - Statistics, Nonparametric
MH  - Swine
MH  - Tunica Intima/*drug effects/pathology
EDAT- 2007/10/02 09:00
MHDA- 2007/11/09 09:00
CRDT- 2007/10/02 09:00
PHST- 2007/04/18 00:00 [received]
PHST- 2007/06/12 00:00 [revised]
PHST- 2007/06/15 00:00 [accepted]
PHST- 2007/10/02 09:00 [pubmed]
PHST- 2007/11/09 09:00 [medline]
PHST- 2007/10/02 09:00 [entrez]
AID - S0022-5223(07)01098-7 [pii]
AID - 10.1016/j.jtcvs.2007.06.017 [doi]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 2007 Oct;134(4):1033-9. doi: 
      10.1016/j.jtcvs.2007.06.017.

PMID- 9151061
OWN - NLM
STAT- MEDLINE
DCOM- 19970722
LR  - 20190512
IS  - 1010-7940 (Print)
IS  - 1010-7940 (Linking)
VI  - 11
IP  - 4
DP  - 1997 Apr
TI  - The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for 
      prevention of mediastinal bleeding in patients receiving aspirin before coronary 
      artery bypass operations.
PG  - 798-800
AB  - Patients undergoing primary myocardial revascularization were randomized to one 
      of three drug regimens (low-dose aprotinin, epsilon-aminocaproic Acid or 
      tranexamic Acid) to determine which drug regimen would most effectively reduce 
      post-operative bleeding and the need for blood products. All patients had 
      received 325 mg of aspirin within 48 h before operation. All three drug regimens 
      reduced the requirements for blood products and postoperative bleeding after 
      coronary artery bypass operations. There was, however, no significant difference 
      between drug regimens.
FAU - Landymore, R W
AU  - Landymore RW
FAU - Murphy, J T
AU  - Murphy JT
FAU - Lummis, H
AU  - Lummis H
FAU - Carter, C
AU  - Carter C
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Letter
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European 
      Association for Cardio-thoracic Surgery
JID - 8804069
RN  - 0 (Antifibrinolytic Agents)
RN  - 6T84R30KC1 (Tranexamic Acid)
RN  - 9087-70-1 (Aprotinin)
RN  - R16CO5Y76E (Aspirin)
RN  - U6F3787206 (Aminocaproic Acid)
SB  - IM
MH  - Aminocaproic Acid/*administration & dosage
MH  - Antifibrinolytic Agents/*administration & dosage
MH  - Aprotinin/*administration & dosage
MH  - Aspirin/administration & dosage/*adverse effects
MH  - *Coronary Artery Bypass
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Postoperative Hemorrhage/blood/*prevention & control
MH  - Tranexamic Acid/*administration & dosage
MH  - Treatment Outcome
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - S1010794096011268 [pii]
AID - 10.1016/s1010-7940(96)01126-8 [doi]
PST - ppublish
SO  - Eur J Cardiothorac Surg. 1997 Apr;11(4):798-800. doi: 
      10.1016/s1010-7940(96)01126-8.

PMID- 3360054
OWN - NLM
STAT- MEDLINE
DCOM- 19880531
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 34
IP  - 1
DP  - 1988
TI  - Drug use before hospital admission in Zimbabwe.
PG  - 87-90
AB  - Drug use before hospital admission was studied prospectively in 284 consecutive 
      patients admitted to general medical wards in Zimbabwe. Drugs were used by 84% of 
      patients. Self-medication was used by 143 (50%) patients, aspirin (54%) and 
      chloroquine (17%) being the most commonly used drugs. Traditional medicines were 
      used by 55 (19%) patients. Drugs dispensed from orthodox medical sources were 
      taken by 128 (45%) patients. Analgesics (22%), antibiotics (18%), and chloroquine 
      (13%) were the commonest drugs dispensed. Urine screening tests were performed 
      and were positive for aspirin in 37% of cases, chloroquine (33%), and antibiotics 
      (20%). Adverse drug reactions requiring hospital admission occurred in 14 
      patients (10 orthodox medicines, 4 traditional medicines). Drug use before 
      hospital admission, which is often poorly documented, is a source of potential 
      drug toxicity and may obscure a diagnosis of infective illness.
FAU - Taylor, H G
AU  - Taylor HG
AD  - Mpilo Hospital, Bulawayo, Zimbabwe.
FAU - Stein, C M
AU  - Stein CM
FAU - Jongeling, G
AU  - Jongeling G
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Analgesics)
RN  - 0 (Anti-Bacterial Agents)
RN  - 886U3H6UFF (Chloroquine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/therapeutic use/urine
MH  - Anti-Bacterial Agents/therapeutic use/urine
MH  - Aspirin/therapeutic use/urine
MH  - Chloroquine/therapeutic use/urine
MH  - *Drug Therapy
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Female
MH  - *Hospitalization
MH  - Humans
MH  - Male
MH  - Medicine, Traditional
MH  - Prospective Studies
MH  - *Self Medication
MH  - Time Factors
MH  - Zimbabwe
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.1007/BF01061424 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1988;34(1):87-90. doi: 10.1007/BF01061424.

PMID- 19214910
OWN - NLM
STAT- MEDLINE
DCOM- 20090428
LR  - 20131121
IS  - 1098-9064 (Electronic)
IS  - 0094-6176 (Linking)
VI  - 34
IP  - 8
DP  - 2008 Nov
TI  - Clinical utility of the PFA-100.
PG  - 709-33
LID - 10.1055/s-0029-1145254 [doi]
AB  - The PFA-100 (platelet function analyzer) is a relatively new tool for the 
      investigation of primary hemostasis. This article reviews the history of the 
      PFA-100 and details its clinical utility in several settings. The PFA-100 was 
      first introduced to us in 1995 in an issue of Seminars in Thrombosis And 
      Hemostasis, which included data from a field trial headed by Dr. Eberhard Mammen. 
      Since that time, the PFA-100 has featured in nearly 500 publications and some 35 
      reviews. The PFA-100 has potential utility in monitoring antiplatelet therapy 
      (including aspirin) and as a screening tool for investigating possible von 
      Willebrand disease (VWD) and various platelet disorders. The PFA-100 also has 
      potential value for monitoring DDAVP (desmopressin) therapy in both VWD and 
      functional platelet disorders. Most recent attention has focused on sensitivity 
      to antiplatelet medication, where a new language has also emerged, with 
      researchers talking about "aspirin resistance," "aspirin responsiveness," and 
      "aspirin nonresponsiveness." Ultimately, the greatest strengths of the PFA-100 
      are its simplicity in use and excellent sensitivity to various hemostatic 
      disturbances. However, because it is a "global" test system for primary 
      hemostasis, this also creates a significant limitation because the PFA-100 is not 
      specific for, nor predictive of, any particular disorder. However, used 
      appropriately, the PFA-100 can be considered a worthwhile addition to hemostasis 
      laboratories involved in the identification or therapeutic monitoring of primary 
      hemostatic disorders. The potential future applications for this simple 
      instrument are also briefly assessed.
FAU - Favaloro, Emmanuel J
AU  - Favaloro EJ
AD  - Department of Haematology, Institute of Clinical Pathology and Medical Research, 
      Westmead Hospital, NSW, Australia. emmanuel.favaloro@swahs.health.nsw.gov.au
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090212
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis
MH  - Drug Monitoring/methods
MH  - Hemostasis
MH  - Humans
MH  - Platelet Function Tests/*instrumentation
MH  - von Willebrand Diseases/*blood
RF  - 174
EDAT- 2009/02/14 09:00
MHDA- 2009/04/29 09:00
CRDT- 2009/02/14 09:00
PHST- 2009/02/14 09:00 [entrez]
PHST- 2009/02/14 09:00 [pubmed]
PHST- 2009/04/29 09:00 [medline]
AID - 10.1055/s-0029-1145254 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2008 Nov;34(8):709-33. doi: 10.1055/s-0029-1145254. Epub 
      2009 Feb 12.

PMID- 918588
OWN - NLM
STAT- MEDLINE
DCOM- 19771229
LR  - 20161123
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 107
IP  - 38
DP  - 1977 Sep 24
TI  - [The value of acetylsalicylic acid for the prevention of postoperative 
      thromboembolic complications].
PG  - 1335-8
AB  - All studies on the value of acetylsalicylic acid for the prevention of 
      postoperative thromboembolic complications have been evaluated. Controlled, 
      prospective and randomized studies have been analyzed only where the incidence of 
      postoperative deep vein thrombosis or pulmonary emboli was proven by objective 
      diagnostic methods such as the fibrinogen test, phlebography or autopsy. In 6 
      studies there is no significant reduction in the incidence of deep vein 
      thrombosis in general surgical and orthopedic patients after acetylsalicylic acid 
      prevention. One study, though it has definite methodological defects, does 
      suggest a significant reduction in the number of postoperative fatal pulmonary 
      emboli in 120 patients with fractures of the upper end of the femur. On the basis 
      of all these data, the prevention of postoperative thromboembolic complications 
      by means of acetylsalicylic acid cannot be recommended.
FAU - Pfenninger, M
AU  - Pfenninger M
FAU - Gruber, U F
AU  - Gruber UF
LA  - ger
PT  - Journal Article
TT  - Wert der Acetylsalicylsäure zur Prophylaxe postoperativer thromboembolischer 
      Komplikationen.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 0 (Coumarins)
RN  - 0 (Dextrans)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Coumarins/therapeutic use
MH  - Dextrans/therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Postoperative Complications
MH  - Thromboembolism/*prevention & control
EDAT- 1977/09/24 00:00
MHDA- 1977/09/24 00:01
CRDT- 1977/09/24 00:00
PHST- 1977/09/24 00:00 [pubmed]
PHST- 1977/09/24 00:01 [medline]
PHST- 1977/09/24 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1977 Sep 24;107(38):1335-8.

PMID- 27378554
OWN - NLM
STAT- MEDLINE
DCOM- 20170411
LR  - 20220321
IS  - 1552-6259 (Electronic)
IS  - 0003-4975 (Linking)
VI  - 102
IP  - 6
DP  - 2016 Dec
TI  - Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary 
      Artery Bypass Grafting During Dual Antiplatelet Therapy?
PG  - 2010-2017
LID - S0003-4975(16)30482-9 [pii]
LID - 10.1016/j.athoracsur.2016.05.003 [doi]
AB  - BACKGROUND: Up to 15% of patients require coronary artery bypass grafting (CABG) 
      during dual antiplatelet therapy. Available evidence suggests an association 
      between platelet reactivity and CABG-related bleeding. However, platelet 
      reactivity cutoffs for bleeding remain elusive. We sought to explore the 
      association between platelet reactivity and bleeding. METHODS: Patients on 
      aspirin and a P2Y(12) receptor inhibitor within 48 hours before isolated CABG 
      (n = 149) were enrolled in this prospective study. Blood was drawn 2 to 4 hours 
      preoperatively and platelet reactivity assessed by light transmittance 
      aggregometry (LTA), vasodilator-stimulated phosphoprotein (VASP) assay, 
      Multiplate analyzer and Innovance PFA2Y. The primary endpoint was calculated red 
      blood cell loss computed as follows: (blood volume × preoperative hematocrit × 
      0.91) - (blood volume × hematocrit × 0.91 on postoperative day 5) + (mL of 
      transfused red blood cells × 0.59). RESULTS: Preoperative platelet reactivity was 
      low [median (interquartile range): LTA: 20 (9-28)%; VASP-PRI: 39 (15-73)%; 
      Multiplate adenosine phosphate test: 16 (12-22) U∗min]. Innovance PFA2Y ≥300 
      seconds, 72%. Median (IQR) red blood cell loss in patients in first the LTA 
      tertile was 1,449 (1,020 to 1,754) mL compared with 1,107 (858 to 1,512) mL and 
      1,075 (811 to 1,269) mL in those in the second and third tertiles, respectively 
      (p < 0.004). Bleeding Academic Research Consortium (BARC)-4 bleeding differed 
      between tertiles (62% versus 46% versus 36%; p = 0.037). In a multivariable 
      linear regression model, aspirin dose ≥300 mg, cardiopulmonary bypass time, 
      EuroSCORE, and tertile distribution of platelet reactivity were significantly 
      associated with red blood cell loss. CONCLUSIONS: A gradual decrease in red blood 
      cell loss and BARC-4 bleeding occurs with increasing platelet reactivity in 
      patients on antiplatelet therapy undergoing CABG. Our findings support current 
      guidelines to determine time of surgery based on an objective measurement of 
      platelet function (Platelet Inhibition and Bleeding in Patients Undergoing 
      Emergent Cardiac Surgery; clinicaltrials.gov NCT01468597).
CI  - Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All 
      rights reserved.
FAU - Mahla, Elisabeth
AU  - Mahla E
AD  - Department of Anesthesiology and Intensive Care Medicine, Medical University of 
      Graz, Graz, Austria.
FAU - Prueller, Florian
AU  - Prueller F
AD  - Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical 
      University of Graz, Graz, Austria.
FAU - Farzi, Sylvia
AU  - Farzi S
AD  - Department of Anesthesiology and Intensive Care Medicine, Medical University of 
      Graz, Graz, Austria.
FAU - Pregartner, Gudrun
AU  - Pregartner G
AD  - Institute for Medical Informatics, Statistics and Documentation, Medical 
      University of Graz, Graz, Austria.
FAU - Raggam, Reinhard B
AU  - Raggam RB
AD  - Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical 
      University of Graz, Graz, Austria.
FAU - Beran, Elisabeth
AU  - Beran E
AD  - Department of Cardiac Surgery, Medical University of Graz, Graz, Austria.
FAU - Toller, Wolfgang
AU  - Toller W
AD  - Department of Anesthesiology and Intensive Care Medicine, Medical University of 
      Graz, Graz, Austria.
FAU - Berghold, Andrea
AU  - Berghold A
AD  - Institute for Medical Informatics, Statistics and Documentation, Medical 
      University of Graz, Graz, Austria.
FAU - Tantry, Udaya S
AU  - Tantry US
AD  - Inova Center for Thrombosis Research and Drug Development, Inova Heart and 
      Vascular Institute, Falls Church, Virginia.
FAU - Gurbel, Paul A
AU  - Gurbel PA
AD  - Inova Center for Thrombosis Research and Drug Development, Inova Heart and 
      Vascular Institute, Falls Church, Virginia. Electronic address: 
      paul.gurbel@inova.org.
LA  - eng
SI  - ClinicalTrials.gov/NCT01468597
PT  - Journal Article
PT  - Observational Study
DEP - 20160701
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - *Blood Loss, Surgical
MH  - *Coronary Artery Bypass
MH  - Drug Therapy, Combination
MH  - Emergencies
MH  - Female
MH  - Heart Valve Prosthesis Implantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Platelet Function Tests
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Postoperative Hemorrhage/*blood/chemically induced/etiology
MH  - Practice Guidelines as Topic
MH  - Preoperative Care
MH  - Prospective Studies
MH  - Purinergic P2Y Receptor Antagonists/administration & 
      dosage/pharmacology/*therapeutic use
EDAT- 2016/07/06 06:00
MHDA- 2017/04/12 06:00
CRDT- 2016/07/06 06:00
PHST- 2015/12/28 00:00 [received]
PHST- 2016/03/23 00:00 [revised]
PHST- 2016/05/02 00:00 [accepted]
PHST- 2016/07/06 06:00 [pubmed]
PHST- 2017/04/12 06:00 [medline]
PHST- 2016/07/06 06:00 [entrez]
AID - S0003-4975(16)30482-9 [pii]
AID - 10.1016/j.athoracsur.2016.05.003 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 2016 Dec;102(6):2010-2017. doi: 
      10.1016/j.athoracsur.2016.05.003. Epub 2016 Jul 1.

PMID- 33758303
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Mar 23
TI  - Low-dose aspirin was associated with an increased risk of cardiovascular events 
      in patients with chronic kidney disease patients and low bodyweight: results from 
      KNOW-CKD study.
PG  - 6691
LID - 10.1038/s41598-021-86192-4 [doi]
LID - 6691
AB  - The benefits and risks of aspirin therapy for patients with chronic kidney 
      disease (CKD) who have a high burden of cardiovascular events (CVE) are 
      controversial. To examine the effects of low-dose aspirin on major clinical 
      outcomes in patients with CKD. As a prospective observational cohort study, using 
      propensity score matching, 531 aspirin recipients and non-recipients were paired 
      for analysis from 2070 patients and fulfilled the inclusion criteria among 2238 
      patients with CKD. The primary outcome was the first occurrence of major CVE. The 
      secondary outcomes were kidney events defined as a > 50% reduction of estimated 
      glomerular filtration rate from baseline, doubling of serum creatinine, or onset 
      of kidney failure with replacement therapy, the all-cause mortality, and bleeding 
      event. The incidence of CVE was significantly greater in low-dose aspirin users 
      than in non-users (HR 1.798; P = 0.011). A significant association between 
      aspirin use and an increased risk of CVE was observed only in the lowest quartile 
      of body weight (HR 4.014; P = 0.019) (Q1 < 60.0 kg). Secondary outcomes were not 
      significantly different between aspirin users and non-users. It needs to be 
      individualized of prescribing low-dose aspirin for the prevention of 
      cardiovascular events in patients with chronic kidney disease, particularly 
      patients with low bodyweight (< 60 kg).
FAU - Oh, Yun Jung
AU  - Oh YJ
AD  - Department of Internal Medicine, Graduate School of Medicine, Gachon University, 
      Incheon, Republic of Korea.
AD  - Division of Nephrology, Department of Internal Medicine, Cheju Halla General 
      Hospital, Cheju, Republic of Korea.
FAU - Kim, Ae Jin
AU  - Kim AJ
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Gachon University College of Medicine, 21, Namdong-daero 774 
      beon-gil, Namdong-gu, Incheon, 21565, Republic of Korea.
AD  - College of Medicine, Gachon University, Incheon, Republic of Korea.
FAU - Ro, Han
AU  - Ro H
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Gachon University College of Medicine, 21, Namdong-daero 774 
      beon-gil, Namdong-gu, Incheon, 21565, Republic of Korea.
AD  - College of Medicine, Gachon University, Incheon, Republic of Korea.
FAU - Chang, Jae Hyun
AU  - Chang JH
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Gachon University College of Medicine, 21, Namdong-daero 774 
      beon-gil, Namdong-gu, Incheon, 21565, Republic of Korea.
AD  - College of Medicine, Gachon University, Incheon, Republic of Korea.
FAU - Lee, Hyun Hee
AU  - Lee HH
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Gachon University College of Medicine, 21, Namdong-daero 774 
      beon-gil, Namdong-gu, Incheon, 21565, Republic of Korea.
AD  - College of Medicine, Gachon University, Incheon, Republic of Korea.
FAU - Chung, Wookyung
AU  - Chung W
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Gachon University College of Medicine, 21, Namdong-daero 774 
      beon-gil, Namdong-gu, Incheon, 21565, Republic of Korea.
AD  - College of Medicine, Gachon University, Incheon, Republic of Korea.
FAU - Hyun, Young Youl
AU  - Hyun YY
AD  - Department of Internal Medicine, Sungkyunkwan University School of Medicine, 
      Kangbuk Samsung Hospital, Seoul, Republic of Korea.
FAU - Lee, Joongyub
AU  - Lee J
AD  - Department of Prevention and Management, School of Medicine, Inha University, 
      Incheon, Republic of Korea.
FAU - Kim, Yeong Hoon
AU  - Kim YH
AD  - Department of Internal Medicine, College of Medicine, Busan Paik Hospital, Inje 
      University, Busan, Republic of Korea.
FAU - Han, Seung Hyeok
AU  - Han SH
AD  - Department of Internal Medicine, College of Medicine, Institute of Kidney Disease 
      Research, Yonsei University, Seoul, Republic of Korea.
FAU - Chae, Dong-Wan
AU  - Chae DW
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul, Republic of Korea.
FAU - Ahn, Curie
AU  - Ahn C
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul, 
      Republic of Korea.
FAU - Oh, Kook-Hwan
AU  - Oh KH
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul, 
      Republic of Korea.
FAU - Jung, Ji Yong
AU  - Jung JY
AD  - Department of Internal Medicine, Graduate School of Medicine, Gachon University, 
      Incheon, Republic of Korea. jyjung@gachon.ac.kr.
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Gachon University College of Medicine, 21, Namdong-daero 774 
      beon-gil, Namdong-gu, Incheon, 21565, Republic of Korea. jyjung@gachon.ac.kr.
AD  - College of Medicine, Gachon University, Incheon, Republic of Korea. 
      jyjung@gachon.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210323
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - *Body Weight
MH  - Cardiovascular Diseases/*epidemiology/*etiology
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Kidney Function Tests
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Renal Insufficiency, Chronic/*complications/diagnosis/*epidemiology
MH  - Risk Assessment
PMC - PMC7988000
COIS- The authors declare no competing interests.
EDAT- 2021/03/25 06:00
MHDA- 2021/10/26 06:00
CRDT- 2021/03/24 06:32
PHST- 2020/09/01 00:00 [received]
PHST- 2021/03/09 00:00 [accepted]
PHST- 2021/03/24 06:32 [entrez]
PHST- 2021/03/25 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
AID - 10.1038/s41598-021-86192-4 [pii]
AID - 86192 [pii]
AID - 10.1038/s41598-021-86192-4 [doi]
PST - epublish
SO  - Sci Rep. 2021 Mar 23;11(1):6691. doi: 10.1038/s41598-021-86192-4.

PMID- 31154631
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20200610
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 36
IP  - 8
DP  - 2019 Aug
TI  - Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable 
      Coronary Artery Disease: A Systematic Review and Meta-Analysis.
PG  - 2062-2071
LID - 10.1007/s12325-019-01004-6 [doi]
AB  - INTRODUCTION: Although aspirin (ASA) is the mainstay of treatment for the 
      prevention of recurrent ischemic stroke, the Clopidogrel versus Aspirin in 
      Patients at Risk of Ischemic Events (CAPRIE) trial showed ASA monotherapy to be 
      inferior to clopidogrel in preventing recurrent adverse cardiovascular outcomes 
      in patients with high cardiac risks. Here, we aimed to systematically compare ASA 
      versus clopidogrel monotherapy for the treatment of patients with stable coronary 
      artery disease (CAD). METHODS: Electronic databases were searched and studies 
      were included if they compared ASA versus clopidogrel monotherapy for the 
      treatment of patients with CAD and they reported adverse clinical outcomes. The 
      latest version of RevMan software (version 5.3) was used as the statistical tool 
      for the data analysis. Odds ratios (OR) and 95% confidence intervals (CI) were 
      generated to interpret the data. RESULTS: A total number of 5497 patients (from 
      years 2003 to 2011) were treated with ASA monotherapy, whereas 2544 patients were 
      treated with clopidogrel monotherapy. Results of this analysis showed no 
      significant difference in composite endpoints (cardiovascular death, myocardial 
      infarction, and stroke) (OR 0.99, 95% CI 0.47-2.10; P = 0.98), all-cause 
      mortality (OR 1.05, 95% CI 0.82-1.33; P = 0.71), cardiac death (OR 0.89, 95% CI 
      0.17-4.74; P = 0.89, myocardial infarction (OR 0.84, 95% CI 0.52-1.36; P = 0.48), 
      stroke (OR 1.26, 95% CI 0.39-4.06; P = 0.70), and bleeding defined by the 
      Bleeding Academic Research Consortium (BARC [grade 3 or above]) (OR 1.28, 95% CI 
      0.78-2.12; P = 0.33). CONCLUSION: This analysis did not show any significant 
      difference in all-cause mortality, cardiac death, myocardial infarction, stroke, 
      and BARC grade 3 or above among CAD patients who were treated with either ASA or 
      clopidogrel monotherapy. However, as a result of the limited data, this 
      hypothesis should be confirmed in other major trials.
FAU - Yuan, Jun
AU  - Yuan J
AD  - Department of Cardiology, The People's Hospital of Guangxi Zhuang Autonomous 
      Region, Nanning, Guangxi, China. nnyuanjun@163.com.
FAU - Xu, Guang Ma
AU  - Xu GM
AD  - Department of Cardiology, The People's Hospital of Guangxi Zhuang Autonomous 
      Region, Nanning, Guangxi, China.
FAU - Ding, Jiawang
AU  - Ding J
AD  - Department of Cardiology, Jingzhou Central Hospital, The Second Clinical Medical 
      College, Yangtze University, Jingzhou, Hubei, China.
LA  - eng
SI  - figshare/10.6084/m9.figshare.8166905
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190601
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/*drug therapy
PMC - PMC6822863
OTO - NOTNLM
OT  - Adverse clinical outcomes
OT  - Aspirin monotherapy
OT  - Cardiology
OT  - Clopidogrel monotherapy
OT  - Coronary artery disease
EDAT- 2019/06/04 06:00
MHDA- 2020/06/11 06:00
CRDT- 2019/06/03 06:00
PHST- 2019/04/16 00:00 [received]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
PHST- 2019/06/03 06:00 [entrez]
AID - 10.1007/s12325-019-01004-6 [pii]
AID - 1004 [pii]
AID - 10.1007/s12325-019-01004-6 [doi]
PST - ppublish
SO  - Adv Ther. 2019 Aug;36(8):2062-2071. doi: 10.1007/s12325-019-01004-6. Epub 2019 
      Jun 1.

PMID- 34389292
OWN - NLM
STAT- MEDLINE
DCOM- 20220214
LR  - 20220505
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 226
IP  - 2
DP  - 2022 Feb
TI  - A randomized controlled trial of low-dose aspirin for the prevention of 
      preeclampsia in women at high risk in China.
PG  - 251.e1-251.e12
LID - S0002-9378(21)00869-3 [pii]
LID - 10.1016/j.ajog.2021.08.004 [doi]
AB  - BACKGROUND: Low-dose aspirin has been the most widely studied preventive drug for 
      preeclampsia. However, guidelines differ considerably from country to country 
      regarding the prophylactic use of aspirin for preeclampsia. There is limited 
      evidence from large trials to determine the effect of 100 mg of aspirin for 
      preeclampsia screening in women with high-risk pregnancies, based on maternal 
      risk factors, and to guide the use of low-dose aspirin in preeclampsia prevention 
      in China. OBJECTIVE: The Low-Dose Aspirin in the Prevention of Preeclampsia in 
      China study was designed to evaluate the effect of 100 mg of aspirin in 
      preventing preeclampsia among high-risk pregnant women screened with maternal 
      risk factors in China, where preeclampsia is highly prevalent, and the status of 
      low-dose aspirin supply is commonly suboptimal. STUDY DESIGN: We conducted a 
      multicenter randomized controlled trial at 13 tertiary hospitals from 11 
      provinces in China between 2016 and 2019. We assumed that the relative reduction 
      in the incidence of preeclampsia was at least 20%, from 20% in the control group 
      to 16% in the aspirin group. Therefore, the targeted recruitment number was 1000 
      participants. Women were randomly assigned to the aspirin or control group in a 
      1:1 allocation ratio. Statistical analyses were performed according to an 
      intention-to-treat basis. The primary outcome was the incidence of preeclampsia, 
      diagnosed along with a systolic blood pressure of ≥140 mm Hg or a diastolic blood 
      pressure of ≥90 mm Hg after 20 weeks of gestation, with a previously normal blood 
      pressure (systolic blood pressure of <140 mm Hg and diastolic blood pressure of 
      <90 mm Hg), and complicated by proteinuria. The secondary outcomes included 
      maternal and neonatal outcomes. Logistic regression analysis was used to 
      determine the significance of difference of preeclampsia incidence between the 
      groups for both the primary and secondary outcomes. Interaction analysis was also 
      performed. RESULTS: A total of 1000 eligible women were recruited between 
      December 2016 and March 2019, of which the final 898 patients were analyzed (464 
      participants in the aspirin group, 434 participants in the control group) on an 
      intention-to-treat basis. No significant difference was found in preeclampsia 
      incidence between the aspirin group (16.8% [78/464]) and the control group (17.1% 
      [74/434]; relative risk, 0.986; 95% confidence interval, 0.738-1.317; P=.924). 
      Likewise, adverse maternal and neonatal outcomes did not differ significantly 
      between the 2 groups. Meanwhile, the incidence of postpartum hemorrhage between 
      the 2 groups was similar (6.5% [30/464] in the aspirin group and 5.3% [23/434] in 
      the control group; relative risk, 1.220; 95% confidence interval, 0.720-2.066; 
      P=.459). We did not find any significant differences in preeclampsia incidence 
      between the 2 groups in the subgroup analysis of the different risk factors. 
      CONCLUSION: A dosage of 100 mg of aspirin per day, initiated from 12 to 20 
      gestational weeks until 34 weeks of gestation, did not reduce the incidence of 
      preeclampsia in pregnant women with high-risk factors in China.
CI  - Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Lin, Li
AU  - Lin L
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational 
      Diabetes Mellitus, Beijing, China.
FAU - Huai, Jing
AU  - Huai J
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational 
      Diabetes Mellitus, Beijing, China.
FAU - Li, Boya
AU  - Li B
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational 
      Diabetes Mellitus, Beijing, China.
FAU - Zhu, Yuchun
AU  - Zhu Y
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational 
      Diabetes Mellitus, Beijing, China.
FAU - Juan, Juan
AU  - Juan J
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational 
      Diabetes Mellitus, Beijing, China.
FAU - Zhang, Meihua
AU  - Zhang M
AD  - Department of Obstetrics and Gynecology, Taiyuan Maternal and Child Health 
      Hospital, Taiyuan, Shanxi, China.
FAU - Cui, Shihong
AU  - Cui S
AD  - Department of Obstetrics and Gynecology, Third Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, Henan, China.
FAU - Zhao, Xianlan
AU  - Zhao X
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, Henan, China.
FAU - Ma, Yuyan
AU  - Ma Y
AD  - Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, 
      Jinan, Shandong, China.
FAU - Zhao, Yangyu
AU  - Zhao Y
AD  - Department of Obstetrics and Gynecology, Peking University Third Hospital, 
      Beijing, China.
FAU - Mi, Yang
AU  - Mi Y
AD  - Department of Obstetrics and Gynecology, Shaanxi Maternity and Child Health Care 
      Hospital, Shaanxi, China.
FAU - Ding, Hongjuan
AU  - Ding H
AD  - Department of Obstetrics and Gynecology, Nanjing Maternity and Child Health Care 
      Hospital, Nanjing, Jiangsu, China.
FAU - Chen, Dunjin
AU  - Chen D
AD  - Department of Obstetrics and Gynecology, The Third Affiliated Hospital of 
      Guangzhou Medical University, Guangdong, China.
FAU - Zhang, Weishe
AU  - Zhang W
AD  - Department of Obstetrics and Gynecology, Xiangya Hospital, Central South 
      University, Changsha, Hunan, China.
FAU - Qi, Hongbo
AU  - Qi H
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of 
      Chongqing Medical University, Chongqing, China.
FAU - Li, Xiaotian
AU  - Li X
AD  - Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, 
      Fudan University, Shanghai, China.
FAU - Li, Guanlin
AU  - Li G
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational 
      Diabetes Mellitus, Beijing, China.
FAU - Chen, Jiahui
AU  - Chen J
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational 
      Diabetes Mellitus, Beijing, China.
FAU - Zhang, Huijing
AU  - Zhang H
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational 
      Diabetes Mellitus, Beijing, China.
FAU - Yu, Mengting
AU  - Yu M
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational 
      Diabetes Mellitus, Beijing, China.
FAU - Sun, Xiaotong
AU  - Sun X
AD  - Department of Obstetrics and Gynecology, Gansu Provincial Hospital, Lanzhou, 
      Gansu, China.
FAU - Yang, Huixia
AU  - Yang H
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing, China; Beijing Key Laboratory of Maternal Fetal Medicine of Gestational 
      Diabetes Mellitus, Beijing, China. Electronic address: yanghuixia@bjmu.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT02797249
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20210810
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Obstet Gynecol. 2022 Apr;226(4):596-597. PMID: 34838800
CIN - Am J Obstet Gynecol. 2022 Apr;226(4):595-596. PMID: 34838803
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - China
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Pregnancy, High-Risk
OTO - NOTNLM
OT  - China
OT  - chronic hypertension
OT  - dose of aspirin
OT  - low-dose aspirin
OT  - preeclampsia
OT  - pregnancy
OT  - pregnancy outcomes
OT  - prepregnancy body mass index
OT  - prevention
OT  - randomized controlled trial
EDAT- 2021/08/15 06:00
MHDA- 2022/02/15 06:00
CRDT- 2021/08/14 05:42
PHST- 2021/03/03 00:00 [received]
PHST- 2021/08/03 00:00 [revised]
PHST- 2021/08/04 00:00 [accepted]
PHST- 2021/08/15 06:00 [pubmed]
PHST- 2022/02/15 06:00 [medline]
PHST- 2021/08/14 05:42 [entrez]
AID - S0002-9378(21)00869-3 [pii]
AID - 10.1016/j.ajog.2021.08.004 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2022 Feb;226(2):251.e1-251.e12. doi: 
      10.1016/j.ajog.2021.08.004. Epub 2021 Aug 10.

PMID- 1309968
OWN - NLM
STAT- MEDLINE
DCOM- 19920214
LR  - 20181130
IS  - 0003-0805 (Print)
IS  - 0003-0805 (Linking)
VI  - 145
IP  - 1
DP  - 1992 Jan
TI  - Release of peptide leukotriene into nasal secretions after local instillation of 
      aspirin in aspirin-sensitive asthmatic patients.
PG  - 65-9
AB  - Although the mechanism of aspirin-induced asthma and rhinitis is unknown, it has 
      been suggested that adverse nasal and bronchial reactions are caused by an 
      increased production of lipoxygenase products. In examining this hypothesis we 
      have measured the release of peptide leukotrienes (PeptLTs), 15-HETE, and 
      prostaglandins in nasal fluids obtained by nasal lavages after instillation of 
      acetylsalycilic acid (ASA) and placebo (saline). Ten ASA-sensitive asthmatics, 10 
      ASA-insensitive asthmatics, and seven healthy subjects were challenged in a 
      double-blind study with normal saline and 12 mg of ASA. Twelve mg were 
      administered based on the results of a previous study that showed that this dose 
      caused minor to moderate symptoms in ASA-sensitive patients. PeptLTs, LTB4, 
      15-HETE, PGE2, PGF2 alpha, and PGD2 were measured by radioimmunoassay methods. 
      Significant levels of PeptLTs were detected in sensitive asthmatic patients 60 
      min after nasal challenge. This change was associated with a significant increase 
      in symptoms. No increase in PeptLTs levels were found, however, in either 
      insensitive patients or healthy subjects. Inhibition of PGE2 and PGF2 alpha 
      release was detected in the three groups after ASA administration. ASA also 
      inhibited PGD2 release in insensitive asthmatic patients but not in both 
      sensitive patients and healthy subjects. These results suggest that an abnormal 
      release of PeptLTs in ASA-sensitive asthmatic patients contributes to nasal and 
      bronchial adverse reactions. The lack of effects on PGD2 release suggests that 
      mast cells from ASA-insensitive patients are more sensitive to ASA than those 
      from sensitive asthmatic patients and healthy subjects.
FAU - Picado, C
AU  - Picado C
AD  - Servei de Pneumologia, Hospital Clinic, Facultad de Medicina, Barcelona, Spain.
FAU - Ramis, I
AU  - Ramis I
FAU - Rosellò, J
AU  - Rosellò J
FAU - Prat, J
AU  - Prat J
FAU - Bulbena, O
AU  - Bulbena O
FAU - Plaza, V
AU  - Plaza V
FAU - Montserrat, J M
AU  - Montserrat JM
FAU - Gelpí, E
AU  - Gelpí E
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Rev Respir Dis
JT  - The American review of respiratory disease
JID - 0370523
RN  - 0 (Albumins)
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - 0 (Leukotrienes)
RN  - 1HGW4DR56D (Leukotriene B4)
RN  - 73945-47-8 (15-hydroxy-5,8,11,13-eicosatetraenoic acid)
RN  - B7IN85G1HY (Dinoprost)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - RXY07S6CZ2 (Prostaglandin D2)
SB  - IM
MH  - Administration, Intranasal
MH  - Adult
MH  - Albumins/metabolism
MH  - Aspirin/administration & dosage/*adverse effects/pharmacology
MH  - Asthma/chemically induced/*metabolism
MH  - Dinoprost/metabolism
MH  - Dinoprostone/metabolism
MH  - Drug Hypersensitivity/metabolism
MH  - Female
MH  - Humans
MH  - Hydroxyeicosatetraenoic Acids/metabolism
MH  - Leukotriene B4/metabolism
MH  - Leukotrienes/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Nasal Mucosa/*metabolism
MH  - Prostaglandin D2/metabolism
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1164/ajrccm/145.1.65 [doi]
PST - ppublish
SO  - Am Rev Respir Dis. 1992 Jan;145(1):65-9. doi: 10.1164/ajrccm/145.1.65.

PMID- 17844731
OWN - NLM
STAT- MEDLINE
DCOM- 20071002
LR  - 20131121
IS  - 1536-0288 (Print)
IS  - 1536-0288 (Linking)
VI  - 21
IP  - 2
DP  - 2007
TI  - Concomitant use of ibuprofen and aspirin.
PG  - 73-4
AB  - Last September, the U.S. Food and Drug Administration (FDA) Center for Drug 
      Evaluation and Research (CDER) published the following notice for consumers and 
      healthcare professionals cautioning about the interference with the antiplatelet 
      effects of low dose aspirin that can occur when aspirin is taken concomitantly 
      with ibuprofen.
CN  - Food and Drug Administration U.S. Department of Health and Human Services
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pain Palliat Care Pharmacother
JT  - Journal of pain & palliative care pharmacotherapy
JID - 101125608
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cardiotonic Agents/administration & dosage/*pharmacology
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ibuprofen/administration & dosage/*pharmacology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
EDAT- 2007/09/12 09:00
MHDA- 2007/10/03 09:00
CRDT- 2007/09/12 09:00
PHST- 2007/09/12 09:00 [pubmed]
PHST- 2007/10/03 09:00 [medline]
PHST- 2007/09/12 09:00 [entrez]
PST - ppublish
SO  - J Pain Palliat Care Pharmacother. 2007;21(2):73-4.

PMID- 25339093
OWN - NLM
STAT- MEDLINE
DCOM- 20160919
LR  - 20220311
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 172
IP  - 23
DP  - 2015 Dec
TI  - Aspirin enhances protective effect of fish oil against thrombosis and 
      injury-induced vascular remodelling.
PG  - 5647-60
LID - 10.1111/bph.12986 [doi]
AB  - BACKGROUND AND PURPOSE: Although aspirin (acetylsalicylic acid) is commonly used 
      to prevent ischaemic events in patients with coronary artery disease, many 
      patients fail to respond to aspirin treatment. Dietary fish oil (FO), containing 
      ω3 polyunsaturated fatty acids (PUFAs), has anti-inflammatory and 
      cardio-protective properties, such as lowering cholesterol and modulating 
      platelet activity. The objective of the present study was to investigate the 
      potential additional effects of aspirin and FO on platelet activity and vascular 
      response to injury. EXPERIMENTAL APPROACH: Femoral arterial remodelling was 
      induced by wire injury in mice. Platelet aggregation, and photochemical- and 
      ferric chloride-induced carotid artery thrombosis were employed to evaluate 
      platelet function. KEY RESULTS: FO treatment increased membrane ω3 PUFA 
      incorporation, lowered plasma triglyceride and cholesterol levels, and reduced 
      systolic BP in mice. FO or aspirin alone inhibited platelet aggregation; however, 
      when combined, they exhibited synergistic suppression of platelet activity in 
      mice, independent of COX-1 inhibition. FO alone, but not aspirin, attenuated 
      arterial neointimal growth in response to injury. Strikingly, a combination of FO 
      and aspirin synergistically inhibited injury-induced neointimal hyperplasia and 
      reduced perivascular inflammatory reactions. Moreover, co-administration of FO 
      and aspirin decreased the expression of pro-inflammatory cytokines and adhesion 
      molecules in inflammatory cells. Consistently, a pro-resolution lipid 
      mediator-Resolvin E1, was significantly elevated in plasma in FO/aspirin-treated 
      mice. CONCLUSIONS AND IMPLICATIONS: Co-administration of FO and low-dose aspirin 
      may act synergistically to protect against thrombosis and injury-induced vascular 
      remodelling in mice. Our results support further investigation of adjuvant FO 
      supplementation for patients with stable coronary artery disease.
CI  - © 2014 The British Pharmacological Society.
FAU - Gong, Yanjun
AU  - Gong Y
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Lin, Minghui
AU  - Lin M
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Piao, Lingjuan
AU  - Piao L
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Li, Xinzhi
AU  - Li X
AD  - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, 
      ON, Canada.
FAU - Yang, Fei
AU  - Yang F
AD  - Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, MOH 
      Key Lab of Thrombosis and Hemostasis, Jiangsu Institute of Hematology, The First 
      Affiliated Hospital, Soochow University, Suzhou, China.
FAU - Zhang, Jian
AU  - Zhang J
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Xiao, Bing
AU  - Xiao B
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Zhang, Qingli
AU  - Zhang Q
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Song, Wen-Liang
AU  - Song WL
AD  - Bridgeport Hospital, Yale New Haven Health System, Bridgeport, CT, USA.
FAU - Yin, Huiyong
AU  - Yin H
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Zhu, Li
AU  - Zhu L
AD  - Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, MOH 
      Key Lab of Thrombosis and Hemostasis, Jiangsu Institute of Hematology, The First 
      Affiliated Hospital, Soochow University, Suzhou, China.
FAU - Funk, Colin D
AU  - Funk CD
AD  - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, 
      ON, Canada.
FAU - Yu, Ying
AU  - Yu Y
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, 
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 
      University of the Chinese Academy of Sciences, Shanghai, China.
LA  - eng
GR  - CIHR-CCI117951/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150112
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Chlorides)
RN  - 0 (Ferric Compounds)
RN  - 0 (Fish Oils)
RN  - R16CO5Y76E (Aspirin)
RN  - U38V3ZVV3V (ferric chloride)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chlorides
MH  - Dietary Supplements
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Femoral Artery/*drug effects/pathology
MH  - Ferric Compounds
MH  - Fish Oils/administration & dosage/*pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Photochemical Processes
MH  - Platelet Aggregation/drug effects
MH  - Structure-Activity Relationship
MH  - Thrombosis/chemically induced/pathology/*prevention & control
MH  - Vascular System Injuries/chemically induced/pathology/*prevention & control
PMC - PMC4667862
EDAT- 2014/10/24 06:00
MHDA- 2016/09/20 06:00
CRDT- 2014/10/24 06:00
PHST- 2014/06/12 00:00 [received]
PHST- 2014/09/15 00:00 [revised]
PHST- 2014/10/16 00:00 [accepted]
PHST- 2014/10/24 06:00 [entrez]
PHST- 2014/10/24 06:00 [pubmed]
PHST- 2016/09/20 06:00 [medline]
AID - BPH12986 [pii]
AID - 10.1111/bph.12986 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2015 Dec;172(23):5647-60. doi: 10.1111/bph.12986. Epub 2015 Jan 
      12.

PMID- 17720521
OWN - NLM
STAT- MEDLINE
DCOM- 20070905
LR  - 20131121
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
VI  - 50
IP  - 3
DP  - 2007 Sep
TI  - Should hemodialysis patients with atrial fibrillation undergo systemic 
      anticoagulation? A cost-utility analysis.
PG  - 421-32
AB  - BACKGROUND: Approximately 14% of hemodialysis patients have atrial fibrillation. 
      Hemodialysis patients with atrial fibrillation appear to be at increased risk of 
      both thromboembolic complications and bleeding. Furthermore, there is uncertainty 
      regarding the efficacy of warfarin or acetylsalicylic acid (ASA) therapy for 
      preventing strokes in this subgroup because they were excluded from relevant 
      trials. STUDY DESIGN: We performed a cost-utility analysis. Probabilistic 
      sensitivity analysis was used to incorporate parameter uncertainty into the 
      model. Expected value of perfect information and scenario analyses were performed 
      to identify the important drivers of the decision and focus future research. 
      SETTING & POPULATION: Base case was a 60-year-old male hemodialysis patient in 
      the United States. MODEL, PERSPECTIVE, & TIME FRAME: A Markov Monte Carlo 
      microsimulation model was constructed from the perspective of the health care 
      payer, and patients were followed up during their lifetime. INTERVENTION: We 
      compared 3 alternative treatment strategies for permanent atrial fibrillation in 
      hemodialysis patients: warfarin, ASA, or no treatment. OUTCOMES: Quality-adjusted 
      survival and cost. RESULTS: ASA and warfarin both prolonged survival compared 
      with no treatment (0.06 and 0.15 quality-adjusted life-years [QALYs], 
      respectively). ASA was associated with an incremental cost-effectiveness ratio of 
      $82,100/QALY. Warfarin provided additional benefits at a cost of $88,400 for each 
      QALY gained relative to ASA. At a threshold of $100,000/QALY, the probabilities 
      that no treatment, warfarin, and ASA were the most efficient therapy were 20%, 
      58%, and 23%, respectively. LIMITATIONS: Parameterization data and costs were 
      taken from US studies and may not be generalizable to other countries. Peritoneal 
      dialysis patients were not included in the analysis. CONCLUSIONS: The high future 
      cost of hemodialysis constrains incremental cost-effectiveness ratios to values 
      greater than commonly cited thresholds ($50,000/QALY). Based on available 
      evidence, warfarin appears to be the optimal therapy to prevent thromboembolic 
      stroke in hemodialysis patients with atrial fibrillation. Additional study is 
      required to determine the efficacy of warfarin and risk of bleeding complications 
      in this population so that patients can make a more informed choice.
FAU - Quinn, Robert R
AU  - Quinn RR
AD  - Department of Medicine, Division of Nephrology, Sunnybrook Health Sciences 
      Centre, Toronto, Canada. robert.quinn@sunnybrook.ca
FAU - Naimark, David M J
AU  - Naimark DM
FAU - Oliver, Matthew J
AU  - Oliver MJ
FAU - Bayoumi, Ahmed M
AU  - Bayoumi AM
LA  - eng
PT  - Case Reports
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Kidney Dis. 2007 Sep;50(3):345-8. PMID: 17720510
MH  - Anticoagulants/*economics/*therapeutic use
MH  - Aspirin/*economics/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy/*economics
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*economics/*therapeutic use
MH  - *Renal Dialysis
MH  - Warfarin/*economics/*therapeutic use
EDAT- 2007/08/28 09:00
MHDA- 2007/09/06 09:00
CRDT- 2007/08/28 09:00
PHST- 2006/12/19 00:00 [received]
PHST- 2007/05/23 00:00 [accepted]
PHST- 2007/08/28 09:00 [pubmed]
PHST- 2007/09/06 09:00 [medline]
PHST- 2007/08/28 09:00 [entrez]
AID - S0272-6386(07)00844-X [pii]
AID - 10.1053/j.ajkd.2007.05.019 [doi]
PST - ppublish
SO  - Am J Kidney Dis. 2007 Sep;50(3):421-32. doi: 10.1053/j.ajkd.2007.05.019.

PMID- 33710126
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20230829
IS  - 1539-2570 (Electronic)
IS  - 0271-6798 (Linking)
VI  - 41
IP  - 5
DP  - 2021 May-Jun 01
TI  - Venous Thromboembolism After Pelvic Osteotomy in Adolescent Patients: A Database 
      Study Characterizing Rates and Current Practices.
PG  - 306-311
LID - 10.1097/BPO.0000000000001798 [doi]
AB  - BACKGROUND: Current risks and practices in medical prophylaxis of venous 
      thromboembolism (VTE) after major elective lower extremity surgeries such as 
      pelvic osteotomies have not been well-defined in the pediatric population. The 
      purpose of this study was to (1) evaluate population rates of VTE in adolescents 
      undergoing pelvic osteotomies, and (2) characterize current practices on types of 
      VTE prophylaxis being utilized after pelvic osteotomies. METHODS: The study 
      evaluated the Pediatric Health Information System database between October 1, 
      2015 and January 1, 2020 for patients between 10 and 18 years of age meeting 
      selected ICD-10 procedure and diagnosis codes relating to pelvic osteotomies. The 
      rate of VTE was calculated within 90 days of index procedure. Types of 
      pharmacologic prophylaxis were characterized. Continuous variables were compared 
      with 2-sample t tests; proportions and categorical variables were compared with 
      Fisher exact or χ2 tests, all with 2-tailed significance <0.05. RESULTS: Of 1480 
      included patients, 9 were diagnosed with VTE within 90 days of surgery (VTE rate: 
      0.61%). Four of 9 (44.4%) had received pharmacologic prophylaxis postoperatively. 
      There were no differences in baseline demographics or length of stay between 
      patients that did or did not develop VTE (P>0.05). Overall, 52.0% received at 
      least one form of pharmacologic prophylaxis postoperatively. The most common 
      pharmacologic prophylaxis used was aspirin (47.6%), of which 64.4% received 81 mg 
      dosing. There was no difference in VTE rates in those with or without prophylaxis 
      (0.52% vs. 0.70%, P=0.75). However, those prescribed prophylaxis were 
      significantly older (15.2±2.3 vs. 13.6±2.4 y, P<0.0001) and had a higher 
      proportion of females (71.8% vs. 54.6%, P<0.01). CONCLUSIONS: The overall rate of 
      VTE in pediatric patients after pelvic osteotomies is non-negligible. There is 
      heterogeneity in the type of anticoagulant utilized; however, VTE prophylaxis is 
      most commonly prescribed in older adolescents and female patients. Guidelines for 
      medical prevention of deep venous thrombosis and pulmonary embolism in the 
      pediatric population are warranted after hip preservation surgery. LEVEL OF 
      EVIDENCE: Level IV, case series.
CI  - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Allahabadi, Sachin
AU  - Allahabadi S
AD  - Department of Orthopaedic Surgery.
FAU - Faust, Millis
AU  - Faust M
AD  - School of Medicine, University of California, San Francisco, San Francisco, CA.
FAU - Swarup, Ishaan
AU  - Swarup I
AD  - Department of Orthopaedic Surgery.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pediatr Orthop
JT  - Journal of pediatric orthopedics
JID - 8109053
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Child
MH  - Databases, Factual
MH  - Elective Surgical Procedures/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Osteotomy/*adverse effects
MH  - Pelvic Bones/*surgery
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pulmonary Embolism/prevention & control
MH  - Venous Thromboembolism/etiology/*prevention & control
COIS- The authors declare no conflicts of interest.
EDAT- 2021/03/13 06:00
MHDA- 2021/07/01 06:00
CRDT- 2021/03/12 12:33
PHST- 2021/03/13 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
PHST- 2021/03/12 12:33 [entrez]
AID - 01241398-202105000-00010 [pii]
AID - 10.1097/BPO.0000000000001798 [doi]
PST - ppublish
SO  - J Pediatr Orthop. 2021 May-Jun 01;41(5):306-311. doi: 
      10.1097/BPO.0000000000001798.

PMID- 33170486
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 51
IP  - 2
DP  - 2021 Feb
TI  - Defining platelet response to acetylsalicylic acid: the relation between 
      inhibition of serum thromboxane B(2) and agonist-induced platelet aggregation.
PG  - 260-264
LID - 10.1007/s11239-020-02334-x [doi]
AB  - Arachidonic acid (AA)-induced platelet aggregation (PA) and serum thromboxane 
      B(2) (TxB(2)) inhibition are widely used to indicate cyclooxygenase-1 activity 
      and the antiplatelet effect of acetylsalicylic acid (ASA). Despite decades of 
      investigations, the relation between these measurements remains unclear. We 
      sought to evaluate the relation between AA-PA and serum TxB(2) inhibition. We 
      serially measured AA-PA (conventional aggregation), serum TxB(2,) plasma ASA and 
      salicylic acid (SA) (liquid chromatography-mass spectrometry), and urinary 
      11-dehydro thromboxane B(2) (u11-dh TxB(2)) (enzyme-linked immunosorbent assay) 
      levels at 10 times over 24 hours in seventeen healthy volunteers receiving a 
      single dose of 162 mg chewed and swallowed ASA (n = 6), 50 mg inhaled ASA 
      (n = 6), or 100 mg inhaled ASA (n = 5) (ClinicalTrials.gov Identifier: 
      NCT04328883, April 1, 2020). Baseline variability was more pronounced with serum 
      TxB(2) (31-680 ng/mL) as compared to maximal AA-PA (65-81%) and u11-dh TxB(2) 
      (1556-4440 pg/mg creatinine). The relation between serum TxB(2) inhibition and 
      AA-PA was stepwise; after 30-40% inhibition of serum TxB(2), AA-PA fell to < 5%. 
      By receiver operating characteristic curve analysis using AA-PA < 5% to define 
      aspirin responsiveness, serum TxB2 inhibition > 49% and u11-dh TxB2 < 1520 pg/mg 
      creatinine met the definition. Our study demonstrates a non-linear relation 
      between serum TxB(2) inhibition and AA-PA. Aggregation was nil once TxB(2) 
      inhibition reached > 49%. Moreover, these results suggest that the definition of 
      > 95% inhibition of serum TxB(2) to indicate the level of platelet COX-1 
      inhibition needed for clinical efficacy may be overestimated and should be 
      re-considered in future translational research investigations that attempt to 
      link the clinical efficacy of ASA with a laboratory measurement cutoff.
FAU - Gurbel, Paul A
AU  - Gurbel PA
AUID- ORCID: 0000-0002-5461-568X
AD  - Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of 
      Baltimore, Baltimore, MD, 21215, USA. pgurbel@lifebridgehealth.org.
FAU - Bliden, Kevin P
AU  - Bliden KP
AD  - Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of 
      Baltimore, Baltimore, MD, 21215, USA.
FAU - Tantry, Udaya S
AU  - Tantry US
AD  - Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of 
      Baltimore, Baltimore, MD, 21215, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04328883
PT  - Journal Article
DEP - 20201110
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Pilot Projects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Thromboxane B2/*antagonists & inhibitors/blood
MH  - Young Adult
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Arachidonic acid
OT  - Platelet aggregation
OT  - Thromboxane B2
EDAT- 2020/11/11 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/11/10 12:14
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/11/10 12:14 [entrez]
AID - 10.1007/s11239-020-02334-x [pii]
AID - 10.1007/s11239-020-02334-x [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2021 Feb;51(2):260-264. doi: 10.1007/s11239-020-02334-x. 
      Epub 2020 Nov 10.

PMID- 3145214
OWN - NLM
STAT- MEDLINE
DCOM- 19890221
LR  - 20161123
IS  - 0014-8318 (Print)
IS  - 0014-8318 (Linking)
VI  - 51
IP  - 5
DP  - 1988 Sep-Oct
TI  - [Analgesic action and pharmacokinetics of lysine acetylsalicylate administered 
      intramuscularly].
PG  - 78-82
AB  - The analgesic effect, acute toxicity and pharmacokinetics of lysine 
      acetylsalicylate (LAS), a water-soluble salt of acetylsalicylic acid (ASA) were 
      studied as compared with a 50% solution of analgin and a 4% solution of 
      amidopyrine at intramuscular administration and ASA administered 
      intragastrically. During inflammation-induced pain in rats LAS exerts a 
      pronounced analgesic effect exceeding the activity of other agents. LD50 of LAS 
      was similar to that of analgin and ASA. LAS toxicity was significantly less than 
      that of amidopyrine. Bioavailability of ASA at intramuscular administration to 
      rabbits was close to that at intravenous injection and significantly higher as 
      compared with intragastric administration.
FAU - Libina, V V
AU  - Libina VV
FAU - Chaĭka, L A
AU  - Chaĭka LA
FAU - Kosheleva, L P
AU  - Kosheleva LP
FAU - Khadzhaĭ, Ia I
AU  - Khadzhaĭ IaI
FAU - Pichugin, V V
AU  - Pichugin VV
LA  - rus
PT  - Comparative Study
PT  - Journal Article
TT  - Anal'geticheskoe deĭstvie i farmakokinetika lizina atsetilsalitsilata pri 
      vnutrimyshechnom vvedenii.
PL  - Russia (Federation)
TA  - Farmakol Toksikol
JT  - Farmakologiia i toksikologiia
JID - 16920420R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 01704YP3MO (Aminopyrine)
RN  - 6429L0L52Y (Dipyrone)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aminopyrine/pharmacokinetics
MH  - Animals
MH  - *Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/pharmacokinetics/toxicity
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacokinetics/toxicity
MH  - Biological Availability
MH  - Dipyrone/pharmacokinetics
MH  - Drug Evaluation, Preclinical
MH  - Female
MH  - Inflammation/chemically induced/drug therapy
MH  - Injections, Intramuscular
MH  - Lethal Dose 50
MH  - Lysine/administration & dosage/*analogs & derivatives/pharmacokinetics/toxicity
MH  - Male
MH  - Rabbits
MH  - Rats
MH  - Time Factors
EDAT- 1988/09/01 00:00
MHDA- 1988/09/01 00:01
CRDT- 1988/09/01 00:00
PHST- 1988/09/01 00:00 [pubmed]
PHST- 1988/09/01 00:01 [medline]
PHST- 1988/09/01 00:00 [entrez]
PST - ppublish
SO  - Farmakol Toksikol. 1988 Sep-Oct;51(5):78-82.

PMID- 18242146
OWN - NLM
STAT- MEDLINE
DCOM- 20080417
LR  - 20131121
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
VI  - 6
IP  - 3
DP  - 2008 Mar
TI  - Peptic ulcerations are related to systemic rather than local effects of low-dose 
      aspirin.
PG  - 309-13
LID - 10.1016/j.cgh.2007.12.018 [doi]
AB  - BACKGROUND & AIMS: Effervescent calcium carbasalate is a calcium-salt of 
      acetylsalicylic acid causing less local gastric damage than acetylsalicylic acid 
      at high doses in healthy controls. The aim of the study was to investigate the 
      incidence of peptic ulcers in a population-based cohort using bioequivalent 
      low-dose acetylsalicylic acid (80 mg) or effervescent calcium carbasalate (100 
      mg). METHODS: Incident acetylsalicylic acid or effervescent calcium carbasalate 
      users were identified from the Integrated Primary Care Information database. The 
      study cohort comprised 19,819 subjects: 11,891 on acetylsalicylic acid and 7928 
      on effervescent calcium carbasalate. Incidence rates for documented peptic ulcer 
      disease confirmed by endoscopy were calculated and time-dependent adjusted Cox 
      regression analysis was used to compare the risk of peptic ulcers for patients 
      using acetylsalicylic acid or effervescent calcium carbasalate. RESULTS: During 
      an average 1.85 years of follow-up evaluation, 115 ulcers were found. The risk 
      for developing a peptic ulcer during drug use was: 3.07 per 1000 person-years for 
      acetylsalicylic acid and 4.31 for effervescent calcium carbasalate. The risk of 
      peptic ulcers was not statistically significantly higher in patients using 
      effervescent calcium carbasalate than in acetylsalicylic acid users (adjusted 
      hazard ratio, 1.39; 95% confidence interval, 0.92-2.12). CONCLUSIONS: The 
      incidence rate of peptic ulcer disease is similar in patients using low-dose 
      effervescent calcium carbasalate compared with regular low-dose acetylsalicylic 
      acid. This implicates that peptic ulcers seem to be related to systemic rather 
      than to local effects of low-dose acetylsalicylic acid.
FAU - van Oijen, Martijn G H
AU  - van Oijen MG
AD  - Department of Gastroenterology, Radboud University Nijmegen Medical Center, 
      Nijmegen, The Netherlands. M.vanOijen@MDL.umcn.nl
FAU - Dieleman, Jeanne P
AU  - Dieleman JP
FAU - Laheij, Robert J F
AU  - Laheij RJ
FAU - Sturkenboom, Miriam C J M
AU  - Sturkenboom MC
FAU - Jansen, Jan B M J
AU  - Jansen JB
FAU - Verheugt, Freek W A
AU  - Verheugt FW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20080131
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal 
      of the American Gastroenterological Association
JID - 101160775
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 8W8T17847W (Urea)
RN  - N667F17JP1 (carbaspirin calcium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects/analogs & derivatives
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Netherlands/epidemiology
MH  - Peptic Ulcer/*chemically induced/epidemiology
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - Urea/administration & dosage/adverse effects/analogs & derivatives
EDAT- 2008/02/05 09:00
MHDA- 2008/04/18 09:00
CRDT- 2008/02/05 09:00
PHST- 2008/02/05 09:00 [pubmed]
PHST- 2008/04/18 09:00 [medline]
PHST- 2008/02/05 09:00 [entrez]
AID - S1542-3565(07)01160-3 [pii]
AID - 10.1016/j.cgh.2007.12.018 [doi]
PST - ppublish
SO  - Clin Gastroenterol Hepatol. 2008 Mar;6(3):309-13. doi: 10.1016/j.cgh.2007.12.018. 
      Epub 2008 Jan 31.

PMID- 33964664
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20220716
IS  - 1532-2823 (Electronic)
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 169
DP  - 2021 Jun
TI  - Aspirin and omega-3 fatty acid status interact in the prevention of 
      cardiovascular diseases in Framingham Heart Study.
PG  - 102283
LID - S0952-3278(21)00046-6 [pii]
LID - 10.1016/j.plefa.2021.102283 [doi]
AB  - BACKGROUND: The roles of omega-3 (n3) fatty acids [eicosapentaenoic acid (EPA) 
      and docosahexaenoic acid (DHA)] and low-dose aspirin in the primary prevention of 
      ischemic cardiovascular disease (CVD) are controversial. Since omega-3 (n3) fatty 
      acids and aspirin affect cyclooxygenase activity in platelets, there could be a 
      clinically-relevant effect of aspirin combined with a particular n3 fatty acid 
      level present in each individual. METHODS: RBC EPA+DHA, arachidonic acid (AA) and 
      docosapentaenoic acid (DPA) were measured in 2500 participants without known CVD 
      in the Framingham Heart Study. We then tested for interactions with reported 
      aspirin use (1004 reported use and 1494 did not) on CVD outcomes. The median 
      follow-up was 7.2 years. RESULTS: Having RBC EPA+DHA in the second quintile 
      (4.2-4.9% of total fatty acids) was associated with significantly reduced risk 
      for future CVD events (relative to the first quintile, <4.2%) in those who did 
      not take aspirin (HR 0.54 (0.30, 0.98)), but in those reporting aspirin use, risk 
      was significantly increased (HR 2.16 (1.19, 3.92)) in this quintile. This 
      interaction remained significant when adjusting for confounders. Significant 
      interactions were also present for coronary heart disease and stroke outcomes 
      using the same quintiles. Similar findings were present for EPA and DHA alone but 
      not for DPA and AA. CONCLUSIONS: There is a complex interaction between aspirin 
      use and RBC EPA+DHA levels on CVD outcomes. This suggests that aspirin use may be 
      beneficial in one omega-3 environment but harmful in another, implying that a 
      personalized approach to both aspirin use and omega-3 supplementation may be 
      needed.
CI  - Copyright © 2021. Published by Elsevier Ltd.
FAU - Block, Robert C
AU  - Block RC
AD  - Department of Public Health Sciences, University of Rochester School of Medicine 
      and Dentistry, Rochester, NY, United States; Cardiology Division, Department of 
      Medicine, University of Rochester School of Medicine and Dentistry, Rochester, 
      New York, United States. Electronic address: robert_block@urmc.rochester.edu.
FAU - Shearer, Gregory C
AU  - Shearer GC
AD  - Department of Nutritional Sciences, Pennsylvania State University, University 
      Park, Pennsylvania, United States.
FAU - Holub, Ashley
AU  - Holub A
AD  - Department of Public Health Sciences, University of Rochester School of Medicine 
      and Dentistry, Rochester, NY, United States.
FAU - Tu, Xin M
AU  - Tu XM
AD  - Division of Biostatistics and Bioinformatics, Department of Family Medicine and 
      Public Health, University of California, San Diego, United States.
FAU - Mousa, Shaker
AU  - Mousa S
AD  - The Pharmaceutical Research Institute, Albany College of Pharmacy and Health 
      Sciences, Rensselaer, NY, United States.
FAU - Brenna, J Thomas
AU  - Brenna JT
AD  - Departments of Pediatrics, Human Nutrition, and Chemistry, Dell Pediatric 
      Research Institute, University of Texas at Austin, United States.
FAU - Harris, William S
AU  - Harris WS
AD  - Department of Internal Medicine, Sanford School of Medicine, University of South 
      Dakota; and OmegaQuant Analytics, LLC, Sioux Falls, SD, United States.
FAU - Tintle, Nathan
AU  - Tintle N
AD  - Department of Mathematics and Statistics, Dordt University, Sioux Center, Iowa, 
      United States.
LA  - eng
SI  - ClinicalTrials.gov/NCT00005121
GR  - HHSN268201500001C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201500001I/HL/NHLBI NIH HHS/United States
GR  - N01HC25195/HL/NHLBI NIH HHS/United States
GR  - R01 HL089590/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210424
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - NS3OZT14QT (docosapentaenoic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arachidonic Acid/*blood
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/blood/*prevention & control
MH  - Docosahexaenoic Acids/*blood
MH  - Eicosapentaenoic Acid/*blood
MH  - Fatty Acids, Unsaturated/*blood
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
PMC - PMC8159885
MID - NIHMS1701183
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Docosahexaenoic acid
OT  - Eicosapentaenoic acid
OT  - Fatty acid
EDAT- 2021/05/09 06:00
MHDA- 2022/02/01 06:00
CRDT- 2021/05/08 20:21
PHST- 2020/12/14 00:00 [received]
PHST- 2021/03/18 00:00 [revised]
PHST- 2021/04/12 00:00 [accepted]
PHST- 2021/05/09 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
PHST- 2021/05/08 20:21 [entrez]
AID - S0952-3278(21)00046-6 [pii]
AID - 10.1016/j.plefa.2021.102283 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2021 Jun;169:102283. doi: 
      10.1016/j.plefa.2021.102283. Epub 2021 Apr 24.

PMID- 23517228
OWN - NLM
STAT- MEDLINE
DCOM- 20131216
LR  - 20130522
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 28
IP  - 6
DP  - 2013 Jun
TI  - Does acetylsalicylic acid or warfarin affect the accuracy of fecal occult blood 
      tests?
PG  - 931-6
LID - 10.1111/jgh.12201 [doi]
AB  - BACKGROUND: Current guidelines for screening of colorectal cancer do not offer 
      specific recommendations for cessation of antithrombotic agents prior to fecal 
      occult blood test (FOBT). AIM: To asess the accuracy of FOBT in patients taking 
      acetylsalicylic acid (ASA) or warfarin. METHODS: A literature search was 
      conducted for studies that investigated the accuracy of FOBT in patients taking 
      ASA and warfarin. The primary outcome was the pooled relative risk (RR) for true 
      positive FOBT for detecting significant colonic neoplasia in patients taking ASA 
      or warfarin compared with controls. The secondary outcome was a pooled RR for 
      true positive in guaiac FOBT (g-FOBT) compared with immunochemical FOBT (i-FOBT). 
      RESULTS: Five observational studies included 759 patients taking ASA and 1652 
      control subjects. In patients taking ASA, pooled RR for true positive FOBT was 
      0.82 (95% confidence interval [CI] 0.73-0.93, P=0.0009), pooled RR for true 
      positive g-FOBT was 0.69 (95% CI 0.60-0.79, P<0.0001), whereas pooled RR for true 
      positive i-FOBT was 1.013 (95% CI 0.81-1.30, P=0.8182). Five observational 
      studies included 806 patients taking warfarin and 10 338 control subjects. In 
      patients taking warfarin, pooled RR for true positive FOBT was 1.559 (95% CI 
      1.349-1.801, P<0.0001). CONCLUSION: The results of our meta-analysis demonstrate 
      that in patients taking ASA, there is a decrease in the positive predictive value 
      (PPV) of g-FOBT but no significant difference in the PPV of i-FOBT compared with 
      control subjects for detecting significant neoplasia. In patients taking 
      warfarin, the PPV of FOBT was increased for detection of colorectal cancer 
      compared with control subjects.
CI  - © 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing 
      Asia Pty Ltd.
FAU - Gandhi, Sumeet
AU  - Gandhi S
AD  - Department of Medicine (Division of Internal Medicine), University of Toronto, 
      Toronto, Canada.
FAU - Narula, Neeraj
AU  - Narula N
FAU - Gandhi, Samir
AU  - Gandhi S
FAU - Marshall, John K
AU  - Marshall JK
FAU - Farkouh, Michael E
AU  - Farkouh ME
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - *Occult Blood
MH  - Reproducibility of Results
MH  - Warfarin/*pharmacology
EDAT- 2013/03/23 06:00
MHDA- 2013/12/18 06:00
CRDT- 2013/03/23 06:00
PHST- 2013/03/06 00:00 [accepted]
PHST- 2013/03/23 06:00 [entrez]
PHST- 2013/03/23 06:00 [pubmed]
PHST- 2013/12/18 06:00 [medline]
AID - 10.1111/jgh.12201 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2013 Jun;28(6):931-6. doi: 10.1111/jgh.12201.

PMID- 2077471
OWN - NLM
STAT- MEDLINE
DCOM- 19910419
LR  - 20131121
IS  - 0030-9311 (Print)
IS  - 0030-9311 (Linking)
VI  - 30
IP  - 9-10
DP  - 1990 Sep-Oct
TI  - Juvenile rheumatoid arthritis (JRA).
PG  - 261-5
AB  - A case of Juvenile Rheumatoid Arthritis in a 12-year-old girl is reported; the 
      patient had been suffering since she was 2.5 years old. The diagnosis was made 
      based on history, clinical symptoms, radiology and laboratory findings. The 
      patient showed abnormalities of the eyes, namely left papillar atrophy and right 
      papillar edema. Osteoporosis was found in the proximal area of the right and left 
      ulna and radius as well as in the lateral epicondylus. Laboratory findings such 
      as rheumatoid factor, LE cells and ANA were negative; the C3 was low; ASTO was 
      within normal ranges and the serum creatinine was 2.3 mg%. When this paper was 
      made the patient was still under outpatient treatment; complaints of arthralgia 
      disappeared after she had been treated with aspirin.
FAU - Elymbra, D
AU  - Elymbra D
AD  - Department of Child Health, School of Medicine, University of North Sumatera/Dr. 
      Pirngadi Hospital, Medan.
FAU - Ramayati, R
AU  - Ramayati R
FAU - Rusdidjas
AU  - Rusdidjas
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Indonesia
TA  - Paediatr Indones
JT  - Paediatrica Indonesiana
JID - 0376416
RN  - 0 (Antibodies, Antinuclear)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Antinuclear/analysis
MH  - *Arthritis, Juvenile/diagnosis/therapy
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Female
MH  - Humans
MH  - Indonesia
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
PST - ppublish
SO  - Paediatr Indones. 1990 Sep-Oct;30(9-10):261-5.

PMID- 7041034
OWN - NLM
STAT- MEDLINE
DCOM- 19820621
LR  - 20180217
IS  - 0030-3755 (Print)
IS  - 0030-3755 (Linking)
VI  - 184
IP  - 4
DP  - 1982
TI  - Biphasic action of prostacyclin on intraocular pressure.
PG  - 204-9
AB  - The effect of exogenous prostacyclin (PGI2) on the rabbit eye was investigated. 
      During intravenous infusion, intraocular pressure readings and changes of the 
      luminal diameters of choroidal veins were recorded simultaneously. 5 ng/kg/min 
      induced a reduction of intraocular pressure and no blood flow changes. 25 
      ng/kg/min resulted in a considerable vasodilatation in the posterior uvea 
      paralleled by an increase in intraocular pressure. These results suggest the 
      explanation that exogenous prostacyclin in high doses causes an augmentation of 
      posterior uveal blood flow and thereby a rise in intraocular pressure. Low (2.5 
      mg/kg BW) or high (17.5 mg/kg BW) aspirin caused no changes in intraocular 
      pressure, indicating a minor role of endogenous prostaglandins in regulating 
      intraocular tension.
FAU - Wizemann, A
AU  - Wizemann A
FAU - Ebinger, G
AU  - Ebinger G
FAU - Krey, H
AU  - Krey H
FAU - Wizemann, V
AU  - Wizemann V
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Ophthalmologica
JT  - Ophthalmologica. Journal international d'ophtalmologie. International journal of 
      ophthalmology. Zeitschrift fur Augenheilkunde
JID - 0054655
RN  - 0 (Prostaglandins)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Choroid/blood supply
MH  - Dose-Response Relationship, Drug
MH  - Epoprostenol/*pharmacology
MH  - Fluorescein Angiography
MH  - Intraocular Pressure/*drug effects
MH  - Prostaglandins/*pharmacology
MH  - Rabbits
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1159/000309207 [doi]
PST - ppublish
SO  - Ophthalmologica. 1982;184(4):204-9. doi: 10.1159/000309207.

PMID- 6546915
OWN - NLM
STAT- MEDLINE
DCOM- 19840605
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 29
IP  - 5
DP  - 1984 May
TI  - In vitro adsorption of bile salts and aspirin to sucralfate.
PG  - 402-6
AB  - Sucralfate, an aluminum salt of sulfated sucrose, is a new drug designed for the 
      treatment of peptic ulcer. Sucralfate has been reported to be useful in a variety 
      of situations including prevention of aspirin-induced gastric mucosal damage. We 
      investigated the in vitro adsorption of bile salts or aspirin to sucralfate in 
      environments simulating the stomach (pH 1.5), small intestine (pH 7), and colon 
      (pH 7.8). Bile salts were incubated with sucralfate, and the quantity of bile 
      salt adsorbed was calculated by subtraction from the amount remaining in solution 
      after centrifugation at 12,500g for 30 min. Adsorption experiments were performed 
      in bile salt solutions at pH 1.5 and 7.0 with 0-10 g/dl sucralfate using 
      glycocholate, glycochenodeoxycholate, taurocholate, taurodeoxycholate, or 
      taurochenodeoxycholate. The dihydroxy-unconjugated bile salts, deoxycholic, and 
      chenodeoxycholic salts were tested at pH 7.8. Binding capacity (micromoles per 
      gram sucralfate) was calculated from the linear regression of micromoles bound vs 
      grams sucralfate incubated. Sucralfate adsorbed all bile salts tested (except 
      taurocholic acid at pH 1.5) but was less effective than cholestyramine. 
      Sucralfate does not adsorb sufficient bile salts at neutral pH to cause bile salt 
      depletion. Aspirin was minimally adsorbed by sucralfate [7.5 mumol (1.4 mg)/g 
      sucralfate, pH 1.5], and thus adsorption of aspirin does not explain the 
      protective effect of sucralfate against aspirin injury.
FAU - Graham, D Y
AU  - Graham DY
FAU - Sackman, J W
AU  - Sackman JW
FAU - Giesing, D H
AU  - Giesing DH
FAU - Runser, D J
AU  - Runser DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Bile Acids and Salts)
RN  - 11041-12-6 (Cholestyramine Resin)
RN  - 54182-58-0 (Sucralfate)
RN  - CPD4NFA903 (Aluminum)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Aluminum/*metabolism
MH  - Aspirin/*metabolism
MH  - Bile Acids and Salts/*metabolism
MH  - Cholestyramine Resin/metabolism
MH  - In Vitro Techniques
MH  - Sucralfate
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
AID - 10.1007/BF01296213 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1984 May;29(5):402-6. doi: 10.1007/BF01296213.

PMID- 9701102
OWN - NLM
STAT- MEDLINE
DCOM- 19980903
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 158
IP  - 15
DP  - 1998 Aug 10-24
TI  - Cost-effectiveness of therapies for patients with nonvalvular atrial 
      fibrillation.
PG  - 1669-77
AB  - BACKGROUND: The most appropriate treatment(s) for patients with atrial 
      fibrillation remains uncertain. OBJECTIVE: To examine the cost-effectiveness of 
      anti-thrombotic and antiarrhythmic treatment strategies for atrial fibrillation. 
      METHODS: We performed decision and cost-effectiveness analyses using a Markov 
      state transition model. We gathered data from the English-language literature 
      using MEDLINE searches and bibliographies from selected articles. We obtained 
      financial data from nationwide physician-fee references, a medical center's cost 
      accounting system, and one of New England's larger managed care organizations. We 
      examined strategies that included combinations of cardioversion, antiarrhythmic 
      therapy with quinidine, sotalol hydrochloride, or amiodarone, and anticoagulant 
      or antiplatelet therapy. RESULTS: For a 65-year-old man with nonvalvular atrial 
      fibrillation, any intervention results in a significant gain in quality-adjusted 
      life years (QALYs) compared with no specific therapy. Use of aspirin results in 
      the largest incremental gain (1.2 QALYs). Cardioversion followed by the use of 
      amiodarone and warfarin together is the most effective strategy, yielding a gain 
      of 2.3 QALYs compared with no specific therapy. The marginal cost-effectiveness 
      ratios of cardioversion followed by aspirin, with or without amiodarone, are 
      $33800 per QALY and $10800 per QALY, respectively. Cardioversion followed by 
      amiodarone and warfarin has a marginal cost-effectiveness ratio of $92400 per 
      QALY compared with amiodarone and aspirin. Strategies that include cardioversion 
      followed by either quinidine or sotalol are both more expensive and less 
      effective than competing strategies. CONCLUSIONS: Cardioversion of patients with 
      nonvalvular atrial fibrillation followed by the use of aspirin alone or with 
      amiodarone has a reasonable marginal cost-effectiveness ratio. While 
      cardioversion followed by the use of amiodarone and warfarin results in the 
      greatest gain in quality-adjusted life expectancy, it is expensive (ie, has a 
      high marginal cost-effectiveness ratio) compared with aspirin and amiodarone. 
      Finally, for patients who are bothered little by symptoms of atrial fibrillation, 
      cardioversion followed by either aspirin or warfarin without subsequent 
      antiarrhythmic therapy is the treatment of choice.
FAU - Eckman, M H
AU  - Eckman MH
AD  - Department of Medicine, New England Medical Center, Boston, Mass 02111, USA. 
      mark.eckman@es.nemc.org
FAU - Falk, R H
AU  - Falk RH
FAU - Pauker, S G
AU  - Pauker SG
LA  - eng
GR  - LM04493/LM/NLM NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 1999 Jan-Feb;130(1):24
MH  - Aged
MH  - Anti-Arrhythmia Agents/*economics/*therapeutic use
MH  - Aspirin/economics/therapeutic use
MH  - Atrial Fibrillation/*economics/*therapy
MH  - Cost-Benefit Analysis
MH  - Costs and Cost Analysis
MH  - Decision Support Techniques
MH  - Electric Countershock/*economics
MH  - Fibrinolytic Agents/*economics/*therapeutic use
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Models, Economic
MH  - Quality of Life
MH  - Warfarin/economics/therapeutic use
EDAT- 1998/08/13 00:00
MHDA- 1998/08/13 00:01
CRDT- 1998/08/13 00:00
PHST- 1998/08/13 00:00 [pubmed]
PHST- 1998/08/13 00:01 [medline]
PHST- 1998/08/13 00:00 [entrez]
AID - 10.1001/archinte.158.15.1669 [doi]
PST - ppublish
SO  - Arch Intern Med. 1998 Aug 10-24;158(15):1669-77. doi: 
      10.1001/archinte.158.15.1669.

PMID- 23732713
OWN - NLM
STAT- MEDLINE
DCOM- 20130802
LR  - 20140130
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 158
IP  - 11
DP  - 2013 Jun 4
TI  - Aspirin versus low-molecular-weight heparin for extended venous thromboembolism 
      prophylaxis after total hip arthroplasty: a randomized trial.
PG  - 800-6
LID - 10.7326/0003-4819-158-11-201306040-00004 [doi]
AB  - BACKGROUND: The role of aspirin in thromboprophylaxis after total hip 
      arthroplasty (THA) is controversial. OBJECTIVE: To compare extended prophylaxis 
      with aspirin and dalteparin for prevention of symptomatic venous thromboembolism 
      (VTE) after THA. DESIGN: Multicenter randomized, controlled trial with a 
      noninferiority design based on a minimal clinically important difference of 2.0%. 
      Randomization was electronically generated; patients were assigned to a treatment 
      group through a Web-based program. Patients, physicians, study coordinators, 
      health care team members, outcome adjudicators, and data analysts were blinded to 
      interventions. (Current Controlled Trials: ISRCTN11902170). SETTING: 12 tertiary 
      care orthopedic referral centers in Canada. PATIENTS: 778 patients who had 
      elective unilateral THA between 2007 and 2010. INTERVENTION: After an initial 10 
      days of dalteparin prophylaxis after elective THA, patients were randomly 
      assigned to 28 days of dalteparin (n = 400) or aspirin (n = 386). MEASUREMENTS: 
      Symptomatic VTE confirmed by objective testing (primary efficacy outcome) and 
      bleeding. RESULTS: Five of 398 patients (1.3%) randomly assigned to dalteparin 
      and 1 of 380 (0.3%) randomly assigned to aspirin had VTE (absolute difference, 
      1.0 percentage point [95% CI, -0.5 to 2.5 percentage points]). Aspirin was 
      noninferior (P < 0.001) but not superior (P = 0.22) to dalteparin. Clinically 
      significant bleeding occurred in 5 patients (1.3%) receiving dalteparin and 2 
      (0.5%) receiving aspirin. The absolute between-group difference in a composite of 
      all VTE and clinically significant bleeding events was 1.7 percentage points (CI, 
      -0.3 to 3.8 percentage points; P = 0.091) in favor of aspirin. LIMITATION: The 
      study was halted prematurely because of difficulty with patient recruitment. 
      CONCLUSION: Extended prophylaxis for 28 days with aspirin was noninferior to and 
      as safe as dalteparin for the prevention of VTE after THA in patients who 
      initially received dalteparin for 10 days. Given its low cost and greater 
      convenience, aspirin may be considered a reasonable alternative for extended 
      thromboprophylaxis after THA. PRIMARY FUNDING SOURCE: Canadian Institutes of 
      Health Research.
FAU - Anderson, David R
AU  - Anderson DR
AD  - Dalhousie University, Halifax, Nova Scotia, Canada. 
      david.anderson@cdha.nshealth.ca
FAU - Dunbar, Michael J
AU  - Dunbar MJ
FAU - Bohm, Eric R
AU  - Bohm ER
FAU - Belzile, Etienne
AU  - Belzile E
FAU - Kahn, Susan R
AU  - Kahn SR
FAU - Zukor, David
AU  - Zukor D
FAU - Fisher, William
AU  - Fisher W
FAU - Gofton, Wade
AU  - Gofton W
FAU - Gross, Peter
AU  - Gross P
FAU - Pelet, Stephane
AU  - Pelet S
FAU - Crowther, Mark
AU  - Crowther M
FAU - MacDonald, Steven
AU  - MacDonald S
FAU - Kim, Paul
AU  - Kim P
FAU - Pleasance, Susan
AU  - Pleasance S
FAU - Davis, Nicki
AU  - Davis N
FAU - Andreou, Pantelis
AU  - Andreou P
FAU - Wells, Philip
AU  - Wells P
FAU - Kovacs, Michael
AU  - Kovacs M
FAU - Rodger, Marc A
AU  - Rodger MA
FAU - Ramsay, Tim
AU  - Ramsay T
FAU - Carrier, Marc
AU  - Carrier M
FAU - Vendittoli, Pascal-Andre
AU  - Vendittoli PA
LA  - eng
SI  - ISRCTN/ISRCTN11902170
GR  - MCT-82948/Canadian Institutes of Health Research/Canada
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
CIN - Ann Intern Med. 2013 Sep 17;159(6):JC12. PMID: 24042383
CIN - Ann Intern Med. 2013 Oct 1;159(7):502. PMID: 24081295
CIN - Ann Intern Med. 2013 Oct 1;159(7):502-3. PMID: 24081296
CIN - Praxis (Bern 1994). 2013 Oct 16;102(21):1323-4. PMID: 24129302
MH  - Adult
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Arthroplasty, Replacement, Hip/*adverse effects
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Dalteparin/adverse effects/*therapeutic use
MH  - Drug Administration Schedule
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Venous Thromboembolism/*prevention & control
EDAT- 2013/06/05 06:00
MHDA- 2013/08/03 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/06/05 06:00 [entrez]
PHST- 2013/06/05 06:00 [pubmed]
PHST- 2013/08/03 06:00 [medline]
AID - 1692573 [pii]
AID - 10.7326/0003-4819-158-11-201306040-00004 [doi]
PST - ppublish
SO  - Ann Intern Med. 2013 Jun 4;158(11):800-6. doi: 
      10.7326/0003-4819-158-11-201306040-00004.

PMID- 31446057
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20201101
IS  - 1873-4596 (Electronic)
IS  - 0891-5849 (Print)
IS  - 0891-5849 (Linking)
VI  - 143
DP  - 2019 Nov 1
TI  - Nitro aspirin (NCX4040) induces apoptosis in PC3 metastatic prostate cancer cells 
      via hydrogen peroxide (H(2)O(2))-mediated oxidative stress.
PG  - 494-509
LID - S0891-5849(19)30967-0 [pii]
LID - 10.1016/j.freeradbiomed.2019.08.025 [doi]
AB  - Non-steroidal anti-inflammatory drugs (NSAID) have shown promise as anticancer 
      agents by inducing cell death apart from their antipyretic, anti-inflammatory and 
      anti-thrombogenic effects. In our current study, we investigated the oxidative 
      stress mediated cell death mechanism of a NSAID derivative NCX4040 (a nitric 
      oxide (NO) releasing form of aspirin) in castration-resistant prostate cancer 
      (CRPC) PC3 cell line. Our data revealed that NCX4040 is more potent than its 
      parent compound aspirin or NO releasing compound DETA NONOate. NCX4040 
      significantly induced hydrogen peroxide formation with ensuing oxidative stress 
      and mitochondrial depolarization resulting in lipid peroxidation, cell cycle 
      arrest, inhibition of colony growth and induction of apoptosis in PC3 cells. 
      Moreover, NCX4040 inhibited migration potential of PC3 cells by depolymerizing 
      F-actin and promoting anoikis. Interestingly, elevated levels of NADPH oxidase 1 
      (NOX1), superoxide dismutase (SOD) 1 and 2 were observed upon NCX4040 treatment. 
      However, down regulation of anti-apoptotic markers B-cell lymphoma 2 (Bcl2) and 
      anti-oxidant thioredoxin reductase 1 (TXNRD1) expression were observed. In 
      addition, NCX4040 down regulated cyclin D1 expression in PC3 cells further 
      supporting the anticancer effect of NCX4040. Western blot analysis revealed that 
      significant down regulation of key anti-apoptotic markers such as cellular 
      inhibitor of apoptosis protein-1 (cIAP1), X-linked inhibitor of apoptosis (XIAP), 
      survivin, and Cellular-Myc (c-Myc). On the other hand, NCX4040-treated cells 
      showed upregulation of phosho histone H2AX (pH2AX), cleaved caspase3 and cleaved 
      Poly [ADP-ribose] polymerase 1 (PARP1). Taken together, our data demonstrate that 
      NCX4040 treatment enhances free radical formation which in turn induces oxidative 
      stress leading to mitochondrial mediated cell death in metastatic PC3 cells.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Chinnapaka, Somaiah
AU  - Chinnapaka S
AD  - Department of Biomedical Sciences, College of Medicine, University of Illinois, 
      Rockford, IL, USA.
FAU - Zheng, Guoxing
AU  - Zheng G
AD  - Department of Biomedical Sciences, College of Medicine, University of Illinois, 
      Rockford, IL, USA.
FAU - Chen, Aoshuang
AU  - Chen A
AD  - Department of Biomedical Sciences, College of Medicine, University of Illinois, 
      Rockford, IL, USA.
FAU - Munirathinam, Gnanasekar
AU  - Munirathinam G
AD  - Department of Biomedical Sciences, College of Medicine, University of Illinois, 
      Rockford, IL, USA. Electronic address: mgnanas@uic.edu.
LA  - eng
GR  - R03 CA212890/CA/NCI NIH HHS/United States
GR  - R03 CA227218/CA/NCI NIH HHS/United States
GR  - R03 CA230829/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190822
PL  - United States
TA  - Free Radic Biol Med
JT  - Free radical biology & medicine
JID - 8709159
RN  - 0 (NCX 4040)
RN  - 0 (Nitro Compounds)
RN  - 0 (Oxidants)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Humans
MH  - Hydrogen Peroxide/*pharmacology
MH  - Male
MH  - Nitro Compounds/*pharmacology
MH  - Oxidants/pharmacology
MH  - Oxidative Stress/*drug effects
MH  - Prostatic Neoplasms/drug therapy/metabolism/*pathology
MH  - Tumor Cells, Cultured
MH  - Wound Healing
PMC - PMC6848783
MID - NIHMS1539881
OTO - NOTNLM
OT  - Catalase
OT  - Free radicals
OT  - Hydrogen peroxide
OT  - NCX4040
OT  - Nitric oxide
OT  - Oxidative stress
OT  - Prostate cancer
COIS- Conflict of interest Authors declare that they do not have conflict of interest.
EDAT- 2019/08/26 06:00
MHDA- 2020/07/23 06:00
CRDT- 2019/08/26 06:00
PHST- 2019/06/10 00:00 [received]
PHST- 2019/08/07 00:00 [revised]
PHST- 2019/08/21 00:00 [accepted]
PHST- 2019/08/26 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
PHST- 2019/08/26 06:00 [entrez]
AID - S0891-5849(19)30967-0 [pii]
AID - 10.1016/j.freeradbiomed.2019.08.025 [doi]
PST - ppublish
SO  - Free Radic Biol Med. 2019 Nov 1;143:494-509. doi: 
      10.1016/j.freeradbiomed.2019.08.025. Epub 2019 Aug 22.

PMID- 18550381
OWN - NLM
STAT- MEDLINE
DCOM- 20090303
LR  - 20131121
IS  - 1010-7940 (Print)
IS  - 1010-7940 (Linking)
VI  - 34
IP  - 2
DP  - 2008 Aug
TI  - The effect of off-pump coronary artery bypass grafting on platelet activation in 
      patients on aspirin therapy until surgery day.
PG  - 365-9; discussion 369
LID - 10.1016/j.ejcts.2008.05.010 [doi]
AB  - OBJECTIVE: Antiplatelet therapy is a class I indication in perioperative care 
      after coronary artery bypass grafting to prevent graft occlusion. We sought to 
      determine whether continuation of aspirin until surgery day suppresses platelet 
      activity in the early period after off-pump coronary artery bypass grafting 
      (OPCAB). MATERIAL AND METHODS: Forty-two patients at mean age of 62.5 (+/-7.9) 
      years were included. Average risk rate (EuroScore logistic) was 2.2 (+/-1.7) %. 
      In all patients collagen/epinephrine stimulated platelet plug formation (closure 
      time, CT) (CEPI-CT, s) using a platelet function analyzer (PFA-100), troponin I 
      (TnI), creatine kinase-MB (CK-MB), ST segment elevation were evaluated a day 
      before surgery, 4h after chest closure, 24 and 120 h after surgery. RESULTS: 
      Preoperative mean CEPI-CT was 224.8 (+/-79.7)s. In 13 (30%) patients aspirin 
      resistance (CEPI-CT<163 s.) was observed. In 4, 24 and 120 h time points CEPI-CT 
      was significantly reduced: 164.4 (+/-79), 168.5 (+/-83.3) and 167.5 (+/-80.4), 
      respectively (p<0,001). TnI and CK-MB (ng/ml) levels raised in respective time 
      points: 4 h (0.26 range 4; 1.9 range 6), 24 h (0.2 range 6; 2.6 range 8), 120 h 
      (0.04 range 2; 0.6 range 5). ST segment elevation (mV) changed in time: 4h (0.7 
      range 3.5), 48 h (0.7 range 2.8) and 120 h after surgery (0.2 range 1.5). There 
      were no significant correlations between CEPI-CT and TnI, CK-MB, ST segment 
      elevation found. CONCLUSION: Aspirin therapy continued until surgery day does not 
      protect against acute platelet activation in patients after OPCAB.
FAU - Suwalski, Grzegorz
AU  - Suwalski G
AD  - Department of Cardiac Surgery, Ist Chair of Cardiology, Medical University of 
      Warsaw, Banacha 1a Street, Warsaw, Poland. grzegorz.suwalski@wp.pl
FAU - Suwalski, Piotr
AU  - Suwalski P
FAU - Filipiak, Krzysztof J
AU  - Filipiak KJ
FAU - Postuła, Marek
AU  - Postuła M
FAU - Majstrak, Franciszek
AU  - Majstrak F
FAU - Opolski, Grzegorz
AU  - Opolski G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20080611
PL  - Germany
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European 
      Association for Cardio-thoracic Surgery
JID - 8804069
RN  - 0 (Hemoglobins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Coronary Artery Bypass, Off-Pump/*methods
MH  - Drug Administration Schedule
MH  - Drug Resistance
MH  - Hematocrit
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Ischemia/prevention & control
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Postoperative Care/methods
MH  - Postoperative Period
MH  - Preoperative Care/methods
MH  - Prospective Studies
EDAT- 2008/06/14 09:00
MHDA- 2009/03/04 09:00
CRDT- 2008/06/14 09:00
PHST- 2007/11/14 00:00 [received]
PHST- 2008/04/28 00:00 [revised]
PHST- 2008/05/07 00:00 [accepted]
PHST- 2008/06/14 09:00 [pubmed]
PHST- 2009/03/04 09:00 [medline]
PHST- 2008/06/14 09:00 [entrez]
AID - S1010-7940(08)00517-4 [pii]
AID - 10.1016/j.ejcts.2008.05.010 [doi]
PST - ppublish
SO  - Eur J Cardiothorac Surg. 2008 Aug;34(2):365-9; discussion 369. doi: 
      10.1016/j.ejcts.2008.05.010. Epub 2008 Jun 11.

PMID- 2468301
OWN - NLM
STAT- MEDLINE
DCOM- 19890512
LR  - 20131121
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 62
IP  - 4
DP  - 1989 Apr
TI  - Angioedema and IgE antibodies to aspirin: a case report.
PG  - 295-8
AB  - We present a case of a patient who developed two episodes of angioedema after 
      taking acetylsalicylic acid orally. Specific IgE antibodies to acetylsalicylic 
      human serum albumin (ASA-HSA) were found. A control group of 37 patients with 
      aspirin intolerance was studied and evidence of specific IgE antibodies was not 
      found. The follow-up of this case shows that in a short period of time the level 
      of specific IgE antibody decreases to undetectable levels similar to the negative 
      control population.
FAU - Blanca, M
AU  - Blanca M
AD  - Internal Medicine Department, Carlos Haya Hospital, Malaga, Spain.
FAU - Perez, E
AU  - Perez E
FAU - Garcia, J J
AU  - Garcia JJ
FAU - Miranda, A
AU  - Miranda A
FAU - Terrados, S
AU  - Terrados S
FAU - Vega, J M
AU  - Vega JM
FAU - Suau, R
AU  - Suau R
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - 0 (Epitopes)
RN  - 0 (Serum Albumin)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioedema/*chemically induced/immunology
MH  - Antibody Formation
MH  - Aspirin/*immunology/metabolism
MH  - Epitopes
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoglobulin E/analysis/*immunology
MH  - Male
MH  - Middle Aged
MH  - Protein Binding
MH  - Radioallergosorbent Test
MH  - Serum Albumin/metabolism
EDAT- 1989/04/01 00:00
MHDA- 1989/04/01 00:01
CRDT- 1989/04/01 00:00
PHST- 1989/04/01 00:00 [pubmed]
PHST- 1989/04/01 00:01 [medline]
PHST- 1989/04/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1989 Apr;62(4):295-8.

PMID- 23286294
OWN - NLM
STAT- MEDLINE
DCOM- 20130813
LR  - 20191112
IS  - 1875-614X (Electronic)
IS  - 1871-5230 (Linking)
VI  - 12
IP  - 1
DP  - 2013
TI  - Cardiovascular adverse effects of anti-inflammatory drugs.
PG  - 55-67
AB  - Anti-inflammatory drugs consist of non-steroidal anti-inflammatory drugs (NSAIDs) 
      including non-selective nsNSAIDs, aspirin, and cyclooxygenase-2 (COX-2)-selective 
      inhibitors also referred to as coxibs, and glucocorticoids (GCs). They are 
      worldwide prescribed drugs for many musculoskeletal conditions, such as 
      osteoarthritis and inflammatory rheumatic diseases. Anti-inflammatory drugs can 
      exert deleterious effects on the cardiovascular system, excluding aspirin. 
      NSAIDs, especially coxibs, have been demonstrated to increase cardiovascular risk 
      and have generated many concerns leading to the reassessment of their 
      benefit/risk ratio. GCs may also induce cardiovascular events, but evidence seems 
      to be less clear. Before prescribing these drugs, an assessment of cardiovascular 
      risk may be judicious. In this review, anti-inflammatory drugs, coxibs, nsNSAIDs 
      and GCs, and the risk of cardiovascular events will be discussed.
FAU - Roubille, Camille
AU  - Roubille C
AD  - Osteoarthritis Research Unit, University of Montreal Hospital Research Center 
      (CRCHUM), Notre-Dame Hospital, 1560 Sherbrooke Street East, Montreal, Quebec, 
      Canada. camille.roubille@gmail.com
FAU - Martel-Pelletier, Johanne
AU  - Martel-Pelletier J
FAU - Davy, Jean-Marc
AU  - Davy JM
FAU - Haraoui, Boulos
AU  - Haraoui B
FAU - Pelletier, Jean-Pierre
AU  - Pelletier JP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Antiinflamm Antiallergy Agents Med Chem
JT  - Anti-inflammatory & anti-allergy agents in medicinal chemistry
JID - 101462262
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Glucocorticoids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology/therapeutic 
      use
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/chemically induced/drug therapy/*epidemiology
MH  - Cardiovascular System/*drug effects
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase 2 Inhibitors/adverse effects/pharmacology/therapeutic use
MH  - Glucocorticoids/*adverse effects/pharmacology/therapeutic use
MH  - Humans
MH  - Risk Assessment
MH  - Treatment Outcome
EDAT- 2013/01/05 06:00
MHDA- 2013/08/14 06:00
CRDT- 2013/01/05 06:00
PHST- 2012/09/14 00:00 [received]
PHST- 2012/11/14 00:00 [revised]
PHST- 2012/12/09 00:00 [accepted]
PHST- 2013/01/05 06:00 [entrez]
PHST- 2013/01/05 06:00 [pubmed]
PHST- 2013/08/14 06:00 [medline]
AID - CMCAIAA-EPUB-20121231-9 [pii]
AID - 10.2174/1871523011312010008 [doi]
PST - ppublish
SO  - Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):55-67. doi: 
      10.2174/1871523011312010008.

PMID- 15182601
OWN - NLM
STAT- MEDLINE
DCOM- 20041027
LR  - 20191108
IS  - 1523-3782 (Print)
IS  - 1523-3782 (Linking)
VI  - 6
IP  - 4
DP  - 2004 Jul
TI  - Clopidogrel: how good is it and how does it work?
PG  - 264-8
AB  - Until recently, long-term antiplatelet therapy for the treatment and prevention 
      of the complications of atherothrombotic disease was limited to aspirin. Although 
      an incredibly cost-effective therapy, in placebo-controlled clinical trials 
      approximately 75% of patients at risk continue to experience thrombotic events 
      despite chronic aspirin therapy. The availability of the thienopyridines, in 
      particular clopidogrel, represents an important addition to the physician's 
      armamentarium. A number of clinical trials have confirmed the efficacy of the 
      combination of clopidogrel and aspirin therapy compared with aspirin alone, with 
      multiple other important large-scale clinical trials currently ongoing. The exact 
      mechanism of this benefit is still being elucidated but is clearly related to the 
      inhibition of the many consequences of platelet activation--vascular 
      inflammation, endothelial dysfunction, and localized 
      angiogenesis/mitogenesis--and not just aggregation.
FAU - Santa-Cruz, Richard A
AU  - Santa-Cruz RA
AD  - Division of Cardiology, University of North Carolina, 130 Mason Farm Road, Chapel 
      Hill, NC 27599-7075, USA.
FAU - Steinhubl, Steven R
AU  - Steinhubl SR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Coronary Artery Disease/*drug therapy
MH  - Drug Therapy, Combination
MH  - Endothelium, Vascular/drug effects/physiopathology
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/*therapeutic use
MH  - Recurrence
MH  - Ticlopidine/*analogs & derivatives/*pharmacology/*therapeutic use
MH  - Treatment Outcome
RF  - 24
EDAT- 2004/06/09 05:00
MHDA- 2004/10/28 09:00
CRDT- 2004/06/09 05:00
PHST- 2004/06/09 05:00 [pubmed]
PHST- 2004/10/28 09:00 [medline]
PHST- 2004/06/09 05:00 [entrez]
AID - 10.1007/s11886-004-0074-z [doi]
PST - ppublish
SO  - Curr Cardiol Rep. 2004 Jul;6(4):264-8. doi: 10.1007/s11886-004-0074-z.

PMID- 26248865
OWN - NLM
STAT- MEDLINE
DCOM- 20160607
LR  - 20150908
IS  - 1558-1497 (Electronic)
IS  - 0197-4580 (Linking)
VI  - 36
IP  - 10
DP  - 2015 Oct
TI  - Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid.
PG  - 2748-56
LID - S0197-4580(15)00329-2 [pii]
LID - 10.1016/j.neurobiolaging.2015.06.018 [doi]
AB  - We here report synthesis for the first time of the acetyl salicylic acid dimer 
      5,5'-methylenebis(2-acetoxybenzoic acid) (DAS). DAS inhibits aberrant complement 
      activation by selectively blocking factor D of the alternative complement pathway 
      and C9 of the membrane attack complex. We have previously identified aurin 
      tricarboxylic and its oligomers as promising agents in this regard. DAS is much 
      more potent, inhibiting erythrocyte hemolysis by complement-activated serum with 
      an IC50 in the 100-170 nanomolar range. There are numerous conditions where 
      self-damage from the complement system has been implicated in the pathology, 
      including such chronic degenerative diseases of aging as Alzheimer's disease, 
      Parkinson's disease, amyotrophic lateral sclerosis, and age-related macular 
      degeneration. Consequently, there is a high priority for the discovery and 
      development of agents that can successfully treat such conditions. DAS holds 
      considerable promise for being such an agent.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Lee, Moonhee
AU  - Lee M
AD  - Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University 
      of British Columbia, Vancouver, British Columbia, Canada.
FAU - Wathier, Matthew
AU  - Wathier M
AD  - Department of Chemistry, University of British Columbia, Vancouver, British 
      Columbia, Canada.
FAU - Love, Jennifer A
AU  - Love JA
AD  - Department of Chemistry, University of British Columbia, Vancouver, British 
      Columbia, Canada.
FAU - McGeer, Edith
AU  - McGeer E
AD  - Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University 
      of British Columbia, Vancouver, British Columbia, Canada.
FAU - McGeer, Patrick L
AU  - McGeer PL
AD  - Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University 
      of British Columbia, Vancouver, British Columbia, Canada. Electronic address: 
      mcgeerpl@mail.ubc.ca.
LA  - eng
PT  - Journal Article
DEP - 20150617
PL  - United States
TA  - Neurobiol Aging
JT  - Neurobiology of aging
JID - 8100437
RN  - 0 (5,5'-methylenebis(2-acetoxybenzoic acid))
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Complement C6)
RN  - 0 (Complement Membrane Attack Complex)
RN  - 4431-00-9 (Aurintricarboxylic Acid)
RN  - EC 3.4.21.46 (Complement Factor D)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alzheimer Disease/drug therapy/etiology
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemical synthesis/pharmacology
MH  - Aurintricarboxylic Acid
MH  - Benzhydryl Compounds/chemical synthesis/*pharmacology
MH  - Cats
MH  - Cells, Cultured
MH  - Complement Activation/*drug effects
MH  - Complement C6/antagonists & inhibitors
MH  - Complement Factor D/*antagonists & inhibitors
MH  - Complement Membrane Attack Complex
MH  - Complement Pathway, Alternative
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Drug Discovery
MH  - Erythrocytes/drug effects
MH  - Hemolysis/drug effects
MH  - Humans
MH  - Macular Degeneration/drug therapy/etiology
MH  - Molecular Targeted Therapy
MH  - Rats
OTO - NOTNLM
OT  - Age-related macular degeneration
OT  - Alzheimer's disease
OT  - C9
OT  - Factor B
OT  - Factor D
OT  - Membrane attack complex
OT  - Properdin
EDAT- 2015/08/08 06:00
MHDA- 2016/06/09 06:00
CRDT- 2015/08/08 06:00
PHST- 2015/03/23 00:00 [received]
PHST- 2015/06/10 00:00 [revised]
PHST- 2015/06/11 00:00 [accepted]
PHST- 2015/08/08 06:00 [entrez]
PHST- 2015/08/08 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - S0197-4580(15)00329-2 [pii]
AID - 10.1016/j.neurobiolaging.2015.06.018 [doi]
PST - ppublish
SO  - Neurobiol Aging. 2015 Oct;36(10):2748-56. doi: 
      10.1016/j.neurobiolaging.2015.06.018. Epub 2015 Jun 17.

PMID- 3629557
OWN - NLM
STAT- MEDLINE
DCOM- 19871022
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 47
IP  - 3
DP  - 1987 Aug 1
TI  - Comparison of the effect of acetylsalicylic acid on platelet function in male and 
      female patients with ischemic stroke.
PG  - 295-304
AB  - The aim of this study was to observe whether acetylsalicylic acid (ASA) had 
      different effects in both sexes. Out of the ischemic stroke patients who were 
      admitted to the National Taiwan University Hospital (NTUH), those who had not 
      taken ASA or ASA-like drugs for more than 2 weeks were selected for this study. 
      For the diagnosis of ischemic stroke, computed tomography (CT) of the brain was 
      performed in all cases, and for differential diagnosis, other necessary 
      procedures were employed in a few cases. The serum salicylate (SA) level was 
      measured by Trinder's method, thromboxane B2 (TXB2) and 6-keto-PGF1 alpha by 
      radioimmunoassay, threshold concentration of adenosine diphosphate (ADP) by 
      Born's method, and circulating platelet aggregates (CPA) by Wu and Hoak's method. 
      The present study showed that the means of serum SA levels after administration 
      of the same dose of ASA were not significantly different between the two sexes. 
      After ingestion of ASA, a single dose of 75 mg, 300 mg or 600 mg, or 300 mg 4 
      times a day, mean plasma TXB2 levels were significantly suppressed and mean 
      threshold concentrations of ADP were significantly elevated in the two sexes. 
      After administration of above-mentioned various doses of ASA, the abnormally high 
      plasma TXB2 levels and abnormally low threshold concentrations of ADP and CPA 
      ratios were significantly normalized in both male and female patients. Plasma 
      6-keto-PGF1 alpha levels were not influenced by ingestion of ASA 75 mg, but 
      significantly depressed by administration of ASA 300 mg in both sexes. There were 
      no sex differences in the antiplatelet effect of ASA in this experiment.
FAU - Lee, T K
AU  - Lee TK
FAU - Chen, Y C
AU  - Chen YC
FAU - Kuo, T L
AU  - Kuo TL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Salicylates)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Adenosine Diphosphate/pharmacology
MH  - Aged
MH  - Aspirin/administration & dosage/blood/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Brain Ischemia/*blood
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Sex Factors
MH  - Thromboxane B2/blood
EDAT- 1987/08/01 00:00
MHDA- 1987/08/01 00:01
CRDT- 1987/08/01 00:00
PHST- 1987/08/01 00:00 [pubmed]
PHST- 1987/08/01 00:01 [medline]
PHST- 1987/08/01 00:00 [entrez]
AID - 0049-3848(87)90143-5 [pii]
AID - 10.1016/0049-3848(87)90143-5 [doi]
PST - ppublish
SO  - Thromb Res. 1987 Aug 1;47(3):295-304. doi: 10.1016/0049-3848(87)90143-5.

PMID- 32122448
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 41
IP  - 2
DP  - 2020 Mar 1
TI  - Prevalence and management of aspirin hypersensitivity in a cardiology practice.
PG  - 120-125
LID - 10.2500/aap.2020.41.190032 [doi]
AB  - Background: Data are lacking with concern to the prevalence and management of 
      aspirin (ASA) hypersensitivity. Objective: To study the prevalence, different 
      types of reactions, and implications for clinical management of ASA 
      hypersensitivity in a cardiology practice. Methods: We conducted an electronic 
      medical record review of 11,375 individuals, 5052 (44%) in the ambulatory 
      setting, and 6323 (56%) admitted for percutaneous coronary intervention (PCI), 
      from January 2012 to December 2013. Results: The prevalence of ASA 
      hypersensitivity was 1.88% (n = 214). Skin reactions were the most common (40 
      [19%]), followed by angioedema (10 [4.6%]), respiratory (9 [4.2%]), and 
      anaphylaxis (6 [2.8%]). No records were found for 74 patients (34.5%), and 69 
      patients (32.2%) were mistakenly labeled as allergic for having gastrointestinal 
      symptoms. Of the 214 patients who had documented ASA hypersensitivity, 108 
      individuals (50.46%) had coronary artery disease. The medications at discharge 
      were the following: ASA (30 [14%]), thienopyridine (48 [22%]), a combination of 
      ASA and thienopyridine (13 [6%]), anticoagulation only (26 [12%]), and no 
      antiplatelet (97 [43%]). Conclusion: ASA hypersensitivity is often not documented 
      correctly or is often misdiagnosed or not appropriately managed. There is a need 
      for improved management of ASA hypersensitivity, including appropriate referral 
      for ASA desensitization and combating unnecessary avoidance in patients with 
      intolerance due to adverse effects.
FAU - Orgeron, Gabriela M
AU  - Orgeron GM
AD  - From the Medstar Union Memorial Hospital, Baltimore, Maryland, and.
FAU - Havistin, Ruby
AU  - Havistin R
AD  - From the Medstar Union Memorial Hospital, Baltimore, Maryland, and.
FAU - Hahn, Laura S
AU  - Hahn LS
AD  - From the Medstar Union Memorial Hospital, Baltimore, Maryland, and.
FAU - Wang, John
AU  - Wang J
AD  - From the Medstar Union Memorial Hospital, Baltimore, Maryland, and.
FAU - Crichlow, Candace
AU  - Crichlow C
AD  - From the Medstar Union Memorial Hospital, Baltimore, Maryland, and.
FAU - Mugmon, Marc
AU  - Mugmon M
AD  - From the Medstar Union Memorial Hospital, Baltimore, Maryland, and.
FAU - Mahajan, Anshul
AU  - Mahajan A
AD  - From the Medstar Union Memorial Hospital, Baltimore, Maryland, and.
FAU - Jourdan, Anthony
AU  - Jourdan A
AD  - Georgetown University School of Medicine, Washington DC.
FAU - Sekhsaria, Sudhir
AU  - Sekhsaria S
AD  - From the Medstar Union Memorial Hospital, Baltimore, Maryland, and.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Allergens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Allergens/*adverse effects/immunology
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Coronary Disease/diagnosis/*epidemiology
MH  - Diagnostic Errors/prevention & control
MH  - Drug Hypersensitivity/diagnosis/*epidemiology
MH  - Electronic Health Records
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention
MH  - Prevalence
MH  - Retrospective Studies
MH  - United States/epidemiology
MH  - Young Adult
EDAT- 2020/03/04 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/03/04 06:00
PHST- 2020/03/04 06:00 [entrez]
PHST- 2020/03/04 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.2500/aap.2020.41.190032 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2020 Mar 1;41(2):120-125. doi: 10.2500/aap.2020.41.190032.

PMID- 11769881
OWN - NLM
STAT- MEDLINE
DCOM- 20020312
LR  - 20131121
IS  - 1081-0943 (Print)
IS  - 1081-0943 (Linking)
VI  - 19
IP  - 4
DP  - 2001 Nov
TI  - An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary 
      prevention of cardiovascular events and cancer and their potential preventive 
      role in bladder carcinogenesis: part I.
PG  - 294-305
AB  - Aspirin and the nonsteroidal anti-inflammatory drugs (NSAIDs) have been 
      commercially available for decades, and their ability to reduce pain and 
      inflammation are well known. The ability of these agents to cause adverse effects 
      are also known, and the search for newer NSAIDs with less side effects 
      accelerated after the two isoforms of cyclooxygenase (COX) (COX-1 and COX-2) were 
      discovered. The selective COX-2 inhibitors seem to have equivalent efficacy, but 
      potentially less gastrointestinal adverse effects than the traditional NSAIDs. 
      Recent concern that the selective COX-2 inhibitors could increase cardiovascular 
      events requires more investigation. In the meantime, aspirin continues to receive 
      attention as a potential primary cardiovascular agent because of its antiplatelet 
      effects and past and current clinical trials. Several trials have demonstrated 
      that low-dose aspirin may significantly reduce the risk of myocardial infarction 
      and other cardiovascular events. However, the benefits of aspirin need to be 
      weighed against its primary side effect in these situations (hemorrhagic stroke). 
      Patients at low risk for future cardiovascular events are probably not good 
      candidates for this therapy; however, those individuals with a high risk of a 
      future cardiovascular event may qualify for this therapy. Aspirin has also 
      demonstrated a potential ability to reduce the risk of deep venous thrombosis and 
      pulmonary embolism. A recent large trial of low-dose aspirin after major surgery 
      revealed that this agent could also have some activity in the venous component of 
      the human body. Aspirin may also have some applicability for reducing side 
      effects of oral estrogens in men with advanced prostate cancer. Thus, it seems as 
      if aspirin, NSAIDS, and even the selective COX-2 inhibitors may have therapeutic 
      potential far beyond reducing pain and general inflammation. These overall 
      observations and effects provided some of the impetus to investigate their 
      potential ability to reduce the risk and possibly progression of a number of 
      cancers. A few already available over-the-counter products and prescriptions seem 
      to be receiving attention as possible anticancer agents.
FAU - Moyad, M A
AU  - Moyad MA
AD  - Department of Surgery, University of Michigan Medical Center, Ann Arbor 
      48109-0330, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Urol Oncol
JT  - Seminars in urologic oncology
JID - 9514993
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Humans
MH  - Isoenzymes/*antagonists & inhibitors
MH  - Membrane Proteins
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prostaglandin-Endoperoxide Synthases
MH  - Pulmonary Embolism/prevention & control
MH  - Stroke/etiology
MH  - Venous Thrombosis/prevention & control
RF  - 118
EDAT- 2002/01/05 10:00
MHDA- 2002/03/13 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/03/13 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
PST - ppublish
SO  - Semin Urol Oncol. 2001 Nov;19(4):294-305.

PMID- 10878621
OWN - NLM
STAT- MEDLINE
DCOM- 20000823
LR  - 20191104
IS  - 1522-1946 (Print)
IS  - 1522-1946 (Linking)
VI  - 50
IP  - 3
DP  - 2000 Jul
TI  - Combination therapy with clopidogrel and aspirin after coronary stenting.
PG  - 276-9
AB  - Combination antiplatelet therapy using aspirin and ticlopidine has been the 
      standard of care for prevention of subacute thrombosis following coronary stent 
      implantation. However, the use of ticlopidine is associated with a significant 
      risk of adverse hematologic side effects. Clopidogrel is an inhibitor of 
      ADP-induced platelet aggregation that has a better safety profile than 
      ticlopidine. We examined the 30-day clinical outcome following coronary stent 
      implantation in 253 consecutive patients treated with clopidogrel and aspirin. 
      Follow-up was achieved in 99% of patients and four adverse events were 
      documented. Two patients had angiographically confirmed subacute stent thrombosis 
      (0.8%), and both of these patients underwent successful repeat angioplasty at the 
      stent site. There were two patient deaths during follow-up (0. 8%). One was 
      sudden within 1 week of stent placement and the other occurred in a patient with 
      multisystem organ failure after an extensive myocardial infarction that antedated 
      the stent procedure, with no clinical evidence for stent thrombosis. The combined 
      frequency of subacute stent thrombosis and death was 1.6%. This is comparable to 
      prior studies using the combination of ticlopidine and aspirin following 
      stenting. Therefore, clopidogrel in combination with aspirin appears to be a safe 
      and effective therapy in the prevention of subacute thrombosis following coronary 
      stent implantation.
FAU - Kolansky, D M
AU  - Kolansky DM
AD  - Cardiovascular Division, Department of Medicine, Hospital of the University of 
      Pennsylvania, Philadelphia 19104, USA. kolansky@mail.med.upenn.edu
FAU - Klugherz, B D
AU  - Klugherz BD
FAU - Curran, S C
AU  - Curran SC
FAU - Herrmann, H C
AU  - Herrmann HC
FAU - Magness, K
AU  - Magness K
FAU - Wilensky, R L
AU  - Wilensky RL
FAU - Hirshfeld, J W Jr
AU  - Hirshfeld JW Jr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Catheter Cardiovasc Interv. 2000 Jul;50(3):280-1. PMID: 10878622
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Coronary Disease/*therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - *Stents
MH  - Thrombosis/*prevention & control
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2000/07/06 11:00
MHDA- 2000/08/29 11:01
CRDT- 2000/07/06 11:00
PHST- 2000/07/06 11:00 [pubmed]
PHST- 2000/08/29 11:01 [medline]
PHST- 2000/07/06 11:00 [entrez]
AID - 10.1002/1522-726X(200007)50:3<276::AID-CCD2>3.0.CO;2-P [pii]
AID - 10.1002/1522-726x(200007)50:3<276::aid-ccd2>3.0.co;2-p [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2000 Jul;50(3):276-9. doi: 
      10.1002/1522-726x(200007)50:3<276::aid-ccd2>3.0.co;2-p.

PMID- 26304466
OWN - NLM
STAT- MEDLINE
DCOM- 20160920
LR  - 20220316
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 8
IP  - 11
DP  - 2015 Nov
TI  - Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in 
      the Aspirin/Folate Polyp Prevention Study (AFPPS).
PG  - 1061-8
LID - 10.1158/1940-6207.CAPR-15-0212 [doi]
AB  - Aspirin has been shown to protect against colorectal neoplasms; however, the 
      optimal chemopreventive dose and underlying mechanisms are unclear. We aimed to 
      study the relationship between prostanoid metabolites and aspirin's effect on 
      adenoma occurrence. We used data from the Aspirin/Folate Polyp Prevention Study, 
      in which 1,121 participants with a recent adenoma were randomized to placebo or 
      two doses of aspirin (81 or 325 mg/d) to be taken until the next surveillance 
      colonoscopy, anticipated about 3 years later. Urinary metabolites of prostanoids 
      (PGE-M, PGI-M, and dTxB2) were measured using liquid chromatography/mass 
      spectrometry or GC/NICI-MS in 876 participants near the end of treatment 
      follow-up. Poisson regression with a robust error variance was used to calculate 
      relative risks and 95% confidence intervals. PGE-M, PGI-M, and dTxB2 levels were 
      28%, 37%, and 60% proportionately lower, respectively, in individuals who took 
      325 mg of aspirin compared with individuals who took placebo (all P < 0.001). 
      Similarly, among individuals who took 81 mg of aspirin, PGE-M, PGI-M, and dTxB2 
      were, respectively, 18%, 30%, and 57% proportionally lower compared with placebo 
      (all P < 0.005). None of the metabolites or their ratios were statistically 
      significantly associated with the risk of adenoma occurrence. The effect of 
      aspirin in reducing adenoma risk was independent of prostanoid levels. Aspirin 
      use is associated with lower levels of urinary prostanoid metabolites. However, 
      our findings do not support the hypothesis that these metabolites are associated 
      with adenoma occurrence, suggesting that COX-dependent mechanisms may not 
      completely explain the chemopreventive effect of aspirin on colorectal neoplasms.
CI  - ©2015 American Association for Cancer Research.
FAU - Fedirko, Veronika
AU  - Fedirko V
AD  - Department of Epidemiology, Rollins School of Public Health, Winship Cancer 
      Institute, Emory University, Atlanta, Georgia. vfedirk@emory.edu 
      jabaron@med.unc.edu.
FAU - Bradshaw, Patrick T
AU  - Bradshaw PT
AD  - Department of Nutrition, Gillings School of Global Public Health, University of 
      North Carolina, Chapel Hill, North Carolina.
FAU - Figueiredo, Jane C
AU  - Figueiredo JC
AD  - Department of Preventive Medicine, Keck School of Medicine, University of 
      Southern California, Los Angeles, California.
FAU - Sandler, Robert S
AU  - Sandler RS
AD  - Department of Medicine, University of North Carolina, Chapel Hill, North 
      Carolina.
FAU - Barry, Elizabeth L
AU  - Barry EL
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New 
      Hampshire.
FAU - Ahnen, Dennis J
AU  - Ahnen DJ
AD  - Department of Veterans Affairs Medical Center, Denver, Colorado.
FAU - Milne, Ginger L
AU  - Milne GL
AD  - Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee.
FAU - Bresalier, Robert S
AU  - Bresalier RS
AD  - Department of Gastrointestinal Medicine and Nutrition, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas.
FAU - Baron, John A
AU  - Baron JA
AD  - Department of Medicine, University of North Carolina School of Medicine, Chapel 
      Hill, North Carolina. vfedirk@emory.edu jabaron@med.unc.edu.
LA  - eng
GR  - K12 CA120780/CA/NCI NIH HHS/United States
GR  - K12CA120780/CA/NCI NIH HHS/United States
GR  - CA059005/CA/NCI NIH HHS/United States
GR  - P30 DK056338/DK/NIDDK NIH HHS/United States
GR  - R01 CA059005/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20150824
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Prostaglandins)
RN  - 935E97BOY8 (Folic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/*prevention & control
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Chromatography, Gas
MH  - Chromatography, Liquid
MH  - Colonoscopy
MH  - Colorectal Neoplasms/drug therapy/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Folic Acid/chemistry/*therapeutic use
MH  - Humans
MH  - Male
MH  - Mass Spectrometry
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Poisson Distribution
MH  - Prostaglandins/metabolism/*urine
PMC - PMC4633350
MID - NIHMS728153
COIS- Conflict of interest Dr. Baron and Dartmouth College hold a use patent for the 
      chemopreventive use of aspirin, currently not licensed.
EDAT- 2015/08/26 06:00
MHDA- 2016/09/22 06:00
CRDT- 2015/08/26 06:00
PHST- 2015/05/22 00:00 [received]
PHST- 2015/08/18 00:00 [accepted]
PHST- 2015/08/26 06:00 [entrez]
PHST- 2015/08/26 06:00 [pubmed]
PHST- 2016/09/22 06:00 [medline]
AID - 1940-6207.CAPR-15-0212 [pii]
AID - 10.1158/1940-6207.CAPR-15-0212 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2015 Nov;8(11):1061-8. doi: 
      10.1158/1940-6207.CAPR-15-0212. Epub 2015 Aug 24.

PMID- 26725920
OWN - NLM
STAT- MEDLINE
DCOM- 20170120
LR  - 20181113
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Print)
IS  - 1755-5914 (Linking)
VI  - 34
IP  - 2
DP  - 2016 Apr
TI  - Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 
      mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease 
      Prevention in Patients at GI Risk.
PG  - 59-66
LID - 10.1111/1755-5922.12172 [doi]
AB  - INTRODUCTION: In two, 6-month, randomized, double-blind Phase 3 trials, PA32540 
      (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) compared 
      to aspirin alone was associated with fewer endoscopic gastric and duodenal ulcers 
      in patients requiring aspirin therapy for secondary cardiovascular disease (CVD) 
      prevention who were at risk for upper gastrointestinal (UGI) events. AIMS: In 
      this 12-month, open-label, multicenter Phase 3 study, we evaluated the long-term 
      cardiovascular and gastrointestinal safety of PA32540 in subjects who were taking 
      aspirin 325 mg daily for ≥ 3 months for secondary CVD prevention and were at risk 
      for aspirin-associated UGI events. Enrolled subjects received PA32540 once daily 
      for up to 12 months and were assessed at baseline, month 1, month 6, and month 
      12. RESULTS: The overall safety population consisted of 379 subjects, and 290 
      subjects (76%) were on PA32540 for ≥ 348 days (12-month completers). Adverse 
      events (AEs) caused study withdrawal in 13.5% of subjects, most commonly 
      gastroesophageal reflux disease (1.1%). Treatment-emergent AEs occurred in 76% of 
      the safety population (11% treatment-related) and 73% of 12-month completers (8% 
      treatment-related). The most common treatment-related AE was dyspepsia (2%). One 
      subject had a gastric ulcer observed on for-cause endoscopy. There were five 
      cases of adjudicated nonfatal myocardial infarction, one nonfatal stroke, and one 
      cardiovascular death, but none considered treatment-related. CONCLUSIONS: 
      Long-term treatment with PA32540 once daily for up to 12 months in subjects at 
      risk for aspirin-associated UGI events is not associated with any new or 
      unexpected safety events.
CI  - © 2016 The Authors. Cardiovascular Therapeutics Published by John Wiley & Sons 
      Ltd.
FAU - Goldstein, Jay L
AU  - Goldstein JL
AD  - NorthShore University HealthSystem, Evanston, IL, USA.
FAU - Whellan, David J
AU  - Whellan DJ
AD  - Thomas Jefferson University, Philadelphia, PA, USA.
FAU - Scheiman, James M
AU  - Scheiman JM
AD  - University of Michigan Medical Center, Ann Arbor, MI, USA.
FAU - Cryer, Byron L
AU  - Cryer BL
AD  - University of Texas Southwestern Medical Center, Dallas, TX, USA.
FAU - Eisen, Glenn M
AU  - Eisen GM
AD  - Oregon Health and Science University, Portland, OR, USA.
FAU - Lanas, Angel
AU  - Lanas A
AD  - University of Zaragoza, Zaragoza, Spain.
FAU - Fort, John G
AU  - Fort JG
AD  - POZEN Inc., Chapel Hill, NC, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00995410
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Dosage Forms)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Dosage Forms
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/*administration & dosage
MH  - Peptic Ulcer/chemically induced/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Treatment Outcome
PMC - PMC5069577
OTO - NOTNLM
OT  - Aspirin
OT  - Dyspepsia
OT  - Gastroesophageal reflux disease
OT  - Gastrointestinal
OT  - Omeprazole
OT  - Secondary cardiovascular disease prevention
EDAT- 2016/01/05 06:00
MHDA- 2017/01/21 06:00
CRDT- 2016/01/05 06:00
PHST- 2016/01/05 06:00 [entrez]
PHST- 2016/01/05 06:00 [pubmed]
PHST- 2017/01/21 06:00 [medline]
AID - CDR12172 [pii]
AID - 10.1111/1755-5922.12172 [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2016 Apr;34(2):59-66. doi: 10.1111/1755-5922.12172.

PMID- 9825950
OWN - NLM
STAT- MEDLINE
DCOM- 19990204
LR  - 20181113
IS  - 0114-5916 (Print)
IS  - 0114-5916 (Linking)
VI  - 19
IP  - 5
DP  - 1998 Nov
TI  - Drug therapy for acute ischaemic stroke: risks versus benefits.
PG  - 373-82
AB  - Stroke is a very common medical emergency that, until recently, had no specific 
      treatment. Following the results of several major trials (including 2 
      'mega-trials'), aspirin (acetylsalicylic acid) can be recommended for the 
      majority of patients with acute ischaemic stroke. While the benefit of aspirin is 
      only modest, i.e. an increase of 11 per 1000 long term independent survivors, the 
      public health benefit in the world will be substantial as this treatment could be 
      given to millions of patients with acute ischaemic stroke each year. Heparin is 
      associated with a reduction in early recurrent ischaemic stroke, but there is no 
      net benefit because of a similar sized excess of recurrent haemorrhagic stroke 
      (even for those in atrial fibrillation). Thrombolytic therapy has not been so 
      widely tested and the results of the small trials to date have yielded 
      conflicting results. The only positive publication to date (comprised of 2 
      related trials) evaluated the recombinant tissue plasminogen activator alteplase, 
      but such treatment is probably only indicated for highly selected patients. 
      Further trials are almost certainly required and it would be unwise to change 
      clinical practice based on the current evidence. No other stroke treatments have 
      been shown to be beneficial, and much larger trials will be required to confirm 
      or refute possible moderate benefits of treatment. A well organised stroke 
      service and participation in clinical trials will improve the future care of 
      patients with acute ischaemic stroke.
FAU - Lindley, R I
AU  - Lindley RI
AD  - Department of Clinical Neurosciences, University of Edinburgh, Western General 
      Hospital, Scotland. ril@skull.dcn.ed.ac.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - 0 (Neuroprotective Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Neuroprotective Agents/*therapeutic use
MH  - Risk Assessment
MH  - *Thrombolytic Therapy
RF  - 40
EDAT- 1998/11/24 00:00
MHDA- 1998/11/24 00:01
CRDT- 1998/11/24 00:00
PHST- 1998/11/24 00:00 [pubmed]
PHST- 1998/11/24 00:01 [medline]
PHST- 1998/11/24 00:00 [entrez]
AID - 10.2165/00002018-199819050-00004 [doi]
PST - ppublish
SO  - Drug Saf. 1998 Nov;19(5):373-82. doi: 10.2165/00002018-199819050-00004.

PMID- 9550777
OWN - NLM
STAT- MEDLINE
DCOM- 19980619
LR  - 20131121
IS  - 0028-2162 (Print)
IS  - 0028-2162 (Linking)
VI  - 141
IP  - 44
DP  - 1997 Nov 1
TI  - [Antithrombotic treatment following acute ischemic heart disease: acetylsalicylic 
      acid and (or) oral anticoagulants?; ASPECT-II, a new study].
PG  - 2129-31
AB  - In order to compare the efficacy and safety of three regimens of long-term 
      antithrombotic treatment in patients with acute ischaemic syndromes, a 
      prospective, randomized, open-label, multicentre study is being conducted in 
      which 60-70 Dutch hospitals will participate. Eligible patients discharged 
      following hospitalization for acute myocardial infarction or unstable angina 
      pectoris are randomly assigned to receive either (a) adjusted full intensity oral 
      anticoagulation (target range: 3.0-4.0 International Normalised Ratio (INR), (b) 
      low dose aspirin or (c) combined therapy of low dose aspirin and adjusted low 
      intensity oral anticoagulation (target range INR: 2.0-2.5). It is planned to 
      enroll 8,700 patients within three years. During an estimated mean follow-up of 
      2.5 years the evolutions of total mortality, non-fatal myocardial infarction, 
      non-fatal stroke and major bleeding complication will be assessed.
FAU - van Es, R F
AU  - van Es RF
AD  - ASPECT-II Coördinatiecentrum, Rotterdam.
FAU - Grobbee, D E
AU  - Grobbee DE
FAU - Deckers, J W
AU  - Deckers JW
FAU - Bak, A A
AU  - Bak AA
FAU - Verheugt, F W
AU  - Verheugt FW
FAU - Jonker, J J
AU  - Jonker JJ
LA  - dut
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Review
TT  - Antitrombotische behandeling na een acute ischemische hartziekte: 
      acetylsalicylzuur en (of) orale anticoagulantia?; ASPECT-II, een nieuw onderzoek.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prospective Studies
RF  - 19
EDAT- 1998/04/29 00:00
MHDA- 1998/04/29 00:01
CRDT- 1998/04/29 00:00
PHST- 1998/04/29 00:00 [pubmed]
PHST- 1998/04/29 00:01 [medline]
PHST- 1998/04/29 00:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 1997 Nov 1;141(44):2129-31.

PMID- 23298691
OWN - NLM
STAT- MEDLINE
DCOM- 20131223
LR  - 20220409
IS  - 1872-6054 (Electronic)
IS  - 0168-8510 (Linking)
VI  - 110
IP  - 1
DP  - 2013 Apr
TI  - Non-prescription medicines for pain and fever--a comparison of recommendations 
      and counseling from staff in pharmacy and general sales stores.
PG  - 76-83
LID - S0168-8510(12)00333-8 [pii]
LID - 10.1016/j.healthpol.2012.12.006 [doi]
AB  - OBJECTIVES: The purpose of this study is to map and analyze the content and 
      quality of the encounter when customers buy non-prescription medicines for pain 
      and fever. METHODS: 297 pharmacies and 801 general sales stores (GSS) in Sweden 
      were selected. A "Mystery shopper" exercise was conducted. Three scenarios were 
      used and a total of 366 units were selected for each scenario. There were in 
      total 625 observers: 208 in the child with fever scenario, 225 in the Reliv 
      scenario, and 192 in the painkiller during pregnancy scenario. DATA COLLECTION: 
      21st September to 20th November 2011. RESULTS: In two out of three visits to GSS, 
      the staff proposed a medicine for a heavily pregnant woman. The staff suggested 
      in 9% of the visits a medicine that is inappropriate in late pregnancy. The 
      corresponding percentage in pharmacies was 1%. Both pharmacies and GSS proposed, 
      in 6% a medicine that is inappropriate for babies to a feverish child. Only 16% 
      of the pharmacists and 14% of the staff in GSS asked for the age of the child. 
      General sales staff recommended in 10% ibuprofen and in 4% an acetylsalicylic 
      acid product when an acetaminophen preparation was requested. The corresponding 
      percentage in the pharmacy were 4% ibuprofen, 2% diclofenac, and 1% an 
      acetylsalicylic acid product. CONCLUSIONS: The staff in GSS and pharmacies do not 
      pay sufficient attention to the heterogeneity of painkillers, which lead to 
      inappropriate recommendations.
CI  - Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
FAU - Bardage, Carola
AU  - Bardage C
AD  - Dept of Rational Use of Medicines, Medical Products Agency, P.O. Box 26, SE-751 
      03, Uppsala, Sweden. carola.bardage@mpa.se
FAU - Westerlund, Tommy
AU  - Westerlund T
FAU - Barzi, Sahra
AU  - Barzi S
FAU - Bernsten, Cecilia
AU  - Bernsten C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20130106
PL  - Ireland
TA  - Health Policy
JT  - Health policy (Amsterdam, Netherlands)
JID - 8409431
RN  - 0 (Analgesics)
RN  - 0 (Antipyretics)
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
MH  - Acetaminophen/therapeutic use
MH  - Analgesics/*therapeutic use
MH  - Antipyretics/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Child
MH  - Commerce/statistics & numerical data
MH  - Contraindications
MH  - Counseling/statistics & numerical data
MH  - Female
MH  - Fever/*drug therapy
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Infant
MH  - Nonprescription Drugs/*therapeutic use
MH  - Pain/*drug therapy
MH  - Pharmacies/*statistics & numerical data
MH  - Pregnancy
MH  - Sweden
EDAT- 2013/01/10 06:00
MHDA- 2013/12/24 06:00
CRDT- 2013/01/10 06:00
PHST- 2012/05/10 00:00 [received]
PHST- 2012/12/07 00:00 [revised]
PHST- 2012/12/08 00:00 [accepted]
PHST- 2013/01/10 06:00 [entrez]
PHST- 2013/01/10 06:00 [pubmed]
PHST- 2013/12/24 06:00 [medline]
AID - S0168-8510(12)00333-8 [pii]
AID - 10.1016/j.healthpol.2012.12.006 [doi]
PST - ppublish
SO  - Health Policy. 2013 Apr;110(1):76-83. doi: 10.1016/j.healthpol.2012.12.006. Epub 
      2013 Jan 6.

PMID- 23075823
OWN - NLM
STAT- MEDLINE
DCOM- 20130401
LR  - 20161125
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 27
IP  - 6
DP  - 2012 Nov
TI  - Antiplatelet therapy and proton pump inhibition: cause for concern?
PG  - 642-50
LID - 10.1097/HCO.0b013e32835830b6 [doi]
AB  - PURPOSE OF REVIEW: To review the current evidence on the clinical significance of 
      the drug-drug interactions between the available antiplatelet agents and proton 
      pump inhibitors (PPIs). RECENT FINDINGS: Gastrointestinal bleeding is associated 
      with higher rates of morbidity and mortality following a myocardial infarction. 
      PPIs are commonly used to prevent gastrointestinal bleeding. PPIs can attenuate 
      metabolism of clopidogrel to its active metabolite by inhibiting various hepatic 
      CYP450 enzymes, mainly CYP2C19. Concomitant use of a PPI with clopidogrel reduces 
      clopidogrel active metabolite generation and subsequent platelet inhibition. In 
      observational studies, the clinical significance of this drug-drug interaction is 
      mixed. Evidence from the only randomized trial studying the clinical implications 
      of the PPI-clopidogrel interaction did not demonstrate any difference in 
      cardiovascular outcomes but did show a reduction in gastrointestinal bleeding 
      with use of a PPI. SUMMARY: The drug-drug interaction between antiplatelet agents 
      and PPIs at the enzymatic level does not seem to result in worse clinical 
      outcomes. The risk of gastrointestinal bleeding with antiplatelet therapy is 
      substantial. Clinicians should use PPIs in selected high-risk patients to prevent 
      gastrointestinal bleeding.
FAU - Depta, Jeremiah P
AU  - Depta JP
AD  - Division of Cardiology, Department of Medicine, Washington University School of 
      Medicine, St Louis, Missouri, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aryl Hydrocarbon Hydroxylases
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Platelets
MH  - Cytochrome P-450 CYP2C19
MH  - Gastrointestinal Hemorrhage/chemically induced/*drug therapy/etiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Proton Pump Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
EDAT- 2012/10/19 06:00
MHDA- 2013/04/02 06:00
CRDT- 2012/10/19 06:00
PHST- 2012/10/19 06:00 [entrez]
PHST- 2012/10/19 06:00 [pubmed]
PHST- 2013/04/02 06:00 [medline]
AID - 00001573-201211000-00013 [pii]
AID - 10.1097/HCO.0b013e32835830b6 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2012 Nov;27(6):642-50. doi: 10.1097/HCO.0b013e32835830b6.

PMID- 22015094
OWN - NLM
STAT- MEDLINE
DCOM- 20120104
LR  - 20131121
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 105 Suppl 1
DP  - 2011 Oct
TI  - Acetylsalicylic acid-triggered 15-HETE generation by peripheral leukocytes for 
      identifying ASA sensitivity.
PG  - S81-3
LID - 10.1016/S0954-6111(11)70017-8 [doi]
AB  - BACKGROUND: Exposure to acetylsalicylic acid (ASA) may exacerbate respiratory or 
      skin diseases or induce anaphylactoid reactions in apparently healthy 
      individuals. We wanted to evaluate the clinical and diagnostic utility of 
      measuring ASA-induced 15-hydroxyeicosatetraenoic acid (15-HETE) generation. 
      METHODS: We performed a prospective single-blind study with 26 subjects 
      undergoing clinical evaluation and/or ASA provocation testing. We also included 
      12 control subjects. Peripheral blood leukocytes were incubated with 500 μM ASA 
      and 15-HETE release was measured by competitive ELISA. RESULTS: We found that 18 
      subjects were ASA-tolerant and 8 were ASA-intolerant. The mean increase in 
      15-HETE in intolerant subjects was 34% and this was comparable to the mean 
      increase of 30% observed in ASA-tolerant subjects. A similar mean increase was 
      also observed in control subjects. The ROC calculation showed that the optimal 
      diagnostic threshold would be an increase of greater than 33%. However, the 
      sensitivity of this increase was only 63% and the specificity was 50%. 
      CONCLUSIONS: Our data suggest that further studies are needed before the 
      ASA-induced 15-HETE test can be used in clinical practice.
CI  - Copyright © 2011 Elsevier Ltd. All rights reserved.
FAU - Korosec, Peter
AU  - Korosec P
AD  - University Clinic of Respiratory and Allergic Diseases Colnik, Colnik, Slovenia. 
      peter.korosec@klinika-golnik.si
FAU - Tisler, Ursa
AU  - Tisler U
FAU - Bajrovic, Nissera
AU  - Bajrovic N
FAU - Silar, Mira
AU  - Silar M
FAU - Mrhar, Ales
AU  - Mrhar A
FAU - Kosnik, Mitja
AU  - Kosnik M
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - 73945-47-8 (15-hydroxy-5,8,11,13-eicosatetraenoic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/pharmacology
MH  - Drug Hypersensitivity/*diagnosis/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Hydroxyeicosatetraenoic Acids/*adverse effects/biosynthesis
MH  - Leukocytes/*drug effects
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Sensitivity and Specificity
MH  - Single-Blind Method
EDAT- 2011/11/02 06:00
MHDA- 2012/01/05 06:00
CRDT- 2011/10/22 06:00
PHST- 2011/10/22 06:00 [entrez]
PHST- 2011/11/02 06:00 [pubmed]
PHST- 2012/01/05 06:00 [medline]
AID - S0954-6111(11)70017-8 [pii]
AID - 10.1016/S0954-6111(11)70017-8 [doi]
PST - ppublish
SO  - Respir Med. 2011 Oct;105 Suppl 1:S81-3. doi: 10.1016/S0954-6111(11)70017-8.

PMID- 19026709
OWN - NLM
STAT- MEDLINE
DCOM- 20090306
LR  - 20161124
IS  - 0300-483X (Print)
IS  - 0300-483X (Linking)
VI  - 255
IP  - 3
DP  - 2009 Jan 31
TI  - An effective antidote for paraquat poisonings: the treatment with lysine 
      acetylsalicylate.
PG  - 187-93
LID - 10.1016/j.tox.2008.10.015 [doi]
AB  - Sodium salicylate (NaSAL) has been shown to have a multifactorial protection 
      mechanism against paraquat (PQ)-induced toxicity, due to its ability to modulate 
      inflammatory signalling systems, to prevent oxidative stress and to its capacity 
      to chelate PQ. Considering that currently there is no pharmaceutical formulation 
      available for parenteral administration of NaSAL, the aim of the present study 
      was to evaluate the antidotal feasibility of a salicylate prodrug, lysine 
      acetylsalicylate (LAS), accessible for parenteral administrations. PQ was 
      administered to Wistar rats by gavage (125mg/kg of PQ ion) and the treatment was 
      performed intraperitoneally with different doses (100, 200 and 400mg/kg of body 
      weight) of LAS. Survival rate was followed during 30 days and living animals at 
      this endpoint were sacrificed for lung, kidney, liver, jejune and heart 
      histological analysis. It was shown, that the salicylate prodrug, LAS, available 
      in a large number of hospitals, is also effective in the treatment of PQ 
      intoxications. From all tested LAS doses, 200mg/kg assured animal's full 
      survival. Comparatively to 60% of mortality observed in PQ only exposed animals, 
      the lethality was higher (80%) in the group that received 400mg/kg of LAS 2h 
      after PQ administration. The dose of 100mg/kg of LAS showed only a modest 
      protection (60% of survival). Collagen deposition was observed by histological 
      analysis in survived animals of all experimental groups, being less pronounced in 
      animals receiving 200mg/kg of LAS, reinforcing the importance of this dose 
      against tissue damage induced by PQ. The results allow us to suggest that LAS 
      should be considered in the hospital treatment of PQ poisonings.
FAU - Dinis-Oliveira, R J
AU  - Dinis-Oliveira RJ
AD  - REQUIMTE, Department of Toxicology, Faculty of Pharmacy, University of Porto, 
      Porto, Portugal. ricardinis@sapo.pt
FAU - Pontes, H
AU  - Pontes H
FAU - Bastos, M L
AU  - Bastos ML
FAU - Remião, F
AU  - Remião F
FAU - Duarte, J A
AU  - Duarte JA
FAU - Carvalho, F
AU  - Carvalho F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081106
PL  - Ireland
TA  - Toxicology
JT  - Toxicology
JID - 0361055
RN  - 0 (Antidotes)
RN  - K3Z4F929H6 (Lysine)
RN  - PLG39H7695 (Paraquat)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Antidotes/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Jejunum/pathology
MH  - Kidney/pathology
MH  - Liver/pathology
MH  - Lung/pathology
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Myocardium/pathology
MH  - Paraquat/*poisoning
MH  - Poisoning/drug therapy
MH  - Rats
MH  - Rats, Wistar
EDAT- 2008/11/26 09:00
MHDA- 2009/03/07 09:00
CRDT- 2008/11/26 09:00
PHST- 2008/09/29 00:00 [received]
PHST- 2008/10/20 00:00 [revised]
PHST- 2008/10/21 00:00 [accepted]
PHST- 2008/11/26 09:00 [entrez]
PHST- 2008/11/26 09:00 [pubmed]
PHST- 2009/03/07 09:00 [medline]
AID - S0300-483X(08)00502-7 [pii]
AID - 10.1016/j.tox.2008.10.015 [doi]
PST - ppublish
SO  - Toxicology. 2009 Jan 31;255(3):187-93. doi: 10.1016/j.tox.2008.10.015. Epub 2008 
      Nov 6.

PMID- 17906612
OWN - NLM
STAT- MEDLINE
DCOM- 20071120
LR  - 20131121
IS  - 1745-8390 (Electronic)
IS  - 1745-8382 (Linking)
VI  - 3
IP  - 10
DP  - 2007 Oct
TI  - New endogenous anti-inflammatory and proresolving lipid mediators: implications 
      for rheumatic diseases.
PG  - 570-9; quiz 1 p following 589
AB  - Prostaglandins and leukotrienes are lipid mediators that carry out pivotal roles 
      in host defense and acute inflammation. Failure to completely resolve an acute 
      inflammatory response can lead to chronic inflammation, scarring, and eventual 
      loss of tissue function. Until recently, it was thought that tissue resolution of 
      acute inflammation was a passive event. However, it is now known than lipoxins, 
      which--like prostaglandins and leukotrienes--are also derived from arachidonic 
      acid, are active anti-inflammatory and proresolution mediators, acting in part by 
      reducing neutrophil entry to the inflammation site and stimulating the uptake of 
      apoptotic polymorphonuclear leukocytes by macrophages. Novel families of locally 
      acting and locally generated mediators derived from omega-3 polyunsaturated fatty 
      acids have also been identified as biosynthetically active components in the 
      resolution phase of inflammation. The new families of chemical mediators are 
      termed 'resolvins' and 'protectins' because individual members of each family are 
      stereospecific in controlling the duration and magnitude of inflammation in 
      animal models. Possible deficiencies in the biosynthesis of lipoxins, resolvins, 
      and protectins, and/or their signal transduction, might underlie some aspects of 
      pathogenesis in chronic inflammatory diseases.
FAU - Yacoubian, Stephanie
AU  - Yacoubian S
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Serhan, Charles N
AU  - Serhan CN
LA  - eng
GR  - GM38765/GM/NIGMS NIH HHS/United States
GR  - P50-DE016191/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Nat Clin Pract Rheumatol
JT  - Nature clinical practice. Rheumatology
JID - 101261802
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Leukotrienes)
RN  - 0 (Lipoxins)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Fatty Acids, Omega-3/physiology
MH  - Humans
MH  - Inflammation/immunology/*physiopathology
MH  - Inflammation Mediators/immunology/*physiology
MH  - Leukocytes/physiology
MH  - Leukotrienes/physiology
MH  - Lipoxins/immunology/*physiology
MH  - Prostaglandins/physiology
MH  - Rheumatic Diseases/*drug therapy
RF  - 67
EDAT- 2007/10/02 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/10/02 09:00
PHST- 2007/01/11 00:00 [received]
PHST- 2007/06/04 00:00 [accepted]
PHST- 2007/10/02 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/10/02 09:00 [entrez]
AID - ncprheum0616 [pii]
AID - 10.1038/ncprheum0616 [doi]
PST - ppublish
SO  - Nat Clin Pract Rheumatol. 2007 Oct;3(10):570-9; quiz 1 p following 589. doi: 
      10.1038/ncprheum0616.

PMID- 10885615
OWN - NLM
STAT- MEDLINE
DCOM- 20001019
LR  - 20181130
IS  - 1045-1056 (Print)
IS  - 1045-1056 (Linking)
VI  - 28
IP  - 2
DP  - 2000 Jun
TI  - Evaluation and validation of virus removal by ultrafiltration during the 
      production of diaspirin crosslinked haemoglobin (DCLHb).
PG  - 81-94
AB  - Virus retention during ultrafiltration through A/G Technology filter cartridges 
      was investigated to characterize the removal process and validate the degree of 
      virus titre reduction during the filtration of red blood cell haemolysates 
      performed as part of the production of diaspirin crosslinked haemoglobin (DCLHb). 
      When viruses were suspended in phosphate buffered saline solution, retention was 
      greater with larger sized viruses and smaller filter pore size. Virus titre was 
      maintained at starting levels in the filter retentate circuit during the course 
      of filtration, suggesting that the virus removal mechanism is predominantly size 
      exclusion. Evaluation of specific processing variables indicated that the 
      retention of phiX174 virus was increased in the presence of red blood cell 
      haemolysate or at high membrane crossflow rates and transmembrane pressures, 
      while the retention of EMC virus was less sensitive to variations in these 
      parameters. Using these results to design a validation protocol, log reduction 
      values of >7.9 were demonstrated for the retention of human immunodeficiency 
      virus, pseudorabies virus and bovine viral diarrhoea viruses, 7.6 for hepatitis A 
      virus, and 4.2 for porcine parvovirus. It was also shown that the retention of 
      viruses was maintained during repetitive use of the same filter cartridge.
FAU - Azari, M
AU  - Azari M
AD  - Hemoglobin Therapeutics Program, Baxter Healthcare Corporation, Round Lake, IL 
      60073-9799, USA.
FAU - Boose, J A
AU  - Boose JA
FAU - Burhop, K E
AU  - Burhop KE
FAU - Camacho, T
AU  - Camacho T
FAU - Catarello, J
AU  - Catarello J
FAU - Darling, A
AU  - Darling A
FAU - Ebeling, A A
AU  - Ebeling AA
FAU - Estep, T N
AU  - Estep TN
FAU - Pearson, L
AU  - Pearson L
FAU - Guzder, S
AU  - Guzder S
FAU - Herren, J
AU  - Herren J
FAU - Ogle, K
AU  - Ogle K
FAU - Paine, J
AU  - Paine J
FAU - Rohn, K
AU  - Rohn K
FAU - Sarajari, R
AU  - Sarajari R
FAU - Sun, C S
AU  - Sun CS
FAU - Zhang, L
AU  - Zhang L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Biologicals
JT  - Biologicals : journal of the International Association of Biological 
      Standardization
JID - 9004494
RN  - 0 (Hemoglobins)
RN  - 0 (Membranes, Artificial)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/isolation & purification
MH  - Bacteriophage phi X 174
MH  - Cell Line
MH  - Diarrhea Viruses, Bovine Viral
MH  - *Drug Contamination
MH  - Encephalomyocarditis virus
MH  - Equipment Design
MH  - Erythrocytes
MH  - Evaluation Studies as Topic
MH  - HIV
MH  - Hemoglobins/*isolation & purification
MH  - Hemolysis
MH  - Hepatovirus
MH  - Herpesvirus 1, Suid
MH  - Humans
MH  - Macaca mulatta
MH  - Membranes, Artificial
MH  - Particle Size
MH  - Parvovirus
MH  - Safety
MH  - Swine
MH  - *Ultrafiltration/instrumentation
MH  - Viral Plaque Assay
MH  - *Viruses
EDAT- 2000/07/08 11:00
MHDA- 2000/10/21 11:01
CRDT- 2000/07/08 11:00
PHST- 2000/07/08 11:00 [pubmed]
PHST- 2000/10/21 11:01 [medline]
PHST- 2000/07/08 11:00 [entrez]
AID - S1045-1056(00)90246-X [pii]
AID - 10.1006/biol.2000.0246 [doi]
PST - ppublish
SO  - Biologicals. 2000 Jun;28(2):81-94. doi: 10.1006/biol.2000.0246.

PMID- 8997364
OWN - NLM
STAT- MEDLINE
DCOM- 19970220
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 271
IP  - 6 Pt 2
DP  - 1996 Dec
TI  - Lysine acetylsalicylate modifies aphagia and thermogenic changes induced by 
      lateral hypothalamic lesion.
PG  - R1638-42
AB  - These experiments test the effect of intraperitoneal injection of lysine 
      acetylsalicylate on 1) food intake and 2) the sympathetic and thermogenic changes 
      induced by lesion of the lateral hypothalamus (LH). Food intake, firing rate of 
      the nerves innervating interscapular brown adipose tissue (IBAT), and IBAT and 
      colonic temperatures (TIBAT and TC) were monitored in male Sprague-Dawley rats 
      lesioned in the LH. These variables were measured before and after 
      intraperitoneal injection of lysine acetylsalicylate. The same variables were 
      also monitored in 1) lesioned rats with intraperitoneal administration of saline, 
      2) sham-lesioned animals with intraperitoneal injection of lysine 
      acetylsalicylate, and 3) sham-lesioned rats with intraperitoneal injection of 
      saline. The results show that lysine acetylsalicylate modifies the aphagia by 
      increasing food intake and also reduces the enhancements in firing rate, TIBAT, 
      and TC induced by LH lesion. These findings suggest that prostaglandin synthesis 
      plays a key role in the control of eating behavior in LH-lesioned rats by acting 
      on the sympathetic and thermogenic changes induced by LH lesion.
FAU - Monda, M
AU  - Monda M
AD  - Dipartimento di Fisiologia Umana e Funzioni Biologiche Integrate Filippo 
      Bottazzi, Seconda Università di Napoli, Italy.
FAU - Sullo, A
AU  - Sullo A
FAU - De Luca, E
AU  - De Luca E
FAU - Pellicano, M P
AU  - Pellicano MP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adipose Tissue, Brown/innervation/physiopathology
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Body Temperature/*drug effects
MH  - Colon/physiopathology
MH  - Eating/drug effects
MH  - Electrophysiology
MH  - Feeding and Eating Disorders/*physiopathology
MH  - *Hypothalamic Area, Lateral
MH  - Hypothalamic Diseases/physiopathology
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sympathetic Nervous System/physiopathology
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - 10.1152/ajpregu.1996.271.6.R1638 [doi]
PST - ppublish
SO  - Am J Physiol. 1996 Dec;271(6 Pt 2):R1638-42. doi: 
      10.1152/ajpregu.1996.271.6.R1638.

PMID- 7848194
OWN - NLM
STAT- MEDLINE
DCOM- 19950309
LR  - 20190830
IS  - 0004-8666 (Print)
IS  - 0004-8666 (Linking)
VI  - 34
IP  - 3
DP  - 1994 Jun
TI  - Autoimmune disease and pregnancy.
PG  - 251-8
AB  - Autoimmune diseases are relatively common in women, and tend to occur in the 
      childbearing years. These disorders fall broadly into two groups: (i) Multisystem 
      diseases such as systemic lupus erythematosus (SLE) and related connective tissue 
      disorders (CTD). This group includes the 'pre-clinical' antiphospholipid or lupus 
      obstetric syndrome which may first manifest itself as a pregnancy disorder 
      causing recurrent abortion, fetal death, fetal growth retardation and early onset 
      severe pre-eclampsia. (ii) Tissue- or organ-specific disorders such as autoimmune 
      thrombocytopaenic purpura (ATP), autoimmune thyroid disease (Graves' disease, 
      Hashimoto's autoimmune thyroiditis, and post-postum thyroiditis), autoimmune 
      haemolytic anaemia, and the very rare myasthenia gravis. The study of autoimmune 
      diseases against the background of pregnancy as an experimental system of nature 
      has provided important insights into the nature of the disease processes and the 
      relevance or otherwise of circulating autoantibodies to pathological effects. 
      Thus, for example, if neonatal manifestations of adult disease are causally 
      related to the transfer of autoantibodies across the placenta, they will 
      disappear over a time course consistent with the catabolism of IgG, providing no 
      permanent damage is produced. Conversely, if autoantibodies are demonstrable in 
      the neonate, in the absence of clinical effects, they may only be an 
      epiphenomenon of the maternal disease. In addition, on occasions, disease 
      manifestations may be seen in the baby when the mother shows none. This may occur 
      when the mother is in remission, but still has circulating antibodies, or when 
      she has an occult form of the disease.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Jones, W R
AU  - Jones WR
AD  - Department of Obstetrics & Gynaecology, Flinders Medical Centre, Adelaide.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Aust N Z J Obstet Gynaecol
JT  - The Australian & New Zealand journal of obstetrics & gynaecology
JID - 0001027
RN  - 9005-49-6 (Heparin)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Autoimmune Diseases/drug therapy/*immunology
MH  - Embryonic and Fetal Development
MH  - Female
MH  - Heparin/administration & dosage/therapeutic use
MH  - Humans
MH  - Maternal-Fetal Exchange/immunology
MH  - Prednisolone/administration & dosage/adverse effects/therapeutic use
MH  - Pregnancy/*physiology
RF  - 51
EDAT- 1994/06/01 00:00
MHDA- 1994/06/01 00:01
CRDT- 1994/06/01 00:00
PHST- 1994/06/01 00:00 [pubmed]
PHST- 1994/06/01 00:01 [medline]
PHST- 1994/06/01 00:00 [entrez]
AID - 10.1111/j.1479-828x.1994.tb01067.x [doi]
PST - ppublish
SO  - Aust N Z J Obstet Gynaecol. 1994 Jun;34(3):251-8. doi: 
      10.1111/j.1479-828x.1994.tb01067.x.

PMID- 1297896
OWN - NLM
STAT- MEDLINE
DCOM- 19930503
LR  - 20131121
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 14
IP  - 10
DP  - 1992 Dec
TI  - Pharmacokinetics and relative bioavailability of a new chewable, buffered 
      acetylsalicylic acid tablet formulation in comparison to a conventional plain 
      tablet.
PG  - 805-11
AB  - The pharmacokinetics of acetylsalicylic acid (ASA) and its main metabolite 
      salicylic acid (SA) following single dose administration of a new chewable, 
      buffered ASA tablet formulation and a conventional plain ASA tablet formulation 
      were investigated in 12 healthy male subjects. The volunteers received in a 
      randomized, crossover design two pharmaceutical units of both formulations 
      containing 500 mg ASA each after an overnight fast on an empty stomach. ASA and 
      SA in the collected plasma and urine samples were determined using an internally 
      standardized validated HPLC method. Regarding the normalized extent parameters 
      for ASA, an increase of about 114% for the maximum concentration (Cmax,norm) and 
      about 16% for the area under the curve (AUC0----infinity,norm) was found for the 
      new chewable, buffered tablet formulation as compared to the plain tablet. 
      Comparing the corresponding parameters for the main metabolite, both formulations 
      were statistically equivalent. The quotient of normalized areas (QAUC0-20min, 
      norm/AUC0----infinity,norm) for ASA was higher by about 124% for the new 
      formulation, indicating an increased and faster absorption during the first 20 
      min after administration. The time of the concentration maximum did not differ 
      statistically. These data indicate that the new chewable, buffered ASA tablet 
      formulation shows a significant benefit as compared to the plain ASA tablet. The 
      new tablet produced higher plasma ASA concentrations in a shorter time, which is 
      clinically important since higher ASA concentrations are assumed to be related to 
      an improved analgesic efficacy.
FAU - Lücker, P W
AU  - Lücker PW
AD  - Institut für klinische Pharmakologie Bobenheim, Prof. Dr. Lücker GmbH, Grünstadt, 
      Germany.
FAU - Wetzelsberger, N
AU  - Wetzelsberger N
FAU - Schettler, T
AU  - Schettler T
FAU - Rogalla, K
AU  - Rogalla K
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Biological Availability
MH  - Humans
MH  - Male
MH  - Salicylates/blood/urine
MH  - Tablets
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 1992 Dec;14(10):805-11.

PMID- 7524381
OWN - NLM
STAT- MEDLINE
DCOM- 19941117
LR  - 20131121
IS  - 0201-7563 (Print)
IS  - 0201-7563 (Linking)
IP  - 2
DP  - 1993 Mar-Apr
TI  - [Substantiation of the use of prostaglandin- and kininogenesis in general 
      anesthesia and postoperative analgesia].
PG  - 3-9
AB  - The expediency of introducing prostaglandin- and kininogenesis inhibitors 
      (acelysin and kontrykal) into general anesthesia and postoperative analgesia has 
      been substantiated and the advantages of the application of these specific 
      nonopiate components of surgical analgesia have been shown. The above inhibitors 
      alleviate local and general homeostasis disorders associated with excessive 
      production of prostaglandins and kinins during surgical trauma and increase the 
      efficacy of analgesia, reducing the need in narcotic analgesics.
FAU - Osipova, N A
AU  - Osipova NA
FAU - Sviridov, S V
AU  - Sviridov SV
LA  - rus
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Obosnovanie primeneniia ingibitorov prostaglandino- i kininogeneza v komplekse 
      obshcheĭ anestezii i posleoperatsionnogo obezvolivaniia.
PL  - Russia (Federation)
TA  - Anesteziol Reanimatol
JT  - Anesteziologiia i reanimatologiia
JID - 7705399
RN  - 0 (Analgesics)
RN  - 0 (Drug Combinations)
RN  - 0 (Kinins)
RN  - 0 (Prostaglandins)
RN  - 0 (acetylsalicylate, glycine, lysine drug combination)
RN  - 9087-70-1 (Aprotinin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analgesics/*therapeutic use
MH  - *Anesthesia, General
MH  - Aprotinin/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Glycine/*therapeutic use
MH  - Humans
MH  - Kinins/biosynthesis
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Prostaglandins/biosynthesis
MH  - Time Factors
EDAT- 1993/03/01 00:00
MHDA- 1993/03/01 00:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 1993/03/01 00:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
PST - ppublish
SO  - Anesteziol Reanimatol. 1993 Mar-Apr;(2):3-9.

PMID- 35644114
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220608
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 151
DP  - 2022 Jul
TI  - Polysaccharide-protein complex from coelomic fluid of Dendrobaena veneta 
      earthworm exerts a multi-pathway antiplatelet effect without coagulopathy and 
      cytotoxicity.
PG  - 113205
LID - S0753-3322(22)00594-7 [pii]
LID - 10.1016/j.biopha.2022.113205 [doi]
AB  - There is a pressing need to identify novel antiplatelet agents, an alternative to 
      acetylsalicylic acid and thienopyridines, to broaden the prevention of 
      cardiovascular events, the leading cause of global morbidity and mortality. 
      Invertebrate coelomocytes structurally and functionally resemble the 
      thrombocyte-like cells of vertebrates; therefore, the coelomic fluid in which 
      they are suspended may contain agents controlling their clumping abilities. 
      However, whether coelomocytes-free coelomic fluid may also affect human platelet 
      activities was not a subject of any study. This study aimed to screen the in 
      vitro antiplatelet and anticoagulant activities of the polysaccharide-protein 
      complex from Dendrobaena veneta coelomic fluid (25-100 µg/mL) (PPC-DV). All 
      tested fluid concentrations induced significant (42.4-52.5%) inhibition of 
      adenosine-5'-diphosphate (ADP)-induced aggregation of human platelets at a level 
      comparable to that of 140 µmol/L acetylsalicylic acid. Its relevant antiplatelet 
      effect (27.2-45.9%) was also evidenced in the thrombin receptor-activating 
      peptide-6 (TRAP-6) assay. Moreover, 50 and 100 µg/mL of PPC-DV inhibited 
      arachidonic acid-inducible aggregation. No coagulopathic or cytotoxic effects of 
      PPC-DV were observed. The study indicates that PPC-DV, at a concentration of at 
      least 50 µg/mL, exerts a favorable antiplatelet effect by targeting at least 
      three pathways (P2Y(12) receptor, cyclooxygenase-1, and protease-activated 
      receptor-1), justifying further experimental and clinical investigations on its 
      use in cardiovascular disease prevention.
CI  - Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Poniedziałek, Barbara
AU  - Poniedziałek B
AD  - Department of Environmental Medicine, Poznan University of Medical Sciences, 
      60-806 Poznan, Poland. Electronic address: bpon@ump.edu.pl.
FAU - Rosińska, Joanna
AU  - Rosińska J
AD  - Department of Environmental Medicine, Poznan University of Medical Sciences, 
      60-806 Poznan, Poland.
FAU - Rzymski, Piotr
AU  - Rzymski P
AD  - Department of Environmental Medicine, Poznan University of Medical Sciences, 
      60-806 Poznan, Poland.
FAU - Fiołka, Marta
AU  - Fiołka M
AD  - Department of Immunobiology, Institute of Biology and Biochemistry, Maria 
      Curie-Skłodowska University, Lublin, Poland.
LA  - eng
PT  - Journal Article
DEP - 20220526
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polysaccharides)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Platelets
MH  - Humans
MH  - *Oligochaeta
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Polysaccharides/pharmacology
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Human platelet
OT  - Natural antiplatelet agents
OT  - Thrombosis
EDAT- 2022/06/02 06:00
MHDA- 2022/06/09 06:00
CRDT- 2022/06/01 10:21
PHST- 2022/04/15 00:00 [received]
PHST- 2022/05/19 00:00 [revised]
PHST- 2022/05/24 00:00 [accepted]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/06/01 10:21 [entrez]
AID - S0753-3322(22)00594-7 [pii]
AID - 10.1016/j.biopha.2022.113205 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2022 Jul;151:113205. doi: 10.1016/j.biopha.2022.113205. Epub 
      2022 May 26.

PMID- 12563458
OWN - NLM
STAT- MEDLINE
DCOM- 20030508
LR  - 20190916
IS  - 0104-4230 (Print)
IS  - 0104-4230 (Linking)
VI  - 48
IP  - 4
DP  - 2002 Oct-Dec
TI  - [Effect of acetylsalicylic acid on the reproductive performance and on offspring 
      from wistar rats].
PG  - 312-6
AB  - The aim of this paper was to perform a randomized, controlled and blinded study 
      to investigate if a therapeutic dose of acetylsalicylic acid (ASA), taken by 
      pregnant women, may also cause embryotoxic or congenital abnormalities on 
      experimental animal. METHODS: Females were confirmed to have mated by 
      observations of sperm in a vaginal smear. The day on which spermatozoa were found 
      in the vaginal smear was considered as day 1 of gestation (GD1). After 
      randomization, mated females were assigned to experimental groups and 
      individually caged, were given 50 mg/kg/day of acetylsalicylic acid, by needle 
      gavage once daily, during two different periods of pregnancy. One group of dams 
      (n=11) received aspirin from day 1 to 4 of pregnancy (before embryonic 
      implantation) for evaluation of the blastocysts, and another group received 
      aspirin from day 6 to 15 of pregnancy (organogenic period) for fetal evaluation. 
      Control groups (n=12) received distilled water in same volume and during same 
      periods as their respective experimental groups. RESULTS AND CONCLUSION: The 
      treatment of the dams with ASA, according to minimal therapeutic dose used for 
      humans, did not cause embryotoxic or major malformations on experimental animal 
      but was responsible for rate increased of fetuses presenting ureteric dilatation. 
      After analysis of the data, it appears that, although direct conclusive evidence 
      of adverse effects in humans is lacking, a potential hazard dose exists and thus 
      the indiscriminate use of acetylsalicylic acid (aspirin) is contraindicated.
FAU - Damasceno, Débora Cristina
AU  - Damasceno DC
AD  - Faculdade Estadual de Medicina de Marília, São Paulo, Brasil. decaito@bol.com.br
FAU - Volpato, Gustavo Tadeu
AU  - Volpato GT
FAU - Person, Osmar Clayton
AU  - Person OC
FAU - Yoshida, Alessandra
AU  - Yoshida A
FAU - Rudge, Marilza Vieira Cunha
AU  - Rudge MV
FAU - Calderon, Iracema de Mattos Paranhos
AU  - Calderon Ide M
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Efeito do ácido acetilsalicílico na performance reprodutiva e na prole de ratas 
      wistar.
DEP - 20030128
PL  - Brazil
TA  - Rev Assoc Med Bras (1992)
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/adverse effects
MH  - Blastomeres/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical
MH  - Female
MH  - Fetus/drug effects
MH  - Pregnancy
MH  - Pregnancy, Animal/*drug effects
MH  - Random Allocation
MH  - Rats
MH  - Rats, Wistar
MH  - Salicylates/administration & dosage/*adverse effects
MH  - Single-Blind Method
EDAT- 2003/02/04 04:00
MHDA- 2003/05/09 05:00
CRDT- 2003/02/04 04:00
PHST- 2003/02/04 04:00 [pubmed]
PHST- 2003/05/09 05:00 [medline]
PHST- 2003/02/04 04:00 [entrez]
AID - S0104-42302002000400036 [pii]
AID - 10.1590/s0104-42302002000400036 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras (1992). 2002 Oct-Dec;48(4):312-6. doi: 
      10.1590/s0104-42302002000400036. Epub 2003 Jan 28.

PMID- 3927970
OWN - NLM
STAT- MEDLINE
DCOM- 19851004
LR  - 20190704
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 60
IP  - 4
DP  - 1985 Aug
TI  - Cumulative antiplatelet effect of low-dose enteric coated aspirin.
PG  - 635-42
AB  - Enteric coated aspirin (ECA) at doses of 325-1300 mg is an effective alternative 
      to regular aspirin for inhibition of platelet activity while avoiding gastric 
      irritation. The objectives of this study were to determine: (1) the lowest 
      chronic dose of ECA providing effective inhibition of platelet activities, (2) 
      the time course of the inhibition, and (3) the reappearance of platelet 
      cyclo-oxygenase activity. Seven subjects were studied before and after seven 
      daily doses of 40-325 mg ECA. Serum thromboxane (TX) B2 levels indicated that the 
      lowest dose of ECA resulting in greater than 90% inhibition of platelet 
      cyclo-oxygenase was 80 mg/d. Platelet aggregation and ATP release in response to 
      collagen (1 microgram/ml) and arachidonic acid (1 mM) were abolished and bleeding 
      times were prolonged from 6.1 +/- 1.5 min to 9.7 +/- 2.8 min (mean +/- SD, P less 
      than 0.01). Examination of platelet cyclo-oxygenase activity on a daily basis 
      revealed that 24 h after the first 80 mg dose serum TXB2 had decreased by 
      approximately 60% and was suppressed by more than 90% after four doses. Recovery 
      of platelet cyclo-oxygenase activity after a single 80 mg dose of ECA was delayed 
      for 48-72 h indicating that aspirin reached the systemic circulation. We conclude 
      that chronic inhibition of platelet activity may be achieved in a cumulative 
      manner with 80 mg ECA/d.
FAU - Jakubowski, J A
AU  - Jakubowski JA
FAU - Stampfer, M J
AU  - Stampfer MJ
FAU - Vaillancourt, R
AU  - Vaillancourt R
FAU - Deykin, D
AU  - Deykin D
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Triphosphate/blood
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects/enzymology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandin-Endoperoxide Synthases/blood
MH  - Tablets, Enteric-Coated
MH  - Thromboxane B2/blood
EDAT- 1985/08/01 00:00
MHDA- 1985/08/01 00:01
CRDT- 1985/08/01 00:00
PHST- 1985/08/01 00:00 [pubmed]
PHST- 1985/08/01 00:01 [medline]
PHST- 1985/08/01 00:00 [entrez]
AID - 10.1111/j.1365-2141.1985.tb07467.x [doi]
PST - ppublish
SO  - Br J Haematol. 1985 Aug;60(4):635-42. doi: 10.1111/j.1365-2141.1985.tb07467.x.

PMID- 7894888
OWN - NLM
STAT- MEDLINE
DCOM- 19950427
LR  - 20171116
IS  - 1367-8280 (Print)
IS  - 1367-8280 (Linking)
VI  - 109
IP  - 3
DP  - 1994 Nov
TI  - Anticholinesterases and experimental envenomation by Naja.
PG  - 265-8
AB  - Danger from snake bites, especially those of Elapidae, pose a public health 
      problem in a large number of tropical and sub-tropical countries. Since the 
      advent of serotherapy, the morality rate has decreased, but suitable sera are not 
      always available, explaining the usefulness of developing symptomatic treatments. 
      The present study is a test of the preventative and curative efficacy of 
      anticholinesterases in the treatment of Naja haje haje venom envenomation. It is 
      clearly shown that the early use of these products leads to a considerable 
      increase in the LD50 in mice having undergone experimental envenomation.
FAU - Guieu, R
AU  - Guieu R
AD  - Laboratoire de Biochimie, Faculté de Médecine secteur Nord, Marseille, France.
FAU - Rosso, J P
AU  - Rosso JP
FAU - Rochat, H
AU  - Rochat H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Comp Biochem Physiol C Pharmacol Toxicol Endocrinol
JT  - Comparative biochemistry and physiology. Part C, Pharmacology, toxicology & 
      endocrinology
JID - 9516060
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Elapid Venoms)
RN  - 3982TWQ96G (Neostigmine)
RN  - 7C0697DR9I (Atropine)
RN  - CJ0O37KU29 (Verapamil)
RN  - K3Z4F929H6 (Lysine)
RN  - KVI301NA53 (Pyridostigmine Bromide)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Atropine/therapeutic use
MH  - Cholinesterase Inhibitors/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Elapid Venoms/*toxicity
MH  - *Elapidae
MH  - Female
MH  - Lethal Dose 50
MH  - Lysine/analogs & derivatives/therapeutic use
MH  - Mice
MH  - Neostigmine/therapeutic use
MH  - Pyridostigmine Bromide/therapeutic use
MH  - Snake Bites/*drug therapy
MH  - Verapamil/therapeutic use
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
PST - ppublish
SO  - Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1994 Nov;109(3):265-8.

PMID- 6231713
OWN - NLM
STAT- MEDLINE
DCOM- 19840518
LR  - 20161123
IS  - 0390-5748 (Print)
IS  - 0390-5748 (Linking)
VI  - 13 Suppl 3
DP  - 1983
TI  - [The effect of lysine acetylsalicylate on hemorrheological changes induced 
      through ischemic exertion in patients with vascular disease].
PG  - 315-21
AB  - This study has been performed to evaluate the in vivo effect of acetylsalicylic 
      acid (ASA) i.v. infusion at two different dosages: 500 and 2,000 mg on the main 
      hemorheological parameters (blood viscosity and filtrability, hematocrit) and on 
      beta-thromboglobulin (a platelet-specific protein) in patients with peripheral 
      obliterative arterial disease, before and after an ischemic exercise. The results 
      obtained before and 3 and 24 h after the drug administration induced us to think 
      that platelet-specific substances released during the ischemic exercise can 
      affect the hemorheological parameters and that ASA may be able to interfere with 
      these reactions by inhibiting the platelet release.
FAU - Vittoria, A
AU  - Vittoria A
FAU - Guerrini, M
AU  - Guerrini M
FAU - Pieragalli, D
AU  - Pieragalli D
FAU - Del Bigo, C
AU  - Del Bigo C
FAU - Martelli, G
AU  - Martelli G
FAU - Franchi, M
AU  - Franchi M
FAU - Messa, G
AU  - Messa G
FAU - Blardi, P
AU  - Blardi P
FAU - Galigani, C
AU  - Galigani C
FAU - Di Perri, T
AU  - Di Perri T
LA  - ita
PT  - Journal Article
TT  - Azione dell'acetilsalicilato di lisina sulle alterazioni emoreologiche indotte 
      dallo sforzo ischemico in pazienti vasculopatici.
PL  - Italy
TA  - Ric Clin Lab
JT  - La Ricerca in clinica e in laboratorio
JID - 7613947
RN  - 0 (Analgesics)
RN  - 0 (beta-Thromboglobulin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Analgesics
MH  - Arterial Occlusive Diseases/*blood
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Viscosity/*drug effects
MH  - Erythrocytes/physiology
MH  - Female
MH  - Hematocrit
MH  - Humans
MH  - Intermittent Claudication/*drug therapy
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Time Factors
MH  - Ultrafiltration
MH  - beta-Thromboglobulin/analysis
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Ric Clin Lab. 1983;13 Suppl 3:315-21.

PMID- 30985534
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20210109
IS  - 1531-5487 (Electronic)
IS  - 1044-3983 (Print)
IS  - 1044-3983 (Linking)
VI  - 30
IP  - 4
DP  - 2019 Jul
TI  - Metabolic Syndrome and the Effectiveness of Low-dose Aspirin on Reproductive 
      Outcomes.
PG  - 573-581
LID - 10.1097/EDE.0000000000001019 [doi]
AB  - BACKGROUND: Metabolic syndrome is associated with increases in both inflammation 
      and aspirin resistance, but effectiveness of aspirin in improving reproductive 
      health among women with metabolic syndrome is unknown. We evaluated the 
      effectiveness of low-dose aspirin in improving reproductive outcomes across 
      metabolic syndrome score. METHODS: The EAGeR trial randomly assigned 1228 women 
      with a history of pregnancy loss to receive 81 mg aspirin or placebo for up to 
      six menstrual cycles of attempting pregnancy and, if they became pregnant, 
      throughout pregnancy. We assessed components of metabolic syndrome at enrollment, 
      including: waist circumference ≥88 cm, triglycerides ≥150 mg/dl, high-density 
      lipoprotein ≤50 mg/dl, blood pressure ≥130 mmHg systolic or ≥85 mmHg diastolic, 
      and glucose ≥100 mg/dl. We summed components to calculate metabolic syndrome 
      score. RESULTS: A total of 229 participants (20%) met full criteria for metabolic 
      syndrome, 207 (18%) had two components, 366 (31%) one component, and 372 (32%) no 
      components. Among those without any component of metabolic syndrome, aspirin was 
      associated with 10.7 [95% confidence interval (CI) = 1.2, 20.2] more pregnancies 
      and 13.7 (95% CI = 3.3, 24.0) more live births per 100 couples. Effects were 
      attenuated as metabolic syndrome score increased and we observed no clear effect 
      of aspirin on pregnancy or live birth among women with metabolic syndrome. 
      CONCLUSIONS: Low-dose aspirin is most effective in increasing pregnancy and live 
      birth among women with no or few components of metabolic syndrome. Reduced 
      effectiveness among women with metabolic syndrome may be due to differences in 
      effective dose or aspirin resistance.
FAU - Nobles, Carrie J
AU  - Nobles CJ
AD  - From the Epidemiology Branch, Division of Intramural Population Health Research, 
      Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, MD.
FAU - Mendola, Pauline
AU  - Mendola P
AD  - From the Epidemiology Branch, Division of Intramural Population Health Research, 
      Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, MD.
FAU - Mumford, Sunni L
AU  - Mumford SL
AD  - From the Epidemiology Branch, Division of Intramural Population Health Research, 
      Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, MD.
FAU - Kim, Keewan
AU  - Kim K
AD  - From the Epidemiology Branch, Division of Intramural Population Health Research, 
      Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, MD.
FAU - Sjaarda, Lindsey
AU  - Sjaarda L
AD  - From the Epidemiology Branch, Division of Intramural Population Health Research, 
      Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, MD.
FAU - Hill, Micah
AU  - Hill M
AD  - Department of Obstetrics and Gynecology, Walter Reed National Military Medical 
      Center, Bethesda, MD.
FAU - Silver, Robert M
AU  - Silver RM
AD  - Obstetrics and Gynecology, School of Medicine, University of Utah, Salt Lake 
      City, UT.
FAU - Naimi, Ashley I
AU  - Naimi AI
AD  - Department of Epidemiology, School of Public Health, University of Pittsburgh, 
      Pittsburgh, PA.
FAU - Perkins, Neil J
AU  - Perkins NJ
AD  - From the Epidemiology Branch, Division of Intramural Population Health Research, 
      Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, MD.
FAU - Schisterman, Enrique F
AU  - Schisterman EF
AD  - From the Epidemiology Branch, Division of Intramural Population Health Research, 
      Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, MD.
LA  - eng
GR  - R01 HD093602/HD/NICHD NIH HHS/United States
GR  - ZIA HD008795-10/ImNIH/Intramural NIH HHS/United States
GR  - ZIA HD008795-11/ImNIH/Intramural NIH HHS/United States
GR  - ZIA HD008795-12/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Epidemiology
JT  - Epidemiology (Cambridge, Mass.)
JID - 9009644
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Spontaneous/etiology/*prevention & control
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infertility, Female/*drug therapy
MH  - Live Birth
MH  - Metabolic Syndrome/*drug therapy
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Pregnancy Outcome
MH  - Prospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
PMC - PMC6548668
MID - NIHMS1525335
COIS- Conflicts of Interest: None declared
EDAT- 2019/04/16 06:00
MHDA- 2020/07/18 06:00
CRDT- 2019/04/16 06:00
PHST- 2019/04/16 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
PHST- 2019/04/16 06:00 [entrez]
AID - 10.1097/EDE.0000000000001019 [doi]
PST - ppublish
SO  - Epidemiology. 2019 Jul;30(4):573-581. doi: 10.1097/EDE.0000000000001019.

PMID- 11472699
OWN - NLM
STAT- MEDLINE
DCOM- 20010816
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 88
IP  - 3
DP  - 2001 Aug 1
TI  - Profile and prevalence of aspirin resistance in patients with cardiovascular 
      disease.
PG  - 230-5
AB  - We determined the prevalence and clinical predictors of aspirin resistance by 
      prospectively studying 325 patients with stable cardiovascular disease who were 
      receiving aspirin (325 mg/day for > or =7 days) but no other antiplatelet agents. 
      We also compared the detection of aspirin resistance with optical platelet 
      aggregation, a widely accepted method, with a newer, more rapid method, the 
      platelet function analyzer (PFA)-100, a whole blood test that measures platelet 
      adhesion and aggregation ex vivo. Blood samples were analyzed in a blinded 
      fashion for aspirin resistance by optical aggregation using adenosine diphosphate 
      (ADP) and arachidonic acid, and by PFA-100 using collagen and/or epinephrine and 
      collagen and/or ADP cartridges to measure aperture closure time. Aspirin 
      resistance was defined as a mean aggregation of > or =70% with 10 microM ADP and 
      a mean aggregation of > or =20% with 0.5 mg/ml arachidonic acid. Aspirin 
      semiresponders were defined as meeting one, but not both of the above criteria. 
      Aspirin resistance by PFA-100 was defined as having a normal collagen and/or 
      epinephrine closure time (< or =193 seconds). By optical aggregation, 5.5% of the 
      patients were aspirin resistant and 23.8% were aspirin semiresponders. By 
      PFA-100, 9.5% of patients were aspirin resistant. Of the 18 patients who were 
      aspirin resistant by aggregation, 4 were also aspirin resistant by PFA-100. 
      Patients who were either aspirin resistant or aspirin semiresponders were more 
      likely to be women (34.4% vs 17.3%, p = 0.001) and less likely to be smokers (0% 
      vs 8.3%, p = 0.004) compared with aspirin-sensitive patients. There was a trend 
      toward increased age in patients with aspirin resistance or aspirin 
      semiresponders (65.7 vs 61.3 years, p = 0.06). There were no differences in 
      aspirin sensitivity by race, diabetes, platelet count, renal disease, or liver 
      disease.
FAU - Gum, P A
AU  - Gum PA
AD  - Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, 
      USA.
FAU - Kottke-Marchant, K
AU  - Kottke-Marchant K
FAU - Poggio, E D
AU  - Poggio ED
FAU - Gurm, H
AU  - Gurm H
FAU - Welsh, P A
AU  - Welsh PA
FAU - Brooks, L
AU  - Brooks L
FAU - Sapp, S K
AU  - Sapp SK
FAU - Topol, E J
AU  - Topol EJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Cardiol. 2001 Dec 1;88(11):1348-9. PMID: 11728374
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*blood
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prevalence
MH  - Prospective Studies
MH  - Sex Factors
EDAT- 2001/07/27 10:00
MHDA- 2001/08/17 10:01
CRDT- 2001/07/27 10:00
PHST- 2001/07/27 10:00 [pubmed]
PHST- 2001/08/17 10:01 [medline]
PHST- 2001/07/27 10:00 [entrez]
AID - S0002-9149(01)01631-9 [pii]
AID - 10.1016/s0002-9149(01)01631-9 [doi]
PST - ppublish
SO  - Am J Cardiol. 2001 Aug 1;88(3):230-5. doi: 10.1016/s0002-9149(01)01631-9.

PMID- 30745129
OWN - NLM
STAT- MEDLINE
DCOM- 20190529
LR  - 20190529
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 63
DP  - 2019 May
TI  - Medical and endovascular treatments of symptomatic intracranial stenosis. A 
      Bayesian network meta-analysis.
PG  - 84-90
LID - S0967-5868(18)30617-9 [pii]
LID - 10.1016/j.jocn.2019.01.040 [doi]
AB  - Intracranial stenosis is a well-established stroke risk factor with an increase 
      of stroke recurrence or TIA up to 12.6% at 1 year. Treatments are different: 
      medical and endovascular. We performed a multiple treatment comparison analysis 
      to detect the best treatment in reducing the risk of stroke recurrence. We 
      searched in Medline, Embase, Cochrane Central Register of Controlled Trials 
      databases between 1979 and October 2017. Inclusion criteria were prospective 
      randomized trials that evaluated patients with TIA or stroke due to intracranial 
      stenosis and treated with different medical therapies and/or endovascular 
      procedures. Primary endpoint was the recurrence of TIA or stroke in the territory 
      of intracranial stenosis, while secondary endpoint was represented by any stroke 
      or vascular death. Multiple treatment comparison meta-analysis based on a 
      Bayesian fixed and random effects Poisson model was performed. Seven trials were 
      included with a total of 1337 patients. At multiple treatment comparison, no 
      significant differences between treatments were observed for both primary (median 
      fixed effect standard OR: 0.40; 95%CI: 0.02-1.07) and secondary endpoints (median 
      random effect standard OR: 1.17; 95%CI: 0.32-1.92). Treatment with aspirin alone 
      ranked with high values both for primary and secondary endpoints (surface under 
      the cumulative ranking curve of 70% and 82%, respectively). In patients with 
      symptomatic intracranial stenosis, no differences between treatments were 
      observed. However, aspirin alone was more effective than stenting in the 
      reduction of TIA or stroke recurrences, with a better safety profile than oral 
      anticoagulants.
CI  - Copyright © 2019 Elsevier Ltd. All rights reserved.
FAU - Vidale, S
AU  - Vidale S
AD  - Department of Neurology & Stroke Unit, Sant'Anna Hospital, Como, Italy. 
      Electronic address: simone.vidale@asst-lariana.it.
FAU - Agostoni, E
AU  - Agostoni E
AD  - Department of Neurology, Niguarda Ca' Granda Hospital, Milan, Italy.
FAU - Grampa, G
AU  - Grampa G
AD  - Department of Neurology & Stroke Unit, Sant'Anna Hospital, Como, Italy.
FAU - Consoli, A
AU  - Consoli A
AD  - Service de Neuroradiologie Diagnostique et Thérapeutique, Hopital Foch, Paris, 
      France; Interventional Neurovascular Unit, Careggi University Hospital, Florence, 
      Italy.
FAU - Consoli, D
AU  - Consoli D
AD  - Department of Neurology, "G. Jazzolino" Hospital, Vibo Valentia, Italy.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20190208
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Bayes Theorem
MH  - Cerebrovascular Disorders/drug therapy/*surgery
MH  - Constriction, Pathologic/drug therapy/*surgery
MH  - Endovascular Procedures/adverse effects/*methods
MH  - Humans
MH  - Postoperative Complications/*epidemiology
MH  - Stroke/*epidemiology
OTO - NOTNLM
OT  - Network meta-analysis
OT  - Symptomatic intracranial stenosis
OT  - Treatment
EDAT- 2019/02/13 06:00
MHDA- 2019/05/30 06:00
CRDT- 2019/02/13 06:00
PHST- 2018/04/08 00:00 [received]
PHST- 2019/01/04 00:00 [revised]
PHST- 2019/01/28 00:00 [accepted]
PHST- 2019/02/13 06:00 [pubmed]
PHST- 2019/05/30 06:00 [medline]
PHST- 2019/02/13 06:00 [entrez]
AID - S0967-5868(18)30617-9 [pii]
AID - 10.1016/j.jocn.2019.01.040 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2019 May;63:84-90. doi: 10.1016/j.jocn.2019.01.040. Epub 2019 
      Feb 8.

PMID- 3747549
OWN - NLM
STAT- MEDLINE
DCOM- 19861023
LR  - 20191030
IS  - 0160-5402 (Print)
IS  - 0160-5402 (Linking)
VI  - 16
IP  - 2
DP  - 1986 Sep
TI  - Quantitative assessment of subcutaneous fibrinolysis in the rat.
PG  - 125-38
AB  - A clot lysis model in the rat was described which was responsive to manipulation 
      of the fibrinolytic system. By employing [125I]-labeled fibrinogen in homologous, 
      plasminogen-deficient plasma, clots were prepared in Teflon-perforated cylinders 
      and were implanted subcutaneously. After a brief lag phase, lysis proceeded 
      essentially linearly with 70% of the clot resolved within 12 days. Enhancement of 
      lysis was achieved with a stimulator of fibrinolysis, stanozolol; and inhibition, 
      with the antifibrinolytic, tranexamic acid. Other drugs affecting blood pressure, 
      inflammation, or connective tissue growth had no effect on lysis. Interstitial 
      fluid collected from empty cylinders and fluid obtained from the recovered clots 
      were monitored for plasminogen, alpha 2-antiplasmin, plasminogen activator, and 
      plasminogen activator inhibitor using sensitive and specific assays. All of these 
      fibrinolytic proteins were quantitated relative to their plasma concentrations. 
      The most striking differences between the two fluids and plasma were a threefold 
      higher concentration of the plasminogen activator inhibitor and only traces of 
      free tissue plasminogen activator in the fluids. Nevertheless, significant tissue 
      plasminogen activator was delivered to the clot. It was concluded that lysis 
      occurred via delivery of the fibrinolytic system in interstitial fluid. It is 
      suggested that this model is a technically simple and quantitative screen in vivo 
      for potentially fibrinolytic or antifibrinolytic agents.
FAU - Kirstein, C G
AU  - Kirstein CG
FAU - Tuttle, P R
AU  - Tuttle PR
FAU - Berger, H Jr
AU  - Berger H Jr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Methods
JT  - Journal of pharmacological methods
JID - 7806596
RN  - 9001-31-4 (Fibrin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Coagulation
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Fibrin/metabolism
MH  - *Fibrinolysis
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Skin/*metabolism
MH  - Time Factors
EDAT- 1986/09/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
AID - 0160-5402(86)90018-5 [pii]
AID - 10.1016/0160-5402(86)90018-5 [doi]
PST - ppublish
SO  - J Pharmacol Methods. 1986 Sep;16(2):125-38. doi: 10.1016/0160-5402(86)90018-5.

PMID- 27428004
OWN - NLM
STAT- MEDLINE
DCOM- 20170726
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 7
DP  - 2016
TI  - The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely 
      Explained by Selection Bias: Results from Three Different Study Designs in 
      Clinical Practice.
PG  - e0159179
LID - 10.1371/journal.pone.0159179 [doi]
LID - e0159179
AB  - BACKGROUND: We conducted three differently designed nested case-control studies 
      to evaluate whether the protective effect of low-dose aspirin against colorectal 
      cancer (CRC) is explained by selection bias. METHODS: Using a large validated UK 
      primary care database, we followed different cohorts of patients, who varied in 
      their demographic and clinical characteristics, to identify first ever cases of 
      CRC. In Studies 1 and 2, two cohorts were followed, i) new users of low-dose 
      aspirin at start of follow-up (N = 170,336 in Study 1, N = 171,527 in Study 2) 
      and either ii) non-users of low-dose aspirin (Study 1, N = 170,336) or new users 
      of paracetamol (Study 2, N = 149,597) at start of follow-up. In Study 3 a single 
      cohort of individuals näive to low-dose aspirin at the start of observation was 
      followed. Controls were selected using incidence sampling and logistic regression 
      used to obtain an unbiased estimate of the incidence rate ratio (RR) with 95% 
      confidence intervals (CIs). Low-dose aspirin exposure was analyzed 'as-treated' 
      before the index date (CRC date for cases, random date for controls). RESULTS: In 
      the three studies, median (maximum) follow-up was 5.1 (12), 5.8 (12) and 7.5 (13) 
      years, respectively. 3033 incident CRC cases were identified in Study 1, 3174 in 
      Study 2, and 12,333 in Study 3. Current use of low-dose aspirin was associated 
      with a significantly reduced risk of 34%, 29% and 31% in the three studies, 
      respectively; corresponding RRs (95% CIs) were 0.66 (0.60-0.73), 0.71 (0.63-0.80) 
      and 0.69 (0.64-0.74). In each study, significantly reduced risks of CRC were seen 
      when low-dose aspirin was used for primary or secondary cardiovascular disease 
      prevention, in both sexes, and across all age groups evaluated. CONCLUSION: 
      Low-dose aspirin is associated with a significantly reduced risk of CRC. The 
      consistency of our findings across different studies makes selection bias an 
      unlikely explanation.
FAU - Cea Soriano, Lucía
AU  - Cea Soriano L
AD  - Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain.
FAU - Soriano-Gabarró, Montse
AU  - Soriano-Gabarró M
AD  - Epidemiology, Bayer Pharma AG, Berlin, Germany.
FAU - García Rodríguez, Luis A
AU  - García Rodríguez LA
AD  - Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20160718
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Anticarcinogenic Agents/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Case-Control Studies
MH  - Colorectal Neoplasms/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Selection Bias
PMC - PMC4948817
COIS- Competing Interests: This study was funded by Bayer Pharma AG. LCS and LAGR work 
      for CEIFE, which has received a research grant from Bayer Pharma AG. LAGR has 
      also served as an advisory board member for Bayer Pharma AG. MSG is a salaried, 
      full-time employee of Bayer Pharma AG. This does not alter the authors' adherence 
      to PLOS ONE policies on sharing data and materials.
EDAT- 2016/07/20 06:00
MHDA- 2017/07/27 06:00
CRDT- 2016/07/19 06:00
PHST- 2016/01/08 00:00 [received]
PHST- 2016/06/28 00:00 [accepted]
PHST- 2016/07/19 06:00 [entrez]
PHST- 2016/07/20 06:00 [pubmed]
PHST- 2017/07/27 06:00 [medline]
AID - PONE-D-16-00881 [pii]
AID - 10.1371/journal.pone.0159179 [doi]
PST - epublish
SO  - PLoS One. 2016 Jul 18;11(7):e0159179. doi: 10.1371/journal.pone.0159179. 
      eCollection 2016.

PMID- 35926565
OWN - NLM
STAT- MEDLINE
DCOM- 20220908
LR  - 20221027
IS  - 1096-0333 (Electronic)
IS  - 0041-008X (Linking)
VI  - 452
DP  - 2022 Oct 1
TI  - Identification of target and pathway of aspirin combined with Lipitor treatment 
      in prostate cancer through integrated bioinformatics analysis.
PG  - 116169
LID - S0041-008X(22)00314-3 [pii]
LID - 10.1016/j.taap.2022.116169 [doi]
AB  - PURPOSE: Our previous studies have confirmed that aspirin combined with Lipitor 
      inhibited the development of prostate cancer (PCa), but the mechanisms need to be 
      comprehensively expounded. The study aims to screen out the hub genes of 
      combination therapy and to explore their association with the pathogenesis and 
      prognosis of PCa. METHODS: Gene expressions were quantified by RNA sequencing 
      (RNA-seq). Altered biological function, pathways of differentially expressed 
      genes (DEGs), protein-protein interaction network, the filtering of hub genes, 
      gene co-expression and the pathogenesis and prognosis were revealed by 
      bioinformatics analysis. The correlation between hub gene expression and patient 
      survival was validated by Kaplan-Meier. The effects of silent DNA replication and 
      sister chromatid cohesion 1 (siDSCC1) combined with Lipitor and aspirin on DSCC1 
      expression, viability, invasion and migration of PCa cells were detected by 
      qRT-PCR, Wound healing and transwell assays. RESULTS: 157 overlapped DEGs 
      involved in FoxO, PI3K-Akt and p53 signaling pathways were identified. Ten hub 
      genes (NEIL3, CDC7, DSCC1, CDC25C, PRIM1, MCM10, FBXO5, DTL, SERPINE1, EXO1) were 
      verified to be correlated with the pathology and prognosis of PCa. DSCC1 
      silencing not only inhibited the viability, migration and invasion of PCa cells, 
      but also strengthened the suppressing effects of Lipitor and aspirin alone or in 
      combination on PCa cells. CONCLUSION: The enrichment pathways and targets of 
      Lipitor combined with aspirin in PCa are discovered, and DSCC1 silencing can 
      potentiate the effect of Lipitor combined with aspirin in the treatment of PCa.
CI  - Copyright © 2022. Published by Elsevier Inc.
FAU - Wang, Xiao
AU  - Wang X
AD  - School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City 
      529020, China.
FAU - Wu, Yi
AU  - Wu Y
AD  - Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
FAU - Liu, Junlei
AU  - Liu J
AD  - Allan H. Conney Laboratory for Anticancer Research, School of Biomedical and 
      Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, 
      China.
FAU - Xu, Xuetao
AU  - Xu X
AD  - School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City 
      529020, China.
FAU - Sheng, Zhaojun
AU  - Sheng Z
AD  - School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City 
      529020, China.
FAU - Liu, Wenfeng
AU  - Liu W
AD  - School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City 
      529020, China.
FAU - Chen, Min
AU  - Chen M
AD  - School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City 
      529020, China.
FAU - Ma, Yanyan
AU  - Ma Y
AD  - School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City 
      529020, China.
FAU - Zhao, Denggao
AU  - Zhao D
AD  - School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City 
      529020, China.
FAU - Li, Dongli
AU  - Li D
AD  - School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City 
      529020, China.
FAU - Zheng, Xi
AU  - Zheng X
AD  - Department of Chemical Biology, Ernest Mario School of Pharmacy, Ruters 
      University, Piscataway NJ08854, USA. Electronic address: zhengxi_xizh@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220801
PL  - United States
TA  - Toxicol Appl Pharmacol
JT  - Toxicology and applied pharmacology
JID - 0416575
RN  - 0 (Cell Cycle Proteins)
RN  - A0JWA85V8F (Atorvastatin)
RN  - EC 2.7.1.- (CDC7 protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.7.- (DNA Primase)
RN  - EC 2.7.7.- (PRIM1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Atorvastatin
MH  - Cell Cycle Proteins/metabolism
MH  - *Computational Biology
MH  - DNA Primase/genetics/metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - *Prostatic Neoplasms/drug therapy/genetics/metabolism
MH  - Protein Serine-Threonine Kinases
OTO - NOTNLM
OT  - Aspirin
OT  - DNA replication and sister chromatid cohesion 1
OT  - Lipitor
OT  - Prostate cancer
COIS- Declaration of Competing Interest The authors declare no conflicts of interest.
EDAT- 2022/08/05 06:00
MHDA- 2022/09/09 06:00
CRDT- 2022/08/04 19:22
PHST- 2022/02/17 00:00 [received]
PHST- 2022/06/27 00:00 [revised]
PHST- 2022/07/12 00:00 [accepted]
PHST- 2022/08/05 06:00 [pubmed]
PHST- 2022/09/09 06:00 [medline]
PHST- 2022/08/04 19:22 [entrez]
AID - S0041-008X(22)00314-3 [pii]
AID - 10.1016/j.taap.2022.116169 [doi]
PST - ppublish
SO  - Toxicol Appl Pharmacol. 2022 Oct 1;452:116169. doi: 10.1016/j.taap.2022.116169. 
      Epub 2022 Aug 1.

PMID- 31104152
OWN - NLM
STAT- MEDLINE
DCOM- 20200304
LR  - 20200309
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Linking)
VI  - 21
IP  - 7
DP  - 2019 May 18
TI  - Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart 
      Disease Patients: a Review.
PG  - 56
LID - 10.1007/s11886-019-1152-6 [doi]
AB  - PURPOSE OF REVIEW: Stable and unstable ischemic heart disease are a growing 
      component in all facets of healthcare, including ER visits, hospitalizations, and 
      financial costs. With the changing emphasis of healthcare shifting towards the 
      outpatient setting, the onus is on clinicians to appropriately manage such 
      patients to avoid adverse effects and complications. Antithrombotic medications, 
      including aspirin, P2Y(12) inhibitors, and rivaroxaban, are currently prescribed 
      or have potential roles in the management of secondary cardiovascular prevention 
      in ischemic heart disease patients. While the majority of studies and findings 
      involve aspirin and clopidogrel, newer oral anticoagulation drugs are arriving, 
      prompting new research to assess their impact on preventing mortality, myocardial 
      infarction, and stroke in such patients. RECENT FINDINGS: Aspirin has a 
      well-established history of safety and efficacy in management of secondary 
      cardiovascular protection in ischemic heart disease patients. A dual-antiplatelet 
      regimen, most commonly including aspirin plus clopidogrel, has been documented to 
      be effective as well in achieving the same goals. Newer agents, such as 
      rivaroxaban, are being analyzed to see if there is scope to include these agents 
      for secondary prevention. One recent study, the COMPASS trial, revealed the major 
      concern of these newer medications: while better cardiovascular outcomes were 
      achieved in subjects on aspirin plus rivaroxaban, this was accomplished in the 
      setting of a higher rate of major bleeding events. In conclusion, the evidence 
      thus far has not been significant enough for the American College of Cardiology 
      to recommend the incorporation of oral anticoagulants in the management of stable 
      ischemic heart disease patients, in contrast to aspirin and clopidogrel. As the 
      antithrombotic and antiischemic properties of these newer agents seem evident, so 
      does their potential for increase in risk of bleeding events. Doctors have to 
      individually tailor antithrombotic medication decisions based on the patient's 
      risk-benefit profile.
FAU - Shanker, Aaron
AU  - Shanker A
AD  - Paul L. Foster School of Medicine, Department of Internal Medicine, Texas Tech 
      University Health Sciences Center, 4800 Alberta Avenue, El Paso, TX, 79905, USA. 
      Aaron.Shanker@ttuhsc.edu.
FAU - Bhupathi, Vivek
AU  - Bhupathi V
AD  - Paul L. Foster School of Medicine, Department of Internal Medicine, Texas Tech 
      University Health Sciences Center, 4800 Alberta Avenue, El Paso, TX, 79905, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190518
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Clopidogrel/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/*administration & dosage/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Rivaroxaban/*administration & dosage/therapeutic use
MH  - *Secondary Prevention
OTO - NOTNLM
OT  - Acute coronary syndromes
OT  - Aspirin
OT  - Clopidogrel
OT  - Coronary artery disease
OT  - Ischemic heart disease
OT  - Rivaroxaban
OT  - Secondary cardiovascular prevention
EDAT- 2019/05/20 06:00
MHDA- 2020/03/05 06:00
CRDT- 2019/05/20 06:00
PHST- 2019/05/20 06:00 [entrez]
PHST- 2019/05/20 06:00 [pubmed]
PHST- 2020/03/05 06:00 [medline]
AID - 10.1007/s11886-019-1152-6 [pii]
AID - 10.1007/s11886-019-1152-6 [doi]
PST - epublish
SO  - Curr Cardiol Rep. 2019 May 18;21(7):56. doi: 10.1007/s11886-019-1152-6.

PMID- 16673282
OWN - NLM
STAT- MEDLINE
DCOM- 20060725
LR  - 20131121
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 32
IP  - 3
DP  - 2006 Apr
TI  - Risk stratification, staging, and treatment of patients with polycythemia vera: 
      Italian and European collaboration on low-dose aspirin in polycythemia data.
PG  - 276-82
AB  - The clinical course of polycythemia vera (PV) is marked by a high incidence of 
      thrombotic complications, which represent the main cause of morbidity and 
      mortality. Major predictors of vascular events are increasing age and previous 
      thrombosis. Myelosuppressive drugs can reduce the rate of thrombosis, but there 
      is concern that their use increases the risk of transformation into acute 
      leukemia. To tackle this dilemma, a risk-oriented management strategy is 
      recommended. Low-risk patients should be treated with phlebotomy and low-dose 
      aspirin based on the results of the European Collaboration on Low-Dose Aspirin in 
      Polycythemia study. Cytotoxic therapy is indicated in high-risk patients, and the 
      drug of choice is hydroxyurea because its leukemogenicity is low. New therapeutic 
      options, that theoretically are devoid of leukemic risk (such as interferon alpha 
      and imatinib), should be reserved for selected patients and require additional 
      clinical experience.
FAU - Finazzi, Guido
AU  - Finazzi G
AD  - Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy. 
      gfinazzi@ospedaliriuniti.bergamo.it
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cooperative Behavior
MH  - Drug Therapy
MH  - Europe
MH  - Humans
MH  - Italy
MH  - Phlebotomy
MH  - Polycythemia Vera/*diagnosis/*therapy
MH  - Risk Assessment
RF  - 29
EDAT- 2006/05/05 09:00
MHDA- 2006/07/26 09:00
CRDT- 2006/05/05 09:00
PHST- 2006/05/05 09:00 [pubmed]
PHST- 2006/07/26 09:00 [medline]
PHST- 2006/05/05 09:00 [entrez]
AID - 10.1055/s-2006-939439 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2006 Apr;32(3):276-82. doi: 10.1055/s-2006-939439.

PMID- 7099931
OWN - NLM
STAT- MEDLINE
DCOM- 19820910
LR  - 20131121
IS  - 0301-1518 (Print)
IS  - 0301-1518 (Linking)
VI  - 11
IP  - 20
DP  - 1982 May 1
TI  - [Anti-platelet aggregation therapy and ischaemic cerebral accidents due to 
      atheroma (author's transl)].
PG  - 1543-7
AB  - Most controlled studies of the effects of anticoagulants on ischaemic cerebral 
      accidents due to atheroma were carried out in the 60's and failed to show 
      long-term beneficial results. Anti-platelet aggregation agents, such as 
      dipyridamole, clofibrate and sulfinpyrazone, did not prove more effective. A 
      well-conducted co-operative Canadian study has recently shown that aspirin in 
      doses of 1300 mg/day reduced by 19% the risk of ischaemic cerebral accident or 
      death and that this risk is further reduced in the subgroup of non-diabetic male 
      patients without history of infarction. Another American co-operative study 
      suggests that aspirin is more effective in patients who had several transient 
      episodes of cerebral ischaemia and that an atheromatous lesion is present. No 
      combination of anti-platelet aggregation agents is demonstrably superior to 
      aspirin. The present tendency is to administer heparin immediately after 
      ischaemic cerebral accidents.
FAU - Autret, A
AU  - Autret A
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Traitement anti-agrégant plaquettaire de la pathologie ischémique cérébrale liée 
      à l'athérome.
PL  - France
TA  - Nouv Presse Med
JT  - La Nouvelle presse medicale
JID - 0312552
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Arteriosclerosis/*complications
MH  - Aspirin/therapeutic use
MH  - Brain Ischemia/*drug therapy/etiology
MH  - Humans
MH  - Platelet Aggregation/*drug effects
EDAT- 1982/05/01 00:00
MHDA- 1982/05/01 00:01
CRDT- 1982/05/01 00:00
PHST- 1982/05/01 00:00 [pubmed]
PHST- 1982/05/01 00:01 [medline]
PHST- 1982/05/01 00:00 [entrez]
PST - ppublish
SO  - Nouv Presse Med. 1982 May 1;11(20):1543-7.

PMID- 2442566
OWN - NLM
STAT- MEDLINE
DCOM- 19871002
LR  - 20131121
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 94
IP  - 3
DP  - 1987 Sep
TI  - Efficacy of iloprost (ZK36374) versus aspirin in preventing heparin-induced 
      platelet activation during cardiac operations.
PG  - 405-13
AB  - For patients with heparin-induced platelet activation, reexposure to heparin can 
      result in profound thrombocytopenia, intravascular thrombosis, and hemorrhage. We 
      compared the ability of aspirin to that of iloprost (ZK36374), an analogue of 
      prostacyclin, in preventing heparin-induced platelet activation and thus 
      permitting a cardiac operation in a patient with heparin-induced platelet 
      activation. Despite abolishing thromboxane A2 synthesis, aspirin (4 mmol/L) 
      failed to prevent either in vitro heparin-induced platelet aggregation (65.0% 
      without versus 59% with aspirin) or carbon 14-serotonin release (81.8% without 
      versus 59.7% with aspirin). In contrast, iloprost (0.01 mumol/L) prevented both 
      in vitro heparin-induced platelet aggregation (65% without versus 5.0% with 
      iloprost) and release (81.8% without versus 0% with iloprost). Consequently, a 
      continuous infusion of iloprost was begun before administration of heparin, 
      continued throughout cardiopulmonary bypass, and discontinued 15 minutes after 
      administration of protamine. The whole blood platelet count (209,000/microliter) 
      remained stable after intraoperative administration of heparin 
      (238,000/microliter) and was 115,000/microliter after the operation. No 
      spontaneous platelet aggregates were observed in samples of platelet-rich plasma 
      after heparin administration, and no platelet transfusions were required. Plasma 
      levels of platelet factor 4 rose from 27 to 725 ng/ml after heparin 
      administration but then declined during bypass to 50 ng/ml. Beta thromboglobulin 
      levels only rose from 92 to 496 ng/ml with administration of heparin. 
      Fibrinopeptide A levels fell from 72 to 22 ng/ml after heparin and remained 
      stable throughout bypass. The template bleeding time was 7.5 minutes 
      preoperatively and 8.0 minutes postoperatively. The postoperative chest tube 
      drainage (12 hours) was 475 ml, and platelets responded normally to adenosine 
      diphosphate. In conclusion, iloprost but not aspirin completely prevented 
      heparin-induced platelet activation in vitro. Furthermore, iloprost effectively 
      prevented this syndrome clinically, which permitted a safe cardiac operation in 
      this patient with heparin-induced platelet activation.
FAU - Kappa, J R
AU  - Kappa JR
FAU - Horn, M K 3rd
AU  - Horn MK 3rd
FAU - Fisher, C A
AU  - Fisher CA
FAU - Cottrell, E D
AU  - Cottrell ED
FAU - Ellison, N
AU  - Ellison N
FAU - Addonizio, V P Jr
AU  - Addonizio VP Jr
LA  - eng
GR  - HL07048/HL/NHLBI NIH HHS/United States
GR  - HL22346/HL/NHLBI NIH HHS/United States
PT  - Case Reports
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Heparin Antagonists)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - JED5K35YGL (Iloprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Cardiac Surgical Procedures/*methods
MH  - Epoprostenol/*therapeutic use
MH  - Female
MH  - Heparin Antagonists/*therapeutic use
MH  - Humans
MH  - Iloprost
EDAT- 1987/09/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1987/09/01 00:00
PHST- 1987/09/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1987/09/01 00:00 [entrez]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1987 Sep;94(3):405-13.

PMID- 30199814
OWN - NLM
STAT- MEDLINE
DCOM- 20190129
LR  - 20190129
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 229
DP  - 2018 Oct
TI  - Assessment of NICE and USPSTF guidelines for identifying women at high risk of 
      pre-eclampsia for tailoring aspirin prophylaxis in pregnancy: An individual 
      participant data meta-analysis.
PG  - 159-166
LID - S0301-2115(18)30958-8 [pii]
LID - 10.1016/j.ejogrb.2018.08.587 [doi]
AB  - OBJECTIVE: To assess the accuracy of the National Institute of Health and Care 
      Excellence (NICE) and United States Preventive Services Task Force (USPSTF) 
      guidelines for predicting pre-eclampsia in pregnancy to guide aspirin 
      prophylaxis. STUDY DESIGN: We conducted an individual participant data 
      meta-analysis using the Perinatal Antiplatelet Review of International Studies 
      (PARIS) dataset. This dataset includes randomised controlled trials (RCTs) of 
      antiplatelet therapy for primary prevention of pre-eclampsia conducted in 
      international antenatal care settings. RCTs were eligible if they enrolled 
      pregnant women up to 28 weeks'gestation, reported risk factors, and assessed 
      pre-eclampsia. Women assigned to the control arm (no antiplatelet agent) were 
      included. Both guidelines recommend aspirin if ≥1 high-risk factors or ≥2 
      moderate-risk factors. Two moderate-risk factors (body mass index and pregnancy 
      interval) were unavailable. Pre-eclampsia was the primary outcome. The secondary 
      outcomes were pre-eclampsia defined by gestational age at delivery (<37 weeks 
      versus ≥37 weeks; <34 weeks versus ≥34 weeks). We assessed the performance of the 
      NICE and USPSTF approaches for parous and nulliparous women by estimating 
      sensitivity, specificity, positive predictive value (PPV) and negative predictive 
      value (NPV) for predicting pre-eclampsia, the number-needed-to-screen (NNS) and 
      the number-needed-to-treat (NNT) to prevent one pre-eclampsia event. RESULTS: 
      Three RCTs were eligible (4524 women, 221 pre-eclampsia cases). Using the NICE 
      guidelines, 9.4% of 1020 parous women were classified as screen-positive with a 
      sensitivity of 26.4% (95% confidence interval 16.4-39.6%), specificity 91.5% 
      (89.6-93.1%), PPV 14.6% (8.9-23.0%) and NPV 95.8% (94.3-96.9%). The NNS was 729 
      and NNT 69. For 3504 nulliparous women, 3% were classified as screen-positive 
      with a sensitivity of 8.9% (5.5-14.4%), specificity 97.2% (96.6-97.8%), PPV 14.2% 
      (8.7-21.9%), NPV 95.5% (94.8-96.1%). The NNS was 2336 and NNT 71. The USPSTF 
      approach demonstrated similar performance. CONCLUSION: The NICE and USPSTF 
      guidelines offer a simple and specific approach for recommending aspirin 
      prophylaxis for women at high-risk of pre-eclampsia where more advanced screening 
      methods are not available. However, the low detection rate limits its value in 
      clinical practice, in particular for nulliparous women, and raises the need for 
      development of an improved simple risk prediction tool.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Al-Rubaie, Ziad T A
AU  - Al-Rubaie ZTA
AD  - School of Medicine, The University of Notre Dame Australia, Sydney, NSW, 
      Australia. Electronic address: ziad.alrubaie1@my.nd.edu.au.
FAU - Askie, Lisa M
AU  - Askie LM
AD  - NHMRC Clinical Trial Centre, University of Sydney, Sydney, NSW, Australia. 
      Electronic address: lisa.askie@ctc.usyd.edu.au.
FAU - Hudson, H Malcolm
AU  - Hudson HM
AD  - NHMRC Clinical Trial Centre, University of Sydney, Sydney, NSW, Australia; 
      Department of Statistics, Macquarie University, Sydney, NSW, Australia. 
      Electronic address: malcolm.hudson@ctc.usyd.edu.au.
FAU - Ray, Joel G
AU  - Ray JG
AD  - Departments of Medicine, Health Policy Management and Evaluation, and Obstetrics 
      and Gynecology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, 
      Canada. Electronic address: rayj@smh.ca.
FAU - Jenkins, Gregory
AU  - Jenkins G
AD  - Department of Obstetrics, Westmead Hospital, Sydney, NSW, Australia. Electronic 
      address: drgj@norwestog.com.
FAU - Lord, Sarah J
AU  - Lord SJ
AD  - School of Medicine, The University of Notre Dame Australia, Sydney, NSW, 
      Australia; NHMRC Clinical Trial Centre, University of Sydney, Sydney, NSW, 
      Australia. Electronic address: sally.lord@nd.edu.au.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20180902
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Parity
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Practice Guidelines as Topic
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Risk Assessment
OTO - NOTNLM
OT  - Aspirin
OT  - NICE guidelines
OT  - Pre-eclampsia
OT  - Prediction
OT  - USPSTF guidelines
OT  - Validation
EDAT- 2018/09/11 06:00
MHDA- 2019/01/30 06:00
CRDT- 2018/09/11 06:00
PHST- 2018/06/10 00:00 [received]
PHST- 2018/08/29 00:00 [revised]
PHST- 2018/08/31 00:00 [accepted]
PHST- 2018/09/11 06:00 [pubmed]
PHST- 2019/01/30 06:00 [medline]
PHST- 2018/09/11 06:00 [entrez]
AID - S0301-2115(18)30958-8 [pii]
AID - 10.1016/j.ejogrb.2018.08.587 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2018 Oct;229:159-166. doi: 
      10.1016/j.ejogrb.2018.08.587. Epub 2018 Sep 2.

PMID- 28902079
OWN - NLM
STAT- MEDLINE
DCOM- 20190318
LR  - 20190318
IS  - 1536-3678 (Electronic)
IS  - 1077-4114 (Linking)
VI  - 40
IP  - 6
DP  - 2018 Aug
TI  - Concomitant Administration of High-dose Methotrexate and Low-dose Aspirin Without 
      Any Delay in Methotrexate Clearance in a Patient With Osteosarcoma: A Case Report 
      and Review of the Literature.
PG  - e392-e393
LID - 10.1097/MPH.0000000000000939 [doi]
AB  - BACKGROUND: Methotrexate (MTX) is a commonly used agent in the treatment of 
      oncology patients whose clearance depends on renal health maintaining glomerular 
      filtration and tubular secretion. Thus concomitant use of other drugs that 
      utilize the same mechanism of clearance are generally avoided as this may 
      contribute to increased MTX-associated toxicity. OBSERVATION: Herein, we describe 
      the use of low-dose aspirin with high-dose MTX in a patient with osteosarcoma. 
      CONCLUSION: Concomitant aspirin use did not affect the clearance of high-dose MTX 
      and the patient did not experience any MTX-related toxicity including mucositis 
      or renal impairment.
FAU - Renzi, Samuele
AU  - Renzi S
AD  - Divisions of Haematology/Oncology, The Hospital for Sick Children, Toronto, 
      Canada.
FAU - Tsimerman, Ekaterina
AU  - Tsimerman E
FAU - Taylor, Tracey
AU  - Taylor T
FAU - Hopyan, Sevan
AU  - Hopyan S
FAU - Koo, Alicia
AU  - Koo A
FAU - Gupta, Abha
AU  - Gupta A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
RN  - R16CO5Y76E (Aspirin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - *Aspirin/administration & dosage/pharmacokinetics
MH  - *Bone Neoplasms/drug therapy/metabolism
MH  - Child
MH  - Glomerular Filtration Rate/drug effects
MH  - Humans
MH  - Male
MH  - *Methotrexate/administration & dosage/pharmacokinetics
MH  - *Osteosarcoma/drug therapy/metabolism
EDAT- 2017/09/14 06:00
MHDA- 2019/03/19 06:00
CRDT- 2017/09/14 06:00
PHST- 2017/09/14 06:00 [pubmed]
PHST- 2019/03/19 06:00 [medline]
PHST- 2017/09/14 06:00 [entrez]
AID - 10.1097/MPH.0000000000000939 [doi]
PST - ppublish
SO  - J Pediatr Hematol Oncol. 2018 Aug;40(6):e392-e393. doi: 
      10.1097/MPH.0000000000000939.

PMID- 2359889
OWN - NLM
STAT- MEDLINE
DCOM- 19900802
LR  - 20161123
IS  - 0034-5288 (Print)
IS  - 0034-5288 (Linking)
VI  - 48
IP  - 3
DP  - 1990 May
TI  - Effects of aspirin on xylazine-induced hypoxaemia in sheep.
PG  - 386-8
AB  - Aspirin (10 mg kg-1) administered intravenously to conscious sheep four hours 
      before intravenous xylazine injection (50 micrograms kg-1), failed to abolish or 
      attenuate the hypoxaemic effect of xylazine in this species. Serum thromboxane 
      levels measured in one animal revealed that aspirin administered in this way 
      reduced serum thromboxane levels by 95 per cent. Xylazine (3 x 10(-5) M--4 x 
      10(-3) M) failed to induce platelet aggregation in vitro. It appears that the 
      mechanism whereby xylazine causes arterial hypoxaemia in sheep does not involve a 
      cyclo-oxygenase-dependent aggregation of platelets.
FAU - Nolan, A M
AU  - Nolan AM
AD  - Department of Pharmacology, Cambridge.
FAU - Callingham, B A
AU  - Callingham BA
FAU - Evans, R J
AU  - Evans RJ
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Res Vet Sci
JT  - Research in veterinary science
JID - 0401300
RN  - 0 (Thiazines)
RN  - 0 (Thromboxanes)
RN  - 2KFG9TP5V8 (Xylazine)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Hypoxia/chemically induced/prevention & control/*veterinary
MH  - Injections, Intravenous/veterinary
MH  - Male
MH  - Oxygen/blood
MH  - Platelet Aggregation
MH  - Platelet Count/veterinary
MH  - Sheep
MH  - Sheep Diseases/*chemically induced
MH  - Thiazines/*adverse effects
MH  - Thromboxanes/blood
MH  - Xylazine/*adverse effects
EDAT- 1990/05/01 00:00
MHDA- 1990/05/01 00:01
CRDT- 1990/05/01 00:00
PHST- 1990/05/01 00:00 [pubmed]
PHST- 1990/05/01 00:01 [medline]
PHST- 1990/05/01 00:00 [entrez]
PST - ppublish
SO  - Res Vet Sci. 1990 May;48(3):386-8.

PMID- 971774
OWN - NLM
STAT- MEDLINE
DCOM- 19761203
LR  - 20170920
IS  - 0015-0282 (Print)
IS  - 0015-0282 (Linking)
VI  - 27
IP  - 10
DP  - 1976 Oct
TI  - Plasma prostaglandin F 2-alpha levels in dysmenorrehic women.
PG  - 1171-5
AB  - Plasma prostaglandin F 2-alpha (PGF 2-alpha) concentrations were compared in nine 
      ovulatory dysmenorrheic women, one dysmenorrheic oral contraceptive user, and two 
      nondysmenorrheic control subjects, in an effort to demonstrate a relationship 
      between plasma PGF 2-alpha levels and dysmenorrhea. In addition, the effects of 
      aspirin, a known inhibitorof prostaglandins synthesis, on dysmenorrhea and on PGF 
      2-alpha levels were investigated. No statistical difference was demonstrated 
      between the plasma PGF 2-alpha levels of dysmenorrheic and nondysmenorrheic 
      subjects throughout the menstrual cycle. Attainment of an adequate salicylate 
      level was accompanied by a significant decrease in PGF 2-alpha levels. All 
      dysmenorrheic subjects reported improvement in symptoms while taking aspirin. The 
      greatest subjective relief was reported by women who began taking aspirin (10 
      grains every 4 hours) 3 or more days prior to the onset of bleeding.
FAU - Shangold, M M
AU  - Shangold MM
FAU - Aksel, S
AU  - Aksel S
FAU - Schomberg, D W
AU  - Schomberg DW
FAU - Hammond, C B
AU  - Hammond CB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - 0 (Progestins)
RN  - 0 (Prostaglandins F)
RN  - 9002-67-9 (Luteinizing Hormone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Dysmenorrhea/*blood/drug therapy
MH  - Female
MH  - Humans
MH  - Luteinizing Hormone/blood
MH  - Menstruation
MH  - Progestins/blood
MH  - Prostaglandins F/*blood
EDAT- 1976/10/01 00:00
MHDA- 1976/10/01 00:01
CRDT- 1976/10/01 00:00
PHST- 1976/10/01 00:00 [pubmed]
PHST- 1976/10/01 00:01 [medline]
PHST- 1976/10/01 00:00 [entrez]
AID - S0015-0282(16)42135-7 [pii]
PST - ppublish
SO  - Fertil Steril. 1976 Oct;27(10):1171-5.

PMID- 1065285
OWN - NLM
STAT- MEDLINE
DCOM- 19760901
LR  - 20190823
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 5
IP  - 6
DP  - 1975 Dec
TI  - Salicylate therapy and drug interaction in rheumatoid arthritis.
PG  - 518-23
AB  - Salicylates form the basis of drug treatment in rheumatoid arthritis. Despite 
      their use for many decades, there is considerable confusion about what 
      constitutes a regime which will ensure anti-inflammatory properties. We have 
      found that blood vessels in the proposed therapeutic range can be maintained 
      overnight on a four times daily dose regime, using either soluble aspirin (in the 
      form of "Disprin") or aloxiprin ("Palaprin Forte"), and on a 12 hourly regine 
      using an aspirin-sustained release aspirin combination ("BiPrin"). Because of 
      variation in the levels reached using a fixed dosage schedule, treatment should 
      be individualised. No correlation was found between dosage levels and either 
      disease activity or serum albumin levels. No significant alteration in free or 
      total salicylate levels was found following the addition of indomethacin to 
      therapy.
FAU - Barraclough, D R
AU  - Barraclough DR
FAU - Muirden, K D
AU  - Muirden KD
FAU - Laby, B
AU  - Laby B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Indomethacin/blood/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Salicylates/blood
EDAT- 1975/12/01 00:00
MHDA- 1975/12/01 00:01
CRDT- 1975/12/01 00:00
PHST- 1975/12/01 00:00 [pubmed]
PHST- 1975/12/01 00:01 [medline]
PHST- 1975/12/01 00:00 [entrez]
AID - 10.1111/j.1445-5994.1975.tb03855.x [doi]
PST - ppublish
SO  - Aust N Z J Med. 1975 Dec;5(6):518-23. doi: 10.1111/j.1445-5994.1975.tb03855.x.

PMID- 15840736
OWN - NLM
STAT- MEDLINE
DCOM- 20060302
LR  - 20220408
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 39
IP  - 6
DP  - 2005 Jun
TI  - Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any 
      correlation?
PG  - 1013-8
AB  - BACKGROUND: Platelet glycoprotein (GP) IIb/IIIa receptors play an inevitable role 
      in platelet aggregation. The GP IIIa gene is polymorphic (PlA1/PlA2) and the 
      presence of a PlA2 allele might be associated with an increased risk for acute 
      coronary syndrome (ACS). OBJECTIVE: To examine the prevalence of the PlA2 allele 
      in patients with ACS and in subjects with or without aspirin resistance. METHODS: 
      The prevalence of the PlA2 allele was assessed in 158 patients with ACS and PlA2 
      compared with its prevalence in 199 healthy volunteers. The antiplatelet efficacy 
      of aspirin was examined in all patients with ACS, as well as in 69 individuals 
      who had suffered ischemic stroke and in 58 high-risk subjects without any known 
      ischemic vascular events. RESULTS: PlA2 prevalence was significantly higher in 
      patients with ACS (59/158) than in the control group (51/199; p < 0.05). Carriers 
      of the PlA2 allele had a significantly higher risk of developing ACS, even after 
      an adjustment to the risk factors (OR 5.74; 95% CI 1.75 to 18.8; p = 0.004). The 
      occurrence of the PlA2 allele was significantly higher among patients with 
      aspirin resistance than in subjects who demonstrated an appropriate response to 
      the drug (allele frequencies, 0.21 vs 0.14; p < 0.05). All patients homozygous 
      for the PlA2 allele had an inadequate platelet response to aspirin. CONCLUSIONS: 
      Our results support the hypothesis that carriers of the PlA2 allele might have an 
      increased risk for ACS. PlA2 homozygosity was associated with an inadequate 
      response to aspirin therapy. Our data further suggest that patients with PlA2 
      allele homozygosity might benefit from antiplatelet therapy based on adenosine 
      diphosphate antagonists throughout secondary treatment for prevention of ACS.
FAU - Papp, Elod
AU  - Papp E
AD  - First Department of Medicine, School of Medicine, University of Pecs, Pecs, 
      Hungary. elod.papp@aok.pte.hu
FAU - Havasi, Viktoria
AU  - Havasi V
FAU - Bene, Judit
AU  - Bene J
FAU - Komlosi, Katalin
AU  - Komlosi K
FAU - Czopf, Laszlo
AU  - Czopf L
FAU - Magyar, Eva
AU  - Magyar E
FAU - Feher, Csaba
AU  - Feher C
FAU - Feher, Gergely
AU  - Feher G
FAU - Horvath, Beata
AU  - Horvath B
FAU - Marton, Zsolt
AU  - Marton Z
FAU - Alexy, Tamas
AU  - Alexy T
FAU - Habon, Tamas
AU  - Habon T
FAU - Szabo, Levente
AU  - Szabo L
FAU - Toth, Kalman
AU  - Toth K
FAU - Melegh, Bela
AU  - Melegh B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20050419
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Integrin beta3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alleles
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Drug Resistance
MH  - Dyslipidemias/complications
MH  - Female
MH  - Gene Frequency
MH  - Genotype
MH  - Humans
MH  - Hungary
MH  - Hypertension/complications
MH  - Integrin beta3/*genetics
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/complications/*drug therapy/genetics
MH  - Obesity/complications
MH  - Platelet Function Tests
MH  - *Polymorphism, Genetic
MH  - Risk Factors
MH  - Smoking
MH  - Syndrome
EDAT- 2005/04/21 09:00
MHDA- 2006/03/03 09:00
CRDT- 2005/04/21 09:00
PHST- 2005/04/21 09:00 [pubmed]
PHST- 2006/03/03 09:00 [medline]
PHST- 2005/04/21 09:00 [entrez]
AID - aph.1E227 [pii]
AID - 10.1345/aph.1E227 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2005 Jun;39(6):1013-8. doi: 10.1345/aph.1E227. Epub 2005 Apr 
      19.

PMID- 21219589
OWN - NLM
STAT- MEDLINE
DCOM- 20110729
LR  - 20131121
IS  - 1751-553X (Electronic)
IS  - 1751-5521 (Linking)
VI  - 33
IP  - 3
DP  - 2011 Jun
TI  - The assessment of aspirin resistance by using light transmission and multiple 
      electrode aggregometry.
PG  - 305-9
LID - 10.1111/j.1751-553X.2010.01286.x [doi]
AB  - INTRODUCTION: The issues related to aspirin [acetylsalicylic acid (ASA)] 
      resistance are still under debate. Depending on the method of assessment and 
      studied patients, the prevalence of ASA resistance is rather heterogeneous, 
      ranging from 5% to 45%. The method most commonly used for assessing platelet 
      function is their aggregation. ASA irreversibly inhibits cyclooxygenase-1 (COX-1) 
      by acetylation. METHODS: This study aimed to compare light transmission 
      aggregometry (LTA) and multiple electrode aggregometry (MEA) for the measurement 
      of ASA resistance, using arachidonic acid as an inducer of the reaction. RESULTS: 
      The study comprised 101 patients with stable ischemic heart disease taking a 
      daily dose of 100 mg of ASA. The rates of ASA resistance were 22.22% and 21.21% 
      as detected by LTA and MEA, respectively. The two methods were statistically 
      compared using Spearman's nonparametric correlation analysis, with a positive 
      significant correlation (P=0.01) and medium positive dependence between the 
      methods (r=0.0539). CONCLUSION: If ASA resistance is detected by laboratory 
      tests, replacement of ASA or its combination with other antiplatelet drugs as 
      well as increased dosage may be considered.
CI  - © 2011 Blackwell Publishing Ltd.
FAU - Ulehlova, J
AU  - Ulehlova J
AD  - Department of Hemato-Oncology, University Hospital, Olomouc, Czech Republic. 
      jana.maliskova@email.cz
FAU - Slavik, L
AU  - Slavik L
FAU - Krcova, V
AU  - Krcova V
FAU - Hutyra, M
AU  - Hutyra M
FAU - Galuszka, J
AU  - Galuszka J
FAU - Indrak, K
AU  - Indrak K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110111
PL  - England
TA  - Int J Lab Hematol
JT  - International journal of laboratory hematology
JID - 101300213
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - *Platelet Function Tests
MH  - Sensitivity and Specificity
EDAT- 2011/01/12 06:00
MHDA- 2011/07/30 06:00
CRDT- 2011/01/12 06:00
PHST- 2011/01/12 06:00 [entrez]
PHST- 2011/01/12 06:00 [pubmed]
PHST- 2011/07/30 06:00 [medline]
AID - 10.1111/j.1751-553X.2010.01286.x [doi]
PST - ppublish
SO  - Int J Lab Hematol. 2011 Jun;33(3):305-9. doi: 10.1111/j.1751-553X.2010.01286.x. 
      Epub 2011 Jan 11.

PMID- 11503839
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20131121
IS  - 1167-7422 (Print)
IS  - 1167-7422 (Linking)
VI  - 8
IP  - 43
DP  - 1999 Oct
TI  - Ticlopidine: a second look. No further use in routine practice.
PG  - 142-4
AB  - (1) The clinical file on ticlopidine is based mainly on a placebo-controlled 
      trial involving patients with lower-limb arterial disease, and two large 
      double-blind trials in the post-stroke period, in which the comparator was a 
      placebo in one and aspirin in the other. (2) Ticlopidine proved more effective 
      than the placebo in both indications. In secondary prevention of ischaemic 
      stroke, ticlopidine has a moderate advantage over aspirin in terms of efficacy 
      but carries a risk of serious adverse effects, especially haematological. (3) An 
      indirect comparison suggests that clopidogrel, another antiplatelet drug 
      chemically close to ticlopidine, has comparable efficacy in cardiovascular 
      prevention and no severe adverse effects to date.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - France
TA  - Prescrire Int
JT  - Prescrire international
JID - 9439295
RN  - 0 (Fibrinolytic Agents)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - *Fibrinolytic Agents/adverse effects/therapeutic use
MH  - Humans
MH  - Stroke/*drug therapy
MH  - *Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2001/08/16 10:00
MHDA- 2001/08/17 10:01
CRDT- 2001/08/16 10:00
PHST- 2001/08/16 10:00 [pubmed]
PHST- 2001/08/17 10:01 [medline]
PHST- 2001/08/16 10:00 [entrez]
PST - ppublish
SO  - Prescrire Int. 1999 Oct;8(43):142-4.

PMID- 2082487
OWN - NLM
STAT- MEDLINE
DCOM- 19910509
LR  - 20191029
IS  - 0896-0569 (Print)
IS  - 0896-0569 (Linking)
VI  - 12
DP  - 1990
TI  - Effect of dipyridamole and aspirin on vein graft patency after coronary bypass 
      operations.
PG  - 5-10
AB  - Antiplatelet therapy with dipyridamole, 100 mg q.i.d., starting 2 days before 
      surgery, followed by aspirin, 325 mg t.i.d. plus dipyridamole, 75 mg t.i.d., 7 
      hours after surgery was assessed in the prevention of saphenous vein bypass graft 
      occlusion. Early (less than or equal to 1 month) and late (1 year) occlusions 
      were reduced both on a per patient and a per distal anastomosis basis. Bleeding 
      complications were not increased. Graft occlusion in high-risk situations 
      (low-flow grafts and endarterectomy) was reduced, but not eliminated, by this 
      antiplatelet regimen. The authors recommend this combination of dipyridamole 
      before surgery, adding aspirin after surgery, to prevent coronary artery bypass 
      graft occlusion.
FAU - Chesebro, J H
AU  - Chesebro JH
AD  - Department of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 
      Rochester, MN 55905.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Thromb Res Suppl
JT  - Thrombosis research. Supplement
JID - 8309239
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Risk Factors
MH  - Saphenous Vein/transplantation
MH  - Vascular Patency/drug effects
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1016/0049-3848(90)90433-d [doi]
PST - ppublish
SO  - Thromb Res Suppl. 1990;12:5-10. doi: 10.1016/0049-3848(90)90433-d.

PMID- 37352067
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20230701
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 102
IP  - 25
DP  - 2023 Jun 23
TI  - Pre-aspirin use has no benefit on the neurological disability and mortality after 
      cardiovascular events: A nation-wide population-based cohort study.
PG  - e34109
LID - 10.1097/MD.0000000000034109 [doi]
LID - e34109
AB  - To evaluate the effects of aspirin in the primary prevention, we evaluated 
      disability grades and mortality after ischemic/hemorrhagic stroke and myocardial 
      infarction (MI). A retrospective nation-wide propensity score-matched cohort 
      study was performed using the Korean National Health Information Database. From 
      3,060,639 subjects who were older than 55 and performed national health 
      examinations in 2004 and 2005, we selected the aspirin group (N = 8770) was 
      composed of patients who had received aspirin prior to cardiovascular events. Cox 
      proportional hazards model was used to compare the acquisition times for 
      neurologic disability grades and survival times between the aspirin and control 
      groups. Only in hemorrhagic stroke, the severe neurologic disability risk was 
      higher in the aspirin group (hazard ratio [HR], 1.21; 95% confidence interval 
      [CI], 1.02-1.42). The aspirin group was associated with higher 90-day (HR, 1.33; 
      95% CI, 1.23-1.44) and long-term mortality risk (HR, 1.06; 95% CI, 1.03-1.10) 
      after pooling 3 events. The old age was a strong risk factor for 90-day mortality 
      in hemorrhagic stroke (50s: reference; 60s: HR 2.21, 95% CI 1.50-3.25; 70s: HR 
      3.63, 95% CI 2.48-5.30; 80s: HR 6.69, 95% CI 4.54-9.65; >90s: HR 11.28, 95% CI 
      6.46-19.70). Pre-aspirin use in cardiovascular events has detrimental effects on 
      severe neurological disability in hemorrhagic stroke and short-/long-term 
      mortality in 3 cardiovascular events. The use of aspirin for the primary 
      prevention especially in the elderly should be very cautious because the old age 
      is a strong risk factor for 90-day mortality after hemorrhagic stroke.
CI  - Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Kim, Jong Hun
AU  - Kim JH
AUID- ORCID: 0000-0002-2594-1048
AD  - Department of Neurology, National Health Insurance Service Ilsan Hospital, 
      Goyang, South Korea.
FAU - Park, Dougho
AU  - Park D
AD  - Department of Rehabilitation Medicine, Pohang Stroke and Spine Hospital, Pohang, 
      South Korea.
FAU - Lim, Hyun Sun
AU  - Lim HS
AD  - Research and Analysis Team, National Health Insurance Service Ilsan Hospital, 
      Goyang, South Korea.
FAU - Kang, Min Jin
AU  - Kang MJ
AD  - Research and Analysis Team, National Health Insurance Service Ilsan Hospital, 
      Goyang, South Korea.
FAU - Lee, Jun Hong
AU  - Lee JH
AD  - Department of Neurology, National Health Insurance Service Ilsan Hospital, 
      Goyang, South Korea.
FAU - Yoon, Seo Yeon
AU  - Yoon SY
AD  - Department of Physical Medicine & Rehabilitation, Korea University Guro Hospital, 
      Seoul, Republic of Korea.
FAU - Kim, Hyoung Seop
AU  - Kim HS
AUID- ORCID: 0000-0002-5310-4802
AD  - Department of Physical Medicine and Rehabilitation, National Health Insurance 
      Service Ilsan Hospital, Goyang, South Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Cohort Studies
MH  - Retrospective Studies
MH  - *Hemorrhagic Stroke
MH  - *Stroke/prevention & control
MH  - *Cardiovascular Diseases/drug therapy/prevention & control
MH  - Platelet Aggregation Inhibitors
PMC - PMC10289750
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2023/06/23 19:11
MHDA- 2023/06/26 06:42
CRDT- 2023/06/23 12:33
PHST- 2023/06/26 06:42 [medline]
PHST- 2023/06/23 19:11 [pubmed]
PHST- 2023/06/23 12:33 [entrez]
AID - 00005792-202306230-00048 [pii]
AID - 10.1097/MD.0000000000034109 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2023 Jun 23;102(25):e34109. doi: 
      10.1097/MD.0000000000034109.

PMID- 20826133
OWN - NLM
STAT- MEDLINE
DCOM- 20110121
LR  - 20171116
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 648
IP  - 1-3
DP  - 2010 Dec 1
TI  - Activity of a new hydrogen sulfide-releasing aspirin (ACS14) on pathological 
      cardiovascular alterations induced by glutathione depletion in rats.
PG  - 139-45
LID - 10.1016/j.ejphar.2010.08.039 [doi]
AB  - We investigated the effects of the hydrogen sulfide (H₂S)-releasing derivatives 
      of aspirin (ACS14) and salicylic acid (ACS21) in a rat model of metabolic 
      syndrome induced by glutathione (GSH) depletion, causing hypertension and other 
      pathological cardiovascular alterations. GSH depletion was induced in normal rats 
      by the GSH-synthase inhibitor buthionine sulfoximine (BSO, 30 mmol/L day for 
      seven days in the drinking water). Systolic blood pressure and heart rate were 
      measured daily by the tail-cuff method, and plasma thromboxane B₂, 
      6-keto-prostaglandin F(2α), 8-isoprostane, GSH, insulin and glucose were 
      determined at the end of the seven-day BSO schedule. In addition, 
      ischemia/reperfusion-induced myocardial dysfunction and endothelial dysfunction 
      were assayed on isolated heart and aortic rings, respectively. Unlike aspirin and 
      salicylic acid, ACS14 and ACS21 reduced BSO-induced hypertension, also lowering 
      plasma levels of thromboxane B₂, 8-isoprostane and insulin, while GSH remained in 
      the control range. Neither ACS14 nor ACS21 caused gastric lesions. Both restored 
      the endothelial dysfunction observed in aortic rings from BSO-treated rats, and 
      in ischemia/reperfusion experiments they lowered left ventricular end-diastolic 
      pressure, consequently improving the developed pressure and the maximum rise and 
      fall of left ventricular pressure. Together with this improvement of heart 
      mechanics there were reductions in the activity of creatine kinase and lactate 
      dehydrogenase in the cardiac perfusate. This implies that H₂S released by both 
      ACS14 and ACS21 was involved in protecting the heart from ischemia/reperfusion, 
      and significantly limited vascular endothelial dysfunction in aortic tissue and 
      the related hypertension.
CI  - Copyright © 2010 Elsevier B.V. All rights reserved.
FAU - Rossoni, Giuseppe
AU  - Rossoni G
AD  - Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, University of 
      Milan, Via Vanvitelli 32, 20129 Milan, Italy. giuseppe.rossoni@unimi.it
FAU - Manfredi, Barbara
AU  - Manfredi B
FAU - Tazzari, Valerio
AU  - Tazzari V
FAU - Sparatore, Anna
AU  - Sparatore A
FAU - Trivulzio, Silvio
AU  - Trivulzio S
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Berti, Ferruccio
AU  - Berti F
LA  - eng
PT  - Journal Article
DEP - 20100915
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EC 2.7.3.2 (Creatine Kinase)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Aorta/drug effects/metabolism/pathology/physiopathology
MH  - Aspirin/analogs & derivatives/*chemistry/*pharmacology/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Consciousness
MH  - Creatine Kinase/metabolism
MH  - Endothelium, Vascular/drug effects/physiopathology
MH  - Gastric Mucosa/drug effects
MH  - Glutathione/*deficiency/metabolism
MH  - Heart/*drug effects/physiopathology
MH  - Heart Rate/drug effects
MH  - Hydrogen Sulfide/*chemistry
MH  - L-Lactate Dehydrogenase/metabolism
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Metabolic Syndrome/chemically induced/drug therapy/metabolism/physiopathology
MH  - Myocardial Reperfusion Injury/metabolism/physiopathology
MH  - Myocardium/*metabolism
MH  - Oxidative Stress/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Vasodilation/drug effects
EDAT- 2010/09/10 06:00
MHDA- 2011/01/22 06:00
CRDT- 2010/09/10 06:00
PHST- 2010/02/24 00:00 [received]
PHST- 2010/07/19 00:00 [revised]
PHST- 2010/08/25 00:00 [accepted]
PHST- 2010/09/10 06:00 [entrez]
PHST- 2010/09/10 06:00 [pubmed]
PHST- 2011/01/22 06:00 [medline]
AID - S0014-2999(10)00843-5 [pii]
AID - 10.1016/j.ejphar.2010.08.039 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2010 Dec 1;648(1-3):139-45. doi: 10.1016/j.ejphar.2010.08.039. 
      Epub 2010 Sep 15.

PMID- 26363848
OWN - NLM
STAT- MEDLINE
DCOM- 20160502
LR  - 20220311
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
VI  - 67
IP  - 1
DP  - 2016 Jan
TI  - Approach to the Patient With a Negative Anion Gap.
PG  - 143-50
LID - S0272-6386(15)01055-0 [pii]
LID - 10.1053/j.ajkd.2015.07.024 [doi]
AB  - When anion gap calculation generates a very small or negative number, an 
      explanation must be sought. Sporadic (nonreproducible) measurement errors and 
      systematic (reproducible) laboratory errors must be considered. If an error is 
      ruled out, 2 general possibilities exist. A true anion gap reduction can be 
      generated by either reduced concentrations of unmeasured anions such as albumin 
      or increased concentrations of unmeasured cations such as magnesium, calcium, or 
      lithium. This teaching case describes a patient with aspirin (salicylate) 
      poisoning whose anion gap was markedly reduced (-47 mEq/L). The discussion 
      systematically reviews the possibilities and provides the explanation for this 
      unusual laboratory result.
CI  - Copyright © 2016 National Kidney Foundation, Inc. Published by Elsevier Inc. All 
      rights reserved.
FAU - Emmett, Michael
AU  - Emmett M
AD  - Nephrology Division, Department of Internal Medicine, Baylor University Medical 
      Center, Dallas, TX. Electronic address: m.emmett@baylorhealth.edu.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20150910
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acid-Base Imbalance/chemically induced/diagnosis/therapy
MH  - Aspirin/poisoning
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Suicide, Attempted
OTO - NOTNLM
OT  - Low anion gap
OT  - aspirin toxicity
OT  - bromism
OT  - negative anion gap
OT  - pseudohyperchloremia
OT  - salicylate poisoning
EDAT- 2015/09/14 06:00
MHDA- 2016/05/03 06:00
CRDT- 2015/09/14 06:00
PHST- 2014/12/29 00:00 [received]
PHST- 2015/07/29 00:00 [accepted]
PHST- 2015/09/14 06:00 [entrez]
PHST- 2015/09/14 06:00 [pubmed]
PHST- 2016/05/03 06:00 [medline]
AID - S0272-6386(15)01055-0 [pii]
AID - 10.1053/j.ajkd.2015.07.024 [doi]
PST - ppublish
SO  - Am J Kidney Dis. 2016 Jan;67(1):143-50. doi: 10.1053/j.ajkd.2015.07.024. Epub 
      2015 Sep 10.

PMID- 23124108
OWN - NLM
STAT- MEDLINE
DCOM- 20130802
LR  - 20131121
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 441
IP  - 1-2
DP  - 2013 Jan 30
TI  - Detoxifying emulsion for overdosed aspirin intoxication.
PG  - 598-602
LID - S0378-5173(12)00978-7 [pii]
LID - 10.1016/j.ijpharm.2012.10.038 [doi]
AB  - Aspirin overdose could lead to intoxication, with the clinical manifestations of 
      vomit, pulmonary edema and severe dyspnea. Stomach washing, emetics and activated 
      charcoal are the common treatments with a limited efficiency for the 
      intoxication. In this study, an active emulsion for aspirin intoxication was 
      prepared with the detoxifying efficiency of 100% in less than 15 min, with the 
      conditions of dodecane used as the oil phase, 8% Abil EM90 as the surfactant and 
      0.1 mol/L sodium hydroxide as the inner aqueous phase in a volume ratio of 2 
      between internal aqueous phase and the oil phase.
CI  - Copyright © 2012. Published by Elsevier B.V.
FAU - Zhang, Wenjun
AU  - Zhang W
AD  - Laboratoire de Génie des Procédés et Matériaux, Ecole Centrale Paris, 92295 
      Châtenay-Malabry, France. belindawj@gmail.com
FAU - Stambouli, Moncef
AU  - Stambouli M
FAU - Pareau, Dominique
AU  - Pareau D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121102
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Abil EM90)
RN  - 0 (Alkanes)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antidotes)
RN  - 0 (Emulsions)
RN  - 0 (Trimethylsilyl Compounds)
RN  - 11A386X1QH (n-dodecane)
RN  - 55X04QC32I (Sodium Hydroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alkanes/chemistry
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*poisoning
MH  - Antidotes/chemistry/*pharmacology
MH  - Aspirin/administration & dosage/*poisoning
MH  - Drug Overdose
MH  - Emulsions
MH  - Sodium Hydroxide/chemistry
MH  - Time Factors
MH  - Trimethylsilyl Compounds/chemistry
EDAT- 2012/11/06 06:00
MHDA- 2013/08/03 06:00
CRDT- 2012/11/06 06:00
PHST- 2012/07/06 00:00 [received]
PHST- 2012/10/10 00:00 [revised]
PHST- 2012/10/24 00:00 [accepted]
PHST- 2012/11/06 06:00 [entrez]
PHST- 2012/11/06 06:00 [pubmed]
PHST- 2013/08/03 06:00 [medline]
AID - S0378-5173(12)00978-7 [pii]
AID - 10.1016/j.ijpharm.2012.10.038 [doi]
PST - ppublish
SO  - Int J Pharm. 2013 Jan 30;441(1-2):598-602. doi: 10.1016/j.ijpharm.2012.10.038. 
      Epub 2012 Nov 2.

PMID- 8200748
OWN - NLM
STAT- MEDLINE
DCOM- 19940706
LR  - 20131121
IS  - 0300-9831 (Print)
IS  - 0300-9831 (Linking)
VI  - 64
IP  - 1
DP  - 1994
TI  - Effects of prolonged aspirin or acetaminophen administration to rats on liver 
      folate content and distribution. Relation to DNA methylation and 
      S-adenosylmethionine.
PG  - 41-6
AB  - The study was aimed at determining the effects of longterm administration to rats 
      of aspirin or acetaminophen (ACAP) on liver folate content and distribution as 
      well as whether or not hepatocyte DNA was methylated at the end of the 
      treatments. In addition, S-adenosylmethionine and S-adenosylhomocysteine hepatic 
      concentrations were determined. In liver, aspirin or ACAP administration were not 
      associated with important changes in total folate content or glutamic acid chain 
      length distribution. DNA methylation assessed by comparing the extent to which 
      DNA from livers of control or treated animals could be methylated in vitro using 
      (3H-methyl)S-Ado Met as methyl donor, resulted in similar [3H] methyl 
      incorporation into DNA regardless of the drug. The long-term administration of 
      the analgesics did not result in significant changes in S-AdoMet/S-AdoHcy ratios.
FAU - Varela-Moreiras, G
AU  - Varela-Moreiras G
AD  - Departamento de Nutrición I, Facultad de Farmacia, Universidad Complutense, 
      Ciudad Universitaria, Madrid, Spain.
FAU - Ragel, C
AU  - Ragel C
FAU - Ruiz-Roso, B
AU  - Ruiz-Roso B
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int J Vitam Nutr Res
JT  - International journal for vitamin and nutrition research. Internationale 
      Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de 
      vitaminologie et de nutrition
JID - 1273304
RN  - 362O9ITL9D (Acetaminophen)
RN  - 7LP2MPO46S (S-Adenosylmethionine)
RN  - 9007-49-2 (DNA)
RN  - 935E97BOY8 (Folic Acid)
RN  - 979-92-0 (S-Adenosylhomocysteine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*administration & dosage/pharmacology
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology
MH  - DNA/*drug effects/metabolism
MH  - Drug Administration Schedule
MH  - Folic Acid/*metabolism
MH  - Liver/*drug effects/metabolism
MH  - Male
MH  - Methylation
MH  - Rats
MH  - Rats, Wistar
MH  - S-Adenosylhomocysteine/analysis
MH  - S-Adenosylmethionine/analysis
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Vitam Nutr Res. 1994;64(1):41-6.

PMID- 2813856
OWN - NLM
STAT- MEDLINE
DCOM- 19891212
LR  - 20190828
IS  - 0167-0115 (Print)
IS  - 0167-0115 (Linking)
VI  - 26
IP  - 1
DP  - 1989 Aug
TI  - Close arterial infusion of calcitonin gene-related peptide into the rat stomach 
      inhibits aspirin- and ethanol-induced hemorrhagic damage.
PG  - 35-46
AB  - Afferent neuron-mediated gastric mucosal protection has been suggested to result 
      from the local release of vasodilator peptides such as calcitonin gene-related 
      peptide (CGRP) from afferent nerve endings within the stomach. The present study, 
      therefore, examined whether rat alpha-CGRP, administered via different routes, is 
      able to protect against mucosal injury induced by gastric perfusion with 25% 
      ethanol or acidified aspirin (25 mM, pH 1.5) in urethane-anesthetized rats. Close 
      arterial infusion of CGRP (15 pmol/min) to the stomach, via a catheter placed in 
      the abdominal aorta proximal to the celiac artery, significantly reduced gross 
      mucosal damage caused by ethanol and aspirin whereas mean arterial blood pressure 
      (BP) was not altered. Intravenous infusion of CGRP (50 pmol/min) did not affect 
      aspirin-induced mucosal injury but significantly enhanced ethanol-induced lesion 
      formation. Intravenous CGRP (50 pmol/min) also lowered BP and increased the 
      gastric clearance of [14C]aminopyrine, an indirect measure of gastric mucosal 
      blood flow while basal gastric output of acid and bicarbonate was not altered. 
      Intragastric administration of CGRP (260 nM) significantly inhibited 
      aspirin-induced mucosal damage but did not influence damage in response to 
      ethanol. BP, gastric clearance of [14C]aminopyrine, and gastric output of acid 
      and bicarbonate remained unaltered by intragastric CGRP. These data indicate that 
      only close arterial administration of CGRP to the rat stomach, at doses devoid of 
      a systemic hypotensive effect, is able to protect against both ethanol- and 
      aspirin-induced mucosal damage. As this route of administration closely resembles 
      local release of the peptide in the stomach, CGRP may be considered as a 
      candidate mediator of afferent nerve-induced gastric mucosal protection.
FAU - Lippe, I T
AU  - Lippe IT
AD  - University of Graz, Department of Experimental and Clinical Pharmacology, 
      Austria.
FAU - Lorbach, M
AU  - Lorbach M
FAU - Holzer, P
AU  - Holzer P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Regul Pept
JT  - Regulatory peptides
JID - 8100479
RN  - 0 (Vasodilator Agents)
RN  - 3K9958V90M (Ethanol)
RN  - JHB2QIZ69Z (Calcitonin Gene-Related Peptide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/antagonists & inhibitors/*toxicity
MH  - Calcitonin Gene-Related Peptide/administration & dosage/*pharmacology
MH  - Ethanol/antagonists & inhibitors/*toxicity
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Gastrointestinal Hemorrhage/*chemically induced/prevention & control
MH  - Infusions, Intra-Arterial
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Vasodilator Agents/administration & dosage/*pharmacology
EDAT- 1989/08/01 00:00
MHDA- 1989/08/01 00:01
CRDT- 1989/08/01 00:00
PHST- 1989/08/01 00:00 [pubmed]
PHST- 1989/08/01 00:01 [medline]
PHST- 1989/08/01 00:00 [entrez]
AID - 0167-0115(89)90102-X [pii]
AID - 10.1016/0167-0115(89)90102-x [doi]
PST - ppublish
SO  - Regul Pept. 1989 Aug;26(1):35-46. doi: 10.1016/0167-0115(89)90102-x.

PMID- 19644597
OWN - NLM
STAT- MEDLINE
DCOM- 20100106
LR  - 20181201
IS  - 0720-9355 (Print)
IS  - 0720-9355 (Linking)
VI  - 29
IP  - 3
DP  - 2009 Aug
TI  - The present state of aspirin and clopidogrel resistance.
PG  - 285-90
AB  - Antiplatelet therapy has demonstrated significant clinical benefit in the 
      treatment of acute coronary syndrome. However, as with any treatment strategy it 
      has been unable to prevent all cardiovascular events. This is far from surprising 
      when considering the complexity of arterial thrombosis and more specifically 
      platelet physiology. This lack of treatment success has provoked the introduction 
      of various diagnostic tests and testing platforms with the intent of guiding and 
      optimizing clinical treatment. Such tests have resulted in the generation of 
      clinical data that suggest suboptimal response to antiplatelet agents such as 
      aspirin and clopidogrel. In the case of both aspirin and clopidogrel, this 
      suboptimal response has been termed resistance. Drug resistance would imply a 
      lack of pharmacological response that has not been specifically investigated in 
      many of the clinical studies performed to date. Rather, the term resistance has 
      been used to describe various facets of platelet activation and aggregation 
      relative to the testing method. Many of these measured parameters are not 
      addressed in the therapeutic intent of the antiplatelet drug in question.
FAU - Guyer, K E
AU  - Guyer KE
AD  - Department of Chemistry, Indiana University, South Bend, 1700 Mishawaka Avenue, 
      South Bend, IN 46634, USA. kguyer@iusb.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Hamostaseologie
JT  - Hamostaseologie
JID - 8204531
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Coronary Disease/drug therapy
MH  - Drug Monitoring/methods
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
RF  - 53
EDAT- 2009/08/01 09:00
MHDA- 2010/01/07 06:00
CRDT- 2009/08/01 09:00
PHST- 2009/08/01 09:00 [entrez]
PHST- 2009/08/01 09:00 [pubmed]
PHST- 2010/01/07 06:00 [medline]
AID - 09030285 [pii]
PST - ppublish
SO  - Hamostaseologie. 2009 Aug;29(3):285-90.

PMID- 17169626
OWN - NLM
STAT- MEDLINE
DCOM- 20070130
LR  - 20181201
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 98
IP  - 12A
DP  - 2006 Dec 18
TI  - Identification of and management approaches for the high-risk patient.
PG  - 22Q-29Q
AB  - Atherothrombosis is a systemic disease that often involves the coronary, 
      cerebrovascular, and peripheral arterial circulations. The presence of multiple 
      risk factors, even in asymptomatic patients, greatly increases the risk of future 
      cardiovascular disease. Antiplatelet therapy potentially has a valuable role 
      across the full spectrum of atherothrombotic disorders. The role of aspirin is 
      well established, and the benefits of clopidogrel have been demonstrated in 
      clinical trials. The Clopidogrel for High Atherothrombotic Risk and Ischemic 
      Stabilization, Management and Avoidance (CHARISMA) trial is currently under way 
      to determine whether the combination of clopidogrel plus aspirin is superior to 
      aspirin plus placebo in >15,000 patients with stable atherothrombosis. The 
      results of the CHARISMA trial are expected to provide further information on the 
      optimal management of patients with stable atherothrombosis with respect to both 
      antiplatelet therapy and overall management.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, 
      Ohio 44195, USA. bhattd@ccf.org
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20061023
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Coronary Artery Bypass
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Thromboembolism/physiopathology/*prevention & control
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
RF  - 16
EDAT- 2006/12/16 09:00
MHDA- 2007/01/31 09:00
CRDT- 2006/12/16 09:00
PHST- 2006/12/16 09:00 [pubmed]
PHST- 2007/01/31 09:00 [medline]
PHST- 2006/12/16 09:00 [entrez]
AID - S0002-9149(06)01743-7 [pii]
AID - 10.1016/j.amjcard.2006.09.021 [doi]
PST - ppublish
SO  - Am J Cardiol. 2006 Dec 18;98(12A):22Q-29Q. doi: 10.1016/j.amjcard.2006.09.021. 
      Epub 2006 Oct 23.

PMID- 6758745
OWN - NLM
STAT- MEDLINE
DCOM- 19830214
LR  - 20190825
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 12
IP  - 5
DP  - 1982 Oct
TI  - Non-steroidal anti-inflammatory drugs and blood pressure.
PG  - 478-82
AB  - The effects of aspirin (1950 mg/day orally) or indomethacin (75 mg/day orally) on 
      blood pressure were investigated in normotensive volunteers and hypertensive 
      patients receiving antihypertensive medication. Aspirin (1950 mg/day) did not 
      change blood pressure or body weight in normotensive or treated hypertensive 
      subjects. No significant change in plasma renin concentration was seen with 
      aspirin (1950 mg/day) in treated hypertensive subjects. Indomethacin (75 mg/day) 
      significantly increased blood pressure in normotensive subjects and treated 
      hypertensive subjects. Body weight increased significantly in the treated 
      hypertensive subjects but not normotensive subjects. In treated hypertensive 
      subjects indomethacin (75 mg/day) did not change plasma volume, but significantly 
      decreased plasma renin concentration.
FAU - Mills, E H
AU  - Mills EH
FAU - Whitworth, J A
AU  - Whitworth JA
FAU - Andrews, J
AU  - Andrews J
FAU - Kincaid-Smith, P
AU  - Kincaid-Smith P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 0 (Anti-Inflammatory Agents)
RN  - EC 3.4.23.15 (Renin)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Blood Pressure Determination
MH  - Body Weight
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Indomethacin/pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Plasma Volume/drug effects
MH  - Posture
MH  - Random Allocation
MH  - Renin/blood
EDAT- 1982/10/01 00:00
MHDA- 1982/10/01 00:01
CRDT- 1982/10/01 00:00
PHST- 1982/10/01 00:00 [pubmed]
PHST- 1982/10/01 00:01 [medline]
PHST- 1982/10/01 00:00 [entrez]
AID - 10.1111/j.1445-5994.1982.tb03826.x [doi]
PST - ppublish
SO  - Aust N Z J Med. 1982 Oct;12(5):478-82. doi: 10.1111/j.1445-5994.1982.tb03826.x.

PMID- 3111000
OWN - NLM
STAT- MEDLINE
DCOM- 19870807
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 46
IP  - 2
DP  - 1987 Apr 15
TI  - Aspirin decreases fibrinolytic potential during venous occlusion, but not during 
      acute physical activity.
PG  - 205-12
AB  - It has previously been observed that aspirin diminishes the increase in blood 
      fibrinolytic activity during arm venous occlusion. We studied the duration of 
      this inhibitory effect on fibrinolytic response during 20 minutes arm venous 
      occlusion and its effect on fibrinolytic response during acute physical activity 
      (standardized stress testing on treadmill) in 10 healthy male volunteers. 
      Fibrinolytic activity was measured with euglobulin clot lysis time and fibrin 
      plates before and after both stimuli, and t-PA release estimated as the 
      difference between post- and prestimulation values (fibrinolytic potential: FP). 
      Venous occlusions were performed before aspirin ingestion and then on the first, 
      second, third, and fourth to eighth day after aspirin. Stress testing was carried 
      out on two successive days before and after aspirin ingestion. Aspirin did not 
      affect basal fibrinolytic activity, but significantly decreased FP during 
      occlusion. This effect was sustained for the whole period of observation. To the 
      contrary, aspirin did not influence FP during acute physical activity. The 
      different effect of aspirin on fibrinolytic response during venous occlusion and 
      physical activity suggested that different mechanisms were involved in t-PA 
      release during both stimuli.
FAU - Keber, I
AU  - Keber I
FAU - Jereb, M
AU  - Jereb M
FAU - Keber, D
AU  - Keber D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arm/blood supply
MH  - Aspirin/*pharmacology
MH  - Constriction
MH  - Fibrinolysis/*drug effects
MH  - Humans
MH  - Male
MH  - Physical Exertion
MH  - Tissue Plasminogen Activator/metabolism
EDAT- 1987/04/15 00:00
MHDA- 1987/04/15 00:01
CRDT- 1987/04/15 00:00
PHST- 1987/04/15 00:00 [pubmed]
PHST- 1987/04/15 00:01 [medline]
PHST- 1987/04/15 00:00 [entrez]
AID - 10.1016/0049-3848(87)90282-9 [doi]
PST - ppublish
SO  - Thromb Res. 1987 Apr 15;46(2):205-12. doi: 10.1016/0049-3848(87)90282-9.

PMID- 37291924
OWN - NLM
STAT- MEDLINE
DCOM- 20230613
LR  - 20230619
IS  - 1671-167X (Print)
IS  - 1671-167X (Linking)
VI  - 55
IP  - 3
DP  - 2023 Jun 18
TI  - [Comparison of aspirin treatment strategies for primary prevention of 
      cardiovascular diseases: A decision-analytic Markov modelling study].
PG  - 480-487
AB  - OBJECTIVE: To compare the expected population impact of benefit and risk of 
      aspirin treatment strategies for the primary prevention of cardiovascular 
      diseases recommended by different guidelines in the Chinese Electronic Health 
      Records Research in Yinzhou (CHERRY) study. METHODS: A decision-analytic Markov 
      model was used to simulate and compare different strategies of aspirin treatment, 
      including: Strategy ①: Aspirin treatment for Chinese adults aged 40-69 years with 
      a high 10-year cardiovascular risk, recommended by the 2020 Chinese Guideline on 
      the Primary Prevention of Cardiovascular Diseases; Strategy ②: Aspirin treatment 
      for Chinese adults aged 40-59 years with a high 10-year cardiovascular risk, 
      recommended by the 2022 United States Preventive Services Task Force 
      Recommendation Statement on Aspirin Use to Prevent Cardiovascular Disease; 
      Strategy ③: Aspirin treatment for Chinese adults aged 40-69 years with a high 
      10-year cardiovascular risk and blood pressure well-controlled (< 150/90 mmHg), 
      recommended by the 2019 Guideline on the Assessment and Management of 
      Cardio-vascular Risk in China. The high 10-year cardiovascular risk was defined 
      as the 10-year predicted risk over 10% based on the 2019 World Health 
      Organization non-laboratory model. The Markov model simulated different 
      strategies for ten years (cycles) with parameters mainly from the CHERRY study or 
      published literature. Quality-adjusted life year (QALY) and the number needed to 
      treat (NNT) for each ischemic event (including myocardial infarction and ischemic 
      stroke) were calculated to assess the effectiveness of the different strategies. 
      The number needed to harm (NNH) for each bleeding event (including hemorrhagic 
      stroke and gastrointestinal bleeding) was calculated to assess the safety. The 
      NNT for each net benefit (i.e., the difference of the number of ischemic events 
      could be prevented and the number of bleeding events would be added) was also 
      calculated. One-way sensitivity analysis on the uncertainty of the incidence rate 
      of cardiovascular diseases and probabilistic sensitivity analysis on the 
      uncertainty of hazard ratios of interventions were conducted. RESULTS: A total of 
      212 153 Chinese adults, were included in this study. The number of people who 
      were recommended for aspirin treatment Strategies ①-③ was 34 235, 2 813, and 25 
      111, respectively. The Strategy ③ could gain the most QALY of 403 [95% 
      uncertainty interval (UI): 222-511] years. Compared with Strategy ①, Strategy ③ 
      had similar efficiency but better safety, with the extra NNT of 4 (95%UI: 3-4) 
      and NNH of 39 (95%UI: 19-132). The NNT per net benefit was 131 (95%UI: 102-239) 
      for Strategy ①, 256 (95%UI: 181-737) for Strategy ②, and 132 (95%UI: 104-232) for 
      Strategy ③, making Strategy ③ the most favorable option with a better QALY and 
      safety, along with similar efficiency in terms of net benefit. The results were 
      consistent in the sensitivity analyses. CONCLUSION: The aspirin treatment 
      strategies recommended by the updated guidelines on the primary prevention of 
      cardiovascular diseases showed a net benefit for high-risk Chinese adults from 
      developed areas. However, to balance effectiveness and safety, aspirin is 
      suggested to be used for primary prevention of cardiovascular diseases with 
      consideration for blood pressure control, resulting in better intervention 
      efficiency.
FAU - Zhang, M L
AU  - Zhang ML
AD  - Department of Epidemiology and Biostatistics, Peking University School of Public 
      Health, Beijing 100191, China.
FAU - Liu, Q P
AU  - Liu QP
AD  - Department of Epidemiology and Biostatistics, Peking University School of Public 
      Health, Beijing 100191, China.
FAU - Gong, C
AU  - Gong C
AD  - Department of Epidemiology and Biostatistics, Peking University School of Public 
      Health, Beijing 100191, China.
FAU - Wang, J M
AU  - Wang JM
AD  - Department of Epidemiology and Biostatistics, Peking University School of Public 
      Health, Beijing 100191, China.
FAU - Zhou, T J
AU  - Zhou TJ
AD  - Department of Epidemiology and Biostatistics, Peking University School of Public 
      Health, Beijing 100191, China.
FAU - Liu, X F
AU  - Liu XF
AD  - Department of Epidemiology and Biostatistics, Peking University School of Public 
      Health, Beijing 100191, China.
FAU - Shen, P
AU  - Shen P
AD  - Yinzhou District Center for Disease Control and Prevention, Ningbo 315101, 
      Zhejiang, China.
FAU - Lin, H B
AU  - Lin HB
AD  - Yinzhou District Center for Disease Control and Prevention, Ningbo 315101, 
      Zhejiang, China.
FAU - Tang, X
AU  - Tang X
AD  - Department of Epidemiology and Biostatistics, Peking University School of Public 
      Health, Beijing 100191, China.
AD  - Key Laboratory of Epidemiology of Major Diseases(Peking University), Ministry of 
      Education, Beijing 100191, China.
FAU - Gao, P
AU  - Gao P
AD  - Department of Epidemiology and Biostatistics, Peking University School of Public 
      Health, Beijing 100191, China.
AD  - Center of Real-world Evidence Evaluation, Peking University Clinical Research 
      Institute, Beijing 100191, China.
AD  - Key Laboratory of Epidemiology of Major Diseases(Peking University), Ministry of 
      Education, Beijing 100191, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Beijing Da Xue Xue Bao Yi Xue Ban
JT  - Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health 
      sciences
JID - 101125284
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control/epidemiology
MH  - Gastrointestinal Hemorrhage
MH  - *Myocardial Infarction/prevention & control
MH  - Primary Prevention/methods
MH  - Middle Aged
MH  - Aged
PMC - PMC10258046
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular diseases
OT  - Markov model
OT  - Primary prevention
EDAT- 2023/06/09 06:42
MHDA- 2023/06/12 06:42
CRDT- 2023/06/09 03:58
PHST- 2023/06/12 06:42 [medline]
PHST- 2023/06/09 06:42 [pubmed]
PHST- 2023/06/09 03:58 [entrez]
AID - bjdxxbyxb-55-3-480 [pii]
AID - 10.19723/j.issn.1671-167X.2023.03.014 [doi]
PST - ppublish
SO  - Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Jun 18;55(3):480-487. doi: 
      10.19723/j.issn.1671-167X.2023.03.014.

PMID- 19232433
OWN - NLM
STAT- MEDLINE
DCOM- 20090924
LR  - 20181201
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 124
IP  - 2
DP  - 2009 Jun
TI  - Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing 
      percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
PG  - 193-8
LID - 10.1016/j.thromres.2009.01.009 [doi]
AB  - INTRODUCTION: Large individual variability in clopidogrel responses has been 
      reported. However, mechanisms of the non-responsiveness are unclear. Our aim was 
      to study the extent of platelet inhibition at the receptor level by in vitro 
      receptor antagonists of P2Y(12) (AR-C69931MX, cangrelor) and P2Y(1) (adenosine 
      3',5'diphosphate) in aspirin treated patients with coronary artery disease (CAD) 
      prior to and after in vivo clopidogrel. MATERIALS AND METHODS: 51 aspirin-treated 
      (100 mg/day) patients participated. Blood was collected before and after 
      administration of clopidogrel at 300 mg loading dose on day one, followed by 75 
      mg/d for four days. Aggregation in platelet-rich plasma was assessed. RESULTS: In 
      20% of patients clopidogrel failed to inhibit platelet responses to ADP. These 
      non-responders had also decreased sensitivity to an in vitro P2Y(12)-receptor 
      antagonist compared with the responders (mean inhibition of aggregation 25 vs. 
      32%, difference of means 7% (95% CI 2-12%), P<0.02). Moreover, the 
      P2Y(12)-receptor inhibition by in vivo clopidogrel correlated with the inhibition 
      by in vitro ARMX measured prior to administration of clopidogrel. Neither 
      P2Y(1)-receptor activity, thrombin generation while on aspirin nor basal platelet 
      activity associated with clopidogrel responses. CONCLUSIONS: Concomitant aspirin 
      and clopidogrel treatment failed to suppress platelet activity in 20% of 
      patients. Non-responders to clopidogrel had decreased responses also to another 
      ADP receptor antagonist, which suggests that the impaired response occurs at the 
      level of P2Y(12)-receptor.
FAU - Lepäntalo, Aino
AU  - Lepäntalo A
AD  - Department of Medicine, Division of Hematology, Helsinki University Central 
      Hospital, Helsinki, Finland. aino.lepantalo@uta.fi
FAU - Virtanen, Kari S
AU  - Virtanen KS
FAU - Reséndiz, Julio C
AU  - Reséndiz JC
FAU - Mikkelsson, Jussi
AU  - Mikkelsson J
FAU - Viiri, Leena E
AU  - Viiri LE
FAU - Karhunen, Pekka J
AU  - Karhunen PJ
FAU - Lassila, Riitta
AU  - Lassila R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090215
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2 Receptor Antagonists)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Monophosphate/pharmacology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Clopidogrel
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Purinergic P2 Receptor Antagonists
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Treatment Outcome
EDAT- 2009/02/24 09:00
MHDA- 2009/09/25 06:00
CRDT- 2009/02/24 09:00
PHST- 2008/04/22 00:00 [received]
PHST- 2008/12/29 00:00 [revised]
PHST- 2009/01/15 00:00 [accepted]
PHST- 2009/02/24 09:00 [entrez]
PHST- 2009/02/24 09:00 [pubmed]
PHST- 2009/09/25 06:00 [medline]
AID - S0049-3848(09)00030-9 [pii]
AID - 10.1016/j.thromres.2009.01.009 [doi]
PST - ppublish
SO  - Thromb Res. 2009 Jun;124(2):193-8. doi: 10.1016/j.thromres.2009.01.009. Epub 2009 
      Feb 15.

PMID- 16507859
OWN - NLM
STAT- MEDLINE
DCOM- 20061101
LR  - 20181201
IS  - 0903-1936 (Print)
IS  - 0903-1936 (Linking)
VI  - 27
IP  - 3
DP  - 2006 Mar
TI  - A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension.
PG  - 578-84
AB  - Idiopathic pulmonary arterial hypertension (IPAH) is characterised by in situ 
      thrombosis and increased thromboxane (Tx) A2 synthesis; however, there are no 
      studies of antiplatelet therapy in IPAH. The aim of the current study was to 
      determine the biochemical effects of aspirin (ASA) and clopidogrel on platelet 
      function and eicosanoid metabolism in patients with IPAH. A randomised, 
      double-blind, placebo-controlled crossover study of ASA 81 mg once daily and 
      clopidogrel 75 mg once daily was performed. Plasma P-selectin levels and 
      aggregometry were measured after exposure to adenosine diphosphate, arachidonic 
      acid and collagen. Serum levels of TxB2 and urinary metabolites of TxA2 and 
      prostaglandin I2 (Tx-M and PGI-M, respectively) were assessed. A total of 19 IPAH 
      patients were enrolled, of whom nine were being treated with continuous 
      intravenous epoprostenol. ASA and clopidogrel significantly reduced platelet 
      aggregation to arachidonic acid and adenosine diphosphate, respectively. ASA 
      significantly decreased serum TxB2, urinary Tx-M levels and the Tx-M/PGI-M ratio, 
      whereas clopidogrel had no effect on eicosanoid levels. Neither drug 
      significantly lowered plasma P-selectin levels. Epoprostenol use did not affect 
      the results. In conclusion, aspirin and clopidogrel inhibited platelet 
      aggregation, and aspirin reduced thromboxane metabolite production without 
      affecting prostaglandin I2 metabolite synthesis. Further clinical trials of 
      aspirin in patients with idiopathic pulmonary arterial hypertension should be 
      performed.
FAU - Robbins, I M
AU  - Robbins IM
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, and 
      Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
FAU - Kawut, S M
AU  - Kawut SM
FAU - Yung, D
AU  - Yung D
FAU - Reilly, M P
AU  - Reilly MP
FAU - Lloyd, W
AU  - Lloyd W
FAU - Cunningham, G
AU  - Cunningham G
FAU - Loscalzo, J
AU  - Loscalzo J
FAU - Kimmel, S E
AU  - Kimmel SE
FAU - Christman, B W
AU  - Christman BW
FAU - Barst, R J
AU  - Barst RJ
LA  - eng
GR  - HL67771/HL/NHLBI NIH HHS/United States
GR  - RR00095/RR/NCRR NIH HHS/United States
GR  - RR00645/RR/NCRR NIH HHS/United States
GR  - RR15534/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Clopidogrel
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/*therapeutic use
MH  - Thromboxane A2/*biosynthesis
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2006/03/02 09:00
MHDA- 2006/11/02 09:00
CRDT- 2006/03/02 09:00
PHST- 2006/03/02 09:00 [pubmed]
PHST- 2006/11/02 09:00 [medline]
PHST- 2006/03/02 09:00 [entrez]
AID - 27/3/578 [pii]
AID - 10.1183/09031936.06.00095705 [doi]
PST - ppublish
SO  - Eur Respir J. 2006 Mar;27(3):578-84. doi: 10.1183/09031936.06.00095705.

PMID- 23582126
OWN - NLM
STAT- MEDLINE
DCOM- 20130628
LR  - 20131121
IS  - 1603-6824 (Electronic)
IS  - 0041-5782 (Linking)
VI  - 175
IP  - 15
DP  - 2013 Apr 8
TI  - [Use of NSAIDs in rheumatoid arthritis should be limited].
PG  - 1039-41
AB  - In a Cochrane review the safety of non-steroidal anti-inflammatory drugs 
      (NSAIDs), including aspirin in people receiving methotrexate (MTX) for rheumatoid 
      arthritis was evaluated. A total of 17 publications were analyzed. Concurrent use 
      anti-inflammatory doses of aspirin with MTX were associated with renal and 
      hepatic side effects, whereas NSAIDs appeared to be safe. Nevertheless there are 
      well-known gastrointestinal, cardiovascular and renal side effects from NSAIDs. 
      In my opinion, use of NSAIDs in rheumatoid arthritis should be limited, as there 
      are better and less risky alternatives.
FAU - Lindberg, Mats
AU  - Lindberg M
AD  - Akutcentret, Sygehus Sønderjylland, Egelund 10, 6200 Aabenraa, Denmark. 
      mli@dadlnet.dk
LA  - dan
PT  - English Abstract
PT  - Journal Article
TT  - NSAID er sjældent indiceret ved reumatoid artritis--gennemgang af et 
      Cochranereview.
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antirheumatic Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Antirheumatic Agents/*adverse effects/therapeutic use
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Drug Interactions
MH  - Drug Therapy, Combination/adverse effects
MH  - Humans
MH  - Methotrexate/*adverse effects/therapeutic use
MH  - Review Literature as Topic
EDAT- 2013/04/16 06:00
MHDA- 2013/07/03 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/16 06:00 [entrez]
PHST- 2013/04/16 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - VP07120434 [pii]
PST - ppublish
SO  - Ugeskr Laeger. 2013 Apr 8;175(15):1039-41.

PMID- 16614614
OWN - NLM
STAT- MEDLINE
DCOM- 20060531
LR  - 20191210
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 35
IP  - 4 Pt 2
DP  - 2006 Apr
TI  - [Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no 
      significant benefits. Results of the Match study].
PG  - 679-82
AB  - Antiplatelet therapy is the reference treatment for secondary prevention after 
      noncardioembolic ischemic stroke. The main aim of the Match study was to compare 
      the combination of aspirin (75 mg) and clopidogrel (75 mg) with clopidogrel (75 
      mg) alone in secondary prevention after recent ischemic stroke or transcient 
      ischemic attack in high-risk patients. The incidence of the composite principal 
      endpoint (ischemic stroke, myocardial infarction, vascular death, or acute 
      ischemic event causing hospitalization) was 15.7% at 18 months in patients in the 
      aspirin-clopidogrel arm, compared with 16.7% in the placebo-clopidogrel arm. The 
      relative risk reduction (6.4%) was not significant (95%CI, -4.6 to 16.3; 
      p=0.244). Patients receiving the combination of aspirin and clopidogrel had more 
      life-threatening bleeding than those treated by clopidogrel alone (2.6% vs 1.3%; 
      95%CI, 1.3 to 2.6; p<0.001). Recruitment that began too late and an over-selected 
      population, with overrepresentation of patients with diabetes and small vessel 
      disease in particular, may partly explain these negative results.
FAU - Calvet, David
AU  - Calvet D
AD  - Service de Neurologie, Hôpital Sainte-Anne et Université Paris V René Descartes. 
      d.calvet@ch-sainte-anne.fr
FAU - Touzé, Emmanuel
AU  - Touzé E
FAU - Mas, Jean-Louis
AU  - Mas JL
LA  - fre
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Review
TT  - Absence de bénéfice significatif de l'adjonction d'aspirine au clopidogrel en 
      prévention secondaire après un accident ischémique cérébral. Résultats de l'étude 
      Match.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cerebral Infarction/epidemiology
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Hospitalization
MH  - Humans
MH  - Ischemic Attack, Transient/epidemiology
MH  - Multicenter Studies as Topic
MH  - Myocardial Infarction/epidemiology
MH  - Patient Selection
MH  - Placebos
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Stroke/epidemiology/*prevention & control
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Time Factors
RF  - 23
EDAT- 2006/04/15 09:00
MHDA- 2006/06/01 09:00
CRDT- 2006/04/15 09:00
PHST- 2006/04/15 09:00 [pubmed]
PHST- 2006/06/01 09:00 [medline]
PHST- 2006/04/15 09:00 [entrez]
AID - S0755-4982(06)74662-0 [pii]
AID - 10.1016/s0755-4982(06)74662-0 [doi]
PST - ppublish
SO  - Presse Med. 2006 Apr;35(4 Pt 2):679-82. doi: 10.1016/s0755-4982(06)74662-0.

PMID- 35450774
OWN - NLM
STAT- MEDLINE
DCOM- 20221122
LR  - 20221122
IS  - 1532-1932 (Electronic)
IS  - 1521-6934 (Linking)
VI  - 84
DP  - 2022 Nov
TI  - Screening for preeclampsia in twin pregnancies.
PG  - 55-65
LID - S1521-6934(22)00047-5 [pii]
LID - 10.1016/j.bpobgyn.2022.03.008 [doi]
AB  - Twin pregnancies are an important risk factor for preeclampsia, a hypertensive 
      disorder of pregnancy that is associated with a significant risk of maternal and 
      perinatal morbidity. Given the burden of preeclampsia, the identification of 
      women at high risk in early pregnancy is essential to allow for preventive 
      strategies and close monitoring. In singleton pregnancies, the risk factors for 
      preeclampsia are well established, and a combined first-trimester prediction 
      model has been shown to adequately predict preterm disease. Furthermore, 
      intervention with low-dose aspirin at 150 mg/day in those identified as high-risk 
      reduces the rate of preterm preeclampsia by 62%. In contrast, risk factors for 
      preeclampsia in twin pregnancies are less established, the proposed screening 
      models have shown poor performance with high false-positive rates, and the 
      benefit of aspirin for the prevention of preeclampsia is not clearly 
      demonstrated. In this review, we examine the literature assessing prediction and 
      prevention of preeclampsia in twin pregnancies.
CI  - Copyright © 2022. Published by Elsevier Ltd.
FAU - Francisco, Carla
AU  - Francisco C
AD  - Department of Obstetrics and Gynaecology, Hospital Beatriz Ângelo, Avenida 
      Carlos, Teixeira 3, 2674-514 Loures, Portugal. Electronic address: 
      carla.francisco@gmail.com.
FAU - Gamito, Mariana
AU  - Gamito M
AD  - Department of Obstetrics and Gynaecology, Hospital Beatriz Ângelo, Avenida 
      Carlos, Teixeira 3, 2674-514 Loures, Portugal. Electronic address: 
      marianaapogamito@gmail.com.
FAU - Reddy, Maya
AU  - Reddy M
AD  - Department of Obstetrics and Gynaecology, Monash University, 246 Clayton Road, 
      Clayton, Melbourne, Victoria, Australia. Electronic address: 
      maya.reddy@monash.edu.
FAU - Rolnik, Daniel L
AU  - Rolnik DL
AD  - Department of Obstetrics and Gynaecology, Monash University, 246 Clayton Road, 
      Clayton, Melbourne, Victoria, Australia. Electronic address: 
      daniel.rolnik@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220331
PL  - Netherlands
TA  - Best Pract Res Clin Obstet Gynaecol
JT  - Best practice & research. Clinical obstetrics & gynaecology
JID - 101121582
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Pregnancy
MH  - Infant, Newborn
MH  - Humans
MH  - Pregnancy, Twin
MH  - *Pre-Eclampsia/diagnosis/epidemiology/prevention & control
MH  - Aspirin/therapeutic use
MH  - Pregnancy Trimester, First
MH  - *Hypertension
OTO - NOTNLM
OT  - Aspirin
OT  - Multiple pregnancy
OT  - Prediction
OT  - Preeclampsia
OT  - Prevention
OT  - Twins
COIS- Declaration of competing interest The authors report no conflicts of interest.
EDAT- 2022/04/23 06:00
MHDA- 2022/11/23 06:00
CRDT- 2022/04/22 07:03
PHST- 2022/01/04 00:00 [received]
PHST- 2022/03/13 00:00 [accepted]
PHST- 2022/04/23 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2022/04/22 07:03 [entrez]
AID - S1521-6934(22)00047-5 [pii]
AID - 10.1016/j.bpobgyn.2022.03.008 [doi]
PST - ppublish
SO  - Best Pract Res Clin Obstet Gynaecol. 2022 Nov;84:55-65. doi: 
      10.1016/j.bpobgyn.2022.03.008. Epub 2022 Mar 31.

PMID- 25475110
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20181113
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Print)
IS  - 1355-6037 (Linking)
VI  - 101
IP  - 5
DP  - 2015 Mar
TI  - Individualised prediction of alternate-day aspirin treatment effects on the 
      combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in 
      healthy women.
PG  - 369-76
LID - 10.1136/heartjnl-2014-306342 [doi]
AB  - BACKGROUND: The value of aspirin in primary prevention of cancer and 
      cardiovascular disease (CVD) remains unclear. The aim of this study was to 
      identify women who benefit from alternate-day aspirin with regard to all relevant 
      outcomes, including cancer, CVD and major gastrointestinal bleeding. METHODS: 
      Long term follow-up data of 27 939 healthy women with baseline plasma samples in 
      the Women's Health Study, a randomised trial of 100 mg alternate-day aspirin 
      versus placebo, were used to develop competing risks models for individualised 
      prediction of absolute risk reduction of the combination of CVD, cancer and major 
      gastrointestinal bleeding by aspirin. RESULTS: Although aspirin was associated 
      with a modestly decreased 15-year risk of colorectal cancer, CVD, and in some 
      women non-colorectal cancer, aspirin treatment resulted in a negative treatment 
      effect in the majority of women if gastrointestinal bleeding was also taken into 
      account. The excess risk of major gastrointestinal bleeding by aspirin increased 
      with age, but the benefits for colorectal cancer and CVD risk were also greater 
      at higher age. Decision curves indicated that selective treatment of women 
      ≥65 years may improve net benefit compared to treating all, none and 
      prediction-based treatment. The observed 15-year number needed to treat to 
      prevent one event among women ≥65 years was 29 (95% CI 12 to 102). CONCLUSIONS: 
      Concurrent evaluation of the absolute effects on cancer, CVD and major 
      gastrointestinal bleeding showed that alternate-day use of low-dose aspirin is 
      ineffective or harmful in the majority of women in primary prevention. Selective 
      treatment of women ≥65 years with aspirin may improve net benefit. TRIAL 
      REGISTRATION NUMBER: NCT00000479.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - van Kruijsdijk, Rob C M
AU  - van Kruijsdijk RC
AD  - Department of Vascular Medicine, University Medical Centre Utrecht, Utrecht, The 
      Netherlands.
FAU - Visseren, Frank L J
AU  - Visseren FL
AD  - Department of Vascular Medicine, University Medical Centre Utrecht, Utrecht, The 
      Netherlands.
FAU - Ridker, Paul M
AU  - Ridker PM
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical 
      School, Boston, Massachusetts, USA.
FAU - Dorresteijn, Johannes A N
AU  - Dorresteijn JA
AD  - Department of Vascular Medicine, University Medical Centre Utrecht, Utrecht, The 
      Netherlands.
FAU - Buring, Julie E
AU  - Buring JE
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical 
      School, Boston, Massachusetts, USA.
FAU - van der Graaf, Yolanda
AU  - van der Graaf Y
AD  - Julius Centre for Health Sciences and Primary Care, University Medical Centre 
      Utrecht, Utrecht, The Netherlands.
FAU - Cook, Nancy R
AU  - Cook NR
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical 
      School, Boston, Massachusetts, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00000479
GR  - HL099355/HL/NHLBI NIH HHS/United States
GR  - R01 HL043851/HL/NHLBI NIH HHS/United States
GR  - CA047988/CA/NCI NIH HHS/United States
GR  - UM1 CA182913/CA/NCI NIH HHS/United States
GR  - R01 CA047988/CA/NCI NIH HHS/United States
GR  - R01 HL080467/HL/NHLBI NIH HHS/United States
GR  - HL080467/HL/NHLBI NIH HHS/United States
GR  - RC1 HL099355/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20141204
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 2014;349:g7466. PMID: 25499889
MH  - Age Factors
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Decision Support Techniques
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Hemorrhage/chemically induced/*epidemiology
MH  - Humans
MH  - Middle Aged
MH  - Neoplasms/epidemiology/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Primary Prevention
MH  - Risk Assessment
MH  - United States/epidemiology
PMC - PMC4536552
MID - NIHMS713910
OTO - NOTNLM
OT  - CORONARY ARTERY DISEASE
OT  - MALIGNENCY
EDAT- 2014/12/06 06:00
MHDA- 2015/05/12 06:00
CRDT- 2014/12/06 06:00
PHST- 2014/12/06 06:00 [entrez]
PHST- 2014/12/06 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - heartjnl-2014-306342 [pii]
AID - 10.1136/heartjnl-2014-306342 [doi]
PST - ppublish
SO  - Heart. 2015 Mar;101(5):369-76. doi: 10.1136/heartjnl-2014-306342. Epub 2014 Dec 
      4.

PMID- 25233235
OWN - NLM
STAT- MEDLINE
DCOM- 20150814
LR  - 20141029
IS  - 1742-2051 (Electronic)
IS  - 1742-2051 (Linking)
VI  - 10
IP  - 12
DP  - 2014 Dec
TI  - Probing of the combined effect of bisquaternary ammonium antimicrobial agents and 
      acetylsalicylic acid on model phospholipid membranes: differential scanning 
      calorimetry and mass spectrometry studies.
PG  - 3155-62
LID - 10.1039/c4mb00420e [doi]
AB  - A model molecular biosystem of hydrated dipalmitoylphosphatidylcholine (DPPC) 
      bilayers that mimics cell biomembranes is used to probe combined membranotropic 
      effects of drugs by instrumental techniques of molecular biophysics. Differential 
      scanning calorimetry reveals that doping of the DPPC model membrane with 
      individual bisquaternary ammonium compounds (BQAC) decamethoxinum, ethonium, 
      thionium and acetylsalicylic acid (ASA) leads to lowering of the membrane melting 
      temperature (Tm) pointing to membrane fluidization. Combined application of the 
      basic BQAC and acidic ASA causes an opposite effect on Tm (increase), 
      corresponding to the membrane densification. Thus, modulation of the 
      membranotropic effects upon combined use of the drugs studied can be revealed at 
      the level of model membranes. Formation of noncovalent supramolecular complexes 
      of the individual BQACs and ASA with DPPC molecules, which may be involved in the 
      mechanism of the drug-membrane interaction at the molecular level, is 
      demonstrated by electrospray ionization (ESI) mass spectrometry. In the ternary 
      (DPPC + ASA + BQAC) model systems, the stable complexes of the BQAC dication with 
      the ASA anion, which may be responsible for modulation of the membranotropic 
      effects of the drugs, were recorded by ESI mass spectrometry. The proposed 
      approach can be further developed for preliminary evaluation of the combined 
      effects of the drugs at the level of model lipid membranes prior to tests on 
      living organisms.
FAU - Kasian, N A
AU  - Kasian NA
AD  - Institute for Scintillation Materials of the National Academy of Sciences of 
      Ukraine, 60, Lenin ave., 61001 Kharkov, Ukraine. kasian@isma.kharkov.ua.
FAU - Pashynska, V A
AU  - Pashynska VA
FAU - Vashchenko, O V
AU  - Vashchenko OV
FAU - Krasnikova, A O
AU  - Krasnikova AO
FAU - Gömöry, A
AU  - Gömöry A
FAU - Kosevich, M V
AU  - Kosevich MV
FAU - Lisetski, L N
AU  - Lisetski LN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Mol Biosyst
JT  - Molecular bioSystems
JID - 101251620
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Phospholipids)
RN  - 0 (Quaternary Ammonium Compounds)
RN  - 0 (decamethoxinum)
RN  - 21954-74-5 (Ethonium)
RN  - 2644-64-6 (1,2-Dipalmitoylphosphatidylcholine)
RN  - 76597-98-3 (thionium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 1,2-Dipalmitoylphosphatidylcholine/chemistry
MH  - Anti-Infective Agents/*chemistry
MH  - Aspirin/*chemistry
MH  - Calorimetry, Differential Scanning
MH  - Mass Spectrometry
MH  - Models, Molecular
MH  - Phospholipids/chemistry
MH  - Quaternary Ammonium Compounds/*chemistry
EDAT- 2014/09/19 06:00
MHDA- 2015/08/15 06:00
CRDT- 2014/09/19 06:00
PHST- 2014/09/19 06:00 [entrez]
PHST- 2014/09/19 06:00 [pubmed]
PHST- 2015/08/15 06:00 [medline]
AID - 10.1039/c4mb00420e [doi]
PST - ppublish
SO  - Mol Biosyst. 2014 Dec;10(12):3155-62. doi: 10.1039/c4mb00420e.

PMID- 2750927
OWN - NLM
STAT- MEDLINE
DCOM- 19890816
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 257
IP  - 1 Pt 2
DP  - 1989 Jul
TI  - Renal metabolism and urinary excretion of thromboxane B2 in the rat.
PG  - F77-85
AB  - We wanted to evaluate whether the kidney tissue can metabolize thromboxane (Tx) 
      B2 and, specifically, whether the 2,3-dinor metabolite might be formed in the 
      kidney and excreted in the urine. For this purpose, we used an isolated perfused 
      kidney preparation exposed to vehicle or TxB2 at different infusion rates. 
      Approximately 96% of the total TxB2 infused was recovered in the venous effluent, 
      whereas approximately 1% was found in urine. Isolated perfused kidneys exposed to 
      [3H]TxB2 eliminated in the urine 1.2% of the [3H]TxB2 infused, measured by 
      thin-layer chromatographic analysis, and actively metabolized [3H]TxB2 to 
      2,3-dinor-TxB2, 11-dehydro-TxB2, and possibly 2,3,4,5-tetranor-TxB1. No 
      metabolites of TxB2 were recovered in the venous effluent. As a marker of renal 
      TxB2 metabolic activity, urinary 2,3-dinor-TxB2 was quantified by high-resolution 
      gas chromatography-negative-ion chemical ionization mass spectrometry. The 
      2,3-dinor-TxB2 was detected both before and during TxB2 infusion in urinary 
      samples but not in the venous effluent. The ratio of 2,3-dinor-TxB2-TxB2 
      increased during the infusion reaching a peak value immediately after stopping 
      the TxB2 infusion. These results indicate that, in the rat, the kidney tissue 
      metabolizes TxB2 to 2,3-dinor-TxB2, and both TxB2 and 2,3-dinor-TxB2 are excreted 
      in the urine.
FAU - Benigni, A
AU  - Benigni A
AD  - Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
FAU - Chiabrando, C
AU  - Chiabrando C
FAU - Perico, N
AU  - Perico N
FAU - Fanelli, R
AU  - Fanelli R
FAU - Patrono, C
AU  - Patrono C
FAU - FitzGerald, G A
AU  - FitzGerald GA
FAU - Remuzzi, G
AU  - Remuzzi G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Kidney/*metabolism
MH  - Perfusion
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Thromboxane B2/*metabolism
EDAT- 1989/07/01 00:00
MHDA- 1989/07/01 00:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 1989/07/01 00:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
AID - 10.1152/ajprenal.1989.257.1.F77 [doi]
PST - ppublish
SO  - Am J Physiol. 1989 Jul;257(1 Pt 2):F77-85. doi: 10.1152/ajprenal.1989.257.1.F77.

PMID- 23472840
OWN - NLM
STAT- MEDLINE
DCOM- 20130926
LR  - 20220317
IS  - 1520-5827 (Electronic)
IS  - 0743-7463 (Linking)
VI  - 29
IP  - 13
DP  - 2013 Apr 2
TI  - Encapsulation of hydrophobic drugs in Pluronic F127 micelles: effects of drug 
      hydrophobicity, solution temperature, and pH.
PG  - 4350-6
LID - 10.1021/la304836e [doi]
AB  - Three drugs, ibuprofen, aspirin, and erythromycin, are encapsulated in spherical 
      Pluronic F127 micelles. The shapes and the size distributions of the micelles in 
      dilute, aqueous solutions, with and without drugs, are ascertained using 
      cryo-scanning electron microscopy and dynamic light scattering (DLS) experiments, 
      respectively. Uptake of drugs above a threshold concentration is seen to reduce 
      the critical micellization temperature of the solution. The mean hydrodynamic 
      radii and polydispersities of the micelles are found to increase with decrease in 
      temperature and in the presence of drug molecules. The hydration of the micellar 
      core at lower temperatures is verified using fluorescence measurements. 
      Increasing solution pH leads to the ionization of the drugs incorporated in the 
      micellar cores. This causes rupture of the micelles and release of the drugs into 
      the solution at the highest solution pH value of 11.36 investigated here and is 
      studied using DLS and fluorescence spectrocopy.
FAU - Basak, Rajib
AU  - Basak R
AD  - Raman Research Institute, Bangalore, India.
FAU - Bandyopadhyay, Ranjini
AU  - Bandyopadhyay R
LA  - eng
PT  - Journal Article
DEP - 20130319
PL  - United States
TA  - Langmuir
JT  - Langmuir : the ACS journal of surfaces and colloids
JID - 9882736
RN  - 0 (Micelles)
RN  - 0 (Solutions)
RN  - 106392-12-5 (Poloxamer)
RN  - 63937KV33D (Erythromycin)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Erythromycin/*chemistry
MH  - Hydrogen-Ion Concentration
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Ibuprofen/*chemistry
MH  - Micelles
MH  - Molecular Structure
MH  - Particle Size
MH  - Poloxamer/*chemistry
MH  - Solutions
MH  - Surface Properties
MH  - *Temperature
EDAT- 2013/03/12 06:00
MHDA- 2013/09/27 06:00
CRDT- 2013/03/12 06:00
PHST- 2013/03/12 06:00 [entrez]
PHST- 2013/03/12 06:00 [pubmed]
PHST- 2013/09/27 06:00 [medline]
AID - 10.1021/la304836e [doi]
PST - ppublish
SO  - Langmuir. 2013 Apr 2;29(13):4350-6. doi: 10.1021/la304836e. Epub 2013 Mar 19.

PMID- 6740546
OWN - NLM
STAT- MEDLINE
DCOM- 19840813
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 51
IP  - 2
DP  - 1984 Apr 30
TI  - Platelet-platelet recognition during aggregation: distinct mechanisms determined 
      by the release reaction.
PG  - 145-9
AB  - Fixed platelets, bearing covalently bound fibrinogen, were previously shown to 
      participate passively in aggregation induced by thrombin or A23187. The bound 
      fibrinogen was specifically required for the interaction. The present study 
      examines the role of the release reaction in controlling the passive 
      participation of the fixed platelets in aggregation. Aggregation of fresh 
      platelets induced by low ADP concentration (less than or equal to 2 microM) was 
      not augmented by the fixed platelets, but was augmented when higher 
      concentrations of ADP were employed. Fixed platelets failed to enhance 
      aggregation of aspirin-treated fresh platelets induced by 10 microM ADP; the 
      augmentation capability was reconstituted by a supernatant fraction from 
      platelets activated by 10 microM ADP in the presence of EDTA. The binding of 
      soluble fibrinogen to activated fresh platelets occurred regardless of the 
      release reaction, but the interaction of fragmented fixed platelets bearing bound 
      fibrinogen with aggregating fresh platelets was apparent only when release took 
      place. It is concluded that fibrinogen covalently bound to fixed platelets is 
      selectively recognized by released compound(s).
FAU - Agam, G
AU  - Agam G
FAU - Livne, A
AU  - Livne A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*physiology
MH  - Dose-Response Relationship, Drug
MH  - Fibrinogen/physiology
MH  - Humans
MH  - *Platelet Aggregation/drug effects
EDAT- 1984/04/30 00:00
MHDA- 1984/04/30 00:01
CRDT- 1984/04/30 00:00
PHST- 1984/04/30 00:00 [pubmed]
PHST- 1984/04/30 00:01 [medline]
PHST- 1984/04/30 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1984 Apr 30;51(2):145-9.

PMID- 2669039
OWN - NLM
STAT- MEDLINE
DCOM- 19890918
LR  - 20131121
IS  - 0379-1629 (Print)
IS  - 0379-1629 (Linking)
VI  - 14
IP  - 2
DP  - 1989 May
TI  - [Aspirin. Pseudo-allergic reactions].
PG  - 79-87
AB  - The author reviewed 2000 clinical records of his private allergy patients chosen 
      at random. 197 records (9.7%) labeled "allergic to aspirin" were culled. 41 
      (2.1%) were acute cases and 153 (7.6%) had a history of "intolerance to aspirin". 
      The main symptoms were angioedema or angioedema and urticaria in the majority of 
      patients. No deaths were recorded. Each clinical record was surveyed and 61% of 
      the acute cases and 72% of the patients with a history of intolerance to aspirin 
      had a personal history of atopy. Family history of atopy was present in 63 and 
      73%, respectively. There was no history of atopy in 12% of the acute cases and in 
      7% of those with a history of intolerance to aspirin. 56 to 65% of these groups, 
      respectively, had allergic rhinitis and 17 and 34%, had asthma. 23% of these 
      patients showed allergic reactions simultaneously to Pyrazolones and between 12 
      and 22% showed allergy to Penicillin, and between 2 and 12%, to Acetominophene. 
      The only food to which statistically significant allergy occurred was pancake, in 
      12%. 53% of the acute cases and 89% of those with a history of intolerance to 
      aspirin showed a pseudoallergic reaction with products which contain aspirin or 
      non steroidal antiinflamatory agents. 80% of the acute cases were treated with 
      aqueous 1:1000 solution of epinephirine subcutaneously. 100% were given 
      antihistaminics I.M. or orally and 61% were given steroids. Each patient was 
      furnished with a list of the main aspirin containing products and non steroidal 
      antiinflammatory agents, which cross react with aspirin.
FAU - Díaz Isaacs, M
AU  - Díaz Isaacs M
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspirina. Reacciones pseudo-alérgicas.
PL  - Panama
TA  - Rev Med Panama
JT  - Revista medica de Panama
JID - 7706654
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Drug Hypersensitivity/complications/*etiology/therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
RF  - 7
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
PST - ppublish
SO  - Rev Med Panama. 1989 May;14(2):79-87.

PMID- 32736957
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20201110
IS  - 1590-3729 (Electronic)
IS  - 0939-4753 (Linking)
VI  - 30
IP  - 10
DP  - 2020 Sep 24
TI  - Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study.
PG  - 1806-1812
LID - S0939-4753(20)30250-7 [pii]
LID - 10.1016/j.numecd.2020.06.021 [doi]
AB  - BACKGROUND AND AIMS: Diabetic retinopathy (DR) is the most common microvascular 
      complication of diabetes. Diabetic macroangiopathies, particularly cardiovascular 
      (CV) diseases, seem closely related to diabetes microvascular complications. 
      Aspirin represents the most prescribed compound in CV prevention. Aspirin impact 
      on DR is still object of debate. As it is already recommended among diabetics at 
      high CV risk, aim of this study was to assess a potential relationship between DR 
      and aspirin therapy, in a type 2 diabetes cohort of patients screened through 
      telemedicine. METHODS AND RESULTS: NO Blind is a cross-sectional, multicenter, 
      observational study, which involved nine Italian outpatient clinics. Primary 
      endpoint was the assessment of the relationship between aspirin treatment and DR. 
      2068 patients were enrolled in the study, subsequently split in two 
      subpopulations according to either the presence or absence of DR. Overall, 995 
      subjects were under aspirin therapy. After adjusting for most common potential 
      confounders, age and gender, aspirin reveals significantly associated with DR 
      (OR: 1.72, 95%CI: 1.58-2.89, p = 0.002) and proliferative DR (PDR) (OR: 1.89, 
      95%CI: 1.24-2.84, p = 0.003). Association comes lost further adjusting for MACEs 
      (OR: 1.28, 95%CI: 0.85-1.42, p = 0.157) (Model 4) and eGFR (OR: 0.93; 95%CI: 
      0.71-1.22; p = 0.591) (Model 5). CONCLUSION: In this multicenter cross-sectional 
      study including a large sample of outpatients with T2DM, we showed that aspirin 
      was not associated with DR after adjustment for several cardio-metabolic 
      confounders. However, as partially confirmed by our findings, and related to the 
      well-known pro-hemorrhagic effect of aspirin, its use should be individually 
      tailored, even by telemedicine tools.
CI  - Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study 
      of Atherosclerosis, the Italian Society of Human Nutrition and the Department of 
      Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. 
      All rights reserved.
FAU - Pafundi, Pia Clara
AU  - Pafundi PC
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy.
FAU - Galiero, Raffaele
AU  - Galiero R
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy.
FAU - Caturano, Alfredo
AU  - Caturano A
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy.
FAU - Acierno, Carlo
AU  - Acierno C
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy.
FAU - de Sio, Chiara
AU  - de Sio C
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy.
FAU - Vetrano, Erica
AU  - Vetrano E
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy.
FAU - Nevola, Riccardo
AU  - Nevola R
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy.
FAU - Gelso, Aldo
AU  - Gelso A
AD  - "Villa Dei Fiori" Hospital, Corso Italia, 157, 80011, Acerra (Naples), Italy.
FAU - Bono, Valeria
AU  - Bono V
AD  - IRCCS Fondazione G. B. Bietti, Via Livenza, 3, 00198, Rome, Italy.
FAU - Costagliola, Ciro
AU  - Costagliola C
AD  - University of Molise, Department of Medicine & Health Sciences "Vincenzo 
      Tiberio", Via Francesco De Sanctis, 1, 86100, Campobasso, Italy.
FAU - Marfella, Raffaele
AU  - Marfella R
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy.
FAU - Sardu, Celestino
AU  - Sardu C
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy.
FAU - Rinaldi, Luca
AU  - Rinaldi L
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy.
FAU - Salvatore, Teresa
AU  - Salvatore T
AD  - University of Campania "Luigi Vanvitelli", Department of Precision Medicine, Via 
      de Crecchio, 7, 80138, Naples, Italy.
FAU - Adinolfi, Luigi Elio
AU  - Adinolfi LE
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy.
FAU - Sasso, Ferdinando Carlo
AU  - Sasso FC
AD  - University of Campania "Luigi Vanvitelli", Department of Advanced Medical and 
      Surgical Sciences, Piazza Luigi Miraglia 2, 80138, Naples, Italy. Electronic 
      address: ferdinandocarlo.sasso@unicampania.it.
CN  - No Blind Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20200629
PL  - Netherlands
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/diagnosis/etiology/*prevention & control
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/complications/diagnosis/*drug therapy
MH  - Diabetic Retinopathy/diagnosis/*etiology
MH  - Female
MH  - Humans
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Diabetes complications
OT  - Diabetic retinopathy
OT  - Type 2 diabetes
COIS- Declaration of competing interest None of the authors have any 
      financial/conflicting interest to disclose.
EDAT- 2020/08/02 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/06/20 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - S0939-4753(20)30250-7 [pii]
AID - 10.1016/j.numecd.2020.06.021 [doi]
PST - ppublish
SO  - Nutr Metab Cardiovasc Dis. 2020 Sep 24;30(10):1806-1812. doi: 
      10.1016/j.numecd.2020.06.021. Epub 2020 Jun 29.

PMID- 20875599
OWN - NLM
STAT- MEDLINE
DCOM- 20110127
LR  - 20131121
IS  - 1873-3573 (Electronic)
IS  - 0039-9140 (Linking)
VI  - 82
IP  - 5
DP  - 2010 Oct 15
TI  - Electromagnetic induction detector for capillary electrophoresis and its 
      application in pharmaceutical analysis.
PG  - 1935-42
LID - 10.1016/j.talanta.2010.08.013 [doi]
AB  - A new electromagnetic induction detector for capillary electrophoresis and its 
      application are described. The detector is consisted of an inductor, a resistor, 
      a high-frequency signal generator and a high-frequency millivoltmeter. The 
      conditions affecting the response of the detector, including dimension of the 
      magnetic ring, position of the capillary, number of coil turns, frequency, 
      excitation voltage and value of the resistor were examined and optimized. The 
      feasibility of the proposed detector was evaluated by detection of inorganic ions 
      and separation of amino aids. Its quantification applicability was investigated 
      by determination of aspirin and paracetamol in pharmaceutical preparation (Akafen 
      powder). The primary factors affecting separation efficiency, which include 
      variety of buffer, buffer concentration, injection time and injection height and 
      separation voltage, were researched. Experimental results demonstrated that this 
      new detector showed a well-defined correlation between sample concentrations and 
      responses (r=0.997-0.999), with detection limits of 30 μmol L(-1) for aspirin and 
      10 μmol L(-1) for paracetamol, as well as good reproducibility and stability. 
      Compared with currently available detection techniques, this new detector has 
      several advantages, such as simple construction, no complicated elements, ease of 
      assembly and operation, and potential for universal applications. It can be an 
      alternative to the traditional methods in the quality control of the 
      pharmaceutical preparations.
CI  - Copyright © 2010 Elsevier B.V. All rights reserved.
FAU - Yang, Xiu-Juan
AU  - Yang XJ
AD  - School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 
      510006, PR China.
FAU - Chen, Zuan-Guang
AU  - Chen ZG
FAU - Liu, Cui
AU  - Liu C
FAU - Li, Ou-Lian
AU  - Li OL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100819
PL  - Netherlands
TA  - Talanta
JT  - Talanta
JID - 2984816R
RN  - 0 (Indicators and Reagents)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Solutions)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Aspirin/*analysis
MH  - *Electromagnetic Fields
MH  - Electrophoresis, Capillary/*instrumentation/*methods
MH  - Indicators and Reagents
MH  - Limit of Detection
MH  - Pharmaceutical Preparations/*analysis/standards
MH  - Quality Control
MH  - Solutions
EDAT- 2010/09/30 06:00
MHDA- 2011/01/29 06:00
CRDT- 2010/09/30 06:00
PHST- 2010/04/21 00:00 [received]
PHST- 2010/08/02 00:00 [revised]
PHST- 2010/08/12 00:00 [accepted]
PHST- 2010/09/30 06:00 [entrez]
PHST- 2010/09/30 06:00 [pubmed]
PHST- 2011/01/29 06:00 [medline]
AID - S0039-9140(10)00630-2 [pii]
AID - 10.1016/j.talanta.2010.08.013 [doi]
PST - ppublish
SO  - Talanta. 2010 Oct 15;82(5):1935-42. doi: 10.1016/j.talanta.2010.08.013. Epub 2010 
      Aug 19.

PMID- 781226
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 2
DP  - 1976
TI  - Fenoprofen calcium therapy in rheumatoid arthritis.
PG  - 18-25
AB  - Fenoprofen calcium (FC) was compared to aspirin (ASA) in 20 patients with 
      rheumatoid arthritis in a double-blind parallel study. The average daily dose was 
      2.0 gm of FC, or 3.6 gm of ASA. Most patients on FC therapy responded similarly 
      to those receiving ASA, but FC was slightly better in reducing morning stiffness, 
      walking time, fatigue severity, and activity index. More FC treated than ASA 
      treated patients became worse when placebo was substituted after one year of 
      therapy, with a greater increase in the number and severity of painful and 
      swollen joints, in addition to the above mentioned parameters. This suggests a 
      greater suppression of the inflammatory process during FC therapy. FC was well 
      tolerated and had a greater antirheumatic effect than aspirin. Both drugs were 
      superior to placebo.
FAU - Zuckner, J
AU  - Zuckner J
FAU - Auclair, R J
AU  - Auclair RJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Fenoprofen/*therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Phenylpropionates/*therapeutic use
MH  - Time Factors
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1976;2:18-25.

PMID- 30807451
OWN - NLM
STAT- MEDLINE
DCOM- 20200130
LR  - 20220410
IS  - 1537-1948 (Electronic)
IS  - 0025-7079 (Print)
IS  - 0025-7079 (Linking)
VI  - 57
IP  - 10
DP  - 2019 Oct
TI  - Ascertainment of Aspirin Exposure Using Structured and Unstructured Large-scale 
      Electronic Health Record Data.
PG  - e60-e64
LID - 10.1097/MLR.0000000000001065 [doi]
AB  - BACKGROUND: Aspirin impacts risk for important outcomes such as cancer, 
      cardiovascular disease, and gastrointestinal bleeding. However, ascertaining 
      exposure to medications available both by prescription and over-the-counter such 
      as aspirin for research and quality improvement purposes is a challenge. 
      OBJECTIVES: Develop and validate a strategy for ascertaining aspirin exposure, 
      utilizing a combination of structured and unstructured data. RESEARCH DESIGN: 
      This is a retrospective cohort study. SUBJECTS: In total, 1,869,439 Veterans who 
      underwent usual care colonoscopy 1999-2014 within the Department of Veterans 
      Affairs. MEASURES: Aspirin exposure and dose were obtained from an ascertainment 
      strategy combining query of structured medication records available in electronic 
      health record databases and unstructured data extracted from free-text progress 
      notes. Prevalence of any aspirin exposure and dose-specific exposure were 
      estimated. Positive predictive value and negative predictive value were used to 
      assess strategy performance, using manual chart review as the reference standard. 
      RESULTS: Our combined strategy for ascertaining aspirin exposure using structured 
      and unstructured data reached a positive predictive value and negative predictive 
      value of 99.2% and 97.5% for any exposure, and 92.6% and 98.3% for dose-specific 
      exposure. Estimated prevalence of any aspirin exposure was 36.3% (95% confidence 
      interval: 36.2%-36.4%) and dose-specific exposure was 35.4% (95% confidence 
      interval: 35.3%-35.5%). CONCLUSIONS: A readily accessible approach utilizing a 
      combination of structured medication records and query of unstructured data can 
      be used to ascertain aspirin exposure when manual chart review is impractical.
FAU - Bustamante, Ranier
AU  - Bustamante R
AD  - VA San Diego Healthcare System.
FAU - Earles, Ashley
AU  - Earles A
AD  - VA San Diego Healthcare System.
FAU - Murphy, James D
AU  - Murphy JD
AD  - University of California, San Diego.
AD  - Moores Cancer Center, La Jolla, CA.
FAU - Bryant, Alex K
AU  - Bryant AK
AD  - University of California, San Diego.
FAU - Patterson, Olga V
AU  - Patterson OV
AD  - VA Salt Lake City Health Care System.
AD  - University of Utah, Salt Lake City, UT.
FAU - Gawron, Andrew J
AU  - Gawron AJ
AD  - VA Salt Lake City Health Care System.
AD  - University of Utah, Salt Lake City, UT.
FAU - Kaltenbach, Tonya
AU  - Kaltenbach T
AD  - San Francisco VA Medical Center.
AD  - University of California, San Francisco, San Francisco, CA.
FAU - Whooley, Mary A
AU  - Whooley MA
AD  - San Francisco VA Medical Center.
AD  - University of California, San Francisco, San Francisco, CA.
FAU - Fisher, Deborah A
AU  - Fisher DA
AD  - Durham VA Medical Center.
AD  - Duke University, Durham, NC.
FAU - Saini, Sameer D
AU  - Saini SD
AD  - VA Ann Arbor Healthcare System.
AD  - University of Michigan, Ann Arbor, MI.
FAU - Gupta, Samir
AU  - Gupta S
AD  - VA San Diego Healthcare System.
AD  - University of California, San Diego.
AD  - Moores Cancer Center, La Jolla, CA.
FAU - Liu, Lin
AU  - Liu L
AD  - VA San Diego Healthcare System.
AD  - University of California, San Diego.
AD  - Moores Cancer Center, La Jolla, CA.
LA  - eng
GR  - I01 HX001574/HX/HSRD VA/United States
GR  - IP1 HX002002/HX/HSRD VA/United States
GR  - R37 CA222866/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Med Care
JT  - Medical care
JID - 0230027
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Colonoscopy/statistics & numerical data
MH  - Data Collection/*methods
MH  - Databases, Factual
MH  - Drug Prescriptions/statistics & numerical data
MH  - Drug-Related Side Effects and Adverse Reactions/epidemiology/etiology
MH  - Electronic Health Records/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nonprescription Drugs/therapeutic use
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - United States/epidemiology
MH  - Veterans/statistics & numerical data
PMC - PMC6703965
MID - NIHMS1517858
COIS- The authors declare no conflict of interest.
EDAT- 2019/02/27 06:00
MHDA- 2020/01/31 06:00
CRDT- 2019/02/27 06:00
PHST- 2019/02/27 06:00 [pubmed]
PHST- 2020/01/31 06:00 [medline]
PHST- 2019/02/27 06:00 [entrez]
AID - 10.1097/MLR.0000000000001065 [doi]
PST - ppublish
SO  - Med Care. 2019 Oct;57(10):e60-e64. doi: 10.1097/MLR.0000000000001065.

PMID- 2513898
OWN - NLM
STAT- MEDLINE
DCOM- 19900209
LR  - 20190501
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 299
IP  - 6710
DP  - 1989 Nov 18
TI  - Aspirin use and chronic diseases: a cohort study of the elderly.
PG  - 1247-50
AB  - OBJECTIVE: To evaluate the associations between the use of aspirin and the 
      incidences of cardiovascular diseases, cancers, and other chronic diseases. 
      DESIGN: Postal questionnaire survey to elicit details of aspirin use. SETTING: 
      Californian retirement community. SUBJECTS: All 22,781 residents of the community 
      (white, affluent, and well educated) were sent a questionnaire that included 
      questions on medical history and the use of drugs such as analgesics, laxatives, 
      and vitamin supplements. In all 61% responded (13,987, 8881 women and 5106 men; 
      median age 73). They formed the cohort that was followed up for 6 1/2 years using 
      discharge summaries from three hospitals serving the area and death certificates 
      from the health department. Only 13 respondents were lost to follow up but seemed 
      not to have died. MAIN OUTCOME MEASURES: Incidences of cardiovascular diseases, 
      cancers, gastrointestinal bleeding, ulcers, and cataracts were compared in 
      participants who did and did not take aspirin daily. RESULTS: Age adjusted 
      incidences were computed with an internal standard and five age groups. By 1 
      January 1988 there had been 25 incident cases of kidney cancer among all 
      participants; 341 incident cases of stroke, 253 of acute myocardial infarction, 
      220 of ischaemic heart disease, and 317 of other heart disease were reported 
      among respondents without a reported history of angina, myocardial infarction, or 
      stroke. The incidence of kidney cancer was raised among those who took aspirin 
      daily compared with those who did not take it, although the increase was 
      significant only in men (relative risks = 6.3, 95% confidence interval 2.2 to 17, 
      for men and 2.1, 0.53 to 8.5, for women). Those who took aspirin daily showed no 
      increased risk of any other cancer, except colon cancer for both sexes combined 
      (relative risk = 1.5, 1.1 to 2.2). The risk of acute myocardial infarction was 
      reduced slightly among regular users of aspirin in men but not women. The risk of 
      ischaemic heart disease was almost doubled in those who took aspirin daily 
      compared with non-users (relative risks = 1.9, 1.1 to 3.1, for men and 1.7, 1.1 
      to 2.7, for women). Small, non-significant increased risks of stroke were 
      observed in both sexes. CONCLUSION: The daily use of aspirin increased the risk 
      of kidney cancer and ischaemic heart disease.
FAU - Paganini-Hill, A
AU  - Paganini-Hill A
AD  - Department of Preventive Medicine, University of Southern California School of 
      Medicine, Los Angeles 90033-0800.
FAU - Chao, A
AU  - Chao A
FAU - Ross, R K
AU  - Ross RK
FAU - Henderson, B E
AU  - Henderson BE
LA  - eng
GR  - CA17054/CA/NCI NIH HHS/United States
GR  - CA32197/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 1990 Jan 13;300(6717):116-8. PMID: 2105756
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/therapeutic use
MH  - California/epidemiology
MH  - Cataract/epidemiology
MH  - Chronic Disease
MH  - Cohort Studies
MH  - Coronary Disease/*chemically induced
MH  - Female
MH  - Gastrointestinal Hemorrhage/epidemiology
MH  - Humans
MH  - Kidney Neoplasms/*chemically induced
MH  - Male
MH  - Myocardial Infarction/epidemiology
MH  - Peptic Ulcer/epidemiology
MH  - Retirement
MH  - Risk
PMC - PMC1838122
EDAT- 1989/11/18 00:00
MHDA- 1989/11/18 00:01
CRDT- 1989/11/18 00:00
PHST- 1989/11/18 00:00 [pubmed]
PHST- 1989/11/18 00:01 [medline]
PHST- 1989/11/18 00:00 [entrez]
AID - 10.1136/bmj.299.6710.1247 [doi]
PST - ppublish
SO  - BMJ. 1989 Nov 18;299(6710):1247-50. doi: 10.1136/bmj.299.6710.1247.

PMID- 17340471
OWN - NLM
STAT- MEDLINE
DCOM- 20070530
LR  - 20151119
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 33
IP  - 2
DP  - 2007 Mar
TI  - Aspirin resistance: does it exist?
PG  - 210-4
AB  - Aspirin irreversibly inhibits platelet cyclooxygenase-1 (COX-1). Aspirin 
      sensitivity can be measured easily by its inhibition of arachidonic acid (AA) 
      -induced platelet aggregation. Aspirin resistance has to be defined by its 
      inability to inhibit COX-1. By using this definition, aspirin resistance very 
      likely does not exist. A specific rapid laboratory test using either AA-induced 
      platelet aggregation or AA-induced malondialdehyde production in platelet-rich 
      plasma is needed to test aspirin sensitivity. The reports on so-called aspirin 
      resistance are usually due to noncompliance of aspirin intake or consumption of 
      inadequate doses of aspirin. In addition, data generated from using nonspecific 
      platelet function tests have added confusion to this observed phenomenon of 
      aspirin resistance.
FAU - Rao, Gundu H R
AU  - Rao GH
AD  - Laboratory Medicine & Pathology, Lillehei Heart Institute, University of 
      Minnesota, Minneapolis, Minnesota, USA.
FAU - Michiels, Jan Jaques
AU  - Michiels JJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 27YG812J1I (Arachidonic Acid)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid
MH  - Aspirin/*pharmacokinetics
MH  - Clinical Laboratory Techniques/standards
MH  - Cyclooxygenase 1/drug effects
MH  - Diagnostic Errors/prevention & control
MH  - *Drug Resistance
MH  - Humans
RF  - 21
EDAT- 2007/03/07 09:00
MHDA- 2007/05/31 09:00
CRDT- 2007/03/07 09:00
PHST- 2007/03/07 09:00 [pubmed]
PHST- 2007/05/31 09:00 [medline]
PHST- 2007/03/07 09:00 [entrez]
AID - 10.1055/s-2007-969036 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2007 Mar;33(2):210-4. doi: 10.1055/s-2007-969036.

PMID- 27400191
OWN - NLM
STAT- MEDLINE
DCOM- 20170829
LR  - 20170829
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 220
DP  - 2016 Oct 1
TI  - Optimal duration of dual antiplatelet therapy after drug-eluting stent 
      implantation: Meta-analysis of randomized controlled trials.
PG  - 895-900
LID - S0167-5273(16)31076-2 [pii]
LID - 10.1016/j.ijcard.2016.06.070 [doi]
AB  - OBJECTIVE: After implantation of drug-eluting stents (DES), patients usually 
      receive 6-12months of dual antiplatelet therapy (DAPT). However, the optimal 
      duration of DAPT is controversial. Therefore, we performed a meta-analysis of 
      randomized controlled trials to assess the risks and benefits of different DAPT 
      durations. METHODS: We searched the literature using MEDLINE, Scopus, EMBASE, ISI 
      Web of Science, Cochrane Library, ClinicalTrials.gov and recent conference 
      proceedings, and included those trials randomizing patients to receive different 
      durations of DAPT after DES implantation and reporting frequencies of 
      cardiovascular and bleeding events. Data from eleven trials were analyzed using 
      RevMan. RESULTS: Compared to 12-month DAPT treatment, extended DAPT significantly 
      reduced the frequencies of myocardial infarction (OR 0.54 95% CI: 0.43-0.66; 
      p<0.00001) and stent thrombosis (OR 0.36 95% CI: 0.24-0.55; p<0.00001), but the 
      risks of major bleeding (OR 1.54 95% CI 1.22-1.96) and all-cause mortality (OR 
      1.43 95% CI 1.14-1.81) were substantially increased. There was no significant 
      difference in stroke, cardiovascular mortality or repeat revascularization. 
      Compared to short-term DAPT, 12-month DAPT or longer was associated with 
      increased major bleeds (OR 1.98 95% CI: 1.26-3.11). No significant differences 
      were found in the risk of other primary outcomes. CONCLUSION: 12-month DAPT 
      appears to be a pragmatic compromise between preventing stent thrombosis and 
      increasing bleeding risk. Patients at high bleeding risk should have shorter 
      duration DAPT while those with low bleeding risk can be considered for DAPT 
      beyond 12months.
CI  - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Fei, Yue
AU  - Fei Y
AD  - Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The 
      University of Hong Kong, Pokfulam, Hong Kong, China.
FAU - Tsoi, Man Fung
AU  - Tsoi MF
AD  - Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The 
      University of Hong Kong, Pokfulam, Hong Kong, China.
FAU - Cheung, Tommy Tsang
AU  - Cheung TT
AD  - Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The 
      University of Hong Kong, Pokfulam, Hong Kong, China; Partner State Key Laboratory 
      of Pharmaceutical Biotechnology, The University of Hong Kong, Pokfulam, Hong 
      Kong, China.
FAU - Cheung, Bernard Man Yung
AU  - Cheung BM
AD  - Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The 
      University of Hong Kong, Pokfulam, Hong Kong, China; Partner State Key Laboratory 
      of Pharmaceutical Biotechnology, The University of Hong Kong, Pokfulam, Hong 
      Kong, China; Research Centre of Heart, Brain, Hormone and Healthy Aging, The 
      University of Hong Kong, Pokfulam, Hong Kong, China; Institute of Cardiovascular 
      Science and Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China. 
      Electronic address: mycheung@hku.hk.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20160623
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Drug-Eluting Stents/adverse effects/*trends
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - *Randomized Controlled Trials as Topic/methods
MH  - Time Factors
OTO - NOTNLM
OT  - Bleeding
OT  - Drug-eluting stent
OT  - Dual antiplatelet therapy
OT  - Meta-analysis
EDAT- 2016/07/12 06:00
MHDA- 2017/08/30 06:00
CRDT- 2016/07/12 06:00
PHST- 2016/04/25 00:00 [received]
PHST- 2016/06/21 00:00 [accepted]
PHST- 2016/07/12 06:00 [entrez]
PHST- 2016/07/12 06:00 [pubmed]
PHST- 2017/08/30 06:00 [medline]
AID - S0167-5273(16)31076-2 [pii]
AID - 10.1016/j.ijcard.2016.06.070 [doi]
PST - ppublish
SO  - Int J Cardiol. 2016 Oct 1;220:895-900. doi: 10.1016/j.ijcard.2016.06.070. Epub 
      2016 Jun 23.

PMID- 32027781
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2162-3279 (Electronic)
VI  - 10
IP  - 3
DP  - 2020 Mar
TI  - Association of aspirin resistance with 4-hydroxynonenal and its impact on 
      recurrent cerebral infarction in patients with acute cerebral infarction.
PG  - e01562
LID - 10.1002/brb3.1562 [doi]
LID - e01562
AB  - OBJECTIVES: To investigate the association of aspirin resistance (AR) with the 
      plasma 4-hydroxynonenal (4-HNE) level and its impact on recurrent cerebral 
      infarction (CI) in patients with acute cerebral infarction (ACI) who were 
      receiving aspirin therapy. METHODS: One hundred and fifty-four ACI patients who 
      previously received aspirin therapy (100 mg/day) were enrolled. Whole urine (for 
      measuring 11dhTXB2 and creatinine) along with blood (for measuring the plasma 
      4-HNE level) were collected at least 7 days after the patients received aspirin. 
      A cutoff of 1500 pg/mg of 11dhTXB2/ creatinine was used to determine AR. A 
      follow-up period to monitor recurrence CI events was 1 year. In addition, blood 
      testing was performed when the patients were first admitted to hospital. RESULTS: 
      Forty-six of the 154 enrolled patients (29.9%) were found to be AR. No 
      statistical difference in age, sex, hypertension, diabetes mellitus, coronary 
      disease, smoking status, NIHSS score, TOAST classification, platelet count, 
      thrombocytocrit, LDL-C, HDL-C, TG, and TC was found between the AR and 
      aspirin-sensitive (AS) patients, but the plasma 4-HNE level was found to be 
      higher in the AR patients than AS patients (p < .05). Multiple logistic 
      regression analysis showed that the 4-HNE level was associated with a higher risk 
      of AR (OR = 1.034; 95% CI = 1.011-1.058; p < .05). Moreover, 1-year follow-up 
      showed that AR was more prevalent in patients with recurrent CI (26 (56.6%)) than 
      those without (20/(43.5%)) (p < .001). CONCLUSIONS: The plasma 4-HNE level is 
      strongly associated with AR and thus may be a factor contributing to AR. Patients 
      with AR have a greater risk of recurrence CI.
CI  - © 2020 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.
FAU - Guo, Juan
AU  - Guo J
AUID- ORCID: 0000-0002-9665-3449
AD  - Department of Neurology, Shengjing Hospital, China Medical University, Shenyang, 
      China.
FAU - Wang, Jue
AU  - Wang J
AD  - Department of Neurology, Shengjing Hospital, China Medical University, Shenyang, 
      China.
FAU - Guo, Yanxia
AU  - Guo Y
AD  - Department of Neurology, Shengjing Hospital, China Medical University, Shenyang, 
      China.
FAU - Feng, Juan
AU  - Feng J
AUID- ORCID: 0000-0002-1815-7036
AD  - Department of Neurology, Shengjing Hospital, China Medical University, Shenyang, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20200206
PL  - United States
TA  - Brain Behav
JT  - Brain and behavior
JID - 101570837
RN  - 0 (Aldehydes)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - K1CVM13F96 (4-hydroxy-2-nonenal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aldehydes/*blood
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cerebral Infarction/*blood/drug therapy
MH  - Drug Resistance/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Recurrence
PMC - PMC7066347
OTO - NOTNLM
OT  - 4-hydroxynonenal
OT  - acute cerebral infarction
OT  - aspirin resistance
OT  - recurrent cerebral infarction
COIS- None declared.
EDAT- 2020/02/07 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/02/07 06:00
PHST- 2019/05/14 00:00 [received]
PHST- 2020/01/07 00:00 [revised]
PHST- 2020/01/09 00:00 [accepted]
PHST- 2020/02/07 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
PHST- 2020/02/07 06:00 [entrez]
AID - BRB31562 [pii]
AID - 10.1002/brb3.1562 [doi]
PST - ppublish
SO  - Brain Behav. 2020 Mar;10(3):e01562. doi: 10.1002/brb3.1562. Epub 2020 Feb 6.

PMID- 29329092
OWN - NLM
STAT- MEDLINE
DCOM- 20180305
LR  - 20220318
IS  - 1873-376X (Electronic)
IS  - 1570-0232 (Linking)
VI  - 1074-1075
DP  - 2018 Feb 1
TI  - Effect of aspirin on the pharmacokinetics and absorption of panax notoginseng 
      saponins.
PG  - 25-33
LID - S1570-0232(17)31473-3 [pii]
LID - 10.1016/j.jchromb.2017.12.033 [doi]
AB  - BACKGROUND: Panax notoginseng saponins, a traditional Chinese medicine 
      extraction, and aspirin are both widely used to treat cerebral infarction in 
      China. Good results in clinical practice have been achieved, when Panax 
      notoginseng saponins was taken together with aspirin. METHODS: To investigate the 
      interaction of the two drugs in vivo, the concentration of notoginsenoside R(1), 
      ginsenoside Rg(1), Rb(1), Re and Rd. in blood were simultaneously measured by 
      UPLC/MS/MS. Sample preparation was carried out by the protein precipitation 
      technique with an internal standard saikosaponin A standard. The separation of 
      six components was achieved by using an ACQUITY UPLC ®BEH C18 column (1.7μm 
      2.1×100mm) by gradient elution using water (containing 0.2% formic acid) and 
      acetonitrile (containing 0.2% formic acid) as the mobile phase at a flow rate of 
      0.2mL/min. The pharmacokinetic parameters were determined using non-compartmental 
      analysis. The transport of notoginsenoside R(1), ginsenoside Rg(1), Rb(1), Re and 
      Rd. in MDCK -MDR1 cell monolayer was also used to verify the conclusion of 
      pharmacokinetic drug-drug interaction and study the mechanism of drug 
      interaction. RESULTS: The concentrations of the five components increased in a 
      certain extent when the two drugs administered together in rats. The values of 
      apparent permeability coefficients were significantly increased when the two 
      drugs were used together. Aspirin and salicylic acid could destroy the tight 
      junction protein and open the intercellular space to increase the absorption of 
      Panax notoginseng saponins. CONCLUSION: Pharmacokinetic drug-drug interaction in 
      vivo existed between Panax notoginseng saponins and aspirin. The drug-drug 
      interaction mainly occurred in the process of absorption.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Tian, Zhihao
AU  - Tian Z
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6#, 
      WangjingZhonghuanNanlu, Chaoyang District, Beijing 100102, China; School of 
      Pharmaceutical Science, Tsinghua University, Shuangqinglu, Beijing, China.
FAU - Pang, Huanhuan
AU  - Pang H
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6#, 
      WangjingZhonghuanNanlu, Chaoyang District, Beijing 100102, China; School of 
      Pharmaceutical Science, Tsinghua University, Shuangqinglu, Beijing, China.
FAU - Zhang, Qiang
AU  - Zhang Q
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6#, 
      WangjingZhonghuanNanlu, Chaoyang District, Beijing 100102, China; School of 
      Pharmaceutical Science, Tsinghua University, Shuangqinglu, Beijing, China.
FAU - Du, Shouying
AU  - Du S
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6#, 
      WangjingZhonghuanNanlu, Chaoyang District, Beijing 100102, China; School of 
      Pharmaceutical Science, Tsinghua University, Shuangqinglu, Beijing, China. 
      Electronic address: dumenzidi123@163.com.
FAU - Lu, Yang
AU  - Lu Y
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6#, 
      WangjingZhonghuanNanlu, Chaoyang District, Beijing 100102, China; School of 
      Pharmaceutical Science, Tsinghua University, Shuangqinglu, Beijing, China. 
      Electronic address: landocean28@163.com.
FAU - Zhang, Lin
AU  - Zhang L
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6#, 
      WangjingZhonghuanNanlu, Chaoyang District, Beijing 100102, China; School of 
      Pharmaceutical Science, Tsinghua University, Shuangqinglu, Beijing, China.
FAU - Bai, Jie
AU  - Bai J
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6#, 
      WangjingZhonghuanNanlu, Chaoyang District, Beijing 100102, China; School of 
      Pharmaceutical Science, Tsinghua University, Shuangqinglu, Beijing, China.
FAU - Li, Pengyue
AU  - Li P
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6#, 
      WangjingZhonghuanNanlu, Chaoyang District, Beijing 100102, China; School of 
      Pharmaceutical Science, Tsinghua University, Shuangqinglu, Beijing, China.
FAU - Li, Danqi
AU  - Li D
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6#, 
      WangjingZhonghuanNanlu, Chaoyang District, Beijing 100102, China; School of 
      Pharmaceutical Science, Tsinghua University, Shuangqinglu, Beijing, China.
FAU - Zhao, Mengdi
AU  - Zhao M
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6#, 
      WangjingZhonghuanNanlu, Chaoyang District, Beijing 100102, China; School of 
      Pharmaceutical Science, Tsinghua University, Shuangqinglu, Beijing, China.
FAU - Chen, Xiaonan
AU  - Chen X
AD  - School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6#, 
      WangjingZhonghuanNanlu, Chaoyang District, Beijing 100102, China; School of 
      Pharmaceutical Science, Tsinghua University, Shuangqinglu, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20180102
PL  - Netherlands
TA  - J Chromatogr B Analyt Technol Biomed Life Sci
JT  - Journal of chromatography. B, Analytical technologies in the biomedical and life 
      sciences
JID - 101139554
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Saponins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacokinetics/pharmacology
MH  - Cell Membrane/drug effects
MH  - Dogs
MH  - Drugs, Chinese Herbal/*pharmacokinetics/pharmacology
MH  - Herb-Drug Interactions
MH  - Limit of Detection
MH  - Linear Models
MH  - Madin Darby Canine Kidney Cells
MH  - Panax notoginseng/*chemistry
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reproducibility of Results
MH  - Saponins/*blood/chemistry/*pharmacokinetics/pharmacology
OTO - NOTNLM
OT  - Aspirin
OT  - Drug-drug interaction
OT  - Panax notoginseng saponins
OT  - Pharmacokinetic
OT  - Transport
EDAT- 2018/01/13 06:00
MHDA- 2018/03/06 06:00
CRDT- 2018/01/13 06:00
PHST- 2017/08/26 00:00 [received]
PHST- 2017/11/12 00:00 [revised]
PHST- 2017/12/25 00:00 [accepted]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/03/06 06:00 [medline]
PHST- 2018/01/13 06:00 [entrez]
AID - S1570-0232(17)31473-3 [pii]
AID - 10.1016/j.jchromb.2017.12.033 [doi]
PST - ppublish
SO  - J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Feb 1;1074-1075:25-33. doi: 
      10.1016/j.jchromb.2017.12.033. Epub 2018 Jan 2.

PMID- 7338950
OWN - NLM
STAT- MEDLINE
DCOM- 19820624
LR  - 20131121
IS  - 0098-4108 (Print)
IS  - 0098-4108 (Linking)
VI  - 8
IP  - 5-6
DP  - 1981 Nov-Dec
TI  - Enhancement of experimental atherosclerosis by aspirin.
PG  - 899-906
AB  - The effect of aspirin on experimentally induced atherosclerosis was studied in 
      rabbits. Rabbits were placed on an atherogenic diet containing either no aspirin 
      or 0.2% aspirin supplement. Control rabbits were fed regular rabbit food or 
      rabbit food supplemented with 0.2% aspirin. Ingestion of aspirin from the diets 
      containing aspirin was equivalent to a daily dose of 100 mg/kg. As expected, 2 mo 
      after the rabbits were placed on the atherogenic diet, extensive atheromatous 
      lesions were observed on gross examination sporadically distributed along the 
      walls of the aorta. The coronary arteries also exhibited atheromatous lesions on 
      microscopic examination. Addition of aspirin to the atherogenic diet intensified 
      the atherosclerosis as measured by proliferation of the intima of the aorta and 
      coronary arteries and increased occurrence and distribution of atheromatous 
      plaques. It is concluded that, under the conditions of this experiment, the 
      addition of aspirin to an atherogenic diet greatly intensified atherogenesis.
FAU - Debons, A F
AU  - Debons AF
FAU - Fani, K
AU  - Fani K
FAU - Jimenez, F A
AU  - Jimenez FA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Toxicol Environ Health
JT  - Journal of toxicology and environmental health
JID - 7513622
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta/pathology
MH  - Arteriosclerosis/*pathology
MH  - Aspirin/*adverse effects
MH  - Coronary Vessels/pathology
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
EDAT- 1981/11/01 00:00
MHDA- 1981/11/01 00:01
CRDT- 1981/11/01 00:00
PHST- 1981/11/01 00:00 [pubmed]
PHST- 1981/11/01 00:01 [medline]
PHST- 1981/11/01 00:00 [entrez]
AID - 10.1080/15287398109530124 [doi]
PST - ppublish
SO  - J Toxicol Environ Health. 1981 Nov-Dec;8(5-6):899-906. doi: 
      10.1080/15287398109530124.

PMID- 28244660
OWN - NLM
STAT- MEDLINE
DCOM- 20170810
LR  - 20170810
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 32 Suppl 1
DP  - 2017 Mar
TI  - Bioactive food chemicals and gastrointestinal symptoms: a focus of salicylates.
PG  - 73-77
LID - 10.1111/jgh.13702 [doi]
AB  - Bioactive food chemicals are substances present in food that are capable of 
      interacting with living cells causing changes in physiological functions. 
      Salicylic acid (SA), a plant hormone involved in plant immune response, is one 
      such bioactive food chemical. Aspirin, a commercially available SA, might play 
      beneficial roles in cardiovascular health and colon cancer. It may also cause 
      urticaria, angioedema, asthma, and gastrointestinal symptoms in SA-sensitive 
      individuals. Dietary SA might exert similar beneficial effects and/or may induce 
      similar symptoms in hypersensitive individuals. Food-related SA sensitivity in 
      relation to gastrointestinal symptoms is not well documented besides a few 
      self-reported questionnaires and the knowledge that low doses of aspirin 
      (equivalent of high dietary intake) can cause gastrointestinal injury. The only 
      direct evidence that suggests benefits of reducing dietary SA was reported in 
      asthmatic individuals. Although SA sensitivity in relation to gut symptoms in 
      susceptible individuals is accepted by clinicians, the detection of this disease 
      remains a challenge because of the complicated nature of dietary challenges and 
      the risk of oral aspirin provocation tests in patients with severe 
      hypersensitivity reactions. Given the non-IgE mediated nature of the disease, in 
      vitro assays like basophil activation may have failed to produce reliable 
      results. However, given the simplicity of this assay, further studies need to be 
      formulated to firmly establish its reliability. Formulation of proper dietary 
      strategies for symptom control is also impossible given the controversial and 
      scant nature of the data on SA content of food. This issue needs to be resolved 
      to formulate proper dietary strategies for effective symptom control.
CI  - © 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & 
      Sons Australia, Ltd.
FAU - Malakar, Sreepurna
AU  - Malakar S
AD  - Department of Gastroenterology, Monash University and Alfred Hospital, Melbourne, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - Basophils
MH  - Food Analysis
MH  - Food Hypersensitivity/etiology/prevention & control
MH  - Gastrointestinal Diseases/*etiology/*prevention & control
MH  - Humans
MH  - Immunologic Tests
MH  - Irritable Bowel Syndrome/*etiology/*prevention & control
MH  - Salicylic Acid/*adverse effects/analysis
OTO - NOTNLM
OT  - aspirin
OT  - basophil activation test
OT  - dietary therapy
OT  - food composition
OT  - food hypersensitivity
OT  - irritable bowel syndrome
EDAT- 2017/03/01 06:00
MHDA- 2017/08/11 06:00
CRDT- 2017/03/01 06:00
PHST- 2016/11/28 00:00 [accepted]
PHST- 2017/03/01 06:00 [entrez]
PHST- 2017/03/01 06:00 [pubmed]
PHST- 2017/08/11 06:00 [medline]
AID - 10.1111/jgh.13702 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:73-77. doi: 10.1111/jgh.13702.

PMID- 30217228
OWN - NLM
STAT- MEDLINE
DCOM- 20190123
LR  - 20190123
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 19
IP  - 1
DP  - 2018 Sep 14
TI  - Research on the mechanism of drug-drug interaction between salvianolate injection 
      and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a 
      PK-PD trial.
PG  - 491
LID - 10.1186/s13063-018-2861-7 [doi]
LID - 491
AB  - BACKGROUND: Coronary heart disease (CHD) is a common cardiovascular disease 
      accounting for 10-20% mortality by heart disease worldwide. The gold standard 
      treatment to manage CHD is aspirin, which may prevent myocardial infarction and 
      sudden death; however, long-term use of aspirin may increase its side effects. 
      Currently, more and more clinicians are exploring different approaches to use the 
      right combination of medicine to enhance the efficacy and reduce side effects. 
      Salvianolate can significantly inhibit the aggregation and activation of 
      platelets in patients with CHD; however, its optimum combination with western 
      medicine is not established or supported by clinical trial results. 
      METHODS/DESIGN: This trial is a prospectively planned, open-labeled, 
      parallel-grouped, single-centered clinical trial with aggregated 
      pharmacodynamics-pharmacokinetics (PK-PD) data. All treatment courses will last 
      for 10 days and blood sample will be acquired before administration on days 8, 9, 
      and 10, and after administration at 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 
      8 h, 12 h, and 24 h on day 10. This trial uses PK-PD modeling to provide a 
      description of the concentration-effect relationship and an estimate of 
      pharmacological potency of the medicine. The primary outcome will be changes in 
      aspirin esterase and catechol-o-methyltransferase (COMT) activity at different 
      blood concentrations to determine the PK-PD characteristics of the combination of 
      salvianolate and aspirin, followed by analysis of the correlation between 
      exposure level and pharmacodynamic index of the medicines. DISCUSSION: This trial 
      will aim to evaluate the relationship between changes in the pharmacokinetics and 
      therapeutic effect index in the combined use of salvianolate and aspirin. It also 
      discusses the possible mechanism of medicine combination in the treatment for CHD 
      and provides an experimental basis for a clinically rational medicine 
      combination. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03306550 . Registered on 
      9 October 2017. ClinicalTrials.gov 
      https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0007D8H&selectaction=Edit&uid=U0003QY8&ts=2&cx=oiuc9g.
FAU - Zhang, Wantong
AU  - Zhang W
AD  - China Academy of Chinese Medicine Science, Xiyuan Hospital, Beijing, 100091, 
      China.
FAU - Zhu, Baochen
AU  - Zhu B
AD  - Beijing University of Traditional Chinese Medicine, Beijing, 100029, China.
FAU - Cao, Weiyi
AU  - Cao W
AD  - China Academy of Chinese Medicine Science, Xiyuan Hospital, Beijing, 100091, 
      China.
FAU - Li, Rui
AU  - Li R
AD  - China Academy of Chinese Medicine Science, Xiyuan Hospital, Beijing, 100091, 
      China. crystal005@163.com.
FAU - Wang, Shuge
AU  - Wang S
AD  - China Academy of Chinese Medicine Science, Xiyuan Hospital, Beijing, 100091, 
      China. dushu2001@126.com.
FAU - Gao, Rui
AU  - Gao R
AD  - China Academy of Chinese Medicine Science, Xiyuan Hospital, Beijing, 100091, 
      China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03306550
GR  - zz0908022/Xiyuan Hospital of China Academy of Chinese Medical Sciences/
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20180914
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Plant Extracts)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (salvianolate)
RN  - EC 2.1.1.6 (COMT protein, human)
RN  - EC 2.1.1.6 (Catechol O-Methyltransferase)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.- (acetylsalicylic acid hydrolase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/blood/*pharmacokinetics
MH  - Carboxylic Ester Hydrolases/*blood
MH  - Catechol O-Methyltransferase/*blood
MH  - China
MH  - Coronary Disease/blood/diagnosis/*drug therapy
MH  - Drug Monitoring
MH  - Drug Therapy, Combination
MH  - Female
MH  - *Herb-Drug Interactions
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - *Models, Biological
MH  - Plant Extracts/administration & dosage/adverse effects/blood/*pharmacokinetics
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/blood/*pharmacokinetics
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC6137745
OTO - NOTNLM
OT  - CHD
OT  - Drug–drug interactions
OT  - Medicine combination
OT  - Metabolic enzymes
OT  - PK-PD
OT  - Salvianolate
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Institutional ethics approval for the 
      trial was obtained from the Ethics Committee of Xiyuan Hospital. Informed consent 
      will be obtained from all participants by one of the clinical investigators. 
      Study investigators and treating physicians will be the guarantors of data 
      confidentiality for the participants in each trial, according to the privacy 
      rules of clinical practice. Patients will be asked for permission for data 
      analysis conducted anonymously for research purposes. All study investigators 
      will have access to the final trial dataset. Trial results will be disseminated 
      via publication and study participants will be informed directly. CONSENT FOR 
      PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they 
      have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral 
      with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2018/09/16 06:00
MHDA- 2019/01/24 06:00
CRDT- 2018/09/16 06:00
PHST- 2017/12/04 00:00 [received]
PHST- 2018/08/16 00:00 [accepted]
PHST- 2018/09/16 06:00 [entrez]
PHST- 2018/09/16 06:00 [pubmed]
PHST- 2019/01/24 06:00 [medline]
AID - 10.1186/s13063-018-2861-7 [pii]
AID - 2861 [pii]
AID - 10.1186/s13063-018-2861-7 [doi]
PST - epublish
SO  - Trials. 2018 Sep 14;19(1):491. doi: 10.1186/s13063-018-2861-7.

PMID- 31347430
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210110
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 8
IP  - 15
DP  - 2019 Aug 6
TI  - Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients 
      Within 48 Hours of Symptom Onset.
PG  - e012652
LID - 10.1161/JAHA.119.012652 [doi]
LID - e012652
AB  - Background The aim of the present study was to investigate the efficacy and 
      safety of antiplatelet (aspirin plus cilostazol) dual therapy for patients with 
      noncardioembolic stroke within 48 hours of symptom onset. Methods and Results The 
      ADS (Acute Aspirin Plus Cilostazol Dual Therapy for Non-Cardiogenic Stroke 
      Patients Within 48 Hours of Symptom Onset ) study is an investigator-initiated, 
      prospective, multicenter (34 hospitals in Japan), randomized, open-label, and 
      aspirin-controlled trial. Acute stroke patients with noncardioembolic stroke 
      within 48 hours of onset were studied. The subjects were randomly allocated to 
      combination therapy with aspirin 81 to 200 mg plus cilostazol 200 mg (dual group) 
      and single therapy with aspirin 81 to 200 mg (aspirin group) for 14 days. After 
      the 14 days, all patients took the cilostazol 200 mg for 3 months. A primary 
      efficacy outcome was defined as any one of the following occurring (neurological 
      deterioration, symptomatic stroke recurrence, or transient ischemic attack) 
      within 14 days. A primary safety outcome included intracerebral hemorrhage and 
      subarachnoid hemorrhage. Between May 2011 and June 2017, 1201 patients (796 [66%] 
      men; median age, 69 [61-77] years) randomized 1:1 to either the dual group or the 
      aspirin group were analyzed. Initial National Institutes of Health Stroke Scale 
      score was 2 (1-4) in both groups (P=0.830). A primary efficacy outcome was 
      observed in 11% in the dual group and 11% in the aspirin group (P=0.853). A 
      primary safety outcome occurred in 2 (0.3%) in the dual group and in 1 (0.2%) in 
      the aspirin group (P=0.624). Conclusions Dual antiplatelet therapy using 
      cilostazol and aspirin was safe but did not reduce the rate of short-term 
      neurological worsening. Clinical Trial Registration URL: 
      umin.ac.jp/ctr/index/htm. Unique identifier: UMIN000004950.
FAU - Aoki, Junya
AU  - Aoki J
AD  - Department of Neurological Science Graduate School of Medicine Nippon Medical 
      School Tokyo Japan.
AD  - Department of Stroke Medicine Kawasaki Medical School Okayama Japan.
FAU - Iguchi, Yasuyuki
AU  - Iguchi Y
AD  - Department of Neurology Jikei University School of Medicine Tokyo Japan.
FAU - Urabe, Takao
AU  - Urabe T
AD  - Department of Neurology Juntendo University Urayasu Hospital Chiba Japan.
FAU - Yamagami, Hiroshi
AU  - Yamagami H
AD  - Department of Neurology, Stroke Center Kobe City Medical Center General Hospital 
      Hyogo Japan.
FAU - Todo, Kenichi
AU  - Todo K
AD  - Department of Neurology, Stroke Center Kobe City Medical Center General Hospital 
      Hyogo Japan.
FAU - Fujimoto, Shigeru
AU  - Fujimoto S
AD  - Department of Cerebrovascular Medicine, Stroke Center Steel Memorial Yawata 
      Hospital Fukuoka Japan.
FAU - Idomari, Koji
AU  - Idomari K
AD  - Department of Stroke Medicine Okinawa Kyodo Hospital Okinawa Japan.
FAU - Kaneko, Nobuyuki
AU  - Kaneko N
AD  - Department of Stroke Medicine Okinawa Kyodo Hospital Okinawa Japan.
FAU - Iwanaga, Takeshi
AU  - Iwanaga T
AD  - Department of Stroke Medicine Okayama Red Cross Hospital Okayama Japan.
FAU - Terasaki, Tadashi
AU  - Terasaki T
AD  - Department of Neurology Japanese Red Cross Kumamoto Hospital Kumamoto Japan.
FAU - Tanaka, Ryota
AU  - Tanaka R
AD  - Department of Neurology Faculty of Medicine Juntendo University Tokyo Japan.
FAU - Yamamoto, Nobuaki
AU  - Yamamoto N
AD  - Department of Clinical Neurosciences Institute of Biomedical Sciences Tokushima 
      University Tokushima Japan.
FAU - Tsujino, Akira
AU  - Tsujino A
AD  - Department of Neurology and Strokology Nagasaki University Hospital Nagasaki 
      Japan.
FAU - Nomura, Koichi
AU  - Nomura K
AD  - Department of Neurology Shioda Hospital Chiba Japan.
FAU - Abe, Koji
AU  - Abe K
AD  - Department of Neurology Okayama University Medical School Okayama Japan.
FAU - Uno, Masaaki
AU  - Uno M
AD  - Department of Neurosurgery Kawasaki Medical School Okayama Japan.
FAU - Okada, Yasushi
AU  - Okada Y
AD  - Department of Cerebrovascular Medicine and Neurology Clinical Research Institute 
      National Hospital Organization Kyushu Medical Center Fukuoka Japan.
FAU - Matsuoka, Hideki
AU  - Matsuoka H
AD  - Department of Cerebrovascular Medicine NHO Kagoshima Medical Center Kagoshima 
      Japan.
FAU - Yamagata, Sen
AU  - Yamagata S
AD  - Department of Neurosurgery Kurashiki Central Hospital Okayama Japan.
FAU - Yamamoto, Yasumasa
AU  - Yamamoto Y
AD  - Department of Neurology Kyoto Second Red Cross Hospital Kyoto Japan.
FAU - Yonehara, Toshiro
AU  - Yonehara T
AD  - Department of Neurology Stroke Center Saiseikai Kumamoto Hospital Kumamoto Japan.
FAU - Inoue, Takeshi
AU  - Inoue T
AD  - Department of Stroke Medicine Kawasaki Medical School General Medical Center 
      Kawasaki Medical School Okayama Japan.
FAU - Yagita, Yoshiki
AU  - Yagita Y
AD  - Department of Stroke Medicine Kawasaki Medical School Okayama Japan.
FAU - Kimura, Kazumi
AU  - Kimura K
AD  - Department of Neurological Science Graduate School of Medicine Nippon Medical 
      School Tokyo Japan.
AD  - Department of Stroke Medicine Kawasaki Medical School Okayama Japan.
CN  - ADS Investigators
LA  - eng
SI  - UMIN-CTR/UMIN000004950
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190726
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cilostazol/*administration & dosage/adverse effects
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Prospective Studies
MH  - Stroke/*drug therapy
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC6761671
OTO - NOTNLM
OT  - antiplatelet drug
OT  - clinical trial
OT  - ischemic stroke
OT  - noncardioembolic stroke
EDAT- 2019/07/28 06:00
MHDA- 2021/01/05 06:00
CRDT- 2019/07/27 06:00
PHST- 2019/07/27 06:00 [entrez]
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - JAH34304 [pii]
AID - 10.1161/JAHA.119.012652 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2019 Aug 6;8(15):e012652. doi: 10.1161/JAHA.119.012652. Epub 
      2019 Jul 26.

PMID- 6614327
OWN - NLM
STAT- MEDLINE
DCOM- 19831008
LR  - 20190627
IS  - 0002-9610 (Print)
IS  - 0002-9610 (Linking)
VI  - 146
IP  - 3
DP  - 1983 Sep
TI  - Polytetrafluoroethylene grafts in the peripheral venous circulation of rabbits.
PG  - 355-9
AB  - We demonstrated by venography that the patency of 3 mm PTFE grafts in the jugular 
      veins of rabbits could be maintained by pretreating the animals with either an 
      anticoagulant (warfarin sodium) or an antiplatelet agent (aspirin, dipyridamole, 
      or both). Examination of the lining of the grafts up to 4 months after grafting 
      by scanning electron microscopy or light microscopy showed that endothelial cells 
      extended across the anastomosis for a short distance and that a neointima lined 
      the remainder of the graft. This lining could hypertrophy to the point of almost 
      occluding the graft unless the drugs were continued.
FAU - Friedman, E W
AU  - Friedman EW
FAU - Hamilton, A J
AU  - Hamilton AJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Surg
JT  - American journal of surgery
JID - 0370473
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Dipyridamole/pharmacology
MH  - Female
MH  - Graft Survival/drug effects
MH  - Jugular Veins/*surgery
MH  - Male
MH  - Polytetrafluoroethylene/*therapeutic use
MH  - Rabbits
MH  - Warfarin/pharmacology
EDAT- 1983/09/01 00:00
MHDA- 1983/09/01 00:01
CRDT- 1983/09/01 00:00
PHST- 1983/09/01 00:00 [pubmed]
PHST- 1983/09/01 00:01 [medline]
PHST- 1983/09/01 00:00 [entrez]
AID - 0002-9610(83)90415-4 [pii]
AID - 10.1016/0002-9610(83)90415-4 [doi]
PST - ppublish
SO  - Am J Surg. 1983 Sep;146(3):355-9. doi: 10.1016/0002-9610(83)90415-4.

PMID- 7017493
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 72
IP  - 7
DP  - 1981 Feb 28
TI  - [Broncaspin in respiratory diseases in pediatrics. Clinical contribution].
PG  - 417-22
AB  - Broncaspin (guacetisal) has been administered rectally to 42 children suffering 
      from inflammatory diseases of the upper and lower airways, most cases being 
      complicated by bronchospasm. Treatment involving a dose of 1-2 suppositories of 
      0.5 g/die up to six years of age, and 2 suppositories/die after the sixth year 
      always produced a good antipyretic and anti-cough effect. The preparation was 
      outstanding for speed of action, local and general tolerance, and the absence of 
      haematological, hepatic or renal side-effects. The new drug is considered to be a 
      valuable instrument for anti-inflammatory and anti-cough treatment in acute 
      diseases of the airways in infancy.
FAU - Mora, P
AU  - Mora P
FAU - Levi, P
AU  - Levi P
FAU - Marostica, G
AU  - Marostica G
LA  - ita
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Il Broncaspin nelle affezioni respiratorie in pediatria. Contributo clinico.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Bronchitis/drug therapy
MH  - Bronchopneumonia/drug therapy
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Cough/drug therapy
MH  - Dyspnea/drug therapy
MH  - Fever/drug therapy
MH  - Humans
MH  - Infant
MH  - Laryngitis/drug therapy
MH  - Pharyngitis/drug therapy
MH  - Respiratory Tract Diseases/*drug therapy
MH  - Tracheitis/drug therapy
EDAT- 1981/02/28 00:00
MHDA- 1981/02/28 00:01
CRDT- 1981/02/28 00:00
PHST- 1981/02/28 00:00 [pubmed]
PHST- 1981/02/28 00:01 [medline]
PHST- 1981/02/28 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1981 Feb 28;72(7):417-22.

PMID- 9493899
OWN - NLM
STAT- MEDLINE
DCOM- 19980415
LR  - 20131121
IS  - 1386-0291 (Print)
IS  - 1386-0291 (Linking)
VI  - 17
IP  - 4
DP  - 1997 Jul-Aug
TI  - Inhibition of shear-induced platelet aggregation by Chinese herbal medicines.
PG  - 315-8
AB  - Shear-induced platelet aggregation (SIPA) plays an important role in vascular 
      diseases. In this study, SIPA was generated by a computerized cone-plate 
      apparatus. Six compounds from Chinese herbal medicine were selected for in vitro 
      and in vivo tests. Rabbit and rat were involved in the tests accordingly. 
      Ligustrazine hydrochloridi appeared to be most effective for inhibition of SIPA. 
      The inhibition rate of SIPA reached 44.2% (p < 0.01) for an in vitro 
      concentration of 1 mg/ml, and 46.1% (p < 0.01) for an in vivo dose of 50 mg/kg.
FAU - Liao, F L
AU  - Liao FL
AD  - Institute of Chinese Materia Medica, China Academy of Traditional Chinese 
      Medicine, Beijing.
FAU - Li, B
AU  - Li B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Rabbits
MH  - Rats
MH  - Rats, Wistar
MH  - Stress, Mechanical
EDAT- 1997/07/01 00:00
MHDA- 1998/03/11 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1998/03/11 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 1997 Jul-Aug;17(4):315-8.

PMID- 1098134
OWN - NLM
STAT- MEDLINE
DCOM- 19751106
LR  - 20131121
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 10
IP  - 5
DP  - 1975
TI  - The effects of acetylsalicylic acid on the human gastric mucosa as revealed by 
      gastrocamera.
PG  - 495-9
AB  - The influence on the gastric mucosa of acetylsalicylic acid (ASA) given as a 
      buffered solution (Bamyl-SR, AB Hässle, Sweden) and as a conventional 
      disintegrating tablet (MagnecylR, ACO, Sweden) has been compared in 7 healthy 
      volunteers, using the gastrocamera technique. The study was performed crossover 
      with randomized treatment periods. The dosage of ASA was 1 g 3 times daily for 3 
      days. Before and after each treatment period gastrocamera examinations were 
      performed. The evaluation of the gastro-camera films was made blindly. It was 
      found that after the ASA-tablets all subjects had multiple and prominent 
      erosions. However, in all subjects the erosive effects on the gastric mucosa were 
      less pronounced with the buffered solution. It was concluded that any person 
      taking conventional ASA-tablets in a dose of 1 g 3 times daily for 3 days runs 
      the risk of developing lesions of the gastric mucosa. This risk is less when ASA 
      is taken in the form of a buffered solution.
FAU - Edmar, D
AU  - Edmar D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Clinical Trials as Topic
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Gastroscopy/methods
MH  - Humans
MH  - Male
MH  - Photography
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol. 1975;10(5):495-9.

PMID- 9805346
OWN - NLM
STAT- MEDLINE
DCOM- 19990111
LR  - 20191102
IS  - 0928-6586 (Print)
IS  - 0928-6586 (Linking)
VI  - 5
IP  - 3
DP  - 1998 Sep
TI  - Low-dose aspirin and risk of cataract and subtypes in a randomized trial of U.S. 
      physicians.
PG  - 133-42
AB  - PURPOSE: To examine whether low-dose aspirin (325 mg on alternate days) reduces 
      the risk of age-related cataract and subtypes. This report extends previous 
      findings, including both subtypes and additional newly identified incident cases 
      since the earlier report. METHODS: All 20,979 participants in the Physicians' 
      Health Study, a randomized trial of aspirin and beta-carotene among U.S. male 
      physicians age 40-84 in 1982, who did not report cataract at baseline were 
      included. Average follow-up was five years. The main outcome measure was 
      incident, age-related cataract responsible for a reduction in best-corrected 
      visual acuity to 20/30 or worse, based on self-report confirmed by medical record 
      review. RESULTS: 501 age-related cataracts were diagnosed during follow-up, 
      including 416 with nuclear sclerosis and 212 with a posterior subcapsular 
      component; 318 cataracts progressed to surgical extraction. Overall, there were 
      245 cataracts in the aspirin group and 256 in the placebo group (relative risk 
      [RR], 0.94; 95% confidence interval [CI], 0.79 to 1.13; P = 0.52). Cataract 
      extractions were 19% less frequent in the aspirin than in the placebo group (RR, 
      0.81; 95% CI, 0.65 to 1.01; P = 0.06). In subgroup analyses of subtypes, aspirin 
      takers had a lower risk of posterior subcapsular cataract (RR, 0.74; 95% CI, 0.57 
      to 0.98; P = 0.03) but not nuclear sclerosis (RR, 0.96; 95% CI, 0.79 to 1.16; P = 
      0.65) cataract. CONCLUSIONS: Overall, these randomized trial data tend to exclude 
      a large benefit of five years of low-dose aspirin therapy on cataract development 
      and extraction. The data are compatible with a modest benefit on cataract 
      extraction for this duration of aspirin therapy. Subgroup analyses raise the 
      possibility of a modest, but potentially important, protective effect of aspirin 
      on posterior subcapsular cataract, a particularly disabling subtype.
FAU - Christen, W G
AU  - Christen WG
AD  - Division of Preventive Medicine, Harvard Medical School, Boston, MA, USA.
FAU - Manson, J E
AU  - Manson JE
FAU - Glynn, R J
AU  - Glynn RJ
FAU - Ajani, U A
AU  - Ajani UA
FAU - Schaumberg, D A
AU  - Schaumberg DA
FAU - Sperduto, R D
AU  - Sperduto RD
FAU - Buring, J E
AU  - Buring JE
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA40360/CA/NCI NIH HHS/United States
GR  - EY06633/EY/NEI NIH HHS/United States
GR  - HL34595/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Ophthalmic Epidemiol
JT  - Ophthalmic epidemiology
JID - 9435674
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cataract/epidemiology/*prevention & control
MH  - Cataract Extraction/statistics & numerical data
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Physicians
MH  - Retrospective Studies
MH  - United States/epidemiology
EDAT- 1998/11/07 00:00
MHDA- 1998/11/07 00:01
CRDT- 1998/11/07 00:00
PHST- 1998/11/07 00:00 [pubmed]
PHST- 1998/11/07 00:01 [medline]
PHST- 1998/11/07 00:00 [entrez]
AID - 10.1076/opep.5.3.133.8368 [doi]
PST - ppublish
SO  - Ophthalmic Epidemiol. 1998 Sep;5(3):133-42. doi: 10.1076/opep.5.3.133.8368.

PMID- 34433896
OWN - NLM
STAT- MEDLINE
DCOM- 20211104
LR  - 20211104
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Aug 25
TI  - Low-dose aspirin confers a survival benefit in patients with pathological 
      advanced-stage oral squamous cell carcinoma.
PG  - 17161
LID - 10.1038/s41598-021-96614-y [doi]
LID - 17161
AB  - Oral squamous cell carcinoma (OSCC) remains one of the most challenging clinical 
      problems in the field due to its high rate of locoregional and distant 
      metastases. However, studies that assess the association between aspirin use and 
      survival in patients with OSCC are limited. Moreover, patients that recruited 
      from those studies might have tumors that arose from different anatomic regions 
      of the head and neck, including the oral cavity, oropharynx, etc. Since tumors 
      within these distinct anatomic regions are unique in the context of epidemiology 
      and tumor progression, we sought to evaluate the association of aspirin use with 
      squamous cell carcinomas located within the oral cavity only. In this 10-year 
      cohort study, we evaluated aspirin use and survival rates in relation to clinical 
      characteristics as well as duration of aspirin use in patients with OSCC. Our 
      findings suggest that OSCC patients with aspirin use for more than 180 days 
      showed improved overall and disease-specific survival rates. Aspirin also 
      improves survival in patients across various stages of OSCC. Cox regression 
      models indicated that aspirin use was associated with a good prognosis. In 
      conclusion, this evidence indicates that aspirin may be potentially used as an 
      adjuvant therapy for OSCC.
CI  - © 2021. The Author(s).
FAU - Luo, Sheng-Dean
AU  - Luo SD
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung, 833, Taiwan.
AD  - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung 
      University, No. 259, Wenhua 1st Rd., Guishan District, Taoyüan, 333, Taiwan.
FAU - Wu, Shao-Chun
AU  - Wu SC
AD  - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung 
      University, No. 259, Wenhua 1st Rd., Guishan District, Taoyüan, 333, Taiwan.
AD  - Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung, 833, Taiwan.
FAU - Chen, Wei-Chih
AU  - Chen WC
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung, 833, Taiwan.
FAU - Wu, Ching-Nung
AU  - Wu CN
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Kaohsiung, 833, Taiwan.
FAU - Chiu, Tai-Jan
AU  - Chiu TJ
AD  - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung 
      University, No. 259, Wenhua 1st Rd., Guishan District, Taoyüan, 333, Taiwan.
AD  - Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and 
      Chang Gung University College of Medicine, Kaohsiung, 833, Taiwan.
FAU - Yang, Yao-Hsu
AU  - Yang YH
AD  - Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Chiayi, 
      Taiwan.
AD  - Health Information and Epidemiology Laboratory of Chang Gung Memorial Hospital, 
      Chiayi, Taiwan.
AD  - School of Traditional Chinese Medicine, College of Medicine, Chang Gung 
      University, Taoyüan, Taiwan.
FAU - Li, Shau-Hsuan
AU  - Li SH
AD  - Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and 
      Chang Gung University College of Medicine, Kaohsiung, 833, Taiwan.
FAU - Fang, Fu-Min
AU  - Fang FM
AD  - Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and 
      Chang Gung University College of Medicine, Kaohsiung, Taiwan.
FAU - Huang, Tai-Lin
AU  - Huang TL
AD  - Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and 
      Chang Gung University College of Medicine, Kaohsiung, 833, Taiwan.
FAU - Hsiao, Chang-Chun
AU  - Hsiao CC
AD  - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung 
      University, No. 259, Wenhua 1st Rd., Guishan District, Taoyüan, 333, Taiwan. 
      cchsiao@mail.cgu.edu.tw.
AD  - Division of Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial 
      Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan. 
      cchsiao@mail.cgu.edu.tw.
FAU - Chen, Chang-Han
AU  - Chen CH
AD  - Department of Applied Chemistry, and Graduate Institute of Biomedicine and 
      Biomedical Technology, National Chi Nan University, Nantou, 54561, Taiwan. 
      chench7@gmail.com.
AD  - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. 
      chench7@gmail.com.
AD  - Department of Medical Research, Chung Shan Medical University Hospital, Taichung 
      City, 40201, Taiwan. chench7@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210825
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Carcinoma, Squamous Cell/complications/*epidemiology/pathology
MH  - Cardiovascular Diseases/complications/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mouth Neoplasms/complications/*epidemiology/pathology
MH  - Neoplasm Staging
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Survival Analysis
PMC - PMC8387371
COIS- The authors declare no competing interests.
EDAT- 2021/08/27 06:00
MHDA- 2021/11/05 06:00
CRDT- 2021/08/26 06:02
PHST- 2021/01/31 00:00 [received]
PHST- 2021/08/12 00:00 [accepted]
PHST- 2021/08/26 06:02 [entrez]
PHST- 2021/08/27 06:00 [pubmed]
PHST- 2021/11/05 06:00 [medline]
AID - 10.1038/s41598-021-96614-y [pii]
AID - 96614 [pii]
AID - 10.1038/s41598-021-96614-y [doi]
PST - epublish
SO  - Sci Rep. 2021 Aug 25;11(1):17161. doi: 10.1038/s41598-021-96614-y.

PMID- 8565519
OWN - NLM
STAT- MEDLINE
DCOM- 19960306
LR  - 20190706
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 24
IP  - 1
DP  - 1996 Jan
TI  - Role of endothelin in the cardiovascular effects of diaspirin crosslinked and 
      stroma reduced hemoglobin.
PG  - 137-47
AB  - OBJECTIVES: Diaspirin crosslinked hemoglobin is a resuscitative solution with 
      excellent oxygen-carrying capacity. Diaspirin crosslinked hemoglobin produces an 
      immediate increase in blood pressure and marked regional circulatory changes in 
      rats and pigs. Our objective was to determine the role of endothelin in the 
      cardiovascular actions of diaspirin crosslinked hemoglobin (modified) and 
      (unmodified) stroma reduced hemoglobin solutions. DESIGN: Prospective, randomized 
      comparison of cardiovascular effects of diaspirin crosslinked and stroma reduced 
      hemoglobin in control rats and in rats pretreated with 
      cyclo(D-Asp-Pro-D-Val-Leu-D-Trp) (BQ-123), an endothelin-A receptor antagonist. 
      SETTING: Research laboratory. SUBJECTS: Male Sprague-Dawley rats. INTERVENTIONS: 
      Modified, highly purified, and heat pasteurized (diaspirin crosslinked) and 
      unmodified (stroma reduced) hemoglobin in control (untreated) and BQ-123 (5 
      mg/kg/hr iv)-treated rats. MEASUREMENTS AND MAIN RESULTS: Infusion of stroma 
      reduced hemoglobin (400 mg/kg iv) in control rats produced an increase in blood 
      pressure (43%) and total peripheral resistance (65%) without any change in heart 
      rate, cardiac output, and stroke volume. Stroma reduced hemoglobin decreased 
      blood flow to the kidneys and liver, increased blood flow to the heart, and had 
      no effect on blood flow to the brain, gastrointestinal tract, spleen, 
      musculoskeletal system, skin, and mesentery and pancreas. Infusion of stroma 
      reduced hemoglobin in rats treated with BQ-123 (5 mg/kg/hr iv) increased the 
      blood pressure to a similar degree when compared with control rats, but the 
      increase in total peripheral resistance was significantly attenuated. The stroma 
      reduced hemoglobin-induced decrease in blood flow to the kidneys and liver was 
      significantly attenuated in BQ-123-treated rats as compared with control rats. 
      However, the stroma reduced hemoglobin-induced increase in blood flow to the 
      heart of BQ-123-treated rats was similar to the increase in control rats. 
      Infusion of diaspirin crosslinked hemoglobin (400 mg/kg iv) produced increases in 
      blood pressure (81%), cardiac output (36%), stroke volume (30%), and total 
      peripheral vascular resistance (45%), along with increases in blood flow to the 
      heart, spleen, gastrointestinal tract, and skin of control rats. The blood flows 
      to the brain, kidneys, liver, musculoskeletal system, and mesentery and pancreas 
      were not altered by diaspirin crosslinked hemoglobin in control rats. The 
      increases in blood pressure, cardiac output, stroke volume, and total peripheral 
      vascular resistance by diaspirin crosslinked hemoglobin were significantly 
      blocked in BQ-123-treated rats as compared with control rats. The increases in 
      blood flow to the heart, spleen, and skin by diaspirin crosslinked hemoglobin 
      were significantly blocked in BQ-123-treated rats as compared with control rats. 
      Diaspirin crosslinked hemoglobin produced an increase in the blood flow to the 
      brain and a decrease in blood flow to the kidney and musculoskeletal system of 
      BQ-123-treated rats as compared with control rats. Blood plasma endothelin-1-like 
      immunoreactivity was found to be significantly increased after treatment with 
      diaspirin crosslinked hemoglobin or stroma reduced hemoglobin. CONCLUSIONS: The 
      endothelin-A receptor antagonist, BQ-123, could attenuate the systemic 
      hemodynamic and regional circulatory effects of diaspirin crosslinked hemoglobin 
      and stroma reduced hemoglobin. However, the increase in blood flow to the heart 
      induced by stroma reduced hemoglobin could not be attenuated by BQ-123.
FAU - Gulati, A
AU  - Gulati A
AD  - Department of Pharmaceutics and Pharmacodynamics, University of Illinois at 
      Chicago, USA.
FAU - Sharma, A C
AU  - Sharma AC
FAU - Singh, G
AU  - Singh G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Endothelin Receptor Antagonists)
RN  - 0 (Endothelins)
RN  - 0 (Hemoglobins)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (Plasma Substitutes)
RN  - 0 (hemoglobin, stroma free)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S2A8YZM151 (cyclo(Trp-Asp-Pro-Val-Leu))
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Pressure/drug effects
MH  - Endothelin Receptor Antagonists
MH  - Endothelins/blood/*physiology
MH  - *Hemodynamics/drug effects
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Peptides, Cyclic/pharmacology
MH  - Plasma Substitutes/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/drug effects
MH  - Vascular Resistance/drug effects
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1097/00003246-199601000-00023 [doi]
PST - ppublish
SO  - Crit Care Med. 1996 Jan;24(1):137-47. doi: 10.1097/00003246-199601000-00023.

PMID- 8279693
OWN - NLM
STAT- MEDLINE
DCOM- 19940210
LR  - 20161123
IS  - 0003-2417 (Print)
IS  - 0003-2417 (Linking)
VI  - 42
IP  - 11
DP  - 1993 Nov
TI  - [Postoperative pain therapy. The efficacy of a serotonin antagonist (GR 
      38032F;ondansetron) and the prostaglandin synthesis inhibitor lysin 
      acetylsalicylate (Aspisol)].
PG  - 800-6
AB  - Serotonin is one of the many neurotransmitters involved in nociception. Serotonin 
      antagonists may therefore reduce postoperative pain. In the present study we 
      examined whether the new 5-HT3 receptor antagonist GR 38032F (ondansetron) 
      reduced postoperative pain after minor surgery and compared its effectiveness 
      with that of lysin acetyl salicylate (Aspisol). METHODS. A series of 100 patients 
      of both sexes who were undergoing minor surgery were enrolled in this study. 
      Patients who did not need analgesic medication within the first 3 h after surgery 
      were regarded as "dropouts", and the rest were studied for 24 h. In a preliminary 
      study (n = 19) patients received ondansetron i.v. in increasing dosages (6, 12, 
      24, 48, 96 and 128 micrograms.kg-1) to evaluate the analgesic potency of this 
      drug. In the main double-blind, randomized, study (n = 81), three groups were 
      formed, and patients received 50 micrograms.kg-1 or 100 micrograms.kg-1 
      ondansetron i.v. or saline only i.v. Analgesia was evaluated by visual analogue 
      (VAS) and verbal rating scales (VRS). If pain persisted patients received 1.8 g 
      lysin acetylsalicylate (LAS) i.v. RESULTS. There were 6 (out of 19) patients in 
      the preliminary study and 36 (out of 81) patients in the main study who were 
      dropouts; that is to say they did not require any analgesic medication within the 
      first 3 h, but 12 of these dropouts needed analgesic medication more than 3 h 
      after end of surgery. Pain was reduced by 82% from baseline in 7 out of 13 
      patients in the preliminary study (11 men, 2 women). In the main study (n = 45, 
      28 men, 17 women) 100 micrograms.kg-1 ondansetron did not show a better analgesic 
      effect than 50 micrograms.kg-1, and there was no significant difference between 
      ondansetron and saline. VAS showed a reduction in pain from 6.9 +/- 2.0, 6.8 +/- 
      1.5 and 6.6 +/- 1.8 to 4.1 +/- 2.4, 3.4 +/- 2.2 and 3.4 +/- 2.1 in the 50 
      micrograms.kg-1, 100 micrograms.kg-1 and saline groups, respectively, within 60 
      min after i.v. application. VRS diminished from 2.5 +/- 0.5, 2.5 +/- 0.6 and 2.4 
      +/- 0.5 to 1.7 +/- 0.7, 1.5 +/- 0.8 and 1.5 +/- 0.7, respectively. There were 26 
      patients who experienced no pain relief in response to ondansetron or placebo and 
      who therefore received LAS, and 21 of these then experienced significant pain 
      reduction. CONCLUSION. Pain after minor surgery does not appear to be a major 
      problem. For 42 out of 100 patients no analgesics were needed within the first 3 
      h after end of surgery. Ondansetron was no more effective than placebo in 
      reducing postoperative pain. Lysin acetylsalicylate, however, may be an effective 
      alternative to opioids for the treatment of postoperative pain.
FAU - Doenicke, A
AU  - Doenicke A
AD  - Institut für Anaesthesiologie, Ludwig-Maximilians-Universität München.
FAU - Mayer, M
AU  - Mayer M
FAU - Vogginger, T
AU  - Vogginger T
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Postoperative Schmerztherapie. Die Wirksamkeit eines Serotoninantagonisten (GR 
      38032F; Ondansetron) und des Prostaglandinsynthesehemmers Lysinacetylsalicylat 
      (Aspisol).
PL  - Germany
TA  - Anaesthesist
JT  - Der Anaesthesist
JID - 0370525
RN  - 0 (Analgesics)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 4AF302ESOS (Ondansetron)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Analgesics/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Ondansetron/*therapeutic use
MH  - Pain, Postoperative/*drug therapy
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PST - ppublish
SO  - Anaesthesist. 1993 Nov;42(11):800-6.

PMID- 23563035
OWN - NLM
STAT- MEDLINE
DCOM- 20131022
LR  - 20200106
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 65
IP  - 1
DP  - 2013
TI  - Effects of acetylsalicylic acid on the levels of sulfane sulfur and non-protein 
      sulfhydryl groups in mouse tissues.
PG  - 173-8
AB  - BACKGROUND: The study is focused on searching for the link between 
      acetylsalicylic acid (ASA) and sulfur metabolism. The present work aimed to 
      investigate the effect of ASA on the level of the sulfane sulfur and non-protein 
      thiol compounds (NPSH) in the liver and kidneys of mice. METHODS: The study was 
      conducted on female albino Swiss mice weighing approximately 20 g. The 
      experimental group was treated intraperitoneally (ip) with aspirin, lysine salt, 
      at a dose of 10 mg (on pure aspirin basis)/kg for 5 days. The control group was 
      treated ip with 0.9% NaCl in a volume of 0.2 ml for 5 days. The experimental and 
      control mice were sacrificed by cervical dislocation on 5th day of the 
      experiment, 3 h after the last injection. The homogenates of livers and kidneys 
      were next used for assaying the levels of NPSH and sulfane sulfur-containing 
      compounds. RESULTS: The results indicate that in the liver of ASA-treated mice, 
      the level of the cyanolysable sulfane sulfur decreased compared to the control 
      group, whereas in the kidney, its level significantly increased. The opposite 
      results in the liver and kidney were observed also for NPSH, namely ASA elicited 
      a drop in NPSH level in the liver, and elevated it in the kidney. CONCLUSION: The 
      results of the present study suggest that ASA affects sulfur metabolism, in 
      particular, renal and hepatic production of sulfane sulfur and NPSH in mice.
FAU - Bilska-Wilkosz, Anna
AU  - Bilska-Wilkosz A
AD  - Medical Biochemistry, Department of Human Developmental Biology, Jagiellonian 
      University, Medical College, Kopernika 7, PL 31-034 Kraków, Poland. 
      mbbilska@cyf-kr.edu.pl
FAU - Ochenduszka, Magdalena
AU  - Ochenduszka M
FAU - Iciek, Małgorzata
AU  - Iciek M
FAU - Sokołowska-Jeżewicz, Maria
AU  - Sokołowska-Jeżewicz M
FAU - Wiliński, Bogdan
AU  - Wiliński B
FAU - Góralska, Marta
AU  - Góralska M
FAU - Srebro, Zbigniew
AU  - Srebro Z
FAU - Włodek, Lidia
AU  - Włodek L
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Sulfhydryl Compounds)
RN  - 70FD1KFU70 (Sulfur)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Injections, Intraperitoneal
MH  - Kidney/drug effects/metabolism
MH  - Liver/drug effects/metabolism
MH  - Mice
MH  - Sulfhydryl Compounds/*metabolism
MH  - Sulfur/*metabolism
EDAT- 2013/04/09 06:00
MHDA- 2013/10/23 06:00
CRDT- 2013/04/09 06:00
PHST- 2012/01/25 00:00 [received]
PHST- 2012/09/14 00:00 [revised]
PHST- 2013/04/09 06:00 [entrez]
PHST- 2013/04/09 06:00 [pubmed]
PHST- 2013/10/23 06:00 [medline]
AID - S1734-1140(13)70975-7 [pii]
AID - 10.1016/s1734-1140(13)70975-7 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2013;65(1):173-8. doi: 10.1016/s1734-1140(13)70975-7.

PMID- 21104348
OWN - NLM
STAT- MEDLINE
DCOM- 20110525
LR  - 20211020
IS  - 1534-6307 (Electronic)
IS  - 1523-3774 (Linking)
VI  - 13
IP  - 1
DP  - 2011 Feb
TI  - Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: 
      where do we stand?
PG  - 59-69
LID - 10.1007/s11926-010-0149-3 [doi]
AB  - Persistently positive antiphospholipid antibodies (aPLs) with thrombosis and/or 
      pregnancy morbidity are the hallmark of the antiphospholipid syndrome. However, 
      aPL-positive patients with no prior history of thrombosis exist. On the basis of 
      a limited number of studies that predominantly included systemic lupus 
      erythematosus patients, aPL-positive patients without previous thrombosis have a 
      0% to 3.8% annual incident thrombosis risk. Given that every positive aPL test is 
      not clinically significant and every aPL-positive patient does not have the same 
      thrombosis risk, risk stratification (based on aPL profile, age, systemic 
      autoimmune diseases, and traditional cardiovascular disease or venous thrombosis 
      risk factors) is crucial to determine the first thrombosis risk in aPL-positive 
      patients. The optimal primary thrombosis prevention strategy in patients with 
      clinically significant aPL profiles should include 1) regular monitoring and 
      elimination of non-aPL thrombosis risk factors, 2) aggressive management of 
      clinical and subclinical systemic autoimmune disease activity, and 3) patient 
      counseling and education. The protective effect of low-dose aspirin against 
      incident thrombosis in patients with clinically significant aPL profiles is not 
      supported by randomized controlled data; general population cardiovascular 
      disease risk prediction tools and prevention guidelines formulated based on 
      risk-benefit calculations should play a role in the decision whether to recommend 
      low-dose aspirin. The effectiveness of hydroxychloroquine, statins, or their 
      combination remains to be determined by well-designed randomized controlled 
      trials.
FAU - Barbhaiya, Medha
AU  - Barbhaiya M
AD  - Department of Medicine, Weill Medical College of Cornell University, New York, 
      NY, USA.
FAU - Erkan, Doruk
AU  - Erkan D
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Rheumatol Rep
JT  - Current rheumatology reports
JID - 100888970
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Antiphospholipid
MH  - Anticoagulants/therapeutic use
MH  - Antiphospholipid Syndrome/*complications
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Pregnancy
MH  - Thrombosis/*etiology/*prevention & control
EDAT- 2010/11/26 06:00
MHDA- 2011/05/26 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2011/05/26 06:00 [medline]
AID - 10.1007/s11926-010-0149-3 [doi]
PST - ppublish
SO  - Curr Rheumatol Rep. 2011 Feb;13(1):59-69. doi: 10.1007/s11926-010-0149-3.

PMID- 20211296
OWN - NLM
STAT- MEDLINE
DCOM- 20100402
LR  - 20221207
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 159
IP  - 3
DP  - 2010 Mar
TI  - Rationale, design, and baseline data of the Japanese Primary Prevention Project 
      (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in 
      patients with multiple risk factors for vascular events.
PG  - 361-369.e4
LID - 10.1016/j.ahj.2009.11.030 [doi]
AB  - BACKGROUND: Prevention of atherosclerotic disease has become an important public 
      health priority in Japan due to the aging of the population and changes in diet 
      and lifestyle factors. METHODS: The Japanese Primary Prevention Project (JPPP) is 
      a multicenter, open-label, randomized, parallel-group trial that is evaluating 
      primary prevention with low-dose aspirin in Japanese patients aged 60 to 85 years 
      with hypertension, dyslipidemia, or diabetes mellitus. The study cohort will be 
      followed for a mean of 4 years. The primary end point is a composite of death 
      from cardiovascular causes (including fatal myocardial infarction [MI], fatal 
      stroke, and other cardiovascular death), nonfatal stroke (ischemic or 
      hemorrhagic), and nonfatal MI. Key secondary end points include a composite of 
      cardiovascular death, nonfatal stroke, nonfatal MI, transient ischemic attack, 
      angina pectoris, or arteriosclerotic disease requiring surgery or intervention; 
      each component of the primary end point; noncerebrovascular and noncardiovascular 
      death; and extracranial hemorrhage requiring transfusion or hospitalization. End 
      point assessment is done by a central adjudication committee that is blinded to 
      treatment assignments. RESULTS: Enrollment began in March 2005 and was completed 
      in June 2007. A total of 14,466 patients were randomly allocated to receive 
      enteric-coated aspirin, 100 mg/d, or no aspirin. At randomization, the study 
      cohort had a mean (SD) age of 70.6 (6.2) years; 57.8% were women, 85.0% had 
      hypertension, 71.7% had dyslipidemia, and 33.9% had diabetes. In the study 
      cohort, 80.4% of patients had > or =3 risk factors. CONCLUSION: The JPPP is the 
      largest primary prevention trial of aspirin in a Japanese population that is 
      investigating whether the benefit of aspirin in reducing risk of vascular events 
      outweighs any bleeding risk in elderly patients with multiple risk factors.
FAU - Teramoto, Tamio
AU  - Teramoto T
AD  - Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan. 
      ttera@med.teikyo-u.ac.jp
FAU - Shimada, Kazuyuki
AU  - Shimada K
FAU - Uchiyama, Shinichiro
AU  - Uchiyama S
FAU - Sugawara, Masahiro
AU  - Sugawara M
FAU - Goto, Yoshio
AU  - Goto Y
FAU - Yamada, Nobuhiro
AU  - Yamada N
FAU - Oikawa, Shinichi
AU  - Oikawa S
FAU - Ando, Katsuyuki
AU  - Ando K
FAU - Ishizuka, Naoki
AU  - Ishizuka N
FAU - Yamazaki, Tsutomu
AU  - Yamazaki T
FAU - Yokoyama, Kenji
AU  - Yokoyama K
FAU - Murata, Mitsuru
AU  - Murata M
FAU - Ikeda, Yasuo
AU  - Ikeda Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Asian People
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cohort Studies
MH  - Diabetes Mellitus/drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Dyslipidemias/drug therapy
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Hypertension/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - *Research Design
MH  - Risk Factors
MH  - Vascular Diseases/ethnology/*etiology/*prevention & control
EDAT- 2010/03/10 06:00
MHDA- 2010/04/03 06:00
CRDT- 2010/03/10 06:00
PHST- 2009/05/22 00:00 [received]
PHST- 2009/11/25 00:00 [accepted]
PHST- 2010/03/10 06:00 [entrez]
PHST- 2010/03/10 06:00 [pubmed]
PHST- 2010/04/03 06:00 [medline]
AID - S0002-8703(09)00955-7 [pii]
AID - 10.1016/j.ahj.2009.11.030 [doi]
PST - ppublish
SO  - Am Heart J. 2010 Mar;159(3):361-369.e4. doi: 10.1016/j.ahj.2009.11.030.

PMID- 11929396
OWN - NLM
STAT- MEDLINE
DCOM- 20020906
LR  - 20190901
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 16
IP  - 4
DP  - 2002 Apr
TI  - Helicobacter pylori increases the risk of upper gastrointestinal bleeding in 
      patients taking low-dose aspirin.
PG  - 779-86
AB  - AIM: To evaluate the role of Helicobacter pylori infection and other clinical 
      factors in the risk of upper gastrointestinal bleeding in patients taking 
      low-dose aspirin. SUBJECTS AND METHODS: A case-control study was carried out of 
      consecutive current users of low-dose aspirin admitted because of upper 
      gastrointestinal bleeding. Within a cohort of 695 patients with upper 
      gastrointestinal bleeding, 98 patients had taken low-dose aspirin and no other 
      non-steroidal anti-inflammatory drug. Controls were 147 low-dose aspirin users 
      without upper gastrointestinal bleeding of similar age, sex and extent of aspirin 
      use as cases. H. pylori infection was determined by CagA/VacA serology and 
      13C-urea breath test in all cases and controls. Adjusted odds ratios (OR) are 
      provided. RESULTS: H. pylori infection was identified as an independent risk 
      factor of upper gastrointestinal bleeding in this population (OR, 4.7; 95% 
      confidence interval (95% CI), 2.0-10.9), but the presence of CagA-positive 
      serology was not. Other risk factors identified were a previous ulcer history 
      (OR, 15.2; 95% CI, 3.8-60.1), alcohol use (OR, 4.2; 95% CI, 1.7-10.4) and use of 
      calcium channel blockers (OR, 2.54; 95% CI, 1.25-5.14). Antisecretory therapy 
      (OR, 0.1; 95% CI, 0.02-0.3) and nitrovasodilators (OR, 0.2; 95% CI, 0.1-0.6) 
      decreased the risk of bleeding. CONCLUSIONS: H. pylori infection is a risk factor 
      for upper gastrointestinal bleeding in low-dose aspirin users, which might have 
      therapeutic implications in high-risk patients.
FAU - Lanas, A
AU  - Lanas A
AD  - Service of Gastroenterology, University Hospital Lozano Blesa, Zaragoza, Spain. 
      alanas@posta.unizar.es
FAU - Fuentes, J
AU  - Fuentes J
FAU - Benito, R
AU  - Benito R
FAU - Serrano, P
AU  - Serrano P
FAU - Bajador, E
AU  - Bajador E
FAU - Sáinz, R
AU  - Sáinz R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Female
MH  - Gastrointestinal Hemorrhage/*etiology
MH  - Helicobacter Infections/*complications
MH  - *Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Risk Factors
EDAT- 2002/04/04 10:00
MHDA- 2002/09/07 10:01
CRDT- 2002/04/04 10:00
PHST- 2002/04/04 10:00 [pubmed]
PHST- 2002/09/07 10:01 [medline]
PHST- 2002/04/04 10:00 [entrez]
AID - 1230 [pii]
AID - 10.1046/j.1365-2036.2002.01230.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2002 Apr;16(4):779-86. doi: 
      10.1046/j.1365-2036.2002.01230.x.

PMID- 10756616
OWN - NLM
STAT- MEDLINE
DCOM- 20000504
LR  - 20181113
IS  - 0960-1643 (Print)
IS  - 0960-1643 (Linking)
VI  - 49
IP  - 446
DP  - 1999 Sep
TI  - Iron deficiency anaemia and aspirin use in old age.
PG  - 729-30
AB  - Aspirin is being increasingly prescribed for cardiovascular protection, but is 
      also recognized to have significant gastrointestinal side-effects. Whether 
      chronic aspirin consumption causes iron deficiency is undetermined, and there is 
      little information available regarding iron deficiency and aspirin use in old 
      age. We studied the relationship between iron deficiency anaemia and regular 
      aspirin prescription in old age.
FAU - Black, D A
AU  - Black DA
AD  - Queen Mary's Hospital, Sidcup.
FAU - Fraser, C M
AU  - Fraser CM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of 
      General Practitioners
JID - 9005323
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia, Iron-Deficiency/*chemically induced
MH  - Aspirin/*adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects
PMC - PMC1313502
EDAT- 2000/04/11 09:00
MHDA- 2000/05/08 09:00
CRDT- 2000/04/11 09:00
PHST- 2000/04/11 09:00 [pubmed]
PHST- 2000/05/08 09:00 [medline]
PHST- 2000/04/11 09:00 [entrez]
PST - ppublish
SO  - Br J Gen Pract. 1999 Sep;49(446):729-30.

PMID- 23094528
OWN - NLM
STAT- MEDLINE
DCOM- 20121204
LR  - 20131121
IS  - 0041-4301 (Print)
IS  - 0041-4301 (Linking)
VI  - 54
IP  - 3
DP  - 2012 May-Jun
TI  - Fetal and neonatal effects of anticoagulants used in pregnancy: a review.
PG  - 207-15
AB  - There are several relative (promising regarding a reduction in placenta-mediated 
      complications such as preeclampsia) and absolute (e.g. a recurrent or recent 
      thromboembolic event, mechanical heart valves) reasons for use of anticoagulant 
      drugs during pregnancy. Warfarin readily crosses the placenta because of its low 
      molecular weight, and is associated with a distinctive embryopathy known as fetal 
      warfarin syndrome when exposure occurs between the sixth and twelfth weeks of 
      gestation. Warfarin embryopathy may be avoided by stopping warfarin and switching 
      to heparin when pregnancy is achieved or as soon as possible after conception. 
      Heparins, unfractionated heparin and low molecular weight heparin are the 
      preferred agents for anticoagulation in pregnancy because they show no 
      transplacental passage due to their high molecular weights. Both heparins and 
      warfarin are safe for the infant during breastfeeding. Aspirin is prescribed with 
      increasing frequency to reduce the risk of miscarriage and poor pregnancy 
      outcome. Although aspirin crosses the placenta, it is safe in low doses. However, 
      the safety of higher doses of aspirin during the first pregnancy is uncertain.
FAU - Yurdakök, Murat
AU  - Yurdakök M
AD  - Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, 
      Turkey.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Turkey
TA  - Turk J Pediatr
JT  - The Turkish journal of pediatrics
JID - 0417505
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/*pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Breast Feeding
MH  - Female
MH  - Fetus/drug effects
MH  - Heparin/adverse effects/*pharmacology
MH  - Humans
MH  - Infant, Newborn
MH  - Maternal-Fetal Exchange
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*drug therapy
MH  - Pregnancy Outcome
MH  - Risk Factors
MH  - Warfarin/adverse effects/*pharmacology
EDAT- 2012/10/26 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/10/26 06:00
PHST- 2012/10/26 06:00 [entrez]
PHST- 2012/10/26 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
PST - ppublish
SO  - Turk J Pediatr. 2012 May-Jun;54(3):207-15.

PMID- 15077972
OWN - NLM
STAT- MEDLINE
DCOM- 20040726
LR  - 20131121
IS  - 0273-1223 (Print)
IS  - 0273-1223 (Linking)
VI  - 49
IP  - 4
DP  - 2004
TI  - Electrochemical oxidation of drug residues in water by the example of 
      tetracycline, gentamicine and aspirin.
PG  - 201-6
AB  - Electro-chemical oxidation as a method to destroy drug residues like aspirin, 
      tetracycline or gentamicine in water was investigated with C-anodes (modified by 
      manganese oxides) and Pt anodes. The mechanism of aspirin and tetracycline 
      oxidation and the influence of the biocide effect was observed using GC-MS and 
      three different microbiological tests. In general, the biological availability 
      increases with progressive oxidation of the antibiotics.
FAU - Weichgrebe, D
AU  - Weichgrebe D
AD  - Institute of Water Quality and Waste Management, University of Hanover, 
      Welfengarten 1, 30167 Hannover, Germany. weichgrebe@isah.uni-hannover.de
FAU - Danilova, E
AU  - Danilova E
FAU - Rosenwinkel, K H
AU  - Rosenwinkel KH
FAU - Vedenjapin, A A
AU  - Vedenjapin AA
FAU - Baturova, M
AU  - Baturova M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Water Sci Technol
JT  - Water science and technology : a journal of the International Association on 
      Water Pollution Research
JID - 9879497
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Gentamicins)
RN  - 0 (Water Pollutants)
RN  - F8VB5M810T (Tetracycline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Bacterial Agents/chemistry/*isolation & purification
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*isolation & purification
MH  - Aspirin/chemistry/*isolation & purification
MH  - Drug Residues/*isolation & purification
MH  - Electrochemistry
MH  - Gentamicins/chemistry/*isolation & purification
MH  - Oxidation-Reduction
MH  - Tetracycline/chemistry/*isolation & purification
MH  - Waste Disposal, Fluid/*methods
MH  - Water Pollutants/*isolation & purification
MH  - Water Purification/*methods
EDAT- 2004/04/14 05:00
MHDA- 2004/07/28 05:00
CRDT- 2004/04/14 05:00
PHST- 2004/04/14 05:00 [pubmed]
PHST- 2004/07/28 05:00 [medline]
PHST- 2004/04/14 05:00 [entrez]
PST - ppublish
SO  - Water Sci Technol. 2004;49(4):201-6.

PMID- 37392173
OWN - NLM
STAT- MEDLINE
DCOM- 20230901
LR  - 20230902
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 15
DP  - 2023 Aug
TI  - Low-dose aspirin can inhibit exosomal release induced by radiotherapy in breast 
      cancer and attenuate its inhibitory effect on NK cell proliferation.
PG  - 16386-16404
LID - 10.1002/cam4.6274 [doi]
AB  - BACKGROUND: Breast cancer (BC) seriously threatens women's health. Aspirin plays 
      a key role in the treatment and prognosis of BC. OBJECTIVE: To explore the effect 
      of low-dose aspirin on BC radiotherapy through the mechanism of exosomes and 
      natural killer (NK) cells. METHODS: BC cells were injected into the left chest 
      wall to establish a BC model in nude mice. Tumor morphology and size were 
      observed. Immunohistochemical staining for Ki-67 was used to observe the 
      proliferation of tumor cells. TUNEL was used to detect the apoptosis of cancer 
      cells. Protein levels of exosomal biogenesis- and secretion-related genes (Rab 
      11, Rab27a, Rab27b, CD63, and Alix) were detected by Western blot. Flow cytometry 
      was used to detect apoptosis. Transwell assays were used to detect cell 
      migration. A clonogenic assay was used to detect cell proliferation. Exosomes of 
      BT549 and 4T1-Luc cells were extracted and observed by electron microscopy. After 
      the coculture of exosomes and NK cells, the activity of NK cells was detected by 
      CCK-8. RESULTS: The protein expression of genes related to exosomal genesis and 
      secretion (Rab 11, Rab27a, Rab27b, CD63, and Alix) in BT549 and 4T1-Luc cells was 
      upregulated under radiotherapy treatment. Low doses of aspirin inhibited exosome 
      release from BT549 and 4T1-Luc cells and alleviated the inhibitory effect of BC 
      cell exosomes on NK cell proliferation. In addition, knocking down Rab27a reduced 
      the protein levels of exosome-related and secretion-related genes in BC cells, 
      further enhancing the promotive effect of aspirin on NK cell proliferation, while 
      overexpressing Rab27a had the opposite effect. Aspirin was combined at a 
      radiotherapeutic dose of 10 Gy to enhance the radiotherapy sensitivity of 
      radiotherapy-tolerant BC cells (BT549R and 4T1-LucR). Animal experiments have 
      also verified that aspirin can promote the killing effect of radiotherapy on 
      cancer cells and significantly inhibit tumor growth. CONCLUSION: Low doses of 
      aspirin can inhibit the release of BC exosomes induced by radiotherapy and weaken 
      their inhibition of NK cell proliferation, promoting radiotherapy resistance.
CI  - © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Wang, Li
AU  - Wang L
AD  - Department of Radiotherapy, Third Affiliated Hospital of Kunming Medical 
      University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, China.
FAU - Hu, Zaoxiu
AU  - Hu Z
AD  - Department of Pathology, Third Affiliated Hospital of Kunming Medical University 
      (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, China.
FAU - Chen, Ceshi
AU  - Chen C
AD  - Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy 
      of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming, China.
FAU - Chen, Ting
AU  - Chen T
AD  - Department of Nuclear Medicine, Third Affiliated Hospital of Kunming Medical 
      University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, China.
FAU - Yao, Zhihong
AU  - Yao Z
AD  - Bone and Soft Tissue Tumors Research Center, Third Affiliated Hospital of Kunming 
      Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, 
      China.
FAU - Li, Wenhui
AU  - Li W
AUID- ORCID: 0000-0002-0312-7993
AD  - Department of Radiotherapy, Third Affiliated Hospital of Kunming Medical 
      University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, China.
FAU - Yang, Zuozhang
AU  - Yang Z
AUID- ORCID: 0000-0002-0763-5805
AD  - Bone and Soft Tissue Tumors Research Center, Third Affiliated Hospital of Kunming 
      Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230701
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Female
MH  - Mice, Nude
MH  - Aspirin/pharmacology
MH  - Cell Proliferation
MH  - Cell Movement
MH  - *Exosomes/metabolism
MH  - Cell Line, Tumor
MH  - *Neoplasms/metabolism
PMC - PMC10469664
OTO - NOTNLM
OT  - aspirin
OT  - breast cancer
OT  - exosomes
OT  - natural killer cells
OT  - radiotherapy
COIS- The authors declare that they have no competing interests.
EDAT- 2023/07/01 21:08
MHDA- 2023/09/01 06:42
CRDT- 2023/07/01 08:43
PHST- 2023/05/26 00:00 [revised]
PHST- 2022/11/28 00:00 [received]
PHST- 2023/06/02 00:00 [accepted]
PHST- 2023/09/01 06:42 [medline]
PHST- 2023/07/01 21:08 [pubmed]
PHST- 2023/07/01 08:43 [entrez]
AID - CAM46274 [pii]
AID - 10.1002/cam4.6274 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Aug;12(15):16386-16404. doi: 10.1002/cam4.6274. Epub 2023 Jul 1.

PMID- 15763611
OWN - NLM
STAT- MEDLINE
DCOM- 20050411
LR  - 20220330
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 27
IP  - 1
DP  - 2005 Jan
TI  - The long-term cost-effectiveness of clopidogrel plus aspirin in patients 
      undergoing percutaneous coronary intervention in Sweden.
PG  - 100-10
AB  - BACKGROUND: The Percutaneous Coronary Intervention-Clopidogrel in Unstable Angina 
      to Prevent Recurrent Events (PCI-CURE) study, which examined the effect of adding 
      clopidogrel to aspirin versus aspirin alone in patients with unstable coronary 
      artery disease (CAD) undergoing PCI, found a relative risk reduction in 
      cardiovascular deaths and myocardial infarction among those treated with 
      clopidogrel. In addition, a within-trial cost-effectiveness analysis showed 
      favorable costs per event avoided. However, to estimate the long-term effects, a 
      modeling approach is necessary. OBJECTIVES: The purpose of this study was to 
      estimate the long-term cost-effectiveness of treating patients undergoing PCI 
      with clopidogrel plus aspirin in Sweden. METHODS: A Markov model was developed. 
      Transition probabilities were estimated based on a register of patients treated 
      in the coronary care units at 74 (out of 78) hospitals throughout Sweden. 
      Patients were assumed to be treated for 1 year with an effect based on data from 
      the PCI-CURE study. Costs were collected from published sources and recalculated 
      to year-2004 Euros (Euro 1.00 = USD 1.24). Life-years gained were used as the 
      measure of effectiveness. The perspective was that of the Swedish society, with a 
      separate analysis using a health care cost perspective. RESULTS: After inclusion 
      and exclusion criteria were applied, 3474 patients were included in the model 
      analysis. The model predicted a net gain in survival of 0.04 year per patient 
      when adding clopidogrel. This yielded a net increase of Euros 449 if only direct 
      costs were included; with indirect costs, the net increase was Euros 332. The 
      resulting cost-effectiveness ratios were Euros 10,993 and Euros 8127 per 
      life-year gained. CONCLUSIONS: The predicted cost-effectiveness ratios were well 
      below the threshold values generally considered cost-effective. Adding 
      clopidogrel to aspirin appeared to be cost-effective in this model analysis of 
      patients with unstable CAD undergoing PCI in Sweden.
FAU - Lindgren, Peter
AU  - Lindgren P
AD  - Department of Cardiovascular Epidemiology, Institute of Environmental Medicine, 
      Karolinska Institute, Stockholm, Sweden. peter.lindgren@imm.ki.se
FAU - Stenestrand, Ulf
AU  - Stenestrand U
FAU - Malmberg, Klas
AU  - Malmberg K
FAU - Jönsson, Bengt
AU  - Jönsson B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/*economics/therapeutic use
MH  - Clopidogrel
MH  - Computer Simulation
MH  - Coronary Disease/economics/therapy
MH  - Cost-Benefit Analysis
MH  - Drug Administration Schedule
MH  - Drug Costs
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Models, Economic
MH  - Monte Carlo Method
MH  - Platelet Aggregation Inhibitors/administration & dosage/*economics/therapeutic 
      use
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/*economics/therapeutic 
      use
MH  - Time Factors
EDAT- 2005/03/15 09:00
MHDA- 2005/04/12 09:00
CRDT- 2005/03/15 09:00
PHST- 2004/11/22 00:00 [accepted]
PHST- 2005/03/15 09:00 [pubmed]
PHST- 2005/04/12 09:00 [medline]
PHST- 2005/03/15 09:00 [entrez]
AID - S0149-2918(05)00009-3 [pii]
AID - 10.1016/j.clinthera.2005.01.008 [doi]
PST - ppublish
SO  - Clin Ther. 2005 Jan;27(1):100-10. doi: 10.1016/j.clinthera.2005.01.008.

PMID- 10459730
OWN - NLM
STAT- MEDLINE
DCOM- 19991005
LR  - 20181113
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 15
IP  - 1
DP  - 1999 Jul
TI  - Aspirin and heparin in acute ischaemic stroke in older patients.
PG  - 29-36
AB  - Over four-fifths of all strokes are due to thrombotic or embolic occlusion of 
      cerebral arteries. There is a strong rationale for considering antithrombotic 
      therapy for the treatment of patients with acute ischaemic stroke. Antiplatelet 
      therapy with 150 to 300 mg of aspirin (acetylsalicylic acid) started within the 
      first 48 hours of an ischaemic stroke improves patient outcome in the short and 
      long term, with a low risk of adverse effects. Anticoagulants such as heparin may 
      reduce the risk of developing deep venous thrombosis and pulmonary embolism in 
      patients with stroke, but randomised controlled trials have demonstrated a 
      significant and dose-dependent risk of intracranial haemorrhage. The routine use 
      of parenteral anticoagulants, including unfractionated heparin, 
      low-molecular-weight heparins and heparinoids in the acute phase of ischaemic 
      stroke is not associated with any net short or long term benefit. Aspirin is, 
      therefore, the antithrombotic drug of choice in the treatment of acute ischaemic 
      stroke.
FAU - Gubitz, G J
AU  - Gubitz GJ
AD  - Department of Clinical Neurosciences, The University of Edinburgh, Scotland. 
      gg@skull.dcn.ed.ac.uk
FAU - Sandercock, P A
AU  - Sandercock PA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/*drug therapy/prevention & control
MH  - Cerebral Hemorrhage/chemically induced
MH  - Cerebrovascular Disorders/prevention & control
MH  - Geriatrics
MH  - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
RF  - 33
EDAT- 1999/08/25 00:00
MHDA- 1999/08/25 00:01
CRDT- 1999/08/25 00:00
PHST- 1999/08/25 00:00 [pubmed]
PHST- 1999/08/25 00:01 [medline]
PHST- 1999/08/25 00:00 [entrez]
AID - 10.2165/00002512-199915010-00003 [doi]
PST - ppublish
SO  - Drugs Aging. 1999 Jul;15(1):29-36. doi: 10.2165/00002512-199915010-00003.

PMID- 35124115
OWN - NLM
STAT- MEDLINE
DCOM- 20220314
LR  - 20220314
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 616
DP  - 2022 Mar 25
TI  - Simultaneous improvement of physical stability, dissolution, bioavailability, and 
      antithrombus efficacy of Aspirin and Ligustrazine through cocrystallization.
PG  - 121541
LID - S0378-5173(22)00095-3 [pii]
LID - 10.1016/j.ijpharm.2022.121541 [doi]
AB  - A novel 1:1 cocrystal between two cardiovascular drugs, aspirin (ASA) and 
      ligustrazine (tetramethylpyrazine, TMP) has been synthesized and characterized. 
      The structure of this drug-drug cocrystal, ASA-TMP, was determined using single 
      crystal X-ray crystallography. The ASA-TMP cocrystal exhibits a significantly 
      reduced sublimation tendency than TMP. Importantly, cocrystallization 
      simultaneously improves bioavailability of both parent drugs. This suggests the 
      possibility of developing a more effective antithrombosis drug therapy given the 
      synergistic pharmacological effects of the two parent drugs.
CI  - Copyright © 2022 Elsevier B.V. All rights reserved.
FAU - Wang, Kairu
AU  - Wang K
AD  - College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei 
      071000, China.
FAU - Hao, Yanshuang
AU  - Hao Y
AD  - College of Animal Science and Technology, Hebei Agricultural University, Baoding, 
      Hebei 071000, China.
FAU - Wang, Chenguang
AU  - Wang C
AD  - Pharmaceutical Materials Science and Engineering Laboratory, Department of 
      Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN 
      55455, USA.
FAU - Zhao, Xinghua
AU  - Zhao X
AD  - College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei 
      071000, China.
FAU - He, Xin
AU  - He X
AD  - College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei 
      071000, China. Electronic address: dyhexin@hebau.edu.cn.
FAU - Sun, Changquan Calvin
AU  - Sun CC
AD  - Pharmaceutical Materials Science and Engineering Laboratory, Department of 
      Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN 
      55455, USA. Electronic address: sunx0053@umn.edu.
LA  - eng
PT  - Journal Article
DEP - 20220203
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Pyrazines)
RN  - R16CO5Y76E (Aspirin)
RN  - V80F4IA5XG (tetramethylpyrazine)
SB  - IM
MH  - *Aspirin
MH  - Biological Availability
MH  - Crystallization
MH  - Pyrazines
MH  - Solubility
OTO - NOTNLM
OT  - Antithrombosis
OT  - Aspirin
OT  - Bioavailability
OT  - Cocrystal
OT  - Ligustrazine
EDAT- 2022/02/07 06:00
MHDA- 2022/03/15 06:00
CRDT- 2022/02/06 20:31
PHST- 2021/12/30 00:00 [received]
PHST- 2022/01/28 00:00 [revised]
PHST- 2022/01/30 00:00 [accepted]
PHST- 2022/02/07 06:00 [pubmed]
PHST- 2022/03/15 06:00 [medline]
PHST- 2022/02/06 20:31 [entrez]
AID - S0378-5173(22)00095-3 [pii]
AID - 10.1016/j.ijpharm.2022.121541 [doi]
PST - ppublish
SO  - Int J Pharm. 2022 Mar 25;616:121541. doi: 10.1016/j.ijpharm.2022.121541. Epub 
      2022 Feb 3.

PMID- 647888
OWN - NLM
STAT- MEDLINE
DCOM- 19780724
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 58
IP  - 1
DP  - 1978 Jul
TI  - A case-control study of regular aspirin use and coronary deaths.
PG  - 35-8
AB  - Information was collected for a large number of coronary risk factors on a series 
      of 568 married, white men, aged 30--70 years, who died from coronary heart 
      disease. Information on the same risk factors was collected on an equal number of 
      living controls matched on age, sex, marital status and neighborhood. For regular 
      aspirin users (i.e. greater than or equal to 4 days per week) compared with 
      non-users, the crude matched pair risk ratio estimate was 1.0 (95% confidence 
      limits 0.9--1.1). Even after controlling for possible confounding effects of 
      other variables using a paired multiple logistic regression analysis, there was 
      no evidence of association. These data provide no evidence for a preventive role 
      of regular aspirin intake in coronary deaths.
FAU - Hennekens, C H
AU  - Hennekens CH
FAU - Karlson, L K
AU  - Karlson LK
FAU - Rosner, B
AU  - Rosner B
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Coronary Disease/*mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Research Design
MH  - Retrospective Studies
MH  - Risk
MH  - Self Medication
EDAT- 1978/07/01 00:00
MHDA- 1978/07/01 00:01
CRDT- 1978/07/01 00:00
PHST- 1978/07/01 00:00 [pubmed]
PHST- 1978/07/01 00:01 [medline]
PHST- 1978/07/01 00:00 [entrez]
AID - 10.1161/01.cir.58.1.35 [doi]
PST - ppublish
SO  - Circulation. 1978 Jul;58(1):35-8. doi: 10.1161/01.cir.58.1.35.

PMID- 10232449
OWN - NLM
STAT- MEDLINE
DCOM- 19990629
LR  - 20190822
IS  - 0903-1936 (Print)
IS  - 0903-1936 (Linking)
VI  - 13
IP  - 3
DP  - 1999 Mar
TI  - Haemoptysis after breath-hold diving.
PG  - 697-9
AB  - Pulmonary oedema has been described in swimmers and self-contained underwater 
      breathing apparatus (Scuba) divers. This study reports three cases of haemoptysis 
      secondary to alveolar haemorrhage in breath-hold divers. Contributory factors, 
      such as haemodynamic modifications secondary to immersion, cold exposure, 
      exercise and exposure to an increase in ambient pressure, could explain this type 
      of accident. Furthermore, these divers had taken aspirin, which may have 
      aggravated the bleeding.
FAU - Boussuges, A
AU  - Boussuges A
AD  - Service de Réanimation Médicale, Hôpital Salvator, Marseille, France.
FAU - Pinet, C
AU  - Pinet C
FAU - Thomas, P
AU  - Thomas P
FAU - Bergmann, E
AU  - Bergmann E
FAU - Sainty, J M
AU  - Sainty JM
FAU - Vervloet, D
AU  - Vervloet D
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Apnea
MH  - Aspirin/administration & dosage/adverse effects
MH  - Disease-Free Survival
MH  - Diving/*injuries
MH  - Hemoptysis/diagnosis/*etiology/therapy
MH  - Hemothorax/diagnosis/*etiology/therapy
MH  - Humans
MH  - Male
MH  - Positive-Pressure Respiration
MH  - Pulmonary Edema/diagnosis/*etiology/therapy
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
EDAT- 1999/05/08 00:00
MHDA- 1999/05/08 00:01
CRDT- 1999/05/08 00:00
PHST- 1999/05/08 00:00 [pubmed]
PHST- 1999/05/08 00:01 [medline]
PHST- 1999/05/08 00:00 [entrez]
AID - 10.1183/09031936.99.13369799 [doi]
PST - ppublish
SO  - Eur Respir J. 1999 Mar;13(3):697-9. doi: 10.1183/09031936.99.13369799.

PMID- 15993794
OWN - NLM
STAT- MEDLINE
DCOM- 20050908
LR  - 20191210
IS  - 1090-0233 (Print)
IS  - 1090-0233 (Linking)
VI  - 170
IP  - 1
DP  - 2005 Jul
TI  - Assessment of a platelet function analyser in horses: reference range and 
      influence of a platelet aggregation inhibitor.
PG  - 108-12
AB  - The objective of this study was to assess whether a new human platelet function 
      analyser (the PFA-100) could be used to evaluate platelet function in horses and 
      detect acetylsalicylic acid (ASA)-induced platelet dysfunctions. Citrated blood 
      samples from 40 healthy horses were processed to obtain reference values for 
      closure time (CT) using cartridges with collagen-ADP (CT-ADP) and 
      collagen-epinephrine (CT-EPI) as platelet agonists. In addition, CT-ADP and 
      CT-EPI were also measured before and 24 h after oral ASA administration in 
      another 12 healthy horses. The sensitivity and specificity of the test were also 
      determined. In normal horses, means+/-SD value for CT-ADP was 85.1+/-13.1 s 
      (median, 82 s), and CT-EPI ranged from 158 to >300 s (median 291 s). Calculated 
      reference ranges were 60.5-115.9 s and 158.5->300 s for CT-ADP and CT-EPI, 
      respectively. Administration of ASA significantly (P<0.001) prolonged CT-ADP 
      values from 91.0+/-13 to 113.5+/-14.4 s, and CT-EPI values were also 
      significantly (P<0.008) prolonged after ASA administration. Sensitivity and 
      specificity results for ADP cartridges showed that a prolonged CT value would be 
      highly suggestive of a platelet aggregation inhibition. In conclusion, ADP 
      cartridges can be used in horses to assess primary haemostasis and may be a 
      valuable test for the detection of platelet aggregation inhibition.
FAU - Segura, D
AU  - Segura D
AD  - Departament de Medicina i Cirurgia Animals, Facultat de Veterinària, Universitat 
      Autònoma de Barcelona, 08193 Bellaterra, Barcelona. didac.segura@uab.es
FAU - Monreal, L
AU  - Monreal L
FAU - Espada, Y
AU  - Espada Y
FAU - Pastor, J
AU  - Pastor J
FAU - Mayós, I
AU  - Mayós I
FAU - Homedes, J
AU  - Homedes J
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Vet J
JT  - Veterinary journal (London, England : 1997)
JID - 9706281
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/blood
MH  - Female
MH  - Horses/*blood
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/blood
MH  - Platelet Function Tests/instrumentation/*veterinary
MH  - Predictive Value of Tests
MH  - Reference Values
EDAT- 2005/07/05 09:00
MHDA- 2005/09/09 09:00
CRDT- 2005/07/05 09:00
PHST- 2004/05/21 00:00 [accepted]
PHST- 2005/07/05 09:00 [pubmed]
PHST- 2005/09/09 09:00 [medline]
PHST- 2005/07/05 09:00 [entrez]
AID - S1090-0233(04)00135-2 [pii]
AID - 10.1016/j.tvjl.2004.05.013 [doi]
PST - ppublish
SO  - Vet J. 2005 Jul;170(1):108-12. doi: 10.1016/j.tvjl.2004.05.013.

PMID- 7460475
OWN - NLM
STAT- MEDLINE
DCOM- 19810413
LR  - 20190512
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 29
IP  - 1
DP  - 1981 Jan
TI  - Phenytoin-salicylate interaction.
PG  - 56-60
AB  - Ten healthy adult subjects took a single daily dose of phenytoin for 9 days to 
      achieve a steady-state serum phenytoin concentration in the therapeutic range. 
      While continuing on phenytoin, subjects took increasing doses of salicylate in a 
      step-wise fashion, each dose (325, 650, and 975 mg) given every 4 hr for 48 hr. 
      Serum (total) and salivary (free) phenytoin concentrations and serum salicylate 
      concentrations were measured before and after each dose level of salicylate. 
      Protein binding displacement of phenytoin by salicylate occurred only at the 
      highest salicylate dose. Serum phenytoin control levels fell from 13.5 +/- 1.2 to 
      10.3 +/- 0.8 micrograms/ml (p less than 0.01), salivary phenytoin levels rose 
      from 0.97 +/- 0.09 to 1.13 +/- 0.12 micrograms/ml (p less than 0.05), and 
      phenytoin free fraction (salivary/serum ratio) increased from 7.14 +/- 0.34% to 
      10.66 +/- 0.57% (p less than 0.01) in the highest salicylate dose periods. There 
      was no difference in these parameters during low-dose or intermediate-dose 
      salicylate therapy. Linear-regression analysis failed to show a relationship 
      between serum salicylate concentration and serum or salivary phenytoin 
      concentration. Although high-dose salicylate induced protein binding displacement 
      of phenytoin, it is unlikely that this is of clinical importance since the rise 
      (16%) in the free (salivary) phenytoin concentration was small. Serum total 
      phenytoin concentration may fall during salicylate therapy but the dose of 
      phenytoin should not be altered unless there are overt signs of toxicity.
FAU - Leonard, R F
AU  - Leonard RF
FAU - Knott, P J
AU  - Knott PJ
FAU - Rankin, G O
AU  - Rankin GO
FAU - Robinson, D S
AU  - Robinson DS
FAU - Melnick, D E
AU  - Melnick DE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Blood Proteins)
RN  - 6158TKW0C5 (Phenytoin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/blood
MH  - Blood Proteins/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Phenytoin/*adverse effects/blood/metabolism
MH  - Protein Binding
MH  - Saliva/metabolism
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1038/clpt.1981.10 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1981 Jan;29(1):56-60. doi: 10.1038/clpt.1981.10.

PMID- 33922
OWN - NLM
STAT- MEDLINE
DCOM- 19790526
LR  - 20131121
IS  - 0020-725X (Print)
IS  - 0020-725X (Linking)
VI  - 23
IP  - 4
DP  - 1978
TI  - A quantitative study of the effects of acetylsalicylic acid on spermatogenesis 
      and organs of the rat.
PG  - 282-7
AB  - Although the occurrence of prostaglandins in the male reproductive organs is 
      consistent, their physiological role in fertility and reproduction is not known. 
      The influence of acetylsalicylic acid, an inhibitor of prostaglandin synthesis, 
      on the male reproductive tract was investigated in Sprague-Dawley rats of proven 
      fertility. Acetylsalicylic acid dissolved in phosphate buffer was administered 
      once a day at two dosages (300 mg/kg body weight and 150 mg/kg body weight) over 
      a period of 12 days and a period of 6 days. The animals were killed 24 hours 
      after the final treatment and the testes, epididymides, ductus deferens, seminal 
      vesicles, kidneys, and adrenal glands were removed and placed in Bouin's 
      solution. Subsequently, the tissues were cleaned and weighed and the testes were 
      prepared for quantitative study under the light microscope. Organ weights were 
      not significantly altered in the animals that were treated with acetylsalicylic 
      acid. Cell counts indicated that there was a significant increase in the mean 
      number of preleptotene spermatocytes and spermatids in those animals treated with 
      the drug for 6 days at a dose of 150 mg/kg body weight. Treatment at the same 
      dosage for a period of 12 days produced a significant decrease in the mean 
      numbers of preleptotene and pachytene spermatocytes and spermatids. The mean 
      diameter of the seminiferous tubules was also significantly decreased in the 
      latter group of animals. In the group of animals treated with ASA for 12 days at 
      a dose of 300 mg/kg body weight the mean diameter of the seminiferous tubules was 
      significantly increased. No clear conclusion as to the effect of the drug on 
      spermatogenesis or the various organs could be drawn.
FAU - Scott, J E
AU  - Scott JE
FAU - Persaud, T V
AU  - Persaud TV
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Fertil
JT  - International journal of fertility
JID - 0374717
RN  - 0 (Prostaglandin Antagonists)
RN  - 3XMK78S47O (Testosterone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cell Count
MH  - Male
MH  - Organ Size/*drug effects
MH  - *Prostaglandin Antagonists
MH  - Rats
MH  - Seminiferous Tubules/drug effects
MH  - Spermatocytes/drug effects
MH  - Spermatogenesis/*drug effects
MH  - Testis/drug effects
MH  - Testosterone/blood
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Fertil. 1978;23(4):282-7.

PMID- 25187667
OWN - NLM
STAT- MEDLINE
DCOM- 20151015
LR  - 20220311
IS  - 1539-7262 (Electronic)
IS  - 0022-2275 (Print)
IS  - 0022-2275 (Linking)
VI  - 55
IP  - 11
DP  - 2014 Nov
TI  - Short-term n-3 fatty acid supplementation but not aspirin increases plasma 
      proresolving mediators of inflammation.
PG  - 2401-7
LID - 10.1194/jlr.M045583 [doi]
AB  - Resolution of inflammation is an active process involving specialized 
      proresolving mediators (SPM) formed from the n-3 fatty acids. This study examined 
      the effect of n-3 fatty acid supplementation and aspirin on plasma SPMs in 
      healthy humans. Healthy volunteers (n = 21) were supplemented with n-3 fatty 
      acids (2.4g/day) for 7 days with random assignment to take aspirin (300 mg/day) 
      or placebo from day 5 to day 7. Blood was collected at baseline (day 0), day 5, 
      and day 7. Plasma 18R/S-HEPE, E-series resolvins, 17R/S-HDHA, D-series resolvins, 
      14R/S-HDHA, and MaR-1 were measured by LC/MS/MS. At baseline concentrations of E- 
      and D- series resolvins and the upstream precursors 18R/S-HEPE, 17R/S-HDHA ranged 
      from 0.1nM to 0.2nM. 14R/S-HDHA was 3-fold higher than the other SPMs at baseline 
      but MaR-1 was below the limit of detection. Supplementation with n-3 fatty acids 
      significantly increased RvE1, 18R/S-HEPE, 17R/S-HDHA, and 14R/S-HDHA but not 
      other SPMs. The addition of aspirin after 5 days of n-3 fatty acids did not 
      affect concentrations of any SPM. N-3 fatty acid supplementation for 5 days 
      results in concentrations of SPMs that are biologically active in healthy humans. 
      Aspirin administered after n-3 fatty acids did not offer any additional benefit 
      in elevating the levels of SPMs.
CI  - Copyright © 2014 by the American Society for Biochemistry and Molecular Biology, 
      Inc.
FAU - Barden, Anne
AU  - Barden A
AD  - School of Medicine and Pharmacology, University of Western Australia, Perth, 
      Australia.
FAU - Mas, Emilie
AU  - Mas E
AD  - School of Medicine and Pharmacology, University of Western Australia, Perth, 
      Australia.
FAU - Croft, Kevin D
AU  - Croft KD
AD  - School of Medicine and Pharmacology, University of Western Australia, Perth, 
      Australia.
FAU - Phillips, Michael
AU  - Phillips M
AD  - Royal Perth Hospital Unit, and Western Australian Institute for Medical Research, 
      University of Western Australia, Perth, Australia.
FAU - Mori, Trevor A
AU  - Mori TA
AD  - School of Medicine and Pharmacology, University of Western Australia, Perth, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140903
PL  - United States
TA  - J Lipid Res
JT  - Journal of lipid research
JID - 0376606
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Inflammation Mediators)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Fatty Acids, Omega-3/chemistry/*pharmacology
MH  - Female
MH  - Humans
MH  - Inflammation Mediators/*blood
MH  - Isomerism
MH  - Male
MH  - Middle Aged
PMC - PMC4617141
OTO - NOTNLM
OT  - inflammation
OT  - n-3 fatty acids
OT  - protectins
OT  - resolvins
EDAT- 2014/09/05 06:00
MHDA- 2015/10/16 06:00
CRDT- 2014/09/05 06:00
PHST- 2014/09/05 06:00 [entrez]
PHST- 2014/09/05 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - S0022-2275(20)34991-9 [pii]
AID - m045583 [pii]
AID - 10.1194/jlr.M045583 [doi]
PST - ppublish
SO  - J Lipid Res. 2014 Nov;55(11):2401-7. doi: 10.1194/jlr.M045583. Epub 2014 Sep 3.

PMID- 15461878
OWN - NLM
STAT- MEDLINE
DCOM- 20041216
LR  - 20191109
IS  - 1366-5278 (Print)
IS  - 1366-5278 (Linking)
VI  - 8
IP  - 40
DP  - 2004 Oct
TI  - Clopidogrel used in combination with aspirin compared with aspirin alone in the 
      treatment of non-ST-segment-elevation acute coronary syndromes: a systematic 
      review and economic evaluation.
PG  - iii-iv, xv-xvi, 1-141
AB  - OBJECTIVES: To review systematically the clinical effectiveness and the 
      cost-effectiveness of clopidogrel used in combination with standard therapy 
      including aspirin, compared with standard therapy alone for the treatment of 
      non-ST-segment elevation acute coronary syndromes (ACS). DATA SOURCES: Electronic 
      databases. Manufacturers' submissions. REVIEW METHODS: Studies were selected 
      using rigorous criteria. The quality of randomised controlled trials (RCTs) was 
      assessed according to criteria based on NHS CRD Report No. 4, and the quality of 
      systematic reviews was assessed according to the guidelines for the Database of 
      Reviews of Effect (DARE) criteria. The quality of economic evaluations was 
      assessed according to a specifically tailored checklist. The clinical 
      effectiveness and cost-effectiveness of clopidogrel in combination with standard 
      therapy compared with standard therapy alone were synthesised through a narrative 
      review with full tabulation of the results of the included studies. In the 
      economic evaluations, a cost-effectiveness model was constructed using the best 
      available evidence to determine cost-effectiveness in a UK setting. RESULTS: One 
      RCT (the CURE trial) was a randomised, double-blind, placebo-controlled trial of 
      high quality and showed that clopidogrel in addition to aspirin was significantly 
      more effective than placebo plus aspirin in patients with non-ST-segment 
      elevation ACS for the composite outcome of death from cardiovascular causes, 
      non-fatal myocardial infarction or stroke over the 9-month treatment period. 
      However, clopidogrel was associated with a significantly higher number of 
      episodes of both major and minor bleeding. The results from the five systematic 
      reviews that assessed the adverse events associated with long-term aspirin use 
      showed that aspirin was associated with a significantly higher incidence of 
      haemorrhagic stroke, extracranial haemorrhage and gastrointestinal haemorrhage 
      compared with placebo. Of the cost-effectiveness evidence reviewed, only the 
      manufacturer's submission was considered relevant from the perspective of the 
      NHS. The review of this evidence highlighted potential limitations within the 
      submission in its use of data and in the model structure used. These limitations 
      led to the development of a new model with the aim of providing a more reliable 
      estimate of the cost-effectiveness from the perspective of the UK NHS. This model 
      indicated that clopidogrel appears cost-effective compared with standard care 
      alone in patients with non-ST-elevation ACS as long as the NHS is willing to pay 
      GBP6078 per quality of life year (QALY). The results were most sensitive to the 
      inclusion of additional strategies that assessed alternative treatment durations 
      with clopidogrel. Although treatment with clopidogrel for 12 months remained 
      cost-effective for the overall cohort, provisional findings indicate that the 
      shorter treatment durations may be more cost-effective in patients at low risk. 
      CONCLUSIONS: The results of the CURE trial indicate that clopidogrel in 
      combination with aspirin was significantly more effective than placebo combined 
      with aspirin in a wide range of patients with ACS. This benefit was largely 
      related to a reduction in Q-wave myocardial infarction. There was no 
      statistically significant benefit in relation to mortality. The trial data 
      suggested that a substantial part of the benefit derived from clopidogrel is 
      achieved by 3 months, with a further small benefit over the remaining 9 months of 
      chronic treatment. The results from the base-case model suggest that treatment 
      with clopidogrel as an adjunct to standard therapy (including aspirin) for 12 
      months, compared with standard therapy alone, is cost-effective in non-ST 
      elevation ACS patients as long as the health service is willing to pay GBP6078 
      per additional QALY. However, although treatment with clopidogrel for 12 months 
      remained cost-effective for the overall cohort, provisional findings indicate 
      that the shorter treatment durations may be more cost-effective in patients at 
      low risk. To estimate the exact length of time that clopidogrel in addition to 
      standard therapy should be prescribed for patients with non-ST-segment ACS would 
      require a prospective trial that randomised patients to various durations of 
      therapy. This would accurately assess whether a 'rebound' phenomenon occurs in 
      patients if clopidogrel were stopped after 3 months of treatment.
FAU - Main, C
AU  - Main C
AD  - Centre for Reviews and Dissemination, University of York, UK.
FAU - Palmer, S
AU  - Palmer S
FAU - Griffin, S
AU  - Griffin S
FAU - Jones, L
AU  - Jones L
FAU - Orton, V
AU  - Orton V
FAU - Sculpher, M
AU  - Sculpher M
FAU - Henderson, R
AU  - Henderson R
FAU - Sudlow, C
AU  - Sudlow C
FAU - Hawkins, N
AU  - Hawkins N
FAU - Riemsma, R
AU  - Riemsma R
LA  - eng
GR  - 063668/Wellcome Trust/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Health Technol Assess
JT  - Health technology assessment (Winchester, England)
JID - 9706284
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/economics/*therapeutic use
MH  - Clopidogrel
MH  - Coronary Disease/diagnosis/*drug therapy/economics
MH  - Cost-Benefit Analysis
MH  - Drug Therapy, Combination
MH  - Electrocardiography
MH  - Humans
MH  - Platelet Aggregation Inhibitors/economics/*therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/*analogs & derivatives/economics/*therapeutic use
MH  - Treatment Outcome
RF  - 477
EDAT- 2004/10/06 09:00
MHDA- 2004/12/17 09:00
CRDT- 2004/10/06 09:00
PHST- 2004/10/06 09:00 [pubmed]
PHST- 2004/12/17 09:00 [medline]
PHST- 2004/10/06 09:00 [entrez]
AID - 02-24-01 [pii]
AID - 10.3310/hta8400 [doi]
PST - ppublish
SO  - Health Technol Assess. 2004 Oct;8(40):iii-iv, xv-xvi, 1-141. doi: 
      10.3310/hta8400.

PMID- 3908675
OWN - NLM
STAT- MEDLINE
DCOM- 19860206
LR  - 20131121
IS  - 0024-7758 (Print)
IS  - 0024-7758 (Linking)
VI  - 30
IP  - 12
DP  - 1985 Dec
TI  - Efficacy of fenoprofen in the treatment of primary dysmenorrhea.
PG  - 915-9
AB  - We compared fenoprofen calcium, 200 mg; fenoprofen calcium, 400 mg; aspirin, 650 
      mg; and a placebo in 85 women for the relief of primary dysmenorrhea in a 
      double-blind, clinical trial. The usefulness of these drugs was judged from data 
      obtained over four consecutive menstrual periods on: restriction of daily 
      activity, pain intensity scores, need for rescue analgesics, withdrawal due to 
      lack of efficacy, and adverse events. Both fenoprofen, 200 mg, and fenoprofen, 
      400 mg, offered significant (P less than .01) pain relief when compared to 
      placebo and aspirin. Analyses of data on 1, 2 and 3 indicated that aspirin was 
      not significantly different from placebo. The aspirin-treated group reported the 
      greatest number of adverse reactions, but the differences between the four groups 
      were not statistically significant. Our study lends support to the concept of a 
      "plateau analgesic effect" of nonsteroidal antiinflammatory drugs (NSAIDs): 
      fenoprofen, 200 mg, appears to be as effective as fenoprofen, 400 mg. When this 
      type of drug fails to provide relief for a woman suffering from primary 
      dysmenorrhea, switching to another NSAID may be more appropriate than increasing 
      the dosage and the probability of dosage-related side effects.
FAU - Osathanondh, R
AU  - Osathanondh R
FAU - Caldwell, B V
AU  - Caldwell BV
FAU - Kaul, A F
AU  - Kaul AF
FAU - Sokoloff, B J
AU  - Sokoloff BJ
FAU - White, R M
AU  - White RM
FAU - Scavone, J M
AU  - Scavone JM
FAU - Burt, R A
AU  - Burt RA
FAU - Naftolin, F
AU  - Naftolin F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Reprod Med
JT  - The Journal of reproductive medicine
JID - 0173343
RN  - 0 (Analgesics)
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analgesics/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Dysmenorrhea/*drug therapy
MH  - Female
MH  - Fenoprofen/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Pain/drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - Random Allocation
EDAT- 1985/12/01 00:00
MHDA- 1985/12/01 00:01
CRDT- 1985/12/01 00:00
PHST- 1985/12/01 00:00 [pubmed]
PHST- 1985/12/01 00:01 [medline]
PHST- 1985/12/01 00:00 [entrez]
PST - ppublish
SO  - J Reprod Med. 1985 Dec;30(12):915-9.

PMID- 15452309
OWN - NLM
STAT- MEDLINE
DCOM- 20050518
LR  - 20190514
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 63
IP  - 6
DP  - 2004 Sep 28
TI  - Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin 
      combination.
PG  - 1099-101
AB  - The authors assessed the prevalence of headaches following extended-release 
      dipyridamole/aspirin combination (DAC), and the efficacy of acetaminophen in the 
      treatment of these headaches. Following DAC, 38.7% of the participants developed 
      headaches. The headaches were self-limited (69.4% placebo efficacy in 2 hours) 
      and the incidence markedly declined over time. Acetaminophen was no more 
      effective than placebo in the acute and preemptive treatment of these headaches.
FAU - Lipton, R B
AU  - Lipton RB
AD  - Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park 
      Avenue, Bronx, NY 10461, USA. Rlipton@aecom.yu.edu
FAU - Bigal, M E
AU  - Bigal ME
FAU - Kolodner, K B
AU  - Kolodner KB
FAU - Gorelick, P B
AU  - Gorelick PB
FAU - Wilks, K
AU  - Wilks K
FAU - Schoebelock, M
AU  - Schoebelock M
FAU - Davidai, G
AU  - Davidai G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Aged
MH  - Analgesics, Non-Narcotic/*therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dipyridamole/administration & dosage/*adverse effects
MH  - Drug Combinations
MH  - Female
MH  - Headache/chemically induced/*drug therapy/prevention & control
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Remission, Spontaneous
MH  - Risk
MH  - Treatment Failure
EDAT- 2004/09/29 05:00
MHDA- 2005/05/19 09:00
CRDT- 2004/09/29 05:00
PHST- 2004/09/29 05:00 [pubmed]
PHST- 2005/05/19 09:00 [medline]
PHST- 2004/09/29 05:00 [entrez]
AID - 63/6/1099 [pii]
AID - 10.1212/01.wnl.0000138494.66691.07 [doi]
PST - ppublish
SO  - Neurology. 2004 Sep 28;63(6):1099-101. doi: 10.1212/01.wnl.0000138494.66691.07.

PMID- 9218889
OWN - NLM
STAT- MEDLINE
DCOM- 19970821
LR  - 20131121
IS  - 0011-4162 (Print)
IS  - 0011-4162 (Linking)
VI  - 59
IP  - 6
DP  - 1997 Jun
TI  - A new triad: sensitivity to aspirin, allergic rhinitis, and severe allergic 
      reaction to ingested aeroallergens.
PG  - 311-4
AB  - Increasing attention has recently been paid to a group of patients who experience 
      anaphylaxis after ingestion of foods prepared with mite-contaminated wheat flour. 
      We present three cases of this syndrome, which occurs more often in young adults 
      with allergic rhinitis and/or asthma. We have observed an increased frequency of 
      sensitivity to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), 
      manifested as urticaria or angioedema, in patients with this condition.
FAU - Sánchez-Borges, M
AU  - Sánchez-Borges M
AD  - Pediatrics Department, Centro Médico-Docente La Trinidad, Caracas, Venezuela.
FAU - Capriles-Hulett, A
AU  - Capriles-Hulett A
FAU - Capriles-Behrens, E
AU  - Capriles-Behrens E
FAU - Fernandez-Caldas, E
AU  - Fernandez-Caldas E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Drug Hypersensitivity/diagnosis/*etiology
MH  - Female
MH  - Flour
MH  - *Food Contamination
MH  - Humans
MH  - Hypersensitivity/drug therapy/*etiology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - *Mites
MH  - Rhinitis/drug therapy/*etiology/physiopathology
RF  - 11
EDAT- 1997/06/01 00:00
MHDA- 1997/06/01 00:01
CRDT- 1997/06/01 00:00
PHST- 1997/06/01 00:00 [pubmed]
PHST- 1997/06/01 00:01 [medline]
PHST- 1997/06/01 00:00 [entrez]
PST - ppublish
SO  - Cutis. 1997 Jun;59(6):311-4.

PMID- 1173629
OWN - NLM
STAT- MEDLINE
DCOM- 19750926
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 232
IP  - 9
DP  - 1975 Jun 2
TI  - Acute rheumatic fever in adults.
PG  - 925-8
AB  - Acute rheumatic fever (ARF) in 53 adults was characterized by a severe, febrile 
      migratory polyarthritis involving primarily large joints in the lower 
      extremities, with evidence of an antecedent streptococcal infection. Carditis, 
      present in only eight (15%) of the adults, was mild and transient. The 
      characteristic abnormality in laboratory findings was an erythrocyte 
      sedimentation rate (Westergren) greater than 100 mm/hr. Response to high-dose 
      aspirin therapy was prompt and dramatic in all patients. Mild andevanescent 
      abnormalities of both renal function and hepatic function (not aspirin-mediated) 
      were detected in 51% and 64%, respectively. A common disorder in San Antonio, ARF 
      has distinctive symptoms. It can be readily diagnosed and promptly treated. In 
      the adult, it is almost exclusively a syndrome of events severe but transient in 
      the joints, and mild and transient in the heart, kidneys, and liver.
FAU - Barnert, A L
AU  - Barnert AL
FAU - Terry, E E
AU  - Terry EE
FAU - Persellin, R H
AU  - Persellin RH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Arthritis, Rheumatoid/diagnosis
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blood Sedimentation
MH  - Female
MH  - Humans
MH  - Kidney/physiopathology
MH  - Liver/physiopathology
MH  - Male
MH  - Middle Aged
MH  - *Rheumatic Fever/diagnosis/epidemiology/therapy
MH  - Rheumatic Heart Disease/diagnosis
MH  - Streptococcal Infections/complications
MH  - Texas
EDAT- 1975/06/02 00:00
MHDA- 1975/06/02 00:01
CRDT- 1975/06/02 00:00
PHST- 1975/06/02 00:00 [pubmed]
PHST- 1975/06/02 00:01 [medline]
PHST- 1975/06/02 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1975 Jun 2;232(9):925-8.

PMID- 29984591
OWN - NLM
STAT- MEDLINE
DCOM- 20191016
LR  - 20191016
IS  - 1557-900X (Electronic)
IS  - 0892-7790 (Linking)
VI  - 32
IP  - 9
DP  - 2018 Sep 12
TI  - Does Continuation of Low-Dose Aspirin During Robot-Assisted Radical Prostatectomy 
      Compromise Surgical Outcomes?
PG  - 852-858
LID - 10.1089/end.2018.0390 [doi]
AB  - OBJECTIVE: To evaluate the perioperative outcomes and 90-day complication rates 
      of continuation of low-dose aspirin through surgery in patients undergoing 
      robot-assisted radical prostatectomy (RARP). A significant proportion of patients 
      undergoing RARP are on antiplatelet medications for primary or secondary 
      prevention of cardiovascular events. However, there is still a relative lack of 
      data with regard to the advantages and complications of continuing these 
      medications through surgery. MATERIALS AND METHODS: Our usual protocol of RARP 
      entails continuation of low-dose aspirin (75 mg once a day) for patients who are 
      already on antiplatelet agents. We conducted a retrospective audit of a 
      prospectively maintained database of 116 cases of RARP performed by a single 
      surgical team in 1 year. Patients were divided into low-dose aspirin group (AG) 
      (n = 31) and nonaspirin group (NAG) (n = 85). The primary objective was to 
      compare the 90-day complication rates to assess the safety profile. Secondary 
      objective was to compare perioperative parameters such as estimated blood loss, 
      blood transfusion rates, fall in hemoglobin (Hb) level, drain outputs on day 1, 
      days to drain removal, lymph node yield, and margin positivity. Subgroup 
      comparison was performed between patients on aspirin for primary prevention 
      (n = 15) and NAG. RESULTS: Both groups were well matched for preoperative 
      parameters except for significantly higher comorbidities and American Society of 
      Anesthesiologists (ASA) score class in AG. Console time, blood loss, fall in Hb 
      level, drain output, drain and catheter removal days, day of discharge, and lymph 
      node yield were comparable. Margin positivity was significantly higher in NAG. 
      Ninety-day complication rates were not significantly different between the two 
      groups (p = 0.218) with only one major complication (Clavien-Dindo grade 4 
      hypotension requiring intensive care unit admission) in AG. Subgroup comparison 
      demonstrated similar outcomes. CONCLUSION: Low-dose aspirin can be safely 
      continued perioperatively during RARP, without increasing the bleeding-related 
      complications and overall 90-day complication rates.
FAU - Tamhankar, Ashwin Sunil
AU  - Tamhankar AS
AD  - Department of Urooncology, Max Institute of Cancer Care , New Delhi, India .
FAU - Patil, Saurabh Ramesh
AU  - Patil SR
AD  - Department of Urooncology, Max Institute of Cancer Care , New Delhi, India .
FAU - Ahluwalia, Puneet
AU  - Ahluwalia P
AD  - Department of Urooncology, Max Institute of Cancer Care , New Delhi, India .
FAU - Gautam, Gagan
AU  - Gautam G
AD  - Department of Urooncology, Max Institute of Cancer Care , New Delhi, India .
LA  - eng
PT  - Journal Article
DEP - 20180828
PL  - United States
TA  - J Endourol
JT  - Journal of endourology
JID - 8807503
RN  - 0 (Hemoglobins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Loss, Surgical/statistics & numerical data
MH  - Blood Transfusion/statistics & numerical data
MH  - Drainage/statistics & numerical data
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Prostatectomy/*methods
MH  - Prostatic Neoplasms/*surgery
MH  - Retrospective Studies
MH  - Robotic Surgical Procedures/*methods
OTO - NOTNLM
OT  - 90-day complication rates
OT  - coronary artery disease
OT  - low-dose aspirin
OT  - major adverse cardiac events
OT  - robot-assisted radical prostatectomy
EDAT- 2018/07/10 06:00
MHDA- 2019/10/17 06:00
CRDT- 2018/07/10 06:00
PHST- 2018/07/10 06:00 [pubmed]
PHST- 2019/10/17 06:00 [medline]
PHST- 2018/07/10 06:00 [entrez]
AID - 10.1089/end.2018.0390 [doi]
PST - ppublish
SO  - J Endourol. 2018 Sep 12;32(9):852-858. doi: 10.1089/end.2018.0390. Epub 2018 Aug 
      28.

PMID- 29240976
OWN - NLM
STAT- MEDLINE
DCOM- 20180126
LR  - 20200225
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 12
IP  - 12
DP  - 2017 Dec 14
TI  - Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular 
      events.
PG  - CD005158
LID - 10.1002/14651858.CD005158.pub4 [doi]
LID - CD005158
AB  - BACKGROUND: Aspirin is the prophylactic antiplatelet drug of choice for people 
      with cardiovascular disease. Adding a second antiplatelet drug to aspirin may 
      produce additional benefit for people at high risk and people with established 
      cardiovascular disease. This is an update to a previously published review from 
      2011. OBJECTIVES: To review the benefit and harm of adding clopidogrel to aspirin 
      therapy for preventing cardiovascular events in people who have coronary disease, 
      ischaemic cerebrovascular disease, peripheral arterial disease, or were at high 
      risk of atherothrombotic disease, but did not have a coronary stent. SEARCH 
      METHODS: We updated the searches of CENTRAL (2017, Issue 6), MEDLINE (Ovid, 1946 
      to 4 July 2017) and Embase (Ovid, 1947 to 3 July 2017) on 4 July 2017. We also 
      searched ClinicalTrials.gov and the WHO ICTRP portal, and handsearched reference 
      lists. We applied no language restrictions. SELECTION CRITERIA: We included all 
      randomised controlled trials comparing over 30 days use of aspirin plus 
      clopidogrel with aspirin plus placebo or aspirin alone in people with coronary 
      disease, ischaemic cerebrovascular disease, peripheral arterial disease, or at 
      high risk of atherothrombotic disease. We excluded studies including only people 
      with coronary drug-eluting stent (DES) or non-DES, or both. DATA COLLECTION AND 
      ANALYSIS: We collected data on mortality from cardiovascular causes, all-cause 
      mortality, fatal and non-fatal myocardial infarction, fatal and non-fatal 
      ischaemic stroke, major and minor bleeding. The overall treatment effect was 
      estimated by the pooled risk ratio (RR) with 95% confidence interval (CI), using 
      a fixed-effect model (Mantel-Haenszel); we used a random-effects model in cases 
      of moderate or severe heterogeneity (I(2) ≥ 30%). We assessed the quality of the 
      evidence using the GRADE approach. We used GRADE profiler (GRADE Pro) to import 
      data from Review Manager to create a 'Summary of findings' table. MAIN RESULTS: 
      The search identified 13 studies in addition to the two studies in the previous 
      version of our systematic review. Overall, we included data from 15 trials with 
      33,970 people. We completed a 'Risk of bias' assessment for all studies. The risk 
      of bias was low in four trials because they were at low risk of bias for all key 
      domains (random sequence generation, allocation concealment, blinding, selective 
      outcome reporting and incomplete outcome data), even if some of them were funded 
      by the pharmaceutical industry.Analysis showed no difference in the effectiveness 
      of aspirin plus clopidogrel in preventing cardiovascular mortality (RR 0.98, 95% 
      CI 0.88 to 1.10; participants = 31,903; studies = 7; moderate quality evidence), 
      and no evidence of a difference in all-cause mortality (RR 1.05, 95% CI 0.87 to 
      1.25; participants = 32,908; studies = 9; low quality evidence).There was a lower 
      risk of fatal and non-fatal myocardial infarction with clopidogrel plus aspirin 
      compared with aspirin plus placebo or aspirin alone (RR 0.78, 95% CI 0.69 to 
      0.90; participants = 16,175; studies = 6; moderate quality evidence). There was a 
      reduction in the risk of fatal and non-fatal ischaemic stroke (RR 0.73, 95% CI 
      0.59 to 0.91; participants = 4006; studies = 5; moderate quality 
      evidence).However, there was a higher risk of major bleeding with clopidogrel 
      plus aspirin compared with aspirin plus placebo or aspirin alone (RR 1.44, 95% CI 
      1.25 to 1.64; participants = 33,300; studies = 10; moderate quality evidence) and 
      of minor bleeding (RR 2.03, 95% CI 1.75 to 2.36; participants = 14,731; studies = 
      8; moderate quality evidence).Overall, we would expect 13 myocardial infarctions 
      and 23 ischaemic strokes be prevented for every 1000 patients treated with the 
      combination in a median follow-up period of 12 months, but 9 major bleeds and 33 
      minor bleeds would be caused during a median follow-up period of 10.5 and 6 
      months, respectively. AUTHORS' CONCLUSIONS: The available evidence demonstrates 
      that the use of clopidogrel plus aspirin in people at high risk of cardiovascular 
      disease and people with established cardiovascular disease without a coronary 
      stent is associated with a reduction in the risk of myocardial infarction and 
      ischaemic stroke, and an increased risk of major and minor bleeding compared with 
      aspirin alone. According to GRADE criteria, the quality of evidence was moderate 
      for all outcomes except all-cause mortality (low quality evidence) and adverse 
      events (very low quality evidence).
FAU - Squizzato, Alessandro
AU  - Squizzato A
AD  - Research Center on Thromboembolic Disorders and Antithrombotic Therapies, 
      Department of Medicine and Surgery, School of Medicine, University of Insubria, 
      c/o Medicina 1, ASST Settelaghi Ospedale di Circolo, viale Borri, 57, Varese, 
      Italy, 21100.
FAU - Bellesini, Marta
AU  - Bellesini M
FAU - Takeda, Andrea
AU  - Takeda A
FAU - Middeldorp, Saskia
AU  - Middeldorp S
FAU - Donadini, Marco Paolo
AU  - Donadini MP
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20171214
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2011 Jan 19;(1):CD005158. PMID: 21249668
CIN - Ann Intern Med. 2018 Apr 17;168(8):JC45. PMID: 29677252
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Clopidogrel
MH  - Drug Therapy, Combination/adverse effects/methods
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
PMC - PMC6486024
COIS- AS: none MB: none AT: none SM: reports grants and fees paid to her institution 
      from GSK, BMS/Pfizer, Aspen, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Sanofi 
      and Sanquin Blood Supply. MPD: No relevant conflict of interest to declare for 
      the work under consideration. I only declare that, for some congresses, the 
      travel, accomodation and meeting expenses have been paid by different 
      pharmaceutical companies.
EDAT- 2017/12/15 06:00
MHDA- 2018/01/27 06:00
CRDT- 2017/12/15 06:00
PHST- 2017/12/15 06:00 [pubmed]
PHST- 2018/01/27 06:00 [medline]
PHST- 2017/12/15 06:00 [entrez]
AID - CD005158.pub4 [pii]
AID - 10.1002/14651858.CD005158.pub4 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2017 Dec 14;12(12):CD005158. doi: 
      10.1002/14651858.CD005158.pub4.

PMID- 11503810
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20131121
IS  - 1167-7422 (Print)
IS  - 1167-7422 (Linking)
VI  - 8
IP  - 44
DP  - 1999 Dec
TI  - Clopidogrel: new preparation. An alternative to aspirin.
PG  - 163-4
AB  - (1) Clopidogrel, an antiplatelet drug chemically similar to ticlopidine, is 
      marketed in France for secondary prevention of thrombotic complications in 
      patients with a history of myocardial infarction, ischaemic stroke or peripheral 
      arterial disease. (2) Marketing authorisation was based mainly on the CAPRIE 
      trial, a study that involved 19,815 patients. In this trial of secondary 
      cardiovascular prevention, clopidogrel was slightly more effective than aspirin 
      (325 mg/day) according to a statistical analysis of a combined end point 
      (ischaemic stroke, or myocardial infarction, or death of vascular causes). The 
      difference was more marked in the subgroup of patients with obstructive arterial 
      disease of the lower limbs. (3) Clopidogrel was well tolerated in this trial. The 
      only adverse effects more frequent on clopidogrel than on aspirin were rash and 
      diarrhoea. (4) Clopidogrel showed no haematological toxicity, an adverse effect 
      that restricts the use of ticlopidine. (5) The lack of long-term follow-up in 
      real clinical settings prevents any meaningful estimation of the safety profile 
      or of the risk of drug interactions.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - France
TA  - Prescrire Int
JT  - Prescrire international
JID - 9439295
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - *Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - *Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Stroke/prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2001/08/16 10:00
MHDA- 2001/08/17 10:01
CRDT- 2001/08/16 10:00
PHST- 2001/08/16 10:00 [pubmed]
PHST- 2001/08/17 10:01 [medline]
PHST- 2001/08/16 10:00 [entrez]
PST - ppublish
SO  - Prescrire Int. 1999 Dec;8(44):163-4.

PMID- 11009481
OWN - NLM
STAT- MEDLINE
DCOM- 20001107
LR  - 20200930
IS  - 0363-6135 (Print)
IS  - 0363-6135 (Linking)
VI  - 279
IP  - 4
DP  - 2000 Oct
TI  - Diaspirin cross-linked Hb and norepinephrine prevent the sepsis-induced increase 
      in critical O(2) delivery.
PG  - H1922-30
AB  - We hypothesized that support of arterial perfusion pressure with diaspirin 
      cross-linked Hb (DCLHb) would prevent the sepsis-induced attenuation in the 
      systemic O(2) delivery-O(2) uptake relationship. Awake septic rats were treated 
      with a chronic infusion of DCLHb or a reference treatment [norepinephrine (NE)] 
      to increase mean arterial pressure by 10-20% over 18 h. Septic and sham control 
      groups received normal saline. Isovolemic hemodilution to create anemic hypoxia 
      was then performed in a metabolic box during continuous measurement of systemic 
      O(2) uptake. O(2) delivery was calculated from hemodynamic variables, and the 
      critical point of O(2) delivery (DO(2 crit)) was determined using piecewise 
      regression analysis of the O(2) delivery-O(2) uptake relationship. Sepsis 
      increased DO(2 crit) from 4.99 +/- 0.17 to 6.69 +/- 0.42 ml x min(-1) x 100 g(-1) 
      (P < 0.01), while O(2) extraction capacity was decreased (P < 0.05). DCLHb and NE 
      infusion prevented the sepsis-induced increase in DO(2 crit) [4.56 +/- 0.42 ml x 
      min(-1) x 100 g(-1) (P < 0.01) and 5.04 +/- 0.56 ml x min(-1) x 100 g(-1) (P < 
      0.05), respectively]. This was explained by a 59% increase in O(2) extraction 
      capacity in the DCLHb group compared with septic controls (P < 0.05), whereas NE 
      treatment decreased systemic O(2) uptake in anemic hypoxia (1.51 +/- 0.08 vs. 
      1.87 +/- 0.1 ml x min(-1) x 100 g(-1) in septic controls, P < 0.05). We conclude 
      that DCLHb ameliorated O(2) extraction capacity in the septic microcirculation, 
      whereas NE decreased the metabolic demands of the tissues.
FAU - Sielenkämper, A W
AU  - Sielenkämper AW
AD  - The A. C. Burton Vascular Biology Laboratory, Victoria Hospital Research 
      Institute, and The University of Western Ontario, London, Ontario, Canada N6A 
      4G5.
FAU - Yu, P
AU  - Yu P
FAU - Eichelbrönner, O
AU  - Eichelbrönner O
FAU - MacDonald, T
AU  - MacDonald T
FAU - Martin, C M
AU  - Martin CM
FAU - Chin-Yee, I H
AU  - Chin-Yee IH
FAU - Sibbald, W J
AU  - Sibbald WJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Physiol Heart Circ Physiol
JT  - American journal of physiology. Heart and circulatory physiology
JID - 100901228
RN  - 0 (Hemoglobins)
RN  - 0 (Vasoconstrictor Agents)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Bacterial Infections/*blood/metabolism
MH  - Biological Availability
MH  - Blood Pressure/drug effects
MH  - Hemodilution
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Norepinephrine/*pharmacology
MH  - Oxygen/*blood
MH  - Oxygen Consumption/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Time Factors
MH  - Vasoconstrictor Agents/*pharmacology
EDAT- 2000/09/29 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/29 11:00
PHST- 2000/09/29 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/29 11:00 [entrez]
AID - 10.1152/ajpheart.2000.279.4.H1922 [doi]
PST - ppublish
SO  - Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H1922-30. doi: 
      10.1152/ajpheart.2000.279.4.H1922.

PMID- 22542155
OWN - NLM
STAT- MEDLINE
DCOM- 20130320
LR  - 20181201
IS  - 1532-1916 (Electronic)
IS  - 1521-6918 (Linking)
VI  - 26
IP  - 2
DP  - 2012 Apr
TI  - Balancing the risk and benefits of low-dose aspirin in clinical practice.
PG  - 173-84
LID - 10.1016/j.bpg.2012.01.015 [doi]
AB  - Antiplatelet agents are widely used in primary and secondary prevention of 
      cardiovascular events. The scientific evidence has provided strong support for 
      the benefits of aspirin in decreasing the risk of cardiovascular events in a wide 
      range of pathologies. The relatively rare occurrence of major bleeding 
      complications should not be underestimated, mainly due to its high 
      morbi-mortality. The assessment of both gastrointestinal risk and cardiovascular 
      benefits of low-dose aspirin for any individual patient may be difficult in 
      clinical practice. In this review, we summarize the evidence supporting the 
      efficacy of aspirin and the risks of side effects due to hemorrhagic 
      complications. This article proposes a unifying framework for application to help 
      the clinician in the decision making process of individuals who have different 
      risk of cardiovascular and bleeding events with different examples. Finally, new 
      developments in the field directed towards individualized risk assessment 
      strategies are described.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Casado-Arroyo, Rubén
AU  - Casado-Arroyo R
AD  - Heart Rhythm Management Center, Cardiovascular Center, Free University of 
      Brussels (UZ Brussel) VUB, Brussels, Belgium. rbcasado@gmail.com
FAU - Gargallo, Carla
AU  - Gargallo C
FAU - Lanas Arbeloa, Angel
AU  - Lanas Arbeloa A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Gastroenterol
JT  - Best practice & research. Clinical gastroenterology
JID - 101120605
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Colorectal Neoplasms/prevention & control
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Hemorrhage/*chemically induced/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*adverse effects
MH  - Primary Prevention
MH  - Risk Assessment
MH  - Secondary Prevention
MH  - Upper Gastrointestinal Tract/*drug effects
EDAT- 2012/05/01 06:00
MHDA- 2013/03/21 06:00
CRDT- 2012/05/01 06:00
PHST- 2011/12/12 00:00 [received]
PHST- 2012/01/21 00:00 [revised]
PHST- 2012/01/24 00:00 [accepted]
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
AID - S1521-6918(12)00016-9 [pii]
AID - 10.1016/j.bpg.2012.01.015 [doi]
PST - ppublish
SO  - Best Pract Res Clin Gastroenterol. 2012 Apr;26(2):173-84. doi: 
      10.1016/j.bpg.2012.01.015.

PMID- 1101758
OWN - NLM
STAT- MEDLINE
DCOM- 19751211
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 83
IP  - 4
DP  - 1975 Oct
TI  - Naproxen in rheumatoid arthritis. A controlled trial.
PG  - 470-5
AB  - The efficacy of naproxen in treating rheumatoid arthritis patients was evaluated 
      in a double-blind clinical trial using aspirin as the control drug. The study was 
      conducted at seven centers and involved 80 patients. After an unequivocal 
      increase in disease activity during a drug-free period, patients were randomly 
      assigned to either drug and continued in the trial for 16 weeks. Some patients 
      took low maintenance doses of corticosteroids, or gold salts, or both throughout 
      the trial. Both test drugs significantly decreased disease activity as measured 
      by a number of ways. By objective measurements, naproxen was as effective as 
      aspirin, although patients in the naproxen-treated group entered the trial with 
      more severe disease. By some subjective evaluations, naproxen was considered more 
      effective than aspirin. Although patients taking naproxen had less frequent 
      gastrointestinal side effects and fewer symptoms VIIIth nerve toxicity, the 
      differences were not statistically significant. We conclude that naproxen is a 
      useful addition to the physician's armamentarium for the treatment of rheumatoid 
      arthritis.
FAU - Bowers, D E
AU  - Bowers DE
FAU - Dyer, H R
AU  - Dyer HR
FAU - Fosdick, W M
AU  - Fosdick WM
FAU - Keller, K E
AU  - Keller KE
FAU - Rosenberg, A L
AU  - Rosenberg AL
FAU - Sussman, P
AU  - Sussman P
FAU - Vancil, M E
AU  - Vancil ME
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Naphthaleneacetic Acids)
RN  - 57Y76R9ATQ (Naproxen)
RN  - 7440-57-5 (Gold)
RN  - 9009-79-4 (Rheumatoid Factor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Sedimentation
MH  - Clinical Trials as Topic
MH  - Female
MH  - Gold/therapeutic use
MH  - Humans
MH  - Male
MH  - Naphthaleneacetic Acids/*therapeutic use
MH  - Naproxen/adverse effects/*therapeutic use
MH  - Rheumatoid Factor/analysis
EDAT- 1975/10/01 00:00
MHDA- 1975/10/01 00:01
CRDT- 1975/10/01 00:00
PHST- 1975/10/01 00:00 [pubmed]
PHST- 1975/10/01 00:01 [medline]
PHST- 1975/10/01 00:00 [entrez]
AID - 10.7326/0003-4819-83-4-470 [doi]
PST - ppublish
SO  - Ann Intern Med. 1975 Oct;83(4):470-5. doi: 10.7326/0003-4819-83-4-470.

PMID- 9560791
OWN - NLM
STAT- MEDLINE
DCOM- 19980529
LR  - 20190516
IS  - 0916-7250 (Print)
IS  - 0916-7250 (Linking)
VI  - 60
IP  - 3
DP  - 1998 Mar
TI  - Increased ductal responsiveness to PGE2 after maternal treatment with aspirin and 
      ibuprofen.
PG  - 377-9
AB  - This work was conducted to determine whether aspirin and ibuprofen, when 
      administered prenatally may potentiate a reopening of the neonatal ductus 
      arteriosus (DA) induced by PGE2 after postnatal closure. In the first experiment, 
      a subcutaneous injection of PGE2 (4 microgram(s)) was administered to newborn 
      rats 3 hr after a Cesarean delivery from pregnant females which had been orally 
      given 100 or 300 mg/kg/day of aspirin and 10 or 30 mg/kg/day of ibuprofen on days 
      18, 19 and 20 of gestation. The ratio of the DA to the pulmonary artery (PA) was 
      determined at intervals after the injection. The DA/PA ratio was significantly 
      higher in newborn rats from mothers who were transplacentally administered these 
      agents than the control. We also examined the hypothesis that maternal treatment 
      with nonsteroidal anti-inflammatory drugs (NSAID), such as aspirin and ibuprofen, 
      inhibits the catabolism of PGE2 and that the increased reopening of the DA was 
      partly due to this inhibition. 15-hydroxy prostaglandin dehydrogenase (15-PGDH) 
      in neonatal lungs, the key enzyme involved in catalyzing PGE2 to convert it to 
      its inactive metabolite 15-keto-PGE2, was not affected by maternal treatment with 
      aspirin and ibuprofen. These results suggest that the increased ductal 
      responsiveness to PGE2 in newborn rats was a common response after maternal NSAID 
      treatment, but the catabolism of PGE2 in the lungs did not always contribute to 
      this response.
FAU - Takizawa, T
AU  - Takizawa T
AD  - Department of Developmental and Reproductive Biotechnology, Azabu University 
      School of Veterinary Medicine, Kanagawa, Japan.
FAU - Ikeda, Y
AU  - Ikeda Y
FAU - Kawahata, M
AU  - Kawahata M
FAU - Togashi, H
AU  - Togashi H
FAU - Yamamoto, M
AU  - Yamamoto M
FAU - Arishima, K
AU  - Arishima K
FAU - Masaoka, T
AU  - Masaoka T
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Vet Med Sci
JT  - The Journal of veterinary medical science
JID - 9105360
RN  - EC 1.1.1.- (Hydroxyprostaglandin Dehydrogenases)
RN  - EC 1.1.1.141 (15-hydroxyprostaglandin dehydrogenase)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Animals, Newborn
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cesarean Section
MH  - Dinoprostone/*pharmacology
MH  - Ductus Arteriosus/*drug effects/physiology
MH  - Female
MH  - Gestational Age
MH  - Hydroxyprostaglandin Dehydrogenases/metabolism
MH  - Ibuprofen/administration & dosage/*pharmacology
MH  - Lung/enzymology
MH  - Pregnancy
MH  - *Prenatal Exposure Delayed Effects
MH  - Pulmonary Artery/*drug effects/embryology/physiology
MH  - Rats
MH  - Rats, Wistar
EDAT- 1998/04/30 00:00
MHDA- 1998/04/30 00:01
CRDT- 1998/04/30 00:00
PHST- 1998/04/30 00:00 [pubmed]
PHST- 1998/04/30 00:01 [medline]
PHST- 1998/04/30 00:00 [entrez]
AID - 10.1292/jvms.60.377 [doi]
PST - ppublish
SO  - J Vet Med Sci. 1998 Mar;60(3):377-9. doi: 10.1292/jvms.60.377.

PMID- 15815775
OWN - NLM
STAT- MEDLINE
DCOM- 20050628
LR  - 20131121
IS  - 0022-9032 (Print)
IS  - 0022-9032 (Linking)
VI  - 62
IP  - 1
DP  - 2005 Jan
TI  - Aspirin resistance in ischaemic heart disease.
PG  - 14-25
AB  - BACKGROUND: In spite of the usage of acetylsalicylic acid (aspirin) in the 
      secondary prevention of ischaemic heart disease (IHD), new thrombo-embolic events 
      occur in more than half of patients. Aspirin resistance may be partially 
      responsible for this phenomenon. AIM: To assess the prevalence of aspirin 
      resistance in patients with IHD and to correlate this phenomenon with the 
      progression of atherosclerosis, concomitant diseases and other medication. 
      METHODS: The study group consisted of 205 patients (mean age 65.8 years, 95 
      females) with stable angina, recent coronary angiography and positive result of 
      non-invasive stress tests, treated with 75 mg of aspirin for at least one week. 
      Platelet aggregation was measured using the optical aggregation method. Aspirin 
      resistance was defined as a mean collagen and ATP-induced platelet aggregation 
      >70%. RESULTS: Aspirin resistance was found in 41 (20%) patients and was 
      significantly associated with previous coronary artery bypass grafting (CABG) 
      (p<0.01) and three-vessel disease (p<0.05). Previous CABG was the only 
      independent risk factor for the presence of aspirin resistance (OR 5.6; 95% CI 
      2.0-15.4; p<0.01). CONCLUSIONS: Aspirin resistance is present in 20% of patients 
      with stable angina. Previous CABG is an independent risk factor of this 
      phenomenon.
FAU - Kuliczkowski, Wiktor
AU  - Kuliczkowski W
AD  - Department of Cardiology, Medical Academy, Wrocław, Poland.
FAU - Halawa, Bogumił
AU  - Halawa B
FAU - Korolko, Bozena
AU  - Korolko B
FAU - Mazurek, Walentyna
AU  - Mazurek W
LA  - eng
LA  - pol
PT  - Journal Article
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Ischemia/*drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Prevalence
MH  - Risk Factors
EDAT- 2005/04/09 09:00
MHDA- 2005/06/29 09:00
CRDT- 2005/04/09 09:00
PHST- 2005/04/09 09:00 [pubmed]
PHST- 2005/06/29 09:00 [medline]
PHST- 2005/04/09 09:00 [entrez]
PST - ppublish
SO  - Kardiol Pol. 2005 Jan;62(1):14-25.

PMID- 30146931
OWN - NLM
STAT- MEDLINE
DCOM- 20181105
LR  - 20220409
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 379
IP  - 16
DP  - 2018 Oct 18
TI  - Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
PG  - 1529-1539
LID - 10.1056/NEJMoa1804988 [doi]
AB  - BACKGROUND: Diabetes mellitus is associated with an increased risk of 
      cardiovascular events. Aspirin use reduces the risk of occlusive vascular events 
      but increases the risk of bleeding; the balance of benefits and hazards for the 
      prevention of first cardiovascular events in patients with diabetes is unclear. 
      METHODS: We randomly assigned adults who had diabetes but no evident 
      cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching 
      placebo. The primary efficacy outcome was the first serious vascular event (i.e., 
      myocardial infarction, stroke or transient ischemic attack, or death from any 
      vascular cause, excluding any confirmed intracranial hemorrhage). The primary 
      safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, 
      sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other 
      serious bleeding). Secondary outcomes included gastrointestinal tract cancer. 
      RESULTS: A total of 15,480 participants underwent randomization. During a mean 
      follow-up of 7.4 years, serious vascular events occurred in a significantly lower 
      percentage of participants in the aspirin group than in the placebo group (658 
      participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval 
      [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 
      participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the 
      placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the 
      excess being gastrointestinal bleeding and other extracranial bleeding. There was 
      no significant difference between the aspirin group and the placebo group in the 
      incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 
      [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term 
      follow-up for these outcomes is planned. CONCLUSIONS: Aspirin use prevented 
      serious vascular events in persons who had diabetes and no evident cardiovascular 
      disease at trial entry, but it also caused major bleeding events. The absolute 
      benefits were largely counterbalanced by the bleeding hazard. (Funded by the 
      British Heart Foundation and others; ASCEND Current Controlled Trials number, 
      ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
CN  - ASCEND Study Collaborative Group
FAU - Bowman, Louise
AU  - Bowman L
FAU - Mafham, Marion
AU  - Mafham M
FAU - Wallendszus, Karl
AU  - Wallendszus K
FAU - Stevens, Will
AU  - Stevens W
FAU - Buck, Georgina
AU  - Buck G
FAU - Barton, Jill
AU  - Barton J
FAU - Murphy, Kevin
AU  - Murphy K
FAU - Aung, Theingi
AU  - Aung T
FAU - Haynes, Richard
AU  - Haynes R
FAU - Cox, Jolyon
AU  - Cox J
FAU - Murawska, Aleksandra
AU  - Murawska A
FAU - Young, Allen
AU  - Young A
FAU - Lay, Michael
AU  - Lay M
FAU - Chen, Fang
AU  - Chen F
FAU - Sammons, Emily
AU  - Sammons E
FAU - Waters, Emma
AU  - Waters E
FAU - Adler, Amanda
AU  - Adler A
FAU - Bodansky, Jonathan
AU  - Bodansky J
FAU - Farmer, Andrew
AU  - Farmer A
FAU - McPherson, Roger
AU  - McPherson R
FAU - Neil, Andrew
AU  - Neil A
FAU - Simpson, David
AU  - Simpson D
FAU - Peto, Richard
AU  - Peto R
FAU - Baigent, Colin
AU  - Baigent C
FAU - Collins, Rory
AU  - Collins R
FAU - Parish, Sarah
AU  - Parish S
FAU - Armitage, Jane
AU  - Armitage J
LA  - eng
SI  - ClinicalTrials.gov/NCT00135226
GR  - MC_U137686861/MRC_/Medical Research Council/United Kingdom
GR  - SP/08/010/25939/BHF_/British Heart Foundation/United Kingdom
GR  - MC_UU_12026/5/MRC_/Medical Research Council/United Kingdom
GR  - SP/14/3/31114/BHF_/British Heart Foundation/United Kingdom
GR  - MC_U137686853/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180826
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Nat Rev Cardiol. 2018 Nov;15(11):651. PMID: 30237429
CIN - N Engl J Med. 2018 Oct 18;379(16):1572-1574. PMID: 30332575
CIN - J R Coll Physicians Edinb. 2018 Dec;48(4):332-333. PMID: 30488889
CIN - Ann Intern Med. 2018 Dec 18;169(12):JC67. PMID: 30557420
CIN - Internist (Berl). 2019 Feb;60(2):209-216. PMID: 30645666
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Diabetes Complications/epidemiology/*prevention & control
MH  - Diabetes Mellitus/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Poisson Distribution
MH  - *Primary Prevention
MH  - Risk Factors
FIR - Sleight, P
IR  - Sleight P
FIR - Weissberg, P
IR  - Weissberg P
FIR - Samani, N
IR  - Samani N
FIR - Detering, E
IR  - Detering E
FIR - Aubonnet, P
IR  - Aubonnet P
FIR - Sandercock, P
IR  - Sandercock P
FIR - Gerstein, H
IR  - Gerstein H
FIR - Gray, R
IR  - Gray R
FIR - Hennekens, C
IR  - Hennekens C
FIR - Fletcher, L
IR  - Fletcher L
FIR - Achiri, P
IR  - Achiri P
FIR - Armitage, A
IR  - Armitage A
FIR - Bateman, S
IR  - Bateman S
FIR - Booker, V
IR  - Booker V
FIR - Brown, K
IR  - Brown K
FIR - Butcher, F
IR  - Butcher F
FIR - Butler, E
IR  - Butler E
FIR - Butler, S
IR  - Butler S
FIR - Cobb, L
IR  - Cobb L
FIR - Collett, A
IR  - Collett A
FIR - Colmenero, P
IR  - Colmenero P
FIR - Crowther, J
IR  - Crowther J
FIR - Fathers, S
IR  - Fathers S
FIR - Frederick, K
IR  - Frederick K
FIR - Goodfellow, E
IR  - Goodfellow E
FIR - Goodwin, E
IR  - Goodwin E
FIR - Hope, C
IR  - Hope C
FIR - Karnad, A
IR  - Karnad A
FIR - Keyte, V
IR  - Keyte V
FIR - King, M
IR  - King M
FIR - Knight, S
IR  - Knight S
FIR - Lam, N
IR  - Lam N
FIR - Lee, R
IR  - Lee R
FIR - Machin, O
IR  - Machin O
FIR - Mohammed, N
IR  - Mohammed N
FIR - Panicker, A
IR  - Panicker A
FIR - Pank, L
IR  - Pank L
FIR - Papadaki, A
IR  - Papadaki A
FIR - Pearson-Burton, E
IR  - Pearson-Burton E
FIR - Pickworth, S
IR  - Pickworth S
FIR - Qiao, Y R
IR  - Qiao YR
FIR - Radley, A
IR  - Radley A
FIR - Roberts, E
IR  - Roberts E
FIR - Roby, K
IR  - Roby K
FIR - Sayer, J
IR  - Sayer J
FIR - Shah, S
IR  - Shah S
FIR - Smith, S
IR  - Smith S
FIR - Sutherland, S
IR  - Sutherland S
FIR - Thorne, H
IR  - Thorne H
FIR - Timadjer, A
IR  - Timadjer A
FIR - Vandenberg, K
IR  - Vandenberg K
FIR - Willett, M
IR  - Willett M
FIR - Wincott, M
IR  - Wincott M
FIR - Wise, C
IR  - Wise C
FIR - Woods, J
IR  - Woods J
FIR - Yates, S
IR  - Yates S
FIR - Alexander, A
IR  - Alexander A
FIR - Beebe, S
IR  - Beebe S
FIR - Black, J
IR  - Black J
FIR - Bromhall, L
IR  - Bromhall L
FIR - Bulbulia, R
IR  - Bulbulia R
FIR - Cowan, H
IR  - Cowan H
FIR - Dasgupta, T
IR  - Dasgupta T
FIR - Gaba, K
IR  - Gaba K
FIR - Herrington, W
IR  - Herrington W
FIR - Hirt, L
IR  - Hirt L
FIR - Isaew, A
IR  - Isaew A
FIR - James, J
IR  - James J
FIR - Judge, P
IR  - Judge P
FIR - Lawson, A
IR  - Lawson A
FIR - Lewis, D
IR  - Lewis D
FIR - Llewellyn-Bennett, R
IR  - Llewellyn-Bennett R
FIR - Lochhead, H
IR  - Lochhead H
FIR - Majoni, W
IR  - Majoni W
FIR - Morris, D
IR  - Morris D
FIR - Murray, C
IR  - Murray C
FIR - Naessens, K
IR  - Naessens K
FIR - Porter, T
IR  - Porter T
FIR - Rahimi, K
IR  - Rahimi K
FIR - Reith, C
IR  - Reith C
FIR - Storey, B
IR  - Storey B
FIR - Taylor-Clarke, M
IR  - Taylor-Clarke M
FIR - Toghill, V
IR  - Toghill V
FIR - Tomson, J
IR  - Tomson J
FIR - Walter, K
IR  - Walter K
FIR - Young, L
IR  - Young L
FIR - Harding, P
IR  - Harding P
FIR - Adamska, L
IR  - Adamska L
FIR - Bennett, D
IR  - Bennett D
FIR - Berry, C
IR  - Berry C
FIR - Booth, J
IR  - Booth J
FIR - Bu, Y
IR  - Bu Y
FIR - Coates, G
IR  - Coates G
FIR - Craig, M
IR  - Craig M
FIR - Crawford, J
IR  - Crawford J
FIR - Dalton, P
IR  - Dalton P
FIR - Daniels, C
IR  - Daniels C
FIR - Dawe, C
IR  - Dawe C
FIR - Delmestri, A
IR  - Delmestri A
FIR - Guo, X
IR  - Guo X
FIR - Karreman, J
IR  - Karreman J
FIR - Kurien, R
IR  - Kurien R
FIR - McDougall, A
IR  - McDougall A
FIR - Mostefai, Y
IR  - Mostefai Y
FIR - Nunn, M
IR  - Nunn M
FIR - Offer, A
IR  - Offer A
FIR - Prajapati, N
IR  - Prajapati N
FIR - Price, J
IR  - Price J
FIR - Syed, S
IR  - Syed S
FIR - Turakani, M
IR  - Turakani M
FIR - Clark, S
IR  - Clark S
FIR - Emmens, K
IR  - Emmens K
FIR - Hill, M
IR  - Hill M
FIR - Kourellias, K
IR  - Kourellias K
FIR - Radley, M
IR  - Radley M
FIR - Wintour, J
IR  - Wintour J
FIR - Allworth, M
IR  - Allworth M
FIR - Boggs, L
IR  - Boggs L
FIR - Chavagnon, T
IR  - Chavagnon T
FIR - Cox, R
IR  - Cox R
FIR - Cwikowska, J
IR  - Cwikowska J
FIR - Glass, T
IR  - Glass T
FIR - Goodwin, N
IR  - Goodwin N
FIR - Gordon, A
IR  - Gordon A
FIR - Gordon, J
IR  - Gordon J
FIR - Guest, C
IR  - Guest C
FIR - Hickman, C
IR  - Hickman C
FIR - Hill, J
IR  - Hill J
FIR - Hrusecka, R
IR  - Hrusecka R
FIR - Illingworth, N
IR  - Illingworth N
FIR - Ji, J M
IR  - Ji JM
FIR - Lacey, M
IR  - Lacey M
FIR - Luker, N
IR  - Luker N
FIR - Nafousi, K
IR  - Nafousi K
FIR - Norris, S
IR  - Norris S
FIR - Plunkett, N
IR  - Plunkett N
FIR - Sansom, L
IR  - Sansom L
FIR - Shellard, R
IR  - Shellard R
FIR - Taylor, J
IR  - Taylor J
FIR - Taylor, P
IR  - Taylor P
FIR - Wheeler, J
IR  - Wheeler J
FIR - Williams, T
IR  - Williams T
FIR - Yeung, M
IR  - Yeung M
FIR - Meyer-Bothling, U
IR  - Meyer-Bothling U
FIR - Dean, J
IR  - Dean J
FIR - Car, J
IR  - Car J
FIR - Dornhorst, A
IR  - Dornhorst A
FIR - MacInerney, R
IR  - MacInerney R
FIR - De, P
IR  - De P
FIR - Bodmer, C
IR  - Bodmer C
FIR - Wagstaff, R
IR  - Wagstaff R
FIR - Browne, M
IR  - Browne M
FIR - Humphries, T
IR  - Humphries T
FIR - Kemp, T
IR  - Kemp T
FIR - Menon, G
IR  - Menon G
FIR - Ulahannan, T
IR  - Ulahannan T
FIR - Hammond, P
IR  - Hammond P
FIR - Johnston, C
IR  - Johnston C
FIR - O'Hare, J P
IR  - O'Hare JP
FIR - Burrows, T
IR  - Burrows T
FIR - Griffiths, H
IR  - Griffiths H
FIR - Atkin, S
IR  - Atkin S
FIR - Walton, C
IR  - Walton C
FIR - Twomey, P
IR  - Twomey P
FIR - Bilous, R
IR  - Bilous R
FIR - Newrick, P
IR  - Newrick P
FIR - Idris, I
IR  - Idris I
FIR - Lloyd-Mostyn, R
IR  - Lloyd-Mostyn R
FIR - Gray, J
IR  - Gray J
FIR - Mallya, S
IR  - Mallya S
FIR - Sands, K
IR  - Sands K
FIR - Hasan, Z
IR  - Hasan Z
FIR - Malik, R
IR  - Malik R
FIR - Hawthorne, G
IR  - Hawthorne G
FIR - Jones-Unwin, C
IR  - Jones-Unwin C
FIR - Gelding, S
IR  - Gelding S
FIR - Porcheret, M
IR  - Porcheret M
FIR - Bennett, S
IR  - Bennett S
FIR - Lewis-Barned, N
IR  - Lewis-Barned N
FIR - Evans, P
IR  - Evans P
FIR - Martin, S
IR  - Martin S
FIR - Nyman, C
IR  - Nyman C
FIR - Olczak, S
IR  - Olczak S
FIR - White, C
IR  - White C
FIR - McLeod, A
IR  - McLeod A
FIR - Capps, N
IR  - Capps N
FIR - Cummings, M
IR  - Cummings M
FIR - Reynolds, T
IR  - Reynolds T
FIR - Gazis, T
IR  - Gazis T
FIR - Muthusamy, R
IR  - Muthusamy R
FIR - Muzulu, S
IR  - Muzulu S
FIR - Natha, S
IR  - Natha S
FIR - Simpson, H
IR  - Simpson H
FIR - Ramtoola, S
IR  - Ramtoola S
FIR - Hutchesson, A
IR  - Hutchesson A
FIR - Fleming, S
IR  - Fleming S
FIR - Tan, G D
IR  - Tan GD
FIR - MacLeod, K
IR  - MacLeod K
FIR - Brand, C
IR  - Brand C
FIR - Broadbent, D
IR  - Broadbent D
FIR - Vora, J
IR  - Vora J
FIR - Bhatnagar, D
IR  - Bhatnagar D
FIR - Mishra, B
IR  - Mishra B
FIR - Reckless, J
IR  - Reckless J
FIR - Hughes, E
IR  - Hughes E
FIR - Robertson, D
IR  - Robertson D
FIR - Thomas, C
IR  - Thomas C
FIR - Hyer, S
IR  - Hyer S
FIR - Rodin, A
IR  - Rodin A
FIR - Gilbey, S
IR  - Gilbey S
FIR - Gable, D
IR  - Gable D
FIR - Baxter, M
IR  - Baxter M
FIR - Hale, P
IR  - Hale P
FIR - Kong, N
IR  - Kong N
FIR - Burrows, G
IR  - Burrows G
FIR - Chowdhury, T
IR  - Chowdhury T
FIR - Peterson, D
IR  - Peterson D
FIR - Paisey, R
IR  - Paisey R
FIR - Chattington, P
IR  - Chattington P
FIR - Clements, M
IR  - Clements M
FIR - Singhal, P
IR  - Singhal P
FIR - Jafree, A
IR  - Jafree A
FIR - Williams, C
IR  - Williams C
FIR - Caldwell, G
IR  - Caldwell G
FIR - Signy, M
IR  - Signy M
FIR - Gallen, I
IR  - Gallen I
FIR - Jennings, P
IR  - Jennings P
EDAT- 2018/08/28 06:00
MHDA- 2018/11/06 06:00
CRDT- 2018/08/28 06:00
PHST- 2018/08/28 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
PHST- 2018/08/28 06:00 [entrez]
AID - 10.1056/NEJMoa1804988 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Oct 18;379(16):1529-1539. doi: 10.1056/NEJMoa1804988. Epub 
      2018 Aug 26.

PMID- 27341534
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20181202
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 251
DP  - 2016 Aug
TI  - Aspirin and cardiovascular primary prevention in non-endstage chronic kidney 
      disease: A meta-analysis.
PG  - 177-182
LID - S0021-9150(16)30258-1 [pii]
LID - 10.1016/j.atherosclerosis.2016.06.013 [doi]
AB  - BACKGROUND AND AIMS: Chronic kidney disease is a strong independent predictor of 
      cardiovascular disease. No published meta-analyses on the use of aspirin for the 
      primary prevention of cardiovascular disease in chronic kidney disease exist. We 
      therefore performed a systematic review and meta-analysis of this subject. 
      METHODS: We used a pre-defined and registered protocol (PROSPERO identification 
      CRD42014008860). We searched Medline and Embase between 1996 and July 2015. 
      Inclusion criteria were adult subjects with non-endstage chronic kidney disease 
      (CKD) and no history of cardiovascular disease. The co-primary outcomes were 
      major cardiovascular events and all-cause mortality. Secondary outcomes included 
      bleeding-related events. We used a random effects model to pool data. RESULTS: 
      Three trials were identified and two of these provided previously unpublished 
      data. The studies included 4468 participants and 16,740 person-years of 
      follow-up. There were no statistically significant reductions in the risk of 
      major cardiovascular events (RR 0.92, 95% CI 0.49 to 1.73, p = 0.79, I(2) 71%) or 
      mortality (RR 0.74, 95% CI 0.55 to 1.00, p = 0.05, I(2) 0%) with aspirin compared 
      to the control group. Major bleeding events were increased with aspirin though 
      (RR 1.98, 95% CI 1.11 to 3.52, p = 0.02, I(2) 0%). CONCLUSIONS: There is no clear 
      benefit of aspirin for the primary prevention of cardiovascular events in CKD and 
      no statistically significant reduction in mortality. Aspirin is likely to 
      increase the risk of major bleeding events. Currently, insufficient randomised 
      control trial data exists to recommend universal use or avoidance of aspirin for 
      primary prevention of cardiovascular events in CKD.
CI  - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Major, Rupert W
AU  - Major RW
AD  - Department of Health Sciences, University of Leicester, UK; John Walls Renal 
      Unit, University Hospitals of Leicester, UK. Electronic address: rwlm2@le.ac.uk.
FAU - Oozeerally, Issaam
AU  - Oozeerally I
AD  - John Walls Renal Unit, University Hospitals of Leicester, UK.
FAU - Dawson, Simon
AU  - Dawson S
AD  - John Walls Renal Unit, University Hospitals of Leicester, UK.
FAU - Riddleston, Helen
AU  - Riddleston H
AD  - John Walls Renal Unit, University Hospitals of Leicester, UK.
FAU - Gray, Laura J
AU  - Gray LJ
AD  - Department of Health Sciences, University of Leicester, UK.
FAU - Brunskill, Nigel J
AU  - Brunskill NJ
AD  - John Walls Renal Unit, University Hospitals of Leicester, UK; Department of 
      Infection, Immunity and Inflammation, University of Leicester, UK.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20160610
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Blood Pressure
MH  - Cardiovascular Diseases/complications/*drug therapy
MH  - Cardiovascular System/drug effects
MH  - Clinical Trials as Topic
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Primary Prevention/*methods
MH  - Renal Insufficiency, Chronic/complications/*drug therapy
MH  - Research Design
MH  - Stroke/prevention & control
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Chronic kidney disease
OT  - Primary prevention
EDAT- 2016/06/25 06:00
MHDA- 2017/12/27 06:00
CRDT- 2016/06/25 06:00
PHST- 2016/03/23 00:00 [received]
PHST- 2016/05/19 00:00 [revised]
PHST- 2016/06/08 00:00 [accepted]
PHST- 2016/06/25 06:00 [entrez]
PHST- 2016/06/25 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - S0021-9150(16)30258-1 [pii]
AID - 10.1016/j.atherosclerosis.2016.06.013 [doi]
PST - ppublish
SO  - Atherosclerosis. 2016 Aug;251:177-182. doi: 
      10.1016/j.atherosclerosis.2016.06.013. Epub 2016 Jun 10.

PMID- 15099277
OWN - NLM
STAT- MEDLINE
DCOM- 20050119
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 2
IP  - 5
DP  - 2004 May
TI  - Increased levels of soluble tissue factor during long-term treatment with 
      warfarin in patients after an acute myocardial infarction.
PG  - 726-30
AB  - Antithrombotic treatment with warfarin and/or aspirin is widely used in 
      preventing recurrence of thrombotic events after an acute myocardial infarction 
      (AMI). The objective of this study was to evaluate the long-term influence of 
      warfarin at different INR levels and/or aspirin on some hemostatic variables in 
      patients after an AMI. A subpopulation of the WARIS-II trial in which patients 
      after an acute MI were randomly assigned to treatment with aspirin 160 mg d(-1), 
      aspirin 75 mg d(-1) and warfarin (target INR 2.0-2.5) or warfarin (target INR 
      2.8-4.2) was studied. Fasting blood samples were collected before randomization 
      5-7 days after the AMI, after 6 weeks and 4 years for determinations of 
      prothrombin fragment 1 + 2 (F1 + 2), soluble tissue factor (sTF), D-dimer and 
      fibrinogen. In the warfarin-alone group as compared with the aspirin-alone group 
      significantly lower levels of F1 + 2 and D-dimer (P < 0.001 for both), but 
      significantly higher levels of sTF (P = 0.007) were found after 6 weeks. The same 
      pattern was found after 4 years. When comparing the combined group with the 
      aspirin alone group, similar profiles were seen. The levels of F1 + 2 in the 
      combined group were, however, significantly higher than in the warfarin alone 
      group after 6 weeks and 4 years (both P < 0.01). During long-term treatment with 
      warfarin in patients after an AMI increased levels of sTF were found. However, 
      significantly reduced levels of the coagulation products were obtained, 
      indicating reduced thrombin generation. The increased levels of sTF during 
      warfarin therapy are suggested to appear on the basis of reduced consumption.
FAU - Seljeflot, I
AU  - Seljeflot I
AD  - Center for Clinical Research, Ulleval University Hospital, Oslo, Norway. 
      ingebjorg.seljeflot@ulleval.no
FAU - Hurlen, M
AU  - Hurlen M
FAU - Arnesen, H
AU  - Arnesen H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Biomarkers)
RN  - 0 (Blood Coagulation Factors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9035-58-9 (Thromboplastin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/therapeutic use
MH  - Biomarkers/blood
MH  - Blood Coagulation Factors/analysis
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemostasis/drug effects
MH  - Humans
MH  - International Normalized Ratio
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*blood/*drug therapy
MH  - Solubility
MH  - Thromboplastin/analysis/*drug effects
MH  - Time Factors
MH  - Warfarin/*pharmacology/therapeutic use
EDAT- 2004/04/22 05:00
MHDA- 2005/01/20 09:00
CRDT- 2004/04/22 05:00
PHST- 2004/04/22 05:00 [pubmed]
PHST- 2005/01/20 09:00 [medline]
PHST- 2004/04/22 05:00 [entrez]
AID - S1538-7836(22)15764-8 [pii]
AID - 10.1111/j.1538-7836.2004.00676.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2004 May;2(5):726-30. doi: 10.1111/j.1538-7836.2004.00676.x.

PMID- 2664522
OWN - NLM
STAT- MEDLINE
DCOM- 19890822
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 321
IP  - 6
DP  - 1989 Aug 10
TI  - The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio 
      of thromboxane A2 to prostacyclin in relatively high risk pregnancies.
PG  - 351-6
AB  - We carried out a prospective, randomized, double-blind, placebo-controlled study 
      to investigate the capacity of aspirin to prevent pregnancy-induced hypertension 
      and to alter prostaglandin metabolism. A total of 791 pregnant women with various 
      risk factors for pre-eclamptic toxemia were screened with use of the rollover 
      test (a comparison of blood pressure before and after the woman rolls from her 
      left side to her back) during week 28 or 29 of gestation. Of 69 women with 
      abnormal results (an increase in blood pressure during the rollover test), 65 
      entered the study and were treated with a daily dose of either aspirin (100 mg; 
      34 women) or placebo (31 women) during the third trimester of pregnancy. The 
      number of women in whom pregnancy-induced hypertension developed was 
      significantly lower among the aspirin-treated than among the placebo-treated 
      women (4 [11.8 percent] vs. 11 [35.5 percent]; P = 0.024); the same was true for 
      the incidence of preeclamptic toxemia (1 [2.9 percent] vs 7 [22.6 percent]; P = 
      0.019). The mean ratio of serum levels of thromboxane A2 to serum levels of 
      prostacyclin metabolites after three weeks of treatment decreased by 34.7 percent 
      in the aspirin-treated group but increased by 51.2 percent in the placebo-treated 
      group. No serious maternal or neonatal side effects of treatment occurred in 
      either group. We conclude that low daily doses of aspirin taken during the third 
      trimester of pregnancy significantly reduce the incidence of pregnancy-induced 
      hypertension and pre-eclamptic toxemia in women at high risk for these disorders, 
      possibly through the correction of an imbalance between levels of thromboxane and 
      prostacyclin.
FAU - Schiff, E
AU  - Schiff E
AD  - Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Sackler 
      School of Medicine, Tel Aviv University, Israel.
FAU - Peleg, E
AU  - Peleg E
FAU - Goldenberg, M
AU  - Goldenberg M
FAU - Rosenthal, T
AU  - Rosenthal T
FAU - Ruppin, E
AU  - Ruppin E
FAU - Tamarkin, M
AU  - Tamarkin M
FAU - Barkai, G
AU  - Barkai G
FAU - Ben-Baruch, G
AU  - Ben-Baruch G
FAU - Yahal, I
AU  - Yahal I
FAU - Blankstein, J
AU  - Blankstein J
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 1990 Jan 18;322(3):204-5. PMID: 2294442
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Epoprostenol/*blood
MH  - Female
MH  - Humans
MH  - Hypertension/*prevention & control
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*prevention & control
MH  - Prospective Studies
MH  - Random Allocation
MH  - Thromboxane A2/*blood
EDAT- 1989/08/10 00:00
MHDA- 1989/08/10 00:01
CRDT- 1989/08/10 00:00
PHST- 1989/08/10 00:00 [pubmed]
PHST- 1989/08/10 00:01 [medline]
PHST- 1989/08/10 00:00 [entrez]
AID - 10.1056/NEJM198908103210603 [doi]
PST - ppublish
SO  - N Engl J Med. 1989 Aug 10;321(6):351-6. doi: 10.1056/NEJM198908103210603.

PMID- 10728018
OWN - NLM
STAT- MEDLINE
DCOM- 20000523
LR  - 20191103
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 9
IP  - 3
DP  - 2000 Apr
TI  - Early and pre-discharge aspirin administration among patients with acute 
      myocardial infarction: current clinical practice and trends in the United States.
PG  - 207-15
AB  - OBJECTIVES: The purpose of our study was to determine the frequency of aspirin 
      administration among patients with acute myocardial infarction (MI) as dictated 
      by physicians practicing in the United States. BACKGROUND: Aspirin (ASA), a 
      widely available, inexpensive and generally well-tolerated platelet inhibitor, is 
      recommended for patients with acute coronary syndromes, including acute MI. 
      However, there is concern that aspirin is underutilized in daily clinical 
      practice. METHODS: Early (<24 hours) and predischarge ASA administration were 
      determined among 220,171 patients with suspected acute MI enrolled in the Second 
      National Registry of Myocardial Infarction (NRMI 2) between June, 1994 and April 
      30, 1996. RESULTS: Overall, 165,122 (74.9%) of patients received ASA within 24 
      hours of hospital admission, whereas 55,049 patients did not. Early ASA 
      recipients were younger, more often male, arrived at the hospital earlier, and 
      were more likely to be classified as Killip Class II or less compared to those 
      who did not receive ASA. Patients who received aspirin were also more likely to 
      have chest pain, electrocardiographic ST segment elevation, and tended to arrive 
      at the hospital earlier than those who did not receive ASA. However, over 20% of 
      patients with ST segment elevation did not receive early ASA therapy. From the 
      total cohort of early ASA recipients, only 69% received ASA at the time of 
      hospital discharge. Trends in early and pre-discharge aspirin administration over 
      a 2 year time period in all patients (72.6 to 75.1% and 71.5 to 74.6%, 
      respectively; p < 0. 001) and in specific patient subsets were encouraging with a 
      gradual but steady increase; however, utilization remained comparatively low in 
      women and the elderly. By multivariable analysis, in-hospital recurrent MI (OR 
      0.90, 95% CI;.78-1.0, p = 0.04), stroke (OR 0.65, 95% CI,.52-.80, p < 0.001) and 
      death (OR 0.24, 95% CI,.22-.26, p < 0. 001) occurred less frequently when ASA was 
      administered within 24 hours of hospitalization. CONCLUSION: Aspirin is currently 
      underutilized in routine clinical practice as both primary and adjunctive forms 
      of therapy in MI, especially among patients known to be at risk for recurrent 
      cardiothrombotic events. The targeted and timely use of aspirin reduces early 
      cardiovascular events and should remain a priority in national health care 
      efforts.
FAU - Becker, R C
AU  - Becker RC
AD  - Cardiovascular Thrombosis Research Center, University of Massachusetts Medical 
      School, Worcester, MA 01655, USA. richard.becker@Banyan.ummed.edu
FAU - Burns, M
AU  - Burns M
FAU - Gore, J M
AU  - Gore JM
FAU - Lambrew, C
AU  - Lambrew C
FAU - French, W
AU  - French W
FAU - Rogers, W J
AU  - Rogers WJ
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/standards
MH  - Cohort Studies
MH  - Combined Modality Therapy/statistics & numerical data
MH  - Databases, Factual
MH  - Drug Therapy/statistics & numerical data/trends
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myocardial Infarction/complications/*drug therapy
MH  - Registries
MH  - Reperfusion
MH  - Secondary Prevention
MH  - Time Factors
EDAT- 2000/03/23 09:00
MHDA- 2000/06/08 09:00
CRDT- 2000/03/23 09:00
PHST- 2000/03/23 09:00 [pubmed]
PHST- 2000/06/08 09:00 [medline]
PHST- 2000/03/23 09:00 [entrez]
AID - 10.1023/a:1018706425864 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2000 Apr;9(3):207-15. doi: 10.1023/a:1018706425864.

PMID- 3865233
OWN - NLM
STAT- MEDLINE
DCOM- 19860121
LR  - 20191030
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 20
IP  - 1
DP  - 1985 Oct
TI  - Salicylate antagonizes the antiinflammatory action of aspirin in the rat.
PG  - 23-8
AB  - On the ground of conflicting evidence concerning the interaction of salicylate 
      and aspirin, we investigated the results of such interaction on carrageenin edema 
      of the rat hind paw. Aspirin and sodium salicylate were administered by stomach 
      tube either singly or in combination, at a dose of 50 mg/kg each. The 
      antiinflammatory effect was significantly greater when aspirin was administered 
      prior to salicylate than when aspirin followed salicylate. It is therefore 
      suggested that salicylate may antagonize the action of aspirin in vivo, and that 
      the temporal order in which the two drugs interact with cyclooxygenase may be an 
      important determinant of the outcome.
FAU - Telias, I D
AU  - Telias ID
FAU - Zvi, Z B
AU  - Zvi ZB
FAU - Danon, A
AU  - Danon A
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Salicylates)
RN  - 9000-07-1 (Carrageenan)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Carrageenan
MH  - Drug Antagonism
MH  - Edema/chemically induced/*drug therapy
MH  - Kinetics
MH  - Male
MH  - Rats
MH  - Salicylates/*therapeutic use
MH  - Salicylic Acid
EDAT- 1985/10/01 00:00
MHDA- 1985/10/01 00:01
CRDT- 1985/10/01 00:00
PHST- 1985/10/01 00:00 [pubmed]
PHST- 1985/10/01 00:01 [medline]
PHST- 1985/10/01 00:00 [entrez]
AID - 10.1016/0262-1746(85)90091-5 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1985 Oct;20(1):23-8. doi: 
      10.1016/0262-1746(85)90091-5.

PMID- 34210661
OWN - NLM
STAT- MEDLINE
DCOM- 20211119
LR  - 20211119
IS  - 1755-5248 (Electronic)
IS  - 0012-6543 (Linking)
VI  - 59
IP  - 8
DP  - 2021 Aug
TI  - Aspirin and gastrointestinal bleeding risk in older people.
PG  - 117
LID - 10.1136/dtb.2021.000037 [doi]
AB  - Overview of: Mahady SE, Margolis KL, Chan A, et al Major GI bleeding in older 
      persons using aspirin: incidence and risk factors in the ASPREE randomised 
      controlled trial. Gut. 2021. 717-24.
CI  - © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and 
      permissions. Published by BMJ.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210701
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Double-Blind Method
MH  - Gastrointestinal Hemorrhage/*chemically induced/*epidemiology
MH  - Humans
MH  - Proton Pump Inhibitors/administration & dosage
MH  - Risk Factors
OTO - NOTNLM
OT  - drug-related side effects and adverse reactions
OT  - healthcare quality, access, and evaluation
EDAT- 2021/07/03 06:00
MHDA- 2021/11/20 06:00
CRDT- 2021/07/02 05:49
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/11/20 06:00 [medline]
PHST- 2021/07/02 05:49 [entrez]
AID - dtb.2021.000037 [pii]
AID - 10.1136/dtb.2021.000037 [doi]
PST - ppublish
SO  - Drug Ther Bull. 2021 Aug;59(8):117. doi: 10.1136/dtb.2021.000037. Epub 2021 Jul 
      1.

PMID- 31621809
OWN - NLM
STAT- MEDLINE
DCOM- 20210616
LR  - 20210616
IS  - 2374-2445 (Electronic)
IS  - 2374-2437 (Print)
IS  - 2374-2437 (Linking)
VI  - 5
IP  - 12
DP  - 2019 Dec 1
TI  - Association Between Aspirin Use and Biliary Tract Cancer Survival.
PG  - 1802-1804
LID - 10.1001/jamaoncol.2019.4328 [doi]
AB  - This database study analyzes the association between aspirin use and survival in 
      patients with biliary tract cancer.
FAU - Jackson, Sarah S
AU  - Jackson SS
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Rockville, Maryland.
FAU - Pfeiffer, Ruth M
AU  - Pfeiffer RM
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Rockville, Maryland.
FAU - Liu, Zhiwei
AU  - Liu Z
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Rockville, Maryland.
FAU - Anderson, Lesley A
AU  - Anderson LA
AD  - Centre for Public Health, School of Medicine, Dentistry and Biomedical Science, 
      Queen's University Belfast, United Kingdom.
FAU - Tsai, Huei-Ting
AU  - Tsai HT
AD  - Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research 
      US Food and Drug Administration, Silver Spring, Maryland.
AD  - Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 
      Georgetown University, Washington, DC.
FAU - Gadalla, Shahinaz M
AU  - Gadalla SM
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Rockville, Maryland.
FAU - Koshiol, Jill
AU  - Koshiol J
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Rockville, Maryland.
LA  - eng
PT  - Letter
PL  - United States
TA  - JAMA Oncol
JT  - JAMA oncology
JID - 101652861
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - JAMA Oncol. 2019 Dec 1;5(12):1811. PMID: 31830216
CIN - JAMA Oncol. 2020 May 1;6(5):783-784. PMID: 32191269
CIN - JAMA Oncol. 2020 May 1;6(5):784. PMID: 32191283
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Biliary Tract Neoplasms/*drug therapy/mortality/pathology
MH  - Case-Control Studies
MH  - Comorbidity
MH  - Electronic Health Records
MH  - Humans
MH  - Neoplasm Staging
MH  - Survival Analysis
MH  - Treatment Outcome
PMC - PMC6802421
COIS- Conflict of Interest Disclosures: None reported.
EDAT- 2019/10/18 06:00
MHDA- 2021/06/17 06:00
CRDT- 2019/10/18 06:00
PHST- 2019/10/18 06:00 [pubmed]
PHST- 2021/06/17 06:00 [medline]
PHST- 2019/10/18 06:00 [entrez]
AID - 2752784 [pii]
AID - cld190020 [pii]
AID - 10.1001/jamaoncol.2019.4328 [doi]
PST - ppublish
SO  - JAMA Oncol. 2019 Dec 1;5(12):1802-1804. doi: 10.1001/jamaoncol.2019.4328.

PMID- 17140757
OWN - NLM
STAT- MEDLINE
DCOM- 20070425
LR  - 20131125
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 43
IP  - 4
DP  - 2007 Mar 12
TI  - Does the preferred orientation of crystallites in tablets affect the intrinsic 
      dissolution?
PG  - 1315-23
AB  - The aim of this study was to examine the effect of preferred orientation of 
      crystallites, i.e. texture, on the intrinsic dissolution rate of some active 
      pharmaceutical ingredients. Although it has often been speculated that the 
      intrinsic dissolution of pharmaceutical tablets is affected by texture, no 
      experimental evidence of this effect has been reported. The texture of 
      acetylsalicylic acid, tolbutamide, carbamazepine and entacapone tablets was 
      measured using three different methods both before and after the dissolution 
      measurements. To clarify the effect of texture, texturizing and less-texturizing 
      batches of each material were used. The texturizing batches had big needle or 
      plate-like particles and the less-texturizing batches were prepared by grinding 
      the texturizing powders. The USP rotation disc method was used to measure the 
      intrinsic dissolution rate of the samples. The results indicated that the 
      acetylsalicylic acid, tolbutamide and entacapone tablets texturized strongly in 
      compression and the grinding of the texturizing powders decreased the degree of 
      texture. Also the carbamazepine tablets were slightly texturized. All of the 
      texture measurement methods used were found to give acceptable and consistent 
      results and therefore a special texture goniometer is not required to perform 
      these measurements. The intrinsic dissolution rate of all the tablets compacted 
      from the ground powder was slightly higher than the intrinsic dissolution rate of 
      the more texturized samples. However, these differences were not significant on a 
      large scale. After the dissolution tests the degree of texture of the samples was 
      decreased. The intrinsic dissolution rates of the samples were presumably 
      affected by several different parameters such as texture, solubility, pH, surface 
      energetics and crystal strains. Although only small differences were found 
      between the intrinsic dissolution rates of texturized and less texturized samples 
      the effect of texture on the dissolution behavior of the pharmaceuticals should 
      be considered when performing accurate intrinsic dissolution studies.
FAU - Tenho, Mikko
AU  - Tenho M
AD  - Department of Physics, University of Turku, FI-20014 Turku, Finland. 
      mikko.tenho@utu.fi
FAU - Heinänen, Paula
AU  - Heinänen P
FAU - Tanninen, Veli Pekka
AU  - Tanninen VP
FAU - Lehto, Vesa-Pekka
AU  - Lehto VP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20061130
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Catechols)
RN  - 0 (Nitriles)
RN  - 0 (Tablets)
RN  - 33CM23913M (Carbamazepine)
RN  - 4975G9NM6T (entacapone)
RN  - 982XCM1FOI (Tolbutamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Carbamazepine/*chemistry
MH  - Catechols/*chemistry
MH  - Crystallization
MH  - Hydrogen-Ion Concentration
MH  - Nitriles/*chemistry
MH  - Particle Size
MH  - Solubility
MH  - Tablets
MH  - Tolbutamide/*chemistry
EDAT- 2006/12/05 09:00
MHDA- 2007/04/26 09:00
CRDT- 2006/12/05 09:00
PHST- 2006/07/05 00:00 [received]
PHST- 2006/09/29 00:00 [revised]
PHST- 2006/10/24 00:00 [accepted]
PHST- 2006/12/05 09:00 [pubmed]
PHST- 2007/04/26 09:00 [medline]
PHST- 2006/12/05 09:00 [entrez]
AID - S0731-7085(06)00730-8 [pii]
AID - 10.1016/j.jpba.2006.10.038 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2007 Mar 12;43(4):1315-23. doi: 10.1016/j.jpba.2006.10.038. 
      Epub 2006 Nov 30.

PMID- 17192131
OWN - NLM
STAT- MEDLINE
DCOM- 20070329
LR  - 20181201
IS  - 1175-3277 (Print)
IS  - 1175-3277 (Linking)
VI  - 6
IP  - 6
DP  - 2006
TI  - Clopidogrel bisulfate: in ST-segment elevation myocardial infarction.
PG  - 407-14
AB  - Clopidogrel bisulfate (hereafter, clopidogrel), a selective inhibitor of 
      ADP-induced platelet aggregation, is approved for the reduction of 
      atherothrombotic events in patients with ST-segment elevation myocardial 
      infarction (STEMI). In COMMIT/CCS-2, a well designed trial in 45,852 adult 
      patients with STEMI, relative to aspirin alone, clopidogrel 75 mg/day plus 
      aspirin treatment significantly reduced the risk of both coprimary endpoints: the 
      composite endpoint of reinfarction, stroke, or death from any cause and the risk 
      of death from any cause. Based on the findings of this trial, treating 1000 
      patients for approximately 2 weeks with clopidogrel is associated with nine fewer 
      patient deaths, reinfarctions, or strokes during treatment. In CLARITY-TIMI 28, a 
      well designed supportive study in 3491 adult patients with STEMI, clopidogrel 
      plus aspirin reduced the odds that a composite primary endpoint event of an 
      occluded infarct-related artery, recurrent myocardial infarction, or death from 
      any cause would occur versus aspirin plus placebo. Clopidogrel treatment was 
      generally well tolerated in these clinical trials, with no significant 
      between-group difference in the rate of major bleeding in either trial. 
      Experience in other patient populations (e.g. those with recent myocardial 
      infarction, recent ischemic stroke, or established peripheral arterial disease) 
      has shown that longer-term (< or =3 years) clopidogrel monotherapy is generally 
      well tolerated.
FAU - Dickie, Jennifer S
AU  - Dickie JS
AD  - Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz
FAU - Scott, Lesley J
AU  - Scott LJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Cardiovasc Drugs. 2006;6(6):415-6. PMID: 17192132
CIN - Am J Cardiovasc Drugs. 2006;6(6):415-6. PMID: 17192133
CIN - Am J Cardiovasc Drugs. 2006;6(6):415. PMID: 17192134
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
RF  - 21
EDAT- 2006/12/29 09:00
MHDA- 2007/03/30 09:00
CRDT- 2006/12/29 09:00
PHST- 2006/12/29 09:00 [pubmed]
PHST- 2007/03/30 09:00 [medline]
PHST- 2006/12/29 09:00 [entrez]
AID - 668 [pii]
AID - 10.2165/00129784-200606060-00008 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2006;6(6):407-14. doi: 10.2165/00129784-200606060-00008.

PMID- 20452654
OWN - NLM
STAT- MEDLINE
DCOM- 20101129
LR  - 20181201
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 126
IP  - 2
DP  - 2010 Aug
TI  - Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on 
      whole blood coagulation and arterial thrombosis in rats.
PG  - 124-9
LID - 10.1016/j.thromres.2010.04.005 [doi]
AB  - INTRODUCTION: Activated platelets facilitate blood coagulation by providing 
      factor V and a procoagulant surface for prothrombinase. Here, we investigated the 
      potential synergy of a potent factor Xa/prothrombinase inhibitor, TAK-442, plus 
      aspirin or clopidogrel in preventing arterial thrombosis and whole blood 
      coagulation. METHODS: Thrombus formation was initiated by FeCl(3)-induced rat 
      carotid injury. Bleeding time was evaluated with the rat tail transection model. 
      Whole blood coagulation was assessed by thromboelastographic examination (TEG) 
      for which blood obtained from control, aspirin-, or clopidogrel-treated rats was 
      transferred to a TEG analyzer containing, collagen or adenosine diphosphate 
      (ADP), and TAK-442 or vehicle. RESULTS: TAK-442 (3mg/kg, po), aspirin (100mg/kg, 
      po) or clopidogrel (3mg/kg, po) alone had no significant effect on thrombus 
      formation, whereas the combination of TAK-442 with aspirin and clopidogrel 
      remarkably prolonged the time to thrombus formation without additional 
      significant prolongation of bleeding time. TEG demonstrated that the onset of 
      collagen-induced blood coagulation were slightly longer in aspirin-treated rats 
      than control; however, when the blood from aspirin-treated rats was subsequently 
      treated in vitro with 100 nM TAK-442, the onset of clotting was significantly 
      prolonged. In contrast, only marginal prolongation was observed with TAK-442 
      treatment of blood from control animals. The onset time of ADP-induced blood 
      coagulation was slightly longer in clopidogrel-treated rats compared with 
      control, and it was further extended by TAK-442 treatment. CONCLUSION: These 
      results demonstrate that blood coagulation can be markedly delayed by the 
      addition of TAK-442 to antiplatelets treatment which could contribute to 
      synergistic antithrombotic efficacy in these settings.
CI  - (c) 2010 Elsevier Ltd. All rights reserved.
FAU - Konishi, Noriko
AU  - Konishi N
AD  - Pharmacology Research Laboratories, Takeda Pharmaceutical Company Ltd., Osaka, 
      Japan.
FAU - Hiroe, Katsuhiko
AU  - Hiroe K
FAU - Kawamura, Masaki
AU  - Kawamura M
LA  - eng
PT  - Journal Article
DEP - 20100510
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 
      (1-(1-(3-((6-chloronaphthalen-2-yl)sulfonyl)-2-hydroxypropanoyl)piperidin-4-yl)tetrahydropyrimidin-2(1H)-one)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyrimidinones)
RN  - 0 (Sulfones)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Tests
MH  - Clopidogrel
MH  - Drug Synergism
MH  - *Factor Xa Inhibitors
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Pyrimidinones/pharmacology/*therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sulfones/pharmacology/*therapeutic use
MH  - Thrombosis/*drug therapy
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2010/05/11 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/05/11 06:00
PHST- 2009/12/11 00:00 [received]
PHST- 2010/03/19 00:00 [revised]
PHST- 2010/04/07 00:00 [accepted]
PHST- 2010/05/11 06:00 [entrez]
PHST- 2010/05/11 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - S0049-3848(10)00230-6 [pii]
AID - 10.1016/j.thromres.2010.04.005 [doi]
PST - ppublish
SO  - Thromb Res. 2010 Aug;126(2):124-9. doi: 10.1016/j.thromres.2010.04.005. Epub 2010 
      May 10.

PMID- 8837252
OWN - NLM
STAT- MEDLINE
DCOM- 19970311
LR  - 20190905
IS  - 0036-5599 (Print)
IS  - 0036-5599 (Linking)
VI  - 30
IP  - 3
DP  - 1996 Jun
TI  - Blood loss in long-term aspirin users undergoing transurethral prostatectomy.
PG  - 203-6
AB  - As aspirin is now widely used for preventing recurrence of cardiovascular and 
      cerebrovascular disorders, many men selected for transurethral resection of the 
      prostate (TURP) are aspirin users. The previous indication for aspirin as a 
      preoperatively administered antithrombotic agent is no longer common. In this 
      study we investigated the blood loss in long-term aspirin users (250 mg/day) 
      undergoing TURP. The mean blood loss in the 40 aspirin users was 358 (range 
      50-1550) ml, and in a control group of 42 men it was 478 (40-2400) ml. When mean 
      blood loss was correlated to operating time and prostatic weight, the intergroup 
      difference was not significant. In the late postoperative period two 
      aspirin-treated men had bleeding with tamponade of the urinary bladder requiring 
      emptying in the operating room. As blood loss was not enhanced by aspirin use, 
      avoidance of aspirin before TURP appears to be unnecessary.
FAU - Ala-Opas, M Y
AU  - Ala-Opas MY
AD  - Urological Division, University Hospital of Kuopio, Finland.
FAU - Grönlund, S S
AU  - Grönlund SS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Urol Nephrol
JT  - Scandinavian journal of urology and nephrology
JID - 0114501
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects
MH  - *Blood Loss, Surgical
MH  - Blood Volume
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Organ Size
MH  - Prostate/anatomy & histology
MH  - *Prostatectomy
MH  - Time Factors
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
AID - 10.3109/00365599609181300 [doi]
PST - ppublish
SO  - Scand J Urol Nephrol. 1996 Jun;30(3):203-6. doi: 10.3109/00365599609181300.

PMID- 14578781
OWN - NLM
STAT- MEDLINE
DCOM- 20031120
LR  - 20220318
IS  - 0032-1052 (Print)
IS  - 0032-1052 (Linking)
VI  - 112
IP  - 6
DP  - 2003 Nov
TI  - Dextran-related complications in head and neck microsurgery: do the benefits 
      outweigh the risks? A prospective randomized analysis.
PG  - 1534-9
AB  - Increased experience with free-tissue transfer has minimized flap loss secondary 
      to microvascular thrombosis, yet pharmacologic antithrombotic prophylaxis 
      continues to be used routinely. Currently there is no consensus on the ideal 
      pharmacologic agent, dosing, or efficacy. Low-molecular-weight dextran has been 
      widely used for prophylaxis due to its properties of volume expansion and 
      enhanced microrheology. Significant systemic morbidity (pulmonary morbidity, 
      cardiac morbidity, anaphylaxis) is known to occur with use of 
      low-molecular-weight dextran. The purpose of this study was to evaluate morbidity 
      associated with postoperative low-molecular-weight dextran and aspirin 
      prophylaxis in head and neck microsurgery patients. This study was a randomized 
      prospective analysis of 100 consecutive patients undergoing microvascular 
      reconstruction for head and neck malignancy during a 2-year period. Patients were 
      randomized into one of three postoperative antithrombotic prophylaxis treatment 
      groups: low-molecular-weight dextran 20 cc/hour for 48 hours (n = 35), 
      low-molecular-weight dextran 20 cc/hour for 120 hours (n = 32), or aspirin 325 
      mg/day for 120 hours (n = 27). Six patients were excluded intraoperatively due to 
      the need for systemic heparin therapy. Treatment groups were compared for age, 
      sex, prior medical problems, duration of anesthesia, and intraoperative fluid 
      intake. Flap outcome and the incidence of local and systemic complications were 
      evaluated in the treatment groups. Patient ages ranged from 12 to 84 years (mean 
      age, 58 years). No significant difference was found among the treatment groups 
      with respect to age, sex, prior medical problems, duration of anesthesia, 
      intraoperative fluid intake, and the distribution of donor and recipient sites. 
      There were no total flap losses and two partial flap losses in this series. Three 
      flaps were reexplored and all were salvaged. The incidence of systemic 
      complications (congestive heart failure, myocardial infarction, pulmonary edema, 
      pleural effusion, and pneumonia) was as follows: low-molecular-weight dextran 120 
      hours, 51 percent; low-molecular-weight dextran 48 hours, 29 percent; and 
      aspirin, 7 percent. Analysis of these data suggests that the method of 
      prophylaxis had no effect on overall flap survival. However, the incidence of 
      systemic complications was significantly related to the method of prophylaxis, 
      with patients receiving low-molecular-weight dextran 120 hours and 48 hours at a 
      7.2 and 3.9 times greater relative risk, respectively, of developing a systemic 
      complication compared with patients receiving aspirin. The results of this study 
      have eliminated the routine use of low-molecular-weight dextran prophylaxis at 
      our institution in an effort to reduce morbidity in head and neck microsurgical 
      reconstruction.
FAU - Disa, Joseph J
AU  - Disa JJ
AD  - Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. disaj@mskcc.org
FAU - Polvora, Virginia P
AU  - Polvora VP
FAU - Pusic, Andrea L
AU  - Pusic AL
FAU - Singh, Bhuvinesh
AU  - Singh B
FAU - Cordeiro, Peter G
AU  - Cordeiro PG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Plast Reconstr Surg
JT  - Plastic and reconstructive surgery
JID - 1306050
RN  - 0 (Anticoagulants)
RN  - 0 (Dextrans)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Plast Reconstr Surg. 2004 Sep 15;114(4):1008; author reply 1008-9. PMID: 15468416
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Child
MH  - Dextrans/*adverse effects/therapeutic use
MH  - Female
MH  - Head and Neck Neoplasms/*surgery
MH  - Humans
MH  - Male
MH  - Microsurgery
MH  - Middle Aged
MH  - Molecular Weight
MH  - Postoperative Complications/prevention & control
MH  - Prospective Studies
MH  - *Surgical Flaps/blood supply
MH  - Thrombosis/prevention & control
EDAT- 2003/10/28 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/10/28 05:00
PHST- 2003/10/28 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/10/28 05:00 [entrez]
AID - 10.1097/01.PRS.0000083378.58757.54 [doi]
PST - ppublish
SO  - Plast Reconstr Surg. 2003 Nov;112(6):1534-9. doi: 
      10.1097/01.PRS.0000083378.58757.54.

PMID- 32745092
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Aspirin versus low-molecular-weight heparin for venous thromboembolism 
      prophylaxis in orthopaedic trauma patients: A patient-centered randomized 
      controlled trial.
PG  - e0235628
LID - 10.1371/journal.pone.0235628 [doi]
LID - e0235628
AB  - BACKGROUND: Emerging evidence suggests aspirin may be an effective venous 
      thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer 
      bleeding complications. We used a patient-centered weighted composite outcome to 
      globally evaluate aspirin versus low-molecular-weight heparin (LMWH) for VTE 
      prevention in fracture patients. METHODS: We conducted an open-label randomized 
      clinical trial of adult patients admitted to an academic trauma center with an 
      operative extremity fracture, or a pelvis or acetabular fracture. Patients were 
      randomized to receive LMWH (enoxaparin 30-mg) twice daily (n = 164) or aspirin 
      81-mg twice daily (n = 165). The primary outcome was a composite endpoint of 
      bleeding complications, deep surgical site infection, deep vein thrombosis, 
      pulmonary embolism, and death within 90 days of injury. A Global Rank test and 
      weighted time to event analysis were used to determine the probability of 
      treatment superiority for LMWH, given a 9% patient preference margin for oral 
      administration over skin injections. RESULTS: Overall, 18 different combinations 
      of outcomes were experienced by patients in the study. Ninety-nine patients in 
      the aspirin group (59.9%) and 98 patients in the LMWH group (59.4%) were 
      event-free within 90 days of injury. Using a Global Rank test, the LMWH had a 
      50.4% (95% CI, 47.7-53.2%, p = 0.73) probability of treatment superiority over 
      aspirin. In the time to event analysis, LMWH had a 60.5% probability of treatment 
      superiority over aspirin with considerable uncertainty (95% CI, 24.3-88.0%, p = 
      0.59). CONCLUSION: The findings of the Global Rank test suggest no evidence of 
      superiority between LMWH or aspirin for VTE prevention in fracture patients. LMWH 
      demonstrated a 60.5% VTE prevention benefit in the weighted time to event 
      analysis. However, this difference did not reach statistical significance and was 
      similar to the elicited patient preferences for aspirin.
FAU - Haac, Bryce E
AU  - Haac BE
AD  - Department of Surgery, R A Cowley Shock Trauma Center, University of Maryland 
      School of Medicine, Baltimore, Maryland, United States of America.
FAU - O'Hara, Nathan N
AU  - O'Hara NN
AUID- ORCID: 0000-0003-0537-3474
AD  - Department of Orthopaedics, R A Cowley Shock Trauma Center, University of 
      Maryland School of Medicine, Baltimore, Maryland, United States of America.
FAU - Manson, Theodore T
AU  - Manson TT
AD  - Department of Orthopaedics, R A Cowley Shock Trauma Center, University of 
      Maryland School of Medicine, Baltimore, Maryland, United States of America.
FAU - Slobogean, Gerard P
AU  - Slobogean GP
AUID- ORCID: 0000-0002-9111-9239
AD  - Department of Orthopaedics, R A Cowley Shock Trauma Center, University of 
      Maryland School of Medicine, Baltimore, Maryland, United States of America.
FAU - Castillo, Renan C
AU  - Castillo RC
AD  - Department of Health Policy and Management, Johns Hopkins University Bloomberg 
      School of Public Health, Baltimore, Maryland, United States of America.
FAU - O'Toole, Robert V
AU  - O'Toole RV
AD  - Department of Orthopaedics, R A Cowley Shock Trauma Center, University of 
      Maryland School of Medicine, Baltimore, Maryland, United States of America.
FAU - Stein, Deborah M
AU  - Stein DM
AD  - Department of Surgery, R A Cowley Shock Trauma Center, University of Maryland 
      School of Medicine, Baltimore, Maryland, United States of America.
CN  - ADAPT Investigators
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200803
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Enoxaparin/adverse effects/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Fractures, Bone/*complications
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Venous Thromboembolism/complications/*prevention & control
MH  - Young Adult
PMC - PMC7398524
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/04 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/02/26 00:00 [received]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - PONE-D-20-05342 [pii]
AID - 10.1371/journal.pone.0235628 [doi]
PST - epublish
SO  - PLoS One. 2020 Aug 3;15(8):e0235628. doi: 10.1371/journal.pone.0235628. 
      eCollection 2020.

PMID- 30758744
OWN - NLM
STAT- MEDLINE
DCOM- 20200318
LR  - 20200318
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 36
IP  - 3
DP  - 2019 Mar
TI  - Effect of Caffeine on the Bioavailability and Pharmacokinetics of an 
      Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study.
PG  - 597-607
LID - 10.1007/s12325-019-0891-5 [doi]
AB  - INTRODUCTION: Caffeine is used as an adjuvant in analgesic combinations to 
      enhance their efficacy. The present study aimed to determine the effect of 
      caffeine on the pharmacokinetics of acetylsalicylic acid (ASA) and paracetamol 
      when used as a fixed-dose ASA/paracetamol/caffeine combination. METHODS: In this 
      single-centre, two-way, cross-over phase I study, volunteers fasted overnight 
      (≥ 12 h) and randomly received single oral doses of 250 mg ASA/200 mg paracetamol 
      (reference) or 250 mg ASA/200 mg paracetamol/50 mg caffeine (test). Blood samples 
      were collected before and up to 24 h after dosing. The primary end points were 
      the area under the concentration-time curve from zero to infinity (AUC(0-∞)) and 
      maximum plasma concentration (C(max)) for ASA, salicylic acid (SA) and 
      paracetamol from the two combinations. The main secondary end points were 
      AUC(0-∞) and C(max) of caffeine and time to reach C(max) (t(max)) of all drugs. 
      RESULTS: Eighteen healthy male volunteers (32.5 ± 10.5 years) participated in the 
      study. The geometric means of C(max) for ASA, SA and paracetamol were similar in 
      the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 
      15.8, 2.42 µg/ml, respectively). The geometric mean of AUC(0-∞) for ASA, SA and 
      paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, 
      respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, 
      respectively. The medians of t(max) for ASA, SA and paracetamol were similar 
      between the two groups. The point estimates for the ratios of AUC(0-∞) and C(max) 
      for test versus reference regarding ASA, SA and paracetamol were within the 
      predefined equivalence limits. The two treatments were well tolerated. 
      CONCLUSION: Caffeine did not affect the pharmacokinetics of ASA and paracetamol 
      when used as an adjuvant in ASA/paracetamol fixed-dose combination under fasting 
      conditions, suggesting that caffeine enhances the analgesic efficacy of these 
      drugs by pharmacodynamic rather than pharmacokinetic interactions. FUNDING: 
      Sanofi-Aventis Deutschland GmbH.
FAU - Weiser, Thomas
AU  - Weiser T
AD  - Medical Affairs CHC, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 
      Frankfurt am Main, Germany. thomas.weiser@sanofi.com.
FAU - Weigmann, Harald
AU  - Weigmann H
AD  - Medical Affairs CHC, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 
      Frankfurt am Main, Germany.
LA  - eng
SI  - figshare/10.6084/m9.figshare.7558871
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190213
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Analgesics)
RN  - 0 (Drug Combinations)
RN  - 0 (acetaminophen, aspirin, caffeine drug combination)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
MH  - Acetaminophen/*pharmacokinetics/pharmacology
MH  - Adult
MH  - Analgesics/*pharmacokinetics
MH  - Area Under Curve
MH  - Aspirin/*pharmacokinetics/pharmacology
MH  - Caffeine/*pharmacology
MH  - Cross-Over Studies
MH  - Drug Combinations
MH  - Fasting
MH  - Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Young Adult
PMC - PMC6824350
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Caffeine
OT  - Fixed-dose combination
OT  - Pain
OT  - Paracetamol
OT  - Pharmacokinetics
EDAT- 2019/02/14 06:00
MHDA- 2020/03/19 06:00
CRDT- 2019/02/14 06:00
PHST- 2018/11/23 00:00 [received]
PHST- 2019/02/14 06:00 [pubmed]
PHST- 2020/03/19 06:00 [medline]
PHST- 2019/02/14 06:00 [entrez]
AID - 10.1007/s12325-019-0891-5 [pii]
AID - 891 [pii]
AID - 10.1007/s12325-019-0891-5 [doi]
PST - ppublish
SO  - Adv Ther. 2019 Mar;36(3):597-607. doi: 10.1007/s12325-019-0891-5. Epub 2019 Feb 
      13.

PMID- 20526535
OWN - NLM
STAT- MEDLINE
DCOM- 20100816
LR  - 20220321
IS  - 1537-744X (Electronic)
IS  - 2356-6140 (Print)
IS  - 1537-744X (Linking)
VI  - 10
DP  - 2010 Jun 2
TI  - Lipoxin and aspirin-triggered lipoxins.
PG  - 1048-64
LID - 10.1100/tsw.2010.113 [doi]
AB  - Lipoxins and their 15 epimers, aspirin triggered lipoxins (ATL), are eicosanoids 
      derived from sequential lipoxygenase (LO) metabolism of arachidonic acid. The 
      main routes of lipoxin biosynthesis involve cooperation between 15- and 5-LO, and 
      between 12- and 5-LO. ATL are generated by interactions between 5-LO and 
      aspirin-acetylated cyclooxygenase-2. Cellular models recapitulating these 
      interactions involve leukocytes, platelets, vascular endothelium, and epithelium. 
      To circumvent rapid lipoxin and ATL metabolism and inactivation, stable analogs, 
      bearing potent and long-lasting biological activity, have been synthesized. Some 
      of these analogs displayed therapeutic potential by showing strong 
      anti-inflammatory activity in a number of animal models of disease, including 
      reperfusion injury; arthritis; gastrointestinal, renal, respiratory, and vascular 
      inflammatory disorders; eye damage; periodontitis; and selected infectious 
      diseases. Counter-regulatory signaling by lipoxin A4 and 15-epi-lipoxin A4 is 
      triggered by the activation of a seven-transmembrane domain receptor, termed 
      FPR2/ALX, which is highly expressed in myeloid cells and has been recognized as a 
      main anti-inflammatory receptor.
FAU - Romano, Mario
AU  - Romano M
AD  - Department of Biomedical Sciences, Aging Research Center, Ce.S.I., Gabriele 
      D'Annunzio University Foundation, Chieti, Italy. mromano@unich.it
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100602
PL  - United States
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
RN  - 0 (Lipoxins)
RN  - EC 1.13.11.12 (Lipoxygenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Disease Models, Animal
MH  - Lipoxins/*biosynthesis/metabolism
MH  - Lipoxygenase/metabolism
PMC - PMC5763664
EDAT- 2010/06/09 06:00
MHDA- 2010/08/17 06:00
CRDT- 2010/06/08 06:00
PHST- 2010/06/08 06:00 [entrez]
PHST- 2010/06/09 06:00 [pubmed]
PHST- 2010/08/17 06:00 [medline]
AID - 458217 [pii]
AID - 10.1100/tsw.2010.113 [doi]
PST - epublish
SO  - ScientificWorldJournal. 2010 Jun 2;10:1048-64. doi: 10.1100/tsw.2010.113.

PMID- 28700151
OWN - NLM
STAT- MEDLINE
DCOM- 20180416
LR  - 20180416
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 12
IP  - 541
DP  - 2016 Nov 30
TI  - [Common medications and prostate cancer : what is the association ?].
PG  - 2068-2071
AB  - A possible association between prostate cancer and metabolic syndrome has 
      recently been observed. Further, multiple experimental and epidemiologic studies 
      have recently reported a probable association between common medications and 
      prostate cancer. In this article, we summarize the results of those studies that 
      explore the role of aspirin, oral antidiabetic medication and statins.
FAU - Rakauskas, Arnas
AU  - Rakauskas A
AD  - Service d'urologie, CHUV, 1011 Lausanne.
FAU - Grilo, Nuno
AU  - Grilo N
AD  - Service d'urologie, CHUV, 1011 Lausanne.
FAU - M'Baya, Olivier
AU  - M'Baya O
AD  - Service d'urologie, CHUV, 1011 Lausanne.
FAU - Jichlinski, Patrice
AU  - Jichlinski P
AD  - Service d'urologie, CHUV, 1011 Lausanne.
FAU - Valerio, Massimo
AU  - Valerio M
AD  - Service d'urologie, CHUV, 1011 Lausanne.
FAU - Berthold, Dominik
AU  - Berthold D
AD  - Service d'oncologie, CHUV, 1011 Lausanne.
LA  - fre
PT  - Journal Article
TT  - Médicaments usuels en médecine de premier recours et cancer de la prostate : 
      quelle relation ?
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/*adverse 
      effects
MH  - Hypoglycemic Agents/administration & dosage/*adverse effects
MH  - Male
MH  - Metabolic Syndrome/epidemiology
MH  - Prostatic Neoplasms/epidemiology/*etiology
COIS- Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
EDAT- 2017/07/13 06:00
MHDA- 2018/04/17 06:00
CRDT- 2017/07/13 06:00
PHST- 2017/07/13 06:00 [entrez]
PHST- 2017/07/13 06:00 [pubmed]
PHST- 2018/04/17 06:00 [medline]
PST - ppublish
SO  - Rev Med Suisse. 2016 Nov 30;12(541):2068-2071.

PMID- 19253428
OWN - NLM
STAT- MEDLINE
DCOM- 20100330
LR  - 20220327
IS  - 1008-9292 (Print)
IS  - 1008-9292 (Linking)
VI  - 38
IP  - 1
DP  - 2009 Jan
TI  - [Aspirin-PEI-beta-CyD as a novel non-viral vector for gene transfer].
PG  - 46-52
AB  - OBJECTIVE: To develop a novel non-viral gene delivery vector based on 
      PEI-beta-CyD as backbone modified with aspirin, and to identify its 
      physicochemical characters. METHODS: 1, 1-carbonyldiimidazole (CDI) was used to 
      bind aspirin onto PEI-beta-CyD to form PEI-beta-CyD-ASP. (1)H-NMR, FT-IR, UV and 
      XRD were used to confirm the polymer structure. The ability of condensation was 
      demonstrated by gel retardation assay. MTT assay was used to test the cell 
      viability in B16, Hela and A293 cell lines. Transfection efficiency of the 
      polymer was tested in B16 cells. RESULT: The structure of PEI-beta-CyD-ASP was 
      confirmed by (1)H-NMR, FT-IR, UV and XRD, which efficiently condensed plasmid DNA 
      at the N/P ratio of 4. The copolymer showed low cytotoxicity and high 
      transfection efficiency in B16 cells. CONCLUSION: The synthesized 
      aspirin-PEI-beta-CyD might be a potential gene delivery vector.
FAU - Wang, Zhong-Ren
AU  - Wang ZR
AD  - Institute of Chemical Biology and Pharmaceutical Chemistry, Zhejiang University, 
      Hangzhou 310028, China.
FAU - Chen, Dan
AU  - Chen D
FAU - Zhou, Jun
AU  - Zhou J
FAU - Tang, Gu-Ping
AU  - Tang GP
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhejiang Da Xue Xue Bao Yi Xue Ban
JT  - Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical 
      sciences
JID - 100927946
RN  - 0 (beta-Cyclodextrins)
RN  - 9002-98-6 (Polyethyleneimine)
RN  - JV039JZZ3A (betadex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Cell Line
MH  - *Gene Transfer Techniques
MH  - Genetic Therapy/methods
MH  - Humans
MH  - Polyethyleneimine/*chemistry
MH  - beta-Cyclodextrins/*chemistry
EDAT- 2009/03/03 09:00
MHDA- 2010/03/31 06:00
CRDT- 2009/03/03 09:00
PHST- 2009/03/03 09:00 [entrez]
PHST- 2009/03/03 09:00 [pubmed]
PHST- 2010/03/31 06:00 [medline]
AID - 10.3785/j.issn.1008-9292.2009.01.007 [doi]
PST - ppublish
SO  - Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009 Jan;38(1):46-52. doi: 
      10.3785/j.issn.1008-9292.2009.01.007.

PMID- 16539843
OWN - NLM
STAT- MEDLINE
DCOM- 20061024
LR  - 20131121
IS  - 1671-4083 (Print)
IS  - 1671-4083 (Linking)
VI  - 27
IP  - 4
DP  - 2006 Apr
TI  - Effects of aspirin on number, activity and inducible nitric oxide synthase of 
      endothelial progenitor cells from peripheral blood.
PG  - 430-6
AB  - AIM: To investigate whether aspirin has an influence on endothelial progenitor 
      cells (EPC). METHODS: Total mononuclear cells (MNC) were isolated from peripheral 
      blood by Ficoll density gradient centrifugation, then cells were plated on 
      fibronectin-coated culture dishes. After 7 d of culture, attached cells were 
      stimulated with aspirin (to achieve final concentrations of 1, 2, 5, and 10 
      mmol/L) for 3, 6, 12, and 24 h. EPC were characterized as adherent cells that 
      were double positive for 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine low 
      density lipoprotein (DiLDL) uptake and lectin binding by direct fluorescent 
      staining. EPC proliferation and migration were assayed using a 3-(4,5-dimethyl-2 
      thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and a modified Boyden 
      chamber assay, respectively. An EPC adhesion assay was performed by replating the 
      EPC on fibronectin-coated dishes, and then adherent cells were counted. In vitro 
      vasculogenesis activity was assayed by using an in vitro vasculogenesis kit. 
      Inducible nitric oxide synthase (iNOS) was assayed by Western blotting. RESULTS: 
      Incubation of isolated human MNC with aspirin decreased the number of EPC. 
      Aspirin also decreased the proliferative, migratory, adhesive, and in vitro 
      vasculogenesis capacity of EPC, and also their iNOS levels in a concentration- 
      and time-dependent manner. CONCLUSION: Aspirin decreases (1) the number of EPC; 
      (2) the proliferative, migratory, adhesive and in vitro vasculogenesis capacities 
      of EPC; and (3) iNOS levels in EPC.
FAU - Chen, Tu-Gang
AU  - Chen TG
AD  - Department of Cardiovascular Disease, First Affiliated Hospital, Medical School 
      of Zhejiang University, Hangzhou 310003, China.
FAU - Chen, Jun-Zhu
AU  - Chen JZ
FAU - Xie, Xu-Dong
AU  - Xie XD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Acta Pharmacol Sin
JT  - Acta pharmacologica Sinica
JID - 100956087
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cell Adhesion/drug effects
MH  - Cell Movement/*drug effects
MH  - Cell Proliferation/*drug effects
MH  - Cell Separation
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Leukocytes, Mononuclear/cytology
MH  - Neovascularization, Physiologic
MH  - Nitric Oxide Synthase Type II/*metabolism
MH  - *Stem Cells/cytology/enzymology
EDAT- 2006/03/17 09:00
MHDA- 2006/10/25 09:00
CRDT- 2006/03/17 09:00
PHST- 2006/03/17 09:00 [pubmed]
PHST- 2006/10/25 09:00 [medline]
PHST- 2006/03/17 09:00 [entrez]
AID - 10.1111/j.1745-7254.2006.00298.x [doi]
PST - ppublish
SO  - Acta Pharmacol Sin. 2006 Apr;27(4):430-6. doi: 10.1111/j.1745-7254.2006.00298.x.

PMID- 31828756
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1399-6576 (Electronic)
IS  - 0001-5172 (Linking)
VI  - 64
IP  - 4
DP  - 2020 Apr
TI  - Assessment of platelet function after discontinuation of ticagrelor.
PG  - 526-531
LID - 10.1111/aas.13524 [doi]
AB  - BACKGROUND: Patients presenting with acute coronary syndromes (ACS) are often 
      treated by percutaneous coronary intervention (PCI) with insertion of coronary 
      artery stents and a majority receive dual antiplatelet therapy (DAPT), usually a 
      combination of a COX-1 inhibitor (aspirin) and a P2Y(12) inhibitor (eg 
      ticagrelor). Not seldom the question arises as to when DAPT should be 
      discontinued prior to interventional surgery. This study was done with the 
      primary aim of investigating thrombocyte function immediately prior to and after 
      discontinuation of ticagrelor. MATERIALS AND METHODS: In this prospective, 
      longitudinal, observational study including 24 patients, venous blood was 
      obtained from patients on day 0, before stopping maintenance dose of 90 mg 
      ticagrelor twice daily, and then on days 1, 3, 5, and 8, after discontinuation. 
      Samples were analyzed using Multiplate(®) and VerifyNow(®) . RESULTS: Prior to 
      urgent surgery platelet aggregation >30 aggregation units (Multiplate(®) ) and 
      >208 P2Y(12) reaction units (VerifyNow(®) ) have been shown to correlate with 
      reduced risk of peri- and postoperative bleeding risk. On day 3 after ticagrelor 
      discontinuation, 100% (P = .016) and 67% (P=<.001) of patients had reached these 
      levels on Multiplate(®) and VerifyNow(®) , respectively. On day 5, the 
      corresponding figures were 100% (P = .016) and 78% (P=<.001). CONCLUSION: 
      Discontinuation of ticagrelor for 3 days resulted in return of adequate platelet 
      function in all patients on Multiplate(®) and in a majority of patients on 
      VerifyNow(®) , indicating a lower bleeding risk. A bedside test for platelet 
      function may be considered if time to anticipated surgery is less than 5 days 
      after ticagrelor discontinuation.
CI  - © 2019 The Acta Anaesthesiologica Scandinavica Foundation. Published by John 
      Wiley & Sons Ltd.
FAU - Söderberg, Martin
AU  - Söderberg M
AUID- ORCID: 0000-0002-4911-3538
AD  - Department of Perioperative Medicine and Intensive Care, Karolinska University 
      Hospital, Stockholm, Sweden.
FAU - Holm, Manne
AU  - Holm M
AD  - Department of Perioperative Medicine and Intensive Care, Karolinska University 
      Hospital, Stockholm, Sweden.
FAU - Gupta, Anil
AU  - Gupta A
AD  - Department of Perioperative Medicine and Intensive Care, Karolinska University 
      Hospital, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20191227
PL  - England
TA  - Acta Anaesthesiol Scand
JT  - Acta anaesthesiologica Scandinavica
JID - 0370270
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology
MH  - Drug Therapy, Combination/methods
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Platelet Function Tests/methods
MH  - Prospective Studies
MH  - Ticagrelor/*administration & dosage/pharmacology
OTO - NOTNLM
OT  - Multiplate
OT  - VerifyNow
OT  - platelet function
OT  - ticagrelor
EDAT- 2019/12/13 06:00
MHDA- 2021/05/18 06:00
CRDT- 2019/12/13 06:00
PHST- 2019/07/17 00:00 [received]
PHST- 2019/11/22 00:00 [revised]
PHST- 2019/11/27 00:00 [accepted]
PHST- 2019/12/13 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2019/12/13 06:00 [entrez]
AID - 10.1111/aas.13524 [doi]
PST - ppublish
SO  - Acta Anaesthesiol Scand. 2020 Apr;64(4):526-531. doi: 10.1111/aas.13524. Epub 
      2019 Dec 27.

PMID- 37395227
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230809
IS  - 1473-5687 (Electronic)
IS  - 0954-691X (Linking)
VI  - 35
IP  - 9
DP  - 2023 Sep 1
TI  - Effect of aspirin use on survival in patients with hepatocellular carcinoma.
PG  - 1037-1043
LID - 10.1097/MEG.0000000000002601 [doi]
AB  - BACKGROUND: Hepatocellular carcinoma (HCC) is the seventh most prevalent cancer 
      globally and is the third leading cause of cancer-related mortality. AIM: The aim 
      of this study was to evaluate the effect of aspirin use on the survival rates of 
      individuals diagnosed with HCC. METHODS: The patients were divided into two 
      groups: those who used aspirin and those who did not. Aspirin use was defined as 
      individuals who had used aspirin either before or after the diagnosis of HCC. 
      Aspirin usage was determined based on prescription records. The criteria for 
      aspirin use were defined as a minimum of 3 months and a minimum daily dose of 
      100 mg. Survival time; The time elapsed after the diagnosis of HCC was calculated 
      as 'months'. RESULT: Of the 300 cohorts studied in our study, 104 (34.6%) were 
      using aspirin, while 196 (65.4%) were not. It was observed that bleeding occurred 
      only in the patient group taking aspirin ( P  = 0.002). When evaluated in terms 
      of survival time, it was observed that it was significantly higher in the patient 
      group using aspirin ( P  = 0.001). Aspirin use was identified as factors that 
      significantly impact survival ( P  < 0.05). Aspirin use was identified as 
      independent risk factors that significantly impact of survival ( P  < 0.05). 
      CONCLUSION: The aspirin group had a similar metabolic and liver reserve as the 
      other group and had a longer survival despite being older and more comorbid 
      diseases.
CI  - Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Aktan, Hakan
AU  - Aktan H
AD  - Cukurova University Gastroenterology Department, Adana.
FAU - Ozdemir, Asena Ayca
AU  - Ozdemir AA
AD  - Mersin University, Department of Medical Education, Mersin, Turkey.
FAU - Karaoğullarindan, Ümit
AU  - Karaoğullarindan Ü
AD  - Cukurova University Gastroenterology Department, Adana.
LA  - eng
PT  - Journal Article
DEP - 20230703
PL  - England
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Aspirin/therapeutic use
MH  - *Carcinoma, Hepatocellular/pathology
MH  - *Liver Neoplasms/pathology
MH  - Risk Factors
MH  - Survival Rate
EDAT- 2023/07/03 06:42
MHDA- 2023/07/31 06:42
CRDT- 2023/07/03 05:45
PHST- 2023/07/31 06:42 [medline]
PHST- 2023/07/03 06:42 [pubmed]
PHST- 2023/07/03 05:45 [entrez]
AID - 00042737-990000000-00203 [pii]
AID - 10.1097/MEG.0000000000002601 [doi]
PST - ppublish
SO  - Eur J Gastroenterol Hepatol. 2023 Sep 1;35(9):1037-1043. doi: 
      10.1097/MEG.0000000000002601. Epub 2023 Jul 3.

PMID- 26093650
OWN - NLM
STAT- MEDLINE
DCOM- 20160411
LR  - 20181113
IS  - 1573-6903 (Electronic)
IS  - 0364-3190 (Linking)
VI  - 40
IP  - 7
DP  - 2015 Jul
TI  - Aspirin Inhibits Degenerative Changes of Aneurysmal Wall in a Rat Model.
PG  - 1537-45
LID - 10.1007/s11064-015-1603-4 [doi]
AB  - Aneurysmal subarachnoid hemorrhage still has a high mortality and morbidity 
      despite notable advances in surgical approaches to cerebral aneurysm (CA). We 
      examined the role of aspirin in vascular inflammation and degeneration. CA was 
      induced in male Sprague-Dawley rats by ligating left common carotid artery and 
      bilateral posterior renal arteries with or without aspirin treatment. The right 
      anterior cerebral artery/olfactory artery (ACA/OA) bifurcations were stripped and 
      assessed morphologically after Verhoeff's Van Gieson staining. Blood sample was 
      obtained to examine circulating CD34(+) CD133(+) endothelial progenitor cells 
      (EPCs), platelet aggregation and platelet counts. Macrophages infiltration in 
      aneurysmal wall was evaluated by immunohistochemistry. Expression of matrix 
      metalloproteinase-2 and 9 (MMP-2 and 9), nuclear factor kappa B (NF-κB), 
      macrophage chemoattractant protein-1 (MCP-1) and vascular cell adhesion 
      molecule-1 (VCAM-1) was examined by RT-PCR. 2 months after CA induction, 
      surgically treated rats manifested aneurysmal degeneration in ACA/OA 
      bifurcations. Aspirin-treated rats exhibited a significant decrease in 
      degradation of internal elastic lamina (IEL), medial layer thinning, CA size and 
      macrophages infiltration with reduced expression of MMP-2 and 9 compared with 
      rats in the CA group. RT-PCR demonstrated that the upregulation of NF-κB, MCP-1 
      and VCAM-1 after CA induction was reversed by aspirin treatment. Aspirin 
      treatment following CA induction increased circulating EPCs to near control 
      levels and reduced platelet aggregation without changing platelet counts. The 
      evidence suggested that aspirin significantly reduced degeneration of aneurysm 
      walls by inhibiting macrophages-mediated chronic inflammation and mobilizing 
      EPCs.
FAU - Li, Shengjie
AU  - Li S
AD  - Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 
      Neurological Institute, Key Laboratory of Post-trauma Neuro-repair and 
      Regeneration in Central Nervous System, Ministry of Education, Tianjin Key 
      Laboratory of Injuries, Variations and Regeneration of Nervous System, Anshan 
      Road, Heping District, Tianjin, 300052, People's Republic of China.
FAU - Wang, Dehui
AU  - Wang D
FAU - Tian, Ye
AU  - Tian Y
FAU - Wei, Huijie
AU  - Wei H
FAU - Zhou, Ziwei
AU  - Zhou Z
FAU - Liu, Li
AU  - Liu L
FAU - Wang, Dong
AU  - Wang D
FAU - Dong, Jing-Fei
AU  - Dong JF
FAU - Jiang, Rongcai
AU  - Jiang R
FAU - Zhang, Jianning
AU  - Zhang J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150621
PL  - United States
TA  - Neurochem Res
JT  - Neurochemical research
JID - 7613461
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Intracranial Aneurysm/*pathology
MH  - Male
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tunica Intima/*drug effects/pathology
EDAT- 2015/06/22 06:00
MHDA- 2016/04/12 06:00
CRDT- 2015/06/22 06:00
PHST- 2015/01/22 00:00 [received]
PHST- 2015/05/04 00:00 [accepted]
PHST- 2015/03/18 00:00 [revised]
PHST- 2015/06/22 06:00 [entrez]
PHST- 2015/06/22 06:00 [pubmed]
PHST- 2016/04/12 06:00 [medline]
AID - 10.1007/s11064-015-1603-4 [doi]
PST - ppublish
SO  - Neurochem Res. 2015 Jul;40(7):1537-45. doi: 10.1007/s11064-015-1603-4. Epub 2015 
      Jun 21.

PMID- 31751455
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1460-2229 (Electronic)
IS  - 0263-2136 (Linking)
VI  - 37
IP  - 3
DP  - 2020 Jul 23
TI  - A comparison of contemporary versus older studies of aspirin for primary 
      prevention.
PG  - 290-296
LID - 10.1093/fampra/cmz080 [doi]
AB  - BACKGROUND: Recent aspirin trials have not shown similar benefits for primary 
      prevention as older studies. OBJECTIVE: To compare benefits and harms of aspirin 
      for primary prevention before and after widespread use of statins and colorectal 
      cancer screening. METHODS: We compared studies of aspirin for primary prevention 
      that recruited patients from 2005 onward with previous individual patient data 
      (IPD) meta-analyses that recruited patients from 1978 to 2002. Data for 
      contemporary studies were synthesized using random-effects models. We report 
      vascular [major adverse cardiovascular events (MACE), myocardial infarction (MI) 
      and stroke], bleeding, cancer and mortality outcomes. RESULTS: The IPD analyses 
      of older studies included 95 456 patients for CV prevention and 25 270 for cancer 
      mortality, while the four newer studies had 61 604 patients. Relative risks for 
      vascular outcomes for older versus newer studies follow: MACE: 0.89 [95% 
      confidence interval (CI) 0.83-0.95] versus 0.93 (0.86-0.99); fatal haemorrhagic 
      stroke: 1.73 (1.11-2.72) versus 1.06 (0.66-1.70); any ischaemic stroke: 0.86 
      (0.74-1.00) versus 0.86 (0.75-0.98); any MI: 0.84 (0.77-0.92) versus 0.88 
      (0.77-1.00); and non-fatal MI: 0.79 (0.71-0.88) versus 0.94 (0.83-1.08). Cancer 
      death was not significantly decreased in newer studies (1.11, 0.92-1.34). Major 
      haemorrhage was significantly increased (older studies RR 1.48, 95% CI 1.25-1.76 
      versus newer studies RR 1.37, 1.24-1.53). There was no effect on all-cause 
      mortality, cardiovascular mortality, fatal stroke or fatal MI. CONCLUSIONS: Per 
      1200 persons taking aspirin for primary prevention for 5 years, there will be 4 
      fewer MACEs, 3 fewer ischaemic strokes, 3 more intracranial haemorrhages and 8 
      more major bleeding events. Aspirin should no longer be recommended for primary 
      prevention.
CI  - © The Author(s) 2019. Published by Oxford University Press. All rights 
      reserved.For permissions, please e-mail: journals.permissions@oup.com.
FAU - Moriarty, Frank
AU  - Moriarty F
AD  - HRB Centre for Primary Care Research, Royal College of Surgeons in Ireland, 
      Dublin, Ireland.
FAU - Ebell, Mark H
AU  - Ebell MH
AD  - College of Public Health, University of Georgia, Athens, GA, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - England
TA  - Fam Pract
JT  - Family practice
JID - 8500875
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Intracranial Hemorrhages/*chemically induced/epidemiology
MH  - Neoplasms/mortality/prevention & control
MH  - Primary Prevention/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/mortality/*prevention & control
OTO - NOTNLM
OT  - aspirin
OT  - cancer
OT  - cardiovascular disease
OT  - meta-analysis
OT  - primary prevention
OT  - stroke
OT  - systematic review
EDAT- 2019/11/22 06:00
MHDA- 2021/08/11 06:00
CRDT- 2019/11/22 06:00
PHST- 2019/11/22 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
PHST- 2019/11/22 06:00 [entrez]
AID - 5637484 [pii]
AID - 10.1093/fampra/cmz080 [doi]
PST - ppublish
SO  - Fam Pract. 2020 Jul 23;37(3):290-296. doi: 10.1093/fampra/cmz080.

PMID- 16062025
OWN - NLM
STAT- MEDLINE
DCOM- 20060221
LR  - 20180614
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Linking)
VI  - 41
IP  - 7
DP  - 2005
TI  - [Influence of preoperative treatment with aspirin or heparin on platelet function 
      and intensity of postoperative bleeding in early period after coronary artery 
      bypass surgery].
PG  - 577-83
AB  - OBJECTIVE: The aim of the study was to evaluate influence of preoperative 
      treatment with aspirin or heparin on platelet function and intensity of 
      postoperative blood loss in early period after coronary artery bypass grafting 
      (CABG). MATERIAL AND METHODS: Study involved 75 patients (men) with ischemic 
      heart disease, who underwent CABG. Patients were divided into three groups: 
      aspirin pretreated (I group, n=25), heparin pretreated (II group, n=22) and III 
      group (n=28) had no antiplatelet or anticoagulant pretreatment. At 24 h after 
      surgery all patients started treatment with aspirin (ASS 100, Bayer), which 
      lasted all hospitalization period. We have evaluated preoperative coagulation 
      parameters: activated partial thromboplastin time, international normalized 
      ratio, and fibrinogen level. Also we have compared platelet count, platelet 
      aggregation induced by adenosine diphosphate during preoperative period, at 1 h, 
      20 h and at 7 day after surgery. RESULTS: Preoperative coagulation parameters 
      were comparable in all groups. Platelet count was also similar. One hour after 
      surgery platelet count remarkably decreased in all groups (p<0.001); at 20 hours 
      after surgery changes remained the same and at 7 day a significant increase was 
      observed in all groups (p<0.001). The lowest rate of preoperative platelet 
      aggregation was found in I group (p<0.05). At 1 hour after surgery platelet 
      aggregation decreased significantly in all groups, particularly in III group 
      (p<0.001). At 20 hours after surgery platelet aggregation had a tendency to reach 
      previous level and increased substantially in all groups. We have found more than 
      10% increase in platelet aggregation at 7 day compared to 20 hours 
      postoperatively. These changes were observed in 32% (p<0.05), 27.3% (p<0.05) and 
      35.7% (p<0.001) of patients in the group I, II and III, respectively. 
      Postoperative blood loss was significantly lowest in II group (p<0.01). 
      CONCLUSIONS: Our investigation shows that preoperative treatment with aspirin or 
      heparin had no remarkable influence on dynamics of platelet function in early 
      period after CABG. The least blood loss was observed in patients with heparin 
      pretreatment.
FAU - Veikutiene, Audrone
AU  - Veikutiene A
AD  - Clinic of Cardiac Surgery, Kaunas University of Medicine Hospital, Kaunas, 
      Lithuania. aveikutiene@hotmail.com
FAU - Sirvinskas, Edmundas
AU  - Sirvinskas E
FAU - Grybauskas, Pranas
AU  - Grybauskas P
FAU - Cimbolaityte, Jūrate
AU  - Cimbolaityte J
FAU - Mongirdiene, Ausra
AU  - Mongirdiene A
FAU - Veikutis, Vincentas
AU  - Veikutis V
LA  - lit
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Aspirino ar heparino, vartojamo iki operacijos, itaka trombocitu funkcijai bei 
      kraujavimo intensyvumui po aortos vainikiniu jungciu operaciju.
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/administration & dosage/pharmacology/*therapeutic use
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Blood Coagulation Tests
MH  - Blood Platelets/*drug effects
MH  - *Coronary Artery Bypass
MH  - Data Interpretation, Statistical
MH  - Fibrinolytic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Heparin/administration & dosage/pharmacology/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/surgery
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Platelet Count
MH  - Postoperative Care
MH  - Postoperative Hemorrhage/drug therapy/*prevention & control
MH  - Preoperative Care
EDAT- 2005/08/03 09:00
MHDA- 2006/02/24 09:00
CRDT- 2005/08/03 09:00
PHST- 2005/08/03 09:00 [pubmed]
PHST- 2006/02/24 09:00 [medline]
PHST- 2005/08/03 09:00 [entrez]
AID - 0507-05 [pii]
PST - ppublish
SO  - Medicina (Kaunas). 2005;41(7):577-83.

PMID- 26002770
OWN - NLM
STAT- MEDLINE
DCOM- 20180131
LR  - 20181113
IS  - 1475-5785 (Electronic)
IS  - 1353-8047 (Print)
IS  - 1353-8047 (Linking)
VI  - 22
IP  - 4
DP  - 2016 Aug
TI  - A randomised controlled trial of low-dose aspirin for the prevention of fractures 
      in healthy older people: protocol for the ASPREE-Fracture substudy.
PG  - 297-301
LID - 10.1136/injuryprev-2015-041655 [doi]
AB  - BACKGROUND: Disability, mortality and healthcare burden from fractures in older 
      people is a growing problem worldwide. Observational studies suggest that aspirin 
      may reduce fracture risk. While these studies provide room for optimism, 
      randomised controlled trials are needed. This paper describes the rationale and 
      design of the ASPirin in Reducing Events in the Elderly (ASPREE)-Fracture 
      substudy, which aims to determine whether daily low-dose aspirin decreases 
      fracture risk in healthy older people. METHODS: ASPREE is a double-blind, 
      randomised, placebo-controlled primary prevention trial designed to assess 
      whether daily active treatment using low-dose aspirin extends the duration of 
      disability-free and dementia-free life in 19 000 healthy older people recruited 
      from Australian and US community settings. This substudy extends the ASPREE trial 
      data collection to determine the effect of daily low-dose aspirin on fracture and 
      fall-related hospital presentation risk in the 16 500 ASPREE participants aged 
      ≥70 years recruited in Australia. The intervention is a once daily dose of 
      enteric-coated aspirin (100 mg) versus a matching placebo, randomised on a 1:1 
      basis. The primary outcome for this substudy is the occurrence of any 
      fracture-vertebral, hip and non-vert-non-hip-occurring post randomisation. 
      Fall-related hospital presentations are a secondary outcome. DISCUSSION: This 
      substudy will determine whether a widely available, simple and inexpensive health 
      intervention-aspirin-reduces the risk of fractures in older Australians. If it is 
      demonstrated to safely reduce the risk of fractures and serious falls, it is 
      possible that aspirin might provide a means of fracture prevention. TRIAL 
      REGISTRATION NUMBER: The protocol for this substudy is registered with the 
      Australian New Zealand Clinical Trials Registry (ACTRN12615000347561).
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://www.bmj.com/company/products-services/rights-and-licensing/
FAU - Barker, Anna L
AU  - Barker AL
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia.
FAU - Seeman, Ego
AU  - Seeman E
AD  - Department of Endocrinology and Medicine, Austin Health, University of Melbourne, 
      Melbourne, Australia.
FAU - Ward, Stephanie A
AU  - Ward SA
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia Monash Ageing 
      Research Centre (MONARC), School of Public Health and Preventive Medicine, Monash 
      University, Melbourne, Australia.
FAU - Sanders, Kerrie M
AU  - Sanders KM
AUID- ORCID: 0000-0002-2718-6592
AD  - Department of Medicine, NorthWest Academic Centre, University of Melbourne, 
      Melbourne, Australia Institute for Health and Ageing, Australian Catholic 
      University, Melbourne, Australia.
FAU - Khosla, Sundeep
AU  - Khosla S
AD  - Endocrine Research Unit, College of Medicine, Mayo Clinic, Rochester, USA.
FAU - Cumming, Robert G
AU  - Cumming RG
AD  - School of Public Health, University of Sydney, Sydney, Australia.
FAU - Pasco, Julie A
AU  - Pasco JA
AD  - Department of Medicine, NorthWest Academic Centre, University of Melbourne, 
      Melbourne, Australia Epi-Centre for Healthy Ageing, School of Medicine, Deakin 
      University, Geelong, Australia.
FAU - Bohensky, Megan A
AU  - Bohensky MA
AD  - Department of Medicine, Melbourne EpiCentre, University of Melbourne, Melbourne, 
      Australia.
FAU - Ebeling, Peter R
AU  - Ebeling PR
AD  - Department of Medicine, School of Clinical Sciences, Monash University, Clayton, 
      Australia.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia.
FAU - Lockery, Jessica E
AU  - Lockery JE
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia.
FAU - Talevski, Jason
AU  - Talevski J
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia.
CN  - ASPREE Investigator Group
LA  - eng
SI  - ANZCTR/ACTRN12615000347561
GR  - U01 AG029824/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150521
PL  - England
TA  - Inj Prev
JT  - Injury prevention : journal of the International Society for Child and Adolescent 
      Injury Prevention
JID - 9510056
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Accidental Falls/*statistics & numerical data
MH  - Activities of Daily Living
MH  - Aged
MH  - Aspirin/*administration & dosage/*pharmacology
MH  - Australia/epidemiology
MH  - Cyclooxygenase Inhibitors/*administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Fractures, Bone/*prevention & control
MH  - Humans
MH  - Male
MH  - Observational Studies as Topic
MH  - *Primary Prevention/methods
MH  - Self Care
MH  - United States/epidemiology
PMC - PMC4879092
MID - NIHMS742142
COIS- Competing interests None declared.
EDAT- 2015/05/24 06:00
MHDA- 2018/02/01 06:00
CRDT- 2015/05/24 06:00
PHST- 2015/04/17 00:00 [received]
PHST- 2015/04/21 00:00 [accepted]
PHST- 2015/05/24 06:00 [entrez]
PHST- 2015/05/24 06:00 [pubmed]
PHST- 2018/02/01 06:00 [medline]
AID - injuryprev-2015-041655 [pii]
AID - 10.1136/injuryprev-2015-041655 [doi]
PST - ppublish
SO  - Inj Prev. 2016 Aug;22(4):297-301. doi: 10.1136/injuryprev-2015-041655. Epub 2015 
      May 21.

PMID- 8960641
OWN - NLM
STAT- MEDLINE
DCOM- 19970123
LR  - 20191101
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 128
IP  - 6
DP  - 1996 Dec
TI  - Hemoglobin-induced contraction of pig pulmonary veins.
PG  - 579-84
AB  - The effects of hemoglobin Ao (HbAo), alpha alpha cross-linked hemoglobin (alpha 
      alphaHb), cyanomet alpha alpha cross-linked hemoglobin (cyanomet alpha alphaHb), 
      and human serum albumin (HSA) were compared under basal conditions and during 
      relaxation with acetylcholine (ACh), sodium nitroprusside (SNP), and papaverine 
      (PAP) in porcine pulmonary veins. Isometric tension changes were recorded in 
      isolated rings (3 to 4 mm) that were suspended in Krebs solution bubbled with 95% 
      O2/5% CO2. Increasing concentrations of HbAo and alpha alphaHb (10(-9) - 3 x 
      10(-6) mol/L) caused concentration-dependent increases in tension that reached a 
      maximum of 4.20 +/- 0.3 gm and 3.78 +/- 0.6 gm, respectively. Cyanomet alpha 
      alphaHb and HSA (10(-9) - 3 x 10(-6) mol/L) did not cause significant increases 
      in tension. The maximum responses to HbAo and alpha alphaHb were significantly 
      increased during relaxation with ACh and SNP but not with PAP. In contrast, SNP 
      (10(-4) mol/L) and PAP (10(-5) mol/L), but not ACh, reversed contractions induced 
      by HbAo and alpha alphaHb. These studies support the concept that 
      hemoglobin-induced vascular contraction is primarily mediated by inactivation of 
      the vasodilator nitric oxide in vitro. We suggest that this mechanism is common 
      to acellular hemoglobins in which the ligand binding site is unimpaired and in 
      which the heme iron is in the ferrous (+2) state.
FAU - Muldoon, S M
AU  - Muldoon SM
AD  - Uniformed Services University of the Health Sciences, Department of 
      Anesthesiology, Bethesda, MD 20814, USA.
FAU - Ledvina, M A
AU  - Ledvina MA
FAU - Hart, J L
AU  - Hart JL
FAU - Macdonald, V W
AU  - Macdonald VW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Hemoglobins)
RN  - 0 (Serum Albumin)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 333DO1RDJY (Serotonin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hemoglobins/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Lung/*blood supply/drug effects
MH  - Male
MH  - Muscle Contraction/*drug effects/physiology
MH  - Muscle, Smooth, Vascular/*drug effects/physiology
MH  - Nitric Oxide/physiology
MH  - Serotonin/pharmacology
MH  - Serum Albumin/pharmacology
MH  - Swine
MH  - Veins/*drug effects/physiology
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - S0022-2143(96)90130-4 [pii]
AID - 10.1016/s0022-2143(96)90130-4 [doi]
PST - ppublish
SO  - J Lab Clin Med. 1996 Dec;128(6):579-84. doi: 10.1016/s0022-2143(96)90130-4.

PMID- 18979210
OWN - NLM
STAT- MEDLINE
DCOM- 20091117
LR  - 20220316
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 117
IP  - 1
DP  - 2009 Sep
TI  - Association between NSAIDs use and breast cancer risk: a systematic review and 
      meta-analysis.
PG  - 141-50
LID - 10.1007/s10549-008-0228-6 [doi]
AB  - The association between non-steroidal anti-inflammatory drugs (NSAIDs) use and 
      breast cancer has remained controversial. Therefore, an overall quantitative 
      estimate of the association needs to be studied. A systematic review and 
      meta-analysis was executed to explore the pooled estimate for relative risk (RR) 
      and 95% confidence interval (CI) using random or fixed effects models based on 
      heterogeneity analysis. Overall 26 studies with 528,705 participants were 
      included. The RR of NSAIDs use and the incidence of breast cancer was 0.94 (95% 
      CI: 0.88-1.00) with random effects model. A slight reduction of breast cancer by 
      taking aspirin and ibuprofen was both observed with pooled RR of 0.91 (95% CI: 
      0.83-0.98) and 0.81 (95% CI: 0.67-0.97), respectively. Our results indicate that 
      NSAIDs use is associated with a slight decrease for the development of breast 
      cancer with a marginally statistical significant difference. The associations are 
      slightly more obvious in aspirin and ibuprofen use.
FAU - Zhao, Ya-shuang
AU  - Zhao YS
AD  - Department of Epidemiology, Harbin Medical University, Heilongjiang, People's 
      Republic of China. zhao_yashuang@263.net
FAU - Zhu, Sui
AU  - Zhu S
FAU - Li, Xiang-wei
AU  - Li XW
FAU - Wang, Fan
AU  - Wang F
FAU - Hu, Fu-lan
AU  - Hu FL
FAU - Li, Dan-dan
AU  - Li DD
FAU - Zhang, Wen-cui
AU  - Zhang WC
FAU - Li, Xia
AU  - Li X
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20081102
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Breast Neoplasms/*prevention & control
MH  - Female
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Risk Factors
RF  - 71
EDAT- 2008/11/04 09:00
MHDA- 2009/11/18 06:00
CRDT- 2008/11/04 09:00
PHST- 2008/10/11 00:00 [received]
PHST- 2008/10/14 00:00 [accepted]
PHST- 2008/11/04 09:00 [pubmed]
PHST- 2009/11/18 06:00 [medline]
PHST- 2008/11/04 09:00 [entrez]
AID - 10.1007/s10549-008-0228-6 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2009 Sep;117(1):141-50. doi: 10.1007/s10549-008-0228-6. 
      Epub 2008 Nov 2.

PMID- 35708845
OWN - NLM
STAT- MEDLINE
DCOM- 20220929
LR  - 20221207
IS  - 1615-2573 (Electronic)
IS  - 0910-8327 (Linking)
VI  - 37
IP  - 11
DP  - 2022 Nov
TI  - Kidney function deterioration is dependent on blood pressure levels: 11.2 year 
      follow-up in diabetic patients.
PG  - 1873-1881
LID - 10.1007/s00380-022-02085-0 [doi]
AB  - There is little evidence of how blood pressure level over 10 years affects the 
      decline of estimated glomerular filtration rate (eGFR) in diabetic patients. The 
      Japanese primary prevention of atherosclerosis with aspirin for diabetes (JPAD) 
      trial was a multicenter, randomized, clinical trial done from 2002 to 2008. After 
      completion of the JPAD trial, we followed up the patients until 2019 as a cohort 
      study. We defined late-stage kidney disease (LSKD) as eGFR < 30 ml/min/1.73 m(2) 
      or hemodialysis. Based on the mean value of systolic blood pressure (SBP) 
      obtained average 7 times during the follow-up, we divided the patients into three 
      groups: a high SBP group (n = 607, SBP ≥ 140 mm Hg); a moderate SBP group 
      (n = 989, 140 > SBP ≥ 130 mm Hg); or a low SBP group (n = 913, SBP < 130 mm Hg). 
      There was no significant deference in the mean eGFR among the high SBP, moderate 
      SBP and low SBP groups on registration. The incidence rate of LSKD was 
      significantly higher in the high SBP (HR 2.02, 95% CI 1.36-3.01) and moderate SBP 
      (HR 1.54, 95% CI 1.07-2.20) groups than in the low SBP group (Log-Rank 
      P = 0.0018). Cox proportional hazards model analysis revealed that the high SBP 
      (HR, 1.57, P = 0.049) and moderate SBP (HR, 1.52, P = 0.037) were independent 
      factors after adjustment for proteinuria ≥  ± , age ≥ 65 years, men, body mass 
      index ≥ 24 kg/m(2), duration of diabetes ≥ 7.0 years, statin usage, 
      eGFR ≥ 60 ml/min/1.73 m(2), hemoglobin A1c ≥ 7.2%, and smoking status. Our 
      11.2 year follow-up study demonstrated that mean SBP was independently associated 
      with the progression to LSKD in diabetic patients. These findings may become new 
      evidence that SBP less than 130 mm Hg is recommended for diabetic patients to 
      prevent progression to LSKD.
CI  - © 2022. Springer Japan KK, part of Springer Nature.
FAU - Soejima, Hirofumi
AU  - Soejima H
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan. 
      yuuki@gpo.kumamoto-u.ac.jp.
AD  - Health Care Center, Kumamoto University, Kumamoto, Japan. 
      yuuki@gpo.kumamoto-u.ac.jp.
FAU - Ogawa, Hisao
AU  - Ogawa H
AD  - Kumamoto University, Kumamoto, Japan.
FAU - Morimoto, Takeshi
AU  - Morimoto T
AD  - Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, 
      Japan.
FAU - Okada, Sadanori
AU  - Okada S
AD  - Department of Diabetes and Endocrinology, Nara Medical University, Kashihara, 
      Japan.
FAU - Matsumoto, Chisa
AU  - Matsumoto C
AD  - Department of Cardiology, Center for Health Surveillance and Preventive Medicine, 
      Tokyo Medical University Hospital, Tokyo, Japan.
FAU - Nakayama, Masafumi
AU  - Nakayama M
AD  - Nakayama Cardiovascular Clinic, Amakusa, Japan.
FAU - Masuda, Izuru
AU  - Masuda I
AD  - Takeda Hospital Medical Examination Center, Kyoto, Japan.
FAU - Jinnouchi, Hideaki
AU  - Jinnouchi H
AD  - Department of Internal Medicine, Jinnouchi Hospital Diabetes Care Center, 
      Kumamoto, Japan.
FAU - Waki, Masako
AU  - Waki M
AD  - Food Safety Commission of Japan, Tokyo, Japan.
FAU - Saito, Yoshihiko
AU  - Saito Y
AD  - Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.
CN  - JPAD Trial Investigators
LA  - eng
GR  - 18K08521/Japan Society for the Promotion of Science/
GR  - H16-Junkanki-004/Ministry of Health, Labour and Welfare/
GR  - H27-Junkanki-Ippan-001/Ministry of Health, Labour and Welfare/
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20220616
PL  - Japan
TA  - Heart Vessels
JT  - Heart and vessels
JID - 8511258
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Pressure
MH  - Cohort Studies
MH  - *Diabetes Mellitus
MH  - Follow-Up Studies
MH  - Glomerular Filtration Rate/physiology
MH  - Glycated Hemoglobin
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - *Hypertension/complications/drug therapy/epidemiology
MH  - Kidney
MH  - *Kidney Diseases
MH  - Male
MH  - Risk Factors
OTO - NOTNLM
OT  - Estimated glomerular filtration rate
OT  - Hemodialysis
OT  - Late-stage kidney disease
OT  - Systolic blood pressure
FIR - Waki, Masako
IR  - Waki M
FIR - Saito, Yoshihiko
IR  - Saito Y
FIR - Miwa, Kimiaki
IR  - Miwa K
FIR - Akahoshi, Kazunobu
IR  - Akahoshi K
FIR - Misumi, Kenji
IR  - Misumi K
FIR - Araki, Haruo
IR  - Araki H
FIR - Mitsudo, Yutaka
IR  - Mitsudo Y
FIR - Kondo, Norifumi
IR  - Kondo N
FIR - Ashihara, Kenichi
IR  - Ashihara K
FIR - Yumoto, Shinya
IR  - Yumoto S
FIR - Horimoto, Masashi
IR  - Horimoto M
FIR - Doi, Osamu
IR  - Doi O
FIR - Doijiri, Kenichi
IR  - Doijiri K
FIR - Fukami, Ryo
IR  - Fukami R
FIR - Shimabukuro, Michio
IR  - Shimabukuro M
FIR - Egusa, Genshi
IR  - Egusa G
FIR - Goto, Kazuo
IR  - Goto K
FIR - Hanaoka, Yoichi
IR  - Hanaoka Y
FIR - Kimura, Yoshihiro
IR  - Kimura Y
FIR - Haraguchi, Yoshikuni
IR  - Haraguchi Y
FIR - Haraguchi, Osamu
IR  - Haraguchi O
FIR - Hasegawa, Atsushi
IR  - Hasegawa A
FIR - Shioya, Yoshiko
IR  - Shioya Y
FIR - Shioya, Yosuke
IR  - Shioya Y
FIR - Tanaka, Eiitiro
IR  - Tanaka E
FIR - Yamada, Kazuhiko
IR  - Yamada K
FIR - Atsumi, Toshiya
IR  - Atsumi T
FIR - Tanazawa, Satoshi
IR  - Tanazawa S
FIR - Horio, Yutaka
IR  - Horio Y
FIR - Ichihara, Seishi
IR  - Ichihara S
FIR - Yasuda, Isao
IR  - Yasuda I
FIR - Ikeda, Tsuneo
IR  - Ikeda T
FIR - Ikemura, Makoto
IR  - Ikemura M
FIR - Imamoto, Chieko
IR  - Imamoto C
FIR - Iseri, Yoshihisa
IR  - Iseri Y
FIR - Iwai, Ken
IR  - Iwai K
FIR - Okamoto, Shinya
IR  - Okamoto S
FIR - Sugiyama, Seigo
IR  - Sugiyama S
FIR - Kamura, Masanori
IR  - Kamura M
FIR - Kan, Hirofumi
IR  - Kan H
FIR - Kiyota, Mayumi
IR  - Kiyota M
FIR - Kawamura, Kyousuke
IR  - Kawamura K
FIR - Ono, Takashi
IR  - Ono T
FIR - Koga, Takeshi
IR  - Koga T
FIR - Kinuwaki, Etsuo
IR  - Kinuwaki E
FIR - Naito, Hiromichi
IR  - Naito H
FIR - Kozuma, Kazuo
IR  - Kozuma K
FIR - Kudou, Kiyotaka
IR  - Kudou K
FIR - Morikami, Yasuhiro
IR  - Morikami Y
FIR - Yasue, Hirofumi
IR  - Yasue H
FIR - Mizuno, Yuji
IR  - Mizuno Y
FIR - Fujimoto, Hisao
IR  - Fujimoto H
FIR - Matsuyama, Kozaburo
IR  - Matsuyama K
FIR - Fujii, Hiromi
IR  - Fujii H
FIR - Kamijikkoku, Syuichi
IR  - Kamijikkoku S
FIR - Kuwahara, Tetsuo
IR  - Kuwahara T
FIR - Takaoka, Kyoji
IR  - Takaoka K
FIR - Machii, Kazuo
IR  - Machii K
FIR - Maeda, Kazutaka
IR  - Maeda K
FIR - Mahara, Keiji
IR  - Mahara K
FIR - Maki, Akira
IR  - Maki A
FIR - Manda, Naoki
IR  - Manda N
FIR - Marutsuka, Kousuke
IR  - Marutsuka K
FIR - Sameshima, Naoki
IR  - Sameshima N
FIR - Gi, Toshihiro
IR  - Gi T
FIR - Matsunaga, Terufumi
IR  - Matsunaga T
FIR - Matsuo, Syuichi
IR  - Matsuo S
FIR - Okubo, Hiroto
IR  - Okubo H
FIR - Minagawa, Fuyuki
IR  - Minagawa F
FIR - Minoda, Kotaro
IR  - Minoda K
FIR - Miyata, Junichi
IR  - Miyata J
FIR - Matsuo, Takeshi
IR  - Matsuo T
FIR - Momosaki, Sueo
IR  - Momosaki S
FIR - Munakata, Tetsuo
IR  - Munakata T
FIR - Nakamura, Tomoki
IR  - Nakamura T
FIR - Nagano, Hisatoshi
IR  - Nagano H
FIR - Goshi, Kazuto
IR  - Goshi K
FIR - Sugimoto, Keisuke
IR  - Sugimoto K
FIR - Naomi, Shojiro
IR  - Naomi S
FIR - Nasu, Toshiaki
IR  - Nasu T
FIR - Tanaka, Hiroyuki
IR  - Tanaka H
FIR - Sonoda, Ryuji
IR  - Sonoda R
FIR - Kajiwara, Keizo
IR  - Kajiwara K
FIR - Odo, Takafumi
IR  - Odo T
FIR - Ogata, Hirofumi
IR  - Ogata H
FIR - Ogihara, Masayuki
IR  - Ogihara M
FIR - Ogura, Tateo
IR  - Ogura T
FIR - Oka, Keishiro
IR  - Oka K
FIR - Kawashima, Eiji
IR  - Kawashima E
FIR - Oshima, Eiji
IR  - Oshima E
FIR - Ozaki, Ken
IR  - Ozaki K
FIR - Ozawa, Seiji
IR  - Ozawa S
FIR - Shono, Hiroyuki
IR  - Shono H
FIR - Sakamoto, Yasuhiro
IR  - Sakamoto Y
FIR - Sakurai, Nobuko
IR  - Sakurai N
FIR - Wakabayashi, Chikashi
IR  - Wakabayashi C
FIR - Sawada, Tomohiro
IR  - Sawada T
FIR - Shibata, Junji
IR  - Shibata J
FIR - Shimono, Hisashi
IR  - Shimono H
FIR - Iemura, Akihiro
IR  - Iemura A
FIR - Matsutani, Akira
IR  - Matsutani A
FIR - Suefuji, Hisakazu
IR  - Suefuji H
FIR - Sugiyama, Hiromichi
IR  - Sugiyama H
FIR - Hokamaki, Jun
IR  - Hokamaki J
FIR - Komori, Kenichi
IR  - Komori K
FIR - Kinoshita, Yoshimi
IR  - Kinoshita Y
FIR - Murakami, Hironori
IR  - Murakami H
FIR - Hashiguchi, Jun
IR  - Hashiguchi J
FIR - Hashiguchi, Yasuhiro
IR  - Hashiguchi Y
FIR - Sawai, Koryo
IR  - Sawai K
FIR - Hifumi, Atuko
IR  - Hifumi A
FIR - Seo, Koji
IR  - Seo K
FIR - Toihata, Masamitsu
IR  - Toihata M
FIR - Tokube, Koji
IR  - Tokube K
FIR - Ogawa, Hiroshi
IR  - Ogawa H
FIR - Tomita, Fumishi
IR  - Tomita F
FIR - Taguchi, Madoka
IR  - Taguchi M
FIR - Tsubokura, Toshio
IR  - Tsubokura T
FIR - Tsuchiya, Tatsuaki
IR  - Tsuchiya T
FIR - Tsuda, Kaoru
IR  - Tsuda K
FIR - Tsurusaki, Ryuichiro
IR  - Tsurusaki R
FIR - Obata, Kenji
IR  - Obata K
FIR - Watanabe, Katumi
IR  - Watanabe K
FIR - Hayasida, Raisuke
IR  - Hayasida R
FIR - Ishibashi, Yutaka
IR  - Ishibashi Y
FIR - Osamura, Yoshiaki
IR  - Osamura Y
FIR - Yamanaka, Yoshito
IR  - Yamanaka Y
FIR - Sonoda, Kazuhiro
IR  - Sonoda K
FIR - Iwaoka, Taisuke
IR  - Iwaoka T
FIR - Yokota, Hiromitsu
IR  - Yokota H
FIR - Yoshinari, Motoki
IR  - Yoshinari M
FIR - Abe, Nanami
IR  - Abe N
FIR - Ando, Noriaki
IR  - Ando N
FIR - Bando, Hiroshi
IR  - Bando H
FIR - Takami, Takeshi
IR  - Takami T
FIR - Doi, Michiaki
IR  - Doi M
FIR - Fujii, Yoshihiro
IR  - Fujii Y
FIR - Fukuda, Masahiro
IR  - Fukuda M
FIR - Fukuoka, Yoshiaki
IR  - Fukuoka Y
FIR - Hamano, Masayoshi
IR  - Hamano M
FIR - Takaoka, Minoru
IR  - Takaoka M
FIR - Hasegawa, Hiromi
IR  - Hasegawa H
FIR - Yabuta, Ikuo
IR  - Yabuta I
FIR - Higami, Kenshi
IR  - Higami K
FIR - Higami, Satomi
IR  - Higami S
FIR - Yasuno, Akiko
IR  - Yasuno A
FIR - Fujinaga, Yuriko
IR  - Fujinaga Y
FIR - Onishi, Yoko
IR  - Onishi Y
FIR - Yoshimura, Katsutoshi
IR  - Yoshimura K
FIR - Minami, Shigetoshi
IR  - Minami S
FIR - Nakashima, Takao
IR  - Nakashima T
FIR - Horie, Hiroaki
IR  - Horie H
FIR - Horii, Kazuko
IR  - Horii K
FIR - Matsumura, Norihiko
IR  - Matsumura N
FIR - Ikuno, Tetsuo
IR  - Ikuno T
FIR - Katsuyama, Yoshiyuki
IR  - Katsuyama Y
FIR - Uemura, Shiro
IR  - Uemura S
FIR - Kikukawa, Masao
IR  - Kikukawa M
FIR - Kanauchi, Masao
IR  - Kanauchi M
FIR - Kuzuya, Hideshi
IR  - Kuzuya H
FIR - Iwasaki, Arata
IR  - Iwasaki A
FIR - Koutani, Takehiko
IR  - Koutani T
FIR - Makino, Hisaharu
IR  - Makino H
FIR - Miki, Hiroshi
IR  - Miki H
FIR - Misugi, Susumu
IR  - Misugi S
FIR - Naito, Masaki
IR  - Naito M
FIR - Naito, Masatoshi
IR  - Naito M
FIR - Nakano, Yukitaka
IR  - Nakano Y
FIR - Nakatani, Akira
IR  - Nakatani A
FIR - Nakatani, Fumihiko
IR  - Nakatani F
FIR - Horii, Manabu
IR  - Horii M
FIR - Yabuta, Matahiro
IR  - Yabuta M
FIR - Seno, Ayako
IR  - Seno A
FIR - Kawata, Hiroyuki
IR  - Kawata H
FIR - Samejima, Kenichi
IR  - Samejima K
FIR - Onoue, Kenji
IR  - Onoue K
FIR - Kawakami, Rika
IR  - Kawakami R
FIR - Nakano, Tomoya
IR  - Nakano T
FIR - Ueda, Tomoya
IR  - Ueda T
FIR - Soeda, Tsunenari
IR  - Soeda T
FIR - Kita, Yoko
IR  - Kita Y
FIR - Inoue, Fumitaka
IR  - Inoue F
FIR - Yamano, Shigeru
IR  - Yamano S
FIR - Iwama, Hajime
IR  - Iwama H
FIR - Sakan, Hirokazu
IR  - Sakan H
FIR - Suzuki, Megumi
IR  - Suzuki M
FIR - Kagoshima, Tadashi
IR  - Kagoshima T
FIR - Nakai, Takehito
IR  - Nakai T
FIR - Hashimoto, Toshio
IR  - Hashimoto T
FIR - Nishitani, Yoshiharu
IR  - Nishitani Y
FIR - Kobayashi, Yoshiyuki
IR  - Kobayashi Y
FIR - Hoda, Koichi
IR  - Hoda K
FIR - Uejima, Junko
IR  - Uejima J
FIR - Morikawa, Yoshinobu
IR  - Morikawa Y
FIR - Kawano, Takahiro
IR  - Kawano T
FIR - Yamada, Hideki
IR  - Yamada H
FIR - Nishimoto, Kazuo
IR  - Nishimoto K
FIR - Ohsumi, Kyouyuki
IR  - Ohsumi K
FIR - Ote, Nobushige
IR  - Ote N
FIR - Oya, Akiko
IR  - Oya A
FIR - Nishiura, Kimiaki
IR  - Nishiura K
FIR - Masuda, Joji
IR  - Masuda J
FIR - Ban, Keiichiro
IR  - Ban K
FIR - Kyoda, Yusuke
IR  - Kyoda Y
FIR - Sawada, Izumi
IR  - Sawada I
FIR - Sawada, Yoko
IR  - Sawada Y
FIR - Okada, Koichi
IR  - Okada K
FIR - Yazaki, Akihiro
IR  - Yazaki A
FIR - Hanatani, Masakazu
IR  - Hanatani M
FIR - Sutani, Toshio
IR  - Sutani T
FIR - Hiramori, Yuko
IR  - Hiramori Y
FIR - Tanaka, Yuya
IR  - Tanaka Y
FIR - Igaki, Toshiro
IR  - Igaki T
FIR - Tomioka, Yukio
IR  - Tomioka Y
FIR - Shiiki, Hideo
IR  - Shiiki H
FIR - Sugihara, Kiyotaka
IR  - Sugihara K
FIR - Hayashi, Motomu
IR  - Hayashi M
FIR - Sasaki, Yasunobu
IR  - Sasaki Y
FIR - Matsukura, Yasuo
IR  - Matsukura Y
FIR - Ueda, Michiaki
IR  - Ueda M
FIR - Ueyama, Masakuni
IR  - Ueyama M
FIR - Uyama, Hideto
IR  - Uyama H
FIR - Yamada, Hiroharu
IR  - Yamada H
FIR - Yamaga, Kenichi
IR  - Yamaga K
FIR - Nakajima, Tamio
IR  - Nakajima T
FIR - Yoshimoto, Kazumi
IR  - Yoshimoto K
FIR - Yoshimura, Midori
IR  - Yoshimura M
EDAT- 2022/06/17 06:00
MHDA- 2022/09/30 06:00
CRDT- 2022/06/16 11:58
PHST- 2021/11/01 00:00 [received]
PHST- 2022/04/20 00:00 [accepted]
PHST- 2022/06/17 06:00 [pubmed]
PHST- 2022/09/30 06:00 [medline]
PHST- 2022/06/16 11:58 [entrez]
AID - 10.1007/s00380-022-02085-0 [pii]
AID - 10.1007/s00380-022-02085-0 [doi]
PST - ppublish
SO  - Heart Vessels. 2022 Nov;37(11):1873-1881. doi: 10.1007/s00380-022-02085-0. Epub 
      2022 Jun 16.

PMID- 8440792
OWN - NLM
STAT- MEDLINE
DCOM- 19930401
LR  - 20190825
IS  - 0342-4642 (Print)
IS  - 0342-4642 (Linking)
VI  - 19
IP  - 1
DP  - 1993
TI  - Aspirin effect on early and late changes in acute lung injury in sheep.
PG  - 13-21
AB  - OBJECTIVE: There have been several studies that have already explored the 
      potential beneficial role of cyclo-oxygenase (CO) inhibitors on oleic acid 
      (OA)-induced lung injury in different species. These studies report no 
      significant effect of CO inhibition, though thromboxane B2 (TxB2) was effectively 
      blocked. However, recent studies indicate that pre-treatment with aspirin (ASA) 
      preserve gas exchange in OA lung injury in dogs. Aim of our study has been to 
      evaluate the potential beneficial effects of the pre-treatment with low doses of 
      ASA on gas exchange, hemodynamics, respiratory mechanics, prostanoids and lung 
      histology in OA-induced lung injury in sheep. DESIGN: 0.09 ml/kg of OA was 
      administered into the right atrium of 14 anaesthetized sheep. Six received a 
      bolus of ASA (10 mg/kg i.v.) 30 min before OA, the others saline as placebo. 
      MEASUREMENTS AND RESULTS: Pulmonary and tissue gas exchange, pulmonary and 
      systematic hemodynamics, respiratory system mechanics, TxB2 and 6-keto-PGF1 
      alpha, leukocytes and platelets concentrations were measured throughout the 
      subsequent 3 h and lung histology was effected at end-experiment. The principal 
      findings of our study are: 1) ASA reduces OA-induced early pulmonary 
      vasoconstriction and bronchoconstriction, parallelled by a suppression of TxB2 
      generation; 2) the late increase in pulmonary artery pressure and airway 
      resistance due to OA is not inhibited by ASA; 3) the early disturbance in 
      pulmonary gas exchange is reduced by ASA, whereas the late severe deterioration 
      is exaggerated by ASA; 4) the stability of tissue exchange ratio (R) at 
      approximately 1 in ASA-group compared to its fall to approximately 0.7 in 
      controls. CONCLUSION: Our findings suggest that ASA: 1) is only effective to 
      treat the very transient TxB2-induced pulmonary vasoconstriction resulting in 
      hydrostatic edema, and it is ineffective, even accentuates, the subsequent major 
      pulmonary endothelial cell injury leading to alveolar flooding that is unrelated 
      to TxB2; 2) has a transient protective effect on the TxB2-induced early 
      bronchospasm; 3) has a biphasic behaviour on gas exchange, with a benefit which 
      lasts only one hour and then results in a worse gas exchange; 4) has an 
      immediate, stabilizing, persisting effect on R, contrasting with its transient 
      effect on pulmonary hemodynamics and PaO2.
FAU - Chelucci, G L
AU  - Chelucci GL
AD  - Dipartimento di Fisiopatologia Clinica, Università di Firenze, Italia.
FAU - Boncinelli, S
AU  - Boncinelli S
FAU - Marsili, M
AU  - Marsili M
FAU - Lorenzi, P
AU  - Lorenzi P
FAU - Allegra, A
AU  - Allegra A
FAU - Linden, M
AU  - Linden M
FAU - Chelucci, A
AU  - Chelucci A
FAU - Merciai, V
AU  - Merciai V
FAU - Cresci, F
AU  - Cresci F
FAU - Rostagno, C
AU  - Rostagno C
AU  - et al.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Intensive Care Med
JT  - Intensive care medicine
JID - 7704851
RN  - 0 (Oleic Acids)
RN  - 2UMI9U37CP (Oleic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/metabolism
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Gas Analysis
MH  - Hemodynamics/drug effects
MH  - Least-Squares Analysis
MH  - Lung/pathology
MH  - Lung Diseases/chemically induced/*physiopathology
MH  - Oleic Acid
MH  - Oleic Acids
MH  - Premedication
MH  - Pulmonary Gas Exchange/*drug effects
MH  - Respiration/drug effects
MH  - Sheep
MH  - Thromboxane B2/metabolism
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1007/BF01709272 [doi]
PST - ppublish
SO  - Intensive Care Med. 1993;19(1):13-21. doi: 10.1007/BF01709272.

PMID- 12618872
OWN - NLM
STAT- MEDLINE
DCOM- 20030417
LR  - 20220317
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 88
IP  - 5
DP  - 2003 Mar 10
TI  - Aspirin use and cancers of the upper aerodigestive tract.
PG  - 672-4
AB  - The role of aspirin on the risk of cancers of the upper aerodigestive tract was 
      investigated in the combined data of three Italian case-control studies, 
      including 965 cases and 1779 hospital controls. The odds ratio was 0.33 for users 
      of > or = 5 years, and 0.51 for > or = 5 years since first use.
FAU - Bosetti, C
AU  - Bosetti C
AD  - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. 
      bosetti@marionegri.it
FAU - Talamini, R
AU  - Talamini R
FAU - Franceschi, S
AU  - Franceschi S
FAU - Negri, E
AU  - Negri E
FAU - Garavello, W
AU  - Garavello W
FAU - La Vecchia, C
AU  - La Vecchia C
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Carcinoma, Squamous Cell/*chemically induced
MH  - Case-Control Studies
MH  - Esophageal Neoplasms/*chemically induced
MH  - Humans
MH  - Multivariate Analysis
MH  - Odds Ratio
PMC - PMC2376339
EDAT- 2003/03/06 04:00
MHDA- 2003/04/18 05:00
CRDT- 2003/03/06 04:00
PHST- 2003/03/06 04:00 [pubmed]
PHST- 2003/04/18 05:00 [medline]
PHST- 2003/03/06 04:00 [entrez]
AID - 6600820 [pii]
AID - 10.1038/sj.bjc.6600820 [doi]
PST - ppublish
SO  - Br J Cancer. 2003 Mar 10;88(5):672-4. doi: 10.1038/sj.bjc.6600820.

PMID- 3066205
OWN - NLM
STAT- MEDLINE
DCOM- 19890323
LR  - 20131121
IS  - 0379-0363 (Print)
IS  - 0379-0363 (Linking)
VI  - 25
DP  - 1988
TI  - The pharmacological profile of non-opioid (OTC) analgesics: aspirin, paracetamol 
      (acetaminophen), ibuprofen, and phenazones.
PG  - 9-19
AB  - All non-opioid analgesics are believed to act via inhibition of cyclo-oxygenase. 
      With respect to their inhibitory potency towards the enzyme, these drugs differ 
      not only from most non-steroidal anti-inflammatory drugs but also among 
      themselves. The differences appear to be of some therapeutic relevance. They 
      explain why many non-steroidal anti-inflammatory drugs are unsuitable for 
      over-the-counter (OTC) use and why the OTC drugs have different profiles of 
      effects and side effects. In addition, the suitability of non-opioid analgesics 
      in everyday practice is widely determined by their pharmacokinetic parameters. 
      These parameters are here compiled for aspirin, paracetamol (acetaminophen), 
      ibuprofen, and metamizol (dipyrone), then compared, and finally evaluated as to 
      their therapeutic implications.
FAU - Brune, K
AU  - Brune K
AD  - Department of Pharmacology, University of Erlangen-Nürnberg, Federal Republic of 
      Germany.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Agents Actions Suppl
JT  - Agents and actions. Supplements
JID - 7801014
RN  - 0 (Analgesics)
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/*pharmacokinetics/pharmacology
MH  - Analgesics/*pharmacokinetics/pharmacology/therapeutic use
MH  - Animals
MH  - Aspirin/*pharmacokinetics/pharmacology
MH  - Humans
MH  - Ibuprofen/*pharmacokinetics/pharmacology
MH  - Nonprescription Drugs/*pharmacokinetics/pharmacology/therapeutic use
RF  - 40
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Agents Actions Suppl. 1988;25:9-19.

PMID- 1004943
OWN - NLM
STAT- MEDLINE
DCOM- 19770224
LR  - 20190902
IS  - 0031-3025 (Print)
IS  - 0031-3025 (Linking)
VI  - 8
IP  - 3
DP  - 1976 Jul
TI  - Studies on the modification of renal lesions due to aspirin and oxyphenbutazone 
      in the rat and the effects on the kidney of 2:4 dinitrophenol.
PG  - 179-84
AB  - Cortical tubular necrosis induced by either aspirin (300 mg/kg) or 
      oxyphenbutazone (444 mg/kg) was reduced if probenecid (300 mg/kg) was 
      administered at the same time. The prior administration of aspirin (600 mg/kg) 
      reduced the tubular necrosis that follows administration of oxyphenbutazone (444 
      mg/kg) alone, thus demonstrating that some degree of cross-tolerance between the 
      two drugs occurs. Phenacetin pretreatment (597 mg/kg) was less effective, while 
      paracetamol (503 mg/kg) was without effect in this regard. Those substances that 
      reduced the oxyphenbutazone-induced cortical lesion also ameliorated the focal 
      degenerative change in the lower nephron attributed to this drug. Oral 
      administration of 2:4 dinitrophenol (20 mg/kg) led to only minor cortical tubular 
      necrosis in a few animals.
FAU - Arnold, L
AU  - Arnold L
FAU - Collins, C
AU  - Collins C
FAU - Starmer, G A
AU  - Starmer GA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pathology
JT  - Pathology
JID - 0175411
RN  - 0 (Dinitrophenols)
RN  - 362O9ITL9D (Acetaminophen)
RN  - ER0CTH01H9 (Phenacetin)
RN  - H806S4B3NS (Oxyphenbutazone)
RN  - PO572Z7917 (Probenecid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Acute Kidney Injury/*chemically induced
MH  - Animals
MH  - Aspirin/therapeutic use/*toxicity
MH  - Dinitrophenols/*toxicity
MH  - Female
MH  - Kidney Tubular Necrosis, Acute/*chemically induced/prevention & control
MH  - Oxyphenbutazone/*toxicity
MH  - Phenacetin/therapeutic use
MH  - Probenecid/therapeutic use
MH  - Rats
EDAT- 1976/07/01 00:00
MHDA- 1976/07/01 00:01
CRDT- 1976/07/01 00:00
PHST- 1976/07/01 00:00 [pubmed]
PHST- 1976/07/01 00:01 [medline]
PHST- 1976/07/01 00:00 [entrez]
AID - 10.3109/00313027609058995 [doi]
PST - ppublish
SO  - Pathology. 1976 Jul;8(3):179-84. doi: 10.3109/00313027609058995.

PMID- 29667460
OWN - NLM
STAT- MEDLINE
DCOM- 20181009
LR  - 20210109
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 29
IP  - 5
DP  - 2018 Jul
TI  - Clinical utility of remote platelet function measurement using P-selectin: 
      assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders.
PG  - 425-430
LID - 10.1080/09537104.2018.1445839 [doi]
AB  - Vascular diseases such as myocardial infarction and ischemic stroke are 
      associated with increased platelet function whilst the risk of recurrence is 
      reduced by antiplatelet agents such as aspirin, clopidogrel, and prasugrel. 
      However, some patients exhibit high platelet reactivity, especially with 
      clopidogrel. Existing platelet function tests may not be ideal in that they can 
      be expensive, are often time consuming, and measurements must be made near to the 
      patient and within a few hours of blood collection. Platelet activation leads to 
      translocation of P-selectin from alpha-granules to the cell surface. Following 
      activation with arachidonic acid (which is blocked by aspirin) or adenosine 
      diphosphate (inhibited by clopidogrel) and fixation, samples may be stored or 
      posted to a laboratory performing flow cytometric quantification of platelet 
      P-selectin expression. Acute myocardial infarction and ischemic stroke are 
      associated with high platelet reactivity on clopidogrel in 6-58% of patients when 
      assessed with P-selectin expression, and high reactivity was associated with an 
      increased risk of recurrence after myocardial infarction. Use of P-selectin 
      expression tests may also be of relevance to surgical and veterinary practice and 
      the diagnosis of mild bleeding disorders. The present review explores this topic 
      in further detail.
FAU - Bath, Philip M
AU  - Bath PM
AD  - a Stroke Trials Unit, Division of Clinical Neuroscience , University of 
      Nottingham , Nottingham, UK.
FAU - May, Jane
AU  - May J
AD  - a Stroke Trials Unit, Division of Clinical Neuroscience , University of 
      Nottingham , Nottingham, UK.
FAU - Heptinstall, Stan
AU  - Heptinstall S
AD  - a Stroke Trials Unit, Division of Clinical Neuroscience , University of 
      Nottingham , Nottingham, UK.
LA  - eng
GR  - 10/104/24/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20180418
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*metabolism
MH  - Clopidogrel
MH  - Female
MH  - Hemorrhage/*drug therapy
MH  - Humans
MH  - Male
MH  - P-Selectin/*metabolism
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests/*methods
MH  - Prasugrel Hydrochloride/pharmacology/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - P-selectin
OT  - bleeding
OT  - function
OT  - platelet
OT  - stroke
EDAT- 2018/04/19 06:00
MHDA- 2018/10/10 06:00
CRDT- 2018/04/19 06:00
PHST- 2018/04/19 06:00 [pubmed]
PHST- 2018/10/10 06:00 [medline]
PHST- 2018/04/19 06:00 [entrez]
AID - 10.1080/09537104.2018.1445839 [doi]
PST - ppublish
SO  - Platelets. 2018 Jul;29(5):425-430. doi: 10.1080/09537104.2018.1445839. Epub 2018 
      Apr 18.

PMID- 10763209
OWN - NLM
STAT- MEDLINE
DCOM- 20000427
LR  - 20190826
IS  - 0248-8663 (Print)
IS  - 0248-8663 (Linking)
VI  - 21 Suppl 1
DP  - 2000 Mar
TI  - [Aspirin and antiphospholipid syndrome].
PG  - 83s-88s
AB  - Antiphospholipid syndrome is the most frequent cause of acquired thrombophilia. 
      Aspirin may have some indications. CURRENT KONWLEDGE AND KEY POINTS: The 
      usefulness of low doses of aspirin is now well demonstrated in the prevention of 
      obstetric complications associated with antiphospholipid antibodies (especially 
      pregnancy loss). When heparin is combined with low-dose aspirin, the recurrent 
      rate of fetal loss is lower than 30%. In patients with arterial or venous 
      thrombosis, there is a high rate of recurrence during the two first years except 
      if high-dose warfarin was used (i.e., INR > or = 3). The association 
      warfarin-aspirin in secondary prevention of thrombosis may be evaluated in 
      prospective studies. It is not so clear in the literature and in our experience 
      that warfarin is superior to aspirin in stroke recurrence prevention in patients 
      with antiphospholipid antibodies, except in Sneddon's syndrome. There are no 
      guidelines in primary thrombosis prevention in patients with antiphospholipid 
      antibodies. In lupus patients, aspirin may not be sufficient after many years of 
      follow-up in preventing a first episode of thrombosis. Prospective studies may be 
      undertaken. Atherosclerotic patients with antiphospholipid antibodies are 
      particularly exposed to the risk of thrombosis after revascularisation or 
      angioplasty and stent implantation. Aspirin may have a place in those patients 
      but these must be evaluated. FUTUR PROSPECTS AND PROJECTS: Except in prevention 
      of obstetric complications, the usefulness of aspirin in patients with 
      antiphospholipid antibodies must be evaluated in prospective studies.
FAU - Hachulla, E
AU  - Hachulla E
AD  - Service de médecine interne, hôpital Huriez, CHRU, Lille, France.
FAU - Piette, A M
AU  - Piette AM
FAU - Hatron, P Y
AU  - Hatron PY
FAU - Blétry, O
AU  - Blétry O
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspirine et syndrome des antiphospholipides.
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Antiphospholipid Syndrome/complications/*drug therapy
MH  - Arteriosclerosis/prevention & control
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fetal Death/*prevention & control
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Primary Prevention
MH  - Recurrence
MH  - Risk Factors
MH  - Thrombosis/*prevention & control
MH  - Warfarin/administration & dosage/therapeutic use
RF  - 50
EDAT- 2000/04/14 09:00
MHDA- 2000/04/29 09:00
CRDT- 2000/04/14 09:00
PHST- 2000/04/14 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/04/14 09:00 [entrez]
AID - S0248-8663(00)88729-9 [pii]
AID - 10.1016/s0248-8663(00)88729-9 [doi]
PST - ppublish
SO  - Rev Med Interne. 2000 Mar;21 Suppl 1:83s-88s. doi: 10.1016/s0248-8663(00)88729-9.

PMID- 6861544
OWN - NLM
STAT- MEDLINE
DCOM- 19830811
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 84
IP  - 1
DP  - 1983 Jul
TI  - Pregnancy in 20 patients with bioprosthetic valve replacement.
PG  - 26-8
AB  - We studied twenty women who became pregnant after porcine bioprosthetic valve 
      replacement. Six patients had aortic valve, seven mitral, and seven aortic plus 
      mitral valve replacement. All women were treated with aspirin (1 g daily or 500 
      mg every 48 hours) during pregnancy, delivery, and the postdelivery period. 
      Thirteen patients experienced atrial fibrillation. There were 27 pregnancies with 
      three ending in abortion. Twenty five normal babies were delivered. There was no 
      maternal mortality or morbidity from thromboembolism or hemorrhage. Comparison of 
      the pregnancy course of these women and the general population shows no 
      difference with respect to fetal or maternal morbidity and mortality. Pregnant 
      women with bioprosthetic valve replacement treated with aspirin had normal 
      pregnancies without the risk of thromboembolism. Fetal and perinatal morbidity 
      and mortality was also within normal limits.
FAU - Nuñez, L
AU  - Nuñez L
FAU - Larrea, J L
AU  - Larrea JL
FAU - Gil Aguado, M
AU  - Gil Aguado M
FAU - Reque, J A
AU  - Reque JA
FAU - Matorras, R
AU  - Matorras R
FAU - Minguez, J A
AU  - Minguez JA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aortic Valve
MH  - Aspirin/*therapeutic use
MH  - *Bioprosthesis
MH  - Female
MH  - Fetus/drug effects
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Mitral Valve
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*prevention & control
MH  - Risk
MH  - Thromboembolism/*prevention & control
EDAT- 1983/07/01 00:00
MHDA- 1983/07/01 00:01
CRDT- 1983/07/01 00:00
PHST- 1983/07/01 00:00 [pubmed]
PHST- 1983/07/01 00:01 [medline]
PHST- 1983/07/01 00:00 [entrez]
AID - S0012-3692(16)38469-0 [pii]
AID - 10.1378/chest.84.1.26 [doi]
PST - ppublish
SO  - Chest. 1983 Jul;84(1):26-8. doi: 10.1378/chest.84.1.26.

PMID- 15211349
OWN - NLM
STAT- MEDLINE
DCOM- 20160423
LR  - 20181130
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 44
IP  - 6
DP  - 2004
TI  - [Stroke and Other Thromboembolic Complications of Atrial Fibrillation. Part III. 
      Prevention With Aspirin].
PG  - 87-94
AB  - In part III of a series of papers on epidemiology and drug prevention of stroke 
      and other thromboembolic complications of atrial fibrillation the authors present 
      data on clinical pharmacology of aspirin as well as discussion of results of 
      randomized trials in which cerebroprotective efficacy and safety of the use of 
      aspirin for primary and secondary prevention of thromboembolism was studied in 
      comparison with placebo and warfarin. According to cumulative data of 6 
      randomized studies average stroke risk lowering caused by aspirin was 22%. In 
      primary prevention of stroke aspirin did not increase substantially frequency of 
      serious bleedings. However in secondary prevention trials its use was associated 
      with significant increase of serious bleeding rates. Thus in patients with atrial 
      fibrillation aspirin compared with warfarin less effectively prevents stroke but 
      causes fewer serious bleedings.
FAU - Preobrazhenskiĭ, D V
AU  - Preobrazhenskiĭ DV
AD  - Presidential Medical Center of Russia; ul. Marshala Timoschenko, 15, 121356 
      Moscow, Russia; S. Konukorlu Medical Center, Gaziantep, Turkey.
FAU - Sidorenko, B A
AU  - Sidorenko BA
FAU - Kiktev, V G
AU  - Kiktev VG
FAU - Batyraliev, T A
AU  - Batyraliev TA
FAU - Pershukov, I V
AU  - Pershukov IV
LA  - rus
PT  - Journal Article
TT  - Insul't i drugie tromboémbolicheskie oslozhneniia pri mertsanii predserdiĭ. 
      Chast' III. Profilaktika s pomoshch'iu aspirina.
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - *Aspirin/administration & dosage
MH  - *Atrial Fibrillation
MH  - Humans
MH  - Stroke
MH  - Warfarin/administration & dosage
EDAT- 2004/06/24 05:00
MHDA- 2016/04/24 06:00
CRDT- 2004/06/24 05:00
PHST- 2004/06/24 05:00 [pubmed]
PHST- 2016/04/24 06:00 [medline]
PHST- 2004/06/24 05:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 2004;44(6):87-94.

PMID- 16607074
OWN - NLM
STAT- MEDLINE
DCOM- 20061027
LR  - 20151119
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 17
IP  - 1
DP  - 2006 Jan
TI  - Lack of significant effect of low doses of aspirin on the concentrations of 
      C-reactive protein in a group of individuals with atherothrombotic risk factors 
      and vascular events.
PG  - 19-22
AB  - Atherothrombosis is associated with the presence of a microinflammatory response, 
      usually monitored by the use of C-reactive protein (CRP) measurements. In the 
      Physician Health Study it was suggested that individuals who benefit most from 
      the treatment are those who have enhanced concentrations of this biomarker. The 
      possibility was suggested that one of the mechanisms of action of aspirin in 
      thrombotic prevention is through its anti-inflammatory properties in terms of 
      reducing the concentration of CRP. We conducted a regression analysis in a cohort 
      of 3888 apparently healthy individuals and those with atherothrombotic risk 
      factors and vascular events, 370 of whom were under the treatment of low doses 
      (<or= 325 mg/day) of aspirin. The significant determinants of CRP concentrations 
      included body mass index, oral contraceptives, hormonal replacement therapy, 
      gender, low-density lipoprotein cholesterol, high-density lipoprotein 
      cholesterol, triglycerides, physical activity, age, smoking status and the 
      presence of diabetes mellitus but not the use of low dose of aspirin. We conclude 
      that the use of low doses (<or= 325 mg/day) of aspirin does not have a 
      significant role in the modulation of CRP concentrations in apparently healthy 
      individuals and those with atherothrombotic risk factors and vascular events. The 
      anti-atherothrombotic activity of this drug is probably not mediated through a 
      significant reduction of the concentration of this protein.
FAU - Rogowski, Ori
AU  - Rogowski O
AD  - Department of Medicine D and Institute for Special Medical Examinations (MALRAM), 
      Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv 
      University, Tel-Aviv, Israel.
FAU - Shapira, Itzhak
AU  - Shapira I
FAU - Ben Assayag, Einor
AU  - Ben Assayag E
FAU - Bornstein, Nathan M
AU  - Bornstein NM
FAU - Toker, Sharon
AU  - Toker S
FAU - Melamed, Samuel
AU  - Melamed S
FAU - Shirom, Arie
AU  - Shirom A
FAU - Berliner, Shlomo
AU  - Berliner S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacology
MH  - Arteriosclerosis/*drug therapy/prevention & control
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Biomarkers/blood
MH  - C-Reactive Protein/*drug effects/metabolism
MH  - Epidemiologic Methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Thrombosis/*drug therapy/prevention & control
MH  - Treatment Outcome
EDAT- 2006/04/12 09:00
MHDA- 2006/10/28 09:00
CRDT- 2006/04/12 09:00
PHST- 2006/04/12 09:00 [pubmed]
PHST- 2006/10/28 09:00 [medline]
PHST- 2006/04/12 09:00 [entrez]
AID - 00001721-200601000-00004 [pii]
AID - 10.1097/01.mbc.0000198050.27387.ea [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2006 Jan;17(1):19-22. doi: 
      10.1097/01.mbc.0000198050.27387.ea.

PMID- 19436943
OWN - NLM
STAT- MEDLINE
DCOM- 20100119
LR  - 20220310
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
VI  - 44
IP  - 9
DP  - 2009
TI  - Low-dose aspirin is a prominent cause of bleeding ulcers in patients who 
      underwent emergency endoscopy.
PG  - 912-8
LID - 10.1007/s00535-009-0074-2 [doi]
AB  - OBJECTIVE: This study aimed to clarify the current situation of bleeding peptic 
      ulcers and examined the temporal changes in the pathogenic mechanisms requiring 
      emergency endoscopy. PATIENTS AND METHODS: Study subjects were 285 bleeding 
      peptic ulcer patients who received emergency endoscopy in Saga Medical School 
      Hospital between 2000 and 2007. The ratios of H. pylori infection, NSAID use and 
      low-dose aspirin use were analyzed for differences between the two periods by 
      chi-square test. Logistic regression analysis was used to investigate factors 
      such as patient characteristics that influenced the differences between each 
      period. RESULTS: A total of 221 (77.5%) patients were identified as H. 
      pylori-positive. One hundred (35.1%) patients reported a history of NSAID use 
      within 4 weeks. Among NSAID users, 41 patients received daily low-dose aspirin. 
      One hundred forty-one patients had bleeding ulcers in 2000-2003 and 144 patients 
      in 2004-2007. The odds ratio (OR) between the periods was 0.806 (95% CI, 
      0.461-1.409) for H. pylori infection and 1.590 (95% CI, 0.973-2.598) for NSAID 
      usage. In contrast, the proportion of patients who took low-dose aspirin was 9.9% 
      in the first period and 18.8% in the second period, and the difference was 
      statistically significant (OR 2.093; 95% CI, 1.047-4.185). Logistic regression 
      analysis revealed that cardiovascular disease and cerebral vascular disease were 
      associated with aspirin use. CONCLUSION: This study indicates that the causes of 
      bleeding ulcers are changing, and the increasing use of low-dose aspirin might 
      become a major cause of bleeding ulcers.
FAU - Nakayama, Masayuki
AU  - Nakayama M
AD  - Department of Internal Medicine, Saga Medical School, Saga, Japan.
FAU - Iwakiri, Ryuichi
AU  - Iwakiri R
FAU - Hara, Megumi
AU  - Hara M
FAU - Ootani, Hibiki
AU  - Ootani H
FAU - Shimoda, Ryo
AU  - Shimoda R
FAU - Tsunada, Seiji
AU  - Tsunada S
FAU - Sakata, Hiroyuki
AU  - Sakata H
FAU - Fujimoto, Kazuma
AU  - Fujimoto K
LA  - eng
PT  - Journal Article
DEP - 20090513
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Cerebrovascular Disorders/drug therapy
MH  - Chi-Square Distribution
MH  - Emergency Medical Services
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Helicobacter Infections/*complications
MH  - Helicobacter pylori/isolation & purification
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*etiology
MH  - Prospective Studies
EDAT- 2009/05/14 09:00
MHDA- 2010/01/20 06:00
CRDT- 2009/05/14 09:00
PHST- 2009/02/02 00:00 [received]
PHST- 2009/04/16 00:00 [accepted]
PHST- 2009/05/14 09:00 [entrez]
PHST- 2009/05/14 09:00 [pubmed]
PHST- 2010/01/20 06:00 [medline]
AID - 10.1007/s00535-009-0074-2 [doi]
PST - ppublish
SO  - J Gastroenterol. 2009;44(9):912-8. doi: 10.1007/s00535-009-0074-2. Epub 2009 May 
      13.

PMID- 18573187
OWN - NLM
STAT- MEDLINE
DCOM- 20090205
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 6
IP  - 9
DP  - 2008 Sep
TI  - Initiation and persistence of warfarin or aspirin in patients with chronic atrial 
      fibrillation in general practice: do the appropriate patients receive stroke 
      prophylaxis?
PG  - 1500-6
LID - 10.1111/j.1538-7836.2008.03059.x [doi]
AB  - BACKGROUND: Practice guidelines recommend long-term stroke prophylaxis in 
      patients with chronic atrial fibrillation (cAF). OBJECTIVES: To examine treatment 
      initiation and persistence and factors that influence the choice of cAF 
      treatment. PATIENTS/METHODS: This study used the General Practice Research 
      Database, including computerized medical records of general practitioners in the 
      UK. Patients aged 40+ years with cAF after 1 January 2000 were included. Cox 
      proportional hazards regression models evaluated initiation and treatment 
      continuation over time of warfarin and aspirin. Treatment discontinuation was 
      defined as no repeat prescription within a three-month period after the expected 
      end of the treatment course. RESULTS: The study population included 41 910 cAF 
      patients. Elderly patients (aged 85+) were less likely to start warfarin 
      [relative rate (RR) = 0.16, 95% confidence interval (CI) 0.15-0.18] and more 
      likely to start aspirin (RR = 1.66, 95% CI 1.47-1.88) than patients aged 40-64 
      years. A history of dementia (RR = 0.28, 95% CI 0.17-0.44) and falls (RR = 0.76, 
      95% CI 0.70-0.83) also reduced the likelihood of warfarin initiation. Adjusting 
      for age and gender, higher stroke risk (CHADS2 score) was not found to be 
      associated with initiation of warfarin or aspirin contrary to current guidelines 
      recommendations. One-year persistence was 70% for warfarin and 50% for aspirin. 
      Treatment persistence was higher in elderly patients using warfarin and aspirin. 
      A higher CHADS(2) score was associated with improved persistence only with 
      warfarin. CONCLUSIONS: The low likelihood of patients with cAF in general 
      practice remaining on treatment long-term indicates that not all benefits as 
      observed in clinical trials may be achieved in usual clinical practice.
FAU - Gallagher, A M
AU  - Gallagher AM
AD  - General Practice Research Database, Medicines and Healthcare Products Regulatory 
      Agency, London, UK.
FAU - Rietbrock, S
AU  - Rietbrock S
FAU - Plumb, J
AU  - Plumb J
FAU - van Staa, T P
AU  - van Staa TP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080628
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Thromb Haemost. 2008 Oct;6(10):1622-4. PMID: 18680537
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/pharmacokinetics/*therapeutic use
MH  - Aspirin/pharmacokinetics/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Stroke/*prevention & control
MH  - Warfarin/pharmacokinetics/*therapeutic use
EDAT- 2008/06/25 09:00
MHDA- 2009/02/06 09:00
CRDT- 2008/06/25 09:00
PHST- 2008/06/25 09:00 [pubmed]
PHST- 2009/02/06 09:00 [medline]
PHST- 2008/06/25 09:00 [entrez]
AID - S1538-7836(22)13245-9 [pii]
AID - 10.1111/j.1538-7836.2008.03059.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2008 Sep;6(9):1500-6. doi: 10.1111/j.1538-7836.2008.03059.x. 
      Epub 2008 Jun 28.

PMID- 30132244
OWN - NLM
STAT- MEDLINE
DCOM- 20181114
LR  - 20181114
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 46
IP  - 4
DP  - 2018 Nov
TI  - Antithrombotic therapy after mitral valve repair: VKA or aspirin?
PG  - 473-481
LID - 10.1007/s11239-018-1724-0 [doi]
AB  - The optimal antithrombotic therapy following mitral valve repair (MVr) is still a 
      matter of debate. Therefore, we evaluated the rate of thromboembolic and bleeding 
      complications of two antithrombotic prevention strategies: vitamin K antagonists 
      (VKA) versus aspirin. Consecutive patients who underwent MVr between 2004 and 
      2016 at three Dutch hospitals were evaluated for thromboembolic and bleeding 
      complications during three postoperative months. The primary endpoint was the 
      combined incidence of thromboembolic and bleeding complications to determine the 
      net clinical benefit of VKA strategy as compared with aspirin. Secondary 
      objectives were to evaluate both thromboembolic and bleeding rates separately and 
      to identify predictors for both complications. A total of 469 patients were 
      analyzed, of whom 325 patients (69%) in the VKA group and 144 patients (31%) in 
      the aspirin group. Three months postoperatively, the cumulative incidence of the 
      combined end point of the study was 9.2% (95%CI 6.1-12) in the VKA group and 11% 
      (95%CI 6.0-17) in the aspirin group [adjusted hazard ratio (HR) 1.6, 95%CI 
      0.83-3.1]. Moreover, no significant differences were observed in thromboembolic 
      rates (adjusted HR 0.82, 95%CI 0.16-4.2) as well as in major bleeding rates 
      (adjusted HR 1.89, 95%CI 0.90-3.9). VKA and aspirin therapy showed a similar 
      event rate of 10% during 3 months after MVr in patients without prior history of 
      AF. In both treatment groups thromboembolic event rate was low and major bleeding 
      rates were comparable. Future prospective, randomized trials are warranted to 
      corroborate our findings.
FAU - van der Wall, Sake J
AU  - van der Wall SJ
AD  - Department of Thrombosis and Hemostasis, Leiden University Medical Centre, 
      Albinusdreef 2, 2300 RC, Leiden, The Netherlands. s.j.van_der_wall@lumc.nl.
FAU - Olsthoorn, Jules R
AU  - Olsthoorn JR
AD  - Department of Cardio-Thoracic Surgery, Maastricht University Medical Centre, 
      Maastricht, The Netherlands.
FAU - Heuts, Samuel
AU  - Heuts S
AD  - Department of Cardio-Thoracic Surgery, Maastricht University Medical Centre, 
      Maastricht, The Netherlands.
FAU - Klautz, Robert J M
AU  - Klautz RJM
AD  - Department of Cardio-Thoracic Surgery, Leiden University Medical Centre, Leiden, 
      The Netherlands.
FAU - Tomsic, Anton
AU  - Tomsic A
AD  - Department of Cardio-Thoracic Surgery, Leiden University Medical Centre, Leiden, 
      The Netherlands.
FAU - Jansen, Evert K
AU  - Jansen EK
AD  - Department of Cardio-Thoracic Surgery, VU University Medical Centre, Amsterdam, 
      The Netherlands.
FAU - Vonk, Alexander B A
AU  - Vonk ABA
AD  - Department of Cardio-Thoracic Surgery, VU University Medical Centre, Amsterdam, 
      The Netherlands.
FAU - Sardari Nia, Peyman
AU  - Sardari Nia P
AD  - Department of Cardio-Thoracic Surgery, Maastricht University Medical Centre, 
      Maastricht, The Netherlands.
FAU - Klok, Frederikus A
AU  - Klok FA
AD  - Department of Thrombosis and Hemostasis, Leiden University Medical Centre, 
      Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
FAU - Huisman, Menno V
AU  - Huisman MV
AD  - Department of Thrombosis and Hemostasis, Leiden University Medical Centre, 
      Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Fibrinolytic Agents)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - J Thromb Thrombolysis. 2018 Sep 10;:. PMID: 30203248
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiac Surgical Procedures
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Annuloplasty/adverse effects/*methods
MH  - Retrospective Studies
MH  - Thromboembolism/prevention & control
MH  - Vitamin K/*antagonists & inhibitors
PMC - PMC6182386
OTO - NOTNLM
OT  - Antithrombotic therapy
OT  - Bleeding
OT  - Mitral valve annuloplasty
OT  - Mitral valve repair
OT  - Thromboembolism
COIS- CONFLICT OF INTEREST: Frederikus A. Klok reports research grants from Bayer, 
      Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi-Sankyo, MSD and Actelion. 
      Menno V. Huisman reports research grants from ZONMW, Pfizer-BMS, 
      Boehringer-Ingelheim and Daiichi-Sankyo as well as fees for lectures from 
      Pfizer-BMS, Boehringer-Ingelheim and Daiichi-Sankyo. All other authors declare 
      that they have no competing interests. ETHICAL APPROVAL: The institutional review 
      board of the LUMC, VUmc and MUMC approved the study protocol and waived the need 
      for informed consent due to the observational design.
EDAT- 2018/08/23 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/08/23 06:00
PHST- 2018/08/23 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
PHST- 2018/08/23 06:00 [entrez]
AID - 10.1007/s11239-018-1724-0 [pii]
AID - 1724 [pii]
AID - 10.1007/s11239-018-1724-0 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2018 Nov;46(4):473-481. doi: 10.1007/s11239-018-1724-0.

PMID- 26776588
OWN - NLM
STAT- MEDLINE
DCOM- 20161021
LR  - 20181202
IS  - 1875-0834 (Electronic)
IS  - 1760-2734 (Linking)
VI  - 17 Suppl 1
DP  - 2015 Dec
TI  - Secondary prevention of cardiogenic arterial thromboembolism in the cat: The 
      double-blind, randomized, positive-controlled feline arterial thromboembolism; 
      clopidogrel vs. aspirin trial (FAT CAT).
PG  - S306-17
LID - S1760-2734(15)00095-8 [pii]
LID - 10.1016/j.jvc.2015.10.004 [doi]
AB  - OBJECTIVES: To determine if clopidogrel administration is associated with a 
      reduced likelihood of recurrent cardiogenic arterial thromboembolism (CATE) in 
      cats compared to aspirin administration. Secondary aims were to determine if 
      clopidogrel administration had an effect on the composite endpoint of recurrent 
      CATE and cardiac death and to identify adverse effects of chronic clopidogrel or 
      aspirin therapy. ANIMALS: Seventy-five cats that survived a CATE event. METHODS: 
      Multicenter, double-blind, randomized, positive-controlled study. Cats were 
      assigned to clopidogrel (18.75 mg/cat PO q 24 h) or aspirin (81 mg/cat PO q 72 
      h). Kaplan-Meier survival curves were created for each endpoint and the log rank 
      test performed to compare treatment groups with respect to time to event and the 
      likelihood of the event occurring. RESULTS: The mean age of all cats was 8.0 ± 
      3.5 yr and 57/75 (76%) were male (p < 0.001); 62/75 (83%) were mixed breed with 
      the remainder including Persian, Abyssinian, American Shorthair, Bengal, Birman, 
      Himalayan, Maine Coon, Ragdoll, Snowshoe, and Sphynx breeds. Only 15% (11/75) of 
      cats had a history of heart disease recorded prior to the CATE event. Clopidogrel 
      administration was associated with significantly reduced likelihood of recurrent 
      CATE compared to aspirin (p = 0.024) and had a longer median time to recurrence 
      [443 (95% CI 185-990) days vs. 192 (95% CI 62-364) days, respectively]. 
      Clopidogrel was also associated with a significantly reduced likelihood of the 
      composite endpoint of recurrent CATE or cardiac death (p = 0.033) with a longer 
      median time to event [346 (95% CI 146-495) days vs. 128 (95% CI 58-243) days]. 
      CONCLUSIONS: Clopidogrel administration significantly reduces the likelihood of 
      recurrent CATE compared with aspirin in cats; both drugs were well tolerated.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Hogan, Daniel F
AU  - Hogan DF
AD  - Purdue University, College of Veterinary Medicine, Department of Veterinary 
      Clinical Sciences, 625 Harrison Street, West Lafayette, IN 47907-2026, USA. 
      Electronic address: hogandf@purdue.edu.
FAU - Fox, Philip R
AU  - Fox PR
AD  - Caspary Institute, The Animal Medical Center, 510 East 62nd Street, New York, NY 
      10065, USA.
FAU - Jacob, Kristin
AU  - Jacob K
AD  - CVCA-Cardiac Care for Pets, 1209 Cromwell Bridge Road, Towson, MD 21286, USA.
FAU - Keene, Bruce
AU  - Keene B
AD  - North Carolina State University, College of Veterinary Medicine, Department of 
      Clinical Sciences, 1060 William Moore Drive, Raleigh, NC 27607, USA.
FAU - Laste, Nancy J
AU  - Laste NJ
AD  - MSPCA-Angell Animal Medical Center, 350 South Huntington Ave., Boston, MA 02130, 
      USA.
FAU - Rosenthal, Steven
AU  - Rosenthal S
AD  - CVCA-Cardiac Care for Pets, 1209 Cromwell Bridge Road, Towson, MD 21286, USA.
FAU - Sederquist, Kimberly
AU  - Sederquist K
AD  - Purdue University, College of Veterinary Medicine, Veterinary Teaching Hospital, 
      625 Harrison Street, West Lafayette, IN 47907-2026, USA.
FAU - Weng, Hsin-Yi
AU  - Weng HY
AD  - Purdue University, College of Veterinary Medicine, Department of Comparative 
      Pathobiology, 625 Harrison Street, West Lafayette, IN 47907-2026, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Vet Cardiol
JT  - Journal of veterinary cardiology : the official journal of the European Society 
      of Veterinary Cardiology
JID - 101163270
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cat Diseases/*prevention & control
MH  - Cats
MH  - Clopidogrel
MH  - Double-Blind Method
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Thromboembolism/prevention & control/*veterinary
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Antithrombotics
OT  - Cardioembolic
OT  - Infarction
OT  - Thromboprophylaxis
OT  - Thrombosis
EDAT- 2016/01/19 06:00
MHDA- 2016/10/22 06:00
CRDT- 2016/01/19 06:00
PHST- 2014/11/17 00:00 [received]
PHST- 2015/09/09 00:00 [revised]
PHST- 2015/10/07 00:00 [accepted]
PHST- 2016/01/19 06:00 [entrez]
PHST- 2016/01/19 06:00 [pubmed]
PHST- 2016/10/22 06:00 [medline]
AID - S1760-2734(15)00095-8 [pii]
AID - 10.1016/j.jvc.2015.10.004 [doi]
PST - ppublish
SO  - J Vet Cardiol. 2015 Dec;17 Suppl 1:S306-17. doi: 10.1016/j.jvc.2015.10.004.

PMID- 23872509
OWN - NLM
STAT- MEDLINE
DCOM- 20140623
LR  - 20181202
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 18
IP  - 6
DP  - 2013 Nov
TI  - Comparison of on-treatment platelet reactivity between triple antiplatelet 
      therapy with cilostazol and standard dual antiplatelet therapy in patients 
      undergoing coronary interventions: a meta-analysis.
PG  - 533-43
LID - 10.1177/1074248413495971 [doi]
AB  - BACKGROUND: The recent literature has shown that triple antiplatelet therapy with 
      cilostazol in addition to the standard dual antiplatelet therapy with aspirin and 
      clopidogrel may reduce platelet reactivity and improve clinical outcomes 
      following percutaneous coronary intervention. The purpose of this meta-analysis 
      is to compare the efficacy of triple antiplatelet therapy and dual antiplatelet 
      therapy in regard to on-treatment platelet reactivity. METHODS: Nine studies (n = 
      2179) comparing on-treatment platelet reactivity between dual antiplatelet 
      therapy (n = 1193) and triple antiplatelet therapy (n = 986) in patients 
      undergoing percutaneous coronary intervention were included. Primary end points 
      were P2Y12 reaction unit (PRU) and platelet reactivity index (PRI). Secondary end 
      points were platelet aggregation with adenosine diphosphate (ADP) 5 and 20 µmol/L 
      and P2Y12% inhibition. Mean difference (MD) and 95% confidence intervals (CI) 
      were computed and 2-sided α error <.05 was considered as a level of significance. 
      RESULTS: Compared to dual antiplatelet therapy, triple antiplatelet therapy had 
      significantly lower maximum platelet aggregation with ADP 5 µmol/L (MD: -14.4, 
      CI: -21.6 to -7.2, P < .001) and 20 µmol/L (MD: -14.9, CI: -22.9 to -6.8, P < 
      .001), significantly lower PRUs (MD: -45, CI: -59.4 to -30.6, P < .001) and PRI 
      (MD: -26, CI: -36.8 to -15.2, P < .001), and significantly higher P2Y12% 
      inhibition (MD: 18.5, CI: 2.3 to 34.6, P = .025). CONCLUSION: Addition of 
      cilostazol to conventional dual antiplatelet therapy significantly lowers 
      platelet reactivity and may explain a decrease in thromboembolic events following 
      coronary intervention; however, additional studies evaluating clinical outcomes 
      will be helpful to determine the benefit of triple antiplatelet therapy.
FAU - Panchal, Hemang B
AU  - Panchal HB
AD  - 1Department of Internal Medicine, East Tennessee State University, Johnson City, 
      TN, USA.
FAU - Shah, Tejaskumar
AU  - Shah T
FAU - Patel, Parthavkumar
AU  - Patel P
FAU - Albalbissi, Kais
AU  - Albalbissi K
FAU - Molnar, Janos
AU  - Molnar J
FAU - Coffey, Brandon
AU  - Coffey B
FAU - Khosla, Sandeep
AU  - Khosla S
FAU - Ramu, Vijay
AU  - Ramu V
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20130719
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - A74586SNO7 (Clopidogrel)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cilostazol
MH  - Clopidogrel
MH  - Coronary Artery Disease/therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Tetrazoles/administration & dosage/pharmacology/*therapeutic use
MH  - Thromboembolism/epidemiology/prevention & control
MH  - Ticlopidine/administration & dosage/analogs & 
      derivatives/pharmacology/therapeutic use
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - cilostazol
OT  - percutaneous coronary intervention
OT  - platelet reactivity
EDAT- 2013/07/23 06:00
MHDA- 2014/06/24 06:00
CRDT- 2013/07/23 06:00
PHST- 2013/07/23 06:00 [entrez]
PHST- 2013/07/23 06:00 [pubmed]
PHST- 2014/06/24 06:00 [medline]
AID - 1074248413495971 [pii]
AID - 10.1177/1074248413495971 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):533-43. doi: 
      10.1177/1074248413495971. Epub 2013 Jul 19.

PMID- 12885487
OWN - NLM
STAT- MEDLINE
DCOM- 20030814
LR  - 20190611
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 362
IP  - 9379
DP  - 2003 Jul 19
TI  - Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal 
      carcinomas.
PG  - 230-2
AB  - CONTEXT: Colorectal cancer is the second most common cause of cancer-related 
      mortality in the west. The high incidence and mortality make effective prevention 
      an important public-health and economic issue. Non-steroidal anti-inflammatory 
      drugs (NSAIDs) can inhibit colorectal carcinogenesis and are among the few agents 
      known to be chemopreventive. Randomised trials have shown that sulindac and 
      celecoxib suppress the development of adenomatous polyps and cause regression of 
      existing polyps in patients with familial adenomatous polyposis (FAP), who have a 
      high risk for developing colorectal cancer. The mechanisms by which NSAIDs 
      inhibit neoplastic growth are not fully known. STARTING POINT: Two recently 
      reported randomised placebo-controlled trials show a chemopreventive effect of 
      aspirin in populations other than those with FAP (Robert Sandler and colleagues, 
      N Engl J Med 2003; 348: 883-90; John Baron and colleagues, N Engl J Med 2003; 
      348: 891-99). In the Sandler study 635 patients with colorectal cancer were 
      randomised to receive 325 mg aspirin or placebo daily. After a follow-up of 
      around 31 months, the mean number of adenomas was lower in the aspirin group than 
      in the placebo group, corresponding to a relative risk of any recurrent adenoma 
      in the aspirin group of 0.65. In the Baron study 1121 patients with colorectal 
      adenomas were assigned to receive 81 or 325 mg aspirin or placebo daily. 
      Follow-up colonoscopy, 32 months after the index endoscopy, showed an incidence 
      of one or more adenomas of 38% in the 81 mg aspirin group, 45% in the 325 mg 
      aspirin group, and 47% in the placebo group. Together, these studies indicate a 
      moderate chemopreventive effect of aspirin in populations with an intermediate 
      risk of developing colorectal cancer. WHERE NEXT? The anticancer properties of 
      NSAIDs have been demonstrated in vitro and in animal studies, epidemiological 
      reports, and intervention studies. Several mechanisms through which NSAIDs alter 
      colonic carcinogenesis have been elucidated, including the induction of apoptosis 
      in neoplastic cells, via mechanisms dependent and independent of cyclo-oxygenase. 
      Some studies have suggested an important role for the cell-cycle regulating 
      protein p21 in mediating the chemopreventive effect of sulindac. A decrease in 
      p21 expression may be one of the main oncogenic events in the development of 
      colorectal cancer. Thus p21 could be the molecular link in the chemopreventive 
      effects of NSAIDs.
FAU - Huls, G
AU  - Huls G
AD  - Department of Internal Medicine, University Hospital Groningen, Groningen, 
      Netherlands. g.huls@int.azg.nl <g.huls@int.azg.nl>
FAU - Koornstra, J J
AU  - Koornstra JJ
FAU - Kleibeuker, J H
AU  - Kleibeuker JH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CDKN1A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (Cyclins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cell Cycle/drug effects
MH  - Chemoprevention
MH  - Colorectal Neoplasms/drug therapy/metabolism/*prevention & control
MH  - Cyclin-Dependent Kinase Inhibitor p21
MH  - Cyclins/metabolism
MH  - Humans
MH  - Molecular Biology
RF  - 26
EDAT- 2003/07/30 05:00
MHDA- 2003/08/15 05:00
CRDT- 2003/07/30 05:00
PHST- 2003/07/30 05:00 [pubmed]
PHST- 2003/08/15 05:00 [medline]
PHST- 2003/07/30 05:00 [entrez]
AID - S0140673603139153 [pii]
AID - 10.1016/s0140-6736(03)13915-3 [doi]
PST - ppublish
SO  - Lancet. 2003 Jul 19;362(9379):230-2. doi: 10.1016/s0140-6736(03)13915-3.

PMID- 26940135
OWN - NLM
STAT- MEDLINE
DCOM- 20170303
LR  - 20220321
IS  - 2374-2445 (Electronic)
IS  - 2374-2437 (Print)
IS  - 2374-2437 (Linking)
VI  - 2
IP  - 6
DP  - 2016 Jun 1
TI  - Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer.
PG  - 762-9
LID - 10.1001/jamaoncol.2015.6396 [doi]
AB  - IMPORTANCE: The US Preventive Services Task Force recently recommended the use of 
      aspirin to prevent colorectal cancer and cardiovascular disease among many US 
      adults. However, the association of aspirin use with the risk for other cancer 
      types and the potential population-wide effect of aspirin use on cancer, 
      particularly within the context of screening, remain uncertain. OBJECTIVES: To 
      examine the potential benefits of aspirin use for overall and subtype-specific 
      cancer prevention at a range of doses and durations of use and to estimate the 
      absolute benefit of aspirin in the context of screening. DESIGN, SETTING, AND 
      PARTICIPANTS: Two large US prospective cohort studies, the Nurses' Health Study 
      (1980-2010) and Health Professionals Follow-up Study (1986-2012), followed up 
      135 965 health care professionals (88 084 women and 47 881 men, respectively) who 
      reported on aspirin use biennially. The women were aged 30 to 55 years at 
      enrollment in 1976; the men, aged 40 to 75 years in 1986. Final follow-up was 
      completed on June 30, 2012, for the Nurses' Health Study cohort and January 31, 
      2010, for the Health Professionals Follow-up Study cohort, and data were accessed 
      from September 15, 2014, to December 17, 2015. MAIN OUTCOMES AND MEASURES: 
      Relative risks (RRs) for incident cancers and population-attributable risk (PAR). 
      RESULTS: Among the 88 084 women and 47 881 men who underwent follow-up for as 
      long as 32 years, 20 414 cancers among women and 7571 cancers among men were 
      documented. Compared with nonregular use, regular aspirin use was associated with 
      a lower risk for overall cancer (RR, 0.97; 95% CI, 0.94-0.99), which was 
      primarily owing to a lower incidence of gastrointestinal tract cancers (RR, 0.85; 
      95% CI, 0.80-0.91), especially colorectal cancers (RR, 0.81; 95% CI, 0.75-0.88). 
      The benefit of aspirin on gastrointestinal tract cancers appeared evident with 
      the use of at least 0.5 to 1.5 standard aspirin tablets per week; the minimum 
      duration of regular use associated with a lower risk was 6 years. Among 
      individuals older than 50 years, regular aspirin use could prevent 33 colorectal 
      cancers per 100 000 person-years (PAR, 17.0%) among those who had not undergone a 
      lower endoscopy and 18 colorectal cancers per 100 000 person-years (PAR, 8.5%) 
      among those who had. Regular aspirin use was not associated with the risk for 
      breast, advanced prostate, or lung cancer. CONCLUSIONS AND RELEVANCE: Long-term 
      aspirin use was associated with a modest but significantly reduced risk for 
      overall cancer, especially gastrointestinal tract tumors. Regular aspirin use may 
      prevent a substantial proportion of colorectal cancers and complement the 
      benefits of screening.
FAU - Cao, Yin
AU  - Cao Y
AD  - Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, 
      Massachusetts2Clinical and Translational Epidemiology Unit, Massachusetts General 
      Hospital and Harvard Medical School, Boston3Division of Gastroenterology, 
      Massachusetts General.
FAU - Nishihara, Reiko
AU  - Nishihara R
AD  - Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, 
      Massachusetts4Department of Epidemiology, Harvard T. H. Chan School of Public 
      Health, Boston, Massachusetts 5Department of Biostatistics, Harvard T. H. Chan 
      School of Public Heal.
FAU - Wu, Kana
AU  - Wu K
AD  - Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, 
      Massachusetts.
FAU - Wang, Molin
AU  - Wang M
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, 
      Massachusetts 5Department of Biostatistics, Harvard T. H. Chan School of Public 
      Health, Boston, Massachusetts.
FAU - Ogino, Shuji
AU  - Ogino S
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, 
      Massachusetts 6Department of Medical Oncology, Dana-Farber Cancer Institute and 
      Harvard Medical School, Boston, Massachusetts7Department of Pathology, Brigham 
      and Women's Hosp.
FAU - Willett, Walter C
AU  - Willett WC
AD  - Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, 
      Massachusetts4Department of Epidemiology, Harvard T. H. Chan School of Public 
      Health, Boston, Massachusetts 8Channing Division of Network Medicine, Brigham and 
      Women's Hospital a.
FAU - Spiegelman, Donna
AU  - Spiegelman D
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, 
      Massachusetts.
FAU - Fuchs, Charles S
AU  - Fuchs CS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical 
      School, Boston, Massachusetts8Channing Division of Network Medicine, Brigham and 
      Women's Hospital and Harvard Medical School, Boston, Massachusetts.
FAU - Giovannucci, Edward L
AU  - Giovannucci EL
AD  - Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, 
      Massachusetts4Department of Epidemiology, Harvard T. H. Chan School of Public 
      Health, Boston, Massachusetts 8Channing Division of Network Medicine, Brigham and 
      Women's Hospital a.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and 
      Harvard Medical School, Boston3Division of Gastroenterology, Massachusetts 
      General Hospital and Harvard Medical School, Boston8Channing Division of Network 
      Medicine, Brigham.
LA  - eng
GR  - R35 CA197735/CA/NCI NIH HHS/United States
GR  - P01 CA087969/CA/NCI NIH HHS/United States
GR  - R01 CA151993/CA/NCI NIH HHS/United States
GR  - R01 CA137178/CA/NCI NIH HHS/United States
GR  - K24 DK098311/DK/NIDDK NIH HHS/United States
GR  - UM1 CA186107/CA/NCI NIH HHS/United States
GR  - UM1 CA167552/CA/NCI NIH HHS/United States
GR  - K07 CA190673/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - JAMA Oncol
JT  - JAMA oncology
JID - 101652861
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 2016;352:i1319. PMID: 26944713
CIN - JAMA Oncol. 2016 Oct 1;2(10 ):1372-1373. PMID: 27532272
CIN - JAMA Oncol. 2016 Oct 1;2(10 ):1370. PMID: 27533285
CIN - JAMA Oncol. 2016 Oct 1;2(10 ):1370-1371. PMID: 27533476
CIN - JAMA Oncol. 2016 Oct 1;2(10 ):1371. PMID: 27533621
CIN - JAMA Oncol. 2016 Oct 1;2(10 ):1371-1372. PMID: 27533744
CIN - Am J Nurs. 2017 Jun;117(6):70. PMID: 28541994
EIN - JAMA Oncol. 2019 Apr 1;5(4):579. PMID: 30844032
CIN - JAMA Oncol. 2019 Apr 1;5(4):578-579. PMID: 30844040
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Colorectal Neoplasms/epidemiology/pathology/*prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Neoplasms/epidemiology/pathology/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
PMC - PMC4900902
MID - NIHMS767598
COIS- Conflict of Interest Disclosures: Dr Chan reports serving as a paid consultant 
      for Bayer Healthcare, Pfizer, Inc, and Pozen, Inc. Dr Fuchs has been a consultant 
      and/or a scientific advisor for Eli Lilly, Entrinsic Health, Pfizer, Merck, 
      Sanofi, Roche, Genentech, Merrimack Pharmaceuticals, Dicerna, Bayer, Celgene, 
      Agios, Gilead Sciences, Five Prime Therapeutics, Taiho, and KEW. No other 
      disclosures were reported.
EDAT- 2016/03/05 06:00
MHDA- 2017/03/04 06:00
CRDT- 2016/03/05 06:00
PHST- 2016/03/05 06:00 [entrez]
PHST- 2016/03/05 06:00 [pubmed]
PHST- 2017/03/04 06:00 [medline]
AID - 2497878 [pii]
AID - coi150118 [pii]
AID - 10.1001/jamaoncol.2015.6396 [doi]
PST - ppublish
SO  - JAMA Oncol. 2016 Jun 1;2(6):762-9. doi: 10.1001/jamaoncol.2015.6396.

PMID- 17826048
OWN - NLM
STAT- MEDLINE
DCOM- 20080610
LR  - 20131121
IS  - 0939-6411 (Print)
IS  - 0939-6411 (Linking)
VI  - 68
IP  - 3
DP  - 2008 Mar
TI  - Compaction of lactose drug mixtures: quantification of the extent of 
      incompatibility by FT-Raman spectroscopy.
PG  - 802-10
AB  - It is well known that lactoses interact with drugs containing amino groups and 
      undergo the Maillard reaction. Lactose monohydrate may also interact with 
      moisture sensitive drugs and affect the stability of the drug. These interactions 
      were analyzed using three model drugs - Thiaminchloride hydrochloride, 
      Nicotinamide and Acetylsalicylic acid - which interact with spray-dried lactose 
      or anhydrous lactose. FT-Raman spectroscopy was used for the first time to 
      qualitatively and quantitatively analyze these excipient drug interactions in 
      powders and tablets. Both lactoses undergo the Maillard reaction with 
      Thiaminchloride hydrochloride. Nicotinamide did not react with the lactoses 
      because the amide group is protected against the reaction with the lactoses. Only 
      a transition from beta- to alpha-lactose was noticed. The moisture sensitive drug 
      Acetylsalicylic acid remained stable even when the tablets were stored under 
      accelerated conditions (40 degrees C and 75% RH). The crystal water of lactose 
      monohydrate (spray-dried lactose) had no influence on the drug stability but a 
      transition from beta- to alpha-lactose was noticed. In conclusion, FT-Raman 
      spectroscopy is a fast and valuable tool for a quantitative determination of the 
      extents of incompatibility in solid dosage forms.
FAU - Flemming, Anett
AU  - Flemming A
AD  - Martin-Luther-University Halle-Wittenberg, Institute of Pharmaceutical Technology 
      and Biopharmacy, Halle/Saale, Germany.
FAU - Picker-Freyer, Katharina M
AU  - Picker-Freyer KM
LA  - eng
PT  - Journal Article
DEP - 20070808
PL  - Netherlands
TA  - Eur J Pharm Biopharm
JT  - European journal of pharmaceutics and biopharmaceutics : official journal of 
      Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
JID - 9109778
RN  - 25X51I8RD4 (Niacinamide)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
RN  - X66NSO3N35 (Thiamine)
SB  - IM
MH  - Aspirin/chemistry
MH  - *Drug Incompatibility
MH  - Lactose/*chemistry
MH  - Niacinamide/chemistry
MH  - Spectrum Analysis, Raman/*methods
MH  - Temperature
MH  - Thiamine/chemistry
EDAT- 2007/09/11 09:00
MHDA- 2008/06/11 09:00
CRDT- 2007/09/11 09:00
PHST- 2007/03/30 00:00 [received]
PHST- 2007/07/26 00:00 [revised]
PHST- 2007/07/27 00:00 [accepted]
PHST- 2007/09/11 09:00 [pubmed]
PHST- 2008/06/11 09:00 [medline]
PHST- 2007/09/11 09:00 [entrez]
AID - S0939-6411(07)00284-6 [pii]
AID - 10.1016/j.ejpb.2007.07.012 [doi]
PST - ppublish
SO  - Eur J Pharm Biopharm. 2008 Mar;68(3):802-10. doi: 10.1016/j.ejpb.2007.07.012. 
      Epub 2007 Aug 8.

PMID- 10658001
OWN - NLM
STAT- MEDLINE
DCOM- 20000303
LR  - 20181130
IS  - 8750-7587 (Print)
IS  - 0161-7567 (Linking)
VI  - 88
IP  - 2
DP  - 2000 Feb
TI  - Effects of primary resuscitation from shock on distribution of myocardial blood 
      flow.
PG  - 373-85
AB  - Hemorrhagic shock alters heterogeneity of regional myocardial perfusion (RMP) in 
      the presence of critical coronary stenosis in pigs. Conventional resuscitation 
      has failed to reverse these effects. We hypothesized that improvement of the 
      resuscitation regime would lead to restoration of RMP heterogeneity. 
      Diaspirin-cross-linked hemoglobin (10 g/dl; DCLHb) and human serum albumin (8.0 
      g/dl; HSA) were used. After baseline, a branch of the left coronary artery was 
      stenosed; thereafter, hemorrhagic shock was induced. Resuscitation was performed 
      with either DCLHb or HSA. At baseline, the fractcal dimension (D) of 
      subendocardial myocardium was 1.31 +/- 0.083 (HSA) and 1.35 +/- 0.106 (DCLHb) 
      (mean +/- SD). Coronary stenosis increased subendocardial D slightly but 
      consistently only in the DCLHb group (1.39 +/- 0.104; P < 0.05). Shock reduced 
      subendocardial D: 1.21 +/- 0.093 (HSA; P = 0.10), 1.25 +/- 0.092 (DCLHb; P < 
      0.05). Administration of DCLHb increased subendocardial D in 7 of 10 animals 
      (1.31 +/- 0.097; P = 0.066). HSA was ineffective in this respect. DCLHb infusion 
      restored arterial pressure and increased cardiac index (CI) to 80% of baseline 
      values. Administration of HSA left animals hypotensive (69 mmHg) and increased CI 
      to 122% of the average baseline value. Shock-induced disturbances of the 
      distribution of RMP were improved by administration of DCLHb but not by HSA.
FAU - Kleen, M
AU  - Kleen M
AD  - Institute for Surgical Research, University of Munich, 81366 Munich, Germany. 
      kleen@icf.med.uni-muenchen.de
FAU - Habler, O
AU  - Habler O
FAU - Meisner, F
AU  - Meisner F
FAU - Kemming, G
AU  - Kemming G
FAU - Pape, A
AU  - Pape A
FAU - Messmer, K
AU  - Messmer K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Appl Physiol (1985)
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
RN  - 0 (Hemoglobins)
RN  - 0 (Serum Albumin)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Coronary Circulation/drug effects/*physiology
MH  - Coronary Vessels/drug effects/*physiopathology
MH  - Hemodynamics/drug effects/physiology
MH  - Hemoglobins/pharmacology
MH  - Humans
MH  - Hypotension/etiology
MH  - Middle Aged
MH  - *Resuscitation
MH  - Serum Albumin/adverse effects/pharmacology
MH  - Shock, Hemorrhagic/*physiopathology/therapy
MH  - Swine
EDAT- 2000/02/05 09:00
MHDA- 2000/03/11 09:00
CRDT- 2000/02/05 09:00
PHST- 2000/02/05 09:00 [pubmed]
PHST- 2000/03/11 09:00 [medline]
PHST- 2000/02/05 09:00 [entrez]
AID - 10.1152/jappl.2000.88.2.373 [doi]
PST - ppublish
SO  - J Appl Physiol (1985). 2000 Feb;88(2):373-85. doi: 10.1152/jappl.2000.88.2.373.

PMID- 31339137
OWN - NLM
STAT- MEDLINE
DCOM- 20200220
LR  - 20200220
IS  - 1477-9234 (Electronic)
IS  - 1477-9226 (Linking)
VI  - 48
IP  - 41
DP  - 2019 Nov 7
TI  - Spiropyrans for light-controlled drug delivery.
PG  - 15537-15544
LID - 10.1039/c9dt02092f [doi]
AB  - The supramolecular assembly of acetylsalicylic acid to a merocyanine-Zn complex 
      translates into a photo-controllable drug delivery system. Herein, we present the 
      synthesis and spectroscopic analysis of a three-component assembly combining a 
      spiropyran derivative, a zinc(ii) cation, and acetylsalicylic acid. The ON/OFF 
      system can be modulated by safe and easily affordable stimuli, for the specific 
      delivery of more than one active compound. Our results confirm the formation of a 
      ternary system in solution, where the behaviour is dominated by photo-induced 
      responses, and pave the way for the use of such smart platforms for medicinal 
      chemistry purposes.
FAU - Cardano, Francesca
AU  - Cardano F
AD  - Istituto Italiano di Tecnologia (IIT), Nano Carbon Materials, via Livorno 60, 
      10144 Turin, Italy. silvia.giordani@dcu.ie and University of Genoa, Department of 
      Chemistry and Industrial Chemistry, via Dodecaneso 31, 16146 Genoa, Italy.
FAU - Del Canto, Elisa
AU  - Del Canto E
AD  - Trinity College Dublin, School of Chemistry, College Green, Dublin 2, Ireland.
FAU - Giordani, Silvia
AU  - Giordani S
AUID- ORCID: 0000-0002-9212-5067
AD  - Istituto Italiano di Tecnologia (IIT), Nano Carbon Materials, via Livorno 60, 
      10144 Turin, Italy. silvia.giordani@dcu.ie and Dublin City University, School of 
      Chemical Sciences, Glasnevin, Dublin 9, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20190724
PL  - England
TA  - Dalton Trans
JT  - Dalton transactions (Cambridge, England : 2003)
JID - 101176026
RN  - 0 (Benzopyrans)
RN  - 0 (Drug Carriers)
RN  - 0 (Indoles)
RN  - 0 (Nitro Compounds)
RN  - 0 (spiropyran)
RN  - J41CSQ7QDS (Zinc)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Benzopyrans/*chemistry
MH  - Drug Carriers/*chemistry
MH  - Indoles/*chemistry
MH  - *Light
MH  - Nitro Compounds/*chemistry
MH  - Photochemical Processes
MH  - Zinc/chemistry
EDAT- 2019/07/25 06:00
MHDA- 2020/02/23 06:00
CRDT- 2019/07/25 06:00
PHST- 2019/07/25 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
PHST- 2019/07/25 06:00 [entrez]
AID - 10.1039/c9dt02092f [doi]
PST - ppublish
SO  - Dalton Trans. 2019 Nov 7;48(41):15537-15544. doi: 10.1039/c9dt02092f. Epub 2019 
      Jul 24.

PMID- 27930812
OWN - NLM
STAT- MEDLINE
DCOM- 20180426
LR  - 20210109
IS  - 1097-458X (Electronic)
IS  - 0749-1581 (Print)
IS  - 0749-1581 (Linking)
VI  - 55
IP  - 6
DP  - 2017 Jun
TI  - Assessing 2D electrophoretic mobility spectroscopy (2D MOSY) for analytical 
      applications.
PG  - 584-588
LID - 10.1002/mrc.4558 [doi]
AB  - Electrophoretic displacement of charged entity phase modulates the spectrum 
      acquired in electrophoretic NMR experiments, and this modulation can be presented 
      via 2D FT as 2D mobility spectroscopy (MOSY) spectra. We compare in various mixed 
      solutions the chemical selectivity provided by 2D MOSY spectra with that provided 
      by 2D diffusion-ordered spectroscopy (DOSY) spectra and demonstrate, under the 
      conditions explored, a superior performance of the former method. 2D MOSY 
      compares also favourably with closely related LC-NMR methods. The shape of 2D 
      MOSY spectra in complex mixtures is strongly modulated by the pH of the sample, a 
      feature that has potential for areas such as in drug discovery and metabolomics. 
      Copyright © 2016 The Authors. Magnetic Resonance in Chemistry published by John 
      Wiley & Sons Ltd.
CI  - Copyright © 2016 The Authors. Magnetic Resonance in Chemistry published by John 
      Wiley & Sons Ltd.
FAU - Fang, Yuan
AU  - Fang Y
AD  - Division of Applied Physical Chemistry, Department of Chemistry, KTH Royal 
      Institute of Technology, Teknikringen 30, SE-10044, Stockholm, Sweden.
FAU - Yushmanov, Pavel V
AU  - Yushmanov PV
AD  - P&L Scientific Instrument Services, Box 1241, SE-18124, Lidingö, Sweden.
FAU - Furó, István
AU  - Furó I
AD  - Division of Applied Physical Chemistry, Department of Chemistry, KTH Royal 
      Institute of Technology, Teknikringen 30, SE-10044, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20170201
PL  - England
TA  - Magn Reson Chem
JT  - Magnetic resonance in chemistry : MRC
JID - 9882600
RN  - 0 (Amino Acids)
RN  - 0 (Complex Mixtures)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/analysis
MH  - Amino Acids/analysis
MH  - Aspirin/analysis
MH  - Caffeine/analysis
MH  - Complex Mixtures/*analysis
MH  - Diffusion
MH  - Electrophoretic Mobility Shift Assay/*methods
MH  - Hydrogen-Ion Concentration
MH  - Magnetic Resonance Spectroscopy/*methods
MH  - Tablets
PMC - PMC5434926
OTO - NOTNLM
OT  - 1H
OT  - 2D DOSY NMR
OT  - LC-NMR
OT  - NMR
OT  - acid
OT  - base
OT  - electrophoretic NMR
OT  - electrophoretic mobility
OT  - ion
OT  - self-diffusion
EDAT- 2016/12/09 06:00
MHDA- 2018/04/27 06:00
CRDT- 2016/12/09 06:00
PHST- 2016/10/19 00:00 [received]
PHST- 2016/11/29 00:00 [revised]
PHST- 2016/11/30 00:00 [accepted]
PHST- 2016/12/09 06:00 [pubmed]
PHST- 2018/04/27 06:00 [medline]
PHST- 2016/12/09 06:00 [entrez]
AID - MRC4558 [pii]
AID - 10.1002/mrc.4558 [doi]
PST - ppublish
SO  - Magn Reson Chem. 2017 Jun;55(6):584-588. doi: 10.1002/mrc.4558. Epub 2017 Feb 1.

PMID- 28463896
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20220321
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 267
IP  - 1
DP  - 2018 Jan
TI  - A Meta-analysis of the Impact of Aspirin, Clopidogrel, and Dual Antiplatelet 
      Therapy on Bleeding Complications in Noncardiac Surgery.
PG  - 1-10
LID - 10.1097/SLA.0000000000002279 [doi]
AB  - OBJECTIVE: The aim of this study was to determine the bleeding risks associated 
      with single (aspirin) and dual (aspirin + clopidogrel) antiplatelet therapy 
      (DAPT) versus placebo or no treatment in adults undergoing noncardiac surgery. 
      SUMMARY OF BACKGROUND DATA: The impact of antiplatelet therapy on bleeding during 
      noncardiac surgery remains controversial. A meta-analysis was performed to 
      examine the risk associated with single and DAPT. METHODS: A systematic review of 
      antiplatelet therapy, noncardiac surgery, and perioperative bleeding was 
      performed. Peer-reviewed sources and meeting abstracts from relevant societies 
      were queried. Studies without a control group, or those that only examined 
      patients with coronary stents, were excluded. Primary endpoints were transfusion 
      and reintervention for bleeding. RESULTS: Of 11,592 references, 46 studies met 
      inclusion criteria. In a meta-analysis of >30,000 patients, the relative risk 
      (RR) of transfusion versus control was 1.14 [95% confidence interval (CI) 
      1.03-1.26, P = 0.009] for aspirin, and 1.33 (1.15-1.55, P = 0.001) for DAPT. 
      Clopidogrel had an elevated risk, but data were too heterogeneous to analyze. The 
      RR of bleeding requiring reintervention was not significantly higher for any 
      agent compared to control [RR 0.96 (0.76-1.22, P = 0.76) for aspirin, 1.84 
      (0.87-3.87, P = 0.11) for clopidogrel, and 1.51 (0.92-2.49, P = 0.1) for DAPT]. 
      Subanalysis of thoracic and abdominal procedures was similar. There was no 
      difference in RR for myocardial infarction [1.06 (0.79-1.43)], stroke [0.97 
      (0.71-1.33)], or mortality [0.97 (0.87-1.1)]. CONCLUSIONS: Antiplatelet therapy 
      at the time of noncardiac surgery confers minimal bleeding risk with no 
      difference in thrombotic complications. In many cases, it is safe to continue 
      antiplatelet therapy in patients with important indications for their use.
FAU - Columbo, Jesse A
AU  - Columbo JA
AD  - Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
AD  - The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH.
AD  - VA Outcomes Group, Veterans Health Administration, White River Junction, VT.
AD  - VA Quality Scholars, Veterans Health Administration, White River Junction, VT.
FAU - Lambour, Andrew J
AU  - Lambour AJ
AD  - Department of General Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
FAU - Sundling, Rebecca A
AU  - Sundling RA
AD  - The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH.
FAU - Chauhan, Nirali B
AU  - Chauhan NB
AD  - The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH.
FAU - Bessen, Sarah Y
AU  - Bessen SY
AD  - The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH.
FAU - Linshaw, David L
AU  - Linshaw DL
AD  - Department of General Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
FAU - Kang, Ravinder
AU  - Kang R
AD  - The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH.
AD  - VA Outcomes Group, Veterans Health Administration, White River Junction, VT.
AD  - VA Quality Scholars, Veterans Health Administration, White River Junction, VT.
AD  - Department of General Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
FAU - Riblet, Natalie B V
AU  - Riblet NBV
AD  - The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH.
FAU - Goodney, Philip P
AU  - Goodney PP
AD  - Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
AD  - The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH.
AD  - VA Outcomes Group, Veterans Health Administration, White River Junction, VT.
FAU - Stone, David H
AU  - Stone DH
AD  - Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Surg. 2018 Jan;267(1):11-12. PMID: 28692473
CIN - Ann Surg. 2018 Aug;268(2):e33. PMID: 28742706
CIN - Ann Surg. 2018 Aug;268(2):e33. PMID: 28817442
MH  - Aspirin/administration & dosage/*adverse effects
MH  - *Blood Loss, Surgical
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Risk Factors
MH  - Surgical Procedures, Operative/*adverse effects
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
EDAT- 2017/05/04 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/05/03 06:00
PHST- 2017/05/04 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/05/03 06:00 [entrez]
AID - 10.1097/SLA.0000000000002279 [doi]
PST - ppublish
SO  - Ann Surg. 2018 Jan;267(1):1-10. doi: 10.1097/SLA.0000000000002279.

PMID- 2307673
OWN - NLM
STAT- MEDLINE
DCOM- 19900409
LR  - 20210210
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 265
IP  - 8
DP  - 1990 Mar 15
TI  - Dynamics and reactivity of HbXL99 alpha. A cross-linked hemoglobin derivative.
PG  - 4449-54
AB  - Resonance Raman spectroscopy, transient absorption, and fluroescence techniques 
      have been employed to investigate the structure and dynamics of the 
      alpha-cross-linked hemoglobin derivative, HbXL99 alpha. The resonance Raman 
      spectra of the deoxy form of HbXL99 alpha are identical to those of native NbA 
      (VFe-His approximately 222 cm-1), which exhibit a T-state (low affinity) 
      structure regardless of solvent conditions. The resonance Raman spectra of the 
      transient heme photoproduct resulting from CO photolysis from HbXL99 alpha appear 
      to have structures intermediate between deoxy-T and ligand-bound R structures 
      (VFe-His approximately 222 cm-1). Time-resolved resonance Raman data of HbXL99 
      alpha-CO show that complete CO recombination occurs after approximately 5 ms, 
      with only a small amount of the CO-bound species reforming within approximately 
      200 ns (geminate recombination). Transient absorption spectra of HbXL99 alpha-O2 
      indicate that the extent of sub-nanosecond geminate recombination of O2 is also 
      reduced in the cross-linked derivative relative to native HbA. The decrease in 
      tryptophan fluorescence of HbXL99 alpha upon oxygenation further indicates that 
      tertiary structural changes at the alpha 1-beta 2 interface upon ligation are 
      apparently reduced, but not eliminated in the cross-linked derivative relative to 
      HbA.
FAU - Larsen, R W
AU  - Larsen RW
AD  - Department of Chemistry, University of New Mexico, Albuquerque 87131.
FAU - Chavez, M D
AU  - Chavez MD
FAU - Ondrias, M R
AU  - Ondrias MR
FAU - Courtney, S H
AU  - Courtney SH
FAU - Friedman, J M
AU  - Friedman JM
FAU - Lin, M J
AU  - Lin MJ
FAU - Hirsch, R E
AU  - Hirsch RE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (hemoglobin XL99alpha)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 7U1EE4V452 (Carbon Monoxide)
RN  - 8DUH1N11BX (Tryptophan)
RN  - 9034-51-9 (Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives
MH  - Carbon Monoxide
MH  - Cross-Linking Reagents
MH  - Fluorescence
MH  - *Hemoglobin A
MH  - *Hemoglobins
MH  - Hydrogen-Ion Concentration
MH  - Photolysis
MH  - Spectrum Analysis, Raman
MH  - Tryptophan
EDAT- 1990/03/15 00:00
MHDA- 1990/03/15 00:01
CRDT- 1990/03/15 00:00
PHST- 1990/03/15 00:00 [pubmed]
PHST- 1990/03/15 00:01 [medline]
PHST- 1990/03/15 00:00 [entrez]
AID - S0021-9258(19)39585-7 [pii]
PST - ppublish
SO  - J Biol Chem. 1990 Mar 15;265(8):4449-54.

PMID- 18217142
OWN - NLM
STAT- MEDLINE
DCOM- 20080221
LR  - 20221207
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 99
IP  - 1
DP  - 2008 Jan
TI  - Magnitude and time course of platelet inhibition with extended release 
      dipyridamole with or without aspirin in healthy Japanese volunteers. The AGgrenox 
      versus Aspirin Therapy Evaluation (AGATE-Japan).
PG  - 116-20
LID - 10.1160/TH07-09-0563 [doi]
AB  - Randomized trials showed greater stroke prevention with extended release 
      dipyridamole in combination with low dose aspirin than with either aspirin or 
      dipyridamole alone. However, most studies with this formulation (Aggrenox) were 
      carried out in Europe and North America. Considering potential inter-racial 
      differences in drug response, we conducted a small randomized study in healthy 
      Japanese volunteers to compare antiplatelet regimens with regard to the changes 
      in the platelet biomarkers. Thirty healthy volunteers (18-40 years old, 15 male 
      and 15 female) of Japanese descent were randomized to Aggrenox (n = 17) or 
      aspirin 81 mg (n = 13 volunteers) for 30 days. Platelet function was assessed at 
      baseline, and on days 15, and 30 by conventional aggregometry, whole blood flow 
      cytometry, and cartridge-based analyzer. Both Aggrenox and aspirin provided 
      sustained platelet inhibition at Day 15 and Day 30. Therapy with Aggrenox, 
      however, was associated with more prominent and significant inhibition of 
      collagen-induced aggregation (p = 0.08, Day 15), as well as prolongation of the 
      closure time (p = 0.001, Day 30); diminished expression of platelet endothelial 
      cell adhesion molecule-1 (PECAM-1) (p = 0.02, Day 30), glycoprotein IIb (GPIIb) 
      antigen (p = 0.001 and 0.024 for Day 15 and Day 30), and GPIIb/IIIa activity by 
      PAC-1 antibody (p = 0.014 and 0.03), CD62 (P-selectin) (p = 0.03 for Day 15 and 
      Day 30), as well as inhibition of protease activated receptors (PAR-1) associated 
      with intact WEDE-15 (p = 0.002 and 0.003) and SPAN-12 (p = 0.002 and 0.04) 
      thrombin receptors when compared with aspirin. The magnitude and durability of 
      platelet response after Aggrenox in healthy Japanese is similar to those effects 
      observed in Caucasians and African-Americans. A larger study to assess drug 
      efficacy and safety in the Japanese post-stroke patients is warranted.
FAU - Serebruany, Victor L
AU  - Serebruany VL
AD  - HeartDrug Research Laboratories, Baltimore, Maryland, USA. heartdrug@aol.com
FAU - Malinin, Alex I
AU  - Malinin AI
FAU - Hanley, Dan F
AU  - Hanley DF
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Antigens, CD)
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Biomarkers)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Membrane Glycoproteins)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antigens, CD/blood
MH  - Asian People
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Biomarkers/blood
MH  - Blood Platelets/*drug effects/immunology/metabolism
MH  - Delayed-Action Preparations
MH  - Dipyridamole/administration & dosage/*pharmacology
MH  - Drug Combinations
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Function Tests/methods
MH  - Platelet Membrane Glycoproteins/metabolism
MH  - Reference Values
MH  - Research Design
MH  - Time Factors
EDAT- 2008/01/25 09:00
MHDA- 2008/02/22 09:00
CRDT- 2008/01/25 09:00
PHST- 2008/01/25 09:00 [pubmed]
PHST- 2008/02/22 09:00 [medline]
PHST- 2008/01/25 09:00 [entrez]
AID - 08010116 [pii]
AID - 10.1160/TH07-09-0563 [doi]
PST - ppublish
SO  - Thromb Haemost. 2008 Jan;99(1):116-20. doi: 10.1160/TH07-09-0563.

PMID- 9357241
OWN - NLM
STAT- MEDLINE
DCOM- 19971216
LR  - 20131121
IS  - 0019-5847 (Print)
IS  - 0019-5847 (Linking)
VI  - 95
IP  - 2
DP  - 1997 Feb
TI  - Role of low dose aspirin in prevention of pregnancy induced hypertension.
PG  - 43-4, 47
AB  - In a prospective randomised clinical study 50 primi or multigravidae with history 
      of essential hypertension or pregnancy induced hypertension (PIH) in previous 
      pregnancy were selected from antenatal clinics, on the basis of positive roll 
      over test (ROT) carried out between 28 to 30 weeks of pregnancy. The study group 
      comprised 25 women who received 50 mg aspirin daily from day of positive ROT till 
      37 weeks of pregnancy. Other 25 women served as control. The incidence of PIH in 
      study and control group was 4% versus 28% and that of pre-term birth was 4% 
      versus 24%. The mean birth weight of newborns in the two groups was 3.04 +/- 0.38 
      kg and 2.71 +/- 0.48 kg respectively. All these differences were statistically 
      significant. No adverse maternal or neonatal complication due to aspirin was 
      observed.
FAU - Tewari, S
AU  - Tewari S
AD  - Department of Obstetrics and Gynaecology, Pt BDS PGIMS, Rohtak.
FAU - Kaushish, R
AU  - Kaushish R
FAU - Sharma, S
AU  - Sharma S
FAU - Gulati, N
AU  - Gulati N
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - India
TA  - J Indian Med Assoc
JT  - Journal of the Indian Medical Association
JID - 7505608
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Hypertension/etiology/*prevention & control
MH  - Pre-Eclampsia/etiology/*prevention & control
MH  - Pregnancy
MH  - Prenatal Care
MH  - Prospective Studies
EDAT- 1997/02/01 00:00
MHDA- 1997/11/14 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1997/11/14 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
PST - ppublish
SO  - J Indian Med Assoc. 1997 Feb;95(2):43-4, 47.

PMID- 3900975
OWN - NLM
STAT- MEDLINE
DCOM- 19851106
LR  - 20190912
IS  - 0091-7435 (Print)
IS  - 0091-7435 (Linking)
VI  - 14
IP  - 2
DP  - 1985 Mar
TI  - A randomized trial of aspirin and beta-carotene among U.S. physicians.
PG  - 165-8
AB  - The Physicians' Health Study is a randomized, placebo-controlled, double-blind 
      clinical trial underway in the United States to assess the effects of aspirin 
      (325 mg q.o.d.) on total cardiovascular mortality, and of beta-carotene (50 mg 
      q.o.d.) on cancer incidence. The participants are 22,071 U.S. male physicians 
      between the ages of 40-84 years. The design of the study is 2 x 2 factorial, 
      which enables us to address two important research questions simultaneously. The 
      trial is conducted entirely by mail, which involves sending calendar packs of 
      drugs and questionnaires on health status and compliance, initially at six-month 
      then at annual intervals. Compliance and follow-up rates to date are excellent. 
      The large size of the trial, its simple design, and the use of highly motivated, 
      dedicated, and health-conscious physicians should allow us to perform definitive 
      tests of whether low-dose aspirin consumption reduces total cardiovascular 
      mortality and beta-carotene decreases cancer incidence in a healthy population.
FAU - Hennekens, C H
AU  - Hennekens CH
FAU - Eberlein, K
AU  - Eberlein K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
RN  - 01YAE03M7J (beta Carotene)
RN  - 36-88-4 (Carotenoids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/mortality
MH  - Carotenoids/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*drug therapy/epidemiology
MH  - Physicians
MH  - Random Allocation
MH  - Research Design
MH  - Time Factors
MH  - beta Carotene
EDAT- 1985/03/01 00:00
MHDA- 1985/03/01 00:01
CRDT- 1985/03/01 00:00
PHST- 1985/03/01 00:00 [pubmed]
PHST- 1985/03/01 00:01 [medline]
PHST- 1985/03/01 00:00 [entrez]
AID - 10.1016/0091-7435(85)90031-3 [doi]
PST - ppublish
SO  - Prev Med. 1985 Mar;14(2):165-8. doi: 10.1016/0091-7435(85)90031-3.

PMID- 1947079
OWN - NLM
STAT- MEDLINE
DCOM- 19911218
LR  - 20181130
IS  - 0033-8419 (Print)
IS  - 0033-8419 (Linking)
VI  - 181
IP  - 3
DP  - 1991 Dec
TI  - Current use of screening laboratory tests before abdominal interventions: a 
      survey of 603 radiologists.
PG  - 669-73
AB  - A survey of 2,153 radiologists was conducted to assess both their current 
      practices of evaluating hemostatic function and their use of blood tests before 
      performing image-guided nonvascular abdominal interventions. Among the 603 (28%) 
      who responded, more radiologists routinely perform prothrombin time (81%) or 
      partial thromboplastin time (78%) tests than platelet counts (59%), and 
      relatively few (7%) obtain bleeding times. The most common practice (51%) is to 
      order all of the first three tests. Use of laboratory tests is quite common 
      (greater than 75%) before biopsy of splenic masses, hemangiomas, or hepatomas and 
      before all catheter insertions. These tests are used less frequently (less than 
      or equal to 70%) before fine-needle procedures, including biopsy and cyst 
      aspiration. Only one-third of the radiologists alter their evaluation in patients 
      who have taken aspirin. Most respondents (64%) believe that there should be 
      written guidelines on how to evaluate patients before interventional procedures. 
      Virtually all (97%) thought such evaluation should be the radiologist's 
      responsibility.
FAU - Silverman, S G
AU  - Silverman SG
AD  - Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115.
FAU - Coughlin, B F
AU  - Coughlin BF
FAU - Seltzer, S E
AU  - Seltzer SE
FAU - Swensson, R G
AU  - Swensson RG
FAU - Mueller, P R
AU  - Mueller PR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Radiology
JT  - Radiology
JID - 0401260
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Biopsy, Needle
MH  - Bleeding Time
MH  - *Blood Coagulation Tests/statistics & numerical data
MH  - Catheterization
MH  - Humans
MH  - Practice Patterns, Physicians'
MH  - *Radiography, Abdominal
MH  - *Radiology, Interventional
MH  - Suction
MH  - Surveys and Questionnaires
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
AID - 10.1148/radiology.181.3.1947079 [doi]
PST - ppublish
SO  - Radiology. 1991 Dec;181(3):669-73. doi: 10.1148/radiology.181.3.1947079.

PMID- 29775206
OWN - NLM
STAT- MEDLINE
DCOM- 20191029
LR  - 20191029
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 58
IP  - 9
DP  - 2018 Sep
TI  - Prospective Determination of Aspirin Sensitivity in Patients Resistant to Low 
      Dose Aspirin: A Proof of Concept Study.
PG  - 1157-1163
LID - 10.1002/jcph.1259 [doi]
AB  - This study tested the capability of an assay to predict aspirin response and 
      reduce ischemic events, and healthcare costs, and delays to optimal treatment. 
      Patients who needed aspirin in the course of normal medical care were included. 
      Patients were excluded if they had disorders affecting platelet function, alcohol 
      use within 24 hours of a test, or NSAID use. Dose escalation of chewable aspirin 
      from 81 mg, to 162 mg, to 325 mg daily occurred based on the results of whole 
      blood impedance aggregation testing to the agonists, collagen (1ug/mL, 5 ug/mL) 
      and arachidonate (0.5 mM) after 10-14 days of treatment. The experimental in 
      vitro test was conducted in triplicate by performing aggregometry on samples 
      spiked to a concentration of 10 uM of aspirin in 0.05% dimethyl sulfoxide. Of the 
      36 patients who were compliant 16 were found to be resistant to the antiplatelet 
      effects of 81 mg daily aspirin. Nine of these patients were predicted to stay 
      resistant despite dose increase. Once tested at higher doses, ten remained 
      resistant. Seven of the 16 patients were predicted to become sensitive to a 
      higher dose while six actually did. Predicted response to increased doses of 
      aspirin was in good agreement with actual response. Sensitivity of the assay was 
      83% and specificity was 80%. Results are promising and indicate that it is 
      possible to predict, with reasonable accuracy, if a patient will have an adequate 
      platelet response to aspirin or if the patient will never respond to aspirin 
      necessitating an alternative antiplatelet regimen. Larger, multisite studies are 
      inevitably needed.
CI  - © 2018, The American College of Clinical Pharmacology.
FAU - Westphal, Erica S
AU  - Westphal ES
AD  - Dent Neurologic Institute, Amherst, NY, USA.
FAU - Rainka, Michelle
AU  - Rainka M
AD  - Dent Neurologic Institute, Amherst, NY, USA.
FAU - Amsler, Michelle
AU  - Amsler M
AD  - Dent Neurologic Institute, Amherst, NY, USA.
FAU - Aladeen, Traci
AU  - Aladeen T
AD  - Dent Neurologic Institute, Amherst, NY, USA.
FAU - Wisniewski, Caitlin
AU  - Wisniewski C
AD  - Dent Neurologic Institute, Amherst, NY, USA.
FAU - Bates, Vernice
AU  - Bates V
AD  - Dent Neurologic Institute, Amherst, NY, USA.
FAU - Gengo, Fran M
AU  - Gengo FM
AD  - Dent Neurologic Institute, Amherst, NY, USA.
AD  - Schools of Pharmacy and Medicine, University at Buffalo, Buffalo, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20180518
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests/methods
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - DMSO
OT  - aspirin
OT  - doseABSTRACT
OT  - pharmacodynanic
OT  - pharmacokinetic
OT  - resistance
OT  - stroke
EDAT- 2018/05/19 06:00
MHDA- 2019/10/30 06:00
CRDT- 2018/05/19 06:00
PHST- 2018/02/07 00:00 [received]
PHST- 2018/04/16 00:00 [accepted]
PHST- 2018/05/19 06:00 [pubmed]
PHST- 2019/10/30 06:00 [medline]
PHST- 2018/05/19 06:00 [entrez]
AID - 10.1002/jcph.1259 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2018 Sep;58(9):1157-1163. doi: 10.1002/jcph.1259. Epub 2018 May 
      18.

PMID- 6956924
OWN - NLM
STAT- MEDLINE
DCOM- 19821202
LR  - 20191031
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 9
IP  - 2
DP  - 1982 Aug
TI  - Modification of anti-hypertensive action of verapamil by inhibition of endogenous 
      prostaglandin synthesis.
PG  - 167-9
AB  - Verapamil, a known Ca++ antagonist, has vasodilator properties and is of use in 
      the management of mild to moderate hypertension. It is also known to possess PGE2 
      antagonistic properties and thus may enhance prostacyclin synthesis of action in 
      the vascular endothelial cells. This may contribute to its antihypertensive 
      action. Blocking of endogenous synthesis of prostaglandins by acetyl salicylic 
      acid reversed the beneficial effect of verapamil in hypertensive patients. This 
      supports the concept that the vasodilator and anti-hypertensive properties of 
      verapamil are mediated in part by the modulation of prostaglandin system.
FAU - Das, U N
AU  - Das UN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Prostaglandins)
RN  - CJ0O37KU29 (Verapamil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Prostaglandins/biosynthesis
MH  - Verapamil/*therapeutic use
EDAT- 1982/08/01 00:00
MHDA- 1982/08/01 00:01
CRDT- 1982/08/01 00:00
PHST- 1982/08/01 00:00 [pubmed]
PHST- 1982/08/01 00:01 [medline]
PHST- 1982/08/01 00:00 [entrez]
AID - 10.1016/0262-1746(82)90005-1 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1982 Aug;9(2):167-9. doi: 
      10.1016/0262-1746(82)90005-1.

PMID- 7340440
OWN - NLM
STAT- MEDLINE
DCOM- 19820614
LR  - 20190825
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 11
IP  - 6-7
DP  - 1981 Dec
TI  - Synthesis and biological activity of some structural analogs of 
      platelet-activating factor (PAF-acether).
PG  - 558-9
AB  - Platelet-activating factor (PAF-acether), a mediator of anaphylaxis and 
      inflammation, is a 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine. Some 
      analogs of PAF-acether were prepared by total synthesis or by partial synthesis 
      from commercially available phospholipids and tested for platelet aggregating 
      activity. This study indicated that the ether linkage at the position 1 of 
      sn-glycerol and the short acyl chain at position 2 are structural features 
      required for biological activity.
FAU - Ténce, M
AU  - Ténce M
FAU - Michel, E
AU  - Michel E
FAU - Coeffier, E
AU  - Coeffier E
FAU - Polonsky, J
AU  - Polonsky J
FAU - Godfroid, J J
AU  - Godfroid JJ
FAU - Benveniste, J
AU  - Benveniste J
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Lysophosphatidylcholines)
RN  - 0 (Phospholipids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - In Vitro Techniques
MH  - Lysophosphatidylcholines/*chemical synthesis/pharmacology
MH  - Phospholipids/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
MH  - Structure-Activity Relationship
EDAT- 1981/12/01 00:00
MHDA- 1981/12/01 00:01
CRDT- 1981/12/01 00:00
PHST- 1981/12/01 00:00 [pubmed]
PHST- 1981/12/01 00:01 [medline]
PHST- 1981/12/01 00:00 [entrez]
AID - 10.1007/BF01978739 [doi]
PST - ppublish
SO  - Agents Actions. 1981 Dec;11(6-7):558-9. doi: 10.1007/BF01978739.

PMID- 1094517
OWN - NLM
STAT- MEDLINE
DCOM- 19750909
LR  - 20190911
IS  - 0300-9130 (Print)
IS  - 0300-9130 (Linking)
VI  - 165
IP  - 1
DP  - 1975
TI  - [The effect of acetyl-salicylic-acid and a pyrido-pyrimidine-derivate on the 
      rejection of allotransplanted canine kidneys (author's transl)].
PG  - 67-73
AB  - The effects of anti-thrombotic drugs-Acetyl-salicylic-acid and 
      2-Piperazinly-4-thiomorpholino-pyrido(3,2-d)-pyrimidin-sulfat-trihydrat-on 
      rejection reactions of renal allografts in dogs have been studied. From the 
      clinical point of view no effectiveness of the two drugs can be found, whereas 
      the histological findings do clearly show diminished rejection reactions in the 
      Acetylsalicylic-acid group.
FAU - Jennes, B
AU  - Jennes B
FAU - Wagner, W
AU  - Wagner W
FAU - Meridies, R
AU  - Meridies R
FAU - Kollias, G
AU  - Kollias G
FAU - Jacobi, E
AU  - Jacobi E
FAU - Huth, F
AU  - Huth F
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Wirkung von Acetylsalicylsäure und einum Pyrido-pyrimidin-Derivat auf die 
      Abstobetaung allotransplantierter Nieren im Tierexperiment.
PL  - Germany
TA  - Res Exp Med (Berl)
JT  - Research in experimental medicine. Zeitschrift fur die gesamte experimentelle 
      Medizin einschliesslich experimenteller Chirurgie
JID - 0324736
RN  - 0 (Pyrimidines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dogs
MH  - Graft Rejection/*drug effects
MH  - Kidney/pathology
MH  - Kidney Cortex/pathology
MH  - *Kidney Transplantation
MH  - Platelet Adhesiveness/drug effects
MH  - Pyrimidines/*pharmacology
MH  - Transplantation, Homologous
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 10.1007/BF01856451 [doi]
PST - ppublish
SO  - Res Exp Med (Berl). 1975;165(1):67-73. doi: 10.1007/BF01856451.

PMID- 20402644
OWN - NLM
STAT- MEDLINE
DCOM- 20110202
LR  - 20190923
IS  - 1875-5402 (Electronic)
IS  - 1386-2073 (Linking)
VI  - 13
IP  - 7
DP  - 2010 Aug
TI  - Electrochemical behavior of triflusal, aspirin and their metabolites at glassy 
      carbon and boron doped diamond electrodes.
PG  - 569-77
AB  - The electrochemical behavior of triflusal (TRF) and aspirin (ASA), before and 
      after hydrolysis in water and in alkaline medium using two different electrode 
      surfaces, glassy carbon and boron doped diamond, was study by differential pulse 
      voltammetry over a wide pH range. The hydrolysis products are 
      2-(hydroxyl)-4-(trifluoromethyl)-benzoic acid (HTB) for triflusal and salicylic 
      acid (SA) for aspirin, which in vivo represent their main metabolites. The 
      hydrolysis processes were also followed by spectrophotometry. The UV results 
      showed complete hydrolysis after one hour for TRF and after two hours for ASA in 
      alkaline solution. The glassy carbon electrode enables only indirect 
      determination of TRF and ASA through the electrochemical detection of their 
      hydrolysis products HTB and SA, respectively. The oxidation processes of HTB and 
      SA are pH dependent and involve different numbers of electrons and protons. 
      Moreover, the difference between the oxidation peak potential of SA and HTB was 
      equal to 100 mV in the studied pH range from 1 to 8 due to the CF3 of the 
      aromatic ring of HTB molecule. Due to its wider oxidation potential range, the 
      boron doped diamond electrode was used to study the direct oxidation of TRF and 
      ASA, as well as of their respective metabolites HTB and SA.
FAU - Enache, Teodor Adrian
AU  - Enache TA
AD  - Departamento de Química, Universidade de Coimbra, Portugal.
FAU - Fatibello-Filho, Orlando
AU  - Fatibello-Filho O
FAU - Oliveira-Brett, Ana Maria
AU  - Oliveira-Brett AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Comb Chem High Throughput Screen
JT  - Combinatorial chemistry & high throughput screening
JID - 9810948
RN  - 0 (Alkalies)
RN  - 0 (Salicylates)
RN  - 059QF0KO0R (Water)
RN  - 1Z0YFI05OO (triflusal)
RN  - 7440-44-0 (Carbon)
RN  - 7782-40-3 (Diamond)
RN  - N9E3X5056Q (Boron)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alkalies/chemistry
MH  - Aspirin/*chemistry/metabolism
MH  - Boron/*chemistry
MH  - Carbon/*chemistry
MH  - Diamond/*chemistry
MH  - Electrochemistry
MH  - Electrodes
MH  - Glass/*chemistry
MH  - High-Throughput Screening Assays/methods
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - Molecular Structure
MH  - Particle Size
MH  - Salicylates/*chemistry/metabolism
MH  - Salicylic Acid/*chemistry/metabolism
MH  - Surface Properties
MH  - Water/chemistry
EDAT- 2010/04/21 06:00
MHDA- 2011/02/03 06:00
CRDT- 2010/04/21 06:00
PHST- 2009/11/08 00:00 [received]
PHST- 2009/12/30 00:00 [accepted]
PHST- 2010/04/21 06:00 [entrez]
PHST- 2010/04/21 06:00 [pubmed]
PHST- 2011/02/03 06:00 [medline]
AID - BSP/CCHTS/E-Pub/00068 [pii]
AID - 10.2174/1386207311004070569 [doi]
PST - ppublish
SO  - Comb Chem High Throughput Screen. 2010 Aug;13(7):569-77. doi: 
      10.2174/1386207311004070569.

PMID- 7007057
OWN - NLM
STAT- MEDLINE
DCOM- 19810421
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 18
IP  - 6
DP  - 1980 Nov
TI  - Assessment of analgesics in dental surgery outpatients.
PG  - 479-82
AB  - The usefulness of the dental outpatient model for evaluating the efficacy of mild 
      analgesics, first described by Cooper and Beaver, is demonstrated in five 
      separate, double-blind, randomised, single-dose, parallel-group studies. Pain 
      intensity and pain relief were recorded at hourly intervals for 3 h following the 
      administration of aspirin 1000 mg and placebo. In all five studies aspirin was 
      significantly more effective than placebo, with relatively small variability of 
      the response between the studies. The method is simple, reliable and sensitive 
      and complements the inpatient studies of postoperative pain hitherto more 
      frequently used.
FAU - von Graffenried, B
AU  - von Graffenried B
FAU - Nüesch, E
AU  - Nüesch E
FAU - Maeglin, B
AU  - Maeglin B
FAU - Hägler, W
AU  - Hägler W
FAU - Kuhn, M
AU  - Kuhn M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Outpatients
MH  - Pain, Postoperative/*drug therapy
MH  - Patient Compliance
MH  - Placebos/*therapeutic use
MH  - Time Factors
MH  - Tooth Extraction
EDAT- 1980/11/01 00:00
MHDA- 1980/11/01 00:01
CRDT- 1980/11/01 00:00
PHST- 1980/11/01 00:00 [pubmed]
PHST- 1980/11/01 00:01 [medline]
PHST- 1980/11/01 00:00 [entrez]
AID - 10.1007/BF00874659 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1980 Nov;18(6):479-82. doi: 10.1007/BF00874659.

PMID- 6679508
OWN - NLM
STAT- MEDLINE
DCOM- 19841101
LR  - 20131121
IS  - 0251-1649 (Print)
IS  - 0251-1649 (Linking)
VI  - 3
IP  - 1
DP  - 1983
TI  - Recovery of acetylsalicylic acid and indalpine (LM 5008) after buccal 
      partitioning.
PG  - 5-7
AB  - The recoveries were compared of acetylsalicylic acid (ASA) and indalpine (1) 
      after buccal absorption in three trained human volunteers. Recovery of the poorly 
      lipid soluble ASA was less than 1% at pH 5 or 8, while that of the lipid soluble 
      I was 19% and 13% at pH 5 and 8 respectively. This difference in recovery may 
      represent a difference in their storage within the buccal mucosa dependent on 
      their different lipid solubilities.
FAU - Blackett, A
AU  - Blackett A
FAU - Brion, N
AU  - Brion N
FAU - Turner, P
AU  - Turner P
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int J Clin Pharmacol Res
JT  - International journal of clinical pharmacology research
JID - 8110183
RN  - 0 (Piperidines)
RN  - R16CO5Y76E (Aspirin)
RN  - V35562QSVT (indalpine)
SB  - IM
MH  - Absorption
MH  - Aspirin/*metabolism
MH  - Cheek
MH  - Chemistry, Pharmaceutical
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Mouth Mucosa/*metabolism
MH  - Piperidines/*metabolism
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Res. 1983;3(1):5-7.

PMID- 31025592
OWN - NLM
STAT- MEDLINE
DCOM- 20200508
LR  - 20210312
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Print)
IS  - 0785-3890 (Linking)
VI  - 51
IP  - 2
DP  - 2019 Mar
TI  - Low-dose aspirin and risk of upper/lower gastrointestinal bleeding by bleed 
      severity: a cohort study with nested case-control analysis using primary care 
      electronic health records from the United Kingdom.
PG  - 182-192
LID - 10.1080/07853890.2019.1591635 [doi]
AB  - Introduction: Risks of low-dose aspirin-associated upper and lower 
      gastrointestinal bleeds (UGIB/LGIB) may vary by severity and presence of 
      cardiovascular disease (CVD). No study has quantified these risks for UGIB and 
      LGIB in the same real-world study population. Patients and methods: Using UK 
      primary care data, 199,049 new users of low-dose aspirin (75-300 mg/day) and 1:1 
      matched non-users were followed to identify incident UGIB (N = 1843)/LGIB 
      (N = 2763) cases. Nested case-control analyses compared current low-dose aspirin 
      vs. non-use on UGIB/LGIB risk. Results: Adjusted incidence rate ratios (ORs; 95% 
      CIs) were 1.62 (1.42-1.86) for non-fatal UGIB, 1.63 (1.47-1.81) for non-fatal 
      LGIB, 0.77 (0.51-1.16) for fatal UGIB, 1.29 (0.50-3.36) for fatal LGIB. For 
      hospitalizations, adjusted ORs (95% CIs) were 1.55 (1.32-1.81) for UGIB and 1.89 
      (1.58-2.27) for LGIB; for referred only cases, they were 1.52 (1.26-1.84) for 
      UGIB and 1.54 (1.37-1.73) for LGIB. In primary CVD prevention, adjusted ORs (95% 
      CI) were 1.62 (1.38-1.90) for UGIB and 1.60 (1.42-1.81) for LGIB; in secondary 
      CVD prevention, they were 1.16 (0.89-1.50) for UGIB and 1.67 (1.34-2.09) for 
      LGIB. Conclusion: Low-dose aspirin was associated with increased risks of 
      non-fatal but not fatal UGIB/LGIB. Key message Low-dose aspirin is associated 
      with an increased risks of non-fatal UGIB/LGIB but not fatal UGIB/LGIB.
FAU - García Rodríguez, Luis A
AU  - García Rodríguez LA
AD  - a Spanish Centre for Pharmacoepidemiologic Research (CEIFE) , Madrid , Spain.
FAU - Lanas, Angel
AU  - Lanas A
AD  - b Servicio de Aparato Digestivo , Hospital Clínico, University of Zaragoza , IIS 
      Aragón , Zaragoza , Spain.
AD  - c CIBERehd , Madrid , Spain.
FAU - Soriano-Gabarró, Montse
AU  - Soriano-Gabarró M
AD  - d Epidemiology, Bayer AG , Berlin , Germany.
FAU - Cea Soriano, Lucía
AU  - Cea Soriano L
AD  - a Spanish Centre for Pharmacoepidemiologic Research (CEIFE) , Madrid , Spain.
AD  - e Department of Public Health and Maternal Child Health, Faculty of Medicine , 
      Complutense University of Madrid , Madrid , Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190426
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Comorbidity
MH  - Electronic Health Records
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/mortality
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Primary Health Care/statistics & numerical data
MH  - Severity of Illness Index
MH  - United Kingdom/epidemiology
PMC - PMC7856917
OTO - NOTNLM
OT  - Upper gastrointestinal bleeding
OT  - aspirin
OT  - lower gastrointestinal bleeding
COIS- LCS and LAGR work for CEIFE, which has received research funding from Bayer AG. 
      LAGR has received honoraria for serving on advisory boards for Bayer AG. AL has 
      previously received a research grant from Bayer AG and has served as an advisory 
      board member for Bayer AG and Bayer HealthCare. MS-G is a full-time employee of 
      Bayer AG.
EDAT- 2019/04/27 06:00
MHDA- 2020/05/10 06:00
CRDT- 2019/04/27 06:00
PHST- 2019/04/27 06:00 [pubmed]
PHST- 2020/05/10 06:00 [medline]
PHST- 2019/04/27 06:00 [entrez]
AID - 1591635 [pii]
AID - 10.1080/07853890.2019.1591635 [doi]
PST - ppublish
SO  - Ann Med. 2019 Mar;51(2):182-192. doi: 10.1080/07853890.2019.1591635. Epub 2019 
      Apr 26.

PMID- 27312830
OWN - NLM
STAT- MEDLINE
DCOM- 20170222
LR  - 20170817
IS  - 2233-6869 (Electronic)
IS  - 1598-9992 (Linking)
VI  - 67
IP  - 6
DP  - 2016 Jun 25
TI  - [Nonsteroidal Anti-inflammatory Drug and Aspirin-induced Peptic Ulcer Disease].
PG  - 300-12
LID - 10.4166/kjg.2016.67.6.300 [doi]
AB  - Despite decreasing Helicobacter pylori prevalence, the prevalence of peptic ulcer 
      disease is increasing in the aged population, mainly due to increasing use of 
      NSAIDs to manage pain and inflammation. In addition, low dose aspirin is employed 
      as an anti-coagulant for those who have suffered or are at high risk of ischemic 
      stroke and cardiovascular disease. However, NSAIDs and aspirin are injurious to 
      mucosa of stomach and duodenum. NSAID-induced inhibition of mucosal prostaglandin 
      synthesis is thought to be a major mechanism of gastrointestinal mucosal injury. 
      The proportion of elderly has increased rapidly in Korea, with the proportion 
      over 65 years old expected to be 24.3% in 2030. In this higher-risk population, 
      the strategy to reduce the incidence of NSAID-related peptic ulcers and 
      complications such as bleeding, obstruction and perforation is very important. 
      Proton pump inhibitors (PPIs) with cyclooxygenase-2 inhibitor can be used for 
      reducing the risk of NSAID-related ulcers and upper gastrointestinal (GI) 
      complications. However, continuous use of PPI has several problems. In addition, 
      NSAID-related problems in the lower GI tract have increased, in contrast to the 
      decrease of NSAID-related upper GI disease. The aim of this review is to provide 
      an evidence-based knowledge regarding the mechanism, complications of treatment, 
      and prevention strategies for NSAID- or aspirin-related peptic ulcer disease in 
      Korea.
FAU - Shim, Young Kwang
AU  - Shim YK
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, Korea.
FAU - Kim, Nayoung
AU  - Kim N
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, Korea.
AD  - Department of Internal Medicine and Liver Research Institute, Seoul National 
      University College of Medicine, Seoul, Korea.
LA  - kor
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - Korean J Gastroenterol
JT  - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JID - 101189416
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Proton Pump Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cell Membrane Permeability
MH  - Cyclooxygenase 1/metabolism
MH  - Guidelines as Topic
MH  - Helicobacter Infections/complications/diagnosis/drug therapy
MH  - Humans
MH  - Peptic Ulcer/*diagnosis/epidemiology/etiology
MH  - Proton Pump Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Non-steroidal anti-inflammatory agents
OT  - Peptic ulcer
EDAT- 2016/06/18 06:00
MHDA- 2017/02/23 06:00
CRDT- 2016/06/18 06:00
PHST- 2016/06/18 06:00 [entrez]
PHST- 2016/06/18 06:00 [pubmed]
PHST- 2017/02/23 06:00 [medline]
AID - 10.4166kjg.2016.67.6.300 [pii]
AID - 10.4166/kjg.2016.67.6.300 [doi]
PST - ppublish
SO  - Korean J Gastroenterol. 2016 Jun 25;67(6):300-12. doi: 10.4166/kjg.2016.67.6.300.

PMID- 9596230
OWN - NLM
STAT- MEDLINE
DCOM- 19980611
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 29
IP  - 5
DP  - 1998 May
TI  - Aspirin use and incident stroke in the cardiovascular health study. CHS 
      Collaborative Research Group.
PG  - 887-94
AB  - BACKGROUND AND PURPOSE: Randomized clinical trials testing aspirin in relatively 
      low-risk, middle-aged people have consistently shown small increases in stroke 
      associated with aspirin use. We analyzed the relationship between the regular use 
      of aspirin and incident ischemic and hemorrhagic stroke among people aged 65 
      years or older participating in the Cardiovascular Health Study. METHODS: We 
      conducted a multivariate analysis of incident stroke rates in a prospectively 
      assessed, observational cohort of 5011 elderly people followed for a mean of 4.2 
      years. RESULTS: Participants had a mean age of 72 years, and 58% were women. 
      Twenty-three percent used aspirin frequently, and 17% used aspirin infrequently 
      at study entry. Frequent aspirin use was associated with an increased rate of 
      ischemic stroke compared with nonusers (relative risk= 1.6; 95% confidence 
      interval [CI], 1.2 to 2.2; P=0.001). After adjustment for other stroke risk 
      factors, women who used aspirin frequently or infrequently at study entry had a 
      1.8-fold (95% CI, 1.2 to 2.8) and 1.6-fold (95% CI, 0.9 to 3.0) increased risk of 
      ischemic stroke, respectively (P<0.01, test for trend), compared with nonusers. 
      In men, aspirin use was not statistically significantly associated with stroke 
      risk. Findings were similar when aspirin use in the years before the incident 
      stroke was used in the modeling. Aspirin use at entry was also associated with a 
      4-fold (95% CI, 1.6 to 10.0) increase in risk of hemorrhagic stroke for both 
      infrequent and frequent users of aspirin (P=0.003). CONCLUSIONS: Aspirin use was 
      associated with increased risks of ischemic stroke in women and hemorrhagic 
      stroke overall in this elderly cohort, after adjustment for other stroke 
      predictors. The possibility exists of confounding by reasons for aspirin use 
      rather than cause and effect. Whether regular aspirin use increases stroke risk 
      for elderly people without cardiovascular disease can only be determined by 
      randomized clinical trials.
FAU - Kronmal, R A
AU  - Kronmal RA
AD  - Department of Biostatistics, University of Washington, Seattle, USA. 
      kronmal@biostat.washington.edu
FAU - Hart, R G
AU  - Hart RG
FAU - Manolio, T A
AU  - Manolio TA
FAU - Talbert, R L
AU  - Talbert RL
FAU - Beauchamp, N J
AU  - Beauchamp NJ
FAU - Newman, A
AU  - Newman A
LA  - eng
GR  - N01-HC-85079/HC/NHLBI NIH HHS/United States
GR  - N01-HC-85080/HC/NHLBI NIH HHS/United States
GR  - N01-HC-85081/HC/NHLBI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 1998 May;29(5):885-6. PMID: 9596229
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Brain Ischemia/chemically induced
MH  - Cardiovascular Diseases/*prevention & control/therapy
MH  - Cerebral Hemorrhage/chemically induced
MH  - Cerebrovascular Disorders/*chemically induced/epidemiology
MH  - Cohort Studies
MH  - Cyclooxygenase Inhibitors/*administration & dosage/adverse effects/therapeutic 
      use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Regression Analysis
MH  - Risk Factors
MH  - Sex Factors
MH  - Time Factors
EDAT- 1998/05/22 00:00
MHDA- 1998/05/22 00:01
CRDT- 1998/05/22 00:00
PHST- 1998/05/22 00:00 [pubmed]
PHST- 1998/05/22 00:01 [medline]
PHST- 1998/05/22 00:00 [entrez]
AID - 10.1161/01.str.29.5.887 [doi]
PST - ppublish
SO  - Stroke. 1998 May;29(5):887-94. doi: 10.1161/01.str.29.5.887.

PMID- 11160773
OWN - NLM
STAT- MEDLINE
DCOM- 20010426
LR  - 20181130
IS  - 0066-4219 (Print)
IS  - 0066-4219 (Linking)
VI  - 52
DP  - 2001
TI  - Novel platelet inhibitors.
PG  - 161-84
AB  - Platelet-inhibitory drugs are of proven benefit to individuals who suffer from 
      atherosclerotic cardiovascular disease. Despite substantial effort to identify 
      more potent platelet-inhibitory agents, aspirin, an irreversible inhibitor of 
      platelet cyclooxygenase activity, remains the standard against which other drugs 
      are judged. Drugs that appear to be at least as efficacious as aspirin in 
      specific clinical settings include the thienopyridines ticlopidine and 
      clopidogrel, specific inhibitors of ADP-stimulated platelet function, and the 
      phosphodiesterase 3 inhibitor cilostazol. Ligand binding to the platelet integrin 
      alphaIIbbeta3 (GPIIb-IIIa), a prerequisite for platelet thrombus formation, has 
      been a prominent target for drug development. Currently, three types of 
      alphaIIbbeta3 antagonists are available: the monoclonal antibody Fab fragment 
      abciximab, cyclic peptides based on the Arg-Gly-Asp (RGD) or related amino acid 
      motifs, and RGD-based peptidomimetics. The efficacy of each type of alphaIIbbeta3 
      antagonist in the setting of acute coronary artery disease has been confirmed in 
      multicenter clinical trials.
FAU - Bennett, J S
AU  - Bennett JS
AD  - Hematology-Oncology Division, Department of Medicine, University of Pennsylvania 
      School of Medicine, Philadelphia, Pennsylvania 19104, USA. 
      bennetts@mail.med.upenn.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Annu Rev Med
JT  - Annual review of medicine
JID - 2985151R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis/*drug therapy
MH  - Aspirin/pharmacology/supply & distribution/therapeutic use
MH  - Blood Platelets/drug effects/physiology
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Adhesiveness/drug effects/physiology
MH  - Platelet Aggregation/drug effects/physiology
MH  - Platelet Aggregation Inhibitors/pharmacology/supply & distribution/*therapeutic 
      use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Ticlopidine/*analogs & derivatives/pharmacology/supply & distribution/therapeutic 
      use
MH  - Treatment Outcome
RF  - 132
EDAT- 2001/02/13 11:00
MHDA- 2001/05/01 10:01
CRDT- 2001/02/13 11:00
PHST- 2001/02/13 11:00 [pubmed]
PHST- 2001/05/01 10:01 [medline]
PHST- 2001/02/13 11:00 [entrez]
AID - 52/1/161 [pii]
AID - 10.1146/annurev.med.52.1.161 [doi]
PST - ppublish
SO  - Annu Rev Med. 2001;52:161-84. doi: 10.1146/annurev.med.52.1.161.

PMID- 23240590
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20131121
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 40
IP  - 2
DP  - 2013 Feb
TI  - Female, but not male, mice show delayed cutaneous wound healing following aspirin 
      administration.
PG  - 90-6
LID - 10.1111/1440-1681.12043 [doi]
AB  - Cyclo-oxygenase (COX) is an enzyme that participates in the wound healing 
      process. Aspirin, a non-steroidal anti-inflammatory drug, simultaneously inhibits 
      the aromatase activity of COX-1 and COX-2 isoforms, which is needed for 
      prostaglandin synthesis. The aim of the present study was to determine whether 
      aspirin, and thus COX inhibition, distinctly affects cutaneous wound healing in 
      female and male mice. Female and male BALB/c mice were treated with aspirin (25 
      mg/kg per day) for 16 days until they were killed. The control group received 
      vehicle (saline) only. A full-thickness excisional lesion was made on the back, 2 
      days after aspirin administration started, and macroscopic, histological and 
      biochemical parameters were evaluated. Sections were stained and immunostained 
      for microscopic analysis. Myeloperoxidase (MPO) activity, hydroxyproline quantity 
      and the protein expression of von Willebrand factor (vWF) and vascular 
      endothelial growth factor (VEGF) were also determined. Female control and 
      aspirin-treated groups exhibited delayed wound closure and re-epithelization 
      compared with the male control and aspirin-treated groups, respectively. The 
      female control group exhibited reduced MPO activity and a decreased number of 
      macrophage inhibitory factor-positive cells compared with the male control group. 
      In the female aspirin-treated group, MPO activity and the number of 
      F4/80-positive macrophages was higher than in the control group. Collagen was 
      reduced only in the female aspirin-treated group. The expression of vWF and VEGF 
      protein was increased in the female aspirin-treated group. In conclusion, aspirin 
      administration impaired the wound healing process in BALB/c female, but not male, 
      mice.
CI  - © 2012 The Authors Clinical and Experimental Pharmacology and Physiology © 2012 
      Wiley Publishing Asia Pty Ltd.
FAU - dos Santos, Jeanine S
AU  - dos Santos JS
AD  - Department of Histology and Embryology, State University of Rio de Janeiro, Rio 
      de Janeiro, Brazil.
FAU - Monte-Alto-Costa, Andréa
AU  - Monte-Alto-Costa A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - *Sex Characteristics
MH  - Skin/*drug effects/*injuries/pathology
MH  - Time Factors
MH  - Wound Healing/*drug effects/physiology
EDAT- 2012/12/18 06:00
MHDA- 2013/10/18 06:00
CRDT- 2012/12/18 06:00
PHST- 2012/07/18 00:00 [received]
PHST- 2012/11/22 00:00 [revised]
PHST- 2012/12/12 00:00 [accepted]
PHST- 2012/12/18 06:00 [entrez]
PHST- 2012/12/18 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - 10.1111/1440-1681.12043 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2013 Feb;40(2):90-6. doi: 10.1111/1440-1681.12043.

PMID- 17498483
OWN - NLM
STAT- MEDLINE
DCOM- 20080414
LR  - 20190922
IS  - 1672-1977 (Print)
IS  - 1672-1977 (Linking)
VI  - 5
IP  - 3
DP  - 2007 May
TI  - [Pathogenesis and prevention tactics of aspirin resistance].
PG  - 259-62
AB  - Aspirin (acetylsalicylic acid) is a nonsteroidal anti-inflammatory drug. Despite 
      its wide uses for more than 100 years, knowledge about mechanism of action and 
      therapeutic issues of aspirin are still under discussion. The use of aspirin has 
      been changed from an analgesic, anti-pyretic and anti-inflammatory agent to an 
      anti-thrombotic agent, especially in secondary prevention of cardiovascular 
      events. Aspirin has reduced the risk of cardiovascular events by 25%. However, 
      the phenomenon of "aspirin resistance" has been described that in 5%-60% of 
      patients aspirin may not achieve adequate efficacy of suppressing platelet 
      activity. The convinced causes of this phenomenon are still unknown. It is 
      probably due to drugs interaction, inadequate dosage and so on. By far the 
      existing studies of aspirin are insufficient to explain all phenomena of aspirin 
      resistance. And the results are not always uniform about the same research. 
      Therefore, the characteristics in different population with aspirin resistance 
      may account for the complexity. It is unrealistic to elucidate all aspirin 
      resistance by only one pathway. More studies are required to investigate the 
      mechanisms in different population respectively. According to the theory of 
      traditional Chinese medicine and the trait of cardiovascular disease, which often 
      relapses and has a long history, aspirin resistance should be considered as 
      collaterals disease. It can be treated with aspirin and traditional Chinese drugs 
      which have the power to strengthen body resistance, reduce phlegm, remove blood 
      stasis and toxic materials from meridians. The problem of aspirin resistance 
      might be solved by this way, because the traditional Chinese medicine has the 
      superiority of selecting appropriate therapeutic methods based on syndrome 
      differentiation for different population and regulating the whole body's 
      function. Subsequently, cardiovascular disease might be effectively prevented.
FAU - Zhang, Ren-gang
AU  - Zhang RG
AD  - Cardiovascular Department, First Affiliated Hospital, Tianjin University of 
      Traditional Chinese Medicine, Tianjin 300193, China.
FAU - Zhang, Jun-ping
AU  - Zhang JP
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhong Xi Yi Jie He Xue Bao
JT  - Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
JID - 101199657
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/drug therapy
MH  - Diagnosis, Differential
MH  - Drug Resistance/*drug effects
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - *Medicine, Chinese Traditional
MH  - Phytotherapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
EDAT- 2007/05/15 09:00
MHDA- 2008/04/15 09:00
CRDT- 2007/05/15 09:00
PHST- 2007/05/15 09:00 [pubmed]
PHST- 2008/04/15 09:00 [medline]
PHST- 2007/05/15 09:00 [entrez]
AID - 167219772007030259 [pii]
AID - 10.3736/jcim20070306 [doi]
PST - ppublish
SO  - Zhong Xi Yi Jie He Xue Bao. 2007 May;5(3):259-62. doi: 10.3736/jcim20070306.

PMID- 29265902
OWN - NLM
STAT- MEDLINE
DCOM- 20181219
LR  - 20191201
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 29
IP  - 8
DP  - 2018 Dec
TI  - Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug.
PG  - 773-778
LID - 10.1080/09537104.2017.1416076 [doi]
AB  - Cancer metastasis is a dynamic process during which cancer cells separate from a 
      primary tumor, migrate through the vessel wall into the bloodstream, and 
      extravasate at distant sites to form secondary colonies. During this process, 
      circulating tumor cells are subjected to shear stress forces from blood flow, and 
      in contact with plasma proteins and blood cells of the immune and hemostatic 
      system, including platelets. Many studies have shown an association between high 
      platelet count and cancer metastasis, suggesting that platelets may play an 
      occult role in tumorigenesis. This mini-review summarizes recent and emerging 
      discoveries of mechanisms by which cancer cells activate platelets and the role 
      of activated platelets in promoting tumor growth and metastasis. Moreover, the 
      review discusses how aspirin has the potential for being clinically used as an 
      adjuvant in cancer therapy.
FAU - Mitrugno, Annachiara
AU  - Mitrugno A
AD  - a Department of Biomedical Engineering , Oregon Health & Science University, 
      Portland, OR, USA.
AD  - b Cell, Developmental & Cancer Biology , Oregon Health & Science University, 
      Portland, OR, USA.
AD  - c Division of Hematology & Medical Oncology , Oregon Health & Science University, 
      Portland, OR, USA.
AD  - e Knight Cancer Institute, School of Medicine , Oregon Health & Science 
      University , Portland , OR , USA.
FAU - Sylman, Joanna L
AU  - Sylman JL
AD  - a Department of Biomedical Engineering , Oregon Health & Science University, 
      Portland, OR, USA.
AD  - f VA Palo Alto Health Care System , Palo Alto , CA , USA.
AD  - g Department of Radiology, Canary Center at Stanford , Stanford University School 
      of Medicine , Stanford , CA , USA.
FAU - Rigg, Rachel A
AU  - Rigg RA
AD  - a Department of Biomedical Engineering , Oregon Health & Science University, 
      Portland, OR, USA.
AD  - b Cell, Developmental & Cancer Biology , Oregon Health & Science University, 
      Portland, OR, USA.
AD  - c Division of Hematology & Medical Oncology , Oregon Health & Science University, 
      Portland, OR, USA.
FAU - Tassi Yunga, Samuel
AU  - Tassi Yunga S
AD  - d Cancer Early Detection & Advanced Research Center , Oregon Health & Science 
      University, Portland, OR, USA.
AD  - e Knight Cancer Institute, School of Medicine , Oregon Health & Science 
      University , Portland , OR , USA.
FAU - Shatzel, Joseph J
AU  - Shatzel JJ
AD  - c Division of Hematology & Medical Oncology , Oregon Health & Science University, 
      Portland, OR, USA.
AD  - e Knight Cancer Institute, School of Medicine , Oregon Health & Science 
      University , Portland , OR , USA.
FAU - Williams, Craig D
AU  - Williams CD
AD  - h School of Pharmacy , Oregon State University , Portland , OR , USA.
FAU - McCarty, Owen J T
AU  - McCarty OJT
AD  - a Department of Biomedical Engineering , Oregon Health & Science University, 
      Portland, OR, USA.
AD  - b Cell, Developmental & Cancer Biology , Oregon Health & Science University, 
      Portland, OR, USA.
AD  - c Division of Hematology & Medical Oncology , Oregon Health & Science University, 
      Portland, OR, USA.
AD  - e Knight Cancer Institute, School of Medicine , Oregon Health & Science 
      University , Portland , OR , USA.
LA  - eng
GR  - R01 GM116184/GM/NIGMS NIH HHS/United States
GR  - R01 HL101972/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20171221
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Neoplasm Metastasis
MH  - *Neoplasms/blood/drug therapy/pathology
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Count
PMC - PMC6185807
MID - NIHMS1507490
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer
OT  - Platelets
COIS- Declaration of interest The authors have no conflicts of interest to declare.
EDAT- 2017/12/22 06:00
MHDA- 2018/12/20 06:00
CRDT- 2017/12/22 06:00
PHST- 2017/12/22 06:00 [pubmed]
PHST- 2018/12/20 06:00 [medline]
PHST- 2017/12/22 06:00 [entrez]
AID - 10.1080/09537104.2017.1416076 [doi]
PST - ppublish
SO  - Platelets. 2018 Dec;29(8):773-778. doi: 10.1080/09537104.2017.1416076. Epub 2017 
      Dec 21.

PMID- 19317290
OWN - NLM
STAT- MEDLINE
DCOM- 20090605
LR  - 20181201
IS  - 0001-5385 (Print)
IS  - 0001-5385 (Linking)
VI  - 64
IP  - 1
DP  - 2009 Feb
TI  - Cost-effectiveness of statins in the primary prevention of cardiovascular 
      disease: a systematic review and economic analysis for Belgium.
PG  - 1-10
AB  - OBJECTIVES: 8% of total drug spending by the Belgian government goes to statins. 
      The aim of this study is to determine the cost-effectiveness of statins for the 
      primary prevention of cardiovascular disease (CVD) in middle-aged Belgian 
      populations. METHODS AND RESULTS: Economic evaluations were identified in a 
      systematic literature search and were critically appraised. Furthermore, because 
      prices decreased drastically, a previously published model was adapted applying 
      recent cost data from the Belgian national health insurance. Eleven full economic 
      evaluations were identified. Nine studies compared statins with no treatment and 
      presented heterogeneous results. If alternative interventions, such as smoking 
      cessation or low-dose aspirin treatment were included in the analysis, statin 
      therapy became less cost-effective. Prescribing the cheapest statin on the 
      Belgian market (< Euro 90 medication cost per year) resulted in an incremental 
      cost of Euro 29,173 per life-year gained (LYG) in a male high-risk group aged 60 
      compared to low-dose aspirin. The incremental cost in a male moderate-risk group 
      aged 50 was Euro 87,022/LYG. Low-dose aspirin was more cost-effective ranging 
      from Euro 3,854/LYG to Euro 29,509/LYG compared to smoking cessation therapy. 
      Smoking cessation therapy was the most cost-effective intervention, providing 
      savings compared to no treatment. CONCLUSIONS: In Belgium, the cost-effectiveness 
      of statins for the primary prevention of CVD is rather elevated in comparison 
      with low-dose aspirin, even if the cheapest statin is prescribed. From an 
      economic point of view, prevention with low-dose aspirin is more cost-effective 
      and may present a first choice in primary prevention. Smoking cessation, which is 
      a dominant strategy, should be encouraged at all times.
FAU - Neyt, Mattias
AU  - Neyt M
AD  - Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium. 
      Mattias.Neyt@kce.fgov.be
FAU - De Laet, Chris
AU  - De Laet C
FAU - Van Brabandt, Hans
AU  - Van Brabandt H
FAU - Franco, Oscar
AU  - Franco O
FAU - Ramaekers, Dirk
AU  - Ramaekers D
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Acta Cardiol
JT  - Acta cardiologica
JID - 0370570
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/economics/therapeutic use
MH  - Belgium
MH  - Cardiovascular Diseases/drug therapy/economics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Health Policy
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/economics/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Models, Economic
MH  - Platelet Aggregation Inhibitors/economics/therapeutic use
MH  - Primary Prevention/*economics/methods
MH  - Risk Assessment
MH  - Smoking Cessation/economics
RF  - 27
EDAT- 2009/03/26 09:00
MHDA- 2009/06/06 09:00
CRDT- 2009/03/26 09:00
PHST- 2009/03/26 09:00 [entrez]
PHST- 2009/03/26 09:00 [pubmed]
PHST- 2009/06/06 09:00 [medline]
AID - 10.2143/AC.64.1.2034354 [doi]
PST - ppublish
SO  - Acta Cardiol. 2009 Feb;64(1):1-10. doi: 10.2143/AC.64.1.2034354.

PMID- 6785949
OWN - NLM
STAT- MEDLINE
DCOM- 19810723
LR  - 20170511
IS  - 0001-5385 (Print)
IS  - 0001-5385 (Linking)
VI  - 35
IP  - 6
DP  - 1980
TI  - Effects of antiplatelet and calcium antagonist drugs on infarct size in rats.
PG  - 419-27
AB  - The authors performed the experimental model of infarct-like myocardial lesions 
      in rats treated with large doses of ISP. Myocardial necrosis was assessed on the 
      basis of serum enzyme changes as well as of gross and microscopic findings. The 
      infarct size was measured by a direct enzymatic method assaying creatine kinase 
      (CK) depletion in infarcted myocardium. Pretreatment of the infarcted rats with 
      antiplatelet (Lysin Acetyl Salicylate) or calcium antagonist drugs (Verapamil or 
      Nifedipine) allowed the reduction of the necrotic area. Since a smaller size of 
      infarct was achieved through different types of interventions it should be 
      suggested that ISP-myocardial damage is due to several effects of the drug 
      involving metabolic, vascular and/or coagulative patterns.
FAU - Genovese, A
AU  - Genovese A
FAU - Chiariello, M
AU  - Chiariello M
FAU - Latte, S
AU  - Latte S
FAU - de Alfieri, W
AU  - de Alfieri W
FAU - Cacciapuoti, A A
AU  - Cacciapuoti AA
FAU - Condorelli, M
AU  - Condorelli M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Cardiol
JT  - Acta cardiologica
JID - 0370570
RN  - CJ0O37KU29 (Verapamil)
RN  - EC 2.7.3.2 (Creatine Kinase)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - K3Z4F929H6 (Lysine)
RN  - L628TT009W (Isoproterenol)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Calcium/*antagonists & inhibitors
MH  - Creatine Kinase/metabolism
MH  - Isoproterenol/pharmacology
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Myocardial Infarction/*pathology
MH  - Nifedipine/pharmacology
MH  - Platelet Aggregation
MH  - Rats
MH  - Verapamil/pharmacology
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Cardiol. 1980;35(6):419-27.

PMID- 19419861
OWN - NLM
STAT- MEDLINE
DCOM- 20090717
LR  - 20131121
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 19
IP  - 11
DP  - 2009 Jun 1
TI  - Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs 
      of aspirin, indomethacin and ibuprofen: synthesis, biological evaluation and 
      nitric oxide release studies.
PG  - 3014-8
LID - 10.1016/j.bmcl.2009.04.059 [doi]
AB  - A new group of hybrid nitric oxide (NO) releasing anti-inflammatory (AI) ester 
      prodrugs (NONO-NSAIDs) wherein a 1,3-dinitrooxy-2-propyl (12a-c), or 
      O(2)-acetoxymethyl-1-[2-(methyl)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (14a-c), 
      NO-donor moiety is directly attached to the carboxylic acid group of aspirin, 
      indomethacin or ibuprofen were synthesized. NO release from the dinitrooxypropyl, 
      or diazen-1-ium-1,2-diolate, ester prodrugs was increased substantially upon 
      incubation in the presence of l-cysteine (12a-c) or rat serum (14a-c). The ester 
      prodrugs (12a-c, 14a-c), which did not inhibit the COX-1 isozyme, exhibited 
      modest inhibitory activity against the COX-2 isozyme. The NONO-NSAIDs 12a-c and 
      14a-c exhibited in vivo AI activity that was similar to that exhibited by the 
      parent drug aspirin, indomethacin or ibuprofen when the same oral dose 
      (micromol/kg) was administered. These similarities in oral potency profiles 
      suggest these NONO-NSAIDs act as classical prodrugs that require metabolic 
      activation by esterase-mediated hydrolysis. Hybrid NO-donor/anti-inflammatory 
      prodrugs of this type (NONO-NSAIDs) offer a potential drug design concept 
      targeted toward the development of anti-inflammatory drugs with reduced adverse 
      gastrointestinal effects.
FAU - Abdellatif, Khaled R A
AU  - Abdellatif KR
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Alta, Canada.
FAU - Chowdhury, Morshed Alam
AU  - Chowdhury MA
FAU - Dong, Ying
AU  - Dong Y
FAU - Das, Dipankar
AU  - Das D
FAU - Yu, Gang
AU  - Yu G
FAU - Velázquez, Carlos A
AU  - Velázquez CA
FAU - Suresh, Mavanur R
AU  - Suresh MR
FAU - Knaus, Edward E
AU  - Knaus EE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090420
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Prodrugs)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemical 
      synthesis/chemistry/pharmacology
MH  - Aspirin/*analogs & derivatives/chemical synthesis/pharmacology
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Drug Design
MH  - Humans
MH  - Ibuprofen/*analogs & derivatives/chemical synthesis/pharmacology
MH  - Indomethacin/*analogs & derivatives/chemical synthesis/pharmacology
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Donors/*chemical synthesis/chemistry/pharmacology
MH  - Prodrugs/*chemical synthesis/chemistry/pharmacology
MH  - Rats
MH  - Sheep
EDAT- 2009/05/08 09:00
MHDA- 2009/07/18 09:00
CRDT- 2009/05/08 09:00
PHST- 2009/03/24 00:00 [received]
PHST- 2009/04/06 00:00 [revised]
PHST- 2009/04/07 00:00 [accepted]
PHST- 2009/05/08 09:00 [entrez]
PHST- 2009/05/08 09:00 [pubmed]
PHST- 2009/07/18 09:00 [medline]
AID - S0960-894X(09)00515-0 [pii]
AID - 10.1016/j.bmcl.2009.04.059 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2009 Jun 1;19(11):3014-8. doi: 10.1016/j.bmcl.2009.04.059. 
      Epub 2009 Apr 20.

PMID- 6617077
OWN - NLM
STAT- MEDLINE
DCOM- 19831123
LR  - 20190511
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 34
IP  - 4
DP  - 1983 Oct
TI  - Availability of salicylate from salsalate and aspirin.
PG  - 539-45
AB  - Salicylate availability from salsalate (SSA) and aspirin (ASA) was examined in 
      six rheumatoid arthritis patients in a multiple-dose double-blind crossover 
      study. Doses contained equimolar amounts of salicylic acid. After initial ASA 
      treatment to achieve therapeutic salicylate levels (150 to 300 micrograms/ml) the 
      patients received equimolar doses of SSA or ASA. When steady state was achieved 
      patients were hospitalized, and blood and urine specimens were obtained during 
      three dosing intervals and during the washout period that followed. Thereafter, 
      patients were placed on the alternate medication for at least a week and the 
      in-hospital pattern was repeated. Despite insignificant differences in absorption 
      of the formulations, as measured by urinary salicylate recovery, the plasma 
      salicylic acid AUC was lower after SSA. Evidence indicates that this apparent 
      lower availability of salicylate from SSA is due to incomplete hydrolysis to 
      salicylic acid, the unhydrolyzed SSA being excreted mainly as glucuronide 
      conjugates.
FAU - Dromgoole, S H
AU  - Dromgoole SH
FAU - Cassell, S
AU  - Cassell S
FAU - Furst, D E
AU  - Furst DE
FAU - Paulus, H E
AU  - Paulus HE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Gentisates)
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - V9MO595C9I (salicylsalicylic acid)
RN  - VP36V95O3T (2,5-dihydroxybenzoic acid)
SB  - IM
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/*metabolism/therapeutic use
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - *Gentisates
MH  - Humans
MH  - Hydroxybenzoates/urine
MH  - Male
MH  - Salicylates/*metabolism/therapeutic use
MH  - Salicylic Acid
EDAT- 1983/10/01 00:00
MHDA- 1983/10/01 00:01
CRDT- 1983/10/01 00:00
PHST- 1983/10/01 00:00 [pubmed]
PHST- 1983/10/01 00:01 [medline]
PHST- 1983/10/01 00:00 [entrez]
AID - 0009-9236(83)90151-0 [pii]
AID - 10.1038/clpt.1983.211 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1983 Oct;34(4):539-45. doi: 10.1038/clpt.1983.211.

PMID- 18325
OWN - NLM
STAT- MEDLINE
DCOM- 19770929
LR  - 20190402
IS  - 0304-4920 (Print)
IS  - 0304-4920 (Linking)
VI  - 22
IP  - 2
DP  - 1976 Dec 31
TI  - Brain monoamines act through the prostaglandin release to influence the body 
      temperature.
PG  - 55-64
AB  - In the present study, the thermal responses induced by intraventicular 
      administration of pyrogen prostaglandin E1, the brain monoamines norepinephrine 
      and serotonin, and the antipyretic sodium acetylsalicylate (aspirin) were 
      measured in conscious rabbits to assess the possible involvement of these 
      substances in fever production. The body temperatures, metabolic rate, 
      respiratory evaporative heat loss and vasomotor activity in response to the 
      administration of these drugs were measured. The results showed that sodium 
      acetylsalicylate, an inhibitor of prostaglandin synthetase, antagonizes the 
      norepinephrine induced fever but not the prostaglandin fever. The data also 
      showed that the serotonin induced hypothermia was reversed by prostaglandin 
      administration. Thus, the fact strongly suggest that the prostaglandin E1 serves 
      as a fever-prducing mediator in the central nervous system. Also, the 
      norepinephrine fever and serotonin hpyothermia, respectively, may be associated 
      with an increase and a decrease in prostaglandin synthesis in the brain.
FAU - Lin, M T
AU  - Lin MT
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - India
TA  - Chin J Physiol
JT  - The Chinese journal of physiology
JID - 7804502
RN  - 0 (Neurotransmitter Agents)
RN  - 0 (Prostaglandins E)
RN  - 333DO1RDJY (Serotonin)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Body Temperature/*drug effects
MH  - Body Temperature Regulation/drug effects
MH  - Injections, Intraventricular
MH  - Male
MH  - Neurotransmitter Agents/administration & dosage/*pharmacology
MH  - Norepinephrine/pharmacology
MH  - Oxygen Consumption/drug effects
MH  - Prostaglandins E/administration & dosage/*pharmacology
MH  - Rabbits
MH  - Serotonin/pharmacology
EDAT- 1976/12/31 00:00
MHDA- 1976/12/31 00:01
CRDT- 1976/12/31 00:00
PHST- 1976/12/31 00:00 [pubmed]
PHST- 1976/12/31 00:01 [medline]
PHST- 1976/12/31 00:00 [entrez]
PST - ppublish
SO  - Chin J Physiol. 1976 Dec 31;22(2):55-64.

PMID- 1441314
OWN - NLM
STAT- MEDLINE
DCOM- 19921217
LR  - 20161018
IS  - 1019-5297 (Print)
IS  - 1019-5297 (Linking)
IP  - 2
DP  - 1992 Feb
TI  - [Acetylsalicylic acid ultraphonophoresis in the treatment of the pain syndrome in 
      patients with lumbar osteochondrosis].
PG  - 102-5
AB  - Data are reported of an experimental-clinical substantiation and therapeutic use 
      of acetylsalicylic acid ultraphonophoresis of pain syndromes of radicular and 
      reflex genesis in 144 patients with lumbar osteochondrosis. Improvement was noted 
      in 57.3% in severe pain, 31.2% in moderate pain, and 75% in mild pain. Aspirin 
      ultraphonophoresis was effective in pain syndrome of radicular genesis in 71% of 
      cases and in 60.5% of reflex genesis.
FAU - Shchekoldin, P I
AU  - Shchekoldin PI
FAU - Oranskiĭ, I E
AU  - Oranskiĭ IE
FAU - Obrazova, R G
AU  - Obrazova RG
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Ul'trafonoforez atsetilsalitsilovoĭ kisloty v lechenii bolevogo sindroma u 
      bol'nykh poiasnichnym osteokhondrozom.
PL  - Ukraine
TA  - Lik Sprava
JT  - Likars'ka sprava
JID - 9601540
RN  - 0 (Solutions)
RN  - R16CO5Y76E (Aspirin)
RN  - YOW8V9698H (Dimethyl Sulfoxide)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Dimethyl Sulfoxide
MH  - Drug Evaluation
MH  - Drug Evaluation, Preclinical
MH  - Drug Stability
MH  - Female
MH  - Humans
MH  - *Lumbar Vertebrae
MH  - Male
MH  - Middle Aged
MH  - Osteochondritis/complications/*drug therapy
MH  - Pain/*drug therapy/etiology
MH  - *Phonophoresis
MH  - Skin Absorption/drug effects
MH  - Solutions
MH  - Spondylitis/complications/*drug therapy
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
PST - ppublish
SO  - Lik Sprava. 1992 Feb;(2):102-5.

PMID- 3355566
OWN - NLM
STAT- MEDLINE
DCOM- 19880511
LR  - 20190612
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 151
IP  - 3
DP  - 1988 Mar 30
TI  - Aspirin prevents the nonenzymatic glycosylation and carbamylation of the human 
      eye lens crystallins in vitro.
PG  - 991-6
AB  - When the human eye lens homogenate which was incubated with [14C]-acetylsalicylic 
      acid (aspirin) and separated into alpha-, beta-, and gamma - crystallins by 
      Sepharose 6B gel-filtration, the radiolabel was found in all the three 
      crystallins. The significant decreases in the free zeta-amino groups of aspirin 
      treated crystallins as compared to the untreated ones indicate the probable sites 
      of acetylation in the crystallins. The inhibition of the binding of [14C]-glucose 
      and [14C]-cyanate to the aspirin pre-treated crystallins suggests that prior 
      acetylation with aspirin prevents the occurrence of the nonenzymatic 
      glycosylation and carbamylation of the lens crystallins in vitro.
FAU - Rao, G N
AU  - Rao GN
AD  - Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA 
      30322.
FAU - Cotlier, E
AU  - Cotlier E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Crystallins)
RN  - 0 (Cyanates)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/*pharmacology
MH  - Chromatography, Gel
MH  - Crystallins/*metabolism
MH  - Cyanates/metabolism
MH  - Glucose/metabolism
MH  - Glycosylation
MH  - Humans
MH  - Lens, Crystalline/drug effects/*metabolism
EDAT- 1988/03/30 00:00
MHDA- 1988/03/30 00:01
CRDT- 1988/03/30 00:00
PHST- 1988/03/30 00:00 [pubmed]
PHST- 1988/03/30 00:01 [medline]
PHST- 1988/03/30 00:00 [entrez]
AID - S0006-291X(88)80463-7 [pii]
AID - 10.1016/s0006-291x(88)80463-7 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1988 Mar 30;151(3):991-6. doi: 
      10.1016/s0006-291x(88)80463-7.

PMID- 24055635
OWN - NLM
STAT- MEDLINE
DCOM- 20131212
LR  - 20161125
IS  - 1096-0384 (Electronic)
IS  - 0003-9861 (Linking)
VI  - 539
IP  - 1
DP  - 2013 Nov 1
TI  - Acetylsalicylic acid (aspirin) and salicylic acid interaction with the human 
      erythrocyte membrane bilayer induce in vitro changes in the morphology of 
      erythrocytes.
PG  - 9-19
LID - S0003-9861(13)00282-8 [pii]
LID - 10.1016/j.abb.2013.09.006 [doi]
AB  - Despite the well-documented information, there are insufficient reports 
      concerning the effects of salicylate compounds on the structure and functions of 
      cell membranes, particularly those of human erythrocytes. With the aim to better 
      understand the molecular mechanisms of the interaction of acetylsalicylic acid 
      (ASA) and salicylic acid (SA) with cell membranes, human erythrocyte membranes 
      and molecular models were utilized. These consisted of bilayers of 
      dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylethanolamine 
      (DMPE), representative of phospholipid classes located in the outer and inner 
      monolayers of the human erythrocyte membrane, respectively. The capacity of ASA 
      and SA to perturb the multibilayer structures of DMPC and DMPE was evaluated by 
      X-ray diffraction while DMPC unilamellar vesicles (LUV) were studied by 
      fluorescence spectroscopy. Moreover, we took advantage of the capability of 
      differential scanning calorimetry (DSC) to detect the changes in the thermotropic 
      phase behavior of lipid bilayers resulting from ASA and SA interaction with PC 
      and PE molecules. In an attempt to further elucidate their effects on cell 
      membranes, the present work also examined their influence on the morphology of 
      intact human erythrocytes by means of defocusing and scanning electron 
      microscopy, while isolated unsealed human erythrocyte membranes (IUM) were 
      studied by fluorescence spectroscopy. Results indicated that both salicylates 
      interact with human erythrocytes and their molecular models in a 
      concentration-dependent manner perturbing their bilayer structures.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Suwalsky, Mario
AU  - Suwalsky M
AD  - Faculty of Chemical Sciences, University of Concepción, Concepción, Chile. 
      Electronic address: msuwalsk@udec.cl.
FAU - Belmar, Jessica
AU  - Belmar J
FAU - Villena, Fernando
AU  - Villena F
FAU - Gallardo, María José
AU  - Gallardo MJ
FAU - Jemiola-Rzeminska, Malgorzata
AU  - Jemiola-Rzeminska M
FAU - Strzalka, Kazimierz
AU  - Strzalka K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130918
PL  - United States
TA  - Arch Biochem Biophys
JT  - Archives of biochemistry and biophysics
JID - 0372430
RN  - 0 (Lipid Bilayers)
RN  - 0 (Phosphatidylethanolamines)
RN  - 0 (Unilamellar Liposomes)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - U86ZGC74V5 (Dimyristoylphosphatidylcholine)
RN  - Z37OX1ASNK (1,2-dimyristoylphosphatidylethanolamine)
SB  - IM
MH  - Aspirin/*metabolism/*pharmacology
MH  - Cell Shape/drug effects
MH  - Dimyristoylphosphatidylcholine/metabolism
MH  - Erythrocyte Membrane/*drug effects/*metabolism
MH  - Humans
MH  - Lipid Bilayers/*metabolism
MH  - Phosphatidylethanolamines/metabolism
MH  - Salicylic Acid/*metabolism/*pharmacology
MH  - Unilamellar Liposomes/metabolism
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Aspirin
OT  - Erythrocyte membrane
OT  - Phospholipid bilayer
OT  - Salicylic acid
EDAT- 2013/09/24 06:00
MHDA- 2013/12/18 06:00
CRDT- 2013/09/24 06:00
PHST- 2013/08/07 00:00 [received]
PHST- 2013/09/06 00:00 [revised]
PHST- 2013/09/10 00:00 [accepted]
PHST- 2013/09/24 06:00 [entrez]
PHST- 2013/09/24 06:00 [pubmed]
PHST- 2013/12/18 06:00 [medline]
AID - S0003-9861(13)00282-8 [pii]
AID - 10.1016/j.abb.2013.09.006 [doi]
PST - ppublish
SO  - Arch Biochem Biophys. 2013 Nov 1;539(1):9-19. doi: 10.1016/j.abb.2013.09.006. 
      Epub 2013 Sep 18.

PMID- 23827403
OWN - NLM
STAT- MEDLINE
DCOM- 20131203
LR  - 20181202
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 112
IP  - 8
DP  - 2013 Oct 15
TI  - Meta-analysis of cilostazol versus aspirin for the secondary prevention of 
      stroke.
PG  - 1230-4
LID - S0002-9149(13)01292-7 [pii]
LID - 10.1016/j.amjcard.2013.05.067 [doi]
AB  - Aspirin is the most widely prescribed antiplatelet agent for the secondary 
      prevention of stroke. Cilostazol, an antiplatelet and vasodilating agent, has 
      shown promise for the secondary prevention of stroke. A systematic review and 
      meta-analysis of randomized controlled trials using Ovid MEDLINE, PubMed, and 
      Excerpta Medica (EMBASE) was searched up to October 2012. Four trials, in 3,917 
      patients, comparing cilostazol with aspirin were identified. Compared with 
      aspirin, cilostazol was associated with a 73% reduction in hemorrhagic stroke 
      (relative risk [RR] 0.27, 95% confidence interval [CI] 0.13 to 0.54, p = 0.0002), 
      28% reduction in the composite end point of stroke, myocardial infarction, or 
      vascular death (RR 0.72, 95% CI 0.57 to 0.89, p = 0.003), and 48% reduction in 
      total hemorrhagic events (RR 0.52, 95% CI 0.34 to 0.79, p = 0.002), with trend 
      for lesser gastrointestinal bleeds (RR 0.60, 95% CI 0.34 to 1.06, p = 0.08). In 
      conclusion, compared with aspirin, cilostazol is associated with significantly 
      less hemorrhagic stroke, the combined end point of stroke, myocardial infarction, 
      and vascular death, and total hemorrhagic events, with numerically fewer 
      gastrointestinal bleeds when used for the secondary prevention of stroke.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Dinicolantonio, James J
AU  - Dinicolantonio JJ
AD  - Wegmans Pharmacy, Ithaca, New York. Electronic address: jjdinicol@gmail.com.
FAU - Lavie, Carl J
AU  - Lavie CJ
FAU - Fares, Hassan
AU  - Fares H
FAU - Menezes, Arthur R
AU  - Menezes AR
FAU - O'Keefe, James H
AU  - O'Keefe JH
FAU - Bangalore, Sripal
AU  - Bangalore S
FAU - Messerli, Franz H
AU  - Messerli FH
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20130702
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - 0 (Vasodilator Agents)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cilostazol
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Secondary Prevention
MH  - Stroke/*prevention & control
MH  - Tetrazoles/*therapeutic use
MH  - Vasodilator Agents/therapeutic use
EDAT- 2013/07/06 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/07/06 06:00
PHST- 2013/04/17 00:00 [received]
PHST- 2013/05/17 00:00 [revised]
PHST- 2013/05/17 00:00 [accepted]
PHST- 2013/07/06 06:00 [entrez]
PHST- 2013/07/06 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - S0002-9149(13)01292-7 [pii]
AID - 10.1016/j.amjcard.2013.05.067 [doi]
PST - ppublish
SO  - Am J Cardiol. 2013 Oct 15;112(8):1230-4. doi: 10.1016/j.amjcard.2013.05.067. Epub 
      2013 Jul 2.

PMID- 2337034
OWN - NLM
STAT- MEDLINE
DCOM- 19900613
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 65
IP  - 18
DP  - 1990 May 15
TI  - Pericardial effusion after cardiac surgery in children and effects of aspirin for 
      prevention.
PG  - 1238-41
AB  - Seventy-four children aged 0.3 to 21.4 years (median 4.0) were followed 
      echocardiographically on days 4, 7, 14 and 28 (+/- 2 days) after cardiac surgery 
      to evaluate the incidence of postoperative pericardial effusion, to identify the 
      patients at greatest risk of developing an effusion and to evaluate the use of 
      aspirin as prophylaxis against pericardial effusion. Pericardial effusion was 
      graded relative to the size of the aortic root from grade 0 (no effusion) to 
      grade 5 (larger than the aortic root dimension). Patients were randomly divided 
      into 2 groups: group 1 (32 patients) received aspirin 60 mg/kg/day for 7 days 
      starting on the third postoperative day; group 2 (42 patients) received no 
      aspirin. Forty-eight patients (65%) developed an effusion during the study 
      period, 3 required pericardiocentesis and 1 died of tamponade. All patients with 
      tamponade had a grade 4 effusion. Age or type of operation did not alter the 
      cumulative incidence of significant effusion. No patient with a grade 0 effusion 
      on the first echocardiogram developed a grade 4 or 5 effusion. Results in groups 
      1 and 2 were similar. Pericardial effusions are common in the first month after 
      cardiac surgery. Patients with no effusion in the immediate postoperative period 
      appear to be at lesser risk of developing a grade 4 effusion in the first month 
      after operation. Finally, aspirin prophylaxis against postoperative pericardial 
      effusions did not significantly alter the outcome in this small series of 
      patients.
FAU - Béland, M J
AU  - Béland MJ
AD  - Department of Pediatrics, Montreal Children's Hospital, McGill University, 
      Quebec, Canada.
FAU - Paquet, M
AU  - Paquet M
FAU - Gibbons, J E
AU  - Gibbons JE
FAU - Tchervenkov, C I
AU  - Tchervenkov CI
FAU - Dobell, A R
AU  - Dobell AR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cardiac Surgical Procedures/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Echocardiography
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Pericardial Effusion/diagnosis/etiology/*prevention & control
EDAT- 1990/05/15 00:00
MHDA- 1990/05/15 00:01
CRDT- 1990/05/15 00:00
PHST- 1990/05/15 00:00 [pubmed]
PHST- 1990/05/15 00:01 [medline]
PHST- 1990/05/15 00:00 [entrez]
AID - 0002-9149(90)90980-F [pii]
AID - 10.1016/0002-9149(90)90980-f [doi]
PST - ppublish
SO  - Am J Cardiol. 1990 May 15;65(18):1238-41. doi: 10.1016/0002-9149(90)90980-f.

PMID- 34347244
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20211102
IS  - 1865-7265 (Electronic)
IS  - 1865-7265 (Linking)
VI  - 14
IP  - 6
DP  - 2021 Dec
TI  - Esophageal achalasia with mucosal damage due to enteric-coated aspirin.
PG  - 1598-1601
LID - 10.1007/s12328-021-01494-4 [doi]
AB  - A 76-year-old man was referred to our hospital for examination and treatment of 
      dysphagia. He has been taking enteric-coated aspirin for myocardial infarction. 
      Esophagogastroduodenoscopy (EGD) revealed the presence of esophageal ulcers in 
      the distal esophagus and five to six tablets of enteric-coated aspirin. The 
      esophageal ulcers were believed to have been caused by the retention of aspirin 
      within the esophagus due to achalasia. We substituted enteric-coated aspirin with 
      powdered aspirin. A follow-up EGD performed 1 month later showed improvement of 
      esophageal mucosa. The patient was diagnosed with type I achalasia. Per-oral 
      endoscopic myotomy was performed, and his symptoms improved after the procedure. 
      Although a few studies have investigated the direct effect of aspirin, none of 
      them has reported on the direct effect of aspirin on the esophagus. It might be 
      effective to administer powdered aspirin for patients with achalasia to prevent 
      esophageal ulcers caused by the direct effect of aspirin.
CI  - © 2021. Japanese Society of Gastroenterology.
FAU - Tatsuta, Tetsuya
AU  - Tatsuta T
AD  - Department of Gastroenterology and Hematology, Hirosaki University Graduate 
      School of Medicine, Aomori, Japan.
FAU - Chinda, Daisuke
AU  - Chinda D
AUID- ORCID: 0000-0003-1690-5923
AD  - Division of Endoscopy, Hirosaki University Hospital, 5-Zaifu-cho, Hirosaki, 
      Aomori, 036-8562, Japan. chinda@hirosaki-u.ac.jp.
FAU - Mikami, Tatsuya
AU  - Mikami T
AD  - Department of Innovation Center for Health Promotion, Hirosaki University 
      Graduate School of Medicine, Aomori, Japan.
FAU - Suto, Shinya
AU  - Suto S
AD  - Department of Gastroenterology and Hematology, Hirosaki University Graduate 
      School of Medicine, Aomori, Japan.
FAU - Akitaya, Kazuki
AU  - Akitaya K
AD  - Department of Gastroenterology and Hematology, Hirosaki University Graduate 
      School of Medicine, Aomori, Japan.
FAU - Igarashi, Shohei
AU  - Igarashi S
AD  - Department of Gastroenterology and Hematology, Hirosaki University Graduate 
      School of Medicine, Aomori, Japan.
FAU - Hasui, Keisuke
AU  - Hasui K
AD  - Department of Gastroenterology and Hematology, Hirosaki University Graduate 
      School of Medicine, Aomori, Japan.
FAU - Kikuchi, Hidezumi
AU  - Kikuchi H
AD  - Department of Gastroenterology and Hematology, Hirosaki University Graduate 
      School of Medicine, Aomori, Japan.
FAU - Hiraga, Hiroto
AU  - Hiraga H
AD  - Department of Gastroenterology and Hematology, Hirosaki University Graduate 
      School of Medicine, Aomori, Japan.
FAU - Sawaya, Manabu
AU  - Sawaya M
AD  - Department of Gastroenterology and Hematology, Hirosaki National Hospital, 
      Aomori, Japan.
FAU - Sakuraba, Hirotake
AU  - Sakuraba H
AD  - Department of Gastroenterology and Hematology, Hirosaki University Graduate 
      School of Medicine, Aomori, Japan.
FAU - Shimoyama, Tadashi
AU  - Shimoyama T
AD  - Aomori General Health Examination Center, Aomori, Japan.
FAU - Fukuda, Shinsaku
AU  - Fukuda S
AD  - Department of Gastroenterology and Hematology, Hirosaki University Graduate 
      School of Medicine, Aomori, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20210804
PL  - Japan
TA  - Clin J Gastroenterol
JT  - Clinical journal of gastroenterology
JID - 101477246
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects
MH  - *Deglutition Disorders
MH  - Endoscopy, Digestive System
MH  - *Esophageal Achalasia/chemically induced/surgery
MH  - Humans
MH  - Male
OTO - NOTNLM
OT  - Enteric-coated aspirin
OT  - Esophageal achalasia
OT  - Esophageal ulcer
OT  - Per-oral endoscopic myotomy
EDAT- 2021/08/05 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/08/04 12:35
PHST- 2021/06/22 00:00 [received]
PHST- 2021/07/30 00:00 [accepted]
PHST- 2021/08/05 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/08/04 12:35 [entrez]
AID - 10.1007/s12328-021-01494-4 [pii]
AID - 10.1007/s12328-021-01494-4 [doi]
PST - ppublish
SO  - Clin J Gastroenterol. 2021 Dec;14(6):1598-1601. doi: 10.1007/s12328-021-01494-4. 
      Epub 2021 Aug 4.

PMID- 34992227
OWN - NLM
STAT- MEDLINE
DCOM- 20220216
LR  - 20220216
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Jan 6
TI  - Management of validation of HPLC method for determination of acetylsalicylic acid 
      impurities in a new pharmaceutical product.
PG  - 1
LID - 10.1038/s41598-021-99269-x [doi]
LID - 1
AB  - The work mainly focused on a validation of the method for determining the content 
      of salicylic acid and individual unknown impurities in new pharmaceutical 
      product-tablets containing: 75, 100 or 150 mg of acetylsalicylic acid and glycine 
      in the amount of 40 mg for each dosage. The separation of the components was 
      carried out by means of HPLC, using a Waters Symmetry C18 column (4.6 × 250 mm, 
      5 μm) as the stationary phase. The mobile phase consisted of a mixture of 85% 
      orthophosphoric acid, acetonitrile and purified water (2:400:600 V/V/V). 
      Detection was carried out at a wavelength of 237 nm, with a constant flow rate of 
      1.0 ml min(-1). In order to verify the method, linearity, precision 
      (repeatability and reproducibility), accuracy, specificity, range, robustness, 
      system precision, stability of the test and standard solution, limit of 
      quantification and forced degradation were determined. Validation tests were 
      performed in accordance with ICH (International Conference on Harmonisation of 
      Technical Requirements for Registration of Pharmaceuticals for Human Use) 
      guidelines. The method was validated successfully. It was confirmed that the 
      method in a tested range of 0.005-0.40% salicylic acid with respect to 
      acetylsalicylic acid content is linear, precise and accurate.
CI  - © 2022. The Author(s).
FAU - Kowalska, Małgorzata
AU  - Kowalska M
AD  - Department of Management and Product Quality, Faculty of Chemical Engineering and 
      Commodity Science, Kazimierz Pulaski University of Technology and Humanities, 27 
      Chrobrego St, 26-600, Radom, Poland. mkowalska7@vp.pl.
FAU - Woźniak, Magdalena
AU  - Woźniak M
AD  - Department of Management and Product Quality, Faculty of Chemical Engineering and 
      Commodity Science, Kazimierz Pulaski University of Technology and Humanities, 27 
      Chrobrego St, 26-600, Radom, Poland.
AD  - Medicofarma S.A., 13 Tarnobrzeska St, 26-613, Radom, Poland.
FAU - Kijek, Michał
AU  - Kijek M
AD  - Medicofarma S.A., 13 Tarnobrzeska St, 26-613, Radom, Poland.
FAU - Mitrosz, Paulina
AU  - Mitrosz P
AD  - Department of Management and Product Quality, Faculty of Chemical Engineering and 
      Commodity Science, Kazimierz Pulaski University of Technology and Humanities, 27 
      Chrobrego St, 26-600, Radom, Poland.
FAU - Szakiel, Jerzy
AU  - Szakiel J
AD  - Department of Non-Food Product Quality and Safety, Cracow University of 
      Economics, Rakowicka St. 27, 31-510, Cracow, Poland.
FAU - Turek, Paweł
AU  - Turek P
AD  - Department of Non-Food Product Quality and Safety, Cracow University of 
      Economics, Rakowicka St. 27, 31-510, Cracow, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220106
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - *Drug Contamination
MH  - Glycine
MH  - Limit of Detection
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Tablets
PMC - PMC8738756
COIS- The authors declare no competing interests.
EDAT- 2022/01/08 06:00
MHDA- 2022/02/17 06:00
CRDT- 2022/01/07 06:15
PHST- 2021/07/06 00:00 [received]
PHST- 2021/09/08 00:00 [accepted]
PHST- 2022/01/07 06:15 [entrez]
PHST- 2022/01/08 06:00 [pubmed]
PHST- 2022/02/17 06:00 [medline]
AID - 10.1038/s41598-021-99269-x [pii]
AID - 99269 [pii]
AID - 10.1038/s41598-021-99269-x [doi]
PST - epublish
SO  - Sci Rep. 2022 Jan 6;12(1):1. doi: 10.1038/s41598-021-99269-x.

PMID- 3705620
OWN - NLM
STAT- MEDLINE
DCOM- 19860528
LR  - 20131121
IS  - 0049-8254 (Print)
IS  - 0049-8254 (Linking)
VI  - 16
IP  - 3
DP  - 1986 Mar
TI  - The metabolism of aspirin in man: a population study.
PG  - 239-49
AB  - The metabolism of a 900 mg oral dose of aspirin has been investigated in 129 
      healthy volunteers. For this purpose, the 0-12 h urine was collected and analysed 
      for the following excretion products: salicylic acid, its acyl and phenolic 
      glucuronides, salicyluric acid, its phenolic glucuronide and gentisic acid. The 
      total excretion of salicylate and metabolites was normally distributed within the 
      population group studied, showing a 2.5-fold variation: a mean of 68.1% of the 
      dose was recovered in 12 h. The excretion of salicylic acid was found to be 
      highly variable within the study panel (1.3-31% of dose in 12 h), and was related 
      to both urine volume and pH. Salicyluric acid was the major metabolite in the 
      majority of the volunteers and its excretion was normally distributed amongst the 
      study panel. The elimination of this metabolite ranged from 19.8 to 65% of the 
      dose and was related to the total recovery of salicylate. The excretion of the 
      two salicyl glucuronides was highly variable, ranging from 0.8 to 42% of the 
      dose. The elimination of the glucuronides was inversely related to that of 
      salicyluric acid. Gentisic acid and salicyluric acid phenolic glucuronide were 
      minor metabolites of salicylate, accounting for 1 and 3% of the dose, 
      respectively. The recovery of gentisic acid was statistically significantly 
      greater in female subjects than in males, whilst the opposite was found for 
      salicyluric acid and total salicylate. However, these differences were small in 
      magnitude.
FAU - Hutt, A J
AU  - Hutt AJ
FAU - Caldwell, J
AU  - Caldwell J
FAU - Smith, R L
AU  - Smith RL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Xenobiotica
JT  - Xenobiotica; the fate of foreign compounds in biological systems
JID - 1306665
RN  - 0 (Glucuronates)
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Adult
MH  - Aspirin/*metabolism/urine
MH  - Biotransformation
MH  - Female
MH  - Glucuronates/metabolism
MH  - Glycine/metabolism
MH  - Hippurates/urine
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Salicylates/urine
MH  - Salicylic Acid
MH  - Sex Factors
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
AID - 10.3109/00498258609043527 [doi]
PST - ppublish
SO  - Xenobiotica. 1986 Mar;16(3):239-49. doi: 10.3109/00498258609043527.

PMID- 11280681
OWN - NLM
STAT- MEDLINE
DCOM- 20010802
LR  - 20191104
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 29
IP  - 1
DP  - 2001 Jan
TI  - Vasoconstrictive response of rat mesenteric arterioles following infusion of 
      cross-linked, polymerized, and conjugated hemoglobin solutions.
PG  - 19-30
AB  - Infusion of hemoglobin-based oxygen-carrying solutions (HBOCs) produce an 
      immediate rise in blood pressure with most solutions, both in animals and humans, 
      as a result of systemic and pulmonary vasoconstriction. Autoregulation of the O2 
      supply by the microvasculature has been proposed as a phenomenon involved in the 
      vasoconstriction elicited by HBOCs. Nevertheless, little is known about the 
      ability of various HBOCs to induce constriction in the microcirculation according 
      to their specific physicochemical properties (viscosity, molecular weight, P50, 
      etc.). This study was therefore designed to assess the effects of three HBOCs, 
      that is, bis(3.5-dibromosalicyl) fumarate-crosslinked hemoglobin (alphaalpha-Hb), 
      dextran-benzene-tetracarboxylate-conjugated hemoglobin (Hb-Dex-BTC) and 
      o-raffinose-oligomerized hemoglobin (o-raffinose-Hb), on the vascular tone of rat 
      mesenteric arterioles (diameter, 15-25 microm) viewed microscopically in moderate 
      hemodilution conditions. The effects of HBOCs were compared to those elicited by 
      a reference solution of hydroxyethyl starch (HES-200) infused in the same 
      conditions. In each experimental group, a fall in arteriolar diameter was 
      observed 2 min and 5 min after infusion of the solution. The maximum changes were 
      observed in Hb-Dex-BTC and o-raffinose-Hb groups, in which diameter decreased 
      from 6.9 +/- 0.5% and 5.2 +/- 0.7%, respectively, 2 min after infusion. The 
      changes in arteriolar diameter induced by Hb-Dex-BTC and o-raffinose-Hb were 
      significantly higher than those elicited by HES-200 and alphaalpha-Hb. In 
      conclusion, our data indicate that moderate hemodilution with HBOCs induces 
      instantaneous constriction in rat mesenteric arterioles, with amplitudes 
      depending on both pharmacological and physicochemical properties of the 
      hemoglobin solution infused.
FAU - Caron, A
AU  - Caron A
AD  - Department of Hematology and Physiology, Faculty of Pharmacy, University Henri 
      Poincaré-Nancy 1, France.
FAU - Malfatti, E
AU  - Malfatti E
FAU - Aguejouf, O
AU  - Aguejouf O
FAU - Faivre-Fiorina, B
AU  - Faivre-Fiorina B
FAU - Menu, P
AU  - Menu P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Dextrans)
RN  - 0 (Hemoglobins)
RN  - 0 (O-raffinose cross-linked human hemoglobin)
RN  - 0 (hemoglobin XL99alpha)
RN  - 0 (hemoglobin-dextran 10-benzene-tetracarboxylate)
RN  - N5O3QU595M (Raffinose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arterioles/drug effects/physiology
MH  - Aspirin/administration & dosage/analogs & derivatives/pharmacology
MH  - Blood Substitutes/administration & dosage/*pharmacology
MH  - Dextrans/administration & dosage/pharmacology
MH  - Hemoglobins/administration & dosage/pharmacology
MH  - Humans
MH  - Infusions, Intra-Arterial
MH  - Male
MH  - Mesentery/*blood supply
MH  - Raffinose/administration & dosage/analogs & derivatives/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Vasoconstriction/*drug effects
EDAT- 2001/03/31 10:00
MHDA- 2001/08/03 10:01
CRDT- 2001/03/31 10:00
PHST- 2001/03/31 10:00 [pubmed]
PHST- 2001/08/03 10:01 [medline]
PHST- 2001/03/31 10:00 [entrez]
AID - 10.1081/bio-100001253 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 2001 Jan;29(1):19-30. doi: 
      10.1081/bio-100001253.

PMID- 9351604
OWN - NLM
STAT- MEDLINE
DCOM- 19971118
LR  - 20181201
IS  - 1073-449X (Print)
IS  - 1073-449X (Linking)
VI  - 156
IP  - 4 Pt 1
DP  - 1997 Oct
TI  - Diaspirin crosslinked hemoglobin improves systemic oxygen uptake in oxygen 
      supply-dependent septic rats.
PG  - 1066-72
AB  - Diaspirin crosslinked hemoglobin (DCLHb) is a cell-free hemoglobin derived from 
      human erythrocytes. DCLHb has been shown to improve blood flow to vital organs in 
      healthy and septic animals. In this study, we determined the efficacy of DCLHb by 
      comparing its effect on systemic O2 uptake to freshly stored and aged red blood 
      cells (RBCs) in septic rats. Twenty-four hours after induction of sepsis by cecal 
      ligation and perforation, O2 supply dependency was created by isovolemic 
      hemodilution with rat plasma. In O2 supply dependency, rats were randomized to 
      receive an exchange transfusion of 7.5 ml "fresh" RBCs (stored < 6 d; Hct: 70%), 
      "fresh" diluted RBCs (stored < 6 d; Hct: 30%), "old" RBCs (stored 28 to 35 d; 
      Hct: 70%), or DCLHb (Hb: 100 g/L). We found, that survival following O2 supply 
      dependency and transfusion with old RBCs was poor (33% versus 91.7% in the other 
      groups; p < 0.01), precluding further analysis of post-transfusion data from this 
      group. Systemic O2 uptake increased in all remaining groups (p < 0.001), while 
      systemic O2 delivery increased with "fresh" RBCs (p < 0.0001) and "fresh" diluted 
      RBCs (p < 0.05) but not with DCLHb. Systemic O2 extraction increased with DCLHb 
      as compared to baseline (p < 0.05) and to the other groups (p < 0.0001). Improved 
      tissue oxygenation was associated with an increase in blood pressure and a fall 
      in arterial lactate in all groups. We conclude that transfusion of DCLHb or 
      "fresh" RBCs was efficacious at increasing systemic O2 uptake in O2 
      supply-dependent, septic rats.
FAU - Sielenkämper, A W
AU  - Sielenkämper AW
AD  - A.C. Burton Vascular Biology Laboratory, Victoria Hospital Research Institute and 
      University of Western Ontario, London, Canada.
FAU - Chin-Yee, I H
AU  - Chin-Yee IH
FAU - Martin, C M
AU  - Martin CM
FAU - Sibbald, W J
AU  - Sibbald WJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 33X04XA5AT (Lactic Acid)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Blood Gas Analysis
MH  - Blood Substitutes/*pharmacology/therapeutic use
MH  - Erythrocyte Transfusion
MH  - Erythrocytes/drug effects/*physiology
MH  - Hemodilution
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/drug effects/metabolism/*pharmacology/therapeutic use
MH  - Humans
MH  - Lactic Acid/blood
MH  - Male
MH  - Oxygen Consumption/drug effects/*physiology
MH  - Random Allocation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sepsis/blood/physiopathology/*therapy
EDAT- 1997/11/14 00:00
MHDA- 1997/11/14 00:01
CRDT- 1997/11/14 00:00
PHST- 1997/11/14 00:00 [pubmed]
PHST- 1997/11/14 00:01 [medline]
PHST- 1997/11/14 00:00 [entrez]
AID - 10.1164/ajrccm.156.4.9609097 [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1066-72. doi: 
      10.1164/ajrccm.156.4.9609097.

PMID- 8694316
OWN - NLM
STAT- MEDLINE
DCOM- 19960829
LR  - 20190704
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 83
IP  - 2
DP  - 1996 Aug
TI  - Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb) on brain 
      injury after temporary focal cerebral ischemia in rats.
PG  - 342-7
AB  - Previous studies have shown that diaspirin cross-linked hemoglobin (DCLHb, 10 
      g/dL) decreases cerebral ischemia and the resultant injury in a dose-dependent 
      manner, requiring large volumes of DCLHb for maximum efficacy. We assessed the 
      effect of a more concentrated (20 g/dL) and more hyperoncotic preparation of 
      DCLHb on cerebral infarction volume. Immediately after middle cerebral artery 
      occlusion, rats were randomized to one of the following groups: Control, 
      hematocrit not manipulated; 10/Hb, hematocrit decreased to 30% with 10% DCLHb 
      (oncotic pressure 43 mm Hg); 7.5/Alb, hematocrit decreased to 30% with 7.5% 
      albumin (oncotic pressure 43 mm Hg); 20/Hb, the same dose of DCLHb (20%, oncotic 
      pressure 129 mm Hg) as the 10/HB group (half the volume); or 15/Alb, the same 
      dose of albumin (15%, oncotic pressure 130 mm Hg) as the 7.5/Alb group half the 
      volume). After 90 min of ischemia, 72 h of reperfusion was allowed. Infarction 
      volume (mm3, mean +/- sd) was less in the DCLHb groups (10/Hb = 79 +/- 17; 20/HB 
      = 51 +/- 14) than the oncotically matched albumin groups (7.5/Alb = 124 +/- 21; 
      15/Alb = 85 +/- 18) and the Control group (135 +/- 17) (P < 0.05). These data 
      indicate that in this model of cerebral ischemia, DCLHb decreases ischemic brain 
      injury more effectively than albumin, and that a hyperoncotic preparation of 
      DCLHb is preferable.
FAU - Cole, D J
AU  - Cole DJ
AD  - Department of Anesthesiology, Loma Linda University, California 92354, USA.
FAU - Drummond, J C
AU  - Drummond JC
FAU - Patel, P M
AU  - Patel PM
FAU - Nary, J C
AU  - Nary JC
FAU - Applegate, R L 2nd
AU  - Applegate RL 2nd
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Coloring Agents)
RN  - 0 (Hemoglobins)
RN  - 0 (Serum Albumin)
RN  - 0 (Tetrazolium Salts)
RN  - 7OL20RET2I (triphenyltetrazolium)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Blood Volume
MH  - Brain/*drug effects/pathology
MH  - Cerebral Infarction/pathology/*prevention & control
MH  - Coloring Agents
MH  - Dose-Response Relationship, Drug
MH  - Exchange Transfusion, Whole Blood
MH  - Hematocrit
MH  - Hemodilution
MH  - Hemoglobins/administration & dosage/*therapeutic use
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Osmotic Pressure
MH  - Random Allocation
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Reperfusion
MH  - Serum Albumin/administration & dosage/therapeutic use
MH  - Tetrazolium Salts
EDAT- 1996/08/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - 10.1097/00000539-199608000-00024 [doi]
PST - ppublish
SO  - Anesth Analg. 1996 Aug;83(2):342-7. doi: 10.1097/00000539-199608000-00024.

PMID- 36449182
OWN - NLM
STAT- MEDLINE
DCOM- 20230307
LR  - 20230307
IS  - 1179-6901 (Electronic)
IS  - 1174-5886 (Print)
IS  - 1174-5886 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Mar
TI  - Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy 
      Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
PG  - 35-42
LID - 10.1007/s40268-022-00408-0 [doi]
AB  - BACKGROUND AND OBJECTIVE: Systemic lupus erythematosus (SLE) is an autoimmune 
      disease, with hydroxychloroquine being the main therapeutic agent for the 
      treatment of SLE. This research explored the effects of hydroxychloroquine 
      combined with low-dose aspirin on maternal and infant outcomes and cytokines of 
      pregnant women with SLE. METHODS: Ninety pregnant women with SLE were divided 
      into the hydroxychloroquine (HCQ) group (45 cases) and the hydroxychloroquine 
      combined with low-dose aspirin (HCQASP) group (45 cases) by random number table. 
      Patients in the HCQ group were treated with oral administration of 
      hydroxychloroquine, while patients in the HCQASP group were treated with low-dose 
      aspirin based on oral administration of hydroxychloroquine. Pregnancy outcomes, 
      fetal outcomes, and cytokine levels were statistically analyzed. RESULTS: The 
      HCQASP group had a significantly higher proportion of full-term pregnancies and a 
      significantly lower proportion of hypertension, prematurity, and pregnancy loss 
      than the HCQ group. Neonates in the HCQASP group also had significantly higher 
      birth weights and Apgar scores and a significantly lower proportion of neonatal 
      asphyxia than the HCQ group. After treatment, the HCQASP group had significantly 
      higher interleukin (IL-2) and interferon (IFN)-γ levels and significantly lower 
      IL-4 and IL-10 levels than the HCQ group. CONCLUSION: Hydroxychloroquine combined 
      with low-dose aspirin can effectively improve the pregnancy outcomes of pregnant 
      women with SLE by affecting the levels of T helper (Th) 2 and Th1 cytokines.
CI  - © 2022. The Author(s).
FAU - Zhang, Na
AU  - Zhang N
AD  - Department of Clinical Pharmacy, The Fourth Hospital of Shijiazhuang, No. 16 
      North Tangu Street, Shijiazhuang, 050000, Hebei, China.
FAU - Zhang, Hong-Xia
AU  - Zhang HX
AD  - Department of Pharmacy, The Fourth Hospital of Shijiazhuang, No. 16 North Tangu 
      Street, Shijiazhuang, 050000, Hebei, China.
FAU - Li, Yu-Wei
AU  - Li YW
AD  - Department of Pharmacy, The Fourth Hospital of Shijiazhuang, No. 16 North Tangu 
      Street, Shijiazhuang, 050000, Hebei, China.
FAU - Li, Yuan
AU  - Li Y
AD  - Department of General Internal Medicine, The Fourth Hospital of Shijiazhuang, No. 
      16 North Tangu Street, Shijiazhuang, 050000, Hebei, China. 
      liyuandoctor9898@sina.com.
LA  - eng
GR  - 201200773/Shijiazhuang science and technology research and development plan/
PT  - Journal Article
DEP - 20221130
PL  - New Zealand
TA  - Drugs R D
JT  - Drugs in R&D
JID - 100883647
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Cytokines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Infant, Newborn
MH  - Humans
MH  - Female
MH  - Pregnancy
MH  - Hydroxychloroquine
MH  - Pregnancy Outcome
MH  - *Antirheumatic Agents
MH  - Pregnant Women
MH  - Cytokines
MH  - *Lupus Erythematosus, Systemic/chemically induced/drug therapy
MH  - Aspirin/therapeutic use
PMC - PMC9985524
COIS- Na Zhang, Hong-Xia Zhang, Yu-Wei Li, and Yuan Li declare that they have no 
      conflicts of interest in relation to this work.
EDAT- 2022/12/01 06:00
MHDA- 2023/03/08 06:00
CRDT- 2022/11/30 11:21
PHST- 2022/10/26 00:00 [accepted]
PHST- 2022/12/01 06:00 [pubmed]
PHST- 2023/03/08 06:00 [medline]
PHST- 2022/11/30 11:21 [entrez]
AID - 10.1007/s40268-022-00408-0 [pii]
AID - 408 [pii]
AID - 10.1007/s40268-022-00408-0 [doi]
PST - ppublish
SO  - Drugs R D. 2023 Mar;23(1):35-42. doi: 10.1007/s40268-022-00408-0. Epub 2022 Nov 
      30.

PMID- 12413587
OWN - NLM
STAT- MEDLINE
DCOM- 20030930
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 107
IP  - 1-2
DP  - 2002 Jul 15
TI  - Effects of combined therapy of clopidogrel and aspirin in preventing thrombus 
      formation on mechanical heart valves in an ex vivo rabbit model.
PG  - 39-43
AB  - BACKGROUND: The aim of our study was to investigate the efficacy of the 
      combination of clopidogrel and aspirin in the prevention of thrombus formation on 
      artificial heart valves in an experimental rabbit model as compared to 
      anticoagulation with warfarin. METHODS: Studies were performed after oral 
      administration of clopidogrel and aspirin in group I (n=9) for 5 days, after 
      5+/-2 days treatment with warfarin in group II (n=9) and without medication in 
      group III (n=9). Leaflets from Sulzer Carbomedics bileaflet valves were placed in 
      a flow chamber. The flow chamber was filled with blood in a continuous 
      circulation between the carotid artery and the jugular vein. RESULTS: In group 
      III, the flow chamber was clotted after a median of 15 min of circulation. Weight 
      analysis before and after 1 h of perfusion showed that the median thrombus weight 
      was 9.1 mg in group I, 14.4 mg in group II and 33.7 mg in group III. Further 
      analysis by electron microscopy showed fewer platelets and erythrocytes on 
      leaflets in group I than on leaflet surfaces in group II. CONCLUSION: Clopidogrel 
      and aspirin were more effective than warfarin in preventing thrombus formation on 
      artificial heart valve leaflets in our investigation. This rabbit model with a 
      high dosage of clopidogrel and aspirin, and a short-time exposure of the heart 
      valve leaflets to rabbit blood under laminar flow, should be further evaluated 
      with respect to whether it can give information about antithrombotic regimens in 
      patients after mechanical heart valve replacement.
FAU - Schlitt, A
AU  - Schlitt A
AD  - II Medical Department, Johannes Gutenberg-University Mainz, 55101, Mainz, 
      Germany. xelschlitt@gmx.net
FAU - Hauroeder, B
AU  - Hauroeder B
FAU - Buerke, M
AU  - Buerke M
FAU - Peetz, D
AU  - Peetz D
FAU - Victor, A
AU  - Victor A
FAU - Hundt, F
AU  - Hundt F
FAU - Bickel, C
AU  - Bickel C
FAU - Meyer, J
AU  - Meyer J
FAU - Rupprecht, H J
AU  - Rupprecht HJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Clopidogrel
MH  - Drug Evaluation, Preclinical
MH  - Drug Therapy, Combination
MH  - Heart Valve Prosthesis/*adverse effects
MH  - In Vitro Techniques
MH  - Male
MH  - Microscopy, Electron
MH  - Rabbits
MH  - Thrombosis/drug therapy/pathology/*prevention & control
MH  - Ticlopidine/administration & dosage/analogs & derivatives/*pharmacology
MH  - Warfarin/pharmacology
EDAT- 2002/11/05 04:00
MHDA- 2003/10/01 05:00
CRDT- 2002/11/05 04:00
PHST- 2002/11/05 04:00 [pubmed]
PHST- 2003/10/01 05:00 [medline]
PHST- 2002/11/05 04:00 [entrez]
AID - S0049384802001858 [pii]
AID - 10.1016/s0049-3848(02)00185-8 [doi]
PST - ppublish
SO  - Thromb Res. 2002 Jul 15;107(1-2):39-43. doi: 10.1016/s0049-3848(02)00185-8.

PMID- 37313939
OWN - NLM
STAT- MEDLINE
DCOM- 20230615
LR  - 20230713
IS  - 1998-3751 (Electronic)
IS  - 0253-7613 (Print)
IS  - 0253-7613 (Linking)
VI  - 55
IP  - 2
DP  - 2023 Mar-Apr
TI  - Role of intravenous aspirin versus oral aspirin in the treatment of acute 
      coronary syndrome: Answering a clinical query by systematic review and 
      meta-analysis of randomized controlled trials.
PG  - 133-137
LID - 10.4103/ijp.ijp_1147_20 [doi]
AB  - BACKGROUND: Aspirin is indicated in the emergency management of acute coronary 
      syndrome. However, oral aspirin has erratic bioavailability compared to i.v. 
      formulation. OBJECTIVE: The objective of this study was to evaluate the 
      comparative efficacy and safety of intravenous (IV) and oral aspirin in acute 
      coronary syndrome. STUDY DESIGN: This was a systematic review and meta-analysis. 
      RESULTS: Two randomized controlled trials were included. Compared to oral 
      aspirin, lower platelet aggregability was seen with IV aspirin at 5 min and 20 
      min. Lower thromboxane B2 and lower platelet CD-62p levels were noted in the IV 
      group; however, no significant difference was observed in terms of "composite 
      cardiovascular death, stroke, and myocardial infarction (MI) at 4-6 weeks," "any 
      cause mortality," "cardiovascular mortality," "occurrence of stroke," and 
      "occurrence of MI/reinfarction." However, no difference was noted in terms of the 
      occurrence of serious adverse events. CONCLUSION: IV aspirin showed some 
      advantages in terms of platelet aggregability biomarkers at 20 min and 1 week 
      with comparable safety to oral aspirin. No difference was seen in terms of 
      clinical outcomes (at 24 h, 7, and 30 days) and the occurrence of serious adverse 
      events.
FAU - Kaur, Hardeep
AU  - Kaur H
AD  - Department of Pharmacology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Sarma, Phulen
AU  - Sarma P
AD  - Department of Pharmacology, AIIMS, Guwahati, India.
FAU - Bhattacharyya, Anusuya
AU  - Bhattacharyya A
AD  - Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, 
      India.
FAU - Rohit, Manojkumar
AU  - Rohit M
AD  - Department of Cardiology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Prajapat, Manisha
AU  - Prajapat M
AD  - Department of Pharmacology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Kumar, Subodh
AU  - Kumar S
AD  - Department of Pharmacology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Prakash, Ajay
AU  - Prakash A
AD  - Department of Pharmacology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Medhi, Bikash
AU  - Medhi B
AD  - Department of Pharmacology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - India
TA  - Indian J Pharmacol
JT  - Indian journal of pharmacology
JID - 7902477
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Acute Coronary Syndrome/drug therapy
MH  - Aspirin/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Administration, Intravenous
MH  - *Stroke/drug therapy/prevention & control
PMC - PMC10335641
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - intravenous aspirin
OT  - oral aspirin
COIS- None
EDAT- 2023/06/14 13:06
MHDA- 2023/06/15 06:41
CRDT- 2023/06/14 06:14
PHST- 2023/06/15 06:41 [medline]
PHST- 2023/06/14 13:06 [pubmed]
PHST- 2023/06/14 06:14 [entrez]
AID - Indian J Pharmacol_2023_55_2_133_378025 [pii]
AID - IJPharm-55-133 [pii]
AID - 10.4103/ijp.ijp_1147_20 [doi]
PST - ppublish
SO  - Indian J Pharmacol. 2023 Mar-Apr;55(2):133-137. doi: 10.4103/ijp.ijp_1147_20.

PMID- 26591559
OWN - NLM
STAT- MEDLINE
DCOM- 20160211
LR  - 20181023
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 87
IP  - 9
DP  - 2015
TI  - [Acetylsalicylic acid for the prevention of primary myocardial infarction and 
      ischemic stroke].
PG  - 91-96
LID - 10.17116/terarkh201587991-96 [doi]
AB  - There is evidence that acetylsalicylic acid (ASA) is effective in preventing 
      events in a number of cardiovascular diseases. However, there is a number of 
      unresolved problems concerning the efficiency and suitability of its use as an 
      agent for the prevention of cardiovascular events (CVEs) (myocardial infarction 
      (Ml) and/or ischemic stroke (IS) and/or death) in subjects without any clinical 
      manifestations and/or diagnosed coronary heart disease (primary prevention of 
      CVEs). The aim of the review is to compare the current recommendations of, 
      professional communities for the.use of ASA as an agent for the primary 
      prevention of CVEs, to analyze cohort studies and meta-analyses that are not 
      included in the above recommendations (2013-2014), and to consider particular 
      issues on ASA administration (resistance to ASA; barriers to its preventive use). 
      The analysis performed suggests that there is no convincing evidence that it is 
      reasonable to use ASA as a population-wide prevention strategy. The studies and 
      meta-analyses often show conflicting data, which is likely to be associated with 
      the clinical features of population groups included in the studies, with the 
      presence or absence of ASA resistance and motivation for therapy. According to 
      the current clinical recommendations, the results of studies and meta-analysis, 
      and expert's opinions, deciding whether it is expedient to use ASA as an agent 
      for the prevention of primary MI and/or IS and death from atherosclerostic 
      vascular events should be based on the assessment of an individual's risks for 
      the above disorders, which are related to a risk for hemorrhages due to ASA 
      intake.
FAU - Samorodskaya, I V
AU  - Samorodskaya IV
AD  - State Research Centre for Preventive Medicine, Ministry of Health of Russia, 
      Moscow, Russia.
FAU - Bolotova, E V
AU  - Bolotova EV
AD  - Kuban State Medical University, Ministry of Health of Russia, Krasnodar, Russia.
FAU - Boytsov, S A
AU  - Boytsov SA
AD  - State Research Centre for Preventive Medicine, Ministry of Health of Russia, 
      Moscow, Russia.
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage/adverse effects
MH  - Chemoprevention/methods
MH  - *Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Preventive Health Services/methods
MH  - Risk Adjustment
MH  - Stroke/*prevention & control
EDAT- 2015/11/26 06:00
MHDA- 2016/02/13 06:00
CRDT- 2015/11/24 06:00
PHST- 2015/11/24 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/02/13 06:00 [medline]
AID - 10.17116/terarkh201587991-96 [doi]
PST - ppublish
SO  - Ter Arkh. 2015;87(9):91-96. doi: 10.17116/terarkh201587991-96.

PMID- 7108792
OWN - NLM
STAT- MEDLINE
DCOM- 19821029
LR  - 20190512
IS  - 0022-3751 (Print)
IS  - 1469-7793 (Electronic)
IS  - 0022-3751 (Linking)
VI  - 326
DP  - 1982 May
TI  - Reduction of the bradykinin-induced activation of feline group III and IV muscle 
      receptors by acetylsalicylic acid.
PG  - 269-83
AB  - 1. In chloralose-anaesthetized cats, the influence of systemically or locally 
      applied acetylsalicylic acid (ASA) on the responses of thin-fibre muscle 
      receptors to close-arterial injections of bradykinin was studied. 2. Many of the 
      slowly conducting (group III and IV) muscle afferents had a background activity 
      of low frequency. This discharge was either unaffected or slightly increased by 
      the ASA doses used. In two units which had a very high discharge rate ASA led to 
      a marked decrease in background activity. 3. On local (I.A. or I.M.) injection of 
      ASA, doses below 1 mg were sufficient for reducing the bradykinin-induced 
      activations of group III and IV muscle receptors. The reduction lasted for about 
      15-30 min. 4. On systemic (I.V.) administration of ASA (50 mg/kg body weight) the 
      reduction in response magnitude to bradykinin became significant 8 min after 
      injection of the analgesic. The effect was maximal about 10 min later and lasted 
      for more than 60 min. 5. Five receptors were found which gave a repeated response 
      to 5-hydroxytryptamine (5-HT) injected at 10 min intervals. The 5-HT-induced 
      activations could not be reduced by ASA (50 mg/kg I.V.). 6. Most of the receptors 
      responding to bradykinin had a high threshold on mechanical stimulation and thus 
      were probably nociceptors. It is concluded that the reduction of their 
      bradykinin-induced activations reflects the suppression of nociceptive 
      information by an analgesic. Since the recordings were obtained from primary 
      afferent units the data constitute direct evidence for a peripheral action of 
      ASA.
FAU - Mense, S
AU  - Mense S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Physiol
JT  - The Journal of physiology
JID - 0266262
RN  - 0 (Receptors, Serotonin)
RN  - R16CO5Y76E (Aspirin)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Action Potentials/drug effects
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bradykinin/administration & dosage/*pharmacology
MH  - Cats
MH  - Muscles/*drug effects/innervation/physiology
MH  - Receptors, Serotonin/drug effects/physiology
MH  - Sensory Receptor Cells/*drug effects
PMC - PMC1251473
EDAT- 1982/05/01 00:00
MHDA- 1982/05/01 00:01
CRDT- 1982/05/01 00:00
PHST- 1982/05/01 00:00 [pubmed]
PHST- 1982/05/01 00:01 [medline]
PHST- 1982/05/01 00:00 [entrez]
AID - 10.1113/jphysiol.1982.sp014191 [doi]
PST - ppublish
SO  - J Physiol. 1982 May;326:269-83. doi: 10.1113/jphysiol.1982.sp014191.

PMID- 37024312
OWN - NLM
STAT- MEDLINE
DCOM- 20230620
LR  - 20230620
IS  - 1943-4693 (Electronic)
IS  - 0027-9684 (Linking)
VI  - 115
IP  - 3
DP  - 2023 Jun
TI  - Immigration and use of preventive aspirin by Hispanics and non-Hispanic whites 
      and non-Hispanic blacks in the US.
PG  - 314-318
LID - S0027-9684(23)00037-8 [pii]
LID - 10.1016/j.jnma.2023.03.002 [doi]
AB  - BACKGROUND: In the US, little is known about aspirin use as a preventive measure 
      for cardiovascular disease by immigration status. METHODS: Combined data from the 
      National Health and Nutrition Examination Survey (NHANES) 2015-2016 and 2017- 
      March 2020 (pre-pandemic data) were analyzed. Persons were asked about 
      demographics including country of birth and those aged 40 years and older were 
      asked about current use of aspirin to prevent cardiovascular disease (CVD). 
      RESULTS: Among 2,321 born in the US, preventive aspirin use was significantly 
      more prevalent (39.6%) than among 910 others (27.5%, p < 0.01). However, after 
      stratifying by race/ethnicity and history of CVD, the difference was significant 
      only in Hispanics with CVD. In logistic regression analyses in Hispanics 
      controlling for age, gender and education, the US born had significantly higher 
      odds of aspirin use in those with or without CVD. DISCUSSION: Among US Hispanics, 
      use of aspirin for prevention of CVD was more prevalent in those born in the US 
      than in others.
CI  - Copyright © 2023 National Medical Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Carr, Tyler
AU  - Carr T
AD  - MSII, Howard University College of Medicine, 520 W St NW, Washington, DC 20059, 
      USA. Electronic address: tyler.carr@bison.howard.edu.
FAU - Gillum, Richard
AU  - Gillum R
AD  - Professor, Department of Medicine, Howard University College of Medicine, 
      Washington, DC 20059 USA. Electronic address: rfg2.howard.edu@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20230405
PL  - United States
TA  - J Natl Med Assoc
JT  - Journal of the National Medical Association
JID - 7503090
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Middle Aged
MH  - Aspirin/therapeutic use
MH  - Black or African American
MH  - *Cardiovascular Diseases/prevention & control
MH  - Emigration and Immigration
MH  - *Ethnicity
MH  - Nutrition Surveys
MH  - United States/epidemiology
MH  - White
MH  - Hispanic or Latino
OTO - NOTNLM
OT  - Aspirin
OT  - Black
OT  - Country of birth
OT  - Hispanic
OT  - Immigration
OT  - Nativity
EDAT- 2023/04/07 06:00
MHDA- 2023/06/19 13:08
CRDT- 2023/04/06 22:00
PHST- 2022/10/25 00:00 [received]
PHST- 2023/02/08 00:00 [revised]
PHST- 2023/03/14 00:00 [accepted]
PHST- 2023/06/19 13:08 [medline]
PHST- 2023/04/07 06:00 [pubmed]
PHST- 2023/04/06 22:00 [entrez]
AID - S0027-9684(23)00037-8 [pii]
AID - 10.1016/j.jnma.2023.03.002 [doi]
PST - ppublish
SO  - J Natl Med Assoc. 2023 Jun;115(3):314-318. doi: 10.1016/j.jnma.2023.03.002. Epub 
      2023 Apr 5.

PMID- 23618958
OWN - NLM
STAT- MEDLINE
DCOM- 20131231
LR  - 20130528
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 450
IP  - 1-2
DP  - 2013 Jun 25
TI  - Properties of aspirin modified enteric polymer prepared by hot-melt mixing.
PG  - 259-67
LID - S0378-5173(13)00337-2 [pii]
LID - 10.1016/j.ijpharm.2013.04.036 [doi]
AB  - Melt mixing in batch equipment or continuous extruders is a technique that 
      recently gained the attention of the pharmaceutical industry. The present work 
      has employed hot-melt mixing to prepare a modified enteric matrix, as a 
      delayed-release dosage form. Different concentrations of aspirin (ASP) ranging 
      from 10 to -30% (w/w) were melt-mixed with a plasticized methacrylic acid 
      copolymer, Eudragit(®) L100-55 in a batch mixer for 5 min at 100 °C which is 
      above the plasticized polymer's glass transition temperature and below the ASP's 
      melting point. The samples were cooled down to room temperature and compressed to 
      thin discs. Processing ASP with Eudragit(®) L100-55 did not promote hydrolysis of 
      ASP. X-ray diffraction spectra obtained at room temperature revealed that aspirin 
      was present in a crystalline state. However, at elevated temperatures the 
      dissolved aspirin displayed a plasticizing effect by reducing the glass 
      transition temperature (Tg) and lowering the viscosity of the polymer in 
      proportion to its increasing concentration. The addition of ASP altered to some 
      extent the rheological behavior of the polymer from rubbery to viscous. However, 
      the amount of ASP loading had no significant impact on the dissolution profiles. 
      The samples met USP delayed-release requirements and the API release mechanism 
      was shown to be diffusion dominant.
CI  - Copyright © 2013 Elsevier B.V. All rights reserved.
FAU - Chomcharn, Nonjaros
AU  - Chomcharn N
AD  - Otto H. York Department of Chemical, Biological and Pharmaceutical Engineering, 
      New Jersey Institute of Technology, Newark, NJ 0710, USA.
FAU - Xanthos, Marino
AU  - Xanthos M
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130422
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Acrylic Resins)
RN  - 0 (Citrates)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Eudragit L100-55)
RN  - 8Z96QXD6UM (ethyl citrate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acrylic Resins/chemistry
MH  - Aspirin/*chemistry
MH  - Citrates/chemistry
MH  - Delayed-Action Preparations/chemistry
MH  - Drug Compounding/methods
MH  - Hot Temperature
MH  - Rheology
MH  - Solubility
MH  - Transition Temperature
MH  - X-Ray Diffraction
EDAT- 2013/04/27 06:00
MHDA- 2014/01/01 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/12/12 00:00 [received]
PHST- 2013/03/04 00:00 [revised]
PHST- 2013/04/15 00:00 [accepted]
PHST- 2013/04/27 06:00 [entrez]
PHST- 2013/04/27 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
AID - S0378-5173(13)00337-2 [pii]
AID - 10.1016/j.ijpharm.2013.04.036 [doi]
PST - ppublish
SO  - Int J Pharm. 2013 Jun 25;450(1-2):259-67. doi: 10.1016/j.ijpharm.2013.04.036. 
      Epub 2013 Apr 22.

PMID- 28481152
OWN - NLM
STAT- MEDLINE
DCOM- 20180417
LR  - 20180417
IS  - 1743-1328 (Electronic)
IS  - 0161-6412 (Linking)
VI  - 39
IP  - 8
DP  - 2017 Aug
TI  - Aspirin attenuates spontaneous recurrent seizures in the chronically epileptic 
      mice.
PG  - 744-757
LID - 10.1080/01616412.2017.1326657 [doi]
AB  - OBJECTIVE: Neuroinflammatory processes are pathologic hallmarks of both 
      experimental and human epilepsy, and could be implicated in the neuronal 
      hyperexcitability. Aspirin represents one of the non-selective nonsteroidal 
      anti-inflammatory drugs with fewer side effects in long-term application. This 
      study was carried out to assess the anti-epileptic effects of aspirin when 
      administered during the chronic stage of temporal lobe epilepsy [TLE] in mice. 
      The alteration of hippocampal neurogenesis was also examined for raising a 
      possible mechanism underlying the protective effect of anti-inflammatory 
      treatment in the TLE. METHODS: Two months after pilocarpine-induced status 
      epilepticus, the chronically epileptic mice were treated with aspirin (20 mg, 
      60 mg or 80 mg/kg) once a day for 10 weeks. Spontaneous recurrent seizures were 
      monitored by video camera for 2 weeks. To evaluate the profile of hippocampal 
      neurogenesis, the newly generated cells in the dentate gyrus were labeled by the 
      proliferation marker BrdU. The newborn neurons that extended axons to CA3 area 
      were visualized by cholera toxin B subunit retrograde tracing. RESULTS: 
      Administration of aspirin with a dosage of 60 mg or 80 mg/kg initiated at 
      2 months after pilocarpine-induced status epilepticus significantly reduced the 
      frequency and duration of spontaneous recurrent seizures. Aspirin treatment also 
      increased the number of newborn neurons with anatomic integration through 
      improving the survival of the newly generated cells. CONCLUSION: Aspirin 
      treatment during the chronic stage of TLE could attenuate the spontaneous 
      recurrent seizures in mice. Promotion of hippocampal neurogenesis and inhibition 
      of COX-PGE2 pathway might partly contribute to this anti-epileptic effect. 
      Highlights • Aspirin attenuates spontaneous recurrent seizures of chronically 
      epileptic mice • Aspirin increases neurogenesis of chronically epileptic 
      hippocampus by improving the survival of newly generated cells • Promotion of 
      hippocampal neurogenesis and inhibition of COX-PGE2 pathway might partly 
      contribute to anti-epileptic effects of aspirin.
FAU - Zhu, Kun
AU  - Zhu K
AD  - a Institute of Neurobiology , School of Basic Medical Sciences, Xi'an Jiaotong 
      University Health Science Center , Xi'an , China.
FAU - Hu, Ming
AU  - Hu M
AD  - a Institute of Neurobiology , School of Basic Medical Sciences, Xi'an Jiaotong 
      University Health Science Center , Xi'an , China.
AD  - b Department of Human Anatomy, Histology and Embryology , School of Basic Medical 
      Sciences, Xi'an Jiaotong University Health Science Center , Xi'an , China.
FAU - Yuan, Bo
AU  - Yuan B
AD  - a Institute of Neurobiology , School of Basic Medical Sciences, Xi'an Jiaotong 
      University Health Science Center , Xi'an , China.
FAU - Liu, Jian-Xin
AU  - Liu JX
AD  - a Institute of Neurobiology , School of Basic Medical Sciences, Xi'an Jiaotong 
      University Health Science Center , Xi'an , China.
FAU - Liu, Yong
AU  - Liu Y
AD  - a Institute of Neurobiology , School of Basic Medical Sciences, Xi'an Jiaotong 
      University Health Science Center , Xi'an , China.
LA  - eng
PT  - Journal Article
DEP - 20170507
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - *Epilepsy, Temporal Lobe
MH  - Female
MH  - Hippocampus/*drug effects
MH  - Mice
MH  - Neurogenesis/*drug effects
MH  - *Seizures
OTO - NOTNLM
OT  - Aspirin
OT  - epilepsy
OT  - hippocampus
OT  - inflammation
OT  - neurogenesis
EDAT- 2017/05/10 06:00
MHDA- 2018/04/18 06:00
CRDT- 2017/05/09 06:00
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2018/04/18 06:00 [medline]
PHST- 2017/05/09 06:00 [entrez]
AID - 10.1080/01616412.2017.1326657 [doi]
PST - ppublish
SO  - Neurol Res. 2017 Aug;39(8):744-757. doi: 10.1080/01616412.2017.1326657. Epub 2017 
      May 7.

PMID- 21945907
OWN - NLM
STAT- MEDLINE
DCOM- 20120319
LR  - 20181201
IS  - 1846-9558 (Electronic)
IS  - 1330-0075 (Linking)
VI  - 61
IP  - 3
DP  - 2011 Sep 1
TI  - Simultaneous estimation of ramipril, acetylsalicylic acid and atorvastatin 
      calcium by chemometrics assisted UV-spectrophotometric method in capsules.
PG  - 283-96
LID - 10.2478/v10007-011-0027-1 [doi]
AB  - In the present work, three different spectrophotometric methods for simultaneous 
      estimation of ramipril, aspirin and atorvastatin calcium in raw materials and in 
      formulations are described. Overlapped data was quantitatively resolved by using 
      chemometric methods, viz. inverse least squares (ILS), principal component 
      regression (PCR) and partial least squares (PLS). Calibrations were constructed 
      using the absorption data matrix corresponding to the concentration data matrix. 
      The linearity range was found to be 1-5, 10-50 and 2-10 μg mL-1 for ramipril, 
      aspirin and atorvastatin calcium, respectively. The absorbance matrix was 
      obtained by measuring the zero-order absorbance in the wavelength range between 
      210 and 320 nm. A training set design of the concentration data corresponding to 
      the ramipril, aspirin and atorvastatin calcium mixtures was organized 
      statistically to maximize the information content from the spectra and to 
      minimize the error of multivariate calibrations. By applying the respective 
      algorithms for PLS 1, PCR and ILS to the measured spectra of the calibration set, 
      a suitable model was obtained. This model was selected on the basis of RMSECV and 
      RMSEP values. The same was applied to the prediction set and capsule formulation. 
      Mean recoveries of the commercial formulation set together with the figures of 
      merit (calibration sensitivity, selectivity, limit of detection, limit of 
      quantification and analytical sensitivity) were estimated. Validity of the 
      proposed approaches was successfully assessed for analyses of drugs in the 
      various prepared physical mixtures and formulations.
FAU - Sankar, A S Kamatchi
AU  - Sankar AS
AD  - Adhiparasakthi College of Pharmacy, Melmaruvathur-603319, India.
FAU - Vetrichelvan, Thangarasu
AU  - Vetrichelvan T
FAU - Venkappaya, Devashya
AU  - Venkappaya D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Poland
TA  - Acta Pharm
JT  - Acta pharmaceutica (Zagreb, Croatia)
JID - 9303678
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Capsules)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Pyrroles)
RN  - A0JWA85V8F (Atorvastatin)
RN  - L35JN3I7SJ (Ramipril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis/chemistry
MH  - Anticholesteremic Agents/*analysis/chemistry
MH  - Antihypertensive Agents/*analysis/chemistry
MH  - Aspirin/*analysis/chemistry
MH  - Atorvastatin
MH  - Calibration
MH  - Capsules/chemistry
MH  - Chemistry, Pharmaceutical
MH  - Heptanoic Acids/*analysis/chemistry
MH  - Humans
MH  - Least-Squares Analysis
MH  - Models, Theoretical
MH  - Pyrroles/*analysis/chemistry
MH  - Ramipril/*analysis/chemistry
MH  - Regression Analysis
MH  - Reproducibility of Results
MH  - Spectrophotometry, Ultraviolet/*methods
EDAT- 2011/09/29 06:00
MHDA- 2012/03/20 06:00
CRDT- 2011/09/28 06:00
PHST- 2011/09/28 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2012/03/20 06:00 [medline]
AID - E8X208484224525R [pii]
AID - 10.2478/v10007-011-0027-1 [doi]
PST - ppublish
SO  - Acta Pharm. 2011 Sep 1;61(3):283-96. doi: 10.2478/v10007-011-0027-1.

PMID- 16750421
OWN - NLM
STAT- MEDLINE
DCOM- 20061201
LR  - 20181201
IS  - 1471-4892 (Print)
IS  - 1471-4892 (Linking)
VI  - 6
IP  - 4
DP  - 2006 Aug
TI  - Lipoxins and new lipid mediators in the resolution of inflammation.
PG  - 414-20
AB  - Lipoxins and aspirin-triggered lipoxins are lipid mediators generated from 
      arachidonic acid that act to reduce inflammation and promote resolution. In 
      addition, two new families of lipid mediators were uncovered, namely resolvins 
      (resolution phase interaction products) and protectins, which derive from omega-3 
      polyunsaturated fatty acid. They possess potent anti-inflammatory, 
      neuroprotective and pro-resolving properties. Eicosapentaenoic acid-derived 
      mediators are denoted resolvins of the E series, and those biosynthesized from 
      docosahexaenoic acid are resolvins of the D series (RvDs) and protectins. Aspirin 
      impinges on these systems, triggering formation of the epimeric 17R-series 
      RvDs--denoted as 'aspirin-triggered-RvDs'--which possess bioactivity in vivo 
      equivalent to that evoked by their 17S-series counterparts (i.e. RvDs). These 
      bioactive molecules open new avenues and approaches to therapeutic interventions 
      via accelerated resolution of inflammation.
FAU - Schwab, Jan M
AU  - Schwab JM
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and 
      Harvard Medical School, 75 Francis Street, Boston MA 02115, USA.
FAU - Serhan, Charles N
AU  - Serhan CN
LA  - eng
GR  - P50-DE016191/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20060605
PL  - England
TA  - Curr Opin Pharmacol
JT  - Current opinion in pharmacology
JID - 100966133
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - GND3JH08JA (5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/pharmacology/therapeutic use
MH  - Disease Models, Animal
MH  - Docosahexaenoic Acids/metabolism
MH  - Eicosapentaenoic Acid/analogs & derivatives/metabolism
MH  - Humans
MH  - Inflammation/drug therapy/*metabolism
MH  - Lipid Metabolism/drug effects
MH  - Lipoxins/*metabolism
MH  - Signal Transduction/drug effects
RF  - 33
EDAT- 2006/06/06 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/06/06 09:00
PHST- 2006/02/03 00:00 [received]
PHST- 2006/02/03 00:00 [accepted]
PHST- 2006/06/06 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/06/06 09:00 [entrez]
AID - S1471-4892(06)00088-9 [pii]
AID - 10.1016/j.coph.2006.02.006 [doi]
PST - ppublish
SO  - Curr Opin Pharmacol. 2006 Aug;6(4):414-20. doi: 10.1016/j.coph.2006.02.006. Epub 
      2006 Jun 5.

PMID- 27595478
OWN - NLM
STAT- MEDLINE
DCOM- 20170828
LR  - 20181202
IS  - 1558-1365 (Electronic)
IS  - 1042-3699 (Linking)
VI  - 28
IP  - 4
DP  - 2016 Nov
TI  - Aspirin, Plavix, and Other Antiplatelet Medications: What the Oral and 
      Maxillofacial Surgeon Needs to Know.
PG  - 497-506
LID - S1042-3699(16)30033-4 [pii]
LID - 10.1016/j.coms.2016.06.003 [doi]
AB  - Most patients with coronary artery disease and peripheral vascular disease are on 
      long-term antiplatelet therapy and dual therapy. Achieving a balance between 
      ischemic and bleeding risk remains an important factor in managing patients on 
      antiplatelet therapy. For most outpatient surgical procedures, maintenance and 
      continuation of this therapy are recommended. Consultation with the patient's 
      cardiologist, physician, and/or vascular surgeon is always recommended before 
      interrupting or withholding this treatment modality.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Ghantous, Andre E
AU  - Ghantous AE
AD  - Division of Cardiology, Department of Medicine, Yale University School of 
      Medicine, 333 Cedar St., New Haven, CT 06510, USA.
FAU - Ferneini, Elie M
AU  - Ferneini EM
AD  - Private Practice, Greater Waterbury OMS, 435 Highland Avenue, Suite 100, 
      Cheshire, CT 06410, USA; Beau Visage Med Spa, 435 Highland Avenue, Suite 100, 
      Cheshire, CT 06410, USA; Division of Oral and Maxillofacial Surgery, Department 
      of Craniofacial Sciences, University of Connecticut, 263 Farmington Avenue, 
      Farmington, CT 06030, USA. Electronic address: eferneini@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160829
PL  - United States
TA  - Oral Maxillofac Surg Clin North Am
JT  - Oral and maxillofacial surgery clinics of North America
JID - 9001454
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Clopidogrel
MH  - Coronary Artery Disease/drug therapy
MH  - Humans
MH  - Medication Therapy Management
MH  - *Oral Surgical Procedures
MH  - Peripheral Vascular Diseases/drug therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Angioplasty
OT  - Antiplatelet therapy
OT  - Aspirin
OT  - Bleeding
OT  - Cardiac stenting
OT  - Clopidogrel
OT  - Coronary artery disease
OT  - Myocardial infarction
EDAT- 2016/09/07 06:00
MHDA- 2017/08/29 06:00
CRDT- 2016/09/06 06:00
PHST- 2016/09/07 06:00 [pubmed]
PHST- 2017/08/29 06:00 [medline]
PHST- 2016/09/06 06:00 [entrez]
AID - S1042-3699(16)30033-4 [pii]
AID - 10.1016/j.coms.2016.06.003 [doi]
PST - ppublish
SO  - Oral Maxillofac Surg Clin North Am. 2016 Nov;28(4):497-506. doi: 
      10.1016/j.coms.2016.06.003. Epub 2016 Aug 29.

PMID- 7400948
OWN - NLM
STAT- MEDLINE
DCOM- 19801024
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 69
IP  - 8
DP  - 1980 Aug
TI  - Aspirin--a national survey IV: In vitro dissolution of aspirin formulations.
PG  - 967-70
AB  - The results of a national survey of the in vitro dissolution rates of aspirin 
      tablets are presented. Dissolution profiles by both the proposed USP XX basket 
      method and a paddle method are compared. The methods were used to analyze 59 
      tablet formulations representing 38 manufacturers. Each tablet was subjected to 
      the dissolution procedure in 500 ml of pH 4.5 buffer solution, and an aliquot was 
      sampled automatically and analyzed by an automated system. In 30 min, 22% of the 
      samples tested using the basket method failed the proposed USP XX dissolution 
      requirement. Seventy-five percent of the samples tested By the paddle method also 
      failed the proposed dissolution requirement.
FAU - Juhl, W E
AU  - Juhl WE
FAU - Kirchhoefer, R D
AU  - Kirchhoefer RD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Alcohols)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alcohols
MH  - *Aspirin
MH  - Chemistry, Pharmaceutical
MH  - Solubility
MH  - Tablets
MH  - Time Factors
EDAT- 1980/08/01 00:00
MHDA- 1980/08/01 00:01
CRDT- 1980/08/01 00:00
PHST- 1980/08/01 00:00 [pubmed]
PHST- 1980/08/01 00:01 [medline]
PHST- 1980/08/01 00:00 [entrez]
AID - S0022-3549(15)43324-6 [pii]
AID - 10.1002/jps.2600690827 [doi]
PST - ppublish
SO  - J Pharm Sci. 1980 Aug;69(8):967-70. doi: 10.1002/jps.2600690827.

PMID- 23018006
OWN - NLM
STAT- MEDLINE
DCOM- 20131028
LR  - 20220408
IS  - 0210-5705 (Print)
IS  - 0210-5705 (Linking)
VI  - 35 Suppl 1
DP  - 2012 Sep
TI  - [Gastrointestinal bleeding associated with NSAIDs, antiplatelet therapy and 
      anticoagulant agent].
PG  - 35-42
LID - S0210-5705(12)70032-8 [pii]
LID - 10.1016/S0210-5705(12)70032-8 [doi]
AB  - Following the trends observed for the last 2-3 years, the most significant and 
      recent advances in the area of gastrointestinal lesions associated with 
      anti-inflammatory drugs (NSAIDs) have focused on adverse effects in the distal 
      intestine and on issues related to the toxicity associated with antiplatelet 
      therapy. New data reinforce evidence that NSAIDs and antiplatelet therapy are 
      associated with an increased risk of serious complications in both the upper and 
      lower gastrointestinal tract, opening up several lines of research in prevention 
      and therapy based on probiotics, antibiotics and mucosal protectants. The 
      interaction between Helicobacter pylori infection and NSAIDs or aspirin remains 
      controversial but a positive interaction between this bacterium and NSAIDs seems 
      to be reinforced. Several systematic reviews confirm that the combination of 
      gastrotoxic drugs significantly increases the risk of gastrointestinal bleeding, 
      which should reinforce existing prevention strategies, and that new anticoagulant 
      agents do not appear to reduce the risk of gastrointestinal bleeding. Once 
      gastrointestinal hemorrhage has occurred, several studies have indicated the need 
      to implement simpler prognostic scales than those used today. Notable innovations 
      are the development of a disposable endoscope for acute upper gastrointestinal 
      bleeding events and a promising new hemostatic technique, hemospray, applied 
      locally over the bleeding lesion.
CI  - Copyright © 2012 Elsevier España, S.L. All rights reserved.
FAU - Lanas, Angel
AU  - Lanas A
AD  - Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, 
      Universidad de Zaragoza, IIS Aragón, CIBERehd, Zaragoza, Spain. alanas@unizar.es
LA  - spa
PT  - Journal Article
TT  - Hemorragia gastrointestinal asociada a antiinflamatorios no esteroideos, agentes 
      antiplaquetarios y anticoagulantes.
PL  - Spain
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Anticoagulants/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Gastrointestinal Hemorrhage/*chemically induced/etiology
MH  - Helicobacter Infections/complications
MH  - Helicobacter pylori
MH  - Humans
MH  - Intestinal Diseases/chemically induced
MH  - Platelet Aggregation Inhibitors/*adverse effects
EDAT- 2012/10/04 06:00
MHDA- 2013/10/29 06:00
CRDT- 2012/09/29 06:00
PHST- 2012/09/29 06:00 [entrez]
PHST- 2012/10/04 06:00 [pubmed]
PHST- 2013/10/29 06:00 [medline]
AID - S0210-5705(12)70032-8 [pii]
AID - 10.1016/S0210-5705(12)70032-8 [doi]
PST - ppublish
SO  - Gastroenterol Hepatol. 2012 Sep;35 Suppl 1:35-42. doi: 
      10.1016/S0210-5705(12)70032-8.

PMID- 33999149
OWN - NLM
STAT- MEDLINE
DCOM- 20211214
LR  - 20211214
IS  - 1944-7922 (Electronic)
IS  - 1060-3271 (Linking)
VI  - 104
IP  - 6
DP  - 2021 Dec 11
TI  - Estimation of Multiple Fixed-Dose Combination Products of Ramipril and Aspirin by 
      GERV-Chromatography Using DoE and Risk-Based Enhanced Analytical Quality by 
      Design Approach.
PG  - 1726-1741
LID - 10.1093/jaoacint/qsab073 [doi]
AB  - BACKGROUND: Numerous chromatographic methods have been published for estimation 
      of fixed-dose combinations (FDCs) of aspirin and ramipril with other drugs. But 
      no published report has been found which promotes simultaneous estimation of FDCs 
      of aspirin and ramipril with other drugs using a single chromatography condition. 
      OBJECTIVE: Hence, the HPTLC method was developed for simultaneous estimation of 
      FDCs of aspirin and ramipril with the drugs under study to save solvent, cost, 
      and time for analysis using a risk- and DoE-based AQbD approach. METHOD: The 
      risk-based AQbD approach was implemented using the risk priority number (RPN) 
      ranking and filtering method as per the ICH Q9 guideline. The DoE-based AQbD 
      approach was applied through a screening study using Placket-Burman design, 
      followed by response surface analysis by Box-Behnken design as per the ICH Q8 
      guideline. RESULTS: The risks from critical method risk parameters were mitigated 
      by navigating method operable design ranges and framing the control strategy for 
      the target method. The method was validated as per ICH Q2 (R1) guidelines. The 
      developed method was applied for simultaneous assay of six different FDCs of 
      aspirin and ramipril and results agreed with the label claims. CONCLUSIONS: The 
      developed method is the best alternative to published chromatographic methods for 
      estimation of the FDC products under study and saves solvent, time, and cost of 
      analysis. Hence, the developed "GERV"-chromatography method is found to be green 
      (G), economical (E), robust (R), and versatile (V), for estimation of the said 
      FDC products. HIGHLIGHTS: Development of GERV-chromatography for simultaneous 
      estimation of multiple FDCs of ramipril and aspirin using a risk-based AQbD 
      approach. Application of the developed method for simultaneous estimation of six 
      different FDC products.
CI  - © AOAC INTERNATIONAL 2021. All rights reserved. For permissions, please email: 
      journals.permissions@oup.com.
FAU - Prajapati, Pintu B
AU  - Prajapati PB
AUID- ORCID: 0000-0002-0374-4529
AD  - Department of Quality Assurance, Maliba Pharmacy College, Uka Tarsadia 
      University, Bardoli-Mahuva Road, Tarsadi, Mahuva, Surat, 394 350 Gujarat, India.
FAU - Jayswal, Kajal V
AU  - Jayswal KV
AUID- ORCID: 0000-0001-9648-5724
AD  - Department of Quality Assurance, Maliba Pharmacy College, Uka Tarsadia 
      University, Bardoli-Mahuva Road, Tarsadi, Mahuva, Surat, 394 350 Gujarat, India.
FAU - Shah, Shailesh A
AU  - Shah SA
AUID- ORCID: 0000-0002-1039-9882
AD  - Department of Quality Assurance, Maliba Pharmacy College, Uka Tarsadia 
      University, Bardoli-Mahuva Road, Tarsadi, Mahuva, Surat, 394 350 Gujarat, India.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J AOAC Int
JT  - Journal of AOAC International
JID - 9215446
RN  - L35JN3I7SJ (Ramipril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - Chromatography, High Pressure Liquid
MH  - *Ramipril
MH  - Research Design
EDAT- 2021/05/18 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/05/17 12:39
PHST- 2020/10/21 00:00 [received]
PHST- 2021/04/16 00:00 [revised]
PHST- 2021/05/06 00:00 [accepted]
PHST- 2021/05/18 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/05/17 12:39 [entrez]
AID - 6276992 [pii]
AID - 10.1093/jaoacint/qsab073 [doi]
PST - ppublish
SO  - J AOAC Int. 2021 Dec 11;104(6):1726-1741. doi: 10.1093/jaoacint/qsab073.

PMID- 35577054
OWN - NLM
STAT- MEDLINE
DCOM- 20221103
LR  - 20230103
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 122
IP  - 11
DP  - 2022 Nov
TI  - Clopidogrel Monotherapy versus Aspirin Monotherapy in Patients with Established 
      Cardiovascular Disease: Systematic Review and Meta-Analysis.
PG  - 1879-1887
LID - 10.1055/a-1853-2952 [doi]
AB  - BACKGROUND:  There is no clear consensus on whether aspirin offers better 
      outcomes in terms of secondary cardiovascular disease prevention compared with 
      clopidogrel. OBJECTIVE:  The aim of the study was to compare the safety and 
      efficacy of clopidogrel versus aspirin in patients with established 
      cardiovascular disease. METHODS:  A systematic review of MEDLINE (via PubMed), 
      Scopus, and Cochrane Library databases (last search date: August 28, 2021) was 
      performed according to the PRISMA (Preferred Reporting Items for Systematic 
      Reviews and Meta-analyses) statement for randomized control trials (RCTs) of 
      clopidogrel versus aspirin as monotherapy in patients with established 
      cardiovascular disease. Random-effects meta-analyses were performed. RESULTS: 
       Five RCTs incorporating 26,855 patients (clopidogrel: 13,426; aspirin: 13,429) 
      were included. No statistically significant difference was observed between 
      clopidogrel and aspirin in terms of all-cause mortality (odds ratio [OR]: 1.01 
      [95% confidence interval, CI: 0.91-1.13]; p = 0.83), ischemic stroke (OR: 0.87 
      [95% CI: 0.71-1.06]; p = 0.16), and major bleeding rates (OR: 0.77 [95% CI: 
      0.56-1.06]; p = 0.11). Patients receiving clopidogrel had borderline lower risk 
      for major adverse cardiovascular events (MACE) (OR: 0.84 [95% CI: 0.71-1.00]; 
      p = 0.05) and lower risk for nonfatal myocardial infarction (OR: 0.83 [95% CI: 
      0.71-0.97]; p = 0.02, relative risk reduction = 16.9%, absolute risk 
      reduction = 0.5%, number needed to treat = 217 for a mean period of 20 months) 
      compared with patients receiving aspirin. CONCLUSION:  In patients with 
      established cardiovascular disease, clopidogrel was associated with a 17% 
      relative-risk reduction for nonfatal MI, borderline decreased risk for MACE, and 
      similar risk for all-cause mortality, stroke, and major bleeding compared with 
      aspirin. PROTOCOL REGISTRATION:  PROSPERO CRD42021283866.
CI  - Thieme. All rights reserved.
FAU - Tasoudis, Panagiotis T
AU  - Tasoudis PT
AUID- ORCID: 0000-0001-7735-9474
AD  - Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, 
      University of Thessaly, Larissa, Greece.
FAU - Kyriakoulis, Ioannis G
AU  - Kyriakoulis IG
AD  - Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, 
      University of Thessaly, Larissa, Greece.
FAU - Sagris, Dimitrios
AU  - Sagris D
AD  - Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, 
      University of Thessaly, Larissa, Greece.
FAU - Diener, Hans Christoph
AU  - Diener HC
AD  - Department of Neuroepidemiology, University of Duisburg-Essen, Essen, Germany.
FAU - Ntaios, George
AU  - Ntaios G
AD  - Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, 
      University of Thessaly, Larissa, Greece.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220516
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
CIN - Ann Intern Med. 2022 Dec;175(12):JC137. PMID: 36469913
MH  - Humans
MH  - Clopidogrel/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/etiology
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Stroke/prevention & control
MH  - Hemorrhage/chemically induced
MH  - Drug Therapy, Combination
COIS- G.N. discloses speaker fees/Advisory Boards/Research support from Abbott; Amgen; 
      Bayer; BMS/Pfizer; Boehringer-Ingelheim; Elpen; Galenica; and Sanofi. Hans C.D. 
      received honoraria for participation in clinical trials, contribution to advisory 
      boards or oral presentations from: Abbott, BMS, Boehringer Ingelheim, 
      Daiichi-Sankyo, Medtronic, Novo-Nordisk, Pfizer, Portola, and WebMD Global. 
      Boehringer Ingelheim provided financial support for research projects. H.C.D. 
      received research grants from the German Research Council (DFG), German Ministry 
      of Education and Research (BMBF), European Union, NIH, Bertelsmann Foundation, 
      and Heinz-Nixdorf Foundation. Hans H.C.D.er was the German PI in the CAPRIE 
      trial. The other authors report no conflict of interest.
EDAT- 2022/05/17 06:00
MHDA- 2022/11/04 06:00
CRDT- 2022/05/16 19:25
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/11/04 06:00 [medline]
PHST- 2022/05/16 19:25 [entrez]
AID - 10.1055/a-1853-2952 [doi]
PST - ppublish
SO  - Thromb Haemost. 2022 Nov;122(11):1879-1887. doi: 10.1055/a-1853-2952. Epub 2022 
      May 16.

PMID- 19061719
OWN - NLM
STAT- MEDLINE
DCOM- 20090122
LR  - 20171116
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 156
IP  - 5
DP  - 2008 Nov
TI  - Platelet reactivity and response to aspirin in subjects with the metabolic 
      syndrome.
PG  - 1002.e1-1002.e7
LID - 10.1016/j.ahj.2008.08.002 [doi]
AB  - BACKGROUND: Metabolic syndrome (MS) is associated with a prothrombotic state and 
      predicts the subsequent development of type 2 diabetes mellitus. We hypothesized 
      that similar to diabetes, subjects with MS may have increased platelet 
      reactivity, and reduced response to aspirin. We, therefore, compared platelet 
      reactivity and response to aspirin among subjects with MS and healthy volunteers. 
      METHODS: Fifty subjects with MS, defined by Adult Treatment Panel III criteria 
      (age 44+/-9 years, 80% women, body mass index 35+/-8 kg/m2) were compared to 50 
      healthy controls who met none of the MS criteria (age 40+/-7 years, 80% women, 
      body mass index: 24+/-3 kg/m2). Blood samples were taken before and 24 hours 
      after 325 mg aspirin (single dose). Platelet function was evaluated by 
      aggregation in response to 1.5 mmol/L arachidonic acid, 1 microg/mL collagen, and 
      5 and 20 micromol/L adenosine diphosphate; the VerifyNow Aspirin assay 
      (Accumetrics Inc, San Diego, CA); Impact-R Cone and Plate(let) Analyzer 
      (shear-dependent test) (DiaMed, Cresier, Switzerland) and flow cytometric 
      determination of P-selectin expression and activated glycoprotein IIb/IIIa 
      expression; and reticulated platelets (reflecting platelet turnover). RESULTS: 
      Subjects with MS had higher baseline P-selectin levels (14.5+/-5 vs 11.3+/-4 mean 
      fluorescence intensity, P=.002), reticulated platelets (2.8%+/-3% vs 1.2%+/-1%, 
      P=.04) and platelet deposition under flow (Impact-R 7.5%+/-2% vs 5.9%+/-2%, 
      P=.003). Subjects with MS also had lower response to aspirin, as evaluated by the 
      change in all platelet aggregation assays and the VerifyNow score. CONCLUSIONS: 
      Subjects with MS appear to have increased baseline platelet reactivity and 
      turnover and a lower antiplatelet response to aspirin. Further research is 
      required to elucidate platelet properties in subjects with MS and find ways to 
      modify them.
FAU - Vaduganathan, Muthiah
AU  - Vaduganathan M
AD  - The Methodist Hospital Research Institute, Baylor College of Medicine, Houston, 
      TX 77030, USA.
FAU - Alviar, Carlos L
AU  - Alviar CL
FAU - Arikan, Mehmet E
AU  - Arikan ME
FAU - Tellez, Armando
AU  - Tellez A
FAU - Guthikonda, Sadishar
AU  - Guthikonda S
FAU - DeLao, Timothy
AU  - DeLao T
FAU - Granada, Juan F
AU  - Granada JF
FAU - Kleiman, Neal S
AU  - Kleiman NS
FAU - Ballantyne, Christie M
AU  - Ballantyne CM
FAU - Lev, Eli I
AU  - Lev EI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/*physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolic Syndrome/*blood
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 2008/12/09 09:00
MHDA- 2009/01/23 09:00
CRDT- 2008/12/09 09:00
PHST- 2008/04/06 00:00 [received]
PHST- 2008/08/03 00:00 [accepted]
PHST- 2008/12/09 09:00 [pubmed]
PHST- 2009/01/23 09:00 [medline]
PHST- 2008/12/09 09:00 [entrez]
AID - S0002-8703(08)00659-5 [pii]
AID - 10.1016/j.ahj.2008.08.002 [doi]
PST - ppublish
SO  - Am Heart J. 2008 Nov;156(5):1002.e1-1002.e7. doi: 10.1016/j.ahj.2008.08.002.

PMID- 28797987
OWN - NLM
STAT- MEDLINE
DCOM- 20180606
LR  - 20220317
IS  - 2148-5607 (Electronic)
IS  - 1300-4948 (Linking)
VI  - 28
IP  - 5
DP  - 2017 Sep
TI  - Continued use of low-dose aspirin may increase risk of bleeding after 
      gastrointestinal endoscopic submucosal dissection: A meta-analysis.
PG  - 329-336
LID - 10.5152/tjg.2017.16573 [doi]
AB  - BACKGROUND/AIMS: Endoscopic submucosal dissection has been widely accepted. At 
      present, the number of antiplatelet (APT) users has been growing. Moreover, 
      because of high risks of thromboembolism, some patients need to continuously 
      receive APT agents. The relationship between hemorrhage and continuous therapy 
      with low-dose aspirin (LDA) remains controversial. MATERIALS AND METHODS: A 
      systematic search was conducted; studies were screened out- if data of 
      no-anticoagulant/APT drugs use and interrupted and continued-LDA use were 
      reported separately. The Newcastle-scale was chosen to assess the quality of the 
      included studies. Review Manager 5.2 was used for quality assessment statistical 
      analysis, and the odd ratio (OR) and 95% confidence interval (CI) were 
      calculated. RESULTS: Pooled data suggested a significantly higher bleeding ratio 
      in the LDA-continued group compared to both the LDA-interrupted group (OR=2.05, 
      95% CI=1.05-3.99) and no-anticoagulant/APT group (OR=2.89, 95% CI=1.86-4.47). 
      However, the LDA-interrupted group did not differ significantly from the 
      no-anticoagulant/APT group. The en bloc resection rates of the LDA-continued 
      group versus the LDA-interrupted group, the LDA-continued group versus 
      no-anticoagulant/APT group, and the LDA-interrupted group versus the 
      no-anticoagulant/APT group were similar (OR=0.82, 95% CI=0.21-3.24, p=0.78; 
      OR=0.80, 95% CI=0.24-2.65, p=0.71; OR=1.41, 95% CI=0.38-5.24, p=0.60, 
      respectively). CONCLUSION: There is an extremely high ratio of bleeding in the 
      LDA-continued group compared to both the LDA-interrupted group and 
      no-anticoagulant/APT group. All groups had similar ratios of en bloc resection.
FAU - Wu, Wei
AU  - Wu W
AD  - Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, 
      China. yuhonggang1968@126.com.
FAU - Chen, Jingdi
AU  - Chen J
FAU - Ding, Qianshan
AU  - Ding Q
FAU - Yang, Dongmei
AU  - Yang D
FAU - Yu, Honggang
AU  - Yu H
FAU - Lin, Jun
AU  - Lin J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20170809
PL  - Turkey
TA  - Turk J Gastroenterol
JT  - The Turkish journal of gastroenterology : the official journal of Turkish Society 
      of Gastroenterology
JID - 9515841
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Endoscopic Mucosal Resection/*adverse effects
MH  - Gastrointestinal Neoplasms/*surgery
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Postoperative Hemorrhage/*etiology
MH  - Risk Factors
EDAT- 2017/08/12 06:00
MHDA- 2018/06/07 06:00
CRDT- 2017/08/12 06:00
PHST- 2017/08/12 06:00 [pubmed]
PHST- 2018/06/07 06:00 [medline]
PHST- 2017/08/12 06:00 [entrez]
AID - 10.5152/tjg.2017.16573 [doi]
PST - ppublish
SO  - Turk J Gastroenterol. 2017 Sep;28(5):329-336. doi: 10.5152/tjg.2017.16573. Epub 
      2017 Aug 9.

PMID- 31082433
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20200909
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 304
DP  - 2019 Jun 28
TI  - [Thrombus targeting aspirin particles for near infrared imaging and on-demand 
      therapy of thrombotic vascular diseases].
PG  - 164-172
LID - S0168-3659(19)30260-3 [pii]
LID - 10.1016/j.jconrel.2019.05.012 [doi]
AB  - A blood clot (thrombus) is formed as a final product of the hemostatic process 
      with two major components, a mesh of cross-linked fibrin and platelets activated 
      by high concentration of hydrogen peroxide (H(2)O(2)). Thrombus formation impedes 
      blood flow to brain and heart and is a principle cause of life-threatening 
      diseases such as stroke and myocardial infarction. Aspirin has been widely used 
      for the treatment and prevention of various cardiovascular diseases, but is 
      unable to target a thrombus and scavenge a high level of H(2)O(2). In this study, 
      we report thrombus targeting aspirin polyconjugate particles (T-APP) as a near 
      infrared imaging agent and on-demand therapeutic agent for thrombotic vascular 
      diseases. T-APP were formulated from H(2)O(2)-activatable aspirin polyconjugate, 
      fibrin-specific peptides and fluorescent IR780. In mouse models of tail bleeding 
      and arterial thrombosis, T-APP targeted the thrombosed vessels rapidly with 
      excellent specificity. T-APP also exerted highly strong antithrombotic activity 
      in the thrombosed vessel by suppressing anti-inflammatory cytokines and 
      inhibiting platelet activation. Based on the unique features such as specific 
      thrombus targeting, H(2)O(2) scavenging, and on-demand therapeutic actions, the 
      rationally engineered T-APP have important ramifications on imaging and on-demand 
      therapy of thrombotic disorders.
CI  - Copyright © 2019 Elsevier B.V. All rights reserved.
FAU - Lee, Jeonghun
AU  - Lee J
AD  - Department of BIN Convergence Technology, Chonbuk National University, 
      Baekjedaero 567, Jeonju, Chonbuk 54896, Republic of Korea.
FAU - Jeong, Lipjeong
AU  - Jeong L
AD  - Department of BIN Convergence Technology, Chonbuk National University, 
      Baekjedaero 567, Jeonju, Chonbuk 54896, Republic of Korea.
FAU - Jung, Eunkyeong
AU  - Jung E
AD  - Department of BIN Convergence Technology, Chonbuk National University, 
      Baekjedaero 567, Jeonju, Chonbuk 54896, Republic of Korea.
FAU - Ko, Changgon
AU  - Ko C
AD  - Department of BIN Convergence Technology, Chonbuk National University, 
      Baekjedaero 567, Jeonju, Chonbuk 54896, Republic of Korea.
FAU - Seon, Semee
AU  - Seon S
AD  - Department of BIN Convergence Technology, Chonbuk National University, 
      Baekjedaero 567, Jeonju, Chonbuk 54896, Republic of Korea.
FAU - Noh, Joungyoun
AU  - Noh J
AD  - Department of Polymer·Nano Science and Technology, Chonbuk National University, 
      Baekjedaero 567, Jeonju, Chonbuk 54896, Republic of Korea.
FAU - Lee, Dongwon
AU  - Lee D
AD  - Department of BIN Convergence Technology, Chonbuk National University, 
      Baekjedaero 567, Jeonju, Chonbuk 54896, Republic of Korea; Department of 
      Polymer·Nano Science and Technology, Chonbuk National University, Baekjedaero 
      567, Jeonju, Chonbuk 54896, Republic of Korea. Electronic address: 
      dlee@chonbuk.ac.kr.
LA  - fre
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190510
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Cytokines)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polymers)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Fibrinolytic Agents/administration & dosage/*pharmacology
MH  - Hemorrhage/chemically induced
MH  - Hydrogen Peroxide/metabolism
MH  - Mice
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Polymers/chemistry
MH  - Thrombosis/*drug therapy
OTO - NOTNLM
OT  - Antiplatelet activity
OT  - Aspirin
OT  - Hydrogen peroxide
OT  - Polyconjugate
OT  - Thrombus
EDAT- 2019/05/15 06:00
MHDA- 2020/09/10 06:00
CRDT- 2019/05/15 06:00
PHST- 2019/01/03 00:00 [received]
PHST- 2019/04/10 00:00 [revised]
PHST- 2019/05/06 00:00 [accepted]
PHST- 2019/05/15 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
PHST- 2019/05/15 06:00 [entrez]
AID - S0168-3659(19)30260-3 [pii]
AID - 10.1016/j.jconrel.2019.05.012 [doi]
PST - ppublish
SO  - J Control Release. 2019 Jun 28;304:164-172. doi: 10.1016/j.jconrel.2019.05.012. 
      Epub 2019 May 10.

PMID- 18574277
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20170602
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 133
IP  - 6 Suppl
DP  - 2008 Jun
TI  - Acute ST-segment elevation myocardial infarction: American College of Chest 
      Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
PG  - 708S-775S
LID - S0012-3692(08)60129-4 [pii]
LID - 10.1378/chest.08-0665 [doi]
AB  - This chapter about fibrinolytic, antiplatelet, and antithrombin treatment for 
      acute ST-segment elevation (STE) myocardial infarction (MI) is part of the 
      American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 
      (8th Edition). Grade 1 recommendations are strong and indicate that the benefits 
      do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that 
      individual patient values may lead to different choices (for a full understanding 
      of the grading see the chapter by Guyatt et al, CHEST 2008; 
      133[suppl]:123S-131S). Among the key recommendations in this chapter are the 
      following: for patients with ischemic symptoms characteristic of acute MI of < or 
      = 12 h in duration and persistent STE, we recommend that all undergo rapid 
      evaluation for reperfusion (primary percutaneous coronary intervention [PCI] or 
      fibrinolytic) therapy and have a reperfusion strategy implemented promptly after 
      contact with the health-care system (Grade 1A). For patients with ischemic 
      symptoms characteristic of acute MI of < or = 12 h in duration and persistent 
      STE, we recommend administration of streptokinase, anistreplase, alteplase, 
      reteplase, or tenecteplase over no fibrinolytic therapy (all Grade 1A). For 
      patients with symptom duration < or = 6 h, we recommend the administration of 
      alteplase or tenecteplase over streptokinase (both Grade 1A). We recommend 
      aspirin over no aspirin therapy followed by indefinite therapy (Grade 1A); we 
      also recommend clopidogrel in addition to aspirin for up to 28 days (Grade 1A). 
      In addition to aspirin and other antiplatelet therapies, we recommend the use of 
      antithrombin therapy (eg, unfractionated heparin (UFH), enoxaparin, or 
      fondaparinux) over no antithrombin therapy (Grade 1A), including for those 
      patients receiving fibrinolysis (and regardless of which lytic agent is 
      administered), primary PCI, or patients not receiving reperfusion therapy.
FAU - Goodman, Shaun G
AU  - Goodman SG
AD  - Michael's Hospital, University of Toronto, and Canadian Heart Research Centre, 
      Toronto, ON, Canada. Electronic address: goodmans@smh.toronto.on.ca.
FAU - Menon, Venu
AU  - Menon V
AD  - Cleveland Clinic Foundation, Cleveland, OH.
FAU - Cannon, Christopher P
AU  - Cannon CP
AD  - Brigham and Women's Hospital, Boston, MA.
FAU - Steg, Gabriel
AU  - Steg G
AD  - Hôpital Bichat, Paris, France.
FAU - Ohman, E Magnus
AU  - Ohman EM
AD  - Duke University Medical Center, Durham, NC.
FAU - Harrington, Robert A
AU  - Harrington RA
AD  - Duke University Medical Center, Durham, NC.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Chest. 2008 Oct;134(4):892
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Electrocardiography
MH  - *Evidence-Based Medicine
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/diagnosis/*drug therapy/therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2008/07/24 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/07/24 09:00
PHST- 2008/07/24 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/24 09:00 [entrez]
AID - S0012-3692(08)60129-4 [pii]
AID - 10.1378/chest.08-0665 [doi]
PST - ppublish
SO  - Chest. 2008 Jun;133(6 Suppl):708S-775S. doi: 10.1378/chest.08-0665.

PMID- 17311118
OWN - NLM
STAT- MEDLINE
DCOM- 20070403
LR  - 20190608
IS  - 0828-282X (Print)
IS  - 1916-7075 (Electronic)
IS  - 0828-282X (Linking)
VI  - 23
IP  - 2
DP  - 2007 Feb
TI  - The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current 
      perspective on cardiovascular risks.
PG  - 125-31
AB  - There is strong evidence from randomized clinical trials that the highly 
      selective cox-2 inhibitors (coxibs), compared with placebo, cause an excess of 
      serious cardiovascular events that are not mitigated by low-dose acetylsalicylic 
      acid. Both Health Canada and the Food and Drug Administration have concluded that 
      the excess cardiovascular events may be a 'class effect' of all the nonsteroidal 
      anti-inflammatory drugs (NSAIDs), including traditional NSAIDs (tNSAIDs) and 
      coxibs, and now require appropriate black box labelling of all these agents. 
      Celecoxib and lumiracoxib are the only coxibs remaining on the market in Canada. 
      The prostanoid pathways, the roles of cox-1 and cox-2, as well as the inhibitory 
      effects of acetylsalicylic acid, traditional tNSAIDs and the coxibs, are briefly 
      reviewed. Current recommendations for the ongoing use of coxibs and the tNSAIDs 
      are summarized.
FAU - Cairns, J A
AU  - Cairns JA
AD  - University of British Columbia, Vancouver, Canada. jacairns@medd.med.ubc.ca
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cardiovascular Diseases/*chemically induced
MH  - Cyclooxygenase 2 Inhibitors/*pharmacology
MH  - Humans
PMC - PMC2650648
EDAT- 2007/02/22 09:00
MHDA- 2007/04/04 09:00
CRDT- 2007/02/22 09:00
PHST- 2007/02/22 09:00 [pubmed]
PHST- 2007/04/04 09:00 [medline]
PHST- 2007/02/22 09:00 [entrez]
AID - S0828-282X(07)70732-8 [pii]
AID - cjc230125 [pii]
AID - 10.1016/s0828-282x(07)70732-8 [doi]
PST - ppublish
SO  - Can J Cardiol. 2007 Feb;23(2):125-31. doi: 10.1016/s0828-282x(07)70732-8.

PMID- 11070137
OWN - NLM
STAT- MEDLINE
DCOM- 20010405
LR  - 20191104
IS  - 1059-941X (Print)
IS  - 1059-941X (Linking)
VI  - 9
IP  - 2
DP  - 2000 Jun
TI  - Dental erosion and aspirin headache powders: a clinical report.
PG  - 95-8
AB  - The causes of tooth erosion are varied, but all are associated with a chemical 
      attack on the teeth and resulting loss of tooth structure. Etiologic factors 
      related to erosion cited in the literature include bulimia, eating acidic foods, 
      soft drink consumption, acid reflux, and swimming, among others. This clinical 
      report suggests that chronic use of headache powders can also be a factor leading 
      to tooth erosion.
FAU - McCracken, M
AU  - McCracken M
AD  - Department of Restorative Dentistry, University of Alabama School of Dentistry, 
      1530 3rd Avenue South, Birmingham, AL 35294, USA. mikemc@uab.edu
FAU - O'Neal, S J
AU  - O'Neal SJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Prosthodont
JT  - Journal of prosthodontics : official journal of the American College of 
      Prosthodontists
JID - 9301275
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Powders)
RN  - R16CO5Y76E (Aspirin)
MH  - Administration, Sublingual
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Crowns
MH  - Female
MH  - Follow-Up Studies
MH  - Headache/drug therapy
MH  - Humans
MH  - Occlusal Splints
MH  - Powders
MH  - Tooth Erosion/*etiology/therapy
MH  - Vertical Dimension
EDAT- 2000/11/09 11:00
MHDA- 2001/04/06 10:01
CRDT- 2000/11/09 11:00
PHST- 2000/11/09 11:00 [pubmed]
PHST- 2001/04/06 10:01 [medline]
PHST- 2000/11/09 11:00 [entrez]
AID - S1059941X00078025 [pii]
AID - 10.1111/j.1532-849x.2000.00095.x [doi]
PST - ppublish
SO  - J Prosthodont. 2000 Jun;9(2):95-8. doi: 10.1111/j.1532-849x.2000.00095.x.

PMID- 21306212
OWN - NLM
STAT- MEDLINE
DCOM- 20110826
LR  - 20211020
IS  - 1744-8360 (Electronic)
IS  - 1473-7175 (Print)
IS  - 1473-7175 (Linking)
VI  - 11
IP  - 2
DP  - 2011 Feb
TI  - Antiplatelet resistance in stroke.
PG  - 251-63
LID - 10.1586/ern.10.203 [doi]
AB  - Although the exact prevalence of antiplatelet resistance in ischemic stroke is 
      not known, estimates about the two most widely used antiplatelet agents - aspirin 
      and clopidogrel - suggest that the resistance rate is high, irrespective of the 
      definition used and parameters measured. Inadequate antiplatelet responsiveness 
      correlates with an increased risk of recurrent ischemic vascular events in 
      patients with stroke and acute coronary syndrome. It is not currently known 
      whether tailoring antiplatelet therapy based on platelet function test results 
      translates into a more effective strategy to prevent secondary vascular events 
      after stroke. Large-scale clinical trials using a universally accepted definition 
      and standardized measurement techniques for antiplatelet resistance are needed to 
      demonstrate whether a 'platelet-function test-guided antiplatelet treatment' 
      strategy translates into improved stroke care. This article gives an overview of 
      the clinical importance of laboratory antiplatelet resistance, describes the 
      challenges for platelet-function test-guided antiplatelet treatment and discusses 
      practical issues about the management of patients with aspirin and/or clopidogrel 
      resistance.
FAU - Topçuoglu, Mehmet Akif
AU  - Topçuoglu MA
AD  - Hacettepe University Hospitals, Department of Neurology, Ankara, Turkey.
FAU - Arsava, Ethem Murat
AU  - Arsava EM
FAU - Ay, Hakan
AU  - Ay H
LA  - eng
GR  - R01 NS059710/NS/NINDS NIH HHS/United States
GR  - R01 NS059710-02/NS/NINDS NIH HHS/United States
GR  - R01-NS059710/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - England
TA  - Expert Rev Neurother
JT  - Expert review of neurotherapeutics
JID - 101129944
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*complications
MH  - Aspirin/adverse effects/metabolism/*therapeutic use
MH  - Clopidogrel
MH  - Cyclooxygenase Inhibitors/adverse effects/therapeutic use
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Platelet Function Tests
MH  - Risk
MH  - Secondary Prevention
MH  - Stroke/*drug therapy/prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
PMC - PMC3086673
MID - NIHMS284137
EDAT- 2011/02/11 06:00
MHDA- 2011/08/30 06:00
CRDT- 2011/02/11 06:00
PHST- 2011/02/11 06:00 [entrez]
PHST- 2011/02/11 06:00 [pubmed]
PHST- 2011/08/30 06:00 [medline]
AID - 10.1586/ern.10.203 [doi]
PST - ppublish
SO  - Expert Rev Neurother. 2011 Feb;11(2):251-63. doi: 10.1586/ern.10.203.

PMID- 16364973
OWN - NLM
STAT- MEDLINE
DCOM- 20060522
LR  - 20181201
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 27
IP  - 6
DP  - 2006 Mar
TI  - Aspirin and clopidogrel resistance: an emerging clinical entity.
PG  - 647-54
AB  - Antiplatelet therapy is a cornerstone of cardiovascular medicine. Aspirin and 
      clopidogrel have emerged as critical therapies in the treatment of cardiovascular 
      disease. Despite their efficacy, patients on these medications continue to suffer 
      complications. Millions of patients are currently on low-dose antiplatelet 
      therapy but it is unknown how many of these patients are under-treated or on the 
      wrong medication. Aspirin and clopidogrel resistance are emerging clinical 
      entities with potentially severe consequences such as recurrent myocardial 
      infarction, stroke, or death. The mechanism of resistance remains incompletely 
      defined, but there are specific clinical, cellular, and genetic factors that 
      influence therapeutic failure. These factors range from physicians who fail to 
      prescribe these medications despite appropriate indications to polymorphisms of 
      platelet membrane glycoproteins. Rapid and accurate diagnosis of antiplatelet 
      resistance also remains an issue as new bedside tests are developed. By 
      understanding the mechanism of therapeutic failure and by improving the diagnosis 
      of this clinical entity, a new era of individualized antiplatelet therapy may 
      arise with routine measurements of platelet activity in the same way that 
      cholesterol, blood pressure, and blood sugar are followed, thus improving the 
      care for millions of people.
FAU - Wang, Thomas H
AU  - Wang TH
AD  - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid 
      Avenue, Cleveland, OH 44195, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
FAU - Topol, Eric J
AU  - Topol EJ
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20051219
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2006 Jul;27(14):1754; author reply 1754-5. PMID: 16751205
CIN - Eur Heart J. 2006 Dec;27(23):2900; author reply 2900-1. PMID: 17015405
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clopidogrel
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
RF  - 98
EDAT- 2005/12/21 09:00
MHDA- 2006/05/23 09:00
CRDT- 2005/12/21 09:00
PHST- 2005/12/21 09:00 [pubmed]
PHST- 2006/05/23 09:00 [medline]
PHST- 2005/12/21 09:00 [entrez]
AID - ehi684 [pii]
AID - 10.1093/eurheartj/ehi684 [doi]
PST - ppublish
SO  - Eur Heart J. 2006 Mar;27(6):647-54. doi: 10.1093/eurheartj/ehi684. Epub 2005 Dec 
      19.

PMID- 25533258
OWN - NLM
STAT- MEDLINE
DCOM- 20150417
LR  - 20141223
IS  - 0040-5930 (Print)
IS  - 0040-5930 (Linking)
VI  - 72
IP  - 1
DP  - 2015 Jan
TI  - [Management of frostbite in and outside of the doctor's surgery].
PG  - 55-7
LID - 10.1024/0040-5930/a000640 [doi]
AB  - Frostbite is most likely to happen in combination with accidents, intoxications 
      or psychiatric emergencies and typically affects smaller, more exposed areas of 
      the body, such as fingers, toes, nose, ears, cheeks and chin. The preclinical 
      treatment consists of rapid rewarming of the injured tissue in a water-bath that 
      is held between 38 - 42 °C (hand-hot) in a stable, warm environment. A new 
      clssification allows a faster assessment of the outcome. New retrospective 
      studies suggest the efficacy of thrombolysis or prostacyclin analogues against 
      spasm and thrombosis for a better outcome.
FAU - Durrer, Bruno
AU  - Durrer B
AD  - Caremed Praxis Lauterbrunnen/Mürren, Lauterbrunnen.
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Management von lokalen Kälteschäden in und außerhalb der Praxis.
PL  - Switzerland
TA  - Ther Umsch
JT  - Therapeutische Umschau. Revue therapeutique
JID - 0407224
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Finger Injuries/diagnosis/therapy
MH  - Frostbite/*diagnosis/etiology/*therapy
MH  - *General Practice
MH  - Humans
MH  - Rewarming/methods
MH  - Toes/injuries
EDAT- 2014/12/24 06:00
MHDA- 2015/04/18 06:00
CRDT- 2014/12/24 06:00
PHST- 2014/12/24 06:00 [entrez]
PHST- 2014/12/24 06:00 [pubmed]
PHST- 2015/04/18 06:00 [medline]
AID - Q4327L6423321N1V [pii]
AID - 10.1024/0040-5930/a000640 [doi]
PST - ppublish
SO  - Ther Umsch. 2015 Jan;72(1):55-7. doi: 10.1024/0040-5930/a000640.

PMID- 14716957
OWN - NLM
STAT- MEDLINE
DCOM- 20040423
LR  - 20200825
IS  - 0304-4602 (Print)
IS  - 0304-4602 (Linking)
VI  - 32
IP  - 6
DP  - 2003 Nov
TI  - Clinical profile and treatment outcome of livedoid vasculitis: a case series.
PG  - 835-9
AB  - INTRODUCTION: Livedoid vasculitis is a painful ulcerative condition affecting the 
      legs that is often difficult to treat. In this case series, the clinical profile 
      of 6 patients with livedoid vasculitis and their treatment response to aspirin 
      and pentoxifylline are reported. MATERIALS AND METHODS: This is an open trial. 
      Investigations to exclude secondary causes of livedoid vasculitis were done. Skin 
      biopsies were performed for histology and direct immunofluorescence. Four 
      patients were treated with pentoxifylline and 2 with aspirin. Response to 
      treatment was assessed at the third and sixth weeks. Thereafter, treatment was 
      individualised according to each patient's clinical response. RESULTS: Only 1 out 
      of 6 patients had a good response. This patient was treated with pentoxifylline. 
      Most patients required treatment with drugs such as prednisolone, colchicine and 
      azathioprine to control disease activity after the trial period. CONCLUSION: 
      Pentoxifylline or aspirin did not result in significant improvement for most of 
      our patients when used alone. Combination with immunosuppressive treatment 
      yielded better results.
FAU - Lee, S S
AU  - Lee SS
AD  - National Skin Centre, 1 Mandalay Road, Singapore 308205. joycelee@nsc.gov.sg
FAU - Ang, P
AU  - Ang P
FAU - Tan, S H
AU  - Tan SH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Singapore
TA  - Ann Acad Med Singap
JT  - Annals of the Academy of Medicine, Singapore
JID - 7503289
RN  - 0 (Gout Suppressants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Colchicine/therapeutic use
MH  - Drug Therapy, Combination
MH  - Gout Suppressants/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pentoxifylline/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Vasculitis/*drug therapy
EDAT- 2004/01/14 05:00
MHDA- 2004/04/24 05:00
CRDT- 2004/01/14 05:00
PHST- 2004/01/14 05:00 [pubmed]
PHST- 2004/04/24 05:00 [medline]
PHST- 2004/01/14 05:00 [entrez]
PST - ppublish
SO  - Ann Acad Med Singap. 2003 Nov;32(6):835-9.

PMID- 6542377
OWN - NLM
STAT- MEDLINE
DCOM- 19841227
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 34
IP  - 9
DP  - 1984
TI  - [Animal experimental studies on the question of the interaction of paracetamol 
      and acetylsalicylic acid].
PG  - 992-1001
AB  - The mutual effects of acetylsalicylic acid and paracetamol used in combination 
      were studied in rats and mice. The antiexudative effects of acetylsalicylic acid 
      in the edema tests on the hind paw of the rat, the antipyretic activity against 
      yeast-fever of the rat and the analgesic effect on the inflamed hind paw of the 
      rat was potentiated by paracetamol given simultaneously. The biosynthesis of 
      prostaglandins in vitro by an enzyme preparation from bovine seminal vesicles was 
      inhibited by acetylsalicylic acid and paracetamol in additive synergistic mode. 
      The hepatotoxicity of paracetamol in mice measured by an increase of GOT in serum 
      is antagonized by acetylsalicylic acid in dose-dependent manner. The suppression 
      of the hepatotoxicity of paracetamol by acetylsalicylic acid in mice is not the 
      consequence of interaction during absorption. The 3H-content of the liver 
      following an oral dose of 3H-paracetamol is not influenced by acetylsalicylic 
      acid given in combination with paracetamol. The mechanism of interactions between 
      acetylsalicylic acid and paracetamol is discussed.
FAU - Engelhardt, G
AU  - Engelhardt G
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Tierexperimentelle Untersuchungen zur Frage des Zusammenwirkens von Paracetamol 
      und Acetylsalicylsäure.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Prostaglandins)
RN  - 362O9ITL9D (Acetaminophen)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/metabolism/*pharmacology/toxicity
MH  - Animals
MH  - Aspirin/*pharmacology/toxicity
MH  - Body Temperature/drug effects
MH  - Exudates and Transudates/drug effects
MH  - Female
MH  - Glutathione/metabolism
MH  - Liver/drug effects
MH  - Male
MH  - Mice
MH  - Prostaglandins/biosynthesis
MH  - Rats
MH  - Stomach Ulcer/chemically induced
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1984;34(9):992-1001.

PMID- 15487851
OWN - NLM
STAT- MEDLINE
DCOM- 20050218
LR  - 20181130
IS  - 0723-5003 (Print)
IS  - 0723-5003 (Linking)
VI  - 99 Suppl 1
DP  - 2004 Aug 15
TI  - [Current pharmacological principles to inhibit platelet function and their 
      clinical implications. Focus on clopidogrel].
PG  - 3-7
AB  - Clopidogrel is a further-developed analog of ticlopidine and currently the only 
      therapeutic alternative for long-term prophylaxis and therapy of 
      atherothrombosis. According to the CAPRIE trial, clopidogrel causes significantly 
      less gastrointestinal bleeding than plain aspirin (ASA). There is an increased 
      antiplatelet efficacy by combining clopidogrel with ASA as shown in several 
      clinical trials, such as CURE and CREDO. An active metabolite of clopidogrel 
      causes irreversible inhibition of the P2Y12-ADP receptor at the platelet surface, 
      but does not alter the metabolism of arachidonic acid. Clopidogrel has additional 
      effects on the ADP-induced expression of adhesion molecules (P-selectin, 
      GPIIb/IIIa) and inflammatory mediators (CD40L). These actions, shown ex vivo, 
      might be clinically relevant. Similar to ASA there can be variable antiplatelet 
      activities of Clopidogrel. Their frequency can not be precisely estimated yet. 
      There is neither a generally accepted definition of insufficient responsiveness 
      (against inhibitors of platelet function) nor any generally accepted procedure to 
      measure it, including definition of normal range.
FAU - Schrör, Karsten
AU  - Schrör K
AD  - Institut für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum, 
      Heinrich-Heine-Universität Düsseldorf. kschroer@uni-duesseldorf.de
LA  - ger
PT  - Journal Article
TT  - Aktuelle pharmakologische Prinzipien der Plättchenfunktionshemmung und ihre 
      Implikationen für die Klinik. Fokus auf Clopidogrel.
PL  - Germany
TA  - Med Klin (Munich)
JT  - Medizinische Klinik (Munich, Germany : 1983)
JID - 8303501
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacokinetics/pharmacology/toxicity
MH  - Clopidogrel
MH  - Embolism, Cholesterol/*blood/prevention & control
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/*pharmacology/toxicity
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/*analogs & derivatives/pharmacokinetics/*pharmacology/toxicity
EDAT- 2004/10/19 09:00
MHDA- 2005/02/19 09:00
CRDT- 2004/10/19 09:00
PHST- 2004/10/19 09:00 [pubmed]
PHST- 2005/02/19 09:00 [medline]
PHST- 2004/10/19 09:00 [entrez]
PST - ppublish
SO  - Med Klin (Munich). 2004 Aug 15;99 Suppl 1:3-7.

PMID- 9167391
OWN - NLM
STAT- MEDLINE
DCOM- 19970624
LR  - 20131121
IS  - 0038-3139 (Print)
IS  - 0038-3139 (Linking)
VI  - 93
IP  - 5
DP  - 1997 May
TI  - Cooperative Cardiovascular Project.
PG  - 177-9
AB  - This national project evaluated elements of care for patients admitted for acute 
      myocardial infarction. Opportunities for improving processes of care, especially 
      in the use and timing of aspirin and thrombolytics, were identified. Additional 
      data regarding other quality indicators is available. It is hoped that this data 
      can be used to help create or incorporate changes in existing AMI protocols, 
      ultimately improving care and outcomes for these patients.
FAU - Gunter, N
AU  - Gunter N
AD  - Carolina Medical Review Project Team, Columbia, SC 29210, USA.
FAU - Moore, L
AU  - Moore L
FAU - Odom, P
AU  - Odom P
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J S C Med Assoc
JT  - Journal of the South Carolina Medical Association (1975)
JID - 7503045
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Medicare
MH  - Myocardial Infarction/*therapy
MH  - Pilot Projects
MH  - South Carolina
MH  - United States
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
PST - ppublish
SO  - J S C Med Assoc. 1997 May;93(5):177-9.

PMID- 1011303
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 16
IP  - 9
DP  - 1976 Sep
TI  - Management of small arterial injuries: clinical and experimental studies.
PG  - 681-5
AB  - Twenty-five patients with 35 severed small arteries of the wrist, calf, or ankle 
      are presented. Included are six cases of total ischemia of the wrist or ankle. 
      Twenty-two repairs and thirteen ligations were performed. There was only one 
      amputation from arterial insufficiency. We recommend repair both to preserve 
      tissue and to restore optimum flow. By use of meticulous interrupted suture 
      technique, optical magnification, and heparin and aspirin administration, a high 
      degree of arterial patency can be achieved.
FAU - Kelly, G
AU  - Kelly G
FAU - Eiseman, B
AU  - Eiseman B
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Brachial Artery/*injuries
MH  - Femoral Artery/*injuries
MH  - Follow-Up Studies
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Postoperative Complications/prevention & control
MH  - Thrombosis/prevention & control
MH  - Vascular Surgical Procedures
EDAT- 1976/09/01 00:00
MHDA- 1976/09/01 00:01
CRDT- 1976/09/01 00:00
PHST- 1976/09/01 00:00 [pubmed]
PHST- 1976/09/01 00:01 [medline]
PHST- 1976/09/01 00:00 [entrez]
AID - 10.1097/00005373-197609000-00001 [doi]
PST - ppublish
SO  - J Trauma. 1976 Sep;16(9):681-5. doi: 10.1097/00005373-197609000-00001.

PMID- 27432692
OWN - NLM
STAT- MEDLINE
DCOM- 20170717
LR  - 20180531
IS  - 1916-7075 (Electronic)
IS  - 0828-282X (Linking)
VI  - 32
IP  - 11
DP  - 2016 Nov
TI  - Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in 
      Atrial Fibrillation Patients With Contraindications to Anticoagulation.
PG  - 1355.e9-1355.e14
LID - S0828-282X(16)00164-1 [pii]
LID - 10.1016/j.cjca.2016.02.056 [doi]
AB  - BACKGROUND: Percutaneous left atrial appendage closure (LAAC) is increasingly 
      performed as an alternative to oral anticoagulation (OAC) in patients with 
      nonvalvular atrial fibrillation (AF). We sought to evaluate the 
      cost-effectiveness of treating OAC contraindicated patients with LAAC compared 
      with aspirin alone. METHODS: A probabilistic patient-level Markov microsimulation 
      model with a lifetime horizon was performed to assess the discounted lifetime 
      costs, quality-adjusted life years, and incremental cost-effectiveness ratio of 
      LAAC compared with aspirin for patients with AF with contraindications to OAC. 
      Baseline characteristics were based on a published multicenter Canadian LAAC 
      experience. Clinical events included stroke, bleeding, myocardial infarction, and 
      procedure-related complications. Event rates for stroke and bleeding were based 
      on the CHA(2)DS(2)-VASc and HAS-BLED scores. The relative efficacies of LAAC and 
      aspirin, as well as utility scores, were obtained from the published literature. 
      Canadian procedural and long-term costs were obtained from the Ontario Case 
      Costing Initiative and the Ontario Ministry of Health and Long Term Care. 
      RESULTS: Aspirin was less effective than LAAC (4.25 ± 0.53 vs 4.66 ± 0.34 
      quality-adjusted life years, respectively). The average discounted lifetime cost 
      was CAD$30,748 ± 11,600 for LAAC and $38,974 ± 18,783 for aspirin. Thus, LAAC was 
      dominant, being more effective and less expensive. Our results were robust with a 
      relatively low degree of uncertainty, as LAAC was the preferred option in more 
      than 90% of simulations at a willingness-to-pay threshold of $50,000. 
      CONCLUSIONS: LAAC is a novel stroke preventative therapy for nonvalvular AF and 
      is a cost-effective alternative to aspirin in patients with contraindications to 
      OAC.
CI  - Copyright © 2016. Published by Elsevier Inc.
FAU - Saw, Jacqueline
AU  - Saw J
AD  - Division of Cardiology, Vancouver General Hospital, University of British 
      Columbia, Vancouver, British Columbia, Canada. Electronic address: 
      jsaw@mail.ubc.ca.
FAU - Bennell, Maria C
AU  - Bennell MC
AD  - Schulich Heart Center, Division of Cardiology, Sunnybrook Health Sciences Center, 
      University of Toronto, Toronto, Ontario, Canada.
FAU - Singh, Sheldon M
AU  - Singh SM
AD  - Schulich Heart Center, Division of Cardiology, Sunnybrook Health Sciences Center, 
      University of Toronto, Toronto, Ontario, Canada.
FAU - Wijeysundera, Harindra C
AU  - Wijeysundera HC
AD  - Schulich Heart Center, Division of Cardiology, Sunnybrook Health Sciences Center, 
      University of Toronto, Toronto, Ontario, Canada; Institute for Clinical 
      Evaluative Sciences (ICES), Toronto, Ontario, Canada; Institute for Health 
      Policy, Management and Evaluation (IHPME), University of Toronto, Toronto, 
      Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20160223
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants
MH  - Aspirin/*economics/therapeutic use
MH  - Atrial Appendage/surgery
MH  - Atrial Fibrillation/drug therapy/*economics/*surgery
MH  - Contraindications
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Models, Economic
MH  - Platelet Aggregation Inhibitors/*economics/therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Stroke/*prevention & control
MH  - *Therapeutic Occlusion/economics/instrumentation
EDAT- 2016/10/30 06:00
MHDA- 2017/07/18 06:00
CRDT- 2016/07/20 06:00
PHST- 2015/12/30 00:00 [received]
PHST- 2016/02/02 00:00 [revised]
PHST- 2016/02/18 00:00 [accepted]
PHST- 2016/10/30 06:00 [pubmed]
PHST- 2017/07/18 06:00 [medline]
PHST- 2016/07/20 06:00 [entrez]
AID - S0828-282X(16)00164-1 [pii]
AID - 10.1016/j.cjca.2016.02.056 [doi]
PST - ppublish
SO  - Can J Cardiol. 2016 Nov;32(11):1355.e9-1355.e14. doi: 10.1016/j.cjca.2016.02.056. 
      Epub 2016 Feb 23.

PMID- 35245223
OWN - NLM
STAT- MEDLINE
DCOM- 20220620
LR  - 20230721
IS  - 1526-7598 (Electronic)
IS  - 0003-2999 (Linking)
VI  - 135
IP  - 1
DP  - 2022 Jul 1
TI  - Association Between Aspirin Use and Sepsis Outcomes: A National Cohort Study.
PG  - 110-117
LID - 10.1213/ANE.0000000000005943 [doi]
AB  - BACKGROUND: Aspirin has anti-inflammatory and antiplatelet activities and 
      directly inhibits bacterial growth. These effects of aspirin may improve survival 
      in patients with sepsis. We retrospectively reviewed a large national health 
      database to test the relationship between prehospital aspirin use and sepsis 
      outcomes. METHODS: We conducted a retrospective population-based cohort study 
      using the National Health Insurance Research Database of Taiwan from 2001 to 2011 
      to examine the relationship between aspirin use before hospital admission and 
      sepsis outcomes. The association between aspirin use and 90-day mortality in 
      sepsis patients was determined using logistic regression models and weighting 
      patients by the inverse probability of treatment weighting (IPTW) with the 
      propensity score. Kaplan-Meier survival curves for each IPTW cohort were plotted 
      for 90-day mortality. For sensitivity analyses, restricted mean survival times 
      (RMSTs) were calculated based on Kaplan-Meier curves with 3-way IPTW analysis 
      comparing current use, past use, and nonuse. RESULTS: Of 52,982 patients with 
      sepsis, 12,776 took aspirin before hospital admission (users), while 39,081 did 
      not take any antiplatelet agents including aspirin before hospital admission 
      (nonusers). After IPTW analysis, we found that when compared to nonusers, 
      patients who were taking aspirin within 90 days before sepsis onset had a lower 
      90-day mortality rate (IPTW odds ratio [OR], 0.90; 95% confidence interval [CI], 
      0.88-0.93; P < .0001). Based on IPTW RMST analysis, nonusers had an average 
      survival of 71.75 days, while current aspirin users had an average survival of 
      73.12 days. The difference in mean survival time was 1.37 days (95% CI, 
      0.50-2.24; P = .002). CONCLUSIONS: Aspirin therapy before hospital admission is 
      associated with a reduced 90-day mortality in sepsis patients.
CI  - Copyright © 2022 International Anesthesia Research Society.
FAU - Hsu, Wan-Ting
AU  - Hsu WT
AD  - From the Department of Epidemiology, Harvard T.H. Chan School of Public Health, 
      Boston, Massachusetts.
FAU - Porta, Lorenzo
AU  - Porta L
AD  - Department of Emergency Medicine, School of Medicine and Surgery, Università 
      degli studi di Milano Bicocca, Milan, Italy.
FAU - Chang, I-Jing
AU  - Chang IJ
AD  - Department of Dermatology, Taipei Medical University Hospital, Taipei, Taiwan.
FAU - Dao, Quynh-Lan
AU  - Dao QL
AD  - Department of Medicine, Warren Alpert Medical School of Brown University, 
      Providence, Rhode Island.
FAU - Tehrani, Babak M
AU  - Tehrani BM
AD  - Department of Medicine, Warren Alpert Medical School of Brown University, 
      Providence, Rhode Island.
FAU - Hsu, Tzu-Chun
AU  - Hsu TC
AD  - Department of Emergency Medicine, National Taiwan University Hospital, Taipei, 
      Taiwan.
FAU - Lee, Chien-Chang
AU  - Lee CC
AD  - Department of Dermatology, Taipei Medical University Hospital, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220304
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Cohort Studies
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - *Sepsis/diagnosis/drug therapy
COIS- The authors declare no conflicts of interest.
EDAT- 2022/03/05 06:00
MHDA- 2022/06/22 06:00
CRDT- 2022/03/04 17:11
PHST- 2022/03/05 06:00 [pubmed]
PHST- 2022/06/22 06:00 [medline]
PHST- 2022/03/04 17:11 [entrez]
AID - 00000539-202207000-00017 [pii]
AID - 10.1213/ANE.0000000000005943 [doi]
PST - ppublish
SO  - Anesth Analg. 2022 Jul 1;135(1):110-117. doi: 10.1213/ANE.0000000000005943. Epub 
      2022 Mar 4.

PMID- 3228627
OWN - NLM
STAT- MEDLINE
DCOM- 19890420
LR  - 20161018
IS  - 0100-879X (Print)
IS  - 0100-879X (Linking)
VI  - 21
IP  - 3
DP  - 1988
TI  - Platelet regeneration time: a statistical approach.
PG  - 471-3
AB  - The determination of platelet regeneration half-time (PRT t1/2) by measuring 
      malondialdehyde after intake of acetylsalicylic acid is a simple nonisotopic 
      method for the estimation of platelet survival. There is no available information 
      concerning the populational distribution of PRT t1/2. Consequently, there is 
      controversy about the utilization of parametric or nonparametric statistical 
      tests in studies of PRT. In the present study, we demonstrate the closeness of 
      the fit of log PRT t1/2 to the normal (Gaussian) distribution.
FAU - Lopes, A A
AU  - Lopes AA
AD  - Laboratório de Pesquisa do Instituto do Coração, Faculdade de Medicina, 
      Universidade de São Paulo, Brasil.
FAU - Maeda, N Y
AU  - Maeda NY
FAU - Chamone, D A
AU  - Chamone DA
FAU - Sauaia, N
AU  - Sauaia N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Brazil
TA  - Braz J Med Biol Res
JT  - Brazilian journal of medical and biological research = Revista brasileira de 
      pesquisas medicas e biologicas
JID - 8112917
RN  - 0 (Malonates)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*physiology
MH  - Cell Survival
MH  - Humans
MH  - Malonates/*blood
MH  - Malondialdehyde/*blood
MH  - Platelet Function Tests
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Braz J Med Biol Res. 1988;21(3):471-3.

PMID- 7397355
OWN - NLM
STAT- MEDLINE
DCOM- 19801024
LR  - 20131121
IS  - 0365-9615 (Print)
IS  - 0365-9615 (Linking)
VI  - 89
IP  - 6
DP  - 1980 Jun
TI  - [Effect of trypsin on intravascular erythrocytes aggregation].
PG  - 671-3
AB  - The role of proteolytic enzymes in intravascular aggregation of red cells was 
      studied in experiments on rats by intravital microscopy. Intravenous injection of 
      trypsin (40--50 mg/kg) combined with heparin (1000 units/kg) produces marked 
      intravascular aggregation of red cells. Preliminary infusion of pentoxyphyllin 
      (20 mg/kg) or acetylsalicylic acid (100 mg/kg) blocked this process. A conclusion 
      is made about an important role of proteolytic enzymes play in the development of 
      microcirculatory disorders. A possible mechanism of the aggregating action of 
      trypsin and approaches to its correction are discussed.
FAU - Sheremet'ev, Iu A
AU  - Sheremet'ev IuA
FAU - Levin, G Ia
AU  - Levin GIa
FAU - Shtykhno, Iu M
AU  - Shtykhno IuM
FAU - Udovichenko, V I
AU  - Udovichenko VI
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Vliianie tripsina na vnutrisosudistuiu agregatsiiu éritrotsitov.
PL  - Russia (Federation)
TA  - Biull Eksp Biol Med
JT  - Biulleten' eksperimental'noi biologii i meditsiny
JID - 0370627
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.4 (Trypsin)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Erythrocyte Aggregation/*drug effects
MH  - Heparin/pharmacology
MH  - Pentoxifylline/pharmacology
MH  - Rats
MH  - Trypsin/*pharmacology
EDAT- 1980/06/01 00:00
MHDA- 1980/06/01 00:01
CRDT- 1980/06/01 00:00
PHST- 1980/06/01 00:00 [pubmed]
PHST- 1980/06/01 00:01 [medline]
PHST- 1980/06/01 00:00 [entrez]
PST - ppublish
SO  - Biull Eksp Biol Med. 1980 Jun;89(6):671-3.

PMID- 1626454
OWN - NLM
STAT- MEDLINE
DCOM- 19920811
LR  - 20150901
IS  - 0001-6578 (Print)
IS  - 0001-6578 (Linking)
VI  - 33
IP  - 1
DP  - 1992 Jan-Feb
TI  - Kawasaki disease with Reye syndrome: report of one case.
PG  - 67-71
AB  - A seven-month-old girl was admitted to the Pediatrics Department of Mackay 
      Memorial Hospital with the following symptoms and signs: (1) high fever for more 
      than five days; (2) injection of bilateral conjunctiva; (3) bright red lips with 
      strawberry tongue; (4) edematous change of palms and soles, followed by digit 
      desquamation; (5) an ill-defined, erythematous plaque on the scar of the BCG. 
      Kawasaki disease was diagnosed, and high dose aspirin (100 mg/kg/day) and 
      intravenous gamma-globulin (IVIG) (400 mg/kg/day) were given for four days. The 
      patient was afebrile on the second day after IVIG infusion, and was discharged 
      six days after admission. A small single daily dose of aspirin (10 mg/kg/day) was 
      given after the afebrile days. Unfortunately, vomiting and consciousness 
      disturbance were noted one day after discharge. Laboratory data showed elevated 
      aspartate aminotransferase (AST), alanine aminotransferase (ALT) and ammonia. 
      Hypoglycemia and prolonged PT and PTT were also noted. Reye syndrome was 
      suspected, and the patient was admitted to the intensive care unit for further 
      management. A liver biopsy gave findings consistent with Reye syndrome. In spite 
      of intensive treatment, the infant expired on the second day after admission. In 
      a review of the literature, no correlation between these two syndromes was found. 
      This rare case is presented to warn that Reye syndrome may follow Kawasaki 
      disease when aspirin has been prescribed at a high dose.
FAU - Lee, J H
AU  - Lee JH
AD  - Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan, R.O.C.
FAU - Hung, H Y
AU  - Hung HY
FAU - Huang, F Y
AU  - Huang FY
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi
JT  - Zhonghua Minguo xiao er ke yi xue hui za zhi [Journal]. Zhonghua Minguo xiao er 
      ke yi xue hui
JID - 16210470R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Humans
MH  - Infant
MH  - Mucocutaneous Lymph Node Syndrome/*complications
MH  - Reye Syndrome/*etiology
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1992 Jan-Feb;33(1):67-71.

PMID- 8499879
OWN - NLM
STAT- MEDLINE
DCOM- 19930701
LR  - 20131121
IS  - 0867-7077 (Print)
IS  - 0867-7077 (Linking)
VI  - 61
IP  - 1-2
DP  - 1993
TI  - [Aspirin-sensitive urticaria; a clinical study].
PG  - 24-8
AB  - In the paper clinical characteristics of patients with aspirin-induced urticaria 
      were performed. The group of 71 patients, 49 women (69%) and 22 men (31%), mean 
      age of sensitivity symptoms demonstration--32.5 years, underwent allergological, 
      laryngological and histamine dihydrochloride inhalatory tests. Nasal polyps were 
      found in 2 persons (2.8%), atopic diseases in 23 persons (32.3%) and at least one 
      feature of atopy in 37 persons (51.9%). 49 subjects (69%) suffered from urticaria 
      which was not associated with ingestion of aspirin. In 22 patients urticaria 
      developed solely due to aspirin. Urticaria not associated with aspirin had been 
      presents for 2 weeks to 30 years before the onset of sensitivity to aspirin. The 
      authors conclude that aspirin-sensitive urticaria results from concomitance of 
      two different phenomena in one person, i.e. sensitivity to aspirin and urticaria 
      not associated with ingestion of the drug.
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
AD  - Kliniki Pneumonologii i Alergologii Instytutu Medycyny Wewnetrznej AM w Lodzi.
FAU - Szmidt, M
AU  - Szmidt M
FAU - Rozniecki, J
AU  - Rozniecki J
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Pokrzywka z nadwrazliwościa na aspiryne; studium kliniczne.
PL  - Poland
TA  - Pneumonol Alergol Pol
JT  - Pneumonologia i alergologia polska
JID - 9302892
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Bronchial Provocation Tests
MH  - Drug Hypersensitivity/*diagnosis/etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Urticaria/*chemically induced
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Pneumonol Alergol Pol. 1993;61(1-2):24-8.

PMID- 35285177
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220716
IS  - 2198-3844 (Electronic)
IS  - 2198-3844 (Linking)
VI  - 9
IP  - 14
DP  - 2022 May
TI  - Acid-Responsive Dual-Targeted Nanoparticles Encapsulated Aspirin Rescue the 
      Immune Activation and Phenotype in Autism Spectrum Disorder.
PG  - e2104286
LID - 10.1002/advs.202104286 [doi]
LID - 2104286
AB  - The treatment of autism spectrum disorder (ASD) is one of the most difficult 
      challenges in neurodevelopmental diseases, because of the unclear pathogenesis 
      research and low brain-lesion targeting efficiency. Besides, maternal immune 
      activation has been reported as the most mature and widely used model of ASD and 
      aspirin-triggered lipoxin A4 is a potent anti-inflammatory mediator being 
      involved in the resolution of neuroinflammation in ASD. Therefore, an aspirin 
      encapsulated cascade drug delivery system (Asp@TMNPs) is established, which can 
      successively target the blood-brain barrier (BBB) and microglial cells and 
      response to the acid microenvironment in lysosome. As a result, the mitochondrial 
      oxidative stress, DNA damage, and inflammation of microglial cells are 
      prominently alleviated. After the treatment of Asp@TMNPs, the social interaction, 
      stereotype behavior, and anxious condition of ASD mice are notably improved and 
      the activation of microglial cells is inhibited. Overall, this system 
      successively penetrates the BBB and targets microglial cells, therefore, it 
      significantly enhances the intracephalic drug accumulation and improves 
      anti-neuroinflammatory efficacy of aspirin, providing a promising strategy for 
      ASD treatment.
CI  - © 2022 The Authors. Advanced Science published by Wiley-VCH GmbH.
FAU - He, Xueqin
AU  - He X
AD  - Key Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of 
      Birth Defects and Related Diseases of Women and Children of Ministry of 
      Education, West China Second University Hospital, West China School of Pharmacy, 
      Sichuan University, Chengdu, 610041, China.
FAU - Xie, Jiang
AU  - Xie J
AD  - Key Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of 
      Birth Defects and Related Diseases of Women and Children of Ministry of 
      Education, West China Second University Hospital, West China School of Pharmacy, 
      Sichuan University, Chengdu, 610041, China.
AD  - Department of pediatrics, Chengdu Third People's Hospital, Chengdu, 610041, 
      China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Key Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of 
      Birth Defects and Related Diseases of Women and Children of Ministry of 
      Education, West China Second University Hospital, West China School of Pharmacy, 
      Sichuan University, Chengdu, 610041, China.
FAU - Wang, Xiaorong
AU  - Wang X
AD  - Key Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of 
      Birth Defects and Related Diseases of Women and Children of Ministry of 
      Education, West China Second University Hospital, West China School of Pharmacy, 
      Sichuan University, Chengdu, 610041, China.
FAU - Jia, Xufeng
AU  - Jia X
AD  - Key Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of 
      Birth Defects and Related Diseases of Women and Children of Ministry of 
      Education, West China Second University Hospital, West China School of Pharmacy, 
      Sichuan University, Chengdu, 610041, China.
AD  - Department of pediatrics, Chengdu Third People's Hospital, Chengdu, 610041, 
      China.
FAU - Yin, Heng
AU  - Yin H
AD  - Key Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of 
      Birth Defects and Related Diseases of Women and Children of Ministry of 
      Education, West China Second University Hospital, West China School of Pharmacy, 
      Sichuan University, Chengdu, 610041, China.
AD  - Department of pediatrics, Chengdu Third People's Hospital, Chengdu, 610041, 
      China.
FAU - Qiu, Zhongqing
AU  - Qiu Z
AD  - Key Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of 
      Birth Defects and Related Diseases of Women and Children of Ministry of 
      Education, West China Second University Hospital, West China School of Pharmacy, 
      Sichuan University, Chengdu, 610041, China.
AD  - Department of pediatrics, Chengdu Third People's Hospital, Chengdu, 610041, 
      China.
FAU - Yang, Zhihang
AU  - Yang Z
AD  - Key Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of 
      Birth Defects and Related Diseases of Women and Children of Ministry of 
      Education, West China Second University Hospital, West China School of Pharmacy, 
      Sichuan University, Chengdu, 610041, China.
FAU - Chen, Jiao
AU  - Chen J
AD  - State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen 
      University, Xiamen, 361102, China.
FAU - Ji, Zhiliang
AU  - Ji Z
AD  - State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen 
      University, Xiamen, 361102, China.
FAU - Yu, Wenqi
AU  - Yu W
AD  - Key Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of 
      Birth Defects and Related Diseases of Women and Children of Ministry of 
      Education, West China Second University Hospital, West China School of Pharmacy, 
      Sichuan University, Chengdu, 610041, China.
FAU - Chen, Meiwan
AU  - Chen M
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Institute of 
      Chinese Medical Sciences, University of Macau, Macau, 999078, China.
FAU - Xu, Wenming
AU  - Xu W
AD  - Key Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of 
      Birth Defects and Related Diseases of Women and Children of Ministry of 
      Education, West China Second University Hospital, West China School of Pharmacy, 
      Sichuan University, Chengdu, 610041, China.
FAU - Gao, Huile
AU  - Gao H
AUID- ORCID: 0000-0002-5355-7238
AD  - Key Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of 
      Birth Defects and Related Diseases of Women and Children of Ministry of 
      Education, West China Second University Hospital, West China School of Pharmacy, 
      Sichuan University, Chengdu, 610041, China.
LA  - eng
GR  - 81872806/National Natural Science Foundation of China/
GR  - B18035/111 Project/
GR  - 2019-YF05-00498-SN/Chengdu Science and Technology Project/
GR  - 2021YJ0170/Science and Technology Plan Project of Sichuan Province/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220313
PL  - Germany
TA  - Adv Sci (Weinh)
JT  - Advanced science (Weinheim, Baden-Wurttemberg, Germany)
JID - 101664569
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - *Autism Spectrum Disorder/drug therapy/genetics/pathology
MH  - Mice
MH  - Microglia/pathology
MH  - *Nanoparticles
MH  - Phenotype
PMC - PMC9108608
OTO - NOTNLM
OT  - aspirin
OT  - autism spectrum disorder
OT  - nanoparticles
OT  - neuro-inflammation
COIS- The authors declare no conflict of interest.
EDAT- 2022/03/15 06:00
MHDA- 2022/05/18 06:00
CRDT- 2022/03/14 06:03
PHST- 2022/02/21 00:00 [revised]
PHST- 2021/09/26 00:00 [received]
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/03/14 06:03 [entrez]
AID - ADVS3753 [pii]
AID - 10.1002/advs.202104286 [doi]
PST - ppublish
SO  - Adv Sci (Weinh). 2022 May;9(14):e2104286. doi: 10.1002/advs.202104286. Epub 2022 
      Mar 13.

PMID- 12680565
OWN - NLM
STAT- MEDLINE
DCOM- 20030430
LR  - 20191107
IS  - 0889-4655 (Print)
IS  - 0889-4655 (Linking)
VI  - 18
IP  - 2
DP  - 2003 Apr-Jun
TI  - Benefits of aggressive drug therapy.
PG  - 79-84
AB  - Significant advances have been made in both the development and implementation of 
      drug therapy in the primary and secondary prevention of cardiovascular disease. 
      Defining "aggressive" drug therapy mandates consideration of the target 
      population, timing of initiation, time of administration, and, often, dose 
      titration to achieve a desired effect on relevant "biomarkers" such as 
      low-density lipoprotein levels. This review focuses on 2 groups of drug therapies 
      now proven effective in prevention, namely the statins and antiplatelet drugs 
      (aspirin, clopidogrel). Angiotensin-converting enzyme inhibitor(s), angiotensin 
      receptor blockers, and beta blockers are also proven of great value but are only 
      noted in the table.
FAU - Oken, Keith
AU  - Oken K
AD  - Division of Cardiovascular Diseases, Mayo Clinic, Jacksonville, FL 32224, USA.
FAU - Fletcher, Gerald
AU  - Fletcher G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Cardiovasc Nurs
JT  - The Journal of cardiovascular nursing
JID - 8703516
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clopidogrel
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & 
      dosage/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*therapeutic use
MH  - Ticlopidine/*administration & dosage/analogs & derivatives/*therapeutic use
RF  - 44
EDAT- 2003/04/12 05:00
MHDA- 2003/05/06 05:00
CRDT- 2003/04/12 05:00
PHST- 2003/04/12 05:00 [pubmed]
PHST- 2003/05/06 05:00 [medline]
PHST- 2003/04/12 05:00 [entrez]
AID - 10.1097/00005082-200304000-00002 [doi]
PST - ppublish
SO  - J Cardiovasc Nurs. 2003 Apr-Jun;18(2):79-84. doi: 
      10.1097/00005082-200304000-00002.

PMID- 30417662
OWN - NLM
STAT- MEDLINE
DCOM- 20190404
LR  - 20190404
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 14
IP  - 6
DP  - 2018 Nov
TI  - Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an 
      evaluation of COMPASS.
PG  - 443-453
LID - 10.2217/fca-2018-0059 [doi]
AB  - The cardiovascular outcomes for people using anticoagulation strategies 
      (NCT01776424) trial randomized 27,395 patients with stable coronary artery 
      disease or peripheral artery disease (PAD) to receive rivaroxaban 5 mg 
      twice-daily alone, the combination of rivaroxaban 2.5 mg twice-daily and aspirin 
      100 mg daily, or aspirin 100 mg daily alone. The combination arm resulted in a 
      24% reduction in the primary end point of cardiovascular death, stroke or 
      myocardial infarction, and an 18% reduction in mortality. Rivaroxaban alone did 
      not produce any additional benefit compared with aspirin. The combination therapy 
      also reduced major adverse limb events, including amputation, in patients with 
      PAD. Based on these results, the addition of rivaroxaban to aspirin is expected 
      to substantially reduce morbidity and mortality in patients with stable coronary 
      or PAD.
FAU - Bhagirath, Vinai C
AU  - Bhagirath VC
AD  - Department of Medicine, McMaster University, Hamilton, ON, L8S 4K1, Canada.
AD  - Population Health Research Institute, Hamilton, ON, L8L 2X2, Canada.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AD  - Department of Medicine, McMaster University, Hamilton, ON, L8S 4K1, Canada.
AD  - Population Health Research Institute, Hamilton, ON, L8L 2X2, Canada.
FAU - Anand, Sonia S
AU  - Anand SS
AD  - Department of Medicine, McMaster University, Hamilton, ON, L8S 4K1, Canada.
AD  - Population Health Research Institute, Hamilton, ON, L8L 2X2, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT01776424
PT  - Journal Article
DEP - 20181112
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Therapy, Combination
MH  - Factor Xa Inhibitors/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Rivaroxaban/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular disease
OT  - rivaroxaban
EDAT- 2018/11/13 06:00
MHDA- 2019/04/05 06:00
CRDT- 2018/11/13 06:00
PHST- 2018/11/13 06:00 [pubmed]
PHST- 2019/04/05 06:00 [medline]
PHST- 2018/11/13 06:00 [entrez]
AID - 10.2217/fca-2018-0059 [doi]
PST - ppublish
SO  - Future Cardiol. 2018 Nov;14(6):443-453. doi: 10.2217/fca-2018-0059. Epub 2018 Nov 
      12.

PMID- 31590909
OWN - NLM
STAT- MEDLINE
DCOM- 20200326
LR  - 20200326
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 124
IP  - 11
DP  - 2019 Dec 1
TI  - Usefulness of Aspirin for Primary Prevention of Atherosclerotic Cardiovascular 
      Disease.
PG  - 1785-1789
LID - S0002-9149(19)31009-4 [pii]
LID - 10.1016/j.amjcard.2019.08.040 [doi]
AB  - Aspirin use in the prevention of cardiovascular events has been a mainstay of 
      treatment for decades. However, the use of aspirin in primary prevention of 
      atherosclerotic cardiovascular disease has recently come under scrutiny. Several 
      recent studies have evaluated the use of aspirin in primary prevention and the 
      results suggest that in many patients the risks may outweigh the benefits. Closer 
      examination of these trials suggests that the use of aspirin therapy for primary 
      prevention may have a role but likely needs a more tailored approach and that 
      caution is needed in prescribing aspirin for primary prevention. In conclusion, 
      in this article we review the evolving evidence for aspirin in the primary 
      prevention of atherosclerotic cardiovascular disease.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Thobani, Aneesha
AU  - Thobani A
AD  - Division of Internal Medicine, Department of Medicine, Emory University School of 
      Medicine, Atlanta, Georgia.
FAU - Dhindsa, Devinder S
AU  - Dhindsa DS
AD  - Division of Cardiology, Department of Medicine, Emory University School of 
      Medicine, Atlanta, Georgia.
FAU - DeMoss, Benjamin D
AU  - DeMoss BD
AD  - Division of Cardiology, Department of Medicine, Emory University School of 
      Medicine, Atlanta, Georgia.
FAU - Raad, Mohamad
AU  - Raad M
AD  - Division of Internal Medicine, Department of Medicine, Emory University School of 
      Medicine, Atlanta, Georgia.
FAU - Sandesara, Pratik B
AU  - Sandesara PB
AD  - Division of Cardiology, Department of Medicine, Emory University School of 
      Medicine, Atlanta, Georgia.
FAU - Sperling, Laurence S
AU  - Sperling LS
AD  - Division of Cardiology, Department of Medicine, Emory University School of 
      Medicine, Atlanta, Georgia. Electronic address: lsperli@emory.edu.
FAU - Baer, Jefferson T
AU  - Baer JT
AD  - Division of Cardiology, Department of Medicine, Emory University School of 
      Medicine, Atlanta, Georgia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190909
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Atherosclerosis/prevention & control
MH  - Cardiovascular Diseases/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Primary Prevention/*methods
EDAT- 2019/10/09 06:00
MHDA- 2020/03/27 06:00
CRDT- 2019/10/09 06:00
PHST- 2019/06/22 00:00 [received]
PHST- 2019/08/13 00:00 [revised]
PHST- 2019/08/19 00:00 [accepted]
PHST- 2019/10/09 06:00 [pubmed]
PHST- 2020/03/27 06:00 [medline]
PHST- 2019/10/09 06:00 [entrez]
AID - S0002-9149(19)31009-4 [pii]
AID - 10.1016/j.amjcard.2019.08.040 [doi]
PST - ppublish
SO  - Am J Cardiol. 2019 Dec 1;124(11):1785-1789. doi: 10.1016/j.amjcard.2019.08.040. 
      Epub 2019 Sep 9.

PMID- 3529538
OWN - NLM
STAT- MEDLINE
DCOM- 19861023
LR  - 20131121
IS  - 0041-3232 (Print)
IS  - 0041-3232 (Linking)
VI  - 38
IP  - 3
DP  - 1986 Sep
TI  - A randomized double blind trial of aspirin versus placebo in cholera and 
      non-cholera diarrhoea.
PG  - 221-5
AB  - A randomized double blind controlled clinical trial was conducted on 30 patients 
      with cholera and 18 patients with severe non-cholera diarrhoea, to study the 
      antisecretory effect of acetylsalicylic acid (aspirin). The criteria for 
      selection of patients was a stool output of 4 ml/kg per hour over 6 hours of 
      baseline observation. On inclusion into the study, the groups were comparable in 
      sex, age, body weight, duration of diarrhoea and severity of dehydration. Aspirin 
      and placebo (starch) were given by mouth in doses of 25 mg/kg/day for 24 hours in 
      four equally divided doses. Fourteen patients with cholera and 10 with 
      non-cholera diarrhoea received aspirin and the others received placebo. The 
      aspirin and the placebo groups did not differ in their rate of stool output. The 
      results suggest that aspirin in the above mentioned dose has no antisecretory 
      activity.
FAU - Islam, A
AU  - Islam A
FAU - Bardhan, P K
AU  - Bardhan PK
FAU - Islam, M R
AU  - Islam MR
FAU - Rahman, M
AU  - Rahman M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Trop Geogr Med
JT  - Tropical and geographical medicine
JID - 0376231
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cholera/*drug therapy
MH  - Clinical Trials as Topic
MH  - Diarrhea/*drug therapy
MH  - Double-Blind Method
MH  - Feces/analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Random Allocation
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
PST - ppublish
SO  - Trop Geogr Med. 1986 Sep;38(3):221-5.

PMID- 36030623
OWN - NLM
STAT- MEDLINE
DCOM- 20220926
LR  - 20221106
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 441
DP  - 2022 Oct 15
TI  - Assessment of on-treatment platelet reactivity at high and low shear stress and 
      platelet activation status after the addition of dipyridamole to aspirin in the 
      early and late phases after TIA and ischaemic stroke.
PG  - 120334
LID - S0022-510X(22)00196-4 [pii]
LID - 10.1016/j.jns.2022.120334 [doi]
AB  - BACKGROUND: Data are limited on the ability of dipyridamole to additionally 
      inhibit platelet function/reactivity in ischaemic cerebrovascular disease (CVD) 
      patients on aspirin. AIMS: To assess inhibition of platelet function/reactivity 
      and platelet activation with dipyridamole in CVD. METHODS: This prospective, 
      observational study assessed TIA/ischaemic stroke patients before (baseline; 
      N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding 
      dipyridamole to aspirin. Platelet function/reactivity at high shear stress 
      (PFA-100® C-ADP) and low shear stress (VerifyNow® P2Y12 and Multiplate® ADP 
      assays), and platelet activation status (% expression of CD62P, CD63 and 
      leucocyte-platelet complexes on whole blood flow cytometry) were quantified. 
      'Dipyridamole-high on-treatment platelet reactivity (HTPR)' was defined as 
      failure to inhibit ADP-induced platelet aggregation +/- adhesion compared with 
      the patient's baseline on aspirin monotherapy by more than twice the 
      coefficient-of-variation of the assay after adding dipyridamole to aspirin. 
      RESULTS: Dipyridamole-HTPR was identified in 71.4-75% of patients on PFA-100 
      C-ADP, 83.9-86.8% of patients on VerifyNow P2Y12, and 81.5-83.3% of patients on 
      Multiplate ADP assays. There were no changes in CD62P/CD63 expression (P ≥ 0.18), 
      or consistent changes in leucocyte-platelet complexes in CVD patients overall at 
      14d or 90d vs. baseline after commencing dipyridamole. Monocyte-platelet 
      complexes increased in the patient subgroup with dipyridamole-HTPR at 14d and 90d 
      on PFA-100, and at 14d on VerifyNow (P ≤ 0.04), but not in those without 
      dipyridamole-HTPR. DISCUSSION: Additional antiplatelet effects of dipyridamole 
      are detectable under high and low shear stress conditions with user-friendly 
      platelet function/reactivity tests ex vivo. Increasing circulating 
      monocyte-platelet complexes over time are associated with dipyridamole-HTPR.
CI  - Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Lim, S T
AU  - Lim ST
AD  - Department of Neurology, Tallaght University Hospital/The Adelaide and Meath 
      Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, 
      Ireland; Stroke Service, Tallaght University Hospital/The Adelaide and Meath 
      Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, 
      Ireland; Department of Clinical Neurosciences, Royal Free Campus, UCL Queen 
      Square Institute of Neurology, London, UK.
FAU - Murphy, S J X
AU  - Murphy SJX
AD  - Department of Neurology, Tallaght University Hospital/The Adelaide and Meath 
      Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, 
      Ireland; Stroke Service, Tallaght University Hospital/The Adelaide and Meath 
      Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, 
      Ireland.
FAU - Murphy, S M
AU  - Murphy SM
AD  - Department of Neurology, Tallaght University Hospital/The Adelaide and Meath 
      Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, 
      Ireland; Stroke Service, Tallaght University Hospital/The Adelaide and Meath 
      Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, 
      Ireland; Academic Unit of Neurology, School of Medicine, Trinity College Dublin, 
      Dublin, Ireland.
FAU - Coughlan, T
AU  - Coughlan T
AD  - Stroke Service, Tallaght University Hospital/The Adelaide and Meath Hospital, 
      Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, Ireland; 
      Age-Related Health Care Department, Tallaght University Hospital/The Adelaide and 
      Meath Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), 
      Dublin, Ireland.
FAU - O'Neill, D
AU  - O'Neill D
AD  - Stroke Service, Tallaght University Hospital/The Adelaide and Meath Hospital, 
      Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, Ireland; 
      Age-Related Health Care Department, Tallaght University Hospital/The Adelaide and 
      Meath Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), 
      Dublin, Ireland.
FAU - Tierney, S
AU  - Tierney S
AD  - Department of Vascular Surgery, Tallaght University Hospital/The Adelaide and 
      Meath Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), 
      Dublin, Ireland.
FAU - Egan, B
AU  - Egan B
AD  - Department of Vascular Surgery, Tallaght University Hospital/The Adelaide and 
      Meath Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), 
      Dublin, Ireland.
FAU - Collins, D R
AU  - Collins DR
AD  - Stroke Service, Tallaght University Hospital/The Adelaide and Meath Hospital, 
      Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, Ireland; 
      Age-Related Health Care Department, Tallaght University Hospital/The Adelaide and 
      Meath Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), 
      Dublin, Ireland.
FAU - McCarthy, A J
AU  - McCarthy AJ
AD  - Department of Neurology, Tallaght University Hospital/The Adelaide and Meath 
      Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, 
      Ireland; Stroke Service, Tallaght University Hospital/The Adelaide and Meath 
      Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, 
      Ireland; Academic Unit of Neurology, School of Medicine, Trinity College Dublin, 
      Dublin, Ireland.
FAU - Lim, S-Y
AU  - Lim SY
AD  - Faculty of Health and Medical Sciences, Taylor's University, Selangor Darul 
      Ehsan, Malaysia.
FAU - Smith, D R
AU  - Smith DR
AD  - Department of Neurology, Tallaght University Hospital/The Adelaide and Meath 
      Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, 
      Ireland; Vascular Neurology Research Foundation, c/o Department of Neurology, 
      Tallaght University Hospital/AMNCH, Dublin, Ireland; Stroke Service, Tallaght 
      University Hospital/The Adelaide and Meath Hospital, Dublin, incorporating the 
      National Children's Hospital (AMNCH), Dublin, Ireland; Academic Unit of 
      Neurology, School of Medicine, Trinity College Dublin, Dublin, Ireland.
FAU - Cox, D
AU  - Cox D
AD  - School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in 
      Ireland, Dublin, Ireland; Irish Centre for Vascular Biology, Dublin, Ireland.
FAU - McCabe, D J H
AU  - McCabe DJH
AD  - Department of Neurology, Tallaght University Hospital/The Adelaide and Meath 
      Hospital, Dublin, incorporating the National Children's Hospital (AMNCH), Dublin, 
      Ireland; Vascular Neurology Research Foundation, c/o Department of Neurology, 
      Tallaght University Hospital/AMNCH, Dublin, Ireland; Stroke Service, Tallaght 
      University Hospital/The Adelaide and Meath Hospital, Dublin, incorporating the 
      National Children's Hospital (AMNCH), Dublin, Ireland; Department of Clinical 
      Neurosciences, Royal Free Campus, UCL Queen Square Institute of Neurology, 
      London, UK; Irish Centre for Vascular Biology, Dublin, Ireland; Stroke Clinical 
      Trials Network Ireland, Dublin, Ireland; Academic Unit of Neurology, School of 
      Medicine, Trinity College Dublin, Dublin, Ireland. Electronic address: 
      dominick.mccabe@tuh.ie.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220711
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/metabolism/pharmacology
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets
MH  - *Brain Ischemia/metabolism
MH  - Dipyridamole/metabolism/pharmacology/therapeutic use
MH  - Humans
MH  - *Ischemic Attack, Transient/drug therapy
MH  - *Ischemic Stroke
MH  - Platelet Activation
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Prospective Studies
MH  - *Stroke
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - Dipyridamole-high on-treatment platelet reactivity (HTPR)
OT  - Flow cytometry
OT  - Ischaemic stroke
OT  - Platelet function/reactivity
OT  - Shear stress
OT  - TIA
EDAT- 2022/08/29 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/08/28 18:10
PHST- 2021/09/20 00:00 [received]
PHST- 2022/05/30 00:00 [revised]
PHST- 2022/06/30 00:00 [accepted]
PHST- 2022/08/29 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/08/28 18:10 [entrez]
AID - S0022-510X(22)00196-4 [pii]
AID - 10.1016/j.jns.2022.120334 [doi]
PST - ppublish
SO  - J Neurol Sci. 2022 Oct 15;441:120334. doi: 10.1016/j.jns.2022.120334. Epub 2022 
      Jul 11.

PMID- 24453093
OWN - NLM
STAT- MEDLINE
DCOM- 20141028
LR  - 20181203
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
VI  - 16
IP  - 1
DP  - 2014 Jan
TI  - Evidence-based co-medication in heart failure: necessary or bystander?
PG  - 1-3
LID - 10.1002/ejhf.46 [doi]
AB  - This article refers to 'Impact of aspirin and statins on longterm survival in 
      patients with acute myocardial infarction complicated by heart failure: an 
      analysis in 1746 patients' by C. Lewinter et al., published in this issue on page 
      95-102.
FAU - Verheugt, Freek W A
AU  - Verheugt FW
AD  - P.C. Hooftstraat 188, 1071 CH Amsterdam, The Netherlands.
LA  - eng
PT  - Comment
PT  - Editorial
DEP - 20131214
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Eur J Heart Fail. 2014 Jan;16(1):95-102. PMID: 24453098
MH  - Aspirin/*therapeutic use
MH  - Heart Failure/*mortality
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - *Inpatients
MH  - Male
MH  - Myocardial Infarction/*drug therapy
EDAT- 2014/01/24 06:00
MHDA- 2014/10/29 06:00
CRDT- 2014/01/24 06:00
PHST- 2014/01/24 06:00 [entrez]
PHST- 2014/01/24 06:00 [pubmed]
PHST- 2014/10/29 06:00 [medline]
AID - 10.1002/ejhf.46 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2014 Jan;16(1):1-3. doi: 10.1002/ejhf.46. Epub 2013 Dec 14.

PMID- 3697333
OWN - NLM
STAT- MEDLINE
DCOM- 19880202
LR  - 20131121
IS  - 0391-5387 (Print)
IS  - 0391-5387 (Linking)
VI  - 9
IP  - 4
DP  - 1987 Jul-Aug
TI  - [Kawasaki disease. Description of a case with atypical onset and course].
PG  - 509-11
AB  - The authors, pointing out this case, intend to lay emphasis upon the possibility 
      that, within a clinical-nosological entity complex itself, there were atypic 
      forms (persisting pulmonary infiltration, marked hepatosplenomegaly, noticeably 
      delayed thrombocitosis), for which only a careful estimate of all the elements 
      permits the diagnosis.
FAU - Buccino, A
AU  - Buccino A
AD  - II Divisione Pediatrica, Ospedale Pausilipon, Napoli, Italia.
FAU - Buonagura, G
AU  - Buonagura G
FAU - Villani, S
AU  - Villani S
FAU - Sannino, A
AU  - Sannino A
FAU - Pellegrini, F
AU  - Pellegrini F
FAU - Cimaglia, M L
AU  - Cimaglia ML
LA  - ita
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - La malattia di Kawasaki. Descrizione di un caso ad esordio e decorso atipici.
PL  - Italy
TA  - Pediatr Med Chir
JT  - La Pediatria medica e chirurgica : Medical and surgical pediatrics
JID - 8100625
RN  - 0 (Adrenal Cortex Hormones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Mucocutaneous Lymph Node Syndrome/drug therapy/*physiopathology
EDAT- 1987/07/01 00:00
MHDA- 1987/07/01 00:01
CRDT- 1987/07/01 00:00
PHST- 1987/07/01 00:00 [pubmed]
PHST- 1987/07/01 00:01 [medline]
PHST- 1987/07/01 00:00 [entrez]
PST - ppublish
SO  - Pediatr Med Chir. 1987 Jul-Aug;9(4):509-11.

PMID- 6504977
OWN - NLM
STAT- MEDLINE
DCOM- 19841227
LR  - 20131121
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 39
IP  - 8
DP  - 1984 Aug
TI  - [The evaluation of non-isothermal short-term tests of drug solutions].
PG  - 541-6
AB  - Non-isothermal short-term tests to examine the stability of drug solutions, are 
      critically discussed with regard to their application to simple and complex 
      reaction mechanisms. The influence of additional temperature dependences (ionic 
      product of water, activity coefficient) is assayed. By example of the 
      decomposition of tetracaine hydrochloride and acetylsalicylic acid, the 
      evaluation of experimental results is discussed considering these factors.
FAU - Kersten, D
AU  - Kersten D
FAU - Göber, B
AU  - Göber B
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Zur Auswertung nichtisothermer Kurzzeittests von Arzneistofflösungen.
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Buffers)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0619F35CGV (Tetracaine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis
MH  - Buffers
MH  - Catalysis
MH  - Chemistry, Pharmaceutical/methods
MH  - Chromatography, Gas
MH  - Drug Stability
MH  - Evaluation Studies as Topic
MH  - Pharmaceutical Preparations/*analysis
MH  - Temperature
MH  - Tetracaine/analysis
MH  - Thermodynamics
MH  - Time Factors
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1984 Aug;39(8):541-6.

PMID- 160158
OWN - NLM
STAT- MEDLINE
DCOM- 19800228
LR  - 20141120
IS  - 0303-6464 (Print)
IS  - 0303-6464 (Linking)
VI  - 67
IP  - 6
DP  - 1979
TI  - [Thrombelastographic studies made to objectify the effects of Grisaldon upon the 
      process of coagulation (author's transl)].
PG  - 579-82
AB  - Thrombelastographic studies of the mode of action of Grisaldon showed that this 
      preparation, unlike the pure substance of acetylsalicylic acid, has no 
      appreciable coagulation-accelerating and fibrin-stabilizing effects. In addition, 
      it was possible to show that an antifibrinolytic effect of the p-oxybenzoic acid 
      propyl ester (Grisaldon component), which has been described in the literature, 
      is not produced.
FAU - Fröhlich, M
AU  - Fröhlich M
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Thrombelastographische Untersuchungen zur Objektivierung der Einwirkung von 
      Grisaldon auf den Gerinnugsprozess.
PL  - Germany
TA  - Zahn Mund Kieferheilkd Zentralbl
JT  - Zahn-, Mund-, und Kieferheilkunde mit Zentralblatt
JID - 0434643
RN  - 0 (Drug Combinations)
RN  - 0 (Parabens)
RN  - 0 (Powders)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Coagulation/*drug effects
MH  - Drug Combinations
MH  - Drug Evaluation
MH  - Humans
MH  - In Vitro Techniques
MH  - Parabens/therapeutic use
MH  - Powders
MH  - *Thrombelastography
MH  - Whole Blood Coagulation Time
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Zahn Mund Kieferheilkd Zentralbl. 1979;67(6):579-82.

PMID- 17252362
OWN - NLM
STAT- MEDLINE
DCOM- 20070308
LR  - 20171116
IS  - 0012-0472 (Print)
IS  - 0012-0472 (Linking)
VI  - 132
IP  - 5
DP  - 2007 Feb 2
TI  - [Acute myocardial infarction after discontinuing aspirin two years after 
      implantation of a drug-eluting coronary stent].
PG  - 201-4
AB  - HISTORY AND ADMISSION FINDINGS: A 48-year-old man was admitted to our cardiac 
      catheterization unit with severe chest pain 75 minutes after onset of symptoms. 
      Two years before he had undergone percutaneous coronary intervention (PCI) for 
      stable angina pectoris with implantation of a drug-eluting stent (TAXUS) into the 
      proximal left anterior descending artery. Antiplatelet therapy with 75 mg 
      clopidogrel was given for one year, together with 100 mg aspirin. Subsequently he 
      was put on low-dose aspirin monotherapy. Eight days before admission aspirin was 
      discontinued because a tooth extraction was planned. DIAGNOSTIC PROCEDURES: The 
      ECG showed significant ST-segment elevation in the precordial leads V1-5. 
      TREATMENT AND OUTCOME: 90 minutes after onset of symptoms coronary angiography 
      was performed and an in-stent thrombosis of the proximal left coronary artery was 
      diagnosed. A successful PCI was performed and abiximab given. The creatine kinase 
      concentration increased to a maximum of 3170 U/l. The pre-discharge 
      echocardiogram showed a slightly reduced left ventricular ejection fraction. 
      After the procedure the patient was stable and free of chest pain and he was 
      discharged from the hospital after one week. CONCLUSION: Discontinuing 
      antiplatelet therapy, even years after implantation of a drug-eluting coronary 
      stent, increases the risk of a late stent thrombosis. This should be taken into 
      account especially before any procedure, even with a low bleeding risk such as 
      tooth extractions. Antiplatelet treatment should be continued, even if there is a 
      risk increasing minor bleeding complications, so that any life-threatening 
      complication of an acute myocardial infarction is avoided.
FAU - Krüth, P
AU  - Krüth P
AD  - Herzzentrum Ludwigshafen, Medizinische Klinik B, Ludwigshafen/Rhein.
FAU - Heer, T
AU  - Heer T
FAU - Senges, J
AU  - Senges J
FAU - Zeymer, U
AU  - Zeymer U
LA  - ger
PT  - Case Reports
PT  - Journal Article
TT  - Akuter Herzinfarkt nach Absetzen von Acetylsalicylsäure 2 Jahre nach Implantation 
      eines Medikamenten-freisetzenden Stents.
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina Pectoris/therapy
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Contraindications
MH  - Coronary Angiography
MH  - Coronary Thrombosis/diagnostic imaging/*etiology
MH  - Electrocardiography
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*etiology/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Risk Factors
MH  - Stents/classification
MH  - Tooth Extraction
EDAT- 2007/01/26 09:00
MHDA- 2007/03/09 09:00
CRDT- 2007/01/26 09:00
PHST- 2007/01/26 09:00 [pubmed]
PHST- 2007/03/09 09:00 [medline]
PHST- 2007/01/26 09:00 [entrez]
AID - 10.1055/s-2007-959310 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2007 Feb 2;132(5):201-4. doi: 10.1055/s-2007-959310.

PMID- 32997790
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 148
IP  - 6
DP  - 2021 Mar 15
TI  - A potential role for aspirin in the prevention and treatment of 
      cholangiocarcinoma.
PG  - 1323-1330
LID - 10.1002/ijc.33323 [doi]
AB  - Cholangiocarcinoma is the second most common primary hepatic cancer, with a 
      rising incidence worldwide. Owing to late diagnosis and limited treatment 
      options, the prognosis for cholangiocarcinoma remains dismal, compelling a search 
      for new treatments. As aspirin exhibits a well-supported chemopreventive effect 
      on common cancers, researchers have proposed using aspirin as a potential 
      preventive and adjuvant agent for cholangiocarcinoma. In the present review of 
      the literature, we provide a background on cholangiocarcinoma and potential 
      mechanisms of action underlying the anticancer effect of aspirin. Although the 
      exact mode of action remains unclear, multiple downstream effects of aspirin may 
      interfere with cholangiocarcinogenesis, tumour growth and metastasis-including 
      inhibiting the COX-2 pathway, preventing platelet aggregation and modulating 
      certain proteins and signalling. This review also summarises evidence to support 
      the chemopreventive effects of aspirin on common cancers, particularly colorectal 
      cancer and discusses studies that report a positive outcome of aspirin in 
      cholangiocarcinoma. Regular use of aspirin is associated with a reduced incidence 
      of colorectal cancers as well as cholangiocarcinomas, and improved survival. 
      Aspirin thus appears to play a role in the primary prevention and treatment of 
      cholangiocarcinoma. However, further studies are needed to confirm these benefits 
      and to establish a cause-and-effect relationship.
CI  - © 2020 Union for International Cancer Control.
FAU - Shen, Xizi
AU  - Shen X
AD  - Faculty of Medicine, The University of Queensland, Brisbane, Australia.
FAU - Shen, Xingping
AU  - Shen X
AUID- ORCID: 0000-0003-0747-2265
AD  - Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201012
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bile Duct Neoplasms/*therapy
MH  - Cholangiocarcinoma/*therapy
MH  - Colorectal Neoplasms/epidemiology
MH  - Humans
MH  - Incidence
OTO - NOTNLM
OT  - antineoplastic drugs
OT  - aspirin
OT  - bile-duct cancer
OT  - chemoprevention
OT  - cholangiocarcinoma
EDAT- 2020/10/01 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/09/30 17:12
PHST- 2020/02/26 00:00 [received]
PHST- 2020/08/11 00:00 [revised]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/09/30 17:12 [entrez]
AID - 10.1002/ijc.33323 [doi]
PST - ppublish
SO  - Int J Cancer. 2021 Mar 15;148(6):1323-1330. doi: 10.1002/ijc.33323. Epub 2020 Oct 
      12.

PMID- 10819416
OWN - NLM
STAT- MEDLINE
DCOM- 20000824
LR  - 20191103
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 17
IP  - 3
DP  - 2000 May-Jun
TI  - An enhanced process for encapsulating aspirin in ethyl cellulose microcapsules by 
      solvent evaporation in an O/W emulsion.
PG  - 269-77
AB  - An enhanced process for microencapsulating aspirin in ethylcellulose was 
      demonstrated using an oil-in-water emulsification/solvent evaporation technique. 
      Methylene chloride (CH2Cl2) was used as the dispersed medium and water as the 
      dispersing medium. The recovered weight, particle size distribution, aspirin 
      loading efficiency, and the aspirin release rate of microcapsules were analysed. 
      The addition of appropriate amounts of non-solvent (n-heptane) prior to the 
      emulsification increases the recovered weight, but decreases the size of the 
      formed microcapsules. The addition of non-solvent also changes the microcapsule 
      characteristics, resulting in a coarser surface and an increased release rate. 
      Increasing the polymer (ethylcellulose) concentration in the dispersed phase 
      increases the size of the microcapsules, the recovered weight, and loading 
      efficiency, but decreases the release rate. The release rate follows first-order 
      kinetics during the first 12 h, suggesting a monolithic system with aspirin 
      uniformly distributed in the microcapsule.
FAU - Yang, C Y
AU  - Yang CY
AD  - Department of Chemical Engineering, National Cheng Kung University, Tainan, 
      Taiwan, Republic of China.
FAU - Tsay, S Y
AU  - Tsay SY
FAU - Tsiang, R C
AU  - Tsiang RC
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Capsules)
RN  - 0 (Emulsions)
RN  - 0 (Oils)
RN  - 0 (Solvents)
RN  - 059QF0KO0R (Water)
RN  - 7Z8S9VYZ4B (ethyl cellulose)
RN  - 9004-34-6 (Cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Capsules
MH  - Cellulose/analogs & derivatives
MH  - Drug Compounding
MH  - Emulsions
MH  - Microscopy, Electron, Scanning
MH  - Oils
MH  - Particle Size
MH  - Solvents
MH  - Viscosity
MH  - Water
EDAT- 2000/05/20 09:00
MHDA- 2000/08/29 11:01
CRDT- 2000/05/20 09:00
PHST- 2000/05/20 09:00 [pubmed]
PHST- 2000/08/29 11:01 [medline]
PHST- 2000/05/20 09:00 [entrez]
AID - 10.1080/026520400288256 [doi]
PST - ppublish
SO  - J Microencapsul. 2000 May-Jun;17(3):269-77. doi: 10.1080/026520400288256.

PMID- 25048480
OWN - NLM
STAT- MEDLINE
DCOM- 20150413
LR  - 20220408
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 55
IP  - 5
DP  - 2014 Sep
TI  - Safety and efficacy of switching anticoagulation to aspirin three months after 
      successful radiofrequency catheter ablation of atrial fibrillation.
PG  - 1238-45
LID - 10.3349/ymj.2014.55.5.1238 [doi]
AB  - PURPOSE: Although current guidelines recommend continuing the same antithrombotic 
      strategy regardless of rhythm control after radiofrequency catheter ablation 
      (RFCA) of atrial fibrillation (AF), anticoagulation has a risk of major bleeding. 
      We evaluated the safety of switching warfarin to aspirin in patients with 
      successful AF ablation. MATERIALS AND METHODS: Among 721 patients who underwent 
      RFCA of AF, 608 patients (age, 57.3±10.9 years; 77.0% male, 75.5% paroxysmal AF) 
      who had no evidence of AF recurrence at 3 months post-RFCA were included. We 
      compared the thromboembolic and hemorrhagic events in patients for whom warfarin 
      was switched to aspirin (ASA group; n=296) and patients who were kept on warfarin 
      therapy (W group; n=312). RESULTS: There were no significant differences in 
      CHA₂DS₂-VASc or HAS-BLED scores between the groups. In 30 patients in the ASA 
      group and 37 patients in W group, AF recurred and warfarin was restarted or 
      maintained during the 18.0±12.2 months of follow-up. There were no significant 
      differences in thromboembolic (0.3% vs. 1.0%, p=0.342) and major bleeding 
      incidences (0.7% vs. 0.6%, p=0.958) between ASA and W groups during the follow-up 
      period. In the 259 patients with a CHA₂DS₂-VASc score≥2, there were no 
      significant differences in thromboembolism (0.8% and 2.2%, p=0.380) or major 
      bleeding incidences (0.8% and 1.4%, p=0.640) between ASA and W groups. 
      CONCLUSION: Switching warfarin to aspirin 3 months after successful RFCA of AF 
      could be as safe and efficacious as long-term anticoagulation even in patients 
      with CHA₂DS₂-VASc score≥2. However, strict rhythm monitoring cannot be 
      overemphasized.
FAU - Uhm, Jae-Sun
AU  - Uhm JS
AD  - Division of Cardiology, Department of Internal Medicine, Severance Hospital, 
      Yonsei University College of Medicine, Seoul, Korea.
FAU - Won, Hoyoun
AU  - Won H
AD  - Division of Cardiology, Department of Internal Medicine, Severance Hospital, 
      Yonsei University College of Medicine, Seoul, Korea.
FAU - Joung, Boyoung
AU  - Joung B
AD  - Division of Cardiology, Department of Internal Medicine, Severance Hospital, 
      Yonsei University College of Medicine, Seoul, Korea.
FAU - Nam, Gi-Byoung
AU  - Nam GB
AD  - Division of Cardiology, Department of Internal Medicine, Asan Medical Center, 
      University of Ulsan College of Medicine, Seoul, Korea.
FAU - Choi, Kee-Joon
AU  - Choi KJ
AD  - Division of Cardiology, Department of Internal Medicine, Asan Medical Center, 
      University of Ulsan College of Medicine, Seoul, Korea.
FAU - Lee, Moon-Hyoung
AU  - Lee MH
AD  - Division of Cardiology, Department of Internal Medicine, Severance Hospital, 
      Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, You-Ho
AU  - Kim YH
AD  - Division of Cardiology, Department of Internal Medicine, Asan Medical Center, 
      University of Ulsan College of Medicine, Seoul, Korea.
FAU - Pak, Hui-Nam
AU  - Pak HN
AD  - Division of Cardiology, Department of Internal Medicine, Severance Hospital, 
      Yonsei University College of Medicine, Seoul, Korea. hnpak@yuhs.ac.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Atrial Fibrillation/*surgery
MH  - Catheter Ablation
MH  - Female
MH  - Hemorrhage/epidemiology
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/epidemiology
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Thromboembolism/epidemiology
MH  - Treatment Outcome
MH  - Warfarin/administration & dosage/*therapeutic use
PMC - PMC4108807
OTO - NOTNLM
OT  - Anticoagulation
OT  - aspirin
OT  - atrial fibrillation
OT  - catheter ablation
COIS- The authors have no financial conflicts of interest.
EDAT- 2014/07/23 06:00
MHDA- 2015/04/14 06:00
CRDT- 2014/07/23 06:00
PHST- 2014/07/23 06:00 [entrez]
PHST- 2014/07/23 06:00 [pubmed]
PHST- 2015/04/14 06:00 [medline]
AID - 2014091238 [pii]
AID - 10.3349/ymj.2014.55.5.1238 [doi]
PST - ppublish
SO  - Yonsei Med J. 2014 Sep;55(5):1238-45. doi: 10.3349/ymj.2014.55.5.1238.

PMID- 2799549
OWN - NLM
STAT- MEDLINE
DCOM- 19891102
LR  - 20131121
IS  - 0370-8179 (Print)
IS  - 0370-8179 (Linking)
VI  - 117
IP  - 1-2
DP  - 1989 Jan-Feb
TI  - [Antiaggregation agents in the prevention of venous graft occlusion in arterial 
      reconstruction].
PG  - 73-86
AB  - Activated platelets are the most important factor in all 3 occlusive processes 
      which successively take place in venous graft in arterial reconstruction. 
      Therefore antithrombotic therapy, and especially aspirin, receives more and more 
      attention in prolonging the life of the grafts. The first prerequisite for 
      optimal clinical effect of aspirin is the beginning of therapy before or on the 
      day of the operation. The second prerequisite is related to the dose (300 mg), 
      which achieves the fast and complete inhibition of thromboxane production with 
      partial and transient inhibition of prostacyclin production with elimination of 
      undesired effects like the prolongation of bleeding time, greater depression of 
      prostacyclin synthesis and gastric bleeding.
FAU - Anojcić, S
AU  - Anojcić S
FAU - Pavlović, S
AU  - Pavlović S
LA  - srp
PT  - English Abstract
PT  - Journal Article
TT  - Antiagregacijski lekovi u sprecavanju okluzije venskog transplantata kod 
      arterijskih rekonstrukcija.
PL  - Serbia
TA  - Srp Arh Celok Lek
JT  - Srpski arhiv za celokupno lekarstvo
JID - 0027440
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/prevention & control
MH  - Thrombosis/etiology/*prevention & control
MH  - Veins/*transplantation
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Srp Arh Celok Lek. 1989 Jan-Feb;117(1-2):73-86.

PMID- 159985
OWN - NLM
STAT- MEDLINE
DCOM- 19800228
LR  - 20131121
IS  - 0302-2137 (Print)
IS  - 0302-2137 (Linking)
VI  - 57
IP  - 4
DP  - 1979 Aug
TI  - On the enzymatic response to injury and its mediators.
PG  - 211-9
AB  - The enzymatic response to injury appears as an increase in enzymatic activity in 
      the periphery of burns and other injuries. The following processes constitute the 
      enzymatic response: 1) release, 2) activation and 3) synthesis of enzymes. 
      Processes 2) and 3) are dependent upon the fibroblast, which is an activated 
      fibrocyte. Among the fibrocyte activators, and thus among the mediators of the 
      enzymatic response, are histamine, serotonin, kinins, prostaglandins etc. The 
      effects of non-steroidal anti-inflammatory drugs on the enzymatic response to 
      burn injury were studied. Indomethacin, mefenamic acid or aspirin, suspended in 
      carboxymethylcellulose, were given to rats by stomach tube. Controls received 
      carboxymethylcellulose only. Circular burns were inflicted on anaesthetized 
      animals which were killed 30 min, 2 h or 4 h after burning. The burns were 
      studied histologically and enzyme histochemically by using the methods for 
      prostaglandin synthetase, esterases, and adenosine triphosphatase. Aspirin had no 
      effect on the enzymatic response. Mefenamic acid and indomethacin caused a less 
      severe enzymatic response in the 4-h groups as compared to control rats.
FAU - Raekallio, J
AU  - Raekallio J
FAU - Nieminen, L
AU  - Nieminen L
LA  - eng
PT  - Journal Article
PL  - Finland
TA  - Med Biol
JT  - Medical biology
JID - 0417300
RN  - 0 (Anti-Inflammatory Agents)
RN  - 367589PJ2C (Mefenamic Acid)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - EC 3.6.1.- (Adenosine Triphosphatases)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adenosine Triphosphatases/metabolism
MH  - Alkaline Phosphatase/metabolism
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Burns/drug therapy/*enzymology
MH  - Indomethacin/pharmacology/therapeutic use
MH  - Inflammation/enzymology
MH  - Male
MH  - Mefenamic Acid/pharmacology/therapeutic use
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Rats
MH  - Skin/*enzymology
MH  - Wounds and Injuries/*enzymology
EDAT- 1979/08/01 00:00
MHDA- 1979/08/01 00:01
CRDT- 1979/08/01 00:00
PHST- 1979/08/01 00:00 [pubmed]
PHST- 1979/08/01 00:01 [medline]
PHST- 1979/08/01 00:00 [entrez]
PST - ppublish
SO  - Med Biol. 1979 Aug;57(4):211-9.

PMID- 7522785
OWN - NLM
STAT- MEDLINE
DCOM- 19941027
LR  - 20161021
IS  - 1027-3646 (Print)
IS  - 1027-3646 (Linking)
VI  - 80
IP  - 2
DP  - 1994 Feb
TI  - [The activity of the lymphatic vessels under conditions of experimental stress 
      exposures].
PG  - 34-48
AB  - Lymphangions were found to possess a considerable ability for temperature 
      adaptation under modelled stressful effects on humans. The minute volume of 
      lymphangions was found to linearly depend on the temperature of bathing solution 
      within the range of 22-41 degrees C. Aspirin and other non-steroid analgetic 
      agents were found to exert an obvious dose-dependent negative inotropic effect on 
      electric potentials and contractile activity of a lymphangion. 
      Clinical-experimental assessment and physiological justification of action of a 
      new perfusion solution: polyvisoline, was given.
FAU - Orlov, R S
AU  - Orlov RS
FAU - Erofeev, N P
AU  - Erofeev NP
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Deiatel'nost' limfaticheskikh sosudov v usloviiakh stressornykh 
      éksperimental'nykh vozdeĭstviĭ.
PL  - Russia (Federation)
TA  - Fiziol Zh Im I M Sechenova
JT  - Fiziologicheskii zhurnal imeni I.M. Sechenova
JID - 9308360
RN  - 0 (Alcohols)
RN  - 0 (Salts)
RN  - 144638-34-6 (polyvisoline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alcohols/pharmacology/therapeutic use
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cattle
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation
MH  - Drug Evaluation, Preclinical
MH  - Electrophysiology
MH  - Humans
MH  - In Vitro Techniques
MH  - Ischemia/physiopathology
MH  - Leg/blood supply
MH  - Liver Diseases/drug therapy/physiopathology
MH  - Lymph/drug effects/physiology
MH  - Lymphatic System/drug effects/*physiopathology
MH  - Male
MH  - Muscle Contraction/drug effects/physiology
MH  - Muscle, Smooth/drug effects/physiopathology
MH  - Salts/pharmacology/therapeutic use
MH  - Stress, Physiological/*physiopathology
MH  - Temperature
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
PST - ppublish
SO  - Fiziol Zh Im I M Sechenova. 1994 Feb;80(2):34-48.

PMID- 31382819
OWN - NLM
STAT- MEDLINE
DCOM- 20191202
LR  - 20191202
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 17
IP  - 9
DP  - 2019 Sep
TI  - Aspirin for the primary prevention of cardiovascular disease: latest evidence.
PG  - 633-643
LID - 10.1080/14779072.2019.1651199 [doi]
AB  - Introduction: While the clinical merits of aspirin in secondary cardiovascular 
      disease (CVD) prevention remain undisputed, its role in primary prevention is 
      controversial. Recently, three trials of primary prevention reported neutral net 
      benefit results or evidence of harm for aspirin in patients with no overt CVD. 
      Areas covered: This article aims to inform clinical practitioners by appraising 
      the current body of evidence on the use of aspirin for primary CVD prevention, 
      ranging from general pharmacology to clinical outcomes and future directions. 
      Expert opinion: Based on meta-analyses incorporating latest trials in the field 
      of primary prevention, the modest reduction in ischemic events with aspirin, if 
      any, is offset by a modest increase in nonfatal bleeding. Improved control of CVD 
      risk factors and broader use of statins may have reduced the thrombotic 
      complications of atherosclerosis, thus limiting the opportunity for aspirin to 
      prevent clinical CVD events in the contemporary era. As such, decision-making 
      about aspirin for primary prevention is challenging even when selected patients 
      are considered and involves careful weighing of risks and benefits. Ongoing 
      investigations conducted in patients with cancer could rapidly modify the current 
      perception of the unfavorable benefit-risk ratio of aspirin in patients with no 
      overt CVD.
FAU - Capodanno, Davide
AU  - Capodanno D
AD  - Division of Cardiology, A.O.U, "Policlinico-Vittorio Emanuele", University of 
      Catania , Catania , Italy.
FAU - Ingala, Salvatore
AU  - Ingala S
AD  - Division of Cardiology, A.O.U, "Policlinico-Vittorio Emanuele", University of 
      Catania , Catania , Italy.
FAU - Calderone, Dario
AU  - Calderone D
AD  - Division of Cardiology, A.O.U, "Policlinico-Vittorio Emanuele", University of 
      Catania , Catania , Italy.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - Division of Cardiology, Department of Medicine, University of Florida College of 
      Medicine , Jacksonville , FL , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190816
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Atherosclerosis/drug therapy
MH  - Cardiovascular Diseases/*prevention & control
MH  - Decision Making
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Patient Selection
MH  - Primary Prevention/methods
OTO - NOTNLM
OT  - Aspirin
OT  - antiplatelet therapy
OT  - cardiovascular disease
OT  - primary prevention
EDAT- 2019/08/07 06:00
MHDA- 2019/12/04 06:00
CRDT- 2019/08/07 06:00
PHST- 2019/08/07 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2019/08/07 06:00 [entrez]
AID - 10.1080/14779072.2019.1651199 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2019 Sep;17(9):633-643. doi: 
      10.1080/14779072.2019.1651199. Epub 2019 Aug 16.

PMID- 23294895
OWN - NLM
STAT- MEDLINE
DCOM- 20140116
LR  - 20190318
IS  - 1471-4973 (Electronic)
IS  - 1471-4892 (Linking)
VI  - 13
IP  - 2
DP  - 2013 Apr
TI  - Aspirin and aspirin resistance in coronary artery disease.
PG  - 242-50
LID - S1471-4892(12)00241-X [pii]
LID - 10.1016/j.coph.2012.12.004 [doi]
AB  - Aspirin is still the mainstay of antiplatelet therapy in the secondary prevention 
      of coronary artery disease. However certain patients do not benefit from the 
      antithrombotic effects of aspirin. The phenomenon of so-called aspirin resistance 
      can be considered from the clinical and laboratory perspective. A variety of 
      methods have emerged for the laboratory diagnosis of aspirin resistance. None of 
      them is considered ideal as they provide conflicting information with significant 
      inter-individual variability and weak correlation between them. With the 
      mechanisms of aspirin resistance not fully understood and the phenomenon commonly 
      observed in individuals with poor compliance, the existence of aspirin resistance 
      has been challenged. The aim of this review is to present recent data on the 
      impact of aspirin resistance in primary and secondary prevention of coronary 
      artery disease.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Kasmeridis, Charalampos
AU  - Kasmeridis C
AD  - University of Birmingham Centre for Cardiovascular Sciences, City Hospital, 
      Birmingham, UK.
FAU - Apostolakis, Stavros
AU  - Apostolakis S
FAU - Lip, Gregory Y H
AU  - Lip GY
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130105
PL  - England
TA  - Curr Opin Pharmacol
JT  - Current opinion in pharmacology
JID - 100966133
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy/prevention & control
MH  - *Drug Resistance
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2013/01/09 06:00
MHDA- 2014/01/17 06:00
CRDT- 2013/01/09 06:00
PHST- 2012/10/09 00:00 [received]
PHST- 2012/12/17 00:00 [revised]
PHST- 2012/12/17 00:00 [accepted]
PHST- 2013/01/09 06:00 [entrez]
PHST- 2013/01/09 06:00 [pubmed]
PHST- 2014/01/17 06:00 [medline]
AID - S1471-4892(12)00241-X [pii]
AID - 10.1016/j.coph.2012.12.004 [doi]
PST - ppublish
SO  - Curr Opin Pharmacol. 2013 Apr;13(2):242-50. doi: 10.1016/j.coph.2012.12.004. Epub 
      2013 Jan 5.

PMID- 10709440
OWN - NLM
STAT- MEDLINE
DCOM- 20000414
LR  - 20151119
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 54
IP  - 6
DP  - 1999 Nov-Dec
TI  - [Awareness of 125 patients of the rules for using their non-steroidal 
      anti-inflammatory agent].
PG  - 683-8
AB  - A total of 125 inpatients from a rheumatology unit were interviewed to assess 
      their awareness of the rules for using a prescribed NSAID. Two per cent were 
      unaware that they were receiving an NSAID, and 13 per cent and 71 per cent 
      respectively did not know the name or the dosage. Twenty-two per cent admitted 
      excessive intake, and 2 per cent simultaneous intake of two NSAIDs. Some declared 
      that in the absence of adequate improvement they would take another NSAID (17 per 
      cent) or aspirin (26 per cent) simultaneously. Fifty-nine per cent were unaware 
      that aspirin is an anti-inflammatory drug, 3 per cent thought that taking a 
      double dosage on alternate days was safe, and 46 per cent that taking a stronger 
      dose at the beginning of treatment was an efficient and safe procedure. The 
      replies of patients who had read the directions for use (69 per cent) did not 
      differ from those of patients who had not (31 per cent). Fourteen per cent of 
      patients declared that they would not advise their physicians after buying NSAIDs 
      over the counter.
FAU - Berthelot, J M
AU  - Berthelot JM
AD  - Service de Rhumatologie, CHU Nantes, Hôtel-Dieu, France.
FAU - Millet, S
AU  - Millet S
FAU - Chatelier, B
AU  - Chatelier B
FAU - Ripoll, N
AU  - Ripoll N
FAU - Maugars, Y
AU  - Maugars Y
FAU - Prost, A
AU  - Prost A
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Connaissance par 125 patients des règles de prise de leur anti-inflammatoire non 
      stéroïdien.
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Drug Interactions
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nonprescription Drugs
MH  - Patient Compliance
MH  - Patient Education as Topic
MH  - Patients/*psychology
MH  - Physician-Patient Relations
MH  - Risk Factors
MH  - Self Administration
MH  - Self Medication
MH  - Surveys and Questionnaires
EDAT- 2000/03/10 09:00
MHDA- 2000/04/25 09:00
CRDT- 2000/03/10 09:00
PHST- 2000/03/10 09:00 [pubmed]
PHST- 2000/04/25 09:00 [medline]
PHST- 2000/03/10 09:00 [entrez]
PST - ppublish
SO  - Therapie. 1999 Nov-Dec;54(6):683-8.

PMID- 7458516
OWN - NLM
STAT- MEDLINE
DCOM- 19810327
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 141
IP  - 2
DP  - 1981 Feb
TI  - Prevention of cigarette smoking-induced platelet aggregate formation by aspirin.
PG  - 206-7
AB  - The purpose of this study was to determine whether aspirin could prevent a 
      decrease in the platelet aggregate ratio that we previously found after cigarette 
      smoking. Twenty healthy nonsmokers, who had not taken aspirin in the preceding 
      seven days, smoked two tobacco cigarettes without filters during a 20-minute 
      period. The mean platelet aggregate ratios before and after smoking were 0.91 and 
      0.80, respectively. When the experiments were repeated 48 hours later and seven 
      to 18 hours after the ingestion of one tablet of aspirin (0.32 g), there was no 
      decrease in the platelet aggregate ratio after smoking. The mean post-smoking 
      platelet aggregate ration after aspirin (0.93) was significantly higher than 
      before aspirin. We conclude that aspirin prevented cigarette smoking-induced 
      platelet aggregate formation.
FAU - Davis, J W
AU  - Davis JW
FAU - Davis, R F
AU  - Davis RF
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/etiology/prevention & control
MH  - Platelet Aggregation/*drug effects
MH  - Smoking
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1981 Feb;141(2):206-7.

PMID- 950178
OWN - NLM
STAT- MEDLINE
DCOM- 19761002
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 5
IP  - 2
DP  - 1976
TI  - Inhibition of platelet aggregation by acetylsalicylic acid and other inhibitors.
PG  - 85-95
AB  - Effects on platelet aggregation were examined of acetylsalicylic acid (ASA), 
      indomethacin and a number of other agents including dipyridamole, phenylbutazone 
      and sulfinpyrazone under standardized conditions. The Born turbidometric method 
      of measuring platelet aggregation was used with collagen as the stimulus for 
      aggregation. ASA and indomethacin were shown to be among the most potent 
      inhibitors of aggregation, being active at minimal effective concentrations of 
      1-3 mug/ml using a 10 min time of pre-incubation with the platelet-rich plasma 
      (degree of aggregation inhibition was time dependent). Most of the other agents 
      tested were also active in vitro and both prostaglandin E1 and adenosine were 
      more potent than ASA or indomethacin. However, these agents were shown not to 
      exert significant inhibitory effects when administered orally to rats (dose 10 
      and 30 mg/kg). ASA proved to be effective in doses as low as 3 mg/kg, and 
      indomethacin in doses as low as 1 mg/kg orally. The inhibitory effects of ASA on 
      aggregation remained for several days after a single oral dose, whereas the 
      effects of indomethacin disappeared within 24 h.
FAU - Seuter, F
AU  - Seuter F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Rats
MH  - Time Factors
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1159/000214122 [doi]
PST - ppublish
SO  - Haemostasis. 1976;5(2):85-95. doi: 10.1159/000214122.

PMID- 36089729
OWN - NLM
STAT- MEDLINE
DCOM- 20220913
LR  - 20220913
IS  - 1681-7168 (Electronic)
IS  - 1022-386X (Linking)
VI  - 32
IP  - 9
DP  - 2022 Sep
TI  - Comparison of Low Molecular Weight Heparin Used alone or Combined with Aspirin in 
      the Treatment of Fetal Growth Restriction.
PG  - 1228-1229
LID - 10.29271/jcpsp.2022.09.1228 [doi]
AB  - The objective of the study was to compare the efficacy of low-molecular weight 
      heparin (LMWH) alone and use in the combination with aspirin in the treatment of 
      fetal growth restriction (FGR) patients. Ninety-six FGR patients were divided 
      into the LMWH group (n=48) and the combined group (n=48), according to the 
      different treatments. This research showed after treatment, values of PI, RI and 
      S/D, serum IL-6 and TNF-α in the combined group were lower than those in the LMWH 
      group (all p <0.001). The frequency of pregnancy complications and adverse 
      neonatal outcomes in the combined group were 2 (4.2%) lower than the LMWH group 
      (p=0.045, 0.025). Combination of LMWH with aspirin in FGR patients effectively 
      reduced levels of IL-6 and TNF-α within the mother, improved fetal developmental 
      parameters, and reduced the frequency of pregnancy complications and adverse 
      neonatal outcomes compared with LMWH treatment alone. Key Words: Fetal growth 
      restriction (FGR), Low-molecular weight heparin (LMWH), Aspirin, Pregnancy, 
      Newborn.
FAU - He, Saiqiong
AU  - He S
AD  - Department of Obstetrics, Xinchang people's Hospital, Shaoxing, China.
FAU - Liang, Lingling
AU  - Liang L
AD  - Department of Gynaecology, Xinchang people's Hospital, Shaoxing, China.
FAU - He, Sailin
AU  - He S
AD  - Department of Pediatrics, Xinchang Hospital of Traditional Chinese Medicine, 
      Shaoxing, China.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Coll Physicians Surg Pak
JT  - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
JID - 9606447
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Fetal Growth Retardation/drug therapy
MH  - *Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Infant, Newborn
MH  - Interleukin-6
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - Tumor Necrosis Factor-alpha
EDAT- 2022/09/13 06:00
MHDA- 2022/09/14 06:00
CRDT- 2022/09/12 00:41
PHST- 2022/05/30 00:00 [received]
PHST- 2022/07/28 00:00 [accepted]
PHST- 2022/09/12 00:41 [entrez]
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
AID - 040579197 [pii]
AID - 10.29271/jcpsp.2022.09.1228 [doi]
PST - ppublish
SO  - J Coll Physicians Surg Pak. 2022 Sep;32(9):1228-1229. doi: 
      10.29271/jcpsp.2022.09.1228.

PMID- 1689791
OWN - NLM
STAT- MEDLINE
DCOM- 19900412
LR  - 20221207
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 335
IP  - 8689
DP  - 1990 Mar 10
TI  - Trial of iloprost versus aspirin treatment for critical limb ischaemia of 
      thromboangiitis obliterans. The TAO Study.
PG  - 555-7
AB  - 152 patients with thromboangiitis obliterans (Buerger's disease) and pain from 
      critical leg ischaemia were randomly allocated to receive iloprost, a chemically 
      stable prostacyclin analogue, or low-dose aspirin, for 28 days in a double-blind 
      trial. On review, 19 patients did not fulfil the stringent entry criteria. Of the 
      other 133 patients, 98 also had leg ulcers. After 21-28 days, 58 (85%) of 68 
      iloprost-treated patients showed ulcer healing or relief of ischaemic pain, 
      compared with 11 (17%) of 65 in the aspirin-treated group. 43 (63%) on iloprost 
      treatment had complete relief of pain, compared with 18 (28%) on aspirin. Ulcers 
      healed completely in 18 of 52 (35%) who received iloprost compared with 6 of 46 
      (13%) who received aspirin. 6 months after the start of treatment, the response 
      rate was 45 of 51 (88%) patients treated with iloprost compared with 12 of 44 
      (21%) patients treated with aspirin.
FAU - Fiessinger, J N
AU  - Fiessinger JN
AD  - Service de Pathologie Vasculaire, Hôpital Broussais, Paris, France.
FAU - Schäfer, M
AU  - Schäfer M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Arrhythmia Agents)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - JED5K35YGL (Iloprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Amputation, Surgical
MH  - Anti-Arrhythmia Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Arm/*blood supply
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Evaluation
MH  - Epoprostenol/administration & dosage/adverse effects/*therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Iloprost
MH  - Ischemia/*drug therapy/etiology
MH  - Leg/*blood supply/surgery
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Thromboangiitis Obliterans/*complications/surgery
EDAT- 1990/03/10 00:00
MHDA- 1990/03/10 00:01
CRDT- 1990/03/10 00:00
PHST- 1990/03/10 00:00 [pubmed]
PHST- 1990/03/10 00:01 [medline]
PHST- 1990/03/10 00:00 [entrez]
AID - 0140-6736(90)90346-7 [pii]
AID - 10.1016/0140-6736(90)90346-7 [doi]
PST - ppublish
SO  - Lancet. 1990 Mar 10;335(8689):555-7. doi: 10.1016/0140-6736(90)90346-7.

PMID- 17165280
OWN - NLM
STAT- MEDLINE
DCOM- 20070117
LR  - 20211203
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 97
IP  - 5
DP  - 2006 Nov
TI  - Effect of leukotriene modifier drugs on the safety of oral aspirin challenges.
PG  - 688-93
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease can be diagnosed with oral 
      aspirin challenges and treated with aspirin desensitization. OBJECTIVE: To 
      evaluate whether controller medications, particularly leukotriene modifier drugs, 
      taken during oral aspirin challenges can reduce the risk of severe asthmatic 
      responses. METHODS: The medical records of 676 patients who had undergone oral 
      aspirin challenges, followed by aspirin desensitization, were reviewed. Asthmatic 
      responses were stratified based on severity of bronchospastic response or lack of 
      response. The effect of pretreatment with controller medications on the outcome 
      of oral aspirin challenges was measured. RESULTS: Leukotriene modifier drugs had 
      the most significant effect in protecting the lower airways from severe reactions 
      (P = .004). The protective effect of leukotriene modifier drugs was observed in 
      patients already taking systemic corticosteroids, where the addition of 
      leukotriene modifier drugs significantly shifted the response toward a milder 
      asthmatic response (P < .001). CONCLUSION: Protection from significant 
      aspirin-induced bronchospasm during oral aspirin challenge can be accomplished 
      with leukotriene modifier drugs. The use of a combination of inhaled 
      corticosteroids, long-acting beta-agonists, systemic corticosteroids, and 
      leukotriene modifier drugs stabilized underlying airways in preparation for a 
      reasonably safe and accurate oral aspirin challenge. However, only pretreatment 
      with leukotriene modifier drugs enhanced the safety of oral aspirin challenge in 
      patients with aspirin-exacerbated respiratory disease by significantly decreasing 
      the degree of asthmatic responses. Therefore, outpatient oral aspirin challenges 
      in most well-selected patients appear to be a reasonable decision.
FAU - White, Andrew
AU  - White A
AD  - Department of Allergy and Immunology, Naval Medical Center San Diego, San Diego, 
      California 92106, USA. drew_white@hotmail.com
FAU - Ludington, Elizabeth
AU  - Ludington E
FAU - Mehra, Purvi
AU  - Mehra P
FAU - Stevenson, Donald D
AU  - Stevenson DD
FAU - Simon, Ronald A
AU  - Simon RA
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Acetates)
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Cyclopropanes)
RN  - 0 (Indoles)
RN  - 0 (Leukotriene Antagonists)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 0 (Phenylcarbamates)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - 0 (Sulfonamides)
RN  - 0 (Tosyl Compounds)
RN  - MHM278SD3E (montelukast)
RN  - R16CO5Y76E (Aspirin)
RN  - V1L22WVE2S (zileuton)
RN  - X6Q56QN5QC (Hydroxyurea)
RN  - XZ629S5L50 (zafirlukast)
SB  - IM
MH  - Acetates/therapeutic use
MH  - Adolescent
MH  - Adrenal Cortex Hormones/pharmacology/therapeutic use
MH  - Adult
MH  - Aged
MH  - Anti-Asthmatic Agents/therapeutic use
MH  - Aspirin/adverse effects/immunology/*therapeutic use
MH  - Asthma/chemically induced/immunology/prevention & control
MH  - Cyclopropanes
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*drug therapy/immunology/prevention & control
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Hydroxyurea/analogs & derivatives/therapeutic use
MH  - Indoles
MH  - Leukotriene Antagonists/*therapeutic use
MH  - Lipoxygenase Inhibitors/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Phenylcarbamates
MH  - Quinolines/therapeutic use
MH  - Sulfides
MH  - Sulfonamides
MH  - Tosyl Compounds/therapeutic use
MH  - Treatment Outcome
EDAT- 2006/12/15 09:00
MHDA- 2007/01/18 09:00
CRDT- 2006/12/15 09:00
PHST- 2006/12/15 09:00 [pubmed]
PHST- 2007/01/18 09:00 [medline]
PHST- 2006/12/15 09:00 [entrez]
AID - S1081-1206(10)61101-5 [pii]
AID - 10.1016/S1081-1206(10)61101-5 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2006 Nov;97(5):688-93. doi: 
      10.1016/S1081-1206(10)61101-5.

PMID- 22267096
OWN - NLM
STAT- MEDLINE
DCOM- 20120306
LR  - 20131121
IS  - 1541-8243 (Electronic)
IS  - 0038-4348 (Linking)
VI  - 105
IP  - 2
DP  - 2012 Feb
TI  - Aspirin in primary and secondary prevention in elderly adults revisited.
PG  - 82-6
LID - 10.1097/SMJ.0b013e3182426eef [doi]
AB  - Despite the frequency and long duration of aspirin use, its role in primary and 
      secondary prevention in older adults is not well studied. This review takes a 
      critical look at the available literature on aspirin efficacy in elderly adults, 
      and some relevant guidelines for practicing physicians are suggested.
FAU - Wilson, Ryan
AU  - Wilson R
AD  - Department of Medicine, University of Florida College of Medicine, Jacksonville, 
      FL 32209, USA.
FAU - Gazzala, Jawahar
AU  - Gazzala J
FAU - House, Jeff
AU  - House J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - *Practice Guidelines as Topic
MH  - Primary Prevention/*methods
MH  - Risk Factors
MH  - Secondary Prevention/*methods
MH  - Thrombosis/*prevention & control
EDAT- 2012/01/24 06:00
MHDA- 2012/03/07 06:00
CRDT- 2012/01/24 06:00
PHST- 2012/01/24 06:00 [entrez]
PHST- 2012/01/24 06:00 [pubmed]
PHST- 2012/03/07 06:00 [medline]
AID - 00007611-201202000-00006 [pii]
AID - 10.1097/SMJ.0b013e3182426eef [doi]
PST - ppublish
SO  - South Med J. 2012 Feb;105(2):82-6. doi: 10.1097/SMJ.0b013e3182426eef.

PMID- 9822499
OWN - NLM
STAT- MEDLINE
DCOM- 19981223
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 179
IP  - 5
DP  - 1998 Nov
TI  - Maternal serum thromboxane B2 concentrations do not predict improved outcomes in 
      high-risk pregnancies in a low-dose aspirin trial. The National Institute of 
      Child Health and Human Development Network of Maternal-Fetal Medical Units.
PG  - 1193-9
AB  - OBJECTIVE: The aim of the study was too determine whether, in a low-dose aspirin 
      trial in high-risk pregnancies, a decrease in maternal serum thromboxane B2 level 
      predicted improved pregnancy outcomes. STUDY DESIGN: This multicenter, 
      randomized, double-blind trial included 2539 women, 1010 of whom had sufficient 
      serum samples at enrollment and at 24 to 28 weeks' gestation, 34 to 38 weeks' 
      gestation, or both to assess longitudinal changes in thromboxane B2 level and 
      their effects on pregnancy outcomes. Women were randomly assigned between 13 and 
      26 weeks' gestation to receive daily aspirin (60 mg) or placebo. RESULTS: Overall 
      and in all subgroups women assigned to receive aspirin had markedly lower 
      maternal thromboxane B2 concentration values than did those assigned to receive a 
      placebo (P =.0001). Changes in thromboxane levels were not, however, correlated 
      with adverse pregnancy outcomes. Women with >/=50% reduction in maternal serum 
      thromboxane B2 concentrations from baseline had occurrences of preeclampsia (P 
      =.922), preterm birth (P =.375), small for gestational age neonates (P =.938), 
      and grade III or IV intraventricular hemorrhage (P = 1.000) similar to those of 
      women who had <50% reduction. Similar results were found for women with 
      thromboxane B2 level decreases of <15 versus >15 ng/mL and women with thromboxane 
      B2 level decreases to <10 versus >/=10, <5 versus >/=5, and <1 versus >/=1 ng/mL. 
      Maternal thromboxane B2 concentrations at enrollment were also not predictive of 
      adverse outcomes. CONCLUSION: Neither maternal serum thromboxane B2 
      concentrations at enrollment nor their subsequent reduction were predictive of 
      adverse pregnancy outcomes in a low-dose aspirin trial.
FAU - Hauth, J
AU  - Hauth J
AD  - University of Alabama at Birmingham, the University of Tennessee, Memphis, TN, 
      USA.
FAU - Sibai, B
AU  - Sibai B
FAU - Caritis, S
AU  - Caritis S
FAU - VanDorsten, P
AU  - VanDorsten P
FAU - Lindheimer, M
AU  - Lindheimer M
FAU - Klebanoff, M
AU  - Klebanoff M
FAU - MacPherson, C
AU  - MacPherson C
FAU - Landon, M
AU  - Landon M
FAU - Paul, R
AU  - Paul R
FAU - Miodovnik, M
AU  - Miodovnik M
FAU - Meis, P
AU  - Meis P
FAU - Dombrowski, M
AU  - Dombrowski M
FAU - Thurnau, G
AU  - Thurnau G
FAU - Walsh, S
AU  - Walsh S
FAU - McNellis, D
AU  - McNellis D
FAU - Roberts, J M
AU  - Roberts JM
LA  - eng
GR  - HD19897/HD/NICHD NIH HHS/United States
GR  - HD21410/HD/NICHD NIH HHS/United States
GR  - HD21434/HD/NICHD NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cyclooxygenase Inhibitors/*administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Osmolar Concentration
MH  - Predictive Value of Tests
MH  - Pregnancy/*blood
MH  - *Pregnancy Outcome
MH  - Risk Factors
MH  - Thromboxane B2/*blood
EDAT- 1998/11/20 00:00
MHDA- 1998/11/20 00:01
CRDT- 1998/11/20 00:00
PHST- 1998/11/20 00:00 [pubmed]
PHST- 1998/11/20 00:01 [medline]
PHST- 1998/11/20 00:00 [entrez]
AID - S0002937898701309 [pii]
AID - 10.1016/s0002-9378(98)70130-9 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1998 Nov;179(5):1193-9. doi: 10.1016/s0002-9378(98)70130-9.

PMID- 35240044
OWN - NLM
STAT- MEDLINE
DCOM- 20220406
LR  - 20220406
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 399
IP  - 10329
DP  - 2022 Mar 12
TI  - Safety and efficacy of aspirin, unfractionated heparin, both, or neither during 
      endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, 
      randomised controlled trial.
PG  - 1059-1069
LID - S0140-6736(22)00014-9 [pii]
LID - 10.1016/S0140-6736(22)00014-9 [doi]
AB  - BACKGROUND: Aspirin and unfractionated heparin are often used during endovascular 
      stroke treatment to improve reperfusion and outcomes. However, the effects and 
      risks of anti-thrombotics for this indication are unknown. We therefore aimed to 
      assess the safety and efficacy of intravenous aspirin, unfractionated heparin, 
      both, or neither started during endovascular treatment in patients with ischaemic 
      stroke. METHODS: We did an open-label, multicentre, randomised controlled trial 
      with a 2 × 3 factorial design in 15 centres in the Netherlands. We enrolled adult 
      patients (ie, ≥18 years) with ischaemic stroke due to an intracranial 
      large-vessel occlusion in the anterior circulation in whom endovascular treatment 
      could be initiated within 6 h of symptom onset. Eligible patients had a score of 
      2 or more on the National Institutes of Health Stroke Scale, and a CT or MRI 
      ruling out intracranial haemorrhage. Randomisation was done using a web-based 
      procedure with permuted blocks and stratified by centre. Patients were randomly 
      assigned (1:1) to receive either periprocedural intravenous aspirin (300 mg 
      bolus) or no aspirin, and randomly assigned (1:1:1) to receive moderate-dose 
      unfractionated heparin (5000 IU bolus followed by 1250 IU/h for 6 h), low-dose 
      unfractionated heparin (5000 IU bolus followed by 500 IU/h for 6 h), or no 
      unfractionated heparin. The primary outcome was the score on the modified Rankin 
      Scale at 90 days. Symptomatic intracranial haemorrhage was the main safety 
      outcome. Analyses were based on intention to treat, and treatment effects were 
      expressed as odds ratios (ORs) or common ORs, with adjustment for baseline 
      prognostic factors. This trial is registered with the International Standard 
      Randomised Controlled Trial Number, ISRCTN76741621. FINDINGS: Between Jan 22, 
      2018, and Jan 27, 2021, we randomly assigned 663 patients; of whom, 628 (95%) 
      provided deferred consent or died before consent could be asked and were included 
      in the modified intention-to-treat population. On Feb 4, 2021, after unblinding 
      and analysis of the data, the trial steering committee permanently stopped 
      patient recruitment and the trial was stopped for safety concerns. The risk of 
      symptomatic intracranial haemorrhage was higher in patients allocated to receive 
      aspirin than in those not receiving aspirin (43 [14%] of 310 vs 23 [7%] of 318; 
      adjusted OR 1·95 [95% CI 1·13-3·35]) as well as in patients allocated to receive 
      unfractionated heparin than in those not receiving unfractionated heparin (44 
      [13%] of 332 vs 22 [7%] of 296; 1·98 [1·14-3·46]). Both aspirin (adjusted common 
      OR 0·91 [95% CI 0·69-1·21]) and unfractionated heparin (0·81 [0·61-1·08]) led to 
      a non-significant shift towards worse modified Rankin Scale scores. 
      INTERPRETATION: Periprocedural intravenous aspirin and unfractionated heparin 
      during endovascular stroke treatment are both associated with an increased risk 
      of symptomatic intracranial haemorrhage without evidence for a beneficial effect 
      on functional outcome. FUNDING: The Collaboration for New Treatments of Acute 
      Stroke consortium, the Brain Foundation Netherlands, the Ministry of Economic 
      Affairs, Stryker, Medtronic, Cerenovus, and the Dutch Heart Foundation.
CI  - Copyright © 2022 Elsevier Ltd. All rights reserved.
FAU - van der Steen, Wouter
AU  - van der Steen W
AD  - Department of Neurology, Erasmus MC University Medical Center, Rotterdam, 
      Netherlands; Department of Radiology and Nuclear Medicine, Erasmus MC University 
      Medical Center, Rotterdam, Netherlands. Electronic address: 
      w.vandersteen@erasmusmc.nl.
FAU - van de Graaf, Rob A
AU  - van de Graaf RA
AD  - Department of Neurology, Erasmus MC University Medical Center, Rotterdam, 
      Netherlands; Department of Radiology and Nuclear Medicine, Erasmus MC University 
      Medical Center, Rotterdam, Netherlands.
FAU - Chalos, Vicky
AU  - Chalos V
AD  - Department of Neurology, Erasmus MC University Medical Center, Rotterdam, 
      Netherlands; Department of Radiology and Nuclear Medicine, Erasmus MC University 
      Medical Center, Rotterdam, Netherlands; Department of Public Health, Erasmus MC 
      University Medical Center, Rotterdam, Netherlands.
FAU - Lingsma, Hester F
AU  - Lingsma HF
AD  - Department of Public Health, Erasmus MC University Medical Center, Rotterdam, 
      Netherlands.
FAU - van Doormaal, Pieter Jan
AU  - van Doormaal PJ
AD  - Department of Radiology and Nuclear Medicine, Erasmus MC University Medical 
      Center, Rotterdam, Netherlands.
FAU - Coutinho, Jonathan M
AU  - Coutinho JM
AD  - Department of Neurology, Amsterdam University Medical Centers, location AMC, 
      Amsterdam, Netherlands.
FAU - Emmer, Bart J
AU  - Emmer BJ
AD  - Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, 
      location AMC, Amsterdam, Netherlands.
FAU - de Ridder, Inger
AU  - de Ridder I
AD  - Department of Neurology, Maastricht University Medical Centre, Cardiovascular 
      Research Institute Maastricht, Maastricht, Netherlands.
FAU - van Zwam, Wim
AU  - van Zwam W
AD  - Department of Radiology and Nuclear Medicine, Maastricht University Medical 
      Centre, Cardiovascular Research Institute Maastricht, Maastricht, Netherlands.
FAU - van der Worp, H Bart
AU  - van der Worp HB
AD  - Department of Neurology and Neurosurgery, Brain Center, University Medical Center 
      Utrecht, Utrecht, Netherlands.
FAU - van der Schaaf, Irene
AU  - van der Schaaf I
AD  - Department of Radiology, Brain Center, University Medical Center Utrecht, 
      Utrecht, Netherlands.
FAU - Gons, Rob A R
AU  - Gons RAR
AD  - Department of Neurology, Catharina Hospital, Eindhoven, Netherlands.
FAU - Yo, Lonneke S F
AU  - Yo LSF
AD  - Department of Radiology, Catharina Hospital, Eindhoven, Netherlands.
FAU - Boiten, Jelis
AU  - Boiten J
AD  - Department of Neurology, Haaglanden Medical Centre, The Hague, Netherlands.
FAU - van den Wijngaard, Ido
AU  - van den Wijngaard I
AD  - Department of Neurology, Haaglanden Medical Centre, The Hague, Netherlands; 
      Department of Radiology, Haaglanden Medical Centre, The Hague, Netherlands.
FAU - Hofmeijer, Jeannette
AU  - Hofmeijer J
AD  - Department of Neurology, Rijnstate Hospital, Arnhem, Netherlands.
FAU - Martens, Jasper
AU  - Martens J
AD  - Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, 
      Netherlands.
FAU - Schonewille, Wouter
AU  - Schonewille W
AD  - Department of Neurology, St Antonius Hospital, Nieuwegein, Netherlands.
FAU - Vos, Jan Albert
AU  - Vos JA
AD  - Department of Radiology, St Antonius Hospital, Nieuwegein, Netherlands.
FAU - Tuladhar, Anil Man
AU  - Tuladhar AM
AD  - Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, 
      Radboud University Medical Center, Nijmegen, Netherlands.
FAU - de Laat, Karlijn F
AU  - de Laat KF
AD  - Department of Neurology, HagaZiekenhuis, The Hague, Netherlands.
FAU - van Hasselt, Boudewijn
AU  - van Hasselt B
AD  - Department of Radiology, Isala, Zwolle, Netherlands.
FAU - Remmers, Michel
AU  - Remmers M
AD  - Department of Neurology, Amphia Hospital, Breda, Netherlands.
FAU - Vos, Douwe
AU  - Vos D
AD  - Department of Radiology, Amphia Hospital, Breda, Netherlands.
FAU - Rozeman, Anouk
AU  - Rozeman A
AD  - Department of Neurology, Albert Schweitzer Hospital, Dordrecht, Netherlands.
FAU - Elgersma, Otto
AU  - Elgersma O
AD  - Department of Radiology, Albert Schweitzer Hospital, Dordrecht, Netherlands.
FAU - Uyttenboogaart, Maarten
AU  - Uyttenboogaart M
AD  - Department of Neurology, University Medical Center Groningen, Groningen, 
      Netherlands; Department of Radiology, Medical Imaging Center, University Medical 
      Center Groningen, Groningen, Netherlands.
FAU - Bokkers, Reinoud P H
AU  - Bokkers RPH
AD  - Department of Radiology, Medical Imaging Center, University Medical Center 
      Groningen, Groningen, Netherlands.
FAU - van Tuijl, Julia
AU  - van Tuijl J
AD  - Department of Neurology, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands.
FAU - Boukrab, Issam
AU  - Boukrab I
AD  - Department of Radiology, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands.
FAU - van den Berg, René
AU  - van den Berg R
AD  - Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, 
      location AMC, Amsterdam, Netherlands.
FAU - Beenen, Ludo F M
AU  - Beenen LFM
AD  - Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, 
      location AMC, Amsterdam, Netherlands.
FAU - Roosendaal, Stefan D
AU  - Roosendaal SD
AD  - Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, 
      location AMC, Amsterdam, Netherlands.
FAU - Postma, Alida Annechien
AU  - Postma AA
AD  - Department of Radiology and Nuclear Medicine, Maastricht University Medical 
      Centre, Cardiovascular Research Institute Maastricht, Maastricht, Netherlands.
FAU - Krietemeijer, Menno
AU  - Krietemeijer M
AD  - Department of Radiology, Catharina Hospital, Eindhoven, Netherlands.
FAU - Lycklama, Geert
AU  - Lycklama G
AD  - Department of Radiology, Haaglanden Medical Centre, The Hague, Netherlands.
FAU - Meijer, Frederick J A
AU  - Meijer FJA
AD  - Department of Medical Imaging, Donders Institute for Brain, Cognition and 
      Behaviour, Radboud University Medical Center, Nijmegen, Netherlands.
FAU - Hammer, Sebastiaan
AU  - Hammer S
AD  - Department of Radiology, HagaZiekenhuis, The Hague, Netherlands.
FAU - van der Hoorn, Anouk
AU  - van der Hoorn A
AD  - Department of Radiology, Medical Imaging Center, University Medical Center 
      Groningen, Groningen, Netherlands.
FAU - Yoo, Albert J
AU  - Yoo AJ
AD  - Texas Stroke Institute, Dallas-Fort Worth, TX, USA.
FAU - Gerrits, Dick
AU  - Gerrits D
AD  - Medisch Spectrum Twente, Enschede, Netherlands.
FAU - Truijman, Martine T B
AU  - Truijman MTB
AD  - Department of Neurology, Erasmus MC University Medical Center, Rotterdam, 
      Netherlands.
FAU - Zinkstok, Sanne
AU  - Zinkstok S
AD  - Tergooi, Hilversum, Netherlands.
FAU - Koudstaal, Peter J
AU  - Koudstaal PJ
AD  - Department of Neurology, Erasmus MC University Medical Center, Rotterdam, 
      Netherlands.
FAU - Manschot, Sanne
AU  - Manschot S
AD  - Department of Neurology, Haaglanden Medical Centre, The Hague, Netherlands.
FAU - Kerkhoff, Henk
AU  - Kerkhoff H
AD  - Department of Neurology, Albert Schweitzer Hospital, Dordrecht, Netherlands.
FAU - Nieboer, Daan
AU  - Nieboer D
AD  - Department of Public Health, Erasmus MC University Medical Center, Rotterdam, 
      Netherlands.
FAU - Berkhemer, Olvert
AU  - Berkhemer O
AD  - Department of Neurology, Erasmus MC University Medical Center, Rotterdam, 
      Netherlands; Department of Radiology and Nuclear Medicine, Erasmus MC University 
      Medical Center, Rotterdam, Netherlands; Department of Radiology & Nuclear 
      Medicine, Amsterdam University Medical Centers, location AMC, Amsterdam, 
      Netherlands.
FAU - Wolff, Lennard
AU  - Wolff L
AD  - Department of Radiology and Nuclear Medicine, Erasmus MC University Medical 
      Center, Rotterdam, Netherlands.
FAU - van der Sluijs, P Matthijs
AU  - van der Sluijs PM
AD  - Department of Radiology and Nuclear Medicine, Erasmus MC University Medical 
      Center, Rotterdam, Netherlands.
FAU - van Voorst, Henk
AU  - van Voorst H
AD  - Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, 
      location AMC, Amsterdam, Netherlands; Department of Biomedical Engineering and 
      Physics, Amsterdam University Medical Centers, location AMC, Amsterdam, 
      Netherlands.
FAU - Tolhuisen, Manon
AU  - Tolhuisen M
AD  - Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, 
      location AMC, Amsterdam, Netherlands; Department of Biomedical Engineering and 
      Physics, Amsterdam University Medical Centers, location AMC, Amsterdam, 
      Netherlands.
FAU - Roos, Yvo B W E M
AU  - Roos YBWEM
AD  - Department of Neurology, Amsterdam University Medical Centers, location AMC, 
      Amsterdam, Netherlands.
FAU - Majoie, Charles B L M
AU  - Majoie CBLM
AD  - Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, 
      location AMC, Amsterdam, Netherlands.
FAU - Staals, Julie
AU  - Staals J
AD  - Department of Neurology, Maastricht University Medical Centre, Cardiovascular 
      Research Institute Maastricht, Maastricht, Netherlands.
FAU - van Oostenbrugge, Robert J
AU  - van Oostenbrugge RJ
AD  - Department of Neurology, Maastricht University Medical Centre, Cardiovascular 
      Research Institute Maastricht, Maastricht, Netherlands.
FAU - Jenniskens, Sjoerd F M
AU  - Jenniskens SFM
AD  - Department of Medical Imaging, Donders Institute for Brain, Cognition and 
      Behaviour, Radboud University Medical Center, Nijmegen, Netherlands.
FAU - van Dijk, Lukas C
AU  - van Dijk LC
AD  - Department of Radiology, HagaZiekenhuis, The Hague, Netherlands.
FAU - den Hertog, Heleen M
AU  - den Hertog HM
AD  - Department of Neurology, Isala, Zwolle, Netherlands.
FAU - van Es, Adriaan C G M
AU  - van Es ACGM
AD  - Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.
FAU - van der Lugt, Aad
AU  - van der Lugt A
AD  - Department of Radiology and Nuclear Medicine, Erasmus MC University Medical 
      Center, Rotterdam, Netherlands.
FAU - Dippel, Diederik W J
AU  - Dippel DWJ
AD  - Department of Neurology, Erasmus MC University Medical Center, Rotterdam, 
      Netherlands.
FAU - Roozenbeek, Bob
AU  - Roozenbeek B
AD  - Department of Neurology, Erasmus MC University Medical Center, Rotterdam, 
      Netherlands; Department of Radiology and Nuclear Medicine, Erasmus MC University 
      Medical Center, Rotterdam, Netherlands.
CN  - MR CLEAN-MED investigators
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20220228
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2022 Mar 12;399(10329):1025-1026. PMID: 35240045
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - *Brain Ischemia/therapy
MH  - Heparin/adverse effects
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - *Stroke/etiology
MH  - Treatment Outcome
COIS- Declaration of interests BR and DWJD report financial support for the current 
      manuscript from the CONTRAST consortium, all paid to their institution. AvdL, BR, 
      HBvdW, CBLMM, DWJD, and MU report funding from the Dutch Heart Foundation, all 
      paid to their institution. AvdL and DWJD report funding from the Dutch Brain 
      foundation paid to their institution. AvdL, BJE, DWJD, and MU report funding from 
      Health Holland Top Sector Life Sciences & Health, all paid to their institution. 
      AvdH, BJE, BR, DWJD, JAV, JMC, and RvdB report grants from the Netherlands 
      Organisation for Health Research and Development, all paid to their institution. 
      AvdL, AJY, HBvdW, CBLMM, and DWJD report funding from Stryker, all paid to their 
      institution. AvdL, AJY, DWJD, and RPHB report funding from Cerenovus, all paid to 
      their institution. AvdL, AJY, DWJD, and JMC report funding from Medtronic, all 
      paid to their institution. AvdL, AJY, and DWJD report funding from Penumbra, all 
      paid to their institution. AvdL and DWJD report funding from Thrombolytic Science 
      paid to their institution. AJY, CBLMM and YBWEMR are minor shareholders of 
      Nicolab. AJY reports funding from Genentech paid to his institution; consulting 
      fees from Penumbra, Cerenovus, Philips, and Vesalio paid to himself; participates 
      in an advisory board of Philips, Nicolab, XCath, and HCA; is part of the 
      endovascular safety monitor of the NIH MOST trial; is an associate editor of the 
      Stroke: Vascular and Interventional Neurology journal; and is a stock owner of 
      Insera. AAP reports institutional grants from Siemens Healthineers and Bayer 
      Healthcare. FJAM reports reimbursements for lectures for Speaker Bureau and Canon 
      Medical Systems. AMT reports being a junior staff member of the Dutch Heart 
      Foundation. BJE reports being a delegate of the Netherlands in the European Union 
      of Medical Specialists Neuroradiology. HBvdW reports grants from the European 
      Union, and participation in an advisory board of Bayer Healthcare and LivaNova, 
      all paid to their institution. CBLMM received funds from the European Commission, 
      TWIN foundation, and Health Evaluation Netherlands, all paid to their 
      institution. JMC reports funding from the Dutch Thrombosis Society and the Dr CJ 
      Vaillant Foundation; consulting fees from Bayer Healthcare, Boehringer, and 
      Portola, all paid to their institution; a fellowship from the European Stroke 
      Organisation; and is a member of the writing committee of the European Stroke 
      Organisation guideline on cerebral venous thrombosis, both unpaid. WvZ reports 
      consulting and speaker fees from Philips, Stryker, Cerenovus, and NicoLab, all 
      paid to their institution; and participation in advisory boards of WeTrust 
      (Philips), Solonda (Anaconda), and InExtremis (CHU Montpellier). All other 
      authors declare no competing interests.
EDAT- 2022/03/04 06:00
MHDA- 2022/04/07 06:00
CRDT- 2022/03/03 20:12
PHST- 2021/12/09 00:00 [received]
PHST- 2021/12/27 00:00 [revised]
PHST- 2022/01/04 00:00 [accepted]
PHST- 2022/03/04 06:00 [pubmed]
PHST- 2022/04/07 06:00 [medline]
PHST- 2022/03/03 20:12 [entrez]
AID - S0140-6736(22)00014-9 [pii]
AID - 10.1016/S0140-6736(22)00014-9 [doi]
PST - ppublish
SO  - Lancet. 2022 Mar 12;399(10329):1059-1069. doi: 10.1016/S0140-6736(22)00014-9. 
      Epub 2022 Feb 28.

PMID- 34622875
OWN - NLM
STAT- MEDLINE
DCOM- 20211019
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 40
DP  - 2021 Oct 8
TI  - Management of chronic rhinosinusitis with nasal polyps in Samter triad by 
      low-dose ASA desensitization or dupilumab.
PG  - e27471
LID - 10.1097/MD.0000000000027471 [doi]
LID - e27471
AB  - Samter triad is a chronic condition where patients suffer from intolerance to 
      aspirin, recurring nasal polyposis and bronchial asthma. Causative treatment is 
      often hard. Potential approaches are the daily intake of acetylsalicylic acid 
      (ASA), shunting arachidonic acid into the lipoxygenase pathway, and a subsequent 
      habituation to this constant inflammatory stimulus. Alternatively, the paramount 
      interleukins 4 and 13 may be antagonized by the monoclonal antibody dupilumab. 
      Hence, we evaluated the daily intake of 100 mg ASA and systemic dupilumab 
      (300 mg s.c. every 2 weeks) therapy in refractory patients for its efficacy and 
      compliance.We conducted a retrospective chart review for the efficacy and 
      compliance of both continuous ASA desensitization and systemic dupilumab therapy 
      for refractory patients.Thirty-one patients were included in this retrospective 
      chart review, mean follow-up was 20.4 ± 15.7 months. All patients underwent ASA 
      desensitization. Twenty-one patients had eventually discontinued therapy after 
      5.8 ± 4.5 months; 11 for its side effects, 12 for its inefficacy. Twenty patients 
      developed sinunasal complaints soon thereafter. Ten patients were still 
      undergoing desensitization (mean duration 15.3 ± 15.7 months). These patients had 
      a higher prevalence of concomitant anti-asthmatic medication. Seventeen 
      refractory patients underwent systemic dupilumab therapy. After 6.4 ± 2.7 months 
      of treatment, sinunasal outcome test (68.1 ± 13.9 vs 20.1 ± 13.9) and visual 
      analogue scales of overall complaints (8.7 ± 0.9 vs 2.2 ± 1.5) as well as 
      endoscopic findings and olfactory function (brief smell identification test; 
      3.5 ± 2.6 vs 8.6 ± 2.4) all improved significantly.A considerable number of 
      patients with Samter triad discontinued ASA desensitization, equally for 
      ineffectiveness or side effects. If desensitization is to be effective, special 
      care needs to be taken in respect to concomitant anti-asthmatic medication. 
      Dupilumab is highly effective and safe in treating refractory patients.
CI  - Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Bertlich, Mattis
AU  - Bertlich M
AUID- ORCID: 0000-0002-6479-5899
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, 
      Ludwig-Maximilians University of Munich, Marchioninistr. 15, Munich, Federal 
      Republic of Germany.
AD  - Department of Dermatology, University Hospital, Ludwig-Maximilians University of 
      Munich, Thalkirchner Str. 48, Munich, Federal Republic of Germany.
FAU - Ihler, Friedrich
AU  - Ihler F
AUID- ORCID: 0000-0001-7066-4994
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, 
      Ludwig-Maximilians University of Munich, Marchioninistr. 15, Munich, Federal 
      Republic of Germany.
FAU - Bertlich, Ines
AU  - Bertlich I
AUID- ORCID: 0000-0003-2905-3846
AD  - Department of Dermatology, University Hospital, Ruprecht-Karls University of 
      Heidelberg, Im Neuenheimer Feld 440, Heidelberg, Federal Republic of Germany.
FAU - Weiss, Bernhard G
AU  - Weiss BG
AUID- ORCID: 0000-0002-8368-0149
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, 
      Ludwig-Maximilians University of Munich, Marchioninistr. 15, Munich, Federal 
      Republic of Germany.
FAU - Gröger, Moritz
AU  - Gröger M
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, 
      Ludwig-Maximilians University of Munich, Marchioninistr. 15, Munich, Federal 
      Republic of Germany.
FAU - Haubner, Frank
AU  - Haubner F
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, 
      Ludwig-Maximilians University of Munich, Marchioninistr. 15, Munich, Federal 
      Republic of Germany.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 420K487FSG (dupilumab)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Desensitization, Immunologic/adverse effects/*methods
MH  - Drug Hypersensitivity/*epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/*epidemiology
MH  - Retrospective Studies
MH  - Rhinitis/epidemiology
MH  - Sex Factors
MH  - Sinusitis/epidemiology
MH  - Time Factors
MH  - Young Adult
PMC - PMC8500659
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/10/09 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/10/08 08:44
PHST- 2021/03/22 00:00 [received]
PHST- 2021/09/20 00:00 [accepted]
PHST- 2021/10/08 08:44 [entrez]
PHST- 2021/10/09 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - 00005792-202110080-00049 [pii]
AID - MD-D-21-02280 [pii]
AID - 10.1097/MD.0000000000027471 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Oct 8;100(40):e27471. doi: 
      10.1097/MD.0000000000027471.

PMID- 16210047
OWN - NLM
STAT- MEDLINE
DCOM- 20051121
LR  - 20131121
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 116
IP  - 4
DP  - 2005 Oct
TI  - Failure of tacrolimus to prevent aspirin-induced respiratory reactions in 
      patients with aspirin-exacerbated respiratory disease.
PG  - 755-60
AB  - BACKGROUND: In patients with aspirin-exacerbated respiratory disease (AERD), 
      pretreatment with asthma controller medications (leukotriene modifiers, inhaled 
      or systemic corticosteroids, and salmeterol) partially modifies the severity of 
      aspirin-induced asthmatic reactions. OBJECTIVE: A recent study showed that 
      pretreatment with tacrolimus completely prevented aspirin-induced respiratory 
      reactions and might allow silent aspirin desensitization. METHODS: Ten patients 
      with rhinosinusitis, nasal polyps, and asthma had a history of asthma attacks 
      after ingesting aspirin and nonsteroidal anti-inflammatory drugs. All underwent 
      baseline oral aspirin challenges and had typical respiratory reactions. They were 
      then randomized to receive tacrolimus (0.1 mg/kg weight; 8 patients) or placebo 
      (2 patients) in a double-blind protocol before rechallenge with aspirin using the 
      previous provoking dose of aspirin. In addition, respiratory reactions sustained 
      by 50 consecutive patients with AERD during 2004 were recorded, analyzed, and 
      compared with the tacrolimus/placebo-treated patients to determine whether there 
      were any differences. RESULTS: Tacrolimus pretreatment failed to block 
      respiratory reactions to provoking doses of aspirin in 5 of 8 patients with AERD, 
      and in the other 3 patients did not block higher doses of aspirin. The results of 
      oral aspirin challenges in the control population of 50 patients were compared 
      with either the baseline or postchallenge data from the tacrolimus-pretreated or 
      placebo-pretreated patients with AERD, and there were no significant differences. 
      CONCLUSIONS: Use of tacrolimus as add-on pretreatment to prevent reactions to 
      aspirin in patients with AERD or to achieve the goal of silent aspirin 
      desensitization could not be accomplished.
FAU - Stevenson, Donald D
AU  - Stevenson DD
AD  - Division of Allergy, Asthma and Immunology, Scripps Clinic, La Jolla, CA 92037, 
      USA. dstevemd@aol.com
FAU - Mehra, Purvi K
AU  - Mehra PK
FAU - White, Andrew A
AU  - White AA
FAU - Gupta, Sameer
AU  - Gupta S
FAU - Woessner, Katherine M
AU  - Woessner KM
FAU - Simon, Ronald A
AU  - Simon RA
LA  - eng
GR  - M01-RR00833/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20050721
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunosuppressive Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse 
      effects/immunology
MH  - Aspirin/administration & dosage/*adverse effects/immunology
MH  - Asthma/*etiology/immunology/*prevention & control
MH  - Desensitization, Immunologic
MH  - Double-Blind Method
MH  - Drug Hypersensitivity/etiology/immunology/prevention & control
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Tacrolimus/*pharmacology
EDAT- 2005/10/08 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/10/08 09:00
PHST- 2005/04/20 00:00 [received]
PHST- 2005/05/08 00:00 [revised]
PHST- 2005/05/12 00:00 [accepted]
PHST- 2005/10/08 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/10/08 09:00 [entrez]
AID - S0091-6749(05)01319-9 [pii]
AID - 10.1016/j.jaci.2005.05.020 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2005 Oct;116(4):755-60. doi: 10.1016/j.jaci.2005.05.020. 
      Epub 2005 Jul 21.

PMID- 12925457
OWN - NLM
STAT- MEDLINE
DCOM- 20030930
LR  - 20131121
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 108
IP  - 9
DP  - 2003 Sep 2
TI  - Safety of an aspirin-alone regimen after intracoronary stenting with a 
      heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic 
      Regimen of Aspirin Alone) study.
PG  - 1078-83
AB  - BACKGROUND: Stent thrombosis is an infrequent complication of intracoronary 
      stenting that often has devastating clinical consequences. This study assesses 
      the additional benefit of heparin coating with the BX VELOCITY Balloon-Expandable 
      Stent with HEPACOAT, Carmeda end-point attached heparin (HEPACOAT) in patients 
      with de novo or restenotic native coronary artery lesions treated with aspirin 
      monotherapy after optimal stenting. METHODS AND RESULTS: This was a multicenter, 
      prospective, nonrandomized, pilot study. Two hundred patients (69% men; mean age, 
      64.1+/-11.2 years) meeting the eligibility criteria were treated with the 
      HEPACOAT stent and aspirin alone after stenting. Any other antiplatelet or 
      anticoagulation therapy was not permitted. Procedural success was achieved in all 
      patients. There were 3 postprocedural non-Q-wave myocardial infarctions. The 
      primary end point of stent thrombosis at 30 days occurred in 2 of 200 patients 
      (1%): in one after blunt chest trauma and in the other in the setting of 
      essential thrombocytosis. Major adverse cardiac events (death, myocardial 
      infarction, target lesion revascularization, and coronary artery bypass grafting) 
      were observed at 30 days in 5 of 200 (2.5%) patients. CONCLUSIONS: The BX 
      VELOCITY stent with HEPACOAT and aspirin alone after the procedure was safe in 
      select patients with de novo or restenotic lesions in native coronary arteries. 
      Heparin coating provides additional protection against stent thrombosis.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, 
      New York, NY 10021, USA. rmehran@crf.org
FAU - Aymong, Eve D
AU  - Aymong ED
FAU - Ashby, Dale T
AU  - Ashby DT
FAU - Fischell, Tim
AU  - Fischell T
FAU - Whitworth, Hall Jr
AU  - Whitworth H Jr
FAU - Siegel, Robert
AU  - Siegel R
FAU - Thomas, William
AU  - Thomas W
FAU - Wong, S Chiu
AU  - Wong SC
FAU - Narasimaiah, Raj
AU  - Narasimaiah R
FAU - Lansky, Alexandra J
AU  - Lansky AJ
FAU - Leon, Martin B
AU  - Leon MB
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20030818
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Combined Modality Therapy
MH  - Coronary Angiography
MH  - Coronary Stenosis/diagnosis/drug therapy/*therapy
MH  - Coronary Thrombosis/*prevention & control
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - *Stents/adverse effects
EDAT- 2003/08/20 05:00
MHDA- 2003/10/01 05:00
CRDT- 2003/08/20 05:00
PHST- 2003/08/20 05:00 [pubmed]
PHST- 2003/10/01 05:00 [medline]
PHST- 2003/08/20 05:00 [entrez]
AID - 01.CIR.0000086347.31341.F9 [pii]
AID - 10.1161/01.CIR.0000086347.31341.F9 [doi]
PST - ppublish
SO  - Circulation. 2003 Sep 2;108(9):1078-83. doi: 10.1161/01.CIR.0000086347.31341.F9. 
      Epub 2003 Aug 18.

PMID- 8394644
OWN - NLM
STAT- MEDLINE
DCOM- 19930913
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 72
IP  - 5
DP  - 1993 Aug 15
TI  - Comparison of efficacy of low molecular weight heparin (parnaparin) with that of 
      unfractionated heparin in the presence of activated platelets in healthy 
      subjects.
PG  - 450-4
AB  - Arterial thrombosis is typically platelet-rich. In this study, it is shown that 
      heparin levels resulting in the usual activated partial thromboplastin time 
      therapeutic range provide only a small anticoagulant effect in the presence of 
      activated platelets. Thrombin inhibition is also negligible when heparin is added 
      to platelet-rich plasma. Aspirin improves the anticoagulant effect of heparin in 
      these circumstances, but the degree of anticoagulation is still considerably 
      lower than that observed in platelet-poor plasma. A low molecular weight heparin 
      (parnaparin) is more active in the presence of activated platelets (such as may 
      occur in acute coronary syndromes) regardless of whether aspirin is used 
      concomitantly.
FAU - Melandri, G
AU  - Melandri G
AD  - Institute of Cardiology, University of Bologna, Italy.
FAU - Semprini, F
AU  - Semprini F
FAU - Cervi, V
AU  - Cervi V
FAU - Candiotti, N
AU  - Candiotti N
FAU - Branzi, A
AU  - Branzi A
FAU - Palazzini, E
AU  - Palazzini E
FAU - Magnani, B
AU  - Magnani B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.5 (Thrombin)
RN  - M316WT19D8 (parnaparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Heparin/*pharmacology
MH  - Heparin, Low-Molecular-Weight/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Partial Thromboplastin Time
MH  - Platelet Activation/*drug effects
MH  - Reference Values
MH  - Thrombin/drug effects
EDAT- 1993/08/15 00:00
MHDA- 1993/08/15 00:01
CRDT- 1993/08/15 00:00
PHST- 1993/08/15 00:00 [pubmed]
PHST- 1993/08/15 00:01 [medline]
PHST- 1993/08/15 00:00 [entrez]
AID - 0002-9149(93)91139-9 [pii]
AID - 10.1016/0002-9149(93)91139-9 [doi]
PST - ppublish
SO  - Am J Cardiol. 1993 Aug 15;72(5):450-4. doi: 10.1016/0002-9149(93)91139-9.

PMID- 31137688
OWN - NLM
STAT- MEDLINE
DCOM- 20191121
LR  - 20200225
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 24
IP  - 10
DP  - 2019 May 24
TI  - Investigation of Direct Model Transferability Using Miniature Near-Infrared 
      Spectrometers.
LID - 10.3390/molecules24101997 [doi]
LID - 1997
AB  - Recent developments in compact near infrared (NIR) instruments, including both 
      handheld and process instruments, have enabled easy and affordable deployment of 
      multiple instruments for various field and online or inline applications. 
      However, historically, instrument-to-instrument variations could prohibit success 
      when applying calibration models developed on one instrument to additional 
      instruments. Despite the usefulness of calibration transfer techniques, they are 
      difficult to apply when a large number of instruments and/or a large number of 
      classes are involved. Direct model transferability was investigated in this study 
      using miniature near-infrared (MicroNIR™) spectrometers for both classification 
      and quantification problems. For polymer classification, high cross-unit 
      prediction success rates were achieved with both conventional chemometric 
      algorithms and machine learning algorithms. For active pharmaceutical ingredient 
      quantification, low cross-unit prediction errors were achieved with the most 
      commonly used partial least squares (PLS) regression method. This direct model 
      transferability is enabled by the robust design of the MicroNIR™ hardware and 
      will make deployment of multiple spectrometers for various applications more 
      manageable.
FAU - Sun, Lan
AU  - Sun L
AD  - Viavi Solutions Inc., 1402 Mariner Way, Santa Rosa, CA 95407, USA. 
      Lan.Sun@viavisolutions.com.
FAU - Hsiung, Chang
AU  - Hsiung C
AD  - Viavi Solutions Inc., 1402 Mariner Way, Santa Rosa, CA 95407, USA. 
      Chang.Hsiung@viavisolutions.com.
FAU - Smith, Valton
AU  - Smith V
AD  - Viavi Solutions Inc., 1402 Mariner Way, Santa Rosa, CA 95407, USA. 
      Valton.Smith@viavisolutions.com.
LA  - eng
PT  - Journal Article
DEP - 20190524
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Polymers)
RN  - 3G6A5W338E (Caffeine)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/chemistry
MH  - Aspirin/chemistry
MH  - Caffeine/chemistry
MH  - Calibration
MH  - *Models, Molecular
MH  - Pharmaceutical Preparations/analysis
MH  - Polymers/chemistry
MH  - Spectroscopy, Near-Infrared/*methods
PMC - PMC6571657
OTO - NOTNLM
OT  - MicroNIR™
OT  - NIR
OT  - PLS
OT  - PLS-DA
OT  - SIMCA
OT  - SVM
OT  - TreeBagger
OT  - calibration transfer
OT  - direct model transferability
OT  - hier-SVM
COIS- The authors declare no conflicts of interest.
EDAT- 2019/05/30 06:00
MHDA- 2019/11/22 06:00
CRDT- 2019/05/30 06:00
PHST- 2019/04/17 00:00 [received]
PHST- 2019/05/15 00:00 [revised]
PHST- 2019/05/23 00:00 [accepted]
PHST- 2019/05/30 06:00 [entrez]
PHST- 2019/05/30 06:00 [pubmed]
PHST- 2019/11/22 06:00 [medline]
AID - molecules24101997 [pii]
AID - molecules-24-01997 [pii]
AID - 10.3390/molecules24101997 [doi]
PST - epublish
SO  - Molecules. 2019 May 24;24(10):1997. doi: 10.3390/molecules24101997.

PMID- 23729469
OWN - NLM
STAT- MEDLINE
DCOM- 20130906
LR  - 20211021
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Print)
IS  - 0305-1048 (Linking)
VI  - 41
IP  - Web Server issue
DP  - 2013 Jul
TI  - PELE web server: atomistic study of biomolecular systems at your fingertips.
PG  - W322-8
LID - 10.1093/nar/gkt454 [doi]
AB  - PELE, Protein Energy Landscape Exploration, our novel technology based on protein 
      structure prediction algorithms and a Monte Carlo sampling, is capable of 
      modelling the all-atom protein-ligand dynamical interactions in an efficient and 
      fast manner, with two orders of magnitude reduced computational cost when 
      compared with traditional molecular dynamics techniques. PELE's heuristic 
      approach generates trial moves based on protein and ligand perturbations followed 
      by side chain sampling and global/local minimization. The collection of accepted 
      steps forms a stochastic trajectory. Furthermore, several processors may be run 
      in parallel towards a collective goal or defining several independent 
      trajectories; the whole procedure has been parallelized using the Message Passing 
      Interface. Here, we introduce the PELE web server, designed to make the whole 
      process of running simulations easier and more practical by minimizing input file 
      demand, providing user-friendly interface and producing abstract outputs (e.g. 
      interactive graphs and tables). The web server has been implemented in C++ using 
      Wt (http://www.webtoolkit.eu) and MySQL (http://www.mysql.com). The PELE web 
      server, accessible at http://pele.bsc.es, is free and open to all users with no 
      login requirement.
FAU - Madadkar-Sobhani, Armin
AU  - Madadkar-Sobhani A
AD  - Joint BSC-IRB Research Program in Computational Biology, Barcelona Supercomputing 
      Center, Barcelona, Spain. armin.madadkar@bsc.es
FAU - Guallar, Victor
AU  - Guallar V
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - England
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
RN  - 0 (Ligands)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - EC 3.1.1.4 (Phospholipases A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Aspirin/chemistry
MH  - Internet
MH  - Ligands
MH  - Models, Molecular
MH  - Monte Carlo Method
MH  - Phospholipases A2/chemistry
MH  - *Protein Conformation
MH  - Receptors, Cytoplasmic and Nuclear/chemistry
MH  - *Software
PMC - PMC3692087
EDAT- 2013/06/05 06:00
MHDA- 2013/09/07 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/06/05 06:00 [entrez]
PHST- 2013/06/05 06:00 [pubmed]
PHST- 2013/09/07 06:00 [medline]
AID - gkt454 [pii]
AID - 10.1093/nar/gkt454 [doi]
PST - ppublish
SO  - Nucleic Acids Res. 2013 Jul;41(Web Server issue):W322-8. doi: 10.1093/nar/gkt454. 
      Epub 2013 May 31.

PMID- 8103094
OWN - NLM
STAT- MEDLINE
DCOM- 19930930
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 45
IP  - 6
DP  - 1993 Jun
TI  - Hydrolysis and stability of acetylsalicylic acid in stearylamine-containing 
      liposomes.
PG  - 496-9
AB  - The hydrolysis and the stabilization of acetylsalicylic acid (ASA) in liposomes 
      at 30 degrees C were studied. The liposomes consisted of 
      dimyristoylphosphatidylcholine (DMPC) and stearylamine. At pH 4.0 and 8.0, the 
      pseudo-first-order rate constants (kobs) in DMPC: stearylamine (2: 1 mole ratio) 
      liposomes were approximately 60% of the values in control solutions (kB) if ASA 
      was incorporated via the organic phase. In contrast, when ASA was added via the 
      aqueous phase, kobs = kB at pH 4.0 but kobs < kB at pH 8.0 and kobs increased 
      with the fraction of stearylamine in the liposomes. However, when ASA was added 
      via the organic phase, reactions occurred which resulted in the loss of ASA as a 
      function of the time period between phase admixture and the point of film 
      hydration. A product of the reactions was determined by IR and TLC to be 
      N-stearylacetamide. Both the initial loss of ASA and the increase in stability 
      decreased as the DMPC: stearylamine mole ratio increased. A mechanism of 
      aminolysis occurring in the organic solvent and at liposome surfaces between ASA 
      and stearylamine or DMPC at pH 8.0 has been suggested. It is concluded that the 
      orientation of ASA and the ordered structural environment of the bilayers 
      minimizes the aminolytic and hydrolytic reactions.
FAU - Habib, M J
AU  - Habib MJ
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Canada.
FAU - Rogers, J A
AU  - Rogers JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Amines)
RN  - 0 (Liposomes)
RN  - 0 (Solutions)
RN  - 7V31YC746X (Chloroform)
RN  - FFV58UNY7O (stearylamine)
RN  - R16CO5Y76E (Aspirin)
RN  - U86ZGC74V5 (Dimyristoylphosphatidylcholine)
SB  - IM
MH  - Amines/*chemistry
MH  - Aspirin/*chemistry
MH  - Chemistry, Pharmaceutical
MH  - Chloroform/chemistry
MH  - Dimyristoylphosphatidylcholine/chemistry
MH  - Drug Stability
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - Kinetics
MH  - Liposomes
MH  - Solutions
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1993.tb05586.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1993 Jun;45(6):496-9. doi: 10.1111/j.2042-7158.1993.tb05586.x.

PMID- 1513188
OWN - NLM
STAT- MEDLINE
DCOM- 19920930
LR  - 20141120
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 14
IP  - 5
DP  - 1992 Jun
TI  - Influence of buffered and unbuffered acetylsalicylic acid on dental enamel and 
      dentine in human teeth: an in vitro pilot study.
PG  - 339-46
AB  - An in vitro study was conducted to investigate the erosive effect of buffered and 
      unbuffered acetylsalicylic acid (ASA) on dental enamel and dentine in human teeth 
      by scanning electron microscopy. In order to standardize the specimens and to 
      improve comparability the dental enamel and dentine were superficially abraded. 
      The enamel and dentine specimens were therefore particularly sensitive to the 
      influences of acid agents. Concentrated solution of buffered chewable ASA tablets 
      (500 mg ASA and 300 mg calcium carbonate in 5 ml water) showed no changes in the 
      enamel surface structure after exposure times of 1 min, 5 min and 60 min. In 
      contrast, minimal corrosive effects were already seen after exposure of the 
      enamel surface to the unbuffered ASA solutions for 1 min. After exposure times of 
      5 min and 60 min erosion of the enamel was more pronounced. Immersion in the 
      unbuffered ASA solution led to clearly visible micromorphological changes on the 
      dentine surfaces even after exposure for 1 min. Exposure of the dentine specimens 
      to the buffered ASA solutions led to only very slight changes in the surface 
      morphology. Therefore, the scanning electron micrograph after exposure to 
      buffered ASA is comparable to the picture of untreated dentine.
FAU - Rogalla, K
AU  - Rogalla K
AD  - Pharmaforschungszentrum, Bayer AG, Wuppertal, Germany.
FAU - Finger, W
AU  - Finger W
FAU - Hannig, M
AU  - Hannig M
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - 0 (Buffers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Buffers
MH  - Dental Enamel/*drug effects/ultrastructure
MH  - Dentin/*drug effects
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - In Vitro Techniques
MH  - Microscopy, Electron, Scanning
EDAT- 1992/06/01 00:00
MHDA- 1992/06/01 00:01
CRDT- 1992/06/01 00:00
PHST- 1992/06/01 00:00 [pubmed]
PHST- 1992/06/01 00:01 [medline]
PHST- 1992/06/01 00:00 [entrez]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 1992 Jun;14(5):339-46.

PMID- 12000397
OWN - NLM
STAT- MEDLINE
DCOM- 20020628
LR  - 20190704
IS  - 0007-0963 (Print)
IS  - 0007-0963 (Linking)
VI  - 146
IP  - 5
DP  - 2002 May
TI  - Malignant atrophic papulosis in an infant.
PG  - 916-8
AB  - We report a 7-month-old girl with malignant atrophic papulosis (Degos' disease). 
      She also showed spontaneous aggregation of platelets. A good clinical response 
      was obtained by treatment with aspirin and dipyridamole.
FAU - Torrelo, A
AU  - Torrelo A
AD  - Department of Dermatology, Hospital del Niño Jesús, Menéndez Pelayo 65, 28009 
      Madrid, Spain.
FAU - Sevilla, J
AU  - Sevilla J
FAU - Mediero, I G
AU  - Mediero IG
FAU - Candelas, D
AU  - Candelas D
FAU - Zambrano, A
AU  - Zambrano A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Infant
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Skin Diseases, Papulosquamous/blood/*diagnosis/drug therapy
EDAT- 2002/05/10 10:00
MHDA- 2002/06/29 10:01
CRDT- 2002/05/10 10:00
PHST- 2002/05/10 10:00 [pubmed]
PHST- 2002/06/29 10:01 [medline]
PHST- 2002/05/10 10:00 [entrez]
AID - 4677 [pii]
AID - 10.1046/j.1365-2133.2002.04677.x [doi]
PST - ppublish
SO  - Br J Dermatol. 2002 May;146(5):916-8. doi: 10.1046/j.1365-2133.2002.04677.x.

PMID- 3928264
OWN - NLM
STAT- MEDLINE
DCOM- 19851003
LR  - 20190908
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 9
IP  - 7
DP  - 1985
TI  - Successful treatment of biliary colic with intravenous ketoprofen or lysine 
      acetylsalicylate.
PG  - 454-60
AB  - In a double-blind trial, 60 patients with biliary colic were allocated at random 
      to receive 200 mg ketoprofen, 1.8 g lysine acetylsalicylate or placebo by 
      intravenous bolus. The patients were asked to rate their pain at intervals within 
      3 hours of injection and to indicate their overall pain experience on a visual 
      analogue scale. Both ketoprofen and lysine acetylsalicylate proved significantly 
      more effective than placebo in relieving pain, with no significant difference 
      between them. A good analgesic response, reflected by complete or almost complete 
      relief of pain within 30 minutes of injection, was recorded in 4, 17, and 16 
      patients, respectively, in the placebo, ketoprofen, and lysine acetylsalicylate 
      treatment groups. All drugs were well tolerated. It is concluded that the results 
      provide further evidence for a useful therapeutic role of prostaglandin 
      inhibitors in the treatment of biliary colic.
FAU - Magrini, M
AU  - Magrini M
FAU - Rivolta, G
AU  - Rivolta G
FAU - Movilia, P G
AU  - Movilia PG
FAU - Moretti, M P
AU  - Moretti MP
FAU - Liverta, C
AU  - Liverta C
FAU - Bruni, G
AU  - Bruni G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Analgesics)
RN  - 0 (Phenylpropionates)
RN  - 90Y4QC304K (Ketoprofen)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analgesics/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Biliary Tract Diseases/*drug therapy/etiology
MH  - Clinical Trials as Topic
MH  - Colic/*drug therapy/etiology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Ketoprofen/*therapeutic use
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pain/drug therapy
MH  - Phenylpropionates/*therapeutic use
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1185/03007998509109619 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1985;9(7):454-60. doi: 10.1185/03007998509109619.

PMID- 25521453
OWN - NLM
STAT- MEDLINE
DCOM- 20150527
LR  - 20181202
IS  - 1523-1747 (Electronic)
IS  - 0022-202X (Linking)
VI  - 135
IP  - 4
DP  - 2015 Apr
TI  - Aspirin and nonsteroidal anti-inflammatory drugs can prevent cutaneous squamous 
      cell carcinoma: a systematic review and meta-analysis.
PG  - 975-983
LID - S0022-202X(15)37185-2 [pii]
LID - 10.1038/jid.2014.531 [doi]
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDS) have received increasing attention 
      as potential chemopreventive agents of skin cancer, but evidence is inconsistent. 
      To investigate whether the use of aspirin and other NSAIDS reduces the risk of 
      squamous cell carcinoma (SCC), we conducted a systematic review on the basis of 
      published epidemiologic studies and calculated summary estimates for aspirin, 
      nonaspirin NSAIDS, and any NSAIDS use. Summary estimates from nine studies (five 
      case-control, three cohort, and one intervention) indicated significantly reduced 
      risks of SCC among users of nonaspirin NSAIDS (relative risk (RR) 0.85, 95% 
      confidence interval (CI) 0.78-0.94) and among users of any NSAIDS (RR 0.82, 95% 
      CI 0.71-0.94) compared with nonusers with the effect seen particularly in those 
      with previous actinic skin tumors. A reduced risk was also observed among aspirin 
      users, although with borderline statistical significance (RR 0.88 95% CI 
      0.75-1.03). There was significant heterogeneity between studies regarding SCC 
      risk estimates for aspirin use and any NSAIDS use. These findings suggest that 
      NSAIDS collectively have the potential to prevent the development of cutaneous 
      SCC.
FAU - Muranushi, Chiho
AU  - Muranushi C
AD  - School of Population Health, University of Queensland, Brisbane, Queensland, 
      Australia.
FAU - Olsen, Catherine M
AU  - Olsen CM
AD  - Cancer and Population Studies Group, QIMR Berghofer Medical Research Institute, 
      Brisbane, Queensland, Australia.
FAU - Pandeya, Nirmala
AU  - Pandeya N
AD  - School of Population Health, University of Queensland, Brisbane, Queensland, 
      Australia; Cancer and Population Studies Group, QIMR Berghofer Medical Research 
      Institute, Brisbane, Queensland, Australia.
FAU - Green, Adèle C
AU  - Green AC
AD  - Cancer and Population Studies Group, QIMR Berghofer Medical Research Institute, 
      Brisbane, Queensland, Australia; Institute of Inflammation and Repair, University 
      of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK. 
      Electronic address: Adele.Green@qimrberghofer.edu.au.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20141218
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Anticarcinogenic Agents/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Carcinoma, Squamous Cell/*prevention & control
MH  - Humans
MH  - Skin Neoplasms/*prevention & control
EDAT- 2014/12/19 06:00
MHDA- 2015/05/28 06:00
CRDT- 2014/12/19 06:00
PHST- 2014/07/02 00:00 [received]
PHST- 2014/09/09 00:00 [revised]
PHST- 2014/09/15 00:00 [accepted]
PHST- 2014/12/19 06:00 [entrez]
PHST- 2014/12/19 06:00 [pubmed]
PHST- 2015/05/28 06:00 [medline]
AID - S0022-202X(15)37185-2 [pii]
AID - 10.1038/jid.2014.531 [doi]
PST - ppublish
SO  - J Invest Dermatol. 2015 Apr;135(4):975-983. doi: 10.1038/jid.2014.531. Epub 2014 
      Dec 18.

PMID- 20122039
OWN - NLM
STAT- MEDLINE
DCOM- 20100303
LR  - 20211020
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Print)
IS  - 0002-8614 (Linking)
VI  - 58
IP  - 1
DP  - 2010 Jan
TI  - Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the 
      Baltimore longitudinal study of aging.
PG  - 38-43
LID - 10.1111/j.1532-5415.2009.02618.x [doi]
AB  - OBJECTIVES: To examine the relations between the use of nonaspirin, nonsteroidal 
      anti-inflammatory drugs (NSAIDs) and aspirin and age-related change in multiple 
      domains of cognitive function in community-dwelling individuals without dementia. 
      DESIGN: Longitudinal, with measures obtained on one to 18 occasions over up to 45 
      years. SETTING: General community. PARTICIPANTS: A volunteer sample of up to 
      2,300 participants from the Baltimore Longitudinal Study of Aging free of 
      diagnosed dementia. MEASUREMENTS: At each visit, reported NSAID or aspirin use 
      (yes/no) and tests of verbal and visual memory, attention, perceptuo-motor speed, 
      confrontation naming, executive function, and mental status. RESULTS: 
      Mixed-effects regression models revealed that NSAID use was associated with less 
      prospective decline on the Blessed Information-Memory-Concentration (I-M-C) Test, 
      a mental status test weighted for memory and concentration (P<.001), and Part B 
      of the Trail Making Test, a test of perceptuo-motor speed and mental flexibility 
      (P<.05). In contrast, aspirin use was related to greater prospective decline on 
      the Blessed I-M-C Test (P<.05) and the Benton Visual Retention Test, a test of 
      visual memory (P<.001). CONCLUSION: Consistent with studies of incident dementia, 
      NSAID users without dementia displayed less prospective decline in cognitive 
      function, but on only two cognitive measures. In contrast, aspirin use was 
      associated with greater prospective cognitive decline on select measures, 
      potentially reflecting its common use for vascular disease prophylaxis. Effect 
      sizes were small, calling into question clinical significance, although overall 
      public health significance may be meaningful.
FAU - Waldstein, Shari R
AU  - Waldstein SR
AD  - Department of Psychology, University of Maryland, Baltimore County, 1000 Hilltop 
      Circle, Baltimore, MD 21250, USA. waldstei@umbc.edu
FAU - Wendell, Carrington Rice
AU  - Wendell CR
FAU - Seliger, Stephen L
AU  - Seliger SL
FAU - Ferrucci, Luigi
AU  - Ferrucci L
FAU - Metter, E Jeffrey
AU  - Metter EJ
FAU - Zonderman, Alan B
AU  - Zonderman AB
LA  - eng
GR  - Z01 AG000185-18/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cognition/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Prospective Studies
MH  - Young Adult
PMC - PMC2832849
MID - NIHMS177084
COIS- Conflict of Interest: No authors report any conflicts of interest relevant to 
      this manuscript.
EDAT- 2010/02/04 06:00
MHDA- 2010/03/04 06:00
CRDT- 2010/02/04 06:00
PHST- 2010/02/04 06:00 [entrez]
PHST- 2010/02/04 06:00 [pubmed]
PHST- 2010/03/04 06:00 [medline]
AID - JGS2618 [pii]
AID - 10.1111/j.1532-5415.2009.02618.x [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2010 Jan;58(1):38-43. doi: 10.1111/j.1532-5415.2009.02618.x.

PMID- 21134339
OWN - NLM
STAT- MEDLINE
DCOM- 20110328
LR  - 20191111
IS  - 1488-2353 (Electronic)
IS  - 0147-958X (Linking)
VI  - 33
IP  - 6
DP  - 2010 Dec 1
TI  - A survey evaluating surgeons' peri-operative usage of acetyl-salicylic acid (ASA) 
      and their willingness to enroll their patients in a perioperative ASA randomized 
      controlled trial.
PG  - E375-83
AB  - PURPOSE: Major cardiovascular complications associated with noncardiac surgery 
      represent a substantial population health problem for which there are no 
      established efficacious and safe prophylactic interventions. Acetyl-salicylic 
      acid (ASA) represents a promising intervention. The objective of this study was 
      to determine surgeons' perioperative usage of ASA, and if they would enroll their 
      patients in a perioperative ASA randomized controlled trial (RCT). METHODS: 
      Cross-sectional survey of all practicing Canadian general, orthopedic, and 
      vascular surgeons. Our mailed, self-administered survey asked surgeons to 
      consider only their patients who were at risk of a major perioperative 
      cardiovascular complication. RESULTS: The response rate was 906/1854 (49%). For 
      patients taking ASA chronically, there was marked variability regarding ASA 
      continuation prior to surgery amongst the general and orthopedic surgeons, 
      whereas 76% of vascular surgeons continued ASA in 81-100% of their patients. For 
      patients not taking ASA chronically, approaches to starting ASA prior to surgery 
      were variable amongst the vascular surgeons, whereas 70% of general and 82% of 
      orthopaedic surgeons did not start ASA. For patients taking ASA chronically, 73% 
      of general surgeons, 70% of orthopaedic surgeons, and 36% of vascular surgeons 
      would allow at least 40% of their patients to participate in a perioperative RCT 
      comparing stopping versus continuing ASA. For patients not taking ASA 
      chronically, most general (76%), orthopaedic (67%), and vascular (51%) surgeons 
      would allow at least 40% of their patients to participate in a perioperative RCT 
      comparing starting ASA versus placebo. CONCLUSION: This national survey 
      demonstrates that perioperative ASA usage as reported by surgeons is variable, 
      identifying the need for, and community interest in, a large perioperative ASA 
      trial.
FAU - Hiralal, Rajesh
AU  - Hiralal R
AD  - McMaster University Health Sciences Centre, 1200 Main Street West, Hamilton, 
      Ontario, Canada. philipj@mcmaster.ca
FAU - Guyatt, Gordon
AU  - Guyatt G
FAU - Bhandari, Mohit
AU  - Bhandari M
FAU - Cook, Deborah
AU  - Cook D
FAU - Berwanger, Otavio
AU  - Berwanger O
FAU - De Beer, Justin
AU  - De Beer J
FAU - Cina, Claudio
AU  - Cina C
FAU - Buckley, Norm
AU  - Buckley N
FAU - Villar, Juan Carlos
AU  - Villar JC
FAU - Montori, Victor
AU  - Montori V
FAU - Marcaccio, Michael
AU  - Marcaccio M
FAU - Paul, James
AU  - Paul J
FAU - Whiteacre, Laura
AU  - Whiteacre L
FAU - Devereaux, P J
AU  - Devereaux PJ
LA  - eng
PT  - Journal Article
DEP - 20101201
PL  - Canada
TA  - Clin Invest Med
JT  - Clinical and investigative medicine. Medecine clinique et experimentale
JID - 7804071
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Canada
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Physicians/*psychology/*statistics & numerical data
MH  - Randomized Controlled Trials as Topic
EDAT- 2010/12/08 06:00
MHDA- 2011/03/29 06:00
CRDT- 2010/12/08 06:00
PHST- 2010/12/01 00:00 [received]
PHST- 2010/12/08 06:00 [entrez]
PHST- 2010/12/08 06:00 [pubmed]
PHST- 2011/03/29 06:00 [medline]
AID - 10.25011/cim.v33i6.14588 [doi]
PST - epublish
SO  - Clin Invest Med. 2010 Dec 1;33(6):E375-83. doi: 10.25011/cim.v33i6.14588.

PMID- 22631032
OWN - NLM
STAT- MEDLINE
DCOM- 20121116
LR  - 20191112
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 12
IP  - 4
DP  - 2012 Aug 1
TI  - Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without 
      esomeprazole 20 mg in healthy volunteers.
PG  - 217-24
AB  - BACKGROUND: The absence of a pharmacokinetic interaction between the proton pump 
      inhibitor esomeprazole (40 mg) and acetylsalicylic acid (aspirin, ASA; 325 mg) 
      has previously been established. OBJECTIVE: This study set out to investigate the 
      potential for pharmacodynamic interaction between low-dose ASA and esomeprazole 
      in healthy volunteers, by measuring ASA antiplatelet activity. STUDY DESIGN: This 
      was a single-center, open-label, two-period, randomized crossover study. 
      PARTICIPANTS: Healthy male and female volunteers aged 18-75 years were included. 
      All volunteers received ASA 81 mg once daily for 5 days prior to the study 
      (pre-screen). Subjects were eligible for inclusion if they had aspirin reactivity 
      units (ARU, as measured by the VerifyNow ASA assay) of <550 on Day 6. 
      INTERVENTION: After pre-screening and a washout period of at least 14 days, 
      eligible volunteers received ASA 81 mg with or without esomeprazole 20 mg once 
      daily for 5 days in randomized order, with a 14-day washout between treatments. 
      MAIN OUTCOME MEASURE: The main outcome measure was the antiplatelet activity of 
      ASA, as assessed by ARU ratio relative to baseline in the VerifyNow ASA assay; 
      suppression of serum thromboxane B(2) (TXB(2)) was a secondary endpoint. 
      Statistical comparisons were made using linear mixed models. RESULTS: A total of 
      29 volunteers (19 aged ≥50 years; 8 women; 21 men) were evaluable for 
      pharmacodynamic analysis (per protocol). All volunteers on both treatments 
      achieved ARU <550 at Day 6. The geometric mean ratio of Day 6 to Day 1 (baseline) 
      platelet aggregation was 0.70 (95% confidence interval [CI] 0.68, 0.72) with ASA 
      alone and 0.71 (95% CI 0.69, 0.74) with ASA + esomeprazole. The ratio of platelet 
      aggregation (ASA + esomeprazole/ASA) was 1.02 (95% CI 0.99, 1.05). ASA 
      administered alone or with esomeprazole reduced serum TXB(2) by more than 99.5%. 
      The ratio of suppression of serum TXB(2) levels (ASA + esomeprazole/ASA) was 1.06 
      (95% CI 0.88, 1.29). The combination of ASA and esomeprazole was well tolerated. 
      CONCLUSION: No pharmacodynamic interaction between low-dose ASA and esomeprazole 
      was found with regard to platelet function. TRIAL REGISTRATION: Registered at 
      ClinicalTrials. gov as NCT01199328.
FAU - Andersson, Tommy
AU  - Andersson T
AD  - Clinical RD, AstraZeneca RD, Mölndal, Sweden. tommy.andersson@astrazeneca.com
FAU - Morrison, Dennis
AU  - Morrison D
FAU - Nagy, Péter
AU  - Nagy P
FAU - Pisupati, Jaya
AU  - Pisupati J
FAU - Schettler, Jared
AU  - Schettler J
FAU - Warner, Timothy D
AU  - Warner TD
LA  - eng
SI  - ClinicalTrials.gov/NCT01199328
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - N3PA6559FT (Esomeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*pharmacology
MH  - Cross-Over Studies
MH  - Drug Interactions
MH  - Esomeprazole/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Proton Pump Inhibitors/*pharmacology
MH  - Thromboxane B2/antagonists & inhibitors/blood
MH  - Young Adult
EDAT- 2012/05/29 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/05/29 06:00
PHST- 2012/05/29 06:00 [entrez]
PHST- 2012/05/29 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.1007/BF03261830 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2012 Aug 1;12(4):217-24. doi: 10.1007/BF03261830.

PMID- 32375621
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20200717
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 60
IP  - 3
DP  - 2020 Mar 18
TI  - [Primary prevention of chronic non-communicable diseases and acetylsalicylic 
      acid: ambiguity of opinions].
PG  - 96-101
LID - 10.18087/cardio.2020.3.n928 [doi]
AB  - Chronic noninfectious diseases (cardiovascular, bronchopulmonary, oncological 
      diseases and diabetes mellitus) are presently the most common cause of death 
      worldwide, with cardiovascular diseases (CVD) being predominant. For this reason, 
      the key goal of a physician is not only to treat but also to prevent diseases. 
      Acetylsalicylic acid (ASA) is considered one of the most effective drugs for 
      secondary prevention of CVD. However, the use of ASA for primary prevention is 
      still debated. Results of many studies of ASA are inconsistent. Some studies have 
      suggested that using ASA in patients aged 40-70 with a high 10-year risk of CVD 
      and a low risk of bleeding may reduce the incidence of CVD. Administration of ASA 
      to patients with a high or medium risk of CVD is also considered.
FAU - Larina, V N
AU  - Larina VN
AD  - Pirogov Russian National Research Medical University of the Ministry of Health of 
      the Russian Federation.
FAU - Gaydina, T A
AU  - Gaydina TA
AD  - Pirogov Russian National Research Medical University of the Ministry of Health of 
      the Russian Federation.
FAU - Mkrtychev, D S
AU  - Mkrtychev DS
AD  - Pirogov Russian National Research Medical University of the Ministry of Health of 
      the Russian Federation.
FAU - Kuznetsova, V A
AU  - Kuznetsova VA
AD  - Pirogov Russian National Research Medical University of the Ministry of Health of 
      the Russian Federation.
FAU - Snezhko, Z V
AU  - Snezhko ZV
AD  - I.M. Sechenov First Moscow State Medical University.
LA  - rus
PT  - Journal Article
DEP - 20200318
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - *Cardiovascular Diseases
MH  - Humans
MH  - Middle Aged
MH  - *Noncommunicable Diseases/prevention & control
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Primary Prevention
MH  - Secondary Prevention
EDAT- 2020/05/08 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/05/08 06:00
PHST- 2019/11/02 00:00 [received]
PHST- 2019/12/18 00:00 [accepted]
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
AID - 10.18087/cardio.2020.3.n928 [doi]
PST - epublish
SO  - Kardiologiia. 2020 Mar 18;60(3):96-101. doi: 10.18087/cardio.2020.3.n928.

PMID- 30520421
OWN - NLM
STAT- MEDLINE
DCOM- 20190103
LR  - 20190103
IS  - 1361-6528 (Electronic)
IS  - 0957-4484 (Linking)
VI  - 30
IP  - 5
DP  - 2019 Feb 1
TI  - Fabrication of step-by-step drug release system both sensitive to magnetic field 
      and temperature based on layered double hydroxides and PNIPAM.
PG  - 055103
LID - 10.1088/1361-6528/aaf095 [doi]
AB  - Fabrication of environmental sensitive and controllable drug release systems is 
      urgently needed. In this paper, thermosensitive and magnetic response drug 
      release systems were fabricated via layer-by-layer technique using 
      acetylsalicylic acid (AA) intercalated ZnAl-LDH as core, poly 
      (N-isopropylacrylamide) (PNIPAM) and AA micelles as well as small size ZnAl-LDH 
      sheets as building blocks of the shell. By forming anionic micelles, cationic 
      PNIPAM macromolecules were sandwiched in the LDH sheets with cationic charges 
      which provided a novel way of fabrication of drug release systems. The 
      characteristics of the building blocks, the fabrication process and the release 
      behaviors of the as-prepared drug release systems were characterized in detail. 
      Due to the micro-environmental difference of AA in the core and shell of the 
      systems, step-by-step release behaviors were observed. Also the drug release 
      systems showed obvious temperature and magnetic field dependent responsibility. 
      The obtained assembly is a potential drug release system.
FAU - Lv, Fengzhu
AU  - Lv F
AD  - School of Materials Science and Technology, China University of Geosciences 
      (Beijing), Beijing, People's Republic of China.
FAU - Li, Chong
AU  - Li C
FAU - Ma, Yong
AU  - Ma Y
FAU - Sun, Zhengle
AU  - Sun Z
FAU - Li, Rui
AU  - Li R
FAU - Zhao, Zidong
AU  - Zhao Z
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nanotechnology
JT  - Nanotechnology
JID - 101241272
RN  - 0 (Acrylic Resins)
RN  - 0 (Hydroxides)
RN  - 0 (Micelles)
RN  - 0 (Pharmaceutical Preparations)
RN  - 25189-55-3 (poly-N-isopropylacrylamide)
RN  - 9159UV381P (hydroxide ion)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acrylic Resins/*chemistry
MH  - Aspirin/chemistry
MH  - Drug Liberation/*drug effects
MH  - Hydroxides/*chemistry
MH  - Magnetic Fields
MH  - Micelles
MH  - Pharmaceutical Preparations/*chemistry
MH  - Temperature
EDAT- 2018/12/07 06:00
MHDA- 2019/01/04 06:00
CRDT- 2018/12/07 06:00
PHST- 2018/12/07 06:00 [entrez]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/01/04 06:00 [medline]
AID - 10.1088/1361-6528/aaf095 [doi]
PST - ppublish
SO  - Nanotechnology. 2019 Feb 1;30(5):055103. doi: 10.1088/1361-6528/aaf095.

PMID- 7531031
OWN - NLM
STAT- MEDLINE
DCOM- 19950309
LR  - 20131121
IS  - 1102-416X (Print)
IS  - 1102-416X (Linking)
IP  - 574
DP  - 1994
TI  - Dielectric spectroscopy of human blood.
PG  - 87-9
AB  - Impedance measurement is an established technique for studying the passive 
      electric properties of cell membranes. Dispersions can be detected by studying 
      the electric properties (capacitance and conductance) in the radio-frequency 
      range (kHz-mHz). The theoretical interpretation is based on the Maxwell-Wagner 
      effect at the interface between the cytoplasm and the cell membrane. The specific 
      electric variables of the membrane, the cytoplasm, as well as the surrounding 
      plasma (medium) are estimated by non-linear regression fitting and appropriate 
      equations. Using a four-electrode technique, we have measured the impedance with 
      a commercial instrument working in the frequency range of 0.2-10 mHz interfaced 
      to a computer. Differences were found in conductivity and capacitance of blood 
      from 1) persons exposed to organic solvents, 2) patients with metal exposure, and 
      3) patients with cardiovascular disease. The effects of plasma components and 
      haematocrit are crucial when undertaking measurements on whole blood. The results 
      are difficult to interpret but we consider perturbations in the erythrocyte 
      membrane to be involved. Potential clinical applications will be promoted by the 
      development of the software.
FAU - Beving, H
AU  - Beving H
AD  - Department of Experimental Surgery, Karolinska Hospital, Stockholm, Sweden.
FAU - Eriksson, G
AU  - Eriksson G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Surg Suppl
JT  - The European journal of surgery. Supplement. : = Acta chirurgica. Supplement
JID - 9114489
RN  - 0 (Metals)
RN  - 3FPU23BG52 (Toluene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Cells/drug effects/*physiology
MH  - Cell Membrane/physiology
MH  - *Electric Conductivity
MH  - Electrodes
MH  - Humans
MH  - Metals/pharmacology
MH  - Signal Processing, Computer-Assisted
MH  - Toluene/pharmacology
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Eur J Surg Suppl. 1994;(574):87-9.

PMID- 3118440
OWN - NLM
STAT- MEDLINE
DCOM- 19871217
LR  - 20180216
IS  - 0025-7931 (Print)
IS  - 0025-7931 (Linking)
VI  - 52
IP  - 2
DP  - 1987
TI  - Pulmonary haemodynamics during exercise after low and high doses of 
      acetylsalicylic acid in sheep.
PG  - 94-100
AB  - Despite comparable increases in cardiac output there is a greater reduction in 
      pulmonary vascular resistance (PVR) in sheep during exercise than in dog or man. 
      The mechanism for this marked reduction in PVR in sheep is unknown. To assess the 
      role of arachidonic acid metabolites in producing this low PVR we measured the 
      effect of intravenous acetylsalicylic acid (ASA, 10 mg/kg) on PVR at rest and 
      during exercise in sheep. ASA caused a slight rise in resting PVR (p less than 
      0.05), but did not affect the exercise-induced decrease in PVR. High-dose ASA 
      (100 mg/kg), presumably sufficient to block the lipoxygenase pathway produced the 
      same responses as low-dose ASA which should only block the cyclo-oxygenase 
      pathway. Products of the cyclo-oxygenase and lipoxygenase pathways which include 
      vasodilator prostaglandins, have only a minor role in maintaining low pulmonary 
      vascular resistance at rest and have no demonstrable role in the reduced PVR that 
      occurs during exercise in sheep.
FAU - Coates, G
AU  - Coates G
AD  - Department of Radiology (Nuclear Medicine), McMaster University, Chedoke-McMaster 
      Hospitals, Hamilton, Ont., Canada.
FAU - O'Brodovich, H
AU  - O'Brodovich H
FAU - Jefferies, A L
AU  - Jefferies AL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Respiration
JT  - Respiration; international review of thoracic diseases
JID - 0137356
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cyclooxygenase Inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hemodynamics/*drug effects
MH  - Male
MH  - *Physical Exertion
MH  - Pulmonary Circulation/*drug effects
MH  - Sheep
MH  - Vascular Resistance/drug effects
OID - NASA: 88042246
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1159/000195310 [doi]
PST - ppublish
SO  - Respiration. 1987;52(2):94-100. doi: 10.1159/000195310.

PMID- 10752830
OWN - NLM
STAT- MEDLINE
DCOM- 20000419
LR  - 20190706
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 28
IP  - 3
DP  - 2000 Mar
TI  - Diaspirin cross-linked hemoglobin improves mucosal perfusion in the ileum of 
      septic rats.
PG  - 782-7
AB  - OBJECTIVE: To determine the effect of a bolus infusion of diaspirin cross-linked 
      hemoglobin (DCLHb or hemoglobin crosfumaril) on the ileal mucosal 
      microcirculation in septic rats. DESIGN: Prospective, randomized, single-blinded 
      study. SETTING: University-affiliated animal research laboratory. SUBJECTS: 
      Twenty-four male Sprague-Dawley rats, weighing 320-380 g. INTERVENTIONS: Under 
      inhalational anesthesia, arterial and venous catheters were inserted and sepsis 
      was created by cecal ligation and perforation (CLP). Twenty-four hours later, 
      animals were reanesthetized and ventilated. Via midline abdominal incision, the 
      ileum was mobilized and prepared for intravital microscopy. Post-CLP hemodynamic 
      values were obtained, and videomicroscopy was performed on four to ten villi. 
      Animals were then randomized to receive 2 mL of DCLHb solution (100 mg/mL; n = 
      12) or pentastarch (n = 12) intravenously, and measurements were repeated after 
      20 mins. Rats treated with DCLHb then received nitroprusside to restore mean 
      arterial pressure to post-CLP levels, and final measurements were obtained 15 
      mins later. MEASUREMENTS AND MAIN RESULTS: Cardiac index increased with both 
      treatments (p < .001), whereas systemic vascular resistance index and mean 
      arterial blood pressure were augmented only with DCLHb (p < .0001 compared with 
      pentastarch). Intercapillary areas (ICA; inversely related to capillary density) 
      were determined using computerized image analysis. ICA size decreased after 
      treatment, from 974 +/- 79 to 791 +/- 106 microm2 with DCLHb and from 1044 +/- 90 
      to 840 +/- 82 microm2 with pentastarch (both p < .05). Red blood cell velocity in 
      terminal arterioles, as assessed by velocimetry from the recorded images, 
      increased by 15% with both treatments (p < .05). Restoration of mean arterial 
      pressure to post-CLP levels in DCLHb animals by nitroprusside infusion abolished 
      the effects of the hemoglobin solution on ICA size and red blood cell velocity. 
      CONCLUSION: Both DCLHb and pentastarch infusion improved microcirculatory 
      perfusion in the ileum of septic rats. In addition, DCLHb also exhibited 
      vasopressor properties, which in combination with improved perfusion may be 
      particularly useful in the treatment of sepsis.
FAU - Sielenkämper, A W
AU  - Sielenkämper AW
AD  - A.C. Burton Vascular Biology Laboratory, Victoria Hospital Research Institute, 
      The University of Western Ontario, London, Canada.
FAU - Eichelbrönner, O
AU  - Eichelbrönner O
FAU - Martin, C M
AU  - Martin CM
FAU - Madorin, S W
AU  - Madorin SW
FAU - Chin-Yee, I H
AU  - Chin-Yee IH
FAU - Sibbald, W J
AU  - Sibbald WJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Crit Care Med. 2000 Jul;28(7):2679-81. PMID: 10921632
MH  - Animals
MH  - Arterioles/drug effects
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Blood Substitutes/*pharmacology/therapeutic use
MH  - Capillaries/drug effects
MH  - Exchange Transfusion, Whole Blood/methods
MH  - Hemodynamics
MH  - Hemoglobins/*pharmacology/therapeutic use
MH  - Ileum/*blood supply/drug effects/pathology
MH  - Intestinal Mucosa/*blood supply/drug effects/pathology
MH  - Male
MH  - Microcirculation/drug effects
MH  - Prospective Studies
MH  - Random Allocation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sepsis/*drug therapy
MH  - Single-Blind Method
EDAT- 2001/02/07 11:00
MHDA- 2001/02/07 11:01
CRDT- 2001/02/07 11:00
PHST- 2001/02/07 11:00 [pubmed]
PHST- 2001/02/07 11:01 [medline]
PHST- 2001/02/07 11:00 [entrez]
AID - 10.1097/00003246-200003000-00029 [doi]
PST - ppublish
SO  - Crit Care Med. 2000 Mar;28(3):782-7. doi: 10.1097/00003246-200003000-00029.

PMID- 33541120
OWN - NLM
STAT- MEDLINE
DCOM- 20211027
LR  - 20211027
IS  - 1740-7753 (Electronic)
IS  - 1740-7745 (Linking)
VI  - 18
IP  - 4
DP  - 2021 Aug
TI  - Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial 
      Assessing Benefits and Long-Term Effectiveness) trial.
PG  - 449-456
LID - 10.1177/1740774520988838 [doi]
AB  - BACKGROUND: ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits 
      and Long-Term Effectiveness) is a pragmatic clinical trial examining high-dose 
      versus low-dose aspirin among patients with cardiovascular disease. ADAPTABLE is 
      leveraging novel approaches for clinical trial conduct to expedite study 
      completion and reduce costs. One pivotal aspect of the trial conduct is 
      maximizing clinician engagement. METHODS/RESULTS: Clinician engagement can be 
      diminished by barriers including time limitations, insufficient research 
      infrastructure, lack of research training, inadequate compensation for research 
      activities, and clinician beliefs. We used several key approaches to boost 
      clinician engagement such as empowering clinician champions, including a variety 
      of clinicians, nurses and advanced practice providers, periodic newsletters and 
      coordinated team celebrations, and deploying novel technological solutions. 
      Specifically, some centers generated electronic health records-based best 
      practice advisories and research dashboards. Future large pragmatic trials will 
      benefit from standardization of the various clinician engagement strategies 
      especially studies leveraging electronic health records-based approaches like 
      research dashboards. Financial or academic "credit" for clinician engagement in 
      clinical research may boost participation rates in clinical studies. CONCLUSION: 
      Maximizing clinician engagement is important for the success of clinical trials; 
      the strategies employed in the ADAPTABLE trial may serve as a template for future 
      pragmatic studies.
FAU - Kochar, Ajar
AU  - Kochar A
AUID- ORCID: 0000-0003-3570-2136
AD  - Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, 
      USA.
FAU - Summers, Mary B
AU  - Summers MB
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, 
      USA.
FAU - Benziger, Catherine P
AU  - Benziger CP
AD  - St Mary's Heart and Vascular Center, Essentia Health, Duluth, MN, USA.
FAU - Marquis-Gravel, Guillaume
AU  - Marquis-Gravel G
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, 
      USA.
FAU - DeWalt, Darren A
AU  - DeWalt DA
AD  - The Cecil G. Sheps Center for Health Services Research, University of North 
      Carolina, Chapel Hill, NC, USA.
FAU - Pepine, Carl J
AU  - Pepine CJ
AD  - Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, USA.
FAU - Gupta, Kamal
AU  - Gupta K
AD  - Department of Cardiovascular Medicine, University of Kansas Medical School, 
      Kansas City, KS, USA.
FAU - Bradley, Steven M
AU  - Bradley SM
AUID- ORCID: 0000-0003-4006-6760
AD  - Division of Cardiology, Minneapolis Heart Institute and Minneapolis Heart 
      Institute Foundation, Minneapolis, MN, USA.
FAU - Dodson, John A
AU  - Dodson JA
AD  - Leon H. Charney Division of Cardiology, New York University School of Medicine, 
      New York, NY, USA.
FAU - Lampert, Brent C
AU  - Lampert BC
AD  - Division of Cardiovascular Medicine, Wexner Medical Center, The Ohio State 
      University, Columbus, OH, USA.
FAU - Robertson, Holly
AU  - Robertson H
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, 
      USA.
FAU - Polonsky, Tamar S
AU  - Polonsky TS
AD  - Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA.
FAU - Jones, W Schuyler
AU  - Jones WS
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, 
      USA.
FAU - Effron, Mark B
AU  - Effron MB
AD  - John Ochsner Heart and Vascular Institute, The University of Queensland Ochsner 
      Clinical School, New Orleans, LA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210204
PL  - England
TA  - Clin Trials
JT  - Clinical trials (London, England)
JID - 101197451
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage
MH  - *Cardiovascular Diseases/drug therapy/prevention & control
MH  - Electronic Health Records
MH  - Humans
MH  - Patient-Centered Care
MH  - *Pragmatic Clinical Trials as Topic
MH  - *Research Design
MH  - Research Personnel
OTO - NOTNLM
OT  - Pragmatic clinical trials
OT  - clinician engagement
OT  - electronic health records
EDAT- 2021/02/06 06:00
MHDA- 2021/10/28 06:00
CRDT- 2021/02/05 05:37
PHST- 2021/02/06 06:00 [pubmed]
PHST- 2021/10/28 06:00 [medline]
PHST- 2021/02/05 05:37 [entrez]
AID - 10.1177/1740774520988838 [doi]
PST - ppublish
SO  - Clin Trials. 2021 Aug;18(4):449-456. doi: 10.1177/1740774520988838. Epub 2021 Feb 
      4.

PMID- 33526728
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210203
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 309
DP  - 2020 Dec
TI  - CARDIOVASCULAR EVENT ASSESSMENT IN PATIENTS WITH NONOBSTRUCTIVE CORONARY ARTERY 
      DISEASE UNDERGOING DUAL ANTIPLATELET TREATMENT.
PG  - 43-46
AB  - The aim of our study was to learn the differences in baseline presentation 
      between NObCAD and obstructive coronary artery disease (ObCAD) subjects, to 
      compare the likelihood of several clinical outcomes and the rate of primary 
      endpoints between this groups. Out study included 165 patients: 115 patients with 
      NObCAD ACS, 50 - with ObCAD ACS. Inclusion criteria: age >18 year; Presence of 
      any atherosclerotic stenosis greater than 20% but less than 50% in the left main 
      coronary artery, and greater than 20% but less than 70% in any other major 
      epicardial coronary artery. Рatients with NObCAD ACS were randomly assign in an 
      1:1 ratio in 2 group: Group A (n=55) received dual antiplatelet treatment with 
      aspirin 100-160 mg once daily and clopidogrel 75 mg once daily for three months. 
      Group B (n=60) received only aspirin 100-160 mg once daily for three months. 50 
      patients with ObCAD ACS entered in group C - controlled group, patients were 
      treated according appropriate treatment guidelines. Clinical, demographic and 
      treatment data were investigated. Demographic variables included age and gender. 
      Comorbidities included smoking, diabetes, hyperlipidemia, hypertension, obesity, 
      and prior history of heart disease (angina, heart failure, myocardial infarction, 
      coronary artery bypass grafting, and percutaneous coronary intervention), renal 
      and liver disease. ECG changes and initial laboratory data were recorded. 
      Laboratory analyses: CBC, urine test, serum lipid profile, fasting blood glucose 
      and HbA1C, creatinine and eGFR, liver enzymes were provided. All patients 
      underwent coronary angiography. Data describing patient management included use 
      of β-blockers, aspirin, ACE inhibitors or angiotensin receptor blockers, 
      lipid-lowering agents. We categorized each patient by CAD extent. To accomplish 
      this, we categorized each patient by CAD severity in a single, double, or 
      triple-vessel distribution. Follow-up evaluations were performed at one, two and 
      three months and 1 year. At these visits was assessed primary endpoints - MACE 
      (Major adverse cardiac events): 1year hospitalization for Myocardial infarction 
      or other cardiovascular causes after index angiography, cardiovascular death, 
      revascularization, survival. We studied type and frequency of bleeding during 
      treatment and follow up period. After data assessment we can tell, that the 
      combination of clopidogrel and aspirin was not significantly more effective than 
      aspirin alone in reducing the rate of myocardial infarction, but there was 
      significant difference between groups regarding the CVD event rates, 
      revascularization frequency and bleeding rate.
FAU - Sikharulidze, I
AU  - Sikharulidze I
AD  - 1M. Tsinamdzgvrishvili Centre of Cardiology, Georgia.
FAU - Chelidze, K
AU  - Chelidze K
AD  - 2The First University Clinic of Tbilisi State Medical University, Georgia.
FAU - Mamatsashvili, I
AU  - Mamatsashvili I
AD  - 2The First University Clinic of Tbilisi State Medical University, Georgia.
LA  - eng
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Clopidogrel
MH  - *Coronary Artery Disease/drug therapy
MH  - Humans
MH  - *Myocardial Infarction
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Treatment Outcome
EDAT- 2021/02/03 06:00
MHDA- 2021/02/04 06:00
CRDT- 2021/02/02 06:03
PHST- 2021/02/02 06:03 [entrez]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
PST - ppublish
SO  - Georgian Med News. 2020 Dec;(309):43-46.

PMID- 11091033
OWN - NLM
STAT- MEDLINE
DCOM- 20001227
LR  - 20190915
IS  - 0741-8329 (Print)
IS  - 0741-8329 (Linking)
VI  - 21
IP  - 3
DP  - 2000 Jul
TI  - Aspirin attenuates the anxiolytic actions of ethanol.
PG  - 287-90
AB  - The present study examined the effect of aspirin on the anxiolytic action of 
      ethanol. Previous research has shown that ethanol reliably produces an anxiolytic 
      effect on rodent's plus-maze performance while aspirin has been demonstrated to 
      attenuate several of ethanol's behavioral actions. Female Sprague-Dawley rats 
      were given s.c. aspirin doses of 0 or 150 mg/kg, followed 30 min later by s.c. 
      ethanol doses of 0, 1.0 or 1.6 g/kg. After 5 min, animals were tested in the 
      elevated plus-maze. Although aspirin did not have a significant effect on 
      anxiety-related behavior, it did attenuate the anxiolytic action of ethanol at 
      the dose of 1.0 g/kg, but not at the 1.6 g/kg dose. Thus, aspirin by itself does 
      not appear to possess anxiolytic actions, but does modify the anxiolytic actions 
      of 1.0 g/kg, but not 1.6 g/kg ethanol.
FAU - LaBuda, C J
AU  - LaBuda CJ
AD  - Department of Psychology, University of Texas at Arlington, Box 19528, 76019, 
      Arlington, TX, USA. labuda@imaginemail.com
FAU - Fuchs, P N
AU  - Fuchs PN
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Alcohol
JT  - Alcohol (Fayetteville, N.Y.)
JID - 8502311
RN  - 0 (Central Nervous System Depressants)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anxiety/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Central Nervous System Depressants/*therapeutic use
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Drug Interactions
MH  - Ethanol/*therapeutic use
MH  - Female
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2000/11/25 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/25 11:00
PHST- 2000/11/25 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/25 11:00 [entrez]
AID - S0741-8329(00)00097-5 [pii]
AID - 10.1016/s0741-8329(00)00097-5 [doi]
PST - ppublish
SO  - Alcohol. 2000 Jul;21(3):287-90. doi: 10.1016/s0741-8329(00)00097-5.

PMID- 17097413
OWN - NLM
STAT- MEDLINE
DCOM- 20070308
LR  - 20181201
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 98
IP  - 10A
DP  - 2006 Nov 20
TI  - Clopidogrel response variability, resistance, or both?
PG  - 18N-24N
AB  - Dual antiplatelet therapy represents an important advance for patients with 
      established cardiovascular disease. Variable platelet response and potential 
      resistance to therapy have emerged with aspirin and clopidogrel. There is no 
      clear and accepted definition of clopidogrel resistance, but patients with lower 
      responses to clopidogrel are at risk for ischemic events, particularly when they 
      undergo percutaneous coronary intervention. Inconsistent nomenclature about this 
      lower response has led to confusion about its potential clinical importance. The 
      concern about nomenclature is less important than answers to key questions such 
      as its mechanisms, how and in whom to measure platelet function, what levels of 
      inhibition are associated with failure of therapy, what levels are adequate for 
      improved clinical outcomes, and in what ways therapy could be altered in patients 
      with lower responses to improve measures of platelet function and clinical 
      outcomes. One option may be to target more aggressive intervention (higher 
      loading and maintenance doses of clopidogrel or alternative agents) to specific 
      patients who are at greater risk and/or least responsive to standard therapies. 
      Clinically useful risk stratification requires an easily performed and 
      reproducible measure of platelet aggregation, as well as standardized definitions 
      of response that correlate with clinical outcomes. Point-of-care assays of 
      platelet function may ultimately improve the ability of clinicians to modify 
      therapy on the basis of response.
FAU - Wiviott, Stephen D
AU  - Wiviott SD
AD  - TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and 
      Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. 
      swiviott@partners.org
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060928
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Humans
MH  - Myocardial Infarction/blood/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Platelet Function Tests
MH  - Research Design
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
RF  - 57
EDAT- 2006/11/14 09:00
MHDA- 2007/03/09 09:00
CRDT- 2006/11/14 09:00
PHST- 2006/11/14 09:00 [pubmed]
PHST- 2007/03/09 09:00 [medline]
PHST- 2006/11/14 09:00 [entrez]
AID - S0002-9149(06)01731-0 [pii]
AID - 10.1016/j.amjcard.2006.09.010 [doi]
PST - ppublish
SO  - Am J Cardiol. 2006 Nov 20;98(10A):18N-24N. doi: 10.1016/j.amjcard.2006.09.010. 
      Epub 2006 Sep 28.

PMID- 12209007
OWN - NLM
STAT- MEDLINE
DCOM- 20021028
LR  - 20181113
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 99
IP  - 19
DP  - 2002 Sep 17
TI  - Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density 
      lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, 
      and atherogenesis in hypercholesterolemic mice.
PG  - 12467-70
AB  - The effects of chronic treatment with nitric oxide-containing aspirin 
      (NO-aspirin, NCX-4016) in comparison with regular aspirin or placebo on the 
      development of a chronic disease such as atherosclerosis were investigated in 
      hypercholesterolemic low-density lipoprotein (LDL)-receptor-deficient mice. Male 
      mice were assigned randomly to receive in a volume of 10 ml/kg either placebo (n 
      = 10), 30 mg/kg/day NO-aspirin (n = 10), or 18 mg/kg/day of regular aspirin (n = 
      10). After 12 weeks of treatment, the computer-assisted imaging analysis revealed 
      that NO-aspirin reduced the aortic cumulative lesion area by 39.8 +/- 12.3% 
      compared with that of the placebo (P < 0.001). Regular aspirin did not reduce 
      significantly aortic lesions (-5.1 +/- 2.3%) compared with the placebo [P = 
      0.867, not significant (NS)]. Furthermore, NO-aspirin reduced significantly 
      plasma LDL oxidation compared with aspirin and placebo, as shown by the 
      significant reduction of malondialdehyde content (P < 0.001) as well as by the 
      prolongation of lag-time (P < 0.01). Similarly, systemic oxidative stress, 
      measured by plasma isoprostanes, was significantly reduced by treatment with 
      NCX-4016 (P < 0.05). More importantly, mice treated with NO-aspirin revealed by 
      immunohistochemical analysis of aortic serial sections a significant decrease in 
      the intimal presence of oxidation-specific epitopes of oxLDL (E06 monoclonal 
      antibody, P < 0.01), and macrophages-derived foam cells (F4/80 monoclonal 
      antibody, P < 0.05), compared with placebo or aspirin. These data indicate that 
      enhanced NO release by chronic treatment with the NO-containing aspirin has 
      antiatherosclerotic and antioxidant effects in the arterial wall of 
      hypercholesterolemic mice.
FAU - Napoli, Claudio
AU  - Napoli C
AD  - Department of Medicine, School of Medicine, Federico II University of Naples, 
      80131 Naples, Italy. cnapoli@ucsd.edu
FAU - Ackah, Eric
AU  - Ackah E
FAU - De Nigris, Filomena
AU  - De Nigris F
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - D'Armiento, Francesco P
AU  - D'Armiento FP
FAU - Crimi, Ettore
AU  - Crimi E
FAU - Condorelli, Mario
AU  - Condorelli M
FAU - Sessa, William C
AU  - Sessa WC
LA  - eng
GR  - HL57665/HL/NHLBI NIH HHS/United States
GR  - HL41371/HL/NHLBI NIH HHS/United States
GR  - HL64793/HL/NHLBI NIH HHS/United States
GR  - R01 HL064793/HL/NHLBI NIH HHS/United States
GR  - R01 HL057665/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20020903
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Receptors, LDL)
RN  - 0 (oxidized low density lipoprotein)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta, Thoracic/drug effects/metabolism/pathology
MH  - Arteriosclerosis/etiology/*prevention & control
MH  - Aspirin/administration & dosage/analogs & derivatives/*pharmacology
MH  - Foam Cells/drug effects/pathology
MH  - Hypercholesterolemia/*complications/*drug therapy
MH  - Lipoproteins, LDL/*blood/chemistry/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Nitric Oxide Donors/administration & dosage/*pharmacology
MH  - Oxidation-Reduction
MH  - Oxidative Stress/drug effects
MH  - Receptors, LDL/deficiency/genetics
PMC - PMC129468
EDAT- 2002/09/05 10:00
MHDA- 2002/10/29 04:00
CRDT- 2002/09/05 10:00
PHST- 2002/09/05 10:00 [pubmed]
PHST- 2002/10/29 04:00 [medline]
PHST- 2002/09/05 10:00 [entrez]
AID - 192244499 [pii]
AID - pq1902012467 [pii]
AID - 10.1073/pnas.192244499 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12467-70. doi: 
      10.1073/pnas.192244499. Epub 2002 Sep 3.

PMID- 2736098
OWN - NLM
STAT- MEDLINE
DCOM- 19890803
LR  - 20190824
IS  - 0886-4470 (Print)
IS  - 0886-4470 (Linking)
VI  - 115
IP  - 7
DP  - 1989 Jul
TI  - Aspirin abolishes tinnitus caused by spontaneous otoacoustic emissions. A case 
      study.
PG  - 871-5
AB  - A series of experimental tests are presented indicating that numerous spontaneous 
      otoacoustic emissions (SOAEs) are likely to provide the basis of monaural 
      tinnitus for one female patient. For this patient, (1) the tinnitus disappeared 
      only when all SOAE components were suppressed, (2) with all but one emission 
      suppressed, the frequency of an external tone said to match the pitch of the 
      tinnitus was close to the frequency of the unsuppressed SOAE, and (3) the 
      isomasking contour for the tinnitus was frequency specific. All these tests 
      indicated that the patient was likely to be hearing SOAEs. During subsequent 
      aspirin administration, her SOAEs disappeared and her perception of her tinnitus 
      was radically altered. The tinnitus was no longer described as monaural and 
      "tonal" but instead was described as being "noise in the head."
FAU - Penner, M J
AU  - Penner MJ
AD  - Department of Psychology, University of Maryland, College Park 20742.
LA  - eng
GR  - NINCDS 17170/DS/DS NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Otolaryngol Head Neck Surg
JT  - Archives of otolaryngology--head & neck surgery
JID - 8603209
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cochlea/*physiology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Perceptual Masking
MH  - Tinnitus/*drug therapy/etiology
EDAT- 1989/07/01 00:00
MHDA- 1989/07/01 00:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 1989/07/01 00:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
AID - 10.1001/archotol.1989.01860310109034 [doi]
PST - ppublish
SO  - Arch Otolaryngol Head Neck Surg. 1989 Jul;115(7):871-5. doi: 
      10.1001/archotol.1989.01860310109034.

PMID- 1777222
OWN - NLM
STAT- MEDLINE
DCOM- 19920306
LR  - 20190918
IS  - 0785-3890 (Print)
IS  - 0785-3890 (Linking)
VI  - 23
IP  - 6
DP  - 1991 Dec
TI  - Is pre-eclampsia preventable?
PG  - 671-3
AB  - Pre-eclampsia is characterised by reduced utero-placental blood flow which in 
      turn results from vascular damage occurring early in pregnancy. Endothelial 
      damage and reduced prostacyclin and nitric oxide synthesis will initiate 
      excessive platelet aggregation, fibrin deposition and vascular occlusion. 
      Prevention of pre-eclampsia is dependent on affecting this process. Antiplatelet 
      therapy is being assessed as a prophylaxis. Screening tests using increased 
      platelet turnover as their basis are also being assessed.
FAU - Elder, M G
AU  - Elder MG
AD  - Postgraduate Medical School Institute of Obstetrics and Gynaecology, Hammersmith 
      Hospital, London, U.K.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 5.3.99.5 (Thromboxane-A Synthase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/etiology/*prevention & control
MH  - Pregnancy
MH  - Thromboxane-A Synthase/*antagonists & inhibitors
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
AID - 10.3109/07853899109148101 [doi]
PST - ppublish
SO  - Ann Med. 1991 Dec;23(6):671-3. doi: 10.3109/07853899109148101.

PMID- 4036444
OWN - NLM
STAT- MEDLINE
DCOM- 19851009
LR  - 20131121
IS  - 0042-8817 (Print)
IS  - 0042-8817 (Linking)
IP  - 3
DP  - 1985 Jul-Aug
TI  - [Experimental arterial microanastomoses].
PG  - 54-60
AB  - The morphological changes in the walls of 40 arterial microanastomoses were 
      studied in experiments. The initial signs of endothelization appear in 3 days and 
      the process ends by the 9th-12th day. The tissue reaction to the different suture 
      material is of the same type and its degree is not linked with the type of 
      synthetic thread used. Minimum injury inflicted to the intima and the other coats 
      of the vascular wall and pre- and postoperative use of acetylsalicylic acid are 
      measures preventing occlusion and stenosis of the anastomosis.
FAU - Dobzhanskiĭ, N V
AU  - Dobzhanskiĭ NV
FAU - Lozhnikova, S M
AU  - Lozhnikova SM
FAU - Vysotskaia, V G
AU  - Vysotskaia VG
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Izuchenie arterial'nykh mikroanastomozov v éksperimente.
PL  - Russia (Federation)
TA  - Zh Vopr Neirokhir Im N N Burdenko
JT  - Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
JID - 7809757
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Carotid Arteries/*surgery
MH  - Chinchilla
MH  - Constriction, Pathologic
MH  - Femoral Artery/*surgery
MH  - Microsurgery
MH  - Postoperative Complications/prevention & control
MH  - Thrombosis/prevention & control
MH  - Time Factors
MH  - Wound Healing
EDAT- 1985/07/01 00:00
MHDA- 1985/07/01 00:01
CRDT- 1985/07/01 00:00
PHST- 1985/07/01 00:00 [pubmed]
PHST- 1985/07/01 00:01 [medline]
PHST- 1985/07/01 00:00 [entrez]
PST - ppublish
SO  - Zh Vopr Neirokhir Im N N Burdenko. 1985 Jul-Aug;(3):54-60.

PMID- 29747326
OWN - NLM
STAT- MEDLINE
DCOM- 20190208
LR  - 20190215
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 46
IP  - 4
DP  - 2018 Apr 24
TI  - [Current status and the consistency analysis of using two criteria for decision 
      making of aspirin use for the primary prevention of ischemic cardiovascular 
      disease in outpatients].
PG  - 298-303
LID - 10.3760/cma.j.issn.0253-3758.2018.04.009 [doi]
AB  - Objective: To compare the consistency and accuracy of using 2 criteria for 
      decision making of aspirin use for the primary prevention of ischemic 
      cardiovascular disease (ISCVD) and explore the current status and related factors 
      of aspirin use for the primary prevention of ISCVD in Chinese outpatients. 
      Methods: This cross-sectional study enrolled 3 018 outpatients with hypertension, 
      diabetes, or hypercholesterolemia, who visited the General Practice (GP) clinics 
      of Anzhen hospital in Beijing from September to December 2015 were enrolled in. 
      The information of risk factors for ISCVD and use of aspirin was collected. Both 
      quantitative and qualitative criteria were used to make the decision of aspirin 
      use for primary prevention of ISCVD in this patient cohort. Quantitative criteria 
      were derived from the 2011 Chinese guideline of cardiovascular disease 
      prevention: aspirin use for primary cardiovascular disease prevention in 
      population with risk of ISCVD in the next 10 years≥10%. Qualitative criteria were 
      derived from the Chinese expert consensus on the aspirin use issued in 2013: 
      aspirin should be given for the purpose of primary ISCVD in population with≥3 
      risk factors:(1) men aged ≥50 years or postmenopausal women; (2) hypertensive 
      subjects with blood pressure ≤150/90 mmHg(1 mmHg=0.133 kPa);(3) diabetes; (4) 
      hypocholesteremia; (5) obesity with body mass index (BMI)≥28 kg/m(2); (6) 
      Smokers;(7) with familiar premature ISCVD history (male<55 years, female<65 
      years). Demographic data of participants were obtained by questionnaire, on-site 
      measurements or screening previous medical records. Results: 67.1% participants 
      (n=2 024) should be recommended to take aspirin as primary prevention medication 
      using 10-year risk of ISCVD≥10% as the criteria, and 77.9% participants (n=2 350) 
      should be recommended to take aspirin as primary prevention medication using 
      number of risk factors≥3 as the criteria. With 10-year risk of ISCVD≥10% as the 
      gold standard and risk factors≥3 as the evaluation criteria, the sensitivity was 
      97%, specificity was 61%, the consistency rate was 85%, Kappa value was 0.628 
      (U=35.824, P<0.001) , indicating that the consistency of the 2 criteria was good. 
      The percentage of real-world aspirin use for primary prevention of ISCVD in this 
      cohort was significantly higher for participants evaluated with the 10-year risk 
      of ISCVD≥10% than that evaluated with 3 risk factors (53.1% vs. 49.2%, 
      χ(2)=6.523, P=0.011). 12.7% participants with 10-year risk of ISCVD<10% and 6.6% 
      participants with<3 risk factors took aspirin for the primary prevention of ISCVD 
      in this cohort. Age, smoking, hypertension, diabetes and hypercholesterolemia 
      were significantly related to the aspirin use in this cohort, relative ORs were 
      1.047 (95%CI 1.035-1.060) , 1.969 (95%CI 1.403-2.762) , 2.065 (95%CI 1.623-3.629) 
      , 3.493 (95%CI 2.726-4.475, and 1.344 (95%CI 1.109-1.628) , respectively. Obesity 
      and familial history of premature ISCVD were not related to the aspirin use, 
      relative ORs were 1.137 (95%CI 0.828-1.562) and 0.986 (95%CI 0.767-1.266) . 
      Conclusions: The consistency of the 2 criteria for decision making of aspirin use 
      for the primary prevention of ISCVD is good and about 50% participants who should 
      be recommended to the use of aspirin for the primary prevention of ISCVD took the 
      aspirin in the real-world scenario. The use of aspirin as primary prevention 
      strategy for ISCVD in the real-world scenario is related to age, smoking, 
      hypertension, diabetes and hypercholesterolemia.
FAU - Zuo, H J
AU  - Zuo HJ
AD  - Beijing Anzhen Hospital, Capital Medical University, Department of Community 
      Health Research, Beijing Institute of Heart Lung and Blood Vessel Diseases, 
      Beijing 100029, China.
FAU - Deng, L Q
AU  - Deng LQ
FAU - Wang, J W
AU  - Wang JW
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Cross-Sectional Studies
MH  - *Decision Making
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/prevention & control
MH  - Outpatients
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - *Primary Prevention
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular diseases
OT  - Primary prevention
EDAT- 2018/05/12 06:00
MHDA- 2019/02/09 06:00
CRDT- 2018/05/11 06:00
PHST- 2018/05/11 06:00 [entrez]
PHST- 2018/05/12 06:00 [pubmed]
PHST- 2019/02/09 06:00 [medline]
AID - 10.3760/cma.j.issn.0253-3758.2018.04.009 [doi]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2018 Apr 24;46(4):298-303. doi: 
      10.3760/cma.j.issn.0253-3758.2018.04.009.

PMID- 16608908
OWN - NLM
STAT- MEDLINE
DCOM- 20060731
LR  - 20220408
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 40
IP  - 5
DP  - 2006 May
TI  - Sex difference in the antiplatelet effect of aspirin in patients with stroke.
PG  - 812-7
AB  - BACKGROUND: There is substantial interpatient variability in response to aspirin 
      after an ischemic stroke or transient ischemic attack (TIA), as assessed by ex 
      vivo effects of aspirin on platelet aggregation. The factors contributing to this 
      variability are not well defined. OBJECTIVE: To determine whether demographic, 
      social, or clinical characteristics are associated with ex vivo response to 
      aspirin in patients with a history of stroke or TIA. METHODS: Eighty-one patients 
      who were taking aspirin for secondary stroke prevention and underwent ex vivo 
      platelet aggregation studies were identified. The medical records of eligible 
      patients were reviewed by clinicians who specialize in the management of stroke 
      patients. Characteristics were compared between 45 patients who had a complete 
      response to aspirin and 36 patients who exhibited an incomplete (partial) 
      response to aspirin based on the results of platelet aggregation testing. 
      RESULTS: The median (range) aspirin dose was similar in complete (325; 81-1950 
      mg/day) and partial (325; 81-1300 mg/day) responders. There was no association 
      between aspirin response and age, race, body mass index, medical history, smoking 
      status, or use of statin or hormone replacement therapy. However, sex was 
      significantly associated with response to aspirin, with more women in the partial 
      versus complete responder group (75% vs 49%; p = 0.02). CONCLUSIONS: Our data 
      suggest that aspirin may be less effective at inhibiting platelet aggregation in 
      women compared with men who have a history of ischemic stroke or TIA.
FAU - Cavallari, Larisa H
AU  - Cavallari LH
AD  - Department of Pharmacy Practice, College of Pharmacy, University of Illinois at 
      Chicago, Chicago, IL 60612-7230, USA. humma@uic.edu
FAU - Helgason, Cathy M
AU  - Helgason CM
FAU - Brace, Larry D
AU  - Brace LD
FAU - Viana, Marlos A G
AU  - Viana MA
FAU - Nutescu, Edith A
AU  - Nutescu EA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060411
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Sex Factors
MH  - Stroke/*prevention & control
EDAT- 2006/04/13 09:00
MHDA- 2006/08/01 09:00
CRDT- 2006/04/13 09:00
PHST- 2006/04/13 09:00 [pubmed]
PHST- 2006/08/01 09:00 [medline]
PHST- 2006/04/13 09:00 [entrez]
AID - aph.1G569 [pii]
AID - 10.1345/aph.1G569 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2006 May;40(5):812-7. doi: 10.1345/aph.1G569. Epub 2006 Apr 11.

PMID- 36571569
OWN - NLM
STAT- MEDLINE
DCOM- 20230330
LR  - 20230330
IS  - 1531-8249 (Electronic)
IS  - 0364-5134 (Linking)
VI  - 93
IP  - 4
DP  - 2023 Apr
TI  - Genotype-Guided Dual Antiplatelet Use for Transient Ischemic Attack and Minor 
      Stroke by Imaging Status: Subgroup Analysis of the CHANCE-2 Trial.
PG  - 783-792
LID - 10.1002/ana.26589 [doi]
AB  - OBJECTIVE: This study was performed to investigate whether ticagrelor/aspirin 
      versus clopidogrel/aspirin can further reduce the residual risk of stroke 
      recurrence in patients with positive diffusion-weighted imaging (DWI) in the 
      High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) 
      trial. METHODS: Patients with DWI data in the CHANCE-2 trial were included and 
      divided into those with and without acute infarction according to their DWI 
      findings. The primary efficacy outcome and safety outcome were stroke recurrence 
      and moderate to severe bleeding within 3 months of follow-up, respectively. 
      RESULTS: Of the 6,412 patients enrolled in the CHANCE-2 trial, 5,796 (90.4%) 
      patients with DWI data were included in the subgroup analysis. A total of 4,369 
      patients (75.4%) had an acute infarction on DWI. Patients with positive DWI had 
      higher risk of recurrent stroke (8.1%) than those without infarction (2.2%) 
      within 3-month follow-up. Compared with clopidogrel/aspirin, ticagrelor/aspirin 
      was associated with lower risk of stroke in patients with positive DWI (hazard 
      ratio [HR] = 0.65, 95% confidence interval [CI] = 0.52-0.80, p < 0.001) than in 
      those negative DWI (HR = 1.22, 95% CI = 0.55-2.72, p = 0.63), with a significant 
      interaction association (p for interaction = 0.049). The risk of moderate to 
      severe bleeding was similar between ticagrelor/aspirin and clopidogrel/aspirin 
      treatment in the different groups. INTERPRETATION: Our study demonstrates that 
      imaging evaluation should be emphasized before targeting the best candidates for 
      genotype-guided dual antiplatelet therapy in future clinical research and 
      practice. ANN NEUROL 2023;93:783-792.
CI  - © 2022 American Neurological Association.
FAU - Jing, Jing
AU  - Jing J
AUID- ORCID: 0000-0001-9822-5758
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Tiantan Neuroimaging Center of Excellence, Beijing, China.
FAU - Xie, Xuewei
AU  - Xie X
AUID- ORCID: 0000-0001-8154-1957
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Johnston, S Claiborne
AU  - Johnston SC
AD  - Dell Medical School, University of Texas at Austin, Austin, TX, USA.
FAU - Bath, Philip M
AU  - Bath PM
AD  - Stroke Trials Unit, Mental Health and Clinical Neuroscience, University of 
      Nottingham, Nottingham, UK.
FAU - Li, Zixiao
AU  - Li Z
AUID- ORCID: 0000-0002-4713-5418
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Zhao, Xingquan
AU  - Zhao X
AUID- ORCID: 0000-0001-8345-5147
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Liu, Liping
AU  - Liu L
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Wang, Yilong
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Xu, Qin
AU  - Xu Q
AUID- ORCID: 0000-0002-8039-709X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Wang, Anxin
AU  - Wang A
AUID- ORCID: 0000-0003-4351-2877
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Jiang, Yong
AU  - Jiang Y
AUID- ORCID: 0000-0001-7700-6054
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Li, Hao
AU  - Li H
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Meng, Xia
AU  - Meng X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
CN  - CHANCE-2 Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT04078737
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230120
PL  - United States
TA  - Ann Neurol
JT  - Annals of neurology
JID - 7707449
RN  - R16CO5Y76E (Aspirin)
RN  - A74586SNO7 (Clopidogrel)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
SB  - IM
MH  - Humans
MH  - Aspirin/therapeutic use/adverse effects
MH  - Cerebral Infarction
MH  - Clopidogrel/therapeutic use
MH  - Drug Therapy, Combination
MH  - Genotype
MH  - Hemorrhage/chemically induced
MH  - *Ischemic Attack, Transient/diagnostic imaging/drug therapy
MH  - Platelet Aggregation Inhibitors
MH  - *Stroke/diagnostic imaging/drug therapy
MH  - Ticagrelor/therapeutic use
MH  - Treatment Outcome
EDAT- 2022/12/27 06:00
MHDA- 2023/03/29 06:05
CRDT- 2022/12/26 10:22
PHST- 2022/12/22 00:00 [revised]
PHST- 2022/10/04 00:00 [received]
PHST- 2022/12/23 00:00 [accepted]
PHST- 2023/03/29 06:05 [medline]
PHST- 2022/12/27 06:00 [pubmed]
PHST- 2022/12/26 10:22 [entrez]
AID - 10.1002/ana.26589 [doi]
PST - ppublish
SO  - Ann Neurol. 2023 Apr;93(4):783-792. doi: 10.1002/ana.26589. Epub 2023 Jan 20.

PMID- 6411585
OWN - NLM
STAT- MEDLINE
DCOM- 19831021
LR  - 20190908
IS  - 8750-2836 (Print)
IS  - 8750-2836 (Linking)
VI  - 18
IP  - 9
DP  - 1983 Sep
TI  - Treatment of juvenile arthritis.
PG  - 121-4, 129, 133-6
AB  - Arthritis in children takes a number of different forms, each with a different 
      prognosis and different treatment regimen. They fall into three major categories: 
      pauciarticular disease, polyarticular disease, and systemic-onset disease. 
      Presentation and management of these and several other subtypes are discussed in 
      the context of a multidisciplinary team approach that must involve the family.
FAU - Baum, J
AU  - Baum J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hosp Pract (Off Ed)
JT  - Hospital practice (Office ed.)
JID - 8404149
RN  - 0 (Anti-Inflammatory Agents)
RN  - 57Y76R9ATQ (Naproxen)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Arthritis, Juvenile/*drug therapy/physiopathology
MH  - Aspirin/adverse effects/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Male
MH  - Naproxen/adverse effects/therapeutic use
MH  - Sex Factors
MH  - Tolmetin/adverse effects/therapeutic use
EDAT- 1983/09/01 00:00
MHDA- 1983/09/01 00:01
CRDT- 1983/09/01 00:00
PHST- 1983/09/01 00:00 [pubmed]
PHST- 1983/09/01 00:01 [medline]
PHST- 1983/09/01 00:00 [entrez]
AID - 10.1080/21548331.1983.11702633 [doi]
PST - ppublish
SO  - Hosp Pract (Off Ed). 1983 Sep;18(9):121-4, 129, 133-6. doi: 
      10.1080/21548331.1983.11702633.

PMID- 7223763
OWN - NLM
STAT- MEDLINE
DCOM- 19810625
LR  - 20131121
IS  - 0002-9335 (Print)
IS  - 0002-9335 (Linking)
VI  - 47
IP  - 3
DP  - 1981 Mar
TI  - Case study: complications associated with anticoagulant therapy.
PG  - 179-82
AB  - A 42 year old male with gram negative pneumonia complicated by deep venous 
      thrombosis was followed throughout his hospital stay and for two weeks following 
      discharge. The treatment course is divided into five treatment periods, each with 
      accompanying commentary. Drug interactions and neutralizations as well as dietary 
      factors contributed to a complicated course. Laboratory determinations were used 
      to directly evaluate therapeutic anticoagulant effects, and dosage regimens were 
      adjusted to achieve desired anticoagulant levels.
FAU - Davis, G L
AU  - Davis GL
FAU - Mutnick, A H
AU  - Mutnick AH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Med Technol
JT  - The American journal of medical technology
JID - 0370505
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Drug Interactions
MH  - Hemorrhage/chemically induced
MH  - Heparin/administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Thrombophlebitis/*drug therapy
MH  - Warfarin/administration & dosage/adverse effects
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
PST - ppublish
SO  - Am J Med Technol. 1981 Mar;47(3):179-82.

PMID- 19437334
OWN - NLM
STAT- MEDLINE
DCOM- 20090910
LR  - 20131121
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 20
IP  - 3
DP  - 2009 May
TI  - Cross validation of aspirin effect in healthy individuals by Impact-R and 
      PFA-100: a double blind randomized placebo controlled trial.
PG  - 171-6
LID - 10.1080/09537100902745117 [doi]
AB  - The main objective of this study was to compare testing for aspirin response in 
      healthy volunteers by two high shear methods in a randomized double blind placebo 
      controlled study. Seventeen healthy male individuals were randomized for aspirin 
      160 mg per day for 7-10 days, and 20 age matched controls for placebo for the 
      same period. At study entry and 7-10 days thereafter we determined high 
      shear-induced platelet adhesion to polystyrene after pre-incubation with 
      arachidonic acid using the Cone and Plate(let) analyzer (Impact-R), and the 
      closure time of collagen/epinephrine cartridges obtained by the PFA-100 
      (CEPI-CT). Platelet adhesion to polystyrene after preincubation with arachidonic 
      acid was median 3.7% (range 0.6-8.0) before study entry and median 6.7% (range 
      2.8-11.0) after 7-10 days of aspirin (p < 0.001). Changes were not significant in 
      the placebo group. By the PFA-100 CEPI-CT was median 211 s (range 130-300 s) 
      before aspirin, and 300 s in all individuals taking aspirin for 7-10 days (p < 
      0.001). Post-treatment data obtained by the Impact-R and PFA-100 were discordant 
      in seven cases from the placebo group, and in one subject on aspirin. The 
      response to aspirin varied considerably among healthy individuals, but both 
      methods were suitable to demonstrate the aspirin effect. There was, however, a 
      significant level of absent concordance between the tests. Since the trial design 
      cannot provide data on the specificity of the different tests, only clinical 
      experience can determine their usefulness.
FAU - Gouya, Ghazaleh
AU  - Gouya G
AD  - Department of Clinical Pharmacology, Vienna, Austria. 
      ghazaleh.gouya@meduniwien.ac.at
FAU - Jilma, Bernd
AU  - Jilma B
FAU - Niel, Marianne
AU  - Niel M
FAU - Eichelberger, Beate
AU  - Eichelberger B
FAU - Wolzt, Michael
AU  - Wolzt M
FAU - Panzer, Simon
AU  - Panzer S
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*pharmacology
MH  - Cell Adhesion/drug effects
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Reference Values
MH  - Young Adult
EDAT- 2009/05/14 09:00
MHDA- 2009/09/11 06:00
CRDT- 2009/05/14 09:00
PHST- 2009/05/14 09:00 [entrez]
PHST- 2009/05/14 09:00 [pubmed]
PHST- 2009/09/11 06:00 [medline]
AID - 911118137 [pii]
AID - 10.1080/09537100902745117 [doi]
PST - ppublish
SO  - Platelets. 2009 May;20(3):171-6. doi: 10.1080/09537100902745117.

PMID- 33075261
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20201222
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 173
IP  - 8
DP  - 2020 Oct 20
TI  - In ACS treated with drug-eluting stents and 3 mo of DAPT, ticagrelor monotherapy 
      reduced clinical events at 1 y vs. DAPT.
PG  - JC43
LID - 10.7326/ACPJ202010200-043 [doi]
AB  - Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor 
      with aspirin on major bleeding and cardiovascular events in patients with acute 
      coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323:2407-16. 
      32543684.
FAU - Bavishi, Chirag
AU  - Bavishi C
AD  - Lifespan Cardiovascular Institute, Warren Alpert Medical School of Brown 
      University, Providence, Rhode Island, USA (C.B.).
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - JAMA. 2020 Jun 16;323(23):2407-2416. PMID: 32543684
MH  - *Acute Coronary Syndrome/drug therapy
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Ticagrelor/therapeutic use
EDAT- 2020/10/20 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/10/19 20:08
PHST- 2020/10/19 20:08 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
AID - 10.7326/ACPJ202010200-043 [doi]
PST - ppublish
SO  - Ann Intern Med. 2020 Oct 20;173(8):JC43. doi: 10.7326/ACPJ202010200-043.

PMID- 6812163
OWN - NLM
STAT- MEDLINE
DCOM- 19821202
LR  - 20190825
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 23
IP  - 5
DP  - 1982 May
TI  - Aspirin inhibits arachidonic acid metabolism via lipoxygenase and cyclo-oxygenase 
      in hamster isolated lungs.
PG  - 731-41
AB  - The effect of aspirin on the fate of exogenous arachidonic acid (AA) was 
      investigated in isolated perfused lungs of female hamsters. During pulmonary 
      infusion of aspirin (10 microM, 100 microM, or 1 mM) 45 nmol of 14C-AA was 
      infused in two minutes into the pulmonary circulation. The nonrecirculating 
      perfusion effluent was collected for 6 minutes after the beginning of the AA 
      infusion. Arachidonate infusion increased the perfusion pressure. This pressor 
      response was completely abolished by 1 mM aspirin. When aspirin was infused into 
      the pulmonary circulation, the amount of radioactivity was increased in the 
      perfused lungs and decreased dose dependently in the nonrecirculating perfusion 
      effluent. The amount of unmetabolized free arachidonate was not changed 
      significantly by aspirin in the perfused lungs or in the perfusion effluent. In 
      the effluent the amounts of all arachidonate metabolites, which were extracted 
      with ethyl acetate first at pH 7.4 and then at pH 3.5 and analysed by thin layer 
      chromatography, were decreased quite similarly by aspirin. The formation of 
      arachidonate metabolites was completely inhibited by 1 mM aspirin. In the 
      perfused lung tissue the amount of 14C-AA was increased by aspirin in 
      phospholipids and neutral lipids. The present study indicates that the metabolism 
      of arachidonic acid is inhibited by aspirin in hamster lungs not only via 
      cyclo-oxygenase but also via other lipoxygenases.
FAU - Paajanen, H
AU  - Paajanen H
FAU - Männistö, J
AU  - Männistö J
FAU - Uotila, P
AU  - Uotila P
LA  - eng
GR  - ES-01684-20/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Arachidonic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/*metabolism
MH  - Aspirin/*pharmacology
MH  - Cricetinae
MH  - *Cyclooxygenase Inhibitors
MH  - Female
MH  - *Lipoxygenase Inhibitors
MH  - Lung/drug effects/*enzymology
MH  - Mesocricetus
MH  - Perfusion
EDAT- 1982/05/01 00:00
MHDA- 1982/05/01 00:01
CRDT- 1982/05/01 00:00
PHST- 1982/05/01 00:00 [pubmed]
PHST- 1982/05/01 00:01 [medline]
PHST- 1982/05/01 00:00 [entrez]
AID - S0090-6980(82)80011-7 [pii]
AID - 10.1016/s0090-6980(82)80011-7 [doi]
PST - ppublish
SO  - Prostaglandins. 1982 May;23(5):731-41. doi: 10.1016/s0090-6980(82)80011-7.

PMID- 26369686
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 21
IP  - 35
DP  - 2015
TI  - Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene 
      Polymorphism.
PG  - 5066-72
AB  - The risk of gastrointestinal (GI) bleeding is increased in association with the 
      use of low-dose aspirin (LDA). There are few studies of the association between 
      genetic polymorphisms and the risks of aspirin-induced ulcer or its 
      complications. Individuals with two single nucleotide polymorphisms (SNPs) of 
      cyclooxygenase-1 (COX-1), A-842G and C50T, exhibit increased sensitivity to 
      aspirin and lower prostaglandin synthesis capacity but the polymorphism lacked 
      statistical significance in relation to an association with bleeding peptic 
      ulcer. In our previous Japanese study, SLCO1B1 521TT genotype and the SLCO1B1 *1b 
      haplotype were significantly associated with the risk of peptic ulcer and ulcer 
      bleeding in patients taking LDA, especially in the patients with angiotensin 
      converting enzyme inhibitor (ACEI), angiotensin type 1 receptor blocker (ARB), or 
      statin co-treatment. Protonpump inhibitors (PPIs) are recommended for patients 
      who require antiplatelet therapy and have a history of upper GI bleeding. The 
      interaction between PPIs and consequent impaired effectiveness of clopidogrel has 
      caused concern regarding the effect of genetic polymorphisms of the CYP2C19 which 
      mediates conversion of clopidogrel to its active metabolite. The later recent 
      genome-wide analysis of SNPs indicated the association of several SNPs with small 
      bowel bleeding in Japanese patients taking LDA. The data are still lacking and 
      further prospective studies are needed to identify the specific gene 
      polymorphisms as risk or protective factors for GI bleeding associated with LDA.
FAU - Shiotani, Akiko
AU  - Shiotani A
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, 577 Matsushima Kurashiki City, Okayama Prefecture 701-0192, Japan. 
      shiotani@med.kawasaki-m.ac.jp.
FAU - Fujita, Yoshihiko
AU  - Fujita Y
FAU - Nishio, Kazuto
AU  - Nishio K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Hemorrhage/*chemically induced/genetics/prevention & control
MH  - Gastrointestinal Tract/*drug effects/pathology
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Polymorphism, Single Nucleotide
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Risk Factors
EDAT- 2015/09/16 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/06/19 00:00 [received]
PHST- 2015/09/14 00:00 [accepted]
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - CPD-EPUB-70381 [pii]
AID - 10.2174/1381612821666150915105537 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2015;21(35):5066-72. doi: 10.2174/1381612821666150915105537.

PMID- 15806298
OWN - NLM
STAT- MEDLINE
DCOM- 20050802
LR  - 20190606
IS  - 1107-3756 (Print)
IS  - 1107-3756 (Linking)
VI  - 15
IP  - 5
DP  - 2005 May
TI  - Aspirin blocks binding of photosensitizer SnET2 into human serum albumin: 
      implications for photodynamic therapy.
PG  - 777-83
AB  - Tin etiopurpurin dichloride (SnET2) is one of the photosensitizers under 
      investigation to be used in photodynamic therapy of prostate cancer. The drug is 
      delivered intravenously, transported in vivo by liposomes and plasma proteins and 
      localized within the prostate. SnET2 exists in two tautomeric forms (I - closed 
      ring, II - open ring) with I converting spontaneously into the more energetically 
      stable form II at physiological pH. Up to approximately 50% of the drug can be 
      carried by serum albumin, although this association can increase photo-bleaching 
      and diminish the drug efficiency. Molecular modeling and force field calculations 
      indicate that Sudlow Site I in human serum albumin (HSA) is the most probable 
      binding site for both forms of SnET2, with the porphyrin moiety nestling between 
      domains IIA and IB, and the esterolytic side group oriented toward domain IIIA of 
      HSA. Other drugs, including aspirin, bind to the same part of HSA. SnET2 does not 
      bind to HSA when pre-incubated with aspirin, which confirms that its place of 
      binding to this protein must be located near Lys199. This observation could be 
      exploited to improve photo-efficiency of SnET2 by finding drugs that could 
      compete with the photosensitizer for binding into Sudlow Site I of HSA.
FAU - Skrzypczak-Jankun, E
AU  - Skrzypczak-Jankun E
AD  - Urology Research Center, Department of Urology, Medical College of Ohio, Toledo, 
      OH 43614, USA.
FAU - Borbulevych, O Y
AU  - Borbulevych OY
FAU - Melillo, A
AU  - Melillo A
FAU - Keck, R
AU  - Keck R
FAU - Soriano-Garcia, M
AU  - Soriano-Garcia M
FAU - Aniola, J
AU  - Aniola J
FAU - Niedre, M
AU  - Niedre M
FAU - Lilge, L
AU  - Lilge L
FAU - Selman, S H
AU  - Selman SH
FAU - Jankun, J
AU  - Jankun J
LA  - eng
GR  - CA109625/CA/NCI NIH HHS/United States
GR  - CA79450/CA/NCI NIH HHS/United States
GR  - CA90524/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Porphyrins)
RN  - 0 (Serum Albumin)
RN  - 466G63QE7G (tin etiopurpurin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Binding Sites
MH  - Binding, Competitive
MH  - Humans
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Photochemotherapy
MH  - Photosensitizing Agents/*chemistry
MH  - Porphyrins/*chemistry
MH  - Serum Albumin/*chemistry
EDAT- 2005/04/05 09:00
MHDA- 2005/08/03 09:00
CRDT- 2005/04/05 09:00
PHST- 2005/04/05 09:00 [pubmed]
PHST- 2005/08/03 09:00 [medline]
PHST- 2005/04/05 09:00 [entrez]
AID - 10.3892/ijmm.15.5.777 [doi]
PST - ppublish
SO  - Int J Mol Med. 2005 May;15(5):777-83. doi: 10.3892/ijmm.15.5.777.

PMID- 17578607
OWN - NLM
STAT- MEDLINE
DCOM- 20080124
LR  - 20181113
IS  - 0941-4355 (Print)
IS  - 0941-4355 (Linking)
VI  - 15
IP  - 10
DP  - 2007 Oct
TI  - Low-dose aspirin for the prevention of venous thromboembolism in breast cancer 
      patients treated with infusional chemotherapy after insertion of central vein 
      catheter.
PG  - 1213-7
AB  - BACKGROUND: We previously demonstrated a high incidence (7.7%) of venous 
      thromboembolism (VTE) in breast cancer patients treated with infusional 
      chemotherapy after insertion of central vein catheters (CVC). The aim of this 
      study was to evaluate the efficacy and safety of low-dose aspirin for the 
      prevention of VTE. PATIENTS AND METHODS: In a monocentric prospective study, 
      patients with stage II-IV breast cancer, who underwent CVC insertion for 
      continuous infusional chemotherapy, were assigned to receive low-dose aspirin 
      (100 mg daily). Treatment was started after CVC implantation and continued until 
      the last day of chemotherapy. Patients were assessed for safety and for the 
      incidence of symptomatic deep venous thrombosis (DVT) confirmed by color-Doppler 
      ultrasonography. RESULTS: Between April 2000 and March 2004, 188 consecutive 
      patients were included in the study. Median age was 48 years (range 22-83), 31 
      patients (16%) had concomitant hypertension, and 14 patients (7.4%) were smokers. 
      Median duration of treatment with aspirin was 3.6 months (range 0.4-5.7). A DVT 
      confirmed by color-Doppler ultrasonography was observed in four patients (2.1%; 
      95% confidence interval, 0.58-5.35%). Side effects included mild epistaxis (three 
      patients, 1.5%) and mild gastric pain (two patients, 1%). No major bleeding 
      complication or International Normal Ratio alteration occurred. CONCLUSIONS: 
      Administration of low-dose aspirin is safe and seems to correlate with a low risk 
      of DVT in breast cancer patients treated with infusional chemotherapy. Further 
      randomized studies comparing low-dose aspirin with other anticoagulative agents 
      are warranted.
FAU - Curigliano, Giuseppe
AU  - Curigliano G
AD  - Division of Medical Oncology, Department of Medicine, European Institute of 
      Oncology, Via Ripamonti 435, 20141 Milan, Italy.
FAU - Balduzzi, Alessandra
AU  - Balduzzi A
FAU - Cardillo, Anna
AU  - Cardillo A
FAU - Ghisini, Raffaella
AU  - Ghisini R
FAU - Peruzzotti, Giulia
AU  - Peruzzotti G
FAU - Orlando, Laura
AU  - Orlando L
FAU - Torrisi, Rosalba
AU  - Torrisi R
FAU - Dellapasqua, Silvia
AU  - Dellapasqua S
FAU - Lunghi, Loredana
AU  - Lunghi L
FAU - Goldhirsch, Aron
AU  - Goldhirsch A
FAU - Colleoni, Marco
AU  - Colleoni M
LA  - eng
PT  - Journal Article
DEP - 20070620
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Support Care Cancer. 2008 Mar;16(3):311-2; author reply 313-4. PMID: 18197432
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Breast Neoplasms/classification/complications/*drug therapy
MH  - *Catheterization, Central Venous
MH  - Female
MH  - Humans
MH  - *Infusions, Intravenous
MH  - Italy
MH  - Middle Aged
MH  - Prospective Studies
MH  - Venous Thromboembolism/*prevention & control
EDAT- 2007/06/21 09:00
MHDA- 2008/01/25 09:00
CRDT- 2007/06/21 09:00
PHST- 2007/01/24 00:00 [received]
PHST- 2007/05/16 00:00 [accepted]
PHST- 2007/06/21 09:00 [pubmed]
PHST- 2008/01/25 09:00 [medline]
PHST- 2007/06/21 09:00 [entrez]
AID - 10.1007/s00520-007-0277-0 [doi]
PST - ppublish
SO  - Support Care Cancer. 2007 Oct;15(10):1213-7. doi: 10.1007/s00520-007-0277-0. Epub 
      2007 Jun 20.

PMID- 1806380
OWN - NLM
STAT- MEDLINE
DCOM- 19920513
LR  - 20131121
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 12 Suppl G
DP  - 1991 Dec
TI  - What is the role of invasive intervention after coronary thrombolysis?
PG  - 43-6
AB  - Intervention to improve coronary flow after coronary patency has been restored by 
      coronary thrombolysis is attractive in concept, but has been proved disappointing 
      in practice. A number of randomized clinical trials which compared outcome after 
      thrombolysis with and without early or delayed intervention has shown no benefit 
      towards intervention in terms of survival or other clinical measurements. This 
      may partly reflect the imperfection of current intervention techniques, 
      particularly a high re-occlusion rate, and partly as yet unsolved problems of 
      myocardial preservation. Revascularization does have an important role in 
      patients who develop recurrent ischaemia after thrombolysis, or in patients with 
      multi-vessel disease who initially present as myocardial infarction patients.
FAU - de Bono, D P
AU  - de Bono DP
AD  - Department of Cardiology, University of Leicester, Glenfield General Hospital, 
      U.K.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/*therapeutic use
MH  - Combined Modality Therapy
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - *Thrombolytic Therapy
RF  - 25
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
PST - ppublish
SO  - Eur Heart J. 1991 Dec;12 Suppl G:43-6.

PMID- 17139447
OWN - NLM
STAT- MEDLINE
DCOM- 20070223
LR  - 20131121
IS  - 0925-4692 (Print)
IS  - 0925-4692 (Linking)
VI  - 14
IP  - 5-6
DP  - 2006 Dec
TI  - Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of 
      measuring TNF-alpha.
PG  - 256-9
AB  - Aspirin and other cyclooxygenase inhibitors can increase levels of tumor necrosis 
      factor-alpha and engage pro-apoptosis paths and/or anti-apoptosis paths. 
      Seemingly conflicting data are briefly reviewed. Aspirin has been shown to 
      slightly increase survival duration in multiple myeloma. In this brief note 
      caution is raised about use of aspirin and COX inhibitors generally in 
      inflammatory states and specifically in myeloma. Should they increase tumor 
      necrosis factor-alpha they could exacerbate disease. A figure is presented 
      showing the tendency for interleukin-6 and tumor necrosis factor-alpha, both 
      demonstrated to be growth factors in myeloma, to be counter-regulated. Since both 
      are now easily measured by specialty labs, it would be reasonable to monitor 
      these during myeloma treatment generally, and particularly when using aspirin, 
      COX inhibitors, or any other drug with potential to increase these growth 
      factors.
FAU - Kast, R E
AU  - Kast RE
AD  - University of Vermont, 2 Church Street, Burlington, VT 05401, USA. 
      kast887@hotmail.com
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (NF-kappa B)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - *Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - *Cyclooxygenase Inhibitors/administration & dosage/adverse effects/therapeutic 
      use
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - *Multiple Myeloma/metabolism/pathology
MH  - NF-kappa B/*metabolism
MH  - *Tumor Necrosis Factor-alpha/analysis/metabolism
EDAT- 2006/12/02 09:00
MHDA- 2007/02/24 09:00
CRDT- 2006/12/02 09:00
PHST- 2006/12/02 09:00 [pubmed]
PHST- 2007/02/24 09:00 [medline]
PHST- 2006/12/02 09:00 [entrez]
AID - 10.1007/s10787-006-1532-6 [doi]
PST - ppublish
SO  - Inflammopharmacology. 2006 Dec;14(5-6):256-9. doi: 10.1007/s10787-006-1532-6.

PMID- 29908361
OWN - NLM
STAT- MEDLINE
DCOM- 20200729
LR  - 20220331
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
VI  - 17
IP  - 5
DP  - 2019 Apr
TI  - Incidence of Upper and Lower Gastrointestinal Bleeding in New Users of Low-Dose 
      Aspirin.
PG  - 887-895.e6
LID - S1542-3565(18)30619-0 [pii]
LID - 10.1016/j.cgh.2018.05.061 [doi]
AB  - BACKGROUND & AIMS: There are few data on the incidence of upper and lower 
      gastrointestinal bleeding (UGIB and LGIB) from observational studies of low-dose 
      aspirin users. We aimed to estimate incidence rates of UGIB and LGIB in a large 
      cohort of new users of low-dose aspirin in the United Kingdom, with subanalyses 
      of hospitalization status and fatalities. METHODS: We performed a 
      population-based study of 199,079 new users of low-dose aspirin (median age, 64.0 
      years) identified from the Health Improvement Network primary care database 
      (2000-2012). Individuals were followed for a median 5.4 years (maximum, 14 years) 
      to identify new cases of UGIB and LGIB. Following multistep validation, we 
      calculated overall and age- and sex-specific incidence rates; we performed 
      subanalyses for health care use and death within 30 days of GIB. We also 
      estimated rates within a matched (1:1) cohort of nonusers of low-dose aspirin at 
      the start of the follow-up period. RESULTS: The low-dose aspirin users had 1115 
      UGIB events and 1936 LGIB events; most subjects with UGIB events (58.9%) were 
      hospitalized, whereas most subjects with LGIB events were referred to secondary 
      care (72.8%). Crude incidence rates of GIB per 1000 person-years were 0.97 for 
      subjects with UGIB (95% CI, 0.91-1.02) and 1.68 for subjects with LGIB (95% CI, 
      1.60-1.75). Incidence rates per 1000 person-years for patients hospitalized for 
      GIB were 0.57 for UGIB (95% CI, 0.53-0.61) and 0.45 for LGIB (95% CI, 0.42-0.49); 
      for referred (but not hospitalized) cases, these values were 0.39 for UGIB (95% 
      CI, 0.36-0.43) and 1.22 for LGIB (1.16-1.29). Incidence rates per 1000 
      person-years were 0.06 for fatal UGIB (95% CI, 0.04-0.07), 0.01 for fatal LGIB 
      (95% CI, 0.01-0.02), 0.91 for nonfatal UGIB (95% CI, 0.86-0.97), and 1.66 for 
      nonfatal LGIB (95% CI, 1.59-1.74). Among nonusers of low-dose aspirin, incidence 
      rates per 1000 person-years were 0.67 (95% CI, 0.63-0.75) for UGIB and 0.76 (95% 
      CI, 0.72-0.82) for LGIB. CONCLUSION: In a population-based study of low-dose 
      aspirin users, the incidence of LGIB was higher than the incidence of UGIB. 
      However, incidence rates of hospitalized GI bleeds and 30-day mortality rates 
      were lower for LGIB than for UGIB. These estimates are valuable for benefit-risk 
      assessments of low-dose aspirin for cardiovascular and colorectal cancer 
      prevention.
CI  - Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
FAU - Cea Soriano, Lucía
AU  - Cea Soriano L
AD  - Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain; Department of 
      Public Health and Maternal and Child Health, Faculty of Medicine, Complutense 
      University of Madrid, Madrid, Spain. Electronic address: luciaceife@gmail.com.
FAU - Lanas, Angel
AU  - Lanas A
AD  - Servicio de Aparato Digestivo, Hospital Clínico, University of Zaragoza, IIS 
      Aragón, Zaragoza, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
FAU - Soriano-Gabarró, Montse
AU  - Soriano-Gabarró M
AD  - Epidemiology, Bayer AG, Berlin, Germany.
FAU - García Rodríguez, Luis A
AU  - García Rodríguez LA
AD  - Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180614
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal 
      of the American Gastroenterological Association
JID - 101160775
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Hemorrhage/*chemically induced/*epidemiology/mortality
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Survival Analysis
MH  - United Kingdom/epidemiology
OTO - NOTNLM
OT  - Ischemic Vascular Disease Prophylaxis
OT  - Major Bleeding
OT  - Observational Study
OT  - UK
EDAT- 2018/06/17 06:00
MHDA- 2020/07/30 06:00
CRDT- 2018/06/17 06:00
PHST- 2018/01/19 00:00 [received]
PHST- 2018/05/17 00:00 [revised]
PHST- 2018/05/26 00:00 [accepted]
PHST- 2018/06/17 06:00 [pubmed]
PHST- 2020/07/30 06:00 [medline]
PHST- 2018/06/17 06:00 [entrez]
AID - S1542-3565(18)30619-0 [pii]
AID - 10.1016/j.cgh.2018.05.061 [doi]
PST - ppublish
SO  - Clin Gastroenterol Hepatol. 2019 Apr;17(5):887-895.e6. doi: 
      10.1016/j.cgh.2018.05.061. Epub 2018 Jun 14.

PMID- 9341992
OWN - NLM
STAT- MEDLINE
DCOM- 19971105
LR  - 20191102
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 130
IP  - 3
DP  - 1997 Sep
TI  - Effects of diaspirin-cross-linked hemoglobin (DCLHb) on the microcirculation of 
      striated skin muscle in the hamster: a study on safety and toxicity.
PG  - 314-27
AB  - Hemoglobin-based oxygen-carrying solutions are reported to exert vasoconstrictor 
      effects and to enhance oxygen radical formation, particularly during 
      ischemia-reperfusion. This study investigates whether diaspirin-cross-linked 
      hemoglobin (DCLHb) affects the microvascular integrity of striated skin muscle. 
      The microcirculation model in the hamster and intravital fluorescence microscopy 
      were applied for investigation of the microvascular changes in striated skin 
      muscle. Hypervolemic infusion (500 mg x kg(-1), I.V.) and isovolemic exchange 
      transfusion (3.3 gm x kg(-1) I.V.; hematocrit 30%) with DCLHb (1) led to a 
      short-lasting (0 to 2 minutes) arteriolar constriction (approximately 20% 
      reduction in baseline diameter), (2) significantly influenced arteriolar 
      vasomotion, (3) increased venular red blood cell velocity by 1.5-fold (p < 0.05 
      vs dextran, Mr 60,000), and (4) did not enhance microvascular 
      leukocyte-endothelium interaction or endothelial permeability. Resuscitation from 
      severe hemorrhagic shock with autologous blood (AuB) or DCLHb (33 ml x kg(-1), 
      I.V.) immediately restored mean arterial pressure and heart rate, whereas 6% 
      dextran (60 kd)(Dx-60) did not return these parameters to baseline. Venular red 
      blood cell velocity was restored to 110% of baseline after DCLHb, to 90% of 
      baseline after AuB, and to 45% of baseline after Dx-60. Leukocyte-endothelium 
      interaction was significantly enhanced after resuscitation with AuB and Dx-60, 
      whereas this phenomenon was absent after DCLHb. These data demonstrate that DCLHb 
      increases venular red blood cell velocity under both nonischemic and postischemic 
      conditions without inducing enhanced leukocyte-endothelium interaction in the 
      microcirculation of striated skin muscle.
FAU - Nolte, D
AU  - Nolte D
AD  - Institute for Surgical Research, Klinikum Grosshadern, 
      Ludwig-Maximilians-University of Munich, Germany.
FAU - Botzlar, A
AU  - Botzlar A
FAU - Pickelmann, S
AU  - Pickelmann S
FAU - Bouskela, E
AU  - Bouskela E
FAU - Messmer, K
AU  - Messmer K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Substitutes/*pharmacology
MH  - Blood Volume
MH  - Cricetinae
MH  - Diffusion Chambers, Culture
MH  - Endothelium, Vascular/metabolism
MH  - Exchange Transfusion, Whole Blood
MH  - Hemoglobins/*pharmacology
MH  - Leukocytes/metabolism
MH  - Male
MH  - Mesocricetus
MH  - Microcirculation/*drug effects
MH  - Muscle, Skeletal/*blood supply/drug effects
MH  - Reperfusion Injury/drug therapy
MH  - Skin/*blood supply/drug effects
EDAT- 1997/10/28 00:00
MHDA- 1997/10/28 00:01
CRDT- 1997/10/28 00:00
PHST- 1997/10/28 00:00 [pubmed]
PHST- 1997/10/28 00:01 [medline]
PHST- 1997/10/28 00:00 [entrez]
AID - S0022-2143(97)90027-5 [pii]
AID - 10.1016/s0022-2143(97)90027-5 [doi]
PST - ppublish
SO  - J Lab Clin Med. 1997 Sep;130(3):314-27. doi: 10.1016/s0022-2143(97)90027-5.

PMID- 28927346
OWN - NLM
STAT- MEDLINE
DCOM- 20180328
LR  - 20220408
IS  - 1941-0921 (Electronic)
IS  - 1941-7381 (Print)
IS  - 1941-0921 (Linking)
VI  - 10
IP  - 2
DP  - 2018 Mar/Apr
TI  - Deep Venous Thrombosis Prophylaxis in Anterior Cruciate Ligament Reconstructive 
      Surgery: What Is the Current State of Practice?
PG  - 156-159
LID - 10.1177/1941738117730576 [doi]
AB  - BACKGROUND: Venous thromboembolism (VTE) is a significant perioperative risk with 
      many common orthopaedic procedures. Currently, there is no standardized 
      recommendation for the use of VTE prophylaxis during anterior cruciate ligament 
      (ACL) reconstruction. This study sought to evaluate the current prophylactic 
      practices of fellowship-trained sports medicine orthopaedic surgeons in the 
      United States. HYPOTHESIS: Very few surgeons use perioperative VTE prophylaxis 
      for ACL reconstructive surgery. STUDY DESIGN: Survey. METHODS: Surveys were 
      emailed to the alumni networks of 4 large ACGME-accredited sports medicine 
      fellowship programs. Questions were focused on their current use of chemical and 
      nonchemical VTE prophylaxis. RESULTS: Surveys were completed by 142 surgeons in 
      the United States, yielding a response rate of 32%. Of those who responded, 50.7% 
      stated that they routinely use chemical prophylaxis, with 95.5% of those using 
      aspirin (acetylsalicylic acid [ASA]). There was no standardized dosing protocol, 
      with respondents using ASA 325 mg once (46%) or twice daily (26%) or ASA 81 mg 
      once (18%) or twice (10%) daily. The most common reason for not including 
      chemical prophylaxis within the reconstruction procedure was that it is 
      unnecessary given the low risk of VTE. Physicians also based their prophylaxis 
      regimen more on their own clinical experience than concern for litigation. 
      CONCLUSION: Half of all sports medicine fellowship-trained surgeons surveyed 
      routinely use chemical VTE prophylaxis after ACL reconstruction, with more than 
      90% of those using ASA. Of those using ASA, there was no prevailing dosing 
      protocol. For those not using chemical prophylaxis, the most important reason was 
      that it was felt to be unnecessary due to the risks outweighing the benefits. 
      Those who do not regularly use chemical prophylaxis would be willing to, however, 
      if a patient had a personal or family history of clotting disorder or is 
      currently on birth control. Additionally, clinical experience was the primary 
      driver for a current prophylaxis protocol. CLINICAL RELEVANCE: This survey study 
      evaluating the use of VTE prophylaxis with ACL reconstruction lends clinical 
      insight to the current practice of a large, geographically diverse group of 
      fellowship-trained sports medicine orthopaedic surgeons in the United States.
FAU - Keller, Robert A
AU  - Keller RA
AD  - Kerlan Jobe Orthopaedic Clinic, Los Angeles, California.
FAU - Moutzouros, Vasilios
AU  - Moutzouros V
AD  - Henry Ford Hospital, Detroit, Michigan.
FAU - Dines, Joshua S
AU  - Dines JS
AD  - Hospital for Special Surgery, New York, New York.
FAU - Bush-Joseph, Charles A
AU  - Bush-Joseph CA
AD  - Midwest Orthopaedics at Rush University Medical Center, Chicago, Illinois.
FAU - Limpisvasti, Orr
AU  - Limpisvasti O
AD  - Kerlan Jobe Orthopaedic Clinic, Los Angeles, California.
LA  - eng
PT  - Journal Article
DEP - 20170919
PL  - United States
TA  - Sports Health
JT  - Sports health
JID - 101518422
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anterior Cruciate Ligament Injuries/surgery
MH  - *Anterior Cruciate Ligament Reconstruction
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Early Ambulation
MH  - Fibrinolytic Agents/administration & dosage/therapeutic use
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Surveys
MH  - Humans
MH  - Motion Therapy, Continuous Passive
MH  - *Orthopedic Surgeons
MH  - Postoperative Complications/*prevention & control
MH  - Risk Factors
MH  - Stockings, Compression
MH  - United States
MH  - Venous Thrombosis/*prevention & control
PMC - PMC5857726
OTO - NOTNLM
OT  - ACL
OT  - anterior cruciate ligament reconstruction
OT  - deep venous thrombosis
OT  - prophylaxis
OT  - venous thromboembolism
COIS- The authors report no potential conflicts of interest in the development and 
      publication of this article.
EDAT- 2017/09/21 06:00
MHDA- 2018/03/29 06:00
CRDT- 2017/09/21 06:00
PHST- 2017/09/21 06:00 [pubmed]
PHST- 2018/03/29 06:00 [medline]
PHST- 2017/09/21 06:00 [entrez]
AID - 10.1177_1941738117730576 [pii]
AID - 10.1177/1941738117730576 [doi]
PST - ppublish
SO  - Sports Health. 2018 Mar/Apr;10(2):156-159. doi: 10.1177/1941738117730576. Epub 
      2017 Sep 19.

PMID- 18409054
OWN - NLM
STAT- MEDLINE
DCOM- 20080709
LR  - 20131121
IS  - 0253-6269 (Print)
IS  - 0253-6269 (Linking)
VI  - 31
IP  - 3
DP  - 2008 Mar
TI  - Evaluation of the stability of aspirin in solid state by the programmed 
      humidifying and non-isothermal experiments.
PG  - 381-9
LID - 10.1007/s12272-001-1168-7 [doi]
AB  - The influence of both moisture and heat on the stability of aspirin was 
      investigated by a single pair of experiments, one with programmed humidity 
      control and the other non-isothermal, rather than many standard isothermal 
      studies, each at constant relative humidity. In experiments, we adopted the 
      acid-base back titration method to measure the content of aspirin in the presence 
      of its degradation products. It was found that the degradation of aspirin could 
      be expressed as ln[(c0-c)/c]=kt+D, where D was a lag time item not related to 
      humidity and temperature. The relationship between the degradation rate constant 
      k and humidity Hr) and temperature T could be described as Arrhenius equation 
      multiplied by an exponential item of relative humidity: k = A . exp(mHr) . 
      exp(-(Ea/RT)), where A, Ea and m were the pre-exponential factor, observed 
      activation energy, and a parameter related to humidity, respectively. The results 
      obtained from the programmed humidifying and non-isothermal experiments, 
      A=(1.09+/-2.04)x10(12) h(-1), Ea=(93.5+/-2.2) kJ . mol(-1) and m=1.18+/-0.19, 
      were comparable to those from isothermal studies at constant humidity, 
      A=(1.71+/-0.35)x10(12) h(-1), Ea=(94.9+/-0.7) kJ . mol(-1) and m=1.20+/-0.02. 
      Since the programmed humidifying and non-isothermal experiments save time, labor 
      and materials, it is suggested that the new experimental method can be used to 
      investigate the stability of drugs unstable to both moisture and heat, instead of 
      many classical isothermal experiments at constant humidity.
FAU - Li, Lin-Li
AU  - Li LL
AD  - Key Laboratory of Drug Targeting, West China School of Pharmacy, Sichuan 
      University, No. 17, Section 3, Renmin South Road, Chengdu 610041, China. 
      ysylilinli@sina.com
FAU - Zhan, Xian-Cheng
AU  - Zhan XC
FAU - Tao, Jian-Lin
AU  - Tao JL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080413
PL  - Korea (South)
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
RN  - 0 (Dosage Forms)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Dosage Forms
MH  - Drug Stability
MH  - *Humidity
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Models, Chemical
MH  - Reproducibility of Results
MH  - Technology, Pharmaceutical/*methods
MH  - *Temperature
MH  - Titrimetry
MH  - Water/*chemistry
EDAT- 2008/04/15 09:00
MHDA- 2008/07/10 09:00
CRDT- 2008/04/15 09:00
PHST- 2007/07/08 00:00 [received]
PHST- 2008/04/15 09:00 [pubmed]
PHST- 2008/07/10 09:00 [medline]
PHST- 2008/04/15 09:00 [entrez]
AID - 10.1007/s12272-001-1168-7 [doi]
PST - ppublish
SO  - Arch Pharm Res. 2008 Mar;31(3):381-9. doi: 10.1007/s12272-001-1168-7. Epub 2008 
      Apr 13.

PMID- 17877660
OWN - NLM
STAT- MEDLINE
DCOM- 20071219
LR  - 20181201
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 61
IP  - 10
DP  - 2007 Oct
TI  - Prevention of secondary stroke and transient ischaemic attack with antiplatelet 
      therapy: the role of the primary care physician [corrected].
PG  - 1739-48
AB  - BACKGROUND: Stroke risk is heightened among patients who have had a primary 
      stroke or transient ischaemic attack (TIA). The primary care physician is in the 
      best position to monitor these patients for stroke recurrence. Because stroke 
      recurrence can occur shortly after the primary event, guidelines recommend 
      initiating antiplatelet therapy as soon as possible. Aspirin, with or without 
      extended-release dipyridamole (ER-DP), and clopidogrel are options for such 
      patients. Low-dose aspirin (75-150 mg/day) has the same efficacy as higher doses 
      but with less gastrointestinal bleeding. Clopidogrel remains an option for 
      prevention of secondary events and may benefit patients with symptomatic 
      atherothrombosis, but its combined use with aspirin can harm patients with 
      multiple risk factors and no history of symptomatic cerebrovascular, 
      cardiovascular or peripheral vascular disease. RESULTS: Low dose aspirin is 
      effective in secondary stroke prevention. Trials assessing aspirin plus ER-DP 
      have shown that the combination is more effective than aspirin monotherapy in 
      preventing stroke, with efficacy increasing among higher risk patients, notably 
      those with prior stroke/TIA. Clopidogrel does not appear to have as much 
      advantage over aspirin in secondary stroke prevention as aspirin plus ER-DP. 
      Smoking cessation and cholesterol, blood glucose and blood pressure control are 
      also important concerns in preventing recurrent stroke. In choosing 
      pharmacological therapy, the physician must consider the individual patient's 
      risk factors and tolerance, as well as other issues, such as use of aspirin among 
      patients with ulcers. CONCLUSION: Antiplatelet therapy is effective in secondary 
      stroke prevention. Low dose aspirin can be used first-line, but aspirin plus 
      ER-DP improves efficacy. Clopidogrel is another option in secondary stroke 
      prevention, especially for aspirin-intolerant patients, but it appears to have 
      less advantage over aspirin than aspirin plus ER-DP, and its combined use with 
      aspirin has only marginally better efficacy and increased bleeding risk.
FAU - Kirshner, H S
AU  - Kirshner HS
AD  - Department of Neurology and Vanderbilt Stroke Center, Nashville, TN 37232-2551, 
      USA. howard.kirshner@vanderbilt.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Int J Clin Pract. 2007 Nov;61(11):1957
MH  - Aged
MH  - Aspirin/adverse effects/economics/therapeutic use
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Dipyridamole/adverse effects/economics/therapeutic use
MH  - Drug Therapy, Combination
MH  - *Family Practice
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Middle Aged
MH  - *Physician's Role
MH  - Platelet Aggregation Inhibitors/adverse effects/economics/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Stroke/*prevention & control
MH  - Ticlopidine/adverse effects/analogs & derivatives/economics/therapeutic use
MH  - Treatment Outcome
RF  - 44
EDAT- 2007/09/20 09:00
MHDA- 2007/12/20 09:00
CRDT- 2007/09/20 09:00
PHST- 2007/09/20 09:00 [pubmed]
PHST- 2007/12/20 09:00 [medline]
PHST- 2007/09/20 09:00 [entrez]
AID - IJCP1515 [pii]
AID - 10.1111/j.1742-1241.2007.01515.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2007 Oct;61(10):1739-48. doi: 10.1111/j.1742-1241.2007.01515.x.

PMID- 4122059
OWN - NLM
STAT- MEDLINE
DCOM- 19730705
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 7812
DP  - 1973 May 19
TI  - Aspirin in radiation-induced diarrhoea.
PG  - 1131
FAU - Mennie, A T
AU  - Mennie AT
FAU - Dalley, V
AU  - Dalley V
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Diarrhea/*drug therapy/etiology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Radiotherapy/*adverse effects
MH  - Uterine Neoplasms/radiotherapy
OID - PIP: 001185
OID - POP: 00086279
OAB - The side effects of nausea and diarrhea have frequently been observed following 
      the administration of prostaglandin E2 or F2alpha for the induction of labor or 
      abortion. The oral administration of prostaglandin E1 to volunteers has elicited 
      similar reactions. Reports that aspirin might relieve some types of nausea or 
      diarrhea led to the testing of aspirin against the diarrhea induced by the 
      radiation therapy of cancer of the uterine cervix. The treatment of cervical 
      cancer by a combination of external radiation and radium often produces diarrhea, 
      probably because loops of bowel in the path of X-rays are damaged. 15 women 
      between the ages of 47 and 65 who had been irradiated for cancer of the cervix 
      and who had developed diarrhea that failed to respond to conventional therapy 
      participated in a preliminary trial. When conventional therapy failed, it was 
      abandoned and each patient was given 900 mg of soluble aspirin B.P. ("Slfrin") by 
      mouth, 4 times daily. In 4 patients the diarrhea cleared up completely within 24 
      hours of taking the aspirin. The diarrhea was improved in 8 patients, although in 
      2 it relapsed 48 hours after improvement was 1st observed. Colicky pain which 
      accompanied diarrhea in 3 patients disappeared during aspirin therapy. 1 patient 
      who had severe nausea experienced marked relief. The findings indicate that 
      aspirin may be of value in the treatment of diarrhea induced by radiation. Since 
      prostaglandin synthesis can be provoked by many different forms of stimulation, 
      and because aspirin at low concentrations inhibits this synthesis, it is 
      suggested that prostaglandins are involved in radiation induced diarrhea. A 
      carefully controlled trial of aspirin in the treatment of radiation induced 
      diarrhea is now being conducted.
OABL- eng
OTO - PIP
OT  - Biology
OT  - Cancer
OT  - *Cervical Cancer
OT  - *Diarrhea
OT  - Diseases
OT  - Endocrine System
OT  - Neoplasms
OT  - Physiology
OT  - *Prostaglandins
OT  - *Treatment--side effects
GN  - PIP: TJ: LANCET.
EDAT- 1973/05/19 00:00
MHDA- 1973/05/19 00:01
CRDT- 1973/05/19 00:00
PHST- 1973/05/19 00:00 [pubmed]
PHST- 1973/05/19 00:01 [medline]
PHST- 1973/05/19 00:00 [entrez]
AID - S0140-6736(73)90451-0 [pii]
AID - 10.1016/s0140-6736(73)90451-0 [doi]
PST - ppublish
SO  - Lancet. 1973 May 19;1(7812):1131. doi: 10.1016/s0140-6736(73)90451-0.

PMID- 12187862
OWN - NLM
STAT- MEDLINE
DCOM- 20021112
LR  - 20191106
IS  - 0340-9937 (Print)
IS  - 0340-9937 (Linking)
VI  - 27
IP  - 4
DP  - 2002 Jun
TI  - [Prevention of arterial thromboembolisms in patients with atrial fibrillation].
PG  - 322-8
AB  - BACKGROUND: Patients with atrial fibrillation have a 5% risk per year for 
      ischemic stroke. The aim of antithrombotic therapy is to prevent arterial 
      thromboembolic events. As anticoagulation increases the frequency of bleeding, 
      the risk and benefits of this therapy have to be assessed for each patient. 
      PATIENTS AT RISK: The patients can be classified as low risk (< 2% stroke/year), 
      medium risk (2-6% stroke/year), and high-risk patients (> 6% stroke/year). 
      Parameters for the risk stratification are the patient age and cardiac as well as 
      non-cardiac diseases. PREVENTION: Patients with a low risk need no 
      anticoagulation or can take aspirin. Patients with a high risk should receive 
      oral anticoagulation with an INR range from 2.0 to 3.0. Newer guidelines 
      recommend also for patients with intermediate level of stroke risk instead of 
      aspirin the prescription of oral anticoagulation. Patients with a medium risk can 
      interrupt the oral anticoagulation before surgery or invasive diagnostic 
      procedures for 1 week, patients with a high risk should receive heparin. 3-4 
      weeks before and after cardioversion the standard therapy is oral 
      anticoagulation.
FAU - Schuchert, Andreas
AU  - Schuchert A
AD  - Abteilung für Kardiologie, Medizinische Klinik, Universitätsklinikum 
      Hamburg-Eppendorf. schuchert@uke.uni-hamburg.de
FAU - Meinertz, Thomas
AU  - Meinertz T
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Prävention arterieller Thromboembolien bei Patienten mit Vorhofflimmern.
PL  - Germany
TA  - Herz
JT  - Herz
JID - 7801231
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects
MH  - Atrial Fibrillation/*complications/drug therapy
MH  - Female
MH  - Humans
MH  - Intracranial Embolism/etiology/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Thromboembolism/etiology/*prevention & control
EDAT- 2002/08/22 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/08/22 10:00
PHST- 2002/08/22 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/08/22 10:00 [entrez]
AID - 10.1007/s00059-002-2389-0 [doi]
PST - ppublish
SO  - Herz. 2002 Jun;27(4):322-8. doi: 10.1007/s00059-002-2389-0.

PMID- 7199241
OWN - NLM
STAT- MEDLINE
DCOM- 19820412
LR  - 20131121
IS  - 0001-5482 (Print)
IS  - 0001-5482 (Linking)
VI  - 147
IP  - 3
DP  - 1981
TI  - Effects of acetylsalicylic acid and prostaglandin on endotoxin-induced pulmonary 
      platelet sequestration.
PG  - 161-2
AB  - Previous experimental studies have shown that soft tissue trauma and endotoxin 
      shock cause pulmonary platelet trapping. In the soft tissue trauma model it has 
      been found that this event can be obviated by pretreatment with aspirin and 
      prostaglandin E1 in combination. This study was made to determine the effect of 
      these two drugs on endotoxin-induced pulmonary platelet trapping. Dogs with 
      51Cr-tagged platelets were injected with 20 mg endotoxin E. coli. The dogs were 
      kept in shock for 2 hours and then sacrificed. The dogs were kept in shock for 2 
      hours and then sacrified. The amount of platelet sequestration in the lungs was 
      determined by measuring the 51Cr activity in the lungs. The results of the study 
      showed that prostaglandin alone decreases pulmonary platelet trapping induced by 
      endotoxin, but aspirin, either alone or together with prostaglandin E1, has no 
      positive effect. This could be explained by the fact that acetylsalicylic acid 
      depresses endogenous prostaglandin, and thus decreases the blood concentration of 
      available prostaglandin.
FAU - Thörnee, L J
AU  - Thörnee LJ
FAU - Kuenzig, M
AU  - Kuenzig M
FAU - Thörne, L J
AU  - Thörne LJ
LA  - eng
GR  - HL 13466/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Sweden
TA  - Acta Chir Scand
JT  - Acta chirurgica Scandinavica
JID - 7906530
RN  - 0 (Endotoxins)
RN  - 0 (Prostaglandins E)
RN  - F5TD010360 (Alprostadil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alprostadil
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - *Blood Platelets
MH  - Dogs
MH  - Drug Therapy, Combination
MH  - Endotoxins/*adverse effects
MH  - Female
MH  - Lung/*pathology
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Prostaglandins E/administration & dosage/*pharmacology
MH  - Shock, Septic/*blood/drug therapy/etiology
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Chir Scand. 1981;147(3):161-2.

PMID- 16335593
OWN - NLM
STAT- MEDLINE
DCOM- 20060111
LR  - 20171116
IS  - 1122-9497 (Print)
IS  - 1122-9497 (Linking)
VI  - 37
IP  - 2
DP  - 2005 Aug
TI  - Ultrastructural investigations on protective effects of NCX 4016 (nitroaspirin) 
      on macrovascular endothelium in diabetic Wistar rats.
PG  - 205-13
AB  - The effect of a nitric oxide-donating aspirin derivative, 2-acetoxy-benzoate 
      3-(nitroxy-methyl)phenyl ester (NCX 4016), and aspirin on the aortic endothelium 
      of diabetic rats was investigated by using scanning and transmission electron 
      microscopy. Control and streptozotocin-treated rats were used. Metabolic control 
      was assessed by measuring blood and urine metabolites, and 24-h urine volume. The 
      ultrastructural study was performed after 7 weeks of diabetes and 6 weeks of 
      therapy. Streptozotocin treatment induced a persistent hyperglycemia which was 
      not influenced by the pharmacological treatments. Values of blood metabolites 
      were in line with the diabetic status. Both scanning and transmission electron 
      microscopy revealed that aortic endothelium was severely damaged in all diabetic 
      rats except for the NCX 4016 treated ones. Our data document the protective 
      effects of NCX 4016 on the vascular endothelium of diabetic rats. Since aspirin 
      had no protective action, NCX 4016 may have exerted its beneficial action by 
      releasing nitric oxide.
FAU - Ambrosini, M V
AU  - Ambrosini MV
AD  - Department of Experimental Medicine and Biochemical Sciences, University of 
      Perugia, Italy. neurbisp@unipg.it
FAU - Mariucci, G
AU  - Mariucci G
FAU - Rambotti, M G
AU  - Rambotti MG
FAU - Tantucci, M
AU  - Tantucci M
FAU - Covarelli, C
AU  - Covarelli C
FAU - De Angelis, L
AU  - De Angelis L
FAU - Del Soldato, P
AU  - Del Soldato P
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - J Submicrosc Cytol Pathol
JT  - Journal of submicroscopic cytology and pathology
JID - 8804312
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aorta/drug effects/pathology/ultrastructure
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Diabetes Mellitus, Experimental/*complications
MH  - Endothelium, Vascular/*drug effects/pathology/ultrastructure
MH  - Male
MH  - Microscopy, Electron, Scanning
MH  - Microscopy, Electron, Transmission
MH  - Rats
MH  - Rats, Wistar
MH  - Vascular Diseases/etiology/pathology/*prevention & control
EDAT- 2005/12/13 09:00
MHDA- 2006/01/13 09:00
CRDT- 2005/12/13 09:00
PHST- 2005/12/13 09:00 [pubmed]
PHST- 2006/01/13 09:00 [medline]
PHST- 2005/12/13 09:00 [entrez]
PST - ppublish
SO  - J Submicrosc Cytol Pathol. 2005 Aug;37(2):205-13.

PMID- 620868
OWN - NLM
STAT- MEDLINE
DCOM- 19780321
LR  - 20190902
IS  - 0011-9075 (Print)
IS  - 0011-9075 (Linking)
VI  - 156
IP  - 2
DP  - 1978
TI  - Effect of topical salicylic acid on animal epidermopoiesis.
PG  - 89-96
AB  - In contrast to its antihyperplastic effect on pathological proliferation of the 
      epidermis, salicylic acid promotes epidermopoiesis in the normal guinea pig skin. 
      After the application of 1% w/w salicylic acid in acetone-ethanol for 4 weeks, 
      the thickness of the surface epithelium was increased by 40% and that of the deep 
      epithelium by 19%. The mitotic index rose by 17%.
FAU - Weirich, E G
AU  - Weirich EG
FAU - Longauer, J K
AU  - Longauer JK
FAU - Kirkwood, A H
AU  - Kirkwood AH
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Dermatologica
JT  - Dermatologica
JID - 0211607
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology
MH  - Epidermis/*drug effects/physiology
MH  - Epithelium/drug effects/physiology
MH  - Guinea Pigs
MH  - Hydrocortisone/administration & dosage/pharmacology
MH  - Mitosis/*drug effects
MH  - Mitotic Index
MH  - Salicylates/administration & dosage/*pharmacology
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1159/000250902 [doi]
PST - ppublish
SO  - Dermatologica. 1978;156(2):89-96. doi: 10.1159/000250902.

PMID- 287936
OWN - NLM
STAT- MEDLINE
DCOM- 19790927
LR  - 20131121
IS  - 0028-8446 (Print)
IS  - 0028-8446 (Linking)
VI  - 89
IP  - 631
DP  - 1979 Mar 14
TI  - Pyloric obstruction caused by aspirin: case report.
PG  - 174-5
AB  - A case of pyloric obstruction caused by ingestion of enteric-coated aspirin 
      tablets is presented. The patient was predisposed by previous pyloric stenosis. A 
      barium meal study was diagnostic. The patient later had a massive 
      gastro-intestinal haemorrhage requiring surgical repair. The hazards of aspirin 
      ingestion in such a patient are discussed.
FAU - Sherry, E
AU  - Sherry E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - New Zealand
TA  - N Z Med J
JT  - The New Zealand medical journal
JID - 0401067
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - Hematemesis/etiology
MH  - Humans
MH  - Pyloric Stenosis/*complications
MH  - Tablets, Enteric-Coated/*adverse effects
EDAT- 1979/03/14 00:00
MHDA- 1979/03/14 00:01
CRDT- 1979/03/14 00:00
PHST- 1979/03/14 00:00 [pubmed]
PHST- 1979/03/14 00:01 [medline]
PHST- 1979/03/14 00:00 [entrez]
PST - ppublish
SO  - N Z Med J. 1979 Mar 14;89(631):174-5.

PMID- 21813162
OWN - NLM
STAT- MEDLINE
DCOM- 20120322
LR  - 20131121
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 128
IP  - 5
DP  - 2011 Nov
TI  - Anticoagulation therapy with combined low dose aspirin and warfarin following 
      mechanical heart valve replacement.
PG  - e91-4
LID - 10.1016/j.thromres.2011.07.006 [doi]
AB  - INTRODUCTION: This study was designed to evaluate safety and efficacy of combined 
      low dose aspirin and warfarin therapy following mechanical heart valve 
      replacement. METHODS: A total of 1496 patients (686 males, mean age 35±8.5 years) 
      undergoing mechanical heart valvular replacement were randomly divided into study 
      (warfarin plus 75-100 mg aspirin) or control (warfarin only) group. International 
      normalized ratio (INR) and prothrombin time was maintained at 1.8-2.5 and 1.5-2.0 
      times of the normal value, respectively. Thromboembolic events and major 
      bleedings were registered during follow up. RESULTS: Patients were followed up 
      for 24±9 months. The average dose of warfarin in the study and control group was 
      2.92±0.87 mg and 2.89±0.79 mg, respectively (p>0.05). The overall thromboembolic 
      events in study group were lower than in control group (2.1% vs. 3.6%, p=0.044). 
      No statistically significant differences were found in hemorrhage events (3.5% 
      vs. 3.7%, p>0.05) or mortality (0.3% vs 0.4%, p>0.05) between the two groups. 
      CONCLUSIONS: Following mechanical valve replacement, combined low dose aspirin 
      and warfarin therapy was associated with a greater reduction in thromboembolism 
      events than warfarin therapy alone. This combined treatment was not associated 
      with an increase in the rate of major bleeding or mortality.
CI  - Crown Copyright © 2011. Published by Elsevier Ltd. All rights reserved.
FAU - Dong, Ming-Feng
AU  - Dong MF
AD  - Department of Cardiac Surgery, Liaocheng People's Hospital and Liaocheng Clinical 
      School of Taishan Medical University, Liaocheng, Shandong, 252000, P.R. China.
FAU - Ma, Zeng-Shan
AU  - Ma ZS
FAU - Ma, Sheng-Jun
AU  - Ma SJ
FAU - Chai, Shou-Dong
AU  - Chai SD
FAU - Tang, Pei-Zhe
AU  - Tang PZ
FAU - Yao, Dao-Kuo
AU  - Yao DK
FAU - Wang, Le-Xin
AU  - Wang LX
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20110803
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Female
MH  - Heart Valve Prosthesis Implantation/*adverse effects
MH  - Hemorrhage/drug therapy/prevention & control
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Prothrombin Time
MH  - Thromboembolism/drug therapy/prevention & control
MH  - Treatment Outcome
MH  - Warfarin/administration & dosage/therapeutic use
MH  - Young Adult
EDAT- 2011/08/05 06:00
MHDA- 2012/03/23 06:00
CRDT- 2011/08/05 06:00
PHST- 2011/05/17 00:00 [received]
PHST- 2011/06/29 00:00 [revised]
PHST- 2011/07/05 00:00 [accepted]
PHST- 2011/08/05 06:00 [entrez]
PHST- 2011/08/05 06:00 [pubmed]
PHST- 2012/03/23 06:00 [medline]
AID - S0049-3848(11)00352-5 [pii]
AID - 10.1016/j.thromres.2011.07.006 [doi]
PST - ppublish
SO  - Thromb Res. 2011 Nov;128(5):e91-4. doi: 10.1016/j.thromres.2011.07.006. Epub 2011 
      Aug 3.

PMID- 3046645
OWN - NLM
STAT- MEDLINE
DCOM- 19881024
LR  - 20190503
IS  - 0007-0769 (Print)
IS  - 0007-0769 (Linking)
VI  - 60
IP  - 2
DP  - 1988 Aug
TI  - Long term clinical outcome of coronary surgery and assessment of the benefit 
      obtained with postoperative aspirin and dipyridamole.
PG  - 111-6
AB  - Three hundred and twenty patients originally entered into a randomised study to 
      assess the effect of aspirin and dipyridamole on the patency of coronary bypass 
      grafts one year after operation were clinically reassessed a mean of 6.6 years 
      (range 4.3-8.6) after operation. Patients were recruited between 1978 and 1982 
      after the present policy of total revascularisation had been adopted. During the 
      follow up period there were 25 deaths of which 17 were due to cardiac causes 
      (average annual cardiac mortality 0.8%). Of 280 patients available for contact, 
      250 (89.3%) attended an outpatient interview. Ninety four (37.6%) patients 
      complained of recurrent angina but in only 23 (9.2%) was this severe. Two hundred 
      and eleven (84.4%) of the 250 patients underwent exercise stress testing. There 
      were 73 (34.6%) abnormal tests of which 52 were in the group of 94 patients with 
      recurrent angina. Myocardial infarction occurred in nine of the 250 patients 
      during the follow up period. Twenty six patients (10.4%) had reinvestigation for 
      symptoms. This group had a graft occlusion rate of 52%. Half these patients have 
      required reoperation and 20 of 22 occluded or severely stenosed grafts were 
      replaced. In only two instances were vein grafts inserted into vessels with new 
      disease. Half of the original group were given aspirin (330 mg three times a day) 
      plus dipyridamole (75 mg three times a day). Of the 250 patients interviewed, 122 
      took aspirin and dipyridamole from the second postoperative day for a mean of 25 
      months, with warfarin for three months. The other 128 patients took placebo for a 
      mean of 23 months together with warfarin for three months. This long term 
      treatment with aspirin plus dipyridamole conferred no significant benefit for all 
      clinical outcomes measured at a mean of 6.6 years.
FAU - Gershlick, A H
AU  - Gershlick AH
AD  - Department of Cardiology, London Chest Hospital.
FAU - Lyons, J P
AU  - Lyons JP
FAU - Wright, J E
AU  - Wright JE
FAU - Sturridge, M F
AU  - Sturridge MF
FAU - Layton, C A
AU  - Layton CA
FAU - Balcon, R
AU  - Balcon R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br Heart J
JT  - British heart journal
JID - 0370634
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina Pectoris/etiology
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - *Coronary Artery Bypass/adverse effects/mortality
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/complications/*prevention & control
MH  - Humans
MH  - Postoperative Care/methods
MH  - Random Allocation
PMC - PMC1216531
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
AID - 10.1136/hrt.60.2.111 [doi]
PST - ppublish
SO  - Br Heart J. 1988 Aug;60(2):111-6. doi: 10.1136/hrt.60.2.111.

PMID- 25858054
OWN - NLM
STAT- MEDLINE
DCOM- 20160722
LR  - 20161125
IS  - 2213-2201 (Electronic)
VI  - 3
IP  - 5
DP  - 2015 Sep-Oct
TI  - Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease.
PG  - 711-8
LID - S2213-2198(15)00120-8 [pii]
LID - 10.1016/j.jaip.2015.03.001 [doi]
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is a chronic illness 
      of progressive recurrent sinus disease with nasal polyps and asthma. No 
      population-based comprehensive surveys of patients with AERD have been carried 
      out to assess specific quality-of-life impact or perceptions of treatment 
      benefit. OBJECTIVE: This survey analyzed perceptions and quality of life in those 
      living with AERD and queried patient observations of treatment effectiveness. The 
      survey assessed whether dietary and nutritional support was used to manage AERD, 
      and if so, whether there was a perceived benefit. METHODS: This survey was 
      publicized through clinics that treat patients with AERD, Web sites, and online 
      blogs. RESULTS: Results are reported for 190 patients. Most subjects reported an 
      adverse effect of AERD on quality of life. Chronic nasal symptoms followed by 
      decreased sense of smell were reported to have the greatest impact on quality of 
      life—in 81 (43%) and 74 (39%), respectively. Those who lost their ability to 
      smell (n = 65; 34%) reported that they missed the enjoyment of food and eating 
      the most. A minority indicated that a combination of medications (aspirin, 
      leukotriene receptor antagonist, zileuton, or omalizumab) was more effective than 
      1 alone. Of those surveyed, 120 (63%) respondents felt that components of their 
      diet contributed to their disease and 147 (77%) respondents reported having 
      reactions after alcohol consumption. CONCLUSIONS: Patients with AERD live with 
      frustration and report a poor quality of life in spite of several pharmacologic 
      treatments including aspirin desensitization followed by daily aspirin. Despite 
      ongoing medical therapy, the burden of disease in AERD remains high.
CI  - Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Ta, Von
AU  - Ta V
AD  - Scripps Clinic, San Diego, Calif. Electronic address: ta.von@scrippshealth.org.
FAU - White, Andrew A
AU  - White AA
AD  - Scripps Clinic, San Diego, Calif.
LA  - eng
PT  - Journal Article
DEP - 20150407
PL  - United States
TA  - J Allergy Clin Immunol Pract
JT  - The journal of allergy and clinical immunology. In practice
JID - 101597220
RN  - 0 (Allergens)
RN  - 2P471X1Z11 (Omalizumab)
RN  - R16CO5Y76E (Aspirin)
RN  - V1L22WVE2S (zileuton)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
CIN - J Allergy Clin Immunol Pract. 2015 Sep-Oct;3(5):719-20. PMID: 26362552
MH  - Adult
MH  - Alcohol Drinking/adverse effects
MH  - Allergens/immunology
MH  - Aspirin/administration & dosage/adverse effects/immunology
MH  - Asthma, Aspirin-Induced/*diagnosis/therapy
MH  - Chronic Disease
MH  - Drug Interactions
MH  - *Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Hydroxyurea/administration & dosage/adverse effects/analogs & derivatives
MH  - *Immunotherapy
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/*diagnosis/etiology/therapy
MH  - Omalizumab/administration & dosage/adverse effects
MH  - Quality of Life
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Aspirin-exacerbated respiratory disease
OT  - Aspirin-induced asthma
OT  - Desensitization
OT  - Quality of life
OT  - Survey
EDAT- 2015/04/11 06:00
MHDA- 2016/07/23 06:00
CRDT- 2015/04/11 06:00
PHST- 2015/01/08 00:00 [received]
PHST- 2015/02/25 00:00 [revised]
PHST- 2015/03/02 00:00 [accepted]
PHST- 2015/04/11 06:00 [entrez]
PHST- 2015/04/11 06:00 [pubmed]
PHST- 2016/07/23 06:00 [medline]
AID - S2213-2198(15)00120-8 [pii]
AID - 10.1016/j.jaip.2015.03.001 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol Pract. 2015 Sep-Oct;3(5):711-8. doi: 
      10.1016/j.jaip.2015.03.001. Epub 2015 Apr 7.

PMID- 3582479
OWN - NLM
STAT- MEDLINE
DCOM- 19870716
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 32
IP  - 2
DP  - 1987
TI  - Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid 
      arthritis.
PG  - 153-8
AB  - The pharmacokinetics of salicyl phenolic glucuronide (SPG) and other salicylic 
      acid (SA) metabolites were studied at three aspirin dosage regimens in eight 
      patients with rheumatoid arthritis. Each patient received 1, 2 and 4 g enteric 
      coated aspirin (ASA) daily in ascending order. At the end of each 2-week dosage 
      period, plasma and urine were collected over a dosage interval for the estimation 
      of various pharmacokinetic parameters. With increasing ASA dosage, mean clearance 
      of SA to SPG was approximately constant (1.8 +/- 0.3, 1.7 +/- 0.2, and 1.5 +/- 
      0.2 ml/min at 1, 2 and 4 g/day, respectively) when related to plasma 
      concentrations of total SA. The percentage of the ASA dosage recovered in urine 
      as SPG increased from 5.2 +/- 1.1 to 7.1 +/- 1.1 to 10.5 +/- 1.7 at 1, 2 and 4 
      g/day, respectively. It was concluded, however, that the conversion of SA to SPG 
      is saturable, since the mean clearance of SA to SPG decreased when calculated 
      with respect to the plasma concentration of unbound SA (13.4 +/- 1.6, 11.0 +/- 
      1.4, and 6.6 +/- 1.9 ml/min at 1, 2 and 4 g/day, respectively). The kinetics of 
      the formation and excretion of salicylurate and the excretion of gentisate were 
      similar to those found in previous studies.
FAU - Bochner, F
AU  - Bochner F
FAU - Graham, G G
AU  - Graham GG
FAU - Polverino, A
AU  - Polverino A
FAU - Imhoff, D M
AU  - Imhoff DM
FAU - Tregenza, R A
AU  - Tregenza RA
FAU - Rolan, P E
AU  - Rolan PE
FAU - Cleland, L G
AU  - Cleland LG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Glucuronates)
RN  - 0 (Salicylates)
RN  - 7695-70-7 (1-salicylate glucuronide)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/drug therapy/*metabolism
MH  - Aspirin/administration & dosage/metabolism/therapeutic use
MH  - Female
MH  - Glucuronates/*metabolism/urine
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - Salicylates/blood/*metabolism/urine
MH  - Salicylic Acid
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1007/BF00542188 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1987;32(2):153-8. doi: 10.1007/BF00542188.

PMID- 22564296
OWN - NLM
STAT- MEDLINE
DCOM- 20121227
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 18
IP  - 21
DP  - 2012
TI  - Antiplatelet therapy in children: why so different from adults'?
PG  - 3019-33
AB  - Antiplatelet agents are administered in the treatment of a large number of adult 
      diseases: coronary heart disease, ischemic stroke, peripheral arterial disease, 
      arrhythmias with their thromboembolic complications, primary and secondary 
      prevention. In childhood however, the situation is substantially different. The 
      lack of large interventional trials on the use of antiplatelet drugs in children, 
      has led to greater uncertainty, and a less extensive use of these drugs, limited 
      to fewer indications. The purpose of this article was to review the studies 
      conducted to date on the use of antiplatelet agents in children. A concerted 
      effort has been made to identify which are the shared therapeutic indications of 
      this class of compounds, the recommended dose, the contraindications and the 
      possible side effects. In brief, an attempt has been made to ascertain the 
      interesting potential of these drugs which are so often neglected in children.
FAU - Bassareo, Pier Paolo
AU  - Bassareo PP
AD  - Department of Cardiovascular and Neurological Sciences, University of Cagliari, 
      Italy. piercard@inwind.it
FAU - Fanos, Vassilios
AU  - Fanos V
FAU - Iacovidou, Nicoletta
AU  - Iacovidou N
FAU - Mercuro, Giuseppe
AU  - Mercuro G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Platelets/cytology/*physiology
MH  - Child Development
MH  - Child, Preschool
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Pediatrics/methods
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Reye Syndrome/*chemically induced/physiopathology
MH  - Thrombosis/*drug therapy
EDAT- 2012/05/09 06:00
MHDA- 2012/12/28 06:00
CRDT- 2012/05/09 06:00
PHST- 2011/11/13 00:00 [received]
PHST- 2011/12/20 00:00 [accepted]
PHST- 2012/05/09 06:00 [entrez]
PHST- 2012/05/09 06:00 [pubmed]
PHST- 2012/12/28 06:00 [medline]
AID - CPD-EPUB-20120503-003 [pii]
AID - 10.2174/1381612811209023019 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2012;18(21):3019-33. doi: 10.2174/1381612811209023019.

PMID- 10405650
OWN - NLM
STAT- MEDLINE
DCOM- 19990728
LR  - 20190722
IS  - 0846-5371 (Print)
IS  - 0846-5371 (Linking)
VI  - 50
IP  - 3
DP  - 1999 Jun
TI  - Transrectal ultrasound-guided biopsy of the prostate: relation between ASA use 
      and bleeding complications.
PG  - 173-6
AB  - OBJECTIVE: To determine the relation between ASA ingestion and the incidence of 
      bleeding complications after transrectal ultrasound (TRUS)-guided biopsy of the 
      prostate. METHODS: Overall, 1810 patients with suspected prostate disease were 
      followed after biopsy. ASA use was determined before the procedure. A TRUS-guided 
      sextant biopsy was performed and patients were contacted immediately and by 
      follow-up telephone call to determine whether there were any immediate or delayed 
      bleeding complications. RESULTS: Overall, 46 subjects (2.5%) had bleeding 
      complications. Of the 54 subjects reporting current use of ASA, 2 (3.7%) had such 
      complications. This difference was not significant. CONCLUSION: There was no 
      evidence of an association between the use of ASA and postbiopsy bleeding 
      complications.
FAU - Herget, E J
AU  - Herget EJ
AD  - Department of Diagnostic Imaging, Foothills Hospital, Calgary, Alta.
FAU - Saliken, J C
AU  - Saliken JC
FAU - Donnelly, B J
AU  - Donnelly BJ
FAU - Gray, R R
AU  - Gray RR
FAU - Wiseman, D
AU  - Wiseman D
FAU - Brunet, G
AU  - Brunet G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Can Assoc Radiol J
JT  - Canadian Association of Radiologists journal = Journal l'Association canadienne 
      des radiologistes
JID - 8812910
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Biopsy, Needle/*instrumentation
MH  - Endosonography/*instrumentation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Prospective Studies
MH  - Prostate/pathology
MH  - Prostatic Neoplasms/*pathology
MH  - Rectum
MH  - Risk Factors
EDAT- 1999/07/16 00:00
MHDA- 1999/07/16 00:01
CRDT- 1999/07/16 00:00
PHST- 1999/07/16 00:00 [pubmed]
PHST- 1999/07/16 00:01 [medline]
PHST- 1999/07/16 00:00 [entrez]
PST - ppublish
SO  - Can Assoc Radiol J. 1999 Jun;50(3):173-6.

PMID- 17726295
OWN - NLM
STAT- MEDLINE
DCOM- 20071120
LR  - 20221207
IS  - 1340-3478 (Print)
IS  - 1340-3478 (Linking)
VI  - 14
IP  - 4
DP  - 2007 Aug
TI  - Aspirin for primary prevention of atherosclerotic disease in Japan.
PG  - 159-66
AB  - Atherosclerotic disease is the most prevalent cause of death worldwide. The ratio 
      of coronary heart disease/cerebrovascular disease differs between Japan and 
      Western countries and the incidence of hemorrhagic stroke and gastrointestinal 
      bleeding is higher in Japan. Thus, the threshold for aspirin administration for 
      primary prevention has been controversial in Japan. Much anecdotal data from 
      Western countries and from Japan has implied that the threshold for administering 
      aspirin to those with risk factors for coronary heart disease is higher than that 
      recommended in Western countries, and that the potential candidates for primary 
      prevention in Japan seem to be diabetic patients. The Japanese primary Prevention 
      of atherosclerosis with Aspirin for Diabetes (JPAD) trial involving 2,530 
      patients with type 2 diabetes started in December 2002. Compared to other primary 
      prevention trials, this trial offered an acceptable sample size, a standard 
      aspirin dosage, and gender balance. Because stroke is the most significant 
      component of all atherosclerotic diseases in Japan, the impact of primary 
      prevention with aspirin on stroke should be understood. Thus, the JPAD trial 
      should generate reliable data on primary prevention with aspirin for diabetic 
      patients that would also be relevant to other countries.
FAU - Morimoto, Takeshi
AU  - Morimoto T
AD  - Center for Medical Education, Kyoto University Graduate School of Medicine, 
      Japan.
FAU - Nakayama, Masafumi
AU  - Nakayama M
FAU - Saito, Yoshihiko
AU  - Saito Y
FAU - Ogawa, Hisao
AU  - Ogawa H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20070829
PL  - Japan
TA  - J Atheroscler Thromb
JT  - Journal of atherosclerosis and thrombosis
JID - 9506298
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - *Asian People
MH  - Aspirin/*therapeutic use
MH  - Atherosclerosis/*ethnology/*prevention & control
MH  - Humans
MH  - Japan/epidemiology
RF  - 40
EDAT- 2007/08/30 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/08/30 09:00
PHST- 2007/08/30 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/08/30 09:00 [entrez]
AID - JST.JSTAGE/jat/E482 [pii]
AID - 10.5551/jat.e482 [doi]
PST - ppublish
SO  - J Atheroscler Thromb. 2007 Aug;14(4):159-66. doi: 10.5551/jat.e482. Epub 2007 Aug 
      29.

PMID- 8183749
OWN - NLM
STAT- MEDLINE
DCOM- 19940616
LR  - 20190501
IS  - 0032-5473 (Print)
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 70
IP  - 821
DP  - 1994 Mar
TI  - Consultant views on the use of aspirin in acute cerebrovascular disease: 
      implications for clinical trials.
PG  - 185-7
AB  - A questionnaire was sent to all 155 consultant physicians and geriatricians in 
      the Yorkshire region who routinely admit patients with acute stroke in order to 
      ascertain: (a) current opinion regarding the prescription of aspirin to patients 
      with various manifestations of cerebrovascular disease, in particular the timing 
      of initial treatment; and (b) the perceived role of computed tomography (CT) 
      scans in relation to such therapy. The response rate was 81% (126/155). Aspirin 
      was reported to be prescribed routinely by 75% (95/126) of physicians for 
      patients with completed stroke. Amongst those prescribing aspirin, treatment was 
      reported to be initiated routinely within 48 hours of the onset of symptoms by 
      63% (60/95). Only 10% (6/60) of these physicians reported that they would 
      withhold aspirin therapy until the result of a cranial CT scan was known, 
      although 43% (26/60) thought a CT scan was desirable. Our survey, which for 
      logistical reasons is one of opinion rather than actual practice, suggests that 
      aspirin is probably being prescribed acutely (less than 48 hours) after stroke to 
      a significant number of patients and often without a pretreatment CT scan. As 
      with patients who have had a CT scan, the balance of risks and benefits of this 
      practice are unknown. We conclude that it would be ethical for acute treatment 
      trials to allow randomization to aspirin without prior CT scan.
FAU - Kent, J
AU  - Kent J
AD  - Department of Neurology, St James's University Hospital, Leeds, UK.
FAU - Bamford, J
AU  - Bamford J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - *Attitude of Health Personnel
MH  - Cerebrovascular Disorders/diagnostic imaging/*drug therapy
MH  - Clinical Trials as Topic
MH  - Geriatrics
MH  - Humans
MH  - Time Factors
MH  - Tomography, X-Ray Computed
PMC - PMC2397851
EDAT- 1994/03/01 00:00
MHDA- 1994/03/01 00:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 1994/03/01 00:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
AID - 10.1136/pgmj.70.821.185 [doi]
PST - ppublish
SO  - Postgrad Med J. 1994 Mar;70(821):185-7. doi: 10.1136/pgmj.70.821.185.

PMID- 34743317
OWN - NLM
STAT- MEDLINE
DCOM- 20220422
LR  - 20230330
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 111
IP  - 4
DP  - 2022 Apr
TI  - Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet 
      Count and Cytoreductive Therapy in Essential Thrombocythemia.
PG  - 939-949
LID - 10.1002/cpt.2485 [doi]
AB  - Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by 
      enhanced platelet production and thrombotic complications. The inhibition of 
      platelet cyclooxygenase (COX) activity by the standard once-daily aspirin is 
      mostly incomplete due to accelerated thrombopoiesis. The phase II Aspirin 
      Regimens in EsSential thrombocythemia (ARES) trial has recently compared the 
      efficacy of once- vs. twice- or three-times daily low-dose aspirin in inhibiting 
      platelet thromboxane (TX) A(2) production, as reflected by serum (s) TXB(2) 
      measurements. The present substudy characterized the determinants of the highly 
      variable response to the standard aspirin 100 mg once-daily regimen in fully 
      compliant patients with ET and the effects of the experimental dosing regimens on 
      response variability. By multivariable analysis, the platelet count (directly) 
      and cytoreductive treatment (inversely) were significantly associated with 
      sTXB(2) values in 218 patients with ET. However, the platelet count positively 
      correlated with sTXB(2) in patients not being treated with cytoreductive drugs 
      (ρ = 0.51, P < 0.01, n = 84), but not in patients on cytoreduction. Patients in 
      the lowest sTXB(2) quartile were older, more often on cytoreductive drugs, had 
      lower platelet count and Janus-Associated Kinase2 (JAK2)-V617F allele frequency 
      as compared with patients in the upper sTXB(2) quartiles. After 2 weeks of a 
      twice- or 3-times daily aspirin regimen, the association between the platelet 
      count and sTXB(2) became similar in cytoreduced and non-cytoreduced patients. In 
      conclusion, the platelet count appears the strongest determinant of TXA(2) 
      inhibition by once-daily low-dose aspirin in ET, with different patterns 
      depending of cytoreductive treatment. More frequent aspirin dosing restores 
      adequate platelet inhibition and reduces interindividual variability, 
      independently of cytoreduction.
CI  - © 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley 
      Periodicals LLC on behalf of American Society for Clinical Pharmacology and 
      Therapeutics.
FAU - Tosetto, Alberto
AU  - Tosetto A
AD  - Hematology Department, Ospedale San Bortolo, Vicenza, Italy.
FAU - Rocca, Bianca
AU  - Rocca B
AUID- ORCID: 0000-0001-8304-6423
AD  - Department of Safety and Bioethics Section of Pharmacology, Catholic University 
      School of Medicine, Rome, Italy.
AD  - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
FAU - Petrucci, Giovanna
AU  - Petrucci G
AD  - Department of Safety and Bioethics Section of Pharmacology, Catholic University 
      School of Medicine, Rome, Italy.
AD  - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
FAU - Betti, Silvia
AU  - Betti S
AD  - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
FAU - Soldati, Denise
AU  - Soldati D
AD  - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
FAU - Rossi, Elena
AU  - Rossi E
AD  - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
AD  - Department of Radiological and Hematological Sciences, Section of Hematology, 
      Catholic University School of Medicine, Rome, Italy.
FAU - Timillero, Andrea
AU  - Timillero A
AD  - Hematology Project Foundation, Vicenza, Italy.
FAU - Cavalca, Viviana
AU  - Cavalca V
AD  - Centro Cardiologico Monzino, IRCCS, Milano, Italy.
FAU - Porro, Benedetta
AU  - Porro B
AD  - Centro Cardiologico Monzino, IRCCS, Milano, Italy.
FAU - Iurlo, Alessandra
AU  - Iurlo A
AUID- ORCID: 0000-0002-4401-0812
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      University of Milano, Milano, Italy.
FAU - Cattaneo, Daniele
AU  - Cattaneo D
AUID- ORCID: 0000-0002-7571-023X
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      University of Milano, Milano, Italy.
FAU - Bucelli, Cristina
AU  - Bucelli C
AD  - Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      University of Milano, Milano, Italy.
FAU - Dragani, Alfredo
AU  - Dragani A
AD  - Hematology Department, S. Spirito Hospital, Pescara, Italy.
FAU - Di Ianni, Mauro
AU  - Di Ianni M
AD  - Hematology Department, S. Spirito Hospital, Pescara, Italy.
FAU - Ranalli, Paola
AU  - Ranalli P
AD  - Hematology Department, S. Spirito Hospital, Pescara, Italy.
FAU - Palandri, Francesca
AU  - Palandri F
AD  - Dipartimento Attività Integrata, Dipartimento di Oncologia e di Ematologia, 
      Azienda Ospedaliero, Universitaria di Bologna IRCCS Policlinico S. 
      Orsola-Malpighi, Bologna, Italy.
FAU - Vianelli, Nicola
AU  - Vianelli N
AD  - Dipartimento Attività Integrata, Dipartimento di Oncologia e di Ematologia, 
      Azienda Ospedaliero, Universitaria di Bologna IRCCS Policlinico S. 
      Orsola-Malpighi, Bologna, Italy.
FAU - Beggiato, Eloise
AU  - Beggiato E
AD  - Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della 
      Scienza di Torino, Torino, Italy.
FAU - Lanzarone, Giuseppe
AU  - Lanzarone G
AD  - Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della 
      Scienza di Torino, Torino, Italy.
FAU - Ruggeri, Marco
AU  - Ruggeri M
AD  - Hematology Department, Ospedale San Bortolo, Vicenza, Italy.
FAU - Carli, Giuseppe
AU  - Carli G
AD  - Hematology Department, Ospedale San Bortolo, Vicenza, Italy.
FAU - Elli, Elena Maria
AU  - Elli EM
AD  - Division of Haematology and Bone Marrow Transplantation Unit, Ospedale San 
      Gerardo, ASST Monza, Monza, Italy.
FAU - Priolo, Stefania
AU  - Priolo S
AD  - Division of Haematology and Bone Marrow Transplantation Unit, Ospedale San 
      Gerardo, ASST Monza, Monza, Italy.
FAU - Randi, Maria Luigia
AU  - Randi ML
AUID- ORCID: 0000-0001-7945-1864
AD  - Department of Medicine - DIMED, University of Padova, Padova, Italy.
FAU - Bertozzi, Irene
AU  - Bertozzi I
AUID- ORCID: 0000-0003-2888-9596
AD  - Department of Medicine - DIMED, University of Padova, Padova, Italy.
FAU - Loscocco, Giuseppe Gaetano
AU  - Loscocco GG
AD  - Department of Experimental and Clinical Medicine, CRIMM-Center of Research and 
      Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria 
      Careggi, University of Firenze, Firenze, Italy.
FAU - Ricco, Alessandra
AU  - Ricco A
AD  - Department of Emergency and Organ Transplantation (DETO), Hematology Section, 
      University of Bari Aldo Moro, Bari, Italy.
FAU - Specchia, Giorgina
AU  - Specchia G
AD  - University of Bari Aldo Moro, Bari, Italy.
FAU - Vannucchi, Alessandro Maria
AU  - Vannucchi AM
AD  - Department of Experimental and Clinical Medicine, CRIMM-Center of Research and 
      Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria 
      Careggi, University of Firenze, Firenze, Italy.
FAU - Rodeghiero, Francesco
AU  - Rodeghiero F
AD  - Hematology Project Foundation, Vicenza, Italy.
FAU - De Stefano, Valerio
AU  - De Stefano V
AD  - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
AD  - Department of Radiological and Hematological Sciences, Section of Hematology, 
      Catholic University School of Medicine, Rome, Italy.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - Department of Safety and Bioethics Section of Pharmacology, Catholic University 
      School of Medicine, Rome, Italy.
CN  - Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211120
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Clin Pharmacol Ther. 2023 May;113(5):1161. PMID: 36994888
MH  - *Aspirin/administration & dosage
MH  - Cytoreduction Surgical Procedures
MH  - Humans
MH  - Platelet Aggregation Inhibitors
MH  - Platelet Count
MH  - *Thrombocythemia, Essential/drug therapy
MH  - *Thromboxanes
PMC - PMC9299058
COIS- A.T. has received consultant and speaker fees from Bayer AG, Novo‐Nordisk, and 
      Werfen. B.R. has received consultant and speaker fees from Bayer AG, and 
      MedScape. A.I. has received speaker fees from Novartis, Pfizer, and Incyte. 
      A.M.V. has received consultant and speaker fees from AOP Orphan Pharmaceuticals, 
      Celgene, Novartis, Takeda and BMS. V.D.S. has received consultant and speaker 
      fees from Alexion, Amgen, AOP Orphan Pharmaceuticals Celgene, Grifols, Novartis, 
      Takeda, Abbvie, SOBI, and research grants from Novartis. C.P. reports receiving 
      consultant and speaker fees from Acticor Biotech, Amgen, Bayer, GlaxoSmithKline, 
      Eli Lilly, Tremeau, and Zambon; he chairs the Scientific Advisory Board of the 
      International Aspirin Foundation. All other authors declared no competing 
      interests for this work.
EDAT- 2021/11/08 06:00
MHDA- 2022/04/23 06:00
CRDT- 2021/11/07 20:50
PHST- 2021/07/20 00:00 [received]
PHST- 2021/10/27 00:00 [accepted]
PHST- 2021/11/08 06:00 [pubmed]
PHST- 2022/04/23 06:00 [medline]
PHST- 2021/11/07 20:50 [entrez]
AID - CPT2485 [pii]
AID - 10.1002/cpt.2485 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2022 Apr;111(4):939-949. doi: 10.1002/cpt.2485. Epub 2021 
      Nov 20.

PMID- 30178577
OWN - NLM
STAT- MEDLINE
DCOM- 20190228
LR  - 20191210
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 45
IP  - 1
DP  - 2019 Jan
TI  - Does low-dose aspirin improve pregnancy rate in women undergoing frozen-thawed 
      embryo transfer cycle? A pilot double-blind, randomized placebo-controlled trial.
PG  - 156-163
LID - 10.1111/jog.13802 [doi]
AB  - AIM: To evaluate the effect of adjuvant low-dose aspirin therapy on clinical 
      pregnancy rate and uterine perfusion in women undergoing frozen-thawed embryo 
      transfer (FET) cycles. METHODS: This study was performed as a pilot randomized, 
      double-blind placebo-controlled trial, from May 2012 to February 2015. Overall, 
      60 available eligible women who were candidates for FET were randomly assigned to 
      two groups receiving either 100 mg oral aspirin (n =30) or placebo (n =30). The 
      primary outcome measure was clinical pregnancy rate. Secondary outcome measures 
      were pulsatility index (PI), resistance index (RI), implantation rate, live birth 
      rate and miscarriage rate. RESULTS: There was no significant difference in 
      endometrial thickness, PI and RI. However, the study group had higher rates of 
      clinical pregnancy, implantation, live birth (P = 0.042, P = 0.031 and P = 0.007, 
      respectively) and lower rate of miscarriage (P = 0.020) as compared to the 
      control group. Twin birth rate was comparable between the two groups. CONCLUSION: 
      Our pilot study demonstrated that administration of low-dose aspirin in FET 
      cycles results in better pregnancy, implantation and live birth rates without 
      changing the uterine hemodynamics or endometrial thickness. However, further 
      randomized clinical studies in larger populations are needed to confirm these 
      findings.
CI  - © 2018 Japan Society of Obstetrics and Gynecology.
FAU - Madani, Tahereh
AU  - Madani T
AD  - Department of Endocrinology and Female Infertility, Reproductive Biomedicine 
      Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, 
      Iran.
FAU - Ahmadi, Firoozeh
AU  - Ahmadi F
AD  - Department of Reproductive Imaging, Reproductive Biomedicine Research Center, 
      Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
FAU - Jahangiri, Nadia
AU  - Jahangiri N
AUID- ORCID: 0000-0003-4768-1571
AD  - Department of Endocrinology and Female Infertility, Reproductive Biomedicine 
      Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, 
      Iran.
FAU - Bahmanabadi, Akram
AU  - Bahmanabadi A
AD  - Department of Endocrinology and Female Infertility, Reproductive Biomedicine 
      Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, 
      Iran.
FAU - Bagheri Lankarani, Narges
AU  - Bagheri Lankarani N
AD  - Department of Epidemiology and Reproductive Health, Reproductive Biomedicine 
      Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, 
      Iran.
LA  - eng
GR  - Royan Infertility Research Center/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20180903
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - 0 (Hematologic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abortion, Spontaneous/epidemiology
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cryopreservation/statistics & numerical data
MH  - Double-Blind Method
MH  - *Embryo Implantation
MH  - Embryo Transfer/*methods/statistics & numerical data
MH  - Female
MH  - Hematologic Agents/administration & dosage/*pharmacology
MH  - Humans
MH  - *Live Birth/epidemiology
MH  - Outcome Assessment, Health Care/*statistics & numerical data
MH  - Pilot Projects
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Young Adult
OTO - NOTNLM
OT  - aspirin
OT  - frozen-thawed embryo transfer cycle
OT  - pregnancy rate
OT  - pulsatility index
OT  - resistance index
EDAT- 2018/09/05 06:00
MHDA- 2019/03/01 06:00
CRDT- 2018/09/05 06:00
PHST- 2018/02/14 00:00 [received]
PHST- 2018/08/07 00:00 [accepted]
PHST- 2018/09/05 06:00 [pubmed]
PHST- 2019/03/01 06:00 [medline]
PHST- 2018/09/05 06:00 [entrez]
AID - 10.1111/jog.13802 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2019 Jan;45(1):156-163. doi: 10.1111/jog.13802. Epub 2018 
      Sep 3.

PMID- 16776633
OWN - NLM
STAT- MEDLINE
DCOM- 20060926
LR  - 20161018
IS  - 1434-6621 (Print)
IS  - 1434-6621 (Linking)
VI  - 44
IP  - 7
DP  - 2006
TI  - Usefulness of whole blood aggregometry and its comparison with thromboxane 
      generation assay in monitoring acetylsalicylic acid effectiveness--a 
      multiparametric study in rats.
PG  - 853-62
AB  - BACKGROUND: There is a need for consensus concerning universal methodological 
      criteria for detection of suboptimal response to acetylsalicylic acid (ASA) 
      therapy. Therefore, animal models to test for ASA effectiveness remain of 
      interest. Our objective was to verify the usefulness of multiparametric 
      whole-blood impedance aggregometry and thromboxane A(2) generation, which are the 
      most popular techniques used for monitoring of ASA treatment effectiveness. 
      METHODS: Using multiparametric analysis of whole-blood impedance aggregometry, we 
      examined which parameters of platelet aggregation or disaggregation allow for the 
      best discrimination between ASA-treated (4 or 40 mg/kg for 60 days) and 
      non-treated male rats. The effectiveness of ASA-mediated inhibition of platelet 
      cyclooxygenase-1 was verified by determination of plasma thromboxane B(2) and 
      urine 11-dehydro-thromboxane B(2), accepted as reference assays for monitoring of 
      ASA-mediated platelet cyclooxygenase-1 inhibition. RESULTS: Two of the platelet 
      agonists used, collagen (1 mg/L) and arachidonic acid (0.5 mmol/L), allowed 
      discrimination of control and ASA-treated animals, whereas adenosine diphosphate 
      (5 micromol/L) was not effective. It is noteworthy that only ASA-mediated changes 
      in duration of the rising phase for platelet aggregation and the area under the 
      curve for collagen-induced aggregation allowed significant discrimination between 
      low and high ASA dose and remained correlated with the reference parameter, 
      plasma thromboxane B(2). CONCLUSIONS: Analysis of aggregation curves, routinely 
      based only on the amplitude and rate of platelet aggregation, may not be enough 
      discriminative to distinguish between varying ASA doses and treatment schedules.
FAU - Nocun, Marek
AU  - Nocun M
AD  - Department of Hemostasis and Hemostatic Disorders, Medical University of Lodz, 
      University Hospital No. 2, Lodz, Poland.
FAU - Golanski, Jacek
AU  - Golanski J
FAU - Lapshina, Elena
AU  - Lapshina E
FAU - Zavodnik, Leu
AU  - Zavodnik L
FAU - Dobaczewski, Marcin
AU  - Dobaczewski M
FAU - Kazmierczak, Piotr
AU  - Kazmierczak P
FAU - Markuszewski, Leszek
AU  - Markuszewski L
FAU - Zavodnik, Ilya
AU  - Zavodnik I
FAU - Watala, Cezary
AU  - Watala C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine
JID - 9806306
RN  - 0 (Biomarkers)
RN  - 0 (Thromboxanes)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biomarkers
MH  - Blood Platelets/cytology/drug effects/metabolism
MH  - Cell Aggregation/drug effects
MH  - Collagen/pharmacology
MH  - Male
MH  - Nephelometry and Turbidimetry
MH  - Platelet Aggregation/*drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Thromboxanes/*biosynthesis
MH  - Time Factors
EDAT- 2006/06/17 09:00
MHDA- 2006/09/27 09:00
CRDT- 2006/06/17 09:00
PHST- 2006/06/17 09:00 [pubmed]
PHST- 2006/09/27 09:00 [medline]
PHST- 2006/06/17 09:00 [entrez]
AID - 10.1515/CCLM.2006.157 [doi]
PST - ppublish
SO  - Clin Chem Lab Med. 2006;44(7):853-62. doi: 10.1515/CCLM.2006.157.

PMID- 7751513
OWN - NLM
STAT- MEDLINE
DCOM- 19950622
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 95
IP  - 5 Pt 1
DP  - 1995 May
TI  - Steroid-sparing effect of inhaled lysine acetylsalicylate and furosemide in 
      high-dose beclomethasone-dependent asthma.
PG  - 937-43
AB  - BACKGROUND: Inhaled lysine acetylsalicylate and furosemide exert a mutually 
      potentiating protective activity on experimentally induced bronchoconstriction in 
      asthma. OBJECTIVE: Our purpose was to investigate the clinical effectiveness of 
      combined treatment of asthma with inhaled lysine acetylsalicylate and furosemide. 
      METHODS: We performed a randomized, double-blind, crossover study in nine 
      patients with chronic asthma requiring a high dose (2 mg/day) of inhaled 
      beclomethasone for clinical control. Patients were treated with a combination of 
      720 mg inhaled lysine acetylsalicylate and 40 mg furosemide twice daily, or with 
      matched placebo in addition to inhaled steroids. The dose of inhaled steroids was 
      reduced by half every 15 days and eventually suspended unless a patient's 
      respiratory condition worsened. RESULTS: During treatment with placebo, all 
      patients had worsening of asthma at dosages of 1 or 0.5 mg/day beclomethasone 
      (mean +/- SE, 833 +/- 83 micrograms/day). During combined treatment complete 
      suspension of inhaled steroids in two patients and reduction to 0.5 to 0.25 mg in 
      the remaining seven patients (mean, 250 +/- 72 micrograms/day) was achieved, with 
      a mean reduction of 71% +/- 7%. Forced expiratory volume in 1 second, weekly peak 
      expiratory flow rate, symptom score, and bronchodilator intake remained 
      significantly better with combined treatment than with placebo. CONCLUSIONS: 
      Treatment with inhaled lysine acetylsalicylate and furosemide allows a 
      considerable sparing of inhaled steroids without significant side effects in 
      patients with severe asthma.
FAU - Bianco, S
AU  - Bianco S
AD  - Institute of Respiratory and Cardiovascular Diseases, Ospedale S. Raffaele, 
      University of Milan, Italy.
FAU - Vaghi, A
AU  - Vaghi A
FAU - Robuschi, M
AU  - Robuschi M
FAU - Refini, R M
AU  - Refini RM
FAU - Pieroni, M G
AU  - Pieroni MG
FAU - Sestini, P
AU  - Sestini P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - K3Z4F929H6 (Lysine)
RN  - KGZ1SLC28Z (Beclomethasone)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Asthma/*drug therapy
MH  - Beclomethasone/*therapeutic use
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Furosemide/*therapeutic use
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
AID - S0091-6749(95)70092-7 [pii]
AID - 10.1016/s0091-6749(95)70092-7 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1995 May;95(5 Pt 1):937-43. doi: 
      10.1016/s0091-6749(95)70092-7.

PMID- 10937957
OWN - NLM
STAT- MEDLINE
DCOM- 20000824
LR  - 20190513
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 1
IP  - 4
DP  - 1999 Dec
TI  - Antithrombotic therapy in heart failure: a randomized comparison of warfarin vs. 
      aspirin (HELAS).
PG  - 419-23
AB  - It is uncertain whether anti-thrombotic treatment reduces the incidence of 
      thrombo-embolism in patients with heart failure, so there is a need for a large 
      scale controlled study to assess the effects of anti-thrombotic therapy in this 
      setting. We report the design of a randomized controlled multicenter double blind 
      trial examining the effects of aspirin, warfarin and placebo in patients with 
      heart failure on the risk of thrombo-embolism. We planned to recruit 6000 
      patients with heart failure without contraindications to anticoagulants or 
      antiplatelet agents and to follow them for a mean time of 2 years following 
      randomization. The study was planned to determine the rate of thrombo-embolic and 
      haemorrhagic events and death among patients randomized to aspirin, warfarin and 
      placebo, stratified according to the presence or absence of underlying coronary 
      disease. Ancillary studies parallel to the main study will attempt to identify 
      clinical and echocardiographic risk factors for thrombo-embolism and will also 
      examine whether hemostatic or neurohormonal mechanisms contribute to an increase 
      in the risk of thrombo-embolism in patients with heart failure. We hoped that the 
      results of the study would improve the clinical management and cost-effectiveness 
      of treatment for patients with heart failure. However, the recruitment of 
      patients proved more difficult than expected and a number of centers decided not 
      to participate. To avoid a great delay it was decided by the principal 
      investigators and submitted to the executive committee to terminate enrolment in 
      this study when 300 patients had been enrolled, and accept that this is a pilot 
      study.
FAU - Cokkinos, D V
AU  - Cokkinos DV
AD  - Cardiology Department, Medical School, University of Athens, Greece.
FAU - Toutouzas, P K
AU  - Toutouzas PK
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Heart Failure/*complications
MH  - Humans
MH  - Longitudinal Studies
MH  - Middle Aged
MH  - Thromboembolism/complications/*prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2000/08/11 11:00
MHDA- 2000/08/29 11:01
CRDT- 2000/08/11 11:00
PHST- 2000/08/11 11:00 [pubmed]
PHST- 2000/08/29 11:01 [medline]
PHST- 2000/08/11 11:00 [entrez]
AID - S1388-9842(99)00055-0 [pii]
AID - 10.1016/s1388-9842(99)00055-0 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 1999 Dec;1(4):419-23. doi: 10.1016/s1388-9842(99)00055-0.

PMID- 7655719
OWN - NLM
STAT- MEDLINE
DCOM- 19951004
LR  - 20191023
IS  - 0954-6928 (Print)
IS  - 0954-6928 (Linking)
VI  - 6
IP  - 4
DP  - 1995 Apr
TI  - Two-pronged antiplatelet therapy with aspirin and ticlopidine without systemic 
      anticoagulation: an alternative therapeutic strategy after bailout stent 
      implantation.
PG  - 341-5
AB  - BACKGROUND: Intracoronary stent implantation for failed angioplasty is associated 
      with a relatively high incidence of coronary and peripheral complications. On the 
      basis of previous clinical and experimental data, we investigated a protocol of 
      intensive antiplatelet therapy, with aspirin (200 mg) and ticlopidine (500 mg), 
      without oral anticoagulation, and with only periprocedural heparin, after stent 
      implantation. METHODS: Between November 1993 and May 1994, 650 patients underwent 
      balloon angioplasty in our institution. Stent implantation was attempted in 45 
      patients because of acute (58%) or threatened acute (22%) closure, or because the 
      result of the primary angioplasty was inadequate (9%). RESULTS: Stents were 
      successfully implanted in 42 (93%) patients. Two patients were not enrolled in 
      the protocol (referring physician preference in one, metallic heart valve 
      prosthesis in the other). In the remaining 40 patients, two sustained Q-wave 
      infarctions and three sustained non Q-wave infarctions, which were already 
      established at the time of stent implantation. No further clinical events 
      occurred during hospitalization. During follow-up (mean 3.2 months) none of the 
      patients died and none developed unstable angina or myocardial infarction. 
      Ticlopidine-related rash occurred in two patients who were consequently put on 
      warfarin therapy instead. CONCLUSIONS: Antiplatelet therapy with ticlopidine and 
      aspirin, without systemic anticoagulation, appears to be a promising alternative 
      to the classical approach with heparin and warfarin therapy, which requires 
      intensive biological monitoring. This approach considerably simplifies patient 
      management, and it could reduce the need for prolonged hospitalization.
FAU - Van Belle, E
AU  - Van Belle E
AD  - Division of Cardiology B, Hôpital Cardiologique, Lille, France.
FAU - McFadden, E P
AU  - McFadden EP
FAU - Lablanche, J M
AU  - Lablanche JM
FAU - Bauters, C
AU  - Bauters C
FAU - Hamon, M
AU  - Hamon M
FAU - Bertrand, M E
AU  - Bertrand ME
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Coron Artery Dis
JT  - Coronary artery disease
JID - 9011445
RN  - 9005-49-6 (Heparin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Disease/drug therapy/*therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/administration & dosage/therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
MH  - Prognosis
MH  - Prospective Studies
MH  - *Stents
MH  - Ticlopidine/administration & dosage/*therapeutic use
EDAT- 1995/04/01 00:00
MHDA- 1995/04/01 00:01
CRDT- 1995/04/01 00:00
PHST- 1995/04/01 00:00 [pubmed]
PHST- 1995/04/01 00:01 [medline]
PHST- 1995/04/01 00:00 [entrez]
AID - 10.1097/00019501-199504000-00012 [doi]
PST - ppublish
SO  - Coron Artery Dis. 1995 Apr;6(4):341-5. doi: 10.1097/00019501-199504000-00012.

PMID- 37062109
OWN - NLM
STAT- MEDLINE
DCOM- 20230525
LR  - 20230628
IS  - 1872-7603 (Electronic)
IS  - 0165-0378 (Linking)
VI  - 157
DP  - 2023 Jun
TI  - Cell-free fetal DNA impairs trophoblast migration in a TLR9-dependent manner and 
      can be reversed by hydroxychloroquine.
PG  - 103945
LID - S0165-0378(23)00151-1 [pii]
LID - 10.1016/j.jri.2023.103945 [doi]
AB  - Growing evidence suggests a relationship between elevated circulating 
      placental-derived cell-free fetal DNA (cffDNA) and preeclampsia. Hypomethylation 
      of CpG motifs, a hallmark of cffDNA, allows it to activate Toll-like receptor 9 
      (TLR9). Using an in vitro human first trimester extravillous trophoblast cell 
      model, we sought to determine if trophoblast-derived cffDNA and ODN 2216, a 
      synthetic unmethylated CpG oligodeoxynucleotide, directly impacted spontaneous 
      trophoblast migration. The role of the DNA sensors TLR9, AIM2, and cGAS was 
      assessed using the inhibitor A151. To test whether any effects could be reversed 
      by therapeutic agents, trophoblasts were treated with or without cffDNA or ODN 
      2216 with or without aspirin (ASA; a known cGAS inhibitor), aspirin-triggered 
      lipoxin (ATL), or hydroxychloroquine (HCQ; a known TLR9 inhibitor). 
      Trophoblast-derived cffDNA and ODN 2216 reduced trophoblast migration without 
      affecting cell viability. Reduced trophoblast migration in response to cffDNA or 
      ODN 2216 was reversed by A151. cffDNA inhibition of trophoblast migration was 
      reversed by HCQ, while ASA or ATL had no effect. In contrast ODN 2216 inhibition 
      of trophoblast migration was reversed by ASA, ATL and HCQ. Our findings suggest 
      that cffDNA can exert a local effect on placental function by impairing 
      trophoblast migration through activation of innate immune DNA sensors. HCQ, a 
      known TLR9 inhibitor, reversed the effects of cffDNA on trophoblast migration. 
      Greater insights into the molecular underpinnings of how cffDNA impacts 
      placentation can aid in our understanding of the pathogenesis of preeclampsia, 
      and in the development of novel therapeutic approaches for preeclampsia therapy.
CI  - Copyright © 2023 Elsevier B.V. All rights reserved.
FAU - León-Martínez, Daisy
AU  - León-Martínez D
AD  - Department of Obstetrics, Gynecology & Reproductive Sciences, Yale School of 
      Medicine, New Haven, CT, USA.
FAU - Lynn, Tatyana
AU  - Lynn T
AD  - Department of Obstetrics, Gynecology & Reproductive Sciences, Yale School of 
      Medicine, New Haven, CT, USA.
FAU - Abrahams, Vikki M
AU  - Abrahams VM
AD  - Department of Obstetrics, Gynecology & Reproductive Sciences, Yale School of 
      Medicine, New Haven, CT, USA. Electronic address: vikki.abrahams@yale.edu.
LA  - eng
PT  - Journal Article
DEP - 20230405
PL  - Ireland
TA  - J Reprod Immunol
JT  - Journal of reproductive immunology
JID - 8001906
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 0 (Toll-Like Receptor 9)
RN  - 0 (Cell-Free Nucleic Acids)
RN  - 9007-49-2 (DNA)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (TLR9 protein, human)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - Trophoblasts/physiology
MH  - Placenta
MH  - Hydroxychloroquine
MH  - Toll-Like Receptor 9
MH  - *Pre-Eclampsia
MH  - *Cell-Free Nucleic Acids/pharmacology
MH  - Cell Line
MH  - DNA/pharmacology
MH  - Aspirin/pharmacology
OTO - NOTNLM
OT  - Cell-free fetal DNA
OT  - Migration
OT  - Placenta
OT  - Preeclampsia
OT  - TLR9
OT  - Trophoblast
COIS- Declaration of Competing Interest The authors declare that there are no conflicts 
      of interest.
EDAT- 2023/04/17 06:00
MHDA- 2023/05/25 06:42
CRDT- 2023/04/16 18:00
PHST- 2022/10/24 00:00 [received]
PHST- 2023/02/13 00:00 [revised]
PHST- 2023/04/03 00:00 [accepted]
PHST- 2023/05/25 06:42 [medline]
PHST- 2023/04/17 06:00 [pubmed]
PHST- 2023/04/16 18:00 [entrez]
AID - S0165-0378(23)00151-1 [pii]
AID - 10.1016/j.jri.2023.103945 [doi]
PST - ppublish
SO  - J Reprod Immunol. 2023 Jun;157:103945. doi: 10.1016/j.jri.2023.103945. Epub 2023 
      Apr 5.

PMID- 36867398
OWN - NLM
STAT- MEDLINE
DCOM- 20230329
LR  - 20230524
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 83
IP  - 5
DP  - 2023 Apr
TI  - Aspirin for the Prevention of Early and Severe Pre-Eclampsia Recurrence: A 
      Real-World Population-Based Study.
PG  - 429-437
LID - 10.1007/s40265-023-01842-3 [doi]
AB  - BACKGROUND: Many clinical trials have reported that low-dose aspirin decreases 
      the risk of pre-eclampsia in women with prior pre-eclampsia. However, its impact 
      in a real-world population has not been fully assessed. OBJECTIVES: To assess the 
      rates of low-dose aspirin initiation during pregnancy in women with a history of 
      pre-eclampsia, and to evaluate the impact of low-dose aspirin in prevention of 
      pre-eclampsia recurrence in a real-world population. STUDY DESIGN: CONCEPTION is 
      a French nationwide cohort study which uses data from the country's National 
      Health Data System database. We included all women in France who gave birth at 
      least twice between 2010-2018, and who had pre-eclampsia during their first 
      pregnancy. Every dispensing of low-dose aspirin (75-300 mg) between the beginning 
      of their second pregnancy and 36 weeks of gestation (WG) was identified. We used 
      Poisson regression models to estimate the adjusted incidence rate ratios (aIRRs) 
      of receiving aspirin at least once during their second pregnancy. In women who 
      had early and/or severe pre-eclampsia during their first pregnancy, we estimated 
      the IRRs of pre-eclampsia recurrence during their second pregnancy according to 
      the aspirin therapy. RESULTS: In 28,467 women who were included in the study, the 
      aspirin initiation rate during the second pregnancy ranged from 27.8% for women 
      in whose first pregnancy the pre-eclampsia was mild and late, to 79.9% for those 
      women whose pre-eclampsia was severe and early. Just over half (54.3%) of those 
      treated with aspirin-initiated treatment before 16 WG and adhered to treatment. 
      Compared with women with mild and late pre-eclampsia, the aIRRs (95% CI) for 
      receiving aspirin at least once during the second pregnancy were 1.94 (1.86-2.03) 
      for women with severe and late pre-eclampsia, 2.34 (2.17-2.52) for those with 
      early and mild pre-eclampsia, and 2.87 [2.74-3.01] for those with early and 
      severe pre-eclampsia E. Social deprivation was associated with a lower initiation 
      of aspirin (IRR = 0.74 [0.70-0.78]). Aspirin was not associated with a lower risk 
      of mild and late pre-eclampsia, severe and late pre-eclampsia, or mild and early 
      pre-eclampsia during the second pregnancy. The aIRRs for severe and early 
      pre-eclampsia during the second pregnancy were 0.77 (0.62-0.95) for women who 
      received prescribed aspirin at least once, 0.71 (0.5-0.89) for those who 
      initiated aspirin therapy before 16 WG, and 0.60 (0.47-0.77) for those who 
      adhered to aspirin treatment throughout their second pregnancy. The risk of 
      severe and early pre-eclampsia was lower only when the prescribed mean daily dose 
      was ≥ 100 mg/day. CONCLUSION: In women with a history of pre-eclampsia, aspirin 
      initiation during a second pregnancy and adherence to the prescribed dosage were 
      largely insufficient, especially for women experiencing social deprivation. 
      Aspirin initiated before 16 WG at a dose ≥ 100 mg/day was associated with a lower 
      risk of severe and early pre-eclampsia.
CI  - © 2023. The Author(s).
FAU - Lailler, Grégory
AU  - Lailler G
AUID- ORCID: 0000-0001-6838-8804
AD  - Santé publique France, Saint-Maurice, France. 
      gregory.lailler@santepubliquefrance.fr.
AD  - Université Paris Est, Créteil, France. gregory.lailler@santepubliquefrance.fr.
FAU - Grave, Clémence
AU  - Grave C
AD  - Santé publique France, Saint-Maurice, France.
FAU - Gabet, Amélie
AU  - Gabet A
AD  - Santé publique France, Saint-Maurice, France.
FAU - Regnault, Nolwenn
AU  - Regnault N
AD  - Santé publique France, Saint-Maurice, France.
FAU - Deneux-Tharaux, Catherine
AU  - Deneux-Tharaux C
AD  - Obstetrical Perinatal and Pediatric Epidemiology Research Team, EPOPé, Centre for 
      Epidemiology and Statistics Sorbonne Paris Cité (CRESS), INSERM, Paris, France.
AD  - Université Paris Cité, Paris, France.
FAU - Kretz, Sandrine
AU  - Kretz S
AD  - Centre de diagnostic et de thérapeutique, Hôtel Dieu, AP-HP, Paris, France.
FAU - Tsatsaris, Vassilis
AU  - Tsatsaris V
AD  - Université Paris Cité, Paris, France.
AD  - Maternité Port-Royal, FHU PREMA, Assistance Publique Hôpitaux de Paris, Hôpital 
      Cochin, Paris, France.
FAU - Plu-Bureau, Geneviève
AU  - Plu-Bureau G
AD  - Obstetrical Perinatal and Pediatric Epidemiology Research Team, EPOPé, Centre for 
      Epidemiology and Statistics Sorbonne Paris Cité (CRESS), INSERM, Paris, France.
AD  - Université Paris Cité, Paris, France.
AD  - Unité de gynécologie médicale, APHP, Hôpital Port-Royal Cochin, Paris, France.
FAU - Blacher, Jacques
AU  - Blacher J
AD  - Université Paris Cité, Paris, France.
AD  - Centre de diagnostic et de thérapeutique, Hôtel Dieu, AP-HP, Paris, France.
FAU - Olie, Valérie
AU  - Olie V
AD  - Santé publique France, Saint-Maurice, France.
LA  - eng
PT  - Journal Article
DEP - 20230303
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - *Pre-Eclampsia/drug therapy/prevention & control/epidemiology
MH  - Cohort Studies
MH  - Platelet Aggregation Inhibitors/therapeutic use
PMC - PMC10042896
COIS- S.K. reports, outside the submitted work, nonfinancial support from Lilly France, 
      Novo Nordisk, Novartis Pharma, Roche diabetes care, Lifescan, Abbott France, 
      Sanofi, ViiV Healthcare, Servier, Becton Dickinson, and personal fees from 
      Icomed, Pascaleo, BT3SI, M3global research. J.B. reports, outside the submitted 
      work, personal fees from Abbott, Bayer, Bottu, Ferring, Steripharma, Kantar, 
      Teriak, personal fees and non-financial support from Pfizer, Quantum Genomics, 
      personal fees from Sanofi and Servier. All other authors (GL, CG, AG, NR, CDT, 
      VT, GPB, JB, and VO) declare no conflict of interest that might be relevant to 
      this work.
EDAT- 2023/03/04 06:00
MHDA- 2023/03/29 06:05
CRDT- 2023/03/03 11:22
PHST- 2023/01/31 00:00 [accepted]
PHST- 2023/03/29 06:05 [medline]
PHST- 2023/03/04 06:00 [pubmed]
PHST- 2023/03/03 11:22 [entrez]
AID - 10.1007/s40265-023-01842-3 [pii]
AID - 1842 [pii]
AID - 10.1007/s40265-023-01842-3 [doi]
PST - ppublish
SO  - Drugs. 2023 Apr;83(5):429-437. doi: 10.1007/s40265-023-01842-3. Epub 2023 Mar 3.

PMID- 37315243
OWN - NLM
STAT- MEDLINE
DCOM- 20230616
LR  - 20230616
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 123
IP  - 5
DP  - 2023
TI  - [Acetylsalicylic acid in primary and secondary prevention of atherosclerotic 
      cardiovascular disease].
PG  - 58-64
LID - 10.17116/jnevro202312305158 [doi]
AB  - The article is devoted to an urgent problem - primary and secondary prevention of 
      atherosclerotic cardiovascular diseases. Modern approaches to management tactics 
      depending on age and the appointment of antiplatelet therapy with acetylsalicylic 
      acid in low doses from 75 to 150 mg/day are presented. At the same time, the 
      relatively high effectiveness of the use of ASA for primary prevention in men 
      40-69 years old without an increased risk of bleeding from the gastrointestinal 
      tract is shown. Low doses of ASA provide little benefit in reducing the risk of 
      CVD in people 40 years and older, when there is no history of CVD, but at the 
      same time they are at increased risk of CVD.
FAU - Oynotkinova, O Sh
AU  - Oynotkinova OS
AUID- ORCID: 0000-0002-9856-8643
AD  - Research Institute of Health Organization and Medical Management, Moscow, Russia.
AD  - Central State Medical Academy of the Office of the President of the Russian 
      Federation, Moscow, Russia.
FAU - Matskeplishvili, S T
AU  - Matskeplishvili ST
AUID- ORCID: 0000-0002-5670-167X
AD  - Lomonosov Moscow State University, Moscow, Russia.
FAU - Maslennikova, O M
AU  - Maslennikova OM
AUID- ORCID: 0000-0001-9599-7381
AD  - Central State Medical Academy of the Office of the President of the Russian 
      Federation, Moscow, Russia.
FAU - Pavlov, A I
AU  - Pavlov AI
AUID- ORCID: 0000-0003-1836-7946
AD  - National Medical Research Center for High Medical Technologies - Vishnevsky 
      Central Military Clinical Hospital, Krasnogorsk, Russia.
FAU - Poberezhskaya, A G
AU  - Poberezhskaya AG
AUID- ORCID: 0009-0003-5054-3302
AD  - Sochi Central Clinical Hospital, Sochi, Russia.
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Primenenie atsetilsalitsilovoi kisloty pri pervichnoi i vtorichnoi profilaktike 
      ateroskleroticheskikh serdechno-sosudistykh zabolevanii.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Male
MH  - Humans
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - Secondary Prevention
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - *Atherosclerosis/prevention & control
MH  - Gastrointestinal Tract
OTO - NOTNLM
OT  - atherosclerotic cardiovascular diseases
OT  - intestinal soluble acetylsalicylic acid
OT  - ischemic stroke
OT  - low doses
OT  - primary
OT  - secondary prevention
EDAT- 2023/06/14 19:10
MHDA- 2023/06/16 06:42
CRDT- 2023/06/14 15:59
PHST- 2023/06/16 06:42 [medline]
PHST- 2023/06/14 19:10 [pubmed]
PHST- 2023/06/14 15:59 [entrez]
AID - 10.17116/jnevro202312305158 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(5):58-64. doi: 
      10.17116/jnevro202312305158.

PMID- 23291440
OWN - NLM
STAT- MEDLINE
DCOM- 20130709
LR  - 20161125
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 76
DP  - 2013 Mar 25
TI  - In situ monitoring of powder blending by non-invasive Raman spectrometry with 
      wide area illumination.
PG  - 28-35
LID - S0731-7085(12)00665-6 [pii]
LID - 10.1016/j.jpba.2012.12.003 [doi]
AB  - A 785nm diode laser and probe with a 6mm spot size were used to obtain spectra of 
      stationary powders and powders mixing at 50rpm in a high shear convective 
      blender. Two methods of assessing the effect of particle characteristics on the 
      Raman sampling depth for microcrystalline cellulose (Avicel), aspirin or sodium 
      nitrate were compared: (i) the information depth, based on the diminishing Raman 
      signal of TiO(2) in a reference plate as the depth of powder prior to the plate 
      was increased, and (ii) the depth at which a sample became infinitely thick, 
      based on the depth of powder at which the Raman signal of the compound became 
      constant. The particle size, shape, density and/or light absorption capability of 
      the compounds were shown to affect the "information" and "infinitely thick" 
      depths of individual compounds. However, when different sized fractions of 
      aspirin were added to Avicel as the main component, the depth values of aspirin 
      were the same and matched that of the Avicel: 1.7mm for the "information" depth 
      and 3.5mm for the "infinitely thick" depth. This latter value was considered to 
      be the minimum Raman sampling depth when monitoring the addition of aspirin to 
      Avicel in the blender. Mixing profiles for aspirin were obtained non-invasively 
      through the glass wall of the vessel and could be used to assess how the aspirin 
      blended into the main component, identify the end point of the mixing process 
      (which varied with the particle size of the aspirin), and determine the 
      concentration of aspirin in real time. The Raman procedure was compared to two 
      other non-invasive monitoring techniques, near infrared (NIR) spectrometry and 
      broadband acoustic emission spectrometry. The features of the mixing profiles 
      generated by the three techniques were similar for addition of aspirin to Avicel. 
      Although Raman was less sensitive than NIR spectrometry, Raman allowed compound 
      specific mixing profiles to be generated by studying the mixing behaviour of an 
      aspirin-aspartame-Avicel mixture.
CI  - Copyright © 2013 Elsevier B.V. All rights reserved.
FAU - Allan, Pamela
AU  - Allan P
AD  - WestCHEM, Department of Pure and Applied Chemistry and CPACT, University of 
      Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, UK.
FAU - Bellamy, Luke J
AU  - Bellamy LJ
FAU - Nordon, Alison
AU  - Nordon A
FAU - Littlejohn, David
AU  - Littlejohn D
FAU - Andrews, John
AU  - Andrews J
FAU - Dallin, Paul
AU  - Dallin P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121213
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Nitrates)
RN  - 0 (Powders)
RN  - 15FIX9V2JP (titanium dioxide)
RN  - 8M4L3H2ZVZ (sodium nitrate)
RN  - 9004-34-6 (Cellulose)
RN  - D1JT611TNE (Titanium)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Cellulose/*chemistry
MH  - Drug Compounding
MH  - Lasers, Semiconductor
MH  - Nitrates/*chemistry
MH  - Particle Size
MH  - Powders
MH  - Spectroscopy, Near-Infrared/methods
MH  - Spectrum Analysis, Raman/*methods
MH  - Titanium/chemistry
EDAT- 2013/01/08 06:00
MHDA- 2013/07/10 06:00
CRDT- 2013/01/08 06:00
PHST- 2012/09/02 00:00 [received]
PHST- 2012/12/03 00:00 [revised]
PHST- 2012/12/04 00:00 [accepted]
PHST- 2013/01/08 06:00 [entrez]
PHST- 2013/01/08 06:00 [pubmed]
PHST- 2013/07/10 06:00 [medline]
AID - S0731-7085(12)00665-6 [pii]
AID - 10.1016/j.jpba.2012.12.003 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2013 Mar 25;76:28-35. doi: 10.1016/j.jpba.2012.12.003. Epub 
      2012 Dec 13.

PMID- 809913
OWN - NLM
STAT- MEDLINE
DCOM- 19751228
LR  - 20191028
IS  - 0340-1227 (Print)
IS  - 0340-1227 (Linking)
VI  - 367
IP  - 4
DP  - 1975 Sep 18
TI  - [The effect of acetylsalicylic acid, extremely restricted movement and a 
      cholesterol-rich diet on atheromatosis of the rabbit aorta: comparative 
      investigations (author's transl)].
PG  - 307-23
AB  - A multifactorial model for demonstrating the pathogenesis of the diet-induced 
      atheromatosis of the rabbit is described. We examined the effect of various diets 
      (atherogenetic, rich in fibre, mixed, normal) and of extreme restriction of 
      movement, with and without doses of acetylsalicylic acid. The aorta showed 
      uniforms morphological findings; 1. Acetylsalicilic acid no influence on the 
      cholesterol-induced atheromatosis of the rabbit; 2. An atherogenic diet and a 
      diet rich in raw fibre caused different degrees of sclerosis of the aorta; this 
      was related to the cholesterol content of the mixed diet, which was 50% less than 
      the cholesterol content of the atherogenic diet; 3. Macro- and microscopic 
      examination showed that extreme restriction of movement alone has no demonstrable 
      effect on the aorta of the rabbit; 4. The cholesterol-induced atheromatosis 
      showed significantly less involvement of the aorta when there was extreme 
      restriction of movement in addition to the diet; 5. In none of the test groups 
      could we demonstrate any effect of PAT I on platelet adhesiveness; 6. The test 
      conditions did not result in an activation of the contact phase of the 
      haemocoagulation system.
FAU - Höpker, W W
AU  - Höpker WW
FAU - Hofmann, W
AU  - Hofmann W
FAU - Weiss, J
AU  - Weiss J
FAU - Zimmermann, R
AU  - Zimmermann R
FAU - Walter, E
AU  - Walter E
FAU - Dittmar, H A
AU  - Dittmar HA
FAU - Weizel, A
AU  - Weizel A
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Vergleichende Untersuchungen zur Wirkung von Acetylsalicylsäure, hochgradiger 
      Bewegungseinschränkung und cholesterinreicher Diät auf die Atheromatose der 
      Kaninchenaorta.
PL  - Germany
TA  - Virchows Arch A Pathol Anat Histol
JT  - Virchows Archiv. A, Pathological anatomy and histology
JID - 7505137
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta/drug effects/physiopathology
MH  - Arteriosclerosis/*physiopathology
MH  - Aspirin/*pharmacology
MH  - *Diet, Atherogenic
MH  - *Immobilization
MH  - Male
MH  - Platelet Adhesiveness/drug effects
MH  - Rabbits
OID - NASA: 76035144
EDAT- 1975/09/18 00:00
MHDA- 1975/09/18 00:01
CRDT- 1975/09/18 00:00
PHST- 1975/09/18 00:00 [pubmed]
PHST- 1975/09/18 00:01 [medline]
PHST- 1975/09/18 00:00 [entrez]
AID - 10.1007/BF01239338 [doi]
PST - ppublish
SO  - Virchows Arch A Pathol Anat Histol. 1975 Sep 18;367(4):307-23. doi: 
      10.1007/BF01239338.

PMID- 25300316
OWN - NLM
STAT- MEDLINE
DCOM- 20150814
LR  - 20211021
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Print)
IS  - 1477-9072 (Linking)
VI  - 12
IP  - 11
DP  - 2014 Nov
TI  - PA32540 for the secondary prevention of cardiovascular disease in patients at 
      risk for aspirin-associated gastric ulcers.
PG  - 1251-60
LID - 10.1586/14779072.2014.967214 [doi]
AB  - Prescribed in patients with a history of myocardial infarction, stroke, transient 
      ischemic attack, coronary intervention or bypass surgery, aspirin is one of the 
      medications most commonly used in the secondary prevention of cardiovascular 
      diseases. It has become a mainstay of therapy after years of solid evidence 
      supporting its efficacy in clinical trials. However, a number of risks and side 
      effects accompany its benefits, including the notable risk of bleeding and 
      gastrointestinal side effects. Numerous mechanisms have been proposed to 
      attenuate these effects to promote adherence and to expand the population for 
      which aspirin is a reasonable treatment option. A polypill or combination 
      formulation that includes a proton pump inhibitor, a drug commonly prescribed 
      alongside aspirin, is one potential avenue of therapy. One such combination pill, 
      PA32540, has undergone Phase I and Phase III trials and shows promising safety 
      and efficacy results in these preliminary trials.
FAU - Duffy, Danielle
AU  - Duffy D
AD  - Thomas Jefferson University, Philadelphia, PA 19107, USA.
FAU - Rooney, Bridget
AU  - Rooney B
FAU - Adams, Suzanne
AU  - Adams S
FAU - Whellan, David J
AU  - Whellan DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20141010
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Secondary Prevention
MH  - *Stomach Ulcer/complications/drug therapy
PMC - PMC4743601
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular disease
OT  - omeprazole
OT  - polypill
OT  - secondary prevention
EDAT- 2014/10/11 06:00
MHDA- 2015/08/15 06:00
CRDT- 2014/10/11 06:00
PHST- 2014/10/11 06:00 [entrez]
PHST- 2014/10/11 06:00 [pubmed]
PHST- 2015/08/15 06:00 [medline]
AID - 967214 [pii]
AID - 10.1586/14779072.2014.967214 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2014 Nov;12(11):1251-60. doi: 
      10.1586/14779072.2014.967214. Epub 2014 Oct 10.

PMID- 10829351
OWN - NLM
STAT- MEDLINE
DCOM- 20000608
LR  - 20191104
IS  - 0012-6543 (Print)
IS  - 0012-6543 (Linking)
VI  - 38
IP  - 3
DP  - 2000 Mar
TI  - Tackling myocardial infarction.
PG  - 17-22
AB  - Myocardial infarction is dangerous. Among people in the UK who develop an acute 
      coronary event, in particular myocardial infarction, around 35-40% die within 24 
      hours of the condition's onset and 40-50% within a month. Here, we discuss 
      management up to and following admission to hospital, concentrating on the use of 
      aspirin, thrombolytic therapy, coronary angioplasty, 
      angiotensin-converting-enzyme (ACE) inhibitors and beta-blockers.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Thrombolytic Therapy/methods
RF  - 60
EDAT- 2000/06/01 09:00
MHDA- 2000/06/10 09:00
CRDT- 2000/06/01 09:00
PHST- 2000/06/01 09:00 [pubmed]
PHST- 2000/06/10 09:00 [medline]
PHST- 2000/06/01 09:00 [entrez]
AID - 10.1136/dtb.2000.38317 [doi]
PST - ppublish
SO  - Drug Ther Bull. 2000 Mar;38(3):17-22. doi: 10.1136/dtb.2000.38317.

PMID- 666518
OWN - NLM
STAT- MEDLINE
DCOM- 19780828
LR  - 20131121
IS  - 0003-9055 (Print)
IS  - 0003-9055 (Linking)
VI  - 32
IP  - 2
DP  - 1978
TI  - [Effect of aspirin and indomethacin on changes caused by Pateurella multocida 
      toxins in calves].
PG  - 247-50
AB  - Acetylsalicyclic acid acid (50 mg/kg die) and indomethacin (1.5 mg/kg die) were 
      administered to calves three days prior to intravenous application of endotoxin. 
      Such treatment resulted in delayed occurence of clinical symptoms and higher 
      survival rates, as compared to untreated controls. Parameters relating to 
      coagulation physiology, changed by endotoxin, were not controllable with 
      statistical security by administration of acetylsalicyclic acid indomethacin.
FAU - Schimmel, I
AU  - Schimmel I
FAU - Schimmel, D
AU  - Schimmel D
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Beeinflussung der durch Pasteurella-multocida-Endotoxin veru-sachten 
      Veränderungen bei Kälbern durch Azetylsalizylsäure und Indometazin.
PL  - Germany
TA  - Arch Exp Veterinarmed
JT  - Archiv fur experimentelle Veterinarmedizin
JID - 0372410
RN  - 0 (Bacterial Toxins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Bacterial Toxins/*poisoning
MH  - Cattle
MH  - Female
MH  - Indomethacin/*therapeutic use
MH  - Male
MH  - Pasteurella/immunology
MH  - Poisoning/*prevention & control
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
PST - ppublish
SO  - Arch Exp Veterinarmed. 1978;32(2):247-50.

PMID- 15580145
OWN - NLM
STAT- MEDLINE
DCOM- 20050201
LR  - 20220331
IS  - 1533-001X (Print)
IS  - 1533-001X (Linking)
VI  - 4 Suppl 4
DP  - 2004
TI  - Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice 
      or necessary?
PG  - S33-41
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for their 
      anti-inflammatory, analgesic, and anti-pyretic effects, whereas low-dose aspirin 
      (also an NSAID) is used for cardiovascular prophylaxis. The main concern limiting 
      use of these drugs is their gastrointestinal (GI) toxicity. GI side effects 
      include ulcers (found at endoscopy in 15%-30% of patients using NSAIDs 
      regularly), complications such as upper GI bleeding (annual incidence of 
      1.0%-1.5%), and development of upper GI symptoms such as dyspepsia (occurring in 
      up to 60% of patients taking NSAIDs). Histamine-2 receptor antagonists are not 
      effective at preventing NSAID-induced gastric ulcers when used at standard doses, 
      although they can decrease upper GI symptoms. Misoprostol effectively decreases 
      NSAID-induced ulcers and GI complications but is used infrequently in the United 
      States-perhaps because of issues of compliance (multiple daily doses) and side 
      effects (eg, diarrhea, dyspepsia). Once-daily proton pump inhibitor (PPI) therapy 
      also decreases the development of NSAID-associated ulcers and recurrent 
      NSAID-related ulcer complications; it also decreases upper GI symptoms in NSAID 
      users. In patients using aspirin, the addition of a cyclooxygenase-2-specific 
      inhibitor appears to significantly increase GI risk to the level of a 
      nonselective NSAID; aspirin plus a nonselective NSAID appears to increase GI risk 
      still higher. Patients taking low-dose aspirin who have risk factors for GI 
      complications (including concomitant nonselective NSAID therapy) should receive 
      medical co-therapy, such as a PPI.
FAU - Laine, Loren
AU  - Laine L
AD  - Division of Gastrointestinal & Liver Diseases, Department of Medicine, University 
      of Southern California School of Medicine, Los Angeles, California, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Rev Gastroenterol Disord
JT  - Reviews in gastroenterological disorders
JID - 101140143
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0E43V0BB57 (Misoprostol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cyclooxygenase Inhibitors/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Misoprostol/therapeutic use
MH  - *Proton Pump Inhibitors
MH  - Risk Factors
MH  - Stomach Ulcer/chemically induced/drug therapy/epidemiology
RF  - 47
EDAT- 2004/12/08 09:00
MHDA- 2005/02/03 09:00
CRDT- 2004/12/08 09:00
PHST- 2004/12/08 09:00 [pubmed]
PHST- 2005/02/03 09:00 [medline]
PHST- 2004/12/08 09:00 [entrez]
PST - ppublish
SO  - Rev Gastroenterol Disord. 2004;4 Suppl 4:S33-41.

PMID- 10776056
OWN - NLM
STAT- MEDLINE
DCOM- 20000518
LR  - 20131121
IS  - 1661-8157 (Print)
IS  - 1661-8157 (Linking)
VI  - 89
IP  - 13
DP  - 2000 Mar 23
TI  - [Transient ischemic attacks and prolonged reversible ischemic neurologic deficit. 
      Diagnosis, differential diagnosis and treatment].
PG  - 542-8
AB  - Cerebral and ocular ischemic events are classified according to their duration 
      and localisation in transient (< 24 hours) or permanent (> or = 24 hours) 
      cerebral (transient ischemic attack (TIA), cerebral infarct) and ocular 
      (amaurosis fugax, retinal infarct) deficits. The terms "Prolonged Reversible 
      Ischemic Neurological Deficit" (PRIND, > or = 24 hours to < or = 7 days) and 
      "Reversible Ischemic Neurological Deficit" (RIND, > or = 24 hours to < or = 3 
      days) are no longer used. The differential diagnosis of TIAs and ischemic strokes 
      is discussed. Ischemic strokes are an emergency and should be referred within 
      five hours at the latest to a centre, which offers around the clock acute 
      therapies such as fibrinolysis and an organised stroke management. Secondary 
      stroke prevention after TIA or stroke encompasses the treatment of vascular risk 
      factors, carotid endarterectomy, anticoagulation in the presence of cardiac 
      embolism (target international normalised ratio, 2.5; range 2.0-3.0) and the 
      administration of platelet inhibitors. Carotid endarterectomy is indicated, when 
      luminal narrowing is at least 70%, and not indicated when it is less than 50%. 
      The benefit of endarterectomy in 50-69% stenoses decreases, and individual 
      predictors of the operation risk are useful for choosing the appropriate 
      treatment. Patients without indication for carotid endarterectomy or oral 
      anticoagulation are treated with platelet inhibitors. We use the combination 
      dipyridamole-aspirin as first choice drug, because it has been shown to be 
      superior to aspirin and dipyridamole alone. In the presence of adverse effects or 
      contraindications for dipyridamole we prescribe aspirin (100-300 mg daily). We 
      administer clopidogrel (75 mg daily) if dipyridamole and aspirin are not 
      indicated, have caused adverse effects, or did not prevent ocular or cerebral 
      ischemic events.
FAU - Mosso, M
AU  - Mosso M
AD  - Neurologische Klinik, UniversitätsSpital, Zürich.
FAU - Baumgartner, R W
AU  - Baumgartner RW
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Transiente ischämische Attacke und prolongiertes reversibles ischämisches 
      neurologisches Defizit. Diagnose, Differentialdiagnose und Behandlung.
PL  - Switzerland
TA  - Praxis (Bern 1994)
JT  - Praxis
JID - 101468093
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - Brain Ischemia/*diagnosis/therapy
MH  - Cerebral Infarction/diagnosis/surgery
MH  - Diagnosis, Differential
MH  - Dipyridamole/administration & dosage/adverse effects
MH  - Endarterectomy, Carotid
MH  - Humans
MH  - Ischemic Attack, Transient/*diagnosis/therapy
MH  - Neurologic Examination
RF  - 48
EDAT- 2000/04/25 09:00
MHDA- 2000/05/20 09:00
CRDT- 2000/04/25 09:00
PHST- 2000/04/25 09:00 [pubmed]
PHST- 2000/05/20 09:00 [medline]
PHST- 2000/04/25 09:00 [entrez]
PST - ppublish
SO  - Praxis (Bern 1994). 2000 Mar 23;89(13):542-8.

PMID- 36946460
OWN - NLM
STAT- MEDLINE
DCOM- 20230718
LR  - 20230718
IS  - 1523-5378 (Electronic)
IS  - 1083-4389 (Linking)
VI  - 28
IP  - 4
DP  - 2023 Aug
TI  - Preventive effect of Helicobacter pylori eradication on the coronary heart 
      diseases depending on age and sex with a median follow-up of 51 months.
PG  - e12969
LID - 10.1111/hel.12969 [doi]
AB  - BACKGROUND: The association between Helicobacter pylori (HP) infection and 
      coronary heart disease (CHD) is controversial. This study aimed to investigate 
      the effect of H. pylori eradication on CHD, especially in terms of age and sex. 
      MATERIALS AND METHODS: From May 2003 to March 2022, 4765 subjects with H. pylori 
      infection and without CHD (median follow-up: 51 months) were prospectively 
      enrolled. The participants were categorized into two groups: H. pylori 
      eradication and H. pylori non-eradication. After propensity-score matching (PSM), 
      the effect of H. pylori eradication on CHD was analyzed using Cox proportional 
      hazards. RESULTS: There were no significant differences in age, sex, alcohol 
      consumption, smoking habits, history of diabetes, hypertension, and dyslipidemia, 
      and aspirin intake between the eradication and non-eradication groups (3783 vs. 
      982) before and after PSM. Multivariate analysis after PSM showed that H. pylori 
      eradication (HR: 0.489, CI: 0.314-0.761, p = .002), age (HR: 1.027, CI: 
      1.007-1.047, p = .007), hypertension (HR: 2.133, CI: 1.337-3.404, p = 001), 
      dyslipidemia (HR: 1.758, CI: 1.086-2.848, p = .022), and aspirin intake (HR: 
      2.508, CI: 1.566-4.017, p < .001) were associated with CHD development. H. pylori 
      eradication prevented CHD in males ≤65 years (HR: 0.133, CI: 0.039-0.455, 
      p = .001), but not in those aged >65 years (p = .078) (p for interaction = .022). 
      In contrast, females aged >65 years (HR: 0.260, CI: 0.110-0.615, p = .002) were 
      protected by H. pylori eradication and not those ≤65 years (p = .485) (p for 
      interaction = .003). This preventive effect increased more after PSM, 
      particularly in males ≤65 years and females >65 years. CONCLUSIONS: H. pylori 
      eradication prevented CHD and this effect was different depending on age and sex.
CI  - © 2023 John Wiley & Sons Ltd.
FAU - Kim, Sang Bin
AU  - Kim SB
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Kim, Nayoung
AU  - Kim N
AUID- ORCID: 0000-0002-9397-0406
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
AD  - Department of Internal Medicine and Liver Research Institute, Seoul National 
      University, Seoul, South Korea.
FAU - Park, Jaehyung
AU  - Park J
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Hwang, In-Chang
AU  - Hwang IC
AUID- ORCID: 0000-0003-4966-3924
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Lim, Seon Hee
AU  - Lim SH
AUID- ORCID: 0000-0001-6174-7165
AD  - Department of Internal Medicine, Healthcare System Gangnam Center Seoul National 
      University Hospital, and Healthcare Research Institute, Seoul, South Korea.
FAU - Song, Du Hyun
AU  - Song DH
AUID- ORCID: 0000-0002-2903-0786
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Choi, Yonghoon
AU  - Choi Y
AUID- ORCID: 0000-0002-1331-969X
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Yoon, Hyuk
AU  - Yoon H
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Shin, Cheol Min
AU  - Shin CM
AUID- ORCID: 0000-0003-2265-9845
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Park, Young Soo
AU  - Park YS
AUID- ORCID: 0000-0003-1893-7726
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
FAU - Lee, Dong Ho
AU  - Lee DH
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, South Korea.
AD  - Department of Internal Medicine and Liver Research Institute, Seoul National 
      University, Seoul, South Korea.
FAU - Ahn, Soyeon
AU  - Ahn S
AD  - Medical Research Collaborating Center, Seoul National University Bundang 
      Hospital, Seongnam, South Korea.
LA  - eng
GR  - 06-2020-0184/Seoul National University Bundang Hospital/
GR  - 02-2020-0041/Seoul National University Bundang Hospital/
PT  - Journal Article
DEP - 20230322
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Male
MH  - Female
MH  - Humans
MH  - *Helicobacter Infections/complications/drug therapy/prevention & control
MH  - *Helicobacter pylori
MH  - Follow-Up Studies
MH  - Risk Factors
MH  - *Coronary Disease/epidemiology/prevention & control/complications
MH  - *Hypertension/complications/drug therapy
MH  - Aspirin/therapeutic use/pharmacology
MH  - Anti-Bacterial Agents/therapeutic use/pharmacology
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - age
OT  - coronary disease
OT  - eradication
OT  - sex
EDAT- 2023/03/23 06:00
MHDA- 2023/07/18 13:07
CRDT- 2023/03/22 07:52
PHST- 2023/02/21 00:00 [revised]
PHST- 2022/12/20 00:00 [received]
PHST- 2023/03/03 00:00 [accepted]
PHST- 2023/07/18 13:07 [medline]
PHST- 2023/03/23 06:00 [pubmed]
PHST- 2023/03/22 07:52 [entrez]
AID - 10.1111/hel.12969 [doi]
PST - ppublish
SO  - Helicobacter. 2023 Aug;28(4):e12969. doi: 10.1111/hel.12969. Epub 2023 Mar 22.

PMID- 7010985
OWN - NLM
STAT- MEDLINE
DCOM- 19810528
LR  - 20180330
IS  - 0002-9165 (Print)
IS  - 0002-9165 (Linking)
VI  - 34
IP  - 2
DP  - 1981 Feb
TI  - Vitamin E and aspirin depress prostaglandins in protection of chickens against 
      Escherichia coli infection.
PG  - 245-51
AB  - The hypothesis was tested that vitamin E protects chickens from a lethal 
      Escherichia coli infection by inhibiting the biosynthesis of prostaglandins, 
      thereby activating humoral immunity and phagocytosis. When chickens were fed 
      supplement vitamin E at the level of 300 mg/kg diet, which is six times the 
      presently used dietary level, endogenous PGE1, PGE2, and PGF2 alpha levels 
      decreased in the immunopoietic organs, bursa, and spleen. Antibody titers to E. 
      coli lipopolysaccharide and phagocytosis increased at the same time. Infection 
      slightly increased prostaglandin levels and vitamin E appeared to compensate for 
      this increase. Aspirin, a known prostaglandin inhibitor acted synergistically 
      with vitamin E in depressing endogenous PG levels in bursa and decreasing 
      mortality from E. coli infection.
FAU - Likoff, R O
AU  - Likoff RO
FAU - Guptill, D R
AU  - Guptill DR
FAU - Lawrence, L M
AU  - Lawrence LM
FAU - McKay, C C
AU  - McKay CC
FAU - Mathias, M M
AU  - Mathias MM
FAU - Nockels, C F
AU  - Nockels CF
FAU - Tengerdy, R P
AU  - Tengerdy RP
LA  - eng
GR  - AI-13710/AI/NIAID NIH HHS/United States
GR  - HL-18239/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
RN  - 0 (Prostaglandins)
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antibody Formation/drug effects
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Bursa of Fabricius/metabolism
MH  - Chickens
MH  - Escherichia coli Infections/immunology/*metabolism
MH  - Phagocytosis/drug effects
MH  - Prostaglandins/biosynthesis/*metabolism
MH  - Spleen/metabolism
MH  - Vitamin E/*pharmacology/therapeutic use
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
AID - 10.1093/ajcn/34.2.245 [doi]
PST - ppublish
SO  - Am J Clin Nutr. 1981 Feb;34(2):245-51. doi: 10.1093/ajcn/34.2.245.

PMID- 1891022
OWN - NLM
STAT- MEDLINE
DCOM- 19911016
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 325
IP  - 16
DP  - 1991 Oct 17
TI  - Suppression of thromboxane A2 but not of systemic prostacyclin by 
      controlled-release aspirin.
PG  - 1137-41
AB  - BACKGROUND: The antithrombotic efficacy of aspirin is attributed to its 
      inhibition of the enzyme prostaglandin G/H synthase, which is necessary for the 
      formation of thromboxane A2 in platelets. Thromboxane A2 is a potent 
      vasoconstrictor and platelet agonist. However, the formation of prostacyclin by 
      vascular endothelium also requires prostaglandin G/H synthase, and prostacyclin 
      exerts opposite effects on platelet function and vascular tone. We wanted to see 
      whether controlled-release aspirin would affect the formation of thromboxane A2 
      but not prostacyclin by reducing the aspirin concentration that reaches the 
      posthepatic circulation. METHODS: A controlled-release formulation containing 75 
      mg of aspirin, designed to release 10 mg per hour, was developed to inhibit 
      prostaglandin G/H synthase in platelets in the prehepatic circulation. The 
      effects of the controlled-release preparation on plasma levels of aspirin and 
      salicylate, serum levels of thromboxane B2, and urinary dinor metabolites of 
      prostacyclin and thromboxane B2 (measured by gas chromatography-mass 
      spectrometry) were compared with those of conventional immediate-release aspirin 
      in normal volunteers. Prostacyclin release was stimulated by intravenous 
      bradykinin. RESULTS: Steady-state inhibition of serum thromboxane B2 required two 
      to four days and appeared slower with 75 mg of controlled-release than with the 
      same amount of immediate-release aspirin. Maximal inhibition was achieved rapidly 
      by adding a single loading dose of 162.5 mg of immediate-release aspirin to the 
      regimen. Over a 28-day period, suppression of thromboxane A2 with this regimen 
      was comparable to that with immediate-release aspirin taken either as 162.5 mg 
      daily or as 325 mg on alternate days, despite the minimal systemic 
      bioavailability of controlled-release aspirin. Bleeding time was prolonged to a 
      similar degree with each of the three regimens. The five- to sixfold increase in 
      the prostacyclin metabolite induced by bradykinin was depressed by pretreatment 
      for four days with 75 mg of immediate-release aspirin, but not by 75 mg of 
      controlled-release aspirin. CONCLUSIONS: Maximal inhibition of platelet 
      thromboxane A2 production was sustained during long-term dosing with 
      controlled-release aspirin, whereas basal prostacyclin biosynthesis fell only 
      slightly and systemic synthesis of prostacyclin stimulated by bradykinin was 
      preserved. Controlled-release aspirin may facilitate determination of the 
      clinical importance of preserving prostacyclin during platelet inhibition in 
      humans.
FAU - Clarke, R J
AU  - Clarke RJ
AD  - Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN 37232.
FAU - Mayo, G
AU  - Mayo G
FAU - Price, P
AU  - Price P
FAU - FitzGerald, G A
AU  - FitzGerald GA
LA  - eng
GR  - HL 30400/HL/NHLBI NIH HHS/United States
GR  - TWO 4262/TW/FIC NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Salicylates)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/metabolism
MH  - Bradykinin/pharmacology
MH  - Delayed-Action Preparations
MH  - Depression, Chemical
MH  - Drug Administration Schedule
MH  - Epoprostenol/*biosynthesis/urine
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/blood
MH  - Thromboxane A2/*antagonists & inhibitors/blood/urine
EDAT- 1991/10/17 00:00
MHDA- 1991/10/17 00:01
CRDT- 1991/10/17 00:00
PHST- 1991/10/17 00:00 [pubmed]
PHST- 1991/10/17 00:01 [medline]
PHST- 1991/10/17 00:00 [entrez]
AID - 10.1056/NEJM199110173251605 [doi]
PST - ppublish
SO  - N Engl J Med. 1991 Oct 17;325(16):1137-41. doi: 10.1056/NEJM199110173251605.

PMID- 22232732
OWN - NLM
STAT- MEDLINE
DCOM- 20121116
LR  - 20181201
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 52
IP  - 7
DP  - 2012 Jul
TI  - The pattern of platelet response to clopidogrel in Iranian patients after 
      percutaneous coronary intervention.
PG  - 1098-105
LID - 10.1177/0091270011407499 [doi]
AB  - Despite certain clinical benefit in using clopidogrel in patients undergoing 
      percutaneous coronary intervention (PCI), some patients do not attain adequate 
      antiplatelet effects. In this study, the authors investigated the response to 
      clopidogrel in Iranian patients after PCI. Patients who were candidates for 
      elective PCI were enrolled in this study. All patients had received aspirin 80 to 
      325 mg daily for ≥1 week before PCI. Blood samples were taken from patients at 
      baseline, 2 hours after taking a 600-mg loading dose of clopidogrel, and 24 hours 
      and 30 days after stenting. Platelet aggregation was measured by light 
      transmittance aggregometry with adenosine diphosphate (5 and 20 μM) and 
      arachidonic acid (500 and 5000 μg/mL). One hundred twelve patients were included 
      (79 men, 33 women). Maximal and minimal clopidogrel nonresponsiveness occurred at 
      2 hours (26%) and 48 hours (13%) after taking 600 mg clopidogrel, respectively. 
      Pretreatment platelet reactivity had no effects on posttreatment platelet 
      reactivity. Moreover, clopidogrel responsiveness did not correlate with 
      pretreatment reactivity. Patients' demographic and procedural characteristics had 
      no significant effect on clopidogrel responsiveness. The frequency of clopidogrel 
      nonresponsiveness in this study was similar to other studies. However, 
      clopidogrel required more than 2 hours for induction of its maximal antiplatelet 
      effect in this study.
FAU - Namazi, Soha
AU  - Namazi S
AD  - Department of Pharmacotherapy, Faculty of Pharmacy, Shiraz University of Medical 
      Sciences, Shiraz, Iran. snamazi@sums.ac.ir
FAU - Khalili, Andia
AU  - Khalili A
FAU - Kojuri, Javad
AU  - Kojuri J
FAU - Azarpira, Negar
AU  - Azarpira N
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120109
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/*methods
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clopidogrel
MH  - Cross-Sectional Studies
MH  - Dose-Response Relationship, Drug
MH  - Drug-Eluting Stents
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Iran
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Ticlopidine/*analogs & derivatives/pharmacology
MH  - Time Factors
EDAT- 2012/01/11 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/01/11 06:00
PHST- 2012/01/11 06:00 [entrez]
PHST- 2012/01/11 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 0091270011407499 [pii]
AID - 10.1177/0091270011407499 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2012 Jul;52(7):1098-105. doi: 10.1177/0091270011407499. Epub 
      2012 Jan 9.

PMID- 16882378
OWN - NLM
STAT- MEDLINE
DCOM- 20070406
LR  - 20181113
IS  - 0960-1643 (Print)
IS  - 0960-1643 (Linking)
VI  - 56
IP  - 529
DP  - 2006 Aug
TI  - The use of cardiovascular risk factor information in practice databases: making 
      the best of patient data.
PG  - 600-5
AB  - BACKGROUND: Primary care teams record cardiovascular risk factor data on their 
      patients to help them identify and treat patients eligible for prevention. 
      However, it is not known to what extent this information is already available to 
      clinicians, or the extent to which it is used. AIM: To assess the extent to which 
      risk factor is recorded, and to determine the cost-effectiveness of using 
      recorded risk factor information in order to identify and treat eligible 
      patients. DESIGN OF STUDY: An Excel-based model of the incremental costs and 
      benefits of assessment and treatment. SETTING: Two general practices in the West 
      Midlands. METHOD: Untreated, non-diabetic patients, aged 35-74 years, were 
      identified from each practice, and risk factor data was uploaded into an Excel 
      spreadsheet. The completeness of risk factor data was assessed. The costs and 
      benefits of assessing and treating patients, in descending order of estimated 
      cardiovascular risk, were then modelled. RESULTS: In each practice, 72.9% and 
      77.7% of patients had a record of their blood pressure, 26.9% and 25.7% were 
      eligible for at least one treatment: aspirin was the most common treatment 
      followed by antihypertensives. With patients systematically assessed in 
      descending order of cardiovascular risk, 78% of eligible patients and 87% of 
      preventable cardiovascular events are found in the first two deciles of the 
      target population. CONCLUSIONS: Lack of risk factor information is not the 
      principal constraint on cardiovascular prevention. Practices have sufficient risk 
      factor data to inform an efficient, targeted prevention strategy.
FAU - Marshall, Tom
AU  - Marshall T
AD  - Senior lecturer in public health, University of Birmingham, Birmingham, UK. 
      T.P.Marshall@bham.ac.uk
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of 
      General Practitioners
JID - 9005323
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br J Gen Pract. 2006 Nov;56(532):883-4. PMID: 17132357
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/economics/therapeutic use
MH  - Aspirin/economics/therapeutic use
MH  - Blood Pressure
MH  - Cardiovascular Diseases/economics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Data Collection
MH  - Databases as Topic
MH  - Family Practice/economics/*standards
MH  - Humans
MH  - Middle Aged
MH  - Pilot Projects
MH  - Primary Prevention/economics/*standards
MH  - Risk Factors
PMC - PMC1874524
EDAT- 2006/08/03 09:00
MHDA- 2007/04/07 09:00
CRDT- 2006/08/03 09:00
PHST- 2006/08/03 09:00 [pubmed]
PHST- 2007/04/07 09:00 [medline]
PHST- 2006/08/03 09:00 [entrez]
PST - ppublish
SO  - Br J Gen Pract. 2006 Aug;56(529):600-5.

PMID- 19827153
OWN - NLM
STAT- MEDLINE
DCOM- 20100202
LR  - 20211020
IS  - 0008-543X (Print)
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 115
IP  - 24
DP  - 2009 Dec 15
TI  - Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal 
      cancer diagnosis.
PG  - 5662-71
LID - 10.1002/cncr.24705 [doi]
AB  - BACKGROUND: Nonsteroidal anti-inflammatory drug (NSAID) use has been associated 
      with a decreased colorectal cancer (CRC) risk. However, to the best of the 
      authors' knowledge, the effects of NSAID on clinical outcomes after CRC diagnosis 
      are not well defined. The authors investigated the association between 
      prediagnosis NSAID use and mortality after CRC diagnosis among women in the 
      California Teachers Study cohort. METHODS: Women aged <85 years participating in 
      the California Teachers Study, without a prior CRC diagnosis at baseline 
      (1995-1996), and who were diagnosed with CRC during follow-up through December 
      2005, were eligible for analysis of the association between prediagnosis NSAID 
      use and mortality. NSAID use (including aspirin and ibuprofen) was collected 
      through a self-administered questionnaire. Cancer occurrence was identified 
      through California Cancer Registry linkage. Multivariate Cox proportional hazards 
      regression models were used to estimate hazards ratios (HR) for death and 95% 
      confidence intervals (95% CIs). RESULTS: Among 621 CRC patients who were 
      identified, 64% reported no prediagnosis regular NSAID use, 17% reported use of 1 
      to 6 days/week, and 20% reported daily use. A duration of NSAID use <5 years was 
      reported by 17% of patients and a use of >or=5 years was reported by 18%. Regular 
      prediagnosis NSAID use (1-3 days/week, 4-6 days/week, and daily) versus none was 
      associated with improved overall survival (OS) (HR, 0.71; 95% CI, 0.53-0.95) and 
      CRC-specific survival (HR, 0.58; 95% CI 0.40-0.84) after adjustment for 
      clinically relevant factors. Prediagnosis NSAID use >or=5 years (vs none) was 
      found to be associated with improved OS (HR, 0.55; 95% CI, 0.37-0.84) and 
      CRC-specific survival (HR, 0.40; 95% CI, 0.23-0.71) in adjusted analyses. 
      CONCLUSIONS: When used regularly or over a prolonged duration before CRC 
      diagnosis, NSAIDs are associated with decreased mortality among female CRC 
      patients.
CI  - Copyright (c) 2009 American Cancer Society.
FAU - Zell, Jason A
AU  - Zell JA
AD  - Genetic Epidemiology Research Institute and Department of Epidemiology, 
      University of California at Irvine, Irvine, California 92697-7550, USA. 
      jzell@uci.edu
FAU - Ziogas, Argyrios
AU  - Ziogas A
FAU - Bernstein, Leslie
AU  - Bernstein L
FAU - Clarke, Christina A
AU  - Clarke CA
FAU - Deapen, Dennis
AU  - Deapen D
FAU - Largent, Joan A
AU  - Largent JA
FAU - Neuhausen, Susan L
AU  - Neuhausen SL
FAU - Stram, Daniel O
AU  - Stram DO
FAU - Ursin, Giske
AU  - Ursin G
FAU - Anton-Culver, Hoda
AU  - Anton-Culver H
LA  - eng
GR  - U55/CCR921930-02/PHS HHS/United States
GR  - R25 CA085771/CA/NCI NIH HHS/United States
GR  - P30 ES007048/ES/NIEHS NIH HHS/United States
GR  - P30 ES 07,048/ES/NIEHS NIH HHS/United States
GR  - R25 CA85771/CA/NCI NIH HHS/United States
GR  - N01-PC-15,105/PC/NCI NIH HHS/United States
GR  - R01 CA077398/CA/NCI NIH HHS/United States
GR  - R01 CA77398/CA/NCI NIH HHS/United States
GR  - N01-PC-35,136/PC/NCI NIH HHS/United States
GR  - N01PC35139/CA/NCI NIH HHS/United States
GR  - N02 PC015105/PC/NCI NIH HHS/United States
GR  - R01 CA077398-10/CA/NCI NIH HHS/United States
GR  - K05 CA136967/CA/NCI NIH HHS/United States
GR  - R01 CA077398-11/CA/NCI NIH HHS/United States
GR  - N01PC35136/CA/NCI NIH HHS/United States
GR  - K05 CA136967-01A1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Carcinoma/*mortality
MH  - Colorectal Neoplasms/*mortality
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
PMC - PMC3008399
MID - NIHMS250512
EDAT- 2009/10/15 06:00
MHDA- 2010/02/03 06:00
CRDT- 2009/10/15 06:00
PHST- 2009/10/15 06:00 [entrez]
PHST- 2009/10/15 06:00 [pubmed]
PHST- 2010/02/03 06:00 [medline]
AID - 10.1002/cncr.24705 [doi]
PST - ppublish
SO  - Cancer. 2009 Dec 15;115(24):5662-71. doi: 10.1002/cncr.24705.

PMID- 23993980
OWN - NLM
STAT- MEDLINE
DCOM- 20150219
LR  - 20131217
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 141
IP  - 1
DP  - 2014 Jan
TI  - Mechanisms of aspirin resistance.
PG  - 69-78
LID - S0163-7258(13)00181-2 [pii]
LID - 10.1016/j.pharmthera.2013.08.005 [doi]
AB  - Aspirin is integral to the secondary prevention of cardiovascular disease and 
      acts to impair the development of platelet-mediated atherothromboembolic events 
      by irreversible inhibition of platelet cyclooxygenase-1 (COX-1). Inhibition of 
      this enzyme prevents the synthesis of the potent pro-aggregatory prostanoid 
      thromboxane A2. A large number of patients continue to experience 
      atherothromboembolic events despite aspirin therapy, so-called 'aspirin treatment 
      failure', and this is multifactorial in aetiology. Approximately 10% however do 
      not respond appropriately to aspirin in a phenomenon known as 'aspirin 
      resistance', which is defined by various laboratory techniques. In this review we 
      discuss the reasons for aspirin resistance in a systematic manner, starting from 
      prescription of the drug and ending at the level of the platelet. Poor medication 
      adherence has been shown to be a cause of apparent aspirin resistance, and may in 
      fact be the largest contributory factor. Also important is high platelet turnover 
      due to underlying inflammatory processes, such as atherosclerosis and its 
      complications, leading to faster regeneration of platelets, and hence of COX-1, 
      at a rate that diminishes the efficacy of once daily dosing. Recent developments 
      include the identification of platelet glycoprotein IIIa as a potential biomarker 
      (as well as possible underlying mechanism) for aspirin resistance and the 
      discovery of an anion efflux pump that expels intracellular aspirin from 
      platelets. The absolute as well as relative contributions of such factors to the 
      phenomenon of aspirin resistance are the subject of continuing research.
CI  - © 2013.
FAU - Floyd, Christopher N
AU  - Floyd CN
AD  - Department of Clinical Pharmacology, Cardiovascular Division, King's College 
      London, London, UK.
FAU - Ferro, Albert
AU  - Ferro A
AD  - Department of Clinical Pharmacology, Cardiovascular Division, King's College 
      London, London, UK. Electronic address: albert.ferro@kcl.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130829
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Integrin beta3)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacokinetics/*pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/metabolism
MH  - Cyclooxygenase 1/drug effects/metabolism
MH  - Cyclooxygenase Inhibitors/pharmacokinetics/*pharmacology/therapeutic use
MH  - Drug Interactions
MH  - *Drug Resistance
MH  - Humans
MH  - Integrin beta3/drug effects/metabolism
MH  - Medication Adherence
MH  - Tachyphylaxis
MH  - Thromboembolism/*drug therapy/prevention & control
MH  - Thromboxane A2/antagonists & inhibitors/metabolism
MH  - Treatment Failure
OTO - NOTNLM
OT  - AA
OT  - Aspirin
OT  - CABG
OT  - COX
OT  - Cardiovascular
OT  - LTA
OT  - MRP4
OT  - NSAID
OT  - PGE(2)
OT  - PGH(2)
OT  - PGI(2)
OT  - PPI
OT  - Platelet
OT  - Resistance
OT  - TXA(2)
OT  - TXB(2)
OT  - Thrombosis
OT  - arachidonic acid
OT  - coronary artery bypass graft
OT  - cyclooxygenase
OT  - light transmission aggregometry
OT  - multidrug resistant protein 4
OT  - non-steroidal anti-inflammatory drug
OT  - prostaglandin E(2)
OT  - prostaglandin H(2)
OT  - prostaglandin I(2) (prostacyclin)
OT  - proton pump inhibitor
OT  - thromboxane A(2)
OT  - thromboxane B(2)
EDAT- 2013/09/03 06:00
MHDA- 2015/02/20 06:00
CRDT- 2013/09/03 06:00
PHST- 2013/07/18 00:00 [received]
PHST- 2013/07/30 00:00 [accepted]
PHST- 2013/09/03 06:00 [entrez]
PHST- 2013/09/03 06:00 [pubmed]
PHST- 2015/02/20 06:00 [medline]
AID - S0163-7258(13)00181-2 [pii]
AID - 10.1016/j.pharmthera.2013.08.005 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2014 Jan;141(1):69-78. doi: 10.1016/j.pharmthera.2013.08.005. 
      Epub 2013 Aug 29.

PMID- 7277191
OWN - NLM
STAT- MEDLINE
DCOM- 19811118
LR  - 20190913
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 4
IP  - 1
DP  - 1981 Jan
TI  - Effect of taurine on drug absorption from the rat gastrointestinal tract.
PG  - 35-41
AB  - Effect of taurine on drug absorption from the rat gastrointestinal tract was 
      investigated by using in situ loop method for the stomach and in situ 
      recirculation method for the small or large intestine. Aspirin absorption from 
      the stomach or the small intestine was enhanced by the presence of taurine, but 
      not from the large intestine. The absorption enhancement effect of taurine was 
      not only site-specific, but also substrate-specific. Taurine increased the 
      absorption of aminopyrine from the small intestine, but not from the stomach. On 
      the other hand, the absorption of salicylamide, o-methoxybenzoic acid and 
      o-ethoxybenzoic acid was enhanced in the stomach, although they were not 
      influenced in the small intestine. Furthermore, among the taurine analogues 
      investigated only homotaurine showed the taurine-like action in the small 
      intestine. Glycine also increased the gastric absorption of aspirin. These 
      effects were observed neither by the pretreatment of the intestine with taurine, 
      nor by i.v. administered taurine. Taurine at the site of drug absorption, even at 
      a low concentration, seems to influence the drug absorption due to its effect on 
      the permeability characteristics of the mucosal membrane.
FAU - Kimura, T
AU  - Kimura T
FAU - Kim, K S
AU  - Kim KS
FAU - Sezaki, H
AU  - Sezaki H
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Pharmaceutical Preparations)
RN  - 1EQV5MLY3D (Taurine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Intestinal Absorption/*drug effects
MH  - Male
MH  - Pharmaceutical Preparations/*metabolism
MH  - Rats
MH  - Structure-Activity Relationship
MH  - Taurine/*pharmacology
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1248/bpb1978.4.35 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1981 Jan;4(1):35-41. doi: 10.1248/bpb1978.4.35.

PMID- 17499658
OWN - NLM
STAT- MEDLINE
DCOM- 20070608
LR  - 20191210
IS  - 1532-8171 (Electronic)
IS  - 0735-6757 (Linking)
VI  - 25
IP  - 4
DP  - 2007 May
TI  - A risk score to predict silent myocardial ischemia in patients with coronary 
      artery disease under aspirin therapy presenting with upper gastrointestinal 
      hemorrhage.
PG  - 406-13
AB  - BACKGROUND: Silent myocardial ischemia (SMI) is a relatively common complication 
      in patients with coronary artery disease (CAD) under aspirin therapy presenting 
      with upper gastrointestinal hemorrhage (UGIH). AIM: This study was conducted to 
      develop and prospectively validate a risk prediction score to identify SMI in 
      patients undergoing aspirin therapy for CAD presenting with UGIH in the emergency 
      department (ED). METHODS: This was a 2-phase noninterventional study. In the 
      derivation phase, adults with CAD under aspirin therapy (100 mg once daily) 
      presenting to the ED with UGIH were retrospectively recruited. By multiple 
      logistic regression analysis, we derived a risk score from 224 patients that 
      predicts the patients' risk of SMI. In the validation phase, we prospectively 
      validated this score using receiver operating characteristic curves with data 
      from 110 patients. We also developed a fast-track screening procedure from this 
      score. RESULTS: There were 56 patients (25.0%) and 29 patients (26.4%) with SMI 
      in the derivation and validation sets, respectively. Independent multivariate 
      predictors of SMI were age of older than 75 years, severity of CAD, systolic 
      blood pressure of less than 110 mm Hg, diastolic blood pressure of less than 85 
      mm Hg, hematocrit of less than 30%, and blood urea nitrogen-creatinine ratio of 
      more than 30. The area under receiver operating characteristic curve for the rule 
      was 0.93 in the derivation set and 0.96 in the validation set. At the cutoff 
      value of 5 points or higher, the sensitivity and specificity of the fast-track 
      screening procedure for SMI were 96.6% and 86.4%, respectively. The positive and 
      negative predictive values were 71.8% and 98.6%, respectively. CONCLUSIONS: This 
      simple risk prediction score is easily calculated and is based on rapidly 
      available clinical and laboratory data in the ED. It can be used to stratify 
      patients undergoing aspirin therapy for CAD presenting with UGIH by risk of SMI.
FAU - Chen, Chien-Chih
AU  - Chen CC
AD  - Department of Emergency Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei 
      111, Taiwan.
FAU - Chong, Chee-Fah
AU  - Chong CF
FAU - Kuo, Cheng-Deng
AU  - Kuo CD
FAU - Wang, Tzong-Luen
AU  - Wang TL
LA  - eng
PT  - Journal Article
PT  - Validation Study
PL  - United States
TA  - Am J Emerg Med
JT  - The American journal of emergency medicine
JID - 8309942
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Coronary Artery Disease/*complications/*drug therapy
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Multivariate Analysis
MH  - Myocardial Ischemia/*diagnosis/*etiology
MH  - Prospective Studies
MH  - Risk Assessment/methods
MH  - Sensitivity and Specificity
EDAT- 2007/05/15 09:00
MHDA- 2007/06/09 09:00
CRDT- 2007/05/15 09:00
PHST- 2006/08/07 00:00 [received]
PHST- 2006/09/11 00:00 [revised]
PHST- 2006/09/25 00:00 [accepted]
PHST- 2007/05/15 09:00 [pubmed]
PHST- 2007/06/09 09:00 [medline]
PHST- 2007/05/15 09:00 [entrez]
AID - S0735-6757(06)00406-2 [pii]
AID - 10.1016/j.ajem.2006.09.009 [doi]
PST - ppublish
SO  - Am J Emerg Med. 2007 May;25(4):406-13. doi: 10.1016/j.ajem.2006.09.009.

PMID- 3232127
OWN - NLM
STAT- MEDLINE
DCOM- 19890419
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 52
IP  - 6
DP  - 1988 Dec 15
TI  - Potentiation of platelet interaction with collagen substrates by heparin is 
      insensitive to aspirin.
PG  - 573-85
AB  - The effects of two standard, unfractionated heparin preparations on 
      collagen-induced adhesion and aggregation of platelets were studied by Born 
      aggregometry and scanning electron microscopy (SEM). Heparin from porcine 
      intestinal mucosa (HI) and from bovine lung (HL) added to human PRP in the 
      concentration of 2.5 to 5.0 U/ml (1) did not induce platelet aggregation in 
      suspension by itself but stimulated it in combination with the subthreshold doses 
      of fibrillar human collagen type III (CIII); (2) increased by 1.5-2.0 fold the 
      adhesion, but did not affect platelet spreading on a surface coated with human 
      collagen type IV (CIV); and (3) enlarged by 2.5-3.0 fold the area of the 
      CIII-coated surface covered with aggregates, increasing both the number and the 
      size of surface-bound aggregates. Aspirin blocked platelet aggregation in 
      suspension induced by low, near threshold doses, of fibrillar CIII and by 
      subthreshold doses of CIII in combination with heparin, but had no effect on 
      platelet aggregation induced by high (greater than 10 threshold) doses of CIII. 
      Aspirin failed to decrease platelet adhesion to and spreading on CIV substrate, 
      and formation of surface-bound aggregates on CIII substrate in the absence as 
      well as in the presence of heparin.
FAU - Mazurov, A V
AU  - Mazurov AV
AD  - USSR Cardiology Research Center, Academy of Medical Sciences, Moscow.
FAU - Sinitsyn, V E
AU  - Sinitsyn VE
FAU - Repin, V S
AU  - Repin VS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Collagen/*metabolism
MH  - Drug Interactions
MH  - Heparin/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Microscopy, Electron, Scanning
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 1988/12/15 00:00
MHDA- 1988/12/15 00:01
CRDT- 1988/12/15 00:00
PHST- 1988/12/15 00:00 [pubmed]
PHST- 1988/12/15 00:01 [medline]
PHST- 1988/12/15 00:00 [entrez]
AID - 10.1016/0049-3848(88)90130-2 [doi]
PST - ppublish
SO  - Thromb Res. 1988 Dec 15;52(6):573-85. doi: 10.1016/0049-3848(88)90130-2.

PMID- 27741174
OWN - NLM
STAT- MEDLINE
DCOM- 20170620
LR  - 20210108
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 128
IP  - 5
DP  - 2016 Nov
TI  - Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated 
      Pregnancy Complications: A Randomized Controlled Trial.
PG  - 1053-1063
LID - 10.1097/AOG.0000000000001673 [doi]
AB  - OBJECTIVE: To evaluate whether daily enoxaparin, added to low-dose aspirin, 
      started before 14 weeks of gestation reduces placenta-mediated complications in 
      pregnant women with previous severe preeclampsia diagnosed before 34 weeks of 
      gestation. METHODS: In this open-label multicenter randomized trial, we enrolled 
      consenting pregnant women with previous severe preeclampsia diagnosed before 34 
      weeks of gestation, gestational age at randomization of 7-13 weeks, singleton 
      pregnancy, and no plan for anticoagulation. Eligible patients were randomly 
      assigned to a one-to-one ratio to receive daily either 4,000 international units 
      enoxaparin plus 100 mg aspirin or 100 mg aspirin alone. Randomization was done by 
      a web-based randomization system. The primary composite outcome comprised 
      maternal death, perinatal death, preeclampsia, small for gestational age (less 
      than the 10th percentile), and placental abruption. A sample size of 232 women 
      equally divided into two groups was needed to detect a significant reduction in 
      primary outcome from 55% in the aspirin group to 36.7% in the enoxaparin-aspirin 
      group (α: 0.05, β: 0.8, two-sided). RESULTS: Between November 14, 2009, and 
      February 21, 2015, 257 participants were enrolled. Baseline demographic and 
      clinical factors were similar between groups. Eight women were excluded after 
      randomization (six in the enoxaparin-aspirin group and two in the aspirin group), 
      leaving 124 participants assigned to enoxaparin-aspirin and 125 to aspirin. Five 
      participants were lost to follow-up (two in the enoxaparin-aspirin group and 
      three in the aspirin group). There was no significant difference between the 
      groups in the primary outcome: enoxaparin-aspirin 42 of 122 (34.4%) compared with 
      aspirin alone 50 of 122 (41%) (relative risk 0.84, 95% confidence interval 
      0.61-1.16, P=.29). The occurrence of complications did not differ between the two 
      groups. CONCLUSION: Antepartum prophylactic enoxaparin does not significantly 
      reduce placenta-mediated complications in women receiving low-dose aspirin for 
      previous severe preeclampsia diagnosed before 34 weeks of gestation. CLINICAL 
      TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT00986765.
FAU - Haddad, Bassam
AU  - Haddad B
AD  - University Paris Est Créteil and CHI Créteil, Créteil, CHU Hôpital mère-enfant, 
      Nantes, AP-HP, Hôpital Robert Debré, Paris, CHU Hôpital Jeanne de Flandre, Lille, 
      CHU Saint Etienne, Saint Etienne, CHU Brest, Brest, University Paris Descartes 
      and AP-HP Hôpital Cochin, Paris, University Paris 11 and AP-HP Hôpital Antoine 
      Béclère, Clamart, AP-Hôpitaux de Marseilles-Hôpital Nord, Marseilles, CHU Nîmes, 
      Nîmes, and University Paris Est Créteil and AP-HP Hôpital Henri Mondor, Créteil, 
      France.
FAU - Winer, Norbert
AU  - Winer N
FAU - Chitrit, Yvon
AU  - Chitrit Y
FAU - Houfflin-Debarge, Véronique
AU  - Houfflin-Debarge V
FAU - Chauleur, Céline
AU  - Chauleur C
FAU - Bages, Karine
AU  - Bages K
FAU - Tsatsaris, Vassilis
AU  - Tsatsaris V
FAU - Benachi, Alexandra
AU  - Benachi A
FAU - Bretelle, Florence
AU  - Bretelle F
FAU - Gris, Jean-Christophe
AU  - Gris JC
FAU - Bastuji-Garin, Sylvie
AU  - Bastuji-Garin S
CN  - Heparin-Preeclampsia (HEPEPE) Trial Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00986765
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Enoxaparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Obstet Gynecol. 2017 Feb;129(2):387-388. PMID: 28121820
CIN - Obstet Gynecol. 2017 Feb;129(2):388. PMID: 28121821
MH  - Abruptio Placentae
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Enoxaparin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
EDAT- 2016/10/26 06:00
MHDA- 2017/06/21 06:00
CRDT- 2016/10/15 06:00
PHST- 2016/10/26 06:00 [pubmed]
PHST- 2017/06/21 06:00 [medline]
PHST- 2016/10/15 06:00 [entrez]
AID - 00006250-201611000-00017 [pii]
AID - 10.1097/AOG.0000000000001673 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2016 Nov;128(5):1053-1063. doi: 10.1097/AOG.0000000000001673.

PMID- 21592450
OWN - NLM
STAT- MEDLINE
DCOM- 20110811
LR  - 20220129
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 124
IP  - 7
DP  - 2011 Jul
TI  - Effect of aspirin on mortality in the primary prevention of cardiovascular 
      disease.
PG  - 621-9
LID - 10.1016/j.amjmed.2011.01.018 [doi]
AB  - OBJECTIVE: The lack of a mortality benefit of aspirin in prior meta-analyses of 
      primary prevention trials of cardiovascular disease has contributed to 
      uncertainty about the balance of benefits and risks of aspirin in primary 
      prevention. We performed an updated meta-analysis of randomized controlled trials 
      of aspirin to obtain best estimates of the effect of aspirin on mortality in 
      primary prevention. METHODS: Eligible articles were identified by searches of 
      electronic databases and reference lists. Outcomes of interest were all-cause 
      mortality, cardiovascular mortality, myocardial infarction, stroke, and bleeding. 
      Data were pooled from individual trials using the DerSimonian-Laird 
      random-effects model, and results are presented as relative risk (RR) and 95% 
      confidence intervals (CIs). RESULTS: Nine randomized controlled trials enrolling 
      100,076 participants were included. Aspirin reduced all-cause mortality (RR 0.94; 
      95% CI, 0.88-1.00), myocardial infarction (RR 0.83; 95% CI, 0.69-1.00), ischemic 
      stroke (RR 0.86; 95% CI, 0.75-0.98), and the composite of myocardial infarction, 
      stroke, or cardiovascular death (RR 0.88; 95% CI, 0.83-0.94), but did not reduce 
      cardiovascular mortality (RR 0.96; 95% CI, 0.84-1.09). Aspirin increased the risk 
      of hemorrhagic stroke (RR 1.36; 95% CI, 1.01-1.82), major bleeding (RR 1.66; 95% 
      CI, 1.41-1.95), and gastrointestinal bleeding (RR 1.37; 95% CI, 1.15-1.62). A 
      lack of availability of patient-level data precluded exploration of benefits and 
      risks of aspirin in key subgroups. CONCLUSION: Aspirin prevents deaths, 
      myocardial infarction, and ischemic stroke, and increases hemorrhagic stroke and 
      major bleeding when used in the primary prevention of cardiovascular disease.
CI  - Copyright © 2011 Elsevier Inc. All rights reserved.
FAU - Raju, Nina
AU  - Raju N
AD  - Haematology Unit, Queensland Pathology and Department of Internal Medicine, 
      Prince Charles Hospital, Brisbane, Australia.
FAU - Sobieraj-Teague, Magdalena
AU  - Sobieraj-Teague M
FAU - Hirsh, Jack
AU  - Hirsh J
FAU - O'Donnell, Martin
AU  - O'Donnell M
FAU - Eikelboom, John
AU  - Eikelboom J
LA  - eng
GR  - G9534799/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20110517
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Med. 2012 Feb;125(2):e13. PMID: 22269629
CIN - Am J Med. 2012 Dec;125(12):e11. PMID: 23164487
CIN - Am J Med. 2016 May;129(5):e35-6. PMID: 27126466
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Cardiovascular Agents/administration & dosage/adverse effects/*pharmacology
MH  - *Cause of Death
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*epidemiology/mortality/*prevention & control
MH  - Primary Prevention/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Stroke/*epidemiology/mortality/*prevention & control
EDAT- 2011/05/20 06:00
MHDA- 2011/08/13 06:00
CRDT- 2011/05/20 06:00
PHST- 2010/09/20 00:00 [received]
PHST- 2010/12/29 00:00 [revised]
PHST- 2011/01/12 00:00 [accepted]
PHST- 2011/05/20 06:00 [entrez]
PHST- 2011/05/20 06:00 [pubmed]
PHST- 2011/08/13 06:00 [medline]
AID - S0002-9343(11)00263-4 [pii]
AID - 10.1016/j.amjmed.2011.01.018 [doi]
PST - ppublish
SO  - Am J Med. 2011 Jul;124(7):621-9. doi: 10.1016/j.amjmed.2011.01.018. Epub 2011 May 
      17.

PMID- 25903695
OWN - NLM
STAT- MEDLINE
DCOM- 20160511
LR  - 20151013
IS  - 1945-239X (Electronic)
IS  - 0021-9665 (Linking)
VI  - 53
IP  - 9
DP  - 2015 Oct
TI  - Isolation, Characterization of a Potential Degradation Product of Aspirin and an 
      HPLC Method for Quantitative Estimation of Its Impurities.
PG  - 1491-7
LID - 10.1093/chromsci/bmv043 [doi]
AB  - In this work, a new degradation product of Aspirin was isolated, characterized 
      and analyzed along with other impurities. New unknown degradation product 
      referred as UP was observed exceeding the limit of ICH Q3B identification 
      thresholds in the stability study of Aspirin and Dipyridamole capsule. The UP 
      isolated from the thermal degradation sample was further studied by IR, Mass and 
      (1)H NMR spectrometry, revealing structural similarities with the parent 
      molecule. Finally, UP was identified as a new compound generated from the 
      interaction of Aspirin and Salicylic acid to form a dehydrated product. A 
      specific HPLC method was developed and validated for the analysis of UP and other 
      Aspirin impurities (A, B, C, E and other unknown degradation products). The 
      proposed method was successfully employed for estimation of Aspirin impurities in 
      a pharmaceutical preparation of Aspirin (Immediate Release) and Dipyridamole 
      (Extended Release) Capsules.
CI  - © The Author 2015. Published by Oxford University Press. All rights reserved. For 
      Permissions, please email: journals.permissions@oup.com.
FAU - Acharya, Subasranjan
AU  - Acharya S
AD  - Vergo Pharmaceutical Research Laboratories Pvt. Ltd, ADL, Plot No. B5, Phase-1A, 
      Verna Industrial Estate, Salcatte, Verna, Goa 403722, India 
      subasranjan.acharya@vergopharma.com.
FAU - Daniel, Alex
AU  - Daniel A
AD  - Vergo Pharmaceutical Research Laboratories Pvt. Ltd, ADL, Plot No. B5, Phase-1A, 
      Verna Industrial Estate, Salcatte, Verna, Goa 403722, India.
FAU - Gyadangi, Bharath
AU  - Gyadangi B
AD  - Vergo Pharmaceutical Research Laboratories Pvt. Ltd, ADL, Plot No. B5, Phase-1A, 
      Verna Industrial Estate, Salcatte, Verna, Goa 403722, India.
FAU - Ramsamy, Sriramulu
AU  - Ramsamy S
AD  - Vergo Pharmaceutical Research Laboratories Pvt. Ltd, ADL, Plot No. B5, Phase-1A, 
      Verna Industrial Estate, Salcatte, Verna, Goa 403722, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150422
PL  - United States
TA  - J Chromatogr Sci
JT  - Journal of chromatographic science
JID - 0173225
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Drug Contamination
MH  - Hot Temperature
MH  - Linear Models
MH  - Nuclear Magnetic Resonance, Biomolecular
MH  - Reproducibility of Results
MH  - Salicylic Acid/chemistry
MH  - Sensitivity and Specificity
EDAT- 2015/04/24 06:00
MHDA- 2016/05/12 06:00
CRDT- 2015/04/24 06:00
PHST- 2014/08/20 00:00 [received]
PHST- 2015/04/24 06:00 [entrez]
PHST- 2015/04/24 06:00 [pubmed]
PHST- 2016/05/12 06:00 [medline]
AID - bmv043 [pii]
AID - 10.1093/chromsci/bmv043 [doi]
PST - ppublish
SO  - J Chromatogr Sci. 2015 Oct;53(9):1491-7. doi: 10.1093/chromsci/bmv043. Epub 2015 
      Apr 22.

PMID- 24433232
OWN - NLM
STAT- MEDLINE
DCOM- 20151021
LR  - 20220129
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 25
IP  - 8
DP  - 2014
TI  - A platelet P-selectin test predicts adverse cardiovascular events in patients 
      with acute coronary syndromes treated with aspirin and clopidogrel.
PG  - 612-8
LID - 10.3109/09537104.2013.863858 [doi]
AB  - There is wide variation in response to antiplatelet therapy and high on-treatment 
      platelet reactivity is associated with adverse cardiovascular events. The 
      objective here was to determine whether the results of a novel strategy for 
      assessing platelet reactivity (based on P-selectin measurement) are associated 
      with clinical outcomes in patients with acute coronary syndromes (ACS). This was 
      a prospective cohort study of 100 ACS patients taking aspirin and clopidogrel. 
      P-selectin tests designed to assess response to P2Y12 antagonists or aspirin were 
      performed alongside light transmission aggregometry. For the P2Y12 P-selectin 
      test, an optimal cutoff for high platelet reactivity was determined by receiver 
      operating characteristic (ROC) curve analysis. Patients were divided into two 
      cohorts based on this value: patients with (n = 42) or without (n = 58) high 
      platelet reactivity. The primary endpoint was defined as the composite of 
      cardiovascular death, myocardial infarction and stent thrombosis. After 12 
      months, the primary endpoint occurred in 12 patients. ROC curve analysis 
      determined that the P2Y12 P-selectin test results were predictive of the primary 
      endpoint (area under curve = 0.69, p = 0.046). The primary endpoint occurred more 
      frequently in patients with high on-treatment platelet reactivity compared to 
      those without (21.4% vs. 5.2%; hazard ratio (HR) 4.14; p = 0.026). The P2Y12 
      P-selectin test results correlated with light transmission aggregometry (Spearman 
      p < 0.0001). Using the Aspirin P-selectin test, only two patients demonstrated 
      high on-treatment platelet reactivity. This study suggests that a P2Y12 
      P-selectin test is capable of detecting high on-treatment platelet reactivity, 
      which is associated with subsequent cardiovascular events.
FAU - Thomas, Mark R
AU  - Thomas MR
AD  - Cardiovascular Medicine, School of Clinical Sciences, University of Nottingham , 
      Nottingham , UK.
FAU - Wijeyeratne, Yanushi D
AU  - Wijeyeratne YD
FAU - May, Jane A
AU  - May JA
FAU - Johnson, Andrew
AU  - Johnson A
FAU - Heptinstall, Stan
AU  - Heptinstall S
FAU - Fox, Susan C
AU  - Fox SC
LA  - eng
GR  - MC_G0900866/MRC_/Medical Research Council/United Kingdom
GR  - MR/L001594/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20140116
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - P-Selectin/*metabolism
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Platelet Function Tests
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acute coronary syndromes
OT  - P-selectin
OT  - aspirin
OT  - clopidogrel
OT  - platelet function testing
EDAT- 2014/01/18 06:00
MHDA- 2015/10/22 06:00
CRDT- 2014/01/18 06:00
PHST- 2014/01/18 06:00 [entrez]
PHST- 2014/01/18 06:00 [pubmed]
PHST- 2015/10/22 06:00 [medline]
AID - 10.3109/09537104.2013.863858 [doi]
PST - ppublish
SO  - Platelets. 2014;25(8):612-8. doi: 10.3109/09537104.2013.863858. Epub 2014 Jan 16.

PMID- 19202951
OWN - NLM
STAT- MEDLINE
DCOM- 20090324
LR  - 20170306
VI  - 118
IP  - 12
DP  - 2008 Dec
TI  - Resistance to acetylsalicylic acid in patients after ischemic stroke.
PG  - 727-33
AB  - INTRODUCTION: Acetylsalicylic acid (ASA) due to its antiplatelet action is used 
      in ischemic stroke therapy. The platelet response to ASA shows an interindividual 
      variation. Decreased platelet sensitivity to ASA is termed as resistance to ASA. 
      OBJECTIVES: The aim of the study was to assess the prevalence of resistance to 
      ASA in stroke patients and discover dependence between resistance to ASA and 
      stroke recurrence and certain genetic and environmental factors. PATIENTS AND 
      METHODS: 59 patients aged 22-83 years (mean age: 53) who had ischemic stroke 
      within the period of 1 month to 10 years prior to the study were analyzed. 51 
      patients received ASA in a daily dose of 75 mg, and 8 in a higher dose. ASA had 
      been taken since the stroke episode. Resistance was analyzed using the PFA-100 
      and optical aggregometer, with adenosine diphosphate, collagen and arachidonic 
      acid as platelet agonists. RESULTS: Resistance to ASA in patients after stroke is 
      observed with frequency ranging from 9% in arachidonic acid-induced aggregometry 
      to 65% in the PFA-100. There were correlations between platelet aggregation in 
      response to various agonists (r = 0.37-0.77, p < or = 0.005), and between 
      collagen-induced aggregation and the PFA-100 (r = -0.33, p = 0.016). Platelet 
      aggregation induced by arachidonic acid (r = 0.39, p = 0.029) correlated with the 
      stroke recurrence (n = 12). ASA resistance detected in aggregometry in response 
      to collagen was more common in patients with 807CT genotype for Ia glycoprotein 
      (p = 0.05), and in patients with diabetes (p = 0.039). CONCLUSIONS: In patients 
      after ischemic stroke resistance to ASA is commonly observed. In patients with 
      diabetes or C807Tglycoprotein Ia gene CT polymorphisms this phenomenon is more 
      frequently detected.
FAU - Zytkiewicz, Marcin
AU  - Zytkiewicz M
AD  - Department of Internal Diseases, Public Healthcare Centre Poznań, Nowe Miasto, 
      Poland. m.zytkiewicz@interia.pl
FAU - Giełwanowska, Liwia
AU  - Giełwanowska L
FAU - Wojtasińska, Ewelina
AU  - Wojtasińska E
FAU - Psuja, Piotr
AU  - Psuja P
FAU - Zawilska, Krystyna
AU  - Zawilska K
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Pol Arch Med Wewn
JT  - Polskie Archiwum Medycyny Wewnetrznej
JID - 0401225
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/drug effects
MH  - Brain Ischemia/*drug therapy
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Poland
MH  - Prognosis
MH  - Risk Assessment
MH  - Stroke/*drug therapy
MH  - Treatment Outcome
EDAT- 2009/02/11 09:00
MHDA- 2009/03/25 09:00
CRDT- 2009/02/11 09:00
PHST- 2009/02/11 09:00 [entrez]
PHST- 2009/02/11 09:00 [pubmed]
PHST- 2009/03/25 09:00 [medline]
PST - ppublish
SO  - Pol Arch Med Wewn. 2008 Dec;118(12):727-33.

PMID- 12556983
OWN - NLM
STAT- MEDLINE
DCOM- 20030606
LR  - 20181130
IS  - 1432-9417 (Print)
IS  - 1432-9417 (Linking)
VI  - 7
IP  - 1
DP  - 2003 Jan
TI  - [Oxygen-carrying solutions improve tissue oxygenation in striated skin muscle 
      subjected to critical ischemia].
PG  - 31-5
AB  - AIM: The aim of the present study was to investigate the effects of the 
      oxygen-carrying hemoglobin solution DCLHb (diaspirin-crosslinked hemoglobin) on 
      microvascular perfusion and tissue oxygenation in striated skin muscle after the 
      induction of critical ischemia followed by reperfusion. MATERIAL AND METHODS: 
      Using intravital fluorescence microscopy the functional capillary density was 
      analyzed in the striated skin muscle of Syrian golden hamsters before the 
      induction of a 4-h period of ischemia and again after 0.5 h, 2 h and 24 h of 
      reperfusion ( n=8 in each group). In other animals ( n=8 in each group), the 
      identical protocol was applied to determine tissue oxygenation by means of the 
      multi-wire surface electrode (MDO, Eschweiler, Kiel, Germany). Animals in the 
      treatment group ( n=8) received a bolus infusion of 5 ml of DCLHb per kg of body 
      wt. (10 g/dl; Baxter, Ill., USA) 15 min before reperfusion. Control animals ( 
      n=8) received equivalent volumes of isotonic saline (Braun, Melsungen, Germany). 
      RESULTS. Functional capillary density was dramatically reduced in control 
      animals, while in DCLHb-treated animals significantly higher values were 
      observed. Efficient restoration of tissue PO(2) was also seen in DCLHb-treated 
      animals and not in control animals. CONCLUSIONS: These results show that the 
      oxygen-carrying solution DCLHb is significantly more efficient than the commonly 
      used crystalloid solutions in restoration of tissue PO(2) after 
      ischemia-reperfusion. The use of this solution therefore appears promising as a 
      means of protecting the tissue put at risk by ischemia from reperfusion damage.
FAU - Nolte, D
AU  - Nolte D
AD  - Universitätsklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie, 
      Knappschaftskrankenhaus Bochum-Langendreer, Ruhr-Universität Bochum. 
      dirk.nolte@ruhr-uni-bochum.de
FAU - Pickelmann, S
AU  - Pickelmann S
FAU - Swaid, S
AU  - Swaid S
FAU - Hölzle, F
AU  - Hölzle F
FAU - Wolff, K-D
AU  - Wolff KD
LA  - ger
PT  - Journal Article
TT  - Sauerstoff tragende Lösungen verbessern die Gewebeoxygenation im quergestreiften 
      Hautmuskel nach kritischer Ischämiezeit.
DEP - 20021115
PL  - Germany
TA  - Mund Kiefer Gesichtschir
JT  - Mund-, Kiefer- und Gesichtschirurgie : MKG
JID - 9716576
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Blood Substitutes/*pharmacology
MH  - Capillaries/drug effects/physiopathology
MH  - Cricetinae
MH  - Hemoglobins/*pharmacology
MH  - Ischemia/*physiopathology
MH  - Mesocricetus
MH  - Microcirculation/drug effects/physiopathology
MH  - Microscopy, Fluorescence
MH  - Muscle, Skeletal/*blood supply
MH  - Oxygen Consumption/*drug effects/physiology
MH  - Regional Blood Flow/drug effects/physiology
MH  - Skin/*blood supply
EDAT- 2003/01/31 04:00
MHDA- 2003/06/07 05:00
CRDT- 2003/01/31 04:00
PHST- 2003/01/31 04:00 [pubmed]
PHST- 2003/06/07 05:00 [medline]
PHST- 2003/01/31 04:00 [entrez]
AID - 10.1007/s10006-002-0424-1 [doi]
PST - ppublish
SO  - Mund Kiefer Gesichtschir. 2003 Jan;7(1):31-5. doi: 10.1007/s10006-002-0424-1. 
      Epub 2002 Nov 15.

PMID- 17999786
OWN - NLM
STAT- MEDLINE
DCOM- 20080110
LR  - 20151119
IS  - 1050-6586 (Print)
IS  - 1050-6586 (Linking)
VI  - 21
IP  - 5
DP  - 2007 Sep-Oct
TI  - Exhaled inflammatory markers in aspirin-induced asthma syndrome.
PG  - 542-7
AB  - BACKGROUND: Interleukin (IL)-4 and IL-6, respectively, markers of neutrophilic 
      and eosinophilic inflammation, were analyzed in nasal and oral exhaled breath 
      condensate to understand the inflammation of upper and lower airways in subjects 
      with aspirin-induced asthma (AIA) syndrome, evaluating possible differences 
      between AIA and the single pathological conditions included in AIA syndrome. 
      METHODS: Twelve patients with AIA, 17 patients with mild asthma (MA), 12 patients 
      with nasal polyposis (NP), 11 patients with mild asthma + nasal polyposis (MA + 
      NP), and 10 healthy subjects (HSs) were enrolled. Nasal and oral exhaled IL-4 and 
      IL-6 were measured by enzyme immunoassay kit. RESULTS: Higher levels of nasal and 
      oral exhaled IL-4 and IL-6 were observed in AIA compared with MA, NP, MA + NP, 
      and HSs. Moreover, a positive correlation was identified between nasal exhaled 
      IL-4 and IL-6 and, respectively, the number of neutrophils and eosinophils and in 
      nasal scraping. CONCLUSION: The concentration of eosinophilic and neutrophilic 
      markers in upper and lower airways of subjects with AIA syndrome is higher 
      compared with HS and subjects with MA, NP, and MA + NP.
FAU - Carpagnano, Giovanna E
AU  - Carpagnano GE
AD  - Institute of Respiratory Disease, Department of Medical and Occupational 
      Sciences, University of Foggia, Foggia, Italy. ge.carpagnano@unifg.it
FAU - Resta, Onofrio
AU  - Resta O
FAU - Gelardi, Matteo
AU  - Gelardi M
FAU - Spanevello, Antonio
AU  - Spanevello A
FAU - Di Gioia, Giuseppe
AU  - Di Gioia G
FAU - Giliberti, Tiziana
AU  - Giliberti T
FAU - Depalo, Annarita
AU  - Depalo A
FAU - Foschino Barbaro, Maria P
AU  - Foschino Barbaro MP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Rhinol
JT  - American journal of rhinology
JID - 8807268
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-6)
RN  - 207137-56-2 (Interleukin-4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/metabolism/*pharmacology
MH  - Asthma/*immunology
MH  - Biomarkers/chemistry
MH  - Eosinophils/metabolism
MH  - Exhalation
MH  - Female
MH  - Humans
MH  - Inflammation
MH  - Interleukin-4/metabolism
MH  - Interleukin-6/metabolism
MH  - Lung/pathology
MH  - Male
MH  - Middle Aged
MH  - Neutrophils/metabolism
MH  - Respiration
MH  - Skin Tests
MH  - Syndrome
EDAT- 2007/11/15 09:00
MHDA- 2008/01/11 09:00
CRDT- 2007/11/15 09:00
PHST- 2007/11/15 09:00 [pubmed]
PHST- 2008/01/11 09:00 [medline]
PHST- 2007/11/15 09:00 [entrez]
AID - 10.2500/ajr.2007.21.3066 [doi]
PST - ppublish
SO  - Am J Rhinol. 2007 Sep-Oct;21(5):542-7. doi: 10.2500/ajr.2007.21.3066.

PMID- 26696522
OWN - NLM
STAT- MEDLINE
DCOM- 20170406
LR  - 20170406
IS  - 1549-7879 (Electronic)
IS  - 1522-6514 (Linking)
VI  - 18
IP  - 9
DP  - 2016 Sep
TI  - Phytoremediation of aspirin and tetracycline by Brassica juncea.
PG  - 929-35
LID - 10.1080/15226514.2015.1131230 [doi]
AB  - With the increasing release of pharmaceutical drugs in the environment, research 
      is in progress for investigating alternative methods for their remediation. 
      Various studies have shown the phytoremediation potential of Brassica juncea for 
      metals. The current study was aimed at evaluating the phytoremediation potential 
      of B. juncea for two different pharmaceutical drugs i.e. aspirin and tetracycline 
      in in-vitro conditions. The seeds of B. juncea were germinated and grown for a 
      period of 28 and 24 days for aspirin and tetracycline, respectively. The study 
      analyzed the remediation rate of B. juncea for the selected drugs in three 
      different sets of varying concentration along with any phytotoxic effects exerted 
      by the drugs on the seeds. Preliminary results showed that the average 
      remediation rate of aspirin and tetracycline at the end of experiment was 
      approximately 90% and 71%, respectively. As initial drug concentrations were 
      increased in the media, the remediation rate also improved. However, at higher 
      concentrations, the plants showed phytotoxicity as depicted by the decrease in 
      shoot length of the germinated seeds. These preliminary results indicated that B. 
      juncea could tolerate and remediate pharmaceutical drugs such as analgesics and 
      antibiotics.
FAU - Gahlawat, Sonal
AU  - Gahlawat S
AD  - a Department of Biotechnology , Jaypee Institute of Information Technology, 
      Sec-62 , Noida , U.P. , India.
FAU - Gauba, Pammi
AU  - Gauba P
AD  - a Department of Biotechnology , Jaypee Institute of Information Technology, 
      Sec-62 , Noida , U.P. , India.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Phytoremediation
JT  - International journal of phytoremediation
JID - 101136878
RN  - 0 (Soil Pollutants)
RN  - F8VB5M810T (Tetracycline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*metabolism
MH  - Biodegradation, Environmental
MH  - Hydroponics
MH  - Mustard Plant/*metabolism
MH  - Soil Pollutants/*metabolism
MH  - Tetracycline/*metabolism
OTO - NOTNLM
OT  - Brassica juncea, aspirin
OT  - phytoremediation
OT  - phytotoxicity
OT  - tetracycline
EDAT- 2015/12/24 06:00
MHDA- 2017/04/07 06:00
CRDT- 2015/12/24 06:00
PHST- 2015/12/24 06:00 [entrez]
PHST- 2015/12/24 06:00 [pubmed]
PHST- 2017/04/07 06:00 [medline]
AID - 10.1080/15226514.2015.1131230 [doi]
PST - ppublish
SO  - Int J Phytoremediation. 2016 Sep;18(9):929-35. doi: 
      10.1080/15226514.2015.1131230.

PMID- 3879751
OWN - NLM
STAT- MEDLINE
DCOM- 19860916
LR  - 20131121
IS  - 0378-6501 (Print)
IS  - 0378-6501 (Linking)
VI  - 11
IP  - 8
DP  - 1985
TI  - Gentisate, a salicylate metabolite with antioxidant properties.
PG  - 463-7
AB  - Concentrations of gentisate found in plasma and synovial fluid were in excess of 
      concentrations required to exert an antioxidant effect in vitro. Studies of 
      diphenol/aminophenols suggested that an ortho or para configuration of functional 
      groups was required for this in vitro antioxidant activity. Animal studies 
      indicated some correlations between in vitro activity and pharmacology of these 
      agents.
FAU - Cleland, L G
AU  - Cleland LG
FAU - Whitehouse, M W
AU  - Whitehouse MW
FAU - Betts, W H
AU  - Betts WH
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Drugs Exp Clin Res
JT  - Drugs under experimental and clinical research
JID - 7802135
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Gentisates)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Antioxidants
MH  - Arthritis, Rheumatoid/metabolism
MH  - Aspirin/metabolism/therapeutic use
MH  - Biotransformation
MH  - Gentisates/*metabolism/pharmacology
MH  - Humans
MH  - Joint Diseases/drug therapy/*metabolism
MH  - Rats
MH  - Salicylates/metabolism
MH  - Synovial Fluid/*metabolism
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Drugs Exp Clin Res. 1985;11(8):463-7.

PMID- 6742879
OWN - NLM
STAT- MEDLINE
DCOM- 19840727
LR  - 20190501
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Print)
IS  - 0003-9888 (Linking)
VI  - 59
IP  - 6
DP  - 1984 Jun
TI  - Complete recovery after profound acidosis (pH 6.49).
PG  - 573-4
AB  - We describe an infant with profound acidosis caused by chronic therapeutic 
      salicylate poisoning. The confirmed arterial blood pH of 6.49 must be close to 
      the limit of tolerable acidity and is the lowest such value in our experience. 
      Full recovery was made.
FAU - Khan, M I
AU  - Khan MI
FAU - Miller, M T
AU  - Miller MT
FAU - Bartlett, M
AU  - Bartlett M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acidosis/blood/*chemically induced
MH  - Aspirin/*poisoning
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Infant
PMC - PMC1628767
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
AID - 10.1136/adc.59.6.573 [doi]
PST - ppublish
SO  - Arch Dis Child. 1984 Jun;59(6):573-4. doi: 10.1136/adc.59.6.573.

PMID- 16128237
OWN - NLM
STAT- MEDLINE
DCOM- 20051201
LR  - 20190922
IS  - 0920-5063 (Print)
IS  - 0920-5063 (Linking)
VI  - 16
IP  - 8
DP  - 2005
TI  - Mass uptake study of the diffusion of water and SBF into poly(2-hydroxyethyl 
      methacrylate-co-tetrahydrofurfuryl methacrylate) containing aspirin or vitamin 
      B12.
PG  - 1047-61
AB  - The ingress of water and Kokubo simulated body fluid (SBF) into 
      poly(2-hydroxyethyl methacrylate) (PHEMA), and its co-polymers with 
      tetrahydrofurduryl methacrylate (THFMA), loaded with either one of two model 
      drugs, vitamin B12 or aspirin, was studied by mass uptake over the temperature 
      range 298-318 K. The polymers were studied as cylinders and were loaded with 
      either 5 wt% or 10 wt% of the drugs. From DSC studies it was observed that 
      vitamin B12 behaved as a physical cross-linker restricting chain segmental 
      mobility, and so had a small anti-plasticisation effect on PHEMA and the 
      co-polymers rich in HEMA, but almost no effect on the Tg of co-polymers rich in 
      THFMA. On the other hand, aspirin exhibited a plasticising effect on PHEMA and 
      the co-polymers. All of the polymers were found to absorb water and SBF according 
      to a Fickian diffusion mechanism. The polymers were all found to swell to a 
      greater extent in SBF than in water, which was attributed to the presence of Tris 
      buffer in the SBF. The sorptions of the two penetrants were found to follow 
      Fickian kinetics in all cases and the diffusion coefficients at 310 K for SBF 
      were found to be smaller than those for water, except for the polymers containing 
      aspirin where the diffusion coefficients were higher than for the other systems. 
      For example, for sorption into PHEMA the diffusion coefficient for water was 1.41 
      x 10(-11) m2/s and for SBF was 0.79 x 10(-11) m2/s, but in the presence of 5 wt% 
      aspirin the corresponding values were 1.27 x 10(-11) m2/s and 1.25 x 10(-11) 
      m2/s, respectively. The corresponding values for PHEMA loaded with 5 wt% B12 were 
      1.25 x 10(-11) m2/s and 0.74 x 10(-11) m2/s, respectively.
FAU - Chowdhury, Mohammad A
AU  - Chowdhury MA
AD  - Polymer Materials and Radiation Group, Department of Chemistry, The University of 
      Queensland, Brisbane, QLD 4072, Australia.
FAU - Hill, David J T
AU  - Hill DJ
FAU - Whittaker, Andrew K
AU  - Whittaker AK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Biomater Sci Polym Ed
JT  - Journal of biomaterials science. Polymer edition
JID - 9007393
RN  - 0 (Methacrylates)
RN  - 0 (Polymers)
RN  - 0 (poly(hydroxyethyl methacrylate-co-tetrahydrofurfuryl methacrylate))
RN  - 059QF0KO0R (Water)
RN  - P6YC3EG204 (Vitamin B 12)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Body Fluids/*chemistry
MH  - Calorimetry, Differential Scanning
MH  - Diffusion
MH  - Methacrylates/*chemistry
MH  - Molecular Structure
MH  - Polymers/*chemistry
MH  - Vitamin B 12/*chemistry
MH  - Water/*chemistry
EDAT- 2005/09/01 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/09/01 09:00
PHST- 2005/09/01 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/09/01 09:00 [entrez]
AID - 10.1163/1568562054414685 [doi]
PST - ppublish
SO  - J Biomater Sci Polym Ed. 2005;16(8):1047-61. doi: 10.1163/1568562054414685.

PMID- 237748
OWN - NLM
STAT- MEDLINE
DCOM- 19751003
LR  - 20131121
IS  - 0012-0472 (Print)
IS  - 0012-0472 (Linking)
VI  - 100
IP  - 23
DP  - 1975 Jun 6
TI  - [The effect of aspirin, antacids, alcohol, and bile acids on transmural potential 
      difference of the human stomach (author's transl)].
PG  - 1263-8
AB  - The effect of orally administered buffered and unbuffered aspirin, antacids, 
      alcohol and bile salts on functional changes in the gastric mucosal barrier was 
      assessed by measuring gastric transmural potential differences (PD) in healthy 
      subjects. In contrast to buffered aspirin, unbuffered aspirin caused a marked 
      decrease in transmural PD due to its known effect of enhancing H+ back-diffusion. 
      Simultaneous administration of antacids prevented the aspirin-induced drop of 
      transmural PD. Ethanol (20% w/v), whisky (45% w/v), wine (6-7% ethanol), bile 
      salts and ox-bile reduced transmural PD in healthy subjects. The measurement of 
      transmural PD is a simple and sensitive method for detecting functional changes 
      in the gastric mucosal barrier induced by drugs known to alter mucosal 
      permeability.
FAU - Caspary, W F
AU  - Caspary WF
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Einfluss von Aspirin, Antacida, Alkohol und Gallensäuren auf die transmurale 
      elektrische Potentialdifferenz des menschlichen Magens.
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Antacids)
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Buffers)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antacids/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Bile Acids and Salts/*pharmacology
MH  - Buffers
MH  - Electricity
MH  - Ethanol/*pharmacology
MH  - Gastric Acidity Determination
MH  - Gastric Juice
MH  - Gastric Mucosa/drug effects
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Permeability
MH  - Stomach/*drug effects
EDAT- 1975/06/06 00:00
MHDA- 1975/06/06 00:01
CRDT- 1975/06/06 00:00
PHST- 1975/06/06 00:00 [pubmed]
PHST- 1975/06/06 00:01 [medline]
PHST- 1975/06/06 00:00 [entrez]
AID - 10.1055/s-0028-1106368 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 1975 Jun 6;100(23):1263-8. doi: 10.1055/s-0028-1106368.

PMID- 21112505
OWN - NLM
STAT- MEDLINE
DCOM- 20110401
LR  - 20211020
IS  - 1558-1950 (Electronic)
IS  - 1052-5157 (Linking)
VI  - 21
IP  - 1
DP  - 2011 Jan
TI  - Chemoprevention in Barrett's esophagus: A pill a day?
PG  - 155-70
LID - 10.1016/j.giec.2010.09.005 [doi]
AB  - Esophageal adenocarcinoma is increasing in incidence. The main risk factor is the 
      premalignant condition of Barrett's esophagus. There is great interest in 
      chemoprevention to prevent or slow malignant transformation. There are many 
      agents proposed as playing a role in chemoprevention; however, none is licensed 
      for this role as yet. Aspirin possesses many favorable qualities for 
      chemoprevention and is the focus of the largest randomized control trial in this 
      field.
CI  - Copyright © 2011 Elsevier Inc. All rights reserved.
FAU - Jankowski, Janusz A
AU  - Jankowski JA
AD  - Digestive Diseases Centre, Leicester Royal Infirmary, Infirmary Square, 
      Leicester, LE1 5WW, UK. j.a.jankowski@qmul.ac.uk
FAU - Hooper, Patricia A
AU  - Hooper PA
LA  - eng
GR  - 4584/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Gastrointest Endosc Clin N Am
JT  - Gastrointestinal endoscopy clinics of North America
JID - 9202792
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenocarcinoma/*prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Barrett Esophagus/pathology/*prevention & control
MH  - Diet
MH  - Esophageal Neoplasms/*prevention & control
MH  - Humans
MH  - Precancerous Conditions/pathology/*prevention & control
MH  - Proton Pump Inhibitors/*therapeutic use
EDAT- 2010/11/30 06:00
MHDA- 2011/04/02 06:00
CRDT- 2010/11/30 06:00
PHST- 2010/11/30 06:00 [entrez]
PHST- 2010/11/30 06:00 [pubmed]
PHST- 2011/04/02 06:00 [medline]
AID - S1052-5157(10)00124-8 [pii]
AID - 10.1016/j.giec.2010.09.005 [doi]
PST - ppublish
SO  - Gastrointest Endosc Clin N Am. 2011 Jan;21(1):155-70. doi: 
      10.1016/j.giec.2010.09.005.

PMID- 9588376
OWN - NLM
STAT- MEDLINE
DCOM- 19980603
LR  - 20190709
IS  - 0002-8614 (Print)
IS  - 0002-8614 (Linking)
VI  - 46
IP  - 5
DP  - 1998 May
TI  - Underutilization of aspirin in older patients with prior myocardial infarction at 
      the time of admission to a nursing home.
PG  - 615-6
AB  - OBJECTIVE: To investigate the prevalence of aspirin use in older patients with 
      prior myocardial infarction at the time of admission to a nursing home. DESIGN: 
      In a prospective study, the prevalence of aspirin use in 350 consecutive older 
      patients with documented Q-wave myocardial infarction and no contraindications to 
      aspirin use was investigated in patients aged 60 years or older at the time of 
      admission to a nursing home. SETTING: A large, long-term, healthcare facility. 
      PATIENTS: The patients included 231 women and 119 men, mean age 81 +/- 8 years 
      (range 60 to 100). MEASUREMENTS AND MAIN RESULTS: Of the 350 patients with 
      documented Q-wave myocardial infarction and no contraindications to aspirin 
      therapy, 60 patients (17%) were receiving aspirin at the time of admission to the 
      nursing home. CONCLUSION: There is a marked underutilization of aspirin in the 
      treatment of older patients with documented prior myocardial infarction at the 
      time of admission to a nursing home.
FAU - Aronow, W S
AU  - Aronow WS
AD  - Hebrew Hospital Home, Bronx, New York 10475, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Geriatr Soc. 1999 Jan;47(1):120-1. PMID: 9920243
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Drug Utilization
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - *Nursing Homes
MH  - Patient Admission
MH  - Prospective Studies
MH  - Recurrence
EDAT- 1998/05/20 00:00
MHDA- 1998/05/20 00:01
CRDT- 1998/05/20 00:00
PHST- 1998/05/20 00:00 [pubmed]
PHST- 1998/05/20 00:01 [medline]
PHST- 1998/05/20 00:00 [entrez]
AID - 10.1111/j.1532-5415.1998.tb01079.x [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 1998 May;46(5):615-6. doi: 10.1111/j.1532-5415.1998.tb01079.x.

PMID- 22877800
OWN - NLM
STAT- MEDLINE
DCOM- 20121010
LR  - 20181201
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 164
IP  - 2
DP  - 2012 Aug
TI  - Is there an association between aspirin dosing and cardiac and bleeding events 
      after treatment of acute coronary syndrome? A systematic review of the 
      literature.
PG  - 153-162.e5
LID - 10.1016/j.ahj.2012.04.001 [doi]
AB  - BACKGROUND: Current acetylsalicylic acid (ASA) dosing algorithms for the 
      prevention of secondary thrombotic events in acute coronary syndrome (ACS) 
      patients are inconsistent and lack sufficient data support. METHODS: We performed 
      a systematic review of the literature for studies that assessed clinical outcomes 
      in patients with ACS following coronary stent insertion (SI) or medical treatment 
      (MT). Acetylsalicylic acid dosing was stratified into low- (<160 mg) and high- (≥ 
      160 mg) dose categories. Outcomes were assessed at 1, 6, and 12 months and 
      included major bleeding, myocardial infarction, and all-cause death. A 
      random-effects meta-analysis was used to estimate the value of the mean for each 
      outcome variable. RESULTS: Of 12,472 publications identified, 136 studies with 
      289,330 patients were analyzed. In the 1-month SI analysis, proportions of 
      patients (95% CI) in the low- and high-dose ASA categories experiencing major 
      bleeding were 2.1% (1.5-2.6) and 1.9% (0.0-3.8); proportions with myocardial 
      infarction were 2.1% (1.3-2.8) and 1.8% (0.9-2.6); and proportions of all-cause 
      death were 2.8% (2.2-3.4) and 2.4% (1.3-3.5), respectively. Results were similar 
      in the MT analysis, except that major bleeding rates for low and high doses were 
      1.7% (1.3-2.2) and 4.0% (2.2-5.8), respectively. Regression analyses suggested 
      that the proportion of patients reporting each of the outcomes evaluated were not 
      significantly different between the low- and high-dose categories, with the 
      exception of the 1-month major bleeding following MT. CONCLUSIONS: Our results 
      suggest no improved clinical outcomes associated with higher ASA maintenance 
      doses in ACS patients receiving SI or MT. In the MT analysis, there was more 
      major bleeding in the first month after an ACS event with high-dose ASA.
CI  - Copyright © 2012 Mosby, Inc. All rights reserved.
FAU - Berger, Jeffrey S
AU  - Berger JS
AD  - New York University Medical Center, New York, NY 10016, USA. 
      jeffrey.berger@nyumc.org
FAU - Sallum, Rachel H
AU  - Sallum RH
FAU - Katona, Brian
AU  - Katona B
FAU - Maya, Juan
AU  - Maya J
FAU - Ranganathan, Gayatri
AU  - Ranganathan G
FAU - Xu, Yingxin
AU  - Xu Y
FAU - Mwamburi, Mkaya
AU  - Mwamburi M
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20120717
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Agents/therapeutic use
MH  - Cardiovascular Diseases/*chemically induced
MH  - Coronary Artery Bypass
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*adverse effects
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prosthesis Implantation
MH  - Stents
EDAT- 2012/08/11 06:00
MHDA- 2012/10/12 06:00
CRDT- 2012/08/11 06:00
PHST- 2011/07/20 00:00 [received]
PHST- 2012/04/05 00:00 [accepted]
PHST- 2012/08/11 06:00 [entrez]
PHST- 2012/08/11 06:00 [pubmed]
PHST- 2012/10/12 06:00 [medline]
AID - S0002-8703(12)00242-6 [pii]
AID - 10.1016/j.ahj.2012.04.001 [doi]
PST - ppublish
SO  - Am Heart J. 2012 Aug;164(2):153-162.e5. doi: 10.1016/j.ahj.2012.04.001. Epub 2012 
      Jul 17.

PMID- 34677825
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20220511
IS  - 1479-828X (Electronic)
IS  - 0004-8666 (Linking)
VI  - 62
IP  - 2
DP  - 2022 Apr
TI  - Associations between aspirin prophylaxis and fetal growth and preeclampsia in 
      women with pregestational diabetes.
PG  - 268-273
LID - 10.1111/ajo.13449 [doi]
AB  - BACKGROUND: Current guidelines recommend low-dose aspirin for preeclampsia 
      prophylaxis in all women with pregestational (type one and type two) diabetes 
      mellitus. Most trials showing the efficacy of low-dose aspirin in reducing 
      preeclampsia risk have either excluded or included only small numbers of such 
      women. AIM: To evaluate the association of low-dose aspirin prophylaxis in women 
      with pregestational diabetes with the incidence of large for gestational age 
      (LGA) infants and preeclampsia. MATERIALS AND METHODS: A retrospective 
      observational study of pregnancies to women with pregestational diabetes. 
      Outcomes included rates of LGA and preeclampsia. Women were prescribed low-dose 
      aspirin prophylaxis from early pregnancy according to physician discretion after 
      considering preeclampsia risk. Statistical analyses assessed the group overall 
      and with stratification by diabetes type and other preeclampsia risk factors. 
      RESULTS: Of 716 pregnancies, aspirin was prescribed in 296 (41%). Preeclampsia 
      occurred more frequently in women who received aspirin (58 of 296, 20%) than 
      those who did not (39 of 420, 9%, P < 0.001). This association was maintained 
      after adjustment for diabetes type and other preeclampsia risk factors (adjusted 
      odds ratio (aOR) 1.78; 95% CI 1.02-3.11). LGA infants were commoner in women with 
      type one diabetes of short duration who took aspirin (aOR 2.21; 95% CI 
      1.05-4.66). CONCLUSION: Low-dose aspirin use in women with pregestational 
      diabetes may be associated with an increased risk of preeclampsia. In women with 
      type one diabetes of short duration aspirin use may be associated with an 
      increased risk of LGA infants. The retrospective nature of this study is 
      acknowledged and assessment of such prophylaxis by further studies is warranted.
CI  - © 2021 The Royal Australian and New Zealand College of Obstetricians and 
      Gynaecologists.
FAU - Shrestha Khatri, Nely
AU  - Shrestha Khatri N
AUID- ORCID: 0000-0002-5399-4171
AD  - Department of Obstetrics and Gynaecology, King Edward Memorial Hospital, Perth, 
      Western Australia, Australia.
FAU - White, Scott W
AU  - White SW
AD  - Maternal and Fetal Medicine Service, Division of Obstetrics and Gynaecology, The 
      University of Western Australia, King Edward Memorial Hospital, Perth, Western 
      Australia, Australia.
FAU - Graham, Dorothy F
AU  - Graham DF
AD  - Faculty of Health and Medical Sciences Obstetrics and Gynaecology, The University 
      of Western Australia, King Edward Memorial Hospital, Perth, Western Australia, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20211022
PL  - Australia
TA  - Aust N Z J Obstet Gynaecol
JT  - The Australian & New Zealand journal of obstetrics & gynaecology
JID - 0001027
RN  - 0 (Analgesics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics
MH  - Aspirin/therapeutic use
MH  - *Diabetes Mellitus
MH  - Female
MH  - Fetal Development
MH  - Humans
MH  - *Pre-Eclampsia/epidemiology/prevention & control
MH  - Pregnancy
MH  - Retrospective Studies
MH  - Weight Gain
OTO - NOTNLM
OT  - aspirin
OT  - preeclampsia
OT  - pregestational diabetes
EDAT- 2021/10/23 06:00
MHDA- 2022/05/03 06:00
CRDT- 2021/10/22 12:30
PHST- 2021/09/21 00:00 [revised]
PHST- 2020/11/22 00:00 [received]
PHST- 2021/10/03 00:00 [accepted]
PHST- 2021/10/23 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
PHST- 2021/10/22 12:30 [entrez]
AID - 10.1111/ajo.13449 [doi]
PST - ppublish
SO  - Aust N Z J Obstet Gynaecol. 2022 Apr;62(2):268-273. doi: 10.1111/ajo.13449. Epub 
      2021 Oct 22.

PMID- 671247
OWN - NLM
STAT- MEDLINE
DCOM- 19780925
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 67
IP  - 8
DP  - 1978 Aug
TI  - Solid dispersion of pharmaceutical ternary systems I: Phase diagram of 
      aspirin-acetaminophen-urea system.
PG  - 1109-11
AB  - The phase diagram of an aspirin-acetaminophen-urea system was constructed. The 
      data obtained by the thermomicroscopic method showed that the binary systems of 
      aspirin-acetaminophen, aspirin-urea, and acetaminophen-urea are simple eutectic 
      mixtures with negligible formation of solid solutions or molecular compounds. The 
      equilateral triangular phase diagram of the ternary system revealed that it 
      forms, upon solidification, solid dispersions of the mechanical mixture type. The 
      ternary eutectic corresponded to a composition of 60% aspirin, 20% acetaminophen, 
      and 20% urea at 72 degrees. The method of calculating the composition finally 
      solidified melts, lying within any area of the phase diagram, is presented. Use 
      of the phase diagram in selecting the optimum ratio of components to enhance 
      dissolution rates of these drugs may be possible.
FAU - el-Banna, H M
AU  - el-Banna HM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 8W8T17847W (Urea)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acetaminophen
MH  - *Aspirin
MH  - Drug Combinations
MH  - Models, Chemical
MH  - Thermodynamics
MH  - *Urea
EDAT- 1978/08/01 00:00
MHDA- 1978/08/01 00:01
CRDT- 1978/08/01 00:00
PHST- 1978/08/01 00:00 [pubmed]
PHST- 1978/08/01 00:01 [medline]
PHST- 1978/08/01 00:00 [entrez]
AID - S0022-3549(15)42146-X [pii]
AID - 10.1002/jps.2600670822 [doi]
PST - ppublish
SO  - J Pharm Sci. 1978 Aug;67(8):1109-11. doi: 10.1002/jps.2600670822.

PMID- 7994405
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Diaspirin crosslinked hemoglobin (DCLHb): control of pressor effect with 
      anti-hypertensive agents.
PG  - 819-25
AB  - Diaspirin crosslinked hemoglobin (DCLHb) administration elevates mean arterial 
      pressure (MAP). The purpose of this study was to determine whether commonly used 
      antihypertensive agents could control this pressor effect in rats. Awake rats 
      were injected intravenously (i.v.) with 280 mg/kg of DCLHb. Fifteen minutes later 
      when MAP was 25-30% above baseline and heart rate (HR) was reciprocally 
      decreased, prazosin (2 mg/kg;an alpha adrenergic blocker), nitroglycerine (NTG; 
      10-150 mcg/min; a nitrovasodilator), nicardipine (0.204-0.08 mg/hr; a calcium 
      channel blocker) or labetalol (5 mg/kg; an alpha/beta adrenergic blocker) was 
      administered i.v. All four classes of antihypertensive agents promptly restored 
      MAP to baseline. Coincident with the return of MAP to baseline, HR was restored 
      to baseline in prazosin and NTG treated animals, however, bradycardia persisted 
      in those animals treated with nicardipine and labetalol, most likely due to the 
      negative chronotropic properties of these agents. We conclude that the pressor 
      effect of DCLHb can be readily controlled with at least four different classes of 
      commonly used antihypertensive agents.
FAU - Bilello, K
AU  - Bilello K
AD  - Department of Surgery, Uniformed Services University of the Health Sciences, 
      Bethesda, MD 20814.
FAU - Schultz, S
AU  - Schultz S
FAU - Powell, C
AU  - Powell C
FAU - Jaffin, J
AU  - Jaffin J
FAU - Cole, F
AU  - Cole F
FAU - Malcolm, D
AU  - Malcolm D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - CZ5312222S (Nicardipine)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
RN  - R5H8897N95 (Labetalol)
RN  - XM03YJ541D (Prazosin)
SB  - IM
MH  - Animals
MH  - Antihypertensive Agents/*pharmacology
MH  - Aspirin/*analogs & derivatives/toxicity
MH  - Blood Pressure/*drug effects
MH  - Blood Substitutes/*toxicity
MH  - Hemoglobins/*toxicity
MH  - Hypertension/drug therapy/etiology
MH  - Labetalol/pharmacology
MH  - Nicardipine/pharmacology
MH  - Nitroglycerin/pharmacology
MH  - Prazosin/pharmacology
MH  - Rats
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117916 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):819-25. doi: 
      10.3109/10731199409117916.

PMID- 2215187
OWN - NLM
STAT- MEDLINE
DCOM- 19901119
LR  - 20190918
IS  - 0738-1085 (Print)
IS  - 0738-1085 (Linking)
VI  - 11
IP  - 3
DP  - 1990
TI  - Time of low-dose acetylsalicylic acid administration influences in vivo platelet 
      function and thrombus formation following arteriotomy and intimectomy; an 
      experimental study in small arteries of rabbits.
PG  - 209-14
AB  - To investigate if low-dose acetylsalicylic acid (ASA), 4 mg/kg b.w., infused 
      peroperatively or 10 hours preoperatively has antithrombotic effects, the central 
      arteries of rabbit ears were prepared and 32P-labeled platelets injected. 
      Arteriotomy and intimectomy were performed and blood flow was restored. Bleeding 
      times at the sites of arteriotomy/intimectomy, in vivo accumulations of 
      isotope-labeled platelets, amounts of red thrombotic material, and patency were 
      recorded. Bleeding times following arterial puncture and the effect of ASA on 
      thromboxane production were studied separately. Ten hours after ASA 
      administration, bleeding times were shortened at the sites of 
      arteriotomy/intimectomy but were prolonged following arterial puncture. Platelet 
      accumulations were lower in patent vessels in this group than in an untreated 
      control group. Peroperative ASA treatment increased but treatment 10 hours prior 
      to blood flow restoration did not significantly affect the number of occlusions. 
      Thromboxane production in ASA-treated rabbits is largely inhibited even 14 hours 
      after administration.
FAU - Salemark, L
AU  - Salemark L
AD  - Department of Experimental Research, Malmö General Hospital, University of Lund, 
      Sweden.
FAU - Wieslander, J B
AU  - Wieslander JB
FAU - Dougan, P
AU  - Dougan P
FAU - Arnljots, B
AU  - Arnljots B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Microsurgery
JT  - Microsurgery
JID - 8309230
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteries/pathology/surgery
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Platelets/chemistry/*drug effects
MH  - Ear, External/*blood supply
MH  - Female
MH  - Male
MH  - Microscopy, Electron, Scanning
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Rabbits
MH  - Thrombosis/*physiopathology
MH  - Thromboxane B2/blood
MH  - Time Factors
MH  - Vascular Patency
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1002/micr.1920110304 [doi]
PST - ppublish
SO  - Microsurgery. 1990;11(3):209-14. doi: 10.1002/micr.1920110304.

PMID- 30221595
OWN - NLM
STAT- MEDLINE
DCOM- 20181105
LR  - 20220409
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 379
IP  - 16
DP  - 2018 Oct 18
TI  - Effect of Aspirin on All-Cause Mortality in the Healthy Elderly.
PG  - 1519-1528
LID - 10.1056/NEJMoa1803955 [doi]
AB  - BACKGROUND: In the primary analysis of the Aspirin in Reducing Events in the 
      Elderly (ASPREE) trial, now published in the Journal, we report that the daily 
      use of aspirin did not provide a benefit with regard to the primary end point of 
      disability-free survival among older adults. A numerically higher rate of the 
      secondary end point of death from any cause was observed with aspirin than with 
      placebo. METHODS: From 2010 through 2014, we enrolled community-dwelling persons 
      in Australia and the United States who were 70 years of age or older (or ≥65 
      years of age among blacks and Hispanics in the United States) and did not have 
      cardiovascular disease, dementia, or disability. Participants were randomly 
      assigned to receive 100 mg of enteric-coated aspirin or placebo. Deaths were 
      classified according to the underlying cause by adjudicators who were unaware of 
      trial-group assignments. Hazard ratios were calculated to compare mortality 
      between the aspirin group and the placebo group, and post hoc exploratory 
      analyses of specific causes of death were performed. RESULTS: Of the 19,114 
      persons who were enrolled, 9525 were assigned to receive aspirin and 9589 to 
      receive placebo. A total of 1052 deaths occurred during a median of 4.7 years of 
      follow-up. The risk of death from any cause was 12.7 events per 1000 person-years 
      in the aspirin group and 11.1 events per 1000 person-years in the placebo group 
      (hazard ratio, 1.14; 95% confidence interval [CI], 1.01 to 1.29). Cancer was the 
      major contributor to the higher mortality in the aspirin group, accounting for 
      1.6 excess deaths per 1000 person-years. Cancer-related death occurred in 3.1% of 
      the participants in the aspirin group and in 2.3% of those in the placebo group 
      (hazard ratio, 1.31; 95% CI, 1.10 to 1.56). CONCLUSIONS: Higher all-cause 
      mortality was observed among apparently healthy older adults who received daily 
      aspirin than among those who received placebo and was attributed primarily to 
      cancer-related death. In the context of previous studies, this result was 
      unexpected and should be interpreted with caution. (Funded by the National 
      Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583 .).
FAU - McNeil, John J
AU  - McNeil JJ
AUID- ORCID: 0000-0002-1049-5129
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Woods, Robyn L
AU  - Woods RL
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Lockery, Jessica E
AU  - Lockery JE
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Reid, Christopher M
AU  - Reid CM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Kirpach, Brenda
AU  - Kirpach B
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Shah, Raj C
AU  - Shah RC
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Ives, Diane G
AU  - Ives DG
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Storey, Elsdon
AU  - Storey E
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Ryan, Joanne
AU  - Ryan J
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Tonkin, Andrew M
AU  - Tonkin AM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Newman, Anne B
AU  - Newman AB
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Williamson, Jeff D
AU  - Williamson JD
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Margolis, Karen L
AU  - Margolis KL
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Abhayaratna, Walter P
AU  - Abhayaratna WP
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Stocks, Nigel
AU  - Stocks N
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Fitzgerald, Sharyn M
AU  - Fitzgerald SM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Orchard, Suzanne G
AU  - Orchard SG
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Trevaks, Ruth E
AU  - Trevaks RE
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Beilin, Lawrence J
AU  - Beilin LJ
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Donnan, Geoffrey A
AU  - Donnan GA
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Gibbs, Peter
AU  - Gibbs P
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Johnston, Colin I
AU  - Johnston CI
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Radziszewska, Barbara
AU  - Radziszewska B
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Grimm, Richard
AU  - Grimm R
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
FAU - Murray, Anne M
AU  - Murray AM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., M.R.N., R.L.W., J.E.L., R.W., C.M.R., E.S., J.R., A.M.T., S.M.F., 
      S.G.O., R.E.T., C.I.J.), Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and Florey 
      Institute of Neuroscience and Mental Health, University of Melbourne, Parkville 
      (G.A.D.), VIC, Menzies Institute for Medical Research, University of Tasmania, 
      Hobart (M.R.N.), the School of Public Health, Curtin University (C.M.R.), and the 
      School of Medicine, Royal Perth Hospital, University of Western Australia 
      (L.J.B.), Perth, College of Medicine, Biology, and Environment, Australian 
      National University, Canberra, ACT (W.P.A.), and Discipline of General Practice, 
      University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman Center for 
      Outcomes and Clinical Research, Hennepin Healthcare Research Institute (B.K., 
      R.G., A.M.M.), and the Division of Geriatrics, Department of Medicine (A.M.M.), 
      Hennepin Healthcare, HealthPartners Institute (K.L.M.), and the University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, Department of Epidemiology, 
      University of Pittsburgh, Pittsburgh (D.G.I., A.B.N.); Sticht Center on Aging and 
      Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department 
      of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); 
      the Department of Pharmacy Practice and Science, College of Pharmacy and 
      Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      Iowa City (M.E.E.); and the Division of Geriatrics and Clinical Gerontology, 
      National Institute on Aging, Bethesda, MD (B.R.).
CN  - ASPREE Investigator Group
LA  - eng
SI  - ClinicalTrials.gov/NCT01038583
GR  - P30 AG010161/AG/NIA NIH HHS/United States
GR  - P30 AG049638/AG/NIA NIH HHS/United States
GR  - U01 AG029824/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180916
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 2019 Feb;156(3):534-538. PMID: 30529298
CIN - Internist (Berl). 2019 Feb;60(2):209-216. PMID: 30645666
CIN - MMW Fortschr Med. 2019 Feb;161(2):35. PMID: 30721495
CIN - N Engl J Med. 2019 May 2;380(18):1775. PMID: 31042833
CIN - N Engl J Med. 2019 May 2;380(18):1775. PMID: 31042834
CIN - N Engl J Med. 2019 May 2;380(18):1775-1776. PMID: 31042835
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Australia
MH  - Cause of Death
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced/mortality
MH  - Humans
MH  - Independent Living
MH  - Male
MH  - *Mortality
MH  - Neoplasms/mortality
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Treatment Failure
MH  - United States
PMC - PMC6433466
MID - NIHMS1512091
FIR - Chan, Andrew
IR  - Chan A
FIR - Demons, Jamehl
IR  - Demons J
FIR - Espinoza, Sara
IR  - Espinoza S
FIR - Goetz, Matthew
IR  - Goetz M
FIR - Liew, Danny
IR  - Liew D
FIR - Meyskens, Frank
IR  - Meyskens F
FIR - Zalcberg, John
IR  - Zalcberg J
FIR - Ives, Diane
IR  - Ives D
FIR - Berk, Michael
IR  - Berk M
FIR - Bernstein, Wendy
IR  - Bernstein W
FIR - Brauer, Donna
IR  - Brauer D
FIR - Burns, Christine
IR  - Burns C
FIR - Chong, Trevor
IR  - Chong T
FIR - Cloud, Geoff
IR  - Cloud G
FIR - Eaton, Charles
IR  - Eaton C
FIR - Fitzgerald, Paul
IR  - Fitzgerald P
FIR - Haydon, Andrew
IR  - Haydon A
FIR - Jelinek, Michael
IR  - Jelinek M
FIR - Macrae, Finlay
IR  - Macrae F
FIR - Mahady, Suzanne
IR  - Mahady S
FIR - Malik, Mobin
IR  - Malik M
FIR - McLean, Catriona
IR  - McLean C
FIR - Rodriguez, Luz
IR  - Rodriguez L
FIR - Satterfield, Suzanne
IR  - Satterfield S
FIR - Tie, Jeanne
IR  - Tie J
FIR - van Londen, Gijsberta
IR  - van Londen G
FIR - Ward, Stephanie
IR  - Ward S
FIR - Wood, Erica
IR  - Wood E
FIR - Mohr, Jay
IR  - Mohr J
FIR - Anderson, Garnet
IR  - Anderson G
FIR - Connolly, Stuart
IR  - Connolly S
FIR - Friedman, Larry
IR  - Friedman L
FIR - Manson, JoAnn
IR  - Manson J
FIR - Sano, Mary
IR  - Sano M
FIR - Morrison, Sean
IR  - Morrison S
FIR - Ohman, Erik Magnus
IR  - Ohman EM
FIR - Hadley, Evan
IR  - Hadley E
FIR - Hannah, Judy
IR  - Hannah J
FIR - Romashkan, Sergei
IR  - Romashkan S
FIR - Ford, Leslie
IR  - Ford L
FIR - Richmond, Ellen
IR  - Richmond E
FIR - Umar, Asad
IR  - Umar A
FIR - Lockett, Trevor
IR  - Lockett T
FIR - Lewis, Beth
IR  - Lewis B
FIR - Obisesan, Thomas
IR  - Obisesan T
FIR - Gilbertson, Dave
IR  - Gilbertson D
FIR - Collyer, Taya
IR  - Collyer T
FIR - Rigby, Jason
IR  - Rigby J
FIR - Pruksawongsin, Kunnapoj
IR  - Pruksawongsin K
FIR - Hay, Nino
IR  - Hay N
FIR - Jachno, Kim
IR  - Jachno K
FIR - Smith, Catherine
IR  - Smith C
FIR - Ekram, A R M Saifuddin
IR  - Ekram ARMS
FIR - Gardam, Madeleine
IR  - Gardam M
FIR - Luong, Henry
IR  - Luong H
FIR - Montgomery, Tim
IR  - Montgomery T
FIR - Plate, Megan
IR  - Plate M
FIR - Rojas, Laura
IR  - Rojas L
FIR - Tominaga, Anna
IR  - Tominaga A
FIR - Wadeson, Katrina
IR  - Wadeson K
FIR - Hopkins, Sarah
IR  - Hopkins S
FIR - Nichols, Trisha
IR  - Nichols T
FIR - Johnson, Ashley
IR  - Johnson A
FIR - Prozinski, Molly
IR  - Prozinski M
FIR - Robinson-O’Brien, Ramona
IR  - Robinson-O’Brien R
FIR - Tessum, Nate
IR  - Tessum N
FIR - Aloia, John
IR  - Aloia J
FIR - Anton, Steve
IR  - Anton S
FIR - Burns, Jeffery
IR  - Burns J
FIR - Burton, Gary
IR  - Burton G
FIR - Ferris, Darron
IR  - Ferris D
FIR - Honasoge, Mahalakshmi
IR  - Honasoge M
FIR - Hsia, Daniel
IR  - Hsia D
FIR - Katzman, Steven
IR  - Katzman S
FIR - Kottam, Anupama
IR  - Kottam A
FIR - Nesbitt, Shawna
IR  - Nesbitt S
FIR - Ochoa, Augusto
IR  - Ochoa A
FIR - Pemu, Pricilla
IR  - Pemu P
FIR - Peterson, Kevin
IR  - Peterson K
FIR - Powell, James
IR  - Powell J
FIR - Pressman, Gregg
IR  - Pressman G
FIR - Robinson, William III
IR  - Robinson W III
FIR - Satterfield, Susanne
IR  - Satterfield S
FIR - Thorburn, Christine
IR  - Thorburn C
FIR - Volpi, Elena
IR  - Volpi E
FIR - Wiggins, Jocelyn
IR  - Wiggins J
FIR - Wilson, Peter
IR  - Wilson P
FIR - Womack, Catherine
IR  - Womack C
FIR - Abdullah, M
IR  - Abdullah M
FIR - Abdul-Ridha, S
IR  - Abdul-Ridha S
FIR - Aboud, E
IR  - Aboud E
FIR - Abraham, A
IR  - Abraham A
FIR - Abraham, J
IR  - Abraham J
FIR - Abraham, K
IR  - Abraham K
FIR - Abrahams, M
IR  - Abrahams M
FIR - Adad, S
IR  - Adad S
FIR - Adams, C
IR  - Adams C
FIR - Africa, N
IR  - Africa N
FIR - Afroze, S
IR  - Afroze S
FIR - Agarwal, D
IR  - Agarwal D
FIR - Agbarakwe, C
IR  - Agbarakwe C
FIR - Ah Sang, W
IR  - Ah Sang W
FIR - Ahern, T
IR  - Ahern T
FIR - Ahmad, Y
IR  - Ahmad Y
FIR - Ahmad, Z
IR  - Ahmad Z
FIR - Ahmed, L
IR  - Ahmed L
FIR - Ajam, A
IR  - Ajam A
FIR - Akhter, R
IR  - Akhter R
FIR - Akram, Z
IR  - Akram Z
FIR - Alagarswami, K
IR  - Alagarswami K
FIR - Alam, M
IR  - Alam M
FIR - Alavi, E
IR  - Alavi E
FIR - Aldridge, L
IR  - Aldridge L
FIR - Alethan, A
IR  - Alethan A
FIR - Alexander, K
IR  - Alexander K
FIR - Alexander, L
IR  - Alexander L
FIR - Alexopoulos, M
IR  - Alexopoulos M
FIR - Ali, B
IR  - Ali B
FIR - Ali, M
IR  - Ali M
FIR - Allan, J
IR  - Allan J
FIR - Allen, C
IR  - Allen C
FIR - Allen, G
IR  - Allen G
FIR - Allen, S
IR  - Allen S
FIR - Allin, P
IR  - Allin P
FIR - Al-Musawy, R
IR  - Al-Musawy R
FIR - Alpren, C
IR  - Alpren C
FIR - Al-Tawil, I
IR  - Al-Tawil I
FIR - Alwyn, T
IR  - Alwyn T
FIR - Amor, P
IR  - Amor P
FIR - Anam, T
IR  - Anam T
FIR - Anderson, G
IR  - Anderson G
FIR - Anderson, L
IR  - Anderson L
FIR - Anderson, N
IR  - Anderson N
FIR - Anderson, P
IR  - Anderson P
FIR - Anderson, R
IR  - Anderson R
FIR - Anderson-Dalheim, H
IR  - Anderson-Dalheim H
FIR - Andrada, E
IR  - Andrada E
FIR - Andre, S
IR  - Andre S
FIR - Andrews, L
IR  - Andrews L
FIR - Andric, A
IR  - Andric A
FIR - Andric, M
IR  - Andric M
FIR - Ang, J
IR  - Ang J
FIR - Ansari, A
IR  - Ansari A
FIR - Arakji, A M
IR  - Arakji AM
FIR - Arambeploa, Y
IR  - Arambeploa Y
FIR - Ark, R
IR  - Ark R
FIR - Arnaudon, F P
IR  - Arnaudon FP
FIR - Arndt, P M
IR  - Arndt PM
FIR - Aroney, T
IR  - Aroney T
FIR - Arthurson, J
IR  - Arthurson J
FIR - Arunachalam, T
IR  - Arunachalam T
FIR - Asim, N
IR  - Asim N
FIR - Aslam, I
IR  - Aslam I
FIR - Assad, S
IR  - Assad S
FIR - Astley, N
IR  - Astley N
FIR - Athari, M
IR  - Athari M
FIR - Atkins, C
IR  - Atkins C
FIR - Atkins, M
IR  - Atkins M
FIR - Aufgang, M
IR  - Aufgang M
FIR - Aung, K
IR  - Aung K
FIR - Aurora, G
IR  - Aurora G
FIR - Auteri, S
IR  - Auteri S
FIR - Avergun, A
IR  - Avergun A
FIR - Awwad, A
IR  - Awwad A
FIR - Azad, C
IR  - Azad C
FIR - Azra, S
IR  - Azra S
FIR - Babovic, A
IR  - Babovic A
FIR - Baig, M
IR  - Baig M
FIR - Baker, J
IR  - Baker J
FIR - Baker, S
IR  - Baker S
FIR - Baker, T
IR  - Baker T
FIR - Bakhilova, N
IR  - Bakhilova N
FIR - Baldam, A
IR  - Baldam A
FIR - Baldassa, A
IR  - Baldassa A
FIR - Baldi, C
IR  - Baldi C
FIR - Balkwill, C
IR  - Balkwill C
FIR - Balogun, O
IR  - Balogun O
FIR - Ban, A
IR  - Ban A
FIR - Banerjee, P
IR  - Banerjee P
FIR - Banning, M
IR  - Banning M
FIR - Bansal, S
IR  - Bansal S
FIR - Barkas, R
IR  - Barkas R
FIR - Barker, A
IR  - Barker A
FIR - Barker, D
IR  - Barker D
FIR - Barnes, A
IR  - Barnes A
FIR - Barnes, N
IR  - Barnes N
FIR - Barnetson, W
IR  - Barnetson W
FIR - Barratt, I
IR  - Barratt I
FIR - Barrett, D A
IR  - Barrett DA
FIR - Barrett, Meagan
IR  - Barrett M
FIR - Barrett, Michelle
IR  - Barrett M
FIR - Barrett, P
IR  - Barrett P
FIR - Barrett, T
IR  - Barrett T
FIR - Barson, P
IR  - Barson P
FIR - Barstad, C
IR  - Barstad C
FIR - Barton, W
IR  - Barton W
FIR - Bartram, M
IR  - Bartram M
FIR - Bartusek, P
IR  - Bartusek P
FIR - Basser, S
IR  - Basser S
FIR - Bassett, S
IR  - Bassett S
FIR - Batchelor, L
IR  - Batchelor L
FIR - Batt, D
IR  - Batt D
FIR - Batty, A
IR  - Batty A
FIR - Baum, S
IR  - Baum S
FIR - Baxter, M
IR  - Baxter M
FIR - Beaton, G
IR  - Beaton G
FIR - Beaumont, J
IR  - Beaumont J
FIR - Beavis, D
IR  - Beavis D
FIR - Beckett, V
IR  - Beckett V
FIR - Beech, M
IR  - Beech M
FIR - Beilby, J
IR  - Beilby J
FIR - Bekal, S
IR  - Bekal S
FIR - Bell, A
IR  - Bell A
FIR - Bendtsen, L
IR  - Bendtsen L
FIR - Benedict, D
IR  - Benedict D
FIR - Benjamin, T
IR  - Benjamin T
FIR - Bennett, P
IR  - Bennett P
FIR - Bennie, G
IR  - Bennie G
FIR - Bennie, S
IR  - Bennie S
FIR - Bennison, S
IR  - Bennison S
FIR - Benson, A
IR  - Benson A
FIR - Benson, R
IR  - Benson R
FIR - Benson, S
IR  - Benson S
FIR - Bergin, J
IR  - Bergin J
FIR - Bergin, S
IR  - Bergin S
FIR - Berryman, G
IR  - Berryman G
FIR - Berryman, J
IR  - Berryman J
FIR - Bertram, H
IR  - Bertram H
FIR - Bertuch, G
IR  - Bertuch G
FIR - Bettenay, G
IR  - Bettenay G
FIR - Bettiol, L
IR  - Bettiol L
FIR - Bills, R
IR  - Bills R
FIR - Birch, J
IR  - Birch J
FIR - Bird, Rachel
IR  - Bird R
FIR - Bird, Robert
IR  - Bird R
FIR - Birks, R
IR  - Birks R
FIR - Blake, R
IR  - Blake R
FIR - Blakney, A
IR  - Blakney A
FIR - Blashki, M
IR  - Blashki M
FIR - Bleach, G
IR  - Bleach G
FIR - Bloch, B
IR  - Bloch B
FIR - Bodenstein, M
IR  - Bodenstein M
FIR - Boga, V
IR  - Boga V
FIR - Bollen, C
IR  - Bollen C
FIR - Boltin, P
IR  - Boltin P
FIR - Boon, B
IR  - Boon B
FIR - Booth, G
IR  - Booth G
FIR - Borg, A
IR  - Borg A
FIR - Bornstein, D
IR  - Bornstein D
FIR - Bottcher, C
IR  - Bottcher C
FIR - Bourke, J
IR  - Bourke J
FIR - Bourke, M
IR  - Bourke M
FIR - Boutcher, S
IR  - Boutcher S
FIR - Bowden, J
IR  - Bowden J
FIR - Bowen, J
IR  - Bowen J
FIR - Bowring, B
IR  - Bowring B
FIR - Boyce, C
IR  - Boyce C
FIR - Boyd, J
IR  - Boyd J
FIR - Brack, R
IR  - Brack R
FIR - Bradshaw, A
IR  - Bradshaw A
FIR - Brady, P
IR  - Brady P
FIR - Braithwaite, J
IR  - Braithwaite J
FIR - Braude, G
IR  - Braude G
FIR - Brayshaw, N
IR  - Brayshaw N
FIR - Breen, M
IR  - Breen M
FIR - Bresnahan, R
IR  - Bresnahan R
FIR - Briddon, P
IR  - Briddon P
FIR - Bridge, A
IR  - Bridge A
FIR - Briggs, S J
IR  - Briggs SJ
FIR - Brimage, R F
IR  - Brimage RF
FIR - Britten-Jones, W
IR  - Britten-Jones W
FIR - Brkic, M
IR  - Brkic M
FIR - Broadby, M
IR  - Broadby M
FIR - Bromberger, D
IR  - Bromberger D
FIR - Brommeyer, A
IR  - Brommeyer A
FIR - Broom, I
IR  - Broom I
FIR - Brophy, T
IR  - Brophy T
FIR - Brough, J
IR  - Brough J
FIR - Brougham, J P
IR  - Brougham JP
FIR - Broun, C
IR  - Broun C
FIR - Brown, I D
IR  - Brown ID
FIR - Brown, J
IR  - Brown J
FIR - Brown, M B
IR  - Brown MB
FIR - Brown, M P
IR  - Brown MP
FIR - Brown, R
IR  - Brown R
FIR - Brownbill, C
IR  - Brownbill C
FIR - Brownbill, L
IR  - Brownbill L
FIR - Browne, M
IR  - Browne M
FIR - Brownstein, M
IR  - Brownstein M
FIR - Bruce, A
IR  - Bruce A
FIR - Brunacci, F
IR  - Brunacci F
FIR - Brunner, C
IR  - Brunner C
FIR - Bruorton, M
IR  - Bruorton M
FIR - Buccheri, V
IR  - Buccheri V
FIR - Buchanan, D
IR  - Buchanan D
FIR - Buckley, J
IR  - Buckley J
FIR - Bulle, B
IR  - Bulle B
FIR - Bundy, K
IR  - Bundy K
FIR - Burke, M
IR  - Burke M
FIR - Busch, G
IR  - Busch G
FIR - Bush, C P
IR  - Bush CP
FIR - Butrev, A
IR  - Butrev A
FIR - Bvirakare, J
IR  - Bvirakare J
FIR - Bvumbura, B F
IR  - Bvumbura BF
FIR - Bye, J
IR  - Bye J
FIR - Byrne, C
IR  - Byrne C
FIR - Byrne, P
IR  - Byrne P
FIR - Cain, M
IR  - Cain M
FIR - Calcutt, I
IR  - Calcutt I
FIR - Calder, K
IR  - Calder K
FIR - Caldwell, M
IR  - Caldwell M
FIR - Callan, C
IR  - Callan C
FIR - Cameron, A
IR  - Cameron A
FIR - Cameron, David
IR  - Cameron D
FIR - Cameron, Donald
IR  - Cameron D
FIR - Cameron, T
IR  - Cameron T
FIR - Campbell, David
IR  - Campbell D
FIR - Campbell, Donald
IR  - Campbell D
FIR - Campbell, Geoffrey
IR  - Campbell G
FIR - Campbell, Guy
IR  - Campbell G
FIR - Campbell, P H
IR  - Campbell PH
FIR - Campbell, R
IR  - Campbell R
FIR - Carroll, N
IR  - Carroll N
FIR - Carroll, V
IR  - Carroll V
FIR - Carson, J
IR  - Carson J
FIR - Carson, R
IR  - Carson R
FIR - Carter, L
IR  - Carter L
FIR - Carter, P
IR  - Carter P
FIR - Carter, R
IR  - Carter R
FIR - Carter, S
IR  - Carter S
FIR - Cartwright, P
IR  - Cartwright P
FIR - Cassidy, P
IR  - Cassidy P
FIR - Catchpole, M
IR  - Catchpole M
FIR - Cato, G
IR  - Cato G
FIR - Celada, R
IR  - Celada R
FIR - Chai, F
IR  - Chai F
FIR - Chalabi, A
IR  - Chalabi A
FIR - Chalissery, P
IR  - Chalissery P
FIR - Chalmers, M L
IR  - Chalmers ML
FIR - Chamberlain, H
IR  - Chamberlain H
FIR - Chamoun, R
IR  - Chamoun R
FIR - Chan, B
IR  - Chan B
FIR - Chan, C
IR  - Chan C
FIR - Chan, C K
IR  - Chan CK
FIR - Chan, F W
IR  - Chan FW
FIR - Chan, K
IR  - Chan K
FIR - Chandran, S
IR  - Chandran S
FIR - Chandrananth, M
IR  - Chandrananth M
FIR - Chandrananth, S
IR  - Chandrananth S
FIR - Chang, C
IR  - Chang C
FIR - Chang, V
IR  - Chang V
FIR - Chang, W
IR  - Chang W
FIR - Changakoti, A
IR  - Changakoti A
FIR - Chantler, R
IR  - Chantler R
FIR - Chao, D
IR  - Chao D
FIR - Chao, S
IR  - Chao S
FIR - Charlton, P
IR  - Charlton P
FIR - Chattersee, A
IR  - Chattersee A
FIR - Chau, G
IR  - Chau G
FIR - Chaung, Y
IR  - Chaung Y
FIR - Chawtur, V
IR  - Chawtur V
FIR - Cheah, H-H
IR  - Cheah HH
FIR - Cheah, S
IR  - Cheah S
FIR - Cheasley, A
IR  - Cheasley A
FIR - Chee, H
IR  - Chee H
FIR - Chen, D
IR  - Chen D
FIR - Cheng, W
IR  - Cheng W
FIR - Chesney, D
IR  - Chesney D
FIR - Chew, D
IR  - Chew D
FIR - Chhabra, P
IR  - Chhabra P
FIR - Chia, I
IR  - Chia I
FIR - Chia, P
IR  - Chia P
FIR - Chiang, A
IR  - Chiang A
FIR - Chiang, S
IR  - Chiang S
FIR - Chiew, I
IR  - Chiew I
FIR - Chiew, L
IR  - Chiew L
FIR - Chikarsal, A
IR  - Chikarsal A
FIR - Chin, J
IR  - Chin J
FIR - Chin, M
IR  - Chin M
FIR - Chipman, J S
IR  - Chipman JS
FIR - Chipperfield, C
IR  - Chipperfield C
FIR - Chisholm, H
IR  - Chisholm H
FIR - Chisholm, L
IR  - Chisholm L
FIR - Chiu, A
IR  - Chiu A
FIR - Chiu, C
IR  - Chiu C
FIR - Chiu, D
IR  - Chiu D
FIR - Chiu, T
IR  - Chiu T
FIR - Chizik, L
IR  - Chizik L
FIR - Choksey, H
IR  - Choksey H
FIR - Choo, E
IR  - Choo E
FIR - Chow, Amy
IR  - Chow A
FIR - Chow, Andrew
IR  - Chow A
FIR - Choy, C
IR  - Choy C
FIR - Chu, S
IR  - Chu S
FIR - Chua, A
IR  - Chua A
FIR - Chuah, T
IR  - Chuah T
FIR - Chung, J
IR  - Chung J
FIR - Cimpoescu, T
IR  - Cimpoescu T
FIR - Clapton, J
IR  - Clapton J
FIR - Clark, Benedict
IR  - Clark B
FIR - Clark, Benjamin
IR  - Clark B
FIR - Clark, M
IR  - Clark M
FIR - Clark, R
IR  - Clark R
FIR - Clarke, A
IR  - Clarke A
FIR - Clarke, D
IR  - Clarke D
FIR - Clarke, S
IR  - Clarke S
FIR - Cleary, G
IR  - Cleary G
FIR - Clerigo, L
IR  - Clerigo L
FIR - Clohesy, S
IR  - Clohesy S
FIR - Close, S
IR  - Close S
FIR - Cochrane, F
IR  - Cochrane F
FIR - Cohen, I S
IR  - Cohen IS
FIR - Cohen, J
IR  - Cohen J
FIR - Colahan, R
IR  - Colahan R
FIR - Collins, J
IR  - Collins J
FIR - Colman, W
IR  - Colman W
FIR - Colvin, R
IR  - Colvin R
FIR - Conde, S
IR  - Conde S
FIR - Connell, P
IR  - Connell P
FIR - Connellan, M
IR  - Connellan M
FIR - Connor, W
IR  - Connor W
FIR - Connors, G
IR  - Connors G
FIR - Conos, M
IR  - Conos M
FIR - Conron, D
IR  - Conron D
FIR - Conroy, J
IR  - Conroy J
FIR - Conway, C
IR  - Conway C
FIR - Cooper, M
IR  - Cooper M
FIR - Cooper, S
IR  - Cooper S
FIR - Cope, A
IR  - Cope A
FIR - Corrigan, Simon
IR  - Corrigan S
FIR - Corrigan, Sue
IR  - Corrigan S
FIR - Coughlan, P
IR  - Coughlan P
FIR - Coulter, E
IR  - Coulter E
FIR - Counsel, L
IR  - Counsel L
FIR - Court, D
IR  - Court D
FIR - Courtis, G
IR  - Courtis G
FIR - Cousens, A
IR  - Cousens A
FIR - Craig, L
IR  - Craig L
FIR - Crameri, M
IR  - Crameri M
FIR - Cranswick, M
IR  - Cranswick M
FIR - Crawford, J
IR  - Crawford J
FIR - Crawford, M
IR  - Crawford M
FIR - Crawford, P
IR  - Crawford P
FIR - Crawford, R
IR  - Crawford R
FIR - Crick, S
IR  - Crick S
FIR - Crimmins, B
IR  - Crimmins B
FIR - Cristofaro, R
IR  - Cristofaro R
FIR - Croatto, J
IR  - Croatto J
FIR - Crompton, A
IR  - Crompton A
FIR - Cronin, E
IR  - Cronin E
FIR - Crookes, J
IR  - Crookes J
FIR - Cross, B
IR  - Cross B
FIR - Cross, D
IR  - Cross D
FIR - Cross, M
IR  - Cross M
FIR - Crow, P
IR  - Crow P
FIR - Crowe, J E
IR  - Crowe JE
FIR - Crowe, P
IR  - Crowe P
FIR - Crowley, H
IR  - Crowley H
FIR - Cruickshank, J
IR  - Cruickshank J
FIR - Cummins, R
IR  - Cummins R
FIR - Cunneen, A
IR  - Cunneen A
FIR - Cunningham, A
IR  - Cunningham A
FIR - Cunningham, N
IR  - Cunningham N
FIR - Cunningham, P
IR  - Cunningham P
FIR - Curnow, D
IR  - Curnow D
FIR - Curran, J
IR  - Curran J
FIR - Curran, M
IR  - Curran M
FIR - Currie, A
IR  - Currie A
FIR - Curtis, R
IR  - Curtis R
FIR - Cusack, J
IR  - Cusack J
FIR - Dabash, K
IR  - Dabash K
FIR - Dabestani, V
IR  - Dabestani V
FIR - Dadabhay, Z
IR  - Dadabhay Z
FIR - Daglas, D
IR  - Daglas D
FIR - Dagley, P
IR  - Dagley P
FIR - Danesh, S
IR  - Danesh S
FIR - Dang, D
IR  - Dang D
FIR - Daniels, R
IR  - Daniels R
FIR - Darby, J P
IR  - Darby JP
FIR - Darko, N
IR  - Darko N
FIR - Darling, J
IR  - Darling J
FIR - Darlington, B
IR  - Darlington B
FIR - Das, J
IR  - Das J
FIR - Das, P
IR  - Das P
FIR - Date, M
IR  - Date M
FIR - Datta, C
IR  - Datta C
FIR - Datta, S
IR  - Datta S
FIR - Davenport, C
IR  - Davenport C
FIR - Davey, G
IR  - Davey G
FIR - Davey, M
IR  - Davey M
FIR - Davey, P
IR  - Davey P
FIR - Davidson, C L
IR  - Davidson CL
FIR - Davidson, D
IR  - Davidson D
FIR - Davies, M
IR  - Davies M
FIR - Davies-Hakeem, A
IR  - Davies-Hakeem A
FIR - Davis, G
IR  - Davis G
FIR - Davis, K
IR  - Davis K
FIR - Davis, Paul
IR  - Davis P
FIR - Davis, Peter
IR  - Davis P
FIR - Davis, S
IR  - Davis S
FIR - Dawe, N
IR  - Dawe N
FIR - Dawes, R
IR  - Dawes R
FIR - Dawkins, P
IR  - Dawkins P
FIR - Dawson, G
IR  - Dawson G
FIR - Dawson, P
IR  - Dawson P
FIR - Dawson, R
IR  - Dawson R
FIR - Day, P
IR  - Day P
FIR - Daya, M
IR  - Daya M
FIR - Dayasagar, D
IR  - Dayasagar D
FIR - D’Costa, L
IR  - D’Costa L
FIR - De Clifford, M
IR  - De Clifford M
FIR - De Gleria, S
IR  - De Gleria S
FIR - De Poi, C
IR  - De Poi C
FIR - De Silva, M
IR  - De Silva M
FIR - De Silva, P
IR  - De Silva P
FIR - De Steiger, R
IR  - De Steiger R
FIR - De Villiers, D
IR  - De Villiers D
FIR - De Wit, E
IR  - De Wit E
FIR - Debnath, R
IR  - Debnath R
FIR - Deery, R
IR  - Deery R
FIR - De Lanerolle, D
IR  - De Lanerolle D
FIR - Del Rio, F
IR  - Del Rio F
FIR - Delaney, S
IR  - Delaney S
FIR - Delitzsch, S S
IR  - Delitzsch SS
FIR - Demaio, F
IR  - Demaio F
FIR - Demian, M
IR  - Demian M
FIR - Demirtzoglou, J
IR  - Demirtzoglou J
FIR - Denton, T
IR  - Denton T
FIR - Derrick, L
IR  - Derrick L
FIR - Deshmukh, K
IR  - Deshmukh K
FIR - Dessauer, J
IR  - Dessauer J
FIR - Devavittiya, C
IR  - Devavittiya C
FIR - Devereux, D
IR  - Devereux D
FIR - Dewan, D
IR  - Dewan D
FIR - Dewhurst, H
IR  - Dewhurst H
FIR - Dhar, A
IR  - Dhar A
FIR - Dhillon, D
IR  - Dhillon D
FIR - Di Carlo, M
IR  - Di Carlo M
FIR - Di Dio, A
IR  - Di Dio A
FIR - Di Marco, A
IR  - Di Marco A
FIR - Dickman, J
IR  - Dickman J
FIR - Dillon, L
IR  - Dillon L
FIR - Dinh, Q-T
IR  - Dinh QT
FIR - Dissanayake, D
IR  - Dissanayake D
FIR - Dissanayake, M
IR  - Dissanayake M
FIR - Dissanayake, T
IR  - Dissanayake T
FIR - Divakaran, K
IR  - Divakaran K
FIR - Dixit, U
IR  - Dixit U
FIR - Dixon, H
IR  - Dixon H
FIR - Dixon, N
IR  - Dixon N
FIR - Djakic, E
IR  - Djakic E
FIR - Dobson, C
IR  - Dobson C
FIR - Dodd, L
IR  - Dodd L
FIR - Dodds, P
IR  - Dodds P
FIR - Dodic, A
IR  - Dodic A
FIR - Dodic, M
IR  - Dodic M
FIR - Doley, A
IR  - Doley A
FIR - Dolguina, S
IR  - Dolguina S
FIR - Dolling, C
IR  - Dolling C
FIR - Donaghy, F
IR  - Donaghy F
FIR - Donald, H
IR  - Donald H
FIR - Donelan, E
IR  - Donelan E
FIR - Donohue, M
IR  - Donohue M
FIR - Dooland, J
IR  - Dooland J
FIR - Dooley, H
IR  - Dooley H
FIR - Doslo, S
IR  - Doslo S
FIR - Douglas, A
IR  - Douglas A
FIR - Dover, P
IR  - Dover P
FIR - Downe, G
IR  - Downe G
FIR - Drake, P
IR  - Drake P
FIR - Dry, D
IR  - Dry D
FIR - Duane, P
IR  - Duane P
FIR - Dubash, A
IR  - Dubash A
FIR - Dubetz, D
IR  - Dubetz D
FIR - Duff, P
IR  - Duff P
FIR - Duke, R
IR  - Duke R
FIR - Dumitrescu, C
IR  - Dumitrescu C
FIR - Dunbar, A
IR  - Dunbar A
FIR - Dunbar, S
IR  - Dunbar S
FIR - Dunn, S
IR  - Dunn S
FIR - Duong, N H
IR  - Duong NH
FIR - Dutta, N
IR  - Dutta N
FIR - Dutton, M
IR  - Dutton M
FIR - Duval, A
IR  - Duval A
FIR - Dyson-Berry, J
IR  - Dyson-Berry J
FIR - Eade, P
IR  - Eade P
FIR - Eaton, D
IR  - Eaton D
FIR - Ebert, K
IR  - Ebert K
FIR - Edib, K
IR  - Edib K
FIR - Edillo, E
IR  - Edillo E
FIR - Edmonds, J
IR  - Edmonds J
FIR - Edwards, F
IR  - Edwards F
FIR - Edwards, P A
IR  - Edwards PA
FIR - Edwards, S
IR  - Edwards S
FIR - Eftekharuddin, M
IR  - Eftekharuddin M
FIR - Egan, A
IR  - Egan A
FIR - Egan, P
IR  - Egan P
FIR - Ehrenreich, S
IR  - Ehrenreich S
FIR - Ehsan, E
IR  - Ehsan E
FIR - Elberg, L
IR  - Elberg L
FIR - Elisha, B
IR  - Elisha B
FIR - Elisha, R
IR  - Elisha R
FIR - Elkhoury, H
IR  - Elkhoury H
FIR - Ellerton, K
IR  - Ellerton K
FIR - Elliot-Smith, A
IR  - Elliot-Smith A
FIR - Elmore, R
IR  - Elmore R
FIR - Elshenawy, I
IR  - Elshenawy I
FIR - Elsherif, S
IR  - Elsherif S
FIR - Elsouki, M
IR  - Elsouki M
FIR - Elton, P
IR  - Elton P
FIR - Emmerson, M
IR  - Emmerson M
FIR - Emmett, S I
IR  - Emmett SI
FIR - English, J
IR  - English J
FIR - Enten, P
IR  - Enten P
FIR - Entwistle, J
IR  - Entwistle J
FIR - Epa, W
IR  - Epa W
FIR - Erhardt, A
IR  - Erhardt A
FIR - Etta, J
IR  - Etta J
FIR - Evans, M
IR  - Evans M
FIR - Everitt, T
IR  - Everitt T
FIR - Ewing, J
IR  - Ewing J
FIR - Fahkok, B
IR  - Fahkok B
FIR - Faigen, M
IR  - Faigen M
FIR - Fair, A
IR  - Fair A
FIR - Fairbrother, C
IR  - Fairbrother C
FIR - Fanning, J
IR  - Fanning J
FIR - Fantasia, M
IR  - Fantasia M
FIR - Farag, E
IR  - Farag E
FIR - Fardell, K
IR  - Fardell K
FIR - Farrant, J
IR  - Farrant J
FIR - Farrell, P
IR  - Farrell P
FIR - Farrow, J
IR  - Farrow J
FIR - Fassett, M
IR  - Fassett M
FIR - Faull, P A
IR  - Faull PA
FIR - Ferguson, P
IR  - Ferguson P
FIR - Fernando, Sujeewa
IR  - Fernando S
FIR - Fernando, Sumudu
IR  - Fernando S
FIR - Ferruccio, A
IR  - Ferruccio A
FIR - Fidge, J H
IR  - Fidge JH
FIR - Field, P
IR  - Field P
FIR - Figurireo, L
IR  - Figurireo L
FIR - Fisher, H
IR  - Fisher H
FIR - Fisher, J
IR  - Fisher J
FIR - Fitzgerald, E
IR  - Fitzgerald E
FIR - Fitzgerald, M
IR  - Fitzgerald M
FIR - Fitzgerald, R
IR  - Fitzgerald R
FIR - Fitzpatrick, H
IR  - Fitzpatrick H
FIR - Fitzpatrick, J
IR  - Fitzpatrick J
FIR - Fitzpatrick, P
IR  - Fitzpatrick P
FIR - Fitzpatrick, T
IR  - Fitzpatrick T
FIR - Flaherty, P
IR  - Flaherty P
FIR - Flanagan, D
IR  - Flanagan D
FIR - Flanagan, T
IR  - Flanagan T
FIR - Flew, S
IR  - Flew S
FIR - Fonseka, P P
IR  - Fonseka PP
FIR - Foo, J
IR  - Foo J
FIR - Foo, S
IR  - Foo S
FIR - Foo, Y
IR  - Foo Y
FIR - Foong, E
IR  - Foong E
FIR - Ford, D
IR  - Ford D
FIR - Foster, D
IR  - Foster D
FIR - Fourlanos, V
IR  - Fourlanos V
FIR - Fowler, I
IR  - Fowler I
FIR - Fox, D
IR  - Fox D
FIR - Fox, F
IR  - Fox F
FIR - Fox, M
IR  - Fox M
FIR - Fox, P
IR  - Fox P
FIR - Fox-Smith, D
IR  - Fox-Smith D
FIR - Francis, J
IR  - Francis J
FIR - Francis, R
IR  - Francis R
FIR - Frank, O
IR  - Frank O
FIR - Franks, A
IR  - Franks A
FIR - Fredericks, A
IR  - Fredericks A
FIR - Freeman, E
IR  - Freeman E
FIR - French, L
IR  - French L
FIR - Frew, B
IR  - Frew B
FIR - Friebel, D
IR  - Friebel D
FIR - Friebel, T
IR  - Friebel T
FIR - Frost, S
IR  - Frost S
FIR - Fryer, D
IR  - Fryer D
FIR - Fuller, J
IR  - Fuller J
FIR - Fung, W
IR  - Fung W
FIR - Fung, W P
IR  - Fung WP
FIR - Furphy, S
IR  - Furphy S
FIR - Gabutina, C
IR  - Gabutina C
FIR - Gaggin, S
IR  - Gaggin S
FIR - Galbraith, S
IR  - Galbraith S
FIR - Gale, M
IR  - Gale M
FIR - Gall, J
IR  - Gall J
FIR - Gallichio, V
IR  - Gallichio V
FIR - Gangell, A W
IR  - Gangell AW
FIR - Garde, M A
IR  - Garde MA
FIR - Gardner, S S
IR  - Gardner SS
FIR - Gardner, T
IR  - Gardner T
FIR - Garland, J
IR  - Garland J
FIR - Garra, G
IR  - Garra G
FIR - Garrow, S
IR  - Garrow S
FIR - Garvey, J
IR  - Garvey J
FIR - Gauden, M
IR  - Gauden M
FIR - Gault, A
IR  - Gault A
FIR - Gaur, D
IR  - Gaur D
FIR - Gavralas, A
IR  - Gavralas A
FIR - George, N
IR  - George N
FIR - George, S
IR  - George S
FIR - Georgy, M
IR  - Georgy M
FIR - Gerendasi, R
IR  - Gerendasi R
FIR - Geschke, H
IR  - Geschke H
FIR - Giannakakis, J
IR  - Giannakakis J
FIR - Gidley, G
IR  - Gidley G
FIR - Gilani, M
IR  - Gilani M
FIR - Giles, P
IR  - Giles P
FIR - Gill, K
IR  - Gill K
FIR - Gill, P
IR  - Gill P
FIR - Gill, R
IR  - Gill R
FIR - Gillis, C
IR  - Gillis C
FIR - Gilmore, A
IR  - Gilmore A
FIR - Gilovitz, M
IR  - Gilovitz M
FIR - Gingold, R
IR  - Gingold R
FIR - Glaspole, D
IR  - Glaspole D
FIR - Glowinski, L
IR  - Glowinski L
FIR - Glue, A L
IR  - Glue AL
FIR - Godakumbura, P
IR  - Godakumbura P
FIR - Godavarthy, R
IR  - Godavarthy R
FIR - Goel, A
IR  - Goel A
FIR - Goeltom, C
IR  - Goeltom C
FIR - Goldberg, E
IR  - Goldberg E
FIR - Goldberg, J
IR  - Goldberg J
FIR - Golets, M
IR  - Golets M
FIR - Gong, V
IR  - Gong V
FIR - Goode, J
IR  - Goode J
FIR - Goodman, C
IR  - Goodman C
FIR - Goodwin, R J
IR  - Goodwin RJ
FIR - Gopathy, S
IR  - Gopathy S
FIR - Gordon, M
IR  - Gordon M
FIR - Gough, S
IR  - Gough S
FIR - Govender, M
IR  - Govender M
FIR - Gow, K
IR  - Gow K
FIR - Gowrie, B
IR  - Gowrie B
FIR - Goy, P
IR  - Goy P
FIR - Grabowski, C
IR  - Grabowski C
FIR - Graddon, J
IR  - Graddon J
FIR - Granek, A
IR  - Granek A
FIR - Gray, J M
IR  - Gray JM
FIR - Gray, M
IR  - Gray M
FIR - Gray, T
IR  - Gray T
FIR - Grbac, E
IR  - Grbac E
FIR - Greacen, J
IR  - Greacen J
FIR - Greculescu, E
IR  - Greculescu E
FIR - Green, J
IR  - Green J
FIR - Greenwood, E
IR  - Greenwood E
FIR - Griffin, E
IR  - Griffin E
FIR - Griffith, V
IR  - Griffith V
FIR - Griffiths, A
IR  - Griffiths A
FIR - Griffiths, G
IR  - Griffiths G
FIR - Griffiths, J
IR  - Griffiths J
FIR - Griffiths, K
IR  - Griffiths K
FIR - Grigorian, A R
IR  - Grigorian AR
FIR - Grinzi, P
IR  - Grinzi P
FIR - Grogan, H
IR  - Grogan H
FIR - Grokop, G
IR  - Grokop G
FIR - Grossman, L
IR  - Grossman L
FIR - Grove, A
IR  - Grove A
FIR - Gruzauskas, A
IR  - Gruzauskas A
FIR - Gu, M
IR  - Gu M
FIR - Guest, S
IR  - Guest S
FIR - Guindi, N
IR  - Guindi N
FIR - Guo, H
IR  - Guo H
FIR - Gurney, R
IR  - Gurney R
FIR - Guy, J
IR  - Guy J
FIR - Guymer, J
IR  - Guymer J
FIR - Gwynn, R
IR  - Gwynn R
FIR - Gyorki, J
IR  - Gyorki J
FIR - Habibi, S
IR  - Habibi S
FIR - Hachem, C
IR  - Hachem C
FIR - Hackett, A
IR  - Hackett A
FIR - Hackett, J
IR  - Hackett J
FIR - Haddad, J
IR  - Haddad J
FIR - Haddad, M
IR  - Haddad M
FIR - Hadley, E
IR  - Hadley E
FIR - Hagger, R
IR  - Hagger R
FIR - Haider, Z
IR  - Haider Z
FIR - Hain, R
IR  - Hain R
FIR - Hajicosta, T
IR  - Hajicosta T
FIR - Hales, P
IR  - Hales P
FIR - Hall, J
IR  - Hall J
FIR - Hall, P
IR  - Hall P
FIR - Hall, Robert
IR  - Hall R
FIR - Hall, Roslyn
IR  - Hall R
FIR - Hall, S
IR  - Hall S
FIR - Halliburton, K
IR  - Halliburton K
FIR - Halliday, A
IR  - Halliday A
FIR - Halliday, B
IR  - Halliday B
FIR - Halliday, J
IR  - Halliday J
FIR - Hamblen, K
IR  - Hamblen K
FIR - Hamel, J
IR  - Hamel J
FIR - Hamer, I
IR  - Hamer I
FIR - Hamilton, J
IR  - Hamilton J
FIR - Hamilton, R F
IR  - Hamilton RF
FIR - Hammond, T
IR  - Hammond T
FIR - Hanbury, R
IR  - Hanbury R
FIR - Hancock, A
IR  - Hancock A
FIR - Hand, R
IR  - Hand R
FIR - Hanna, A
IR  - Hanna A
FIR - Hanna, M
IR  - Hanna M
FIR - Hanna, S
IR  - Hanna S
FIR - Hanson, G
IR  - Hanson G
FIR - Hanson, P D
IR  - Hanson PD
FIR - Haque, E
IR  - Haque E
FIR - Haran, C
IR  - Haran C
FIR - Haran, T
IR  - Haran T
FIR - Hare, W J
IR  - Hare WJ
FIR - Harewood, A
IR  - Harewood A
FIR - Haripersad, S
IR  - Haripersad S
FIR - Harman, A
IR  - Harman A
FIR - Harmer, D
IR  - Harmer D
FIR - Harms, P
IR  - Harms P
FIR - Harnden, C
IR  - Harnden C
FIR - Harrington, M
IR  - Harrington M
FIR - Harris, A
IR  - Harris A
FIR - Harris, M
IR  - Harris M
FIR - Harrison, M
IR  - Harrison M
FIR - Harrison, S
IR  - Harrison S
FIR - Hart, E
IR  - Hart E
FIR - Hartley, D
IR  - Hartley D
FIR - Hartley, P
IR  - Hartley P
FIR - Hartnett, M
IR  - Hartnett M
FIR - Harvey, C
IR  - Harvey C
FIR - Haslam, K
IR  - Haslam K
FIR - Hassani, I
IR  - Hassani I
FIR - Hassett, R B
IR  - Hassett RB
FIR - Hastings, W
IR  - Hastings W
FIR - Hattingh, A
IR  - Hattingh A
FIR - Hawke, I
IR  - Hawke I
FIR - Hawkins, C
IR  - Hawkins C
FIR - Hayes, V
IR  - Hayes V
FIR - Heale, J
IR  - Heale J
FIR - Healy, G
IR  - Healy G
FIR - Hebblewhite, A
IR  - Hebblewhite A
FIR - Hechtman, A
IR  - Hechtman A
FIR - Hedgland, A
IR  - Hedgland A
FIR - Heffernan, C
IR  - Heffernan C
FIR - Heikkinen, M N
IR  - Heikkinen MN
FIR - Heinrich, C
IR  - Heinrich C
FIR - Henderson, J
IR  - Henderson J
FIR - Henry, F
IR  - Henry F
FIR - Herath, S
IR  - Herath S
FIR - Herbert, A
IR  - Herbert A
FIR - Herbst, D
IR  - Herbst D
FIR - Hermiz, S
IR  - Hermiz S
FIR - Herrman, J
IR  - Herrman J
FIR - Hesse, M
IR  - Hesse M
FIR - Hetherington, J
IR  - Hetherington J
FIR - Hetzel, R
IR  - Hetzel R
FIR - Hewett, R
IR  - Hewett R
FIR - Hides, R
IR  - Hides R
FIR - Higgins, C D
IR  - Higgins CD
FIR - Hildred, S
IR  - Hildred S
FIR - Hill, A
IR  - Hill A
FIR - Hilton, C
IR  - Hilton C
FIR - Hince, R
IR  - Hince R
FIR - Hines, C
IR  - Hines C
FIR - Hinton, C
IR  - Hinton C
FIR - Hipolito, A
IR  - Hipolito A
FIR - Ho, C K
IR  - Ho CK
FIR - Ho, L
IR  - Ho L
FIR - Hoar, J
IR  - Hoar J
FIR - Hocking, L
IR  - Hocking L
FIR - Hodge, A
IR  - Hodge A
FIR - Hodgkins, A
IR  - Hodgkins A
FIR - Hodgson, J
IR  - Hodgson J
FIR - Hogbin, J
IR  - Hogbin J
FIR - Hok, S
IR  - Hok S
FIR - Holder, B
IR  - Holder B
FIR - Holland, D
IR  - Holland D
FIR - Holland, M
IR  - Holland M
FIR - Hollins, B
IR  - Hollins B
FIR - Homewood, M
IR  - Homewood M
FIR - Hong Zhou, A
IR  - Hong Zhou A
FIR - Honig, J
IR  - Honig J
FIR - Honigman, S
IR  - Honigman S
FIR - Hookham, D
IR  - Hookham D
FIR - Hooper, W
IR  - Hooper W
FIR - Hope, L
IR  - Hope L
FIR - Horman, J
IR  - Horman J
FIR - Horng, T
IR  - Horng T
FIR - Hornstein, I
IR  - Hornstein I
FIR - Horriat, M
IR  - Horriat M
FIR - Horvat, J
IR  - Horvat J
FIR - Hossain, M
IR  - Hossain M
FIR - Hough, P
IR  - Hough P
FIR - Howe, J
IR  - Howe J
FIR - Howson, W
IR  - Howson W
FIR - Hubczenko, I
IR  - Hubczenko I
FIR - Hubel, M
IR  - Hubel M
FIR - Hughes, J
IR  - Hughes J
FIR - Hughes, P
IR  - Hughes P
FIR - Hunter, D
IR  - Hunter D
FIR - Huq, S
IR  - Huq S
FIR - Hussain, A
IR  - Hussain A
FIR - Hutchins, I
IR  - Hutchins I
FIR - Hutchinson, A
IR  - Hutchinson A
FIR - Hyam, P
IR  - Hyam P
FIR - Hyare, K
IR  - Hyare K
FIR - Iakovidis, B
IR  - Iakovidis B
FIR - Ibragimov, M
IR  - Ibragimov M
FIR - Idris, M
IR  - Idris M
FIR - Ierace, C
IR  - Ierace C
FIR - Ikladios, A
IR  - Ikladios A
FIR - Imgraben, P
IR  - Imgraben P
FIR - Ingham, C
IR  - Ingham C
FIR - Ip, A
IR  - Ip A
FIR - Ip, Y
IR  - Ip Y
FIR - Iqbal, A
IR  - Iqbal A
FIR - Iqbal, M
IR  - Iqbal M
FIR - Irvine, G
IR  - Irvine G
FIR - Irwin, V
IR  - Irwin V
FIR - Iser, D
IR  - Iser D
FIR - Islam, N
IR  - Islam N
FIR - Islam, S
IR  - Islam S
FIR - Isles, J K
IR  - Isles JK
FIR - Ismail, A
IR  - Ismail A
FIR - Ivanoff, G
IR  - Ivanoff G
FIR - Iwe, N
IR  - Iwe N
FIR - Jackett, R B
IR  - Jackett RB
FIR - Jackson, M
IR  - Jackson M
FIR - Jackson, N
IR  - Jackson N
FIR - Jackson, P
IR  - Jackson P
FIR - Jackson, T
IR  - Jackson T
FIR - Jacoup, M
IR  - Jacoup M
FIR - Jaensch, E
IR  - Jaensch E
FIR - Jain, P
IR  - Jain P
FIR - Jain, S
IR  - Jain S
FIR - Jaiswal, N
IR  - Jaiswal N
FIR - Jaksic, A
IR  - Jaksic A
FIR - Jakubowicz, I
IR  - Jakubowicz I
FIR - Jamel, B
IR  - Jamel B
FIR - James, J
IR  - James J
FIR - Jameson, D
IR  - Jameson D
FIR - Jansz, C
IR  - Jansz C
FIR - Jarman, E
IR  - Jarman E
FIR - Jassi, I
IR  - Jassi I
FIR - Jayasinghe, S
IR  - Jayasinghe S
FIR - Jayatilake, J
IR  - Jayatilake J
FIR - Jayaweera, V
IR  - Jayaweera V
FIR - Jeanes, R
IR  - Jeanes R
FIR - Jeanneret, C I
IR  - Jeanneret CI
FIR - Jedynak, S
IR  - Jedynak S
FIR - Jeffries, L
IR  - Jeffries L
FIR - Jegadeesh, K
IR  - Jegadeesh K
FIR - Jenkins, P
IR  - Jenkins P
FIR - Jennings, C
IR  - Jennings C
FIR - Jenny, C
IR  - Jenny C
FIR - Jiang, Y Y
IR  - Jiang YY
FIR - Jigau, C
IR  - Jigau C
FIR - Jinadasa, C
IR  - Jinadasa C
FIR - Joel, S
IR  - Joel S
FIR - John, R
IR  - John R
FIR - Johns, P
IR  - Johns P
FIR - Johnson, C
IR  - Johnson C
FIR - Johnson, J
IR  - Johnson J
FIR - Johnson, M
IR  - Johnson M
FIR - Johnson, N
IR  - Johnson N
FIR - Johnson, W
IR  - Johnson W
FIR - Johnston, B
IR  - Johnston B
FIR - Johnston, K
IR  - Johnston K
FIR - Johnston, M
IR  - Johnston M
FIR - Johnston, R
IR  - Johnston R
FIR - Johnston, T
IR  - Johnston T
FIR - Jones, G
IR  - Jones G
FIR - Jones, I
IR  - Jones I
FIR - Jones, L
IR  - Jones L
FIR - Jones, M
IR  - Jones M
FIR - Jones, S
IR  - Jones S
FIR - Jones, Tania
IR  - Jones T
FIR - Jones, Tudor
IR  - Jones T
FIR - Joshi, M
IR  - Joshi M
FIR - Joshi, Naveen
IR  - Joshi N
FIR - Joshi, Nirupama
IR  - Joshi N
FIR - Joske, F
IR  - Joske F
FIR - Joubert, C
IR  - Joubert C
FIR - Jovanovic, B
IR  - Jovanovic B
FIR - Joyce, R
IR  - Joyce R
FIR - Judd, A M
IR  - Judd AM
FIR - Judd, J
IR  - Judd J
FIR - Kaaden, J P
IR  - Kaaden JP
FIR - Kabat, L
IR  - Kabat L
FIR - Kabourakis, F
IR  - Kabourakis F
FIR - Kaippilly, A
IR  - Kaippilly A
FIR - Kajani, H
IR  - Kajani H
FIR - Kamale, A
IR  - Kamale A
FIR - Kaminsky, L
IR  - Kaminsky L
FIR - Kanapathipillai, U
IR  - Kanapathipillai U
FIR - Kanashuk, L
IR  - Kanashuk L
FIR - Kao, R
IR  - Kao R
FIR - Kapadia, P
IR  - Kapadia P
FIR - Kapadia, V
IR  - Kapadia V
FIR - Karmouche, R
IR  - Karmouche R
FIR - Kaur, K J
IR  - Kaur KJ
FIR - Kavanagh, T
IR  - Kavanagh T
FIR - Kay, A
IR  - Kay A
FIR - Kay, B
IR  - Kay B
FIR - Kaye, S
IR  - Kaye S
FIR - Keane, K
IR  - Keane K
FIR - Keating, B
IR  - Keating B
FIR - Keecha, E
IR  - Keecha E
FIR - Keecha, J
IR  - Keecha J
FIR - Keenan, P
IR  - Keenan P
FIR - Keillar, P
IR  - Keillar P
FIR - Kemp, G
IR  - Kemp G
FIR - Kemp, P
IR  - Kemp P
FIR - Kennedy, M
IR  - Kennedy M
FIR - Kennedy, U
IR  - Kennedy U
FIR - Kennett, S
IR  - Kennett S
FIR - Kesarapu, S
IR  - Kesarapu S
FIR - Khan, F
IR  - Khan F
FIR - Khan, I
IR  - Khan I
FIR - Khan, M
IR  - Khan M
FIR - Khong, C K
IR  - Khong CK
FIR - Khoo, F
IR  - Khoo F
FIR - Khoo, J
IR  - Khoo J
FIR - Khoo, S
IR  - Khoo S
FIR - Khoshghalb, A
IR  - Khoshghalb A
FIR - Kiefer, J
IR  - Kiefer J
FIR - Kiley, M
IR  - Kiley M
FIR - Kilov, G
IR  - Kilov G
FIR - Kimpton, N
IR  - Kimpton N
FIR - King, S C
IR  - King SC
FIR - Kingston, R
IR  - Kingston R
FIR - Kinsella, P
IR  - Kinsella P
FIR - Kipouridis, A
IR  - Kipouridis A
FIR - Kirwan, A
IR  - Kirwan A
FIR - Kisselev, S
IR  - Kisselev S
FIR - Kitchen, J
IR  - Kitchen J
FIR - Kloot, S
IR  - Kloot S
FIR - Knaggs, J
IR  - Knaggs J
FIR - Knight, E
IR  - Knight E
FIR - Knobel, J
IR  - Knobel J
FIR - Knowles, D
IR  - Knowles D
FIR - Knowles, P
IR  - Knowles P
FIR - Kogosowski, S
IR  - Kogosowski S
FIR - Kok, Jereth
IR  - Kok J
FIR - Kok, Joyce
IR  - Kok J
FIR - Kollios, D
IR  - Kollios D
FIR - Konopnicki, H
IR  - Konopnicki H
FIR - Koravos, A
IR  - Koravos A
FIR - Korol, P
IR  - Korol P
FIR - Kosky, A R
IR  - Kosky AR
FIR - Kote Somashekarappa, M
IR  - Kote Somashekarappa M
FIR - Kottegoda-Vithana, E
IR  - Kottegoda-Vithana E
FIR - Kotur, S
IR  - Kotur S
FIR - Kozminsky, M
IR  - Kozminsky M
FIR - Kraner, G
IR  - Kraner G
FIR - Kraus, D H
IR  - Kraus DH
FIR - Krell, I
IR  - Krell I
FIR - Kruytbosch, C
IR  - Kruytbosch C
FIR - Kuay, V
IR  - Kuay V
FIR - Kucminska, A
IR  - Kucminska A
FIR - Kulatunga, P
IR  - Kulatunga P
FIR - Kulinski, M
IR  - Kulinski M
FIR - Kumar, J
IR  - Kumar J
FIR - Kumar, R
IR  - Kumar R
FIR - Kumar, S
IR  - Kumar S
FIR - Kumarage, D
IR  - Kumarage D
FIR - Kumaraswamy, S
IR  - Kumaraswamy S
FIR - Kunze, M
IR  - Kunze M
FIR - Kurien, S
IR  - Kurien S
FIR - Kuruvilla, P
IR  - Kuruvilla P
FIR - Kwong, R
IR  - Kwong R
FIR - Kyaw, Z
IR  - Kyaw Z
FIR - Kyriacopoulos, J
IR  - Kyriacopoulos J
FIR - Lackner, P J
IR  - Lackner PJ
FIR - Lahanis, C
IR  - Lahanis C
FIR - Lajoie, D
IR  - Lajoie D
FIR - Lajoie, K
IR  - Lajoie K
FIR - Lakshmanan, A
IR  - Lakshmanan A
FIR - Lal, A
IR  - Lal A
FIR - Lalor, E
IR  - Lalor E
FIR - Lam, D
IR  - Lam D
FIR - Lambooij, C
IR  - Lambooij C
FIR - Lancaster, M
IR  - Lancaster M
FIR - Landa, L
IR  - Landa L
FIR - Landers, J
IR  - Landers J
FIR - Lane, R
IR  - Lane R
FIR - Langston, K
IR  - Langston K
FIR - Lapin, S
IR  - Lapin S
FIR - Lath, P
IR  - Lath P
FIR - Lau-Gooey, T
IR  - Lau-Gooey T
FIR - Lawlor-Smith, L
IR  - Lawlor-Smith L
FIR - Le Couteur, S
IR  - Le Couteur S
FIR - Le, P
IR  - Le P
FIR - Le Riche, M
IR  - Le Riche M
FIR - Le, V
IR  - Le V
FIR - Le, W
IR  - Le W
FIR - Leber, D
IR  - Leber D
FIR - Ledner, A
IR  - Ledner A
FIR - Lee, B
IR  - Lee B
FIR - Lee, C
IR  - Lee C
FIR - Lee, D
IR  - Lee D
FIR - Lee, F B
IR  - Lee FB
FIR - Lee, Jade
IR  - Lee J
FIR - Lee, James
IR  - Lee J
FIR - Lee, Jessicasu-Yin
IR  - Lee JY
FIR - Lee, John
IR  - Lee J
FIR - Lees, K
IR  - Lees K
FIR - Lees, R
IR  - Lees R
FIR - Lees, W
IR  - Lees W
FIR - Leffler, P
IR  - Leffler P
FIR - Lenton, J
IR  - Lenton J
FIR - Leong, R
IR  - Leong R
FIR - Leow, L
IR  - Leow L
FIR - Leow, P
IR  - Leow P
FIR - Leow, Y
IR  - Leow Y
FIR - Leslie, N
IR  - Leslie N
FIR - Lester, S E
IR  - Lester SE
FIR - Lewi, L
IR  - Lewi L
FIR - Lewis, P
IR  - Lewis P
FIR - Lewis, R
IR  - Lewis R
FIR - Li, A
IR  - Li A
FIR - Li, J
IR  - Li J
FIR - Liang, J
IR  - Liang J
FIR - Liang, Xs
IR  - Liang X
FIR - Libhaber, H
IR  - Libhaber H
FIR - Lichtblau, B
IR  - Lichtblau B
FIR - Lickiss, T
IR  - Lickiss T
FIR - Liedvogel, M
IR  - Liedvogel M
FIR - Liew, K
IR  - Liew K
FIR - Light, L
IR  - Light L
FIR - Lightfoot, W
IR  - Lightfoot W
FIR - Lim, C
IR  - Lim C
FIR - Lim, D
IR  - Lim D
FIR - Lim, H
IR  - Lim H
FIR - Lim, H S
IR  - Lim HS
FIR - Lim, J
IR  - Lim J
FIR - Lim, S G
IR  - Lim SG
FIR - Limaye, S
IR  - Limaye S
FIR - Limbu, Y
IR  - Limbu Y
FIR - Lindenmayer, J
IR  - Lindenmayer J
FIR - Lindstedt, P
IR  - Lindstedt P
FIR - Lines, A
IR  - Lines A
FIR - Ling, J
IR  - Ling J
FIR - Ling, R
IR  - Ling R
FIR - Linton, J
IR  - Linton J
FIR - Linton, S
IR  - Linton S
FIR - Linton, T
IR  - Linton T
FIR - Liow, C
IR  - Liow C
FIR - Liow, Y C
IR  - Liow YC
FIR - Lip, L
IR  - Lip L
FIR - Lipson, D
IR  - Lipson D
FIR - Liu, S
IR  - Liu S
FIR - Liu, Y
IR  - Liu Y
FIR - Liubinas, R
IR  - Liubinas R
FIR - Liveriadis, T
IR  - Liveriadis T
FIR - Lizner, S
IR  - Lizner S
FIR - Lloyd, M
IR  - Lloyd M
FIR - Lo, B
IR  - Lo B
FIR - Lo, C
IR  - Lo C
FIR - Lock, P
IR  - Lock P
FIR - Lockhart, M
IR  - Lockhart M
FIR - Logan, M
IR  - Logan M
FIR - Loke, K P
IR  - Loke KP
FIR - Long, Matthew
IR  - Long M
FIR - Long, Michael
IR  - Long M
FIR - Longworth, W
IR  - Longworth W
FIR - Loo, K H
IR  - Loo KH
FIR - Lopez-Hernandez, S
IR  - Lopez-Hernandez S
FIR - Lord, R J
IR  - Lord RJ
FIR - Louw, J
IR  - Louw J
FIR - Louw, T T
IR  - Louw TT
FIR - Low, B
IR  - Low B
FIR - Low, F
IR  - Low F
FIR - Lowe, M
IR  - Lowe M
FIR - Lowther, D
IR  - Lowther D
FIR - Loxley, P
IR  - Loxley P
FIR - Lu, P
IR  - Lu P
FIR - Lu, S
IR  - Lu S
FIR - Lucarelli, A
IR  - Lucarelli A
FIR - Lui, G
IR  - Lui G
FIR - Lui, K
IR  - Lui K
FIR - Lui, R
IR  - Lui R
FIR - Luke, C
IR  - Luke C
FIR - Lukic, N
IR  - Lukic N
FIR - Lupton, J
IR  - Lupton J
FIR - Luscombe, T
IR  - Luscombe T
FIR - Luttrell, C L
IR  - Luttrell CL
FIR - Lyall, A
IR  - Lyall A
FIR - Lynch, J
IR  - Lynch J
FIR - Lynn, K
IR  - Lynn K
FIR - Lyon, D
IR  - Lyon D
FIR - Lyon, E
IR  - Lyon E
FIR - Lyons, S
IR  - Lyons S
FIR - Macaulay, G
IR  - Macaulay G
FIR - Macaulay, K
IR  - Macaulay K
FIR - MacIndoe, A
IR  - MacIndoe A
FIR - MacIsaac, P
IR  - MacIsaac P
FIR - Maciver, R
IR  - Maciver R
FIR - Mackay, B
IR  - Mackay B
FIR - Mackay, J
IR  - Mackay J
FIR - Mackinnon, D
IR  - Mackinnon D
FIR - Mackle, R
IR  - Mackle R
FIR - Macphail, J
IR  - Macphail J
FIR - Madawala, N
IR  - Madawala N
FIR - Madden, J
IR  - Madden J
FIR - Madeley, C
IR  - Madeley C
FIR - Madhanpall, N
IR  - Madhanpall N
FIR - Magarey, J
IR  - Magarey J
FIR - Magill, M
IR  - Magill M
FIR - Mah, S
IR  - Mah S
FIR - Mahadeva, S P
IR  - Mahadeva SP
FIR - Mahendran, S
IR  - Mahendran S
FIR - Maher, J
IR  - Maher J
FIR - Maher, M
IR  - Maher M
FIR - Mahmood, Aamir
IR  - Mahmood A
FIR - Mahmood, Abbas
IR  - Mahmood A
FIR - Maier, K
IR  - Maier K
FIR - Majchrzak, W
IR  - Majchrzak W
FIR - Majeed, J
IR  - Majeed J
FIR - Makar, A
IR  - Makar A
FIR - Makohon, R
IR  - Makohon R
FIR - Malcher, P
IR  - Malcher P
FIR - Malcolm, H E
IR  - Malcolm HE
FIR - Malcolm, M
IR  - Malcolm M
FIR - Mallett, S
IR  - Mallett S
FIR - Mallik, A
IR  - Mallik A
FIR - Manderson, J
IR  - Manderson J
FIR - Mane, S
IR  - Mane S
FIR - Mangan, G
IR  - Mangan G
FIR - Manifold, M
IR  - Manifold M
FIR - Manoliadis, M
IR  - Manoliadis M
FIR - Manovel, B
IR  - Manovel B
FIR - Mansour, A
IR  - Mansour A
FIR - Manton, D
IR  - Manton D
FIR - Marano, F
IR  - Marano F
FIR - Marchant, D
IR  - Marchant D
FIR - Mariajoseph, G
IR  - Mariajoseph G
FIR - Marinos, A
IR  - Marinos A
FIR - Marinucci, D
IR  - Marinucci D
FIR - Marrows, M
IR  - Marrows M
FIR - Marsh, D
IR  - Marsh D
FIR - Martin, C
IR  - Martin C
FIR - Martin, G
IR  - Martin G
FIR - Martin, R
IR  - Martin R
FIR - Marton, F
IR  - Marton F
FIR - Martynova, L
IR  - Martynova L
FIR - Mason, N
IR  - Mason N
FIR - Masood, U
IR  - Masood U
FIR - Massaud, M
IR  - Massaud M
FIR - Massy-Westropp, P
IR  - Massy-Westropp P
FIR - Masters, B
IR  - Masters B
FIR - Mather, J
IR  - Mather J
FIR - Mathews, R A
IR  - Mathews RA
FIR - Mathieson, G
IR  - Mathieson G
FIR - Mauro, M
IR  - Mauro M
FIR - Mauviel, P A
IR  - Mauviel PA
FIR - Maxfield, N
IR  - Maxfield N
FIR - Mayhead, C
IR  - Mayhead C
FIR - Mazengiya, S
IR  - Mazengiya S
FIR - Mazhar, A
IR  - Mazhar A
FIR - Mbachilin, G
IR  - Mbachilin G
FIR - McAllan, A
IR  - McAllan A
FIR - McCallum, H
IR  - McCallum H
FIR - McCann, N
IR  - McCann N
FIR - McCarthy, A
IR  - McCarthy A
FIR - McCleary, A
IR  - McCleary A
FIR - McClelland, R
IR  - McClelland R
FIR - McConville, D S
IR  - McConville DS
FIR - McCorkell, J
IR  - McCorkell J
FIR - McCormack, G
IR  - McCormack G
FIR - McCormick, H
IR  - McCormick H
FIR - McCowan, M
IR  - McCowan M
FIR - McCutcheon, J
IR  - McCutcheon J
FIR - McDonald, A G
IR  - McDonald AG
FIR - McDonald, A S
IR  - McDonald AS
FIR - McDonald, I R
IR  - McDonald IR
FIR - McDonald, J
IR  - McDonald J
FIR - McDonald, N
IR  - McDonald N
FIR - McDonald, S
IR  - McDonald S
FIR - McEniery, A
IR  - McEniery A
FIR - McEntee, K
IR  - McEntee K
FIR - McGee, R
IR  - McGee R
FIR - McGinity, P
IR  - McGinity P
FIR - McGowan, N
IR  - McGowan N
FIR - McGowan, R
IR  - McGowan R
FIR - McGrath, L
IR  - McGrath L
FIR - McGuire, Paul
IR  - McGuire P
FIR - McGuire, Precious
IR  - McGuire P
FIR - McHardy, C
IR  - McHardy C
FIR - McHenry, K
IR  - McHenry K
FIR - McIllree, R
IR  - McIllree R
FIR - McKay, M
IR  - McKay M
FIR - McKellar, C
IR  - McKellar C
FIR - McKelvie, M
IR  - McKelvie M
FIR - McKenzie, S I
IR  - McKenzie SI
FIR - McKeown, J
IR  - McKeown J
FIR - McKeown, M
IR  - McKeown M
FIR - McKernan, S
IR  - McKernan S
FIR - McKinnon, A
IR  - McKinnon A
FIR - McLaren, G
IR  - McLaren G
FIR - McLeod, I
IR  - McLeod I
FIR - McMahon, A
IR  - McMahon A
FIR - McMaster, I
IR  - McMaster I
FIR - McNab, N R
IR  - McNab NR
FIR - McNaughton, E L
IR  - McNaughton EL
FIR - McNiff, M
IR  - McNiff M
FIR - McPherson, C
IR  - McPherson C
FIR - Meaney, J
IR  - Meaney J
FIR - Medlicott, M
IR  - Medlicott M
FIR - Medres, R
IR  - Medres R
FIR - Megally, R
IR  - Megally R
FIR - Mehta, K
IR  - Mehta K
FIR - Mellios, O
IR  - Mellios O
FIR - Melvani, R
IR  - Melvani R
FIR - Mencel, J
IR  - Mencel J
FIR - Mendick, S
IR  - Mendick S
FIR - Mendis, L
IR  - Mendis L
FIR - Menzies, J
IR  - Menzies J
FIR - Mercado, M
IR  - Mercado M
FIR - Mesiha, S
IR  - Mesiha S
FIR - Meyer, P L
IR  - Meyer PL
FIR - Meyer, R
IR  - Meyer R
FIR - Miceli, A
IR  - Miceli A
FIR - Michaelson, T
IR  - Michaelson T
FIR - Michail, A
IR  - Michail A
FIR - Michelmore, K
IR  - Michelmore K
FIR - Miezis, V
IR  - Miezis V
FIR - Milan, S
IR  - Milan S
FIR - Milky, S
IR  - Milky S
FIR - Miller, K
IR  - Miller K
FIR - Milner, J
IR  - Milner J
FIR - Milone, R
IR  - Milone R
FIR - Milton, C
IR  - Milton C
FIR - Milward, N
IR  - Milward N
FIR - Mirhom, R
IR  - Mirhom R
FIR - Mirranay, S
IR  - Mirranay S
FIR - Mishricky, H
IR  - Mishricky H
FIR - Misso, R
IR  - Misso R
FIR - Mitchell, A
IR  - Mitchell A
FIR - Mitchell, D
IR  - Mitchell D
FIR - Mitchell, L
IR  - Mitchell L
FIR - Mobilia, G
IR  - Mobilia G
FIR - Moffitt, M
IR  - Moffitt M
FIR - Mohr, V
IR  - Mohr V
FIR - Moller, Gary
IR  - Moller G
FIR - Moller, Graeme
IR  - Moller G
FIR - Molloy, P
IR  - Molloy P
FIR - Molloy, T
IR  - Molloy T
FIR - Molyneux, P
IR  - Molyneux P
FIR - Monaghan, C
IR  - Monaghan C
FIR - Monash, D
IR  - Monash D
FIR - Moncrieff, S
IR  - Moncrieff S
FIR - Monzon, M
IR  - Monzon M
FIR - Mooney, T
IR  - Mooney T
FIR - Moore, E
IR  - Moore E
FIR - Moran, J
IR  - Moran J
FIR - Morgan, G
IR  - Morgan G
FIR - Morgan, M
IR  - Morgan M
FIR - Morgan, N
IR  - Morgan N
FIR - Morris, N
IR  - Morris N
FIR - Morris, S
IR  - Morris S
FIR - Morrison, H
IR  - Morrison H
FIR - Morrow, S
IR  - Morrow S
FIR - Morton, R
IR  - Morton R
FIR - Moschou, C
IR  - Moschou C
FIR - Moulding, S
IR  - Moulding S
FIR - Moule, V
IR  - Moule V
FIR - Mouzakis, V
IR  - Mouzakis V
FIR - Mudunna, D
IR  - Mudunna D
FIR - Mudzi, S
IR  - Mudzi S
FIR - Mulkearns, P
IR  - Mulkearns P
FIR - Mullen, D
IR  - Mullen D
FIR - Mulvey, G
IR  - Mulvey G
FIR - Mungi, D
IR  - Mungi D
FIR - Munro, L
IR  - Munro L
FIR - Muraledaran, S
IR  - Muraledaran S
FIR - Murphy, B
IR  - Murphy B
FIR - Murphy, G
IR  - Murphy G
FIR - Murray, A
IR  - Murray A
FIR - Murray, B
IR  - Murray B
FIR - Murray, E
IR  - Murray E
FIR - Murray, H
IR  - Murray H
FIR - Murray, S
IR  - Murray S
FIR - Murtagh, C
IR  - Murtagh C
FIR - Nadarajah, M
IR  - Nadarajah M
FIR - Naiker, S
IR  - Naiker S
FIR - Naing, W
IR  - Naing W
FIR - Nandha, R
IR  - Nandha R
FIR - Nankervis, J
IR  - Nankervis J
FIR - Naoum, A
IR  - Naoum A
FIR - Nash, C
IR  - Nash C
FIR - Nashed, M
IR  - Nashed M
FIR - Nasreen, N
IR  - Nasreen N
FIR - Nath-Chand, U
IR  - Nath-Chand U
FIR - Neagle, M
IR  - Neagle M
FIR - Nelson, C
IR  - Nelson C
FIR - Nelson, M R
IR  - Nelson MR
FIR - Nesbitt, P
IR  - Nesbitt P
FIR - Neuberger, M
IR  - Neuberger M
FIR - Newman, S
IR  - Newman S
FIR - Newton, S
IR  - Newton S
FIR - Ng, D
IR  - Ng D
FIR - Ng, H
IR  - Ng H
FIR - Ng, S
IR  - Ng S
FIR - Nguyen, D
IR  - Nguyen D
FIR - Nguyen, H Q
IR  - Nguyen HQ
FIR - Nguyen, H T
IR  - Nguyen HT
FIR - Nguyen, T
IR  - Nguyen T
FIR - Nguyen-Ngoc, M
IR  - Nguyen-Ngoc M
FIR - Nice, P
IR  - Nice P
FIR - Nicholls, P
IR  - Nicholls P
FIR - Nicholson, D
IR  - Nicholson D
FIR - Nicola, N
IR  - Nicola N
FIR - Nicolettou, N
IR  - Nicolettou N
FIR - Nicolson, I
IR  - Nicolson I
FIR - Nield, S
IR  - Nield S
FIR - Nikolic, V
IR  - Nikolic V
FIR - Nikolovska-Buzevski, N
IR  - Nikolovska-Buzevski N
FIR - Nilsson, A
IR  - Nilsson A
FIR - Nimmo, A
IR  - Nimmo A
FIR - Nisselle, P
IR  - Nisselle P
FIR - Nitchingham, S
IR  - Nitchingham S
FIR - Niven, A
IR  - Niven A
FIR - Nnopu, E
IR  - Nnopu E
FIR - Noonan, L
IR  - Noonan L
FIR - Norton, C
IR  - Norton C
FIR - Norton, G
IR  - Norton G
FIR - Notini, G
IR  - Notini G
FIR - Nwaegerue, E D
IR  - Nwaegerue ED
FIR - Nylander, P
IR  - Nylander P
FIR - O’Brien, C
IR  - O’Brien C
FIR - O’Connor, A
IR  - O’Connor A
FIR - O’Connor, D A
IR  - O’Connor DA
FIR - O’Donovan, B
IR  - O’Donovan B
FIR - O’Driscoll, E
IR  - O’Driscoll E
FIR - Oechsle, G
IR  - Oechsle G
FIR - Offor, J
IR  - Offor J
FIR - Ogilvie, B
IR  - Ogilvie B
FIR - O’Halloran, J
IR  - O’Halloran J
FIR - O’Hanlon, P
IR  - O’Hanlon P
FIR - Okolie, K
IR  - Okolie K
FIR - Olaniyi, I
IR  - Olaniyi I
FIR - O’Leary, B
IR  - O’Leary B
FIR - O’Leary, K
IR  - O’Leary K
FIR - Olesen, J
IR  - Olesen J
FIR - Oliver, P
IR  - Oliver P
FIR - Olomola, O
IR  - Olomola O
FIR - Olszewski, C
IR  - Olszewski C
FIR - Olukolu, G
IR  - Olukolu G
FIR - Omarjee, A
IR  - Omarjee A
FIR - Omidiora, A A
IR  - Omidiora AA
FIR - Omifolaji, S
IR  - Omifolaji S
FIR - O’Neill, A
IR  - O’Neill A
FIR - O’Neill, C O
IR  - O’Neill CO
FIR - Ong, B P
IR  - Ong BP
FIR - Ong, M
IR  - Ong M
FIR - Ooruthiran, M
IR  - Ooruthiran M
FIR - Oppermann, B L
IR  - Oppermann BL
FIR - Orbach, E
IR  - Orbach E
FIR - Orgonas, R
IR  - Orgonas R
FIR - Orsillo, M
IR  - Orsillo M
FIR - Ostberg, M
IR  - Ostberg M
FIR - O’Sullivan, C
IR  - O’Sullivan C
FIR - O’Sullivan, J
IR  - O’Sullivan J
FIR - O’Sullivan, P J
IR  - O’Sullivan PJ
FIR - O’Toole, C
IR  - O’Toole C
FIR - O’Toole, M
IR  - O’Toole M
FIR - Otuonye, D
IR  - Otuonye D
FIR - Owen, T
IR  - Owen T
FIR - Padilla, C
IR  - Padilla C
FIR - Page, A
IR  - Page A
FIR - Pahuja, P
IR  - Pahuja P
FIR - Palmer, A
IR  - Palmer A
FIR - Pan, J
IR  - Pan J
FIR - Panozzo, D
IR  - Panozzo D
FIR - Pantillano, E
IR  - Pantillano E
FIR - Papagelis, A
IR  - Papagelis A
FIR - Papas, E
IR  - Papas E
FIR - Pape, A
IR  - Pape A
FIR - Paransothy, P
IR  - Paransothy P
FIR - Parghi, N
IR  - Parghi N
FIR - Parker, A
IR  - Parker A
FIR - Parker, J
IR  - Parker J
FIR - Parker, S
IR  - Parker S
FIR - Parkes, H
IR  - Parkes H
FIR - Parletta, E
IR  - Parletta E
FIR - Parry, B
IR  - Parry B
FIR - Pasha, M
IR  - Pasha M
FIR - Patel, G
IR  - Patel G
FIR - Patel, M
IR  - Patel M
FIR - Pathirana, A
IR  - Pathirana A
FIR - Patterson, R
IR  - Patterson R
FIR - Pattichis, I
IR  - Pattichis I
FIR - Pattison, J
IR  - Pattison J
FIR - Pava, C
IR  - Pava C
FIR - Peachey, D
IR  - Peachey D
FIR - Pearce, E
IR  - Pearce E
FIR - Pearce, R
IR  - Pearce R
FIR - Pearse, B
IR  - Pearse B
FIR - Pearson, R
IR  - Pearson R
FIR - Pech, M
IR  - Pech M
FIR - Peduru-Arachchige, A
IR  - Peduru-Arachchige A
FIR - Pellegrini, P
IR  - Pellegrini P
FIR - Pellizzari, G
IR  - Pellizzari G
FIR - Pereira, V
IR  - Pereira V
FIR - Perera, B
IR  - Perera B
FIR - Perera, L
IR  - Perera L
FIR - Perlesz, A
IR  - Perlesz A
FIR - Perraton, R
IR  - Perraton R
FIR - Perry, H
IR  - Perry H
FIR - Perry, S
IR  - Perry S
FIR - Perry, W
IR  - Perry W
FIR - Pervaiz, Z
IR  - Pervaiz Z
FIR - Peters, L
IR  - Peters L
FIR - Pham, H
IR  - Pham H
FIR - Phan, C
IR  - Phan C
FIR - Phan, T
IR  - Phan T
FIR - Phare, A
IR  - Phare A
FIR - Philip, J
IR  - Philip J
FIR - Philips, J
IR  - Philips J
FIR - Phillips, A
IR  - Phillips A
FIR - Philpot, J
IR  - Philpot J
FIR - Phiri, R
IR  - Phiri R
FIR - Pickavance, M
IR  - Pickavance M
FIR - Piekarski, D
IR  - Piekarski D
FIR - Pienkos, J
IR  - Pienkos J
FIR - Piez, W
IR  - Piez W
FIR - Pilgrim, C
IR  - Pilgrim C
FIR - Pillai, B K
IR  - Pillai BK
FIR - Pinder, R
IR  - Pinder R
FIR - Pinkstone, J
IR  - Pinkstone J
FIR - Pinson, J
IR  - Pinson J
FIR - Pither, A
IR  - Pither A
FIR - Plenderleith, J
IR  - Plenderleith J
FIR - Pliatsios, B
IR  - Pliatsios B
FIR - Plunkett, M
IR  - Plunkett M
FIR - Pokharel, C
IR  - Pokharel C
FIR - Poland, D
IR  - Poland D
FIR - Polgar, V
IR  - Polgar V
FIR - Polmear, D
IR  - Polmear D
FIR - Poologanathan, G
IR  - Poologanathan G
FIR - Pope, I
IR  - Pope I
FIR - Popp, L
IR  - Popp L
FIR - Portelli, A
IR  - Portelli A
FIR - Potter, T
IR  - Potter T
FIR - Powell, Kendra
IR  - Powell K
FIR - Powell, Kristine
IR  - Powell K
FIR - Powell, V
IR  - Powell V
FIR - Power, R
IR  - Power R
FIR - Powles, A
IR  - Powles A
FIR - Poynton, N
IR  - Poynton N
FIR - Pranavan, S
IR  - Pranavan S
FIR - Prasad, R
IR  - Prasad R
FIR - Praszkier, S
IR  - Praszkier S
FIR - Preiss, J
IR  - Preiss J
FIR - Pretorius, P
IR  - Pretorius P
FIR - Price, C
IR  - Price C
FIR - Price, I
IR  - Price I
FIR - Price, K
IR  - Price K
FIR - Price, M
IR  - Price M
FIR - Priest, C
IR  - Priest C
FIR - Pring, M
IR  - Pring M
FIR - Profitt, C
IR  - Profitt C
FIR - Protassow, A
IR  - Protassow A
FIR - Psaradellis, I J A
IR  - Psaradellis IJA
FIR - Psycharis, J
IR  - Psycharis J
FIR - Pucilowski, D
IR  - Pucilowski D
FIR - Pun, K
IR  - Pun K
FIR - Qamar, F
IR  - Qamar F
FIR - Quach, S
IR  - Quach S
FIR - Radcliff, E
IR  - Radcliff E
FIR - Radcliffe, B
IR  - Radcliffe B
FIR - Radcliffe, J
IR  - Radcliffe J
FIR - Radford, J
IR  - Radford J
FIR - Ragg, P
IR  - Ragg P
FIR - Rahel, E
IR  - Rahel E
FIR - Rahim, T
IR  - Rahim T
FIR - Rahman, F
IR  - Rahman F
FIR - Rahmanamlashi, N
IR  - Rahmanamlashi N
FIR - Rajasooriar, S
IR  - Rajasooriar S
FIR - Rajendra, I
IR  - Rajendra I
FIR - Rajini, E
IR  - Rajini E
FIR - Raman, A
IR  - Raman A
FIR - Ramsay, A
IR  - Ramsay A
FIR - Ramsey, J
IR  - Ramsey J
FIR - Rana, U
IR  - Rana U
FIR - Rankin, M
IR  - Rankin M
FIR - Rao, U V
IR  - Rao UV
FIR - Rapley, M
IR  - Rapley M
FIR - Rasaratnam, S
IR  - Rasaratnam S
FIR - Rashid, A
IR  - Rashid A
FIR - Ratnaike, L
IR  - Ratnaike L
FIR - Rattan, J
IR  - Rattan J
FIR - Ratten, K
IR  - Ratten K
FIR - Rattraywood, C
IR  - Rattraywood C
FIR - Rayner, E
IR  - Rayner E
FIR - Rea, J
IR  - Rea J
FIR - Rea, P C
IR  - Rea PC
FIR - Reddy, Sanganakal
IR  - Reddy S
FIR - Reddy, Shradhanand
IR  - Reddy S
FIR - Reed, R
IR  - Reed R
FIR - Reeves, C
IR  - Reeves C
FIR - Reichl, T
IR  - Reichl T
FIR - Reid, J
IR  - Reid J
FIR - Reid, K
IR  - Reid K
FIR - Remyn, P
IR  - Remyn P
FIR - Renfrey, S
IR  - Renfrey S
FIR - Renouf, E
IR  - Renouf E
FIR - Renshaw, P
IR  - Renshaw P
FIR - Retchford, A
IR  - Retchford A
FIR - Reynolds, F
IR  - Reynolds F
FIR - Reza, R
IR  - Reza R
FIR - Rezk, L
IR  - Rezk L
FIR - Rhee, J
IR  - Rhee J
FIR - Rhodes, F
IR  - Rhodes F
FIR - Rice, A
IR  - Rice A
FIR - Richards, J
IR  - Richards J
FIR - Richards, R
IR  - Richards R
FIR - Richardson, A
IR  - Richardson A
FIR - Richardson, G T
IR  - Richardson GT
FIR - Richardson, R
IR  - Richardson R
FIR - Richardson, T
IR  - Richardson T
FIR - Ridgers, D
IR  - Ridgers D
FIR - Ridgers, M J
IR  - Ridgers MJ
FIR - Rieger, W
IR  - Rieger W
FIR - Rienits, H
IR  - Rienits H
FIR - Rigoni, M
IR  - Rigoni M
FIR - Riley, J
IR  - Riley J
FIR - Rillstone, D
IR  - Rillstone D
FIR - Rimmer, D E
IR  - Rimmer DE
FIR - Ringelblum, D
IR  - Ringelblum D
FIR - Riseley, J
IR  - Riseley J
FIR - Roberts, A
IR  - Roberts A
FIR - Roberts, I
IR  - Roberts I
FIR - Roberts, J
IR  - Roberts J
FIR - Roberts, M
IR  - Roberts M
FIR - Roberts, S
IR  - Roberts S
FIR - Robinson, J
IR  - Robinson J
FIR - Robinson, R
IR  - Robinson R
FIR - Robson, A
IR  - Robson A
FIR - Roche, V
IR  - Roche V
FIR - Rodda, C
IR  - Rodda C
FIR - Rodway, P
IR  - Rodway P
FIR - Roebuck, R
IR  - Roebuck R
FIR - Rogers, D
IR  - Rogers D
FIR - Rogers, S
IR  - Rogers S
FIR - Roman, F
IR  - Roman F
FIR - Romas, D
IR  - Romas D
FIR - Ronan, C
IR  - Ronan C
FIR - Rope, S
IR  - Rope S
FIR - Rose, A
IR  - Rose A
FIR - Rose, D F
IR  - Rose DF
FIR - Rose, G
IR  - Rose G
FIR - Rose, K
IR  - Rose K
FIR - Rosen, N
IR  - Rosen N
FIR - Rosenblatt, J
IR  - Rosenblatt J
FIR - Ross, K
IR  - Ross K
FIR - Ross, Mary
IR  - Ross M
FIR - Ross, T
IR  - Ross T
FIR - Roth, J
IR  - Roth J
FIR - Rothfield, J
IR  - Rothfield J
FIR - Roubos, N
IR  - Roubos N
FIR - Roufael, A D
IR  - Roufael AD
FIR - Rounsevell, J
IR  - Rounsevell J
FIR - Rouse, W
IR  - Rouse W
FIR - Roushdy, B
IR  - Roushdy B
FIR - Rowe, R
IR  - Rowe R
FIR - Rowland, G
IR  - Rowland G
FIR - Roy, A
IR  - Roy A
FIR - Royston, A
IR  - Royston A
FIR - Rubin, J
IR  - Rubin J
FIR - Russell, G
IR  - Russell G
FIR - Ryan, F
IR  - Ryan F
FIR - Ryan, N
IR  - Ryan N
FIR - Ryan, S
IR  - Ryan S
FIR - Sabet, A
IR  - Sabet A
FIR - Sabetypeyman, F
IR  - Sabetypeyman F
FIR - Sachdev, A
IR  - Sachdev A
FIR - Saddik, A
IR  - Saddik A
FIR - Sadhai, R
IR  - Sadhai R
FIR - Saeed, S
IR  - Saeed S
FIR - Sahhar, C
IR  - Sahhar C
FIR - Saka, M
IR  - Saka M
FIR - Salauddin, M
IR  - Salauddin M
FIR - Salter, E
IR  - Salter E
FIR - Salter, M
IR  - Salter M
FIR - Samaddar, A
IR  - Samaddar A
FIR - Samarakkody, A
IR  - Samarakkody A
FIR - Samararatna, M
IR  - Samararatna M
FIR - Samarsekera, C
IR  - Samarsekera C
FIR - Samuel-John, D
IR  - Samuel-John D
FIR - Sandars, M
IR  - Sandars M
FIR - Sanders, J
IR  - Sanders J
FIR - Sanderson, L
IR  - Sanderson L
FIR - Sandhu, N
IR  - Sandhu N
FIR - Sandrasegaram, S
IR  - Sandrasegaram S
FIR - Sangsari, A
IR  - Sangsari A
FIR - Saprid, J
IR  - Saprid J
FIR - Sarkis, K
IR  - Sarkis K
FIR - Sasse, C
IR  - Sasse C
FIR - Satter, F
IR  - Satter F
FIR - Satyadharma, K
IR  - Satyadharma K
FIR - Saul, J
IR  - Saul J
FIR - Scaife, R
IR  - Scaife R
FIR - Schaap, M
IR  - Schaap M
FIR - Scheelings, F T
IR  - Scheelings FT
FIR - Schinckel, H
IR  - Schinckel H
FIR - Schlesinger, P
IR  - Schlesinger P
FIR - Schlicht, S
IR  - Schlicht S
FIR - Schmidt, M
IR  - Schmidt M
FIR - Schneeweiss, A
IR  - Schneeweiss A
FIR - Schroeder, E
IR  - Schroeder E
FIR - Scully, S
IR  - Scully S
FIR - Searle, R
IR  - Searle R
FIR - Sebastian, T
IR  - Sebastian T
FIR - Seeto, R
IR  - Seeto R
FIR - Segal, G
IR  - Segal G
FIR - Segal, L
IR  - Segal L
FIR - Seidel, B
IR  - Seidel B
FIR - Selga, A
IR  - Selga A
FIR - Senanayake, I
IR  - Senanayake I
FIR - Seneviratne, M
IR  - Seneviratne M
FIR - Seneviratne, T
IR  - Seneviratne T
FIR - Senini, D
IR  - Senini D
FIR - Senior, J
IR  - Senior J
FIR - Seow, L
IR  - Seow L
FIR - Sepetavc, D
IR  - Sepetavc D
FIR - Serafim, A
IR  - Serafim A
FIR - Serban, R
IR  - Serban R
FIR - Sexton, P
IR  - Sexton P
FIR - Shahat, M
IR  - Shahat M
FIR - Shamoun, Y
IR  - Shamoun Y
FIR - Shanmugarajah, K
IR  - Shanmugarajah K
FIR - Shannon, G
IR  - Shannon G
FIR - Sharif, A
IR  - Sharif A
FIR - Shariff, A
IR  - Shariff A
FIR - Sharma, A
IR  - Sharma A
FIR - Sharma, D
IR  - Sharma D
FIR - Sharma, M
IR  - Sharma M
FIR - Sharma, P
IR  - Sharma P
FIR - Sharma, R
IR  - Sharma R
FIR - Sharma, S
IR  - Sharma S
FIR - Sharma, U
IR  - Sharma U
FIR - Sharp, V
IR  - Sharp V
FIR - Sheen-Apostol, J
IR  - Sheen-Apostol J
FIR - Sheikh Mohamed, M
IR  - Sheikh Mohamed M
FIR - Sher, J
IR  - Sher J
FIR - Sherley, M
IR  - Sherley M
FIR - Shi, B
IR  - Shi B
FIR - Shimmin, M B
IR  - Shimmin MB
FIR - Shing, D
IR  - Shing D
FIR - Shires, S E
IR  - Shires SE
FIR - Shmerling, A
IR  - Shmerling A
FIR - Shortis, P
IR  - Shortis P
FIR - Shroot, A D
IR  - Shroot AD
FIR - Shute, J
IR  - Shute J
FIR - Sia, M
IR  - Sia M
FIR - Siapantas, S
IR  - Siapantas S
FIR - Sidhwarni, R
IR  - Sidhwarni R
FIR - Siemienowicz, J
IR  - Siemienowicz J
FIR - Siew, H C
IR  - Siew HC
FIR - Sigalov, E
IR  - Sigalov E
FIR - Silver, D
IR  - Silver D
FIR - Simes, L
IR  - Simes L
FIR - Simonson, F
IR  - Simonson F
FIR - Simpson, R
IR  - Simpson R
FIR - Simpson, T
IR  - Simpson T
FIR - Simpson, W
IR  - Simpson W
FIR - Singh, B
IR  - Singh B
FIR - Singh, D
IR  - Singh D
FIR - Singh, H
IR  - Singh H
FIR - Singh, M
IR  - Singh M
FIR - Singh, R
IR  - Singh R
FIR - Siow, C L
IR  - Siow CL
FIR - Sitlington, R
IR  - Sitlington R
FIR - Sivapalan, C
IR  - Sivapalan C
FIR - Skeat, J
IR  - Skeat J
FIR - Skehan, M
IR  - Skehan M
FIR - Skeklios, L
IR  - Skeklios L
FIR - Skinner, T
IR  - Skinner T
FIR - Sklovsky, C J
IR  - Sklovsky CJ
FIR - Slabbert, J
IR  - Slabbert J
FIR - Slaney, G M
IR  - Slaney GM
FIR - Slattery, C
IR  - Slattery C
FIR - Sleaby, E
IR  - Sleaby E
FIR - Sleiman, C
IR  - Sleiman C
FIR - Slesenger, J
IR  - Slesenger J
FIR - Slimming, T
IR  - Slimming T
FIR - Sloan, C
IR  - Sloan C
FIR - Sloane, R
IR  - Sloane R
FIR - Slonim, D
IR  - Slonim D
FIR - Slot, P
IR  - Slot P
FIR - Smagas, T
IR  - Smagas T
FIR - Smart, M
IR  - Smart M
FIR - Smibert, L
IR  - Smibert L
FIR - Smiley, J
IR  - Smiley J
FIR - Smith, D
IR  - Smith D
FIR - Smith, G
IR  - Smith G
FIR - Smith, J
IR  - Smith J
FIR - Smith, P
IR  - Smith P
FIR - Smith, R
IR  - Smith R
FIR - Smith, Stephen
IR  - Smith S
FIR - Smith, Stuart
IR  - Smith S
FIR - Smith, V
IR  - Smith V
FIR - Smylie, D
IR  - Smylie D
FIR - Sneyd, S
IR  - Sneyd S
FIR - Snow, S
IR  - Snow S
FIR - Sobol, G
IR  - Sobol G
FIR - Soccio, M
IR  - Soccio M
FIR - Solanki, V
IR  - Solanki V
FIR - Soloczynskiyj, A
IR  - Soloczynskiyj A
FIR - Solomon, D
IR  - Solomon D
FIR - Somerville, M
IR  - Somerville M
FIR - Song, J
IR  - Song J
FIR - Soo, D
IR  - Soo D
FIR - Soo, L
IR  - Soo L
FIR - Soo, T
IR  - Soo T
FIR - Soo, T M
IR  - Soo TM
FIR - Sood, R
IR  - Sood R
FIR - Sooknandan, S
IR  - Sooknandan S
FIR - Soon, M
IR  - Soon M
FIR - Sosnin, M
IR  - Sosnin M
FIR - Spanos, N
IR  - Spanos N
FIR - Spargo, J S
IR  - Spargo JS
FIR - Speirs, B
IR  - Speirs B
FIR - Spencer, H
IR  - Spencer H
FIR - Spencer, J
IR  - Spencer J
FIR - Spottiswood, M
IR  - Spottiswood M
FIR - Spring, M
IR  - Spring M
FIR - Squires, L
IR  - Squires L
FIR - Stabelos, G
IR  - Stabelos G
FIR - Stagg, M
IR  - Stagg M
FIR - Stanley, L
IR  - Stanley L
FIR - Stark, A
IR  - Stark A
FIR - Steel, A
IR  - Steel A
FIR - Steer, N
IR  - Steer N
FIR - Steiner, H
IR  - Steiner H
FIR - Stephanson, A
IR  - Stephanson A
FIR - Stephens, G
IR  - Stephens G
FIR - Stephenson, A
IR  - Stephenson A
FIR - Sterling, B R
IR  - Sterling BR
FIR - Stevens, B
IR  - Stevens B
FIR - Stevens, P
IR  - Stevens P
FIR - Stevenson, J
IR  - Stevenson J
FIR - Stewart, C
IR  - Stewart C
FIR - Stewart, R
IR  - Stewart R
FIR - Sticklen, E
IR  - Sticklen E
FIR - Stiebel, P
IR  - Stiebel P
FIR - Stillger, J M
IR  - Stillger JM
FIR - Stinerman, I
IR  - Stinerman I
FIR - Stobie, M
IR  - Stobie M
FIR - Stobie, T
IR  - Stobie T
FIR - Stojkovski, S
IR  - Stojkovski S
FIR - Stone, A
IR  - Stone A
FIR - Stowe, S
IR  - Stowe S
FIR - Stoyanova, V
IR  - Stoyanova V
FIR - Strasser, K
IR  - Strasser K
FIR - Strong, J
IR  - Strong J
FIR - Struk, H
IR  - Struk H
FIR - Stuart, A
IR  - Stuart A
FIR - Su, J
IR  - Su J
FIR - Sujecki, M
IR  - Sujecki M
FIR - Suka, R
IR  - Suka R
FIR - Sullivan, T
IR  - Sullivan T
FIR - Sululola, A
IR  - Sululola A
FIR - Sumathipala, A
IR  - Sumathipala A
FIR - Suntesic, L
IR  - Suntesic L
FIR - Sutherland, D
IR  - Sutherland D
FIR - Sutherland, I
IR  - Sutherland I
FIR - Sutherland, R
IR  - Sutherland R
FIR - Sutton, J
IR  - Sutton J
FIR - Swart, R
IR  - Swart R
FIR - Sweet, M
IR  - Sweet M
FIR - Sweet, R
IR  - Sweet R
FIR - Syed, Z
IR  - Syed Z
FIR - Sykes, J
IR  - Sykes J
FIR - Sylivris, A
IR  - Sylivris A
FIR - Symon, B
IR  - Symon B
FIR - Szabo, R
IR  - Szabo R
FIR - Sze, J
IR  - Sze J
FIR - Szenczy, C
IR  - Szenczy C
FIR - Sze-Tho, R
IR  - Sze-Tho R
FIR - Szymanski, I
IR  - Szymanski I
FIR - Szymanski, R
IR  - Szymanski R
FIR - Tadrous, M
IR  - Tadrous M
FIR - Taft, D
IR  - Taft D
FIR - Taine, M
IR  - Taine M
FIR - Talic, D
IR  - Talic D
FIR - Tan, Elaine
IR  - Tan E
FIR - Tan, Eng
IR  - Tan E
FIR - Tan, G
IR  - Tan G
FIR - Tan, H M
IR  - Tan HM
FIR - Tanovic, A
IR  - Tanovic A
FIR - Tasiopoulos, A
IR  - Tasiopoulos A
FIR - Tate, K
IR  - Tate K
FIR - Tattersall, I
IR  - Tattersall I
FIR - Taverna, C
IR  - Taverna C
FIR - Taylor, J
IR  - Taylor J
FIR - Taylor, R
IR  - Taylor R
FIR - Taylor, S
IR  - Taylor S
FIR - Teo, K
IR  - Teo K
FIR - Teoh, C
IR  - Teoh C
FIR - Teperman, B
IR  - Teperman B
FIR - Tereszkiewicz, W
IR  - Tereszkiewicz W
FIR - Thanenthiran, R
IR  - Thanenthiran R
FIR - Thangarajah, C
IR  - Thangarajah C
FIR - Thangavel, B
IR  - Thangavel B
FIR - Thann, Z
IR  - Thann Z
FIR - The, S
IR  - The S
FIR - Theophilos, M
IR  - Theophilos M
FIR - Theris, N
IR  - Theris N
FIR - Thiru, K
IR  - Thiru K
FIR - Thiru, M
IR  - Thiru M
FIR - Thomas, G
IR  - Thomas G
FIR - Thomas, P
IR  - Thomas P
FIR - Thompson, D
IR  - Thompson D
FIR - Thompson, L
IR  - Thompson L
FIR - Thompson, W
IR  - Thompson W
FIR - Thomson, B
IR  - Thomson B
FIR - Thorne, A
IR  - Thorne A
FIR - Thornley, J
IR  - Thornley J
FIR - Thorpe, V
IR  - Thorpe V
FIR - Thottakurichi, R
IR  - Thottakurichi R
FIR - Thurairajah, A
IR  - Thurairajah A
FIR - Thurairajah, S
IR  - Thurairajah S
FIR - Thyagarajan, T
IR  - Thyagarajan T
FIR - Tiet, Q
IR  - Tiet Q
FIR - Tillekeratne, K
IR  - Tillekeratne K
FIR - Tine, S
IR  - Tine S
FIR - Tinning, R
IR  - Tinning R
FIR - Tinston, C
IR  - Tinston C
FIR - To, E
IR  - To E
FIR - Tolentino, C
IR  - Tolentino C
FIR - Tom, H
IR  - Tom H
FIR - Tomar, D
IR  - Tomar D
FIR - Tomic, M
IR  - Tomic M
FIR - Tomyn, L
IR  - Tomyn L
FIR - Toohill, G
IR  - Toohill G
FIR - Tooth, M
IR  - Tooth M
FIR - Tormey, S
IR  - Tormey S
FIR - Toua, P
IR  - Toua P
FIR - Trainor, S
IR  - Trainor S
FIR - Tran, C
IR  - Tran C
FIR - Tran, E
IR  - Tran E
FIR - Tran, L D
IR  - Tran LD
FIR - Tran, T Q
IR  - Tran TQ
FIR - Trethowan, K
IR  - Trethowan K
FIR - Trevena, R
IR  - Trevena R
FIR - Trigg, P
IR  - Trigg P
FIR - Trivett, B
IR  - Trivett B
FIR - Try, R
IR  - Try R
FIR - Tsigopoulos, A
IR  - Tsigopoulos A
FIR - Tucker, D
IR  - Tucker D
FIR - Tunaley, S
IR  - Tunaley S
FIR - Turnbull, H
IR  - Turnbull H
FIR - Turnbull, S
IR  - Turnbull S
FIR - Turner, J
IR  - Turner J
FIR - Twycross, W
IR  - Twycross W
FIR - Tynan, D
IR  - Tynan D
FIR - Tyndall, P
IR  - Tyndall P
FIR - Tyshing, W
IR  - Tyshing W
FIR - Uchendu, F
IR  - Uchendu F
FIR - Uhlenbruch, B
IR  - Uhlenbruch B
FIR - Uluca, U
IR  - Uluca U
FIR - Unkenstein, D
IR  - Unkenstein D
FIR - Urie, J P
IR  - Urie JP
FIR - Vaiopoulos, T
IR  - Vaiopoulos T
FIR - Van Ammers, E
IR  - Van Ammers E
FIR - Van Der Merwe, D
IR  - Van Der Merwe D
FIR - Van Der Spek, A
IR  - Van Der Spek A
FIR - Van Der Vlist, R
IR  - Van Der Vlist R
FIR - Van Opstal, E
IR  - Van Opstal E
FIR - Vanderzeil, G
IR  - Vanderzeil G
FIR - Vanderzeil, T
IR  - Vanderzeil T
FIR - Vanker, L
IR  - Vanker L
FIR - Vanmali, H
IR  - Vanmali H
FIR - Varghese, A
IR  - Varghese A
FIR - Varney, W
IR  - Varney W
FIR - Vasquez, I
IR  - Vasquez I
FIR - Vasudevan, S
IR  - Vasudevan S
FIR - Veal, M
IR  - Veal M
FIR - Venables, S
IR  - Venables S
FIR - Venkatram, G
IR  - Venkatram G
FIR - Verghese, P
IR  - Verghese P
FIR - Verma, H
IR  - Verma H
FIR - Verma, R
IR  - Verma R
FIR - Verso, M
IR  - Verso M
FIR - Victor, A
IR  - Victor A
FIR - Vijayakumar, V
IR  - Vijayakumar V
FIR - Vijayanand, P
IR  - Vijayanand P
FIR - Viljoen, E
IR  - Viljoen E
FIR - Vincent, F
IR  - Vincent F
FIR - Vinci, A
IR  - Vinci A
FIR - Vinci, G
IR  - Vinci G
FIR - Viney, P
IR  - Viney P
FIR - Visvalingam, C
IR  - Visvalingam C
FIR - Von Caemmerer, A
IR  - Von Caemmerer A
FIR - Vonschmidt, J K
IR  - Vonschmidt JK
FIR - Vorich, R
IR  - Vorich R
FIR - Vrij, R
IR  - Vrij R
FIR - Vyas, S
IR  - Vyas S
FIR - Wai, T
IR  - Wai T
FIR - Waid, S
IR  - Waid S
FIR - Wakefield, B
IR  - Wakefield B
FIR - Walder, D
IR  - Walder D
FIR - Waldron, C M
IR  - Waldron CM
FIR - Waldron, M
IR  - Waldron M
FIR - Wales, S
IR  - Wales S
FIR - Walker, B
IR  - Walker B
FIR - Walker, G
IR  - Walker G
FIR - Walker, R
IR  - Walker R
FIR - Walker, W
IR  - Walker W
FIR - Wall, R
IR  - Wall R
FIR - Wallace, J
IR  - Wallace J
FIR - Wallace, K
IR  - Wallace K
FIR - Wallis, I
IR  - Wallis I
FIR - Wang, S
IR  - Wang S
FIR - Wang, X
IR  - Wang X
FIR - Wang, Z
IR  - Wang Z
FIR - Ward, C
IR  - Ward C
FIR - Ward, R
IR  - Ward R
FIR - Ward, S
IR  - Ward S
FIR - Wardlaw, P
IR  - Wardlaw P
FIR - Wark, A
IR  - Wark A
FIR - Warr, A
IR  - Warr A
FIR - Warren, M
IR  - Warren M
FIR - Waters, L
IR  - Waters L
FIR - Watson, A
IR  - Watson A
FIR - Watson, S
IR  - Watson S
FIR - Watt, G
IR  - Watt G
FIR - Watt, J
IR  - Watt J
FIR - Watterson, J
IR  - Watterson J
FIR - Waugh, R
IR  - Waugh R
FIR - Wazid, M
IR  - Wazid M
FIR - Wearne, E
IR  - Wearne E
FIR - Webb, I
IR  - Webb I
FIR - Webber, C
IR  - Webber C
FIR - Webber, E
IR  - Webber E
FIR - Webber, S
IR  - Webber S
FIR - Webster, D L
IR  - Webster DL
FIR - Webster, J
IR  - Webster J
FIR - Webster, Peter
IR  - Webster P
FIR - Webster, Philip
IR  - Webster P
FIR - Weerasinghe, S
IR  - Weerasinghe S
FIR - Weerasoorya, M
IR  - Weerasoorya M
FIR - Weinrich, J
IR  - Weinrich J
FIR - Welberry, L
IR  - Welberry L
FIR - Weller, A
IR  - Weller A
FIR - Wells, S
IR  - Wells S
FIR - Welsh, D
IR  - Welsh D
FIR - Weng, M
IR  - Weng M
FIR - Wenig, M
IR  - Wenig M
FIR - Wettesinghe, I
IR  - Wettesinghe I
FIR - Wexler, P
IR  - Wexler P
FIR - White, A
IR  - White A
FIR - White, G
IR  - White G
FIR - White, Roxana
IR  - White R
FIR - Whitehouse, J
IR  - Whitehouse J
FIR - Whitehouse, L
IR  - Whitehouse L
FIR - Whitehouse, R
IR  - Whitehouse R
FIR - Whitfield, K
IR  - Whitfield K
FIR - Whitfield, S
IR  - Whitfield S
FIR - Whitney, W
IR  - Whitney W
FIR - Wiehle, G
IR  - Wiehle G
FIR - Wight, R
IR  - Wight R
FIR - Wild, I
IR  - Wild I
FIR - Wilding, S
IR  - Wilding S
FIR - Wildman, G
IR  - Wildman G
FIR - Williams, A
IR  - Williams A
FIR - Williams, G
IR  - Williams G
FIR - Williams, J
IR  - Williams J
FIR - Williams, M
IR  - Williams M
FIR - Williams, P D
IR  - Williams PD
FIR - Williams, S
IR  - Williams S
FIR - Williams, W
IR  - Williams W
FIR - Willis, M
IR  - Willis M
FIR - Wilson, A
IR  - Wilson A
FIR - Win, N
IR  - Win N
FIR - Wiseman, J
IR  - Wiseman J
FIR - Wishart, W
IR  - Wishart W
FIR - Wivell, F
IR  - Wivell F
FIR - Wong, C
IR  - Wong C
FIR - Wong, C S
IR  - Wong CS
FIR - Wong, D
IR  - Wong D
FIR - Wong, John K
IR  - Wong JK
FIR - Wong, Johnny
IR  - Wong J
FIR - Wong, Ju-Min
IR  - Wong JM
FIR - Wong, P
IR  - Wong P
FIR - Wong, P T
IR  - Wong PT
FIR - Wong, Y
IR  - Wong Y
FIR - Wood, P
IR  - Wood P
FIR - Woods, R
IR  - Woods R
FIR - Woodward, P
IR  - Woodward P
FIR - Wooff, D
IR  - Wooff D
FIR - Woolf, S
IR  - Woolf S
FIR - Worboys, P
IR  - Worboys P
FIR - Worboys, P C
IR  - Worboys PC
FIR - Wrennall, R
IR  - Wrennall R
FIR - Wright, Adrian
IR  - Wright A
FIR - Wright, Antony
IR  - Wright A
FIR - Wright, L
IR  - Wright L
FIR - Wright, Richard
IR  - Wright R
FIR - Wright, Robert
IR  - Wright R
FIR - Wrobel, K
IR  - Wrobel K
FIR - Wu, D
IR  - Wu D
FIR - Wu, E
IR  - Wu E
FIR - Wu, L
IR  - Wu L
FIR - Xiao, M
IR  - Xiao M
FIR - Yacoub, M
IR  - Yacoub M
FIR - Yang, A
IR  - Yang A
FIR - Yang, J
IR  - Yang J
FIR - Yang, R
IR  - Yang R
FIR - Yates, D
IR  - Yates D
FIR - Yazbek, P
IR  - Yazbek P
FIR - Yeaman, C
IR  - Yeaman C
FIR - Yeo, M
IR  - Yeo M
FIR - Yeung Shi Chung, D
IR  - Yeung Shi Chung D
FIR - Yiap, D
IR  - Yiap D
FIR - Yilmaz, S
IR  - Yilmaz S
FIR - Yogaranandan, D
IR  - Yogaranandan D
FIR - Young, D
IR  - Young D
FIR - Young, R
IR  - Young R
FIR - Young, S
IR  - Young S
FIR - Yousef, M
IR  - Yousef M
FIR - Yousif, K
IR  - Yousif K
FIR - Youssef, D
IR  - Youssef D
FIR - Yu, Z
IR  - Yu Z
FIR - Yuille, R
IR  - Yuille R
FIR - Zagorksi, M
IR  - Zagorksi M
FIR - Zail, S
IR  - Zail S
FIR - Zain, M
IR  - Zain M
FIR - Zallmann, A
IR  - Zallmann A
FIR - Zeng, L
IR  - Zeng L
FIR - Zhao, S
IR  - Zhao S
FIR - Zhao, W
IR  - Zhao W
FIR - Zheng, M
IR  - Zheng M
FIR - Zhou, D
IR  - Zhou D
FIR - Ziccone, M
IR  - Ziccone M
FIR - Zimmerman, J
IR  - Zimmerman J
FIR - Zwijnenburg, A
IR  - Zwijnenburg A
EDAT- 2018/09/18 06:00
MHDA- 2018/11/06 06:00
CRDT- 2018/09/18 06:00
PHST- 2018/09/18 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
PHST- 2018/09/18 06:00 [entrez]
AID - 10.1056/NEJMoa1803955 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Oct 18;379(16):1519-1528. doi: 10.1056/NEJMoa1803955. Epub 
      2018 Sep 16.

PMID- 24825043
OWN - NLM
STAT- MEDLINE
DCOM- 20150402
LR  - 20171116
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 18
IP  - 1 Suppl
DP  - 2014
TI  - Chronic anti-platelet therapy: a contraindication for platelet-rich plasma 
      intra-articular injections?
PG  - 55-9
LID - 7270 [pii]
AB  - We report the case of a 50 years-old man who complained persisting knee pain that 
      limited almost completely his sport performance. Since he previously underwent 
      multiple aortocoronaric by-passes, he presented a chronic anti-aggregant therapy. 
      In spite of this clinical history, he was still sport active and able to run 
      long-distance races, until knee symptoms limited is activity level. Conservative 
      treatment approaches proved to be unsuccessful, thus we decided to treat him by 3 
      Platelet-rich Plasma (PRP) injections even if chronic anti-aggregant therapy is 
      generally regarded as a contra-indication for PRP, since this kind of drugs 
      impairs platelet function and granules' release. Despite these premises, the 
      clinical outcome was very satisfactory and the patient was able to rapidly resume 
      intensive running activity. This experience opens new questions regarding the 
      real potential of PRP in treating degenerative musculo-skeletal disorders, and in 
      particular on its range of biological actions and on its limitations for clinical 
      application.
FAU - Di Matteo, B
AU  - Di Matteo B
AD  - Biomechanics Laboratory, II Orthopaedic and Traumatology Clinic, Rizzoli 
      Orthopaedic Institute, Bologna, Italy. berardo.dimatteo@gmail.com.
FAU - Filardo, G
AU  - Filardo G
FAU - Lo Presti, M
AU  - Lo Presti M
FAU - Kon, E
AU  - Kon E
FAU - Marcacci, M
AU  - Marcacci M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Contraindications
MH  - Humans
MH  - Injections, Intra-Articular
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis, Knee/*therapy
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - *Platelet-Rich Plasma
MH  - Treatment Outcome
EDAT- 2014/05/16 06:00
MHDA- 2015/04/04 06:00
CRDT- 2014/05/15 06:00
PHST- 2014/05/15 06:00 [entrez]
PHST- 2014/05/16 06:00 [pubmed]
PHST- 2015/04/04 06:00 [medline]
AID - 7270 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2014;18(1 Suppl):55-9.

PMID- 7837966
OWN - NLM
STAT- MEDLINE
DCOM- 19950302
LR  - 20190606
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 74
IP  - 1
DP  - 1995 Jan
TI  - The treatment of rheumatic carditis: a review and meta-analysis.
PG  - 1-12
AB  - We performed a meta-analysis of the literature on the treatment of established 
      rheumatic carditis to determine if corticosteroid therapy is superior to 
      salicylates in preventing the sequela of inflammation--valvular damage. We 
      identified 22 reports of comparative trials published since the introduction of 
      corticosteroids in 1949. Five of the 22 studies met the criteria we established 
      for the meta-analysis, which included using randomization and a 1-year follow-up 
      for the presence of a new pathologic apical systolic murmur. Based on the 
      meta-analysis, the advantage of corticosteroid treatment over salicylates in 
      preventing a pathologic murmur at 1 year posttreatment is not statistically 
      significant (estimated odds ratio 0.88; 95% confidence interval: 0.53 to 1.46). 
      However, the meta-analysis is dominated by 1 large negative trial, and there was 
      significant heterogeneity in the results obtained from the studies in the 
      meta-analysis; thus, the question of whether corticosteroid therapy is marginally 
      superior to salicylates for the prevention of valvular heart disease from 
      rheumatic fever remains open.
FAU - Albert, D A
AU  - Albert DA
AD  - Department of Medicine, University of Chicago, Illinois 60637.
FAU - Harel, L
AU  - Harel L
FAU - Karrison, T
AU  - Karrison T
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Adrenal Cortex Hormones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Myocarditis/*drug therapy/etiology
MH  - Rheumatic Heart Disease/*drug therapy
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1097/00005792-199501000-00001 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 1995 Jan;74(1):1-12. doi: 10.1097/00005792-199501000-00001.

PMID- 1594261
OWN - NLM
STAT- MEDLINE
DCOM- 19920626
LR  - 20210112
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 48
IP  - 3
DP  - 1992 Mar
TI  - A new topical treatment for acute herpetic neuralgia and post-herpetic neuralgia: 
      the aspirin/diethyl ether mixture. An open-label study plus a double-blind 
      controlled clinical trial.
PG  - 383-390
LID - 10.1016/0304-3959(92)90088-S [doi]
AB  - Topical aspirin/diethyl ether (ADE) mixture was used to treat 45 consecutive 
      patients with acute herpetic neuralgia (AHN) (n = 28) and with post-herpetic 
      neuralgia (PHN) (n = 17) in an open-label study. Good-to-excellent results were 
      achieved by 93% of AHN patients and by 65% of PHN patients. Earlier treatment 
      yielded better results for the AHN but not the PHN group. The topical treatment 
      seemed to accelerate the healing of acute herpetic skin lesions and possibly 
      modulate the severity of the herpetic infection. Furthermore, a striking 
      reduction in the percentage of AHN patients developing PHN was observed in the 
      treated group, as compared with the disease natural history reported in the 
      literature (4 vs. 50-70%). Treatment tolerance was excellent with no adverse 
      effect observed. In addition to the open trial, a pilot double-blind crossover 
      placebo-controlled study (n = 11) compared the analgesic efficacy of ADE with two 
      other NSAID (indomethacin and diclofenac) drug/ether mixtures. Aspirin (but not 
      indomethacin and diclofenac) was significantly superior to placebo as regards 
      pain relief (P less than 0.05).
FAU - De Benedittis, Giuseppe
AU  - De Benedittis G
AD  - Pain Research and Treatment Unit, Institute of Neurosurgery, University of Milan, 
      MilanItaly Institute of Dermatology II, University of Milan, MilanItaly.
FAU - Besana, Francesco
AU  - Besana F
FAU - Lorenzetti, Ariberto
AU  - Lorenzetti A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - 0 (Drug Combinations)
RN  - 0F5N573A2Y (Ether)
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
EIN - Pain 1992 Aug;50(2):245
MH  - Acute Disease
MH  - Administration, Topical
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Diclofenac/therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Ether/*administration & dosage/adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Herpes Zoster/*drug therapy
MH  - Humans
MH  - Indomethacin/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Neuralgia/*drug therapy/etiology
MH  - Skin Diseases/chemically induced
EDAT- 1992/03/01 00:00
MHDA- 1992/03/01 00:01
CRDT- 1992/03/01 00:00
PHST- 1992/03/01 00:00 [pubmed]
PHST- 1992/03/01 00:01 [medline]
PHST- 1992/03/01 00:00 [entrez]
AID - 00006396-199203000-00013 [pii]
AID - 10.1016/0304-3959(92)90088-S [doi]
PST - ppublish
SO  - Pain. 1992 Mar;48(3):383-390. doi: 10.1016/0304-3959(92)90088-S.

PMID- 25267425
OWN - NLM
STAT- MEDLINE
DCOM- 20150713
LR  - 20211021
IS  - 1759-5010 (Electronic)
IS  - 1759-5002 (Linking)
VI  - 11
IP  - 11
DP  - 2014 Nov
TI  - Decade in review--peripheral vascular disease: 10 Years of breakthroughs in 
      peripheral vascular disease.
PG  - 635-6
LID - 10.1038/nrcardio.2014.153 [doi]
AB  - Clinical trials published during the past decade have had substantial effects on 
      the treatment of peripheral vascular diseases. In this article, I discuss ten 
      important trials that have influenced treatment for common vascular disorders, 
      including peripheral artery disease, abdominal aortic aneurysm, renal artery 
      disease, extracranial carotid artery disease, and venous thromboembolism.
FAU - Creager, Mark A
AU  - Creager MA
AD  - Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, 
      MA 02115, USA.
LA  - eng
PT  - Journal Article
DEP - 20140930
PL  - England
TA  - Nat Rev Cardiol
JT  - Nature reviews. Cardiology
JID - 101500075
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Endarterectomy
MH  - Endovascular Procedures
MH  - Exercise Therapy
MH  - Humans
MH  - Peripheral Vascular Diseases/complications/*therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Stents
EDAT- 2014/10/01 06:00
MHDA- 2015/07/15 06:00
CRDT- 2014/10/01 06:00
PHST- 2014/10/01 06:00 [entrez]
PHST- 2014/10/01 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - nrcardio.2014.153 [pii]
AID - 10.1038/nrcardio.2014.153 [doi]
PST - ppublish
SO  - Nat Rev Cardiol. 2014 Nov;11(11):635-6. doi: 10.1038/nrcardio.2014.153. Epub 2014 
      Sep 30.

PMID- 10849251
OWN - NLM
STAT- MEDLINE
DCOM- 20000725
LR  - 20190921
IS  - 0140-7783 (Print)
IS  - 0140-7783 (Linking)
VI  - 23
IP  - 2
DP  - 2000 Apr
TI  - The pharmacokinetics and effects of intravenously administered carprofen and 
      salicylate on gastrointestinal mucosa and selected biochemical measurements in 
      healthy cats.
PG  - 73-9
AB  - The pharmacokinetics of carprofen, a propionic acid-derived nonsteroidal 
      anti-inflammatory (NSAID), and its effect on gastrointestinal mucosa, complete 
      blood counts (CBC) and biochemical indicators of liver and renal function were 
      investigated in healthy cats using a randomized crossover design. A single dose 
      of 4 mg/kg of carprofen (Zenecarp(R) Injection), normal saline, or 20 mg/kg of 
      DL-lysine acetyl salicylate (Vetalgine(R)) was given intravenously (i.v.) to each 
      of five cats with a washout period of 2 weeks between treatments. Endoscopy of 
      the stomach and duodenum 8 h postinjection revealed one acetyl 
      salicylate-(aspirin)-treated cat with minor pinpoint erosions. None of the other 
      cats in the three treatment groups had evidence of bleeding or ulceration. Serum 
      biochemistry measurements of blood urea nitrogen (BUN), alanine transferase (ALT) 
      and alkaline phosphatase (ALP) and complete blood counts (CBC) were not 
      significantly altered from pretreatment values by the single dose of salicylate 
      or carprofen (P < 0.05). Early and extended sample time points suggest that the 
      pharmacokinetics of carprofen in the cat fit a 2-compartment model, with a long 
      elimination half-life (t1/2) of 20.1 +/- 16.6 h, an area under the plasma 
      concentration-time curve (AUC) of 637 (+/- 237) microgram.mL/h and a volume of 
      distribution (Vdss) of 0.14 +/- 0.05 L/kg. Intravenously administered aspirin fit 
      a 2-compartment model and had a long elimination half-life (t1/2) of 22.2 +/- 3.1 
      h, an AUC of 3824.2 +/- 506.7 microgram.mL/h and a volume of distribution (Vdss) 
      of 0.17 +/- 0. 01 L/kg.
FAU - Parton, K
AU  - Parton K
AD  - Institute of Veterinary, Animal and Biomedical Sciences, Massey University, 
      Palmerston North, New Zealand. k.parton@massey.ac.nz
FAU - Balmer, T V
AU  - Balmer TV
FAU - Boyle, J
AU  - Boyle J
FAU - Whittem, T
AU  - Whittem T
FAU - MacHon, R
AU  - MacHon R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Carbazoles)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - FFL0D546HO (carprofen)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Alanine Transaminase/blood
MH  - Alkaline Phosphatase/blood
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/*pharmacokinetics/pharmacology
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/*analogs & 
      derivatives/*pharmacokinetics/pharmacology
MH  - Blood Urea Nitrogen
MH  - Carbazoles/administration & dosage/*pharmacokinetics/pharmacology
MH  - Cats
MH  - Cross-Over Studies
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Half-Life
MH  - Injections, Intravenous
MH  - Kidney/drug effects
MH  - Liver/drug effects
MH  - Lysine/administration & dosage/*analogs & 
      derivatives/pharmacokinetics/pharmacology
MH  - Male
EDAT- 2000/06/10 09:00
MHDA- 2000/08/01 11:00
CRDT- 2000/06/10 09:00
PHST- 2000/06/10 09:00 [pubmed]
PHST- 2000/08/01 11:00 [medline]
PHST- 2000/06/10 09:00 [entrez]
AID - jvp253 [pii]
AID - 10.1046/j.1365-2885.2000.00253.x [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 2000 Apr;23(2):73-9. doi: 10.1046/j.1365-2885.2000.00253.x.

PMID- 981705
OWN - NLM
STAT- MEDLINE
DCOM- 19770103
LR  - 20190823
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 12
IP  - 5
DP  - 1976 Nov
TI  - Effect of aspirin on prostaglandin synthesis by human platelets.
PG  - 829-35
AB  - When platelet rich plasma is exposed to N-ethylmaleimide, a ten fold increase in 
      measurable prostaglandin E synthesis occurs. This effect is almost completely 
      abolished within 2 hours of ingestion of 600 mg of aspirin by human volunteers. 
      Recovery of this platelet function is slow for the first two days, returning 
      sharply to normal over the next six days and plateauing approximately 8 days 
      following initial removal from aspirin. It is suggested from these studies that 
      platelet prostaglandin E production following NEM may be a useful test of 
      platelet function.
FAU - Jafari, E
AU  - Jafari E
FAU - Saleem, A
AU  - Saleem A
FAU - Shaikh, B S
AU  - Shaikh BS
FAU - Demers, L M
AU  - Demers LM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Prostaglandins E)
RN  - O3C74ACM9V (Ethylmaleimide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*metabolism
MH  - Ethylmaleimide/pharmacology
MH  - Humans
MH  - Prostaglandins E/*biosynthesis
MH  - Time Factors
EDAT- 1976/11/01 00:00
MHDA- 1976/11/01 00:01
CRDT- 1976/11/01 00:00
PHST- 1976/11/01 00:00 [pubmed]
PHST- 1976/11/01 00:01 [medline]
PHST- 1976/11/01 00:00 [entrez]
AID - 0090-6980(76)90056-3 [pii]
AID - 10.1016/0090-6980(76)90056-3 [doi]
PST - ppublish
SO  - Prostaglandins. 1976 Nov;12(5):829-35. doi: 10.1016/0090-6980(76)90056-3.

PMID- 35810307
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20221207
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Jul 9
TI  - Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 
      infection: a randomised clinical trial (RESIST trial).
PG  - 606
LID - 10.1186/s12879-022-07570-5 [doi]
LID - 606
AB  - BACKGROUND: Statins and aspirin have been proposed for treatment of COVID-19 
      because of their anti-inflammatory and anti-thrombotic properties. Several 
      observational studies have shown favourable results. There is a need for a 
      randomised controlled trial. METHODS: In this single-center, open-label, 
      randomised controlled trial, 900 RT-PCR positive COVID-19 patients requiring 
      hospitalisation, were randomly assigned to receive either atorvastatin 40 mg 
      (Group A, n = 224), aspirin 75 mg (Group B, n = 225), or both (Group C, n = 225) 
      in addition to standard of care for 10 days or until discharge whichever was 
      earlier or only standard of care (Group D, n = 226). The primary outcome variable 
      was clinical deterioration to WHO Ordinal Scale for Clinical Improvement ≥ 6. The 
      secondary outcome was change in serum C-reactive protein, interleukin-6, and 
      troponin I. RESULTS: The primary outcome occurred in 25 (2.8%) patients: 7 (3.2%) 
      in Group A, 3 (1.4%) in Group B, 8 (3.6%) in Group C, and 7 (3.2%) in Group D. 
      There was no difference in primary outcome across the study groups (P = 0.463). 
      Comparison of all patients who received atorvastatin or aspirin with the control 
      group (Group D) also did not show any benefit [Atorvastatin: HR 1.0 (95% CI 
      0.41-2.46) P = 0.99; Aspirin: HR 0.7 (95% CI 0.27-1.81) P = 0.46]. The secondary 
      outcomes revealed lower serum interleukin-6 levels among patients in Groups B and 
      C. There was no excess of adverse events. CONCLUSIONS: Among patients admitted 
      with mild to moderate COVID-19 infection, additional treatment with aspirin, 
      atorvastatin, or a combination of the two does not prevent clinical 
      deterioration. Trial Registry Number CTRI/2020/07/026791 ( http://ctri.nic.in ; 
      registered on 25/07/2020).
CI  - © 2022. The Author(s).
FAU - Ghati, Nirmal
AU  - Ghati N
AD  - Department of Cardiology, Jai Prakash Narayan Apex Trauma Center, All India 
      Institute of Medical Sciences (AIIMS), New Delhi, India.
FAU - Bhatnagar, Sushma
AU  - Bhatnagar S
AD  - Department of Onco-Anaesthesia, Dr. B.R.A Institute-Rotary Cancer Hospital, All 
      India Institute of Medical Sciences (AIIMS), New Delhi, India.
FAU - Mahendran, Manjit
AU  - Mahendran M
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), New 
      Delhi, India.
FAU - Thakur, Abhishek
AU  - Thakur A
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), New 
      Delhi, India.
FAU - Prasad, Kshitij
AU  - Prasad K
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), New 
      Delhi, India.
FAU - Kumar, Devesh
AU  - Kumar D
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), New 
      Delhi, India.
FAU - Dwivedi, Tanima
AU  - Dwivedi T
AD  - Department of Laboratory Medicine, National Cancer Institute (Jhajjar, Haryana), 
      All India Institute of Medical Sciences (AIIMS), New Delhi, India.
FAU - Mani, Kalaivani
AU  - Mani K
AD  - Department of Biostatistics, All India Institute of Medical Sciences (AIIMS), New 
      Delhi, India.
FAU - Tiwari, Pawan
AU  - Tiwari P
AD  - Department of Pulmonary Medicine and Sleep Disorders, All India Institute of 
      Medical Sciences (AIIMS), New Delhi, India.
FAU - Gupta, Ritu
AU  - Gupta R
AD  - Department of Laboratory Oncology, Dr. B.R.A Institute-Rotary Cancer Hospital, 
      All India Institute of Medical Sciences (AIIMS), New Delhi, India.
FAU - Mohan, Anant
AU  - Mohan A
AD  - Department of Pulmonary Medicine and Sleep Disorders, All India Institute of 
      Medical Sciences (AIIMS), New Delhi, India.
FAU - Saxena, Anita
AU  - Saxena A
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), New 
      Delhi, India.
FAU - Guleria, Randeep
AU  - Guleria R
AD  - Department of Pulmonary Medicine and Sleep Disorders, All India Institute of 
      Medical Sciences (AIIMS), New Delhi, India.
FAU - Deepti, Siddharthan
AU  - Deepti S
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), New 
      Delhi, India. deeptikailath@gmail.com.
AD  - Department of Cardiology, Cardiothoracic Sciences Centre, All India Institute of 
      Medical Sciences, Ansari Nagar, New Delhi, 110029, India. 
      deeptikailath@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220709
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Interleukin-6)
RN  - A0JWA85V8F (Atorvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Atorvastatin/therapeutic use
MH  - *Clinical Deterioration
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Interleukin-6
MH  - SARS-CoV-2
MH  - Treatment Outcome
MH  - *COVID-19 Drug Treatment
PMC - PMC9270743
OTO - NOTNLM
OT  - Aspirin
OT  - COVID-19
OT  - Serum IL-6
OT  - Statin
OT  - WHO ordinal scale
COIS- We declare no competing interests.
EDAT- 2022/07/10 06:00
MHDA- 2022/07/14 06:00
CRDT- 2022/07/09 23:25
PHST- 2022/03/08 00:00 [received]
PHST- 2022/05/27 00:00 [accepted]
PHST- 2022/07/09 23:25 [entrez]
PHST- 2022/07/10 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
AID - 10.1186/s12879-022-07570-5 [pii]
AID - 7570 [pii]
AID - 10.1186/s12879-022-07570-5 [doi]
PST - epublish
SO  - BMC Infect Dis. 2022 Jul 9;22(1):606. doi: 10.1186/s12879-022-07570-5.

PMID- 25887192
OWN - NLM
STAT- MEDLINE
DCOM- 20160127
LR  - 20150430
IS  - 1473-6500 (Electronic)
IS  - 0952-7907 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Jun
TI  - Aspirin in the perioperative period: a review of the recent literature.
PG  - 349-55
LID - 10.1097/ACO.0000000000000200 [doi]
AB  - PURPOSE OF REVIEW: The indications for aspirin (ASA) for both primary and 
      secondary prevention of thrombotic events continue to evolve. We review some of 
      these indications and the recent literature regarding the perioperative 
      administration of ASA. RECENT FINDINGS: ASA for primary prevention of cardiac 
      ischemia, stroke, cancer, and death remains controversial. When used for primary 
      prevention, ASA may be safely discontinued perioperatively. Patients with 
      coronary or carotid artery stents should continue to receive ASA perioperatively. 
      For patients with ischemic heart disease currently receiving ASA for secondary 
      prevention of cardiac ischemia and stroke undergoing general surgery, orthopedic 
      surgery, ophthalmological surgery, cardiovascular surgery, major vascular 
      surgery, or a urological procedure, continuation of ASA is probably well 
      tolerated, but further study is required. There is no indication to initiate ASA 
      perioperatively in patients with stable ischemic heart disease as the risks 
      outweigh the benefits. Until further data become available, decisions regarding 
      the perioperative continuation of ASA should be made on a case-by-case 
      risk-benefit analysis. SUMMARY: The continuation or discontinuation of ASA 
      perioperatively remains a complicated issue. Further, well designed trials are 
      needed for additional clarification.
FAU - Kiberd, Mathew B
AU  - Kiberd MB
AD  - Departments of Critical Care Medicine, Anesthesiology, and Pharmacology, 
      Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Hall, Richard I
AU  - Hall RI
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Anaesthesiol
JT  - Current opinion in anaesthesiology
JID - 8813436
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Drug Interactions
MH  - Humans
MH  - Intraoperative Complications/prevention & control
MH  - Perioperative Care/*methods
MH  - Perioperative Period
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Thromboembolism/*prevention & control
EDAT- 2015/04/19 06:00
MHDA- 2016/01/28 06:00
CRDT- 2015/04/19 06:00
PHST- 2015/04/19 06:00 [entrez]
PHST- 2015/04/19 06:00 [pubmed]
PHST- 2016/01/28 06:00 [medline]
AID - 10.1097/ACO.0000000000000200 [doi]
PST - ppublish
SO  - Curr Opin Anaesthesiol. 2015 Jun;28(3):349-55. doi: 10.1097/ACO.0000000000000200.

PMID- 8431407
OWN - NLM
STAT- MEDLINE
DCOM- 19930318
LR  - 20190914
IS  - 0266-4356 (Print)
IS  - 0266-4356 (Linking)
VI  - 31
IP  - 1
DP  - 1993 Feb
TI  - Temporomandibular joint synovial fluid analysis.
PG  - 15-20
AB  - A method for the estimation of the synovial fluid volume of the temporomandibular 
      joint (TMJ) is described. Patients are administered 1.2 g of aspirin and the 
      concentration of salicylate in plasma and in saline aspirates of the TMJ is 
      measured by a sensitive high performance liquid chromatography assay. The ratio 
      of the concentration of salicylate in the saline aspirate to that in the plasma 
      allows the volume of the synovial fluid to be calculated. The method would also 
      allow the determination of the concentration and the absolute amount of putative 
      mediators of pathology in the upper joint.
FAU - Aghabeigi, B
AU  - Aghabeigi B
AD  - Joint Department of Maxillofacial Surgery and Oral Medicine, Eastman Dental and 
      University College Hospitals, University of London.
FAU - Henderson, B
AU  - Henderson B
FAU - Hopper, C
AU  - Hopper C
FAU - Harris, M
AU  - Harris M
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Br J Oral Maxillofac Surg
JT  - The British journal of oral & maxillofacial surgery
JID - 8405235
RN  - 0 (Hemoglobins)
RN  - 0 (Salicylates)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*analysis/blood
MH  - Biopsy, Needle/instrumentation/methods
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/analysis/blood
MH  - Sodium Chloride
MH  - Synovial Fluid/*chemistry
MH  - Temporomandibular Joint/*chemistry
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
AID - 10.1016/0266-4356(93)90090-j [doi]
PST - ppublish
SO  - Br J Oral Maxillofac Surg. 1993 Feb;31(1):15-20. doi: 
      10.1016/0266-4356(93)90090-j.

PMID- 19299662
OWN - NLM
STAT- MEDLINE
DCOM- 20090624
LR  - 20161203
IS  - 1543-2548 (Electronic)
IS  - 1534-0384 (Linking)
VI  - 9
IP  - 1
DP  - 2009 Feb
TI  - Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.
PG  - 31-9
LID - 10.1124/mi.9.1.8 [doi]
AB  - Aspirin has been a commercial drug for over a century, although for most of this 
      history, an understanding of its mechanism of action, as an inhibitor of 
      cyclooxygenase (COX) activity and thus of prostanoid synthesis, was lacking. Over 
      the past fifty years, a large number of other nonsteroidal antiinflammatory drugs 
      (NSAIDs) have been developed, and a much deeper understanding of inflammation and 
      prostanoid action has emerged. Indeed, a new class of selective inhibitors of the 
      cyclooxygenase-2 isozyme was introduced, about ten years ago, and these so-called 
      coxibs quickly became regarded as preferable, in certain clinical contexts, to 
      avoid side effects associated with the use of aspirin and previously developed 
      NSAIDs. This regard for coxibs has been challenged, sometimes infamously, as 
      cardiovascular events associated with coxib use have become apparent. A variety 
      of clinical trials have led to seemingly conflicting data concerning the roles of 
      COX-1 and COX-2, and the implications of their relative inhibition, in 
      cardiovascular health and disease. In this Review, the authors offer an 
      assessment of drug pharmacokinetics and enzyme physiology that reconciles 
      cardiovascular appraisals from a wide array of clinical data.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. 
      carlo.patrono@rm.unicatt.it
FAU - Baigent, Colin
AU  - Baigent C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Mol Interv
JT  - Molecular interventions
JID - 101093789
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cyclooxygenase 2 Inhibitors/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - *Randomized Controlled Trials as Topic
RF  - 48
EDAT- 2009/03/21 09:00
MHDA- 2009/06/25 09:00
CRDT- 2009/03/21 09:00
PHST- 2009/03/21 09:00 [entrez]
PHST- 2009/03/21 09:00 [pubmed]
PHST- 2009/06/25 09:00 [medline]
AID - 9/1/31 [pii]
AID - 10.1124/mi.9.1.8 [doi]
PST - ppublish
SO  - Mol Interv. 2009 Feb;9(1):31-9. doi: 10.1124/mi.9.1.8.

PMID- 17184645
OWN - NLM
STAT- MEDLINE
DCOM- 20070104
LR  - 20131121
IS  - 1552-6259 (Electronic)
IS  - 0003-4975 (Linking)
VI  - 83
IP  - 1
DP  - 2007 Jan
TI  - Dose-related efficacy of aspirin after coronary surgery in patients With Pl(A2) 
      polymorphism (NCT00262275).
PG  - 134-8
AB  - BACKGROUND: To evaluate the impact of the genetic polymorphisms affecting aspirin 
      response using platelet aggregation and the response to different aspirin doses 
      after cardiopulmonary bypass, we performed a subanalysis of the results from a 
      randomized trial evaluating low- and medium-dose aspirin and clopidogrel. 
      METHODS: Blood was collected from consenting patients and DNA extracted. 
      Polymerase chain reaction and restriction fragment length polymorphism analysis 
      was performed to detect Pl(A2), C807T, and A842/C50T polymorphisms. Aspirin 
      efficacy was assessed using light transmission platelet aggregometry, and 
      reported as percentage aggregation and EC50 concentrations using the technique of 
      Born. RESULTS: Of 90 patients, 80 consented to further genetic testing, of whom 
      63 patients were randomly assigned to medium- (325 mg) or low-dose (100 mg) 
      aspirin. The Pl(A2), C807T, and A842/C50T gene frequencies were 30%, 66%, and 
      21%, respectively, with no identifiable differences in the baseline platelet 
      aggregation. Postoperatively, after 5 days of aspirin, platelet aggregation was 
      consistently but not significantly impaired with Pl(A2) and A842/C50T carriers 
      and consistently but not significantly improved with C50T carriers. An 
      interaction term was identified on percentage aggregation and EC50 using 
      epinephrine. The interaction coefficient describes a higher aggregation of 19% 
      (95% confidence interval: 2 to 36; p = 0.03) and less inhibition with an EC50 of 
      -2.07 (-4.19 to 0.04; p = 0.06) in patients who were both Pl(A2) positive and 
      receiving low-dose aspirin. CONCLUSIONS: Genetic polymorphisms that affect the 
      response to aspirin are common. The impaired response of persons with the Pl(A2) 
      polymorphism to aspirin may be dose related, with significant improvement 
      observed in patients using medium- rather than low-dose aspirin.
FAU - Lim, Eric
AU  - Lim E
AD  - Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, United 
      Kingdom. eric.lim@cvsnet.org
FAU - Carballo, Sebastian
AU  - Carballo S
FAU - Cornelissen, Jacqueline
AU  - Cornelissen J
FAU - Ali, Ziad A
AU  - Ali ZA
FAU - Grignani, Robert
AU  - Grignani R
FAU - Bellm, Sarah
AU  - Bellm S
FAU - Large, Stephen
AU  - Large S
LA  - eng
SI  - ClinicalTrials.gov/NCT00262275
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Thorac Surg. 2007 Jan;83(1):138-9. PMID: 17184646
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiopulmonary Bypass
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*genetics
MH  - *Polymorphism, Genetic
EDAT- 2006/12/23 09:00
MHDA- 2007/01/05 09:00
CRDT- 2006/12/23 09:00
PHST- 2006/06/08 00:00 [received]
PHST- 2006/07/30 00:00 [revised]
PHST- 2006/08/01 00:00 [accepted]
PHST- 2006/12/23 09:00 [pubmed]
PHST- 2007/01/05 09:00 [medline]
PHST- 2006/12/23 09:00 [entrez]
AID - S0003-4975(06)01525-6 [pii]
AID - 10.1016/j.athoracsur.2006.08.002 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 2007 Jan;83(1):134-8. doi: 10.1016/j.athoracsur.2006.08.002.

PMID- 6468470
OWN - NLM
STAT- MEDLINE
DCOM- 19841019
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 26
IP  - 5
DP  - 1984
TI  - A comparative study of the effects of aspirin and paracetamol (acetaminophen) on 
      platelet aggregation and bleeding time.
PG  - 567-71
AB  - In a double blind, randomised trial, the effects of 1 g aspirin and 1 g 
      paracetamol were compared on bleeding time and platelet aggregation in 40 
      volunteers (20 females). Also investigated was the relationship between plasma 
      aspirin esterase activity and both bleeding time and platelet aggregation after 
      aspirin. Following 1 g aspirin there was a significant increase in bleeding time 
      at 24 h (p less than 0.01). A significant reduction (P less than 0.01) in 
      platelet aggregation with collagen was observed at 1, 6 and 24 h after aspirin, 
      but no significant reduction (P greater than 0.05) was observed with ADP. 
      Paracetamol had no effect on bleeding time or platelet aggregation. Plasma 
      aspirin esterase activity ranged from 0.26-0.6 mumol/ml/min. A significant 
      negative correlation (R = -0.55, P less than 0.001) was observed between 
      percentage increase in bleeding time (24 h) and plasma aspirin esterase activity. 
      Further significant correlations were observed between plasma aspirin esterase 
      activity and change in platelet aggregation with collagen at 1 h (R = 0.68, P 
      less than 0.001), 6 h (R = -0.73, P less than 0.001) and 24 h (R = -0.67, P less 
      than 0.001). These results suggest that it might be possible to predict an 
      individual's haemostatic response to aspirin from knowledge of their plasma 
      aspirin esterase activity.
FAU - Seymour, R A
AU  - Seymour RA
FAU - Williams, F M
AU  - Williams FM
FAU - Oxley, A
AU  - Oxley A
FAU - Ward, A
AU  - Ward A
FAU - Fearns, M
AU  - Fearns M
FAU - Brighan, K
AU  - Brighan K
FAU - Rawlins, M D
AU  - Rawlins MD
FAU - Jones, P M
AU  - Jones PM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 362O9ITL9D (Acetaminophen)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.- (acetylsalicylic acid hydrolase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - *Bleeding Time
MH  - Carboxylic Ester Hydrolases/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - *Platelet Function Tests
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1007/BF00543486 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1984;26(5):567-71. doi: 10.1007/BF00543486.

PMID- 10830560
OWN - NLM
STAT- MEDLINE
DCOM- 20000608
LR  - 20220409
IS  - 0002-9629 (Print)
IS  - 0002-9629 (Linking)
VI  - 319
IP  - 5
DP  - 2000 May
TI  - Idiopathic adrenal hemorrhage.
PG  - 340-2
AB  - A case of idiopathic adrenal hemorrhage is reported. A 76-year-old woman 
      exhibited a left adrenal tumor, 3 cm in diameter, on abdominal computed 
      tomography. The patient was receiving aspirin medication for atrial fibrillation. 
      There was no evidence of increased adrenal hormones. The mass enlarged to 6 cm in 
      diameter within 18 months, and malignancy was suspected. The mass was diagnosed 
      as adrenal hematoma by operative findings.
FAU - Kamishirado, H
AU  - Kamishirado H
AD  - Department of Cardiology, Koshigaya Hospital, Dokkyo University School of 
      Medicine, Saitama, Japan.
FAU - Inoue, T
AU  - Inoue T
FAU - Fujito, T
AU  - Fujito T
FAU - Akiya, K
AU  - Akiya K
FAU - Ishiyama, E
AU  - Ishiyama E
FAU - Sakuma, M
AU  - Sakuma M
FAU - Takayanagi, K
AU  - Takayanagi K
FAU - Hayashi, T
AU  - Hayashi T
FAU - Morooka, S
AU  - Morooka S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Gland Diseases/*diagnosis/etiology
MH  - Aged
MH  - Aspirin/adverse effects
MH  - Female
MH  - Hematoma/*diagnosis/etiology
MH  - Hemorrhage/*diagnosis/etiology
MH  - Humans
EDAT- 2000/06/01 09:00
MHDA- 2000/06/10 09:00
CRDT- 2000/06/01 09:00
PHST- 2000/06/01 09:00 [pubmed]
PHST- 2000/06/10 09:00 [medline]
PHST- 2000/06/01 09:00 [entrez]
AID - S0002-9629(15)40763-3 [pii]
AID - 10.1097/00000441-200005000-00013 [doi]
PST - ppublish
SO  - Am J Med Sci. 2000 May;319(5):340-2. doi: 10.1097/00000441-200005000-00013.

PMID- 33682838
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Print)
IS  - 0392-4203 (Linking)
VI  - 92
IP  - 1
DP  - 2020 Dec 22
TI  - Food Dependent Exercise-Induced Anaphylaxis in pediatric age. Can we trust the 
      oral food challenge with exercise and acetylsalicylic acid?
PG  - e2021068
LID - 10.23750/abm.v92i1.10093 [doi]
LID - e2021068
AB  - Food-dependent exercise-induced anaphylaxis (FDEIA) is an IgE-mediated allergy 
      resulting from the combination of the ingestion of an offending food and physical 
      exercise. According literature, oral food challenge (OFC) followed by physical 
      exercise (OFCPE) should be considered the diagnostic gold standard. In the 
      absence of adverse reactions, other cofactors should be added (e.g. 
      acetylsalicylic acid, alcohol in adulthood), one at a time. But many other 
      factors increase patient's reactivity. This could reduce the sensitivity of the 
      OFCPE and, consequently, make instructions for patients less reliable. On the 
      other hand, the addition of cofactors not reported by the patient may reduce test 
      specificity. With the help of two exemplary stories, that present opposite 
      outcomes, diagnostic difficulties of FDEIA are discussed.
FAU - Miceli Sopo, Stefano
AU  - Miceli Sopo S
AD  - Allergy Unit, Pediatrics Section, Department of Woman and Child Health, 
      Policlinico Gemelli Universitary Foundation IRCCS, Catholic University of Sacre 
      Hearth, Rome 00168, Italy.. stefano.micelisopo@unicatt.it.
FAU - Gelsomino, Mariannita
AU  - Gelsomino M
AD  - Allergy Unit, Pediatrics Section, Department of Woman and Child Health, 
      Policlinico Gemelli Universitary Foundation IRCCS, Catholic University of Sacre 
      Hearth, Rome 00168, Italy.. mariannita.gelsomino@gmail.com.
FAU - Del Vescovo, Ester
AU  - Del Vescovo E
AD  - Allergy Unit, Pediatrics Section, Department of Woman and Child Health, 
      Policlinico Gemelli Universitary Foundation IRCCS, Catholic University of Sacre 
      Hearth, Rome 00168, Italy.. esterdelvescovo@gmail.com.
FAU - Bersani, Giulia
AU  - Bersani G
AD  - Allergy Unit, Pediatrics Section, Department of Woman and Child Health, 
      Policlinico Gemelli Universitary Foundation IRCCS, Catholic University of Sacre 
      Hearth, Rome 00168, Italy.. giuliabersani83@hotmail.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20201222
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anaphylaxis/chemically induced/diagnosis
MH  - Aspirin/adverse effects
MH  - Child
MH  - *Exercise
MH  - Female
MH  - *Food Hypersensitivity
MH  - Humans
MH  - Male
PMC - PMC7975926
COIS- Each author declares that he or she has no commercial associations (e.g. 
      consultancies, stock ownership, equity interest, patent/licensing arrangement 
      etc.) that might pose a conflict of interest in connection with the submitted 
      article.
EDAT- 2021/03/09 06:00
MHDA- 2021/06/04 06:00
CRDT- 2021/03/08 08:43
PHST- 2020/06/26 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2021/03/08 08:43 [entrez]
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
AID - ACTA-92-68 [pii]
AID - 10.23750/abm.v92i1.10093 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Dec 22;92(1):e2021068. doi: 10.23750/abm.v92i1.10093.

PMID- 31669214
OWN - NLM
STAT- MEDLINE
DCOM- 20200420
LR  - 20200420
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 572
DP  - 2019 Dec 15
TI  - Aspirin-loaded nanoexosomes as cancer therapeutics.
PG  - 118786
LID - S0378-5173(19)30831-2 [pii]
LID - 10.1016/j.ijpharm.2019.118786 [doi]
AB  - The long history of discovery and recently encouraging studies of the anti-cancer 
      effect of aspirin promise a closer step to widely used aspirin-based medication 
      in cancer therapy. To resolve the poor water-solubility of aspirin and low 
      encapsulation efficiency of exosomes for further developing a new delivery of 
      aspirin as anti-cancer treatment, our nanoamorphous exosomal delivery platform 
      was established. In this study, the anti-tumour effects of nanoamorphous 
      aspirin-loaded exosomes with exosomes derived from breast and colorectal cancer 
      cells, were comprehensively studied using both in vitro and in vivo models. These 
      exosomes displayed enhanced cellular uptake via both clathrin-dependent and 
      -independent endocytosis pathways, and significantly improved cytotoxicity of 
      aspirin to breast and colorectal cancer cells, accompanied by the enhanced 
      apoptosis and autophagy. Remarkably, this nanoamorphous exosomal platform endowed 
      aspirin with the unprecedented cancer stem cell eradication capacity. Further 
      animal study demonstrated that this developed exosomal system was able to 
      efficiently deliver aspirin to in vivo tumours. The active targeting of these 
      exosomes to tumour was further improved by conjugating an aptamer specifically 
      targeting EpCAM protein. Hence, this nanoamorphous structured exosome system 
      effectively transformed aspirin into a potential cancer stem cell killer with 
      distinguished properties for clinical translation.
CI  - Copyright © 2019 Elsevier B.V. All rights reserved.
FAU - Tran, Phuong H L
AU  - Tran PHL
AD  - School of Medicine, and Centre for Molecular and Medical Research, Deakin 
      University, Waurn Ponds, VIC 3216, Australia. Electronic address: 
      phuong.tran1@deakin.edu.au.
FAU - Wang, Tao
AU  - Wang T
AD  - School of Nursing, Zhengzhou University, Zhengzhou 450001, PR China; Centre for 
      Comparative Genomics, Murdoch University, Perth, WA 6150, Australia.
FAU - Yin, Wang
AU  - Yin W
AD  - School of Medicine, and Centre for Molecular and Medical Research, Deakin 
      University, Waurn Ponds, VIC 3216, Australia.
FAU - Tran, Thao T D
AU  - Tran TTD
AD  - Department for Management of Science and Technology Development, Ton Duc Thang 
      University, Ho Chi Minh City, VietNam; Faculty of Pharmacy, Ton Duc Thang 
      University, Ho Chi Minh City, VietNam.
FAU - Nguyen, Tuong N G
AU  - Nguyen TNG
AD  - School of Medicine, and Centre for Molecular and Medical Research, Deakin 
      University, Waurn Ponds, VIC 3216, Australia.
FAU - Lee, Beom-Jin
AU  - Lee BJ
AD  - College of Pharmacy, Ajou University, Suwon 16499, Republic of Korea.
FAU - Duan, Wei
AU  - Duan W
AD  - School of Medicine, and Centre for Molecular and Medical Research, Deakin 
      University, Waurn Ponds, VIC 3216, Australia. Electronic address: 
      wei.duan@deakin.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20191024
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/administration & dosage/chemistry/*pharmacology
MH  - Autophagy/drug effects
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Colorectal Neoplasms/*drug therapy/metabolism/pathology
MH  - *Drug Carriers
MH  - Drug Delivery Systems/*instrumentation
MH  - Endocytosis
MH  - Exosomes/*metabolism
MH  - Female
MH  - HT29 Cells
MH  - Humans
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - *Nanoparticles
MH  - Neoplastic Stem Cells/*drug effects/metabolism/pathology
MH  - Tissue Distribution
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - Aspirin
OT  - Breast cancer
OT  - Cancer stem cell
OT  - Colorectal cancer
OT  - Exosome
EDAT- 2019/11/02 06:00
MHDA- 2020/04/21 06:00
CRDT- 2019/11/01 06:00
PHST- 2019/07/24 00:00 [received]
PHST- 2019/09/17 00:00 [revised]
PHST- 2019/10/10 00:00 [accepted]
PHST- 2019/11/02 06:00 [pubmed]
PHST- 2020/04/21 06:00 [medline]
PHST- 2019/11/01 06:00 [entrez]
AID - S0378-5173(19)30831-2 [pii]
AID - 10.1016/j.ijpharm.2019.118786 [doi]
PST - ppublish
SO  - Int J Pharm. 2019 Dec 15;572:118786. doi: 10.1016/j.ijpharm.2019.118786. Epub 
      2019 Oct 24.

PMID- 24905189
OWN - NLM
STAT- MEDLINE
DCOM- 20150204
LR  - 20140617
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 13
IP  - 7
DP  - 2014 Jul
TI  - Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on 
      cardiovascular and GI toxicity.
PG  - 903-17
LID - 10.1517/14740338.2014.924924 [doi]
AB  - INTRODUCTION: The aging of the population in the US and other countries means 
      that a large number of people will likely take NSAIDs for the relief of pain and 
      low-dose aspirin (LD-ASA) for cardioprotection. However, the cardioprotective 
      value of LD-ASA can be compromised in patients who take NSAIDs concomitantly, 
      because some NSAIDs competitively bind to critical amino-acid residues on 
      cyclooxygenase (COX) enzymes and interfere with the mechanism of antiplatelet 
      activity of LD-ASA. AREAS COVERED: A review of the literature was conducted to 
      provide an overview of current issues surrounding the concomitant use of NSAIDs 
      and LD-ASA, to explore potential mechanisms for this drug-drug interaction and to 
      consider current and future treatment options that may mitigate the risk 
      associated with their concomitant use. EXPERT OPINION: NSAIDs offer effective 
      pain relief for the most common forms of pain, such as low back pain, 
      musculoskeletal pain associated with arthritis, postsurgical pain, headache, 
      acute pain syndromes, menstrual pain and dental pain. The development of NSAID 
      formulations that offer effective pain control with fewer or less serious adverse 
      effects due to interference with ASA would be a valuable medical advance. Several 
      promising treatment options and regimens may be available in the future.
FAU - Nalamachu, Srinivas
AU  - Nalamachu S
AD  - International Clinical Research Institute , Overland Park, KS , USA.
FAU - Pergolizzi, Joseph V
AU  - Pergolizzi JV
FAU - Raffa, Robert B
AU  - Raffa RB
FAU - Lakkireddy, Dhanunjaya R
AU  - Lakkireddy DR
FAU - Taylor, Robert Jr
AU  - Taylor R Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140606
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Cardiovascular System/*drug effects
MH  - Drug Interactions
MH  - Gastrointestinal Tract/*drug effects
MH  - Humans
OTO - NOTNLM
OT  - aspirin
OT  - cardioprotection
OT  - drug–drug interaction
OT  - non-steroidal anti-inflammatory drugs
EDAT- 2014/06/07 06:00
MHDA- 2015/02/05 06:00
CRDT- 2014/06/07 06:00
PHST- 2014/06/07 06:00 [entrez]
PHST- 2014/06/07 06:00 [pubmed]
PHST- 2015/02/05 06:00 [medline]
AID - 10.1517/14740338.2014.924924 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2014 Jul;13(7):903-17. doi: 10.1517/14740338.2014.924924. 
      Epub 2014 Jun 6.

PMID- 36126795
OWN - NLM
STAT- MEDLINE
DCOM- 20230207
LR  - 20230402
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 151
IP  - 2
DP  - 2023 Feb
TI  - Mechanisms by which dupilumab normalizes eicosanoid metabolism and restores 
      aspirin-tolerance in AERD: A hypothesis.
PG  - 310-313
LID - S0091-6749(22)01215-5 [pii]
LID - 10.1016/j.jaci.2022.09.012 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is associated with overproduction 
      of proinflammatory cysteinyl leukotrienes (CysLTs), defective generation of 
      anti-inflammatory prostaglandin E(2) (PGE(2)), and reduced expression of the EP2 
      receptor for PGE(2). Reduced PGE(2) synthesis results from the downregulation of 
      inducible COX-2. Because PGE(2) signaling via EP2 inhibits the 
      5-lipoxygenase/leukotriene C(4) synthase-dependent pathway, the deficient levels 
      of both PGE(2) and EP2 likely contribute to the excessive baseline production of 
      cysteinyl leukotrienes in patients with AERD compared with in patients with 
      aspirin-tolerant asthma. The COX-2 pathway is regulated by an autocrine metabolic 
      loop involving IL-1β, IL-1 receptor type I, EP2, COX-2, membrane-bound PGE(2) 
      prostaglandin E(2) synthase-1, and PGE(2). Previous studies reported that this 
      metabolic loop is dysregulated in patients with AERD. When the downexpressed EP2 
      receptor is normalized, the entire loop returns to its normal function. 
      Cotreatment of airway cells from healthy subjects with IL-4 and IFN-γ induces 
      alterations in the metabolic loop similar to those seen in patients with AERD. In 
      these patients, IL-4, which is produced in excess in airways of patients with 
      AERD, likely contributes to the alteration of normal functioning of the autocrine 
      metabolic loop involving IL-1β, IL-1 receptor type I, EP2, COX-2, membrane-bound 
      PGE(2) prostaglandin E(2) synthase-1, and PGE(2). We hypothesized that by 
      blocking IL-4 action, dupilumab normalizes EP2 expression and restores the normal 
      functioning of the COX-2 pathway autocrine metabolic loop, thereby normalizing 
      the synthesis of PGE(2) and restoring aspirin tolerance.
CI  - Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Picado, César
AU  - Picado C
AD  - Department of Respiratory Diseases, Hospital Clinic, University of Barcelona, 
      Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi I Sunyer, 
      Barcelona, Spain; Centro de Investigaciones Biomédicas en Red de Enfermedades 
      Respiratorias, Madrid, Spain. Electronic address: cpicado@ub.edu.
FAU - Mullol, Joaquim
AU  - Mullol J
AD  - Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; 
      Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias, 
      Madrid, Spain; Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic 
      Barcelona, Barcelona, Spain.
FAU - Roca-Ferrer, Jordi
AU  - Roca-Ferrer J
AD  - Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; 
      Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic Barcelona, 
      Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220917
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - R16CO5Y76E (Aspirin)
RN  - 420K487FSG (dupilumab)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - 207137-56-2 (Interleukin-4)
RN  - 0 (cysteinyl-leukotriene)
RN  - 0 (Leukotrienes)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - EC 5.3.99.3 (Prostaglandin-E Synthases)
RN  - 0 (Receptors, Prostaglandin E, EP2 Subtype)
RN  - 0 (Receptors, Interleukin-1)
SB  - IM
MH  - Humans
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cyclooxygenase 2
MH  - Interleukin-4
MH  - *Asthma, Aspirin-Induced/drug therapy/metabolism
MH  - Leukotrienes
MH  - Dinoprostone/metabolism
MH  - *Asthma/drug therapy
MH  - Prostaglandin-E Synthases/genetics
MH  - Receptors, Prostaglandin E, EP2 Subtype/metabolism
MH  - Receptors, Interleukin-1
OTO - NOTNLM
OT  - Aspirin
OT  - asthma
OT  - dupilumab
OT  - leukotriene
OT  - nonsteroidal anti-inflammatory drug
OT  - prostaglandin E(2)
EDAT- 2022/09/21 06:00
MHDA- 2023/02/08 06:00
CRDT- 2022/09/20 19:24
PHST- 2022/06/18 00:00 [received]
PHST- 2022/08/29 00:00 [revised]
PHST- 2022/09/08 00:00 [accepted]
PHST- 2022/09/21 06:00 [pubmed]
PHST- 2023/02/08 06:00 [medline]
PHST- 2022/09/20 19:24 [entrez]
AID - S0091-6749(22)01215-5 [pii]
AID - 10.1016/j.jaci.2022.09.012 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2023 Feb;151(2):310-313. doi: 10.1016/j.jaci.2022.09.012. 
      Epub 2022 Sep 17.

PMID- 8322647
OWN - NLM
STAT- MEDLINE
DCOM- 19930803
LR  - 20131121
IS  - 0002-838X (Print)
IS  - 0002-838X (Linking)
VI  - 48
IP  - 1
DP  - 1993 Jul
TI  - Prophylactic drug therapy in cerebrovascular disease.
PG  - 85-90
AB  - Aspirin in doses of 325 mg to 1,300 mg per day is the drug of choice for 
      prophylactic therapy in cerebrovascular disease. Ticlopidine, a platelet 
      antagonist, is available for use in patients who cannot tolerate aspirin or who 
      have not had success with aspirin therapy. Although ticlopidine is more effective 
      than aspirin in preventing stroke, its use may be somewhat limited due to cost 
      and the uncommon but serious side effect of neutropenia. Low-dose warfarin 
      remains the drug of choice for the prevention of cardioembolic stroke. The role 
      of warfarin in ischemic cerebrovascular disease is unknown.
FAU - Unwin, D H
AU  - Unwin DH
AD  - University of Texas Southwestern Medical Center, Dallas.
FAU - Greenlee, R G Jr
AU  - Greenlee RG Jr
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am Fam Physician
JT  - American family physician
JID - 1272646
RN  - 5Q7ZVV76EI (Warfarin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/*drug therapy/*prevention & control
MH  - Humans
MH  - Ticlopidine/therapeutic use
MH  - Warfarin/therapeutic use
RF  - 33
EDAT- 1993/07/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
PST - ppublish
SO  - Am Fam Physician. 1993 Jul;48(1):85-90.

PMID- 35647761
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220614
IS  - 1468-2834 (Electronic)
IS  - 0002-0729 (Linking)
VI  - 51
IP  - 6
DP  - 2022 Jun 1
TI  - Apolipoprotein E*Ɛ2 carriers exhibit high aspirin-treated platelet reactivity and 
      low cardiovascular risk during long-term aspirin treatment.
LID - afac119 [pii]
LID - 10.1093/ageing/afac119 [doi]
AB  - OBJECTIVE: Apolipoprotein E (APOE) loci, including rs429358 (Ɛ4) and rs7412 (Ɛ2), 
      are involved in cardiovascular (CV) health. However, their effect on the 
      CV-protective effect of aspirin remains unknown. METHODS: A total of 515 
      aspirin-treated individuals with existing CV diseases were recruited, and their 
      APOE genotypes, platelet functions and other routine laboratory parameters were 
      assessed when they enrolled. The first major CV events (myocardial infarction, 
      stroke, revascularisation and CV death) and all CV events (major CV events plus 
      unstable angina and transient ischaemic attack) during a mean 5.2-year follow-up 
      period were recorded. RESULTS: After adjusting for age, gender, BMI, lifestyle, 
      lipid profiles and other CV drugs and comorbidities, Ɛ2 carriers were found to 
      exhibit ~80% lower risk of major CV and 60% lower risk of all CV (HR = 0.186, CI: 
      0.048-0.715, P = 0.014; HR = 0.435, CI: 0.234-0.812, P = 0.009, respectively) 
      than Ɛ2 noncarriers. Furthermore, high incidence of high platelet reactivity 
      assessed by arachidonic acid-induced light transmission aggregometry (23.4 vs. 
      13.7%, P = 0.038), triglyceride and haemoglobin and low low-density lipoprotein 
      were observed. Ɛ4 carriers had slightly increased cholesterol and 
      hypercholesterolemia incidence relative to Ɛ4 noncarriers. CONCLUSIONS: Our 
      results demonstrated that APOE*Ɛ2 carriers can derive additional CV benefit from 
      long-term aspirin treatment. Moreover, it was observed that APOE2 interacts with 
      cyclooxygenase-1 (COX-1) and upregulates its activity. The CV-protective effect 
      of aspirin in Ɛ2 carriers is likely attributed to APOE2 upregulating vascular 
      COX-1-mediated CV protective pathway, together with aspirin partially inhibiting 
      platelet COX-1-mediated platelet aggregation.
CI  - © The Author(s) 2022. Published by Oxford University Press on behalf of the 
      British Geriatrics Society. All rights reserved. For permissions, please email: 
      journals.permissions@oup.com.
FAU - Li, Xiao-Li
AU  - Li XL
AD  - Department of the Eighth Healthcare, Second Medical Center, National Clinical 
      Research Center for Geriatric Diseases, Chinese People's Liberation Army General 
      Hospital, Beijing 1000853, China.
FAU - Wang, Qiang
AU  - Wang Q
AD  - Department of Urology, Peking University People's Hospital, Beijing 100044, 
      China.
FAU - Jia, Guo-Dong
AU  - Jia GD
AD  - Department of the Eighth Healthcare, Second Medical Center, National Clinical 
      Research Center for Geriatric Diseases, Chinese People's Liberation Army General 
      Hospital, Beijing 1000853, China.
FAU - Yin, Hui-Jun
AU  - Yin HJ
AD  - Department of the Eighth Healthcare, Second Medical Center, National Clinical 
      Research Center for Geriatric Diseases, Chinese People's Liberation Army General 
      Hospital, Beijing 1000853, China.
FAU - Wang, Yao-Hui
AU  - Wang YH
AD  - Department of the Eighth Healthcare, Second Medical Center, National Clinical 
      Research Center for Geriatric Diseases, Chinese People's Liberation Army General 
      Hospital, Beijing 1000853, China.
FAU - Hu, Chao
AU  - Hu C
AD  - Department of the Eighth Healthcare, Second Medical Center, National Clinical 
      Research Center for Geriatric Diseases, Chinese People's Liberation Army General 
      Hospital, Beijing 1000853, China.
FAU - Wang, Xiao-Qing
AU  - Wang XQ
AD  - Department of the Eighth Healthcare, Second Medical Center, National Clinical 
      Research Center for Geriatric Diseases, Chinese People's Liberation Army General 
      Hospital, Beijing 1000853, China.
FAU - Yang, Yang
AU  - Yang Y
AD  - Department of the Eighth Healthcare, Second Medical Center, National Clinical 
      Research Center for Geriatric Diseases, Chinese People's Liberation Army General 
      Hospital, Beijing 1000853, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Age Ageing
JT  - Age and ageing
JID - 0375655
RN  - 0 (Apolipoprotein E2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Apolipoprotein E2/genetics
MH  - *Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/diagnosis/genetics/prevention & control
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - Risk Factors
OTO - NOTNLM
OT  - apolipoprotein E
OT  - aspirin
OT  - atherosclerosis
OT  - cardiovascular disease
OT  - high platelet reactivity
OT  - older people
EDAT- 2022/06/02 06:00
MHDA- 2022/06/07 06:00
CRDT- 2022/06/01 11:57
PHST- 2021/12/01 00:00 [received]
PHST- 2022/03/30 00:00 [revised]
PHST- 2022/06/01 11:57 [entrez]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
AID - 6596556 [pii]
AID - 10.1093/ageing/afac119 [doi]
PST - ppublish
SO  - Age Ageing. 2022 Jun 1;51(6):afac119. doi: 10.1093/ageing/afac119.

PMID- 10498385
OWN - NLM
STAT- MEDLINE
DCOM- 19991130
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 95
IP  - 4
DP  - 1999 Aug 15
TI  - Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol.
PG  - 155-61
AB  - The effects of a bioflavonoid mixture, Pycnogenol, were assessed on platelet 
      function in humans. Cigarette smoking increased heart rate and blood pressure. 
      These increases were not influenced by oral consumption of Pycnogenol or Aspirin 
      just before smoking. However, increased platelet reactivity yielding aggregation 
      2 hours after smoking was prevented by 500 mg Aspirin or 100 mg Pycnogenol in 22 
      German heavy smokers. In a group of 16 American smokers, blood pressure increased 
      after smoking. It was unchanged after intake of 500 mg Aspirin or 125 mg 
      Pycnogenol. In another group of 19 American smokers, increased platelet 
      aggregation was more significantly reduced by 200 than either 150 mg or 100 mg 
      Pycnogenol supplementation. This study showed that a single, high dose, 200 mg 
      Pycnogenol, remained effective for over 6 days against smoking-induced platelet 
      aggregation. Smoking increased platelet aggregation that was prevented after 
      administration of 500 mg Aspirin and 125 mg Pycnogenol. Thus, smoking-induced 
      enhanced platelet aggregation was inhibited by 500 mg Aspirin as well as by a 
      lower range of 100-125 mg Pycnogenol. Aspirin significantly (p<0.001) increased 
      bleeding time from 167 to 236 seconds while Pycnogenol did not. These 
      observations suggest an advantageous risk-benefit ratio for Pycnogenol.
FAU - Pütter, M
AU  - Pütter M
AD  - Department of Neurology, Westfälische Wilhelms-Universität Münster, Germany.
FAU - Grotemeyer, K H
AU  - Grotemeyer KH
FAU - Würthwein, G
AU  - Würthwein G
FAU - Araghi-Niknam, M
AU  - Araghi-Niknam M
FAU - Watson, R R
AU  - Watson RR
FAU - Hosseini, S
AU  - Hosseini S
FAU - Rohdewald, P
AU  - Rohdewald P
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Flavonoids)
RN  - 0 (Plant Extracts)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 50JZ5Z98QY (pycnogenols)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Bleeding Time
MH  - Drug Therapy, Combination
MH  - Female
MH  - Flavonoids/*therapeutic use
MH  - Germany
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Plant Extracts
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Smoking/*adverse effects
MH  - United States
EDAT- 1999/09/25 00:00
MHDA- 1999/09/25 00:01
CRDT- 1999/09/25 00:00
PHST- 1999/09/25 00:00 [pubmed]
PHST- 1999/09/25 00:01 [medline]
PHST- 1999/09/25 00:00 [entrez]
AID - S0049384899000304 [pii]
AID - 10.1016/s0049-3848(99)00030-4 [doi]
PST - ppublish
SO  - Thromb Res. 1999 Aug 15;95(4):155-61. doi: 10.1016/s0049-3848(99)00030-4.

PMID- 34731917
OWN - NLM
STAT- MEDLINE
DCOM- 20211105
LR  - 20220428
IS  - 2306-4102 (Print)
IS  - 2306-4102 (Linking)
VI  - 35
IP  - 2
DP  - 2021 Mar-Apr
TI  - [Comparative study between enoxaparin and salicylic acetyl acid in antithrombotic 
      prophylaxis for patients undergoing total knee arthroplasty].
PG  - 163-168
AB  - INTRODUCTION: There is still controversy regarding thrombo-prophylaxis for the 
      reduction of thromboembolic disease in major orthopedic surgery. OBJECTIVE: To 
      answer the following question: is there a difference in the effectiveness and 
      safety in the antithrombotic management of patients with a traditional regimen of 
      enoxaparin against acetyl salicylic acid? MATERIAL AND METHODS: The surgeries 
      were performed by 3 surgeons; the sample was randomized and the patients were 
      subjected to the study criteria. We evaluated efficacy and safety as well as the 
      need for readmission and secondary variables such as infection, acute myocardial 
      infarction (AMI), cerebral vascular disease and death with a follow-up of 90 
      days. RESULTS: The total sample was 402 patients; 214 in the enoxaparin group and 
      188 in the aspirin group. There were 5 cases (1.24%) with thromboembolic disease, 
      3 (1.4%) enoxaparin and 2 (1.06%) aspirin without significant difference (p = 
      0.23). In terms of safety, major bleeding was zero in both groups, with minor 
      bleeding in 7 patients (1.74%), 4 (1.86%) were from the enoxaparin group and 3 
      (1.59%) from the aspirin group without significant differences (p = 0.82). 
      Secondary outcomes showed 5 (1.24%) superficial surgical wound infections and one 
      AMI in the first 30 days of the procedure in the enoxaparin group. CONCLUSION: 
      Aspirin as monotherapy is safe, effective in antithrombotic prophylaxis in 
      patients operated on total knee arthroplasty.
FAU - Cortes-De la Fuente, A A
AU  - Cortes-De la Fuente AA
AD  - Centro Médico (ISSEMyM) Instituto de Seguridad Social del Estado de México y 
      Municipios, Toluca, Estado de México. México.
FAU - Villalobos-Campuzano, C
AU  - Villalobos-Campuzano C
AD  - Centro Médico (ISSEMyM) Instituto de Seguridad Social del Estado de México y 
      Municipios, Toluca, Estado de México. México.
FAU - Bucio-Paticio, B
AU  - Bucio-Paticio B
AD  - Centro Médico (ISSEMyM) Instituto de Seguridad Social del Estado de México y 
      Municipios, Toluca, Estado de México. México.
FAU - Valencia-Martínez, G
AU  - Valencia-Martínez G
AD  - Centro Médico (ISSEMyM) Instituto de Seguridad Social del Estado de México y 
      Municipios, Toluca, Estado de México. México.
FAU - Martínez-Montiel, O
AU  - Martínez-Montiel O
AD  - Centro Médico (ISSEMyM) Instituto de Seguridad Social del Estado de México y 
      Municipios, Toluca, Estado de México. México.
LA  - spa
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Estudio comparativo entre enoxaparina y ácido acetilsalicílico en profilaxis 
      antitrombótica para pacientes sometidos a artroplastía total de rodilla.
PL  - Mexico
TA  - Acta Ortop Mex
JT  - Acta ortopedica mexicana
JID - 101190312
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - *Arthroplasty, Replacement, Hip
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/therapeutic use
MH  - Enoxaparin/therapeutic use
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Postoperative Complications
MH  - Salicylic Acid
OTO - NOTNLM
OT  - Prophylaxis
OT  - acetylsalicylic acid
OT  - antithrombotic
OT  - knee
OT  - prosthesis
OT  - surgery
EDAT- 2021/11/04 06:00
MHDA- 2021/11/06 06:00
CRDT- 2021/11/03 20:12
PHST- 2021/11/03 20:12 [entrez]
PHST- 2021/11/04 06:00 [pubmed]
PHST- 2021/11/06 06:00 [medline]
AID - S2306-4102(21)101860-0 [pii]
PST - ppublish
SO  - Acta Ortop Mex. 2021 Mar-Apr;35(2):163-168.

PMID- 6874413
OWN - NLM
STAT- MEDLINE
DCOM- 19830923
LR  - 20131121
IS  - 0263-8290 (Print)
IS  - 0263-8290 (Linking)
VI  - 37
IP  - 3
DP  - 1983 May
TI  - The effect of aspirin and linoleic acid on platelet aggregation, platelet fatty 
      acid composition and haemostasis in man.
PG  - 197-208
AB  - The effect of linoleic acid and of aspirin on platelet aggregation has been 
      measured in six healthy volunteers with a new platelet aggregometer (Wellcome) 
      designed to be used with whole blood. The subjects were given a controlled diet 
      for 6 weeks during which their platelet aggregation, platelet fatty acid 
      composition, dilute blood clot lysis time, bleeding time and serum cholesterol 
      and triglycerides were measured. A basal diet typical of that normally eaten in 
      the UK was fed for 3 weeks, then for a further 2 weeks 60 ml/d of safflower seed 
      oil was added to the diet. Finally there was a further week on the basal diet and 
      on the last day the subjects each took 900 mg of aspirin. The effects of the 
      safflower seed oil was to increase platelet linoleic acid (C18:2 omega 6) content 
      from 5.53 +/- 0.52 micrograms to 10.1 +/- 0.92 micrograms/100 micrograms total 
      fatty acids (P less than 0.001), to decrease platelet aggregation to ADP, and to 
      decreased serum cholesterol. Fibrinolysis and bleeding times were unaltered. 
      Aspirin decreased platelet aggregation, prolonged bleeding time and increased 
      platelet arachidonic acid (C20:4 omega 6) from 24.7 +/- 0.38 micrograms to 25.8 
      +/- 0.61 micrograms/100 micrograms total fatty acids (P less than 0.01). The 
      Wellcome whole blood aggregometer is a sensitive test of platelet function and 
      using it linoleic acid has been shown to reduce aggregation in conjunction with 
      an increase in polyunsaturated fatty acid content of the platelet membrane.
FAU - Challen, A D
AU  - Challen AD
FAU - Branch, W J
AU  - Branch WJ
FAU - Cummings, J H
AU  - Cummings JH
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Hum Nutr Clin Nutr
JT  - Human nutrition. Clinical nutrition
JID - 8207516
RN  - 0 (Fatty Acids)
RN  - 0 (Linoleic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/analysis/*drug effects
MH  - Diet
MH  - Fatty Acids/analysis
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Linoleic Acids/*pharmacology
MH  - Male
MH  - Platelet Aggregation/*drug effects
EDAT- 1983/05/01 00:00
MHDA- 1983/05/01 00:01
CRDT- 1983/05/01 00:00
PHST- 1983/05/01 00:00 [pubmed]
PHST- 1983/05/01 00:01 [medline]
PHST- 1983/05/01 00:00 [entrez]
PST - ppublish
SO  - Hum Nutr Clin Nutr. 1983 May;37(3):197-208.

PMID- 27364228
OWN - NLM
STAT- MEDLINE
DCOM- 20170419
LR  - 20170419
IS  - 1827-1898 (Electronic)
IS  - 0031-0808 (Linking)
VI  - 58
IP  - 4
DP  - 2016 Dec
TI  - Effect of aspirin in addition to oral anticoagulants in stable coronary artery 
      disease outpatients with an indication for anticoagulation.
PG  - 271-285
AB  - Antithrombotic management of outpatients with stable coronary artery disease 
      (CAD) who also have an indication for long-term oral anticoagulation (OAC) is 
      critical in daily practice, firstly because these patients are frequently seen, 
      and secondly because they have shown a high risk of both ischemic events and 
      bleeding as compared to patients without OAC. The current guidelines recommend 
      that most of such patients should be treated with OAC alone (without any 
      antiplatelet therapy) after 12 months of stability even when a stent has been 
      implanted. Robust data are however very sparse and level of evidence very low to 
      support such a strategy. The goal of the present manuscript is to review all 
      available evidences to help the physician's choices in this specific context and 
      to highlight the unsolved issues that should be addressed by new studies in the 
      near future.
FAU - Schurtz, Guillaume
AU  - Schurtz G
AD  - Hemodynamic Center and Unit of Emergency and Intensive Care Medicine, 
      Cardiopulmonary Institute, Lille University Hospitals, Lille, France - 
      gilles_lemesle@yahoo.fr.
FAU - Bauters, Christophe
AU  - Bauters C
FAU - Ducrocq, Gregory
AU  - Ducrocq G
FAU - Lamblin, Nicolas
AU  - Lamblin N
FAU - Lemesle, Gilles
AU  - Lemesle G
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160701
PL  - Italy
TA  - Panminerva Med
JT  - Panminerva medica
JID - 0421110
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/complications/drug therapy
MH  - Coronary Artery Disease/complications/*drug therapy
MH  - Humans
MH  - Outpatients
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Vitamin K/antagonists & inhibitors
EDAT- 2016/07/02 06:00
MHDA- 2017/04/20 06:00
CRDT- 2016/07/02 06:00
PHST- 2016/07/02 06:00 [pubmed]
PHST- 2017/04/20 06:00 [medline]
PHST- 2016/07/02 06:00 [entrez]
AID - R41Y9999N00A16070101 [pii]
PST - ppublish
SO  - Panminerva Med. 2016 Dec;58(4):271-285. Epub 2016 Jul 1.

PMID- 26179687
OWN - NLM
STAT- MEDLINE
DCOM- 20160421
LR  - 20150716
IS  - 1028-768X (Print)
IS  - 1028-768X (Linking)
VI  - 24
IP  - 1
DP  - 2015 Mar
TI  - Infectious Mononucleosis Complicated with Acute Cerebral Infarction: A Case 
      Report.
PG  - 25-9
AB  - PURPOSE: Infectious mononucleosis (IM) complicated with a neurological 
      manifestation, including acute cerebellar ataxia, Guillain-Barre syndrome, 
      meningitis, encephalitis, cranial nerve palsies, optic neuritis or transverse 
      myelitis, has been rarely reported; however, IM complicated with acute cerebral 
      infarction has never been reported in the literature. CASE REPORT: A 49-year-old 
      man with diabetic mellitus suffered from IM with fever, pharyngitis, parotiditis 
      with lymphadenopathies, thrombocytopenia and splenomegaly. After two weeks of 
      conservative treatment, left upper limb paresis and left hemihypesthesia 
      occurred. Neuroimaging demonstrated acute ischemic stroke involving the right 
      frontal lobe. In view of the underlying infection, immediate intravenous rt-PA 
      was not recommended; hence, oral aspirin 100 mg daily was prescribed and he 
      received regular rehabilitation in the subsequent follow up. CONCLUSION: Although 
      IM is known to be self-limited, it could contribute to acute cerebral infarction, 
      which is a rare IM neurological complication.
FAU - Chen, Jiann-Jy
AU  - Chen JJ
AD  - Department of Neuro-Medical Scientific Center, Buddhist Tzu Chi General Hospital, 
      Taichung Branch, Taichung.
FAU - Chang, Hsin-Feng
AU  - Chang HF
AD  - Faculty of Chinese Medicine, Chinese Medical College, China Medical University, 
      Taichung.
FAU - Liu, Chih-Yang
AU  - Liu CY
AD  - Department of Neurology, Buddhist Tzu Chi General Hospital, Taipei Branch, New 
      Taipei, Taiwan.
FAU - Chen, Dem-Lion
AU  - Chen DL
AD  - G-Home Clinic for Otorhinolaryngology and Neurology, Kaohsiung, Taiwan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Acta Neurol Taiwan
JT  - Acta neurologica Taiwanica
JID - 9815355
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/administration & dosage/pharmacology
MH  - Cerebral Infarction/drug therapy/*etiology
MH  - Fever/etiology
MH  - Fibrinolytic Agents/administration & dosage/pharmacology
MH  - Humans
MH  - Infectious Mononucleosis/*complications
MH  - Male
MH  - Middle Aged
MH  - Parotitis/etiology
EDAT- 2015/07/17 06:00
MHDA- 2016/04/22 06:00
CRDT- 2015/07/17 06:00
PHST- 2015/07/17 06:00 [entrez]
PHST- 2015/07/17 06:00 [pubmed]
PHST- 2016/04/22 06:00 [medline]
AID - 10196099/241025 [pii]
PST - ppublish
SO  - Acta Neurol Taiwan. 2015 Mar;24(1):25-9.

PMID- 16338269
OWN - NLM
STAT- MEDLINE
DCOM- 20060214
LR  - 20131121
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 150
IP  - 6
DP  - 2005 Dec
TI  - Prevalence and management of hypertension in acute coronary syndrome patients 
      varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum 
      Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) 
      randomized clinical trials.
PG  - 1260-7
AB  - BACKGROUND: Hypertension affects 1 billion individuals worldwide and is an 
      independent risk factor for death after acute coronary syndromes (ACS). METHODS: 
      We examined the prevalence and medical treatment of hypertension among 15,904 ACS 
      patients randomized in the SYMPHONY and 2nd SYMPHONY trials. Analyses were 
      performed overall and according to sex for the United States and across 
      international practice. Multivariable models identified factors associated with 
      use of antihypertensive medication classes and examined the association of 
      hypertension and sex with mortality. RESULTS: In the United States, hypertension 
      was more prevalent in women than in men, overall (63% vs 50%) and within every 
      decile of age. Hypertensive women more often received calcium-channel blockers 
      (35% vs 30%) and diuretics (33% vs 19%) and less often received beta-blockers 
      (51% vs 57%). Angiotensin-converting enzyme inhibitor use was similar (35% vs 
      34%). Women received multiple agents more frequently than did men: 2 agents, 35% 
      vs 30%; > or = 3 agents, 16% vs 13%. Female sex independently predicted 
      drug-class use only for diuretics. Mortality was higher in hypertensive women 
      than in hypertensive men; after multivariable adjustment, mortality was similar 
      without evidence of a differential association between hypertension and mortality 
      according to sex. Although there was international variation in the use of 
      individual classes of agents, the overall findings by sex were similar across 
      regions. CONCLUSION: Hypertension is more prevalent in women than in men with 
      ACS, and its medical management varies by sex, but its association with mortality 
      is similar. Opportunities exist to improve medical therapy and outcomes in women 
      with hypertension.
FAU - Frazier, Camille G
AU  - Frazier CG
AD  - Duke University Medical Center, Clinical Research Institute, Durham, NC, USA.
FAU - Shah, Svati H
AU  - Shah SH
FAU - Armstrong, Paul W
AU  - Armstrong PW
FAU - Bhapkar, Manjushri V
AU  - Bhapkar MV
FAU - McGuire, Darren K
AU  - McGuire DK
FAU - Sadowski, Zygmunt
AU  - Sadowski Z
FAU - Kristinsson, Arni
AU  - Kristinsson A
FAU - Aylward, Philip E
AU  - Aylward PE
FAU - Klein, Werner W
AU  - Klein WW
FAU - Weaver, W Douglas
AU  - Weaver WD
FAU - Newby, L Kristin
AU  - Newby LK
CN  - SYMPHONY and the Second SYMPHONY Investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Angina, Unstable/drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Chemistry, Pharmaceutical
MH  - Coronary Disease/*complications
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy/epidemiology/mortality
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*drug therapy/mortality
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Sex Characteristics
EDAT- 2005/12/13 09:00
MHDA- 2006/02/16 09:00
CRDT- 2005/12/13 09:00
PHST- 2005/02/27 00:00 [received]
PHST- 2005/08/08 00:00 [accepted]
PHST- 2005/12/13 09:00 [pubmed]
PHST- 2006/02/16 09:00 [medline]
PHST- 2005/12/13 09:00 [entrez]
AID - S0002-8703(05)00787-8 [pii]
AID - 10.1016/j.ahj.2005.08.004 [doi]
PST - ppublish
SO  - Am Heart J. 2005 Dec;150(6):1260-7. doi: 10.1016/j.ahj.2005.08.004.

PMID- 36469913
OWN - NLM
STAT- MEDLINE
DCOM- 20221223
LR  - 20230103
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 175
IP  - 12
DP  - 2022 Dec
TI  - In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not 
      stroke or mortality.
PG  - JC137
LID - 10.7326/J22-0094 [doi]
AB  - Tasoudis PT, Kyriakoulis IG, Sagris D, et al. Clopidogrel monotherapy versus 
      aspirin monotherapy in patients with established cardiovascular disease: 
      systematic review and meta-analysis. Thromb Haemost. 2022;122:1879-87. 35577054.
FAU - Goel, Akshay
AU  - Goel A
AD  - Westchester Medical Center, New York Medical College, Valhalla, New York, USA 
      (A.G., A.H.M.).
FAU - Malik, Aaqib H
AU  - Malik AH
AD  - Westchester Medical Center, New York Medical College, Valhalla, New York, USA 
      (A.G., A.H.M.).
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20221206
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
RN  - A74586SNO7 (Clopidogrel)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
CON - Thromb Haemost. 2022 Nov;122(11):1879-1887. PMID: 35577054
MH  - Humans
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/chemically induced
MH  - Clopidogrel
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - *Stroke/chemically induced
EDAT- 2022/12/06 06:00
MHDA- 2022/12/22 06:00
CRDT- 2022/12/05 17:02
PHST- 2022/12/06 06:00 [pubmed]
PHST- 2022/12/22 06:00 [medline]
PHST- 2022/12/05 17:02 [entrez]
AID - 10.7326/J22-0094 [doi]
PST - ppublish
SO  - Ann Intern Med. 2022 Dec;175(12):JC137. doi: 10.7326/J22-0094. Epub 2022 Dec 6.

PMID- 37105921
OWN - NLM
STAT- MEDLINE
DCOM- 20230501
LR  - 20230513
IS  - 1944-7930 (Electronic)
IS  - 1539-6509 (Linking)
VI  - 35
IP  - 175
DP  - 2023 Apr 1
TI  - Meta-Analysis of the Efficacy of Low Molecular Weight Heparin and Aspirin in the 
      Treatment of Thrombosis During Pregnancy and Effects on Coagulation Function.
PG  - 104-115
LID - 10.24976/Discov.Med.202335175.11 [doi]
AB  - BACKGROUND: At present, there is no comprehensive evaluation of the efficacy and 
      safety of low molecular weight heparin (LMWH) for the treatment of thrombophilia 
      during pregnancy in clinical practice. This study aimed to systematically 
      evaluate the efficacy of LMWH in the treatment of patients and its effects on 
      coagulation function, thereby providing a reference for the clinical treatment 
      and prognosis evaluation of thrombophilia during pregnancy. METHODS: Database 
      PubMed, Web of Science and Embase as well as China National Knowledge 
      Infrastructure and Wanfang Database were applied for the search of data. A 
      comparative study on the efficacy of LMWH in the treatment of gestational 
      thrombophilia was enrolled. Stata 16.0 software (Stata, College Station, TX, USA) 
      was utilized to conduct the meta-analysis. RESULTS: A total of 487 relevant 
      articles were retrieved and 14 studies were finally included. Patients in the 
      LMWH combined with the low-dose aspirin group had a significantly higher live 
      birth rate than those in the aspirin or LMWH treat group (OR (odds ratio) = 4.54, 
      95% CI (confidence interval): 2.76, 7.45). The adverse effects rate was lower in 
      the LMWH combined with the low-dose aspirin group than in the aspirin or LMWH 
      treatment group (OR = 0.40, 95% CI: 0.29, 0.56). After treatment, patients in the 
      LMWH combined with the low-dose aspirin group had significantly lower D-dimer 
      (SMD (standardized mean differences) = -1.50, 95% CI: -2.19, 0.80) and platelet 
      count (PLT; SMD = -0.13, 95% CI: -0.35, 0.09) than those in the aspirin or LMWH 
      treatment group. However, activated partial thromboplastin time (APTT; SMD = 
      0.16, 95% CI: -0.10, 0.42), thrombin time (TT; SMD = 0.60, 95% CI: -0.14, 1.34), 
      plasma prothrombin time (PT; SMD = 0.42, 95% CI: -0.71, 1.56), and fibrin values 
      (FIB; SMD = -0.92, 95% CI: -2.12, 0.28) were significantly higher in the LMWH 
      combined with low-dose aspirin group than those in the aspirin or LMWH treatment 
      group. CONCLUSIONS: LMWH heparin combined with low-dose aspirin can effectively 
      correct coagulation function in pregnant women, improve prothrombotic state and 
      increase the live birth rate, which has high clinical value.
FAU - Yin, Meng
AU  - Yin M
AD  - Department of Laboratory Medicine, Shengjing Hospital of China Medical University 
      (Liaoning Clinical Research Center for Laboratory Medicine), 110004 Shenyang, 
      Liaoning, China.
FAU - Qin, Xiaosong
AU  - Qin X
AD  - Department of Laboratory Medicine, Shengjing Hospital of China Medical University 
      (Liaoning Clinical Research Center for Laboratory Medicine), 110004 Shenyang, 
      Liaoning, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Discov Med
JT  - Discovery medicine
JID - 101250006
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Humans
MH  - Female
MH  - Pregnancy
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - *Thrombophilia/chemically induced/drug therapy
MH  - *Thrombosis/drug therapy/chemically induced
OTO - NOTNLM
OT  - aspirin
OT  - coagulation
OT  - low molecular weight heparin (LMWH)
OT  - meta-analysis
OT  - pregnancy
OT  - thrombophilia
EDAT- 2023/04/28 00:42
MHDA- 2023/05/01 06:42
CRDT- 2023/04/27 22:22
PHST- 2023/05/01 06:42 [medline]
PHST- 2023/04/28 00:42 [pubmed]
PHST- 2023/04/27 22:22 [entrez]
AID - 1682407418350-509830722 [pii]
AID - 10.24976/Discov.Med.202335175.11 [doi]
PST - ppublish
SO  - Discov Med. 2023 Apr 1;35(175):104-115. doi: 10.24976/Discov.Med.202335175.11.

PMID- 21815879
OWN - NLM
STAT- MEDLINE
DCOM- 20120118
LR  - 20211020
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Print)
IS  - 0785-3890 (Linking)
VI  - 43
IP  - 7
DP  - 2011 Nov
TI  - Overcoming limitations of current antiplatelet drugs: a concerted effort for more 
      profitable strategies of intervention.
PG  - 531-44
LID - 10.3109/07853890.2011.582137 [doi]
AB  - Platelets play a central role in the pathophysiology of atherothrombosis, an 
      inappropriate platelet activation leading to acute ischemic complications (acute 
      myocardial infarction, ischemic stroke). In view of this, platelets are a major 
      target for pharmacotherapy. Presently, the main classes of antiplatelet agents 
      approved for the use in such complications are aspirin and thienopyridines. 
      Although antiplatelet treatment with these two types of drugs, alone or in 
      combination, leads to a significant reduction of non-fatal myocardial infarction 
      (-32%), non-fatal stroke (-25%), and of cardiovascular death (-17%), a residual 
      risk persists. Newer antiplatelet agents have addressed some, but not all, these 
      limitations. Vis-à-vis their net clinical benefit, the higher potency of some of 
      them is associated with a rise in bleeding complications. Moreover, newer 
      thienopyridines do not show advantages over and above the older ones as to 
      reduction of stroke. A concerted effort that takes into consideration clinical, 
      genetic, and laboratory information is increasingly recognized as a major 
      direction to be pursued in the area. The well-established road signs of clinical 
      epidemiology will provide major information to define newer potentially useful 
      targets for platelet pharmacology.
FAU - Di Minno, Matteo Nicola Dario
AU  - Di Minno MN
AD  - Department of Clinical and Experimental Medicine, Regional Reference Centre for 
      Coagulation Disorders, 'Federico II' University, Naples, Italy.
FAU - Guida, Anna
AU  - Guida A
FAU - Camera, Marina
AU  - Camera M
FAU - Colli, Susanna
AU  - Colli S
FAU - Di Minno, Giovanni
AU  - Di Minno G
FAU - Tremoli, Elena
AU  - Tremoli E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110805
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thienopyridines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Atherosclerosis/complications/*drug therapy/physiopathology
MH  - Drug Delivery Systems
MH  - Drug Design
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/etiology/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Stroke/etiology/prevention & control
MH  - Thienopyridines/adverse effects/pharmacology/therapeutic use
MH  - Thrombosis/etiology/physiopathology/*prevention & control
PMC - PMC3231843
EDAT- 2011/08/06 06:00
MHDA- 2012/01/19 06:00
CRDT- 2011/08/06 06:00
PHST- 2011/08/06 06:00 [entrez]
PHST- 2011/08/06 06:00 [pubmed]
PHST- 2012/01/19 06:00 [medline]
AID - 10.3109/07853890.2011.582137 [doi]
PST - ppublish
SO  - Ann Med. 2011 Nov;43(7):531-44. doi: 10.3109/07853890.2011.582137. Epub 2011 Aug 
      5.

PMID- 26890552
OWN - NLM
STAT- MEDLINE
DCOM- 20180118
LR  - 20191210
IS  - 1476-5543 (Electronic)
IS  - 0743-8346 (Linking)
VI  - 36
IP  - 6
DP  - 2016 Jun
TI  - The impact of low-dose aspirin on preterm birth: secondary analysis of a 
      randomized controlled trial.
PG  - 427-31
LID - 10.1038/jp.2016.3 [doi]
AB  - OBJECTIVE: The objective of this study is to determine whether low-dose aspirin 
      (LDA) reduced the rate of preterm birth (PTB) in a cohort of women at high risk 
      for preeclampsia. STUDY DESIGN: Secondary analysis of the Maternal-Fetal Medicine 
      Units High-Risk Aspirin trial. Preterm births were categorized by phenotype: 
      indicated, spontaneous or due to preterm premature rupture of membranes (PPROMs). 
      RESULTS: Of 1789 randomized women, 30.5% delivered before 37 weeks (18.5% 
      indicated, 5.8% spontaneous and 6.2% following preterm PPROMs). Among women 
      randomized to LDA, we observed a trend favoring fewer PTBs due to spontaneous 
      preterm labor and preterm PPROMs, odds ratio (OR: 0.826 (0.620, 1.099)); the 
      incidence of indicated PTBs appeared unchanged, OR: 0.999 (0.787, 1.268). 
      CONCLUSION: Although not reaching significance, we observed an effect size 
      similar to other studies of both low- and high-risk women. These results support 
      findings from other studies assessing LDA as a PTB prevention strategy.
FAU - Allshouse, A A
AU  - Allshouse AA
AD  - University of Colorado School of Public Health, Aurora, CO, USA.
FAU - Jessel, R H
AU  - Jessel RH
AD  - Department of Obstetrics and Gynecology, University of Colorado Denver, Aurora, 
      CO, USA.
FAU - Heyborne, K D
AU  - Heyborne KD
AD  - Department of Obstetrics and Gynecology, University of Colorado Denver, Aurora, 
      CO, USA.
AD  - Department of Obstetrics and Gynecology, Denver Health and Hospital Authority, 
      Denver, CO, USA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160218
PL  - United States
TA  - J Perinatol
JT  - Journal of perinatology : official journal of the California Perinatal 
      Association
JID - 8501884
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - Preterm Premature Rupture of the Membranes
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - *Aspirin/administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fetal Membranes, Premature Rupture/*prevention & control
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Obstetric Labor, Premature/*prevention & control
MH  - Outcome and Process Assessment, Health Care
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Premature Birth/*prevention & control
EDAT- 2016/02/19 06:00
MHDA- 2018/01/19 06:00
CRDT- 2016/02/19 06:00
PHST- 2015/08/25 00:00 [received]
PHST- 2015/12/10 00:00 [revised]
PHST- 2016/01/04 00:00 [accepted]
PHST- 2016/02/19 06:00 [entrez]
PHST- 2016/02/19 06:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
AID - jp20163 [pii]
AID - 10.1038/jp.2016.3 [doi]
PST - ppublish
SO  - J Perinatol. 2016 Jun;36(6):427-31. doi: 10.1038/jp.2016.3. Epub 2016 Feb 18.

PMID- 17396240
OWN - NLM
STAT- MEDLINE
DCOM- 20070806
LR  - 20181201
IS  - 0003-2417 (Print)
IS  - 0003-2417 (Linking)
VI  - 56
IP  - 4
DP  - 2007 Apr
TI  - [Coronary stents, dual antiplatelet therapy and peri-operative problems].
PG  - 401-10; quiz 411-2
AB  - Up to 90% of all percutaneous coronary interventions include coronary artery 
      stenting. Dual antiplatelet therapy, usually involving acetylsalicyl acid 
      combined with clopidogrel, is mandatory for patients with coronary artery stents. 
      The duration of antiplatelet therapy for bare metal stents is 3-4 weeks, for drug 
      eluting stents 6-12 months. Preoperative discontinuation of both drugs increases 
      the risk of stent thrombosis, continuation the risk of relevant bleeding. 
      According to the recommendations of anaesthesiological and cardiological 
      societies, perioperative management has to balance the risk of bleeding vs stent 
      thrombosis. Surgery involving a high risk of bleeding can require the 
      discontinuance of both substances. In cases of high thrombosis risk, at least the 
      acetylsalicyl acid should be continued until the day of surgery. For patients 
      under antiplatelet therapy scheduled for local anaesthesia, national 
      recommendations exist. A close collaboration between the anaesthesiologist, 
      cardiologist and surgeon is essential for appropriate pre-, intra- and 
      postoperative management.
FAU - Metzler, H
AU  - Metzler H
AD  - Universitätsklinik für Anästhesiologie und Intensivmedizin, Medizinische 
      Universität Graz, Auenbruggerplatz 29, 8036 Graz. helfried.metzler@meduni-graz.at
FAU - Huber, K
AU  - Huber K
FAU - Kozek-Langenecker, S
AU  - Kozek-Langenecker S
FAU - Vicenzi, M N
AU  - Vicenzi MN
FAU - Münch, A
AU  - Münch A
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Koronare Stents, duale Antiplättchentherapie und die perioperative Problematik.
PL  - Germany
TA  - Anaesthesist
JT  - Der Anaesthesist
JID - 0370525
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Anaesthesist. 2007 Oct;56(10):1073; author reply 1073-4. PMID: 17882390
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clopidogrel
MH  - Humans
MH  - Perioperative Care
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Function Tests
MH  - *Stents
MH  - Thrombosis/etiology
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
RF  - 46
EDAT- 2007/03/31 09:00
MHDA- 2007/08/07 09:00
CRDT- 2007/03/31 09:00
PHST- 2007/03/31 09:00 [pubmed]
PHST- 2007/08/07 09:00 [medline]
PHST- 2007/03/31 09:00 [entrez]
AID - 10.1007/s00101-007-1171-3 [doi]
PST - ppublish
SO  - Anaesthesist. 2007 Apr;56(4):401-10; quiz 411-2. doi: 10.1007/s00101-007-1171-3.

PMID- 11035355
OWN - NLM
STAT- MEDLINE
DCOM- 20001114
LR  - 20131121
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 183
IP  - 4
DP  - 2000 Oct
TI  - Does aspirin have a role in improving pregnancy outcome for women with the 
      antiphospholipid syndrome? A randomized controlled trial.
PG  - 1008-12
AB  - OBJECTIVE: This pilot investigation was undertaken to assess the efficacy of 
      low-dose aspirin therapy for the treatment of women with antiphospholipid 
      antibodies when recurrent miscarriage is the only sequela. STUDY DESIGN: A 
      double-blind, randomized, placebo-controlled trial was conducted in the setting 
      of the recurrent miscarriage clinic of a tertiary referral obstetric hospital. 
      The participants were 50 women with a history of recurrent miscarriages (>/=3) 
      and antiphospholipid antibodies. Women with systemic lupus erythematosus or a 
      history of thrombosis were excluded. Women were recruited after full 
      investigative screening at the recurrent miscarriage clinic. Women with >/=3 
      fetal losses and persistently positive results for antiphospholipid antibodies 
      were randomly allocated to receive either aspirin (75 mg daily) or placebo. 
      Investigators, clinicians, and patients were blinded to the treatment. Rates of 
      live births, antenatal complications, and delivery and neonatal outcomes were 
      recorded prospectively. Data were compared by chi(2) analysis with Yates' 
      correction, the Fisher exact test, or the Student t test as appropriate. RESULTS: 
      There were 10 exclusions after random assignment because of inappropriate 
      inclusion. Eighty-five percent of the placebo (17/20) group and 80% of the 
      aspirin-treated group (16/20) were delivered of live infants. This difference was 
      not significant. There were no significant differences in antenatal complications 
      or neonatal morbidity between the groups. CONCLUSIONS: This preliminary study 
      suggests that low-dose aspirin has no additional benefit when added to supportive 
      care for women for whom recurrent early fetal loss is the only sequela of the 
      antiphospholipid syndrome. This live birth rate with supportive care alone 
      exceeds the published live birth rates for women with antiphospholipid 
      antibody-mediated recurrent fetal loss who were treated with heparin or 
      corticosteroids. This trial, like all other trials in this field, is small, but 
      its results bring into question the need for pharmacologic intervention for women 
      with antiphospholipid syndrome for whom recurrent fetal loss is the only sequela. 
      Our results highlight the need for a large randomized controlled trial to 
      identify the optimal treatment for this group of women and justify the inclusion 
      of a placebo arm in any such trial.
FAU - Pattison, N S
AU  - Pattison NS
AD  - Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New 
      Zealand.
FAU - Chamley, L W
AU  - Chamley LW
FAU - Birdsall, M
AU  - Birdsall M
FAU - Zanderigo, A M
AU  - Zanderigo AM
FAU - Liddell, H S
AU  - Liddell HS
FAU - McDougall, J
AU  - McDougall J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Obstet Gynecol. 2001 Aug;185(2):523-4. PMID: 11518923
MH  - Adult
MH  - Antiphospholipid Syndrome/*drug therapy/physiopathology
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy/physiopathology
MH  - *Pregnancy Outcome
EDAT- 2000/10/18 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/18 11:00
PHST- 2000/10/18 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/18 11:00 [entrez]
AID - S0002-9378(00)36425-0 [pii]
AID - 10.1067/mob.2000.106754 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2000 Oct;183(4):1008-12. doi: 10.1067/mob.2000.106754.

PMID- 2910129
OWN - NLM
STAT- MEDLINE
DCOM- 19890209
LR  - 20190627
IS  - 0002-9610 (Print)
IS  - 0002-9610 (Linking)
VI  - 157
IP  - 1
DP  - 1989 Jan
TI  - Effects of aspirin and acetic acid on intracellular pH in necturus gastric 
      mucosa.
PG  - 66-73
AB  - Intracellular microelectrode techniques were employed to examine the effects of 
      luminal aspirin and acetic acid on intracellular pH and cell membrane potential 
      in the surface epithelial cells of Necturus antrum. Antral mucosa was mounted in 
      a modified Ussing chamber, and intracellular pH was determined from the 
      difference between the potentials recorded by intracellular conventional and 
      pH-sensitive microelectrodes. Under neutral conditions (pH7), aspirin (5 mM) 
      hyperpolarized (-7.5 +/- 1 mV, p less than 0.0001) and acetic acid (5 mM) 
      depolarized (+4 +/- 0.08 mV, p less than 0.001) cell membrane potential. Neither 
      agent had any significant effect on intracellular pH. Under acidic conditions (pH 
      4.5), aspirin (5 mM) reduced the intracellular pH from 6.99 +/- 0.03 to 6.87 +/- 
      0.04 (p less than 0.001) and depolarized cell membrane potential from -36.7 +/- 
      1.5 to -30.3 +/- 1.6 mV, p less than 0.001). Similarly, acetic acid (5 mM) 
      acidified the cells (-0.20 +/- 0.02, p less than 0.001) and depolarized cell 
      membrane potential (+9.6 +/- 1.9 mV, p less than 0.01). These changes suggest 
      that, in the absence of luminal acid, small organic acids, such as aspirin and 
      acetic acid, may have complex effects on the ionic conductances of the surface 
      cell membranes without altering intracellular pH. In contrast, under acidic 
      conditions, these agents increase the permeability of the apical cell 
      membrane-to-acid back-diffusion from the gastric lumen.
FAU - Ashley, S W
AU  - Ashley SW
AD  - Department of Surgery, Washington University School of Medicine, St. Louis, 
      Missouri.
FAU - Soybel, D I
AU  - Soybel DI
FAU - Moore, C D
AU  - Moore CD
FAU - Cheung, L Y
AU  - Cheung LY
LA  - eng
GR  - R01 AM 25998-09/AM/NIADDK NIH HHS/United States
GR  - R01 AM 35191-02/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Surg
JT  - American journal of surgery
JID - 0370473
RN  - 0 (Acetates)
RN  - Q40Q9N063P (Acetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/*pharmacology
MH  - Acetic Acid
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - *Gastric Acidity Determination
MH  - Gastric Mucosa/*analysis/drug effects
MH  - Hydrogen-Ion Concentration
MH  - Membrane Potentials
MH  - Necturus maculosus
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 0002-9610(89)90421-2 [pii]
AID - 10.1016/0002-9610(89)90421-2 [doi]
PST - ppublish
SO  - Am J Surg. 1989 Jan;157(1):66-73. doi: 10.1016/0002-9610(89)90421-2.

PMID- 7439264
OWN - NLM
STAT- MEDLINE
DCOM- 19810226
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 18
IP  - 5
DP  - 1980 Nov
TI  - A study of the effect of aspirin on the pharmacokinetics of oral and intravenous 
      diclofenac sodium.
PG  - 415-8
AB  - Previous studies have shown that aspirin interacts with orally administered 
      diclofenac sodium, causing reduced peak concentrations, lower levels and 
      decreased areas under curves. In this study, diclofenac sodium was administered 
      orally and intravenously with and without aspirin, to 6 healthy female 
      volunteers. After intravenous dosing both plasma levels and areas under curves 
      were significantly reduced although none of the rate constants was affected. The 
      volume of distribution of diclofenac was increased as was the plasma clearance. 
      Oral administration with aspirin also resulted in lower plasma levels, 
      particularly peak levels, and areas under curves. Comparison of AUC's for both 
      modes of administration with and without aspirin suggested that lower levels 
      after oral administration were not due to impaired absorption. These observations 
      are best explained by decreased protein binding and increased biliary excretion 
      of diclofenac in the presence of salicylate.
FAU - Willis, J V
AU  - Willis JV
FAU - Kendall, M J
AU  - Kendall MJ
FAU - Jack, D B
AU  - Jack DB
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Phenylacetates)
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Biological Availability
MH  - Diclofenac/administration & dosage/*metabolism
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Kinetics
MH  - Male
MH  - Phenylacetates/*metabolism
EDAT- 1980/11/01 00:00
MHDA- 1980/11/01 00:01
CRDT- 1980/11/01 00:00
PHST- 1980/11/01 00:00 [pubmed]
PHST- 1980/11/01 00:01 [medline]
PHST- 1980/11/01 00:00 [entrez]
AID - 10.1007/BF00636795 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1980 Nov;18(5):415-8. doi: 10.1007/BF00636795.

PMID- 2637415
OWN - NLM
STAT- MEDLINE
DCOM- 19900719
LR  - 20131121
IS  - 0029-8484 (Print)
IS  - 0029-8484 (Linking)
VI  - 77
IP  - 1
DP  - 1989 Jun
TI  - [Preliminary studies on phagocytosis of cultured mouse peritoneal macrophage 
      exposed to anti-inflammatory agents].
PG  - 117-36
AB  - The effect of anti-inflammatory agents, indomethacin, acetylsalicylic acid, and 
      dexamethasone on phagocytosis of cultured mouse peritoneal macrophages was 
      studied. Peritoneal macrophages, obtained from CBA/N mice were cultivated on 
      plastic dishes (35mm in diameter) with Dulbecco's modified Eagle medium 
      supplemented with 10% fetal bovine serum. Phagocytosis, as determined by uptake 
      of Latex particles into the macrophages were suppressed by treatment with 
      indomethacin, acetylsalicylic acid or dexamethasone. The level of suppression by 
      dexamethasone was greater than by indomethacine or acetylsalicylic acid. The 
      similar inhibition of phagocytosis by these agents was observed with elicited 
      macrophages, obtained from the mice treated with 3% thioglycollate medium.
FAU - Sakuma, Y
AU  - Sakuma Y
LA  - jpn
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Shigaku
JT  - Shigaku = Odontology; journal of Nihon Dental College
JID - 1275704
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cells, Cultured
MH  - Dexamethasone/*pharmacology
MH  - Indomethacin/*pharmacology
MH  - Macrophages/*drug effects
MH  - Mice
MH  - Phagocytosis/*drug effects
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
PST - ppublish
SO  - Shigaku. 1989 Jun;77(1):117-36.

PMID- 636742
OWN - NLM
STAT- MEDLINE
DCOM- 19780524
LR  - 20141120
IS  - 0300-970X (Print)
IS  - 0300-970X (Linking)
VI  - 25
IP  - 1
DP  - 1978 Feb
TI  - Lysine acetylisalicylate inhibits the protein synthesis in the rat gastric mucosa 
      in vivo and in vitro.
PG  - 52-4
AB  - Lysine acetylsalicylate (LAS), a water soluble derivative of acetylsalicylic acid 
      and parenterally administrable analgesic, locally inhibits the incorporation of 
      14C protein hydrolysate into proteins of the rat isolated gastric mucosa. A 
      similar effect on protein synthesis was observed after s.c. administration of the 
      drug, whereas DNA and RNA synthesis were not affected. Obviously, LAS inhibits 
      the translation step during biosynthesis of proteins. It is conceivable that this 
      effect contributes to the potential ulcerogenic action of acetylsalicylate and 
      that parenteral administration is not a criteria to protect the stomach from 
      salicylate-induced side effects.
FAU - Pichl, J
AU  - Pichl J
FAU - Mitznegg, P
AU  - Mitznegg P
FAU - Subramanian, N
AU  - Subramanian N
FAU - Sprügel, W
AU  - Sprügel W
FAU - Domschke, W
AU  - Domschke W
FAU - Estler, C J
AU  - Estler CJ
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Acta Hepatogastroenterol (Stuttg)
JT  - Acta hepato-gastroenterologica
JID - 0340734
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Gastric Mucosa/drug effects/*metabolism
MH  - In Vitro Techniques
MH  - Lysine/pharmacology
MH  - Male
MH  - *Protein Biosynthesis
MH  - Rats
EDAT- 1978/02/01 00:00
MHDA- 1978/02/01 00:01
CRDT- 1978/02/01 00:00
PHST- 1978/02/01 00:00 [pubmed]
PHST- 1978/02/01 00:01 [medline]
PHST- 1978/02/01 00:00 [entrez]
PST - ppublish
SO  - Acta Hepatogastroenterol (Stuttg). 1978 Feb;25(1):52-4.

PMID- 8128701
OWN - NLM
STAT- MEDLINE
DCOM- 19940413
LR  - 20181113
IS  - 0093-0415 (Print)
IS  - 0093-0415 (Linking)
VI  - 160
IP  - 1
DP  - 1994 Jan
TI  - Ticlopidine hydrochloride use and threatened stroke.
PG  - 43-7
AB  - Ticlopidine hydrochloride is an antiplatelet agent of proven antithrombotic 
      efficacy that in December 1991 became available for general clinical use in the 
      United States. The relative value of ticlopidine compared with aspirin, also an 
      effective antiplatelet agent, has become a key clinical issue. Whereas 
      ticlopidine is somewhat more effective than aspirin for preventing stroke in 
      certain populations, it is also more expensive and potentially toxic. We 
      recommend its use for patients with threatened stroke who are intolerant of 
      aspirin and for patients who have cerebral ischemic symptoms despite aspirin 
      therapy. Patients surviving major ischemic stroke make up a third group for whom 
      ticlopidine use may be recommended in preference to aspirin. The use of 
      ticlopidine rather than aspirin in patients with other cerebrovascular conditions 
      is not strongly supported by existing data. The risk-benefit-cost equation 
      involving ticlopidine versus other antithrombotic therapies is complex, rendering 
      a wide range of acceptable management practices. If reliable laboratory 
      monitoring for neutropenia during the first 3 months of therapy is not feasible, 
      ticlopidine should not be used.
FAU - Rothrock, J F
AU  - Rothrock JF
AD  - Department of Neurosciences, University of California, School of Medicine, San 
      Diego 92103-8466.
FAU - Hart, R G
AU  - Hart RG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - West J Med
JT  - The Western journal of medicine
JID - 0410504
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Humans
MH  - Ticlopidine/adverse effects/*therapeutic use
PMC - PMC1022253
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - West J Med. 1994 Jan;160(1):43-7.

PMID- 1406001
OWN - NLM
STAT- MEDLINE
DCOM- 19921125
LR  - 20190911
IS  - 0196-8092 (Print)
IS  - 0196-8092 (Linking)
VI  - 12
IP  - 5
DP  - 1992
TI  - Effect of aspirin on photodynamic therapy utilizing chloroaluminum sulfonated 
      phthalocyanine (CASP).
PG  - 494-9
AB  - The efficacy of photodynamic therapy (PDT) is mediated through a direct vascular 
      effect. Interference with platelet function and resulting vascular stasis have 
      been recently demonstrated utilizing the photosensitizer dihematoporphyrin ether 
      (DHE). We examined the effect of aspirin, a known inhibitor of both 
      cyclooxygenase and platelet activity, on PDT using chloroaluminum sulfonated 
      phthalocyanine (CASP). Thirty-six rats implanted with a window chamber were given 
      either 0.1 mg/kg (low dose) or 10 mg/kg (high dose) aspirin immediately before, 
      immediately after, or 6 hours after the completion of CASP-PDT. Aspirin in either 
      dosage did not appear to have any effect on the window vasculature when given 
      immediately after light exposure. A moderate inhibition of vascular response was 
      seen in animals treated with aspirin pre-PDT, whereas high-dose aspirin 
      completely abrogated the CASP-PDT vascular response when given 6 hours post-PDT. 
      These data indicate that aspirin can effect CASP-PDT in both time-dependent and 
      dose-dependent fashions.
FAU - Stern, S J
AU  - Stern SJ
AD  - Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer 
      Center, Houston 77030.
FAU - Craig, J R
AU  - Craig JR
FAU - Flock, S
AU  - Flock S
FAU - Small, S
AU  - Small S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Lasers Surg Med
JT  - Lasers in surgery and medicine
JID - 8007168
RN  - 0 (Indoles)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Radiation-Sensitizing Agents)
RN  - 104469-80-9 (chloroaluminum tetrasulfophthalocyanine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Indoles/*therapeutic use
MH  - Organometallic Compounds/*therapeutic use
MH  - *Photochemotherapy
MH  - Radiation-Sensitizing Agents/therapeutic use
MH  - Rats
MH  - Rats, Inbred F344
MH  - Skin/blood supply/drug effects/radiation effects
MH  - Skin Window Technique
MH  - Spectrophotometry
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1002/lsm.1900120507 [doi]
PST - ppublish
SO  - Lasers Surg Med. 1992;12(5):494-9. doi: 10.1002/lsm.1900120507.

PMID- 9394582
OWN - NLM
STAT- MEDLINE
DCOM- 19980120
LR  - 20131121
IS  - 0369-4739 (Print)
IS  - 0369-4739 (Linking)
VI  - 45
IP  - 10
DP  - 1997 Oct
TI  - [A prospective study on the timing of discontinuation of aspirin before coronary 
      artery bypass grafting].
PG  - 1710-4
AB  - The effects of the timing of discontinuation of aspirin before coronary artery 
      bypass grafting (CABG) on postoperative blood loss and blood requirements were 
      examined in 22 patients undergoing elective CABG, who were randomly assigned into 
      two groups. In Group I (11 patients), aspirin was discontinued two days before 
      the operation and in Group II (11 patients), aspirin was continued up to the 
      operation. The other 40 patients, who did not take aspirin for at least seven 
      days before the operation, served as a control Group. There were no differences 
      in preoperative data including the platelet count and the hemoglobin 
      concentration, nor in operative variables such as operation time, cardiopulmonary 
      bypass duration and aortic crossclamp time among the groups. Although 
      postoperative blood loss (six hours' loss; Group I 218 ml, Group II 183 ml and 
      control Group 172 ml) and red blood cells transfusion requirements were not 
      different among the groups, platelet concentrates transfusion was more frequently 
      required in Group II (54.5%) as compared with control Group (7.5%) and Group I 
      (9.1%). The difference between Group II and the control Group reached statistical 
      significance (p < 0.01), but there was no significant difference between Group I 
      and control Group. This fact suggests that preoperative two days' discontinuation 
      of aspirin works as effectively as seven days' discontinuation.
FAU - Matsuzaki, K
AU  - Matsuzaki K
AD  - Department of Cardiovascular Surgery, Matsuyama Red Cross Hospital, Ehime, Japan.
FAU - Okabe, H
AU  - Okabe H
FAU - Kajihara, N
AU  - Kajihara N
FAU - Haraguchi, N
AU  - Haraguchi N
FAU - Nagano, I
AU  - Nagano I
FAU - Tatewaki, H
AU  - Tatewaki H
FAU - Matsui, K
AU  - Matsui K
LA  - jpn
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Japan
TA  - Nihon Kyobu Geka Gakkai Zasshi
JT  - [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai
JID - 19130180R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Blood Loss, Surgical
MH  - Cardiopulmonary Bypass
MH  - *Coronary Artery Bypass
MH  - Coronary Disease/surgery
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Time Factors
EDAT- 1997/12/12 00:00
MHDA- 1997/12/12 00:01
CRDT- 1997/12/12 00:00
PHST- 1997/12/12 00:00 [pubmed]
PHST- 1997/12/12 00:01 [medline]
PHST- 1997/12/12 00:00 [entrez]
PST - ppublish
SO  - Nihon Kyobu Geka Gakkai Zasshi. 1997 Oct;45(10):1710-4.

PMID- 2219967
OWN - NLM
STAT- MEDLINE
DCOM- 19901119
LR  - 20131121
IS  - 0049-8254 (Print)
IS  - 0049-8254 (Linking)
VI  - 20
IP  - 8
DP  - 1990 Aug
TI  - Comparative metabolism of high doses of aspirin in man and rat.
PG  - 847-54
AB  - 1. Metabolism of aspirin was studied in 10 human volunteers who took a 
      therapeutic dose (600 mg) by mouth and in nine patients who took aspirin in 
      overdose. 2. Salicyluric acid was the major urinary metabolite in volunteers 
      (63.1 +/- 8.4% of dose in 0-8 h). In overdose patients, salicyluric acid in urine 
      was decreased (30.0 +/- 8.2%, 0-24 h, P less than 0.001) and there was increased 
      elimination of salicyclic acid (34.1%, P less than 0.005), salicyl acyl 
      glucuronide (14.4%, P less than 0.05) and gentisuric acid (5.3%). 3. Metabolism 
      of orally administered 14C-aspirin in rats over a 10-fold dose range (10-100 
      mg/kg) resulted in excretion of 81-91% dose in urine in the first 24 h. 
      Salicyclic acid was the major urinary metabolite (43-51% dose). Excretion of 
      salicyluric acid decreased with increasing dose, whereas gentisic acid and 
      salicyl phenolic and acyl glucuronides increased. 4. The profile of aspirin 
      metabolites was qualitatively similar in man and rat but there were quantitative 
      differences. Limited capacity to form salicyluric acid was observed in both 
      species. Dependence on this pathway in rat was low and was compensated by 
      increased utilization of other routes; dependence on salicyluric acid formation 
      in man was high and in overdose, compensation by other routes was incomplete.
FAU - Patel, D K
AU  - Patel DK
AD  - School of Pharmacy and Pharmacology, University of Bath, UK.
FAU - Notarianni, L J
AU  - Notarianni LJ
FAU - Bennett, P N
AU  - Bennett PN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Xenobiotica
JT  - Xenobiotica; the fate of foreign compounds in biological systems
JID - 1306665
RN  - 0 (Gentisates)
RN  - 0 (Glucuronates)
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 25351-24-0 (gentisuric acid)
RN  - 29315-53-5 (salicylacyl glucuronide)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacokinetics/poisoning
MH  - Female
MH  - Gentisates/urine
MH  - Glucuronates/urine
MH  - Hippurates/urine
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Salicylates/urine
MH  - Salicylic Acid
EDAT- 1990/08/01 00:00
MHDA- 1990/08/01 00:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 1990/08/01 00:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
AID - 10.3109/00498259009046898 [doi]
PST - ppublish
SO  - Xenobiotica. 1990 Aug;20(8):847-54. doi: 10.3109/00498259009046898.

PMID- 31037399
OWN - NLM
STAT- MEDLINE
DCOM- 20190612
LR  - 20200225
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 145
IP  - 6
DP  - 2019 Jun
TI  - Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks 
      of cancer.
PG  - 1387-1403
LID - 10.1007/s00432-019-02902-6 [doi]
AB  - PURPOSE: Aspirin, one of the most commonly used nonsteroidal anti-inflammatory 
      drugs (NAIDS), not only shows cancer chemoprevention effects but also improves 
      cancer therapeutic effects when combined with other therapies. Studies that focus 
      on aspirin regulation of the hallmarks of cancer and the associated molecular 
      mechanisms facilitate a more thorough understanding of aspirin in mediating 
      chemoprevention and may supply additional information for the development of 
      novel cancer therapeutic agents. METHODS: The relevant literatures from PubMed 
      have been reviewed in this article. RESULTS: Current studies have revealed that 
      aspirin regulates almost all the hallmarks of cancer. Within tumor tissue, 
      aspirin suppresses the bioactivities of cancer cells themselves and deteriorates 
      the tumor microenvironment that supports cancer progression. In addition to tumor 
      tissues, blocking of platelet activation also contributes to the ability of 
      aspirin to inhibit cancer progression. In terms of the molecular mechanism, 
      aspirin targets oncogenes and cancer-related signaling pathways and activates 
      certain tumor suppressors. CONCLUSION: Beyond a chemopreventive agent, aspirin is 
      a master regulator of the hallmarks of cancer.
FAU - Zhang, Xiao
AU  - Zhang X
AD  - Department of Pathology, Harbin Medical University, Harbin, 150086, China.
FAU - Feng, Yukuan
AU  - Feng Y
AD  - Key Laboratory of Heilongjiang Province for Cancer Prevention and Control, 
      Mudanjiang Medical University, Mudanjiang, 157011, China.
FAU - Liu, Xi
AU  - Liu X
AD  - Center of Cardiovascular Disease, Inner Mongolia People's Hospital, Hohhot, 
      010017, Inner Mongolia, China.
FAU - Ma, Jianhui
AU  - Ma J
AD  - Department of Pathology, Harbin Medical University, Harbin, 150086, China.
FAU - Li, Yafei
AU  - Li Y
AD  - Department of Pathology, Harbin Medical University, Harbin, 150086, China.
FAU - Wang, Tianzhen
AU  - Wang T
AD  - Department of Pathology, Harbin Medical University, Harbin, 150086, China. 
      wtzpath@163.com.
FAU - Li, Xiaobo
AU  - Li X
AUID- ORCID: 0000-0003-1037-3903
AD  - Department of Pathology, Harbin Medical University, Harbin, 150086, China. 
      lixiaobo@ems.hrbmu.edu.cn.
LA  - eng
GR  - Grant No. 81871976/National Natural Science Foundation of China/
GR  - 81772498/National Natural Science Foundation of China/
GR  - Grant No. 31501158/National Natural Science Foundation of China/
GR  - H2016006/Natural Science Foundation of Heilongjiang Province/
GR  - Grant No. H2018009/Natural Science Foundation of Heilongjiang Province/
PT  - Journal Article
PT  - Review
DEP - 20190429
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Anticarcinogenic Agents
MH  - Aspirin/*pharmacology
MH  - Energy Metabolism
MH  - Humans
MH  - Neoplasms/*drug therapy/metabolism/pathology/prevention & control
MH  - Platelet Activation/drug effects
MH  - Tumor Microenvironment/drug effects
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer
OT  - Cancer therapy
OT  - Hallmark of cancers
EDAT- 2019/05/01 06:00
MHDA- 2019/06/14 06:00
CRDT- 2019/05/01 06:00
PHST- 2018/12/20 00:00 [received]
PHST- 2019/03/22 00:00 [accepted]
PHST- 2019/05/01 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2019/05/01 06:00 [entrez]
AID - 10.1007/s00432-019-02902-6 [pii]
AID - 10.1007/s00432-019-02902-6 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2019 Jun;145(6):1387-1403. doi: 
      10.1007/s00432-019-02902-6. Epub 2019 Apr 29.

PMID- 33930107
OWN - NLM
STAT- MEDLINE
DCOM- 20220330
LR  - 20220531
IS  - 2055-6845 (Electronic)
IS  - 2055-6837 (Print)
VI  - 7
IP  - 6
DP  - 2021 Nov 3
TI  - Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS 
      trial and beyond.
PG  - 547-556
LID - 10.1093/ehjcvp/pvab035 [doi]
AB  - Historically, aspirin has been the primary treatment for the prevention of 
      ischaemic events in patients with coronary artery disease. For patients 
      undergoing percutaneous coronary intervention (PCI) standard treatment has been 
      12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, 
      followed by aspirin monotherapy; however, DAPT is undeniably associated with an 
      increased risk of bleeding. For over a decade novel P2Y12 inhibitors, which have 
      increased specificity, potency, and efficacy have been available, prompting 
      studies which have tested whether these newer agents can be used in aspirin-free 
      antiplatelet regimens to augment clinical benefits in patients post-PCI. Among 
      these studies, the GLOBAL LEADERS trial is the largest by cohort size, and so far 
      has provided a wealth of evidence in a variety of clinical settings and patient 
      groups. This article summarizes the state-of-the-art evidence obtained from the 
      GLOBAL LEADERS and other trials of aspirin-free strategies.
CI  - © The Author(s) 2021. Published by Oxford University Press on behalf of the 
      European Society of Cardiology.
FAU - Wang, Rutao
AU  - Wang R
AD  - Department of Cardiology, Xijing Hospital, Changle West Road 127, Xi'an 710032, 
      China.
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), 
      University Road, Galway H91 TK33, Ireland.
AD  - Department of Cardiology, Radboud University Medical Center, Geert Grooteplein 
      Zuid 8, 6525 GA Nijmegen, The Netherlands.
FAU - Wu, Sijing
AU  - Wu S
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), 
      University Road, Galway H91 TK33, Ireland.
AD  - Department of Cardiology, Beijing Anzhen Hospital, Anzhen road No.2, Beijing 
      100029, China.
AD  - Department of Cardiology, Academic Medical Center, University of Amsterdam, 
      Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
FAU - Gamal, Amr
AU  - Gamal A
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), 
      University Road, Galway H91 TK33, Ireland.
AD  - Department of Cardiology, North Cumbria University Hospitals NHS Trust, Newtown 
      Road, Cumbria CA2 7HY, UK.
AD  - Department of Cardiology, Zagazig University, Zagazig, Sharkia, 44519, Egypt.
FAU - Gao, Chao
AU  - Gao C
AD  - Department of Cardiology, Xijing Hospital, Changle West Road 127, Xi'an 710032, 
      China.
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), 
      University Road, Galway H91 TK33, Ireland.
AD  - Department of Cardiology, Radboud University Medical Center, Geert Grooteplein 
      Zuid 8, 6525 GA Nijmegen, The Netherlands.
FAU - Hara, Hironori
AU  - Hara H
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), 
      University Road, Galway H91 TK33, Ireland.
AD  - Department of Cardiology, Academic Medical Center, University of Amsterdam, 
      Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
FAU - Kawashima, Hideyuki
AU  - Kawashima H
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), 
      University Road, Galway H91 TK33, Ireland.
AD  - Department of Cardiology, Academic Medical Center, University of Amsterdam, 
      Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
FAU - Ono, Masafumi
AU  - Ono M
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), 
      University Road, Galway H91 TK33, Ireland.
AD  - Department of Cardiology, Academic Medical Center, University of Amsterdam, 
      Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
FAU - van Geuns, Robert-Jan
AU  - van Geuns RJ
AD  - Department of Cardiology, Radboud University Medical Center, Geert Grooteplein 
      Zuid 8, 6525 GA Nijmegen, The Netherlands.
FAU - Vranckx, Pascal
AU  - Vranckx P
AD  - Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa 
      Ziekenhuis, Stadsomvaart 11, 3500 Hasselt, Belgium.
AD  - Faculty of Medicine and Life Sciences, University of Hasselt, Martelarenlaan 42, 
      3500 Hasselt, Belgium.
FAU - Windecker, Stephan
AU  - Windecker S
AUID- ORCID: 0000-0003-2653-6762
AD  - Department of Cardiology, Bern University Hospital, Freiburgstrasse 4, 3010 Bern, 
      Switzerland.
FAU - Onuma, Yoshinobu
AU  - Onuma Y
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), 
      University Road, Galway H91 TK33, Ireland.
FAU - Serruys, Patrick W
AU  - Serruys PW
AUID- ORCID: 0000-0002-9636-1104
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), 
      University Road, Galway H91 TK33, Ireland.
AD  - Department of Cardiology, Imperial College London, Exhibition Rd, London SW7 2BX, 
      UK.
FAU - Garg, Scot
AU  - Garg S
AD  - Department of Cardiology, East Lancashire Hospitals NHS Trust, Haslingden Rd, 
      Blackburn BB2 3HH, Lancashire, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J Cardiovasc Pharmacother
JT  - European heart journal. Cardiovascular pharmacotherapy
JID - 101669491
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel/therapeutic use
MH  - Dual Anti-Platelet Therapy/adverse effects/methods
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - *Platelet Aggregation Inhibitors/therapeutic use
PMC - PMC8566303
OTO - NOTNLM
OT  - GLOBAL LEADERS
OT  - P2Y12 inhibitor
OT  - Percutaneous coronary intervention
OT  - Randomized clinical trials
OT  -  Aspirin-free therapy
EDAT- 2021/05/01 06:00
MHDA- 2022/03/31 06:00
CRDT- 2021/04/30 17:41
PHST- 2021/03/20 00:00 [received]
PHST- 2021/04/21 00:00 [revised]
PHST- 2021/04/28 00:00 [accepted]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2022/03/31 06:00 [medline]
PHST- 2021/04/30 17:41 [entrez]
AID - 6261071 [pii]
AID - pvab035 [pii]
AID - 10.1093/ehjcvp/pvab035 [doi]
PST - ppublish
SO  - Eur Heart J Cardiovasc Pharmacother. 2021 Nov 3;7(6):547-556. doi: 
      10.1093/ehjcvp/pvab035.

PMID- 7188723
OWN - NLM
STAT- MEDLINE
DCOM- 19800327
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 92
IP  - 2 Pt 1
DP  - 1980 Feb
TI  - Thrombotic thrombocytopenic purpura: combined treatment with plasmapheresis and 
      antiplatelet agents.
PG  - 149-55
AB  - Seven of eight patients with thrombotic thrombocytopenic purpura who were treated 
      with both exchange plasmapheresis and antiplatelet agents (aspirin and 
      dipyridamole) achieved complete remission. The eighth patient appeared to fail on 
      this regimen but responded to corticosteroids and splenectomy. A ninth patient 
      attained full remission after therapy with only aspirin and dipyridamole. The 
      antiplatelet agents appeared to play an important role in the response of four 
      patients. Eight patients received maintenance aspirin and dipyridamole. This 
      maintenance therapy may have prevented relapses of thrombotic thrombocytopenic 
      purpura in some patients as evidence of active, subclinical disease persisted for 
      many weeks in most patients. Treatment with maintenance antiplatelet agents was 
      discontinued in five patients after 7 to 18 months and no patient has relapsed. 
      An effective therapeutic regimen for thrombotic throbocytopenic purpura would 
      include initial therapy with exchange plasmapheresis, aspirin, and dipyridamole 
      and maintenance therapy with antiplatelet agents.
FAU - Myers, T J
AU  - Myers TJ
FAU - Wakem, C J
AU  - Wakem CJ
FAU - Ball, E D
AU  - Ball ED
FAU - Tremont, S J
AU  - Tremont SJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Plasmapheresis
MH  - Prednisone/therapeutic use
MH  - Purpura, Thrombotic Thrombocytopenic/*therapy
MH  - Splenectomy
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
AID - 10.7326/0003-4819-92-2-149 [doi]
PST - ppublish
SO  - Ann Intern Med. 1980 Feb;92(2 Pt 1):149-55. doi: 10.7326/0003-4819-92-2-149.

PMID- 7787123
OWN - NLM
STAT- MEDLINE
DCOM- 19950725
LR  - 20191101
IS  - 1040-872X (Print)
IS  - 1040-872X (Linking)
VI  - 7
IP  - 2
DP  - 1995 Apr
TI  - Low-dose aspirin therapy in obstetrics.
PG  - 135-9
AB  - The results of four large controlled clinical trials, encompassing over 13,000 
      pregnant women, indicate that low-dose aspirin is of benefit in the prevention of 
      pre-eclampsia in women at high risk. The preventive effect on fetal growth 
      retardation seems to be small, and no therapeutic benefits could be established. 
      Low-dose aspirin appears to be safe for mother, fetus, and neonate.
FAU - Wallenburg, H C
AU  - Wallenburg HC
AD  - Institute of Obstetrics and Gynecology, Erasmus University Medical School, 
      Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Obstet Gynecol
JT  - Current opinion in obstetrics & gynecology
JID - 9007264
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
RF  - 20
EDAT- 1995/04/01 00:00
MHDA- 1995/04/01 00:01
CRDT- 1995/04/01 00:00
PHST- 1995/04/01 00:00 [pubmed]
PHST- 1995/04/01 00:01 [medline]
PHST- 1995/04/01 00:00 [entrez]
AID - 10.1097/00001703-199504000-00011 [doi]
PST - ppublish
SO  - Curr Opin Obstet Gynecol. 1995 Apr;7(2):135-9. doi: 
      10.1097/00001703-199504000-00011.

PMID- 53429
OWN - NLM
STAT- MEDLINE
DCOM- 19760209
LR  - 20220310
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 7942
DP  - 1975 Nov 15
TI  - Treatment of radiation-induced gastrointestinal distress with acetylsalicylate.
PG  - 942-3
AB  - Highly buffered acetylsalicylate was used to treat diarrhoea and other 
      gastrointestinal side-effects of radiotherapy in 28 women who were receiving 
      treatment for uterine cancer. In a double-blind, balanced, and randomised trial, 
      acetylsalicylate significantly reduced the number of bowel motions and relieved 
      abdominal pain and flatulence.
FAU - Mennie, A T
AU  - Mennie AT
FAU - Dalley, V M
AU  - Dalley VM
FAU - Dinneen, L C
AU  - Dinneen LC
FAU - Collier, H O
AU  - Collier HO
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Antacids)
RN  - 0 (Buffers)
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antacids/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Buffers
MH  - Clinical Trials as Topic
MH  - Diarrhea/*drug therapy/etiology
MH  - Drug Combinations
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Nausea/*drug therapy/etiology
MH  - Radiation Injuries/*drug therapy
MH  - Radiotherapy/*adverse effects
MH  - Uterine Cervical Neoplasms/radiotherapy
EDAT- 1975/11/15 00:00
MHDA- 1975/11/15 00:01
CRDT- 1975/11/15 00:00
PHST- 1975/11/15 00:00 [pubmed]
PHST- 1975/11/15 00:01 [medline]
PHST- 1975/11/15 00:00 [entrez]
AID - S0140-6736(75)90358-X [pii]
AID - 10.1016/s0140-6736(75)90358-x [doi]
PST - ppublish
SO  - Lancet. 1975 Nov 15;2(7942):942-3. doi: 10.1016/s0140-6736(75)90358-x.

PMID- 11727398
OWN - NLM
STAT- MEDLINE
DCOM- 20020430
LR  - 20191105
IS  - 0889-8529 (Print)
IS  - 0889-8529 (Linking)
VI  - 30
IP  - 4
DP  - 2001 Dec
TI  - Treatment for the procoagulant state in type 2 diabetes.
PG  - 1011-30
AB  - A procoagulant state has been found to exist in diabetes mellitus. There may be 
      activation of the intrinsic coagulation system, decreased fibrinolytic activity, 
      or alterations in platelet function. Intensive glycemic control with insulin is 
      effective in reducing the impact of this procoagulant state by favorably 
      affecting all three components of the system. Decreased fibrinolytic activity, as 
      influenced by plasma PAI-1 levels, may be favorably affected by weight loss, 
      exercise, a low-GI diet, or by metformin, thiazolidinediones, gemfibrozil, and 
      ACE inhibitor therapy. Insulin has variable effects on plasma PAI-1 activity. 
      Estrogens will lower the elevated PAI-1 levels seen in the menopausal state. 
      Collaborative trial evidence supports the use of low-dose aspirin as a primary or 
      secondary prevention strategy in diabetic persons who are at high cardiovascular 
      risk. A recent study suggests that this category includes virtually every type 2 
      diabetic individual in the United States. The American Diabetes Association 
      recommends enteric-coated aspirin, 81 to 325 mg/day, as the first choice. In the 
      case of aspirin allergy, clopidrogel is an alternate choice. Thus, recognition of 
      and therapy for a procoagulant state in diabetes mellitus is likely to result in 
      a decrease in the atherothrombotic events that characterize the later stages of 
      this disease.
FAU - Colwell, J A
AU  - Colwell JA
AD  - Department of Medicine, Diabetes Center, Medical University of South Carolina, 
      Charleston, South Carolina, USA. colwelja@musc.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Endocrinol Metab Clin North Am
JT  - Endocrinology and metabolism clinics of North America
JID - 8800104
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Coagulation Disorders/*complications/drug therapy/physiopathology
MH  - Blood Platelets/drug effects/physiology
MH  - Diabetes Mellitus/*blood/physiopathology
MH  - Female
MH  - Fibrinolysis/drug effects/physiology
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Male
MH  - Plasminogen Activator Inhibitor 1/physiology
RF  - 86
EDAT- 2001/12/01 10:00
MHDA- 2002/05/01 10:01
CRDT- 2001/12/01 10:00
PHST- 2001/12/01 10:00 [pubmed]
PHST- 2002/05/01 10:01 [medline]
PHST- 2001/12/01 10:00 [entrez]
AID - S0889-8529(05)70225-5 [pii]
AID - 10.1016/s0889-8529(05)70225-5 [doi]
PST - ppublish
SO  - Endocrinol Metab Clin North Am. 2001 Dec;30(4):1011-30. doi: 
      10.1016/s0889-8529(05)70225-5.

PMID- 10072923
OWN - NLM
STAT- MEDLINE
DCOM- 19990415
LR  - 20131121
IS  - 0253-9756 (Print)
IS  - 0253-9756 (Linking)
VI  - 18
IP  - 4
DP  - 1997 Jul
TI  - Inhibitory effects of copper-aspirin complex on platelet aggregation.
PG  - 358-62
AB  - AIM: To study the inhibitory effects of copper-aspirin complex (CuAsp) on 
      platelet aggregation. METHODS: With adenosine diphosphate the effects of CuAsp on 
      platelet aggregation in vitro or in vivo were investigated. Radioimmunoassay and 
      fluorophotometry were used to measure thromboxane B2 (TXB2) generation from 
      platelets, the levels of TXB2 and of 6-keto-PGF1 alpha in plasma and the platelet 
      serotonin release reaction. RESULTS: In vitro, CuAsp inhibited arachidonic acid 
      (AA)-induced aggregation (IC50 = 17 mumol.L-1, 95% confidence limits: 9-33 
      mumol.L-1), the release of 5-HT (IC50 = 19 mumol.L-1, 95% confidence limits: 
      10-30 mumol.L-1), and TXB2 generation from platelets (P < 0.05). CuAsp 10 mg.kg-1 
      i.g. selectively inhibited AA-induced aggregation, and increased the 6-keto-PGF1 
      alpha concentration in plasma while decreased that of TXB2. CONCLUSION: CuAsp, in 
      vitro or in vivo, shows more potent inhibitory effects on AA-induced aggregation 
      than aspirin (Asp), related to the inhibition of platelet cyclooxygenase and the 
      release of active substances from platelets.
FAU - Shen, Z Q
AU  - Shen ZQ
AD  - Yunnan Pharmacological Laboratories of Natural Products, Kunming Medical College, 
      China.
FAU - Chen, Z H
AU  - Chen ZH
FAU - Ma, G Y
AU  - Ma GY
FAU - Wang, D C
AU  - Wang DC
FAU - Wu, W L
AU  - Wu WL
FAU - Liu, W P
AU  - Liu WP
FAU - Yang, Y K
AU  - Yang YK
FAU - Xiong, H Z
AU  - Xiong HZ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Yao Li Xue Bao
JT  - Zhongguo yao li xue bao = Acta pharmacologica Sinica
JID - 8100330
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - 333DO1RDJY (Serotonin)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Platelets/metabolism
MH  - Female
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rabbits
MH  - Serotonin/blood
MH  - Thromboxane B2/biosynthesis
EDAT- 1997/07/01 00:00
MHDA- 1999/03/12 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1999/03/12 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
PST - ppublish
SO  - Zhongguo Yao Li Xue Bao. 1997 Jul;18(4):358-62.

PMID- 9186381
OWN - NLM
STAT- MEDLINE
DCOM- 19970625
LR  - 20220317
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 349
IP  - 9066
DP  - 1997 Jun 7
TI  - CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients 
      with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative 
      Group.
PG  - 1641-9
AB  - BACKGROUND: Aspirin is effective in the treatment of acute myocardial infarction 
      and in the long-term prevention of serious vascular events in survivors of stroke 
      and myocardial infarction. There is, however, no reliable evidence on the 
      effectiveness of early aspirin use in acute ischaemic stroke. METHODS: The 
      Chinese Acute Stroke Trial (CAST) was a large randomised, placebo-controlled 
      trial of the effects in hospital of aspirin treatment (160 mg/day) started within 
      48 h of the onset of suspected acute ischaemic stroke and continued in hospital 
      for up to 4 weeks. The primary endpoints were death from any cause during the 
      4-week treatment period and death or dependence at discharge, and the analyses 
      were by intention to treat. 21,106 patients with acute ischaemic stroke were 
      enrolled in 413 Chinese hospitals at a mean of 25 h after the onset of symptoms 
      (10,554 aspirin, 10,552 placebo). 87% had a CT scan before randomisation. It was 
      prospectively planned that the results would be analysed in parallel with those 
      of the concurrent. International Stroke Trial (IST) of 20,000 patients with acute 
      stroke from other countries. FINDINGS: There was a significant 14% (SD 7) 
      proportional reduction in mortality during the scheduled treatment period (343 
      [3.3%] deaths among aspirin-allocated patients vs 398 [3.9%] deaths among 
      placebo-allocated patients; 2p = 0.04). There were significantly fewer recurrent 
      ischaemic strokes in the aspirin-allocated than in the placebo-allocated group 
      (167 [1.6%] vs 215 [2.1%]; 2p = 0.01) but slightly more haemorrhagic strokes (115 
      [1.1%] vs 93 [0.9%]; 2p > 0.1). For the combined in-hospital endpoint of death or 
      non-fatal stroke at 4 weeks, there was a 12% (6) proportional risk reduction with 
      aspirin (545 [5.3%] vs 614 [5.9%]; 2p = 0.03), an absolute difference of 6.8 
      (3.2) fewer cases per 1000. At discharge, 3153 (30.5%) aspirin-allocated patients 
      and 3266 (31.6%) placebo-allocated patients were dead or dependent, corresponding 
      to 11.4 (6.4) fewer per 1000 in favour of aspirin (2p = 0.08). INTERPRETATION: 
      There are two major trials of aspirin in acute ischaemic stroke. Taken together, 
      CAST and the similarly large IST show reliably that aspirin started early in 
      hospital produces a small but definite net benefit, with about 9 (SD 3) fewer 
      deaths or non-fatal strokes per 1000 in the first few weeks (2p = 0.001), and 
      with 13 (5) fewer dead or dependent per 1000 after some weeks or months of 
      follow-up (2p < 0.01).
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 1997 Aug 9;350(9075):440; author reply 443-4. PMID: 9259671
CIN - Lancet. 1997 Aug 9;350(9075):440-1; author reply 443-4. PMID: 9259673
CIN - Lancet. 1997 Aug 9;350(9075):442-3; author reply 443-4. PMID: 9259676
CIN - Lancet. 1997 Aug 9;350(9075):443; author reply 443-4. PMID: 9259677
CIN - Lancet. 1997 Aug 9;350(9075):443; author reply 443-4. PMID: 9259678
MH  - Acute Disease
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Pressure
MH  - Cerebrovascular Disorders/*drug therapy/mortality/physiopathology
MH  - China
MH  - Female
MH  - Follow-Up Studies
MH  - Hospital Mortality
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Recurrence
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
EDAT- 1997/06/07 00:00
MHDA- 1997/06/07 00:01
CRDT- 1997/06/07 00:00
PHST- 1997/06/07 00:00 [pubmed]
PHST- 1997/06/07 00:01 [medline]
PHST- 1997/06/07 00:00 [entrez]
AID - S0140673697040105 [pii]
PST - ppublish
SO  - Lancet. 1997 Jun 7;349(9066):1641-9.

PMID- 11601840
OWN - NLM
STAT- MEDLINE
DCOM- 20020501
LR  - 20220311
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 22
IP  - 20
DP  - 2001 Oct
TI  - Management of atrial fibrillation: discrepancy between guideline recommendations 
      and actual practice exposes patients to risk for complications.
PG  - 1954-9
AB  - AIMS: To assess compliance to guidelines in the management of patients with 
      atrial fibrillation. METHODS AND RESULTS: A total of 728 questionnaires were 
      mailed to physicians with the intention of studying 'theoretical' compliance to 
      practice guidelines. A retrospective evaluation of 200 records from consecutive 
      patients hospitalized with atrial fibrillation was performed in order to verify 
      'actual' compliance to guidelines. The response rate to the questionnaires was 
      68%. More than 94% of the physicians stated that patients with risk factors for 
      thromboembolic complications and chronic atrial fibrillation should receive 
      long-term warfarin treatment. Of evaluated records, 108 patients were in chronic 
      atrial fibrillation with at least one risk factor for stroke, and with no known 
      contraindication to warfarin. In this group, only 40% received warfarin. 
      Moreover, several other discrepancies were detected as regards the use of 
      antiarrhythmic therapy. CONCLUSION: This study reveals a clear discrepancy 
      between recommendations in guidelines and actual practice in patients with atrial 
      fibrillation. The most important finding was a significant under use of 
      thromboembolic prophylaxis in patients at high risk for such events. 
      Implementation and the study of adherence to management guidelines on atrial 
      fibrillation need to be carefully reviewed by surveys of actual clinical practice 
      in order to establish reasonable therapeutic quality.
CI  - Copyright 2001 The European Society of Cardiology.
FAU - Frykman, V
AU  - Frykman V
AD  - Department of Cardiology, Karolinska Hospital, Stockholm, Sweden.
FAU - Beerman, B
AU  - Beerman B
FAU - Rydén, L
AU  - Rydén L
FAU - Rosenqvist, M
AU  - Rosenqvist M
CN  - Medical Products Agency
CN  - Swedish Society of Cardiology
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/economics/standards/therapeutic use
MH  - Aspirin/economics/standards/therapeutic use
MH  - Atrial Fibrillation/diagnosis/*therapy
MH  - Defibrillators, Implantable/standards
MH  - Echocardiography
MH  - Electrocardiography
MH  - Fees, Pharmaceutical
MH  - Guidelines as Topic
MH  - Humans
MH  - Middle Aged
MH  - Patient Compliance/psychology
MH  - Practice Guidelines as Topic
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - Time
MH  - Time Factors
MH  - Treatment Outcome
MH  - United Kingdom/epidemiology
MH  - United States/epidemiology
MH  - Warfarin/economics/standards/therapeutic use
EDAT- 2001/10/17 10:00
MHDA- 2002/05/02 10:01
CRDT- 2001/10/17 10:00
PHST- 2001/10/17 10:00 [pubmed]
PHST- 2002/05/02 10:01 [medline]
PHST- 2001/10/17 10:00 [entrez]
AID - S0195668X00923005 [pii]
AID - 10.1053/euhj.2000.2300 [doi]
PST - ppublish
SO  - Eur Heart J. 2001 Oct;22(20):1954-9. doi: 10.1053/euhj.2000.2300.

PMID- 28005245
OWN - NLM
STAT- MEDLINE
DCOM- 20171207
LR  - 20171209
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 161
IP  - 3
DP  - 2017 Feb
TI  - Aspirin/antiplatelet agent use improves disease-free survival and reduces the 
      risk of distant metastases in Stage II and III triple-negative breast cancer 
      patients.
PG  - 463-471
LID - 10.1007/s10549-016-4081-8 [doi]
AB  - PURPOSE: The objective is to define the therapeutic role of antiplatelet agents 
      in a triple-negative breast cancer (TNBC) population. METHODS: We performed 
      retrospective analysis using the UTSW TNBC registry containing data from 222 
      Stage II-III TNBC patients treated between 1998 and 2016. Univariate analysis and 
      multivariable logistic regression models were constructed to identify factors 
      associated with disease-free survival (DFS), distant metastases rate (DMR), and 
      overall survival outcomes. Antiplatelet drug use was determined by review of 
      electronic medical records. RESULTS: A total of 65 patients used antiplatelet 
      (AP) agents, and 157 patients did not use AP agents. Median follow-up for AP and 
      non-AP groups was 41.3 and 40.9 months, respectively. There was an improvement in 
      the AP group compared with the control group in 5-year DFS (80.4% at 5 years 
      compared with 62.3% in the control group, p = 0.04) and 5-year DMR (8.8 vs. 
      31.9%, p = 0.007). In multivariate analysis, AP use was found to be significantly 
      associated with improvements in DFS and DMR. CONCLUSIONS: We illustrate that 
      antiplatelet agent use improves DMR and DFS among a stage II and III TNBC 
      population despite our short follow-up evaluation. Longer follow-up evaluation 
      will be required to determine additional outcome advantage for antiplatelet agent 
      use. Our findings support consideration of investigation of antiplatelet therapy 
      as an adjunctive therapy for TNBC at high risk for disease recurrence.
FAU - Shiao, J
AU  - Shiao J
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA.
FAU - Thomas, K M
AU  - Thomas KM
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA.
FAU - Rahimi, A S
AU  - Rahimi AS
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA.
FAU - Rao, R
AU  - Rao R
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Yan, Jingsheng
AU  - Yan J
AD  - Department of Clinical Sciences, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Xie, Xian-Jin
AU  - Xie XJ
AD  - Department of Clinical Sciences, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - DaSilva, M
AU  - DaSilva M
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Spangler, A
AU  - Spangler A
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA.
FAU - Leitch, M
AU  - Leitch M
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Wooldridge, R
AU  - Wooldridge R
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Rivers, A
AU  - Rivers A
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Farr, D
AU  - Farr D
AD  - Department of Surgery, Division of Surgical Oncology, University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Haley, B
AU  - Haley B
AD  - Department of Medical Oncology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Kim, D W Nathan
AU  - Kim DW
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA. 
      Nathan.kim@utsouthwestern.edu.
LA  - eng
PT  - Journal Article
DEP - 20161222
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Breast Neoplasms
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Treatment Outcome
MH  - Triple Negative Breast Neoplasms/diagnosis/*drug therapy/*mortality
OTO - NOTNLM
OT  - Anti-platelet
OT  - Aspirin
OT  - Estrogen receptor negative
OT  - Metastases
OT  - Triple negative
EDAT- 2016/12/23 06:00
MHDA- 2017/12/08 06:00
CRDT- 2016/12/23 06:00
PHST- 2016/10/13 00:00 [received]
PHST- 2016/12/08 00:00 [accepted]
PHST- 2016/12/23 06:00 [pubmed]
PHST- 2017/12/08 06:00 [medline]
PHST- 2016/12/23 06:00 [entrez]
AID - 10.1007/s10549-016-4081-8 [pii]
AID - 10.1007/s10549-016-4081-8 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2017 Feb;161(3):463-471. doi: 10.1007/s10549-016-4081-8. 
      Epub 2016 Dec 22.

PMID- 24355265
OWN - NLM
STAT- MEDLINE
DCOM- 20140224
LR  - 20220321
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 70
IP  - 1
DP  - 2014 Jan
TI  - Aspirin use and melanoma risk: a review of the literature.
PG  - 187-91
LID - S0190-9622(13)01041-4 [pii]
LID - 10.1016/j.jaad.2013.09.045 [doi]
AB  - In view of the increasing incidence of melanoma, it is critical to find effective 
      preventive approaches. Contradictory evidence has been reported with regard to 
      the possible association of aspirin use and the risk of melanoma. We review these 
      studies and seek to elucidate the mechanism by which aspirin may produce a 
      chemoprotective effect against melanoma.
CI  - Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. 
      All rights reserved.
FAU - Famenini, Shannon
AU  - Famenini S
AD  - David Geffen School of Medicine, University of California Los Angeles, Los 
      Angeles, California. Electronic address: sfamenini@mednet.ucla.edu.
FAU - Young, Lorraine C
AU  - Young LC
AD  - Division of Dermatology, Department of Medicine, David Geffen School of Medicine, 
      University of California Los Angeles, Los Angeles, California.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Melanoma/*prevention & control
MH  - Skin Neoplasms/*prevention & control
OTO - NOTNLM
OT  - CI
OT  - HR
OT  - NSAID
OT  - aspirin
OT  - confidence interval
OT  - hazard ratio
OT  - melanoma
OT  - nonsteroidal anti-inflammatory drugs
EDAT- 2013/12/21 06:00
MHDA- 2014/02/25 06:00
CRDT- 2013/12/21 06:00
PHST- 2013/08/27 00:00 [received]
PHST- 2013/09/20 00:00 [revised]
PHST- 2013/09/21 00:00 [accepted]
PHST- 2013/12/21 06:00 [entrez]
PHST- 2013/12/21 06:00 [pubmed]
PHST- 2014/02/25 06:00 [medline]
AID - S0190-9622(13)01041-4 [pii]
AID - 10.1016/j.jaad.2013.09.045 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2014 Jan;70(1):187-91. doi: 10.1016/j.jaad.2013.09.045.

PMID- 34253265
OWN - NLM
STAT- MEDLINE
DCOM- 20221109
LR  - 20221201
IS  - 1475-2700 (Electronic)
IS  - 0954-4224 (Linking)
VI  - 35
IP  - 2
DP  - 2022 Dec
TI  - Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in 
      cardiovascular diseases and colorectal adenomas.
PG  - 295-307
LID - 10.1017/S0954422421000238 [doi]
AB  - Aspirin (acetylsalicylic acid, ASA) is inexpensive and is established in 
      preventing cardiovascular disease (CVD) and colorectal adenomas. Omega-3 (n3) 
      polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA) and 
      docosahexaenoic acid (DHA) have also shown benefit in preventing CVD. The 
      combination could be an effective preventative measure in patients with such 
      diseases. ASA and n3 PUFA reduced the risk of CVD in ASA-resistant or diabetic 
      patients. EPA- and DHA-deficient patients also benefited the most from n3 PUFA 
      supplementation. Synergistic effects between ASA and EPA and DHA are 'V-shaped' 
      such that optimal ASA efficacy is dependent on EPA and DHA concentrations in 
      blood. In colorectal adenomas, ASA (300 mg/d) and EPA reduced adenoma burden in a 
      location- and subtype-specific manner. Low doses of ASA (75-100 mg/d) were used 
      in CVD prevention; however, ultra-low doses (30 mg/d) can also reduce thrombosis. 
      EPA-to-DHA ratio is also important with regard to efficacy. DHA is more effective 
      in reducing blood pressure and modulating systemic inflammation; however, 
      high-dose EPA can lower CVD events in high-risk individuals. Although current 
      literature has yet to examine ASA and DHA in preventing CVD, such combination 
      warrants further investigation. To increase adherence to ASA and n3 PUFA 
      supplementation, combination dosage form may be required to improve outcomes.
FAU - Wang, Ivan E
AU  - Wang IE
AUID- ORCID: 0000-0002-1318-9522
AD  - The Pharmaceutical Research Institute, Albany College of Pharmacy and Health 
      Sciences, 1 Discovery Drive, Rensselaer, NY122144, USA.
FAU - Yi, Shana
AU  - Yi S
AD  - Department of Public Health Sciences, and Cardiology Division, Department of 
      Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood 
      Avenue, Rochester, NY14642, USA.
FAU - Block, Robert C
AU  - Block RC
AD  - Department of Public Health Sciences, and Cardiology Division, Department of 
      Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood 
      Avenue, Rochester, NY14642, USA.
FAU - Mousa, Shaker A
AU  - Mousa SA
AUID- ORCID: 0000-0002-9294-015X
AD  - The Pharmaceutical Research Institute, Albany College of Pharmacy and Health 
      Sciences, 1 Discovery Drive, Rensselaer, NY122144, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210713
PL  - England
TA  - Nutr Res Rev
JT  - Nutrition research reviews
JID - 9113797
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Fatty Acids, Omega-3)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - 25167-62-8 (Docosahexaenoic Acids)
SB  - IM
MH  - Humans
MH  - *Cardiovascular Diseases/prevention & control
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Fatty Acids, Omega-3/pharmacology/therapeutic use
MH  - Eicosapentaenoic Acid/therapeutic use
MH  - Docosahexaenoic Acids/pharmacology/therapeutic use
MH  - *Adenoma/prevention & control/drug therapy
MH  - *Colorectal Neoplasms/prevention & control/drug therapy
MH  - Dietary Supplements
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Colorectal adenoma
OT  - Colorectal cancer
OT  - DHA
OT  - EPA
OT  - Fish oil
OT  - Low-dose aspirin
OT  - Omega-3 fatty acids
OT  - Thrombosis
EDAT- 2021/07/14 06:00
MHDA- 2022/11/10 06:00
CRDT- 2021/07/13 05:38
PHST- 2021/07/14 06:00 [pubmed]
PHST- 2022/11/10 06:00 [medline]
PHST- 2021/07/13 05:38 [entrez]
AID - S0954422421000238 [pii]
AID - 10.1017/S0954422421000238 [doi]
PST - ppublish
SO  - Nutr Res Rev. 2022 Dec;35(2):295-307. doi: 10.1017/S0954422421000238. Epub 2021 
      Jul 13.

PMID- 11479480
OWN - NLM
STAT- MEDLINE
DCOM- 20010830
LR  - 20131121
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 142
IP  - 2
DP  - 2001 Aug
TI  - Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet 
      aggregation during physical exercise in patients with coronary artery disease.
PG  - E1
AB  - BACKGROUND: Strenuous exercise can be a major trigger for coronary thrombosis and 
      it enhances platelet aggregation. METHODS: We evaluated the effect of 
      antiplatelet therapy on shear stress-induced platelet aggregation (SIPA), in 
      addition to agonist-induced aggregation, before and immediately after ergometer 
      exercise in patients with stable coronary artery diseases (CAD). Forty-eight 
      patients with stable CAD were randomly distributed into 3 groups: no antiplatelet 
      drug (patient control, n = 16), aspirin (ASA) monotherapy (n = 16), and combined 
      therapy with ticlopidine (TIC) and ASA (n = 16). RESULTS: There were significant 
      increases in not only adenosine phosphate (ADP)- and collagen-induced platelet 
      aggregation but also in SIPA during exercise by the patient control group. ASA 
      monotherapy did not attenuate the enhanced ADP-induced aggregation nor SIPA. 
      Combined ASA + TIC therapy significantly inhibited SIPA as well as ADP-induced 
      aggregation both before and after exercise. Significant increases in levels of 
      plasma von Willebrand factor (vWF) occurred during exercise, and these 
      antiplatelet therapies had no apparent effect on increased vWF levels during 
      exercise. Exercise induced a significant increase in the plasma 
      thrombin-antithrombin III complex level with no significant changes in the level 
      of plasmin-plasmin inhibitor complex level in all 3 groups. CONCLUSIONS: Combined 
      therapy with ASA + TIC effectively inhibited increased platelet aggregability in 
      response to acute exercise, with no effects on coagulant or fibrinolytic 
      potentials in patients with CAD. The data suggest that TIC combined with ASA may 
      be superior to ASA alone in preventing acute coronary events during exercise in 
      patients with coronary atherosclerotic disease.
FAU - Kitai, T
AU  - Kitai T
AD  - 1st and 2nd Departments of Internal Medicine, Mie University School of Medicine, 
      Tsu, Mie, Japan.
FAU - Nishikawa, M
AU  - Nishikawa M
FAU - Tanigawa, T
AU  - Tanigawa T
FAU - Okinaka, T
AU  - Okinaka T
FAU - Wada, H
AU  - Wada H
FAU - Shiku, H
AU  - Shiku H
FAU - Ikeda, Y
AU  - Ikeda Y
FAU - Ito, M
AU  - Ito M
FAU - Isaka, N
AU  - Isaka N
FAU - Nakano, T
AU  - Nakano T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Adenine Nucleotides)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenine Nucleotides/*blood
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Coronary Disease/blood/*prevention & control
MH  - Coronary Thrombosis/blood/prevention & control
MH  - Drug Administration Schedule
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Ticlopidine/administration & dosage/pharmacology/*therapeutic use
EDAT- 2001/08/02 10:00
MHDA- 2001/08/31 10:01
CRDT- 2001/08/02 10:00
PHST- 2001/08/02 10:00 [pubmed]
PHST- 2001/08/31 10:01 [medline]
PHST- 2001/08/02 10:00 [entrez]
AID - S0002-8703(01)91534-0 [pii]
AID - 10.1067/mhj.2001.116485 [doi]
PST - ppublish
SO  - Am Heart J. 2001 Aug;142(2):E1. doi: 10.1067/mhj.2001.116485.

PMID- 6393886
OWN - NLM
STAT- MEDLINE
DCOM- 19850214
LR  - 20151119
IS  - 0003-9780 (Print)
IS  - 0003-9780 (Linking)
VI  - 272
IP  - 1
DP  - 1984 Nov
TI  - Antiaggregatory efficacy and its time-course after application of acetylsalicylic 
      acid, prostacyclin and nafazatrom in vivo.
PG  - 150-8
AB  - Antiaggregatory potency and time courses of their respective efficacy were 
      assessed for acetylsalicylic acid, prostaglandin (PGI2) and nafazatrom, a 
      stimulator of PGI2-release from endothelial cells, and were compared in vivo. 
      Endothelial cell damage was induced by excitation of intravascular 
      fluoresceinisothio-cycanate-dextran. Time from onset of the noxious stimulus to 
      aggregate appearance (TAA) was assessed and dose-dependently delayed by 
      antithrombotic compounds. PGI2 was two orders of magnitude more effective than 
      nafazatrom, acetylsalicylic acid was three orders of magnitude less effective 
      than nafazatrom. Whereas the antiaggregatory potency of PGI2 decreased after 3.1 
      min to 50%, the antithrombotic efficacy of both, ASA and nafazatrom, further 
      increased after a single bolus injection.
FAU - Herrmann, K S
AU  - Herrmann KS
LA  - eng
PT  - Journal Article
PL  - Belgium
TA  - Arch Int Pharmacodyn Ther
JT  - Archives internationales de pharmacodynamie et de therapie
JID - 0405353
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrazolones)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - K94216221B (nafazatrom)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cricetinae
MH  - Epoprostenol/*pharmacology
MH  - Mesocricetus
MH  - Platelet Aggregation/*drug effects
MH  - Pyrazoles/*pharmacology
MH  - *Pyrazolones
MH  - Time Factors
EDAT- 1984/11/01 00:00
MHDA- 1984/11/01 00:01
CRDT- 1984/11/01 00:00
PHST- 1984/11/01 00:00 [pubmed]
PHST- 1984/11/01 00:01 [medline]
PHST- 1984/11/01 00:00 [entrez]
PST - ppublish
SO  - Arch Int Pharmacodyn Ther. 1984 Nov;272(1):150-8.

PMID- 7370071
OWN - NLM
STAT- MEDLINE
DCOM- 19800627
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 30
IP  - 1
DP  - 1980
TI  - [Influence of phospholipids and their combination with prothrombin complex and 
      calcium ions on coagulation in mice and rabbits both normal and affected by 
      acetylsalicylic acid (author's transl)].
PG  - 30-3
AB  - The influence of phospholipids and their combination with prothrombin and calcium 
      on coagulation both normal and affected by acetylsalicylic acid (ASA) was 
      investigated by determination of the bleeding time of mice, thrombelastographic 
      (TEG) measurements and counting of thrombocytes of rabbits. Bleeding times and 
      times of the TEG were prolonged after oral application of ASA, while thrombus 
      stability was not altered. The number of thrombocytes decreased. Bleeding- and 
      TEG-times normalized after injection of phospholipids. This effect was increased 
      and of longer duration when phospholipids were combined with calcium and 
      prothrombin. Decrease of the number of thrombocytes caused by pretreatment with 
      ASA normalized only after injection of phospholipids together with prothrombin 
      and calcium. The number of thrombocytes was not negatively influenced by the 
      therapy in animals with normal coagulation.
FAU - Ronneberger, H
AU  - Ronneberger H
FAU - Schwinn, H
AU  - Schwinn H
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Der Einfluss der kombinierten Applikation von Phospholipiden, Prothrombin-Komplex 
      und Kalziumionen auf die normale und die durch Acetylsalicylsäure gestörte 
      Blutgerinnung bei Mäusen und Kaninchen.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Phospholipids)
RN  - 9001-26-7 (Prothrombin)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Calcium/*pharmacology
MH  - Drug Interactions
MH  - Mice
MH  - Phospholipids/*pharmacology
MH  - Prothrombin/*physiology
MH  - Rabbits
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1980;30(1):30-3.

PMID- 32192592
OWN - NLM
STAT- MEDLINE
DCOM- 20201002
LR  - 20230315
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Print)
IS  - 0015-0282 (Linking)
VI  - 113
IP  - 3
DP  - 2020 Mar
TI  - Physical activity and incidence of subclinical and clinical pregnancy loss: a 
      secondary analysis in the effects of aspirin in gestation and reproduction 
      randomized trial.
PG  - 601-608.e1
LID - S0015-0282(19)32497-5 [pii]
LID - 10.1016/j.fertnstert.2019.10.027 [doi]
AB  - OBJECTIVE: To estimate the association between physical activity and risk of 
      subclinical and clinical pregnancy loss among women with a history of pregnancy 
      loss. DESIGN: Prospective cohort study as a secondary analysis of the Effects of 
      Aspirin in Gestation and Reproduction randomized controlled trial of 
      preconception-initiated low-dose aspirin among women with one or two prior 
      pregnancy losses. SETTING: Four U.S. clinical centers, 2007-2011. PATIENT(S): 
      Women with confirmed pregnancy (n = 785) as determined from hCG testing in 
      longitudinally collected biospecimens. MAIN OUTCOME MEASURE(S): Subclinical loss 
      of pregnancy detected only by hCG testing and clinically recognized loss. 
      RESULT(S): Among 785 women (mean [SD] age, 28.7 [4.6] years) with an 
      hCG-confirmed pregnancy, 188 (23.9%) experienced pregnancy loss. In multivariable 
      models adjusted for confounders, compared with the first tertile of physical 
      activity (median = 7.7 metabolic equivalent of task hours/week), there was a 
      roughly twofold higher risk of subclinical loss in the second (risk ratio = 2.06; 
      95% confidence interval, 1.03-4.14) and third tertiles (risk ratio = 1.92; 95% 
      confidence interval, 0.94-3.90), with median metabolic equivalent of task 
      hours/week of 27.8 and 95.7, respectively. No relations were observed between 
      physical activity and clinically recognized loss. CONCLUSION(S): Risk related to 
      physical activity is different for pregnancy failure close to the time of 
      implantation compared with that for later, clinical pregnancy loss. Higher 
      physical activity levels were associated with an elevated risk of subclinical 
      loss (i.e., pregnancies detected only by hCG, n = 55); however, no relationship 
      was observed with clinically recognized loss. Further work is required to confirm 
      these findings, assess generalizability to women without prior losses, and 
      evaluate mechanisms. ETHICAL APPROVAL: Each participating center's Institutional 
      Review Board approved the study, and participants provided written informed 
      consent. The trial was registered on ClinicalTrials.gov (NCT00467363), and a Data 
      Safety and Monitoring Board provided oversight.
CI  - Copyright © 2019 American Society for Reproductive Medicine. All rights reserved.
FAU - Russo, Lindsey M
AU  - Russo LM
AD  - Department of Biostatistics and Epidemiology, University of Massachusetts 
      Amherst, Amherst, Massachusetts.
FAU - Whitcomb, Brian W
AU  - Whitcomb BW
AD  - Department of Biostatistics and Epidemiology, University of Massachusetts 
      Amherst, Amherst, Massachusetts. Electronic address: bwhitcom@umass.edu.
FAU - Freeman, Joshua R
AU  - Freeman JR
AD  - Department of Biostatistics and Epidemiology, University of Massachusetts 
      Amherst, Amherst, Massachusetts; Epidemiology Branch, Division of Intramural 
      Population Health Research, Eunice Kennedy Shriver National Institute of Child 
      Health and Human Development, Bethesda, Maryland.
FAU - Mumford, Sunni L
AU  - Mumford SL
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, Maryland.
FAU - Sjaarda, Lindsey A
AU  - Sjaarda LA
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, Maryland.
FAU - Perkins, Neil J
AU  - Perkins NJ
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, Maryland.
FAU - Schliep, Karen C
AU  - Schliep KC
AD  - Department of Family and Preventive Medicine, University of Utah Health, Salt 
      Lake City, Utah.
FAU - Grewal, Jagteshwar
AU  - Grewal J
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, Maryland.
FAU - Silver, Robert M
AU  - Silver RM
AD  - Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake 
      City, Utah.
FAU - Schisterman, Enrique F
AU  - Schisterman EF
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 
      Bethesda, Maryland.
LA  - eng
SI  - ClinicalTrials.gov/NCT00467363
GR  - K01 AG058781/AG/NIA NIH HHS/United States
GR  - L50 HD099868/HD/NICHD NIH HHS/United States
GR  - Z01 HD008795/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Spontaneous/*epidemiology/etiology
MH  - Adolescent
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Asymptomatic Diseases
MH  - Cohort Studies
MH  - Exercise/*physiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Infant, Newborn
MH  - Preconception Care/*methods
MH  - Pregnancy/*drug effects
MH  - Pregnancy Complications/prevention & control
MH  - Pregnancy Outcome
MH  - Reproduction/*drug effects
MH  - Risk Factors
MH  - Young Adult
PMC - PMC7994027
MID - NIHMS1679832
OTO - NOTNLM
OT  - Physical activity
OT  - biospecimen
OT  - epidemiology
OT  - longitudinal
OT  - pregnancy loss
EDAT- 2020/03/21 06:00
MHDA- 2020/10/03 06:00
CRDT- 2020/03/21 06:00
PHST- 2019/07/03 00:00 [received]
PHST- 2019/09/04 00:00 [revised]
PHST- 2019/10/13 00:00 [accepted]
PHST- 2020/03/21 06:00 [entrez]
PHST- 2020/03/21 06:00 [pubmed]
PHST- 2020/10/03 06:00 [medline]
AID - S0015-0282(19)32497-5 [pii]
AID - 10.1016/j.fertnstert.2019.10.027 [doi]
PST - ppublish
SO  - Fertil Steril. 2020 Mar;113(3):601-608.e1. doi: 10.1016/j.fertnstert.2019.10.027.

PMID- 21327512
OWN - NLM
STAT- MEDLINE
DCOM- 20110624
LR  - 20211020
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 31
IP  - 3
DP  - 2011 Apr
TI  - Antiplatelet agents in cardiovascular disease.
PG  - 306-9
LID - 10.1007/s11239-011-0558-9 [doi]
AB  - Despite improvements in the treatment of acute coronary syndromes (ACS), 
      cardiovascular disease remains the leading cause of death in the United States. 
      Antiplatelet agents, such as aspirin and clopidogrel, play an important role in 
      the treatment of patients with ACS, particularly those at high risk for whom 
      treatment may yield the greatest benefits. The main challenge in preventing and 
      managing ACS is to tailor treatment for each patient by taking into consideration 
      patient characteristics, comorbidities, underlying short- and long-term risk 
      factors, ischemic and bleeding risks, and expected individual responses to 
      different medications. Several new alternatives providing more rapid and 
      consistent platelet inhibition than aspirin and clopidogrel have been introduced 
      for routine treatment of patients with ACS. These new treatments seem to provide 
      additional benefits without a significant increase in the risk of bleeding, if 
      used for the appropriate patients. In this article, we review the new 
      antiplatelet agents being developed as well as their pharmacological 
      characteristics, potential clinical indications, and key interactions with other 
      antithrombotic drugs.
FAU - Lopes, Renato D
AU  - Lopes RD
AD  - Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 2400 
      Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA. 
      renato.lopes@duke.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/mortality
MH  - Clopidogrel
MH  - Hemorrhage/chemically induced/mortality
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - United States
EDAT- 2011/02/18 06:00
MHDA- 2011/06/28 06:00
CRDT- 2011/02/18 06:00
PHST- 2011/02/18 06:00 [entrez]
PHST- 2011/02/18 06:00 [pubmed]
PHST- 2011/06/28 06:00 [medline]
AID - 10.1007/s11239-011-0558-9 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2011 Apr;31(3):306-9. doi: 10.1007/s11239-011-0558-9.

PMID- 11544947
OWN - NLM
STAT- MEDLINE
DCOM- 20011025
LR  - 20190921
IS  - 0017-8470 (Print)
IS  - 0017-8470 (Linking)
VI  - 52
IP  - 8
DP  - 2001 Aug
TI  - [Malignant atrophic papulosis (Köhlmeier-Degos): diagnosis, therapy and course].
PG  - 734-7
AB  - A 71-year-old male patient presented with malignant atrophic papulosis 
      (Köhlmeier-Degos disease). He developed multiple distinctive cutaneous lesions. 
      The histopathological findings showed an obliterated arteriole with a 
      wedge-shaped area of ulcerated and necrobiotic dermis. Laboratory tests were 
      within normal limits or not specific. Although the involvement of the 
      gastrointestinal tract and other organs has been noted in approximately 60% of 
      the reported cases, in this patient so far the skin seems to be the only involved 
      site. There is no proven effective therapy for Köhlmeier-Degos disease. In our 
      case treatment with pentoxifylline and aspirin led to healing of all skin lesions 
      within 3 months. One year after beginning treatment, the patient showed neither 
      new cutaneous lesions, nor any signs of systemic involvement. The combination of 
      pentoxifylline and aspirin should be considered when planning treatment 
      strategies for malignant atrophic papulosis.
FAU - Vicktor, C
AU  - Vicktor C
AD  - Dermatologische Klinik des Klinikum Buch, Berlin.
FAU - Schultz-Ehrenburg, U
AU  - Schultz-Ehrenburg U
LA  - ger
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Papulosis maligna atrophicans (Köhlmeier-Degos). Diagnose, Therapie, Verlauf.
PL  - Germany
TA  - Hautarzt
JT  - Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
JID - 0372755
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/administration & dosage/therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Pentoxifylline/administration & dosage/therapeutic use
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Skin/pathology
MH  - *Skin Diseases, Papulosquamous/diagnosis/drug therapy/pathology
MH  - Syndrome
MH  - Time Factors
EDAT- 2001/09/08 10:00
MHDA- 2001/10/26 10:01
CRDT- 2001/09/08 10:00
PHST- 2001/09/08 10:00 [pubmed]
PHST- 2001/10/26 10:01 [medline]
PHST- 2001/09/08 10:00 [entrez]
AID - 10.1007/s001050170092 [doi]
PST - ppublish
SO  - Hautarzt. 2001 Aug;52(8):734-7. doi: 10.1007/s001050170092.

PMID- 1744989
OWN - NLM
STAT- MEDLINE
DCOM- 19920116
LR  - 20190725
IS  - 0021-5198 (Print)
IS  - 0021-5198 (Linking)
VI  - 56
IP  - 4
DP  - 1991 Aug
TI  - A reliable method for the production of antral gastric ulcer by a combination of 
      2-deoxy-D-glucose, aspirin and ammonia in rats.
PG  - 475-81
AB  - In order to establish a reliable method for the production of gastric antral 
      ulcer in rats, combined treatments with three factors: a vagal stimulant, a 
      mucosal barrier breaker and a necrotizing agent were investigated. By the 
      combined administration of 2-deoxy-D-glucose (2-DG; 200 mg/kg, i.v.), aspirin 
      (100-400 mg/kg, p.o.) and hydrochloric acid (0.15 and 0.35 N, 0.5-1.5 ml/100 g, 
      p.o.) or ammonia solution (0.5-1.0%, 0.5-1.5 ml/100 g, p.o.), gastric lesions 
      were prominently induced in sites of both the corpus and antrum on day 2. The 
      largest antral ulcer was induced by the combination of 2-DG (200 mg/kg), aspirin 
      (200 mg/kg) and ammonia solution (1%, 10 ml/kg); and the mean antral ulcer index 
      (mm2) was 43.1 +/- 4.4 and the incidence was 100%. The antral ulcer was found to 
      penetrate the muscularis mucosae and still observed on day 21 and day 28 after 
      ulcer induction in a few cases. From these findings, it was indicated that this 
      antral ulcer would be a useful model for studying the etiology and therapy of 
      gastric ulcer disease.
FAU - Uchida, M
AU  - Uchida M
AD  - Department of Drug Evaluation and Toxicological Sciences, Faculty of 
      Pharmaceutical Sciences, Chiba University, Japan.
FAU - Yano, S
AU  - Yano S
FAU - Watanabe, K
AU  - Watanabe K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Jpn J Pharmacol
JT  - Japanese journal of pharmacology
JID - 2983305R
RN  - 7664-41-7 (Ammonia)
RN  - 9G2MP84A8W (Deoxyglucose)
RN  - QTT17582CB (Hydrochloric Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Ammonia/administration & dosage/*toxicity
MH  - Animals
MH  - Aspirin/administration & dosage/*toxicity
MH  - Deoxyglucose/administration & dosage/*toxicity
MH  - *Disease Models, Animal
MH  - Drug Interactions
MH  - Hydrochloric Acid/administration & dosage/*toxicity
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach Ulcer/*chemically induced
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
AID - 10.1254/jjp.56.475 [doi]
PST - ppublish
SO  - Jpn J Pharmacol. 1991 Aug;56(4):475-81. doi: 10.1254/jjp.56.475.

PMID- 18798121
OWN - NLM
STAT- MEDLINE
DCOM- 20081113
LR  - 20191111
IS  - 1097-9867 (Electronic)
IS  - 1083-7450 (Linking)
VI  - 13
IP  - 5
DP  - 2008
TI  - Quality control of multi-component, intact pharmaceutical tablets with three 
      different near-infrared apparatuses.
PG  - 333-43
LID - 10.1080/10837450802390232 [doi]
AB  - The purpose of this study was to develop a robust and versatile near infrared 
      (NIR) analysis protocol for the quality control of intact tablets containing two 
      active pharmaceutical ingredients, acetylsalicylic acid (ASA) and caffeine, as 
      well as three excipients. Reference samples were prepared and a calibration model 
      built for each apparatus. All components of the formulation were characterized by 
      transmission measurements with NIR spectroscopy (NIRS). The study was performed 
      with three different Fourier transform NIR apparatuses and chemometric models. 
      Calibration was carried out by the partial least squares regression method and a 
      pre-processing technique to optimize the efficiency of the models. High 
      performance liquid chromatography was the reference method for obtaining active 
      pharmaceutical ingredient concentration values used in model building. It also 
      served as a reference for chemometric model validation. Eighteen samples were 
      analyzed by chemometric modeling to predict each component's concentration. Four 
      out of five ingredients were quantified precisely with the three chemometric 
      models developed. ASA quantification uncertainty ranges were between 1.0 and 
      1.1%, and the average error was less than 5% for caffeine. More than 99.9% of 
      tablet content were analyzed and quantified. The results show that a versatile 
      in-line or at-line NIRS method, with three different chemometric models built 
      from three different acquisition apparatuses, can be developed without sample 
      preparation for pharmaceutical tablet quality control of existing products.
FAU - Cournoyer, A
AU  - Cournoyer A
AD  - Université de Montréal, Faculty of Pharmacy, Montreal, Quebec.
FAU - Simard, J-S
AU  - Simard JS
FAU - Cartilier, L
AU  - Cartilier L
FAU - Abatzoglou, N
AU  - Abatzoglou N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharm Dev Technol
JT  - Pharmaceutical development and technology
JID - 9610932
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/analysis/chemistry
MH  - Aspirin/*analysis/chemistry
MH  - Caffeine/*analysis/chemistry
MH  - Central Nervous System Stimulants/analysis/chemistry
MH  - Chromatography, High Pressure Liquid/methods
MH  - Excipients/chemistry
MH  - Least-Squares Analysis
MH  - Quality Control
MH  - Spectroscopy, Fourier Transform Infrared/*methods
MH  - Spectroscopy, Near-Infrared/*methods
MH  - Tablets
MH  - Technology, Pharmaceutical/methods
EDAT- 2008/09/18 09:00
MHDA- 2008/11/14 09:00
CRDT- 2008/09/18 09:00
PHST- 2008/09/18 09:00 [pubmed]
PHST- 2008/11/14 09:00 [medline]
PHST- 2008/09/18 09:00 [entrez]
AID - 902500427 [pii]
AID - 10.1080/10837450802390232 [doi]
PST - ppublish
SO  - Pharm Dev Technol. 2008;13(5):333-43. doi: 10.1080/10837450802390232.

PMID- 10644618
OWN - NLM
STAT- MEDLINE
DCOM- 20000621
LR  - 20200930
IS  - 0363-6119 (Print)
IS  - 0363-6119 (Linking)
VI  - 278
IP  - 1
DP  - 2000 Jan
TI  - Systemic hemodynamics and renal function in hemorrhaged dogs resuscitated with 
      cross-linked hemoglobin.
PG  - R28-33
AB  - Cross-linked hemoglobin (XL-Hb) infused into dogs increases mean arterial 
      pressure (MAP) but decreases blood flow to the renal (RBF), mesenteric (MBF), and 
      iliac (IBF) circulations. These actions differ markedly from dextran infusion 
      (which increases RBF, MBF, and IBF without altering MAP) and may be due to 
      scavenging of nitric oxide by XL-Hb. However, because the hormonal milieu 
      regulating regional circulation is altered during hemorrhage (when XL-Hb may be 
      used), we studied whether systemic hemodynamics, RBF, MBF, IBF, and renal 
      excretory function in hemorrhaged dogs was altered when resuscitated with XL-Hb 
      compared with dextran (n = 6 each). Hemorrhage decreased MAP by 25% due to a 75% 
      decline in cardiac output. RBF, MBF, and IBF all fell by 33, 64, and 72%, 
      respectively (P<0.05 each). There was also a fall in glomerular filtration rate 
      (GFR), urinary flow, and sodium excretion (P<0.05 each). After resuscitation, 
      MAP, cardiac output, RBF, MBF, IBF, and GFR all recovered to basal values with 
      either XL-Hb or dextran. Urinary flow and sodium excretion increased to above 
      basal levels with dextran (both by 3.5-fold; P<0.05) or XL-Hb (by 7.5- and 
      10-fold, respectively; P<0.05). We conclude that resuscitation with XL-Hb after 
      hemorrhage not only increases MAP, but also restores RBF, MBF, IBF, GFR, and 
      urinary sodium and volume excretion analogously to dextran. The results contrast 
      with those in normal dogs and suggest that nitric oxide inhibition does not 
      impair hemodynamic and renal function recovery during hemorrhage.
FAU - Stulak, J M
AU  - Stulak JM
AD  - Department of Physiology and Biophysics and Divisions of Hypertension and 
      Nephrology, Mayo School of Medicine, Mayo Clinic, Rochester, Minnesota 55905, 
      USA.
FAU - Juncos, L A
AU  - Juncos LA
FAU - Haas, J A
AU  - Haas JA
FAU - Romero, J C
AU  - Romero JC
LA  - eng
GR  - HL-16496/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol Regul Integr Comp Physiol
JT  - American journal of physiology. Regulatory, integrative and comparative 
      physiology
JID - 100901230
RN  - 0 (Dextrans)
RN  - 0 (Hemoglobins)
RN  - 0 (Plasma Substitutes)
RN  - 0 (hemoglobin XL99alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Cardiovascular System/drug effects
MH  - Dextrans/therapeutic use
MH  - Diuresis/drug effects
MH  - Dogs
MH  - Hemodynamics/*drug effects
MH  - Hemoglobins/*therapeutic use
MH  - Hemorrhage/*physiopathology/*therapy
MH  - Ilium/blood supply
MH  - Kidney/*drug effects/*physiopathology
MH  - Natriuresis/drug effects
MH  - Plasma Substitutes/therapeutic use
MH  - Regional Blood Flow/drug effects
MH  - Renal Circulation/drug effects
MH  - *Resuscitation
MH  - Splanchnic Circulation/drug effects
EDAT- 2000/01/25 09:00
MHDA- 2000/06/24 11:00
CRDT- 2000/01/25 09:00
PHST- 2000/01/25 09:00 [pubmed]
PHST- 2000/06/24 11:00 [medline]
PHST- 2000/01/25 09:00 [entrez]
AID - 10.1152/ajpregu.2000.278.1.R28 [doi]
PST - ppublish
SO  - Am J Physiol Regul Integr Comp Physiol. 2000 Jan;278(1):R28-33. doi: 
      10.1152/ajpregu.2000.278.1.R28.

PMID- 9920356
OWN - NLM
STAT- MEDLINE
DCOM- 19990322
LR  - 20191021
IS  - 0785-3890 (Print)
IS  - 0785-3890 (Linking)
VI  - 30
IP  - 6
DP  - 1998 Dec
TI  - Increased tendency towards gingival bleeding caused by joint effect of 
      alpha-tocopherol supplementation and acetylsalicylic acid.
PG  - 542-6
LID - 10.3109/07853899709002602 [doi]
AB  - Alpha-tocopherol (vitamin E) may play a role in the treatment of arterial 
      thromboembolic disease, possibly by inhibiting platelet aggregation. Thus far, no 
      clinical evidence exists for this effect. The objective of this study was to 
      assess the effect of alpha-tocopherol supplementation on gingival bleeding either 
      in combination with acetylsalicylic acid (ASA) or without it. This study was an 
      end-point examination of a random sample of male smokers who had participated in 
      a controlled clinical trial, the Alpha-Tocopherol, Beta-Carotene Cancer 
      Prevention Study (ATBC Study) for 5-7 years. The study included 409 men aged 
      55-74 years of whom 191 received alpha-tocopherol supplementation (50 mg/day); 56 
      used ASA, 30 received both and 132 received neither. Gingival bleeding was 
      examined by probing with a WHO probe and reported as a percentage of bleeding 
      sites adjusted by the logistic regression model. Gingival bleeding was more 
      common in those who received alpha-tocopherol compared with nonreceivers among 
      subjects with a high prevalence of dental plaque (P < 0.05). ASA alone increased 
      bleeding only slightly. The highest risk of gingival bleeding was among those who 
      took both alpha-tocopherol and ASA (33.4% of probed sites bleeding vs 25.8% among 
      subjects taking neither alpha-tocopherol nor ASA, P < 0.001). In the ATBC Study, 
      more deaths from haemorrhagic stroke and fewer from ischaemic heart disease were 
      observed among those participants who received alpha-tocopherol compared with 
      those who did not. Based on the results of the present study and the ATBC Study, 
      we conclude that alpha-tocopherol supplementation may increase the risk of 
      clinically important bleedings, particularly when combined with ASA.
FAU - Liede, K E
AU  - Liede KE
AD  - Institute of Dentistry, University of Helsinki, Finland. 
      kliede@hammas.helsinki.fi
FAU - Haukka, J K
AU  - Haukka JK
FAU - Saxén, L M
AU  - Saxén LM
FAU - Heinonen, O P
AU  - Heinonen OP
LA  - eng
GR  - 1-CN-45165/CN/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 01YAE03M7J (beta Carotene)
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Humans
MH  - Lung Neoplasms/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Periodontal Index
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Random Allocation
MH  - Vitamin E/*adverse effects/therapeutic use
MH  - beta Carotene/therapeutic use
EDAT- 1999/01/27 00:00
MHDA- 1999/01/27 00:01
CRDT- 1999/01/27 00:00
PHST- 1999/01/27 00:00 [pubmed]
PHST- 1999/01/27 00:01 [medline]
PHST- 1999/01/27 00:00 [entrez]
AID - 10.3109/07853899709002602 [doi]
PST - ppublish
SO  - Ann Med. 1998 Dec;30(6):542-6. doi: 10.3109/07853899709002602.

PMID- 8784132
OWN - NLM
STAT- MEDLINE
DCOM- 19961112
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 27
IP  - 9
DP  - 1996 Sep
TI  - Combined neuroprotection and reperfusion therapy for stroke. Effect of lubeluzole 
      and diaspirin cross-linked hemoglobin in experimental focal ischemia.
PG  - 1571-6; discussion 1576-7
AB  - BACKGROUND AND PURPOSE: In search of a better treatment for acute ischemic 
      stroke, we evaluated the use of lubeluzole and hemodilution with diaspirin 
      cross-linked hemoglobin (DCLHb) therapy to test whether treatment with two 
      complementary acting compounds provides more potent protection than either 
      treatment alone. METHODS: We used unilateral reversible middle cerebral artery 
      (MCA) and common carotid artery (CCA) occlusion of various durations in 
      Long-Evans rats to produce ischemic cortical lesions. We calculated the average 
      maximal lesion volume (Volmax) and the time required to produce half maximal 
      lesion size (T50) in control animals (n = 31) and evaluated the effects on 
      cerebral perfusion and infarct size of treatment with lubeluzole (n = 23), 
      hemodilution (to 30% hematocrit) with albumin (n = 17) or DCLHb (n = 23), and 
      combined lubeluzole + DCLHb therapy initiated 15 minutes after MCA/CCA occlusion. 
      RESULTS: The Volmax produced by MCA/CCA occlusion in control animals was 138.5 
      +/- 7.7 mm3, and T50 was 98.5 +/- 10.2 minutes. Lubeluzole alone reduced Volmax 
      by 53% with no significant effect on T50. In contrast to lubeluzole, DCLHb 
      hemodilution prolonged T50 by 68% with no significant effect on Volmax. 
      Prolongation of T50 by DCLHb was not due to hemodilution itself, since a similar 
      degree of hemodilution with albumin had no effect. Finally, combined 
      lubeluzole+DCLHb rescued 72% of the tissue and augmented the effect of lubeluzole 
      alone by 40% (Volmax, 66.3 +/- 13.0 versus 39.4 +/- 12.2 mm3) while prolonging 
      T50 by 31%. CONCLUSIONS: Combination therapy for acute stroke using compounds 
      with complementary action can result in more complete attenuation of neuronal 
      damage and demonstrates the possible clinical utility of combined neuroprotective 
      and reperfusion therapies.
FAU - Aronowski, J
AU  - Aronowski J
AD  - Department of Neurology, University of Texas Medical School, Houston 77030, USA.
FAU - Strong, R
AU  - Strong R
FAU - Grotta, J C
AU  - Grotta JC
LA  - eng
GR  - NS-23979/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Hemoglobins)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Piperidines)
RN  - 0 (Thiazoles)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - V2SIB71583 (lubeluzole)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Cardiovascular Agents/*therapeutic use
MH  - Cerebral Infarction/pathology
MH  - Cerebrovascular Disorders/blood/*therapy
MH  - Drug Therapy, Combination
MH  - Hemodilution
MH  - Hemoglobins/*therapeutic use
MH  - Male
MH  - Neuroprotective Agents/*therapeutic use
MH  - Piperidines/*therapeutic use
MH  - Rats
MH  - Rats, Inbred Strains
MH  - *Reperfusion
MH  - Thiazoles/*therapeutic use
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - 10.1161/01.str.27.9.1571 [doi]
PST - ppublish
SO  - Stroke. 1996 Sep;27(9):1571-6; discussion 1576-7. doi: 10.1161/01.str.27.9.1571.

PMID- 3170419
OWN - NLM
STAT- MEDLINE
DCOM- 19881122
LR  - 20171213
IS  - 8750-7587 (Print)
IS  - 0161-7567 (Linking)
VI  - 65
IP  - 2
DP  - 1988 Aug
TI  - Effects of increased pulmonary vascular tone on gas exchange in canine oleic acid 
      pulmonary edema.
PG  - 662-8
AB  - Pulmonary gas exchange was investigated before and after an increase in pulmonary 
      vascular tone induced by administration of acetylsalicylic acid (ASA), 
      indomethacin, or almitrine in 32 pentobarbital-anesthetized and ventilated 
      (fraction of inspired O2 0.4) dogs with oleic acid lung injury. Pulmonary 
      vascular tone was evaluated by five-point pulmonary arterial pressure 
      (PAP)/cardiac index (Q) plots and intrapulmonary shunt was measured using a SF6 
      infusion. PAP/Q plots were rectilinear in all experimental conditions. In control 
      dogs (n = 8), oleic acid (0.09 ml/kg iv) increased PAP over the range of Q 
      studied (1-5 l.min-1.m-2). At the same Q, arterial PO2 fell from 186 +/- 11 to 65 
      +/- 8 (SE) Torr and intrapulmonary shunt rose from 5 +/- 1 to 50 +/- 6% 90 min 
      after oleic acid injection. These changes remained stable during the generation 
      of two consecutive PAP/Q plots. ASA (1 g iv, n = 8), indomethacin (2 mg/kg iv, n 
      = 8), and almitrine (8 micrograms.kg-1.min-1 iv, n = 8) produced a further 
      increase in PAP at each level of Q. ASA and indomethacin, respectively, increased 
      arterial PO2 from 61 +/- 4 to 70 +/- 3 Torr (P less than 0.05) and from 70 +/- 6 
      to 86 +/- 6 Torr (P less than 0.05) and decreased intrapulmonary shunt from 61 
      +/- 5 to 44 +/- 4% (P less than 0.05) and from 44 +/- 5 to 29 +/- 4% (P less than 
      0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Leeman, M
AU  - Leeman M
AD  - Respiratory Research Unit, Erasme University Hospital, Brussels, Belgium.
FAU - Lejeune, P
AU  - Lejeune P
FAU - Hallemans, R
AU  - Hallemans R
FAU - Mélot, C
AU  - Mélot C
FAU - Naeije, R
AU  - Naeije R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Appl Physiol (1985)
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
RN  - 0 (Oleic Acids)
RN  - 0 (Piperazines)
RN  - 2UMI9U37CP (Oleic Acid)
RN  - 9A1222NBG4 (Almitrine)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Almitrine
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Gas Analysis
MH  - Blood Pressure
MH  - Cardiac Output
MH  - Dogs
MH  - Indomethacin/pharmacology
MH  - Lung/*blood supply/drug effects/physiopathology
MH  - Oleic Acid
MH  - Oleic Acids
MH  - Oxygen/blood
MH  - Piperazines/pharmacology
MH  - Pulmonary Edema/chemically induced/*physiopathology
MH  - *Pulmonary Gas Exchange
MH  - Vascular Resistance/drug effects
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
AID - 10.1152/jappl.1988.65.2.662 [doi]
PST - ppublish
SO  - J Appl Physiol (1985). 1988 Aug;65(2):662-8. doi: 10.1152/jappl.1988.65.2.662.

PMID- 29412449
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20191210
IS  - 1365-2168 (Electronic)
IS  - 0007-1323 (Linking)
VI  - 105
IP  - 4
DP  - 2018 Mar
TI  - Use of aspirin and bleeding-related complications after hepatic resection.
PG  - 429-438
LID - 10.1002/bjs.10697 [doi]
AB  - BACKGROUND: The operative risk of hepatectomy under antiplatelet therapy is 
      unknown. This study sought to assess the outcomes of elective hepatectomy 
      performed with or without aspirin continuation in a well balanced matched cohort. 
      METHODS: Data were retrieved from a multicentre prospective observational study. 
      Aspirin and control groups were compared by non-standardized methods and by 
      propensity score (PS) matching analysis. The main outcome was severe 
      (Dindo-Clavien grade IIIa or more) haemorrhage. Other outcomes analysed were 
      intraoperative transfusion, overall haemorrhage, major morbidity, comprehensive 
      complication index (CCI) score, thromboembolic complications, ischaemic 
      complications and mortality. RESULTS: Before matching, there were 118 patients in 
      the aspirin group and 1685 in the control group. ASA fitness grade, 
      cardiovascular disease, previous history of angina pectoris, angioplasty, 
      diabetes, use of vitamin K antagonists, cirrhosis and type of hepatectomy were 
      significantly different between the groups. After PS matching, 108 patients were 
      included in each group. There were no statistically significant differences 
      between the aspirin and control groups in severe haemorrhage (6·5 versus 5·6 per 
      cent respectively; odds ratio (OR) 1·18, 95 per cent c.i. 0·38 to 3·62), 
      intraoperative transfusion (23·4 versus 23·7 per cent; OR 0·98, 0·51 to 1·87), 
      overall haemorrhage (10·2 versus 12·0 per cent; OR 0·83, 0·35 to 1·94), CCI score 
      (24 versus 28; P = 0·520), major complications (23·1 versus 13·9 per cent; OR 
      1·82, 0·92 to 3·79) and 90-day mortality (5·6 versus 4·6 per cent; OR 1·21, 0·36 
      to 4·09). CONCLUSION: This observational study suggested that aspirin 
      continuation is not associated with a higher rate of bleeding-related 
      complications after elective hepatic surgery.
CI  - © 2018 BJS Society Ltd Published by John Wiley & Sons Ltd.
FAU - Gelli, M
AU  - Gelli M
AUID- ORCID: 0000-0001-9807-4021
AD  - Centre Hépato-Biliaire, Assistance Publique - Hôpitaux de Paris (AP-HP) Hôpital 
      Paul-Brousse, Villejuif, France.
FAU - Allard, M A
AU  - Allard MA
AD  - Centre Hépato-Biliaire, Assistance Publique - Hôpitaux de Paris (AP-HP) Hôpital 
      Paul-Brousse, Villejuif, France.
AD  - Institut National de la Santé et de la Recherche Médicale, Unité 1193, Université 
      Paris-Saclay, Villejuif, France.
AD  - Université Paris-Sud, Unité Mixte de Recherche (UMR)-S 1193, Université 
      Paris-Saclay, Villejuif, France.
FAU - Farges, O
AU  - Farges O
AD  - Département de Chirurgie Hépato-pancréato-biliaire, AP-HP Hôpital Beaujon, 
      Clichy, France.
FAU - Paugam-Burtz, C
AU  - Paugam-Burtz C
AD  - Département d'Anesthésie et Réanimation, AP-HP Hôpital Beaujon, Clichy, France.
FAU - Mabrut, J Y
AU  - Mabrut JY
AD  - Département de Chirurgie Générale et Digestive et de la Transplantation Hépatique 
      et Intestinale, Hôpital de la Croix-Rousse, Lyon, France.
FAU - Regimbeau, J M
AU  - Regimbeau JM
AUID- ORCID: 0000-0001-9908-8265
AD  - Département de Chirurgie Digestive, Centre Hospitalier Universitaire (CHU) 
      Amiens-Picardie, Amiens, France.
FAU - Vibert, E
AU  - Vibert E
AD  - Centre Hépato-Biliaire, Assistance Publique - Hôpitaux de Paris (AP-HP) Hôpital 
      Paul-Brousse, Villejuif, France.
AD  - Institut National de la Santé et de la Recherche Médicale, Unité 1193, Université 
      Paris-Saclay, Villejuif, France.
AD  - Université Paris-Sud, Unité Mixte de Recherche (UMR)-S 1193, Université 
      Paris-Saclay, Villejuif, France.
FAU - Boleslawski, E
AU  - Boleslawski E
AUID- ORCID: 0000-0003-3286-8608
AD  - Université Lille, Centre National de la Recherche Scientifique, Service de 
      Chirurgie Digestive et Transplantations, CHU Lille, UMR8161, Lille, France.
CN  - Association de Chirurgie Hepato-Biliaire et de Transplantation Hépatique 
      (ACHBT)-French Hepatectomy Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20180207
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Loss, Surgical
MH  - Drug Administration Schedule
MH  - *Elective Surgical Procedures
MH  - Female
MH  - Follow-Up Studies
MH  - *Hepatectomy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Perioperative Care/*adverse effects/methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Postoperative Hemorrhage/*chemically induced/epidemiology
MH  - Prospective Studies
FIR - Adam, R
IR  - Adam R
FIR - Aussilhou, B
IR  - Aussilhou B
FIR - Badaoui, R
IR  - Badaoui R
FIR - Bonnet, A
IR  - Bonnet A
FIR - Castaing, D
IR  - Castaing D
FIR - Cherqui, D
IR  - Cherqui D
FIR - Cosse, C
IR  - Cosse C
FIR - Darnis, B
IR  - Darnis B
FIR - Dokmak, S
IR  - Dokmak S
FIR - Dondero, F
IR  - Dondero F
FIR - Fulbert, M
IR  - Fulbert M
FIR - Gazon, M
IR  - Gazon M
FIR - Klapisz, L
IR  - Klapisz L
FIR - Lebuffe, G
IR  - Lebuffe G
FIR - M'ba, L
IR  - M'ba L
FIR - Millet, G
IR  - Millet G
FIR - Mohkam, K
IR  - Mohkam K
FIR - Nguyen, M
IR  - Nguyen M
FIR - Pham, V H
IR  - Pham VH
FIR - Pruvot, F-R
IR  - Pruvot FR
FIR - Antonios, R
IR  - Antonios R
FIR - Sa Cunha, A
IR  - Sa Cunha A
FIR - Soubrane, O
IR  - Soubrane O
FIR - Truant, S
IR  - Truant S
EDAT- 2018/02/08 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/02/08 06:00
PHST- 2017/04/22 00:00 [received]
PHST- 2017/07/08 00:00 [revised]
PHST- 2017/08/22 00:00 [accepted]
PHST- 2018/02/08 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/02/08 06:00 [entrez]
AID - 10.1002/bjs.10697 [doi]
PST - ppublish
SO  - Br J Surg. 2018 Mar;105(4):429-438. doi: 10.1002/bjs.10697. Epub 2018 Feb 7.

PMID- 2575690
OWN - NLM
STAT- MEDLINE
DCOM- 19900307
LR  - 20190828
IS  - 0378-8741 (Print)
IS  - 0378-8741 (Linking)
VI  - 27
IP  - 1-2
DP  - 1989 Nov
TI  - Effects of cryptolepine alone and in combination with dipyridamole on a mouse 
      model of arterial thrombosis.
PG  - 141-8
AB  - The effects of cryptolepine alone and in combination with other antiplatelet 
      agents have been investigated using a mouse model of arterial thrombosis. 
      Intraperitoneal premedication with crytolepine produced 25% maximal protection at 
      1 mg/kg while dipyridamole producedd a 20% maximal effect at 2 mg/kg. Higher 
      doses of cryptolepine showed a reduced effect. In contrast, indomethacin and 
      aspirin produced a dose-related and higher degree of protection. A combination of 
      cryptolepine and dipyridamole was more effective than when the individual drugs 
      were used alone. The use of 20% ethanol as a dosage vehicle enhanced the 
      protective effects of all drugs tested and the ethanol vehicle alone provided 45% 
      protection.
FAU - Oyekan, A O
AU  - Oyekan AO
AD  - Department of Pharmacology, College of Medicine, University of Lagos, Nigeria.
FAU - Okafor, J P
AU  - Okafor JP
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Alkaloids)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Indole Alkaloids)
RN  - 0 (Indoles)
RN  - 0 (Quinolines)
RN  - 480-26-2 (cryptolepine)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adrenergic alpha-Antagonists/*pharmacology
MH  - Alkaloids/*pharmacology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Dipyridamole/*pharmacology
MH  - *Fibrinolytic Agents
MH  - Indole Alkaloids
MH  - *Indoles
MH  - Indomethacin/pharmacology
MH  - Male
MH  - Mice
MH  - *Quinolines
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
AID - 0378-8741(89)90086-X [pii]
AID - 10.1016/0378-8741(89)90086-x [doi]
PST - ppublish
SO  - J Ethnopharmacol. 1989 Nov;27(1-2):141-8. doi: 10.1016/0378-8741(89)90086-x.

PMID- 4020652
OWN - NLM
STAT- MEDLINE
DCOM- 19850925
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 74
IP  - 6
DP  - 1985 Jun
TI  - Effect of molecular structure variation on the disintegrant action of sodium 
      starch glycolate.
PG  - 647-50
AB  - The effect of variation in the degree of cross-linkage and extent of 
      carboxymethylation on the disintegration and dissolution properties of sodium 
      starch glycolate has been examined. Samples of sodium starch glycolate were 
      evaluated for particle size distributions and bulk and tapped densities. The bulk 
      powders were also tested for sedimentation volumes, water uptake, and bulk 
      swelling. Direct compression formulations containing aspirin and 
      hydrochlorothiazide and varying concentrations of the modified starches were 
      tableted on a rotary tablet press and evaluated for weight variation, hardness, 
      disintegration, and dissolution. The results indicate that relatively small 
      changes in molecular structure can cause substantial modification of disintegrant 
      properties and suggest that the specifications for one commercially available 
      sodium starch glycolate are within optimal specifications for both cross-linkage 
      and degree of substitution.
FAU - Rudnic, E M
AU  - Rudnic EM
FAU - Kanig, J L
AU  - Kanig JL
FAU - Rhodes, C T
AU  - Rhodes CT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Excipients)
RN  - 0 (Glycolates)
RN  - 0 (Tablets)
RN  - 059QF0KO0R (Water)
RN  - 0J48LPH2TH (Hydrochlorothiazide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Drug Compounding
MH  - Excipients
MH  - *Glycolates
MH  - Hardness Tests
MH  - Hydrochlorothiazide
MH  - Solubility
MH  - Tablets
MH  - Temperature
MH  - Water
EDAT- 1985/06/01 00:00
MHDA- 1985/06/01 00:01
CRDT- 1985/06/01 00:00
PHST- 1985/06/01 00:00 [pubmed]
PHST- 1985/06/01 00:01 [medline]
PHST- 1985/06/01 00:00 [entrez]
AID - S0022-3549(15)46738-3 [pii]
AID - 10.1002/jps.2600740613 [doi]
PST - ppublish
SO  - J Pharm Sci. 1985 Jun;74(6):647-50. doi: 10.1002/jps.2600740613.

PMID- 377471
OWN - NLM
STAT- MEDLINE
DCOM- 19790829
LR  - 20191028
IS  - 0301-3847 (Print)
IS  - 0301-3847 (Linking)
IP  - 27
DP  - 1979
TI  - Clinical comparison of fenbufen and aspirin in osteoarthritis.
PG  - 1-7
AB  - The objective of the study was to compare efficacy and safety of Fenbufen and 
      Aspirin in osteoarthritis. The study was a double-blind, randomized trial with 
      crossover. The test subjects were treated for 4 weeks with 600 mg Fenbufen and 
      for 4 weeks with 3.6 g Aspirin per day. 35 patients with osteoarthritis of the 
      knee and 18 patients with osteoarthritis of the hip participated in the study. 
      The physical measurements of osteoarthritis activity showed significant 
      improvement with both Fenbufen and Aspirin. The drugs were comparable with 
      respect to: 1) improvement of physical m-easurements, 2) investigator's 
      assessments, and 3) patients' assessments. A smaller number of patients reported 
      drug-related side effects with Fenbufen than with Aspirin. 57% of the patients 
      reported side effects during treatment with Aspirin and 40% during treatment with 
      Fenbufen. There were no abnormalities discovered in haematologic or biochemical 
      tests performed during the course of the trial.
FAU - Valtonen, E J
AU  - Valtonen EJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Norway
TA  - Scand J Rheumatol Suppl
JT  - Scandinavian journal of rheumatology. Supplement
JID - 0400360
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Propionates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Biphenyl Compounds/administration & dosage/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Hip Joint
MH  - Humans
MH  - Knee Joint
MH  - Male
MH  - Movement
MH  - Osteoarthritis/*drug therapy
MH  - Pain
MH  - Propionates/administration & dosage/adverse effects/*therapeutic use
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.3109/03009747909108250 [doi]
PST - ppublish
SO  - Scand J Rheumatol Suppl. 1979;(27):1-7. doi: 10.3109/03009747909108250.

PMID- 1571820
OWN - NLM
STAT- MEDLINE
DCOM- 19920601
LR  - 20190827
IS  - 0954-7894 (Print)
IS  - 0954-7894 (Linking)
VI  - 22
IP  - 2
DP  - 1992 Feb
TI  - Altered distribution of IgG subclasses in aspirin-induced asthma: high IgG4, low 
      IgG1.
PG  - 283-7
AB  - We have determined IgG subclass concentrations in 100 patients with 
      aspirin-induced asthma and 80 healthy controls. Patients on chronic 
      corticotherapy (n = 64) had significantly lower total IgG levels than patients 
      not receiving steroids (n = 36) or controls. Corticotherapy was not associated 
      with changes in the subclass distributions. In patients, the most striking 
      finding was elevation of IgG4. It was not related to corticotherapy or serum IgE 
      levels. The rise in IgG4 was accompanied by a modest, though statistically 
      significant, depression of IgG1. No changes of IgG2 and IgG3 concentrations were 
      observed. Thus, aspirin-induced asthma is characterized by a distinct pattern of 
      distributions of IgG subclasses. It is suggested that in aspirin-induced asthma 
      elevation of IgG4 might result from chronic antigenic stimulation, of viral 
      origin, and that determination of IgG subclass distribution might be of clinical 
      interest.
FAU - Szczeklik, A
AU  - Szczeklik A
AD  - Department of Medicine, Copernicus Academy of Medicine, Cracow, Poland.
FAU - Schmitz-Schumann, M
AU  - Schmitz-Schumann M
FAU - Nizankowska, E
AU  - Nizankowska E
FAU - Milewski, M
AU  - Milewski M
FAU - Roehlig, F
AU  - Roehlig F
FAU - Virchow, C
AU  - Virchow C
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - 0 (Immunoglobulin G)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*immunology
MH  - Asthma/*immunology
MH  - Humans
MH  - Immunoglobulin G/*analysis
MH  - Tissue Distribution
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
AID - 10.1111/j.1365-2222.1992.tb03084.x [doi]
PST - ppublish
SO  - Clin Exp Allergy. 1992 Feb;22(2):283-7. doi: 10.1111/j.1365-2222.1992.tb03084.x.

PMID- 27077841
OWN - NLM
STAT- MEDLINE
DCOM- 20161214
LR  - 20200225
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 21
IP  - 4
DP  - 2016 Apr 12
TI  - Hybrid Compounds Strategy in the Synthesis of Oleanolic Acid Skeleton-NSAID 
      Derivatives.
PG  - 420
LID - 10.3390/molecules21040420 [doi]
LID - 420
AB  - The current study focuses on the synthesis of several hybrid individuals 
      combining a natural oleanolic acid skeleton and synthetic nonsteroidal 
      anti-inflammatory drug moieties (NSAIDs). It studied structural modifications of 
      the oleanolic acid structure by use of the direct reactivity of hydroxyl or 
      hydroxyimino groups at position C-3 of the triterpenoid skeleton with the 
      carboxylic function of anti-inflammatory drugs leading to new perspective 
      compounds with high potential pharmacological activities. Novel ester- and 
      iminoester-type derivatives of oleanolic unit with the different NSAIDs, such as 
      ibuprofen, aspirin, naproxen, and ketoprofen, were obtained and characterized. 
      Moreover, preliminary research of compounds obtaining structure stability under 
      acidic conditions was examined and the PASS method of prediction of activity 
      spectra for substances was used to estimate the potential biological activity of 
      these compounds.
FAU - Pawełczyk, Anna
AU  - Pawełczyk A
AD  - Department of Organic Chemistry, Pharmaceutical Faculty, Poznan University of 
      Medical Sciences, Grunwaldzka 6, 60-780 Poznań, Poland. apaw@ump.edu.pl.
FAU - Olender, Dorota
AU  - Olender D
AD  - Department of Organic Chemistry, Pharmaceutical Faculty, Poznan University of 
      Medical Sciences, Grunwaldzka 6, 60-780 Poznań, Poland. dolender@ump.edu.pl.
FAU - Sowa-Kasprzak, Katarzyna
AU  - Sowa-Kasprzak K
AD  - Department of Organic Chemistry, Pharmaceutical Faculty, Poznan University of 
      Medical Sciences, Grunwaldzka 6, 60-780 Poznań, Poland. kasik@ump.edu.pl.
FAU - Zaprutko, Lucjusz
AU  - Zaprutko L
AD  - Department of Organic Chemistry, Pharmaceutical Faculty, Poznan University of 
      Medical Sciences, Grunwaldzka 6, 60-780 Poznań, Poland. zaprutko@ump.edu.pl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160412
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 57Y76R9ATQ (Naproxen)
RN  - 6SMK8R7TGJ (Oleanolic Acid)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents/chemical synthesis/*chemistry
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis/*chemistry
MH  - Aspirin/chemistry/therapeutic use
MH  - Humans
MH  - Ibuprofen/chemistry/therapeutic use
MH  - Inflammation/*drug therapy
MH  - Ketoprofen/chemistry/therapeutic use
MH  - Molecular Structure
MH  - Naproxen/chemistry/therapeutic use
MH  - Oleanolic Acid/chemical synthesis/*chemistry
PMC - PMC6273679
OTO - NOTNLM
OT  - NSAIDs
OT  - aspirin
OT  - hybrid compounds
OT  - ibuprofen
OT  - ketoprofen
OT  - naproxen
OT  - oleanolic acid
OT  - oleanolic oxime
COIS- The authors declare no conflict of interest.
EDAT- 2016/04/15 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/04/15 06:00
PHST- 2016/02/08 00:00 [received]
PHST- 2016/03/15 00:00 [revised]
PHST- 2016/03/23 00:00 [accepted]
PHST- 2016/04/15 06:00 [entrez]
PHST- 2016/04/15 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - molecules21040420 [pii]
AID - molecules-21-00420 [pii]
AID - 10.3390/molecules21040420 [doi]
PST - epublish
SO  - Molecules. 2016 Apr 12;21(4):420. doi: 10.3390/molecules21040420.

PMID- 22975919
OWN - NLM
STAT- MEDLINE
DCOM- 20130329
LR  - 20190827
IS  - 1348-2246 (Electronic)
IS  - 0910-6340 (Linking)
VI  - 28
IP  - 9
DP  - 2012
TI  - Matrix-assisted laser desorption ionization mass spectrometry of maltohexaose and 
      acetylsalicylic acid using alkali metal cation-substituted zeolites.
PG  - 901-4
AB  - Using alkali-metal cation-substituted zeolites and 2,4,6-trihydroxyacetophenone 
      (THAP), which is a typical organic matrix molecule for matrix-assisted laser 
      desorption ionization (MALDI), mass spectrometry has been performed for 
      maltohexaose and acetylsalicylic acid, and the cation-selective ionization of 
      these analytes was achieved. It is found that a complex of cation-substituted 
      zeolite and THAP can be applicable to a compound that is hard to be ionized by a 
      proton adduction in conventional MALDI.
FAU - Suzuki, Junya
AU  - Suzuki J
AD  - Department of Chemistry, Graduate School of Science and Engineering, Tokyo 
      Metropolitan University, Japan.
FAU - Fujino, Tatsuya
AU  - Fujino T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Anal Sci
JT  - Analytical sciences : the international journal of the Japan Society for 
      Analytical Chemistry
JID - 8511078
RN  - 0 (Acetophenones)
RN  - 0 (Cations)
RN  - 0 (Metals, Alkali)
RN  - 0 (Oligosaccharides)
RN  - 0 (Protons)
RN  - 1318-02-1 (Zeolites)
RN  - 34620-77-4 (maltohexaose)
RN  - 8L7XD8830T (2,4,6-trihydroxyacetophenone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetophenones/chemistry
MH  - Aspirin/*analysis
MH  - Cations/chemistry
MH  - Metals, Alkali/*chemistry
MH  - Oligosaccharides/*analysis
MH  - Protons
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
MH  - Zeolites/*chemistry
EDAT- 2012/09/15 06:00
MHDA- 2013/03/30 06:00
CRDT- 2012/09/15 06:00
PHST- 2012/09/15 06:00 [entrez]
PHST- 2012/09/15 06:00 [pubmed]
PHST- 2013/03/30 06:00 [medline]
AID - DN/JST.JSTAGE/analsci/28.901 [pii]
AID - 10.2116/analsci.28.901 [doi]
PST - ppublish
SO  - Anal Sci. 2012;28(9):901-4. doi: 10.2116/analsci.28.901.

PMID- 6500381
OWN - NLM
STAT- MEDLINE
DCOM- 19850104
LR  - 20191210
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 14
IP  - 4
DP  - 1984
TI  - Influence of sex, blood group, secretor character, smoking habits, 
      acetylsalicylic acid, oral contraceptives, fasting and general health state on 
      blood coagulation variables in randomly selected young adults.
PG  - 312-9
AB  - Blood samples were drawn from 129 randomly selected young adults. Intake of 
      acetylsalicylic acid (ASA), contraceptive drugs, smoking habits and health state 
      were registered. Males had significantly higher systolic blood pressure, shorter 
      bleeding time and lower VIII:C. Smoking was only correlated to some variables 
      assessed in the female group. Users of oral contraceptives smoked more, had a 
      shorter bleeding time and higher fibrinogen levels. Factor VIIIR;Ag was elevated 
      only in female smokers with blood group non-O. Non-secretors had shorter bleeding 
      times and a tendency towards higher VIIIR:Ag.
FAU - Wahlberg, T B
AU  - Wahlberg TB
FAU - Blombäck, M
AU  - Blombäck M
FAU - Magnusson, D
AU  - Magnusson D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Blood Group Antigens)
RN  - 0 (Contraceptives, Oral)
RN  - 0 (Lewis Blood Group Antigens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology
MH  - *Blood Coagulation/drug effects
MH  - Blood Group Antigens
MH  - Contraceptives, Oral/pharmacology
MH  - Fasting
MH  - Female
MH  - Humans
MH  - Lewis Blood Group Antigens
MH  - Male
MH  - Sex Factors
MH  - Smoking
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1159/000215081 [doi]
PST - ppublish
SO  - Haemostasis. 1984;14(4):312-9. doi: 10.1159/000215081.

PMID- 10976519
OWN - NLM
STAT- MEDLINE
DCOM- 20010118
LR  - 20190831
IS  - 0968-0896 (Print)
IS  - 0968-0896 (Linking)
VI  - 8
IP  - 7
DP  - 2000 Jul
TI  - Triazene drug metabolites. Part 17: Synthesis and plasma hydrolysis of 
      acyloxymethyl carbamate derivatives of antitumour triazenes.
PG  - 1719-25
AB  - A series of 3-acyloxymethyloxycarbonyl-1-aryl-3-methyltriazenes 5 was synthesised 
      by the sequential reaction of 1-aryl-3-methyltriazenes with (i) chloromethyl 
      chloroformate, (ii) NaI in dry acetone, and (iii) either the silver carboxylate 
      or the carboxylic acids in the presence of silver carbonate. The hydrolysis of 
      these compounds was studied in pH 7.7 isotonic phosphate buffer and in human 
      plasma. Triazene acyloxycarbamates demonstrated their ability to act as 
      substrates for plasma enzymes. For compound 5f, a pH-rate profile was obtained 
      which showed the hydrolysis to involve acid-base catalysis. The reaction is also 
      buffer catalysed. Thus, at pH 7.7, pH-independent, base-catalysed and 
      buffer-catalysed processes all contribute to the hydrolysis reaction. The 
      sensitivity of the hydrolysis reaction to various structural parameters in the 
      substrates indicates that hydrolysis occurs at the ester rather than the 
      carbamate functionality. In plasma, the rates of hydrolysis correlate with 
      partition coefficients, the most lipophilic compounds being the most stable. An 
      aspirin derivative suffers two consecutive enzymatic reactions, the scission of 
      the aspirin acetyl group being followed by the scission of the acyloxy ester 
      group. These results indicate that triazene acyloxymethyl carbamates are prodrugs 
      of the antitumour monomethyltriazenes. They combine chemical stability with a 
      rapid enzymatic hydrolysis, and are consequently good candidates for further 
      prodrug development. Moreover, this type of derivative allowed the synthesis of 
      mutual prodrugs, associating the antitumour monomethyltriazenes with 
      anti-inflammatory NSAIDs as well as with the anticancer agent butyric acid.
FAU - Carvalho, E
AU  - Carvalho E
AD  - Centro de Estudos de Ciências Farmacêuticas, Faculdade de Farmácia, Universidade 
      de Lisboa, Lisbon, Portugal.
FAU - Francisco, A P
AU  - Francisco AP
FAU - Iley, J
AU  - Iley J
FAU - Rosa, E
AU  - Rosa E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Bioorg Med Chem
JT  - Bioorganic & medicinal chemistry
JID - 9413298
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Carbamates)
RN  - 0 (Prodrugs)
RN  - 0 (Triazenes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/chemical synthesis/metabolism
MH  - Aspirin/metabolism/pharmacology
MH  - Carbamates/*chemical synthesis/chemistry/*metabolism/pharmacology
MH  - Chromatography, High Pressure Liquid
MH  - Drug Stability
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - Kinetics
MH  - Plasma/enzymology
MH  - Prodrugs/chemical synthesis/metabolism/pharmacokinetics
MH  - Structure-Activity Relationship
MH  - Triazenes/*chemical synthesis/*metabolism/pharmacokinetics/*pharmacology
EDAT- 2000/09/08 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/08 11:00
PHST- 2000/09/08 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/08 11:00 [entrez]
AID - S0968-0896(00)00100-0 [pii]
AID - 10.1016/s0968-0896(00)00100-0 [doi]
PST - ppublish
SO  - Bioorg Med Chem. 2000 Jul;8(7):1719-25. doi: 10.1016/s0968-0896(00)00100-0.

PMID- 8771423
OWN - NLM
STAT- MEDLINE
DCOM- 19961204
LR  - 20190817
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 22
IP  - 4
DP  - 1996 Jun
TI  - Growth markers in the human gastric mucosa during adaptation to continued aspirin 
      administration.
PG  - 282-7
AB  - The mechanism of gastric mucosal adaptation to continued aspirin (ASA) 
      administration is unknown. We have investigated growth and proliferation markers 
      in healthy subjects under prolonged ASA treatment. In eight healthy volunteers, 
      ASA treatment (2 g/day) was continued for 14 days. Endoscopy was performed before 
      medication; at days 3, 7, and 14 of ASA treatment; and at days 16 and 18 (2 and 4 
      days, respectively, after medication was ceased). Gastric biopsies from oxyntic 
      and antral mucosa were studied by histology and by histochemistry for 
      proliferating cell nuclear antigen (PCNA), epidermal growth factor (EGF), 
      transforming growth factor-alpha (TGF-alpha), and epidermal growth factor 
      receptor (EGFr). ASA treatment did not change the expression of EGF and EGFr 
      significantly. The PCNA index showed local inconsistent variations. However, 
      increased TGF-alpha expression after ASA was noted, particularly in hyperplastic 
      surface epithelium. Edema and teleangiectases were common in gastric mucosa after 
      ASA. An increasing incidence of foveolar hyperplasia was also noted in the antral 
      mucosa. Healthy subjects on prolonged ASA treatment gradually develop parameters 
      of chronic reactive gastritis accompanied by increased TGF-alpha expression in 
      gastric surface epithelial cells, especially in hyperplastic areas.
FAU - Stachura, J
AU  - Stachura J
AD  - Department of Medicine B, University of Münster, Germany.
FAU - Konturek, J W
AU  - Konturek JW
FAU - Dembinski, A
AU  - Dembinski A
FAU - Domschke, W
AU  - Domschke W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Transforming Growth Factor alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Adaptation, Physiological
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Biomarkers
MH  - Drug Tolerance
MH  - Gastric Mucosa/*drug effects/metabolism/physiology
MH  - Humans
MH  - Hyperplasia
MH  - Male
MH  - Transforming Growth Factor alpha/metabolism
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
AID - 10.1097/00004836-199606000-00008 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 1996 Jun;22(4):282-7. doi: 
      10.1097/00004836-199606000-00008.

PMID- 17473044
OWN - NLM
STAT- MEDLINE
DCOM- 20070629
LR  - 20220331
IS  - 0002-8177 (Print)
IS  - 0002-8177 (Linking)
VI  - 138
IP  - 5
DP  - 2007 May
TI  - Prevention of premature discontinuation of dual antiplatelet therapy in patients 
      with coronary artery stents: a science advisory from the American Heart 
      Association, American College of Cardiology, Society for Cardiovascular 
      Angiography and Interventions, American College of Surgeons, and American Dental 
      Association, with representation from the American College of Physicians.
PG  - 652-5
AB  - BACKGROUND: and Overview. Dual antiplatelet therapy with aspirin and a 
      thienopyridine has been shown to reduce cardiac events after coronary stenting. 
      However, many patients and health care providers prematurely discontinue dual 
      antiplatelet therapy, which greatly increases the risk of stent thrombosis, 
      myocardial infarction and death. CONCLUSIONS AND CLINICAL IMPLICATIONS: This 
      advisory stresses the importance of 12 months of dual antiplatelet therapy after 
      placement of a drug-eluting stent and educating patients and health care 
      providers about hazards of premature discontinuation. It also recommends 
      postponing elective surgery for one year, and if surgery cannot be deferred, 
      considering the continuation of aspirin during the perioperative period in 
      high-risk patients with drug-eluting stents.
FAU - Grines, Cindy L
AU  - Grines CL
AD  - William Beaumont Hospital, Royal Oak, Michigan, USA.
FAU - Bonow, Robert O
AU  - Bonow RO
FAU - Casey, Donald E Jr
AU  - Casey DE Jr
FAU - Gardner, Timothy J
AU  - Gardner TJ
FAU - Lockhart, Peter B
AU  - Lockhart PB
FAU - Moliterno, David J
AU  - Moliterno DJ
FAU - O'Gara, Patrick
AU  - O'Gara P
FAU - Whitlow, Patrick
AU  - Whitlow P
CN  - American Heart Association
CN  - American College of Cardiology
CN  - Society for Cardiovascular Angiography and Interventions
CN  - American College of Surgeons
CN  - American Dental Association
CN  - American College of Physicians
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Coronary Disease/*surgery
MH  - Coronary Thrombosis/prevention & control
MH  - Drug Administration Schedule
MH  - Education, Professional
MH  - Elective Surgical Procedures
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Patient Education as Topic
MH  - Perioperative Care
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Postoperative Complications/prevention & control
MH  - Pyridines/administration & dosage/therapeutic use
MH  - Risk Factors
MH  - *Stents
MH  - Time Factors
EDAT- 2007/05/03 09:00
MHDA- 2007/06/30 09:00
CRDT- 2007/05/03 09:00
PHST- 2007/05/03 09:00 [pubmed]
PHST- 2007/06/30 09:00 [medline]
PHST- 2007/05/03 09:00 [entrez]
AID - S0002-8177(14)62367-9 [pii]
AID - 10.14219/jada.archive.2007.0237 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 2007 May;138(5):652-5. doi: 10.14219/jada.archive.2007.0237.

PMID- 17295287
OWN - NLM
STAT- MEDLINE
DCOM- 20070807
LR  - 20131121
IS  - 1522-1946 (Print)
IS  - 1522-1946 (Linking)
VI  - 69
IP  - 3
DP  - 2007 Feb 15
TI  - Prevention of premature discontinuation of dual antiplatelet therapy in patients 
      with coronary artery stents: a science advisory from the American Heart 
      Association, American College of Cardiology, Society for Cardiovascular 
      Angiography and Interventions, American College of Surgeons, and American Dental 
      Association, with representation from the American College of Physicians.
PG  - 334-40
AB  - Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to 
      reduce cardiac events after coronary stenting. However, many patients and 
      healthcare providers prematurely discontinue dual antiplatelet therapy, which 
      greatly increases the risk of stent thrombosis, myocardial infarction, and death. 
      This advisory stresses the importance of 12 months of dual antiplatelet therapy 
      after placement of a drug-eluting stent and educating the patient and healthcare 
      providers about hazards of premature discontinuation. It also recommends 
      postponing elective surgery for 1 year, and if surgery cannot be deferred, 
      considering the continuation of aspirin during the perioperative period in 
      high-risk patients with drug-eluting stents.
CI  - (c) 2007 the American Heart Association, Inc., the American College of Cardiology 
      Foundation, the Society for Cardiovascular Angiography and Interventions, the 
      American College of Surgeons, and the American Dental Association
FAU - Grines, Cindy L
AU  - Grines CL
FAU - Bonow, Robert O
AU  - Bonow RO
FAU - Casey, Donald E Jr
AU  - Casey DE Jr
FAU - Gardner, Timothy J
AU  - Gardner TJ
FAU - Lockhart, Peter B
AU  - Lockhart PB
FAU - Moliterno, David J
AU  - Moliterno DJ
FAU - O'Gara, Patrick
AU  - O'Gara P
FAU - Whitlow, Patrick
AU  - Whitlow P
CN  - American Heart Association
CN  - American College of Cardiology
CN  - Society for Cardiovascular Angiography and Interventions
CN  - American College of Surgeons
CN  - American Dental Association
CN  - American College of Physicians
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PT  - Review
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Coated Materials, Biocompatible)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Advisory Committees
MH  - Aspirin/standards/therapeutic use
MH  - Blood Vessel Prosthesis Implantation/adverse effects/standards
MH  - Coated Materials, Biocompatible/standards/therapeutic use
MH  - Coronary Thrombosis/etiology/prevention & control
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*standards/*therapeutic use
MH  - Pyridines/standards/therapeutic use
MH  - Stents/adverse effects/*standards
MH  - Time Factors
MH  - United States
RF  - 36
EDAT- 2007/02/14 09:00
MHDA- 2007/08/08 09:00
CRDT- 2007/02/14 09:00
PHST- 2007/02/14 09:00 [pubmed]
PHST- 2007/08/08 09:00 [medline]
PHST- 2007/02/14 09:00 [entrez]
AID - 10.1002/ccd.21124 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2007 Feb 15;69(3):334-40. doi: 10.1002/ccd.21124.

PMID- 29090588
OWN - NLM
STAT- MEDLINE
DCOM- 20181121
LR  - 20181121
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 29
IP  - 7
DP  - 2018 Nov
TI  - Decreased turnover aspirin resistance by bidaily aspirin intake and efficient 
      cytoreduction in myeloproliferative neoplasms.
PG  - 723-728
LID - 10.1080/09537104.2017.1361018 [doi]
AB  - Essential thrombocythemia (ET) and polycythemia vera (PV) are myeloproliferative 
      neoplasms (MPN) with an increased risk of arterial and venous thrombosis. Aspirin 
      is recommended to reduce this risk, but resistance to antiplatelet therapy seems 
      to hamper its efficacy in some patients. We have previously shown that multiple 
      electrode aggregometry (MEA) was a valuable tool to assess aspirin resistance in 
      MPN. In this study, MEA was used to assess the reduction in aspirin resistance 
      after bi-daily (BID) aspirin intake or cytoreduction. Fifty one MPN patients (31 
      ET and 20 PV) receiving 75 mg aspirin once daily (OD) or BID, with or without 
      cytoreductive treatment, were analyzed. Aspirin resistance was assessed using 
      whole blood MEA (Multiplate®, Roche Diagnostics, Meylan, France). In all 
      patients, global aspirin resistance consisted mainly of turnover resistance 
      (TOR). 94% of patients with OD aspirin intake and without cytoreduction displayed 
      biological aspirin resistance. By switching to a BID aspirin regimen, the 
      proportion of resistant patients reduced to 47%. Cytoreduction also contributed 
      to reduce aspirin resistance in a similar way (50% of aspirin resistant 
      patients). Combining cytoreduction and BID aspirin regimen was the most efficient 
      way to reduce aspirin resistance yielding to 12% resistant patients. Moreover, a 
      nonlinear correlation was observed between TOR and naive platelet counts 
      regardless of aspirin regimen. Last, mutational status did not seem to affect 
      TOR. This study confirmed that BID aspirin is biologically more effective than OD 
      aspirin in reduction of aspirin resistance. The latter was achieved through a 
      reduction in TOR which was also decreased by cytoreductive therapy.
FAU - Perrier-Cornet, Andréas
AU  - Perrier-Cornet A
AD  - a Service d'Hématologie Biologique , CHU de Brest , Brest , France.
FAU - Ianotto, Jean-Christophe
AU  - Ianotto JC
AD  - b Service d'Hématologie Clinique , CHU de Brest , Brest , France.
FAU - Mingant, Fanny
AU  - Mingant F
AD  - a Service d'Hématologie Biologique , CHU de Brest , Brest , France.
FAU - Perrot, Maëla
AU  - Perrot M
AD  - a Service d'Hématologie Biologique , CHU de Brest , Brest , France.
FAU - Lippert, Eric
AU  - Lippert E
AD  - a Service d'Hématologie Biologique , CHU de Brest , Brest , France.
FAU - Galinat, Hubert
AU  - Galinat H
AD  - a Service d'Hématologie Biologique , CHU de Brest , Brest , France.
LA  - eng
PT  - Journal Article
DEP - 20171101
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Biomarkers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*pharmacokinetics
MH  - Biomarkers
MH  - Blood Platelets/drug effects/metabolism
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Myeloproliferative Disorders/*complications/diagnosis/drug therapy/etiology
MH  - Platelet Aggregation/drug effects
MH  - Platelet Count
MH  - Platelet Function Tests
MH  - Premedication
MH  - Thrombosis/drug therapy/*etiology/*prevention & control
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin resistance
OT  - multiple electrode aggregometry
OT  - myeloproliferative neoplasm
OT  - platelet turnover
EDAT- 2017/11/02 06:00
MHDA- 2018/11/22 06:00
CRDT- 2017/11/02 06:00
PHST- 2017/11/02 06:00 [pubmed]
PHST- 2018/11/22 06:00 [medline]
PHST- 2017/11/02 06:00 [entrez]
AID - 10.1080/09537104.2017.1361018 [doi]
PST - ppublish
SO  - Platelets. 2018 Nov;29(7):723-728. doi: 10.1080/09537104.2017.1361018. Epub 2017 
      Nov 1.

PMID- 20598487
OWN - NLM
STAT- MEDLINE
DCOM- 20101124
LR  - 20211020
IS  - 1873-6823 (Electronic)
IS  - 0741-8329 (Print)
IS  - 0741-8329 (Linking)
VI  - 44
IP  - 5
DP  - 2010 Aug
TI  - Effects of aspirin on gastroduodenal permeability in alcoholics and controls.
PG  - 447-56
LID - 10.1016/j.alcohol.2010.05.004 [doi]
AB  - Alcohol and nonsteroidal anti-inflammatory drugs are noxious agents that can 
      disrupt the integrity of the gastroduodenal mucosal and damage the epithelial 
      barrier and lead to increased gastroduodenal permeability. Moreover, it is not 
      uncommon that patients are exposed to these two barrier stressors at the same 
      time. It is thus important to know how simultaneous exposure affects the 
      gastroduodenal barrier, and acquiring that knowledge was the goal of this study. 
      We used a method that has been widely used for the assessment of injury to the 
      gastroduodenal barrier induced by these noxious agents-measurement of 
      gastroduodenal permeability as indicated by urinary excretion of ingested 
      sucrose. We used gas chromatography to measure the amount of sucrose excreted in 
      the urine over the 5-12h after ingestion of a bolus of sucrose. The 148 
      participants in the study included 92 alcoholics and 56 healthy controls. All 
      study subjects had a baseline permeability test. To determine whether addition of 
      a second noxious agent, in addition to chronic alcohol, further decreases 
      gastroduodenal barrier integrity, a subset of 118 study subjects participated in 
      another permeability test in which they were exposed to aspirin. For this test, 
      participants ingested 1,300 mg aspirin twice, 12 and 1h before the final 
      permeability test. The baseline permeability test showed that alcoholics have 
      significantly higher gastroduodenal permeability than controls. Aspirin caused a 
      significant within-group absolute increase in gastroduodenal permeability in both 
      alcoholics and controls (+7.72%, P=.003 and +2.25%, P=.011, respectively), but 
      the magnitude of these increases was not significantly different from each other. 
      Baseline permeability did vary by gender, self-reported illegal drug use, and 
      employment type. The extent of the permeability increase after aspirin ingestion 
      varied with illegal drug use and recruitment site (a surrogate marker of 
      socioeconomic status). Our data show that alcoholics have greater gastroduodenal 
      permeability than healthy controls. This difference was independent of the 
      duration of any preceding period of sobriety, gender, smoking history, or illicit 
      drug abuse. The injurious effects of alcohol on the gastroduodenal epithelial 
      barrier are long lasting, persisting even after 7 days of sobriety. Although, 
      acute aspirin and chronic alcohol each increase intestinal permeability in 
      alcoholics, their effects appear to be additive rather than synergistic.
CI  - 2010 Elsevier Inc. All rights reserved.
FAU - Farhadi, Ashkan
AU  - Farhadi A
AD  - Department of Medicine, Rush University, Chicago, IL, USA.
FAU - Keshavarzian, Ali
AU  - Keshavarzian A
FAU - Kwasny, Mary J
AU  - Kwasny MJ
FAU - Shaikh, Maliha
AU  - Shaikh M
FAU - Fogg, Louis
AU  - Fogg L
FAU - Lau, Cynthia
AU  - Lau C
FAU - Fields, Jeremy Z
AU  - Fields JZ
FAU - Forsyth, Christopher B
AU  - Forsyth CB
LA  - eng
GR  - R01 AA013745-02/AA/NIAAA NIH HHS/United States
GR  - R01 AA013745-05/AA/NIAAA NIH HHS/United States
GR  - AA13745/AA/NIAAA NIH HHS/United States
GR  - R01 AA013745/AA/NIAAA NIH HHS/United States
GR  - R01 AA013745-04/AA/NIAAA NIH HHS/United States
GR  - R01 AA013745-01A1/AA/NIAAA NIH HHS/United States
GR  - R01 AA013745-03/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100703
PL  - United States
TA  - Alcohol
JT  - Alcohol (Fayetteville, N.Y.)
JID - 8502311
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 57-50-1 (Sucrose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Alcoholism/*physiopathology
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Digestive System/*drug effects/metabolism
MH  - Female
MH  - Gastric Mucosa/drug effects/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Permeability/drug effects
MH  - Sucrose/urine
PMC - PMC2932827
MID - NIHMS219278
COIS- Potential competing interests: none
EDAT- 2010/07/06 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/07/06 06:00
PHST- 2009/10/09 00:00 [received]
PHST- 2010/04/27 00:00 [revised]
PHST- 2010/05/12 00:00 [accepted]
PHST- 2010/07/06 06:00 [entrez]
PHST- 2010/07/06 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - S0741-8329(10)00044-3 [pii]
AID - 10.1016/j.alcohol.2010.05.004 [doi]
PST - ppublish
SO  - Alcohol. 2010 Aug;44(5):447-56. doi: 10.1016/j.alcohol.2010.05.004. Epub 2010 Jul 
      3.

PMID- 20394978
OWN - NLM
STAT- MEDLINE
DCOM- 20110104
LR  - 20161125
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 76
IP  - 6
DP  - 2010 Dec
TI  - Idiopathic partial thrombosis of the corpus cavernosum.
PG  - 1373-4
LID - 10.1016/j.urology.2009.12.058 [doi]
AB  - We report the case of an idiopathic partial segmental thrombosis of the left 
      corpus cavernosum. The diagnosis was made by physical examination and 
      radiological imaging. The patient was treated conservatively with aspirin, and 
      follow-up imaging at 3 and 7 months revealed mild persistent thrombosis. Erectile 
      function was maintained at 1 year follow-up.
CI  - Copyright © 2010 Elsevier Inc. All rights reserved.
FAU - Patel, Rakesh P
AU  - Patel RP
AD  - Division of Urology, Department of Surgery, University of Pennsylvania Health 
      System, Philadelphia, Pennsylvania 19104, USA.
FAU - Mucksavage, Phillip
AU  - Mucksavage P
FAU - Ramchandani, Parvati
AU  - Ramchandani P
FAU - Hanno, Philip M
AU  - Hanno PM
FAU - Malkowicz, S Bruce
AU  - Malkowicz SB
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20100414
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Penis/*blood supply
MH  - Thrombosis/*diagnostic imaging/drug therapy
MH  - *Tomography, X-Ray Computed
MH  - Young Adult
EDAT- 2010/04/17 06:00
MHDA- 2011/01/05 06:00
CRDT- 2010/04/17 06:00
PHST- 2009/11/25 00:00 [received]
PHST- 2009/11/25 00:00 [revised]
PHST- 2009/12/29 00:00 [accepted]
PHST- 2010/04/17 06:00 [entrez]
PHST- 2010/04/17 06:00 [pubmed]
PHST- 2011/01/05 06:00 [medline]
AID - S0090-4295(10)00048-8 [pii]
AID - 10.1016/j.urology.2009.12.058 [doi]
PST - ppublish
SO  - Urology. 2010 Dec;76(6):1373-4. doi: 10.1016/j.urology.2009.12.058. Epub 2010 Apr 
      14.

PMID- 32912725
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 1701-2163 (Print)
IS  - 1701-2163 (Linking)
VI  - 42
IP  - 12
DP  - 2020 Dec
TI  - A Pilot Randomized Trial Comparing the Effects of 80 versus 160 mg of Aspirin on 
      Midtrimester Uterine Artery Pulsatility Index in Women with a History of 
      Preeclampsia.
PG  - 1498-1504
LID - S1701-2163(20)30488-6 [pii]
LID - 10.1016/j.jogc.2020.05.013 [doi]
AB  - OBJECTIVE: To compare the effects of 80 mg and 160 mg of aspirin, initiated in 
      the first trimester of pregnancy, on mid-trimester uterine artery pulsatility 
      index (UtA-PI) in women with a history of preeclampsia. METHODS: We performed a 
      pilot double-blind randomized controlled trial. Pregnant women with a history of 
      preeclampsia were recruited between 10(0/7) and 13(6/7) weeks gestation and 
      randomly assigned to take either 80 or 160 mg of aspirin daily at bedtime from 
      randomization to 35(6/7) weeks gestation. The primary outcome was mean UtA-PI at 
      22-24 weeks. Secondary outcomes included the rate of fetal growth restriction and 
      preeclampsia, stratified as term (≥37 weeks), preterm (<37 weeks), and 
      early-onset (<34 weeks) preeclampsia. RESULTS: A total of 107 participants were 
      randomized, including 41 (38%) with a history of preterm preeclampsia and 16 
      (15%) with a history of early-onset preeclampsia. We observed no significant 
      difference in mean UtA-PI at 22-24 weeks between the 2 groups (0.97; 95% CI 
      0.88-1.05 vs. 0.97; 95% CI 0.88-1.07, P = 0.9). The rates of fetal growth 
      restriction (8% vs. 2%; P = 0.20); preeclampsia (12% vs. 15%; P = 0.78), preterm 
      preeclampsia (4% vs. 2%; P = 0.56), and early-onset preeclampsia (0% vs. 2%; 
      P = 0.52) were similar in both groups. No serious adverse events associated with 
      the study treatment were reported. CONCLUSION: We observed no significant 
      difference in UtA-PI between the two doses of aspirin, but we observed low rates 
      of fetal growth restriction and preterm and early-onset preeclampsia (all less 
      than 5%). The benefits of aspirin for the prevention of preterm preeclampsia is 
      probably not related to the improvement of deep placentation alone.
CI  - Copyright © 2020 The Society of Obstetricians and Gynaecologists of Canada/La 
      Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. 
      All rights reserved.
FAU - Tapp, Sylvie
AU  - Tapp S
AD  - Reproduction, Mother and Child Health Unit, Research Center of the CHU de Québec 
      - Université Laval, Québec City, QC.
FAU - Guerby, Paul
AU  - Guerby P
AD  - Reproduction, Mother and Child Health Unit, Research Center of the CHU de Québec 
      - Université Laval, Québec City, QC; Department of Obstetrics, Paule de Viguier 
      Hospital, CHU Toulouse, INSERM U1048, Toulouse, France.
FAU - Girard, Mario
AU  - Girard M
AD  - Reproduction, Mother and Child Health Unit, Research Center of the CHU de Québec 
      - Université Laval, Québec City, QC.
FAU - Roberge, Stéphanie
AU  - Roberge S
AD  - Reproduction, Mother and Child Health Unit, Research Center of the CHU de Québec 
      - Université Laval, Québec City, QC.
FAU - Côté, Stéphane
AU  - Côté S
AD  - Department of Medicine, CHU de Québec-Université Laval, Québec City, QC.
FAU - Ferreira, Ema
AU  - Ferreira E
AD  - Faculty of Pharmacy, Université de Montréal, Montréal, QC; Department of 
      Pharmacy, CHU Ste-Justine, Montréal, QC.
FAU - Leclair, Grégoire
AU  - Leclair G
AD  - Faculty of Pharmacy, Université de Montréal, Montréal, QC.
FAU - Bujold, Emmanuel
AU  - Bujold E
AD  - Reproduction, Mother and Child Health Unit, Research Center of the CHU de Québec 
      - Université Laval, Québec City, QC; Department of Obstetrics, Gynecology and 
      Reproduction, Faculty of Medicine, Université Laval, Québec City, QC. Electronic 
      address: emmanuel.bujold@crchudequebec.ulaval.ca.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200617
PL  - Netherlands
TA  - J Obstet Gynaecol Can
JT  - Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et 
      gynecologie du Canada : JOGC
JID - 101126664
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Canada/epidemiology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fetal Growth Retardation/epidemiology/*prevention & control
MH  - Humans
MH  - Infant, Newborn
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pre-Eclampsia/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Pregnancy Trimester, Second
MH  - Treatment Outcome
MH  - *Ultrasonography, Prenatal
MH  - Uterine Artery/*diagnostic imaging
OTO - NOTNLM
OT  - aspirin
OT  - preeclampsia
OT  - pregnancy
OT  - ultrasound
OT  - uterine artery doppler
EDAT- 2020/09/12 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/09/11 05:37
PHST- 2020/04/05 00:00 [received]
PHST- 2020/05/21 00:00 [revised]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/09/11 05:37 [entrez]
AID - S1701-2163(20)30488-6 [pii]
AID - 10.1016/j.jogc.2020.05.013 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Can. 2020 Dec;42(12):1498-1504. doi: 
      10.1016/j.jogc.2020.05.013. Epub 2020 Jun 17.

PMID- 24999794
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20140708
IS  - 1531-7072 (Electronic)
IS  - 1070-5295 (Linking)
VI  - 20
IP  - 4
DP  - 2014 Aug
TI  - Prevention of renal dysfunction in postoperative elderly patients.
PG  - 451-9
LID - 10.1097/MCC.0000000000000107 [doi]
AB  - PURPOSE OF REVIEW: To describe the effect of ageing on kidney function and to 
      summarize the benefits of advocated measures to prevent perioperative acute 
      kidney injury (AKI) in elderly patients. RECENT FINDINGS: Given a reduced renal 
      reserve and the burden of comorbidities, the senescent kidney is susceptible to 
      develop perioperative AKI and is less able to recover when injury occurs. Current 
      evidence suggests that preoperative statin therapy, tight glycemic control or 
      urine alkalinization with bicarbonate do not protect the kidneys from harm. The 
      theoretical kidney protective effect of preoperative aspirin therapy or renal 
      vasodilatation with atrial natriuretic peptide or fenoldopam is only supported by 
      low-quality evidence that needs further evaluation. Although questions regarding 
      the amount and timing of fluid resuscitation during surgery are seeking answers 
      in ongoing multicenter studies, the harmful effect of hydroxyethyl starches (HES) 
      and hyperchloremic solutions is now surrounded by strong evidence. SUMMARY: The 
      future increase in elderly patients being exposed to surgery calls for improved 
      perioperative management to prevent collaterally increased AKI. Although 
      pharmacological therapies aiming to protect the kidneys from harm are under 
      evaluation, hemodynamic optimization and avoidance of nephrotoxic drugs, 
      including HES and hyperchloremic solutions, are critical for the elderly 
      perioperative patient.
FAU - Mårtensson, Johan
AU  - Mårtensson J
AD  - aDepartment of Physiology and Pharmacology, Section of Anaesthesia and Intensive 
      Care Medicine, Karolinska Institutet, Stockholm, Sweden bDepartment of Intensive 
      Care, Austin Hospital, Melbourne cDepartment of Epidemiology and Preventive 
      Medicine, Australian and New Zealand Intensive Care Research Centre, Monash 
      University, Melbourne, Victoria, Australia.
FAU - Bellomo, Rinaldo
AU  - Bellomo R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Crit Care
JT  - Current opinion in critical care
JID - 9504454
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Kidney Injury/*prevention & control
MH  - Aged
MH  - Aging/physiology
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Kidney/*physiopathology
MH  - Postoperative Care
MH  - Postoperative Complications/*prevention & control
EDAT- 2014/07/08 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/07/08 06:00
PHST- 2014/07/08 06:00 [entrez]
PHST- 2014/07/08 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - 00075198-201408000-00018 [pii]
AID - 10.1097/MCC.0000000000000107 [doi]
PST - ppublish
SO  - Curr Opin Crit Care. 2014 Aug;20(4):451-9. doi: 10.1097/MCC.0000000000000107.

PMID- 7229512
OWN - NLM
STAT- MEDLINE
DCOM- 19810720
LR  - 20131121
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 97
IP  - 6
DP  - 1981 Jun
TI  - Platelets increase neutrophil adherence in vitro to nylon fiber.
PG  - 812-9
AB  - The effect of platelets on the adherence of neutrophils to nylon fiber was 
      assessed in whole blood samples and purified neutrophil suspensions in the 
      presence or absence of plasma. In whole blood samples, increasing numbers of 
      platelets were associated (r = 0.47, p less than 0.02) with increasing adherence 
      of neutrophils. Addition of platelets in plasma to purified neutrophil 
      suspensions increased (p less than 0.05) neutrophil adherence from 76.2% +/- 1.4 
      to 88.0% +/- 2.0. Similarly, addition of washed platelets without plasma also 
      increased (p less than 0.05) neutrophil adherence from 67.9% +/- 5.8 (without 
      added platelets) to 94.2% +/- 1.6 (with 300,000 platelets/mm3 added). In 
      contrast, no augmentation of neutrophil adherence occurred if platelets had their 
      aggregation response suppressed by pretreating platelet donors with aspirin. SEM 
      supported these findings by showing platelets in close association with 
      neutrophils adhering to nylon fiber. These findings emphasize the importance of 
      platelet numbers and reactivity on the adherence of neutrophils.
FAU - Rasp, F L
AU  - Rasp FL
FAU - Clawson, C C
AU  - Clawson CC
FAU - Repine, J E
AU  - Repine JE
LA  - eng
GR  - HBL-11880/HB/NHLBI NIH HHS/United States
GR  - HL24248/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Nylons)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*physiology
MH  - Cell Adhesion/drug effects
MH  - Humans
MH  - Microscopy, Electron, Scanning
MH  - Neutrophils/*physiology
MH  - *Nylons
MH  - Platelet Count
EDAT- 1981/06/01 00:00
MHDA- 1981/06/01 00:01
CRDT- 1981/06/01 00:00
PHST- 1981/06/01 00:00 [pubmed]
PHST- 1981/06/01 00:01 [medline]
PHST- 1981/06/01 00:00 [entrez]
AID - 0022-2143(81)90204-3 [pii]
PST - ppublish
SO  - J Lab Clin Med. 1981 Jun;97(6):812-9.

PMID- 30295098
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20190128
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 19
IP  - 17
DP  - 2018 Dec
TI  - Embracing the polypill as a cardiovascular therapeutic: is this the best 
      strategy?
PG  - 1857-1865
LID - 10.1080/14656566.2018.1532501 [doi]
AB  - Cardiovascular disease (CVD) is an important cause of mortality and morbidity 
      worldwide. CVD morbidity and mortality are associated with significant financial 
      costs related to hospitalization, medication, and lost productivity. The concept 
      of the 'polypill' for the reduction of cardiovascular risk was proposed in 2000. 
      A polypill is a fixed combination of drugs in a single tablet or capsule. The 
      initial polypill consisted of three different classes of antihypertensive drugs 
      (each at half dose), in addition to aspirin, a statin, and folic acid. The 
      challenge today is to produce polypills containing drugs with established 
      efficacy and complementary actions. Areas covered: The authors provide their 
      expert perspectives on the polypill and consider the randomized clinical trials 
      that have evaluated the safety, efficacy, adherence, and cost-effectiveness of 
      polypills. Expert opinion: The polypill makes prescribing easier by reducing the 
      need for complex treatment algorithms and dose titration. It also appears to be 
      cost-effective. However, there are several issues that need to be addressed 
      before the polypill can be used routinely. A single polypill formulation may not 
      be suitable for all patients. It may be necessary to develop several types of 
      polypill to meet the needs of different patient groups.
FAU - Franczyk, Beata
AU  - Franczyk B
AD  - a Department of Nephrology, Hypertension and Family Medicine , Medical University 
      of Lodz , Lodz , Poland.
FAU - Gluba-Brzózka, Anna
AU  - Gluba-Brzózka A
AD  - b Department of Nephrology, Hypertension and Family Medicine , WAM Teaching 
      Hospital , Lodz , Poland.
FAU - Jurkiewicz, Łukasz
AU  - Jurkiewicz Ł
AD  - b Department of Nephrology, Hypertension and Family Medicine , WAM Teaching 
      Hospital , Lodz , Poland.
FAU - Penson, Peter
AU  - Penson P
AUID- ORCID: 0000-0001-6763-1489
AD  - c School of Pharmacy and Biomolecular Sciences , Liverpool John Moores University 
      , Liverpool , UK.
FAU - Banach, Maciej
AU  - Banach M
AUID- ORCID: 0000-0001-6690-6874
AD  - d Department of Hypertension , Medical University of Lodz , Lodz , Poland.
FAU - Rysz, Jacek
AU  - Rysz J
AD  - a Department of Nephrology, Hypertension and Family Medicine , Medical University 
      of Lodz , Lodz , Poland.
LA  - eng
PT  - Journal Article
DEP - 20181009
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 935E97BOY8 (Folic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/*administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cardiovascular Agents/*administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cost-Benefit Analysis
MH  - Drug Combinations
MH  - Folic Acid/administration & dosage
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & 
      dosage/therapeutic use
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Polypill
OT  - cardiovascular disease
OT  - primary and secondary prevention
EDAT- 2018/10/09 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/10/09 06:00
PHST- 2018/10/09 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/10/09 06:00 [entrez]
AID - 10.1080/14656566.2018.1532501 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2018 Dec;19(17):1857-1865. doi: 
      10.1080/14656566.2018.1532501. Epub 2018 Oct 9.

PMID- 21057697
OWN - NLM
STAT- MEDLINE
DCOM- 20110518
LR  - 20131121
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 105
IP  - 1
DP  - 2011 Jan
TI  - Effects of aspirin and desmopressin on platelet reactivity in patients undergoing 
      cardiac surgery with extracorporeal circulation.
PG  - 113-21
LID - 10.1160/TH10-07-0471 [doi]
AB  - The effect of desmopressin on platelet function in patients with continued 
      antiplatelet therapy undergoing cardiac surgery is discussed controversially. We 
      assessed platelet reactivity in 86 patients undergoing elective coronary artery 
      bypass grafting (CABG) under extracorporeal circulation. Twenty-nine of these 
      patients were without preoperative antiplatelet therapy (group A), while 57 were 
      treated with acetylsalicylic acid (ASA) 100 mg qd up to the day of surgery. Out 
      of this cohort, 24 patients received no desmopressin perioperatively (group B), 
      whereas 33 patients were treated with desmopressin 0.4 microg/kg after 
      administration of protamine due to increased bleeding tendency (group C). 
      Multiple electrode platelet aggregometry with arachidonic acid as agonist showed 
      a marked decrease of platelet reactivity in patients without antiplatelet therapy 
      immediately after extracorporeal circulation compared to preoperative control 
      (375 ± 227 vs. 749 ± 330 AU*min, p<0.001). Platelet reactivity recovered to 
      preoperative controls in group A at 24 hours after protamine administration (662 
      ± 295 AU*min). Platelet reactivity in patients on ASA was not decreased further 
      after extracorporeal circulation (group B: 197 ± 126 vs. 251 ± 203 AU*min, 
      p=0.14; group C: 212 ± 100 vs. 245 ± 248 AU*min, p=0.43) and improved 
      significantly within 24 hours. A statistically significant effect of 
      desmopressin, however, could not be determined (group B: 392 ± 223 AU*min; group 
      C: 439 ± 324 AU*min at 24 hours after protamine, p=0.63 for between-subjects 
      contrast). Our data suggest that desmopressin does not affect platelet reactivity 
      in patients on ASA undergoing CABG and is, therefore, not useful in this clinical 
      setting.
FAU - Keyl, Cornelius
AU  - Keyl C
AD  - Department of Anaesthesiology, Heart Centre Bad Krozingen, Bad Krozingen, 
      Germany. cornelius.keyl@herzzentrum.de
FAU - Kmitta, Eliane
AU  - Kmitta E
FAU - Kueri, Ssmi
AU  - Kueri S
FAU - Zietak, Tomasz
AU  - Zietak T
FAU - Trenk, Dietmar
AU  - Trenk D
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20101105
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Hemostatics)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Protamines)
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Cardiac Surgical Procedures/*methods
MH  - Coronary Artery Bypass/*methods
MH  - Deamino Arginine Vasopressin/administration & dosage/*pharmacology
MH  - Female
MH  - Hemostatics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors
MH  - Protamines/administration & dosage
EDAT- 2010/11/09 06:00
MHDA- 2011/05/19 06:00
CRDT- 2010/11/09 06:00
PHST- 2010/07/22 00:00 [received]
PHST- 2010/10/08 00:00 [accepted]
PHST- 2010/11/09 06:00 [entrez]
PHST- 2010/11/09 06:00 [pubmed]
PHST- 2011/05/19 06:00 [medline]
AID - 10-07-0471 [pii]
AID - 10.1160/TH10-07-0471 [doi]
PST - ppublish
SO  - Thromb Haemost. 2011 Jan;105(1):113-21. doi: 10.1160/TH10-07-0471. Epub 2010 Nov 
      5.

PMID- 24363153
OWN - NLM
STAT- MEDLINE
DCOM- 20150115
LR  - 20211021
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 39
IP  - 4
DP  - 2014 Dec
TI  - The evaluation method for antiplatelet effect of acetylsalicylic acid.
PG  - 327-33
LID - 10.1007/s13318-013-0170-9 [doi]
AB  - Reduced platelet aggregation by acetylsalicylic acid administration has been 
      associated with adverse outcomes in patients with thrombotic diseases, thus it is 
      important to determine aspirin resistance in those cases. The antiplatelet effect 
      of acetylsalicylic acid is rarely measured, but it has many problems. The aim of 
      this study was to find the evaluation method for antiplatelet effect after 
      administration of acetylsalicylic acid. We developed a particle counting method 
      based upon laser light scattering, and utilized the platelet aggregation 
      agonists, collagen, at 0.25, 0.5 and 1.0 μg/mL, and adenosine diphosphate (ADP), 
      at 0.5, 1.0 and 2.0 μM, to determine their effective concentrations. Seventeen 
      healthy volunteers were administered acetylsalicylic acid at 162 mg/day, with 
      platelet aggregation determined before and 20 min after administration. In all 
      subjects, the rate of platelet aggregation induced by 1.0 μg/mL of collagen 
      before taking acetylsalicylic acid was the highest value obtained, while 20 min 
      after acetylsalicylic acid administration, aggregation induced by collagen at 
      1.0 μg/mL was significantly decreased as compared to before administration. As 
      for the other concentrations of collagen and all those of ADP tested, platelet 
      aggregation was either not significantly induced before taking acetylsalicylic 
      acid or the rate of aggregation was not significantly decreased after taking 
      acetylsalicylic acid. Our results indicate that collagen at 1.0 μg/mL is 
      appropriate as a platelet aggregation agonist for evaluating the antiplatelet 
      effect of acetylsalicylic acid. Thus, it is useful that the measurement is 
      performed only once.
FAU - Yokoyama, Haruko
AU  - Yokoyama H
AD  - Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, 
      Tokyo, 192-0392, Japan.
FAU - Mastumura, Takashi
AU  - Mastumura T
FAU - Soeda, Shinji
AU  - Soeda S
FAU - Suzuki, Yuji
AU  - Suzuki Y
FAU - Watanabe, Masayuki
AU  - Watanabe M
FAU - Kashiwakura, Emiko
AU  - Kashiwakura E
FAU - Saso, Takayuki
AU  - Saso T
FAU - Ikeda, Noriyuki
AU  - Ikeda N
FAU - Tokuoka, Kentaro
AU  - Tokuoka K
FAU - Kitagawa, Yasuhisa
AU  - Kitagawa Y
FAU - Yamada, Yasuhiko
AU  - Yamada Y
LA  - eng
PT  - Journal Article
DEP - 20131222
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Collagen/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 2013/12/24 06:00
MHDA- 2015/01/16 06:00
CRDT- 2013/12/24 06:00
PHST- 2013/03/17 00:00 [received]
PHST- 2013/12/07 00:00 [accepted]
PHST- 2013/12/24 06:00 [entrez]
PHST- 2013/12/24 06:00 [pubmed]
PHST- 2015/01/16 06:00 [medline]
AID - 10.1007/s13318-013-0170-9 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 2014 Dec;39(4):327-33. doi: 
      10.1007/s13318-013-0170-9. Epub 2013 Dec 22.

PMID- 12907257
OWN - NLM
STAT- MEDLINE
DCOM- 20040621
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 32
IP  - 6
DP  - 2003 Aug 21
TI  - Simultaneous determination of aspirin and isosorbide 5-mononitrate in formulation 
      by reversed phase high pressure liquid chromatography.
PG  - 1145-8
AB  - A simple, precise and rapid reversed phase HPLC method was developed for the 
      simultaneous estimation of aspirin (AS) and isosorbide 5-mononitrate (ISM) in 
      combined formulation. The method was carried out on a Thermo Quest C18 column 
      using a mixture of water:methanol (water pH adjusted to 3.4 using dilute 
      orthophosphoric acid) and detection was carried out at 215 nm using chlorzoxazone 
      as internal standard. Both the drugs showed linearity in the range of 2-10 
      microg/ml and limits of quantification was found to be 4 and 40 ng/ml for AS and 
      ISM, respectively.
FAU - Gandhimathi, M
AU  - Gandhimathi M
AD  - Department of Pharmaceutical Analysis, College of Pharmacy, Sri Ramakrishna 
      Institute of Paramedical Sciences, 395, Sarojini Naidu Street, 641 044, Tamil 
      Nadu, Coimbatore, India. gands72@yahoo.co.in
FAU - Ravi, T K
AU  - Ravi TK
FAU - Abraham, Annie
AU  - Abraham A
FAU - Thomas, Renu
AU  - Thomas R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - H0DE420U8G (Chlorzoxazone)
RN  - IA7306519N (Isosorbide Dinitrate)
RN  - LX1OH63030 (isosorbide-5-mononitrate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chlorzoxazone/analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Isosorbide Dinitrate/*analogs & derivatives/*analysis
MH  - Reference Standards
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
EDAT- 2003/08/09 05:00
MHDA- 2004/06/24 05:00
CRDT- 2003/08/09 05:00
PHST- 2003/08/09 05:00 [pubmed]
PHST- 2004/06/24 05:00 [medline]
PHST- 2003/08/09 05:00 [entrez]
AID - S0731708503002486 [pii]
AID - 10.1016/s0731-7085(03)00248-6 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2003 Aug 21;32(6):1145-8. doi: 
      10.1016/s0731-7085(03)00248-6.

PMID- 1519210
OWN - NLM
STAT- MEDLINE
DCOM- 19921006
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 67
IP  - 5
DP  - 1992 May 4
TI  - A randomized and blinded comparison of three bleeding time techniques: the Ivy 
      method, and the Simplate II method in two directions.
PG  - 514-8
AB  - We compared the Ivy bleeding time method and two alternatives of the Simplate II 
      method (incisions in horizontal and vertical direction) with each other, with 
      regard to the sensitivity, the specificity, the costs and the burden for the 
      patient. In the aspirin study an aspirin-induced bleeding defect was used. 
      Seventy-two healthy volunteers were randomized to receive either 500 mg 
      acetylsalicylic acid (ASA) or a placebo. Double blinding was maintained 
      throughout the study. In the anticoagulation study 62 patients participated, who 
      received oral anticoagulants (OAC) for various reasons. All participants received 
      two bleeding time methods. The burden for the participants of each method was 
      screened by a small standard questionnaire. The differences in sensitivity and 
      specificity between the three methods proved minimal. The Ivy method was more 
      often preferred by the participants than the Simplate methods. Since a choice on 
      the basis of sensitivity and specificity appears not possible, we prefer the Ivy 
      method because of lower costs and less burden.
FAU - Srámek, R
AU  - Srámek R
AD  - Department of Clinical Epidemiology, University Hospital Leiden, The Netherlands.
FAU - Srámek, A
AU  - Srámek A
FAU - Koster, T
AU  - Koster T
FAU - Briët, E
AU  - Briët E
FAU - Rosendaal, F R
AU  - Rosendaal FR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Thromb Haemost. 1993 May 3;69(5):523-4. PMID: 8357429
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects
MH  - *Bleeding Time
MH  - Cost-Benefit Analysis
MH  - Double-Blind Method
MH  - Humans
MH  - Methods
MH  - Middle Aged
MH  - Reference Values
MH  - Sensitivity and Specificity
EDAT- 1992/05/04 00:00
MHDA- 1992/05/04 00:01
CRDT- 1992/05/04 00:00
PHST- 1992/05/04 00:00 [pubmed]
PHST- 1992/05/04 00:01 [medline]
PHST- 1992/05/04 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1992 May 4;67(5):514-8.

PMID- 3704997
OWN - NLM
STAT- MEDLINE
DCOM- 19860530
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 55
IP  - 1
DP  - 1986 Feb 28
TI  - Long lasting sitting position and haemostasis.
PG  - 119-21
AB  - Blood coagulation, fibrinolysis and platelet aggregability were assessed in 8 
      physicians aged 30-40 years, who had travelled non-stop by car from Salonica to 
      Athens (510 km) and returned to Salonica after 48 h of rest and after 
      administration of 1 g of aspirin. At the end of journey A, platelet aggregability 
      was found to be increased (6 out of 8 persons), AT III was decreased by 30% (p 
      less than 0.001), the F VIII:C / F VIIIR: Ag ratio was decreased (p less than 
      0.02) and ELT was prolonged. At the end of journey B the findings were the 
      following: platelet aggregation was not affected, the decrease of AT III was not 
      statistically significant and ELT was significantly shortened (p less than 
      0.005). A common finding of both journeys was the increase of platelet counts at 
      the end (p less than 0.005). The correlation between long lasting sitting and the 
      response of the haemostatic balance is suggested. The influence of aspirin is 
      discussed.
FAU - Makris, P E
AU  - Makris PE
FAU - Louizou, C
AU  - Louizou C
FAU - Markakis, C
AU  - Markakis C
FAU - Tsakiris, D A
AU  - Tsakiris DA
FAU - Mandalaki, T
AU  - Mandalaki T
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Fibrinolysis/drug effects
MH  - *Hemostasis/drug effects
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - *Posture
MH  - Thrombosis/etiology/prevention & control
EDAT- 1986/02/28 00:00
MHDA- 1986/02/28 00:01
CRDT- 1986/02/28 00:00
PHST- 1986/02/28 00:00 [pubmed]
PHST- 1986/02/28 00:01 [medline]
PHST- 1986/02/28 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1986 Feb 28;55(1):119-21.

PMID- 871376
OWN - NLM
STAT- MEDLINE
DCOM- 19770902
LR  - 20181113
IS  - 0007-1021 (Print)
IS  - 0007-1021 (Linking)
VI  - 58
IP  - 3
DP  - 1977 Jun
TI  - The synergistic effect of aspirin and dipyridamole upon platelet thrombi in 
      living blood vessels.
PG  - 268-72
AB  - In rabbits previously injected i.v. with alloxan, serial observations of platelet 
      thrombus formation in response to topical adenosine diphosphate (ADP) at sites of 
      electrical injuries in pial arteries have been made. Using this model we have 
      studied the effects of oral daily doses of dipyridamole (Persantin) and acetyl 
      salicylic acid (ASA) upon platelet thrombus formation. Oral daily doses of 42 mg 
      of ASA and 6 mg dipyridamole given separately in alloxan-treated rabbits are 
      without effect. When given together orally, 42 mg and 6 mg respectively reduced 
      the level of sensitivity to ADP for producing platelet thrombi to that 
      established for the rabbits before the injection of alloxan. But withdrawal of 
      these combined doses of dipyridamole and ASA caused the sensitivity of ADP for 
      platelet thrombus formation to be raised to the much increased level present in 
      rabbits soon after they are given i.v. alloxan. This apparent synergistic 
      behaviour displayed by dipyridamole and ASA in these rabbits results in 
      antithrombotic effects which are clearly absent when these two agents are given 
      separately. It is of interest that the dose levels used here are equivalent, an a 
      body weight ratio, to those being used in man in the current Persantin-Aspirin 
      Reinfarction Study.
FAU - Honour, A J
AU  - Honour AJ
FAU - Hockaday, T D
AU  - Hockaday TD
FAU - Mann, J I
AU  - Mann JI
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Exp Pathol
JT  - British journal of experimental pathology
JID - 0372543
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 6SW5YHA5NG (Alloxan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Alloxan
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dipyridamole/*pharmacology
MH  - Drug Synergism
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
MH  - Thrombosis/chemically induced
PMC - PMC2041135
EDAT- 1977/06/01 00:00
MHDA- 1977/06/01 00:01
CRDT- 1977/06/01 00:00
PHST- 1977/06/01 00:00 [pubmed]
PHST- 1977/06/01 00:01 [medline]
PHST- 1977/06/01 00:00 [entrez]
PST - ppublish
SO  - Br J Exp Pathol. 1977 Jun;58(3):268-72.

PMID- 12217369
OWN - NLM
STAT- MEDLINE
DCOM- 20030304
LR  - 20190819
IS  - 0960-894X (Print)
IS  - 0960-894X (Linking)
VI  - 12
IP  - 19
DP  - 2002 Oct 7
TI  - Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and 
      selective cyclooxygenase-2 inhibitors.
PG  - 2753-6
AB  - A group of isomers possessing a 2-, 3-, or 4-acetoxy moiety on the 3-phenyl 
      substituent of rofecoxib were synthesized that exhibit highly potent, and 
      selective, COX-2 inhibitory activity that have the potential to acetylate the 
      COX-2 isozyme.
FAU - Rahim, M Abdur
AU  - Rahim MA
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Canada.
FAU - Rao, P N Praveen
AU  - Rao PN
FAU - Knaus, Edward E
AU  - Knaus EE
LA  - eng
SI  - PDB/1CX2
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Lactones)
RN  - 0 (Membrane Proteins)
RN  - 0 (Sulfones)
RN  - 0QTW8Z7MCR (rofecoxib)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/chemistry/pharmacology
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*chemical synthesis/*chemistry
MH  - Humans
MH  - Isoenzymes/genetics/*metabolism
MH  - Isomerism
MH  - Lactones/*chemistry
MH  - Membrane Proteins
MH  - Models, Molecular
MH  - Prostaglandin-Endoperoxide Synthases/genetics/*metabolism
MH  - Sulfones
EDAT- 2002/09/10 10:00
MHDA- 2003/03/05 04:00
CRDT- 2002/09/10 10:00
PHST- 2002/09/10 10:00 [pubmed]
PHST- 2003/03/05 04:00 [medline]
PHST- 2002/09/10 10:00 [entrez]
AID - S0960894X02005371 [pii]
AID - 10.1016/s0960-894x(02)00537-1 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2002 Oct 7;12(19):2753-6. doi: 
      10.1016/s0960-894x(02)00537-1.

PMID- 8873135
OWN - NLM
STAT- MEDLINE
DCOM- 19970110
LR  - 20190701
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 214
IP  - 1
DP  - 1996 Aug 16
TI  - Topical acetylsalicylate attenuates capsaicin induced pain, flare and allodynia 
      but not thermal hyperalgesia.
PG  - 72-4
AB  - The effect of acetylsalicylic acid (ASA) on capsaicin-evoked activation of 
      cutaneous nociceptors was tested in a double blind study in 10 volunteers. 
      Capsaicin (2% in ethanol) was applied topically for 30 min. Topical ASA (0.25 
      g/ml) reduced pain intensity and axon reflex flare size. Also, areas of secondary 
      hyperalgesia to light touch and pin-prick were diminished. In contrast, 
      capsaicin-induced heat hyperalgesia was unaffected by ASA. It is concluded that 
      ASA counteracts the excitatory effects of capsaicin on nociceptors and mechanical 
      hyperalgesia but not its sensitizing action to heat.
FAU - Schmelz, M
AU  - Schmelz M
AD  - Department of Physiology and Experimental Pathophysiology, University of 
      Erlangen-Nürnberg, Germany. schmelz@ipb.uni-erlangen.de
FAU - Kress, M
AU  - Kress M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - R16CO5Y76E (Aspirin)
RN  - S07O44R1ZM (Capsaicin)
SB  - IM
MH  - Administration, Topical
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Capsaicin
MH  - Double-Blind Method
MH  - Hot Temperature
MH  - Humans
MH  - Hyperalgesia/*drug therapy/etiology/physiopathology
MH  - Pain/chemically induced/*drug therapy
MH  - Palliative Care
MH  - Sensation Disorders/chemically induced/*drug therapy
EDAT- 1996/08/16 00:00
MHDA- 1996/08/16 00:01
CRDT- 1996/08/16 00:00
PHST- 1996/08/16 00:00 [pubmed]
PHST- 1996/08/16 00:01 [medline]
PHST- 1996/08/16 00:00 [entrez]
AID - S0304394096128688 [pii]
AID - 10.1016/0304-3940(96)12868-8 [doi]
PST - ppublish
SO  - Neurosci Lett. 1996 Aug 16;214(1):72-4. doi: 10.1016/0304-3940(96)12868-8.

PMID- 9026383
OWN - NLM
STAT- MEDLINE
DCOM- 19970218
LR  - 20181130
IS  - 2522-9028 (Print)
IS  - 2522-9028 (Linking)
VI  - 41
IP  - 5-6
DP  - 1995 Sep-Dec
TI  - [The effect of Val'kofen tablets for children on the function of the 
      gastrointestinal tract and liver in an experiment].
PG  - 111-6
AB  - It was prepared new child's medicinal form, the tablets "Valcophene" for making a 
      wider variety of pediatric preparation's. It is studied the influence of 
      "Valcophene" on the functional state of alimentary canal in experiment on rat's. 
      Results investigation's are testified to absence of ulcerative action in new 
      child's preparations. Studying influence in liver functional state is provided 
      for new children's preparation "Valcophene" too. The chronic experiment is showed 
      that "Valcophene" didn't influence on liver in experimental animals.
FAU - Shapovalova, V O
AU  - Shapovalova VO
LA  - ukr
PT  - Comparative Study
PT  - Journal Article
TT  - Vplyv tabletok dlia diteĭ "Val'kofen" na funktsional'nyĭ stan 
      shlunkovo-kyshkovoho traktu ta pechinku v eksperymenti.
PL  - Ukraine
TA  - Fiziol Zh (1994)
JT  - Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994)
JID - 9601541
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
RN  - YQE403BP4D (Phenobarbital)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/*pharmacology/toxicity
MH  - Caffeine/*pharmacology/toxicity
MH  - Digestive System/*drug effects
MH  - Drug Combinations
MH  - Female
MH  - Gastric Juice/drug effects/metabolism
MH  - Gastric Mucosa/drug effects/metabolism
MH  - Liver/*drug effects/enzymology
MH  - Male
MH  - Phenobarbital/*pharmacology/toxicity
MH  - Rats
MH  - Tablets
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
PST - ppublish
SO  - Fiziol Zh (1994). 1995 Sep-Dec;41(5-6):111-6.

PMID- 3635127
OWN - NLM
STAT- MEDLINE
DCOM- 19860619
LR  - 20131121
IS  - 0029-6465 (Print)
IS  - 0029-6465 (Linking)
VI  - 21
IP  - 2
DP  - 1986 Jun
TI  - Pharmacologic approach to ischemic stroke management.
PG  - 289-96
AB  - Currently, pharmacologic intervention is directed toward preventing further 
      spread of damage in the patient with cerebrovascular disease. Anti-platelet 
      agents decrease platelet aggregation responses and anticoagulants decrease 
      formation of the fibrin plug. In addition to the potential clinical benefits of 
      these agents, risks must be considered. Patient education and compliance are 
      major factors for consideration when assessing and monitoring treatment plans. 
      Therefore, it is beneficial to the patient for health care teams to engage in 
      multidisciplinary rounds which foster a consistent approach to treatment and 
      allow each team member to make his unique contribution to the overall care of the 
      patient.
FAU - Kasuya, A
AU  - Kasuya A
FAU - Holm, K
AU  - Holm K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nurs Clin North Am
JT  - The Nursing clinics of North America
JID - 0042033
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cerebrovascular Disorders/*drug therapy
MH  - Dipyridamole/adverse effects/therapeutic use
MH  - Drug Interactions
MH  - Heparin/adverse effects/therapeutic use
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Monitoring, Physiologic
MH  - Risk
MH  - Warfarin/adverse effects/therapeutic use
EDAT- 1986/06/01 00:00
MHDA- 1986/06/01 00:01
CRDT- 1986/06/01 00:00
PHST- 1986/06/01 00:00 [pubmed]
PHST- 1986/06/01 00:01 [medline]
PHST- 1986/06/01 00:00 [entrez]
PST - ppublish
SO  - Nurs Clin North Am. 1986 Jun;21(2):289-96.

PMID- 7175988
OWN - NLM
STAT- MEDLINE
DCOM- 19830225
LR  - 20220330
IS  - 0731-3810 (Print)
IS  - 0731-3810 (Linking)
VI  - 19
IP  - 5
DP  - 1982 Jul
TI  - Evaluation of activated charcoal-sorbitol suspension as an antidote.
PG  - 433-44
AB  - Studies in rats were performed to evaluate the effect of sorbitol on the 
      antidotal efficacy of activated charcoal against four test drugs and to 
      investigate the influence of storage upon the antidotal effect of activated 
      charcoal-sorbitol suspension. The antidotal potency of activated charcoal was not 
      diminished by sorbitol solution 70% w/v. In fact, it was enhanced by the sorbitol 
      solution, as indicated by greater decrease in peak tissue drug concentration, 
      compared to the effect produced by activated charcoal in aqueous suspension. 
      Furthermore, storage of activated charcoal in sorbitol for as long as 1 year did 
      not reduce the antidotal-efficiency of the absorbent.
FAU - Picchioni, A L
AU  - Picchioni AL
FAU - Chin, L
AU  - Chin L
FAU - Gillespie, T
AU  - Gillespie T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Toxicol Clin Toxicol
JT  - Journal of toxicology. Clinical toxicology
JID - 8213460
RN  - 0 (Antidotes)
RN  - 0 (Drug Combinations)
RN  - 16291-96-6 (Charcoal)
RN  - 3U6IO1965U (Chlorpheniramine)
RN  - 506T60A25R (Sorbitol)
RN  - 886U3H6UFF (Chloroquine)
RN  - I4744080IR (Pentobarbital)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antidotes/*therapeutic use
MH  - Aspirin/analysis/blood
MH  - Charcoal/*therapeutic use
MH  - Chloroquine/analysis/blood
MH  - Chlorpheniramine/*analysis/blood
MH  - Drug Combinations
MH  - Drug Evaluation, Preclinical
MH  - Liver/analysis
MH  - Male
MH  - Pentobarbital/analysis/blood
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Sorbitol/*therapeutic use
EDAT- 1982/07/01 00:00
MHDA- 1982/07/01 00:01
CRDT- 1982/07/01 00:00
PHST- 1982/07/01 00:00 [pubmed]
PHST- 1982/07/01 00:01 [medline]
PHST- 1982/07/01 00:00 [entrez]
AID - 10.3109/15563658208992498 [doi]
PST - ppublish
SO  - J Toxicol Clin Toxicol. 1982 Jul;19(5):433-44. doi: 10.3109/15563658208992498.

PMID- 7664027
OWN - NLM
STAT- MEDLINE
DCOM- 19951010
LR  - 20191031
IS  - 1023-3830 (Print)
IS  - 1023-3830 (Linking)
VI  - 44
IP  - 1
DP  - 1995 Jan
TI  - Involvement of brain serotonergic system in the antinociceptive action of 
      acetylsalicylic acid in the rat.
PG  - 30-5
AB  - The pain-threshold in the hot-plate test and serotonin (5-HT) receptor binding 
      capacity in the cortex and pontine areas of rat brain were studied after 
      intraperitoneal (ip) administration of acetyl salicylate of lysine equivalent to 
      400 mg/kg of acetylsalicylic acid (ASA). The antinociceptive activity of ASA was 
      prevented by ip pre-treatment with Parachlorophenylalanine (PCPA) at the rate of 
      100 mg/kg/day for 4 days. PCPA pre-treatment increased the number of 5-HT 
      receptors and abolished the ASA-induced reduction in 5-HT receptor binding 
      capacity in the cortex but did not affect serum salicylate levels. These results 
      provide support for the hypothesis that the antinociceptive action of ASA, at 
      least in the hot-plate test, involves the central serotonergic system.
FAU - Pini, L A
AU  - Pini LA
AD  - Clinical Pharmacology Unit, University of Modena, Italy.
FAU - Sandrini, M
AU  - Sandrini M
FAU - Vitale, G
AU  - Vitale G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Analgesics)
RN  - 0 (Receptors, Serotonin)
RN  - 0 (Salicylates)
RN  - 333DO1RDJY (Serotonin)
RN  - R16CO5Y76E (Aspirin)
RN  - R5J7E3L9SP (Fenclonine)
SB  - IM
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacokinetics/*pharmacology
MH  - Behavior, Animal/drug effects
MH  - Brain/*physiology
MH  - Cerebral Cortex/drug effects/metabolism
MH  - Fenclonine/pharmacology
MH  - Injections, Intraperitoneal
MH  - Male
MH  - Pain Threshold/drug effects
MH  - Pons/drug effects/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Serotonin/drug effects/metabolism
MH  - Salicylates/blood
MH  - Serotonin/*physiology
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1007/BF01630485 [doi]
PST - ppublish
SO  - Inflamm Res. 1995 Jan;44(1):30-5. doi: 10.1007/BF01630485.

PMID- 14558930
OWN - NLM
STAT- MEDLINE
DCOM- 20031120
LR  - 20190513
IS  - 0021-9665 (Print)
IS  - 0021-9665 (Linking)
VI  - 41
IP  - 8
DP  - 2003 Sep
TI  - A rapid high-performance liquid chromatographic method for the simultaneous 
      quantitation of aspirin, salicylic acid, and caffeine in effervescent tablets.
PG  - 393-7
AB  - A rapid reversed-phase high-performance liquid chromatographic procedure is 
      developed and validated for the simultaneous quantitation of aspirin, salicylic 
      acid, and caffeine extracted from an effervescent tablet. The method uses a 
      Hypersil C18 column (5 micro m, 15 cm x 4.6 mm) for an isocratic elution in a 
      water-methanol-acetic acid mobile phase at a wavelength of 275 nm. The tablets' 
      buffering effects and acid neutralizing capacity require an extraction solvent of 
      methanol-formic acid. The range of linearity for aspirin is 0.5-1.25 mg/mL, 
      caffeine 0.065-0.195 mg/mL, and salicylic acid 0.4-6.0% of aspirin. The overall 
      recovery is 100.2%, 100.7%, and 99.2% for aspirin, caffeine, and salicylic acid, 
      respectively. Under the conditions of the method, aspirin, caffeine, and 
      salicylic acid are adequately resolved with proper peak symmetry in less than 7 
      min.
FAU - Sawyer, MaryJean
AU  - Sawyer M
AD  - Bayer HealthCare, Consumer Care Division, 36 Columbia Road, Morristown, NJ 07962, 
      USA. MaryJean.Sawyer.B@Bayer.com
FAU - Kumar, Vimal
AU  - Kumar V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Chromatogr Sci
JT  - Journal of chromatographic science
JID - 0173225
RN  - 0 (Tablets)
RN  - 3G6A5W338E (Caffeine)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Reference Standards
MH  - Reproducibility of Results
MH  - Salicylic Acid/*analysis
MH  - Sensitivity and Specificity
MH  - Tablets/*chemistry
EDAT- 2003/10/16 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/10/16 05:00
PHST- 2003/10/16 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/10/16 05:00 [entrez]
AID - 10.1093/chromsci/41.8.393 [doi]
PST - ppublish
SO  - J Chromatogr Sci. 2003 Sep;41(8):393-7. doi: 10.1093/chromsci/41.8.393.

PMID- 11861091
OWN - NLM
STAT- MEDLINE
DCOM- 20020424
LR  - 20190916
IS  - 0720-048X (Print)
IS  - 0720-048X (Linking)
VI  - 41
IP  - 3
DP  - 2002 Mar
TI  - Enhancement characteristics of the microbubble agent Levovist: reproducibility 
      and interaction with aspirin.
PG  - 179-83
AB  - We investigated the reproducibility of Doppler enhancement indices following 
      intravenous bolus injections of Levovist (Schering AG, Berlin) microbubbles. We 
      also aimed to determine whether observations from animal studies suggesting that 
      aspirin potentiates microbubble enhancement were reproducible in humans. In five 
      healthy volunteers, time enhancement profiles of Doppler intensity following 
      repeated bolus injections of Levovist were acquired from the common carotid 
      artery, hepatic vein and kidney using spectral and power Doppler before and after 
      oral aspirin (600 mg). Peak enhancement (PE), area under the curve (AUC) and 
      decay slopes (lambda) were calculated. Hepatic vein contrast arrival time (AT) 
      was determined subjectively. Well-defined carotid enhancement was seen in 19/20 
      injections. Reproducibility was high (r > 0.8). PE and AUG were unaffected by 
      aspirin, but lambda was slightly reduced (P = 0.02). Renal power Doppler profiles 
      were well defined (10/10) with no significant changes of AUC, PE or lambda after 
      aspirin. Our study demonstrates good reproducibility of carotid spectral Doppler 
      time intensitometry with Levovist in man. Aspirin does not have a significant 
      effect on enhancement indices except carotid spectral Doppler decay. We conclude 
      that aspirin is unlikely to potentiate microbubble enhancement, as seen in animal 
      studies.
FAU - Heckemann, Rolf A
AU  - Heckemann RA
AD  - Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. soundray@gmx.de
FAU - Harvey, Christopher J
AU  - Harvey CJ
FAU - Blomley, Martin J K
AU  - Blomley MJ
FAU - Eckersley, Robert J
AU  - Eckersley RJ
FAU - Butler-Barnes, Jenny
AU  - Butler-Barnes J
FAU - Jayaram, Vijay
AU  - Jayaram V
FAU - Cosgrove, David O
AU  - Cosgrove DO
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Eur J Radiol
JT  - European journal of radiology
JID - 8106411
RN  - 0 (Contrast Media)
RN  - 0 (Polysaccharides)
RN  - 127279-08-7 (SHU 508)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Carotid Artery, Common/diagnostic imaging
MH  - *Contrast Media
MH  - Drug Interactions
MH  - Hepatic Veins/diagnostic imaging
MH  - Humans
MH  - Kidney/diagnostic imaging
MH  - Male
MH  - Polysaccharides/*pharmacology
MH  - Reproducibility of Results
MH  - *Ultrasonography, Doppler
EDAT- 2002/02/28 10:00
MHDA- 2002/04/25 10:01
CRDT- 2002/02/28 10:00
PHST- 2002/02/28 10:00 [pubmed]
PHST- 2002/04/25 10:01 [medline]
PHST- 2002/02/28 10:00 [entrez]
AID - S0720048X01004600 [pii]
AID - 10.1016/s0720-048x(01)00460-0 [doi]
PST - ppublish
SO  - Eur J Radiol. 2002 Mar;41(3):179-83. doi: 10.1016/s0720-048x(01)00460-0.

PMID- 17636639
OWN - NLM
STAT- MEDLINE
DCOM- 20071018
LR  - 20200511
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 2
DP  - 2007 Jul 18
TI  - WITHDRAWN: Antiplatelet agents for preventing and treating pre-eclampsia.
PG  - CD000492
AB  - BACKGROUND: Pre-eclampsia is associated with deficient intravascular production 
      of prostacyclin, a vasodilator, and excessive production of thromboxane, a 
      platelet-derived vasoconstrictor and stimulant of platelet aggregation. These 
      observations led to the hypotheses that antiplatelet agents, and low dose aspirin 
      in particular, might prevent or delay the development of pre-eclampsia. 
      OBJECTIVES: To assess the effectiveness and safety of antiplatelet agents when 
      given to women at risk of developing pre-eclampsia, and to those with established 
      pre-eclampsia. SEARCH STRATEGY: This review drew on the search strategy developed 
      for the Pregnancy and Childbirth Group as a whole. The Cochrane Controlled Trials 
      Register was also searched, The Cochrane Library 1999 Issue 1, Embase was 
      searched from 1994-1999 and hand searches were performed of the congress 
      proceedings of the International and European Societies for the Study of 
      Hypertension in Pregnancy. SELECTION CRITERIA: All randomised trials comparing 
      antiplatelet agents with either placebo or no antiplatelet agent during 
      pregnancy. Quasi random study designs were excluded. Participants were pregnant 
      women considered to be at risk of developing pre-eclampsia, and those with 
      pre-eclampsia before delivery. Women treated postpartum were excluded. 
      Interventions were any comparisons of an antiplatelet agent (such as low dose 
      aspirin or dipyridamole) with either placebo or no antiplatelet agent. DATA 
      COLLECTION AND ANALYSIS: Assessment of trials for inclusion in the review and 
      extraction of data was performed independently and unblinded by two reviewers. 
      Data were entered into the Review Manager software and double checked. MAIN 
      RESULTS: Forty two trials involving over 32,000 women were included in this 
      review, with 30,563 women in the prevention trials. There is a 15% reduction in 
      the risk of pre-eclampsia associated with the use of antiplatelet agents [32 
      trials with 29,331 women; relative risk (RR) 0.85, 95% confidence interval (0.78, 
      0.92); Number needed to treat (NNT) 89, (59, 167)]. This reduction is regardless 
      of risk status at trial entry or whether a placebo was used, and irrespective of 
      the dose of aspirin or gestation at randomisation.Twenty three trials (28,268 
      women) reported preterm delivery. There is a small (8%) reduction in the risk of 
      delivery before 37 completed weeks [RR 0.92, (0.88, 0.97); NNT 72 (44, 200)]. 
      Baby deaths were reported in 30 trials (30,093 women). Overall there is a 14% 
      reduction in baby deaths in the antiplatelet group [RR 0.86, (0.75, 0.98); NNT 
      250 (125, >10000)]. Small for gestational age babies were reported in 25 trials 
      (20,349 women), with no overall difference between the groups, RR 0.92, (0.84, 
      1.01). There were no significant differences between treatment and control groups 
      in any other measures of outcome. Five trials compared antiplatelet agents with 
      placebo or no antiplatelet agent for the treatment of pre-eclampsia. There are 
      insufficient data for any firm conclusions about the possible effects of these 
      agents when used for treatment of pre-eclampsia. AUTHORS' CONCLUSIONS: 
      Antiplatelet agents, in this review largely low dose aspirin, have small-moderate 
      benefits when used for prevention of pre-eclampsia. Further information is 
      required to assess which women are most likely to benefit, when treatment should 
      be started, and at what dose.
FAU - Knight, M
AU  - Knight M
FAU - Duley, L
AU  - Duley L
FAU - Henderson-Smart, D J
AU  - Henderson-Smart DJ
FAU - King, J F
AU  - King JF
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20070718
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2000;(2):CD000492. PMID: 10796208
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*drug therapy/prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
RF  - 103
EDAT- 2007/07/20 09:00
MHDA- 2007/10/19 09:00
CRDT- 2007/07/20 09:00
PHST- 2007/07/20 09:00 [pubmed]
PHST- 2007/10/19 09:00 [medline]
PHST- 2007/07/20 09:00 [entrez]
AID - 10.1002/14651858.CD000492.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2007 Jul 18;(2):CD000492. doi: 
      10.1002/14651858.CD000492.pub2.

PMID- 15836564
OWN - NLM
STAT- MEDLINE
DCOM- 20050816
LR  - 20131121
IS  - 0017-8748 (Print)
IS  - 0017-8748 (Linking)
VI  - 45
IP  - 4
DP  - 2005 Apr
TI  - Aspirin is efficacious for the treatment of acute migraine.
PG  - 283-92
AB  - BACKGROUND: More than 50% of migraine sufferers rely on over-the-counter 
      medications for the treatment of migraine. Along with other over-the-counter 
      products, aspirin is considered by the US Headache Consortium to be an option for 
      first-line migraine treatment. This study assessed the efficacy and tolerability 
      of aspirin versus placebo for the acute treatment of a single acute attack of 
      migraine. METHODS: This prospective, randomized, double-blind, parallel-group, 
      placebo-controlled study evaluated the efficacy of a single, 1000-mg dose of 
      aspirin for the treatment of acute moderate to severe migraine, with or without 
      aura. Subjects recorded all study evaluations in a diary at baseline and at .5, 
      1, 2, 3, 4, 5, 6, and 24 hours after treatment. Pain was rated on a 4-point 
      ordinal scale from no pain to severe pain. The primary efficacy end point was 
      headache response at 2 hours. Secondary efficacy parameters included reduction of 
      nausea, photophobia and phonophobia, pain intensity difference, and headache 
      recurrence at 24 hours. RESULTS: Of 485 subjects enrolled, 409 took study 
      medication and 401 treated a confirmed migraine attack (201 with aspirin and 200 
      with placebo). Baseline demographic and migraine characteristics were not 
      significantly different between groups. The 2-hour headache response rate was 52% 
      with aspirin versus 34% with placebo (P<.001). Aspirin was significantly more 
      effective than placebo for pain reduction beginning 1 hour after dosing (P<.001) 
      and continuing throughout the 6-hour evaluation period. Significantly (P<.05), 
      more subjects were pain free from the 1-hour evaluation through the 6-hour 
      evaluation. Of the aspirin-treated subjects, 20% were pain free at 2 hours versus 
      only 6% of placebo-treated subjects. At 24 hours, the headache recurrence rate 
      was 21.8% for aspirin (23 of 105 subjects) and 27.7% for placebo (19 of 68 
      subjects). Only 34% of aspirin-treated subjects needed rescue medication at 24 
      hours compared with 52% of placebo-treated subjects (P<.001). Aspirin was well 
      tolerated, and adverse events were not significantly different between groups. 
      CONCLUSIONS: This study demonstrates that aspirin is safe and effective for 
      treatment of acute migraine in appropriately selected patients.
FAU - Lipton, Richard B
AU  - Lipton RB
AD  - Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10467, 
      USA.
FAU - Goldstein, Jerome
AU  - Goldstein J
FAU - Baggish, Jeffrey S
AU  - Baggish JS
FAU - Yataco, Alberto R
AU  - Yataco AR
FAU - Sorrentino, James V
AU  - Sorrentino JV
FAU - Quiring, John N
AU  - Quiring JN
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Evid Based Nurs. 2005 Oct;8(4):107. PMID: 16247877
MH  - Acute Disease
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Migraine Disorders/*drug therapy
MH  - Prospective Studies
MH  - Treatment Outcome
EDAT- 2005/04/20 09:00
MHDA- 2005/08/17 09:00
CRDT- 2005/04/20 09:00
PHST- 2005/04/20 09:00 [pubmed]
PHST- 2005/08/17 09:00 [medline]
PHST- 2005/04/20 09:00 [entrez]
AID - HED05065 [pii]
AID - 10.1111/j.1526-4610.2005.05065.x [doi]
PST - ppublish
SO  - Headache. 2005 Apr;45(4):283-92. doi: 10.1111/j.1526-4610.2005.05065.x.

PMID- 30599316
OWN - NLM
STAT- MEDLINE
DCOM- 20200325
LR  - 20200325
IS  - 1879-0534 (Electronic)
IS  - 0010-4825 (Linking)
VI  - 105
DP  - 2019 Feb
TI  - A prediction method for plasma concentration by using a nonlinear grey Bernoulli 
      combined model based on a self-memory algorithm.
PG  - 81-91
LID - S0010-4825(18)30402-5 [pii]
LID - 10.1016/j.compbiomed.2018.12.004 [doi]
AB  - The goal of this work is to present and explore the application of a novel 
      nonlinear grey Bernoulli combined model based on a self-memory algorithm, 
      abbreviated as SA-NGBM, for modeling single-peaked sequences of time samples of 
      acetylsalicylate plasma concentration following oral dosing. The 
      self-memorization SA-NGBM routine reduces the dependence on a solitary initial 
      value, as the initial state of the model utilizes multiple time samples. To test 
      its forecasting performance, the SA-NGBM was used to extrapolate the plasma 
      concentration predicted data, in comparison with the later time samples. The 
      results were contrasted with those of the traditional optimized NGBM (ONGBM), 
      exponential smoothing (ES) and simple moving average (SMA) using four popular 
      accuracy and significance tests. That comparison showed that the SA-NGBM was much 
      more accurate and efficient for matching the individual, nonlinear-system 
      stochastic fluctuations than the existing ONGBM, ES and SMA models. The findings 
      have potential applications for signal matching to similar small sample size, 
      single-peaked, plasma concentration series.
CI  - Copyright © 2018. Published by Elsevier Ltd.
FAU - Guo, Xiaojun
AU  - Guo X
AD  - School of Science, Nantong University, Nantong, 226019, China. Electronic 
      address: guoxj159@ntu.edu.cn.
FAU - Liu, Sifeng
AU  - Liu S
AD  - College of Economics and Management, Nanjing University of Aeronautics and 
      Astronautics, Nanjing, 211106, China.
FAU - Yang, Yingjie
AU  - Yang Y
AD  - Institute of Artificial Intelligence, De Montfort University, Leicester, LE1 9BH, 
      UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181205
PL  - United States
TA  - Comput Biol Med
JT  - Computers in biology and medicine
JID - 1250250
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Algorithms
MH  - Aspirin/*pharmacokinetics
MH  - Humans
MH  - *Models, Biological
MH  - Nonlinear Dynamics
MH  - Plasma/*metabolism
OTO - NOTNLM
OT  - Grey prediction theory
OT  - Nonlinear grey Bernoulli model
OT  - Plasma concentration
OT  - Self-memory algorithm
EDAT- 2019/01/02 06:00
MHDA- 2020/03/26 06:00
CRDT- 2019/01/02 06:00
PHST- 2018/05/29 00:00 [received]
PHST- 2018/11/24 00:00 [revised]
PHST- 2018/12/04 00:00 [accepted]
PHST- 2019/01/02 06:00 [pubmed]
PHST- 2020/03/26 06:00 [medline]
PHST- 2019/01/02 06:00 [entrez]
AID - S0010-4825(18)30402-5 [pii]
AID - 10.1016/j.compbiomed.2018.12.004 [doi]
PST - ppublish
SO  - Comput Biol Med. 2019 Feb;105:81-91. doi: 10.1016/j.compbiomed.2018.12.004. Epub 
      2018 Dec 5.

PMID- 19785798
OWN - NLM
STAT- MEDLINE
DCOM- 20091211
LR  - 20131121
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 153
DP  - 2009
TI  - [Acetylsalicylic acid in patients with diabetes mellitus: can be used for 
      secondary but not primary prevention of cardiovascular events].
PG  - A109
AB  - There is no consensus in international guidelines about the role of 
      acetylsalicylic acid in primary prevention of cardiovascular events in patients 
      with diabetes mellitus.Primary prevention trials suggest that in diabetic 
      patients, acetylsalicylic acid has either no or less favourable effects in 
      preventing cardiovascular events compared to patients with other cardiovascular 
      risk factors.Increased platelet activity, increased activation of clotting 
      factors and interaction between glycation and acetylation are the most plausible 
      explanations for this loss of efficacy in patients with diabetes mellitus.The 
      evidence for the use of alternative antiplatelet therapy in addition or instead 
      of acetylsalicylic acid is too limited to recommend this as an alternative 
      preventive method. Also increasing the dose of acetylsalicylic acid is probably 
      not worthwhile.We do not recommend acetylsalicylic acid as primary prevention of 
      cardiovascular events in patients with diabetes mellitus, but we do recommend it 
      as a means of secondary prevention.
FAU - Klomp, Carolijn M C
AU  - Klomp CM
AD  - Academisch Ziekenhuis Maastricht, afd. Interne Geneeskunde, Maastricht, The 
      Netherlands. c.klomp@mumc.nl
FAU - ten Cate, Hugo
AU  - ten Cate H
FAU - Stehouwer, Coen D A
AU  - Stehouwer CD
FAU - Schaper, Nicolaas C
AU  - Schaper NC
LA  - dut
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Acetylsalicylzuur bij patiënten met diabetes mellitus: niet voor primaire, wél 
      voor secundaire preventie van hart-vaatziekten.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Complications/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Risk Factors
MH  - Secondary Prevention
RF  - 27
EDAT- 2009/09/30 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/09/30 06:00
PHST- 2009/09/30 06:00 [entrez]
PHST- 2009/09/30 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2009;153:A109.

PMID- 34264335
OWN - NLM
STAT- MEDLINE
DCOM- 20220321
LR  - 20221207
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 114
IP  - 1
DP  - 2022 Jan 11
TI  - Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men.
PG  - 123-129
LID - 10.1093/jnci/djab129 [doi]
AB  - BACKGROUND: Thromboxane A2 (TXA2) is a platelet- and cyclooxygenase-derived 
      eicosanoid that has been linked to metastasis. We investigated the role of TXA2 
      in the development of lethal prostate cancer in African American (AA) and 
      European American (EA) men. METHODS: We measured urinary 11-dehydrothromboxane B2 
      (TXB2), a stable metabolite of TXA2, with mass spectrometry. Samples were 
      obtained from 977 cases and 1022 controls at time of recruitment. We applied 
      multivariable logistic and Cox regression modeling to examine associations of 
      TXB2 with prostate cancer and patient survival. The median survival follow-up was 
      8.4 years, with 246 deaths among cases. Aspirin use was assessed with a 
      questionnaire. Race was self-reported. RESULTS: Urinary TXB2 was inversely 
      associated with aspirin use. High (>median) TXB2 was associated with prostate 
      cancer in AA (adjusted odds ratio [OR] = 1.50, 95% confidence interval [CI] = 
      1.13 to 2.00) but not EA men (OR = 1.07, 95% CI = 0.82 to 1.40), suggesting 
      upregulated TXA2 synthesis in AA men with prostate cancer. High TXB2 was 
      positively associated with metastatic prostate cancer (OR = 2.60, 95% CI = 1.08 
      to 6.28) compared with low (≤median) TXB2. Furthermore, high TXB2 was also 
      associated with all-cause (adjusted hazard ratio = 1.59, 95% CI = 1.06 to 2.40) 
      and prostate cancer-specific mortality (hazard ratio = 4.74, 95% CI = 1.62 to 
      13.88) in AA men only. CONCLUSIONS: We report a distinct association of TXB2 with 
      prostate cancer outcomes in AA men. In this high-risk group of men, upregulation 
      of TXA2 synthesis may promote metastasis and lethal disease. Our observation 
      identifies a potential benefit of aspirin in preventing lethal prostate cancer 
      through inhibition of TXA2 synthesis.
CI  - Published by Oxford University Press 2021. This work is written by US Government 
      employees and is in the public domain in the US.
FAU - Kiely, Maeve
AU  - Kiely M
AUID- ORCID: 0000-0002-4539-1223
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
FAU - Milne, Ginger L
AU  - Milne GL
AUID- ORCID: 0000-0003-3890-151X
AD  - Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University 
      Medical Center, Nashville, TN, USA.
FAU - Minas, Tsion Z
AU  - Minas TZ
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
FAU - Dorsey, Tiffany H
AU  - Dorsey TH
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
FAU - Tang, Wei
AU  - Tang W
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
FAU - Smith, Cheryl J
AU  - Smith CJ
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
FAU - Baker, Francine
AU  - Baker F
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
FAU - Loffredo, Christopher A
AU  - Loffredo CA
AD  - Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, 
      Georgetown University Medical Center, Washington, DC, USA.
FAU - Yates, Clayton
AU  - Yates C
AD  - Department of Biology, Center for Cancer Research, Tuskegee University, Tuskegee, 
      AL, USA.
FAU - Cook, Michael B
AU  - Cook MB
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, Bethesda, MD, USA.
FAU - Ambs, Stefan
AU  - Ambs S
AUID- ORCID: 0000-0001-7651-9309
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer 
      Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Black or African American
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Male
MH  - *Prostatic Neoplasms
MH  - Thromboxane A2
MH  - Thromboxane B2/urine
PMC - PMC8755482
EDAT- 2021/07/16 06:00
MHDA- 2022/03/22 06:00
CRDT- 2021/07/15 12:19
PHST- 2021/03/09 00:00 [received]
PHST- 2021/04/29 00:00 [revised]
PHST- 2021/06/23 00:00 [accepted]
PHST- 2021/07/16 06:00 [pubmed]
PHST- 2022/03/22 06:00 [medline]
PHST- 2021/07/15 12:19 [entrez]
AID - 6321959 [pii]
AID - djab129 [pii]
AID - 10.1093/jnci/djab129 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2022 Jan 11;114(1):123-129. doi: 10.1093/jnci/djab129.

PMID- 35775785
OWN - NLM
STAT- MEDLINE
DCOM- 20221109
LR  - 20221109
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 33
IP  - 7
DP  - 2022 Nov
TI  - Perioperative anticoagulation recommendations for cutaneous oncologic surgery: a 
      review of the literature.
PG  - 2940-2945
LID - 10.1080/09546634.2022.2097161 [doi]
AB  - Consistent perioperative management is important to the practice of dermatologic 
      surgery. With the widespread use of anticoagulant medications, such as aspirin, 
      warfarin, clopidogrel, factor Xa inhibitors, and thrombin inhibitors for a number 
      of cardiovascular indications, it is important to standardize the use of these 
      drugs in the setting of skin cancer surgery. Limited literature is available, 
      however, regarding recommendations for dermatological perioperative 
      anticoagulation management. Most published manuscripts involving anticoagulation 
      and skin cancer surgery focus on complications and outcomes rather than providing 
      guidelines for decision-making. In addition, survey studies have largely shown 
      that even with existing recommendations in the literature, many dermatologists 
      continue to have varying management of these medications. Overall, this review 
      finds compelling evidence to support the safety of continuing anticoagulation 
      therapy, such as warfarin, aspirin, and clopidogrel throughout treatment for 
      cutaneous malignancies. It is important that dermatologists, while having primary 
      care and cardiology available for consultation, are aware of the safety data and 
      feel comfortable managing their patients perioperatively.
FAU - Shah, Hemali
AU  - Shah H
AUID- ORCID: 0000-0002-8407-9339
AD  - Albany Medical College, Albany, NY, USA.
FAU - Frech, Fabio Stefano
AU  - Frech FS
AUID- ORCID: 0000-0002-0689-6464
AD  - Dr. Phillip Frost Department of Dermatology, University of Miami School of 
      Medicine, Miami, FL, USA.
FAU - Dreyfuss, Isabella
AU  - Dreyfuss I
AD  - Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, 
      Davie, FL, USA.
FAU - Hernandez, Loren
AU  - Hernandez L
AD  - Dr. Phillip Frost Department of Dermatology, University of Miami School of 
      Medicine, Miami, FL, USA.
FAU - Nouri, Keyvan
AU  - Nouri K
AD  - Dr. Phillip Frost Department of Dermatology, University of Miami School of 
      Medicine, Miami, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220707
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Warfarin/therapeutic use
MH  - Clopidogrel
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Skin Neoplasms/surgery/drug therapy
OTO - NOTNLM
OT  - Perioperative anticoagulation
OT  - bleeding
OT  - complications
OT  - cutaneous surgery
EDAT- 2022/07/02 06:00
MHDA- 2022/11/10 06:00
CRDT- 2022/07/01 08:13
PHST- 2022/07/02 06:00 [pubmed]
PHST- 2022/11/10 06:00 [medline]
PHST- 2022/07/01 08:13 [entrez]
AID - 10.1080/09546634.2022.2097161 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2022 Nov;33(7):2940-2945. doi: 10.1080/09546634.2022.2097161. 
      Epub 2022 Jul 7.

PMID- 25803957
OWN - NLM
STAT- MEDLINE
DCOM- 20150428
LR  - 20150325
IS  - 0332-3102 (Print)
IS  - 0332-3102 (Linking)
VI  - 108
IP  - 2
DP  - 2015 Feb
TI  - Acute stroke unit improves stroke management-four years on from INASC.
PG  - 51-3
AB  - The Irish Heart Foundation carried out the Irish National Audit of Stroke Care 
      (INASC) in 2008. Management practices were significantly poorer than those in the 
      UK Sentinel audits. Since then an acute stroke unit has been established in 
      University Hospital Limerick. A stroke database was established. 12 key 
      indicators of stroke management audited by INASC were identified. Results were 
      compared to those in INASC. 89 stroke patients were admitted. 8 of the 12 key 
      indicators scored significantly better than in INASC. 92.5% had a brain scan 
      within 24hrs (INASC-40%, p = < 0.001). 100% of ischaemic strokes received 
      anti-thrombotics (INASC-85%, p = 0.001). 94% had rehab goals agreed by MDT (22% 
      in INASC p = 0.0000). 55% were treated in stroke unit (2% in INASC, p = 0.0000). 
      MDT input improved with regard to physiotherapy (87% vs 43% in INASC, p = < 0.02) 
      and SALT (74% vs 26%, p = < 0.02). Stroke management has significantly improved 
      from 2008, however some deficiencies remain.
FAU - Shanahan, E
AU  - Shanahan E
FAU - Keenan, R
AU  - Keenan R
FAU - Cunningham, N
AU  - Cunningham N
FAU - O'Malley, G
AU  - O'Malley G
FAU - O'Connor, M
AU  - O'Connor M
FAU - Lyons, D
AU  - Lyons D
FAU - Peters, C
AU  - Peters C
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Ir Med J
JT  - Irish medical journal
JID - 0430275
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Deglutition
MH  - Female
MH  - Hospital Units/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuroimaging
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Prospective Studies
MH  - Stroke/epidemiology/physiopathology/*therapy
EDAT- 2015/03/26 06:00
MHDA- 2015/04/29 06:00
CRDT- 2015/03/26 06:00
PHST- 2015/03/26 06:00 [entrez]
PHST- 2015/03/26 06:00 [pubmed]
PHST- 2015/04/29 06:00 [medline]
PST - ppublish
SO  - Ir Med J. 2015 Feb;108(2):51-3.

PMID- 22531881
OWN - NLM
STAT- MEDLINE
DCOM- 20130708
LR  - 20220310
IS  - 1432-1238 (Electronic)
IS  - 0342-4642 (Linking)
VI  - 38
IP  - 8
DP  - 2012 Aug
TI  - Manifold beneficial effects of acetyl salicylic acid and nonsteroidal 
      anti-inflammatory drugs on sepsis.
PG  - 1249-57
LID - 10.1007/s00134-012-2570-8 [doi]
AB  - INTRODUCTION: Acetyl salicylic acid (ASA) and nonsteroidal anti-inflammatory 
      drugs (NSAIDs) may have potential as adjunctive agents for sepsis. MATERIALS: 
      This review considers the large body of literature that indicates a basis for 
      sepsis therapy with ASA and suggests an agenda for future intervention studies in 
      sepsis prevention and treatment. ASA and NSAIDs have beneficial effects in 
      numerous experimental models of sepsis. Low doses of ASA of 100 mg/day or less 
      trigger synthesis of lipoxins that are anti-inflammatory and aid in resolution of 
      inflammation. Higher doses of ASA and NSAIDs act to reduce NF-κB stimulation and 
      inhibit numerous septic pathways. While a previous randomised controlled trial of 
      ibuprofen failed to show a reduction in mortality in sepsis, it did reduce 
      clinical manifestations of sepsis. More recent observational studies have shown 
      reduction in sepsis or acute lung injury leading to lower mortality in ICU 
      patients treated with ASA. CONCLUSIONS: Low-dose ASA appears to be beneficial in 
      the prevention and treatment of sepsis and SIRS. If proven, this intervention 
      would have a major, cost-effective impact on sepsis care.
FAU - Eisen, Damon P
AU  - Eisen DP
AD  - Victorian Infectious Diseases Service, Royal Melbourne Hospital, Grattan St, 
      Parkville, VIC 3050, Australia. damon.eisen@mh.org.au
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120425
PL  - United States
TA  - Intensive Care Med
JT  - Intensive care medicine
JID - 7704851
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipoxins)
RN  - 0 (NF-kappa B)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Inflammation/metabolism/prevention & control
MH  - Lipoxins/biosynthesis
MH  - NF-kappa B/antagonists & inhibitors
MH  - Sepsis/*prevention & control
MH  - Staphylococcal Infections/prevention & control
MH  - Staphylococcus aureus/pathogenicity
EDAT- 2012/04/26 06:00
MHDA- 2013/07/09 06:00
CRDT- 2012/04/26 06:00
PHST- 2011/12/21 00:00 [received]
PHST- 2012/03/19 00:00 [accepted]
PHST- 2012/04/26 06:00 [entrez]
PHST- 2012/04/26 06:00 [pubmed]
PHST- 2013/07/09 06:00 [medline]
AID - 10.1007/s00134-012-2570-8 [doi]
PST - ppublish
SO  - Intensive Care Med. 2012 Aug;38(8):1249-57. doi: 10.1007/s00134-012-2570-8. Epub 
      2012 Apr 25.

PMID- 19096466
OWN - NLM
STAT- MEDLINE
DCOM- 20090109
LR  - 20131121
IS  - 0807-7096 (Electronic)
IS  - 0029-2001 (Linking)
VI  - 128
IP  - 21
DP  - 2008 Nov 6
TI  - [Should platelet inhibitors be discontinued before gastrointestinal endoscopy?].
PG  - 2440-2
AB  - BACKGROUND: . In Norway, different attitudes prevail to discontinuation of 
      antiplatelet agents, such as ASA, NSAID, ADP-receptor inhibitors (clopidogrel and 
      ticlopidine) phosphodiestase inhibitors (dipyridamole) and glycoprotein IIb/IIIa 
      receptor inhibitors (abciximab and eptifibatide), before endoscopic procedures. 
      The Norwegian Association of Gastroenterology have appointed a group, consisting 
      of a medical and a surgical gastroenterologist, a haematologist, a cardiologist 
      and a pharmacologist, to review literature concerning the issue in order to give 
      a recommendation. MATERIAL AND METHODS: Literature retrieved from a 
      non-systematic search of Pubmed was critically reviewed by the study group. 
      RESULTS: No randomised controlled studies were found to have addressed the 
      problem. Two prospective and three retrospective studies have compared the 
      frequency of bleeding complications for patients using or not using ASA/NSAID 
      during endoscopic papillotomy or polypectomy. The studies showed either no 
      differences in bleeding complications, or only an increase in mild, self-limiting 
      haemorrhage for those using ASA/NSAID. INTERPRETATION: The group recommends that 
      all gastroenterological procedures may be performed on patients taking ASA/NSAID 
      provided there are no pre-existing bleeding disorders. As no clinical data are 
      available for other antiplatelet agents, the group recommends to stop the 
      treatment for 7 days before the procedure, but this will have to be balanced 
      against the risk of thrombosis associated with the discontinuation.
FAU - Hofstad, Bjørn
AU  - Hofstad B
AD  - Gastromedisinsk avdeling Ullevål universitetssykehus 0407 Oslo. bjho@uus.no
FAU - Nesbakken, Arild
AU  - Nesbakken A
FAU - Eritsland, Jan
AU  - Eritsland J
FAU - Brørs, Odd
AU  - Brørs O
FAU - Sandset, Per Morten
AU  - Sandset PM
LA  - nor
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Bør blodplatehemmere seponeres før gastrointestinal endoskopi?
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny 
      raekke
JID - 0413423
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - *Endoscopy, Gastrointestinal/adverse effects
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Hemorrhage/etiology/prevention & control
MH  - Practice Guidelines as Topic
MH  - Risk Factors
MH  - Thrombosis/etiology/prevention & control
RF  - 20
EDAT- 2008/12/20 09:00
MHDA- 2009/01/10 09:00
CRDT- 2008/12/20 09:00
PHST- 2008/12/20 09:00 [entrez]
PHST- 2008/12/20 09:00 [pubmed]
PHST- 2009/01/10 09:00 [medline]
AID - 1754689 [pii]
PST - ppublish
SO  - Tidsskr Nor Laegeforen. 2008 Nov 6;128(21):2440-2.

PMID- 9191696
OWN - NLM
STAT- MEDLINE
DCOM- 19970710
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 42
IP  - 5 Suppl
DP  - 1997 May
TI  - Effect of small-volume resuscitation on intracranial pressure and related 
      cerebral variables.
PG  - S48-53
AB  - BACKGROUND: Head injury outcome is adversely affected by the presence of 
      hypotension. Therapies directed at rapidly correcting hypotension may improve 
      outcome. METHODS: In two separate studies, we investigated small-volume 
      resuscitation (4 mL/kg) using Ringer's lactate, hypertonic saline and dextran, 
      and diaspirin cross-linked hemoglobin in a porcine model of cryogenic brain 
      injury and shock. RESULTS: Small-volume resuscitation with hypertonic saline and 
      dextran and diaspirin cross-linked hemoglobin significantly improved mean 
      arterial pressure and cerebral perfusion pressure compared with Ringer's lactate. 
      These data suggest that small-volume resuscitation with hypertonic saline and 
      dextran or diaspirin cross-linked hemoglobin may effectively limit or prevent 
      secondary ischemic brain injury after head injury and shock.
FAU - Shackford, S R
AU  - Shackford SR
AD  - Department of Surgery, University of Vermont, Burlington 05401, USA.
LA  - eng
GR  - P20 NS30324-03/NS/NINDS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Dextrans)
RN  - 0 (Hemoglobins)
RN  - 0 (Isotonic Solutions)
RN  - 0 (Plasma Substitutes)
RN  - 0 (Ringer's Lactate)
RN  - 0 (Saline Solution, Hypertonic)
RN  - 0 (hemoglobin XL99alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Brain Injuries/complications/physiopathology/*therapy
MH  - Cerebrovascular Circulation/drug effects
MH  - Dextrans/*therapeutic use
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Drug Therapy, Combination
MH  - Fluid Therapy/methods
MH  - Hemoglobins/*therapeutic use
MH  - Intracranial Pressure/*drug effects
MH  - Isotonic Solutions/*therapeutic use
MH  - Plasma Substitutes/*therapeutic use
MH  - Ringer's Lactate
MH  - Saline Solution, Hypertonic/*therapeutic use
MH  - Shock, Traumatic/*etiology
MH  - Swine
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - 10.1097/00005373-199705001-00009 [doi]
PST - ppublish
SO  - J Trauma. 1997 May;42(5 Suppl):S48-53. doi: 10.1097/00005373-199705001-00009.

PMID- 7211579
OWN - NLM
STAT- MEDLINE
DCOM- 19810513
LR  - 20190825
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 10
IP  - 5
DP  - 1980 Nov
TI  - Total serum copper and ceruloplasmin levels following administration of copper 
      aspirinate to rats and guinea-pigs.
PG  - 465-70
AB  - Total serum copper and ceruloplasmin oxidase activities have been measured over a 
      24-h period in rats and guinea-pigs treated with 100 mg/kg body weight of copper 
      (II) aspirinate. In the rat, administration s.c. produced higher total serum 
      copper levels than oral administration at all time intervals studied, whereas in 
      the guinea-pig, oral administration produced the higher level after 1 h and s.c. 
      administration the higher level after 5 h. In both species, the rate of 
      elimination of the additional copper was faster following oral administration. 
      Ceruloplasmin oxidase activity appeared to be inhibited in certain cases but rose 
      in all cases except for orally treated rats after 24 h. The initial rise in serum 
      copper was due mainly to copper present on albumin. The increased albumin copper 
      was detected directly by electrophoresis of serum samples and subsequent 
      determination of the copper level in the portions of the strip which contained 
      proteins. After s.c. administration to the rat, the amount of ultrafilterable 
      copper was raised by a detectable amount. 7 h after s.c. or oral administration 
      of copper aspirinate, the thiol concentration of the serum was reduced in both 
      rats and guinea-pigs. The relationship of these levels to the anti-inflammatory 
      action of copper (II) aspirinate in rats and guinea-pigs is discussed.
FAU - Brown, D H
AU  - Brown DH
FAU - Dunlop, J
AU  - Dunlop J
FAU - Smith, W E
AU  - Smith WE
FAU - Teape, J
AU  - Teape J
FAU - Lewis, A J
AU  - Lewis AJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Sulfhydryl Compounds)
RN  - 789U1901C5 (Copper)
RN  - EC 1.16.3.1 (Ceruloplasmin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/metabolism
MH  - Ceruloplasmin/*metabolism
MH  - Copper/administration & dosage/*blood/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Guinea Pigs
MH  - Inflammation/drug therapy
MH  - Kinetics
MH  - Male
MH  - Rats
MH  - Sulfhydryl Compounds/blood
EDAT- 1980/11/01 00:00
MHDA- 1980/11/01 00:01
CRDT- 1980/11/01 00:00
PHST- 1980/11/01 00:00 [pubmed]
PHST- 1980/11/01 00:01 [medline]
PHST- 1980/11/01 00:00 [entrez]
AID - 10.1007/BF01968048 [doi]
PST - ppublish
SO  - Agents Actions. 1980 Nov;10(5):465-70. doi: 10.1007/BF01968048.

PMID- 1452929
OWN - NLM
STAT- MEDLINE
DCOM- 19921231
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 20
IP  - 7
DP  - 1992 Dec
TI  - Counteraction of the vasodilator effects of enalapril by aspirin in severe heart 
      failure.
PG  - 1549-55
AB  - OBJECTIVES: This study was undertaken to determine if a standard dose of aspirin 
      interacts relevantly with the circulatory effects of enalapril in severe heart 
      failure. BACKGROUND: The frequent association of heart failure with coronary 
      artery disease confers potential for combined treatment with an 
      angiotensin-converting enzyme inhibitor and the prostaglandin synthesis inhibitor 
      aspirin, the pharmacodynamic actions of which are, in part, mutually opposed. 
      METHODS: In 18 patients, on 3 consecutive days, hemodynamic measurements were 
      performed at baseline and 4 h after administration of a double placebo, enalapril 
      (10 mg) plus placebo and enalapril plus aspirin (350 mg) according to a 
      double-blind, randomized, crossover protocol. RESULTS: Enalapril given before 
      aspirin led to significant decreases in systemic vascular resistance, left 
      ventricular filling pressure and total pulmonary resistance together with a 
      significant increase in cardiac output. When given with or on the day after 
      aspirin, enalapril did not elicit significant changes in any of these variables. 
      There was a clear tendency to lower values for pulmonary artery pressure on all 
      regimens, and slowing of the heart rate was incurred whether or not aspirin had 
      been given. Chi-square analysis of the individual responses showed that the 
      probability of effecting a decrease in systemic vascular resistance > or = 300 
      dynes.s.cm-5 was six times greater when enalapril was given without aspirin (p < 
      0.01). CONCLUSIONS: In severe heart failure, the prostaglandin synthesis 
      inhibition by aspirin counteracts the systemic arterial vasodilation of 
      angiotensin-converting enzyme inhibition with enalapril and substantiates its 
      dependence on the integrity of prostaglandin metabolism. Trends toward reductions 
      of pulmonary artery pressure and slowing of the heart rate were still observed, 
      presumably subsequent to lowered norepinephrine concentrations indicating 
      maintenance of prostaglandin-independent actions of angiotensin-converting enzyme 
      inhibition.
FAU - Hall, D
AU  - Hall D
AD  - Department of Cardiology, German Heart Center, Munich.
FAU - Zeitler, H
AU  - Zeitler H
FAU - Rudolph, W
AU  - Rudolph W
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 69PN84IO1A (Enalapril)
RN  - EC 3.4.23.15 (Renin)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Chi-Square Distribution
MH  - Chronic Disease
MH  - Coronary Disease/complications
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Enalapril/administration & dosage/*pharmacology/therapeutic use
MH  - Female
MH  - Heart Failure/*drug therapy/etiology/physiopathology
MH  - Heart Rate/drug effects
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Norepinephrine/blood
MH  - Pulmonary Circulation/drug effects
MH  - Pulmonary Wedge Pressure/drug effects
MH  - Renin/blood/drug effects
MH  - Severity of Illness Index
MH  - Vascular Resistance/drug effects
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
AID - 0735-1097(92)90449-W [pii]
AID - 10.1016/0735-1097(92)90449-w [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1992 Dec;20(7):1549-55. doi: 10.1016/0735-1097(92)90449-w.

PMID- 1136978
OWN - NLM
STAT- MEDLINE
DCOM- 19750905
LR  - 20131121
IS  - 0002-9289 (Print)
IS  - 0002-9289 (Linking)
VI  - 32
IP  - 3
DP  - 1975 Mar
TI  - Inhibition by ice cream of the antidotal efficacy of activated charcoal.
PG  - 289-91
AB  - A study was conducted to determine if ice cream and sherbet interfered with the 
      adsorption of aspirin onto activated charcoal both in vivo and in vitro. An 
      aqueous suspension of 20 g activated charcoal decreased the absorption of 1 g 
      aspirin by 65%; the same dose of activated charcoal with 50 g of ice cream 
      reduced aspirin absorption by only 42% under otherwise identical conditions. In 
      vitro tests showed that different ice creams and sherbet decrease the adsoprtion 
      of aspirin onto activated charcoal. Thus, although ice cream is useful for 
      preparing palatable suspensions of activated charcoal, it decreases appreciably 
      the antidotal efficacy of the adsorbent.
FAU - Levy, G
AU  - Levy G
FAU - Soda, D M
AU  - Soda DM
FAU - Lampman, T A
AU  - Lampman TA
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Hosp Pharm
JT  - American journal of hospital pharmacy
JID - 0370474
RN  - 0 (Antidotes)
RN  - 0 (Pharmaceutical Vehicles)
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antidotes/*pharmacology
MH  - Aspirin/*metabolism
MH  - Charcoal/*pharmacology
MH  - Depression, Chemical
MH  - Humans
MH  - *Ice Cream
MH  - Intestinal Absorption/*drug effects
MH  - Male
MH  - Pharmaceutical Vehicles
EDAT- 1975/03/01 00:00
MHDA- 1975/03/01 00:01
CRDT- 1975/03/01 00:00
PHST- 1975/03/01 00:00 [pubmed]
PHST- 1975/03/01 00:01 [medline]
PHST- 1975/03/01 00:00 [entrez]
PST - ppublish
SO  - Am J Hosp Pharm. 1975 Mar;32(3):289-91.

PMID- 25332245
OWN - NLM
STAT- MEDLINE
DCOM- 20150126
LR  - 20220410
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 32
IP  - 33
DP  - 2014 Nov 20
TI  - Daily aspirin use and prostate cancer-specific mortality in a large cohort of men 
      with nonmetastatic prostate cancer.
PG  - 3716-22
LID - 10.1200/JCO.2013.54.8875 [doi]
AB  - PURPOSE: In a recent analysis of a large clinical database, postdiagnosis aspirin 
      use was associated with 57% lower prostate cancer-specific mortality (PCSM) among 
      men diagnosed with nonmetastatic prostate cancer. However, information on this 
      association remains limited. We assessed the association between daily aspirin 
      use and PCSM in a large prospective cohort. PATIENTS AND METHODS: This analysis 
      included men diagnosed with nonmetastatic prostate cancer between enrollment in 
      the Cancer Prevention Study-II Nutrition Cohort in 1992 or 1993 and June 2009. 
      Aspirin use was reported at enrollment, in 1997, and every 2 years thereafter. 
      During follow-up through 2010, there were 441 prostate cancer deaths among 8,427 
      prostate cancer cases with information on prediagnosis aspirin use and 301 
      prostate cancer deaths among 7,118 prostate cancer cases with information on 
      postdiagnosis aspirin use. RESULTS: Compared with no aspirin use, neither 
      prediagnosis nor postdiagnosis daily aspirin use were statistically significantly 
      associated with PCSM (prediagnosis use, multivariable-adjusted hazard ratio (HR) 
      = 0.92, 95% CI 0.72 to 1.17, postdiagnosis use, HR = 0.98; 95% CI, 0.74 to 1.29). 
      However, among men diagnosed with high-risk cancers (≥ T3 and/or Gleason score ≥ 
      8), postdiagnosis daily aspirin use was associated with lower PCSM (HR = 0.60; 
      95% CI, 0.37 to 0.97), with no clear difference by dose (low-dose, typically 81 
      mg per day, HR = 0.50; 95% CI, 0.27 to 0.92, higher dose, HR = 0.73; 95% CI, 0.40 
      to 1.34). CONCLUSION: A randomized trial of aspirin among men diagnosed with 
      nonmetastatic prostate cancer was recently funded. Our results suggest any 
      additional randomized trials addressing this question should prioritize enrolling 
      men with high-risk cancers and need not use high doses.
CI  - © 2014 by American Society of Clinical Oncology.
FAU - Jacobs, Eric J
AU  - Jacobs EJ
AD  - Eric J. Jacobs, Christina C. Newton, Victoria L. Stevens, Peter T. Campbell, 
      Susan M. Gapstur, American Cancer Society, Atlanta, GA; and Stephen J. Freedland, 
      Durham Veterans Affairs Medical Center and Duke Prostate Center, Duke Cancer 
      Institute, Duke University, Durham, NC. Eric.Jacobs@cancer.org.
FAU - Newton, Christina C
AU  - Newton CC
AD  - Eric J. Jacobs, Christina C. Newton, Victoria L. Stevens, Peter T. Campbell, 
      Susan M. Gapstur, American Cancer Society, Atlanta, GA; and Stephen J. Freedland, 
      Durham Veterans Affairs Medical Center and Duke Prostate Center, Duke Cancer 
      Institute, Duke University, Durham, NC.
FAU - Stevens, Victoria L
AU  - Stevens VL
AD  - Eric J. Jacobs, Christina C. Newton, Victoria L. Stevens, Peter T. Campbell, 
      Susan M. Gapstur, American Cancer Society, Atlanta, GA; and Stephen J. Freedland, 
      Durham Veterans Affairs Medical Center and Duke Prostate Center, Duke Cancer 
      Institute, Duke University, Durham, NC.
FAU - Campbell, Peter T
AU  - Campbell PT
AD  - Eric J. Jacobs, Christina C. Newton, Victoria L. Stevens, Peter T. Campbell, 
      Susan M. Gapstur, American Cancer Society, Atlanta, GA; and Stephen J. Freedland, 
      Durham Veterans Affairs Medical Center and Duke Prostate Center, Duke Cancer 
      Institute, Duke University, Durham, NC.
FAU - Freedland, Stephen J
AU  - Freedland SJ
AD  - Eric J. Jacobs, Christina C. Newton, Victoria L. Stevens, Peter T. Campbell, 
      Susan M. Gapstur, American Cancer Society, Atlanta, GA; and Stephen J. Freedland, 
      Durham Veterans Affairs Medical Center and Duke Prostate Center, Duke Cancer 
      Institute, Duke University, Durham, NC.
FAU - Gapstur, Susan M
AU  - Gapstur SM
AD  - Eric J. Jacobs, Christina C. Newton, Victoria L. Stevens, Peter T. Campbell, 
      Susan M. Gapstur, American Cancer Society, Atlanta, GA; and Stephen J. Freedland, 
      Durham Veterans Affairs Medical Center and Duke Prostate Center, Duke Cancer 
      Institute, Duke University, Durham, NC.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141020
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - CA Cancer J Clin. 2015 Mar;65(2):83-4. PMID: 25640813
CIN - J Clin Oncol. 2015 Jul 1;33(19):2226. PMID: 25847923
CIN - J Clin Oncol. 2015 Jul 1;33(19):2226-7. PMID: 25847928
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cohort Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Prostatic Neoplasms/*mortality
EDAT- 2014/10/22 06:00
MHDA- 2015/01/27 06:00
CRDT- 2014/10/22 06:00
PHST- 2014/10/22 06:00 [entrez]
PHST- 2014/10/22 06:00 [pubmed]
PHST- 2015/01/27 06:00 [medline]
AID - JCO.2013.54.8875 [pii]
AID - 10.1200/JCO.2013.54.8875 [doi]
PST - ppublish
SO  - J Clin Oncol. 2014 Nov 20;32(33):3716-22. doi: 10.1200/JCO.2013.54.8875. Epub 
      2014 Oct 20.

PMID- 12362241
OWN - NLM
STAT- MEDLINE
DCOM- 20030703
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 88
IP  - 4
DP  - 2002 Oct
TI  - Aurintricarboxylic acid attenuates intimal thickening after balloon injury of the 
      rabbit aorta.
PG  - 668-72
AB  - Injury to the arterial wall initiates a cascade of events including platelet 
      deposition and an increase in procoagulant activity of the vessel wall that is 
      associated with intimal thickening and vascular wall remodeling. This study was 
      designed to characterize the effects of aurintricarboxylic acid (ATA), an 
      inhibitor of von Willebrand factor function, on vascular procoagulant activity 
      and the development of intimal thickening after balloon-induced injury to the 
      rabbit aorta. Treatment with ATA, aspirin, or the combination of agents at doses 
      that attenuated platelet aggregation decreased platelet deposition and 
      procoagulant activity bound to the vessel wall after injury. Treatment with ATA 
      reduced the intimal thickening observed 2 weeks after injury. Surprisingly, 
      aspirin treatment had no effect on intimal thickening. These data indicate that 
      inhibition of platelet deposition, while it is able to attenuate local thrombin 
      elaboration, is not alone sufficient to attenuate subsequent intimal thickening 
      that occurs in response to arterial injury.
FAU - Waissbluth, Alvaro
AU  - Waissbluth A
AD  - Department of Internal Medecine, Cardiovascular Division, Campus Box 8086, 
      Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 
      63110, USA.
FAU - Ghigliotti, Giorgio
AU  - Ghigliotti G
FAU - Abendschein, Dana R
AU  - Abendschein DR
FAU - Eisenberg, Paul R
AU  - Eisenberg PR
FAU - Schwartz, David
AU  - Schwartz D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 4431-00-9 (Aurintricarboxylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon/*adverse effects
MH  - Animals
MH  - Aorta/drug effects/injuries/*pathology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Aurintricarboxylic Acid/administration & dosage/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Platelets/pathology
MH  - Drug Therapy, Combination
MH  - Endothelium, Vascular/drug effects/injuries/pathology
MH  - Rabbits
MH  - Stents/adverse effects
EDAT- 2002/10/04 04:00
MHDA- 2003/07/04 05:00
CRDT- 2002/10/04 04:00
PHST- 2002/10/04 04:00 [pubmed]
PHST- 2003/07/04 05:00 [medline]
PHST- 2002/10/04 04:00 [entrez]
AID - 02100668 [pii]
PST - ppublish
SO  - Thromb Haemost. 2002 Oct;88(4):668-72.

PMID- 6767449
OWN - NLM
STAT- MEDLINE
DCOM- 19800530
LR  - 20190514
IS  - 0003-4932 (Print)
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 191
IP  - 2
DP  - 1980 Feb
TI  - Prophylaxis of venous thromboembolism: analysis of cost effectiveness.
PG  - 207-18
AB  - The rapidly expanding literature regarding prevention of venous thromboembolism 
      is confusing and contradictory, but, when analysed in the aggregate, the 
      collective experience permits a judgment about the relative efficacy of different 
      prophylactic regimens in specific patient populations, who vary in the risk 
      factors predisposing them to thromboembolism. The dollar cost of the several 
      approaches to prevention and their consequences should also be a matter of 
      concern. Efficacy and dollar cost together determine cost effectiveness, which 
      provides a practical guide to selection of the prophylactic approach appropriate 
      to an individual patient.
FAU - Salzman, E W
AU  - Salzman EW
FAU - Davies, G C
AU  - Davies GC
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 0 (Dextrans)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Dextrans/administration & dosage/therapeutic use
MH  - Heparin/administration & dosage/therapeutic use
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Pulmonary Embolism/prevention & control
MH  - Risk
MH  - Thromboembolism/economics/*prevention & control
MH  - Thrombophlebitis/economics/*prevention & control
PMC - PMC1345610
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
AID - 10.1097/00000658-198002000-00013 [doi]
PST - ppublish
SO  - Ann Surg. 1980 Feb;191(2):207-18. doi: 10.1097/00000658-198002000-00013.

PMID- 26456703
OWN - NLM
STAT- MEDLINE
DCOM- 20161031
LR  - 20210109
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 81
IP  - 2
DP  - 2016 Feb
TI  - Celecoxib interferes to a limited extent with aspirin-mediated inhibition of 
      platelets aggregation.
PG  - 316-26
LID - 10.1111/bcp.12801 [doi]
AB  - AIMS: The aim of the study was to analyze the interaction between celecoxib and 
      low dose aspirin for COX-1 binding and its consequences on the aspirin-mediated 
      antiplatelet effects. METHODS: We investigated ex vivo the interaction between 
      celecoxib and aspirin for COX-1 binding and measured the resulting antiplatelet 
      effects. We applied mechanism-based pharmacokinetic-pharmacodynamic (PKPD) 
      modelling to analyze these data and to predict in vivo platelet aggregation for 
      different doses and administration schedules of aspirin and celecoxib. RESULTS: 
      The predictions of the PK-PD model were consistent with results from previous 
      studies that investigated interaction between aspirin and celecoxib. The 
      modelling results indicate that celecoxib can attenuate to a limited extent the 
      in vivo antiplatelet effects of low dose aspirin. The extent of this interaction 
      can be substantial (up to 15% increase in platelet aggregation by 200 mg day(-1) 
      celecoxib when combined with low dose aspirin) during the first days of aspirin 
      administration in patients who are already treated with celecoxib, and it cannot 
      be prevented by separate administration of the interacting drugs. CONCLUSIONS: At 
      the recommended therapeutic doses, celecoxib can attenuate to a limited extent 
      the in vivo antiplatelet effects of low dose aspirin. Patients receiving a 
      combination of low dose aspirin and the recommended doses of celecoxib were not 
      identified to have increased risk of cardiovascular and cerebrovascular events 
      due to competition between these drugs for COX-1 binding. Interaction between low 
      dose aspirin and other COX-2 inhibitors and its clinical consequences requires 
      further investigation.
CI  - © 2015 The British Pharmacological Society.
FAU - Ruzov, Mark
AU  - Ruzov M
AD  - Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, 
      Ben-Gurion University of the Negev, Beer Sheva.
FAU - Rimon, Gilad
AU  - Rimon G
AD  - Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, 
      Ben-Gurion University of the Negev, Beer Sheva.
FAU - Pikovsky, Oleg
AU  - Pikovsky O
AD  - Blood Bank & Hematology Institute, Soroka University Medical Center, Beer Sheva, 
      Israel.
FAU - Stepensky, David
AU  - Stepensky D
AD  - Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, 
      Ben-Gurion University of the Negev, Beer Sheva.
LA  - eng
PT  - Journal Article
DEP - 20151215
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics/pharmacology
MH  - Binding, Competitive
MH  - Celecoxib/administration & dosage/blood/*pharmacokinetics/pharmacology
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase 2 Inhibitors/administration & 
      dosage/blood/*pharmacokinetics/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Models, Biological
MH  - Platelet Aggregation/*drug effects
MH  - Young Adult
PMC - PMC4833168
OTO - NOTNLM
OT  - COX-1 enzyme
OT  - celecoxib
OT  - drug−drug interaction
OT  - low dose aspirin anti-aggregation effect
OT  - pharmacokinetic−pharmacodynamic modelling
EDAT- 2015/10/13 06:00
MHDA- 2016/11/01 06:00
CRDT- 2015/10/13 06:00
PHST- 2015/07/14 00:00 [received]
PHST- 2015/09/17 00:00 [revised]
PHST- 2015/10/09 00:00 [accepted]
PHST- 2015/10/13 06:00 [entrez]
PHST- 2015/10/13 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - BCP12801 [pii]
AID - 10.1111/bcp.12801 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2016 Feb;81(2):316-26. doi: 10.1111/bcp.12801. Epub 2015 Dec 
      15.

PMID- 10340612
OWN - NLM
STAT- MEDLINE
DCOM- 19990819
LR  - 20190819
IS  - 0960-894X (Print)
IS  - 0960-894X (Linking)
VI  - 9
IP  - 9
DP  - 1999 May 3
TI  - Bioreductively-activated prodrugs for targeting hypoxic tissues: elimination of 
      aspirin from 2-nitroimidazole derivatives.
PG  - 1267-72
AB  - 2-Nitroimidazoles were synthesised substituted with aspirin or salicylic acid, as 
      leaving groups linked through the (imidazol-5-yl)methyl position. Activation of 
      aqueous solutions by CO2*- (a model one-electron reductant) resulted in release 
      of aspirin or salicylate, probably via the 2-hydroxyaminoimidazole. The analogous 
      2-nitroimidazole with bromide as leaving group eliminated bromide in < 1 ms via 
      the radical-anion.
FAU - Everett, S A
AU  - Everett SA
AD  - Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, 
      Middlesex, UK.
FAU - Naylor, M A
AU  - Naylor MA
FAU - Patel, K B
AU  - Patel KB
FAU - Stratford, M R
AU  - Stratford MR
FAU - Wardman, P
AU  - Wardman P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (Bromides)
RN  - 0 (Nitroimidazoles)
RN  - 0 (Prodrugs)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*chemistry
MH  - Bromides/chemistry
MH  - Cell Hypoxia/*drug effects
MH  - Humans
MH  - Nitroimidazoles/*chemical synthesis
MH  - Prodrugs/*chemistry
MH  - Salicylates/chemistry
MH  - Time Factors
EDAT- 1999/05/26 00:00
MHDA- 1999/05/26 00:01
CRDT- 1999/05/26 00:00
PHST- 1999/05/26 00:00 [pubmed]
PHST- 1999/05/26 00:01 [medline]
PHST- 1999/05/26 00:00 [entrez]
AID - S0960894X99001717 [pii]
AID - 10.1016/s0960-894x(99)00171-7 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 1999 May 3;9(9):1267-72. doi: 
      10.1016/s0960-894x(99)00171-7.

PMID- 2809646
OWN - NLM
STAT- MEDLINE
DCOM- 19891211
LR  - 20190828
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 236
IP  - 7
DP  - 1989 Oct
TI  - Adult-onset metachromatic leucodystrophy presenting without psychiatric symptoms.
PG  - 427-9
AB  - A 24-year-old man presented with a spastic and ataxic condition resembling 
      chronic-progressive multiple sclerosis. Radiological examination revealed 
      symmetrical diffuse paraventricular demyelination. Electrophysiological findings 
      suggested additional involvement of the brain stem and the peripheral nervous 
      system. The diagnosis of adult-onset metachromatic leucodystrophy was confirmed 
      by biochemical and ultrastructural examination. In contrast to almost all adult 
      cases reported so far, psychiatric symptoms were not present.
FAU - Klemm, E
AU  - Klemm E
AD  - Department of Neurology, University of Bonn, Federal Republic of Germany.
FAU - Conzelmann, E
AU  - Conzelmann E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/urine
MH  - Biopsy
MH  - Diagnosis, Differential
MH  - Electrophysiology
MH  - Family Health
MH  - Humans
MH  - Leukodystrophy, Metachromatic/*diagnosis/physiopathology
MH  - Male
MH  - Mental Disorders/*diagnosis
MH  - Rectum/pathology
MH  - Tomography, X-Ray Computed
EDAT- 1989/10/01 00:00
MHDA- 1989/10/01 00:01
CRDT- 1989/10/01 00:00
PHST- 1989/10/01 00:00 [pubmed]
PHST- 1989/10/01 00:01 [medline]
PHST- 1989/10/01 00:00 [entrez]
AID - 10.1007/BF00314905 [doi]
PST - ppublish
SO  - J Neurol. 1989 Oct;236(7):427-9. doi: 10.1007/BF00314905.

PMID- 20145575
OWN - NLM
STAT- MEDLINE
DCOM- 20100527
LR  - 20181201
IS  - 1529-8809 (Electronic)
IS  - 0022-5282 (Linking)
VI  - 68
IP  - 5
DP  - 2010 May
TI  - Diaspirin cross-linked hemoglobin infusion did not influence base deficit and 
      lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient 
      resuscitation.
PG  - 1158-71
LID - 10.1097/TA.0b013e3181bbfaac [doi]
AB  - BACKGROUND: Diaspirin cross-linked hemoglobin (DCLHb) has demonstrated a pressor 
      effect that could adversely affect traumatic hemorrhagic shock patients through 
      diminished perfusion to vital organs, causing base deficit (BD) and lactate 
      abnormalities. METHODS: Data from two parallel, multicenter traumatic hemorrhagic 
      shock clinical trials from 17 US Emergency Departments and 27 European Union 
      prehospital services using DCLHb, a hemoglobin-based resuscitation fluid. 
      RESULTS: In the 219 patients, the mean age was 37.3 years, 64% of the patients 
      sustained a blunt injury, 48% received DCLHb resuscitation, and the overall 
      28-day mortality rate was 36.5%. BD data did not differ by treatment group (DCLHb 
      vs. normal saline [NS]) at any time point. Study entry BD was higher in patients 
      who died when compared with survivors in both studies (US: -14.7 vs. -9.3 and 
      European Union: -11.1 vs. -4.1 mEq/L, p < 0.003) and at the first three time 
      points after resuscitation. No differences in BD based on treatment group were 
      observed in either those who survived or those who died from the hemorrhagic 
      shock. US lactate data did not differ by treatment group (DCLHb vs. NS) at any 
      time point. Study entry lactates were higher in US patients who ultimately died 
      when compared with survivors (82.4 vs. 56.1 mmol/L, p < 0.003) and at all five 
      postresuscitation time points. No lactate differences were observed between DCLHb 
      and NS survivors or in those who died based on treatment group. CONCLUSIONS: 
      Although patients who died had more greatly altered perfusion than those who 
      survived, DCLHb treatment of traumatic hemorrhagic shock patients was not 
      associated with BD or lactate abnormalities that would indicate poor perfusion.
FAU - Sloan, Edward P
AU  - Sloan EP
AD  - Department of Emergency Medicine, University of Illinois at Chicago, Chicago, 
      Illinois 60612, USA. edsloan@uic.edu
FAU - Koenigsberg, Max D
AU  - Koenigsberg MD
FAU - Philbin, Nora B
AU  - Philbin NB
FAU - Gao, Weihua
AU  - Gao W
CN  - DCLHb Traumatic Hemorrhagic Shock Study Group
CN  - European HOST Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Hemoglobins)
RN  - 33X04XA5AT (Lactic Acid)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acidosis, Lactic/blood/*epidemiology/etiology
MH  - Adult
MH  - Aspirin/adverse effects/*analogs & derivatives/chemistry/therapeutic use
MH  - Emergency Medical Services
MH  - Emergency Treatment
MH  - Europe/epidemiology
MH  - Fluid Therapy/adverse effects/methods
MH  - Hemoglobins/adverse effects/chemistry/*therapeutic use
MH  - Humans
MH  - Lactic Acid/blood
MH  - Multicenter Studies as Topic
MH  - Regression Analysis
MH  - Resuscitation/adverse effects/*methods
MH  - Shock, Hemorrhagic/complications/*drug therapy/mortality
MH  - Shock, Traumatic/complications/*drug therapy/mortality
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - United States/epidemiology
MH  - Water-Electrolyte Imbalance/*epidemiology/etiology
MH  - Wounds and Injuries/complications
FIR - Sloan, Edward P
IR  - Sloan EP
FIR - Koenigsberg, Max D
IR  - Koenigsberg MD
FIR - Dalsey, William C
IR  - Dalsey WC
FIR - Kaplan, Mark
IR  - Kaplan M
FIR - Taggart, Pamela
IR  - Taggart P
FIR - Santora, Thomas A
IR  - Santora TA
FIR - Runge, Jeffrey
IR  - Runge J
FIR - Edwards, Lucinda A
IR  - Edwards LA
FIR - Gibbs, Michael A
IR  - Gibbs MA
FIR - Tinkoff, Glen
IR  - Tinkoff G
FIR - McGraw, Patty
IR  - McGraw P
FIR - O'Conner, Robert
IR  - O'Conner R
FIR - Cydulka, Rita K
IR  - Cydulka RK
FIR - Fallon, William F
IR  - Fallon WF
FIR - Plaisier, Brian
IR  - Plaisier B
FIR - Smith, J Stanley Jr
IR  - Smith JS Jr
FIR - Cooney, Robert N
IR  - Cooney RN
FIR - Shand, Margaret
IR  - Shand M
FIR - Cipolle, Mark D
IR  - Cipolle MD
FIR - Pasquale, Michael D
IR  - Pasquale MD
FIR - Robb, Wendy J
IR  - Robb WJ
FIR - Ochsner, Gage
IR  - Ochsner G
FIR - Davis, Frank E
IR  - Davis FE
FIR - Rondina, Joseph
IR  - Rondina J
FIR - Rodman, George H Jr
IR  - Rodman GH Jr
FIR - Miralgia, Charles
IR  - Miralgia C
FIR - Misinski, Maureen
IR  - Misinski M
FIR - Brunett, Patrick H
IR  - Brunett PH
FIR - Bryan, James H
IR  - Bryan JH
FIR - McDevitt, Colleen
IR  - McDevitt C
FIR - Provost, David
IR  - Provost D
FIR - Colpi, Mary Jane
IR  - Colpi MJ
FIR - Stoltzfus, Russel
IR  - Stoltzfus R
FIR - Bynoe, Raymond P
IR  - Bynoe RP
FIR - Hamm, Jay D
IR  - Hamm JD
FIR - Stewart, N John
IR  - Stewart NJ
FIR - Amsden, Dave
IR  - Amsden D
FIR - Walukewicz, Christine
IR  - Walukewicz C
FIR - Wachtel, Thomas
IR  - Wachtel T
FIR - Coniglio, Ray
IR  - Coniglio R
FIR - Hemminger, Lee
IR  - Hemminger L
FIR - Mallory, Mary Nan S
IR  - Mallory MN
FIR - Carillo, Eddy
IR  - Carillo E
FIR - Miller, Richard L
IR  - Miller RL
FIR - Miller, Ashlee
IR  - Miller A
FIR - Gens, David R
IR  - Gens DR
FIR - Joseph, Laura A
IR  - Joseph LA
FIR - Owens, Mehrunissa H
IR  - Owens MH
FIR - Peitzman, Andrew B
IR  - Peitzman AB
FIR - Borst, Marilyn J
IR  - Borst MJ
FIR - Woods, Randy J
IR  - Woods RJ
FIR - Morris, John A
IR  - Morris JA
FIR - Jenkins, Judy
IR  - Jenkins J
FIR - Harviel, J Duncan
IR  - Harviel JD
FIR - Jordan, Marion
IR  - Jordan M
FIR - Wang, Dennis
IR  - Wang D
FIR - Beylo, Lisa
IR  - Beylo L
FIR - Brandenburg, Kristin Y
IR  - Brandenburg KY
FIR - Dougherty, James A
IR  - Dougherty JA
FIR - White, Lynn J
IR  - White LJ
FIR - Muakkassa, Farid
IR  - Muakkassa F
FIR - Harchelroad, Fred
IR  - Harchelroad F
FIR - Potts, Kris
IR  - Potts K
FIR - Levitt, M Andrew
IR  - Levitt MA
FIR - Portoni, Ed
IR  - Portoni E
FIR - Hirvela, Eva
IR  - Hirvela E
FIR - Wall, Mathew J Jr
IR  - Wall MJ Jr
FIR - Mattox, Kenneth L
IR  - Mattox KL
FIR - Mendez, Alex
IR  - Mendez A
FIR - Holevar, Michele
IR  - Holevar M
FIR - Merlotti, Gary
IR  - Merlotti G
FIR - Berry, Sue
IR  - Berry S
FIR - Sloan, Edward P
IR  - Sloan EP
FIR - Barrett, John
IR  - Barrett J
FIR - Nagy, Kim
IR  - Nagy K
FIR - Stapleton, Steve
IR  - Stapleton S
FIR - March, Juan A
IR  - March JA
FIR - Copeland, Susan
IR  - Copeland S
FIR - Catrou, Paul
IR  - Catrou P
FIR - Perdrizet, George A
IR  - Perdrizet GA
FIR - Rescrol, Donna
IR  - Rescrol D
FIR - Jacobs, Lenworth
IR  - Jacobs L
FIR - Kowalenko, Terry
IR  - Kowalenko T
FIR - Dereczyk, Barry
IR  - Dereczyk B
FIR - Rivers, Emanuel P
IR  - Rivers EP
FIR - Nyachowe, Pascal
IR  - Nyachowe P
FIR - Mikhil, Judy
IR  - Mikhil J
FIR - Fantus, Richard
IR  - Fantus R
FIR - Ward, Sharon
IR  - Ward S
FIR - Langdorf, Mark
IR  - Langdorf M
FIR - Simon, Ronald
IR  - Simon R
FIR - Martinez, Dennis
IR  - Martinez D
FIR - Botner, Kate
IR  - Botner K
FIR - O'Neill, Patricia Ann
IR  - O'Neill PA
FIR - Sinert, Richard
IR  - Sinert R
FIR - Eisenberg, Karen Sue
IR  - Eisenberg KS
FIR - Howanitz, Joan H
IR  - Howanitz JH
FIR - Gore, Dennis C
IR  - Gore DC
FIR - Lockhart, Sherry
IR  - Lockhart S
FIR - Chibelski, Heather
IR  - Chibelski H
FIR - Zun, Les
IR  - Zun L
FIR - Kinsela, Annette
IR  - Kinsela A
FIR - Uehara, Dennis
IR  - Uehara D
FIR - Maves, Jeffrey
IR  - Maves J
FIR - Hevesy, George Z
IR  - Hevesy GZ
FIR - Badellino, Michael
IR  - Badellino M
FIR - Buckman, Robert
IR  - Buckman R
FIR - Go, Steven
IR  - Go S
FIR - Morse, Ginger
IR  - Morse G
FIR - Casper, Berna Sue
IR  - Casper BS
FIR - McSwain, Norman Jr
IR  - McSwain N Jr
FIR - Wanstrath, Ruth Ann
IR  - Wanstrath RA
FIR - Luchette, Fred A
IR  - Luchette FA
FIR - Branson, Richard D
IR  - Branson RD
FIR - Davis, Kenneth Jr
IR  - Davis K Jr
FIR - Fildes, John J
IR  - Fildes JJ
FIR - Clemmons-Brown, Connie A
IR  - Clemmons-Brown CA
FIR - Roehr, Cindy
IR  - Roehr C
FIR - Meislin, Harvey
IR  - Meislin H
FIR - Gomez, Cheryle
IR  - Gomez C
FIR - Velmahos, George C
IR  - Velmahos GC
FIR - Tatevossian, Raymond
IR  - Tatevossian R
FIR - Lewis, Roger J
IR  - Lewis RJ
FIR - Berry, Donald
IR  - Berry D
FIR - Fost, Norman
IR  - Fost N
FIR - Krome, Ronald
IR  - Krome R
FIR - Washington, Geraldine
IR  - Washington G
FIR - Fisher, Marian
IR  - Fisher M
FIR - Bechhofer, Robin
IR  - Bechhofer R
FIR - Cook, Tom
IR  - Cook T
FIR - Schultz, Melissa
IR  - Schultz M
FIR - Przybelski, Robert
IR  - Przybelski R
FIR - Blue, John
IR  - Blue J
FIR - Goldberg, Cynthia
IR  - Goldberg C
FIR - Stern, Kathleen
IR  - Stern K
FIR - Houghton, Jaime
IR  - Houghton J
FIR - Nanavaty, Maulik
IR  - Nanavaty M
FIR - Estep, Timothy
IR  - Estep T
FIR - Saunders, Michael
IR  - Saunders M
FIR - Schmitz, Tom
IR  - Schmitz T
FIR - Alted
IR  - Alted
FIR - Todorov
IR  - Todorov
FIR - Vanderpas
IR  - Vanderpas
FIR - Fox
IR  - Fox
FIR - Decroix
IR  - Decroix
FIR - Schtickzelle
IR  - Schtickzelle
FIR - Beaucourt
IR  - Beaucourt
FIR - Bouletreau
IR  - Bouletreau
FIR - Collombel
IR  - Collombel
FIR - Samii
IR  - Samii
FIR - Mazière
IR  - Mazière
FIR - Ossart
IR  - Ossart
FIR - Dabadie
IR  - Dabadie
FIR - Bertrand
IR  - Bertrand
FIR - Coriat
IR  - Coriat
FIR - Guerrini
IR  - Guerrini
FIR - Chauvin
IR  - Chauvin
FIR - Bladier
IR  - Bladier
FIR - Delacoux
IR  - Delacoux
FIR - Marty
IR  - Marty
FIR - Bemer
IR  - Bemer
FIR - Desmonts
IR  - Desmonts
FIR - Stoessel
IR  - Stoessel
FIR - Freysz
IR  - Freysz
FIR - Duvaldestin
IR  - Duvaldestin
FIR - Goossens
IR  - Goossens
FIR - Payen
IR  - Payen
FIR - Rouvier
IR  - Rouvier
FIR - Cathala
IR  - Cathala
FIR - Adenet
IR  - Adenet
FIR - Rousseaux
IR  - Rousseaux
FIR - Ducasse
IR  - Ducasse
FIR - Pasteyer
IR  - Pasteyer
FIR - Feiss
IR  - Feiss
FIR - Reinhart
IR  - Reinhart
FIR - Dick
IR  - Dick
FIR - Gotzen
IR  - Gotzen
FIR - Weinand
IR  - Weinand
FIR - Ellinger
IR  - Ellinger
FIR - Tappe
IR  - Tappe
FIR - Regel
IR  - Regel
FIR - Schmucker
IR  - Schmucker
FIR - Röse
IR  - Röse
FIR - Sokolowski
IR  - Sokolowski
FIR - Motsch
IR  - Motsch
FIR - Unertl
IR  - Unertl
FIR - Katz
IR  - Katz
FIR - Benad
IR  - Benad
FIR - Schuff-Werner
IR  - Schuff-Werner
FIR - Bergner
IR  - Bergner
FIR - Schüttler
IR  - Schüttler
FIR - Hergert
IR  - Hergert
FIR - Lestin
IR  - Lestin
FIR - Bion, J
IR  - Bion J
FIR - Ferdinande, P
IR  - Ferdinande P
FIR - Grootendorst, A
IR  - Grootendorst A
FIR - Little, R
IR  - Little R
FIR - Robertson, C
IR  - Robertson C
FIR - Spahn, D
IR  - Spahn D
FIR - Spiegelhalter, D
IR  - Spiegelhalter D
FIR - Webb, A
IR  - Webb A
FIR - Holmstrom, S
IR  - Holmstrom S
FIR - Gerard, D
IR  - Gerard D
FIR - Reppucci, T
IR  - Reppucci T
FIR - Morrison, A
IR  - Morrison A
FIR - Blue, J
IR  - Blue J
FIR - Goldberg, C
IR  - Goldberg C
FIR - Przybelski, R
IR  - Przybelski R
FIR - Stern, K
IR  - Stern K
FIR - Houghton, J
IR  - Houghton J
FIR - Sperelakis, R
IR  - Sperelakis R
FIR - Wallace, K
IR  - Wallace K
FIR - Petty, J
IR  - Petty J
FIR - Balma, D
IR  - Balma D
FIR - Bottoms, B
IR  - Bottoms B
FIR - Carli, P
IR  - Carli P
EDAT- 2010/02/11 06:00
MHDA- 2010/05/28 06:00
CRDT- 2010/02/11 06:00
PHST- 2010/02/11 06:00 [entrez]
PHST- 2010/02/11 06:00 [pubmed]
PHST- 2010/05/28 06:00 [medline]
AID - 10.1097/TA.0b013e3181bbfaac [doi]
PST - ppublish
SO  - J Trauma. 2010 May;68(5):1158-71. doi: 10.1097/TA.0b013e3181bbfaac.

PMID- 19171806
OWN - NLM
STAT- MEDLINE
DCOM- 20090226
LR  - 20211020
IS  - 1538-3679 (Electronic)
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 169
IP  - 2
DP  - 2009 Jan 26
TI  - Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and 
      risk of breast cancer among premenopausal women in the Nurses' Health Study II.
PG  - 115-21; discussion 121
LID - 10.1001/archinternmed.2008.537 [doi]
AB  - BACKGROUND: The use of aspirin and other nonsteroidal anti-inflammatory drugs 
      (NSAIDs) is widespread for treatment of common symptoms such as headaches, 
      muscular pain, and inflammation. In addition, the chemopreventive use of NSAIDs 
      is increasingly common for heart disease and colon cancer. Evidence of a 
      protective association with breast cancer risk has been inconsistent, and few 
      data exist for premenopausal women. METHODS: We assessed the associations for use 
      of aspirin, other NSAIDs, and acetaminophen with breast cancer risk among 
      premenopausal women in the prospective Nurses' Health Study II. In total, 112,292 
      women, aged 25 to 42 years and free of cancer in 1989, were followed up until 
      June 2003. Multivariate relative risks and 95% confidence intervals were 
      calculated by Cox proportional hazards models, adjusting for age and other 
      important breast cancer risk factors. RESULTS: Overall, 1345 cases of invasive 
      premenopausal breast cancer were documented. Regular use of aspirin (> or = 2 
      times per week) was not significantly associated with breast cancer risk 
      (relative risk, 1.07; 95% confidence interval, 0.89-1.29). Regular use of either 
      nonaspirin NSAIDs or acetaminophen also was not consistently associated with 
      breast cancer risk. Results did not vary by frequency (days per week), dose 
      (tablets per week), or duration of use. Furthermore, associations with each drug 
      category did not vary substantially by estrogen and progesterone receptor status 
      of the tumor. CONCLUSION: These data suggest that the use of aspirin, other 
      NSAIDs, and acetaminophen is not associated with a reduced risk of breast cancer 
      among premenopausal women.
FAU - Eliassen, A Heather
AU  - Eliassen AH
AD  - Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and 
      Harvard Medical School, 181 Longwood Ave, Boston, MA 02115, USA. 
      heather.eliassen@channing.harvard.edu
FAU - Chen, Wendy Y
AU  - Chen WY
FAU - Spiegelman, Donna
AU  - Spiegelman D
FAU - Willett, Walter C
AU  - Willett WC
FAU - Hunter, David J
AU  - Hunter DJ
FAU - Hankinson, Susan E
AU  - Hankinson SE
LA  - eng
GR  - R01 CA050385/CA/NCI NIH HHS/United States
GR  - R25 CA098566-02/CA/NCI NIH HHS/United States
GR  - R25 CA098566/CA/NCI NIH HHS/United States
GR  - R01 CA050385-20/CA/NCI NIH HHS/United States
GR  - CA50385/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*administration & dosage/adverse effects
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Breast Neoplasms/*chemically induced
MH  - Female
MH  - Humans
MH  - Premenopause
MH  - Risk Factors
PMC - PMC2632770
MID - NIHMS52946
EDAT- 2009/01/28 09:00
MHDA- 2009/02/27 09:00
CRDT- 2009/01/28 09:00
PHST- 2009/01/28 09:00 [entrez]
PHST- 2009/01/28 09:00 [pubmed]
PHST- 2009/02/27 09:00 [medline]
AID - 169/2/115 [pii]
AID - 10.1001/archinternmed.2008.537 [doi]
PST - ppublish
SO  - Arch Intern Med. 2009 Jan 26;169(2):115-21; discussion 121. doi: 
      10.1001/archinternmed.2008.537.

PMID- 18425953
OWN - NLM
STAT- MEDLINE
DCOM- 20080613
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 2
DP  - 2008 Apr 16
TI  - Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
PG  - CD006503
LID - 10.1002/14651858.CD006503.pub2 [doi]
AB  - BACKGROUND: Polycythaemia vera and essential thrombocythaemia are chronic 
      Philadelphia-negative myeloproliferative disorders, which increase the risk of 
      arterial and venous thrombosis as well as bleeding. In addition to the different 
      therapeutic strategies available, aspirin is often used to prevent platelet 
      aggregation. OBJECTIVES: To quantify the benefit and harm of antiplatelet drugs 
      for long-term primary and secondary prophylaxis of arterial and venous thrombotic 
      events in patients with polycythaemia vera or essential thrombocythaemia. SEARCH 
      STRATEGY: Our searched included the CENTRAL (The Cochrane Library, issue 1 2007), 
      MEDLINE (1966 to 2007) and EMBASE (1980 to 2007) databases, online registers of 
      ongoing trials and conference proceedings. The date of the last search was March 
      2007. SELECTION CRITERIA: All randomised controlled trials (RCTs) comparing 
      long-term (>6 months) use of an antiplatelet drug versus placebo or no treatment 
      in patients with polycythaemia vera or essential thrombocythaemia, diagnosed by 
      established international criteria, with data for at least one of the selected 
      outcomes, were included. DATA COLLECTION AND ANALYSIS: Using a predefined 
      extraction form, we collected and analysed the following data where appropriate: 
      mortality from arterial and venous thrombotic events, mortality from bleeding 
      episodes, fatal and non-fatal arterial thrombotic events, fatal and non-fatal 
      venous thrombotic events, micro-circulation events, transient neurological and 
      ocular manifestations, major and minor bleeding episodes, all-cause mortality and 
      any adverse events. We based quantitative analysis of outcome data on an 
      intention-to-treat principle. The overall treatment effect was estimated by the 
      pooled odds ratio (OR) with 95% confidence interval (CI) using a fixed-effect 
      model (Mantel-Haenszel). MAIN RESULTS: Two RCTs that investigated 630 patients 
      with an established diagnosis of polycythaemia vera, with no clear indication or 
      contraindication to aspirin therapy, were included in this review. The use of 
      aspirin, compared with placebo, was associated with a lower risk of fatal 
      thrombotic events (although this benefit was not statistically significant (OR 
      0.20, 95% CI 0.03 to 1.14)) and did not increase the risk of major bleeding (OR 
      0.99, 95% CI 0.23 to 4.36). No studies have been published in patients with 
      essential thrombocythaemia or studying other antiplatelet drugs. AUTHORS' 
      CONCLUSIONS: The available evidence suggests that the use of aspirin is 
      associated with a statistically non-significant reduction in the risk of fatal 
      thrombotic events, without an increased risk of major bleeding, when compared 
      with no treatment in patients polycythaemia vera who have no clear indication or 
      contraindication to aspirin therapy.
FAU - Squizzato, A
AU  - Squizzato A
AD  - University of Insubria, Department of Clinical Medicine, viale Borri, 57, Varese, 
      Italy, 21100. alexsquizzo@libero.it
FAU - Romualdi, E
AU  - Romualdi E
FAU - Middeldorp, S
AU  - Middeldorp S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20080416
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UIN - Cochrane Database Syst Rev. 2013;4:CD006503. PMID: 23633335
MH  - Anticoagulants/administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Polycythemia Vera/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Thrombocythemia, Essential/*drug therapy
MH  - Thrombosis/*prevention & control
RF  - 26
EDAT- 2008/04/22 09:00
MHDA- 2008/06/14 09:00
CRDT- 2008/04/22 09:00
PHST- 2008/04/22 09:00 [pubmed]
PHST- 2008/06/14 09:00 [medline]
PHST- 2008/04/22 09:00 [entrez]
AID - 10.1002/14651858.CD006503.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006503. doi: 
      10.1002/14651858.CD006503.pub2.

PMID- 34432623
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211011
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 70
IP  - 6S
DP  - 2021 Jul
TI  - Primary Prevention of CVD with Aspirin: Benefits vs Risks.
PG  - S41-S46
LID - 10.12788/jfp.0222 [doi]
AB  - Low-dose aspirin (acetylsalicylic acid [ASA]; 75 to 100 mg/d) is widely used in 
      the prevention of cardiovascular (CV) events based on the results of large-scale 
      studies supporting a benefit. However, questions remain regarding the 
      benefit-risk relationship in certain settings since long-term use of ASA is not 
      devoid of risk. Incontrovertible evidence supports the benefits of ASA treatment, 
      which exceed the risks, in patients who have had a previous CV event (myocardial 
      infarction, stroke, unstable angina, or transient ischemic attack). Nonetheless, 
      the question remains for those patients who have not had a previous event 
      (primary prevention), where the risk of CV events is lower and, consequently, the 
      absolute benefit is also lower than in patients who have a history of a CV event 
      or its equivalent (secondary prevention). Recent evidence from large-scale 
      clinical trials shows that administration of low-dose ASA is associated with a 
      reduced risk of CV events with a corresponding small absolute increase in the 
      risk of major bleeding (eg, gastrointestinal bleeding and hemorrhagic stroke). 
      Although the benefit and the risk of low-dose ASA in primary prevention are 
      numerically similar, the clinical consequences of an increased risk of bleeding 
      and a decreased risk of a CV event may not be equivalent. If these data are 
      applied to patients with higher levels of CV outcome risk, more patients may 
      potentially benefit from aspirin use in primary prevention.
FAU - Weisman, Steven M
AU  - Weisman SM
FAU - Brunton, Stephen
AU  - Brunton S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Trials as Topic
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Secondary Prevention
EDAT- 2021/08/26 06:00
MHDA- 2021/10/12 06:00
CRDT- 2021/08/25 17:19
PHST- 2021/08/25 17:19 [entrez]
PHST- 2021/08/26 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
AID - jfp.0222 [pii]
AID - 10.12788/jfp.0222 [doi]
PST - ppublish
SO  - J Fam Pract. 2021 Jul;70(6S):S41-S46. doi: 10.12788/jfp.0222.

PMID- 26695072
OWN - NLM
STAT- MEDLINE
DCOM- 20170403
LR  - 20181202
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 42
IP  - 1
DP  - 2016 Jul
TI  - Platelet reactivity in patients undergoing transcatheter aortic valve 
      implantation.
PG  - 11-8
LID - 10.1007/s11239-015-1322-3 [doi]
AB  - Thromboembolic events, primarily stroke, might complicate transcatheter 
      aortic-valve implantation (TAVI) procedures in 3-5 % of cases. Thus, it is common 
      to administer aspirin and clopidogrel pharmacotherapy for 3-6 months following 
      TAVI in order to prevent those events. The biologic response to the dual anti 
      platelet treatment (DAPT) is heterogeneous, e.g. low response, known as high on 
      treatment platelet reactivity (HTPR) may be associated with adverse 
      thromboembolic events. Little is known about the prevalence of HTPR among 
      patients undergoing TAVI. To assess the variability in response and rates of 
      residual platelet reactivity in patients undergoing TAVI. We examined platelet 
      reactivity in response to clopidogrel and aspirin in 40 consecutive patients 
      (mean age 81.7 ± 6.5 years, 66.7 % women) who underwent successful TAVI using the 
      VerifyNow P2Y12 assay and the multiple electrode aggregometry assay (Multiplate 
      analyzer) in response to adenosine diphosphate and arachidonic acid respectively, 
      at different time points before and following TAVI. Before TAVI, the majority of 
      patients were on antiplatelet therapy (68.5 % aspirin, 12.5 % clopidogrel, 12.5 % 
      DAPT). Following the procedure all patients were on DAPT or clopidogrel and 
      warfarin. Among analyzed patients, 41 % had HTPR for clopidogrel and 12.5 % for 
      aspirin at baseline, which did not significantly change 1-month following the 
      procedure (p = 0.81 and p  = 0.33, respectively). In conclusion, patients 
      undergoing TAVI for severe aortic stenosis and treated with DAPT have high rates 
      of residual platelet reactivity during the peri-procedural period and up to 
      1-month thereafter. These findings may have clinical implications for the 
      anti-platelet management of TAVI patients.
FAU - Orvin, Katia
AU  - Orvin K
AD  - Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah 
      Tikva, Israel. katiaorvin@gmail.com.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 
      katiaorvin@gmail.com.
FAU - Eisen, Alon
AU  - Eisen A
AD  - Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah 
      Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Perl, Leor
AU  - Perl L
AD  - Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah 
      Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Zemer-Wassercug, Noa
AU  - Zemer-Wassercug N
AD  - Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah 
      Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Codner, Pablo
AU  - Codner P
AD  - Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah 
      Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Assali, Abid
AU  - Assali A
AD  - Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah 
      Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Vaknin-Assa, Hana
AU  - Vaknin-Assa H
AD  - Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah 
      Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Lev, Eli I
AU  - Lev EI
AD  - Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah 
      Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Kornowski, Ran
AU  - Kornowski R
AD  - Cardiology Department, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah 
      Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aortic Valve Stenosis/surgery
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Thromboembolism/etiology
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
MH  - Transcatheter Aortic Valve Replacement/*adverse effects
MH  - Warfarin/pharmacology/therapeutic use
OTO - NOTNLM
OT  - HTPR
OT  - Multiplate analyzer
OT  - TAVI
OT  - Verifynow
EDAT- 2015/12/24 06:00
MHDA- 2017/04/04 06:00
CRDT- 2015/12/24 06:00
PHST- 2015/12/24 06:00 [entrez]
PHST- 2015/12/24 06:00 [pubmed]
PHST- 2017/04/04 06:00 [medline]
AID - 10.1007/s11239-015-1322-3 [pii]
AID - 10.1007/s11239-015-1322-3 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2016 Jul;42(1):11-8. doi: 10.1007/s11239-015-1322-3.

PMID- 33053982
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1007-3418 (Print)
IS  - 1007-3418 (Linking)
VI  - 28
IP  - 9
DP  - 2020 Sep 20
TI  - [Effect of aspirin on hepatocellular carcinoma and its related mechanism].
PG  - 799-802
LID - 10.3760/cma.j.cn501113-20190929-00360 [doi]
AB  - Aspirin, as a traditional non-steroidal anti-inflammatory drug, has therapeutic 
      and preventive effects on gastrointestinal tumors. Hepatocellular carcinoma is 
      one of the most common malignant tumors in the digestive tract, so it is 
      necessary to find effective preventive and therapeutic measures. This article 
      reviews the research progress and mechanism of aspirin on hepatocellular 
      carcinoma with a view to provide references for future clinical treatment.
FAU - Liu, Y W
AU  - Liu YW
AD  - Department of Hepatology, The First Hospital of Jilin University, Changchun 
      130021, China.
FAU - Xu, H Q
AU  - Xu HQ
AD  - Department of Hepatology, The First Hospital of Jilin University, Changchun 
      130021, China.
FAU - Zhou, Q
AU  - Zhou Q
AD  - Department of Hepatology, The First Hospital of Jilin University, Changchun 
      130021, China.
FAU - Niu, J Q
AU  - Niu JQ
AD  - Department of Hepatology, The First Hospital of Jilin University, Changchun 
      130021, China.
LA  - chi
GR  - 2015CB554304/National Key Basic Research Development Program/
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhonghua Gan Zang Bing Za Zhi
JT  - Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of 
      hepatology
JID - 9710009
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Carcinoma, Hepatocellular
MH  - *Gastrointestinal Neoplasms
MH  - Humans
MH  - *Liver Neoplasms/drug therapy
OTO - NOTNLM
OT  - Aspirin
OT  - Hepatocellular carcinoma
OT  - Mechanism
EDAT- 2020/10/16 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/10/15 04:20
PHST- 2020/10/15 04:20 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.3760/cma.j.cn501113-20190929-00360 [doi]
PST - ppublish
SO  - Zhonghua Gan Zang Bing Za Zhi. 2020 Sep 20;28(9):799-802. doi: 
      10.3760/cma.j.cn501113-20190929-00360.

PMID- 18156036
OWN - NLM
STAT- MEDLINE
DCOM- 20080107
LR  - 20150616
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 370
IP  - 9605
DP  - 2007 Dec 22
TI  - Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory 
      drugs in patients with risk of cardiovascular events taking low-dose aspirin?
PG  - 2138-51
AB  - Cyclo-oxygenase-2 selective inhibitors and non-selective non-steroidal 
      anti-inflammatory drugs (NSAIDs) are associated with increased risk of acute 
      cardiovascular events. Only aspirin offers primary and secondary cardiovascular 
      prophylaxis, but trials have not answered directly whether low-dose aspirin is 
      cardioprotective with COX-2 inhibitors. A large inception cohort study showed 
      that concomitant use of aspirin reduced risk of cardiovascular events when given 
      with rofecoxib, celecoxib, sulindac, meloxicam, and indometacin but not when 
      given with ibuprofen. In large trials assessing gastrointestinal safety, there 
      were fewer gastrointestinal events in patients using both COX-2 inhibitors and 
      aspirin than in those using non-selective NSAIDs and aspirin; significantly fewer 
      uncomplicated upper gastrointestinal events took place in the MEDAL trial. 
      Analysis of VIGOR and two capsule endoscopy studies showed significantly less 
      distal gastrointestinal blood loss with COX-2 inhibitors than with non-selective 
      NSAIDs. Endoscopy trials showed that low-dose aspirin does not diminish the 
      gastrointestinal benefits of COX-2 inibitors over non-selective NSAIDs. In an 
      elderly epidemiological cohort receiving aspirin, both celecoxib and rofecoxib 
      reduced risk of admission for gastrointestinal events. Comparison of the 
      cardiovascular and gastrointestinal risks is difficult: likelihood and severity 
      of cardiovascular events differ between individuals, agents, and exposure. 
      Mortality associated with gastrointestinal events is less frequent than with 
      cardiovascular events, but asymptomatic ulcers can result in severe 
      complications. Data support the conclusion that COX-2 inhibitors are preferable 
      to non-selective NSAIDs in patients with chronic pain and cardiovascular risk 
      needing low-dose aspirin, but relative risks and benefits should be assessed 
      individually for each patient.
FAU - Strand, Vibeke
AU  - Strand V
AD  - Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA. 
      Vstrand@stanford.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cyclooxygenase Inhibitors/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pain/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
RF  - 182
EDAT- 2007/12/25 09:00
MHDA- 2008/01/08 09:00
CRDT- 2007/12/25 09:00
PHST- 2007/12/25 09:00 [pubmed]
PHST- 2008/01/08 09:00 [medline]
PHST- 2007/12/25 09:00 [entrez]
AID - S0140-6736(07)61909-6 [pii]
AID - 10.1016/S0140-6736(07)61909-6 [doi]
PST - ppublish
SO  - Lancet. 2007 Dec 22;370(9605):2138-51. doi: 10.1016/S0140-6736(07)61909-6.

PMID- 33524534
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211011
IS  - 1873-3441 (Electronic)
IS  - 0939-6411 (Linking)
VI  - 160
DP  - 2021 Mar
TI  - Stomach pH before vs. after different bariatric surgery procedures: Clinical 
      implications for drug delivery.
PG  - 152-157
LID - S0939-6411(21)00030-8 [pii]
LID - 10.1016/j.ejpb.2021.01.016 [doi]
AB  - Stomach pH may vary following bariatric surgery, with implications for drug 
      delivery/bioavailability. Yet, this parameter has not been studied. In this work, 
      gastric content was aspirated from patients before, immediately after, and the 
      day after different bariatric procedures, and pH was immediately measured. 
      Compared to pre-surgery (1.8), pH was increased one day after one-anastomosis 
      gastric bypass (OAGB) and sleeve gastrectomy (LSG) by 3-4 pH units; pH 
      immediately after these procedures was in between the other 2 time points. 
      Post-OAGB pH was significantly higher than post-LSG (6.4 and 4.9, respectively). 
      Prior adjustable gastric band did not significantly alter baseline pH. We then 
      performed drug dissolution studies of the antiplatelet drugs dipyridamole and 
      aspirin, mimicking pre-surgery, post-LSG and post-OAGB conditions, implementing 
      our pH results and other relevant physiological parameters. Dipyridamole, a weak 
      base, completely dissolved (100% of dose) under pre-surgery conditions, while 
      dissolution was hampered under post-LSG (5%) and post-OAGB (0.25%) conditions, 
      due to solubility limit. Aspirin was not released from enteric-coated tablet 
      under pre-surgery or post-LSG gastric conditions, however, >75% dissolved within 
      15 min under post-OAGB gastric conditions, indicating potential failure of 
      enteric coating, depending on the bariatric procedure. In conclusion, special 
      care should be taken when using pH-dependent drugs and drug products after 
      bariatric surgery, and the use of pH-independent formulations should be 
      preferred. Overall, this research revealed the interim gastric pH after different 
      bariatric procedures, and potentially important effects on post-bariatric oral 
      drug delivery and treatment.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Porat, Daniel
AU  - Porat D
AD  - Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health 
      Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
FAU - Vaynshtein, Julie
AU  - Vaynshtein J
AD  - Department of Surgery B, Soroka University Medical Center, Beer-Sheva 84101, 
      Israel.
FAU - Gibori, Roni
AU  - Gibori R
AD  - Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health 
      Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
FAU - Avramoff, Opal
AU  - Avramoff O
AD  - Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health 
      Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
FAU - Shaked, Gad
AU  - Shaked G
AD  - Department of Surgery B, Soroka University Medical Center, Beer-Sheva 84101, 
      Israel.
FAU - Dukhno, Oleg
AU  - Dukhno O
AD  - Department of Surgery B, Soroka University Medical Center, Beer-Sheva 84101, 
      Israel.
FAU - Czeiger, David
AU  - Czeiger D
AD  - Department of Surgery B, Soroka University Medical Center, Beer-Sheva 84101, 
      Israel.
FAU - Sebbag, Gilbert
AU  - Sebbag G
AD  - Department of Surgery B, Soroka University Medical Center, Beer-Sheva 84101, 
      Israel.
FAU - Dahan, Arik
AU  - Dahan A
AD  - Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health 
      Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel. 
      Electronic address: arikd@bgu.ac.il.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20210130
PL  - Netherlands
TA  - Eur J Pharm Biopharm
JT  - European journal of pharmaceutics and biopharmaceutics : official journal of 
      Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
JID - 9109778
RN  - 0 (Tablets)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacokinetics
MH  - Bariatric Surgery/*adverse effects
MH  - Dipyridamole/administration & dosage/pharmacokinetics
MH  - Drug Liberation
MH  - Female
MH  - Gastric Mucosa/*metabolism/surgery
MH  - Gastrointestinal Contents/*chemistry
MH  - Humans
MH  - *Hydrogen-Ion Concentration
MH  - Male
MH  - Middle Aged
MH  - Postoperative Period
MH  - Preoperative Period
MH  - Tablets
OTO - NOTNLM
OT  - Adjustable gastric band
OT  - Aspirin
OT  - Dipyridamole
OT  - Drug dissolution
OT  - Enteric coating
OT  - Gastric pH
OT  - Laparoscopic sleeve gastrectomy
OT  - One anastomosis gastric bypass
EDAT- 2021/02/02 06:00
MHDA- 2021/10/12 06:00
CRDT- 2021/02/01 20:11
PHST- 2020/12/13 00:00 [received]
PHST- 2021/01/18 00:00 [revised]
PHST- 2021/01/24 00:00 [accepted]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
PHST- 2021/02/01 20:11 [entrez]
AID - S0939-6411(21)00030-8 [pii]
AID - 10.1016/j.ejpb.2021.01.016 [doi]
PST - ppublish
SO  - Eur J Pharm Biopharm. 2021 Mar;160:152-157. doi: 10.1016/j.ejpb.2021.01.016. Epub 
      2021 Jan 30.

PMID- 22385219
OWN - NLM
STAT- MEDLINE
DCOM- 20130718
LR  - 20220316
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 24
IP  - 2
DP  - 2013
TI  - Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic 
      patients during therapy with clopidogrel and aspirin.
PG  - 145-50
LID - 10.3109/09537104.2012.661107 [doi]
AB  - Diabetes mellitus (DM) is associated with increased platelet activation and 
      reduced platelet inhibition by clopidogrel. Prostaglandin E1 (PGE1) stimulates 
      adenyl cyclase activity in platelets and increases cyclic AMP concentrations, 
      which inhibit Ca(2+)release and platelet aggregation induced by P2Y1 receptor 
      activation. PGE1 is included in the VerifyNow P2Y12 assay to suppress P2Y1 
      induced platelet aggregation. We hypothesized that diabetes mellitus may be 
      associated with altered response to PGE1 in subjects treated with clopidogrel. 
      Subjects with established coronary artery disease who were taking clopidogrel 
      75 mg daily and aspirin for >14 days were enrolled (n = 96). Diabetic (n = 34) 
      were compared with non-diabetic subjects (n = 62). VerifyNow P2Y12 assay and 
      light transmittance aggregometry (LTA) were performed using ADP as agonist with 
      and without addition of PGE1. Genomic DNA was genotyped for common cytochrome 
      P450 (CYP) 2C19 variants using Taqman assays. Residual on-treatment platelet 
      aggregation induced by 20 µM ADP was not significantly different between subjects 
      with and without DM. Addition of 22 nM and 88 nM PGE1 to 20 µM ADP resulted in a 
      significant reduction of maximal platelet aggregation (MPA). Residual LTA 
      platelet aggregation with PGE1 and VerifyNow P2Y12 platelet reactivity were 
      significantly higher in subjects with DM than those without DM and in carriers of 
      CYP 2C19*2 polymorphism. We conclude that an impaired inhibitory response to PGE1 
      may contribute to the high platelet reactivity phenotype in subjects with DM 
      treated with clopidogrel. Addition of PGE1 to ADP agonist platelet assays may 
      identify subjects with blunted inhibitory response to prostaglandins and result 
      in a higher proportion of subjects with DM being classified as non-responders.
FAU - Kreutz, Rolf P
AU  - Kreutz RP
AD  - Krannert Institute of Cardiology, Indiana University School of Medicine , IN 
      46202, USA. rkreutz@iupui.edu
FAU - Nystrom, Perry
AU  - Nystrom P
FAU - Kreutz, Yvonne
AU  - Kreutz Y
FAU - Miao, Jia
AU  - Miao J
FAU - Kovacs, Richard
AU  - Kovacs R
FAU - Desta, Zeruesenay
AU  - Desta Z
FAU - Flockhart, David A
AU  - Flockhart DA
FAU - Jin, Yan
AU  - Jin Y
LA  - eng
GR  - UL1 RR025761/RR/NCRR NIH HHS/United States
GR  - UL1 TR001108/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20120302
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - F5TD010360 (Alprostadil)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Aged
MH  - Alprostadil/*pharmacology
MH  - Aryl Hydrocarbon Hydroxylases/genetics
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Cytochrome P-450 CYP2C19
MH  - Diabetes Mellitus/drug therapy/genetics
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
PMC - PMC4028123
MID - NIHMS579506
EDAT- 2012/03/06 06:00
MHDA- 2013/07/19 06:00
CRDT- 2012/03/06 06:00
PHST- 2012/03/06 06:00 [entrez]
PHST- 2012/03/06 06:00 [pubmed]
PHST- 2013/07/19 06:00 [medline]
AID - 10.3109/09537104.2012.661107 [doi]
PST - ppublish
SO  - Platelets. 2013;24(2):145-50. doi: 10.3109/09537104.2012.661107. Epub 2012 Mar 2.

PMID- 6873610
OWN - NLM
STAT- MEDLINE
DCOM- 19830920
LR  - 20151119
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 85
IP  - 3
DP  - 1983 Sep
TI  - Impairment of aminopyrine clearance in aspirin-damaged canine gastric mucosa.
PG  - 643-9
AB  - Using an in vivo canine chambered stomach preparation, the clearance of 
      [14C]aminopyrine across mucosa when intravenously infused and the back-diffusion 
      of this substance from gastric lumen to mucosa when topically applied to gastric 
      epithelium were evaluated in aspirin-damaged gastric epithelium. In mucosa 
      damaged by either 20 mM or 40 mM aspirin, the recovery of [14C]aminopyrine, when 
      topically mixed with acid (pH = 1.1) perfusate solution, was not significantly 
      different from nondamaged control mucosa. In addition, the degree of "trapping" 
      of this substance from back-diffusion was not different in damaged mucosa from 
      that observed in nondamaged epithelium. In contrast, when [14C]aminopyrine was 
      intravenously infused, its clearance was significantly impaired in 
      aspirin-damaged mucosa when compared with control studies, as evidenced by the 
      increased "trapping" of this substance in injured epithelium. These findings 
      indicate that movement of aminopyrine from plasma to gastric lumen is impaired in 
      damaged epithelium, making the aminopyrine clearance technique an unreliable 
      method to accurately measure absolute gastric blood flow in this experimental 
      setting.
FAU - Miller, T A
AU  - Miller TA
FAU - Henagan, J M
AU  - Henagan JM
FAU - Loy, T M
AU  - Loy TM
LA  - eng
GR  - AM 25838/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Carbon Radioisotopes)
RN  - 01704YP3MO (Aminopyrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aminopyrine
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Carbon Radioisotopes
MH  - Diffusion
MH  - Dogs
MH  - Epithelium/drug effects
MH  - Female
MH  - Gastric Mucosa/blood supply/*drug effects
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Regional Blood Flow
EDAT- 1983/09/01 00:00
MHDA- 1983/09/01 00:01
CRDT- 1983/09/01 00:00
PHST- 1983/09/01 00:00 [pubmed]
PHST- 1983/09/01 00:01 [medline]
PHST- 1983/09/01 00:00 [entrez]
AID - S0016508583002292 [pii]
PST - ppublish
SO  - Gastroenterology. 1983 Sep;85(3):643-9.

PMID- 27329582
OWN - NLM
STAT- MEDLINE
DCOM- 20180509
LR  - 20220331
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 6
DP  - 2016 Jun 22
TI  - Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency 
      Catheter Ablation: Results of a Prospective active controlled Study.
PG  - 28439
LID - 10.1038/srep28439 [doi]
LID - 28439
AB  - We conducted a prospective, single-center, active controlled study from July 2013 
      to January 2015, in Chinese patients with rapid ventricular arrhythmia who had 
      received radiofrequency catheter ablation (RFCA) treatment to determine formation 
      of lower extremity deep vein thrombosis (LDVT) post RFCA procedure, and evaluated 
      the effect of rivaroxaban on LDVT. Patients with asymptomatic pulmonary 
      thromboembolism who had not received any other anticoagulant and had received no 
      more than 36 hours of treatment with unfractionated heparin were included. Post 
      RFCA procedure, patients received either rivaroxaban (10 mg/d for 14 days 
      beginning 2-3 hours post-operation; n = 86) or aspirin (100 mg/d for 3 months 
      beginning 2-3 hours post-operation; n = 90). The primary outcome was a composite 
      of LDVT occurrence, change in diameter of femoral veins, and safety outcomes that 
      were analyzed based on major or minor bleeding events. In addition, blood flow 
      velocity was determined. No complete occlusive thrombus or bleeding events were 
      reported with either of the group. The lower incidence rate of non-occluded 
      thrombus in rivaroxaban (5.8%) compared to the aspirin group (16.7%) indicates 
      rivaroxaban may be administered post-RFCA to prevent and treat femoral venous 
      thrombosis in a secure and effective way with a faster inset of action than 
      standard aspirin therapy.
FAU - Li, Lan
AU  - Li L
AD  - Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang 
      Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
FAU - Zhang, Bao-Jian
AU  - Zhang BJ
AD  - Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang 
      Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
FAU - Zhang, Bao-Ku
AU  - Zhang BK
AD  - Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang 
      Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
FAU - Ma, Jun
AU  - Ma J
AD  - Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang 
      Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
FAU - Liu, Xu-Zheng
AU  - Liu XZ
AD  - Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang 
      Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
FAU - Jiang, Shu-Bin
AU  - Jiang SB
AD  - Coronary care unit, Affiliated hospital of Traditional Chinese Medicine, Xinjiang 
      Medical University, 116 Huanghe Rd, Shayibake District, Urumuqi 830000, China.
LA  - eng
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20160622
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arrhythmias, Cardiac/*surgery
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Catheter Ablation/*adverse effects
MH  - China
MH  - Female
MH  - *Femoral Vein
MH  - Humans
MH  - Lower Extremity
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Rivaroxaban/*administration & dosage/therapeutic use
MH  - Treatment Outcome
MH  - Venous Thrombosis/*drug therapy/etiology/*prevention & control
MH  - Young Adult
PMC - PMC4916462
EDAT- 2016/06/23 06:00
MHDA- 2018/05/10 06:00
CRDT- 2016/06/23 06:00
PHST- 2016/03/03 00:00 [received]
PHST- 2016/06/06 00:00 [accepted]
PHST- 2016/06/23 06:00 [entrez]
PHST- 2016/06/23 06:00 [pubmed]
PHST- 2018/05/10 06:00 [medline]
AID - srep28439 [pii]
AID - 10.1038/srep28439 [doi]
PST - epublish
SO  - Sci Rep. 2016 Jun 22;6:28439. doi: 10.1038/srep28439.

PMID- 10963290
OWN - NLM
STAT- MEDLINE
DCOM- 20001222
LR  - 20181130
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 22
IP  - 3
DP  - 2000 Mar
TI  - Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin 
      monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness 
      analysis.
PG  - 362-70; discussion 360-1
AB  - OBJECTIVE: The goal of this health economic analysis was to asses the 
      cost-effectiveness of a fixed combination of aspirin plus extended-release 
      dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for 
      prevention of recurrent ischemic stroke. BACKGROUND: The second European Stroke 
      Prevention Study (ASA/ESPS-2), a large-scale clinical trial, demonstrated that a 
      new therapy--a fixed combination of ASA/ER-DP--is more effective than ASA 
      monotherapy for the prevention of recurrent ischemic stroke. METHODS: We used 
      data from ESPS-2 to create a health economic model that estimates the incremental 
      cost and cost-effectiveness of ASA/ER-DP during the 2-year time frame after an 
      ischemic stroke. The model was developed from a payor perspective. The analysis 
      used direct cost estimates for stroke from a Medicare claims database analysis. 
      Efficacy data were obtained from clinical trials to determine the incremental 
      cost per stroke averted for ASA/ER-DP or clopidogrel versus ASA. Sensitivity 
      analyses also were conducted to test the reliability and robustness of the model. 
      RESULTS: The results of the analysis demonstrated that ASA/ER-DP was 
      cost-effective compared with ASA monotherapy for the secondary prevention of 
      stroke, with a cost-effectiveness ratio of $28,472. The model remained robust 
      over a range of assumptions and cost estimates. Clopidogrel, however, was not 
      cost-effective compared with ASA (cost per stroke averted, $161,316) in either 
      the base-case analysis or any of the sensitivity analyses. CONCLUSION: ASA/ER-DP 
      thus offers a cost-effective alternative to ASA monotherapy for the prevention of 
      recurrent ischemic stroke.
FAU - Shah, H
AU  - Shah H
AD  - Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 
      06877-0368,USA.
FAU - Gondek, K
AU  - Gondek K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*economics/therapeutic use
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Dipyridamole/economics/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*economics/therapeutic use
MH  - Recurrence
MH  - Stroke/*economics/prevention & control
MH  - Ticlopidine/*analogs & derivatives/economics/therapeutic use
EDAT- 2000/08/30 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/30 11:00
PHST- 2000/08/30 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/30 11:00 [entrez]
AID - S0149-2918(00)80041-7 [pii]
AID - 10.1016/S0149-2918(00)80041-7 [doi]
PST - ppublish
SO  - Clin Ther. 2000 Mar;22(3):362-70; discussion 360-1. doi: 
      10.1016/S0149-2918(00)80041-7.

PMID- 2105067
OWN - NLM
STAT- MEDLINE
DCOM- 19900221
LR  - 20190628
IS  - 0003-3022 (Print)
IS  - 0003-3022 (Linking)
VI  - 72
IP  - 1
DP  - 1990 Jan
TI  - Contribution of prostacyclin to D-tubocurarine-induced hypotension in humans.
PG  - 28-32
AB  - In order to evaluate the role of prostacyclin in d-tubocurarine-induced 
      hypotension in human, the authors examined the relationship of changes of 
      arterial blood pressure and plasma 6-keto-PGF1 alpha level following iv 
      administration of d-tubocurarine (dTc), with or without prior administration of 
      aspirin and H1 antagonist. The bolus injection of dTc 0.6 mg/kg caused a 
      significant decrease in mean arterial pressure (MAP) that was associated with a 
      significant increase in plasma 6-keto-PGF1 alpha (P less than 0.05 in both). The 
      maximum MAP decrease and plasma 6-keto-PGF1 alpha increase were noted at 2 min 
      after dTc administration. Pretreatment with aspirin DL-lysine (25 mg/kg) or 
      diphenhydramine (1 mg/kg) significantly attenuated the responses of MAP (P less 
      than 0.05 in both) and plasma 6-keto-PGF1 alpha level (P less than 0.01 for 
      aspirin group, P less than 0.05 for diphenhydramine group). There was a 
      significant correlation between the changes in plasma 6-keto-PGF1 alpha and those 
      in MAP (Kendall tau (tau) = -0.504, P less than 0.01). These findings suggest 
      that a bolus injection of dTc induces a release of prostacyclin through H1 
      receptor, which is responsible for the dTc-induced transient decrease of blood 
      pressure in humans.
FAU - Hatano, Y
AU  - Hatano Y
AD  - Department of Anesthesia, Kyoto University Hospital, Japan.
FAU - Arai, T
AU  - Arai T
FAU - Noda, J
AU  - Noda J
FAU - Komatsu, K
AU  - Komatsu K
FAU - Shinkura, R
AU  - Shinkura R
FAU - Nakajima, Y
AU  - Nakajima Y
FAU - Sawada, M
AU  - Sawada M
FAU - Mori, K
AU  - Mori K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesthesiology
JT  - Anesthesiology
JID - 1300217
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 8GTS82S83M (Diphenhydramine)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - W9YXS298BM (Tubocurarine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Adult
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Blood Pressure/drug effects
MH  - Depression, Chemical
MH  - Diphenhydramine/pharmacology
MH  - Epoprostenol/*physiology
MH  - Female
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Hypotension/*chemically induced
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Stimulation, Chemical
MH  - Tubocurarine/*pharmacology
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1097/00000542-199001000-00006 [doi]
PST - ppublish
SO  - Anesthesiology. 1990 Jan;72(1):28-32. doi: 10.1097/00000542-199001000-00006.

PMID- 21255534
OWN - NLM
STAT- MEDLINE
DCOM- 20110324
LR  - 20190608
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 49
IP  - 2
DP  - 2011 Feb
TI  - Evaluation of bioequivalence between a single-capsule formulation of esomeprazole 
      40 mg and acetylsalicylic acid 325 mg and the monotherapies given separately in 
      healthy volunteers.
PG  - 169-76
AB  - OBJECTIVE: The aim of this study was to investigate the bioequivalence of a 
      single oral dose of esomeprazole 40 mg and acetylsalicylic acid 325 mg when 
      formulated as a single capsule, relative to the components given as separate 
      monotherapies. METHODS: This was an open, randomized, single-center, single-dose, 
      2-stage group sequential design, 2-way crossover study (NCT00688428) in 49 
      healthy adult volunteers (29 women). In each treatment period, subjects received 
      a single dose of esomeprazole 40 mg and ASA 325 mg formulated as a single capsule 
      or as separate monotherapies given in combination. Treatment periods were 
      separated by a washout period of at least 6 days. The bioequivalence of a 
      single-capsule formulation of esomeprazole 40 mg and ASA 325 mg relative to the 
      monotherapies given individually was assessed by the geometric mean ratios of the 
      area under the plasma concentration-time curve (AUC) and observed maximum plasma 
      concentration (Cmax). If the 94% confidence interval (CI) of the geometric mean 
      ratios of AUC and Cmax were within 0.80 - 1.25, bioequivalence would be 
      established. A 94% CI was used to compensate for the multiple analyses of the 
      study design, and to assure that the actual overall confidence level was 90%. 
      RESULTS: The geometric mean ratios of the AUC for esomeprazole 40 mg and ASA 325 
      mg when administered in the single capsule formulation, relative to the 
      monotherapies were 0.97 (94% CI, 0.90 - 1.04) and 1.04 (94% CI, 1.00 - 1.08). The 
      corresponding mean geometric ratios for Cmax were 0.99 (94% CI, 0.90 - 1.09) and 
      1.02 (94% CI, 0.92 - 1.13). CONCLUSIONS: Treatment with esomeprazole 40 mg and 
      ASA 325 mg formulated as a single capsule is bioequivalent to the separate 
      monotherapies of esomeprazole 40 mg and ASA 325 mg when given in combination as 
      separately-administered drugs in healthy adult subjects.
FAU - Niazi, M
AU  - Niazi M
AD  - AstraZeneca R&D, Mölndal, Sweden. Mohammad.Niazi@astrazeneca.com
FAU - Andersson, T
AU  - Andersson T
FAU - Nauclér, E
AU  - Nauclér E
FAU - Næsdal, J
AU  - Næsdal J
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Capsules)
RN  - 0 (Drug Combinations)
RN  - N3PA6559FT (Esomeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Capsules
MH  - Cross-Over Studies
MH  - Drug Combinations
MH  - Esomeprazole/administration & dosage/*pharmacokinetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Therapeutic Equivalency
EDAT- 2011/01/25 06:00
MHDA- 2011/03/25 06:00
CRDT- 2011/01/25 06:00
PHST- 2011/01/25 06:00 [entrez]
PHST- 2011/01/25 06:00 [pubmed]
PHST- 2011/03/25 06:00 [medline]
AID - 8346 [pii]
AID - 10.5414/cp201400 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2011 Feb;49(2):169-76. doi: 10.5414/cp201400.

PMID- 11988654
OWN - NLM
STAT- MEDLINE
DCOM- 20020610
LR  - 20191210
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 52
IP  - 5
DP  - 2002 May
TI  - Post hoc mortality analysis of the efficacy trial of diaspirin cross-linked 
      hemoglobin in the treatment of severe traumatic hemorrhagic shock.
PG  - 887-95
AB  - BACKGROUND: The efficacy trial of diaspirin cross-linked hemoglobin (DCLHb) in 
      traumatic hemorrhagic shock demonstrated an unexpected mortality imbalance, 
      prompting a three-step review to better understand the cause of this finding. 
      METHODS: Patients were enrolled in this DCLHb hemorrhagic shock study using 
      28-day mortality as the primary endpoint. Mortality data were primarily analyzed 
      using the TRISS method and a nonblinded clinical review, followed by an 
      independent Pennsylvania Trauma Outcome Study (PTOS)-derived probability of 
      survival analyses. Finally, a trauma expert conducted a blinded clinical review 
      of cases incorrectly predicted by these PTOS analyses. RESULTS: More of the DCLHb 
      patients predicted to survive using TRISS actually died than in the control 
      subgroup (24% vs. 3%, p < 0.002). Nonblinded clinical review noted that 72% of 
      the patients who died had prior traumatic arrest, a presenting Glasgow Coma Scale 
      score of 3, or a base deficit > 15 mEq/L. DCLHb patients predicted to survive 
      using PTOS also more often died than did control patients (30% vs. 8%, p < 0.04). 
      Blinded clinical review determined that 94% of the deaths were clinically 
      justified. Both the TRISS and the PTOS models gave an adjusted mortality relative 
      risk of 2.3, similar to the unadjusted risk data. CONCLUSION: Mortality analysis 
      in this shock study involved both clinical case reviews and mortality prediction 
      models. Despite the observation that nearly all of the deaths were clinically 
      justified, the TRISS and PTOS models demonstrated excess unpredicted deaths in 
      the DCLHb subgroup. A combined process, using both mortality prediction models 
      and clinical case reviews, is useful in trauma studies that use a mortality 
      endpoint.
FAU - Sloan, Edward P
AU  - Sloan EP
AD  - Department of Emergency Medicine, University of Illinois at Chicago, 60612, USA. 
      edsloan@uic.edu
FAU - Koenigsberg, Max
AU  - Koenigsberg M
FAU - Brunett, Patrick H
AU  - Brunett PH
FAU - Bynoe, Raymond P
AU  - Bynoe RP
FAU - Morris, John A
AU  - Morris JA
FAU - Tinkoff, Glen
AU  - Tinkoff G
FAU - Dalsey, William C
AU  - Dalsey WC
FAU - Ochsner, M Gage
AU  - Ochsner MG
CN  - DCLHb Traumatic Hemorrhagic Shock Study Group
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Trauma. 2002 Nov;53(5):1031; author reply 1031-2. PMID: 12435966
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*analogs & derivatives/*therapeutic use
MH  - Female
MH  - Hemoglobins/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Shock, Hemorrhagic/*drug therapy/*mortality
MH  - Shock, Traumatic/*drug therapy/*mortality
MH  - Survival Analysis
MH  - Trauma Severity Indices
EDAT- 2002/05/04 10:00
MHDA- 2002/06/11 10:01
CRDT- 2002/05/04 10:00
PHST- 2002/05/04 10:00 [pubmed]
PHST- 2002/06/11 10:01 [medline]
PHST- 2002/05/04 10:00 [entrez]
AID - 10.1097/00005373-200205000-00011 [doi]
PST - ppublish
SO  - J Trauma. 2002 May;52(5):887-95. doi: 10.1097/00005373-200205000-00011.

PMID- 20886344
OWN - NLM
STAT- MEDLINE
DCOM- 20110406
LR  - 20211020
IS  - 1432-1262 (Electronic)
IS  - 0179-1958 (Linking)
VI  - 26
IP  - 1
DP  - 2011 Jan
TI  - Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms 
      involving downregulation of IL-6-STAT3 signaling pathway.
PG  - 13-22
LID - 10.1007/s00384-010-1060-0 [doi]
AB  - BACKGROUND AND AIMS: Aspirin is associated with a reduced risk of colorectal 
      cancer (CRC), and it showed inhibited effects on interleukin 6 (IL-6)/signal 
      transducer and activator of transcription 3 (STAT3) signaling pathway which is 
      thought to play an important role in intestinal inflammation and the 
      tumorigenesis of CRC. METHODS: Mouse model for inflammation-related CRC was 
      induced by a combined treatment with azoxymethane (AOM) and dextran sodium 
      sulfate (DSS) in BALB/c mice. Effects of aspirin on tumor number and size and 
      apoptosis of CRC cells were investigated. Key molecules of IL-6-STAT3 pathway, 
      such as IL-6, sIL-6R, phosphorylated STAT3, and their downstream anti-apoptotic 
      genes Bcl-2 and Bcl-xl, were assessed by ELISA and Western blot. RESULTS: 
      Treatment with aspirin significantly promoted CRC cell apoptosis in 
      AOM/DSS-induced CRC mice in vivo. The expression level of IL-6, which is an 
      upstream molecule of STAT3 and capable of activating STAT3, was reduced in 
      aspirin-treated mice. Furthermore, the phosphorylated form of STAT3 and the 
      levels of STAT3's target gene products such as Bcl-xl and Bcl-2, which are 
      essential for cell growth and survival, were also decreased in aspirin-treated 
      mice. CONCLUSIONS: Our data suggested that the protective mechanisms of aspirin 
      in CRC may be associated with its effects on induction of CRC cell apoptosis and 
      suppression of IL-6-STAT3 signaling pathway, which implied that aspirin has a 
      potential therapeutic activity in CRC.
FAU - Tian, Yun
AU  - Tian Y
AD  - Cancer Research Institute, the First Affiliated Hospital, China Medical 
      University, Shenyang 110001, China.
FAU - Ye, Ying
AU  - Ye Y
FAU - Gao, Wei
AU  - Gao W
FAU - Chen, Hong
AU  - Chen H
FAU - Song, Ting
AU  - Song T
FAU - Wang, Daqing
AU  - Wang D
FAU - Mao, Xiaoyun
AU  - Mao X
FAU - Ren, Changshan
AU  - Ren C
LA  - eng
PT  - Journal Article
DEP - 20101001
PL  - Germany
TA  - Int J Colorectal Dis
JT  - International journal of colorectal disease
JID - 8607899
RN  - 0 (Interleukin-6)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (Stat3 protein, mouse)
RN  - 0 (bcl-X Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Body Weight/drug effects
MH  - Colorectal Neoplasms/drug therapy/metabolism/*pathology
MH  - Disease Models, Animal
MH  - Down-Regulation/*drug effects
MH  - Inflammation/metabolism/pathology
MH  - Interleukin-6/*metabolism
MH  - Intestinal Mucosa/metabolism
MH  - Intestines/drug effects/pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Phosphorylation/drug effects
MH  - STAT3 Transcription Factor/*metabolism
MH  - Signal Transduction/*drug effects
MH  - Tumor Burden/drug effects
MH  - bcl-X Protein/metabolism
EDAT- 2010/10/05 06:00
MHDA- 2011/04/07 06:00
CRDT- 2010/10/02 06:00
PHST- 2010/09/17 00:00 [accepted]
PHST- 2010/10/02 06:00 [entrez]
PHST- 2010/10/05 06:00 [pubmed]
PHST- 2011/04/07 06:00 [medline]
AID - 10.1007/s00384-010-1060-0 [doi]
PST - ppublish
SO  - Int J Colorectal Dis. 2011 Jan;26(1):13-22. doi: 10.1007/s00384-010-1060-0. Epub 
      2010 Oct 1.

PMID- 9737475
OWN - NLM
STAT- MEDLINE
DCOM- 19980928
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 82
IP  - 5B
DP  - 1998 Sep 10
TI  - Rationale for the management of coronary syndromes with low-molecular-weight 
      heparins.
PG  - 15L-18L
AB  - The well-documented disadvantages of unfractionated heparin in the management of 
      coronary syndromes, such as unpredictable bioavailability and maintenance of 
      therapeutic range, has prompted several studies into the benefits of 
      low-molecular-weight heparins (LMWHs). The favorable pharmacologic properties of 
      LMWHs include a binding affinity for antithrombin III, anti-factor IIa activity, 
      excellent bioavailability, minimal protein binding, predictable anticoagulant 
      response, and clinical tolerance by patients. LMWHs are also characterized by 
      having a specific anti-factor Xa effect and inducing only a small prolongation in 
      general clotting tests-i.e., activated partial thromboplastin time, prothrombin 
      time, and antithrombin activity-when used in high doses. Several studies have 
      recently demonstrated that LMWHs are superior to placebo and are at least equal 
      or superior to standard heparin when added to aspirin for the treatment of 
      unstable angina and following non-Q-wave myocardial infarction. These studies, 
      which include Thrombolysis in Myocardial Infarction (TIMI) 11A and Efficacy and 
      Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin in 
      Non-Q-wave Coronary Events (ESSENCE), will be reviewed and discussed.
FAU - Gurfinkel, E
AU  - Gurfinkel E
AD  - Instituto de Cardiologia y Cirugia Cardiovascular, Fundacion Favaloro, Buenos 
      Aires, Argentina.
FAU - Fareed, J
AU  - Fareed J
FAU - Antman, E
AU  - Antman E
FAU - Cohen, M
AU  - Cohen M
FAU - Mautner, B
AU  - Mautner B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Syndrome
RF  - 37
EDAT- 1998/09/16 00:00
MHDA- 1998/09/16 00:01
CRDT- 1998/09/16 00:00
PHST- 1998/09/16 00:00 [pubmed]
PHST- 1998/09/16 00:01 [medline]
PHST- 1998/09/16 00:00 [entrez]
AID - S0002-9149(98)00107-6 [pii]
AID - 10.1016/s0002-9149(98)00107-6 [doi]
PST - ppublish
SO  - Am J Cardiol. 1998 Sep 10;82(5B):15L-18L. doi: 10.1016/s0002-9149(98)00107-6.

PMID- 28132418
OWN - NLM
STAT- MEDLINE
DCOM- 20180403
LR  - 20201216
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Linking)
VI  - 121
IP  - 1
DP  - 2017 Jul
TI  - Switching, Adverse Effects and Use of Over-the-Counter Analgesics among Users of 
      Oral Anticoagulants: A Pharmacy-based Survey.
PG  - 37-43
LID - 10.1111/bcpt.12762 [doi]
AB  - Oral anticoagulants are widely used but information on important aspects in that 
      respect is not available from medical registers or clinical databases. Therefore, 
      we conducted a survey including patients filling a prescription for oral 
      anticoagulants at two large Danish community pharmacies. We collected information 
      concerning the patients' knowledge of their anticoagulant treatment including 
      prior drug switching. Further, patients were asked about use of over-the-counter 
      analgesics, adverse effects and how the treatment affected their everyday life. 
      Among 335 eligible patients, 301 (90%) agreed to participate. Atrial fibrillation 
      was the most common indication (65%), and most patients filled a prescription for 
      a non-vitamin K antagonist oral anticoagulant (NOAC) (58%). Among the 12% (n = 
      35) of participants who had switched oral anticoagulant treatment, 69% had 
      switched from a vitamin K antagonist (VKA) to a NOAC. Switching was most 
      frequently caused by inconvenience (34%) and adverse effects (23%). Although half 
      of all patients had recently bought over-the-counter analgesics, purchase of 
      ibuprofen and aspirin was rare (6%). More VKA users than NOAC users felt limited 
      in their everyday life because of anticoagulant treatment (18% versus 9%). Among 
      non-incident NOAC users, 21% had experienced adverse effects during their current 
      treatment. Based on first-hand information from a large sample of anticoagulant 
      users, we conclude that the main drug-related issues leading to anticoagulant 
      switching and perceived limitations in everyday life were inconvenience and 
      adverse effects. This varied between drug groups. Further, use of NSAIDs obtained 
      over the counter was rare.
CI  - © 2017 Nordic Association for the Publication of BCPT (former Nordic 
      Pharmacological Society).
FAU - Hellfritzsch, Maja
AU  - Hellfritzsch M
AD  - Department of Public Health, Clinical Pharmacology and Pharmacy, University of 
      Southern Denmark, Odense, Denmark.
AD  - OPEN, Odense Patient data Explorative Network, Odense University Hospital, 
      Odense, Denmark.
FAU - Hyllested, Lea Maria Rønneberg
AU  - Hyllested LMR
AD  - Copenhagen Sønderbro Pharmacy, Copenhagen, Denmark.
FAU - Meegaard, Line
AU  - Meegaard L
AD  - Marselisborg Pharmacy, Højbjerg, Denmark.
FAU - Wiberg-Hansen, Alexander
AU  - Wiberg-Hansen A
AD  - Copenhagen Sønderbro Pharmacy, Copenhagen, Denmark.
FAU - Grove, Erik Lerkevang
AU  - Grove EL
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
AD  - Faculty of Health, Institute of Clinical Medicine, Aarhus University, Aarhus, 
      Denmark.
FAU - Pottegård, Anton
AU  - Pottegård A
AD  - Department of Public Health, Clinical Pharmacology and Pharmacy, University of 
      Southern Denmark, Odense, Denmark.
AD  - Copenhagen Sønderbro Pharmacy, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20170308
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - 0 (Analgesics)
RN  - 0 (Anticoagulants)
RN  - 0 (Nonprescription Drugs)
RN  - 0 (Prescription Drugs)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Analgesics/*pharmacology/therapeutic use
MH  - Anticoagulants/*pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Denmark
MH  - Drug Substitution/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Ibuprofen/pharmacology/therapeutic use
MH  - Male
MH  - Nonprescription Drugs/*pharmacology/therapeutic use
MH  - Pharmacies/statistics & numerical data
MH  - Pilot Projects
MH  - Prescription Drugs/*pharmacology/therapeutic use
MH  - Surveys and Questionnaires
EDAT- 2017/01/31 06:00
MHDA- 2018/04/04 06:00
CRDT- 2017/01/30 06:00
PHST- 2016/11/08 00:00 [received]
PHST- 2017/01/23 00:00 [accepted]
PHST- 2017/01/31 06:00 [pubmed]
PHST- 2018/04/04 06:00 [medline]
PHST- 2017/01/30 06:00 [entrez]
AID - 10.1111/bcpt.12762 [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2017 Jul;121(1):37-43. doi: 10.1111/bcpt.12762. 
      Epub 2017 Mar 8.

PMID- 487454
OWN - NLM
STAT- MEDLINE
DCOM- 19791229
LR  - 20190911
IS  - 0309-1651 (Print)
IS  - 0309-1651 (Linking)
VI  - 3
IP  - 5
DP  - 1979 Aug
TI  - Evaluation of a biochemical method for measuring platelet life-span.
PG  - 441-5
AB  - Acetylsalicylic Acid (Aspirin) inhibits the formation of Malonaldehyde, a 
      degradation product of the proaggregating Prostaglandins, during the life-span 
      platelets in the circulating blood. After ingestion of 1.5 g of aspirin, there is 
      a blockage of the formation of Malonaldehyde, followed by a progressive return to 
      normal values, after an average of 8 days, in a healthy person. This fact is 
      applied to the determination of half-life, found to be 3.7 +/- 1.3 days; a value 
      in accord with those found by the isotopic method using 51Cr. The 
      reproductibility of this method indicates a clinical application.
FAU - Stoltz, J F
AU  - Stoltz JF
FAU - Voisin, P
AU  - Voisin P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cell Biol Int Rep
JT  - Cell biology international reports
JID - 7708050
RN  - 0 (Malonates)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacology
MH  - Blood Platelets/metabolism/*physiology
MH  - *Cell Survival
MH  - Depression, Chemical
MH  - Female
MH  - Hematologic Tests
MH  - Humans
MH  - Male
MH  - Malonates/*biosynthesis
MH  - Malondialdehyde/*biosynthesis
EDAT- 1979/08/01 00:00
MHDA- 1979/08/01 00:01
CRDT- 1979/08/01 00:00
PHST- 1979/08/01 00:00 [pubmed]
PHST- 1979/08/01 00:01 [medline]
PHST- 1979/08/01 00:00 [entrez]
AID - 10.1016/0309-1651(79)90005-5 [doi]
PST - ppublish
SO  - Cell Biol Int Rep. 1979 Aug;3(5):441-5. doi: 10.1016/0309-1651(79)90005-5.

PMID- 25192852
OWN - NLM
STAT- MEDLINE
DCOM- 20150804
LR  - 20141208
IS  - 1879-0003 (Electronic)
IS  - 0141-8130 (Linking)
VI  - 72
DP  - 2015 Jan
TI  - Cyclodextrin-grafted chitosan hydrogels for controlled drug delivery.
PG  - 299-308
LID - S0141-8130(14)00574-1 [pii]
LID - 10.1016/j.ijbiomac.2014.08.030 [doi]
AB  - A series of β-cyclodextrin-grafted carboxymethyl chitosan hydrogels (CD-g-CMCs) 
      were prepared from carboxymethyl chitosan (CMC) and carboxymethyl β-chitosan 
      (CMCD) using a water-soluble carbodiimide as a crosslinker in the presence of 
      N-hydroxysuccinimide. Details of the hydrogel structures were determined via FTIR 
      and solid-state NMR spectroscopic analyses. Increasing the feed ratio of CMCD to 
      CMC in the reaction mixture led to an increase in CD grafting within the gel 
      networks comprising CMC; this was confirmed by SEM observations and rheological 
      analysis of the swollen hydrogels. The prepared CD-g-CMC hydrogels exhibited 
      absorption properties toward acetylsalicylic acid (ASA, or Aspirin) due to the 
      presence of CD in the structure; the amount of ASA absorbed into the hydrogels 
      was enhanced with an increase in the amount of CD incorporated within the 
      hydrogels. In addition, CD-g-CMC hydrogels provided a slower release of the 
      entrapped ASA in comparison to the ASA release profile of a solely CMC-containing 
      hydrogel. From these results, CD-g-CMC hydrogels have the potential to function 
      as a biodegradable active material with controlled drug release ability.
CI  - Copyright © 2014 Elsevier B.V. All rights reserved.
FAU - Kono, Hiroyuki
AU  - Kono H
AD  - Department of Science and Engineering for Materials, Tomakomai National College 
      of Technology, Nishikioka 443, Tomakomai, Hokkaido 059 1275, Japan. Electronic 
      address: kono@sem.tomakomai-ct.ac.jp.
FAU - Teshirogi, Taku
AU  - Teshirogi T
AD  - Department of Science and Engineering for Materials, Tomakomai National College 
      of Technology, Nishikioka 443, Tomakomai, Hokkaido 059 1275, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140902
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
RN  - 0 (Cyclodextrins)
RN  - 0 (Hydrogels)
RN  - 0 (Succinimides)
RN  - 2491-17-0 (CME-Carbodiimide)
RN  - 9012-76-4 (Chitosan)
RN  - MJE3791M4T (N-hydroxysuccinimide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/chemistry
MH  - CME-Carbodiimide/chemistry
MH  - Chitosan/administration & dosage/*chemistry
MH  - Cyclodextrins/administration & dosage/*chemistry
MH  - *Drug Delivery Systems
MH  - Drug Liberation
MH  - Humans
MH  - Hydrogels/administration & dosage/*chemistry
MH  - Rheology
MH  - Succinimides/administration & dosage/chemistry
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Carboxymethyl chitosan
OT  - Carboxymethyl cyclodextrin
OT  - Controlled drug release
OT  - Hydrogel
EDAT- 2014/09/07 06:00
MHDA- 2015/08/05 06:00
CRDT- 2014/09/07 06:00
PHST- 2014/02/28 00:00 [received]
PHST- 2014/08/08 00:00 [revised]
PHST- 2014/08/09 00:00 [accepted]
PHST- 2014/09/07 06:00 [entrez]
PHST- 2014/09/07 06:00 [pubmed]
PHST- 2015/08/05 06:00 [medline]
AID - S0141-8130(14)00574-1 [pii]
AID - 10.1016/j.ijbiomac.2014.08.030 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2015 Jan;72:299-308. doi: 10.1016/j.ijbiomac.2014.08.030. 
      Epub 2014 Sep 2.

PMID- 22542152
OWN - NLM
STAT- MEDLINE
DCOM- 20130320
LR  - 20181201
IS  - 1532-1916 (Electronic)
IS  - 1521-6918 (Linking)
VI  - 26
IP  - 2
DP  - 2012 Apr
TI  - Gastrointestinal lesions and complications of low-dose aspirin in the 
      gastrointestinal tract.
PG  - 141-51
LID - 10.1016/j.bpg.2012.01.016 [doi]
AB  - Low dose aspirin (ASA) use has been associated with a wide range of adverse side 
      effects in the upper gastrointestinal (GI) tract, which range from troublesome 
      symptoms without mucosal lesions to more serious toxicity, including ulcers, GI 
      bleeding, perforation and even death. Upper GI symptoms in low dose ASA users are 
      common but often careless or misinterpreted and they are not always related to 
      the presence of mucosal injury. Usually, low dose ASA related ulcers are 
      reasonably small and asymptomatic, and probably heal over a period of weeks to a 
      few months. But, the real clinical problem occurs when the ulcer results in a GI 
      complication (mostly bleeding). The estimated average excess risk of symptomatic 
      or complicated ulcer related to low dose ASA is five cases per 1000 ASA users per 
      year. Death is the worst outcome of GI complications in low dose ASA users, but 
      data about this aspect are scarce. Current evidence indicates that low dose ASA 
      can damage the lower GI tract also, but the real size of the problem is still 
      unknown.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Sostres, Carlos
AU  - Sostres C
AD  - Service of Digestive Diseases, University Hospital Lozano Blesa, Zaragoza, Spain. 
      carlossostres@gmail.com
FAU - Gargallo, Carla J
AU  - Gargallo CJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Gastroenterol
JT  - Best practice & research. Clinical gastroenterology
JID - 101120605
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Gastrointestinal Diseases/*chemically induced/complications/mortality
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Gastrointestinal Tract/drug effects
MH  - Humans
MH  - Lower Gastrointestinal Tract/drug effects
MH  - Peptic Ulcer/chemically induced
MH  - Upper Gastrointestinal Tract/drug effects
EDAT- 2012/05/01 06:00
MHDA- 2013/03/21 06:00
CRDT- 2012/05/01 06:00
PHST- 2011/12/02 00:00 [received]
PHST- 2012/01/20 00:00 [revised]
PHST- 2012/01/24 00:00 [accepted]
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
AID - S1521-6918(12)00017-0 [pii]
AID - 10.1016/j.bpg.2012.01.016 [doi]
PST - ppublish
SO  - Best Pract Res Clin Gastroenterol. 2012 Apr;26(2):141-51. doi: 
      10.1016/j.bpg.2012.01.016.

PMID- 31574890
OWN - NLM
STAT- MEDLINE
DCOM- 20191009
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 39
DP  - 2019 Sep
TI  - Long-term aspirin use for cancer primary prevention: A protocol for updated 
      systematic review and subgroup meta-analysis of randomized clinical trials.
PG  - e17382
LID - 10.1097/MD.0000000000017382 [doi]
LID - e17382
AB  - BACKGROUND: Long-term use of aspirin for primary prevention of cancer remains 
      inconclusive, and variation in the effects of aspirin use on cancer outcomes by 
      cancer site, aspirin dose, follow-up duration, or different populations has never 
      been systematically evaluated. METHODS: Seven electronic databases (PubMed, 
      EMBASE, ClinicalTrials.gov, etc) will be searched from inception to September 30, 
      2019. Randomized clinical trials (RCTs) comparing aspirin versus no aspirin in 
      participants without pre-existing cancer and reporting cancer incidence, and/or 
      cancer mortality outcomes will be selected and assessed for inclusion. The 
      Cochrane's Risk of Bias Tool and the Jadad scale will be used to evaluate the 
      risk of bias and the methodologic quality of the RCTs. Data will be screened and 
      extracted by independent investigators. Total cancer incidence will be defined as 
      the primary clinical endpoint, and total cancer mortality, all-cause mortality, 
      and the risk of major bleeding will be the secondary outcomes. Subgroup analyses 
      based on cancer site, aspirin dose, follow-up duration, or different populations 
      will be conducted. Analyses will be performed using Review Manager 5.3, 
      Comprehensive Meta-Analysis 2.0, and Trial Sequential Analysis (TSA) software. 
      RESULTS: This study will systematically evaluate the effects of long-term aspirin 
      use on total cancer incidence, cancer mortality, all-cause mortality, and the 
      risk of major bleeding. Subgroup analyses will indicate whether the effects of 
      aspirin on cancer outcomes are associated with cancer site, daily dose of 
      aspirin, follow-up duration, or different subgroup of participants. The results 
      will be submitted and published in a peer-reviewed scientific journal. 
      CONCLUSIONS: This systematic review will systematically evaluate the efficacy and 
      safety of long-term use of aspirin for primary prevention of cancer and determine 
      whether there are some potential influencing factors affecting the effects of 
      aspirin on cancer outcomes, thus strengthening the evidence base for the clinical 
      practice and future research of this intervention.
FAU - Wu, Qibiao
AU  - Wu Q
AD  - State Key Laboratory of Quality Research in Chinese Medicine.
AD  - Faculty of Chinese Medicine.
FAU - Chen, Hongwei
AU  - Chen H
AD  - State Key Laboratory of Quality Research in Chinese Medicine.
AD  - Faculty of Medicine, Macau University of Science and Technology, Macau.
FAU - Yao, Xiaojun
AU  - Yao X
AD  - State Key Laboratory of Quality Research in Chinese Medicine.
AD  - Faculty of Chinese Medicine.
FAU - Li, Ting
AU  - Li T
AD  - State Key Laboratory of Quality Research in Chinese Medicine.
AD  - Faculty of Chinese Medicine.
FAU - Xu, Cong
AU  - Xu C
AD  - State Key Laboratory of Quality Research in Chinese Medicine.
AD  - Faculty of Chinese Medicine.
FAU - Wang, Jue
AU  - Wang J
AD  - State Key Laboratory of Quality Research in Chinese Medicine.
AD  - Faculty of Chinese Medicine.
FAU - Sui, Xinbing
AU  - Sui X
AD  - Department of Medical Oncology, Holistic Integrative Oncology Institutes and 
      Holistic Integrative Cancer Center of Traditional Chinese and Western Medicine, 
      the Affiliated Hospital of Hangzhou Normal University.
AD  - Department of Cancer Pharmacology, Holistic Integrative Pharmacy Institutes, 
      College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.
FAU - Leung, Elaine Lai-Han
AU  - Leung EL
AD  - State Key Laboratory of Quality Research in Chinese Medicine.
AD  - Faculty of Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Meta-Analysis as Topic
MH  - Neoplasms/epidemiology/*prevention & control
MH  - Primary Prevention/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Time Factors
PMC - PMC6775419
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/10/03 06:00
MHDA- 2019/10/11 06:00
CRDT- 2019/10/03 06:00
PHST- 2019/10/03 06:00 [entrez]
PHST- 2019/10/03 06:00 [pubmed]
PHST- 2019/10/11 06:00 [medline]
AID - 00005792-201909270-00099 [pii]
AID - MD-D-19-07018 [pii]
AID - 10.1097/MD.0000000000017382 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Sep;98(39):e17382. doi: 10.1097/MD.0000000000017382.

PMID- 3765947
OWN - NLM
STAT- MEDLINE
DCOM- 19861120
LR  - 20131121
IS  - 0044-4197 (Print)
IS  - 0044-4197 (Linking)
VI  - 108
IP  - 15
DP  - 1986
TI  - [Changes in the reaction of the cardiovascular system to angiotensin II in 
      pregnancy modified by aspirin].
PG  - 906-13
AB  - The experiments were done in pregnant and in nonpregnant rabbits, anesthesized 
      with urethane. Arterial blood pressure was measured directly in carotid artery, 
      estimating changes of blood pressure after infusions and injections of 
      angiotensin II. It was found, that in pregnant rabbits systolic blood pressure 
      and diastolic blood pressure was higher than in non-pregnant animals. Aspirin was 
      given into jugular vein and caused a significant decrease of blood pressure in 
      both groups of animals during whole time of experiment. Aspirin augmented the 
      elevations of blood pressure, caused by angiotensin II.
FAU - Paradowski, A
AU  - Paradowski A
FAU - Celewicz, Z
AU  - Celewicz Z
FAU - Klinke, R
AU  - Klinke R
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Reaktionsveränderungen des Kreislaufsystems auf Angiotensin II bei schwangeren 
      Kaninchen unter dem Einfluss von Aspirin.
PL  - Germany
TA  - Zentralbl Gynakol
JT  - Zentralblatt fur Gynakologie
JID - 21820100R
RN  - 11128-99-7 (Angiotensin II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin II/*pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Female
MH  - Infusions, Intravenous
MH  - Pregnancy
MH  - Pregnancy, Animal/*drug effects
MH  - Rabbits
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Zentralbl Gynakol. 1986;108(15):906-13.

PMID- 16554658
OWN - NLM
STAT- MEDLINE
DCOM- 20060928
LR  - 20131121
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 73
IP  - 1
DP  - 2006
TI  - Low-dose aspirin affects the clinicopathological features of gastric cancer.
PG  - 54-9
AB  - BACKGROUND/AIMS: There have been investigations on the chemopreventive effect of 
      nonsteroidal anti-inflammatory drugs (NSAIDs) in gastric cancer and also on the 
      association between cyclo-oxygenase 2 expression and the clinicopathological 
      features of gastric cancer. However, it is not yet clear whether the 
      cardioprotective properties of low-dose aspirin could affect the biological 
      behavior of gastric cancer. This study was aimed at investigating the association 
      between the use of low-dose aspirin and clinicopathological features of gastric 
      cancer in human. METHOD: A case-control study was performed retrospectively by 
      comparing the clinicopathological parameters between two groups of gastric 
      cancers, 47 (30.5%) low-dose aspirin users and 107 (69.5%) non-aspirin users who 
      were diagnosed and underwent operation for gastric cancers. RESULTS: The gastric 
      cancers of aspirin user group showed favorable clinicopathological features, such 
      as earlier tumor stage (overall stage, T and N stage: p < 0.001, <0.001, and 
      0.002, respectively), smaller size (p = 0.03), and intestinal type rather than 
      diffuse type (p = 0.004). But these differences were significant only in 
      non-cardiac cancer while cardiac cancer patients showed no significant 
      association with low-dose aspirin usage (overall stage, T stage, N stage, tumor 
      size, and histological type: p <0.001, <0.001, 0.003, 0.035, and 0.004, 
      respectively, by Cochran-Mantel-Haenszel statistics). CONCLUSION: The use of 
      low-dose aspirin might affect the clinicopathological features in gastric 
      cancers, and possibly have a favorable protective effect on the progression of 
      gastric cancer in a subset of non-cardiac gastric cancer patients.
CI  - Copyright (c) 2006 S. Karger AG, Basel.
FAU - Hwang, Hye Jin
AU  - Hwang HJ
AD  - Department of Internal Medicine, Institute of Gastroenterology, Brain Korea 21 
      Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
FAU - Youn, Young Hoon
AU  - Youn YH
FAU - Kim, Jie-Hyun
AU  - Kim JH
FAU - Chung, Jae Bock
AU  - Chung JB
FAU - Lee, Yong Chan
AU  - Lee YC
LA  - eng
PT  - Journal Article
DEP - 20060322
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Case-Control Studies
MH  - Chi-Square Distribution
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoplasm Staging
MH  - Stomach Neoplasms/*pathology
EDAT- 2006/03/24 09:00
MHDA- 2006/09/29 09:00
CRDT- 2006/03/24 09:00
PHST- 2005/09/15 00:00 [received]
PHST- 2005/11/18 00:00 [accepted]
PHST- 2006/03/24 09:00 [pubmed]
PHST- 2006/09/29 09:00 [medline]
PHST- 2006/03/24 09:00 [entrez]
AID - 92248 [pii]
AID - 10.1159/000092248 [doi]
PST - ppublish
SO  - Digestion. 2006;73(1):54-9. doi: 10.1159/000092248. Epub 2006 Mar 22.

PMID- 16485701
OWN - NLM
STAT- MEDLINE
DCOM- 20060601
LR  - 20170214
IS  - 0267-6591 (Print)
IS  - 0267-6591 (Linking)
VI  - 21
IP  - 1
DP  - 2006 Jan
TI  - Influence of aspirin or heparin on platelet function and postoperative blood loss 
      after coronary artery bypass surgery.
PG  - 61-6
AB  - The aim of the study was to assess the effect of aspirin or heparin pretreatment 
      on platelet function and bleeding in the early postoperative period after 
      coronary artery bypass grafting (CABG) surgery. Seventy-five male patients with 
      coronary artery disease who underwent CABG with cardiopulmonary bypass (CPB) were 
      studied. The patients were divided into three groups: Group 1 (n=25) included 
      patients receiving aspirin pretreatment, Group 2 (n=22) received heparin 
      pretreatment, and Group 3 (n=28) included patients who received no antiplatelet 
      or anticoagulant pretreatment. Twenty-four hours after surgery, all patients were 
      administered aspirin therapy that was continued throughout their hospitalization 
      period. We assessed the following preoperative blood coagulation indices: 
      activated partial thromboplastin time (aPTT), international normalized ratio 
      (INR), and fibrinogen. We compared platelet count and platelet aggregation 
      induced by adenosinediphosphate (ADP) before surgery, 1 h after surgery, 20 h 
      after surgery and on the seventh postoperative day. We assessed drained blood 
      loss within 20 postoperative hours. Preoperative blood coagulation indices did 
      not differ among the groups. Platelet count was also similar. One hour after 
      surgery, platelet count significantly decreased in all groups (p<0.001), after 20 
      postoperative hours it did not undergo any marked changes, and on the seventh 
      postoperative day, it significantly increased in all groups (p<0.001). Before 
      surgery, the lowest index of ADP-induced platelet aggregation was found in Group 
      1 (p<0.05). One hour after surgery, platelet aggregation significantly decreased 
      in all groups, most markedly in Group 3 (p<0.001), yet after 20 h, its 
      restitution tendency and a significant increase in all groups was noted. On the 
      seventh day, a further increase in the statistical mean platelet aggregation 
      value was noted in Groups 2 and 3. Comparison of platelet aggregation after 20 
      postoperative hours and on the seventh day after surgery revealed a significantly 
      higher than 10% increase of the index in 32% of patients in Group 1 (p<0.05), 
      27.3% of patients in Group 2 (p<0.05) and in 35.7% of patients in Group 3 
      (p<0.001). The lowest statistically significant value of postoperative blood loss 
      was noted in Group 2 (p<0.01). Our study has shown that aspirin or heparin 
      pretreatment had no impact on the dynamics of platelet function in the early 
      postoperative period after CABG. The lowest postoperative blood loss was noted in 
      patients pretreated with heparin.
FAU - Sirvinskas, Edmundas
AU  - Sirvinskas E
AD  - Institute for Biomedical Research, Kaunas University of Medicine, Kaunas, 
      Lithuania. sirdiskr@kmu.lt
FAU - Veikutiene, Audrone
AU  - Veikutiene A
FAU - Grybauskas, Pranas
AU  - Grybauskas P
FAU - Cimbolaityte, Jurate
AU  - Cimbolaityte J
FAU - Mongirdiene, Ausra
AU  - Mongirdiene A
FAU - Veikutis, Vincentas
AU  - Veikutis V
FAU - Raliene, Laima
AU  - Raliene L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Perfusion
JT  - Perfusion
JID - 8700166
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Coagulation Tests
MH  - Blood Platelets/*drug effects
MH  - Coronary Artery Bypass/*adverse effects/methods
MH  - Heparin/adverse effects/*pharmacology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Count
MH  - Postoperative Care
MH  - Postoperative Hemorrhage/chemically induced/*prevention & control
MH  - Sensitivity and Specificity
EDAT- 2006/02/21 09:00
MHDA- 2006/06/02 09:00
CRDT- 2006/02/21 09:00
PHST- 2006/02/21 09:00 [pubmed]
PHST- 2006/06/02 09:00 [medline]
PHST- 2006/02/21 09:00 [entrez]
AID - 10.1191/0267659106pf845oa [doi]
PST - ppublish
SO  - Perfusion. 2006 Jan;21(1):61-6. doi: 10.1191/0267659106pf845oa.

PMID- 3588510
OWN - NLM
STAT- MEDLINE
DCOM- 19870716
LR  - 20190903
IS  - 0901-9928 (Print)
IS  - 0901-9928 (Linking)
VI  - 60
IP  - 3
DP  - 1987 Mar
TI  - Similar effects of acetylsalicylic acid and morphine on immediate responses to 
      acute noxious stimulation.
PG  - 167-70
AB  - The formalin and writhing tests in mice were employed to investigate a possible 
      delay in the onset of antinociceptive action of acetylsalicylic acid (ASA). Drugs 
      were given 30 min. before the noxious stimulation by either formalin or acetic 
      acid. In the formalin test, the difference between the drug treated groups and 
      the control group reach statistical significance within 30 sec. of noxious 
      stimulation. ASA (400 mg/kg intraperitoneally) and morphine (5 mg/kg 
      intraperitoneally) treated groups were not significantly different in any of the 
      ten periods (30 sec. each) that were analysed during the first 5 min. In the 
      writhing test, the number of writhings in response to intraperitoneal injection 
      of acetic acid was counted during the first 20 min. The difference between the 
      drug treated groups and the control group reached statistical significance after 
      3 min. both for ASA (400 mg/kg subcutaneously) and morphine (2 mg/kg 
      subcutaneously) and no significant differences between the drug treated groups 
      were found in any of the one min. periods that were analysed. Thus no delay of 
      onset in the action of ASA compared to morphine could be demonstrated, and ASA 
      seems to be antinociceptive also in acute non-inflammatory pain. Actions apart 
      from inhibition of the synthesis of prostaglandins are suggested for this effect 
      of ASA.
FAU - Hunskaar, S
AU  - Hunskaar S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Pharmacol Toxicol
JT  - Pharmacology & toxicology
JID - 8702180
RN  - 0 (Analgesics)
RN  - 76I7G6D29C (Morphine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesics
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Injections, Intraperitoneal
MH  - Injections, Subcutaneous
MH  - Male
MH  - Mice
MH  - Morphine/*pharmacology
MH  - Nociceptors/drug effects
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 10.1111/j.1600-0773.1987.tb01726.x [doi]
PST - ppublish
SO  - Pharmacol Toxicol. 1987 Mar;60(3):167-70. doi: 
      10.1111/j.1600-0773.1987.tb01726.x.

PMID- 15542410
OWN - NLM
STAT- MEDLINE
DCOM- 20050222
LR  - 20131121
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 6
IP  - 6
DP  - 2004 Oct
TI  - The effect of aspirin on the ventilatory response to exercise in chronic heart 
      failure.
PG  - 745-8
AB  - INTRODUCTION: Patients with chronic heart failure (CHF) experience breathlessness 
      and fatigue on exercise. One of the abnormalities seen on maximal exercise 
      testing is an increased ventilatory response to exercise (VE/VCO(2) slope). The 
      cause of this is unknown, but is likely to be due to a combination of interacting 
      peripheral and central factors. Recent data have demonstrated a relation between 
      VE/VCO(2) slope and prostaglandin levels in contracting muscles. The present 
      study examined the influence of the presence of a potent non-selective 
      prostaglandin inhibitor, aspirin, on the ventilatory response to exercise in a 
      group of patients with CHF. METHODS: We investigated the ventilatory response to 
      exercise of 120 consecutive patients in sinus rhythm attending a specialist heart 
      failure clinic. We excluded those taking clopidogrel (six patients) and those on 
      both warfarin and aspirin or taking other non-steroidal anti-inflammatory agents 
      (five patients). The other 109 patients were grouped according to whether they 
      were taking aspirin (n=52 (48%)) or not (n=57 (52%)). Each patient underwent 
      echocardiography to assess left ventricular function, and exercise testing with 
      metabolic gas exchange to derive peak oxygen consumption (pVO(2)) and the 
      VE/VCO(2) slope. RESULTS: The groups were similar in terms of age, (67 (13) vs. 
      66 (12) years; P=0.34) drug use, heart failure aetiology, left ventricular 
      function (ejection fraction; 33.3 (9.4) vs. 31.8 (9.9)%; P=0.05)) and exercise 
      tolerance (pVO(2); 20.4 (5.3) vs. 19.9 (6.0); P=0.68, and VE/VCO(2) slope; 35.4 
      (6.2) vs. 35.7 (9.3); P=0.73). There was no difference in the ventilatory 
      response to exercise or the symptoms of breathlessness between the two groups. 
      CONCLUSIONS: Aspirin does not appear to affect exercise performance in CHF.
FAU - Witte, Klaus K A
AU  - Witte KK
AD  - Department of Academic Cardiology, Castle Hill Hospital, Castle Road, Cottingham 
      Hull, HU16 5JQ, UK. klauswhite@hotmail.com
FAU - Clark, Andrew L
AU  - Clark AL
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Exercise Test
MH  - Female
MH  - Heart Failure/*physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption
MH  - Respiration/*drug effects
MH  - Ventricular Function, Left
EDAT- 2004/11/16 09:00
MHDA- 2005/02/23 09:00
CRDT- 2004/11/16 09:00
PHST- 2003/07/11 00:00 [received]
PHST- 2003/10/01 00:00 [revised]
PHST- 2003/11/19 00:00 [accepted]
PHST- 2004/11/16 09:00 [pubmed]
PHST- 2005/02/23 09:00 [medline]
PHST- 2004/11/16 09:00 [entrez]
AID - S1388984203002538 [pii]
AID - 10.1016/j.ejheart.2003.11.008 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2004 Oct;6(6):745-8. doi: 10.1016/j.ejheart.2003.11.008.

PMID- 3248117
OWN - NLM
STAT- MEDLINE
DCOM- 19890615
LR  - 20151119
IS  - 0232-766X (Print)
IS  - 0232-766X (Linking)
VI  - 47
IP  - 10-11
DP  - 1988
TI  - Individually controlled acetylsalicyclic acid (ASA) in the long-term treatment of 
      patients with arteriosclerosis.
PG  - S303-6
AB  - A simple method to measure the biological effect of ASA based on the 
      determination of the desaggregation rate (DR) of platelet aggregation induced by 
      ADP is described. DR correlates with the inhibition of the production of 
      malondialdehyde (MDA) by platelets (r = 0.66, P less than 0.001). Therefore, the 
      DR was used for laboratory monitoring of the ASA effect. Here we report on a 
      study including 41 patients with peripheral arterial disease and/or coronary 
      heart disease before treatment and after receiving ASA in an individually 
      controlled dosage regimen. Before treatment we found an increased level of MDA, 
      150-200% compared with healthy volunteers (n = 16). Extremely different doses of 
      ASA were required to normalize initially elevated MDA-levels in patients. This 
      normalization of MDA was found to correspond to a DR of at least 50% (in 
      comparison to 0-13% without treatment). When judging the ASA-dose individually 
      from the 50%-DR we demonstrated that there were no differences of the levels of 
      cyclooxygenase- and lipoxygenase-derived eicosanoids between healthy volunteers 
      (n = 16) and arteriosclerotic patients receiving 100-250 mg ASA/d (n = 18), 500 
      mg ASA/d (n = 17), or 750-1500 mg ASA/d (n = 6).
FAU - Misselwitz, F
AU  - Misselwitz F
AD  - Central Institute for Cardiovascular Research, Academy of Sciences, Berlin-Buch, 
      G.D.R.
FAU - Norden, C
AU  - Norden C
FAU - Heine, H
AU  - Heine H
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Biomed Biochim Acta
JT  - Biomedica biochimica acta
JID - 8304435
RN  - 0 (Biomarkers)
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Adenosine Diphosphate/pharmacology
MH  - Arteriosclerosis/blood/*drug therapy
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Biomarkers/blood
MH  - Humans
MH  - Hydroxyeicosatetraenoic Acids/blood
MH  - Malondialdehyde/blood
MH  - Platelet Aggregation/*drug effects
MH  - Reference Values
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Biomed Biochim Acta. 1988;47(10-11):S303-6.

PMID- 3572936
OWN - NLM
STAT- MEDLINE
DCOM- 19870609
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 14
IP  - 1
DP  - 1987 Feb
TI  - Salicylate toxicity in elderly patients with rheumatoid arthritis.
PG  - 60-6
AB  - Using the American Rheumatism Association Medical Information System, we studied 
      the effect of age upon salicylate toxicity in elderly patients with rheumatoid 
      arthritis. Data were gathered from 545 patients by self-reported questionnaires 
      for the 6 months and also the 7 days before the visit of interest. With one week 
      data and weight adjusted doses in 253 patients in whom data were available, age 
      related differences in lower gastrointestinal symptoms (p = 0.05) and tinnitus (p 
      = 0.01) were found, despite the fact that elderly patients (E) took less 
      salicylate than younger ones (y)--E [39.1 +/- 2.4 (SD) mg/kg/day] vs Y [49.8 +/- 
      3.89 mg/kg/day] (p = 0.02). Our data indicate a difference in salicylate dynamics 
      among the elderly (i.e., increased toxicity in the face of decreased salicylate 
      doses).
FAU - Grigor, R R
AU  - Grigor RR
FAU - Spitz, P W
AU  - Spitz PW
FAU - Furst, D E
AU  - Furst DE
LA  - eng
GR  - AM21395/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Central Nervous System Diseases/chemically induced
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/*adverse effects/therapeutic use
MH  - Tinnitus/chemically induced
EDAT- 1987/02/01 00:00
MHDA- 1987/02/01 00:01
CRDT- 1987/02/01 00:00
PHST- 1987/02/01 00:00 [pubmed]
PHST- 1987/02/01 00:01 [medline]
PHST- 1987/02/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1987 Feb;14(1):60-6.

PMID- 22458577
OWN - NLM
STAT- MEDLINE
DCOM- 20120731
LR  - 20131121
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 10
IP  - 4
DP  - 2012 Apr
TI  - Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable 
      vascular disease: an era of new anticoagulants.
PG  - 433-9
LID - 10.1586/erc.12.19 [doi]
AB  - Atrial fibrillation (AF) is a major cause of ischemic stroke, especially in the 
      elderly. There are currently enough data to support the notion that 
      anticoagulation with warfarin or dabigatran is far superior to aspirin in the 
      prevention of stroke or systemic embolism in AF. Aspirin is the preferred 
      modality in patients who are either not candidates for anticoagulation, such as 
      patients with increased risk for bleeding, low-risk patients based on the CHADS2 
      score or patients who have difficulty in maintaining a therapeutic international 
      normalized ratio. There is no dispute on the recommendations regarding stroke 
      prevention in high-risk patients (CHADS2 risk score of 2 and beyond) with AF. 
      However, there is some controversy regarding the appropriate strategy 
      (anticoagulation vs aspirin) for stroke prevention in low-risk patients 
      (CHA2DS2-VASc score of 0-1). Novel oral anticoagulant drugs (direct thrombin 
      inhibitors and Factor Xa inhibitors) might further diminish the role of aspirin 
      for stroke prevention in AF due to their superior efficacy, lack of need for 
      monitoring of therapeutic effects and lower bleeding risk when compared with 
      warfarin, especially in patients with stable vascular disease.
FAU - Turagam, Mohit K
AU  - Turagam MK
AD  - Department of Medicine, University of Wisconsin School of Medicine and Public 
      Health, 3116 MFCB, 1685 Highland Avenue, Madison, WI 53705, USA. 
      mturagam@medicine.wisc.edu
FAU - Velagapudi, Poonam
AU  - Velagapudi P
FAU - Leal, Miguel A
AU  - Leal MA
FAU - Kocheril, Abraham G
AU  - Kocheril AG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Guidelines as Topic
MH  - Humans
MH  - Stroke/etiology/*prevention & control
MH  - Vascular Diseases/*complications
EDAT- 2012/03/31 06:00
MHDA- 2012/08/01 06:00
CRDT- 2012/03/31 06:00
PHST- 2012/03/31 06:00 [entrez]
PHST- 2012/03/31 06:00 [pubmed]
PHST- 2012/08/01 06:00 [medline]
AID - 10.1586/erc.12.19 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2012 Apr;10(4):433-9. doi: 10.1586/erc.12.19.

PMID- 22395760
OWN - NLM
STAT- MEDLINE
DCOM- 20120719
LR  - 20131121
IS  - 1473-6527 (Electronic)
IS  - 0951-7375 (Linking)
VI  - 25
IP  - 3
DP  - 2012 Jun
TI  - Do aspirin and statins prevent severe sepsis?
PG  - 345-50
LID - 10.1097/QCO.0b013e3283520ed7 [doi]
AB  - PURPOSE OF REVIEW: Sepsis is an inflammatory condition associated with 
      significant morbidity and mortality. Given the lack of specific therapies for the 
      condition, prevention has garnered significant interest and increased importance. 
      The article reviews the current literature regarding the use of aspirin and 
      statins for the prevention of sepsis. RECENT FINDINGS: Aspirin and statins have 
      been integral in the prevention of atherosclerotic disease. Additionally, statins 
      have proven beneficial in the prevention of nonatherosclerotic conditions 
      secondary to their pleiotropic effects. In animal models, this pleiotropism 
      modulates many inflammatory pathways of sepsis. The platelet also plays an 
      integral role in this inflammatory cascade of sepsis. Scientific data indicates 
      that antiplatelet therapy, including aspirin, may attenuate these undesirable 
      effects of platelets. Finally, observational studies have shown that patients 
      taking statins have a decreased incidence of sepsis and septic shock, and aspirin 
      may potentiate these benefits. SUMMARY: Sepsis is a deadly and costly condition 
      with no available, specific treatment options. The statins and aspirin are well 
      tolerated and widely used for prevention of cardiovascular disease. Because of 
      their effects on the immune system and inflammatory pathways, they may present 
      viable medical options for the prevention of sepsis.
FAU - Sanchez, Michael A
AU  - Sanchez MA
AD  - Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, 
      Louisiana State University Health Sciences Center, Baton Rouge, Louisiana 70805, 
      USA.
FAU - Thomas, Christopher B
AU  - Thomas CB
FAU - O'Neal, Hollis R
AU  - O'Neal HR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Infect Dis
JT  - Current opinion in infectious diseases
JID - 8809878
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Inflammation/prevention & control
MH  - Models, Animal
MH  - Sepsis/*prevention & control
EDAT- 2012/03/08 06:00
MHDA- 2012/07/20 06:00
CRDT- 2012/03/08 06:00
PHST- 2012/03/08 06:00 [entrez]
PHST- 2012/03/08 06:00 [pubmed]
PHST- 2012/07/20 06:00 [medline]
AID - 10.1097/QCO.0b013e3283520ed7 [doi]
PST - ppublish
SO  - Curr Opin Infect Dis. 2012 Jun;25(3):345-50. doi: 10.1097/QCO.0b013e3283520ed7.

PMID- 36732824
OWN - NLM
STAT- MEDLINE
DCOM- 20230206
LR  - 20230206
IS  - 2047-783X (Electronic)
IS  - 0949-2321 (Print)
IS  - 0949-2321 (Linking)
VI  - 28
IP  - 1
DP  - 2023 Feb 2
TI  - Aspirin 75 mg to prevent preeclampsia in high-risk pregnancies: a retrospective 
      real-world study in China.
PG  - 56
LID - 10.1186/s40001-023-01024-7 [doi]
LID - 56
AB  - BACKGROUND: Several randomized clinical trials showed that aspirin could decrease 
      the incidence of preeclampsia (PE) in women at high risk, but data from sources 
      other than traditional clinical trials that investigating the preventive effect 
      of aspirin 75 mg on PE is still lacking, especially in mainland China. We aimed 
      to use Chinese real-world data to estimate the preventive effect of low-dose 
      aspirin (LDA) on PE. METHODS: Clinical data of pregnant women who were at high 
      risk of PE and had their first prenatal visit at the affiliated Taicang People's 
      Hospital of Soochow University during November 31, 2018 and May 10, 2021 was 
      retrospectively analyzed. Among the 266 included pregnant women, 115 individuals 
      treated with aspirin 75 mg per day and the other 151 without such treatment were 
      considered as the LDA group and the control group, respectively. RESULTS: In the 
      LDA group, 64 (55.65%) of 115 pregnant women took aspirin before 16 weeks of 
      gestation. Besides, 12 (10.43%) and 34 (22.52%) women developed PE in the LDA 
      group and control group, respectively; the aspirin prophylaxis was associated 
      with a lower risk of PE (odds ratio = 0.40, 95% confidence interval = 0.20-0.82, 
      P = 0.0098). In addition, LDA is slightly more effective when initiated before 
      16 weeks of gestation or in those without chronic hypertension, when compared 
      with their counterparts. CONCLUSION: Prophylaxis with 75 mg per day of aspirin in 
      high-risk women resulted in a significantly lower incidence of PE than that in 
      the control group.
CI  - © 2023. The Author(s).
FAU - Xiao, Yue
AU  - Xiao Y
AD  - Taicang Affiliated Hospital of Soochow University, The First People's Hospital of 
      Taicang, 58 Changsheng Road, Suzhou, 215413, China.
AD  - Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric 
      Diseases, School of Public Health, Medical College of Soochow University, 199 
      Renai Road, Suzhou, 215123, Jiangsu, China.
FAU - Ling, Qi
AU  - Ling Q
AD  - Taicang Affiliated Hospital of Soochow University, The First People's Hospital of 
      Taicang, 58 Changsheng Road, Suzhou, 215413, China.
FAU - Yao, Mengxin
AU  - Yao M
AD  - Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric 
      Diseases, School of Public Health, Medical College of Soochow University, 199 
      Renai Road, Suzhou, 215123, Jiangsu, China.
FAU - Gu, Yingjie
AU  - Gu Y
AD  - Department of Obstetrics and Gynecology, International Peace Maternity and Child 
      Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 
      China.
FAU - Lan, Yanshi
AU  - Lan Y
AD  - Taicang Affiliated Hospital of Soochow University, The First People's Hospital of 
      Taicang, 58 Changsheng Road, Suzhou, 215413, China.
FAU - Liu, Songliang
AU  - Liu S
AD  - Taicang Affiliated Hospital of Soochow University, The First People's Hospital of 
      Taicang, 58 Changsheng Road, Suzhou, 215413, China.
FAU - Yin, Jieyun
AU  - Yin J
AD  - Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric 
      Diseases, School of Public Health, Medical College of Soochow University, 199 
      Renai Road, Suzhou, 215123, Jiangsu, China. jyyin@suda.edu.cn.
FAU - Ma, Qiuping
AU  - Ma Q
AD  - Taicang Affiliated Hospital of Soochow University, The First People's Hospital of 
      Taicang, 58 Changsheng Road, Suzhou, 215413, China. 343587729@qq.com.
LA  - eng
GR  - 82273635/Jieyun Yin/
GR  - TC2021JCYL03/Qiuping Ma/
PT  - Journal Article
DEP - 20230202
PL  - England
TA  - Eur J Med Res
JT  - European journal of medical research
JID - 9517857
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Pregnancy
MH  - Humans
MH  - Male
MH  - *Pre-Eclampsia/epidemiology/prevention & control/drug therapy
MH  - Retrospective Studies
MH  - Pregnancy, High-Risk
MH  - Aspirin/therapeutic use
MH  - Pregnancy Trimester, First
PMC - PMC9893656
OTO - NOTNLM
OT  - Low-dose aspirin
OT  - Preeclampsia
OT  - Real-world study
COIS- The authors declare that they have no competing interests.
EDAT- 2023/02/04 06:00
MHDA- 2023/02/07 06:00
CRDT- 2023/02/03 00:04
PHST- 2022/10/04 00:00 [received]
PHST- 2023/01/20 00:00 [accepted]
PHST- 2023/02/03 00:04 [entrez]
PHST- 2023/02/04 06:00 [pubmed]
PHST- 2023/02/07 06:00 [medline]
AID - 10.1186/s40001-023-01024-7 [pii]
AID - 1024 [pii]
AID - 10.1186/s40001-023-01024-7 [doi]
PST - epublish
SO  - Eur J Med Res. 2023 Feb 2;28(1):56. doi: 10.1186/s40001-023-01024-7.

PMID- 8707212
OWN - NLM
STAT- MEDLINE
DCOM- 19960909
LR  - 20161123
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 130
IP  - 7
DP  - 1996 Apr 1
TI  - [Prolonged fever in painless subacute thyroiditis--diagnosis by gallium scan].
PG  - 453-5, 504
AB  - Patients with subacute, granulomatous thyroiditis usually present with a typical 
      clinical picture of fever, anterior neck pain and an exquisitely tender thyroid. 
      Abnormal thyroid function tests and suppressed radio-iodine uptake strongly 
      support the diagnosis. Occasionally the disease may simulate systemic or 
      malignant disease when it presents atypically, without signs or symptoms directly 
      related to the thyroid, We report a 43-year-old man who presented with fever of 
      unknown origin. A diagnosis of silent thyroiditis was made from evidence of 
      biochemical thyrotoxicosis, intense gallium-67 citrate thyroidal localization, 
      and an excellent response to aspirin.
FAU - Baytner-Zamir, H
AU  - Baytner-Zamir H
AD  - Medicine B Dept., Hillel Yaffe Medical Center, Hadera.
FAU - Zelikovsky, L
AU  - Zelikovsky L
FAU - Jarchowsky, J
AU  - Jarchowsky J
LA  - heb
PT  - Case Reports
PT  - Journal Article
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - 0 (Gallium Radioisotopes)
RN  - 0 (Iodine Radioisotopes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - *Fever
MH  - *Gallium Radioisotopes
MH  - Humans
MH  - Iodine Radioisotopes
MH  - Male
MH  - Radionuclide Imaging
MH  - Thyroid Function Tests
MH  - Thyroid Gland/diagnostic imaging
MH  - Thyroiditis/*diagnostic imaging/physiopathology
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
PST - ppublish
SO  - Harefuah. 1996 Apr 1;130(7):453-5, 504.

PMID- 2954312
OWN - NLM
STAT- MEDLINE
DCOM- 19870629
LR  - 20131121
IS  - 0301-0481 (Print)
IS  - 0301-0481 (Linking)
VI  - 62
IP  - 6
DP  - 1987 Mar 15
TI  - [Acetylsalicylic acid and pyrazole allergy or pseudo-allergy?].
PG  - 470-8
AB  - In a multicentric study by the European Study Group of Drug Allergy, 69 patients 
      suffering from immediate type reaction after the intake of non-steroidal 
      antiphlogistica were examined with regard to allergy or pseudo-allergy. Apart 
      from the scratch test on the original substance, we performed cutaneous tests 
      with salicyloyl and pyrazol conjugates, and determined IgE and IgG by means of a 
      modified RAST method. There were 3 groups to be distinguished: (1) "intolerance" 
      reaction of the aspirin type as a pseudo-allergic reaction (15 cases); (2) true 
      IgE-mediated allergy (16 cases); (3) pyrazol "idiosyncrasy" (33 cases). 5 
      patients showed a combination of the three pathomechanisms.
FAU - Fabro, L
AU  - Fabro L
FAU - Wüthrich, B
AU  - Wüthrich B
FAU - Wälti, M
AU  - Wälti M
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Acetylsalicylsäure- und Pyrazol-Allergie oder Pseudo-Allergie?
PL  - Germany
TA  - Z Hautkr
JT  - Zeitschrift fur Hautkrankheiten
JID - 0367576
RN  - 0 (Pyrazoles)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Drug Eruptions/*etiology
MH  - Humans
MH  - Hypersensitivity, Immediate/etiology
MH  - Intradermal Tests
MH  - Pyrazoles/*adverse effects
MH  - Structure-Activity Relationship
EDAT- 1987/03/15 00:00
MHDA- 1987/03/15 00:01
CRDT- 1987/03/15 00:00
PHST- 1987/03/15 00:00 [pubmed]
PHST- 1987/03/15 00:01 [medline]
PHST- 1987/03/15 00:00 [entrez]
PST - ppublish
SO  - Z Hautkr. 1987 Mar 15;62(6):470-8.

PMID- 27028445
OWN - NLM
STAT- MEDLINE
DCOM- 20170320
LR  - 20191210
IS  - 1179-1896 (Electronic)
IS  - 1175-5652 (Linking)
VI  - 14
IP  - 4
DP  - 2016 Aug
TI  - Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus 
      Warfarin Alone in Mechanical Valve Prostheses.
PG  - 431-440
LID - 10.1007/s40258-016-0238-1 [doi]
AB  - BACKGROUND: The use of combined therapy of antiplatelet and anticoagulant versus 
      anticoagulant alone to reduce instances of thromboembolic events in patients with 
      heart valve prostheses is an established standard of care in many countries but 
      not in Egypt. A previous Markov model cost-effectiveness study on Egyptian 
      patients aged 50-60 years demonstrated that the combined therapy reduces the 
      overall treatment cost. However, due to the lack of actual real-world data on 
      cost-effectiveness and the limitation of the Markov model study to 50- to 
      60-year-old patients, the Egyptian medical community is still questioning whether 
      the added benefit is worth the cost. OBJECTIVE: To assess, from the perspective 
      of the Egyptian health sector, the cost-effectiveness of the combined use of 
      warfarin and low-dose aspirin (75 mg) versus that of warfarin alone in patients 
      with mechanical heart valve prostheses who began therapy between the age of 15 
      and 50 years. METHODS: An economic evaluation was conducted alongside a 
      randomized, controlled trial to assess the cost-effectiveness of the combined 
      therapy in patients with mechanical valve prostheses. A total of 316 patients 
      aged between 15 and 50 years were included in the study and randomly assigned to 
      a group treated with both warfarin and aspirin or a group treated with warfarin 
      alone. RESULTS: The patients in the combined therapy group exhibited a 
      significantly longer duration of protection against the first event. Fewer 
      primary events were observed in the patients treated with warfarin plus aspirin 
      than in those treated with warfarin alone (1.4 %/year, vs. 4.8 %/year), and a 
      higher mean quality-adjusted life-years (QALYs) value over 4 years was obtained 
      for the group treated with warfarin plus aspirin (difference 0.058; 95 % CI 
      0.013-0.118), although this difference did not reach a conventional level of 
      statistical significance. The total costs over a 4-year period were lower with 
      the combined therapy (difference -US$244; 95 % CI -US$483.1 to -US$3.8), which 
      yielded an incremental cost-effectiveness ratio of -US$4206 per QALY gained. 
      Thus, the combined therapy was dominant. All costs were reported in US dollars 
      (USD) for the financial year 2014. CONCLUSIONS: The results of this analysis 
      indicate that from the perspective of the Egyptian health sector, the addition of 
      aspirin to the typical warfarin therapy is more effective and less costly for 
      patients with mechanical valve prostheses than treatment with warfarin alone. 
      This combined strategy could be adopted to prevent the complications of 
      mechanical valve prostheses. Our study adds to the body of evidence supporting 
      the option of warfarin-plus-aspirin therapy for patients with mechanical valve 
      prostheses.
FAU - El-Hamamsy, Manal H
AU  - El-Hamamsy MH
AD  - Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
FAU - Elsisi, Gihan H
AU  - Elsisi GH
AD  - Faculty of Pharmacy, German University in Cairo, Cairo, Egypt. 
      gihanhamdyelsisi@hotmail.com.
AD  - Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs, Cairo, 
      Egypt. gihanhamdyelsisi@hotmail.com.
FAU - Eldessouki, Randa
AU  - Eldessouki R
AD  - Faculty of Medicine, Fayoum University, Fayoum, Egypt.
FAU - Elmazar, Mohamed M
AU  - Elmazar MM
AD  - Faculty of Pharmacy, The British University in Egypt (BUE), Cairo, Egypt.
FAU - Taha, Ahmed S
AU  - Taha AS
AD  - Faculty of Medicine, Ain Shams University, Cairo, Egypt.
AD  - Cardiothoracic Surgery Unit, Ain Shams University Hospitals, Cairo, Egypt.
FAU - Awad, Basma F
AU  - Awad BF
AD  - Faculty of Medicine, Ain Shams University, Cairo, Egypt.
AD  - Cardiothoracic Surgery Unit, Ain Shams University Hospitals, Cairo, Egypt.
FAU - Elmansy, Hossam
AU  - Elmansy H
AD  - Faculty of Business Administration, Canadian International College, Cairo, Egypt.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - New Zealand
TA  - Appl Health Econ Health Policy
JT  - Applied health economics and health policy
JID - 101150314
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticoagulants/economics/therapeutic use
MH  - Aspirin/*economics/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Drug Therapy, Combination/economics
MH  - Egypt
MH  - Female
MH  - Heart Valve Prosthesis/adverse effects/*economics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outcome and Process Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/economics/therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Thromboembolism/*economics/etiology/prevention & control
MH  - Warfarin/*economics
MH  - Young Adult
EDAT- 2016/03/31 06:00
MHDA- 2017/03/21 06:00
CRDT- 2016/03/31 06:00
PHST- 2016/03/31 06:00 [entrez]
PHST- 2016/03/31 06:00 [pubmed]
PHST- 2017/03/21 06:00 [medline]
AID - 10.1007/s40258-016-0238-1 [pii]
AID - 10.1007/s40258-016-0238-1 [doi]
PST - ppublish
SO  - Appl Health Econ Health Policy. 2016 Aug;14(4):431-440. doi: 
      10.1007/s40258-016-0238-1.

PMID- 2609979
OWN - NLM
STAT- MEDLINE
DCOM- 19900222
LR  - 20151119
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 24
IP  - 6
DP  - 1989
TI  - [Determination of aspirin and nicotinic acid in plasma when used in combination].
PG  - 407-12
AB  - An ultraviolet spectrophotometric method has been developed for indirect 
      determination of aspirin (ASA) using the difference between total salicylic acid 
      and free salicylic acid in rabbit plasma. Recoveries of salicylic acid were found 
      to be above 98.4% and the method was linear from 8-160 micrograms with a 
      correlation coefficient of 0.9999. The coefficient of variation was less than 
      3.85%. Using this method for ASA and Carlson's method for nicotinic acid (NA), 
      the plasma concentrations of these two drugs were determined when they were used 
      iv alone or in combination in rabbits. The results analysed by a micro-computer 
      were fitted to a two compartment open model with first-order elimination. Among 
      the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group 
      (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h 
      and 361.63 micrograms.h/ml, respectively, both significantly different from those 
      for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 
      157.71 micrograms.h/ml, respectively (p less than 0.01). For ASA, no significant 
      differences were demonstrated. The mechanism and significance of the prolonged 
      T1/2 (beta) of NA were discussed.
FAU - Wu, Y
AU  - Wu Y
FAU - Wu, B J
AU  - Wu BJ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 2679MF687A (Niacin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacokinetics
MH  - Drug Therapy, Combination
MH  - Female
MH  - Male
MH  - Niacin/*pharmacokinetics
MH  - Rabbits
MH  - Spectrophotometry, Ultraviolet
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Yao Xue Xue Bao. 1989;24(6):407-12.

PMID- 23290104
OWN - NLM
STAT- MEDLINE
DCOM- 20130909
LR  - 20181202
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 92
IP  - 38
DP  - 2012 Oct 16
TI  - [Correlation between antiplatelet resistance and recurrent cardiac ischemic 
      events of patients with acute myocardial infarction].
PG  - 2677-80
AB  - OBJECTIVE: To evaluate the predictive value of antiplatelet resistance assessed 
      by whole blood electronic impedance aggregometry (EIA) for the risk of recurrent 
      cardiac ischemic events in patients with acute myocardial infarction (AMI) who 
      underwent coronary stenting. METHODS: We enrolled 109 patients with AMI, 72 
      (66.1%) men and 37 (33.9%) women with mean age (63 ± 12) years, who were treated 
      with aspirin and clopidogrel daily after coronary stenting. EIA used arachidonic 
      acid (AA) and adenosine diphosphate (ADP) as inductors to measure platelet 
      aggregation inhibited by aspirin and clopidogrel respectively. The subjects were 
      divided into four groups: pure aspirin resistant group (AR, electrical impedance 
      > 0 Ω), pure clopidogrel resistant group (CR, electrical impedance ≥ 10 Ω), dual 
      resistant group (DR) and dual sensitive group (DS). The primary outcomes were 
      recurrent cardiac ischemic events during the 12-month follow-up. RESULTS: 
      Antiplatelet resistance occurred more often in patients with type 2 diabetes (P = 
      0.027). The platelet counts (PLT) were higher in antiplatelet resistant groups 
      than DS group (P = 0.013). During the 12-month follow-up, the antiplatelet 
      resistant patients had a higher incidence of recurrent cardiac ischemic events 
      and stent thrombosis (ST) than the patients without (12.5%, 10.0%, 50.0% vs 3.8%, 
      P = 0.036; 6.3%, 10.0%, 50.0% vs 1.3%, P = 0.000; respectively). Binary Logistic 
      regression indicated that dual resistance remained an independent predicator of 
      recurrence cardiac ischemic events and ST (OR 5.99, 95%CI 1.05 - 34.34, P = 
      0.045; OR 6.36, 95%CI 1.13 - 35.78, P = 0.036; respectively). CONCLUSIONS: As a 
      physiological assessment of platelet reactivity, EIA is a convenient and accurate 
      option for measuring aspirin resistance. Antiplatelet resistance assessed by EIA 
      is paralleled to clinical events. Dual resistance is an independent predicator 
      for ST and recurrence cardiac ischemic events in patients with AMI.
FAU - Li, Lei
AU  - Li L
AD  - Department of Cardiology, Peking University Third Hospital.
FAU - Han, Jiang-li
AU  - Han JL
FAU - Li, Hai-yan
AU  - Li HY
FAU - Qiao, Rui
AU  - Qiao R
FAU - Yu, Hai-yi
AU  - Yu HY
FAU - Zeng, Hui
AU  - Zeng H
FAU - Gao, Wei
AU  - Gao W
FAU - Zhang, Jie
AU  - Zhang J
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - *Drug Resistance
MH  - Electric Impedance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/*etiology
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests/methods
MH  - Predictive Value of Tests
MH  - Recurrence
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
EDAT- 2013/01/08 06:00
MHDA- 2013/09/10 06:00
CRDT- 2013/01/08 06:00
PHST- 2013/01/08 06:00 [entrez]
PHST- 2013/01/08 06:00 [pubmed]
PHST- 2013/09/10 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2012 Oct 16;92(38):2677-80.

PMID- 8607726
OWN - NLM
STAT- MEDLINE
DCOM- 19960517
LR  - 20220408
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 156
IP  - 4
DP  - 1996 Feb 26
TI  - Bleeding during antithrombotic therapy in patients with atrial fibrillation. The 
      Stroke Prevention in Atrial Fibrillation Investigators.
PG  - 409-16
AB  - BACKGROUND: The Stroke Prevention in Atrial Fibrillation II study compared 
      warfarin vs aspirin for stroke prevention in atrial fibrillation. Bleeding 
      complications importantly detracted from warfarin's net effectiveness, 
      particularly among older patients. OBJECTIVES: To analyze bleeding complications 
      according to assigned therapy. To identify risk factors for bleeding during 
      anticoagulation. METHODS: Eleven hundred patients (mean age, 70 years) were 
      randomized to 325 mg of aspirin daily (enteric coated) vs warfarin (target 
      prothrombin time ratio, 1.3 to 1.8; approximate international normalized ratio, 
      2.0 to 4.5). Major hemorrhages were defined prospectively. RESULTS: The rate of 
      major bleeding while receiving warfarin was 2.3% per year (95% confidence 
      interval [CI], 1.7 to 3.2) vs 1.1% per year (95% CI, 0.7 to 1.8) while receiving 
      aspirin (relative risk, 2.1; 95% CI, 1.1 to 3.1; P = .02). Intracranial 
      hemorrhage occurred at 0.9% per year (95% CI, 0.5 to 1.5) with warfarin and 0.3% 
      per year (95% CI, 0.1 to 0.8) with aspirin (relative risk, 2.4; P = .08). Age (P 
      = .006), increasing number of prescribed medications (P = .007), and intensity of 
      anticoagulation (P = .02) were independent risks for bleeding at any site during 
      anticoagulation. The rate of major hemorrhage was 1.7% per year in patients aged 
      75 years or younger who received anticoagulation vs 4.2% per year in older 
      patients (relative risk, 2.6, P = .009); rates by age for intracranial bleeding 
      were 0.6% per year and 1.8% per year, respectively (P = .05). CONCLUSION: 
      Advancing age and more intense anticoagulation increase the risk of major 
      hemorrhage in patients given warfarin for stroke prevention.
LA  - eng
GR  - R01-NS-24224/NS/NINDS NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Intern Med. 1997 Jun 23;157(12):1385. PMID: 9201014
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Cerebrovascular Disorders/etiology/*prevention & control
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Warfarin/*adverse effects/therapeutic use
EDAT- 1996/02/26 00:00
MHDA- 1996/02/26 00:01
CRDT- 1996/02/26 00:00
PHST- 1996/02/26 00:00 [pubmed]
PHST- 1996/02/26 00:01 [medline]
PHST- 1996/02/26 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1996 Feb 26;156(4):409-16.

PMID- 3189434
OWN - NLM
STAT- MEDLINE
DCOM- 19881222
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 159
IP  - 5
DP  - 1988 Nov
TI  - Low-dose aspirin. I. Effect on angiotensin II pressor responses and blood 
      prostaglandin concentrations in pregnant women sensitive to angiotensin II.
PG  - 1035-43
AB  - Decreased incidence of proteinuric hypertension after low-dose aspirin therapy is 
      hypothesized to be a consequence of selective thromboxane A2 inhibition and 
      sparing of prostacyclin. This study was designed to ascertain if low-dose aspirin 
      therapy (81 mg/day for 1 week) alters vascular refractoriness to angiotensin II 
      and the prostacyclin/thromboxane A2 ratio in pregnant women sensitive to 
      angiotensin II (n = 17). Low-dose aspirin increased the effective pressor dose of 
      angiotensin II from 5.9 +/- 2.4 to 10.2 +/- 5.5 ng/kg/min (p less than 0.01, mean 
      +/- SD). Platelet-derived serum thromboxane B2 (a metabolite of thromboxane A2), 
      a measure of therapy compliance, decreased from 1804 +/- 1771 to 132 +/- 206 
      pg/ml (p less than 0.01). Plasma thromboxane B2 decreased from 130 +/- 107 to 19 
      +/- 12 pg/ml (p less than 0.01). Inhibition was not selective because 
      6-keto-prostaglandin F1 alpha (a metabolite of prostacyclin) also decreased from 
      243 +/- 90 to 163 +/- 90 pg/ml (p = 0.039) and prostaglandin E2 was reduced from 
      155 +/- 67 to 95 +/- 40 pg/ml (p = 0.014). Decreases in thromboxane B2, however, 
      were significantly greater (75% +/- 19%) than decreases in 6-keto-prostaglandin 
      F1 alpha (21% +/- 33%) or prostaglandin E2 (29% +/- 36%); thus the 
      6-keto-prostaglandin F1 alpha/thromboxane B2 ratio increased from 3.1 +/- 2.0 to 
      12.4 +/- 9.9 (p less than 0.01). Although low-dose aspirin increases the 
      effective pressor dose of angiotensin II, it does not return to normal pregnancy 
      values. This observation is consistent with the hypothesis that this represents 
      only a partial selective prostaglandin inhibition.
FAU - Spitz, B
AU  - Spitz B
AD  - Department of Obstetrics and Gynecology, University of Texas Southwestern Medical 
      Center, Dallas 75235.
FAU - Magness, R R
AU  - Magness RR
FAU - Cox, S M
AU  - Cox SM
FAU - Brown, C E
AU  - Brown CE
FAU - Rosenfeld, C R
AU  - Rosenfeld CR
FAU - Gant, N F
AU  - Gant NF
LA  - eng
GR  - HD08783/HD/NICHD NIH HHS/United States
GR  - HD24971/HD/NICHD NIH HHS/United States
GR  - HL34150/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Prostaglandins)
RN  - 11128-99-7 (Angiotensin II)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin II/*therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Drug Administration Schedule
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Hypertension/prevention & control
MH  - Osmolar Concentration
MH  - Parity
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/prevention & control
MH  - Prostaglandins/*blood
MH  - Thromboxane B2/blood
EDAT- 1988/11/01 00:00
MHDA- 1988/11/01 00:01
CRDT- 1988/11/01 00:00
PHST- 1988/11/01 00:00 [pubmed]
PHST- 1988/11/01 00:01 [medline]
PHST- 1988/11/01 00:00 [entrez]
AID - 0002-9378(88)90406-1 [pii]
AID - 10.1016/0002-9378(88)90406-1 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1988 Nov;159(5):1035-43. doi: 10.1016/0002-9378(88)90406-1.

PMID- 22144567
OWN - NLM
STAT- MEDLINE
DCOM- 20120412
LR  - 20211021
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 125
IP  - 2
DP  - 2012 Jan 17
TI  - Using stress testing to guide primary prevention of coronary heart disease among 
      intermediate-risk patients: a cost-effectiveness analysis.
PG  - 260-70
LID - 10.1161/CIRCULATIONAHA.111.041293 [doi]
AB  - BACKGROUND: Noninvasive stress testing might guide the use of aspirin and statins 
      for primary prevention of coronary heart disease, but it is unclear if such a 
      strategy would be cost effective. METHODS AND RESULTS: We compared the status 
      quo, in which the current national use of aspirin and statins was simulated, with 
      3 other strategies: (1) full implementation of Adult Treatment Panel III 
      guidelines, (2) a treat-all strategy in which all intermediate-risk persons 
      received statins (men and women) and aspirin (men only), and (3) a test-and-treat 
      strategy in which all persons with an intermediate risk of coronary heart disease 
      underwent stress testing and those with a positive test were treated with 
      high-intensity statins (men and women) and aspirin (men only). Healthcare costs, 
      coronary heart disease events, and quality-adjusted life years from 2011 to 2040 
      were projected. Under a variety of assumptions, the treat-all strategy was the 
      most effective and least expensive strategy. Stress electrocardiography was more 
      effective and less expensive than other test-and-treat strategies, but it was 
      less expensive than treat all only if statin cost exceeded $3.16/pill or if 
      testing increased adherence from <22% to >75%. However, stress 
      electrocardiography could be cost effective in persons initially nonadherent to 
      the treat-all strategy if it raised their adherence to 5% and cost saving if it 
      raised their adherence to 13%. CONCLUSIONS: When generic high-potency statins are 
      available, noninvasive cardiac stress testing to target preventive medications is 
      not cost effective unless it substantially improves adherence.
CI  - © 2011 American Heart Association, Inc.
FAU - Galper, Benjamin Z
AU  - Galper BZ
AD  - Brigham and Women's Hospital, Cardiovascular Division, 75 Francis St, Boston, MA 
      02115, USA. bgalper@partners.org
FAU - Moran, Andrew
AU  - Moran A
FAU - Coxson, Pamela G
AU  - Coxson PG
FAU - Pletcher, Mark J
AU  - Pletcher MJ
FAU - Heidenreich, Paul
AU  - Heidenreich P
FAU - Lazar, Lawrence D
AU  - Lazar LD
FAU - Rodondi, Nicolas
AU  - Rodondi N
FAU - Wang, Y Claire
AU  - Wang YC
FAU - Goldman, Lee
AU  - Goldman L
LA  - eng
GR  - K08 HL089675/HL/NHLBI NIH HHS/United States
GR  - K08 HL089675-01A1/HL/NHLBI NIH HHS/United States
GR  - 1K08HL089675-01A1/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20111205
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/economics/therapeutic use
MH  - Computer Simulation
MH  - Coronary Disease/diagnosis/*economics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Electrocardiography/methods
MH  - *Exercise Test
MH  - Female
MH  - *Health Care Costs
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/economics/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Quality-Adjusted Life Years
MH  - Risk Assessment
PMC - PMC3265963
MID - NIHMS347194
COIS- Conflict of Interest Disclosures: None
EDAT- 2011/12/07 06:00
MHDA- 2012/04/13 06:00
CRDT- 2011/12/07 06:00
PHST- 2011/12/07 06:00 [entrez]
PHST- 2011/12/07 06:00 [pubmed]
PHST- 2012/04/13 06:00 [medline]
AID - CIRCULATIONAHA.111.041293 [pii]
AID - 10.1161/CIRCULATIONAHA.111.041293 [doi]
PST - ppublish
SO  - Circulation. 2012 Jan 17;125(2):260-70. doi: 10.1161/CIRCULATIONAHA.111.041293. 
      Epub 2011 Dec 5.

PMID- 20306421
OWN - NLM
STAT- MEDLINE
DCOM- 20100507
LR  - 20161125
IS  - 0867-7077 (Print)
IS  - 0867-7077 (Linking)
VI  - 78
IP  - 2
DP  - 2010
TI  - [Acoustic rhinometry in the evaluation of intranasal aspirin challenge].
PG  - 103-11
AB  - Nasal lysine aspirin (Lys-ASA) challenge is an alternative to oral and bronchial 
      challenges in the diagnosis of aspirin (ASA) hypersensitivity. The aim of the 
      study was to evaluate the acoustic rhinometry as an objective method of 
      assessment of Lys-ASA nasal challenge. MATERIAL AND METHODS: Twenty patients with 
      aspirin induced asthma (ASA-S) and 10 controls (ASA-NS group: 5 patients with 
      allergic rhinitis and 5 healthy subjects) were included. Nasal challenge was 
      performed with placebo (saline) and 14.4 mg of Lys-ASA introduced as aerosol to 
      both nostrils (total dose: 16 mg of acetylsalicylic acid). Measurements of nasal 
      volume bilaterally were performed with the use of acoustic rhinometer before and 
      1, 2, 4 and 24 hours after the challenge. For further analysis the sum of both 
      nasal cavities volume at the level of 2 to 5 cm from nostrils was used. RESULTS: 
      Mean total bilateral volume in ASA-S group after placebo was: 7.74, 6.21, 7.11, 
      7.12, 7.24 cm(3) and 7.24, 5.77, 6.31, 6.27, 6.98 cm(3) after Lys-ASA (before and 
      after 1, 2, 4 and 24 hours, respectively; p = 0,048 and p = 0,02, in 2nd and 4th 
      hour, Lys-ASA v. placebo, Wilcoxon's test). With cut off point of nasal volume 
      decrease by 10% in the 1st hour the sensitivity of the test was 70%, specificity 
      60%, positive predictive value 77.78% and negative predictive value 50%. 
      CONCLUSIONS: In conclusion, acoustic rhinometry with measurement of nasal 
      cavities volume changes at 2 to 5 cm from nostrils does not appear to be 
      sufficiently sensitive and specific as a single method for evaluation of studied 
      challenge method.
FAU - Kupczyk, Maciej
AU  - Kupczyk M
AD  - Klinika Chorób Wewnetrznych, Astmy i Alergii Uniwersytetu Medycznego w Łodzi, ul. 
      Kopcińskiego 22, Łodz.
FAU - Kupryś-Lipińska, Izabela
AU  - Kupryś-Lipińska I
FAU - Bocheńska-Marciniak, Małgorzata
AU  - Bocheńska-Marciniak M
FAU - Kuna, Piotr
AU  - Kuna P
LA  - pol
PT  - Comparative Study
PT  - Journal Article
TT  - Rinometria akustyczna w ocenie donosowej próby prowokacyjnej aspiryna lizynowa.
PL  - Poland
TA  - Pneumonol Alergol Pol
JT  - Pneumonologia i alergologia polska
JID - 9302892
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Intranasal
MH  - Adult
MH  - *Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
MH  - Aspirin/administration & dosage/*analogs & derivatives
MH  - Asthma, Aspirin-Induced/*diagnosis
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Nasal Provocation Tests/*methods
MH  - Predictive Value of Tests
MH  - Rhinometry, Acoustic/*methods
MH  - Sensitivity and Specificity
EDAT- 2010/03/23 06:00
MHDA- 2010/05/08 06:00
CRDT- 2010/03/23 06:00
PHST- 2010/03/23 06:00 [entrez]
PHST- 2010/03/23 06:00 [pubmed]
PHST- 2010/05/08 06:00 [medline]
PST - ppublish
SO  - Pneumonol Alergol Pol. 2010;78(2):103-11.

PMID- 6499847
OWN - NLM
STAT- MEDLINE
DCOM- 19850123
LR  - 20190620
IS  - 0014-2956 (Print)
IS  - 0014-2956 (Linking)
VI  - 145
IP  - 2
DP  - 1984 Dec 3
TI  - Glucose-6-phosphate dehydrogenase. A transferred nuclear Overhauser enhancement 
      study of NADP+ conformations in enzyme-coenzyme binary complexes.
PG  - 365-71
AB  - The conformation of NADP+ in glucose-6-phosphate-dehydrogenase--NADP+ binary 
      complexes has been investigated using proton-proton transferred nuclear 
      Overhauser enhancement measurements to determine interproton distance ratios 
      between bound NADP+ protons. The enzymes from Saccharomyces cerevisiae (brewer's 
      yeast and baker's yeast) and Hansenula jadinii (Candida utilis, Torula utilis) 
      form binary complexes with NADP+ in which the glycosidic bond of the adenine 
      moiety is in the anti conformation whereas that of the nicotinamide moiety exists 
      as a syn (69-70%)/anti (30-40%) mixture. The enzymes have similar subunit sizes 
      (Mr approximately 58 000) and it is shown that they bind NADP+ in essentially 
      similar conformations. Inactivation of the baker's yeast enzyme with 
      acetylsalicylic acid caused little if any alteration in the conformation of bound 
      NADP+, and the presence of NADP+ during inactivation afforded very little 
      protection to the enzyme. Inactivation rates were, however, lower in the presence 
      of glucose 6-phosphate. It is concluded that the epsilon-amino group of the 
      lysine residue that is acetylated during the inactivation reaction with 
      acetylsalicylic acid is not necessary for binary complex formation between the 
      enzyme and NADP+, but that it is situated in a part of the molecule affected by 
      formation of the enzyme--glucose-6-phosphate complex. The implication of the 
      findings for the catalytic process, and related evolutionary aspects, are 
      discussed briefly.
FAU - Gronenborn, A M
AU  - Gronenborn AM
FAU - Clore, G M
AU  - Clore GM
FAU - Hobbs, L
AU  - Hobbs L
FAU - Jeffery, J
AU  - Jeffery J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Biochem
JT  - European journal of biochemistry
JID - 0107600
RN  - 53-59-8 (NADP)
RN  - EC 1.1.1.49 (Glucosephosphate Dehydrogenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - *Glucosephosphate Dehydrogenase/antagonists & inhibitors
MH  - Kinetics
MH  - Magnetic Resonance Spectroscopy
MH  - Molecular Conformation
MH  - *NADP
MH  - Protein Conformation
MH  - Yeasts/enzymology
EDAT- 1984/12/03 00:00
MHDA- 1984/12/03 00:01
CRDT- 1984/12/03 00:00
PHST- 1984/12/03 00:00 [pubmed]
PHST- 1984/12/03 00:01 [medline]
PHST- 1984/12/03 00:00 [entrez]
AID - 10.1111/j.1432-1033.1984.tb08563.x [doi]
PST - ppublish
SO  - Eur J Biochem. 1984 Dec 3;145(2):365-71. doi: 10.1111/j.1432-1033.1984.tb08563.x.

PMID- 579700
OWN - NLM
STAT- MEDLINE
DCOM- 19780310
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 38
IP  - 4
DP  - 1977 Dec 15
TI  - Measurement of nucleotide pools in platelets using high pressure liquid 
      chromatography.
PG  - 990-1001
AB  - We have devised an improved high pressure liquid chromatographic technique 
      whereby serotonin, nucleosides, cyclic nucleotides, namely cAMP and cGMP, and 
      5'mono-, 5'di-, and 5'tri-nucleotides can be analyzed. The cyclic nucleotides 
      have been measured in picomolar quantities. All nucleotides can be quantitated in 
      a single step separation in 75 min using a 0.0015 M phosphoric acids vs. 1M pH 
      4.8 ammonium phosphate gradient. 5/10 ml of platelet-rich plasma furnishes an 
      adequate sample for complete analysis. Nucleotide levels in platelets from 16 
      normal donors expressed in 10(11) platelets are as follows: cAMP, 6.32 (4.15) 
      nanomoles and AMP, 0.32 (0.14); ADP, 2.48 (0.67); ATP 3.78 (0.68); GDP 0.38 
      (0.07) and GTP, 0.45 (0.07) micromoles. ADP and ATP values are lower than those 
      previously published. However, the total nucleotide level approaches published 
      values. Upon aggregation with thrombin, approximately 50% of ADP and 40% ATP is 
      releaseed. Release is complete by 2 min. Thrombin is the most potent releasing 
      agent with collagen and ADP occupying an intermediate role and epinephrine being 
      the least effective. Upon aggregation cyclic AMP levels diminish along the other 
      nucleotides. Patients with asthma showed depression of ADP, ATP, GDP and GTP 
      levels.
FAU - D'Souza, L
AU  - D'Souza L
FAU - Glueck, H I
AU  - Glueck HI
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Nucleotides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Asthma/physiopathology
MH  - Blood Platelets/*analysis/drug effects
MH  - Chromatography, High Pressure Liquid/methods
MH  - Nucleotides/*analysis
EDAT- 1977/12/15 00:00
MHDA- 1977/12/15 00:01
CRDT- 1977/12/15 00:00
PHST- 1977/12/15 00:00 [pubmed]
PHST- 1977/12/15 00:01 [medline]
PHST- 1977/12/15 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1977 Dec 15;38(4):990-1001.

PMID- 32165345
OWN - NLM
STAT- MEDLINE
DCOM- 20200723
LR  - 20210616
IS  - 1878-8769 (Electronic)
IS  - 1878-8750 (Linking)
VI  - 138
DP  - 2020 Jun
TI  - Association Between Aspirin Use and Risk of Aneurysmal Subarachnoid Hemorrhage: 
      A Meta-analysis.
PG  - 299-308
LID - S1878-8750(20)30138-8 [pii]
LID - 10.1016/j.wneu.2020.01.120 [doi]
AB  - OBJECTIVE: To assess the association between aspirin use and risk of aneurysmal 
      subarachnoid hemorrhage (aSAH). METHODS: A systematic search was performed in 
      various databases updated on October 22, 2019. The heterogeneity test was 
      performed for each outcome variable. Random-effect model and fixed-effect model 
      were respectively conducted according to the heterogeneity statistics. Trial 
      sequential analysis was used to control random errors. RESULTS: Ten studies 
      involving 1,107,616 patients were involved in this meta-analysis. No significant 
      association was shown between aspirin users and non-aspirin users regarding the 
      risk of aSAH (odds ratio [OR]: 0.981, 95% confidential interval [CI]: 
      0.773-1.312, P = 0.897]. The results of subgroup analyses indicated that the risk 
      of aSAH was notably associated with a short-term use of aspirin (<3 months) (OR: 
      1.697, 95% CI: 1.175-2.452, P = 0.005), but not aspirin use for 3-12 months (OR: 
      1.026, 95% CI: 0.609-1.730, P = 0.922), 1-3 years (OR: 0.942, 95% CI: 
      0.660-1.346, P = 0.744), >3 years (OR: 0.892, 95% CI: 0.573-1.389, P = 0.612), ≤2 
      times per week (OR: 0.857, 95% CI: 0.560-1.313, P = 0.479), ≥3 times per week 
      (OR: 1.104, 95% CI: 0.555-2.193, P = 0.778) and former use (OR: 1.029, 95% CI: 
      0.482-2.196, P = 0.941). CONCLUSIONS: A short-term use of aspirin (<3 months) is 
      associated with an elevated risk of aSAH, whereas the role of its long-term use 
      in either decreasing or increasing the risk of aSAH still requires well-designed, 
      large-scale randomized control trials for verification.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Qian, Chunsheng
AU  - Qian C
AD  - Department of Neurosurgery, The Jintan Hospital Affiliated to Jiangsu University, 
      Changzhou, Jiangsu, China.
FAU - He, Yunwen
AU  - He Y
AD  - Department of Neurosurgery, The Jintan Hospital Affiliated to Jiangsu University, 
      Changzhou, Jiangsu, China.
FAU - Li, Yihuan
AU  - Li Y
AD  - Department of Neurosurgery, The Jintan Hospital Affiliated to Jiangsu University, 
      Changzhou, Jiangsu, China.
FAU - Chen, Chuanxin
AU  - Chen C
AD  - Department of Neurosurgery, The Jintan Hospital Affiliated to Jiangsu University, 
      Changzhou, Jiangsu, China.
FAU - Zhang, Bin
AU  - Zhang B
AD  - Department of Neurosurgery, The Jintan Hospital Affiliated to Jiangsu University, 
      Changzhou, Jiangsu, China. Electronic address: zhangbindoctor200@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20200309
PL  - United States
TA  - World Neurosurg
JT  - World neurosurgery
JID - 101528275
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - World Neurosurg. 2021 Feb;146:394. PMID: 33607731
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Subarachnoid Hemorrhage/*epidemiology/prevention & control
OTO - NOTNLM
OT  - Aspirin
OT  - Intracranial aneurysm
OT  - Meta-analysis
OT  - Subarachnoid hemorrhage
OT  - Trial sequential analysis
EDAT- 2020/03/14 06:00
MHDA- 2020/07/24 06:00
CRDT- 2020/03/14 06:00
PHST- 2019/12/03 00:00 [received]
PHST- 2020/01/13 00:00 [revised]
PHST- 2020/01/16 00:00 [accepted]
PHST- 2020/03/14 06:00 [pubmed]
PHST- 2020/07/24 06:00 [medline]
PHST- 2020/03/14 06:00 [entrez]
AID - S1878-8750(20)30138-8 [pii]
AID - 10.1016/j.wneu.2020.01.120 [doi]
PST - ppublish
SO  - World Neurosurg. 2020 Jun;138:299-308. doi: 10.1016/j.wneu.2020.01.120. Epub 2020 
      Mar 9.

PMID- 19805650
OWN - NLM
STAT- MEDLINE
DCOM- 20091113
LR  - 20131121
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 120
IP  - 16
DP  - 2009 Oct 20
TI  - Bleeding increases the risk of ischemic events in patients with peripheral 
      arterial disease.
PG  - 1569-76
LID - 10.1161/CIRCULATIONAHA.109.858365 [doi]
AB  - BACKGROUND: Patients with peripheral arterial disease are at high risk of 
      ischemic events and therefore are treated with antithrombotics. In patients with 
      coronary artery disease or cerebrovascular disease, bleeding is related to the 
      subsequent occurrence of ischemic events. Our objective was to assess whether 
      this is also the case in patients with peripheral arterial disease. METHODS AND 
      RESULTS: All patients from the Dutch Bypass and Oral Anticoagulants or Aspirin 
      (BOA) Study, a multicenter randomized trial comparing oral anticoagulants with 
      aspirin after infrainguinal bypass surgery, were included. The primary outcome 
      event was the composite of nonfatal myocardial infarction, nonfatal ischemic 
      stroke, major amputation, and cardiovascular death. To identify major bleeding as 
      an independent predictor for ischemic events, crude and adjusted hazard ratios 
      with 95% confidence intervals were calculated with multivariable Cox regression 
      models. From 1995 until 1998, 2650 patients were included with 101 nonfatal major 
      bleedings. During a mean follow-up of 14 months, the primary outcome event 
      occurred in 218 patients; 22 events were preceded by a major bleeding. The mean 
      time between major bleeding and the primary outcome event was 4 months. Major 
      bleeding was associated with a 3-fold increased risk of subsequent ischemic 
      events (crude hazard ratio, 3.0; 95% confidence interval, 1.9 to 4.6; adjusted 
      hazard ratio, 3.0; 95% confidence interval, 1.9 to 4.7). CONCLUSIONS: In patients 
      with peripheral arterial disease, as in patients with coronary artery disease or 
      cerebrovascular disease, major bleeding was independently associated with major 
      ischemic complications. Without compromising the benefits of antithrombotics, 
      these findings call for caution relative to the risks of major bleeding.
FAU - van Hattum, Eline S
AU  - van Hattum ES
AD  - Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, the 
      Netherlands. e.vanhattum@umcutrecht.nl
FAU - Algra, Ale
AU  - Algra A
FAU - Lawson, James A
AU  - Lawson JA
FAU - Eikelboom, Bert C
AU  - Eikelboom BC
FAU - Moll, Frans L
AU  - Moll FL
FAU - Tangelder, Marco J D
AU  - Tangelder MJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20091005
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/*adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Cerebral Hemorrhage/chemically induced
MH  - Confidence Intervals
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Groin/blood supply
MH  - Hemorrhage/*chemically induced/*complications/epidemiology
MH  - Humans
MH  - Incidence
MH  - Ischemia/*etiology
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/*drug therapy/surgery
MH  - Postoperative Care
MH  - Proportional Hazards Models
MH  - Risk Factors
EDAT- 2009/10/07 06:00
MHDA- 2009/11/17 06:00
CRDT- 2009/10/07 06:00
PHST- 2009/10/07 06:00 [entrez]
PHST- 2009/10/07 06:00 [pubmed]
PHST- 2009/11/17 06:00 [medline]
AID - CIRCULATIONAHA.109.858365 [pii]
AID - 10.1161/CIRCULATIONAHA.109.858365 [doi]
PST - ppublish
SO  - Circulation. 2009 Oct 20;120(16):1569-76. doi: 10.1161/CIRCULATIONAHA.109.858365. 
      Epub 2009 Oct 5.

PMID- 3671199
OWN - NLM
STAT- MEDLINE
DCOM- 19871124
LR  - 20191210
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 82
IP  - 5
DP  - 1987 Oct
TI  - Unproven arthritis remedies. How to approach the problem.
PG  - 305-8, 310, 312 passim
AB  - The traditional medical model (ie, history taking, physical examination, 
      diagnosis, and treatment) is not sufficient in the management of chronic diseases 
      such as arthritis. The complex social interactions that lead patients toward and 
      away from traditional medical treatment must be recognized and addressed. 
      Physicians need to acknowledge the likelihood that their patients may use 
      unproven arthritis remedies and to make an effort to reduce the problem. Clinical 
      research on the use of unproven remedies is needed, especially as it relates to 
      complex physician-patient interactions. A good patient-physician relationship 
      remains the basis of good clinical medicine and increases the likelihood of 
      patient compliance.
FAU - Wasner, C K
AU  - Wasner CK
AD  - Oregon Health Sciences University School of Medicine, Portland.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 7440-57-5 (Gold)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis/psychology/*therapy
MH  - Aspirin/therapeutic use
MH  - Denial, Psychological
MH  - Gold/therapeutic use
MH  - Humans
MH  - Medicine, Traditional
MH  - Patient Compliance
MH  - Patient Education as Topic
MH  - Physician-Patient Relations
EDAT- 1987/10/01 00:00
MHDA- 1987/10/01 00:01
CRDT- 1987/10/01 00:00
PHST- 1987/10/01 00:00 [pubmed]
PHST- 1987/10/01 00:01 [medline]
PHST- 1987/10/01 00:00 [entrez]
AID - 10.1080/00325481.1987.11700017 [doi]
PST - ppublish
SO  - Postgrad Med. 1987 Oct;82(5):305-8, 310, 312 passim. doi: 
      10.1080/00325481.1987.11700017.

PMID- 793217
OWN - NLM
STAT- MEDLINE
DCOM- 19770125
LR  - 20131121
IS  - 0323-5580 (Print)
IS  - 0323-5580 (Linking)
VI  - 9
IP  - 3
DP  - 1976
TI  - [Effect of acetylsalicylic acid on immunologically induced morphologic changes 
      after experimental lung transplantation (light and electron microscopic study)].
PG  - 141-9
AB  - In 3 comparing series the behavior of platelets after experimental lung 
      transplantation was examined in 33 dogs. After allogenic transplantations (21 
      animals) the ultrastructural findings were pathologic changes of the platelets, 
      such as hyperaggregability with irreversible aggregation prevailing, as well as 
      capillary wall alterations. X-rays showed considerable reduction of functioning 
      parenchyma. Since these findings were absent in animals which underwent merely 
      pulmonary re-implantation (4 animals) and can be considered a controll group, the 
      authors conclude that these alterations are caused by mainly immunologic 
      reactions. Acetylsalicylic acid given to animals with grafted lungs significantly 
      inhibited is specific and certainly immuneinduced pathologic development. 
      Absolutely necessary, therefore, appears the application of such aggregation 
      inhibitor as additional treatment in lung transplantations.
FAU - Hoyer, J
AU  - Hoyer J
FAU - Garbe, L
AU  - Garbe L
FAU - Sicardi, F
AU  - Sicardi F
FAU - Noirclerc, M
AU  - Noirclerc M
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Wirkung von Azetylsalizylsäure auf immuninduzierte, morphologische 
      Thrombozytenveränderungen nach experimenteller Lungentransplantation (Eine licht- 
      und elektronenmikroskopische Studie).
PL  - Germany
TA  - Z Exp Chir
JT  - Zeitschrift fur experimentelle Chirurgie
JID - 0154510
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antibody Formation/drug effects
MH  - Aspirin/*pharmacology
MH  - Dogs
MH  - Female
MH  - Lung/cytology/ultrastructure
MH  - *Lung Transplantation
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Replantation
MH  - Transplantation, Homologous
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Exp Chir. 1976;9(3):141-9.

PMID- 9162290
OWN - NLM
STAT- MEDLINE
DCOM- 19970528
LR  - 20161124
IS  - 0869-2092 (Print)
IS  - 0869-2092 (Linking)
VI  - 60
IP  - 1
DP  - 1997 Jan-Feb
TI  - [A biochemiluminescent analysis of the pharmacotherapeutic activity of 
      acetylsalicylic acid in combination with quercetin in a hypoxic syndrome].
PG  - 62-4
AB  - The effect of acetylsalicylic acid in combination with quercetin on blood serum 
      biochemiluminescence in the hypoxic syndrome was studied. Possessing marked 
      antioxidant activity, this drug combination prevented changes in the kinetics of 
      blood serum luminescence in all periods of the investigation.
FAU - Luk'ianchuk, V D
AU  - Luk'ianchuk VD
FAU - Savchenkova, L V
AU  - Savchenkova LV
FAU - Semenova, I A
AU  - Semenova IA
LA  - rus
PT  - Comparative Study
PT  - Journal Article
TT  - Biokhemiliuminestsentnyĭ analiz farmakoterapevticheskoĭ aktivnosti 
      atsetilsalitsilovoĭ kisloty v kombinatsii s kvertsetinom pri gipoksicheskom 
      sindrome.
PL  - Russia (Federation)
TA  - Eksp Klin Farmakol
JT  - Eksperimental'naia i klinicheskaia farmakologiia
JID - 9215981
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 9IKM0I5T1E (Quercetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Drug Therapy, Combination
MH  - Fever/blood/drug therapy
MH  - Hypoxia/blood/*drug therapy
MH  - Luminescent Measurements
MH  - Male
MH  - Quercetin/pharmacology/*therapeutic use
MH  - Rats
MH  - Rats, Wistar
MH  - Syndrome
MH  - Time Factors
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Eksp Klin Farmakol. 1997 Jan-Feb;60(1):62-4.

PMID- 6468878
OWN - NLM
STAT- MEDLINE
DCOM- 19841012
LR  - 20131121
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 87
IP  - 4
DP  - 1984 Oct
TI  - Influence of vagotomy on mucosal protection against alcohol-induced gastric 
      damage in the rat.
PG  - 903-8
AB  - We examined the role of the vagus nerve in mediating the protective effects of 
      subcutaneous 16,16-dimethyl prostaglandin E2 (16,16-dmPGE2) or of the mild 
      irritant 30% ethanol (topically) against gastric mucosal injury induced by 
      concentrated solutions of ethanol. Anesthetized rats underwent either truncal 
      vagotomy or sham truncal vagotomy and were studied acutely or 7 days later. Under 
      acute conditions, in rats with intact vagi, oral saline followed by 100% ethanol 
      produced severe gastric hemorrhagic and necrotic lesions throughout the glandular 
      gastric mucosa. Oral 30% ethanol or pretreatment with 16,16-dmPGE2 (5, 10, or 25 
      micrograms/kg) before giving oral saline significantly reduced the magnitude of 
      injury when mucosa was subsequently exposed to 100% ethanol. In animals with 
      truncal vagotomy, the protective effect of 16,16-dmPGE2 or 30% ethanol was not 
      observed. Similar results were noted when animals were studied 7 days after sham 
      or truncal vagotomy. In other studies, the ability of 16,16-dmPGE2 to prevent 
      gastric injury induced by 50% ethanol or 80 mM aspirin in acid solution (160 mM 
      HCl) with and without prior vagotomy was compared. Although 16,16-dmPGE2 (5 or 25 
      micrograms/kg) pretreatment significantly reduced the degree of gastric damage 
      induced by both agents in the nonvagotomized state, and by aspirin under 
      vagotomized conditions, only partial protection by 16,16-dmPGE2 against ethanol 
      injury was observed in the vagotomized state. These results suggest that the 
      mechanisms whereby prostaglandins mediate their protective effects against 
      aspirin and ethanol may be different and that the vagus nerve influences the 
      ability of 16,16-dmPGE2 and of the mild irritant 30% ethanol to prevent 
      alcohol-induced gastric injury in the rat stomach.
FAU - Henagan, J M
AU  - Henagan JM
FAU - Smith, G S
AU  - Smith GS
FAU - Seidel, E R
AU  - Seidel ER
FAU - Miller, T A
AU  - Miller TA
LA  - eng
GR  - AM25838/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Prostaglandins)
RN  - 3K9958V90M (Ethanol)
RN  - 9G2MP84A8W (Deoxyglucose)
RN  - M790V82VAC (16,16-Dimethylprostaglandin E2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 16,16-Dimethylprostaglandin E2/pharmacology
MH  - Animals
MH  - Aspirin/antagonists & inhibitors/toxicity
MH  - Deoxyglucose/pharmacology
MH  - Ethanol/antagonists & inhibitors/*toxicity
MH  - Female
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Prostaglandins/*physiology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Vagotomy
MH  - Vagus Nerve/drug effects/*physiology
EDAT- 1984/10/01 00:00
MHDA- 1984/10/01 00:01
CRDT- 1984/10/01 00:00
PHST- 1984/10/01 00:00 [pubmed]
PHST- 1984/10/01 00:01 [medline]
PHST- 1984/10/01 00:00 [entrez]
AID - S0016508584002596 [pii]
PST - ppublish
SO  - Gastroenterology. 1984 Oct;87(4):903-8.

PMID- 11714031
OWN - NLM
STAT- MEDLINE
DCOM- 20020419
LR  - 20190605
IS  - 0916-7250 (Print)
IS  - 0916-7250 (Linking)
VI  - 63
IP  - 10
DP  - 2001 Oct
TI  - Comparison of the upper gastrointestinal effects of etodolac and aspirin in 
      healthy dogs.
PG  - 1131-3
AB  - Fifteen healthy castrated male dogs were separated into three treatment groups 
      that were administered etodolac, aspirin and a placebo orally, respectively. All 
      treatments were continued for 28 days. The animals were examined endoscopically 
      on days 0, 3, 7, 10, 14, 17, 21, 24 and 28. There were no gastrointestinal 
      mucosal lesions in either the etodolac or the placebo group, whereas some gastric 
      lesions developed in the aspirin group after day 17. We considered that etodolac 
      could be used for long-term treatments in dogs with fewer side-effects on the 
      gastric mucosa than aspirin.
FAU - Nishihara, K
AU  - Nishihara K
AD  - Laboratory of Veterinary Internal Medicine, Obihiro University of Agriculture and 
      Veterinary, Medicine, Hokkaido, Japan.
FAU - Kikuchi, H
AU  - Kikuchi H
FAU - Kanno, T
AU  - Kanno T
FAU - Tanabe, S
AU  - Tanabe S
FAU - Sarashina, T
AU  - Sarashina T
FAU - Uzuka, Y
AU  - Uzuka Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - J Vet Med Sci
JT  - The Journal of veterinary medical science
JID - 9105360
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 2M36281008 (Etodolac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*pharmacology
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Dogs/*metabolism
MH  - Endoscopy, Gastrointestinal/veterinary
MH  - Etodolac/administration & dosage/adverse effects/*pharmacology
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Intestinal Mucosa/*drug effects/pathology
MH  - Male
MH  - Random Allocation
MH  - Statistics, Nonparametric
EDAT- 2001/11/21 10:00
MHDA- 2002/04/20 10:01
CRDT- 2001/11/21 10:00
PHST- 2001/11/21 10:00 [pubmed]
PHST- 2002/04/20 10:01 [medline]
PHST- 2001/11/21 10:00 [entrez]
AID - 10.1292/jvms.63.1131 [doi]
PST - ppublish
SO  - J Vet Med Sci. 2001 Oct;63(10):1131-3. doi: 10.1292/jvms.63.1131.

PMID- 22338992
OWN - NLM
STAT- MEDLINE
DCOM- 20120405
LR  - 20190513
IS  - 0026-4075 (Print)
IS  - 0026-4075 (Linking)
VI  - 177
IP  - 1
DP  - 2012 Jan
TI  - Mast cell activation syndrome masquerading as agranulocytosis.
PG  - 113-7
AB  - Acquired agranulocytosis is a rare, life-threatening disorder. The few known 
      causes/associations usually are readily identifiable (e.g., drug reaction, Felty 
      syndrome, megaloblastosis, large granular lymphocytic leukemia, etc.). We report 
      a novel association with mast cell disease. A 61-year-old morbidly obese man 
      developed rheumatoid arthritis unresponsive to several medications. 
      Agranulocytosis developed shortly after sulfasalazine was started but did not 
      improve when the drug was soon stopped. Other symptoms across many systems 
      developed including hives and presyncope. Marrow aspiration and biopsy showed 
      only neutropenia. Serum tryptase was mildly elevated; urinary prostaglandin D2 
      was markedly elevated. Other causes were not found. Mast cell activation syndrome 
      (MCAS) was diagnosed. Oral antihistamines, montelukast, and cromolyn were 
      unhelpful; aspirin was initially felt contraindicated. Imatinib immediately 
      increased neutrophils from 0% to 25% but did not help symptoms; subsequent 
      addition of aspirin increased neutrophils further and abated symptoms. Different 
      presentations of different MCAS patients reflect elaboration of different 
      mediators likely consequent to different Kit mutations. Mast cells (MCs) help 
      regulate adipocytes, and adipocytes can inhibit granulopoiesis; thus, a 
      Kit-mutated MC clone may have directly and/or indirectly driven agranulocytosis. 
      MCAS should be considered in otherwise idiopathic agranulocytosis presenting with 
      comorbidities best explained by MC mediator release.
FAU - Afrin, Lawrence B
AU  - Afrin LB
AD  - Section of Hematology/Oncology, Medical Service, Ralph H. Johnson Veterans 
      Affairs Medical Center, Charleston, SC 29401, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Mil Med
JT  - Military medicine
JID - 2984771R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Agranulocytosis/diagnosis
MH  - Aspirin/therapeutic use
MH  - Comorbidity
MH  - Diagnosis, Differential
MH  - Humans
MH  - Male
MH  - Mastocytosis, Systemic/*diagnosis/drug therapy
MH  - Middle Aged
MH  - United States
MH  - Veterans
EDAT- 2012/02/22 06:00
MHDA- 2012/04/06 06:00
CRDT- 2012/02/21 06:00
PHST- 2012/02/21 06:00 [entrez]
PHST- 2012/02/22 06:00 [pubmed]
PHST- 2012/04/06 06:00 [medline]
AID - 10.7205/milmed-d-11-00111 [doi]
PST - ppublish
SO  - Mil Med. 2012 Jan;177(1):113-7. doi: 10.7205/milmed-d-11-00111.

PMID- 20159155
OWN - NLM
STAT- MEDLINE
DCOM- 20100507
LR  - 20211020
IS  - 1542-0086 (Electronic)
IS  - 0006-3495 (Print)
IS  - 0006-3495 (Linking)
VI  - 98
IP  - 4
DP  - 2010 Feb 17
TI  - Partitioning of nonsteroidal antiinflammatory drugs in lipid membranes: a 
      molecular dynamics simulation study.
PG  - 586-95
LID - 10.1016/j.bpj.2009.10.046 [doi]
AB  - Using the potential of mean constrained force method, molecular dynamics 
      simulations with atomistic details were performed to examine the partitioning and 
      nature of interactions of two nonsteroidal antiinflammatory drugs, namely aspirin 
      and ibuprofen, in bilayers of dipalmitoylphosphatidylcholine. Two charge states 
      (neutral and anionic) of the drugs were simulated to understand the effect of 
      protonation or pH on drug partitioning. Both drugs, irrespective of their charge 
      state, were found to have high partition coefficients in the lipid bilayer from 
      water. However, the values and trends of the free energy change and the location 
      of the minima in the bilayer are seen to be influenced by the drug structure and 
      charge state. In the context of the transport of the drugs through the bilayer, 
      the charged forms were found to permeate fully hydrated in contrast to the 
      neutral forms that permeate unhydrated.
CI  - Copyright 2010 Biophysical Society. Published by Elsevier Inc. All rights 
      reserved.
FAU - Boggara, Mohan Babu
AU  - Boggara MB
AD  - Department of Chemical and Biomolecular Engineering, University of Houston, 
      Houston, Texas, USA.
FAU - Krishnamoorti, Ramanan
AU  - Krishnamoorti R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biophys J
JT  - Biophysical journal
JID - 0370626
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipid Bilayers)
RN  - 059QF0KO0R (Water)
RN  - 2644-64-6 (1,2-Dipalmitoylphosphatidylcholine)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - 1,2-Dipalmitoylphosphatidylcholine/chemistry
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*metabolism
MH  - Aspirin/chemistry/metabolism
MH  - Cell Membrane/chemistry/*metabolism
MH  - Cell Membrane Permeability
MH  - Hydrogen Bonding
MH  - Hydrogen-Ion Concentration
MH  - Ibuprofen/chemistry/metabolism
MH  - Lipid Bilayers/chemistry/*metabolism
MH  - Liquid Crystals/chemistry
MH  - *Molecular Dynamics Simulation
MH  - Static Electricity
MH  - Thermodynamics
MH  - Water/chemistry
PMC - PMC2820636
EDAT- 2010/02/18 06:00
MHDA- 2010/05/08 06:00
CRDT- 2010/02/18 06:00
PHST- 2009/08/05 00:00 [received]
PHST- 2009/10/13 00:00 [revised]
PHST- 2009/10/16 00:00 [accepted]
PHST- 2010/02/18 06:00 [entrez]
PHST- 2010/02/18 06:00 [pubmed]
PHST- 2010/05/08 06:00 [medline]
AID - S0006-3495(09)01688-9 [pii]
AID - BPJ1181 [pii]
AID - 10.1016/j.bpj.2009.10.046 [doi]
PST - ppublish
SO  - Biophys J. 2010 Feb 17;98(4):586-95. doi: 10.1016/j.bpj.2009.10.046.

PMID- 26729528
OWN - NLM
STAT- MEDLINE
DCOM- 20170117
LR  - 20170117
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 17
IP  - 4
DP  - 2016 Aug
TI  - Studies on Aspirin Crystals Generated by a Modified Vapor Diffusion Method.
PG  - 988-94
LID - 10.1208/s12249-015-0432-8 [doi]
AB  - The objectives of the current investigation were (1) to study the influence of 
      selected two different non-solvents (diethylether and dichloromethane) on the 
      drug crystal formation of a model drug, aspirin (ASP-I) by the modified vapor 
      diffusion method and (2) to characterize and compare the generated crystals 
      (ASP-II and ASP-III) using different analytical techniques with that of 
      unprocessed ASP-I. When compared to the classical vapor diffusion method which 
      consumes about 15 days to generate drug crystals, the modified method needs only 
      12 h to get the same. Fourier transform-infrared spectroscopy (FT-IR) reveals 
      that the internal structures of ASP-II and ASP-III crystals were identical when 
      compared with ASP-I. Although the drug crystals showed a close similarity in 
      X-ray diffraction patterns, the difference in the relative intensities of some of 
      the diffraction peaks (especially at 2θ values of around 7.7 and 15.5) could be 
      attributed to the crystal habit or crystal size modification. Similarly, the 
      differential scanning calorimetry (DSC) study speculates that only the crystal 
      habit modifications might occur but without involving any change in internal 
      structure of the generated drug polymorphic form I. This is further substantiated 
      from the scanning electron microscopy (SEM) pictures that indicated the formation 
      of platy shape for the ASP-II crystals and needle shape for the ASP-III crystals. 
      In addition, the observed slow dissolution of ASP crystals should indicate 
      polymorph form I formation. Thus, the modified vapor diffusion method could 
      routinely be used to screen and legally secure all possible forms of other drug 
      entities too.
FAU - Mittal, Amit
AU  - Mittal A
AD  - Lovely School of Pharmaceutical Sciences, Lovely Professional University, 
      Jalandhar-Delhi, G.T. Road (NH-1), Phagwara, Jalandhar, Punjab, India, 144411.
FAU - Malhotra, Deepak
AU  - Malhotra D
AD  - Lovely School of Pharmaceutical Sciences, Lovely Professional University, 
      Jalandhar-Delhi, G.T. Road (NH-1), Phagwara, Jalandhar, Punjab, India, 144411.
FAU - Jain, Preeti
AU  - Jain P
AD  - Lovely School of Pharmaceutical Sciences, Lovely Professional University, 
      Jalandhar-Delhi, G.T. Road (NH-1), Phagwara, Jalandhar, Punjab, India, 144411.
FAU - Kalia, Anupama
AU  - Kalia A
AD  - Lovely School of Pharmaceutical Sciences, Lovely Professional University, 
      Jalandhar-Delhi, G.T. Road (NH-1), Phagwara, Jalandhar, Punjab, India, 144411.
FAU - Shunmugaperumal, Tamilvanan
AU  - Shunmugaperumal T
AD  - Lovely School of Pharmaceutical Sciences, Lovely Professional University, 
      Jalandhar-Delhi, G.T. Road (NH-1), Phagwara, Jalandhar, Punjab, India, 144411. 
      tamilvanan1@yahoo.co.in.
LA  - eng
PT  - Journal Article
DEP - 20151016
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Solvents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Calorimetry, Differential Scanning/methods
MH  - Crystallization
MH  - Diffusion
MH  - Drug Stability
MH  - Microscopy, Electron, Scanning/methods
MH  - Solubility
MH  - Solvents/chemistry
MH  - Spectroscopy, Fourier Transform Infrared/methods
MH  - X-Ray Diffraction/methods
OTO - NOTNLM
OT  - aspirin
OT  - crystal habit
OT  - crystallization
OT  - scanning electron microscopy
OT  - vapor diffusion
EDAT- 2016/01/06 06:00
MHDA- 2017/01/18 06:00
CRDT- 2016/01/06 06:00
PHST- 2015/06/30 00:00 [received]
PHST- 2015/10/08 00:00 [accepted]
PHST- 2016/01/06 06:00 [entrez]
PHST- 2016/01/06 06:00 [pubmed]
PHST- 2017/01/18 06:00 [medline]
AID - 10.1208/s12249-015-0432-8 [pii]
AID - 10.1208/s12249-015-0432-8 [doi]
PST - ppublish
SO  - AAPS PharmSciTech. 2016 Aug;17(4):988-94. doi: 10.1208/s12249-015-0432-8. Epub 
      2015 Oct 16.

PMID- 30608202
OWN - NLM
STAT- MEDLINE
DCOM- 20191211
LR  - 20210109
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 7
IP  - 21
DP  - 2018 Nov 6
TI  - Aspirin Use and Cardiovascular Outcome in Patients With Type 2 Diabetes Mellitus 
      and Heart Failure: A Population-Based Cohort Study.
PG  - e010033
LID - 10.1161/JAHA.118.010033 [doi]
LID - e010033
AB  - Background Aspirin is of uncertain benefit for primary prevention in patients 
      with type 2 diabetes mellitus (T2D). We assessed whether primary prevention with 
      aspirin is beneficial in patients with T2D and heart failure ( HF ). Methods and 
      Results Data from The Health Improvement Network, a UK multicenter prospective 
      primary care database, were analyzed. Those with T2D and HF , age ≥55 years, and 
      no previous history of myocardial infarction and/or coronary artery disease, 
      stroke, peripheral artery disease, or atrial fibrillation were included. We 
      compared outcomes for those on aspirin to no aspirin after diagnosis of HF and 
      T2D and assessed the role of a >75-mg dose. The primary outcome was a composite 
      of all-cause mortality and hospitalization for HF ; secondary outcomes were 
      nonfatal stroke, nonfatal myocardial infarction, or major bleeding. There were 
      5967 participants on aspirin and 6567 not on aspirin. The mean age ( SD ) was 
      75.3 (9.6) years, 53.9% were men, and the mean follow-up ( SD ) was for 5 (4.2) 
      years. After propensity-score matching and further multivariable adjustment, 
      aspirin was significantly associated with a decrease in the primary outcome and 
      all-cause mortality (hazard ratio=0.88, 95% confidence interval 0.82-0.93; 0.88, 
      0.83-0.94], respectively); and an increased risk of nonfatal myocardial 
      infarction (hazard ratio=1.66; 95% confidence interval 1.49-1.85) and nonfatal 
      stroke (hazard ratio=1.23, 1.01-1.50). Major bleedings and hospitalization for HF 
      were not significantly higher with aspirin (hazard ratio=0.68, 0.45-1.03; 0.87, 
      0.66-1.15, respectively). There was no additional benefit for a dose >75 mg. 
      Conclusions Primary prevention with aspirin in patients with T2D and HF is 
      associated with lower all-cause mortality.
FAU - Abi Khalil, Charbel
AU  - Abi Khalil C
AD  - 1 Joan and Sanford I. Weill Department of Medicine Weill Cornell Medicine Doha 
      Qatar.
AD  - 2 Department of Genetic Medicine Weill Cornell Medicine Doha Qatar.
AD  - 4 Adult Cardiology Heart Hospital Hamad Medical Corporation Doha Qatar.
FAU - Omar, Omar M
AU  - Omar OM
AD  - 3 Clinical Research Core Department of Medicine Weill Cornell Medicine Doha 
      Qatar.
FAU - Al Suwaidi, Jassim
AU  - Al Suwaidi J
AD  - 1 Joan and Sanford I. Weill Department of Medicine Weill Cornell Medicine Doha 
      Qatar.
AD  - 4 Adult Cardiology Heart Hospital Hamad Medical Corporation Doha Qatar.
FAU - Taheri, Shahrad
AU  - Taheri S
AD  - 1 Joan and Sanford I. Weill Department of Medicine Weill Cornell Medicine Doha 
      Qatar.
AD  - 3 Clinical Research Core Department of Medicine Weill Cornell Medicine Doha 
      Qatar.
AD  - 5 Department of Medicine Qatar Metabolic Institute Hamad Medical Corporation Doha 
      Qatar.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*etiology/*prevention & control
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Female
MH  - Heart Failure/*complications
MH  - Humans
MH  - Male
MH  - *Primary Prevention
MH  - Treatment Outcome
PMC - PMC6404217
OTO - NOTNLM
OT  - aspirin
OT  - death
OT  - diabetes mellitus
OT  - heart failure
EDAT- 2019/01/05 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/01/05 06:00
PHST- 2019/01/05 06:00 [entrez]
PHST- 2019/01/05 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
AID - JAH33601 [pii]
AID - 10.1161/JAHA.118.010033 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2018 Nov 6;7(21):e010033. doi: 10.1161/JAHA.118.010033.

PMID- 35363360
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220615
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 26
IP  - 6
DP  - 2022 Mar
TI  - Aspirin resistance among patients with new and recurrent ischemic heart disease 
      episodes in Qassim region, Saudi Arabia.
PG  - 2106-2116
LID - 28358 [pii]
LID - 10.26355/eurrev_202203_28358 [doi]
AB  - OBJECTIVE: Aspirin resistance is described as the failure of aspirin to decrease 
      the production of thromboxane A2 by platelets, which is the mechanism by which 
      aspirin decreases platelet activation and aggregation. This study was performed 
      to assess the prevalence of aspirin resistance among cardiovascular patients in 
      al-Qassim, Saudi Arabia. PATIENTS AND METHODS: The study used a survey of 
      patients with first and recurrent attacks of ischemic heart disease (IHD) and 
      available data from blood samples processed using a VerifyNow® kit, which 
      measures aspirin reaction units (ARUs). RESULTS: A total of 119 patients were 
      included: 45 with their first IHD episodes and 74 with recurrent episodes. Of the 
      surveyed patients, 40% with a first episode were younger than 50 years old, and 
      75.6% of them have been diagnosed with IHD during the previous 5 years. Of the 
      patients with recurrent attacks, 45.9% were older than 60 years, and 54.1% of 
      them have been diagnosed more than 5 years before. The group with first episodes 
      of IHD had 133.2 ARUs, whereas the group with recurrent episodes had 168.5 ARUs 
      (p=0.105). In the recurrent-episode group, 77% had diabetes; in the first-episode 
      group, only 37.8% had diabetes (p≤0.001). Overall, 46.2% were overweight, 54.6% 
      were nonsmokers, and 82.4% underwent percutaneous coronary intervention. 
      CONCLUSIONS: The study participants in both the new and recurrent IHD groups 
      showed no sign of aspirin resistance. The presence of cardiovascular risk factors 
      increased the likelihood of episode recurrence.
FAU - Alsharidah, A S
AU  - Alsharidah AS
AD  - Department of Physiology, College of Medicine, Qassim University, Saudi Arabia, 
      Qassim, Buraidah. ashriedt@qu.edu.sa.
FAU - Alsuhaibani, D S
AU  - Alsuhaibani DS
FAU - Alsuhaibani, H A
AU  - Alsuhaibani HA
FAU - Alsharidah, M S
AU  - Alsharidah MS
FAU - Hafez Abdel-Moneim, A-M
AU  - Hafez Abdel-Moneim AM
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets
MH  - Drug Resistance
MH  - Humans
MH  - Middle Aged
MH  - *Myocardial Ischemia/drug therapy/epidemiology
MH  - Platelet Aggregation
MH  - *Platelet Aggregation Inhibitors/pharmacology
MH  - Saudi Arabia/epidemiology
EDAT- 2022/04/02 06:00
MHDA- 2022/04/08 06:00
CRDT- 2022/04/01 12:22
PHST- 2022/04/01 12:22 [entrez]
PHST- 2022/04/02 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
AID - 28358 [pii]
AID - 10.26355/eurrev_202203_28358 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2022 Mar;26(6):2106-2116. doi: 
      10.26355/eurrev_202203_28358.

PMID- 29681616
OWN - NLM
STAT- MEDLINE
DCOM- 20190610
LR  - 20190613
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 118
IP  - 9
DP  - 2018 May
TI  - Progress in preventive therapy for cancer: a reminiscence and personal viewpoint.
PG  - 1155-1161
LID - 10.1038/s41416-018-0039-4 [doi]
AB  - Prophylactic drug treatment with aspirin, statins and anti-hypertensive agents 
      has had a major impact on the incidence of cardiovascular disease and is now well 
      established. Progress in therapeutic cancer prevention has been much slower; only 
      recently have effective agents been clearly established. Breast cancer has led 
      the way and endocrine agents used to treat it-notably tamoxifen and the aromatase 
      inhibitors-have now been shown to have a substantial preventive effect as well. 
      However, these agents carry some toxicity and thus identifying high-risk women 
      who are likely to benefit most is a key priority. In contrast, the ability of 
      low-dose aspirin to prevent about one-third of colorectal, gastric, and 
      oesophageal cancers, combined with its much lower toxicity profile, make it 
      attractive for a much larger proportion of the general population. Vaccination 
      against the human papilloma virus is also a preventive intervention with large 
      benefits for the whole population. Here I recall my involvement in these 
      initiatives and offer a personal viewpoint on what has been achieved and what 
      remains to be done.
FAU - Cuzick, Jack
AU  - Cuzick J
AD  - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen 
      Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. 
      j.cuzick@qmul.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Personal Narrative
PT  - Review
DEP - 20180423
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Papillomavirus Vaccines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents, Hormonal/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects
MH  - Breast Neoplasms/drug therapy/mortality
MH  - Cancer Vaccines/therapeutic use
MH  - Clinical Trials as Topic/statistics & numerical data
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Neoplasms/drug therapy/mortality/*prevention & control
MH  - Papillomavirus Vaccines/therapeutic use
MH  - Primary Prevention/methods/*trends
PMC - PMC5943239
COIS- The author’s institution has received funding or material without cost for 
      research studies from AstraZeneca, Aventis Pharma, Myriad Genetics, Bayer, 
      Qiagen, Beckton Dickinson, Hologic, Abbott, Genera Biosystems, Roche, Trovagene 
      and Cepheid. J.C. has received honoraria or consulting fees from AstraZeneca, 
      Myriad Genetics, Bayer, Roche, Qiagen, Becton Dickinson, Roche, Trovagene, Merck, 
      Atossa Genetics and Cancer Prevention Pharmaceuticals.
EDAT- 2018/04/24 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/04/24 06:00
PHST- 2017/11/14 00:00 [received]
PHST- 2018/01/26 00:00 [accepted]
PHST- 2017/11/14 00:00 [revised]
PHST- 2018/04/24 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2018/04/24 06:00 [entrez]
AID - 10.1038/s41416-018-0039-4 [pii]
AID - 39 [pii]
AID - 10.1038/s41416-018-0039-4 [doi]
PST - ppublish
SO  - Br J Cancer. 2018 May;118(9):1155-1161. doi: 10.1038/s41416-018-0039-4. Epub 2018 
      Apr 23.

PMID- 26369684
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 21
IP  - 35
DP  - 2015
TI  - Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin 
      Users.
PG  - 5082-8
AB  - Low-dose aspirin (LDA) has been increasingly used worldwide to prevent 
      atherothrombotic events. At the same time, the adverse events, most frequent of 
      which are gastrointestinal (GI) ulcers and complications have been raising a big 
      concern with its wider use. These adverse events including reflux and dyspeptic 
      symptoms not only jeopardize adherence of LDA, but my cause more serious 
      outcomes. To reduce GI events by informing best evidence for physicians 
      prescribing LDA, guidelines were published some years ago. Since then, more 
      clinical evidence concerning preventive strategies for upper GI events has been 
      accumulated. Notable differences between East and West are also recognized in 
      terms of primary prevention strategy. Among several options to provide 
      cardiovascular protection with LDA while reducing GI risk, PPI co-therapy is 
      considered to be preferred approach for wider populations according to recent 
      cost-effectiveness analyses based on increasing awareness of importance on 
      adherence of LDA together with declining cost of PPI. This review will focus on 
      these new developments on the prevention of upper gastrointestinal ulcer and 
      complications in LDA users.
FAU - Sugano, Kentaro
AU  - Sugano K
AD  - Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, 
      Tochigi, 329- 0498, Japan. sugano@jichi.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Hemorrhage/*chemically induced/prevention & control
MH  - Humans
MH  - Peptic Ulcer/*chemically induced/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Practice Guidelines as Topic
MH  - Proton Pump Inhibitors/administration & dosage/therapeutic use
EDAT- 2015/09/16 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/06/19 00:00 [received]
PHST- 2015/09/14 00:00 [accepted]
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - CPD-EPUB-70383 [pii]
AID - 10.2174/1381612821666150915105834 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2015;21(35):5082-8. doi: 10.2174/1381612821666150915105834.

PMID- 7905660
OWN - NLM
STAT- MEDLINE
DCOM- 19940307
LR  - 20190814
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 28
IP  - 12
DP  - 1993 Dec
TI  - Effects of ebrotidine on aspirin-induced gastric mucosal damage and blood flow in 
      humans.
PG  - 1047-50
AB  - Nonsteroidal anti-inflammatory agents (NSAIDs) such as aspirin (ASA) damage the 
      gastric mucosa both in normal subjects and in arthritic patients. The aim of this 
      study was to investigate the protective action of a new H2-receptor antagonist, 
      ebrotidine, in the prevention of ASA-induced acute mucosal injury in the stomach 
      of healthy volunteers. In a double-blind randomized crossover study 10 male 
      volunteers received treatment with either placebo plus ASA (500 mg) or ebrotidine 
      (800 mg) plus ASA twice daily for 3 days with 10 days' washout period between 
      treatments. The mean number of gastric erosions seen at endoscopy after treatment 
      with ebrotidine plus ASA (2.0 +/- 0.3) was significantly lower than that after 
      placebo plus ASA (3.7 +/- 0.2). This reduction in lesion core by ebrotidine was 
      accompanied by a significant increase in gastric blood flow (by 15% in corpus and 
      26% in antrum), by a rise in transmucosal potential difference (by 12%), and by a 
      decrease of mucosal microbleeding. Ebrotidine afforded substantial protection 
      from ASA-induced injury to the gastric mucosa, and this was accompanied by 
      increase of the mucosal blood flow. We conclude that ebrotidine provides mucosal 
      protection for patients taking NSAIDs.
FAU - Konturek, S J
AU  - Konturek SJ
AD  - Institute of Physiology, Academy of Medicine, Cracow, Poland.
FAU - Kwiecien, N
AU  - Kwiecien N
FAU - Sito, E
AU  - Sito E
FAU - Obtulowicz, W
AU  - Obtulowicz W
FAU - Kaminski, K
AU  - Kaminski K
FAU - Oleksy, J
AU  - Oleksy J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzenesulfonates)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Thiazoles)
RN  - R16CO5Y76E (Aspirin)
RN  - TMZ3IBW2OW (ebrotidine)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Anti-Ulcer Agents/*pharmacology
MH  - Aspirin/adverse effects/*antagonists & inhibitors
MH  - Benzenesulfonates/*pharmacology
MH  - Blood Flow Velocity/drug effects
MH  - Double-Blind Method
MH  - Gastric Mucosa/blood supply/*drug effects/pathology
MH  - Histamine H2 Antagonists/*pharmacology
MH  - Humans
MH  - Male
MH  - Reference Values
MH  - Thiazoles/*pharmacology
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
AID - 10.3109/00365529309098307 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 1993 Dec;28(12):1047-50. doi: 10.3109/00365529309098307.

PMID- 22363809
OWN - NLM
STAT- MEDLINE
DCOM- 20120629
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 7
IP  - 2
DP  - 2012
TI  - Monocyte gene expression signature of patients with early onset coronary artery 
      disease.
PG  - e32166
LID - 10.1371/journal.pone.0032166 [doi]
LID - e32166
AB  - The burden of cardiovascular disease (CVD) cannot be fully addressed by therapy 
      targeting known pathophysiological pathways. Even with stringent control of all 
      risk factors CVD events are only diminished by half. A number of additional 
      pathways probably play a role in the development of CVD and might serve as novel 
      therapeutic targets. Genome wide expression studies represent a powerful tool to 
      identify such novel pathways. We compared the expression profiles in monocytes 
      from twenty two young male patients with premature familial CAD with those from 
      controls matched for age, sex and smoking status, without a family history of 
      CVD. Since all patients were on statins and aspirin treatment, potentially 
      affecting the expression of genes in monocytes, twelve controls were subsequently 
      treated with simvastatin and aspirin for 6 and 2 weeks, respectively. By whole 
      genome expression arrays six genes were identified to have differential 
      expression in the monocytes of patients versus controls; ABCA1, ABCG1 and RGS1 
      were downregulated in patients, whereas ADRB2, FOLR3 and GSTM1 were upregulated. 
      Differential expression of all genes, apart from GSTM1, was confirmed by qPCR. 
      Aspirin and statins altered gene expression of ABCG1 and ADBR2. All finding were 
      validated in a second group of twenty four patients and controls. Differential 
      expression of ABCA1, RSG1 and ADBR2 was replicated. In conclusion, we identified 
      these 3 genes to be expressed differently in CAD cases which might play a role in 
      the pathogenesis of atherosclerotic vascular disease.
FAU - Sivapalaratnam, Suthesh
AU  - Sivapalaratnam S
AD  - Department of Vascular Medicine, Academic Medical Center, Amsterdam, The 
      Netherlands. s.sivapalaratnam@amc.uva.nl
FAU - Basart, Hanneke
AU  - Basart H
FAU - Watkins, Nicholas A
AU  - Watkins NA
FAU - Maiwald, Stepanie
AU  - Maiwald S
FAU - Rendon, Augusto
AU  - Rendon A
FAU - Krishnan, Unni
AU  - Krishnan U
FAU - Sondermeijer, Brigitte M
AU  - Sondermeijer BM
FAU - Creemers, Esther E
AU  - Creemers EE
FAU - Pinto-Sietsma, Sara J
AU  - Pinto-Sietsma SJ
FAU - Hovingh, Kees
AU  - Hovingh K
FAU - Ouwehand, Willem H
AU  - Ouwehand WH
FAU - Kastelein, John J P
AU  - Kastelein JJ
FAU - Goodall, Alison H
AU  - Goodall AH
FAU - Trip, Mieke D
AU  - Trip MD
LA  - eng
GR  - RG/09/012/28096/BHF_/British Heart Foundation/United Kingdom
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120221
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/therapeutic use
MH  - Case-Control Studies
MH  - Coronary Artery Disease/drug therapy/*genetics/*pathology
MH  - *Gene Expression Profiling
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/therapeutic use
MH  - Male
MH  - Monocytes/drug effects/*metabolism
MH  - Polymerase Chain Reaction
MH  - Reproducibility of Results
PMC - PMC3283726
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2012/03/01 06:00
MHDA- 2012/06/30 06:00
CRDT- 2012/02/25 06:00
PHST- 2011/10/10 00:00 [received]
PHST- 2012/01/19 00:00 [accepted]
PHST- 2012/02/25 06:00 [entrez]
PHST- 2012/03/01 06:00 [pubmed]
PHST- 2012/06/30 06:00 [medline]
AID - PONE-D-11-19951 [pii]
AID - 10.1371/journal.pone.0032166 [doi]
PST - ppublish
SO  - PLoS One. 2012;7(2):e32166. doi: 10.1371/journal.pone.0032166. Epub 2012 Feb 21.

PMID- 10874542
OWN - NLM
STAT- MEDLINE
DCOM- 20001031
LR  - 20190915
IS  - 1044-3983 (Print)
IS  - 1044-3983 (Linking)
VI  - 11
IP  - 4
DP  - 2000 Jul
TI  - Reduced incidence of colorectal adenoma among long-term users of nonsteroidal 
      antiinflammatory drugs: a pooled analysis of published studies and a new 
      population-based study.
PG  - 376-81
AB  - Chronic treatment with nonsteroidal antiinflammatory drugs (NSAIDs) has been 
      associated with a reduced risk of colorectal cancer, but less information is 
      available on the relationship between NSAIDs and colorectal adenoma. We carried 
      out a population-based cohort study with nested case-control analysis to 
      determine the association between the use of aspirin and individual NSAIDs and 
      the risk of colorectal adenoma. The General Practice Research Database in the 
      United Kingdom was the source population. We followed 943,903 persons who were 
      40-79 years of age and free of colorectal adenoma or other cancer at baseline, 
      which varied between January 1994 and September 1997. There were 1,864 incident 
      cases of colorectal adenoma, for an incidence rate of 6.8 per 10,000 
      person-years. Compared with non-users, long-term users (1 year and more) of 
      nonaspirin NSAIDs had a 40% decreased risk of colorectal adenoma (relative risk = 
      0.6; 95% confidence interval = 0.4-0.9). Long-term NSAID use was still associated 
      with a reduced risk 1 year after stopping NSAID treatment. Use of most individual 
      NSAIDs conferred a reduced risk. The risk of developing colorectal adenoma was 
      reduced in long-term users of aspirin at doses of 300 mg daily (relative risk = 
      0.6; 95% confidence interval = 0.4-1.0), but reduced risk was not evident with 
      daily doses of 75 and 150 mg aspirin. These results add further support to the 
      value of NSAIDs as a candidate for primary prevention of colorectal tumors.
FAU - García Rodríguez, L A
AU  - García Rodríguez LA
AD  - Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain.
FAU - Huerta-Alvarez, C
AU  - Huerta-Alvarez C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Epidemiology
JT  - Epidemiology (Cambridge, Mass.)
JID - 9009644
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/*epidemiology/prevention & control
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Colorectal Neoplasms/*epidemiology/prevention & control
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
EDAT- 2000/06/30 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/06/30 11:00
PHST- 2000/06/30 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/06/30 11:00 [entrez]
AID - 10.1097/00001648-200007000-00003 [doi]
PST - ppublish
SO  - Epidemiology. 2000 Jul;11(4):376-81. doi: 10.1097/00001648-200007000-00003.

PMID- 29781078
OWN - NLM
STAT- MEDLINE
DCOM- 20180725
LR  - 20180725
IS  - 0017-0011 (Print)
IS  - 0017-0011 (Linking)
VI  - 89
IP  - 4
DP  - 2018
TI  - Prediction of preeclampsia developing at term.
PG  - 217-20
LID - 10.5603/GP.a2018.0037 [doi]
AB  - Preterm preeclampsia (PE), occurring at < 37 weeks' gestation, can be predicted 
      from as early as 11-13 weeks and prevented with the use of aspirin. In contrast, 
      term PE, which is more common than preterm-PE and it can be associated with 
      important maternal morbidity and mortality, cannot be effectively predicted at 
      11-13 weeks and cannot be prevented by the prophy-lactic use of aspirin. This 
      paper briefly reviews the pathogenesis of term PE and discusses strategies 
      available for its prediction.
FAU - Huluta, Iulia
AU  - Huluta I
FAU - Panaitescu, Anca Maria
AU  - Panaitescu AM
AD  - "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; 
      Filantropia Clinical Hospital, Bucharest, Bld Ion Mihalache nr 11, Romania. 
      panaitescu.anca@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Poland
TA  - Ginekol Pol
JT  - Ginekologia polska
JID - 0374641
RN  - 0 (Biomarkers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Biomarkers/*blood
MH  - *Early Diagnosis
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*diagnosis/*drug therapy
MH  - Predictive Value of Tests
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Pregnancy Trimester, Third
MH  - Young Adult
OTO - NOTNLM
OT  - PLGF
OT  - SFLT-1
OT  - aspirin
OT  - pravastatin
OT  - preeclampsia
EDAT- 2018/05/22 06:00
MHDA- 2018/07/26 06:00
CRDT- 2018/05/22 06:00
PHST- 2017/12/26 00:00 [received]
PHST- 2018/03/16 00:00 [accepted]
PHST- 2018/02/04 00:00 [revised]
PHST- 2018/05/22 06:00 [entrez]
PHST- 2018/05/22 06:00 [pubmed]
PHST- 2018/07/26 06:00 [medline]
AID - VM/OJS/J/56668 [pii]
AID - 10.5603/GP.a2018.0037 [doi]
PST - ppublish
SO  - Ginekol Pol. 2018;89(4):217-20. doi: 10.5603/GP.a2018.0037.

PMID- 2190651
OWN - NLM
STAT- MEDLINE
DCOM- 19900713
LR  - 20190903
IS  - 0006-5242 (Print)
IS  - 0006-5242 (Linking)
VI  - 60
IP  - 5
DP  - 1990 May
TI  - Current concepts for a drug-induced inhibition of formation and action of 
      thromboxane A2.
PG  - 261-8
AB  - Urinary and plasma metabolites of thromboxane A2 (TxA2) indicate an increased 
      TxA2 synthesis in a number of diseases, whereby TxA2 is assumed to contribute to 
      the underlying pathomechanisms by its profound effects on platelet aggregation 
      and smooth muscle contraction. In some clinical situations the increment in TxA2 
      biosynthesis is accompanied by an increased formation of prostacyclin (PGI2) 
      which is one of the most potent inhibitors of platelet activation and smooth 
      muscle contraction. Therefore, drugs are being developed which suppress the 
      formation or action of TxA2 without interfering with its functional antagonist 
      PGI2. Low doses of acetylsalicyclic acid (ASA) preferentially inhibit 
      cyclooxygenase activity in platelets and the synthesis of TxA2 in vivo. However, 
      neither low doses (approximately 300 mg/day) nor very low doses spare the 
      formation of PGI2 completely. Despite its limited selectivity, very low dose ASA 
      (approximately 40 mg/day) provides an attractive perspective in TxA2 
      pharmacology. Although thromboxane synthase inhibitors selectively suppress TxA2 
      biosynthesis PGH2 can accumulate instead of TxA2 and substitute for TxA2 at their 
      common TxA2/PGH2 receptors. Thromboxane synthase inhibitors can only exert 
      platelet-inhibiting and vasodilating effects if PGH2 rapidly isomerizes to 
      functional antagonists like PGI2 that can be formed from platelet-derived PGH2 by 
      the vessel wall. TxA2/PGH2 receptor antagonists provide a specific and effective 
      approach for inhibition of TxA2. These inhibitors do not interfere with the 
      synthesis of PGI2 and other prostanoids but prevent TxA2 and PGH2 from activating 
      platelets and inducing smooth muscle contractions. Most of the available 
      TxA2/PGH2 receptor antagonists produce a competitive antagonism that can be 
      overcome by high agonist concentrations. Since in certain disease states very 
      high local TxA2 concentrations are to be antagonized, non-competitive receptor 
      antagonists may be of particular interest. Some recent TxA2/PGH2 receptor 
      antagonists produce such a non-competitive type of inhibition due to their low 
      dissociation rate constant. As a consequence, agonists like TxA2 or PGH2 only 
      reach a hemiequilibrium state at their receptors, previously occupied by those 
      antagonists. A combination of a thromboxane synthase inhibitor with a TxA2/PGH2 
      receptor antagonist presents a very high inhibitory potential that utilizes the 
      dual activities of the synthase inhibitor to increase PGI2 formation and of the 
      receptor antagonist to antagonize PGH2 and TxA2. Such combinations or dual 
      inhibitors, combining both moieties in one compound, prolong the skin bleeding 
      time to a greater extent than thromboxane synthase inhibitors and even more than 
      low dose ASA or TxA2/PGH2 receptor antagonists.
FAU - Patscheke, H
AU  - Patscheke H
AD  - Institute for Clinical Chemistry, Klinikum Mannheim, University of Heidelberg, 
      Federal Republic of Germany.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Blut
JT  - Blut
JID - 0173401
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Humans
MH  - Thromboxane A2/antagonists & inhibitors/*physiology
RF  - 116
EDAT- 1990/05/01 00:00
MHDA- 1990/05/01 00:01
CRDT- 1990/05/01 00:00
PHST- 1990/05/01 00:00 [pubmed]
PHST- 1990/05/01 00:01 [medline]
PHST- 1990/05/01 00:00 [entrez]
AID - 10.1007/BF01736225 [doi]
PST - ppublish
SO  - Blut. 1990 May;60(5):261-8. doi: 10.1007/BF01736225.

PMID- 2521745
OWN - NLM
STAT- MEDLINE
DCOM- 19890323
LR  - 20131121
IS  - 0033-8419 (Print)
IS  - 0033-8419 (Linking)
VI  - 170
IP  - 3 Pt 2
DP  - 1989 Mar
TI  - Noncoronary angioplasty.
PG  - 921-40
AB  - PTA is an established method of revascularization in a variety of medical 
      conditions. It is performed for specific morphologic and clinical indications. 
      PTA is the procedure of choice in Fontaine stage IIB through IV lower extremity 
      ischemia due to iliac and/or femoropopliteal stenosis or short occlusion. Its 
      role is less certain in infrapopliteal disease, although current studies have 
      begun to establish long-term effectiveness. PTA is the procedure of choice for 
      renal revascularization in renovascular hypertension due to fibromuscular disease 
      or non-ostial atherosclerosis, selected cases of renal artery stenosis associated 
      with renal insufficiency, and transplant renal artery stenosis. It is also useful 
      in treating the renovascular component of complex hypertension and may be 
      indicated in severe renal artery stenosis (75%-99%), even in the absence of 
      clinically demonstrable RVHTN. PTA has limited applications in the venous system 
      and only short-term success in the treatment of stenoses in dialysis access 
      fistulas. PTA often serves as an important adjunct to surgical revascularization 
      by providing improved inflow or outflow. PTA is the procedure of choice when 
      anatomically feasible in subclavian steal syndrome. The role of PTA in carotid 
      artery disease, particularly atheromatous disease of the internal carotid artery, 
      is uncertain. The same may be said of PTA for vertebral artery stenosis, although 
      the overwhelming majority of vertebral artery stenoses are morphologically 
      suitable for PTA. PTA and surgery are both effective in the treatment of 
      abdominal angina. There are more data available to verify the long-term patency 
      of thromboendarterectomy and bypass grafts than PTA for mesenteric ischemia. 
      However, since the technical success for PTA is high and since coronary 
      co-morbidity is the most common cause of perioperative mortality in surgical 
      series, PTA should be seriously considered as the procedure of first choice. 
      Serious complications of PTA occur in approximately 5% of cases. Two to three 
      percent of PTA patients have complications requiring surgery or causing a 
      prolongation or alteration of hospital course. The morbidity, mortality, and cost 
      associated with PTA are low. The discomfort is minor, and postprocedural recovery 
      rapid. The major limitations of PTA include its unsuitability for some lesions 
      (long-segment occlusions and stenoses, orifice lesions, eccentric lesions) and 
      postangioplasty restenosis. These problems are being addressed by ongoing 
      laboratory and clinical research. In the near future, it is likely that 
      endoluminal transmural sonography of the vessel wall will help guide our 
      interventions.
FAU - Becker, G J
AU  - Becker GJ
AD  - Department of Radiology, Indiana University School of Medicine, Indianapolis 
      46223.
FAU - Katzen, B T
AU  - Katzen BT
FAU - Dake, M D
AU  - Dake MD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Radiology
JT  - Radiology
JID - 0401260
RN  - 9005-49-6 (Heparin)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon
MH  - Aspirin/therapeutic use
MH  - Constriction, Pathologic/therapy
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Nifedipine/therapeutic use
MH  - Nitroglycerin/therapeutic use
MH  - Vascular Diseases/*therapy
RF  - 304
EDAT- 1989/03/01 00:00
MHDA- 1989/03/01 00:01
CRDT- 1989/03/01 00:00
PHST- 1989/03/01 00:00 [pubmed]
PHST- 1989/03/01 00:01 [medline]
PHST- 1989/03/01 00:00 [entrez]
AID - 10.1148/radiology.170.3.2521745 [doi]
PST - ppublish
SO  - Radiology. 1989 Mar;170(3 Pt 2):921-40. doi: 10.1148/radiology.170.3.2521745.

PMID- 26883867
OWN - NLM
STAT- MEDLINE
DCOM- 20160725
LR  - 20190221
IS  - 1432-1203 (Electronic)
IS  - 0340-6717 (Linking)
VI  - 135
IP  - 4
DP  - 2016 Apr
TI  - New molecular insights into modulation of platelet reactivity in aspirin-treated 
      patients using a network-based approach.
PG  - 403-414
LID - 10.1007/s00439-016-1642-1 [doi]
AB  - Platelet reactivity (PR) is variable between individuals and modulates clinical 
      outcome in cardiovascular (CV) patients treated with antiplatelet drugs. Although 
      several data point to a genetic control of platelet reactivity, the genes 
      contributing to the modulation of this phenotype are not clearly identified. 
      Integration of data derived from high-throughput technologies may yield novel 
      insights into the molecular mechanisms that govern platelet reactivity. The aim 
      of this study is to identify candidate genes modulating platelet reactivity in 
      aspirin-treated CV patients using an integrative network-based approach. Patients 
      with extreme high (n = 6) or low PR (n = 6) were selected and data derived from 
      quantitative proteomic of platelets and platelet sub-cellular fractions, as well 
      as from transcriptomic analysis were integrated with a network biology approach. 
      Two modules within the network containing 123 and 182 genes were identified. We 
      then specifically assessed the level of miRNAs in these two groups of patients. 
      Among the 12 miRNAs differentially expressed, 2 (miR-135a-5p and miR-204-5p) 
      correlated with PR. The predicted targets of these miRNAs were mapped onto the 
      network, allowing the identification of seven overlapping genes (THBS1, CDC42, 
      CORO1C, SPTBN1, TPM3, GTPBP2, and MAPRE2), suggesting a synergistic effect of 
      these two miRNAs on these predicted targets. Integration of several omics data 
      sets allowed the identification of 2 candidate miRNAs and 7 candidate genes 
      regulating platelet reactivity in aspirin-treated CV patients.
FAU - Zufferey, Anne
AU  - Zufferey A
AD  - Division of Angiology and Haemostasis, University Hospitals of Geneva, Rue 
      Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.
AD  - Translational Biomarker Group, Human Protein Sciences Department, University of 
      Geneva, Geneva, Switzerland.
AD  - Geneva Platelet Group, University of Geneva, Geneva, Switzerland.
FAU - Ibberson, Mark
AU  - Ibberson M
AD  - Vital-IT Group, SIB Swiss Institute of Bioinformatics, University of Lausanne, 
      Lausanne, Switzerland.
FAU - Reny, Jean-Luc
AU  - Reny JL
AD  - Geneva Platelet Group, University of Geneva, Geneva, Switzerland.
AD  - Division of Internal Medicine, and Rehabilitation, Trois-Chêne Hospital, 
      University Hospitals of Geneva, Geneva, Switzerland.
FAU - Nolli, Séverine
AU  - Nolli S
AD  - Division of Angiology and Haemostasis, University Hospitals of Geneva, Rue 
      Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.
AD  - Geneva Platelet Group, University of Geneva, Geneva, Switzerland.
FAU - Schvartz, Domitille
AU  - Schvartz D
AD  - Translational Biomarker Group, Human Protein Sciences Department, University of 
      Geneva, Geneva, Switzerland.
FAU - Docquier, Mylène
AU  - Docquier M
AD  - iGE3 Genomics Platform, University of Geneva, Geneva, Switzerland.
FAU - Xenarios, Ioannis
AU  - Xenarios I
AD  - Vital-IT Group, SIB Swiss Institute of Bioinformatics, University of Lausanne, 
      Lausanne, Switzerland.
AD  - Swiss-Prot Group, SIB Swiss Institute of Bioinformatics, Geneva, Switzerland.
FAU - Sanchez, Jean-Charles
AU  - Sanchez JC
AD  - Translational Biomarker Group, Human Protein Sciences Department, University of 
      Geneva, Geneva, Switzerland.
FAU - Fontana, Pierre
AU  - Fontana P
AUID- ORCID: 0000-0003-1546-0774
AD  - Division of Angiology and Haemostasis, University Hospitals of Geneva, Rue 
      Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. pierre.fontana@hcuge.ch.
AD  - Geneva Platelet Group, University of Geneva, Geneva, Switzerland. 
      pierre.fontana@hcuge.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160216
PL  - Germany
TA  - Hum Genet
JT  - Human genetics
JID - 7613873
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Messenger)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Humans
MH  - MicroRNAs/genetics
MH  - Proteomics
MH  - RNA, Messenger/genetics
EDAT- 2016/02/18 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/02/18 06:00
PHST- 2015/10/30 00:00 [received]
PHST- 2016/01/23 00:00 [accepted]
PHST- 2016/02/18 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - 10.1007/s00439-016-1642-1 [pii]
AID - 10.1007/s00439-016-1642-1 [doi]
PST - ppublish
SO  - Hum Genet. 2016 Apr;135(4):403-414. doi: 10.1007/s00439-016-1642-1. Epub 2016 Feb 
      16.

PMID- 2402740
OWN - NLM
STAT- MEDLINE
DCOM- 19901019
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 63
IP  - 3
DP  - 1990 Jun 28
TI  - Non-occlusive bleeding times may improve the value of Ivy bleeding times.
PG  - 371-4
AB  - The present studies measured bleeding times, without venous occlusion, in a 
      series of patients, whose bleeding times (+ venostasis) consistently exceeded 20 
      min. During these tests, the amount of blood loss (expressed as mg/min) was also 
      quantitated. To allow comparison, normal controls were studied before and 
      following aspirin ingestion. In normal controls, the mean standard Ivy bleeding 
      time was 5.0 with a range of 2.5 to 7.5 min. Two hours after aspirin (650 mg), 
      this increased to 7.3 min (range 4.0-12.0). For comparison, the non-occlusive 
      bleeding time averaged 3.8 min (1.0-6.5) and after aspirin 5.3 min (2.5-11.5). 
      The measured amount of blood loss was 5.0 mg/min (0-10.5 mg/min) under all of the 
      above conditions. At the other extreme, patients with severe bone marrow failure 
      had occluded and non-occluded bleeding times in excess of 20 min. Moreover, these 
      were often associated with excess blood loss. By contrast, patients with "Ivy" 
      values greater than 20 min in association with platelet counts greater than 
      10,000/microliters had unpredictable bleeding parameters. In the latter group, 
      the non-occluded values ranged from 1 to greater than 20 min. Of particular note, 
      the non-occlusive times appeared to correlate with spontaneous bleeding 
      manifestations. Only a rare patient (1/37), whose non-occluded value was less 
      than 20 min, had worrisome bleeding. By contrast, serious bleeding manifestations 
      were observed in 39% whose non-occluded value exceeded 20 min. This was even 
      higher (64%) in those with a non-occluded value greater than 20 min and excess 
      blood loss.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Zeigler, Z R
AU  - Zeigler ZR
AD  - Department of Medicine, Montefiore Hospital, University of Pittsburgh School of 
      Medicine, PA 15213.
LA  - eng
GR  - 1 RO1 HL 35069-01/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arm/blood supply
MH  - Aspirin/pharmacology
MH  - *Bleeding Time
MH  - Bone Marrow Diseases/blood
MH  - Constriction
MH  - Female
MH  - Humans
MH  - Male
MH  - Methods
MH  - Platelet Count
MH  - *Platelet Function Tests
EDAT- 1990/06/28 00:00
MHDA- 1990/06/28 00:01
CRDT- 1990/06/28 00:00
PHST- 1990/06/28 00:00 [pubmed]
PHST- 1990/06/28 00:01 [medline]
PHST- 1990/06/28 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1990 Jun 28;63(3):371-4.

PMID- 7361900
OWN - NLM
STAT- MEDLINE
DCOM- 19800514
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 238
IP  - 2
DP  - 1980 Feb
TI  - Intravenous indomethacin and aspirin reduce basal gastric mucosal blood flow in 
      dogs.
PG  - G131-4
AB  - The effect of two known inhibitors of prostaglandin synthesis, indomethacin and 
      aspirin, on blood flow was studied in six Heidenhain pouch and three antral pouch 
      dogs. The unstimulated gastric mucosa was bathed with 0.15 M HCl and clearance of 
      [14C]-aminopyrine was used as an index of changes in mucosal blood flow. 
      [14C]aminopyrine clearance was measured during three 15-min predrug periods and 
      five 15 min-postdrug periods. Either indomethacin (10 mg . kg-1), aspirin (100 mg 
      . kg-1), or 0.15 M NaCl were given intravenously as a bolus. Indomethacin reduced 
      mucosal blood flow in the Heidenhain pouch 52% (P less than 0.05) and in the 
      antral pouch 52% (P less than 0.05). Aspirin reduced Heidenhain pouch mucosal 
      blood flow 31% (P less than 0.05). Indomethacin caused no significant change in 
      electrical potential difference or in net flux of H+ or Na+ in Heidenhain 
      pouches. Indomethacin (10 mg . kg-1 iv) produced no change in mean arterial 
      pressure. We conclude that indomethacin and aspirin reduce unstimulated gastric 
      mucosal blood flow, suggesting that endogenous prostaglandin may contribute to 
      its maintenance.
FAU - Kauffman, G L Jr
AU  - Kauffman GL Jr
FAU - Aures, D
AU  - Aures D
FAU - Grossman, M I
AU  - Grossman MI
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dogs
MH  - Gastric Mucosa/*blood supply
MH  - Indomethacin/*pharmacology
MH  - Regional Blood Flow/drug effects
MH  - Stomach/blood supply
MH  - Wakefulness/physiology
EDAT- 1980/02/11 19:15
MHDA- 1980/02/11 19:16
CRDT- 1980/02/11 19:15
PHST- 1980/02/11 19:15 [pubmed]
PHST- 1980/02/11 19:16 [medline]
PHST- 1980/02/11 19:15 [entrez]
AID - 10.1152/ajpgi.1980.238.2.G131 [doi]
PST - ppublish
SO  - Am J Physiol. 1980 Feb;238(2):G131-4. doi: 10.1152/ajpgi.1980.238.2.G131.

PMID- 3577806
OWN - NLM
STAT- MEDLINE
DCOM- 19870602
LR  - 20141120
IS  - 0326-6656 (Print)
IS  - 0326-6656 (Linking)
VI  - 36
IP  - 3
DP  - 1986
TI  - Non-enzymatic acetylation of proteins by aspirin as protection against the 
      secondary complications of diabetes mellitus.
PG  - 313-6
AB  - The non-enzymic glycosylation of proteins has been implicated as a contributing 
      pathogenia in the secondary complications of diabetes mellitus. The reversible 
      acetylation of proteins by aspirin could slow down the advance of the biochemical 
      lesion in well-controlled patients. The rate of acetylation of albumin by aspirin 
      at 37 degrees C and pH = 7.30 was found to proceed two orders of magnitude faster 
      than the glycosylation, providing a basis for therapeutic possibilities for the 
      complications of diabetes mellitus.
FAU - Hun-Opfer, C
AU  - Hun-Opfer C
FAU - Mata-Segreda, J F
AU  - Mata-Segreda JF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Argentina
TA  - Acta Physiol Pharmacol Latinoam
JT  - Acta physiologica et pharmacologica latinoamericana : organo de la Asociacion 
      Latinoamericana de Ciencias Fisiologicas y de la Asociacion Latinoamericana de 
      Farmacologia
JID - 8409686
RN  - 0 (Serum Albumin)
RN  - 9006-59-1 (Ovalbumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/*pharmacology
MH  - Diabetes Complications
MH  - Diabetes Mellitus/*metabolism
MH  - Glycosylation
MH  - Humans
MH  - In Vitro Techniques
MH  - Ovalbumin/*metabolism
MH  - Serum Albumin/*metabolism
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Physiol Pharmacol Latinoam. 1986;36(3):313-6.

PMID- 27296110
OWN - NLM
STAT- MEDLINE
DCOM- 20170119
LR  - 20181113
IS  - 1746-6148 (Electronic)
IS  - 1746-6148 (Linking)
VI  - 12
IP  - 1
DP  - 2016 Jun 14
TI  - Evaluation on antithrombotic effect of aspirin eugenol ester from the view of 
      platelet aggregation, hemorheology, TXB2/6-keto-PGF1α and blood biochemistry in 
      rat model.
PG  - 108
LID - 10.1186/s12917-016-0738-0 [doi]
LID - 108
AB  - BACKGROUND: Based on the prodrug principle, aspirin and eugenol, as starting 
      precursors, were esterified to synthesize aspirin eugenol ester (AEE). The aim of 
      the present study was to evaluate the antithrombotic effect of AEE in an animal 
      disease model. In order to compare the therapeutic effects of AEE and its 
      precursors, aspirin, eugenol and a combination of aspirin and eugenol were 
      designed at the same molar quantities as the AEE medium dose in the control 
      group. METHODS: After oral administration of AEE (dosed at 18, 36 and 72 mg/kg) 
      for seven days, rats were treated with k-carrageenan to induce tail thrombosis. 
      Following the same method, aspirin (20 mg/kg), eugenol (18 mg/kg) and 0.5 % 
      CMC-Na (30 mg/kg) were administered as control drug. Different drug effects on 
      platelet aggregation, hemorheology, TXB2/6-keto-PGF1α ratio and blood 
      biochemistry were studied. RESULTS: AEE significantly inhibited ADP and 
      AA-induced platelet aggregation in vivo. AEE also significantly reduced blood and 
      plasma viscosity. Moreover, AEE down-regulated TXB2 and up-regulated 
      6-keto-PGF1α, normalizing the TXB2/6-keto-PGF1α ratio and blood biochemical 
      profile. In comparison with aspirin and eugenol, AEE produced more positive 
      therapeutic effects than its precursors under the same molar quantity. 
      CONCLUSION: It may be concluded that AEE was a good candidate for new 
      antithrombotic and antiplatelet medicine. Additionally, this study may help to 
      understand how AEE works on antithrombosis in different ways.
FAU - Ma, Ning
AU  - Ma N
AD  - Key Lab of New Animal Drug Project, Gansu Province, Lanzhou, 730050, People's 
      Republic of China.
AD  - Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, 
      Lanzhou, 730050, People's Republic of China.
AD  - Lanzhou Institute of Husbandry and Pharmaceutical Science of CAAS, Lanzhou, 
      730050, People's Republic of China.
FAU - Liu, Xi-Wang
AU  - Liu XW
AD  - Key Lab of New Animal Drug Project, Gansu Province, Lanzhou, 730050, People's 
      Republic of China.
AD  - Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, 
      Lanzhou, 730050, People's Republic of China.
AD  - Lanzhou Institute of Husbandry and Pharmaceutical Science of CAAS, Lanzhou, 
      730050, People's Republic of China.
FAU - Yang, Ya-Jun
AU  - Yang YJ
AD  - Key Lab of New Animal Drug Project, Gansu Province, Lanzhou, 730050, People's 
      Republic of China.
AD  - Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, 
      Lanzhou, 730050, People's Republic of China.
AD  - Lanzhou Institute of Husbandry and Pharmaceutical Science of CAAS, Lanzhou, 
      730050, People's Republic of China.
FAU - Shen, Dong-Shuai
AU  - Shen DS
AD  - Key Lab of New Animal Drug Project, Gansu Province, Lanzhou, 730050, People's 
      Republic of China.
AD  - Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, 
      Lanzhou, 730050, People's Republic of China.
AD  - Lanzhou Institute of Husbandry and Pharmaceutical Science of CAAS, Lanzhou, 
      730050, People's Republic of China.
FAU - Zhao, Xiao-Le
AU  - Zhao XL
AD  - Key Lab of New Animal Drug Project, Gansu Province, Lanzhou, 730050, People's 
      Republic of China.
AD  - Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, 
      Lanzhou, 730050, People's Republic of China.
AD  - Lanzhou Institute of Husbandry and Pharmaceutical Science of CAAS, Lanzhou, 
      730050, People's Republic of China.
FAU - Mohamed, Isam
AU  - Mohamed I
AD  - Key Lab of New Animal Drug Project, Gansu Province, Lanzhou, 730050, People's 
      Republic of China.
AD  - Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, 
      Lanzhou, 730050, People's Republic of China.
AD  - Lanzhou Institute of Husbandry and Pharmaceutical Science of CAAS, Lanzhou, 
      730050, People's Republic of China.
FAU - Kong, Xiao-Jun
AU  - Kong XJ
AD  - Key Lab of New Animal Drug Project, Gansu Province, Lanzhou, 730050, People's 
      Republic of China.
AD  - Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, 
      Lanzhou, 730050, People's Republic of China.
AD  - Lanzhou Institute of Husbandry and Pharmaceutical Science of CAAS, Lanzhou, 
      730050, People's Republic of China.
FAU - Li, Jian-Yong
AU  - Li JY
AD  - Key Lab of New Animal Drug Project, Gansu Province, Lanzhou, 730050, People's 
      Republic of China. lijy1971@163.com.
AD  - Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, 
      Lanzhou, 730050, People's Republic of China. lijy1971@163.com.
AD  - Lanzhou Institute of Husbandry and Pharmaceutical Science of CAAS, Lanzhou, 
      730050, People's Republic of China. lijy1971@163.com.
AD  - No.335, Jiangouyan, Qilihe District, Lanzhou, 730050, China. lijy1971@163.com.
LA  - eng
PT  - Journal Article
DEP - 20160614
PL  - England
TA  - BMC Vet Res
JT  - BMC veterinary research
JID - 101249759
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/*blood
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Blood Chemical Analysis
MH  - Eugenol/administration & dosage/*analogs & derivatives/pharmacology
MH  - Fibrinolytic Agents/*pharmacology
MH  - Hemorheology/drug effects
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Thrombosis/blood/drug therapy
MH  - Thromboxane A2/*blood
PMC - PMC4907079
OTO - NOTNLM
OT  - Aspirin eugenol ester (AEE)
OT  - Blood viscosity
OT  - Platelet aggregation
OT  - Rat
OT  - Thrombosis
OT  - k-carrageenan
EDAT- 2016/06/15 06:00
MHDA- 2017/01/20 06:00
CRDT- 2016/06/15 06:00
PHST- 2016/02/01 00:00 [received]
PHST- 2016/06/07 00:00 [accepted]
PHST- 2016/06/15 06:00 [entrez]
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/01/20 06:00 [medline]
AID - 10.1186/s12917-016-0738-0 [pii]
AID - 738 [pii]
AID - 10.1186/s12917-016-0738-0 [doi]
PST - epublish
SO  - BMC Vet Res. 2016 Jun 14;12(1):108. doi: 10.1186/s12917-016-0738-0.

PMID- 31471666
OWN - NLM
STAT- MEDLINE
DCOM- 20230315
LR  - 20230315
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Print)
IS  - 1523-3782 (Linking)
VI  - 21
IP  - 10
DP  - 2019 Aug 30
TI  - Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of 
      Implementation Strategies and Management of Common Clinical Scenarios.
PG  - 115
LID - 10.1007/s11886-019-1198-5 [doi]
LID - 115
AB  - PURPOSE OF REVIEW: Peripheral artery disease (PAD) affects an estimated 200 
      million people worldwide and is associated with significant cardiovascular 
      morbidity and mortality. Cardiovascular risk is further increased among 
      individuals with polyvascular disease, where either cerebrovascular or coronary 
      artery disease is present in addition to PAD. In this review, we present common 
      clinical scenarios encountered when managing patients with PAD and provide an 
      evidence-based approach to prescribing optimal antithrombotics in this 
      population. RECENT FINDINGS: The COMPASS trial recently demonstrated that 
      rivaroxaban 2.5 mg BID + ASA daily significantly reduces major adverse cardiac 
      and limb events in patients with PAD. Despite these advances, morbidity following 
      MALE events remains high. With widespread approval by federal health regulators, 
      the COMPASS regimen should be strongly considered in PAD patients who do not have 
      a high bleeding risk. Implementing the COMPASS regimen in patients with PAD, 
      along with other vascular risk reduction strategies, will have a substantial 
      impact on reducing atherothromboembolic risk in patients with established 
      vascular disease.
FAU - McClure, Graham R
AU  - McClure GR
AD  - Division of Vascular Surgery, McMaster University, Hamilton, Ontario, Canada.
AD  - Department of Clinical Epidemiology and Biostatistics, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Kaplovitch, Eric
AU  - Kaplovitch E
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Narula, Sukrit
AU  - Narula S
AD  - Department of Clinical Epidemiology and Biostatistics, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Population Health Research Institute, 237 Barton St East, Hamilton, ON, L8L 2X2, 
      Canada.
FAU - Bhagirath, Vinai C
AU  - Bhagirath VC
AD  - Population Health Research Institute, 237 Barton St East, Hamilton, ON, L8L 2X2, 
      Canada.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Anand, Sonia S
AU  - Anand SS
AD  - Population Health Research Institute, 237 Barton St East, Hamilton, ON, L8L 2X2, 
      Canada. anands@mcmaster.ca.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 
      anands@mcmaster.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190830
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
SB  - IM
MH  - Humans
MH  - *Anticoagulants/therapeutic use
MH  - *Aspirin/administration & dosage/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Drug Therapy, Combination
MH  - *Factor Xa Inhibitors/administration & dosage/therapeutic use
MH  - Fibrinolytic Agents/therapeutic use
MH  - *Peripheral Arterial Disease/drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - *Rivaroxaban/administration & dosage/therapeutic use
MH  - Thrombolytic Therapy
PMC - PMC6717183
OTO - NOTNLM
OT  - Antithrombotics
OT  - Aspirin
OT  - Peripheral artery disease
OT  - Rivaroxaban
COIS- Graham R. McClure, Eric Kaplovitch, and Sukrit Narula declare that they have no 
      conflict of interest. Vinai C. Bhagirath reports grants and personal fees from 
      Pfizer, and personal fees from Bayer. Sonia S. Anand reports grants and personal 
      fees from Bayer.
EDAT- 2019/09/01 06:00
MHDA- 2020/04/17 06:00
CRDT- 2019/09/01 06:00
PHST- 2019/09/01 06:00 [entrez]
PHST- 2019/09/01 06:00 [pubmed]
PHST- 2020/04/17 06:00 [medline]
AID - 10.1007/s11886-019-1198-5 [pii]
AID - 1198 [pii]
AID - 10.1007/s11886-019-1198-5 [doi]
PST - epublish
SO  - Curr Cardiol Rep. 2019 Aug 30;21(10):115. doi: 10.1007/s11886-019-1198-5.

PMID- 34562772
OWN - NLM
STAT- MEDLINE
DCOM- 20220303
LR  - 20220303
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 209
DP  - 2021 Oct
TI  - Aspirin and growth, rupture of unruptured intracranial aneurysms: A systematic 
      review and meta-analysis.
PG  - 106949
LID - S0303-8467(21)00478-9 [pii]
LID - 10.1016/j.clineuro.2021.106949 [doi]
AB  - OBJECTIVES: Aspirin has been suggested as a potential therapeutic strategy to 
      prevent the growth and rupture of unruptured intracranial aneurysms (UIAs), but 
      there is still controversy. The aim of this systematic review and meta-analysis 
      is to determine the association between aspirin use and growth, rupture of UIAs. 
      METHODS: We performed a systematic literature search of electronic databases to 
      identify cohort and case-control studies investigating the relationship between 
      aspirin use and growth or rupture of UIAs. Pooled odds ratio (OR) with 
      corresponding 95% confidence interval (CI) were calculated using a random effects 
      model. Heterogeneity among studies was quantified using the I(2) statistic, and 
      potential publication bias was assessed using funnel plots. Sensitivity analysis 
      was performed to verify the robustness of the intention-to-treat results. 
      Subgroup analysis was conducted according to the frequency of aspirin use. 
      RESULTS: We identified 8 studies comprising 10,518 participants. The risk of bias 
      was low to moderate. The pooled estimate showed that aspirin use was associated 
      with a lower likelihood of growth of UIAs (OR = 0.25, 95% CI = 0.11-0.55; 
      p = 0.0005) without statistical heterogeneity (p for Cochran Q statistic = 0.62, 
      I(2) = 0%). Likewise, aspirin intake also significant decreased 58% risk of 
      intracranial aneurysms rupture (OR = 0.42, 95% CI = 0.29-0.60; p < 0.00001) with 
      moderate heterogeneity (p for Cochran Q statistic = 0.005, I(2) = 66%). Similar 
      results were observed in the sensitivity analysis. Pooled OR of aspirin frequency 
      subgroup analysis for less than or equal to 2 times per week was 0.82 (95%CI = 
      0.40-1.72; I(2) = 0%), for at least 3 times per week to daily was 0.25 (95%CI = 
      0.12-053; I(2) = 0%), for daily was 0.59 (95%CI: 0.47-0.74; I(2) = 0%), and for 
      unknown was 0.26 (95%CI: 0.15-0.45; I(2) = 51%). CONCLUSIONS: The results of this 
      systematic review and meta-analysis indicates a beneficial effect of aspirin on 
      growth and rupture of UIAs.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Guo, Yu
AU  - Guo Y
AD  - Graduate School, Qinghai University, Xining, Qinghai, China.
FAU - Guo, Xin-Mei
AU  - Guo XM
AD  - Biomedical Engineering Research Center, Kunming Medical University, Kunming, 
      Yunnan, China.
FAU - Zhao, Kai
AU  - Zhao K
AD  - Graduate School, Qinghai University, Xining, Qinghai, China.
FAU - Yang, Ming-Fei
AU  - Yang MF
AD  - Department of Neurosurgery, Qinghai Provincial People's Hospital, Xining, 
      Qinghai, China. Electronic address: iloveyoucmu@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20210917
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aneurysm, Ruptured/*prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Intracranial Aneurysm/*prevention & control
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Growth
OT  - Meta-analysis
OT  - Rupture
OT  - Unruptured intracranial aneurysms
EDAT- 2021/09/26 06:00
MHDA- 2022/03/04 06:00
CRDT- 2021/09/25 20:20
PHST- 2021/08/13 00:00 [received]
PHST- 2021/09/10 00:00 [revised]
PHST- 2021/09/13 00:00 [accepted]
PHST- 2021/09/26 06:00 [pubmed]
PHST- 2022/03/04 06:00 [medline]
PHST- 2021/09/25 20:20 [entrez]
AID - S0303-8467(21)00478-9 [pii]
AID - 10.1016/j.clineuro.2021.106949 [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 2021 Oct;209:106949. doi: 10.1016/j.clineuro.2021.106949. 
      Epub 2021 Sep 17.

PMID- 24508877
OWN - NLM
STAT- MEDLINE
DCOM- 20150204
LR  - 20140317
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 124
DP  - 2014 Apr 24
TI  - Selective spectrophotometric methods for determination of ternary mixture with 
      overlapping spectra: a comparative study.
PG  - 389-96
LID - S1386-1425(14)00040-7 [pii]
LID - 10.1016/j.saa.2014.01.020 [doi]
AB  - Comparable double divisor ratio spectra derivative, area under curve of 
      derivative ratio and mean centering of ratio spectra spectrophotometric methods 
      were introduced for determination of orphenadrine citrate (ORPH), caffeine (CAF) 
      and aspirin (ASP); a combination for symptomatic relief of mild to moderate pain 
      of acute musculoskeletal disorders; with evident accuracy and precision. The 
      suggested methods have the advantage over the previously published 
      spectrophotometric method for determination of the same combination in that they 
      did not require a preliminary separation step and able to resolve the ternary 
      mixture, with severe overlapping spectra, with competent sensitivity and 
      selectivity. The recommended methods allow the determination of ORPH, CAF and ASP 
      in the range of 2-32, 2-28 and 3-28 μg mL(-1), respectively. The validity of the 
      proposed methods was examined by analysis of different laboratory prepared 
      mixtures of ORPH, CAF and ASP and assay of their tablet formulation where 
      reliable results were obtained. Statistical analysis between the suggested 
      spectrophotometric methods and the reported HPLC method using student's-t and 
      F-ratio tests reveals that the suggested methods are as accurate and precise as 
      the reported one.
CI  - Copyright © 2014 Elsevier B.V. All rights reserved.
FAU - Abdelrahman, Maha M
AU  - Abdelrahman MM
AD  - Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Beni-Suef 
      University, Alshaheed Shehata Ahmad Hegazy St., 62514 Beni-Suef, Egypt. 
      Electronic address: maha.abdelrahman@pharm.bsu.edu.eg.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20140121
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 3G6A5W338E (Caffeine)
RN  - AL805O9OG9 (Orphenadrine)
RN  - R16CO5Y76E (Aspirin)
RN  - Y4S76JWI15 (Methanol)
SB  - IM
MH  - Area Under Curve
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Chemistry, Pharmaceutical
MH  - Kinetics
MH  - Methanol/chemistry
MH  - Orphenadrine/*analysis
MH  - Reference Standards
MH  - Spectrophotometry/*methods
OTO - NOTNLM
OT  - Area under curve
OT  - Aspirin
OT  - Caffeine
OT  - Double divisor
OT  - Mean centering
OT  - Orphenadrine citrate
EDAT- 2014/02/11 06:00
MHDA- 2015/02/05 06:00
CRDT- 2014/02/11 06:00
PHST- 2013/11/11 00:00 [received]
PHST- 2014/01/10 00:00 [revised]
PHST- 2014/01/12 00:00 [accepted]
PHST- 2014/02/11 06:00 [entrez]
PHST- 2014/02/11 06:00 [pubmed]
PHST- 2015/02/05 06:00 [medline]
AID - S1386-1425(14)00040-7 [pii]
AID - 10.1016/j.saa.2014.01.020 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2014 Apr 24;124:389-96. doi: 
      10.1016/j.saa.2014.01.020. Epub 2014 Jan 21.

PMID- 11129967
OWN - NLM
STAT- MEDLINE
DCOM- 20010322
LR  - 20131121
IS  - 0028-2162 (Print)
IS  - 0028-2162 (Linking)
VI  - 144
IP  - 49
DP  - 2000 Dec 2
TI  - [Acetylsalicylic acid versus coumarin derivatives in atrial fibrillation].
PG  - 2336-40
AB  - Atrial fibrillation is a chronic disorder, which significantly increases the risk 
      of stroke. The risk of stroke largely depends on cardiac failure, age, sex, the 
      presence of hypertension and a history of previousthromboembolism. In low risk 
      patients with atrial fibrillation stroke can effectively be prevented with 
      acetylsalicylic acid (100-200 mg/day). With increasing stroke risk coumarin 
      derivatives are more effective than acetylsalicylic acid and its use has an 
      acceptable bleeding risk. The target international normalized ratio (INR) should 
      be between 2.0 and 3.0.
FAU - Verheugt, F W
AU  - Verheugt FW
AD  - Universitair Medisch Centrum St. Radboud, Hartcentrum, afd. Cardiologie, Postbus 
      9101, 6500 HB Nijmegen. f.verheugt@cardio.azn.nl
LA  - dut
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Acetylsalicylzuur versus cumarinederivaten bij atriumfibrilleren.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Anticoagulants)
RN  - 0 (Coumarins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ned Tijdschr Geneeskd. 2002 Jul 6;146(27):1298; author reply 1298. PMID: 12138679
MH  - Adult
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Clinical Trials as Topic
MH  - Coumarins/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - International Normalized Ratio
MH  - Practice Guidelines as Topic
MH  - Risk Factors
MH  - Stroke/etiology/*prevention & control
RF  - 16
EDAT- 2000/12/29 11:00
MHDA- 2001/03/27 10:01
CRDT- 2000/12/29 11:00
PHST- 2000/12/29 11:00 [pubmed]
PHST- 2001/03/27 10:01 [medline]
PHST- 2000/12/29 11:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2000 Dec 2;144(49):2336-40.

PMID- 2899772
OWN - NLM
STAT- MEDLINE
DCOM- 19880908
LR  - 20220408
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8607
DP  - 1988 Aug 13
TI  - Randomised trial of intravenous streptokinase, oral aspirin, both, or neither 
      among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 
      (Second International Study of Infarct Survival) Collaborative Group.
PG  - 349-60
AB  - 17,187 patients entering 417 hospitals up to 24 hours (median 5 hours) after the 
      onset of suspected acute myocardial infarction were randomised, with placebo 
      control, between: (i) a 1-hour intravenous infusion of 1.5 MU of streptokinase; 
      (ii) one month of 160 mg/day enteric-coated aspirin; (iii) both active 
      treatments; or (iv) neither. Streptokinase alone and aspirin alone each produced 
      a highly significant reduction in 5-week vascular mortality: 791/8592 (9.2%) 
      among patients allocated streptokinase infusion vs 1029/8595 (12.0%) among those 
      allocated placebo infusion (odds reduction: 25% SD 4; 2p less than 0.00001); 
      804/8587 (9.4%) vascular deaths among patients allocated aspirin tablets vs 
      1016/8600 (11.8%) among those allocated placebo tablets (odds reduction: 23% SD 
      4; 2p less than 0.00001). The combination of streptokinase and aspirin was 
      significantly (2p less than 0.0001) better than either agent alone. Their 
      separate effects on vascular deaths appeared to be additive: 343/4292 (8.0%) 
      among patients allocated both active agents vs 568/4300 (13.2%) among those 
      allocated neither (odds reduction: 42% SD 5; 95% confidence limits 34-50%). There 
      was evidence of benefit from each agent even for patients treated late after pain 
      onset (odds reductions at 0-4, 5-12, and 13-24 hours: 35% SD 6, 16% SD 7, and 21% 
      SD 12 for streptokinase alone; 25% SD 7, 21% SD 7, and 21% SD 12 for aspirin 
      alone; and 53% SD 8, 32% SD 9, and 38% SD 15 for the combination of streptokinase 
      and aspirin). Streptokinase was associated with an excess of bleeds requiring 
      transfusion (0.5% vs 0.2%) and of confirmed cerebral haemorrhage (0.1% vs 0.0%), 
      but with fewer other strokes (0.6% vs 0.8%). These "other" strokes may have 
      included a few undiagnosed cerebral haemorrhages, but still there was no increase 
      in total strokes (0.7% streptokinase vs 0.8% placebo infusion). Aspirin 
      significantly reduced non-fatal reinfarction (1.0% vs 2.0%) and non-fatal stroke 
      (0.3% vs 0.6%), and was not associated with any significant increase in cerebral 
      haemorrhage or in bleeds requiring transfusion. An excess of non-fatal 
      reinfarction was reported when streptokinase was used alone, but this appeared to 
      be entirely avoided by the addition of aspirin. Those allocated the combination 
      of streptokinase and aspirin had significantly fewer reinfarctions (1.8% vs 
      2.9%), strokes (0.6% vs 1.1%), and deaths (8.0% vs 13.2%) than those allocated 
      neither. The differences in vascular and in all-cause mortality produced by 
      streptokinase and by aspirin remain highly significant (2p less than 0.001 for 
      each) after the median of 15 months of follow-up thus far available.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 1997 May 24;349(9064):1551. PMID: 9167479
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Cause of Death
MH  - Cerebral Hemorrhage/chemically induced
MH  - Clinical Trials as Topic
MH  - Drug Evaluation
MH  - Drug Hypersensitivity/etiology
MH  - Drug Therapy, Combination
MH  - Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Myocardial Infarction/*drug therapy/mortality/physiopathology
MH  - Prognosis
MH  - Random Allocation
MH  - Recurrence
MH  - Streptokinase/*administration & dosage/adverse effects/therapeutic use
EDAT- 1988/08/13 00:00
MHDA- 1988/08/13 00:01
CRDT- 1988/08/13 00:00
PHST- 1988/08/13 00:00 [pubmed]
PHST- 1988/08/13 00:01 [medline]
PHST- 1988/08/13 00:00 [entrez]
AID - S0140-6736(88)92833-4 [pii]
PST - ppublish
SO  - Lancet. 1988 Aug 13;2(8607):349-60.

PMID- 8879427
OWN - NLM
STAT- MEDLINE
DCOM- 19970218
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 24
IP  - 5
DP  - 1996 Sep
TI  - The cytotoxic activities of human hemoglobin and diaspirin crosslinked 
      hemoglobin.
PG  - 533-51
AB  - It is well known that hemoglobin (Hb) possesses many oxidative enzyme activities, 
      including a pseudo-peroxidase activity. It has also been shown by many 
      investigators that various peroxidases in the presence of hydrogen peroxide and a 
      halide ion exert a potent cytotoxic activity toward various mammalian cell types. 
      It has further been observed by various investigators that the administration of 
      relatively large amounts of purified Hb or a Hb derivative to a host animal 
      during resuscitation experiments leads to a number of unrelated types of tissue 
      damage and cell damage in the host. The first objective of this investigation was 
      to determine if the observed tissue and cell damage may be due to a cytotoxic 
      activity that Hb may exert in vivo analogous to that of the peroxidases. We also 
      showed some time ago that peroxidases are able to activate peritoneal macrophages 
      to the cytocidal state. Hence, we also addressed the question whether or not Hb 
      is able to activate macrophages in a similar manner. Our results were negative 
      with regard to both questions. Further investigations indicated that, unlike the 
      peroxidases, ferryl-Hb is unable to oxidize iodide to iodine at a measurable 
      rate, which appears to be the reason for the lack of cytotoxic activity.
FAU - Hsia, N
AU  - Hsia N
AD  - Department of Cell Biology and Biochemistry, Texas Tech University Health 
      Sciences Center, Lubbock 79430, USA.
FAU - Everse, J
AU  - Everse J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Cytotoxins)
RN  - 0 (Hemoglobins)
RN  - 0 (bis(3,5-dibromosalicyl)fumarate-crosslinked hemoglobin A(0))
RN  - 54651-57-9 (hemoglobin A(0))
RN  - 9034-51-9 (Hemoglobin A)
RN  - EC 1.11.1.- (Peroxidases)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/toxicity
MH  - Blood Substitutes/*toxicity
MH  - Cytotoxins/*toxicity
MH  - Hemoglobin A/*toxicity
MH  - Hemoglobins/*toxicity
MH  - Hemolysis/drug effects
MH  - Macrophage Activation
MH  - Macrophages/drug effects
MH  - Peroxidases/toxicity
MH  - Rabbits
MH  - Toxicity Tests
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - 10.3109/10731199609117445 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1996 Sep;24(5):533-51. doi: 
      10.3109/10731199609117445.

PMID- 14725581
OWN - NLM
STAT- MEDLINE
DCOM- 20040416
LR  - 20190901
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 19 Suppl 1
DP  - 2004 Feb
TI  - Review article: appropriate use of proton pump inhibitors with traditional 
      nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors.
PG  - 60-5
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used 
      classes of medications in the USA, annually accounting for over 100 million 
      prescriptions. Gastrointestinal complications associated with NSAIDs are common, 
      and result in a substantial amount of morbidity and mortality, despite the advent 
      of the cyclooxygenase-2 selective inhibitors or 'coxibs'. Emerging clinical and 
      economic data suggest that, depending on the baseline risk to patients, the use 
      of a traditional NSAID alone or in combination with a proton pump inhibitor are 
      effective and well tolerated alternatives to coxibs. The optimal therapeutic 
      strategy for NSAID selection and use of co-therapy should be guided by a 
      consideration of each patient's risk of having an adverse event arising from the 
      NSAID. Patients at the highest risk for gastrointestinal complications with 
      traditional NSAIDs are those with a history of an ulcer or ulcer complication, 
      those of advanced age (greater than 65 years), and those receiving concurrent 
      aspirin, anticoagulants or corticosteroid therapy. Proton pump inhibitor 
      co-therapy is highly effective in reducing NSAID-related dyspeptic symptoms, 
      healing the injured mucosa even in those who continue to ingest NSAIDs, and 
      preventing gastrointestinal complications. In addition to their selective use in 
      patients who experience NSAID-related dyspepsia and other symptoms, proton pump 
      inhibitor co-therapy should be considered in those at high risk (with coxib or 
      traditional NSAID therapy) and is necessary in high-risk patients receiving 
      aspirin, with or without NSAID therapy.
FAU - Kimmey, M B
AU  - Kimmey MB
AD  - Division of Gastroenterology, University of Washington School of Medicine, 
      Seattle, Washington 98195, USA. Kimmey@u.washington.edu
FAU - Lanas, A
AU  - Lanas A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - 0 (Proton Pump Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*adverse effects
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Humans
MH  - Isoenzymes/antagonists & inhibitors
MH  - Membrane Proteins
MH  - Prostaglandin-Endoperoxide Synthases
MH  - *Proton Pump Inhibitors
MH  - Risk Factors
RF  - 40
EDAT- 2004/01/17 05:00
MHDA- 2004/04/17 05:00
CRDT- 2004/01/17 05:00
PHST- 2004/01/17 05:00 [pubmed]
PHST- 2004/04/17 05:00 [medline]
PHST- 2004/01/17 05:00 [entrez]
AID - 1840 [pii]
AID - 10.1111/j.0953-0673.2004.01840.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:60-5. doi: 
      10.1111/j.0953-0673.2004.01840.x.

PMID- 29953191
OWN - NLM
STAT- MEDLINE
DCOM- 20180724
LR  - 20180724
IS  - 0019-5499 (Print)
IS  - 0019-5499 (Linking)
VI  - 60
IP  - 1
DP  - 2016 Jan-Mar
TI  - Aspirin Resistance in Different Doses by Bleeding Time and Urinary 
      11-dehydro-thromboxane B2.
PG  - 30-7
AB  - The aim of the present study was the evaluation bleeding time (BT) in comparison 
      to Urinary 11-dehydro thromboxane B2 (TXB2) regarding different ASA frequent 
      dosages used in Borujerd city. This is a double blind randomized clinical trial 
      on 370 subjects aged 35 years and older, referred to clinical offices in 
      Borujerd. All ischemic heart disease’s patients were randomly assigned to 4 ASA 
      dose groups (80 mg, 81 mg, 100 mg and 325 mg) and one group-matched control group 
      without any IHD. BT was measured by Ivy method; TXB2 was measured in a urine 
      sample, both at least 5 days after ASA consumption. Probale AR was indicated if 
      TXB2 was normal or higher than normal higher limit values, or BT was normal or 
      lower than normal higher values. (IRCT201202026958N3) Probale AR was present in 
      37.6% and 64% resistance by BT and TXB2, respectively. All 4 treated groups had 
      higher TXB2 levels than the control group/normal values (p>0.05). Also, urinary 
      TXB2 level correlated positively with BT. Given the simplicity and low costs of 
      its performance it might be of some potential use in developing countries. 
      However, due to IVY method limitations it cannot be perceived as a tool to assess 
      such specific aspects of platlat function or aspirin resistance.
FAU - Maleki, Ali
AU  - Maleki A
FAU - Cheraghi, Mostafa
AU  - Cheraghi M
FAU - Kerman, Scott Reza Jafarian
AU  - Kerman SRJ
FAU - Montazeri, Mahdi
AU  - Montazeri M
FAU - Rashidi, Negin
AU  - Rashidi N
FAU - Ghanavati, Reza
AU  - Ghanavati R
FAU - Foroughi, Saeid
AU  - Foroughi S
FAU - Alyari, Farshid
AU  - Alyari F
FAU - Ahmadvand, Hassan
AU  - Ahmadvand H
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Physiol Pharmacol
JT  - Indian journal of physiology and pharmacology
JID - 0374707
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - *Bleeding Time
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*drug therapy/physiopathology/urine
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Thromboxane B2/*analogs & derivatives/urine
EDAT- 2016/01/01 00:00
MHDA- 2018/07/25 06:00
CRDT- 2018/06/29 06:00
PHST- 2018/06/29 06:00 [entrez]
PHST- 2016/01/01 00:00 [pubmed]
PHST- 2018/07/25 06:00 [medline]
PST - ppublish
SO  - Indian J Physiol Pharmacol. 2016 Jan-Mar;60(1):30-7.

PMID- 15840434
OWN - NLM
STAT- MEDLINE
DCOM- 20050601
LR  - 20131121
IS  - 0300-483X (Print)
IS  - 0300-483X (Linking)
VI  - 210
IP  - 2-3
DP  - 2005 Jun 1
TI  - Macrophage activation by a vanadyl-aspirin complex is dependent on L-type calcium 
      channel and the generation of nitric oxide.
PG  - 205-12
AB  - Bone homeostasis is the result of a tight balance between bone resorption and 
      bone formation where macrophage activation is believed to contribute to bone 
      resorption. We have previously shown that a vanadyl(IV)-aspirin complex (VOAspi) 
      regulates cell proliferation and differentiation of osteoblasts in culture. In 
      this study, we assessed VOAspi and VO effects and their possible mechanism of 
      action on a mouse macrophage cell line RAW 264.7. Both vanadium compounds 
      inhibited cell proliferation in a dose-dependent manner. Nifedipine completely 
      reversed the VOAspi-induced macrophage cytotoxicity, while it could not block the 
      effect of VO. VOAspi also stimulated nitric oxide (NO) production, the oxidation 
      of dihydrorhodamine 123 (DHR-123) and enhanced the expression of both 
      constitutive and inducible isoforms of nitric oxide syntases (NOS). All these 
      effects were abolished by nifedipine. Altogether our finding give evidence that 
      VOAspi-induced macrophage cytotoxicity is dependent on L-type calcium channel and 
      the generation of NO though the induction of eNOS and iNOS. Contrary, the parent 
      compound VO exerted a cytotoxic effect by mechanisms independent of a calcium 
      entry and the NO/NOS activation.
FAU - Molinuevo, María Silvina
AU  - Molinuevo MS
AD  - Cátedra de Bioquímica Patológica, Facultad de Ciencias Exactas, Universidad 
      Nacional de La Plata, Departamento de Ciencias Biologicas, 47 y 115, 1900 La 
      Plata, Buenos Aires, Argentina.
FAU - Etcheverry, Susana Beatriz
AU  - Etcheverry SB
FAU - Cortizo, Ana María
AU  - Cortizo AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Toxicology
JT  - Toxicology
JID - 0361055
RN  - 0 (Calcium Channels, L-Type)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Vanadium Compounds)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*toxicity
MH  - Blotting, Western
MH  - Calcium Channels, L-Type/*metabolism
MH  - Cell Line
MH  - Cell Proliferation/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Macrophage Activation/*drug effects
MH  - Macrophages/*drug effects/metabolism
MH  - Mice
MH  - Microscopy, Fluorescence
MH  - Nitric Oxide/*biosynthesis
MH  - Nitric Oxide Synthase/biosynthesis
MH  - Reactive Oxygen Species/metabolism
MH  - Vanadium Compounds/*toxicity
EDAT- 2005/04/21 09:00
MHDA- 2005/06/02 09:00
CRDT- 2005/04/21 09:00
PHST- 2004/12/09 00:00 [received]
PHST- 2005/02/02 00:00 [revised]
PHST- 2005/02/05 00:00 [accepted]
PHST- 2005/04/21 09:00 [pubmed]
PHST- 2005/06/02 09:00 [medline]
PHST- 2005/04/21 09:00 [entrez]
AID - S0300-483X(05)00090-9 [pii]
AID - 10.1016/j.tox.2005.02.016 [doi]
PST - ppublish
SO  - Toxicology. 2005 Jun 1;210(2-3):205-12. doi: 10.1016/j.tox.2005.02.016.

PMID- 35921721
OWN - NLM
STAT- MEDLINE
DCOM- 20221107
LR  - 20221204
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
VI  - 279
DP  - 2022 Nov
TI  - Aspirin Administration Mitigates Platelet Hyperaggregability After Splenectomy in 
      a Murine Model.
PG  - 548-556
LID - S0022-4804(22)00381-X [pii]
LID - 10.1016/j.jss.2022.06.026 [doi]
AB  - INTRODUCTION: Patients who undergo splenectomy (SPLN) have an estimated 10%-35% 
      risk of venous thromboembolic events; however, the underlying mechanism and 
      strategy for prevention have yet to be identified. The goals of this study were 
      to 1) investigate platelet aggregation after SPLN, 2) examine if aspirin 
      administration could mitigate this effect, and 3) determine if concomitant 
      hemorrhage would affect post-SPLN platelet function and response to aspirin. 
      METHODS: Murine models of operative SPLN and submandibular bleed (SMB) were 
      utilized. Mice were randomized to eight groups as follows: untouched, SPLN, sham 
      (laparotomy only), SMB, SPLN + SMB, SPLN + aspirin (ASA), SMB + ASA, and 
      SPLN + SMB + ASA. Aspirin (50 mg/kg) was administered on postoperative days 
      (PODs) one and two via oral gavage. Mice were euthanized on POD 3, platelet 
      counts were obtained, and blood samples were analyzed via rotational 
      thromboelastometry and impedance aggregometry with adenosine diphosphate (ADP) 
      and arachidonic acid (AA) as agonists. RESULTS: By POD 3, SPLN mice displayed a 
      significant thrombocytosis compared to untouched, SMB, and sham SPLN mice. 
      Clotting time and clot formation time were significantly decreased in SPLN and 
      SPLN + SMB cohorts compared to untouched and sham controls with elevated mean 
      clot firmness. SPLN mice also displayed a significant increase in ADP- and 
      AA-mediated platelet aggregability compared to untouched controls, SMB, and 
      SPLN + SMB. ASA significantly decreased platelet aggregation via both ADP and AA 
      signaling in SPLN and SPLN + SMB cohorts without affecting viscoelastic 
      coagulation testing. CONCLUSIONS: Platelet hyperaggregability after SPLN is 
      mediated by both ADP and AA signaling. Early aspirin administration may prevent 
      increased platelet aggregation exacerbated after polytrauma.
CI  - Copyright © 2022 Elsevier Inc. All rights reserved.
FAU - Wallen, Taylor E
AU  - Wallen TE
AD  - Department of Surgery, University of Cincinnati, Cincinnati, Ohio. Electronic 
      address: wallentr@ucmail.uc.edu.
FAU - Youngs, Jackie
AU  - Youngs J
AD  - Department of Surgery, University of Cincinnati, Cincinnati, Ohio.
FAU - Baucom, Matthew R
AU  - Baucom MR
AD  - Department of Surgery, University of Cincinnati, Cincinnati, Ohio.
FAU - Turner, Kevin
AU  - Turner K
AD  - Department of Surgery, University of Cincinnati, Cincinnati, Ohio.
FAU - Schuster, Rebecca
AU  - Schuster R
AD  - Department of Surgery, University of Cincinnati, Cincinnati, Ohio.
FAU - England, Lisa
AU  - England L
AD  - Department of Surgery, University of Cincinnati, Cincinnati, Ohio.
FAU - Pritts, Timothy A
AU  - Pritts TA
AD  - Department of Surgery, University of Cincinnati, Cincinnati, Ohio.
FAU - Goodman, Michael D
AU  - Goodman MD
AD  - Department of Surgery, University of Cincinnati, Cincinnati, Ohio.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20220731
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Adenosine Diphosphate/pharmacology
MH  - Arachidonic Acid
MH  - *Aspirin/pharmacology
MH  - Blood Platelets
MH  - Disease Models, Animal
MH  - Platelet Aggregation/physiology
MH  - Platelet Aggregation Inhibitors
MH  - Platelet Function Tests
MH  - *Splenectomy/adverse effects
OTO - NOTNLM
OT  - Aggregation
OT  - Arachidonic acid
OT  - Aspirin
OT  - Coagulation
OT  - Splenectomy
OT  - Thrombocytosis
EDAT- 2022/08/04 06:00
MHDA- 2022/09/24 06:00
CRDT- 2022/08/03 18:15
PHST- 2021/12/31 00:00 [received]
PHST- 2022/05/24 00:00 [revised]
PHST- 2022/06/09 00:00 [accepted]
PHST- 2022/08/04 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/08/03 18:15 [entrez]
AID - S0022-4804(22)00381-X [pii]
AID - 10.1016/j.jss.2022.06.026 [doi]
PST - ppublish
SO  - J Surg Res. 2022 Nov;279:548-556. doi: 10.1016/j.jss.2022.06.026. Epub 2022 Jul 
      31.

PMID- 19348
OWN - NLM
STAT- MEDLINE
DCOM- 19771014
LR  - 20131121
IS  - 0015-8178 (Print)
IS  - 0015-8178 (Linking)
VI  - 95
IP  - 31
DP  - 1977 Aug 18
TI  - [Antacids and gastric mucosa. Protective effect of an antacid on acetylsalicylic 
      acid induced functional lesions in the human gastric mucosa].
PG  - 1931-4
AB  - Salicylates do induce functional and morphological changes of the gastric mucosa: 
      increased H+-back-diffusion, increased Na+-influx, and increased blood loss. 
      Several functional parameters of the gastric mucosal barrier correlate with the 
      transmural electrical potential difference (PD) which can be used as a sensitive, 
      but unspecific parameter to detect functional changes of the gastric mucosal 
      barrier. The effect of a salicylate alone and in presence of a liquid antiacid 
      (Gastropulgit Gel) on transmural PD was measured in healthy volunteers. The 
      presence of an antacid prevented the salicylate-induced drop of transmural PD. 
      The tested antacid seems to exert a protective effect towards acute damage of the 
      gastric mucosa induced by salicylates.
FAU - Caspary, W F
AU  - Caspary WF
FAU - Kausch, H
AU  - Kausch H
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Antazida und Magenschleimhaut. Protektiver Effekt eines Antazidums auf 
      Azetylsalizylsäure-bedingte funktionelle Schädigung der menschlichen 
      Magenschleimhaut.
PL  - Germany
TA  - Fortschr Med
JT  - Fortschritte der Medizin
JID - 2984763R
RN  - 0 (Antacids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antacids/*therapeutic use
MH  - Aspirin/*adverse effects
MH  - Drug Evaluation
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Membrane Potentials
EDAT- 1977/08/18 00:00
MHDA- 1977/08/18 00:01
CRDT- 1977/08/18 00:00
PHST- 1977/08/18 00:00 [pubmed]
PHST- 1977/08/18 00:01 [medline]
PHST- 1977/08/18 00:00 [entrez]
PST - ppublish
SO  - Fortschr Med. 1977 Aug 18;95(31):1931-4.

PMID- 11533433
OWN - NLM
STAT- MEDLINE
DCOM- 20011025
LR  - 20190503
IS  - 0963-8172 (Print)
IS  - 0963-8172 (Linking)
VI  - 10 Suppl 1
IP  - Suppl 1
DP  - 2001 Sep
TI  - Importance of risk communication and decision making in cardiovascular conditions 
      in older patients: a discussion paper.
PG  - i19-22
AB  - Atrial fibrillation and aortic stenosis commonly present doctors and patients 
      with difficult decisions about the risks and benefits of treatment options and 
      are both often inappropriately undertreated. Patients may be confused by risk 
      information and doctors may be aware of patients' limitations and use this to 
      manipulate choices to the ones desired by the doctors. This paper examines the 
      importance of risk communication and discusses difficulties that can arise in 
      decision making in these two common cardiovascular conditions.
FAU - Dudley, N
AU  - Dudley N
AD  - St James's University Hospital, Leeds LS9 7TF, UK. Nigel.Dudley@leedsth.nhs.uk
LA  - eng
PT  - Journal Article
PL  - England
TA  - Qual Health Care
JT  - Quality in health care : QHC
JID - 9209948
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aortic Valve Stenosis/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - *Communication
MH  - *Decision Making
MH  - Humans
MH  - Informed Consent
MH  - *Patient Participation
MH  - *Physician-Patient Relations
MH  - *Risk Assessment
MH  - Warfarin/adverse effects/*therapeutic use
PMC - PMC1765741
EDAT- 2001/09/05 10:00
MHDA- 2001/10/26 10:01
CRDT- 2001/09/05 10:00
PHST- 2001/09/05 10:00 [pubmed]
PHST- 2001/10/26 10:01 [medline]
PHST- 2001/09/05 10:00 [entrez]
AID - 10.1136/qhc.0100019.. [doi]
PST - ppublish
SO  - Qual Health Care. 2001 Sep;10 Suppl 1(Suppl 1):i19-22. doi: 
      10.1136/qhc.0100019...

PMID- 20193517
OWN - NLM
STAT- MEDLINE
DCOM- 20160423
LR  - 20181201
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 48
IP  - 12
DP  - 2009 Dec
TI  - [The effect of different dosage of aspirin on inflammatory biomarkers and 
      prognosis in acute coronary syndrome.].
PG  - 1008-11
AB  - OBJECTIVE: To observe and assess the effect of different dosages of aspirin on 
      inflammatory biomarkers, hemorheology (platelet aggregation rate) and clinical 
      prognosis in patients with acute coronary syndrome (ACS). METHODS: ACS patients 
      were randomly assigned to receive different dosages of aspirin treatment orally. 
      Patients in group A, B and C took 100 mg, 500 mg and 1000 mg of aspirin per day 
      respectively. They were treated and followed-up for 1 year. High-sensitivity 
      C-reactive protein (hsCRP), IL-6, tumor necrosis TNFalpha and platelet 
      aggregation rate were examined and major adverse cardiac events (MACE) were 
      recorded. RESULTS: A total of 312 patients with ACS were enrolled in the study. 
      The baseline characteristics of the three groups were not different with respect 
      to age, gender, cardiovascular risk profile, level of inflammatory biomarkers and 
      concomitant treatment before and after randomization. The levels of baseline 
      serum hsCRP, IL-6 and TNFalpha were higher in subjects of the study as compared 
      with normal reference value (P < 0.05, < 0.05, < 0.01) and they decreased 
      significantly after therapy with 3 different doses of aspirin (detected at 30 
      days, 6 months and 12 months, P < 0.001), but there were no significant 
      differences among the three groups (P > 0.05). Rehospitalization, MACE and the 
      change of platelet aggregation ratio were not significantly different among the 
      three groups. The incidence of gastrointestinal complaints was significantly 
      higher in groups B and C than in group A (P < 0.05). CONCLUSIONS: The levels of 
      serum inflammatory biomarker increase in patients with ACS. Aspirin therapy may 
      decrease the level of inflammatory markers significantly, but increasing the 
      dosage of aspirin from 100 mg to 1000 mg daily does not decrease the level of 
      inflammatory markers and the clinical MACEs further. However, the incidence of 
      gastrointestinal complaints increase significantly with the increase of aspirin 
      dosage.
FAU - Ren, Wen-Lin
AU  - Ren WL
AD  - Cardiac Center, People Hospital, Beijing 100044, China. Email: 
      dayi.hu@medmail.com.cn.
FAU - Song, Li-Fen
AU  - Song LF
FAU - Liang, Yu-Qing
AU  - Liang YQ
FAU - Li, Rui-Jie
AU  - Li RJ
FAU - Yin, Zhi-Nong
AU  - Yin ZN
FAU - Xu, Yu-Yun
AU  - Xu YY
FAU - Hu, Da-Yi
AU  - Hu DY
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acute Coronary Syndrome/therapy
MH  - *Aspirin/administration & dosage
MH  - Biomarkers
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prognosis
MH  - Risk Factors
MH  - Ticlopidine/therapeutic use
EDAT- 2010/03/03 06:00
MHDA- 2016/04/24 06:00
CRDT- 2010/03/03 06:00
PHST- 2010/03/03 06:00 [entrez]
PHST- 2010/03/03 06:00 [pubmed]
PHST- 2016/04/24 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2009 Dec;48(12):1008-11.

PMID- 15569143
OWN - NLM
STAT- MEDLINE
DCOM- 20050203
LR  - 20131121
IS  - 0742-3071 (Print)
IS  - 0742-3071 (Linking)
VI  - 21
IP  - 12
DP  - 2004 Dec
TI  - Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
PG  - 1368-71
AB  - AIMS: To examine the proportion of UK Prospective Diabetes Study (UKPDS) patients 
      with Type 2 diabetes taking aspirin regularly for the primary and secondary 
      prevention of cardiovascular disease (CVD) before and after publication of the 
      1997 American Diabetes Association (ADA) Clinical Practice Recommendations and 
      the 1998 Joint British Recommendations on the Prevention of Coronary Disease in 
      Clinical Practice. METHODS: UKPDS annual review data from 1996/7 (n = 3190) and 
      2000/1 (n = 2467) were used to determine the prevalence of patients taking 
      aspirin regularly in relation to known CVD risk factors and pre-existing CVD. 
      RESULTS: Patients taking aspirin regularly were more often male than female (24 
      vs. 20%, P = 0.0033), older (66 +/- 8 vs. 62 +/- 9 years, P < 0.0001) and less 
      often Afro-Caribbean than White Caucasian or Indian Asian (11 vs. 23 vs. 22%, 
      respectively, P < 0.0001). Between 1996/7 and 2000/1 aspirin use in patients 
      without pre-existing CVD increased from 17 to 31% (P < 0.0001) and for those with 
      pre-existing CVD from 76 to 82% (P = 0.032). CONCLUSION: The majority of patients 
      with pre-existing CVD were taking aspirin regularly. Although aspirin use in 
      those without pre-existing CVD approximately doubled after publication of the ADA 
      and Joint British Recommendations, less than two-thirds of these high-risk 
      patients were being treated according to guidelines. This may relate to a lack of 
      convincing evidence for primary CVD prevention or failure to adhere to 
      guidelines. It may be that more trial data is needed to convince clinicians of 
      the value of aspirin therapy in Type 2 diabetes.
FAU - Cull, C A
AU  - Cull CA
AD  - Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, 
      University of Oxford, UK. carole.cull@dtu.ox.ac.uk
FAU - Neil, H A W
AU  - Neil HA
FAU - Holman, R R
AU  - Holman RR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Distribution
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Guideline Adherence
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Sex Distribution
EDAT- 2004/12/01 09:00
MHDA- 2005/02/04 09:00
CRDT- 2004/12/01 09:00
PHST- 2004/12/01 09:00 [pubmed]
PHST- 2005/02/04 09:00 [medline]
PHST- 2004/12/01 09:00 [entrez]
AID - DME1328 [pii]
AID - 10.1111/j.1464-5491.2004.01328.x [doi]
PST - ppublish
SO  - Diabet Med. 2004 Dec;21(12):1368-71. doi: 10.1111/j.1464-5491.2004.01328.x.

PMID- 25807432
OWN - NLM
STAT- MEDLINE
DCOM- 20151023
LR  - 20181202
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 19
IP  - 5
DP  - 2015
TI  - Effects of platelet infusion, anticoagulant and other risk factors on the 
      rehaemorrhagia after surgery of hypertensive cerebral hemorrhage.
PG  - 795-9
LID - 8623 [pii]
AB  - OBJECTIVE: Our objective is to explore the effect of platelet infusion, 
      anticoagulant and other risk factors on the rehaemorrhagia after surgery of 
      hypertensive cerebral hemorrhage (HCH), and to provide a reference for the 
      prevention and treatment of rehaemorrhagia in patients with HCH. PATIENTS AND 
      METHODS: The patients with HCH admitted during April, 2007-June, 2012 in our 
      hospital were selected. The general data such as age and gender, disease course, 
      past pathogenic characters, past and present medical history such as treatment, 
      personal history, family history and son on, were collected. The data were 
      analyzed by t test, ANOVA, Chi-squared test and logistic regression analysis. 
      RESULTS: The application of aspirin and platelets has significant effect on 
      rehaemorrhagia after surgery of HCH: 72 patients received aspirin, of which 14 
      cases had rehaemorrhagia while 197 patients did not receive aspirin, of which 20 
      cases had rehaemorrhagia. The difference between these two groups was 
      statistically significant (p < 0.05). 186 patients received platelet infusions, 
      of which 18 cases had rehaemorrhagia whereas among other 83 patients not 
      receiving platelet infusions, 16 cases had rehaemorrhagia. Statistical analysis 
      showed a significant difference between these two groups (p < 0.05). In the 
      univariate logistic regression analysis of related data in patients with 
      rehaemorrhagia after surgery of HCH, diastolic or systolic blood pressure at 
      admission, the time from onset to surgery, coagulation disorder, surgical method, 
      hematoma volume, cerebral hemia, effect of hematoma clearance and GCS at 
      admission were the potential risk factors for rehaemorrhagia after surgery of HCH 
      (p < 0.05). In the multivariate logistic regression analysis of related data in 
      the same patients, diastolic blood pressure at admission (> 120 mmHg), systolic 
      blood pressure at admission (> 200 mmHg), the time from onset to surgery and 
      coagulation disorder were screened out (p < 0.05) to be associated with 
      rehaemorrhagia. CONCLUSIONS: Aspirin increased the risk of rehaemorrhagia after 
      surgery of HCH. On the contrary, infusion of platelets decreased the risk of 
      rehaemorrhagia and improved the prognosis of patients. High diastolic and/or high 
      systolic blood pressure at admission, ultra-early surgery after onset of HCH and 
      coagulation disorder were related with rehaemorrhagia after operation of HCH. Our 
      results indicate that rehaemorrhagia rate can be decreased by controlling related 
      risk factors.
FAU - Chen, T
AU  - Chen T
AD  - Department of  Neurosurgery, Qilu  Hospital of Shandong University, Jinan,  
      China. drchenteng@hotmail.com.
FAU - Xu, G
AU  - Xu G
FAU - Tan, D
AU  - Tan D
FAU - Wu, C
AU  - Wu C
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Blood Loss, Surgical/prevention & control
MH  - Female
MH  - Hematoma/surgery
MH  - Humans
MH  - Intracranial Hemorrhage, Hypertensive/*prevention & control/*surgery
MH  - Male
MH  - Middle Aged
MH  - Platelet Transfusion/adverse effects/*methods
MH  - Prognosis
MH  - Recurrence
MH  - Risk Factors
EDAT- 2015/03/26 06:00
MHDA- 2015/10/24 06:00
CRDT- 2015/03/26 06:00
PHST- 2015/03/26 06:00 [entrez]
PHST- 2015/03/26 06:00 [pubmed]
PHST- 2015/10/24 06:00 [medline]
AID - 8623 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2015;19(5):795-9.

PMID- 9113889
OWN - NLM
STAT- MEDLINE
DCOM- 19970513
LR  - 20190606
IS  - 0835-7900 (Print)
IS  - 0835-7900 (Linking)
VI  - 10
IP  - 7
DP  - 1996 Nov-Dec
TI  - NSAID gastroenteropathy: past, present and future.
PG  - 451-9
AB  - The toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) in the 
      gastrointestinal tract continues to be a major limitation to their use in the 
      treatment of inflammatory disorders. Better understanding of the pathogenesis of 
      NSAID enteropathy has facilitated the development of novel NSAIDs that spare the 
      gastrointestinal tract. In particular, identification and characterization of the 
      inducible form of prostaglandin synthase has led to the design of novel NSAIDs 
      that specifically target that enzyme. The pathogenesis of NSAID gastroenteropathy 
      is reviewed, as are the strategies that have been used in the past and are used 
      now to develop NSAIDs that spare the gastrointestinal tract. Also reviewed are 
      the strategies being employed to achieve this goal in the future.
FAU - Wallace, J L
AU  - Wallace JL
AD  - Intestinal Disease Research Unit, Faculty of Medicine, University of Calgary, 
      Alberta. wallacej@acs.ucalgary.ca
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Canada
TA  - Can J Gastroenterol
JT  - Canadian journal of gastroenterology = Journal canadien de gastroenterologie
JID - 8807867
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/chemistry/pharmacology
MH  - Aspirin/adverse effects/chemistry/pharmacology
MH  - Chemistry, Pharmaceutical
MH  - Chemoprevention
MH  - Cyclooxygenase Inhibitors/adverse effects/chemistry/pharmacology
MH  - Drug Design
MH  - Forecasting
MH  - Gastrointestinal Diseases/*chemically induced/prevention & control
MH  - Humans
MH  - Nitric Oxide/metabolism
MH  - Prostaglandin-Endoperoxide Synthases/classification/drug effects/metabolism
RF  - 88
EDAT- 1996/11/01 00:00
MHDA- 1996/11/01 00:01
CRDT- 1996/11/01 00:00
PHST- 1996/11/01 00:00 [pubmed]
PHST- 1996/11/01 00:01 [medline]
PHST- 1996/11/01 00:00 [entrez]
AID - 10.1155/1996/850710 [doi]
PST - ppublish
SO  - Can J Gastroenterol. 1996 Nov-Dec;10(7):451-9. doi: 10.1155/1996/850710.

PMID- 29119255
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20180710
IS  - 1618-2650 (Electronic)
IS  - 1618-2642 (Linking)
VI  - 410
IP  - 1
DP  - 2018 Jan
TI  - Combining Raman and laser induced breakdown spectroscopy by double pulse lasing.
PG  - 277-286
LID - 10.1007/s00216-017-0719-6 [doi]
AB  - A new approach combining Raman spectrometry and laser induced breakdown 
      spectrometry (LIBS) within a single laser event was suggested. A pulsed solid 
      state Nd:YAG laser running in double pulse mode (two frequency-doubled sequential 
      nanosecond laser pulses with dozens microseconds delay) was used to combine two 
      spectrometry methods within a single instrument (Raman/LIBS spectrometer). First, 
      a low-energy laser pulse (power density far below ablation threshold) was used 
      for Raman measurements while a second powerful laser pulse created the plasma 
      suitable for LIBS analysis. A short time delay between two successive pulses 
      allows measuring LIBS and Raman spectra at different moments but within a single 
      laser flash-lamp pumping. Principal advantages of the developed instrument 
      include high quality Raman/LIBS spectra acquisition (due to optimal gating for 
      Raman/LIBS independently) and absence of target thermal alteration during Raman 
      measurements. A series of high quality Raman and LIBS spectra were acquired for 
      inorganic salts (gypsum, anhydrite) as well as for pharmaceutical samples 
      (acetylsalicylic acid). To the best of our knowledge, the quantitative analysis 
      feasibility by combined Raman/LIBS instrument was demonstrated for the first time 
      by calibration curves construction for acetylsalicylic acid (Raman) and copper 
      (LIBS) in gypsum matrix. Combining ablation pulses and Raman measurements 
      (LIBS/Raman measurements) within a single instrument makes it an efficient tool 
      for identification of samples hidden by non-transparent covering or performing 
      depth profiling analysis including remote sensing. Graphical abstract Combining 
      Raman and laser induced breakdown spectroscopy by double pulse lasing.
FAU - Lednev, Vasily N
AU  - Lednev VN
AD  - National University of Science and Technology MISiS, Leninsky Ave. 4, Moscow, 
      119991, Russia. vasilylednev@gmail.com.
AD  - Prokhorov General Physics Institute, Russian Academy of Science, Vavilov Str. 38, 
      Moscow, 119991, Russia. vasilylednev@gmail.com.
FAU - Pershin, Sergey M
AU  - Pershin SM
AD  - Prokhorov General Physics Institute, Russian Academy of Science, Vavilov Str. 38, 
      Moscow, 119991, Russia.
FAU - Sdvizhenskii, Pavel A
AU  - Sdvizhenskii PA
AD  - National University of Science and Technology MISiS, Leninsky Ave. 4, Moscow, 
      119991, Russia.
FAU - Grishin, Mikhail Ya
AU  - Grishin MY
AD  - Prokhorov General Physics Institute, Russian Academy of Science, Vavilov Str. 38, 
      Moscow, 119991, Russia.
AD  - Moscow Institute of Physics and Technology (State University), Dolgoprudny, 
      Moscow Region, 141701, Russia.
FAU - Fedorov, Alexander N
AU  - Fedorov AN
AD  - Prokhorov General Physics Institute, Russian Academy of Science, Vavilov Str. 38, 
      Moscow, 119991, Russia.
FAU - Bukin, Vladimir V
AU  - Bukin VV
AD  - Prokhorov General Physics Institute, Russian Academy of Science, Vavilov Str. 38, 
      Moscow, 119991, Russia.
FAU - Oshurko, Vadim B
AU  - Oshurko VB
AD  - Moscow State University of Technology Stankin, Moscow, 127055, Russia.
FAU - Shchegolikhin, Alexander N
AU  - Shchegolikhin AN
AD  - Institute of Biochemical Physics, Russian Academy of Sciences, 4 Kosygin St., 
      Moscow, 119991, Russia.
LA  - eng
GR  - 15-03-09154, 15-38-70025/Russian Foundation for Basic Research/
GR  - 16-19-10656/Russian Science Foundation/
GR  - 3.6634.2017/6.7/Ministry of Education and Science of the Russian Federation/
PT  - Journal Article
DEP - 20171108
PL  - Germany
TA  - Anal Bioanal Chem
JT  - Analytical and bioanalytical chemistry
JID - 101134327
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WAT0DDB505 (Calcium Sulfate)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry
MH  - Aspirin/chemistry
MH  - Calcium Sulfate/chemistry
MH  - Equipment Design
MH  - Lasers
MH  - Spectrum Analysis, Raman/*instrumentation
OTO - NOTNLM
OT  - Double pulse
OT  - LIBS
OT  - Laser induced breakdown spectroscopy
OT  - Quantitative analysis
OT  - Raman scattering
EDAT- 2017/11/10 06:00
MHDA- 2018/02/27 06:00
CRDT- 2017/11/10 06:00
PHST- 2017/06/15 00:00 [received]
PHST- 2017/10/20 00:00 [accepted]
PHST- 2017/10/10 00:00 [revised]
PHST- 2017/11/10 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
PHST- 2017/11/10 06:00 [entrez]
AID - 10.1007/s00216-017-0719-6 [pii]
AID - 10.1007/s00216-017-0719-6 [doi]
PST - ppublish
SO  - Anal Bioanal Chem. 2018 Jan;410(1):277-286. doi: 10.1007/s00216-017-0719-6. Epub 
      2017 Nov 8.

PMID- 30839406
OWN - NLM
STAT- MEDLINE
DCOM- 20190819
LR  - 20200511
IS  - 1728-7731 (Electronic)
IS  - 1726-4901 (Linking)
VI  - 82
IP  - 1
DP  - 2019 Jan
TI  - Does continued aspirin mono-therapy lead to a higher bleeding risk after total 
      knee arthroplasty?
PG  - 60-65
LID - 10.1016/j.jcma.2018.08.002 [doi]
AB  - BACKGROUND: Evidence about the risk of bleeding and thromboembolism because of 
      aspirin mono-therapy in total knee arthroplasty (TKA) is scant. We wanted to 
      validate the risks of bleeding and thromboembolism with continued aspirin 
      mono-therapy in unilateral and simultaneous bilateral TKA. METHODS: We enrolled a 
      series of 1655 patients who underwent unilateral or simultaneous bilateral TKA 
      between December 2010 and December 2012. Drainage amount, postoperative 
      hemoglobin level, change in hemoglobin, calculated blood loss, incidence and the 
      amount of blood transfused, and the proportion of thromboembolic events were 
      compared between patients who were and patients who were not on continued aspirin 
      mono-therapy. RESULTS: Calculated blood loss (969.1 ± 324.9 vs. 904.0 ± 315.5 
      ml), transfusion amounts (1.3 ± 1.5 vs. 1.0 ± 1.3 IU), and percentage of 
      transfused patients (53.0% vs. 40.2%) were higher in unilateral TKA patients on 
      continued aspirin mono-therapy. Outcome parameters and the proportion of DVT 
      between groups were not significantly different. One patient (0.3%) not on 
      aspirin mono-therapy developed a pulmonary embolism, and two others (0.6%) had 
      cerebrovascular events. CONCLUSION: Despite the slightly higher risks of 
      bleeding, continuing aspirin mono-therapy during TKA might be safe with low risks 
      of perioperative cerebrovascular, cardiovascular, and venous thromboembolic 
      events.
FAU - Chen, Cheng-Fong
AU  - Chen CF
AD  - Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital, 
      Taipei, Taiwan, ROC.
AD  - Department of Orthopaedics, School of Medicine, National Yang-Ming University, 
      Taipei, Taiwan, ROC.
FAU - Tsai, Shang-Wen
AU  - Tsai SW
AD  - Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital, 
      Taipei, Taiwan, ROC.
AD  - Department of Orthopaedics, School of Medicine, National Yang-Ming University, 
      Taipei, Taiwan, ROC.
FAU - Wu, Po-Kuei
AU  - Wu PK
AD  - Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital, 
      Taipei, Taiwan, ROC.
AD  - Department of Orthopaedics, School of Medicine, National Yang-Ming University, 
      Taipei, Taiwan, ROC.
FAU - Chen, Chao-Ming
AU  - Chen CM
AD  - Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital, 
      Taipei, Taiwan, ROC.
AD  - Department of Orthopaedics, School of Medicine, National Yang-Ming University, 
      Taipei, Taiwan, ROC.
FAU - Chen, Wei-Ming
AU  - Chen WM
AD  - Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital, 
      Taipei, Taiwan, ROC.
AD  - Department of Orthopaedics, School of Medicine, National Yang-Ming University, 
      Taipei, Taiwan, ROC.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Chin Med Assoc
JT  - Journal of the Chinese Medical Association : JCMA
JID - 101174817
RN  - R16CO5Y76E (Aspirin)
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Aspirin/*adverse effects
MH  - *Blood Loss, Surgical
MH  - Humans
MH  - Middle Aged
MH  - Risk
EDAT- 2019/03/07 06:00
MHDA- 2019/08/20 06:00
CRDT- 2019/03/07 06:00
PHST- 2019/03/07 06:00 [entrez]
PHST- 2019/03/07 06:00 [pubmed]
PHST- 2019/08/20 06:00 [medline]
AID - 02118582-201901000-00012 [pii]
AID - 10.1016/j.jcma.2018.08.002 [doi]
PST - ppublish
SO  - J Chin Med Assoc. 2019 Jan;82(1):60-65. doi: 10.1016/j.jcma.2018.08.002.

PMID- 17179820
OWN - NLM
STAT- MEDLINE
DCOM- 20070305
LR  - 20131121
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 18
IP  - 1
DP  - 2007 Jan
TI  - Assessment of biochemical aspirin resistance at rest and immediately after 
      exercise testing.
PG  - 9-13
AB  - Some aspirin-treated patients experience thromboembolic events, a phenomenon 
      termed 'aspirin resistance', which may be clinical or biochemical by definition. 
      Physical exercise is known to enhance platelet secretion and aggregability. To 
      evaluate the presence of biochemical aspirin resistance at rest and immediately 
      after exercise in individuals with stable coronary artery disease or coronary 
      artery disease risk factors. We prospectively enrolled 101 patients who had 
      received 100 or 300 mg/day enteric-coated aspirin for at least 7 days. 
      Biochemical aspirin resistance (defined as normal collagen-epinephrine closure 
      time < 165 s) was studied using the standardized platelet function analyzer. Of 
      the 101 patients, 63 were aspirin sensitive both at rest and immediately after 
      exercise, 18 exhibited biochemical aspirin resistance both at rest and after 
      exercise, and 20 were aspirin sensitive at rest but exhibited biochemical aspirin 
      resistance immediately after exercise. The results of exercise testing were 
      similar in all three groups (each P > 0.05). Our results indicate that in almost 
      20% of the patients, aspirin did not seem to protect against exercise-induced 
      platelet activation, despite the presence of aspirin sensitivity at rest. We did 
      not, however, determine the extent to which the biochemical aspirin resistance 
      noted in our study applied to clinical events.
FAU - Gulmez, Oyku
AU  - Gulmez O
AD  - Department of Cardiology, Baskent University Faculty of Medicine, Ankara, Turkey. 
      gulmezoyku@yahoo.com
FAU - Yildirir, Aylin
AU  - Yildirir A
FAU - Bal, Ugur
AU  - Bal U
FAU - Konas, Necibe Didem
AU  - Konas ND
FAU - Aydinalp, Alp
AU  - Aydinalp A
FAU - Demir, Ozlem
AU  - Demir O
FAU - Atar, Ilyas
AU  - Atar I
FAU - Ertan, Cagatay
AU  - Ertan C
FAU - Ozin, Bulent
AU  - Ozin B
FAU - Muderrisoglu, Haldun
AU  - Muderrisoglu H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Drug Resistance/*physiology
MH  - Exercise/physiology
MH  - Exercise Test/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Platelet Function Tests
MH  - Rest/*physiology
EDAT- 2006/12/21 09:00
MHDA- 2007/03/06 09:00
CRDT- 2006/12/21 09:00
PHST- 2006/12/21 09:00 [pubmed]
PHST- 2007/03/06 09:00 [medline]
PHST- 2006/12/21 09:00 [entrez]
AID - 00001721-200701000-00002 [pii]
AID - 10.1097/MBC.0b013e328010bd26 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2007 Jan;18(1):9-13. doi: 
      10.1097/MBC.0b013e328010bd26.

PMID- 27008426
OWN - NLM
STAT- MEDLINE
DCOM- 20170315
LR  - 20170315
IS  - 1520-6890 (Electronic)
IS  - 0009-2665 (Linking)
VI  - 116
IP  - 9
DP  - 2016 May 11
TI  - Modeling Polymorphic Molecular Crystals with Electronic Structure Theory.
PG  - 5567-613
LID - 10.1021/acs.chemrev.5b00648 [doi]
AB  - Interest in molecular crystals has grown thanks to their relevance to 
      pharmaceuticals, organic semiconductor materials, foods, and many other 
      applications. Electronic structure methods have become an increasingly important 
      tool for modeling molecular crystals and polymorphism. This article reviews 
      electronic structure techniques used to model molecular crystals, including 
      periodic density functional theory, periodic second-order Møller-Plesset 
      perturbation theory, fragment-based electronic structure methods, and diffusion 
      Monte Carlo. It also discusses the use of these models for predicting a variety 
      of crystal properties that are relevant to the study of polymorphism, including 
      lattice energies, structures, crystal structure prediction, polymorphism, phase 
      diagrams, vibrational spectroscopies, and nuclear magnetic resonance 
      spectroscopy. Finally, tools for analyzing crystal structures and intermolecular 
      interactions are briefly discussed.
FAU - Beran, Gregory J O
AU  - Beran GJ
AD  - Department of Chemistry, University of California , Riverside, California 92521, 
      United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160323
PL  - United States
TA  - Chem Rev
JT  - Chemical reviews
JID - 2985134R
RN  - 0 (Oxalates)
RN  - 142M471B3J (Carbon Dioxide)
RN  - 996-98-5 (oxalic acid hydrazide)
RN  - J64922108F (Benzene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Benzene/chemistry
MH  - Carbon Dioxide/chemistry
MH  - Crystallization
MH  - Magnetic Resonance Spectroscopy
MH  - *Models, Molecular
MH  - Monte Carlo Method
MH  - Oxalates/chemistry
MH  - Spectrophotometry, Infrared
MH  - Spectrum Analysis, Raman
EDAT- 2016/03/24 06:00
MHDA- 2017/03/16 06:00
CRDT- 2016/03/24 06:00
PHST- 2016/03/24 06:00 [entrez]
PHST- 2016/03/24 06:00 [pubmed]
PHST- 2017/03/16 06:00 [medline]
AID - 10.1021/acs.chemrev.5b00648 [doi]
PST - ppublish
SO  - Chem Rev. 2016 May 11;116(9):5567-613. doi: 10.1021/acs.chemrev.5b00648. Epub 
      2016 Mar 23.

PMID- 8723832
OWN - NLM
STAT- MEDLINE
DCOM- 19961231
LR  - 20161123
IS  - 0743-684X (Print)
IS  - 0743-684X (Linking)
VI  - 12
IP  - 4
DP  - 1996 May
TI  - The effect of combined treatment with dextran 40 and acetylsalicylic acid on 
      patency in severely traumatized small veins and arteries: an experimental study 
      in the rabbit.
PG  - 221-6
AB  - The effects of pharmacologic intervention on the fates of severely traumatized 
      small veins and arteries have been studied in a rabbit model. Controls were given 
      bolus doses of saline and a group treated with a combination of dextran 40 and 
      acetylsalicylic acid starting prior to traumatization and continuing until 
      postoperative day 5. Relative to controls, bleeding times in the treated group 
      were significantly lengthened in arteries but not in veins, and venous patency 
      significantly improved throughout the interval ending 2 weeks postoperatively. 
      Arterial patency was at first highly improved but by 2 weeks, occlusion was 
      virtually 100 percent. Since some of the occlusions took place more than a week 
      after traumatization, the effects of antithrombotic agents on patency may need to 
      be evaluated over considerably longer time periods than has previously been the 
      rule.
FAU - Salemark, L
AU  - Salemark L
AD  - Department of Plastic and Reconstructive Surgery, University Hospital M A S, 
      Malmö, Sweden.
FAU - Knudsen, F
AU  - Knudsen F
FAU - Dougan, P
AU  - Dougan P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Reconstr Microsurg
JT  - Journal of reconstructive microsurgery
JID - 8502670
RN  - 0 (Dextrans)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteries/*injuries/*surgery
MH  - Aspirin/*therapeutic use
MH  - Dextrans/*therapeutic use
MH  - Hemorrhage/drug therapy
MH  - Rabbits
MH  - Vascular Patency
MH  - Veins/*injuries/*surgery
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 10.1055/s-2007-1006480 [doi]
PST - ppublish
SO  - J Reconstr Microsurg. 1996 May;12(4):221-6. doi: 10.1055/s-2007-1006480.

PMID- 1868762
OWN - NLM
STAT- MEDLINE
DCOM- 19910918
LR  - 20181130
IS  - 0412-4057 (Print)
IS  - 0412-4057 (Linking)
VI  - 24
IP  - 1
DP  - 1991 Feb
TI  - [Effect of chronic antiplatelet treatment on platelet activating factor-induced 
      platelet activity in stroke].
PG  - 21-3, 61
AB  - The effect of chronic antiplatelet treatment on PAF--induced platelet 
      aggregation, ATP--release, and cytoplasmic ionized calcium was studied in 20 
      acute ischemic stroke patients. Chronic antiplatelet treatment failed to suppress 
      these PAF--induced platelet responses. We speculate that selective PAF 
      antagonists may be useful in suppressing PAF--induced platelet activation, and 
      thereby possibly improve the treatment of stroke.
FAU - Han, E
AU  - Han E
AD  - Dept. of Neurology Affiliated Hospital, Shandong Medical University.
FAU - Joseph, R
AU  - Joseph R
FAU - Grunfeld, S
AU  - Grunfeld S
FAU - Welch, K M
AU  - Welch KM
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Shen Jing Jing Shen Ke Za Zhi
JT  - Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and 
      psychiatry
JID - 16210510R
RN  - 0 (Platelet Activating Factor)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adenosine Triphosphate/metabolism
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Calcium/blood
MH  - Cerebrovascular Disorders/blood/*drug therapy
MH  - Female
MH  - Humans
MH  - Ibuprofen/pharmacology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Platelet Activating Factor/*physiology
MH  - Platelet Aggregation/*drug effects
EDAT- 1991/02/01 00:00
MHDA- 1991/02/01 00:01
CRDT- 1991/02/01 00:00
PHST- 1991/02/01 00:00 [pubmed]
PHST- 1991/02/01 00:01 [medline]
PHST- 1991/02/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1991 Feb;24(1):21-3, 61.

PMID- 6979849
OWN - NLM
STAT- MEDLINE
DCOM- 19820807
LR  - 20131121
IS  - 0361-803X (Print)
IS  - 0361-803X (Linking)
VI  - 139
IP  - 1
DP  - 1982 Jul
TI  - Aspirin and systemic heparinization in diagnostic and interventional 
      neuroradiology.
PG  - 139-42
AB  - To decrease the risk of iatrogenic thromboembolic complications during 
      interventional procedures with coaxial catheter systems, aspirin and systemic 
      heparinization were used in 57 consecutive cases. No thromboembolic complications 
      occurred. This group was compared with a second group of 25 patients who also had 
      interventional procedures with coaxial systems but who had only a continuous 
      heparinized drip infusion flushing the inside of the coaxial system. Two patients 
      had an embolic complication and two others had thrombus formation inside or 
      outside the catheters without neurologic symptoms. The use of systemic 
      heparinization has been extended to all prolonged angiographic procedures except 
      in cases of acute or recent subarachnoid hemorrhage.
FAU - Debrun, G M
AU  - Debrun GM
FAU - Viñuela, F V
AU  - Viñuela FV
FAU - Fox, A J
AU  - Fox AJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AJR Am J Roentgenol
JT  - AJR. American journal of roentgenology
JID - 7708173
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiography/*adverse effects
MH  - Aspirin/*therapeutic use
MH  - Catheterization/*adverse effects
MH  - Embolization, Therapeutic/adverse effects
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Thromboembolism/*prevention & control
EDAT- 1982/07/01 00:00
MHDA- 1982/07/01 00:01
CRDT- 1982/07/01 00:00
PHST- 1982/07/01 00:00 [pubmed]
PHST- 1982/07/01 00:01 [medline]
PHST- 1982/07/01 00:00 [entrez]
AID - 10.2214/ajr.139.1.139 [doi]
PST - ppublish
SO  - AJR Am J Roentgenol. 1982 Jul;139(1):139-42. doi: 10.2214/ajr.139.1.139.

PMID- 728235
OWN - NLM
STAT- MEDLINE
DCOM- 19790226
LR  - 20190718
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 31
IP  - 2
DP  - 1978 Oct
TI  - Platelet aggregation studies in coronary artery disease. Past 4. Effect of 
      aspirin.
PG  - 169-75
AB  - We evaluated platelet aggregation in vitro in blood samples drawn simultaneously 
      from aorta and coronary sinus. Platelet aggregation was significantly lower in 
      the coronary venous blood than in the aortic blood in patients with coronary 
      artery disease. Lower platelet counts were also observed in coronary venous 
      blood. No such differences were seen in subjects with normal coronary arteries. 
      Oral administration of aspirin eliminated the differences in platelet aggregation 
      and counts across the myocardial vascular bed. These observations suggest that 
      platelet sequestration in the myocardial vasculature may be related to the 
      presence of disease in the coronary arteries.
FAU - Mehta, J
AU  - Mehta J
FAU - Mehta, P
AU  - Mehta P
FAU - Burger, C
AU  - Burger C
FAU - Pepine, C J
AU  - Pepine CJ
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Cell Count/drug effects
MH  - Coronary Disease/*blood
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
EDAT- 1978/10/01 00:00
MHDA- 1978/10/01 00:01
CRDT- 1978/10/01 00:00
PHST- 1978/10/01 00:00 [pubmed]
PHST- 1978/10/01 00:01 [medline]
PHST- 1978/10/01 00:00 [entrez]
AID - 0021-9150(78)90162-4 [pii]
AID - 10.1016/0021-9150(78)90162-4 [doi]
PST - ppublish
SO  - Atherosclerosis. 1978 Oct;31(2):169-75. doi: 10.1016/0021-9150(78)90162-4.

PMID- 15332389
OWN - NLM
STAT- MEDLINE
DCOM- 20041130
LR  - 20211203
IS  - 0903-1936 (Print)
IS  - 0903-1936 (Linking)
VI  - 24
IP  - 2
DP  - 2004 Aug
TI  - Montelukast protects against nasal lysine-aspirin challenge in patients with 
      aspirin-induced asthma.
PG  - 226-30
AB  - Aspirin-induced asthma (AIA) is associated with increased production of cysteinyl 
      leukotrienes (CysLT). Although leukotriene CysLT1-receptor antagonists improve 
      lower airway outcomes in AIA, their effects and dose-response in the upper airway 
      is less well documented. The present study evaluated the dose-response for 
      montelukast (ML) against nasal lysine-aspirin challenge in patients with AIA. A 
      total of 12 patients with a clear-cut history of AIA were randomised in 
      double-blind cross-over fashion to receive single doses of ML 10 mg, ML 40 mg, or 
      placebo (PL), with nasal lysine-aspirin challenge performed 12 h after dosing. 
      Measurements of peak nasal inspiratory flow (PNIF), nasal blockage visual 
      analogue scale (VAS) and forced expiratory volume in one second (FEV1) were made 
      over 120 min after nasal lysine-aspirin challenge. Prechallenge values for 
      mean+/-SEM PNIF (L x min(-1)) were not significantly different comparing all 
      groups: ML 10 mg (132+/-10), ML 40 mg (125+/-12) and PL (132+/-11). There was no 
      significant difference comparing the maximum % PNIF fall from baseline between 
      screening (46+/-6) and PL (45+/-6). The maximum % PNIF fall from baseline was 
      significantly greater with PL (45+/-6) compared to either ML 10 mg (34+/-6) or ML 
      40 mg (32+/-5). There was also a significantly greater mean % PNIF response over 
      120 min after lysine-aspirin challenge for PL (26+/-7) compared to either ML 10 
      mg (14+/-6) or ML 40 mg (17+/-6). There were no significant differences for the 
      maximum or mean % PNIF fall from baseline comparing ML 10 mg and ML 40 mg. A 
      significant increase in nasal blockage VAS score was observed between baseline 
      and 60 min or 120 min with PL but not with ML 10 mg or ML 40 mg. There were no 
      significant differences for either the maximum or mean % FEV1 over 120 min as 
      change from baseline comparing all groups. A single 10 mg dose of montelukast 
      partially protected against the local effects of nasal lysine-aspirin challenge, 
      with no further benefit at 40 mg. Nasal lysine-aspirin challenge appeared to be a 
      reproducible and safe method in assessing patients with aspirin-induced asthma.
FAU - Lee, D K C
AU  - Lee DK
AD  - Asthma and Allergy Research Group, Ninewells Hospital and Medical School, 
      University of Dundee, Dundee, Scotland, UK.
FAU - Haggart, K
AU  - Haggart K
FAU - Robb, F M
AU  - Robb FM
FAU - Lipworth, B J
AU  - Lipworth BJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - 0 (Acetates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Leukotrienes)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - 0 (cysteinyl-leukotriene)
RN  - K3Z4F929H6 (Lysine)
RN  - K848JZ4886 (Cysteine)
RN  - MHM278SD3E (montelukast)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acetates/*administration & dosage
MH  - Administration, Inhalation
MH  - Adult
MH  - Aspirin/*adverse effects/*analogs & derivatives/pharmacology
MH  - Asthma/*chemically induced/*prevention & control
MH  - Confidence Intervals
MH  - Cross-Over Studies
MH  - Cyclopropanes
MH  - Cysteine/drug effects/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Leukotrienes/*metabolism
MH  - Lysine/*adverse effects/*analogs & derivatives/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Nasal Provocation Tests
MH  - Peak Expiratory Flow Rate
MH  - Quinolines/*administration & dosage
MH  - Reference Values
MH  - Reproducibility of Results
MH  - Spirometry
MH  - Sulfides
EDAT- 2004/08/31 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/08/31 05:00
PHST- 2004/08/31 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/08/31 05:00 [entrez]
AID - 10.1183/09031936.04.00100303 [doi]
PST - ppublish
SO  - Eur Respir J. 2004 Aug;24(2):226-30. doi: 10.1183/09031936.04.00100303.

PMID- 8425302
OWN - NLM
STAT- MEDLINE
DCOM- 19930303
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 87
IP  - 2
DP  - 1993 Feb
TI  - Effect of aspirin on coronary collateral blood flow.
PG  - 583-9
AB  - BACKGROUND: Although aspirin exerts beneficial antiplatelet activity in patients 
      with coronary artery disease, cyclooxygenase blockade produced by aspirin causes 
      a potentially deleterious effect by interrupting endothelial production of 
      prostacyclin. Collateral vessels that develop in response to coronary occlusion 
      display prominent endothelial cell proliferation and undergo vasoconstriction in 
      response to indomethacin. This study was performed to test the hypothesis that 
      cyclooxygenase blockade with aspirin would cause constriction of coronary 
      collateral vessels and that such vasoconstriction would be reversed with 
      nitroglycerin. METHODS AND RESULTS: Collateral vessel growth was induced by 
      embolic occlusion of the left anterior descending coronary artery in dogs. Four 
      to 6 months later, coronary collateral flow was measured as retrograde flow from 
      the cannulated collateral-dependent artery. Aspirin (1 mg/kg i.v.) caused 70 +/- 
      8% blockade of the increase in coronary blood flow produced by intra-arterial 
      arachidonic acid and decreased retrograde flow from 37 +/- 7 to 28 +/- 7 ml/min 
      (p < 0.03). Increasing the dose of aspirin to 15 mg/kg i.v. caused 91 +/- 3% 
      blockade of the response to arachidonic acid and further decreased retrograde 
      flow to 21 +/- 4 ml/min (p < 0.01). After aspirin administration, nitroglycerin 
      (150 micrograms/min i.c.) reversed the collateral constriction and increased 
      retrograde flow to 37 +/- 10 ml/min (p < 0.01). CONCLUSIONS: These data suggest 
      that products of cyclooxygenase metabolism cause tonic vasodilation of 
      well-developed coronary collateral vessels. Blockade of cyclooxygenase with even 
      low-dose aspirin caused collateral vessel constriction with a decrease in 
      collateral blood flow. However, nitroglycerin was able to fully reverse 
      aspirin-induced collateral vasoconstriction and restore flow to the control 
      level.
FAU - Altman, J D
AU  - Altman JD
AD  - Department of Medicine, University of Minnesota Medical School, Minneapolis 
      55455.
FAU - Dulas, D
AU  - Dulas D
FAU - Pavek, T
AU  - Pavek T
FAU - Bache, R J
AU  - Bache RJ
LA  - eng
GR  - HL-20598/HL/NHLBI NIH HHS/United States
GR  - HL-32427/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*pharmacology
MH  - Collateral Circulation/*drug effects
MH  - Coronary Circulation/*drug effects
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Dogs
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Male
MH  - Nitroglycerin/pharmacology
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
AID - 10.1161/01.cir.87.2.583 [doi]
PST - ppublish
SO  - Circulation. 1993 Feb;87(2):583-9. doi: 10.1161/01.cir.87.2.583.

PMID- 7349091
OWN - NLM
STAT- MEDLINE
DCOM- 19830214
LR  - 20131121
IS  - 0004-069X (Print)
IS  - 0004-069X (Linking)
VI  - 29
IP  - 6
DP  - 1981
TI  - Influence of aspirin and/or anabolic steroid (nandrolone decanoate) on 
      experimental metastasis formation.
PG  - 697-701
AB  - The influence on transpulmonary passage by an inhibitor of platelet aggregation, 
      aspirin, and/or anabolic steroid, (Nandrolone decanoate), was investigated in 
      syngeneic CBA mice. An increase of extrapulmonary metastases was used as a 
      measure of increased redistribution of tumor cells from lungs to other organs. 
      Aspirin alone did not reduce metastasis formation in lungs and did not 
      significantly increase transpulmonary passage of tumor cells. The anabolic 
      steroid increased the metastasis crop only in the lungs. However, treatment with 
      the two compounds together increased the metastases in lungs and extrapulmonary 
      organs. The results disclosed that in this system inhibition of platelet 
      aggregation did not reduce metastasis formation but in combination with another 
      drug, an anabolic steroid, it increased the number of experimental metastases.
FAU - Zbytniewski, Z
AU  - Zbytniewski Z
FAU - Kanclerz, A
AU  - Kanclerz A
FAU - Boeryd, B
AU  - Boeryd B
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Arch Immunol Ther Exp (Warsz)
JT  - Archivum immunologiae et therapiae experimentalis
JID - 0114365
RN  - 6PG9VR430D (Nandrolone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Drug Interactions
MH  - Mice
MH  - Nandrolone/*pharmacology
MH  - *Neoplasm Metastasis
MH  - Platelet Aggregation/drug effects
MH  - Sarcoma, Experimental/*pathology
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Arch Immunol Ther Exp (Warsz). 1981;29(6):697-701.

PMID- 7116442
OWN - NLM
STAT- MEDLINE
DCOM- 19821202
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 2
IP  - 1
DP  - 1982 Mar
TI  - Aspirin treatment of migraine attacks: plasma drug level data.
PG  - 9-14
AB  - Plasma aspirin and salicylate levels were measured at intervals over a two hour 
      period during migraine attacks in 10 subjects given 900 mg oral aspirin alone, in 
      10 subjects given 900 mg oral aspirin plus 10 mg oral metoclopramide, and in 10 
      subjects given 900 mg oral aspirin plus an intramuscular injection of 10 mg 
      metoclopramide. Higher peak aspirin and salicylate levels occurred in patients 
      given aspirin with metoclopramide. Aspirin tended to appear in plasma earlier in 
      patients given aspirin with oral metoclopramide than in patients given aspirin 
      alone, or aspirin with intramuscular metoclopramide. Patients given aspirin with 
      oral metoclopramide tended to obtain better early pain relief than the other two 
      treatment groups, though by one hour from dosage use of injected metoclopramide 
      was also associated with better pain relief.
FAU - Ross-Lee, L
AU  - Ross-Lee L
FAU - Heazlewood, V
AU  - Heazlewood V
FAU - Tyrer, J H
AU  - Tyrer JH
FAU - Eadie, M J
AU  - Eadie MJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Salicylates)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/blood/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Metoclopramide/administration & dosage/therapeutic use
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Salicylates/blood
MH  - Time Factors
EDAT- 1982/03/01 00:00
MHDA- 1982/03/01 00:01
CRDT- 1982/03/01 00:00
PHST- 1982/03/01 00:00 [pubmed]
PHST- 1982/03/01 00:01 [medline]
PHST- 1982/03/01 00:00 [entrez]
AID - 10.1046/j.1468-2982.1982.0201009.x [doi]
PST - ppublish
SO  - Cephalalgia. 1982 Mar;2(1):9-14. doi: 10.1046/j.1468-2982.1982.0201009.x.

PMID- 15507891
OWN - NLM
STAT- MEDLINE
DCOM- 20050208
LR  - 20131121
IS  - 0392-9590 (Print)
IS  - 0392-9590 (Linking)
VI  - 23
IP  - 2
DP  - 2004 Jun
TI  - Effects of acetylsalicylic acid on experimental atherogenesis induced in rabbits.
PG  - 139-43
AB  - AIM: Inflammation related processes play a key role in the current etiologic 
      model of atherosclerosis and its acute complications. In addition, 
      platelet-derived growth factors stimulate the neointimal proliferation of 
      restenosis after coronary interventions. Reducing platelet accumulation at 
      treated sites may attenuate restenosis. The purpose of this experimental study 
      was to investigate the effect of acetylsalicylic acid (ASA), a widely used 
      anti-platelet and anti-inflammatory agent on the development and extent of 
      atherosclerosis. METHODS: Fourty-eight male white New Zealand rabbits were 
      separated in 4 groups (12 animals each group). Group I received a diet of 2% 
      cholesterol and 6% corn oil for 3 months. Group II received a diet of 2% 
      cholesterol and 6% corn oil and in addition received 3 mg of ASA/kg daily 
      intramuscular (i.m.) for 3 months. Group III received the same diet, and in 
      addition received 10 mg of ASA/kg daily i.m. for 3 months. Group IV received the 
      same diet and in addition received 50 mg of ASA/kg daily i.m. for 3 months. 
      Animals were sacrificed after 3 months. RESULTS: ASA reduced the serum levels of 
      total cholesterol, total lipids, triglycerides and LDL cholesterol. There was 
      significant difference in the extent of atherosclerotic lesions between animals 
      which received different doses of ASA and that animals which did not received any 
      ASA. High dose ASA treatment resulted in an increase in fasting plasma glucose, 
      associated with a reduction in total cholesterol and triglycerides. CONCLUSION: 
      Our results suggest that there is a protective effect on atherosclerosis 
      development of ASA down stream from where it lowers plasma fatty acid 
      concentrations. However, further studies are required to verify that effect.
FAU - Kouraklis, G
AU  - Kouraklis G
AD  - 2nd Department of Propedeutic Surgery and Laboratory of Experimental Surgery and 
      Surgical Research, School of Medicine, University of Athens, Athens, Greece. 
      gkouraklis@hotmail.com
FAU - Patapis, P
AU  - Patapis P
FAU - Misiakos, E
AU  - Misiakos E
FAU - Glinavou, A
AU  - Glinavou A
FAU - Sioka, C
AU  - Sioka C
FAU - Karayiannakos, P E
AU  - Karayiannakos PE
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Int Angiol
JT  - International angiology : a journal of the International Union of Angiology
JID - 8402693
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Arteriosclerosis/*prevention & control
MH  - Aspirin/*pharmacology
MH  - Diet, Atherogenic
MH  - Male
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rabbits
EDAT- 2004/10/28 09:00
MHDA- 2005/02/09 09:00
CRDT- 2004/10/28 09:00
PHST- 2004/10/28 09:00 [pubmed]
PHST- 2005/02/09 09:00 [medline]
PHST- 2004/10/28 09:00 [entrez]
PST - ppublish
SO  - Int Angiol. 2004 Jun;23(2):139-43.

PMID- 36374376
OWN - NLM
STAT- MEDLINE
DCOM- 20221215
LR  - 20230129
IS  - 1534-6315 (Electronic)
IS  - 1529-7322 (Print)
IS  - 1529-7322 (Linking)
VI  - 22
IP  - 12
DP  - 2022 Dec
TI  - Urinary Leukotriene E4 as a Biomarker in NSAID-Exacerbated Respiratory Disease 
      (N-ERD): a Systematic Review and Meta-analysis.
PG  - 209-229
LID - 10.1007/s11882-022-01049-8 [doi]
AB  - PURPOSE OF REVIEW: Non-steroidal exacerbated respiratory disease (N-ERD) 
      currently requires aspirin challenge testing for diagnosis. Urinary leukotriene 
      E4 (uLTE(4)) has been extensively investigated as potential biomarker in N-ERD. 
      We aimed to assess the usefulness of uLTE(4) as a biomarker in the diagnosis of 
      N-ERD. RECENT FINDINGS: N-ERD, formerly known as aspirin-intolerant asthma (AIA), 
      is characterised by increased leukotriene production. uLTE(4) indicates cysteinyl 
      leukotriene production, and a potential biomarker in N-ERD. Although several 
      studies and have examined the relationship between uLTE(4) and N-ERD, the 
      usefulness of uLTE(4) as a biomarker in a clinical setting remains unclear. 
      FINDINGS: Our literature search identified 38 unique eligible studies, 35 were 
      included in the meta-analysis. Meta-analysis was performed (i.e. pooled 
      standardised mean difference (SMD) with 95% confidence intervals (95% CI)) and 
      risk of bias assessed (implementing Cochrane Handbook for Systematic Reviews of 
      Diagnostic Test Accuracy (Cochrane DTA)). Data from 3376 subjects was analysed 
      (1354 N-ERD, 1420 ATA, and 602 HC). uLTE(4) was higher in N-ERD vs ATA (n = 35, 
      SMD 0.80; 95% CI 0.72-0.89). uLTE4 increased following aspirin challenge in N-ERD 
      (n = 12, SMD 0.56; 95% CI 0.26-0.85) but not ATA (n = 8, SMD 0.12; 
      CI - 0.08-0.33). This systematic review and meta-analysis showed that uLTE(4) is 
      higher in N-ERD than ATA or HC. Likewise, people with N-ERD have greater 
      increases in uLTE(4) following aspirin challenge. However, due to the varied 
      uLTE(4) measurement and result reporting practice, clinical utility of these 
      findings is limited. Future studies should be standardised to increase clinical 
      significance and interpretability of the results.
CI  - © 2022. Crown.
FAU - Marquette, Malcolm
AU  - Marquette M
AUID- ORCID: 0000-0002-6229-2729
AD  - Department of Respiratory Medicine, Norwich University Hospital, NorfolkNorwich, 
      UK. m.marquette@uea.ac.uk.
AD  - Norwich Medical School, University of East Anglia, Norwich, UK. 
      m.marquette@uea.ac.uk.
FAU - Tailor, Bhavesh V
AU  - Tailor BV
AD  - Norwich Medical School, University of East Anglia, Norwich, UK.
FAU - Calder, Philip C
AU  - Calder PC
AD  - School of Human Development and Health, Faculty of Medicine, University of 
      Southampton, Southampton, UK.
AD  - NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS 
      Foundation Trust and University of Southampton, Southampton, UK.
FAU - Curtis, Peter J
AU  - Curtis PJ
AD  - Department of Nutrition and Preventive Medicine, Norwich Medical School, 
      University of East Anglia, Norwich, UK.
FAU - Loke, Yoon
AU  - Loke Y
AD  - Norwich Medical School, University of East Anglia, Norwich, UK.
FAU - Wilson, Andrew M
AU  - Wilson AM
AD  - Department of Respiratory Medicine, Norwich University Hospital, NorfolkNorwich, 
      UK.
AD  - Norwich Medical School, University of East Anglia, Norwich, UK.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20221114
PL  - United States
TA  - Curr Allergy Asthma Rep
JT  - Current allergy and asthma reports
JID - 101096440
RN  - 75715-89-8 (Leukotriene E4)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Leukotriene E4
MH  - *Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/adverse effects
PMC - PMC9732072
OTO - NOTNLM
OT  - Aspirin-intolerance
OT  - Asthma
OT  - N-ERD
OT  - Non-steroidal anti-inflammatory respiratory disease
OT  - Samter’s
OT  - Urinary leukotrienes E4
COIS- The authors declare that they have no conflict of interest.
EDAT- 2022/11/15 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/11/14 11:30
PHST- 2022/10/18 00:00 [accepted]
PHST- 2022/11/15 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
PHST- 2022/11/14 11:30 [entrez]
AID - 10.1007/s11882-022-01049-8 [pii]
AID - 1049 [pii]
AID - 10.1007/s11882-022-01049-8 [doi]
PST - ppublish
SO  - Curr Allergy Asthma Rep. 2022 Dec;22(12):209-229. doi: 
      10.1007/s11882-022-01049-8. Epub 2022 Nov 14.

PMID- 14583979
OWN - NLM
STAT- MEDLINE
DCOM- 20040504
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 4
DP  - 2003
TI  - Antiplatelet and anticoagulation for patients with prosthetic heart valves.
PG  - CD003464
AB  - BACKGROUND: Patients with prosthetic heart valves are at increased risk for valve 
      thrombosis and arterial thromboembolism. Oral anticoagulation alone, or the 
      addition of antiplatelet drugs, has been used to minimize this risk. An important 
      issue is the effectiveness and safety of the latter strategy. OBJECTIVES: To 
      compare the effectiveness and safety of adding antiplatelet therapy to standard 
      oral anticoagulation among patients with prosthetic heart valves. SEARCH 
      STRATEGY: We searched the Cochrane Central Register of Controlled Trials 
      (Cochrane Library Issue 2, 2003), MEDLINE (January 1966 to August 2002), EMBASE 
      (January 1988 to July 2001) and reference lists of individual reports, review 
      articles, meta-analyses, and consensus statements. SELECTION CRITERIA: All 
      reports of randomised controlled trials comparing standard dose oral 
      anticoagulation to standard dose oral anticoagulation and antiplatelet therapy in 
      patients with one or more prosthetic heart valves. We included reports published 
      in any language or in abstract form. DATA COLLECTION AND ANALYSIS: Two reviewers 
      independently performed the search strategy, assessed trials for inclusion 
      criteria, study quality, and extracted data. Adverse effects information was 
      collected from the trials. MAIN RESULTS: Eleven studies involving 2,428 subjects 
      met the inclusion criteria. Year of publication ranged from 1971 to 2000. 
      Compared with anticoagulation alone, the addition of an antiplatelet agent 
      reduced the risk of thromboembolic events (odds ratio 0.39 (95% confidence 
      interval 0.28 to 0.56; p<0.00001)) and total mortality (odds ratio 0.55 (95% 
      confidence interval 0.40 to 0.77; p=0.0003)). Aspirin and dipyridamole reduced 
      these events similarly. The risk of major bleeding was increased when 
      antiplatelet agents were added to oral anticoagulants (odds ratio 1.66 (95% 
      confidence interval 1.18 to 2.34; p=0.003)). For major bleeding, there was no 
      evidence of heterogeneity between aspirin and dipyridamole and in the comparison 
      of trials performed before and after 1990, around the time when anticoagulation 
      standardization with the international normalized ratio was being implemented. 
      REVIEWER'S CONCLUSIONS: Adding antiplatelet therapy, either dipyridamole or 
      low-dose aspirin, to oral anticoagulation decreases the risk of systemic embolism 
      or death among patients with prosthetic heart valves. The risk of major bleeding 
      is increased with antiplatelet therapy. These results apply to patients with 
      mechanical prosthetic valves or those with biological valves and indicators of 
      high risk such as atrial fibrillation or prior thromboembolic events. The 
      effectiveness and safety of low dose aspirin (100 mg daily) appears to be similar 
      to higher dose aspirin and dipyridamole.
FAU - Little, S H
AU  - Little SH
AD  - Division of Cardiology, Department of Medicine, London Health Sciences Centre, 
      University of Western Ontario, 375 South Street, London, Ontario, Canada, N6A 
      4G5.
FAU - Massel, D R
AU  - Massel DR
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UIN - Cochrane Database Syst Rev. 2013;7:CD003464. PMID: 23839768
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Heart Valve Prosthesis/*adverse effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Thromboembolism/*prevention & control
RF  - 42
EDAT- 2003/10/30 05:00
MHDA- 2004/05/05 05:00
CRDT- 2003/10/30 05:00
PHST- 2003/10/30 05:00 [pubmed]
PHST- 2004/05/05 05:00 [medline]
PHST- 2003/10/30 05:00 [entrez]
AID - 10.1002/14651858.CD003464 [doi]
PST - ppublish
SO  - Cochrane Database Syst Rev. 2003;(4):CD003464. doi: 10.1002/14651858.CD003464.

PMID- 524304
OWN - NLM
STAT- MEDLINE
DCOM- 19800324
LR  - 20131121
IS  - 0040-3709 (Print)
IS  - 0040-3709 (Linking)
VI  - 20
IP  - 2
DP  - 1979 Oct
TI  - Aspirin: teratogenic evaluation in the dog.
PG  - 313-20
AB  - Beagle bitches were administered aspirin at either 100 or 400 mg/kg/day between 
      Days 15 and 22 or Days 23 and 30 postmating, and corresponding control groups 
      were dosed with vehicle during one of these same time periods. Maternotoxicity 
      was evident in all dogs dosed with 400 mg/kg/day of aspirin, but no signs of 
      toxicity were observed when 400 mg/kg/day of aspirin was administered from Days 
      15 to 22 postmating. Teratogenicity, as evidenced by 50% malformation rate, was 
      seen in fetuses from dams treated with 400 mg/kg/day on Days 23 to30 postmating. 
      Observed malformations included, but were not limited to cleft 
      palate,micrognathia, anasarca, cardiovascular malformations, and tial anomalies. 
      No evidence of embryotoxic or teratogenic effects was seen in fetuses from either 
      100 mg/kg/day dosage level group. Examination of fetuses from 12 untreated 
      litters and 4 vehicle-control litters revealed a very low spontaneous 
      malformation rate confined almost entirely to minor tail abnormalities. These 
      data support use of the dog as an acceptable alternative species in teratogenic 
      screening.
FAU - Robertson, R T
AU  - Robertson RT
FAU - Allen, H L
AU  - Allen HL
FAU - Bokelman, D L
AU  - Bokelman DL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Teratology
JT  - Teratology
JID - 0153257
RN  - 0 (Teratogens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced/epidemiology
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fetal Death/chemically induced
MH  - Gestational Age
MH  - Pregnancy
MH  - *Teratogens
EDAT- 1979/10/01 00:00
MHDA- 1979/10/01 00:01
CRDT- 1979/10/01 00:00
PHST- 1979/10/01 00:00 [pubmed]
PHST- 1979/10/01 00:01 [medline]
PHST- 1979/10/01 00:00 [entrez]
AID - 10.1002/tera.1420200215 [doi]
PST - ppublish
SO  - Teratology. 1979 Oct;20(2):313-20. doi: 10.1002/tera.1420200215.

PMID- 31489509
OWN - NLM
STAT- MEDLINE
DCOM- 20200312
LR  - 20210110
IS  - 1248-9204 (Electronic)
IS  - 1248-9204 (Linking)
VI  - 23
IP  - 6
DP  - 2019 Dec
TI  - Continuation of low-dose acetylsalicylic acid during perioperative period of 
      laparoscopic inguinal hernia repair is safe: results of a prospective clinical 
      trial.
PG  - 1141-1148
LID - 10.1007/s10029-019-02040-5 [doi]
AB  - PURPOSE: Patients taking acetylsalicylic acid are common in surgical departments; 
      in most cases, acetylsalicylic acid is discontinued 5-7 days before the operation 
      to minimize the intra- and postoperative bleeding, but the perioperative 
      management of patients under antithrombotic and anticoagulative treatments is 
      controversial. This study aims to address whether the low-dose acetylsalicylic 
      acid increases bleeding and occurrence of postoperative complications after 
      laparoscopic inguinal hernia repair when it was only ceased on the operation day. 
      METHOD: From July 2017 to January 2019, 901 patients including 781 (86.7%) male 
      and 120 (13.3%) female patients underwent laparoscopic inguinal hernia repair 
      using trans-abdominal preperitoneal (TAPP) technique were recruited, among whom 
      152 (16.9%) had been taking low-dose (100 mg per day) acetylsalicylic acid which 
      was continued during hospitalization except the operation day. The 
      intra-operative bleeding volume, postoperative pain, overall occurrence of 
      complications such as seroma, hematoma, scrotal edema, calf muscle venous 
      thrombosis, and the time of resuming normal activities were compared with 
      patients on whom these medications were not needed. RESULTS: The age, BMI, 
      hospital stay, ASA classification, morbidity of CHD and hypertension, FIB value, 
      and the time of resuming normal activities of patients taking acetylsalicylic 
      acid were higher (p < 0.05). There was no significant difference on mean 
      operative time, intra-operative bleeding volume, and the occurrence postoperative 
      complications among two groups. CONCLUSION: For patients with inguinal hernias, 
      laparoscopic TAPP repair is completely safe to be performed on those taking 
      low-dose acetylsalicylic acid when it was only ceased on the operation day, with 
      intravenous salvianolate given after the operation instead.
FAU - Yan, Z
AU  - Yan Z
AD  - Department of General Surgery, Qilu Hospital, Shandong University, 107#, Wenhua 
      Xi Road, Jinan, 250012, Shandong, People's Republic of China.
FAU - Liu, Y
AU  - Liu Y
AD  - Department of Hernia and Abdominal Wall Surgery, Beijing Chaoyang Hospital, 
      Capital Medical University, Beijing, 100043, People's Republic of China.
FAU - Ruze, R
AU  - Ruze R
AD  - Department of General Surgery, Qilu Hospital, Shandong University, 107#, Wenhua 
      Xi Road, Jinan, 250012, Shandong, People's Republic of China.
FAU - Xiong, Y
AU  - Xiong Y
AD  - Department of General Surgery, Qilu Hospital, Shandong University, 107#, Wenhua 
      Xi Road, Jinan, 250012, Shandong, People's Republic of China.
FAU - Han, H
AU  - Han H
AD  - Department of General Surgery, Qilu Hospital, Shandong University, 107#, Wenhua 
      Xi Road, Jinan, 250012, Shandong, People's Republic of China.
FAU - Zhan, H
AU  - Zhan H
AD  - Department of General Surgery, Qilu Hospital, Shandong University, 107#, Wenhua 
      Xi Road, Jinan, 250012, Shandong, People's Republic of China.
FAU - Wang, M
AU  - Wang M
AD  - Department of Hernia and Abdominal Wall Surgery, Beijing Chaoyang Hospital, 
      Capital Medical University, Beijing, 100043, People's Republic of China.
FAU - Zhang, G
AU  - Zhang G
AUID- ORCID: 0000-0001-5308-0129
AD  - Department of General Surgery, Qilu Hospital, Shandong University, 107#, Wenhua 
      Xi Road, Jinan, 250012, Shandong, People's Republic of China. 
      guangyongzhang@hotmail.com.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20190905
PL  - France
TA  - Hernia
JT  - Hernia : the journal of hernias and abdominal wall surgery
JID - 9715168
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hernia, Inguinal/*surgery
MH  - Herniorrhaphy/*adverse effects
MH  - Humans
MH  - Laparoscopy
MH  - Male
MH  - Middle Aged
MH  - Perioperative Period
MH  - Postoperative Complications/chemically induced/etiology
MH  - Postoperative Hemorrhage/*chemically induced/etiology
MH  - Prospective Studies
MH  - Surgical Mesh
MH  - Young Adult
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Anticoagulant
OT  - Complication
OT  - Inguinal hernia
OT  - Laparoscopic repair
OT  - TAPP
EDAT- 2019/09/07 06:00
MHDA- 2020/03/13 06:00
CRDT- 2019/09/07 06:00
PHST- 2019/05/22 00:00 [received]
PHST- 2019/08/22 00:00 [accepted]
PHST- 2019/09/07 06:00 [pubmed]
PHST- 2020/03/13 06:00 [medline]
PHST- 2019/09/07 06:00 [entrez]
AID - 10.1007/s10029-019-02040-5 [pii]
AID - 10.1007/s10029-019-02040-5 [doi]
PST - ppublish
SO  - Hernia. 2019 Dec;23(6):1141-1148. doi: 10.1007/s10029-019-02040-5. Epub 2019 Sep 
      5.

PMID- 20920233
OWN - NLM
STAT- MEDLINE
DCOM- 20110811
LR  - 20211020
IS  - 1471-2318 (Electronic)
IS  - 1471-2318 (Linking)
VI  - 10
DP  - 2010 Sep 29
TI  - Is there an association between low dose aspirin and anemia (without overt 
      bleeding)? Narrative review.
PG  - 71
LID - 10.1186/1471-2318-10-71 [doi]
AB  - BACKGROUND: Overt bleeding associated with low dose aspirin (LDA) is 
      well-recognized, little attention is given to the possibility of association 
      between LDA and occult bleeding, although this is known to occur in healthy 
      volunteers. LDA is used increasingly in primary and secondary prevention of a 
      number of medical conditions, many of which are common in older people, as is 
      anemia. Anemia in older people is associated with adverse outcomes including 
      disability, morbidity and mortality. The purpose of this study was to review the 
      evidence that LDA might cause anemia without overt bleeding. METHODS: An 
      extensive narrative review was carried out. Electronic searching (including 
      database links) and reference lists of reports were used to identify studies 
      reporting on use of aspirin ≤325 mg/day and anemia or change in hemoglobin (Hb) 
      without overt bleeding. Data were extracted from reports of trials, adverse drug 
      reactions (ADRs) and prevalence studies of adults aged ≥18 years, published since 
      1980. RESULTS: There are few relevant data, with considerable heterogeneity among 
      trial designs, duration, and patient characteristics in studies of LDA. In five 
      randomised trials (n = 5879) in (mostly secondary) prevention, the majority of 
      patients were men without peptic ulcer disease aged 50-70 years and no consistent 
      association between LDA and change in Hb was found. In two smaller studies (n = 
      609) of primary prevention in healthy patients aged ≥70 years, there was a small 
      but statistically significant fall in Hb with LDA. Observational studies, and 
      data from trials in which use of LDA was not a primary focus of the study, were 
      inconclusive. CONCLUSIONS: It is not clear whether there is an association 
      between LDA and anemia in the absence of overt bleeding, but there may be an 
      association between LDA and fall in Hb in (a subset of) older patients. The 
      available evidence has significant limitations, which are discussed; studies 
      including more older patients, and publication of individual patient data, would 
      help clarify this important matter.
FAU - Gaskell, Helen
AU  - Gaskell H
AD  - Department of Clinical Geratology, John Radcliffe Hospital, Headington, Oxford 
      OX3 9DU, UK. helen.gaskell@pru.ox.ac.uk
FAU - Derry, Sheena
AU  - Derry S
FAU - Moore, R Andrew
AU  - Moore RA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20100929
PL  - England
TA  - BMC Geriatr
JT  - BMC geriatrics
JID - 100968548
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Anemia/blood/chemically induced/*epidemiology
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Erythrocyte Indices/drug effects/physiology
MH  - Hemorrhage/blood/chemically induced/*epidemiology
MH  - Humans
MH  - Narration
MH  - Randomized Controlled Trials as Topic/methods
PMC - PMC2956719
EDAT- 2010/10/06 06:00
MHDA- 2011/08/13 06:00
CRDT- 2010/10/06 06:00
PHST- 2010/02/17 00:00 [received]
PHST- 2010/09/29 00:00 [accepted]
PHST- 2010/10/06 06:00 [entrez]
PHST- 2010/10/06 06:00 [pubmed]
PHST- 2011/08/13 06:00 [medline]
AID - 1471-2318-10-71 [pii]
AID - 10.1186/1471-2318-10-71 [doi]
PST - epublish
SO  - BMC Geriatr. 2010 Sep 29;10:71. doi: 10.1186/1471-2318-10-71.

PMID- 15876010
OWN - NLM
STAT- MEDLINE
DCOM- 20051018
LR  - 20181201
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 22 Suppl 4
DP  - 2004
TI  - The value of clopidogrel in addition to standard therapy in reducing 
      atherothrombotic events.
PG  - 29-41
AB  - The recent multinational, randomised, prospective studies Clopidogrel in Unstable 
      Angina to Prevent Recurrent Events (CURE), Percutaneous Coronary Intervention 
      substudy of CURE (PCI-CURE) and Clopidogrel for the Reduction of Events During 
      Observation (CREDO) have demonstrated the clinical efficacy and safety of 
      clopidogrel for the treatment of patients with non-ST-segment elevation acute 
      coronary syndromes (ACS), including those undergoing percutaneous coronary 
      intervention. In these settings, clopidogrel significantly reduces the risk of 
      atherothrombotic events, with relative risk reductions of 20-30% (absolute risk 
      reduction 1.9-3.0%). Health economic evaluations based on data from these studies 
      conducted in Europe and the United States have clearly demonstrated the 
      cost-effectiveness of clopidogrel in combination with aspirin compared with 
      aspirin alone for the management of ACS. Within-trial evaluations based on CURE 
      and PCI-CURE data showed that treatment with clopidogrel on top of standard 
      therapy reduced the cost of initial hospitalisation as well as the total cost 
      associated with hospitalisations. Long-term economic analyses based on the CURE 
      study demonstrate that clopidogrel is cost saving in the Netherlands and that the 
      cost per life-year gained (LYG) in other European countries is between Euros 549 
      and Euros 5048. In the United States, the cost per LYG for clopidogrel has been 
      assessed at US dollars 6173 on the basis of CURE, US dollars 5910 for PCI-CURE 
      and US dollars 3685 for CREDO, all of which are considerably lower than that 
      associated with common cardiovascular benchmarks. The results are robust and 
      consistent across different countries using varying costing strategies and 
      estimates of survival. In conclusion, these data demonstrate that clopidogrel in 
      combination with aspirin for the management of ACS is both clinically effective 
      and cost-effective in this setting.
FAU - Weintraub, William
AU  - Weintraub W
AD  - Emory Center for Outcomes Research, Division of Cardiology, Department of 
      Medicine, Emory University School of Medicine, Atlanta, GA 30306, USA. 
      wweintr@emory.edu
FAU - Jönsson, Bengt
AU  - Jönsson B
FAU - Bertrand, Michel
AU  - Bertrand M
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Multicenter Study
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - Angioplasty, Balloon, Coronary/methods/statistics & numerical data
MH  - Arterial Occlusive Diseases/drug therapy/*prevention & control
MH  - Aspirin/pharmacology/therapeutic use
MH  - Benchmarking/*standards
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ticlopidine/*analogs & derivatives/economics/pharmacology/therapeutic use
EDAT- 2005/05/07 09:00
MHDA- 2005/10/19 09:00
CRDT- 2005/05/07 09:00
PHST- 2005/05/07 09:00 [pubmed]
PHST- 2005/10/19 09:00 [medline]
PHST- 2005/05/07 09:00 [entrez]
AID - 10.2165/00019053-200422004-00006 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2004;22 Suppl 4:29-41. doi: 10.2165/00019053-200422004-00006.

PMID- 25361218
OWN - NLM
STAT- MEDLINE
DCOM- 20160222
LR  - 20191210
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 262
IP  - 6
DP  - 2015 Dec
TI  - Association Between Preoperative Aspirin-dosing Strategy and Mortality After 
      Coronary Artery Bypass Graft Surgery.
PG  - 1150-6
LID - 10.1097/SLA.0000000000000951 [doi]
AB  - OBJECTIVE: To determine whether preoperative aspirin-acetylsalicylic acid 
      (ASA)-timing or dose independently affects 30-day all-cause mortality. 
      BACKGROUND: Preoperative ASA administration is associated with reduced morbidity 
      and mortality after coronary artery bypass graft (CABG). However, data are 
      lacking regarding optimal timing and dosing of ASA. METHODS: We retrospectively 
      reviewed data from 3018 consecutive patients who underwent CABG surgery between 
      July 2005 and May 2011. Patients were assigned to 3 groups according to the time 
      of the last preoperative ASA dose: (1) 24 hours or less preoperatively 
      (n = 1173), (2) between 24 and 72 hours (n = 876), and (3) more than 72 hours or 
      none (n = 969). In a separate analysis, patients were grouped according to ASA 
      dose: 81 mg (n = 1285), 325 mg (n = 1004), and none (n = 543). The primary 
      outcome was 30-day all-cause mortality. RESULTS: The 30-day mortality rate was 
      significantly lower in patients who took ASA 24 hours or less preoperatively 
      (1.5%) than in those who took it between 24 and 72 hours (3.2%) or more than 
      72 hours or none (2.9%). Multivariate analysis showed that ASA within 24 hours 
      preoperatively was associated with reduced mortality (odds ratio [OR], 0.41; 95% 
      confidence interval [CI], 0.20-0.82; P = 0.01). Moreover, mortality was 
      significantly reduced for patients taking 81 mg of ASA (1.4%) compared with 
      325 mg (2.9%) or none (3.9%). Multivariate analysis demonstrated that 81 mg of 
      ASA decreased mortality risk by 66% (OR, 0.34; 95% CI, 0.18-0.66; P < 0.01), 
      whereas 325 mg of ASA had no mortality benefit (OR, 0.74; 95% CI, 0.41-1.35; 
      P = 0.33) compared with no ASA. CONCLUSIONS: Low-dose ASA use within 24 hours of 
      CABG is independently associated with decreased early postoperative mortality.
FAU - Deng, Yi
AU  - Deng Y
AD  - *Department of Anesthesiology, Baylor College of Medicine, Houston, TX 
      †Department of Biostatistics and Epidemiology, Texas Heart Institute, Houston, TX 
      ‡Division of Cardiovascular Anesthesiology, Texas Heart Institute, Baylor St. 
      Luke's Medical Center, Houston, TX §Department of Cardiovascular Surgery, Texas 
      Heart Institute, Houston, TX.
FAU - Pisklak, Paul V
AU  - Pisklak PV
FAU - Lee, Vei-Vei
AU  - Lee VV
FAU - Tolpin, Daniel A
AU  - Tolpin DA
FAU - Collard, Charles D
AU  - Collard CD
FAU - Elayda, MacArthur A
AU  - Elayda MA
FAU - Coselli, Joseph
AU  - Coselli J
FAU - Pan, Wei
AU  - Pan W
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Surg. 2017 May;265(5):e65. PMID: 25828866
CIN - Ann Surg. 2017 May;265(5):e65-e66. PMID: 28394789
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Coronary Artery Bypass/*mortality
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Postoperative Complications/mortality/*prevention & control
MH  - Preoperative Care/*methods
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2014/11/02 06:00
MHDA- 2016/02/24 06:00
CRDT- 2014/11/01 06:00
PHST- 2014/11/01 06:00 [entrez]
PHST- 2014/11/02 06:00 [pubmed]
PHST- 2016/02/24 06:00 [medline]
AID - 10.1097/SLA.0000000000000951 [doi]
PST - ppublish
SO  - Ann Surg. 2015 Dec;262(6):1150-6. doi: 10.1097/SLA.0000000000000951.

PMID- 12475558
OWN - NLM
STAT- MEDLINE
DCOM- 20030213
LR  - 20191106
IS  - 0968-4328 (Print)
IS  - 0968-4328 (Linking)
VI  - 33
IP  - 7-8
DP  - 2002
TI  - In vitro fibrillogenesis of the amyloid beta 1-42 peptide: cholesterol 
      potentiation and aspirin inhibition.
PG  - 609-26
AB  - Understanding the formation of extracellular amyloid neurofibrillar 
      bundles/senile plaques and their role in the development of Alzheimer's disease 
      is of considerable interest to neuroscientists and clinicians. Major components 
      of the extracellular neurofibrillar bundles are polymerized amyloid beta (Abeta) 
      peptides (1-40), (1-42) and (1-43), derived in vivo from the soluble amyloid 
      precursor protein (sAPP) by proteolytic (beta- and gamma-secretase) cleavage. The 
      Abeta(1-42) peptide is widely considered to be of greatest significance in 
      relation to the pathogenesis of Alzheimer's disease. A well-defined 
      ultrastructural characteristic within Alzheimer dense plaques is the presence of 
      helical fibrils that are believed to consist of polymerized amyloid beta, 
      together with other associated proteins such as the serum amyloid P protein, 
      apolipoprotein E isoform epsilon 4, alpha1-anti-chymotrypsin, catalase, 
      glycoproteins, proteoglycans, cholesterol and other lipids. The spontaneous in 
      vitro fibrillogenesis of chemically synthesized Abeta(1-42) peptide (rat 
      sequence), following 20h incubation at 37 degrees C, has been assessed from 
      uranyl acetate negatively stained specimens studied by transmission electron 
      microscopy (TEM). Amyloid beta(1-42) peptide fibrillogenesis in the presence of 
      cholesterol has been investigated using aqueous suspensions of microcrystalline 
      cholesterol and cholesteryl acetate, globular particles of cholesteryl oleate, a 
      soluble (micellar) cholesterol derivative (polyoxyethyl cholesteryl 
      sebacate/cholesteryl PEG 600 sebacate), cholesterol-sphingomyelin liposomes and 
      sphingomyelin liposomes. In all these cases, with the exception of cholesteryl 
      oleate, considerable potentiation of long smooth helical fibril formation 
      occurred, compared to 20h 37 degrees C control samples containing the Abeta(1-42) 
      peptide alone. The binding of polyoxyethyl cholesteryl sebacate micelles to 
      helical Abeta fibrils/filaments and the binding of fibrils to the surface of 
      cholesterol and cholesteryl acetate microcrystals, and to a lesser extent on 
      cholesteryl oleate globules, indicates an affinity of the Abeta peptide for 
      cholesterol. This potentiation of Abeta(1-42) polymerization is likely to be 
      mediated at the molecular level via hydrophobic interaction between the amino 
      acid side chains of the peptide and the tetracyclic sterol nucleus. Addition of 
      cupric sulphate (0.1mM) to the Abeta solution produced large disorganized fibril 
      aggregates. Inclusion of 1mM aspirin (sodium acetylsalicylate) in the Abeta 
      peptide alone and as an addition to Abeta peptide solution containing 
      cholesterol, cholesteryl acetate, soluble cholesterol, sphingomyelin and 
      sphingomyelin-cholesterol liposomes, and to 0.1mM cupric sulphate solution, 
      completely inhibited fibrillogenesis. Instead, only non-crystalline diffuse, 
      non-filamentous microaggregates of insoluble Abeta particles were found, free and 
      attached to the sterol particles. The in vitro system presented here provides a 
      way to rapidly monitor at the structural/TEM level other compounds (e.g. 
      chelating agents, drugs, beta-sheet breaking peptides and anti-oxidants) for 
      their effects on amyloid beta peptide fibrillogenesis (and on preformed fibril 
      disassembly) in parallel with in vitro biochemical studies and in vivo studies 
      using animal models of Alzheimer's disease as well as studies on man.
FAU - Harris, J R
AU  - Harris JR
AD  - Institute of Zoology, University of Mainz, D-55099 Mainz, Germany. 
      rharris@mail.uni-mainz.de
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Micron
JT  - Micron (Oxford, England : 1993)
JID - 9312850
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Peptides)
RN  - 0 (Sphingomyelins)
RN  - 789U1901C5 (Copper)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alzheimer Disease/physiopathology
MH  - Amyloid beta-Peptides/*chemistry
MH  - Animals
MH  - Aspirin/chemistry/*pharmacology
MH  - Cholesterol/chemistry/*pharmacology
MH  - Copper/chemistry/pharmacology
MH  - Dimerization
MH  - Humans
MH  - Microscopy, Electron
MH  - Peptides/chemical synthesis/*chemistry
MH  - Rats
MH  - Sphingomyelins/chemistry/pharmacology
EDAT- 2002/12/12 04:00
MHDA- 2003/02/14 04:00
CRDT- 2002/12/12 04:00
PHST- 2002/12/12 04:00 [pubmed]
PHST- 2003/02/14 04:00 [medline]
PHST- 2002/12/12 04:00 [entrez]
AID - S096843280200029X [pii]
AID - 10.1016/s0968-4328(02)00029-x [doi]
PST - ppublish
SO  - Micron. 2002;33(7-8):609-26. doi: 10.1016/s0968-4328(02)00029-x.

PMID- 22128425
OWN - NLM
STAT- MEDLINE
DCOM- 20111215
LR  - 20131121
IS  - 0083-8969 (Print)
IS  - 0083-8969 (Linking)
VI  - 52
DP  - 2009
TI  - The effect of acupuncture on leukocyte levels in peripheral blood is modified by 
      aspirin.
PG  - 61-2
AB  - It has been shown that acupuncture can modify circulating levels of 
      subpopulations of leukocytes. There have been few investigations on the effect of 
      acupuncture on prostaglandins metabolism. Aspirin is capable of inhibiting the 
      metabolism of prostaglandins and to produce several pharmacological effects. The 
      objective of this study was to determine whether prior administration of aspirin 
      could modify the action of acupuncture on levels of circulating leukocytes. 
      Fourteen healthy males (age: 19-23 years) were recruited from a university 
      student population. This study was a placebo-controlled, prospective, cross-over 
      design. Subjects were randomly assigned into A or B groups. Group A received 
      aspirin 500 mg and group B placebo, after 1 week of a washout period, group A 
      received placebo and group B aspirin. Subjects were given acupuncture with manual 
      needling in GV14 (Dazhui) acupoint 2 hr after receiving medication. The needle 
      was stimulated for 10 sec and was kept in place for 5 min. Leukocytes and their 
      subpopulations were quantified in blood samples taken immediately before and 2 hr 
      after acupuncture treatment. In each subject pre-acupuncture values were compared 
      to those post-acupuncture. The results showed that acupuncture significantly 
      increased overall leukocytes (p=0.006) and neutrophils (p<0.001). Aspirin 
      partially inhibited these effects. The data suggest that the effect of 
      acupuncture on leukocytes may be related to levels of prostaglandins.
FAU - Rivas-Vilchis, José Federico
AU  - Rivas-Vilchis JF
AD  - Especialización en Acupuntura y Fitoterapia, Departamento de Ciencias de la 
      Salud, Universidad Autónoma Metropolitana, Iztapalapa, México. jfrv@xanum.uam.mx
FAU - Barrera-Escorcia, Eduardo
AU  - Barrera-Escorcia E
FAU - Fregoso-Padilla, Martha
AU  - Fregoso-Padilla M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Proc West Pharmacol Soc
JT  - Proceedings of the Western Pharmacology Society
JID - 7505899
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acupuncture Therapy
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Cross-Over Studies
MH  - Humans
MH  - Leukocyte Count
MH  - Leukocytes/*drug effects
MH  - Male
MH  - Prospective Studies
MH  - Prostaglandins/metabolism
EDAT- 2009/01/01 00:00
MHDA- 2011/12/16 06:00
CRDT- 2011/12/01 06:00
PHST- 2011/12/01 06:00 [entrez]
PHST- 2009/01/01 00:00 [pubmed]
PHST- 2011/12/16 06:00 [medline]
PST - ppublish
SO  - Proc West Pharmacol Soc. 2009;52:61-2.

PMID- 7761514
OWN - NLM
STAT- MEDLINE
DCOM- 19950629
LR  - 20220318
IS  - 0032-1052 (Print)
IS  - 0032-1052 (Linking)
VI  - 95
IP  - 7
DP  - 1995 Jun
TI  - The antithrombotic effects of ticlopidine and aspirin in a microvascular 
      thrombogenic model.
PG  - 1258-64
AB  - In the effort to reduce a persistently significant failure rate in free tissue 
      transfers and digital replantations, the efficacy of two oral platelet 
      inhibitors, aspirin and ticlopidine, was examined using the arterial inversion 
      graft, a known microvascular thrombogenic model. Forty male New Zealand White 
      rabbits were used to create eighty 5-mm inversion grafts. Four groups were 
      blindly given perioperative oral drug therapy: ticlopidine, aspirin, both, or 
      neither (control). Vessel patency was evaluated at 1 hour and 1 week after 
      surgery. The patency rate for the control group was 20 percent at 1 hour and 5 
      percent at 1 week. The drug-treated patency rates at 1 hour and 1 week, 
      respectively, were 45 percent (p = 0.046) and 15 percent for ticlopidine, 35 
      percent and 10 percent for aspirin, and 45 percent (p = 0.046) and 20 percent for 
      the combination therapy. This study shows that ticlopidine alone or in 
      combination with aspirin significantly increases the 1-hour patency rates in a 
      reliable thrombosis model, but it fails to show a significant increase in the 
      final patency rates by either drug administered alone or in combination. The 
      benefit in clinical microvascular surgery of either aspirin or ticlopidine is not 
      determined by this study.
FAU - Basile, A P
AU  - Basile AP
AD  - Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, 
      Boston, USA.
FAU - Fiala, T G
AU  - Fiala TG
FAU - Yaremchuk, M J
AU  - Yaremchuk MJ
FAU - May, J W Jr
AU  - May JW Jr
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Plast Reconstr Surg
JT  - Plastic and reconstructive surgery
JID - 1306050
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Femoral Artery/surgery
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Male
MH  - Microsurgery
MH  - Rabbits
MH  - Thrombosis/*prevention & control
MH  - Ticlopidine/*therapeutic use
MH  - Vascular Patency/drug effects
EDAT- 1995/06/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
AID - 10.1097/00006534-199506000-00018 [doi]
PST - ppublish
SO  - Plast Reconstr Surg. 1995 Jun;95(7):1258-64. doi: 
      10.1097/00006534-199506000-00018.

PMID- 3923028
OWN - NLM
STAT- MEDLINE
DCOM- 19850723
LR  - 20161123
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 61
IP  - 1
DP  - 1985 Jul
TI  - Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to 
      glucose in noninsulin-dependent diabetes mellitus.
PG  - 160-6
AB  - To assess whether the beneficial effects of salicylates compounds and 
      sulfonylureas on insulin secretion in patients with noninsulin-dependent diabetes 
      mellitus could be ascribed to inhibition of prostaglandin E (PGE) synthesis, 
      insulin responses to iv glucose pulses were determined in diabetic patients 
      during infusion of lysine acetylsalicylate (LAS) or tolbutamide, with or without 
      a concurrent infusion of PGE2. In these diabetic patients, the augmenting effects 
      of LAS on glucose-induced insulin secretion were abolished by PGE2 infusion. 
      Partial restoration by tolbutamide infusion of the first and second phases of 
      glucose-induced insulin secretion was not affected by the administration of PGE2. 
      The stimulatory effects of LAS and tolbutamide on insulin secretion were 
      additive, suggesting separate mechanisms of action. Since salicylates and 
      sulfonylureas lower plasma glucose concentrations, we also evaluated whether 
      prevention of the fall in the prestimulus glucose level could result in a further 
      amplification of insulin release. Resetting the prestimulus glucose level to 
      control values by infusing glucose caused a further increase in the second, but 
      not the first, phase of glucose-induced insulin secretion, indicating that the 
      prestimulus glucose level had a role in regulating subsequent insulin release. 
      These results indicate that salicylates, but not sulfonylureas, exert their acute 
      insulinotropic effect in noninsulin-dependent diabetic patients by inhibiting 
      endogenous PGE synthesis and support the idea that endogenous PGE may play a role 
      in the impaired insulin response to glucose in this form of human diabetes.
FAU - Giugliano, D
AU  - Giugliano D
FAU - Ceriello, A
AU  - Ceriello A
FAU - Saccomanno, F
AU  - Saccomanno F
FAU - Quatraro, A
AU  - Quatraro A
FAU - Paolisso, G
AU  - Paolisso G
FAU - D'Onofrio, F
AU  - D'Onofrio F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Prostaglandins E)
RN  - 982XCM1FOI (Tolbutamide)
RN  - IY9XDZ35W2 (Glucose)
RN  - K3Z4F929H6 (Lysine)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Dinoprostone
MH  - Drug Interactions
MH  - *Glucose
MH  - Humans
MH  - Insulin/*blood
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Middle Aged
MH  - *Prostaglandins E
MH  - Tolbutamide/*pharmacology
EDAT- 1985/07/01 00:00
MHDA- 1985/07/01 00:01
CRDT- 1985/07/01 00:00
PHST- 1985/07/01 00:00 [pubmed]
PHST- 1985/07/01 00:01 [medline]
PHST- 1985/07/01 00:00 [entrez]
AID - 10.1210/jcem-61-1-160 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 1985 Jul;61(1):160-6. doi: 10.1210/jcem-61-1-160.

PMID- 24917218
OWN - NLM
STAT- MEDLINE
DCOM- 20150413
LR  - 20211021
IS  - 2210-7711 (Electronic)
VI  - 36
IP  - 4
DP  - 2014 Aug
TI  - Patient characteristics among users of analgesic over-the-counter aspirin in a 
      Danish pharmacy setting.
PG  - 693-6
LID - 10.1007/s11096-014-9968-z [doi]
AB  - BACKGROUND: Use of over-the-counter (OTC) high-dose acetylsalicylic acid (ASA) is 
      a risk factor for experiencing gastric bleeding. However, more detailed knowledge 
      on the characteristics of users of OTC ASA is needed. OBJECTIVE: To characterise 
      users of OTC high-dose ASA in a Danish pharmacy setting. METHOD: We conducted an 
      interview based survey among users of OTC high-dose ASA. Questions were asked 
      regarding: (1) demographic characteristics; (2) use patterns; (3) knowledge about 
      adverse events; (4) risk factors for experiencing gastric bleeding; (5) reasons 
      for choosing an ASA-containing medicine; and (6) whether their GP was informed on 
      their use of high-dose ASA. RESULTS: One-hundred-seventeen interviews were 
      completed. Nineteen percent and 37 % used high-dose ASA on a daily or weekly 
      basis respectively. Sixty-eighth percent found high-dose ASA to be more effective 
      than other analgesics. Fourty-seven percent had one or more risk factors for 
      experiencing ulcer bleeding, most commonly age >60 years (32 %) and previous 
      peptic ulcer (9 %). The most well-known adverse events were abdominal pain (32 %) 
      and peptic ulcer (26 %). The most common source of information was friends and 
      family (32 %). CONCLUSION: A large proportion of users of high-dose ASA have risk 
      factors for experiencing gastric bleeding. Health-care professionals needs to 
      provide more information on potential adverse events.
FAU - Pottegård, Anton
AU  - Pottegård A
AD  - Clinical Pharmacology, Institute of Public Health, University of Southern 
      Denmark, JB Winsløwsvej 19, 2, 5000, Odense C, Denmark, 
      apottegaard@health.sdu.dk.
FAU - Kviesgaard, Ann-Katrine
AU  - Kviesgaard AK
FAU - Hesse, Ulrik
AU  - Hesse U
FAU - Moreno, Søren Ilsøe
AU  - Moreno SI
FAU - Hansen, Jane Møller
AU  - Hansen JM
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20140612
PL  - Netherlands
TA  - Int J Clin Pharm
JT  - International journal of clinical pharmacy
JID - 101554912
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analgesics, Non-Narcotic/administration & dosage/*adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Denmark/epidemiology
MH  - Female
MH  - Health Care Surveys
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nonprescription Drugs/administration & dosage/*adverse effects/therapeutic use
MH  - Patient Education as Topic
MH  - *Patient Medication Knowledge
MH  - Peptic Ulcer/chemically induced/epidemiology
MH  - Peptic Ulcer Hemorrhage/chemically induced/epidemiology
MH  - Pharmacies
MH  - Risk Factors
MH  - Self Medication/*adverse effects
MH  - Young Adult
EDAT- 2014/06/12 06:00
MHDA- 2015/04/14 06:00
CRDT- 2014/06/12 06:00
PHST- 2013/11/21 00:00 [received]
PHST- 2014/05/31 00:00 [accepted]
PHST- 2014/06/12 06:00 [entrez]
PHST- 2014/06/12 06:00 [pubmed]
PHST- 2015/04/14 06:00 [medline]
AID - 10.1007/s11096-014-9968-z [doi]
PST - ppublish
SO  - Int J Clin Pharm. 2014 Aug;36(4):693-6. doi: 10.1007/s11096-014-9968-z. Epub 2014 
      Jun 12.

PMID- 36164018
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20230124
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 22 Suppl 2
DP  - 2022 Oct
TI  - MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and 
      Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults 
      With Essential Thrombocythemia.
PG  - S342-S343
LID - S2152-2650(22)01469-0 [pii]
LID - 10.1016/S2152-2650(22)01469-0 [doi]
AB  - CONTEXT: There is an unmet need for treatment options for patients with essential 
      thrombocythemia (ET) who require cytoreduction who may or may not have been 
      treated with hydroxyurea (HU) or anagrelide (ANA), which is commonly used outside 
      of North America. In addition to the reduction of thrombotic risk, treatment 
      options for ET should reduce all blood cell types, prevent disease progression, 
      and modify the disease. OBJECTIVE: To assess the efficacy of ropeginterferon 
      alfa-2b-njft (P1101) in adults with ET who live in the US or Canada. DESIGN: 
      Single-arm, open-label study includes a 28-day screening period, a 12-month 
      treatment phase, and a 28-day follow-up period, for a total trial duration of 14 
      months. P1101 will be administered every 2 weeks during the treatment phase at 
      each study visit, and once a maintenance dose is identified for a patient, 
      bi-weekly minor assessment visits may be replaced with phone visits. A subsequent 
      extension phase will supply P1101 to patients deriving benefit for a total of 3 
      years of treatment. SETTING: Study results will impact the general management of 
      patients with ET. PATIENTS OR OTHER PARTICIPANTS: Adults diagnosed with ET 
      according to the WHO 2016 criteria with a platelet count at screening >4 50 × 
      10(9)/L, cytoreductive treatment naïve or with prior HU and/or ANA may 
      participate. Patients with a history or presence of clinically relevant 
      depression, risk of suicide, or autoimmune disease may not participate. 
      INTERVENTIONS: P1101 will be administered subcutaneously every 2 weeks at the 
      starting dose of 250 mcg (Week 0), 350 mcg (Week 2), and target optimal dose of 
      500 mcg (Week 4) and remain fixed for the 12-month treatment period. Subjects 
      currently on HU or ANA will follow a pre-specified dose-tapering schedule. All 
      subjects will receive low-dose aspirin unless contraindicated. MAIN OUTCOME 
      MEASURES: The primary endpoint is a durable response defined as the proportion of 
      subjects who achieve simultaneous peripheral blood count remission (platelets 
      ≤400×10(9)/L and WBC <10 × 10(9)/L) for at least 80% of bi-weekly measurements 
      consecutively between weeks 32-52. This study is being sponsored by 
      PharmaEssentia USA.
CI  - Copyright © 2022 Elsevier Inc. All rights reserved.
FAU - Verstovsek, Srdan
AU  - Verstovsek S
AD  - University of Texas MD Anderson Cancer Center, Houston, USA.
FAU - Mesa, Ruben
AU  - Mesa R
AD  - UT Health San Antonio Cancer Center, San Antonio, USA.
FAU - Mascarenhas, John
AU  - Mascarenhas J
AD  - Mount Sinai, New York, USA.
FAU - Tashi, Tsewang
AU  - Tashi T
AD  - University of Utah Health, Salt Lake City, USA.
FAU - Shih, Weichung
AU  - Shih W
AD  - Rutgers University, Newark, USA.
FAU - Sato, Toshiaki
AU  - Sato T
AD  - PharmaEssentia Japan KK, Tokyo, Japan.
FAU - Urbanski, Raymond
AU  - Urbanski R
AD  - PharmaEssentia USA Corp., Burlington, USA.
FAU - Zagrijtschuk, Oleh
AU  - Zagrijtschuk O
AD  - PharmaEssentia USA Corp., Burlington, USA.
FAU - Zimmerman, Craig
AU  - Zimmerman C
AD  - PharmaEssentia USA Corp., Burlington, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - R16CO5Y76E (Aspirin)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Blood Platelets
MH  - Humans
MH  - Hydroxyurea/therapeutic use
MH  - Platelet Count
MH  - *Thrombocythemia, Essential/drug therapy
OTO - NOTNLM
OT  - MPN
OT  - P1101
OT  - Trial-in-Progress
OT  - essential thrombocythemia
OT  - interferon
OT  - myeloproliferative neoplasm
OT  - ropeginterferon alfa-2b-njft
EDAT- 2022/09/28 06:00
MHDA- 2023/01/26 06:00
CRDT- 2022/09/27 01:14
PHST- 2022/09/27 01:14 [entrez]
PHST- 2022/09/28 06:00 [pubmed]
PHST- 2023/01/26 06:00 [medline]
AID - S2152-2650(22)01469-0 [pii]
AID - 10.1016/S2152-2650(22)01469-0 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S342-S343. doi: 
      10.1016/S2152-2650(22)01469-0.

PMID- 33360227
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1532-866X (Electronic)
IS  - 0049-0172 (Linking)
VI  - 51
IP  - 1
DP  - 2021 Feb
TI  - The efficacy and safety of second-line treatments of refractory and/or high risk 
      pregnant antiphospholipid syndrome patients. A systematic literature review 
      analyzing 313 pregnancies.
PG  - 28-35
LID - S0049-0172(20)30286-9 [pii]
LID - 10.1016/j.semarthrit.2020.10.001 [doi]
AB  - OBJECTIVE: The most efficacious strategy to manage pregnant patients with 
      antiphospholipid syndrome (APS) refractory to conventional heparin/low-dose 
      aspirin treatment or at high risk of adverse pregnancy outcomes has not been 
      determined with any degree of certainty. The study set out to evaluate the 
      efficacy and safety of the second-line treatments most frequently used in 
      addition to conventional therapy, and the data were analyzed to identify which 
      is/are associated to the best pregnancy outcomes. METHODS: A systematic review of 
      the literature on studies concerning second-line treatments for refractory and/or 
      high risk pregnant APS women published between February 2006 and February 2020 
      was conducted. The records were retrieved by searching Medline via Pubmed, the 
      Web of Science platform, the Cochrane library database and clinicaltrials.gov. 
      RESULTS: Fourteen studies met the eligibility criteria of the review: six 
      retrospective cohort studies, one case-control, one case-series and six case 
      reports. The results of single treatment protocols based upon hydroxychloroquine 
      (HCQ), low-dose steroids (LDS), intravenous immunoglobulins (IVIG), plasma 
      exchange (PE) or pravastatin and of combination protocols based upon HCQ+LDS, 
      IVIG+LDS, PE+LDS and PE+IVIG used during 313 pregnancies in 303 APS women were 
      analyzed and compared. The second-line treatments produced 261/313 (83.4%) live 
      births; severe pregnancy complications were registered in 75/313 (24%) 
      pregnancies. Drug side-effects were observed in 3/313 (0.9%) pregnancies. 
      Statistical analysis identified a significantly higher live birth rate and/or a 
      significantly lower number of severe complications in the pregnancies treated 
      with IVIG, HCQ, pravastatin, PE+IVIG and PE+LDS. CONCLUSION: Our results suggest 
      using low-dose IVIG (< 2 g/Kg/month) or HCQ 400 mg/day starting before pregnancy 
      in women with APS refractory to conventional therapy, while high-dose IVIG 
      (2 g/Kg/month) associated with PE or alone in those with high risk±refractory 
      APS.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Ruffatti, Amelia
AU  - Ruffatti A
AD  - Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua 
      Italy. Electronic address: amelia.ruffatti@unipd.it.
FAU - Tonello, Marta
AU  - Tonello M
AD  - Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua 
      Italy.
FAU - Favaro, Maria
AU  - Favaro M
AD  - Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua 
      Italy.
FAU - Del Ross, Teresa
AU  - Del Ross T
AD  - Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua 
      Italy.
FAU - Calligaro, Antonia
AU  - Calligaro A
AD  - Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua 
      Italy.
FAU - Ruffatti, Alessandra Teresa
AU  - Ruffatti AT
AD  - Gynaecology and Obstetrics Unit, Department of Woman and Child Health, University 
      Hospital of Padua, Padua, Italy.
FAU - Gervasi, Maria Teresa
AU  - Gervasi MT
AD  - Gynaecology and Obstetrics Unit, Department of Woman and Child Health, University 
      Hospital of Padua, Padua, Italy.
FAU - Hoxha, Ariela
AU  - Hoxha A
AD  - Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua 
      Italy; Internal Medicine Unit, Department of Medicine, San Bortolo Hospital, 
      Vicenza, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20201217
PL  - United States
TA  - Semin Arthritis Rheum
JT  - Seminars in arthritis and rheumatism
JID - 1306053
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Antiphospholipid Syndrome/complications/drug therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - *Pregnancy Complications/drug therapy
MH  - Pregnancy Outcome
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Antiphospholipid syndrome
OT  - Hydroxychloroquine
OT  - Intravenous immunoglobulins
OT  - Low-dose steroids
OT  - Plasma exchange
OT  - Pregnancy
COIS- Declaration of Competing Interest The authors declare they have no conflict of 
      interest with respect to this manuscript.
EDAT- 2020/12/29 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/12/28 11:07
PHST- 2020/08/18 00:00 [received]
PHST- 2020/09/23 00:00 [revised]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/12/28 11:07 [entrez]
AID - S0049-0172(20)30286-9 [pii]
AID - 10.1016/j.semarthrit.2020.10.001 [doi]
PST - ppublish
SO  - Semin Arthritis Rheum. 2021 Feb;51(1):28-35. doi: 
      10.1016/j.semarthrit.2020.10.001. Epub 2020 Dec 17.

PMID- 34403016
OWN - NLM
STAT- MEDLINE
DCOM- 20230316
LR  - 20230316
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 37
IP  - 2
DP  - 2023 Apr
TI  - Aspirin Blocks the Infarct-Size Limiting Effect of Ischemic Postconditioning in 
      the Rat.
PG  - 221-224
LID - 10.1007/s10557-021-07241-8 [doi]
AB  - BACKGROUND: Ischemic postconditioning (PostC), repetitive cycles of re-occlusion, 
      and reperfusion of the infarct-related artery immediately after reperfusion have 
      been shown to limit myocardial infarct size in various animal models. Yet, 
      translating the model into the clinical setting was disappointing, several 
      clinical trials showing neutral effect. We hypothesized that aspirin loading 
      could explain the differences between the pre-clinical and clinical studies. 
      METHODS: Male Sprague Dawley rats were subjected to 30-min coronary artery 
      ligation. At 25 min of ischemia, animals received intravenous aspirin (20 mg/kg) 
      or vehicle. Upon reperfusion half of the rats were randomized to PostC (3 cycles 
      of 10-s re-occlusion/10-s reperfusion. After 4-h reperfusion, rats were 
      euthanized. Area at risk was assessed by blue dye and infarct size by 
      2,3,5-triphenyl-tetrazolium-chloride (TTC). RESULTS: Body weight and the size of 
      the ischemic area at risk were comparable among groups. Infarct size expressed as 
      a percentage of the ischemic area at risk was significantly smaller in the PostC 
      group (13.9 ± 0.4%; p < 0.001) compared to the control group (31.0 ± 2.2%). 
      Aspirin alone had no effect on infarct size (29.0 ± 2.6%). Yet, aspirin 
      completely blocked the protective effect of PostC (33.3 ± 1.1%). CONCLUSIONS: 
      Aspirin, administered before reperfusion, blocks the infarct size limiting 
      effects of PostC in the rat.
CI  - © 2021. Springer Science+Business Media, LLC, part of Springer Nature.
FAU - Birnbaum, Yochai
AU  - Birnbaum Y
AUID- ORCID: 0000-0001-7653-6328
AD  - The Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, TX, USA.
FAU - Ye, Regina
AU  - Ye R
AD  - University of Texas At Austin, Austin, TX, USA.
FAU - Ye, Yumei
AU  - Ye Y
AD  - The Department of Biochemistry and Molecular Biology, University of Texas Medical 
      Branch, 301 University Blvd, BSB 648, Galveston, TX, 77555, USA. yumye@utmb.edu.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210817
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Rats
MH  - Male
MH  - Animals
MH  - *Ischemic Postconditioning
MH  - Aspirin/pharmacology
MH  - Rats, Sprague-Dawley
MH  - *Myocardial Reperfusion Injury/prevention & control
MH  - *Myocardial Infarction/prevention & control
MH  - Ischemia
OTO - NOTNLM
OT  - Aspirin
OT  - Heart
OT  - Infarct size
OT  - Postconditioning
OT  - Reperfusion injury
EDAT- 2021/08/18 06:00
MHDA- 2023/03/17 06:00
CRDT- 2021/08/17 12:26
PHST- 2021/08/12 00:00 [accepted]
PHST- 2021/08/18 06:00 [pubmed]
PHST- 2023/03/17 06:00 [medline]
PHST- 2021/08/17 12:26 [entrez]
AID - 10.1007/s10557-021-07241-8 [pii]
AID - 10.1007/s10557-021-07241-8 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2023 Apr;37(2):221-224. doi: 10.1007/s10557-021-07241-8. 
      Epub 2021 Aug 17.

PMID- 11092090
OWN - NLM
STAT- MEDLINE
DCOM- 20001208
LR  - 20190513
IS  - 0007-1420 (Print)
IS  - 0007-1420 (Linking)
VI  - 56
IP  - 2
DP  - 2000
TI  - Aspirin or heparin in acute stroke.
PG  - 413-21
AB  - Acute stroke treatment using aspirin and/or heparin was studied in the 
      International Stroke Trial (IST) and Chinese Acute Stroke Trial (CAST) which 
      randomised over 40,000 patients altogether. Combining the results demonstrated 
      that aspirin (150-300 mg) given within 48 h of the onset of stroke produced a 
      small but significant improvement in outcome (death or dependency) 4 weeks to 6 
      months after stroke of about 1 patient per 100 treated. There was a significant 
      reduction in recurrent ischaemic stroke of similar degree, which was not 
      associated with significant increase in cerebral haemorrhage. Therefore, aspirin 
      should be used as early secondary prevention against recurrent stroke, after 
      excluding cerebral haemorrhage by scanning the patient. Heparin does not improve 
      clinical outcome after stroke even in patients in atrial fibrillation. It 
      decreased recurrent ischaemic stroke significantly in IST, but at the cost of a 
      significant increase in cerebral haemorrhage. Low molecular weight heparins and 
      heparinoids have not proved any more beneficial. Therefore, heparin does not 
      appear to be a useful routine therapy in acute stroke. The use of heparin should, 
      therefore, be limited to patients at high risk of deep vein thrombosis or early 
      recurrence.
FAU - Pereira, A C
AU  - Pereira AC
AD  - Department of Clinical Neurology, Institute of Neurology, University College 
      London, UK.
FAU - Brown, M M
AU  - Brown MM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Br Med Bull
JT  - British medical bulletin
JID - 0376542
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/*therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/*drug therapy
RF  - 27
EDAT- 2000/11/25 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/25 11:00
PHST- 2000/11/25 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/25 11:00 [entrez]
AID - 10.1258/0007142001903058 [doi]
PST - ppublish
SO  - Br Med Bull. 2000;56(2):413-21. doi: 10.1258/0007142001903058.

PMID- 1486588
OWN - NLM
STAT- MEDLINE
DCOM- 19930222
LR  - 20190509
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 26
IP  - 10
DP  - 1992 Oct
TI  - Stimulus-response curves for hypoxic pulmonary vasoconstriction in piglets.
PG  - 944-9
AB  - OBJECTIVE: The aim was to characterise stimulus-response curves for hypoxic 
      pulmonary vasoconstriction and to observe the effects of drugs reputed to enhance 
      it: aspirin (a cyclo-oxygenase inhibitor), and doxapram (a peripheral 
      chemoreceptor agonist). METHODS: Mean pulmonary artery pressure (Ppa) versus 
      fraction of inspired O2 (FIO2) relationships were studied in 18 intact 
      anaesthetised piglets, before and after the intravenous administration, in random 
      order, of either physiological saline, 1 g aspirin, or 20 mg.kg-1 doxapram. 
      Cardiac output (Q) was kept constant, to avoid passive Q dependent changes in 
      Ppa. RESULTS: A progressive decrease in FIO2 from 100% to 12% was associated with 
      an average increase in Ppa from 19 to 38 mm Hg (p < 0.001). When FIO2 was further 
      decreased to 8%, Ppa decreased to 32 mm Hg (p < 0.01). This stimulus-response 
      curve was unaffected by saline, but displaced in a non-PO2-dependent manner to 
      higher Ppa by doxapram and by aspirin. CONCLUSIONS: The pulmonary vascular 
      response to inspiratory hypoxia in intact anaesthetised piglets is biphasic, with 
      a maximum at an FIO2 of 12%. Neither aspirin nor doxapram affect the shape of 
      this stimulus-response curve, and in particular do not prevent low FIO2 
      associated inhibition of hypoxic pulmonary vasoconstriction.
FAU - De Canniere, D
AU  - De Canniere D
AD  - Laboratory of Cardiovascular and Respiratory Physiology, Erasme University 
      Hospital, Brussels, Belgium.
FAU - Stefanidis, C
AU  - Stefanidis C
FAU - Hallemans, R
AU  - Hallemans R
FAU - Delcroix, M
AU  - Delcroix M
FAU - Brimioulle, S
AU  - Brimioulle S
FAU - Naeije, R
AU  - Naeije R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 94F3830Q73 (Doxapram)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Pressure/drug effects
MH  - Doxapram/pharmacology
MH  - Hypoxia/*physiopathology
MH  - Pulmonary Artery/*physiopathology
MH  - Stimulation, Chemical
MH  - Swine
MH  - Vasoconstriction/drug effects/*physiology
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 10.1093/cvr/26.10.944 [doi]
PST - ppublish
SO  - Cardiovasc Res. 1992 Oct;26(10):944-9. doi: 10.1093/cvr/26.10.944.

PMID- 25056582
OWN - NLM
STAT- MEDLINE
DCOM- 20141211
LR  - 20211021
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 83
IP  - 9
DP  - 2014 Aug 26
TI  - Aspirin for acute stroke of unknown etiology in resource-limited settings: a 
      decision analysis.
PG  - 787-93
LID - 10.1212/WNL.0000000000000730 [doi]
AB  - OBJECTIVE: To analyze the potential impact of aspirin on outcome at hospital 
      discharge after acute stroke in resource-limited settings without access to 
      neuroimaging to distinguish ischemic stroke from intracerebral hemorrhage (ICH). 
      METHODS: A decision analysis was conducted to evaluate aspirin use in all 
      patients with acute stroke of unknown type for the duration of initial 
      hospitalization. Data were obtained from the International Stroke Trial and 
      Chinese Acute Stroke Trial. Predicted in-hospital mortality and stroke recurrence 
      risk were determined across the worldwide reported range of the proportion of 
      strokes caused by ICH. Sensitivity analyses were performed on aspirin-associated 
      relative risks in patients with ICH. RESULTS: At the highest reported proportion 
      of strokes due to ICH from a large epidemiologic study (34% in sub-Saharan 
      Africa), aspirin initiation after acute stroke of undetermined etiology is 
      predicted to reduce in-hospital mortality (from 85/1,000 without treatment to 
      81/1,000 with treatment), in-hospital stroke recurrence (58/1,000 to 50/1,000), 
      and combined risk of in-hospital mortality or stroke recurrence (127/1,000 to 
      114/1,000). Benefits of aspirin therapy remained in sensitivity analyses across a 
      range of plausible parameter estimates for relative risks associated with aspirin 
      initiation after ICH. CONCLUSION: Aspirin treatment for the period of initial 
      hospitalization after acute stroke of undetermined etiology is predicted to 
      decrease acute stroke-related mortality and in-hospital stroke recurrence even at 
      the highest reported proportion of acute strokes due to ICH. In the absence of 
      clinical trials to test this approach empirically, clinical decisions require 
      patient-specific evaluation of risks and benefits of aspirin in this context.
CI  - © 2014 American Academy of Neurology.
FAU - Berkowitz, Aaron L
AU  - Berkowitz AL
AD  - From the Department of Neurology, Brigham and Women's Hospital (A.L.B., 
      S.H.-Y.C.), and the Department of Neurology, Massachusetts General Hospital 
      (M.B.W., M.T.B.), Harvard Medical School, Boston, MA. aberkowitz3@partners.org.
FAU - Westover, M Brandon
AU  - Westover MB
AD  - From the Department of Neurology, Brigham and Women's Hospital (A.L.B., 
      S.H.-Y.C.), and the Department of Neurology, Massachusetts General Hospital 
      (M.B.W., M.T.B.), Harvard Medical School, Boston, MA.
FAU - Bianchi, Matt T
AU  - Bianchi MT
AD  - From the Department of Neurology, Brigham and Women's Hospital (A.L.B., 
      S.H.-Y.C.), and the Department of Neurology, Massachusetts General Hospital 
      (M.B.W., M.T.B.), Harvard Medical School, Boston, MA.
FAU - Chou, Sherry H-Y
AU  - Chou SH
AD  - From the Department of Neurology, Brigham and Women's Hospital (A.L.B., 
      S.H.-Y.C.), and the Department of Neurology, Massachusetts General Hospital 
      (M.B.W., M.T.B.), Harvard Medical School, Boston, MA.
LA  - eng
GR  - K23 NS073806/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20140723
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Neurology. 2014 Aug 26;83(9):778-9. PMID: 25056579
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - *Decision Support Techniques
MH  - Female
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/*drug therapy
PMC - PMC4155044
EDAT- 2014/07/25 06:00
MHDA- 2014/12/17 06:00
CRDT- 2014/07/25 06:00
PHST- 2014/07/25 06:00 [entrez]
PHST- 2014/07/25 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
AID - WNL.0000000000000730 [pii]
AID - NEUROLOGY2013555847 [pii]
AID - 10.1212/WNL.0000000000000730 [doi]
PST - ppublish
SO  - Neurology. 2014 Aug 26;83(9):787-93. doi: 10.1212/WNL.0000000000000730. Epub 2014 
      Jul 23.

PMID- 21422062
OWN - NLM
STAT- MEDLINE
DCOM- 20110929
LR  - 20220311
IS  - 1460-2369 (Electronic)
IS  - 1355-4786 (Linking)
VI  - 17
IP  - 4
DP  - 2011 Jul-Aug
TI  - Is aspirin effective in women undergoing in vitro fertilization (IVF)? Results 
      from an individual patient data meta-analysis (IPD MA).
PG  - 501-9
LID - 10.1093/humupd/dmr007 [doi]
AB  - BACKGROUND: Aspirin is believed to improve the outcome of IVF, but previous 
      conventional meta-analyses on the subject are conflicting. Therefore, we 
      performed a meta-analysis with individual patient data (IPD MA) of randomized 
      clinical trials (RCTs) on the subject. METHODS: A systematic literature search 
      was conducted to identify RCTs assessing the effectiveness of aspirin in IVF. 
      Authors were asked to share their original data. In a one step meta-analytic 
      approach, the treatment effect of aspirin was estimated with odds ratios (ORs) 
      and 95% confidence intervals (CIs) using logistic regression, based on the 
      intention to treat principle. RESULTS: Ten studies fulfilled the inclusion 
      criteria. Authors of six studies provided IPD, including 1119 patients (562 
      placebo and 557 aspirin). There were 160 clinical pregnancies in the aspirin 
      (28.8%) and 179 (31.9%) in the placebo group [OR 0.86, 95% CI (0.69-1.1)]. There 
      were 129 ongoing pregnancies in the aspirin (23.6%) and 147 in the placebo group 
      (26.7%) [OR 0.85, 95% CI (0.65-1.1)]. Whereas the conventional meta-analysis 
      limited to studies that could provide IPD showed an OR of 0.89 (95% CI 0.69-1.2), 
      the conventional meta-analysis limited to the eight studies of which method of 
      randomization could be confirmed showed an OR of 0.94 (95% CI 0.76-1.17) and the 
      conventional meta-analysis including all 10 eligible RCTs identified with our 
      search changed the OR to 1.07 (95% CI 0.81-1.41). This difference in direction of 
      effect, derived from the studies not able to share IPD of which quality of 
      randomization could not be confirmed. CONCLUSIONS: Aspirin does not improve 
      pregnancy rates after IVF.
FAU - Groeneveld, E
AU  - Groeneveld E
AD  - Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, VU 
      University Medical Centre, Amsterdam, The Netherlands. e.groeneveld@vumc.nl
FAU - Broeze, K A
AU  - Broeze KA
FAU - Lambers, M J
AU  - Lambers MJ
FAU - Haapsamo, M
AU  - Haapsamo M
FAU - Dirckx, K
AU  - Dirckx K
FAU - Schoot, B C
AU  - Schoot BC
FAU - Salle, B
AU  - Salle B
FAU - Duvan, C I
AU  - Duvan CI
FAU - Schats, R
AU  - Schats R
FAU - Mol, B W
AU  - Mol BW
FAU - Hompes, P G A
AU  - Hompes PG
CN  - IPD MARIA study group
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20110321
PL  - England
TA  - Hum Reprod Update
JT  - Human reproduction update
JID - 9507614
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fertilization in Vitro/*drug effects
MH  - Humans
MH  - Intention to Treat Analysis
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Randomized Controlled Trials as Topic
EDAT- 2011/03/23 06:00
MHDA- 2011/10/01 06:00
CRDT- 2011/03/23 06:00
PHST- 2011/03/23 06:00 [entrez]
PHST- 2011/03/23 06:00 [pubmed]
PHST- 2011/10/01 06:00 [medline]
AID - dmr007 [pii]
AID - 10.1093/humupd/dmr007 [doi]
PST - ppublish
SO  - Hum Reprod Update. 2011 Jul-Aug;17(4):501-9. doi: 10.1093/humupd/dmr007. Epub 
      2011 Mar 21.

PMID- 9868857
OWN - NLM
STAT- MEDLINE
DCOM- 19990113
LR  - 20190826
IS  - 0021-1265 (Print)
IS  - 0021-1265 (Linking)
VI  - 167
IP  - 4
DP  - 1998 Oct-Dec
TI  - Bleeding times and the antithrombotic effects of high-dose aspirin, hirudin and 
      heparins in the rat.
PG  - 216-20
AB  - Bleeding can occur unexpectedly during antithrombotic therapy. Impaired 
      haemostasis is commonly measured by the bleeding time. We measured it by 3 
      methods in controls and in anticoagulated animals and related it to their 
      antithrombotic status. In 42 control rats template, tail-tip transection and 
      needle occlusion bleeding times correlated poorly (r = 0.05-0.34). The template 
      method had the best range (mean 126.97 +/- SEM secs) and consistency. In 10 
      control animals it correlated mildly (r = 0.55) with venous thrombus in the same 
      animal. Thrombus was measured by its weight deposited on platinum wires (2 cm 
      long, 0.4 mm diameter) set in vein and in artery for 1 h. In respective groups of 
      10 rats, a decrease of mean thrombogenesis was obtained using aspirin, heparin 
      and low molecular weight heparin in 2 dosages and hirudin in 1 dosage. The drugs 
      reduced mean venous thrombus by 13-86 per cent of the mean control thrombus, and 
      prolonged the mean template bleeding time by 29-199 per cent. The ranking of the 
      drugs according to their increase of template bleeding time was virtually the 
      same as the ranking given by their reduction of thrombus weight (Spearman rank 
      coefficient 0.81, sig 0.007). The transection test produced a similar ranking and 
      similar correlation with thrombus (0.71, sig 0.049). Low molecular weight heparin 
      induced the greatest thrombus reduction (39 per cent) for least prolongation of 
      bleeding time (24 per cent). Arterial thrombus was more variable. The bleeding 
      times and thrombus weight were measured in each animal of 2 groups given aspirin, 
      the template method correlating mildly with venous thrombus reduction (r = 0.23, 
      0.58 respectively), the transection method with arterial (0.74, 0.45) and the 
      occlusion test poorly with either (0.13, 0.22). Bleeding time lengthens with 
      increasing antithrombotic effect of drugs, but not in direct proportion, nor 
      similarly with each drug.
FAU - Lavelle, S M
AU  - Lavelle SM
AD  - Department of Experimental Medicine, University College, Galway, Ireland.
FAU - MacIomhair, M
AU  - MacIomhair M
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
RN  - 0 (Antithrombins)
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antithrombins/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Fibrinolytic Agents/*pharmacology
MH  - Hemostasis/*drug effects
MH  - Heparin/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Time Factors
EDAT- 1998/12/30 00:00
MHDA- 1998/12/30 00:01
CRDT- 1998/12/30 00:00
PHST- 1998/12/30 00:00 [pubmed]
PHST- 1998/12/30 00:01 [medline]
PHST- 1998/12/30 00:00 [entrez]
AID - 10.1007/BF02937415 [doi]
PST - ppublish
SO  - Ir J Med Sci. 1998 Oct-Dec;167(4):216-20. doi: 10.1007/BF02937415.

PMID- 8115666
OWN - NLM
STAT- MEDLINE
DCOM- 19940331
LR  - 20190909
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 18
IP  - 1
DP  - 1994 Jan
TI  - Analgesic-antiinflammatory drugs inhibit orbicularis oculi reflexes in humans via 
      a central mode of action.
PG  - 101-13
AB  - 1. A cross-over single blind study examined the possible central effects of 
      non-opioid analgesic drugs on the trigeminal reflexes. 2. The corneal reflex and 
      blink reflex (R1, R2) were recorded electromyographically and response areas 
      measured in healthy volunteers before and after intramuscular injection of 
      piroxicam (40 mg); and after intravenous injection of lysine acetylsalicylate 
      (500 mg). After the last drug recording the subjects received intravenous 
      naloxone (2 mg) followed 5 minutes later by further reflex testing. Saline was 
      used as a placebo in control experiments. 3. Both analgesics reduced the corneal 
      reflex: piroxicam induced a 27% and lysine acetylsalicylate a 21% a reduction 
      that naloxone did not reverse. Neither drug reduced the early or the late 
      component of the blink reflex. 4. The marked inhibitory changes that the two 
      non-narcotic analgesics produced on the corneal reflex--a nociceptive 
      response--indicate a centrally-mediated action. 5. Naloxone's failure to reverse 
      the induced analgesia argues against opiate receptor mediation.
FAU - Ferracuti, S
AU  - Ferracuti S
AD  - Department of Psychiatry and Medical Psychology, University of Rome, Italy.
FAU - Leardi, M G
AU  - Leardi MG
FAU - Cruccu, G
AU  - Cruccu G
FAU - Fabbri, A
AU  - Fabbri A
FAU - Itil, T M
AU  - Itil TM
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 13T4O6VMAM (Piroxicam)
RN  - 36B82AMQ7N (Naloxone)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Blinking/drug effects
MH  - Cornea/drug effects
MH  - Electric Stimulation
MH  - Evoked Potentials/drug effects
MH  - Humans
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Naloxone/pharmacology
MH  - Piroxicam/pharmacology
MH  - Reflex/*drug effects
MH  - Single-Blind Method
MH  - Trigeminal Nerve/drug effects
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 0278-5846(94)90027-2 [pii]
AID - 10.1016/0278-5846(94)90027-2 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jan;18(1):101-13. doi: 
      10.1016/0278-5846(94)90027-2.

PMID- 16034926
OWN - NLM
STAT- MEDLINE
DCOM- 20051130
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 3
DP  - 2005 Jul 20
TI  - Triflusal for preventing serious vascular events in people at high risk.
PG  - CD004296
AB  - BACKGROUND: Aspirin is the standard treatment for secondary prevention of stroke 
      and other vascular events. Several studies suggest that triflusal may have a 
      better safety profile. OBJECTIVES: To determine in people at high risk of 
      vascular events whether triflusal is an effective and safe treatment for primary 
      and secondary prevention of serious vascular events. SEARCH STRATEGY: We searched 
      the trials registers of the following Cochrane Review Groups: Stroke Group (last 
      searched October 2004), Heart Group, Peripheral Vascular Diseases Group and 
      Metabolic and Endocrine Disorders Group (last searched May 2003). In addition, we 
      searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The 
      Cochrane Library Issue 2, 2003), MEDLINE (1977 to 2003) and EMBASE (1980 to 
      2003). We searched reference lists and contacted researchers in the field, 
      authors of relevant trials and the drug manufacturer. SELECTION CRITERIA: 
      Randomised and quasi-randomised studies comparing triflusal with placebo or 
      aspirin in people at high risk of vascular events. DATA COLLECTION AND ANALYSIS: 
      Two authors independently assessed trial quality and extracted data. The primary 
      outcome was a serious vascular event (non-fatal acute myocardial infarction 
      (AMI), non-fatal ischemic or hemorrhagic stroke, or vascular death). Other 
      efficacy and safety measures collected were frequency of different vascular 
      events, adverse events, minor and major hemorrhages. MAIN RESULTS: (1) Aspirin 
      versus triflusal: five studies enrolled patients with stroke or transient 
      ischemic attack (TIA) (4 trials; 2944 patients; followed for 6 to 47 months) or 
      AMI (one trial; 2275 patients; followed for 35 days). Entry criteria were similar 
      within each subgroup of patients. Patient groups were appropriately selected and 
      well matched. The primary outcome in all trials was a composite outcome of 
      vascular events. Trials had no important bias except in one study (217 patients). 
      For the primary outcome of a serious vascular event there was no significant 
      difference between triflusal and aspirin; the odds ratio (OR) was 1.04 (95% 
      confidence interval (CI) 0.87 to 1.23). Significant differences were found for 
      frequency of hemorrhages, both minor (OR 1.60, 95% CI 1.31 to 1.95) and major (OR 
      2.34, 95% CI 1.58 to 3.46) and for non-hemorrhagic gastrointestinal adverse 
      events (OR 0.84, 95% CI 0.75 to 0.95). Sensitivity analysis of well versus poorly 
      allocated trials showed no significant differences. (2) Triflusal versus placebo: 
      two trials enrolled patients with unstable angina (281 patients) or peripheral 
      arteriopathy (122 patients), who were followed for 6 months. Triflusal was 
      associated with a reduction in serious vascular events (OR 2.29, 95% CI 1.01 to 
      5.19; OR greater than 1 favours triflusal) and with a higher frequency of adverse 
      events (OR 1.68, 95% CI 1.00 to 2.80). AUTHORS' CONCLUSIONS: No significant 
      differences were found between triflusal and aspirin for secondary prevention of 
      serious vascular events in patients with stroke or TIA and AMI. However, our 
      review cannot exclude moderate differences in efficacy. Triflusal was associated 
      with a lower risk of hemorrhagic complications.
FAU - Costa, J
AU  - Costa J
AD  - Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina Lisboa, 
      Av. Prof. Egas Moniz, Lisboa, Portugal, 1649-028. movementdisord@mail.telepac.pt
FAU - Ferro, J M
AU  - Ferro JM
FAU - Matias-Guiu, J
AU  - Matias-Guiu J
FAU - Alvarez-Sabin, J
AU  - Alvarez-Sabin J
FAU - Torres, F
AU  - Torres F
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20050720
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 1Z0YFI05OO (triflusal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Salicylates/adverse effects/*therapeutic use
MH  - Stroke/*prevention & control
RF  - 44
EDAT- 2005/07/22 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/07/22 09:00
PHST- 2005/07/22 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/07/22 09:00 [entrez]
AID - 10.1002/14651858.CD004296.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004296. doi: 
      10.1002/14651858.CD004296.pub2.

PMID- 9198149
OWN - NLM
STAT- MEDLINE
DCOM- 19970808
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 78
IP  - 1
DP  - 1997 Jul
TI  - Antiplatelet therapy with aspirin in acute ischaemic stroke.
PG  - 180-2
AB  - Antiplatelet therapy with aspirin, started within 48 hr of an acute ischaemic 
      stroke, is safe and effective, avoiding about 10 deaths and early recurrent 
      strokes per 1,000 patients treated. The reduction in early recurrent ischaemic 
      stroke is not offset by any significant increase in intracranial haemorrhage. 
      Immediate antiplatelet therapy in acute ischaemic stroke also seems to be 
      associated with better long-term functional outcome, reducing the proportion of 
      patients dead or dependent 6 months after the stroke. Aspirin is the only 
      antiplatelet agent which has been evaluated adequately in acute ischaemic stroke. 
      In this setting a dose is required which is large enough to achieve rapid 
      inhibition of thromboxane biosynthesis and around 160-300 mg is required. If the 
      patient can swallow safely, aspirin can be administered by mouth, if not, then 
      per rectum as a suppository.
FAU - Sandercock, P
AU  - Sandercock P
AD  - Department of Clinical Neurosciences, Western General Hospital, Edinburgh, 
      Scotland. PAGS@skull.den.ed.ac.uk
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Routes
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1997 Jul;78(1):180-2.

PMID- 9447555
OWN - NLM
STAT- MEDLINE
DCOM- 19980506
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 16
IP  - 1
DP  - 1997 Sep
TI  - Direct assay and shelf-life monitoring of aspirin tablets using Raman 
      spectroscopy.
PG  - 87-94
AB  - A comparison was made between Raman and high-performance liquid chromatography 
      (HPLC) analysis of aspirin tablets. The basis was an assay of aspirin content and 
      the determination of salicylic acid produced by decomposition. Raman observations 
      were performed directly on both intact and powdered tablet material. The limit of 
      detection of HPLC with an ultraviolet detector is lower than that of the Raman 
      measurement, but both are adequate for this application. The reproducibility of 
      the Raman measurement is somewhat better than that of the HPLC measurement. Both 
      methods were used in a degradation study in which samples were stored in a humid 
      atmosphere for a maximum period of 8 weeks. Aside from somewhat higher salicylic 
      acid responses from the HPLC method, which were attributed to hydrolysis during 
      chromatography, results from the two methods were comparable. Direct Raman 
      measurements are faster and do not require the use of solvents.
FAU - Wang, C
AU  - Wang C
AD  - Athena Neurosciences, San Francisco, CA 94080, USA.
FAU - Vickers, T J
AU  - Vickers TJ
FAU - Mann, C K
AU  - Mann CK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*analysis
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid/methods
MH  - Drug Storage
MH  - Reproducibility of Results
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Spectrophotometry, Ultraviolet
MH  - Spectrum Analysis, Raman/methods
MH  - Tablets
EDAT- 1998/02/03 00:00
MHDA- 1998/02/03 00:01
CRDT- 1998/02/03 00:00
PHST- 1998/02/03 00:00 [pubmed]
PHST- 1998/02/03 00:01 [medline]
PHST- 1998/02/03 00:00 [entrez]
AID - S0731708597000058 [pii]
AID - 10.1016/s0731-7085(97)00005-8 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1997 Sep;16(1):87-94. doi: 10.1016/s0731-7085(97)00005-8.

PMID- 10231040
OWN - NLM
STAT- MEDLINE
DCOM- 19990512
LR  - 20220419
IS  - 0015-0282 (Print)
IS  - 0015-0282 (Linking)
VI  - 71
IP  - 5
DP  - 1999 May
TI  - Low-dose aspirin treatment improves ovarian responsiveness, uterine and ovarian 
      blood flow velocity, implantation, and pregnancy rates in patients undergoing in 
      vitro fertilization: a prospective, randomized, double-blind placebo-controlled 
      assay.
PG  - 825-9
AB  - OBJECTIVE: To determine the effects of low-dose aspirin on ovarian response, 
      uterine and ovarian blood flow velocity, and implantation and pregnancy rates in 
      patients undergoing IVF. DESIGN: Prospective, randomized, double-blind 
      placebo-controlled assay. SETTING: Department of Reproductive Medicine, CER 
      Medical Institute, Buenos Aires, Argentina. PATIENT(S): Two hundred ninety-eight 
      infertile patients (mean [+/- SDI age, 35.6+/-4.09 years) undergoing IVF cycles. 
      INTERVENTION(S): In the treatment group, 149 patients underwent controlled 
      ovarian hyperstimulation and received a daily dose of 100 mg of aspirin. In the 
      control group, 149 patients underwent controlled ovarian hyperstimulation in 
      association with placebo. MAIN OUTCOME MEASURE(S): Number of follicles, number of 
      oocytes retrieved, serum E2 levels, uterine and ovarian pulsatility index, 
      cancellation rate, number of embryos transferred, and implantation and pregnancy 
      rates. RESULT(S): There were statistically significant differences between the 
      treatment group and the control group, respectively, in the number of follicles 
      (19.8+/-7.2 versus 10.2+/-5.3), number of oocytes retrieved (16.2+/-6.7 versus 
      8.6+/-4.6), serum E2 levels (2,923.8+/-1,023.4 versus 1,614.3+/-791.7 pg/mL), 
      uterine pulsatility index (1.22+/-0.34 versus 1.96+/-0.58), ovarian pulsatility 
      index (1.18+/-0.31 versus 1.99+/-0.56), pregnancy rate (45% versus 28%), and 
      implantation rate (17.8% versus 9.2%). CONCLUSION(S): Low-dose aspirin treatment 
      significantly improves ovarian responsiveness, uterine and ovarian blood flow 
      velocity, and implantation and pregnancy rates in IVF patients.
FAU - Rubinstein, M
AU  - Rubinstein M
AD  - Department of Reproductive Medicine, CER Medical Institute, Buenos Aires, 
      Argentina.
FAU - Marazzi, A
AU  - Marazzi A
FAU - Polak de Fried, E
AU  - Polak de Fried E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Fertil Steril 1999 Oct;72(4):755
CIN - Fertil Steril. 1999 Oct;72(4):752-3; author reply 754-5. PMID: 10521129
CIN - Fertil Steril. 2000 May;73(5):1069-71. PMID: 10785243
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Flow Velocity/drug effects
MH  - Double-Blind Method
MH  - Embryo Implantation/*drug effects
MH  - Female
MH  - *Fertilization in Vitro
MH  - Humans
MH  - Ovary/*blood supply/diagnostic imaging/*drug effects
MH  - Pregnancy
MH  - *Pregnancy Rate
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Ultrasonography, Doppler
MH  - Uterus/*blood supply/diagnostic imaging/*drug effects
EDAT- 1999/05/07 02:02
MHDA- 2000/03/18 09:00
CRDT- 1999/05/07 02:02
PHST- 1999/05/07 02:02 [pubmed]
PHST- 2000/03/18 09:00 [medline]
PHST- 1999/05/07 02:02 [entrez]
AID - S0015-0282(99)00088-6 [pii]
AID - 10.1016/s0015-0282(99)00088-6 [doi]
PST - ppublish
SO  - Fertil Steril. 1999 May;71(5):825-9. doi: 10.1016/s0015-0282(99)00088-6.

PMID- 12575249
OWN - NLM
STAT- MEDLINE
DCOM- 20030310
LR  - 20131121
IS  - 1000-5625 (Print)
IS  - 1000-5625 (Linking)
VI  - 27
IP  - 1
DP  - 2002 Feb 28
TI  - [Simultaneous determination of four components in the compound child 
      phenobarbital tablet using ultraviolet spectrophotometry].
PG  - 83-4
AB  - OBJECTIVE: To establish a method to determine four components in the child 
      phenobarbital tablet. METHODS: Ultraviolet spectrophotometry was used to 
      determine four components without separation. RESULTS: The contents of aspirin, 
      phenacetin, caffeine and phenobarbital could be measured simultaneously. The 
      average recoveries of four components in simulated samples and the compound child 
      phenobarbital tablet samples were 99.0%, 98.9%, 99.8%, and 101%, respectively, 
      and relative standard deviations of those were 2.0%, 2.0%, 2.9%, and 2.2%, 
      respectively. CONCLUSION: The method is simple, fast, reliable, and can be used 
      to monitor the quality of compound drugs.
FAU - Wen, Li
AU  - Wen L
AD  - Department of Chemistry, Xiangya School of Medicine, Central South University, 
      Changsha 410078, China.
FAU - Fang, Hui-hui
AU  - Fang HH
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Hunan Yi Ke Da Xue Xue Bao
JT  - Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical 
      University
JID - 9424769
RN  - 0 (Tablets)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
RN  - YQE403BP4D (Phenobarbital)
SB  - IM
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Child
MH  - Child, Preschool
MH  - Drug Compounding
MH  - Humans
MH  - Infant
MH  - Phenacetin/*analysis
MH  - Phenobarbital/*analysis
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets
EDAT- 2003/02/11 04:00
MHDA- 2003/03/11 04:00
CRDT- 2003/02/11 04:00
PHST- 2003/02/11 04:00 [pubmed]
PHST- 2003/03/11 04:00 [medline]
PHST- 2003/02/11 04:00 [entrez]
PST - ppublish
SO  - Hunan Yi Ke Da Xue Xue Bao. 2002 Feb 28;27(1):83-4.

PMID- 6719258
OWN - NLM
STAT- MEDLINE
DCOM- 19840611
LR  - 20190727
IS  - 0362-2436 (Print)
IS  - 0362-2436 (Linking)
VI  - 9
IP  - 1
DP  - 1984 Jan-Feb
TI  - The conservative treatment of sciatica.
PG  - 54-6
AB  - The mainstay of rational treatment of acute sciatica involves bed rest and 
      antiinflammatory drugs. The authors recommended 2 weeks of complete bed rest with 
      progressive gradual mobilization over the next 7-10 days. Buffered aspirin in a 
      dosage of 10-15 grains every 4 hours is prescribed both for its analgesic effect 
      as well as for its antiinflammatory properties. Through the low-back school, the 
      patient is instructed in low-back hygiene. Physically capable patients are 
      encouraged to begin an aerobic exercise program. In the absence of absolute 
      indications for surgery (cauda equina syndrome or marked progressive muscle 
      weakness) it seems reasonable to permit up to 3 months of conservative therapy 
      before recommending surgery.
FAU - Bell, G R
AU  - Bell GR
FAU - Rothman, R H
AU  - Rothman RH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Spine (Phila Pa 1976)
JT  - Spine
JID - 7610646
RN  - 0 (Muscle Relaxants, Central)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Bed Rest
MH  - Female
MH  - Humans
MH  - Male
MH  - Manipulation, Orthopedic
MH  - Muscle Relaxants, Central/therapeutic use
MH  - Physical Exertion
MH  - Physical Therapy Modalities
MH  - Prognosis
MH  - Sciatica/*therapy
MH  - Time Factors
MH  - Traction
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1097/00007632-198401000-00012 [doi]
PST - ppublish
SO  - Spine (Phila Pa 1976). 1984 Jan-Feb;9(1):54-6. doi: 
      10.1097/00007632-198401000-00012.

PMID- 15868068
OWN - NLM
STAT- MEDLINE
DCOM- 20060314
LR  - 20220317
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 252
IP  - 11
DP  - 2005 Nov
TI  - Non-adherence to aspirin or oral anticoagulants in secondary prevention after 
      ischaemic stroke.
PG  - 1316-21
AB  - BACKGROUND: The effectiveness of medication is influenced by treatment adherence. 
      After TIA or minor disabling stroke patients usually are advised to take 
      antithrombotic medication. Stroke patients are an interesting group of patients 
      with respect to adherence, since cardiovascular risk factors and stroke may 
      (indirectly) negatively influence brain function, which can affect adherence. We 
      investigated determinants of non-adherence in patients who used aspirin or oral 
      anticoagulation after cerebral ischaemia of arterial origin. METHODS: Data of 
      patients prospectively followed in two clinical trials (the Dutch TIA Trial and 
      the Stroke Prevention In Reversible Ischaemia Trial) were analysed with Cox 
      proportional hazards modelling. RESULTS: In the two trials 3796 patients were 
      treated with aspirin. During a mean follow-up of 2.1 years, 689 patients (18%) 
      prematurely stopped treatment, 305 (8 %) did so without a clear medical reason 
      (non-adherence). Age >or= 65 years and the use of 300 instead of 30 mg of aspirin 
      were independently associated with non-adherence. Diastolic blood pressure of 
      >or= 90 mmHg and dizziness were associated with better adherence. Of 651 patients 
      on oral anticoagulation, 143 patients (22 %) stopped after a mean follow-up of 
      1.0 year, 66 (10 %) did so because of nonadherence. No statistically significant 
      determinants for non-adherence were identified. CONCLUSION: As found in the 
      literature on nonadherence in general, age of >or= 65 years and a higher dose of 
      aspirin (300 mg versus 30 mg) were independently associated with non-adherence 
      with aspirin treatment that was prescribed for secondary prevention after 
      cerebral ischaemia of arterial origin. Older patients may require extra 
      encouragement to continue antithrombotic treatment. Lower doses of aspirin may 
      improve treatment adherence.
FAU - De Schryver, E L L M
AU  - De Schryver EL
AD  - Dept. of Neurology, University Medical Centre, Utrecht, The Netherlands. 
      e.deschryver@neuro.azu.nl
FAU - van Gijn, J
AU  - van Gijn J
FAU - Kappelle, L J
AU  - Kappelle LJ
FAU - Koudstaal, P J
AU  - Koudstaal PJ
FAU - Algra, A
AU  - Algra A
CN  - Dutch TIA trial and SPIRIT study groups
LA  - eng
PT  - Journal Article
DEP - 20050429
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Compliance
MH  - Stroke/*prevention & control
EDAT- 2005/05/04 09:00
MHDA- 2006/03/15 09:00
CRDT- 2005/05/04 09:00
PHST- 2004/12/11 00:00 [received]
PHST- 2005/02/14 00:00 [accepted]
PHST- 2005/02/07 00:00 [revised]
PHST- 2005/05/04 09:00 [pubmed]
PHST- 2006/03/15 09:00 [medline]
PHST- 2005/05/04 09:00 [entrez]
AID - 10.1007/s00415-005-0858-0 [doi]
PST - ppublish
SO  - J Neurol. 2005 Nov;252(11):1316-21. doi: 10.1007/s00415-005-0858-0. Epub 2005 Apr 
      29.

PMID- 29512148
OWN - NLM
STAT- MEDLINE
DCOM- 20200703
LR  - 20211228
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 176
IP  - 8
DP  - 2019 Apr
TI  - Eicosanoids in platelets and the effect of their modulation by aspirin in the 
      cardiovascular system (and beyond).
PG  - 988-999
LID - 10.1111/bph.14196 [doi]
AB  - Platelets are important players in thrombosis and haemostasis with their function 
      being modulated by mediators in the blood and the vascular wall. Among these, 
      eicosanoids can both stimulate and inhibit platelet reactivity. Platelet 
      Cyclooxygenase (COX)-1-generated Thromboxane (TX)A(2) is the primary prostanoid 
      that stimulates platelet aggregation; its action is counter-balanced by 
      prostacyclin, a product of vascular COX. Prostaglandin (PG)D(2) , PGE(2) and 
      12-hydroxyeicosatraenoic acid (HETE), or 15-HETE, are other prostanoid modulators 
      of platelet activity, but some also play a role in carcinogenesis. Aspirin 
      permanently inhibits platelet COX-1, underlying its anti-thrombotic and 
      anti-cancer action. While the use of aspirin as an anti-cancer drug is 
      increasingly encouraged, its continued use in addition to P(2) Y(12) receptor 
      antagonists for the treatment of cardiovascular diseases is currently debated. 
      Aspirin not only suppresses TXA(2) but also prevents the synthesis of both known 
      and unknown antiplatelet eicosanoid pathways, potentially lessening the efficacy 
      of dual antiplatelet therapies. LINKED ARTICLES: This article is part of a themed 
      section on Eicosanoids 35 years from the 1982 Nobel: where are we now? To view 
      the other articles in this section visit 
      http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc.
CI  - © 2018 The Authors. British Journal of Pharmacology published by John Wiley & 
      Sons Ltd on behalf of British Pharmacological Society.
FAU - Crescente, Marilena
AU  - Crescente M
AUID- ORCID: 0000-0003-3164-512X
AD  - Centre for Immunobiology, Blizard Institute, Barts and The London School of 
      Medicine and Dentistry, Queen Mary University of London, London, UK.
FAU - Menke, Laura
AU  - Menke L
AUID- ORCID: 0000-0001-9120-0734
AD  - Centre for Immunobiology, Blizard Institute, Barts and The London School of 
      Medicine and Dentistry, Queen Mary University of London, London, UK.
FAU - Chan, Melissa V
AU  - Chan MV
AD  - Centre for Immunobiology, Blizard Institute, Barts and The London School of 
      Medicine and Dentistry, Queen Mary University of London, London, UK.
FAU - Armstrong, Paul C
AU  - Armstrong PC
AUID- ORCID: 0000-0003-0904-677X
AD  - Centre for Immunobiology, Blizard Institute, Barts and The London School of 
      Medicine and Dentistry, Queen Mary University of London, London, UK.
FAU - Warner, Timothy D
AU  - Warner TD
AUID- ORCID: 0000-0003-3988-4408
AD  - Centre for Immunobiology, Blizard Institute, Barts and The London School of 
      Medicine and Dentistry, Queen Mary University of London, London, UK.
LA  - eng
GR  - PG/15/47/31591/BHF_/British Heart Foundation/United Kingdom
GR  - PG/15/79/31777/BHF_/British Heart Foundation/United Kingdom
GR  - PG/17/40/33028/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180419
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Eicosanoids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/*metabolism
MH  - Cardiovascular System/drug effects/*metabolism
MH  - Eicosanoids/*metabolism
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
PMC - PMC6451075
COIS- The authors declare no conflicts of interest.
EDAT- 2018/03/08 06:00
MHDA- 2020/07/04 06:00
CRDT- 2018/03/08 06:00
PHST- 2017/11/08 00:00 [received]
PHST- 2018/02/21 00:00 [revised]
PHST- 2018/02/22 00:00 [accepted]
PHST- 2018/03/08 06:00 [pubmed]
PHST- 2020/07/04 06:00 [medline]
PHST- 2018/03/08 06:00 [entrez]
AID - BPH14196 [pii]
AID - 10.1111/bph.14196 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2019 Apr;176(8):988-999. doi: 10.1111/bph.14196. Epub 2018 Apr 
      19.

PMID- 18955670
OWN - NLM
STAT- MEDLINE
DCOM- 20081202
LR  - 20230815
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 118
IP  - 20
DP  - 2008 Nov 11
TI  - Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation 
      depends on the quality of international normalized ratio control achieved by 
      centers and countries as measured by time in therapeutic range.
PG  - 2029-37
LID - 10.1161/CIRCULATIONAHA.107.750000 [doi]
AB  - BACKGROUND: Oral anticoagulation (OAC) therapy is effective in atrial 
      fibrillation but requires vigilance to maintain the international normalized 
      ratio in the therapeutic range. This report examines how differences in time in 
      therapeutic range (TTR) between centers and between countries affect the outcomes 
      of OAC therapy. METHODS AND RESULTS: In a posthoc analysis, the TTRs of patients 
      on OAC in a randomized trial of OAC versus clopidogrel plus aspirin (Atrial 
      Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events 
      [ACTIVE W]) were used to calculate the mean TTR for each of 526 centers and 15 
      countries. Proportional-hazards analysis, with and without adjustment for 
      baseline variables, was performed, with patients stratified by TTR quartile and 
      country. A wide variation in TTRs was found between centers, with mean TTRs for 
      centers in the 4 quartiles of 44%, 60%, 69%, and 78%. For patients at centers 
      below the median TTR (65%), no treatment benefit was demonstrated as measured by 
      relative risk for vascular events of clopidogrel plus aspirin versus OAC 
      (relative risk, 0.93; 95% confidence interval, 0.70 to 1.24; P=0.61). However, 
      for patients at centers with a TTR above the study median, OAC had a marked 
      benefit, reducing vascular events by >2-fold (relative risk, 2.14; 95% confidence 
      interval, 1.61 to 2.85; P<0.0001). Mean TTR also varied between countries from 
      46% to 78%; relative risk (clopidogrel plus aspirin versus OAC) varied from 0.6 
      to 3.6 (a 5-fold difference). A population-average model predicted that a TTR of 
      58% would be needed to be confident that patients would benefit from being on 
      OAC. CONCLUSIONS: A wide variation exists in international normalized ratio 
      control, as measured by TTR, between clinical centers and between countries, 
      which has a major impact on the treatment benefit of OAC therapy. For centers and 
      countries, a target threshold TTR exists (estimated between 58% and 65%) below 
      which there appears to be little benefit of OAC over antiplatelet therapy.
FAU - Connolly, Stuart J
AU  - Connolly SJ
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada. connostu@phri.ca
FAU - Pogue, Janice
AU  - Pogue J
FAU - Eikelboom, John
AU  - Eikelboom J
FAU - Flaker, Gregory
AU  - Flaker G
FAU - Commerford, Patrick
AU  - Commerford P
FAU - Franzosi, Maria Grazia
AU  - Franzosi MG
FAU - Healey, Jeffrey S
AU  - Healey JS
FAU - Yusuf, Salim
AU  - Yusuf S
CN  - ACTIVE W Investigators
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20081027
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Brazil
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Europe
MH  - Humans
MH  - *International Normalized Ratio
MH  - Middle Aged
MH  - North America
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Quality Control
MH  - South Africa
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2008/10/29 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/10/29 09:00
PHST- 2008/10/29 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/10/29 09:00 [entrez]
AID - CIRCULATIONAHA.107.750000 [pii]
AID - 10.1161/CIRCULATIONAHA.107.750000 [doi]
PST - ppublish
SO  - Circulation. 2008 Nov 11;118(20):2029-37. doi: 10.1161/CIRCULATIONAHA.107.750000. 
      Epub 2008 Oct 27.

PMID- 21069664
OWN - NLM
STAT- MEDLINE
DCOM- 20101206
LR  - 20200511
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 11
DP  - 2010 Nov 10
TI  - WITHDRAWN: Antihistamines versus aspirin for itching in late pregnancy.
PG  - CD000027
LID - 10.1002/14651858.CD000027.pub2 [doi]
AB  - BACKGROUND: While not common, itching in pregnancy (not due to liver disease) can 
      be distressing. OBJECTIVES: The objective of this review was to assess the 
      effects of treatment for itching in late pregnancy. SEARCH STRATEGY: We searched 
      the Cochrane Pregnancy and Childbirth Group trials register (January 2007). 
      SELECTION CRITERIA: Randomised trials of treatments for itching in women in late 
      pregnancy with normal liver function. DATA COLLECTION AND ANALYSIS: Two review 
      authors independently assessed trial quality and extracted data. MAIN RESULTS: 
      One study of 38 women was included. This was a small crossover trial, using 
      alternate allocation. The trial compared a histamine, chlorpheniramine, with 
      aspirin. Aspirin was more effective than chlorpheniramine in relieving itching 
      (odds ratio 2.39, 95% confidence interval 1.25 to 4.57). However, 
      chlorpheniramine was more effective than aspirin when a rash was present. 
      AUTHORS' CONCLUSIONS: Aspirin appears to be more effective than chlorpheniramine 
      for relief of itching in pregnancy when no rash is present. If there is a rash, 
      chlorpheniramine may be more effective.
FAU - Young, Gavin
AU  - Young G
AD  - Temple Sowerby Medical Practice, Linden Park, Temple Sowerby, Penrith, Cumbria, 
      UK, CA10 1RW.
FAU - Jewell, David
AU  - Jewell D
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20101110
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Antipruritics)
RN  - 0 (Histamine H1 Antagonists)
RN  - 3U6IO1965U (Chlorpheniramine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2000;(2):CD000027. PMID: 10796091
MH  - Antipruritics/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Chlorpheniramine/*therapeutic use
MH  - Female
MH  - Histamine H1 Antagonists/*therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Pregnancy Trimester, Third
MH  - Pruritus/*drug therapy
EDAT- 2010/11/12 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/11/12 06:00
PHST- 2010/11/12 06:00 [entrez]
PHST- 2010/11/12 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.1002/14651858.CD000027.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2010 Nov 10;(11):CD000027. doi: 
      10.1002/14651858.CD000027.pub2.

PMID- 10796091
OWN - NLM
STAT- MEDLINE
DCOM- 20000706
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 2
DP  - 2000
TI  - Antihistamines versus aspirin for itching in late pregnancy.
PG  - CD000027
AB  - BACKGROUND: While not common, itching in pregnancy (not due to liver disease) can 
      be distressing. OBJECTIVES: The objective of this review was to assess the 
      effects of treatment for itching in late pregnancy. SEARCH STRATEGY: We searched 
      the Cochrane Pregnancy and Childbirth Group trials register. In addition, the 
      Cochrane Controlled Trials Register (CENTRAL/CCTR) was searched. Date of last 
      search: April 1999. SELECTION CRITERIA: Randomised trials of treatments for 
      itching in women in late pregnancy with normal liver function. DATA COLLECTION 
      AND ANALYSIS: Trial quality was assessed and data were extracted independently by 
      two reviewers. MAIN RESULTS: One study of 38 women was included. This was a small 
      crossover trial, using alternate allocation. The trial compared a histamine, 
      chlorpheniramine, with aspirin. Aspirin was more effective than chlorpheniramine 
      in relieving itching (odds ratio 2. 39, 95% confidence interval 1.25 to 4.57). 
      However chlorpheniramine was more effective than aspirin when a rash was present. 
      REVIEWER'S CONCLUSIONS: Aspirin appears to be more effective than 
      chlorpheniramine for relief of itching in pregnancy when no rash is present. If 
      there is a rash, chlorpheniramine may be more effective.
FAU - Young, G L
AU  - Young GL
AD  - Barn Croft Surgery, Temple Sowerby, Penrith, Cumbria, CA10 1RZ. 
      youngjckvg@compuserve.com
FAU - Jewell, D
AU  - Jewell D
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Antipruritics)
RN  - 0 (Histamine H1 Antagonists)
RN  - 3U6IO1965U (Chlorpheniramine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UIN - Cochrane Database Syst Rev. 2010;(11):CD000027. PMID: 21069664
MH  - Antipruritics/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Chlorpheniramine/*therapeutic use
MH  - Female
MH  - Histamine H1 Antagonists/*therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Pregnancy Trimester, Third
MH  - Pruritus/*drug therapy
RF  - 1
EDAT- 2000/05/05 09:00
MHDA- 2000/07/08 11:00
CRDT- 2000/05/05 09:00
PHST- 2000/05/05 09:00 [pubmed]
PHST- 2000/07/08 11:00 [medline]
PHST- 2000/05/05 09:00 [entrez]
AID - CD000027 [pii]
AID - 10.1002/14651858.CD000027 [doi]
PST - ppublish
SO  - Cochrane Database Syst Rev. 2000;(2):CD000027. doi: 10.1002/14651858.CD000027.

PMID- 16807018
OWN - NLM
STAT- MEDLINE
DCOM- 20061109
LR  - 20131121
IS  - 1090-7807 (Print)
IS  - 1090-7807 (Linking)
VI  - 182
IP  - 1
DP  - 2006 Sep
TI  - Selective J-resolved spectra: a double pulsed field gradient spin-echo approach.
PG  - 29-37
AB  - A simple method to obtain selective J-resolved spectra is presented, which relies 
      on the refocusing properties of double pulsed field gradient spin-echoes and 
      provides unambiguous assignment of the measured coupling constants. The proposed 
      examples show how this method is of general applicability, and requires no more 
      than a simple optimization strategy to produce artifact-free spectra. Examples of 
      application include the determination of a small, long-range coupling constant 
      (0.7 Hz) in trans-retinal and Halpha couplings in a tripeptide.
FAU - Rastrelli, Federico
AU  - Rastrelli F
AD  - Dipartimento di Scienze Chimiche, Università di Padova, via Marzolo 1, 35131 
      Padova, Italy. federico.rastrelli@unipd.it
FAU - Bagno, Alessandro
AU  - Bagno A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060627
PL  - United States
TA  - J Magn Reson
JT  - Journal of magnetic resonance (San Diego, Calif. : 1997)
JID - 9707935
RN  - 5688UTC01R (Tretinoin)
RN  - H9Y79VD43J (Strychnine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Molecular Structure
MH  - Nuclear Magnetic Resonance, Biomolecular/*methods
MH  - Signal Processing, Computer-Assisted
MH  - Strychnine/chemistry
MH  - Tretinoin/chemistry
EDAT- 2006/06/30 09:00
MHDA- 2006/11/11 09:00
CRDT- 2006/06/30 09:00
PHST- 2006/03/15 00:00 [received]
PHST- 2006/04/24 00:00 [revised]
PHST- 2006/06/05 00:00 [accepted]
PHST- 2006/06/30 09:00 [pubmed]
PHST- 2006/11/11 09:00 [medline]
PHST- 2006/06/30 09:00 [entrez]
AID - S1090-7807(06)00152-2 [pii]
AID - 10.1016/j.jmr.2006.06.004 [doi]
PST - ppublish
SO  - J Magn Reson. 2006 Sep;182(1):29-37. doi: 10.1016/j.jmr.2006.06.004. Epub 2006 
      Jun 27.

PMID- 10448540
OWN - NLM
STAT- MEDLINE
DCOM- 19991013
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 19
IP  - 6
DP  - 1999 Jul
TI  - Acetylsalicylic acid in the treatment of headache.
PG  - 545-51
AB  - Acetylsalicylic acid (ASA) is used to treat a broad range of symptoms and 
      disorders. Since its discovery in 1897, it has been used to treat fever and 
      rheumatic pain, to inhibit the formation of thrombocytes, to prevent myocardial 
      ischemia and strokes, and as preventive medication against neoplasms. ASA is best 
      known, however, as a headache medication. For this function alone, ASA underwent 
      an evolution: from powder to tablet to effervescent and chewable tablets. In 
      addition to these oral formulations, an injectable form was developed in the 
      1970s for intravenous and intramuscular application. Furthermore, coated 
      (slow-releasing) tablets are now used in the prophylactic treatment of migraine. 
      The various forms of ASA used to treat headache are discussed and the controlled 
      studies conducted to evaluate ASA's efficacy in headache treatment are 
      summarized.
FAU - Limmroth, V
AU  - Limmroth V
AD  - Department of Neurology, University Hospital Essen, Germany. 
      volker.limmroth@t-online.de
FAU - Katsarava, Z
AU  - Katsarava Z
FAU - Diener, H C
AU  - Diener HC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Headache/*drug therapy
MH  - Humans
MH  - Migraine Disorders/*drug therapy
MH  - Treatment Outcome
RF  - 36
EDAT- 1999/08/17 00:00
MHDA- 1999/08/17 00:01
CRDT- 1999/08/17 00:00
PHST- 1999/08/17 00:00 [pubmed]
PHST- 1999/08/17 00:01 [medline]
PHST- 1999/08/17 00:00 [entrez]
AID - 10.1046/j.1468-2982.1999.019006545.x [doi]
PST - ppublish
SO  - Cephalalgia. 1999 Jul;19(6):545-51. doi: 10.1046/j.1468-2982.1999.019006545.x.

PMID- 1295515
OWN - NLM
STAT- MEDLINE
DCOM- 19930422
LR  - 20141120
IS  - 0037-8771 (Print)
IS  - 0037-8771 (Linking)
VI  - 68
IP  - 10
DP  - 1992 Oct
TI  - [Effect of ASA on the interaction of von Willebrand factor with the platelet 
      membrane].
PG  - 607-12
AB  - Ristocetin induces a conformational change on von Willebrand Factor (vWF) similar 
      to that due to the interaction with the subendothelium, by which the former can 
      interact with the Glycoprotein-1 B (GPIB) of the platelet membrane and trigger 
      aggregation and granule content secretion. Platelet Rich Plasma (PRP) treated 
      with Acetyl Salicylic Acid (ASA) loses completely the aggregability induced by 
      addition of Ristocetin whereas ASA-treated and successively Washed Platelets 
      (AWP) supplemented with normal plasma (PPP) give an aggregation and a secretory 
      response to Ristocetin similar to that given by PRP; similarly normal Washed 
      Platelets (WP) supplemented with ASA-treated plasma (APPP) give identical 
      aggregation, and secretion by Ristocetin addition. Ours results indicate that the 
      Ristocetin-vWF complex can trigger two distinct intraplatelet metabolic pathways. 
      A first well known way starts from the activation of Phospholipase A-2 (PL-A2), 
      by which arachidonic acid is produced, that, in turn, undergoes the metabolic 
      pathway leading to Thromboxane A-2; this pathway can be blocked by the 
      intraplatelet ASA by irreversible inactivation of Cyclooxygenase, but it is 
      insensitive to the extra-platelet ASA. A second, independent metabolic pathway, 
      can be triggered by intact vWF, but not by the ASA treated one. It is insensitive 
      to intraplatelet ASA and therefore unrelated to the arachidonic acid metabolism. 
      This pathway could start from the activation of Phospholipase C (PL-C).
FAU - Ferri, A
AU  - Ferri A
AD  - Istituto di Chimica Biologica, Università di Ferrara.
FAU - Anello, G
AU  - Anello G
FAU - Calza, R
AU  - Calza R
FAU - Bozza, A
AU  - Bozza A
LA  - ita
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Effetto di ASA sull'interazione del fattore di von Willebrand con la membrana 
      piastrinica.
PL  - Italy
TA  - Boll Soc Ital Biol Sper
JT  - Bollettino della Societa italiana di biologia sperimentale
JID - 7506962
RN  - 0 (Platelet Membrane Glycoproteins)
RN  - 0 (von Willebrand Factor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Membrane Glycoproteins/*drug effects
MH  - Protein Binding/drug effects
MH  - von Willebrand Factor/*drug effects
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
PST - ppublish
SO  - Boll Soc Ital Biol Sper. 1992 Oct;68(10):607-12.

PMID- 25541030
OWN - NLM
STAT- MEDLINE
DCOM- 20151008
LR  - 20150124
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 135
IP  - 2
DP  - 2015 Feb
TI  - The use of aspirin for primary and secondary prevention in venous thromboembolism 
      and other cardiovascular disorders.
PG  - 217-25
LID - S0049-3848(14)00672-0 [pii]
LID - 10.1016/j.thromres.2014.11.036 [doi]
AB  - Cardiovascular disease (CVD) includes a number of conditions such as myocardial 
      infarction, coronary heart disease, stroke, and venous thromboembolism. CVD is a 
      leading health problem worldwide and a major cause of mortality, morbidity, and 
      disability; it is also associated with high healthcare costs. The incidence of 
      CVD is predicted to increase in the forthcoming years, and thus it is crucial 
      that physicians are aware of the benefits and limitations of the available 
      therapies to ensure patients receive optimized treatment. Current clinical 
      practice guidelines provide recommendations on the use of anticoagulants and 
      antiplatelets for both the prevention and treatment of CVD. Aspirin is the most 
      studied antiplatelet agent in this context. The benefits of aspirin are well 
      documented and supported by data from robust clinical trials for CVD conditions, 
      such as acute coronary syndrome and stroke prevention in patients with atrial 
      fibrillation. However, the clinical benefits of aspirin are less clear for other 
      conditions, namely for primary prevention of venous thromboembolism after major 
      orthopaedic surgery, particularly in comparison with newer drugs such as the 
      direct oral anticoagulants. This article provides an outline of the current 
      guidelines and a critical assessment of the efficacy and safety data supporting 
      the recommendations for the use of aspirin in the treatment and prevention of 
      venous thromboembolism and other cardiovascular disorders.
CI  - Copyright © 2015 Elsevier Ltd. All rights reserved.
FAU - Cohen, A T
AU  - Cohen AT
AD  - Department of Haematological Medicine, Guy's and St Thomas' Hospitals, London, 
      UK. Electronic address: alexander.cohen@kcl.ac.uk.
FAU - Imfeld, S
AU  - Imfeld S
AD  - Vascular Medicine, King's College Hospital, London, UK; Department of Angiology, 
      University Hospital Basel, Switzerland.
FAU - Markham, J
AU  - Markham J
AD  - Vascular Medicine, King's College Hospital, London, UK.
FAU - Granziera, S
AU  - Granziera S
AD  - Vascular Medicine, King's College Hospital, London, UK; University of Padova, 
      Department of Medicine (DIMED), Padova, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20141213
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention/*methods
MH  - Secondary Prevention/*methods
MH  - Venous Thromboembolism/*prevention & control
OTO - NOTNLM
OT  - Anticoagulant
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Orthopaedic
OT  - Practice guideline
EDAT- 2014/12/30 06:00
MHDA- 2015/10/09 06:00
CRDT- 2014/12/27 06:00
PHST- 2014/07/24 00:00 [received]
PHST- 2014/10/30 00:00 [revised]
PHST- 2014/11/01 00:00 [accepted]
PHST- 2014/12/27 06:00 [entrez]
PHST- 2014/12/30 06:00 [pubmed]
PHST- 2015/10/09 06:00 [medline]
AID - S0049-3848(14)00672-0 [pii]
AID - 10.1016/j.thromres.2014.11.036 [doi]
PST - ppublish
SO  - Thromb Res. 2015 Feb;135(2):217-25. doi: 10.1016/j.thromres.2014.11.036. Epub 
      2014 Dec 13.

PMID- 22009986
OWN - NLM
STAT- MEDLINE
DCOM- 20120716
LR  - 20181201
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 18
IP  - 2
DP  - 2012 Mar-Apr
TI  - Measurement of shear-activated platelet aggregate formation in non-anticoagulated 
      blood: utility in detection of clopidogrel-aspirin-induced platelet dysfunction.
PG  - 140-9
LID - 10.1177/1076029611423387 [doi]
AB  - We studied the ability of a new instrument, the PlaCor PRT that measures 
      shear-induced platelet aggregation in fingerstick, non-anticoagulated blood 
      without added agonists, to detect platelet dysfunction ex vivo. Platelet 
      reactivity time (PRT) and whole blood aggregation (WBA) were measured in 160 
      healthy volunteers, before and after aspirin and in 170 participants with 
      established vascular disease or risk factors thereof treated with aspirin ± 
      clopidogrel. Pretreatment PRT and WBA were significantly correlated (collagen r = 
      -.63; arachidonate r = -.65; P < .0001). Following aspirin, the mean PRT 
      increased from 82 to 142 seconds (P < .0001), and in participants treated with 
      clopidogrel-aspirin, the mean PRT (286 seconds, n = 65) was significantly longer 
      than with aspirin alone (166 seconds, n = 105; P < .001). Only 13% of PRTs of 
      participants treated with clopidogrel and aspirin were within the normal range. 
      We conclude that the PlaCor PRT is a simple, rapid, point-of-care instrument that 
      compares favorably with published descriptions of other platelet function 
      instruments.
FAU - Johnson, Gerhard J
AU  - Johnson GJ
AD  - Hematology-Oncology Section, Medical Service, Veterans Affairs Health Care 
      System, Minneapolis, MN 55417, USA. johns337@umn.edu
FAU - Sharda, Anish V
AU  - Sharda AV
FAU - Rao, Gundu H R
AU  - Rao GH
FAU - Ereth, Mark H
AU  - Ereth MH
FAU - Laxson, David D
AU  - Laxson DD
FAU - Owen, Whyte G
AU  - Owen WG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20111017
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9007-34-5 (Collagen)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects/pharmacology/therapeutic use
MH  - Blood Platelet Disorders/blood/chemically induced/*diagnosis
MH  - Blood Specimen Collection/*methods
MH  - Cardiovascular Diseases/blood
MH  - Clopidogrel
MH  - Collagen/pharmacology
MH  - Cross-Sectional Studies
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Equipment Design
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*adverse effects/pharmacology/therapeutic use
MH  - Platelet Function Tests/*instrumentation
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - Stress, Mechanical
MH  - Thrombophilia/blood/drug therapy
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacology/therapeutic use
MH  - Warfarin/adverse effects/pharmacology/therapeutic use
EDAT- 2011/10/20 06:00
MHDA- 2012/07/17 06:00
CRDT- 2011/10/20 06:00
PHST- 2011/10/20 06:00 [entrez]
PHST- 2011/10/20 06:00 [pubmed]
PHST- 2012/07/17 06:00 [medline]
AID - 1076029611423387 [pii]
AID - 10.1177/1076029611423387 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):140-9. doi: 10.1177/1076029611423387. 
      Epub 2011 Oct 17.

PMID- 10720771
OWN - NLM
STAT- MEDLINE
DCOM- 20000504
LR  - 20190819
IS  - 0378-4274 (Print)
IS  - 0378-4274 (Linking)
VI  - 112-113
DP  - 2000 Mar 15
TI  - Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer.
PG  - 493-8
AB  - Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been 
      associated with reduced risk of colorectal cancer. Moreover, the NSAID sulindac 
      reduces the number and size of polyps in patients with familial adenomatous 
      polyposis. The mechanisms of these effects of NSAIDs are not known but several 
      lines of evidence suggest the involvement of the inhibition of the inducible 
      isoform of prostaglandin H synthase (known as COX-2). Specific COX-2 inhibitors, 
      showing an improved profile of gastrointestinal safety vis-à-vis conventional 
      NSAIDs, provide interesting tools to probe the COX-2 dependence of the apparent 
      protection against colorectal cancer associated with the use of NSAIDs.
FAU - Patrignani, P
AU  - Patrignani P
AD  - Department of Medicine and Aging, Division of Pharmacology, 'G. D'Annunzio' 
      University of Chieti, School of Medicine, Via dei Vestine, 31, 66013, Chieti, 
      Italy. ppatrignani@unich.it
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Toxicol Lett
JT  - Toxicology letters
JID - 7709027
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 184SNS8VUH (Sulindac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenomatous Polyposis Coli/*prevention & control
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/antagonists & inhibitors/*therapeutic use
MH  - Aspirin/antagonists & inhibitors/*therapeutic use
MH  - Colorectal Neoplasms/*prevention & control
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Humans
MH  - Sulindac/therapeutic use
RF  - 30
EDAT- 2000/03/18 09:00
MHDA- 2000/05/08 09:00
CRDT- 2000/03/18 09:00
PHST- 2000/03/18 09:00 [pubmed]
PHST- 2000/05/08 09:00 [medline]
PHST- 2000/03/18 09:00 [entrez]
AID - S0378427499002106 [pii]
AID - 10.1016/s0378-4274(99)00210-6 [doi]
PST - ppublish
SO  - Toxicol Lett. 2000 Mar 15;112-113:493-8. doi: 10.1016/s0378-4274(99)00210-6.

PMID- 8532271
OWN - NLM
STAT- MEDLINE
DCOM- 19960201
LR  - 20190818
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 87
IP  - 1
DP  - 1996 Jan
TI  - A randomized controlled trial of aspirin in patients with abnormal uterine artery 
      blood flow.
PG  - 74-8
AB  - OBJECTIVE: To evaluate color Doppler imaging of the uterine arteries as a 
      screening test in nulliparous women, and to examine the role of low-dose aspirin 
      therapy in pregnancies with abnormal uteroplacental resistance. METHODS: At the 
      routine 18-week fetal morphology ultrasound scan, 955 nulliparous women underwent 
      color Doppler imaging of the uterine arteries. Abnormal uteroplacental vascular 
      resistance was defined with respect to both the systolic-diastolic ratio of the 
      flow velocity waveform and the presence of an ipsilateral early diastolic notch. 
      Those with abnormal uterine artery waveforms were asked to participate in a 
      randomized controlled trial of aspirin therapy. Pregnancy outcomes were compared 
      in women with normal or abnormal flow velocity waveforms, as well as in the two 
      arms of the intervention study. RESULTS: Of 186 women with abnormal 
      uteroplacental resistance according to criteria defined previously, 102 agreed to 
      randomization to either low-dose aspirin (100 mg/day) or placebo for the 
      remainder of the pregnancy. Abnormal uterine artery flow velocity waveforms were 
      associated with statistically significant increases in preeclampsia (11 versus 
      4%), birth weight below the tenth percentile (28 versus 11%), and adverse 
      pregnancy outcome (45 versus 28%). Prophylactic aspirin therapy did not result in 
      a significant reduction in pregnancy complications. CONCLUSION: Abnormal 
      uteroplacental resistance at 18 weeks' gestation was associated with a 
      significant increase in adverse pregnancy outcome. Low-dose aspirin did not 
      reduce pregnancy complications in women with uteroplacental insufficiency.
FAU - Morris, J M
AU  - Morris JM
AD  - Department of Obstetrics and Gynecology, University of Sydney, Nepean Hospital, 
      Penrith, Australia.
FAU - Fay, R A
AU  - Fay RA
FAU - Ellwood, D A
AU  - Ellwood DA
FAU - Cook, C M
AU  - Cook CM
FAU - Devonald, K J
AU  - Devonald KJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arteries/physiopathology
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*drug therapy/physiopathology
MH  - Pregnancy Outcome
MH  - Regional Blood Flow
MH  - Uterus/*blood supply
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 0029784495003401 [pii]
AID - 10.1016/0029-7844(95)00340-1 [doi]
PST - ppublish
SO  - Obstet Gynecol. 1996 Jan;87(1):74-8. doi: 10.1016/0029-7844(95)00340-1.

PMID- 8237316
OWN - NLM
STAT- MEDLINE
DCOM- 19931222
LR  - 20190821
IS  - 0001-6470 (Print)
IS  - 0001-6470 (Linking)
VI  - 64
IP  - 5
DP  - 1993 Oct
TI  - Increased blood loss after preoperative NSAID. Retrospective study of 186 hip 
      arthroplasties.
PG  - 522-4
AB  - We have evaluated bleeding during and after hip replacement in 186 patients in 
      relation to preoperative intake of nonsteroidal anti-inflammatory drugs (NSAID) 
      combined with low molecular weight heparin. NSAID was associated with increased 
      preoperative bleeding and blood transfusion requirements.
FAU - Faunø, P
AU  - Faunø P
AD  - Department of Orthopedics E, University Hospital of Arhus, Denmark.
FAU - Petersen, K D
AU  - Petersen KD
FAU - Husted, S E
AU  - Husted SE
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Orthop Scand
JT  - Acta orthopaedica Scandinavica
JID - 0370352
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Enoxaparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - *Blood Loss, Surgical/prevention & control
MH  - Enoxaparin/*adverse effects/therapeutic use
MH  - Female
MH  - Hip Prosthesis/*adverse effects/methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Premedication/*adverse effects
MH  - Retrospective Studies
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
AID - 10.3109/17453679308993683 [doi]
PST - ppublish
SO  - Acta Orthop Scand. 1993 Oct;64(5):522-4. doi: 10.3109/17453679308993683.

PMID- 1683479
OWN - NLM
STAT- MEDLINE
DCOM- 19920102
LR  - 20131121
IS  - 0030-6002 (Print)
IS  - 0030-6002 (Linking)
VI  - 132
IP  - 27
DP  - 1991 Jul 7
TI  - [Prostaglandins and damage to the gastric mucosa].
PG  - 1461-7
AB  - The author critically analyses the involvement of prostaglandins in peptic 
      ulceration. Clinical evidence suggests that for the treatment of peptic ulcer 
      other available drugs (e.g. H2-blockers) are as effective and have fewer 
      side-effects. A potential role in prevention of drug induced gastric mucosal 
      damage (NSAID, ASA) may be verified in further studies.
FAU - Varró, V
AU  - Varró V
AD  - Szent-Györgyi Albert Orvostudományi Egyetem, I. sz. Belgyógyászati Klinika.
LA  - hun
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - A prostaglandinok és a gyomornyálkahártya károsodása.
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Gastric Mucosa/drug effects
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Peptic Ulcer Hemorrhage/chemically induced
MH  - Prostaglandins/adverse effects/*therapeutic use
MH  - Stomach Ulcer/*drug therapy
RF  - 32
EDAT- 1991/07/07 00:00
MHDA- 1991/07/07 00:01
CRDT- 1991/07/07 00:00
PHST- 1991/07/07 00:00 [pubmed]
PHST- 1991/07/07 00:01 [medline]
PHST- 1991/07/07 00:00 [entrez]
PST - ppublish
SO  - Orv Hetil. 1991 Jul 7;132(27):1461-7.

PMID- 26149039
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 13 Suppl 1
DP  - 2015 Jun
TI  - Role of aspirin for prevention and treatment of perioperative cardiovascular 
      events.
PG  - S297-303
LID - 10.1111/jth.12975 [doi]
AB  - Among adults undergoing non-cardiac surgery who are at risk of a myocardial 
      infarction, a long-standing question has been whether these patients should 
      receive aspirin throughout the perioperative period. A large (n = 10,010 
      patients) international trial (POISE-2) demonstrated that perioperative aspirin 
      did not prevent myocardial infarction, and the result was consistent both for 
      patients who had been taking aspirin before the trial (continuation stratum, 4382 
      patients) and for patients who had not been taking aspirin before the trial 
      (initiation stratum, 5628 patients). Aspirin did, however, increase the risk of 
      major bleeding. Therefore, the best evidence does not support the use of aspirin 
      for the prevention of myocardial infarction in patients undergoing non-cardiac 
      surgery. In patients who have an indication for long-term aspirin usage and have 
      their aspirin held during the perioperative period, it is important to ensure 
      aspirin is restarted after the high-risk period for bleeding has passed (i.e., 
      8-10 days after surgery).
CI  - © 2015 International Society on Thrombosis and Haemostasis.
FAU - Duceppe, E
AU  - Duceppe E
AD  - Department of Clinical Epidemiology and Biostatistics, McMaster University, 
      Hamilton, ON, Canada.
FAU - Mrkobrada, M
AU  - Mrkobrada M
AD  - Department of Medicine, Schulich School of Medicine & Dentistry, Western 
      University, London, ON, Canada.
FAU - Thomas, S
AU  - Thomas S
AD  - Department of Medicine, University of Rochester, Rochester, NY, USA.
FAU - Devereaux, P J
AU  - Devereaux PJ
AD  - Department of Clinical Epidemiology and Biostatistics, McMaster University, 
      Hamilton, ON, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
AD  - Perioperative Medicine and Surgical Research Unit, Population Health Research 
      Institute, Hamilton, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Agents/*administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/etiology/mortality/*prevention & control
MH  - Perioperative Period
MH  - Risk Assessment
MH  - Risk Factors
MH  - Surgical Procedures, Operative/*adverse effects/mortality
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin
OT  - cardiology
OT  - cardiovascular diseases
OT  - myocardial infarction
OT  - perioperative care
EDAT- 2015/07/08 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/07/08 06:00
PHST- 2015/07/08 06:00 [entrez]
PHST- 2015/07/08 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - S1538-7836(22)04254-4 [pii]
AID - 10.1111/jth.12975 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2015 Jun;13 Suppl 1:S297-303. doi: 10.1111/jth.12975.

PMID- 26688324
OWN - NLM
STAT- MEDLINE
DCOM- 20161024
LR  - 20170917
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 138
DP  - 2016 Feb
TI  - Sonorheometry assessment of platelet function in cardiopulmonary bypass patients: 
      Correlation of blood clot stiffness with platelet integrin αIIbβ3 activity, 
      aspirin usage, and transfusion risk.
PG  - 96-102
LID - S0049-3848(15)30212-7 [pii]
LID - 10.1016/j.thromres.2015.11.036 [doi]
AB  - BACKGROUND: Impaired platelet function may underlie bleeding associated with 
      cardiopulmonary bypass (CPB) and at present is incompletely evaluated with 
      existing diagnostic technologies. Sonorheometry (SR) is a recently developed 
      ultrasound-based technology that quantifies hemostasis and platelet activity from 
      a blood sample by measuring ex vivo clot stiffness (S). We hypothesized that 
      impaired platelet-fibrin interactions as assessed by SR would correlate with 
      transfusion during CPB and history of prior aspirin therapy. METHODS: Thirty-nine 
      patients undergoing elective cardiopulmonary bypass (CPB) were enrolled following 
      informed consent (University of Virginia IRB#14050) in a prospective 
      observational pilot study to assess pre-operative platelet function and 
      transfusion frequency. To assess platelet activity, abciximab was added to blood 
      prior to SR and native S versus abciximab treated S created a differential test 
      for platelet activity. Patient blood samples were activated with kaolin and SR 
      was then used to measure clot stiffness. Patients were transfused with blood 
      products as directed by clinical practice, with the surgical team blinded to SR 
      results. RESULTS: Blood clot stiffness with and without abciximab, was compared 
      in a ratio test (S/Sabciximab) named the Platelet Function Index (PFI). PFI was 
      hypothesized to be positively correlated with platelet contributions through 
      integrin αIIbβ3 to clot stiffness. PFI for CPB subjects was lower for those 
      receiving transfusions than those not receiving transfusions (p<0.006). A 
      receiver-operator characteristics (ROC) analysis correlating the PFI with the 
      blinded surgical team's decision on transfusions that included platelet 
      concentrates generated an area under the curve (AUC) of 0.79 (p<0.001). 
      Additionally, the mean value of PFI for subjects on aspirin therapy was lower 
      than for those not on aspirin therapy (p<0.02) and correlated with a 1.73-fold 
      enhanced risk of receiving a peri-operative transfusion. CONCLUSION: Evaluation 
      of platelet function with SR may help in the specification of blood transfusion 
      needs in cardiac surgery and in the assessment of aspirin effects on risk of 
      surgical bleeding.
CI  - Copyright © 2015 Elsevier Ltd. All rights reserved.
FAU - Viola, Francesco
AU  - Viola F
AD  - Department of Biomedical Engineering, University of Virginia, 415 Lane Rd., 
      Charlottesville, VA 22908, United States. Electronic address: fv7d@virginia.edu.
FAU - Lin-Schmidt, Xiefan
AU  - Lin-Schmidt X
AD  - Department of Biomedical Engineering, University of Virginia, 415 Lane Rd., 
      Charlottesville, VA 22908, United States. Electronic address: 
      XLinschm@its.jnj.com.
FAU - Bhamidipati, Castigliano
AU  - Bhamidipati C
AD  - Department of Surgery, Division of Thoracic and Cardiovascular Surgery, 
      University of Virginia, 1215 Lee Street, Charlottesville, VA 22908, United 
      States. Electronic address: casti.bhamidipati@gmail.com.
FAU - Haverstick, Doris M
AU  - Haverstick DM
AD  - Department Pathology and Clinical Chemistry, University of Virginia, 1215 Lee 
      Street, Charlottesville, VA 22908, United States. Electronic address: 
      dmh2t@virginia.edu.
FAU - Walker, William F
AU  - Walker WF
AD  - Department of Biomedical Engineering, University of Virginia, 415 Lane Rd., 
      Charlottesville, VA 22908, United States; Department of Electrical and Computer 
      Engineering, University of Virginia, 351 McCormick Rd., Charlottesville, VA 
      22904, United States. Electronic address: bwalker@hemosonics.com.
FAU - Ailawadi, Gorav
AU  - Ailawadi G
AD  - Department of Surgery, Division of Thoracic and Cardiovascular Surgery, 
      University of Virginia, 1215 Lee Street, Charlottesville, VA 22908, United 
      States. Electronic address: GA3F@hscmail.mcc.virginia.edu.
FAU - Lawrence, Michael B
AU  - Lawrence MB
AD  - Department of Biomedical Engineering, University of Virginia, 415 Lane Rd., 
      Charlottesville, VA 22908, United States. Electronic address: mbl2a@virginia.edu.
LA  - eng
GR  - R01-EB005433/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151126
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Tests/methods
MH  - Blood Loss, Surgical
MH  - Blood Platelets/cytology/*drug effects/metabolism
MH  - Blood Transfusion
MH  - *Cardiopulmonary Bypass/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests/*methods
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*metabolism
MH  - Prospective Studies
MH  - Ultrasonography/methods
EDAT- 2015/12/22 06:00
MHDA- 2016/10/25 06:00
CRDT- 2015/12/22 06:00
PHST- 2015/07/22 00:00 [received]
PHST- 2015/11/24 00:00 [revised]
PHST- 2015/11/25 00:00 [accepted]
PHST- 2015/12/22 06:00 [entrez]
PHST- 2015/12/22 06:00 [pubmed]
PHST- 2016/10/25 06:00 [medline]
AID - S0049-3848(15)30212-7 [pii]
AID - 10.1016/j.thromres.2015.11.036 [doi]
PST - ppublish
SO  - Thromb Res. 2016 Feb;138:96-102. doi: 10.1016/j.thromres.2015.11.036. Epub 2015 
      Nov 26.

PMID- 20237316
OWN - NLM
STAT- MEDLINE
DCOM- 20100617
LR  - 20220317
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 115
IP  - 21
DP  - 2010 May 27
TI  - SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized 
      controlled trial of low-molecular-weight heparin and low-dose aspirin in women 
      with recurrent miscarriage.
PG  - 4162-7
LID - 10.1182/blood-2010-01-267252 [doi]
AB  - To assess whether treatment with enoxaparin and low-dose aspirin, along with 
      intensive pregnancy surveillance, reduces rate of pregnancy loss compared with 
      intensive pregnancy surveillance alone in women with history of 2 or more 
      consecutive previous pregnancy losses, a parallel group, multicenter, randomized 
      controlled trial was performed in the United Kingdom and New Zealand. 
      Participants (n = 294) presenting for initial antenatal care at fewer than 7 
      weeks' gestation with history of 2 or more consecutive previous pregnancy losses 
      at 24 or fewer weeks' gestation and no evidence of anatomic, endocrine, 
      chromosomal, or immunologic abnormality were randomly assigned to receive either 
      enoxaparin 40 mg subcutaneously and 75 mg of aspirin orally once daily along with 
      intense pregnancy surveillance or intense pregnancy surveillance alone from 
      random assignment until 36 weeks' gestation. The primary outcome measure was 
      pregnancy loss rate. Of the 147 participants receiving pharmacologic 
      intervention, 32 (22%) pregnancy losses occurred, compared with 29 losses (20%) 
      in the 147 subjects receiving intensive surveillance alone, giving an odds ratio 
      of 0.91 (95% confidence interval, 0.52-1.59) of having a successful pregnancy 
      with pharmacologic intervention. Thus, we observed no reduction in pregnancy loss 
      rate with antithrombotic intervention in pregnant women with 2 or more 
      consecutive previous pregnancy losses. The trial was registered at 
      http://www.controlled-trials.com as ISRCTN06774126.
FAU - Clark, Peter
AU  - Clark P
AD  - Department of Transfusion Medicine, Ninewells Hospital and Medical School, 
      Dundee, UK. peterclark@nhs.net
FAU - Walker, Isobel D
AU  - Walker ID
FAU - Langhorne, Peter
AU  - Langhorne P
FAU - Crichton, Lena
AU  - Crichton L
FAU - Thomson, Andrew
AU  - Thomson A
FAU - Greaves, Mike
AU  - Greaves M
FAU - Whyte, Sonia
AU  - Whyte S
FAU - Greer, Ian A
AU  - Greer IA
CN  - Scottish Pregnancy Intervention Study (SPIN) collaborators
LA  - eng
SI  - ISRCTN/ISRCTN06774126
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100317
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*drug therapy/prevention & control
MH  - Adult
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Enoxaparin/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Scotland
FIR - Cumming, G
IR  - Cumming G
FIR - Smith, N
IR  - Smith N
FIR - Crichton, L
IR  - Crichton L
FIR - Brennand, J
IR  - Brennand J
FIR - Cameron, A
IR  - Cameron A
FIR - Gaudoin, M
IR  - Gaudoin M
FIR - Ramsay, J
IR  - Ramsay J
FIR - Maharaj, S
IR  - Maharaj S
FIR - Maclean, M
IR  - Maclean M
FIR - McLellan, D
IR  - McLellan D
FIR - Mathers, A
IR  - Mathers A
FIR - McLintock, C
IR  - McLintock C
FIR - Thornton, J
IR  - Thornton J
FIR - Wisdom, S
IR  - Wisdom S
EDAT- 2010/03/20 06:00
MHDA- 2010/06/18 06:00
CRDT- 2010/03/19 06:00
PHST- 2010/03/19 06:00 [entrez]
PHST- 2010/03/20 06:00 [pubmed]
PHST- 2010/06/18 06:00 [medline]
AID - S0006-4971(20)34968-5 [pii]
AID - 10.1182/blood-2010-01-267252 [doi]
PST - ppublish
SO  - Blood. 2010 May 27;115(21):4162-7. doi: 10.1182/blood-2010-01-267252. Epub 2010 
      Mar 17.

PMID- 12657065
OWN - NLM
STAT- MEDLINE
DCOM- 20030513
LR  - 20190709
IS  - 0002-8614 (Print)
IS  - 0002-8614 (Linking)
VI  - 51
IP  - 4
DP  - 2003 Apr
TI  - Quality of care of Medicare beneficiaries with acute myocardial infarction: who 
      is included in quality improvement measurement?
PG  - 466-75
AB  - OBJECTIVES: To determine the proportion of older patients hospitalized with acute 
      myocardial infarction (AMI) incorporated in a commonly used set of AMI quality 
      indicators. DESIGN: Retrospective analysis of a medical record database. SETTING: 
      Nongovernmental U.S. acute care hospitals. PARTICIPANTS: Medicare patients 
      hospitalized for AMI between January 1994 and February 1996. MEASUREMENTS: 
      Proportion of patients aged 65 and older classified as ideal candidates (without 
      absolute or relative contraindications) for six Centers for Medicare & Medicaid 
      Services AMI quality indicators: aspirin (admission, discharge), beta-blocker 
      (admission, discharge), angiotensin-converting enzyme (ACE) inhibitors at 
      discharge, and time to reperfusion therapy. RESULTS: Of the 149,996 patients 
      eligible for admission therapies, 10.1% were ideal candidates for reperfusion 
      therapy, 65.0% for aspirin, and 34.7% for beta-blockers. Of the 116,919 patients 
      eligible for discharge therapies, 47.7% were ideal candidates for aspirin, 17.6% 
      for beta-blockers, and 15.2% for ACE inhibitors. More than one-quarter (26.8%) of 
      all patients were ineligible for any of the six quality indicators; this 
      proportion increased with age, ranging from 23.7% of patients aged 65 to 69 to 
      30.2% of patients aged 85 and older. CONCLUSION: A substantial proportion of 
      older patients were not included in AMI process quality measurement, with the 
      proportion excluded higher in successively older age groups. The data highlight 
      the need for additional research to determine effective treatment strategies for 
      patients for whom the evidence base for clinical decision-making remains weak.
FAU - Rathore, Saif S
AU  - Rathore SS
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, Connecticut 06520, USA.
FAU - Wang, Yongfei
AU  - Wang Y
FAU - Radford, Martha J
AU  - Radford MJ
FAU - Ordin, Diana L
AU  - Ordin DL
FAU - Krumholz, Harlan M
AU  - Krumholz HM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/adverse effects/therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Female
MH  - *Geriatrics
MH  - *Hospitalization
MH  - Humans
MH  - Male
MH  - *Medicare
MH  - Myocardial Infarction/*drug therapy
MH  - *Quality of Health Care
MH  - Retrospective Studies
MH  - United States
EDAT- 2003/03/27 05:00
MHDA- 2003/05/14 05:00
CRDT- 2003/03/27 05:00
PHST- 2003/03/27 05:00 [pubmed]
PHST- 2003/05/14 05:00 [medline]
PHST- 2003/03/27 05:00 [entrez]
AID - jgs51154 [pii]
AID - 10.1046/j.1532-5415.2003.51154.x [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2003 Apr;51(4):466-75. doi: 10.1046/j.1532-5415.2003.51154.x.

PMID- 2643773
OWN - NLM
STAT- MEDLINE
DCOM- 19890306
LR  - 20141120
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 320
IP  - 7
DP  - 1989 Feb 16
TI  - Improvement of renal function with selective thromboxane antagonism in lupus 
      nephritis.
PG  - 421-5
AB  - To test the hypothesis that the vasoconstrictor thromboxane A2 may affect renal 
      hemodynamics in lupus nephritis, we examined the short-term effects of a 
      selective thromboxane-receptor antagonist, BM 13,177, and of low-dose aspirin. In 
      a randomized, double-blind, crossover study, 10 patients with biopsy-proved lupus 
      nephritis were given a 48-hour continuous infusion of BM 13,177 or placebo. At 
      base line, seven patients had markedly elevated urinary levels of thromboxane B2, 
      the breakdown product of thromboxane A2. During the infusion of BM 13,177, the 
      inulin clearance rate, which was 68 ml per minute per 1.73 m2 of body-surface 
      area at base line, increased by an average of 24 percent (range, 12 to 47 
      percent; P less than 0.01). Para-aminohippurate clearance was increased to the 
      same extent, with no change in the filtration fraction. The bleeding time 
      doubled, indicating an occupancy of platelet thromboxane receptors of more than 
      95 percent. The hemodynamic changes were associated with a significant increase 
      in sodium excretion from 76 to 118 mmol per day (P less than 0.01) but with no 
      change in arterial blood pressure. In another study, 10 additional patients with 
      lupus nephritis were randomly assigned to receive either placebo or 20 mg of 
      aspirin twice daily for four weeks. The aspirin regimen produced a selective, 
      cumulative inhibition of platelet cyclooxygenase activity and a doubling of 
      bleeding time. However, there was no change in the inulin clearance rate and no 
      change in urinary levels of thromboxane B2 or 6-keto-prostaglandin F1 alpha, 
      which are indicators of renal synthesis of thromboxane A2 and prostacyclin, 
      respectively. We conclude that in lupus nephritis, impairment of renal function 
      is at least in part mediated hemodynamically and is reversible with a thromboxane 
      antagonist. Platelets, however, are not a major source of thromboxane A2 
      synthesis and action within the kidney.
FAU - Pierucci, A
AU  - Pierucci A
AD  - Department of Medicine, University of Rome La Sapienza, Italy.
FAU - Simonetti, B M
AU  - Simonetti BM
FAU - Pecci, G
AU  - Pecci G
FAU - Mavrikakis, G
AU  - Mavrikakis G
FAU - Feriozzi, S
AU  - Feriozzi S
FAU - Cinotti, G A
AU  - Cinotti GA
FAU - Patrignani, P
AU  - Patrignani P
FAU - Ciabattoni, G
AU  - Ciabattoni G
FAU - Patrono, C
AU  - Patrono C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Sulfonamides)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 74574CO5A6 (sulotroban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 1989 Aug 3;321(5):330-1. PMID: 2747776
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Kidney/*drug effects/physiopathology
MH  - Lupus Nephritis/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
MH  - Renal Circulation/drug effects
MH  - Sulfonamides/pharmacology/*therapeutic use
MH  - Thromboxane A2/*antagonists & inhibitors
EDAT- 1989/02/16 00:00
MHDA- 1989/02/16 00:01
CRDT- 1989/02/16 00:00
PHST- 1989/02/16 00:00 [pubmed]
PHST- 1989/02/16 00:01 [medline]
PHST- 1989/02/16 00:00 [entrez]
AID - 10.1056/NEJM198902163200703 [doi]
PST - ppublish
SO  - N Engl J Med. 1989 Feb 16;320(7):421-5. doi: 10.1056/NEJM198902163200703.

PMID- 1811279
OWN - NLM
STAT- MEDLINE
DCOM- 19920603
LR  - 20131121
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 74
IP  - 2
DP  - 1991 Nov
TI  - Effects of combination therapy with low-dose aspirin and warfarin on platelet 
      functions after heart valve replacement.
PG  - 153-65
AB  - To evaluate the efficacy and safety of combination therapy with aspirin and 
      warfarin for preventing the development of thromboembolism, we compared the 
      effects of low-dose aspirin (81 mg/day) on platelet functions to those of 
      ticlopidine (300 mg/day) in heart valve replacement patients. Experiments were 
      performed in two groups; the first group within 1 month after operation (the 
      unstable period) and the second group between 3 months and 3 years after 
      operation (the stable period). At the stable period, low-dose aspirin inhibited 
      platelet aggregation induced by ADP, collagen, or arachidonic acid, and 
      suppressed the increase in intracellular Ca2+ concentration [( Ca2+]i) induced by 
      thrombin significantly. On the other hand, ticlopidine inhibited platelet 
      aggregation induced by ADP or collagen, but did not suppress arachidonic 
      acid-induced aggregation and the thrombin-induced [Ca2+]i increase. At the 
      unstable period, the combination therapy of low-dose aspirin plus warfarin did 
      not prolong the bleeding time compared to ticlopidine plus warfarin. And low-dose 
      aspirin inhibited platelet aggregation induced by ADP, collagen or epinephrine, 
      and especially blocked arachidonic acid-induced aggregation. Ticlopidine 
      inhibited ADP-, collagen- or U-46619-induced aggregation, but did not affect on 
      the increase in [Ca2+]i induced by thrombin. From the results in this study, we 
      suggest that the combination therapy with low-dose aspirin (81 mg/day) and 
      warfarin is safe as an antithrombotic medication in heart valve replacement, and 
      results in the inhibition of platelet functions without any side effect calling 
      for special mention at the early unstable period after operation.
FAU - Kobune, K
AU  - Kobune K
AD  - Department of Pharmacology, Tokyo College of Pharmacy, Japan.
FAU - Inoue, M
AU  - Inoue M
FAU - Morikawa, M
AU  - Morikawa M
FAU - Tsuboi, M
AU  - Tsuboi M
FAU - Takanami, Y
AU  - Takanami Y
FAU - Iwane, Y
AU  - Iwane Y
FAU - Kudo, T
AU  - Kudo T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prostaglandin Endoperoxides, Synthetic)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 76898-47-0 (15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid)
RN  - 9007-34-5 (Collagen)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aged
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects/physiology
MH  - Calcium/blood
MH  - Collagen/pharmacology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Count
MH  - Prostaglandin Endoperoxides, Synthetic/pharmacology
MH  - Thromboembolism/*prevention & control
MH  - Ticlopidine/pharmacology
MH  - Warfarin/administration & dosage/pharmacology/*therapeutic use
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1991 Nov;74(2):153-65.

PMID- 34293946
OWN - NLM
STAT- MEDLINE
DCOM- 20220203
LR  - 20220203
IS  - 1530-8022 (Electronic)
IS  - 0885-3282 (Linking)
VI  - 36
IP  - 2
DP  - 2021 Aug
TI  - Synthesis of casein-γ-polyglutamic acid hydrogels by microbial 
      transglutaminase-mediated gelation for controlled release of drugs.
PG  - 237-245
LID - 10.1177/08853282211011724 [doi]
AB  - Casein-based hydrogels were reported as biodegradability, biocompatibility, and 
      non-toxic materials that had potential in drug delivery. At present, we prepared 
      two kinds of casein/γ-PGA hybrid hydrogels, 1/5 and 1/9, based on the ratio of 
      γ-PGA to casein. The hydrogels were crosslinked by microbial transglutaminase 
      (MTG), the physicochemical properties of the casein/γ-PGA hydrogels were 
      investigated by scanning electron microscopy (SEM) observation, differential 
      scanning calorimetry (DSC) analysis, texture analysis, swelling ratio test, and 
      stability test. The hydrogels showed a well-interconnected sparse and porous 
      structure. The 1/5 casein/γ-PGA hydrogel was much stable, hard, and cohesive than 
      the 1/9 casein/γ-PGA hydrogel, and the 1/5 casein/γ-PGA hydrogel showed a higher 
      swelling ratio and lower degradation rate. To investigate in vitro release 
      behavior, we chose the hydrophilic vitamin B12 and hydrophobic aspirin as the 
      model drugs incorporated into the casein/γ-PGA hydrogels. The 1/5 casein/γ-PGA 
      hydrogel exhibited a good drug release behavior.
FAU - Wang, Xin
AU  - Wang X
AD  - College of Bioengineering, Henan University of Technology, Zhengzhou, Henan, 
      China.
FAU - Gou, Chenchen
AU  - Gou C
AD  - College of Bioengineering, Henan University of Technology, Zhengzhou, Henan, 
      China.
FAU - Gao, Chunyuan
AU  - Gao C
AD  - College of Bioengineering, Henan University of Technology, Zhengzhou, Henan, 
      China.
FAU - Song, Yazhen
AU  - Song Y
AD  - College of Bioengineering, Henan University of Technology, Zhengzhou, Henan, 
      China.
FAU - Zhang, Jinming
AU  - Zhang J
AD  - College of Bioengineering, Henan University of Technology, Zhengzhou, Henan, 
      China.
FAU - Huang, Jihong
AU  - Huang J
AD  - College of Bioengineering, Henan University of Technology, Zhengzhou, Henan, 
      China.
FAU - Hui, Ming
AU  - Hui M
AUID- ORCID: 0000-0003-3801-5614
AD  - College of Bioengineering, Henan University of Technology, Zhengzhou, Henan, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Biomater Appl
JT  - Journal of biomaterials applications
JID - 8813912
RN  - 0 (Bacterial Proteins)
RN  - 0 (Caseins)
RN  - 0 (Drug Carriers)
RN  - 0 (Hydrogels)
RN  - 25513-46-6 (Polyglutamic Acid)
RN  - EC 2.3.2.13 (Transglutaminases)
RN  - P6YC3EG204 (Vitamin B 12)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry/*metabolism
MH  - Bacterial Proteins/chemistry/*metabolism
MH  - Caseins/chemistry
MH  - Drug Carriers/chemical synthesis/*chemistry
MH  - Drug Liberation
MH  - Hydrogels/chemical synthesis/*chemistry
MH  - Polyglutamic Acid/chemistry
MH  - Transglutaminases/chemistry/*metabolism
MH  - Vitamin B 12/chemistry/*metabolism
OTO - NOTNLM
OT  - Casein
OT  - characterization
OT  - controlled drug release
OT  - hydrogel
OT  - γ-PGA
EDAT- 2021/07/24 06:00
MHDA- 2022/02/04 06:00
CRDT- 2021/07/23 05:29
PHST- 2021/07/23 05:29 [entrez]
PHST- 2021/07/24 06:00 [pubmed]
PHST- 2022/02/04 06:00 [medline]
AID - 10.1177/08853282211011724 [doi]
PST - ppublish
SO  - J Biomater Appl. 2021 Aug;36(2):237-245. doi: 10.1177/08853282211011724.

PMID- 22779593
OWN - NLM
STAT- MEDLINE
DCOM- 20121105
LR  - 20131121
IS  - 1089-7690 (Electronic)
IS  - 0021-9606 (Linking)
VI  - 136
IP  - 23
DP  - 2012 Jun 21
TI  - Electron attachment to antipyretics: possible implications of their metabolic 
      pathways.
PG  - 234307
LID - 10.1063/1.4727854 [doi]
AB  - The empty-level structures and formation of negative ion states via resonance 
      attachment of low-energy (0-15 eV) electrons into vacant molecular orbitals in a 
      series of non-steroidal anti-inflammatory drugs (NSAIDs), namely aspirin, 
      paracetamol, phenacetin, and ibuprofen, were investigated in vacuo by electron 
      transmission and dissociative electron attachment (DEA) spectroscopies, with the 
      aim to model the behavior of these antipyretic agents under reductive conditions 
      in vivo. The experimental findings are interpreted with the support of density 
      functional theory calculations. The negative and neutral fragments formed by DEA 
      in the gas phase display similarities with the main metabolites of these commonly 
      used NSAIDs generated in vivo by the action of cytochrome P450 enzymes, as well 
      as with several known active agents. It is concluded that xenobiotic molecules 
      which possess pronounced electron-accepting properties could in principle follow 
      metabolic pathways which parallel the gas-phase dissociative decay channels 
      observed in the DEA spectra at incident electron energies below 1 eV. Unwanted 
      side effects as, e.g., hepatoxicity or carcinogenicity produced by the NSAIDs 
      under study in human organism are discussed within the "free radical model" 
      framework, reported earlier to describe the toxic action of the well-known model 
      toxicant carbon tetrachloride.
FAU - Pshenichnyuk, Stanislav A
AU  - Pshenichnyuk SA
AD  - Institute of Molecule and Crystal Physics, Ufa Research Centre, Russian Academy 
      of Sciences, Prospekt Oktyabrya 151, 450075 Ufa, Russia. sapsh@anrb.ru
FAU - Modelli, Alberto
AU  - Modelli A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Chem Phys
JT  - The Journal of chemical physics
JID - 0375360
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antipyretics)
RN  - 0 (Ions)
RN  - 362O9ITL9D (Acetaminophen)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/*chemistry/metabolism
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry/metabolism
MH  - Antipyretics/*chemistry/metabolism
MH  - Aspirin/*chemistry/metabolism
MH  - Electrons
MH  - Humans
MH  - Ibuprofen/*chemistry/metabolism
MH  - Ions/chemistry/metabolism
MH  - Metabolic Networks and Pathways
MH  - Models, Molecular
MH  - Phenacetin/*chemistry/metabolism
MH  - Quantum Theory
EDAT- 2012/07/12 06:00
MHDA- 2012/11/06 06:00
CRDT- 2012/07/12 06:00
PHST- 2012/07/12 06:00 [entrez]
PHST- 2012/07/12 06:00 [pubmed]
PHST- 2012/11/06 06:00 [medline]
AID - 10.1063/1.4727854 [doi]
PST - ppublish
SO  - J Chem Phys. 2012 Jun 21;136(23):234307. doi: 10.1063/1.4727854.

PMID- 21517643
OWN - NLM
STAT- MEDLINE
DCOM- 20110711
LR  - 20131121
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 16
IP  - 10 Suppl
DP  - 2010 Nov
TI  - A pharmacoeconomic perspective on stroke prevention in atrial fibrillation.
PG  - S284-90
AB  - Atrial fibrillation (AF) is predictive of higher costs for stroke care, in part 
      due to the influence of AF on stroke severity. Costs associated with severe 
      strokes, which are more likely in patients with AF, are about twice those of mild 
      strokes. Thus, adequately weighing the costs associated with stroke care is 
      important when making prevention and treatment recommendations for patients 
      diagnosed with AF. Costs associated with AF are estimated at $6.65 billion 
      annually, which breaks down to 44% for hospitalizations, 29% for the incremental 
      inpatient costs of AF as a comorbid diagnosis, 23% for outpatient treatment of 
      AF, and 4% for medications. A diagnosis of AF should be followed by careful 
      consideration of the treatment plan. Clinicians who tend to underuse warfarin 
      should consider whether the patient has valid contraindications to warfarin or if 
      the risk of stroke would be unacceptably high using the alternative--low-dose 
      aspirin. Optimal use of anticoagulation in patients with AF is projected to 
      result in substantial savings in direct costs. Optimization of anticoagulation 
      therapy in only half of the suboptimally anticoagulated patients with AF would 
      save approximately $1.3 billion annually. New and emerging oral alternatives to 
      warfarin promise to combine the advantages of oral dosing and effective 
      anticoagulation with improvements in safety, leading to reduced monitoring and 
      dose adjustment. As these agents become available, treatment decisions will 
      likely incorporate economic considerations, such as the costs of medication, 
      patient monitoring, and treatment of bleeding events.
FAU - Fendrick, A Mark
AU  - Fendrick AM
AD  - University of Michigan, Ann Arbor, MI, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/economics/therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Drug Monitoring/economics
MH  - Fibrinolytic Agents/*economics/*therapeutic use
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Stroke/*economics/etiology/*prevention & control
MH  - Warfarin/economics/therapeutic use
EDAT- 2011/04/29 06:00
MHDA- 2011/07/12 06:00
CRDT- 2011/04/27 06:00
PHST- 2011/04/27 06:00 [entrez]
PHST- 2011/04/29 06:00 [pubmed]
PHST- 2011/07/12 06:00 [medline]
AID - 35791 [pii]
PST - ppublish
SO  - Am J Manag Care. 2010 Nov;16(10 Suppl):S284-90.

PMID- 21458032
OWN - NLM
STAT- MEDLINE
DCOM- 20111103
LR  - 20131121
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 127
IP  - 6
DP  - 2011 Jun
TI  - Combination warfarin-ASA therapy: which patients should receive it, which 
      patients should not, and why?
PG  - 513-7
LID - 10.1016/j.thromres.2011.02.010 [doi]
AB  - Combination warfarin-ASA therapy is currently used in approximately 800,000 
      patients in North America as long-term treatment for the primary and secondary 
      prevention of atherothrombotic and thromboembolic diseases. Despite a potentially 
      complementary action of anticoagulant and antiplatelet drugs, the use of 
      combination warfarin-ASA therapy is not based on compelling evidence of a net 
      therapeutic benefit, with the exception of patients with a mechanical heart 
      valve. On the other hand, there is more compelling and consistent evidence that 
      combination warfarin-ASA therapy confers a 1.5- to 2.0-fold increased risk for 
      serious bleeding compared with use of warfarin alone. In everyday practice, 
      clinicians should combine the best available evidence with clinical judgment, 
      considering that in most clinical scenarios, clinical practice guideline may not 
      provide clear recommendations for patients who should, and should not, receive 
      combination warfarin-ASA therapy. The objectives of this review are to describe 
      which patients are receiving combined warfarin-aspirin therapy, to summarize the 
      evidence for the therapeutic benefit and harm of combined warfarin-ASA therapy, 
      and to suggest practical guidelines as to which patients should, and should not, 
      receive such treatment.
CI  - Copyright © 2011 Elsevier Ltd. All rights reserved.
FAU - Douketis, James D
AU  - Douketis JD
AD  - Department of Medicine, McMaster University and St Joseph's Healthcare, Hamilton, 
      ON, Canada. jdouket@mcmaster.ca
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110331
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Combined Modality Therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Thromboembolism/prevention & control
MH  - Treatment Outcome
MH  - Warfarin/*administration & dosage/adverse effects
EDAT- 2011/04/05 06:00
MHDA- 2011/11/04 06:00
CRDT- 2011/04/05 06:00
PHST- 2011/01/24 00:00 [received]
PHST- 2011/02/14 00:00 [revised]
PHST- 2011/02/15 00:00 [accepted]
PHST- 2011/04/05 06:00 [entrez]
PHST- 2011/04/05 06:00 [pubmed]
PHST- 2011/11/04 06:00 [medline]
AID - S0049-3848(11)00077-6 [pii]
AID - 10.1016/j.thromres.2011.02.010 [doi]
PST - ppublish
SO  - Thromb Res. 2011 Jun;127(6):513-7. doi: 10.1016/j.thromres.2011.02.010. Epub 2011 
      Mar 31.

PMID- 1342900
OWN - NLM
STAT- MEDLINE
DCOM- 19940222
LR  - 20151119
IS  - 1018-9068 (Print)
IS  - 1018-9068 (Linking)
VI  - 2
IP  - 4
DP  - 1992 Jul-Aug
TI  - Urticaria/angioedema-type sensitivity to aspirin and other nonsteroidal 
      anti-inflammatory drugs. Diagnostic value of anamnesis and challenge test with 
      acetylsalicylic acid.
PG  - 191-5
AB  - The aim of this study was to determine the value of challenge tests with 
      acetylsalicylic acid in the diagnosis of ASA-induced urticaria. The study was 
      performed in 71 patients with suspected urticaria/angioedema-type sensitivity to 
      ASA. Anamnesis confirmed sensitivity in 67 patients (94.4%) and showed that 
      sensitive patients usually suffered from extensive urticaria (37 patients, i.e 
      55.5%) after ingestion of ASA. Eight patients (12%) reacted with loss of 
      consciousness and 4 (6.0%) with edema of the larynx. Oral challenge test with 
      acetylsalicylic acid was performed in 53 patients, in 49 (92.4%) of whom it was 
      positive. Threshold doses of acetylsalicylic acid ranged from 40 to 300 mg. In 11 
      patients, the test was repeated and in 8 it was performed 3 times. It was 
      observed that both the threshold acetylsalicylic acid doses and the time of 
      appearance of sensitivity symptoms were variable. All ASA-sensitive patients 
      reacted to indomethacin in a similar manner as to ASA. Paracetamol, on the other 
      hand, was well tolerated by all 25 evaluated patients with 
      urticaria/angioedema-type sensitivity to ASA.
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
AD  - Department of Pneumonology and Allergology, Medical Academy of Lódź, Poland.
FAU - Szmidt, M
AU  - Szmidt M
FAU - Rozniecki, J
AU  - Rozniecki J
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - J Investig Allergol Clin Immunol
JT  - Journal of investigational allergology & clinical immunology
JID - 9107858
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetaminophen/adverse effects
MH  - Adolescent
MH  - Adult
MH  - Angioedema/*diagnosis/etiology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Eruptions/*diagnosis/etiology
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Immunologic Tests
MH  - Indomethacin/adverse effects
MH  - Male
MH  - Middle Aged
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
PST - ppublish
SO  - J Investig Allergol Clin Immunol. 1992 Jul-Aug;2(4):191-5.

PMID- 36796987
OWN - NLM
STAT- MEDLINE
DCOM- 20230222
LR  - 20230701
IS  - 2214-109X (Electronic)
IS  - 2214-109X (Linking)
VI  - 11
IP  - 3
DP  - 2023 Mar
TI  - Cost-effectiveness of low-dose aspirin for the prevention of preterm birth: a 
      prospective study of the Global Network for Women's and Children's Health 
      Research.
PG  - e436-e444
LID - S2214-109X(22)00548-4 [pii]
LID - 10.1016/S2214-109X(22)00548-4 [doi]
AB  - BACKGROUND: Premature birth is associated with an increased risk of mortality and 
      morbidity, and strategies to prevent preterm birth are few in number and resource 
      intensive. In 2020, the ASPIRIN trial showed the efficacy of low-dose aspirin 
      (LDA) in nulliparous, singleton pregnancies for the prevention of preterm birth. 
      We sought to investigate the cost-effectiveness of this therapy in low-income and 
      middle-income countries. METHODS: In this post-hoc, prospective, 
      cost-effectiveness study, we constructed a probabilistic decision tree model to 
      compare the benefits and costs of LDA treatment compared with standard care using 
      primary data and published results from the ASPIRIN trial. In this analysis from 
      a health-care sector perspective, we considered the costs and effects of LDA 
      treatment, pregnancy outcomes, and neonatal health-care use. We did sensitivity 
      analyses to understand the effect of the price of the LDA regimen, and the 
      effectiveness of LDA in reducing both preterm birth and perinatal death. 
      FINDINGS: In model simulations, LDA was associated with 141 averted preterm 
      births, 74 averted perinatal deaths, and 31 averted hospitalisations per 10 000 
      pregnancies. The reduction in hospitalisation resulted in a cost of US$248 per 
      averted preterm birth, $471 per averted perinatal death, and $15·95 per 
      disability-adjusted life year. INTERPRETATION: LDA treatment in nulliparous, 
      singleton pregnancies is a low-cost, effective treatment to reduce preterm birth 
      and perinatal death. The low cost per disability-adjusted life year averted 
      strengthens the evidence in support of prioritising the implementation of LDA in 
      publicly funded health care in low-income and middle-income countries. FUNDING: 
      Eunice Kennedy Shriver National Institute of Child Health and Human Development.
CI  - Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access 
      article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights 
      reserved.
FAU - Patterson, Jackie K
AU  - Patterson JK
AD  - Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel 
      Hill, NC, USA. Electronic address: jackie_patterson@med.unc.edu.
FAU - Neuwahl, Simon
AU  - Neuwahl S
AD  - RTI International, Research Triangle Park, NC, USA.
FAU - Goco, Norman
AU  - Goco N
AD  - RTI International, Research Triangle Park, NC, USA.
FAU - Moore, Janet
AU  - Moore J
AD  - RTI International, Research Triangle Park, NC, USA.
FAU - Goudar, Shivaprasad S
AU  - Goudar SS
AD  - Jawaharlal Nehru Medical College, KLE University, Belagavi, India.
FAU - Derman, Richard J
AU  - Derman RJ
AD  - Department of Obstetrics and Gynecology, Thomas Jefferson University, 
      Philadelphia, PA, USA.
FAU - Hoffman, Matthew
AU  - Hoffman M
AD  - Department of Obstetrics and Gynecology, Christiana Care, Newark, DE, USA.
FAU - Metgud, Mrityunjay
AU  - Metgud M
AD  - Jawaharlal Nehru Medical College, KLE University, Belagavi, India.
FAU - Somannavar, Manjunath
AU  - Somannavar M
AD  - Jawaharlal Nehru Medical College, KLE University, Belagavi, India.
FAU - Kavi, Avinash
AU  - Kavi A
AD  - Jawaharlal Nehru Medical College, KLE University, Belagavi, India.
FAU - Okitawutshu, Jean
AU  - Okitawutshu J
AD  - Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic 
      Republic of the Congo.
FAU - Lokangaka, Adrien
AU  - Lokangaka A
AD  - Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic 
      Republic of the Congo.
FAU - Tshefu, Antoinette
AU  - Tshefu A
AD  - Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic 
      Republic of the Congo.
FAU - Bose, Carl L
AU  - Bose CL
AD  - Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel 
      Hill, NC, USA.
FAU - Mwapule, Abigail
AU  - Mwapule A
AD  - University Teaching Hospital, Lusaka, Zambia.
FAU - Mwenechanya, Musaku
AU  - Mwenechanya M
AD  - University Teaching Hospital, Lusaka, Zambia.
FAU - Chomba, Elwyn
AU  - Chomba E
AD  - University Teaching Hospital, Lusaka, Zambia.
FAU - Carlo, Waldemar A
AU  - Carlo WA
AD  - Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 
      USA.
FAU - Chicuy, Javier
AU  - Chicuy J
AD  - Instituto de Nutrición de Centro América y Panamá, Guatemala City, Guatemala.
FAU - Figueroa, Lester
AU  - Figueroa L
AD  - Instituto de Nutrición de Centro América y Panamá, Guatemala City, Guatemala.
FAU - Krebs, Nancy F
AU  - Krebs NF
AD  - School of Medicine, University of Colorado, Aurora, CO, USA.
FAU - Jessani, Saleem
AU  - Jessani S
AD  - Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan.
FAU - Saleem, Sarah
AU  - Saleem S
AD  - Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan.
FAU - Goldenberg, Robert L
AU  - Goldenberg RL
AD  - Department of Obstetrics and Gynecology, Columbia University, New York, NY, USA.
FAU - Kurhe, Kunal
AU  - Kurhe K
AD  - Lata Medical Research Foundation, Nagpur & Datta Meghe Institute of Medical 
      Sciences, Sawangi, India.
FAU - Das, Prabir
AU  - Das P
AD  - Lata Medical Research Foundation, Nagpur & Datta Meghe Institute of Medical 
      Sciences, Sawangi, India.
FAU - Patel, Archana
AU  - Patel A
AD  - Lata Medical Research Foundation, Nagpur & Datta Meghe Institute of Medical 
      Sciences, Sawangi, India.
FAU - Hibberd, Patricia L
AU  - Hibberd PL
AD  - School of Public Health, Boston University, Boston, MA, USA.
FAU - Achieng, Emmah
AU  - Achieng E
AD  - Department of Child Health and Paediatrics, School of Medicine, Moi University, 
      Eldoret, Kenya.
FAU - Nyongesa, Paul
AU  - Nyongesa P
AD  - Department of Child Health and Paediatrics, School of Medicine, Moi University, 
      Eldoret, Kenya.
FAU - Esamai, Fabian
AU  - Esamai F
AD  - Department of Child Health and Paediatrics, School of Medicine, Moi University, 
      Eldoret, Kenya.
FAU - Bucher, Sherri
AU  - Bucher S
AD  - School of Medicine, Indiana University, Indianapolis, IN, USA.
FAU - Liechty, Edward A
AU  - Liechty EA
AD  - School of Medicine, Indiana University, Indianapolis, IN, USA.
FAU - Bresnahan, Brian W
AU  - Bresnahan BW
AD  - Department of Radiology, University of Washington, Seattle, WA, USA.
FAU - Koso-Thomas, Marion
AU  - Koso-Thomas M
AD  - Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
      National Institutes of Health, Bethesda, MD, USA.
FAU - McClure, Elizabeth M
AU  - McClure EM
AD  - RTI International, Research Triangle Park, NC, USA.
LA  - eng
GR  - UG1 HD076461/HD/NICHD NIH HHS/United States
GR  - U24 HD092094/HD/NICHD NIH HHS/United States
GR  - UG1 HD078439/HD/NICHD NIH HHS/United States
GR  - UG1 HD076465/HD/NICHD NIH HHS/United States
GR  - UG1 HD078437/HD/NICHD NIH HHS/United States
GR  - UG1 HD078438/HD/NICHD NIH HHS/United States
GR  - UG1 HD076457/HD/NICHD NIH HHS/United States
GR  - UG1 HD076474/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Lancet Glob Health
JT  - The Lancet. Global health
JID - 101613665
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet Glob Health. 2023 Mar;11(3):e314-e315. PMID: 36796969
MH  - Pregnancy
MH  - Female
MH  - Child
MH  - Infant, Newborn
MH  - Humans
MH  - *Premature Birth/prevention & control
MH  - Prospective Studies
MH  - Child Health
MH  - *Perinatal Death
MH  - Cost-Benefit Analysis
MH  - Women's Health
MH  - Aspirin/therapeutic use
PMC - PMC10288322
MID - NIHMS1883714
COIS- Declaration of interests We declare no competing interests.
EDAT- 2023/02/17 06:00
MHDA- 2023/02/22 06:00
CRDT- 2023/02/16 20:59
PHST- 2022/02/25 00:00 [received]
PHST- 2022/10/28 00:00 [revised]
PHST- 2022/12/15 00:00 [accepted]
PHST- 2023/02/16 20:59 [entrez]
PHST- 2023/02/17 06:00 [pubmed]
PHST- 2023/02/22 06:00 [medline]
AID - S2214-109X(22)00548-4 [pii]
AID - 10.1016/S2214-109X(22)00548-4 [doi]
PST - ppublish
SO  - Lancet Glob Health. 2023 Mar;11(3):e436-e444. doi: 10.1016/S2214-109X(22)00548-4.

PMID- 34581662
OWN - NLM
STAT- MEDLINE
DCOM- 20220329
LR  - 20220427
IS  - 1743-1328 (Electronic)
IS  - 0161-6412 (Linking)
VI  - 44
IP  - 4
DP  - 2022 Apr
TI  - Platelet Function Tests Predicting the Efficacy and Safety of Aspirin Secondary 
      Prevention.
PG  - 291-298
LID - 10.1080/01616412.2021.1981103 [doi]
AB  - OBJECTIVE: To precisely prevent stroke, we evaluated three platelet function 
      tests and their associations with clinical outcomes in ischemic stroke patients. 
      METHODS: On-treatment platelet reactivity of acute minor stroke patients taking 
      aspirin plus clopidogrel was tested by light transmittance aggregometry (LTA), 
      thromboelastography (TEG) and platelet function analyzer (PFA). Mann-Whitney U 
      tests and receiver operating characteristic (ROC) curve analysis were used to 
      assess their associations with recurrent events and clinical outcome prediction. 
      RESULTS: 127 acute minor stroke patients were stringently selected and followed 
      for 13 months. Eight patients (6.3%) self-reported the recurrence and 13 (10.2%) 
      patients self-reported bleeding. Recurrent patients displayed significantly 
      higher on-treatment platelet reactivity when measured with LTA (p = 0.030) and 
      PFA (p < 0.001). Further ROC analysis demonstrated that LTA and PFA had 
      modest-to-fair ability to predict stroke recurrence (LTA: area under the curve 
      [AUC], 0.765; 95% CI, 0.584-0.945, PFA: AUC, 0.832; 95% CI, 0.658-1.000). 
      However, TEG (measured by the platelet inhibition rate) could not detect the 
      difference between recurrent patients and non-recurrent patients (p = 0.515) and 
      predict recurrent events (AUC, 0.569; 95% CI, 0.368-0.770). None of the tests 
      were associated with bleeding except for PFA (p < 0.001), with AUC of PFA 
      reaching 0.772 (0.726-0.818). CONCLUSIONS: Of the three tests assessed, the 
      predictive accuracies of PFA and LTA were satisfying for aspirin secondary 
      prevention, while TEG's performance was poor. Only PFA could provide accurate 
      prognostic information for bleeding.
FAU - Cheng, Yue
AU  - Cheng Y
AD  - Department of Neurology, Affiliated Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, Jiangsu, China.
AD  - Nanjing Neurology Clinic Medical Center, Nanjing, China.
AD  - Institute of Brain Science, Nanjing University, Nanjing, China.
FAU - Shao, Tengfei
AU  - Shao T
AD  - Department of Pharmacy, Affiliated Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, Jiangsu, China.
AD  - Nanjing Medical Center for Clinical Pharmacy, Nanjing, China.
FAU - Huang, Lili
AU  - Huang L
AD  - Department of Neurology, Affiliated Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, Jiangsu, China.
AD  - Nanjing Neurology Clinic Medical Center, Nanjing, China.
AD  - Institute of Brain Science, Nanjing University, Nanjing, China.
FAU - Xu, Hengheng
AU  - Xu H
AD  - Department of Neurology, Affiliated Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, Jiangsu, China.
AD  - Nanjing Neurology Clinic Medical Center, Nanjing, China.
AD  - Institute of Brain Science, Nanjing University, Nanjing, China.
FAU - Shao, Pengfei
AU  - Shao P
AD  - Department of Neurology, Affiliated Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, Jiangsu, China.
AD  - Nanjing Neurology Clinic Medical Center, Nanjing, China.
AD  - Institute of Brain Science, Nanjing University, Nanjing, China.
FAU - Yang, Dan
AU  - Yang D
AD  - Department of Neurology, Affiliated Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, Jiangsu, China.
AD  - Nanjing Neurology Clinic Medical Center, Nanjing, China.
AD  - Institute of Brain Science, Nanjing University, Nanjing, China.
FAU - Ge, Weihong
AU  - Ge W
AD  - Department of Pharmacy, Affiliated Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, Jiangsu, China.
AD  - Nanjing Medical Center for Clinical Pharmacy, Nanjing, China.
FAU - Xu, Yun
AU  - Xu Y
AD  - Department of Neurology, Affiliated Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, Jiangsu, China.
AD  - Nanjing Neurology Clinic Medical Center, Nanjing, China.
AD  - Institute of Brain Science, Nanjing University, Nanjing, China.
FAU - Zhang, Meijuan
AU  - Zhang M
AD  - Department of Neurology, Affiliated Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, Jiangsu, China.
AD  - Nanjing Neurology Clinic Medical Center, Nanjing, China.
AD  - Institute of Brain Science, Nanjing University, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20210928
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cerebral Hemorrhage/*chemically induced
MH  - Clopidogrel/pharmacology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Stroke/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacology
MH  - Platelet Function Tests
MH  - *Secondary Prevention
OTO - NOTNLM
OT  - Platelet function tests
OT  - ischemic stroke
OT  - secondary prevention
EDAT- 2021/09/29 06:00
MHDA- 2022/03/30 06:00
CRDT- 2021/09/28 12:14
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2022/03/30 06:00 [medline]
PHST- 2021/09/28 12:14 [entrez]
AID - 10.1080/01616412.2021.1981103 [doi]
PST - ppublish
SO  - Neurol Res. 2022 Apr;44(4):291-298. doi: 10.1080/01616412.2021.1981103. Epub 2021 
      Sep 28.

PMID- 29092979
OWN - NLM
STAT- MEDLINE
DCOM- 20171120
LR  - 20220414
IS  - 2049-4408 (Electronic)
IS  - 2049-4394 (Print)
IS  - 2049-4394 (Linking)
VI  - 99-B
IP  - 11
DP  - 2017 Nov
TI  - Aspirin and the prevention of venous thromboembolism following total joint 
      arthroplasty: commonly asked questions.
PG  - 1420-1430
LID - 10.1302/0301-620X.99B11.BJJ-2017-0337.R2 [doi]
AB  - The number of arthroplasties being performed increases each year. Patients 
      undergoing an arthroplasty are at risk of venous thromboembolism (VTE) and 
      appropriate prophylaxis has been recommended. However, the optimal protocol and 
      the best agent to minimise VTE under these circumstances are not known. Although 
      many agents may be used, there is a difference in their efficacy and the risk of 
      bleeding. Thus, the selection of a particular agent relies on the balance between 
      the desire to minimise VTE and the attempt to reduce the risk of bleeding, with 
      its undesirable, and occasionally fatal, consequences. Acetylsalicylic acid 
      (aspirin) is an agent for VTE prophylaxis following arthroplasty. Many studies 
      have shown its efficacy in minimising VTE under these circumstances. It is 
      inexpensive and well-tolerated, and its use does not require routine blood tests. 
      It is also a 'milder' agent and unlikely to result in haematoma formation, which 
      may increase both the risk of infection and the need for further surgery. Aspirin 
      is also unlikely to result in persistent wound drainage, which has been shown to 
      be associated with the use of agents such as low-molecular-weight heparin (LMWH) 
      and other more aggressive agents. The main objective of this review was to 
      summarise the current evidence relating to the efficacy of aspirin as a VTE 
      prophylaxis following arthroplasty, and to address some of the common questions 
      about its use. There is convincing evidence that, taking all factors into 
      account, aspirin is an effective, inexpensive, and safe form of VTE following 
      arthroplasty in patients without a major risk factor for VTE, such as previous 
      VTE. Cite this article: Bone Joint J 2017;99-B:1420-30.
CI  - ©2017 Azboy et al.
FAU - Azboy, I
AU  - Azboy I
AD  - Rothman Institute at Thomas Jefferson University Hospital, Sheridan Building, 
      Suite 1000, 125 South 9th Street, Philadelphia, PA 19107, USA.
FAU - Barrack, R
AU  - Barrack R
AD  - Washington University Orthopedics, Barnes Jewish Hospital, 660 South Euclid 
      Avenue, Campus Box 8233, St. Louis, Missouri 63110, USA.
FAU - Thomas, A M
AU  - Thomas AM
AD  - The Royal Orthopaedic Hospital, Bristol Road South, Birmingham B31 2AP, UK.
FAU - Haddad, F S
AU  - Haddad FS
AD  - University College London Hospitals, 235 Euston Road, London NW1 2BU, UK and NIHR 
      University College London Hospitals Biomedical Research Centre, UK.
FAU - Parvizi, J
AU  - Parvizi J
AD  - Rothman Institute at Thomas Jefferson University Hospital, Sheridan Building, 
      Suite 1000, 125 South 9th Street, Philadelphia, PA 19107, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Bone Joint J
JT  - The bone & joint journal
JID - 101599229
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - *Arthroplasty, Replacement
MH  - Aspirin/*therapeutic use
MH  - Drug Administration Schedule
MH  - Humans
MH  - Postoperative Complications/*prevention & control
MH  - Practice Guidelines as Topic
MH  - Treatment Outcome
MH  - Venous Thromboembolism/etiology/*prevention & control
PMC - PMC5742873
OTO - NOTNLM
OT  - Arthroplasty
OT  - Aspirin
OT  - Deep venous thrombosis
OT  - Hip arthroplasty
OT  - Knee arthroplasty
OT  - Low molecular heparin
OT  - Prophylaxis
OT  - Pulmonary embolism
OT  - Venous thromboembolism
EDAT- 2017/11/03 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/03 06:00
PHST- 2017/03/16 00:00 [received]
PHST- 2017/07/19 00:00 [accepted]
PHST- 2017/11/03 06:00 [entrez]
PHST- 2017/11/03 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 99-B/11/1420 [pii]
AID - BJJ-2017-0337.R2 [pii]
AID - 10.1302/0301-620X.99B11.BJJ-2017-0337.R2 [doi]
PST - ppublish
SO  - Bone Joint J. 2017 Nov;99-B(11):1420-1430. doi: 
      10.1302/0301-620X.99B11.BJJ-2017-0337.R2.

PMID- 9536767
OWN - NLM
STAT- MEDLINE
DCOM- 19980416
LR  - 20131121
IS  - 0954-7762 (Print)
IS  - 0954-7762 (Linking)
VI  - 94
IP  - 5
DP  - 1998 Feb 4-10
TI  - Oral analgesics: aspirin and paracetamol.
PG  - 59-61
AB  - This article is the third in a series of six looking at the knowledge needed for 
      nurses prescribing. The mode of action, use and side-effects of oral analgesics 
      are considered and drug interactions are also described.
FAU - Courtenay, M
AU  - Courtenay M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Nurs Times
JT  - Nursing times
JID - 0423236
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
MH  - Acetaminophen/*therapeutic use
MH  - Analgesics, Non-Narcotic/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Interactions
MH  - Humans
MH  - *Nursing Assessment
MH  - Pain Measurement
MH  - *Patient Selection
RF  - 4
EDAT- 1998/04/16 00:00
MHDA- 1998/04/16 00:01
CRDT- 1998/04/16 00:00
PHST- 1998/04/16 00:00 [pubmed]
PHST- 1998/04/16 00:01 [medline]
PHST- 1998/04/16 00:00 [entrez]
PST - ppublish
SO  - Nurs Times. 1998 Feb 4-10;94(5):59-61.

PMID- 36444593
OWN - NLM
STAT- MEDLINE
DCOM- 20221130
LR  - 20230217
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Print)
IS  - 1513-7368 (Linking)
VI  - 23
IP  - 11
DP  - 2022 Nov 1
TI  - Aspirin Restores Radiosensitivity in Cervical Cancer Cells by Inducing Mitotic 
      Catastrophe through Downregulating G2/M Effectors.
PG  - 3801-3813
LID - 90372 [pii]
LID - 10.31557/APJCP.2022.23.11.3801 [doi]
AB  - BACKGROUND/AIM: Compromised cell-cycle checkpoint is a major obstacle for 
      rendering radiotherapeutic success of radioresistant cells. Aspirin (ASA), an 
      anti-inflammatory agent was repurposed previously for improving radiotherapy by 
      limiting radiation toxicity. However, the underlying mechanism was unclear. The 
      present study aimed to identify the mechanism of ASA mediated reversal of 
      radioresistance in cervical cancer cells. METHODS: Radioresistant subline SiHa/RR 
      was developed from parental cervical squamous carcinoma cell line SiHa by chronic 
      fractionated irradiation (IR). The radioresistance property of SiHa/RR was 
      confirmed by clonogenic assay. Alteration in cell-cycle by ASA was determined by 
      flow cytometry. ASA induced nuclear damage as consequence of mitotic catastrophe 
      was confirmed by microscopic observation. The interaction between ASA and G2/M 
      regulators was explored through in silico docking analysis and expressional 
      change of them was affirmed by western blotting. Immunofluorescence study to 
      examine Aurora Kinase A localization in presence and absence of ASA treatment was 
      conducted. Finally the radiosensitizing ability of ASA was verified by apoptotic 
      parameters (flow cytometrically and by western blotting). RESULT: Higher colony 
      forming ability of SiHa/RR compared to SiHa became restrained upon ASA (5μM) 
      treatment prior to IR. Flow cytometric analysis of ASA treated cells showed 
      increased G2/M population followed by enlargement of cells displaying giant 
      multinucleated morphology; typical characteristics of mitotic catastrophe. 
      Underlying noteworthy mechanisms involved decreased expressions of G2/M 
      regulatory proteins (Cyclin B1, CDK1, Aurora A Kinase, pAurora A Kinase) in 
      IR/ASA along with inhibiting nuclear localization of Aurora Kinase A in SiHa/RR. 
      Docking results also supported the findings. Prolonged treatment (12 h) with ASA 
      led to apoptosis by altering expressions of Bcl2, Bax and Cytochrome C; which was 
      achieved through the event of mitotic catastrophe. CONCLUSION: This work 
      established that G2/M arrest and mitotic catastrophe can be considered as the 
      principle mechanism of restoration of radiosensitivity in SiHa/RR by ASA 
      pretreatment.
FAU - Das, Salini
AU  - Das S
AD  - Department of Environmental Carcinogenesis & Toxicology, Chittaranjan National 
      Cancer Institute, Kolkata, India.
FAU - Ray, Dilip Kumar
AU  - Ray DK
AD  - Department of Medical Physics, Chittaranjan National Cancer Institute, Kolkata, 
      India.
FAU - Sengupta, Debomita
AU  - Sengupta D
AD  - Department of Environmental Carcinogenesis & Toxicology, Chittaranjan National 
      Cancer Institute, Kolkata, India.
FAU - Mahapatra, Elizabeth
AU  - Mahapatra E
AD  - Department of Environmental Carcinogenesis & Toxicology, Chittaranjan National 
      Cancer Institute, Kolkata, India.
FAU - Biswas, Souvick
AU  - Biswas S
AD  - Department of Environmental Carcinogenesis & Toxicology, Chittaranjan National 
      Cancer Institute, Kolkata, India.
FAU - Roy, Madhumita
AU  - Roy M
AD  - Department of Environmental Carcinogenesis & Toxicology, Chittaranjan National 
      Cancer Institute, Kolkata, India.
FAU - Mukherjee, Sutapa
AU  - Mukherjee S
AUID- ORCID: 0000-0002-4411-7257
AD  - Department of Environmental Carcinogenesis & Toxicology, Chittaranjan National 
      Cancer Institute, Kolkata, India.
LA  - eng
PT  - Journal Article
DEP - 20221101
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - EC 2.7.11.1 (Aurora Kinase A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Uterine Cervical Neoplasms/drug therapy
MH  - Aurora Kinase A
MH  - Aspirin/pharmacology
MH  - Apoptosis
MH  - Cell Line, Tumor
MH  - G2 Phase Cell Cycle Checkpoints
MH  - Radiation Tolerance
PMC - PMC9930979
OTO - NOTNLM
OT  - Aurora Kinase A
OT  - Cervical cancer
OT  - Mitotic catastrophe
OT  - Radioresistance
OT  - aspirin
COIS- The authors declare that they have no conflicts of interests.
EDAT- 2022/11/30 06:00
MHDA- 2022/12/01 06:00
CRDT- 2022/11/29 03:36
PHST- 2022/06/06 00:00 [received]
PHST- 2022/11/29 03:36 [entrez]
PHST- 2022/11/30 06:00 [pubmed]
PHST- 2022/12/01 06:00 [medline]
AID - 90372 [pii]
AID - 10.31557/APJCP.2022.23.11.3801 [doi]
PST - epublish
SO  - Asian Pac J Cancer Prev. 2022 Nov 1;23(11):3801-3813. doi: 
      10.31557/APJCP.2022.23.11.3801.

PMID- 10493216
OWN - NLM
STAT- MEDLINE
DCOM- 19991108
LR  - 20190915
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 10
IP  - 6
DP  - 1999 Sep
TI  - Intravenous acetylsalicylic acid, magnesium and their combination in experimental 
      arterial thrombosis in rats.
PG  - 351-7
AB  - Intravenous acetylsalicylic acid (ASA) and magnesium (Mg) both possess 
      antiplatelet properties and are thus potential inhibitors of the formation of 
      arterial thrombi. Their effect on the dynamic aspects of arterial thrombus 
      formation was investigated following intravenous administration of both 
      substances alone and in combination. A blinded, placebo-controlled, in-vivo study 
      was performed in 71 rats. Thrombus formation was induced by a standardized 
      arteriotomy in the right femoral artery with inversion of the vessel wall during 
      subsequent closure. Thrombus formation was recorded on video tapes and analysed 
      off-line for 30 min. Animals were randomly assigned to one of four groups: 20 mg 
      bolus of ASA followed by 0.3 mmol/h Mg (ASA/Mg group); NaCl followed by 0.3 
      mmol/h Mg (Mg group); 20 mg bolus of ASA followed by NaCl (ASA group); or NaCl 
      throughout the experiment (control group). In the ASA-treated groups, serum 
      levels of thromboxane B2 were reduced significantly, and the Mg-treated groups 
      reached a serum level of Mg just above 2.0 mmol/l. No significant differences 
      were observed in initial or maximum thrombus area or in mean thrombus area during 
      the study period. In the ASA/Mg group, a trend towards reduced thrombus formation 
      was observed (P = 0.06). In the same group, seven of 22 animals developed an 
      occlusive thrombus (P < 0.01), an unexpected adverse event possibly related to 
      the combined administration of ASA and Mg.
FAU - Fuglsang, J
AU  - Fuglsang J
AD  - Institute of Experimental Clinical Research, Skejby Sygehus, Aarhus University 
      Hospital, Denmark.
FAU - Ravn, H B
AU  - Ravn HB
FAU - Toft, G E
AU  - Toft GE
FAU - Thorwest, M
AU  - Thorwest M
FAU - Husted, S E
AU  - Husted SE
FAU - Hjortdal, V E
AU  - Hjortdal VE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 54397-85-2 (Thromboxane B2)
RN  - I38ZP9992A (Magnesium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteriosclerosis/therapy
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Double-Blind Method
MH  - Hemorrhage
MH  - Magnesium/blood/*pharmacology/*therapeutic use
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Single-Blind Method
MH  - Thrombosis/pathology/*therapy
MH  - Thromboxane B2/blood
EDAT- 1999/09/24 00:00
MHDA- 1999/09/24 00:01
CRDT- 1999/09/24 00:00
PHST- 1999/09/24 00:00 [pubmed]
PHST- 1999/09/24 00:01 [medline]
PHST- 1999/09/24 00:00 [entrez]
AID - 10.1097/00001721-199909000-00005 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 1999 Sep;10(6):351-7. doi: 
      10.1097/00001721-199909000-00005.

PMID- 1731928
OWN - NLM
STAT- MEDLINE
DCOM- 19920225
LR  - 20190613
IS  - 0006-2960 (Print)
IS  - 0006-2960 (Linking)
VI  - 31
IP  - 3
DP  - 1992 Jan 28
TI  - Isolation and characterization of the triply oxidized derivative of a 
      cross-linked hemoglobin.
PG  - 717-25
AB  - Hemoglobin A, cross-linked between Lys 99 alpha 1 and Lys 99 alpha 2, was used to 
      obtain a partially oxidized tetramer in which only one of the four hemes remains 
      reduced. Because of the absence of dimerization, asymmetric, partially oxidized 
      derivatives are stable. This is evidenced by the fact that eight of the ten 
      possible oxidation states could be resolved by analytical isoelectric focusing. A 
      triply oxidized hemoglobin population HbXL+3 was isolated whose predominant 
      component was (alpha + alpha +, beta + beta 0). This triferric preparation was 
      examined as a possible model for the triliganded state of ferrous HbA. The 
      aquomet and cyanomet derivatives were characterized by their CD spectra and their 
      kinetic reactions with carbon monoxide. CD spectra in the region of 287 nm showed 
      no apparent change in quaternary structure upon binding ligand to the fourth, 
      ferrous heme. The spectra of the oxy and deoxy forms of the cyanomet and aquomet 
      derivatives of HbXL+3 differed insignificantly and were characteristic of the 
      normal liganded state. Upon addition of inositol hexaphosphate (IHP), both the 
      oxy and deoxy derivatives of the high-spin triaquomet species converted to the 
      native deoxy conformation. In contrast, IHP had no such effect on the 
      conformation of the low-spin cyanomet derivatives of HbXL+3. The kinetics of CO 
      combination as measured by stopped-flow and flash photolysis techniques present a 
      more complex picture. In the presence of IHP the triaquomet derivative does bind 
      CO with rate constants indicative of the T state whether these are measured by 
      the stopped-flow technique or by flash photolysis.(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Fowler, S A
AU  - Fowler SA
AD  - Department of Biochemistry, University of Iowa, Iowa City, 52242.
FAU - Walder, J
AU  - Walder J
FAU - DeYoung, A
AU  - DeYoung A
FAU - Kwiatkowski, L D
AU  - Kwiatkowski LD
FAU - Noble, R W
AU  - Noble RW
LA  - eng
GR  - P01 HL40453/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Cyanides)
RN  - 0 (Macromolecular Substances)
RN  - 0 (Oxyhemoglobins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 142M471B3J (Carbon Dioxide)
RN  - 7IGF0S7R8I (Phytic Acid)
RN  - 9034-51-9 (Hemoglobin A)
RN  - 9062-91-3 (oxyhemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Carbon Dioxide/blood
MH  - Cross-Linking Reagents/pharmacology
MH  - Cyanides/blood
MH  - Hemoglobin A/*metabolism
MH  - Humans
MH  - Isoelectric Focusing
MH  - Kinetics
MH  - Macromolecular Substances
MH  - Oxyhemoglobins/metabolism
MH  - Phytic Acid/blood
EDAT- 1992/01/28 00:00
MHDA- 1992/01/28 00:01
CRDT- 1992/01/28 00:00
PHST- 1992/01/28 00:00 [pubmed]
PHST- 1992/01/28 00:01 [medline]
PHST- 1992/01/28 00:00 [entrez]
AID - 10.1021/bi00118a012 [doi]
PST - ppublish
SO  - Biochemistry. 1992 Jan 28;31(3):717-25. doi: 10.1021/bi00118a012.

PMID- 10609931
OWN - NLM
STAT- MEDLINE
DCOM- 20000128
LR  - 20190910
IS  - 1069-6563 (Print)
IS  - 1069-6563 (Linking)
VI  - 6
IP  - 12
DP  - 1999 Dec
TI  - A proposed consent process in studies that use an exception to informed consent.
PG  - 1283-91
AB  - Federal regulations allow an exception to informed consent when it is not 
      feasible to obtain informed consent in certain emergency research circumstances. 
      A multicenter, randomized, single-blinded, normal saline procedure-controlled 
      efficacy trial of diaspirin cross-linked hemoglobin (DCLHb) in acute traumatic 
      hemorrhagic shock was conducted. The study intended to include 850 of the most 
      severely injured trauma patients with hemorrhage and persistent hypoperfusion as 
      demonstrated by vital signs suggestive of vascular collapse or a base deficit 
      that signified prolonged hypoperfusion. It was anticipated that some patients 
      would be unable to provide informed consent, and that identification and 
      availability of some patients' legally authorized representatives (LARs) would be 
      unlikely within the therapeutic window of the intervention. Each participating 
      institution therefore developed a process to implement exception to informed 
      consent. Each hospital's proposed process was reviewed by the institutional 
      review board, the sponsor, the FDA, and the study's data monitoring committee 
      chair. The goal was the development of local implementation processes by which 
      the best interests of patients and their families could be fulfilled using 
      prospective informed consent, the exception to informed consent, and consent to 
      continue in emergency research, as appropriate for each individual patient. This 
      paper describes the proposed implementation method developed for Cook County 
      Hospital. It includes several important features, 1) prospective informed consent 
      by the patient, when feasible; 2) the ability of the patient to decline 
      participation, even when deemed incompetent to provide prospective informed 
      consent; 3) prospective consent by the family/LAR, when feasible; 4) the use of a 
      scripted abbreviated consent by the patient family/ LAR in life-threatening 
      situations when it is possible only to briefly discuss the research being 
      conducted; 5) independent approval for the use of the consent exception by a 
      second physician immediately prior to patient enrollment; 6) the repeated use of 
      consent to continue (both for the family/LAR and by the patient) when an 
      exception to consent has been utilized; and 7) ongoing review of the informed 
      consent process on a case-by-case basis by the institution's scientific review 
      committee. The authors believe this proposed informed consent process maximizes 
      the communication between investigators, patients and their proxies, and the 
      institution's scientific review committee. Multiple mechanisms exist that allow 
      for consent to be provided or declined, both prior to and after enrollment in the 
      research protocol. The ongoing immediate review of the process allows for process 
      enhancements to be made as needed.
FAU - Sloan, E P
AU  - Sloan EP
AD  - Department of Emergency Medicine, University of Illinois at Chicago, 60612, USA. 
      edsloan@uic.edu
FAU - Nagy, K
AU  - Nagy K
FAU - Barrett, J
AU  - Barrett J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Acad Emerg Med
JT  - Academic emergency medicine : official journal of the Society for Academic 
      Emergency Medicine
JID - 9418450
RN  - 578-19-8 (succinyldisalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Emergency Treatment/*standards
MH  - *Guidelines as Topic
MH  - Humans
MH  - *Informed Consent
MH  - Injury Severity Score
MH  - Mental Competency
MH  - Patient Selection
MH  - Presumed Consent
MH  - Randomized Controlled Trials as Topic/*standards
MH  - Sensitivity and Specificity
MH  - Shock, Hemorrhagic/*drug therapy
MH  - Trauma Centers/*standards
MH  - United States
RF  - 6
EDAT- 1999/12/28 00:00
MHDA- 1999/12/28 00:01
CRDT- 1999/12/28 00:00
PHST- 1999/12/28 00:00 [pubmed]
PHST- 1999/12/28 00:01 [medline]
PHST- 1999/12/28 00:00 [entrez]
AID - 10.1111/j.1553-2712.1999.tb00145.x [doi]
PST - ppublish
SO  - Acad Emerg Med. 1999 Dec;6(12):1283-91. doi: 10.1111/j.1553-2712.1999.tb00145.x.

PMID- 2856598
OWN - NLM
STAT- MEDLINE
DCOM- 19930209
LR  - 20161123
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 10
IP  - 5
DP  - 1988
TI  - Iontophoretic administration of pirprofen or lysine soluble aspirin in the 
      treatment of rheumatic diseases.
PG  - 553-8
AB  - A double-blind study was designed to compare the efficacy and tolerability of 
      pirprofen and lysine soluble aspirin administered by iontophoresis to 80 patients 
      with various painful rheumatic diseases. Treatment lasted two weeks, with five 
      administrations a week, each lasting 20 minutes (direct current; mean intensity, 
      2.3 mA). After five administrations, patients showed significant improvement in 
      pain at rest and on movement, with no significant differences between pirprofen 
      and aspirin. Final results were excellent or good in about 75% of the patients 
      treated and functional improvement was satisfactory in about 80%. There were no 
      side effects.
FAU - Garagiola, U
AU  - Garagiola U
AD  - Ciba-Geigy S.p.A., Medical Department, Origgio (VA), Italy.
FAU - Dacatra, U
AU  - Dacatra U
FAU - Braconaro, F
AU  - Braconaro F
FAU - Porretti, E
AU  - Porretti E
FAU - Pisetti, A
AU  - Pisetti A
FAU - Azzolini, V
AU  - Azzolini V
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Phenylpropionates)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - T7KN291890 (pirprofen)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects/*analogs & derivatives
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Iontophoresis
MH  - Lysine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Movement
MH  - Pain/*drug therapy/etiology
MH  - Phenylpropionates/*administration & dosage/adverse effects
MH  - Rheumatic Diseases/complications/*drug therapy
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1988;10(5):553-8.

PMID- 20569957
OWN - NLM
STAT- MEDLINE
DCOM- 20100928
LR  - 20131121
IS  - 1878-7487 (Electronic)
IS  - 1752-928X (Linking)
VI  - 17
IP  - 5
DP  - 2010 Jul
TI  - Two cases of oral aspirin overdose.
PG  - 280-2
LID - 10.1016/j.jflm.2010.03.001 [doi]
AB  - A 30-year-old woman and a 27-year-old man were found in a parked car after the 
      man had telephoned his father to tell him of their suicide attempt. In spite of 
      emergent hospitalization and intensive care, the woman died. Due to the 
      possibility of his assisting her suicide, medicolegal autopsy and toxicological 
      analysis were performed. On forensic autopsy, no external injuries or 
      pathological findings were detected. The man recovered after 5 days of 
      hospitalization. In spite of a negative toxicological screening test, the police 
      investigation revealed that they may have taken 120 tablets (330 mg/tablet; 
      39,600 mg total dose) of aspirin (acetylsalicylic acid) orally; therefore, we 
      analyzed the concentrations of acetylsalicylic acid and two kinds of metabolite 
      in specimens obtained at autopsy and on emergent hospitalization using high 
      performance liquid chromatography. Acetylsalicylic acid and/or the two 
      metabolites were found in the woman's specimens. These substances were also 
      present in the man's specimens. It is still unclear why the man survived in spite 
      of what appeared to be a fatal aspirin overdose. It was very straightforward to 
      diagnose aspirin poisoning in these cases; however, we have to be aware of 
      poisoning by drugs which are not included in simple drug screening examinations.
CI  - Copyright 2010 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All 
      rights reserved.
FAU - Kato, Hideaki
AU  - Kato H
AD  - Department of Forensic Medicine, Graduate School of Medical Science, Kyoto 
      Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, 
      Kamigyo-ku, Kyoto 602-8566, Japan. hoi@koto.kpu-m.ac.jp
FAU - Yoshimoto, Kanji
AU  - Yoshimoto K
FAU - Ikegaya, Hiroshi
AU  - Ikegaya H
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20100414
PL  - England
TA  - J Forensic Leg Med
JT  - Journal of forensic and legal medicine
JID - 101300022
RN  - 0 (Hypnotics and Sedatives)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 8GTS82S83M (Diphenhydramine)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*poisoning
MH  - Chromatography, High Pressure Liquid
MH  - Diphenhydramine/administration & dosage/adverse effects
MH  - Drug Overdose
MH  - Female
MH  - Forensic Pathology
MH  - Forensic Toxicology
MH  - Gastrointestinal Contents/chemistry
MH  - Humans
MH  - Hypnotics and Sedatives/administration & dosage/adverse effects
MH  - Japan
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*poisoning
MH  - Salicylic Acid/analysis
MH  - *Suicide
EDAT- 2010/06/24 06:00
MHDA- 2010/09/30 06:00
CRDT- 2010/06/24 06:00
PHST- 2009/01/08 00:00 [received]
PHST- 2009/04/08 00:00 [revised]
PHST- 2010/03/05 00:00 [accepted]
PHST- 2010/06/24 06:00 [entrez]
PHST- 2010/06/24 06:00 [pubmed]
PHST- 2010/09/30 06:00 [medline]
AID - S1752-928X(10)00047-8 [pii]
AID - 10.1016/j.jflm.2010.03.001 [doi]
PST - ppublish
SO  - J Forensic Leg Med. 2010 Jul;17(5):280-2. doi: 10.1016/j.jflm.2010.03.001. Epub 
      2010 Apr 14.

PMID- 10846615
OWN - NLM
STAT- MEDLINE
DCOM- 20001019
LR  - 20131121
IS  - 0098-6127 (Print)
IS  - 0098-6127 (Linking)
VI  - 23
IP  - 1
DP  - 1998
TI  - Effect of aspirin on the contractility of aortic smooth muscle and the course of 
      blood pressure development in male spontaneously hypertensive rats.
PG  - 37-55
AB  - The effects of acetylsalicylic acid (ASA) on aortic smooth muscle contractility 
      were studied in aortic rings of male SHR and WKY rats. The rats were administered 
      two intraperitoneal injections of 10 mg/kg of ASA per week for ten weeks. Blood 
      pressure of each rat was monitored twice weekly prior to the i.p. injections. 
      Twenty four hours after the last injection the aortic smooth muscles were 
      evaluated for generation of active tension in response to KCl, Phenylephrine 
      (PE), Clonidine and Norepinephrine (NE). In another set of experiments calcium 
      conductance was evaluated in the presence or absence of endothelium both in ASA 
      treated and non treated animals. We report that aortic rings from ASA-treated SHR 
      animals were more responsive to contractile agents than rings from non-treated 
      SHR male rats. Also, the Ca2+ conductance in vitro was enhanced appreciably in 
      SHR aortic rings denuded of their monolayer of endothelium in response to ASA 
      treatment. No decrease in systolic blood pressure was observed in response to ASA 
      treatment in SHR male rats. These results suggest that acetylsalicylic acid not 
      only may modulate aortic smooth muscle contractility through the metabolites of 
      arachidonic acid but may repair to a great extent the hypertension associated 
      plasma membrane permeability defect of vascular myocytes.
FAU - Rahmani, M A
AU  - Rahmani MA
AD  - Division of Science and Mathematics, Bethune-Cookman College, Daytona Beach, FL 
      32115, USA.
FAU - David, V
AU  - David V
FAU - Huang, M
AU  - Huang M
FAU - DeGray, G
AU  - DeGray G
LA  - eng
GR  - GM 08119/GM/NIGMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Artery
JT  - Artery
JID - 7508494
RN  - 0 (Arachidonic Acids)
RN  - 0 (Receptors, Adrenergic, beta)
RN  - 1WS297W6MV (Phenylephrine)
RN  - 660YQ98I10 (Potassium Chloride)
RN  - MN3L5RMN02 (Clonidine)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Animals
MH  - Aorta/*drug effects
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Calcium/metabolism
MH  - Calcium Signaling/drug effects
MH  - Cell Membrane Permeability/drug effects
MH  - Clonidine/pharmacology
MH  - Endothelium, Vascular/drug effects/physiology
MH  - Hypertension/*drug therapy/genetics
MH  - Injections, Intraperitoneal
MH  - Ion Transport/drug effects
MH  - Male
MH  - Muscle Contraction/drug effects
MH  - Muscle, Smooth, Vascular/*drug effects
MH  - Norepinephrine/pharmacology
MH  - Phenylephrine/pharmacology
MH  - Potassium Chloride/pharmacology
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Rats, Inbred WKY
MH  - Receptors, Adrenergic, beta/drug effects
EDAT- 2000/06/10 09:00
MHDA- 2000/10/21 11:01
CRDT- 2000/06/10 09:00
PHST- 2000/06/10 09:00 [pubmed]
PHST- 2000/10/21 11:01 [medline]
PHST- 2000/06/10 09:00 [entrez]
PST - ppublish
SO  - Artery. 1998;23(1):37-55.

PMID- 27153943
OWN - NLM
STAT- MEDLINE
DCOM- 20170103
LR  - 20181113
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 15
DP  - 2016 May 6
TI  - Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic 
      cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway.
PG  - 75
LID - 10.1186/s12933-016-0383-8 [doi]
LID - 75
AB  - BACKGROUND: Type-2 diabetics have an increased risk of cardiomyopathy, and heart 
      failure is a major cause of death among these patients. Growing evidence 
      indicates that proinflammatory cytokines may induce the development of insulin 
      resistance, and that anti-inflammatory medications may reverse this process. We 
      investigated the effects of the oral administration of zinc and acetylsalicylic 
      acid, in the form of bis(aspirinato)zinc(II)-complex Zn(ASA)2, on different 
      aspects of cardiac damage in Zucker diabetic fatty (ZDF) rats, an experimental 
      model of type-2 diabetic cardiomyopathy. METHODS: Nondiabetic control (ZL) and 
      ZDF rats were treated orally with vehicle or Zn(ASA)2 for 24 days. At the age of 
      29-30 weeks, the electrical activities, left-ventricular functional parameters 
      and left-ventricular wall thicknesses were assessed. Nitrotyrosine 
      immunohistochemistry, TUNEL-assay, and hematoxylin-eosin staining were performed. 
      The protein expression of the insulin-receptor and PI3K/AKT pathway were 
      quantified by Western blot. RESULTS: Zn(ASA)2-treatment significantly decreased 
      plasma glucose concentration in ZDF rats (39.0 ± 3.6 vs 49.4 ± 2.8 mM, P < 0.05) 
      while serum insulin-levels were similar among the groups. Data from cardiac 
      catheterization showed that Zn(ASA)2 normalized the increased left-ventricular 
      diastolic stiffness (end-diastolic pressure-volume relationship: 0.064 ± 0.008 vs 
      0.084 ± 0.014 mmHg/µl; end-diastolic pressure: 6.5 ± 0.6 vs 7.9 ± 0.7 mmHg, P < 
      0.05). Furthermore, ECG-recordings revealed a restoration of prolonged 
      QT-intervals (63 ± 3 vs 83 ± 4 ms, P < 0.05) with Zn(ASA)2. Left-ventricular wall 
      thickness, assessed by echocardiography, did not differ among the groups. However 
      histological examination revealed an increase in the cardiomyocytes' transverse 
      cross-section area in ZDF compared to the ZL rats, which was significantly 
      decreased after Zn(ASA)2-treatment. Additionally, a significant fibrotic 
      remodeling was observed in the diabetic rats compared to ZL rats, and 
      Zn(ASA)2-administered ZDF rats showed a similar collagen content as ZL animals. 
      In diabetic hearts Zn(ASA)2 significantly decreased DNA-fragmentation, and 
      nitro-oxidative stress, and up-regulated myocardial phosphorylated-AKT/AKT 
      protein expression. Zn(ASA)2 reduced cardiomyocyte death in a cellular model of 
      oxidative stress. Zn(ASA)2 had no effects on altered myocardial CD36, GLUT-4, and 
      PI3K protein expression. CONCLUSIONS: We demonstrated that treatment of type-2 
      diabetic rats with Zn(ASA)2 reduced plasma glucose-levels and prevented diabetic 
      cardiomyopathy. The increased myocardial AKT activation could, in part, help to 
      explain the cardioprotective effects of Zn(ASA)2. The oral administration of 
      Zn(ASA)2 may have therapeutic potential, aiming to prevent/treat cardiac 
      complications in type-2 diabetic patients.
FAU - Korkmaz-Icöz, Sevil
AU  - Korkmaz-Icöz S
AD  - Laboratory of Cardiac Surgery, Department of Cardiac Surgery, University Hospital 
      Heidelberg, Im Neuenheimer Feld 326, 69120, Heidelberg, Germany. 
      korkmaz@uni-heidelberg.de.
FAU - Al Said, Samer
AU  - Al Said S
AD  - Laboratory of Cardiac Surgery, Department of Cardiac Surgery, University Hospital 
      Heidelberg, Im Neuenheimer Feld 326, 69120, Heidelberg, Germany.
FAU - Radovits, Tamás
AU  - Radovits T
AD  - Heart and Vascular Center, Semmelweis University, Városmajor u. 68, Budapest, 
      1122, Hungary.
FAU - Li, Shiliang
AU  - Li S
AD  - Laboratory of Cardiac Surgery, Department of Cardiac Surgery, University Hospital 
      Heidelberg, Im Neuenheimer Feld 326, 69120, Heidelberg, Germany.
FAU - Brune, Maik
AU  - Brune M
AD  - Department of Internal Medicine I and Clinical Chemistry, University Hospital 
      Heidelberg, Im Neuenheimer Feld 671, 69120, Heidelberg, Germany.
FAU - Hegedűs, Péter
AU  - Hegedűs P
AD  - Laboratory of Cardiac Surgery, Department of Cardiac Surgery, University Hospital 
      Heidelberg, Im Neuenheimer Feld 326, 69120, Heidelberg, Germany.
FAU - Atmanli, Ayhan
AU  - Atmanli A
AD  - Laboratory of Cardiac Surgery, Department of Cardiac Surgery, University Hospital 
      Heidelberg, Im Neuenheimer Feld 326, 69120, Heidelberg, Germany.
FAU - Ruppert, Mihály
AU  - Ruppert M
AD  - Laboratory of Cardiac Surgery, Department of Cardiac Surgery, University Hospital 
      Heidelberg, Im Neuenheimer Feld 326, 69120, Heidelberg, Germany.
AD  - Heart and Vascular Center, Semmelweis University, Városmajor u. 68, Budapest, 
      1122, Hungary.
FAU - Brlecic, Paige
AU  - Brlecic P
AD  - Laboratory of Cardiac Surgery, Department of Cardiac Surgery, University Hospital 
      Heidelberg, Im Neuenheimer Feld 326, 69120, Heidelberg, Germany.
FAU - Lehmann, Lorenz Heyne
AU  - Lehmann LH
AD  - Department of Cardiology, Angiology and Pulmonology, University Hospital 
      Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
FAU - Lahrmann, Bernd
AU  - Lahrmann B
AD  - Hamamatsu Tissue Imaging and Analysis Center (TIGA), Bioquant, University of 
      Heidelberg, 69120, Heidelberg, Germany.
AD  - Steinbeis Transfer Center for Medical Systems Biology, 69124, Heidelberg, 
      Germany.
FAU - Grabe, Niels
AU  - Grabe N
AD  - Hamamatsu Tissue Imaging and Analysis Center (TIGA), Bioquant, University of 
      Heidelberg, 69120, Heidelberg, Germany.
AD  - Steinbeis Transfer Center for Medical Systems Biology, 69124, Heidelberg, 
      Germany.
AD  - Department of Medical Oncology, National Center for Tumor Diseases, University of 
      Heidelberg, 69120, Heidelberg, Germany.
FAU - Yoshikawa, Yutaka
AU  - Yoshikawa Y
AD  - Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical 
      University, Kyoto, 607-8414, Japan.
FAU - Yasui, Hiroyuki
AU  - Yasui H
AD  - Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical 
      University, Kyoto, 607-8414, Japan.
FAU - Most, Patrick
AU  - Most P
AD  - Molecular and Translational Cardiology, Department of Internal Medicine III, 
      University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, 
      Germany.
FAU - Karck, Matthias
AU  - Karck M
AD  - Laboratory of Cardiac Surgery, Department of Cardiac Surgery, University Hospital 
      Heidelberg, Im Neuenheimer Feld 326, 69120, Heidelberg, Germany.
FAU - Szabó, Gábor
AU  - Szabó G
AD  - Laboratory of Cardiac Surgery, Department of Cardiac Surgery, University Hospital 
      Heidelberg, Im Neuenheimer Feld 326, 69120, Heidelberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160506
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - J41CSQ7QDS (Zinc)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Diabetes Mellitus, Experimental/*drug therapy/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Diabetic Cardiomyopathies/*drug therapy/metabolism
MH  - Heart Ventricles/drug effects/physiopathology
MH  - Male
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Rats
MH  - Rats, Zucker
MH  - Signal Transduction/*drug effects
MH  - Zinc/administration & dosage/*pharmacokinetics
PMC - PMC4858866
OTO - NOTNLM
OT  - Cardiac function
OT  - Diabetic cardiomyopathy
OT  - Type-2 diabetes mellitus
OT  - Zinc-aspirin complex
EDAT- 2016/05/08 06:00
MHDA- 2017/01/04 06:00
CRDT- 2016/05/08 06:00
PHST- 2015/10/30 00:00 [received]
PHST- 2016/04/05 00:00 [accepted]
PHST- 2016/05/08 06:00 [entrez]
PHST- 2016/05/08 06:00 [pubmed]
PHST- 2017/01/04 06:00 [medline]
AID - 10.1186/s12933-016-0383-8 [pii]
AID - 383 [pii]
AID - 10.1186/s12933-016-0383-8 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2016 May 6;15:75. doi: 10.1186/s12933-016-0383-8.

PMID- 1908430
OWN - NLM
STAT- MEDLINE
DCOM- 19910924
LR  - 20181217
IS  - 0018-5043 (Print)
IS  - 0018-5043 (Linking)
VI  - 23
IP  - 4
DP  - 1991 Apr
TI  - Influence of lysine acetyl-salicylate on glucose and arginine stimulated insulin 
      release in man.
PG  - 168-70
AB  - In order to determine the influence of acute inhibition of prostaglandin 
      synthesis on insulin release in man, the influence of lysine acetyl-salicylate 
      (0.9 g) on glucose- and arginine-stimulated insulin release was studied in eight 
      volunteers. No significant differences were found in plasma C-peptide levels 
      between the salicylate and the control study days during administration of 
      arginine (0.5 g/kg; 30 min) nor during a hyperglycemic clamp (glucose level 17 
      mMol/L; 60 minutes). These studies indicate that acute administration of 
      salicylate does not change insulin release in man.
FAU - van Haeften, T W
AU  - van Haeften TW
AD  - Dept. of Endocrinology, Free University Hospital, Amsterdam, The Netherlands.
FAU - Veneman, T F
AU  - Veneman TF
FAU - van der Veen, E A
AU  - van der Veen EA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Insulin)
RN  - 94ZLA3W45F (Arginine)
RN  - IY9XDZ35W2 (Glucose)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Arginine/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Glucose/metabolism
MH  - C-Peptide/blood
MH  - Glucose/*pharmacology
MH  - Humans
MH  - Insulin/blood/*metabolism
MH  - Insulin Secretion
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
EDAT- 1991/04/01 00:00
MHDA- 1991/04/01 00:01
CRDT- 1991/04/01 00:00
PHST- 1991/04/01 00:00 [pubmed]
PHST- 1991/04/01 00:01 [medline]
PHST- 1991/04/01 00:00 [entrez]
AID - 10.1055/s-2007-1003643 [doi]
PST - ppublish
SO  - Horm Metab Res. 1991 Apr;23(4):168-70. doi: 10.1055/s-2007-1003643.

PMID- 10763210
OWN - NLM
STAT- MEDLINE
DCOM- 20000427
LR  - 20220309
IS  - 0248-8663 (Print)
IS  - 0248-8663 (Linking)
VI  - 21 Suppl 1
DP  - 2000 Mar
TI  - [Aspirin, pain and inflammation].
PG  - 89s-96s
AB  - SUBJECT: Acetylsalicylic acid (ASA) is among the most commonly analgesic, 
      antipyretic and anti-inflammatory used drugs. The anti-inflammatory effects of 
      ASA are mediated by the inhibition of cyclooxygenase enzymes with the subsequent 
      decrease of prostaglandin synthesis. NEW DATA: However, since this discovery of 
      Vane in 1971, much of other mechanisms of anti-inflammatory action, without 
      relation with cyclooxygenases, have been proposed. ASA has peripheric analgesic 
      properties by reducing prostaglandin biosynthesis. But there is evidence that the 
      analgesic effects could be mediated by central mechanisms with changes in the 
      monoaminergic and opioid systems. ASA is essentially used in moderate pains with 
      an inflammatory component (rheumatological disorders, headaches, dental and 
      postoperative pains). PERSPECTIVES: The clinical use of ASA at anti-inflammatory 
      dose is less frequent because the other non steroidal anti-inflammatory drugs are 
      as effective as ASA, but they are associated with less side effects. 
      Nevertheless, the synergism of ASA and morphine association and the possible 
      involvement of the central serotonergic and opiatergic systems in the 
      antinociceptive activity of ASA could confer a greater role of ASA in pain 
      management.
FAU - Vergne, P
AU  - Vergne P
AD  - Service de rhumatologie et de thérapeutiques, centre hospitalier universitaire 
      Dupuytren, Limoges, France.
FAU - Bertin, P
AU  - Bertin P
FAU - Trèves, R
AU  - Trèves R
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspirine, douleurs et inflammation.
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Arthritis/drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Child
MH  - Colic/drug therapy
MH  - Controlled Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Headache/drug therapy
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Mice
MH  - Migraine Disorders/drug therapy
MH  - Pain/*drug therapy
MH  - Pain, Postoperative/drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Rats
MH  - Toothache/drug therapy
RF  - 64
EDAT- 2000/04/14 09:00
MHDA- 2000/04/29 09:00
CRDT- 2000/04/14 09:00
PHST- 2000/04/14 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/04/14 09:00 [entrez]
AID - S0248-8663(00)88730-5 [pii]
AID - 10.1016/s0248-8663(00)88730-5 [doi]
PST - ppublish
SO  - Rev Med Interne. 2000 Mar;21 Suppl 1:89s-96s. doi: 10.1016/s0248-8663(00)88730-5.

PMID- 27301652
OWN - NLM
STAT- MEDLINE
DCOM- 20170707
LR  - 20180131
IS  - 1879-3649 (Electronic)
IS  - 1537-1891 (Linking)
VI  - 87
DP  - 2016 Dec
TI  - Dipyrone comedication in aspirin treated stroke patients impairs outcome.
PG  - 66-69
LID - S1537-1891(15)30074-4 [pii]
LID - 10.1016/j.vph.2016.06.003 [doi]
AB  - BACKGROUND: >50% of stroke patients rely on analgesic medication to control pain. 
      Aspirin is the mainstay of medical treatment of stroke patients; however 
      analgesic medication with dipyrone impairs aspirin antiplatelet effects ex-vivo. 
      The clinical impact of this impairment is unknown. Therefore, we aimed to 
      determine aspirin antiplatelet effects and neurological outcome in stroke 
      patients with aspirin and dipyrone comedication. METHODS: We conducted a 
      prospective cohort study in 41 patients with stroke. Primary outcome was 
      pharmacodynamic response to aspirin in dipyrone treated stroke patients. 
      Secondary outcome was neurological recovery after stroke. Pharmacodynamic 
      response to aspirin was measured using arachidonic acid induced aggregation in 
      light-transmission aggregometry. Neurological outcome was determined three months 
      after stroke onset by telephone interview. RESULTS: Patient's characteristics 
      were similar in the aspirin-alone group and the aspirin+dipyrone group. Impaired 
      pharmacodynamic response to aspirin occurred in 62% (14/21) of patients with 
      aspirin and dipyrone co-medication. Only 10% (2/20) of aspirin treated patients 
      without analgesic comedication displayed residual platelet reactivity (P=0.001; 
      odds ratio [OR], 18 [95% CI, 3.2-100]). Excellent neurological recovery (measured 
      by three months follow-up modified Rankin Scale<2) was observed in 80% (16/20) of 
      patients in the aspirin-alone group and 48% (10/21) of patients in the 
      aspirin+dipyrone group (P=0.037; OR, 4.4 [95% CI, 1.1-17.7]). CONCLUSIONS: 
      Dipyrone comedication in patients with stroke impairs pharmacodynamic response to 
      aspirin. This is associated with worse clinical outcome. Therefore dipyrone 
      should be used with caution in aspirin treated stroke patients. CLINICAL TRIAL 
      REGISTRATION: https://clinicaltrials.gov/show/NCT02148939; Identifier: 
      NCT02148939.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Dannenberg, Lisa
AU  - Dannenberg L
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Dusseldorf, Germany.
FAU - Erschoff, Vladimir
AU  - Erschoff V
AD  - Institute for Pharmacology and Clinical Pharmacology, Heinrich Heine University, 
      Dusseldorf, Germany.
FAU - Bönner, Florian
AU  - Bönner F
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Dusseldorf, Germany.
FAU - Gliem, Michael
AU  - Gliem M
AD  - Department of Neurology, Heinrich Heine University, Dusseldorf, Germany.
FAU - Jander, Sebastian
AU  - Jander S
AD  - Department of Neurology, Heinrich Heine University, Dusseldorf, Germany.
FAU - Levkau, Bodo
AU  - Levkau B
AD  - Institute of Pathophysiology, West German Heart and Vascular Center, University 
      Hospital Essen, University of Duisburg-Essen, Essen, Germany.
FAU - Kelm, Malte
AU  - Kelm M
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Dusseldorf, Germany.
FAU - Hohlfeld, Thomas
AU  - Hohlfeld T
AD  - Institute for Pharmacology and Clinical Pharmacology, Heinrich Heine University, 
      Dusseldorf, Germany.
FAU - Zeus, Tobias
AU  - Zeus T
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Dusseldorf, Germany.
FAU - Polzin, Amin
AU  - Polzin A
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Dusseldorf, Germany. Electronic address: 
      Amin.polzin@med.uni-duesseldorf.de.
LA  - eng
SI  - ClinicalTrials.gov/NCT02148939
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20160611
PL  - United States
TA  - Vascul Pharmacol
JT  - Vascular pharmacology
JID - 101130615
RN  - 0 (Analgesics)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Analgesics/administration & dosage/pharmacology
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Cohort Studies
MH  - Dipyrone/*administration & dosage/pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Prospective Studies
MH  - Stroke/*drug therapy
OTO - NOTNLM
OT  - Aspirin
OT  - Dipyrone
OT  - Pharmacology
OT  - Platelet activation
OT  - Platelet aggregation
OT  - Stroke
EDAT- 2016/06/16 06:00
MHDA- 2017/07/08 06:00
CRDT- 2016/06/16 06:00
PHST- 2015/11/04 00:00 [received]
PHST- 2016/06/03 00:00 [revised]
PHST- 2016/06/10 00:00 [accepted]
PHST- 2016/06/16 06:00 [pubmed]
PHST- 2017/07/08 06:00 [medline]
PHST- 2016/06/16 06:00 [entrez]
AID - S1537-1891(15)30074-4 [pii]
AID - 10.1016/j.vph.2016.06.003 [doi]
PST - ppublish
SO  - Vascul Pharmacol. 2016 Dec;87:66-69. doi: 10.1016/j.vph.2016.06.003. Epub 2016 
      Jun 11.

PMID- 3923876
OWN - NLM
STAT- MEDLINE
DCOM- 19850722
LR  - 20141120
IS  - 0002-9645 (Print)
IS  - 0002-9645 (Linking)
VI  - 46
IP  - 5
DP  - 1985 May
TI  - Failure of superoxide dismutase to alter equine arachidonic acid-induced platelet 
      aggregation, in vitro or ex vivo.
PG  - 1104-6
AB  - Superoxide dismutase (SOD), a free radical scavenger with anti-inflammatory 
      activity, was administered IM to horses. Ex vivo platelet aggregation in response 
      to arachidonic acid was monitored to determine whether exogenous SOD altered 
      equine platelet prostaglandin metabolism. Preparations of platelet-rich plasma 
      obtained before SOD administration were incubated with different concentrations 
      of SOD and were aggregated with arachidonic acid. Superoxide dismutase did not 
      exert a demonstrable effect, either ex vivo or in vitro. Aspirin abolished 
      arachidonic acid-induced platelet aggregation in vitro. This indicates that SOD 
      (in the resting state) does not exert an effect on platelet-derived free radicals 
      that could alter the arachidonic acid pathway of equine platelets, that equine 
      platelets do not release free radicals, or that equine platelets are insensitive 
      to the products formed from free radicals by SOD.
FAU - Clemmons, R M
AU  - Clemmons RM
FAU - Lee, M R
AU  - Lee MR
FAU - Bliss, E L
AU  - Bliss EL
FAU - Asbury, A C
AU  - Asbury AC
FAU - Cook, D
AU  - Cook D
FAU - Brown, V
AU  - Brown V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 0 (Arachidonic Acids)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/pharmacology
MH  - Blood Platelets/drug effects
MH  - Female
MH  - Horses/*physiology
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Superoxide Dismutase/*pharmacology
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
PST - ppublish
SO  - Am J Vet Res. 1985 May;46(5):1104-6.

PMID- 7010083
OWN - NLM
STAT- MEDLINE
DCOM- 19810521
LR  - 20131121
IS  - 0026-2633 (Print)
IS  - 0026-2633 (Linking)
VI  - 28
IP  - 112
DP  - 1980
TI  - The role of Aspergillus fumigatus antigens in blood coagulation and platelet 
      function.
PG  - 91-6
AB  - The effects of Aspergillus fumigatus antigens on platelet function of rabbits was 
      studied. A. fumigatus antigens produced spontaneous and irreversible aggregation 
      of platelets. Aspirin, indomethacin or lidocaine did not block the 
      antigen-induced aggregation. However, no aggregations occurred when complement 
      depleted plasma was used. No differences were noted between the strains used. Our 
      findings show that soluble Aspergillus antigens can cause platelet aggregation in 
      vitro, possibly via a complement dependent pathway. The likely implications of 
      these findings in clinical situations are discussed.
FAU - Sheth, N K
AU  - Sheth NK
FAU - Kurup, V P
AU  - Kurup VP
FAU - Barron, B A
AU  - Barron BA
LA  - eng
GR  - AI-15700/AI/NIAID NIH HHS/United States
GR  - HL 15389/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Microbios
JT  - Microbios
JID - 0207257
RN  - 0 (Antigens, Fungal)
RN  - 98PI200987 (Lidocaine)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - *Antigens, Fungal
MH  - Aspergillus fumigatus/*immunology
MH  - Aspirin/pharmacology
MH  - *Blood Coagulation
MH  - Indomethacin/pharmacology
MH  - Lidocaine/pharmacology
MH  - *Platelet Aggregation/drug effects
MH  - Rabbits
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Microbios. 1980;28(112):91-6.

PMID- 1960301
OWN - NLM
STAT- MEDLINE
DCOM- 19920103
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 18
IP  - 7
DP  - 1991 Dec
TI  - Aspirin (75 mg/day) after an episode of unstable coronary artery disease: 
      long-term effects on the risk for myocardial infarction, occurrence of severe 
      angina and the need for revascularization. Research Group on Instability in 
      Coronary Artery Disease in Southeast Sweden.
PG  - 1587-93
AB  - In this study, 796 men with unstable coronary artery disease (that is, unstable 
      angina or non-Q wave myocardial infarction) were randomized to double-blind 
      placebo-controlled treatment with aspirin (75 mg/day). The long-term efficacy was 
      judged from the occurrence of myocardial infarction or death or severe angina 
      necessitating referral to coronary angiography. The risk of myocardial infarction 
      or death was reduced during aspirin treatment--after 1 year, the risk ratio was 
      0.52 (confidence interval 0.37 to 0.72). Severe angina necessitating referral to 
      coronary angiography was less common during aspirin therapy--after 3 months, the 
      risk ratio was 0.59 (0.42 to 0.84) and after 1 year 0.71 (0.56 to 0.91). The 
      combined event rate of myocardial infarction or death or referral to coronary 
      angiography was reduced; after 3 months, the risk ratio was 0.44 (0.30 to 0.66) 
      and after 1 year 0.65 (0.54 to 0.79). The 75-mg aspirin dose was well tolerated 
      and had a high level of patient compliance. Treatment with aspirin (75 mg/day) 
      should be recommended to all men for greater than or equal to 3 months after an 
      episode of unstable coronary artery disease. Long-term therapy should be 
      considered if there are no contraindications or side effects.
FAU - Wallentin, L C
AU  - Wallentin LC
AD  - Department of Internal Medicine, Faculty of Health Sciences, Linköping 
      University, Sweden.
LA  - eng
PT  - Clinical Trial
PT  - Comment
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - J Am Coll Cardiol. 1991 Dec;18(7):1617-26. PMID: 1960305
MH  - Administration, Oral
MH  - Angina, Unstable/diagnostic imaging/*drug therapy/epidemiology
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Coronary Angiography/statistics & numerical data
MH  - Electrocardiography
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Life Tables
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/epidemiology/surgery
MH  - Myocardial Revascularization/statistics & numerical data
MH  - Prospective Studies
MH  - Referral and Consultation/statistics & numerical data
MH  - Risk Factors
MH  - Sweden/epidemiology
MH  - Treatment Outcome
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
AID - 0735-1097(91)90489-V [pii]
AID - 10.1016/0735-1097(91)90489-v [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1991 Dec;18(7):1587-93. doi: 10.1016/0735-1097(91)90489-v.

PMID- 21644253
OWN - NLM
STAT- MEDLINE
DCOM- 20151005
LR  - 20191210
IS  - 1615-9314 (Electronic)
IS  - 1615-9306 (Linking)
VI  - 34
IP  - 16-17
DP  - 2011 Aug
TI  - Simultaneous analysis of acetaminophen, p-aminophenol and aspirin metabolites by 
      hydrophilic interaction and strong anion exchange capillary liquid chromatography 
      coupled to amperometric detection.
PG  - 2072-8
LID - 10.1002/jssc.201100163 [doi]
AB  - A simple and sensitive method has been developed for the simultaneous 
      determination of polar nonsteroidal pharmaceuticals and metabolites, including 
      acetaminophen, p-aminophenol and several aspirin metabolites (salicylic acid, 
      gentisic acid, salicyluric acid and 2,3-dihydroxybenzoic acid), by capillary 
      liquid chromatography with amperometric detection. Using a capillary monolithic 
      column with mixed mode stationary phases and a mobile phase composed of 
      acetonitrile and Tris buffer, rapid separation of six polar analytes was achieved 
      within 8 min, and a hydrophilic interaction and strong anion exchange separation 
      mechanism were exhibited. Method detection limits of six analytes ranged from 10 
      to 50 ng/mL. In terms of precision, the intra- and interday relative standard 
      deviation values in all analytes never exceeded 3.1% for migration time and 8.9% 
      for peak areas, respectively. This method provided a simple, rapid and 
      cost-effective approach for the analysis of polar pharmaceuticals. The 
      applicability of the method in pharmacokinetics was verified by spiking human 
      serum samples with the compounds and analyzing the recoveries.
CI  - Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Zheng, Minmin
AU  - Zheng M
AD  - Key Laboratory of Analysis and Detection Technology for Food Safety, Ministry of 
      Education, Fuzhou University, Fuzhou, P. R. China; College of Chemistry and 
      Chemical Engineering, Fuzhou University, Fuzhou, P. R. China.
FAU - Wu, Yimin
AU  - Wu Y
FAU - Lu, Lanxiang
AU  - Lu L
FAU - Ding, Kang
AU  - Ding K
FAU - Tang, Fengxiang
AU  - Tang F
FAU - Lin, Zian
AU  - Lin Z
FAU - Wu, Xiaoping
AU  - Wu X
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110603
PL  - Germany
TA  - J Sep Sci
JT  - Journal of separation science
JID - 101088554
RN  - 0 (Aminophenols)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - R7P8FRP05V (4-aminophenol)
SB  - IM
MH  - Acetaminophen/*blood/metabolism
MH  - Aged
MH  - Aged, 80 and over
MH  - Aminophenols/*blood/metabolism
MH  - Aspirin/*blood/metabolism
MH  - Chromatography, Ion Exchange/instrumentation/*methods
MH  - Female
MH  - Humans
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Male
OTO - NOTNLM
OT  - Amperometric detection
OT  - Capillary liquid chromatography
OT  - HI/SAX monolithic column
OT  - Polar pharmaceuticals and metabolites
EDAT- 2011/06/07 06:00
MHDA- 2015/10/06 06:00
CRDT- 2011/06/07 06:00
PHST- 2011/02/26 00:00 [received]
PHST- 2011/04/12 00:00 [revised]
PHST- 2011/04/12 00:00 [accepted]
PHST- 2011/06/07 06:00 [entrez]
PHST- 2011/06/07 06:00 [pubmed]
PHST- 2015/10/06 06:00 [medline]
AID - 10.1002/jssc.201100163 [doi]
PST - ppublish
SO  - J Sep Sci. 2011 Aug;34(16-17):2072-8. doi: 10.1002/jssc.201100163. Epub 2011 Jun 
      3.

PMID- 7871375
OWN - NLM
STAT- MEDLINE
DCOM- 19950324
LR  - 20190814
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 29
IP  - 11
DP  - 1994 Nov
TI  - Do infiltrating leukocytes contribute to the adaptation of human gastric mucosa 
      to continued aspirin administration?
PG  - 966-72
AB  - BACKGROUND: Aspirin (ASA)-induced gastropathy decreases with continued ASA 
      ingestion due to the development of gastric mucosal tolerance. However, the 
      mechanism of the gastric mucosal adaptation to repeated ASA challenge is unknown. 
      METHODS: The aim of the present study was to determine the density of leukocytes 
      infiltrating the gastric mucosa in healthy subjects during prolonged treatment 
      with ASA. In eight healthy volunteers ASA treatment (2 g/day) was continued for 
      14 days. Endoscopy was performed before medication, on the 3rd, 7th, and 14th day 
      of ASA treatment, and on the 16th and 18th day (2 and 4 days after medication was 
      stopped). Gastric damage was scored (Lanza score), and gastric biopsy specimens 
      were taken from both the oxyntic and antral mucosa. RESULTS: ASA administration 
      resulted in the development of hemorrhagic erosions, which were most severe on 
      the 3rd day of the medication; later significant reduction of severity of the 
      damage was observed. ASA administration caused an increased mucosal infiltration 
      of leukocytes; leukocyte margination and adherence to endothelia were commonly 
      observed in the gastric mucosa, particularly on the 3rd day of ASA treatment but 
      not later on. Mast cell density increased significantly on the 3rd day of ASA 
      treatment. Density of mast cells later decreased in the antral mucosa but 
      continued to be significantly increased in the oxyntic mucosa up to the 14th day. 
      There was a striking correspondence between mast cell density and endoscopic 
      score of the mucosal damage. Eosinophil density increased significantly during 
      ASA treatment and remained high even after medication was withdrawn. CONCLUSIONS: 
      1) Initial mucosal damage by ASA is followed by gastric adaptation on continuous 
      exposure to this agent; 2) infiltrating leukocytes appear to contribute to the 
      development of gastric mucosal adaptation to ASA; and 3) mast cell density 
      reflects the endoscopic score of gastric damage by ASA.
FAU - Stachura, J
AU  - Stachura J
AD  - Dept. of Medicine B, University of Münster, Germany.
FAU - Konturek, J W
AU  - Konturek JW
FAU - Dembinski, A
AU  - Dembinski A
FAU - Domschke, W
AU  - Domschke W
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Adaptation, Physiological
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Biopsy
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastritis/chemically induced/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced/pathology
MH  - Gastroscopy
MH  - Humans
MH  - Leukocytes/*physiology
MH  - Male
MH  - Mast Cells/*physiology
MH  - Time Factors
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
AID - 10.3109/00365529409094871 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 1994 Nov;29(11):966-72. doi: 10.3109/00365529409094871.

PMID- 7109006
OWN - NLM
STAT- MEDLINE
DCOM- 19821021
LR  - 20190913
IS  - 0731-3810 (Print)
IS  - 0731-3810 (Linking)
VI  - 19
IP  - 2
DP  - 1982 Apr
TI  - Assessment of the efficacy of activated charcoal following gastric lavage in 
      acute drug emergencies.
PG  - 149-65
AB  - The efficacy of administering a slurry of 100 g of activated charcoal (AC) via 
      the gastric tube following lavage was assessed in 25 treated and 37 control 
      patients presenting to the emergency room with chemical evidence of 
      sedative-hypnotics or aspirin in the blood. Efficacy was evaluated as the ability 
      of AC to prevent further absorption as determined by subsequent blood drug 
      concentration changes. Although fewer patients in the AC group showed increased 
      blood drug concentrations, the differences were not statistically significant. 
      Comparison of the mean percent change in blood drug concentrations at various 
      times following treatment produced similar results. Comparisons using subgroups 
      of patients based on the individual drugs, the treatment delay time, and entering 
      functional decompensation showed significant benefit from AC only in the less 
      symptomatic patients. Comparing these results with other studies demonstrating 
      the unequivocal efficacy of early (e.g., 30 min) treatment, it is concluded that 
      the use of AC following lavage may often be too late to benefit most patients. 
      The authors suggest that AC be given in the home, emergency vehicle, or 
      immediately upon admission.
FAU - Comstock, E G
AU  - Comstock EG
FAU - Boisaubin, E V
AU  - Boisaubin EV
FAU - Comstock, B S
AU  - Comstock BS
FAU - Faulkner, T P
AU  - Faulkner TP
LA  - eng
GR  - 1 H81 DA 0175301/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Toxicol Clin Toxicol
JT  - Journal of toxicology. Clinical toxicology
JID - 8213460
RN  - 0 (Barbiturates)
RN  - 0 (Hypnotics and Sedatives)
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Adult
MH  - Aspirin/blood/*poisoning
MH  - Barbiturates/blood/*poisoning
MH  - Charcoal/*therapeutic use
MH  - Drug Evaluation
MH  - Emergencies
MH  - *Gastric Lavage
MH  - Humans
MH  - Hypnotics and Sedatives/blood/*poisoning
MH  - Time Factors
EDAT- 1982/04/01 00:00
MHDA- 1982/04/01 00:01
CRDT- 1982/04/01 00:00
PHST- 1982/04/01 00:00 [pubmed]
PHST- 1982/04/01 00:01 [medline]
PHST- 1982/04/01 00:00 [entrez]
AID - 10.3109/15563658208990377 [doi]
PST - ppublish
SO  - J Toxicol Clin Toxicol. 1982 Apr;19(2):149-65. doi: 10.3109/15563658208990377.

PMID- 35616790
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220716
IS  - 1573-8221 (Electronic)
IS  - 0007-4888 (Print)
IS  - 0007-4888 (Linking)
VI  - 173
IP  - 1
DP  - 2022 May
TI  - Antiplatelet Activity of Riamilovir under Conditions of Lipopolysaccharide 
      Intoxication.
PG  - 41-45
LID - 10.1007/s10517-022-05489-0 [doi]
AB  - We studied the effect of antiviral agent riamilovir on ADP-induced platelet 
      aggregation in the absence and presence of LPS. Unlike acetylsalicylic acid 
      (reference drug), riamilovir did not exhibit antiplatelet effect in vitro. 
      However, it markedly suppressed platelet reactivity in LPS-treated blood samples 
      and was 2.2-fold superior to acetylsalicylic acid in terms of IC(50) value. In in 
      vivo experiments, riamilovir under conditions of hypercytokinemia blocked 
      platelet aggregation in rats by 64%.
CI  - © 2022. Springer Science+Business Media, LLC, part of Springer Nature.
FAU - Spasov, A A
AU  - Spasov AA
AD  - Department of Pharmacology and Bioinformatics, Volgograd State Medical 
      University, Ministry of Health of the Russian Federation, Volgograd, Russia.
FAU - Kucheryavenko, A F
AU  - Kucheryavenko AF
AD  - Department of Pharmacology and Bioinformatics, Volgograd State Medical 
      University, Ministry of Health of the Russian Federation, Volgograd, Russia. 
      aidakucheryavenko@yandex.ru.
FAU - Sirotenko, V S
AU  - Sirotenko VS
AD  - Department of Pharmacology and Bioinformatics, Volgograd State Medical 
      University, Ministry of Health of the Russian Federation, Volgograd, Russia.
FAU - Gaidukova, K A
AU  - Gaidukova KA
AD  - Department of Pharmacology and Bioinformatics, Volgograd State Medical 
      University, Ministry of Health of the Russian Federation, Volgograd, Russia.
FAU - Uskov, G M
AU  - Uskov GM
AD  - Department of Pharmacology and Bioinformatics, Volgograd State Medical 
      University, Ministry of Health of the Russian Federation, Volgograd, Russia.
LA  - eng
PT  - Journal Article
DEP - 20220526
PL  - United States
TA  - Bull Exp Biol Med
JT  - Bulletin of experimental biology and medicine
JID - 0372557
RN  - 0 (Antiviral Agents)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Triazines)
RN  - 0 (Triazoles)
RN  - F2HTG1MH2D (riamilovir)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antiviral Agents/pharmacology
MH  - Aspirin/pharmacology
MH  - Blood Platelets
MH  - *Lipopolysaccharides/pharmacology
MH  - Platelet Aggregation
MH  - *Platelet Aggregation Inhibitors/pharmacology
MH  - Rats
MH  - Triazines
MH  - Triazoles
PMC - PMC9134143
OTO - NOTNLM
OT  - LPS
OT  - hypercytokinemia
OT  - platelet aggregation
OT  - riamilovir
EDAT- 2022/05/27 06:00
MHDA- 2022/06/09 06:00
CRDT- 2022/05/26 11:25
PHST- 2021/11/19 00:00 [received]
PHST- 2022/05/27 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/05/26 11:25 [entrez]
AID - 10.1007/s10517-022-05489-0 [pii]
AID - 5489 [pii]
AID - 10.1007/s10517-022-05489-0 [doi]
PST - ppublish
SO  - Bull Exp Biol Med. 2022 May;173(1):41-45. doi: 10.1007/s10517-022-05489-0. Epub 
      2022 May 26.

PMID- 6606606
OWN - NLM
STAT- MEDLINE
DCOM- 19840224
LR  - 20131121
IS  - 0015-8178 (Print)
IS  - 0015-8178 (Linking)
VI  - 101
IP  - 44
DP  - 1983 Nov 24
TI  - [Optimizing therapeutic success in aortocoronary bypass operations].
PG  - 2044-50
AB  - Left ventricular function improves after aortocoronary bypass operation in 80% of 
      preoperative postextrasystolic reversible asynergic segments, but this usually 
      does not occur in preoperative postextrasystolic irreversible segments. 
      Improvement is often seen even without revascularisation of the corresponding 
      vessel, when a bypass to another stenosed vessel enables enhanced collateral 
      flow. Therefore, it is recommended to graft as many stenosed vessels as possible, 
      even those corresponding to postextrasystolic irreversible segments, to provide 
      beneficial effects in other segments. To achieve a real complete 
      revascularisation, vessels with about 50% stenosis or total occlusion should also 
      be bypassed. For multiple stenosed vessels sequential graft technique is 
      recommended. In lesions not suitable for grafting an endarterectomy should be 
      performed however the risk of intraoperative infarction should be considered. 
      Platelet inhibition after bypass operation results in a significant increase of 
      patency rate. Low dose acetylsalicylic acid is the treatment of choice and should 
      be started very early postoperatively.
FAU - Weber, M
AU  - Weber M
FAU - Theisen, K
AU  - Theisen K
FAU - Jahrmärker, H
AU  - Jahrmärker H
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Optimierung des Therapieerfolgs bei aortokoronarer Bypass-Operation.
PL  - Germany
TA  - Fortschr Med
JT  - Fortschritte der Medizin
JID - 2984763R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Coronary Artery Bypass/*methods
MH  - Coronary Disease/diagnosis/*surgery
MH  - Humans
MH  - Myocardial Contraction
MH  - Postoperative Complications/prevention & control
MH  - Prognosis
EDAT- 1983/11/24 00:00
MHDA- 1983/11/24 00:01
CRDT- 1983/11/24 00:00
PHST- 1983/11/24 00:00 [pubmed]
PHST- 1983/11/24 00:01 [medline]
PHST- 1983/11/24 00:00 [entrez]
PST - ppublish
SO  - Fortschr Med. 1983 Nov 24;101(44):2044-50.

PMID- 22216523
OWN - NLM
STAT- MEDLINE
DCOM- 20120126
LR  - 20211021
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 3
IP  - 6
DP  - 1976 Dec
TI  - The influence of thiethylperazine on the absorption of effervescent aspirin in 
      migraine.
PG  - 1015-21
AB  - The absorption of effervescent aspirin was studied in three groups of patients 
      during attacks of migraine. The first group received intramuscular 
      thiethylperazine 10 min before effervescent aspirin; the second group received 
      intramuscular metoclopramide 10 min before effervescent aspirin; and the third 
      group received effervescent aspirin alone. Where possible each patient was 
      retested when headache-free but under conditions which were otherwise as similar 
      as possible to those during the acute attack. Intramuscular metoclopramide 
      corrected the impairment of drug absorption that occurred during a migraine 
      attack, whereas thiethylperazine did not. In the group of patients treated with 
      thiethylperazine and aspirin, the impairment of absorption did not correlate with 
      the duration of the symptoms, nor with the severity of the headache and nausea. 
      Patients treated with thiethylperazine and aspirin tended to take longer to 
      recover than those patients treated with metoclopramide and aspirin. However, in 
      the thiethylperazine treated group, the time to recover did not correlate with 
      the salicylate level achieved.
FAU - Wainscott, G
AU  - Wainscott G
AD  - The Princess Margaret Migraine Clinic, 22 Charterhouse Square, London, EC1M 6DX.
FAU - Kaspi, T
AU  - Kaspi T
FAU - Volans, G N
AU  - Volans GN
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Antiemetics)
RN  - 8ETK1WAF6R (Thiethylperazine)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antiemetics/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Metoclopramide/administration & dosage
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Thiethylperazine/administration & dosage/*pharmacology
PMC - PMC1428962
EDAT- 1976/12/01 00:00
MHDA- 2012/01/27 06:00
CRDT- 2012/01/06 06:00
PHST- 2012/01/06 06:00 [entrez]
PHST- 1976/12/01 00:00 [pubmed]
PHST- 2012/01/27 06:00 [medline]
AID - 10.1111/j.1365-2125.1976.tb00351.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1976 Dec;3(6):1015-21. doi: 
      10.1111/j.1365-2125.1976.tb00351.x.

PMID- 25158631
OWN - NLM
STAT- MEDLINE
DCOM- 20151117
LR  - 20211021
IS  - 1432-1971 (Electronic)
IS  - 0172-0643 (Linking)
VI  - 36
IP  - 2
DP  - 2015 Feb
TI  - Effects of anti-inflammatory drugs on intravenous immunoglobulin therapy in the 
      acute phase of Kawasaki disease.
PG  - 335-9
LID - 10.1007/s00246-014-1010-7 [doi]
AB  - This retrospective study aimed to investigate the effects of anti-inflammatory 
      drugs (ADs) on intravenous immunoglobulin (IVIG) therapy in the acute phase of 
      Kawasaki disease. In total, 182 pediatric patients who received IVIG therapy for 
      Kawasaki disease between 1999 and 2013 at the Department of Pediatrics, Aomori 
      Prefectural Central Hospital were enrolled. Patients were divided into 2 groups: 
      an S group, including 111 patients who received single IVIG therapy with delayed 
      administration of ADs, and a T group, including 71 patients who received 
      concomitant AIDs with IVIG. During the study, the only ADs administered were 
      aspirin (A: 30 mg/kg/day) or flurbiprofen (F: 3-5 mg/kg/day). Steroids were not 
      administered to any patient. The regimen of the S group was partially used after 
      2004 and was used to all patients after 2009. The following clinical findings 
      were significantly different between the S and T groups: disease onset before 
      2003 (0 vs. 59%, P < 0.001) and after 2009 (70 vs. 0%, P < 0.001), use of 
      2-g/kg/day IVIG therapy (100 vs. 93%, P = 0.034), ADs type (A/F: 62/49 vs. 17/54, 
      P < 0.001), and the prevalence of coronary artery lesions (CAL) up to (1/111 vs. 
      11/71, P < 0.001) and after 30 days of illness (0/111 vs. 4/71, P = 0.022). 
      Logistic regression analysis revealed that IVIG therapy only (S group; P = 0.009) 
      and 2-g/kg/day IVIG therapy (P = 0.015) were significant factors for CAL 
      suppression. The findings revealed a possible negative impact of ADs on initial 
      IVIG therapy in the acute phase of Kawasaki disease. Initial single IVIG therapy 
      with delayed administration of ADs may be useful to suppress CAL caused by 
      Kawasaki disease.
FAU - Nakada, Toshimasa
AU  - Nakada T
AD  - Department of Pediatrics, Aomori Prefectural Central Hospital, Higashi-Tukurimiti 
      2-1-1, Aomori City, Aomori Prefecture, 030-8553, Japan, 
      toshimasanakada@yahoo.co.jp.
LA  - eng
PT  - Journal Article
DEP - 20140827
PL  - United States
TA  - Pediatr Cardiol
JT  - Pediatric cardiology
JID - 8003849
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Drug Interactions
MH  - Female
MH  - Flurbiprofen/*pharmacology/therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*pharmacology/therapeutic use
MH  - Infant
MH  - Logistic Models
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*therapy
MH  - Retrospective Studies
EDAT- 2014/08/28 06:00
MHDA- 2015/11/18 06:00
CRDT- 2014/08/28 06:00
PHST- 2014/05/16 00:00 [received]
PHST- 2014/08/20 00:00 [accepted]
PHST- 2014/08/28 06:00 [entrez]
PHST- 2014/08/28 06:00 [pubmed]
PHST- 2015/11/18 06:00 [medline]
AID - 10.1007/s00246-014-1010-7 [doi]
PST - ppublish
SO  - Pediatr Cardiol. 2015 Feb;36(2):335-9. doi: 10.1007/s00246-014-1010-7. Epub 2014 
      Aug 27.

PMID- 23754790
OWN - NLM
STAT- MEDLINE
DCOM- 20140716
LR  - 20130626
IS  - 1860-7187 (Electronic)
IS  - 1860-7179 (Linking)
VI  - 8
IP  - 7
DP  - 2013 Jul
TI  - Water-soluble nitric-oxide-releasing acetylsalicylic acid (ASA) prodrugs.
PG  - 1199-209
LID - 10.1002/cmdc.201300105 [doi]
AB  - A series of water-soluble (benzoyloxy)methyl esters of acetylsalicylic acid 
      (ASA), commonly known as aspirin, are described. The new derivatives each have 
      alkyl chains containing a nitric oxide (NO)-releasing nitrooxy group and a 
      solubilizing moiety bonded to the benzoyl ring. The compounds were synthesized 
      and evaluated as ASA prodrugs. After conversion to the appropriate salt, most of 
      the derivatives are solid at room temperature and all possess good water 
      solubility. They are quite stable in acid solution (pH 1) and less stable at 
      physiological pH. In human serum, these compounds are immediately metabolized by 
      esterases, producing a mixture of ASA, salicylic acid (SA), and of the related 
      NO-donor benzoic acids, along with other minor products. Due to ASA release, the 
      prodrugs are capable of inhibiting collagen-induced platelet aggregation of human 
      platelet-rich plasma. Simple NO-donor benzoic acids 
      3-hydroxy-4-(3-nitrooxypropoxy)benzoic acid (28) and 
      3-(morpholin-4-ylmethyl)-4-[3-(nitrooxy)propoxy]benzoic acid (48) were also 
      studied as representative models of the whole class of benzoic acids formed 
      following metabolism of the prodrugs in serum. These simplified derivatives did 
      not trigger antiaggregatory activity when tested at 300 μM. Only 28 displays 
      quite potent NO-dependent vasodilatatory action. Further in vivo evaluation of 
      two selected prodrugs, 
      {[2-(acetyloxy)benzoyl]oxy}methyl-3-[(3-[aminopropanoyl)oxy]-4-[3-(nitrooxy)propoxy]benzoate⋅HCl 
      (38) and {[2-(acetyloxy)benzoyl]oxy}methyl 
      3-(morpholin-4-ylmethyl)-4-[3-(nitrooxy)propoxy]benzoate oxalate (49), revealed 
      that their anti-inflammatory activities are similar to that of ASA when tested in 
      the carrageenan-induced paw edema assay in rats. The gastrotoxicity of the two 
      prodrugs was also determined to be lower than that of ASA in a lesion model in 
      rats. Taken together, these results indicated that these NO-donor ASA prodrugs 
      warrant further investigation for clinical application.
CI  - Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Rolando, Barbara
AU  - Rolando B
AD  - Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di 
      Torino, Via Pietro Giuria 9, 10125 Torino, Italy.
FAU - Lazzarato, Loretta
AU  - Lazzarato L
FAU - Donnola, Monica
AU  - Donnola M
FAU - Marini, Elisabetta
AU  - Marini E
FAU - Joseph, Sony
AU  - Joseph S
FAU - Morini, Giuseppina
AU  - Morini G
FAU - Pozzoli, Cristina
AU  - Pozzoli C
FAU - Fruttero, Roberta
AU  - Fruttero R
FAU - Gasco, Alberto
AU  - Gasco A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130610
PL  - Germany
TA  - ChemMedChem
JT  - ChemMedChem
JID - 101259013
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prodrugs)
RN  - 059QF0KO0R (Water)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry/pharmacology
MH  - Aspirin/*chemistry/*pharmacology
MH  - Edema/drug therapy
MH  - Humans
MH  - Male
MH  - Molecular Structure
MH  - Nitric Oxide/*chemistry/pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*chemistry/pharmacology
MH  - Prodrugs/*chemistry/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Solubility
MH  - Water/*chemistry
EDAT- 2013/06/12 06:00
MHDA- 2014/07/17 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/03/05 00:00 [received]
PHST- 2013/06/12 06:00 [entrez]
PHST- 2013/06/12 06:00 [pubmed]
PHST- 2014/07/17 06:00 [medline]
AID - 10.1002/cmdc.201300105 [doi]
PST - ppublish
SO  - ChemMedChem. 2013 Jul;8(7):1199-209. doi: 10.1002/cmdc.201300105. Epub 2013 Jun 
      10.

PMID- 10651661
OWN - NLM
STAT- MEDLINE
DCOM- 20000324
LR  - 20190831
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 14
IP  - 2
DP  - 2000 Feb
TI  - Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric 
      ulcer.
PG  - 203-9
AB  - BACKGROUND: Helicobacter pylori infection and NSAID usage are considered to be 
      independent risk factors for gastric ulcer (GU). Whether they interact to 
      influence the risk of bleeding in GU is unclear. AIM: To determine the prevalence 
      of H. pylori infection and NSAID ingestion in a group of patients with GU and 
      determine their roles in bleeding and non-bleeding GU. METHODS AND RESULTS: From 
      January 1993 to June 1996, a total of 217 GU patients (150 male, 67 female, 
      median age 61 years, range 26-94) were eligible for the study. Eighty-five per 
      cent were H. pylori-positive and 15% were H. pylori-negative. NSAID usage within 
      4 weeks prior to endoscopy was present in 30%, more in the H. pylori-negative 
      than H. pylori-positive patients (59% vs. 25% P = 0.0002). Aspirin was most 
      commonly used (43%). One hundred patients bled from GU (69 male, 31 female, mean 
      age 67 years, range 26-94) and 117 did not (81 male, 36 female, mean age 57 
      years, range 28-86). Univariate logistic regression showed that advanced age (>/= 
      65 years) and NSAID usage carried an increased risk of bleeding GU (odds ratio 
      3.4 and 6.8, respectively) while H. pylori infection alone was not associated 
      with additional risk (OR = 0.8). However, when three variables were considered 
      jointly in a multiple logistic regression, the OR associated with H. pylori 
      infection increased to 2.4, suggesting that in the presence of NSAIDs and 
      advanced age, H. pylori also increases the risk of bleeding GU, indicating an 
      interaction between the variables. CONCLUSION: NSAID usage and advanced age are 
      risk factors for bleeding GU, whereas H. pylori infection by itself is not. In 
      the presence of NSAIDs and advanced age, an increased risk of bleeding GU with H. 
      pylori is observed, indicating the possibility of an interaction between these 
      factors.
FAU - Ng, T M
AU  - Ng TM
AD  - Division of Gastroenterology, Department of Medicine, Changi General Hospital, 
      Singapore.
FAU - Fock, K M
AU  - Fock KM
FAU - Khor, J L
AU  - Khor JL
FAU - Teo, E K
AU  - Teo EK
FAU - Sim, C S
AU  - Sim CS
FAU - Tan, A L
AU  - Tan AL
FAU - Machin, D
AU  - Machin D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Female
MH  - Gastrointestinal Hemorrhage/*etiology
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*drug therapy
MH  - Regression Analysis
MH  - Risk Factors
EDAT- 2000/01/29 09:00
MHDA- 2000/04/01 09:00
CRDT- 2000/01/29 09:00
PHST- 2000/01/29 09:00 [pubmed]
PHST- 2000/04/01 09:00 [medline]
PHST- 2000/01/29 09:00 [entrez]
AID - apt679 [pii]
AID - 10.1046/j.1365-2036.2000.00679.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2000 Feb;14(2):203-9. doi: 
      10.1046/j.1365-2036.2000.00679.x.

PMID- 533290
OWN - NLM
STAT- MEDLINE
DCOM- 19800425
LR  - 20131121
IS  - 0003-987X (Print)
IS  - 0003-987X (Linking)
VI  - 115
IP  - 12
DP  - 1979 Dec
TI  - Possible Kawasaki disease in a 20-year-old woman.
PG  - 1435-6
AB  - We describe a 20-year-old woman in whom an illness developed that was consistent 
      with Kawasaki disease. Kawasaki disease may not be confined exclusively to the 
      pediatric age group.
FAU - Schlossberg, D
AU  - Schlossberg D
FAU - Kandra, J
AU  - Kandra J
FAU - Kreiser, J
AU  - Kreiser J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Arch Dermatol
JT  - Archives of dermatology
JID - 0372433
RN  - 63937KV33D (Erythromycin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aspirin/therapeutic use
MH  - Diagnosis, Differential
MH  - Erythromycin/therapeutic use
MH  - Female
MH  - Humans
MH  - Lymphatic Diseases/*diagnosis
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis
MH  - Staphylococcal Infections/diagnosis
MH  - Streptococcal Infections/diagnosis
EDAT- 1979/12/01 00:00
MHDA- 1979/12/01 00:01
CRDT- 1979/12/01 00:00
PHST- 1979/12/01 00:00 [pubmed]
PHST- 1979/12/01 00:01 [medline]
PHST- 1979/12/01 00:00 [entrez]
PST - ppublish
SO  - Arch Dermatol. 1979 Dec;115(12):1435-6.

PMID- 29804790
OWN - NLM
STAT- MEDLINE
DCOM- 20190619
LR  - 20220331
IS  - 1532-8171 (Electronic)
IS  - 0735-6757 (Linking)
VI  - 36
IP  - 8
DP  - 2018 Aug
TI  - The effect of aspirin in preventing the acute respiratory distress syndrome/acute 
      lung injury: A meta-analysis.
PG  - 1486-1491
LID - S0735-6757(18)30394-2 [pii]
LID - 10.1016/j.ajem.2018.05.017 [doi]
AB  - BACKGROUND: The effects of aspirin in preventing the occurrence of acute 
      respiratory distress syndrome (ARDS)/acute lung injury (ALI) among adult patients 
      are controversial. We aimed to further determine the effectiveness of aspirin in 
      reducing the rate of ARDS/ALI. METHODS: The Pubmed, Embase, Medline, 
      ClinicalTrials.gov, Cochrane Central Register of Controlled Trials (CENTRAL) as 
      well as the Information Sciences Institute (ISI) Web of Science were searched for 
      all controlled studies that research the role of aspirin in adult patients who 
      have the risk of ARDS/ALI. The outcomes were the ARDS/ALI rate and the mortality. 
      Cochrane systematic review software, Review Manager (RevMan), the R software for 
      statistical computing version 3.2.0, and the metafor package were used to test 
      the hypothesis by Mann-Whitney U test. The heterogeneity test and sensitivity 
      analyses were conducted, and random-effects or fixed-effects model was applied to 
      calculate odds ratio (OR) and mean difference (MD) for dichotomous and continuous 
      data, respectively. RESULTS: Six trials involving 6562 patients were pooled in 
      our final study. No significant heterogeneity was found in outcome measures. 
      Aspirin could reduce the rate of ARDS/ALI (OR 0.71, 95% confidence interval (CI) 
      0.58-0.86) but not the mortality (OR 0.87, 95% CI 0.71-1.07). CONCLUSIONS: In 
      patients with risk of ARDS/ALI, aspirin could provide protective effect on the 
      rate of ARDS/ALI, but it could not reduce the mortality.
CI  - Copyright © 2018 Elsevier Inc. All rights reserved.
FAU - Yu, He
AU  - Yu H
AD  - Department of Critical Care Medicine, West China School of Medicine, West China 
      Hospital, Sichuan University, China.
FAU - Ni, Yue-Nan
AU  - Ni YN
AD  - Department of Respiratory and Critical Care Medicine, West China School of 
      Medicine, West China Hospital, Sichuan University, China.
FAU - Liang, Zong-An
AU  - Liang ZA
AD  - Department of Respiratory and Critical Care Medicine, West China School of 
      Medicine, West China Hospital, Sichuan University, China.
FAU - Liang, Bin-Miao
AU  - Liang BM
AD  - Department of Respiratory and Critical Care Medicine, West China School of 
      Medicine, West China Hospital, Sichuan University, China. Electronic address: 
      liangbinmiao@163.com.
FAU - Wang, Yanmei
AU  - Wang Y
AD  - Sichuan 2nd Hospital of Traditional Chinese Medicine, 610041, China. Electronic 
      address: wangyanmeitg@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20180521
PL  - United States
TA  - Am J Emerg Med
JT  - The American journal of emergency medicine
JID - 8309942
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Lung Injury/mortality/*prevention & control
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Respiratory Distress Syndrome/mortality/*prevention & control
OTO - NOTNLM
OT  - Acute lung injury
OT  - Acute respiratory distress syndrome
OT  - Aspirin
OT  - Meta-analysis
OT  - Mortality
EDAT- 2018/05/29 06:00
MHDA- 2019/06/20 06:00
CRDT- 2018/05/29 06:00
PHST- 2018/01/30 00:00 [received]
PHST- 2018/04/19 00:00 [revised]
PHST- 2018/05/12 00:00 [accepted]
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2019/06/20 06:00 [medline]
PHST- 2018/05/29 06:00 [entrez]
AID - S0735-6757(18)30394-2 [pii]
AID - 10.1016/j.ajem.2018.05.017 [doi]
PST - ppublish
SO  - Am J Emerg Med. 2018 Aug;36(8):1486-1491. doi: 10.1016/j.ajem.2018.05.017. Epub 
      2018 May 21.

PMID- 9362035
OWN - NLM
STAT- MEDLINE
DCOM- 19980126
LR  - 20190516
IS  - 0916-7250 (Print)
IS  - 0916-7250 (Linking)
VI  - 59
IP  - 10
DP  - 1997 Oct
TI  - Frequency selectivity on aspirin-induced hearing loss in rats with auditory 
      stimulus-induced conditioned suppression.
PG  - 879-84
AB  - The conditioned suppression technique was employed to examine the acute effects 
      of aspirin on auditory function in rats. Lever pressing behavior for water 
      reinforcement was suppressed in the presence of an auditory stimulus that had 
      been previously paired with electric shocks. A single intravenous injection of 
      aspirin at a dose of 225 mg/kg caused an erroneous lever pressing response in the 
      broad sound intensities of 2 kHz tone stimulus during the conditioned stimulus 
      period. A statistically significant increase in the threshold for 2 kHz was found 
      1 to 72 hr after dosing but not for 4, 8 and 10 kHz. These results suggest that 
      the hearing for low sound frequency in rats is vulnerable to the effects of 
      aspirin. This paradigm in rats may be useful to further assess the different 
      outer hair cells along the cochlear duct and provide an additional evidence for 
      the aspirin ototoxicity research.
FAU - Kurata, K
AU  - Kurata K
AD  - Drug Safety Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, 
      Japan.
FAU - Nishida, N
AU  - Nishida N
FAU - Tsukuda, R
AU  - Tsukuda R
FAU - Suzuki, T
AU  - Suzuki T
FAU - Sato, S
AU  - Sato S
FAU - Tokuriki, M
AU  - Tokuriki M
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Vet Med Sci
JT  - The Journal of veterinary medical science
JID - 9105360
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acoustic Stimulation
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse 
      effects/pharmacology
MH  - Aspirin/administration & dosage/*adverse effects/pharmacology
MH  - Auditory Threshold/drug effects
MH  - Conditioning, Classical/*physiology
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Electric Stimulation
MH  - Evoked Potentials, Auditory, Brain Stem/physiology
MH  - Hair Cells, Auditory, Outer/physiology
MH  - Hearing/drug effects/physiology
MH  - Hearing Loss/chemically induced/physiopathology/*veterinary
MH  - Injections, Intravenous
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Specific Pathogen-Free Organisms
EDAT- 1997/11/15 00:00
MHDA- 1997/11/15 00:01
CRDT- 1997/11/15 00:00
PHST- 1997/11/15 00:00 [pubmed]
PHST- 1997/11/15 00:01 [medline]
PHST- 1997/11/15 00:00 [entrez]
AID - 10.1292/jvms.59.879 [doi]
PST - ppublish
SO  - J Vet Med Sci. 1997 Oct;59(10):879-84. doi: 10.1292/jvms.59.879.

PMID- 6432091
OWN - NLM
STAT- MEDLINE
DCOM- 19840926
LR  - 20190501
IS  - 0267-0623 (Print)
IS  - 0267-0623 (Linking)
VI  - 289
IP  - 6441
DP  - 1984 Aug 11
TI  - Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in 
      patients with normal renal function.
PG  - 347-8
AB  - Two young patients with unimpaired renal and hepatic function were found to have 
      developed metabolic acidosis after treatment for glaucoma and joint pain with a 
      combination of salicylates and carbonic anhydrase inhibitors in normal doses. 
      Carbonic anhydrase inhibitors appear to interact with salicylates to produce 
      serious metabolic acidosis in patients without the predisposing factors generally 
      considered to constitute risks. It is recommended that treatment combining 
      salicylates and carbonic anhydrase inhibitors is either kept to a minimum or 
      avoided.
FAU - Cowan, R A
AU  - Cowan RA
FAU - Hartnell, G G
AU  - Hartnell GG
FAU - Lowdell, C P
AU  - Lowdell CP
FAU - Baird, I M
AU  - Baird IM
FAU - Leak, A M
AU  - Leak AM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Br Med J (Clin Res Ed)
JT  - British medical journal (Clinical research ed.)
JID - 8302911
RN  - 0 (Carbonic Anhydrase Inhibitors)
RN  - 0 (Salicylates)
RN  - 6QT214X4XU (aloxiprin)
RN  - O3FX965V0I (Acetazolamide)
RN  - R16CO5Y76E (Aspirin)
RN  - V9MO595C9I (salicylsalicylic acid)
RN  - VVJ6673MHY (Dichlorphenamide)
SB  - IM
MH  - Acetazolamide/adverse effects
MH  - Acidosis/*chemically induced
MH  - Adult
MH  - Arthritis/drug therapy
MH  - Aspirin/adverse effects/analogs & derivatives
MH  - Carbonic Anhydrase Inhibitors/*adverse effects
MH  - Child
MH  - Dichlorphenamide/adverse effects
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glaucoma/drug therapy
MH  - Humans
MH  - Male
MH  - Salicylates/*adverse effects
PMC - PMC1442363
EDAT- 1984/08/11 00:00
MHDA- 1984/08/11 00:01
CRDT- 1984/08/11 00:00
PHST- 1984/08/11 00:00 [pubmed]
PHST- 1984/08/11 00:01 [medline]
PHST- 1984/08/11 00:00 [entrez]
AID - 10.1136/bmj.289.6441.347 [doi]
PST - ppublish
SO  - Br Med J (Clin Res Ed). 1984 Aug 11;289(6441):347-8. doi: 
      10.1136/bmj.289.6441.347.

PMID- 6868956
OWN - NLM
STAT- MEDLINE
DCOM- 19830811
LR  - 20190814
IS  - 0001-6314 (Print)
IS  - 0001-6314 (Linking)
VI  - 67
IP  - 3
DP  - 1983 Mar
TI  - Propranolol and acetylsalicylic acid in migraine prophylaxis. Double-blind 
      crossover study.
PG  - 181-6
AB  - The aim of this double-blind crossover study was to compare the prophylactic 
      effect of acetylsalicylic acid (ASA) with that of propranolol (PRP) in the 
      treatment of migraine. Plasma concentrations of the two drugs were measured in 
      order to investigate a possible relationship to the clinical effect. Compared to 
      the pretreatment period, PRP and ASA reduced migraine index, frequency, duration, 
      severity of attacks and headache days. Due to the limited number of patients, our 
      results should be cautiously interpreted, however relevant the clinical 
      improvement seemed. Improvement of migraine index was not related to different 
      plasma levels of the two drugs.
FAU - Baldrati, A
AU  - Baldrati A
FAU - Cortelli, P
AU  - Cortelli P
FAU - Procaccianti, G
AU  - Procaccianti G
FAU - Gamberini, G
AU  - Gamberini G
FAU - D'Alessandro, R
AU  - D'Alessandro R
FAU - Baruzzi, A
AU  - Baruzzi A
FAU - Sacquegna, T
AU  - Sacquegna T
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 9Y8NXQ24VQ (Propranolol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/blood/*therapeutic use
MH  - *Clinical Trials as Topic
MH  - *Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/blood/*prevention & control
MH  - Propranolol/blood/*therapeutic use
MH  - *Research Design
EDAT- 1983/03/01 00:00
MHDA- 1983/03/01 00:01
CRDT- 1983/03/01 00:00
PHST- 1983/03/01 00:00 [pubmed]
PHST- 1983/03/01 00:01 [medline]
PHST- 1983/03/01 00:00 [entrez]
AID - 10.1111/j.1600-0404.1983.tb04561.x [doi]
PST - ppublish
SO  - Acta Neurol Scand. 1983 Mar;67(3):181-6. doi: 10.1111/j.1600-0404.1983.tb04561.x.

PMID- 371149
OWN - NLM
STAT- MEDLINE
DCOM- 19790524
LR  - 20181113
IS  - 0093-0415 (Print)
IS  - 0093-0415 (Linking)
VI  - 130
IP  - 3
DP  - 1979 Mar
TI  - Strokes, transient ischemic attacks and asymptomatic bruits.
PG  - 205-17
AB  - Research into noninvasive techniques for evaluating cerebrovascular insufficiency 
      has shown that hemodynamically significant lesions can be identified with 
      considerable accuracy. Concurrently, recent descriptions of carefully applied 
      medical and surgical therapy indicate that thromboembolic stroke can be 
      effectively prevented when patients are allocated to the proper therapeutic 
      protocols. The approach of these two lines of basic investigation to the clinical 
      focal point of stroke control make it imperative that clinicians review the tools 
      at hand for identifying persons at high risk, as well as the available 
      therapeutic alternatives for effective stroke prevention.
FAU - Machleder, H I
AU  - Machleder HI
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - West J Med
JT  - The Western journal of medicine
JID - 0410504
RN  - 0 (Anticoagulants)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Auscultation
MH  - Blood Platelets/drug effects/physiology
MH  - Blood Pressure
MH  - Carotid Arteries/surgery
MH  - Cerebrovascular Disorders/*diagnosis/drug therapy/physiopathology/surgery
MH  - Endarterectomy
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*etiology
MH  - Male
MH  - Middle Aged
MH  - Ophthalmic Artery/physiology
MH  - Pulse
MH  - Risk
MH  - Thromboxane A2/pharmacology
MH  - Ultrasonography
PMC - PMC1238572
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
PST - ppublish
SO  - West J Med. 1979 Mar;130(3):205-17.

PMID- 367795
OWN - NLM
STAT- MEDLINE
DCOM- 19790425
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 14
IP  - 6
DP  - 1978 Dec 18
TI  - Effect of acetylsalicylic acid, paracetamol, and placebo on pain and blood loss 
      in dysmenorrhoeic women.
PG  - 413-6
AB  - The analgesic effect of paracetamol, acetylsalicylic acid, and placebo on 
      dysmenorrhoea were compared in a double-blind crossover study of 30 women. There 
      was a moderate placebo effect, but no significant difference was found between 
      the three treatments. Blood loss was also measured and it did not vary with the 
      type of drug ingested. It is concluded that paracetamol and acetylsalicylic acid 
      in the doses used (0.5 g X 4 for 3 days) were not effective against heavy 
      dysmenorrhoea, and that none of the drugs influenced the amount of blood lost.
FAU - Janbu, T
AU  - Janbu T
FAU - Løkken, P
AU  - Løkken P
FAU - Nesheim, B I
AU  - Nesheim BI
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/*therapeutic use
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Dysmenorrhea/complications/*drug therapy
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Pain/*drug therapy/etiology
MH  - Placebos
EDAT- 1978/12/18 00:00
MHDA- 1978/12/18 00:01
CRDT- 1978/12/18 00:00
PHST- 1978/12/18 00:00 [pubmed]
PHST- 1978/12/18 00:01 [medline]
PHST- 1978/12/18 00:00 [entrez]
AID - 10.1007/BF00716382 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1978 Dec 18;14(6):413-6. doi: 10.1007/BF00716382.

PMID- 1229742
OWN - NLM
STAT- MEDLINE
DCOM- 19760823
LR  - 20131121
IS  - 0340-1855 (Print)
IS  - 0340-1855 (Linking)
VI  - 34
IP  - 5-6
DP  - 1975 May-Jun
TI  - [Transport time for salicylates from blood to joint fluid-- a test of 
      histopathology of the synovial membrane].
PG  - 213-20
AB  - Samples of blood and joint fluid, from sixty patients who had taken Bufferin, 
      were examined for salicylates. The earliest appreance of salicylates occurred in 
      blood between 3 and 13 minutes after intake, and in joint fluid between 11 and 36 
      minutes. The individual time lapse from the first appearance of salicylates in 
      blood to that in joint fluid, designated the transport time, varied presumably 
      with the changes of the synovial membrane caused by diseases; it was small in 
      synovitis following trauma or focal infection and in osteoarthritis of short 
      duration; it was greater in osteoarthritis, psoriatic arthritis, and rheumatoid 
      arthritis of longer duration, and it showed great variations in immediate 
      traumatic synovitis. Salicylates attained maximum concentration in joint fluid 
      100 to 155 minutes after intake. Similar factors as above probably accounted for 
      the differences in these time intervals.
FAU - Soren, A
AU  - Soren A
LA  - ger
PT  - English Abstract
PT  - Journal Article
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/therapeutic use
MH  - *Biological Transport
MH  - Humans
MH  - Hydrarthrosis/drug therapy/metabolism
MH  - Middle Aged
MH  - Osteoarthritis/metabolism
MH  - Salicylates/blood/*metabolism/therapeutic use
MH  - Synovial Fluid/analysis
MH  - Synovitis/metabolism
MH  - Time Factors
EDAT- 1975/05/01 00:00
MHDA- 1975/05/01 00:01
CRDT- 1975/05/01 00:00
PHST- 1975/05/01 00:00 [pubmed]
PHST- 1975/05/01 00:01 [medline]
PHST- 1975/05/01 00:00 [entrez]
PST - ppublish
SO  - Z Rheumatol. 1975 May-Jun;34(5-6):213-20.

PMID- 3393844
OWN - NLM
STAT- MEDLINE
DCOM- 19880812
LR  - 20131121
IS  - 0035-2659 (Print)
IS  - 0035-2659 (Linking)
VI  - 55
IP  - 6
DP  - 1988 Apr 30
TI  - [Therapeutic management of rheumatoid polyarthritis (1988)].
PG  - 459-61
AB  - The authors briefly remind of the broad outline of their therapeutic approach 
      regarding rheumatoid polyarthritis, specifying their attitude towards the main 
      medications currently available. They mainly stress the mistakes too often mad in 
      the long-term treatment of the disease.
FAU - Camus, J P
AU  - Camus JP
AD  - Service de Rhumatologie, Groupe Hospitalier Pitié-Salpêtrière, Paris.
FAU - Koeger, A C
AU  - Koeger AC
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Conduite thérapeutique dans la polyarthrite rhumatoïde (1988).
PL  - France
TA  - Rev Rhum Mal Osteoartic
JT  - Revue du rhumatisme et des maladies osteo-articulaires
JID - 0407211
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - V27W9254FZ (Cortisone)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Cortisone/therapeutic use
MH  - Humans
EDAT- 1988/04/30 00:00
MHDA- 1988/04/30 00:01
CRDT- 1988/04/30 00:00
PHST- 1988/04/30 00:00 [pubmed]
PHST- 1988/04/30 00:01 [medline]
PHST- 1988/04/30 00:00 [entrez]
PST - ppublish
SO  - Rev Rhum Mal Osteoartic. 1988 Apr 30;55(6):459-61.

PMID- 3472328
OWN - NLM
STAT- MEDLINE
DCOM- 19870608
LR  - 20131121
IS  - 0107-8593 (Print)
IS  - 0107-8593 (Linking)
VI  - 26
DP  - 1986
TI  - Temporary threshold shift induced by noise exposure and moderate salicylate 
      intake.
PG  - 41-4
AB  - Temporary threshold shift was examined in 10 voluntary subjects who were exposed 
      on 5 occasions to noise only and on 5 additional occasions to noise after intake 
      of 1 g acetylsalicylic acid (ASA). The results showed no evidence that moderate 
      doses of ASA potentiate temporary threshold shift. Subjects tested before and 1 
      hour after intake of ASA showed hearing improvement after intake of ASA. This 
      threshold shift was confirmed, by a control trial, to depend on a practice effect 
      rather than on the ASA.
FAU - Lindgren, F
AU  - Lindgren F
FAU - Axelsson, A
AU  - Axelsson A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Scand Audiol Suppl
JT  - Scandinavian audiology. Supplementum
JID - 0325221
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Auditory Fatigue/*drug effects
MH  - Humans
MH  - Male
MH  - Noise/*adverse effects
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand Audiol Suppl. 1986;26:41-4.

PMID- 15753114
OWN - NLM
STAT- MEDLINE
DCOM- 20050405
LR  - 20220408
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 352
IP  - 13
DP  - 2005 Mar 31
TI  - A randomized trial of low-dose aspirin in the primary prevention of 
      cardiovascular disease in women.
PG  - 1293-304
AB  - BACKGROUND: Randomized trials have shown that low-dose aspirin decreases the risk 
      of a first myocardial infarction in men, with little effect on the risk of 
      ischemic stroke. There are few similar data in women. METHODS: We randomly 
      assigned 39,876 initially healthy women 45 years of age or older to receive 100 
      mg of aspirin on alternate days or placebo and then monitored them for 10 years 
      for a first major cardiovascular event (i.e., nonfatal myocardial infarction, 
      nonfatal stroke, or death from cardiovascular causes). RESULTS: During follow-up, 
      477 major cardiovascular events were confirmed in the aspirin group, as compared 
      with 522 in the placebo group, for a nonsignificant reduction in risk with 
      aspirin of 9 percent (relative risk, 0.91; 95 percent confidence interval, 0.80 
      to 1.03; P=0.13). With regard to individual end points, there was a 17 percent 
      reduction in the risk of stroke in the aspirin group, as compared with the 
      placebo group (relative risk, 0.83; 95 percent confidence interval, 0.69 to 0.99; 
      P=0.04), owing to a 24 percent reduction in the risk of ischemic stroke (relative 
      risk, 0.76; 95 percent confidence interval, 0.63 to 0.93; P=0.009) and a 
      nonsignificant increase in the risk of hemorrhagic stroke (relative risk, 1.24; 
      95 percent confidence interval, 0.82 to 1.87; P=0.31). As compared with placebo, 
      aspirin had no significant effect on the risk of fatal or nonfatal myocardial 
      infarction (relative risk, 1.02; 95 percent confidence interval, 0.84 to 1.25; 
      P=0.83) or death from cardiovascular causes (relative risk, 0.95; 95 percent 
      confidence interval, 0.74 to 1.22; P=0.68). Gastrointestinal bleeding requiring 
      transfusion was more frequent in the aspirin group than in the placebo group 
      (relative risk, 1.40; 95 percent confidence interval, 1.07 to 1.83; P=0.02). 
      Subgroup analyses showed that aspirin significantly reduced the risk of major 
      cardiovascular events, ischemic stroke, and myocardial infarction among women 65 
      years of age or older. CONCLUSIONS: In this large, primary-prevention trial among 
      women, aspirin lowered the risk of stroke without affecting the risk of 
      myocardial infarction or death from cardiovascular causes, leading to a 
      nonsignificant finding with respect to the primary end point.
CI  - Copyright 2005 Massachusetts Medical Society.
FAU - Ridker, Paul M
AU  - Ridker PM
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, USA.
FAU - Cook, Nancy R
AU  - Cook NR
FAU - Lee, I-Min
AU  - Lee IM
FAU - Gordon, David
AU  - Gordon D
FAU - Gaziano, J Michael
AU  - Gaziano JM
FAU - Manson, Joann E
AU  - Manson JE
FAU - Hennekens, Charles H
AU  - Hennekens CH
FAU - Buring, Julie E
AU  - Buring JE
LA  - eng
GR  - CA-47988/CA/NCI NIH HHS/United States
GR  - HL-43851/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20050307
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2005 Mar 31;352(13):1366-8. PMID: 15755763
CIN - N Engl J Med. 2005 Jun 30;352(26):2751-2; author reply 2751-2. PMID: 15987927
CIN - N Engl J Med. 2005 Jun 30;352(26):2751-2; author reply 2751-2. PMID: 15991356
CIN - Prev Cardiol. 2005 Summer;8(3):181-5. PMID: 16034223
CIN - ACP J Club. 2005 Sep-Oct;143(2):33. PMID: 16134907
CIN - Evid Based Nurs. 2005 Oct;8(4):108. PMID: 16247878
MH  - Age Factors
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*mortality/prevention & control
MH  - Cyclooxygenase Inhibitors/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Primary Prevention
MH  - Proportional Hazards Models
MH  - Risk
MH  - Risk Factors
MH  - Stroke/epidemiology/*prevention & control
EDAT- 2005/03/09 09:00
MHDA- 2005/04/06 09:00
CRDT- 2005/03/09 09:00
PHST- 2005/03/09 09:00 [pubmed]
PHST- 2005/04/06 09:00 [medline]
PHST- 2005/03/09 09:00 [entrez]
AID - NEJMoa050613 [pii]
AID - 10.1056/NEJMoa050613 [doi]
PST - ppublish
SO  - N Engl J Med. 2005 Mar 31;352(13):1293-304. doi: 10.1056/NEJMoa050613. Epub 2005 
      Mar 7.

PMID- 9825274
OWN - NLM
STAT- MEDLINE
DCOM- 19990129
LR  - 20190503
IS  - 1351-0622 (Print)
IS  - 1351-0622 (Linking)
VI  - 15
IP  - 6
DP  - 1998 Nov
TI  - Diagnosis and management of transient ischaemic attacks in accident and 
      emergency.
PG  - 374-9
AB  - Stroke is an important cause of morbidity and mortality. Often the first 
      presentation of cerebrovascular disease is a TIA which will present to the A&E 
      department. Patients who have had a TIA are at increased risk of stroke, 
      myocardial infarction, and vascular death. The risk of stroke after a TIA is 
      greatest in the first year (approximately 11.6%) with a risk of approximately 
      5.9% per year over the first five years. As the risk is highest in the first 
      months following a TIA it is important that the patients are diagnosed 
      accurately, investigated promptly, and referred appropriately for treatment in 
      order that valuable time is not lost. For this reason A&E physicians have a 
      valuable role in the initial assessment and management of the patient. It has 
      been advocated that patients should be seen by a neurologist or physician with an 
      interest in cerebrovascular disease within days of their symptoms and be prepared 
      for surgery within two weeks after a TIA. While it is usually not possible to 
      achieve this ideal, improved cooperation between A&E physicians and these 
      neurologists, general physicians, and geriatricians should lead to the 
      implementation of speedy efficient referral procedures which can only improve 
      patient care. When you next see a patient with a TIA in the A&E department 
      remember what they have to lose. Three questions relating to this article are: 
      (1) How are TIAs subdivided and what clinical features allow this differentation? 
      (2) What are the initial investigations that should be performed in A&E? (3) When 
      are the risks of completed stroke greatest after a TIA? Enumerate these risks. 
      How effective is aspirin at reducting this risks?
FAU - Libetta, C
AU  - Libetta C
AD  - Northern General Hospital, Sheffield.
FAU - Venables, G S
AU  - Venables GS
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Accid Emerg Med
JT  - Journal of accident & emergency medicine
JID - 9433751
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Diagnosis, Differential
MH  - Emergency Treatment
MH  - Humans
MH  - Ischemic Attack, Transient/*diagnosis/*therapy
MH  - Neurologic Examination
PMC - PMC1343209
EDAT- 1998/11/24 00:00
MHDA- 1998/11/24 00:01
CRDT- 1998/11/24 00:00
PHST- 1998/11/24 00:00 [pubmed]
PHST- 1998/11/24 00:01 [medline]
PHST- 1998/11/24 00:00 [entrez]
AID - 10.1136/emj.15.6.374 [doi]
PST - ppublish
SO  - J Accid Emerg Med. 1998 Nov;15(6):374-9. doi: 10.1136/emj.15.6.374.

PMID- 2602610
OWN - NLM
STAT- MEDLINE
DCOM- 19900202
LR  - 20131121
IS  - 0300-8932 (Print)
IS  - 0300-8932 (Linking)
VI  - 42
IP  - 8
DP  - 1989 Oct
TI  - [Use of aspirin in the primary prevention of vascular thrombi. A comparative 
      study with other anti-aggregant drugs].
PG  - 536-40
AB  - We have induced the formation of arterial (carotid) and venous (femoral) thrombi 
      in dogs by means of an intima lesion produced by continuous current. The 
      platelets were labeled with 111In oxine. Groups of 7 mongrel dogs received 
      treatment for 7 days prior to the trial: group I, control; group II, 5 mg/kg body 
      weight/day acetylsalicylic acid; group III, 20 mg/kg body weight/day 
      acetylsalicylic acid; group IV, 15 mg/kg body weight/day triflusal + 5 mg/kg body 
      weight/day dipyridamole; group V, 15 mg/kg body weight/day triflusal; and group 
      VI, 5 mg/kg body weight/day acetylsalicylic acid + 5 mg/kg body weight/day 
      dipyridamole. The only effective treatment for arterial thrombosis prevention was 
      that employed in group II (p less than 0.05). Venous thrombosis was prevented in 
      groups II (p less than 0.01), III (p less than 0.01) and VI (p less than 0.01).
FAU - Escudero, M C
AU  - Escudero MC
FAU - Alvarez, L
AU  - Alvarez L
FAU - Rodríguez, V
AU  - Rodríguez V
FAU - de Haro, J
AU  - de Haro J
FAU - Millán, I
AU  - Millán I
FAU - Castillo-Olivares, J L
AU  - Castillo-Olivares JL
LA  - spa
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Utilización de la aspirina en la prevención primaria de trombos vasculares. 
      Estudio comparativo con otros fármacos antiagregantes.
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 1Z0YFI05OO (triflusal)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Dogs
MH  - Drug Evaluation
MH  - Drug Therapy, Combination
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Salicylates/*therapeutic use
MH  - Thrombosis/*prevention & control
EDAT- 1989/10/01 00:00
MHDA- 1989/10/01 00:01
CRDT- 1989/10/01 00:00
PHST- 1989/10/01 00:00 [pubmed]
PHST- 1989/10/01 00:01 [medline]
PHST- 1989/10/01 00:00 [entrez]
PST - ppublish
SO  - Rev Esp Cardiol. 1989 Oct;42(8):536-40.

PMID- 17945152
OWN - NLM
STAT- MEDLINE
DCOM- 20071127
LR  - 20201216
IS  - 1474-4422 (Print)
IS  - 1474-4422 (Linking)
VI  - 6
IP  - 11
DP  - 2007 Nov
TI  - Atrial fibrillation and stroke prevention.
PG  - 981-93
AB  - Atrial fibrillation (AF) is a common arrhythmia that is associated with 
      substantial morbidity and mortality, particularly due to stroke and 
      thromboembolism. Anticoagulant therapy reduces the risk of stroke, and the 
      greatest benefit is seen in patients at highest absolute risk. Aspirin is a less 
      effective alternative, and any benefit of aspirin might be due to its favourable 
      effects on arterial thrombosis caused by vascular disease. However, anticoagulant 
      therapy remains underused, particularly in the elderly, who probably have the 
      most to gain from stroke prevention owing to their high absolute risk. The 
      underuse of anticoagulation might also be related to uncertain risk of 
      thromboembolism in individual patients and a perceived overestimation of the 
      benefit and underestimation of risk of bleeding with warfarin in clinical trials. 
      In this Review, we summarise the data for and against warfarin and aspirin 
      therapies and discuss the clinical assessments and risk stratifications that 
      guide the use of antithrombotic therapy for stroke prevention in patients with 
      AF. Possible barriers to the uptake of anticoagulation therapy are also 
      discussed.
FAU - Lip, Gregory Y H
AU  - Lip GY
AD  - University Department of Medicine, City Hospital, Birmingham, UK. 
      g.y.h.lip@bham.ac.uk
FAU - Lim, Hoong Sern
AU  - Lim HS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Lancet Neurol
JT  - The Lancet. Neurology
JID - 101139309
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/*prevention & control
MH  - Warfarin/*therapeutic use
RF  - 110
EDAT- 2007/10/20 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/10/20 09:00
PHST- 2007/10/20 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/10/20 09:00 [entrez]
AID - S1474-4422(07)70264-8 [pii]
AID - 10.1016/S1474-4422(07)70264-8 [doi]
PST - ppublish
SO  - Lancet Neurol. 2007 Nov;6(11):981-93. doi: 10.1016/S1474-4422(07)70264-8.

PMID- 10400832
OWN - NLM
STAT- MEDLINE
DCOM- 19990803
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 104
IP  - 1
DP  - 1999 Jul
TI  - Aspirin-induced asthma: advances in pathogenesis and management.
PG  - 5-13
AB  - In some patients with asthma, aspirin (ASA) and all nonsteroidal 
      anti-inflammatory drugs that inhibit cyclooxygenase enzymes (cyclooxygenase-1 and 
      -2) precipitate asthmatic attacks and naso-ocular reactions. This distinct 
      clinical syndrome, called aspirin-induced asthma (AIA), is characterized by a 
      typical sequence of symptoms, intense eosinophilic inflammation of nasal and 
      bronchial tissues, combined with overproduction of cysteinyl-leukotrienes 
      (Cys-LTs). At baseline, cys-LT urinary excretion is augmented, and ASA 
      administration leads to its further temporary increase. After ASA challenge, 
      cys-LTs are released into nasal and bronchial secretions and can be collected in 
      the urine. LTC4 synthase, the terminal enzyme for cys-LT production, is markedly 
      overexpressed in eosinophils and mast cells from bronchial biopsy specimens of 
      most patients with AIA. An allelic variant of LTC4 synthase that enhances enzyme 
      transcription is associated with AIA. Avoiding ASA and nonsteroidal 
      anti-inflammatory drugs does not prevent progression of the inflammatory disease. 
      Corticosteroids continue to be the mainstay of therapy, and anti-LT drugs are 
      also indicated for treatment of the underlying disease. After ASA 
      desensitization, daily ingestion of high doses of ASA reduces inflammatory 
      mucosal disease symptoms, particularly in the nasal passages, in most patients 
      with AIA.
FAU - Szczeklik, A
AU  - Szczeklik A
AD  - Department of Medicine, Jagellonian University School of Medicine, Krakow, 
      Poland.
FAU - Stevenson, D D
AU  - Stevenson DD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced/etiology/therapy
MH  - Humans
RF  - 90
EDAT- 1999/07/10 00:00
MHDA- 1999/07/10 00:01
CRDT- 1999/07/10 00:00
PHST- 1999/07/10 00:00 [pubmed]
PHST- 1999/07/10 00:01 [medline]
PHST- 1999/07/10 00:00 [entrez]
AID - S0091-6749(99)70106-5 [pii]
AID - 10.1016/s0091-6749(99)70106-5 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1999 Jul;104(1):5-13. doi: 10.1016/s0091-6749(99)70106-5.

PMID- 30515923
OWN - NLM
STAT- MEDLINE
DCOM- 20190620
LR  - 20190620
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 45
IP  - 3
DP  - 2019 Mar
TI  - Treatment for patients with recurrent fetal losses positive for anti-cardiolipin 
      beta2 glycoprotein I antibody using Sairei-to (Chai-ling-tang) and low-dose 
      aspirin.
PG  - 549-555
LID - 10.1111/jog.13871 [doi]
AB  - AIM: Recently, it is widely recognized that positivity for anti-phospholipid 
      antibodies is a causative factor for a range of reproductive failures. 
      Anti-cardiolipin beta2 glycoprotein I antibody (anti-CL-beta2-GPI) is a 
      representative anti-phospholipid antibody, which strongly correlates with the 
      development of thrombotic events and diversity of adverse pregnancies. In this 
      series, we aimed to elucidate effective treatment for patients with recurrent 
      fetal losses positive for anti-CL-beta2-GPI using Japanese-modified Chinese 
      herbal medicine. METHODS: Twenty-one patients with recurrent fetal losses who 
      were positive for anti-CL-beta2-GPI were treated with the Japanese-modified 
      Chinese herbal medicine, Sairei-to (Chai-ling-tang), and low-dose aspirin with or 
      without adrenal corticosteroid hormone. Of the 21 patients, the value of 
      anti-CL-beta2-GPI ranged from 1.9 to 3.4 in 10 patients, and it was over 3.5 in 
      11 patients. RESULTS: Of the 21 patients treated with the current protocol, the 
      pregnancy successfully continued in 17 patients (success rate: 81.0%). Of the 
      four patients who showed repeated abortion, chromosome abnormality of chorionic 
      villi was observed in two; thus, the success rate would be 89.5% (17 of 19 cases) 
      on excluding these cases from the evaluation. CONCLUSION: The efficacy of the 
      current treatment adopting the modified Japanese version of the Chinese herbal 
      medicine Sairei-to for patients with recurrent fetal losses positive for 
      anti-CL-beta2-GPI was indicated.
CI  - © 2018 Japan Society of Obstetrics and Gynecology.
FAU - Nonaka, Taro
AU  - Nonaka T
AD  - Department of Obstetrics and Gynecology, Niigata University, Medical and Dental 
      Hospital, Niigata City, Japan.
FAU - Takahashi, Makiko
AU  - Takahashi M
AD  - Department of Obstetrics and Gynecology, Niigata University, Medical and Dental 
      Hospital, Niigata City, Japan.
FAU - Nonaka, Chika
AU  - Nonaka C
AD  - Department of Obstetrics and Gynecology, Niigata University, Medical and Dental 
      Hospital, Niigata City, Japan.
FAU - Haino, Kazufumi
AU  - Haino K
AD  - Department of Obstetrics and Gynecology, Niigata University, Medical and Dental 
      Hospital, Niigata City, Japan.
FAU - Yamaguchi, Masayuki
AU  - Yamaguchi M
AD  - Department of Obstetrics and Gynecology, Niigata University, Medical and Dental 
      Hospital, Niigata City, Japan.
FAU - Enomoto, Takayuki
AU  - Enomoto T
AD  - Department of Obstetrics and Gynecology, Niigata University, Medical and Dental 
      Hospital, Niigata City, Japan.
FAU - Takakuwa, Koichi
AU  - Takakuwa K
AD  - General Center for Perinatal, Maternal and Neonatal Medicine, Niigata University 
      Medical and Dental Hospital, Niigata City, Japan.
LA  - eng
PT  - Journal Article
DEP - 20181204
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - 0 (Autoantibodies)
RN  - 0 (Cardiolipins)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (beta 2-Glycoprotein I)
RN  - 0 (sairei-to)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*drug therapy/immunology
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Autoantibodies/immunology
MH  - Cardiolipins/*immunology
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Treatment Outcome
MH  - beta 2-Glycoprotein I/*immunology
OTO - NOTNLM
OT  - Japanese-modified Chinese herbal medicine
OT  - Sairei-to (Chai-ling-tang)
OT  - anti-cardiolipin beta2 glycoprotein I
OT  - anti-phospholipid antibody
OT  - low-dose aspirin
OT  - reproductive failure
EDAT- 2018/12/06 06:00
MHDA- 2019/06/21 06:00
CRDT- 2018/12/06 06:00
PHST- 2018/06/01 00:00 [received]
PHST- 2018/11/02 00:00 [accepted]
PHST- 2018/12/06 06:00 [pubmed]
PHST- 2019/06/21 06:00 [medline]
PHST- 2018/12/06 06:00 [entrez]
AID - 10.1111/jog.13871 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2019 Mar;45(3):549-555. doi: 10.1111/jog.13871. Epub 2018 
      Dec 4.

PMID- 25803515
OWN - NLM
STAT- MEDLINE
DCOM- 20151230
LR  - 20181202
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 26
IP  - 3
DP  - 2015 Apr
TI  - Antithrombotic therapy in a patient with mild haemophilia A and atrial 
      fibrillation: case report and brief review of the literature.
PG  - 346-9
LID - 10.1097/MBC.0000000000000282 [doi]
AB  - The remarkable advances made in recent decades in the treatment of haemophilia 
      have resulted in a longer life expectancy for haemophilia patients. The care of 
      diseases related to ageing in these patients is becoming of great interest. We 
      briefly discuss the current possibilities for antithrombotic therapy in patients 
      with haemophilia describing the case of a 67-year-old patient with mild 
      haemophilia A and atrial fibrillation requiring antithrombotic therapy.
FAU - Aguilar, Carlos
AU  - Aguilar C
AD  - Hematology Department, Santa Bárbara General Hospital, Soria, Spain.
LA  - eng
GR  - UL1 TR000077/TR/NCATS NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - JQZ1L091Y2 (Dronedarone)
RN  - N3RQ532IUT (Amiodarone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Amiodarone/analogs & derivatives/therapeutic use
MH  - Anti-Arrhythmia Agents/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*complications/drug therapy
MH  - Disease Management
MH  - Dronedarone
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Hemophilia A/*complications
MH  - Hemorrhage/*prevention & control
MH  - Humans
MH  - Male
MH  - Thrombophilia/*drug therapy/etiology
EDAT- 2015/03/25 06:00
MHDA- 2015/12/31 06:00
CRDT- 2015/03/25 06:00
PHST- 2015/03/25 06:00 [entrez]
PHST- 2015/03/25 06:00 [pubmed]
PHST- 2015/12/31 06:00 [medline]
AID - 00001721-201504000-00021 [pii]
AID - 10.1097/MBC.0000000000000282 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2015 Apr;26(3):346-9. doi: 
      10.1097/MBC.0000000000000282.

PMID- 10923362
OWN - NLM
STAT- MEDLINE
DCOM- 20001019
LR  - 20131121
IS  - 0044-2771 (Print)
IS  - 0044-2771 (Linking)
VI  - 38
IP  - 6
DP  - 2000 Jun
TI  - Unusual negative side effects of non-steroidal anti-inflammatory drugs in the 
      proximal colon.
PG  - 499-503
AB  - Two cases of uncommon side effects of non-steroidal anti-inflammatory drugs 
      (NSAID) are presented which show that in special cases NSAID lesions can be 
      located predominantly in the proximal colon, that NSAID-caused lesions may 
      present themselves as diaphragm-like strictures and that alterations by NSAID in 
      this part of the bowel may bring enormous problems for the differential 
      diagnosis.
FAU - Kehrer, G
AU  - Kehrer G
AD  - St.-Vincenz-Krankenhaus Heilbad-Heiligenstadt.
FAU - Bosseckert, H
AU  - Bosseckert H
FAU - Koppe, P
AU  - Koppe P
FAU - Lutz, B
AU  - Lutz B
FAU - Will, U
AU  - Will U
FAU - Zinsser, E
AU  - Zinsser E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Germany
TA  - Z Gastroenterol
JT  - Zeitschrift fur Gastroenterologie
JID - 0033370
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Colonic Diseases/*chemically induced/diagnosis
MH  - Diagnosis, Differential
MH  - Diclofenac/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Intestinal Obstruction/*chemically induced/diagnosis
MH  - Male
MH  - Ulcer/*chemically induced/diagnosis
EDAT- 2000/08/03 11:00
MHDA- 2000/10/21 11:01
CRDT- 2000/08/03 11:00
PHST- 2000/08/03 11:00 [pubmed]
PHST- 2000/10/21 11:01 [medline]
PHST- 2000/08/03 11:00 [entrez]
AID - 10.1055/s-2000-14889 [doi]
PST - ppublish
SO  - Z Gastroenterol. 2000 Jun;38(6):499-503. doi: 10.1055/s-2000-14889.

PMID- 31822218
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20221207
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 8
IP  - 24
DP  - 2019 Dec 17
TI  - Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease: Use Patterns 
      and Impact Across Race and Ethnicity in the Southern Community Cohort Study.
PG  - e013404
LID - 10.1161/JAHA.119.013404 [doi]
LID - e013404
AB  - Background Data are limited on use patterns of low-dose aspirin and its role for 
      primary prevention of cardiovascular disease (CVD) in different racial and ethnic 
      groups. Methods and Results Overall, 65 231 non-Hispanic black and white people 
      aged 40 to 79 years with no history of CVD enrolled from 2002 through 2009 in the 
      SCCS (Southern Community Cohort Study). At cohort entry, the simplified 
      Framingham 10-year CVD risk was calculated, and data related to low-dose aspirin 
      use and clinical and socioeconomic covariates were collected. Race- and 
      ethnicity-specific adjusted odds ratios for characteristics of low-dose aspirin 
      users and hazard ratios for ischemic cardiac death according to aspirin use were 
      calculated using multivariate logistic and Cox regression models. Black 
      participants were less likely to take low-dose aspirin compared with white 
      participants, regardless of CVD risk and covariates (adjusted odds ratio: 0.79; 
      95% CI, 0.75-0.82). Over a median follow-up of 11.3 years, low-dose aspirin use 
      was associated with a trend toward decreased risk of ischemic cardiac death in 
      white participants (adjusted hazard ratio: 0.86; 95% CI, 0.68-1.10), especially 
      in women (adjusted hazard ratio: 0.72; 95% CI, 0.51-1.02), but not in black 
      participants (adjusted hazard ratio: 1.18; 95% CI, 0.98-1.40). Similar trends 
      were observed when the analysis was restricted to high-risk individuals aged 50 
      to 69 or 50 to 59 years, ages for which guidelines consider aspirin for CVD 
      primary prevention. Conclusions Low-dose aspirin use for primary prevention of 
      CVD is lower among black than white patients. Its use might be associated with a 
      disparate impact on ischemic cardiac death according to race and ethnicity. 
      Although additional studies are required, these findings provide no evidence of a 
      beneficial effect of aspirin among black patients for CVD primary prevention.
FAU - Fernandez-Jimenez, Rodrigo
AU  - Fernandez-Jimenez R
AD  - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine 
      at Mount Sinai New York NY.
AD  - Centro Nacional de Investigaciones Cardiovasculares (CNIC) Madrid Spain.
AD  - CIBER de Enfermedades Cardiovasculares (CIBERCV) Madrid Spain.
FAU - Wang, Thomas J
AU  - Wang TJ
AD  - International Epidemiology Institute Rockville MD.
AD  - Department of Medicine Vanderbilt University Medical Center Nashville TN.
FAU - Fuster, Valentin
AU  - Fuster V
AD  - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine 
      at Mount Sinai New York NY.
AD  - Centro Nacional de Investigaciones Cardiovasculares (CNIC) Madrid Spain.
FAU - Blot, William J
AU  - Blot WJ
AD  - International Epidemiology Institute Rockville MD.
AD  - Department of Medicine Vanderbilt University Medical Center Nashville TN.
LA  - eng
GR  - R01 CA092447/CA/NCI NIH HHS/United States
GR  - U01 CA202979/CA/NCI NIH HHS/United States
GR  - P30 CA068485/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20191211
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Black or African American
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention/*methods
MH  - *White People
PMC - PMC6951082
OTO - NOTNLM
OT  - aspirin
OT  - ethnicity
OT  - ischemic heart disease
OT  - primary prevention
EDAT- 2019/12/12 06:00
MHDA- 2020/12/15 06:00
CRDT- 2019/12/12 06:00
PHST- 2019/12/12 06:00 [entrez]
PHST- 2019/12/12 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - JAH34577 [pii]
AID - 10.1161/JAHA.119.013404 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2019 Dec 17;8(24):e013404. doi: 10.1161/JAHA.119.013404. Epub 
      2019 Dec 11.

PMID- 34147660
OWN - NLM
STAT- MEDLINE
DCOM- 20220209
LR  - 20220209
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 170
DP  - 2021 Aug
TI  - Differences in the prevention and control of cardiovascular and cerebrovascular 
      diseases.
PG  - 105737
LID - S1043-6618(21)00321-2 [pii]
LID - 10.1016/j.phrs.2021.105737 [doi]
AB  - At present, the prevention and control of cardiovascular diseases (CAVDs) has 
      made initial advancements, although the prevention and control of cerebrovascular 
      diseases (CEVDs) has not yet achieved the desired progress. In this paper, we 
      review the prevention and control of CEVDs and CAVDs, and analyze the differences 
      in prevention effects, and the pathological and physiological structures 
      pertaining to CEVDs and CAVDs. Combined with the different effects of low-dose 
      aspirin in the primary prevention of CEVDs and CAVDs by meta-analysis, aspirin 
      plays a more important role in the primary prevention of CAVDs than CEVDs. We 
      recognize the misunderstandings and blind spots concerning prevention and control 
      of CEVDs, which can be summarized as follows: (1) CEVDs and CAVDs can be 
      controlled by the same methods and drugs; (2) considering the same pathological 
      factors for cardiovascular diseases; (3) a lack of understanding of the 
      particularity of CEVDs; (4) a focus on platelets and neglect of cerebrovascular 
      protection. In summary, our research clarifies the differences in the prevention 
      measures and drugs used for CEVDs and CAVDs. Of particular concern is the serious 
      lack of preventive drugs for CEVDs in clinical use. An ideal drug for the 
      prevention of CEVDs should have protective effects on the blood, the vascular 
      endothelium, the blood-brain barrier (BBB), and other related factors. Our review 
      aims to highlight several issues in the current prevention of CEVDs and CAVDs, 
      and to provide an optimized plan for preventive drug discovery.
CI  - Copyright © 2021 Elsevier Ltd. All rights reserved.
FAU - Liu, Chengdi
AU  - Liu C
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union 
      Medical College, Beijing 100050, China.
FAU - Du, Lida
AU  - Du L
AD  - King's College Circle, Toronto, Ontario M5S1A8, Canada.
FAU - Wang, Shoubao
AU  - Wang S
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union 
      Medical College, Beijing 100050, China.
FAU - Kong, Linglei
AU  - Kong L
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union 
      Medical College, Beijing 100050, China.
FAU - Zhang, Sen
AU  - Zhang S
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union 
      Medical College, Beijing 100050, China.
FAU - Li, Sha
AU  - Li S
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union 
      Medical College, Beijing 100050, China.
FAU - Zhang, Wen
AU  - Zhang W
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union 
      Medical College, Beijing 100050, China.
FAU - Du, Guanhua
AU  - Du G
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union 
      Medical College, Beijing 100050, China. Electronic address: dugh@imm.ac.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210618
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Agents/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/pathology/physiopathology/*prevention & control
MH  - Cerebrovascular Disorders/pathology/physiopathology/*prevention & control
MH  - Humans
MH  - *Primary Prevention
MH  - Prognosis
MH  - Protective Factors
MH  - Risk Assessment
MH  - Risk Factors
OTO - NOTNLM
OT  - Blind spots
OT  - Cardiovascular diseases
OT  - Cerebrovascular diseases
OT  - Misunderstanding
OT  - Prevention and control
OT  - Preventive drugs
EDAT- 2021/06/21 06:00
MHDA- 2022/02/10 06:00
CRDT- 2021/06/20 20:38
PHST- 2021/04/07 00:00 [received]
PHST- 2021/05/17 00:00 [revised]
PHST- 2021/06/16 00:00 [accepted]
PHST- 2021/06/21 06:00 [pubmed]
PHST- 2022/02/10 06:00 [medline]
PHST- 2021/06/20 20:38 [entrez]
AID - S1043-6618(21)00321-2 [pii]
AID - 10.1016/j.phrs.2021.105737 [doi]
PST - ppublish
SO  - Pharmacol Res. 2021 Aug;170:105737. doi: 10.1016/j.phrs.2021.105737. Epub 2021 
      Jun 18.

PMID- 30784217
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201005
IS  - 1758-5910 (Electronic)
IS  - 1758-5902 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Jan
TI  - Safety of elective laparoscopic cholecystectomy in patients with antiplatelet 
      therapy: Lessons from more than 800 operations in a single tertiary referral 
      institution.
PG  - 33-38
LID - 10.1111/ases.12693 [doi]
AB  - INTRODUCTION: The perioperative antiplatelet management of patients receiving 
      antiplatelet therapy (APT) for elective laparoscopic cholecystectomy (LC) is 
      still controversial. METHODS: A total of 808 patients who underwent elective LC 
      were reviewed. We classified patients in this cohort into three groups according 
      to thromboembolic risks: patients with no thromboembolic risk (non-APT group, 
      n = 653), patients with low thromboembolic risk (APT-LR group, n = 106), patients 
      with high thromboembolic risk (APT-HR group, n = 49). Our perioperative 
      management of patients with high thrombotic risks included preoperative 
      continuation of single aspirin therapy and early postoperative reinstitution. We 
      assessed intraoperative and postoperative bleeding/thrombotic events among three 
      groups. Primary outcome measures were intraoperative bleeding complications 
      (IBCs, blood loss 200 mL or more) and postoperative bleeding complications 
      (PBCs), and the independent risk factors for increased IBC were determined by 
      multivariate analysis. This study was approved by our institutional review board 
      (#17011804). RESULTS: In the current cohort, IBC occurred in 17 (2.1%) patients. 
      Postoperatively, there were three PBCs (0.4%) and two thromboembolic 
      complications (TCs, 0.2%), respectively. The occurrences of IBC and TC did not 
      show any significant difference between the three groups, but PBC was more common 
      in the APT-LR group (P = 0.022). Multivariate analysis showed that only chronic 
      cholecystitis was the independent risk factor for IBC (P < 0.001, odds 
      ratio = 12.355), but preoperative continuation of APT or multiple APT use did not 
      affect IBC. CONCLUSION: We performed elective LC safely in patients receiving APT 
      under rigorous perioperative management of APT. Continuation of aspirin 
      monotherapy is considered in patients with APT during elective LC.
CI  - © 2019 Japan Society for Endoscopic Surgery, Asia Endosurgery Task Force and John 
      Wiley & Sons Australia, Ltd.
FAU - Sakamoto, Yusuke
AU  - Sakamoto Y
AD  - Department of Surgery, Kokura Memorial Hospital, Fukuoka, Japan.
FAU - Fujikawa, Takahisa
AU  - Fujikawa T
AD  - Department of Surgery, Kokura Memorial Hospital, Fukuoka, Japan.
FAU - Kawamura, Yuichiro
AU  - Kawamura Y
AD  - Department of Surgery, Kokura Memorial Hospital, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190219
PL  - Japan
TA  - Asian J Endosc Surg
JT  - Asian journal of endoscopic surgery
JID - 101506753
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - *Blood Loss, Surgical
MH  - *Cholecystectomy, Laparoscopic/adverse effects
MH  - Elective Surgical Procedures/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Postoperative Hemorrhage/*chemically induced/etiology
MH  - Risk Assessment
MH  - Tertiary Care Centers
MH  - Thromboembolism/*prevention & control
MH  - Treatment Outcome
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - antithrombotic management
OT  - laparoscopic cholecystectomy
EDAT- 2019/02/21 06:00
MHDA- 2020/10/06 06:00
CRDT- 2019/02/21 06:00
PHST- 2018/06/03 00:00 [received]
PHST- 2018/12/17 00:00 [revised]
PHST- 2018/12/29 00:00 [accepted]
PHST- 2019/02/21 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
PHST- 2019/02/21 06:00 [entrez]
AID - 10.1111/ases.12693 [doi]
PST - ppublish
SO  - Asian J Endosc Surg. 2020 Jan;13(1):33-38. doi: 10.1111/ases.12693. Epub 2019 Feb 
      19.

PMID- 7514021
OWN - NLM
STAT- MEDLINE
DCOM- 19940616
LR  - 20191023
IS  - 0163-4984 (Print)
IS  - 0163-4984 (Linking)
VI  - 40
IP  - 2
DP  - 1994 Feb
TI  - Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory 
      activity of aspirin.
PG  - 161-76
AB  - The effect of nutritional copper (Cu) deficiency on the antiinflammatory activity 
      and pharmacokinetics of aspirin (ASA) was investigated in rats. Male, weanling 
      Sprague-Dawley rats were fed either a Cu-deficient (CuD) or Cu-sufficient (CuS) 
      diet for 49-50 d. The antiinflammatory activity of ASA was studied using the 
      carrageenan-induced paw edema (CPE) test. ANOVA analyses of edema volumes at 2, 
      3, 4, 5, and 21 h postcarrageenan indicated significant differences between 
      groups. The percent inhibition of edema due to ASA treatment in CuS was lower 
      than that in CuD rats at 5 h, AUC5h, and AUC21h. ASA was found to be 
      significantly more effective in inhibiting the CPE in CuD rats when compared to 
      the CuS rats. Thus, we hypothesized that the increase in ASA's antiinflammatory 
      activity in CuD rats was a result of a decrement in its elimination during 
      nutritional Cu deficiency. The elimination of ASA in CuD and CuS rats was studied 
      using an iv dose of 200 mg/kg. Concentrations of ASA and salicylic acid (SA) were 
      determined in blood; whereas the concentrations of SA, salicylic 
      phenol-glucuronide (SPG), and salicyluric acid (SUA) were determined in urine by 
      HPLC. The results of the pharmacokinetic analyses from blood and urinary data 
      indicated no significant differences in the disposition of ASA between CuD and 
      CuS rats. For instance, the total body clearance for ASA (mean +/- SD, mL/min/kg) 
      was 37.9 +/- 9.4 and 38.5 +/- 13.9 (p > 0.05); and the volume of distribution 
      (Vd) for ASA (mean +/- SD, mL/kg) was 385.5 +/- 110.3 and 397.1.1 +/- 137.9 (p > 
      0.05) for CuD and CuS groups, respectively. Thus, contrary to our hypothesis, the 
      enhanced antiinflammatory activity of ASA in CuD rats does not appear to be 
      mediated via a decrement in the elimination of the drug. In addition, plasma 
      ASA-esterase activity was found to be independent of Cu nutritional status.
FAU - Lopez-Anaya, A
AU  - Lopez-Anaya A
AD  - College of Pharmacy, Xavier University of Louisiana, New Orleans 70125.
FAU - Dawson, C
AU  - Dawson C
FAU - Gonzales, C
AU  - Gonzales C
FAU - Bacolod, M
AU  - Bacolod M
FAU - Kishore, V
AU  - Kishore V
LA  - eng
GR  - S06GM-08008/GM/NIGMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biol Trace Elem Res
JT  - Biological trace element research
JID - 7911509
RN  - 0 (Salicylates)
RN  - 789U1901C5 (Copper)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.- (acetylsalicylic acid hydrolase)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/*pharmacokinetics/*pharmacology
MH  - Carboxylic Ester Hydrolases/blood
MH  - Chromatography, High Pressure Liquid
MH  - Copper/*deficiency/metabolism
MH  - Diet
MH  - Edema/chemically induced/drug therapy
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
AID - 10.1007/BF02950789 [doi]
PST - ppublish
SO  - Biol Trace Elem Res. 1994 Feb;40(2):161-76. doi: 10.1007/BF02950789.

PMID- 19038679
OWN - NLM
STAT- MEDLINE
DCOM- 20090106
LR  - 20181201
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 52
IP  - 23
DP  - 2008 Dec 2
TI  - The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic 
      Anti-Inflammatory Effects) study.
PG  - 1826-1833
LID - S0735-1097(08)03115-X [pii]
LID - 10.1016/j.jacc.2008.08.047 [doi]
AB  - OBJECTIVES: This study was designed to evaluate the effects of long-term 
      clopidogrel and aspirin administration on platelet aggregation, activation, and 
      inflammation. BACKGROUND: Clopidogrel resistance was described in 15% to 30% of 
      patients with short-term therapy, but its antiplatelet effects with long-term 
      therapy is unknown. METHODS: We performed a prospective study of patients 
      undergoing coronary stenting who were on aspirin for > or =5 days but not 
      previously on clopidogrel. Clopidogrel 600 mg was given before stenting. 
      Clopidogrel 75 mg/day and aspirin 325 mg/day were continued for 1 year. 
      Light-transmittance aggregometry with 5-micromol/l adenosine diphosphate and 
      1-mmol/l arachidonic acid stimulation; VerifyNow clopidogrel and aspirin assays; 
      platelet activation receptor expression of CD40L, CD62P, and PAC-1 (antibody 
      against activated glycoprotein IIb/IIIa); and inflammatory markers of soluble 
      CD40L and P-selectin, high-sensitivity C-reactive protein, interleukin-10, and 
      interleukin-18 were measured at baseline; 1 day; and 1, 6, and 12 months. Our 
      primary analysis compared light-transmittance aggregometry aggregation at 1 
      versus 12 months. RESULTS: We enrolled 26 patients who completed a 1-year 
      follow-up. Maximal platelet adenosine diphosphate-stimulated aggregation was 61.8 
      +/- 25.9% at baseline, 22.1 +/- 18.3% at 1 day, 30.6 +/- 16.8% at 1 month, 29.0 
      +/- 13.3% at 6 months, and 26.7 +/- 13.6% at 12 months (p = 0.099 for 12 months 
      vs. 1 month). VerifyNow clopidogrel platelet inhibition was similar at 12 months 
      versus 1 month (38.9 +/- 19.7% vs. 45.6 +/- 26.7%, p = 0.578). Likewise, there 
      was no difference in aspirin's effects on platelet aggregation at 12 months 
      versus 1 month. In contrast, platelet activation receptor expression of CD40L, 
      CD62P, and PAC-1 were higher at 12 months versus 1 month. CONCLUSIONS: Our pilot 
      study showed no attenuation of clopidogrel's effects on platelet aggregation with 
      long-term administration. However, platelet activation receptor expression 
      increased with time and should be further evaluated.
FAU - Saw, Jacqueline
AU  - Saw J
AD  - Division of Cardiology, Vancouver General Hospital, University of British 
      Columbia, Vancouver, British Columbia, Canada. Electronic address: 
      jsaw@interchange.ubc.ca.
FAU - Madsen, Esben Hjorth
AU  - Madsen EH
AD  - Canadian Blood Services, Vancouver, British Columbia, Canada.
FAU - Chan, Sammy
AU  - Chan S
AD  - Canadian Blood Services, Vancouver, British Columbia, Canada.
FAU - Maurer-Spurej, Elisabeth
AU  - Maurer-Spurej E
AD  - Department of Pathology and Laboratory Medicine and Centre for Blood Research, 
      University of British Columbia, Vancouver, British Columbia, Canada; Canadian 
      Blood Services, Vancouver, British Columbia, Canada; Division of Cardiology, St. 
      Paul's Hospital, Vancouver, British Columbia, Canada.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Prospective Studies
MH  - Stents
MH  - Ticlopidine/administration & dosage/*analogs & derivatives
EDAT- 2008/11/29 09:00
MHDA- 2009/01/07 09:00
CRDT- 2008/11/29 09:00
PHST- 2008/05/01 00:00 [received]
PHST- 2008/08/14 00:00 [revised]
PHST- 2008/08/18 00:00 [accepted]
PHST- 2008/11/29 09:00 [pubmed]
PHST- 2009/01/07 09:00 [medline]
PHST- 2008/11/29 09:00 [entrez]
AID - S0735-1097(08)03115-X [pii]
AID - 10.1016/j.jacc.2008.08.047 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2008 Dec 2;52(23):1826-1833. doi: 10.1016/j.jacc.2008.08.047.

PMID- 19383241
OWN - NLM
STAT- MEDLINE
DCOM- 20090610
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 37
IP  - 2
DP  - 2009 Mar-Apr
TI  - What should be the primary treatment in atrial fibrillation: ventricular rate 
      control or sinus rhythm control with long-term anticoagulation?
PG  - 464-71
AB  - Recent trials have favoured ventricular rate control in atrial fibrillation (AF) 
      management, however the present study investigated whether the restoration and 
      maintenance of sinus rhythm with long-term anticoagulation therapy was superior 
      in terms of embolic events and death in 534 patients with an AF duration > 48 h. 
      Patients were randomized and received sinus rhythm control with either aspirin 
      (group 1) or warfarin (group 2), or they were given ventricular rate control 
      (group 3). Cardioversion to sinus rhythm was attempted in 425 patients and was 
      successful in 387 (91.1%) of them. After 3 years' follow-up there were 12, two 
      and 15 embolic events in groups 1, 2 and 3 respectively (significant difference 
      between groups 1 and 2, and 2 and 3) and overall mortalities were four, two and 
      12, respectively (significant difference between groups 2 and 3). It is concluded 
      that patients with an AF duration > 48 h might benefit considerably from sinus 
      rhythm restoration and long-term warfarin therapy in terms of embolic events and 
      mortality.
FAU - Okcun, B
AU  - Okcun B
AD  - Institute of Cardiology, Istanbul University, Istanbul, Turkey.
FAU - Yigit, Z
AU  - Yigit Z
FAU - Yildiz, A
AU  - Yildiz A
FAU - Uzunhasan, I
AU  - Uzunhasan I
FAU - Orta, K
AU  - Orta K
FAU - Baskurt, M
AU  - Baskurt M
FAU - Kaya, A
AU  - Kaya A
FAU - Kucukoglu, S
AU  - Kucukoglu S
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Atrial Fibrillation/*drug therapy/*physiopathology
MH  - Embolism/drug therapy
MH  - Female
MH  - Heart Rate/*drug effects
MH  - Heart Ventricles/drug effects/*physiopathology
MH  - Humans
MH  - Male
MH  - Sinoatrial Node/*drug effects/physiopathology
MH  - Survival Analysis
MH  - Time Factors
MH  - Treatment Outcome
MH  - Warfarin/pharmacology/therapeutic use
EDAT- 2009/04/23 09:00
MHDA- 2009/06/11 09:00
CRDT- 2009/04/23 09:00
PHST- 2009/04/23 09:00 [entrez]
PHST- 2009/04/23 09:00 [pubmed]
PHST- 2009/06/11 09:00 [medline]
AID - 10.1177/147323000903700222 [doi]
PST - ppublish
SO  - J Int Med Res. 2009 Mar-Apr;37(2):464-71. doi: 10.1177/147323000903700222.

PMID- 36480853
OWN - NLM
STAT- MEDLINE
DCOM- 20221215
LR  - 20221215
IS  - 1001-0939 (Print)
IS  - 1001-0939 (Linking)
VI  - 45
IP  - 12
DP  - 2022 Dec 12
TI  - [Aspirin-exacerbated respiratory disease treated with omalizumab: 3 cases report 
      and literature review].
PG  - 1214-1220
LID - 10.3760/cma.j.cn112147-20220311-00194 [doi]
AB  - Objective: To summarize the clinical data of aspirin-exacerbated respiratory 
      disease (AERD) treated with omalizumab in Peking University First Hospital and 
      reviewed the relative literatures. Methods: We analyzed retrospectively the 
      clinical data of three cases of AERD treated with omalizumab in Peking University 
      First Hospital from March 1, 2018 to December 31, 2021. The clinical researches 
      on the treatment of AERD with omalizumab up to January 31, 2022 were retrieved in 
      PubMed, China National Knowledge Infrastructure (CNKI) and Wanfang Data. Results: 
      Our three patients of AERD treated with omalizumab for 32 to 68 weeks obtained 
      relief of symptoms of upper and lower respiratory tract, improvement in lung 
      function, and reduction in percentage of blood eosinophils. There were 14 
      clinical studies on treatment of AERD with omalizumab, including 3 randomized, 
      double-blind and placebo-controlled studies and 11 self-controlled case series 
      studies. The majority of studies showed that omalizumab contributed to improve 
      the symptoms of AERD, decrease the frequency of asthma attacks and reduce 
      systemic glucocorticoid use. Conclusion: Omalizumab can improve the disease 
      control of AERD, but further studies are needed.
FAU - Hu, Y
AU  - Hu Y
AD  - Department of Respiratory and Critical Care Medicine, Peking University First 
      Hospital, Beijing 100034, China.
FAU - Sui, H J
AU  - Sui HJ
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Peking University First 
      Hospital, Beijing 100034, China.
FAU - Zhao, Z T
AU  - Zhao ZT
AD  - Department of Dermatology and Venereology, Peking University First Hospital, 
      Beijing 100034, China.
FAU - Huang, J J
AU  - Huang JJ
AD  - Department of Respiratory and Critical Care Medicine, Peking University First 
      Hospital, Beijing 100034, China.
FAU - Wang, G F
AU  - Wang GF
AD  - Department of Respiratory and Critical Care Medicine, Peking University First 
      Hospital, Beijing 100034, China.
LA  - chi
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhonghua Jie He He Hu Xi Za Zhi
JT  - Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal 
      of tuberculosis and respiratory diseases
JID - 8712226
RN  - 2P471X1Z11 (Omalizumab)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Omalizumab/therapeutic use
MH  - Retrospective Studies
MH  - China
MH  - *Aspirin/adverse effects
MH  - Randomized Controlled Trials as Topic
EDAT- 2022/12/09 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/12/08 22:12
PHST- 2022/12/08 22:12 [entrez]
PHST- 2022/12/09 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
AID - 10.3760/cma.j.cn112147-20220311-00194 [doi]
PST - ppublish
SO  - Zhonghua Jie He He Hu Xi Za Zhi. 2022 Dec 12;45(12):1214-1220. doi: 
      10.3760/cma.j.cn112147-20220311-00194.

PMID- 30563510
OWN - NLM
STAT- MEDLINE
DCOM- 20181220
LR  - 20200225
IS  - 1746-6148 (Electronic)
IS  - 1746-6148 (Linking)
VI  - 14
IP  - 1
DP  - 2018 Dec 18
TI  - Aspirin eugenol ester regulates cecal contents metabolomic profile and microbiota 
      in an animal model of hyperlipidemia.
PG  - 405
LID - 10.1186/s12917-018-1711-x [doi]
LID - 405
AB  - BACKGROUND: Hyperlipidemia, with an increasing of prevalence, has become one of 
      the common metabolic diseases in companion animal clinic. Aspirin eugenol ester 
      (AEE) is a novel compound that exhibits efficacious anti-hyperlipidemia 
      activities. However, its mechanisms are still not completely known. The objective 
      of present study was to investigate the intervention effects of AEE on cecal 
      contents metabonomics profile and microbiota in hyperlipidemia rats. RESULTS: 
      Three groups of rats were fed with a control diet, or high fat diet (HFD) 
      containing or not AEE. The results showed the beneficial effects of AEE in 
      HFD-fed rats such as the reducing of aspartate aminotransferase (AST) and total 
      cholesterol (TCH). Distinct changes in metabonomics profile of cecal contents 
      were observed among control, model and AEE groups. HFD-induced alterations of 
      eight metabolites in cecal contents mainly related with purine metabolism, 
      linoleic acid metabolism, glycerophospholipid metabolism, sphingolipid metabolism 
      and pyrimidine metabolism were reversed by AEE treatment. Principal coordinate 
      analysis (PCoA) and cluster analysis of microbiota showed altered patterns with 
      distinct differences in AEE group versus model group, indicating that AEE 
      treatment improved the negative effects caused by HFD on cecal microbiota. In 
      addition, the correction analysis revealed the possible link between the 
      identified metabolites and cecal microbiota. CONCLUSIONS: This study showed 
      regulation effects of AEE on cecal contents metabonomics profile and microbiota, 
      which could provide information to reveal the possible underlying mechanism of 
      AEE on hyperlipidemia treatment.
FAU - Ma, Ning
AU  - Ma N
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, China.
AD  - College of Veterinary Medicine, Agricultural University of Hebei, Baoding, Hebei, 
      071000, China.
FAU - Liu, Xi-Wang
AU  - Liu XW
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, China.
FAU - Kong, Xiao-Jun
AU  - Kong XJ
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, China.
FAU - Li, Shi-Hong
AU  - Li SH
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, China.
FAU - Jiao, Zeng-Hua
AU  - Jiao ZH
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, China.
FAU - Qin, Zhe
AU  - Qin Z
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, China.
FAU - Yang, Ya-Jun
AU  - Yang YJ
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, China. 
      yangyue10224@163.com.
FAU - Li, Jian-Yong
AU  - Li JY
AUID- ORCID: 0000-0003-3317-0666
AD  - Key Lab of New Animal Drug Project of Gansu Province; Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      No.335, Jiangouyan, Qilihe district, Lanzhou, 730050, China. lijy1971@163.com.
LA  - eng
GR  - No.31402254/National Natural Science Foundation of China/
GR  - 31572573/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20181218
PL  - England
TA  - BMC Vet Res
JT  - BMC veterinary research
JID - 101249759
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cecum/*drug effects/metabolism/*microbiology
MH  - Diet
MH  - Disease Models, Animal
MH  - Eugenol/*analogs & derivatives/pharmacology
MH  - Gastrointestinal Microbiome/*drug effects
MH  - Hyperlipidemias/*microbiology/*physiopathology
MH  - Metabolome/*drug effects
MH  - Rats
PMC - PMC6299661
OTO - NOTNLM
OT  - Aspirin eugenol ester
OT  - Cecal contents
OT  - Gut microbiota
OT  - High fat diet
OT  - Hyperlipidemia
OT  - Metabonomics
OT  - UPLC-Q-TOF/MS
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This study was carried out in 
      accordance with the recommendations of Regulations for the Administration of 
      Affairs Concerning Experimental Animals approved by the State Council of People’s 
      Republic of China. The protocol was approved by Institutional Animal Care and Use 
      Committee of Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese 
      Academy of Agricultural Science. CONSENT FOR PUBLICATION: Not applicable. 
      COMPETING INTERESTS: The authors declare that they have no competing interests. 
      PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional 
      claims in published maps and institutional affiliations.
EDAT- 2018/12/20 06:00
MHDA- 2018/12/21 06:00
CRDT- 2018/12/20 06:00
PHST- 2018/09/04 00:00 [received]
PHST- 2018/11/23 00:00 [accepted]
PHST- 2018/12/20 06:00 [entrez]
PHST- 2018/12/20 06:00 [pubmed]
PHST- 2018/12/21 06:00 [medline]
AID - 10.1186/s12917-018-1711-x [pii]
AID - 1711 [pii]
AID - 10.1186/s12917-018-1711-x [doi]
PST - epublish
SO  - BMC Vet Res. 2018 Dec 18;14(1):405. doi: 10.1186/s12917-018-1711-x.

PMID- 9751197
OWN - NLM
STAT- MEDLINE
DCOM- 19981014
LR  - 20190630
IS  - 0022-3042 (Print)
IS  - 0022-3042 (Linking)
VI  - 71
IP  - 4
DP  - 1998 Oct
TI  - Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice.
PG  - 1635-42
AB  - The neurotoxic effects of the dopamine-selective neurotoxin MPTP (15 mg/kg, 
      s.c.), in mice, were totally prevented by systemic administration of salicylate 
      (ED50 = 40 mg/kg, i.p.), aspirin (ED50 = 60 mg/kg, i.p.), or the soluble lysine 
      salt of aspirin, Aspegic (ED50 = 80 mg/kg, i.p.). The protective effects of 
      aspirin are unlikely to be related to cyclooxygenase inhibition as paracetamol 
      (100 mg/kg, i.p.), diclofenac (100 mg/kg, i.p.), ibuprofen (20 mg/kg, i.p.) and 
      indomethacin (100 mg/kg, i.p.) were ineffective. Dexamethasone (3-30 mg/kg, 
      i.p.), which, like aspirin and salicylate, has been reported to inhibit the 
      transcription factor NF-kappaB, was also ineffective. Aspirin or salicylate (100 
      microM) had no effect on dopamine uptake into striatal synaptosomes or on 
      monoamine oxidase B activity. The neuroprotective effects of salicylate 
      derivatives could perhaps be related to hydroxyl radical scavenging. This was 
      suggested by the fact that hydroxylated metabolites of salicylate (2,3- and 
      2,5-dihydrobenzoic acid) were recovered in brain tissue following the combined 
      administration of MPTP and aspirin to a greater extent than following aspirin 
      alone. The surprising neuroprotective effects of aspirin in an animal model of 
      Parkinson's disease warrant further clinical investigation.
FAU - Aubin, N
AU  - Aubin N
AD  - Central Nervous System Research Department, Synthélabo Recherche, Bagneux, 
      France.
FAU - Curet, O
AU  - Curet O
FAU - Deffois, A
AU  - Deffois A
FAU - Carter, C
AU  - Carter C
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Salicylates)
RN  - 333DO1RDJY (Serotonin)
RN  - 3352-57-6 (Hydroxyl Radical)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 9P21XSP91P (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
RN  - EC 1.4.3.4 (Monoamine Oxidase)
RN  - K3Z4F929H6 (Lysine)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - VTD58H1Z2X (Dopamine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/*antagonists & inhibitors
MH  - Animals
MH  - Aspirin/administration & dosage/analogs & derivatives/*pharmacology/toxicity
MH  - Body Temperature/drug effects
MH  - Corpus Striatum/drug effects/metabolism
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Dexamethasone/pharmacology
MH  - Dopamine/*deficiency/metabolism
MH  - Hydroxybenzoates/metabolism
MH  - Hydroxyl Radical/antagonists & inhibitors/metabolism
MH  - Lysine/analogs & derivatives/pharmacology
MH  - *MPTP Poisoning
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Monoamine Oxidase/drug effects/metabolism
MH  - Salicylates/*pharmacology
MH  - Salicylic Acid
MH  - Serotonin/metabolism
MH  - Synaptosomes/drug effects/enzymology
EDAT- 1998/09/29 00:00
MHDA- 1998/09/29 00:01
CRDT- 1998/09/29 00:00
PHST- 1998/09/29 00:00 [pubmed]
PHST- 1998/09/29 00:01 [medline]
PHST- 1998/09/29 00:00 [entrez]
AID - 10.1046/j.1471-4159.1998.71041635.x [doi]
PST - ppublish
SO  - J Neurochem. 1998 Oct;71(4):1635-42. doi: 10.1046/j.1471-4159.1998.71041635.x.

PMID- 8915104
OWN - NLM
STAT- MEDLINE
DCOM- 19961212
LR  - 20190905
IS  - 0365-6233 (Print)
IS  - 0365-6233 (Linking)
VI  - 329
IP  - 8-9
DP  - 1996 Aug-Sep
TI  - The potential of aspirin in prodrug synthesis: a new potential delivery system of 
      AZT and FLT.
PG  - 417-20
AB  - Aspirin (O-acetylsalicylic acid) has been used to synthesize prodrugs of 
      3'-azido-3'-deoxythymidine (AZT) and 3'-deoxy-3'-fluorothymidine (FLT). The mixed 
      anhydride between aspirin and trifluoroacetic acid was synthesized and reacted 
      with AZT and FLT to give the blocked nucleosides attached through the 5'-O 
      position to the 2-position of 2-methyl-4H-1,3-benzodioxin-4-one. The prodrugs 
      showed the same activities against HIV-1 in MT-4 cells as the original drugs. 
      Hydrolysis of the synthesized prodrugs in the growth medium, used for anti-HIV 
      investigations, resulted in formation of 5-O acetylated drugs which were 
      subsequently hydrolyzed into the original drugs.
FAU - Zahran, M A
AU  - Zahran MA
AD  - Department of Chemistry, Odense University, Denmark.
FAU - Kovács, L
AU  - Kovács L
FAU - el Sakka, I
AU  - el Sakka I
FAU - Pedersen, E B
AU  - Pedersen EB
FAU - Nielsen, C
AU  - Nielsen C
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arch Pharm (Weinheim)
JT  - Archiv der Pharmazie
JID - 0330167
RN  - 0 (Antiviral Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (Prodrugs)
RN  - 4B9XT59T7S (Zidovudine)
RN  - PG53R0DWDQ (alovudine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antiviral Agents/*metabolism
MH  - Aspirin/*metabolism
MH  - Dideoxynucleosides/*metabolism
MH  - *Drug Delivery Systems
MH  - Humans
MH  - Prodrugs/*chemical synthesis
MH  - Zidovudine/*metabolism
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - 10.1002/ardp.19963290809 [doi]
PST - ppublish
SO  - Arch Pharm (Weinheim). 1996 Aug-Sep;329(8-9):417-20. doi: 
      10.1002/ardp.19963290809.

PMID- 19419262
OWN - NLM
STAT- MEDLINE
DCOM- 20090824
LR  - 20131121
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 7
IP  - 5
DP  - 2009 May
TI  - Platelet perturbations in diabetes: implications for cardiovascular disease risk 
      and treatment.
PG  - 541-9
LID - 10.1586/erc.09.30 [doi]
AB  - The prevalence of Type 2 diabetes mellitus (DM) continues to increase globally 
      and brings with it a parallel increase in the associated cardiovascular disease 
      complications. Despite advances in evidence-based therapies for cardiovascular 
      disease risk modification, many of which are especially effective among patients 
      with DM, there remains a residual degree of cardiovascular disease risk 
      associated with DM, yielding opportunity for continued clinical advances. Given 
      the myriad perturbations of platelet function associated with DM, improvements in 
      antiplatelet therapies hold particular promise for this high-risk population of 
      patients, with emerging data from ex vivo assessments and clinical outcomes 
      trials providing a basis of support for this concept.
FAU - Mathewkutty, Shiny
AU  - Mathewkutty S
AD  - Department of Internal Medicine, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - McGuire, Darren K
AU  - McGuire DK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/*physiology
MH  - Cardiovascular Diseases/*drug therapy/etiology
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Humans
MH  - Platelet Activation
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Pyridines/pharmacology/therapeutic use
MH  - Risk
RF  - 85
EDAT- 2009/05/08 09:00
MHDA- 2009/08/25 09:00
CRDT- 2009/05/08 09:00
PHST- 2009/05/08 09:00 [entrez]
PHST- 2009/05/08 09:00 [pubmed]
PHST- 2009/08/25 09:00 [medline]
AID - 10.1586/erc.09.30 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2009 May;7(5):541-9. doi: 10.1586/erc.09.30.

PMID- 9023498
OWN - NLM
STAT- MEDLINE
DCOM- 19970522
LR  - 20191101
IS  - 0969-9546 (Print)
IS  - 0969-9546 (Linking)
VI  - 3
IP  - 3
DP  - 1996 Sep
TI  - Comparative study of the efficacy of lysine acetylsalicylate, indomethacin and 
      pethidine in acute renal colic.
PG  - 183-6
AB  - The aim of this study was to compare the analgesic efficacy of intravenous lysine 
      acetylsalicylate 1.8 g, indomethacin 100 mg and pethidine 100 mg in acute renal 
      colic in a randomized double-blind clinical trial. One hundred and fifty patients 
      with acute renal colic were divided into three groups. The first group received 
      lysine acetylsalicylate 1.8 g, the second group received indomethacin 100 mg and 
      the third group received pethidine 100 mg. The degree of pain relief was recorded 
      5, 15, 30 and 60 min after intravenous administration of the drugs. There was no 
      statistically significant difference between the degree of analgesia provided by 
      pethidine and indomethacin. Lysine acetylsalicylate was less effective than 
      indomethacin and pethidine. It is concluded that intravenous indomethacin is an 
      effective alternative to intravenous pethidine in the treatment of acute renal 
      colic. Intravenous lysine acetylsalicylate is inferior to intravenous 
      indomethacin in treatment of acute renal colic.
FAU - al-Sahlawi, K S
AU  - al-Sahlawi KS
AD  - Department of Emergency, Mubarak Al-Kabeer Hospital, Kuwait.
FAU - Tawfik, O M
AU  - Tawfik OM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Eur J Emerg Med
JT  - European journal of emergency medicine : official journal of the European Society 
      for Emergency Medicine
JID - 9442482
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 9E338QE28F (Meperidine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Analgesics/*therapeutic use
MH  - Analgesics, Opioid/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Colic/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Indomethacin/*therapeutic use
MH  - Kidney Diseases/*drug therapy
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Meperidine/*therapeutic use
MH  - Middle Aged
MH  - Pain Measurement
MH  - Time Factors
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - 10.1097/00063110-199609000-00008 [doi]
PST - ppublish
SO  - Eur J Emerg Med. 1996 Sep;3(3):183-6. doi: 10.1097/00063110-199609000-00008.

PMID- 6445604
OWN - NLM
STAT- MEDLINE
DCOM- 19800722
LR  - 20131121
IS  - 0039-6060 (Print)
IS  - 0039-6060 (Linking)
VI  - 87
IP  - 6
DP  - 1980 Jun
TI  - Antithrombotic therapy for vascular prosthesis: an experimental model testing 
      platelet inhibitory drugs.
PG  - 668-76
AB  - Although Dacron vascular grafts are widely used, they are thrombogenic and rapid 
      blood flow maintains patency. When blood flow is suboptimal, antithrombotic 
      therapy may prevent early occlusion. We evaluated the effect of three platelet 
      inhibitory drugs: acetylsalicylic acid (ASA), dipyridamole (DPM), sulphinpyrazone 
      (SPZ), and a combination of ASA plus DPM on platelet adherence to woven Dacron in 
      an artificial circulation. Heparinized blood from 18 volunteers was divided 
      equally for test and control circuits, and to the test each drug was added in 
      therapeutic concentration. The experiment was repeated ex vivo using blood 
      donated by six volunteers after each had taken, separately for 1 week: (1) no 
      drug; (2) ASA, 300 mg, three times a day; (3) DPM, 100 mg, four times a day; (4) 
      SPZ, 200 mg, four times a day; (5) ASA, 300 mg, plus DPM, 75 mg, combined, three 
      times a day. Platelet count, adhesion and aggregation were measured during the 
      60-minute perfusion, and scanning electron miscroscopy of the graft's luminal 
      surface was performed. ASA was the most effective single agent, significantly 
      impairing platelet function and reducing consumption of platelets by the graft. 
      DPM reduced platelet adherence only in the ex vivo experiment, and its addition 
      to ASA imparted no further influence. Sulphinpyrazone had little effect in either 
      experiment. Antithrombotic therapy with ASA and DPM requires clinical evaluation.
FAU - McCollum, C N
AU  - McCollum CN
FAU - Crow, M J
AU  - Crow MJ
FAU - Rajah, S M
AU  - Rajah SM
FAU - Kester, R C
AU  - Kester RC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
RN  - 0 (Polyethylene Terephthalates)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Circulation
MH  - Blood Platelets/*drug effects/ultrastructure
MH  - *Blood Vessel Prosthesis
MH  - Dipyridamole/administration & dosage/*pharmacology
MH  - Humans
MH  - Methods
MH  - Microscopy, Electron, Scanning
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - *Polyethylene Terephthalates
MH  - Sulfinpyrazone/administration & dosage/*pharmacology
MH  - Thrombosis/prevention & control
EDAT- 1980/06/01 00:00
MHDA- 1980/06/01 00:01
CRDT- 1980/06/01 00:00
PHST- 1980/06/01 00:00 [pubmed]
PHST- 1980/06/01 00:01 [medline]
PHST- 1980/06/01 00:00 [entrez]
AID - 0039-6060(80)90061-6 [pii]
PST - ppublish
SO  - Surgery. 1980 Jun;87(6):668-76.

PMID- 27383649
OWN - NLM
STAT- MEDLINE
DCOM- 20170228
LR  - 20170817
IS  - 1556-9519 (Electronic)
IS  - 1556-3650 (Linking)
VI  - 54
IP  - 9
DP  - 2016 Nov
TI  - Absorption of salicylate powders versus tablets following overdose: a poison 
      center observational study.
PG  - 857-861
AB  - BACKGROUND: Salicylate absorption following overdose of aspirin (ASA) tablet 
      formulations can be prolonged for greater than 24 h. Accordingly, serial serum 
      concentrations are typically recommended to guide treatment. However, there are 
      little published data on absorption following ingestion of powder ASA 
      formulations, and it is not known if delayed ASA absorption occurs following 
      overdose of powder formulations. The objective of this study is to compare the 
      absorption characteristics of powder and tablet formulations of ASA in patients 
      reported to a single poison center. METHODS: Electronic records from an 
      accredited poison center were searched for single substance acute or acute on 
      chronic ingestions of ASA in powder form between 1 January 2002 and 31 January 
      2014. An identical search for ingestions of ASA tablet products between 1 January 
      2012 and 31 December 2013 was undertaken as the comparator group. Other inclusion 
      criteria were age >12 years, documented time of ingestion, treatment in a health 
      care facility within nine hours of ingestion and at least two detectable serum 
      salicylate concentrations. RESULTS: 16 of 25 powder and 22 of 49 tablet cases met 
      inclusion criteria for analysis. Repeat serum salicylate concentrations following 
      ingestion of tablets increased or insignificantly changed in 11 of 22 (50%) 
      cases, and median serum salicylate concentrations in followed cases remained 
      elevated for up to 12 h in some cases. In comparison, serum salicylate 
      concentrations following powder ingestions declined in 15 of 16 (94%) cases. One 
      patient, who ingested a powder product, underwent hemodialysis pursuant to an 
      initial serum salicylate concentration of 96 mg/dL. CONCLUSIONS: In contrast to 
      persistent concentrations following overdose of tablets, the majority of serum 
      salicylate concentrations declined following ingestion of powder formulations. In 
      this small study population, these findings suggest that prolonged absorption is 
      unlikely following ingestions of ASA powders.
FAU - Rose, S Rutherfoord
AU  - Rose SR
AD  - a Division of Clinical Toxicology, Department of Emergency Medicine, Virginia 
      Poison Center , Virginia Commonwealth University , Richmond , VA , USA.
FAU - Cumpston, Kirk L
AU  - Cumpston KL
AD  - a Division of Clinical Toxicology, Department of Emergency Medicine, Virginia 
      Poison Center , Virginia Commonwealth University , Richmond , VA , USA.
FAU - Kim, Janice
AU  - Kim J
AD  - a Division of Clinical Toxicology, Department of Emergency Medicine, Virginia 
      Poison Center , Virginia Commonwealth University , Richmond , VA , USA.
FAU - Difranco, Danielle
AU  - Difranco D
AD  - a Division of Clinical Toxicology, Department of Emergency Medicine, Virginia 
      Poison Center , Virginia Commonwealth University , Richmond , VA , USA.
FAU - Wills, Brandon K
AU  - Wills BK
AD  - a Division of Clinical Toxicology, Department of Emergency Medicine, Virginia 
      Poison Center , Virginia Commonwealth University , Richmond , VA , USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20160706
PL  - England
TA  - Clin Toxicol (Phila)
JT  - Clinical toxicology (Philadelphia, Pa.)
JID - 101241654
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Powders)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/pharmacokinetics/*poisoning
MH  - Aspirin/administration & dosage/pharmacokinetics/*poisoning
MH  - Drug Overdose
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Poison Control Centers
MH  - Powders
MH  - Renal Dialysis/methods
MH  - Retrospective Studies
MH  - Salicylates/*blood
MH  - Tablets
MH  - Time Factors
MH  - Young Adult
OTO - NOTNLM
OT  - ASA
OT  - Absorption
OT  - dosage form
OT  - formulation
OT  - serum concentration
EDAT- 2016/07/08 06:00
MHDA- 2017/03/01 06:00
CRDT- 2016/07/08 06:00
PHST- 2016/07/08 06:00 [pubmed]
PHST- 2017/03/01 06:00 [medline]
PHST- 2016/07/08 06:00 [entrez]
AID - 10.1080/15563650.2016.1204549 [doi]
PST - ppublish
SO  - Clin Toxicol (Phila). 2016 Nov;54(9):857-861. doi: 10.1080/15563650.2016.1204549. 
      Epub 2016 Jul 6.

PMID- 8832303
OWN - NLM
STAT- MEDLINE
DCOM- 19961226
LR  - 20131121
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 34
IP  - 7
DP  - 1996 Jul
TI  - Lack of influence of glycine on the single dose pharmacokinetics of 
      acetylsalicylic acid in man.
PG  - 282-7
AB  - Galenic formulations consisting of acetylsalicylic acid and glycine were 
      developed to improve solubility of the drug, even in case of ingestion without 
      intake of water. It was the aim of this study to investigate the potential 
      influence of glycine on pharmacokinetics after single oral administration of 
      1,000 mg of acetylsalicylic acid. Therefore, a bioequivalence study using a 
      randomized crossover design (reference = without glycine, test = with glycine) in 
      12 healthy male volunteers (age 22 - 38 (median 26) years, body weight 64 - 83 
      (median 75) kg) was performed. Pharmacokinetic characteristics (AUC, Cmax, tmax, 
      t1/2, MRT) were taken or calculated on the basis of plasma concentration/time 
      profiles. For both acetylsalicylic acid and salicylic acid the 90% confidence 
      intervals of the ratios of the expected median values (microT and microR) for the 
      primary characteristics AUC and Cmax of the test and reference formulation were 
      included in the equivalence range of 80 - 125%, which in case of multiplicative 
      model is accepted for concluding bioequivalence. Therefore, lack of influence of 
      glycine on the pharmacokinetics of acetylsalicylic acid including its major 
      metabolite salicylic acid was concluded.
FAU - Schurer, M
AU  - Schurer M
AD  - LAFAA Laboratory for Contract Research in Clinical Pharmacology and 
      Biopharmaceutical Analytics GmbH, Bad Schwartau, Germany.
FAU - Bias-Imhoff, U
AU  - Bias-Imhoff U
FAU - Schulz, H U
AU  - Schulz HU
FAU - Schwantes, U
AU  - Schwantes U
FAU - Riechers, A M
AU  - Riechers AM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/blood/*pharmacokinetics
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Glycine/*pharmacology
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Therapeutic Equivalency
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 1996 Jul;34(7):282-7.

PMID- 26151751
OWN - NLM
STAT- MEDLINE
DCOM- 20160408
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 7
DP  - 2015
TI  - Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit 
      and Harm Analysis.
PG  - e0127194
LID - 10.1371/journal.pone.0127194 [doi]
LID - e0127194
AB  - BACKGROUND: Aspirin is widely used for prevention of cardiovascular disease. In 
      recent years randomized trials also suggested a preventive effect for various 
      types of cancer. We aimed to assess, in a quantitative way, benefits and harms of 
      aspirin for primary prevention of both cardiovascular disease and cancer for a 
      general US population between 40 and 85 years of age. METHODS: We used the 
      Gail/National Cancer Institute approach for assessing benefits and harms. This 
      approach provides a probability that a treatment is more beneficial than harmful 
      and incorporates multiple outcomes, the importance of these outcomes, considers 
      different outcome risks and treats mortality as a competing risk. Our main 
      outcomes were the risks of seven types of cancer, myocardial infarction, ischemic 
      and hemorrhagic stroke and gastrointestinal bleeding. We obtained effect 
      estimates from recent meta-analyses of randomized trials and used baseline risks 
      from the Centers for Disease Control. We conducted four sensitivity analyses to 
      assess the influence of different assumptions about outcome risks and preferences 
      and considered the sampling variation of the effect estimates for aspirin. 
      RESULTS: The main analysis as well as the sensitivity analyses showed that 
      aspirin has more benefits than harms. In the main analysis, the index (positive 
      if number of prevented events > excess number of harm events over 10 years per 
      1,000 persons) ranged from 2 (95% CI 0.0 to 11.8; in women age 45 to 54 years) to 
      8 (95% CI -0.1 to 83.7; in men age 65 to 74 years). In the sensitivity analyses, 
      the index was also positive for all age categories suggesting more benefits than 
      harms. CONCLUSION: This study suggests an overall benefit of aspirin for primary 
      prevention of cardiovascular disease and cancer based on population-based data. 
      For individual preventive counseling, additional benefit harm analyses should 
      explore which individuals should or should not take aspirin based on their risk 
      profile for cardiovascular, cancer and gastrointestinal outcomes and based on 
      their outcome preferences. Thereby, risk-stratified and preference-sensitive 
      prevention could become a reality.
FAU - Stegeman, Inge
AU  - Stegeman I
AD  - Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, 
      Amsterdam, The Netherlands; Department of Otorhinolaryngology-Head and Neck 
      Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Bossuyt, Patrick M
AU  - Bossuyt PM
AD  - Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, 
      Amsterdam, The Netherlands.
FAU - Yu, Tsung
AU  - Yu T
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, Maryland, United States of America.
FAU - Boyd, Cynthia
AU  - Boyd C
AD  - School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States 
      of America.
FAU - Puhan, Milo A
AU  - Puhan MA
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, Maryland, United States of America; Epidemiology, Biostatistics and 
      Prevention Institute, University of Zurich, Zurich, Switzerland.
LA  - eng
GR  - K23 AG032910/AG/NIA NIH HHS/United States
GR  - 1K23AG032910/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150707
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/metabolism/pathology/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/metabolism/pathology/*prevention & control
MH  - Primary Prevention
MH  - Risk Assessment
PMC - PMC4494891
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/07/08 06:00
MHDA- 2016/04/09 06:00
CRDT- 2015/07/08 06:00
PHST- 2014/01/02 00:00 [received]
PHST- 2015/04/13 00:00 [accepted]
PHST- 2015/07/08 06:00 [entrez]
PHST- 2015/07/08 06:00 [pubmed]
PHST- 2016/04/09 06:00 [medline]
AID - PONE-D-13-52201 [pii]
AID - 10.1371/journal.pone.0127194 [doi]
PST - epublish
SO  - PLoS One. 2015 Jul 7;10(7):e0127194. doi: 10.1371/journal.pone.0127194. 
      eCollection 2015.

PMID- 32012310
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 75
IP  - 7
DP  - 2020 Jul
TI  - Artificial neural network identifies nonsteroidal anti-inflammatory drugs 
      exacerbated respiratory disease (N-ERD) cohort.
PG  - 1649-1658
LID - 10.1111/all.14214 [doi]
AB  - BACKGROUND: To date, there has been no reliable in vitro test to either diagnose 
      or differentiate nonsteroidal anti-inflammatory drug (NSAID)-exacerbated 
      respiratory disease (N-ERD). The aim of the present study was to develop and 
      validate an artificial neural network (ANN) for the prediction of N-ERD in 
      patients with asthma. METHODS: This study used a prospective database of patients 
      with N-ERD (n = 121) and aspirin-tolerant (n = 82) who underwent aspirin 
      challenge from May 2014 to May 2018. Eighteen parameters, including clinical 
      characteristics, inflammatory phenotypes based on sputum cells, as well as 
      eicosanoid levels in induced sputum supernatant (ISS) and urine were extracted 
      for the ANN. RESULTS: The validation sensitivity of ANN was 94.12% 
      (80.32%-99.28%), specificity was 73.08% (52.21%-88.43%), and accuracy was 85.00% 
      (77.43%-92.90%) for the prediction of N-ERD. The area under the receiver 
      operating curve was 0.83 (0.71-0.90). CONCLUSIONS: The designed ANN model seems 
      to have powerful prediction capabilities to provide diagnosis of N-ERD. Although 
      it cannot replace the gold-standard aspirin challenge test, the implementation of 
      the ANN might provide an added value for identification of patients with N-ERD. 
      External validation in a large cohort is needed to confirm our results.
CI  - © 2020 The Authors. Allergy published by John Wiley & Sons Ltd.
FAU - Tyrak, Katarzyna Ewa
AU  - Tyrak KE
AD  - 2nd Department of Internal Medicine, Jagiellonian University Medical College, 
      Cracow, Poland.
FAU - Pajdzik, Kinga
AU  - Pajdzik K
AD  - 2nd Department of Internal Medicine, Jagiellonian University Medical College, 
      Cracow, Poland.
FAU - Konduracka, Ewa
AU  - Konduracka E
AD  - Coronary and Heart Failure Department, Jagiellonian University School of 
      Medicine, John Paul II Hospital, Cracow, Poland.
FAU - Ćmiel, Adam
AU  - Ćmiel A
AD  - Department of Applied Mathematics, AGH University of Science and Technology, 
      Cracow, Poland.
FAU - Jakieła, Bogdan
AU  - Jakieła B
AD  - 2nd Department of Internal Medicine, Jagiellonian University Medical College, 
      Cracow, Poland.
FAU - Celejewska-Wójcik, Natalia
AU  - Celejewska-Wójcik N
AD  - 2nd Department of Internal Medicine, Jagiellonian University Medical College, 
      Cracow, Poland.
FAU - Trąd, Gabriela
AU  - Trąd G
AD  - 2nd Department of Internal Medicine, Jagiellonian University Medical College, 
      Cracow, Poland.
FAU - Kot, Adrianna
AU  - Kot A
AD  - 2nd Department of Internal Medicine, Jagiellonian University Medical College, 
      Cracow, Poland.
FAU - Urbańska, Anna
AU  - Urbańska A
AD  - 2nd Department of Internal Medicine, Jagiellonian University Medical College, 
      Cracow, Poland.
FAU - Zabiegło, Ewa
AU  - Zabiegło E
AD  - 2nd Department of Internal Medicine, Jagiellonian University Medical College, 
      Cracow, Poland.
FAU - Kacorzyk, Radosław
AU  - Kacorzyk R
AD  - 2nd Department of Internal Medicine, Jagiellonian University Medical College, 
      Cracow, Poland.
FAU - Kupryś-Lipińska, Izabela
AU  - Kupryś-Lipińska I
AD  - Department of Internal Medicine, Asthma and Allergy, Medical University of Łódź, 
      Łódź, Poland.
FAU - Oleś, Krzysztof
AU  - Oleś K
AD  - Department of Oncological and Reconstructive Surgery, The Maria Sklodowska-Curie 
      Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
FAU - Kuna, Piotr
AU  - Kuna P
AD  - Department of Internal Medicine, Asthma and Allergy, Medical University of Łódź, 
      Łódź, Poland.
FAU - Sanak, Marek
AU  - Sanak M
AUID- ORCID: 0000-0001-7635-8103
AD  - 2nd Department of Internal Medicine, Jagiellonian University Medical College, 
      Cracow, Poland.
FAU - Mastalerz, Lucyna
AU  - Mastalerz L
AUID- ORCID: 0000-0002-8994-0036
AD  - 2nd Department of Internal Medicine, Jagiellonian University Medical College, 
      Cracow, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200303
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pharmaceutical Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/adverse effects
MH  - Humans
MH  - Neural Networks, Computer
MH  - *Pharmaceutical Preparations
MH  - *Respiration Disorders
PMC - PMC7383769
OTO - NOTNLM
OT  - artificial neural network
OT  - aspirin-tolerant asthma
OT  - induced sputum
OT  - nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease 
      (N-ERD)
OT  - support vector machines
COIS- None of the authors have a conflict of interest in relation to this work.
EDAT- 2020/02/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/02/04 06:00
PHST- 2019/06/24 00:00 [received]
PHST- 2019/12/16 00:00 [revised]
PHST- 2020/01/02 00:00 [accepted]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/02/04 06:00 [entrez]
AID - ALL14214 [pii]
AID - 10.1111/all.14214 [doi]
PST - ppublish
SO  - Allergy. 2020 Jul;75(7):1649-1658. doi: 10.1111/all.14214. Epub 2020 Mar 3.

PMID- 16640028
OWN - NLM
STAT- MEDLINE
DCOM- 20060613
LR  - 20161021
IS  - 1211-4286 (Print)
IS  - 1211-4286 (Linking)
VI  - 48
IP  - 3-4
DP  - 2005
TI  - Comparison of the effects on spinal reflexes of acetylsalicylate and metamizol in 
      spinalized and normal rats.
PG  - 149-52
AB  - The effects of nonsteroidal antiinflammatory drugs, acetylsalicylate and 
      metamizol, on spinal monosynaptic reflexes were investigated in spinalized and 
      normal rats. Adult rats (n=36) weighing 150-200 g were anesthetized with ketamine 
      and artificially ventilated. Half of rats were spinalized at C1 level. A 
      laminectomy was performed in the lumbosacral region. Following electrical 
      stimulation of the sciatic nerve by single pulses, reflex potentials were 
      recorded from the ipsilateral L5 ventral root. Acetylsalicylate was administered 
      orally (100 mg/kg for both spinalized and normal rats). Metamizol was 
      administered intramuscularly (15 mg/kg for both spinalized and normal rats). 
      These drug administrations significantly decreased the amplitude of reflex 
      response in all groups (p < 0.05). These data verify that observed inhibition by 
      acetylsalicylicate and metamizol may be at the level of spinal cord. Also we 
      suggested that the cyclooxygenase products of arachidonic acid may play an 
      important role in regulating the reflex potential.
FAU - Genć, Osman
AU  - Genć O
AD  - Pamukkale University, Faculty of Medicine, Department of Physiology, Denizli, 
      Turkey. ogenc@pamukkale.edu.tr
FAU - Turgut, Sebahat
AU  - Turgut S
FAU - Turgut, Günfer
AU  - Turgut G
FAU - Kortunay, Selim
AU  - Kortunay S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Czech Republic
TA  - Acta Medica (Hradec Kralove)
JT  - Acta medica (Hradec Kralove)
JID - 9705947
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cordotomy
MH  - Dipyrone/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Reflex, Monosynaptic/*drug effects
EDAT- 2006/04/28 09:00
MHDA- 2006/06/14 09:00
CRDT- 2006/04/28 09:00
PHST- 2006/04/28 09:00 [pubmed]
PHST- 2006/06/14 09:00 [medline]
PHST- 2006/04/28 09:00 [entrez]
PST - ppublish
SO  - Acta Medica (Hradec Kralove). 2005;48(3-4):149-52.

PMID- 1979886
OWN - NLM
STAT- MEDLINE
DCOM- 19910207
LR  - 20181113
IS  - 0112-1642 (Print)
IS  - 0112-1642 (Linking)
VI  - 10
IP  - 5
DP  - 1990 Nov
TI  - Plantar fasciitis in runners. Treatment and prevention.
PG  - 338-45
AB  - Plantar fasciitis is a common overuse injury found in runners. The plantar 
      fascia, which is responsible for maintaining the integrity of the longitudinal 
      arch, becomes irritated, inflamed or torn by repetitive stresses placed upon it. 
      Commonly cited predisposers of plantar fasciitis are excessive pronation, a flat 
      or cavus foot, tight Achilles tendon, type of training shoes worn, and errors in 
      the training routine. Once the plantar fascia becomes irritated a myriad of 
      conservative measures may be used, including everything from rest, ice and 
      elevation to steroid injections and, if all else fails, surgery. In most cases 
      conservative treatment of one kind or another will alleviate the symptoms of 
      plantar fasciitis. However, it is essential to determine and correct the cause of 
      the problem in order for the runner to resume normal activity levels. Controlling 
      anatomical/biomechanical inefficiencies of the feet, stretching and strengthening 
      exercises for the lower extremity, proper training shoes, and reasonable training 
      routines will alleviate the symptoms of plantar fasciitis in a large percentage 
      of sufferers. To prevent this injury, runners should be aware of the potential 
      overuse injury and take precautionary measures, e.g. seek a 
      biomechanical/anatomical evaluation from a qualified practitioner. The 
      practitioner can then offer suggestions as to the specific steps the runner 
      should follow to prevent the injury condition.
FAU - Warren, B L
AU  - Warren BL
AD  - Department of Human Performance and Health Promotion, University of New Orleans, 
      Louisiana.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Sports Med
JT  - Sports medicine (Auckland, N.Z.)
JID - 8412297
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Biomechanical Phenomena
MH  - Fasciitis/physiopathology/prevention & control/*therapy
MH  - *Foot Injuries
MH  - Humans
MH  - Orthotic Devices
MH  - Rest
MH  - Running/*injuries
MH  - Shoes
RF  - 43
EDAT- 1990/11/01 00:00
MHDA- 1990/11/01 00:01
CRDT- 1990/11/01 00:00
PHST- 1990/11/01 00:00 [pubmed]
PHST- 1990/11/01 00:01 [medline]
PHST- 1990/11/01 00:00 [entrez]
AID - 10.2165/00007256-199010050-00004 [doi]
PST - ppublish
SO  - Sports Med. 1990 Nov;10(5):338-45. doi: 10.2165/00007256-199010050-00004.

PMID- 530287
OWN - NLM
STAT- MEDLINE
DCOM- 19800425
LR  - 20131121
IS  - 0540-889X (Print)
IS  - 0540-889X (Linking)
VI  - 19
IP  - 4
DP  - 1979 Oct
TI  - [Experimental model for the study of the teratogenic interaction of chemical 
      agents and drugs (toluene and acetylsalicylic acid)].
PG  - 299-304
AB  - On the 10th-13th days of pregnancy toluene (3600 mg/m3) by inhalation) and on 
      12th day acetylsalicylic acid (500 mg/kg of body weight per os) were administered 
      to CFY rats and the common effect of these agents was studied. It was established 
      that: 1. the maternal toxicity increased, i.e. increased the mortality rate, 
      decreased the consumption of the food and the gain of weight, increased the 
      relative weight of the liver; 2. the foetal toxicity increased, i.e. increased 
      the mortality rate of foetuses, the rate of the loss of the body weight, the 
      number of the anomalies of the sternum and the incidence of the supernumerary 
      ribs. It is believed, that the non-teratogenic toluene rises the utilization of 
      the glycine and the level of the free salicylic-acid, consequently the 
      embryotoxic effect of the acetylsalicylic-acid. The danger of the occurrence of 
      malformations as an effect of interaction of chemical agents and drugs taken in 
      therapeutic doses is stressed.
FAU - Tátrai, E
AU  - Tátrai E
FAU - Hudák, A
AU  - Hudák A
FAU - Ungváry, G
AU  - Ungváry G
LA  - hun
PT  - English Abstract
PT  - Journal Article
TT  - Modellkísérlet munkahelyi vegyi anyagok és gyógyszerek torzkelto interakciójának 
      vizsgálatára (toluol és acetilszalicilsav).
PL  - Hungary
TA  - Morphol Igazsagugyi Orv Sz
JT  - Morphologiai es igazsagugyi orvosi szemle
JID - 0400757
RN  - 0 (Teratogens)
RN  - 3FPU23BG52 (Toluene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Drug Interactions
MH  - Female
MH  - Models, Biological
MH  - Pregnancy
MH  - Rats
MH  - Teratogens
MH  - Toluene/*toxicity
EDAT- 1979/10/01 00:00
MHDA- 1979/10/01 00:01
CRDT- 1979/10/01 00:00
PHST- 1979/10/01 00:00 [pubmed]
PHST- 1979/10/01 00:01 [medline]
PHST- 1979/10/01 00:00 [entrez]
PST - ppublish
SO  - Morphol Igazsagugyi Orv Sz. 1979 Oct;19(4):299-304.

PMID- 94873
OWN - NLM
STAT- MEDLINE
DCOM- 19800815
LR  - 20131121
IS  - 0323-4347 (Print)
IS  - 0323-4347 (Linking)
VI  - 106
IP  - 5-6
DP  - 1979
TI  - [Study of the platelet aggregation inhibitor MICRISTIN as to its efficacy in the 
      prevention of thromboembolism in the postoperative phase following surgical 
      interventions].
PG  - 810-27
AB  - Clinical test of the acetylsalicylic acid preparation micristin concerning effect 
      and side-effect on the postoperative rate of thromboembolism in general surgery 
      and traumatology. Prospective, randomized, checked double-blind study in 802 
      operated patients: 401 patients with micristin and 401 patients with placebo. 
      Objectivization of findings in highly endangered patients by the radiofibrinogen 
      test, ultrasonic doubler, venography of contrast medium, section. In total there 
      were 149 thromboembolic complications = 18.6%. The placebo control group (401 
      patients) had 52 ensured deep venothrombosises and 8 fatal pulmonary embolisms. 
      The group with micristin treatment (401 patients) had 23 ensured deep 
      venothrombosises and 4 fatal pulmonary embolisms. Significant decrease of the 
      thromboembolism rate by micristin (p = 0.001). Failures concerning the effect of 
      micristin included fractures near the hip. Favourable effects concerned 
      intra-abdominal surgery. Frequent side-effect: increased intra-operative and 
      postoperative bleeding tendency.
FAU - Hartung, B
AU  - Hartung B
FAU - Schreiber, U
AU  - Schreiber U
FAU - Rödiger, H
AU  - Rödiger H
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Testung des Thrombozytenaggregationshemmers MICRISTIN auf seine Wirksamkeit als 
      Thromboembolieprophylaktikum in der postoperativen Phase nach chirurgischen 
      Eingriffen.
PL  - Germany
TA  - Folia Haematol Int Mag Klin Morphol Blutforsch
JT  - Folia haematologica (Leipzig, Germany : 1928)
JID - 0374615
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Postoperative Complications/prevention & control
MH  - Thromboembolism/*prevention & control
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):810-27.

PMID- 1338656
OWN - NLM
STAT- MEDLINE
DCOM- 19930525
LR  - 20131121
IS  - 0032-3756 (Print)
IS  - 0032-3756 (Linking)
VI  - 47
IP  - 42-43
DP  - 1992 Oct 19-26
TI  - [The effect of suloctidil and acetylsalicylic acid on eicosanoid synthesis in 
      human platelets].
PG  - 970-1
AB  - The study aimed at comparing an effect of suloctidil and acetylsalicylic acid on 
      malonyldialdehyde levels resulting from the arachidonic acid metabolism in blood 
      platelets. It was shown that inhibitory effect of suloctidil is more potent than 
      that of acetylsalicylic acid. Therefore the first is more inhibitor of an 
      enzymatic metabolism of arachidonate in blood platelets than the latter.
FAU - Tkaczewski, W
AU  - Tkaczewski W
AD  - III Kliniki Chorób Wewnetrznych IMW.
FAU - Buczyński, A
AU  - Buczyński A
FAU - Dziedziczak-Buczyńska, M
AU  - Dziedziczak-Buczyńska M
FAU - Wachowicz, B
AU  - Wachowicz B
FAU - Kedziora, J
AU  - Kedziora J
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Wpływ syloktydylu i kwasu acetylosalicylowego na synteze prostanoidów w krwinkach 
      płytkowych człowieka.
PL  - Poland
TA  - Pol Tyg Lek
JT  - Polski tygodnik lekarski (Warsaw, Poland : 1960)
JID - 9705468
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
RN  - XV1N1XY17K (Suloctidil)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/enzymology
MH  - Humans
MH  - Malondialdehyde/*blood
MH  - Suloctidil/*pharmacology
EDAT- 1992/10/19 00:00
MHDA- 1992/10/19 00:01
CRDT- 1992/10/19 00:00
PHST- 1992/10/19 00:00 [pubmed]
PHST- 1992/10/19 00:01 [medline]
PHST- 1992/10/19 00:00 [entrez]
PST - ppublish
SO  - Pol Tyg Lek. 1992 Oct 19-26;47(42-43):970-1.

PMID- 2754674
OWN - NLM
STAT- MEDLINE
DCOM- 19890901
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 16
IP  - 5
DP  - 1989 May
TI  - Hypercholesterolemic (type II hyperlipoproteinemic) arthritis.
PG  - 703-5
AB  - The rheumatic manifestations of familial hypercholesterolemia include recurrent 
      Achilles pain or tendinitis, acute mono/oligoarthritis and migratory (rheumatic 
      fever-like) polyarthritis. Diagnosis is made by finding skin and tendon 
      xanthomas, hypercholesterolemia, and ruling out other rheumatic conditions such 
      as rheumatic fever, gout, pseudogout and septic arthritis. A patient, homozygous 
      for familial hypercholesterolemia, with a rheumatic fever-like migratory 
      arthritis is presented.
FAU - Rimon, D
AU  - Rimon D
AD  - Department of Internal Medicine B, Faculty of Medicine, Technion-Israel Institute 
      of Technology, Lady Davis Carmel Hospital, Haifa.
FAU - Cohen, L
AU  - Cohen L
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arthritis/*complications/drug therapy
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Hyperlipoproteinemia Type II/*complications
MH  - Male
MH  - Xanthomatosis/complications
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1989 May;16(5):703-5.

PMID- 1530680
OWN - NLM
STAT- MEDLINE
DCOM- 19921020
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 42
IP  - 5
DP  - 1992 May
TI  - Gastric potential difference measurement as a quantification of gastrointestinal 
      tolerability comparing a buffered acetylsalicylic acid formulation versus plain 
      acetylsalicylic acid.
PG  - 650-3
AB  - Two different acetylsalicylic acid (ASA, CAS 50-78-2) formulations (Aspirin) were 
      compared regarding their gastric mucosal tolerability. After administration of 
      plain ASA, buffered ASA and ASA placebo the decrease of gastric potential 
      difference (GPD) was measured. Evaluation of the GPD parameters showed a better 
      tolerability of buffered ASA than of plain ASA. It was therefore concluded that 
      buffered ASA effects less gastric mucosal irritation than plain ASA.
FAU - Jost, V
AU  - Jost V
AD  - Institut für klinische Pharmakologie Bobenheim, Prof. Dr. Lücker GmbH, Grünstadt, 
      Fed. Rep. of Germany.
FAU - Kuhn, I
AU  - Kuhn I
FAU - Rogalla, K
AU  - Rogalla K
FAU - Theiss, U
AU  - Theiss U
FAU - Lücker, P W
AU  - Lücker PW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Buffers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Buffers
MH  - Digestive System/*drug effects
MH  - Gastric Mucosa/chemistry/drug effects
MH  - Humans
MH  - Male
MH  - Membrane Potentials/drug effects
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1992 May;42(5):650-3.

PMID- 2688044
OWN - NLM
STAT- MEDLINE
DCOM- 19900116
LR  - 20131121
IS  - 0035-2640 (Print)
IS  - 0035-2640 (Linking)
VI  - 39
IP  - 25
DP  - 1989 Nov 1
TI  - [Platelet antiaggregants in cerebral ischemic pathology].
PG  - 2234-40
AB  - Platelet aggregation inhibitors have been more extensively and better studied 
      than all other treatments used in the prevention of cerebral ischaemia. It has 
      been demonstrated that both aspirin (300 mg/day) and ticlopidine (500 mg/day) are 
      effective in the secondary prevention of cerebral ischaemic accidents associated 
      with atherosclerosis, with a 20 and 30 p. 100 respectively reduction of risk. At 
      the moment, there is no evidence that these compounds are effective in the 
      primary prevention or treatment of cerebral infarction in the acute phase. The 
      best way of preventing thromboembolic stroke of cardiac origin is to treat the 
      responsible heart disease and prescribe anticoagulants. However, several studies 
      are in progress to evaluate the effectiveness of aspirin in the primary and 
      secondary prevention of cerebral thromboembolism due to non-valvular atrial 
      fibrillation.
FAU - Adams, D
AU  - Adams D
FAU - Bousser, M G
AU  - Bousser MG
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Antiagrégants plaquettaires en pathologie ischémique cérébrale.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Arteriosclerosis/complications
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/complications
MH  - Brain Ischemia/etiology/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 20
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
PST - ppublish
SO  - Rev Prat. 1989 Nov 1;39(25):2234-40.

PMID- 27920399
OWN - NLM
STAT- MEDLINE
DCOM- 20170815
LR  - 20181023
IS  - 1024-2708 (Print)
IS  - 1024-2708 (Linking)
VI  - 22
IP  - 6
DP  - 2016 Dec
TI  - Anticoagulation for stroke prevention in elderly patients with non-valvular 
      atrial fibrillation: what are the obstacles?
PG  - 608-15
LID - 10.12809/hkmj154803 [doi]
AB  - The elderly with atrial fibrillation are more prone to stroke. Oral 
      anticoagulants such as warfarin are effective in the prevention of atrial 
      fibrillation-associated stroke and systemic embolism. The CHADS(2) or 
      CHA(2)D(2)-VASc score and HAS-BLED score were developed to stratify stroke risk 
      associated with atrial fibrillation and bleeding risk in a patient with atrial 
      fibrillation, respectively, to facilitate the decision for and safe use of oral 
      anticoagulant. Nonetheless, the decision for anticoagulation is not 
      straightforward and the elderly with non-valvular atrial fibrillation are often 
      precluded from anticoagulant prescription. Advanced age and disadvantages 
      associated with the elderly such as fall, comorbidities, cognitive impairment, 
      and polypharmacy contribute to the over-concern of physicians about bleeding 
      risk. Various treatment options such as low-intensity warfarin and aspirin plus 
      clopidogrel have been suggested but are inferior to dose-adjusted warfarin. Novel 
      oral anticoagulants with promising efficacy and convenience hold great appeal. 
      Optimal management of underlying medical conditions and modifiable stroke risk 
      factors, together with intervention to improve the safe use of oral 
      anticoagulants, are useful.
FAU - Wong, C W
AU  - Wong CW
AD  - Department of Medicine and Geriatrics, Caritas Medical Centre, Shamshuipo, Hong 
      Kong.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Hong Kong Med J
JT  - Hong Kong medical journal = Xianggang yi xue za zhi
JID - 9512509
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Comorbidity
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Stroke/etiology/*prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - Aged
OT  - Anticoagulants/therapeutic use
OT  - Atrial fibrillation/classification
OT  - Stroke
EDAT- 2016/12/07 06:00
MHDA- 2017/08/16 06:00
CRDT- 2016/12/07 06:00
PHST- 2016/12/07 06:00 [entrez]
PHST- 2016/12/07 06:00 [pubmed]
PHST- 2017/08/16 06:00 [medline]
AID - 10.12809/hkmj154803 [doi]
PST - ppublish
SO  - Hong Kong Med J. 2016 Dec;22(6):608-15. doi: 10.12809/hkmj154803.

PMID- 6813878
OWN - NLM
STAT- MEDLINE
DCOM- 19821221
LR  - 20191031
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 9
IP  - 1
DP  - 1982 Jul
TI  - Structure-activity studies of aspirin and related compounds on platelet 
      aggregation, arachidonic acid metabolism in platelets and artery, and arterial 
      prostacyclin activity.
PG  - 9-23
AB  - A series of benzoic acid derivatives was tested for specificity of action on 
      human platelet function and platelet prostaglandin (PG) synthesis versus 
      prostacyclin (PGI2) production by rat and rabbit aorta rings. None of the agents 
      tested was more specific for one system than the other. ASA was more potent than 
      2-propionyloxybenzoic acid (2-PBA) in inhibiting platelet function and platelet 
      PG synthesis although the potencies of these agents were comparable in inhibiting 
      PGI2 synthesis. 3-Propionyloxybenzoic acid (3-PBA) caused increased activity in 
      both systems while 2-acetylbenzoic acid (ABA) had only minor effects. A cyclical 
      derivative, 3-methylphthalide (3-MP), inhibited both platelet function and PGI2 
      synthesis although it did not inhibit cyclo-oxygenase activity, suggesting a 
      novel mechanism of action. Thus only minor changes in the ASA molecule could be 
      effected without significant changes in pharmacological activity. The 
      investigation of novel agents such as 3-MP may lead to a better understanding of 
      arachidonate metabolism in different tissues and possibly to the development of 
      more tissue-specific drugs.
FAU - Killackey, J J
AU  - Killackey JJ
FAU - Killackey, B A
AU  - Killackey BA
FAU - Philp, R B
AU  - Philp RB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Arachidonic Acids)
RN  - 0 (Benzoates)
RN  - 0 (Prostaglandins E)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adenosine Triphosphate/blood
MH  - Animals
MH  - Aorta/*metabolism
MH  - Arachidonic Acid
MH  - Arachidonic Acids/*blood
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Benzoates/pharmacology
MH  - Dinoprostone
MH  - Platelet Aggregation/*drug effects
MH  - Prostaglandins E/*metabolism
MH  - Rabbits
MH  - Rats
MH  - Structure-Activity Relationship
EDAT- 1982/07/01 00:00
MHDA- 1982/07/01 00:01
CRDT- 1982/07/01 00:00
PHST- 1982/07/01 00:00 [pubmed]
PHST- 1982/07/01 00:01 [medline]
PHST- 1982/07/01 00:00 [entrez]
AID - 10.1016/0262-1746(82)90068-3 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1982 Jul;9(1):9-23. doi: 10.1016/0262-1746(82)90068-3.

PMID- 27466843
OWN - NLM
STAT- MEDLINE
DCOM- 20170207
LR  - 20170207
IS  - 1662-2847 (Electronic)
IS  - 0065-3071 (Linking)
VI  - 79
DP  - 2016
TI  - Aspirin Exacerbated Respiratory Disease.
PG  - 21-8
LID - 10.1159/000445093 [doi]
AB  - Aspirin exacerbated respiratory disease (AERD) has been defined as a 
      non-steroidal anti-inflammatory drug (NSAID)-triggered hypersensitivity, 
      non-allergic bronchial asthma and chronic rhinosinusitis (CRS) with nasal polyps. 
      The underlying pathophysiology of AERD is not completely understood so far. An 
      altered arachidonic acid metabolism and dysregulated enzyme activity are regarded 
      to be causal. AERD is characterized by recalcitrant CRS with recurrent nasal 
      polyps after sinus surgery, accompanied by difficult to treat bronchial asthma 
      and adverse reaction after NSAID ingestion such as nasal blockage, itching, 
      laryngospasm and severe asthma attacks. Affected individuals suffer from poor 
      quality of life. Besides functional endoscopic sinus surgery, the application of 
      topical and systemic steroids and symptomatic therapy, aspirin desensitization is 
      the only causative treatment option. The diagnostic approach to AERD, the ideal 
      desensitization protocol and especially the following daily maintenance dose is 
      part of an ongoing debate. This article summarizes the current knowledge about 
      the pathophysiology, focuses on modern diagnostic approaches of AERD and 
      discusses various aspirin desensitization protocols with respect to efficacy as 
      well as to undesirable side effects.
CI  - © 2016 S. Karger AG, Basel.
FAU - Fruth, Kai
AU  - Fruth K
FAU - Gosepath, Jan
AU  - Gosepath J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20160728
PL  - Switzerland
TA  - Adv Otorhinolaryngol
JT  - Advances in oto-rhino-laryngology
JID - 0242534
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Rhinitis/*chemically induced
EDAT- 2016/07/29 06:00
MHDA- 2017/02/09 06:00
CRDT- 2016/07/29 06:00
PHST- 2016/07/29 06:00 [entrez]
PHST- 2016/07/29 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
AID - 000445093 [pii]
AID - 10.1159/000445093 [doi]
PST - ppublish
SO  - Adv Otorhinolaryngol. 2016;79:21-8. doi: 10.1159/000445093. Epub 2016 Jul 28.

PMID- 799984
OWN - NLM
STAT- MEDLINE
DCOM- 19770718
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 4
IP  - 2
DP  - 1976
TI  - Nefopam hydrochloride: new analgesic agent.
PG  - 138-43
AB  - Two dose-levels of nefopam hydrochloride (i.e. 30 mg and 60 mg) were compared 
      with two dose-levels of aspirin (i.e. 300 mg and 600 mg) and placebo in 125 male 
      patients having pain associated with muscle disorders. Drugs were given as a 
      single dose and pain intensity and side-effects monitored at thirty minutes and 
      then hourly for four hours. Time-course action of the drugs revealed that aspirin 
      300 mg failed to achieve statistically significant analgesia at any 
      post-treatment observation, whereas nefopam 60 mg was significantly better than 
      placebo (p less than 0-05) at one and three hours in terms of pain intensity and 
      at one hour in terms of pain intensity difference scores. Aspirin 600 mg was 
      significantly different from placebo (p less than 0-05) at all hourly 
      observations for both efficacy parameters, as was nefopam 30 mg (p less than 
      0-01). Summation of pain intensity difference scores showed aspirin 600 mg and 
      nefopam 30 mg to be significantly different from placebo at the 0.025 and 0.005 
      levels respectively.
FAU - Cohen, A
AU  - Cohen A
FAU - Hernandez, C M
AU  - Hernandez CM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Analgesics)
RN  - 0 (Oxazocines)
RN  - 4UP8060B7J (Nefopam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesics
MH  - Aspirin/pharmacology
MH  - Clinical Trials as Topic
MH  - Drug Evaluation
MH  - Humans
MH  - Male
MH  - Nefopam/*pharmacology
MH  - Oxazocines/*pharmacology
MH  - Pain/physiopathology
MH  - Time Factors
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1177/030006057600400211 [doi]
PST - ppublish
SO  - J Int Med Res. 1976;4(2):138-43. doi: 10.1177/030006057600400211.

PMID- 34565058
OWN - NLM
STAT- MEDLINE
DCOM- 20230402
LR  - 20230402
IS  - 1530-6550 (Print)
IS  - 1530-6550 (Linking)
VI  - 22
IP  - 3
DP  - 2021 Sep 24
TI  - FDA PLATO deaths list challenges aspirin dose-ticagrelor interaction.
PG  - 553-555
LID - 10.31083/j.rcm2203066 [doi]
AB  - No abstract present.
CI  - © 2021 The Author(s). Published by IMR Press.
FAU - Serebruany, Victor
AU  - Serebruany V
AD  - Department of Neurology, Johns Hopkins University, Baltimore, MD 21794, USA.
FAU - Tanguay, Jean-Francois
AU  - Tanguay JF
AD  - Montreal Heart Institute, Université de Montréal, Montreal, QC H1B, Canada.
LA  - eng
PT  - News
PL  - Singapore
TA  - Rev Cardiovasc Med
JT  - Reviews in cardiovascular medicine
JID - 100960007
RN  - K72T3FS567 (Adenosine)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - GLH0314RVC (Ticagrelor)
SB  - IM
MH  - Humans
MH  - *Acute Coronary Syndrome
MH  - Adenosine
MH  - Aspirin/adverse effects
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - *Purinergic P2Y Receptor Antagonists
MH  - Ticagrelor
MH  - Treatment Outcome
COIS- The authors declare no conflict of interest.
EDAT- 2021/09/27 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/09/26 21:18
PHST- 2021/08/31 00:00 [received]
PHST- 2021/09/01 00:00 [revised]
PHST- 2021/09/02 00:00 [accepted]
PHST- 2021/09/26 21:18 [entrez]
PHST- 2021/09/27 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - 1632453054247-818878977 [pii]
AID - 10.31083/j.rcm2203066 [doi]
PST - ppublish
SO  - Rev Cardiovasc Med. 2021 Sep 24;22(3):553-555. doi: 10.31083/j.rcm2203066.

PMID- 1118772
OWN - NLM
STAT- MEDLINE
DCOM- 19750528
LR  - 20190702
IS  - 0038-4348 (Print)
IS  - 0038-4348 (Linking)
VI  - 68
IP  - 3
DP  - 1975 Mar
TI  - Aspirin allergy: a clinical study.
PG  - 314-8
AB  - The following beliefs about aspirin sensitivity are widely held: (1) it usually 
      is accompanied by nasal polyps. (2) It occurs primarily in nonallergic patients. 
      (3) Its most common manifestation is asthma. (4) When it is combined with polyps 
      and asthma (the so-called "aspirin triad"), the prognosis is unfavorable. (5) 
      Polypectomy may precipitate asthma in aspirin sensitive patients. This paper, 
      based on a study of 112 private patients, presents clinical evidence to refute 
      these beliefs. It shows the following: (1) Aspirin allergy is accompanied by 
      polyps in less than 5% of cases (13% of asthma patients). (2) In most cases, 
      patients show well-defined allergy to an inhalant, food, or other drug. (3) Its 
      most common manifestations are urticaria and angiodema, not asthma. (4) The 
      prognosis is favorable, whether or not polyps are present. (5) Polypectomy does 
      not precipitate asthma in aspirin-sensitive patients.
FAU - Speer, F
AU  - Speer F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Angioedema/etiology
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/etiology
MH  - Child
MH  - Child, Preschool
MH  - Drug Hypersensitivity/complications/*etiology
MH  - Female
MH  - Food Hypersensitivity/complications/epidemiology
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Kansas
MH  - Male
MH  - Middle Aged
MH  - Missouri
MH  - Nasal Polyps/complications/surgery
MH  - Prognosis
MH  - Respiratory Hypersensitivity/complications
MH  - Skin Tests
MH  - Urticaria/etiology
EDAT- 1975/03/01 00:00
MHDA- 1975/03/01 00:01
CRDT- 1975/03/01 00:00
PHST- 1975/03/01 00:00 [pubmed]
PHST- 1975/03/01 00:01 [medline]
PHST- 1975/03/01 00:00 [entrez]
AID - 10.1097/00007611-197503000-00013 [doi]
PST - ppublish
SO  - South Med J. 1975 Mar;68(3):314-8. doi: 10.1097/00007611-197503000-00013.

PMID- 3827065
OWN - NLM
STAT- MEDLINE
DCOM- 19870331
LR  - 20131121
IS  - 0003-4886 (Print)
IS  - 0003-4886 (Linking)
VI  - 19
IP  - 1
DP  - 1987 Jan
TI  - The idling retina: reversible visual loss in central retinal artery obstruction.
PG  - 3-6
AB  - Based on experimental studies, sustained total central retinal artery obstruction 
      (CRAO) lasting more than one and one-half hours has been considered to cause 
      irreversible retinal damage. We have seen five cases of patients with pure CRAO 
      that lasted longer than one and one-half hours who regained significant visual 
      acuity. Three of the patients had a completely spontaneous improvement in visual 
      acuity to 20/50 or better. In addition, the other two patients regained 
      significant vision to 20/80 or better with a modified treatment regimen of 
      acetazolamide, inhalation of 5% CO2 and 95% O2, and aspirin. No foveola-sparing 
      cilioretinal arteries were present in any of the cases. We introduce the concept 
      of reversible retinal ischemia following unsustained CRAO to account for these 
      unexpected improvements in visual acuity.
FAU - Perkins, S A
AU  - Perkins SA
FAU - Magargal, L E
AU  - Magargal LE
FAU - Augsburger, J J
AU  - Augsburger JJ
FAU - Sanborn, G E
AU  - Sanborn GE
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Ophthalmol
JT  - Annals of ophthalmology
JID - 0210137
RN  - 64ALC7F90C (Dipyridamole)
RN  - O3FX965V0I (Acetazolamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetazolamide/therapeutic use
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Male
MH  - *Retinal Artery
MH  - Retinal Diseases/drug therapy/physiopathology/therapy
MH  - *Vision, Ocular
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Ann Ophthalmol. 1987 Jan;19(1):3-6.

PMID- 6849732
OWN - NLM
STAT- MEDLINE
DCOM- 19830708
LR  - 20190511
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 15
IP  - 1
DP  - 1983 Jan
TI  - Effect of inhibitors of prostaglandin synthesis on hepatic drug clearance.
PG  - 109-11
AB  - The effect of inhibition of prostaglandin synthesis on the systemic clearance of 
      indocyanine green and antipyrine was studied in seven subjects. Antipyrine 
      clearance was not altered by indomethacin suggesting that oxidative metabolism 
      was not affected. Both aspirin and indomethacin decreased the clearance of 
      indocyanine green presumably by reducing liver blood flow. These results suggest 
      that an effect of inhibitors of prostaglandin synthesis on hepatic drug clearance 
      is likely to be confined to high clearance drugs when given systemically.
FAU - Feely, J
AU  - Feely J
FAU - Wood, A J
AU  - Wood AJ
LA  - eng
GR  - AG01395/AG/NIA NIH HHS/United States
GR  - GM15431/GM/NIGMS NIH HHS/United States
GR  - HL14192/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Prostaglandin Antagonists)
RN  - IX6J1063HV (Indocyanine Green)
RN  - R16CO5Y76E (Aspirin)
RN  - T3CHA1B51H (Antipyrine)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Antipyrine/metabolism
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Indocyanine Green/metabolism
MH  - Indomethacin/*pharmacology
MH  - Liver/*metabolism
MH  - Male
MH  - Prostaglandin Antagonists/pharmacology
PMC - PMC1427826
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1983.tb01472.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1983 Jan;15(1):109-11. doi: 
      10.1111/j.1365-2125.1983.tb01472.x.

PMID- 31744311
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20200907
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 54
IP  - 5
DP  - 2020 May
TI  - Pharmacotherapeutic Management Strategies for Thyroid Disease-Induced 
      Pericarditis.
PG  - 486-495
LID - 10.1177/1060028019889065 [doi]
AB  - Objective: To describe the various pharmacotherapeutic strategies in managing 
      thyroid disease-induced pericarditis (TDIP). Considerations for both 
      hypothyroid-induced and hyperthyroid-induced pericarditis will be discussed. Data 
      Sources: A literature search of MEDLINE, including PubMed, was performed 
      inclusive of all years, using the following search terms: thyroid disease, 
      pericardial diseases, pericarditis, acute pericarditis, cholesterol pericarditis, 
      hypothyroidism, hyperthyroidism, colchicine, corticosteroids, nonsteroidal 
      anti-inflammatory drugs (NSAIDs), aspirin, methimazole, propylthiouracil, and 
      P-glycoprotein. Product monographs were reviewed as well. Study Selection and 
      Data Extraction: Relevant English-language studies and data as well as the most 
      current guidelines for diagnosis and management of thyroid and pericardial 
      diseases were considered. Because of limited data regarding the subject matter, 
      no date range limits were established during literature search. Data Synthesis: 
      It is well documented that thyroid dysfunction can adversely affect 
      cardiovascular function. Additionally, there are published guidelines on the 
      diagnosis and management of pericarditis and, separately, thyroid disease. There 
      are limited data, however, on managing TDIP. The sequela of untreated TDIP can be 
      detrimental. Relevance to Patient Care and Clinical Practice: Strategies on 
      managing TDIP are scarcely reported in the literature. This review provides 
      clinicians with a single reference source for treatment strategies toward 
      managing hypothyroidism-induced and hyperthyroidism-induced pericarditis as well 
      as significant drug interactions that can potentially confound the management of 
      hypothyroidism- and hyperthyroidism-induced pericarditis. Conclusions: Treatment 
      of TDIP involves addressing both the thyroid disease as well as the pericarditis. 
      Along with treatment strategies, clinicians should also consider potential 
      drug-drug and drug-disease interactions that can potentially worsen clinical 
      outcomes.
FAU - Schwier, Nicholas C
AU  - Schwier NC
AUID- ORCID: 0000-0002-7295-0676
AD  - University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
FAU - O'Neal, Katherine
AU  - O'Neal K
AD  - University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191119
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Adrenal Cortex Hormones/administration & dosage/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Colchicine/administration & dosage/*therapeutic use
MH  - Drug Interactions
MH  - Humans
MH  - Hyperthyroidism/complications/drug therapy
MH  - Hypothyroidism/complications/drug therapy
MH  - Pericarditis/diagnosis/*drug therapy/etiology
MH  - Thyroid Diseases/complications/*drug therapy
OTO - NOTNLM
OT  - aspirin
OT  - colchicine
OT  - corticosteroids
OT  - hyperthyroidism
OT  - hypothyroidism
OT  - nonsteroidal anti-inflammatory drugs
OT  - pericarditis
OT  - pharmacotherapy
EDAT- 2019/11/21 06:00
MHDA- 2020/09/08 06:00
CRDT- 2019/11/21 06:00
PHST- 2019/11/21 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
PHST- 2019/11/21 06:00 [entrez]
AID - 10.1177/1060028019889065 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2020 May;54(5):486-495. doi: 10.1177/1060028019889065. Epub 
      2019 Nov 19.

PMID- 27846735
OWN - NLM
STAT- MEDLINE
DCOM- 20170206
LR  - 20170206
IS  - 2154-8331 (Print)
IS  - 2154-8331 (Linking)
VI  - 44
IP  - 5
DP  - 2016 Dec
TI  - Perioperative management of dual anti-platelet therapy.
PG  - 237-241
AB  - Dual anti-platelet therapy denotes a regimen of aspirin plus a P2Y(12) receptor 
      inhibitor, clopidogrel, prasugrel, or ticagrelor. Such therapy is a cornerstone 
      of medical management following acute coronary syndromes and is imperative 
      following percutaneous coronary interventions. While there is uncertainty about 
      the optimal duration of dual antiplatelet therapy following percutaneous coronary 
      intervention, the new 2016 American College of Cardiology/American Heart 
      Association Guidelines suggest that for patients with stable ischemic heart 
      disease at least six months of such therapy following a drug eluting stent and 
      one month following a bare metal stent should be implemented. In patients with 
      acute coronary syndrome including non-ST elevation and ST elevation myocardial 
      infarction it is recommended to extend dual antiplatelet therapy treatment to one 
      year in both drug eluting stent and bare metal stent groups. There may be 
      latitude for earlier discontinuation in appropriately selected patients; extended 
      dual antiplatelet therapy beyond one year may be beneficial in others. Herein, we 
      describe current guidelines and evidence supporting if and when dual antiplatelet 
      therapy should be interrupted for surgery for patients who have undergone 
      percutaneous coronary intervention.
FAU - Webster, Tyler D
AU  - Webster TD
AD  - a Department of Internal Medicine , The Icahn School of Medicine at Mount Sinai , 
      New York , NY , USA.
FAU - Vaishnava, Prashant
AU  - Vaishnava P
AD  - b The Mount Sinai Hospital Cardiovascular Institute , New York , NY , USA.
FAU - Eagle, Kim A
AU  - Eagle KA
AD  - c Sam and Jean Frankel Cardiovascular Institute , University of Michigan Health 
      System , Ann Arbor , MI , USA.
LA  - eng
PT  - Journal Article
DEP - 20161204
PL  - England
TA  - Hosp Pract (1995)
JT  - Hospital practice (1995)
JID - 101268948
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Drug-Eluting Stents
MH  - Elective Surgical Procedures/methods
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy/surgery
MH  - Percutaneous Coronary Intervention/methods
MH  - Perioperative Care/*methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Purinergic P2Y Receptor Antagonists/*administration & dosage/therapeutic use
MH  - Time Factors
MH  - United States
OTO - NOTNLM
OT  - DAPT
OT  - Dual-Antiplatelet Therapy
OT  - PCI
OT  - aspirin
OT  - bridging
OT  - clopidogrel
OT  - discontinuation
OT  - perioperative
OT  - surgery
EDAT- 2016/11/17 06:00
MHDA- 2017/02/07 06:00
CRDT- 2016/11/17 06:00
PHST- 2016/11/17 06:00 [pubmed]
PHST- 2017/02/07 06:00 [medline]
PHST- 2016/11/17 06:00 [entrez]
AID - 10.1080/21548331.2016.1260997 [doi]
PST - ppublish
SO  - Hosp Pract (1995). 2016 Dec;44(5):237-241. doi: 10.1080/21548331.2016.1260997. 
      Epub 2016 Dec 4.

PMID- 30221597
OWN - NLM
STAT- MEDLINE
DCOM- 20181105
LR  - 20220408
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 379
IP  - 16
DP  - 2018 Oct 18
TI  - Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
PG  - 1509-1518
LID - 10.1056/NEJMoa1805819 [doi]
AB  - BACKGROUND: Aspirin is a well-established therapy for the secondary prevention of 
      cardiovascular events. However, its role in the primary prevention of 
      cardiovascular disease is unclear, especially in older persons, who have an 
      increased risk. METHODS: From 2010 through 2014, we enrolled community-dwelling 
      men and women in Australia and the United States who were 70 years of age or 
      older (or ≥65 years of age among blacks and Hispanics in the United States) and 
      did not have cardiovascular disease, dementia, or disability. Participants were 
      randomly assigned to receive 100 mg of enteric-coated aspirin or placebo. The 
      primary end point was a composite of death, dementia, or persistent physical 
      disability; results for this end point are reported in another article in the 
      Journal. Secondary end points included major hemorrhage and cardiovascular 
      disease (defined as fatal coronary heart disease, nonfatal myocardial infarction, 
      fatal or nonfatal stroke, or hospitalization for heart failure). RESULTS: Of the 
      19,114 persons who were enrolled in the trial, 9525 were assigned to receive 
      aspirin and 9589 to receive placebo. After a median of 4.7 years of follow-up, 
      the rate of cardiovascular disease was 10.7 events per 1000 person-years in the 
      aspirin group and 11.3 events per 1000 person-years in the placebo group (hazard 
      ratio, 0.95; 95% confidence interval [CI], 0.83 to 1.08). The rate of major 
      hemorrhage was 8.6 events per 1000 person-years and 6.2 events per 1000 
      person-years, respectively (hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P<0.001). 
      CONCLUSIONS: The use of low-dose aspirin as a primary prevention strategy in 
      older adults resulted in a significantly higher risk of major hemorrhage and did 
      not result in a significantly lower risk of cardiovascular disease than placebo. 
      (Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov 
      number, NCT01038583 .).
FAU - McNeil, John J
AU  - McNeil JJ
AUID- ORCID: 0000-0002-1049-5129
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Woods, Robyn L
AU  - Woods RL
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Tonkin, Andrew M
AU  - Tonkin AM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Donnan, Geoffrey A
AU  - Donnan GA
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Reid, Christopher M
AU  - Reid CM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Lockery, Jessica E
AU  - Lockery JE
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Kirpach, Brenda
AU  - Kirpach B
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Storey, Elsdon
AU  - Storey E
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Shah, Raj C
AU  - Shah RC
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Williamson, Jeff D
AU  - Williamson JD
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Margolis, Karen L
AU  - Margolis KL
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Abhayaratna, Walter P
AU  - Abhayaratna WP
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Stocks, Nigel
AU  - Stocks N
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Fitzgerald, Sharyn M
AU  - Fitzgerald SM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Orchard, Suzanne G
AU  - Orchard SG
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Trevaks, Ruth E
AU  - Trevaks RE
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Beilin, Lawrence J
AU  - Beilin LJ
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Johnston, Colin I
AU  - Johnston CI
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Ryan, Joanne
AU  - Ryan J
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Radziszewska, Barbara
AU  - Radziszewska B
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Jelinek, Michael
AU  - Jelinek M
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Malik, Mobin
AU  - Malik M
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Eaton, Charles B
AU  - Eaton CB
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Brauer, Donna
AU  - Brauer D
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Cloud, Geoff
AU  - Cloud G
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Wood, Erica M
AU  - Wood EM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Mahady, Suzanne E
AU  - Mahady SE
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Satterfield, Suzanne
AU  - Satterfield S
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Grimm, Richard
AU  - Grimm R
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
FAU - Murray, Anne M
AU  - Murray AM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.W., R.L.W., A.M.T., M.R.N., C.M.R., J.E.L., E.S., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R., E.M.W., S.E.M.), Baker Heart and Diabetes Institute 
      (C.I.J.), the Department of Cardiology, St. Vincent's Hospital (M.J.), and the 
      Department of Clinical Neurosciences, Central Clinical School, Monash University 
      and Alfred Hospital (G.C.), Melbourne, and Florey Institute of Neuroscience and 
      Mental Health, University of Melbourne, Parkville (G.A.D.), VIC, Menzies 
      Institute for Medical Research, University of Tasmania, Hobart (M.R.N.), the 
      School of Public Health, Curtin University (C.M.R.), and the School of Medicine, 
      Royal Perth Hospital, University of Western Australia (L.J.B.), Perth, the 
      College of Medicine, Biology and Environment, Australian National University, 
      Canberra, ACT (W.P.A.), and the Discipline of General Practice, University of 
      Adelaide, Adelaide, SA (N.S.) - all in Australia; the Berman Center for Outcomes 
      and Clinical Research, Hennepin Healthcare Research Institute, Hennepin 
      Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute (K.L.M.), and the 
      Division of Geriatrics, Department of Medicine, Hennepin Healthcare and the 
      University of Minnesota (A.M.M.), Minneapolis, and the School of Nursing, 
      Minnesota State University, Mankato (D.B.) - all in Minnesota; the Department of 
      Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical 
      Center, Chicago (R.C.S.); Sticht Center on Aging and Alzheimer's Prevention, 
      Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, 
      Wake Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of 
      Pharmacy Practice and Science, College of Pharmacy and Department of Family 
      Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.); the Department of Cardiovascular Medicine, Vascular Medicine 
      Section, Cleveland Clinic, Cleveland (M.M.); the Center for Primary Care and 
      Prevention, Brown University, Providence, RI (C.B.E.); and the University of 
      Tennessee Health Science Center, Memphis (S.S.).
CN  - ASPREE Investigator Group
LA  - eng
SI  - ClinicalTrials.gov/NCT01038583
GR  - P30 AG049638/AG/NIA NIH HHS/United States
GR  - U01 AG029824/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180916
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 2019 Feb;156(3):534-538. PMID: 30529298
CIN - Internist (Berl). 2019 Feb;60(2):209-216. PMID: 30645666
CIN - MMW Fortschr Med. 2019 Feb;161(2):35. PMID: 30721495
CIN - N Engl J Med. 2019 May 2;380(18):1775. PMID: 31042833
CIN - N Engl J Med. 2019 May 2;380(18):1775. PMID: 31042834
CIN - N Engl J Med. 2019 May 2;380(18):1775-1776. PMID: 31042835
CIN - Evid Based Nurs. 2019 Oct;22(4):115. PMID: 31154354
CIN - J Fam Pract. 2020 Apr;69(3):E16-E18. PMID: 32289133
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Australia
MH  - Cardiovascular Diseases/epidemiology/mortality/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Independent Living
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Treatment Failure
MH  - United States
PMC - PMC6289056
MID - NIHMS1512090
FIR - Chan, Andrew
IR  - Chan A
FIR - Demons, Jamehl
IR  - Demons J
FIR - Espinoza, Sara
IR  - Espinoza S
FIR - Goetz, Matthew
IR  - Goetz M
FIR - Liew, Danny
IR  - Liew D
FIR - Meyskens, Frank
IR  - Meyskens F
FIR - Zalcberg, John
IR  - Zalcberg J
FIR - Ives, Diane
IR  - Ives D
FIR - Berk, Michael
IR  - Berk M
FIR - Bernstein, Wendy
IR  - Bernstein W
FIR - Brauer, Donna
IR  - Brauer D
FIR - Burns, Christine
IR  - Burns C
FIR - Chong, Trevor
IR  - Chong T
FIR - Cloud, Geoff
IR  - Cloud G
FIR - Eaton, Charles
IR  - Eaton C
FIR - Fitzgerald, Paul
IR  - Fitzgerald P
FIR - Haydon, Andrew
IR  - Haydon A
FIR - Jelinek, Michael
IR  - Jelinek M
FIR - Macrae, Finlay
IR  - Macrae F
FIR - Mahady, Suzanne
IR  - Mahady S
FIR - Malik, Mobin
IR  - Malik M
FIR - McLean, Catriona
IR  - McLean C
FIR - Rodriguez, Luz
IR  - Rodriguez L
FIR - Satterfield, Suzanne
IR  - Satterfield S
FIR - Tie, Jeanne
IR  - Tie J
FIR - van Londen, Gijsberta
IR  - van Londen G
FIR - Ward, Stephanie
IR  - Ward S
FIR - Wood, Erica
IR  - Wood E
FIR - Mohr, Jay
IR  - Mohr J
FIR - Anderson, Garnet
IR  - Anderson G
FIR - Connolly, Stuart
IR  - Connolly S
FIR - Friedman, Larry
IR  - Friedman L
FIR - Manson, JoAnn
IR  - Manson J
FIR - Sano, Mary
IR  - Sano M
FIR - Morrison, Sean
IR  - Morrison S
FIR - Ohman, Erik Magnus
IR  - Ohman EM
FIR - Hadley, Evan
IR  - Hadley E
FIR - Hannah, Judy
IR  - Hannah J
FIR - Romashkan, Sergei
IR  - Romashkan S
FIR - Ford, Leslie
IR  - Ford L
FIR - Richmond, Ellen
IR  - Richmond E
FIR - Umar, Asad
IR  - Umar A
FIR - Lockett, Trevor
IR  - Lockett T
FIR - Lewis, Beth
IR  - Lewis B
FIR - Obisesan, Thomas
IR  - Obisesan T
FIR - Gilbertson, Dave
IR  - Gilbertson D
FIR - Collyer, Taya
IR  - Collyer T
FIR - Rigby, Jason
IR  - Rigby J
FIR - Pruksawongsin, Kunnapoj
IR  - Pruksawongsin K
FIR - Hay, Nino
IR  - Hay N
FIR - Jachno, Kim
IR  - Jachno K
FIR - Smith, Catherine
IR  - Smith C
FIR - Ekram, A R M Saifuddin
IR  - Ekram ARMS
FIR - Gardam, Madeleine
IR  - Gardam M
FIR - Luong, Henry
IR  - Luong H
FIR - Montgomery, Tim
IR  - Montgomery T
FIR - Plate, Megan
IR  - Plate M
FIR - Rojas, Laura
IR  - Rojas L
FIR - Tominaga, Anna
IR  - Tominaga A
FIR - Wadeson, Katrina
IR  - Wadeson K
FIR - Hopkins, Sarah
IR  - Hopkins S
FIR - Nichols, Trisha
IR  - Nichols T
FIR - Johnson, Ashley
IR  - Johnson A
FIR - Prozinski, Molly
IR  - Prozinski M
FIR - Robinson-O’Brien, Ramona
IR  - Robinson-O’Brien R
FIR - Tessum, Nate
IR  - Tessum N
FIR - Aloia, John
IR  - Aloia J
FIR - Anton, Steve
IR  - Anton S
FIR - Burns, Jeffery
IR  - Burns J
FIR - Burton, Gary
IR  - Burton G
FIR - Ferris, Darron
IR  - Ferris D
FIR - Honasoge, Mahalakshmi
IR  - Honasoge M
FIR - Hsia, Daniel
IR  - Hsia D
FIR - Katzman, Steven
IR  - Katzman S
FIR - Kottam, Anupama
IR  - Kottam A
FIR - Nesbitt, Shawna
IR  - Nesbitt S
FIR - Ochoa, Augusto
IR  - Ochoa A
FIR - Pemu, Pricilla
IR  - Pemu P
FIR - Peterson, Kevin
IR  - Peterson K
FIR - Powell, James
IR  - Powell J
FIR - Pressman, Gregg
IR  - Pressman G
FIR - Robinson, William III
IR  - Robinson W III
FIR - Satterfield, Susanne
IR  - Satterfield S
FIR - Thorburn, Christine
IR  - Thorburn C
FIR - Volpi, Elena
IR  - Volpi E
FIR - Wiggins, Jocelyn
IR  - Wiggins J
FIR - Wilson, Peter
IR  - Wilson P
FIR - Womack, Catherine
IR  - Womack C
FIR - Abdullah, M
IR  - Abdullah M
FIR - Abdul-Ridha, S
IR  - Abdul-Ridha S
FIR - Aboud, E
IR  - Aboud E
FIR - Abraham, A
IR  - Abraham A
FIR - Abraham, J
IR  - Abraham J
FIR - Abraham, K
IR  - Abraham K
FIR - Abrahams, M
IR  - Abrahams M
FIR - Adad, S
IR  - Adad S
FIR - Adams, C
IR  - Adams C
FIR - Africa, N
IR  - Africa N
FIR - Afroze, S
IR  - Afroze S
FIR - Agarwal, D
IR  - Agarwal D
FIR - Agbarakwe, C
IR  - Agbarakwe C
FIR - Ah Sang, W
IR  - Ah Sang W
FIR - Ahern, T
IR  - Ahern T
FIR - Ahmad, Y
IR  - Ahmad Y
FIR - Ahmad, Z
IR  - Ahmad Z
FIR - Ahmed, L
IR  - Ahmed L
FIR - Ajam, A
IR  - Ajam A
FIR - Akhter, R
IR  - Akhter R
FIR - Akram, Z
IR  - Akram Z
FIR - Alagarswami, K
IR  - Alagarswami K
FIR - Alam, M
IR  - Alam M
FIR - Alavi, E
IR  - Alavi E
FIR - Aldridge, L
IR  - Aldridge L
FIR - Alethan, A
IR  - Alethan A
FIR - Alexander, K
IR  - Alexander K
FIR - Alexander, L
IR  - Alexander L
FIR - Alexopoulos, M
IR  - Alexopoulos M
FIR - Ali, B
IR  - Ali B
FIR - Ali, M
IR  - Ali M
FIR - Allan, J
IR  - Allan J
FIR - Allen, C
IR  - Allen C
FIR - Allen, G
IR  - Allen G
FIR - Allen, S
IR  - Allen S
FIR - Allin, P
IR  - Allin P
FIR - Al-Musawy, R
IR  - Al-Musawy R
FIR - Alpren, C
IR  - Alpren C
FIR - Al-Tawil, I
IR  - Al-Tawil I
FIR - Alwyn, T
IR  - Alwyn T
FIR - Amor, P
IR  - Amor P
FIR - Anam, T
IR  - Anam T
FIR - Anderson, G
IR  - Anderson G
FIR - Anderson, L
IR  - Anderson L
FIR - Anderson, N
IR  - Anderson N
FIR - Anderson, P
IR  - Anderson P
FIR - Anderson, R
IR  - Anderson R
FIR - Anderson-Dalheim, H
IR  - Anderson-Dalheim H
FIR - Andrada, E
IR  - Andrada E
FIR - Andre, S
IR  - Andre S
FIR - Andrews, L
IR  - Andrews L
FIR - Andric, A
IR  - Andric A
FIR - Andric, M
IR  - Andric M
FIR - Ang, J
IR  - Ang J
FIR - Ansari, A
IR  - Ansari A
FIR - Arakji, A M
IR  - Arakji AM
FIR - Arambeploa, Y
IR  - Arambeploa Y
FIR - Ark, R
IR  - Ark R
FIR - Arnaudon, F P
IR  - Arnaudon FP
FIR - Arndt, P M
IR  - Arndt PM
FIR - Aroney, T
IR  - Aroney T
FIR - Arthurson, J
IR  - Arthurson J
FIR - Arunachalam, T
IR  - Arunachalam T
FIR - Asim, N
IR  - Asim N
FIR - Aslam, I
IR  - Aslam I
FIR - Assad, S
IR  - Assad S
FIR - Astley, N
IR  - Astley N
FIR - Athari, M
IR  - Athari M
FIR - Atkins, C
IR  - Atkins C
FIR - Atkins, M
IR  - Atkins M
FIR - Aufgang, M
IR  - Aufgang M
FIR - Aung, K
IR  - Aung K
FIR - Aurora, G
IR  - Aurora G
FIR - Auteri, S
IR  - Auteri S
FIR - Avergun, A
IR  - Avergun A
FIR - Awwad, A
IR  - Awwad A
FIR - Azad, C
IR  - Azad C
FIR - Azra, S
IR  - Azra S
FIR - Babovic, A
IR  - Babovic A
FIR - Baig, M
IR  - Baig M
FIR - Baker, J
IR  - Baker J
FIR - Baker, S
IR  - Baker S
FIR - Baker, T
IR  - Baker T
FIR - Bakhilova, N
IR  - Bakhilova N
FIR - Baldam, A
IR  - Baldam A
FIR - Baldassa, A
IR  - Baldassa A
FIR - Baldi, C
IR  - Baldi C
FIR - Balkwill, C
IR  - Balkwill C
FIR - Balogun, O
IR  - Balogun O
FIR - Ban, A
IR  - Ban A
FIR - Banerjee, P
IR  - Banerjee P
FIR - Banning, M
IR  - Banning M
FIR - Bansal, S
IR  - Bansal S
FIR - Barkas, R
IR  - Barkas R
FIR - Barker, A
IR  - Barker A
FIR - Barker, D
IR  - Barker D
FIR - Barnes, A
IR  - Barnes A
FIR - Barnes, N
IR  - Barnes N
FIR - Barnetson, W
IR  - Barnetson W
FIR - Barratt, I
IR  - Barratt I
FIR - Barrett, D A
IR  - Barrett DA
FIR - Barrett, Meagan
IR  - Barrett M
FIR - Barrett, Michelle
IR  - Barrett M
FIR - Barrett, P
IR  - Barrett P
FIR - Barrett, T
IR  - Barrett T
FIR - Barson, P
IR  - Barson P
FIR - Barstad, C
IR  - Barstad C
FIR - Barton, W
IR  - Barton W
FIR - Bartram, M
IR  - Bartram M
FIR - Bartusek, P
IR  - Bartusek P
FIR - Basser, S
IR  - Basser S
FIR - Bassett, S
IR  - Bassett S
FIR - Batchelor, L
IR  - Batchelor L
FIR - Batt, D
IR  - Batt D
FIR - Batty, A
IR  - Batty A
FIR - Baum, S
IR  - Baum S
FIR - Baxter, M
IR  - Baxter M
FIR - Beaton, G
IR  - Beaton G
FIR - Beaumont, J
IR  - Beaumont J
FIR - Beavis, D
IR  - Beavis D
FIR - Beckett, V
IR  - Beckett V
FIR - Beech, M
IR  - Beech M
FIR - Beilby, J
IR  - Beilby J
FIR - Bekal, S
IR  - Bekal S
FIR - Bell, A
IR  - Bell A
FIR - Bendtsen, L
IR  - Bendtsen L
FIR - Benedict, D
IR  - Benedict D
FIR - Benjamin, T
IR  - Benjamin T
FIR - Bennett, P
IR  - Bennett P
FIR - Bennie, G
IR  - Bennie G
FIR - Bennie, S
IR  - Bennie S
FIR - Bennison, S
IR  - Bennison S
FIR - Benson, A
IR  - Benson A
FIR - Benson, R
IR  - Benson R
FIR - Benson, S
IR  - Benson S
FIR - Bergin, J
IR  - Bergin J
FIR - Bergin, S
IR  - Bergin S
FIR - Berryman, G
IR  - Berryman G
FIR - Berryman, J
IR  - Berryman J
FIR - Bertram, H
IR  - Bertram H
FIR - Bertuch, G
IR  - Bertuch G
FIR - Bettenay, G
IR  - Bettenay G
FIR - Bettiol, L
IR  - Bettiol L
FIR - Bills, R
IR  - Bills R
FIR - Birch, J
IR  - Birch J
FIR - Bird, Rachel
IR  - Bird R
FIR - Bird, Robert
IR  - Bird R
FIR - Birks, R
IR  - Birks R
FIR - Blake, R
IR  - Blake R
FIR - Blakney, A
IR  - Blakney A
FIR - Blashki, M
IR  - Blashki M
FIR - Bleach, G
IR  - Bleach G
FIR - Bloch, B
IR  - Bloch B
FIR - Bodenstein, M
IR  - Bodenstein M
FIR - Boga, V
IR  - Boga V
FIR - Bollen, C
IR  - Bollen C
FIR - Boltin, P
IR  - Boltin P
FIR - Boon, B
IR  - Boon B
FIR - Booth, G
IR  - Booth G
FIR - Borg, A
IR  - Borg A
FIR - Bornstein, D
IR  - Bornstein D
FIR - Bottcher, C
IR  - Bottcher C
FIR - Bourke, J
IR  - Bourke J
FIR - Bourke, M
IR  - Bourke M
FIR - Boutcher, S
IR  - Boutcher S
FIR - Bowden, J
IR  - Bowden J
FIR - Bowen, J
IR  - Bowen J
FIR - Bowring, B
IR  - Bowring B
FIR - Boyce, C
IR  - Boyce C
FIR - Boyd, J
IR  - Boyd J
FIR - Brack, R
IR  - Brack R
FIR - Bradshaw, A
IR  - Bradshaw A
FIR - Brady, P
IR  - Brady P
FIR - Braithwaite, J
IR  - Braithwaite J
FIR - Braude, G
IR  - Braude G
FIR - Brayshaw, N
IR  - Brayshaw N
FIR - Breen, M
IR  - Breen M
FIR - Bresnahan, R
IR  - Bresnahan R
FIR - Briddon, P
IR  - Briddon P
FIR - Bridge, A
IR  - Bridge A
FIR - Briggs, S J
IR  - Briggs SJ
FIR - Brimage, R F
IR  - Brimage RF
FIR - Britten-Jones, W
IR  - Britten-Jones W
FIR - Brkic, M
IR  - Brkic M
FIR - Broadby, M
IR  - Broadby M
FIR - Bromberger, D
IR  - Bromberger D
FIR - Brommeyer, A
IR  - Brommeyer A
FIR - Broom, I
IR  - Broom I
FIR - Brophy, T
IR  - Brophy T
FIR - Brough, J
IR  - Brough J
FIR - Brougham, J P
IR  - Brougham JP
FIR - Broun, C
IR  - Broun C
FIR - Brown, I D
IR  - Brown ID
FIR - Brown, J
IR  - Brown J
FIR - Brown, M B
IR  - Brown MB
FIR - Brown, M P
IR  - Brown MP
FIR - Brown, R
IR  - Brown R
FIR - Brownbill, C
IR  - Brownbill C
FIR - Brownbill, L
IR  - Brownbill L
FIR - Browne, M
IR  - Browne M
FIR - Brownstein, M
IR  - Brownstein M
FIR - Bruce, A
IR  - Bruce A
FIR - Brunacci, F
IR  - Brunacci F
FIR - Brunner, C
IR  - Brunner C
FIR - Bruorton, M
IR  - Bruorton M
FIR - Buccheri, V
IR  - Buccheri V
FIR - Buchanan, D
IR  - Buchanan D
FIR - Buckley, J
IR  - Buckley J
FIR - Bulle, B
IR  - Bulle B
FIR - Bundy, K
IR  - Bundy K
FIR - Burke, M
IR  - Burke M
FIR - Busch, G
IR  - Busch G
FIR - Bush, C P
IR  - Bush CP
FIR - Butrev, A
IR  - Butrev A
FIR - Bvirakare, J
IR  - Bvirakare J
FIR - Bvumbura, B F
IR  - Bvumbura BF
FIR - Bye, J
IR  - Bye J
FIR - Byrne, C
IR  - Byrne C
FIR - Byrne, P
IR  - Byrne P
FIR - Cain, M
IR  - Cain M
FIR - Calcutt, I
IR  - Calcutt I
FIR - Calder, K
IR  - Calder K
FIR - Caldwell, M
IR  - Caldwell M
FIR - Callan, C
IR  - Callan C
FIR - Cameron, A
IR  - Cameron A
FIR - Cameron, David
IR  - Cameron D
FIR - Cameron, Donald
IR  - Cameron D
FIR - Cameron, T
IR  - Cameron T
FIR - Campbell, David
IR  - Campbell D
FIR - Campbell, Donald
IR  - Campbell D
FIR - Campbell, Geoffrey
IR  - Campbell G
FIR - Campbell, Guy
IR  - Campbell G
FIR - Campbell, P H
IR  - Campbell PH
FIR - Campbell, R
IR  - Campbell R
FIR - Carroll, N
IR  - Carroll N
FIR - Carroll, V
IR  - Carroll V
FIR - Carson, J
IR  - Carson J
FIR - Carson, R
IR  - Carson R
FIR - Carter, L
IR  - Carter L
FIR - Carter, P
IR  - Carter P
FIR - Carter, R
IR  - Carter R
FIR - Carter, S
IR  - Carter S
FIR - Cartwright, P
IR  - Cartwright P
FIR - Cassidy, P
IR  - Cassidy P
FIR - Catchpole, M
IR  - Catchpole M
FIR - Cato, G
IR  - Cato G
FIR - Celada, R
IR  - Celada R
FIR - Chai, F
IR  - Chai F
FIR - Chalabi, A
IR  - Chalabi A
FIR - Chalissery, P
IR  - Chalissery P
FIR - Chalmers, M L
IR  - Chalmers ML
FIR - Chamberlain, H
IR  - Chamberlain H
FIR - Chamoun, R
IR  - Chamoun R
FIR - Chan, B
IR  - Chan B
FIR - Chan, C
IR  - Chan C
FIR - Chan, C K
IR  - Chan CK
FIR - Chan, F W
IR  - Chan FW
FIR - Chan, K
IR  - Chan K
FIR - Chandran, S
IR  - Chandran S
FIR - Chandrananth, M
IR  - Chandrananth M
FIR - Chandrananth, S
IR  - Chandrananth S
FIR - Chang, C
IR  - Chang C
FIR - Chang, V
IR  - Chang V
FIR - Chang, W
IR  - Chang W
FIR - Changakoti, A
IR  - Changakoti A
FIR - Chantler, R
IR  - Chantler R
FIR - Chao, D
IR  - Chao D
FIR - Chao, S
IR  - Chao S
FIR - Charlton, P
IR  - Charlton P
FIR - Chattersee, A
IR  - Chattersee A
FIR - Chau, G
IR  - Chau G
FIR - Chaung, Y
IR  - Chaung Y
FIR - Chawtur, V
IR  - Chawtur V
FIR - Cheah, H-H
IR  - Cheah HH
FIR - Cheah, S
IR  - Cheah S
FIR - Cheasley, A
IR  - Cheasley A
FIR - Chee, H
IR  - Chee H
FIR - Chen, D
IR  - Chen D
FIR - Cheng, W
IR  - Cheng W
FIR - Chesney, D
IR  - Chesney D
FIR - Chew, D
IR  - Chew D
FIR - Chhabra, P
IR  - Chhabra P
FIR - Chia, I
IR  - Chia I
FIR - Chia, P
IR  - Chia P
FIR - Chiang, A
IR  - Chiang A
FIR - Chiang, S
IR  - Chiang S
FIR - Chiew, I
IR  - Chiew I
FIR - Chiew, L
IR  - Chiew L
FIR - Chikarsal, A
IR  - Chikarsal A
FIR - Chin, J
IR  - Chin J
FIR - Chin, M
IR  - Chin M
FIR - Chipman, J S
IR  - Chipman JS
FIR - Chipperfield, C
IR  - Chipperfield C
FIR - Chisholm, H
IR  - Chisholm H
FIR - Chisholm, L
IR  - Chisholm L
FIR - Chiu, A
IR  - Chiu A
FIR - Chiu, C
IR  - Chiu C
FIR - Chiu, D
IR  - Chiu D
FIR - Chiu, T
IR  - Chiu T
FIR - Chizik, L
IR  - Chizik L
FIR - Choksey, H
IR  - Choksey H
FIR - Choo, E
IR  - Choo E
FIR - Chow, Amy
IR  - Chow A
FIR - Chow, Andrew
IR  - Chow A
FIR - Choy, C
IR  - Choy C
FIR - Chu, S
IR  - Chu S
FIR - Chua, A
IR  - Chua A
FIR - Chuah, T
IR  - Chuah T
FIR - Chung, J
IR  - Chung J
FIR - Cimpoescu, T
IR  - Cimpoescu T
FIR - Clapton, J
IR  - Clapton J
FIR - Clark, Benedict
IR  - Clark B
FIR - Clark, Benjamin
IR  - Clark B
FIR - Clark, M
IR  - Clark M
FIR - Clark, R
IR  - Clark R
FIR - Clarke, A
IR  - Clarke A
FIR - Clarke, D
IR  - Clarke D
FIR - Clarke, S
IR  - Clarke S
FIR - Cleary, G
IR  - Cleary G
FIR - Clerigo, L
IR  - Clerigo L
FIR - Clohesy, S
IR  - Clohesy S
FIR - Close, S
IR  - Close S
FIR - Cochrane, F
IR  - Cochrane F
FIR - Cohen, I S
IR  - Cohen IS
FIR - Cohen, J
IR  - Cohen J
FIR - Colahan, R
IR  - Colahan R
FIR - Collins, J
IR  - Collins J
FIR - Colman, W
IR  - Colman W
FIR - Colvin, R
IR  - Colvin R
FIR - Conde, S
IR  - Conde S
FIR - Connell, P
IR  - Connell P
FIR - Connellan, M
IR  - Connellan M
FIR - Connor, W
IR  - Connor W
FIR - Connors, G
IR  - Connors G
FIR - Conos, M
IR  - Conos M
FIR - Conron, D
IR  - Conron D
FIR - Conroy, J
IR  - Conroy J
FIR - Conway, C
IR  - Conway C
FIR - Cooper, M
IR  - Cooper M
FIR - Cooper, S
IR  - Cooper S
FIR - Cope, A
IR  - Cope A
FIR - Corrigan, Simon
IR  - Corrigan S
FIR - Corrigan, Sue
IR  - Corrigan S
FIR - Coughlan, P
IR  - Coughlan P
FIR - Coulter, E
IR  - Coulter E
FIR - Counsel, L
IR  - Counsel L
FIR - Court, D
IR  - Court D
FIR - Courtis, G
IR  - Courtis G
FIR - Cousens, A
IR  - Cousens A
FIR - Craig, L
IR  - Craig L
FIR - Crameri, M
IR  - Crameri M
FIR - Cranswick, M
IR  - Cranswick M
FIR - Crawford, J
IR  - Crawford J
FIR - Crawford, M
IR  - Crawford M
FIR - Crawford, P
IR  - Crawford P
FIR - Crawford, R
IR  - Crawford R
FIR - Crick, S
IR  - Crick S
FIR - Crimmins, B
IR  - Crimmins B
FIR - Cristofaro, R
IR  - Cristofaro R
FIR - Croatto, J
IR  - Croatto J
FIR - Crompton, A
IR  - Crompton A
FIR - Cronin, E
IR  - Cronin E
FIR - Crookes, J
IR  - Crookes J
FIR - Cross, B
IR  - Cross B
FIR - Cross, D
IR  - Cross D
FIR - Cross, M
IR  - Cross M
FIR - Crow, P
IR  - Crow P
FIR - Crowe, J E
IR  - Crowe JE
FIR - Crowe, P
IR  - Crowe P
FIR - Crowley, H
IR  - Crowley H
FIR - Cruickshank, J
IR  - Cruickshank J
FIR - Cummins, R
IR  - Cummins R
FIR - Cunneen, A
IR  - Cunneen A
FIR - Cunningham, A
IR  - Cunningham A
FIR - Cunningham, N
IR  - Cunningham N
FIR - Cunningham, P
IR  - Cunningham P
FIR - Curnow, D
IR  - Curnow D
FIR - Curran, J
IR  - Curran J
FIR - Curran, M
IR  - Curran M
FIR - Currie, A
IR  - Currie A
FIR - Curtis, R
IR  - Curtis R
FIR - Cusack, J
IR  - Cusack J
FIR - Dabash, K
IR  - Dabash K
FIR - Dabestani, V
IR  - Dabestani V
FIR - Dadabhay, Z
IR  - Dadabhay Z
FIR - Daglas, D
IR  - Daglas D
FIR - Dagley, P
IR  - Dagley P
FIR - Danesh, S
IR  - Danesh S
FIR - Dang, D
IR  - Dang D
FIR - Daniels, R
IR  - Daniels R
FIR - Darby, J P
IR  - Darby JP
FIR - Darko, N
IR  - Darko N
FIR - Darling, J
IR  - Darling J
FIR - Darlington, B
IR  - Darlington B
FIR - Das, J
IR  - Das J
FIR - Das, P
IR  - Das P
FIR - Date, M
IR  - Date M
FIR - Datta, C
IR  - Datta C
FIR - Datta, S
IR  - Datta S
FIR - Davenport, C
IR  - Davenport C
FIR - Davey, G
IR  - Davey G
FIR - Davey, M
IR  - Davey M
FIR - Davey, P
IR  - Davey P
FIR - Davidson, C L
IR  - Davidson CL
FIR - Davidson, D
IR  - Davidson D
FIR - Davies, M
IR  - Davies M
FIR - Davies-Hakeem, A
IR  - Davies-Hakeem A
FIR - Davis, G
IR  - Davis G
FIR - Davis, K
IR  - Davis K
FIR - Davis, Paul
IR  - Davis P
FIR - Davis, Peter
IR  - Davis P
FIR - Davis, S
IR  - Davis S
FIR - Dawe, N
IR  - Dawe N
FIR - Dawes, R
IR  - Dawes R
FIR - Dawkins, P
IR  - Dawkins P
FIR - Dawson, G
IR  - Dawson G
FIR - Dawson, P
IR  - Dawson P
FIR - Dawson, R
IR  - Dawson R
FIR - Day, P
IR  - Day P
FIR - Daya, M
IR  - Daya M
FIR - Dayasagar, D
IR  - Dayasagar D
FIR - D’Costa, L
IR  - D’Costa L
FIR - De Clifford, M
IR  - De Clifford M
FIR - De Gleria, S
IR  - De Gleria S
FIR - De Poi, C
IR  - De Poi C
FIR - De Silva, M
IR  - De Silva M
FIR - De Silva, P
IR  - De Silva P
FIR - De Steiger, R
IR  - De Steiger R
FIR - De Villiers, D
IR  - De Villiers D
FIR - De Wit, E
IR  - De Wit E
FIR - Debnath, R
IR  - Debnath R
FIR - Deery, R
IR  - Deery R
FIR - De Lanerolle, D
IR  - De Lanerolle D
FIR - Del Rio, F
IR  - Del Rio F
FIR - Delaney, S
IR  - Delaney S
FIR - Delitzsch, S S
IR  - Delitzsch SS
FIR - Demaio, F
IR  - Demaio F
FIR - Demian, M
IR  - Demian M
FIR - Demirtzoglou, J
IR  - Demirtzoglou J
FIR - Denton, T
IR  - Denton T
FIR - Derrick, L
IR  - Derrick L
FIR - Deshmukh, K
IR  - Deshmukh K
FIR - Dessauer, J
IR  - Dessauer J
FIR - Devavittiya, C
IR  - Devavittiya C
FIR - Devereux, D
IR  - Devereux D
FIR - Dewan, D
IR  - Dewan D
FIR - Dewhurst, H
IR  - Dewhurst H
FIR - Dhar, A
IR  - Dhar A
FIR - Dhillon, D
IR  - Dhillon D
FIR - Di Carlo, M
IR  - Di Carlo M
FIR - Di Dio, A
IR  - Di Dio A
FIR - Di Marco, A
IR  - Di Marco A
FIR - Dickman, J
IR  - Dickman J
FIR - Dillon, L
IR  - Dillon L
FIR - Dinh, Q-T
IR  - Dinh QT
FIR - Dissanayake, D
IR  - Dissanayake D
FIR - Dissanayake, M
IR  - Dissanayake M
FIR - Dissanayake, T
IR  - Dissanayake T
FIR - Divakaran, K
IR  - Divakaran K
FIR - Dixit, U
IR  - Dixit U
FIR - Dixon, H
IR  - Dixon H
FIR - Dixon, N
IR  - Dixon N
FIR - Djakic, E
IR  - Djakic E
FIR - Dobson, C
IR  - Dobson C
FIR - Dodd, L
IR  - Dodd L
FIR - Dodds, P
IR  - Dodds P
FIR - Dodic, A
IR  - Dodic A
FIR - Dodic, M
IR  - Dodic M
FIR - Doley, A
IR  - Doley A
FIR - Dolguina, S
IR  - Dolguina S
FIR - Dolling, C
IR  - Dolling C
FIR - Donaghy, F
IR  - Donaghy F
FIR - Donald, H
IR  - Donald H
FIR - Donelan, E
IR  - Donelan E
FIR - Donohue, M
IR  - Donohue M
FIR - Dooland, J
IR  - Dooland J
FIR - Dooley, H
IR  - Dooley H
FIR - Doslo, S
IR  - Doslo S
FIR - Douglas, A
IR  - Douglas A
FIR - Dover, P
IR  - Dover P
FIR - Downe, G
IR  - Downe G
FIR - Drake, P
IR  - Drake P
FIR - Dry, D
IR  - Dry D
FIR - Duane, P
IR  - Duane P
FIR - Dubash, A
IR  - Dubash A
FIR - Dubetz, D
IR  - Dubetz D
FIR - Duff, P
IR  - Duff P
FIR - Duke, R
IR  - Duke R
FIR - Dumitrescu, C
IR  - Dumitrescu C
FIR - Dunbar, A
IR  - Dunbar A
FIR - Dunbar, S
IR  - Dunbar S
FIR - Dunn, S
IR  - Dunn S
FIR - Duong, N H
IR  - Duong NH
FIR - Dutta, N
IR  - Dutta N
FIR - Dutton, M
IR  - Dutton M
FIR - Duval, A
IR  - Duval A
FIR - Dyson-Berry, J
IR  - Dyson-Berry J
FIR - Eade, P
IR  - Eade P
FIR - Eaton, D
IR  - Eaton D
FIR - Ebert, K
IR  - Ebert K
FIR - Edib, K
IR  - Edib K
FIR - Edillo, E
IR  - Edillo E
FIR - Edmonds, J
IR  - Edmonds J
FIR - Edwards, F
IR  - Edwards F
FIR - Edwards, P A
IR  - Edwards PA
FIR - Edwards, S
IR  - Edwards S
FIR - Eftekharuddin, M
IR  - Eftekharuddin M
FIR - Egan, A
IR  - Egan A
FIR - Egan, P
IR  - Egan P
FIR - Ehrenreich, S
IR  - Ehrenreich S
FIR - Ehsan, E
IR  - Ehsan E
FIR - Elberg, L
IR  - Elberg L
FIR - Elisha, B
IR  - Elisha B
FIR - Elisha, R
IR  - Elisha R
FIR - Elkhoury, H
IR  - Elkhoury H
FIR - Ellerton, K
IR  - Ellerton K
FIR - Elliot-Smith, A
IR  - Elliot-Smith A
FIR - Elmore, R
IR  - Elmore R
FIR - Elshenawy, I
IR  - Elshenawy I
FIR - Elsherif, S
IR  - Elsherif S
FIR - Elsouki, M
IR  - Elsouki M
FIR - Elton, P
IR  - Elton P
FIR - Emmerson, M
IR  - Emmerson M
FIR - Emmett, S I
IR  - Emmett SI
FIR - English, J
IR  - English J
FIR - Enten, P
IR  - Enten P
FIR - Entwistle, J
IR  - Entwistle J
FIR - Epa, W
IR  - Epa W
FIR - Erhardt, A
IR  - Erhardt A
FIR - Etta, J
IR  - Etta J
FIR - Evans, M
IR  - Evans M
FIR - Everitt, T
IR  - Everitt T
FIR - Ewing, J
IR  - Ewing J
FIR - Fahkok, B
IR  - Fahkok B
FIR - Faigen, M
IR  - Faigen M
FIR - Fair, A
IR  - Fair A
FIR - Fairbrother, C
IR  - Fairbrother C
FIR - Fanning, J
IR  - Fanning J
FIR - Fantasia, M
IR  - Fantasia M
FIR - Farag, E
IR  - Farag E
FIR - Fardell, K
IR  - Fardell K
FIR - Farrant, J
IR  - Farrant J
FIR - Farrell, P
IR  - Farrell P
FIR - Farrow, J
IR  - Farrow J
FIR - Fassett, M
IR  - Fassett M
FIR - Faull, P A
IR  - Faull PA
FIR - Ferguson, P
IR  - Ferguson P
FIR - Fernando, Sujeewa
IR  - Fernando S
FIR - Fernando, Sumudu
IR  - Fernando S
FIR - Ferruccio, A
IR  - Ferruccio A
FIR - Fidge, J H
IR  - Fidge JH
FIR - Field, P
IR  - Field P
FIR - Figurireo, L
IR  - Figurireo L
FIR - Fisher, H
IR  - Fisher H
FIR - Fisher, J
IR  - Fisher J
FIR - Fitzgerald, E
IR  - Fitzgerald E
FIR - Fitzgerald, M
IR  - Fitzgerald M
FIR - Fitzgerald, R
IR  - Fitzgerald R
FIR - Fitzpatrick, H
IR  - Fitzpatrick H
FIR - Fitzpatrick, J
IR  - Fitzpatrick J
FIR - Fitzpatrick, P
IR  - Fitzpatrick P
FIR - Fitzpatrick, T
IR  - Fitzpatrick T
FIR - Flaherty, P
IR  - Flaherty P
FIR - Flanagan, D
IR  - Flanagan D
FIR - Flanagan, T
IR  - Flanagan T
FIR - Flew, S
IR  - Flew S
FIR - Fonseka, P P
IR  - Fonseka PP
FIR - Foo, J
IR  - Foo J
FIR - Foo, S
IR  - Foo S
FIR - Foo, Y
IR  - Foo Y
FIR - Foong, E
IR  - Foong E
FIR - Ford, D
IR  - Ford D
FIR - Foster, D
IR  - Foster D
FIR - Fourlanos, V
IR  - Fourlanos V
FIR - Fowler, I
IR  - Fowler I
FIR - Fox, D
IR  - Fox D
FIR - Fox, F
IR  - Fox F
FIR - Fox, M
IR  - Fox M
FIR - Fox, P
IR  - Fox P
FIR - Fox-Smith, D
IR  - Fox-Smith D
FIR - Francis, J
IR  - Francis J
FIR - Francis, R
IR  - Francis R
FIR - Frank, O
IR  - Frank O
FIR - Franks, A
IR  - Franks A
FIR - Fredericks, A
IR  - Fredericks A
FIR - Freeman, E
IR  - Freeman E
FIR - French, L
IR  - French L
FIR - Frew, B
IR  - Frew B
FIR - Friebel, D
IR  - Friebel D
FIR - Friebel, T
IR  - Friebel T
FIR - Frost, S
IR  - Frost S
FIR - Fryer, D
IR  - Fryer D
FIR - Fuller, J
IR  - Fuller J
FIR - Fung, W
IR  - Fung W
FIR - Fung, W P
IR  - Fung WP
FIR - Furphy, S
IR  - Furphy S
FIR - Gabutina, C
IR  - Gabutina C
FIR - Gaggin, S
IR  - Gaggin S
FIR - Galbraith, S
IR  - Galbraith S
FIR - Gale, M
IR  - Gale M
FIR - Gall, J
IR  - Gall J
FIR - Gallichio, V
IR  - Gallichio V
FIR - Gangell, A W
IR  - Gangell AW
FIR - Garde, M A
IR  - Garde MA
FIR - Gardner, S S
IR  - Gardner SS
FIR - Gardner, T
IR  - Gardner T
FIR - Garland, J
IR  - Garland J
FIR - Garra, G
IR  - Garra G
FIR - Garrow, S
IR  - Garrow S
FIR - Garvey, J
IR  - Garvey J
FIR - Gauden, M
IR  - Gauden M
FIR - Gault, A
IR  - Gault A
FIR - Gaur, D
IR  - Gaur D
FIR - Gavralas, A
IR  - Gavralas A
FIR - George, N
IR  - George N
FIR - George, S
IR  - George S
FIR - Georgy, M
IR  - Georgy M
FIR - Gerendasi, R
IR  - Gerendasi R
FIR - Geschke, H
IR  - Geschke H
FIR - Giannakakis, J
IR  - Giannakakis J
FIR - Gidley, G
IR  - Gidley G
FIR - Gilani, M
IR  - Gilani M
FIR - Giles, P
IR  - Giles P
FIR - Gill, K
IR  - Gill K
FIR - Gill, P
IR  - Gill P
FIR - Gill, R
IR  - Gill R
FIR - Gillis, C
IR  - Gillis C
FIR - Gilmore, A
IR  - Gilmore A
FIR - Gilovitz, M
IR  - Gilovitz M
FIR - Gingold, R
IR  - Gingold R
FIR - Glaspole, D
IR  - Glaspole D
FIR - Glowinski, L
IR  - Glowinski L
FIR - Glue, A L
IR  - Glue AL
FIR - Godakumbura, P
IR  - Godakumbura P
FIR - Godavarthy, R
IR  - Godavarthy R
FIR - Goel, A
IR  - Goel A
FIR - Goeltom, C
IR  - Goeltom C
FIR - Goldberg, E
IR  - Goldberg E
FIR - Goldberg, J
IR  - Goldberg J
FIR - Golets, M
IR  - Golets M
FIR - Gong, V
IR  - Gong V
FIR - Goode, J
IR  - Goode J
FIR - Goodman, C
IR  - Goodman C
FIR - Goodwin, R J
IR  - Goodwin RJ
FIR - Gopathy, S
IR  - Gopathy S
FIR - Gordon, M
IR  - Gordon M
FIR - Gough, S
IR  - Gough S
FIR - Govender, M
IR  - Govender M
FIR - Gow, K
IR  - Gow K
FIR - Gowrie, B
IR  - Gowrie B
FIR - Goy, P
IR  - Goy P
FIR - Grabowski, C
IR  - Grabowski C
FIR - Graddon, J
IR  - Graddon J
FIR - Granek, A
IR  - Granek A
FIR - Gray, J M
IR  - Gray JM
FIR - Gray, M
IR  - Gray M
FIR - Gray, T
IR  - Gray T
FIR - Grbac, E
IR  - Grbac E
FIR - Greacen, J
IR  - Greacen J
FIR - Greculescu, E
IR  - Greculescu E
FIR - Green, J
IR  - Green J
FIR - Greenwood, E
IR  - Greenwood E
FIR - Griffin, E
IR  - Griffin E
FIR - Griffith, V
IR  - Griffith V
FIR - Griffiths, A
IR  - Griffiths A
FIR - Griffiths, G
IR  - Griffiths G
FIR - Griffiths, J
IR  - Griffiths J
FIR - Griffiths, K
IR  - Griffiths K
FIR - Grigorian, A R
IR  - Grigorian AR
FIR - Grinzi, P
IR  - Grinzi P
FIR - Grogan, H
IR  - Grogan H
FIR - Grokop, G
IR  - Grokop G
FIR - Grossman, L
IR  - Grossman L
FIR - Grove, A
IR  - Grove A
FIR - Gruzauskas, A
IR  - Gruzauskas A
FIR - Gu, M
IR  - Gu M
FIR - Guest, S
IR  - Guest S
FIR - Guindi, N
IR  - Guindi N
FIR - Guo, H
IR  - Guo H
FIR - Gurney, R
IR  - Gurney R
FIR - Guy, J
IR  - Guy J
FIR - Guymer, J
IR  - Guymer J
FIR - Gwynn, R
IR  - Gwynn R
FIR - Gyorki, J
IR  - Gyorki J
FIR - Habibi, S
IR  - Habibi S
FIR - Hachem, C
IR  - Hachem C
FIR - Hackett, A
IR  - Hackett A
FIR - Hackett, J
IR  - Hackett J
FIR - Haddad, J
IR  - Haddad J
FIR - Haddad, M
IR  - Haddad M
FIR - Hadley, E
IR  - Hadley E
FIR - Hagger, R
IR  - Hagger R
FIR - Haider, Z
IR  - Haider Z
FIR - Hain, R
IR  - Hain R
FIR - Hajicosta, T
IR  - Hajicosta T
FIR - Hales, P
IR  - Hales P
FIR - Hall, J
IR  - Hall J
FIR - Hall, P
IR  - Hall P
FIR - Hall, Robert
IR  - Hall R
FIR - Hall, Roslyn
IR  - Hall R
FIR - Hall, S
IR  - Hall S
FIR - Halliburton, K
IR  - Halliburton K
FIR - Halliday, A
IR  - Halliday A
FIR - Halliday, B
IR  - Halliday B
FIR - Halliday, J
IR  - Halliday J
FIR - Hamblen, K
IR  - Hamblen K
FIR - Hamel, J
IR  - Hamel J
FIR - Hamer, I
IR  - Hamer I
FIR - Hamilton, J
IR  - Hamilton J
FIR - Hamilton, R F
IR  - Hamilton RF
FIR - Hammond, T
IR  - Hammond T
FIR - Hanbury, R
IR  - Hanbury R
FIR - Hancock, A
IR  - Hancock A
FIR - Hand, R
IR  - Hand R
FIR - Hanna, A
IR  - Hanna A
FIR - Hanna, M
IR  - Hanna M
FIR - Hanna, S
IR  - Hanna S
FIR - Hanson, G
IR  - Hanson G
FIR - Hanson, P D
IR  - Hanson PD
FIR - Haque, E
IR  - Haque E
FIR - Haran, C
IR  - Haran C
FIR - Haran, T
IR  - Haran T
FIR - Hare, W J
IR  - Hare WJ
FIR - Harewood, A
IR  - Harewood A
FIR - Haripersad, S
IR  - Haripersad S
FIR - Harman, A
IR  - Harman A
FIR - Harmer, D
IR  - Harmer D
FIR - Harms, P
IR  - Harms P
FIR - Harnden, C
IR  - Harnden C
FIR - Harrington, M
IR  - Harrington M
FIR - Harris, A
IR  - Harris A
FIR - Harris, M
IR  - Harris M
FIR - Harrison, M
IR  - Harrison M
FIR - Harrison, S
IR  - Harrison S
FIR - Hart, E
IR  - Hart E
FIR - Hartley, D
IR  - Hartley D
FIR - Hartley, P
IR  - Hartley P
FIR - Hartnett, M
IR  - Hartnett M
FIR - Harvey, C
IR  - Harvey C
FIR - Haslam, K
IR  - Haslam K
FIR - Hassani, I
IR  - Hassani I
FIR - Hassett, R B
IR  - Hassett RB
FIR - Hastings, W
IR  - Hastings W
FIR - Hattingh, A
IR  - Hattingh A
FIR - Hawke, I
IR  - Hawke I
FIR - Hawkins, C
IR  - Hawkins C
FIR - Hayes, V
IR  - Hayes V
FIR - Heale, J
IR  - Heale J
FIR - Healy, G
IR  - Healy G
FIR - Hebblewhite, A
IR  - Hebblewhite A
FIR - Hechtman, A
IR  - Hechtman A
FIR - Hedgland, A
IR  - Hedgland A
FIR - Heffernan, C
IR  - Heffernan C
FIR - Heikkinen, M N
IR  - Heikkinen MN
FIR - Heinrich, C
IR  - Heinrich C
FIR - Henderson, J
IR  - Henderson J
FIR - Henry, F
IR  - Henry F
FIR - Herath, S
IR  - Herath S
FIR - Herbert, A
IR  - Herbert A
FIR - Herbst, D
IR  - Herbst D
FIR - Hermiz, S
IR  - Hermiz S
FIR - Herrman, J
IR  - Herrman J
FIR - Hesse, M
IR  - Hesse M
FIR - Hetherington, J
IR  - Hetherington J
FIR - Hetzel, R
IR  - Hetzel R
FIR - Hewett, R
IR  - Hewett R
FIR - Hides, R
IR  - Hides R
FIR - Higgins, C D
IR  - Higgins CD
FIR - Hildred, S
IR  - Hildred S
FIR - Hill, A
IR  - Hill A
FIR - Hilton, C
IR  - Hilton C
FIR - Hince, R
IR  - Hince R
FIR - Hines, C
IR  - Hines C
FIR - Hinton, C
IR  - Hinton C
FIR - Hipolito, A
IR  - Hipolito A
FIR - Ho, C K
IR  - Ho CK
FIR - Ho, L
IR  - Ho L
FIR - Hoar, J
IR  - Hoar J
FIR - Hocking, L
IR  - Hocking L
FIR - Hodge, A
IR  - Hodge A
FIR - Hodgkins, A
IR  - Hodgkins A
FIR - Hodgson, J
IR  - Hodgson J
FIR - Hogbin, J
IR  - Hogbin J
FIR - Hok, S
IR  - Hok S
FIR - Holder, B
IR  - Holder B
FIR - Holland, D
IR  - Holland D
FIR - Holland, M
IR  - Holland M
FIR - Hollins, B
IR  - Hollins B
FIR - Homewood, M
IR  - Homewood M
FIR - Hong Zhou, A
IR  - Hong Zhou A
FIR - Honig, J
IR  - Honig J
FIR - Honigman, S
IR  - Honigman S
FIR - Hookham, D
IR  - Hookham D
FIR - Hooper, W
IR  - Hooper W
FIR - Hope, L
IR  - Hope L
FIR - Horman, J
IR  - Horman J
FIR - Horng, T
IR  - Horng T
FIR - Hornstein, I
IR  - Hornstein I
FIR - Horriat, M
IR  - Horriat M
FIR - Horvat, J
IR  - Horvat J
FIR - Hossain, M
IR  - Hossain M
FIR - Hough, P
IR  - Hough P
FIR - Howe, J
IR  - Howe J
FIR - Howson, W
IR  - Howson W
FIR - Hubczenko, I
IR  - Hubczenko I
FIR - Hubel, M
IR  - Hubel M
FIR - Hughes, J
IR  - Hughes J
FIR - Hughes, P
IR  - Hughes P
FIR - Hunter, D
IR  - Hunter D
FIR - Huq, S
IR  - Huq S
FIR - Hussain, A
IR  - Hussain A
FIR - Hutchins, I
IR  - Hutchins I
FIR - Hutchinson, A
IR  - Hutchinson A
FIR - Hyam, P
IR  - Hyam P
FIR - Hyare, K
IR  - Hyare K
FIR - Iakovidis, B
IR  - Iakovidis B
FIR - Ibragimov, M
IR  - Ibragimov M
FIR - Idris, M
IR  - Idris M
FIR - Ierace, C
IR  - Ierace C
FIR - Ikladios, A
IR  - Ikladios A
FIR - Imgraben, P
IR  - Imgraben P
FIR - Ingham, C
IR  - Ingham C
FIR - Ip, A
IR  - Ip A
FIR - Ip, Y
IR  - Ip Y
FIR - Iqbal, A
IR  - Iqbal A
FIR - Iqbal, M
IR  - Iqbal M
FIR - Irvine, G
IR  - Irvine G
FIR - Irwin, V
IR  - Irwin V
FIR - Iser, D
IR  - Iser D
FIR - Islam, N
IR  - Islam N
FIR - Islam, S
IR  - Islam S
FIR - Isles, J K
IR  - Isles JK
FIR - Ismail, A
IR  - Ismail A
FIR - Ivanoff, G
IR  - Ivanoff G
FIR - Iwe, N
IR  - Iwe N
FIR - Jackett, R B
IR  - Jackett RB
FIR - Jackson, M
IR  - Jackson M
FIR - Jackson, N
IR  - Jackson N
FIR - Jackson, P
IR  - Jackson P
FIR - Jackson, T
IR  - Jackson T
FIR - Jacoup, M
IR  - Jacoup M
FIR - Jaensch, E
IR  - Jaensch E
FIR - Jain, P
IR  - Jain P
FIR - Jain, S
IR  - Jain S
FIR - Jaiswal, N
IR  - Jaiswal N
FIR - Jaksic, A
IR  - Jaksic A
FIR - Jakubowicz, I
IR  - Jakubowicz I
FIR - Jamel, B
IR  - Jamel B
FIR - James, J
IR  - James J
FIR - Jameson, D
IR  - Jameson D
FIR - Jansz, C
IR  - Jansz C
FIR - Jarman, E
IR  - Jarman E
FIR - Jassi, I
IR  - Jassi I
FIR - Jayasinghe, S
IR  - Jayasinghe S
FIR - Jayatilake, J
IR  - Jayatilake J
FIR - Jayaweera, V
IR  - Jayaweera V
FIR - Jeanes, R
IR  - Jeanes R
FIR - Jeanneret, C I
IR  - Jeanneret CI
FIR - Jedynak, S
IR  - Jedynak S
FIR - Jeffries, L
IR  - Jeffries L
FIR - Jegadeesh, K
IR  - Jegadeesh K
FIR - Jenkins, P
IR  - Jenkins P
FIR - Jennings, C
IR  - Jennings C
FIR - Jenny, C
IR  - Jenny C
FIR - Jiang, Y Y
IR  - Jiang YY
FIR - Jigau, C
IR  - Jigau C
FIR - Jinadasa, C
IR  - Jinadasa C
FIR - Joel, S
IR  - Joel S
FIR - John, R
IR  - John R
FIR - Johns, P
IR  - Johns P
FIR - Johnson, C
IR  - Johnson C
FIR - Johnson, J
IR  - Johnson J
FIR - Johnson, M
IR  - Johnson M
FIR - Johnson, N
IR  - Johnson N
FIR - Johnson, W
IR  - Johnson W
FIR - Johnston, B
IR  - Johnston B
FIR - Johnston, K
IR  - Johnston K
FIR - Johnston, M
IR  - Johnston M
FIR - Johnston, R
IR  - Johnston R
FIR - Johnston, T
IR  - Johnston T
FIR - Jones, G
IR  - Jones G
FIR - Jones, I
IR  - Jones I
FIR - Jones, L
IR  - Jones L
FIR - Jones, M
IR  - Jones M
FIR - Jones, S
IR  - Jones S
FIR - Jones, Tania
IR  - Jones T
FIR - Jones, Tudor
IR  - Jones T
FIR - Joshi, M
IR  - Joshi M
FIR - Joshi, Naveen
IR  - Joshi N
FIR - Joshi, Nirupama
IR  - Joshi N
FIR - Joske, F
IR  - Joske F
FIR - Joubert, C
IR  - Joubert C
FIR - Jovanovic, B
IR  - Jovanovic B
FIR - Joyce, R
IR  - Joyce R
FIR - Judd, A M
IR  - Judd AM
FIR - Judd, J
IR  - Judd J
FIR - Kaaden, J P
IR  - Kaaden JP
FIR - Kabat, L
IR  - Kabat L
FIR - Kabourakis, F
IR  - Kabourakis F
FIR - Kaippilly, A
IR  - Kaippilly A
FIR - Kajani, H
IR  - Kajani H
FIR - Kamale, A
IR  - Kamale A
FIR - Kaminsky, L
IR  - Kaminsky L
FIR - Kanapathipillai, U
IR  - Kanapathipillai U
FIR - Kanashuk, L
IR  - Kanashuk L
FIR - Kao, R
IR  - Kao R
FIR - Kapadia, P
IR  - Kapadia P
FIR - Kapadia, V
IR  - Kapadia V
FIR - Karmouche, R
IR  - Karmouche R
FIR - Kaur, K J
IR  - Kaur KJ
FIR - Kavanagh, T
IR  - Kavanagh T
FIR - Kay, A
IR  - Kay A
FIR - Kay, B
IR  - Kay B
FIR - Kaye, S
IR  - Kaye S
FIR - Keane, K
IR  - Keane K
FIR - Keating, B
IR  - Keating B
FIR - Keecha, E
IR  - Keecha E
FIR - Keecha, J
IR  - Keecha J
FIR - Keenan, P
IR  - Keenan P
FIR - Keillar, P
IR  - Keillar P
FIR - Kemp, G
IR  - Kemp G
FIR - Kemp, P
IR  - Kemp P
FIR - Kennedy, M
IR  - Kennedy M
FIR - Kennedy, U
IR  - Kennedy U
FIR - Kennett, S
IR  - Kennett S
FIR - Kesarapu, S
IR  - Kesarapu S
FIR - Khan, F
IR  - Khan F
FIR - Khan, I
IR  - Khan I
FIR - Khan, M
IR  - Khan M
FIR - Khong, C K
IR  - Khong CK
FIR - Khoo, F
IR  - Khoo F
FIR - Khoo, J
IR  - Khoo J
FIR - Khoo, S
IR  - Khoo S
FIR - Khoshghalb, A
IR  - Khoshghalb A
FIR - Kiefer, J
IR  - Kiefer J
FIR - Kiley, M
IR  - Kiley M
FIR - Kilov, G
IR  - Kilov G
FIR - Kimpton, N
IR  - Kimpton N
FIR - King, S C
IR  - King SC
FIR - Kingston, R
IR  - Kingston R
FIR - Kinsella, P
IR  - Kinsella P
FIR - Kipouridis, A
IR  - Kipouridis A
FIR - Kirwan, A
IR  - Kirwan A
FIR - Kisselev, S
IR  - Kisselev S
FIR - Kitchen, J
IR  - Kitchen J
FIR - Kloot, S
IR  - Kloot S
FIR - Knaggs, J
IR  - Knaggs J
FIR - Knight, E
IR  - Knight E
FIR - Knobel, J
IR  - Knobel J
FIR - Knowles, D
IR  - Knowles D
FIR - Knowles, P
IR  - Knowles P
FIR - Kogosowski, S
IR  - Kogosowski S
FIR - Kok, Jereth
IR  - Kok J
FIR - Kok, Joyce
IR  - Kok J
FIR - Kollios, D
IR  - Kollios D
FIR - Konopnicki, H
IR  - Konopnicki H
FIR - Koravos, A
IR  - Koravos A
FIR - Korol, P
IR  - Korol P
FIR - Kosky, A R
IR  - Kosky AR
FIR - Kote Somashekarappa, M
IR  - Kote Somashekarappa M
FIR - Kottegoda-Vithana, E
IR  - Kottegoda-Vithana E
FIR - Kotur, S
IR  - Kotur S
FIR - Kozminsky, M
IR  - Kozminsky M
FIR - Kraner, G
IR  - Kraner G
FIR - Kraus, D H
IR  - Kraus DH
FIR - Krell, I
IR  - Krell I
FIR - Kruytbosch, C
IR  - Kruytbosch C
FIR - Kuay, V
IR  - Kuay V
FIR - Kucminska, A
IR  - Kucminska A
FIR - Kulatunga, P
IR  - Kulatunga P
FIR - Kulinski, M
IR  - Kulinski M
FIR - Kumar, J
IR  - Kumar J
FIR - Kumar, R
IR  - Kumar R
FIR - Kumar, S
IR  - Kumar S
FIR - Kumarage, D
IR  - Kumarage D
FIR - Kumaraswamy, S
IR  - Kumaraswamy S
FIR - Kunze, M
IR  - Kunze M
FIR - Kurien, S
IR  - Kurien S
FIR - Kuruvilla, P
IR  - Kuruvilla P
FIR - Kwong, R
IR  - Kwong R
FIR - Kyaw, Z
IR  - Kyaw Z
FIR - Kyriacopoulos, J
IR  - Kyriacopoulos J
FIR - Lackner, P J
IR  - Lackner PJ
FIR - Lahanis, C
IR  - Lahanis C
FIR - Lajoie, D
IR  - Lajoie D
FIR - Lajoie, K
IR  - Lajoie K
FIR - Lakshmanan, A
IR  - Lakshmanan A
FIR - Lal, A
IR  - Lal A
FIR - Lalor, E
IR  - Lalor E
FIR - Lam, D
IR  - Lam D
FIR - Lambooij, C
IR  - Lambooij C
FIR - Lancaster, M
IR  - Lancaster M
FIR - Landa, L
IR  - Landa L
FIR - Landers, J
IR  - Landers J
FIR - Lane, R
IR  - Lane R
FIR - Langston, K
IR  - Langston K
FIR - Lapin, S
IR  - Lapin S
FIR - Lath, P
IR  - Lath P
FIR - Lau-Gooey, T
IR  - Lau-Gooey T
FIR - Lawlor-Smith, L
IR  - Lawlor-Smith L
FIR - Le Couteur, S
IR  - Le Couteur S
FIR - Le, P
IR  - Le P
FIR - Le Riche, M
IR  - Le Riche M
FIR - Le, V
IR  - Le V
FIR - Le, W
IR  - Le W
FIR - Leber, D
IR  - Leber D
FIR - Ledner, A
IR  - Ledner A
FIR - Lee, B
IR  - Lee B
FIR - Lee, C
IR  - Lee C
FIR - Lee, D
IR  - Lee D
FIR - Lee, F B
IR  - Lee FB
FIR - Lee, Jade
IR  - Lee J
FIR - Lee, James
IR  - Lee J
FIR - Lee, Jessicasu-Yin
IR  - Lee JY
FIR - Lee, John
IR  - Lee J
FIR - Lees, K
IR  - Lees K
FIR - Lees, R
IR  - Lees R
FIR - Lees, W
IR  - Lees W
FIR - Leffler, P
IR  - Leffler P
FIR - Lenton, J
IR  - Lenton J
FIR - Leong, R
IR  - Leong R
FIR - Leow, L
IR  - Leow L
FIR - Leow, P
IR  - Leow P
FIR - Leow, Y
IR  - Leow Y
FIR - Leslie, N
IR  - Leslie N
FIR - Lester, S E
IR  - Lester SE
FIR - Lewi, L
IR  - Lewi L
FIR - Lewis, P
IR  - Lewis P
FIR - Lewis, R
IR  - Lewis R
FIR - Li, A
IR  - Li A
FIR - Li, J
IR  - Li J
FIR - Liang, J
IR  - Liang J
FIR - Liang, Xs
IR  - Liang X
FIR - Libhaber, H
IR  - Libhaber H
FIR - Lichtblau, B
IR  - Lichtblau B
FIR - Lickiss, T
IR  - Lickiss T
FIR - Liedvogel, M
IR  - Liedvogel M
FIR - Liew, K
IR  - Liew K
FIR - Light, L
IR  - Light L
FIR - Lightfoot, W
IR  - Lightfoot W
FIR - Lim, C
IR  - Lim C
FIR - Lim, D
IR  - Lim D
FIR - Lim, H
IR  - Lim H
FIR - Lim, H S
IR  - Lim HS
FIR - Lim, J
IR  - Lim J
FIR - Lim, S G
IR  - Lim SG
FIR - Limaye, S
IR  - Limaye S
FIR - Limbu, Y
IR  - Limbu Y
FIR - Lindenmayer, J
IR  - Lindenmayer J
FIR - Lindstedt, P
IR  - Lindstedt P
FIR - Lines, A
IR  - Lines A
FIR - Ling, J
IR  - Ling J
FIR - Ling, R
IR  - Ling R
FIR - Linton, J
IR  - Linton J
FIR - Linton, S
IR  - Linton S
FIR - Linton, T
IR  - Linton T
FIR - Liow, C
IR  - Liow C
FIR - Liow, Y C
IR  - Liow YC
FIR - Lip, L
IR  - Lip L
FIR - Lipson, D
IR  - Lipson D
FIR - Liu, S
IR  - Liu S
FIR - Liu, Y
IR  - Liu Y
FIR - Liubinas, R
IR  - Liubinas R
FIR - Liveriadis, T
IR  - Liveriadis T
FIR - Lizner, S
IR  - Lizner S
FIR - Lloyd, M
IR  - Lloyd M
FIR - Lo, B
IR  - Lo B
FIR - Lo, C
IR  - Lo C
FIR - Lock, P
IR  - Lock P
FIR - Lockhart, M
IR  - Lockhart M
FIR - Logan, M
IR  - Logan M
FIR - Loke, K P
IR  - Loke KP
FIR - Long, Matthew
IR  - Long M
FIR - Long, Michael
IR  - Long M
FIR - Longworth, W
IR  - Longworth W
FIR - Loo, K H
IR  - Loo KH
FIR - Lopez-Hernandez, S
IR  - Lopez-Hernandez S
FIR - Lord, R J
IR  - Lord RJ
FIR - Louw, J
IR  - Louw J
FIR - Louw, T T
IR  - Louw TT
FIR - Low, B
IR  - Low B
FIR - Low, F
IR  - Low F
FIR - Lowe, M
IR  - Lowe M
FIR - Lowther, D
IR  - Lowther D
FIR - Loxley, P
IR  - Loxley P
FIR - Lu, P
IR  - Lu P
FIR - Lu, S
IR  - Lu S
FIR - Lucarelli, A
IR  - Lucarelli A
FIR - Lui, G
IR  - Lui G
FIR - Lui, K
IR  - Lui K
FIR - Lui, R
IR  - Lui R
FIR - Luke, C
IR  - Luke C
FIR - Lukic, N
IR  - Lukic N
FIR - Lupton, J
IR  - Lupton J
FIR - Luscombe, T
IR  - Luscombe T
FIR - Luttrell, C L
IR  - Luttrell CL
FIR - Lyall, A
IR  - Lyall A
FIR - Lynch, J
IR  - Lynch J
FIR - Lynn, K
IR  - Lynn K
FIR - Lyon, D
IR  - Lyon D
FIR - Lyon, E
IR  - Lyon E
FIR - Lyons, S
IR  - Lyons S
FIR - Macaulay, G
IR  - Macaulay G
FIR - Macaulay, K
IR  - Macaulay K
FIR - MacIndoe, A
IR  - MacIndoe A
FIR - MacIsaac, P
IR  - MacIsaac P
FIR - Maciver, R
IR  - Maciver R
FIR - Mackay, B
IR  - Mackay B
FIR - Mackay, J
IR  - Mackay J
FIR - Mackinnon, D
IR  - Mackinnon D
FIR - Mackle, R
IR  - Mackle R
FIR - Macphail, J
IR  - Macphail J
FIR - Madawala, N
IR  - Madawala N
FIR - Madden, J
IR  - Madden J
FIR - Madeley, C
IR  - Madeley C
FIR - Madhanpall, N
IR  - Madhanpall N
FIR - Magarey, J
IR  - Magarey J
FIR - Magill, M
IR  - Magill M
FIR - Mah, S
IR  - Mah S
FIR - Mahadeva, S P
IR  - Mahadeva SP
FIR - Mahendran, S
IR  - Mahendran S
FIR - Maher, J
IR  - Maher J
FIR - Maher, M
IR  - Maher M
FIR - Mahmood, Aamir
IR  - Mahmood A
FIR - Mahmood, Abbas
IR  - Mahmood A
FIR - Maier, K
IR  - Maier K
FIR - Majchrzak, W
IR  - Majchrzak W
FIR - Majeed, J
IR  - Majeed J
FIR - Makar, A
IR  - Makar A
FIR - Makohon, R
IR  - Makohon R
FIR - Malcher, P
IR  - Malcher P
FIR - Malcolm, H E
IR  - Malcolm HE
FIR - Malcolm, M
IR  - Malcolm M
FIR - Mallett, S
IR  - Mallett S
FIR - Mallik, A
IR  - Mallik A
FIR - Manderson, J
IR  - Manderson J
FIR - Mane, S
IR  - Mane S
FIR - Mangan, G
IR  - Mangan G
FIR - Manifold, M
IR  - Manifold M
FIR - Manoliadis, M
IR  - Manoliadis M
FIR - Manovel, B
IR  - Manovel B
FIR - Mansour, A
IR  - Mansour A
FIR - Manton, D
IR  - Manton D
FIR - Marano, F
IR  - Marano F
FIR - Marchant, D
IR  - Marchant D
FIR - Mariajoseph, G
IR  - Mariajoseph G
FIR - Marinos, A
IR  - Marinos A
FIR - Marinucci, D
IR  - Marinucci D
FIR - Marrows, M
IR  - Marrows M
FIR - Marsh, D
IR  - Marsh D
FIR - Martin, C
IR  - Martin C
FIR - Martin, G
IR  - Martin G
FIR - Martin, R
IR  - Martin R
FIR - Marton, F
IR  - Marton F
FIR - Martynova, L
IR  - Martynova L
FIR - Mason, N
IR  - Mason N
FIR - Masood, U
IR  - Masood U
FIR - Massaud, M
IR  - Massaud M
FIR - Massy-Westropp, P
IR  - Massy-Westropp P
FIR - Masters, B
IR  - Masters B
FIR - Mather, J
IR  - Mather J
FIR - Mathews, R A
IR  - Mathews RA
FIR - Mathieson, G
IR  - Mathieson G
FIR - Mauro, M
IR  - Mauro M
FIR - Mauviel, P A
IR  - Mauviel PA
FIR - Maxfield, N
IR  - Maxfield N
FIR - Mayhead, C
IR  - Mayhead C
FIR - Mazengiya, S
IR  - Mazengiya S
FIR - Mazhar, A
IR  - Mazhar A
FIR - Mbachilin, G
IR  - Mbachilin G
FIR - McAllan, A
IR  - McAllan A
FIR - McCallum, H
IR  - McCallum H
FIR - McCann, N
IR  - McCann N
FIR - McCarthy, A
IR  - McCarthy A
FIR - McCleary, A
IR  - McCleary A
FIR - McClelland, R
IR  - McClelland R
FIR - McConville, D S
IR  - McConville DS
FIR - McCorkell, J
IR  - McCorkell J
FIR - McCormack, G
IR  - McCormack G
FIR - McCormick, H
IR  - McCormick H
FIR - McCowan, M
IR  - McCowan M
FIR - McCutcheon, J
IR  - McCutcheon J
FIR - McDonald, A G
IR  - McDonald AG
FIR - McDonald, A S
IR  - McDonald AS
FIR - McDonald, I R
IR  - McDonald IR
FIR - McDonald, J
IR  - McDonald J
FIR - McDonald, N
IR  - McDonald N
FIR - McDonald, S
IR  - McDonald S
FIR - McEniery, A
IR  - McEniery A
FIR - McEntee, K
IR  - McEntee K
FIR - McGee, R
IR  - McGee R
FIR - McGinity, P
IR  - McGinity P
FIR - McGowan, N
IR  - McGowan N
FIR - McGowan, R
IR  - McGowan R
FIR - McGrath, L
IR  - McGrath L
FIR - McGuire, Paul
IR  - McGuire P
FIR - McGuire, Precious
IR  - McGuire P
FIR - McHardy, C
IR  - McHardy C
FIR - McHenry, K
IR  - McHenry K
FIR - McIllree, R
IR  - McIllree R
FIR - McKay, M
IR  - McKay M
FIR - McKellar, C
IR  - McKellar C
FIR - McKelvie, M
IR  - McKelvie M
FIR - McKenzie, S I
IR  - McKenzie SI
FIR - McKeown, J
IR  - McKeown J
FIR - McKeown, M
IR  - McKeown M
FIR - McKernan, S
IR  - McKernan S
FIR - McKinnon, A
IR  - McKinnon A
FIR - McLaren, G
IR  - McLaren G
FIR - McLeod, I
IR  - McLeod I
FIR - McMahon, A
IR  - McMahon A
FIR - McMaster, I
IR  - McMaster I
FIR - McNab, N R
IR  - McNab NR
FIR - McNaughton, E L
IR  - McNaughton EL
FIR - McNiff, M
IR  - McNiff M
FIR - McPherson, C
IR  - McPherson C
FIR - Meaney, J
IR  - Meaney J
FIR - Medlicott, M
IR  - Medlicott M
FIR - Medres, R
IR  - Medres R
FIR - Megally, R
IR  - Megally R
FIR - Mehta, K
IR  - Mehta K
FIR - Mellios, O
IR  - Mellios O
FIR - Melvani, R
IR  - Melvani R
FIR - Mencel, J
IR  - Mencel J
FIR - Mendick, S
IR  - Mendick S
FIR - Mendis, L
IR  - Mendis L
FIR - Menzies, J
IR  - Menzies J
FIR - Mercado, M
IR  - Mercado M
FIR - Mesiha, S
IR  - Mesiha S
FIR - Meyer, P L
IR  - Meyer PL
FIR - Meyer, R
IR  - Meyer R
FIR - Miceli, A
IR  - Miceli A
FIR - Michaelson, T
IR  - Michaelson T
FIR - Michail, A
IR  - Michail A
FIR - Michelmore, K
IR  - Michelmore K
FIR - Miezis, V
IR  - Miezis V
FIR - Milan, S
IR  - Milan S
FIR - Milky, S
IR  - Milky S
FIR - Miller, K
IR  - Miller K
FIR - Milner, J
IR  - Milner J
FIR - Milone, R
IR  - Milone R
FIR - Milton, C
IR  - Milton C
FIR - Milward, N
IR  - Milward N
FIR - Mirhom, R
IR  - Mirhom R
FIR - Mirranay, S
IR  - Mirranay S
FIR - Mishricky, H
IR  - Mishricky H
FIR - Misso, R
IR  - Misso R
FIR - Mitchell, A
IR  - Mitchell A
FIR - Mitchell, D
IR  - Mitchell D
FIR - Mitchell, L
IR  - Mitchell L
FIR - Mobilia, G
IR  - Mobilia G
FIR - Moffitt, M
IR  - Moffitt M
FIR - Mohr, V
IR  - Mohr V
FIR - Moller, Gary
IR  - Moller G
FIR - Moller, Graeme
IR  - Moller G
FIR - Molloy, P
IR  - Molloy P
FIR - Molloy, T
IR  - Molloy T
FIR - Molyneux, P
IR  - Molyneux P
FIR - Monaghan, C
IR  - Monaghan C
FIR - Monash, D
IR  - Monash D
FIR - Moncrieff, S
IR  - Moncrieff S
FIR - Monzon, M
IR  - Monzon M
FIR - Mooney, T
IR  - Mooney T
FIR - Moore, E
IR  - Moore E
FIR - Moran, J
IR  - Moran J
FIR - Morgan, G
IR  - Morgan G
FIR - Morgan, M
IR  - Morgan M
FIR - Morgan, N
IR  - Morgan N
FIR - Morris, N
IR  - Morris N
FIR - Morris, S
IR  - Morris S
FIR - Morrison, H
IR  - Morrison H
FIR - Morrow, S
IR  - Morrow S
FIR - Morton, R
IR  - Morton R
FIR - Moschou, C
IR  - Moschou C
FIR - Moulding, S
IR  - Moulding S
FIR - Moule, V
IR  - Moule V
FIR - Mouzakis, V
IR  - Mouzakis V
FIR - Mudunna, D
IR  - Mudunna D
FIR - Mudzi, S
IR  - Mudzi S
FIR - Mulkearns, P
IR  - Mulkearns P
FIR - Mullen, D
IR  - Mullen D
FIR - Mulvey, G
IR  - Mulvey G
FIR - Mungi, D
IR  - Mungi D
FIR - Munro, L
IR  - Munro L
FIR - Muraledaran, S
IR  - Muraledaran S
FIR - Murphy, B
IR  - Murphy B
FIR - Murphy, G
IR  - Murphy G
FIR - Murray, A
IR  - Murray A
FIR - Murray, B
IR  - Murray B
FIR - Murray, E
IR  - Murray E
FIR - Murray, H
IR  - Murray H
FIR - Murray, S
IR  - Murray S
FIR - Murtagh, C
IR  - Murtagh C
FIR - Nadarajah, M
IR  - Nadarajah M
FIR - Naiker, S
IR  - Naiker S
FIR - Naing, W
IR  - Naing W
FIR - Nandha, R
IR  - Nandha R
FIR - Nankervis, J
IR  - Nankervis J
FIR - Naoum, A
IR  - Naoum A
FIR - Nash, C
IR  - Nash C
FIR - Nashed, M
IR  - Nashed M
FIR - Nasreen, N
IR  - Nasreen N
FIR - Nath-Chand, U
IR  - Nath-Chand U
FIR - Neagle, M
IR  - Neagle M
FIR - Nelson, C
IR  - Nelson C
FIR - Nelson, M R
IR  - Nelson MR
FIR - Nesbitt, P
IR  - Nesbitt P
FIR - Neuberger, M
IR  - Neuberger M
FIR - Newman, S
IR  - Newman S
FIR - Newton, S
IR  - Newton S
FIR - Ng, D
IR  - Ng D
FIR - Ng, H
IR  - Ng H
FIR - Ng, S
IR  - Ng S
FIR - Nguyen, D
IR  - Nguyen D
FIR - Nguyen, H Q
IR  - Nguyen HQ
FIR - Nguyen, H T
IR  - Nguyen HT
FIR - Nguyen, T
IR  - Nguyen T
FIR - Nguyen-Ngoc, M
IR  - Nguyen-Ngoc M
FIR - Nice, P
IR  - Nice P
FIR - Nicholls, P
IR  - Nicholls P
FIR - Nicholson, D
IR  - Nicholson D
FIR - Nicola, N
IR  - Nicola N
FIR - Nicolettou, N
IR  - Nicolettou N
FIR - Nicolson, I
IR  - Nicolson I
FIR - Nield, S
IR  - Nield S
FIR - Nikolic, V
IR  - Nikolic V
FIR - Nikolovska-Buzevski, N
IR  - Nikolovska-Buzevski N
FIR - Nilsson, A
IR  - Nilsson A
FIR - Nimmo, A
IR  - Nimmo A
FIR - Nisselle, P
IR  - Nisselle P
FIR - Nitchingham, S
IR  - Nitchingham S
FIR - Niven, A
IR  - Niven A
FIR - Nnopu, E
IR  - Nnopu E
FIR - Noonan, L
IR  - Noonan L
FIR - Norton, C
IR  - Norton C
FIR - Norton, G
IR  - Norton G
FIR - Notini, G
IR  - Notini G
FIR - Nwaegerue, E D
IR  - Nwaegerue ED
FIR - Nylander, P
IR  - Nylander P
FIR - O’Brien, C
IR  - O’Brien C
FIR - O’Connor, A
IR  - O’Connor A
FIR - O’Connor, D A
IR  - O’Connor DA
FIR - O’Donovan, B
IR  - O’Donovan B
FIR - O’Driscoll, E
IR  - O’Driscoll E
FIR - Oechsle, G
IR  - Oechsle G
FIR - Offor, J
IR  - Offor J
FIR - Ogilvie, B
IR  - Ogilvie B
FIR - O’Halloran, J
IR  - O’Halloran J
FIR - O’Hanlon, P
IR  - O’Hanlon P
FIR - Okolie, K
IR  - Okolie K
FIR - Olaniyi, I
IR  - Olaniyi I
FIR - O’Leary, B
IR  - O’Leary B
FIR - O’Leary, K
IR  - O’Leary K
FIR - Olesen, J
IR  - Olesen J
FIR - Oliver, P
IR  - Oliver P
FIR - Olomola, O
IR  - Olomola O
FIR - Olszewski, C
IR  - Olszewski C
FIR - Olukolu, G
IR  - Olukolu G
FIR - Omarjee, A
IR  - Omarjee A
FIR - Omidiora, A A
IR  - Omidiora AA
FIR - Omifolaji, S
IR  - Omifolaji S
FIR - O’Neill, A
IR  - O’Neill A
FIR - O’Neill, C O
IR  - O’Neill CO
FIR - Ong, B P
IR  - Ong BP
FIR - Ong, M
IR  - Ong M
FIR - Ooruthiran, M
IR  - Ooruthiran M
FIR - Oppermann, B L
IR  - Oppermann BL
FIR - Orbach, E
IR  - Orbach E
FIR - Orgonas, R
IR  - Orgonas R
FIR - Orsillo, M
IR  - Orsillo M
FIR - Ostberg, M
IR  - Ostberg M
FIR - O’Sullivan, C
IR  - O’Sullivan C
FIR - O’Sullivan, J
IR  - O’Sullivan J
FIR - O’Sullivan, P J
IR  - O’Sullivan PJ
FIR - O’Toole, C
IR  - O’Toole C
FIR - O’Toole, M
IR  - O’Toole M
FIR - Otuonye, D
IR  - Otuonye D
FIR - Owen, T
IR  - Owen T
FIR - Padilla, C
IR  - Padilla C
FIR - Page, A
IR  - Page A
FIR - Pahuja, P
IR  - Pahuja P
FIR - Palmer, A
IR  - Palmer A
FIR - Pan, J
IR  - Pan J
FIR - Panozzo, D
IR  - Panozzo D
FIR - Pantillano, E
IR  - Pantillano E
FIR - Papagelis, A
IR  - Papagelis A
FIR - Papas, E
IR  - Papas E
FIR - Pape, A
IR  - Pape A
FIR - Paransothy, P
IR  - Paransothy P
FIR - Parghi, N
IR  - Parghi N
FIR - Parker, A
IR  - Parker A
FIR - Parker, J
IR  - Parker J
FIR - Parker, S
IR  - Parker S
FIR - Parkes, H
IR  - Parkes H
FIR - Parletta, E
IR  - Parletta E
FIR - Parry, B
IR  - Parry B
FIR - Pasha, M
IR  - Pasha M
FIR - Patel, G
IR  - Patel G
FIR - Patel, M
IR  - Patel M
FIR - Pathirana, A
IR  - Pathirana A
FIR - Patterson, R
IR  - Patterson R
FIR - Pattichis, I
IR  - Pattichis I
FIR - Pattison, J
IR  - Pattison J
FIR - Pava, C
IR  - Pava C
FIR - Peachey, D
IR  - Peachey D
FIR - Pearce, E
IR  - Pearce E
FIR - Pearce, R
IR  - Pearce R
FIR - Pearse, B
IR  - Pearse B
FIR - Pearson, R
IR  - Pearson R
FIR - Pech, M
IR  - Pech M
FIR - Peduru-Arachchige, A
IR  - Peduru-Arachchige A
FIR - Pellegrini, P
IR  - Pellegrini P
FIR - Pellizzari, G
IR  - Pellizzari G
FIR - Pereira, V
IR  - Pereira V
FIR - Perera, B
IR  - Perera B
FIR - Perera, L
IR  - Perera L
FIR - Perlesz, A
IR  - Perlesz A
FIR - Perraton, R
IR  - Perraton R
FIR - Perry, H
IR  - Perry H
FIR - Perry, S
IR  - Perry S
FIR - Perry, W
IR  - Perry W
FIR - Pervaiz, Z
IR  - Pervaiz Z
FIR - Peters, L
IR  - Peters L
FIR - Pham, H
IR  - Pham H
FIR - Phan, C
IR  - Phan C
FIR - Phan, T
IR  - Phan T
FIR - Phare, A
IR  - Phare A
FIR - Philip, J
IR  - Philip J
FIR - Philips, J
IR  - Philips J
FIR - Phillips, A
IR  - Phillips A
FIR - Philpot, J
IR  - Philpot J
FIR - Phiri, R
IR  - Phiri R
FIR - Pickavance, M
IR  - Pickavance M
FIR - Piekarski, D
IR  - Piekarski D
FIR - Pienkos, J
IR  - Pienkos J
FIR - Piez, W
IR  - Piez W
FIR - Pilgrim, C
IR  - Pilgrim C
FIR - Pillai, B K
IR  - Pillai BK
FIR - Pinder, R
IR  - Pinder R
FIR - Pinkstone, J
IR  - Pinkstone J
FIR - Pinson, J
IR  - Pinson J
FIR - Pither, A
IR  - Pither A
FIR - Plenderleith, J
IR  - Plenderleith J
FIR - Pliatsios, B
IR  - Pliatsios B
FIR - Plunkett, M
IR  - Plunkett M
FIR - Pokharel, C
IR  - Pokharel C
FIR - Poland, D
IR  - Poland D
FIR - Polgar, V
IR  - Polgar V
FIR - Polmear, D
IR  - Polmear D
FIR - Poologanathan, G
IR  - Poologanathan G
FIR - Pope, I
IR  - Pope I
FIR - Popp, L
IR  - Popp L
FIR - Portelli, A
IR  - Portelli A
FIR - Potter, T
IR  - Potter T
FIR - Powell, Kendra
IR  - Powell K
FIR - Powell, Kristine
IR  - Powell K
FIR - Powell, V
IR  - Powell V
FIR - Power, R
IR  - Power R
FIR - Powles, A
IR  - Powles A
FIR - Poynton, N
IR  - Poynton N
FIR - Pranavan, S
IR  - Pranavan S
FIR - Prasad, R
IR  - Prasad R
FIR - Praszkier, S
IR  - Praszkier S
FIR - Preiss, J
IR  - Preiss J
FIR - Pretorius, P
IR  - Pretorius P
FIR - Price, C
IR  - Price C
FIR - Price, I
IR  - Price I
FIR - Price, K
IR  - Price K
FIR - Price, M
IR  - Price M
FIR - Priest, C
IR  - Priest C
FIR - Pring, M
IR  - Pring M
FIR - Profitt, C
IR  - Profitt C
FIR - Protassow, A
IR  - Protassow A
FIR - Psaradellis, I J A
IR  - Psaradellis IJA
FIR - Psycharis, J
IR  - Psycharis J
FIR - Pucilowski, D
IR  - Pucilowski D
FIR - Pun, K
IR  - Pun K
FIR - Qamar, F
IR  - Qamar F
FIR - Quach, S
IR  - Quach S
FIR - Radcliff, E
IR  - Radcliff E
FIR - Radcliffe, B
IR  - Radcliffe B
FIR - Radcliffe, J
IR  - Radcliffe J
FIR - Radford, J
IR  - Radford J
FIR - Ragg, P
IR  - Ragg P
FIR - Rahel, E
IR  - Rahel E
FIR - Rahim, T
IR  - Rahim T
FIR - Rahman, F
IR  - Rahman F
FIR - Rahmanamlashi, N
IR  - Rahmanamlashi N
FIR - Rajasooriar, S
IR  - Rajasooriar S
FIR - Rajendra, I
IR  - Rajendra I
FIR - Rajini, E
IR  - Rajini E
FIR - Raman, A
IR  - Raman A
FIR - Ramsay, A
IR  - Ramsay A
FIR - Ramsey, J
IR  - Ramsey J
FIR - Rana, U
IR  - Rana U
FIR - Rankin, M
IR  - Rankin M
FIR - Rao, U V
IR  - Rao UV
FIR - Rapley, M
IR  - Rapley M
FIR - Rasaratnam, S
IR  - Rasaratnam S
FIR - Rashid, A
IR  - Rashid A
FIR - Ratnaike, L
IR  - Ratnaike L
FIR - Rattan, J
IR  - Rattan J
FIR - Ratten, K
IR  - Ratten K
FIR - Rattraywood, C
IR  - Rattraywood C
FIR - Rayner, E
IR  - Rayner E
FIR - Rea, J
IR  - Rea J
FIR - Rea, P C
IR  - Rea PC
FIR - Reddy, Sanganakal
IR  - Reddy S
FIR - Reddy, Shradhanand
IR  - Reddy S
FIR - Reed, R
IR  - Reed R
FIR - Reeves, C
IR  - Reeves C
FIR - Reichl, T
IR  - Reichl T
FIR - Reid, J
IR  - Reid J
FIR - Reid, K
IR  - Reid K
FIR - Remyn, P
IR  - Remyn P
FIR - Renfrey, S
IR  - Renfrey S
FIR - Renouf, E
IR  - Renouf E
FIR - Renshaw, P
IR  - Renshaw P
FIR - Retchford, A
IR  - Retchford A
FIR - Reynolds, F
IR  - Reynolds F
FIR - Reza, R
IR  - Reza R
FIR - Rezk, L
IR  - Rezk L
FIR - Rhee, J
IR  - Rhee J
FIR - Rhodes, F
IR  - Rhodes F
FIR - Rice, A
IR  - Rice A
FIR - Richards, J
IR  - Richards J
FIR - Richards, R
IR  - Richards R
FIR - Richardson, A
IR  - Richardson A
FIR - Richardson, G T
IR  - Richardson GT
FIR - Richardson, R
IR  - Richardson R
FIR - Richardson, T
IR  - Richardson T
FIR - Ridgers, D
IR  - Ridgers D
FIR - Ridgers, M J
IR  - Ridgers MJ
FIR - Rieger, W
IR  - Rieger W
FIR - Rienits, H
IR  - Rienits H
FIR - Rigoni, M
IR  - Rigoni M
FIR - Riley, J
IR  - Riley J
FIR - Rillstone, D
IR  - Rillstone D
FIR - Rimmer, D E
IR  - Rimmer DE
FIR - Ringelblum, D
IR  - Ringelblum D
FIR - Riseley, J
IR  - Riseley J
FIR - Roberts, A
IR  - Roberts A
FIR - Roberts, I
IR  - Roberts I
FIR - Roberts, J
IR  - Roberts J
FIR - Roberts, M
IR  - Roberts M
FIR - Roberts, S
IR  - Roberts S
FIR - Robinson, J
IR  - Robinson J
FIR - Robinson, R
IR  - Robinson R
FIR - Robson, A
IR  - Robson A
FIR - Roche, V
IR  - Roche V
FIR - Rodda, C
IR  - Rodda C
FIR - Rodway, P
IR  - Rodway P
FIR - Roebuck, R
IR  - Roebuck R
FIR - Rogers, D
IR  - Rogers D
FIR - Rogers, S
IR  - Rogers S
FIR - Roman, F
IR  - Roman F
FIR - Romas, D
IR  - Romas D
FIR - Ronan, C
IR  - Ronan C
FIR - Rope, S
IR  - Rope S
FIR - Rose, A
IR  - Rose A
FIR - Rose, D F
IR  - Rose DF
FIR - Rose, G
IR  - Rose G
FIR - Rose, K
IR  - Rose K
FIR - Rosen, N
IR  - Rosen N
FIR - Rosenblatt, J
IR  - Rosenblatt J
FIR - Ross, K
IR  - Ross K
FIR - Ross, Mary
IR  - Ross M
FIR - Ross, T
IR  - Ross T
FIR - Roth, J
IR  - Roth J
FIR - Rothfield, J
IR  - Rothfield J
FIR - Roubos, N
IR  - Roubos N
FIR - Roufael, A D
IR  - Roufael AD
FIR - Rounsevell, J
IR  - Rounsevell J
FIR - Rouse, W
IR  - Rouse W
FIR - Roushdy, B
IR  - Roushdy B
FIR - Rowe, R
IR  - Rowe R
FIR - Rowland, G
IR  - Rowland G
FIR - Roy, A
IR  - Roy A
FIR - Royston, A
IR  - Royston A
FIR - Rubin, J
IR  - Rubin J
FIR - Russell, G
IR  - Russell G
FIR - Ryan, F
IR  - Ryan F
FIR - Ryan, N
IR  - Ryan N
FIR - Ryan, S
IR  - Ryan S
FIR - Sabet, A
IR  - Sabet A
FIR - Sabetypeyman, F
IR  - Sabetypeyman F
FIR - Sachdev, A
IR  - Sachdev A
FIR - Saddik, A
IR  - Saddik A
FIR - Sadhai, R
IR  - Sadhai R
FIR - Saeed, S
IR  - Saeed S
FIR - Sahhar, C
IR  - Sahhar C
FIR - Saka, M
IR  - Saka M
FIR - Salauddin, M
IR  - Salauddin M
FIR - Salter, E
IR  - Salter E
FIR - Salter, M
IR  - Salter M
FIR - Samaddar, A
IR  - Samaddar A
FIR - Samarakkody, A
IR  - Samarakkody A
FIR - Samararatna, M
IR  - Samararatna M
FIR - Samarsekera, C
IR  - Samarsekera C
FIR - Samuel-John, D
IR  - Samuel-John D
FIR - Sandars, M
IR  - Sandars M
FIR - Sanders, J
IR  - Sanders J
FIR - Sanderson, L
IR  - Sanderson L
FIR - Sandhu, N
IR  - Sandhu N
FIR - Sandrasegaram, S
IR  - Sandrasegaram S
FIR - Sangsari, A
IR  - Sangsari A
FIR - Saprid, J
IR  - Saprid J
FIR - Sarkis, K
IR  - Sarkis K
FIR - Sasse, C
IR  - Sasse C
FIR - Satter, F
IR  - Satter F
FIR - Satyadharma, K
IR  - Satyadharma K
FIR - Saul, J
IR  - Saul J
FIR - Scaife, R
IR  - Scaife R
FIR - Schaap, M
IR  - Schaap M
FIR - Scheelings, F T
IR  - Scheelings FT
FIR - Schinckel, H
IR  - Schinckel H
FIR - Schlesinger, P
IR  - Schlesinger P
FIR - Schlicht, S
IR  - Schlicht S
FIR - Schmidt, M
IR  - Schmidt M
FIR - Schneeweiss, A
IR  - Schneeweiss A
FIR - Schroeder, E
IR  - Schroeder E
FIR - Scully, S
IR  - Scully S
FIR - Searle, R
IR  - Searle R
FIR - Sebastian, T
IR  - Sebastian T
FIR - Seeto, R
IR  - Seeto R
FIR - Segal, G
IR  - Segal G
FIR - Segal, L
IR  - Segal L
FIR - Seidel, B
IR  - Seidel B
FIR - Selga, A
IR  - Selga A
FIR - Senanayake, I
IR  - Senanayake I
FIR - Seneviratne, M
IR  - Seneviratne M
FIR - Seneviratne, T
IR  - Seneviratne T
FIR - Senini, D
IR  - Senini D
FIR - Senior, J
IR  - Senior J
FIR - Seow, L
IR  - Seow L
FIR - Sepetavc, D
IR  - Sepetavc D
FIR - Serafim, A
IR  - Serafim A
FIR - Serban, R
IR  - Serban R
FIR - Sexton, P
IR  - Sexton P
FIR - Shahat, M
IR  - Shahat M
FIR - Shamoun, Y
IR  - Shamoun Y
FIR - Shanmugarajah, K
IR  - Shanmugarajah K
FIR - Shannon, G
IR  - Shannon G
FIR - Sharif, A
IR  - Sharif A
FIR - Shariff, A
IR  - Shariff A
FIR - Sharma, A
IR  - Sharma A
FIR - Sharma, D
IR  - Sharma D
FIR - Sharma, M
IR  - Sharma M
FIR - Sharma, P
IR  - Sharma P
FIR - Sharma, R
IR  - Sharma R
FIR - Sharma, S
IR  - Sharma S
FIR - Sharma, U
IR  - Sharma U
FIR - Sharp, V
IR  - Sharp V
FIR - Sheen-Apostol, J
IR  - Sheen-Apostol J
FIR - Sheikh Mohamed, M
IR  - Sheikh Mohamed M
FIR - Sher, J
IR  - Sher J
FIR - Sherley, M
IR  - Sherley M
FIR - Shi, B
IR  - Shi B
FIR - Shimmin, M B
IR  - Shimmin MB
FIR - Shing, D
IR  - Shing D
FIR - Shires, S E
IR  - Shires SE
FIR - Shmerling, A
IR  - Shmerling A
FIR - Shortis, P
IR  - Shortis P
FIR - Shroot, A D
IR  - Shroot AD
FIR - Shute, J
IR  - Shute J
FIR - Sia, M
IR  - Sia M
FIR - Siapantas, S
IR  - Siapantas S
FIR - Sidhwarni, R
IR  - Sidhwarni R
FIR - Siemienowicz, J
IR  - Siemienowicz J
FIR - Siew, H C
IR  - Siew HC
FIR - Sigalov, E
IR  - Sigalov E
FIR - Silver, D
IR  - Silver D
FIR - Simes, L
IR  - Simes L
FIR - Simonson, F
IR  - Simonson F
FIR - Simpson, R
IR  - Simpson R
FIR - Simpson, T
IR  - Simpson T
FIR - Simpson, W
IR  - Simpson W
FIR - Singh, B
IR  - Singh B
FIR - Singh, D
IR  - Singh D
FIR - Singh, H
IR  - Singh H
FIR - Singh, M
IR  - Singh M
FIR - Singh, R
IR  - Singh R
FIR - Siow, C L
IR  - Siow CL
FIR - Sitlington, R
IR  - Sitlington R
FIR - Sivapalan, C
IR  - Sivapalan C
FIR - Skeat, J
IR  - Skeat J
FIR - Skehan, M
IR  - Skehan M
FIR - Skeklios, L
IR  - Skeklios L
FIR - Skinner, T
IR  - Skinner T
FIR - Sklovsky, C J
IR  - Sklovsky CJ
FIR - Slabbert, J
IR  - Slabbert J
FIR - Slaney, G M
IR  - Slaney GM
FIR - Slattery, C
IR  - Slattery C
FIR - Sleaby, E
IR  - Sleaby E
FIR - Sleiman, C
IR  - Sleiman C
FIR - Slesenger, J
IR  - Slesenger J
FIR - Slimming, T
IR  - Slimming T
FIR - Sloan, C
IR  - Sloan C
FIR - Sloane, R
IR  - Sloane R
FIR - Slonim, D
IR  - Slonim D
FIR - Slot, P
IR  - Slot P
FIR - Smagas, T
IR  - Smagas T
FIR - Smart, M
IR  - Smart M
FIR - Smibert, L
IR  - Smibert L
FIR - Smiley, J
IR  - Smiley J
FIR - Smith, D
IR  - Smith D
FIR - Smith, G
IR  - Smith G
FIR - Smith, J
IR  - Smith J
FIR - Smith, P
IR  - Smith P
FIR - Smith, R
IR  - Smith R
FIR - Smith, Stephen
IR  - Smith S
FIR - Smith, Stuart
IR  - Smith S
FIR - Smith, V
IR  - Smith V
FIR - Smylie, D
IR  - Smylie D
FIR - Sneyd, S
IR  - Sneyd S
FIR - Snow, S
IR  - Snow S
FIR - Sobol, G
IR  - Sobol G
FIR - Soccio, M
IR  - Soccio M
FIR - Solanki, V
IR  - Solanki V
FIR - Soloczynskiyj, A
IR  - Soloczynskiyj A
FIR - Solomon, D
IR  - Solomon D
FIR - Somerville, M
IR  - Somerville M
FIR - Song, J
IR  - Song J
FIR - Soo, D
IR  - Soo D
FIR - Soo, L
IR  - Soo L
FIR - Soo, T
IR  - Soo T
FIR - Soo, T M
IR  - Soo TM
FIR - Sood, R
IR  - Sood R
FIR - Sooknandan, S
IR  - Sooknandan S
FIR - Soon, M
IR  - Soon M
FIR - Sosnin, M
IR  - Sosnin M
FIR - Spanos, N
IR  - Spanos N
FIR - Spargo, J S
IR  - Spargo JS
FIR - Speirs, B
IR  - Speirs B
FIR - Spencer, H
IR  - Spencer H
FIR - Spencer, J
IR  - Spencer J
FIR - Spottiswood, M
IR  - Spottiswood M
FIR - Spring, M
IR  - Spring M
FIR - Squires, L
IR  - Squires L
FIR - Stabelos, G
IR  - Stabelos G
FIR - Stagg, M
IR  - Stagg M
FIR - Stanley, L
IR  - Stanley L
FIR - Stark, A
IR  - Stark A
FIR - Steel, A
IR  - Steel A
FIR - Steer, N
IR  - Steer N
FIR - Steiner, H
IR  - Steiner H
FIR - Stephanson, A
IR  - Stephanson A
FIR - Stephens, G
IR  - Stephens G
FIR - Stephenson, A
IR  - Stephenson A
FIR - Sterling, B R
IR  - Sterling BR
FIR - Stevens, B
IR  - Stevens B
FIR - Stevens, P
IR  - Stevens P
FIR - Stevenson, J
IR  - Stevenson J
FIR - Stewart, C
IR  - Stewart C
FIR - Stewart, R
IR  - Stewart R
FIR - Sticklen, E
IR  - Sticklen E
FIR - Stiebel, P
IR  - Stiebel P
FIR - Stillger, J M
IR  - Stillger JM
FIR - Stinerman, I
IR  - Stinerman I
FIR - Stobie, M
IR  - Stobie M
FIR - Stobie, T
IR  - Stobie T
FIR - Stojkovski, S
IR  - Stojkovski S
FIR - Stone, A
IR  - Stone A
FIR - Stowe, S
IR  - Stowe S
FIR - Stoyanova, V
IR  - Stoyanova V
FIR - Strasser, K
IR  - Strasser K
FIR - Strong, J
IR  - Strong J
FIR - Struk, H
IR  - Struk H
FIR - Stuart, A
IR  - Stuart A
FIR - Su, J
IR  - Su J
FIR - Sujecki, M
IR  - Sujecki M
FIR - Suka, R
IR  - Suka R
FIR - Sullivan, T
IR  - Sullivan T
FIR - Sululola, A
IR  - Sululola A
FIR - Sumathipala, A
IR  - Sumathipala A
FIR - Suntesic, L
IR  - Suntesic L
FIR - Sutherland, D
IR  - Sutherland D
FIR - Sutherland, I
IR  - Sutherland I
FIR - Sutherland, R
IR  - Sutherland R
FIR - Sutton, J
IR  - Sutton J
FIR - Swart, R
IR  - Swart R
FIR - Sweet, M
IR  - Sweet M
FIR - Sweet, R
IR  - Sweet R
FIR - Syed, Z
IR  - Syed Z
FIR - Sykes, J
IR  - Sykes J
FIR - Sylivris, A
IR  - Sylivris A
FIR - Symon, B
IR  - Symon B
FIR - Szabo, R
IR  - Szabo R
FIR - Sze, J
IR  - Sze J
FIR - Szenczy, C
IR  - Szenczy C
FIR - Sze-Tho, R
IR  - Sze-Tho R
FIR - Szymanski, I
IR  - Szymanski I
FIR - Szymanski, R
IR  - Szymanski R
FIR - Tadrous, M
IR  - Tadrous M
FIR - Taft, D
IR  - Taft D
FIR - Taine, M
IR  - Taine M
FIR - Talic, D
IR  - Talic D
FIR - Tan, Elaine
IR  - Tan E
FIR - Tan, Eng
IR  - Tan E
FIR - Tan, G
IR  - Tan G
FIR - Tan, H M
IR  - Tan HM
FIR - Tanovic, A
IR  - Tanovic A
FIR - Tasiopoulos, A
IR  - Tasiopoulos A
FIR - Tate, K
IR  - Tate K
FIR - Tattersall, I
IR  - Tattersall I
FIR - Taverna, C
IR  - Taverna C
FIR - Taylor, J
IR  - Taylor J
FIR - Taylor, R
IR  - Taylor R
FIR - Taylor, S
IR  - Taylor S
FIR - Teo, K
IR  - Teo K
FIR - Teoh, C
IR  - Teoh C
FIR - Teperman, B
IR  - Teperman B
FIR - Tereszkiewicz, W
IR  - Tereszkiewicz W
FIR - Thanenthiran, R
IR  - Thanenthiran R
FIR - Thangarajah, C
IR  - Thangarajah C
FIR - Thangavel, B
IR  - Thangavel B
FIR - Thann, Z
IR  - Thann Z
FIR - The, S
IR  - The S
FIR - Theophilos, M
IR  - Theophilos M
FIR - Theris, N
IR  - Theris N
FIR - Thiru, K
IR  - Thiru K
FIR - Thiru, M
IR  - Thiru M
FIR - Thomas, G
IR  - Thomas G
FIR - Thomas, P
IR  - Thomas P
FIR - Thompson, D
IR  - Thompson D
FIR - Thompson, L
IR  - Thompson L
FIR - Thompson, W
IR  - Thompson W
FIR - Thomson, B
IR  - Thomson B
FIR - Thorne, A
IR  - Thorne A
FIR - Thornley, J
IR  - Thornley J
FIR - Thorpe, V
IR  - Thorpe V
FIR - Thottakurichi, R
IR  - Thottakurichi R
FIR - Thurairajah, A
IR  - Thurairajah A
FIR - Thurairajah, S
IR  - Thurairajah S
FIR - Thyagarajan, T
IR  - Thyagarajan T
FIR - Tiet, Q
IR  - Tiet Q
FIR - Tillekeratne, K
IR  - Tillekeratne K
FIR - Tine, S
IR  - Tine S
FIR - Tinning, R
IR  - Tinning R
FIR - Tinston, C
IR  - Tinston C
FIR - To, E
IR  - To E
FIR - Tolentino, C
IR  - Tolentino C
FIR - Tom, H
IR  - Tom H
FIR - Tomar, D
IR  - Tomar D
FIR - Tomic, M
IR  - Tomic M
FIR - Tomyn, L
IR  - Tomyn L
FIR - Toohill, G
IR  - Toohill G
FIR - Tooth, M
IR  - Tooth M
FIR - Tormey, S
IR  - Tormey S
FIR - Toua, P
IR  - Toua P
FIR - Trainor, S
IR  - Trainor S
FIR - Tran, C
IR  - Tran C
FIR - Tran, E
IR  - Tran E
FIR - Tran, L D
IR  - Tran LD
FIR - Tran, T Q
IR  - Tran TQ
FIR - Trethowan, K
IR  - Trethowan K
FIR - Trevena, R
IR  - Trevena R
FIR - Trigg, P
IR  - Trigg P
FIR - Trivett, B
IR  - Trivett B
FIR - Try, R
IR  - Try R
FIR - Tsigopoulos, A
IR  - Tsigopoulos A
FIR - Tucker, D
IR  - Tucker D
FIR - Tunaley, S
IR  - Tunaley S
FIR - Turnbull, H
IR  - Turnbull H
FIR - Turnbull, S
IR  - Turnbull S
FIR - Turner, J
IR  - Turner J
FIR - Twycross, W
IR  - Twycross W
FIR - Tynan, D
IR  - Tynan D
FIR - Tyndall, P
IR  - Tyndall P
FIR - Tyshing, W
IR  - Tyshing W
FIR - Uchendu, F
IR  - Uchendu F
FIR - Uhlenbruch, B
IR  - Uhlenbruch B
FIR - Uluca, U
IR  - Uluca U
FIR - Unkenstein, D
IR  - Unkenstein D
FIR - Urie, J P
IR  - Urie JP
FIR - Vaiopoulos, T
IR  - Vaiopoulos T
FIR - Van Ammers, E
IR  - Van Ammers E
FIR - Van Der Merwe, D
IR  - Van Der Merwe D
FIR - Van Der Spek, A
IR  - Van Der Spek A
FIR - Van Der Vlist, R
IR  - Van Der Vlist R
FIR - Van Opstal, E
IR  - Van Opstal E
FIR - Vanderzeil, G
IR  - Vanderzeil G
FIR - Vanderzeil, T
IR  - Vanderzeil T
FIR - Vanker, L
IR  - Vanker L
FIR - Vanmali, H
IR  - Vanmali H
FIR - Varghese, A
IR  - Varghese A
FIR - Varney, W
IR  - Varney W
FIR - Vasquez, I
IR  - Vasquez I
FIR - Vasudevan, S
IR  - Vasudevan S
FIR - Veal, M
IR  - Veal M
FIR - Venables, S
IR  - Venables S
FIR - Venkatram, G
IR  - Venkatram G
FIR - Verghese, P
IR  - Verghese P
FIR - Verma, H
IR  - Verma H
FIR - Verma, R
IR  - Verma R
FIR - Verso, M
IR  - Verso M
FIR - Victor, A
IR  - Victor A
FIR - Vijayakumar, V
IR  - Vijayakumar V
FIR - Vijayanand, P
IR  - Vijayanand P
FIR - Viljoen, E
IR  - Viljoen E
FIR - Vincent, F
IR  - Vincent F
FIR - Vinci, A
IR  - Vinci A
FIR - Vinci, G
IR  - Vinci G
FIR - Viney, P
IR  - Viney P
FIR - Visvalingam, C
IR  - Visvalingam C
FIR - Von Caemmerer, A
IR  - Von Caemmerer A
FIR - Vonschmidt, J K
IR  - Vonschmidt JK
FIR - Vorich, R
IR  - Vorich R
FIR - Vrij, R
IR  - Vrij R
FIR - Vyas, S
IR  - Vyas S
FIR - Wai, T
IR  - Wai T
FIR - Waid, S
IR  - Waid S
FIR - Wakefield, B
IR  - Wakefield B
FIR - Walder, D
IR  - Walder D
FIR - Waldron, C M
IR  - Waldron CM
FIR - Waldron, M
IR  - Waldron M
FIR - Wales, S
IR  - Wales S
FIR - Walker, B
IR  - Walker B
FIR - Walker, G
IR  - Walker G
FIR - Walker, R
IR  - Walker R
FIR - Walker, W
IR  - Walker W
FIR - Wall, R
IR  - Wall R
FIR - Wallace, J
IR  - Wallace J
FIR - Wallace, K
IR  - Wallace K
FIR - Wallis, I
IR  - Wallis I
FIR - Wang, S
IR  - Wang S
FIR - Wang, X
IR  - Wang X
FIR - Wang, Z
IR  - Wang Z
FIR - Ward, C
IR  - Ward C
FIR - Ward, R
IR  - Ward R
FIR - Ward, S
IR  - Ward S
FIR - Wardlaw, P
IR  - Wardlaw P
FIR - Wark, A
IR  - Wark A
FIR - Warr, A
IR  - Warr A
FIR - Warren, M
IR  - Warren M
FIR - Waters, L
IR  - Waters L
FIR - Watson, A
IR  - Watson A
FIR - Watson, S
IR  - Watson S
FIR - Watt, G
IR  - Watt G
FIR - Watt, J
IR  - Watt J
FIR - Watterson, J
IR  - Watterson J
FIR - Waugh, R
IR  - Waugh R
FIR - Wazid, M
IR  - Wazid M
FIR - Wearne, E
IR  - Wearne E
FIR - Webb, I
IR  - Webb I
FIR - Webber, C
IR  - Webber C
FIR - Webber, E
IR  - Webber E
FIR - Webber, S
IR  - Webber S
FIR - Webster, D L
IR  - Webster DL
FIR - Webster, J
IR  - Webster J
FIR - Webster, Peter
IR  - Webster P
FIR - Webster, Philip
IR  - Webster P
FIR - Weerasinghe, S
IR  - Weerasinghe S
FIR - Weerasoorya, M
IR  - Weerasoorya M
FIR - Weinrich, J
IR  - Weinrich J
FIR - Welberry, L
IR  - Welberry L
FIR - Weller, A
IR  - Weller A
FIR - Wells, S
IR  - Wells S
FIR - Welsh, D
IR  - Welsh D
FIR - Weng, M
IR  - Weng M
FIR - Wenig, M
IR  - Wenig M
FIR - Wettesinghe, I
IR  - Wettesinghe I
FIR - Wexler, P
IR  - Wexler P
FIR - White, A
IR  - White A
FIR - White, G
IR  - White G
FIR - White, Roxana
IR  - White R
FIR - Whitehouse, J
IR  - Whitehouse J
FIR - Whitehouse, L
IR  - Whitehouse L
FIR - Whitehouse, R
IR  - Whitehouse R
FIR - Whitfield, K
IR  - Whitfield K
FIR - Whitfield, S
IR  - Whitfield S
FIR - Whitney, W
IR  - Whitney W
FIR - Wiehle, G
IR  - Wiehle G
FIR - Wight, R
IR  - Wight R
FIR - Wild, I
IR  - Wild I
FIR - Wilding, S
IR  - Wilding S
FIR - Wildman, G
IR  - Wildman G
FIR - Williams, A
IR  - Williams A
FIR - Williams, G
IR  - Williams G
FIR - Williams, J
IR  - Williams J
FIR - Williams, M
IR  - Williams M
FIR - Williams, P D
IR  - Williams PD
FIR - Williams, S
IR  - Williams S
FIR - Williams, W
IR  - Williams W
FIR - Willis, M
IR  - Willis M
FIR - Wilson, A
IR  - Wilson A
FIR - Win, N
IR  - Win N
FIR - Wiseman, J
IR  - Wiseman J
FIR - Wishart, W
IR  - Wishart W
FIR - Wivell, F
IR  - Wivell F
FIR - Wong, C
IR  - Wong C
FIR - Wong, C S
IR  - Wong CS
FIR - Wong, D
IR  - Wong D
FIR - Wong, John K
IR  - Wong JK
FIR - Wong, Johnny
IR  - Wong J
FIR - Wong, Ju-Min
IR  - Wong JM
FIR - Wong, P
IR  - Wong P
FIR - Wong, P T
IR  - Wong PT
FIR - Wong, Y
IR  - Wong Y
FIR - Wood, P
IR  - Wood P
FIR - Woods, R
IR  - Woods R
FIR - Woodward, P
IR  - Woodward P
FIR - Wooff, D
IR  - Wooff D
FIR - Woolf, S
IR  - Woolf S
FIR - Worboys, P
IR  - Worboys P
FIR - Worboys, P C
IR  - Worboys PC
FIR - Wrennall, R
IR  - Wrennall R
FIR - Wright, Adrian
IR  - Wright A
FIR - Wright, Antony
IR  - Wright A
FIR - Wright, L
IR  - Wright L
FIR - Wright, Richard
IR  - Wright R
FIR - Wright, Robert
IR  - Wright R
FIR - Wrobel, K
IR  - Wrobel K
FIR - Wu, D
IR  - Wu D
FIR - Wu, E
IR  - Wu E
FIR - Wu, L
IR  - Wu L
FIR - Xiao, M
IR  - Xiao M
FIR - Yacoub, M
IR  - Yacoub M
FIR - Yang, A
IR  - Yang A
FIR - Yang, J
IR  - Yang J
FIR - Yang, R
IR  - Yang R
FIR - Yates, D
IR  - Yates D
FIR - Yazbek, P
IR  - Yazbek P
FIR - Yeaman, C
IR  - Yeaman C
FIR - Yeo, M
IR  - Yeo M
FIR - Yeung Shi Chung, D
IR  - Yeung Shi Chung D
FIR - Yiap, D
IR  - Yiap D
FIR - Yilmaz, S
IR  - Yilmaz S
FIR - Yogaranandan, D
IR  - Yogaranandan D
FIR - Young, D
IR  - Young D
FIR - Young, R
IR  - Young R
FIR - Young, S
IR  - Young S
FIR - Yousef, M
IR  - Yousef M
FIR - Yousif, K
IR  - Yousif K
FIR - Youssef, D
IR  - Youssef D
FIR - Yu, Z
IR  - Yu Z
FIR - Yuille, R
IR  - Yuille R
FIR - Zagorksi, M
IR  - Zagorksi M
FIR - Zail, S
IR  - Zail S
FIR - Zain, M
IR  - Zain M
FIR - Zallmann, A
IR  - Zallmann A
FIR - Zeng, L
IR  - Zeng L
FIR - Zhao, S
IR  - Zhao S
FIR - Zhao, W
IR  - Zhao W
FIR - Zheng, M
IR  - Zheng M
FIR - Zhou, D
IR  - Zhou D
FIR - Ziccone, M
IR  - Ziccone M
FIR - Zimmerman, J
IR  - Zimmerman J
FIR - Zwijnenburg, A
IR  - Zwijnenburg A
EDAT- 2018/09/18 06:00
MHDA- 2018/11/06 06:00
CRDT- 2018/09/18 06:00
PHST- 2018/09/18 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
PHST- 2018/09/18 06:00 [entrez]
AID - 10.1056/NEJMoa1805819 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Oct 18;379(16):1509-1518. doi: 10.1056/NEJMoa1805819. Epub 
      2018 Sep 16.

PMID- 26776955
OWN - NLM
STAT- MEDLINE
DCOM- 20170522
LR  - 20181202
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 23
IP  - 11
DP  - 2016 Oct 15
TI  - Study of oxidative and inflammatory parameters in LDLr-KO mice treated with a 
      hypercholesterolemic diet: Comparison between the use of Campomanesia xanthocarpa 
      and acetylsalicylic acid.
PG  - 1227-34
LID - S0944-7113(15)00362-1 [pii]
LID - 10.1016/j.phymed.2015.11.010 [doi]
AB  - BACKGROUND: Atherosclerosis is an inflammatory disease that affects the arterial 
      wall leading to myocardial, cerebral, and peripheral ischemic syndromes. The use 
      of low doses of aspirin inhibits platelet aggregation and inflammation and 
      prevents cardiovascular mortality. However, ASA may produce hemorrhagic events. 
      Thus, several studies have sought new natural compounds to suppress platelet 
      aggregation without causing serious adverse effects. PURPOSE: In this sense, this 
      study aims to compare the effects of Campomanesia xanthocarpa plant extract with 
      those of acetylsalicylic acid (ASA) on inflammatory parameters observed in 
      homozygous mice knockout for the low-density lipoprotein receptor (LDLr-KO) 
      treated with a hypercholesterolemic diet. MATERIAL AND METHODS: In this study, 28 
      male LDLr-KO mice were divided into three groups and fed a hypercholesterolemic 
      diet for 4 weeks. Thereafter, the animals that received the hypercholesterolemic 
      diet were treated for 5 days with (1) distilled water, (2) C. xanthocarpa 
      extract, or (3) acetylsalicylic acid. The levels of inflammatory markers were 
      assessed in the blood samples. The gastric tolerability of the animals after oral 
      administration of the treatments was assessed through quantification of the 
      lesions in the gastric mucosa. RESULTS: The levels of proinflammatory cytokines 
      IL-1, IL-6, TNF-α, and INF-γ were reduced to 19.2 ± 3%, 20.4 + 1.3%, 24.7 ± 1.2%, 
      and 20.8 ± 1.7%, respectively, in the group treated with C. xanthocarpa, when 
      compared to control group. Furthermore, treatment with plant extract 
      significantly increased the levels of the anti-inflammatory cytokine IL-10 by 
      27.3 ± 5.9%, but ASA showed no significant effect on the same cytokines when 
      compared to the control group, with the exception of IL-10, which presented an 
      increase of 8.6 ± 3.5%. Treatments with C. xanthocarpa and ASA also caused 
      significant reductions of 26.4 ± 3% and 38.4± 6% in the serum levels of oxLDL, 
      respectively. However, only treatment with C. xanthocarpa reduced the levels of 
      anti-oxLDL antibodies when compared with the control (25.8 ± 6%). In addition, 
      the analyzed extract did not induce ulcerogenic activity, while ASA induced the 
      formation of lesions. CONCLUSION: In conclusion, treatment with C. xanthocarpa 
      causes anti-inflammatory activity in hypercholesterolemic animals, with results 
      superior to those obtained with the use of ASA.
CI  - Copyright © 2015. Published by Elsevier GmbH.
FAU - Klafke, Jonatas Zeni
AU  - Klafke JZ
AD  - Programa de Pós-Graduação em Atenção Integral à Saúde (PPGAIS), Universidade de 
      Cruz Alta (UNICRUZ), 98020-290 Cruz Alta, RS, Brazil; Grupo Multidisciplinar de 
      Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 98020-290 Cruz Alta, RS, 
      Brazil; Centro de Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta 
      (ICCA), 98010-110 Cruz Alta, RS, Brazil. Electronic address: jonzeni@hotmail.com.
FAU - Pereira, Roberta Lelis Dias
AU  - Pereira RL
AD  - Programa de Pós-Graduação em Atenção Integral à Saúde (PPGAIS), Universidade de 
      Cruz Alta (UNICRUZ), 98020-290 Cruz Alta, RS, Brazil; Grupo Multidisciplinar de 
      Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 98020-290 Cruz Alta, RS, 
      Brazil; Centro de Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta 
      (ICCA), 98010-110 Cruz Alta, RS, Brazil.
FAU - Hirsch, Gabriela Elisa
AU  - Hirsch GE
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Centro de Ensino e Pesquisa (CEP), Instituto de 
      Cardiologia de Cruz Alta (ICCA), 98010-110 Cruz Alta, RS, Brazil.
FAU - Parisi, Mariana Migliorini
AU  - Parisi MM
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Centro de Ensino e Pesquisa (CEP), Instituto de 
      Cardiologia de Cruz Alta (ICCA), 98010-110 Cruz Alta, RS, Brazil.
FAU - Porto, Fernando Garcez
AU  - Porto FG
AD  - Programa de Pós-Graduação em Atenção Integral à Saúde (PPGAIS), Universidade de 
      Cruz Alta (UNICRUZ), 98020-290 Cruz Alta, RS, Brazil; Grupo Multidisciplinar de 
      Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 98020-290 Cruz Alta, RS, 
      Brazil; Centro de Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta 
      (ICCA), 98010-110 Cruz Alta, RS, Brazil.
FAU - de Almeida, Amanda Spring
AU  - de Almeida AS
AD  - Programa de Pós-Graduação em Atenção Integral à Saúde (PPGAIS), Universidade de 
      Cruz Alta (UNICRUZ), 98020-290 Cruz Alta, RS, Brazil; Grupo Multidisciplinar de 
      Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 98020-290 Cruz Alta, RS, 
      Brazil; Centro de Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta 
      (ICCA), 98010-110 Cruz Alta, RS, Brazil.
FAU - Rubin, Fabiane Horbach
AU  - Rubin FH
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Centro de Ensino e Pesquisa (CEP), Instituto de 
      Cardiologia de Cruz Alta (ICCA), 98010-110 Cruz Alta, RS, Brazil.
FAU - Schmidt, Aline
AU  - Schmidt A
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Centro de Ensino e Pesquisa (CEP), Instituto de 
      Cardiologia de Cruz Alta (ICCA), 98010-110 Cruz Alta, RS, Brazil.
FAU - Beutler, Henrique
AU  - Beutler H
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil.
FAU - Nascimento, Sabrina
AU  - Nascimento S
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Centro de Ensino e Pesquisa (CEP), Instituto de 
      Cardiologia de Cruz Alta (ICCA), 98010-110 Cruz Alta, RS, Brazil.
FAU - Trevisan, Gabriela
AU  - Trevisan G
AD  - Grupo Multidisciplinar de Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 
      98020-290 Cruz Alta, RS, Brazil; Centro de Ensino e Pesquisa (CEP), Instituto de 
      Cardiologia de Cruz Alta (ICCA), 98010-110 Cruz Alta, RS, Brazil; Programa de 
      Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense 
      (UNESC), 88006-000 Cricíuma, SC, Brazil.
FAU - Brusco, Indiara
AU  - Brusco I
AD  - Programa de Pós-Graduacão em Ciências Biológicas: Bioquímica Toxicológica, 
      Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil.
FAU - de Oliveira, Sara Marchesan
AU  - de Oliveira SM
AD  - Programa de Pós-Graduacão em Ciências Biológicas: Bioquímica Toxicológica, 
      Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil.
FAU - Duarte, Marta Maria Medeiros Frescura
AU  - Duarte MM
AD  - Departamento de Ciências da Saúde, Universidade Luterana do Brasil, 97020 001 
      Santa Maria, RS, Brazil.
FAU - Duarte, Thiago
AU  - Duarte T
AD  - Centro de ciências da saúde, Pós-Graduação em farmacologia Universidade Federal 
      de Santa Maria, 97105-900 Santa Maria, RS, Brazil.
FAU - Viecili, Paulo Ricardo Nazário
AU  - Viecili PR
AD  - Programa de Pós-Graduação em Atenção Integral à Saúde (PPGAIS), Universidade de 
      Cruz Alta (UNICRUZ), 98020-290 Cruz Alta, RS, Brazil; Grupo Multidisciplinar de 
      Saúde (GMS), Universidade de Cruz Alta (UNICRUZ), 98020-290 Cruz Alta, RS, 
      Brazil; Centro de Ensino e Pesquisa (CEP), Instituto de Cardiologia de Cruz Alta 
      (ICCA), 98010-110 Cruz Alta, RS, Brazil. Electronic address: 
      vieciliprn@hotmail.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20151212
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Plant Extracts)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Atherosclerosis/*drug therapy
MH  - Brazil
MH  - Hypercholesterolemia/*drug therapy
MH  - Inflammation/*drug therapy
MH  - Lipoproteins, LDL/blood/drug effects
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Myrtaceae/chemistry
MH  - Oxidative Stress/drug effects
MH  - Plant Extracts/*pharmacology/*therapeutic use
MH  - Plants, Medicinal/chemistry
OTO - NOTNLM
OT  - Cytokines
OT  - High performance liquid chromatography
OT  - Inflammation
OT  - Interleukins
OT  - Medicinal plant
OT  - Phenolic compounds
EDAT- 2016/01/19 06:00
MHDA- 2017/05/23 06:00
CRDT- 2016/01/19 06:00
PHST- 2015/09/29 00:00 [received]
PHST- 2015/11/11 00:00 [revised]
PHST- 2015/11/14 00:00 [accepted]
PHST- 2016/01/19 06:00 [entrez]
PHST- 2016/01/19 06:00 [pubmed]
PHST- 2017/05/23 06:00 [medline]
AID - S0944-7113(15)00362-1 [pii]
AID - 10.1016/j.phymed.2015.11.010 [doi]
PST - ppublish
SO  - Phytomedicine. 2016 Oct 15;23(11):1227-34. doi: 10.1016/j.phymed.2015.11.010. 
      Epub 2015 Dec 12.

PMID- 25868910
OWN - NLM
STAT- MEDLINE
DCOM- 20160614
LR  - 20181202
IS  - 1098-8823 (Print)
IS  - 1098-8823 (Linking)
VI  - 120
DP  - 2015 Jul
TI  - Antiplatelet drug resistance: Molecular insights and clinical implications.
PG  - 21-7
LID - S1098-8823(15)00041-6 [pii]
LID - 10.1016/j.prostaglandins.2015.03.011 [doi]
AB  - Antiplatelet drugs are prescribed to patients with cardiovascular disease in 
      order to reduce their risk of clinically important atherothrombotic events. 
      However, a proportion of patients fail to appropriately respond to these drugs in 
      a heterogeneous phenomenon known as 'antiplatelet drug resistance'. Individuals 
      who are identified as being resistant have a higher cardiovascular risk, but 
      currently there is no clinically validated approach to identify and treat these 
      individuals. Large randomised control trials have attempted to personalise 
      antiplatelet therapy based on platelet function testing, but these have failed to 
      demonstrate improved clinical outcomes. An alternative approach to this 
      non-specific assessment of platelet function is to consider whether antiplatelet 
      therapy may be personalised based on the identification of molecular mechanisms 
      that are known to confer resistance. Here we present molecular insights into the 
      mechanisms for aspirin and clopidogrel resistance, with a discussion of their 
      clinical implications.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Floyd, Christopher N
AU  - Floyd CN
AD  - Department of Clinical Pharmacology, Cardiovascular Division, British Heart 
      Foundation Centre of Research Excellence, King's College London, London, UK.
FAU - Ferro, Albert
AU  - Ferro A
AD  - Department of Clinical Pharmacology, Cardiovascular Division, British Heart 
      Foundation Centre of Research Excellence, King's College London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150411
PL  - United States
TA  - Prostaglandins Other Lipid Mediat
JT  - Prostaglandins & other lipid mediators
JID - 9808648
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Clopidogrel
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Ticlopidine/analogs & derivatives/pharmacology
OTO - NOTNLM
OT  - Antiplatelet
OT  - Aspirin
OT  - Clopidogrel
OT  - Resistance
EDAT- 2015/04/15 06:00
MHDA- 2016/06/15 06:00
CRDT- 2015/04/15 06:00
PHST- 2015/01/21 00:00 [received]
PHST- 2015/03/22 00:00 [revised]
PHST- 2015/03/29 00:00 [accepted]
PHST- 2015/04/15 06:00 [entrez]
PHST- 2015/04/15 06:00 [pubmed]
PHST- 2016/06/15 06:00 [medline]
AID - S1098-8823(15)00041-6 [pii]
AID - 10.1016/j.prostaglandins.2015.03.011 [doi]
PST - ppublish
SO  - Prostaglandins Other Lipid Mediat. 2015 Jul;120:21-7. doi: 
      10.1016/j.prostaglandins.2015.03.011. Epub 2015 Apr 11.

PMID- 30041066
OWN - NLM
STAT- MEDLINE
DCOM- 20190620
LR  - 20190620
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 203
DP  - 2018 Sep
TI  - Aspirin hypersensitivity in patients with coronary artery disease: linking 
      pathophysiology to clinical practice.
PG  - 74-81
LID - S0002-8703(18)30200-X [pii]
LID - 10.1016/j.ahj.2018.06.011 [doi]
AB  - Dual antiplatelet therapy, consisting of aspirin and a P2Y12 receptor antagonist, 
      has been the cornerstone of management in those undergoing percutaneous coronary 
      intervention, reducing stent thromboses and cardiovascular events. Given the 
      pivotal role of aspirin in cardiovascular disease management, patients with 
      aspirin hypersensitivity pose complex clinical challenges. Allergy to aspirin is 
      reported in 1.5-2.6% of patients presenting with cardiac disease. Identification 
      of the subtype of aspirin hypersensitivity will determine suitability for aspirin 
      desensitization, dictate choice of desensitization protocol and inform risk 
      management. Aspirin desensitization is an effective and viable clinical strategy, 
      although it remains underutilised in clinical practice. Collaboration between 
      cardiologists and immunologists should be strongly encouraged to facilitate 
      optimal management of such patients. This review describes the complexity of 
      managing patients with aspirin hypersensitivity in cardiac disease, the 
      indications and risks of aspirin desensitization, and the approach to management 
      of the minority of patients who are unsuitable for desensitization.
CI  - Crown Copyright © 2018. Published by Elsevier Inc. All rights reserved.
FAU - Gnanenthiran, Sonali R
AU  - Gnanenthiran SR
AD  - Department of Cardiology, Concord Repatriation General Hospital, New South Wales, 
      Australia.
FAU - Yiannikas, John
AU  - Yiannikas J
AD  - Department of Cardiology, Concord Repatriation General Hospital, New South Wales, 
      Australia.
FAU - Lowe, Harry C
AU  - Lowe HC
AD  - Department of Cardiology, Concord Repatriation General Hospital, New South Wales, 
      Australia.
FAU - Brieger, David
AU  - Brieger D
AD  - Department of Cardiology, Concord Repatriation General Hospital, New South Wales, 
      Australia.
FAU - Limaye, Sandhya
AU  - Limaye S
AD  - Department of Immunology, Concord Repatriation General Hospital, New South Wales, 
      Australia. Electronic address: Sandhya.Limaye@sswahs.nsw.gov.au.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180704
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy
MH  - Desensitization, Immunologic/*methods
MH  - *Drug Hypersensitivity/epidemiology/etiology/therapy
MH  - *Drug Tolerance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
EDAT- 2018/07/25 06:00
MHDA- 2019/06/21 06:00
CRDT- 2018/07/25 06:00
PHST- 2017/05/06 00:00 [received]
PHST- 2018/06/28 00:00 [accepted]
PHST- 2018/07/25 06:00 [pubmed]
PHST- 2019/06/21 06:00 [medline]
PHST- 2018/07/25 06:00 [entrez]
AID - S0002-8703(18)30200-X [pii]
AID - 10.1016/j.ahj.2018.06.011 [doi]
PST - ppublish
SO  - Am Heart J. 2018 Sep;203:74-81. doi: 10.1016/j.ahj.2018.06.011. Epub 2018 Jul 4.

PMID- 25908066
OWN - NLM
STAT- MEDLINE
DCOM- 20150709
LR  - 20230120
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 65
IP  - 16
DP  - 2015 Apr 28
TI  - Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After 
      Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial.
PG  - 1619-1629
LID - S0735-1097(15)00801-3 [pii]
LID - 10.1016/j.jacc.2015.02.050 [doi]
AB  - BACKGROUND: Patients receiving oral anticoagulation (OAC) who undergo 
      drug-eluting stent (DES) implantation require additional dual antiplatelet 
      therapy with aspirin and clopidogrel. Such triple therapy confers an elevated 
      bleeding risk, and its optimal duration is not known. OBJECTIVES: The goal of 
      this study was to evaluate whether shortening the duration of clopidogrel therapy 
      from 6 months to 6 weeks after DES implantation was associated with a superior 
      net clinical outcome in patients receiving concomitant aspirin and OAC. METHODS: 
      In this randomized, open-label trial, we enrolled patients receiving OAC who 
      underwent DES implantation at 3 European centers between September 2008 and 
      December 2013. A total of 614 patients receiving concomitant aspirin and OAC were 
      randomized to either 6-week clopidogrel therapy (n=307) or 6-month clopidogrel 
      therapy (n=307). The primary endpoint was a composite of death, myocardial 
      infarction (MI), definite stent thrombosis, stroke, or Thrombolysis In Myocardial 
      Infarction (TIMI) major bleeding at 9 months. RESULTS: The primary endpoint 
      occurred in 30 patients (9.8%) in the 6-week group compared with 27 patients 
      (8.8%) in the 6-month group (hazard ratio [HR]: 1.14; 95% CI: 0.68 to 1.91; 
      p=0.63). There were no significant differences for the secondary combined 
      ischemic endpoint of cardiac death, MI, definite stent thrombosis, and ischemic 
      stroke (12 [4.0%] vs. 13 [4.3%]; HR: 0.93; 95% CI: 0.43 to 2.05; p=0.87) or the 
      secondary bleeding endpoint of TIMI major bleeding (16 [5.3%] vs. 12 [4.0%]; HR: 
      1.35; 95% CI: 0.64 to 2.84; p=0.44). CONCLUSIONS: Six weeks of triple therapy was 
      not superior to 6 months with respect to net clinical outcomes. These results 
      suggest that physicians should weigh the trade-off between ischemic and bleeding 
      risk when choosing the shorter or longer duration of triple therapy. (Triple 
      Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation 
      [ISAR-TRIPLE]; NCT00776633).
CI  - Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Fiedler, Katrin A
AU  - Fiedler KA
AD  - Deutsches Herzzentrum München, Technische Universität, Klinik für Herz- und 
      Kreislauferkrankungen, Munich, Germany.
FAU - Maeng, Michael
AU  - Maeng M
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Mehilli, Julinda
AU  - Mehilli J
AD  - Klinikum der Universität München, Ludwig-Maximilians Universität, Medizinische 
      Klinik und Poliklinik I, Munich, Germany; Deutsches Zentrum für Herz 
      Kreislaufforschung, partner site Munich Heart Alliance, Munich, Germany.
FAU - Schulz-Schüpke, Stefanie
AU  - Schulz-Schüpke S
AD  - Deutsches Herzzentrum München, Technische Universität, Klinik für Herz- und 
      Kreislauferkrankungen, Munich, Germany.
FAU - Byrne, Robert A
AU  - Byrne RA
AD  - Deutsches Herzzentrum München, Technische Universität, Klinik für Herz- und 
      Kreislauferkrankungen, Munich, Germany; Deutsches Zentrum für Herz 
      Kreislaufforschung, partner site Munich Heart Alliance, Munich, Germany.
FAU - Sibbing, Dirk
AU  - Sibbing D
AD  - Klinikum der Universität München, Ludwig-Maximilians Universität, Medizinische 
      Klinik und Poliklinik I, Munich, Germany; Deutsches Zentrum für Herz 
      Kreislaufforschung, partner site Munich Heart Alliance, Munich, Germany.
FAU - Hoppmann, Petra
AU  - Hoppmann P
AD  - Klinikum rechts der Isar, Technische Universität, I. Medizinische Klinik und 
      Poliklinik, Munich, Germany.
FAU - Schneider, Simon
AU  - Schneider S
AD  - Klinikum rechts der Isar, Technische Universität, I. Medizinische Klinik und 
      Poliklinik, Munich, Germany.
FAU - Fusaro, Massimiliano
AU  - Fusaro M
AD  - Deutsches Herzzentrum München, Technische Universität, Klinik für Herz- und 
      Kreislauferkrankungen, Munich, Germany.
FAU - Ott, Ilka
AU  - Ott I
AD  - Deutsches Herzzentrum München, Technische Universität, Klinik für Herz- und 
      Kreislauferkrankungen, Munich, Germany.
FAU - Kristensen, Steen D
AU  - Kristensen SD
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Ibrahim, Tareq
AU  - Ibrahim T
AD  - Klinikum rechts der Isar, Technische Universität, I. Medizinische Klinik und 
      Poliklinik, Munich, Germany.
FAU - Massberg, Steffen
AU  - Massberg S
AD  - Klinikum der Universität München, Ludwig-Maximilians Universität, Medizinische 
      Klinik und Poliklinik I, Munich, Germany; Deutsches Zentrum für Herz 
      Kreislaufforschung, partner site Munich Heart Alliance, Munich, Germany.
FAU - Schunkert, Heribert
AU  - Schunkert H
AD  - Deutsches Herzzentrum München, Technische Universität, Klinik für Herz- und 
      Kreislauferkrankungen, Munich, Germany; Deutsches Zentrum für Herz 
      Kreislaufforschung, partner site Munich Heart Alliance, Munich, Germany.
FAU - Laugwitz, Karl-Ludwig
AU  - Laugwitz KL
AD  - Deutsches Zentrum für Herz Kreislaufforschung, partner site Munich Heart 
      Alliance, Munich, Germany; Klinikum rechts der Isar, Technische Universität, I. 
      Medizinische Klinik und Poliklinik, Munich, Germany.
FAU - Kastrati, Adnan
AU  - Kastrati A
AD  - Deutsches Herzzentrum München, Technische Universität, Klinik für Herz- und 
      Kreislauferkrankungen, Munich, Germany; Deutsches Zentrum für Herz 
      Kreislaufforschung, partner site Munich Heart Alliance, Munich, Germany.
FAU - Sarafoff, Nikolaus
AU  - Sarafoff N
AD  - Klinikum der Universität München, Ludwig-Maximilians Universität, Medizinische 
      Klinik und Poliklinik I, Munich, Germany. Electronic address: 
      n.sarafoff@gmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT00776633
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2015 Apr 28;65(16):1630-2. PMID: 25908067
CIN - J Am Coll Cardiol. 2015 Sep 1;66(9):1088-9. PMID: 26314542
CIN - J Am Coll Cardiol. 2015 Sep 1;66(9):1089-90. PMID: 26314543
CIN - J Am Coll Cardiol. 2015 Nov 17;66(20):2266. PMID: 26564608
CIN - J Am Coll Cardiol. 2015 Nov 17;66(20):2266-7. PMID: 26564609
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clopidogrel
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin
OT  - atrial fibrillation
OT  - clopidogrel
OT  - percutaneous coronary intervention
OT  - vitamin K antagonist
EDAT- 2015/04/25 06:00
MHDA- 2015/07/15 06:00
CRDT- 2015/04/25 06:00
PHST- 2014/11/19 00:00 [received]
PHST- 2015/02/21 00:00 [revised]
PHST- 2015/02/23 00:00 [accepted]
PHST- 2015/04/25 06:00 [entrez]
PHST- 2015/04/25 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - S0735-1097(15)00801-3 [pii]
AID - 10.1016/j.jacc.2015.02.050 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2015 Apr 28;65(16):1619-1629. doi: 10.1016/j.jacc.2015.02.050.

PMID- 2966694
OWN - NLM
STAT- MEDLINE
DCOM- 19880616
LR  - 20200304
IS  - 0770-3198 (Print)
IS  - 0770-3198 (Linking)
VI  - 6
IP  - 4
DP  - 1987 Dec
TI  - Effects of aspirin, naloxone and placebo.
PG  - 526-31
AB  - This study was designed to examine the effects of aspirin, naloxone and placebo 
      treatment on serum beta-endorphin concentration and joint pain in patients with 
      rheumatoid arthritis (RA). Ten patients with definite or classical RA were 
      studied. All treatments were administered in a randomized sequence. On each study 
      day, the following measurements were carried out at specified time intervals: 
      serum beta-endorphin concentration, serum salicylate concentration and joint pain 
      score on a visual analogue horizontal scale. We conclude that in patients with 
      rheumatoid arthritis suffering from chronic joint pain, serum beta-endorphin does 
      not appear to play a role in pain relief.
FAU - Mewa, A A
AU  - Mewa AA
AD  - Department of Medicine, McMaster University Health Science Centre, Hamilton, 
      Ontario, Canada.
FAU - Rosenbloom, D
AU  - Rosenbloom D
FAU - Grace, E M
AU  - Grace EM
FAU - Brooks, P
AU  - Brooks P
FAU - Bellamy, N
AU  - Bellamy N
FAU - Denko, C
AU  - Denko C
FAU - Norman, G
AU  - Norman G
FAU - Buchanan, W W
AU  - Buchanan WW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Placebos)
RN  - 36B82AMQ7N (Naloxone)
RN  - 60617-12-1 (beta-Endorphin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/drug therapy/physiopathology
MH  - Aspirin/administration & dosage/blood/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Naloxone/administration & dosage/*therapeutic use
MH  - Pain/blood/*drug therapy
MH  - Pain Measurement
MH  - Placebos
MH  - Random Allocation
MH  - beta-Endorphin/blood
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
AID - 10.1007/BF02330589 [doi]
PST - ppublish
SO  - Clin Rheumatol. 1987 Dec;6(4):526-31. doi: 10.1007/BF02330589.

PMID- 25095738
OWN - NLM
STAT- MEDLINE
DCOM- 20160310
LR  - 20211021
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 39
IP  - 4
DP  - 2015 May
TI  - Impact of aspirin resistance on outcomes among patients following coronary artery 
      bypass grafting: exploratory analysis from randomized controlled trial 
      (NCT01159639).
PG  - 522-31
LID - 10.1007/s11239-014-1127-9 [doi]
AB  - Individual variability in the response to aspirin, has been established by 
      various platelet function assays, however, the clinical relevance of aspirin 
      resistance (AR) in patients undergoing coronary artery bypass grafting (CABG) has 
      to be evaluated. Our working group conducted a randomized controlled trial 
      (NCT01159639) with the aim to assess impact of dual antiplatelet therapy (APT) on 
      outcomes among patients with AR following CABG. Patients that were aspirin 
      resistant on fourth postoperative day (POD 4) were randomly assigned to receive 
      either dual APT with clopidogrel (75 mg) plus aspirin (300 mg)-intervention arm 
      or monotherapy with aspirin (300 mg)-control arm. This exploratory analysis 
      compares clinical outcomes between aspirin resistant patients allocated to 
      control arm and patients that have had adequate platelet inhibitory response to 
      aspirin at POD 4. Both groups were treated with 300 mg of aspirin per day 
      following surgery. We sought to evaluate the impact of early postoperative AR on 
      outcomes among patients following CABG. Exploratory analysis included a total 
      number of 325 patients. Of those, 215 patients with adequate response to aspirin 
      and 110 patients with AR allocated to aspirin monotherapy following randomization 
      protocol. The primary efficacy end point (MACCEs-major adverse cardiac and 
      cardiovascular events) occurred in 10 and 6 % of patients with AR and with 
      adequate aspirin response, respectively (p = 0.27). Non-significant differences 
      were observed in bleeding events occurrence. Subgroup analysis of the primary end 
      point revealed that aspirin resistant patients with BMI > 30 kg/m(2) tend to have 
      a higher occurrence of MACCEs 18 versus 5 % (relative risk 0.44 [95 % CI 
      0.16-1.16]; p = 0.05). This exploratory analysis did not reveal significant 
      impact of aspirin resistance on outcomes among patients undergoing CABG. Further, 
      sufficiently powered studies are needed in order to evaluate clinical relevance 
      of AR in patients undergoing CABG.
FAU - Petricevic, Mate
AU  - Petricevic M
AD  - Department of Cardiac Surgery, University of Zagreb School of Medicine, 
      University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia, 
      petricevic.mate@gmail.com.
FAU - Kopjar, Tomislav
AU  - Kopjar T
FAU - Gasparovic, Hrvoje
AU  - Gasparovic H
FAU - Milicic, Davor
AU  - Milicic D
FAU - Svetina, Lucija
AU  - Svetina L
FAU - Zdilar, Boris
AU  - Zdilar B
FAU - Boban, Marko
AU  - Boban M
FAU - Mihaljevic, Martina Zrno
AU  - Mihaljevic MZ
FAU - Biocina, Bojan
AU  - Biocina B
LA  - eng
SI  - ClinicalTrials.gov/NCT01159639
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clopidogrel
MH  - *Coronary Artery Bypass
MH  - Drug Resistance/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Care/*methods
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
EDAT- 2014/08/07 06:00
MHDA- 2016/03/11 06:00
CRDT- 2014/08/07 06:00
PHST- 2014/08/07 06:00 [entrez]
PHST- 2014/08/07 06:00 [pubmed]
PHST- 2016/03/11 06:00 [medline]
AID - 10.1007/s11239-014-1127-9 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2015 May;39(4):522-31. doi: 10.1007/s11239-014-1127-9.

PMID- 102389
OWN - NLM
STAT- MEDLINE
DCOM- 19790212
LR  - 20190509
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 64
IP  - 3
DP  - 1978 Nov
TI  - Aspirin, protein transacetylation and inhibition of prostaglandin synthetase in 
      the kidney.
PG  - 353-8
AB  - 1 The effect of aspirin on the kidney has been investigated in mice and rabbits. 
      [Acetyl-(14)C]-aspirin was administered intraperitoneally in doses ranging from 
      subtherapeutic to toxic. The degree of acetylation of protein was determined by 
      the radioactivity remaining on protein precipitates of renal cortex and medulla 
      after sequential washing designed to remove non-covalently bound material. 
      Controls were established, by the use of [carboxyl-(14)C]-aspirin.2 The 
      acetyl-(14)C residue was bound to renal proteins in a linear manner in increasing 
      amounts with increasing dosage up to 100 mg/kg. The [carboxyl-(14)C]-aspirin was 
      not bound and thus the salicylate portion of the molecule was not bound 
      covalently to the renal protein. The time course of the acetylation was rapid, 
      consistent with the rate of aspirin absorption. The disappearance of acetylated 
      protein was slow, with a T(1/2) of 112.5 h in the renal cortex, and 129.5 h in 
      the renal medulla.3 Differential centrifugation, Sephadex chromatography and gel 
      electrophoresis were carried out on tissue homogenates to determine the site of 
      acetylation. The acetylation was greatest in the microsomal fraction, although 
      all protein fractions showed some degree of acetylation.4 The prostaglandin 
      synthetase activity of a particulate preparation from rabbit kidney was 
      determined by a spectrophotometric assay of malondialdehyde formation. Aspirin 
      (10 mg/kg, i.v.) significantly inhibited prostaglandin synthetase in the renal 
      cortex and medulla.5 Aspirin and renal proteins undergo a transacetylation 
      reaction resulting in stable acetylated protein, with acetylation being greatest 
      in the microsomal fraction. Aspirin has been shown to inhibit prostaglandin 
      synthetase and this could lead to functional impairment of the tissue.
FAU - Caterson, R J
AU  - Caterson RJ
FAU - Duggin, G G
AU  - Duggin GG
FAU - Horvath, J
AU  - Horvath J
FAU - Mohandas, J
AU  - Mohandas J
FAU - Tiller, D
AU  - Tiller D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Proteins)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - *Cyclooxygenase Inhibitors
MH  - Kidney/drug effects/*enzymology
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Proteins/*metabolism
MH  - Rabbits
PMC - PMC1668579
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1978.tb08657.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1978 Nov;64(3):353-8. doi: 10.1111/j.1476-5381.1978.tb08657.x.

PMID- 2023352
OWN - NLM
STAT- MEDLINE
DCOM- 19910605
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 265
IP  - 20
DP  - 1991 May 22-29
TI  - Diagnosis and management of Kawasaki disease.
PG  - 2699-703
AB  - Kawasaki disease is an acute vasculitis characterized by mucosal inflammation, 
      rash, cervical adenopathy, indurative edema of the hands and feet, and late 
      membranous desquamation of the fingertips. Early cardiac effects include 
      myocarditis (occasionally with congestive heart failure), pericardial 
      inflammation, and, rarely, valve involvement. Coronary artery aneurysms are a 
      long-term concern because coronary thrombosis with myocardial infarction can be a 
      late manifestation. The origin of Kawasaki disease is unknown, but an infectious 
      agent is most likely. Management consists of aspirin for control of fever and 
      inflammatory manifestations and intravenous gamma globulin for the prevention of 
      coronary aneurysm formation. Careful late follow-up is required, especially for 
      patients with persistent coronary abnormalities. Giant aneurysms (greater than 8 
      mm) are more likely to progress to coronary obstructive disease, and coronary 
      bypass grafts have been required for some patients. Late coronary artery 
      manifestations in patients with mild early coronary dilatation have not been 
      described. However, since long-term epidemiologic studies have not yet been 
      performed, it is prudent to consider childhood Kawasaki disease to be a potential 
      risk factor for coronary disease, especially in atherosclerosis-prone Western 
      societies.
FAU - Gersony, W M
AU  - Gersony WM
AD  - Division of Pediatric Cardiology, College of Physicians and Surgeons, Columbia 
      University, New York, NY.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/therapeutic use
MH  - Chronic Disease
MH  - Coronary Aneurysm/diagnosis/therapy
MH  - Humans
MH  - *Mucocutaneous Lymph Node Syndrome/diagnosis/therapy
RF  - 42
EDAT- 1991/05/22 00:00
MHDA- 1991/05/22 00:01
CRDT- 1991/05/22 00:00
PHST- 1991/05/22 00:00 [pubmed]
PHST- 1991/05/22 00:01 [medline]
PHST- 1991/05/22 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1991 May 22-29;265(20):2699-703.

PMID- 25739162
OWN - NLM
STAT- MEDLINE
DCOM- 20150407
LR  - 20191027
IS  - 1098-1861 (Print)
IS  - 1098-1861 (Linking)
VI  - 113
IP  - 5
DP  - 2014 Oct
TI  - Identifying opportunities to improve aspirin utilization for the primary 
      prevention of cardiovascular disease in a regional health care system.
PG  - 190-5; quiz 196
AB  - OBJECTIVE: Aspirin is an important part of primary cardiovascular disease 
      prevention, but little is known about aspirin use patterns in regional health 
      care systems. This study used electronic health records from Marshfield Clinic to 
      identify demographic, geographic, and clinical predictors of aspirin utilization 
      in central Wisconsin adults without cardiovascular disease. METHODS: A 
      cross-sectional design was employed using 2010-2012 data from patients in the 
      Marshfield Epidemiologic Study Area. Individuals who took aspirin-containing 
      medication daily or every other day were considered regular aspirin users. There 
      were a total of 6678 adults in the target region who were clinically indicated 
      for aspirin therapy for primary cardiovascular disease prevention, per national 
      guidelines. RESULTS: Aspirin was generally underutilized in this population, with 
      35% of all clinically indicated adults taking it regularly. Adjusted models found 
      that individuals who were younger, female, not covered by health insurance, did 
      not visit a medical provider regularly, smokers, were not obese, or did not have 
      diabetes were least likely to take aspirin. In addition, there was some local 
      variation in that aspirin use was less common in northeastern communities within 
      the regional service area. CONCLUSION: Several aspirin use disparities were 
      identified in central Wisconsin adults without cardiovascular disease, with 
      particularly low utilization observed in those without diabetes and/or without 
      regular physician contact. Methods of using electronic health records to conduct 
      primary care surveillance as outlined here can be adopted by other large health 
      care systems in the state to optimize future cardiovascular disease prevention 
      initiatives.
FAU - VanWormer, Jeffrey J
AU  - VanWormer JJ
FAU - Miller, Aaron W
AU  - Miller AW
FAU - Rezkalla, H
AU  - Rezkalla H
LA  - eng
GR  - UL1 TR000427/TR/NCATS NIH HHS/United States
GR  - UL1TR000427/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - WMJ
JT  - WMJ : official publication of the State Medical Society of Wisconsin
JID - 9716054
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Cross-Sectional Studies
MH  - Electronic Health Records
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Primary Prevention
MH  - Regional Health Planning
MH  - Wisconsin/epidemiology
PMC - PMC4413896
MID - NIHMS681806
EDAT- 2015/03/06 06:00
MHDA- 2015/04/08 06:00
CRDT- 2015/03/06 06:00
PHST- 2015/03/06 06:00 [entrez]
PHST- 2015/03/06 06:00 [pubmed]
PHST- 2015/04/08 06:00 [medline]
AID - 10.3121/cmr.2014.1250.ps2-12 [doi]
PST - ppublish
SO  - WMJ. 2014 Oct;113(5):190-5; quiz 196. doi: 10.3121/cmr.2014.1250.ps2-12.

PMID- 1084419
OWN - NLM
STAT- MEDLINE
DCOM- 19760901
LR  - 20131121
IS  - 0022-3492 (Print)
IS  - 0022-3492 (Linking)
VI  - 47
IP  - 6
DP  - 1976 Jun
TI  - Gingival hemorrhage related to aspirin ingestion. A case report.
PG  - 355-7
AB  - A case report illustrating the clinical manifestations of platelet defects 
      induced by ingestion of two aspirin tablets has been presented. The specific 
      effects on platelets produced by aspirin ingestion have been summarized and the 
      resultant hemostatic defect explained.
FAU - Foulke, C N
AU  - Foulke CN
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Periodontol
JT  - Journal of periodontology
JID - 8000345
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Blood Platelets/drug effects
MH  - Gingival Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Oral Hemorrhage/*chemically induced
EDAT- 1976/06/01 00:00
MHDA- 1976/06/01 00:01
CRDT- 1976/06/01 00:00
PHST- 1976/06/01 00:00 [pubmed]
PHST- 1976/06/01 00:01 [medline]
PHST- 1976/06/01 00:00 [entrez]
AID - 10.1902/jop.1976.47.6.355 [doi]
PST - ppublish
SO  - J Periodontol. 1976 Jun;47(6):355-7. doi: 10.1902/jop.1976.47.6.355.

PMID- 20654074
OWN - NLM
STAT- MEDLINE
DCOM- 20110913
LR  - 20181201
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 38
IP  - 4
DP  - 2010 Apr
TI  - [Impact of application time of aspirin and clopidogrel on platelet aggregation in 
      patients with acute coronary syndrome].
PG  - 311-4
AB  - OBJECTIVE: To observe the impact of various application time of aspirin and 
      clopidogrel on the circadian rhythm changes of platelet aggregation in patients 
      with acute coronary syndrome. METHODS: Patients with acute coronary syndrome were 
      divided into day-time (8:00) and night-time (20:00) medication group (n = 15 
      each). After plasma concentration reached steady state, platelet aggregation was 
      assessed at 5 time points within 24 hours with a mobile four-channel whole blood 
      impedance aggregometer. The platelet aggregation was induced by ADP and 
      arachidonic acid. Thereafter, the two groups were exchanged and platelet 
      aggregation was assessed in the same way post plasma steady state. RESULTS: 
      Arachidonic acid-induced platelet aggregation was the highest at 10:00 Am [(7.96 
      +/- 3.64) ohm] and the lowest at 0:00 [(6.12 +/- 3.29) ohm, P > 0.05] in day-time 
      group. Platelet aggregation was the highest at 20:00 [(9.40 +/- 5.39) ohm] and 
      the lowest at 10:00 [(5.46 +/- 3.93) ohm], P < 0.05). ADP-induced platelet 
      aggregation was the highest at 10:00 and the lowest at 16:00 in day-time group (P 
      > 0.05) and was the highest at 20:00 and the lowest at 10:00 in night-time group 
      (P > 0.05). Platelet aggregation induced by two inducers was significantly higher 
      at 10:00 in day-time group compared to values in night-time group (all P < 0.05). 
      CONCLUSION: Taking aspirin and clopidogrel at 20:00 was superior to taking the 
      same medications at 8:00 for inhibiting peak platelet aggregation in the morning.
FAU - Li, Zhen
AU  - Li Z
AD  - Department of Cardiology, Second Hospital of Hebei Medical University and 
      Institute of Cardiocerebrovascular Disease of Hebei Province, Shijiazhuang 
      050000, China.
FAU - Liu, Fan
AU  - Liu F
FAU - Cui, Wei
AU  - Cui W
FAU - Xie, Rui-qin
AU  - Xie RQ
FAU - Yang, Xiu-chun
AU  - Yang XC
FAU - Lu, Jing-chao
AU  - Lu JC
FAU - Zheng, Hong-mei
AU  - Zheng HM
FAU - Ren, Xiao-juan
AU  - Ren XJ
FAU - Liu, Jing
AU  - Liu J
LA  - chi
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - *Circadian Rhythm
MH  - Clopidogrel
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Platelet Function Tests
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Time Factors
EDAT- 2010/07/27 06:00
MHDA- 2011/09/14 06:00
CRDT- 2010/07/27 06:00
PHST- 2010/07/27 06:00 [entrez]
PHST- 2010/07/27 06:00 [pubmed]
PHST- 2011/09/14 06:00 [medline]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Apr;38(4):311-4.

PMID- 4026924
OWN - NLM
STAT- MEDLINE
DCOM- 19850906
LR  - 20201209
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 35
IP  - 6
DP  - 1985
TI  - [The bioavailability of combination preparations of acetylsalicylic acid and 
      codeine phosphate].
PG  - 973-6
AB  - Plasma levels time curves of acetylsalicylic acid, salicylic acid, salicyluric 
      acid and codeine were monitored after intravenous, oral and rectal application 
      (single dose) of preparations containing acetylsalicylic acid and codeine. The 
      mean absolute bioavailability of acetylsalicylic acid was 68% after oral 
      application and 60% after rectal application. The corresponding bioavailability 
      data of codeine were 59% and 63%, respectively.
FAU - Spahn, H
AU  - Spahn H
FAU - Altmayer, P
AU  - Altmayer P
FAU - Cattarius-Korb, S
AU  - Cattarius-Korb S
FAU - Krüger, B
AU  - Krüger B
FAU - Lang, E
AU  - Lang E
FAU - Mutschler, E
AU  - Mutschler E
FAU - Sörgel, F
AU  - Sörgel F
LA  - ger
PT  - Journal Article
TT  - Untersuchungen zur Bioverfügbarkeit eines Kombinationspräparates von 
      Acetylsalicylsäure und Codeinphosphat.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Drug Combinations)
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 0 (Suppositories)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/blood/*metabolism
MH  - Biological Availability
MH  - Codeine/administration & dosage/blood/*metabolism
MH  - Drug Combinations
MH  - Hippurates/blood
MH  - Humans
MH  - Injections, Intravenous
MH  - Kinetics
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Suppositories
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1985;35(6):973-6.

PMID- 6750779
OWN - NLM
STAT- MEDLINE
DCOM- 19821202
LR  - 20190908
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 11
IP  - 3
DP  - 1982
TI  - Fecal blood loss caused by two differently microencapsulated acetylsalicylic acid 
      preparations in patients with rheumatoid arthritis. A prospective crossover 
      study.
PG  - 129-32
AB  - In an investigator-blind crossover study, fecal blood loss determined by 
      51Cr-labelled red cells was measured in 17 male patients with rheumatoid 
      arthritis and one with anchylosing spondylitis. In two periods, each of one 
      week's duration and separated by a 3-week wash-out period, the patients received 
      microencapsulated acetylsalicylic acid (ASA) 3 g daily--either iwht 
      time-dependent (Acetard) or with pH-depeendent release (Reumyl). With the 
      exception of one patient, who suffered clinically significant bleeding, both 
      preparations produced only moderate bleeding. The bleeding provoked by ASA with 
      pH-dependent release (median blood loss in ml/day: first period 1.6; last period 
      2.6) was less than with time-dependent release (first period 1.8; last period 
      3.5).
FAU - Dirksen, A
AU  - Dirksen A
FAU - Rasmussen, S N
AU  - Rasmussen SN
FAU - Manthorpe, R
AU  - Manthorpe R
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - 3A3U0GI71G (Magnesium Oxide)
RN  - 56333-49-4 (aspirin, magnesium oxide combination)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Delayed-Action Preparations
MH  - Drug Combinations/adverse effects/therapeutic use
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Intestinal Mucosa/drug effects
MH  - Magnesium Oxide/adverse effects/therapeutic use
MH  - Male
MH  - Melena/*chemically induced
MH  - Middle Aged
MH  - Spondylitis, Ankylosing/drug therapy
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.3109/03009748209098177 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 1982;11(3):129-32. doi: 10.3109/03009748209098177.

PMID- 29803428
OWN - NLM
STAT- MEDLINE
DCOM- 20181003
LR  - 20190318
IS  - 1873-3778 (Electronic)
IS  - 0021-9673 (Linking)
VI  - 1560
DP  - 2018 Jul 27
TI  - Simultaneous concentration and separation of target compounds from multicomponent 
      mixtures by closed-loop recycling countercurrent chromatography.
PG  - 26-34
LID - S0021-9673(18)30615-0 [pii]
LID - 10.1016/j.chroma.2018.05.032 [doi]
AB  - Closed-loop recycling countercurrent chromatography (CLR CCC) with multiple 
      sample injection has been shown to provide simultaneous concentration and 
      separation of target compounds from multicomponent mixtures. Previous analysis of 
      CLR CCC with multiple sample injections has been limited to the ideal recycling 
      model, which neglects the effects caused by the pump and connecting lines. In 
      this study, an analysis of the process is carried out based on the non-ideal 
      recycling model: recycling chromatograms at two points of the closed-loop - the 
      inlet of the column (A) and the outlet of the column (B) - are considered. The 
      sample is repeatedly introduced at the inlet of the column when the circulating 
      peak of target compound passes point A. Analytical expressions are developed, 
      allowing the design and simulation of different variants of simultaneous 
      separation and concentration of target compounds from multicomponent mixtures. 
      Examples of separation of target compounds from three and five-component mixtures 
      are discussed. Experimental results are presented demonstrating a reasonable 
      agreement between the theory and the experiment. Due to its ability to 
      concentrate individual solutes, CRL CCC with multiple sample injections can 
      become an efficient analytical method to determine minor components in complex 
      mixtures.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Kostanyan, Artak
AU  - Kostanyan A
AD  - Kurnakov Institute of General & Inorganic Chemistry, Russian Academy of Sciences, 
      Leninsky Prospekt 31, Moscow 119991, Russia. Electronic address: 
      kost@igic.ras.ru.
FAU - Martynova, Maria
AU  - Martynova M
AD  - Kurnakov Institute of General & Inorganic Chemistry, Russian Academy of Sciences, 
      Leninsky Prospekt 31, Moscow 119991, Russia.
FAU - Erastov, Andrey
AU  - Erastov A
AD  - Kurnakov Institute of General & Inorganic Chemistry, Russian Academy of Sciences, 
      Leninsky Prospekt 31, Moscow 119991, Russia.
FAU - Belova, Vera
AU  - Belova V
AD  - Kurnakov Institute of General & Inorganic Chemistry, Russian Academy of Sciences, 
      Leninsky Prospekt 31, Moscow 119991, Russia.
LA  - eng
PT  - Journal Article
DEP - 20180523
PL  - Netherlands
TA  - J Chromatogr A
JT  - Journal of chromatography. A
JID - 9318488
RN  - 0 (Complex Mixtures)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*isolation & purification
MH  - Caffeine/*isolation & purification
MH  - Complex Mixtures/*chemistry
MH  - Countercurrent Distribution/*instrumentation/*methods
MH  - Recycling
OTO - NOTNLM
OT  - Chromatogram equations
OT  - Closed-loop recycling chromatography
OT  - Countercurrent chromatography
OT  - Multiple sample injections
OT  - Simultaneous separation and concentration
EDAT- 2018/05/29 06:00
MHDA- 2018/10/04 06:00
CRDT- 2018/05/28 06:00
PHST- 2018/01/23 00:00 [received]
PHST- 2018/05/11 00:00 [revised]
PHST- 2018/05/14 00:00 [accepted]
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2018/10/04 06:00 [medline]
PHST- 2018/05/28 06:00 [entrez]
AID - S0021-9673(18)30615-0 [pii]
AID - 10.1016/j.chroma.2018.05.032 [doi]
PST - ppublish
SO  - J Chromatogr A. 2018 Jul 27;1560:26-34. doi: 10.1016/j.chroma.2018.05.032. Epub 
      2018 May 23.

PMID- 17072257
OWN - NLM
STAT- MEDLINE
DCOM- 20070125
LR  - 20140729
IS  - 1698-6946 (Electronic)
IS  - 1698-4447 (Linking)
VI  - 11
IP  - 6
DP  - 2006 Nov 1
TI  - Assessment of PFA-100 system for the measurement of bleeding time in oral 
      surgery.
PG  - E514-9
AB  - The common diagnostic methods to know primary hemostasis have been classified as 
      invasive, depending on the operator, difficult to reproduce and at times not very 
      reliable. Thus, different systems have been proposed to assess bleeding time, one 
      of them being the PFA-100 device, which we present in this paper. OBJECTIVE: 
      Compare specificity between the traditional Ivy method with the PFA-100 system to 
      measure bleeding time. MATERIAL AND METHOD: We obtained a sample of 33 patients 
      between the age of 24-80 years receiving anti-platelet treatment who needed to 
      undergo oral surgery. Bleeding time was obtained by the Ivy method, an INR by an 
      analysis done on the same day and a Coagucheck one hour before surgery as well as 
      measurement of bleeding time with the PFA-100 system. RESULTS: Mean value of 
      bleeding time through the Ivy method was 406.36 sec.. Mean bleeding time with the 
      PFA-100 system for the collagen/epinephrine cartridge was 226.91 sec. and for the 
      collagen/ADP cartridge was 110.27 sec.. All these values were within normality. 
      We observed very high standard deviations with the Ivy method and more regular 
      ones for the PFA-100 system, indicating its greater specificity. We also obtained 
      a large correlation between collagen/epinephrine cartridge and acetylsalicylic 
      acid. CONCLUSIONS: We found greater specificity of the analyzer of PFA-100 
      platelet function for the measurement of bleeding time in relationship with the 
      traditional Ivy method.
FAU - Arrieta Blanco, Juan José
AU  - Arrieta Blanco JJ
AD  - Universidad Europea, Madrid. jjarrieta@fjd.es
FAU - Bartolomé Villar, Begoña
AU  - Bartolomé Villar B
FAU - Juzgado, Antonio
AU  - Juzgado A
FAU - Mourelle Martínez, Rosa
AU  - Mourelle Martínez R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20061101
PL  - Spain
TA  - Med Oral Patol Oral Cir Bucal
JT  - Medicina oral, patologia oral y cirugia bucal
JID - 101231694
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology
MH  - Bleeding Time/*instrumentation
MH  - Equipment Design
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Oral Surgical Procedures
MH  - Platelet Aggregation Inhibitors/pharmacology
EDAT- 2006/10/31 09:00
MHDA- 2007/01/26 09:00
CRDT- 2006/10/31 09:00
PHST- 2006/10/31 09:00 [pubmed]
PHST- 2007/01/26 09:00 [medline]
PHST- 2006/10/31 09:00 [entrez]
AID - 10489429 [pii]
PST - epublish
SO  - Med Oral Patol Oral Cir Bucal. 2006 Nov 1;11(6):E514-9.

PMID- 12034415
OWN - NLM
STAT- MEDLINE
DCOM- 20020613
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 112
IP  - 8
DP  - 2002 Jun 1
TI  - The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent 
      recurrent cardiac events.
PG  - 647-58
AB  - PURPOSE: Despite the success of intravenous glycoprotein IIb/IIIa antagonists, 
      oral formulations have failed to show benefit and have been associated with 
      increased mortality. To understand these findings, we performed a meta-analysis 
      of results from four phase 3 trials. SUBJECTS AND METHODS: Trials were identified 
      by MEDLINE search; review of abstracts from American College of Cardiology, 
      European Society of Cardiology, and American Heart Association scientific 
      sessions; or querying investigators in the field. Published, phase 3, randomized, 
      placebo-controlled trials involving more than 1000 patients with coronary artery 
      disease that compared an oral glycoprotein IIb/IIIa antagonist with or without 
      background aspirin versus aspirin, and that had a planned follow-up of > or =30 
      days, were included. Four trials met these criteria. Odds ratios (ORs) and 95% 
      confidence intervals (CIs) were generated from results, and combined using an 
      empirical Bayes random-effects model. RESULTS: Among 33,326 patients, oral 
      glycoprotein IIb/IIIa agents were associated with 31% increased mortality (OR = 
      1.31; 95% CI: 1.12 to 1.53; P= 0.0001). Results were similar whether the agent 
      was added to (OR = 1.38; 95% CI: 1.15 to 1.67) or substituted for (OR = 1.37; 95% 
      CI: 1.00 to 1.86) aspirin. Ischemic events or sudden death (OR = 1.22; 95% CI: 
      0.91 to 1.63) were also more common. Among patients with acute coronary 
      syndromes, the incidence of myocardial infarction was increased (OR = 1.16; 95% 
      CI: 1.03 to 1.29). CONCLUSION: Oral glycoprotein IIb/IIIa inhibitor therapy is 
      associated with increased mortality and myocardial infarction. No single 
      explanation for these findings is satisfactory; the problem is likely to be 
      multifactorial.
FAU - Newby, L Kristin
AU  - Newby LK
AD  - Duke Clinical Research Institute, Durham, North Carolina 27707, USA.
FAU - Califf, Robert M
AU  - Califf RM
FAU - White, Harvey D
AU  - White HD
FAU - Harrington, Robert A
AU  - Harrington RA
FAU - Van de Werf, Frans
AU  - Van de Werf F
FAU - Granger, Christopher B
AU  - Granger CB
FAU - Simes, R John
AU  - Simes RJ
FAU - Hasselblad, Vic
AU  - Hasselblad V
FAU - Armstrong, Paul W
AU  - Armstrong PW
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Med. 2002 Jun 1;112(8):673-5. PMID: 12034420
CIN - ACP J Club. 2002 Nov-Dec;137(3):85. PMID: 12418825
MH  - Administration, Oral
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Coronary Disease/complications/mortality/*prevention & control
MH  - Death, Sudden, Cardiac
MH  - Humans
MH  - Myocardial Infarction/etiology
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Failure
EDAT- 2002/05/30 10:00
MHDA- 2002/06/14 10:01
CRDT- 2002/05/30 10:00
PHST- 2002/05/30 10:00 [pubmed]
PHST- 2002/06/14 10:01 [medline]
PHST- 2002/05/30 10:00 [entrez]
AID - S0002934302011063 [pii]
AID - 10.1016/s0002-9343(02)01106-3 [doi]
PST - ppublish
SO  - Am J Med. 2002 Jun 1;112(8):647-58. doi: 10.1016/s0002-9343(02)01106-3.

PMID- 15071258
OWN - NLM
STAT- MEDLINE
DCOM- 20040826
LR  - 20131121
IS  - 1385-2264 (Print)
IS  - 1385-2264 (Linking)
VI  - 7
IP  - 4
DP  - 2003 Dec
TI  - Oral anticoagulants vs. aspirin for stroke prevention in patients with 
      non-valvular atrial fibrillation: the verdict is in.
PG  - 374-8
AB  - There is an increased risk of stroke and other cardiovascular events in patients 
      with atrial fibrillation (AF). Three meta-analyses of randomized clinical trials 
      (RCTs) comparing oral anticoagulants (OAC) with aspirin (ASA) arrived at 
      different conclusions regarding the relative efficacy of these agents to prevent 
      ischemic stroke in AF patients. This article summarizes a recently published 
      individual patient meta-analysis of all published RCTs comparing OAC and ASA in 
      AF. In total, 4052 patients randomized to OAC or ASA were similar regarding 
      important prognostic factors. Patients receiving OAC had a significantly lower 
      risk of any stroke (hazard ratio [HR] 0.54 [95% CI 0.43-0.71]), ischemic stroke 
      (HR 0.48 [0.37-0.63]), or cardiovascular events (HR 0.71 [0.59-0.85]). Patients 
      receiving OAC were more likely to experience major bleeding (HR 1.71 
      [1.21-2.41]). The benefit of OAC was most prominent in patients at a high risk of 
      stroke and other cardiovascular events, such as patients with hypertension, 
      diabetes, or previous cerebrovascular events. Overall, OAC improves outcomes for 
      cardiovascular events in AF patients but modestly increases the absolute risk of 
      major bleeding. Since high-risk AF patients appear to benefit most from OAC, 
      determining stroke risk in AF patients is very important.
FAU - van Walraven, Carl
AU  - van Walraven C
AD  - Clinical Epidemiology Unit--Ottawa Health Research Institute, Ottawa, Ontario, 
      Canada. carlv@ohri.ca
FAU - Hart, Robert G
AU  - Hart RG
FAU - Singer, Daniel E
AU  - Singer DE
FAU - Koudstaal, Peter J
AU  - Koudstaal PJ
FAU - Connolly, Stuart
AU  - Connolly S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Card Electrophysiol Rev
JT  - Cardiac electrophysiology review
JID - 9708907
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/*prevention & control
MH  - Treatment Outcome
RF  - 43
EDAT- 2004/04/09 05:00
MHDA- 2004/08/27 05:00
CRDT- 2004/04/09 05:00
PHST- 2004/04/09 05:00 [pubmed]
PHST- 2004/08/27 05:00 [medline]
PHST- 2004/04/09 05:00 [entrez]
AID - 5257229 [pii]
AID - 10.1023/B:CEPR.0000023143.98705.ee [doi]
PST - ppublish
SO  - Card Electrophysiol Rev. 2003 Dec;7(4):374-8. doi: 
      10.1023/B:CEPR.0000023143.98705.ee.

PMID- 23709617
OWN - NLM
STAT- MEDLINE
DCOM- 20131112
LR  - 20220311
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Linking)
VI  - 27
IP  - 9
DP  - 2013 Sep
TI  - Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline.
PG  - 3564-71
LID - 10.1096/fj.13-230276 [doi]
AB  - Hospitalization for major surgery or critical illness often associates with 
      cognitive decline. Inflammation and dysregulation of the innate immune system can 
      exert broad effects in the periphery and central nervous system (CNS), yet the 
      mechanisms underlying memory impairment after surgery remain poorly understood 
      and without effective therapy. Endogenous regulation of acute inflammation is 
      providing novel approaches to treat several disease states including sepsis, 
      pain, obesity and diabetes. Resolvins are potent endogenous lipid mediators 
      biosynthesized during the resolution phase of acute inflammation that display 
      immunoresolvent actions. Here, using a mouse model of surgery-induced cognitive 
      decline we report that orthopedic surgery affects hippocampal neuronal-glial 
      function, including synaptic transmission and plasticity. Systemic prophylaxis 
      with aspirin-triggered resolvin D1 (AT-RvD1: 
      7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid, as little as 100 
      ng dose per mouse) improved memory decline following surgery and abolished signs 
      of synaptic dysfunction. Moreover, delayed administration 24 h after surgery also 
      attenuated signs of neuronal dysfunction postoperatively. AT-RvD1 also limited 
      peripheral damage by modulating the release of systemic interleukin (IL)-6 and 
      improved other clinical markers of tissue injury. Collectively, these results 
      demonstrate a novel role of AT-RvD1 in modulating the proinflammatory milieu 
      after aseptic injury and protecting the brain from neuroinflammation, synaptic 
      dysfunction and cognitive decline. These findings provide novel and safer 
      approaches to treat postoperative cognitive decline and potentially other forms 
      of memory dysfunctions.
FAU - Terrando, Niccolò
AU  - Terrando N
AD  - Karolinska Institutet, Department of Physiology and Pharmacology, Nanna Svart väg 
      2, Stockholm, 171 77, Sweden. niccolo.terrando@ki.se
FAU - Gómez-Galán, Marta
AU  - Gómez-Galán M
FAU - Yang, Ting
AU  - Yang T
FAU - Carlström, Mattias
AU  - Carlström M
FAU - Gustavsson, Daniel
AU  - Gustavsson D
FAU - Harding, Ralph E
AU  - Harding RE
FAU - Lindskog, Maria
AU  - Lindskog M
FAU - Eriksson, Lars I
AU  - Eriksson LI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130524
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (resolvin D1)
RN  - 11062-77-4 (Superoxides)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Brain/drug effects/metabolism
MH  - Cognition/*drug effects
MH  - Docosahexaenoic Acids/*pharmacology/*therapeutic use
MH  - Electrophysiology
MH  - Immunohistochemistry
MH  - In Vitro Techniques
MH  - Locomotion/drug effects
MH  - Long-Term Potentiation/drug effects
MH  - Macrophages, Peritoneal/drug effects/metabolism
MH  - Male
MH  - Mice
MH  - Postoperative Complications/prevention & control
MH  - Superoxides/metabolism
OTO - NOTNLM
OT  - astrocytes
OT  - dementia
OT  - inflammation
OT  - long-term potentiation
OT  - resolution
EDAT- 2013/05/28 06:00
MHDA- 2013/11/13 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/05/28 06:00 [entrez]
PHST- 2013/05/28 06:00 [pubmed]
PHST- 2013/11/13 06:00 [medline]
AID - fj.13-230276 [pii]
AID - 10.1096/fj.13-230276 [doi]
PST - ppublish
SO  - FASEB J. 2013 Sep;27(9):3564-71. doi: 10.1096/fj.13-230276. Epub 2013 May 24.

PMID- 23019080
OWN - NLM
STAT- MEDLINE
DCOM- 20130403
LR  - 20131121
IS  - 1875-9114 (Electronic)
IS  - 0277-0008 (Linking)
VI  - 32
IP  - 11
DP  - 2012 Nov
TI  - Aspirin for primary prevention of cardiovascular disease events.
PG  - 1020-35
LID - 10.1002/phar.1127 [doi]
AB  - Aspirin has been used for the prevention and treatment of cardiovascular disease 
      (CVD) for several decades. The efficacy of aspirin for secondary prevention of 
      cardiovascular disease is well established, but the clinical benefit of aspirin 
      for primary prevention of CVD is less clear. The primary literature suggests that 
      aspirin may provide a reduction in CVD events, but the absolute benefit is small 
      and accompanied by an increase in bleeding. For aspirin to be beneficial for an 
      individual patient, the risk of a future CVD event must be large enough to 
      outweigh the risk of bleeding. The estimation of CVD risk is multifaceted and can 
      involve numerous risk scores and assessments of concomitant comorbidities that 
      confer additional CVD risk. Numerous guidelines provide recommendations for the 
      use of aspirin for primary prevention, but they often contradict one another 
      despite being based on the same clinical trials. Additional literature suggests 
      that the presence of comorbidities that increase CVD risk, such as diabetes 
      mellitus, asymptomatic peripheral arterial disease, or chronic kidney disease, 
      does not ensure that aspirin therapy will be beneficial. Ongoing clinical trials 
      may provide additional insight, but until more data are available, an 
      individualized assessment of CVD risk with careful evaluation of risk and benefit 
      should be performed before recommending aspirin therapy for primary prevention of 
      CVD.
CI  - © 2012 Pharmacotherapy Publications, Inc.
FAU - Nemerovski, Carrie W
AU  - Nemerovski CW
AD  - Department of Pharmacy Services, Henry Ford Hospital, Detroit, Michigan 48202, 
      USA. CNEMERO1@hfhs.org
FAU - Salinitri, Francine D
AU  - Salinitri FD
FAU - Morbitzer, Kathryn A
AU  - Morbitzer KA
FAU - Moser, Lynette R
AU  - Moser LR
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120927
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Cyclooxygenase Inhibitors/adverse effects/*therapeutic use
MH  - *Evidence-Based Medicine
MH  - Female
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - *Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk
MH  - Sex Characteristics
EDAT- 2012/09/29 06:00
MHDA- 2013/04/04 06:00
CRDT- 2012/09/29 06:00
PHST- 2012/09/29 06:00 [entrez]
PHST- 2012/09/29 06:00 [pubmed]
PHST- 2013/04/04 06:00 [medline]
AID - 10.1002/phar.1127 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2012 Nov;32(11):1020-35. doi: 10.1002/phar.1127. Epub 2012 Sep 
      27.

PMID- 28834248
OWN - NLM
STAT- MEDLINE
DCOM- 20190716
LR  - 20190716
IS  - 1748-1716 (Electronic)
IS  - 1748-1708 (Linking)
VI  - 222
IP  - 2
DP  - 2018 Feb
TI  - High doses of anti-inflammatory drugs compromise muscle strength and hypertrophic 
      adaptations to resistance training in young adults.
LID - 10.1111/apha.12948 [doi]
AB  - AIMS: This study tested the hypothesis that high doses of anti-inflammatory drugs 
      would attenuate the adaptive response to resistance training compared with low 
      doses. METHODS: Healthy men and women (aged 18-35 years) were randomly assigned 
      to daily consumption of ibuprofen (IBU; 1200 mg; n = 15) or acetylsalicylic acid 
      (ASA; 75 mg; n = 16) for 8 weeks. During this period, subjects completed 
      supervised knee-extensor resistance training where one leg was subjected to 
      training with maximal volitional effort in each repetition using a flywheel 
      ergometer (FW), while the other leg performed conventional (work-matched across 
      groups) weight-stack training (WS). Before and after training, muscle volume 
      (MRI) and strength were assessed, and muscle biopsies were analysed for gene and 
      protein expression of muscle growth regulators. RESULTS: The increase in m. 
      quadriceps volume was similar between FW and WS, yet was (averaged across legs) 
      greater in ASA (7.5%) compared with IBU (3.7%, group difference 34 cm(3) ; 
      P = 0.029). In the WS leg, muscle strength improved similarly (11-20%) across 
      groups. In the FW leg, increases (10-23%) in muscle strength were evident in both 
      groups yet they were generally greater (interaction effects P < 0.05) for ASA 
      compared with IBU. While our molecular analysis revealed several training 
      effects, the only group interaction (P < 0.0001) arose from a downregulated mRNA 
      expression of IL-6 in IBU. CONCLUSION: Maximal over-the-counter doses of 
      ibuprofen attenuate strength and muscle hypertrophic adaptations to 8 weeks of 
      resistance training in young adults. Thus, young individuals using resistance 
      training to maximize muscle growth or strength should avoid excessive intake of 
      anti-inflammatory drugs.
CI  - © 2017 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.
FAU - Lilja, M
AU  - Lilja M
AD  - Division of Clinical Physiology, Department of Laboratory Medicine, Karolinska 
      Institutet, Karolinska University Hospital, Stockholm, Sweden.
AD  - Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
FAU - Mandić, M
AU  - Mandić M
AD  - Division of Clinical Physiology, Department of Laboratory Medicine, Karolinska 
      Institutet, Karolinska University Hospital, Stockholm, Sweden.
AD  - Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
FAU - Apró, W
AU  - Apró W
AD  - Åstrand Laboratory, Swedish School of Sport and Health Sciences, Stockholm, 
      Sweden.
FAU - Melin, M
AU  - Melin M
AD  - Division of Clinical Physiology, Department of Laboratory Medicine, Karolinska 
      Institutet, Karolinska University Hospital, Stockholm, Sweden.
AD  - Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
AD  - Department of Cardiology, Karolinska Institutet, Karolinska University Hospital, 
      Stockholm, Sweden.
FAU - Olsson, K
AU  - Olsson K
AD  - Division of Clinical Physiology, Department of Laboratory Medicine, Karolinska 
      Institutet, Karolinska University Hospital, Stockholm, Sweden.
AD  - Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
FAU - Rosenborg, S
AU  - Rosenborg S
AD  - Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Gustafsson, T
AU  - Gustafsson T
AD  - Division of Clinical Physiology, Department of Laboratory Medicine, Karolinska 
      Institutet, Karolinska University Hospital, Stockholm, Sweden.
AD  - Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
FAU - Lundberg, T R
AU  - Lundberg TR
AUID- ORCID: 0000-0002-6818-6230
AD  - Division of Clinical Physiology, Department of Laboratory Medicine, Karolinska 
      Institutet, Karolinska University Hospital, Stockholm, Sweden.
AD  - Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20170916
PL  - England
TA  - Acta Physiol (Oxf)
JT  - Acta physiologica (Oxford, England)
JID - 101262545
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
CIN - Acta Physiol (Oxf). 2018 Feb;222(2):. PMID: 29117467
MH  - Adaptation, Physiological/drug effects
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents/*administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Ibuprofen/administration & dosage/adverse effects
MH  - Male
MH  - Muscle Strength/*drug effects
MH  - Muscle, Skeletal/*drug effects
MH  - *Resistance Training
MH  - Young Adult
OTO - NOTNLM
OT  - non-steroidal anti-inflammatory drug
OT  - clinical trial
OT  - inflammation
OT  - muscle hypertrophy
OT  - skeletal muscle
OT  - strength training
EDAT- 2017/08/24 06:00
MHDA- 2019/07/17 06:00
CRDT- 2017/08/24 06:00
PHST- 2017/06/22 00:00 [received]
PHST- 2017/07/20 00:00 [revised]
PHST- 2017/08/17 00:00 [revised]
PHST- 2017/08/17 00:00 [accepted]
PHST- 2017/08/24 06:00 [pubmed]
PHST- 2019/07/17 06:00 [medline]
PHST- 2017/08/24 06:00 [entrez]
AID - 10.1111/apha.12948 [doi]
PST - ppublish
SO  - Acta Physiol (Oxf). 2018 Feb;222(2). doi: 10.1111/apha.12948. Epub 2017 Sep 16.

PMID- 23526241
OWN - NLM
STAT- MEDLINE
DCOM- 20130723
LR  - 20181202
IS  - 2194-9379 (Print)
IS  - 2194-9379 (Linking)
VI  - 63
IP  - 5
DP  - 2013 May
TI  - Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg 
      capsules: a randomized, open-label, single-dose, two-way crossover study in 
      healthy human subjects.
PG  - 250-7
LID - 10.1055/s-0033-1337931 [doi]
AB  - The present study evaluated the bioavailability and bioequivalence of fixed dose 
      combination test formulation (atorvastatin 10 mg and aspirin 150 mg capsule) 
      against marketed reference formulations (Lipitor® tablets 10 mg and Nu-Seals 
      tablets 75 mg). This study was an open label, balanced, randomized, 2-treatment, 
      2-period, 2-sequence, single dose, crossover trial in 80 healthy adult human 
      volunteers under fasting conditions. Plasma concentrations of atorvastatin, 
      aspirin and salicylic acid were quantified using LC-MS/MS method. Pharmacokinetic 
      parameters were estimated by noncompartmental model and mean pharmacokinetic 
      parameters were comparable between test and reference formulations. The mean 
      pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) 
      for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 
      ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 
      10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 
      ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 
      ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively. 
      Where as for salicylic acid, above parameters were (42 357.57 ng.h/mL, 44 139.47 
      ng.h/mL, 9 820.15 ng/mL, 0.24 1/h and 0.23 1/h) and (40 217.08 ng.h/mL, 42 032.44 
      ng.h/mL, 9 569.18 ng/mL, 0.24 1/h and 0.24 1/h) respectively for test and 
      reference formulations. The 90% confidence intervals of atorvastatin and 
      salicylic acid for AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞ parameters 
      were found to be within the acceptable regulatory bioequivalence limits. In 
      conclusion, the new fixed dose combination test formulation was bioequivalent to 
      the reference formulations under fasting conditions.
CI  - © Georg Thieme Verlag KG Stuttgart · New York.
FAU - Tippabhotla, S K
AU  - Tippabhotla SK
AD  - Clinical Pharmacology and Pharmacokinetics, IPDO, Dr. Reddy's Laboratories 
      Limited, Hyderabad, India. sudhakarkt@drreddys.com
FAU - Betha, M R
AU  - Betha MR
FAU - Gadiko, C
AU  - Gadiko C
FAU - Battula, R
AU  - Battula R
FAU - Nakkawar, M
AU  - Nakkawar M
FAU - Cheerla, R
AU  - Cheerla R
FAU - Khan, S M
AU  - Khan SM
FAU - Yergude, S
AU  - Yergude S
FAU - Thota, S
AU  - Thota S
FAU - Vobalaboina, V
AU  - Vobalaboina V
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20130322
PL  - Germany
TA  - Drug Res (Stuttg)
JT  - Drug research
JID - 101602406
RN  - 0 (Capsules)
RN  - 0 (Drug Combinations)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Pyrroles)
RN  - A0JWA85V8F (Atorvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Atorvastatin
MH  - Capsules
MH  - Cross-Over Studies
MH  - Drug Combinations
MH  - Heptanoic Acids/administration & dosage/*pharmacokinetics
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacokinetics
MH  - Male
MH  - Pyrroles/administration & dosage/*pharmacokinetics
MH  - Therapeutic Equivalency
EDAT- 2013/03/26 06:00
MHDA- 2013/07/24 06:00
CRDT- 2013/03/26 06:00
PHST- 2013/03/26 06:00 [entrez]
PHST- 2013/03/26 06:00 [pubmed]
PHST- 2013/07/24 06:00 [medline]
AID - 10.1055/s-0033-1337931 [doi]
PST - ppublish
SO  - Drug Res (Stuttg). 2013 May;63(5):250-7. doi: 10.1055/s-0033-1337931. Epub 2013 
      Mar 22.

PMID- 10796208
OWN - NLM
STAT- MEDLINE
DCOM- 20000706
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 2
DP  - 2000
TI  - Antiplatelet agents for preventing and treating pre-eclampsia.
PG  - CD000492
AB  - BACKGROUND: Pre-eclampsia is associated with deficient intravascular production 
      of prostacyclin, a vasodilator, and excessive production of thromboxane, a 
      platelet-derived vasoconstrictor and stimulant of platelet aggregation. These 
      observations led to the hypotheses that antiplatelet agents, and low dose aspirin 
      in particular, might prevent or delay the development of pre-eclampsia. 
      OBJECTIVES: To assess the effectiveness and safety of antiplatelet agents when 
      given to women at risk of developing pre-eclampsia, and to those with established 
      pre-eclampsia. SEARCH STRATEGY: This review drew on the search strategy developed 
      for the Pregnancy and Childbirth Group as a whole. The Cochrane Controlled Trials 
      Register was also searched, The Cochrane Library 1999 Issue 1, Embase was 
      searched from 1994-1999 and hand searches were performed of the congress 
      proceedings of the International and European Societies for the Study of 
      Hypertension in Pregnancy. SELECTION CRITERIA: All randomised trials comparing 
      antiplatelet agents with either placebo or no antiplatelet agent during 
      pregnancy. Quasi random study designs were excluded. Participants were pregnant 
      women considered to be at risk of developing pre-eclampsia, and those with 
      pre-eclampsia before delivery. Women treated postpartum were excluded. 
      Interventions were any comparisons of an antiplatelet agent (such as low dose 
      aspirin or dipyridamole) with either placebo or no antiplatelet agent. DATA 
      COLLECTION AND ANALYSIS: Assessment of trials for inclusion in the review and 
      extraction of data was performed independently and unblinded by two reviewers. 
      Data were entered into the Review Manager software and double checked. MAIN 
      RESULTS: Forty two trials involving over 32,000 women were included in this 
      review, with 30,563 women in the prevention trials. There is a 15% reduction in 
      the risk of pre-eclampsia associated with the use of antiplatelet agents [32 
      trials with 29,331 women; relative risk (RR) 0.85, 95% confidence interval (0.78, 
      0.92); Number needed to treat (NNT) 89, (59, 167)]. This reduction is regardless 
      of risk status at trial entry or whether a placebo was used, and irrespective of 
      the dose of asprin or gestation at randomisation. Twenty three trials (28,268 
      women) reported preterm delivery. There is a small (8%) reduction in the risk of 
      delivery before 37 completed weeks [RR 0.92, (0.88, 0.97); NNT 72 (44, 200)]. 
      Baby deaths were reported in 30 trials (30,093 women). Overall there is a 14% 
      reduction in baby deaths in the antiplatelet group [RR 0.86, (0. 75, 0.98); NNT 
      250 (125, >10000)]. Small for gestational age babies were reported in 25 trials 
      (20,349 women), with no overall difference between the groups, RR 0.92, (0.84, 
      1.01). There were no significant differences between treatment and control groups 
      in any other measures of outcome. Five trials compared antiplatelet agents with 
      placebo or no antiplatelet agent for the treatment of pre-eclampsia. There are 
      insufficient data for any firm conclusions about the possible effects of these 
      agents when used for treatment of pre-eclampsia. REVIEWER'S CONCLUSIONS: 
      Antiplatelet agents, in this review largely low dose aspirin, have small-moderate 
      benefits when used for prevention of pre-eclampsia. Further information is 
      required to assess which women are most likely to benefit, when treatment should 
      be started, and at what dose.
FAU - Knight, M
AU  - Knight M
AD  - Resource Centre for Randomised Trials, Institute of Health Sciences, Old Road, 
      Headington, Oxford, UK, OX3 7LF. lelia.duley@ndm.ox.ac.uk
FAU - Duley, L
AU  - Duley L
FAU - Henderson-Smart, D J
AU  - Henderson-Smart DJ
FAU - King, J F
AU  - King JF
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UIN - Cochrane Database Syst Rev. 2007;(2):CD000492. PMID: 17636639
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*drug therapy/prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
RF  - 103
EDAT- 2000/05/05 09:00
MHDA- 2000/07/08 11:00
CRDT- 2000/05/05 09:00
PHST- 2000/05/05 09:00 [pubmed]
PHST- 2000/07/08 11:00 [medline]
PHST- 2000/05/05 09:00 [entrez]
AID - CD000492 [pii]
AID - 10.1002/14651858.CD000492 [doi]
PST - ppublish
SO  - Cochrane Database Syst Rev. 2000;(2):CD000492. doi: 10.1002/14651858.CD000492.

PMID- 35164864
OWN - NLM
STAT- MEDLINE
DCOM- 20220216
LR  - 20220219
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 23
IP  - 1
DP  - 2022 Feb 14
TI  - Recruitment to a large scale randomised controlled clinical trial in primary 
      care: the Helicobacter Eradication Aspirin Trial (HEAT).
PG  - 140
LID - 10.1186/s13063-022-06054-w [doi]
LID - 140
AB  - BACKGROUND: The Helicobacter Eradication Aspirin Trial (HEAT) is a multicentre, 
      double blind, randomised controlled trial investigating whether Helicobacter (H.) 
      pylori eradication reduces hospitalisation for peptic ulcer bleeding. Recruited 
      participants were aged 60 and over and taking aspirin (≤325 mg daily) for at 
      least four months prior to consent. Based on results of a pilot study, a sample 
      size calculation predicted 6600 H. pylori-positive randomised participants would 
      be required, from 33,000 volunteers, recruited from 170,000 invited patients. 
      Methodology was therefore designed for recruitment of large numbers of patients 
      from primary care using a novel electronic search tool, automated mail-out and 
      electronic follow-up. Recruitment started in 2012 and completed in 2017. METHODS: 
      All participants were recruited from GP practices, with assistance from the UK 
      Clinical Research Network (UKCRN). H. pylori-positive participants were 
      randomised to one week of eradication treatment or placebo. Recruitment was 
      managed using a bespoke web-based database that communicated directly with a 
      programmed search tool downloaded at participating practices. The primary 
      endpoint is hospitalisation due to peptic ulcer bleeding. The trial will end when 
      87 adjudicated events have occurred, identified from searches of GP databases, 
      review of secondary care admission data and mortality data, and reported events 
      from randomised participants and GPs. RESULTS: HEAT has recruited participants 
      from 1208 GP practices across the UK. Of the 188,875 invitation letters sent, 
      38,771 returned expressions of interest. Of these, 30,166 patients were consented 
      to the trial, of whom 5355 H. pylori-positive participants (17.8% of those 
      consented) were randomised. Mean age at consent was 73.1 ± 6.9 (SD) years and 
      72.2% of participants were male. Of the randomised (H. pylori-positive) 
      participants, 531 have died (as of 17 Sep 2020); none of the deaths was due to 
      trial treatment. CONCLUSION: The HEAT trial methodology has demonstrated that 
      recruitment of large numbers of patients from primary care is attainable, with 
      the assistance of the UKCRN, and could be applied to other clinical outcomes 
      studies. TRIAL REGISTRATION: ClinicalTrials.gov ; registration number NCT01506986 
      . Registered on 10 Jan 2012.
CI  - © 2022. The Author(s).
FAU - Stevenson, Diane J
AU  - Stevenson DJ
AUID- ORCID: 0000-0003-3533-1005
AD  - STAR (Simple Trials for Academic Research) Unit, Nottingham Digestive Diseases 
      Centre, University of Nottingham, Nottingham, UK. 
      diane.stevenson@nottingham.ac.uk.
FAU - Avery, Anthony J
AU  - Avery AJ
AD  - Division of Primary Care, University of Nottingham, Nottingham, UK.
FAU - Coupland, Carol
AU  - Coupland C
AD  - Division of Primary Care, University of Nottingham, Nottingham, UK.
FAU - Hobbs, F D Richard
AU  - Hobbs FDR
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford, 
      Oxford, UK.
FAU - Kendrick, Denise
AU  - Kendrick D
AD  - Division of Primary Care, University of Nottingham, Nottingham, UK.
FAU - Moore, Michael V
AU  - Moore MV
AD  - Primary Care Population Sciences and Medical Education, University of 
      Southampton, Southampton, UK.
FAU - Morris, Clive
AU  - Morris C
AD  - TCR (Nottingham) Ltd., Langley Mill, Nottingham, UK.
FAU - Rubin, Greg P
AU  - Rubin GP
AD  - Institute of Population Health Sciences, Newcastle University, 
      Newcastle-upon-Tyne, UK.
FAU - Smith, Murray D
AU  - Smith MD
AD  - School of Health & Social Care, University of Lincoln, Lincoln, UK.
FAU - Hawkey, Christopher J
AU  - Hawkey CJ
AD  - STAR (Simple Trials for Academic Research) Unit, Nottingham Digestive Diseases 
      Centre, University of Nottingham, Nottingham, UK.
FAU - Dumbleton, Jennifer S
AU  - Dumbleton JS
AD  - STAR (Simple Trials for Academic Research) Unit, Nottingham Digestive Diseases 
      Centre, University of Nottingham, Nottingham, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT01506986
GR  - 09/55/52/National Institute for Health Research Health Technology Assessment 
      programme/
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20220214
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Aspirin/adverse effects
MH  - *Helicobacter
MH  - Hot Temperature
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Primary Health Care
MH  - Treatment Outcome
PMC - PMC8842965
OTO - NOTNLM
OT  - Aspirin
OT  - Clinical research networks
OT  - Clinical trial
OT  - Demographics
OT  - H. pylori
OT  - Primary care
OT  - Recruitment
OT  - Ulcer bleeding
COIS- The authors declare that they have no competing interests.
EDAT- 2022/02/16 06:00
MHDA- 2022/02/17 06:00
CRDT- 2022/02/15 05:32
PHST- 2021/03/23 00:00 [received]
PHST- 2022/01/27 00:00 [accepted]
PHST- 2022/02/15 05:32 [entrez]
PHST- 2022/02/16 06:00 [pubmed]
PHST- 2022/02/17 06:00 [medline]
AID - 10.1186/s13063-022-06054-w [pii]
AID - 6054 [pii]
AID - 10.1186/s13063-022-06054-w [doi]
PST - epublish
SO  - Trials. 2022 Feb 14;23(1):140. doi: 10.1186/s13063-022-06054-w.

PMID- 18038215
OWN - NLM
STAT- MEDLINE
DCOM- 20080422
LR  - 20131121
IS  - 1420-682X (Print)
IS  - 1420-682X (Linking)
VI  - 65
IP  - 3
DP  - 2008 Feb
TI  - Aspirin: recent developments.
PG  - 354-8
AB  - Aspirin exerts anti-thrombotic action by acetylating and inactivating 
      cyclooxygenase-1, preventing the production of thromboxane A2 in platelets. 
      Through this inhibition of platelet function, aspirin is considered as a 
      preventative of ischemic diseases such as coronary and cerebral infarction. 
      However, many studies have revealed that aspirin has other beneficial actions in 
      addition to its anti-platelet activity. For example, aspirin may confer some 
      benefit against colorectal cancer. Here, we discuss the involvement of 
      inflammation in atherosclerosis and how aspirin exerts its beneficial actions in 
      atherosclerotic diseases and cancer.
FAU - Yasuda, O
AU  - Yasuda O
AD  - Department of Geriatric Medicine, Osaka University Graduate School of Medicine 
      2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. yasuda@geriat.med.osaka-u.ac.jp
FAU - Takemura, Y
AU  - Takemura Y
FAU - Kawamoto, H
AU  - Kawamoto H
FAU - Rakugi, H
AU  - Rakugi H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Cell Mol Life Sci
JT  - Cellular and molecular life sciences : CMLS
JID - 9705402
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/metabolism/therapeutic use
MH  - *Aspirin/metabolism/therapeutic use
MH  - Colorectal Neoplasms/drug therapy
MH  - *Cyclooxygenase Inhibitors/metabolism/therapeutic use
MH  - Humans
MH  - Inflammation/drug therapy
MH  - Pain/drug therapy
MH  - *Platelet Aggregation Inhibitors/metabolism/therapeutic use
RF  - 51
EDAT- 2007/11/27 09:00
MHDA- 2008/04/23 09:00
CRDT- 2007/11/27 09:00
PHST- 2007/11/27 09:00 [pubmed]
PHST- 2008/04/23 09:00 [medline]
PHST- 2007/11/27 09:00 [entrez]
AID - 10.1007/s00018-007-7449-4 [doi]
PST - ppublish
SO  - Cell Mol Life Sci. 2008 Feb;65(3):354-8. doi: 10.1007/s00018-007-7449-4.

PMID- 7000106
OWN - NLM
STAT- MEDLINE
DCOM- 19810126
LR  - 20201209
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 52
IP  - 6
DP  - 1980 Jun
TI  - Comparison of i.m. lysine acetylsalicylate and oxycodone in the treatment of pain 
      after operation.
PG  - 613-7
AB  - Lysine acetylsalicylate (LAS) is a soluble salt of acetylsalicylic acid and can 
      be given parenterally. LAS 12.5 mg kg-1 and 25 mg kg-1 were compared with 
      oxycodone 0.15 mg kg-1 in the treatment of pain after operation in 60 patients 
      undergoing varicose vein surgery. Both treatments almost completely relieved 
      moderate to severe pain for the 3-h observation period. The time until the peak 
      of action was longer after LAS (60-90 min) than after oxycodone (30-60 min). No 
      significant differences were found between the smaller and larger doses of LAS, 
      suggesting a plateau effect. Further clinical experiments with LAS using i.v. 
      mode of administration and other pain models are warranted.
FAU - Korttila, K
AU  - Korttila K
FAU - Pentti, O M
AU  - Pentti OM
FAU - Auvinen, J
AU  - Auvinen J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - CD35PMG570 (Oxycodone)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Codeine/*analogs & derivatives
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Injections, Intramuscular
MH  - Male
MH  - Middle Aged
MH  - Oxycodone/administration & dosage/*therapeutic use
MH  - Pain, Postoperative/*drug therapy
MH  - Random Allocation
MH  - Time Factors
MH  - Varicose Veins/surgery
EDAT- 1980/06/01 00:00
MHDA- 1980/06/01 00:01
CRDT- 1980/06/01 00:00
PHST- 1980/06/01 00:00 [pubmed]
PHST- 1980/06/01 00:01 [medline]
PHST- 1980/06/01 00:00 [entrez]
AID - S0007-0912(17)41790-9 [pii]
AID - 10.1093/bja/52.6.613 [doi]
PST - ppublish
SO  - Br J Anaesth. 1980 Jun;52(6):613-7. doi: 10.1093/bja/52.6.613.

PMID- 405838
OWN - NLM
STAT- MEDLINE
DCOM- 19770729
LR  - 20190907
IS  - 0001-6357 (Print)
IS  - 0001-6357 (Linking)
VI  - 35
IP  - 2
DP  - 1977 May
TI  - Sodium acetylsalicylate and the role of prostaglandins in the mechanism of 
      intradental pain.
PG  - 63-7
AB  - In order to study the effect of sodium acetylsalicylate and the role of 
      prostaglandins on intradental nerve impulse activity experiments were performed 
      on the teeth of anaesthetized cats. Nerve impulse activity was induced by 
      mechanical and chemical stimuli and recorded by means of electrodes inserted into 
      dentinal cavities. It was shown that such activity could not be blocked by sodium 
      acetylsalicylate or indomethacin given locally or i.v. PGE2 failed to excite the 
      sensory units when given locally (3.5 microng/ml) or intraarterially (35-140 
      ng/min) alone or in combination with mechanical and thermal stimuli or combined 
      with local application of histamine (10 mg/ml) or bradykinin (10 mg/ml). 
      Intraarterial infusion or arachidonic acid, a precursor to PGE2, PGF2 alpha PGG2 
      and PGH2 failed to change the excitability even on applying local stimuli to the 
      pulp or with local application of histamine or bradykinin. These findings seem to 
      indicate that the increased sensitivity of the tooth to thermal stimuli seen 
      during acute pulpitis is not due to formation of prostaglandins.
FAU - Haegerstam, G
AU  - Haegerstam G
FAU - Edwall, L
AU  - Edwall L
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Odontol Scand
JT  - Acta odontologica Scandinavica
JID - 0370344
RN  - 0 (Arachidonic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandins)
RN  - 0 (Prostaglandins E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Arachidonic Acids/administration & dosage
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cats
MH  - Cyclooxygenase Inhibitors
MH  - Evoked Potentials/*drug effects
MH  - Injections, Intra-Arterial
MH  - Injections, Intravenous
MH  - Prostaglandins/administration & dosage/*physiology
MH  - Prostaglandins E/administration & dosage/*pharmacology
MH  - Tooth/*innervation
MH  - *Toothache/etiology
EDAT- 1977/05/01 00:00
MHDA- 1977/05/01 00:01
CRDT- 1977/05/01 00:00
PHST- 1977/05/01 00:00 [pubmed]
PHST- 1977/05/01 00:01 [medline]
PHST- 1977/05/01 00:00 [entrez]
AID - 10.3109/00016357709055991 [doi]
PST - ppublish
SO  - Acta Odontol Scand. 1977 May;35(2):63-7. doi: 10.3109/00016357709055991.

PMID- 201944
OWN - NLM
STAT- MEDLINE
DCOM- 19780218
LR  - 20180214
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 15
IP  - 6
DP  - 1977
TI  - Study into the mechanism of acetylsalicylic acid-induced bronchoconstriction.
PG  - 529-35
AB  - In order to elucidate the mechanism of the acetylsalicylic acid-induced 
      bronchoconstrictor responses which have been observed in asthmatic patients, 
      experiments were done in cats, anesthetized by chloralose, vagotomized, and 
      completely relaxed by infusion of suxamethonium. In about half of the 
      experiments, the sensitivity of the bronchi to 5-hydroxytryptamine (5-HT) was 
      considerably enhanced after the administration of 5--6 mg/kg acetylsalicylic 
      acid, a dose which had previously been shown to suppress prostaglandin (PG) 
      biosynthesis in the bronchi of the cat completely. No further increase in 
      sensitivity to 5-HT occurred when higher doses of the drug were given. Immediate 
      bronchoconstrictor reactions to the injection of acetylsalicylic acid were rare, 
      in most instances the rise in sensitivity developed slowly during a period of 
      about 30 min. The results are consistent with the assumption that PGE2 displays 
      an antagonistic effect to the mediators of asthmatic bronchoconstriction or to 
      their liberation and that inhibition of PG synthesis by acetylsalicylic acid or 
      related drugs eliminate this function and may thus give rise to bronchospasm.
FAU - Frey, H H
AU  - Frey HH
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Arachidonic Acids)
RN  - 0 (Prostaglandins E)
RN  - 0 (Prostaglandins F)
RN  - 0 (Receptors, Adrenergic, beta)
RN  - 333DO1RDJY (Serotonin)
RN  - 9Y8NXQ24VQ (Propranolol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bronchi/*drug effects
MH  - Cats
MH  - Constriction, Pathologic/chemically induced
MH  - Female
MH  - Male
MH  - Propranolol/pharmacology
MH  - Prostaglandins E/biosynthesis
MH  - Prostaglandins F/biosynthesis
MH  - Receptors, Adrenergic, beta/drug effects
MH  - Serotonin/pharmacology
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1159/000136731 [doi]
PST - ppublish
SO  - Pharmacology. 1977;15(6):529-35. doi: 10.1159/000136731.

PMID- 430164
OWN - NLM
STAT- MEDLINE
DCOM- 19790629
LR  - 20131121
IS  - 0022-3085 (Print)
IS  - 0022-3085 (Linking)
VI  - 50
IP  - 5
DP  - 1979 May
TI  - Surgical postoperative bleeding associated with aspirin ingestion. Report of two 
      cases.
PG  - 682-4
AB  - Two patients are reported in whom repeated postoperative hematomas appeared to be 
      secondary to aspirin-induced platelet defect. Routine bleeding and clotting 
      studies will not demonstrate this platelet-induced coagulopathy. A previous 
      history of massive aspirin ingestion makes such a coagulopathy a serious 
      consideration, but the platelet defect may occur with small doses of aspirin. 
      Such aspirin ingestion should be viewed with great concern by the neurosurgeon. 
      The defect is treatable by platelet transfusion.
FAU - Merriman, E
AU  - Merriman E
FAU - Bell, W
AU  - Bell W
FAU - Long, D M
AU  - Long DM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Neurosurg
JT  - Journal of neurosurgery
JID - 0253357
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Blood Platelet Disorders/*chemically induced
MH  - Hematoma/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neurosurgery
MH  - *Postoperative Complications
MH  - Self Medication/adverse effects
MH  - Substance-Related Disorders
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
AID - 10.3171/jns.1979.50.5.0682 [doi]
PST - ppublish
SO  - J Neurosurg. 1979 May;50(5):682-4. doi: 10.3171/jns.1979.50.5.0682.

PMID- 29915123
OWN - NLM
STAT- MEDLINE
DCOM- 20190826
LR  - 20190826
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 49
IP  - 7
DP  - 2018 Jul
TI  - Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week 
      Before Randomization in the SOCRATES Trial.
PG  - 1678-1685
LID - 10.1161/STROKEAHA.118.020553 [doi]
AB  - BACKGROUND AND PURPOSE: SOCRATES (Acute Stroke or Transient Ischemic Attack 
      Treated With Aspirin or Ticagrelor and Patient Outcomes), comparing ticagrelor 
      with aspirin in patients with acute cerebral ischemia, found a nonsignificant 11% 
      relative risk reduction for stroke, myocardial infarction, or death (P=0.07). 
      Aspirin intake before randomization could enhance the effect of ticagrelor by 
      conferring dual antiplatelet effect during a high-risk period for subsequent 
      stroke. Therefore, we explored the efficacy and safety of ticagrelor versus 
      aspirin in the patients who received any aspirin the week before randomization. 
      METHODS: A prespecified subgroup analysis in SOCRATES (n=13 199), randomizing 
      patients with acute ischemic stroke (National Institutes of Health Stroke Scale 
      score of ≤5) or transient ischemic attack (ABCD(2) score of ≥4) to 90-day 
      treatment with ticagrelor or aspirin. Patients in the prior-aspirin group had 
      received any aspirin within the week before randomization. Primary end point was 
      time to stroke, myocardial infarction, or death. Safety end point was PLATO 
      (Study of Platelet Inhibition and Patient Outcomes) major bleeding. RESULTS: The 
      4232 patients in the prior-aspirin group were older, had more vascular risk 
      factors, and vascular disease than the other patients. In the prior-aspirin 
      group, the primary end point occurred in 138/2130 (6.5%) of patients on 
      ticagrelor and in 177/2102 (8.3%) on aspirin (hazard ratio, 0.76; 95% confidence 
      interval, 0.61-0.95; P=0.02); in patients with no prior-aspirin usage an event 
      occurred in 304/4459 (6.9%) and 320/4508 (7.1%) on ticagrelor and aspirin, 
      respectively (hazard ratio, 0.96; 95% confidence interval, 0.82-1.12; P=0.59). 
      The treatment-by-prior-aspirin interaction was not statistically significant 
      (P=0.10). In the prior-aspirin group, major bleeding occurred in 0.7% and 0.4% of 
      patients on ticagrelor and aspirin, respectively (hazard ratio, 1.58; 95% 
      confidence interval, 0.68-3.65; P=0.28). CONCLUSIONS: In this secondary analysis 
      from SOCRATES, fewer primary end points occurred on ticagrelor treatment than on 
      aspirin in patients receiving aspirin before randomization, but there was no 
      significant treatment-by-prior-aspirin interaction. A new study will investigate 
      the benefit-risk of combining ticagrelor and aspirin in patients with acute 
      cerebral ischemia (URL: https://www.clinicaltrials.gov. Unique identifier: 
      NCT03354429). CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. 
      Unique identifier: NCT01994720.
CI  - © 2018 American Heart Association, Inc.
FAU - Wong, K S Lawrence
AU  - Wong KSL
AD  - From the Department of Medicine and Therapeutics, Chinese University of Hong 
      Kong, Shatin (K.S.L.W.).
FAU - Amarenco, Pierre
AU  - Amarenco P
AD  - Department of Neurology and Stroke Centre, Bichat Hospital, Paris Diderot 
      University, France (P.A.).
FAU - Albers, Gregory W
AU  - Albers GW
AD  - Stanford Stroke Center, Stanford University, CA (G.W.A.).
FAU - Denison, Hans
AU  - Denison H
AD  - Global Medicines Development, AstraZeneca, Gothenburg, Sweden (H.D., P.H., A.H., 
      M.K., P.L.).
FAU - Easton, J Donald
AU  - Easton JD
AD  - Department of Neurology, University of California, San Francisco (J.D.E.).
FAU - Evans, Scott R
AU  - Evans SR
AD  - Department of Biostatistics, Harvard University, Boston, MA (S.R.E.).
FAU - Held, Peter
AU  - Held P
AD  - Global Medicines Development, AstraZeneca, Gothenburg, Sweden (H.D., P.H., A.H., 
      M.K., P.L.).
FAU - Himmelmann, Anders
AU  - Himmelmann A
AD  - Global Medicines Development, AstraZeneca, Gothenburg, Sweden (H.D., P.H., A.H., 
      M.K., P.L.).
FAU - Kasner, Scott E
AU  - Kasner SE
AD  - Department of Neurology, University of Pennsylvania, Philadelphia (S.E.K.).
FAU - Knutsson, Mikael
AU  - Knutsson M
AD  - Global Medicines Development, AstraZeneca, Gothenburg, Sweden (H.D., P.H., A.H., 
      M.K., P.L.).
FAU - Ladenvall, Per
AU  - Ladenvall P
AD  - Global Medicines Development, AstraZeneca, Gothenburg, Sweden (H.D., P.H., A.H., 
      M.K., P.L.).
FAU - Minematsu, Kazuo
AU  - Minematsu K
AD  - Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular 
      Center, Suita, Osaka, Japan (K.M.).
FAU - Molina, Carlos A
AU  - Molina CA
AD  - Stroke Unit, Hospital Vall d'Hebron, Barcelona, Spain (C.A.M.).
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, China (Y.W.).
FAU - Johnston, S Claiborne
AU  - Johnston SC
AD  - Dean's Office, Dell Medical School, University of Texas at Austin (S.C.J.). 
      clay.johnston@utexas.edu.
CN  - SOCRATES Steering Committee and Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT01994720
SI  - ClinicalTrials.gov/NCT03354429
GR  - U01 NS062835/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180618
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Drug Interactions
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/chemically induced
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Stroke/*drug therapy
MH  - Ticagrelor/adverse effects/*therapeutic use
MH  - Treatment Outcome
PMC - PMC6019568
MID - NIHMS969795
OTO - NOTNLM
OT  - aspirin
OT  - platelet aggregation inhibitors
OT  - stroke
OT  - ticagrelor
OT  - transient ischemic attack
EDAT- 2018/06/20 06:00
MHDA- 2019/08/27 06:00
CRDT- 2018/06/20 06:00
PHST- 2018/01/02 00:00 [received]
PHST- 2018/04/24 00:00 [revised]
PHST- 2018/05/14 00:00 [accepted]
PHST- 2018/06/20 06:00 [pubmed]
PHST- 2019/08/27 06:00 [medline]
PHST- 2018/06/20 06:00 [entrez]
AID - STROKEAHA.118.020553 [pii]
AID - 10.1161/STROKEAHA.118.020553 [doi]
PST - ppublish
SO  - Stroke. 2018 Jul;49(7):1678-1685. doi: 10.1161/STROKEAHA.118.020553. Epub 2018 
      Jun 18.

PMID- 29632234
OWN - NLM
STAT- MEDLINE
DCOM- 20190219
LR  - 20220330
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Print)
IS  - 2473-9529 (Linking)
VI  - 2
IP  - 7
DP  - 2018 Apr 10
TI  - Risk of recurrent venous thromboembolism according to baseline risk factor 
      profiles.
PG  - 788-796
LID - 10.1182/bloodadvances.2018017160 [doi]
AB  - The optimal duration of anticoagulation for venous thromboembolism (VTE) is 
      uncertain. In this prespecified analysis, we used data from 2 randomized trials, 
      which compared once-daily rivaroxaban (20 mg or 10 mg) with aspirin (100 mg) or 
      placebo for extended VTE treatment to estimate the risk of recurrence according 
      to baseline risk factor profiles. Index VTE events were centrally classified as 
      unprovoked, or provoked by major transient or persistent, or minor transient or 
      persistent risk factors, and rates of recurrence at 1 year were calculated. A 
      total of 2832 patients received rivaroxaban; 1131 received aspirin, and 590 
      received placebo. With unprovoked VTE, rates of recurrence in the 1173 patients 
      given rivaroxaban, the 468 given aspirin, and the 243 given placebo were 2.0%, 
      5.9%, and 10.0%, respectively. There were no recurrences in patients with VTE 
      provoked by major transient risk factors. With VTE provoked by minor persistent 
      risk factors, recurrence rates in the 1184 patients given rivaroxaban, the 466 
      given aspirin, and the 248 given placebo were 2.4%, 4.5%, and 10.7%, 
      respectively. For patients with minor transient risk factors, recurrence rates 
      were 0.4% in the 268 patients given rivaroxaban, 4.2% in the 121 given aspirin, 
      and 7.1% in the 56 given placebo. Recurrence rates in patients with VTE provoked 
      by minor persistent or minor transient risk factors were not significantly lower 
      than that with unprovoked VTE (hazard ratio [HR], 0.81; 95% confidence interval 
      [CI], 0.56-1.16; and HR, 0.68; 95% CI, 0.32-1.30, respectively). Therefore, such 
      patients may also benefit from extended anticoagulation therapy.
CI  - © 2018 by The American Society of Hematology.
FAU - Prins, Martin H
AU  - Prins MH
AD  - Department of Epidemiology and Technology Assessment, University of Maastricht, 
      Maastricht, The Netherlands.
FAU - Lensing, Anthonie W A
AU  - Lensing AWA
AD  - Bayer AG, Leverkusen, Germany.
FAU - Prandoni, Paolo
AU  - Prandoni P
AD  - Department of Cardiothoracic and Vascular Sciences, Vascular Medicine Unit, 
      University of Padua, Padua, Italy.
FAU - Wells, Philip S
AU  - Wells PS
AD  - Department of Medicine, University of Ottawa and Ottawa Hospital Research 
      Institute, Ottawa, ON, Canada.
FAU - Verhamme, Peter
AU  - Verhamme P
AD  - Vascular Medicine and Hemostasis, University of Leuven, Leuven, Belgium.
FAU - Beyer-Westendorf, Jan
AU  - Beyer-Westendorf J
AD  - Department of Hematology, Medical Clinic I, University Hospital Carl Gustav 
      Carus, Dresden, Germany.
AD  - Department of Haematology and Oncology, King's College, London, United Kingdom.
FAU - Bauersachs, Rupert
AU  - Bauersachs R
AD  - Vascular Medicine, Klinikum Darmstadt, Darmstadt, Germany.
AD  - Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, 
      Germany.
FAU - Bounameaux, Henri
AU  - Bounameaux H
AD  - Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of 
      Medicine, Geneva, Switzerland.
FAU - Brighton, Timothy A
AU  - Brighton TA
AD  - Department of Haematology, Prince of Wales Hospital, Sydney, Australia.
FAU - Cohen, Alexander T
AU  - Cohen AT
AD  - Department of Haematological Medicine, Guy's and St. Thomas' Hospitals, London, 
      United Kingdom.
FAU - Davidson, Bruce L
AU  - Davidson BL
AD  - University of Washington School of Medicine, Seattle, WA.
FAU - Decousus, Hervé
AU  - Decousus H
AD  - Centre d'Investigation Clinique 1408, Sainbiose U1059, Investigation Network On 
      Venous Thromboembolism, Service de Médecine Vasculaire et Thérapeutique, Centre 
      Hospitalo-Universitaire, Hôpital Nord, Saint Etienne, France.
FAU - Kakkar, Ajay K
AU  - Kakkar AK
AD  - Thrombosis Research Institute and University College London, London, United 
      Kingdom.
FAU - van Bellen, Bonno
AU  - van Bellen B
AD  - Hospital Beneficência Portuguesa, São Paulo, Brazil; and.
FAU - Pap, Akos F
AU  - Pap AF
AD  - Bayer AG, Leverkusen, Germany.
FAU - Homering, Martin
AU  - Homering M
AD  - Bayer AG, Leverkusen, Germany.
FAU - Tamm, Miriam
AU  - Tamm M
AD  - Bayer AG, Leverkusen, Germany.
FAU - Weitz, Jeffrey I
AU  - Weitz JI
AD  - Thrombosis and Atherosclerosis Research Institute and McMaster University, 
      Hamilton, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drug Administration Schedule
MH  - Factor Xa Inhibitors/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Recurrence
MH  - Risk Assessment/*methods
MH  - Risk Factors
MH  - Rivaroxaban/administration & dosage/*therapeutic use
MH  - Venous Thromboembolism/drug therapy/*pathology
PMC - PMC5894264
COIS- Conflict-of-interest disclosure: M.H.P. receives consulting fees from Pfizer and 
      Daiichi Sankyo. A.W.A.L., A.F.P., M.H., and M.T. are employees of Bayer. P.P. 
      receives consulting and lecture fees from Bayer, Sanofi, Daiichi Sankyo, and 
      Pfizer. P.S.W. receives grant support, lecture fees, and fees for serving on 
      advisory boards from Bayer; fees for serving on a writing committee from Itreas; 
      consulting fees from Janssen Scientific Affairs; grant support from Bristol-Myers 
      Squibb and Pfizer; and lecture fees from Daiichi Sankyo. P.V. receives grant 
      support, lecture fees, and fees for serving on advisory boards from Boehringer 
      Ingelheim and LEO Pharma; lecture fees from Pfizer and Bristol-Myers Squibb; 
      grant support from Sanofi; lecture fees and fees for serving on advisory boards 
      from Daiichi Sankyo; and fees for serving on an advisory board from Portola 
      Pharmaceuticals. J.B.-W. receives grant support, lecture fees, and fees for 
      serving on advisory boards from Boehringer Ingelheim, Daiichi Sankyo, and Pfizer. 
      R.B. receives consulting and lecture fees from Boehringer Ingelheim, 
      Bristol-Myers Squibb, and Daiichi Sankyo. H.B. receives grant support and fees 
      for serving on the Thrombosis Research Institute Garfield Registry steering 
      committee; consulting fees from Amgen; and fees for serving on advisory boards 
      from Bayer, Pfizer, and Sanofi Aventis. T.A.B. receives lecture fees from Bayer, 
      Novo Nordisk, and GlaxoSmithKline. A.T.C. receives fees for serving on a 
      committee for Boehringer Ingelheim; grant support and fees for serving on 
      committees from Bristol-Myers Squibb and Daiichi Sankyo; consulting fees and fees 
      for serving on steering committees from Johnson & Johnson and Portola; grant 
      support, consulting fees, and fees for serving on committees from Pfizer; and 
      consulting fees from Sanofi, Janssen, and Ono Pharmaceuticals. B.L.D. receives 
      consulting fees from Janssen and Portola. H.D. receives fees for attending 
      symposia from Aspen; fees for serving on advisory boards from Pfizer and 
      Bristol-Myers Squibb; and grant support and fees for board membership from 
      Daiichi Sankyo and Bayer. A.K.K. receives grant support, consulting fees, and 
      lecture fees from Bayer; and consulting and lecture fees from Sanofi, Janssen, 
      Boehringer Ingelheim, and Daiichi Sankyo. B.v.B. receives lecture fees and fees 
      for serving on an advisory board from Bayer and Daiichi Sankyo; and for serving 
      on an advisory board from Bristol-Myers Squibb. J.I.W. receives consulting fees 
      from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Ionis 
      Pharmaceuticals, Janssen, Johnson & Johnson, Novartis, Portola, Pfizer, and 
      Servier.
EDAT- 2018/04/11 06:00
MHDA- 2019/03/21 06:00
CRDT- 2018/04/11 06:00
PHST- 2018/02/08 00:00 [received]
PHST- 2018/02/28 00:00 [accepted]
PHST- 2018/04/11 06:00 [entrez]
PHST- 2018/04/11 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
AID - bloodadvances.2018017160 [pii]
AID - 2018/017160 [pii]
AID - 10.1182/bloodadvances.2018017160 [doi]
PST - ppublish
SO  - Blood Adv. 2018 Apr 10;2(7):788-796. doi: 10.1182/bloodadvances.2018017160.

PMID- 1803142
OWN - NLM
STAT- MEDLINE
DCOM- 19920430
LR  - 20141120
IS  - 0023-2149 (Print)
IS  - 0023-2149 (Linking)
VI  - 69
IP  - 9
DP  - 1991 Sep
TI  - [Characteristics of functional activity of thrombocytes in patients with 
      "aspirin" bronchial asthma].
PG  - 26-9
AB  - Upon comparison of functional activity of platelets and their response to aspirin 
      in 20 subjects with aspirin bronchial asthma, 19 patients with non-aspirin 
      bronchial asthma and 21 healthy controls it was found out that in aspirin asthma 
      platelet count is elevated, their response to aggregation inductors enhances 
      while to aspirin is abnormal, plasmic thromboxane level is reduced. Aspirin 
      asthma patients are believed to have a specific platelet defect.
FAU - Evsiukova, E V
AU  - Evsiukova EV
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Osobennosti funktsional'noĭ aktivnosti trombotsitov u bol'nykh "aspirinovoi" 
      bronkhial'noĭ astmoĭ.
PL  - Russia (Federation)
TA  - Klin Med (Mosk)
JT  - Klinicheskaia meditsina
JID - 2985204R
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/pharmacology
MH  - Asthma/*blood/chemically induced
MH  - Epoprostenol/blood
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Count/drug effects
MH  - Platelet Function Tests
MH  - Stimulation, Chemical
MH  - Thromboxane A2/blood
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
PST - ppublish
SO  - Klin Med (Mosk). 1991 Sep;69(9):26-9.

PMID- 30720135
OWN - NLM
STAT- MEDLINE
DCOM- 20190816
LR  - 20211209
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 54
IP  - 4
DP  - 2019 Apr
TI  - A novel mechanism for the anticancer activity of aspirin and salicylates.
PG  - 1256-1270
LID - 10.3892/ijo.2019.4701 [doi]
AB  - Epidemiological studies indicate that long‑term aspirin usage reduces the 
      incidence of colorectal cancer (CRC) and may protect against other non‑CRC 
      associated adenocarcinomas, including oesophageal cancer. A number of hypotheses 
      have been proposed with respect to the molecular action of aspirin and other 
      non‑steroidal anti‑inflammatory drugs in cancer development. The mechanism by 
      which aspirin exhibits toxicity to CRC has been previously investigated by 
      synthesising novel analogues and derivatives of aspirin in an effort to identify 
      functionally significant moieties. Herein, an early effect of aspirin and 
      aspirin‑like analogues against the SW480 CRC cell line was investigated, with a 
      particular focus on critical molecules in the epidermal growth factor (EGF) 
      pathway. The present authors proposed that aspirin, diaspirin and analogues, and 
      diflunisal (a salicylic acid derivative) may rapidly perturb EGF and EGF receptor 
      (EGFR) internalisation. Upon longer incubations, the diaspirins and thioaspirins 
      may inhibit EGFR phosphorylation at Tyr1045 and Tyr1173. It was additionally 
      demonstrated, using a qualitative approach, that EGF internalisation in the SW480 
      cell line may be directed to endosomes by fumaryldiaspirin using early endosome 
      antigen 1 as an early endosomal marker and that EGF internalisation may also be 
      perturbed in oesophageal cell lines, suggestive of an effect not only restricted 
      to CRC cells. Taken together and in light of our previous findings that the 
      aspirin‑like analogues can affect cyclin D1 expression and nuclear factor‑κB 
      localisation, it was hypothesized that aspirin and aspirin analogues 
      significantly and swiftly perturb the EGFR axis and that the protective activity 
      of aspirin may in part be explained by perturbed EGFR internalisation and 
      activation. These findings may also have implications in understanding the 
      inhibitory effect of aspirin and salicylates on wound healing, given the critical 
      role of EGF in the response to tissue trauma.
FAU - Bashir, Asma'u I J
AU  - Bashir AIJ
AD  - Department of Biomedical Science and Physiology, School of Sciences, Faculty of 
      Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
FAU - Kankipati, Chandra S
AU  - Kankipati CS
AD  - Department of Biomedical Science and Physiology, School of Sciences, Faculty of 
      Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
FAU - Jones, Sarah
AU  - Jones S
AD  - School of Pharmacy, Faculty of Science and Engineering, University of 
      Wolverhampton, Wolverhampton WV1 1LY, UK.
FAU - Newman, Robert M
AU  - Newman RM
AD  - School of Mathematics and Computer Science, Faculty of Science and Engineering, 
      University of Wolverhampton, Wolverhampton WV1 1LY, UK.
FAU - Safrany, Stephen T
AU  - Safrany ST
AD  - School of Medicine, RCSI‑Bahrain, Adliya, Kingdom of Bahrain.
FAU - Perry, Christopher J
AU  - Perry CJ
AD  - School of Pharmacy, Faculty of Science and Engineering, University of 
      Wolverhampton, Wolverhampton WV1 1LY, UK.
FAU - Nicholl, Iain D
AU  - Nicholl ID
AD  - Department of Biomedical Science and Physiology, School of Sciences, Faculty of 
      Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
LA  - eng
PT  - Journal Article
DEP - 20190129
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (CCND1 protein, human)
RN  - 0 (EGF Family of Proteins)
RN  - 0 (NF-kappa B)
RN  - 0 (Salicylates)
RN  - 136601-57-5 (Cyclin D1)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Colorectal Neoplasms/*metabolism
MH  - Cyclin D1/metabolism
MH  - Drug Screening Assays, Antitumor
MH  - EGF Family of Proteins/metabolism
MH  - ErbB Receptors/metabolism
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - NF-kappa B/metabolism
MH  - Phosphorylation/drug effects
MH  - Salicylates/*pharmacology
MH  - Signal Transduction/*drug effects
PMC - PMC6411351
OTO - NOTNLM
OT  - epidermal growth factor
OT  - epidermal growth factor receptor
OT  - aspirin
OT  - colorectal cancer
OT  - endocytosis
EDAT- 2019/02/06 06:00
MHDA- 2019/08/17 06:00
CRDT- 2019/02/06 06:00
PHST- 2018/04/16 00:00 [received]
PHST- 2018/12/18 00:00 [accepted]
PHST- 2019/02/06 06:00 [pubmed]
PHST- 2019/08/17 06:00 [medline]
PHST- 2019/02/06 06:00 [entrez]
AID - ijo-54-04-1256 [pii]
AID - 10.3892/ijo.2019.4701 [doi]
PST - ppublish
SO  - Int J Oncol. 2019 Apr;54(4):1256-1270. doi: 10.3892/ijo.2019.4701. Epub 2019 Jan 
      29.

PMID- 11498915
OWN - NLM
STAT- MEDLINE
DCOM- 20011011
LR  - 20181130
IS  - 1000-8713 (Print)
IS  - 1000-8713 (Linking)
VI  - 16
IP  - 5
DP  - 1998 Sep
TI  - [Research on the separation behavior of acidic drugs in capillary electrophoresis 
      with reversed direction of electroosmotic flow].
PG  - 383-5
AB  - The separation behavior of acidic drugs in capillary electrophoresis with 
      reversal of electroosmotic flow was investigated systematically. Acetylsalicylic 
      acid and its related compound salicylic acid were employed as objective drugs. 
      The cationic surfactant cetyltrimethylammonium bromide (CTAB) was used as 
      reversed reagent for electroosmotic flow. The experimental conditions, such as, 
      cationic surfactant concentration, buffer pH and organic additives, which 
      affected migration time, peak shape and column efficiency, were studied in 
      detail. The experimental results indicated that high speed analysis could be 
      achieved in the capillary electrophoresis with reversed electroosmotic flow 
      induced by cationic surfactant when acidic drugs were analysed. The poor peak 
      shape and low column efficiency caused by the interactions of CTAB with acidic 
      anions would be improved by adding proper organic additive, such as, 
      beta-cyclodextrin or acetonitrile.
FAU - Lin, M
AU  - Lin M
AD  - Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 
      210009.
FAU - Feng, M
AU  - Feng M
FAU - Zhang, Z
AU  - Zhang Z
FAU - An, D
AU  - An D
FAU - Fan, G
AU  - Fan G
LA  - chi
PT  - Journal Article
PL  - China
TA  - Se Pu
JT  - Se pu = Chinese journal of chromatography
JID - 9424804
RN  - 0 (Cetrimonium Compounds)
RN  - 0 (Surface-Active Agents)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - Z7FF1XKL7A (Cetrimonium)
SB  - IM
MH  - Aspirin/*isolation & purification
MH  - Cetrimonium
MH  - Cetrimonium Compounds
MH  - Electrophoresis, Capillary/*methods
MH  - Salicylic Acid/*isolation & purification
MH  - Surface-Active Agents
EDAT- 2001/08/14 10:00
MHDA- 2001/10/12 10:01
CRDT- 2001/08/14 10:00
PHST- 2001/08/14 10:00 [pubmed]
PHST- 2001/10/12 10:01 [medline]
PHST- 2001/08/14 10:00 [entrez]
PST - ppublish
SO  - Se Pu. 1998 Sep;16(5):383-5.

PMID- 326013
OWN - NLM
STAT- MEDLINE
DCOM- 19770729
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 94
IP  - 1
DP  - 1977 Jul
TI  - Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled 
      clinical study in patients with aortic ball valves.
PG  - 101-11
AB  - Prevention of arterial thromboembolism with acetylsalicylic acid (ASA) was 
      studied in 148 patients with single Starr-Edwards aortic ball-valve prostheses. 
      These patients are suitable for such a study because they have a high incidence 
      of arterial emboli derived mainly from thrombi formed on the valves. They were 
      given either 1 Gm. of ASA daily or placebo in combination with anticoagulants, 
      and were observed for 2 years. Only two emboli occurred in patients receiving 
      ASA, none of them severe. In the placebo group 12 thromboembolic episodes were 
      diagnosed in 10 patients, and three with cerebral emboli died; in one a subdural 
      hematoma unrelated to the embolus was found. In addition, one fatal and the one 
      nonfatal intracranial bleeding occurred in each group, whereas gastrointestinal 
      complications were seen more frequently in patients taking ASA. It is concluded 
      that ASA combined with anticoagulants offered a significantly better protection 
      against arterial thromboembolism than did anticoagulant therapy alone.
FAU - Dale, J
AU  - Dale J
FAU - Myhre, E
AU  - Myhre E
FAU - Storstein, O
AU  - Storstein O
FAU - Stormorken, H
AU  - Stormorken H
FAU - Efskind, L
AU  - Efskind L
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Aortic Valve
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Evaluation
MH  - Female
MH  - *Heart Valve Prosthesis/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Thromboembolism/*prevention & control
EDAT- 1977/07/01 00:00
MHDA- 1977/07/01 00:01
CRDT- 1977/07/01 00:00
PHST- 1977/07/01 00:00 [pubmed]
PHST- 1977/07/01 00:01 [medline]
PHST- 1977/07/01 00:00 [entrez]
AID - S0002-8703(77)80351-7 [pii]
AID - 10.1016/s0002-8703(77)80351-7 [doi]
PST - ppublish
SO  - Am Heart J. 1977 Jul;94(1):101-11. doi: 10.1016/s0002-8703(77)80351-7.

PMID- 33437907
OWN - NLM
STAT- MEDLINE
DCOM- 20211222
LR  - 20230308
IS  - 2471-254X (Electronic)
IS  - 2471-254X (Linking)
VI  - 5
IP  - 1
DP  - 2021 Jan
TI  - Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A 
      Systematic Review and Meta-analysis.
PG  - 133-143
LID - 10.1002/hep4.1640 [doi]
AB  - Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related death 
      worldwide, with a growing incidence and poor prognosis. While some recent studies 
      suggest an inverse association between aspirin use and reduced HCC incidence, 
      other data are conflicting. To date, the precise magnitude of risk reduction-and 
      whether there are dose-dependent and duration-dependent associations-remains 
      unclear. To provide an updated and comprehensive assessment of the association 
      between aspirin use and incident HCC risk, we conducted a systematic review and 
      meta-analysis of all observational studies published through September 2020. 
      Using random-effects meta-analysis, we calculated the pooled relative risks (RRs) 
      and 95% confidence intervals (CIs) for the association between aspirin use and 
      incident HCC risk. Where data were available, we evaluated HCC risk according to 
      the defined daily dose of aspirin use. Among 2,389,019 participants, and 20,479 
      cases of incident HCC, aspirin use was associated with significantly lower HCC 
      risk (adjusted RR, 0.61; 95% CI, 0.51-0.73; P ≤ 0.001; I(2) = 90.4%). In subgroup 
      analyses, the magnitude of benefit associated with aspirin was significantly 
      stronger in studies that adjusted for concurrent statin and/or metformin use (RR, 
      0.45; 95% CI, 0.28-0.64) versus those that did not (P (heterogeneity) = 0.02), 
      studies that accounted for cirrhosis (RR, 0.49; 95% CI, 0.45-0.52) versus those 
      that did not (P (heterogeneity) = 0.02), and studies that confirmed HCC through 
      imaging/biopsy (RR, 0.30; 95% CI, 0.15-0.58) compared with billing codes (P 
      (heterogeneity) < 0.001). In four studies, each defined daily dose was associated 
      with significantly lower HCC risk (RR, 0.98; 95% CI, 0.97-0.98), corresponding to 
      an 8.4% risk reduction per year of aspirin use. Conclusion: In this comprehensive 
      systematic review and meta-analysis, aspirin use was associated with a 
      significant reduction in HCC risk. These benefits appeared to increase with 
      increasing dose and duration of aspirin use.
CI  - © 2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC 
      on behalf of American Association for the Study of Liver Diseases.
FAU - Memel, Zoe N
AU  - Memel ZN
AD  - Harvard Medical SchoolBostonMAUSA.
AD  - Department of MedicineMassachusetts General HospitalBostonMAUSA.
FAU - Arvind, Ashwini
AU  - Arvind A
AD  - Harvard Medical SchoolBostonMAUSA.
AD  - Clinical Researcher, Liver Center and Gastrointestinal DivisionMassachusetts 
      General HospitalBostonMAUSA.
FAU - Moninuola, Oluwatoba
AU  - Moninuola O
AD  - Department of Internal MedicineSaint Peter's University Hospital and Rutgers 
      Robert Wood Johnson Medical SchoolNew BrunswickNJUSA.
FAU - Philpotts, Lisa
AU  - Philpotts L
AD  - Harvard Medical SchoolBostonMAUSA.
AD  - Treadwell LibraryMassachusetts General HospitalBostonMAUSA.
FAU - Chung, Raymond T
AU  - Chung RT
AD  - Harvard Medical SchoolBostonMAUSA.
AD  - Clinical and Translational Epidemiology UnitMassachusetts General 
      HospitalBostonMAUSA.
AD  - Gastrointestinal DivisionHepatology and Liver CenterLiver Transplant 
      ProgramMassachusetts General HospitalBostonMAUSA.
FAU - Corey, Kathleen E
AU  - Corey KE
AUID- ORCID: 0000-0003-2882-7264
AD  - Harvard Medical SchoolBostonMAUSA.
AD  - Clinical and Translational Epidemiology UnitMassachusetts General 
      HospitalBostonMAUSA.
AD  - MGH Fatty Liver ClinicHarvard Medical SchoolBostonMAUSA.
FAU - Simon, Tracey G
AU  - Simon TG
AUID- ORCID: 0000-0003-0610-5287
AD  - Harvard Medical SchoolBostonMAUSA.
AD  - Clinical and Translational Epidemiology UnitMassachusetts General 
      HospitalBostonMAUSA.
AD  - Division of GastroenterologyHarvard Medical SchoolBostonMAUSA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201113
PL  - United States
TA  - Hepatol Commun
JT  - Hepatology communications
JID - 101695860
RN  - R16CO5Y76E (Aspirin)
CIN - Hepatol Commun. 2021 Dec;5(12):2151-2152. PMID: 34558827
MH  - Aspirin/*therapeutic use
MH  - Carcinoma, Hepatocellular/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Liver Neoplasms/*epidemiology
MH  - Risk Factors
MH  - *Risk Reduction Behavior
PMC - PMC7789838
EDAT- 2021/01/14 06:00
MHDA- 2021/01/14 06:01
CRDT- 2021/01/13 06:14
PHST- 2020/08/10 00:00 [received]
PHST- 2020/10/03 00:00 [revised]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2021/01/13 06:14 [entrez]
PHST- 2021/01/14 06:00 [pubmed]
PHST- 2021/01/14 06:01 [medline]
AID - 02009842-202101000-00013 [pii]
AID - HEP41640 [pii]
AID - 10.1002/hep4.1640 [doi]
PST - epublish
SO  - Hepatol Commun. 2020 Nov 13;5(1):133-143. doi: 10.1002/hep4.1640. eCollection 
      2021 Jan.

PMID- 18032974
OWN - NLM
STAT- MEDLINE
DCOM- 20080227
LR  - 20131121
IS  - 1528-9117 (Print)
IS  - 1528-9117 (Linking)
VI  - 13
IP  - 6
DP  - 2007 Nov-Dec
TI  - Expertise-based management in essential thrombocythemia and polycythemia vera.
PG  - 372-6
AB  - The clinical courses of polycythemia vera (PV) and essential thrombocythemia (ET) 
      are characterized by an increased incidence of thrombotic and hemorrhagic 
      complications and an inherent tendency to progress into myelofibrosis or acute 
      myeloid leukemia. Major predictors of vascular events are increasing age and 
      previous thrombosis. Myelosuppressive drugs can reduce the rate of thromboses and 
      hemorrhages, but there is concern that their use accelerates the rate of leukemic 
      transformation. Thus, a risk-oriented management strategy is recommended. 
      Low-risk patients with PV should be treated with phlebotomy and low-dose aspirin, 
      whereas those with ET can be left untreated. Cytotoxic agents are recommended in 
      high-risk patients and hydroxyurea is the drug of choice in most patients. 
      Interferon-alpha (IFN-alpha) or anagrelide could be considered in selected young 
      patients or as second-line therapy in those intolerant of hydroxyurea or with 
      refractory disease. The recent identification of the JAK2 V617F mutation in a 
      substantial proportion of patients with PV and ET raises the possibility of a 
      molecularly targeted therapy.
FAU - Finazzi, Guido
AU  - Finazzi G
AD  - Department of Transfusion Medicine, Ospedali Riuniti, Bergamo, Italy. 
      gfinazzi@ospedaliriuniti.bergamo.it
FAU - Barbui, Tiziano
AU  - Barbui T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer J
JT  - Cancer journal (Sudbury, Mass.)
JID - 100931981
RN  - 0 (Antineoplastic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Aspirin/administration & dosage
MH  - Humans
MH  - Polycythemia Vera/*therapy
MH  - Risk Factors
MH  - Thrombocytosis/*therapy
EDAT- 2007/11/23 09:00
MHDA- 2008/02/28 09:00
CRDT- 2007/11/23 09:00
PHST- 2007/11/23 09:00 [pubmed]
PHST- 2008/02/28 09:00 [medline]
PHST- 2007/11/23 09:00 [entrez]
AID - 00130404-200711000-00006 [pii]
AID - 10.1097/PPO.0b013e3181594774 [doi]
PST - ppublish
SO  - Cancer J. 2007 Nov-Dec;13(6):372-6. doi: 10.1097/PPO.0b013e3181594774.

PMID- 26927215
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20190918
IS  - 1873-4316 (Electronic)
IS  - 1389-2010 (Linking)
VI  - 17
IP  - 7
DP  - 2016
TI  - A Prevention of Pre-eclampsia with the Use of Acetylsalicylic Acid and 
      Low-molecular Weight Heparin - Molecular Mechanisms.
PG  - 624-8
AB  - Pre-eclampsia appears to be the main cause for the maternal and fetal morbidity 
      and mortality. Pregnant women with pre-eclampsia are more likely to be threatened 
      with conditions which potentially may be lethal, such as: disseminated 
      intravascular coagulation, cerebral hemorrhage, liver and renal failure. 
      Pregnancy complicated with pre-eclampsia is also associated with a greater risk 
      for iatrogenic prematurity, intrauterine growth retardation, premature abruption 
      of placenta, and even intrauterine fetal death. In the majority of cases the 
      reasons for arterial hypertension among pregnant women remain obscure. For the 
      past decades, there were many abortive attempts in the use of some microelements, 
      vitamins or specific diets, such as polyunsaturated fatty acids, for the 
      prophylaxis of pre-eclampsia. Recently, it has been shown that a prevention of 
      pre-eclampsia with the use of a lowmolecular- weight heparins (LMWHs) and 
      acetylsalicylic acid (ASA) could considerably reduce the frequency of 
      preeclampsia. In this review, we present the studies concerning the applications 
      of LMWHs and aspirin in the prophylaxis of pre-eclampsia and some important data 
      about the mechanisms of anti-inflammatory actions of LMWHs and ASA.
FAU - Darmochwal-Kolarz, Dorota
AU  - Darmochwal-Kolarz D
AD  - Department of Gynecology and Obstetrics, Medical Faculty, University of Rzeszow, 
      35-301 Rzeszow, ul. Lwowska 60, Poland. dorotak@mp.pl.
FAU - Kolarz, Bogdan
AU  - Kolarz B
FAU - Korzeniewski, Michal
AU  - Korzeniewski M
FAU - Kimber-Trojnar, Zaneta
AU  - Kimber-Trojnar Z
FAU - Patro-Malysza, Jolanta
AU  - Patro-Malysza J
FAU - Mierzynski, Radzisław
AU  - Mierzynski R
FAU - Przegalinska-Kałamucka, Monika
AU  - Przegalinska-Kałamucka M
FAU - Oleszczuk, Jan
AU  - Oleszczuk J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Pharm Biotechnol
JT  - Current pharmaceutical biotechnology
JID - 100960530
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/metabolism/*therapeutic use
MH  - Aspirin/metabolism/*therapeutic use
MH  - Female
MH  - Fetal Growth Retardation/diagnosis/metabolism/prevention & control
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Pre-Eclampsia/diagnosis/metabolism/*prevention & control
MH  - Pregnancy
EDAT- 2016/03/02 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/03/02 06:00
PHST- 2015/09/29 00:00 [received]
PHST- 2015/11/12 00:00 [revised]
PHST- 2016/01/25 00:00 [accepted]
PHST- 2016/03/02 06:00 [entrez]
PHST- 2016/03/02 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - CPB-EPUB-74063 [pii]
AID - 10.2174/1389201017666160301103312 [doi]
PST - ppublish
SO  - Curr Pharm Biotechnol. 2016;17(7):624-8. doi: 10.2174/1389201017666160301103312.

PMID- 32005423
OWN - NLM
STAT- MEDLINE
DCOM- 20200602
LR  - 20200602
IS  - 1873-4111 (Electronic)
IS  - 0378-5122 (Linking)
VI  - 133
DP  - 2020 Mar
TI  - Aspirin moderates the association between cardiovascular risk, brain white matter 
      hyperintensity total lesion volume and processing speed in normal ageing.
PG  - 49-53
LID - S0378-5122(19)30644-9 [pii]
LID - 10.1016/j.maturitas.2020.01.001 [doi]
AB  - OBJECTIVES: Cardiovascular risk is associated with cognitive decline and this 
      effect is attributed to brain pathology, including white matter hyperintensity 
      (WMH) burden. Low-dose aspirin is frequently recommended for reducing vascular 
      events. We investigated the effect of taking aspirin on the association between 
      cardiovascular risk, WMH burden and cognitive function. STUDY DESIGN: The study 
      sample was drawn from 318 dementia-free adults aged 67-71 years. Brain magnetic 
      resonance imaging (MRI) scans were acquired from 239 participants. MAIN OUTCOME 
      MEASURES: WMH total lesion volumes (TLV) were extracted using the automated 
      lesion segmentation algorithm. We measured cardiovascular risk by calculating 
      ASSIGN score. Cognitive ability was measured using a test of processing speed. We 
      developed structural equation models to test our hypothesis. RESULTS: Sixty-eight 
      participants (47.1 % male, mean age = 68.8 years) reported that they took 
      aspirin. The demographic measures did not differ significantly by aspirin use. 
      Among aspirin users, there was a strong negative association between WMH TLV and 
      cognition (β = -0.43, p-value < 0.001), while in non-users of aspirin the only 
      significant predictor of poorer cognition was cardiovascular risk (β = -0.17, 
      p-value = 0.001). CONCLUSIONS: Aspirin use moderates the negative effect of WMH 
      burden on cognition. Considering WMH burden in addition to cardiovascular risk 
      could improve the prediction of cognitive decline in older adults with aspirin 
      use.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Khezrian, Mina
AU  - Khezrian M
AD  - Aberdeen Biomedical Imaging Centre, Institute of Medical Sciences, University of 
      Aberdeen, Aberdeen, UK. Electronic address: r03mk17@abdn.ac.uk.
FAU - Waymont, Jennifer M J
AU  - Waymont JMJ
AD  - Aberdeen Biomedical Imaging Centre, Institute of Medical Sciences, University of 
      Aberdeen, Aberdeen, UK.
FAU - Myint, Phyo K
AU  - Myint PK
AD  - Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
FAU - McNeil, Christopher J
AU  - McNeil CJ
AD  - Aberdeen Biomedical Imaging Centre, Institute of Medical Sciences, University of 
      Aberdeen, Aberdeen, UK.
FAU - Whalley, Lawrence J
AU  - Whalley LJ
AD  - Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
FAU - Staff, Roger
AU  - Staff R
AD  - Aberdeen Royal Infirmary, NHS Grampian, Foresterhill, Aberdeen, UK.
FAU - Murray, Alison D
AU  - Murray AD
AD  - Aberdeen Biomedical Imaging Centre, Institute of Medical Sciences, University of 
      Aberdeen, Aberdeen, UK.
LA  - eng
PT  - Journal Article
DEP - 20200107
PL  - Ireland
TA  - Maturitas
JT  - Maturitas
JID - 7807333
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aging/pathology/psychology
MH  - Aspirin/*therapeutic use
MH  - *Cardiovascular Diseases
MH  - *Cognition
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Risk Factors
MH  - White Matter/diagnostic imaging/*pathology
OTO - NOTNLM
OT  - Aspirin
OT  - Brain white matter hyperintensity
OT  - Cardiovascular risk
OT  - Cognition
OT  - Older adults
EDAT- 2020/02/02 06:00
MHDA- 2020/06/03 06:00
CRDT- 2020/02/02 06:00
PHST- 2019/07/09 00:00 [received]
PHST- 2019/12/09 00:00 [revised]
PHST- 2020/01/04 00:00 [accepted]
PHST- 2020/02/02 06:00 [entrez]
PHST- 2020/02/02 06:00 [pubmed]
PHST- 2020/06/03 06:00 [medline]
AID - S0378-5122(19)30644-9 [pii]
AID - 10.1016/j.maturitas.2020.01.001 [doi]
PST - ppublish
SO  - Maturitas. 2020 Mar;133:49-53. doi: 10.1016/j.maturitas.2020.01.001. Epub 2020 
      Jan 7.

PMID- 37641373
OWN - NLM
STAT- MEDLINE
DCOM- 20230831
LR  - 20230831
IS  - 1600-0897 (Electronic)
IS  - 1046-7408 (Linking)
VI  - 90
IP  - 3
DP  - 2023 Sep
TI  - Does adding hydroxychloroquine to empiric treatment improve the live birth rate 
      in refractory obstetrical antiphospholipid syndrome? A systematic review.
PG  - e13761
LID - 10.1111/aji.13761 [doi]
AB  - PROBLEM: The current standard prevention of obstetric complications in patients 
      with antiphospholipid antibody syndrome (APS) is the use of combination low-dose 
      aspirin and low molecular weight heparin. However, 20-30% of women still 
      experience refractory obstetrical APS. Hydroxychloroquine (HCQ) is an 
      immunomodulatory agent that has been shown in laboratory studies to decrease 
      thrombosis risk, support placentation, and minimize the destructive effects of 
      antiphospholipid antibodies. The objective of this study was to evaluate the risk 
      of pregnancy loss upon treatment with HCQ among women with refractory obstetrical 
      APS. METHOD OF STUDY: A systematic review was conducted according to PRISMA 
      guidelines. Studies that evaluated the use of HCQ during pregnancy in women with 
      primary APS were included. The primary outcomes of interest were live birth and 
      pregnancy losses after treatment with HCQ. RESULTS: Twelve studies met inclusion 
      criteria. Three retrospective cohort studies demonstrated improved live birth 
      rate, and four studies demonstrated a reduction in pregnancy loss rate. Two case 
      reports also demonstrated a benefit in the use of HCQ compared to previous 
      obstetrical outcomes. CONCLUSIONS: Our findings suggest a significant benefit of 
      HCQ in addition to aspirin and heparin for patients with APS to mitigate the risk 
      of antiphospholipid antibody mediated obstetrical complications. Randomized 
      controlled trials with standardized patient selection criteria need to be 
      conducted to corroborate these findings.
CI  - © 2023 The Authors. American Journal of Reproductive Immunology published by John 
      Wiley & Sons Ltd.
FAU - Hooper, Allyssa
AU  - Hooper A
AD  - Faculty of Medicine, The University of British Columbia, Vancouver, British 
      Columbia, Canada.
FAU - Bacal, Vanessa
AU  - Bacal V
AUID- ORCID: 0000-0002-6816-5616
AD  - Department of Obstetrics & Gynaecology, The University of Toronto, Toronto, 
      Ontario, Canada.
AD  - Mount Sinai Fertility, Toronto, Ontario, Canada.
FAU - Bedaiwy, Mohamed A
AU  - Bedaiwy MA
AD  - Faculty of Medicine, The University of British Columbia, Vancouver, British 
      Columbia, Canada.
AD  - Department of Obstetrics & Gynecology, The University of British Columbia, 
      Vancouver, British Columbia, Canada.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 0 (Antibodies, Antiphospholipid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Humans
MH  - Female
MH  - *Antiphospholipid Syndrome/drug therapy
MH  - Birth Rate
MH  - Hydroxychloroquine/therapeutic use
MH  - Retrospective Studies
MH  - Antibodies, Antiphospholipid
MH  - *Abortion, Spontaneous
MH  - Aspirin/therapeutic use
OTO - NOTNLM
OT  - antiphospholipid antibody syndrome
OT  - hydroxychloroquine
OT  - miscarriage
OT  - recurrent pregnancy loss
OT  - systematic review
EDAT- 2023/08/29 06:43
MHDA- 2023/08/31 06:41
CRDT- 2023/08/29 01:04
PHST- 2023/07/04 00:00 [revised]
PHST- 2023/05/04 00:00 [received]
PHST- 2023/07/24 00:00 [accepted]
PHST- 2023/08/31 06:41 [medline]
PHST- 2023/08/29 06:43 [pubmed]
PHST- 2023/08/29 01:04 [entrez]
AID - 10.1111/aji.13761 [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 2023 Sep;90(3):e13761. doi: 10.1111/aji.13761.

PMID- 35787862
OWN - NLM
STAT- MEDLINE
DCOM- 20220706
LR  - 20230703
IS  - 1942-5546 (Electronic)
IS  - 0025-6196 (Print)
IS  - 0025-6196 (Linking)
VI  - 97
IP  - 7
DP  - 2022 Jul
TI  - Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used 
      Medications.
PG  - 1345-1362
LID - S0025-6196(22)00131-8 [pii]
LID - 10.1016/j.mayocp.2022.02.027 [doi]
AB  - Drug-induced hyperuricemia and gout present an increasingly prevalent problem in 
      clinical practice. Herein, we review the urate-lowering or urate-raising effects 
      of commonly used agents. We performed a PubMed search using the terms gout, 
      urate, and medication, along with the specific agents/classes described herein. 
      Reports were reviewed until 2022, and original studies were considered if they 
      primarily or secondarily reported the effects of 1 or more drugs on serum urate 
      level. Previous reviews were assessed for references to additional studies that 
      described urate-altering effects of medications. Urate-changing drugs are 
      summarized regarding their magnitude of effect, mechanism of action, and clinical 
      significance. Potentially urate-lowering drugs include angiotensin II receptor 
      blockers, calcium channel blockers, high-dose aspirin and salicylates, some 
      nonsalicylate nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme 
      inhibitors, sodium-glucose cotransporter 2 inhibitors, statins, and fenofibrate. 
      Potentially urate-increasing drugs discussed include diuretics, β-blockers, 
      insulin, pyrazinamide, ethambutol, calcineurin inhibitors, low-dose aspirin, 
      testosterone, and lactate. In patients who have or are at risk for hyperuricemia 
      or gout, an increased awareness of drugs that affect serum urate level may allow 
      for prescribing that effectively treats the indicated problem while minimizing 
      adverse effects on hyperuricemia and gout.
CI  - Copyright © 2022 Mayo Foundation for Medical Education and Research. All rights 
      reserved.
FAU - Leung, Nicole
AU  - Leung N
AD  - Divison of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, 
      NYU Langone Orthopedic Hospital, New York, NY. Electronic address: 
      nicole.leung@nyulangone.org.
FAU - Yip, Kevin
AU  - Yip K
AD  - Department of Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, 
      New York, New York.
FAU - Pillinger, Michael H
AU  - Pillinger MH
AD  - Rheumatology Section, New York Harbor Healthcare System, New York Campus, U.S. 
      Department of Veterans Affairs.
FAU - Toprover, Michael
AU  - Toprover M
AD  - Rheumatology Section, New York Harbor Healthcare System, New York Campus, U.S. 
      Department of Veterans Affairs.
LA  - eng
GR  - KL2 TR001446/TR/NCATS NIH HHS/United States
GR  - UL1 TR001445/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
RN  - 268B43MJ25 (Uric Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Gout/drug therapy
MH  - Humans
MH  - *Hyperuricemia/chemically induced/drug therapy
MH  - Off-Label Use
MH  - Uric Acid
PMC - PMC9575594
MID - NIHMS1794275
COIS- POTENTIAL COMPETING INTERESTS Dr Pillinger is on the data safety monitoring board 
      and advisory board of Horizon Therapeutics. He is also a consultant for Sobi and 
      Fortress Bioscience. Dr Toprover is on the advisory board of Horizon 
      Therapeutics. The other authors report no competing interests.
EDAT- 2022/07/06 06:00
MHDA- 2022/07/07 06:00
CRDT- 2022/07/05 17:53
PHST- 2021/09/22 00:00 [received]
PHST- 2022/02/14 00:00 [revised]
PHST- 2022/02/28 00:00 [accepted]
PHST- 2022/07/05 17:53 [entrez]
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/07/07 06:00 [medline]
AID - S0025-6196(22)00131-8 [pii]
AID - 10.1016/j.mayocp.2022.02.027 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2022 Jul;97(7):1345-1362. doi: 10.1016/j.mayocp.2022.02.027.

PMID- 34593487
OWN - NLM
STAT- MEDLINE
DCOM- 20211020
LR  - 20211020
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 11
IP  - 9
DP  - 2021 Sep 30
TI  - Continuation versus discontinuation of aspirin-based antiplatelet therapy for 
      perioperative bleeding and ischaemic events in adults undergoing neurosurgery: 
      protocol for a systematic review and meta-analysis.
PG  - e046741
LID - 10.1136/bmjopen-2020-046741 [doi]
LID - e046741
AB  - INTRODUCTION: Antiplatelet therapy is commonly used in primary or secondary 
      prevention of atherosclerotic and thrombotic diseases, such as coronary artery 
      disease, transient ischaemic attack or stroke. Recent studies noted that 
      antiplatelet therapy should be continued perioperatively in patients at high risk 
      of thrombosis and low bleeding risk in orthopaedic, spinal or urological surgery. 
      However, evidence in neurosurgery is lacking. Thus, we aim to conduct a 
      systematic review and meta-analysis to assess whether the continuous use of 
      antiplatelet drugs in neurosurgery increases the risk of perioperative bleeding. 
      METHODS AND ANALYSIS: We will search PubMed, Cochrane Central Register of 
      Controlled Trials and Embase using a strategy that combines the terms aspirin, 
      bleeding/ischaemic and neurosurgery. Two reviewers will independently screen all 
      identified abstracts for eligibility and evaluate the risk of bias of the 
      included studies using the Cochrane risk of bias tool for randomised controlled 
      studies and the Newcastle-Ottawa Scale for observational studies (including 
      cohort studies, case-control studies, case series). Discrepancies will be 
      resolved by consultation with a third researcher. We will conduct a systematic 
      review and meta-analysis. If evidence suggests moderate statistical or clinical 
      heterogeneity, we plan to investigate this heterogeneity by performing subgroup 
      analyses and sensitivity analysis. ETHICS AND DISSEMINATION: No ethics approval 
      will be sought as no original data will be collected for this review. Findings 
      will be disseminated through peer-reviewed publication and conference 
      presentations. PROSPERO REGISTRATION NUMBER: CRD42020202590.
CI  - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Xinyan
AU  - Wang X
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical 
      University, Beijing, China.
FAU - Wang, Xinxin
AU  - Wang X
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical 
      University, Beijing, China.
FAU - Yu, Yun
AU  - Yu Y
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical 
      University, Beijing, China.
FAU - Han, Ruquan
AU  - Han R
AUID- ORCID: 0000-0003-4335-8670
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical 
      University, Beijing, China ruquan.han@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Neurosurgery
MH  - *Platelet Aggregation Inhibitors/adverse effects
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC8487199
OTO - NOTNLM
OT  - anticoagulation
OT  - neurosurgery
OT  - stroke
COIS- Competing interests: None declared.
EDAT- 2021/10/02 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/10/01 06:10
PHST- 2021/10/01 06:10 [entrez]
PHST- 2021/10/02 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - bmjopen-2020-046741 [pii]
AID - 10.1136/bmjopen-2020-046741 [doi]
PST - epublish
SO  - BMJ Open. 2021 Sep 30;11(9):e046741. doi: 10.1136/bmjopen-2020-046741.

PMID- 8653842
OWN - NLM
STAT- MEDLINE
DCOM- 19960801
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 93
IP  - 6
DP  - 1996 Mar 15
TI  - Increased shear stress overcomes the antithrombotic platelet inhibitory effect of 
      aspirin in stenosed dog coronary arteries.
PG  - 1201-5
AB  - BACKGROUND: Shear stress is one of the known platelet activating mechanisms that 
      leads to thrombosis. Increased shear stress has also been postulated to reverse 
      the antithrombotic effect of some drugs such as aspirin (ASA). METHODS AND 
      RESULTS: Experiments were conducted in five dogs to determine the minimal shear 
      stress levels that produce acute platelet thrombus formation in mechanically 
      stenosed arteries and the increase in shear required to reverse the 
      antithrombotic effect of ASA. After intimal and medial damage, stenosis was 
      produced in the circumflex coronary artery. We used the finite-difference 
      numerical solution of the Navier-Stokes equation to determine the wall shear 
      stresses in the area of stenosis. At 70+/-6% coronary diameter reduction, cyclic 
      flow reductions (CFRs) caused by acute platelet thrombus formation were observed 
      in the stenosed lumen. At this level of stenosis, the shear stress was 144+/-15 
      Pa. ASA given at a dose of 5 mg/kg IV inhibited in vivo acute platelet-mediated 
      thrombus formation and abolished CFRs in all dogs. However, increasing the 
      stenosis level to 80+/-5% caused the CFRs to return. The shear stress increased 
      with the increased level of stenosis to 226+/-22 Pa. Thus, an average 10% 
      increase in diameter narrowing caused a 56+/-20% increase in shear stress 
      (P<.005) and renewed platelet activation and thrombus formation despite ASA 
      pretreatment. CONCLUSIONS: Individuals who take ASA daily to prevent coronary 
      artery thrombus formation may not be well protected when a change in 
      hemodynamics, such as an acute hypertensive episode, or an increase in stenosis 
      severity due a ruptured atherosclerotic plaque causes an increase in shear 
      stress.
FAU - Maalej, N
AU  - Maalej N
AD  - Cardiology Section, University of Wisconsin-Madison, WI 53792 USA.
FAU - Folts, J D
AU  - Folts JD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 1996 Dec 1;94(11):3002-3. PMID: 8941147
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/physiopathology/*prevention & control
MH  - Dogs
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stress, Mechanical
EDAT- 1996/03/15 00:00
MHDA- 1996/03/15 00:01
CRDT- 1996/03/15 00:00
PHST- 1996/03/15 00:00 [pubmed]
PHST- 1996/03/15 00:01 [medline]
PHST- 1996/03/15 00:00 [entrez]
AID - 10.1161/01.cir.93.6.1201 [doi]
PST - ppublish
SO  - Circulation. 1996 Mar 15;93(6):1201-5. doi: 10.1161/01.cir.93.6.1201.

PMID- 35652196
OWN - NLM
STAT- MEDLINE
DCOM- 20220715
LR  - 20220819
IS  - 2050-6414 (Electronic)
IS  - 2050-6406 (Print)
IS  - 2050-6406 (Linking)
VI  - 10
IP  - 6
DP  - 2022 Jul
TI  - Elective percutaneous liver biopsy and use of aspirin.
PG  - 538-543
LID - 10.1002/ueg2.12254 [doi]
AB  - OBJECTIVES: Percutaneous liver biopsy is an essential diagnostic investigation in 
      hepatology. Among complications, which are rare, bleeding is the most feared. 
      Many patients scheduled for a liver biopsy are taking aspirin. Surprisingly no 
      information is available in the literature on this frequent clinical situation. 
      The American Association for the Study of Liver Diseases (AASLD) position paper 
      on percutaneous liver biopsy does not specifically recommend stopping low dose 
      aspirin prior to an elective percutaneous liver biopsy. The European Association 
      for the Study of the Liver also remains unspecific without giving clear 
      recommendation on stopping or not low dose aspirin before the procedure. The aim 
      of this study is to document current practice concerning the management of 
      patients scheduled for an elective percutaneous biopsy and taking low dose 
      aspirin. DESIGN: An online questionnaire was designed to gather data on current 
      practice on the perioperative management of percutaneous liver biopsy and use of 
      aspirin. SETTINGS: The questionnaire was emailed to AASLD members in September 
      2018. PARTICIPANTS: Four hundred sixty six responses were collected. RESULTS: 
      Seventy eight percent postpone elective percutaneous liver biopsy if 
      International Normalised Ratio is ≥1.5 or Quick ≤50%. Ninety five percent 
      postpone biopsy if platelet count is ≤50,000 × 10(6) /L. Seventy five percent 
      stop low dose aspirin, on average, 6 days prior to the percutaneous liver biopsy. 
      This choice of management does not seem to be related to previous complications 
      since 86% report not having experienced any bleeding in patients taking low dose 
      aspirin. Nevertheless, this practice has logistic consequences since 61% of the 
      respondents postponed a liver biopsy due to intake of low dose aspirin. 
      CONCLUSIONS: Despite the lack of clear statement in guidelines and evidence 
      supporting this practice, three quarters of physicians practicing in hepatology 
      stop low dose aspirin before elective percutaneous liver biopsy.
CI  - © 2022 The Authors. United European Gastroenterology Journal published by Wiley 
      Periodicals LLC on behalf of United European Gastroenterology.
FAU - Reynard, Maxence Emmanuel
AU  - Reynard ME
AUID- ORCID: 0000-0003-0965-7212
AD  - Department for Biomedical Research DBMR, University of Bern, Bern, Switzerland.
FAU - Dufour, Jean-François
AU  - Dufour JF
AD  - Department for Biomedical Research DBMR, University of Bern, Bern, Switzerland.
AD  - Centre des Maladies Digestives, Lausanne, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20220602
PL  - England
TA  - United European Gastroenterol J
JT  - United European gastroenterology journal
JID - 101606807
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - Biopsy/adverse effects
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Liver
MH  - *Platelet Aggregation Inhibitors/adverse effects
PMC - PMC9278580
OTO - NOTNLM
OT  - aspirin
OT  - bleeding
OT  - liver biopsy
OT  - liver disease
COIS- The authors have no conflicts of interest to declare.
EDAT- 2022/06/03 06:00
MHDA- 2022/07/16 06:00
CRDT- 2022/06/02 03:13
PHST- 2022/03/03 00:00 [received]
PHST- 2022/05/02 00:00 [accepted]
PHST- 2022/06/03 06:00 [pubmed]
PHST- 2022/07/16 06:00 [medline]
PHST- 2022/06/02 03:13 [entrez]
AID - UEG212254 [pii]
AID - 10.1002/ueg2.12254 [doi]
PST - ppublish
SO  - United European Gastroenterol J. 2022 Jul;10(6):538-543. doi: 10.1002/ueg2.12254. 
      Epub 2022 Jun 2.

PMID- 15132689
OWN - NLM
STAT- MEDLINE
DCOM- 20050208
LR  - 20131121
IS  - 1525-7797 (Print)
IS  - 1525-7797 (Linking)
VI  - 5
IP  - 3
DP  - 2004 May-Jun
TI  - NMR imaging of the diffusion of water at 37 degrees C into Poly(2-hydroxyethyl 
      methacrylate) containing aspirin or vitamin B(12).
PG  - 971-6
AB  - The ingress of water into poly(2-hydroxyethyl methacrylate), PHEMA, loaded with 
      either one of two model drugs, vitamin B(12) or aspirin, was studied at 37 
      degrees C using three-dimensional NMR imaging. PHEMA was loaded with 5 and 10 wt 
      % of the drugs. From the imaging profiles, it was observed that incorporation of 
      vitamin B(12) into PHEMA resulted in enhanced crack formation on sorption of 
      water and the crack healing behind the diffusion front was slower than for PHEMA 
      without added drug. This was accounted for by the anti-plasticization of PHEMA by 
      vitamin B(12). Crack formation was inhibited in the PHEMA-aspirin systems because 
      of the plasticizing effect of the aspirin on the PHEMA matrix. All of the 
      polymers were found to absorb water according to an underlying Fickian diffusion 
      mechanism. For PHEMA loaded with 5 wt % of aspirin or vitamin B(12), the best 
      values of the water diffusion coefficients were both found to be 1.3 +/- 0.1 x 
      10(-11) m(2) s(-1) at 37 degrees C, while the values for the polymer loaded with 
      10 wt % of the drugs were slightly higher, 1.5 +/- 0.1 x 10(-11) m(2) s(-1).
FAU - Chowdhury, Mohammad A
AU  - Chowdhury MA
AD  - Department of Chemistry, and Centre for Magnetic Resonance, The University of 
      Queensland, Brisbane QLD 4072, Australia.
FAU - Hill, David J T
AU  - Hill DJ
FAU - Whittaker, Andrew K
AU  - Whittaker AK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biomacromolecules
JT  - Biomacromolecules
JID - 100892849
RN  - 0 (Methacrylates)
RN  - 0 (Polymers)
RN  - 059QF0KO0R (Water)
RN  - 6E1I4IV47V (hydroxyethyl methacrylate)
RN  - P6YC3EG204 (Vitamin B 12)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Diffusion
MH  - Hot Temperature
MH  - Magnetic Resonance Spectroscopy/*methods
MH  - Methacrylates/*chemistry
MH  - Polymers/*chemistry
MH  - Vitamin B 12/*chemistry
MH  - Water/*chemistry
EDAT- 2004/05/11 05:00
MHDA- 2005/02/09 09:00
CRDT- 2004/05/11 05:00
PHST- 2004/05/11 05:00 [pubmed]
PHST- 2005/02/09 09:00 [medline]
PHST- 2004/05/11 05:00 [entrez]
AID - 10.1021/bm030079a [doi]
PST - ppublish
SO  - Biomacromolecules. 2004 May-Jun;5(3):971-6. doi: 10.1021/bm030079a.

PMID- 3555690
OWN - NLM
STAT- MEDLINE
DCOM- 19870713
LR  - 20190705
IS  - 0007-1323 (Print)
IS  - 0007-1323 (Linking)
VI  - 74
IP  - 4
DP  - 1987 Apr
TI  - Random control trial of a short course of aspirin and dipyridamole (Persantin) 
      for femorodistal grafts.
PG  - 246-8
AB  - The effect of a short course of anti-platelet agents, started preoperatively, on 
      the patency of femorodistal bypass grafts is unknown. One hundred and forty-eight 
      such grafts were randomized to act as controls or to receive dipyridamole 200 mg 
      b.d. for 48 h pre-operatively and dipyridamole 200 mg b.d. with aspirin 300 mg 
      daily for 6 weeks after surgery. Patients were well-matched and the mean 
      pre-operative pressure index of 0.37 rose to 0.78 during the first postoperative 
      week. No deaths were attributable to the treatment. Ninety-three grafts were 
      autogenous vein and the remainder were prosthetic (GORE-TEX (PTFE), human 
      umbilical vein or externally supported Dacron). At 1 year autogenous vein 
      cumulative patency was 75 per cent. Overall results showed higher patency in the 
      treated group (P = 0.012) which was entirely accounted for by the difference 
      between prosthetic dipyridamole and aspirin group (85 per cent patency) and 
      prosthetic control groups (53 per cent patency, P = 0.005) and arose during the 
      first postoperative month. There were 11 deaths and 8 amputations in the 
      dipyridamole and aspirin group and 8 deaths and 12 amputations in the control 
      group. It is concluded that a six week perioperative course of dipyridamole and 
      aspirin allows the patency of prosthetic femorodistal bypass to approach that of 
      autogenous vein, and the regimen therefore is recommended for patients who may 
      require a prosthetic graft.
FAU - Clyne, C A
AU  - Clyne CA
FAU - Archer, T J
AU  - Archer TJ
FAU - Atuhaire, L K
AU  - Atuhaire LK
FAU - Chant, A D
AU  - Chant AD
FAU - Webster, J H
AU  - Webster JH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Postoperative Period
MH  - *Premedication
MH  - Prosthesis Failure
MH  - Random Allocation
MH  - Vascular Patency/*drug effects
MH  - Veins/*transplantation
EDAT- 1987/04/01 00:00
MHDA- 1987/04/01 00:01
CRDT- 1987/04/01 00:00
PHST- 1987/04/01 00:00 [pubmed]
PHST- 1987/04/01 00:01 [medline]
PHST- 1987/04/01 00:00 [entrez]
AID - 10.1002/bjs.1800740406 [doi]
PST - ppublish
SO  - Br J Surg. 1987 Apr;74(4):246-8. doi: 10.1002/bjs.1800740406.

PMID- 1829313
OWN - NLM
STAT- MEDLINE
DCOM- 19910730
LR  - 20131121
IS  - 0270-2304 (Print)
IS  - 0270-2304 (Linking)
VI  - 11
IP  - 2
DP  - 1991 Jun
TI  - Aspirin in transient ischemic attacks and minor stroke: a meta-analysis.
PG  - 179-91
AB  - An overview analysis of seven randomized controlled trials testing the 
      effectiveness of aspirin in the treatment of patients with transient ischemic 
      attacks and minor strokes was performed. A total of 6409 patients from the seven 
      trials was entered in the analysis; 2182 patients received only aspirin; 1598 
      patients received an aspirin-combination regimen with either sulfinpyrazone or 
      dipyridamole; and 2629 subjects received a placebo. Aspirin alone produced an 18% 
      decrease in all strokes and cardiovascular deaths. The pooling of studies 
      examining aspirin-combination regimens and the larger grouping of studies of 
      aspirin and aspirin-combination regimens led to more striking results. Indeed, 
      significant risk reductions were observed for three of the four outcomes, namely, 
      total deaths, total strokes, and total strokes and cardiovascular deaths, with 
      odds ratios ranging from 0.59 to 0.78. Suggestive, albeit more modest, results 
      were obtained when examining the impact of these regimens on total cardiovascular 
      mortality. The same tendencies have also been observed in three previously 
      published meta-analyses.
FAU - Stachenko, S J
AU  - Stachenko SJ
AD  - Department of Family Medicine, University of Montreal, Quebec, Canada.
FAU - Bravo, G
AU  - Bravo G
FAU - Côté, R
AU  - Côté R
FAU - Boucher, J
AU  - Boucher J
FAU - Battista, R N
AU  - Battista RN
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Fam Pract Res J
JT  - Family practice research journal
JID - 8208228
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cerebrovascular Disorders/*drug therapy/mortality
MH  - Dipyridamole/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/mortality
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Sulfinpyrazone/administration & dosage/therapeutic use
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
PST - ppublish
SO  - Fam Pract Res J. 1991 Jun;11(2):179-91.

PMID- 31425623
OWN - NLM
STAT- MEDLINE
DCOM- 20190924
LR  - 20220907
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 8
IP  - 8
DP  - 2019 Aug 10
TI  - Acetylsalicylic acid (aspirin) for schizophrenia.
PG  - CD012116
LID - 10.1002/14651858.CD012116.pub2 [doi]
LID - CD012116
AB  - BACKGROUND: Schizophrenia is a serious chronic mental illness affecting an 
      estimated 21 million people worldwide and there is increasing evidence linking 
      inflammation in the brain to the pathophysiology of schizophrenia. Antipsychotic 
      drugs are the conventional treatment for people with schizophrenia but are not 
      always fully effective. Acetylsalicylic acid (aspirin) is a non-steroidal 
      anti-inflammatory drug (NSAID) with properties that inhibit the proinflammatory 
      status of the brain. Using aspirin as an adjunct (add-on) treatment to 
      antipsychotics or as a stand-alone treatment could be a novel, relatively 
      inexpensive option for people with schizophrenia. OBJECTIVES: To review the 
      effects of acetylsalicylic acid (aspirin) as adjunct (add-on) or as stand-alone 
      treatment for people with schizophrenia. SEARCH METHODS: We searched the Cochrane 
      Schizophrenia Group's Trials Register (last search 8 March 2018) which is based 
      on regular searches of MEDLINE, Embase, PubMed, CINAHL, BIOSIS, AMED, PsycINFO 
      and registries of Clinical Trials. There are no language, date, document type, or 
      publication status limitations for inclusion of records in the register. 
      SELECTION CRITERIA: Randomised clinical trials focusing on aspirin for people 
      with schizophrenia. DATA COLLECTION AND ANALYSIS: We extracted data 
      independently. For binary outcomes, we calculated risk ratio (RR) and its 95% 
      confidence interval (CI), on an intention-to-treat (ITT) basis. For continuous 
      data, we estimated the mean difference (MD) between groups and its 95% CI. We 
      employed a fixed-effect model for analyses. We assessed risk of bias for included 
      studies and created a 'Summary of findings' table using GRADE. MAIN RESULTS: We 
      included two studies, both comparing the effects of adding aspirin to standard 
      antipsychotic treatment with adding placebo to standard antipsychotic treatment. 
      We were hoping to find high-quality data for seven main outcomes of importance: 
      clinically important change in global state, mental state, cognitive functioning 
      and quality of life, numbers leaving the study early, incidence of 
      gastrointestinal adverse events and hospital admission. Clinically important 
      change data were not reported. Global state data were reported by one study as 
      'unspecified problem necessitating change in dose or type of antipsychotics'; 
      there was no clear difference between treatment groups for this outcome (RR 0.75, 
      95% CI 0.30 to 1.88; studies = 1; participants = 70; very low-quality evidence). 
      Both trials measured mental state using the Positive and Negative Symptom Scale 
      (PANSS), and mean total PANSS endpoint scores favoured the adjunct aspirin group 
      in the medium term (MD -6.56, 95% CI -12.04 to -1.08; studies = 2; participants = 
      130; very low-quality evidence). Less than 10% of each group's participants left 
      the studies early (for any reason) and by around three months there was no clear 
      difference between numbers leaving early from the aspirin group compared to 
      numbers leaving early from the placebo group suggesting aspirin is acceptable (RR 
      1.12, 95% CI 0.40 to 3.14; studies = 2; participants = 130; very low-quality 
      evidence). There was some gastric upset in both groups but rates were not clearly 
      different between the treatment groups (RR 1.03, 95% CI 0.55 to 1.94; studies = 
      1; participants = 70; very low-quality evidence). We are unclear if 'change in 
      hospital status' is an unfavourable outcome or not as one study reported 
      equivocal data (RR 0.56, 95% CI 0.05 to 5.90; studies = 1; participants = 70; 
      very low-quality evidence). It should be noted that all the above results were 
      based on data of very low-quality and were difficult to interpret for clinicians 
      or patients, and that the two studies, completed in the last decade, failed to 
      report any usable outcomes on cognitive functioning or quality of life. AUTHORS' 
      CONCLUSIONS: We highlighted the evidence that some pioneering researchers feel 
      this question is important enough to merit testing in randomised trials. However, 
      we also highlighted that the evidence produced from these trials was weak and 
      inconclusive. It was impossible to draw clear conclusions on the therapeutic 
      value of aspirin for schizophrenia from these short, small and limited trials.
FAU - Schmidt, Lena
AU  - Schmidt L
AD  - Bristol Medical School, University of Bristol, 39 Whatley Road, Bristol, UK, BS8 
      2PL.
FAU - Phelps, Emma
AU  - Phelps E
FAU - Friedel, Johannes
AU  - Friedel J
FAU - Shokraneh, Farhad
AU  - Shokraneh F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20190810
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antipsychotic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - doi: 10.1002/14651858.CD012116
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Antipsychotic Agents/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Humans
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Schizophrenia/*drug therapy
PMC - PMC6699651
COIS- LS: none. EP: none. JF: none. FS: none.
EDAT- 2019/08/20 06:00
MHDA- 2019/09/26 06:00
CRDT- 2019/08/20 06:00
PHST- 2019/08/20 06:00 [pubmed]
PHST- 2019/09/26 06:00 [medline]
PHST- 2019/08/20 06:00 [entrez]
AID - CD012116.pub2 [pii]
AID - 10.1002/14651858.CD012116.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2019 Aug 10;8(8):CD012116. doi: 
      10.1002/14651858.CD012116.pub2.

PMID- 17478266
OWN - NLM
STAT- MEDLINE
DCOM- 20071120
LR  - 20131121
IS  - 0749-3797 (Print)
IS  - 0749-3797 (Linking)
VI  - 32
IP  - 5
DP  - 2007 May
TI  - Aspirin use among adults aged 40 and older in the United States: results of a 
      national survey.
PG  - 403-407
AB  - BACKGROUND: Aspirin is effective for the primary and secondary prevention of 
      cardiovascular events, but its use has been suboptimal. METHODS: Investigators 
      performed a nationally representative Internet-based survey of U.S. consumers 
      aged 40 and older using online databases maintained by Harris Interactive((R)) to 
      measure use of aspirin for cardiovascular disease (CVD) prevention and factors 
      associated with its use. Respondents reported whether they used aspirin therapy 
      regularly for cardiovascular prevention; and provided information about their 
      cardiovascular risk factors, discussions with their healthcare provider about 
      aspirin therapy, and their perceptions about risks and benefits of aspirin. 
      Objective risk of cardiovascular events was estimated using counts of 
      self-reported risk factors. Survey results were weighted to be representative of 
      the general U.S. population. Researchers performed bivariate and multivariate 
      analyses to understand factors associated with aspirin use. RESULTS: A total of 
      1299 adults aged 40 or older completed the survey. Mean age was 55.9, 53% were 
      women, 79% self-identified as white, 10% African American, and 9% Latino. Current 
      regular aspirin use for CVD prevention was reported by 41% of respondents. The 
      factor most strongly associated with aspirin use was reporting a previous 
      conversation with a healthcare provider about aspirin (88% aspirin use among 
      respondents reporting such discussion versus 17% who did not report discussion; 
      odds ratio 36.6, 95% confidence interval 25.9-51.7). CONCLUSIONS: Aspirin use is 
      low, even among patients at increased risk. Better provider-patient communication 
      about aspirin prevention is associated with greater use, and should be a target 
      for future interventions.
FAU - Pignone, Michael
AU  - Pignone M
AD  - General Internal Medicine Division, University of North Carolina at Chapel Hill, 
      Chapel Hill, North Carolina, USA.
FAU - Anderson, George K
AU  - Anderson GK
FAU - Binns, Katherine
AU  - Binns K
FAU - Tilson, Hugh H
AU  - Tilson HH
FAU - Weisman, Steven M
AU  - Weisman SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Am J Prev Med
JT  - American journal of preventive medicine
JID - 8704773
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Health Surveys
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - National Health Programs
MH  - Odds Ratio
MH  - Physician-Patient Relations
MH  - Risk Assessment
MH  - United States
EDAT- 2007/05/05 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/05/05 09:00
PHST- 2006/06/14 00:00 [received]
PHST- 2006/11/30 00:00 [revised]
PHST- 2007/01/11 00:00 [accepted]
PHST- 2007/05/05 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/05/05 09:00 [entrez]
AID - S0749-3797(07)00018-9 [pii]
AID - 10.1016/j.amepre.2007.01.010 [doi]
PST - ppublish
SO  - Am J Prev Med. 2007 May;32(5):403-407. doi: 10.1016/j.amepre.2007.01.010.

PMID- 37531106
OWN - NLM
STAT- MEDLINE
DCOM- 20230803
LR  - 20230805
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 6
IP  - 8
DP  - 2023 Aug 1
TI  - Differences in Use of Clinical Decision Support Tools and Implementation of 
      Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation 
      Quality Metrics in Small Practices by Race and Sex.
PG  - e2326905
LID - 10.1001/jamanetworkopen.2023.26905 [doi]
LID - e2326905
AB  - IMPORTANCE: Practice-level evidence is needed to clarify the value of 
      population-based clinical decision support (CDS) tools in reducing racial and sex 
      disparities in cardiovascular care. OBJECTIVE: To evaluate the association 
      between CDS tools and racial and sex disparities in the aspirin use, blood 
      pressure control, cholesterol management, and smoking cessation (ABCS) care 
      quality metrics among smaller primary care practices. DESIGN, SETTING, AND 
      PARTICIPANTS: This cross-sectional study used practice-level data from the Agency 
      for Healthcare Research and Quality-funded EvidenceNOW initiative. The national 
      initiative from May 1, 2015, to April 30, 2021, spanned 12 US states and focused 
      on improving cardiovascular preventive care by providing quality improvement 
      support to smaller primary care practices. A total of 576 primary care practices 
      in EvidenceNOW submitted both survey data and electronic health record 
      (EHR)-derived ABCS data stratified by race and sex. MAIN OUTCOMES AND MEASURES: 
      Practice-level estimates of disparities between Black and White patients and 
      between male and female patients were calculated as the difference in proportions 
      of eligible patients within each practice meeting ABCS care quality metrics. The 
      association between CDS tools (EHR prompts, standing orders, and clinical 
      registries) and disparities was evaluated by multiply imputed multivariable 
      models for each CDS tool, adjusted for practice rurality, ownership, and size. 
      RESULTS: Across the 576 practices included in the analysis, 219 (38.0%) had 
      patient panels that were more than half White and 327 (56.8%) had panels that 
      were more than half women. The proportion of White compared with Black patients 
      meeting metrics for blood pressure (difference, 5.16% [95% CI, 4.29%-6.02%]; 
      P < .001) and cholesterol management (difference, 1.49% [95% CI, 0.04%-2.93%] 
      P = .04) was higher; the proportion of men meeting metrics for aspirin use 
      (difference, 4.36% [95% CI, 3.34%-5.38%]; P < .001) and cholesterol management 
      (difference, 3.88% [95% CI, 3.14%-4.63%]; P < .001) was higher compared with 
      women. Conversely, the proportion of women meeting practice blood pressure 
      control (difference, -1.80% [95% CI, -2.32% to -1.28%]; P < .001) and smoking 
      cessation counseling (difference, -1.67% [95% CI, -2.38% to -0.95%]; P < .001) 
      metrics was higher compared with men. Use of CDS tools was not associated with 
      differences in race or sex disparities except for the smoking metric. Practices 
      using CDS tools showed a higher proportion of men meeting the smoking counseling 
      metric than women (coefficient, 3.82 [95% CI, 0.95-6.68]; P = .009). CONCLUSIONS 
      AND RELEVANCE: The findings of this cross-sectional study suggest that practices 
      using CDS tools had small disparities that were not statistically significant, 
      but CDS tools were not associated with reductions in disparities. More research 
      is needed on effective practice-level interventions to mitigate disparities.
FAU - Roberts, Madeline M
AU  - Roberts MM
AD  - Department of Epidemiology, Human Genetics, and Environmental Sciences, 
      University of Texas Health Science Center at Houston (UTHealth Houston) School of 
      Public Health, Dallas.
FAU - Marino, Miguel
AU  - Marino M
AD  - Department of Family Medicine, Oregon Health & Science University, Portland.
AD  - School of Public Health, Oregon Health & Science University, Portland.
FAU - Wells, Rebecca
AU  - Wells R
AD  - Department of Management, Policy, & Community Health, UTHealth Houston School of 
      Public Health, Houston.
FAU - Atem, Folefac D
AU  - Atem FD
AD  - Department of Biostatistics and Data Science, UTHealth Houston School of Public 
      Health, Dallas.
FAU - Balasubramanian, Bijal A
AU  - Balasubramanian BA
AD  - Department of Epidemiology, Human Genetics, and Environmental Sciences, 
      University of Texas Health Science Center at Houston (UTHealth Houston) School of 
      Public Health, Dallas.
LA  - eng
GR  - R01 HS023940/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20230801
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
RN  - R16CO5Y76E (Aspirin)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Humans
MH  - Male
MH  - Female
MH  - Aspirin/therapeutic use
MH  - *Smoking Cessation
MH  - Blood Pressure
MH  - *Cardiovascular Diseases/prevention & control
MH  - Benchmarking
MH  - *Hypercholesterolemia
MH  - Primary Health Care
MH  - Cross-Sectional Studies
MH  - *Decision Support Systems, Clinical
MH  - Cholesterol
PMC - PMC10398408
COIS- Conflict of Interest Disclosures: Dr Balasubramanian reported receiving grant 
      funding from the Agency for Healthcare Research and Quality (AHRQ) during the 
      conduct of the study. No other disclosures were reported.
EDAT- 2023/08/02 13:09
MHDA- 2023/08/03 06:42
CRDT- 2023/08/02 11:32
PHST- 2023/08/03 06:42 [medline]
PHST- 2023/08/02 13:09 [pubmed]
PHST- 2023/08/02 11:32 [entrez]
AID - 2807923 [pii]
AID - zoi230777 [pii]
AID - 10.1001/jamanetworkopen.2023.26905 [doi]
PST - epublish
SO  - JAMA Netw Open. 2023 Aug 1;6(8):e2326905. doi: 
      10.1001/jamanetworkopen.2023.26905.

PMID- 25385584
OWN - NLM
STAT- MEDLINE
DCOM- 20150420
LR  - 20220409
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 111
IP  - 47
DP  - 2014 Nov 25
TI  - Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation 
      by nonsteroidal antiinflammatory drugs.
PG  - 16830-5
LID - 10.1073/pnas.1406997111 [doi]
AB  - The cardiovascular safety of nonsteroidal antiinflammatory drugs (NSAIDs) may be 
      influenced by interactions with antiplatelet doses of aspirin. We sought to 
      quantitate precisely the propensity of commonly consumed NSAIDs—ibuprofen, 
      naproxen, and celecoxib—to cause a drug-drug interaction with aspirin in vivo by 
      measuring the target engagement of aspirin directly by MS. We developed a novel 
      assay of cyclooxygenase-1 (COX-1) acetylation in platelets isolated from 
      volunteers who were administered aspirin and used conventional and microfluidic 
      assays to evaluate platelet function. Although ibuprofen, naproxen, and celecoxib 
      all had the potential to compete with the access of aspirin to the substrate 
      binding channel of COX-1 in vitro, exposure of volunteers to a single therapeutic 
      dose of each NSAID followed by 325 mg aspirin revealed a potent drug-drug 
      interaction between ibuprofen and aspirin and between naproxen and aspirin but 
      not between celecoxib and aspirin. The imprecision of estimates of aspirin 
      consumption and the differential impact on the ability of aspirin to inactivate 
      platelet COX-1 will confound head-to-head comparisons of distinct NSAIDs in 
      ongoing clinical studies designed to measure their cardiovascular risk.
FAU - Li, Xuanwen
AU  - Li X
AD  - Institute for Translational Medicine and Therapeutics and.
FAU - Fries, Susanne
AU  - Fries S
AD  - Institute for Translational Medicine and Therapeutics and.
FAU - Li, Ruizhi
AU  - Li R
AD  - Institute of Medicine and Engineering, Department of Chemical and Biomolecular 
      Engineering, University of Pennsylvania, Philadelphia, PA 19104.
FAU - Lawson, John A
AU  - Lawson JA
AD  - Institute for Translational Medicine and Therapeutics and.
FAU - Propert, Kathleen J
AU  - Propert KJ
AD  - Institute for Translational Medicine and Therapeutics and Department of 
      Biostatistics and Epidemiology, Perelman School of Medicine, and.
FAU - Diamond, Scott L
AU  - Diamond SL
AD  - Institute of Medicine and Engineering, Department of Chemical and Biomolecular 
      Engineering, University of Pennsylvania, Philadelphia, PA 19104.
FAU - Blair, Ian A
AU  - Blair IA
AD  - Institute for Translational Medicine and Therapeutics and.
FAU - FitzGerald, Garret A
AU  - FitzGerald GA
AD  - Institute for Translational Medicine and Therapeutics and.
FAU - Grosser, Tilo
AU  - Grosser T
AD  - Institute for Translational Medicine and Therapeutics and tilo@upenn.edu.
LA  - eng
GR  - R01 HL103419/HL/NHLBI NIH HHS/United States
GR  - U54 HL117798/HL/NHLBI NIH HHS/United States
GR  - P01 HL062250/HL/NHLBI NIH HHS/United States
GR  - UL1 TR000003/TR/NCATS NIH HHS/United States
GR  - P30 ES013508/ES/NIEHS NIH HHS/United States
GR  - UL1TR000003/TR/NCATS NIH HHS/United States
GR  - HL062250/HL/NHLBI NIH HHS/United States
GR  - HL103419/HL/NHLBI NIH HHS/United States
GR  - HL117798/HL/NHLBI NIH HHS/United States
GR  - P30ES013508/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20141110
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/enzymology
MH  - Cyclooxygenase 1/*metabolism
MH  - Humans
MH  - Microfluidics
PMC - PMC4250103
OTO - NOTNLM
OT  - MS
OT  - acetylation
OT  - aspirin
OT  - cyclooxygenase
OT  - nonsteroidal antiinflammatory drugs
COIS- The authors declare no conflict of interest.
EDAT- 2014/11/12 06:00
MHDA- 2015/04/22 06:00
CRDT- 2014/11/12 06:00
PHST- 2014/11/12 06:00 [entrez]
PHST- 2014/11/12 06:00 [pubmed]
PHST- 2015/04/22 06:00 [medline]
AID - 1406997111 [pii]
AID - 201406997 [pii]
AID - 10.1073/pnas.1406997111 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16830-5. doi: 
      10.1073/pnas.1406997111. Epub 2014 Nov 10.

PMID- 8961361
OWN - NLM
STAT- MEDLINE
DCOM- 19970310
LR  - 20190830
IS  - 0167-8140 (Print)
IS  - 0167-8140 (Linking)
VI  - 41
IP  - 1
DP  - 1996 Oct
TI  - Effect of acetylsalicylic acid on radiation and cosmetic results after 
      conservative surgery for early breast cancer: a randomized trial.
PG  - 1-6
AB  - BACKGROUND AND PURPOSE: Acetylsalicylic acid (ASA) can reduce the incidence of 
      stroke and myocardial infarction by inhibiting platelet-fibrin thrombi in small 
      blood vessels. To determine if ASA could reduce late effects of radiation therapy 
      mediated by damage to small blood vessels, a prospective, placebo-controlled, 
      double-blind trial was conducted in women with early breast cancer, receiving 
      radiotherapy to the conserved breast. MATERIALS AND METHODS: Cosmetic outcome and 
      late radiotherapy effects were recorded prospectively for 186 women with T1 or 
      T2, pathologically node-negative breast cancer treated with breast conservation 
      and randomized to receive ASA (325 mg daily) or placebo for 1 year from the start 
      of radiation therapy. Radiation was a tangent pair to the breast alone delivering 
      a modal dose of 44 Gy in 16 daily fractions in 22-25 days. RESULTS: Median 
      follow-up is 6.5 years. The use of ASA has not had any effect on the acute 
      (erythema, edema or discomfort) or late (induration, telangiectasia) effects of 
      radiotherapy (all P > 0.10), the patients' or physicians' assessment of the 
      cosmetic outcome (all P > 0.25) or rates of breast recurrence (P > 0.25). 
      CONCLUSION: ASA cannot be recommended to improve the outcome of radiotherapy 
      complementing breast conserving surgery.
FAU - Olivotto, I A
AU  - Olivotto IA
AD  - Division of Radiation Oncology, British Columbia Cancer Agency, Vancouver, 
      Canada.
FAU - Kim-Sing, C
AU  - Kim-Sing C
FAU - Bajdik, C D
AU  - Bajdik CD
FAU - Trevisan, C H
AU  - Trevisan CH
FAU - Ludgate, C M
AU  - Ludgate CM
FAU - Weir, L M
AU  - Weir LM
FAU - Jackson, S M
AU  - Jackson SM
FAU - Basco, V E
AU  - Basco VE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Ireland
TA  - Radiother Oncol
JT  - Radiotherapy and oncology : journal of the European Society for Therapeutic 
      Radiology and Oncology
JID - 8407192
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Breast/*radiation effects
MH  - Breast Neoplasms/*radiotherapy/*surgery
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Mastectomy, Segmental
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Prospective Studies
MH  - Radiation Injuries/*prevention & control
MH  - Radiotherapy Dosage
MH  - Radiotherapy, Adjuvant
MH  - Radiotherapy, High-Energy
MH  - Time Factors
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - S0167-8140(96)91825-3 [pii]
AID - 10.1016/s0167-8140(96)91825-3 [doi]
PST - ppublish
SO  - Radiother Oncol. 1996 Oct;41(1):1-6. doi: 10.1016/s0167-8140(96)91825-3.

PMID- 1773004
OWN - NLM
STAT- MEDLINE
DCOM- 19920304
LR  - 20131121
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 2
IP  - 1
DP  - 1991 Feb
TI  - Reocclusion after thrombolysis: a problem solved by hirudin?
PG  - 97-100
AB  - The effect of recombinant hirudin (r-hir), unfractionated heparin (UFH) and 
      acetylsalicylic acid (ASA) on the incidence of reocclusion after thrombolysis 
      with plasminogen activator (rt-PA) was evaluated in anaesthetized rabbits. 
      Formation of a platelet rich thrombus was achieved by implantation of a copper 
      coil into the iliac artery. The occluded artery was recanalized in six of ten 
      animals by intravenous administration of rt-PA given as a bolus injection of 0.1 
      mg/kg followed by infusion of 0.5 mg/kg/h. Within 1 h after termination of rt-PA 
      infusion rethrombosis was observed in 100% of recanalized vessels. The incidence 
      of reocclusion was diminished by r-hir in a dose-dependent manner to 50% after 
      infusion of 0.05 mg/kg/h and to 25% after 0.1 mg/kg/h. No effect on APTT was 
      detectable in this dosage after 3 h infusion. UFH in a dosage increasing APTT 
      two-fold (35 U/kg/h) did not reduce the reocclusion rate. 100 U/kg/h UFH 
      increased APTT to greater than 3 min and reduced reocclusion rates to 50%. ASA 
      showed a minor effect on the incidence of restenosis whereas the combination of 
      0.1 mg/kg/h r-hir plus bolus injection of 10 mg/kg ASA led to a further reduction 
      in reocclusion rates to only 11% and an increase in reperfusion rates from 60 to 
      90%. Our experiments indicate that the combination of plasminogen activator with 
      r-hir may be a useful approach for the prophylaxis of early reocclusion.
FAU - Rübsamen, K
AU  - Rübsamen K
AD  - Knoll AG, Department of Angiology, Ludwigshafen, Germany.
FAU - Eschenfelder, V
AU  - Eschenfelder V
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hirudins)
RN  - 0 (Recombinant Proteins)
RN  - 138361-64-5 (LU 52369)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Fibrinolytic Agents/pharmacology/*therapeutic use
MH  - Heparin/pharmacology/therapeutic use
MH  - Hirudin Therapy
MH  - Hirudins/*analogs & derivatives/pharmacology
MH  - Iliac Artery
MH  - Partial Thromboplastin Time
MH  - Rabbits
MH  - Recombinant Proteins/pharmacology/therapeutic use
MH  - Recurrence
MH  - Reperfusion
MH  - *Thrombolytic Therapy
MH  - Thrombosis/drug therapy/*prevention & control
MH  - Tissue Plasminogen Activator/*therapeutic use
EDAT- 1991/02/01 00:00
MHDA- 1991/02/01 00:01
CRDT- 1991/02/01 00:00
PHST- 1991/02/01 00:00 [pubmed]
PHST- 1991/02/01 00:01 [medline]
PHST- 1991/02/01 00:00 [entrez]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 1991 Feb;2(1):97-100.

PMID- 21509427
OWN - NLM
STAT- MEDLINE
DCOM- 20120229
LR  - 20220408
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Linking)
VI  - 258
IP  - 11
DP  - 2011 Nov
TI  - Aspirin resistance in patients with acute ischemic stroke.
PG  - 1979-86
LID - 10.1007/s00415-011-6052-7 [doi]
AB  - Aspirin is used in ischemic stroke therapy. However, some patients are not 
      responsive to the antithrombotic action of aspirin. The aim of this study was to 
      assess the prevalence of aspirin resistance in stroke patients and its 
      association with mortality. One-hundred and six patients (mean age 64.9 ± 14.6 
      years, 53 male) with acute ischemic stroke were consecutively recruited. All 
      subjects were taking aspirin regularly. Aspirin responsiveness was determined by 
      Ultegra Rapid Platelet Function Assay-ASA (VerifyNow Aspirin). Aspirin resistance 
      was defined as aspirin reaction unit (ARU) ≥ 550. Aspirin resistance was detected 
      in 35 patients. There were not any significant differences in age, gender and 
      comorbidities between aspirin-resistant and aspirin-sensitive patients. The mean 
      National Institute of Health Stroke Scale (NIHSS) scores of the aspirin-resistant 
      and aspirin-sensitive patients were 15 ± 3 and 12 ± 5, respectively (p = 0.006). 
      Twenty-seven patients had a history of prior ischemic stroke and eight of them 
      had aspirin resistance. Eleven patients died in-hospital and a total of 43 
      patients died during 2 years. Both the in-hospital and 2-year mortality rates 
      were significantly higher in patients with aspirin resistance (20 vs. 5.6%, p = 
      0.038 and 60.0 vs. 31.0%, p = 0.004, respectively). Regression analysis revealed 
      aspirin resistance [odds ratio (OR) 3.097, 95% confidence interval (CI) 
      1.070-8.959, p = 0.037] as an independent predictor of 2-year mortality, as well 
      as age (OR 1.051, 95% CI 1.003-1.102, p = 0.038) and NIHSS scores (OR 1.208, 95% 
      CI 1.016-1.437, p = 0.033). Aspirin resistance is not uncommon in patients with 
      acute ischemic stroke and is associated with short and long term mortality in 
      these patients.
FAU - Ozben, Serkan
AU  - Ozben S
AD  - Department of Neurology, Haseki Educational and Research Hospital, Istanbul, 
      Turkey.
FAU - Ozben, Beste
AU  - Ozben B
FAU - Tanrikulu, Azra Meryem
AU  - Tanrikulu AM
FAU - Ozer, Feriha
AU  - Ozer F
FAU - Ozben, Tomris
AU  - Ozben T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110421
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - *Drug Resistance
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/*drug therapy/*mortality
EDAT- 2011/04/22 06:00
MHDA- 2012/03/01 06:00
CRDT- 2011/04/22 06:00
PHST- 2011/01/20 00:00 [received]
PHST- 2011/04/08 00:00 [accepted]
PHST- 2011/03/19 00:00 [revised]
PHST- 2011/04/22 06:00 [entrez]
PHST- 2011/04/22 06:00 [pubmed]
PHST- 2012/03/01 06:00 [medline]
AID - 10.1007/s00415-011-6052-7 [doi]
PST - ppublish
SO  - J Neurol. 2011 Nov;258(11):1979-86. doi: 10.1007/s00415-011-6052-7. Epub 2011 Apr 
      21.

PMID- 11133261
OWN - NLM
STAT- MEDLINE
DCOM- 20010301
LR  - 20151119
IS  - 0306-9877 (Print)
IS  - 0306-9877 (Linking)
VI  - 56
IP  - 1
DP  - 2001 Jan
TI  - Hypothesized treatment for migraines using low doses of tryptophan, niacin, 
      calcium, caffeine, and acetylsalicylic acid.
PG  - 91-4
AB  - The author hypothesized that existing agents known to influence serotonin blood 
      level, vascular tone, and inflammatory reactions might terminate migraines. The 
      author presented the rationale for using five different agents therapeutically 
      and avoiding two other agents during a migraine. The proposed treatment is to use 
      low doses of tryptophan, niacin, calcium, caffeine, and acetylsalicylic acid 
      (ASA) soon after migraine symptoms are noticed and to avoid during a migraine 
      high-potassium food and magnesium supplements. Preliminary results from 12 
      migraine patients indicated that 9 of 12 (75%) had significant benefit from this 
      approach. Using these five agents together is a novel combination and a new idea 
      for treating migraines.
FAU - Gedye, A
AU  - Gedye A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 2679MF687A (Niacin)
RN  - 3G6A5W338E (Caffeine)
RN  - 8DUH1N11BX (Tryptophan)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Caffeine/administration & dosage/*therapeutic use
MH  - Calcium/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Niacin/administration & dosage/*therapeutic use
MH  - Tryptophan/administration & dosage/*therapeutic use
EDAT- 2001/01/03 11:00
MHDA- 2001/03/07 10:01
CRDT- 2001/01/03 11:00
PHST- 2001/01/03 11:00 [pubmed]
PHST- 2001/03/07 10:01 [medline]
PHST- 2001/01/03 11:00 [entrez]
AID - S0306-9877(00)91117-4 [pii]
AID - 10.1054/mehy.2000.1117 [doi]
PST - ppublish
SO  - Med Hypotheses. 2001 Jan;56(1):91-4. doi: 10.1054/mehy.2000.1117.

PMID- 9396974
OWN - NLM
STAT- MEDLINE
DCOM- 19980106
LR  - 20131121
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 79
IP  - 5
DP  - 1997 Nov
TI  - Localized unilateral periorbital edema induced by aspirin.
PG  - 420-2
AB  - BACKGROUND: Aspirin intolerance manifested as bronchospasm or 
      urticaria/angioedema has been observed since the beginning of this century. 
      OBJECTIVE: To report a novel case of intolerance to aspirin ingestion. METHODS: 
      Case report; routine skin testing; pulmonary function testing; aspirin challenge. 
      RESULTS: A 30-year-old man with a history of left ocular trauma at the age of 10 
      noted a 3-year history of left periorbital angioedema after aspirin but not other 
      nonsteroidal anti-inflammatory drugs. Incremental oral aspirin challenge resulted 
      in this unilateral symptomatology at a dose of 673 mg. CONCLUSION: To the best of 
      our knowledge, this is the first reported case of unilateral periorbital edema 
      following aspirin ingestion.
FAU - Price, K S
AU  - Price KS
AD  - Department of Medicine, Montreal General Hospital, McGill University.
FAU - Thomson, D M
AU  - Thomson DM
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Ann Allergy Asthma Immunol. 1998 Nov;81(5 Pt 1):459. PMID: 9860041
MH  - Adult
MH  - Angioedema/*chemically induced
MH  - Aspirin/*adverse effects
MH  - Drug Tolerance/immunology/physiology
MH  - Humans
MH  - Male
MH  - Orbital Diseases/*chemically induced
EDAT- 1997/12/16 00:00
MHDA- 1997/12/16 00:01
CRDT- 1997/12/16 00:00
PHST- 1997/12/16 00:00 [pubmed]
PHST- 1997/12/16 00:01 [medline]
PHST- 1997/12/16 00:00 [entrez]
AID - S1081-1206(10)63036-0 [pii]
AID - 10.1016/S1081-1206(10)63036-0 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 1997 Nov;79(5):420-2. doi: 
      10.1016/S1081-1206(10)63036-0.

PMID- 37062507
OWN - NLM
STAT- MEDLINE
DCOM- 20230703
LR  - 20230703
IS  - 2589-9333 (Electronic)
IS  - 2589-9333 (Linking)
VI  - 5
IP  - 7
DP  - 2023 Jul
TI  - Which first-trimester risk assessment method for preeclampsia is most suitable? A 
      model-based impact study.
PG  - 100974
LID - S2589-9333(23)00116-7 [pii]
LID - 10.1016/j.ajogmf.2023.100974 [doi]
AB  - BACKGROUND: Low-dose aspirin treatment reduces the risk of preeclampsia among 
      high-risk pregnant women. Internationally, several first-trimester 
      risk-calculation methods are applied. OBJECTIVE: This study aimed to assess the 
      costs and benefits of different first-trimester preeclampsia risk estimation 
      algorithms: EXPECT (an algorithmic prediction model based on maternal 
      characteristics), National Institute for Health and Care Excellence (a checklist 
      of risk factors), and the Fetal Medicine Foundation (a prediction model using 
      additional uterine artery Doppler measurement and laboratory testing) models, 
      coupled with low-dose aspirin treatment, in comparison with no risk assessment. 
      STUDY DESIGN: We constructed a decision analytical model estimating the number of 
      cases of preeclampsia with each strategy and the costs of risk assessment for 
      preeclampsia and early aspirin treatment, expressed in euros (€) in a 
      hypothetical population of 100,000 women. We performed 1-way sensitivity analyses 
      to assess the impact of adherence rates on model outcomes. RESULTS: Application 
      of the EXPECT, National Institute for Health and Care Excellence, and Fetal 
      Medicine Foundation models results in respectively 1.98%, 2.55%, and 1.90% of the 
      women developing preeclampsia, as opposed to 3.00% of women in the case of no 
      risk assessment. Overall, the net financial benefits of the EXPECT, National 
      Institute for Health and Care Excellence, and Fetal Medicine Foundation models 
      relative to no risk assessment are €144, €43, and €38 per patient, respectively. 
      The respective percentages of women receiving aspirin treatment are 18.6%, 10.2%, 
      and 6.0% for the 3 risk assessment methods. CONCLUSION: The EXPECT and Fetal 
      Medicine Foundation model are comparable with regard to numbers of prevented 
      preeclampsia cases, and both are superior to the National Institute for Health 
      and Care Excellence model and to no risk assessment. EXPECT is less 
      resource-demanding and results in the highest cost savings, but also requires the 
      highest number of women to be treated with aspirin. When deciding which strategy 
      is preferable, cost savings and easier use have to be weighed against the degree 
      of overtreatment, although low-dose aspirin has no clear disadvantages during 
      pregnancy.
CI  - Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Strijbos, Lynn T M
AU  - Strijbos LTM
AD  - Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, 
      The Netherlands (Drs. Strijbos). Electronic address: lynn.strijbos@hotmail.nl.
FAU - Hendrix, Manouk L E
AU  - Hendrix MLE
AD  - Department of Obstetrics and Gynaecology, Maastricht University Medical Center+, 
      Maastricht, The Netherlands (Dr. Hendrix, Dr. Al-Nasiry, and Dr Scheepers).
FAU - Al-Nasiry, Salwan
AU  - Al-Nasiry S
AD  - Department of Obstetrics and Gynaecology, Maastricht University Medical Center+, 
      Maastricht, The Netherlands (Dr. Hendrix, Dr. Al-Nasiry, and Dr Scheepers); GROW 
      School for Oncology and Reproduction, Maastricht University, Maastricht, The 
      Netherlands (XX Al-Nasiry and XX Scheepers).
FAU - Smits, Luc J M
AU  - Smits LJM
AD  - Department of Epidemiology, Care and Public Health Research Institute, Maastricht 
      University, Maastricht, The Netherlands (Prof. Smits).
FAU - Scheepers, Hubertina C J
AU  - Scheepers HCJ
AD  - Department of Obstetrics and Gynaecology, Maastricht University Medical Center+, 
      Maastricht, The Netherlands (Dr. Hendrix, Dr. Al-Nasiry, and Dr Scheepers); GROW 
      School for Oncology and Reproduction, Maastricht University, Maastricht, The 
      Netherlands (XX Al-Nasiry and XX Scheepers).
LA  - eng
PT  - Journal Article
DEP - 20230414
PL  - United States
TA  - Am J Obstet Gynecol MFM
JT  - American journal of obstetrics & gynecology MFM
JID - 101746609
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/diagnosis/epidemiology/prevention & control
MH  - Pregnancy Trimester, First
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Risk Assessment
OTO - NOTNLM
OT  - EXPECT
OT  - Fetal Medicine Foundation
OT  - National Institute for Health and Care Excellence
OT  - adherence
OT  - aspirin
OT  - healthcare costs
OT  - preeclampsia
OT  - pregnancies
OT  - prevalence
OT  - risk assessments
EDAT- 2023/04/17 06:00
MHDA- 2023/07/03 06:41
CRDT- 2023/04/16 19:25
PHST- 2023/02/26 00:00 [received]
PHST- 2023/03/09 00:00 [revised]
PHST- 2023/04/10 00:00 [accepted]
PHST- 2023/07/03 06:41 [medline]
PHST- 2023/04/17 06:00 [pubmed]
PHST- 2023/04/16 19:25 [entrez]
AID - S2589-9333(23)00116-7 [pii]
AID - 10.1016/j.ajogmf.2023.100974 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol MFM. 2023 Jul;5(7):100974. doi: 10.1016/j.ajogmf.2023.100974. 
      Epub 2023 Apr 14.

PMID- 25975531
OWN - NLM
STAT- MEDLINE
DCOM- 20160809
LR  - 20181202
IS  - 1097-6779 (Electronic)
IS  - 0016-5107 (Linking)
VI  - 82
IP  - 5
DP  - 2015 Nov
TI  - Periprocedural management of aspirin during colonoscopy: a survey of practice 
      patterns in the United States.
PG  - 895-900
LID - S0016-5107(15)02287-7 [pii]
LID - 10.1016/j.gie.2015.03.1976 [doi]
AB  - BACKGROUND: The risk of postpolypectomy bleeding for patients taking aspirin is 
      low, and gastroenterology society guidelines state that aspirin is likely safe to 
      continue; however, many practices recommend aspirin discontinuation. OBJECTIVE: 
      To characterize practice patterns of periprocedural aspirin use with colonoscopy 
      in the United States. DESIGN: Survey study. SETTING: Endoscopy units in the 
      United States. INTERVENTIONS: We reviewed colonoscopy preparation instruction 
      sheets available online to characterize recommendations regarding periprocedural 
      aspirin use. The endoscopy units that recommended discontinuation of aspirin 
      before colonoscopy were contacted to determine their reasons for doing so. We 
      also determined which endoscopy units were recognized by the American Society for 
      Gastrointestinal Endoscopy (ASGE) quality recognition program. MAIN OUTCOME 
      MEASUREMENTS: Endoscopy unit recommendations regarding aspirin use before 
      colonoscopy. RESULTS: We reviewed colonoscopy preparation instructions from 317 
      endoscopy units, of which 138 (43.5%) recommended continuing aspirin, 103 (32.5%) 
      recommended stopping aspirin, and 76 (24%) requested patients to contact a 
      physician. The most common reasons for recommending aspirin discontinuation were 
      concern about bleeding after polypectomy (62%), perceived minimal downside to 
      stopping aspirin (38%), inertia to changing old policies (20%), and concern about 
      medicolegal implications of postpolypectomy bleeding (15%). There was no 
      significant association between endoscopy unit recommendations about 
      periprocedural aspirin use and ASGE quality certification (P = .17) or type of 
      endoscopy facility (ambulatory surgical center vs hospital affiliated) (P = .55). 
      LIMITATION: Non-response bias. CONCLUSION: Less than half of the endoscopy units 
      surveyed in the United States routinely continue aspirin before screening 
      colonoscopies despite evidence that benefits outweigh the risks. It is important 
      for gastroenterology and cardiology societies to make a firm statement, educate 
      their members, and give them confidence and support to continue aspirin 
      periprocedurally.
CI  - Copyright © 2015 American Society for Gastrointestinal Endoscopy. Published by 
      Elsevier Inc. All rights reserved.
FAU - Robbins, Richard
AU  - Robbins R
AD  - Department of Internal Medicine, University of Texas Southwestern Medical Center, 
      Dallas, Texas, USA.
FAU - Tian, Chenlu
AU  - Tian C
AD  - Department of Gastroenterology, University of Texas Southwestern Medical Center, 
      Dallas, Texas, USA.
FAU - Singal, Amit
AU  - Singal A
AD  - Division of Digestive and Liver Diseases, University of Texas Southwestern 
      Medical Center, Dallas, Texas, USA.
FAU - Agrawal, Deepak
AU  - Agrawal D
AD  - Division of Digestive and Liver Diseases, University of Texas Southwestern 
      Medical Center, Dallas, Texas, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20150512
PL  - United States
TA  - Gastrointest Endosc
JT  - Gastrointestinal endoscopy
JID - 0010505
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Colonic Polyps/*surgery
MH  - Colonoscopy/*methods
MH  - *Disease Management
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Postoperative Hemorrhage/chemically induced/*epidemiology
MH  - *Practice Patterns, Physicians'
MH  - Preoperative Care/methods
MH  - Risk Factors
MH  - *Surveys and Questionnaires
MH  - United States/epidemiology
MH  - Withholding Treatment/statistics & numerical data
EDAT- 2015/05/16 06:00
MHDA- 2016/08/10 06:00
CRDT- 2015/05/16 06:00
PHST- 2014/12/05 00:00 [received]
PHST- 2015/03/25 00:00 [accepted]
PHST- 2015/05/16 06:00 [entrez]
PHST- 2015/05/16 06:00 [pubmed]
PHST- 2016/08/10 06:00 [medline]
AID - S0016-5107(15)02287-7 [pii]
AID - 10.1016/j.gie.2015.03.1976 [doi]
PST - ppublish
SO  - Gastrointest Endosc. 2015 Nov;82(5):895-900. doi: 10.1016/j.gie.2015.03.1976. 
      Epub 2015 May 12.

PMID- 35932165
OWN - NLM
STAT- MEDLINE
DCOM- 20220901
LR  - 20220906
IS  - 1753-0407 (Electronic)
IS  - 1753-0393 (Print)
IS  - 1753-0407 (Linking)
VI  - 14
IP  - 8
DP  - 2022 Aug
TI  - Cilostazol treatment for preventing adverse cardiovascular events in patients 
      with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the 
      ESCAPE study.
PG  - 524-531
LID - 10.1111/1753-0407.13300 [doi]
AB  - BACKGROUND: Previously, in the ESCAPE study, a randomized controlled trial, we 
      found that 12 months of cilostazol administration significantly decreased 
      coronary artery stenosis and the noncalcified plaque component compared with 
      aspirin. The goal of the current study was to evaluate the effect of cilostazol 
      treatment on cardiovascular events up to 7 years after the end of the original 
      study. METHODS: After the end of the ESCAPE study with patients with type 2 
      diabetes mellitus (T2DM) and mild to moderate coronary artery stenosis, we 
      decided to extend the ESCAPE study to investigate the long-term effect of 
      cilostazol and aspirin, named the ESCAPE-extension study. The study participants 
      had been investigated for cardiovascular events for up to 7 years, bringing the 
      total follow-up time to a median of 5.2 years (interquartile range 
      3.6-6.7 years). Adverse events were also investigated. RESULTS: Among 100 
      participants from the original study, 88 were included in this extension study. 
      Cilostazol treatment reduced the incidence of cardiovascular events in the 
      patients with T2DM when compared with aspirin for a 5.2-year median follow-up 
      (hazard ratio 0.24; 95% CI, 0.07-0.83). The cardiovascular benefit of cilostazol 
      therapy was maintained along with age, sex, systolic blood pressure, low-density 
      lipoprotein cholesterol, and coronary artery calcium score. No serious adverse 
      events in the cilostazol group were noted in the follow-up period. CONCLUSIONS: 
      In this ESCAPE-extension study, cilostazol treatment proved its efficacy in 
      reducing cardiovascular events compared with aspirin in diabetic patients with 
      subclinical coronary artery disease, suggesting the beneficial role of cilostazol 
      in the primary prevention of cardiovascular disease.
CI  - © 2022 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai 
      JiaoTong University School of Medicine and John Wiley & Sons Australia, Ltd.
FAU - Sohn, Minji
AU  - Sohn M
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Seongnam, Republic of Korea.
FAU - Chun, Eun Ju
AU  - Chun EJ
AD  - Department of Radiology, Seoul National University Bundang Hospital, Seoul 
      National University College of Medicine, Seongnam, Republic of Korea.
FAU - Lim, Soo
AU  - Lim S
AUID- ORCID: 0000-0002-4137-1671
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Seongnam, Republic of Korea.
LA  - eng
GR  - Korean Diabetes Association/
GR  - Otsuka Pharmaceutical/
GR  - Seoul National University Bundang Hospital/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220805
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cilostazol/therapeutic use
MH  - *Coronary Artery Disease/etiology/prevention & control
MH  - *Coronary Stenosis/chemically induced/drug therapy
MH  - *Diabetes Mellitus, Type 2/chemically induced/complications/drug therapy
MH  - Drug Therapy, Combination
MH  - Follow-Up Studies
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Treatment Outcome
PMC - PMC9426278
OTO - NOTNLM
OT  - cardiovascular diseases
OT  - diabetes mellitus
OT  - platelet aggregation inhibitors
OT  - type 2
OT  - 关键词:2型糖尿病
OT  - 动脉粥样硬化
OT  - 心血管疾病
OT  - 血小板聚集抑制剂
COIS- The authors have no conflicting interests relevant to this article to disclose.
EDAT- 2022/08/07 06:00
MHDA- 2022/09/02 06:00
CRDT- 2022/08/06 03:02
PHST- 2022/06/27 00:00 [revised]
PHST- 2022/04/21 00:00 [received]
PHST- 2022/07/09 00:00 [accepted]
PHST- 2022/08/07 06:00 [pubmed]
PHST- 2022/09/02 06:00 [medline]
PHST- 2022/08/06 03:02 [entrez]
AID - JDB13300 [pii]
AID - 10.1111/1753-0407.13300 [doi]
PST - ppublish
SO  - J Diabetes. 2022 Aug;14(8):524-531. doi: 10.1111/1753-0407.13300. Epub 2022 Aug 
      5.

PMID- 34103192
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220809
IS  - 1535-6280 (Electronic)
IS  - 0146-2806 (Linking)
VI  - 47
IP  - 9
DP  - 2022 Sep
TI  - Cardiovascular Events After Partner Bereavement, What is the Role of Low Dose 
      Aspirin and Beta-Blockers?
PG  - 100883
LID - S0146-2806(21)00098-0 [pii]
LID - 10.1016/j.cpcardiol.2021.100883 [doi]
AB  - Bereavement due to loss of a partner is one of the most stressful life events, 
      often leading to adverse physiological responses. Spousal loss has been 
      associated with an increased morbidity and mortality, particularly from 
      cardiovascular disease. Use of aspirin and/or beta adrenergic blockers have 
      previously been suggested to play a role in cardiovascular risk associated with 
      early bereavement. However, the available literature regarding this topic is 
      limited. In this review article, we explore the potential beneficial role of 
      aspirin and beta blockers in early bereavement. Our systematic review suggests 
      that most studies have found aspirin and beta blockers to be beneficial in 
      preventing adverse cardiovascular outcomes associated with early bereavement. 
      Further randomized controlled long-term studies are warranted with adequate 
      sample size to clearly establish the role of these medications on cardiovascular 
      disease in late bereavement.
CI  - Copyright © 2021 Elsevier Inc. All rights reserved.
FAU - Minhas, Sheharyar
AU  - Minhas S
AD  - Hospitalist, Department of Medicine, Baptist Memorial Hospital, Memphis, TN; 
      Student, Rollins School of Public Health, Emory University, Atlanta, GA. 
      Electronic address: sminhas7@yahoo.com.
FAU - Khan, Amal
AU  - Khan A
AD  - Resident, Department of Internal Medicine, University of University of Kansas - 
      Wichita program, Wichita, KS.
FAU - Naids, Sarah
AU  - Naids S
AD  - Medical Student, College of Medicine, University of Tennessee Health Science 
      Center, Memphis, TN.
FAU - Patel, Jay R
AU  - Patel JR
AD  - Medical Student, College of Medicine, University of Tennessee Health Science 
      Center, Memphis, TN.
FAU - Seitz, Michael Paul
AU  - Seitz MP
AD  - Resident, Department of Internal Medicine, Lenox Hill Hospital, New York, NY.
FAU - Khouzam, Rami N
AU  - Khouzam RN
AD  - Program Director, Interventional Cardiology, University of Tennessee Health 
      Science Center, Memphis, TN; Associate Program Director, Cardiology Fellowship, 
      University of Tennessee Health Science Center, Memphis, TN; Director, Cardiac 
      Cath Labs, Methodist University Hospital, Memphis, TN.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20210508
PL  - Netherlands
TA  - Curr Probl Cardiol
JT  - Current problems in cardiology
JID - 7701802
RN  - 0 (Adrenergic beta-Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/adverse effects
MH  - Aspirin/adverse effects
MH  - *Bereavement
MH  - *Cardiovascular Diseases/drug therapy/epidemiology/prevention & control
MH  - Humans
MH  - Morbidity
EDAT- 2021/06/10 06:00
MHDA- 2022/08/10 06:00
CRDT- 2021/06/09 05:47
PHST- 2021/04/29 00:00 [received]
PHST- 2021/05/02 00:00 [accepted]
PHST- 2021/06/10 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2021/06/09 05:47 [entrez]
AID - S0146-2806(21)00098-0 [pii]
AID - 10.1016/j.cpcardiol.2021.100883 [doi]
PST - ppublish
SO  - Curr Probl Cardiol. 2022 Sep;47(9):100883. doi: 10.1016/j.cpcardiol.2021.100883. 
      Epub 2021 May 8.

PMID- 22174438
OWN - NLM
STAT- MEDLINE
DCOM- 20130325
LR  - 20220409
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 52
IP  - 11
DP  - 2012 Nov
TI  - Modulation of lymphangiogenesis: a new target for aspirin and other nonsteroidal 
      anti-inflammatory agents? A systematic review.
PG  - 1749-54
LID - 10.1177/0091270011431066 [doi]
AB  - Recent studies have implicated that lymphangiogenesis plays a role in the 
      development of metastasis in experimental cancer models and in certain types of 
      human tumors. Epidemiological and laboratory data suggest that non steroidal 
      anti-inflammatory agents (NSAIDs) have antitumor activities, although the 
      mechanisms have not been elucidated. This systematic review aimed to synthesize 
      data on the effect of aspirin and other NSAIDs on lymphangiogenesis. In 
      particular, an answer was attempted to be found for the following primary 
      questions: Is there an effect of aspirin and NSAIDs on lymphangiogenesis? If yes, 
      is this effect mediated through COX-II inhibition or through COX-II-independent 
      mechanisms? Electronical databases were searched with the appropriate search 
      terms for the period from 1966 up to and including February 2011. The few 
      identified experimental trials indicated that aspirin and other NSAIDs inhibit 
      lymphangiogenesis, with a potential decrease in metastatic spread, possibly 
      through COX-II-dependent regulation of VEGF-C expression. COX-II-independent 
      mechanisms of inhibition of lymphangiogenesis by salicylates and the other NSAIDs 
      have not been investigated. Although further research validation is needed, this 
      proposed effect of NSAIDs might have therapeutic implications in chemoprevention, 
      adjuvant chemotherapy, and treatment of metastatic disease.
FAU - Yiannakopoulou, Eugenia
AU  - Yiannakopoulou E
AD  - Department of Basic Medical Lessons, Faculty of Health and Caring Professions, 
      Technological Educational Institute of Athens, Greece . nyiannak@teiath.gr
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20111214
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cyclooxygenase 2/physiology
MH  - Cyclooxygenase 2 Inhibitors/*pharmacology
MH  - Humans
MH  - Lymphangiogenesis/*drug effects
EDAT- 2011/12/17 06:00
MHDA- 2013/03/26 06:00
CRDT- 2011/12/17 06:00
PHST- 2011/12/17 06:00 [entrez]
PHST- 2011/12/17 06:00 [pubmed]
PHST- 2013/03/26 06:00 [medline]
AID - 0091270011431066 [pii]
AID - 10.1177/0091270011431066 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2012 Nov;52(11):1749-54. doi: 10.1177/0091270011431066. Epub 
      2011 Dec 14.

PMID- 8307537
OWN - NLM
STAT- MEDLINE
DCOM- 19940314
LR  - 20131121
IS  - 0015-8178 (Print)
IS  - 0015-8178 (Linking)
VI  - 111
IP  - 33
DP  - 1993 Nov 30
TI  - [Antiphlogistic effect of salicylic acid and its derivatives].
PG  - 530-2
AB  - An overview of the literature on the effects of salicylic acid and its 
      derivatives with particular consideration being given to their antiinflammatory 
      properties is presented. While acetylsalicylic acid, in common with most 
      non-steroidal anti-inflammatory drugs, has a marked inhibitory effect on 
      cyclooxygenase in vitro, salicylic acid only weakly inhibits this enzyme. Animal 
      inflammation models, however, have shown that the two substances are comparable 
      in terms of efficacy. It is therefore assumed that the antiinflammatory 
      properties of salicylic acid and its derivatives are also based on 
      prostaglandin-independent mechanisms. Both salicylates and salicylic acid are 
      used for topical applications. Their penetration into deeper tissue layers, as 
      also their efficacy after local application have been demonstrated in both animal 
      studies and clinical trials.
FAU - Binder, M
AU  - Binder M
AD  - Luitpold Pharma GmbH, München.
FAU - Zeiller, P
AU  - Zeiller P
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Antiphlogistische Wirkung von Salizylsäure und ihren Derivaten.
PL  - Germany
TA  - Fortschr Med
JT  - Fortschritte der Medizin
JID - 2984763R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Salicylates/adverse effects/*therapeutic use
MH  - Salicylic Acid
RF  - 30
EDAT- 1993/11/30 00:00
MHDA- 1993/11/30 00:01
CRDT- 1993/11/30 00:00
PHST- 1993/11/30 00:00 [pubmed]
PHST- 1993/11/30 00:01 [medline]
PHST- 1993/11/30 00:00 [entrez]
PST - ppublish
SO  - Fortschr Med. 1993 Nov 30;111(33):530-2.

PMID- 6164755
OWN - NLM
STAT- MEDLINE
DCOM- 19810709
LR  - 20190829
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 225
IP  - 1
DP  - 1981
TI  - 5-OH-Tryptophane in migraine: clinical and neurophysiological considerations.
PG  - 41-6
AB  - The clinical effects of the protracted treatment with 5-OH Tryptophane (5-HTP) of 
      some patients with chronic migraine are compared with other patients with 
      acetylsalicylic acid. The pain threshold was neurophysiologically determined in 
      migraneous on patients whose response to 5-HTP therapy was specially good. The 
      results with 5-HTP can be accounted for by an action of the substance on the 
      serotonin turnover with activation of the serotoninergic antinociceptive system.
FAU - Boiardi, A
AU  - Boiardi A
FAU - Crenna, P
AU  - Crenna P
FAU - Merati, B
AU  - Merati B
FAU - Negri, S
AU  - Negri S
FAU - Tansini, E
AU  - Tansini E
FAU - Bussone, G
AU  - Bussone G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - C1LJO185Q9 (5-Hydroxytryptophan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 5-Hydroxytryptophan/pharmacology/*therapeutic use
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Nociceptors/drug effects
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1007/BF00313460 [doi]
PST - ppublish
SO  - J Neurol. 1981;225(1):41-6. doi: 10.1007/BF00313460.

PMID- 1246991
OWN - NLM
STAT- MEDLINE
DCOM- 19760311
LR  - 20190509
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 65
IP  - 1
DP  - 1976 Jan
TI  - The effect of thrombocytopenia on the determination of platelet aggregation.
PG  - 79-82
AB  - Platelet aggregation has been widely assumed to be unmeasurable in 
      thrombocytopenic samples. Using a sensitive differential self differential 
      self-calibrating aggregometer, and standard aggregating agents, aggregation was 
      measured in serially diluted platelet-rich plasma. Aggregation induced by ADP or 
      collagen was reproducible at platelet counts as low as 50,000 per cu. mm., and 
      with epinephrine aggregation was reproducible at platelet counts as low as 75,000 
      per cu. mm.
FAU - Levine, P H
AU  - Levine PH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Collagen
MH  - Epinephrine
MH  - Humans
MH  - *Platelet Aggregation/drug effects
MH  - Thrombocytopenia/*blood
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1093/ajcp/65.1.79 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1976 Jan;65(1):79-82. doi: 10.1093/ajcp/65.1.79.

PMID- 9396900
OWN - NLM
STAT- MEDLINE
DCOM- 19971229
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 177
IP  - 5
DP  - 1997 Nov
TI  - The fetoplacental pressor effects of low-dose acetylsalicylic acid and 
      angiotensin II in the ex vivo cotyledon model.
PG  - 1093-6
AB  - OBJECTIVE: Our purpose was to investigate perfusion pressure changes ex vivo 
      induced by angiotensin II on fetoplacental vasculature pretreated with low-dose 
      acetylsalicylic acid. STUDY DESIGN: Two cotyledons from each of 12 placentas were 
      perfused. The intervillous space of one cotyledon was infused with 
      acetylsalicylic acid (5 x 10(-5) mol/L) similar to the serum concentration of 
      women receiving daily low-dose aspirin therapy (60 to 81 mg). The control 
      cotyledon was infused with an equivalent amount of normal saline solution. Two 
      doses of angiotensin II, 1 x 10(-11.5) and 1 x 10(-10) moles, were injected as 
      boluses into the chorionic arteries of each cotyledon. A 3 x 10(-7) mole dose of 
      angiotensin II was also injected into the intervillous space. Statistical 
      analysis was performed with analysis of variance, and results are expressed as 
      mean pressure change in millimeters of mercury +/- SEM. RESULTS: Perfusion 
      pressure response did not vary between cotyledons pretreated with acetylsalicylic 
      acid and control cotyledons when 3 x 10(-7) moles of angiotensin II was injected 
      into the intervillous space (8.0 +/- 1.9 mm Hg vs 9.8 +/- 1.6 mm Hg, p = 0.59). 
      There were no differences between cotyledons in pressure response to 1 x 
      10(-11.5) moles of angiotensin II injected into the fetal circuit (5.9 +/- 0.8 mm 
      Hg vs 6.7 +/- 0.9 mm Hg, p = 0.51). However, in the cotyledons pretreated with 
      acetylsalicylic acid there was a decrease in the pressor response to 1 x 10(-10) 
      moles of angiotensin II (14.1 +/- 1.4 mm Hg vs 21.5 +/- 3.3 mm Hg, p = 0.05). 
      CONCLUSIONS: Low-dose aspirin infused into the intervillous space decreases 
      vasoconstriction elicited by angiotensin II in the fetoplacental compartment. 
      This suggests that maternal low-dose aspirin therapy has effects in the 
      fetoplacental circulation in addition to its effects in the maternal circulation.
FAU - Napolitano, P G
AU  - Napolitano PG
AD  - Division of Maternal-Fetal Medicine, Madigan Army Medical Center, Fort Lewis, 
      Washington, USA.
FAU - Hoeldtke, N J
AU  - Hoeldtke NJ
FAU - Moore, K H
AU  - Moore KH
FAU - Calhoun, B C
AU  - Calhoun BC
FAU - Christensen, E D
AU  - Christensen ED
FAU - Markenson, G R
AU  - Markenson GR
FAU - Hume, R F Jr
AU  - Hume RF Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 11128-99-7 (Angiotensin II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin II/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Female
MH  - Fetus/*blood supply
MH  - Humans
MH  - Perfusion
MH  - Placenta/*blood supply
MH  - Pregnancy
EDAT- 1997/12/16 02:43
MHDA- 2001/03/28 10:01
CRDT- 1997/12/16 02:43
PHST- 1997/12/16 02:43 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1997/12/16 02:43 [entrez]
AID - S0002-9378(97)70021-8 [pii]
AID - 10.1016/s0002-9378(97)70021-8 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1997 Nov;177(5):1093-6. doi: 10.1016/s0002-9378(97)70021-8.

PMID- 26423305
OWN - NLM
STAT- MEDLINE
DCOM- 20160229
LR  - 20181202
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 13
DP  - 2015 Oct 1
TI  - Benefit-harm analysis and charts for individualized and preference-sensitive 
      prevention: example of low dose aspirin for primary prevention of cardiovascular 
      disease and cancer.
PG  - 250
LID - 10.1186/s12916-015-0493-2 [doi]
LID - 250
AB  - BACKGROUND: Clinical practice guidelines provide separate recommendations for 
      different diseases that may be prevented or treated by the same intervention. 
      Also, they commonly provide recommendations for entire populations but not for 
      individuals. To address these two limitations, our aim was to conduct 
      benefit-harm analyses for a wide range of individuals using the example of low 
      dose aspirin for primary prevention of cardiovascular disease and cancer and to 
      develop Benefit-Harm Charts that show the overall benefit-harm balance for 
      individuals. METHODS: We used quantitative benefit-harm modeling that included 16 
      outcomes to estimate the probability that low dose aspirin provides more benefits 
      than harms for a wide range of men and women between 45 and 84 years of age and 
      without a previous myocardial infarction, severe ischemic stroke, or cancer. We 
      repeated the quantitative benefit-harm modeling for different combinations of 
      age, sex, and outcome risks for severe ischemic and hemorrhagic stroke, 
      myocardial infarction, cancers, and severe gastrointestinal bleeds. The analyses 
      considered weights for the outcomes, statistical uncertainty of the effects of 
      aspirin, and death as a competing risk. We constructed Benefit-Harm Charts that 
      show the benefit-harm balance for different combinations of outcome risks. 
      RESULTS: The Benefit-Harm Charts ( http://www.benefit-harm-balance.com ) we have 
      created show that the benefit-harm balance differs largely across a primary 
      prevention population. Low dose aspirin is likely to provide more benefits than 
      harms in men, elderly people, and in those at low risk for severe 
      gastrointestinal bleeds. Individual preferences have a major impact on the 
      benefit-harm balance. If, for example, it is a high priority for individuals to 
      prevent stroke and severe cancers while severe gastrointestinal bleeds are deemed 
      to be of little importance, the benefit-harm balance is likely to favor low dose 
      aspirin for most individuals. Instead, if severe gastrointestinal bleeds are 
      judged to be similarly important compared to the benefit outcomes, low dose 
      aspirin is unlikely to provide more benefits than harms. CONCLUSIONS: 
      Benefit-Harm Charts support individualized benefit-harm assessments and decision 
      making. Similarly, individualized benefit-harm assessments may allow guideline 
      developers to issue more finely granulated recommendations that reduce the risk 
      of over- and underuse of interventions. The example of low dose aspirin for 
      primary prevention of cardiovascular disease and cancer shows that it may be time 
      for guideline developers to provide combined recommendations for different 
      diseases that may be prevented or treated by the same intervention.
FAU - Puhan, Milo A
AU  - Puhan MA
AD  - Department of Epidemiology; Epidemiology, Biostatistics & Prevention Institute, 
      University of Zurich, Hirschengraben 84, Room HRS G29, CH-8001, Zurich, 
      Switzerland. miloalan.puhan@uzh.ch.
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, USA. miloalan.puhan@uzh.ch.
FAU - Yu, Tsung
AU  - Yu T
AD  - Department of Epidemiology; Epidemiology, Biostatistics & Prevention Institute, 
      University of Zurich, Hirschengraben 84, Room HRS G29, CH-8001, Zurich, 
      Switzerland. tsung.yu@uzh.ch.
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, USA. tsung.yu@uzh.ch.
FAU - Stegeman, Inge
AU  - Stegeman I
AD  - Department of Otorhinolaryngology - Head and Neck Surgery, University Medical 
      Center Utrecht, Utrecht, The Netherlands. I.Stegeman@umcutrecht.nl.
AD  - Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The 
      Netherlands. I.Stegeman@umcutrecht.nl.
FAU - Varadhan, Ravi
AU  - Varadhan R
AD  - Department of Biostatistics, Johns Hopkins University Bloomberg School of Public 
      Health, Baltimore, USA. ravi.varadhan@jhu.edu.
AD  - Division of Biostatistics and Bioinformatics, Department of Oncology, Sidney 
      Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, USA. 
      ravi.varadhan@jhu.edu.
FAU - Singh, Sonal
AU  - Singh S
AD  - Division of General Internal Medicine, Johns Hopkins School of Medicine, 
      Baltimore, USA. ssingh31@jhu.edu.
FAU - Boyd, Cynthia M
AU  - Boyd CM
AD  - Center on Aging and Health, Division of Geriatric Medicine and Gerontology, Johns 
      Hopkins School of Medicine, Baltimore, USA. cyboyd@jhmi.edu.
LA  - eng
GR  - K23 AG032910/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151001
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMC Med. 2016 Jul 06;14 (1):101. PMID: 27383519
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*prevention & control
MH  - Primary Prevention/*methods
MH  - Risk Assessment/*methods
PMC - PMC4589917
EDAT- 2015/10/02 06:00
MHDA- 2016/03/02 06:00
CRDT- 2015/10/02 06:00
PHST- 2015/02/03 00:00 [received]
PHST- 2015/09/17 00:00 [accepted]
PHST- 2015/10/02 06:00 [entrez]
PHST- 2015/10/02 06:00 [pubmed]
PHST- 2016/03/02 06:00 [medline]
AID - 10.1186/s12916-015-0493-2 [pii]
AID - 493 [pii]
AID - 10.1186/s12916-015-0493-2 [doi]
PST - epublish
SO  - BMC Med. 2015 Oct 1;13:250. doi: 10.1186/s12916-015-0493-2.

PMID- 34952844
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20220127
IS  - 2009-8774 (Electronic)
IS  - 2305-6983 (Print)
IS  - 2305-6983 (Linking)
VI  - 9
IP  - 4
DP  - 2021 Dec
TI  - Primary care providers should prescribe aspirin to prevent cardiovascular disease 
      based on benefit-risk ratio, not age.
LID - 10.1136/fmch-2021-001475 [doi]
LID - e001475
AB  - Recent guidelines restricted aspirin (ASA) in primary prevention of 
      cardiovascular disease (CVD) to patients <70 years old and more recent guidance 
      to <60.In the most comprehensive prior meta-analysis, the Antithrombotic 
      Trialists Collaboration reported a significant 12% reduction in CVD with similar 
      benefit-risk ratios at older ages. Using Preferred Reporting Items for Systematic 
      Reviews and Meta-Analyses guidelines, four trials were added to an updated 
      meta-analysis.ASA produced a statistically significant 13% reduction in CVD with 
      95% confidence limits (0.83 to 0.92) with similar benefits at older ages in each 
      of the trials.Primary care providers should make individual decisions whether to 
      prescribe ASA based on benefit-risk ratio, not simply age. When the absolute risk 
      of CVD is >10%, benefits of ASA will generally outweigh risks of significant 
      bleeding. ASA should be considered only after implementation of therapeutic 
      lifestyle changes and other drugs of proven benefit such as statins, which are, 
      at the very least, additive to ASA. Our perspective is that individual clinical 
      judgements by primary care providers about prescription of ASA in primary 
      prevention of CVD should be based on our evidence-based solution of weighing all 
      the absolute benefits and risks rather than age. This strategy would do far more 
      good for far more patients as well as far more good than harm in both developed 
      and developing countries. This new and novel strategy for primary care providers 
      to consider in prescribing ASA in primary prevention of CVD is the same as the 
      general approach suggested by Professor Geoffrey Rose decades ago.
CI  - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kim, Kyungmann
AU  - Kim K
AD  - Biostatistics and Medical Informatics, University of Wisconsin-Madison School of 
      Medicine and Public Health, Madison, Wisconsin, USA.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - Medicine and Population Health and Social Medicine, Florida Atlantic University, 
      Charles E Schmidt College of Medicine, Boca Raton, Florida, USA 
      PROFCHHMD@prodigy.net.
FAU - Martinez, Lisa
AU  - Martinez L
AD  - Medicine and Population Health and Social Medicine, Florida Atlantic University, 
      Charles E Schmidt College of Medicine, Boca Raton, Florida, USA.
FAU - Gaziano, J Michael
AU  - Gaziano JM
AD  - Medicine, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Pfeffer, Marc A
AU  - Pfeffer MA
AD  - Medicine, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Biglione, Bianca
AU  - Biglione B
AD  - Medicine and Population Health and Social Medicine, Florida Atlantic University, 
      Charles E Schmidt College of Medicine, Boca Raton, Florida, USA.
FAU - Gitin, Alexander
AU  - Gitin A
AD  - Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
FAU - McCabe, Jeanne Bell
AU  - McCabe JB
AD  - Biostatistics and Medical Informatics, University of Wisconsin-Madison School of 
      Medicine and Public Health, Madison, Wisconsin, USA.
FAU - Cook, Thomas D
AU  - Cook TD
AD  - Biostatistics and Medical Informatics, University of Wisconsin-Madison School of 
      Medicine and Public Health, Madison, Wisconsin, USA.
FAU - DeMets, David L
AU  - DeMets DL
AD  - Biostatistics and Medical Informatics, University of Wisconsin-Madison School of 
      Medicine and Public Health, Madison, Wisconsin, USA.
FAU - Wood, Sarah K
AU  - Wood SK
AD  - Medicine and Population Health and Social Medicine, Florida Atlantic University, 
      Charles E Schmidt College of Medicine, Boca Raton, Florida, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - Fam Med Community Health
JT  - Family medicine and community health
JID - 101700650
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Aspirin/adverse effects
MH  - *Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - Middle Aged
MH  - Odds Ratio
MH  - Primary Health Care
MH  - Risk Assessment
PMC - PMC8710906
OTO - NOTNLM
OT  - cardiovascular diseases
OT  - clinical medicine
OT  - community medicine
OT  - family medicine
OT  - general practice
COIS- Competing interests: CHH reports that he serves as an independent scientist in an 
      advisory role to investigators and sponsors as Chair of data monitoring 
      committees for Amgen, British Heart Foundation, Cadila, Canadian Institutes of 
      Health Research, DalCor, and Regeneron; to the US FDA and UpToDate; receives 
      royalties for authorship or editorship of three textbooks and as co-inventor on 
      patents for inflammatory markers and cardiovascular disease that are held by 
      Brigham and Women’s Hospital; has an investment management relationship with the 
      West- Bacon Group within SunTrust Investment Services, which has discretionary 
      investment authority; does not own any common or preferred stock in any 
      pharmaceutical or medical device company. JMG reports that he serves as a 
      consultant to Bayer. MAP reports that he receives research support from Novartis. 
      He serves as an independent scientist in an advisory role to AstraZeneca, 
      Boehringer-Ingelheim and Eli Lilly Alliance, Corvidia, DalCor, GlaxoSmithKline, 
      NHLBI CONNECTs (Master Protocol Committee), Novartis, Novo Nordisk, Peerbridge 
      and Sanofi; and has equity in DalCor and Peerbridge. DLDM reports that he serves 
      as an independent scientist in an advisory role to the National Institutes of 
      Health, the US Food and Drug Administration (FDA) and the pharmaceutical and 
      medical device industry on the design, monitoring and analysis of trials. He 
      serves on data monitoring committees for Astra Zeneca, Amgen, Action, DalCor, 
      GSK, Merck, Sanofi, Boehringer Ingelheim, Teva and AbbVie. He holds no stock in 
      any pharmaceutical or device company. SKW reports that she serves as an 
      independent scientist in an advisory role to investigators and sponsors as member 
      of three data monitoring committees for Amgen.
EDAT- 2021/12/26 06:00
MHDA- 2022/01/28 06:00
CRDT- 2021/12/25 05:25
PHST- 2021/12/25 05:25 [entrez]
PHST- 2021/12/26 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
AID - fmch-2021-001475 [pii]
AID - 10.1136/fmch-2021-001475 [doi]
PST - ppublish
SO  - Fam Med Community Health. 2021 Dec;9(4):e001475. doi: 10.1136/fmch-2021-001475.

PMID- 24670510
OWN - NLM
STAT- MEDLINE
DCOM- 20140602
LR  - 20191210
IS  - 0807-7096 (Electronic)
IS  - 0029-2001 (Linking)
VI  - 134
IP  - 6
DP  - 2014 Mar 25
TI  - [The polypill as cardiovascular prophylactic: clinical trials].
PG  - 620-3
LID - 10.4045/tidsskr.13.0925 [doi]
AB  - BACKGROUND: Cardiovascular disease dominates globally as the most common cause of 
      death. This challenge may be countered by employing a combination pill (the 
      «polypill») for prophylaxis by everybody above a certain age. The polypill 
      normally contains two to three low-dose antihypertensives, a statin and aspirin. 
      Clinical trials with the polypill are reviewed. METHOD: The databases PubMed and 
      ClinicalTrials.gov were accessed for published, ongoing and planned randomised 
      clinical trials with a polypill, and studies available per June 2013 were 
      identified and evaluated. RESULTS: Six randomised clinical trials with different 
      variations of a polypill have been published. In these, the polypill has been 
      compared either with placebo (n = 3) or other cardiovascularly active 
      pharmacotherapeutic strategies (n = 3). So far, no data on hard endpoints such as 
      morbidity and mortality are available. On the basis of reductions in blood 
      pressure and cholesterol levels, estimated risk reductions for ischemic heart 
      disease and stroke were in the 33-72% and 21-64% ranges, respectively. 
      INTERPRETATION: Additional studies of longer duration and with larger numbers of 
      patients are required to assess the polypill's proposed effects on cardiovascular 
      morbidity and mortality, as well as safety issues.
FAU - Sandli, Oda Kristine
AU  - Sandli OK
AD  - Institutt for laboratoriemedisin, barne- og kvinnesykdommer Norges 
      teknisk-naturvitenskapelige universitet.
FAU - Spigset, Olav
AU  - Spigset O
AD  - Institutt for laboratoriemedisin, barne- og kvinnesykdommer Norges 
      teknisk-naturvitenskapelige universitet og Avdeling for klinisk farmakologi St. 
      Olavs hospital.
FAU - Slørdal, Lars
AU  - Slørdal L
AD  - Institutt for laboratoriemedisin, barne- og kvinnesykdommer Norges 
      teknisk-naturvitenskapelige universitet og Avdeling for klinisk farmakologi St. 
      Olavs hospital.
LA  - nor
PT  - Journal Article
PT  - Review
TT  - Polypillen som kardiovaskulær profylakse--kliniske studier.
DEP - 20140325
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny 
      raekke
JID - 0413423
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Cholesterol, LDL/drug effects
MH  - Clinical Trials as Topic
MH  - *Drug Combinations
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & 
      dosage/therapeutic use
MH  - Outcome Assessment, Health Care
MH  - Risk
EDAT- 2014/03/29 06:00
MHDA- 2014/06/03 06:00
CRDT- 2014/03/28 06:00
PHST- 2014/03/28 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/06/03 06:00 [medline]
AID - 3154212 [pii]
AID - 10.4045/tidsskr.13.0925 [doi]
PST - epublish
SO  - Tidsskr Nor Laegeforen. 2014 Mar 25;134(6):620-3. doi: 10.4045/tidsskr.13.0925. 
      eCollection 2014 Mar 25.

PMID- 9641318
OWN - NLM
STAT- MEDLINE
DCOM- 19981029
LR  - 20190822
IS  - 0378-5955 (Print)
IS  - 0378-5955 (Linking)
VI  - 119
IP  - 1-2
DP  - 1998 May
TI  - Perceptual consequences of the interactions between spontaneous otoacoustic 
      emissions and external tones. I. Monaural diplacusis and aftertones.
PG  - 49-60
AB  - Research into monaural diplacusis has led to the concept of idiotones (tone-like 
      stimuli of cochlea origin). Spontaneous otoacoustic emissions (SOAEs) are 
      tone-like stimuli generated by the cochlea and detected in the ear canal. In 
      diplacusis, the existence of idiotones is inferred from disturbances of the 
      perception of single tones. Spontaneous otoacoustic emissions are measured by 
      placing a small microphone at the entrance to the ear canal. Many of the puzzling 
      properties of the hypothesized idiotones are consistent with measurements of the 
      interaction of SOAEs with external tones. The interactions of the SOAEs with 
      external tones were analyzed acoustically. The perceptual properties evoked by 
      250 ms pulses (presented twice a second) of the acoustic stimuli used in the OAE 
      experiments were systematically investigated. At some stimulus levels, all 
      subjects reported the perception of a second tone alternating with the external 
      tone. The relative pitch of this percept was consistent with the frequency of the 
      SOAE. The frequency dependence of the signal levels needed for the percept had 
      many aspects in common with the suppression tuning curves of the SOAEs. At lower 
      levels of the external tone the subjects sometimes reported a perception of two 
      simultaneous tones. This would be consistent with the subject detecting SOAEs 
      when they are frequency shifted, but not suppressed. The consumption of aspirin 
      by one subject reduced the SOAE into the noise floor and eliminated the monaural 
      diplacusis.
FAU - Long, G
AU  - Long G
AD  - Department of Audiology and Speech Sciences, Purdue University, West Lafayette, 
      IN 47907, USA. long@physics.purdue.edu
LA  - eng
GR  - DC00307/DC/NIDCD NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Hear Res
JT  - Hearing research
JID - 7900445
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acoustic Stimulation
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Cochlea/*physiology
MH  - Ear Canal/*physiology
MH  - Female
MH  - Hearing Disorders/drug therapy/etiology
MH  - Humans
MH  - Otoacoustic Emissions, Spontaneous/drug effects/*physiology
MH  - Pitch Perception/*physiology
MH  - Psychoacoustics
MH  - Sound Localization/*physiology
EDAT- 1998/06/26 00:00
MHDA- 1998/06/26 00:01
CRDT- 1998/06/26 00:00
PHST- 1998/06/26 00:00 [pubmed]
PHST- 1998/06/26 00:01 [medline]
PHST- 1998/06/26 00:00 [entrez]
AID - S0378-5955(98)00032-X [pii]
AID - 10.1016/s0378-5955(98)00032-x [doi]
PST - ppublish
SO  - Hear Res. 1998 May;119(1-2):49-60. doi: 10.1016/s0378-5955(98)00032-x.

PMID- 24840525
OWN - NLM
STAT- MEDLINE
DCOM- 20150204
LR  - 20220129
IS  - 1531-703X (Electronic)
IS  - 1040-8746 (Linking)
VI  - 26
IP  - 4
DP  - 2014 Jul
TI  - Aspirin in gastrointestinal oncology: new data on an old friend.
PG  - 441-7
LID - 10.1097/CCO.0000000000000098 [doi]
AB  - PURPOSE OF REVIEW: The purpose of this review is to assess recent evidence that 
      demonstrates that aspirin has the potential to be an effective preventive and 
      therapeutic agent in gastrointestinal malignancy. RECENT FINDINGS: Long-term 
      follow-up of previous randomized trials of aspirin show that it decreases cancer 
      incidence and mortality with the greatest effects seen on cancers that arise from 
      the gastrointestinal tract. Reduction in distant metastasis and improvements in 
      cancer outcomes appear within 5  years of randomization indicating that aspirin 
      affects tumour growth or the development and spread of metastases from existing 
      cancers or both. In Lynch syndrome (hereditary nonpolyposis colon cancer), 
      aspirin reduces cancer incidence and should be considered standard care. 
      Mutations in the PIK3CA gene may be a potential predictive marker of response to 
      aspirin after a cancer diagnosis, though pharmacological considerations suggest 
      that platelets may be central to the antitumour efficacy of aspirin. SUMMARY: 
      These findings have re-awakened interest in the role of aspirin in the primary 
      prevention of cancer and in the treatment of cancer. Randomized controlled trials 
      are underway to assess the role of aspirin within the treatment algorithms of 
      several solid common cancers.
FAU - Langley, Ruth E
AU  - Langley RE
AD  - aMRC Clinical Trials Unit at University College London, London bOxford Stroke 
      Prevention Research Unit, Oxford University Clinical Academic Graduate School, 
      Oxford, UK.
FAU - Rothwell, Peter M
AU  - Rothwell PM
LA  - eng
GR  - 095626/WT_/Wellcome Trust/United Kingdom
GR  - 12/01/38/DH_/Department of Health/United Kingdom
GR  - MC_U122861325/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Oncol
JT  - Current opinion in oncology
JID - 9007265
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Gastrointestinal Neoplasms/*drug therapy/prevention & control
MH  - Humans
MH  - Neoplasm Metastasis/prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
EDAT- 2014/05/21 06:00
MHDA- 2015/02/05 06:00
CRDT- 2014/05/21 06:00
PHST- 2014/05/21 06:00 [entrez]
PHST- 2014/05/21 06:00 [pubmed]
PHST- 2015/02/05 06:00 [medline]
AID - 10.1097/CCO.0000000000000098 [doi]
PST - ppublish
SO  - Curr Opin Oncol. 2014 Jul;26(4):441-7. doi: 10.1097/CCO.0000000000000098.

PMID- 16699954
OWN - NLM
STAT- MEDLINE
DCOM- 20070126
LR  - 20171116
IS  - 1360-8185 (Print)
IS  - 1360-8185 (Linking)
VI  - 11
IP  - 8
DP  - 2006 Aug
TI  - Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 
      4040, a novel NO-NSAID, in pancreatic cancer cell lines.
PG  - 1321-30
AB  - Although non steroidal antiinflammatory drugs (NSAIDs) have been shown to be 
      effective as chemopreventive agents, important side-effects limit their clinical 
      use. A promising novel class of drugs, nitric oxide-donating NSAIDs (NO-NSAIDs), 
      has been found to be more active than classical NSAIDs. This study explored the 
      effect of the NO-donating aspirin derivative, NCX 4040, on three human pancreatic 
      adenocarcinoma cell lines (Capan-2, MIA PaCa-2 and T3M4). NCX 4040 activity was 
      compared with that of NCX 4016 (an NO(2)-positional isomer of NCX 4040), SNAP (a 
      standard NO-releasing molecule), NCX 4042 (denitrated analog of NCX 4040), and 
      aspirin. NCX 4040 showed a striking cytocidal activity in all cell lines, already 
      inducing significant percentages of apoptotic cells at 10 muM in Capan-2 cell 
      lines. This study focused on the biological mechanisms of sensitivity and 
      resistance to NCX 4040, highlighting that the cytotoxic action of this drug may 
      be due to the hyperexpression of Bax, its translocation to the mitochondria, the 
      release of Cytochrome C, and the activation of caspases-9 and -3, overall in a 
      p53-independent manner. Moreover, the use of a specific COX-2 inhibitor (NS 398) 
      in the experimental models showed that COX-2 hyperexpression could partially 
      explain the resistance mechanisms to NCX 4040.
FAU - Rosetti, Marco
AU  - Rosetti M
AD  - Istituto Oncologico Romagnolo, Meldola, Italy.
FAU - Tesei, Anna
AU  - Tesei A
FAU - Ulivi, Paola
AU  - Ulivi P
FAU - Fabbri, Francesco
AU  - Fabbri F
FAU - Vannini, Ivan
AU  - Vannini I
FAU - Brigliadori, Giovanni
AU  - Brigliadori G
FAU - Amadori, Dino
AU  - Amadori D
FAU - Bolla, Manlio
AU  - Bolla M
FAU - Zoli, Wainer
AU  - Zoli W
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Apoptosis
JT  - Apoptosis : an international journal on programmed cell death
JID - 9712129
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cytotoxins)
RN  - 0 (NCX 4040)
RN  - 0 (NCX 4042)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Nitro Compounds)
RN  - 0 (Salicylates)
RN  - 79032-48-7 (S-Nitroso-N-Acetylpenicillamine)
RN  - EC 3.4.22.- (Caspase 9)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenocarcinoma
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Caspase 9/metabolism
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Cytotoxins/pharmacology
MH  - *Drug Resistance, Neoplasm
MH  - Flow Cytometry
MH  - Humans
MH  - Nitric Oxide Donors/*pharmacology
MH  - Nitro Compounds/*pharmacology
MH  - Pancreatic Neoplasms
MH  - S-Nitroso-N-Acetylpenicillamine/pharmacology
MH  - Salicylates/pharmacology
EDAT- 2006/05/16 09:00
MHDA- 2007/01/27 09:00
CRDT- 2006/05/16 09:00
PHST- 2006/05/16 09:00 [pubmed]
PHST- 2007/01/27 09:00 [medline]
PHST- 2006/05/16 09:00 [entrez]
AID - 10.1007/s10495-006-6986-x [doi]
PST - ppublish
SO  - Apoptosis. 2006 Aug;11(8):1321-30. doi: 10.1007/s10495-006-6986-x.

PMID- 11214765
OWN - NLM
STAT- MEDLINE
DCOM- 20010510
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 56
IP  - 9-10
DP  - 2000 Dec
TI  - Interaction between angiotensin-converting enzyme inhibitors and aspirin: a 
      review.
PG  - 609-20
AB  - Aspirin and angiotensin-converting enzyme inhibitors (ACEIs) are often associated 
      for the treatment of coronary disease and/or chronic heart failure, but 
      conclusions of some prospective and retrospective studies show a possible 
      negative interaction between aspirin and ACEIs. ACEIs inhibit the conversion of 
      angiotensin I to angiotensin II and also the catabolism of bradykinin, which 
      results in increased synthesis of vasodilatory agents [prostaglandins and nitric 
      oxide (NO)], whereas aspirin inhibits prostaglandin synthesis. Thus, a potential 
      interaction from the opposing effects of aspirin and ACEIs could affect the 
      metabolism of bradykinin. We conducted an extensive Medline search, as well as a 
      manual search, of published literature including pharmacodynamic studies and 
      clinical trials concerning the impact of aspirin on the effect of ACEIs in 
      hypertension, coronary disease and chronic heart failure. A review of this 
      literature shows five studies in hypertension (all prospective and using blood 
      pressure as the main criterion of assessment), five in coronary disease (three 
      retrospective and two prospective trials, four of which use mortality as the 
      criterion of assessment) and 13 in chronic heart failure (eight using 
      haemodynamic measurements of which seven are prospective--one prospective study 
      using pulmonary tests, four using clinical events including mortality as 
      criterion of assessment of which two are prospective). The counteraction of ACEI 
      efficacy by aspirin is demonstrated in one out of five studies in hypertension, 
      one out of four of studies in coronary disease and nine out of thirteen in 
      chronic heart failure. This counteraction is more often observed with high 
      dosages of aspirin (greater than 250 mg/day, four out of six studies) and less 
      often with lower dosages (less than or equal to 250 mg/day, three out of 11 
      studies). These studies are retrospective analyses or use haemodynamic 
      end-points, so there is as yet no methodological argument strong enough to 
      contraindicate the aspirin-ACEI association or to prove the clinical relevance of 
      this interaction. In conclusion, prospective studies using mortality as a 
      criterion of assessment are needed to offer the practitioner the answer to the 
      question of ACEI-aspirin association.
FAU - Meune, C
AU  - Meune C
AD  - Internal Medicine, Hospital Lariboisière, Paris, France.
FAU - Mahe, I
AU  - Mahe I
FAU - Mourad, J J
AU  - Mourad JJ
FAU - Simoneau, G
AU  - Simoneau G
FAU - Knellwolf, A L
AU  - Knellwolf AL
FAU - Bergmann, J F
AU  - Bergmann JF
FAU - Caulin, C
AU  - Caulin C
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics, Non-Narcotic/*adverse effects
MH  - Angiotensin-Converting Enzyme Inhibitors/*adverse effects
MH  - Animals
MH  - Aspirin/*adverse effects
MH  - Drug Interactions
MH  - Humans
RF  - 70
EDAT- 2001/02/24 12:00
MHDA- 2001/05/22 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/05/22 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
AID - 10.1007/s002280000210 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2000 Dec;56(9-10):609-20. doi: 10.1007/s002280000210.

PMID- 3966266
OWN - NLM
STAT- MEDLINE
DCOM- 19850219
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 16
IP  - 1
DP  - 1985 Jan-Feb
TI  - Effects of low dose aspirin on platelet function in patients with recent cerebral 
      ischemia.
PG  - 5-9
AB  - We tested the antiplatelet effects of low-dose aspirin in patients with occlusive 
      cerebrovascular disease, because conventional dosage aspirin inhibits vascular 
      synthesis of prostacyclin at the same time that it inhibits platelets. The 
      effects on platelet function and thromboxane A2 synthesis of 40 mg of aspirin 
      daily or 40 mg aspirin plus dipyridamole were measured in 23 patients starting 
      within a week after the onset of cerebral ischemia. All patients had normal 
      baseline platelet aggregation responses to four stimuli: arachidonate, 
      epinephrine, adenosine diphosphate and collagen. The generation of thromboxane A2 
      by platelets, measured as serum thromboxane B2, was also normal. After 3 to 7 
      days of low dose aspirin therapy, platelet aggregation responses were suppressed 
      to the extent observed with higher dosage aspirin. Serotonin release during 
      platelet aggregation was inhibited by more than 95% and thromboxane B2 levels in 
      clotted blood fell by more than 95%. Responses to aspirin treatment were similar 
      in patients with transient ischemic attacks and in those with stroke and were 
      also similar in both sexes. No differences in platelet responses were observed 
      between patients receiving aspirin alone and aspirin plus dipyridamole. Thus 40 
      mg aspirin daily inhibited platelet responses as effectively as higher doses of 
      aspirin in patients who had recent cerebral ischemia and showed a cumulative 
      antiplatelet effect.
FAU - Weksler, B B
AU  - Weksler BB
FAU - Kent, J L
AU  - Kent JL
FAU - Rudolph, D
AU  - Rudolph D
FAU - Scherer, P B
AU  - Scherer PB
FAU - Levy, D E
AU  - Levy DE
LA  - eng
GR  - 5PO NS00346/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 57576-52-0 (Thromboxane A2)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Brain Ischemia/*blood/physiopathology
MH  - Cerebrovascular Disorders/blood/physiopathology
MH  - Dipyridamole/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests
MH  - Thromboxane A2/biosynthesis
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1161/01.str.16.1.5 [doi]
PST - ppublish
SO  - Stroke. 1985 Jan-Feb;16(1):5-9. doi: 10.1161/01.str.16.1.5.

PMID- 30362916
OWN - NLM
STAT- MEDLINE
DCOM- 20190111
LR  - 20230805
IS  - 2376-1032 (Electronic)
IS  - 2376-0540 (Print)
IS  - 2376-0540 (Linking)
VI  - 24
IP  - 11
DP  - 2018 Nov
TI  - Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary 
      Cardiovascular Event Prevention in the Managed Care Setting.
PG  - 1102-1111
LID - 10.18553/jmcp.2018.24.11.1102 [doi]
AB  - BACKGROUND: Cardiovascular disease remains the leading cause of death in adults 
      in the United States and constitutes a substantial portion of overall national 
      health expenditures. Aspirin is generally recommended for primary cardiovascular 
      event prevention based on a given patient's underlying cardiovascular event risk 
      profile, particularly for those aged 50-69 years with a 10-year risk of coronary 
      heart disease of ≥ 10%. Evidence-based clinical guidelines are in agreement for 
      secondary prevention consisting of lifelong, low-dose aspirin therapy following a 
      cardiovascular event. Despite these recommendations, research suggests suboptimal 
      concordance between guidelines and clinical practice. OBJECTIVE: To evaluate the 
      budget impact of appropriate low-dose aspirin use for primary and secondary 
      cardiovascular event prevention compared with current rates of low-dose aspirin 
      use. METHODS: An economic model measuring budget spend for cardiovascular events, 
      aspirin, and aspirin-related adverse events was developed from the perspective of 
      a U.S. payer. The model compared current rates of aspirin use to appropriate 
      rates of aspirin use according to guideline recommendations for both primary and 
      secondary cardiovascular event prevention. RESULTS: For a hypothetical plan with 
      1 million members, an estimated 18,026 patients were on aspirin therapy for 
      primary cardiovascular event prevention, while guidelines recommend that 55,788 
      patients should have been on aspirin therapy for this indication. Optimal aspirin 
      use in the primary cardiovascular event prevention population reduced the number 
      of nonfatal myocardial infarctions (MIs; -367), ischemic strokes (-232), and 
      deaths (-60), with an increase in the number of gastrointestinal bleeds (169) and 
      hemorrhagic strokes (98). Evidence-based guideline-compliant use of aspirin for 
      primary cardiovascular event prevention resulted in total cost savings of 
      approximately $4.2 million over a 5-year time horizon. For secondary 
      cardiovascular event prevention, an estimated 48,663 patients were on aspirin, 
      while clinical guidelines recommend that 71,316 patients should have been on 
      aspirin therapy for this indication. Optimal aspirin use in secondary 
      cardiovascular event prevention reduced the number of nonfatal MIs (-515), 
      ischemic strokes (-375), and deaths (-217), with an increase in the number of 
      gastrointestinal bleeds (98) and hemorrhagic strokes (58). Evidence-based 
      guideline-compliant use of aspirin for secondary cardiovascular event prevention 
      resulted in total cost savings of approximately $11 million over a 5-year time 
      horizon. CONCLUSIONS: Appropriate low-dose aspirin use for primary and secondary 
      cardiovascular event prevention can result in improved patient outcomes with 
      significant cost savings for U.S. payers. As a simple and inexpensive 
      prophylactic measure for cardiovascular event prevention, aspirin use should be 
      carefully considered in all appropriate at-risk adult patients. DISCLOSURES: 
      Development of this manuscript and the corresponding budget impact analysis was 
      funded by Bayer. Coppolecchia, Williamson, and Cameron are employees of Bayer. 
      Carlton, Lennert, and Moradi are employees of Xcenda, a consulting firm that 
      received funding from Bayer to assist in the completion of this study. 
      Khalaf-Gillard was an employee of Xcenda at the time of the study. The 
      corresponding poster was presented at the Academy of Managed Care Pharmacy Nexus 
      2017; October 16-19, 2017; Dallas, TX.
FAU - Carlton, Rashad
AU  - Carlton R
AD  - 1 Xcenda, Palm Harbor, Florida.
FAU - Coppolecchia, Rosa
AU  - Coppolecchia R
AD  - 2 Bayer HealthCare, Whippany, New Jersey.
FAU - Khalaf-Gillard, Kristin
AU  - Khalaf-Gillard K
AD  - 1 Xcenda, Palm Harbor, Florida.
FAU - Lennert, Barb
AU  - Lennert B
AD  - 1 Xcenda, Palm Harbor, Florida.
FAU - Moradi, Ashton
AU  - Moradi A
AD  - 1 Xcenda, Palm Harbor, Florida.
FAU - Williamson, Todd
AU  - Williamson T
AD  - 2 Bayer HealthCare, Whippany, New Jersey.
FAU - Cameron, Jennifer
AU  - Cameron J
AD  - 2 Bayer HealthCare, Whippany, New Jersey.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Manag Care Spec Pharm
JT  - Journal of managed care & specialty pharmacy
JID - 101644425
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/economics
MH  - Budgets
MH  - Cardiovascular Diseases/economics/*prevention & control
MH  - Cost Savings
MH  - Female
MH  - *Health Care Costs
MH  - Humans
MH  - Male
MH  - Managed Care Programs/*economics
MH  - Middle Aged
MH  - Models, Economic
MH  - Platelet Aggregation Inhibitors/*administration & dosage/economics
MH  - Primary Prevention/economics/methods
MH  - Secondary Prevention/economics/methods
MH  - United States
PMC - PMC10397935
COIS- Development of this manuscript and the corresponding budget impact analysis was 
      funded by Bayer. Coppolecchia, Williamson, and Cameron are employees of Bayer. 
      Carlton, Lennert, and Moradi are employees of Xcenda, a consulting firm that 
      received funding from Bayer to assist in the completion of this study. 
      Khalaf-Gillard was an employee of Xcenda at the time of the study. The 
      corresponding poster was presented at the Academy of Managed Care Pharmacy Nexus 
      2017; October 16-19, 2017; Dallas, TX.
EDAT- 2018/10/27 06:00
MHDA- 2019/01/12 06:00
CRDT- 2018/10/27 06:00
PHST- 2018/10/27 06:00 [entrez]
PHST- 2018/10/27 06:00 [pubmed]
PHST- 2019/01/12 06:00 [medline]
AID - 10.18553/jmcp.2018.24.11.1102 [doi]
PST - ppublish
SO  - J Manag Care Spec Pharm. 2018 Nov;24(11):1102-1111. doi: 
      10.18553/jmcp.2018.24.11.1102.

PMID- 11577463
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190901
IS  - 0015-5691 (Print)
IS  - 0015-5691 (Linking)
VI  - 118
IP  - 3
DP  - 2001 Sep
TI  - [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 
      inhibitor, to COX-2 selective inhibitors].
PG  - 219-30
AB  - Aspirin was developed as a non-steroidal anti-inflammatory drug (NSAID) in 1899. 
      During the century after that, aspirin has been found to show its 
      anti-inflammatory, analgesic and anti-pyretic activities by reducing 
      prostaglandins biosynthesis through inhibition of cyclooxygenase (COX); and then 
      COX was found to be constituted of two isoforms, constitutive COX-1 and inducible 
      COX-2. Currently, novel NSAIDs, acting through selective inhibition of COX-2, 
      that have efficacy as excellent as aspirin with significantly lower incidence of 
      gastrointestinal adverse effects are available in America and some other 
      countries, but not in Japan. Physiological and pathophysiological roles of COX-1 
      and COX-2 have been explained from studies in experimental animals, but there are 
      many differences in species and diseases between animals and humans. Thus, 
      physiological and pathophysiological roles of COX-2 were considered from the 
      standpoint of clinical effects of the two latest COX-2 selective inhibitors, 
      celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer 
      together with their adverse effects on gastrointestinal, renal and platelet 
      functions; and the usefulness and limits of COX-2-selective inhibitors were 
      discussed with the trends of new NSAIDs development.
FAU - Nakamura, H
AU  - Nakamura H
AD  - Center of Pharmacovigilance & Regulatory Affairs, Dainippon Pharmaceutical Co., 
      Ltd., 2-6-8 Dosho-machi, Chuo-ku, Osaka 541-0045, Japan. 
      hideo-nakamura@dainippon-pharm.co.jp
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Yakurigaku Zasshi
JT  - Nihon yakurigaku zasshi. Folia pharmacologica Japonica
JID - 0420550
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Isoenzymes)
RN  - 0 (Lactones)
RN  - 0 (Membrane Proteins)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - 0 (Sulfones)
RN  - 0QTW8Z7MCR (rofecoxib)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology/therapeutic 
      use
MH  - Aspirin/adverse effects/*pharmacology/therapeutic use
MH  - Celecoxib
MH  - Clinical Trials as Topic
MH  - Colorectal Neoplasms/prevention & control
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Fever/drug therapy
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Isoenzymes/*antagonists & inhibitors/physiology
MH  - Kidney Diseases/chemically induced
MH  - Lactones/pharmacology/therapeutic use
MH  - Membrane Proteins
MH  - Pain/drug therapy
MH  - Peptic Ulcer/chemically induced
MH  - Prostaglandin-Endoperoxide Synthases/physiology
MH  - Pyrazoles
MH  - Sulfonamides/pharmacology/therapeutic use
MH  - Sulfones
RF  - 34
EDAT- 2001/10/02 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/02 10:00
PHST- 2001/10/02 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/02 10:00 [entrez]
AID - 10.1254/fpj.118.219 [doi]
PST - ppublish
SO  - Nihon Yakurigaku Zasshi. 2001 Sep;118(3):219-30. doi: 10.1254/fpj.118.219.

PMID- 7560667
OWN - NLM
STAT- MEDLINE
DCOM- 19951109
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 96
IP  - 4
DP  - 1995 Oct
TI  - Hydrocortisone sodium succinate does not cross-react with aspirin in 
      aspirin-sensitive patients with asthma.
PG  - 545-8
AB  - BACKGROUND: Bronchospasm after intravenous hydrocortisone treatment has been 
      reported in some patients with aspirin-sensitive respiratory disease. OBJECTIVE: 
      This study was designed to determine the prevalence of sensitivity to 
      hydrocortisone among patients with aspirin-sensitive respiratory disease. 
      METHODS: We performed double-blind, placebo-controlled challenges with aspirin 
      and 100 mg of hydrocortisone sodium succinate administered intravenously in 53 
      subjects. RESULTS: Forty-five of the 53 subjects (85%) undergoing oral aspirin 
      challenge experienced respiratory reactions to aspirin. Forty-four of these 45 
      patients had neither naso-ocular, cutaneous, nor respiratory reactions to 
      hydrocortisone sodium succinate. One aspirin-sensitive subject had bronchospasm 
      and a naso-ocular reaction to hydrocortisone sodium succinate and a naso-ocular 
      reaction with minimal bronchospasm to methylprednisolone sodium succinate. After 
      desensitization to aspirin, and while receiving maintenance aspirin therapy, this 
      subject again reacted to hydrocortisone sodium succinate with bronchospasm and 
      naso-ocular reaction. CONCLUSION: We conclude that aspirin-sensitive patients 
      with asthma are not preferentially sensitive to hydrocortisone and that 
      hydrocortisone sodium succinate does not cross-react or cross-desensitize with 
      aspirin.
FAU - Feigenbaum, B A
AU  - Feigenbaum BA
AD  - Scripps Clinic and Research Foundation, La Jolla, CA 92037, USA.
FAU - Stevenson, D D
AU  - Stevenson DD
FAU - Simon, R A
AU  - Simon RA
LA  - eng
GR  - AI-32834/AI/NIAID NIH HHS/United States
GR  - M0-1RR00833/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adult
MH  - Aspirin/*immunology/pharmacology
MH  - Asthma/*drug therapy/*immunology
MH  - Cross Reactions
MH  - Desensitization, Immunologic
MH  - Double-Blind Method
MH  - Drug Hypersensitivity/*immunology/therapy
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Hydrocortisone/*immunology/*therapeutic use
MH  - Placebos
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - S0091-6749(95)70299-7 [pii]
AID - 10.1016/s0091-6749(95)70299-7 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1995 Oct;96(4):545-8. doi: 10.1016/s0091-6749(95)70299-7.

PMID- 710503
OWN - NLM
STAT- MEDLINE
DCOM- 19790126
LR  - 20190623
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 51
IP  - 3
DP  - 1978 Oct 1
TI  - Aspirin- and indomethacin-induced ulcers and their antagonism by antihistamines.
PG  - 275-83
AB  - Gastric ulceration produced by aspirin and indomethacin was compared in acutely 
      stressed and non-stressed rats. We found a synergism between these 
      anti-inflammatory agents and acute stress in the production of gastric ulcers. 
      Even at relatively high doses, neither agent caused appreciable gastric damage in 
      non-stressed rats, whereas moderate doses of both agents produced massive 
      ulceration in stressed rats. The synergism appears unrelated to the effect of 
      these agents on the pituitary-adrenal response. The size and regional 
      distribution of ulcers produced by aspirin and indomethacin in stressed rats were 
      comparable. However, the dose--response curves of the two drugs were markedly 
      dissimilar. Furthermore, the ulceration produced by indomethacin was attenuated 
      by both H1 and H2 histamine receptor antagonists, whereas ulceration produced by 
      aspirin was attenuated only by an H2 antagonist. The results suggest that the 
      ulcerogenic mechanism of indomethacin may differ from that of aspirin and add to 
      the growing evidence on the importance of endogenous histamine in various forms 
      of gastric ulceration.
FAU - Brown, P A
AU  - Brown PA
FAU - Sawrey, J M
AU  - Sawrey JM
FAU - Vernikos, J
AU  - Vernikos J
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Histamine Antagonists)
RN  - R16CO5Y76E (Aspirin)
RN  - W980KJ009P (Corticosterone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/antagonists & inhibitors/*pharmacology
MH  - Cold Temperature
MH  - Corticosterone/blood
MH  - Histamine Antagonists/*pharmacology/therapeutic use
MH  - Indomethacin/antagonists & inhibitors/*pharmacology
MH  - Male
MH  - Rats
MH  - Restraint, Physical
MH  - Stomach Ulcer/*chemically induced/drug therapy/pathology
MH  - Stress, Physiological/physiopathology
MH  - Time Factors
OID - NASA: 79045493
EDAT- 1978/10/01 00:00
MHDA- 1978/10/01 00:01
CRDT- 1978/10/01 00:00
PHST- 1978/10/01 00:00 [pubmed]
PHST- 1978/10/01 00:01 [medline]
PHST- 1978/10/01 00:00 [entrez]
AID - 0014-2999(78)90412-0 [pii]
AID - 10.1016/0014-2999(78)90412-0 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1978 Oct 1;51(3):275-83. doi: 10.1016/0014-2999(78)90412-0.

PMID- 9143855
OWN - NLM
STAT- MEDLINE
DCOM- 19970722
LR  - 20181113
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 10
IP  - 5
DP  - 1997 May
TI  - Optimal management of chronic leg ulcers in the elderly.
PG  - 341-8
AB  - Chronic leg ulceration is a very common clinical problem in the elderly. Good 
      management depends entirely on making an accurate diagnosis, and planning 
      treatment after considering all aspects of patient well-being. All elderly 
      patients with leg ulcers benefit from an assessment of their vascular status, 
      since the effects of gravity influence treatment and healing irrespective of the 
      diagnosis. The most common causes of ulceration are venous and arterial disease. 
      Diabetes mellitus, pressure, vasculitis, metabolic abnormalities and skin cancer 
      are all unusual causes of leg ulceration, but must be considered in the 
      differential diagnosis. Almost all patients with ulcerated legs benefit from the 
      use of compression bandaging at a level appropriate to their vascular status. In 
      patients with venous ulcers, this can be achieved with a number of bandaging 
      techniques; however, multilayer bandaging appears to be the most cost-effective 
      means available, particularly when combined with community-based leg ulcer 
      clinics. The effects of oral drug therapy for venous and arterial disease have 
      been disappointing. Local dressings are important in ulcers that are not suitable 
      for compression therapy. The choice of dressing depends on the nature of the 
      ulcer and the tolerability of the dressing for the patient.
FAU - Goodfield, M
AU  - Goodfield M
AD  - Department of Dermatology, General Infirmary, Leeds, England.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aging/*pathology
MH  - Arterial Occlusive Diseases/physiopathology
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Bandages
MH  - Combined Modality Therapy
MH  - Diabetes Mellitus/physiopathology
MH  - Humans
MH  - Hypertension/physiopathology
MH  - Leg Ulcer/diagnosis/*drug therapy/therapy
MH  - Metabolic Diseases/physiopathology
MH  - Pentoxifylline/administration & dosage/pharmacology/therapeutic use
MH  - Phosphodiesterase Inhibitors/administration & dosage/pharmacology/therapeutic use
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/therapeutic 
      use
MH  - Pressure Ulcer/physiopathology
MH  - Skin Transplantation
MH  - Vasculitis/physiopathology
MH  - Venous Insufficiency/physiopathology
MH  - Wound Healing/drug effects
RF  - 25
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - 10.2165/00002512-199710050-00003 [doi]
PST - ppublish
SO  - Drugs Aging. 1997 May;10(5):341-8. doi: 10.2165/00002512-199710050-00003.

PMID- 16698007
OWN - NLM
STAT- MEDLINE
DCOM- 20061208
LR  - 20221207
IS  - 0009-8981 (Print)
IS  - 0009-8981 (Linking)
VI  - 372
IP  - 1-2
DP  - 2006 Oct
TI  - The effect of aspirin and vitamins C and E on HbA1c assays.
PG  - 206-9
AB  - BACKGROUND: Aspirin (ASA) and vitamins C and E may inhibit non-enzymatic 
      glycation in vivo and may also interfere with HbA(1c) assays, masking true 
      results. We investigated the effect of usual doses of ASA, vitamin C and E on 
      HbA1c levels in a group of non-diabetic volunteers. METHODS: A randomized 
      clinical trial was performed with 28 healthy non-diabetic individuals. Subjects 
      were allocated to take ASA 200 mg/day, vitamin C 1 g/day, vitamin E 400 mg/day, 
      or to a control group, for a period of 4 months. Blood samples were collected at 
      baseline and at monthly intervals for HbA1c analysis by HPLC Variant II (BioRad), 
      HPLC L-9100 (Merck - Hitachi) and Tina Quant HbA(1c) II immunoassay (Roche). 
      RESULTS: HbA(1c) levels of the control, vitamin C and E groups did not change 
      throughout the study, independently of the method used. HbA(1c) measured by 
      Hitachi L-9100 HPLC increased significantly (P=0.033) at 4 months after ASA 
      intake, although this increase was of only 0.17%. CONCLUSIONS: Treatment with 
      vitamins C and E in pharmacological doses does not have any impact on HbA1c 
      measurements in non-diabetic patients with the three methods employed. ASA 
      induces a modest, not clinically relevant, increase in HbA1c levels with one of 
      the methods.
FAU - Camargo, Joíza L
AU  - Camargo JL
AD  - Clinical Pathology Department, Hospital de Clínicas de Porto Alegre, Porto 
      Alegre, RS, Brazil. jcamargo@hcpa.ufrgs.br
FAU - Stifft, Jonathas
AU  - Stifft J
FAU - Gross, Jorge L
AU  - Gross JL
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20060515
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 0 (Glycated Hemoglobin A)
RN  - 1406-18-4 (Vitamin E)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Chromatography, High Pressure Liquid
MH  - Dose-Response Relationship, Drug
MH  - Glycated Hemoglobin/*analysis
MH  - Humans
MH  - Vitamin E/*pharmacology
EDAT- 2006/05/16 09:00
MHDA- 2006/12/12 09:00
CRDT- 2006/05/16 09:00
PHST- 2006/03/13 00:00 [received]
PHST- 2006/03/24 00:00 [revised]
PHST- 2006/03/25 00:00 [accepted]
PHST- 2006/05/16 09:00 [pubmed]
PHST- 2006/12/12 09:00 [medline]
PHST- 2006/05/16 09:00 [entrez]
AID - S0009-8981(06)00221-X [pii]
AID - 10.1016/j.cca.2006.03.031 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2006 Oct;372(1-2):206-9. doi: 10.1016/j.cca.2006.03.031. Epub 
      2006 May 15.

PMID- 9566778
OWN - NLM
STAT- MEDLINE
DCOM- 19980511
LR  - 20190701
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 62
IP  - 15
DP  - 1998
TI  - The effect of gentamicin on acetylsalicylic acid-induced platelet antiaggregatory 
      action in mouse pial arterioles.
PG  - 1361-9
AB  - Gentamicin (G) treatment (5, 20, 40 and 80 mg kg[-1] day[-1] given 
      intramuscularly for 6 days) was shown to cause a dose-related platelet 
      proaggregatory effect in mouse pial microcirculation. This was associated with a 
      reduction in mouse renal function, indicated by high plasma creatinine and urea 
      concentrations. When G was given at the same doses but as a single injection, it 
      caused no change in renal function or platelet aggregation. Gentamicin (20 and 80 
      mg kg/day, given intramuscularly for 6 days) significantly (P < 0.05) impeded the 
      platelet antiaggregatory effect of acetylsalicylic acid (100 mg kg[-1], 
      intraperitoneally).
FAU - El-Sabban, F M
AU  - El-Sabban FM
AD  - Faculty of Medicine & Health Sciences, UAE University, Al-Ain.
FAU - Ali, B H
AU  - Ali BH
FAU - Bashir, A K
AU  - Bashir AK
FAU - Tanira, M O
AU  - Tanira MO
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Gentamicins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arterioles/drug effects
MH  - Aspirin/*pharmacology
MH  - Drug Interactions
MH  - Gentamicins/*pharmacology
MH  - Male
MH  - Mice
MH  - Pia Mater/*blood supply
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 1998/05/05 00:00
MHDA- 1998/05/05 00:01
CRDT- 1998/05/05 00:00
PHST- 1998/05/05 00:00 [pubmed]
PHST- 1998/05/05 00:01 [medline]
PHST- 1998/05/05 00:00 [entrez]
AID - S0024320598000708 [pii]
AID - 10.1016/s0024-3205(98)00070-8 [doi]
PST - ppublish
SO  - Life Sci. 1998;62(15):1361-9. doi: 10.1016/s0024-3205(98)00070-8.

PMID- 1473880
OWN - NLM
STAT- MEDLINE
DCOM- 19930203
LR  - 20131121
IS  - 0251-1649 (Print)
IS  - 0251-1649 (Linking)
VI  - 12
IP  - 3
DP  - 1992
TI  - Gastric tolerance of single dose unbuffered and buffered acetylsalicylic acid: a 
      randomized comparative endoscopic study in 24 volunteers.
PG  - 133-8
AB  - A randomized, three-way crossover study by gastroscopic examination in 24 healthy 
      male volunteers was performed to compare the gastric tolerance of a single dose 
      of buffered or unbuffered acetylsalicylic acid. Gastroscopic assessment was made 
      two hours after administration of the buffered (800 mg ASA) or unbuffered (500 mg 
      ASA) tablets taken with 200 ml of water. Mucosal changes were rare and of a minor 
      nature. Only two volunteers in the unbuffered ASA group presented minor changes 
      (erythema and oedema). No pathological changes were observed after the buffered 
      ASA. Subjective adverse reactions, e.g. epigastric complaints, were reported by 
      four volunteers in the unbuffered group and by two in the buffered group. Based 
      on the limited number and the minor extent of visible changes, statistical tests 
      did not appear to be warranted. The results indicate that buffered ASA is better 
      tolerated.
FAU - Rogalla, K
AU  - Rogalla K
AD  - Drug Research Centre, Bayer AG, Wuppertal, Germany.
FAU - Lange, R
AU  - Lange R
FAU - Panijel, M
AU  - Panijel M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Int J Clin Pharmacol Res
JT  - International journal of clinical pharmacology research
JID - 8110183
RN  - 0 (Buffers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Buffers
MH  - Gastric Mucosa/*drug effects
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Single-Blind Method
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Res. 1992;12(3):133-8.

PMID- 7923644
OWN - NLM
STAT- MEDLINE
DCOM- 19941110
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 90
IP  - 4
DP  - 1994 Oct
TI  - Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and 
      Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.
PG  - 1624-30
AB  - BACKGROUND: The Thrombolysis and Thrombin Inhibition in Myocardial Infarction 
      (TIMI) 9A trial compared the efficacy and safety of intravenous hirudin with 
      heparin as adjunctive therapy to thrombolysis and aspirin in patients with acute 
      myocardial infarction. The primary safety end point was the occurrence of major 
      hemorrhage or anaphylaxis. METHODS AND RESULTS: Based on experience in phase II 
      trials, TIMI 9A used a hirudin bolus of 0.6 mg/kg followed by a fixed-dose 
      96-hour infusion of 0.2 mg/kg per hour. A modified weight-adjusted heparin 
      regimen was used (5000-U bolus and infusion of 1000 U/h for patients < 80 kg or 
      1300 U/h for patients > or = 80 kg) with titration to a target activated partial 
      thromboplastin time (aPTT) of 60 to 90 seconds. Because rates of hemorrhage in 
      both treatment arms were higher than expected, randomization was suspended in 
      TIMI 9A after 757 patients had been enrolled. Intracranial hemorrhage occurred in 
      1.7% of patients treated with hirudin and 1.9% of those treated with heparin (P = 
      NS). Major spontaneous hemorrhage at a nonintracranial site occurred more 
      frequently in hirudin--than in heparin-treated patients (7.0% versus 3.0%; P = 
      .02), whereas major hemorrhage at instrumented sites was similar (5.2% in both 
      hirudin and heparin groups). Patients who developed a major hemorrhage were older 
      (P < .001) and had higher aPTT values, especially in the first 12 hours after 
      thrombolysis (P = .001). CONCLUSIONS: The rate of major spontaneous hemorrhage 
      for both heparin and hirudin in TIMI 9A was higher than that seen in TIMI 5, TIMI 
      6, and GUSTO 1. This was possibly a result of high levels of anticoagulation at 
      the doses of heparin and hirudin used, low previous estimates of the hemorrhage 
      risk at the doses of hirudin used in TIMI 9A due to the relatively small number 
      of patients receiving that dose in earlier studies, and enrollment of patients at 
      higher risk of hemorrhage. Because a prolonged aPTT was associated with an 
      increased risk of major hemorrhage in both heparin- and hirudin-treated patients, 
      it now appears important to monitor aPTT on a regular basis when using either 
      antithrombin to identify those patients who require downward adjustment of the 
      infusion. TIMI 9B has therefore been configured with a lower hirudin bolus (0.1 
      mg/kg) and infusion (0.1 mg/kg per hour) and lower heparin infusion (1000 U/h 
      without weight adjustment). Infusions of both antithrombins will be titrated to a 
      target aPTT of 55 to 85 seconds.
FAU - Antman, E M
AU  - Antman EM
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Mass. 02115.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Hirudins)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 1994 Oct;90(4):2147-52. PMID: 7923701
MH  - Aged
MH  - Aspirin/adverse effects/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Heparin/adverse effects/therapeutic use
MH  - *Hirudin Therapy
MH  - Hirudins/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Thrombin/*antagonists & inhibitors
MH  - *Thrombolytic Therapy
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 10.1161/01.cir.90.4.1624 [doi]
PST - ppublish
SO  - Circulation. 1994 Oct;90(4):1624-30. doi: 10.1161/01.cir.90.4.1624.

PMID- 18410563
OWN - NLM
STAT- MEDLINE
DCOM- 20081210
LR  - 20151119
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 28
IP  - 1
DP  - 2008 Jul
TI  - Underutilization of gastroprotective strategies in aspirin users at increased 
      risk of upper gastrointestinal complications.
PG  - 88-96
LID - 10.1111/j.1365-2036.2008.03713.x [doi]
AB  - BACKGROUND: Aspirin use is with an increased risk of upper gastrointestinal 
      complications (UGICs). Proton pump inhibitors (PPIs) decrease the risk of UGICs 
      among aspirin users. The distribution of risk factors for UGIC and PPI 
      utilization among aspirin users remains uncharacterized. AIM: To determine the 
      prevalence and predictors of PPI use in high-risk aspirin users. METHODS: Using 
      questionnaires and administrative records, we collected information on aspirin 
      and PPI utilization and risk factors for UGICs from a stratified random sample of 
      subjects with established cardiovascular disease. We calculated the proportion of 
      aspirin users with UGIC risk factors and determined the prevalence of PPI use 
      among aspirin users with risk factors. Regression analysis was used to determine 
      predictors of PPI use among aspirin users. RESULTS: Overall response rate was 
      35%, of whom 86% were regular aspirin users. Seventy-one per cent of aspirin 
      users had at least one risk factor (in addition to cardiac disease) for the 
      development of UGICs. Although a history of UGIC was predictive of PPI use, 44% 
      of aspirin users with a prior history of UGICs did not receive a concomitant PPI, 
      and only 23% of subjects with additional UGIC risk factors were prescribed a PPI. 
      CONCLUSION: There is a high prevalence of UGIC risk factors among aspirin users, 
      and many are not prescribed PPIs as a gastroprotective strategy.
FAU - Targownik, L E
AU  - Targownik LE
AD  - Section of Gastroenterology, Division of Internal Medicine, University of 
      Manitoba, Winnipeg, MB, Canada. targowni@cc.umanitoba.ca
FAU - Metge, C J
AU  - Metge CJ
FAU - Leung, S
AU  - Leung S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080413
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Peptic Ulcer/*chemically induced
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Risk Factors
MH  - Surveys and Questionnaires
EDAT- 2008/04/16 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/04/16 09:00
PHST- 2008/04/16 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/04/16 09:00 [entrez]
AID - APT3713 [pii]
AID - 10.1111/j.1365-2036.2008.03713.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2008 Jul;28(1):88-96. doi: 
      10.1111/j.1365-2036.2008.03713.x. Epub 2008 Apr 13.

PMID- 22570427
OWN - NLM
STAT- MEDLINE
DCOM- 20120913
LR  - 20220331
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 46
IP  - 5
DP  - 2012 May
TI  - Use of aspirin and clopidogrel after coronary artery bypass graft surgery.
PG  - 678-87
LID - 10.1345/aph.1Q692 [doi]
AB  - OBJECTIVE: To evaluate the evidence for the use of dual antiplatelet therapy 
      (DAPT) with aspirin and clopidogrel following coronary artery bypass graft (CABG) 
      surgery. DATA SOURCES: Literature was accessed through PubMed (1950-November 
      2011), EMBASE (1976-November 2011), and the Cochrane databases using the terms 
      clopidogrel and coronary artery bypass graft. Citations from available articles 
      were used for additional references and ClinicalTrials.gov was accessed for 
      abstracts of ongoing studies. STUDY SELECTION AND DATA EXTRACTION: Peer-reviewed 
      studies that evaluated DAPT use after CABG surgery in adult humans were assessed 
      for inclusion. DATA SYNTHESIS: Four randomized clinical trials evaluating 
      surrogate end points and 9 studies (3 subgroup analyses, 6 observational) 
      evaluating clinical outcomes were reviewed. Three clinical trials assessing 
      surrogate end points failed to demonstrate an improvement in graft patency with 
      DAPT use, while 1 clinical trial found an increase in graft patency. As for 
      clinical outcomes, 1 subgroup analysis demonstrated that the benefit of DAPT 
      post-CABG after a non-ST-elevation acute coronary syndrome diminished following 
      surgery, while an observational study demonstrated a trend toward decreased 
      mortality. In post-CABG patients who did not experience acute coronary syndrome, 
      2 subgroup analyses proved inconclusive and an observational study found DAPT use 
      to be associated with reducing in-hospital mortality, while another observational 
      study was not associated with reduced long-term mortality. Three observational 
      studies in off-pump CABG patients showed that DAPT use was feasible. CONCLUSIONS: 
      Evidence for DAPT use following CABG is limited to subgroup analyses, 
      observational studies, and trials with surrogate end points. The majority of 
      clinical trials have failed to demonstrate an improvement in graft patency with 
      DAPT. Current evidence does not support the use of DAPT to improve graft patency, 
      and more evidence from randomized controlled trials assessing clinical outcomes 
      is necessary to make definitive recommendations.
FAU - de Leon, Noelle
AU  - de Leon N
AD  - College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA. 
      nksdeleon@gmail.com
FAU - Jackevicius, Cynthia A
AU  - Jackevicius CA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120508
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Coronary Artery Bypass/methods/*statistics & numerical data
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
EDAT- 2012/05/10 06:00
MHDA- 2012/09/14 06:00
CRDT- 2012/05/10 06:00
PHST- 2012/05/10 06:00 [entrez]
PHST- 2012/05/10 06:00 [pubmed]
PHST- 2012/09/14 06:00 [medline]
AID - aph.1Q692 [pii]
AID - 10.1345/aph.1Q692 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2012 May;46(5):678-87. doi: 10.1345/aph.1Q692. Epub 2012 May 8.

PMID- 21406194
OWN - NLM
STAT- MEDLINE
DCOM- 20110725
LR  - 20211020
IS  - 1090-2422 (Electronic)
IS  - 0014-4827 (Print)
IS  - 0014-4827 (Linking)
VI  - 317
IP  - 10
DP  - 2011 Jun 10
TI  - Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: 
      Relevance to its mechanism of action.
PG  - 1359-67
LID - 10.1016/j.yexcr.2011.03.001 [doi]
AB  - Nitric oxide-donating aspirin (NO-ASA) is a promising agent for cancer 
      prevention. Although studied extensively, its molecular targets and mechanism of 
      action are still unclear. S-nitrosylation of signaling proteins is emerging as an 
      important regulatory mechanism by NO. Here, we examined whether S-nitrosylation 
      of the NF-κB, p53, and Wnt signaling proteins by NO-ASA might explain, in part, 
      its mechanism of action in colon cancer. NO-ASA releases significant amounts of 
      NO detected intracellularly in HCT116 and HT-29 colon cells. Using a modified 
      biotin switch assay we demonstrated that NO-ASA S-nitrosylates the signaling 
      proteins p53, β-catenin, and NF-κB, in colon cancer cells in a time- and 
      concentration-dependent manner. NO-ASA suppresses NF-κB binding to its cognate 
      DNA oligonucleotide, which occurs without changes in the nuclear levels of the 
      NF-κB subunits p65 and p50 and is reversed by dithiothreitol that reduces -S-NO 
      to -SH. In addition to S-nitrosylation, we documented both in vitro and in vivo 
      widespread nitration of tyrosine residues of cellular proteins in response to 
      NO-ASA. Our results suggest that the increased intracellular NO levels following 
      treatment with NO-ASA modulate cell signaling by chemically modifying key protein 
      members of signaling cascades. We speculate that S-nitrosylation and tyrosine 
      nitration are responsible, at least in part, for the inhibitory growth effect of 
      NO-ASA on cancer cell growth and that this may represent a general mechanism of 
      action of NO-releasing agents.
CI  - Copyright © 2011 Elsevier Inc. All rights reserved.
FAU - Williams, Jennie L
AU  - Williams JL
AD  - Division of Cancer Prevention, Stony Brook University, HSC, T17-080, Stony Brook, 
      NY 11794-8173, USA.
FAU - Ji, Ping
AU  - Ji P
FAU - Ouyang, Nengtai
AU  - Ouyang N
FAU - Kopelovich, Levy
AU  - Kopelovich L
FAU - Rigas, Basil
AU  - Rigas B
LA  - eng
GR  - K01 CA106604/CA/NCI NIH HHS/United States
GR  - KO1 CA106604-05/CA/NCI NIH HHS/United States
GR  - R01 CA140487/CA/NCI NIH HHS/United States
GR  - N01CN43302/CA/NCI NIH HHS/United States
GR  - K01 CA106604-05/CA/NCI NIH HHS/United States
GR  - CN43302WMC08WA7/CN/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20110322
PL  - United States
TA  - Exp Cell Res
JT  - Experimental cell research
JID - 0373226
RN  - 0 (NF-kappa B)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (beta Catenin)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 42HK56048U (Tyrosine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Exp Cell Res. 2012 Jun 10;318(10):1185
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Colonic Neoplasms/*drug therapy/*metabolism
MH  - Electrophoretic Mobility Shift Assay
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - NF-kappa B/*metabolism
MH  - Nitric Oxide/*metabolism
MH  - Nitric Oxide Donors/*pharmacology
MH  - Tyrosine/metabolism
MH  - Xenograft Model Antitumor Assays
MH  - beta Catenin/metabolism
PMC - PMC3096692
MID - NIHMS282278
EDAT- 2011/03/17 06:00
MHDA- 2011/07/26 06:00
CRDT- 2011/03/17 06:00
PHST- 2010/09/28 00:00 [received]
PHST- 2011/02/25 00:00 [revised]
PHST- 2011/03/02 00:00 [accepted]
PHST- 2011/03/17 06:00 [entrez]
PHST- 2011/03/17 06:00 [pubmed]
PHST- 2011/07/26 06:00 [medline]
AID - S0014-4827(11)00093-0 [pii]
AID - 10.1016/j.yexcr.2011.03.001 [doi]
PST - ppublish
SO  - Exp Cell Res. 2011 Jun 10;317(10):1359-67. doi: 10.1016/j.yexcr.2011.03.001. Epub 
      2011 Mar 22.

PMID- 18981304
OWN - NLM
STAT- MEDLINE
DCOM- 20081209
LR  - 20230120
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 118
IP  - 21
DP  - 2008 Nov 18
TI  - Antiplatelet therapy use after discharge among acute myocardial infarction 
      patients with in-hospital bleeding.
PG  - 2139-45
LID - 10.1161/CIRCULATIONAHA.108.787143 [doi]
AB  - BACKGROUND: Bleeding among patients with acute myocardial infarction (AMI) is 
      associated with worse long-term outcomes. Although the mechanism underlying this 
      association is unclear, a potential explanation is that withholding antiplatelet 
      therapies long beyond resolution of the bleeding event may contribute to 
      recurrent events. METHODS AND RESULTS: We examined medication use at discharge, 
      1, 6, and 12 months after AMI among 2498 patients in the Prospective Registry 
      Evaluating Myocardial Infarction: Events and Recovery (PREMIER) registry. 
      Bleeding was defined as non-coronary artery bypass graft-related Thrombolysis of 
      Myocardial Infarction major/minor bleeding or transfusion among patients with 
      baseline hematocrit > or =28%. Logistic regression was used to evaluate the 
      association between bleeding during the index AMI hospitalization and medication 
      use. In-hospital bleeding occurred in 301 patients (12%) with AMI. Patients with 
      in-hospital bleeding were less likely to be discharged on aspirin or 
      thienopyridine (adjusted odds ratio=0.45; 95% CI, 0.31 to 0.64; and odds 
      ratio=0.62; 95% CI, 0.42 to 0.91, respectively). At 1 month after discharge, 
      although patients with in-hospital bleeding remained significantly less likely to 
      receive aspirin (odds ratio=0.68; 95% CI, 0.50 to 0.92), use of thienopyridines 
      in the 2 groups started to become similar. By 1 year, antiplatelet therapy use 
      was similar among patients with and without bleeding. Postdischarge cardiology 
      follow-up was associated with greater antiplatelet therapy use than either 
      primary care or no clinical follow-up. CONCLUSIONS: Patients whose index AMI is 
      complicated by bleeding are less likely to be treated with antiplatelet therapies 
      during the first 6 months after discharge. Early reassessment of antiplatelet 
      eligibility may represent an opportunity to reduce the long-term risk of adverse 
      outcomes associated with bleeding.
FAU - Wang, Tracy Y
AU  - Wang TY
AD  - Duke Clinical Research Institute, 2400 Pratt St, Room 0311, Terrace Level, 
      Durham, NC 27705, USA. wang0085@mc.duke.edu
FAU - Xiao, Lan
AU  - Xiao L
FAU - Alexander, Karen P
AU  - Alexander KP
FAU - Rao, Sunil V
AU  - Rao SV
FAU - Kosiborod, Mikhail N
AU  - Kosiborod MN
FAU - Rumsfeld, John S
AU  - Rumsfeld JS
FAU - Spertus, John A
AU  - Spertus JA
FAU - Peterson, Eric D
AU  - Peterson ED
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081103
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Hematocrit
MH  - Hemorrhage/*chemically induced
MH  - Hospitals
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Pyridines/administration & dosage/*adverse effects
MH  - *Registries
MH  - Regression Analysis
EDAT- 2008/11/05 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/11/05 09:00
PHST- 2008/11/05 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/11/05 09:00 [entrez]
AID - CIRCULATIONAHA.108.787143 [pii]
AID - 10.1161/CIRCULATIONAHA.108.787143 [doi]
PST - ppublish
SO  - Circulation. 2008 Nov 18;118(21):2139-45. doi: 10.1161/CIRCULATIONAHA.108.787143. 
      Epub 2008 Nov 3.

PMID- 15881481
OWN - NLM
STAT- MEDLINE
DCOM- 20050602
LR  - 20190911
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 21
IP  - 1
DP  - 2005 Jan
TI  - Modelling the long term cost effectiveness of clopidogrel for the secondary 
      prevention of occlusive vascular events in the UK.
PG  - 101-12
AB  - OBJECTIVE: To assess the long term cost effectiveness of clopidogrel monotherapy 
      compared with acetylsalicylic acid (aspirin; ASA) monotherapy in patients at risk 
      of secondary occlusive vascular events (OVEs) in the UK. DESIGN: Cost utility 
      analysis based on clinical data from CAPRIE (a multicentre randomised controlled 
      trial, involving 19185 patients); long-term effects were extrapolated beyond the 
      trial period using a Markov model populated with data from UK observational 
      studies. Health economic evaluation carried out from the perspective of the UK 
      National Health Service. PARTICIPANTS: A representative cohort of 1000 UK 
      patients aged 60 years (approximate mean age of the CAPRIE population), with the 
      qualifying diagnoses of myocardial infarction, ischaemic stroke and peripheral 
      arterial disease, who are at risk of secondary OVEs (non-fatal myocardial 
      infarction, non-fatal stroke or vascular death). INTERVENTIONS: Patients were 
      assumed to receive treatment with either clopidogrel (75 mg/day) for 2 years 
      followed by ASA (325 mg/day, average) for their remaining lifetime, or ASA alone 
      (325 mg/day, average) for life. MAIN OUTCOME MEASURES: Incremental cost per life 
      year gained and incremental cost per quality-adjusted life year (QALY) gained. 
      RESULTS: In the base case, the incremental cost effectiveness of clopidogrel 
      versus ASA in this population is estimated at 18888 pounds per life year gained 
      and 21 489 pounds per QALY gained. Multiple deterministic and probabilistic 
      sensitivity analyses suggest the model is robust to variations in a wide range of 
      input parameters. CONCLUSION: Two years of treatment with clopidogrel can be 
      considered a cost effective intervention in patients at risk of secondary OVEs in 
      the UK.
FAU - Karnon, Jon
AU  - Karnon J
AD  - School of Health and Related Research (ScHARR), University of Sheffield, Regent 
      Court, 30 Regent Street, Sheffield, S1 4DA, UK. j.karnon@sheffield.ac.uk
FAU - Brennan, Alan
AU  - Brennan A
FAU - Pandor, Abdullah
AU  - Pandor A
FAU - Fowkes, Gerry
AU  - Fowkes G
FAU - Lee, Amanda
AU  - Lee A
FAU - Gray, David
AU  - Gray D
FAU - Coshall, Catherine
AU  - Coshall C
FAU - Nicholls, Charles
AU  - Nicholls C
FAU - Akehurst, Ron
AU  - Akehurst R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/economics/therapeutic use
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Models, Economic
MH  - Platelet Aggregation Inhibitors/*economics/*therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/*analogs & derivatives/*economics/*therapeutic use
MH  - United Kingdom
MH  - Vascular Diseases/*economics/*prevention & control
EDAT- 2005/05/11 09:00
MHDA- 2005/06/03 09:00
CRDT- 2005/05/11 09:00
PHST- 2005/05/11 09:00 [pubmed]
PHST- 2005/06/03 09:00 [medline]
PHST- 2005/05/11 09:00 [entrez]
AID - 10.1185/030079904x18036 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2005 Jan;21(1):101-12. doi: 10.1185/030079904x18036.

PMID- 10405227
OWN - NLM
STAT- MEDLINE
DCOM- 19990923
LR  - 20190817
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 29
IP  - 1
DP  - 1999 Jul
TI  - NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications 
      harmful to the esophagus?
PG  - 32-4
AB  - There are several studies that suggest that aspirin (acetylsalicylic acid [ASA]) 
      and nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with esophagitis 
      or esophageal stricture formation. There are limited data on the potential of 
      low-dose ASA and over-the-counter (OTC) NSAIDs to cause esophageal injury. The 
      goal of this study was to determine whether there is an association between 
      esophageal strictures and ASA/NSAID use, including low-dose ASA and OTC NSAIDs. A 
      total of 79 consecutive patients (mean age, 52.8 years; 38 men, 41 women) 
      referred for endoscopy from 4/1/96 to 11/15/96 for chronic gastroesophageal 
      reflux disease symptoms were evaluated. Data collected include gender, race, and 
      age, NSAID or ASA use, as well as an assessment of dysphagia, heartburn duration, 
      and heartburn frequency. Patients taking NSAIDs or ASA at least twice a week were 
      considered ASA/NSAID users. There were 46 patients without strictures and 33 
      patients with peptic strictures. Patients with strictures were older than 
      patients without strictures (mean age, 58.7 versus 48.6 years; p < 0.01), had 
      longer duration of heartburn symptoms (8.6 versus 6.4 years, p < 0.05), and were 
      more likely to have mucosal injury (50% versus 26.1%). Stricture patients were 
      more likely to use ASA/NSAIDs (63.6% versus 26.1%; p < 0.01). In particular, 
      stricture patients were more likely to use low-dose ASA than patients without 
      strictures (30.3% versus 2.2%; p < 0.01). Otherwise, there were no significant 
      differences with regard to gender, race, or heartburn duration or frequency. 
      Linear regression analysis showed that ASA/NSAID use had a greater influence on 
      the incidence of peptic strictures than age. There is an association between 
      esophageal stricture and ASA/NSAID use, which includes OTC NSAIDs and low-dose 
      ASA.
FAU - Kim, S L
AU  - Kim SL
AD  - Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA 
      30322, USA.
FAU - Hunter, J G
AU  - Hunter JG
FAU - Wo, J M
AU  - Wo JM
FAU - Davis, L P
AU  - Davis LP
FAU - Waring, J P
AU  - Waring JP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Endoscopy, Gastrointestinal
MH  - Esophageal Stenosis/*chemically induced/complications
MH  - Female
MH  - Gastroesophageal Reflux/*complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nonprescription Drugs/administration & dosage/*adverse effects
MH  - Regression Analysis
EDAT- 1999/07/15 00:00
MHDA- 1999/07/15 00:01
CRDT- 1999/07/15 00:00
PHST- 1999/07/15 00:00 [pubmed]
PHST- 1999/07/15 00:01 [medline]
PHST- 1999/07/15 00:00 [entrez]
AID - 10.1097/00004836-199907000-00008 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 1999 Jul;29(1):32-4. doi: 10.1097/00004836-199907000-00008.

PMID- 11816745
OWN - NLM
STAT- MEDLINE
DCOM- 20020130
LR  - 20131121
IS  - 0033-2240 (Print)
IS  - 0033-2240 (Linking)
VI  - 58
IP  - 6
DP  - 2001
TI  - [Aspirin esterase: biochemical and clinical aspects of aspirin catabolism].
PG  - 517-20
AB  - Aspirin, one of the most commonly used drugs, when entering human body is 
      partially subjected to autolytic degradation to salicylic acid. However, 
      hydrolytic degradation through enzymatic reaction, involving aspirin esterase is 
      much more effective. It is obvious, that native drug, aspirin (acetylsalicylic 
      acid) differs in respect of pharmacological properties from its catabolite, 
      salicylic acid, a molecule without functionally important acetyl residue. 
      Therapeutic implications of this simple esterolytic reaction are not yet fully 
      understood. The paper presents current data on the biochemistry of aspirin 
      esterase and clinical aspects of its activity.
FAU - Goździalska, A
AU  - Goździalska A
AD  - Zakład Immunochemii Klinicznej II Katedry Chorób Wewnetrznych Collegium Medicum 
      Uniwersytetu Jagiellońskiego w Krakowie.
FAU - Pajdak, W
AU  - Pajdak W
LA  - pol
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Esteraza aspirynowa--biochemiczne i kliniczne aspekty katabolizmu aspiryny.
PL  - Poland
TA  - Przegl Lek
JT  - Przeglad lekarski
JID - 19840720R
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.- (acetylsalicylic acid hydrolase)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism
MH  - Carboxylic Ester Hydrolases/biosynthesis/*metabolism
MH  - Humans
MH  - Salicylic Acid/metabolism
RF  - 45
EDAT- 2002/01/31 10:00
MHDA- 2002/01/31 10:01
CRDT- 2002/01/31 10:00
PHST- 2002/01/31 10:00 [pubmed]
PHST- 2002/01/31 10:01 [medline]
PHST- 2002/01/31 10:00 [entrez]
PST - ppublish
SO  - Przegl Lek. 2001;58(6):517-20.

PMID- 25593051
OWN - NLM
STAT- MEDLINE
DCOM- 20150317
LR  - 20150116
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 65
IP  - 2
DP  - 2015 Jan 20
TI  - Frequency and practice-level variation in inappropriate aspirin use for the 
      primary prevention of cardiovascular disease: insights from the National 
      Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence 
      registry.
PG  - 111-21
LID - S0735-1097(14)06941-1 [pii]
LID - 10.1016/j.jacc.2014.10.035 [doi]
AB  - BACKGROUND: Among patients without cardiovascular disease (CVD) and low 10-year 
      CVD risk, the risks of gastrointestinal bleeding and hemorrhagic strokes 
      associated with aspirin use outweigh any potential atheroprotective benefit. 
      According to the guidelines on primary prevention of CVD, aspirin use is 
      considered appropriate only in patients with 10-year CVD risk ≥6% and 
      inappropriate in patients with 10-year CVD risk <6%. OBJECTIVES: The goal of this 
      study was to examine the frequency and practice-level variation in inappropriate 
      aspirin use for primary prevention in a large U.S. nationwide registry. METHODS: 
      Within the National Cardiovascular Disease Registry's Practice Innovation and 
      Clinical Excellence registry, we assessed 68,808 unique patients receiving 
      aspirin for primary prevention from 119 U.S. practices. The frequency of 
      inappropriate aspirin use was determined for primary prevention (aspirin use in 
      those with 10-year CVD risk <6%). Using hierarchical regression models, the 
      extent of practice-level variation using the median rate ratio (MRR) was 
      assessed. RESULTS: Inappropriate aspirin use frequency was 11.6% (7,972 of 
      68,808) in the overall cohort. There was significant practice-level variation in 
      inappropriate use (range 0% to 71.8%; median 10.1%; interquartile range 6.4%) for 
      practices; adjusted MRR was 1.63 (95% confidence interval [CI]: 1.47 to 1.77). 
      Results remained consistent after excluding 21,052 women age ≥65 years 
      (inappropriate aspirin use 15.2%; median practice-level inappropriate aspirin use 
      13.8%; interquartile range 8.2%; adjusted MRR 1.61 [95% CI: 1.46 to 1.75]) and 
      after excluding patients with diabetes (inappropriate aspirin use 13.9%; median 
      practice-level inappropriate aspirin use 12.4%; interquartile range 7.6%; 
      adjusted MRR 1.55 [95% CI: 1.41 to 1.67]). CONCLUSIONS: More than 1 in 10 
      patients in this national registry were receiving inappropriate aspirin therapy 
      for primary prevention, with significant practice-level variations. Our findings 
      suggest that there are important opportunities to improve evidence-based aspirin 
      use for the primary prevention of CVD.
CI  - Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Hira, Ravi S
AU  - Hira RS
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas.
FAU - Kennedy, Kevin
AU  - Kennedy K
AD  - Mid America Heart Institute, Saint Luke's Hospital, Kansas City, Missouri.
FAU - Nambi, Vijay
AU  - Nambi V
AD  - Michael E. DeBakey Veteran Affairs Medical Center, Houston, Texas; Section of 
      Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
FAU - Jneid, Hani
AU  - Jneid H
AD  - Michael E. DeBakey Veteran Affairs Medical Center, Houston, Texas; Section of 
      Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
FAU - Alam, Mahboob
AU  - Alam M
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas.
FAU - Basra, Sukhdeep S
AU  - Basra SS
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas.
FAU - Ho, P Michael
AU  - Ho PM
AD  - University of Colorado, Denver, Colorado.
FAU - Deswal, Anita
AU  - Deswal A
AD  - Michael E. DeBakey Veteran Affairs Medical Center, Houston, Texas; Section of 
      Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
FAU - Ballantyne, Christie M
AU  - Ballantyne CM
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas.
FAU - Petersen, Laura A
AU  - Petersen LA
AD  - Michael E. DeBakey Veteran Affairs Medical Center, Houston, Texas; Health Policy, 
      Quality and Informatics Program, Michael E. DeBakey Veteran Affairs Medical 
      Center, Health Services Research and Development Center for Innovations, Houston, 
      Texas; Section of Health Services Research, Department of Medicine, Baylor 
      College of Medicine, Houston, Texas.
FAU - Virani, Salim S
AU  - Virani SS
AD  - Michael E. DeBakey Veteran Affairs Medical Center, Houston, Texas; Health Policy, 
      Quality and Informatics Program, Michael E. DeBakey Veteran Affairs Medical 
      Center, Health Services Research and Development Center for Innovations, Houston, 
      Texas; Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas. Electronic address: virani@bcm.edu.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2015 Jan 20;65(2):122-4. PMID: 25593052
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Confidence Intervals
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/therapeutic use
MH  - Follow-Up Studies
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention/*methods
MH  - Prospective Studies
MH  - *Registries
MH  - Risk Assessment/*methods
MH  - Risk Factors
MH  - United States/epidemiology
OTO - NOTNLM
OT  - aspirin
OT  - inappropriate
OT  - primary prevention
EDAT- 2015/01/17 06:00
MHDA- 2015/03/18 06:00
CRDT- 2015/01/17 06:00
PHST- 2014/07/30 00:00 [received]
PHST- 2014/10/01 00:00 [revised]
PHST- 2014/10/21 00:00 [accepted]
PHST- 2015/01/17 06:00 [entrez]
PHST- 2015/01/17 06:00 [pubmed]
PHST- 2015/03/18 06:00 [medline]
AID - S0735-1097(14)06941-1 [pii]
AID - 10.1016/j.jacc.2014.10.035 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2015 Jan 20;65(2):111-21. doi: 10.1016/j.jacc.2014.10.035.

PMID- 15199480
OWN - NLM
STAT- MEDLINE
DCOM- 20040722
LR  - 20131121
IS  - 1528-9648 (Print)
IS  - 1528-9648 (Linking)
VI  - 3
IP  - 2
DP  - 2003 May
TI  - Low-dose aspirin for primary prevention of cardiovascular disease.
PG  - 177-84
AB  - Progressive atherosclerosis followed by plaque rupture is the leading cause of 
      acute cardiovascular events. Inhibition of platelet aggregation by 
      acetylsalicylic acid (aspirin) reduces recurrent cardiovascular events in 
      secondary prevention trials. By extracting data from available randomized trials 
      that examined aspirin prevention in persons without previously known 
      cardiovascular disease, we evaluated the use of aspirin as a primary prevention 
      measure. Using the raw data presented in the source publication on death, fatal 
      and nonfatal myocardial infarctions, and cerebrovascular accidents, all relative 
      and absolute risk reductions were recalculated with confidence intervals. In 
      healthy men above 45 years of age, men with an increased cardiovascular risk 
      profile, and persons with diabetes mellitus or hypertension, the use of aspirin 
      reduces the incidence of myocardial infarction and has a neutral effect on 
      cerebrovascular events. The protective effect of aspirin is apparently most 
      prominent in those persons with an increased risk of manifest atherosclerotic 
      vascular disease. Notwithstanding these results, for each patient it remains 
      essential to balance the cardiovascular risk profile against the small increased 
      risk of bleeding complications when prescribing aspirin.
FAU - Bredie, Sebastian J H
AU  - Bredie SJ
AD  - Department of Medicine, University Medical Center St Radboud, Nijmegen, The 
      Netherlands. s.bredie@aig.umcn.nl
FAU - Wollersheim, Hub
AU  - Wollersheim H
FAU - Verheugt, Freek W A
AU  - Verheugt FW
FAU - Thien, Theo
AU  - Thien T
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Semin Vasc Med
JT  - Seminars in vascular medicine
JID - 100940307
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - *Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Stroke/prevention & control
EDAT- 2004/06/17 05:00
MHDA- 2004/07/23 05:00
CRDT- 2004/06/17 05:00
PHST- 2004/06/17 05:00 [pubmed]
PHST- 2004/07/23 05:00 [medline]
PHST- 2004/06/17 05:00 [entrez]
AID - 10.1055/s-2003-40675 [doi]
PST - ppublish
SO  - Semin Vasc Med. 2003 May;3(2):177-84. doi: 10.1055/s-2003-40675.

PMID- 10903927
OWN - NLM
STAT- MEDLINE
DCOM- 20000831
LR  - 20171116
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 274
IP  - 1
DP  - 2000 Jul 21
TI  - A common pathway for nitric oxide release from NO-aspirin and glyceryl 
      trinitrate.
PG  - 255-8
AB  - NO-Aspirin (NCX-4016) releases nitric oxide (NO) in biological systems through as 
      yet unidentified mechanisms. In LLC-PK1 kidney epithelial cells, a 5-h 
      pretreatment with glyceryl trinitrate (GTN, 0.1-1 microM) significantly 
      attenuated the cyclic GMP response to a subsequent challenge with both NO-aspirin 
      or GTN. Similarly, NO-aspirin (10-100 microM) was found to induce tolerance to 
      its own cyclic GMP stimulatory action and to that of GTN. In contrast, cyclic GMP 
      stimulation by the spontaneous NO donor SIN-1, which releases NO independently of 
      enzymatic catalysis, remained unimpaired in cells pretreated with GTN or 
      NO-aspirin. The observed cross-tolerance between NO-aspirin and GTN cells 
      indicates that bioactivation pathways of organic nitrates, which have been shown 
      to involve cytochrome P450, may also be responsible for NO release from 
      NO-aspirin. Prolonged treatment with NO-aspirin causes down-regulation of the 
      cellular cyclic GMP response, suggesting that tolerance may occur during therapy 
      with NO-aspirin.
CI  - Copyright 2000 Academic Press.
FAU - Grosser, N
AU  - Grosser N
AD  - Department of Pharmacology and Toxicology, School of Pharmacy, Martin Luther 
      University, Wolfgang-Langenbeck-Str. 4, Halle (Saale), 06099, Germany.
FAU - Schröder, H
AU  - Schröder H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Cyclic N-Oxides)
RN  - 0 (Free Radical Scavengers)
RN  - 0 (Imidazoles)
RN  - 0 (Nitric Oxide Donors)
RN  - 18390-00-6 (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 5O5U71P6VQ (linsidomine)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - D46583G77X (Molsidomine)
RN  - EH04H13L6B (nitroaspirin)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/metabolism
MH  - Cell Line
MH  - Cyclic GMP/metabolism
MH  - Cyclic N-Oxides/pharmacology
MH  - Cytochrome P-450 Enzyme System/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Epithelial Cells/metabolism
MH  - Free Radical Scavengers/pharmacology
MH  - Imidazoles/pharmacology
MH  - Kidney/metabolism
MH  - Molsidomine/analogs & derivatives/pharmacology
MH  - Nitric Oxide/*metabolism
MH  - Nitric Oxide Donors/pharmacology
MH  - Nitroglycerin/metabolism/*pharmacology
MH  - Protein Binding
MH  - Swine
EDAT- 2000/07/25 11:00
MHDA- 2000/09/02 11:01
CRDT- 2000/07/25 11:00
PHST- 2000/07/25 11:00 [pubmed]
PHST- 2000/09/02 11:01 [medline]
PHST- 2000/07/25 11:00 [entrez]
AID - S0006-291X(00)93121-8 [pii]
AID - 10.1006/bbrc.2000.3121 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2000 Jul 21;274(1):255-8. doi: 
      10.1006/bbrc.2000.3121.

PMID- 35014497
OWN - NLM
STAT- MEDLINE
DCOM- 20220314
LR  - 20220314
IS  - 2576-6422 (Electronic)
IS  - 2576-6422 (Linking)
VI  - 4
IP  - 2
DP  - 2021 Feb 15
TI  - Polypyrrole-Coated Mesoporous TiO(2) Nanocomposites Simultaneously Loading DOX 
      and Aspirin Prodrugs for a Synergistic Theranostic and Anti-Inflammatory Effect.
PG  - 1483-1492
LID - 10.1021/acsabm.0c01370 [doi]
AB  - Although a number of therapeutic strategies have been applied in cancer therapy, 
      treatment for cancer metastasis is challenging due to unsatisfactory cure rate 
      and easy cancer recurrence. In our work, nanocomposites (NCs) based on 
      polypyrrole-coated mesoporous TiO(2) with a suitable size are prepared through a 
      modified soft-templating strategy, which integrates double prodrugs (doxorubicin 
      (DOX) prodrug and aspirin prodrug) with superior drug loading capacity. Under 
      external stimulation of near-infrared (NIR) and ultrasound (US), the prepared 
      nanocomposites have an excellent photothermal conversion efficiency (over 50.8%) 
      and a satisfactory sonodynamic therapeutic effect, and simultaneous prodrug 
      activation and drug release occur rapidly under external stimulation. Through 
      intravenous injection, the tumor area can be clearly seen through thermal 
      imaging, benefiting from the enhanced permeability and retention (EPR) effect. 
      Through synergistic therapy, cancer cell toxicity and the tumor inhibition effect 
      are significantly enhanced. Moreover, downregulated inflammatory factors also 
      reduce the risk of cancer recurrence. In general, the designed NCs provide a 
      potential alternative for synergistic therapy as well as downregulation of 
      inflammatory cytokines.
FAU - Chen, Weijian
AU  - Chen W
AD  - State Key Laboratory of Fire Science, University of Science and Technology of 
      China, Swan Lake Road 1, Hefei 230026, Anhui, P. R. China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of 
      University of Science and Technology of China, Division of Life Sciences and 
      Medicine, University of Science and Technology of China, Huangshan Road 443, 
      Hefei 230027, Anhui, P. R. China.
FAU - Cheng, Liang
AU  - Cheng L
AD  - State Key Laboratory of Fire Science, University of Science and Technology of 
      China, Swan Lake Road 1, Hefei 230026, Anhui, P. R. China.
FAU - Du, Wenxiang
AU  - Du W
AD  - State Key Laboratory of Fire Science, University of Science and Technology of 
      China, Swan Lake Road 1, Hefei 230026, Anhui, P. R. China.
FAU - Wang, Jingwen
AU  - Wang J
AD  - State Key Laboratory of Fire Science, University of Science and Technology of 
      China, Swan Lake Road 1, Hefei 230026, Anhui, P. R. China.
FAU - Pan, Wanwan
AU  - Pan W
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of 
      University of Science and Technology of China, Division of Life Sciences and 
      Medicine, University of Science and Technology of China, Huangshan Road 443, 
      Hefei 230027, Anhui, P. R. China.
FAU - Qiu, Shuilai
AU  - Qiu S
AD  - State Key Laboratory of Fire Science, University of Science and Technology of 
      China, Swan Lake Road 1, Hefei 230026, Anhui, P. R. China.
FAU - Song, Lei
AU  - Song L
AD  - State Key Laboratory of Fire Science, University of Science and Technology of 
      China, Swan Lake Road 1, Hefei 230026, Anhui, P. R. China.
FAU - Ma, Xiaopeng
AU  - Ma X
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of 
      University of Science and Technology of China, Division of Life Sciences and 
      Medicine, University of Science and Technology of China, Huangshan Road 443, 
      Hefei 230027, Anhui, P. R. China.
FAU - Hu, Yuan
AU  - Hu Y
AUID- ORCID: 0000-0003-0753-5430
AD  - State Key Laboratory of Fire Science, University of Science and Technology of 
      China, Swan Lake Road 1, Hefei 230026, Anhui, P. R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210203
PL  - United States
TA  - ACS Appl Bio Mater
JT  - ACS applied bio materials
JID - 101729147
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Polymers)
RN  - 0 (Prodrugs)
RN  - 0 (Pyrroles)
RN  - 15FIX9V2JP (titanium dioxide)
RN  - 30604-81-0 (polypyrrole)
RN  - 80168379AG (Doxorubicin)
RN  - D1JT611TNE (Titanium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/pharmacology
MH  - Antineoplastic Agents/chemistry/pharmacology
MH  - Aspirin/chemistry/*pharmacology
MH  - Cell Line, Tumor
MH  - Doxorubicin/chemistry/*pharmacology
MH  - Drug Delivery Systems
MH  - Humans
MH  - Mice
MH  - Nanocomposites/*chemistry
MH  - Polymers/*chemistry
MH  - Precision Medicine
MH  - Prodrugs/chemistry/pharmacology
MH  - Pyrroles/*chemistry
MH  - Titanium/*chemistry
OTO - NOTNLM
OT  - anti-inflammatory effect
OT  - cancer imaging
OT  - mesoporous TiO2 (mTiO2)
OT  - polypyrrole (PPy)
OT  - synergistic therapy
EDAT- 2022/01/12 06:00
MHDA- 2022/03/15 06:00
CRDT- 2022/01/11 08:40
PHST- 2022/01/11 08:40 [entrez]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/03/15 06:00 [medline]
AID - 10.1021/acsabm.0c01370 [doi]
PST - ppublish
SO  - ACS Appl Bio Mater. 2021 Feb 15;4(2):1483-1492. doi: 10.1021/acsabm.0c01370. Epub 
      2021 Feb 3.

PMID- 23083110
OWN - NLM
STAT- MEDLINE
DCOM- 20130312
LR  - 20211021
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 72
IP  - 16
DP  - 2012 Nov 12
TI  - The evolution of antiplatelet therapy in the treatment of acute coronary 
      syndromes: from aspirin to the present day.
PG  - 2087-116
LID - 10.2165/11640880-000000000-00000 [doi]
AB  - Our knowledge of the mechanisms of platelet-mediated thrombosis has increased 
      dramatically over the last 40 years. This increased understanding has identified 
      treatment strategies for acute coronary syndromes (ACS) by targeting key 
      mediators of platelet activation and aggregation processes. Aspirin 
      (acetylsalicylic acid) monotherapy improves patient outcomes by irreversibly 
      inhibiting the cyclooxygenase (COX)-1 enzyme in the arachidonic acid pathway. The 
      later-developed thienopyridines, prodrugs that irreversibly inhibit the P2Y(12) 
      receptor, and therefore adenosine diphosphate (ADP) binding, further enhance 
      platelet inhibition and patient outcomes. The thienopyridine clopidogrel has been 
      the standard of care, but it is limited by variable response and treatment 
      failure. A more potent thienopyridine, prasugrel, requires fewer hepatic 
      metabolic steps for activation, and elicits significantly improved outcomes for 
      patients with ACS. The increased potency of prasugrel is associated with an 
      increase in Thrombolysis in Myocardial Infarction (TIMI)-defined major bleeding 
      compared with clopidogrel. Ticagrelor represents a new chemical class of agents 
      called the cyclopentyltriazolopyrimidines. It interacts reversibly with the 
      platelet P2Y(12) receptor, and does not require metabolic bioactivation for 
      activity. Data show a significant improvement in ischaemic outcomes, including 
      mortality, for ticagrelor compared with clopidogrel, without an increase in 
      overall major bleeding, although non-coronary artery bypass graft bleeding is 
      increased. Glycoprotein IIb/IIIa targeted agents (abciximab, tirofiban and 
      eptifibatide) are also used in ACS patients undergoing percutaneous coronary 
      interventions. These inhibitors utilize a different mechanism of action by 
      preventing fibrinogen-mediated platelet aggregation. Other therapeutic strategies 
      for platelet inhibition are being evaluated, including the investigative 
      protease-activated receptor (PAR)-1 and thromboxane A(2) antagonists. This review 
      highlights the mechanisms of action of these agents, and the continuing evolution 
      of ACS therapy.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - Department of Medicine, Division of Cardiology, University of Florida College of 
      Medicine-Jacksonville, Jacksonville, FL 32209, USA. 
      dominick.angiolillo@jax.ufl.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - 0 (Thienopyridines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/*pharmacology
MH  - Purinergic P2Y Receptor Antagonists/pharmacokinetics/*pharmacology
MH  - Thienopyridines/pharmacokinetics/*pharmacology
EDAT- 2012/10/23 06:00
MHDA- 2013/03/13 06:00
CRDT- 2012/10/23 06:00
PHST- 2012/10/23 06:00 [entrez]
PHST- 2012/10/23 06:00 [pubmed]
PHST- 2013/03/13 06:00 [medline]
AID - 2 [pii]
AID - 10.2165/11640880-000000000-00000 [doi]
PST - ppublish
SO  - Drugs. 2012 Nov 12;72(16):2087-116. doi: 10.2165/11640880-000000000-00000.

PMID- 26067033
OWN - NLM
STAT- MEDLINE
DCOM- 20180130
LR  - 20220321
IS  - 1473-5709 (Electronic)
IS  - 0959-8278 (Linking)
VI  - 25
IP  - 4
DP  - 2016 Jul
TI  - Meta-analysis of aspirin use and risk of lung cancer shows notable results.
PG  - 259-68
LID - 10.1097/CEJ.0000000000000176 [doi]
AB  - Aspirin is a promising agent for chemoprevention of lung cancer. We assessed the 
      association of aspirin use and the development of lung cancer, with a focus on 
      heterogeneity between studies. Databases were searched for relevant studies until 
      September 2014. Studies evaluating the relationship of aspirin use and incidence 
      of lung cancer were considered. Relative risks (RR) were extracted and a pooled 
      estimate was calculated. Heterogeneity was assessed by the I measure, 
      random-effects models, and finite-mixture models. Sources of heterogeneity were 
      investigated using a meta-regression. A decreased risk of lung cancer was found 
      including 20 studies [RR=0.87, 95% confidence interval (CI): 0.79-0.95] on the 
      basis of a random-effects model. Strong heterogeneity was observed (τ=0.0258, 
      I=74.4%). As a result, two subpopulations of studies were identified on the basis 
      of a mixture model. The first subpopulation (42%) has an average RR of 0.64. The 
      remaining subpopulation (58%) shows an RR of 1.04. Different results were found 
      for case-control (RR=0.74, 95% CI: 0.60-0.90) and cohort studies (RR=0.99, 95% 
      CI: 0.93-1.06) in a stratified analysis. In a subgroup analysis, use of aspirin 
      was associated with a decreased risk of non-small-cell lung cancer in 
      case-control studies (RR=0.74; 95% CI: 0.58-0.94). At first glance, our 
      meta-analysis shows an average protective effect. A second glance indicates that 
      there is strong heterogeneity. This leads to a subpopulation with considerable 
      benefit and another subpopulation with no benefit. For further investigations, it 
      is important to identify populations that benefit from aspirin use.
FAU - Hochmuth, Friederike
AU  - Hochmuth F
AD  - Department of Medical Statistics, Computer Sciences and Documentation, Jena 
      University Hospital, Jena, Germany.
FAU - Jochem, Maximilian
AU  - Jochem M
FAU - Schlattmann, Peter
AU  - Schlattmann P
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Cancer Prev
JT  - European journal of cancer prevention : the official journal of the European 
      Cancer Prevention Organisation (ECP)
JID - 9300837
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Databases, Factual
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Prognosis
MH  - Risk Assessment
EDAT- 2015/06/13 06:00
MHDA- 2018/01/31 06:00
CRDT- 2015/06/13 06:00
PHST- 2015/06/13 06:00 [entrez]
PHST- 2015/06/13 06:00 [pubmed]
PHST- 2018/01/31 06:00 [medline]
AID - 10.1097/CEJ.0000000000000176 [doi]
PST - ppublish
SO  - Eur J Cancer Prev. 2016 Jul;25(4):259-68. doi: 10.1097/CEJ.0000000000000176.

PMID- 25035343
OWN - NLM
STAT- MEDLINE
DCOM- 20141022
LR  - 20220311
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Print)
IS  - 1079-5642 (Linking)
VI  - 34
IP  - 9
DP  - 2014 Sep
TI  - Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin 
      on risk of cardiovascular disease.
PG  - 2160-7
LID - 10.1161/ATVBAHA.114.303845 [doi]
AB  - OBJECTIVE: Catechol-O-methyltransferase (COMT), a key enzyme in catecholamine 
      metabolism, is implicated in cardiovascular, sympathetic, and endocrine pathways. 
      This study aimed to confirm preliminary association of COMT genetic variation 
      with incident cardiovascular disease (CVD). It further aimed to evaluate whether 
      aspirin, a commonly used CVD prevention agent, modified the potential association 
      of COMT with incident CVD. APPROACH AND RESULTS: We examined COMT polymorphism 
      rs4680 (MAF [minor allele frequency], 0.47), encoding a nonsynonymous 
      methionine-to-valine substitution, in the Women's Genome Health Study (WGHS), a 
      large population-based cohort of women with randomized allocation to aspirin or 
      vitamin E when compared with placebo and 10-year follow-up. Rs4680 effects were 
      confirmed with COMT polymorphism rs4818 and also examined in Coronary ARtery 
      DIsease Genome-wide Replication and Meta-analysis/The Coronary Artery Disease 
      Genetics Consortium, consortia for genome-wide association studies of coronary 
      artery disease. Among WGHS women allocated to placebo (135 events/n=5811), the 
      rs4680 valine allele was protective against incident CVD relative to the 
      methionine (hazard ratio [HR; 95% confidence interval {CI}], 0.66 [0.51-0.84]; 
      P=0.0007); an association also observed in Coronary ARtery DIsease Genome-wide 
      Replication and Meta-analysis and The Coronary Artery Disease Genetics Consortium 
      (combined P=2.4×10(-5)). In the WGHS, the rs4680 association was abolished by 
      randomized allocation to aspirin, such that valine/valine women experienced 
      higher CVD rates with aspirin allocation when compared with placebo (HR [95% CI], 
      1.85 [1.05-3.25]; P=0.033), whereas methionine/methionine women experienced lower 
      rates (HR [95% CI], 0.60 [0.39-0.93]; P=0.023). Allocation to vitamin E also 
      conferred higher but nonsignificant CVD rates on valine/valine (HR [95% CI], 1.50 
      [0.83-2.70]; P=0.180) when compared with significantly lower rates on 
      methionine/methionine (HR [95% CI], 0.53 [0.34-0.84]; P=0.006) women. Rs4818 
      results were similar. CONCLUSIONS: Common COMT polymorphisms were associated with 
      incident CVD, and this association was modified by randomized allocation to 
      aspirin or vitamin E. Replication of these findings is required.
CI  - © 2014 American Heart Association, Inc.
FAU - Hall, Kathryn T
AU  - Hall KT
AD  - From the Program in Placebo Studies, Division of General Medicine and Primary 
      Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., 
      R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's 
      Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and 
      Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., 
      I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular 
      Sciences, Clinical Research Centre, Glenfield General Hospital, University of 
      Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, 
      Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular 
      Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical 
      Center, Harvard Medical School and Harvard School of Public Health Boston, MA 
      (M.A.M.). kthall@bidmc.harvard.edu.
FAU - Nelson, Christopher P
AU  - Nelson CP
AD  - From the Program in Placebo Studies, Division of General Medicine and Primary 
      Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., 
      R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's 
      Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and 
      Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., 
      I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular 
      Sciences, Clinical Research Centre, Glenfield General Hospital, University of 
      Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, 
      Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular 
      Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical 
      Center, Harvard Medical School and Harvard School of Public Health Boston, MA 
      (M.A.M.).
FAU - Davis, Roger B
AU  - Davis RB
AD  - From the Program in Placebo Studies, Division of General Medicine and Primary 
      Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., 
      R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's 
      Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and 
      Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., 
      I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular 
      Sciences, Clinical Research Centre, Glenfield General Hospital, University of 
      Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, 
      Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular 
      Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical 
      Center, Harvard Medical School and Harvard School of Public Health Boston, MA 
      (M.A.M.).
FAU - Buring, Julie E
AU  - Buring JE
AD  - From the Program in Placebo Studies, Division of General Medicine and Primary 
      Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., 
      R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's 
      Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and 
      Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., 
      I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular 
      Sciences, Clinical Research Centre, Glenfield General Hospital, University of 
      Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, 
      Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular 
      Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical 
      Center, Harvard Medical School and Harvard School of Public Health Boston, MA 
      (M.A.M.).
FAU - Kirsch, Irving
AU  - Kirsch I
AD  - From the Program in Placebo Studies, Division of General Medicine and Primary 
      Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., 
      R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's 
      Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and 
      Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., 
      I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular 
      Sciences, Clinical Research Centre, Glenfield General Hospital, University of 
      Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, 
      Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular 
      Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical 
      Center, Harvard Medical School and Harvard School of Public Health Boston, MA 
      (M.A.M.).
FAU - Mittleman, Murray A
AU  - Mittleman MA
AD  - From the Program in Placebo Studies, Division of General Medicine and Primary 
      Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., 
      R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's 
      Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and 
      Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., 
      I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular 
      Sciences, Clinical Research Centre, Glenfield General Hospital, University of 
      Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, 
      Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular 
      Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical 
      Center, Harvard Medical School and Harvard School of Public Health Boston, MA 
      (M.A.M.).
FAU - Loscalzo, Joseph
AU  - Loscalzo J
AD  - From the Program in Placebo Studies, Division of General Medicine and Primary 
      Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., 
      R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's 
      Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and 
      Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., 
      I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular 
      Sciences, Clinical Research Centre, Glenfield General Hospital, University of 
      Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, 
      Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular 
      Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical 
      Center, Harvard Medical School and Harvard School of Public Health Boston, MA 
      (M.A.M.).
FAU - Samani, Nilesh J
AU  - Samani NJ
AD  - From the Program in Placebo Studies, Division of General Medicine and Primary 
      Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., 
      R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's 
      Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and 
      Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., 
      I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular 
      Sciences, Clinical Research Centre, Glenfield General Hospital, University of 
      Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, 
      Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular 
      Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical 
      Center, Harvard Medical School and Harvard School of Public Health Boston, MA 
      (M.A.M.).
FAU - Ridker, Paul M
AU  - Ridker PM
AD  - From the Program in Placebo Studies, Division of General Medicine and Primary 
      Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., 
      R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's 
      Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and 
      Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., 
      I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular 
      Sciences, Clinical Research Centre, Glenfield General Hospital, University of 
      Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, 
      Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular 
      Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical 
      Center, Harvard Medical School and Harvard School of Public Health Boston, MA 
      (M.A.M.).
FAU - Kaptchuk, Ted J
AU  - Kaptchuk TJ
AD  - From the Program in Placebo Studies, Division of General Medicine and Primary 
      Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., 
      R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's 
      Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and 
      Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., 
      I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular 
      Sciences, Clinical Research Centre, Glenfield General Hospital, University of 
      Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, 
      Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular 
      Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical 
      Center, Harvard Medical School and Harvard School of Public Health Boston, MA 
      (M.A.M.).
FAU - Chasman, Daniel I
AU  - Chasman DI
AD  - From the Program in Placebo Studies, Division of General Medicine and Primary 
      Care, Department of Medicine, Beth Israel Deaconess Medical Center (K.T.H., 
      R.B.D., I.K., T.J.K.), Division of Preventative Medicine, Brigham and Women's 
      Hospital (J.E.B., P.M.R., D.I.C.), and Department of Medicine, Brigham and 
      Women's Hospital (J.L.), Harvard Medical School, Boston, MA (K.T.H., R.B.D., 
      I.K., T.J.K, J.E.B., P.M.R., D.I.C, J.L., M.A.M.); Department of Cardiovascular 
      Sciences, Clinical Research Centre, Glenfield General Hospital, University of 
      Leicester, Leicester, United Kingdom (C.P.N., N.J.S.); Department of Psychology, 
      Plymouth University, Plymouth, United Kingdom (I.K.); and Cardiovascular 
      Epidemiology Research Unit, Division of Cardiology, Beth Israel Deaconess Medical 
      Center, Harvard Medical School and Harvard School of Public Health Boston, MA 
      (M.A.M.).
LA  - eng
GR  - R01AT004662/AT/NCCIH NIH HHS/United States
GR  - K24AT004095/AT/NCCIH NIH HHS/United States
GR  - R01 HL043851/HL/NHLBI NIH HHS/United States
GR  - R01 AT004662/AT/NCCIH NIH HHS/United States
GR  - K24 AT004095/AT/NCCIH NIH HHS/United States
GR  - R01 CA047988/CA/NCI NIH HHS/United States
GR  - HL080467/HL/NHLBI NIH HHS/United States
GR  - UL1 RR025758/RR/NCRR NIH HHS/United States
GR  - UL1 RR 025758/RR/NCRR NIH HHS/United States
GR  - 3R01AT004662-02S1/AT/NCCIH NIH HHS/United States
GR  - R21AT002860/AT/NCCIH NIH HHS/United States
GR  - T32 AT000051/AT/NCCIH NIH HHS/United States
GR  - CA047988/CA/NCI NIH HHS/United States
GR  - R37 HL061795/HL/NHLBI NIH HHS/United States
GR  - R21 AT002860/AT/NCCIH NIH HHS/United States
GR  - R01 HL080467/HL/NHLBI NIH HHS/United States
GR  - T32AT000051/AT/NCCIH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140717
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 1406-18-4 (Vitamin E)
RN  - EC 2.1.1.6 (COMT protein, human)
RN  - EC 2.1.1.6 (Catechol O-Methyltransferase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acid Substitution
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/enzymology/epidemiology/genetics/*prevention & control
MH  - Catechol O-Methyltransferase/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Genome-Wide Association Study
MH  - Humans
MH  - Incidence
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Vitamin E/pharmacology/therapeutic use
PMC - PMC4148908
MID - NIHMS609168
OTO - NOTNLM
OT  - aspirin
OT  - catecholamines
OT  - vitamin E
EDAT- 2014/07/19 06:00
MHDA- 2014/10/23 06:00
CRDT- 2014/07/19 06:00
PHST- 2014/07/19 06:00 [entrez]
PHST- 2014/07/19 06:00 [pubmed]
PHST- 2014/10/23 06:00 [medline]
AID - ATVBAHA.114.303845 [pii]
AID - 10.1161/ATVBAHA.114.303845 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2160-7. doi: 
      10.1161/ATVBAHA.114.303845. Epub 2014 Jul 17.

PMID- 18493679
OWN - NLM
STAT- MEDLINE
DCOM- 20080904
LR  - 20181201
IS  - 1364-5528 (Electronic)
IS  - 0003-2654 (Linking)
VI  - 133
IP  - 6
DP  - 2008 Jun
TI  - Multivariate curve resolution of pH gradient flow injection mixture analysis with 
      correction of the Schlieren effect.
PG  - 774-83
LID - 10.1039/b719245b [doi]
AB  - Multivariate curve resolution using alternating least squares (MCR-ALS) was used 
      to quantify ascorbic (AA) and acetylsalicylic (ASA) acids in four pharmaceutical 
      samples using a flow injection analysis (FIA) system with pH gradient and a diode 
      array (DAD) spectrometer as a detector. Four different pharmaceutical drugs were 
      analyzed, giving a data array of dimensions 51 x 291 x 61, corresponding 
      respectively to number of samples, FIA times and spectral wavelengths. MCR-ALS 
      was applied to these large data sets using different constraints to have optimal 
      resolution and optimal quantitative estimations of the two analytes (AA and ASA). 
      Since both analytes give an acid-basic pair of species contributing to the UV 
      recorded signal, at least four components sholuld be proposed to model AA and ASA 
      in synthetic mixture samples. Moreover, one additional component was needed to 
      resolve accurately the Schlieren effect and another additional component was also 
      needed to model the presence of possible interferences (like caffeine) in the 
      commercial drugs tablets, giving therefore a total number of 6 independent 
      components needed. The best quantification relative errors were around 2% 
      compared to the reference values obtained by HPLC and by the oxidation-reduction 
      titrimetric method, for ASA and AA respectively. In this work, the application of 
      MCR-ALS allowed for the first time the full resolution of the FIA diffusion 
      profile due to the Schlieren effect as an independent signal contribution, 
      suggesting that the proposed MCR-ALS method allows for its accurate correction in 
      FIA-DAD systems.
FAU - Carneiro, Renato L
AU  - Carneiro RL
AD  - Universidade Estadual de Campinas, Instituto de Química, C.P. 6154, CEP, 
      13084-971, Campinas, SP, Brazil.
FAU - Braga, Jez Willian B
AU  - Braga JW
FAU - Poppi, Ronei J
AU  - Poppi RJ
FAU - Tauler, Romà
AU  - Tauler R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080313
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - 0 (Pharmaceutical Preparations)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/analysis
MH  - Aspirin/analysis
MH  - Calibration
MH  - Electronic Data Processing/*methods
MH  - *Flow Injection Analysis
MH  - Least-Squares Analysis
MH  - Multivariate Analysis
MH  - Pharmaceutical Preparations/chemistry
MH  - *Proton-Motive Force
MH  - Spectrophotometry/methods
EDAT- 2008/05/22 09:00
MHDA- 2008/09/05 09:00
CRDT- 2008/05/22 09:00
PHST- 2008/05/22 09:00 [pubmed]
PHST- 2008/09/05 09:00 [medline]
PHST- 2008/05/22 09:00 [entrez]
AID - 10.1039/b719245b [doi]
PST - ppublish
SO  - Analyst. 2008 Jun;133(6):774-83. doi: 10.1039/b719245b. Epub 2008 Mar 13.

PMID- 9656145
OWN - NLM
STAT- MEDLINE
DCOM- 19981015
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 17
IP  - 3
DP  - 1998 Jul
TI  - Assay of effervescent tablets by near-infrared spectroscopy in transmittance and 
      reflectance mode: acetylsalicylic acid in mono and combination formulations.
PG  - 365-74
AB  - Near-infrared spectroscopy (NIRS) was used to determine acetylsalicylic acid 
      (ASA) in three different effervescent tablet formulations. The nominal ASA 
      concentrations were 14.9% in the single substance formulation (ASA Mono), 17.4% 
      in the combination with ascorbic acid (ASA + C) and 8.7% in the combination with 
      paracetamol and ascorbic acid (ASA Combi). In each case the tablet matrix was 
      composed of seven excipients typical of effervescent tablets. All three 
      formulations were measured as intact tablets in diffuse transmittance and 
      reflectance and as powdered tablets in diffuse reflectance. Calibration was 
      carried out by partial least square (PLS) regression of second derivative 
      spectra. High-performance liquid chromatography (HPLC) was used as the reference 
      method. The relative standard errors of calibration (RSEC) achieved for the three 
      NIR methods were between 1.20 and 2.01% for ASA Mono, between 1.91 and 2.21% for 
      ASA + C and between 2.41 and 4.50% for ASA Combi. The results obtained in 
      transmittance mode were comparable with those obtained in reflectance mode, which 
      is normally used in NIRS. In the test sets of ASA Mono and ASA + C relative root 
      mean square (RRMS) values between 2.21 and 3.13% were obtained. The three NIR 
      methods applied are thus suitable for the quantitative determination of ASA in 
      effervescent tablets and have the advantage over HPLC of being rapid and simply 
      carried out with little sample preparation; they are nondestructive and do not 
      require any environmentally harmful reagents.
FAU - Merckle, P
AU  - Merckle P
AD  - Pharmazeutisches Institut der Universität Tübingen, Germany.
FAU - Kovar, K A
AU  - Kovar KA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/analysis
MH  - Ascorbic Acid/analysis
MH  - Aspirin/*analysis
MH  - Chemistry, Pharmaceutical
MH  - Chromatography, High Pressure Liquid/methods
MH  - Spectroscopy, Near-Infrared/*methods
MH  - Tablets/chemistry
EDAT- 1998/07/10 00:00
MHDA- 1998/07/10 00:01
CRDT- 1998/07/10 00:00
PHST- 1998/07/10 00:00 [pubmed]
PHST- 1998/07/10 00:01 [medline]
PHST- 1998/07/10 00:00 [entrez]
AID - S0731-7085(97)00194-5 [pii]
AID - 10.1016/s0731-7085(97)00194-5 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1998 Jul;17(3):365-74. doi: 10.1016/s0731-7085(97)00194-5.

PMID- 8972432
OWN - NLM
STAT- MEDLINE
DCOM- 19970318
LR  - 20131121
IS  - 0381-6605 (Print)
IS  - 0381-6605 (Linking)
VI  - 25
IP  - 6
DP  - 1996 Dec
TI  - Pentoxifylline and acetylsalicylic acid in a pig random skin-flap model.
PG  - 393-8
AB  - OBJECTIVE: Pentoxifylline has been used experimentally, and acetylsalicylic acid 
      (ASA) has been used clinically to improve skin-flap survival. This study tested 
      the efficacy of each drug in the pig random skin-flap model. METHOD: Six flaps 
      were elevated on each hypopigmented pig. After sacrifice on the seventh 
      postoperative day, percent flap survival was determined. Control data were 
      obtained from eleven pigs. Six experimental subjects were treated with 
      pentoxifylline (25 mg/kg/d); six with ASA (8 mg/kg/d); and twelve with a 
      combination of pentoxifylline and ASA (six for 7 days and six for 14 days). 
      RESULTS: The mean flap survival +/- SEM was: 58.0 +/- 4.3% for the pentoxifylline 
      group; 50.3 +/- 3.4% for the ASA group; 56.8 +/- 2.7% and 55.2 +/- 3.4% for the 
      7-day and 14-day combination groups, respectively. There was no significant 
      increase in flap survival with any of the experimental groups when compared to 
      controls (49.6 +/- 1.8%). CONCLUSION: Red blood cell flexibility and platelet 
      aggregation studies documented the expected intravascular drug effects, but did 
      not correlate well with flap survival.
FAU - Pratt, M F
AU  - Pratt MF
AD  - Department of Otolaryngology-Head and Neck Surgery, Eastern Virginia Medical 
      School, Norfolk, USA.
FAU - Williams, P B
AU  - Williams PB
LA  - eng
GR  - GM14595/GM/NIGMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Canada
TA  - J Otolaryngol
JT  - The Journal of otolaryngology
JID - 7610513
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Erythrocyte Count
MH  - *Graft Survival
MH  - Pentoxifylline/*pharmacology
MH  - Platelet Aggregation
MH  - Research Design
MH  - *Surgical Flaps
MH  - *Swine
MH  - Transplantation, Autologous
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
PST - ppublish
SO  - J Otolaryngol. 1996 Dec;25(6):393-8.

PMID- 15604423
OWN - NLM
STAT- MEDLINE
DCOM- 20051223
LR  - 20161122
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 36
IP  - 2
DP  - 2005 Feb
TI  - Biological assessment of aspirin efficacy on healthy individuals: heterogeneous 
      response or aspirin failure?
PG  - 276-80
AB  - BACKGROUND AND PURPOSE: The widespread use of aspirin requires clarification of 
      the aspirin resistance phenomenon. Most studies on this field are focused on 
      patients which may affect the action of aspirin. METHODS: We evaluated the 
      biological efficacy of aspirin in healthy subjects. RESULTS: Agonist-induced 
      platelet aggregation was fully abrogated by 100 mg of aspirin in all individuals. 
      By contrast, with the platelet function analyzer-100 device, 33.3% of the 
      subjects displayed no response. This failure was overcome by 500 mg or by in 
      vitro treatment of blood with 30 mumol/L acetylsalicylic acid. Intake of 100 mg 
      of aspirin efficiently reduced by 75% the level of 11-dehydro thromboxane B2 
      (11-dTxB2) in all cases. However, variability on the pre-aspirin level (range 
      72.4 to 625.9 ng/mmol creatinine) led to substantial differences in the residual 
      amount of the metabolite between subjects treated with aspirin (range 12.9 to 
      118.0 ng/mmol creatinine). Finally, there was no influence of platelet 
      glycoprotein IIb/IIIa (Pro33Leu), platelet glycoprotein Ia/IIa, (C807T), and 
      FXIII (Val34Leu) polymorphisms on the efficacy of aspirin. However, the 
      cyclooxygenase (Cox)-1 50T allele associated with higher level of 11-dTxB2, both 
      before and after aspirin. Moreover, the Cox-2 -765C variant displayed a slightly 
      higher reduction in 11-dTxB2 level on treatment with aspirin. CONCLUSIONS: Our 
      findings suggest that full resistance of healthy subjects to aspirin is rather 
      unlikely. However, differences in aspirin absorption, or pharmacokinetic, or 
      other unrecognized factors may lead to lack of effect of low dose of aspirin in 
      some subjects when using tests like platelet function analyzer-100. Whether Cox 
      polymorphisms are thrombotic risk factor for patients under aspirin will require 
      further research.
FAU - Gonzalez-Conejero, Rocio
AU  - Gonzalez-Conejero R
AD  - University of Murcia, Centro Regional de Hemodonación, Ronda de Garay s/n, 30003, 
      Murcia, Spain. rocio.gonzalez@carm.es
FAU - Rivera, Jose
AU  - Rivera J
FAU - Corral, Javier
AU  - Corral J
FAU - Acuña, Carmen
AU  - Acuña C
FAU - Guerrero, Jose A
AU  - Guerrero JA
FAU - Vicente, Vincente
AU  - Vicente V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20041216
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Integrin alpha2beta1)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - 9013-56-3 (Factor XIII)
RN  - AYI8EX34EU (Creatinine)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/chemistry/*pharmacology
MH  - Creatinine/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Factor XIII/chemistry
MH  - Female
MH  - Genetic Variation
MH  - Genotype
MH  - Humans
MH  - Integrin alpha2beta1/chemistry
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Platelet Function Tests
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/chemistry
MH  - Polymorphism, Genetic
MH  - Risk Factors
MH  - Thromboxane B2/analogs & derivatives/pharmacology
MH  - Time Factors
EDAT- 2004/12/18 09:00
MHDA- 2005/12/24 09:00
CRDT- 2004/12/18 09:00
PHST- 2004/12/18 09:00 [pubmed]
PHST- 2005/12/24 09:00 [medline]
PHST- 2004/12/18 09:00 [entrez]
AID - 01.STR.0000151362.65339.f9 [pii]
AID - 10.1161/01.STR.0000151362.65339.f9 [doi]
PST - ppublish
SO  - Stroke. 2005 Feb;36(2):276-80. doi: 10.1161/01.STR.0000151362.65339.f9. Epub 2004 
      Dec 16.

PMID- 6106688
OWN - NLM
STAT- MEDLINE
DCOM- 19801216
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 32
IP  - 8
DP  - 1980 Aug
TI  - Aspirin binding and the effect of albumin on spontaneous and enzyme-catalysed 
      hydrolysis.
PG  - 537-43
AB  - A method of measuring the binding of aspirin to albumin without the interference 
      of hydrolysis was developed. At concentrations of 10 mg litre-1, aspirin is about 
      85% bound to bovine serum albumin (4 g %), whereas its hydrolysis product, 
      salicylic acid, is 95% bound. Salicylic acid was shown to displace aspirin from 
      albumin binding sites. Both salicylic acid and aspirin bind more strongly to 
      bovine serum albumin than to human serum albumin at protein concentrations of 4 g 
      %. Protein binding protected aspirin against spontaneous hydrolysis although 
      protein-bound aspirin still hydrolysed at a finite rate. In contrast, albumin 
      enhanced the enzyme-catalysed hydrolysis of aspirin. By using a simple model, the 
      rate constants for the individual processes contributing to the overall 
      hydrolysis rate constant in the presence of albumin and esterase are calculated.
FAU - Aarons, L
AU  - Aarons L
FAU - Clifton, P
AU  - Clifton P
FAU - Fleming, G
AU  - Fleming G
FAU - Rowland, M
AU  - Rowland M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Serum Albumin)
RN  - 27432CM55Q (Serum Albumin, Bovine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*blood
MH  - Cattle
MH  - Humans
MH  - Hydrolysis
MH  - Kinetics
MH  - Protein Binding
MH  - Serum Albumin/metabolism
MH  - Serum Albumin, Bovine/metabolism
EDAT- 1980/08/01 00:00
MHDA- 1980/08/01 00:01
CRDT- 1980/08/01 00:00
PHST- 1980/08/01 00:00 [pubmed]
PHST- 1980/08/01 00:01 [medline]
PHST- 1980/08/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1980.tb12991.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1980 Aug;32(8):537-43. doi: 
      10.1111/j.2042-7158.1980.tb12991.x.

PMID- 10696686
OWN - NLM
STAT- MEDLINE
DCOM- 20000320
LR  - 20181130
IS  - 0012-6543 (Print)
IS  - 0012-6543 (Linking)
VI  - 37
IP  - 8
DP  - 1999 Aug
TI  - Clopidogrel and [symbol: see text] ticlopidine--improvements on aspirin?
PG  - 59-61
AB  - Clopidogrel (Plavix-Sanofi Winthrop/Bristol-Myers Squibb) and [symbol: see text] 
      ticlopidine (Ticlid-Sanofi Winthrop) are inhibitors of platelet function and are 
      promoted as potential alternatives to aspirin. Clopidogrel is licensed for the 
      secondary prevention of vascular events in patients with established 
      atherosclerotic disease. The manufacturer claims that clopidogrel is 
      "significantly more effective at reducing myocardial infarction, stroke and 
      vascular death" compared to aspirin. Ticlopidine is licensed as an alternative to 
      aspirin for secondary prevention of stroke and coronary complications in patients 
      with intermittent claudication. However, in the UK, ticlopidine is more commonly 
      used with aspirin to prevent complications following insertion of coronary stents 
      during angioplasty. We consider whether the claims for clopidogrel and the 
      current use of ticlopidine are justified.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clopidogrel
MH  - Contraindications
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stents
MH  - Ticlopidine/*analogs & derivatives/*therapeutic use
RF  - 14
EDAT- 2000/03/04 09:00
MHDA- 2000/03/25 09:00
CRDT- 2000/03/04 09:00
PHST- 2000/03/04 09:00 [pubmed]
PHST- 2000/03/25 09:00 [medline]
PHST- 2000/03/04 09:00 [entrez]
PST - ppublish
SO  - Drug Ther Bull. 1999 Aug;37(8):59-61.

PMID- 21849624
OWN - NLM
STAT- MEDLINE
DCOM- 20120116
LR  - 20211020
IS  - 1521-0103 (Electronic)
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 339
IP  - 2
DP  - 2011 Nov
TI  - Drug discontinuation effects are part of the pharmacology of a drug.
PG  - 324-8
LID - 10.1124/jpet.111.183285 [doi]
AB  - Most reviews of drug withdrawal effects focus on drugs of potential abuse such as 
      opioids, benzodiazepines, etc. Abrupt discontinuation of many other drugs used in 
      medicine cause withdrawal syndromes, some of which can be fatal. Discontinuation 
      of a number of cardiovascular drugs can increase risk of cardiovascular events 
      above that of people not taking these drugs. These include β-adrenergic receptor 
      antagonists, aspirin, HMG-CoA reductase inhibitors (statins), and heparin. 
      Rebound hypertension occurs after abrupt cessation of many antihypertensive 
      drugs. The possibility of discontinuation syndromes has usually been neglected 
      until adverse clinical events force them to be noticed. Attention to the 
      possibility of drug discontinuation effects is an important part of drug safety 
      evaluation.
FAU - Reidenberg, Marcus M
AU  - Reidenberg MM
AD  - Weill Cornell Medical College, 1300 York Ave., New York, NY 10065, USA. 
      mmreid@med.cornell.edu
LA  - eng
GR  - U18 HS016075/HS/AHRQ HHS/United States
GR  - UL1 RR024996/RR/NCRR NIH HHS/United States
GR  - 5U18HS016075/HS/AHRQ HHS/United States
GR  - UL1-RR024996/RR/NCRR NIH HHS/United States
PT  - Lecture
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20110817
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/adverse effects
MH  - Antihypertensive Agents/adverse effects/pharmacology
MH  - Aspirin/adverse effects/pharmacology
MH  - Awards and Prizes
MH  - Cardiovascular Agents/*adverse effects/pharmacology
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/pharmacology
MH  - *Substance Withdrawal Syndrome/pathology/physiopathology
PMC - PMC3200000
EDAT- 2011/08/19 06:00
MHDA- 2012/01/17 06:00
CRDT- 2011/08/19 06:00
PHST- 2011/08/19 06:00 [entrez]
PHST- 2011/08/19 06:00 [pubmed]
PHST- 2012/01/17 06:00 [medline]
AID - jpet.111.183285 [pii]
AID - 3725538 [pii]
AID - 10.1124/jpet.111.183285 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2011 Nov;339(2):324-8. doi: 10.1124/jpet.111.183285. Epub 
      2011 Aug 17.

PMID- 21627478
OWN - NLM
STAT- MEDLINE
DCOM- 20110930
LR  - 20181201
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 7
IP  - 3
DP  - 2011 May
TI  - Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.
PG  - 381-402
LID - 10.2217/fca.11.14 [doi]
AB  - Antiplatelet therapy represents the cornerstone of treatment for the short- and 
      long-term prevention of atherothrombotic disease processes, in particular in 
      high-risk settings such as in patients with acute coronary syndrome and those 
      undergoing percutaneous coronary intervention. Currently, dual antiplatelet 
      therapy with aspirin and clopidogrel represents the most commonly used treatment 
      regimen in these settings. However, a considerable number of patients continue to 
      experience adverse outcomes, including both bleeding and recurrent ischemic 
      events. Numerous investigations have demonstrated that this phenomenon may be, in 
      part, attributed to the broad variability in individual response profiles to this 
      standard antiplatelet treatment regimen, as identified by various assays of 
      platelet function testing. In addition, recent studies have demonstrated that 
      genetic polymorphisms may also have an important role in determining levels of 
      platelet inhibition and may be considered as a tool to identify patients at risk 
      of adverse events. This article provides an overview on antiplatelet drug 
      response variability, an update on definitions, including the role of 
      pharmacodynamic testing, underlying mechanisms - with emphasis on recent 
      understandings on pharmacogenetics and drug-drug interactions - and current and 
      future perspectives on individualized antiplatelet therapy.
FAU - Tello-Montoliu, Antonio
AU  - Tello-Montoliu A
AD  - University of Florida, College of Medicine-Jacksonville, Jacksonville, FL, USA.
FAU - Ueno, Masafumi
AU  - Ueno M
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Coronary Artery Disease/drug therapy/*prevention & control/therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Pharmacogenetics
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Function Tests
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
EDAT- 2011/06/02 06:00
MHDA- 2011/10/01 06:00
CRDT- 2011/06/02 06:00
PHST- 2011/06/02 06:00 [entrez]
PHST- 2011/06/02 06:00 [pubmed]
PHST- 2011/10/01 06:00 [medline]
AID - 10.2217/fca.11.14 [doi]
PST - ppublish
SO  - Future Cardiol. 2011 May;7(3):381-402. doi: 10.2217/fca.11.14.

PMID- 12914541
OWN - NLM
STAT- MEDLINE
DCOM- 20040123
LR  - 20191026
IS  - 0767-3981 (Print)
IS  - 0767-3981 (Linking)
VI  - 17
IP  - 4
DP  - 2003 Aug
TI  - Adverse effects of conventional non-steroidal anti-inflammatory drugs on the 
      upper gastrointestinal tract.
PG  - 393-403
AB  - This article reviews the clinical and epidemiological features of conventional 
      non-steroidal anti-inflammatory drug (NSAID) related peptic ulcer complications, 
      and the associated risk factors. The degree of gastrointestinal toxicity varies 
      widely between the available drugs and with dose of each. The risk of ulcer 
      complications can however be reduced, and perhaps completely removed, by using 
      the lowest dose of the least toxic member of the class. Enteric coating and other 
      delayed release formulations have not been shown to reduce risk. Estimates of the 
      imposed disease burden have varied widely, in part through assuming that risks in 
      selected patient groups will necessarily translate to the general population. 
      Nevertheless, the imposed disease burden is one of the largest associated with 
      current drug treatment. Associated risk factors such as prior ulcer, 
      corticosteroid use and concurrent aspirin as well as general cardiovascular 
      disease will raise the likelihood of an ulcer complication in NSAID takers and 
      non-takers. Therefore, strategies dependent on substituting COX-selective drugs 
      will then be only partially successful.
FAU - Langman, Michael J S
AU  - Langman MJ
AD  - Department of Medicine, Queen Elizabeth Hospital, University of Birmingham, 
      Birmingham B15 2TH, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Clinical Trials as Topic
MH  - Drug Interactions
MH  - Humans
MH  - Nonprescription Drugs/administration & dosage/adverse effects
MH  - Peptic Ulcer/*chemically induced
MH  - Risk Factors
MH  - Tablets, Enteric-Coated
RF  - 65
EDAT- 2003/08/14 05:00
MHDA- 2004/01/24 05:00
CRDT- 2003/08/14 05:00
PHST- 2003/08/14 05:00 [pubmed]
PHST- 2004/01/24 05:00 [medline]
PHST- 2003/08/14 05:00 [entrez]
AID - 179 [pii]
AID - 10.1046/j.1472-8206.2003.00179.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2003 Aug;17(4):393-403. doi: 
      10.1046/j.1472-8206.2003.00179.x.

PMID- 11794967
OWN - NLM
STAT- MEDLINE
DCOM- 20020205
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 94
IP  - 11 Suppl
DP  - 2001 Nov
TI  - [Fibrinolysis in myocardial infarction with EKG elevation. Optimization of 
      myocardial reperfusion by treatment with antithrombotic agents].
PG  - 1259-66
AB  - In the case of acute coronary syndrome with prolonged ST elevation on ECG showing 
      an acute coronary obstruction, the urgent institution of fibrinolysis is a widely 
      validated treatment. Since the first placebo controlled studies with 
      streptokinase until the development of bolus administration rt-PA varieties, 
      fibrinolytic agents have lowered mortality. Associated anti-thrombotic drugs are 
      multiplying in parallel. Their association is recognised as necessary in order to 
      avoid early reocclusions which worsen the prognosis of infarction, the 
      fibrinolysis triggering a harmful prothrombotic effect, notably due to the clot 
      thrombin re-exposed during thrombolysis. Aspirin has an essential place formally 
      demonstrated in ISIS 2. Non-fractionated heparin has more complex effects and its 
      administration protocol in association with fibrinolysis has recently been 
      reviewed with a reduction in dosage because prolonged clotting times during 
      fibrinolysis have provoked a distinct increase in the risk of intracranial 
      haemorrhage. The low molecular weight heparins seem to have become the adjuvant 
      treatment of choice following publication of the ASSENT-3 trial. Pentasaccharide 
      seems attractive. The place of hirudine and its derivatives in the acute phase of 
      MI appear limited after the results of the HERO-2 trial, associating hirulog and 
      streptokinase, with the earlier studies also having been disappointing. The 
      GPIIbIIIa blockers in association with a half dose of fibrinolysis do not 
      aggravate the intracerebral haemorrhagic risk before 75 years old and clearly 
      reduce hospital morbidity in infarction, at the price however of an increase in 
      transfusions.
FAU - Jaïs, C
AU  - Jaïs C
AD  - Service des soins intensifs, hôpital cardiologique du Haut-L'évêque, avenue 
      Magellan, 33604 Pessac.
FAU - Coste, P
AU  - Coste P
FAU - Labèque, J N
AU  - Labèque JN
FAU - Perron, J M
AU  - Perron JM
FAU - Lafitte, S
AU  - Lafitte S
FAU - Zabsonré, P
AU  - Zabsonré P
FAU - Roudaut, R
AU  - Roudaut R
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Fibrinolyse de l'infarctus du myocarde avec sus-décalage ECG. Optimisation de la 
      reperfusion myocardique par le traitement antithrombotique associé.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hirudins)
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cerebral Hemorrhage/chemically induced
MH  - Drug Costs
MH  - Electrocardiography
MH  - Fibrinolytic Agents/*pharmacology/therapeutic use
MH  - Hirudin Therapy
MH  - Hirudins/pharmacology
MH  - Myocardial Infarction/*drug therapy/pathology
MH  - *Myocardial Reperfusion
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Streptokinase/*pharmacology/therapeutic use
RF  - 35
EDAT- 2002/01/25 10:00
MHDA- 2002/02/06 10:01
CRDT- 2002/01/25 10:00
PHST- 2002/01/25 10:00 [pubmed]
PHST- 2002/02/06 10:01 [medline]
PHST- 2002/01/25 10:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1259-66.

PMID- 7955822
OWN - NLM
STAT- MEDLINE
DCOM- 19941220
LR  - 20190512
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 56
IP  - 5
DP  - 1994 Nov
TI  - Caffeine as an analgesic adjuvant in tension headache.
PG  - 576-86
AB  - Six randomized, double-blind, two-period crossover studies, conducted under 
      similar protocols, compared the efficacy of two analgesic combinations containing 
      caffeine with an acetaminophen 1000 mg control and with a placebo in outpatients 
      with episodic tension-type headaches. In four studies, comprising 1900 patients, 
      the caffeine-containing analgesic consisted of a combination of 500 mg 
      acetaminophen, 500 mg aspirin, and 130 mg caffeine (APAP/ASA/CAF). In two 
      studies, comprising 911 patients, the caffeine-containing analgesic consisted of 
      a combination of 1000 mg acetaminophen and 130 mg caffeine (APAP/CAF). Patients 
      self-medicated for moderate or severe headache pain, and with a self-rating 
      record they rated their pain and its relief hourly for 4 hours. In all six 
      studies, the caffeine-containing analgesics were significantly superior both to 
      placebo and to 1000 mg acetaminophen, and acetaminophen was significantly 
      superior to placebo. The significant analgesic adjuvant effect of caffeine was 
      independent of patients' usual caffeine use or their caffeine consumption in the 
      4 hours before medication. For each treatment, the pooled analgesic responses for 
      the four studies of APAP/ASA/CAF were virtually superimposable on the responses 
      in the two APAP/CAF studies. The combinations produced more stomach discomfort, 
      nervousness, and dizziness than acetaminophen or placebo.
FAU - Migliardi, J R
AU  - Migliardi JR
AD  - Bristol-Myers Products, Hillside, NJ 07205.
FAU - Armellino, J J
AU  - Armellino JJ
FAU - Friedman, M
AU  - Friedman M
FAU - Gillings, D B
AU  - Gillings DB
FAU - Beaver, W T
AU  - Beaver WT
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Caffeine/administration & dosage/adverse effects/*therapeutic use
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tension-Type Headache/*drug therapy
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
AID - 10.1038/clpt.1994.179 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1994 Nov;56(5):576-86. doi: 10.1038/clpt.1994.179.

PMID- 22706834
OWN - NLM
STAT- MEDLINE
DCOM- 20120620
LR  - 20220318
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 307
IP  - 21
DP  - 2012 Jun 6
TI  - Association of aspirin use with major bleeding in patients with and without 
      diabetes.
PG  - 2286-94
LID - 10.1001/jama.2012.5034 [doi]
AB  - CONTEXT: The benefit of aspirin for the primary prevention of cardiovascular 
      events is relatively small for individuals with and without diabetes. This 
      benefit could easily be offset by the risk of hemorrhage. OBJECTIVE: To determine 
      the incidence of major gastrointestinal and intracranial bleeding episodes in 
      individuals with and without diabetes taking aspirin. DESIGN, SETTING, AND 
      PARTICIPANTS: A population-based cohort study, using administrative data from 4.1 
      million citizens in 12 local health authorities in Puglia, Italy. Individuals 
      with new prescriptions for low-dose aspirin (≤300 mg) were identified during the 
      index period from January 1, 2003, to December 31, 2008, and were 
      propensity-matched on a 1-to-1 basis with individuals who did not take aspirin 
      during this period. MAIN OUTCOME MEASURES: Hospitalizations for major 
      gastrointestinal bleeding or cerebral hemorrhage occurring after the initiation 
      of antiplatelet therapy. RESULTS: There were 186,425 individuals being treated 
      with low-dose aspirin and 186,425 matched controls without aspirin use. During a 
      median follow-up of 5.7 years, the overall incidence rate of hemorrhagic events 
      was 5.58 (95% CI, 5.39-5.77) per 1000 person-years for aspirin users and 3.60 
      (95% CI, 3.48-3.72) per 1000 person-years for those without aspirin use 
      (incidence rate ratio [IRR], 1.55; 95% CI, 1.48-1.63). The use of aspirin was 
      associated with a greater risk of major bleeding in most of the subgroups 
      investigated but not in individuals with diabetes (IRR, 1.09; 95% CI, 0.97-1.22). 
      Irrespective of aspirin use, diabetes was independently associated with an 
      increased risk of major bleeding episodes (IRR, 1.36; 95% CI, 1.28-1.44). 
      CONCLUSIONS: In a population-based cohort, aspirin use was significantly 
      associated with an increased risk of major gastrointestinal or cerebral bleeding 
      episodes. Patients with diabetes had a high rate of bleeding that was not 
      independently associated with aspirin use.
FAU - De Berardis, Giorgia
AU  - De Berardis G
AD  - Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, 
      S. Maria Imbaro, Italy.
FAU - Lucisano, Giuseppe
AU  - Lucisano G
FAU - D'Ettorre, Antonio
AU  - D'Ettorre A
FAU - Pellegrini, Fabio
AU  - Pellegrini F
FAU - Lepore, Vito
AU  - Lepore V
FAU - Tognoni, Gianni
AU  - Tognoni G
FAU - Nicolucci, Antonio
AU  - Nicolucci A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2012 Jun 6;307(21):2318-20. PMID: 22706838
CIN - Nat Rev Endocrinol. 2012 Aug;8(8):442. PMID: 22733263
CIN - JAMA. 2012 Sep 19;308(11):1088-9; author reply 1090. PMID: 22990257
CIN - JAMA. 2012 Sep 19;308(11):1089-90; author reply 1090. PMID: 22990258
CIN - Evid Based Nurs. 2013 Apr;16(2):55-6. PMID: 23144009
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - *Diabetes Mellitus
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Intracranial Hemorrhages/*chemically induced/epidemiology
MH  - Italy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Risk
EDAT- 2012/06/19 06:00
MHDA- 2012/06/21 06:00
CRDT- 2012/06/19 06:00
PHST- 2012/06/19 06:00 [entrez]
PHST- 2012/06/19 06:00 [pubmed]
PHST- 2012/06/21 06:00 [medline]
AID - 1172042 [pii]
AID - 10.1001/jama.2012.5034 [doi]
PST - ppublish
SO  - JAMA. 2012 Jun 6;307(21):2286-94. doi: 10.1001/jama.2012.5034.

PMID- 26587647
OWN - NLM
STAT- MEDLINE
DCOM- 20160928
LR  - 20220331
IS  - 1662-2804 (Electronic)
IS  - 0300-5186 (Linking)
VI  - 37
DP  - 2015
TI  - Emergency Reversal Strategies for Anticoagulation and Platelet Disorders.
PG  - 51-61
LID - 10.1159/000437113 [doi]
AB  - Bleeding is the most important adverse effect of antithrombotic treatment and may 
      be a major cause of morbidity, longstanding debilitation, and even mortality. In 
      the case of severe hemorrhage in a patient who uses anticoagulant agents, it may 
      be crucial to reverse anticoagulant treatment. Conventional anticoagulants such 
      as vitamin K antagonists can be neutralized by the administration of vitamin K or 
      prothrombin complex concentrates, whereas heparin and heparin derivatives can be 
      counteracted by protamine sulfate. The antihemostatic effect of aspirin and other 
      antiplatelet strategies can be corrected by the administration of platelet 
      concentrate and/or desmopressin. Recently, a new generation of anticoagulants 
      with a greater specificity toward activated coagulation factors as well as new 
      antiplatelet agents have been introduced, and these drugs show efficacy and 
      safety profiles that are at least as good as those of conventional agents in 
      clinical studies. A limitation of these new agents may be the lack of a specific 
      strategy to reverse their effects if a bleeding event occurs, although 
      experimental studies show encouraging results for some of these agents.
CI  - © 2016 S. Karger AG, Basel.
FAU - Levi, Marcel
AU  - Levi M
AD  - Department of Vascular Medicine and Department of Medicine, Academic Medical 
      Center, University of Amsterdam, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20151112
PL  - Switzerland
TA  - Front Neurol Neurosci
JT  - Frontiers of neurology and neuroscience
JID - 101274949
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Hemorrhage/*drug therapy
MH  - Heparin/pharmacology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2015/11/21 06:00
MHDA- 2016/09/30 06:00
CRDT- 2015/11/21 06:00
PHST- 2015/11/21 06:00 [entrez]
PHST- 2015/11/21 06:00 [pubmed]
PHST- 2016/09/30 06:00 [medline]
AID - 000437113 [pii]
AID - 10.1159/000437113 [doi]
PST - ppublish
SO  - Front Neurol Neurosci. 2015;37:51-61. doi: 10.1159/000437113. Epub 2015 Nov 12.

PMID- 2206782
OWN - NLM
STAT- MEDLINE
DCOM- 19901121
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 30
IP  - 2
DP  - 1990 Aug
TI  - Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits 
      platelet aggregation in human whole blood ex vivo.
PG  - 179-86
AB  - 1. In a randomized, double-blind trial we compared the inhibition of the 
      platelet-vessel wall interactions in whole blood ex vivo. There were four groups 
      of 24 healthy volunteers each of whom were treated orally for 3.5 days with 
      either 200 mg dipyridamole (sustained release preparation), 25 mg acetylsalicylic 
      acid, both drugs combined or placebo twice daily. 2. The mean area of all 
      platelets/aggregates was reduced by 6.2% +/- 4.2% (+/- s.e. mean) by placebo (n = 
      23), 19.8% +/- 6.7% by dipyridamole (n = 22), 53.7% +/- 4.9% by acetylsalicylic 
      acid (n = 23) and 71.4% +/- 3.7% by the combination of both drugs (n = 24), when 
      compared with total inhibition of aggregation by EGTA. Thus, low-dose 
      acetylsalicylic acid inhibited aggregation (P less than 0.001). 3. Dipyridamole 
      reduced the size of platelet aggregates (P less than 0.01, two-fold analysis of 
      variance). The reduction was correlated with the individual dipyridamole plasma 
      levels (P less than 0.05, analysis of covariance). The subgroup of large and very 
      large thrombi being formed was also reduced by dipyridamole (P less than 0.05). 
      4. This ex vivo study demonstrates that dipyridamole alone inhibits formation of 
      thrombi on subendothelial matrix and enhances the inhibitory effect of low dose 
      acetylsalicylic acid in this model of thrombosis.
FAU - Müller, T H
AU  - Müller TH
AD  - Department of Research, Dr K. Thomae GmbH, Biberach, FRG.
FAU - Su, C A
AU  - Su CA
FAU - Weisenberger, H
AU  - Weisenberger H
FAU - Brickl, R
AU  - Brickl R
FAU - Nehmiz, G
AU  - Nehmiz G
FAU - Eisert, W G
AU  - Eisert WG
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br J Clin Pharmacol. 1990 Aug;30(2):175-7. PMID: 2206781
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Dipyridamole/blood/*pharmacology
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Endothelium, Vascular/cytology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Malondialdehyde/blood
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Thrombosis/prevention & control
PMC - PMC1368216
EDAT- 1990/08/01 00:00
MHDA- 1990/08/01 00:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 1990/08/01 00:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1990.tb03763.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1990 Aug;30(2):179-86. doi: 
      10.1111/j.1365-2125.1990.tb03763.x.

PMID- 31545683
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20200617
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 140
IP  - 13
DP  - 2019 Sep 24
TI  - Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular 
      Disease.
PG  - 1115-1124
LID - 10.1161/CIRCULATIONAHA.119.040205 [doi]
AB  - Aspirin is the cornerstone of the antithrombotic management of patients with 
      established atherosclerotic cardiovascular disease, but major guidelines provide 
      conflicting recommendations for its use in primary prevention. Findings from 
      recent randomized trials totaling >47 000 patients called into question the net 
      clinical benefits of aspirin in primary prevention for 3 key populations: 
      patients with diabetes mellitus, community-dwelling elderly individuals, and 
      patients without diabetes mellitus who are at intermediate risk for 
      atherosclerotic events. In the context of increasing emphasis on the use of other 
      treatments for primary prevention in patients with moderate-high future risk of 
      developing atherosclerotic cardiovascular disease, the efficacy and safety of 
      aspirin for primary prevention has become uncertain. Key unresolved questions 
      regarding the role of aspirin in primary prevention include the optimal drug 
      formulation, dosing schedule, weight-based dose selection, and interplay between 
      sex and treatment response. In the current era, most patients without established 
      atherosclerotic cardiovascular disease should not be prescribed aspirin. Rather, 
      aggressive management of comorbidities tailored to the expected cardiovascular 
      risk needs to be emphasized. In this context, informed shared decision making 
      between clinicians and patients regarding the use of aspirin for primary 
      prevention of cardiovascular events is a suitable and laudable approach. In this 
      article, we revisit the role of aspirin for the primary prevention of 
      cardiovascular diseases by critically reviewing the key scientific literature, 
      highlight key areas of uncertainties for future research, and propose a 
      decisional framework for clinicians to support prescription of aspirin in primary 
      prevention.
FAU - Marquis-Gravel, Guillaume
AU  - Marquis-Gravel G
AD  - Duke Clinical Research Institute, Durham, NC (G.M.G., M.T.R., A.F.H., W.S.J.).
FAU - Roe, Matthew T
AU  - Roe MT
AD  - Duke Clinical Research Institute, Durham, NC (G.M.G., M.T.R., A.F.H., W.S.J.).
AD  - Duke University Medical Center, Durham, NC (M.T.R., A.F.H., W.S.J.).
FAU - Harrington, Robert A
AU  - Harrington RA
AD  - Division of Cardiovascular Medicine; Cardiovascular Research Institute; 
      Department of Medicine, Stanford University, California (R.A.H.).
FAU - Muñoz, Daniel
AU  - Muñoz D
AD  - Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 
      Nashville, TN (D.M.).
FAU - Hernandez, Adrian F
AU  - Hernandez AF
AD  - Duke Clinical Research Institute, Durham, NC (G.M.G., M.T.R., A.F.H., W.S.J.).
AD  - Duke University Medical Center, Durham, NC (M.T.R., A.F.H., W.S.J.).
FAU - Jones, W Schuyler
AU  - Jones WS
AD  - Duke Clinical Research Institute, Durham, NC (G.M.G., M.T.R., A.F.H., W.S.J.).
AD  - Duke University Medical Center, Durham, NC (M.T.R., A.F.H., W.S.J.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190923
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Decision-Making
MH  - Clinical Protocols
MH  - Clinical Trials as Topic
MH  - Drug Dosage Calculations
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Primary Prevention
MH  - Risk
MH  - Risk Factors
OTO - NOTNLM
OT  - antiplatelets
OT  - aspirin
OT  - atherosclerotic cardiovascular diseases
OT  - cardiovascular diseases
OT  - primary prevention
EDAT- 2019/09/24 06:00
MHDA- 2020/06/18 06:00
CRDT- 2019/09/24 06:00
PHST- 2019/09/24 06:00 [entrez]
PHST- 2019/09/24 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 10.1161/CIRCULATIONAHA.119.040205 [doi]
PST - ppublish
SO  - Circulation. 2019 Sep 24;140(13):1115-1124. doi: 
      10.1161/CIRCULATIONAHA.119.040205. Epub 2019 Sep 23.

PMID- 17481713
OWN - NLM
STAT- MEDLINE
DCOM- 20070927
LR  - 20131121
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 120
IP  - 2
DP  - 2007 Aug
TI  - The relationship between historical aspirin-induced asthma and severity of asthma 
      induced during oral aspirin challenges.
PG  - 273-7
AB  - BACKGROUND: Historical aspirin- or nonsteroidal anti-inflammatory drug 
      (NSAID)-induced reactions might provide predictive information about the severity 
      of reactions in patients with aspirin-exacerbated respiratory disease (AERD) 
      undergoing oral aspirin challenge (OAC). OBJECTIVE: We sought to assess the 
      relationship between historical aspirin- or NSAID-induced bronchial reactions and 
      the severity of bronchial reactions during OAC in patients with AERD. METHODS: 
      Data regarding the provoking doses, treatments, and treatment settings of 
      historical aspirin/NSAID-induced reactions were recorded, analyzed, and compared 
      with the provoking doses, maintenance regimens, and observed decreases in FEV(1) 
      that occurred during OAC in 210 consecutive patients referred with suspected 
      AERD. RESULTS: Of 147 patients who reported seeking acute medical care for their 
      historical aspirin/NSAID-induced asthma attacks, 101 (69%) were treated in an 
      emergency department and released, and 46 (31%) required hospitalization. During 
      OAC in these 147 subjects, 23 (16%) had a 20% to 29% decrease and 14 (10%) had a 
      30% or greater decrease in FEV(1) values from baseline. Of the 46 patients 
      previously hospitalized for aspirin/NSAID-induced asthma attacks, 9 (20%) had a 
      20% to 29% decrease and 6 (13%) had a 30% or greater decrease in FEV(1) during 
      OAC. By contrast, of the 63 patients who treated their prior 
      aspirin/NSAID-induced reactions at home, 5 (8%) had a 20% to 29% decrease and 5 
      (8%) had a 30% or greater decrease in FEV(1) during OAC (P = not significant for 
      both). CONCLUSION: The severity of the historical aspirin/NSAID-induced asthma 
      attack was not predictive of asthma severity during OAC. CLINICAL IMPLICATIONS: 
      These data provide further reassurance regarding the safety of outpatient aspirin 
      desensitization.
FAU - Williams, Adam N
AU  - Williams AN
AD  - Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, CA 92130, 
      USA. a.williams33@yahoo.com .
FAU - Simon, Ronald A
AU  - Simon RA
FAU - Woessner, Katharine M
AU  - Woessner KM
FAU - Stevenson, Donald D
AU  - Stevenson DD
LA  - eng
PT  - Journal Article
DEP - 20070503
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/*physiopathology/therapy
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Forced Expiratory Volume
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - *Medical Records
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Severity of Illness Index
EDAT- 2007/05/08 09:00
MHDA- 2007/09/28 09:00
CRDT- 2007/05/08 09:00
PHST- 2007/02/09 00:00 [received]
PHST- 2007/03/20 00:00 [revised]
PHST- 2007/03/22 00:00 [accepted]
PHST- 2007/05/08 09:00 [pubmed]
PHST- 2007/09/28 09:00 [medline]
PHST- 2007/05/08 09:00 [entrez]
AID - S0091-6749(07)00621-5 [pii]
AID - 10.1016/j.jaci.2007.03.020 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2007 Aug;120(2):273-7. doi: 10.1016/j.jaci.2007.03.020. 
      Epub 2007 May 3.

PMID- 33618686
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20210303
IS  - 1471-2482 (Electronic)
IS  - 1471-2482 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Feb 22
TI  - Effect of platelet inhibition with perioperative aspirin on survival in patients 
      undergoing curative resection for pancreatic cancer: a propensity score matched 
      analysis.
PG  - 98
LID - 10.1186/s12893-021-01083-9 [doi]
LID - 98
AB  - BACKGROUND: The importance of platelets in the pathogenesis of metastasis 
      formation is increasingly recognized. Although evidence from epidemiologic 
      studies suggests positive effects of aspirin on metastasis formation, there is 
      little clinical data on the perioperative use of this drug in pancreatic cancer 
      patients. METHODS: From all patients who received curative intent surgery for 
      pancreatic cancer between 2014 and 2016 at our institution, we identified 18 
      patients that took aspirin at time of admission and continued to throughout the 
      inpatient period. Using propensity score matching, we selected a control group of 
      64 patients without aspirin intake from our database and assessed the effect of 
      aspirin medication on overall, disease-free, and hematogenous metastasis-free 
      survival intervals as endpoints. RESULTS: Aspirin intake proved to be 
      independently associated with improved mean overall survival (OS) (46.5 vs. 
      24.6 months, *p = 0.006), median disease-free survival (DFS) (26 vs. 10.5 months, 
      *p = 0.001) and mean hematogenous metastasis-free survival (HMFS) (41.9 vs. 
      16.3 months, *p = 0.005). Three-year survival rates were 61.1% in patients with 
      aspirin intake vs. 26.3% in patients without aspirin intake. Multivariate cox 
      regression showed significant independent association of aspirin with all three 
      survival endpoints with hazard ratios of 0.36 (95% CI 0.15-0.86) for OS 
      (*p = 0.021), 0.32 (95% CI 0.16-0.63) for DFS (**p = 0.001), and 0.36 (95% CI 
      0.16-0.77) for HMFS (*p = 0.009). CONCLUSIONS: Patients in our retrospective, 
      propensity-score matched study showed significantly better overall survival when 
      taking aspirin while undergoing curative surgery for pancreatic cancer. This was 
      mainly due to a prolonged metastasis-free interval following surgery.
FAU - Pretzsch, E
AU  - Pretzsch E
AD  - Department of General, Visceral, and Transplant Surgery, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - D'Haese, J G
AU  - D'Haese JG
AD  - Department of General, Visceral, and Transplant Surgery, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Renz, B
AU  - Renz B
AD  - Department of General, Visceral, and Transplant Surgery, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Ilmer, M
AU  - Ilmer M
AD  - Department of General, Visceral, and Transplant Surgery, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Schiergens, T
AU  - Schiergens T
AD  - Department of General, Visceral, and Transplant Surgery, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Miksch, R C
AU  - Miksch RC
AD  - Department of General, Visceral, and Transplant Surgery, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Albertsmeier, M
AU  - Albertsmeier M
AD  - Department of General, Visceral, and Transplant Surgery, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Guba, M
AU  - Guba M
AD  - Department of General, Visceral, and Transplant Surgery, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Angele, M K
AU  - Angele MK
AD  - Department of General, Visceral, and Transplant Surgery, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Werner, J
AU  - Werner J
AD  - Department of General, Visceral, and Transplant Surgery, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Nieß, H
AU  - Nieß H
AD  - Department of General, Visceral, and Transplant Surgery, 
      Ludwig-Maximilians-University Munich, Munich, Germany. 
      Hanno.niess@med.uni-muenchen.de.
LA  - eng
PT  - Journal Article
DEP - 20210222
PL  - England
TA  - BMC Surg
JT  - BMC surgery
JID - 100968567
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Humans
MH  - *Pancreatic Neoplasms/surgery
MH  - Perioperative Care
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
PMC - PMC7901208
OTO - NOTNLM
OT  - Actylsalicylic acid
OT  - Adjuvant aspirin
OT  - Circulating tumor cells
OT  - Micrometastasis
OT  - Pancreatic surgery
COIS- The authors declare that they have no competing interests.
EDAT- 2021/02/24 06:00
MHDA- 2021/02/25 06:00
CRDT- 2021/02/23 05:39
PHST- 2020/09/30 00:00 [received]
PHST- 2021/02/01 00:00 [accepted]
PHST- 2021/02/23 05:39 [entrez]
PHST- 2021/02/24 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
AID - 10.1186/s12893-021-01083-9 [pii]
AID - 1083 [pii]
AID - 10.1186/s12893-021-01083-9 [doi]
PST - epublish
SO  - BMC Surg. 2021 Feb 22;21(1):98. doi: 10.1186/s12893-021-01083-9.

PMID- 1391458
OWN - NLM
STAT- MEDLINE
DCOM- 19921118
LR  - 20191028
IS  - 1055-7172 (Print)
IS  - 1055-7172 (Linking)
VI  - 20
IP  - 2-4
DP  - 1992
TI  - Preparation and characterization of diaspirin cross-linked hemoglobin solutions 
      for preclinical studies.
PG  - 423-7
AB  - During 1990 and 1991 the capability for repetitive, consecutive production of 
      DCLHb solution to meet a rigorous and complete set of product criteria was 
      demonstrated. In addition, through periodic monitoring of product stored under 
      controlled conditions, the stability of all lots of DCLHb solution during frozen 
      storage was demonstrated for more than a year. In this way, assurance was 
      provided that the DCLHb solution used in preclinical testing met all product 
      criteria throughout the biological testing period.
FAU - Nelson, D
AU  - Nelson D
AD  - Blood Substitutes Program, Baxter Healthcare Corporation, Los Angeles, CA.
FAU - Azari, M
AU  - Azari M
FAU - Brown, R
AU  - Brown R
FAU - Burhop, K
AU  - Burhop K
FAU - Bush, S
AU  - Bush S
FAU - Catarello, J
AU  - Catarello J
FAU - Chuang, H
AU  - Chuang H
FAU - Downing, C
AU  - Downing C
FAU - Estep, T
AU  - Estep T
FAU - Loewen, A
AU  - Loewen A
AU  - et al.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biomater Artif Cells Immobilization Biotechnol
JT  - Biomaterials, artificial cells, and immobilization biotechnology : official 
      journal of the International Society for Artificial Cells and Immobilization 
      Biotechnology
JID - 9111988
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Solutions)
RN  - 578-19-8 (succinyldisalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives
MH  - Blood Substitutes/*isolation & purification
MH  - Cross-Linking Reagents
MH  - Drug Evaluation, Preclinical
MH  - Drug Stability
MH  - Hemoglobins/*isolation & purification
MH  - Humans
MH  - Solutions
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.3109/10731199209119662 [doi]
PST - ppublish
SO  - Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):423-7. doi: 
      10.3109/10731199209119662.

PMID- 2932858
OWN - NLM
STAT- MEDLINE
DCOM- 19851125
LR  - 20131121
IS  - 0043-5341 (Print)
IS  - 0043-5341 (Linking)
VI  - 135
IP  - 15-16
DP  - 1985 Aug 31
TI  - [Percutaneous transluminal recanalization of chronic stenoses and occlusions of 
      peripheral arteries].
PG  - 384-92
AB  - It is reported on indications and results of percutaneous transluminal 
      angioplasty using the Grüntzig- and Olbert-type balloon catheter technique. It is 
      also referred to the expansion of PTA to the treatment of multiple obliterations 
      in different layers with vascular surgical procedures. Today the essential 
      indications for PTA are iliac stenoses on one or both sides, stenoses of the 
      femoral and popliteal artery as well as short occlusions of the superficial 
      femoral and popliteal artery of less than 10 cm.
FAU - Zeitler, E
AU  - Zeitler E
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Die perkutane transluminale Rekanalisation chronischer Stenosen und Verschlüsse 
      peripherer Arterien.
PL  - Austria
TA  - Wien Med Wochenschr
JT  - Wiener medizinische Wochenschrift (1946)
JID - 8708475
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiography
MH  - *Angioplasty, Balloon
MH  - Arterial Occlusive Diseases/diagnosis/*therapy
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Femoral Artery
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Iliac Artery
MH  - Pelvis/blood supply
MH  - Popliteal Artery
EDAT- 1985/08/31 00:00
MHDA- 1985/08/31 00:01
CRDT- 1985/08/31 00:00
PHST- 1985/08/31 00:00 [pubmed]
PHST- 1985/08/31 00:01 [medline]
PHST- 1985/08/31 00:00 [entrez]
PST - ppublish
SO  - Wien Med Wochenschr. 1985 Aug 31;135(15-16):384-92.

PMID- 2627171
OWN - NLM
STAT- MEDLINE
DCOM- 19900405
LR  - 20191210
IS  - 0389-4118 (Print)
IS  - 0389-4118 (Linking)
VI  - 24
IP  - 6
DP  - 1989 Dec
TI  - [Ethanol-induced discriminative stimulus properties in inbred rats with reference 
      to aspirin, indomethacin and desipramine].
PG  - 490-503
AB  - It is known that ethanol (EtOH) possesses discriminative stimulus (DS) effects, 
      but there has been no report on the effects of aspirin, indomethacin and 
      desipramine on the DS properties of EtOH. Lewis (LEW) and Fischer 344 (F344) rats 
      weighing approximately 80% of free-fed animals were used. In the training 
      process, EtOH (600 and 1200 mg/kg) or saline was administered i.p. once a day 5 
      min prior to beginning of the session according to the following sequence: 
      EtOH-EtOH-saline-saline, under a fixed ratio ten (FR10) schedule. Discriminative 
      test was performed in each animal after the discriminative response had achieved 
      both the two criteria: (1) First Food Pellet (FFP) was below 12 responses and (2) 
      the correct response rate was above 80%. There was no difference in session 
      number to get to the criteria in the discrimination process between LEW and F344. 
      Pentobarbital (PBA) well generalized to EtOH in both strains. The EtOH dose for 
      50% correct responses (FD50) was lower in F344 than in LEW. However, the ED50 for 
      PBA was lower in LEW than in F344. There may be differences in sensitivity to 
      EtOH and PBA. Dose response curve was not affected by pretreatment with aspirin, 
      indomethacin and desipramine. These results suggest that aspirin, indomethacin 
      and desipramine may not markedly affect in EtOH discriminative stimulus effects 
      in LEW and F344 rats.
FAU - Suzuki, T
AU  - Suzuki T
FAU - Shiozaki, Y
AU  - Shiozaki Y
FAU - Misawa, M
AU  - Misawa M
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Arukoru Kenkyuto Yakubutsu Ison
JT  - Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug 
      dependence
JID - 8213278
RN  - I4744080IR (Pentobarbital)
RN  - R16CO5Y76E (Aspirin)
RN  - TG537D343B (Desipramine)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Desipramine/*pharmacology
MH  - Discrimination, Psychological/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Pentobarbital/pharmacology
MH  - Rats
MH  - Rats, Inbred F344
MH  - Rats, Inbred Lew
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
PST - ppublish
SO  - Arukoru Kenkyuto Yakubutsu Ison. 1989 Dec;24(6):490-503.

PMID- 33257413
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20220622
IS  - 1759-8486 (Electronic)
IS  - 1759-8478 (Linking)
VI  - 13
IP  - 9
DP  - 2021 Sep
TI  - Effect of bodyweight on VerifyNow Aspirin platelet function test: a retrospective 
      review.
PG  - 831-834
LID - 10.1136/neurintsurg-2020-016842 [doi]
AB  - BACKGROUND: Antiplatelet therapy is used to prevent stent thrombosis in 
      intracranial stents, but the optimal dose of aspirin is unknown. This study 
      sought to determine whether the degree of platelet inhibition with aspirin is 
      affected by bodyweight as observed through a platelet reactivity assay. METHODS: 
      This is a retrospective review of patients who underwent neurovascular stent 
      placement and had a VerifyNow Aspirin assay result. The primary outcome was the 
      correlation between the VerifyNow Aspirin result, bodyweight, and the initial 
      dose of aspirin. Secondary outcomes included the impact of the VerifyNow P2Y12 
      result and of weight on the incidence of bleeding or a thrombotic event. RESULTS: 
      Of the 142 included patients, 62.7% weighed ≥70 kg and 88.7% were initiated on 
      aspirin 300-325 mg daily. 83.8% achieved a therapeutic VerifyNow Aspirin result. 
      There was minimal correlation between the VerifyNow Aspirin result, bodyweight, 
      and aspirin dose (R(2)=0.02). Between patients who weighed <70 kg versus ≥70 kg, 
      there was no difference in the mean aspirin reaction units (ARU) (449 vs 435, 
      p=0.32) or in the incidence of bleeding (28% vs 17.1%, p=0.14) or a thrombotic 
      event (4% vs 5.3%, p=0.59). No patient experienced stent thrombosis and eight 
      patients experienced in-stent stenosis. In a multivariate analysis, only the 
      VerifyNow P2Y12 result predicted the development of either bleeding or a 
      thrombotic event (p<0.01). CONCLUSIONS: Bodyweight did not influence the 
      likelihood of obtaining a therapeutic VerifyNow Aspirin result. The clinical 
      utility of obtaining VerifyNow Aspirin assays for this patient population is 
      unknown.
CI  - © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Sandler, Melissa
AU  - Sandler M
AUID- ORCID: 0000-0001-9392-2271
AD  - Harborview Medical Center, Seattle, Washington, USA.
FAU - Hoang, Cuong
AU  - Hoang C
AD  - Harborview Medical Center, Seattle, Washington, USA hoangvic@uw.edu.
FAU - Mak, Hannah Y
AU  - Mak HY
AD  - Harborview Medical Center, Seattle, Washington, USA.
FAU - Levitt, Michael R
AU  - Levitt MR
AUID- ORCID: 0000-0003-3612-3347
AD  - Neurological Surgery, University of Washington School of Medicine, Seattle, 
      Washington, USA.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - England
TA  - J Neurointerv Surg
JT  - Journal of neurointerventional surgery
JID - 101517079
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Neurointerv Surg. 2022 Jul;14(7):640-641. PMID: 34750108
MH  - *Aspirin/adverse effects
MH  - Blood Platelets
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Platelet Function Tests
MH  - Retrospective Studies
MH  - *Ticlopidine
OTO - NOTNLM
OT  - aneurysm
OT  - pharmacology
OT  - platelets
COIS- Competing interests: Dr Levitt reports grants from Stryker, Medtronic, and 
      Philips Volcano and others from Metis Innovative, Synchron, Cerebrotech, and 
      eLoupes outside the submitted work.
EDAT- 2020/12/02 06:00
MHDA- 2021/08/21 06:00
CRDT- 2020/12/01 05:54
PHST- 2020/09/09 00:00 [received]
PHST- 2020/11/12 00:00 [revised]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
PHST- 2020/12/01 05:54 [entrez]
AID - neurintsurg-2020-016842 [pii]
AID - 10.1136/neurintsurg-2020-016842 [doi]
PST - ppublish
SO  - J Neurointerv Surg. 2021 Sep;13(9):831-834. doi: 10.1136/neurintsurg-2020-016842. 
      Epub 2020 Nov 30.

PMID- 4574642
OWN - NLM
STAT- MEDLINE
DCOM- 19730719
LR  - 20190501
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Print)
IS  - 0003-9888 (Linking)
VI  - 48
IP  - 4
DP  - 1973 Apr
TI  - Study of antipyretic therapy in current use.
PG  - 313-5
AB  - Several commonly used antipyretic therapies were compared in a series of 67 
      children. All regimens were more effective than exposure alone. Paracetamol and 
      aspirin were comparable in antipyretic effect and superior to tepid sponging 
      alone. The addition of tepid sponging to paracetamol therapy did not further 
      improve the antipyretic response.
FAU - Hunter, J
AU  - Hunter J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
RN  - 0 (Placebos)
RN  - 059QF0KO0R (Water)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Body Temperature
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Fever/drug therapy/*therapy
MH  - Humans
MH  - Infant
MH  - Placebos
MH  - Time Factors
MH  - Water
PMC - PMC1648350
EDAT- 1973/04/01 00:00
MHDA- 1973/04/01 00:01
CRDT- 1973/04/01 00:00
PHST- 1973/04/01 00:00 [pubmed]
PHST- 1973/04/01 00:01 [medline]
PHST- 1973/04/01 00:00 [entrez]
AID - 10.1136/adc.48.4.313 [doi]
PST - ppublish
SO  - Arch Dis Child. 1973 Apr;48(4):313-5. doi: 10.1136/adc.48.4.313.

PMID- 21241362
OWN - NLM
STAT- MEDLINE
DCOM- 20120709
LR  - 20181201
IS  - 1472-8206 (Electronic)
IS  - 0767-3981 (Linking)
VI  - 26
IP  - 2
DP  - 2012 Apr
TI  - Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced 
      tolerance by associated diseases and drugs.
PG  - 307-13
LID - 10.1111/j.1472-8206.2010.00915.x [doi]
AB  - To assess the conditions of prescriptions and tolerance of antiplatelet drugs 
      (APD) in the elderly and to detail the parameters that influence the tolerance of 
      these drugs. Prospective survey in a Department of Geriatric Medicine. Two 
      hundred nineteen patients 70 years and older treated with one or two APD prior to 
      admission were included during 7 months in 2008. We recorded the type of APD, 
      associated diseases, main associated or co-prescribed drugs which could interact 
      with APD and the bleeding adverse events including cutaneous bleeding. The mean 
      age of the 219 patients was 84.5 ± 6.7 years (70-101 years), women 59.4%. Among 
      patients 64.8% received aspirin (mainly 75 mg), 28.3% received clopidogrel and 
      6.8% received their combination; 16.9% of prescriptions were off-label; 51.6% of 
      patients had an associated disease and/or an associated drug which could have 
      increased risk of bleeding event. Among the patients who received a 
      gastric-protective drug, the prescription followed the recommendations of the 
      French Health Authority in 38.9%. We recorded bleeding events in 24.2% of 
      patients at admission and in 18.3% of patients during the hospitalization. 
      Bleeding events were significantly more frequent in patients treated with aspirin 
      than clopidogrel (40.8 vs. 24.2%, P < 0.05) and/or with an associated drug (OR = 
      2.36, 95% CI 1.34-4.14, P < 0.01) and/or an associated disease (OR = 1.22, 95% CI 
      1.01-3.42, P < 0.05). APD treatment was stopped in 28.8% of patients, mainly 
      because lack of indication or bleeding adverse events. Off-label prescriptions of 
      APD were not rare in the elderly, and adverse events are frequent. The results of 
      this preliminary study evoke that medical situations at increased risk of 
      bleeding are perhaps insufficiently evaluated, either in case of prescription of 
      associated drugs with increased bleeding risk or during the follow-up of patients 
      with associated diseases. Cutaneous bleeding events should be more taken into 
      account in prospective studies.
CI  - © 2011 The Authors Fundamental and Clinical Pharmacology © 2011 Société Française 
      de Pharmacologie et de Thérapeutique.
FAU - Cadiou, Gwénaëlle
AU  - Cadiou G
AD  - Service de Médecine Interne Gériatrique, Centre Hospitalo-Universitaire de Rouen, 
      Rouen University Hospital, Rouen F-76031, France.
FAU - Adam, Magali
AU  - Adam M
FAU - Caussin, Marie
AU  - Caussin M
FAU - Landrin, Isabelle
AU  - Landrin I
FAU - Mariette, Natacha
AU  - Mariette N
FAU - Capet, Corinne
AU  - Capet C
FAU - Mouton-Schleifer, Dominique
AU  - Mouton-Schleifer D
FAU - Remy, Elise
AU  - Remy E
FAU - Kadri, Nadir
AU  - Kadri N
FAU - Doucet, Jean
AU  - Doucet J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110118
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - France
MH  - Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Off-Label Use/*statistics & numerical data
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Practice Patterns, Physicians'/standards/*statistics & numerical data
MH  - Prospective Studies
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & 
      derivatives/therapeutic use
EDAT- 2011/01/19 06:00
MHDA- 2012/07/10 06:00
CRDT- 2011/01/19 06:00
PHST- 2011/01/19 06:00 [entrez]
PHST- 2011/01/19 06:00 [pubmed]
PHST- 2012/07/10 06:00 [medline]
AID - 10.1111/j.1472-8206.2010.00915.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2012 Apr;26(2):307-13. doi: 
      10.1111/j.1472-8206.2010.00915.x. Epub 2011 Jan 18.

PMID- 22024267
OWN - NLM
STAT- MEDLINE
DCOM- 20120224
LR  - 20131121
IS  - 1553-4669 (Electronic)
IS  - 1553-4650 (Linking)
VI  - 18
IP  - 6
DP  - 2011 Nov-Dec
TI  - Treatment of endometriosis with local acetylsalicylic acid injection: 
      experimental study in rabbits.
PG  - 800-6
LID - 10.1016/j.jmig.2011.08.721 [doi]
AB  - The objective of the present study was to estimate the effects of introduction of 
      acetylsalicylic acid solution into peritoneal implants in autologous endometrium 
      as a method for treating endometriosis. Forty adult female rabbits were 
      subdivided into 4 groups of 10 rabbits each, and endometriosis was induced via 
      autotransplantation of endometrial fragments into the peritoneal cavity. At 30 
      days after induction of endometriosis, all animals were randomly assigned to 1 of 
      2 protocols. In protocol 1, animals were evaluated at 24 hours after treatment; 
      group 1 (control) received physiologic solution, and group 2 received 
      acetylsalicylic acid. In protocol 2, animals were evaluated at 10 days after 
      treatment, group 3 (control) and group 4 received acetylsalicylic acid. After 
      measuring the lesion, the endometriotic focus was removed and prepared for 
      mounting on slides for histologic analysis. Imaging software was used for 
      analysis of the total remaining area of endometrial tissue. The affected area in 
      acetylsalicylic acid-treated animals was smaller than that in control animals at 
      24 hours and 10 days after treatment; a significant difference was found between 
      control and treated groups (p < .001). Statistical analysis comparing protocols 1 
      and 2 demonstrated no differences between controls groups or acetylsalicylic acid 
      groups (p = .30), and no differences between times (p = .75). Acetylsalicylic 
      acid solution led to less growth (or higher involution) of endometrial implants. 
      Acetylsalicylic acid injected directly into endometriotic foci was effective in 
      their destruction. This presents new perspectives for treatment of endometriosis 
      and for clinical applications based on further clinical studies.
CI  - Copyright © 2011 AAGL. Published by Elsevier Inc. All rights reserved.
FAU - Siqueira, Juliana Menezes
AU  - Siqueira JM
AD  - Department of Surgery, Botucatu Medical School, Sao Paulo State University 
      (UNESP), Botucatu, São Paulo, Brazil.
FAU - Barreto, Adriana Beatriz
AU  - Barreto AB
FAU - Saad-Hossne, Rogério
AU  - Saad-Hossne R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Minim Invasive Gynecol
JT  - Journal of minimally invasive gynecology
JID - 101235322
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Endometriosis/*drug therapy/pathology
MH  - Endometrium/drug effects/pathology
MH  - Female
MH  - Peritoneal Diseases/*drug therapy
MH  - Peritoneum/drug effects/pathology
MH  - Rabbits
MH  - Treatment Outcome
EDAT- 2011/10/26 06:00
MHDA- 2012/03/01 06:00
CRDT- 2011/10/26 06:00
PHST- 2011/06/29 00:00 [received]
PHST- 2011/08/19 00:00 [revised]
PHST- 2011/08/24 00:00 [accepted]
PHST- 2011/10/26 06:00 [entrez]
PHST- 2011/10/26 06:00 [pubmed]
PHST- 2012/03/01 06:00 [medline]
AID - S1553-4650(11)01178-2 [pii]
AID - 10.1016/j.jmig.2011.08.721 [doi]
PST - ppublish
SO  - J Minim Invasive Gynecol. 2011 Nov-Dec;18(6):800-6. doi: 
      10.1016/j.jmig.2011.08.721.

PMID- 19491018
OWN - NLM
STAT- MEDLINE
DCOM- 20090824
LR  - 20131121
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 37
IP  - 3-4
DP  - 2009 Jun 28
TI  - Towards determining appropriate hydrodynamic conditions for in vitro in vivo 
      correlations using computational fluid dynamics.
PG  - 291-9
LID - 10.1016/j.ejps.2009.02.016 [doi]
AB  - One of the earliest level A in vitro dissolution in vivo absorption correlations 
      (IVIVCs) was established by Levy and co-workers in 1965 using a beaker 
      dissolution apparatus Levy et al., 1965. In the current work, the computational 
      fluid dynamics (CFD) package, Fluent((R)), was used to simulate the hydrodynamics 
      within the Levy beaker apparatus and compare them to those within the paddle and 
      basket apparatuses. In vitro velocity values relevant to in vivo dissolution, 
      presented as apparent gastrointestinal fluid velocity (AGV) values, were 
      calculated. The AGV values were estimated from IVIVCs of immediate release (IR) 
      dosage forms in each apparatus and CFD simulations. The simulations from the Levy 
      apparatus revealed complex hydrodynamics in the region of the stirrer blades, and 
      radial inflow at the centre of the beaker base. The calculated AGV values ranged 
      from 0.001 to 0.026ms(-1). In vitro fluid velocities should reflect in vivo 
      dissolution rates affected by natural convection and gastrointestinal motility, 
      in addition to local fluid velocity. The maximum CFD generated velocity at the 
      base of the paddle apparatus at 20rpm was similar to the average maximum AGV 
      value determined, suggesting use of agitation rates which are lower than those 
      commonly used (e.g. 50rpm in the paddle apparatus) may be appropriate when 
      attempting an IVIVC for IR dosage forms.
FAU - D'Arcy, Deirdre M
AU  - D'Arcy DM
AD  - School of Pharmacy and Pharmaceutical Sciences, University of Dublin, Trinity 
      College, Dublin 2, Ireland. ddarcy@tcd.ie
FAU - Healy, Anne Marie
AU  - Healy AM
FAU - Corrigan, Owen I
AU  - Corrigan OI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090306
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 059QF0KO0R (Water)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacokinetics
MH  - Aspirin/administration & dosage/pharmacokinetics
MH  - Body Fluids/physiology
MH  - Chemistry, Pharmaceutical/*methods
MH  - Computer Simulation
MH  - Gastrointestinal Motility
MH  - Gastrointestinal Tract/physiology
MH  - Kinetics
MH  - Reproducibility of Results
MH  - Solubility
MH  - Water
EDAT- 2009/06/06 09:00
MHDA- 2009/08/25 09:00
CRDT- 2009/06/04 09:00
PHST- 2008/04/07 00:00 [received]
PHST- 2009/01/30 00:00 [revised]
PHST- 2009/02/23 00:00 [accepted]
PHST- 2009/06/04 09:00 [entrez]
PHST- 2009/06/06 09:00 [pubmed]
PHST- 2009/08/25 09:00 [medline]
AID - S0928-0987(09)00066-9 [pii]
AID - 10.1016/j.ejps.2009.02.016 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2009 Jun 28;37(3-4):291-9. doi: 10.1016/j.ejps.2009.02.016. Epub 
      2009 Mar 6.

PMID- 11914655
OWN - NLM
STAT- MEDLINE
DCOM- 20030731
LR  - 20190916
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 13
IP  - 2
DP  - 2002 Mar
TI  - Evaluation of the blood coagulation mechanism and platelet aggregation in 
      individuals with mechanical or biological heart prostheses.
PG  - 129-34
AB  - Oral anticoagulants have been widely employed to decrease thrombotic risk by 
      reducing the levels of vitamin K-dependent clotting factors. Paradoxically, the 
      use of oral anticoagulants also decreases the levels of natural anticoagulants 
      (protein C and protein S), which favors the hypercoagulability state. Increased 
      platelet activation has been reported in patients undergoing warfarin treatment. 
      These findings have raised questions about the antagonistic effect of oral 
      anticoagulants and their implications for hemostatic balance. The aim of this 
      study is to determine the relationship between warfarin dosage and prothrombin 
      time [International Normalized Ratio (INR)], platelet aggregation, vitamin 
      K-dependent clotting factors, and protein C and protein S. Blood samples from 27 
      patients were analyzed, seven with mechanical prostheses and 20 with biological 
      prostheses, and 27 controls. Multiple regression analysis showed that factor II 
      most significantly determines the INR. Results showed that the INR, clotting 
      factors, and protein C and protein S activity did not correlate with warfarin 
      dosage, highlighting the need for accurate laboratory monitoring of those 
      undergoing anticoagulant therapy.
FAU - Ferreira, C N
AU  - Ferreira CN
AD  - Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal 
      University of Minas Gerais, Brazil.
FAU - Vieira, L M
AU  - Vieira LM
FAU - Dusse, L M S
AU  - Dusse LM
FAU - Reis, C V
AU  - Reis CV
FAU - Amaral, C F S
AU  - Amaral CF
FAU - Esteves, W A M
AU  - Esteves WA
FAU - Fenelon, L M A
AU  - Fenelon LM
FAU - Carvalho, M G
AU  - Carvalho MG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Anticoagulants)
RN  - 0 (Blood Coagulation Factor Inhibitors)
RN  - 0 (Blood Coagulation Factors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Coagulation/drug effects/*physiology
MH  - Blood Coagulation Factor Inhibitors/metabolism
MH  - Blood Coagulation Factors/metabolism
MH  - Blood Coagulation Tests
MH  - Case-Control Studies
MH  - Drug Evaluation
MH  - Female
MH  - Heart Valve Prosthesis/*adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects/*physiology
MH  - Warfarin/pharmacology/therapeutic use
EDAT- 2002/03/27 10:00
MHDA- 2003/08/02 05:00
CRDT- 2002/03/27 10:00
PHST- 2002/03/27 10:00 [pubmed]
PHST- 2003/08/02 05:00 [medline]
PHST- 2002/03/27 10:00 [entrez]
AID - 10.1097/00001721-200203000-00008 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2002 Mar;13(2):129-34. doi: 
      10.1097/00001721-200203000-00008.

PMID- 3033625
OWN - NLM
STAT- MEDLINE
DCOM- 19870528
LR  - 20190903
IS  - 0901-9928 (Print)
IS  - 0901-9928 (Linking)
VI  - 60
IP  - 2
DP  - 1987 Feb
TI  - Studies on the effect of different inhibitors of arachidonic acid metabolism on 
      glyceryltrinitrate-induced relaxation and cGMP elevation in bovine vascular 
      tissue.
PG  - 110-6
AB  - This study was performed in order to investigate the possible involvement of 
      arachidonic acid metabolites in the mediation of glyceryltrinitrate (GTN)-induced 
      relaxation in isolated bovine mesenteric artery (BMA) and vein (BMV) and in 
      bovine coronary artery (BCA). Concentration-effect curves for GTN were 
      established on the different types of vessels, precontracted with 2.5 microM 
      phenylephrine (BMA) or K+-depolarization (BMV and BCA), in the presence or 
      absence of different inhibitors of the arachidonic acid metabolism. The used 
      inhibitors of arachidonic acid metabolism were: 10 microM quinacrine (a 
      phospholipase A2 inhibitor), 100 microM acetylsalicylic acid, 20 microM 
      indomethacin (cyclooxygenase inhibitors), 3 mM tranylcypromine (inhibitor of PGI2 
      synthesis), 50 microM nordihydroguairetic acid and 40 microM BW 755C 
      (lipoxygenase inhibitors). In addition, SKF 525A (10 microM) was tested on BMA; 
      this agent is considered to block the cytochrome P450-dependent monooxygenase 
      pathway. The effect on the endogenous levels of cyclic nucleotides after 
      treatment with some of the inhibitors were also measured. Quinacrine and 
      acetylsalicylic acid had no statistical significant effect (P greater than 0.05) 
      on the pD2-value for GTN-induced relaxation in BMA, BMV and BCA. The results 
      obtained with indomethacin were very variable. This drug was almost completely 
      without effect on the GTN induced relaxation in BCA. In BMA a significant 
      potentiation of the relaxant response was obtained (P = 0.002), while in BMV a 
      significant inhibition was seen (P = 0.049).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Bornfeldt, K E
AU  - Bornfeldt KE
FAU - Axelsson, K L
AU  - Axelsson KL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Pharmacol Toxicol
JT  - Pharmacology & toxicology
JID - 8702180
RN  - 0 (Arachidonic Acids)
RN  - 0 (Neuromuscular Depolarizing Agents)
RN  - 1WS297W6MV (Phenylephrine)
RN  - 3E3V44J4Z9 (Tranylcypromine)
RN  - 7BO8G1BYQU (Masoprocol)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - H0C805XYDE (Quinacrine)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acids/*metabolism
MH  - Aspirin/metabolism/pharmacology
MH  - Blood Vessels/*drug effects/metabolism
MH  - Cattle
MH  - Cyclic GMP/*metabolism
MH  - In Vitro Techniques
MH  - Masoprocol/pharmacology
MH  - Muscle Contraction/*drug effects
MH  - Muscle Relaxation/*drug effects
MH  - Neuromuscular Depolarizing Agents/pharmacology
MH  - Nitroglycerin/*pharmacology
MH  - Phenylephrine/pharmacology
MH  - Quinacrine/metabolism/pharmacology
MH  - Tranylcypromine/pharmacology
EDAT- 1987/02/01 00:00
MHDA- 1987/02/01 00:01
CRDT- 1987/02/01 00:00
PHST- 1987/02/01 00:00 [pubmed]
PHST- 1987/02/01 00:01 [medline]
PHST- 1987/02/01 00:00 [entrez]
AID - 10.1111/j.1600-0773.1987.tb01507.x [doi]
PST - ppublish
SO  - Pharmacol Toxicol. 1987 Feb;60(2):110-6. doi: 10.1111/j.1600-0773.1987.tb01507.x.

PMID- 8559383
OWN - NLM
STAT- MEDLINE
DCOM- 19960223
LR  - 20190514
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 46
IP  - 1
DP  - 1996 Jan
TI  - Differential effect of aspirin versus warfarin on clinical stroke types in 
      patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation 
      Investigators.
PG  - 238-40
AB  - The Stroke Prevention in Atrial Fibrillation II study compared the efficacy and 
      safety of aspirin and warfarin in patients with atrial fibrillation. Three 
      neurologists, blinded to patient therapy, categorized the pathophysiology of 
      ischemic strokes that occurred in the trial based on predetermined clinical 
      criteria. Upon analyzing the patients being treated with these two drugs, 
      warfarin proved significantly more effective than aspirin in preventing 
      cardioembolic strokes (p = 0.005) and strokes of uncertain pathophysiology (p = 
      0.01). There was no significant difference in the efficacy for prevention of 
      noncardioembolic strokes.
FAU - Miller, V T
AU  - Miller VT
AD  - Statistics and Epidemiology Research Corporation, Seattle, WA 98105, USA.
FAU - Pearce, L A
AU  - Pearce LA
FAU - Feinberg, W M
AU  - Feinberg WM
FAU - Rothrock, J F
AU  - Rothrock JF
FAU - Anderson, D C
AU  - Anderson DC
FAU - Hart, R G
AU  - Hart RG
LA  - eng
GR  - R01-NS-24224/NS/NINDS NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Cerebrovascular Disorders/complications/*drug therapy
MH  - Humans
MH  - Warfarin/*therapeutic use
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1212/wnl.46.1.238 [doi]
PST - ppublish
SO  - Neurology. 1996 Jan;46(1):238-40. doi: 10.1212/wnl.46.1.238.

PMID- 19760979
OWN - NLM
STAT- MEDLINE
DCOM- 20091029
LR  - 20131121
IS  - 0172-6390 (Print)
IS  - 0172-6390 (Linking)
VI  - 56
IP  - 93
DP  - 2009 Jul-Aug
TI  - Correlation between serum triglycerides and gastro-duodenal ulcer associated with 
      low-dose aspirin.
PG  - 1241-4
AB  - BACKGROUND/AIMS: Aspirin significantly increases the risk of peptic ulcer. Since 
      it remains to be determined whether gastroprotective agents should be used 
      routinely in patients without risk factors who are taking aspirin, more risk 
      factors for aspirin-related peptic ulcer should be detected. In the present study 
      was investigated the effects of aspirin on upper gastrointestinal ulcer and 
      potent risk factor for peptic ulcer associated with aspirin in a case-control 
      study. METHODOLOGY: It was identified 137 newly diagnosed gastroduodenal ulcer 
      cases from endoscopic examinees in the Gunma Prefectural Cardiovascular Center. 
      Two controls per case were selected according to sex and age, and we determined 
      274 controls. It was calculated OR and 95% CI of peptic ulcer for serum 
      triglycerides. RESULTS: The use of low-dose aspirin without gastroprotective 
      agents was found to be associated with the risk of peptic ulcer. High serum 
      triglycerides were associated only with aspirin-related peptic ulcer. In 
      contrast, no elevated OR of peptic ulcer was shown in cases without aspirin. 
      CONCLUSIONS: The present study results suggest that hypertriglycerides might be 
      one of the risk factors for peptic ulcer caused by aspirin. These findings 
      indicate that gastroprotective therapy should be considered for preventing peptic 
      ulcer associated with low-dose aspirin in patients with hypertriglyceridemia.
FAU - Fujii, Takaaki
AU  - Fujii T
AD  - Department of General Surgical Science, Graduate School of Medicine, Gunma 
      University 3-39-15 Showa-machi, Maebashi, Gunma 371-8511, Japan. 
      ftakaaki@med.gunma-u.ac.jp
FAU - Nakabayashi, Toshihiro
AU  - Nakabayashi T
FAU - Hashimoto, Shinji
AU  - Hashimoto S
FAU - Kuwano, Hiroyuki
AU  - Kuwano H
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Hepatogastroenterology
JT  - Hepato-gastroenterology
JID - 8007849
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Triglycerides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Duodenal Ulcer/*blood/*chemically induced
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Triglycerides/*blood
EDAT- 2009/09/19 06:00
MHDA- 2009/10/30 06:00
CRDT- 2009/09/19 06:00
PHST- 2009/09/19 06:00 [entrez]
PHST- 2009/09/19 06:00 [pubmed]
PHST- 2009/10/30 06:00 [medline]
PST - ppublish
SO  - Hepatogastroenterology. 2009 Jul-Aug;56(93):1241-4.

PMID- 24420365
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20181202
IS  - 1873-734X (Electronic)
IS  - 1010-7940 (Linking)
VI  - 46
IP  - 2
DP  - 2014 Aug
TI  - Perioperative outcomes of cardiac surgery patients with ongoing ticagrelor 
      therapy: boon and bane of a new drug.
PG  - 198-205
LID - 10.1093/ejcts/ezt571 [doi]
AB  - OBJECTIVES: Ticagrelor (Brilique®) is a novel reversible platelet inhibitor at 
      P2Y12 receptor used in patients with acute coronary syndrome and patients 
      undergoing percutaneous coronary interventions. Unlike clopidogrel (Plavix®), 
      ticagrelor has a quicker offset of action, and therefore, it seems that platelet 
      function recovers faster on discontinuation of therapy. These drugs sometimes 
      cannot be stopped before coronary artery bypass grafting due to the risk of stent 
      thrombosis or in case of emergency operations. Therefore, we investigated whether 
      the continued preoperative use of ticagrelor influences the perioperative course 
      of cardiac surgical patients. METHODS: The perioperative course and clinical 
      outcomes of patients preoperatively receiving ticagrelor + acetylsalicylic acid 
      (ASA) (n = 32) or clopidogrel + ASA (n = 49) until cardiac surgery, performed at 
      University of Goettingen between January 2012 and December 2012, were studied. 
      The study was designed as a retrospective observational study. The observation 
      period started with the surgery and ended after 3 days. P < 0.05 was considered 
      statistically significant. RESULTS: Preoperative data and intraoperative 
      characteristics were almost similar among the groups. In the first 24 h, the 
      median blood loss was 850 [780-1600] ml in the ticagrelor group and 680 [400-860] 
      ml in the clopidogrel group (P = 0.0006). Furthermore, the median red blood cell 
      transfusion (P = 0.0031), the median pooled platelet transfusion (P = 0.0012), 
      the median prothrombin complex concentrate use (P = 0.0114) and the median 
      fibrinogen use (P = 0.0118) were significantly higher in the ticagrelor group 
      compared with the clopidogrel group. However, there was no statistical 
      significance between the two groups regarding intensive care unit and hospital 
      stay, mechanical ventilation time, incidence of acute kidney injury and 
      mortality. Hence, a tendency towards more rethoracotomies due to bleeding in the 
      ticagrelor group was observed (P = 0.0632). CONCLUSIONS: In cardiac surgical 
      patients who are treated with ticagrelor + ASA until surgery, ticagrelor therapy 
      is associated with a significantly higher blood loss, a significantly higher use 
      of blood products and coagulation factors and higher incidence of rethoracotomies 
      for bleeding compared with patients treated with clopidogrel + ASA.
CI  - © The Author 2014. Published by Oxford University Press on behalf of the European 
      Association for Cardio-Thoracic Surgery. All rights reserved.
FAU - Schotola, Hanna
AU  - Schotola H
AD  - Department of Anesthesiology, Emergency and Intensive Care Medicine, 
      Georg-August-University Goettingen, Goettingen, Germany 
      hschotola@med.uni-goettingen.de.
FAU - Bräuer, Anselm
AU  - Bräuer A
AD  - Department of Anesthesiology, Emergency and Intensive Care Medicine, 
      Georg-August-University Goettingen, Goettingen, Germany.
FAU - Meyer, Katharina
AU  - Meyer K
AD  - Department of Anesthesiology, Emergency and Intensive Care Medicine, 
      Georg-August-University Goettingen, Goettingen, Germany.
FAU - Hinz, José
AU  - Hinz J
AD  - Department of Anesthesiology, Emergency and Intensive Care Medicine, 
      Georg-August-University Goettingen, Goettingen, Germany.
FAU - Schöndube, Friedrich Albert
AU  - Schöndube FA
AD  - Department of Thoracic and Cardiovascular Surgery, Georg-August-University 
      Goettingen, Goettingen, Germany.
FAU - Bauer, Martin
AU  - Bauer M
AD  - Department of Anesthesiology, Emergency and Intensive Care Medicine, 
      Georg-August-University Goettingen, Goettingen, Germany.
FAU - Mohite, Prashant Nanasaheb
AU  - Mohite PN
AD  - Department of Cardiothoracic Transplantation and Mechanical Support, Brompton and 
      Harefield Hospital, Harefield, London, UK.
FAU - Danner, Bernd Christoph
AU  - Danner BC
AD  - Department of Thoracic and Cardiovascular Surgery, Georg-August-University 
      Goettingen, Goettingen, Germany.
FAU - Sossalla, Samuel
AU  - Sossalla S
AD  - Department of Cardiology and Respiratory Medicine, Georg-August-University 
      Goettingen, Goettingen, Germany.
FAU - Popov, Aron Frederik
AU  - Popov AF
AD  - Department of Thoracic and Cardiovascular Surgery, Georg-August-University 
      Goettingen, Goettingen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20140112
PL  - Germany
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European 
      Association for Cardio-thoracic Surgery
JID - 8804069
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur J Cardiothorac Surg. 2014 Aug;46(2):205-6. PMID: 24412829
MH  - Adenosine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Blood Transfusion/statistics & numerical data
MH  - Coronary Artery Bypass/*statistics & numerical data
MH  - Female
MH  - Hemorrhage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Perioperative Period/*statistics & numerical data
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/*therapeutic use
MH  - Retrospective Studies
MH  - Ticagrelor
MH  - Treatment Outcome
OTO - NOTNLM
OT  - CABG
OT  - Continued ticagrelor application
OT  - Perioperative outcome
EDAT- 2014/01/15 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/01/15 06:00
PHST- 2014/01/15 06:00 [entrez]
PHST- 2014/01/15 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - ezt571 [pii]
AID - 10.1093/ejcts/ezt571 [doi]
PST - ppublish
SO  - Eur J Cardiothorac Surg. 2014 Aug;46(2):198-205. doi: 10.1093/ejcts/ezt571. Epub 
      2014 Jan 12.

PMID- 17971645
OWN - NLM
STAT- MEDLINE
DCOM- 20080102
LR  - 20131121
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 24 Suppl 1
DP  - 2007
TI  - Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral 
      ischaemia: which is the best for which patient?
PG  - 107-11
AB  - In this paper, an overview is given of trials with oral anticoagulants and 
      dipyridamole in the secondary prevention after transient ischaemic attack or 
      minor stroke. In patients with atrial fibrillation, the secondary preventive 
      treatment of first choice is oral anticoagulation with an aimed international 
      normalised ratio between 2.0 and 3.0. In patients without a cardiac source of 
      embolism, a combination therapy of low-dose aspirin and dipyridamole 200 mg twice 
      daily is the treatment of choice. These treatment strategies do however not 
      prevent all recurrent strokes or vascular complications, and research for more 
      effective strategies is warranted.
CI  - Copyright 2007 S. Karger AG, Basel.
FAU - Halkes, P H A
AU  - Halkes PH
AD  - Department of Neurology, Rudolf Magnus Institute of Neuroscience, Utrecht, The 
      Netherlands.
FAU - Algra, A
AU  - Algra A
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20071101
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Brain Ischemia/*prevention & control
MH  - Dipyridamole/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/prevention & control
RF  - 28
EDAT- 2007/11/29 09:00
MHDA- 2008/01/03 09:00
CRDT- 2007/11/29 09:00
PHST- 2007/11/29 09:00 [pubmed]
PHST- 2008/01/03 09:00 [medline]
PHST- 2007/11/29 09:00 [entrez]
AID - 000107385 [pii]
AID - 10.1159/000107385 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2007;24 Suppl 1:107-11. doi: 10.1159/000107385. Epub 2007 Nov 1.

PMID- 29708890
OWN - NLM
STAT- MEDLINE
DCOM- 20190808
LR  - 20190808
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 33
IP  - 4
DP  - 2018 Jul
TI  - Antithrombotic drugs in cardiovascular medicine: a year in review.
PG  - 369-374
LID - 10.1097/HCO.0000000000000530 [doi]
AB  - PURPOSE OF REVIEW: To provide an up to date review of the most recent randomized 
      clinical trials in the field of antithrombotic drugs for cardiovascular diseases. 
      RECENT FINDINGS: In 2017, low-dose anti-Xa treatment added to aspirin proved to 
      be more efficacious than either treatment alone in patients with stable 
      atherosclerotic disease despite the increase in nonfatal bleeding events. 
      Furthermore, anticoagulation strategy during coronary interventions was again 
      tested in a registry-based trial and showed comparable efficacy and safety 
      between heparin alone and bivalirudin. Data from safety trials demonstrated lower 
      risk of bleeding with dual antithrombotic therapy compared with triple 
      antithrombotic therapy following coronary intervention, albeit these trials were 
      underpowered for efficacy. Although still in its infancy, the role of 
      antithrombotic treatment following transcatheter aortic valve replacement (TAVR) 
      has been investigated in small trials with evidence that a single antiplatelet 
      drug may be noninferior to dual antiplatelet therapy with a better safety 
      profile. SUMMARY: In this review, we discuss the most recent clinical trials 
      investigating antithrombotic drugs for cardiovascular diseases published in 2017.
FAU - Ibrahim, Homam
AU  - Ibrahim H
AD  - Department of Internal Medicine, University of Utah.
AD  - George E. Wahlen VAMC, Salt Lake City, Utah, USA.
FAU - Rondina, Matthew
AU  - Rondina M
AD  - Department of Internal Medicine, University of Utah.
AD  - George E. Wahlen VAMC, Salt Lake City, Utah, USA.
FAU - Welt, Frederick G P
AU  - Welt FGP
AD  - Department of Internal Medicine, University of Utah.
AD  - George E. Wahlen VAMC, Salt Lake City, Utah, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Drug Therapy, Combination
MH  - Factor Xa Inhibitors/*therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Percutaneous Coronary Intervention
MH  - Randomized Controlled Trials as Topic
MH  - Transcatheter Aortic Valve Replacement
EDAT- 2018/05/01 06:00
MHDA- 2019/08/09 06:00
CRDT- 2018/05/01 06:00
PHST- 2018/05/01 06:00 [pubmed]
PHST- 2019/08/09 06:00 [medline]
PHST- 2018/05/01 06:00 [entrez]
AID - 10.1097/HCO.0000000000000530 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2018 Jul;33(4):369-374. doi: 10.1097/HCO.0000000000000530.

PMID- 6375873
OWN - NLM
STAT- MEDLINE
DCOM- 19840823
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 4
IP  - 2
DP  - 1984 Jun
TI  - Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin 
      or placebo for migraine attacks: a double-blind study.
PG  - 107-11
AB  - Aspirin 650 mg and metoclopramide 10 mg in an effervescent preparation 
      (Migravess) were compared with effervescent aspirin 650 mg (Alka-Seltzer) and 
      placebo for common migraine attacks with a double-blind cross-over design. One 
      hundred and eighteen patients with common migraine were entered. Eighty-five 
      patients completed all three forms of treatment, eleven completed two, and six 
      completed one. Medicine was taken when patients were sure they had a migraine 
      attack and not just interval headache. After each form of treatment, they mailed 
      a report form to the investigators. Additional medication was allowed after 2 h 
      and was taken for 79/95 placebo treated attacks, 63/92 Migravess treated attacks, 
      and 51/86 aspirin treated attacks (p less than 0.01). Aspirin was significantly 
      better than placebo for pain but not quite significant for nausea. Migravess was 
      significantly better than placebo for pain and for nausea. There was no 
      significant difference between aspirin and Migravess with regard to analgesic 
      effectiveness (p = 0.33) or to antinausea effect (p = 0.18).
FAU - Tfelt-Hansen, P
AU  - Tfelt-Hansen P
FAU - Olesen, J
AU  - Olesen J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Drug Combinations)
RN  - 0 (aspirin, metoclopramide drug combination)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Combinations/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Metoclopramide/*therapeutic use
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
AID - 10.1046/j.1468-2982.1984.0402107.x [doi]
PST - ppublish
SO  - Cephalalgia. 1984 Jun;4(2):107-11. doi: 10.1046/j.1468-2982.1984.0402107.x.

PMID- 12777914
OWN - NLM
STAT- MEDLINE
DCOM- 20030619
LR  - 20131121
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 54
IP  - 5
DP  - 2003 May
TI  - Single dose of acetylsalicylic acid prevents thromboxane release after tourniquet 
      ischemia.
PG  - 986-9
AB  - BACKGROUND: Ischemia, such as that caused by a tourniquet, stimulates thromboxane 
      (Tx) A(2) synthesis. TxA(2) might sensitize the operated limb to various 
      complications, such as compartment syndrome and thromboembolic events. METHODS: 
      We studied the effect of pretreatment with a single dose of acetylsalicylic acid 
      (ASA) (25, 100, and 500 mg) given 3 hours before surgery on the formation of 
      TxB(2), a stable metabolite of TxA(2), after tourniquet deflation in 32 knee or 
      ankle surgery patients. RESULTS: Tourniquet time varied between 60 +/- 8 to 71 
      +/- 7 (SE) minutes. In control patients without ASA pretreatment, the 
      platelet-produced femoral vein serum TxB(2) concentration over 30 minutes in 
      vitro coagulation increased remarkably (from 40.0 +/- 20 ng/mL to 73.5 +/- 39 
      ng/mL) immediately after tourniquet deflation. Plasma concentrations increased 
      similarly, approximately threefold. Pretreatment with 100 or 500 mg ASA prevented 
      the increase in TxB(2) concentrations. Radial artery concentrations of TxB(2) 
      were similar to venous concentrations in the different treatment groups. 
      CONCLUSION: Pretreatment with a single 100-mg dose of ASA prevents the release of 
      TxB(2) after tourniquet deflation.
FAU - Ojanen, Raimo
AU  - Ojanen R
AD  - Department of Anaesthesia and Intensive Care, Tampere University Hospital, 
      Finland.
FAU - Kaukinen, Liisa
AU  - Kaukinen L
FAU - Seppälä, Erkki
AU  - Seppälä E
FAU - Kaukinen, Seppo
AU  - Kaukinen S
FAU - Vapaatalo, Heikki
AU  - Vapaatalo H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Ischemia/*blood
MH  - Thromboxane B2/*blood
MH  - *Tourniquets
EDAT- 2003/06/05 05:00
MHDA- 2003/06/20 05:00
CRDT- 2003/06/05 05:00
PHST- 2003/06/05 05:00 [pubmed]
PHST- 2003/06/20 05:00 [medline]
PHST- 2003/06/05 05:00 [entrez]
AID - 10.1097/01.TA.0000051589.20214.5A [doi]
PST - ppublish
SO  - J Trauma. 2003 May;54(5):986-9. doi: 10.1097/01.TA.0000051589.20214.5A.

PMID- 3816920
OWN - NLM
STAT- MEDLINE
DCOM- 19870403
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 31
IP  - 4
DP  - 1986
TI  - Inhibition of thrombocyte aggregation by oral motapizone and other drugs.
PG  - 411-4
AB  - Ten healthy subjects took single oral doses of placebo, 8.8 +/- 1.8 mg 
      motapizone, 40 +/- 13 mg captopril, 25 mg dihydralazine, 20 mg nifedipine and 4.5 
      +/- 1.1 mg prazosin in random order, and, as the last preparation 500 mg 
      acetylsalicylic acid. Thrombocyte aggregation induced "ex-vivo" with collagen, 
      ADP and adrenaline was measured before and after 60 min. Immediately before each 
      dose, the "threshold concentration" of each agent was determined in each subject, 
      i.e. the concentration producing about 90% of maximal aggregation. After the 
      preparation had been taken, aggregation was induced with 1-, 2- and 4-times the 
      threshold concentration. Both motapizone and also acetylsalicylic acid caused 
      marked inhibition of aggregation at up to 4-times the threshold concentration; 
      the dose ratio was about 1:50. Motapizone produced greater inhibition of the 
      aggregation induced by ADP and acetylsalicylic acid than of that due to collagen. 
      The inhibitory actions after captopril, dihydralazine, nifedipine and prazosin 
      were weak and did not significantly differ from placebo.
FAU - Schulz, V
AU  - Schulz V
FAU - Fischer, W
AU  - Fischer W
FAU - Hanselle, U
AU  - Hanselle U
FAU - Huhmann, W
AU  - Huhmann W
FAU - Zietsch, V
AU  - Zietsch V
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Pyridazines)
RN  - C4A61P8A37 (motapizone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antihypertensive Agents/pharmacology
MH  - Aspirin/pharmacology
MH  - Cardiovascular Agents/*pharmacology
MH  - Female
MH  - Fibrinolytic Agents/*pharmacology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Pyridazines/*pharmacology
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1007/BF00613515 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1986;31(4):411-4. doi: 10.1007/BF00613515.

PMID- 3827406
OWN - NLM
STAT- MEDLINE
DCOM- 19870417
LR  - 20131121
IS  - 0003-9780 (Print)
IS  - 0003-9780 (Linking)
VI  - 284
IP  - 1
DP  - 1986 Nov
TI  - Antithrombotic efficacy and its time course after application of naftidrofuryl in 
      vivo.
PG  - 145-54
AB  - The antithrombotic efficacy of naftidrofuryl (Naf) was assessed with the 
      following method: an endothelial cell damage is induced in arteriolar vessels of 
      the hamster cheek pouch by intravascular excitation of 
      fluorescein-isothiocyanate-dextran. On these damaged cells, platelets adhere and 
      a stable thrombus grows. This process progressively obstructs the vessel's 
      aperture and hence reduces blood flow. Blood cell velocity may thus be used to 
      quantitate thrombus growth. Thrombus growth is assessed before and repetitively 
      after parenteral application of 1, 5 and 20 mg/kg Naf. Efficacy is compared with 
      10 and 100 mg/kg acetylsalicylic acid. Naf shows a significant antithrombotic 
      property, beginning with a dosage of 1 mg/kg which further increases relative to 
      the dosage, and the stability of thrombi decreased. The antithrombotic 
      effectiveness of Naf increases continuously during 120 min after application. 
      Vessel diameter and cell velocity were the same in compared groups thus excluding 
      an influence of the vasodilatory property of Naf on thrombus growth. Sixty min 
      after application, 5 mg/kg Naf was as effective as 10 mg/kg acetylsalicylic acid.
FAU - Herrmann, K S
AU  - Herrmann KS
FAU - Grosse-Heitmeyer, A
AU  - Grosse-Heitmeyer A
FAU - Kreuzer, H
AU  - Kreuzer H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Belgium
TA  - Arch Int Pharmacodyn Ther
JT  - Archives internationales de pharmacodynamie et de therapie
JID - 0405353
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Furans)
RN  - 42H8PQ0NMJ (Nafronyl)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Cheek/blood supply
MH  - Cricetinae
MH  - *Fibrinolytic Agents
MH  - Furans/*pharmacology
MH  - Mesocricetus
MH  - Nafronyl/*pharmacology
MH  - Regional Blood Flow/drug effects
EDAT- 1986/11/01 00:00
MHDA- 1986/11/01 00:01
CRDT- 1986/11/01 00:00
PHST- 1986/11/01 00:00 [pubmed]
PHST- 1986/11/01 00:01 [medline]
PHST- 1986/11/01 00:00 [entrez]
PST - ppublish
SO  - Arch Int Pharmacodyn Ther. 1986 Nov;284(1):145-54.

PMID- 11010748
OWN - NLM
STAT- MEDLINE
DCOM- 20000922
LR  - 20131121
IS  - 1167-7422 (Print)
IS  - 1167-7422 (Linking)
VI  - 9
IP  - 47
DP  - 2000 Jun
TI  - Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs 
      into account.
PG  - 82-3
AB  - (1) Several antiplatelet drugs have proven preventive efficacy, including 
      aspirin, aspirin + dipyridamole, clopidogrel, ticlopidine and flurbiprofen. They 
      differ mainly in their adverse effects and costs. (2) Aspirin has essentially 
      gastrointestinal adverse effects, whose incidence can be limited by prescribing a 
      daily dose below 350 mg. (3) The addition of dipyridamole to aspirin can cause 
      headache and diarrhoea. (4) Ticlopidine should be avoided because of the risk of 
      agranulocytosis. (5) Adverse effects are less frequent and less severe with 
      clopidogrel than with ticlopidine. (6) Like other nonsteroidal antiinflammatory 
      drugs, flurbiprofen has mainly gastrointestinal adverse effects. (7) Treatment is 
      least costly with low-dose aspirin and most costly with clopidogrel.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Prescrire Int
JT  - Prescrire international
JID - 9439295
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - 64ALC7F90C (Dipyridamole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/economics/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control/therapy
MH  - Cost-Benefit Analysis
MH  - Dipyridamole/economics/therapeutic use
MH  - Drug Costs
MH  - Flurbiprofen/economics/therapeutic use
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/adverse effects/economics/therapeutic use
MH  - Ticlopidine/antagonists & inhibitors/economics/therapeutic use
EDAT- 2000/09/30 11:00
MHDA- 2000/09/30 11:01
CRDT- 2000/09/30 11:00
PHST- 2000/09/30 11:00 [pubmed]
PHST- 2000/09/30 11:01 [medline]
PHST- 2000/09/30 11:00 [entrez]
PST - ppublish
SO  - Prescrire Int. 2000 Jun;9(47):82-3.

PMID- 7003384
OWN - NLM
STAT- MEDLINE
DCOM- 19810219
LR  - 20141120
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 304
IP  - 2
DP  - 1981 Jan 8
TI  - Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin.
PG  - 76-9
AB  - To compare the inhibitory effects of aspirin on prostaglandin synthesized by 
      vessel walls and platelets, we obtained vein segments from five subjects before 
      they were given 150 or 300 mg of aspirin and at various intervals afterward. We 
      then measured prostacyclin (PGI2) synthesis with a radioimmunoassay for its 
      stable metabolite, 6-keto-prostaglandin F1 alpha. Platelet production of 
      thromboxane A2 was measured with a radioimmunoassay for its stable metabolite, 
      thromboxane B2. Two hours after aspirin had been given, 81 to 100 per cent 
      inhibition of PGI2 synthesis was demonstrated; 86 per cent inhibition was still 
      evident in one subject tested eight hours after administration. Simultaneously, 
      platelet production of thromboxane B2 was completely inhibited for more than 24 
      hours. We conclude that there is little difference between the initial inhibitory 
      response of platelet cyclooxygenase and that of vessel-wall cyclooxygenase to 
      these doses of aspirin. Our results also indicate that in male subjects the 
      prolonged template bleeding time after aspirin is not the consequence of 
      selective inhibition of platelet production of thromboxane.
FAU - Preston, F E
AU  - Preston FE
FAU - Whipps, S
AU  - Whipps S
FAU - Jackson, C A
AU  - Jackson CA
FAU - French, A J
AU  - French AJ
FAU - Wyld, P J
AU  - Wyld PJ
FAU - Stoddard, C J
AU  - Stoddard CJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Thromboxanes)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/drug effects/*metabolism
MH  - Epoprostenol/*antagonists & inhibitors/biosynthesis
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - *Prostaglandin Antagonists
MH  - Thromboxane A2/*biosynthesis
MH  - Thromboxanes/*biosynthesis
MH  - Veins/metabolism
EDAT- 1981/01/08 00:00
MHDA- 1981/01/08 00:01
CRDT- 1981/01/08 00:00
PHST- 1981/01/08 00:00 [pubmed]
PHST- 1981/01/08 00:01 [medline]
PHST- 1981/01/08 00:00 [entrez]
AID - 10.1056/NEJM198101083040203 [doi]
PST - ppublish
SO  - N Engl J Med. 1981 Jan 8;304(2):76-9. doi: 10.1056/NEJM198101083040203.

PMID- 12365868
OWN - NLM
STAT- MEDLINE
DCOM- 20021021
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 53
IP  - 5
DP  - 2002 Sep-Oct
TI  - Polycythemia vera--a case report and discussion on pathogenic mechanisms of 
      increased thrombosis.
PG  - 587-91
AB  - Polycythemia vera is a myeloproliferative disorder characterized by increased red 
      cell mass and frequently complicated by venous and arterial thrombosis. The 
      mechanism underlying the increased incidence of thrombotic events remains 
      illusive. Presented in this report are a case of a 77-year-old man diagnosed with 
      polycythemia vera and a review of the current literature on the mechanisms 
      underlying the increased incidence of thrombotic events in polycythemia vera.
FAU - Gumina, Richard J
AU  - Gumina RJ
AD  - Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, 
      USA.
FAU - Foley, David A
AU  - Foley DA
FAU - Tefferi, Ayalew
AU  - Tefferi A
FAU - Rooke, Thom W
AU  - Rooke TW
FAU - Shields, Raymond C
AU  - Shields RC
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arterial Occlusive Diseases/diagnosis/etiology
MH  - Arteriosclerosis Obliterans/diagnosis/etiology
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Diagnosis, Differential
MH  - Humans
MH  - Male
MH  - Phlebotomy
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Polycythemia Vera/*complications/diagnosis/therapy
MH  - Thrombophlebitis/etiology
MH  - Thrombosis/*etiology/prevention & control
EDAT- 2002/10/09 04:00
MHDA- 2002/10/22 04:00
CRDT- 2002/10/09 04:00
PHST- 2002/10/09 04:00 [pubmed]
PHST- 2002/10/22 04:00 [medline]
PHST- 2002/10/09 04:00 [entrez]
AID - 10.1177/000331970205300514 [doi]
PST - ppublish
SO  - Angiology. 2002 Sep-Oct;53(5):587-91. doi: 10.1177/000331970205300514.

PMID- 3901663
OWN - NLM
STAT- MEDLINE
DCOM- 19851107
LR  - 20190820
IS  - 0001-656X (Print)
IS  - 0001-656X (Linking)
VI  - 74
IP  - 5
DP  - 1985 Sep
TI  - Acetylsalicylic acid and juvenile rheumatoid Arthritis. Effect of dosage interval 
      on the serum salicylic acid level.
PG  - 755-9
AB  - A 2-dose regimen and a 3-dose regimen, both with the same daily dose of 
      acetylsalicylic acid, were compared in 8 patients with juvenile rheumatoid 
      arthritis. The regimens were given according to a cross-over design. The serum 
      salicylic acid levels over 24 hours were studied at the end of each treatment 
      period. As expected somewhat greater fluctuations in the salicylic acid levels 
      were observed with the 2-dose than with the 3-dose regimen. However, 
      therapeutically effective serum levels were observed for most of the 24 hour 
      period with both regimens. It is suggested that a 2-dose regimen has advantage 
      with regard to simplicity and compliance. The pharmacokinetic findings indicate 
      that a 2-dose regimen may be useful in patients with juvenile rheumatoid 
      arthritis.
FAU - Kvien, T K
AU  - Kvien TK
FAU - Olsson, B
AU  - Olsson B
FAU - Høyeraal, H M
AU  - Høyeraal HM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Sweden
TA  - Acta Paediatr Scand
JT  - Acta paediatrica Scandinavica
JID - 0000211
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Arthritis, Juvenile/blood/*drug therapy
MH  - Aspirin/*administration & dosage/blood
MH  - Child
MH  - Clinical Trials as Topic
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Salicylates/*blood
EDAT- 1985/09/01 00:00
MHDA- 1985/09/01 00:01
CRDT- 1985/09/01 00:00
PHST- 1985/09/01 00:00 [pubmed]
PHST- 1985/09/01 00:01 [medline]
PHST- 1985/09/01 00:00 [entrez]
AID - 10.1111/j.1651-2227.1985.tb10026.x [doi]
PST - ppublish
SO  - Acta Paediatr Scand. 1985 Sep;74(5):755-9. doi: 
      10.1111/j.1651-2227.1985.tb10026.x.

PMID- 790551
OWN - NLM
STAT- MEDLINE
DCOM- 19761223
LR  - 20131121
IS  - 0301-3847 (Print)
IS  - 0301-3847 (Linking)
VI  - 1976
IP  - 0
DP  - 1976
TI  - Gastroscopic evaluation of the effect of a new anti-rheumatic compound, 
      ketoprofen (19.583 R.P.), on the human gastric mucosa. A double-blind cross-over 
      trial against acetylsalicylic acid.
PG  - 63-72
AB  - The tolerance of the gastric mucosa to a new anti-inflammatory product, 
      ketoprofen (19.583 R.P., Orudis, Profenid N.D.) was compared to the tolerance of 
      acetylsalicylic acid in a double-blind cross-over trial using selected healthy 
      volunteers. The effect of the medication on the gastric mucosa was examined by 
      the use of a gastrocamera technique. The volunteers received during 2 one-week 
      periods either acetylsalicylic acid 3 g daily or ketoprofen 100 mg daily. The 
      sequential diagram shows that the upper barrier was crossed (preference for 
      ketoprofen) when 10 volunteers had been analysed.
FAU - Rahbek, I
AU  - Rahbek I
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Norway
TA  - Scand J Rheumatol Suppl
JT  - Scandinavian journal of rheumatology. Supplement
JID - 0400360
RN  - 0 (Analgesics)
RN  - 0 (Benzophenones)
RN  - 0 (Capsules)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analgesics/*toxicity
MH  - Aspirin/administration & dosage/*toxicity
MH  - Benzophenones/*toxicity
MH  - Capsules
MH  - Clinical Trials as Topic
MH  - Drug Evaluation
MH  - Female
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastroscopy
MH  - Humans
MH  - Ketoprofen/administration & dosage/*toxicity
MH  - Male
MH  - Middle Aged
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Rheumatol Suppl. 1976;1976(0):63-72.

PMID- 1078707
OWN - NLM
STAT- MEDLINE
DCOM- 19750505
LR  - 20131121
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 69
IP  - 2
DP  - 1975 Feb
TI  - Open-heart surgery in von Willebrand's disease.
PG  - 183-7
AB  - The case is presented of a hemophilia carrier, also affected by von Willebrand's 
      disease, who underwent aortic valve replacement. The clinical and laboratory 
      findings of von Willebrand's disease (prolonged bleeding time, low factor VIII, 
      and abnormal platelet activity) are discussed, and a protocol for management of 
      patients with low factor VIII levels (such as hemophilia carriers and subjects 
      with hemophilia A or von Willebrand's disease) undergoing open-heart surgery is 
      proposed. Our case proves that corrective cardiac surgery in similar 
      circumstances is feasible so long as adequate levels of factor VIII are 
      maintained.
FAU - Aris, A
AU  - Aris A
FAU - Pisciotta, A V
AU  - Pisciotta AV
FAU - Hussey, C V
AU  - Hussey CV
FAU - Gale, H
AU  - Gale H
FAU - Lepley, D
AU  - Lepley D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 9001-27-8 (Factor VIII)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aortic Valve Stenosis/complications/*surgery
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Blood Coagulation Tests
MH  - Blood Transfusion
MH  - *Cardiac Surgical Procedures
MH  - Erythrocytes
MH  - Factor VIII/analysis/*therapeutic use
MH  - Female
MH  - Hemophilia A/genetics
MH  - Heterozygote
MH  - Humans
MH  - Methods
MH  - Middle Aged
MH  - Plasma
MH  - Postoperative Care
MH  - Preoperative Care
MH  - von Willebrand Diseases/*complications
EDAT- 1975/02/01 00:00
MHDA- 1975/02/01 00:01
CRDT- 1975/02/01 00:00
PHST- 1975/02/01 00:00 [pubmed]
PHST- 1975/02/01 00:01 [medline]
PHST- 1975/02/01 00:00 [entrez]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1975 Feb;69(2):183-7.

PMID- 34011649
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210602
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 14
IP  - 5
DP  - 2021 May 19
TI  - COVID-19-associated central retinal vein occlusion treated with oral aspirin.
LID - 10.1136/bcr-2021-242987 [doi]
LID - e242987
AB  - This is a case report of central retinal vein occlusion (CRVO) associated with 
      COVID-19 treated with oral aspirin therapy. A 56-year-old woman reported 
      decreased vision in her left eye. Her left eye vision was 6/18, N10. Anterior 
      segment was within normal limits. Left eye fundus was suggestive of CRVO and 
      macular oedema. Optical coherence tomography showed cystoid macular oedema and 
      neurosensory detachment. Blood work-up revealed elevated D-dimer levels and 
      erythrocyte sedimentation rate (ESR). She was started on treatment with low-dose 
      aspirin 150 mg/day. After 1 month, her vision improved to 6/6, N6. Left eye 
      fundus showed reduced retinal haemorrhages and complete resolution of macular 
      oedema. Her repeat blood work-up showed reduced D-dimer and ESR levels. The 
      patient was asked to be reviewed after 3 months. This case highlights that 
      specific treatment for reducing the hypercoagulable state caused by COVID-19 with 
      oral aspirin therapy can result in complete resolution of CRVO macular oedema.
CI  - © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Venkatesh, Ramesh
AU  - Venkatesh R
AD  - Department of Retina and Vitreous, Narayana Nethralaya, Bengaluru, Karnataka, 
      India.
FAU - Reddy, Nikitha Gurram
AU  - Reddy NG
AD  - Department of Retina and Vitreous, Narayana Nethralaya, Bengaluru, Karnataka, 
      India.
FAU - Agrawal, Sameeksha
AU  - Agrawal S
AD  - Department of Retina and Vitreous, Narayana Nethralaya, Bengaluru, Karnataka, 
      India.
FAU - Pereira, Arpitha
AU  - Pereira A
AUID- ORCID: 0000-0002-3356-1256
AD  - Ophthalmology, Betsi Cadwaladr University Health Board, Abergele, UK 
      arpitha.pereira@wales.nhs.uk.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20210519
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *COVID-19
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Middle Aged
MH  - *Retinal Vein Occlusion/diagnosis/drug therapy
MH  - SARS-CoV-2
MH  - Tomography, Optical Coherence
PMC - PMC8137153
OTO - NOTNLM
OT  - COVID-19
OT  - macula
OT  - retina
OT  - venous thromboembolism
COIS- Competing interests: None declared.
EDAT- 2021/05/21 06:00
MHDA- 2021/05/22 06:00
CRDT- 2021/05/20 05:48
PHST- 2021/05/20 05:48 [entrez]
PHST- 2021/05/21 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
AID - 14/5/e242987 [pii]
AID - bcr-2021-242987 [pii]
AID - 10.1136/bcr-2021-242987 [doi]
PST - epublish
SO  - BMJ Case Rep. 2021 May 19;14(5):e242987. doi: 10.1136/bcr-2021-242987.

PMID- 100830
OWN - NLM
STAT- MEDLINE
DCOM- 19781220
LR  - 20190823
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 15
IP  - 5
DP  - 1978 May
TI  - Prostaglandin biosynthesis in rabbit kidney medulla: inhibition in-vitro vs. 
      in-vivo by aspirin, indomethacin and meclofenamic acid.
PG  - 759-72
AB  - The non-steroidal anti-inflammatory drugs aspirin, indomethacin and meclofenamic 
      acid were compared for their potency and duration of inhibition of prostaglandin 
      biosynthesis in rabbit kidney medulla. Indomethacin and meclofenamic acid showed 
      equal potency of inhibition in-vitro (IC50 0.88 micron and 0.85 micron 
      respectively) while aspiring was a much weaker inhibitor (IC50 120 micron). 
      In-vivo, indomethacin was the most powerful inhibitor (ID50 0.034 mg/kg) followed 
      by meclofenamic acid (0.45 mg/kg) and aspirin (2.35 mg/kg). Studies on the 
      duration of in-vivo inhibition by these compounds showed the effect of 
      indomethacin and meclofenamic acid to be completely reversed within 4-6 hours. In 
      contrast, return of kidney prostaglandin biosynthetic activity following aspirin 
      inhibition is very slow and significant inhibition is still present 48 hours 
      after a single aspiring injection. The inhibitory effect of aspirin in-vivo could 
      be blocked by pretreatment with indomethacin, indicating that both drugs interact 
      with related sites on the cyclo-oxygenase enzyme. The irreversible inhibition of 
      the cyclo-oxygenase by aspirin as demonstrated in studies of other investigators 
      suggests that the return of kidney prostaglandin synthetase activity after 
      aspirin inhibition represents synthesis of new cyclo-oxygenase protein.
FAU - Gafni, Y
AU  - Gafni Y
FAU - Schwartzman, M
AU  - Schwartzman M
FAU - Raz, A
AU  - Raz A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandins)
RN  - 0 (ortho-Aminobenzoates)
RN  - 48I5LU4ZWD (Meclofenamic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*pharmacology
MH  - Cyclooxygenase Inhibitors
MH  - Female
MH  - In Vitro Techniques
MH  - Indomethacin/blood/*pharmacology
MH  - Kidney Medulla/drug effects/*metabolism
MH  - Meclofenamic Acid/blood/*pharmacology
MH  - Prostaglandins/*biosynthesis
MH  - Rabbits
MH  - Time Factors
MH  - ortho-Aminobenzoates/*pharmacology
EDAT- 1978/05/01 00:00
MHDA- 1978/05/01 00:01
CRDT- 1978/05/01 00:00
PHST- 1978/05/01 00:00 [pubmed]
PHST- 1978/05/01 00:01 [medline]
PHST- 1978/05/01 00:00 [entrez]
AID - 0090-6980(78)90142-9 [pii]
AID - 10.1016/0090-6980(78)90142-9 [doi]
PST - ppublish
SO  - Prostaglandins. 1978 May;15(5):759-72. doi: 10.1016/0090-6980(78)90142-9.

PMID- 28608238
OWN - NLM
STAT- MEDLINE
DCOM- 20180517
LR  - 20181113
IS  - 1550-7416 (Electronic)
IS  - 1550-7416 (Linking)
VI  - 19
IP  - 5
DP  - 2017 Sep
TI  - The Impact of Disintegrant Type, Surfactant, and API Properties on the 
      Processability and Performance of Roller Compacted Formulations of Acetaminophen 
      and Aspirin.
PG  - 1387-1395
LID - 10.1208/s12248-017-0104-6 [doi]
AB  - In formulation development, certain excipients, even though used in small 
      quantities, can have a significant impact on the processability and performance 
      of the dosage form. In this study, three common disintegrants, croscarmellose 
      sodium (CCS), crospovidone (xPVP), and sodium starch glycolate (SSG) as well as 
      the surfactant sodium lauryl sulfate (SLS) were evaluated for their impact on the 
      processability and performance of a typical dry granulation formulation. Two 
      model compounds, the mechanically brittle and chemically inert acetaminophen and 
      the mechanically ductile carboxylic acid aspirin, were used for the evaluation. 
      It was found that the disintegrants were generally identical in their impact on 
      the processability and little difference was observed in the granulation and 
      compression processes. The exception is that when xPVP was used in the 
      formulation of the brittle acetaminophen, lower compression forces were needed to 
      reach the same tablet hardness, suggesting a binding effect of xPVP for such 
      systems. In general, CCS and xPVP tend to provide slightly better disintegration 
      than SSG. However, in the case of aspirin, a strong hydrogen bonding interaction 
      between the carboxylic acid group of aspirin and the carbonyl group of xPVP was 
      observed, resulting in slower release of the drug after fast disintegration. SLS 
      was found to have a significant impact on the processability due to its 
      lubricating effect, resulting in higher compression forces needed to achieve the 
      target tablet hardness. Due to the higher degree of compression, the 
      disintegration and dissolution of both drugs became slower despite the wetting 
      effect of SLS.
FAU - Zhao, Junshu
AU  - Zhao J
AD  - Drug Product Science and Technology, Bristol-Myers Squibb, 1 Squibb Dr, New 
      Brunswick, New Jersey, 08903, USA. junshu.zhao@bms.com.
FAU - Koo, Otilia
AU  - Koo O
AD  - Drug Product Science and Technology, Bristol-Myers Squibb, 1 Squibb Dr, New 
      Brunswick, New Jersey, 08903, USA.
FAU - Pan, Duohai
AU  - Pan D
AD  - Drug Product Science and Technology, Bristol-Myers Squibb, 1 Squibb Dr, New 
      Brunswick, New Jersey, 08903, USA.
FAU - Wu, Yongmei
AU  - Wu Y
AD  - Drug Product Science and Technology, Bristol-Myers Squibb, 1 Squibb Dr, New 
      Brunswick, New Jersey, 08903, USA.
FAU - Morkhade, Dinesh
AU  - Morkhade D
AD  - Piramal Pharmaceutical Development Services Pvt. Ltd., Ahmedabad, India.
FAU - Rana, Sandeep
AU  - Rana S
AD  - Piramal Pharmaceutical Development Services Pvt. Ltd., Ahmedabad, India.
FAU - Saha, Partha
AU  - Saha P
AD  - Piramal Pharmaceutical Development Services Pvt. Ltd., Ahmedabad, India.
FAU - Marin, Arturo
AU  - Marin A
AD  - Drug Product Science and Technology, Bristol-Myers Squibb, 1 Squibb Dr, New 
      Brunswick, New Jersey, 08903, USA.
LA  - eng
PT  - Journal Article
DEP - 20170612
PL  - United States
TA  - AAPS J
JT  - The AAPS journal
JID - 101223209
RN  - 0 (Surface-Active Agents)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - FZ989GH94E (Povidone)
RN  - K679OBS311 (Carboxymethylcellulose Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*chemistry
MH  - Aspirin/*chemistry
MH  - Carboxymethylcellulose Sodium/pharmacology
MH  - Chemistry, Pharmaceutical
MH  - Povidone/pharmacology
MH  - Solubility
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Surface-Active Agents/*pharmacology
MH  - Tablets
OTO - NOTNLM
OT  - disintegrant
OT  - performance
OT  - processability
OT  - roller compaction
OT  - surfactant
EDAT- 2017/06/14 06:00
MHDA- 2018/05/18 06:00
CRDT- 2017/06/14 06:00
PHST- 2017/03/23 00:00 [received]
PHST- 2017/05/26 00:00 [accepted]
PHST- 2017/06/14 06:00 [pubmed]
PHST- 2018/05/18 06:00 [medline]
PHST- 2017/06/14 06:00 [entrez]
AID - 10.1208/s12248-017-0104-6 [pii]
AID - 10.1208/s12248-017-0104-6 [doi]
PST - ppublish
SO  - AAPS J. 2017 Sep;19(5):1387-1395. doi: 10.1208/s12248-017-0104-6. Epub 2017 Jun 
      12.

PMID- 3331264
OWN - NLM
STAT- MEDLINE
DCOM- 19880919
LR  - 20131121
IS  - 0397-9148 (Print)
IS  - 0397-9148 (Linking)
VI  - 19
IP  - 1
DP  - 1987 Jan
TI  - The effect of prostacyclin on asthma precipitated by aspirin.
PG  - 22-4
AB  - Inhibition of prostacyclin biosynthesis by aspirin might be expected to promote 
      asthmatic attacks in aspirin-intolerant patients. In vitro, prostacyclin inhibits 
      generation of leukotrienes and opposes their bronchoconstrictive action. In a 
      double-blind study we compared the effects of intravenous infusions of 
      prostacyclin with those of its solvent on bronchoconstriction provoked by 
      threshold doses of aspirin in 9 known aspirin-sensitive asthmatics. The intensity 
      of bronchial obstruction precipitated by aspirin was similar during prostacyclin 
      and placebo infusions. There was no difference in other symptoms of intolerance, 
      except for rhinorrhea which seemed accentuated by prostacyclin (possibly because 
      of nasal vasodilatation). Our results suggest that either the inhibitory effects 
      of prostacyclin on leukotrienes described in vitro do not apply in vivo, or the 
      importance of leukotrienes have been overestimated in this type of asthma. 
      Idiosyncrasy to aspirin, which affects 5-10% of adult asthmatics, was thought 
      several decades to be of allergic background, while in fact numerous and 
      extensive immunological studies ruled out typical IgE--mediated allergic 
      mechanisms for aspirin--induced asthma. In 1974, at the Department of Allergy and 
      Clinical Immunology in Cracow, a novel hypothesis was put forward. If stated that 
      in sensitive patients, precipitation of asthmatic attacks by aspirin and by 
      certain nonsteroidal antiinflammatory drugs (NSAID) results from inhibition of 
      specific enzyme in the bronchi, cyclooxygenase, leading to an imbalance of 
      prostanoids in the respiratory tract. Over the years which followed evidence has 
      been accumulated which strongly support this hypothesis.(ABSTRACT TRUNCATED AT 
      250 WORDS)
FAU - Nizankowska, E
AU  - Nizankowska E
AD  - Department of Allergy and Clinical Immunology, Copernicus Academy of Medicine, 
      Cracow, Poland.
FAU - Czerniawska-Mysik, G
AU  - Czerniawska-Mysik G
FAU - Szczeklik, A
AU  - Szczeklik A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - France
TA  - Allerg Immunol (Paris)
JT  - Allergie et immunologie
JID - 0245775
RN  - 0 (Solvents)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/metabolism/physiopathology
MH  - Bronchi/drug effects
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Hypersensitivity/*etiology/prevention & control
MH  - Epoprostenol/administration & dosage/*pharmacology
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Random Allocation
MH  - Solvents
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Allerg Immunol (Paris). 1987 Jan;19(1):22-4.

PMID- 27121596
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20181202
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Print)
IS  - 0892-6638 (Linking)
VI  - 30
IP  - 8
DP  - 2016 Aug
TI  - Specialized proresolving lipid mediators in patients with coronary artery disease 
      and their potential for clot remodeling.
PG  - 2792-801
LID - 10.1096/fj.201500155R [doi]
AB  - Inflammation in arterial walls leads to coronary artery disease (CAD). Because 
      specialized proresolving lipid mediators (SPMs; lipoxins, resolvins, and 
      protectins) stimulate resolution of inflammation in animal models, we tested 
      whether n-3 fatty acids impact SPM profiles in patients with CAD and promote clot 
      remodeling. Six patients with stable CAD were randomly assigned to either 
      treatment with daily 3.36 g Lovaza for 1 yr or without. Targeted lipid 
      mediator-metabololipidomics showed that both groups had absence of resolvin D1 
      (RvD1), RvD2, RvD3, RvD5 and resolvin E1-all of which are present in healthy 
      patients. Those not taking Lovaza had an absence of aspirin-triggered resolvin D3 
      (AT-RvD3) and aspirin-triggered lipoxin B4 (AT-LXB4). Lovaza treatment restored 
      AT-RvD3 and AT-LXB4 and gave levels of RvD6 and aspirin-triggered protectin D1 
      (AT-PD1) twice as high (resolvin E2 ∼5 fold) as well as lower prostaglandins. 
      Principal component analysis indicated positive relationships for patients with 
      CAD who were receiving Lovaza with increased AT-RvD3, RvD6, AT-PD1, and AT-LXB4 
      SPMs identified in Lovaza-treated patients with CAD enhanced ∼50% at 1 nM 
      macrophage uptake of blood clots. These results indicate that patients with CAD 
      have lower levels and/or absence of specific SPMs that were restored with Lovaza; 
      these SPMs promote macrophage phagocytosis of blood clots. Together, they suggest 
      that low vascular SPMs may enable progression of chronic vascular inflammation 
      predisposing to coronary atherosclerosis and to thrombosis.-Elajami, T. K., 
      Colas, R. A., Dalli, J., Chiang, N., Serhan, C. N., Welty, F. K. Specialized 
      proresolving lipid mediators in patients with coronary artery disease and their 
      potential for clot remodeling.
CI  - © FASEB.
FAU - Elajami, Tarec K
AU  - Elajami TK
AD  - Division of Cardiovascular Medicine, Department of Internal Medicine, Beth Israel 
      Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA;
FAU - Colas, Romain A
AU  - Colas RA
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, 
      Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Dalli, Jesmond
AU  - Dalli J
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, 
      Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Chiang, Nan
AU  - Chiang N
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, 
      Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Serhan, Charles N
AU  - Serhan CN
AD  - Center for Experimental Therapeutics and Reperfusion Injury, Department of 
      Anesthesiology, Perioperative and Pain Medicine, Harvard Institutes of Medicine, 
      Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Welty, Francine K
AU  - Welty FK
AD  - Division of Cardiovascular Medicine, Department of Internal Medicine, Beth Israel 
      Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; 
      fwelty@bidmc.harvard.edu.
LA  - eng
GR  - P01 GM095467/GM/NIGMS NIH HHS/United States
GR  - P50 HL083813/HL/NHLBI NIH HHS/United States
GR  - R01 GM038765/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160427
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (Biomarkers)
RN  - 0 (Drug Combinations)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Lipoxins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - D87YGH4Z0Q (Omacor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Biomarkers/blood
MH  - Coronary Disease/*drug therapy/*metabolism
MH  - Docosahexaenoic Acids/*therapeutic use
MH  - Drug Combinations
MH  - Eicosapentaenoic Acid/*therapeutic use
MH  - Fatty Acids, Omega-3
MH  - Female
MH  - Gene Expression Regulation
MH  - Humans
MH  - Lipid Metabolism
MH  - Lipoxins/genetics/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
PMC - PMC4970606
OTO - NOTNLM
OT  - inflammation
OT  - lipoxins
OT  - metabololipidomics
OT  - n-3 fatty acids
OT  - resolvins
EDAT- 2016/04/29 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/04/29 06:00
PHST- 2016/01/18 00:00 [received]
PHST- 2016/04/12 00:00 [accepted]
PHST- 2016/04/29 06:00 [entrez]
PHST- 2016/04/29 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
AID - fj.201500155R [pii]
AID - FJ_201500155R [pii]
AID - 10.1096/fj.201500155R [doi]
PST - ppublish
SO  - FASEB J. 2016 Aug;30(8):2792-801. doi: 10.1096/fj.201500155R. Epub 2016 Apr 27.

PMID- 25816623
OWN - NLM
STAT- MEDLINE
DCOM- 20150417
LR  - 20150328
IS  - 0042-8833 (Print)
IS  - 0042-8833 (Linking)
VI  - 83
IP  - 5
DP  - 2014
TI  - [Effect of polypeptides isolated from cattle abomasum on stomach regenerative 
      processes in rats].
PG  - 26-32
AB  - The effect of polypeptides isolated from cattle abomasum on regenerative 
      processes of rat stomach upon simulating stomach mucosal damage caused by aspirin 
      was studied. Experimental research was carried out on male Wistar rats with 
      initial body weight of 230±20 g. The duration of the experiment was 22 days. The 
      rats were divided into 4 equal groups (n=11). The first (control) group-consisted 
      of the intact animals; animals from experimental groups 2-4 were intragastrically 
      administered acetylsalicylic acid from the 1st to the 7th day for simulating 
      stomach mucosal damage caused by aspirin (300 mg/100 g body weight). From day 8 
      to day 22, the animals were intragastrically adminitered the tested samples in 
      the quantity of 2 ml per animal according tothe scheme: the 2nd group - distilled 
      water, the 3d group - native abomasum extract; the 4 th group - thermally treated 
      abomasum extract. Abomasum extract was obtained by extraction with 0,87% aqueous 
      sodium chloride crushed abomasum and represented a liquid of cream color with 
      protein mass content of 1,3 g/100 g of the product with high content of glutamic 
      acid (15,5 g/100 g protein) and B-group vitamins. Electrophoretic analysis of the 
      extract revealed several high molecular weight fractions in the range of 72 to 55 
      kDa. The bands with molecular masses 52, 43, 40, 37, 34, 26, 17 kDa were most 
      pronounced; the intensive bands in the area 12 kDa and in the range lower than 10 
      kDa were revealed. The results of the conducted study show that the abomasum 
      extracts both in the native and thermally treated form exert therapeutic action 
      on animal with stomach mucosal damage caused by aspirin, have good antiulcer and 
      gastroprotective activities upon stomach mucosa exposure to chemical damaging 
      agents. The analysis of the hematological indices of the animals from the 3rd and 
      4th groups, which received the test samples after simulation, revealed the 
      normalization of leukocyte, lymphocyte, granulocyte and monocyte content. This 
      suggests the recovery of the animals after the disease. In the blood serum of 
      these animals concentration of total bilirubin, cholesterol, triglycerides and 
      glucose and the activity of gamma-glutamine transferase, ASAT and alkaline 
      phosphatase decreased compared with those in animals with the model of stomach 
      mucosal injury; while the total protein content, including the albumin fraction 
      increased. The examination of the internal organs of the animals from the 3rd and 
      4th groups showed that the mucosal and submucosal membrane of the stomach were 
      plicate, the signs of edema were absent, the hyperemia, any changes in mucosa, 
      surface and glandular epithelium were not observed.
FAU - Chernukha, I M
AU  - Chernukha IM
FAU - Bogatyrev, A N
AU  - Bogatyrev AN
FAU - Dydykin, A S
AU  - Dydykin AS
FAU - Aslanova, M A
AU  - Aslanova MA
FAU - Fedulova, L V
AU  - Fedulova LV
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Vopr Pitan
JT  - Voprosy pitaniia
JID - 2984870R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology
MH  - *Anti-Ulcer Agents/chemistry/isolation & purification/pharmacology
MH  - Aspirin/adverse effects/pharmacology
MH  - Cattle
MH  - Male
MH  - Peptic Ulcer/chemically induced/*drug therapy
MH  - *Proteins/chemistry/isolation & purification/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Regeneration/*drug effects
MH  - Rumen/*chemistry
EDAT- 2014/01/01 00:00
MHDA- 2015/04/18 06:00
CRDT- 2015/03/31 06:00
PHST- 2015/03/31 06:00 [entrez]
PHST- 2014/01/01 00:00 [pubmed]
PHST- 2015/04/18 06:00 [medline]
PST - ppublish
SO  - Vopr Pitan. 2014;83(5):26-32.

PMID- 19017382
OWN - NLM
STAT- MEDLINE
DCOM- 20090113
LR  - 20211020
IS  - 1749-8090 (Electronic)
IS  - 1749-8090 (Linking)
VI  - 3
DP  - 2008 Nov 18
TI  - Contegra conduit for reconstruction of the right ventricular outflow tract: a 
      review of published early and mid-time results.
PG  - 62
LID - 10.1186/1749-8090-3-62 [doi]
AB  - OBJECTIVE: The valved conduit Contegra (bovine jugular vein) has being implanted 
      for more than 7 years in the right ventricular outflow tract and it is noted that 
      the available reports have been mixed. The aim of this study is to review the 
      reported evidence in the literature. METHODS: Search of the relevant literature 
      for the primary endpoints of operative mortality and morbidity and secondary 
      endpoints of follow-up haemodynamic performance including severe stenosis, 
      regurgitation and need for reintervention are presented. RESULTS: We selected and 
      analysed 17 series including 767 patients. Commonest indication was Fallot's 
      tetralogy. Operative mortality was 2.6%. Operative morbidity was 13.9%. In 
      follow-up, the incidence of intraconduit stenosis was 10.9% (incidence of 
      stenosis for the 12 millimetre conduit was 83.3% in one series) and that of at 
      least moderate regurgitation was 6.3%.The aspirin users had a stenosis incidence 
      of 10.5% compared to the non-users had a stenosis incidence of 9.6%. CONCLUSION: 
      A dissent on the performance of the Contegra is discussed, while results are 
      satisfactory in the majority of studies apart for the smallest conduits (12 and 
      14 millimetre), suggesting an association to compromised run-off. The role of 
      aspirin as antithrombotic modulator remains controversial.
FAU - Protopapas, Aristotle D
AU  - Protopapas AD
AD  - Department of Biosurgery and Surgical Technology, Imperial College London, St, 
      Mary's Hospital, London, UK. aristotelis.protopapas02@imperial.ac.uk
FAU - Athanasiou, Thanos
AU  - Athanasiou T
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20081118
PL  - England
TA  - J Cardiothorac Surg
JT  - Journal of cardiothoracic surgery
JID - 101265113
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Bioprosthesis
MH  - *Blood Vessel Prosthesis
MH  - Blood Vessel Prosthesis Implantation
MH  - Fibrinolytic Agents/therapeutic use
MH  - Heart Defects, Congenital/*surgery
MH  - Humans
MH  - Ventricular Dysfunction, Right/*surgery
MH  - Ventricular Outflow Obstruction/*surgery
PMC - PMC2596120
EDAT- 2008/11/20 09:00
MHDA- 2009/01/14 09:00
CRDT- 2008/11/20 09:00
PHST- 2008/07/01 00:00 [received]
PHST- 2008/11/18 00:00 [accepted]
PHST- 2008/11/20 09:00 [pubmed]
PHST- 2009/01/14 09:00 [medline]
PHST- 2008/11/20 09:00 [entrez]
AID - 1749-8090-3-62 [pii]
AID - 10.1186/1749-8090-3-62 [doi]
PST - epublish
SO  - J Cardiothorac Surg. 2008 Nov 18;3:62. doi: 10.1186/1749-8090-3-62.

PMID- 34304746
OWN - NLM
STAT- MEDLINE
DCOM- 20220518
LR  - 20220518
IS  - 1467-1107 (Electronic)
IS  - 1047-9511 (Linking)
VI  - 32
IP  - 5
DP  - 2022 May
TI  - Aspirin resistance in infants with shunt-dependent congenital heart disease.
PG  - 705-710
LID - 10.1017/S1047951121002973 [doi]
AB  - INTRODUCTION: Patients with cyanotic heart disease are at an increased risk of 
      developing thrombosis. Aspirin has been the mainstay of prophylactic 
      anticoagulation for shunt-dependent patients with several reports of prevalent 
      aspirin resistance, especially in neonates. We investigate the incidence of 
      aspirin resistance and its relationship to thrombotic events and mortality in a 
      cohort of infants with shunt-dependent physiology. METHODS: Aspirin resistance 
      was assessed using the VerifyNow™ test on infants with single-ventricle 
      physiology following shunt-dependent palliation operations. In-hospital 
      thrombotic events and mortality data were collected. Statistical analysis was 
      performed to evaluate the effect of aspirin resistance on in-hospital thrombotic 
      events and mortality risk. RESULTS: Forty-nine patients were included with 41 of 
      these patients being neonates. Six patients (12%) were aspirin resistant. A birth 
      weight < 2500 grams was a significant factor associated with aspirin resistance 
      (p = 0.04). Following a dose increase or additional dose administration, all 
      patients with initial aspirin resistance had a normal aspirin response. There was 
      no statistically significant difference between aspirin resistance and 
      non-resistance groups with respect to thrombotic events. However, a statistically 
      significant incidence of in-hospital mortality in the presence of thrombotic 
      events was observed amongst aspirin-resistant patients (p = 0.04) in this study. 
      CONCLUSION: Low birth weight was associated with a higher incidence of aspirin 
      resistance. Inadequate initial dosing appears to be the primary reason for 
      aspirin resistance. The presence of both thrombotic events and aspirin resistance 
      was associated with significantly higher in-hospital mortality indicating that 
      these patients warrant closer monitoring.
FAU - Koh, Wonshill
AU  - Koh W
AUID- ORCID: 0000-0002-6519-7743
AD  - The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, 
      OH, USA.
AD  - Department of Pediatrics, University of Cincinnati College of Medicine, 
      Cincinnati, OH, USA.
FAU - Rodts, Megan
AU  - Rodts M
AUID- ORCID: 0000-0003-3231-0823
AD  - The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, 
      OH, USA.
FAU - Nebbia, Ashley
AU  - Nebbia A
AD  - Division of Pharmacy, The Heart Institute, Cincinnati Children's Hospital Medical 
      Center, Cincinnati, OH, USA.
FAU - Sawyer, Jaclyn
AU  - Sawyer J
AD  - Division of Pharmacy, The Heart Institute, Cincinnati Children's Hospital Medical 
      Center, Cincinnati, OH, USA.
FAU - Henry, Brandon
AU  - Henry B
AD  - The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, 
      OH, USA.
FAU - Cooper, David S
AU  - Cooper DS
AD  - The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, 
      OH, USA.
AD  - Department of Pediatrics, University of Cincinnati College of Medicine, 
      Cincinnati, OH, USA.
LA  - eng
PT  - Journal Article
DEP - 20210726
PL  - England
TA  - Cardiol Young
JT  - Cardiology in the young
JID - 9200019
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Heart Defects, Congenital/complications/surgery
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - *Thrombosis/epidemiology/etiology/prevention & control
OTO - NOTNLM
OT  - Thrombosis
OT  - aspirin resistance
OT  - congenital heart disease
OT  - shunt dependent
EDAT- 2021/07/27 06:00
MHDA- 2022/05/19 06:00
CRDT- 2021/07/26 05:29
PHST- 2021/07/27 06:00 [pubmed]
PHST- 2022/05/19 06:00 [medline]
PHST- 2021/07/26 05:29 [entrez]
AID - S1047951121002973 [pii]
AID - 10.1017/S1047951121002973 [doi]
PST - ppublish
SO  - Cardiol Young. 2022 May;32(5):705-710. doi: 10.1017/S1047951121002973. Epub 2021 
      Jul 26.

PMID- 26328807
OWN - NLM
STAT- MEDLINE
DCOM- 20180126
LR  - 20181113
IS  - 2107-0180 (Electronic)
IS  - 0378-7966 (Linking)
VI  - 41
IP  - 6
DP  - 2016 Dec
TI  - Investigation of the Interaction Between Human Serum Albumin and Two Drugs as 
      Binary and Ternary Systems.
PG  - 705-721
AB  - BACKGROUND AND OBJECTIVES: Human serum albumin (HSA) is the most frequent protein 
      in blood plasma. Albumin transports various compounds, preserves osmotic 
      pressure, and buffers pH. A unique feature of albumin is its ability to bind 
      drugs and other bioactive molecules. However, it is important to consider binary 
      and ternary systems of two pharmaceuticals to estimate the effect of the first 
      drug on the second one and physicochemical properties. METHODS: Different 
      techniques including time-resolved, second-derivative and anisotropy fluorescence 
      spectroscopy, resonance light scattering (RLS), critical induced aggregation 
      concentration (C (CIAC)), particle size, zeta potential and stability analysis 
      were employed in this assessment to elucidate the binding behavior of Amlodipine 
      and Aspirin to HSA. Moreover, isothermal titration calorimetric techniques were 
      performed and the QSAR properties were applied to analyze the hydration energy 
      and log P. Multiple sequence alignments were also used to predict the structure 
      and biological characteristics of the HSA binding site. RESULT: Time-resolved 
      fluorescence spectroscopy showed interaction of both drugs to HSA based on a 
      static quenching mechanism. Subsequently, second-derivative fluorescence 
      spectroscopy presented different values of parameter H in binary and ternary 
      systems, which were suggested that tryptophan was in a more polar environment in 
      the ternary system than in a binary system. Moreover, the polydispersity index 
      and results from mean number measurements revealed that the presence of the 
      second drug caused a decrease in the stability of systems and increased the 
      heterogeneity of complex. It is also, observed that the gradual addition of HSA 
      has led to a marked increase in fluorescence anisotropy (r) of Amlodipine and 
      Aspirin which can be suggested that the drugs were located in a restricted 
      environment of the protein as confirmed by Red Edge Excitation Shift (REES) 
      studies. The isothermal titration calorimetric technique demonstrated that the 
      interaction of the drugs with HSA was an enthalpically-driven process. 
      CONCLUSIONS: The present experiment showed that the binding of Amlodipine and 
      Aspirin to HSA induced a conformational change of HSA. It was also identified 
      that the protein binding of the first drug could be affected by the second drug. 
      Such results can be of great use for understanding the pharmacokinetic and 
      pharmacodynamic mechanisms of drugs.
FAU - Abdollahpour, Nooshin
AU  - Abdollahpour N
AD  - Department of Biology, Faculty of Sciences, Young Researchers and Elite Club, 
      Islamic Azad University-Mashhad Branch, Mashhad, Iran.
FAU - Soheili, Vahid
AU  - Soheili V
AD  - Department of Drug Control, School of Pharmacy, Mashhad University of Medical 
      Sciences, Mashhad, Iran. Soheiliv881@mums.ac.ir.
FAU - Saberi, Mohammad Reza
AU  - Saberi MR
AD  - Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of 
      Medical Sciences, Mashhad, Iran.
FAU - Chamani, Jamshidkhan
AU  - Chamani J
AD  - Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad 
      University, Mashhad, Iran. chamani@ibb.ut.ac.ir.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antihypertensive Agents)
RN  - 1J444QC288 (Amlodipine)
RN  - R16CO5Y76E (Aspirin)
RN  - ZIF514RVZR (Serum Albumin, Human)
SB  - IM
MH  - Amlodipine/chemistry/*metabolism
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*metabolism
MH  - Antihypertensive Agents/chemistry/*metabolism
MH  - Aspirin/chemistry/*metabolism
MH  - Binding Sites
MH  - Chemical Phenomena
MH  - Drug Interactions
MH  - Drug Stability
MH  - Humans
MH  - Kinetics
MH  - *Models, Molecular
MH  - Molecular Structure
MH  - Particle Size
MH  - Protein Conformation
MH  - Protein Stability/drug effects
MH  - Protein Unfolding/drug effects
MH  - Quantitative Structure-Activity Relationship
MH  - Serum Albumin, Human/chemistry/*metabolism
MH  - Solubility
MH  - Surface Properties
EDAT- 2015/09/04 06:00
MHDA- 2018/01/27 06:00
CRDT- 2015/09/03 06:00
PHST- 2015/09/04 06:00 [pubmed]
PHST- 2018/01/27 06:00 [medline]
PHST- 2015/09/03 06:00 [entrez]
AID - 10.1007/s13318-015-0297-y [pii]
AID - 10.1007/s13318-015-0297-y [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 2016 Dec;41(6):705-721. doi: 
      10.1007/s13318-015-0297-y.

PMID- 19573120
OWN - NLM
STAT- MEDLINE
DCOM- 20100222
LR  - 20191210
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 26
IP  - 7
DP  - 2009 Jul
TI  - The effect of anti-inflammatory (aspirin and/or statin) therapy on body weight in 
      Type 2 diabetic individuals: EAT, a retrospective study.
PG  - 708-13
LID - 10.1111/j.1464-5491.2009.02747.x [doi]
AB  - AIMS: Obesity is associated with inflammation. Anti-inflammatory interventions 
      such as aspirin and statins (anti-IFRx) might be a novel approach to the 
      treatment of obesity and Type 2 diabetes mellitus (T2DM). The present study was 
      designed to determine whether exposure to anti-IFRx is associated with weight 
      loss in T2DM patients. METHODS: Exposure to anti-IFRx was compared between T2DM 
      patients with a history of weight loss (n = 100) and those with no weight loss or 
      with weight gain (n = 102) during a 1-year follow-up period. Logistic regression 
      was used to develop odds ratios for weight loss status. RESULTS: Subjects who 
      lost weight were more frequently exposed to anti-IFRx (85.0 vs. 71.5%, P = 0.018) 
      than subjects who maintained or gained weight during follow-up. The 158 subjects 
      exposed to anti-IFRx were older (64.2 +/- 9.4 vs. 60.6 +/- 11.2 years, P = 0.04), 
      had longer duration T2DM (14.5 +/- 9.5 vs. 9.0 +/- 9.4 years, P = 0.001), had 
      greater prevalence of dyslipidaemia (72 vs. 19%, P < 0.0001) hypertension (57.3 
      vs. 38.1%, P = 0.03) and cardiovascular disease (37.7 vs. 9.5%, P < 0.0001) than 
      subjects not exposed to anti-IFRx. In a logistic regression model for weight 
      change status, anti-IFRx exposure was significantly associated with weight status 
      (odds ratio = 2.3, 95% confidence interval 1.1-4.8, P = 0.02, an association that 
      persisted), even after controlling for age, sex, baseline body mass index, years 
      since diagnosis, OHA therapy and co-morbidities. CONCLUSIONS: Exposure to 
      anti-IFRx more than doubled the odds of weight loss in T2DM patients. Results of 
      this study justify a randomized clinical trial to determine definitively the role 
      of anti-IFRx in weight loss in subjects with T2DM.
FAU - Boaz, M
AU  - Boaz M
AD  - Epidemiology and Research Unit, Wolfson Medical Center, Holon, Israel. 
      mboaz8@yahoo.com
FAU - Lisy, L
AU  - Lisy L
FAU - Zandman-Goddard, G
AU  - Zandman-Goddard G
FAU - Wainstein, J
AU  - Wainstein J
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology/therapeutic use
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Obesity/metabolism
MH  - Retrospective Studies
MH  - Weight Loss/*drug effects
MH  - Young Adult
EDAT- 2009/07/04 09:00
MHDA- 2010/02/23 06:00
CRDT- 2009/07/04 09:00
PHST- 2009/07/04 09:00 [entrez]
PHST- 2009/07/04 09:00 [pubmed]
PHST- 2010/02/23 06:00 [medline]
AID - DME2747 [pii]
AID - 10.1111/j.1464-5491.2009.02747.x [doi]
PST - ppublish
SO  - Diabet Med. 2009 Jul;26(7):708-13. doi: 10.1111/j.1464-5491.2009.02747.x.

PMID- 7008731
OWN - NLM
STAT- MEDLINE
DCOM- 19810413
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 141
IP  - 3 Spec No
DP  - 1981 Feb 23
TI  - Comparative analgesic efficacies of aspirin and acetaminophen.
PG  - 282-5
AB  - To be considered well designed, a study of analgesic efficacy must be conducted 
      under double-blind conditions with patients randomly allocated to each treatment 
      group. Ideally, the study should include both a placebo and an acceptable 
      standard or reference analgesic. Extraneous variables should be kept to a 
      minimum. The most firmly established pain models have used pain caused by cancer, 
      parturition (including episiotomy), surgery postoperatively, oral surgery, and 
      headache. The cancer pain model is most amenable to crossover or multiple-dose 
      studies because of the chronic nature of the pain. Appropriately designed 
      clinical studies have provided conclusive evidence that aspirin and acetaminophen 
      are equianalgesic and, milligram for milligram, equipotent. There also is some 
      evidence that acetaminophen can reduce swelling in inflammatory conditions other 
      than arthritis (eg, in patients who have had oral surgery).
FAU - Cooper, S A
AU  - Cooper SA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Inflammation/drug therapy
MH  - Pain/*drug therapy
MH  - Surgery, Oral
EDAT- 1981/02/23 00:00
MHDA- 1981/02/23 00:01
CRDT- 1981/02/23 00:00
PHST- 1981/02/23 00:00 [pubmed]
PHST- 1981/02/23 00:01 [medline]
PHST- 1981/02/23 00:00 [entrez]
AID - 10.1001/archinte.141.3.282 [doi]
PST - ppublish
SO  - Arch Intern Med. 1981 Feb 23;141(3 Spec No):282-5. doi: 
      10.1001/archinte.141.3.282.

PMID- 33528005
OWN - NLM
STAT- MEDLINE
DCOM- 20220224
LR  - 20220224
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 113
IP  - 7
DP  - 2021 Jul 1
TI  - Associations of Aspirin and Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs 
      With Colorectal Cancer Mortality After Diagnosis.
PG  - 833-840
LID - 10.1093/jnci/djab008 [doi]
AB  - BACKGROUND: Aspirin use reduces colorectal cancer (CRC) incidence, but there is 
      limited evidence regarding associations of aspirin and non-aspirin non-steroidal 
      anti-inflammatory drugs (NSAIDs) with CRC-specific survival. METHODS: This 
      prospective analysis includes women and men from the Cancer Prevention Study-II 
      Nutrition Cohort who were cancer free at baseline (1992 or 1993) and diagnosed 
      with CRC during incidence follow-up through 2015. Detailed information on aspirin 
      and non-aspirin NSAID use was self-reported on questionnaires at baseline, in 
      1997, and every 2 years thereafter. Pre- and postdiagnosis data were available 
      for 2686 and 1931 participants without distant metastases, respectively, among 
      whom 512 and 251 died from CRC during mortality follow-up through 2016. Secondary 
      analyses examined associations between prediagnosis aspirin use and stage at 
      diagnosis (distant metastatic vs localized or regional). All statistical tests 
      were 2-sided. RESULTS: Long-term regular use of aspirin (>15 times per month) 
      before diagnosis was associated with lower CRC-specific mortality 
      (multivariable-adjusted hazard ratio [HR] = 0.69, 95% confidence interval 
      [CI] = 0.52 to 0.92). Postdiagnosis regular aspirin use was not statistically 
      significantly associated with risk of CRC-specific mortality overall (HR = 0.82, 
      95% CI = 0.62 to 1.09), although participants who began regular aspirin use only 
      after their diagnosis were at lower risk than participants who did not use 
      aspirin at both the pre- and postdiagnosis periods (HR = 0.60, 95% CI = 0.36 to 
      0.98). Long-term aspirin use before diagnosis was also associated with lower odds 
      of diagnosis with distant metastases (multivariable-adjusted odds ratio = 0.73, 
      95% CI = 0.53 to 0.99). CONCLUSIONS: Our results suggest that long-term aspirin 
      use before a diagnosis of nonmetastatic colorectal cancer may be associated with 
      lower CRC-specific mortality after diagnosis, consistent with possible inhibition 
      of micrometastases before diagnosis.
CI  - © The Author(s) 2021. Published by Oxford University Press. All rights reserved. 
      For permissions, please email: journals.permissions@oup.com.
FAU - Figueiredo, Jane C
AU  - Figueiredo JC
AD  - Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, 
      Cedars-Sinai Medical Center, Los Angeles, CA, USA.
FAU - Jacobs, Eric J
AU  - Jacobs EJ
AD  - Department of Population Science, American Cancer Society, Atlanta, GA, USA.
FAU - Newton, Christina C
AU  - Newton CC
AD  - Department of Population Science, American Cancer Society, Atlanta, GA, USA.
FAU - Guinter, Mark A
AU  - Guinter MA
AUID- ORCID: 0000-0001-5547-7795
AD  - Department of Population Science, American Cancer Society, Atlanta, GA, USA.
FAU - Cance, William G
AU  - Cance WG
AD  - Office of the Chief Medical and Scientific Officer, American Cancer Society, 
      Atlanta, GA, USA.
FAU - Campbell, Peter T
AU  - Campbell PT
AUID- ORCID: 0000-0002-5549-2036
AD  - Department of Population Science, American Cancer Society, Atlanta, GA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pharmaceutical Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - doi: 10.1093/eurheartj/djab009
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Colorectal Neoplasms/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Odds Ratio
MH  - *Pharmaceutical Preparations
MH  - Risk Factors
PMC - PMC8246799
EDAT- 2021/02/03 06:00
MHDA- 2022/02/25 06:00
CRDT- 2021/02/02 08:41
PHST- 2020/07/27 00:00 [received]
PHST- 2020/09/21 00:00 [revised]
PHST- 2021/01/14 00:00 [accepted]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2022/02/25 06:00 [medline]
PHST- 2021/02/02 08:41 [entrez]
AID - 6123748 [pii]
AID - djab008 [pii]
AID - 10.1093/jnci/djab008 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2021 Jul 1;113(7):833-840. doi: 10.1093/jnci/djab008.

PMID- 15163984
OWN - NLM
STAT- MEDLINE
DCOM- 20041221
LR  - 20221207
IS  - 1027-6661 (Print)
IS  - 1027-6661 (Linking)
VI  - 10
IP  - 1
DP  - 2004
TI  - [Aspirin versus oral anticoagulants following lower limb arterial 
      reconstructions: what to choose?].
PG  - 12-6
AB  - Graft thrombosis in long-term postoperative period after lower extremity arterial 
      reconstructions often results in limb loss. In some studies prolonged 
      antithrombotic therapy was demonstrated to improve long-term patency of vascular 
      grafts. Nevertheless little consensus exists on the optimal antithrombotic 
      agents. The paper reviews publications on the problem. Oral anticoagulants seem 
      to be feasible for reconstructions with poor outflow. In such cases strict 
      laboratory monitoring of blood coagulation system is mandatory to prevent 
      hemorrhagic complications.
FAU - Pokrovskiĭ, A V
AU  - Pokrovskiĭ AV
AD  - Department of Vascular Surgery, A. V. Vishnevsky Institute of Surgery, Russian 
      Academy of Medical Science, Moscow, Russia.
FAU - Dan, V N
AU  - Dan VN
FAU - Sapelkin, S V
AU  - Sapelkin SV
FAU - Perisaev, G A
AU  - Perisaev GA
FAU - Kharazov, A F
AU  - Kharazov AF
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Aspirin ili oral'nye antikoagulianty posle rekonstruktivnykh sosudistykh 
      operatsiĭ na arteriiakh nizhnikh kozechnosteĭ: chto luchshe?
PL  - Russia (Federation)
TA  - Angiol Sosud Khir
JT  - Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery
JID - 9604504
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Administration Schedule
MH  - Humans
MH  - Lower Extremity/*blood supply
MH  - *Postoperative Care
MH  - Plastic Surgery Procedures/methods
MH  - Venous Thrombosis/physiopathology/*prevention & control/*surgery
MH  - Warfarin/administration & dosage/adverse effects/*therapeutic use
EDAT- 2004/05/28 05:00
MHDA- 2004/12/22 09:00
CRDT- 2004/05/28 05:00
PHST- 2004/05/28 05:00 [pubmed]
PHST- 2004/12/22 09:00 [medline]
PHST- 2004/05/28 05:00 [entrez]
PST - ppublish
SO  - Angiol Sosud Khir. 2004;10(1):12-6.

PMID- 1604441
OWN - NLM
STAT- MEDLINE
DCOM- 19920710
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 65
IP  - 1
DP  - 1992 Jan 1
TI  - In vitro platelets/endothelial cells interactions in presence of acetylsalicylic 
      acid at various dosages.
PG  - 33-43
AB  - Venous endothelium is able to release in vitro substances which modifies platelet 
      aggregation. A vascular fragment incubated in Michaelis buffer (pH 7.30), 
      aliquoted and tested on platelet-rich-plasma partially inhibits the aggregometry 
      parameters. Addition of acetylsalicylic acid (ASA) at ultra low dose (0.1 nM 
      final solution in the incubation tube) presents a reversed effect on this 
      inhibition. To explain this phenomenon, 6-keto-PGF1 alpha and von Willebrand 
      factor were dosed in the incubation media. After determination of an active level 
      of 6-keto-PGF1 alpha (200 pg/100 microliters), 2 series were made: series 1 
      included the values below 200 pg/100 microliters incubation media, series 2, the 
      values above 200 pg/100 microliters incubation media. When the vascular fragment 
      was incubated as described above, the results of aggregometry ratio for series 1 
      were: test A (without ASA): 0.84 +/- 0.18, test B1 (with 0.1 nM of ASA): 0.87 +/- 
      0.13. For series 2, they became: test A: 0.75 +/- 0.27, test B1: 0.93 +/- 0.16. 
      Control was always: 1.00 +/- 0.00. For the same groups, 6-keto-PGF1 alpha values 
      were: for series 1, test A: 81 +/- 57, test B1: 81 +/- 60 pg/100 microliters 
      incubation medium, for series 2, test A: 596 +/- 495, test B1: 383 +/- 263 pg/100 
      microliters incubation medium. Analyses were also performed with 2 high doses of 
      ASA (B2: 10(5) nM and B3: 10(6) nM final solution) in the same experimental 
      conditions. In these groups, aggregation parameters were decreased (0.86 +/- 0.14 
      for 10(5) nM, 0.84 +/- 0.15 for 10(6) nM) as well as 6-keto-PGF1 alpha production 
      (189 +/- 199 for 10(5) nM, 152 +/- 182 for 10(6) nM). For these two last ASA 
      treatments, comparison of the results in groups set up according to the sensitive 
      6-keto-PGF1 alpha value (200 pg/100 microliters solution) showed no modification. 
      So it seems that a certain reactive state, specific of ultra low dose treatment 
      is necessary for the vascular endothelium to be sensitive at such treatment.
FAU - Lalanne, M C
AU  - Lalanne MC
AD  - Laboratoire d'Hématologie, Bordeaux, France.
FAU - Ramboer, I
AU  - Ramboer I
FAU - de Sèze, O
AU  - de Sèze O
FAU - Doutremepuich, C
AU  - Doutremepuich C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (von Willebrand Factor)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/cytology/*drug effects
MH  - Cell Communication/*physiology
MH  - Endothelium, Vascular/cytology/*drug effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Radioimmunoassay
MH  - von Willebrand Factor/analysis
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 0049-3848(92)90223-W [pii]
AID - 10.1016/0049-3848(92)90223-w [doi]
PST - ppublish
SO  - Thromb Res. 1992 Jan 1;65(1):33-43. doi: 10.1016/0049-3848(92)90223-w.

PMID- 30700151
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211203
IS  - 2047-4881 (Electronic)
IS  - 2047-4873 (Print)
IS  - 2047-4873 (Linking)
VI  - 27
IP  - 19
DP  - 2020 Dec
TI  - Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: 
      An updated systematic review and meta-analysis.
PG  - 2034-2041
LID - 10.1177/2047487319825510 [doi]
AB  - BACKGROUND: The safety and efficacy of aspirin for the primary prevention of 
      cardiovascular disease in patients with diabetes mellitus remains controversial. 
      DESIGN: A meta-analysis to investigate the effects of aspirin for the prevention 
      of cardiovascular disease in diabetes mellitus. METHODS: Ten randomized 
      controlled trials were selected using MEDLINE, EMBASE and CENTRAL databases until 
      27 September 2018. Risk ratios (RRs) with 95% confidence intervals (CIs) and risk 
      differences (RDs) reported as incident events per 1000 person-years were 
      calculated. RESULTS: In 33,679 patients, aspirin did not significantly reduce the 
      risk of major adverse cardiovascular outcomes (RR 0.93, 95% CI 0.87-1.00, 
      P = 0.06; RD -0.68 incident cases per 1000 person-years (95% CI -1.54, 0.17)), 
      cardiovascular mortality (RR 0.95, 95% CI 0.83-1.09, P = 0.49; RD 0.11 incident 
      cases per 1000 person-years (95% CI -0.80, 1.02)), myocardial infarction (RR 
      0.91, 95% CI 0.75-1.11, P = 0.36; RD -0.66 incident cases per 1000 person-years 
      (95% CI -2.07, 0.75)), or stroke (RR 0.91, 95% C, 0.76-1.10, P = 0.33; RD -0.55 
      incident cases per 1000 person-years (95% CI -1.57, 0.47)). There was a 
      significantly higher risk of total bleeding associated with aspirin (RR 1.29, 95% 
      CI 1.07-1.55, P = 0.01; RD 1.49 incident cases per 1000 person-years (95% CI 
      0.36, 2.61)). CONCLUSION: The use of aspirin for primary prevention of 
      cardiovascular disease in patients with diabetes mellitus increases the risk of 
      total bleeding without reducing the risk of major adverse cardiovascular 
      outcomes.
FAU - Khan, Safi U
AU  - Khan SU
AD  - Department of Internal Medicine, West Virginia University, USA.
FAU - Ul Abideen Asad, Zain
AU  - Ul Abideen Asad Z
AD  - Department of Cardiovascular Medicine, University of Oklahoma, USA.
FAU - Khan, Muhammad U
AU  - Khan MU
AD  - Department of Internal Medicine, West Virginia University, USA.
FAU - Talluri, Swapna
AU  - Talluri S
AD  - Department of Internal Medicine, Guthrie Health System/Robert Packer Hospital, 
      USA.
FAU - Ali, Farman
AU  - Ali F
AD  - Department of Internal Medicine, Borgress Medical Center, USA.
FAU - Shahzeb Khan, Muhammad
AU  - Shahzeb Khan M
AD  - Department of Internal Medicine, John H Stroger Jr Hospital of Cook County, USA.
FAU - Lone, Ahmad N
AU  - Lone AN
AD  - Department of Internal Medicine, West Virginia University, USA.
FAU - Mookadam, Farouk
AU  - Mookadam F
AD  - Department of Cardiovascular Medicine, Mayo Clinic, USA.
FAU - Krasuski, Richard A
AU  - Krasuski RA
AD  - Department of Cardiovascular Medicine, Duke University School of Medicine, USA.
FAU - Kaluski, Edo
AU  - Kaluski E
AD  - Department of Cardiovascular Medicine, Guthrie Health System/Robert Packer 
      Hospital, USA.
LA  - eng
GR  - U54 GM104942/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190130
PL  - England
TA  - Eur J Prev Cardiol
JT  - European journal of preventive cardiology
JID - 101564430
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur J Prev Cardiol. 2019 Nov;26(16):1781-1782. PMID: 30971127
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - *Diabetes Mellitus
MH  - Diabetic Angiopathies/mortality/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Primary Prevention
PMC - PMC6667306
MID - NIHMS1024083
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - aspirin
OT  - diabetes mellitus
OT  - primary prevention
COIS- Declaration of conflicting interests The authors declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2019/02/01 06:00
MHDA- 2021/11/03 06:00
CRDT- 2019/02/01 06:00
PHST- 2019/02/01 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2019/02/01 06:00 [entrez]
AID - 10.1177/2047487319825510 [doi]
PST - ppublish
SO  - Eur J Prev Cardiol. 2020 Dec;27(19):2034-2041. doi: 10.1177/2047487319825510. 
      Epub 2019 Jan 30.

PMID- 22575418
OWN - NLM
STAT- MEDLINE
DCOM- 20121203
LR  - 20131121
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 130
IP  - 2
DP  - 2012 Aug
TI  - Aspirin response variability after major orthopedic surgery.
PG  - 216-20
LID - 10.1016/j.thromres.2012.04.006 [doi]
AB  - INTRODUCTION: Variability in platelet response to aspirin has been reported in 
      patients undergoing cardiac surgery but has rarely been described in other 
      operative settings and its mechanism remains uncertain. We performed a 
      prospective cohort study to investigate the variability in platelet response to 
      aspirin and to explore its mechanism in patients undergoing major orthopedic 
      surgery. MATERIALS AND METHODS: Twelve aspirin-treated patients undergoing 
      elective hip or knee replacement were recruited. Once-daily aspirin was continued 
      throughout the perioperative period. We measured platelet function using light 
      transmission aggregation (LTA) in response to arachidonic acid (PL(AA)) and serum 
      thromboxane B(2) (TXB(2)) at baseline (before surgery) as well as on days 1, 2, 
      3, 4, 5, 6, and 8 after surgery. We defined aspirin low response as a PL(AA)>20%. 
      RESULTS: Six patients exhibited aspirin low response, which typically started on 
      post-operative days 3 or 4; the remaining 6 patients had normal response to 
      aspirin. Compared to aspirin responders, patients with aspirin low response 
      showed significantly higher serum TXB(2) levels, a more pronounced early decrease 
      in platelet count, and a significantly more rapid recovery of the platelet count 
      after surgery. CONCLUSION: Aspirin response variability occurred in patients 
      after major orthopedic surgery, with one-half of the patients in our study 
      exhibiting post-operative aspirin low response. Increased platelet turnover might 
      be a contributor to aspirin response variability after orthopedic surgery.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Li, Chunjian
AU  - Li C
AD  - Department of Cardiology, First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China. lijay@njmu.edu.cn
FAU - Hirsh, Jack
AU  - Hirsh J
FAU - Sloane, Debi
AU  - Sloane D
FAU - Liang, Yan
AU  - Liang Y
FAU - Bai, Jianling
AU  - Bai J
FAU - Paikin, Jeremy
AU  - Paikin J
FAU - Johnston, Marilyn A
AU  - Johnston MA
FAU - DeBeer, Justin
AU  - DeBeer J
FAU - Eikelboom, John W
AU  - Eikelboom JW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120509
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid/metabolism
MH  - Arthroplasty, Replacement, Hip/adverse effects
MH  - Arthroplasty, Replacement, Knee/adverse effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/cytology/*drug effects
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Count
MH  - Prospective Studies
MH  - Thromboxane B2/blood
EDAT- 2012/05/12 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/05/12 06:00
PHST- 2012/01/30 00:00 [received]
PHST- 2012/03/27 00:00 [revised]
PHST- 2012/04/09 00:00 [accepted]
PHST- 2012/05/12 06:00 [entrez]
PHST- 2012/05/12 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S0049-3848(12)00194-6 [pii]
AID - 10.1016/j.thromres.2012.04.006 [doi]
PST - ppublish
SO  - Thromb Res. 2012 Aug;130(2):216-20. doi: 10.1016/j.thromres.2012.04.006. Epub 
      2012 May 9.

PMID- 3505289
OWN - NLM
STAT- MEDLINE
DCOM- 19890223
LR  - 20181113
IS  - 0035-8797 (Print)
IS  - 0035-8797 (Linking)
VI  - 37
IP  - 303
DP  - 1987 Oct
TI  - Aspirin and Reye's syndrome--do parents know?
PG  - 459-60
AB  - Amid growing concern over the association between aspirin and Reye's syndrome, 
      the Aspirin Foundation has recently mounted a publicity campaign advising against 
      the use of aspirin in children. Of 50 parents questioned at a children's ward of 
      a district general hospital, 46 (92%) had heard of the publicity, 38 via the 
      television. The number of parents who would give aspirin to their child had 
      dropped significantly from 45 before the campaign to five after it (P<0.001); 
      only one parent chose to ignore the advice. The media, particularly television, 
      is again shown to be a potent means of publicity. Despite the very high response 
      to the advice about aspirin none of the parents mentioned Reye's syndrome as the 
      reason.
FAU - Hall, R W
AU  - Hall RW
LA  - eng
PT  - Journal Article
PL  - England
TA  - J R Coll Gen Pract
JT  - The Journal of the Royal College of General Practitioners
JID - 7503107
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J R Coll Gen Pract. 1989 Feb;39(319):76, 78. PMID: 2552100
MH  - Aspirin/*adverse effects
MH  - Attitude to Health
MH  - Child
MH  - Female
MH  - Health Education
MH  - Humans
MH  - Male
MH  - Parents/*psychology
MH  - Reye Syndrome/*chemically induced
PMC - PMC1711069
EDAT- 1987/10/01 00:00
MHDA- 1987/10/01 00:01
CRDT- 1987/10/01 00:00
PHST- 1987/10/01 00:00 [pubmed]
PHST- 1987/10/01 00:01 [medline]
PHST- 1987/10/01 00:00 [entrez]
PST - ppublish
SO  - J R Coll Gen Pract. 1987 Oct;37(303):459-60.

PMID- 33940597
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 137
IP  - 23
DP  - 2021 Jun 10
TI  - Aspirin and antiplatelet treatments in cancer.
PG  - 3201-3211
LID - 10.1182/blood.2019003977 [doi]
AB  - Platelets have been hypothesized to promote certain neoplastic malignancies; 
      however, antiplatelet drugs are still not part of routine pharmacological cancer 
      prevention and treatment protocols. Paracrine interactions between platelets and 
      cancer cells have been implicated in potentiating the dissemination, survival 
      within the circulation, and extravasation of cancer cells at distant sites of 
      metastasis. Signals from platelets have also been suggested to confer epigenetic 
      alterations, including upregulating oncoproteins in circulating tumor cells, and 
      secretion of potent growth factors may play roles in promoting mitogenesis, 
      angiogenesis, and metastatic outgrowth. Thrombocytosis remains a marker of poor 
      prognosis in patients with solid tumors. Experimental data suggest that lowering 
      of platelet count may reduce tumor growth and metastasis. On the basis of the 
      mechanisms by which platelets could contribute to cancer growth and metastasis, 
      it is conceivable that drugs reducing platelet count or platelet activation might 
      attenuate cancer progression and improve outcomes. We will review select 
      pharmacological approaches that inhibit platelets and may affect cancer 
      development and propagation. We begin by presenting an overview of clinical 
      cancer prevention and outcome studies with low-dose aspirin. We then review 
      current nonclinical development of drugs targeted to platelet binding, 
      activation, and count as potential mitigating agents in cancer.
CI  - © 2021 by The American Society of Hematology.
FAU - Tao, Derrick L
AU  - Tao DL
AUID- ORCID: 0000-0001-5306-0259
AD  - Division of Hematology & Medical Oncology.
AD  - Department of Biomedical Engineering, and.
FAU - Tassi Yunga, Samuel
AU  - Tassi Yunga S
AUID- ORCID: 0000-0003-3631-2156
AD  - Department of Biomedical Engineering, and.
AD  - Cancer Early Detection & Advanced Research Center, Oregon Health & Science 
      University, Portland, OR; and.
FAU - Williams, Craig D
AU  - Williams CD
AUID- ORCID: 0000-0003-1628-1612
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State 
      University, Portland, OR.
FAU - McCarty, Owen J T
AU  - McCarty OJT
AUID- ORCID: 0000-0001-9481-0124
AD  - Division of Hematology & Medical Oncology.
AD  - Department of Biomedical Engineering, and.
LA  - eng
GR  - R01 HL101972/HL/NHLBI NIH HHS/United States
GR  - R01 HL144113/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*metabolism/pathology
MH  - Humans
MH  - Neoplasms/*drug therapy/*metabolism/pathology
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
PMC - PMC8351882
OTO - NOTNLM
OT  - P-selectin
OT  - PLATELETS/adhesion and adhesion receptors
OT  - PLATELETS/disorders of platelets
OT  - PLATELETS/physiology of normal platelets
OT  - PLATELETS/platelet interactions with other cells
OT  - PLATELETS/platelets: signal transduction
OT  - aspirin
OT  - cancer
OT  - cancer metastasis
OT  - platelet count
EDAT- 2021/05/04 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/05/03 20:31
PHST- 2020/05/22 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2021/05/04 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/05/03 20:31 [entrez]
AID - S0006-4971(21)00976-9 [pii]
AID - 2021/BLD2019003977C [pii]
AID - 10.1182/blood.2019003977 [doi]
PST - ppublish
SO  - Blood. 2021 Jun 10;137(23):3201-3211. doi: 10.1182/blood.2019003977.

PMID- 7799560
OWN - NLM
STAT- MEDLINE
DCOM- 19950120
LR  - 20131121
IS  - 0301-1542 (Print)
IS  - 0301-1542 (Linking)
VI  - 32
IP  - 9
DP  - 1994 Sep
TI  - [A case of aspirin-induced cough without bronchoconstriction. A new type of 
      aspirin hypersensitivity].
PG  - 883-7
AB  - A 54-year-old woman was admitted to our hospital because of an asthmatic attack. 
      Her first asthma attack occurred when she was 53 years old. It was followed by a 
      flu-like infection, and was preceded for one year perennial rhinitis and loss of 
      the sense of smell. Symptoms were perennial, and unrelated to the seasons. 
      Because these clinical findings resembled those of aspirin-induced asthma (AIA), 
      an aspirin-DL-lysine i.v. challenge test was done. Cough, perspiration, and 
      flushing was provoked within 15 min after aspirin-DL-lysine injection, but FEV1 
      did not change. Respiratory sounds were normal and no wheezing was audible. Other 
      cyclooxygenase inhibitors (ketoprofen, sulpyrine and acetaminophen) provoked the 
      same symptoms. Successively increasing doses of injected aspirin-DL-lysine 
      resulted in complete tolerance to this stimulus. We propose that aspirin-induced 
      cough without bronchoconstriction is a new type of aspirin hypersensitivity.
FAU - Imokawa, S
AU  - Imokawa S
AD  - Second Department of Internal Medicine, Hamamatsu University, School of Medicine.
FAU - Sato, A
AU  - Sato A
FAU - Taniguchi, M
AU  - Taniguchi M
FAU - Toyoshima, M
AU  - Toyoshima M
FAU - Nakazawa, K
AU  - Nakazawa K
FAU - Hayakawa, H
AU  - Hayakawa H
FAU - Chida, K
AU  - Chida K
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Kyobu Shikkan Gakkai Zasshi
JT  - Nihon Kyobu Shikkan Gakkai zasshi
JID - 7505737
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - *Bronchoconstriction
MH  - Cough/*chemically induced/physiopathology
MH  - Drug Hypersensitivity/*etiology/physiopathology
MH  - Female
MH  - Humans
MH  - Middle Aged
EDAT- 1994/09/01 00:00
MHDA- 1994/09/01 00:01
CRDT- 1994/09/01 00:00
PHST- 1994/09/01 00:00 [pubmed]
PHST- 1994/09/01 00:01 [medline]
PHST- 1994/09/01 00:00 [entrez]
PST - ppublish
SO  - Nihon Kyobu Shikkan Gakkai Zasshi. 1994 Sep;32(9):883-7.

PMID- 36866678
OWN - NLM
STAT- MEDLINE
DCOM- 20230403
LR  - 20230831
IS  - 1531-6963 (Electronic)
IS  - 1040-8711 (Print)
IS  - 1040-8711 (Linking)
VI  - 35
IP  - 3
DP  - 2023 May 1
TI  - Antiphospholipid syndrome management: a 2023 update and practical algorithm-based 
      approach.
PG  - 149-160
LID - 10.1097/BOR.0000000000000932 [doi]
AB  - PURPOSE OF REVIEW: Antiphospholipid syndrome (APS) is an acquired 
      thrombo-inflammatory disease that has morbid and sometimes devastating effects on 
      patients and their families. This review will discuss the most recent 
      international societal treatment guidelines and propose practical management 
      algorithms for various APS sub-types. RECENT FINDINGS: APS represents a disease 
      spectrum. Although thrombosis and pregnancy morbidities are traditional hallmarks 
      of APS, a variety of extra-criteria clinical phenotypes can often be seen, which 
      makes clinical management more challenging. Primary APS thrombosis prophylaxis 
      should take a risk-stratified approach. Although vitamin K antagonists (VKAs) or 
      heparin/low molecular weight heparin (LMWH) remain the preferred treatment for 
      secondary APS thrombosis prophylaxis, some international society guidelines 
      support the use of direct oral anticoagulants (DOACs) in certain circumstances. 
      Careful monitoring and individualized obstetric care with the use of aspirin and 
      heparin/LMWH will improve pregnancy outcomes among pregnant individuals with APS. 
      Treatment of microvascular and catastrophic APS remains challenging. While the 
      addition of various immunosuppressive agents is often utilized, further systemic 
      evaluations of their use are warranted before definitive recommendations can be 
      made. Several new therapeutic strategies are on the horizon that might enable 
      more personalized and targeted APS management in the near future. SUMMARY: 
      Although the knowledge of APS pathogenesis has grown in recent years, the 
      management principles and strategies are largely unchanged. There is an unmet 
      need for evaluating pharmacological agents, beyond anticoagulants, that target 
      diverse thromboinflammatory pathways.
CI  - Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Ambati, Amala
AU  - Ambati A
AD  - Division of Rheumatology, Department of Internal Medicine, University of 
      Michigan, Ann Arbor, Michigan, USA.
FAU - Knight, Jason S
AU  - Knight JS
FAU - Zuo, Yu
AU  - Zuo Y
LA  - eng
GR  - K08 AR080205/AR/NIAMS NIH HHS/United States
GR  - R01 HL134846/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230302
PL  - United States
TA  - Curr Opin Rheumatol
JT  - Current opinion in rheumatology
JID - 9000851
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - *Antiphospholipid Syndrome/complications/drug therapy
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Thrombosis/drug therapy
PMC - PMC10364614
MID - NIHMS1875347
COIS- CONFLICTS OF INTEREST The authors have no relevant financial conflicts of 
      interest to disclose.
EDAT- 2023/03/04 06:00
MHDA- 2023/04/03 06:41
PMCR- 2024/05/01
CRDT- 2023/03/03 05:03
PHST- 2024/05/01 00:00 [pmc-release]
PHST- 2023/04/03 06:41 [medline]
PHST- 2023/03/04 06:00 [pubmed]
PHST- 2023/03/03 05:03 [entrez]
AID - 00002281-202305000-00004 [pii]
AID - 10.1097/BOR.0000000000000932 [doi]
PST - ppublish
SO  - Curr Opin Rheumatol. 2023 May 1;35(3):149-160. doi: 10.1097/BOR.0000000000000932. 
      Epub 2023 Mar 2.

PMID- 28120185
OWN - NLM
STAT- MEDLINE
DCOM- 20170502
LR  - 20220316
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 77
IP  - 3
DP  - 2017 Mar
TI  - Drug Therapy for Stable Angina Pectoris.
PG  - 265-284
LID - 10.1007/s40265-017-0691-7 [doi]
AB  - Chronic stable angina pectoris refers to the predictable, reproducible occurrence 
      of pressure or a choking sensation in the chest or adjacent areas caused by 
      myocardial ischemia in association with physical or emotional stress, and 
      cessation of exertion and or sublingual nitroglycerin invariably relieves the 
      discomfort. It is a common presenting symptom of severe narrowing of one or more 
      coronary arteries, non-obstructive coronary arteries, or even when the coronary 
      arteries are angiographically normal. Patients often avoid activities which 
      precipitate symptoms and have impaired quality of life. Most patients with angina 
      pectoris can be managed with lifestyle changes, especially abstinence from 
      smoking and regular exercise, and anti-anginal drugs. However, the choice of 
      initial or combination antianginals as recommended in the guidelines is not 
      evidence based. In addition, patients with stable angina due to coronary artery 
      disease should also receive aspirin and a statin. Treatment of patients with 
      angina and normal coronary arteries remains to be established. The aim of this 
      article is to provide the readers not only with a guideline-based approach, which 
      varies from one country to another, but also an individual-based approach, which 
      takes into consideration circulatory status and the presence or absence of 
      comorbidities in the treatment decision-making process. This manuscript primarily 
      deals with drug therapy of stable angina pectoris and not coronary artery 
      revascularization, which also provides angina relief but is usually reserved for 
      patients who fail to respond to adequate drug therapy.
FAU - Rousan, Talla A
AU  - Rousan TA
AD  - The University of Oklahoma Health Sciences Center and The Veteran Affairs Medical 
      Center, 920 Stanton L. Young Blvd., WP 3010, Oklahoma City, OK, 73104, USA.
FAU - Mathew, Sunil T
AU  - Mathew ST
AD  - The University of Oklahoma Health Sciences Center and The Veteran Affairs Medical 
      Center, 920 Stanton L. Young Blvd., WP 3010, Oklahoma City, OK, 73104, USA.
FAU - Thadani, Udho
AU  - Thadani U
AD  - The University of Oklahoma Health Sciences Center and The Veteran Affairs Medical 
      Center, 920 Stanton L. Young Blvd., WP 3010, Oklahoma City, OK, 73104, USA. 
      udho-thadani@ouhsc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Stable/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Vasodilator Agents/*therapeutic use
EDAT- 2017/01/26 06:00
MHDA- 2017/05/04 06:00
CRDT- 2017/01/26 06:00
PHST- 2017/01/26 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
PHST- 2017/01/26 06:00 [entrez]
AID - 10.1007/s40265-017-0691-7 [pii]
AID - 10.1007/s40265-017-0691-7 [doi]
PST - ppublish
SO  - Drugs. 2017 Mar;77(3):265-284. doi: 10.1007/s40265-017-0691-7.

PMID- 20497673
OWN - NLM
STAT- MEDLINE
DCOM- 20100914
LR  - 20131121
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 123
IP  - 7
DP  - 2010 Apr 5
TI  - Transcatheter closure of patent foramen ovale with the Spider patent foramen 
      ovale occluder: a prospective, single-center trial.
PG  - 834-7
AB  - BACKGROUND: Transcatheter closure of patent foramen ovale (PFO) is a promising 
      alternative to surgical closure or anticoagulation therapy to prevent paradoxical 
      embolic events in patients with PFO. Several different devices have been used for 
      transcatheter PFO closure. The aim of the present study was to evaluate the 
      safety and feasibility for closure of PFO with a new PFO occluder, the Spider PFO 
      occluder. METHODS: The device was implanted in the PFO patients under fluoroscopy 
      and transthoracic echocardiography (TTE) using a 10 French delivery sheath 
      employing a femoral vein approach. Aspirin was administered at 100 mg/d for six 
      months after occlusion. The clinical and echocardiographic follow-up of patients 
      were performed at the 24th hour, 1st month, 3rd month, 6th month, and 12th month 
      after occlusion, and yearly thereafter. RESULTS: The device was implanted 
      successfully in all 55 patients. No major complications occurred during the 
      perioperative period, such as thromboembolism, occluder dislodgement, infection 
      or myocardial infarction. No residual shunt of the atrial level was shown by 
      transesophageal echocardiography, and no latent arrhythmia or cerebral vessel 
      events occurred in any cases during follow-up ((35 +/- 9) months, range 6 - 51 
      months). CONCLUSION: Transcatheter closure of a PFO with the Spider PFO occluder 
      is a safe and effective therapeutic option for the secondary prevention of 
      presumed paradoxical embolism. However, randomized trials comparing this device 
      with other devices and therapies have to be performed.
FAU - Zhang, Cao-Jin
AU  - Zhang CJ
AD  - Department of Cardiology, Guangdong General Hospital & Guangdong Cardiovascular 
      Institute, Guangzhou, Guangdong 510100, China.
FAU - Huang, Yi-Gao
AU  - Huang YG
FAU - Huang, Xin-Sheng
AU  - Huang XS
FAU - Huang, Tao
AU  - Huang T
FAU - Huang, Wen-Hui
AU  - Huang WH
FAU - Shen, Jun-Jun
AU  - Shen JJ
FAU - Xun, Zheng-Rong
AU  - Xun ZR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Cardiac Catheterization/*methods
MH  - Echocardiography
MH  - Female
MH  - Foramen Ovale, Patent/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Young Adult
EDAT- 2010/05/26 06:00
MHDA- 2010/09/15 06:00
CRDT- 2010/05/26 06:00
PHST- 2010/05/26 06:00 [entrez]
PHST- 2010/05/26 06:00 [pubmed]
PHST- 2010/09/15 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2010 Apr 5;123(7):834-7.

PMID- 23745305
OWN - NLM
STAT- MEDLINE
DCOM- 20130712
LR  - 20141120
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 96
IP  - 5
DP  - 2013 May
TI  - Aspirin non-responder in Thai ischemic stroke patients.
PG  - 523-30
AB  - BACKGROUND: An important cause of recurrent ischemic stroke is failure to prevent 
      secondary stroke due to poor control of important stroke risk factors. One of the 
      proposed important risk factor is aspirin resistance. The prevalence of aspirin 
      resistance varied widely. It depended on heterogeneity in studied populations and 
      methods of platelet functional assessment. OBJECTIVE: To describe the prevalence 
      of aspirin resistance based on optical platelet aggregometry in stroke patients 
      who attended the Neurological Institute and investigate the clinical risk factors 
      associated with aspirin resistance. MATERIAL AND METHOD: Three hundred stable 
      ischemic stroke patients, whose aspirin dosage varied between 60 to 325 mg/day 
      for at least 14 days before enrollment were recruited in the present study. 
      Demographic data, modifiable risk factors, and treatment were collected by 
      interview and from medical records. Aspirin resistance was determined by optical 
      platelet aggregation technique, using arachidonicacid (AA) and adenosine 
      diphosphate (ADP) as agonists. RESULTS: The patients were classified into two 
      groups based on their platelet aggregatometry tests (PAT). The cases group (n = 
      40, 13.3%) included both patients with aspirin resistance (n = 2, 0.6%) and 
      aspirin semi-responsiveness (n = 38, 12.7%). The control group was aspirin 
      non-resistance (n = 260, 86.7%). The cases were older (64.8 year vs. 61.26 year, 
      p = 0.049), higher proportion of females (60% vs. 41.5%, p = 0.029), and shorter 
      in height (159.9 CM vs. 164.1 CM, p = 0.007) than the control group. Dosage and 
      duration of the aspirin therapy were the same in both groups. The multivariate 
      analysis showed old age was associated with aspirin resistance. CONCLUSION: The 
      prevalence of aspirin resistance in the present study is 0.6% (95% CI, 
      0.18%-1.38%). The risk factor for aspirin resistance in post stroke patients is 
      aging. No association between duration and aspirin dosage with aspirin resistance 
      was found. The proportion of aspirin resistance was similar to a previous study 
      done in post myocardial infarction patients.
FAU - Suanprasert, Narupat
AU  - Suanprasert N
AD  - Prasat Neurological Institute, Bangkok, Thailand. narupatr@hotmail.com
FAU - Yadee, Thinonkorn
AU  - Yadee T
FAU - Mahasirimongkol, Surakameth
AU  - Mahasirimongkol S
FAU - Jongjaroenprasert, Wallaya
AU  - Jongjaroenprasert W
FAU - Tantirithisak, Tassanee
AU  - Tantirithisak T
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - *Aspirin/pharmacokinetics/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/therapeutic use
MH  - Platelet Function Tests
MH  - Prevalence
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Sex Factors
MH  - *Stroke/epidemiology/etiology/physiopathology/prevention & control
MH  - Thailand/epidemiology
EDAT- 2013/06/12 06:00
MHDA- 2013/07/16 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/06/11 06:00 [entrez]
PHST- 2013/06/12 06:00 [pubmed]
PHST- 2013/07/16 06:00 [medline]
PST - ppublish
SO  - J Med Assoc Thai. 2013 May;96(5):523-30.

PMID- 18351194
OWN - NLM
STAT- MEDLINE
DCOM- 20080513
LR  - 20191027
IS  - 1553-7250 (Print)
IS  - 1553-7250 (Linking)
VI  - 34
IP  - 2
DP  - 2008 Feb
TI  - Patient-directed intervention versus clinician reminders alone to improve aspirin 
      use in diabetes: a cluster randomized trial.
PG  - 98-105
AB  - BACKGROUND: Physician-directed approaches have not eliminated the underuse of 
      effective preventive therapies. METHODS: In a cluster-randomized design, 19 
      physicians caring for 334 eligible patients at least 40 years of age were 
      randomized. All clinicians received computerized reminders at office visits. 
      Intervention physicians received e-mails asking whether aspirin was indicated for 
      each patient. If so, patients received a mailing and nurse telephone call 
      addressing aspirin. The primary outcome was self-reported regular aspirin use. 
      RESULTS: Outcome assessment telephone interviews were completed for 242 (72.5%) 
      patients. At follow-up, aspirin use was reported by 60 (46%) of the 130 
      intervention patients and 44 (39%) of the 112 reminder-only patients, a 
      nonsignificant 7.2% difference (95% confidence interval: -3.9 to 18 percentage 
      points, p = .20). In the subgroup reporting no aspirin use at baseline and no 
      contraindications, 33 (43%) of the 76 intervention and 22 (30%) of the 74 
      reminder-only patients used aspirin, a 10% difference accounting for clustering 
      (95% CI: 2.2 to 18 percentage points, p = .013). DISCUSSION: A patient-directed 
      intervention modestly increased aspirin use among diabetes patients beyond that 
      achieved using computerized clinician reminders for ideal candidates. Obstacles 
      included difficulty contacting patients, real or perceived contraindications, and 
      failure to follow the nurse's advice.
FAU - Persell, Stephen D
AU  - Persell SD
AD  - Division of General Internal Medicine, Feinberg School of Medicine, Northwestern 
      University, Chicago, USA. spersell@nmff.org
FAU - Denecke-Dattalo, Therese A
AU  - Denecke-Dattalo TA
FAU - Dunham, Daniel P
AU  - Dunham DP
FAU - Baker, David W
AU  - Baker DW
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Jt Comm J Qual Patient Saf
JT  - Joint Commission journal on quality and patient safety
JID - 101238023
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Diabetes Mellitus/*drug therapy
MH  - Evidence-Based Medicine
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - *Patient Compliance
MH  - *Physician-Patient Relations
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Reminder Systems
MH  - United States
EDAT- 2008/03/21 09:00
MHDA- 2008/05/14 09:00
CRDT- 2008/03/21 09:00
PHST- 2008/03/21 09:00 [pubmed]
PHST- 2008/05/14 09:00 [medline]
PHST- 2008/03/21 09:00 [entrez]
AID - S1553-7250(08)34012-4 [pii]
AID - 10.1016/s1553-7250(08)34012-4 [doi]
PST - ppublish
SO  - Jt Comm J Qual Patient Saf. 2008 Feb;34(2):98-105. doi: 
      10.1016/s1553-7250(08)34012-4.

PMID- 28472145
OWN - NLM
STAT- MEDLINE
DCOM- 20170915
LR  - 20191210
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 5
DP  - 2017
TI  - Preoperative aspirin use and acute kidney injury after cardiac surgery: A 
      propensity-score matched observational study.
PG  - e0177201
LID - 10.1371/journal.pone.0177201 [doi]
LID - e0177201
AB  - BACKGROUND: The association between preoperative aspirin use and postoperative 
      acute kidney injury (AKI) in cardiovascular surgery is unclear. We sought to 
      evaluate the effect of preoperative aspirin use on postoperative AKI in cardiac 
      surgery. METHODS: A total of 770 patients who underwent cardiovascular surgery 
      under cardiopulmonary bypass were reviewed. Perioperative clinical parameters 
      including preoperative aspirin administration were retrieved. We matched 108 
      patients who took preoperative aspirin continuously with patients who stopped 
      aspirin more than 7 days or did not take aspirin for the month before surgery. 
      The parameters used in the matching included variables related to surgery type, 
      patient's demographics, underlying medical conditions and preoperative 
      medications. RESULTS: In the first seven postoperative days, 399 patients (51.8%) 
      developed AKI, as defined by the Kidney Disease Improving Global Outcomes (KDIGO) 
      criteria and 128 patients (16.6%) required hemodialysis. Most patients took 
      aspirin 100 mg once daily (n = 195, 96.5%) and the remaining 75 mg once daily. 
      Multivariable analysis showed that preoperative maintenance of aspirin was 
      independently associated with decreased incidence of postoperative AKI (odds 
      ratio [OR] 0.46, 95% confidence interval [CI] 0.21-0.98, P = 0.048; after 
      propensity score matching: OR 0.39, 95% CI 0.22-0.67, P = 0.001). Preoperative 
      maintenance of aspirin was associated with less incidence of AKI defined by KDIGO 
      both in the entire and matched cohort (n = 44 [40.7%] vs. 69 [63.9%] in aspirin 
      and non-aspirin group, respectively in matched sample, relative risk [RR] 0.64, 
      95% CI 0.49, 0.83, P = 0.001). Preoperative aspirin was associated with decreased 
      postoperative hospital stay after matching (12 [9-18] days vs. 16 [10-25] in 
      aspirin and non-aspirin group, respectively, P = 0.038). Intraoperative estimated 
      or calculated blood loss using hematocrit difference and estimated total blood 
      volume showed no difference according to aspirin administration in both entire 
      and matched cohort. CONCLUSIONS: Preoperative low dose aspirin administration 
      without discontinuation was protective against postoperative AKI defined by KDIGO 
      criteria independently in both entire and matched cohort. Preoperative aspirin 
      was also associated with decreased hemodialysis requirements and decreased 
      postoperative hospital stay without increasing bleeding. However, differences in 
      AKI and hospital stay were not associated with in-hospital mortality.
FAU - Hur, Min
AU  - Hur M
AD  - Department of Anesthesiology and Pain Medicine, Seoul National University 
      Hospital, Seoul, Republic of Korea.
FAU - Koo, Chang-Hoon
AU  - Koo CH
AD  - Department of Anesthesiology and Pain Medicine, Seoul National University 
      Hospital, Seoul, Republic of Korea.
AD  - Department of Anesthesiology and Pain Medicine, CHA Bundang Medical Center, CHA 
      University, Seongnam-si, Kyeonggi-do, Republic of Korea.
FAU - Lee, Hyung-Chul
AU  - Lee HC
AD  - Department of Anesthesiology and Pain Medicine, Seoul National University 
      Hospital, Seoul, Republic of Korea.
FAU - Park, Sun-Kyung
AU  - Park SK
AD  - Department of Anesthesiology and Pain Medicine, Seoul National University 
      Hospital, Seoul, Republic of Korea.
FAU - Kim, Minkyung
AU  - Kim M
AD  - Department of Anesthesiology and Pain Medicine, Seoul National University 
      Hospital, Seoul, Republic of Korea.
FAU - Kim, Won Ho
AU  - Kim WH
AUID- ORCID: 0000-0003-1748-1296
AD  - Department of Anesthesiology and Pain Medicine, Seoul National University 
      Hospital, Seoul, Republic of Korea.
FAU - Kim, Jin-Tae
AU  - Kim JT
AD  - Department of Anesthesiology and Pain Medicine, Seoul National University 
      Hospital, Seoul, Republic of Korea.
FAU - Bahk, Jae-Hyon
AU  - Bahk JH
AD  - Department of Anesthesiology and Pain Medicine, Seoul National University 
      Hospital, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20170504
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Kidney Injury/*etiology
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Preoperative Period
MH  - Thoracic Surgical Procedures/*adverse effects
PMC - PMC5417712
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2017/05/05 06:00
MHDA- 2017/09/16 06:00
CRDT- 2017/05/05 06:00
PHST- 2017/02/22 00:00 [received]
PHST- 2017/04/24 00:00 [accepted]
PHST- 2017/05/05 06:00 [entrez]
PHST- 2017/05/05 06:00 [pubmed]
PHST- 2017/09/16 06:00 [medline]
AID - PONE-D-17-07148 [pii]
AID - 10.1371/journal.pone.0177201 [doi]
PST - epublish
SO  - PLoS One. 2017 May 4;12(5):e0177201. doi: 10.1371/journal.pone.0177201. 
      eCollection 2017.

PMID- 33813477
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 74
IP  - 2
DP  - 2021
TI  - MORPHOLOGICAL CHANGES OF THE GASTRIC MUCOSA WHILE USING ANTIAGGREGANTS AND 
      PANTOPRAZOLE (AN EXPERIMENTAL STUDY).
PG  - 228-235
AB  - OBJECTIVE: The aim: Was to characterize the morphological peculiarities of the 
      gastric mucosa at early stage of prescription of acetylsalicylic acid (ASA) and 
      clopidogrel as well as to study the impact of pantoprazole on the gastric mucosa 
      to optimize the prophylaxis and treatment of gastropathies induced by ASA and 
      clopidogrel. PATIENTS AND METHODS: Materials and methods: The experiments were 
      performed on 77 non-linear white male rats with the average weight of 150-180 g. 
      Depending on the aim of research, the animals were divided into 7 groups. 
      RESULTS: Results: The administration of pantoprazole in combination with ASA and 
      clopidogrel presented positive trends in neutral glycoproteins amount and 
      contributes to preventing GM necrotic lesions by amplification of protective 
      properties of mucus and stabilization of apoptotic activity of gastric epithelial 
      cells. CONCLUSION: Conclusions: 1. According to our study findings, 
      administration of ASA in combination with clopidogrel results in 2,5 times higher 
      risk of GM erosive lesions. 2. One of the most significant morphological 
      manifestations of gastropathy in ASA and clopidogrel regimen is the development 
      of microerosions, which are poorly diagnosed by macroscopic examination. 3. The 
      use of PAS-reaction makes possible to identify damage to the basal membrane of 
      superficial epitheliocytes, which may be a top-priority morphological criterion 
      of gastropathy induced by ASA or clopidogrel in the absence of an inflammatory 
      reaction. 4. Administration of pantoprazole in combination with ASA and 
      clopidogrel contributes to preventing GM necrotic lesions by amplification of 
      protective properties of mucus and stabilization of apoptotic activity of gastric 
      epithelial cells.
FAU - Yankovetska, Alla G
AU  - Yankovetska AG
AD  - NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE.
FAU - Vernyhorodskyi, Serhii V
AU  - Vernyhorodskyi SV
AD  - NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE.
FAU - Paliy, Iryna G
AU  - Paliy IG
AD  - NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE.
FAU - Zaika, Serhii V
AU  - Zaika SV
AD  - NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
RN  - A74586SNO7 (Clopidogrel)
RN  - D8TST4O562 (Pantoprazole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Aspirin/adverse effects
MH  - Clopidogrel
MH  - Gastric Mucosa
MH  - Male
MH  - Pantoprazole
MH  - Rats
MH  - *Ticlopidine
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - clopidogrel
OT  - morphological changes
OT  - pantoprazole
OT  - stomach erosive lesions
EDAT- 2021/04/05 06:00
MHDA- 2021/04/07 06:00
CRDT- 2021/04/04 21:00
PHST- 2021/04/04 21:00 [entrez]
PHST- 2021/04/05 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PST - ppublish
SO  - Wiad Lek. 2021;74(2):228-235.

PMID- 15599029
OWN - NLM
STAT- MEDLINE
DCOM- 20050112
LR  - 20131121
IS  - 1671-3877 (Print)
IS  - 1671-3877 (Linking)
VI  - 30
IP  - 3
DP  - 2004 Jun
TI  - [Sugar metabolism and its regulation in postharvest ripening kiwifruit].
PG  - 317-24
AB  - Kiwifruit (Actinidia deliciosa cv. Bruno) was used to investigate starch and 
      sugar metabolism and the mechanisms of regulation by acetylsalicylic acid (AsA 
      1.0 mmol/L, pH 3.5), low temperature (0 degrees C) and ethylene (100 microL/L) 
      treatments. There was an increase in amylase activity at the initial stage 
      followed by dramatical decrease in starch content and a rapid increase in hexose 
      content at the rapid stage of fruit ripening and softening, which was associated 
      with an increase in SPS activity, a decrease in acid invertase activity, and the 
      accumulation of sucrose. AsA and low temperature treatments inhibited the amylase 
      activity, slowed down the hydrolysis of starch and the accumulation of hexoses, 
      suppressed the rise of SPS activity and the decline of acid invertase activity in 
      the ripening fruit. The accumulation of sucrose was delayed by AsA and low 
      temperature treatments. However, ethylene application induced amylase activity, 
      accelerated starch hydrolysis, and raised the hexose content. The SPS activity 
      also increased and the sucrose accumulated in the presence of ethylene. It is 
      suggested that the SPS may play a key role in sugar metabolism of postharvest 
      kiwifruit, and it could be activated by hexose and feedback-inhibited by sucrose. 
      AsA, low temperature and ethylene treatments regulate sugar metabolism probably 
      through influencing the SPS activity.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - The State Agriculture Ministry Laboratory of Horticultural Plant Growth, 
      Development and Biotechnology, Laboratory of Fruit Molecular Physiology and 
      Biotechnology, Huajiachi Campus, Zhejiang University, Hangzhou 310029 China.
FAU - Chen, Kun-Song
AU  - Chen KS
FAU - Zhang, Shang-Long
AU  - Zhang SL
FAU - Wang, Jian-Hua
AU  - Wang JH
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhi Wu Sheng Li Yu Fen Zi Sheng Wu Xue Xue Bao
JT  - Zhi wu sheng li yu fen zi sheng wu xue xue bao = Journal of plant physiology and 
      molecular biology
JID - 101156321
RN  - 0 (Ethylenes)
RN  - 0 (Sugar Phosphates)
RN  - 91GW059KN7 (ethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Actinidia/*metabolism
MH  - Aspirin/pharmacology
MH  - *Carbohydrate Metabolism
MH  - Ethylenes/pharmacology
MH  - Sugar Phosphates/biosynthesis
MH  - Temperature
EDAT- 2004/12/16 09:00
MHDA- 2005/01/13 09:00
CRDT- 2004/12/16 09:00
PHST- 2004/12/16 09:00 [pubmed]
PHST- 2005/01/13 09:00 [medline]
PHST- 2004/12/16 09:00 [entrez]
PST - ppublish
SO  - Zhi Wu Sheng Li Yu Fen Zi Sheng Wu Xue Xue Bao. 2004 Jun;30(3):317-24.

PMID- 484632
OWN - NLM
STAT- MEDLINE
DCOM- 19791129
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 135
IP  - 3
DP  - 1979 Oct 1
TI  - The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in 
      women with and without an intrauterine contraceptive device.
PG  - 393-6
AB  - The influence of ASA and paracetamol on menstural blood loss and on some 
      hematologic parameters was investigated in 23 women without an IUD and 10 women 
      with an IUD. Neither in women with normal nor in women with small defects in the 
      hemostatic mechanism were statistically significant increases in menstrual blood 
      losses observed during treatment with ASA or paracetamol when compared to 
      placebo. There was no linear correlation between bleeding time and basal 
      menstrual blood loss or between the blood losses induced by ASA and paracetamol 
      and the bleeding time.
FAU - Hahn, L
AU  - Hahn L
FAU - Petruson, B
AU  - Petruson B
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Hemostasis/drug effects
MH  - Humans
MH  - *Intrauterine Devices, Copper
MH  - Menstruation/*drug effects
MH  - Time Factors
OID - PIP: 792240
OID - POP: 00070787
OAB - The effects of acetylsalicylic acid (ASA) and paracetamol (PA) on the amount of 
      blood shed at menstruation were studied, in a double-blind fashion, as a model of 
      hemostasis. 33 women were studied: 23 without IUDs and 10 with devices in situ. 
      Neither in women with normal nor in women with small defects in the hemostatic 
      mechanism were statistically significant increases in menstrual blood losses 
      observed during treatment with either ASA or PA compared with placebo. The P 
      values for the differences in blood loss between women with normal and pathologic 
      hematology tests were .06, .02, and .07 on ASA, PA, and placebo, respectively. 
      There was no linear correlation between menstrual blood loss and bleeding time in 
      either the IUD group (r=.08) or the women who did not use an IUD (r=.18). Neither 
      were the values for menstrual blood loss after ASA and PA correlated to bleeding 
      time (for the IUD group r=.28 and .09, for nonusers, r=.08 and .06, 
      respectively).
OABL- eng
OTO - PIP
OT  - *Analgesia
OT  - Contraception
OT  - Contraceptive Methods--side effects
OT  - *Double-blind Studies
OT  - Family Planning
OT  - *Iud--side effects
OT  - *Menstruation
OT  - Reproduction
OT  - Research Methodology
OT  - Studies
OT  - Treatment
GN  - PIP: TJ: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY.
EDAT- 1979/10/01 00:00
MHDA- 1979/10/01 00:01
CRDT- 1979/10/01 00:00
PHST- 1979/10/01 00:00 [pubmed]
PHST- 1979/10/01 00:01 [medline]
PHST- 1979/10/01 00:00 [entrez]
AID - 0002-9378(79)90712-9 [pii]
AID - 10.1016/0002-9378(79)90712-9 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1979 Oct 1;135(3):393-6. doi: 10.1016/0002-9378(79)90712-9.

PMID- 16216276
OWN - NLM
STAT- MEDLINE
DCOM- 20051222
LR  - 20220408
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 78
IP  - 5
DP  - 2005 Dec 22
TI  - Analgesic substances derived from natural products (natureceuticals).
PG  - 476-84
AB  - From the first recorded accounts, over 7000 years ago, various forms of natural 
      products have been utilized to treat pain disorders. Prototypical examples of 
      such natural products are the opium poppy (Papaver soniferum) and the bark of the 
      willow tree (Salix spp.). It was not until the 19th century when individual 
      compounds were isolated from these substances and were determined to posses the 
      desired effects. The known sources of these substances have been thoroughly 
      investigated. Over the last several decades, more analgesic substances have been 
      purified from natural products resulting in novel structural classes and 
      mechanisms of actions. Plants and other natural products described in historical 
      ethnobotanical and ethnopharmacological literature have become of more recent 
      interest in drug discovery efforts. These manuscripts and reports are being 
      utilized to aid in the identification of natural products that have been 
      historically employed in the alleviation of pain. A large factor that has 
      highlighted the importance of discovering novel compounds to treat pain has been 
      in the fundamental understanding of the complex mechanisms of pain transmission 
      in the nervous system. Nociceptive processing involves many receptor classes, 
      enzymes and signaling pathways. The identification of novel classes of compounds 
      from natural sources may lead to advancing the understanding of these underlying 
      pharmacological mechanisms. With the potential of uncovering new compounds with 
      idealistic pharmacological profiles (i.e., no side effects, no addictive 
      potential), natural products still hold great promise for the future of drug 
      discovery especially in the treatment of pain disorders and potentially drug 
      addictions.
FAU - McCurdy, Christopher R
AU  - McCurdy CR
AD  - Department of Medicinal Chemistry, School of Pharmacy, National Center for 
      Natural Products Research, Research Institute of Pharmaceutical Sciences, 
      University of Mississippi, University, MS 38677, USA. cmccurdy@olemiss.edu
FAU - Scully, Stephen S
AU  - Scully SS
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20051010
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biological Products)
RN  - 0 (Ion Channels)
RN  - 0 (Receptors, Cannabinoid)
RN  - 0 (Receptors, Cholinergic)
RN  - 0 (TRPV Cation Channels)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/*isolation & purification/*pharmacology/therapeutic use
MH  - Analgesics, Opioid/isolation & purification/pharmacology/therapeutic use
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/isolation & 
      purification/pharmacology/therapeutic use
MH  - Aspirin/isolation & purification/pharmacology/therapeutic use
MH  - Biological Products/*chemistry/*pharmacology
MH  - Humans
MH  - Ion Channels/drug effects
MH  - Pain/drug therapy
MH  - Receptors, Cannabinoid/drug effects
MH  - Receptors, Cholinergic/drug effects
MH  - TRPV Cation Channels/drug effects
RF  - 47
EDAT- 2005/10/12 09:00
MHDA- 2005/12/24 09:00
CRDT- 2005/10/12 09:00
PHST- 2005/03/22 00:00 [received]
PHST- 2005/10/12 09:00 [pubmed]
PHST- 2005/12/24 09:00 [medline]
PHST- 2005/10/12 09:00 [entrez]
AID - S0024-3205(05)00883-0 [pii]
AID - 10.1016/j.lfs.2005.09.006 [doi]
PST - ppublish
SO  - Life Sci. 2005 Dec 22;78(5):476-84. doi: 10.1016/j.lfs.2005.09.006. Epub 2005 Oct 
      10.

PMID- 28079915
OWN - NLM
STAT- MEDLINE
DCOM- 20170502
LR  - 20170502
IS  - 1938-2359 (Electronic)
IS  - 0090-4481 (Linking)
VI  - 46
IP  - 1
DP  - 2017 Jan 1
TI  - Intravenous Immunoglobulin for the Treatment of Kawasaki Disease.
PG  - e25-e28
LID - 10.3928/19382359-20161212-01 [doi]
AB  - Standard first-line therapy for Kawasaki disease (KD) consists of intravenous 
      immunoglobulin (IVIG) and aspirin. Current guidelines recommend 2 g/kg of IVIG 
      and 80 to 100 mg/kg of aspirin administered within the first 10 days of illness. 
      This regimen has marked efficacy in preventing the development of coronary artery 
      aneurysms. Approximately 15% to 20% of treated patients require a second dose of 
      IVIG to control the inflammatory process. The role of adjunctive corticosteroid 
      therapy with IVIG and aspirin is evolving, with Japanese studies showing a clear 
      benefit in those patients at highest risk for development of coronary disease. 
      The challenge in North America has been reliable identification of the 
      highest-risk patients, which still eludes us because the Japanese scoring systems 
      are ineffective in multiethnic populations. Despite its efficacy, the precise 
      mechanism of IVIG's effect in KD is unclear but probably relates to its ability 
      to down-regulate aspects of the up-regulated inflammatory response in patients 
      with KD. [Pediatr Ann. 2017;46(1):e25-e28.].
CI  - Copyright 2017, SLACK Incorporated.
FAU - Shulman, Stanford T
AU  - Shulman ST
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatr Ann
JT  - Pediatric annals
JID - 0356657
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Mucocutaneous Lymph Node Syndrome/*therapy
EDAT- 2017/01/13 06:00
MHDA- 2017/05/04 06:00
CRDT- 2017/01/13 06:00
PHST- 2017/01/13 06:00 [entrez]
PHST- 2017/01/13 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
AID - 10.3928/19382359-20161212-01 [doi]
PST - ppublish
SO  - Pediatr Ann. 2017 Jan 1;46(1):e25-e28. doi: 10.3928/19382359-20161212-01.

PMID- 14677771
OWN - NLM
STAT- MEDLINE
DCOM- 20040316
LR  - 20190922
IS  - 0363-9045 (Print)
IS  - 0363-9045 (Linking)
VI  - 29
IP  - 10
DP  - 2003 Nov
TI  - Preparation and evaluation of high drug content particles.
PG  - 1109-18
AB  - To determine how to prepare high drug content particles using a Wurster fluidized 
      bed to determine realizing the miniaturization of solid dosage forms, aspirin was 
      selected as the model drug and granulated without any additive. In this study, 
      the emphasis was on evaluating the key operation factors of airflow rate and 
      atomizing flow volume. The properties of the resulting particles, such as the 
      average diameter, particle strength, appearance, and compressibility using 
      different airflow rates and atomizing flow volumes, were investigated. 
      Furthermore, detailed optimization of the operation conditions was conducted by 
      artificial neural network (ANN) analysis. The relationship between the 
      controlling factors (powder supplied, concentration of spray liquid, the amount 
      of consumed spray liquid, and spray rate) and the response variables (product 
      yield, median diameter, angle of repose, and degradation of aspirin) was 
      investigated after evaluating the airflow rate and atomizing flow volume effects. 
      The resulting granules under optimum operation conditions showed excellent 
      physicochemical properties such as particle size uniformity, flowability, and 
      compressibility.
FAU - Wang, Xiaoyan
AU  - Wang X
AD  - Shenyang Pharmaceutical University, Shenhe District, Shenyang, China.
FAU - Cui, Fude
AU  - Cui F
FAU - Yonezawa, Yorinobu
AU  - Yonezawa Y
FAU - Sunada, Hisakazu
AU  - Sunada H
LA  - eng
PT  - Journal Article
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Excipients/*chemistry
MH  - Materials Testing
MH  - Particle Size
MH  - Pressure
MH  - Tablets
EDAT- 2003/12/18 05:00
MHDA- 2004/03/18 05:00
CRDT- 2003/12/18 05:00
PHST- 2003/12/18 05:00 [pubmed]
PHST- 2004/03/18 05:00 [medline]
PHST- 2003/12/18 05:00 [entrez]
AID - 10.1081/ddc-120025868 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 2003 Nov;29(10):1109-18. doi: 10.1081/ddc-120025868.

PMID- 25467922
OWN - NLM
STAT- MEDLINE
DCOM- 20151221
LR  - 20181202
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 65
IP  - 2
DP  - 2015 Feb
TI  - Antiplatelet therapy after drug-eluting stent implantation.
PG  - 98-104
LID - S0914-5087(14)00304-9 [pii]
LID - 10.1016/j.jjcc.2014.10.006 [doi]
AB  - Dual antiplatelet therapy (DAPT), which is the combination of aspirin and a 
      platelet P2Y12 inhibitor, is the cornerstone of secondary prevention in ischemic 
      heart disease requiring intracoronary stenting. Although the efficacy of DAPT in 
      the reduction of ischemic events has been well validated, the optimal duration, 
      and indeed combination, of therapy is yet to be established. This area continues 
      to attract debate with new developments in stent design and antiplatelet agents, 
      as well as evolving clinical skill levels. Presently, clinical guidelines 
      advocate the use of DAPT for 6-12 months following drug-eluting stent (DES) 
      implantation, but this can vary according to clinical indication, bleeding risk, 
      and country of practice. Concerns have arisen that unnecessary prolongation of 
      DAPT may be associated with increased bleeding events, as well as cost. Whether 
      these guidelines effectively cater to current stenting techniques, devices, and 
      antiplatelet agents remains to be determined. This review analyzes contemporary 
      issues surrounding DAPT following DES implantation, as researchers continue to 
      seek to strike the optimal balance between bleeding and thrombotic risk. Although 
      reduced DAPT durations continue to show promising results in preventing ischemic 
      events while also mitigating bleeding risk, ultimately the consideration of 
      clinical presentation as well as medical and social history is paramount to 
      guiding the optimal duration and cessation of DAPT.
CI  - Copyright © 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Warren, Josephine
AU  - Warren J
AD  - Mount Sinai Medical Center, New York, NY, USA.
FAU - Baber, Usman
AU  - Baber U
AD  - Mount Sinai Medical Center, New York, NY, USA.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - Mount Sinai Medical Center, New York, NY, USA. Electronic address: 
      roxana.mehran@mountsinai.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141106
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - *Drug-Eluting Stents/adverse effects
MH  - Hemorrhage/prevention & control
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Purinergic P2Y Receptor Antagonists/*administration & dosage
MH  - Secondary Prevention/methods
MH  - Thrombosis/prevention & control
MH  - Time Factors
OTO - NOTNLM
OT  - Drug-eluting stents
OT  - Dual antiplatelet therapy
OT  - Percutaneous coronary intervention
EDAT- 2014/12/04 06:00
MHDA- 2015/12/22 06:00
CRDT- 2014/12/04 06:00
PHST- 2014/09/04 00:00 [received]
PHST- 2014/09/05 00:00 [accepted]
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2015/12/22 06:00 [medline]
AID - S0914-5087(14)00304-9 [pii]
AID - 10.1016/j.jjcc.2014.10.006 [doi]
PST - ppublish
SO  - J Cardiol. 2015 Feb;65(2):98-104. doi: 10.1016/j.jjcc.2014.10.006. Epub 2014 Nov 
      6.

PMID- 24147519
OWN - NLM
STAT- MEDLINE
DCOM- 20140623
LR  - 20131028
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 11
IP  - 11
DP  - 2013 Nov
TI  - Importance of measurement of platelet reactivity to ADP in patients with coronary 
      artery disease: an historical account.
PG  - 1547-56
LID - 10.1586/14779072.2013.839382 [doi]
AB  - The pivotal roles of platelets in physiological hemostasis and pathological 
      thrombosis at the site of plaque rupture are well established. The latter roles 
      provide the fundamental basis for the most widely implemented pharmacologic 
      management of coronary artery disease--dual antiplatelet therapy with aspirin to 
      inhibit platelet thromboxane A2 generation, and a P2Y12 receptor inhibitor to 
      prevent adenosine diphosphate (ADP)-induced platelet activation. Although 
      suboptimal pharmacodynamic efficacy, also described as high on-treatment platelet 
      reactivity to ADP, has been associated with greater risk for post-stenting 
      ischemic event occurrence, enhanced responsiveness is associated with higher risk 
      for bleeding in selected patients. In this review article, we aim to provide an 
      historical account of the one and a half century long journey starting with the 
      first description of platelets through the first report of ex vivo measurement of 
      ADP-induced platelet aggregation, the first demonstration of an association 
      between ADP-induced platelet aggregation and post-stenting ischemic event 
      occurrence, and finally to the most recent description of a 'therapeutic window' 
      concept for P2Y12 receptor inhibitor therapy.
FAU - Tantry, Udaya S
AU  - Tantry US
AD  - Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Cardiac 
      Catheterization Laboratory, 2401 W. Belvedere Ave, Baltimore, MD 21215, USA.
FAU - Mahla, Elisabeth
AU  - Mahla E
FAU - Gesheff, Martin G
AU  - Gesheff MG
FAU - Gurbel, Paul A
AU  - Gurbel PA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131023
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/metabolism/*pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Blood Platelets/drug effects/*metabolism
MH  - Coronary Artery Disease/drug therapy/*physiopathology
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology
MH  - Stents
EDAT- 2013/10/24 06:00
MHDA- 2014/06/24 06:00
CRDT- 2013/10/24 06:00
PHST- 2013/10/24 06:00 [entrez]
PHST- 2013/10/24 06:00 [pubmed]
PHST- 2014/06/24 06:00 [medline]
AID - 10.1586/14779072.2013.839382 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1547-56. doi: 
      10.1586/14779072.2013.839382. Epub 2013 Oct 23.

PMID- 2533210
OWN - NLM
STAT- MEDLINE
DCOM- 19900228
LR  - 20221207
IS  - 0891-6632 (Print)
IS  - 0891-6632 (Linking)
VI  - 3
IP  - 4
DP  - 1989 Oct-Dec
TI  - V.A. Cooperative Study of antiplatelet agents in diabetic patients after 
      amputation for gangrene: unobserved, sudden, and unexpected deaths.
PG  - 191-7
AB  - We report on unobserved, sudden, and unexpected deaths that occurred in a 
      randomized multicenter trial. The long-term effects of aspirin plus dipyridamole 
      on major vascular outcome variables were studied in 231 non insulin-dependent 
      diabetic men with either a recent amputation for gangrene or active gangrene. 
      Depending upon the definition of sudden death used, there were 14, 22, or 17 
      deaths in the drug group versus 6, 6, or 3 deaths in the placebo group (p = 0.04, 
      0.001, or 0.001, respectively). Total deaths from atherosclerotic vascular 
      disease or deaths from all causes did not differ in the two treatment groups. 
      Since this finding of a secondary end point is found only after multiple analyses 
      of the data, it must be interpreted with caution. However, it is suggested that 
      further studies on effects of antiplatelet agents on sudden deaths should be 
      performed.
FAU - Colwell, J A
AU  - Colwell JA
AD  - VA Medical Center, Charleston, SC 29403.
FAU - Bingham, S F
AU  - Bingham SF
FAU - Abraira, C
AU  - Abraira C
FAU - Anderson, J W
AU  - Anderson JW
FAU - Comstock, J P
AU  - Comstock JP
FAU - Kwaan, H C
AU  - Kwaan HC
FAU - Nuttall, F
AU  - Nuttall F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Diabet Complications
JT  - The Journal of diabetic complications
JID - 8708656
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Amputation, Surgical
MH  - Aspirin/*adverse effects/therapeutic use
MH  - *Death, Sudden
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipyridamole/*adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Gangrene/*surgery
MH  - Hospitals, Veterans
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Myocardial Infarction/chemically induced/mortality
MH  - Random Allocation
MH  - Risk Factors
MH  - South Carolina
EDAT- 1989/10/01 00:00
MHDA- 1989/10/01 00:01
CRDT- 1989/10/01 00:00
PHST- 1989/10/01 00:00 [pubmed]
PHST- 1989/10/01 00:01 [medline]
PHST- 1989/10/01 00:00 [entrez]
AID - 10.1016/0891-6632(89)90029-9 [doi]
PST - ppublish
SO  - J Diabet Complications. 1989 Oct-Dec;3(4):191-7. doi: 
      10.1016/0891-6632(89)90029-9.

PMID- 6436031
OWN - NLM
STAT- MEDLINE
DCOM- 19841220
LR  - 20181113
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 27
IP  - 1
DP  - 1984
TI  - Inhibition of platelet function by a controlled release acetylsalicylic acid 
      formulation--single and chronic dosing studies.
PG  - 67-74
AB  - The extent to which a controlled release acetylsalicylic acid (ASA) formulation 
      inhibited platelet function has been evaluated in single and chronic dosing 
      studies. In the single dose study, the platelet inhibitory effect of the 
      controlled release formulation was compared with that of an equivalent dose of 
      soluble ASA and an equimolar dose of sodium salicylate (SA). In the chronic 
      dosing study, ASA dose-response curves for platelet function, including 
      cyclooxygenase activity, were determined for various doses (20-1300 mg) of the 
      controlled release (enteric coated pellets) ASA formulation taken by volunteers 
      daily for one week. Platelet function was assessed by the degree of inhibition of 
      aggregation for several aggregating agents, and the degree of inhibition of 
      activity of platelet cyclooxygenase quantified by the estimation of 
      malondialdehyde (MDA) production. Plasma ASA and SA concentrations were also 
      determined in each study. The controlled release product inhibited platelet 
      function to the same extent as an equimolar dose of soluble ASA, but did so with 
      much lower and sometimes undetectable peak systemic plasma ASA concentrations. 
      SA, the direct metabolite of aspirin, did not have any effect on platelet 
      function. The ASA dose-platelet function response curves obtained from chronic 
      dosing with the controlled release formulation appeared to be similar to those 
      reported previously for the soluble product. The inhibition of platelet function 
      appeared to be unrelated to plasma ASA concentrations.
FAU - Roberts, M S
AU  - Roberts MS
FAU - McLeod, L J
AU  - McLeod LJ
FAU - Cossum, P A
AU  - Cossum PA
FAU - Vial, J H
AU  - Vial JH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Salicylates)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Platelets/*drug effects/enzymology/metabolism
MH  - Cyclooxygenase Inhibitors
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Male
MH  - Malondialdehyde/blood
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Time Factors
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1984;27(1):67-74.

PMID- 7235787
OWN - NLM
STAT- MEDLINE
DCOM- 19810709
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 141
IP  - 6
DP  - 1981 May
TI  - Healing of aspirin-associated peptic ulcer disease despite continued salicylate 
      ingestion.
PG  - 781-3
AB  - Patients who have rheumatic disease and who are undergoing long-term aspirin 
      therapy have a high incidence of peptic ulcer disease. Whether it is possible to 
      heal long-term aspirin-related peptic ulcer disease if aspirin intake is 
      continued is unknown. Nine patients with rheumatic disease who were receiving 
      long-term aspirin therapy and who had 15 endoscopically verified gastric and/or 
      duodenal ulcers were studied. Patients were treated daily with 1,200 mg of 
      cimetidine plus at least 120 mL of antacid (Mylanta II), while continuing aspirin 
      therapy at the same dose and type. By eight weeks, 14 ulcers had healed. This 
      study shows that some aspirin-associated peptic ulcers can be healed, despite 
      continued aspirin intake, by intensive medical therapy aimed at lowering 
      intragastric acidity.
FAU - O'Laughlin, J C
AU  - O'Laughlin JC
FAU - Silvoso, G R
AU  - Silvoso GR
FAU - Ivey, K J
AU  - Ivey KJ
LA  - eng
GR  - RR00287-12/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Antacids)
RN  - 80061L1WGD (Cimetidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antacids/administration & dosage
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cimetidine/administration & dosage
MH  - Duodenal Ulcer/*chemically induced/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Stomach Ulcer/*chemically induced/drug therapy
MH  - Time Factors
EDAT- 1981/05/01 00:00
MHDA- 1981/05/01 00:01
CRDT- 1981/05/01 00:00
PHST- 1981/05/01 00:00 [pubmed]
PHST- 1981/05/01 00:01 [medline]
PHST- 1981/05/01 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1981 May;141(6):781-3.

PMID- 3244834
OWN - NLM
STAT- MEDLINE
DCOM- 19890526
LR  - 20190824
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 36
IP  - 6
DP  - 1988 Dec
TI  - PGE measurement in mouse embryos and uterine/embryo tissue.
PG  - 835-46
AB  - Embryonic tissue of rodents and other species has been reported to produce 
      prostaglandins (PG) of the E series during gestation. We attempted to establish 
      the presence of PGE in C57BL/6J mouse embryos and peri-embryonic tissue as an 
      initial step in examining the role of maternal ethanol treatment on PG 
      production. Gestation day 10 embryos were found not to produce or degrade PGE. 
      However, a tissue complex which included embryonic tissue, peri-embryonic 
      membranes, placenta and uterus was capable of producing PGE from both endogenous 
      and exogenous arachidonic acid. Furthermore, in vivo and in vitro aspirin was 
      able to suppress PGE production from this tissue. It is concluded that gestation 
      day 10 C57BL/6J mouse embryonic tissue, unlike that of rat, is not capable of 
      measurable PGE production. However, uterine and peri-embryonic tissues, needed to 
      support pregnancy, are capable of significant PGE production.
FAU - Anton, R F
AU  - Anton RF
AD  - Veterans Administration Medical Center, Charleston, South Carolina 29403.
FAU - Randall, C L
AU  - Randall CL
FAU - Becker, H C
AU  - Becker HC
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Prostaglandins E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Embryo, Mammalian/*analysis/drug effects
MH  - Female
MH  - In Vitro Techniques
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Pregnancy
MH  - Prostaglandins E/*analysis
MH  - Uterus/*analysis
EDAT- 1988/12/01 00:00
MHDA- 1988/12/01 00:01
CRDT- 1988/12/01 00:00
PHST- 1988/12/01 00:00 [pubmed]
PHST- 1988/12/01 00:01 [medline]
PHST- 1988/12/01 00:00 [entrez]
AID - 0090-6980(88)90060-3 [pii]
AID - 10.1016/0090-6980(88)90060-3 [doi]
PST - ppublish
SO  - Prostaglandins. 1988 Dec;36(6):835-46. doi: 10.1016/0090-6980(88)90060-3.

PMID- 6502361
OWN - NLM
STAT- MEDLINE
DCOM- 19850109
LR  - 20131121
IS  - 0022-3395 (Print)
IS  - 0022-3395 (Linking)
VI  - 70
IP  - 4
DP  - 1984 Aug
TI  - The role of prostaglandins in cercarial (Schistosoma mansoni) response to free 
      fatty acids.
PG  - 584-91
AB  - In examining the structure-activity relationship of a diverse group of chemicals 
      reported to prevent cercarial penetration after topical application, we noticed a 
      moiety that was common to free fatty acids and prostaglandins. Because 
      unsaturated fatty acids have been reported to stimulate cercarial penetration, we 
      hypothesized that cercarial stimulation by skin and fatty acids may invoke 
      prostaglandin mechanisms in cercariae, skin, or both. Thus we compared the 
      stimulation of cercariae by a series of essential and nonessential fatty acids 
      and demonstrated an inhibition of this response by ibuprofen and aspirin, known 
      cyclo-oxygenase inhibitors, and by 13-azaprostanoic acid, a potent antagonist of 
      the thromboxane/endoperoxide receptor. These data led us to postulate a major 
      role for prostaglandins in the cercarial penetration response.
FAU - Salafsky, B
AU  - Salafsky B
FAU - Wang, Y S
AU  - Wang YS
FAU - Kevin, M B
AU  - Kevin MB
FAU - Hill, H
AU  - Hill H
FAU - Fusco, A C
AU  - Fusco AC
LA  - eng
GR  - AI 02656/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Parasitol
JT  - The Journal of parasitology
JID - 7803124
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Prostaglandins)
RN  - 0 (Prostanoic Acids)
RN  - 71629-07-7 (13-azaprostanoic acid)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Fatty Acids, Nonesterified/*pharmacology
MH  - Hydrogen-Ion Concentration
MH  - Ibuprofen/pharmacology
MH  - Prostaglandins/*physiology
MH  - Prostanoic Acids/pharmacology
MH  - Schistosoma mansoni/drug effects/*physiology
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
PST - ppublish
SO  - J Parasitol. 1984 Aug;70(4):584-91.

PMID- 30762284
OWN - NLM
STAT- MEDLINE
DCOM- 20191218
LR  - 20191218
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 66
IP  - 6
DP  - 2019 Jun
TI  - Aspirin in childhood acute ischemic stroke: The evidence for treatment and 
      efficacy testing.
PG  - e27665
LID - 10.1002/pbc.27665 [doi]
AB  - Aspirin is the most commonly prescribed antiplatelet agent worldwide, but 
      evidence supporting its use varies by age and disease process. Despite its 
      frequent use in childhood acute ischemic stroke prevention and management, major 
      knowledge gaps exist about optimal pediatric aspirin use, particularly in this 
      setting, where high-quality clinical trials are urgently needed. This review 
      focuses upon the evidence for aspirin use in childhood acute ischemic stroke, 
      includes a summary of aspirin pharmacology to highlight misconceptions and common 
      clinical situations which may limit its efficacy, and discusses the techniques 
      and potential role of laboratory monitoring of aspirin efficacy in children.
CI  - © 2019 Wiley Periodicals, Inc.
FAU - Boucher, Alexander A
AU  - Boucher AA
AUID- ORCID: 0000-0002-5392-1829
AD  - Department of Pediatrics, Cancer and Blood Diseases Institute, Cincinnati 
      Children's Hospital, Cincinnati, Ohio.
AD  - University of Cincinnati College of Medicine, Cincinnati, Ohio.
FAU - Taylor, J Michael
AU  - Taylor JM
AD  - University of Cincinnati College of Medicine, Cincinnati, Ohio.
AD  - Department of Pediatrics, Division of Neurology, Cincinnati Children's Hospital, 
      Cincinnati, Ohio.
FAU - Luchtman-Jones, Lori
AU  - Luchtman-Jones L
AD  - Department of Pediatrics, Cancer and Blood Diseases Institute, Cincinnati 
      Children's Hospital, Cincinnati, Ohio.
AD  - University of Cincinnati College of Medicine, Cincinnati, Ohio.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190214
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Brain Ischemia/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Practice Guidelines as Topic/*standards
MH  - Stroke/*prevention & control
OTO - NOTNLM
OT  - hemostasis and thrombosis
OT  - non-malignant hematology
OT  - pharmacology
EDAT- 2019/02/15 06:00
MHDA- 2019/12/19 06:00
CRDT- 2019/02/15 06:00
PHST- 2018/12/11 00:00 [received]
PHST- 2019/01/17 00:00 [revised]
PHST- 2019/01/30 00:00 [accepted]
PHST- 2019/02/15 06:00 [pubmed]
PHST- 2019/12/19 06:00 [medline]
PHST- 2019/02/15 06:00 [entrez]
AID - 10.1002/pbc.27665 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2019 Jun;66(6):e27665. doi: 10.1002/pbc.27665. Epub 2019 
      Feb 14.

PMID- 17642389
OWN - NLM
STAT- MEDLINE
DCOM- 20070904
LR  - 20131121
IS  - 1565-1088 (Print)
VI  - 9
IP  - 6
DP  - 2007 Jun
TI  - Aspirin withdrawal prior to invasive medical procedures: a strategy based on 
      thromboembolic and bleeding risk stratification.
PG  - 435-8
AB  - BACKGROUND: The management of aspirin therapy before an invasive procedure poses 
      a frequent clinical dilemma due to uncertainty regarding bleeding versus 
      thromboembolic risks associated with continuation or withdrawal of the drug. 
      There are no evidence-based data to refer to. OBJECTIVES: To assess the opinions 
      of internal medicine physicians regarding aspirin therapy prior to an invasive 
      procedure. METHODS: A questionnaire presenting nine hypothetical cases with 
      different combinations of bleeding and thromboembolic risk was given to 
      physicians in an internal medicine division during a personal interview. For each 
      case the participants had to choose between withdrawal of aspirin prior to an 
      invasive procedure, continuation of aspirin, or substitution of low molecular 
      weight heparin for aspirin. RESULTS: Sixty-one physicians participated in the 
      survey. For a patient with low thromboembolic risk, 77% (95% confidence interval 
      65.3-86.3%), 95% (87.2-98.7%) and 97% (89.6-99.5%) of physicians elected to 
      discontinue aspirin prior to a low, intermediate or high bleeding risk procedure, 
      respectively. For intermediate risk patients, 23% (95% CI 13.7-34.7%), 59% 
      (46.4-70.8%) and 74% (61.7-83.6%) would discontinue aspirin prior to a low, 
      intermediate or high risk procedure, and 5% (95% CI 1.3-12.8%), 23% (13.7-34.7%) 
      and 18% (9.9-29.2%) would substitute LMWH for aspirin. For a patient with high 
      thromboembolic risk, 1.6% (95% CI 0.08-7.8%), 11.5% (5.2-21.4%) and 18% 
      (9.9-29.2%) recommended discontinuing aspirin prior to a low, intermediate or 
      high risk procedure, respectively. In these situations, 18% (95% CI 9.9-29.2%), 
      53% (40.0-64.7%) and 57% (44.8-69.3%), respectively, would substitute LMWH for 
      aspirin. CONCLUSIONS: The results of the current investigation may help 
      practicing physicians to decide whether to discontinue aspirin therapy prior to 
      invasive procedures. The possible use of LMWH to replace aspirin as suggested 
      here should be further evaluated in a controlled clinical study.
FAU - Szalat, Auryan
AU  - Szalat A
AD  - Department of Internal Medicine B, Hadassah-Hebrew University Medical Center, 
      Jerusalem, Israel. auryan@md.huji.ac.il
FAU - Erez, Gilli
AU  - Erez G
FAU - Leitersdorf, Eran
AU  - Leitersdorf E
LA  - eng
PT  - Journal Article
PL  - Israel
TA  - Isr Med Assoc J
JT  - The Israel Medical Association journal : IMAJ
JID - 100930740
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Isr Med Assoc J. 2007 Aug;9(8):631; author reply 631. PMID: 17877078
MH  - Aspirin/*administration & dosage/adverse effects
MH  - *Attitude of Health Personnel
MH  - *Blood Loss, Surgical
MH  - Drug Administration Schedule
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Health Care Surveys
MH  - Heparin, Low-Molecular-Weight/*administration & dosage
MH  - Humans
MH  - Internal Medicine/methods/*statistics & numerical data
MH  - Interviews as Topic
MH  - Preoperative Care/*methods
MH  - Risk Assessment
MH  - Risk Factors
MH  - Surgical Procedures, Operative/classification
MH  - Thromboembolism/*prevention & control
MH  - Time Factors
EDAT- 2007/07/24 09:00
MHDA- 2007/09/05 09:00
CRDT- 2007/07/24 09:00
PHST- 2007/07/24 09:00 [pubmed]
PHST- 2007/09/05 09:00 [medline]
PHST- 2007/07/24 09:00 [entrez]
PST - ppublish
SO  - Isr Med Assoc J. 2007 Jun;9(6):435-8.

PMID- 26873936
OWN - NLM
STAT- MEDLINE
DCOM- 20170814
LR  - 20181113
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Print)
IS  - 0892-6638 (Linking)
VI  - 30
IP  - 5
DP  - 2016 May
TI  - Human plasma platelet-derived exosomes: effects of aspirin.
PG  - 2058-63
LID - 10.1096/fj.201500150R [doi]
AB  - Platelet-derived exosomes mediate platelet atherogenic interactions with 
      endothelial cells and monocytes. A new method for isolation of plasma 
      platelet-derived exosomes is described and used to examine effects of aging and 
      aspirin on exosome cargo proteins. Exosome secretion by purified platelets in 
      vitro did not increase after exposure to thrombin or collagen, as assessed by 
      exosome counts and quantification of the CD81 exosome marker. Thrombin and 
      collagen increased exosome content of α-granule chemokines CXCL4 and CXCL7 and 
      cytoplasmic high-mobility group box 1 (HMGB1) protein, but not membrane platelet 
      glycoprotein VI (GPVI), with dependence on extracellular calcium. Aspirin 
      consumption significantly blocked thrombin- and collagen-induced increases in 
      exosome cargo levels of chemokines and HMGB1, without altering total exosome 
      secretion or GPVI cargo. Plasma platelet-derived exosomes, enriched by absorption 
      with mouse antihuman CD42b [platelet glycoprotein Ib (GPIb)] mAb, had sizes and 
      cargo protein contents similar to those of exosomes from purified platelets. The 
      plasma platelet-derived exosome number is lower and its chemokine and HMGB1 
      levels higher after age 65 yr. Aspirin consumption significantly suppressed cargo 
      protein levels of plasma platelet-derived exosomes without altering total levels 
      of exosomes. Cargo proteins of human plasma platelet-derived exosomes may biomark 
      platelet abnormalities and in vivo effects of drugs.- Goetzl, E. J., Goetzl, L., 
      Karliner, J. S., Tang, N., Pulliam, L. Human plasma platelet-derived exosomes: 
      effects of aspirin.
CI  - © FASEB.
FAU - Goetzl, Edward J
AU  - Goetzl EJ
AD  - Department of Medicine, University of California, San Francisco, California, USA 
      Jewish Home of San Francisco, San Francisco, California, USA 
      edward.goetzl@ucsf.edu.
FAU - Goetzl, Laura
AU  - Goetzl L
AD  - Department of Obstetrics, Gynecology, and Reproductive Sciences, Temple 
      University, Philadelphia, Pennsylvania, USA.
FAU - Karliner, Joel S
AU  - Karliner JS
AD  - Department of Medicine, University of California, San Francisco, California, USA 
      Veterans Affairs Medical Center, San Francisco, California, USA.
FAU - Tang, Norina
AU  - Tang N
AD  - Veterans Affairs Medical Center, San Francisco, California, USA.
FAU - Pulliam, Lynn
AU  - Pulliam L
AD  - Department of Medicine, University of California, San Francisco, California, USA 
      Veterans Affairs Medical Center, San Francisco, California, USA Department of 
      Laboratory Medicine, University of California, San Francisco, California, USA.
LA  - eng
GR  - R21 HL129853/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160212
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/*physiology
MH  - Cells, Cultured
MH  - Exosomes/drug effects/*physiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
PMC - PMC4836374
OTO - NOTNLM
OT  - HMGB1
OT  - atherosclerosis
OT  - chemokines
OT  - glycoproteins
OT  - intercellular communication
EDAT- 2016/02/14 06:00
MHDA- 2017/08/15 06:00
CRDT- 2016/02/14 06:00
PHST- 2015/11/04 00:00 [received]
PHST- 2016/01/29 00:00 [accepted]
PHST- 2016/02/14 06:00 [entrez]
PHST- 2016/02/14 06:00 [pubmed]
PHST- 2017/08/15 06:00 [medline]
AID - fj.201500150R [pii]
AID - FJ_201500150R [pii]
AID - 10.1096/fj.201500150R [doi]
PST - ppublish
SO  - FASEB J. 2016 May;30(5):2058-63. doi: 10.1096/fj.201500150R. Epub 2016 Feb 12.

PMID- 2082486
OWN - NLM
STAT- MEDLINE
DCOM- 19910509
LR  - 20191029
IS  - 0896-0569 (Print)
IS  - 0896-0569 (Linking)
VI  - 12
DP  - 1990
TI  - A review of secondary coronary prevention with dipyridamole and aspirin.
PG  - 43-9
AB  - A large number of placebo-controlled trials of antiplatelet drugs have been 
      carried out. A summary of the results of AMIS, CDP, ISIS-2, PARIS I and II and 
      the Antiplatelet Trialists' Collaboration is presented. It is concluded that two 
      fatal events and three non-fatal events will be averted for every 100 patients 
      given a 2-year course of antiplatelet agents, starting promptly after myocardial 
      infarction.
FAU - Prentice, C R
AU  - Prentice CR
AD  - University Department of Medicine, General Infirmary, Leeds, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Thromb Res Suppl
JT  - Thrombosis research. Supplement
JID - 8309239
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Recurrence
MH  - Risk Factors
RF  - 11
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1016/0049-3848(90)90438-i [doi]
PST - ppublish
SO  - Thromb Res Suppl. 1990;12:43-9. doi: 10.1016/0049-3848(90)90438-i.

PMID- 3910252
OWN - NLM
STAT- MEDLINE
DCOM- 19860226
LR  - 20190511
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 19
IP  - 12
DP  - 1985 Dec
TI  - Adverse effects of high dose aspirin on platelet adhesion to experimental 
      autogenous vein grafts.
PG  - 770-6
AB  - Prostacyclin (PGI2) production and platelet adhesion were studied in veins 
      grafted into the arterial system of rabbits. Animal groups consisted of: no 
      treatment; low dose aspirin (ASA) (0.5 mg . kg-1 X 24 h-1) plus dipyridamole (2 
      mg . kg-1 X 6 h-1); high dose ASA (40 mg . kg-1 X 24 h-1) plus dipyridamole (2 mg 
      . kg-1 X 6 h-1); dipyridamole (2 mg . kg-1 X 6 h-1) alone. Results showed that 
      vein grafts from animals treated with high dose ASA plus dipyridamole produced 
      significantly less PGI2 than the other three groups (p less than 0.05 compared 
      with the dipyridamole group; p less than 0.01 compared with the other two 
      groups). In addition, there was significantly greater platelet deposition on the 
      vein grafts from this high dose ASA group as compared to the low dose ASA group 
      (p less than 0.05). By contrast, animals treated with dipyridamole alone had 
      significantly less platelet deposition compared to both the control and high dose 
      ASA groups (p less than 0.05). High dose ASA given to prevent thrombotic 
      occlusion following coronary artery bypass grafting may, by reducing PGI2, result 
      in enhanced platelet deposition. This in turn is likely to increase intimal 
      hyperplasia as has been demonstrated previously with high dose ASA. Clinical 
      studies, which have shown the early anti-thrombotic benefits of high dose ASA 
      plus dipyridamole, have not measured graft intimal thickness. Since this process 
      is an important cause of graft narrowing, ASA, in high dose, may adversely affect 
      long-term graft survival.
FAU - Gershlick, A H
AU  - Gershlick AH
FAU - Syndercombe Court, Y D
AU  - Syndercombe Court YD
FAU - Murday, A J
AU  - Murday AJ
FAU - Lewis, C T
AU  - Lewis CT
FAU - Mills, P G
AU  - Mills PG
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 64ALC7F90C (Dipyridamole)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/biosynthesis
MH  - Animals
MH  - Aspirin/*adverse effects/pharmacology
MH  - Autoradiography
MH  - Carotid Arteries/metabolism
MH  - Dipyridamole/adverse effects/pharmacology
MH  - Epoprostenol/*biosynthesis
MH  - Graft Occlusion, Vascular/*chemically induced/physiopathology
MH  - Jugular Veins/metabolism/transplantation
MH  - Models, Biological
MH  - Platelet Adhesiveness/*drug effects
MH  - Rabbits
EDAT- 1985/12/01 00:00
MHDA- 1985/12/01 00:01
CRDT- 1985/12/01 00:00
PHST- 1985/12/01 00:00 [pubmed]
PHST- 1985/12/01 00:01 [medline]
PHST- 1985/12/01 00:00 [entrez]
AID - 10.1093/cvr/19.12.770 [doi]
PST - ppublish
SO  - Cardiovasc Res. 1985 Dec;19(12):770-6. doi: 10.1093/cvr/19.12.770.

PMID- 18417070
OWN - NLM
STAT- MEDLINE
DCOM- 20080515
LR  - 20211020
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Linking)
VI  - 10
IP  - 2
DP  - 2008 Apr
TI  - Aspirin resistance in atherosclerosis.
PG  - 149-57
AB  - Clinically, aspirin resistance is defined as the failure of aspirin therapy to 
      prevent an acute vascular thrombotic event despite regular intake of appropriate 
      doses. In the laboratory, aspirin resistance encompasses the drug's failure to 
      attain a particular level of platelet inhibition. From a clinical standpoint, the 
      inability of aspirin to prevent a thrombotic event, despite appropriate 
      cyclooxygenase-1 inhibition, implies the involvement of other factors. Evidence 
      is emerging that aspirin resistance, as defined by residual platelet activity, 
      merely reflects an individual's enhanced basal platelet function and suggests a 
      hereditary component. Due to the multifactorial nature of cardiovascular disease, 
      it is likely that a single therapy like aspirin cannot fully treat and prevent 
      all thrombotic complications in the setting of atherosclerosis.
FAU - Blair, Price
AU  - Blair P
AD  - Boston University School of Medicine, 700 Albany Street, W507, Boston, MA 02118, 
      USA.
FAU - Freedman, Jane E
AU  - Freedman JE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/physiology
MH  - Coronary Artery Disease/*complications/physiopathology
MH  - Coronary Thrombosis/etiology/physiopathology/*prevention & control
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Activation/drug effects/genetics
MH  - Platelet Aggregation/drug effects/genetics
RF  - 50
EDAT- 2008/04/18 09:00
MHDA- 2008/05/16 09:00
CRDT- 2008/04/18 09:00
PHST- 2008/04/18 09:00 [pubmed]
PHST- 2008/05/16 09:00 [medline]
PHST- 2008/04/18 09:00 [entrez]
AID - 10.1007/s11883-008-0022-2 [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2008 Apr;10(2):149-57. doi: 10.1007/s11883-008-0022-2.

PMID- 11252112
OWN - NLM
STAT- MEDLINE
DCOM- 20010503
LR  - 20190813
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 161
IP  - 4
DP  - 2001 Feb 26
TI  - Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of 
      hospitalization for an acute myocardial infarction.
PG  - 538-44
AB  - BACKGROUND: Aspirin and angiotensin-converting enzyme (ACE) inhibitors are 
      recommended for secondary prevention after acute myocardial infarction (AMI), but 
      several studies have suggested that the combination of these medications may 
      produce a negative interaction. OBJECTIVE: To evaluate the effect and interaction 
      of aspirin and ACE inhibitors on mortality among elderly patients who survived a 
      hospitalization for AMI. METHODS: We evaluated the effect and interaction of 
      aspirin and ACE inhibitors on mortality in patients aged 65 years and older who 
      survived hospitalization with a confirmed AMI who were ideal candidates for the 
      therapies. RESULTS: Among the 14 129 patients, 26% received aspirin only, 20% 
      received ACE inhibitors only, 38% received both, and 16% received neither at 
      discharge. In the multivariate analysis, patients who received both aspirin and 
      ACE inhibitors alone had a significantly lower 1-year mortality (adjusted risk 
      ratio [ARR], 0.86 [95% confidence interval (CI), 0.78-0.95] vs 0.85 [95% CI, 
      0.77-0.93], respectively) compared with patients who received neither aspirin nor 
      ACE inhibitors at discharge. Prescribing both aspirin and ACE inhibitors was 
      associated with a slightly lower risk of mortality (ARR, 0.81; 95% CI, 0.74-0.88) 
      than that seen in aspirin-only or ACE inhibitor-only groups, but the difference 
      was not significantly different from the use of either medication alone. 
      CONCLUSIONS: The benefit of ACE inhibitors and aspirin is consistent with what 
      would be expected from overall results of randomized trials; prescribed together, 
      the effect is slightly greater than with either one alone, but not significantly 
      or substantially so.
FAU - Krumholz, H M
AU  - Krumholz HM
AD  - Yale University School of Medicine, 333 Cedar St, PO Box 208025, New Haven, CT 
      06520-8025, USA. harlan.krumholz@yale.edu
FAU - Chen, Y T
AU  - Chen YT
FAU - Wang, Y
AU  - Wang Y
FAU - Radford, M J
AU  - Radford MJ
LA  - eng
GR  - P549-500-96/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Intern Med. 2001 Sep 10;161(16):2048-9. PMID: 11525714
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cohort Studies
MH  - Drug Therapy, Combination
MH  - Hospitalization
MH  - Humans
MH  - Multivariate Analysis
MH  - Myocardial Infarction/blood/*drug therapy/mortality
MH  - Survival Analysis
MH  - United States/epidemiology
EDAT- 2001/03/17 10:00
MHDA- 2001/05/05 10:01
CRDT- 2001/03/17 10:00
PHST- 2001/03/17 10:00 [pubmed]
PHST- 2001/05/05 10:01 [medline]
PHST- 2001/03/17 10:00 [entrez]
AID - ioi00451 [pii]
AID - 10.1001/archinte.161.4.538 [doi]
PST - ppublish
SO  - Arch Intern Med. 2001 Feb 26;161(4):538-44. doi: 10.1001/archinte.161.4.538.

PMID- 3315257
OWN - NLM
STAT- MEDLINE
DCOM- 19880121
LR  - 20191022
IS  - 0742-0528 (Print)
IS  - 0742-0528 (Linking)
VI  - 4
IP  - 1
DP  - 1987
TI  - A chronobiologic approach to ethanol and acidified aspirin injury of the gastric 
      mucosa in the rat.
PG  - 19-29
AB  - Several models of erosive peptic disease have used drug-induced lesions to 
      examine protective mechanisms of the gastric mucosa. Physiological processes such 
      as acid secretion, motility, or epithelial cell turnover have circadian rhythms 
      which may modulate the susceptibility of the gastric mucosa to injury. In this 
      review are described recent studies which demonstrated that susceptibility to 
      gastric mucosal injury by acidified aspirin and absolute ethanol varied with the 
      phases of the light-dark cycle. Acidified aspirin caused significantly more 
      gastric mucosal lesions when administered early in the light phase compared to 
      administration early in the dark phase. The differences in susceptibility were 
      not altered by pretreatment conditions such as immobilization or length of the 
      fasting period. Absolute ethanol also caused significantly greater gastric 
      mucosal injury when administered in the light than in the dark phase, but this 
      difference was only evident in rats immobilized during the pretreatment fasting 
      period. Further studies are needed to correlate circadian susceptibility to 
      drug-induced gastric mucosal injury with physiological defense mechanisms. 
      Careful attention to circadian timekeeping may allow us to refine therapy to 
      optimize physiological defense mechanisms in the stomach.
FAU - Olson, C E
AU  - Olson CE
AD  - Center for Ulcer Research and Education, Wadsworth VA Medical Center Research and 
      Medical Services, Los Angeles.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - England
TA  - Chronobiol Int
JT  - Chronobiology international
JID - 8501362
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/toxicity
MH  - *Circadian Rhythm
MH  - Disease Models, Animal
MH  - Ethanol/toxicity
MH  - Gastric Mucosa/drug effects/*injuries
MH  - Rats
RF  - 40
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1080/07420528709078505 [doi]
PST - ppublish
SO  - Chronobiol Int. 1987;4(1):19-29. doi: 10.1080/07420528709078505.

PMID- 28446712
OWN - NLM
STAT- MEDLINE
DCOM- 20180216
LR  - 20181202
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 9
IP  - 4
DP  - 2017 Apr
TI  - Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma 
      cells to temozolomide therapy.
PG  - 1233-1247
LID - 10.18632/aging.101224 [doi]
AB  - Aberrant activation of sonic hedgehog (SHH)/glioma-associated oncogene homolog 1 
      (GLI1) pathway plays an important role in the tumorigenicity of malignant glioma 
      cells and resistance to temozolomide (TMZ). Here we investigated the aspirin's 
      antineoplastic molecular route by targeting SHH/GLI1 pathway and examined the 
      feasibility of aspirin combined with TMZ therapy. Western blot and quantitative 
      real-time polymerase chain reaction (qRT-PCR) revealed that the activity of the 
      SHH/GLI1 pathway was strongly inhibited by aspirin. Aspirin acted as the glioma 
      growth-inhibitory and pro-apoptosis roles by inhibiting the SHH/GLI1 pathway and 
      reprogramming the epithelial to mesenchymal transition (EMT). The 
      immunofluorescence assay showed aspirin could prevent the nuclear translocation 
      of GLI1 to inhibit its transcriptional regulation. The stable lentiviral 
      overexpression of GLI1 reversed the DNA double strand breaks (DSBs) caused by the 
      GANT61 and TMZ. Furthermore, aspirin combined with TMZ enhanced chemosensitivity 
      and GLI1-induced chemoprotection was partly blocked by aspirin in vitro and in 
      vivo. Collectively, aspirin has a therapeutic potential for SHH/GLI1 targeted 
      therapy against glioma cells. Acquired activation of GLI1 protects glioma cells 
      against TMZ therapy. Impairment of DNA DSBs repair activity might be involved in 
      the route of aspirin-induced chemosensitivity. Combined aspirin with TMZ may be a 
      promising strategy against malignant glioma.
FAU - Ming, Jianguang
AU  - Ming J
AD  - Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
AD  - Chinese Glioma Cooperative Group (CGCG), Beijing 100050, China.
FAU - Sun, Bo
AU  - Sun B
AD  - Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
AD  - Chinese Glioma Cooperative Group (CGCG), Beijing 100050, China.
FAU - Li, Ziwei
AU  - Li Z
AD  - Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
AD  - Chinese Glioma Cooperative Group (CGCG), Beijing 100050, China.
FAU - Lin, Lin
AU  - Lin L
AD  - Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
AD  - Chinese Glioma Cooperative Group (CGCG), Beijing 100050, China.
FAU - Meng, Xiangqi
AU  - Meng X
AD  - Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
AD  - Chinese Glioma Cooperative Group (CGCG), Beijing 100050, China.
FAU - Han, Bo
AU  - Han B
AD  - Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
AD  - Chinese Glioma Cooperative Group (CGCG), Beijing 100050, China.
FAU - Wang, Ruijia
AU  - Wang R
AD  - Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
AD  - Chinese Glioma Cooperative Group (CGCG), Beijing 100050, China.
FAU - Wu, Pengfei
AU  - Wu P
AD  - Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
AD  - Chinese Glioma Cooperative Group (CGCG), Beijing 100050, China.
FAU - Li, Jianlong
AU  - Li J
AD  - Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
AD  - Chinese Glioma Cooperative Group (CGCG), Beijing 100050, China.
FAU - Cai, Jinquan
AU  - Cai J
AD  - Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
AD  - Chinese Glioma Cooperative Group (CGCG), Beijing 100050, China.
AD  - Neuroscience Institute, Heilongjiang Academy of Medical Sciences, Harbin 150086, 
      China.
FAU - Jiang, Chuanlu
AU  - Jiang C
AD  - Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
AD  - Chinese Glioma Cooperative Group (CGCG), Beijing 100050, China.
AD  - Neuroscience Institute, Heilongjiang Academy of Medical Sciences, Harbin 150086, 
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (GLI1 protein, human)
RN  - 0 (Hedgehog Proteins)
RN  - 0 (SHH protein, human)
RN  - 0 (Zinc Finger Protein GLI1)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - R16CO5Y76E (Aspirin)
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/*pharmacology
MH  - Brain Neoplasms/*drug therapy/pathology
MH  - Cell Line, Tumor
MH  - DNA Repair/drug effects
MH  - Dacarbazine/*analogs & derivatives/therapeutic use
MH  - Drug Synergism
MH  - Epithelial-Mesenchymal Transition/drug effects
MH  - Glioma/*drug therapy/pathology
MH  - Hedgehog Proteins/*antagonists & inhibitors
MH  - Humans
MH  - Signal Transduction/*drug effects
MH  - Temozolomide
MH  - Translocation, Genetic/drug effects
MH  - Zinc Finger Protein GLI1/*antagonists & inhibitors
PMC - PMC5425124
OTO - NOTNLM
OT  - DNA damage
OT  - aspirin
OT  - glioma
OT  - hedgehog
OT  - temozolomide
COIS- CONFLICTS OF INTEREST All authors declared no conflict of interest.
EDAT- 2017/04/28 06:00
MHDA- 2018/02/17 06:00
CRDT- 2017/04/28 06:00
PHST- 2016/02/26 00:00 [received]
PHST- 2017/04/06 00:00 [accepted]
PHST- 2017/04/28 06:00 [pubmed]
PHST- 2018/02/17 06:00 [medline]
PHST- 2017/04/28 06:00 [entrez]
AID - 101224 [pii]
AID - 10.18632/aging.101224 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2017 Apr;9(4):1233-1247. doi: 10.18632/aging.101224.

PMID- 27098007
OWN - NLM
STAT- MEDLINE
DCOM- 20170303
LR  - 20170303
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Linking)
VI  - 54
IP  - 11
DP  - 2016 Nov
TI  - Design, synthesis and preliminary evaluation of the anti-inflammatory of the 
      specific selective targeting druggable enzymome cyclooxygenase-2 (COX-2) small 
      molecule.
PG  - 2505-2514
AB  - CONTEXT: Development of a reliable and selective anti-inflammatory agent of 
      cyclooxygenase-2 (COX-2), induced or up-regulated by inflammatory/injury stimulus 
      such as IL-1β, TNF-α and LPS in the various types of organs, tissues and cells, 
      with low side effects is a long-standing medicinal chemistry problem with 
      significant social implications. OBJECTIVE: To target druggable enzymome COX-2 by 
      exploiting NSAIDs and genipin (GEP) in anti-inflammatory infection. MATERIALS AND 
      METHODS: The compound aspirin GEP ester (AGE) was designed by computer-assisted 
      screening, synthesized in the esterification of the acylate derivative and the 
      methylate derivative with Et(3)N, and evaluated with 20, 40 and 60 mg/kg from 
      days 18 to 24 after immunization in collagen-induced arthritis (CIA) rats by the 
      sequential enzymatic experiments, western-blot analysis and pathological 
      observation methods. RESULTS: AGE exhibited higher binding affinity with COX-1 
      and displayed the lowest estimated free energy with COX-2 than other ligands 
      built by hanging NSAIDs with GEP, and was characterized by (1)H NMR, (13)C NMR 
      and HRMS. AGE was competed against COX-2 with molecule-dependent potencies and 
      selectivity (IC(50): 0.36 mM; selectivity index: 275) in the sequential enzymatic 
      experiments and decreased the expression of COX-2 in peripheral blood lymphocytes 
      of CIA rats. AGE (40 and 60 mg/kg) could significantly relieve the secondary hind 
      paw swelling and arthritis index, along with observing AGE attenuated 
      histopathological changes of fibroblast like synovial tissue (FLST) and 
      mesenteric lymph node lymphocytes (MLNL) in CIA rats. DISCUSSION AND CONCLUSION: 
      AGE pharmacophore reported herein may be an effective strategy to develop a novel 
      anti-inflammatory agent and potential inhibitor of COX-2.
FAU - Sun, Liang-Liang
AU  - Sun LL
AD  - a College of Pharmacy, Anhui University of Chinese Medicine , Key Laboratory of 
      Modernized Chinese Medicine in Anhui Province , Hefei , Anhui , P.R. China.
FAU - Wu, Hong
AU  - Wu H
AD  - a College of Pharmacy, Anhui University of Chinese Medicine , Key Laboratory of 
      Modernized Chinese Medicine in Anhui Province , Hefei , Anhui , P.R. China.
FAU - Zhang, Ya-Zhong
AU  - Zhang YZ
AD  - b Anhui Institute for Drug Control , Hefei , Anhui , P.R. China.
FAU - Wang, Rong
AU  - Wang R
AD  - a College of Pharmacy, Anhui University of Chinese Medicine , Key Laboratory of 
      Modernized Chinese Medicine in Anhui Province , Hefei , Anhui , P.R. China.
FAU - Wang, Wen-Yu
AU  - Wang WY
AD  - a College of Pharmacy, Anhui University of Chinese Medicine , Key Laboratory of 
      Modernized Chinese Medicine in Anhui Province , Hefei , Anhui , P.R. China.
FAU - Wang, Wei
AU  - Wang W
AD  - a College of Pharmacy, Anhui University of Chinese Medicine , Key Laboratory of 
      Modernized Chinese Medicine in Anhui Province , Hefei , Anhui , P.R. China.
FAU - Li, Shu-Ping
AU  - Li SP
AD  - a College of Pharmacy, Anhui University of Chinese Medicine , Key Laboratory of 
      Modernized Chinese Medicine in Anhui Province , Hefei , Anhui , P.R. China.
FAU - Dai, Li
AU  - Dai L
AD  - a College of Pharmacy, Anhui University of Chinese Medicine , Key Laboratory of 
      Modernized Chinese Medicine in Anhui Province , Hefei , Anhui , P.R. China.
FAU - Zhang, Zheng-Rong
AU  - Zhang ZR
AD  - a College of Pharmacy, Anhui University of Chinese Medicine , Key Laboratory of 
      Modernized Chinese Medicine in Anhui Province , Hefei , Anhui , P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20160421
PL  - England
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Iridoids)
RN  - A3V2NE52YG (genipin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*chemical synthesis/pharmacology
MH  - Arthritis, Experimental/drug therapy
MH  - Aspirin/chemistry/pharmacology
MH  - Cyclooxygenase 2 Inhibitors/*chemical synthesis/chemistry/pharmacology
MH  - Drug Design
MH  - Iridoids/pharmacology
MH  - Male
MH  - Molecular Docking Simulation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Structure-Activity Relationship
OTO - NOTNLM
OT  - Aspirin genipin ester
OT  - genipin
OT  - pharmacophore
EDAT- 2016/04/22 06:00
MHDA- 2017/03/04 06:00
CRDT- 2016/04/22 06:00
PHST- 2016/04/22 06:00 [pubmed]
PHST- 2017/03/04 06:00 [medline]
PHST- 2016/04/22 06:00 [entrez]
AID - 10.3109/13880209.2016.1160939 [doi]
PST - ppublish
SO  - Pharm Biol. 2016 Nov;54(11):2505-2514. doi: 10.3109/13880209.2016.1160939. Epub 
      2016 Apr 21.

PMID- 7779660
OWN - NLM
STAT- MEDLINE
DCOM- 19950717
LR  - 20131121
IS  - 0007-0947 (Print)
IS  - 0007-0947 (Linking)
VI  - 49
IP  - 3
DP  - 1995 May-Jun
TI  - Atrial fibrillation in the elderly: physicians' attitudes to anticoagulation.
PG  - 123-5
AB  - The use of warfarin and aspirin for the primary prevention of stroke in elderly 
      patients with atrial fibrillation (AF) is controversial. To establish current 
      practice we circulated a questionnaire to 300 geriatricians (G) and 300 
      cardiologists (C). The response rates were 47% G and 51% C. Most physicians 
      prescribed warfarin in AF associated with mitral stenosis (G vs C, 86% vs 89%, 
      NS). Cardiologists were more likely to prescribe warfarin in AF associated with 
      dilated cardiomyopathy (G vs C, 52% vs 86%, P < 0.01). A minority would prescribe 
      warfarin in aortic valve disease and AF (G vs C, 37% vs 24%, P < 0.05) and lone 
      AF (G vs C, 10% vs 26%, P < 0.01). Aspirin was favoured in aortic valve disease 
      and lone AF. The cardiologists were less reluctant to use warfarin in the young 
      and more likely to electrically cardiovert the young with chronic AF.
FAU - King, D
AU  - King D
AD  - Clatterbridge Hospital, Wirral, Merseyside.
FAU - Davies, K N
AU  - Davies KN
FAU - Slee, A
AU  - Slee A
FAU - Silas, J H
AU  - Silas JH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Clin Pract
JT  - The British journal of clinical practice
JID - 0372546
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - *Attitude of Health Personnel
MH  - *Cardiology
MH  - Cerebrovascular Disorders/*prevention & control
MH  - *Geriatrics
MH  - Humans
MH  - Warfarin/therapeutic use
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
PST - ppublish
SO  - Br J Clin Pract. 1995 May-Jun;49(3):123-5.

PMID- 21639969
OWN - NLM
STAT- MEDLINE
DCOM- 20110930
LR  - 20170926
IS  - 1701-2163 (Print)
IS  - 1701-2163 (Linking)
VI  - 33
IP  - 5
DP  - 2011 May
TI  - Prevention of adverse pregnancy outcomes with low-dose ASA in early pregnancy: 
      new perspectives for future randomized trials.
PG  - 480-483
LID - S1701-2163(16)34882-4 [pii]
LID - 10.1016/S1701-2163(16)34882-4 [doi]
AB  - Recent evidence suggests that treatment with low-dose acetylsalicylic acid (ASA) 
      started early in pregnancy could prevent preeclampsia and intrauterine growth 
      restriction (IUGR), two complications involving placental dysfunction. Preterm 
      birth could also potentially be prevented, suggesting that it could share 
      mechanisms of disease with preeclampsia and intrauterine growth restriction. 
      Because there is new evidence that placental dysfunction can be predicted as 
      early as in the first trimester, we argue that there is a need for randomized 
      controlled trials of low-dose ASA for the prevention of preeclampsia, IUGR, and 
      possibly preterm birth among nulliparous women with early indicators of placental 
      dysfunction.
FAU - Bujold, Emmanuel
AU  - Bujold E
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Université Laval, 
      Quebec QC; Centre de Recherche du Centre Hospitalier Universitaire de Québec 
      (CRCHUQ), Quebec QC.
FAU - Tapp, Sylvie
AU  - Tapp S
AD  - Centre de Recherche du Centre Hospitalier Universitaire de Québec (CRCHUQ), 
      Quebec QC; Department of Social and Preventive Medicine, Faculty of Medicine, 
      Université Laval, Quebec QC.
FAU - Audibert, Francois
AU  - Audibert F
AD  - Department of Obstetrics and Gynecology, CHU Hôpital Sainte-Justine, Faculty of 
      Medicine, Université de Montréal, Montreal QC.
FAU - Ferreira, Ema
AU  - Ferreira E
AD  - Department of Pharmacy, CHU Hôpital Sainte-Justine, Faculty of Medicine, 
      Université de Montréal, Montreal QC.
FAU - Forest, Jean-Claude
AU  - Forest JC
AD  - Department of Medical Biology, Faculty of Medicine, Université Laval, Quebec QC.
FAU - Rey, Evelyne
AU  - Rey E
AD  - Departments of Medicine and of Obstetrics and Gynecology, Faculty of Medicine, 
      Université de Montréal, Montreal QC.
FAU - Fraser, William D
AU  - Fraser WD
AD  - Department of Obstetrics and Gynecology, CHU Hôpital Sainte-Justine, Faculty of 
      Medicine, Université de Montréal, Montreal QC.
FAU - Chaillet, Nils
AU  - Chaillet N
AD  - Department of Obstetrics and Gynecology, CHU Hôpital Sainte-Justine, Faculty of 
      Medicine, Université de Montréal, Montreal QC.
FAU - Giguère, Yves
AU  - Giguère Y
AD  - Department of Medical Biology, Faculty of Medicine, Université Laval, Quebec QC.
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Obstet Gynaecol Can
JT  - Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et 
      gynecologie du Canada : JOGC
JID - 101126664
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Humans
MH  - Patient Selection
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
EDAT- 2011/06/07 06:00
MHDA- 2011/10/01 06:00
CRDT- 2011/06/07 06:00
PHST- 2011/06/07 06:00 [entrez]
PHST- 2011/06/07 06:00 [pubmed]
PHST- 2011/10/01 06:00 [medline]
AID - S1701-2163(16)34882-4 [pii]
AID - 10.1016/S1701-2163(16)34882-4 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Can. 2011 May;33(5):480-483. doi: 
      10.1016/S1701-2163(16)34882-4.

PMID- 17979795
OWN - NLM
STAT- MEDLINE
DCOM- 20071207
LR  - 20191027
IS  - 1570-1611 (Print)
IS  - 1570-1611 (Linking)
VI  - 5
IP  - 4
DP  - 2007 Oct
TI  - Monitoring of the antiplatelet drugs effect in patients with coronary artery 
      disease: what is the real clinical impact?
PG  - 293-301
AB  - Antiplatelet therapy is used to reduce the risk of ischemic events in patients 
      with cardiovascular disease. The balance of benefits and risks of antiplatelet 
      drugs in coronary artery disease has been evaluated in large-scale randomised 
      trials, however the absolute benefit for an individual patient and a specific 
      platelet-active drug need further evaluation. Several well-conducted studies have 
      demonstrated a substantial inter-individual variability in the platelet 
      responsiveness to drugs. The historical "gold standard" test of platelet function 
      (optical aggregation) has well established limitations for measuring the effect 
      of antiplatelet drugs. Other new tests developed (i.e. PFA-100, VerifyNow) may 
      overcome some of these limitations but they do not correlate well with each 
      other. Despite these unresolved methodological questions, several recent clinical 
      studies, but not all, suggest a significant correlation between antiplatelet 
      resistance status and serious vascular events. In these conditions, laboratory 
      monitoring for antiplatelet therapies raises several questions: (i) the necessity 
      for a consensus on the definition of resistance and on the best test for 
      evaluation of the condition, (ii) the demonstration that biological resistance 
      has clinical significance, and (iii) the clinical impact of adapting the 
      antiplatelet therapy. Therefore, it is not currently appropriate to test patients 
      or to change therapy on the basis of such tests, other than in prospective and 
      adequately powered clinical trials.
FAU - Christiaens, Luc
AU  - Christiaens L
AD  - Département Médico-Chirurgical de Cardiologie, Centre Hospitalo-Universitaire de 
      Poitiers, Hôpital de la Milétrie, Poitiers, France.
FAU - Macchi, Laurent
AU  - Macchi L
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Coronary Artery Disease/*drug therapy
MH  - *Drug Monitoring
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests/methods
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
RF  - 75
EDAT- 2007/11/06 09:00
MHDA- 2007/12/08 09:00
CRDT- 2007/11/06 09:00
PHST- 2007/11/06 09:00 [pubmed]
PHST- 2007/12/08 09:00 [medline]
PHST- 2007/11/06 09:00 [entrez]
AID - 10.2174/157016107782023361 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2007 Oct;5(4):293-301. doi: 10.2174/157016107782023361.

PMID- 12618069
OWN - NLM
STAT- MEDLINE
DCOM- 20030523
LR  - 20191106
IS  - 1090-0233 (Print)
IS  - 1090-0233 (Linking)
VI  - 165
IP  - 1
DP  - 2003 Jan
TI  - Influence of platelet count, acetylsalicylic acid, von Willebrand's disease, 
      coagulopathies, and haematocrit on results obtained using a platelet function 
      analyser in dogs.
PG  - 43-52
AB  - The platelet function analyser PFA-100 aspirates blood in vitro from a sample 
      reservoir in disposable test cartridges through a microscopic aperture cut into a 
      biologically active membrane at the end of a capillary. In different cartridges 
      the membrane is coated with collagen and adenosine diphosphate (ADP) or collagen 
      and epinephrine (adrenaline) inducing a platelet plug and closure of the 
      aperture. The closure time and total volume of blood flow through the capillary 
      until closure of its aperture were measured. The correlation between platelet 
      count in samples of thrombocytopenic dogs and results of the collagen/ADP 
      cartridge (closure time: r(S)=-0.579; total volume: r(S)=-0.549) was closer than 
      between platelet count and capillary bleeding time. No significant correlation 
      was observed between platelet count and the results obtained with the 
      collagen/epinephrine cartridge. In addition, a higher sensitivity was obtained 
      for the collagen/ADP cartridge. Injection of acetylsalicylic acid into healthy 
      dogs significantly increased closure time and total volume of both types of 
      cartridges (P<0.01). Two dogs with von Willebrand's disease had abnormal values. 
      In contrast, coagulopathies did not significantly influence the results of the 
      platelet function analyser (P>0.05). Despite adequate sensitivity of measurements 
      using the collagen/ADP cartridge to assess quantitative and qualitative platelet 
      disorders in dogs, the influence of haematocrit (P<0.0001) will limit the 
      clinical application of the analyser.
FAU - Mischke, R
AU  - Mischke R
AD  - Clinic for Small Animals, School of Veterinary Medicine Hannover, Hannover, 
      Germany reinhard.mischke@tiho-hannover.de
FAU - Keidel, A
AU  - Keidel A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Vet J
JT  - Veterinary journal (London, England : 1997)
JID - 9706281
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Coagulation Disorders/complications/*veterinary
MH  - Dog Diseases/*diagnosis
MH  - Dogs
MH  - Female
MH  - Hematocrit/*veterinary
MH  - Male
MH  - Platelet Count/*veterinary
MH  - Platelet Function Tests/*instrumentation/*veterinary
MH  - Reference Values
MH  - Sensitivity and Specificity
MH  - Time Factors
MH  - von Willebrand Diseases/complications/*veterinary
EDAT- 2003/03/06 04:00
MHDA- 2003/05/24 05:00
CRDT- 2003/03/06 04:00
PHST- 2003/03/06 04:00 [pubmed]
PHST- 2003/05/24 05:00 [medline]
PHST- 2003/03/06 04:00 [entrez]
AID - S1090023302001697 [pii]
AID - 10.1016/s1090-0233(02)00169-7 [doi]
PST - ppublish
SO  - Vet J. 2003 Jan;165(1):43-52. doi: 10.1016/s1090-0233(02)00169-7.

PMID- 8459653
OWN - NLM
STAT- MEDLINE
DCOM- 19930428
LR  - 20190725
IS  - 0021-5198 (Print)
IS  - 0021-5198 (Linking)
VI  - 61
IP  - 2
DP  - 1993 Feb
TI  - Effect of ibudilast on microcirculation thrombosis in rat inner ear.
PG  - 75-9
AB  - The effect of ibudilast (0.1, 0.3 mg/kg), which has cerebral vasodilating and 
      antiplatelet effects, was evaluated in two models of rat inner ear 
      microcirculation thrombosis by using the photochemical reaction between green 
      light (wave length: 540 nm) and intravenous injection of rose bengal. 
      Furthermore, the inner ear blood flow was measured by a laser-Doppler flowmeter. 
      In the hearing disturbance model, under anesthesia, the compound action potential 
      of the cochlear nerve (AP) was measured by an electrocochleogram. The sound 
      stimulus was an 8-kHz sine wave at 80 dB SPL. The AP was calculated 128 times. In 
      the controls, the AP disappeared about 4 min after the intravenous injection of 
      rose bengal (20 mg/kg). The time required to completely suppress the AP in the 
      animals treated with ibudilast (0.1, 0.3 mg/kg) was significantly prolonged as 
      compared with that in the controls. In the equilibrium dysfunction model, 
      ibudilast (0.1, 0.3 mg/kg) reduced the time of abnormal swimming in the swimming 
      test 24 hr after the completion of photo-illumination. Ibudilast (0.3 mg/kg) 
      increased the inner ear blood flow during the 10-min observation period as 
      compared with the controls, while it did not affect the mean blood pressure. In 
      conclusion, ibudilast increased the inner ear blood flow and was effective in two 
      models of rat inner ear microcirculation thrombosis.
FAU - Umemura, K
AU  - Umemura K
AD  - Department of Pharmacology, Hamamatsu University School of Medicine, Japan.
FAU - Asai, Y
AU  - Asai Y
FAU - Hirata, Y
AU  - Hirata Y
FAU - Uematsu, T
AU  - Uematsu T
FAU - Nakashima, M
AU  - Nakashima M
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Jpn J Pharmacol
JT  - Japanese journal of pharmacology
JID - 2983305R
RN  - 0 (Pyridines)
RN  - 0 (Vasodilator Agents)
RN  - M0TTH61XC5 (ibudilast)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cochlear Nerve/physiology
MH  - Ear, Inner/*blood supply/drug effects
MH  - Hearing Disorders/drug therapy/physiopathology
MH  - Laser-Doppler Flowmetry
MH  - Microcirculation/drug effects
MH  - Postural Balance/drug effects
MH  - Pyridines/*pharmacology/therapeutic use
MH  - Rats
MH  - Rats, Wistar
MH  - Thrombosis/*physiopathology
MH  - Vasodilator Agents/*pharmacology/therapeutic use
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
AID - 10.1254/jjp.61.75 [doi]
PST - ppublish
SO  - Jpn J Pharmacol. 1993 Feb;61(2):75-9. doi: 10.1254/jjp.61.75.

PMID- 23265354
OWN - NLM
STAT- MEDLINE
DCOM- 20130624
LR  - 20131121
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 80
IP  - 2
DP  - 2013 Feb
TI  - Dietary nitrate and reductive polyphenols may potentiate the vascular benefit and 
      alleviate the ulcerative risk of low-dose aspirin.
PG  - 186-90
LID - S0306-9877(12)00506-3 [pii]
LID - 10.1016/j.mehy.2012.11.025 [doi]
AB  - The recent revelation that daily low-dose aspirin not only lowers risk for 
      vascular events, but also can notably decrease risk for a range of 
      adenocarcinomas, decreasing total cancer mortality by about 20%, makes it highly 
      desirable to implement this protective strategy on a population-wide basis. 
      Nonetheless, the fact that low-dose aspirin approximately doubles risk for 
      serious gastrointestinal bleeding may impede health authorities from recommending 
      its use by people judged to be at low cardiovascular risk. Nitric oxide (NO) 
      exerts gastroprotective effects by boosting blood flow and mucus production in 
      the gastric mucosa - effects which demonstrably oppose the pro-ulcerative impact 
      of aspirin and other NSAIDs. A nitrate-rich diet, as well as ingestion of 
      reductive catechol-bearing polyphenols, can collaborate in promoting NO 
      generation in gastric juice, and they are protective in rodent models of gastric 
      ulceration. Moreover, a high-nitrate diet, as well as certain reductive 
      polyphenols such as epicatechin and quercetin, can exert platelet-stabilizing 
      effects complementary to those of aspirin, and act in other ways to preserve 
      vascular health. Hence, diets rich in nitrate and reductive polyphenols have the 
      potential to amplify the vascular-protective benefits of low-dose aspirin, while 
      diminishing its pro-ulcerative risk. Low-dose aspirin may be more unequivocally 
      recommendable within the context of such a dietary strategy.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - McCarty, Mark F
AU  - McCarty MF
AD  - NutriGuard Research, 1051 Hermes Ave., Encinitas, CA 92024, United States. 
      markfmccarty@gmail.com
LA  - eng
PT  - Journal Article
DEP - 20121221
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (Nitrates)
RN  - 0 (Polyphenols)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 8R1V1STN48 (Catechin)
RN  - 9IKM0I5T1E (Quercetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/diet therapy/*prevention & control
MH  - Catechin
MH  - Gastric Mucosa/blood supply/drug effects
MH  - Gastrointestinal Hemorrhage/chemically induced/diet therapy/*prevention & control
MH  - Humans
MH  - Models, Biological
MH  - Nitrates/*pharmacology
MH  - Nitric Oxide/metabolism/pharmacology
MH  - Polyphenols/*pharmacology
MH  - Quercetin
EDAT- 2012/12/26 06:00
MHDA- 2013/06/26 06:00
CRDT- 2012/12/26 06:00
PHST- 2012/04/27 00:00 [received]
PHST- 2012/11/17 00:00 [accepted]
PHST- 2012/12/26 06:00 [entrez]
PHST- 2012/12/26 06:00 [pubmed]
PHST- 2013/06/26 06:00 [medline]
AID - S0306-9877(12)00506-3 [pii]
AID - 10.1016/j.mehy.2012.11.025 [doi]
PST - ppublish
SO  - Med Hypotheses. 2013 Feb;80(2):186-90. doi: 10.1016/j.mehy.2012.11.025. Epub 2012 
      Dec 21.

PMID- 3140408
OWN - NLM
STAT- MEDLINE
DCOM- 19881123
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 51
IP  - 3
DP  - 1988 Aug 1
TI  - Why single daily dose of aspirin may not prevent platelet aggregation.
PG  - 259-66
AB  - The effect of different doses of aspirin on the synergistic activity of sodium 
      arachidonate plus platelet activating factor (paf) ADP or collagen in platelet 
      aggregation was studied in human volunteers. Aggregation studies in platelet rich 
      plasma (PRP) showed that aspirinated platelets, unresponsive to arachidonate, 
      when stirred with threshold concentrations of paf, ADP or collagen, reacted 
      differently according to the dose of aspirin and the time elapsed since 
      ingestion. After a single or daily 50 mg dose for 7-10 days independent of 
      elapsed time until blood withdrawal, a complete synergistic activity was 
      obtained. In PRP samples obtained 24 hours after the last aspirin intake, a 
      complete synergistic aggregation was achieved after a single dose or after 7-10 
      days of 500 mg aspirin ingestion; synergistic effect did not appear when blood 
      was drawn 2.5 hours after intake. The thromboxane B2 concentrations were very low 
      in all samples after PRP stimulation with sodium arachidonate or paf or both. As 
      rationale is that platelet activation in vivo occurs in response to several 
      stimuli, the therapeutic implications of our results is that aspirin may not 
      prevent the agonist potentiation effect when low dose or daily high dose (500mg) 
      are administrated. This may explain the erratic results of most aspirin trials in 
      which this drug was used to suppress platelet function.
FAU - Altman, R
AU  - Altman R
AD  - Centro de Estudios Medicos y Bioquimicos, Buenos Aires, Argentina.
FAU - Scazziota, A
AU  - Scazziota A
FAU - Funes, J C
AU  - Funes JC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Arachidonic Acids)
RN  - 0 (Platelet Activating Factor)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid
MH  - Arachidonic Acids/antagonists & inhibitors
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Collagen/antagonists & inhibitors
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activating Factor/antagonists & inhibitors
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thromboxane B2/biosynthesis
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
AID - 0049-3848(88)90103-X [pii]
AID - 10.1016/0049-3848(88)90103-x [doi]
PST - ppublish
SO  - Thromb Res. 1988 Aug 1;51(3):259-66. doi: 10.1016/0049-3848(88)90103-x.

PMID- 998866
OWN - NLM
STAT- MEDLINE
DCOM- 19770128
LR  - 20190627
IS  - 0002-9610 (Print)
IS  - 0002-9610 (Linking)
VI  - 132
IP  - 6
DP  - 1976 Dec
TI  - Detection and management of hypercoagulability.
PG  - 767-70
AB  - Patients at high risk of having thromboses can be identified not only on the 
      basis of clinical criteria but also on the basis of laboratory studies. With use 
      of a condensed coagulation profile consisting of six laboratory tests, the 
      clinical impression of hypercoagulability can be confirmed in approximately 90 
      per cent of cases. Therapy directed to correct specific laboratory abnormalities 
      may be more efficacious than nonspecific therapy.
FAU - Collins, G J Jr
AU  - Collins GJ Jr
FAU - Ahr, D J
AU  - Ahr DJ
FAU - Rich, N M
AU  - Rich NM
FAU - Andersen, C A
AU  - Andersen CA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Surg
JT  - American journal of surgery
JID - 0370473
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Blood Coagulation Disorders/*diagnosis/drug therapy
MH  - Blood Coagulation Tests
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Warfarin/therapeutic use
EDAT- 1976/12/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1976/12/01 00:00
PHST- 1976/12/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1976/12/01 00:00 [entrez]
AID - 0002-9610(76)90455-4 [pii]
AID - 10.1016/0002-9610(76)90455-4 [doi]
PST - ppublish
SO  - Am J Surg. 1976 Dec;132(6):767-70. doi: 10.1016/0002-9610(76)90455-4.

PMID- 1193427
OWN - NLM
STAT- MEDLINE
DCOM- 19760219
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 16
IP  - 9
DP  - 1975 Sep
TI  - Factors relevant to the prognosis of chronic gastric ulcer.
PG  - 714-8
AB  - The factors that determine the recurrence rate of chronic gastric ulcer were 
      studied in 105 patients. It was found that complete healing of the ulcer 
      significantly reduced the recurrence rate and subsequent need for hospital 
      admission because of ulcer symptoms when this group was compared with those who 
      left hospital with their ulcers unhealed. Those admitted with large ulcers also 
      had a higher recurrence rate. The age and sex of the patient, ingestion of 
      analgesics and cigarette smoking did not influence recurrence. The initial 
      healing rate of the ulcer also had no effect on the subsequent course of the 
      patient.
FAU - Piper, D W
AU  - Piper DW
FAU - Greig, M
AU  - Greig M
FAU - Coupland, G A
AU  - Coupland GA
FAU - Hobbin, E
AU  - Hobbin E
FAU - Shinners, J
AU  - Shinners J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/pharmacology
MH  - Chronic Disease
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Prognosis
MH  - Recurrence
MH  - Sex Factors
MH  - Smoking
MH  - Stomach Ulcer/*diagnosis/therapy
PMC - PMC1413114
EDAT- 1975/09/01 00:00
MHDA- 1975/09/01 00:01
CRDT- 1975/09/01 00:00
PHST- 1975/09/01 00:00 [pubmed]
PHST- 1975/09/01 00:01 [medline]
PHST- 1975/09/01 00:00 [entrez]
AID - 10.1136/gut.16.9.714 [doi]
PST - ppublish
SO  - Gut. 1975 Sep;16(9):714-8. doi: 10.1136/gut.16.9.714.

PMID- 7564348
OWN - NLM
STAT- MEDLINE
DCOM- 19951122
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 26
IP  - 1
DP  - 1995 Jul
TI  - Acute thrombogenicity of arterial prostheses exposed to reduced blood flow in 
      dogs: effects of heparin, aspirin, and prostacyclin.
PG  - 1-5
AB  - Thrombogenesis is considered the principal cause of early failure of arterial 
      grafts. Although antithrombotic drugs are recommended, their efficiency under low 
      blood flow conditions is still being debated. In this study, we evaluated the 
      ability of three drugs to modify the thrombotic properties of blood and, 
      consequently, to influence platelet and fibrin deposition on the luminal surface 
      of polyester arterial prostheses. In dogs receiving saline (control, n = 10), 
      heparin (100 U/kg, n = 5), aspirin (325 mg, n = 5), or prostacyclin (15 
      ng/kg/min, n = 5), a 30-cm, woven, loop-shaped, DeBakey arterial prosthesis was 
      implanted as a substitute for the infrarenal aorta and exposed to reduced blood 
      flow (50 ml/min) for 4 h. The parameters of the blood measured included activated 
      clotting time (ACT) and platelet aggregation with collagen, determined before and 
      after each treatment. Blood deposits were quantified using 111In labeled 
      platelets and 125I-labeled fibrinogen. The ACT was significantly prolonged only 
      after heparin treatment, and platelet aggregation, which was decreased by 35% (p 
      < 0.05) after heparin treatment, was almost abolished after aspirin and 
      prostacyclin treatments. As compared with the control group, both platelet and 
      fibrin uptake on the luminal surface of the prostheses were reduced significantly 
      by heparin by 87 and 37%, respectively. Despite their inhibition of platelet 
      aggregation in vitro, aspirin and prostacyclin induced no significant change in 
      platelet and fibrin deposition on the luminal surface of the woven polyester 
      arterial prostheses under low blood flow conditions. Under such conditions, 
      however, thrombin generation with subsequent platelet-fibrin deposition was 
      prevented by use of heparin anticoagulant therapy.
FAU - Merhi, Y
AU  - Merhi Y
AD  - Department of Surgery, Laval University, Quebec, Canada.
FAU - Bernier, J
AU  - Bernier J
FAU - Marois, Y
AU  - Marois Y
FAU - Guidoin, R
AU  - Guidoin R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polyesters)
RN  - 9001-31-4 (Fibrin)
RN  - 9005-49-6 (Heparin)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Analysis of Variance
MH  - Animals
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Blood Vessel Prosthesis/*adverse effects
MH  - Dogs
MH  - Epoprostenol/administration & dosage/pharmacology/therapeutic use
MH  - Female
MH  - Fibrin/metabolism
MH  - Heparin/administration & dosage/pharmacology/*therapeutic use
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Polyesters/metabolism/therapeutic use
MH  - Renal Circulation/drug effects
MH  - Thrombin Time
MH  - Thrombosis/*drug therapy/prevention & control
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
AID - 10.1097/00005344-199507000-00001 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1995 Jul;26(1):1-5. doi: 
      10.1097/00005344-199507000-00001.

PMID- 7042361
OWN - NLM
STAT- MEDLINE
DCOM- 19820719
LR  - 20131121
IS  - 0140-1610 (Print)
IS  - 0140-1610 (Linking)
VI  - 4
IP  - 1
DP  - 1981
TI  - A double-blind evaluation of oral indoprofen versus ASA in osteoarthritic 
      patients: influence on haemostatic parameters and clinical effects.
PG  - 41-8
AB  - Indoprofen, a non-steroidal anti-inflammatory agent, was investigated in a 
      double-blind, randomized study in 44 osteoarthritic patients for its influence on 
      haemostatic parameters and therapeutic effects. Twenty-two patients received 
      indoprofen orally, 600 mg daily, and a similar group took acetylsalicylic acid 3 
      g daily for 21 days. Platelet count, partial thromboplastin time and prothrombin 
      time showed no variations. Bleeding time wa prolonged and platelet aggregation 
      reduced by both drugs. The effects of ASA, however, were significantly greater. 
      Indoprofen, unlike ASA, showed almost no residual effect seven days after 
      stopping medication. The therapeutic responses to indoprofen and ASA were 
      comparable. However, adverse reactions (pyrosis and gastric pain) were much more 
      frequent in the ASA group (15 patients) than in the indoprofen group (2 
      patients).
FAU - Rubegni, M
AU  - Rubegni M
FAU - Sacchetti, G
AU  - Sacchetti G
FAU - Bruni, G
AU  - Bruni G
FAU - De Mauro, G
AU  - De Mauro G
FAU - Provvedi, D
AU  - Provvedi D
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Eur J Rheumatol Inflamm
JT  - European journal of rheumatology and inflammation
JID - 7805765
RN  - 0 (Phenylpropionates)
RN  - CPE46ZU14N (Indoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Bleeding Time
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Heartburn/chemically induced
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Indoprofen/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/blood/*drug therapy
MH  - Pain/chemically induced
MH  - Phenylpropionates/*therapeutic use
MH  - Platelet Aggregation/*drug effects
MH  - Prothrombin Time
MH  - Stomach
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Eur J Rheumatol Inflamm. 1981;4(1):41-8.

PMID- 24113028
OWN - NLM
STAT- MEDLINE
DCOM- 20140813
LR  - 20220330
IS  - 1559-2030 (Electronic)
IS  - 1551-7144 (Print)
IS  - 1551-7144 (Linking)
VI  - 36
IP  - 2
DP  - 2013 Nov
TI  - Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, 
      controlled trial.
PG  - 555-64
LID - S1551-7144(13)00165-1 [pii]
LID - 10.1016/j.cct.2013.09.014 [doi]
AB  - Cost-effective strategies to maintain healthy active lifestyle in aging 
      populations are required to address the global burden of age-related diseases. 
      ASPREE will examine whether the potential primary prevention benefits of low dose 
      aspirin outweigh the risks in older healthy individuals. Our primary hypothesis 
      is that daily oral 100 mg enteric-coated aspirin will extend a composite primary 
      endpoint termed 'disability-free life' including onset of dementia, total 
      mortality, or persistent disability in at least one of the Katz Activities of 
      Daily Living in 19,000 healthy participants aged 65 years and above ('US 
      minorities') and 70 years and above (non-'US minorities'). ASPREE is a 
      double-blind, randomized, placebo-controlled trial of oral 100mg enteric-coated 
      acetyl salicylic acid (ASA) or matching placebo being conducted in Australian and 
      US community settings on individuals free of dementia, disability and 
      cardiovascular disease (CVD) events. Secondary endpoints are all-cause and cause 
      specific mortality, fatal and non-fatal cardiovascular events, fatal and 
      non-fatal cancer (excluding non-melanoma skin cancer), dementia, mild cognitive 
      impairment, depression, physical disability, and clinically significant bleeding. 
      To 20 September 2013 14,383 participants have been recruited. Recruitment and 
      study completion are anticipated in July 2014 and December 2018 respectively. In 
      contrast to other aspirin trials that have largely focused on cardiovascular 
      endpoints, ASPREE has a unique composite primary endpoint to better capture the 
      overall risk and benefit of aspirin to extend healthy independent lifespan in 
      older adults in the US and Australia.
CI  - © 2013. Published by Elsevier Inc. All rights reserved.
CN  - ASPREE Investigator Group
AD  - Menzies Research Institute Tasmania, University of Tasmania, Private Bag 23, 
      Hobart 7001, Tasmania, Australia.
LA  - eng
SI  - ISRCTN/ISRCTN83772183
GR  - P30 AG024832/AG/NIA NIH HHS/United States
GR  - P30 AG028740/AG/NIA NIH HHS/United States
GR  - U01 AG029824/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20131007
PL  - United States
TA  - Contemp Clin Trials
JT  - Contemporary clinical trials
JID - 101242342
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Activities of Daily Living
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Australia
MH  - Cardiovascular Diseases/prevention & control
MH  - Cognitive Dysfunction/prevention & control
MH  - Dementia/prevention & control
MH  - Depression/prevention & control
MH  - Disabled Persons/statistics & numerical data
MH  - Double-Blind Method
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Mortality
MH  - Neoplasms/prevention & control
MH  - Risk Assessment
MH  - Tablets, Enteric-Coated
MH  - United States
PMC - PMC3919683
MID - NIHMS540891
OTO - NOTNLM
OT  - Aging
OT  - Aspirin
OT  - Clinical trial
OT  - Dementia
OT  - Disability
OT  - Primary prevention
FIR - Grimm, R H
IR  - Grimm RH
FIR - McNeil, J J
IR  - McNeil JJ
FIR - Grimm, R
IR  - Grimm R
FIR - McNeil, J J
IR  - McNeil JJ
FIR - Applegate, W
IR  - Applegate W
FIR - Beilin, L
IR  - Beilin L
FIR - Espinoza, S
IR  - Espinoza S
FIR - Johnston, C I
IR  - Johnston CI
FIR - Kirpach, B
IR  - Kirpach B
FIR - Margolis, K
IR  - Margolis K
FIR - Murray, A
IR  - Murray A
FIR - Nelson, M R
IR  - Nelson MR
FIR - Reid, C M
IR  - Reid CM
FIR - Shah, R
IR  - Shah R
FIR - Storey, E
IR  - Storey E
FIR - Tonkin, A M
IR  - Tonkin AM
FIR - Wilson, P
IR  - Wilson P
FIR - Wolfe, R
IR  - Wolfe R
FIR - Woods, R L
IR  - Woods RL
FIR - McNeil, J J
IR  - McNeil JJ
FIR - Abhayaratna, W
IR  - Abhayaratna W
FIR - Ames, D
IR  - Ames D
FIR - Beilin, L
IR  - Beilin L
FIR - Cobiac, L
IR  - Cobiac L
FIR - Donnan, G
IR  - Donnan G
FIR - Gibbs, P
IR  - Gibbs P
FIR - Head, R
IR  - Head R
FIR - Johnston, C I
IR  - Johnston CI
FIR - Krum, H
IR  - Krum H
FIR - Nelson, M R
IR  - Nelson MR
FIR - Reid, C M
IR  - Reid CM
FIR - Storey, E
IR  - Storey E
FIR - Tonkin, A M
IR  - Tonkin AM
FIR - Wolfe, R
IR  - Wolfe R
FIR - Woods, R L
IR  - Woods RL
FIR - Ives, D
IR  - Ives D
FIR - Nelson, M R
IR  - Nelson MR
FIR - Tonkin, A M
IR  - Tonkin AM
FIR - Jelnik, M
IR  - Jelnik M
FIR - Malik, M
IR  - Malik M
FIR - Williamson, J
IR  - Williamson J
FIR - Donnan, G
IR  - Donnan G
FIR - Eaton, C
IR  - Eaton C
FIR - Weissfeld, J
IR  - Weissfeld J
FIR - Gibbs, P
IR  - Gibbs P
FIR - MacRae, F
IR  - MacRae F
FIR - Rodriguez, L M
IR  - Rodriguez LM
FIR - Shah, R
IR  - Shah R
FIR - Murray, A
IR  - Murray A
FIR - Storey, E
IR  - Storey E
FIR - Newman, A
IR  - Newman A
FIR - Demons, J
IR  - Demons J
FIR - Workman, B
IR  - Workman B
FIR - Wood, E
IR  - Wood E
FIR - Margolis, K
IR  - Margolis K
FIR - Satterfield, S
IR  - Satterfield S
FIR - Reid, C M
IR  - Reid CM
FIR - Gilbertson, D
IR  - Gilbertson D
FIR - Kirpach, B
IR  - Kirpach B
FIR - Lockery, J E
IR  - Lockery JE
FIR - Nelson, M R
IR  - Nelson MR
FIR - Shah, R C
IR  - Shah RC
FIR - Tonkin, A M
IR  - Tonkin AM
FIR - Wolfe, R
IR  - Wolfe R
FIR - Woods, R L
IR  - Woods RL
FIR - Murray, A
IR  - Murray A
FIR - Reid, C M
IR  - Reid CM
FIR - Abhayaratna, W
IR  - Abhayaratna W
FIR - Ernst, M
IR  - Ernst M
FIR - Grimm, R
IR  - Grimm R
FIR - Hannah, J
IR  - Hannah J
FIR - Kirpach, B
IR  - Kirpach B
FIR - Margolis, K
IR  - Margolis K
FIR - McNeil, J J
IR  - McNeil JJ
FIR - Nelson, M R
IR  - Nelson MR
FIR - Newman, A
IR  - Newman A
FIR - Radziszewska, B
IR  - Radziszewska B
FIR - Shah, R
IR  - Shah R
FIR - Storey, E
IR  - Storey E
FIR - Thomas, A
IR  - Thomas A
FIR - Nelson, M R
IR  - Nelson MR
FIR - Gill, G
IR  - Gill G
FIR - Jackson, C
IR  - Jackson C
FIR - Kidd, M
IR  - Kidd M
FIR - Russell, G
IR  - Russell G
FIR - Grimm, R
IR  - Grimm R
FIR - Kirpach, B
IR  - Kirpach B
FIR - Murray, A
IR  - Murray A
FIR - Pressman, G
IR  - Pressman G
FIR - Figueredo, V
IR  - Figueredo V
FIR - Margolis, K
IR  - Margolis K
FIR - Oberoi, M
IR  - Oberoi M
FIR - Ahmad, M
IR  - Ahmad M
FIR - Krstevska, S
IR  - Krstevska S
FIR - Lawson, C
IR  - Lawson C
FIR - Katzman, S
IR  - Katzman S
FIR - Powell, J
IR  - Powell J
FIR - Lang, M
IR  - Lang M
FIR - Bolin, P
IR  - Bolin P
FIR - Wilson, P
IR  - Wilson P
FIR - Le, A
IR  - Le A
FIR - Johnson, T
IR  - Johnson T
FIR - Thomas, A
IR  - Thomas A
FIR - Kruger, D
IR  - Kruger D
FIR - Obisesan, T
IR  - Obisesan T
FIR - Allard, J
IR  - Allard J
FIR - Eaton, C
IR  - Eaton C
FIR - Dodd, K
IR  - Dodd K
FIR - Ott, B
IR  - Ott B
FIR - Pemu, P
IR  - Pemu P
FIR - Hannah, J
IR  - Hannah J
FIR - Radziszewska, B
IR  - Radziszewska B
FIR - Hadley, E
IR  - Hadley E
FIR - Romashkan, S V
IR  - Romashkan SV
FIR - Palaniappan, L
IR  - Palaniappan L
FIR - Jose, P
IR  - Jose P
FIR - Church, T
IR  - Church T
FIR - Myers, V
IR  - Myers V
FIR - Monce, R
IR  - Monce R
FIR - Britt, N
IR  - Britt N
FIR - Gupta, A
IR  - Gupta A
FIR - Keller, J
IR  - Keller J
FIR - Shah, R C
IR  - Shah RC
FIR - Lewis, B
IR  - Lewis B
FIR - Shikany, J
IR  - Shikany J
FIR - Allman, R
IR  - Allman R
FIR - Anton, S
IR  - Anton S
FIR - Pahor, M
IR  - Pahor M
FIR - Burns, J
IR  - Burns J
FIR - Swerdlow, R
IR  - Swerdlow R
FIR - Anderson, H
IR  - Anderson H
FIR - Wiggins, J
IR  - Wiggins J
FIR - Nyquist, L
IR  - Nyquist L
FIR - Peterson, K A
IR  - Peterson KA
FIR - Newman, A B
IR  - Newman AB
FIR - Tindle, H
IR  - Tindle H
FIR - Satterfield, S
IR  - Satterfield S
FIR - Johnson, K C
IR  - Johnson KC
FIR - Womack, C
IR  - Womack C
FIR - Espinoza, S
IR  - Espinoza S
FIR - Birnbaum, L
IR  - Birnbaum L
FIR - Volpi, E
IR  - Volpi E
FIR - Williamson, J
IR  - Williamson J
FIR - Applegate, W B
IR  - Applegate WB
FIR - Demons, J
IR  - Demons J
FIR - Flack, J
IR  - Flack J
FIR - Ference, B
IR  - Ference B
FIR - Singh, M
IR  - Singh M
FIR - Lichtenberg, P
IR  - Lichtenberg P
FIR - Aloia, J
IR  - Aloia J
FIR - Mikhail, M
IR  - Mikhail M
FIR - Anwarrulah, A A
IR  - Anwarrulah AA
FIR - McNeil, J J
IR  - McNeil JJ
FIR - Reid, C M
IR  - Reid CM
FIR - Storey, E
IR  - Storey E
FIR - Tonkin, A M
IR  - Tonkin AM
FIR - Woods, R L
IR  - Woods RL
FIR - Wolfe, R
IR  - Wolfe R
FIR - Krum, H
IR  - Krum H
FIR - Trevaks, R E
IR  - Trevaks RE
FIR - Lockery, J E
IR  - Lockery JE
FIR - Fitzgerald, S M
IR  - Fitzgerald SM
FIR - Abhayaratna, W
IR  - Abhayaratna W
FIR - Johnston, C I
IR  - Johnston CI
FIR - Nelson, M R
IR  - Nelson MR
FIR - Stocks, N
IR  - Stocks N
FIR - Beilin, L
IR  - Beilin L
FIR - Abdul-Ridha, S
IR  - Abdul-Ridha S
FIR - Abraham, K
IR  - Abraham K
FIR - Abraham, A
IR  - Abraham A
FIR - Abraham, J
IR  - Abraham J
FIR - Abrahams, M
IR  - Abrahams M
FIR - Adad, S
IR  - Adad S
FIR - Adams, C
IR  - Adams C
FIR - Africa, N
IR  - Africa N
FIR - Agarwal, D
IR  - Agarwal D
FIR - Agbarakwe, C
IR  - Agbarakwe C
FIR - Ah Sang, W
IR  - Ah Sang W
FIR - Ahern, T
IR  - Ahern T
FIR - Ahmad, Y
IR  - Ahmad Y
FIR - Ahmed, L
IR  - Ahmed L
FIR - Alagarswami, K
IR  - Alagarswami K
FIR - Aldridge, L
IR  - Aldridge L
FIR - Alethan, A
IR  - Alethan A
FIR - Alexander, K
IR  - Alexander K
FIR - Ali, M
IR  - Ali M
FIR - Allan, J
IR  - Allan J
FIR - Allen, G
IR  - Allen G
FIR - Al-Tawil, I
IR  - Al-Tawil I
FIR - Anam, T
IR  - Anam T
FIR - Anderson, R
IR  - Anderson R
FIR - Anderson, L
IR  - Anderson L
FIR - Anderson, G
IR  - Anderson G
FIR - Anderson, P
IR  - Anderson P
FIR - Anderson, K
IR  - Anderson K
FIR - Anderson-Dalheim, H
IR  - Anderson-Dalheim H
FIR - Andrada, E
IR  - Andrada E
FIR - Andre, S
IR  - Andre S
FIR - Andrews, L
IR  - Andrews L
FIR - Andric, A
IR  - Andric A
FIR - Andric, M
IR  - Andric M
FIR - Ang, J
IR  - Ang J
FIR - Ansari, A
IR  - Ansari A
FIR - Arakji, A M
IR  - Arakji AM
FIR - Arambeploa, Y
IR  - Arambeploa Y
FIR - Ark, R
IR  - Ark R
FIR - Arndt, P
IR  - Arndt P
FIR - Arunachalam, T
IR  - Arunachalam T
FIR - Aslam, I
IR  - Aslam I
FIR - Assad, S
IR  - Assad S
FIR - Atkins, C
IR  - Atkins C
FIR - Atkins, M
IR  - Atkins M
FIR - Aufgang, M
IR  - Aufgang M
FIR - Aurora, G
IR  - Aurora G
FIR - Auteri, S
IR  - Auteri S
FIR - Avergun, A
IR  - Avergun A
FIR - Azad, C
IR  - Azad C
FIR - Babovic, A
IR  - Babovic A
FIR - Baker, S
IR  - Baker S
FIR - Baker, T
IR  - Baker T
FIR - Baldam, A
IR  - Baldam A
FIR - Baldi, C
IR  - Baldi C
FIR - Banning, M
IR  - Banning M
FIR - Bansal, S
IR  - Bansal S
FIR - Barnes, A
IR  - Barnes A
FIR - Barnes, N
IR  - Barnes N
FIR - Barnetson, W
IR  - Barnetson W
FIR - Barratt, I
IR  - Barratt I
FIR - Barrett, Meagan
IR  - Barrett M
FIR - Barrett, Michelle
IR  - Barrett M
FIR - Barrett, T
IR  - Barrett T
FIR - Barrett, D A
IR  - Barrett DA
FIR - Barson, P
IR  - Barson P
FIR - Barstad, C
IR  - Barstad C
FIR - Bartram, M
IR  - Bartram M
FIR - Basser, S
IR  - Basser S
FIR - Bassett, S
IR  - Bassett S
FIR - Batchelor, L
IR  - Batchelor L
FIR - Batty, A
IR  - Batty A
FIR - Baxter, M
IR  - Baxter M
FIR - Beaton, G
IR  - Beaton G
FIR - Beaumont, J
IR  - Beaumont J
FIR - Beavis, D
IR  - Beavis D
FIR - Beech, M
IR  - Beech M
FIR - Beilby, J
IR  - Beilby J
FIR - Bekal, S
IR  - Bekal S
FIR - Bell, A
IR  - Bell A
FIR - Bendtsen, L
IR  - Bendtsen L
FIR - Benedict, D
IR  - Benedict D
FIR - Bennett, P
IR  - Bennett P
FIR - Bennie, G
IR  - Bennie G
FIR - Bennie, S
IR  - Bennie S
FIR - Bennison, S
IR  - Bennison S
FIR - Benson, R
IR  - Benson R
FIR - Benson, S
IR  - Benson S
FIR - Bergin, S
IR  - Bergin S
FIR - Bergin, J
IR  - Bergin J
FIR - Berryman, J
IR  - Berryman J
FIR - Berryman, G
IR  - Berryman G
FIR - Bertram, H
IR  - Bertram H
FIR - Bertuch, G
IR  - Bertuch G
FIR - Bettenay, G
IR  - Bettenay G
FIR - Bills, R
IR  - Bills R
FIR - Birch, J
IR  - Birch J
FIR - Birks, R
IR  - Birks R
FIR - Blake, R
IR  - Blake R
FIR - Blakney, A
IR  - Blakney A
FIR - Blanks, D
IR  - Blanks D
FIR - Blashki, M
IR  - Blashki M
FIR - Bleach, G
IR  - Bleach G
FIR - Bollen, C
IR  - Bollen C
FIR - Boltin, P
IR  - Boltin P
FIR - Boon, B
IR  - Boon B
FIR - Booth, G
IR  - Booth G
FIR - Bornstein, D
IR  - Bornstein D
FIR - Bottcher, C
IR  - Bottcher C
FIR - Bourke, J
IR  - Bourke J
FIR - Boutcher, S
IR  - Boutcher S
FIR - Bowen, J
IR  - Bowen J
FIR - Bowring, B
IR  - Bowring B
FIR - Boyce, C
IR  - Boyce C
FIR - Brack, R
IR  - Brack R
FIR - Brady, P
IR  - Brady P
FIR - Braude, G
IR  - Braude G
FIR - Briddon, P
IR  - Briddon P
FIR - Bridge, A
IR  - Bridge A
FIR - Briggs, S
IR  - Briggs S
FIR - Brkic, M
IR  - Brkic M
FIR - Broadby, M
IR  - Broadby M
FIR - Bromberger, D
IR  - Bromberger D
FIR - Brommeyer, A
IR  - Brommeyer A
FIR - Brophy, T
IR  - Brophy T
FIR - Brougham, J
IR  - Brougham J
FIR - Broun, C
IR  - Broun C
FIR - Brown, I
IR  - Brown I
FIR - Brown, J
IR  - Brown J
FIR - Brown, M
IR  - Brown M
FIR - Brownbill, C
IR  - Brownbill C
FIR - Brownstein, M
IR  - Brownstein M
FIR - Bruce, A
IR  - Bruce A
FIR - Buchanan, D
IR  - Buchanan D
FIR - Bulle, B
IR  - Bulle B
FIR - Bundy, K
IR  - Bundy K
FIR - Burke, M
IR  - Burke M
FIR - Busch, G
IR  - Busch G
FIR - Bush, C
IR  - Bush C
FIR - Bvirakare, J
IR  - Bvirakare J
FIR - Bye, J
IR  - Bye J
FIR - Byrne, P
IR  - Byrne P
FIR - Byrne, C
IR  - Byrne C
FIR - Cain, M
IR  - Cain M
FIR - Calcutt, I
IR  - Calcutt I
FIR - Caldwell, M
IR  - Caldwell M
FIR - Callan, C
IR  - Callan C
FIR - Cameron, T
IR  - Cameron T
FIR - Campbell, D
IR  - Campbell D
FIR - Campbell, Geoffrey
IR  - Campbell G
FIR - Campbell, Greg
IR  - Campbell G
FIR - Campbell, P
IR  - Campbell P
FIR - Campbell, R
IR  - Campbell R
FIR - Carroll, V
IR  - Carroll V
FIR - Carson, R
IR  - Carson R
FIR - Carson, J
IR  - Carson J
FIR - Carter, L
IR  - Carter L
FIR - Carter, P
IR  - Carter P
FIR - Carter, S
IR  - Carter S
FIR - Cartwright, P
IR  - Cartwright P
FIR - Cassidy, P
IR  - Cassidy P
FIR - Casson, O
IR  - Casson O
FIR - Catchpole, M
IR  - Catchpole M
FIR - Cato, G
IR  - Cato G
FIR - Celada, R
IR  - Celada R
FIR - Chalmers, M L
IR  - Chalmers ML
FIR - Chamoun, R
IR  - Chamoun R
FIR - Chan, C
IR  - Chan C
FIR - Chan, B
IR  - Chan B
FIR - Chan, L
IR  - Chan L
FIR - Chan, F W
IR  - Chan FW
FIR - Chandrananth, M
IR  - Chandrananth M
FIR - Chandrananth, S
IR  - Chandrananth S
FIR - Chang, V
IR  - Chang V
FIR - Changakoti, A
IR  - Changakoti A
FIR - Chantler, R
IR  - Chantler R
FIR - Chao, S
IR  - Chao S
FIR - Chao, D
IR  - Chao D
FIR - Chattersee, A
IR  - Chattersee A
FIR - Chau, G
IR  - Chau G
FIR - Chawtur, V
IR  - Chawtur V
FIR - Cheah, H-H
IR  - Cheah HH
FIR - Cheasley, A
IR  - Cheasley A
FIR - Chee, H
IR  - Chee H
FIR - Chen, D
IR  - Chen D
FIR - Chesney, D
IR  - Chesney D
FIR - Chhabra, P
IR  - Chhabra P
FIR - Chia, I
IR  - Chia I
FIR - Chiang, S
IR  - Chiang S
FIR - Chiew, L
IR  - Chiew L
FIR - Chikarsal, A
IR  - Chikarsal A
FIR - Chin, J
IR  - Chin J
FIR - Chipman, J
IR  - Chipman J
FIR - Chipperfield, C
IR  - Chipperfield C
FIR - Chisholm, L
IR  - Chisholm L
FIR - Chisholm, H
IR  - Chisholm H
FIR - Chiu, A
IR  - Chiu A
FIR - Chiu, D
IR  - Chiu D
FIR - Chiu, C
IR  - Chiu C
FIR - Chiu, T
IR  - Chiu T
FIR - Choo, E
IR  - Choo E
FIR - Chow, A
IR  - Chow A
FIR - Choy, C
IR  - Choy C
FIR - Chuah, T
IR  - Chuah T
FIR - Cimpoescu, T
IR  - Cimpoescu T
FIR - Clapton, J
IR  - Clapton J
FIR - Clark, M
IR  - Clark M
FIR - Clark, B
IR  - Clark B
FIR - Clark, R
IR  - Clark R
FIR - Clark, B
IR  - Clark B
FIR - Clarke, A
IR  - Clarke A
FIR - Clarke, S
IR  - Clarke S
FIR - Cleary, G
IR  - Cleary G
FIR - Close, S
IR  - Close S
FIR - Cochrane, F
IR  - Cochrane F
FIR - Cohen, J
IR  - Cohen J
FIR - Cohen, I S
IR  - Cohen IS
FIR - Colahan, R
IR  - Colahan R
FIR - Collins, J
IR  - Collins J
FIR - Colvin, R
IR  - Colvin R
FIR - Connell, P
IR  - Connell P
FIR - Connellan, M
IR  - Connellan M
FIR - Connor, W
IR  - Connor W
FIR - Connors, G
IR  - Connors G
FIR - Conos, M
IR  - Conos M
FIR - Conron, D
IR  - Conron D
FIR - Conroy, J
IR  - Conroy J
FIR - Cooper, M
IR  - Cooper M
FIR - Cooper, S
IR  - Cooper S
FIR - Cope, A
IR  - Cope A
FIR - Corrigan, S
IR  - Corrigan S
FIR - Corrigan, S
IR  - Corrigan S
FIR - Coughlan, P
IR  - Coughlan P
FIR - Counsel, L
IR  - Counsel L
FIR - Court, D
IR  - Court D
FIR - Courtis, G
IR  - Courtis G
FIR - Craig, L
IR  - Craig L
FIR - Cranswick, M
IR  - Cranswick M
FIR - Crawford, R
IR  - Crawford R
FIR - Crawford, J
IR  - Crawford J
FIR - Crick, S
IR  - Crick S
FIR - Cristofaro, R
IR  - Cristofaro R
FIR - Crompton, A
IR  - Crompton A
FIR - Cronin, E
IR  - Cronin E
FIR - Crook, C
IR  - Crook C
FIR - Crookes, J
IR  - Crookes J
FIR - Cross, M
IR  - Cross M
FIR - Crow, P
IR  - Crow P
FIR - Crowe, J
IR  - Crowe J
FIR - Cummins, R
IR  - Cummins R
FIR - Cunneen, A
IR  - Cunneen A
FIR - Cunningham, A
IR  - Cunningham A
FIR - Cunningham, N
IR  - Cunningham N
FIR - Curnow, D
IR  - Curnow D
FIR - Curran, M
IR  - Curran M
FIR - Currie, A
IR  - Currie A
FIR - Curtis, R
IR  - Curtis R
FIR - Dabash, K
IR  - Dabash K
FIR - Dabestani, V
IR  - Dabestani V
FIR - Dadabhay, Z
IR  - Dadabhay Z
FIR - Daglas, D
IR  - Daglas D
FIR - Dagley, P
IR  - Dagley P
FIR - Daniels, R
IR  - Daniels R
FIR - Darby, J P
IR  - Darby JP
FIR - Darling, J
IR  - Darling J
FIR - Das, J
IR  - Das J
FIR - Date, M
IR  - Date M
FIR - Davey, G
IR  - Davey G
FIR - Davidson, D
IR  - Davidson D
FIR - Davidson, C
IR  - Davidson C
FIR - Davies, M
IR  - Davies M
FIR - Davis, P
IR  - Davis P
FIR - Davis, G
IR  - Davis G
FIR - Davis, K
IR  - Davis K
FIR - Davis, S
IR  - Davis S
FIR - Davis, P
IR  - Davis P
FIR - Dawkins, P
IR  - Dawkins P
FIR - Dawson, G
IR  - Dawson G
FIR - Dawson, P
IR  - Dawson P
FIR - Dawson, R
IR  - Dawson R
FIR - Day, P
IR  - Day P
FIR - De Clifford, M
IR  - De Clifford M
FIR - De Poi, C
IR  - De Poi C
FIR - De Villiers, D
IR  - De Villiers D
FIR - De Wit, E
IR  - De Wit E
FIR - Del Rio, F
IR  - Del Rio F
FIR - Delaney, S
IR  - Delaney S
FIR - Delitzsch, S
IR  - Delitzsch S
FIR - Demaio, F
IR  - Demaio F
FIR - Demirtzoglou, J
IR  - Demirtzoglou J
FIR - Denton, T
IR  - Denton T
FIR - Derrick, L
IR  - Derrick L
FIR - Deshmukh, K
IR  - Deshmukh K
FIR - Devavittiya, C
IR  - Devavittiya C
FIR - Devereux, D
IR  - Devereux D
FIR - Dewhurst, H
IR  - Dewhurst H
FIR - Dhar, A
IR  - Dhar A
FIR - Dhillon, D
IR  - Dhillon D
FIR - Di Dio, A
IR  - Di Dio A
FIR - Di Marco, A
IR  - Di Marco A
FIR - Dickman, J
IR  - Dickman J
FIR - Dillon, L
IR  - Dillon L
FIR - Dinh, Q-Tuan
IR  - Dinh QT
FIR - Dissanayake, D
IR  - Dissanayake D
FIR - Dissanayake, M
IR  - Dissanayake M
FIR - Divakaran, K
IR  - Divakaran K
FIR - Dixon, H
IR  - Dixon H
FIR - Djakic, E
IR  - Djakic E
FIR - Dobson, C
IR  - Dobson C
FIR - Dodic, A
IR  - Dodic A
FIR - Dodic, M
IR  - Dodic M
FIR - Donaghy, F
IR  - Donaghy F
FIR - Donald, H
IR  - Donald H
FIR - Donelan, E
IR  - Donelan E
FIR - Donohue, M
IR  - Donohue M
FIR - Dooland, J
IR  - Dooland J
FIR - Dooley, H
IR  - Dooley H
FIR - Douglas, A
IR  - Douglas A
FIR - Dover, P
IR  - Dover P
FIR - Downe, G
IR  - Downe G
FIR - Drake, P
IR  - Drake P
FIR - Dry, D
IR  - Dry D
FIR - Duane, P
IR  - Duane P
FIR - Dubash, A
IR  - Dubash A
FIR - Dubetz, D
IR  - Dubetz D
FIR - Duff, P
IR  - Duff P
FIR - Duke, R
IR  - Duke R
FIR - Dunbar, A
IR  - Dunbar A
FIR - Dunbar, S
IR  - Dunbar S
FIR - Duong, N H
IR  - Duong NH
FIR - Dutta, N
IR  - Dutta N
FIR - Duval, A
IR  - Duval A
FIR - Eaton, D
IR  - Eaton D
FIR - Ebert, K
IR  - Ebert K
FIR - Edillo, E
IR  - Edillo E
FIR - Edwards, P A
IR  - Edwards PA
FIR - Edwards, S
IR  - Edwards S
FIR - Edwards, F
IR  - Edwards F
FIR - Egan, A
IR  - Egan A
FIR - Ehrenreich, S
IR  - Ehrenreich S
FIR - El Khoury, H
IR  - El Khoury H
FIR - Elberg, L
IR  - Elberg L
FIR - Elisha, B
IR  - Elisha B
FIR - Elisha, R
IR  - Elisha R
FIR - Ellerton, K
IR  - Ellerton K
FIR - Elmore, R
IR  - Elmore R
FIR - Elshenawy, I
IR  - Elshenawy I
FIR - Emmerson, M
IR  - Emmerson M
FIR - Emmett, S
IR  - Emmett S
FIR - English, J
IR  - English J
FIR - Enten, P
IR  - Enten P
FIR - Erhardt, A
IR  - Erhardt A
FIR - Etta, J
IR  - Etta J
FIR - Evans, M
IR  - Evans M
FIR - Everitt, T
IR  - Everitt T
FIR - Faigen, M
IR  - Faigen M
FIR - Fair, A
IR  - Fair A
FIR - Fanning, J
IR  - Fanning J
FIR - Fantasia, M
IR  - Fantasia M
FIR - Farag, E
IR  - Farag E
FIR - Fardell, K
IR  - Fardell K
FIR - Farrell, P
IR  - Farrell P
FIR - Farrow, J
IR  - Farrow J
FIR - Faull, P A
IR  - Faull PA
FIR - Ferguson, P
IR  - Ferguson P
FIR - Fernando, Sajeewani
IR  - Fernando S
FIR - Fernando, Sujeewa
IR  - Fernando S
FIR - Ferruccio, A
IR  - Ferruccio A
FIR - Fidge, J
IR  - Fidge J
FIR - Field, P
IR  - Field P
FIR - Fisher, H
IR  - Fisher H
FIR - Fisher, J
IR  - Fisher J
FIR - Fitzgerald, M
IR  - Fitzgerald M
FIR - Fitzgerald, R
IR  - Fitzgerald R
FIR - Fitzpatrick, H
IR  - Fitzpatrick H
FIR - Fitzpatrick, J
IR  - Fitzpatrick J
FIR - Fitzpatrick, T
IR  - Fitzpatrick T
FIR - Flaherty, P
IR  - Flaherty P
FIR - Flanagan, D
IR  - Flanagan D
FIR - Flanagan, T
IR  - Flanagan T
FIR - Flew, S
IR  - Flew S
FIR - Fonseka, P P
IR  - Fonseka PP
FIR - Foo, J
IR  - Foo J
FIR - Foong, E
IR  - Foong E
FIR - Ford, D
IR  - Ford D
FIR - Foster, D
IR  - Foster D
FIR - Fox, D
IR  - Fox D
FIR - Fox, F
IR  - Fox F
FIR - Fox, P
IR  - Fox P
FIR - Fox-Smith, D
IR  - Fox-Smith D
FIR - Francis, J
IR  - Francis J
FIR - Frank, O
IR  - Frank O
FIR - Franks, A
IR  - Franks A
FIR - Fredericks, A
IR  - Fredericks A
FIR - Freeman, E
IR  - Freeman E
FIR - French, L
IR  - French L
FIR - Frew, B
IR  - Frew B
FIR - Friebel, D
IR  - Friebel D
FIR - Friebel, T
IR  - Friebel T
FIR - Fryer, D
IR  - Fryer D
FIR - Fuller, J
IR  - Fuller J
FIR - Fung, W
IR  - Fung W
FIR - Fung, W P
IR  - Fung WP
FIR - Furphy, S
IR  - Furphy S
FIR - Gaggin, S
IR  - Gaggin S
FIR - Gall, J
IR  - Gall J
FIR - Gallichio, V
IR  - Gallichio V
FIR - Gangell, A
IR  - Gangell A
FIR - Garde, M A
IR  - Garde MA
FIR - Gardner, S
IR  - Gardner S
FIR - Gardner, T
IR  - Gardner T
FIR - Garland, J
IR  - Garland J
FIR - Garoni, E
IR  - Garoni E
FIR - Garra, G
IR  - Garra G
FIR - Garrow, S
IR  - Garrow S
FIR - Gauden, M
IR  - Gauden M
FIR - Gault, A
IR  - Gault A
FIR - Gaur, D
IR  - Gaur D
FIR - Gavralas, A
IR  - Gavralas A
FIR - George, S
IR  - George S
FIR - George, N
IR  - George N
FIR - Georgy, M
IR  - Georgy M
FIR - Gerendasi, R
IR  - Gerendasi R
FIR - Geschke, H
IR  - Geschke H
FIR - Giannakakis, J
IR  - Giannakakis J
FIR - Gidley, G
IR  - Gidley G
FIR - Gilani, M
IR  - Gilani M
FIR - Giles, P
IR  - Giles P
FIR - Gill, P
IR  - Gill P
FIR - Gilovitz, M
IR  - Gilovitz M
FIR - Gingold, R
IR  - Gingold R
FIR - Glaspole, D
IR  - Glaspole D
FIR - Glowinski, L
IR  - Glowinski L
FIR - Glue, A L
IR  - Glue AL
FIR - Goel, A
IR  - Goel A
FIR - Goldberg, J
IR  - Goldberg J
FIR - Golets, M
IR  - Golets M
FIR - Goodman, C
IR  - Goodman C
FIR - Goodwin, R
IR  - Goodwin R
FIR - Gopathy, S
IR  - Gopathy S
FIR - Gordon, M
IR  - Gordon M
FIR - Gough, S
IR  - Gough S
FIR - Govender, M
IR  - Govender M
FIR - Gow, K
IR  - Gow K
FIR - Gowrie, B
IR  - Gowrie B
FIR - Goy, P
IR  - Goy P
FIR - Grabowski, C
IR  - Grabowski C
FIR - Graddon, J
IR  - Graddon J
FIR - Granek, A
IR  - Granek A
FIR - Gray, T
IR  - Gray T
FIR - Gray, J
IR  - Gray J
FIR - Gray, M
IR  - Gray M
FIR - Grbac, E
IR  - Grbac E
FIR - Greenwood, E
IR  - Greenwood E
FIR - Griffith, V
IR  - Griffith V
FIR - Griffiths, G
IR  - Griffiths G
FIR - Griffiths, K
IR  - Griffiths K
FIR - Grigorian, A
IR  - Grigorian A
FIR - Grinzi, P
IR  - Grinzi P
FIR - Grogan, H
IR  - Grogan H
FIR - Grokop, G
IR  - Grokop G
FIR - Grossman, L
IR  - Grossman L
FIR - Gruzauskas, A
IR  - Gruzauskas A
FIR - Guest, S
IR  - Guest S
FIR - Guindi, N
IR  - Guindi N
FIR - Guo, H
IR  - Guo H
FIR - Gurney, R
IR  - Gurney R
FIR - Gyorki, J
IR  - Gyorki J
FIR - Habibi, S
IR  - Habibi S
FIR - Hachem, C
IR  - Hachem C
FIR - Hackett, J
IR  - Hackett J
FIR - Hackett, A
IR  - Hackett A
FIR - Haddad, M
IR  - Haddad M
FIR - Hagger, R
IR  - Hagger R
FIR - Hain, R
IR  - Hain R
FIR - Hajicosta, T
IR  - Hajicosta T
FIR - Hales, P
IR  - Hales P
FIR - Hall, J
IR  - Hall J
FIR - Hall, P
IR  - Hall P
FIR - Hall, R
IR  - Hall R
FIR - Hall, S
IR  - Hall S
FIR - Halliburton, K
IR  - Halliburton K
FIR - Halliday, A
IR  - Halliday A
FIR - Halliday, B
IR  - Halliday B
FIR - Hamblen, K
IR  - Hamblen K
FIR - Hamilton, R
IR  - Hamilton R
FIR - Hamilton, J
IR  - Hamilton J
FIR - Hammond, T
IR  - Hammond T
FIR - Hand, R
IR  - Hand R
FIR - Hanna, A
IR  - Hanna A
FIR - Hanna, M
IR  - Hanna M
FIR - Hanna, S
IR  - Hanna S
FIR - Hanson, G
IR  - Hanson G
FIR - Hanson, P
IR  - Hanson P
FIR - Haque, M
IR  - Haque M
FIR - Haque, E
IR  - Haque E
FIR - Haran, T R
IR  - Haran TR
FIR - Haran, C
IR  - Haran C
FIR - Hare, W J
IR  - Hare WJ
FIR - Haripersad, S
IR  - Haripersad S
FIR - Harman, A
IR  - Harman A
FIR - Harmer, D
IR  - Harmer D
FIR - Harms, P
IR  - Harms P
FIR - Harnden, C
IR  - Harnden C
FIR - Harris, A
IR  - Harris A
FIR - Harris, M
IR  - Harris M
FIR - Harris, S
IR  - Harris S
FIR - Harrison, M
IR  - Harrison M
FIR - Harrison, S
IR  - Harrison S
FIR - Hart, E
IR  - Hart E
FIR - Hartnett, M
IR  - Hartnett M
FIR - Hassani, I
IR  - Hassani I
FIR - Hassett, B R
IR  - Hassett BR
FIR - Hawke, I
IR  - Hawke I
FIR - Hawkins, C
IR  - Hawkins C
FIR - Hayes, V
IR  - Hayes V
FIR - Hayes, A
IR  - Hayes A
FIR - Heale, J
IR  - Heale J
FIR - Healy, G
IR  - Healy G
FIR - Hebblewhite, A
IR  - Hebblewhite A
FIR - Hedgland, A
IR  - Hedgland A
FIR - Heikkinen, M
IR  - Heikkinen M
FIR - Henderson, J
IR  - Henderson J
FIR - Henry, F
IR  - Henry F
FIR - Herath, A
IR  - Herath A
FIR - Herath, S
IR  - Herath S
FIR - Herbst, D
IR  - Herbst D
FIR - Hermiz, S
IR  - Hermiz S
FIR - Hetherington, J
IR  - Hetherington J
FIR - Hides, R
IR  - Hides R
FIR - Higgins, C
IR  - Higgins C
FIR - Hildred, S
IR  - Hildred S
FIR - Hill, A
IR  - Hill A
FIR - Hilton, C
IR  - Hilton C
FIR - Hince, R
IR  - Hince R
FIR - Hines, C
IR  - Hines C
FIR - Ho, L
IR  - Ho L
FIR - Ho, C K
IR  - Ho CK
FIR - Hocking, L
IR  - Hocking L
FIR - Hocking, L
IR  - Hocking L
FIR - Hodge, A
IR  - Hodge A
FIR - Holland, M
IR  - Holland M
FIR - Hollins, B
IR  - Hollins B
FIR - Hong, Z
IR  - Hong Z
FIR - Honig, J
IR  - Honig J
FIR - Honigman, S
IR  - Honigman S
FIR - Hookham, D
IR  - Hookham D
FIR - Hooper, W
IR  - Hooper W
FIR - Horman, J
IR  - Horman J
FIR - Horng, T
IR  - Horng T
FIR - Hornstein, I
IR  - Hornstein I
FIR - Horriat, M
IR  - Horriat M
FIR - Horvat, J
IR  - Horvat J
FIR - Hough, P
IR  - Hough P
FIR - Howe, J
IR  - Howe J
FIR - Howson, W
IR  - Howson W
FIR - Hubczenko, I
IR  - Hubczenko I
FIR - Hubel, M
IR  - Hubel M
FIR - Hughes, J
IR  - Hughes J
FIR - Hunter, D
IR  - Hunter D
FIR - Hutchinson, A
IR  - Hutchinson A
FIR - Iakovidis, B
IR  - Iakovidis B
FIR - Ibragimov, M
IR  - Ibragimov M
FIR - Imgraben, P
IR  - Imgraben P
FIR - Ip, A
IR  - Ip A
FIR - Iqbal, A
IR  - Iqbal A
FIR - Iqbal, M
IR  - Iqbal M
FIR - Irvine, G
IR  - Irvine G
FIR - Iser, D
IR  - Iser D
FIR - Islam, S
IR  - Islam S
FIR - Isles, J
IR  - Isles J
FIR - Ivanoff, G
IR  - Ivanoff G
FIR - Jackett, R
IR  - Jackett R
FIR - Jackson, T
IR  - Jackson T
FIR - Jackson, N
IR  - Jackson N
FIR - Jain, P
IR  - Jain P
FIR - Jain, S
IR  - Jain S
FIR - Jaiswal, N
IR  - Jaiswal N
FIR - Jakubowicz, I
IR  - Jakubowicz I
FIR - Jamel, B
IR  - Jamel B
FIR - Jansz, C
IR  - Jansz C
FIR - Jarman, E
IR  - Jarman E
FIR - Jarvie, L
IR  - Jarvie L
FIR - Jayatilake, J
IR  - Jayatilake J
FIR - Jayaweera, V
IR  - Jayaweera V
FIR - Jeanneret, C
IR  - Jeanneret C
FIR - Jenkins, P
IR  - Jenkins P
FIR - Jenkins, J
IR  - Jenkins J
FIR - Jennings, C
IR  - Jennings C
FIR - Jhamb, A
IR  - Jhamb A
FIR - Jiang, Y Y
IR  - Jiang YY
FIR - Jigau, C
IR  - Jigau C
FIR - John, R
IR  - John R
FIR - Johnson, M
IR  - Johnson M
FIR - Johnson, N
IR  - Johnson N
FIR - Johnston, R
IR  - Johnston R
FIR - Johnston, B
IR  - Johnston B
FIR - Johnston, K
IR  - Johnston K
FIR - Johnston, T
IR  - Johnston T
FIR - Jones, G
IR  - Jones G
FIR - Jones, I
IR  - Jones I
FIR - Jones, L
IR  - Jones L
FIR - Jones, S
IR  - Jones S
FIR - Joshi, M
IR  - Joshi M
FIR - Joshi, N
IR  - Joshi N
FIR - Joske, F
IR  - Joske F
FIR - Joubert, C
IR  - Joubert C
FIR - Jovanovic, B
IR  - Jovanovic B
FIR - Judd, J
IR  - Judd J
FIR - Judd, A M
IR  - Judd AM
FIR - Kaaden, J
IR  - Kaaden J
FIR - Kabat, L
IR  - Kabat L
FIR - Kabourakis, F
IR  - Kabourakis F
FIR - Kajani, H
IR  - Kajani H
FIR - Kaminsky, L
IR  - Kaminsky L
FIR - Kanapathipillai, U
IR  - Kanapathipillai U
FIR - Kanashuk, L
IR  - Kanashuk L
FIR - Kapadia, P
IR  - Kapadia P
FIR - Kapadia, V
IR  - Kapadia V
FIR - Karmouche, R
IR  - Karmouche R
FIR - Kaur, K J
IR  - Kaur KJ
FIR - Kay, B
IR  - Kay B
FIR - Kaye, S
IR  - Kaye S
FIR - Keating, B
IR  - Keating B
FIR - Keenan, P
IR  - Keenan P
FIR - Keillar, P
IR  - Keillar P
FIR - Kemp, G
IR  - Kemp G
FIR - Kennedy, U
IR  - Kennedy U
FIR - Kesarapu, S
IR  - Kesarapu S
FIR - Khan, I
IR  - Khan I
FIR - Khan, M
IR  - Khan M
FIR - Khong, C K
IR  - Khong CK
FIR - Khoshghalb, A
IR  - Khoshghalb A
FIR - Kiefer, J
IR  - Kiefer J
FIR - Kiley, M
IR  - Kiley M
FIR - Kimpton, N
IR  - Kimpton N
FIR - King, S C
IR  - King SC
FIR - Kingston, R
IR  - Kingston R
FIR - Kipouridis, A
IR  - Kipouridis A
FIR - Kirwan, A
IR  - Kirwan A
FIR - Kisselev, S
IR  - Kisselev S
FIR - Kljakovic, M
IR  - Kljakovic M
FIR - Kloot, S
IR  - Kloot S
FIR - Knaggs, J
IR  - Knaggs J
FIR - Knowles, D
IR  - Knowles D
FIR - Kogosowski, S
IR  - Kogosowski S
FIR - Kok, J
IR  - Kok J
FIR - Kok, F B
IR  - Kok FB
FIR - Konopnicki, H
IR  - Konopnicki H
FIR - Korol, P
IR  - Korol P
FIR - Kosky, A
IR  - Kosky A
FIR - Kottegoda-Vithana, E
IR  - Kottegoda-Vithana E
FIR - Kotur, S U
IR  - Kotur SU
FIR - Kraner, G
IR  - Kraner G
FIR - Kraus, D
IR  - Kraus D
FIR - Kruytbosch, C
IR  - Kruytbosch C
FIR - Kuay, V
IR  - Kuay V
FIR - Kucminska, A
IR  - Kucminska A
FIR - Kulinski, M
IR  - Kulinski M
FIR - Kumar, J
IR  - Kumar J
FIR - Kumar, R
IR  - Kumar R
FIR - Kumar, S
IR  - Kumar S
FIR - Kunze, M
IR  - Kunze M
FIR - Kurien, S
IR  - Kurien S
FIR - Kuruvilla, P
IR  - Kuruvilla P
FIR - Kyaw, Z
IR  - Kyaw Z
FIR - Lackner, P J
IR  - Lackner PJ
FIR - Lajoie, D
IR  - Lajoie D
FIR - Lajoie, K
IR  - Lajoie K
FIR - Lakshmanan, A
IR  - Lakshmanan A
FIR - Lal, A
IR  - Lal A
FIR - Lancaster, M-A
IR  - Lancaster MA
FIR - Landers, J
IR  - Landers J
FIR - Lane, R
IR  - Lane R
FIR - Lapin, S
IR  - Lapin S
FIR - Le, W
IR  - Le W
FIR - Le, V
IR  - Le V
FIR - Le Couteur, S
IR  - Le Couteur S
FIR - Leber, D
IR  - Leber D
FIR - Lee, C
IR  - Lee C
FIR - Lee, D
IR  - Lee D
FIR - Lee, F B
IR  - Lee FB
FIR - Lee, James
IR  - Lee J
FIR - Lee, John
IR  - Lee J
FIR - Lees, K
IR  - Lees K
FIR - Leong, C
IR  - Leong C
FIR - Leong, R
IR  - Leong R
FIR - Leow, P
IR  - Leow P
FIR - Leow, L
IR  - Leow L
FIR - Leslie, N
IR  - Leslie N
FIR - Lester, S E
IR  - Lester SE
FIR - Lewi, L
IR  - Lewi L
FIR - Lewis, P
IR  - Lewis P
FIR - Lewis, R
IR  - Lewis R
FIR - Li, A
IR  - Li A
FIR - Li, J
IR  - Li J
FIR - Liang, X S
IR  - Liang XS
FIR - Libhaber, H
IR  - Libhaber H
FIR - Lichtblau, B
IR  - Lichtblau B
FIR - Lickiss, T
IR  - Lickiss T
FIR - Liedvogel, M
IR  - Liedvogel M
FIR - Light, L
IR  - Light L
FIR - Lightfoot, W
IR  - Lightfoot W
FIR - Lim, H
IR  - Lim H
FIR - Lim, H S
IR  - Lim HS
FIR - Lim, D
IR  - Lim D
FIR - Lim, S G
IR  - Lim SG
FIR - Limaye, S
IR  - Limaye S
FIR - Linton, J
IR  - Linton J
FIR - Linton, S
IR  - Linton S
FIR - Linton, T
IR  - Linton T
FIR - Liow, Y C
IR  - Liow YC
FIR - Liow, C
IR  - Liow C
FIR - Lipson, D
IR  - Lipson D
FIR - Liu, Y
IR  - Liu Y
FIR - Liubinas, R
IR  - Liubinas R
FIR - Lizner, S
IR  - Lizner S
FIR - Lo, C
IR  - Lo C
FIR - Lo, B
IR  - Lo B
FIR - Lockhart, M
IR  - Lockhart M
FIR - Loke, K P
IR  - Loke KP
FIR - Long, M
IR  - Long M
FIR - Longworth, W
IR  - Longworth W
FIR - Loo, K H
IR  - Loo KH
FIR - Lopez-Hernandez, S
IR  - Lopez-Hernandez S
FIR - Lord, R
IR  - Lord R
FIR - Louw, J
IR  - Louw J
FIR - Louw, T
IR  - Louw T
FIR - Lowe, M
IR  - Lowe M
FIR - Lu, P
IR  - Lu P
FIR - Lucarelli, A
IR  - Lucarelli A
FIR - Lui, G
IR  - Lui G
FIR - Lui, K
IR  - Lui K
FIR - Lui, R
IR  - Lui R
FIR - Luke, C
IR  - Luke C
FIR - Luttrell, C
IR  - Luttrell C
FIR - Lyall, A
IR  - Lyall A
FIR - Lynch, J
IR  - Lynch J
FIR - Lyon, E
IR  - Lyon E
FIR - Lyons, S
IR  - Lyons S
FIR - Macaulay, G
IR  - Macaulay G
FIR - MacIndoe, A
IR  - MacIndoe A
FIR - MacIsaac, P
IR  - MacIsaac P
FIR - MacIver, R
IR  - MacIver R
FIR - Mackay, J
IR  - Mackay J
FIR - Mackay, B
IR  - Mackay B
FIR - Madden, J
IR  - Madden J
FIR - Madeley, C
IR  - Madeley C
FIR - Madhanpall, N
IR  - Madhanpall N
FIR - Magarey, J
IR  - Magarey J
FIR - Magill, M
IR  - Magill M
FIR - Mah, S-P
IR  - Mah SP
FIR - Mahendran, S
IR  - Mahendran S
FIR - Maher, J
IR  - Maher J
FIR - Maher, M
IR  - Maher M
FIR - Mahmood, Aamir
IR  - Mahmood A
FIR - Mahmood, Abbas
IR  - Mahmood A
FIR - Majchrzak, W
IR  - Majchrzak W
FIR - Makar, A
IR  - Makar A
FIR - Makohon, R
IR  - Makohon R
FIR - Malcher, P
IR  - Malcher P
FIR - Malcolm, H
IR  - Malcolm H
FIR - Mallett, S
IR  - Mallett S
FIR - Manderson, J
IR  - Manderson J
FIR - Mane, S
IR  - Mane S
FIR - Mangan, G
IR  - Mangan G
FIR - Manifold, M
IR  - Manifold M
FIR - Manoliadis, M
IR  - Manoliadis M
FIR - Manovel, B
IR  - Manovel B
FIR - Mansour, A
IR  - Mansour A
FIR - Manton, D
IR  - Manton D
FIR - Marano, F
IR  - Marano F
FIR - Marchant, D
IR  - Marchant D
FIR - Marinos, A
IR  - Marinos A
FIR - Marsh, D
IR  - Marsh D
FIR - Martin, R
IR  - Martin R
FIR - Marton, F
IR  - Marton F
FIR - Martynova, L
IR  - Martynova L
FIR - Masood, U
IR  - Masood U
FIR - Massaud, M
IR  - Massaud M
FIR - Masters, B
IR  - Masters B
FIR - Mather, J
IR  - Mather J
FIR - Mathews, R
IR  - Mathews R
FIR - Mauro, M
IR  - Mauro M
FIR - Maxfield, N
IR  - Maxfield N
FIR - Mayhead, C
IR  - Mayhead C
FIR - Mc Kelvie, M
IR  - Mc Kelvie M
FIR - Mc Kenzie, S
IR  - Mc Kenzie S
FIR - Mc Laren, G
IR  - Mc Laren G
FIR - McCleese, S
IR  - McCleese S
FIR - McCallum, H
IR  - McCallum H
FIR - McCarthy, A
IR  - McCarthy A
FIR - McCleary, A
IR  - McCleary A
FIR - McClelland, R
IR  - McClelland R
FIR - McCorkell, J
IR  - McCorkell J
FIR - McCormick, H
IR  - McCormick H
FIR - McCormick, G
IR  - McCormick G
FIR - McCowan, M
IR  - McCowan M
FIR - McCutcheon, J
IR  - McCutcheon J
FIR - McDonald, A
IR  - McDonald A
FIR - McDonald, I R
IR  - McDonald IR
FIR - McDonald, J
IR  - McDonald J
FIR - McDonald, N
IR  - McDonald N
FIR - McDonald, S
IR  - McDonald S
FIR - McEniery, A
IR  - McEniery A
FIR - McGinity, P
IR  - McGinity P
FIR - McGrath, L
IR  - McGrath L
FIR - McGuire, P
IR  - McGuire P
FIR - McHardy, C
IR  - McHardy C
FIR - McHenry, K
IR  - McHenry K
FIR - McIllree, R
IR  - McIllree R
FIR - McKay, M
IR  - McKay M
FIR - McKellar, C
IR  - McKellar C
FIR - McKeown, M
IR  - McKeown M
FIR - McLeod, I
IR  - McLeod I
FIR - McMahon, A
IR  - McMahon A
FIR - McMaster, I
IR  - McMaster I
FIR - McNab, N
IR  - McNab N
FIR - McNaughton, E
IR  - McNaughton E
FIR - McNiff, M
IR  - McNiff M
FIR - Meaney, J
IR  - Meaney J
FIR - Medlicott, M
IR  - Medlicott M
FIR - Medres, R
IR  - Medres R
FIR - Megally, R
IR  - Megally R
FIR - Mehta, K
IR  - Mehta K
FIR - Mellios, O
IR  - Mellios O
FIR - Mendick, S
IR  - Mendick S
FIR - Mendis, L
IR  - Mendis L
FIR - Menzies, J
IR  - Menzies J
FIR - Mercado, M
IR  - Mercado M
FIR - Mesiha, S
IR  - Mesiha S
FIR - Meyer, P
IR  - Meyer P
FIR - Mia, M
IR  - Mia M
FIR - Michaelson, T
IR  - Michaelson T
FIR - Michail, A
IR  - Michail A
FIR - Miezis, V
IR  - Miezis V
FIR - Milky, S
IR  - Milky S
FIR - Miller, K
IR  - Miller K
FIR - Milner, J
IR  - Milner J
FIR - Milton, C
IR  - Milton C
FIR - Milward, N
IR  - Milward N
FIR - Mirhom, R
IR  - Mirhom R
FIR - Misso, R
IR  - Misso R
FIR - Mitchell, D
IR  - Mitchell D
FIR - Mitchell, L
IR  - Mitchell L
FIR - Mobilia, G
IR  - Mobilia G
FIR - Mohr, V
IR  - Mohr V
FIR - Molloy, T
IR  - Molloy T
FIR - Monash, D
IR  - Monash D
FIR - Moncrieff, S
IR  - Moncrieff S
FIR - Mooney, T
IR  - Mooney T
FIR - Moore, E
IR  - Moore E
FIR - Moran, J
IR  - Moran J
FIR - Morgan, M
IR  - Morgan M
FIR - Morgan, N
IR  - Morgan N
FIR - Morris, N
IR  - Morris N
FIR - Morris, S
IR  - Morris S
FIR - Moschou, C
IR  - Moschou C
FIR - Moulding, S
IR  - Moulding S
FIR - Mouzakis, V
IR  - Mouzakis V
FIR - Mudunna, D
IR  - Mudunna D
FIR - Mudzi, S
IR  - Mudzi S
FIR - Mulkearns, P
IR  - Mulkearns P
FIR - Muraledaran, S
IR  - Muraledaran S
FIR - Murray, S
IR  - Murray S
FIR - Murtagh, C
IR  - Murtagh C
FIR - Nadarajah, M
IR  - Nadarajah M
FIR - Naiker, S
IR  - Naiker S
FIR - Nandha, R
IR  - Nandha R
FIR - Nankervis, J
IR  - Nankervis J
FIR - Naoum, A
IR  - Naoum A
FIR - Nash, C
IR  - Nash C
FIR - Nasreen, N
IR  - Nasreen N
FIR - Nath-Chand, U
IR  - Nath-Chand U
FIR - Nelson, M R
IR  - Nelson MR
FIR - Nelson, C
IR  - Nelson C
FIR - Nesbitt, P
IR  - Nesbitt P
FIR - Neuberger, M
IR  - Neuberger M
FIR - Newman, S
IR  - Newman S
FIR - Ng, D
IR  - Ng D
FIR - Nguyen, D
IR  - Nguyen D
FIR - Nguyen, H
IR  - Nguyen H
FIR - Nguyen-Ngoc, M
IR  - Nguyen-Ngoc M
FIR - Nicholls, P
IR  - Nicholls P
FIR - Nicholson, D
IR  - Nicholson D
FIR - Nicola, N
IR  - Nicola N
FIR - Nicolettou, N
IR  - Nicolettou N
FIR - Nicolson, I
IR  - Nicolson I
FIR - Nikolic, V
IR  - Nikolic V
FIR - Nikolovska-Buzevski, N
IR  - Nikolovska-Buzevski N
FIR - Nilsson, A
IR  - Nilsson A
FIR - Niven, A
IR  - Niven A
FIR - Nnopu, E
IR  - Nnopu E
FIR - Norton, C
IR  - Norton C
FIR - Norton, G
IR  - Norton G
FIR - Notini, G
IR  - Notini G
FIR - Nylander, P
IR  - Nylander P
FIR - O'Brien, C
IR  - O'Brien C
FIR - O'Connor, D
IR  - O'Connor D
FIR - O'Connor, A
IR  - O'Connor A
FIR - O'Driscoll, E
IR  - O'Driscoll E
FIR - Oechsle, G
IR  - Oechsle G
FIR - Offor, J
IR  - Offor J
FIR - Ogilvie, B
IR  - Ogilvie B
FIR - O'Halloran, J
IR  - O'Halloran J
FIR - O'Hanlon, P
IR  - O'Hanlon P
FIR - Olaniyi, I
IR  - Olaniyi I
FIR - O'Leary, K
IR  - O'Leary K
FIR - Olesen, J
IR  - Olesen J
FIR - Oliver, P
IR  - Oliver P
FIR - Olomola, O
IR  - Olomola O
FIR - Olszewski, C
IR  - Olszewski C
FIR - Olukolu, G
IR  - Olukolu G
FIR - Omarjee, A
IR  - Omarjee A
FIR - Omidiora, A A
IR  - Omidiora AA
FIR - Omifolaji, S
IR  - Omifolaji S
FIR - O'Neill, C
IR  - O'Neill C
FIR - O'Neill, A
IR  - O'Neill A
FIR - Ong, B P
IR  - Ong BP
FIR - Oppermann, B L
IR  - Oppermann BL
FIR - Orbach, E
IR  - Orbach E
FIR - Orsillo, M
IR  - Orsillo M
FIR - Ostberg, M
IR  - Ostberg M
FIR - O'Sullivan, C
IR  - O'Sullivan C
FIR - O'Sullivan, P
IR  - O'Sullivan P
FIR - O'Toole, M
IR  - O'Toole M
FIR - O'Toole, C
IR  - O'Toole C
FIR - Owen, T
IR  - Owen T
FIR - Padilla, C
IR  - Padilla C
FIR - Palmer, A
IR  - Palmer A
FIR - Pan, J
IR  - Pan J
FIR - Papagelis, A
IR  - Papagelis A
FIR - Pape, A
IR  - Pape A
FIR - Paransothy, P
IR  - Paransothy P
FIR - Parghi, N
IR  - Parghi N
FIR - Parkes, H
IR  - Parkes H
FIR - Parletta, E
IR  - Parletta E
FIR - Parry, B
IR  - Parry B
FIR - Pasha, M
IR  - Pasha M
FIR - Patel, G
IR  - Patel G
FIR - Pathirana, A
IR  - Pathirana A
FIR - Patterson, R
IR  - Patterson R
FIR - Pattison, J
IR  - Pattison J
FIR - Pava, C
IR  - Pava C
FIR - Peachey, D
IR  - Peachey D
FIR - Pearce, E
IR  - Pearce E
FIR - Pearse, B
IR  - Pearse B
FIR - Pech, M
IR  - Pech M
FIR - Pellegrini, P
IR  - Pellegrini P
FIR - Pellizzari, G
IR  - Pellizzari G
FIR - Pereira, V
IR  - Pereira V
FIR - Perera, L
IR  - Perera L
FIR - Perlesz, A
IR  - Perlesz A
FIR - Perraton, R
IR  - Perraton R
FIR - Perry, H
IR  - Perry H
FIR - Perry, S
IR  - Perry S
FIR - Phan, T
IR  - Phan T
FIR - Phan, C
IR  - Phan C
FIR - Phare, A
IR  - Phare A
FIR - Philip, J
IR  - Philip J
FIR - Philips, J
IR  - Philips J
FIR - Phillips, A
IR  - Phillips A
FIR - Philpot, J
IR  - Philpot J
FIR - Phiri, R
IR  - Phiri R
FIR - Pickavance, M
IR  - Pickavance M
FIR - Piekarski, D
IR  - Piekarski D
FIR - Pienkos, J
IR  - Pienkos J
FIR - Pilgrim, C
IR  - Pilgrim C
FIR - Pillai, B K
IR  - Pillai BK
FIR - Pinder, R
IR  - Pinder R
FIR - Pither, A
IR  - Pither A
FIR - Plenderleith, J
IR  - Plenderleith J
FIR - Plunkett, M
IR  - Plunkett M
FIR - Pokharel, C
IR  - Pokharel C
FIR - Poland, D
IR  - Poland D
FIR - Polgar, V
IR  - Polgar V
FIR - Polmear, D
IR  - Polmear D
FIR - Popp, L
IR  - Popp L
FIR - Portelli, A
IR  - Portelli A
FIR - Potter, T
IR  - Potter T
FIR - Powell, V
IR  - Powell V
FIR - Powell, K
IR  - Powell K
FIR - Power, R
IR  - Power R
FIR - Poynton, N
IR  - Poynton N
FIR - Prasad, R
IR  - Prasad R
FIR - Praszkier, S
IR  - Praszkier S
FIR - Preiss, J
IR  - Preiss J
FIR - Preston, P
IR  - Preston P
FIR - Pretorius, P
IR  - Pretorius P
FIR - Price, M
IR  - Price M
FIR - Price, K
IR  - Price K
FIR - Price, I
IR  - Price I
FIR - Priest, C
IR  - Priest C
FIR - Pring, M
IR  - Pring M
FIR - Profitt, C
IR  - Profitt C
FIR - Psaradellis, I J A
IR  - Psaradellis IJ
FIR - Psycharis, J
IR  - Psycharis J
FIR - Pun, K
IR  - Pun K
FIR - Radcliffe, B
IR  - Radcliffe B
FIR - Radcliffe, J
IR  - Radcliffe J
FIR - Radford, J
IR  - Radford J
FIR - Ragg, P
IR  - Ragg P
FIR - Rahel, E
IR  - Rahel E
FIR - Rahman, F
IR  - Rahman F
FIR - Rajasooriar, S
IR  - Rajasooriar S
FIR - Ramsey, J
IR  - Ramsey J
FIR - Rao, U
IR  - Rao U
FIR - Rasaratnam, S
IR  - Rasaratnam S
FIR - Ratnaike, L
IR  - Ratnaike L
FIR - Rattan, J
IR  - Rattan J
FIR - Ratten, K
IR  - Ratten K
FIR - Rattraywood, C
IR  - Rattraywood C
FIR - Rea, J
IR  - Rea J
FIR - Rea, P
IR  - Rea P
FIR - Reddy, S
IR  - Reddy S
FIR - Reed, R
IR  - Reed R
FIR - Reeves, C
IR  - Reeves C
FIR - Reid, K
IR  - Reid K
FIR - Reid, J
IR  - Reid J
FIR - Remyn, P
IR  - Remyn P
FIR - Renouf, E
IR  - Renouf E
FIR - Renshaw, P
IR  - Renshaw P
FIR - Retchford, A
IR  - Retchford A
FIR - Reynolds, F
IR  - Reynolds F
FIR - Rhee, J
IR  - Rhee J
FIR - Rhodes, F
IR  - Rhodes F
FIR - Richards, R
IR  - Richards R
FIR - Richardson, T
IR  - Richardson T
FIR - Richardson, G
IR  - Richardson G
FIR - Richardson, R
IR  - Richardson R
FIR - Ridgers, D
IR  - Ridgers D
FIR - Ridgers, M
IR  - Ridgers M
FIR - Rieger, W
IR  - Rieger W
FIR - Rigoni, M
IR  - Rigoni M
FIR - Riley, J
IR  - Riley J
FIR - Rillstone, D
IR  - Rillstone D
FIR - Rimmer, D
IR  - Rimmer D
FIR - Ringelblum, D
IR  - Ringelblum D
FIR - Roberts, I
IR  - Roberts I
FIR - Roberts, J
IR  - Roberts J
FIR - Roberts, S
IR  - Roberts S
FIR - Roberts, A
IR  - Roberts A
FIR - Robinson, J
IR  - Robinson J
FIR - Robson, A
IR  - Robson A
FIR - Rodway, P
IR  - Rodway P
FIR - Roebuck, R
IR  - Roebuck R
FIR - Rogers, S
IR  - Rogers S
FIR - Rogers, D
IR  - Rogers D
FIR - Roman, F
IR  - Roman F
FIR - Rope, S
IR  - Rope S
FIR - Rose, A
IR  - Rose A
FIR - Rose, K
IR  - Rose K
FIR - Rose, G
IR  - Rose G
FIR - Rose, D
IR  - Rose D
FIR - Rosenblatt, J
IR  - Rosenblatt J
FIR - Ross, K
IR  - Ross K
FIR - Ross, T
IR  - Ross T
FIR - Roth, J
IR  - Roth J
FIR - Rothfield, J
IR  - Rothfield J
FIR - Roubos, N
IR  - Roubos N
FIR - Roufael, A D
IR  - Roufael AD
FIR - Rounsevell, J
IR  - Rounsevell J
FIR - Rouse, W
IR  - Rouse W
FIR - Rowe, R
IR  - Rowe R
FIR - Rubin, J
IR  - Rubin J
FIR - Ryan, S
IR  - Ryan S
FIR - Ryan, F
IR  - Ryan F
FIR - Sabet, A
IR  - Sabet A
FIR - Sachdev, A
IR  - Sachdev A
FIR - Saddik, A
IR  - Saddik A
FIR - Sadhai, R
IR  - Sadhai R
FIR - Saeed, S
IR  - Saeed S
FIR - Sahhar, C
IR  - Sahhar C
FIR - Salter, E
IR  - Salter E
FIR - Salter, M
IR  - Salter M
FIR - Samaddar, A
IR  - Samaddar A
FIR - Samararatna, M
IR  - Samararatna M
FIR - Sandars, M
IR  - Sandars M
FIR - Sanders, J
IR  - Sanders J
FIR - Sandrasegaram, S S
IR  - Sandrasegaram SS
FIR - Sangsari, A
IR  - Sangsari A
FIR - Sasse, C
IR  - Sasse C
FIR - Satter, F
IR  - Satter F
FIR - Satyadharma, K
IR  - Satyadharma K
FIR - Saul, J
IR  - Saul J
FIR - Saxena, A
IR  - Saxena A
FIR - Scaife, R
IR  - Scaife R
FIR - Schaap, M
IR  - Schaap M
FIR - Scheelings, F
IR  - Scheelings F
FIR - Schlesinger, P
IR  - Schlesinger P
FIR - Schlicht, S
IR  - Schlicht S
FIR - Schmidt, M
IR  - Schmidt M
FIR - Schroeder, E
IR  - Schroeder E
FIR - Scully, S
IR  - Scully S
FIR - Searle, R
IR  - Searle R
FIR - Sebastian, T
IR  - Sebastian T
FIR - Segal, G
IR  - Segal G
FIR - Segal, L
IR  - Segal L
FIR - Seidel, B
IR  - Seidel B
FIR - Senanayake, I
IR  - Senanayake I
FIR - Seneviratne, M
IR  - Seneviratne M
FIR - Senini, D
IR  - Senini D
FIR - Sepetavc, D
IR  - Sepetavc D
FIR - Serafim, A
IR  - Serafim A
FIR - Serban, R
IR  - Serban R
FIR - Sexton, P
IR  - Sexton P
FIR - Shahat, M
IR  - Shahat M
FIR - Shamoun, Y
IR  - Shamoun Y
FIR - Shanmugarajah, K
IR  - Shanmugarajah K
FIR - Shannon, G
IR  - Shannon G
FIR - Sharif, A
IR  - Sharif A
FIR - Sharma, U
IR  - Sharma U
FIR - Sharma, D
IR  - Sharma D
FIR - Sharma, R
IR  - Sharma R
FIR - Sharma, S
IR  - Sharma S
FIR - Sharp, V
IR  - Sharp V
FIR - Sheen-Apostol, J
IR  - Sheen-Apostol J
FIR - Sheikh, M M
IR  - Sheikh MM
FIR - Sher, J
IR  - Sher J
FIR - Sherley, M
IR  - Sherley M
FIR - Shi, B
IR  - Shi B
FIR - Shing, D
IR  - Shing D
FIR - Shmerling, A
IR  - Shmerling A
FIR - Shortis, P
IR  - Shortis P
FIR - Shroot, A
IR  - Shroot A
FIR - Sia, M
IR  - Sia M
FIR - Siapantas, S
IR  - Siapantas S
FIR - Siemienowicz, J
IR  - Siemienowicz J
FIR - Siew, H C
IR  - Siew HC
FIR - Silver, D
IR  - Silver D
FIR - Singh, D
IR  - Singh D
FIR - Siow, C L
IR  - Siow CL
FIR - Sitlington, R
IR  - Sitlington R
FIR - Sivapalan, C
IR  - Sivapalan C
FIR - Skeat, J
IR  - Skeat J
FIR - Skehan, M
IR  - Skehan M
FIR - Skeklios, L
IR  - Skeklios L
FIR - Sklovsky, C J
IR  - Sklovsky CJ
FIR - Slabbert, J
IR  - Slabbert J
FIR - Slaney, G
IR  - Slaney G
FIR - Sleaby, E
IR  - Sleaby E
FIR - Sleiman, C
IR  - Sleiman C
FIR - Sloan, C
IR  - Sloan C
FIR - Slonim, D
IR  - Slonim D
FIR - Slot, P
IR  - Slot P
FIR - Smart, M
IR  - Smart M
FIR - Smibert, L
IR  - Smibert L
FIR - Smith, D
IR  - Smith D
FIR - Smith, G
IR  - Smith G
FIR - Smith, P
IR  - Smith P
FIR - Smith, R
IR  - Smith R
FIR - Smith, Stephen
IR  - Smith S
FIR - Smith, Stuart
IR  - Smith S
FIR - Smith, J
IR  - Smith J
FIR - Smith, V
IR  - Smith V
FIR - Smylie, D
IR  - Smylie D
FIR - Snow, S
IR  - Snow S
FIR - Soccio, M
IR  - Soccio M
FIR - Soloczynskiyj, A
IR  - Soloczynskiyj A
FIR - Somerville, M
IR  - Somerville M
FIR - Song, J
IR  - Song J
FIR - Soo, L
IR  - Soo L
FIR - Soo, T
IR  - Soo T
FIR - Soo, T M
IR  - Soo TM
FIR - Sooknandan, S
IR  - Sooknandan S
FIR - Soon, M
IR  - Soon M
FIR - Spargo, J
IR  - Spargo J
FIR - Speirs, B
IR  - Speirs B
FIR - Spencer, H
IR  - Spencer H
FIR - Spring, M
IR  - Spring M
FIR - Squires, L
IR  - Squires L
FIR - Srishanmuganathan, J
IR  - Srishanmuganathan J
FIR - Stabelos, G
IR  - Stabelos G
FIR - Stark, A
IR  - Stark A
FIR - Steer, N
IR  - Steer N
FIR - Steiner, H
IR  - Steiner H
FIR - Stephanson, A
IR  - Stephanson A
FIR - Stephens, G
IR  - Stephens G
FIR - Stephenson, A
IR  - Stephenson A
FIR - Sterling, B
IR  - Sterling B
FIR - Stevens, P
IR  - Stevens P
FIR - Stevenson, J
IR  - Stevenson J
FIR - Stewart, C
IR  - Stewart C
FIR - Stewart, R
IR  - Stewart R
FIR - Sticklen, E
IR  - Sticklen E
FIR - Stiebel, P
IR  - Stiebel P
FIR - Stinerman, I
IR  - Stinerman I
FIR - Stobie, M
IR  - Stobie M
FIR - Stobie, T
IR  - Stobie T
FIR - Stone, A
IR  - Stone A
FIR - Stowe, S
IR  - Stowe S
FIR - Stoyanova, V
IR  - Stoyanova V
FIR - Strasser, K
IR  - Strasser K
FIR - Strong, J
IR  - Strong J
FIR - Su, J
IR  - Su J
FIR - Sujecki, M
IR  - Sujecki M
FIR - Sululola, A
IR  - Sululola A
FIR - Sumathipala, A
IR  - Sumathipala A
FIR - Suntesic, L
IR  - Suntesic L
FIR - Sutherland, D
IR  - Sutherland D
FIR - Sutherland, I
IR  - Sutherland I
FIR - Sutton, J
IR  - Sutton J
FIR - Swart, R
IR  - Swart R
FIR - Sweet, R
IR  - Sweet R
FIR - Sweet, M
IR  - Sweet M
FIR - Syeda, J
IR  - Syeda J
FIR - Sykes, J
IR  - Sykes J
FIR - Sylivris, A
IR  - Sylivris A
FIR - Symon, B
IR  - Symon B
FIR - Szabo, R
IR  - Szabo R
FIR - Szental, S
IR  - Szental S
FIR - Sze-Tho, R
IR  - Sze-Tho R
FIR - Szymanski, R
IR  - Szymanski R
FIR - Szymanski, I
IR  - Szymanski I
FIR - Taft, D
IR  - Taft D
FIR - Taine, M
IR  - Taine M
FIR - Tan, G
IR  - Tan G
FIR - Tan, Elaine
IR  - Tan E
FIR - Tan, Eng
IR  - Tan E
FIR - Tan, H M
IR  - Tan HM
FIR - Tasiopoulos, A
IR  - Tasiopoulos A
FIR - Tate, K
IR  - Tate K
FIR - Taverna, C
IR  - Taverna C
FIR - Taylor, J
IR  - Taylor J
FIR - Taylor, S
IR  - Taylor S
FIR - Teo, K
IR  - Teo K
FIR - Teperman, B
IR  - Teperman B
FIR - Tereszkiewicz, W
IR  - Tereszkiewicz W
FIR - Thanenthiran, R
IR  - Thanenthiran R
FIR - Thangarajah, C
IR  - Thangarajah C
FIR - The, S
IR  - The S
FIR - Thiru, K
IR  - Thiru K
FIR - Thompson, L
IR  - Thompson L
FIR - Thompson, D
IR  - Thompson D
FIR - Thompson, W
IR  - Thompson W
FIR - Thorpe, V
IR  - Thorpe V
FIR - Thottakurichi, R
IR  - Thottakurichi R
FIR - Thurairajah, A
IR  - Thurairajah A
FIR - Thurairajah, S
IR  - Thurairajah S
FIR - Thyagarajan, T
IR  - Thyagarajan T
FIR - Tinston, C
IR  - Tinston C
FIR - Tom, H
IR  - Tom H
FIR - Tomar, D
IR  - Tomar D
FIR - Tomic, M
IR  - Tomic M
FIR - Toohill, G
IR  - Toohill G
FIR - Tooth, M
IR  - Tooth M
FIR - Toua, P
IR  - Toua P
FIR - Tran, C
IR  - Tran C
FIR - Tran, L
IR  - Tran L
FIR - Tran, T Q
IR  - Tran TQ
FIR - Trigg, P
IR  - Trigg P
FIR - Tsigopoulos, A
IR  - Tsigopoulos A
FIR - Tucker, D
IR  - Tucker D
FIR - Tunaley, S
IR  - Tunaley S
FIR - Turnbull, S
IR  - Turnbull S
FIR - Twycross, W
IR  - Twycross W
FIR - Tynan, D
IR  - Tynan D
FIR - Tyshing, W
IR  - Tyshing W
FIR - Uhlenbruch, B
IR  - Uhlenbruch B
FIR - Uluca, U
IR  - Uluca U
FIR - Unkenstein, D
IR  - Unkenstein D
FIR - Vaiopoulos, T
IR  - Vaiopoulos T
FIR - Van Ammers, E
IR  - Van Ammers E
FIR - Van Der Merwe, D
IR  - Van Der Merwe D
FIR - Van Der Spek, A
IR  - Van Der Spek A
FIR - Van Der Vlist, R
IR  - Van Der Vlist R
FIR - Van Opstal, E
IR  - Van Opstal E
FIR - Vanderzeil, T
IR  - Vanderzeil T
FIR - Vanker, L
IR  - Vanker L
FIR - Varney, W
IR  - Varney W
FIR - Vasquez, I
IR  - Vasquez I
FIR - Veal, M
IR  - Veal M
FIR - Venables, S
IR  - Venables S
FIR - Verghese, P
IR  - Verghese P
FIR - Verma, H
IR  - Verma H
FIR - Verso, M
IR  - Verso M
FIR - Victor, A
IR  - Victor A
FIR - Vijayakumar, V
IR  - Vijayakumar V
FIR - Viljoen, E
IR  - Viljoen E
FIR - Vincent, F
IR  - Vincent F
FIR - Viney, P
IR  - Viney P
FIR - Von Caemmerer, A
IR  - Von Caemmerer A
FIR - Vonschmidt, J
IR  - Vonschmidt J
FIR - Vorich, R
IR  - Vorich R
FIR - Vrij, R
IR  - Vrij R
FIR - Waid, S
IR  - Waid S
FIR - Wakefield, B
IR  - Wakefield B
FIR - Walder, D
IR  - Walder D
FIR - Wales, S
IR  - Wales S
FIR - Walker, W
IR  - Walker W
FIR - Walker, G
IR  - Walker G
FIR - Walker, B
IR  - Walker B
FIR - Wall, R
IR  - Wall R
FIR - Wallace, K
IR  - Wallace K
FIR - Wallis, I
IR  - Wallis I
FIR - Wang, S
IR  - Wang S
FIR - Wang, X
IR  - Wang X
FIR - Wang, Z
IR  - Wang Z
FIR - Ward, R
IR  - Ward R
FIR - Ward, S
IR  - Ward S
FIR - Wardlaw, P
IR  - Wardlaw P
FIR - Warr, A
IR  - Warr A
FIR - Warren, M
IR  - Warren M
FIR - Waters, L
IR  - Waters L
FIR - Watson, A
IR  - Watson A
FIR - Watson, S
IR  - Watson S
FIR - Watt, G
IR  - Watt G
FIR - Watt, J
IR  - Watt J
FIR - Webb, I
IR  - Webb I
FIR - Webber, C
IR  - Webber C
FIR - Webber, E
IR  - Webber E
FIR - Webster, D
IR  - Webster D
FIR - Webster, J
IR  - Webster J
FIR - Webster, P
IR  - Webster P
FIR - Weerasinghe, S
IR  - Weerasinghe S
FIR - Weerasoorya, M
IR  - Weerasoorya M
FIR - Weinrich, J
IR  - Weinrich J
FIR - Welberry, L
IR  - Welberry L
FIR - Welsh, D
IR  - Welsh D
FIR - Weng, M
IR  - Weng M
FIR - Wenig, M
IR  - Wenig M
FIR - Wexler, P
IR  - Wexler P
FIR - White, A
IR  - White A
FIR - Whitehouse, L
IR  - Whitehouse L
FIR - Whitehouse, R
IR  - Whitehouse R
FIR - Whitehouse, J
IR  - Whitehouse J
FIR - Wiehle, G
IR  - Wiehle G
FIR - Wild, I
IR  - Wild I
FIR - Williams, G
IR  - Williams G
FIR - Williams, J
IR  - Williams J
FIR - Williams, M
IR  - Williams M
FIR - Williams, P D
IR  - Williams PD
FIR - Williams, S
IR  - Williams S
FIR - Williams, W
IR  - Williams W
FIR - Willis, M
IR  - Willis M
FIR - Wiseman, J
IR  - Wiseman J
FIR - Wivell, F
IR  - Wivell F
FIR - Wong, P T
IR  - Wong PT
FIR - Wong, J
IR  - Wong J
FIR - Wong, C
IR  - Wong C
FIR - Wong, C S
IR  - Wong CS
FIR - Woods, R
IR  - Woods R
FIR - Wooff, D
IR  - Wooff D
FIR - Woolf, S
IR  - Woolf S
FIR - Worboys, P
IR  - Worboys P
FIR - Wrennall, R
IR  - Wrennall R
FIR - Wright, Adrian
IR  - Wright A
FIR - Wright, Antony
IR  - Wright A
FIR - Wright, L
IR  - Wright L
FIR - Wright, Richard
IR  - Wright R
FIR - Wright, Robert
IR  - Wright R
FIR - Wu, D
IR  - Wu D
FIR - Wu, L
IR  - Wu L
FIR - Yang, J
IR  - Yang J
FIR - Yates, D
IR  - Yates D
FIR - Yazbek, P
IR  - Yazbek P
FIR - Yeaman, C
IR  - Yeaman C
FIR - Yeo, M
IR  - Yeo M
FIR - Yeung, S C
IR  - Yeung SC
FIR - Young, R
IR  - Young R
FIR - Yousef, M
IR  - Yousef M
FIR - Yousif, K
IR  - Yousif K
FIR - Youssef, D
IR  - Youssef D
FIR - Yu, Z
IR  - Yu Z
FIR - Yuille, R
IR  - Yuille R
FIR - Zagorksi, M
IR  - Zagorksi M
FIR - Zail, S
IR  - Zail S
FIR - Zain, M
IR  - Zain M
FIR - Zallmann, A
IR  - Zallmann A
FIR - Zhao, W
IR  - Zhao W
FIR - Zheng, M
IR  - Zheng M
FIR - Zhou, D
IR  - Zhou D
FIR - Ziccone, M
IR  - Ziccone M
FIR - Zimmerman, J
IR  - Zimmerman J
EDAT- 2013/10/12 06:00
MHDA- 2014/08/15 06:00
CRDT- 2013/10/12 06:00
PHST- 2013/06/28 00:00 [received]
PHST- 2013/09/24 00:00 [revised]
PHST- 2013/09/26 00:00 [accepted]
PHST- 2013/10/12 06:00 [entrez]
PHST- 2013/10/12 06:00 [pubmed]
PHST- 2014/08/15 06:00 [medline]
AID - S1551-7144(13)00165-1 [pii]
AID - 10.1016/j.cct.2013.09.014 [doi]
PST - ppublish
SO  - Contemp Clin Trials. 2013 Nov;36(2):555-64. doi: 10.1016/j.cct.2013.09.014. Epub 
      2013 Oct 7.

PMID- 22605816
OWN - NLM
STAT- MEDLINE
DCOM- 20130212
LR  - 20211021
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 2012
DP  - 2012 Mar 27
TI  - Massive pulmonary thromboembolism after intravenous stroke thrombolysis.
LID - 10.1136/bcr.10.2011.5008 [doi]
LID - bcr1020115008
AB  - The authors present a 76-year-old female with high blood pressure and 
      hypercholesterolaemia as cerebrovascular risk factors, who received intravenous 
      thrombolysis for an ischaemic stroke with a progressive neurological improvement. 
      She was asymptomatic at 48 h and she was transferred to the neurology department 
      where antithrombotic treatment was initiated. She began to sit the following day 
      when she suffered a massive pulmonary embolism (PE). Cardiological study showed 
      patent foramen oval persistence and the presence of an atrial septa aneurysm, and 
      paroxysmal atrial fibrillation. The delay of the onset of the antithrombotic 
      treatment could have been determinant for the massive PE. Thromboembolic 
      complications may be seen after intravenous thrombolysis for ischaemic stroke. An 
      accurate treatment is needed in order to avoid potentially threatening 
      complications such as massive PE.
FAU - Delgado, Montserrat G
AU  - Delgado MG
AD  - Neurology Department, Hospital Universitario Central de Asturias, Oviedo, Spain. 
      mglezdelgado@yahoo.es
FAU - Mauri, Gerard
AU  - Mauri G
FAU - Vega, Juan
AU  - Vega J
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20120327
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects
MH  - Echocardiography
MH  - Female
MH  - Heparin, Low-Molecular-Weight/administration & dosage/adverse effects
MH  - Humans
MH  - Infusions, Intravenous
MH  - Pulmonary Embolism/*chemically induced/*diagnosis
MH  - Stroke/*complications/*drug therapy
MH  - Thrombolytic Therapy/*adverse effects
MH  - Tomography, X-Ray Computed
PMC - PMC3316835
COIS- Competing interests None.
EDAT- 2012/05/19 06:00
MHDA- 2013/02/13 06:00
CRDT- 2012/05/19 06:00
PHST- 2012/05/19 06:00 [entrez]
PHST- 2012/05/19 06:00 [pubmed]
PHST- 2013/02/13 06:00 [medline]
AID - bcr.10.2011.5008 [pii]
AID - 10.1136/bcr.10.2011.5008 [doi]
PST - epublish
SO  - BMJ Case Rep. 2012 Mar 27;2012:bcr1020115008. doi: 10.1136/bcr.10.2011.5008.

PMID- 1339576
OWN - NLM
STAT- MEDLINE
DCOM- 19931119
LR  - 20161021
IS  - 1230-5359 (Print)
IS  - 1230-5359 (Linking)
VI  - 32
IP  - 3-4
DP  - 1992
TI  - Concentrations of antibiotics in alveolar milk after intramammary inlocation of 
      their different doses together with glucose, acetylsalicylic acid or 
      chlormethine.
PG  - 65-77
AB  - After intramammary introduction of penicillin (600 th. i.u.), streptomycin (0.5 
      g), cloxacillin (0.5 g), neomycin (0.5 g), erythromycin (0.5 g) and cefoperazone 
      (0.25 g) in 100 ml of 5% glucose solution the antibiotics' concentrations in the 
      alveolar milk remained for 24 hours or longer on the level higher than MIC in 
      relation to staphylococci and streptococci isolated from cows mastitis. In the 
      first 24 hours the growth of antibiotic activity was little influenced by 
      chlormethine supplement. While addition of ASA increased concentration and 
      prolonged the time of antibiotics remaining on the therapeutic level.
FAU - Malinowski, E
AU  - Malinowski E
AD  - Department of Phsiopathology of Reproduction and Mammary Gland, National 
      Veterinary Research Institute, Poland.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Arch Vet Pol
JT  - Archivum veterinarium Polonicum
JID - 9313674
RN  - 0 (Anti-Bacterial Agents)
RN  - 50D9XSG0VR (Mechlorethamine)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/administration & dosage/*pharmacokinetics
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cattle
MH  - Female
MH  - Glucose/administration & dosage/*pharmacology
MH  - Infusions, Parenteral
MH  - Kinetics
MH  - Mammary Glands, Animal/drug effects/*physiology
MH  - Mechlorethamine/administration & dosage/*pharmacology
MH  - Milk/drug effects/*physiology
MH  - Time Factors
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Arch Vet Pol. 1992;32(3-4):65-77.

PMID- 17030227
OWN - NLM
STAT- MEDLINE
DCOM- 20061204
LR  - 20131121
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 118
IP  - 4
DP  - 2006 Oct
TI  - Clinical and pathologic perspectives on aspirin sensitivity and asthma.
PG  - 773-86; quiz 787-8
AB  - Aspirin and other nonsteroidal anti-inflammatory drugs that inhibit COX-1 induce 
      unique nonallergic reactions, consisting of attacks of rhinitis and asthma. These 
      hypersensitivity reactions occur in a subset of asthmatic subjects, thus 
      identifying them as having this exclusive clinical presentation. We refer to 
      these patients as having aspirin-exacerbated respiratory disease, a disease 
      process that produces devastating eosinophilic inflammation of both the upper and 
      lower respiratory tracts. This review focuses on a description of patients with 
      aspirin-exacerbated respiratory disease, methods available to diagnose their 
      condition, the unique ability of all nonsteroidal anti-inflammatory drugs that 
      inhibit COX-1 to cross-react with aspirin, an update on pathogenesis, and current 
      thoughts about treatment.
FAU - Stevenson, Donald D
AU  - Stevenson DD
AD  - Division of Allergy, Asthma and Immunology and the Department of Medicine, 
      Scripps Clinic and the Scripps Research Institute, La Jolla, USA. 
      dstevemd@AOL.com
FAU - Szczeklik, Andrew
AU  - Szczeklik A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20060901
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/immunology
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/*immunology
MH  - Cross Reactions
MH  - Cyclooxygenase Inhibitors/immunology
MH  - Drug Hypersensitivity/*immunology
MH  - Humans
RF  - 147
EDAT- 2006/10/13 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/10/13 09:00
PHST- 2006/06/16 00:00 [received]
PHST- 2006/07/06 00:00 [revised]
PHST- 2006/07/07 00:00 [accepted]
PHST- 2006/10/13 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/10/13 09:00 [entrez]
AID - S0091-6749(06)01570-3 [pii]
AID - 10.1016/j.jaci.2006.07.024 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2006 Oct;118(4):773-86; quiz 787-8. doi: 
      10.1016/j.jaci.2006.07.024. Epub 2006 Sep 1.

PMID- 9842255
OWN - NLM
STAT- MEDLINE
DCOM- 19981228
LR  - 20131121
IS  - 0034-1193 (Print)
IS  - 0034-1193 (Linking)
VI  - 89
IP  - 10
DP  - 1998 Oct
TI  - [Platelet antiaggregants or anticoagulants in the secondary prevention after 
      myocardial infarct].
PG  - 514-9
AB  - Aspirin and oral anticoagulants are effective treatments in the secondary 
      prevention after myocardial infarction. Aspirin at the dosage of 160-325 mg per 
      day accomplishes a 21% reduction of the recurrences of vascular events (INR: 
      3-4). Oral anticoagulants are likely to be more effective; this therapy however 
      is more demanding for the patient and the referring physician and is associated 
      with a higher risk of hemorrhage. According to the available information from the 
      literature, aspirin should be recommended for the majority of patients surviving 
      after myocardial infarction. Oral anticoagulants should be reserved for 
      post-infarction patients at high risk of thromboembolism and for those patients 
      who present either intolerance to aspirin or recurrence of vascular events during 
      aspirin treatment.
FAU - Di Pasquale, G
AU  - Di Pasquale G
FAU - Ottani, F
AU  - Ottani F
FAU - Ceré, E
AU  - Ceré E
FAU - Biancoli, S
AU  - Biancoli S
FAU - Sassone, B
AU  - Sassone B
FAU - Lombardi, A
AU  - Lombardi A
LA  - ita
PT  - Comparative Study
PT  - Editorial
PT  - English Abstract
PT  - Review
TT  - Antiaggreganti piastrinici o anticoagulanti nella prevenzione secondaria dopo 
      infarto miocardico.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Controlled Clinical Trials as Topic
MH  - Follow-Up Studies
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Myocardial Infarction/complications/drug therapy/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Risk Factors
MH  - Time Factors
RF  - 26
EDAT- 1998/12/08 00:00
MHDA- 1998/12/08 00:01
CRDT- 1998/12/08 00:00
PHST- 1998/12/08 00:00 [pubmed]
PHST- 1998/12/08 00:01 [medline]
PHST- 1998/12/08 00:00 [entrez]
PST - ppublish
SO  - Recenti Prog Med. 1998 Oct;89(10):514-9.

PMID- 8495987
OWN - NLM
STAT- MEDLINE
DCOM- 19930624
LR  - 20131121
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 98
DP  - 1993 Feb
TI  - Effect of aspirin on isoproterenol induced changes in lipid metabolism in rats.
PG  - 30-3
AB  - The effect of aspirin on isoproterenol induced changes in lipid metabolism in 
      rats was studied. Aspirin (1.2 mg/100 g/day) was administered orally for a period 
      of 60 days along with/without isoproterenol (20 mg/100g sc twice at a time 
      interval of 24 h for 2 days). Isoproterenol treated rats showed an increase in 
      the levels of heart cholesterol, triglycerides and free fatty acids. The activity 
      of cholesterol ester synthetase CES was increased significantly with concomitant 
      increase in heart lipid peroxide levels in isoproterenol treatment. Aspirin 
      treatment could restore the enzyme activity to near normal and also reduce the 
      level of lipid peroxides. The lipid changes were minimum in rats treated with 
      aspirin and isoproterenol.
FAU - Manjula, T S
AU  - Manjula TS
AD  - Department of Biochemistry, University of Madras.
FAU - Devi, C S
AU  - Devi CS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Triglycerides)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - EC 3.1.1.- (acid cholesterol ester synthetase)
RN  - EC 3.1.1.13 (Sterol Esterase)
RN  - L628TT009W (Isoproterenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cholesterol/metabolism
MH  - Fatty Acids, Nonesterified/metabolism
MH  - Heart/drug effects
MH  - Isoproterenol/administration & dosage/*pharmacology
MH  - *Lipid Metabolism
MH  - Male
MH  - Myocardium/enzymology/*metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Sterol Esterase/metabolism
MH  - Triglycerides/metabolism
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Med Res. 1993 Feb;98:30-3.

PMID- 9498533
OWN - NLM
STAT- MEDLINE
DCOM- 19980319
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 97
IP  - 8
DP  - 1998 Mar 3
TI  - Aspirin improves endothelial dysfunction in atherosclerosis.
PG  - 716-20
AB  - BACKGROUND: The beneficial effects of aspirin in atherosclerosis are generally 
      attributed to its antiplatelet activities, but its influence on endothelial 
      function remains uncertain. We hypothesized that a cyclooxygenase-dependent 
      constricting factor contributes to the endothelial dysfunction in atherosclerosis 
      and that its action can be reversed by aspirin. METHODS AND RESULTS: In 14 
      patients with coronary atherosclerosis and 5 with risk factors, we tested femoral 
      vascular endothelial function with acetylcholine and substance P and 
      endothelium-independent function with sodium nitroprusside before and after 
      intravenous aspirin. Drugs were infused into the femoral artery, and Doppler flow 
      velocity was measured. Acetylcholine-induced but not substance P-or sodium 
      nitroprusside-induced vasodilation was lower in patients with atherosclerosis 
      than in those with only risk factors. Aspirin had no baseline effect but improved 
      acetylcholine-mediated vasodilation only in patients with atherosclerosis; at the 
      peak dose, acetylcholine-mediated femoral vascular resistance index was 19 +/- 
      5%, P=.002 lower. There was a correlation between the baseline response to 
      acetylcholine and the magnitude of improvement with aspirin (r=.5, P=.05). Thus, 
      patients with a depressed response to acetylcholine had greater improvement with 
      aspirin, and vice versa. The presence of atherosclerosis was an independent 
      determinant of improvement with aspirin. Aspirin had no effect on the responses 
      to either substance P or sodium nitroprusside. CONCLUSIONS: 
      Cyclooxygenase-dependent, endothelium-derived vasoconstrictor release modulates 
      acetylcholine-induced peripheral vasodilation in patients with atherosclerosis. 
      Improvement of endothelial dysfunction with aspirin may improve vasodilation, 
      reduce thrombosis, and inhibit progression of atherosclerosis and provides a 
      pathophysiological basis for the beneficial effects of aspirin in 
      atherosclerosis.
FAU - Husain, S
AU  - Husain S
AD  - Cardiology Branch, National Heart, Lung, and Blood Institute, Bethesda, Md 
      20892-1650, USA.
FAU - Andrews, N P
AU  - Andrews NP
FAU - Mulcahy, D
AU  - Mulcahy D
FAU - Panza, J A
AU  - Panza JA
FAU - Quyyumi, A A
AU  - Quyyumi AA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - 169D1260KM (Nitroprusside)
RN  - 33507-63-0 (Substance P)
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylcholine/pharmacology
MH  - Arteriosclerosis/*drug therapy
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Endothelium, Vascular/*drug effects/physiopathology
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Nitroprusside/pharmacology
MH  - Reproducibility of Results
MH  - Substance P/pharmacology
MH  - Vasodilation/drug effects
MH  - Vasodilator Agents/pharmacology
EDAT- 1998/03/14 00:00
MHDA- 1998/03/14 00:01
CRDT- 1998/03/14 00:00
PHST- 1998/03/14 00:00 [pubmed]
PHST- 1998/03/14 00:01 [medline]
PHST- 1998/03/14 00:00 [entrez]
AID - 10.1161/01.cir.97.8.716 [doi]
PST - ppublish
SO  - Circulation. 1998 Mar 3;97(8):716-20. doi: 10.1161/01.cir.97.8.716.

PMID- 24880912
OWN - NLM
STAT- MEDLINE
DCOM- 20150615
LR  - 20140902
IS  - 1878-0938 (Electronic)
IS  - 1878-0938 (Linking)
VI  - 15
IP  - 5
DP  - 2014 Jul-Aug
TI  - Single antiplatelet therapy after percutaneous coronary intervention in patients 
      allergic to aspirin.
PG  - 308-10
LID - S1553-8389(14)00132-8 [pii]
LID - 10.1016/j.carrev.2014.04.005 [doi]
AB  - Dual antiplatelet therapy including aspirin and a P2Y12 ADP receptor antagonist 
      is given after percutaneous coronary intervention to avoid catastrophic 
      complication of stent thrombosis. Dual antiplatelet therapy is associated with 
      increased bleeding risk and may not be tolerated by many patients. This article 
      presents the patients, which had to be given single antiplatelet therapy after 
      percutaneous coronary intervention and discusses the possible factors responsible 
      for the success of single antiplatelet therapy strategy in these patients, in the 
      current era of newer antiplatelet agents and coronary stents.
CI  - Copyright © 2014 Elsevier Inc. All rights reserved.
FAU - Agarwal, Sanjeev Kumar
AU  - Agarwal SK
AD  - Cardiology, Rashid Hospital, Dubai, UAE. Electronic address: skacardio@yahoo.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20140430
PL  - United States
TA  - Cardiovasc Revasc Med
JT  - Cardiovascular revascularization medicine : including molecular interventions
JID - 101238551
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Drug Hypersensitivity
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thrombosis/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - Clopidogrel
OT  - PCI
OT  - Ticagrelor
EDAT- 2014/06/02 06:00
MHDA- 2015/06/16 06:00
CRDT- 2014/06/02 06:00
PHST- 2014/03/01 00:00 [received]
PHST- 2014/04/21 00:00 [revised]
PHST- 2014/04/22 00:00 [accepted]
PHST- 2014/06/02 06:00 [entrez]
PHST- 2014/06/02 06:00 [pubmed]
PHST- 2015/06/16 06:00 [medline]
AID - S1553-8389(14)00132-8 [pii]
AID - 10.1016/j.carrev.2014.04.005 [doi]
PST - ppublish
SO  - Cardiovasc Revasc Med. 2014 Jul-Aug;15(5):308-10. doi: 
      10.1016/j.carrev.2014.04.005. Epub 2014 Apr 30.

PMID- 881390
OWN - NLM
STAT- MEDLINE
DCOM- 19770917
LR  - 20171213
IS  - 0161-7567 (Print)
IS  - 0161-7567 (Linking)
VI  - 42
IP  - 6
DP  - 1977 Jun
TI  - Prostaglandin synthesis inhibition restores hypoxic pulmonary vasoconstriction.
PG  - 903-8
AB  - Hypoxic pulmonary vasoconstriction in blood-perfused isolated dog lungs 
      progressively diminishes with repeated hypoxic challenges. We investigated the 
      role of prostaglandins in effecting the decay of the hypoxic response by using a 
      double perfusion preparation that could separately perfuse the right and left 
      lungs of a single dog. Degeneration of this response was reversed by the addition 
      of prostaglandin (PG) synthesis inhibitors, aspirin, or indomethacin. Various 
      PG's known to be produced by the lung (PGE1, PGE2, and PGF2alpha), were infused, 
      and only PGE1 abolished hypoxic pulmonary vasoconstriction. Since other workers 
      have shown that lungs can synthesize and release PG's in response to various 
      stimuli, we postulate that PGE1 synthesis in isolated lungs may increase and 
      thereby cause the degeneration of the hypoxic response. The addition of aspirin 
      or indomethacin could inhibit the synthesis of PGE1 and thereby restore hypoxic 
      pulmonary vasoconstriction.
FAU - Alexander, J M
AU  - Alexander JM
FAU - Nyby, M D
AU  - Nyby MD
FAU - Jasberg, K A
AU  - Jasberg KA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Appl Physiol Respir Environ Exerc Physiol
JT  - Journal of applied physiology: respiratory, environmental and exercise physiology
JID - 7801242
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Pressure/drug effects
MH  - Dogs
MH  - Hypoxia/*physiopathology
MH  - Indomethacin/pharmacology
MH  - Prostaglandins/*pharmacology
MH  - Pulmonary Artery
MH  - Pulmonary Circulation/*drug effects
EDAT- 1977/06/01 00:00
MHDA- 1977/06/01 00:01
CRDT- 1977/06/01 00:00
PHST- 1977/06/01 00:00 [pubmed]
PHST- 1977/06/01 00:01 [medline]
PHST- 1977/06/01 00:00 [entrez]
AID - 10.1152/jappl.1977.42.6.903 [doi]
PST - ppublish
SO  - J Appl Physiol Respir Environ Exerc Physiol. 1977 Jun;42(6):903-8. doi: 
      10.1152/jappl.1977.42.6.903.

PMID- 28936833
OWN - NLM
STAT- MEDLINE
DCOM- 20180531
LR  - 20181202
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 41
IP  - 24
DP  - 2016 Dec
TI  - [Mechanism of Salvianolate injection combined with aspirin in treatment of stable 
      angina pectoris based on biomolecules network].
PG  - 4521-4532
LID - 10.4268/cjcmm20162408 [doi]
AB  - Biomolecular network analysis was used to predict the mechanism of Salvianolate 
      injection combined with aspirin for the treatment of stable angina pectoris(SAP). 
      Related genes of Salvianolate injection, aspirin and SAP were obtained from 
      Genecards, STITCH and DisGeNET databases. Agilent literature search software was 
      used to construct biomolecular network; modules were identified by AP, MCODE and 
      MCL methods. DAVID software was used for identification of related KEGG pathways. 
      Results showed that Salvianolate injection and aspirin had a coverage rate of 
      45.92%, 62.56% respectively for SAP molecular network, and the coverage rate was 
      71.64% in combined use. The top 10 important nodes of SAP overlapped with 
      Salvianolate injection and aspirin included MAPK14, MAPK8, IL-6 and IL-8. The 
      important SAP nodes overlapped with Salvianolate injection alone included AKT1 
      and IFNG, and the important SAP nodes overlapped with aspirin included EPHB2 and 
      TP53. Related SAP signaling pathways with combined Salvianolate injection and 
      aspirin included Jak-STAT signaling pathway and MAPK signaling pathway. Related 
      SAP signaling pathways with Salvianolate injection alone included VEGF signaling 
      pathway and type 1 diabetes signaling pathway. Related SAP signaling pathways 
      with aspirin alone included AA metabolism, linoleic acid metabolism signaling 
      pathway, etc. The results showed that Salvianolate injection and aspirin 
      combination had an enhancement effect in treatment of SAP through 
      anti-inflammatory reaction and inhibition of atherosclerosis development; in 
      addition, the combination use may have an additive effect through the 
      antiplatelet aggregation, protecting endothelial cells, regulating blood lipid 
      and regulating glucose metabolism.
CI  - Copyright© by the Chinese Pharmaceutical Association.
FAU - Li, Yuan
AU  - Li Y
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Sciences, Beijing 100700, China.
FAU - Wang, Lian-Xin
AU  - Wang LX
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Sciences, Beijing 100700, China.
FAU - Xie, Yan-Ming
AU  - Xie YM
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Sciences, Beijing 100700, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese 
      materia medica
JID - 8913656
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Plant Extracts)
RN  - 0 (salvianolate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Stable/*drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atherosclerosis/prevention & control
MH  - Humans
MH  - Plant Extracts/*therapeutic use
MH  - Signal Transduction
OTO - NOTNLM
OT  - Salvianolate injection
OT  - aspirin
OT  - biomolecular network analysis
OT  - drug combination
OT  - molecular mechanism
OT  - stable angina pectoris(SAP)
COIS- The authors of this article and the planning committee members and staff have no 
      relevant financial relationships with commercial interests to disclose.
EDAT- 2017/09/25 06:00
MHDA- 2018/06/01 06:00
CRDT- 2017/09/23 06:00
PHST- 2016/06/08 00:00 [received]
PHST- 2017/09/23 06:00 [entrez]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2018/06/01 06:00 [medline]
AID - 10.4268/cjcmm20162408 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2016 Dec;41(24):4521-4532. doi: 10.4268/cjcmm20162408.

PMID- 12806004
OWN - NLM
STAT- MEDLINE
DCOM- 20040322
LR  - 20180705
IS  - 1537-744X (Electronic)
IS  - 2356-6140 (Print)
IS  - 1537-744X (Linking)
VI  - 2
DP  - 2002 Mar 22
TI  - Pharmacogenetics of antiplatelet drugs.
PG  - 791-800
AB  - Pharmacogenetics refers to the genetic factors that influence the response to a 
      drug, often involving genetic variations in drug metabolizing enzymes. The 
      pharmacogenetics of antiplatelet agents is in its infancy and largely reflects 
      variations in drug targets or related genes. One particular gene variant, the 
      PlA2 polymorphism of the glycoprotein (GP) IIb/IIIa receptor, is now emerging as 
      a probable determinant of the response to antiplatelet agents including 
      GPIIb/IIIa antagonists. This variant may in part explain the heterogeneity in the 
      response to GPIIb/IIIa antagonists. The PlA2 genotype appears to be associated 
      with an adverse outcome in patients treated with an oral GPIIb/IIIa antagonist 
      and may be a factor in the observed failure of these agents in unselected 
      populations. However, there are preliminary indications that other antiplatelet 
      agents may have an enhanced effect in PlA2 subjects. Further clinical trials in 
      particular are required to definitively characterize the pharmacogenetic effect 
      of PlA2. Other polymorphisms are also likely to contribute to the 
      pharmacogenetics of antiplatelet agents, but these await investigation.
FAU - Curtin, Ronan
AU  - Curtin R
AD  - Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, 123 
      St. Stephen's Green, Dublin 2, Ireland. rcurtin@rcsi.ie
FAU - Fitzgerald, Desmond J
AU  - Fitzgerald DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20020322
PL  - United States
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacokinetics
MH  - Dipyridamole/*pharmacology
MH  - Humans
MH  - *Pharmacogenetics
MH  - Pyridines/*pharmacokinetics
PMC - PMC6009749
EDAT- 2003/06/14 05:00
MHDA- 2004/03/23 05:00
CRDT- 2003/06/14 05:00
PHST- 2003/06/14 05:00 [pubmed]
PHST- 2004/03/23 05:00 [medline]
PHST- 2003/06/14 05:00 [entrez]
AID - 735059 [pii]
AID - 10.1100/tsw.2002.153 [doi]
PST - epublish
SO  - ScientificWorldJournal. 2002 Mar 22;2:791-800. doi: 10.1100/tsw.2002.153.

PMID- 12090106
OWN - NLM
STAT- MEDLINE
DCOM- 20020807
LR  - 20131121
IS  - 0034-9887 (Print)
IS  - 0034-9887 (Linking)
VI  - 130
IP  - 4
DP  - 2002 Apr
TI  - [Study of the chemical stability of acetylsalicylic acid tablets during storage 
      in pharmacies of Concepción, Chile].
PG  - 409-15
AB  - BACKGROUND: The chemical stability of a pharmaceutical product depends, among 
      other factors, on environmental factors during transport, storage and 
      manipulation of the product. AIM: To study the chemical stability of 
      acetylsalicylic acid (AAS) tablets during ten months of storage in five 
      pharmacies of Concepción, Chile. MATERIAL AND METHODS: Tablets were randomly 
      collected at the beginning of the study and at the third, sixth and tenth month. 
      Quantitative analyses of AAS tablets was carried out by instrumental thin layer 
      chromatography (HPTLC). RESULTS: AAS in tablets was between 99 and 109% at the 
      beginning of the study, between 76 and 110% at three months, between 71% and 112% 
      at six months and between 86 and 110% at ten months of storage. CONCLUSIONS: 
      There was a progressive decrease in the content of acetylsalicylic acid in tables 
      during storage, but it remained between the limits accepted by the United States 
      Pharmacopoeia (USP) (90-110%).
FAU - Mennickent, Sigrid
AU  - Mennickent S
AD  - Departamentos de Farmacia y Bromatología, Nutrición y Dietética, Facultad de 
      Farmacia, Universidad de Concepción, Casilla 237 Concepción, Chile. 
      smennick@udec.cl
FAU - Yates, Tamara
AU  - Yates T
FAU - Vega, Mario
AU  - Vega M
FAU - Gloria Godoy, C
AU  - Gloria Godoy C
FAU - Saelzer, Roberto
AU  - Saelzer R
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Estudio de la estabilidad química de comprimidos de ácido acetilsalicílico 
      mediante un control de estanterías en farmacias de Concepción, Chile.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Chile
MH  - Chromatography, Thin Layer/methods
MH  - Drug Stability
MH  - Drug Storage
MH  - Humidity
MH  - *Pharmacies
MH  - Tablets
MH  - Temperature
MH  - Time Factors
EDAT- 2002/07/02 10:00
MHDA- 2002/08/08 10:01
CRDT- 2002/07/02 10:00
PHST- 2002/07/02 10:00 [pubmed]
PHST- 2002/08/08 10:01 [medline]
PHST- 2002/07/02 10:00 [entrez]
PST - ppublish
SO  - Rev Med Chil. 2002 Apr;130(4):409-15.

PMID- 6781863
OWN - NLM
STAT- MEDLINE
DCOM- 19810521
LR  - 20131121
IS  - 0012-7590 (Print)
IS  - 0012-7590 (Linking)
VI  - 11
IP  - 4
DP  - 1980 Dec
TI  - [Quantification of the attenuation of pain sensation through evoked potentials 
      after the application of mild analgesics (author's transl)].
PG  - 199-204
AB  - Evoked potentials resulting from stimulation of tooth pulp with rectangular 
      impulses were chosen for the indication of the analgesic activity of mild 
      analgesics. If the stimuli were perceived subjectively as equally painful, the 
      amplitudes of the evoked potentials were intraindividually well reproducible. The 
      results are reproducible within one day as well as on different days. According 
      to the large interindividual variation in the amplitude of the evoked potentials, 
      the percentual reduction of the amplitude was a better measure for the analgesic 
      action than the absolute height of the signal. Interindividually, the latencies 
      have shown clear differences whereas they were reproducible for the individuum. 
      The curves for: 1. The percentual reduction of the evoked potentials 2. The 
      diminuation of the subjective pain response 3. The increase in the sensitivity 
      threshold after the application of the drug were principally similar. The results 
      indicate, that the evoked potentials may represent a more sensitive measure of 
      experimentally induced pain in subjective methods.
FAU - Rohdewald, P
AU  - Rohdewald P
FAU - Derendorf, H
AU  - Derendorf H
FAU - Elger, C E
AU  - Elger CE
FAU - Knoll, O
AU  - Knoll O
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Quantifizierung der Dämpfung in der Schmerzempfindung mit Hilfe evozierter 
      Potentiale nach Gabe schwacher Analgetika.
PL  - Germany
TA  - EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb
JT  - EEG-EMG Zeitschrift fur Elektroenzephalographie, Elektromyographie und verwandte 
      Gebiete
JID - 0264413
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Caffeine/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - *Electroencephalography
MH  - Evoked Potentials/drug effects
MH  - Humans
MH  - Sensory Thresholds
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
PST - ppublish
SO  - EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb. 1980 Dec;11(4):199-204.

PMID- 26822279
OWN - NLM
STAT- MEDLINE
DCOM- 20160906
LR  - 20181113
IS  - 1534-4436 (Electronic)
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 116
IP  - 4
DP  - 2016 Apr
TI  - Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated 
      respiratory disease.
PG  - 321-328.e1
LID - S1081-1206(15)00847-9 [pii]
LID - 10.1016/j.anai.2015.12.026 [doi]
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is diagnosed through 
      graded aspirin challenges that induce hypersensitivity reactions and eicosanoid 
      level changes. It is not known whether diagnostically useful changes also occur 
      after low-dose aspirin challenges that do not induce hypersensitivity reactions. 
      OBJECTIVE: To investigate the utility of low-dose oral aspirin challenges for 
      diagnosing AERD by measuring different clinical parameters and eicosanoid 
      changes. METHODS: Sixteen patients with AERD and 13 patients with 
      aspirin-tolerant asthma underwent oral challenges with low-dose (20 or 40 mg) 
      aspirin and diagnostic oral graded aspirin challenges (up to 325 mg of aspirin). 
      Forced expiratory volume in 1 second, nasal peak flow, the fraction of exhaled 
      nitric oxide (FeNO), and eicosanoid levels in plasma and urine were analyzed. 
      RESULTS: In patients with AERD but not in those with aspirin-tolerant asthma, 
      40-mg aspirin challenges induced a significant mean (SEM) decrease from baseline 
      in FeNO (19% [5.1%]; P = .001) without causing any hypersensitivity reaction. The 
      FeNO decrease also occurred after higher-dose aspirin challenges (27.8% [4.9%]; P 
      < .001). The sensitivity and specificity of 40-mg aspirin-induced FeNO changes 
      for identifying AERD were 90% and 100% with an area under the curve of 0.98 (95% 
      CI, 0.92-1.00). The low-dose challenge also induced a significant leukotriene E4 
      urine increase in patients with AERD (from 6.32 [0.08] to 6.91 [0.15] log-pg/mg 
      creatinine; P < .001), but the sensitivity and specificity of these changes were 
      less than for the FeNO changes. CONCLUSION: The low-dose aspirin-induced decrease 
      in FeNO in patients with AERD may be useful for the diagnosis of aspirin allergy 
      without inducing a hypersensitivity reaction. TRIAL REGISTRATION: 
      clinicaltrials.gov Identifier: NCT01320072.
CI  - Copyright © 2016 American College of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Jerschow, Elina
AU  - Jerschow E
AD  - Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York. 
      Electronic address: Elina.Jerschow@einstein.yu.edu.
FAU - Ren, Zhen
AU  - Ren Z
AD  - Jacobi Medical Center, Bronx, New York.
FAU - Hudes, Golda
AU  - Hudes G
AD  - Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
FAU - Sanak, Marek
AU  - Sanak M
AD  - Jagiellonian University Medical College, Krakow, Poland.
FAU - Morales, Esperanza
AU  - Morales E
AD  - Ferkauf Graduate School of Psychology at Yeshiva University, Bronx, New York.
FAU - Schuster, Victor
AU  - Schuster V
AD  - Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
FAU - Spivack, Simon D
AU  - Spivack SD
AD  - Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
FAU - Rosenstreich, David
AU  - Rosenstreich D
AD  - Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
LA  - eng
SI  - ClinicalTrials.gov/NCT01320072
GR  - KL2 TR001071/TR/NCATS NIH HHS/United States
GR  - R01 DK049688/DK/NIDDK NIH HHS/United States
GR  - UL1 TR001073/TR/NCATS NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
DEP - 20160125
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Allergens)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 75715-89-8 (Leukotriene E4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Allergens/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Asthma, Aspirin-Induced/*diagnosis
MH  - Drug Hypersensitivity/*diagnosis
MH  - Female
MH  - Humans
MH  - Immunization/methods
MH  - Leukotriene E4/urine
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide/metabolism
MH  - Sensitivity and Specificity
PMC - PMC4826295
MID - NIHMS748067
COIS- Conflict of interest: Dr. Elina Jerschow holds an Investigator Initiated Research 
      Award IISP39161 from Merck & Co., Inc. Other authors have no potential conflict 
      of interest
EDAT- 2016/01/30 06:00
MHDA- 2016/09/07 06:00
CRDT- 2016/01/30 06:00
PHST- 2015/10/27 00:00 [received]
PHST- 2015/12/18 00:00 [revised]
PHST- 2015/12/22 00:00 [accepted]
PHST- 2016/01/30 06:00 [entrez]
PHST- 2016/01/30 06:00 [pubmed]
PHST- 2016/09/07 06:00 [medline]
AID - S1081-1206(15)00847-9 [pii]
AID - 10.1016/j.anai.2015.12.026 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2016 Apr;116(4):321-328.e1. doi: 
      10.1016/j.anai.2015.12.026. Epub 2016 Jan 25.

PMID- 31569308
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20201207
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Print)
IS  - 2042-6976 (Linking)
VI  - 9
IP  - 12
DP  - 2019 Dec
TI  - Endoscopic sinus surgery improves aspirin treatment response in 
      aspirin-exacerbated respiratory disease patients.
PG  - 1401-1408
LID - 10.1002/alr.22418 [doi]
AB  - BACKGROUND: Aspirin desensitization and treatment benefits most patients with 
      aspirin-exacerbated respiratory disease (AERD), although some patients fail 
      therapy. Our objective was to assess whether recent endoscopic sinus surgery 
      (ESS) improved aspirin treatment outcomes in AERD patients who initially failed 
      aspirin therapy. METHODS: Outcomes of aspirin desensitization and treatment in 
      AERD patients prospectively enrolled were assessed preoperatively and at 4, 12, 
      and 24 weeks after ESS by determining changes in Asthma Control Test (ACT) and 
      Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores and respiratory 
      function. Biomarkers, including fractional excretion of nitric oxide (FeNO), 
      spirometry, nasal inspiratory peak flow (NPF), immunoglobulin E (IgE), and 
      eosinophil count, were measured. RESULTS: Nineteen patients who benefited 
      (responders) and 21 patients who failed (nonresponders) preoperative aspirin 
      treatment with a distant history of ESS (mean, 48 months) were identified. 
      Nonresponders were more likely to be African American (71%, p < 0.01) and have 
      higher baseline IgE levels (252 kU/L vs 87 kU/L in responders, p < 0.01). 24 of 
      the 40 patients (nine responders and 15 non-responders) required subsequent ESS 
      and underwent another aspirin desensitization 3-4 weeks after ESS. All 24 
      patients tolerated a second round of aspirin desensitization and treatment. The 
      primary aspirin therapy was associated with a significant increase in IgE in 
      nonresponders, but there was no significant increase in IgE after the second 
      aspirin desensitization and treatment. CONCLUSION: Antecedent ESS enhances 
      aspirin treatment responses in AERD patients and may convert patients who failed 
      aspirin treatment before surgery to a more responsive phenotype after ESS. 
      Patients with higher baseline serum IgE levels may benefit from ESS performed 
      shortly before aspirin desensitization and therapy.
CI  - © 2019 ARS-AAOA, LLC.
FAU - Shah, Sharan J
AU  - Shah SJ
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Albert Einstein College 
      of Medicine, Bronx, NY.
FAU - Abuzeid, Waleed M
AU  - Abuzeid WM
AUID- ORCID: 0000-0003-2489-0514
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Albert Einstein College 
      of Medicine, Bronx, NY.
FAU - Ponduri, Anusha
AU  - Ponduri A
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Albert Einstein College 
      of Medicine, Bronx, NY.
FAU - Pelletier, Teresa
AU  - Pelletier T
AD  - Division of Allergy & Immunology, Department of Medicine, Albert Einstein College 
      of Medicine, Bronx, NY.
FAU - Ren, Zhen
AU  - Ren Z
AD  - Division of Allergy/Immunology, Department of Medicine, Washington University 
      School of Medicine, St Louis, MO.
FAU - Keskin, Taha
AU  - Keskin T
AD  - Division of Allergy & Immunology, Department of Medicine, Albert Einstein College 
      of Medicine, Bronx, NY.
FAU - Roizen, Gigia
AU  - Roizen G
AD  - Division of Allergy & Immunology, Department of Medicine, Albert Einstein College 
      of Medicine, Bronx, NY.
FAU - Rosenstreich, David
AU  - Rosenstreich D
AD  - Division of Allergy & Immunology, Department of Medicine, Albert Einstein College 
      of Medicine, Bronx, NY.
FAU - Ferastraoaru, Denisa
AU  - Ferastraoaru D
AD  - Division of Allergy & Immunology, Department of Medicine, Albert Einstein College 
      of Medicine, Bronx, NY.
FAU - Jerschow, Elina
AU  - Jerschow E
AUID- ORCID: 0000-0002-9066-2483
AD  - Division of Allergy & Immunology, Department of Medicine, Albert Einstein College 
      of Medicine, Bronx, NY.
LA  - eng
GR  - KL2 TR001071/TR/NCATS NIH HHS/United States
GR  - UL1 TR002556/TR/NCATS NIH HHS/United States
GR  - 5KL2TR001071/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190930
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Asthma, Aspirin-Induced/surgery/*therapy
MH  - *Desensitization, Immunologic
MH  - *Endoscopy
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Male
MH  - Middle Aged
MH  - *Nasal Surgical Procedures
MH  - Treatment Outcome
PMC - PMC6901758
MID - NIHMS1045953
OTO - NOTNLM
OT  - AERD
OT  - aspirin-induced asthma
OT  - asthma
OT  - nasal polyps
OT  - paranasal sinus diseases
OT  - sinusitis
OT  - treatment outcome
COIS- Conflicts of interest: Waleed M. Abuzeid is a consultant for Medtronic, Inc and 
      Intersect ENT. Elina Jerschow has research support from Cumberland 
      Pharmaceuticals, Inc and serves on the Advisory Board for Sanofi/Regeneron and 
      Genentech. None of these interests are relevant to the present work. Other 
      authors have no conflicts of interest to disclose.
EDAT- 2019/10/01 06:00
MHDA- 2020/06/02 06:00
CRDT- 2019/10/01 06:00
PHST- 2019/05/07 00:00 [received]
PHST- 2019/08/04 00:00 [revised]
PHST- 2019/08/06 00:00 [accepted]
PHST- 2019/10/01 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2019/10/01 06:00 [entrez]
AID - 10.1002/alr.22418 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2019 Dec;9(12):1401-1408. doi: 10.1002/alr.22418. Epub 
      2019 Sep 30.

PMID- 16501426
OWN - NLM
STAT- MEDLINE
DCOM- 20060503
LR  - 20131121
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 12
IP  - 3
DP  - 2006 Mar
TI  - The role of aspirin versus aspirin and heparin in cases of recurrent abortions 
      with raised anticardiolipin antibodies.
PG  - CR132-6
AB  - BACKGROUND: The present study was undertaken to compare the role of aspirin 
      versus aspirin plus heparin combination in pregnant women with poor obstetric 
      history and raised anticardiolipin antibodies IgG (IgG(acl)). MATERIAL/METHODS: 
      The study was conducted on 550 pregnant women, 450 with a history of two or more 
      spontaneous abortions forming the study group, while 100 women with one or more 
      live births and no history of abortion were controls. Their blood was tested to 
      assess the level of IgG(acl) by enzyme-linked immunosorbent assay (ELISA). The 
      test was strongly positive in 72 (16%) patients of the study group, who were 
      randomized to receive either low-dose aspirin (80 mg/day) or a combination of 
      low-dose aspirin (80 mg/day) and 5000 IU of unfractionated heparin subcutaneously 
      12 hourly under hospital surveillance. The pregnancy outcomes were statistically 
      compared. RESULTS: Of the 39 patients treated with low-dose aspirin, 24 (61.5%) 
      gave birth to live issues compared with 28 (84.8%) of the 33 women given a 
      combination of aspirin and heparin (p<0.05), an overall success rate of 72.2%. 
      Mean birth weight of the babies given treatment with heparin and aspirin was 
      3.21+/-0.33 kg compared with 2.77+/-0.14 kg achieved with aspirin alone 
      (p<0.001). Both treatments were well tolerated. CONCLUSIONS: The study provides 
      evidence that in cases of recurrent abortions with raised IgG(acl), treatment 
      with a combination of aspirin and heparin showed better outcome than treatment 
      with aspirin alone.
FAU - Goel, Neha
AU  - Goel N
AD  - Department of Anatomy, Lady Hardinge Medical College and Associated Hospitals, 
      New Delhi, India. drashishgupta113@hotmail.com
FAU - Tuli, Anita
AU  - Tuli A
FAU - Choudhry, Rewa
AU  - Choudhry R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20060223
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Anticoagulants)
RN  - 0 (Immunoglobulin G)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*prevention & control
MH  - Adult
MH  - Antibodies, Anticardiolipin/*blood
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Apgar Score
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Birth Weight
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Infant, Newborn
MH  - Live Birth
MH  - Pregnancy
MH  - Pregnancy Outcome
EDAT- 2006/02/28 09:00
MHDA- 2006/05/04 09:00
CRDT- 2006/02/28 09:00
PHST- 2005/08/22 00:00 [received]
PHST- 2006/01/02 00:00 [accepted]
PHST- 2006/02/28 09:00 [pubmed]
PHST- 2006/05/04 09:00 [medline]
PHST- 2006/02/28 09:00 [entrez]
AID - 8070 [pii]
PST - ppublish
SO  - Med Sci Monit. 2006 Mar;12(3):CR132-6. Epub 2006 Feb 23.

PMID- 785608
OWN - NLM
STAT- MEDLINE
DCOM- 19761101
LR  - 20190702
IS  - 0038-4348 (Print)
IS  - 0038-4348 (Linking)
VI  - 69
IP  - 8
DP  - 1976 Aug
TI  - Failure of aspirin to antagonize the antihypertensive effect of spironolactone in 
      low-renin hypertension.
PG  - 1034-6
AB  - Aspirin has been shown to acutely block the natriuretic effect of spironolactone 
      in the mineralocorticoid-treated normal rat, dog, and man. It has been suggested 
      that aspirin is contraindicated in hypertensive patients receiving 
      spironolactone. Five patients with low-renin essential hypertension and two with 
      hypertension due to primary aldosteronism, all of whom have normalized their 
      blood pressure on chronic spironolactone therapy, were cotreated in a 
      double-blind fashion with either aspirin or aspirin-placebo during alternate 
      six-week periods. Aspirin did not appear to alter the effect of spironolactone on 
      blood pressure, serum electrolytes, urea nitrogen, or plasma renin activity.
FAU - Hollifield, J W
AU  - Hollifield JW
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - 0 (Placebos)
RN  - 27O7W4T232 (Spironolactone)
RN  - 9NEZ333N27 (Sodium)
RN  - EC 3.4.23.15 (Renin)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Blood Urea Nitrogen
MH  - Clinical Trials as Topic
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Natriuresis/drug effects
MH  - Placebos
MH  - Potassium/blood
MH  - Renin/*blood
MH  - Sodium/blood
MH  - Spironolactone/*antagonists & inhibitors/therapeutic use
EDAT- 1976/08/01 00:00
MHDA- 1976/08/01 00:01
CRDT- 1976/08/01 00:00
PHST- 1976/08/01 00:00 [pubmed]
PHST- 1976/08/01 00:01 [medline]
PHST- 1976/08/01 00:00 [entrez]
AID - 10.1097/00007611-197608000-00022 [doi]
PST - ppublish
SO  - South Med J. 1976 Aug;69(8):1034-6. doi: 10.1097/00007611-197608000-00022.

PMID- 3370538
OWN - NLM
STAT- MEDLINE
DCOM- 19880701
LR  - 20190720
IS  - 0008-4212 (Print)
IS  - 0008-4212 (Linking)
VI  - 66
IP  - 1
DP  - 1988 Jan
TI  - Aspirin enhances evaporation in hydrated and dehydrated rats.
PG  - 72-6
AB  - The effect of acetysalicylic acid (aspirin) on thermoregulation in a warm 
      environment was studied in hydrated and dehydrated adult rats to test the 
      hypothesis that dehydration hyperthermia can be modified by an antipyretic drug. 
      Metabolic rate (MR), evaporative water loss (EWL), and deep body temperature (Tb) 
      were measured during 2 h of exposure to an ambient temperature of 36 degrees C 
      after the rats had received an oral pellet of aspirin (100 mg.kg-1) or placebo. 
      The dehydrated placebo group had a higher Tb and lower EWL than the hydrated 
      placebo group. Aspirin increased MR and EWL in both hydrated and dehydrated 
      animals. Aspirin did not affect Tb in hydrated rats, but reduced Tb by 0.2 degree 
      C in dehydrated rats during the heat exposure. The elevation in EWL appears to be 
      a thermoregulatory response to increased heat production in both hydrated and 
      dehydrated animals after aspirin treatment. The possibility that aspirin may act 
      in dehydrated animals to restore central thermosensitivity toward hydrated levels 
      needs to be tested further.
FAU - Turlejska, E
AU  - Turlejska E
AD  - Division of Biomedical Sciences, University of California, Riverside 92521-0121.
FAU - Baker, M A
AU  - Baker MA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Body Temperature Regulation/*drug effects
MH  - Dehydration/*physiopathology
MH  - Fever/physiopathology
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Sweating/drug effects
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.1139/y88-013 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 1988 Jan;66(1):72-6. doi: 10.1139/y88-013.

PMID- 7589376
OWN - NLM
STAT- MEDLINE
DCOM- 19951127
LR  - 20161123
IS  - 0903-1936 (Print)
IS  - 0903-1936 (Linking)
VI  - 8
IP  - 6
DP  - 1995 Jun
TI  - Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor 
      response to adenosine 5'-monophosphate (AMP) in asthmatic subjects.
PG  - 905-12
AB  - When administered by inhalation, adenosine 5'-monophosphate (AMP) provokes 
      dose-related bronchoconstriction in asthmatic subjects by a mechanism believed to 
      involve mast cell mediator release. However, little is known of the change in 
      airway responsiveness to AMP after cyclo-oxygenase blockade. The aim of this 
      study was to investigate the effect of the potent cyclo-oxygenase inhibitor, 
      lysine acetylsalicylate (L-ASA) administered by inhalation, on AMP-induced 
      bronchoconstriction in a group of nine asthmatic subjects. The subjects studied 
      attended the laboratory on six separate occasions to receive nebulized L-ASA 
      (solution of 90 mg.ml-1) or matched placebo (glycine solution, 30 mg.ml-1) 15 min 
      prior to bronchoprovocation tests with AMP, histamine and methacholine in a 
      randomized, double-blind order. Changes in airway calibre were followed as forced 
      expiratory volume in one second (FEV1) and agonist responsiveness was expressed 
      as the provocative concentration causing a 20% fall in FEV1 from baseline (PC20). 
      Administration of both L-ASA and glycine solution caused a small but significant 
      acute fall in FEV1 from baseline, which returned to normal within 15 min. When 
      compared to placebo, inhaled L-ASA reduced the airway responsiveness to AMP in 
      all the subjects studied, the geometric mean (range) values for PC20 AMP 
      increasing significantly from 36.3 (7.9-250.5) to 101.8 (27.2-1300) mg.ml-1 after 
      placebo and L-ASA, respectively. Moreover, nebulized L-ASA induced a small but 
      significant reduction in airway responsiveness to histamine, the geometric mean 
      (range) PC20 values for histamine increasing from 2.77 (1.05-5.49) to 4.36 
      (1.69-11.24) mg.ml-1 after placebo and L-ASA, respectively.(ABSTRACT TRUNCATED AT 
      250 WORDS)
FAU - Crimi, N
AU  - Crimi N
AD  - Istituto Malattie Apparato Respiratorio, Università di Catania, Italy.
FAU - Polosa, R
AU  - Polosa R
FAU - Magrì, S
AU  - Magrì S
FAU - Prosperini, G
AU  - Prosperini G
FAU - Milazzo, V L
AU  - Milazzo VL
FAU - Santonocito, G
AU  - Santonocito G
FAU - Mistretta, A
AU  - Mistretta A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0W5ETF9M2K (Methacholine Chloride)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - 820484N8I3 (Histamine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adenosine Monophosphate/*pharmacology
MH  - Administration, Inhalation
MH  - Adult
MH  - Analysis of Variance
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/*pharmacology/therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology/therapeutic 
      use
MH  - Asthma/*drug therapy/physiopathology
MH  - Bronchial Provocation Tests
MH  - Bronchoconstriction/*drug effects
MH  - Cyclooxygenase Inhibitors/administration & dosage/*pharmacology/therapeutic use
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Female
MH  - Histamine/pharmacology
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives/pharmacology/therapeutic 
      use
MH  - Male
MH  - Methacholine Chloride/pharmacology
MH  - Middle Aged
MH  - Respiratory Function Tests
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
PST - ppublish
SO  - Eur Respir J. 1995 Jun;8(6):905-12.

PMID- 6359862
OWN - NLM
STAT- MEDLINE
DCOM- 19840126
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 75
IP  - 5A
DP  - 1983 Nov 14
TI  - Use of antipyretic analgesics in the pediatric patient.
PG  - 121-6
AB  - Fever and pain are the most common issues in pediatric patient management. 
      Acetaminophen, aspirin, and dipyrone are the most commonly used drugs and are 
      equivalent in their efficacy. Dipyrone, used in many parts of the world, but not 
      in the United States, is an effective agent; however, it has been implicated in 
      producing agranulocytosis and anaphylactic shock. The salicylates have 
      anti-inflammatory effects making them appropriate for the treatment of patients 
      with juvenile rheumatoid arthritis, but they are gastric irritants, may impair 
      clotting, and, because of saturable kinetics, may lead to accumulation and 
      toxicity. Acetaminophen is an effective antipyretic and analgesic with few side 
      effects that is toxic only in massive overdose.
FAU - Gladtke, E
AU  - Gladtke E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/metabolism/pharmacology
MH  - Adolescent
MH  - Agranulocytosis/chemically induced
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/adverse effects/metabolism/pharmacology
MH  - Chemical and Drug Induced Liver Injury/etiology
MH  - Child
MH  - Child, Preschool
MH  - Dipyrone/adverse effects/pharmacology
MH  - Drug Hypersensitivity/etiology
MH  - Fever/drug therapy
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Infant
MH  - Pain/drug therapy
MH  - Pediatrics/methods
MH  - Reye Syndrome/chemically induced
RF  - 26
EDAT- 1983/11/14 00:00
MHDA- 1983/11/14 00:01
CRDT- 1983/11/14 00:00
PHST- 1983/11/14 00:00 [pubmed]
PHST- 1983/11/14 00:01 [medline]
PHST- 1983/11/14 00:00 [entrez]
AID - 0002-9343(83)90243-7 [pii]
AID - 10.1016/0002-9343(83)90243-7 [doi]
PST - ppublish
SO  - Am J Med. 1983 Nov 14;75(5A):121-6. doi: 10.1016/0002-9343(83)90243-7.

PMID- 3516104
OWN - NLM
STAT- MEDLINE
DCOM- 19860522
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 146
IP  - 5
DP  - 1986 May
TI  - Low- vs high-dose aspirin. Effects on platelet function in hyperlipoproteinemic 
      and normal subjects.
PG  - 921-5
AB  - Low-dose aspirin may be inadequate for inhibition of platelet function in 
      hyperlipoproteinemics due to increased platelet reactivity. Platelet function was 
      studied in 18 type II hyperlipoproteinemic and 12 normal subjects after at least 
      ten days of treatment with placebo and with low-dose (0.45 mg/kg/day) and 
      high-dose (900 mg/day) aspirin. In the normal and hyperlipoproteinemic subjects, 
      low-dose aspirin produced near maximal (90%) inhibition of platelet thromboxane 
      generation, significant prolongation of the bleeding time, and significant 
      inhibition of platelet aggregation, similar in degree to the inhibition produced 
      by high-dose aspirin. There was no significant difference between 
      hyperlipoproteinemic and normal subjects in any of the platelet function measures 
      before and after aspirin treatment. Thus, a daily 0.45-mg/kg aspirin dose (20 to 
      45 mg) effectively inhibited platelet function in type II hyperlipoproteinemics, 
      who do not appear to have an increased dose requirement for aspirin.
FAU - Zucker, M L
AU  - Zucker ML
FAU - Trowbridge, C
AU  - Trowbridge C
FAU - Woodroof, J
AU  - Woodroof J
FAU - Chernoff, S B
AU  - Chernoff SB
FAU - Reynoso, L
AU  - Reynoso L
FAU - Dujovne, C A
AU  - Dujovne CA
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Lipids)
RN  - 0 (Thromboxanes)
RN  - 37270-94-3 (Platelet Factor 4)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Bleeding Time
MH  - Blood Platelets/metabolism
MH  - Epoprostenol/pharmacology
MH  - Female
MH  - Humans
MH  - Hyperlipoproteinemia Type II/blood/*drug therapy
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Factor 4/analysis
MH  - Thromboxanes/biosynthesis
EDAT- 1986/05/01 00:00
MHDA- 1986/05/01 00:01
CRDT- 1986/05/01 00:00
PHST- 1986/05/01 00:00 [pubmed]
PHST- 1986/05/01 00:01 [medline]
PHST- 1986/05/01 00:00 [entrez]
AID - 10.1001/archinte.146.5.921 [doi]
PST - ppublish
SO  - Arch Intern Med. 1986 May;146(5):921-5. doi: 10.1001/archinte.146.5.921.

PMID- 2503553
OWN - NLM
STAT- MEDLINE
DCOM- 19890921
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 84
IP  - 2
DP  - 1989 Aug
TI  - Inhaled lysine-aspirin as a bronchoprovocation procedure in aspirin-sensitive 
      asthma: its repeatability, absence of a late-phase reaction, and the role of 
      histamine.
PG  - 232-41
AB  - Inhalation of an aerosolized solution of lysine-aspirin has previously been 
      described as a safer technique than oral challenge with aspirin for the diagnosis 
      of aspirin-sensitive asthma. We describe a modification of this method that 
      involves inhalation of serially doubling incremental concentrations of 
      lysine-aspirin by a standardized technique and allows construction of 
      concentration-response curves. In 11 subjects with asthma, mean (SEM) age 48.2 
      (2.9) years, the geometric mean (range) provocation concentrations of histamine 
      and lysine-aspirin required to produce a 20% decrease in FEV1 from baseline were 
      0.6 (0.04 to 3.2) and 48.3 (15.5 to 219) mg/ml, respectively. No relationship was 
      found between these values. In seven of nine subjects investigated on two 
      consecutive occasions, bronchoconstriction with lysine-aspirin was repeatable to 
      within a single doubling concentration difference. Bronchoconstriction provoked 
      by lysine-aspirin was more rapid than with oral aspirin and was not followed by 
      any late asthmatic reaction or increase in nonspecific airway 
      hyperresponsiveness. In six subjects, premedication with the selective H1 
      histamine-receptor antagonist, terfenadine, had no significant effect on 
      bronchoconstriction provoked by inhaled lysine-aspirin, indicating little role 
      for release of histamine in the response. We conclude that inhalation of 
      lysine-aspirin may be used as a bronchoprovocation procedure for the diagnosis 
      and investigation of aspirin-sensitive asthma.
FAU - Phillips, G D
AU  - Phillips GD
AD  - Department of Immunopharmacology, Medicine I, Southampton General Hospital, 
      England.
FAU - Foord, R
AU  - Foord R
FAU - Holgate, S T
AU  - Holgate ST
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Aerosols)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 820484N8I3 (Histamine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aerosols
MH  - *Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/*adverse effects/*analogs & derivatives
MH  - Asthma/*diagnosis/etiology/physiopathology
MH  - Bronchial Provocation Tests/*methods
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Forced Expiratory Volume
MH  - *Histamine
MH  - Humans
MH  - Lysine/adverse effects/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Reproducibility of Results
MH  - Time Factors
EDAT- 1989/08/01 00:00
MHDA- 1989/08/01 00:01
CRDT- 1989/08/01 00:00
PHST- 1989/08/01 00:00 [pubmed]
PHST- 1989/08/01 00:01 [medline]
PHST- 1989/08/01 00:00 [entrez]
AID - 0091-6749(89)90330-8 [pii]
AID - 10.1016/0091-6749(89)90330-8 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1989 Aug;84(2):232-41. doi: 10.1016/0091-6749(89)90330-8.

PMID- 24164572
OWN - NLM
STAT- MEDLINE
DCOM- 20140617
LR  - 20181202
IS  - 1520-5010 (Electronic)
IS  - 0893-228X (Linking)
VI  - 26
IP  - 11
DP  - 2013 Nov 18
TI  - Benchmarking in vitro covalent binding burden as a tool to assess potential 
      toxicity caused by nonspecific covalent binding of covalent drugs.
PG  - 1739-45
LID - 10.1021/tx400301q [doi]
AB  - Despite several advantages of covalent inhibitors (such as increased biochemical 
      efficiency, longer duration of action on the target, and lower efficacious doses) 
      over their reversible binding counterparts, there is a reluctance to use covalent 
      inhibitors as a drug design strategy in pharmaceutical research. This reluctance 
      is due to their anticipated reactions with nontargeted macromolecules. We 
      hypothesized that there may be a threshold limit for nonspecific covalent 
      binding, below which a covalent binding drug may be less likely to cause toxicity 
      due to irreversible binding to off-target macromolecules. Estimation of in vivo 
      covalent binding burden from in vitro data has previously been used as an 
      approach to distinguish those agents more likely to cause toxicity (e.g., 
      hepatotoxicity) via metabolic activation to reactive metabolites. We have 
      extended this approach to nine covalent binding drugs to determine in vitro 
      covalent binding burden. In vitro covalent binding burden was determined by 
      incubating radiolabeled drugs with pooled human hepatocytes. These data were 
      scaled to an estimate of in vivo covalent binding burden by combining the in 
      vitro data with daily dose. Scaled in vivo daily covalent binding burden of 
      marketed covalent drugs was found to be under 10 mg/day, which is in agreement 
      with previously reported threshold value for metabolically activated reversible 
      drugs. Covalent binding was also compared to the intrinsic reactivities of the 
      covalent inhibitors assessed using nucleophiles glutathione and N-α-acetyl 
      lysine. The intrinsic reactivity did not correlate with observed in vitro 
      covalent binding, which demonstrated that the intrinsic reactivity of the 
      electrophilic groups of covalent drugs does not exclusively account for the 
      extent of covalent binding. The ramifications of these findings for consideration 
      of using a covalent strategy in drug design are discussed.
FAU - Dahal, Upendra P
AU  - Dahal UP
AD  - Pharmacokinetics, Dynamics and Metabolism and ‡Worldwide Medicinal Chemistry, 
      Pfizer Inc. , Groton, Connecticut 06340, United States.
FAU - Obach, R Scott
AU  - Obach RS
FAU - Gilbert, Adam M
AU  - Gilbert AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131028
PL  - United States
TA  - Chem Res Toxicol
JT  - Chemical research in toxicology
JID - 8807448
RN  - 0 (Carbon Radioisotopes)
RN  - 0 (Lactones)
RN  - 0 (Nitriles)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Pyrrolidines)
RN  - 10028-17-8 (Tritium)
RN  - 95M8R751W8 (Orlistat)
RN  - GAN16C9B8O (Glutathione)
RN  - I6B4B2U96P (Vildagliptin)
RN  - K3Z4F929H6 (Lysine)
RN  - PJY633525U (Adamantane)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adamantane/analogs & derivatives/chemistry/metabolism/toxicity
MH  - Aspirin/chemistry/metabolism/toxicity
MH  - Carbon Radioisotopes/chemistry
MH  - Cells, Cultured
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Glutathione/chemistry/metabolism
MH  - Half-Life
MH  - Hepatocytes/*drug effects/metabolism
MH  - Humans
MH  - Lactones/chemistry/metabolism/toxicity
MH  - Lysine/chemistry/metabolism
MH  - Nitriles/chemistry/metabolism/toxicity
MH  - Orlistat
MH  - Pharmaceutical Preparations/*chemistry/metabolism
MH  - Pyrrolidines/chemistry/metabolism/toxicity
MH  - Tritium/chemistry
MH  - Vildagliptin
EDAT- 2013/10/30 06:00
MHDA- 2014/06/18 06:00
CRDT- 2013/10/30 06:00
PHST- 2013/10/30 06:00 [entrez]
PHST- 2013/10/30 06:00 [pubmed]
PHST- 2014/06/18 06:00 [medline]
AID - 10.1021/tx400301q [doi]
PST - ppublish
SO  - Chem Res Toxicol. 2013 Nov 18;26(11):1739-45. doi: 10.1021/tx400301q. Epub 2013 
      Oct 28.

PMID- 18274283
OWN - NLM
STAT- MEDLINE
DCOM- 20080414
LR  - 20220318
IS  - 0939-5075 (Print)
IS  - 0341-0382 (Linking)
VI  - 62
IP  - 11-12
DP  - 2007 Nov-Dec
TI  - Antinociceptive and anti-inflammatory effects of saponin and iridoid glycosides 
      from Verbascum pterocalycinum var. mutense Hub.-Mor.
PG  - 813-20
AB  - The anti-inflammatory and antinociceptive properties of four major compounds from 
      the flowers of Verbascum pterocalycinum var. mutense were investigated. Saponin 
      glycosides called ilwensisaponin A and C and iridoid glycosides known as ajugol 
      and picroside IV were isolated from the methanolic extract. A dose-related 
      anti-inflammatory and antinociceptive response were obtained in this study at 
      doses of 100 and 200 mg/kg. The results of the evaluation of the 
      anti-inflammatory activity induced by carrageenan and PGE1 showed that this 
      species possesses active constituents that could diminish the cyclooxygenase 
      activitiy. No effects were observed in the 12-O-tetradecanoylphorbol-13-acetate 
      (TPA)-induced ear edema model. Our results support the anti-inflammatory and 
      analgesic effects of Verbascum pterocalycinum var. mutense. Ilwensisaponins A and 
      C could explain in part the anti-inflammatory and analgesic activities of this 
      species. Although antinociceptive and anti-inflammatory activities of ajugol and 
      picroside IV were found insignificant in the statistical analysis, ilwensisaponin 
      A and C showed notable activity without inducing any apparent acute toxicity as 
      well as gastric damage.
FAU - Akkol, Esra Küpeli
AU  - Akkol EK
AD  - Gazi University, Faculty of Pharmacy, Department of Pharmacognosy, Etiler, 06330, 
      Ankara, Turkey. esrak@gazi.edu.tr
FAU - Tatli, I Irem
AU  - Tatli II
FAU - Akdemir, Zeliha S
AU  - Akdemir ZS
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Z Naturforsch C J Biosci
JT  - Zeitschrift fur Naturforschung. C, Journal of biosciences
JID - 8912155
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Glycosides)
RN  - 0 (Iridoid Glycosides)
RN  - 0 (Plant Extracts)
RN  - 0 (Plant Preparations)
RN  - 0 (Pyrans)
RN  - 0 (Saponins)
RN  - OF59XHX7SR (harpagide)
RN  - R16CO5Y76E (Aspirin)
RN  - Y4S76JWI15 (Methanol)
SB  - IM
MH  - Analgesics/*chemistry/isolation & purification/pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry/isolation & 
      purification/pharmacology
MH  - Aspirin/chemistry/isolation & purification/pharmacology
MH  - Glycosides/*chemistry/isolation & purification/pharmacology
MH  - Iridoid Glycosides
MH  - Male
MH  - Methanol
MH  - Mice
MH  - Models, Molecular
MH  - Motor Activity/drug effects
MH  - Plant Extracts/chemistry/isolation & purification/pharmacology
MH  - Plant Preparations/chemistry/isolation & purification/pharmacology
MH  - Pyrans/chemistry/isolation & purification/pharmacology
MH  - Saponins/*chemistry/isolation & purification/pharmacology
MH  - Verbascum/*chemistry
EDAT- 2008/02/16 09:00
MHDA- 2008/04/15 09:00
CRDT- 2008/02/16 09:00
PHST- 2008/02/16 09:00 [pubmed]
PHST- 2008/04/15 09:00 [medline]
PHST- 2008/02/16 09:00 [entrez]
AID - 10.1515/znc-2007-11-1207 [doi]
PST - ppublish
SO  - Z Naturforsch C J Biosci. 2007 Nov-Dec;62(11-12):813-20. doi: 
      10.1515/znc-2007-11-1207.

PMID- 16778126
OWN - NLM
STAT- MEDLINE
DCOM- 20060718
LR  - 20161122
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 37
IP  - 7
DP  - 2006 Jul
TI  - Intravenous administration of acetylsalicylic acid during endovascular treatment 
      of cerebral aneurysms reduces the rate of thromboembolic events.
PG  - 1816-21
AB  - BACKGROUND AND PURPOSE: The purpose of this study is to analyze the effect of a 
      modified intraoperative anticoagulation strategy including acetylsalicylic acid 
      (ASA) on complication rates during endovascular coil embolization. METHODS: Two 
      hundred and sixty-one cerebral aneurysms were treated in 247 patients by 
      endovascular coil embolization from January 2001 to September 2004. Additional 
      intravenous administration of 250 mg ASA was applied since January 2003. Patients 
      treated before (-ASA; n=102 aneurysms) and after that date (+ASA; n=159 
      aneurysms) were compared. End points were rates of thromboembolism and severity 
      of hemorrhages after intraoperative aneurysm rupture. RESULTS: Thromboembolic 
      events during the procedure were observed more often in the -ASA group (18/102 
      aneurysms, 17.6%) in comparison with the +ASA group (14/159 aneurysms, 8.8%; 
      P=0.028; Fisher exact test). Aneurysm perforation events occurring during or 
      immediately after the procedure were observed equally often in the -ASA group 
      (7/102 aneurysms, 6.9%) in comparison with the +ASA group (10/159 aneurysms, 
      6.3%). CONCLUSIONS: Intravenous application of ASA is feasible and safe during 
      interventional aneurysm embolization. ASA seems to be associated with a 
      significant reduction in the rate of thromboembolic events without increase in 
      the rate or severity of intraoperative bleedings.
FAU - Ries, Thorsten
AU  - Ries T
AD  - Department of Neuroradiology, University Medical Center Hamburg-Eppendorf, 
      Hamburg, Germany.
FAU - Buhk, Jan-Hendrik
AU  - Buhk JH
FAU - Kucinski, Thomas
AU  - Kucinski T
FAU - Goebell, Einar
AU  - Goebell E
FAU - Grzyska, Ulrich
AU  - Grzyska U
FAU - Zeumer, Hermann
AU  - Zeumer H
FAU - Fiehler, Jens
AU  - Fiehler J
LA  - eng
PT  - Journal Article
DEP - 20060615
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cerebral Hemorrhage/chemically induced
MH  - Drug Evaluation
MH  - *Embolization, Therapeutic/adverse effects
MH  - Feasibility Studies
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Intracranial Aneurysm/complications/*therapy
MH  - Intraoperative Care
MH  - Intraoperative Complications/etiology/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Retrospective Studies
MH  - Rupture, Spontaneous
MH  - Subarachnoid Hemorrhage/etiology
MH  - Thromboembolism/etiology/physiopathology/*prevention & control
EDAT- 2006/06/17 09:00
MHDA- 2006/07/19 09:00
CRDT- 2006/06/17 09:00
PHST- 2006/06/17 09:00 [pubmed]
PHST- 2006/07/19 09:00 [medline]
PHST- 2006/06/17 09:00 [entrez]
AID - 01.STR.0000226933.44962.a6 [pii]
AID - 10.1161/01.STR.0000226933.44962.a6 [doi]
PST - ppublish
SO  - Stroke. 2006 Jul;37(7):1816-21. doi: 10.1161/01.STR.0000226933.44962.a6. Epub 
      2006 Jun 15.

PMID- 19639515
OWN - NLM
STAT- MEDLINE
DCOM- 20100617
LR  - 20131121
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 20
IP  - 6
DP  - 2009 Sep
TI  - Rapamycin enhances platelet aggregation induced by adenosine diphosphate in 
      vitro.
PG  - 428-31
LID - 10.1080/09537100903114552 [doi]
AB  - Studies have demonstrated the important role of platelets in the formation of 
      stent thrombosis associated with drug-eluting stents, but little is known about 
      the effects of drugs eluted from stents on platelet function. The extent of 
      platelet aggregation in platelet-rich plasma induced by adenosine diphosphate 
      (ADP) was measured at various doses of rapamycin, and the ability of aspirin to 
      inhibit platelet aggregation was determined at the same concentrations of 
      rapamycin. Compared with lower concentrations, rapamycin at higher doses (>10 
      ng/mL) enhanced platelet aggregation induced by ADP, and the enhancement was 
      significant at 50 ng/mL and 100 ng/mL (P = 0.005 and P = 0.04). The ability of 
      aspirin to inhibit platelet aggregation was reduced at higher concentrations of 
      rapamycin. These data suggest that higher concentrations of rapamycin can enhance 
      platelet aggregation in response to ADP, and reduce the ability of aspirin to 
      inhibit platelet aggregation.
FAU - Wu, Qi
AU  - Wu Q
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Huang, Kai-Sen
AU  - Huang KS
FAU - Chen, Mao
AU  - Chen M
FAU - Huang, De-Jia
AU  - Huang DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adenosine Diphosphate/*pharmacology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Drug-Eluting Stents
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
MH  - Sirolimus/*pharmacology
EDAT- 2009/07/30 09:00
MHDA- 2010/06/18 06:00
CRDT- 2009/07/30 09:00
PHST- 2009/07/30 09:00 [entrez]
PHST- 2009/07/30 09:00 [pubmed]
PHST- 2010/06/18 06:00 [medline]
AID - 913495058 [pii]
AID - 10.1080/09537100903114552 [doi]
PST - ppublish
SO  - Platelets. 2009 Sep;20(6):428-31. doi: 10.1080/09537100903114552.

PMID- 7378908
OWN - NLM
STAT- MEDLINE
DCOM- 19800825
LR  - 20190720
IS  - 0008-4212 (Print)
IS  - 0008-4212 (Linking)
VI  - 58
IP  - 1
DP  - 1980 Jan
TI  - Regional distribution of sodium acetylsalicylate in the brain of normothermic and 
      hyperthermic rabbits.
PG  - 85-8
AB  - This study was designed to determine regional distribution of sodium 
      acetylsalicylate in the brain of normothermic rabbits, rabbits with hyperthermia 
      induced by pyrogen administration, and rabbits with hyperthermia induced by 
      infrared irradiation. Increasing body temperature with either leucocytic pyrogen 
      or infrared light irradiation about doubled the concentration of sodium 
      acetylsalicylate in four regions of the brain. This suggests a more rapid 
      penetration of sodium acetylsalicylate into the brain under hyperthermic 
      conditions. This may explain why the drug lowers body temperature more 
      effectively in febrile animals than in afebrile animals.
FAU - Lin, M T
AU  - Lin MT
FAU - Hoo, S L
AU  - Hoo SL
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Pyrogens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*metabolism
MH  - Brain/*metabolism
MH  - Fever/chemically induced/*metabolism
MH  - Leukocytes
MH  - Male
MH  - Pyrogens/pharmacology
MH  - Rabbits
MH  - Time Factors
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1139/y80-014 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 1980 Jan;58(1):85-8. doi: 10.1139/y80-014.

PMID- 24953043
OWN - NLM
STAT- MEDLINE
DCOM- 20150512
LR  - 20140804
IS  - 1476-928X (Electronic)
IS  - 1476-9271 (Linking)
VI  - 51
DP  - 2014 Aug
TI  - A computational prospect to aspirin side effects: aspirin and COX-1 interaction 
      analysis based on non-synonymous SNPs.
PG  - 57-62
LID - S1476-9271(14)00065-6 [pii]
LID - 10.1016/j.compbiolchem.2014.05.002 [doi]
AB  - Aspirin (ASA) is a commonly used nonsteroidal anti-inflammatory drug (NSAID), 
      which exerts its therapeutic effects through inhibition of cyclooxygenase (COX) 
      isoform 2 (COX-2), while the inhibition of COX-1 by ASA leads to apparent side 
      effects. In the present study, the relationship between COX-1 non-synonymous 
      single nucleotide polymorphisms (nsSNPs) and aspirin related side effects was 
      investigated. The functional impacts of 37 nsSNPs on aspirin inhibition potency 
      of COX-1 with COX-1/aspirin molecular docking were computationally analyzed, and 
      each SNP was scored based on DOCK Amber score. The data predicted that 22 nsSNPs 
      could reduce COX-1 inhibition, while 15 nsSNPs showed increasing inhibition level 
      in comparison to the regular COX-1 protein. In order to perform a comparing 
      state, the Amber scores for two Arg119 mutants (R119A and R119Q) were also 
      calculated. Moreover, among nsSNP variants, rs117122585 represented the closest 
      Amber score to R119A mutant. A separate docking computation validated the score 
      and represented a new binding position for ASA that acetyl group was located 
      within the distance of 3.86Å from Ser529 OH group. This could predict an 
      associated loss of activity of ASA through this nsSNP variant. Our data represent 
      a computational sub-population pattern for aspirin COX-1 related side effects, 
      and provide basis for further research on COX-1/ASA interaction.
CI  - Copyright © 2014 Elsevier Ltd. All rights reserved.
FAU - Marjan, Mojtabavi Naeini
AU  - Marjan MN
AD  - Genetics Division, Department of Biology, Faculty of Science, University of 
      Isfahan, Isfahan, Iran.
FAU - Hamzeh, Mesrian Tanha
AU  - Hamzeh MT
AD  - Genetics Division, Department of Biology, Faculty of Science, University of 
      Isfahan, Isfahan, Iran.
FAU - Rahman, Emamzadeh
AU  - Rahman E
AD  - Genetics Division, Department of Biology, Faculty of Science, University of 
      Isfahan, Isfahan, Iran.
FAU - Sadeq, Vallian
AU  - Sadeq V
AD  - Genetics Division, Department of Biology, Faculty of Science, University of 
      Isfahan, Isfahan, Iran. Electronic address: svallian@biol.ui.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140602
PL  - England
TA  - Comput Biol Chem
JT  - Computational biology and chemistry
JID - 101157394
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*chemistry
MH  - Arginine/chemistry/metabolism
MH  - Aspirin/adverse effects/*chemistry
MH  - Cyclooxygenase 1/*chemistry
MH  - Cyclooxygenase 2/chemistry
MH  - Cyclooxygenase Inhibitors/adverse effects/*chemistry
MH  - Gene Expression
MH  - Humans
MH  - Molecular Docking Simulation
MH  - *Polymorphism, Single Nucleotide
MH  - Sheep
OTO - NOTNLM
OT  - Amber score
OT  - Aspirin
OT  - COX-1
OT  - nsSNP
EDAT- 2014/06/24 06:00
MHDA- 2015/05/13 06:00
CRDT- 2014/06/24 06:00
PHST- 2013/11/17 00:00 [received]
PHST- 2014/05/10 00:00 [revised]
PHST- 2014/05/31 00:00 [accepted]
PHST- 2014/06/24 06:00 [entrez]
PHST- 2014/06/24 06:00 [pubmed]
PHST- 2015/05/13 06:00 [medline]
AID - S1476-9271(14)00065-6 [pii]
AID - 10.1016/j.compbiolchem.2014.05.002 [doi]
PST - ppublish
SO  - Comput Biol Chem. 2014 Aug;51:57-62. doi: 10.1016/j.compbiolchem.2014.05.002. 
      Epub 2014 Jun 2.

PMID- 11714127
OWN - NLM
STAT- MEDLINE
DCOM- 20020220
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 24
IP  - 11
DP  - 2001 Nov
TI  - Effects of low-dose aspirin on endothelial function in hypertensive patients.
PG  - 705-9
AB  - BACKGROUND: It has been reported that administration of low-dose aspirin 
      significantly reduces the frequency of major cardiovascular events in patients 
      with hypertension and coronary artery disease. It is generally considered that 
      the preventative effects of long-term aspirin administration on major 
      cardiovascular events are due to the inhibition of platelet aggregation. 
      HYPOTHESIS: It is not known whether administration of low-dose aspirin restores 
      endothelium-dependent vasodilatation, and this study was undertaken to prove or 
      disprove this question in patients with hypertension. METHODS: Flow-mediated 
      endothelium-dependent dilatation and glyceryl trinitrate-induced 
      endothelium-independent dilatation were investigated in 18 hypertensive patients 
      and 10 normotensive control subjects. In the hypertensive patients, flow-mediated 
      dilatation was investigated and cyclic guanosine monophosphate plasma (cGMP) was 
      measured before and at 8 weeks after the administration of 162 mg of aspirin. 
      RESULTS: Flow-mediated dilatation before aspirin administration was more reduced 
      in the hypertensive patients than in the control subjects (6.4+/-2.0% vs. 
      11.3+/-2.3%, p <0.0001). Glyceryl trinitrate-induced dilatation before aspirin 
      administration was similar in hypertensive patients and control subjects. 
      Flow-mediated dilatation after aspirin administration was improved compared with 
      that before aspirin administration (10.4+/-3.5% vs. 6.4+/-2.0%, p<0.0004). The 
      cGMP product after aspirin administration was significantly higher than that 
      before aspirin administration. CONCLUSIONS: Administration of low-dose aspirin 
      may restore the endothelium-dependent vasodilatation in hypertensive patients. 
      Furthermore, increased nitric oxide production may play a partial role in the 
      improvement in endothelial function induced by administration of low-dose 
      aspirin.
FAU - Monobe, H
AU  - Monobe H
AD  - Department of Cardiovascular Medicine, Okayama University Medical School, Japan.
FAU - Yamanari, H
AU  - Yamanari H
FAU - Nakamura, K
AU  - Nakamura K
FAU - Ohe, T
AU  - Ohe T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Vasodilator Agents)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Volume/drug effects/physiology
MH  - Case-Control Studies
MH  - Cyclic GMP/blood
MH  - Endothelium, Vascular/*drug effects/physiology
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Regional Blood Flow/drug effects/physiology
MH  - Vasodilation/*physiology
MH  - Vasodilator Agents/administration & dosage/*pharmacology
PMC - PMC6655050
EDAT- 2001/11/21 10:00
MHDA- 2002/02/21 10:01
CRDT- 2001/11/21 10:00
PHST- 2001/11/21 10:00 [pubmed]
PHST- 2002/02/21 10:01 [medline]
PHST- 2001/11/21 10:00 [entrez]
AID - CLC4960241104 [pii]
AID - 10.1002/clc.4960241104 [doi]
PST - ppublish
SO  - Clin Cardiol. 2001 Nov;24(11):705-9. doi: 10.1002/clc.4960241104.

PMID- 9556464
OWN - NLM
STAT- MEDLINE
DCOM- 19980423
LR  - 20220321
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 128
IP  - 9
DP  - 1998 May 1
TI  - Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' 
      Health Study.
PG  - 713-20
AB  - BACKGROUND: In contrast to most observational studies, the randomized Physicians' 
      Health Study found no association between aspirin use and colorectal cancer after 
      5 years. OBJECTIVE: To determine the effect of randomly assigned aspirin 
      treatment and self-selected aspirin use on the incidence of colorectal cancer 
      after 12 years and to identify factors influencing the self-selection of regular 
      aspirin use. DESIGN: Randomized clinical trial and prospective cohort study. 
      SETTING: Male physicians throughout the United States. PATIENTS: 22071 healthy 
      male physicians who were 40 to 84 years of age in 1982. INTERVENTION: 325 mg of 
      aspirin every other day. In 1988, the aspirin arm of the randomized trial was 
      stopped early. Participants then chose to receive either aspirin or placebo for 
      the rest of the study. MEASUREMENTS: Annual questionnaires asking about aspirin 
      use and other variables, including occurrence of cancer. RESULTS: Colorectal 
      cancer was diagnosed in 341 patients during the study period. Over 12 years of 
      follow-up, random assignment to aspirin was associated with a relative risk for 
      colorectal cancer of 1.03 (95% CI, 0.83 to 1.28). Various gastrointestinal 
      symptoms and diagnoses were strong predictors of less frequent aspirin use in 
      1988. The relative risk for colorectal cancer in persons who used aspirin 
      frequently after 1988 was 1.07 (CI, 0.75 to 1.53). CONCLUSIONS: In the 
      Physicians' Health Study, both randomized and observational analyses indicate 
      that there is no association between the use of aspirin and the incidence of 
      colorectal cancer. The low dose of aspirin used and the short treatment period 
      may account for the null findings. However, other characteristics associated with 
      the use of aspirin in observational studies remain a plausible alternative 
      explanation.
FAU - Stürmer, T
AU  - Stürmer T
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 
      02215, USA.
FAU - Glynn, R J
AU  - Glynn RJ
FAU - Lee, I M
AU  - Lee IM
FAU - Manson, J E
AU  - Manson JE
FAU - Buring, J E
AU  - Buring JE
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA-34944/CA/NCI NIH HHS/United States
GR  - CA-40360/CA/NCI NIH HHS/United States
GR  - HL-26490/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Colorectal Neoplasms/epidemiology/*prevention & control
MH  - Drug Administration Schedule
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Prospective Studies
MH  - Self Medication
MH  - Surveys and Questionnaires
MH  - United States/epidemiology
EDAT- 1998/12/16 00:00
MHDA- 1998/12/16 00:01
CRDT- 1998/12/16 00:00
PHST- 1998/12/16 00:00 [pubmed]
PHST- 1998/12/16 00:01 [medline]
PHST- 1998/12/16 00:00 [entrez]
AID - 10.7326/0003-4819-128-9-199805010-00003 [doi]
PST - ppublish
SO  - Ann Intern Med. 1998 May 1;128(9):713-20. doi: 
      10.7326/0003-4819-128-9-199805010-00003.

PMID- 7984621
OWN - NLM
STAT- MEDLINE
DCOM- 19941230
LR  - 20131121
IS  - 0032-9533 (Print)
IS  - 0032-9533 (Linking)
IP  - 4
DP  - 1994
TI  - [Liver function in patients with aspirin-induced bronchial asthma].
PG  - 57-60
AB  - Biochemical and immunological studies were performed to study hepatic function in 
      137 patients, out of whom 74 were found to have aspirin-induced bronchial asthma, 
      23 atopic bronchial asthma, 23 infectious allergic bronchial asthma, 17 chronic 
      persistent hepatitis. Cholestatic and hepatodepressive syndromes and hepatic 
      detoxifying and absorptive-excretory dysfunctions were detected in patients with 
      aspirin-induced bronchial asthma. As aspirin-induced bronchial asthma progresses, 
      the rate of hepatobiliary dysfunctions increases, which undoubtedly plays a 
      prominent role in the development of the disease.
FAU - Sizykh, T P
AU  - Sizykh TP
FAU - Efimova, N Iu
AU  - Efimova NIu
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Funktsionalńoe sostoianie pecheni u bolńykh aspirinovoĭ bronkhialńoĭ astmoĭ.
PL  - Russia (Federation)
TA  - Probl Tuberk
JT  - Problemy tuberkuleza
JID - 0414141
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/metabolism
MH  - Asthma/chemically induced/*complications/immunology/metabolism/physiopathology
MH  - Chronic Disease
MH  - Humans
MH  - Liver Diseases/*complications/immunology/metabolism/physiopathology
MH  - Liver Function Tests
MH  - Severity of Illness Index
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Probl Tuberk. 1994;(4):57-60.

PMID- 6499509
OWN - NLM
STAT- MEDLINE
DCOM- 19841226
LR  - 20190908
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 9
IP  - 3
DP  - 1984
TI  - The pharmacokinetics of the individual constituents of an aspirin-metoclopramide 
      combination ('Migravess').
PG  - 153-6
AB  - A study was carried out in 10 healthy volunteers, aged between 22 and 28 years, 
      to investigate the pharmacokinetics of an aspirin-metoclopramide combined 
      preparation compared with those of the individual components given alone. Blood 
      levels were determined before and after administration of a single dose of the 
      three medications given at weekly intervals. No significant difference was found 
      in the bioavailability of either the aspirin or metoclopramide from the 
      combination as compared to the individual components.
FAU - Manniche, P M
AU  - Manniche PM
FAU - Dinneen, L C
AU  - Dinneen LC
FAU - Langemark, M
AU  - Langemark M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Drug Combinations)
RN  - 0 (aspirin, metoclopramide drug combination)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/blood/*metabolism
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid
MH  - Drug Combinations/blood/metabolism
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Metoclopramide/blood/*metabolism
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1185/03007998409109574 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1984;9(3):153-6. doi: 10.1185/03007998409109574.

PMID- 1412097
OWN - NLM
STAT- MEDLINE
DCOM- 19921102
LR  - 20190503
IS  - 0040-6376 (Print)
IS  - 1468-3296 (Electronic)
IS  - 0040-6376 (Linking)
VI  - 47
IP  - 7
DP  - 1992 Jul
TI  - Platelet kinetics in asthmatic patients with and without aspirin intolerance.
PG  - 533-6
AB  - BACKGROUND: A reduced platelet survival time has been described in asthmatic 
      patients. There is also good evidence that platelets are involved in aspirin 
      induced asthma. Since aspirin intolerant patients usually suffer from an active 
      disease and often require anti-inflammatory treatment, it has been suggested that 
      platelet survival time may be shorter in aspirin intolerant asthmatic subjects 
      than in aspirin tolerant subjects. The objective of this study was to investigate 
      this hypothesis. METHODS: Thirteen asthmatic subjects (six aspirin tolerant and 
      seven aspirin intolerant) in a stable clinical condition and ten healthy subjects 
      were studied. Platelet kinetics and survival time were measured with indium-111 
      labelled autologous platelets. RESULTS: Mean (SD) platelet sequestration ratios 
      in the spleen and liver were lower in asthmatic (2.3 (0.9) and 0.6 (0.2) 
      respectively) than in healthy subjects (3.2 (0.7) and 1.1 (0.4) respectively). 
      However, mean (SD) platelet survival time in asthmatic subjects (8 (2.7) days) 
      did not differ from that in healthy subjects (7.6 (1.1) days). No differences 
      were observed in platelet kinetics between aspirin tolerant and aspirin 
      intolerant patients. CONCLUSIONS: These results suggest the existence of an 
      active non-splenic pool of platelets in patients with asthma. However, they 
      failed to show platelet kinetic differences among asthmatic subjects with and 
      without aspirin intolerance and do not support previous studies suggesting an 
      altered platelet survival in stable asthma.
FAU - Plaza, V
AU  - Plaza V
AD  - Serveis de Pneumologia, Hospital Clinic i Provincial de Barcelona, Spain.
FAU - Casals, F
AU  - Casals F
FAU - Alonso, A
AU  - Alonso A
FAU - Picado, C
AU  - Picado C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Thorax
JT  - Thorax
JID - 0417353
RN  - 0 (Indium Radioisotopes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Asthma/*blood
MH  - Blood Platelets/*physiology
MH  - Cell Survival/physiology
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Indium Radioisotopes
MH  - Kinetics
MH  - Male
MH  - Middle Aged
PMC - PMC463864
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
AID - 10.1136/thx.47.7.533 [doi]
PST - ppublish
SO  - Thorax. 1992 Jul;47(7):533-6. doi: 10.1136/thx.47.7.533.

PMID- 9650546
OWN - NLM
STAT- MEDLINE
DCOM- 19980925
LR  - 20201209
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 38
IP  - 6
DP  - 1998 Jun
TI  - Tramadol hydrochloride: analgesic efficacy compared with codeine, aspirin with 
      codeine, and placebo after dental extraction.
PG  - 554-60
AB  - Tramadol hydrochloride is a novel, centrally acting analgesic with two 
      complementary mechanisms of action: opioid and aminergic. Relative to codeine, 
      tramadol has similar analgesic properties but may have fewer constipating, 
      euphoric, and respiratory depressant effects. A two-center randomized 
      double-blind controlled clinical trial was performed to assess the analgesic 
      efficacy and reported side effects of tramadol 100 mg, tramadol 50 mg, codeine 60 
      mg, aspirin (ASA) 650 mg with codeine 60 mg, and placebo. Using a third molar 
      extraction pain model, 200 healthy subjects were enrolled in a 6-hour evaluation 
      after a single dose of drug. Of the 200 patients enrolled, seven provided 
      incomplete efficacy data or discontinued prematurely and one was lost to 
      follow-up. Using standard measures of analgesia, including total pain relief 
      score (TOTPAR), maximum pain relief score (MaxPAR), sum of pain intensity 
      difference scores (SPID), peak pain intensity difference (Peak PID), 
      remedication, and global evaluations, all active treatments were found to be 
      numerically superior to placebo. ASA/codeine was found to be statistically 
      superior to placebo for all measures of efficacy. Tramadol 100 mg was 
      statistically superior to placebo for TOTPAR, SPID, and time of remedication, 
      whereas tramadol 50 mg was statistically superior to placebo onlyfor remedication 
      time. Codeine was not found to be statistically superior to placebo for any 
      efficacy measure. A greater TOTPAR response compared with all other active 
      measures was seen for ASA/codeine during the first 3 hours of study. The 6-hour 
      TOTPAR scores for the tramadol groups and ASA/ codeine group were not 
      significantly different. Gastrointestinal side effects (nausea, dysphagia, 
      vomiting) were reported more frequently with tramadol 100 mg, ASA/ codeine, and 
      codeine 60 mg than with placebo.
FAU - Moore, P A
AU  - Moore PA
AD  - Department of Dental Public Health, University of Pittsburgh, School of Dental 
      Medicine, Pennsylvania 15261, USA.
FAU - Crout, R J
AU  - Crout RJ
FAU - Jackson, D L
AU  - Jackson DL
FAU - Schneider, L G
AU  - Schneider LG
FAU - Graves, R W
AU  - Graves RW
FAU - Bakos, L
AU  - Bakos L
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 39J1LGJ30J (Tramadol)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Analgesia
MH  - Analgesics, Opioid/*therapeutic use
MH  - Analysis of Variance
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Codeine/administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - *Tooth Extraction
MH  - Tramadol/*therapeutic use
EDAT- 1998/07/03 00:00
MHDA- 1998/07/03 00:01
CRDT- 1998/07/03 00:00
PHST- 1998/07/03 00:00 [pubmed]
PHST- 1998/07/03 00:01 [medline]
PHST- 1998/07/03 00:00 [entrez]
AID - 10.1002/j.1552-4604.1998.tb05794.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1998 Jun;38(6):554-60. doi: 10.1002/j.1552-4604.1998.tb05794.x.

PMID- 34915778
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20220430
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 19
IP  - 12
DP  - 2021 Dec
TI  - Appraising the contemporary role of aspirin for primary and secondary prevention 
      of atherosclerotic cardiovascular events.
PG  - 1097-1117
LID - 10.1080/14779072.2021.2020100 [doi]
AB  - INTRODUCTION: Although the role of aspirin for primary prevention of 
      atherosclerotic cardiovascular disease (ASCVD) has been disputed, its use in 
      secondary ASCVD prevention is well established. Recent trials of primary 
      prevention do not suggest a significant net benefit with aspirin, whereas 
      accruing evidence supports adopting aspirin-free strategies in the context of 
      potent P2Y(12) inhibition for the secondary prevention of selected patients 
      undergoing percutaneous coronary intervention. AREAS COVERED: This updated review 
      aims at summarizing and appraising the pharmacological characteristics and the 
      contemporary role of aspirin for the primary and secondary prevention of ASCVD. 
      EXPERT OPINION: Recent trials and metanalyses in the context of primary 
      prevention highlighted a modest reduction in ischemic events with aspirin use, 
      counterbalanced by a significant increase in bleeding events. However, ongoing 
      studies on cancer prevention could modify the current paradigm of the unfavorable 
      benefit-risk ratio of aspirin in patients with no overt ASCVD. Conversely, 
      aspirin use is crucial for secondary ASCVD prevention, both in chronic and acute 
      coronary syndromes. Nevertheless, after a brief period of dual antiplatelet 
      therapy, patients at high bleeding risk may benefit from discontinuation of 
      aspirin if a P2Y(12) inhibitor is used, hence reducing the bleeding risk with no 
      rebound in thrombotic events.
FAU - Calderone, Dario
AU  - Calderone D
AUID- ORCID: 0000-0002-9445-4294
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico-San Marco" University of Catania, Catania, Italy.
FAU - Ingala, Salvatore
AU  - Ingala S
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico-San Marco" University of Catania, Catania, Italy.
FAU - Mauro, Maria Sara
AU  - Mauro MS
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico-San Marco" University of Catania, Catania, Italy.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AUID- ORCID: 0000-0001-8451-2131
AD  - Division of Cardiology, Department of Medicine, University of Florida College of 
      Medicine, Jacksonville, Florida, USA.
FAU - Capodanno, Davide
AU  - Capodanno D
AUID- ORCID: 0000-0002-5156-7723
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico-San Marco" University of Catania, Catania, Italy.
LA  - eng
PT  - Journal Article
DEP - 20211229
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - *Atherosclerosis/prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Primary Prevention
MH  - Secondary Prevention
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - aspirin
OT  - aspirin-free strategies
OT  - cardiovascular disease
OT  - primary prevention
OT  - secondary prevention
EDAT- 2021/12/18 06:00
MHDA- 2022/02/01 06:00
CRDT- 2021/12/17 05:34
PHST- 2021/12/18 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
PHST- 2021/12/17 05:34 [entrez]
AID - 10.1080/14779072.2021.2020100 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2021 Dec;19(12):1097-1117. doi: 
      10.1080/14779072.2021.2020100. Epub 2021 Dec 29.

PMID- 20607467
OWN - NLM
STAT- MEDLINE
DCOM- 20110216
LR  - 20171116
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 27
IP  - 9
DP  - 2010 Sep
TI  - Aspirin use in elderly women receiving medication therapy management services.
PG  - 613-22
LID - 10.1007/s12325-010-0046-1 [doi]
AB  - INTRODUCTION: Cardiovascular disease is the largest single cause of death among 
      women in the US. The American Heart Association guidelines recommend aspirin use 
      in women > or = 65 years of age if blood pressure is controlled and the benefits 
      of cardiovascular risk reduction likely outweigh the risk of bleeding. The 
      objective of this study is to determine the prevalence of aspirin use in elderly 
      women and factors associated with use. METHODS: This retrospective study 
      evaluated aspirin use in women aged > or = 65 years based on cardiovascular and 
      gastrointestinal bleeding risk using a medication therapy management database 
      within a large mid-Atlantic managed care organization. Logistic regression was 
      used to analyze patient-related variables associated with aspirin use. Variables 
      included clinical coronary heart disease (CHD), number of CHD risk factors, 
      diabetes diagnosis, number of chronic medications and presence of 
      contraindications to aspirin. RESULTS: Aspirin use was reported in 50% of 
      patients: 68.0% in the secondary prevention group and 46.3% in the primary 
      prevention group. The percentage of patients using aspirin or with relative 
      aspirin contraindications increased to 84% for the secondary prevention group and 
      65.9% for the primary prevention group. Patients with clinical CHD and those with 
      diabetes and without clinical CHD were 5.88 (P=0.008) and 7.54 (P=0.012) times 
      more likely to utilize aspirin, respectively, than patients with only one CHD 
      risk factor of age. Patients with relative contraindications to aspirin were less 
      likely to use aspirin (P<0.001). CONCLUSION: The high use of aspirin in patients 
      at higher CHD risk supports national recommendations. Clinical practitioners need 
      to carefully assess the value of aspirin in patients at low CHD risk and those 80 
      years of age and beyond where evidence of benefit should be weighed against risk.
FAU - Lee, Helen Y
AU  - Lee HY
AD  - CareFirst BlueCross BlueShield, Baltimore, MD, USA.
FAU - Tong, Yvette P
AU  - Tong YP
FAU - Xing, Shan
AU  - Xing S
FAU - Cooke, Catherine E
AU  - Cooke CE
LA  - eng
PT  - Journal Article
DEP - 20100702
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - R16CO5Y76E (Aspirin)
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aspirin/administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*drug therapy/epidemiology
MH  - Comorbidity
MH  - Contraindications
MH  - Diabetes Mellitus/epidemiology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Frail Elderly/statistics & numerical data
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Logistic Models
MH  - Medication Therapy Management
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Secondary Prevention
MH  - Stroke/epidemiology/prevention & control
EDAT- 2010/07/08 06:00
MHDA- 2011/02/17 06:00
CRDT- 2010/07/08 06:00
PHST- 2010/06/12 00:00 [received]
PHST- 2010/07/08 06:00 [entrez]
PHST- 2010/07/08 06:00 [pubmed]
PHST- 2011/02/17 06:00 [medline]
AID - 10.1007/s12325-010-0046-1 [doi]
PST - ppublish
SO  - Adv Ther. 2010 Sep;27(9):613-22. doi: 10.1007/s12325-010-0046-1. Epub 2010 Jul 2.

PMID- 22849667
OWN - NLM
STAT- MEDLINE
DCOM- 20130114
LR  - 20140731
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 8
IP  - 9
DP  - 2012 Sep
TI  - Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the 
      prevention of gastroduodenal ulcers in cardiovascular patients.
PG  - 1199-208
LID - 10.1517/17425255.2012.712684 [doi]
AB  - INTRODUCTION: Low-dose aspirin (ASA, 75 - 325 mg/day) is widely used for the 
      primary and secondary prevention of cardiovascular (CV) diseases. However, the 
      value of primary prevention ASA is uncertain as the reduction in occlusive events 
      needs to be weighed against the significant increase in major bleedings. 
      Prevention with antisecretory drugs has been proposed to reduce the incidence of 
      ASA-induced gastrointestinal (GI) bleedings, but non-adherence to 
      gastro-protection is of concern, as it significantly increases the risk of upper 
      GI adverse events. Beside patients and physicians education, one approach to 
      overcome non-adherence is the development of fixed-dose combination. AREA 
      COVERED: This review explores the results of clinical studies on the influence of 
      the combination esomeprazole (ESA) and ASA on pharmacokinetic (PK) parameters, 
      and the role for such combination in prevention of CV events in patients at risk 
      of gastric ulcers. EXPERT OPINION: Patients at risk of ASA-induced gastroduodenal 
      ulcer might benefit from a fixed ASA and proton pump inhibitor (PPI) combination. 
      PK and PD parameters suggest there is no significant interaction between these 
      drugs. Nevertheless, attention must be paid on the appropriate use of such 
      combination, that is, still balancing the risk:benefit ratio in a real-life 
      setting, and any increase in the proportion of patients receiving ASA and PPI 
      should be considered as a warning signal.
FAU - Bardou, Marc
AU  - Bardou M
AD  - Centre d'Investigations Cliniques plurithématique 803 (INSERM CIC-P 803), CHU de 
      Dijon, Bâtiment du Pr Marion, Dijon Cedex, France. marc.bardou@u-bourgogne.fr
FAU - Barkun, Alan N
AU  - Barkun AN
FAU - Hamza, Samia
AU  - Hamza S
FAU - Le Ray, Isabelle
AU  - Le Ray I
FAU - Goirand, Françoise
AU  - Goirand F
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120731
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - N3PA6559FT (Esomeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Ulcer Agents/*pharmacokinetics
MH  - Aspirin/*pharmacokinetics/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Drug Interactions
MH  - Esomeprazole/*pharmacokinetics/therapeutic use
MH  - Humans
MH  - Peptic Ulcer/*prevention & control
MH  - Platelet Aggregation Inhibitors/*pharmacokinetics
MH  - Randomized Controlled Trials as Topic
EDAT- 2012/08/02 06:00
MHDA- 2013/01/15 06:00
CRDT- 2012/08/02 06:00
PHST- 2012/08/02 06:00 [entrez]
PHST- 2012/08/02 06:00 [pubmed]
PHST- 2013/01/15 06:00 [medline]
AID - 10.1517/17425255.2012.712684 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1199-208. doi: 
      10.1517/17425255.2012.712684. Epub 2012 Jul 31.

PMID- 6502354
OWN - NLM
STAT- MEDLINE
DCOM- 19850114
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 105
IP  - 6
DP  - 1984 Dec
TI  - Difficulty in achieving therapeutic serum concentrations of salicylate in 
      Kawasaki disease.
PG  - 991-5
AB  - We investigated 49 children (33 boys), mean (+/- SD) age 2.6 +/- 1.8 years (range 
      8 months to 8 years), who had Kawasaki disease treated with acetylsalicylic acid 
      (ASA) 30 to 180 mg/kg. There was good correlation between salicylate doses and 
      serum concentrations (r = 0.69, P less than 0.01); however, large variability 
      existed. With doses less than 80 mg/kg/day there was not a single therapeutic 
      salicylate serum concentration (greater than 20 mg/dl). In children receiving 100 
      to 110 mg/kg/day 55% of the serum concentrations were subtherapeutic. The same 
      pattern persisted with doses greater than 120 mg/kg/day; however, 28% of levels 
      were in the toxic range (greater than 30 mg/dl). There was no evidence of 
      salicylate poisoning in the group; three children receiving greater than 100 
      mg/kg/day had aspirin-induced gastritis. An additional four children, studied 
      prospectively, received ASA 80 to 180 mg/kg/day. The fraction absorbed was 14% to 
      60%, which may be compared to a normal 85% to 90% absorption. Salicylate renal 
      clearance in these children (7.3 to 21 ml/kg/hr) was lower than in hyperthermic 
      children. Their steady-state serum salicylate concentrations were subtherapeutic 
      (7 to 11.5 mg/dl). The high ASA dose needed to overcome the impaired absorption 
      should be accompanied by frequent monitoring of levels because of the 
      unpredictable changes in absorption.
FAU - Koren, G
AU  - Koren G
FAU - MacLeod, S M
AU  - MacLeod SM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*blood/drug therapy
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Salicylates/*blood
MH  - Salicylic Acid
EDAT- 1984/12/01 00:00
MHDA- 1984/12/01 00:01
CRDT- 1984/12/01 00:00
PHST- 1984/12/01 00:00 [pubmed]
PHST- 1984/12/01 00:01 [medline]
PHST- 1984/12/01 00:00 [entrez]
AID - S0022-3476(84)80097-9 [pii]
AID - 10.1016/s0022-3476(84)80097-9 [doi]
PST - ppublish
SO  - J Pediatr. 1984 Dec;105(6):991-5. doi: 10.1016/s0022-3476(84)80097-9.

PMID- 6197344
OWN - NLM
STAT- MEDLINE
DCOM- 19840220
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 25
IP  - 1
DP  - 1984 Jan
TI  - Effect of 16,16 dimethyl prostaglandin E2 on aspirin induced damage to rat 
      gastric epithelial cells in tissue culture.
PG  - 19-25
AB  - Prostaglandins (PGs) protect gastric mucosa against damage produced by 
      acetylsalicylic acid (ASA). Whether this effect of prostaglandins is truly 
      cytoprotective and whether cAMP plays an important role in this effect is 
      uncertain. We studied the effect of: (1) 16,16 dimethyl prostaglandin E2 
      (dmPGE2), isobutylmethyl xanthine (IMX), and dibutyryl cAMP (DBcAMP) on 
      ASA-induced damage to monolayer cultures of rat gastric mucosa composed primarily 
      of mucus cells; (2) dmPGE2 on ASA absorption into the cultured cells. Cell damage 
      was quantitated by 51Cr-release and trypan blue staining. Ten millimoles ASA 
      significantly increased 51Cr-release (indicating cell damage) at pH 5.0, but not 
      at pH 7.4. DmPGE2 significantly reduced ASA-induced increase of 51Cr-release. 
      Isobutylmethyl xanthine did not change the rate of 51Cr-release caused by ASA 
      plus dmPGE2. Dibutyryl cAMP did not significantly alter 51Cr-release caused by 
      ASA. A dose response study of ASA damage showed close correlation between 
      51Cr-release and trypan blue staining (r = 0.93). Dimethyl prostaglandin E2 did 
      not affect 14C-ASA incorporation by the cells at either pH 7.4 or pH 5.0. We 
      conclude that: (1) dmPGE2 exerts a cytoprotective effect on cultured rat gastric 
      cells; (2) cAMP does not play an important role in such cytoprotection; (3) this 
      protection is not because of interference with ASA absorption by prostaglandin.
FAU - Terano, A
AU  - Terano A
FAU - Mach, T
AU  - Mach T
FAU - Stachura, J
AU  - Stachura J
FAU - Tarnawski, A
AU  - Tarnawski A
FAU - Ivey, K J
AU  - Ivey KJ
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Prostaglandins E, Synthetic)
RN  - 63X7MBT2LQ (Bucladesine)
RN  - M790V82VAC (16,16-Dimethylprostaglandin E2)
RN  - R16CO5Y76E (Aspirin)
RN  - TBT296U68M (1-Methyl-3-isobutylxanthine)
SB  - IM
MH  - 1-Methyl-3-isobutylxanthine/pharmacology
MH  - 16,16-Dimethylprostaglandin E2/*pharmacology
MH  - Absorption
MH  - Animals
MH  - Aspirin/metabolism/*pharmacology
MH  - Bucladesine/pharmacology
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Chromium Radioisotopes/metabolism
MH  - Epithelial Cells
MH  - Epithelium/drug effects
MH  - Gastric Mucosa/*drug effects/metabolism
MH  - Prostaglandins E, Synthetic/*pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
PMC - PMC1432242
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1136/gut.25.1.19 [doi]
PST - ppublish
SO  - Gut. 1984 Jan;25(1):19-25. doi: 10.1136/gut.25.1.19.

PMID- 22507986
OWN - NLM
STAT- MEDLINE
DCOM- 20120709
LR  - 20131121
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 421
IP  - 2
DP  - 2012 May 4
TI  - Acetylation and glycation of fibrinogen in vitro occur at specific lysine 
      residues in a concentration dependent manner: a mass spectrometric and isotope 
      labeling study.
PG  - 335-42
LID - 10.1016/j.bbrc.2012.03.154 [doi]
AB  - Aspirin may exert part of its antithrombotic effects through platelet-independent 
      mechanisms. Diabetes is a condition in which the beneficial effects of aspirin 
      are less prominent or absent - a phenomenon called "aspirin resistance". We 
      investigated whether acetylation and glycation occur at specific sites in 
      fibrinogen and if competition between glucose and aspirin in binding to 
      fibrinogen occurs. Our hypothesis was that such competition might be one 
      explanation to "aspirin resistance" in diabetes. After incubation of fibrinogen 
      in vitro with aspirin (0.8 mM, 24 h) or glucose (100 mM, 5-10 days), we found 12 
      modified sites with mass spectrometric techniques. Acetylations in the α-chain: 
      αK191, αK208, αK224, αK429, αK457, αK539, αK562, in the β-chain: βK233, and in 
      the γ-chain: γK170 and γK273. Glycations were found at βK133 and γK75, 
      alternatively γK85. Notably, the lysine 539 is a site involved in FXIII-mediated 
      cross-linking of fibrin. With isotope labeling in vitro, using 
      [(14)C-acetyl]salicylic acid and [(14)C]glucose, a labeling of 0.013-0.084 and 
      0.12-0.5 mol of acetylated and glycated adduct/mol fibrinogen, respectively, was 
      found for clinically (12.9-100 μM aspirin) and physiologically (2-8 mM glucose) 
      relevant plasma concentrations. No competition between acetylation and glycation 
      could be demonstrated. Thus, fibrinogen is acetylated at several lysine residues, 
      some of which are involved in the cross-linking of fibrinogen. This may 
      mechanistically explain why aspirin facilitates fibrin degradation. We find no 
      support for the idea that glycation of fibrin(ogen) interferes with acetylation 
      of fibrinogen.
CI  - Copyright © 2012 Elsevier Inc. All rights reserved.
FAU - Svensson, Jan
AU  - Svensson J
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska 
      University Hospital (Solna), SE-171 76 Stockholm, Sweden. jan.svensson@ki.se
FAU - Bergman, Ann-Charlotte
AU  - Bergman AC
FAU - Adamson, Ulf
AU  - Adamson U
FAU - Blombäck, Margareta
AU  - Blombäck M
FAU - Wallén, Håkan
AU  - Wallén H
FAU - Jörneskog, Gun
AU  - Jörneskog G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120407
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Fibrinolytic Agents)
RN  - 9001-32-5 (Fibrinogen)
RN  - IY9XDZ35W2 (Glucose)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Amino Acid Sequence
MH  - Aspirin/*chemistry
MH  - Fibrinogen/*chemistry
MH  - Fibrinolytic Agents/*chemistry
MH  - Glucose/chemistry
MH  - Glycosylation
MH  - Isotope Labeling
MH  - Lysine/*chemistry
MH  - Mass Spectrometry
MH  - Molecular Sequence Data
MH  - Protein Structure, Tertiary
EDAT- 2012/04/18 06:00
MHDA- 2012/07/10 06:00
CRDT- 2012/04/18 06:00
PHST- 2012/03/29 00:00 [received]
PHST- 2012/03/31 00:00 [accepted]
PHST- 2012/04/18 06:00 [entrez]
PHST- 2012/04/18 06:00 [pubmed]
PHST- 2012/07/10 06:00 [medline]
AID - S0006-291X(12)00648-1 [pii]
AID - 10.1016/j.bbrc.2012.03.154 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2012 May 4;421(2):335-42. doi: 
      10.1016/j.bbrc.2012.03.154. Epub 2012 Apr 7.

PMID- 28551293
OWN - NLM
STAT- MEDLINE
DCOM- 20180116
LR  - 20180116
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
VI  - 26
IP  - 10
DP  - 2017 Oct
TI  - Chronic Use of Aspirin and Total White Matter Lesion Volume: Results from the 
      Women's Health Initiative Memory Study of Magnetic Resonance Imaging Study.
PG  - 2128-2136
LID - S1052-3057(17)30208-2 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2017.04.034 [doi]
AB  - OBJECTIVE: To investigate the relationship between aspirin and subclinical 
      cerebrovascular heath, we evaluated the effect of chronic aspirin use on white 
      matter lesions (WML) volume among women. METHODS: Chronic aspirin use was 
      assessed in 1365 women who participated in the Women's Health Initiative Memory 
      Study of Magnetic Resonance Imaging. Differences in WML volumes between aspirin 
      users and nonusers were assessed with linear mixed models. A number of secondary 
      analyses were performed, including lobe-specific analyses, subgroup analyses 
      based on participants' overall risk of cerebrovascular disease, and a 
      dose-response relationship analysis. RESULTS: The mean age of the women at 
      magnetic resonance imaging examination was 77.6 years. Sixty-one percent of 
      participants were chronic aspirin users. After adjusting for demographic 
      variables and comorbidities, chronic aspirin use was nonsignificantly associated 
      with 4.8% (95% CI: -6.8%, 17.9%) larger WML volumes. These null findings were 
      confirmed in secondary and sensitivity analyses, including an active comparator 
      evaluation where aspirin users were compared to users of nonaspirin nonsteroidal 
      anti-inflammatory drugs or acetaminophen. CONCLUSIONS: There was a nonsignificant 
      difference in WML volumes between aspirin users and nonusers. Further, our 
      results suggest that chronic aspirin use may not have a clinically significant 
      effect on WML volumes in women.
CI  - Published by Elsevier Inc.
FAU - Holcombe, Andrea
AU  - Holcombe A
AD  - Department of Epidemiology, College of Public Health, University of Iowa, Iowa 
      City, Iowa. Electronic address: andrea-holcombe@uiowa.edu.
FAU - Ammann, Eric
AU  - Ammann E
AD  - Department of Epidemiology, College of Public Health, University of Iowa, Iowa 
      City, Iowa.
FAU - Espeland, Mark A
AU  - Espeland MA
AD  - Department of Biostatistical Sciences, School of Medicine, Wake Forest 
      University, Winston-Salem, North Carolina.
FAU - Kelley, Brendan J
AU  - Kelley BJ
AD  - Department of Neurology, Wexner Medical Center, Ohio State University, Columbus, 
      Ohio.
FAU - Manson, JoAnn E
AU  - Manson JE
AD  - Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, 
      Boston, Massachusetts.
FAU - Wallace, Robert
AU  - Wallace R
AD  - Department of Epidemiology, College of Public Health, University of Iowa, Iowa 
      City, Iowa.
FAU - Robinson, Jennifer
AU  - Robinson J
AD  - Department of Epidemiology, College of Public Health, University of Iowa, Iowa 
      City, Iowa.
LA  - eng
PT  - Journal Article
DEP - 20170524
PL  - United States
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National 
      Stroke Association
JID - 9111633
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cognition Disorders/diagnosis/epidemiology/*prevention & control/psychology
MH  - Female
MH  - Humans
MH  - Leukoencephalopathies/diagnostic imaging/epidemiology/*prevention & 
      control/psychology
MH  - Linear Models
MH  - *Magnetic Resonance Imaging
MH  - *Memory
MH  - Predictive Value of Tests
MH  - Protective Factors
MH  - Risk Factors
MH  - Time Factors
MH  - United States/epidemiology
MH  - White Matter/diagnostic imaging/*drug effects
MH  - *Women's Health
OTO - NOTNLM
OT  - Epidemiology
OT  - NSAID
OT  - antiplatelet
OT  - aspirin
OT  - cognition
OT  - white matter lesions
OT  - women's health
EDAT- 2017/05/30 06:00
MHDA- 2018/01/18 06:00
CRDT- 2017/05/29 06:00
PHST- 2017/03/01 00:00 [received]
PHST- 2017/04/29 00:00 [accepted]
PHST- 2017/05/30 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2017/05/29 06:00 [entrez]
AID - S1052-3057(17)30208-2 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2017.04.034 [doi]
PST - ppublish
SO  - J Stroke Cerebrovasc Dis. 2017 Oct;26(10):2128-2136. doi: 
      10.1016/j.jstrokecerebrovasdis.2017.04.034. Epub 2017 May 24.

PMID- 26905072
OWN - NLM
STAT- MEDLINE
DCOM- 20161021
LR  - 20161230
IS  - 1423-0259 (Electronic)
IS  - 0030-3747 (Linking)
VI  - 55
IP  - 4
DP  - 2016
TI  - Corneal Biomechanical Properties in Aspirin Users.
PG  - 199-204
LID - 10.1159/000443892 [doi]
AB  - PURPOSE: To analyze corneal biomechanical properties in aspirin users using an 
      ocular response analyzer. METHODS: This study included 80 eyes of 40 aspirin 
      users and 80 eyes of 40 individuals who did not use aspirin. Corneal hysteresis 
      (CH), the corneal resistance factor (CRF), Goldman-correlated intraocular 
      pressure (IOPg), and corneal compensated intraocular pressure (IOPcc) were 
      measured in all participants. The independent samples t test was used to compare 
      measurements in the aspirin users and nonusers in the total study population, and 
      in the diabetic patient subgroup. Pearson's correlation analysis was used to 
      examine the relationship between the measured variables in the aspirin users and 
      nonusers. RESULTS: Aspirin users (59.08 ± 11.83 years) were older than nonusers 
      (39.82 ± 12.97 years; p < 0.001). The mean CH was significantly lower in the 
      aspirin user group than in the nonuser group (p = 0.013). Mean IOPg and mean 
      IOPcc were also significantly higher in the aspirin user group (p = 0.027 and p = 
      0.002, respectively). The mean CRF was lower in the aspirin user group, but not 
      significantly (p = 0.70). There was a positive correlation between CH and CRF (r 
      = 0.767, p < 0.001), and between CRF and IOPg (r = 0.680, p < 0.001), and a 
      negative correlation between CH and IOPcc (r = -0.415, p < 0.001). CONCLUSIONS: 
      Aspirin should be taken into account when interpreting the results of corneal 
      biomechanical measurements.
CI  - © 2016 S. Karger AG, Basel.
FAU - Celebi, Ali Riza Cenk
AU  - Celebi AR
AD  - Department of Ophthalmology, Acibadem University School of Medicine, Istanbul, 
      Turkey.
FAU - Kilavuzoglu, Ayse Ebru
AU  - Kilavuzoglu AE
FAU - Altiparmak, Ugur Emrah
AU  - Altiparmak UE
FAU - Cosar, Cemile Banu
AU  - Cosar CB
LA  - eng
PT  - Journal Article
DEP - 20160224
PL  - Switzerland
TA  - Ophthalmic Res
JT  - Ophthalmic research
JID - 0267442
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Biomechanical Phenomena
MH  - Case-Control Studies
MH  - Cornea/*drug effects/physiology
MH  - Elasticity/drug effects
MH  - Female
MH  - Humans
MH  - Intraocular Pressure/drug effects
MH  - Male
MH  - Middle Aged
MH  - Tonometry, Ocular
EDAT- 2016/02/26 06:00
MHDA- 2016/10/22 06:00
CRDT- 2016/02/25 06:00
PHST- 2015/08/14 00:00 [received]
PHST- 2016/01/09 00:00 [accepted]
PHST- 2016/02/25 06:00 [entrez]
PHST- 2016/02/26 06:00 [pubmed]
PHST- 2016/10/22 06:00 [medline]
AID - 000443892 [pii]
AID - 10.1159/000443892 [doi]
PST - ppublish
SO  - Ophthalmic Res. 2016;55(4):199-204. doi: 10.1159/000443892. Epub 2016 Feb 24.

PMID- 7882176
OWN - NLM
STAT- MEDLINE
DCOM- 19950412
LR  - 20190720
IS  - 0008-4212 (Print)
IS  - 0008-4212 (Linking)
VI  - 72
IP  - 10
DP  - 1994 Oct
TI  - Potentiation by caffeine of the analgesic effect of aspirin in the pain-induced 
      functional impairment model in the rat.
PG  - 1127-31
AB  - The ability of caffeine to potentiate the analgesic effect of aspirin was studied 
      in the pain-induced functional impairment model in the rat. Female Wistar rats 
      received an intra-articular injection of 30% uric acid in the right hind limb, 
      inducing its dysfunction. Once the dysfunction was complete, animals received 
      aspirin oral doses of 0, 0.55, 0.98, and 1.74 mmol/kg with and without 0.17 
      mmol/kg of caffeine, and the recovery of functionality over time was considered 
      as an expression of analgesia. Blood samples were drawn simultaneously with hind 
      limb functionality determinations, and plasma concentrations of aspirin, 
      salicylic acid, and gentisic acid were measured by high-performance liquid 
      chromatography. Aspirin induced a dose-dependent analgesic effect. Caffeine alone 
      was ineffective. However, caffeine significantly increased the analgesic effect 
      of aspirin at all doses, without modifying aspirin, salicylic acid, or gentisic 
      acid plasma levels. It is concluded that caffeine potentiates the analgesic 
      effect of aspirin by a pharmacodynamic, but not by a pharmacokinetic mechanism.
FAU - Castañeda-Hernández, G
AU  - Castañeda-Hernández G
AD  - Departamento de Farmacología y Toxicología, Instituto Politécnico Nacional, 
      México, D.F.
FAU - Castillo-Méndez, M S
AU  - Castillo-Méndez MS
FAU - López-Muñoz, F J
AU  - López-Muñoz FJ
FAU - Granados-Soto, V
AU  - Granados-Soto V
FAU - Flores-Murrieta, F J
AU  - Flores-Murrieta FJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Gentisates)
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Salicylates)
RN  - 3G6A5W338E (Caffeine)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - VP36V95O3T (2,5-dihydroxybenzoic acid)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*pharmacology
MH  - Caffeine/*pharmacology
MH  - Drug Synergism
MH  - Female
MH  - *Gentisates
MH  - Hindlimb/drug effects/physiopathology
MH  - Hydroxybenzoates/blood
MH  - Pain/*drug therapy
MH  - Rats
MH  - Rats, Wistar
MH  - Salicylates/blood
MH  - Salicylic Acid
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 10.1139/y94-159 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 1994 Oct;72(10):1127-31. doi: 10.1139/y94-159.

PMID- 7106175
OWN - NLM
STAT- MEDLINE
DCOM- 19821021
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 80
IP  - 2-3
DP  - 1982 May 21
TI  - Release of biologically active substances from non-aggregating human platelets.
PG  - 203-7
AB  - Human platelet rich plasma (PRP) prepared from healthy, male volunteers 
      spontaneously release an anti-aggregatory, spasmogenic substance when incubated 
      at 37 degrees C. Similar biological activity was also observed following 
      incubation of platelets resuspended in aqueous solution but not in incubated 
      platelet poor plasma. Human PRP incubated at room temperature or on ice failed to 
      release biologically active substances. Both anti-aggregatory and spasmogenic 
      activity was detected following extraction of incubated PRP into ethyl acetate 
      after acidification. Aspirin (0.9 g) pretreatment reduced the generation of both 
      spasmogen and anti-aggregatory substance when blood was withdrawn 1 h but not 24 
      h after drug treatment. Indomethacin, flurbiprofen or aspirin (all 50 microM) 
      incubated with human PRP in vitro did not affected the production of spasmogenic 
      or anti-aggregatory activity. These results suggest that non-aggregating human 
      platelets generate a spasmogenic, anti-aggregatory prostaglandin.
FAU - Lofts, F J
AU  - Lofts FJ
FAU - Moore, P K
AU  - Moore PK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*metabolism
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Rats
MH  - Spasm/chemically induced
MH  - Stomach/drug effects
EDAT- 1982/05/21 00:00
MHDA- 1982/05/21 00:01
CRDT- 1982/05/21 00:00
PHST- 1982/05/21 00:00 [pubmed]
PHST- 1982/05/21 00:01 [medline]
PHST- 1982/05/21 00:00 [entrez]
AID - 0014-2999(82)90055-3 [pii]
AID - 10.1016/0014-2999(82)90055-3 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1982 May 21;80(2-3):203-7. doi: 10.1016/0014-2999(82)90055-3.

PMID- 15068408
OWN - NLM
STAT- MEDLINE
DCOM- 20040709
LR  - 20131121
IS  - 0269-4727 (Print)
IS  - 0269-4727 (Linking)
VI  - 29
IP  - 2
DP  - 2004 Apr
TI  - Concomitant use of buffered and enteric-coated low-dose aspirin products and 
      antisecretory drugs.
PG  - 183-7
AB  - OBJECTIVE: Buffered and enteric-coated formulations of low-dose aspirin therapy 
      are although expected to avoid gastrointestinal complications, there are reports 
      that these modified products are associated with such complications. One 
      available option for preventing aspirin-induced gastrointestinal complications is 
      the simultaneous use of the agents that inhibit acid secretion such as 
      H(2)-receptor antagonists and proton pump inhibitors. We compared the frequency 
      of prescriptions for antisecretory drugs between users of either buffered or 
      enteric-coated low-dose aspirin. METHODS: Monthly prescriptions at the National 
      Cardiovascular Center for aspirin products and antisecretory drugs were counted 
      from January 1998 to December 2002. Counting was based on information from a 
      prescription database file compiled from a computerized order entry system. 
      Time-series analyses were performed to determine changes in the frequency of 
      prescriptions for low-dose aspirin products and antisecretory drugs. In addition, 
      the frequency of prescriptions for antisecretory drugs was compared in 
      individuals using either buffered or enteric-coated low-dose aspirin. RESULTS: A 
      significant reduction in the frequency of prescriptions for H(2)-receptor 
      antagonists was observed during 2001 in users of enteric-coated low-dose aspirin 
      compared with users of buffered low-dose aspirin users. In contrast, we observed 
      a significant increase in the frequency of prescriptions for H(2)-receptor 
      antagonists in users of enteric-coated low-dose aspirin during 2002. This change 
      in prescribing H(2)-receptor antagonists in users of enteric-coated low-dose 
      aspirin began in the latter half of 2001. Proton pump inhibitors accounted for 
      0.31% of prescriptions in users of buffered low-dose aspirin and 0.47% in users 
      of enteric-coated low-dose aspirin, with this difference being statistically 
      significant. CONCLUSION: The findings of the present study do not support the 
      notion that enteric-coated low-dose aspirin reduces the risk of gastrointestinal 
      complications and is safer than buffered low-dose aspirin products. However the 
      usual caution about making inferences from observational retrospective data is 
      appropriate.
FAU - Takada, M
AU  - Takada M
AD  - Department of Pharmacy, National Cardiovascular Center, Osaka, Japan. 
      takada@hsp.ncvc.go.jp
FAU - Fukumoto, K
AU  - Fukumoto K
FAU - Shibakawa, M
AU  - Shibakawa M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Databases, Factual
MH  - Drug Prescriptions/statistics & numerical data
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Histamine H2 Antagonists/*administration & dosage
MH  - Humans
MH  - Japan/epidemiology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Tablets, Enteric-Coated/administration & dosage/adverse effects
EDAT- 2004/04/08 05:00
MHDA- 2004/07/10 05:00
CRDT- 2004/04/08 05:00
PHST- 2004/04/08 05:00 [pubmed]
PHST- 2004/07/10 05:00 [medline]
PHST- 2004/04/08 05:00 [entrez]
AID - JCP551 [pii]
AID - 10.1111/j.1365-2710.2004.00551.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2004 Apr;29(2):183-7. doi: 10.1111/j.1365-2710.2004.00551.x.

PMID- 11122218
OWN - NLM
STAT- MEDLINE
DCOM- 20010215
LR  - 20190831
IS  - 0954-7894 (Print)
IS  - 0954-7894 (Linking)
VI  - 30
IP  - 12
DP  - 2000 Dec
TI  - A moderate and unspecific release of cysteinyl leukotrienes by aspirin from 
      peripheral blood leucocytes precludes its value for aspirin sensitivity testing 
      in asthma.
PG  - 1785-91
AB  - Aspirin-induced asthma (AIA) is a clinical syndrome related to cysteinyl 
      leukotriene overproduction in airways. The confirmation of the diagnosis requires 
      inconvenient provocation tests with acetyl salicylic acid (ASA). A study was 
      performed to evaluate whether measurement in vitro of cysteinyl leukotrienes 
      (cys-LTs) release by isolated peripheral blood leucocytes, stimulated with ASA, 
      can be of use for diagnosis of AIA. A cellular allergen stimulation test, CAST, 
      was adapted to measure leukotriene release from leucocytes of 32 aspirin-tolerant 
      and 26 aspirin-intolerant asthmatics. The cells were stimulated with Lys-ASA, 
      N-formyl-methionyl-leucyl-phenylalanine (fMLP), or both fMLP and Lys-ASA, in a 
      buffer containing IL-3, and results compared with human leukaemia cell line 
      (Hl-60) response to Lys-ASA. Cys-LTs were measured in cell supernatant fluids by 
      ELISA. ASA had a rather week stimulatory effect on cys-LTs release in both groups 
      of patients. Contrary to some previous studies, no significant differences were 
      found between cys-LTs release by leucocytes from AIA and ATA, or by 
      differentiated Hl-60 cells. Measurement of cysteinyl-leukotriene release by 
      peripheral blood leucocytes pre-treated with aspirin has no value for diagnosis 
      of AIA.
FAU - Pierzchalska, M
AU  - Pierzchalska M
AD  - Department of Medicine, Jagiellonian University Medical School, Cracow, Poland.
FAU - Mastalerz, L
AU  - Mastalerz L
FAU - Sanak, M
AU  - Sanak M
FAU - Zazula, M
AU  - Zazula M
FAU - Szczeklik, A
AU  - Szczeklik A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - 0 (Leukotrienes)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/pharmacology
MH  - Asthma/blood/*chemically induced
MH  - Cells, Cultured
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - HL-60 Cells/drug effects/metabolism
MH  - Humans
MH  - Leukocytes/drug effects/metabolism
MH  - Leukotrienes/*analysis
MH  - Male
MH  - N-Formylmethionine Leucyl-Phenylalanine/pharmacology
EDAT- 2000/12/21 11:00
MHDA- 2001/03/03 10:01
CRDT- 2000/12/21 11:00
PHST- 2000/12/21 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2000/12/21 11:00 [entrez]
AID - cea953 [pii]
AID - 10.1046/j.1365-2222.2000.00953.x [doi]
PST - ppublish
SO  - Clin Exp Allergy. 2000 Dec;30(12):1785-91. doi: 10.1046/j.1365-2222.2000.00953.x.

PMID- 1572035
OWN - NLM
STAT- MEDLINE
DCOM- 19920601
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 85
IP  - 5
DP  - 1992 May
TI  - Increased thromboxane biosynthesis in type IIa hypercholesterolemia.
PG  - 1792-8
AB  - BACKGROUND: Increased platelet thromboxane (TX)A2 production has been described 
      in type IIa hypercholesterolemia. To verify the relevance of these 
      capacity-related measurements to the actual rate of TXA2 biosynthesis in vivo, we 
      studied the urinary excretion of its major enzymatic metabolites in 46 patients 
      with type IIa hypercholesterolemia and 20 age-matched controls. METHODS AND 
      RESULTS: Urinary 11-dehydro-TXB2 and 2,3-dinor-TXB2 were measured by previously 
      validated radioimmunoassays. The excretion rate of 11-dehydro-TXB2 was 
      significantly (p less than 0.001) higher in patients (68.7 +/- 35.1 ng/hr, mean 
      +/- SD) than in controls (22.4 +/- 9.4 ng/hr), with metabolite excretion greater 
      than 2 SD of the normal mean in 74% of the patients. Urinary 11-dehydro-TXB2 was 
      significantly (p less than 0.01) correlated with the threshold aggregating 
      concentration of collagen (r = -0.641) and arachidonate (r = -0.734) and with 
      agonist-induced platelet TXB2 production in vitro (r = 0.647 and 0.748, 
      respectively). Moreover, a statistically significant correlation (r = 0.673, p 
      less than 0.001, n = 66) was found between 11-dehydro-TXB2 excretion and total 
      plasma cholesterol. The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase 
      inhibitor simvastatin (20 mg/day for 6 months) significantly reduced cholesterol 
      levels by 22-28% and urinary 11-dehydro-TXB2 excretion by 32-42% in 10 patients. 
      However, the reduction in the latter did not correlate with the reduction in the 
      former and may have resulted from a nonspecific effect of simvastatin. Moreover, 
      selective inhibition of platelet cyclooxygenase activity by low-dose aspirin (50 
      mg/day for 7 days) was associated with cumulative inhibition of 11-dehydro-TXB2 
      excretion by approximately 70% in six patients. CONCLUSIONS: TXA2 biosynthesis is 
      enhanced in the majority of patients with type IIa hypercholesterolemia; this is, 
      at least in part, a consequence of abnormal cholesterol levels, as suggested by 
      the correlation between the two. Low-dose aspirin can largely suppress increased 
      metabolite excretion, thus suggesting that it reflects TXA2-dependent platelet 
      activation in vivo.
FAU - Davì, G
AU  - Davì G
AD  - Department of Medicine, University of Palermo School of Medicine, Italy.
FAU - Averna, M
AU  - Averna M
FAU - Catalano, I
AU  - Catalano I
FAU - Barbagallo, C
AU  - Barbagallo C
FAU - Ganci, A
AU  - Ganci A
FAU - Notarbartolo, A
AU  - Notarbartolo A
FAU - Ciabattoni, G
AU  - Ciabattoni G
FAU - Patrono, C
AU  - Patrono C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anticholesteremic Agents)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 9LHU78OQFD (Lovastatin)
RN  - AGG2FN16EV (Simvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticholesteremic Agents/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blood Platelets/physiology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Hypercholesterolemia/blood/*metabolism
MH  - Lovastatin/analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Simvastatin
MH  - Thromboxane A2/*biosynthesis
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
AID - 10.1161/01.cir.85.5.1792 [doi]
PST - ppublish
SO  - Circulation. 1992 May;85(5):1792-8. doi: 10.1161/01.cir.85.5.1792.

PMID- 11321173
OWN - NLM
STAT- MEDLINE
DCOM- 20010517
LR  - 20131121
IS  - 0332-3102 (Print)
IS  - 0332-3102 (Linking)
VI  - 94
IP  - 2
DP  - 2001 Feb
TI  - A study of the use of aspirin by general practitioners in suspected myocardial 
      infarction.
PG  - 48-50, 52
AB  - Aspirin's role in the management of suspected myocardial infarction has been well 
      established. The general practitioner is in an ideal position to administer this 
      well proven therapy to suitable patients. This study investigates the extent of 
      use of aspirin by general practitioners in the acute setting in a rural area in 
      the West of Ireland. It comprises two parts. Part one is a prospective survey of 
      all patients referred to Roscommon County Hospital by their G.P. in a four month 
      period with a complaint of chest pain (n=76). Details were taken regarding the 
      characteristics of the pain, use of referral letter, presence of risk factors for 
      ischaemic heart disease and pre-hospital administration of drugs, including 
      aspirin. Part two is a telephone survey of the G.P.s in the referral area. They 
      were asked whether they carried each of six common drugs, including aspirin, in 
      their doctor's bag. Less than two thirds of G.P.s contacted carried aspirin 
      routinely in their bag and less than 10% administered aspirin in patients with 
      chest pain highly suspicious of cardiac ischaemia. Discussion includes a review 
      of relevant recent literature and exploration of possible reasons for the 
      results.
FAU - O'Shea, E B
AU  - O'Shea EB
AD  - Vocational Training Scheme in General Practice, Western Health Board, University 
      College Hospital, Galway. eamonn.oshea@medix-uk.com
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Ireland
TA  - Ir Med J
JT  - Irish medical journal
JID - 0430275
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angina, Unstable/diagnosis/*drug therapy/mortality
MH  - Aspirin/*administration & dosage
MH  - Chest Pain/diagnosis/drug therapy
MH  - Data Collection
MH  - Drug Utilization/*statistics & numerical data
MH  - Family Practice/*methods
MH  - Female
MH  - Humans
MH  - Ireland
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/*drug therapy/mortality
MH  - Prospective Studies
MH  - Sensitivity and Specificity
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2001/04/26 10:00
MHDA- 2001/05/18 10:01
CRDT- 2001/04/26 10:00
PHST- 2001/04/26 10:00 [pubmed]
PHST- 2001/05/18 10:01 [medline]
PHST- 2001/04/26 10:00 [entrez]
PST - ppublish
SO  - Ir Med J. 2001 Feb;94(2):48-50, 52.

PMID- 8709183
OWN - NLM
STAT- MEDLINE
DCOM- 19960906
LR  - 20150901
IS  - 1607-551X (Print)
IS  - 1607-551X (Linking)
VI  - 12
IP  - 3
DP  - 1996 Mar
TI  - [Clinical manifestations and effects of IVGG in patients with Kawasaki disease].
PG  - 159-66
AB  - From Jan 1984 till Dec 1992, 293 patients--180 males and 113 females (M:F = 
      1.5:1)--with Kawasaki disease visited the Pediatric Department of Kaohsiung 
      Medical College Hospital. The mean age from the total cases were 28.5 months (2 
      months-10 years). Fever was the most common clinical symptom, followed by dry 
      cracked lips (93.5%), pharyngeal injection (92.8%) and conjunctivitis (90.5%). 
      Only 62.6% of the total cases had cervical lymph node swelling of which the 
      prevalence was higher than the previous report of the National Taiwan University 
      Hospital in 1985. Two hundred and ninety-three cases were divided randomly into 3 
      groups according to the different treatment regimens. The first group of 199 
      cases whose coronary artery change occurred in 85 cases (42.7%), were treated 
      with aspirin alone. The second group of 80 cases were treated with aspirin and 
      IVGG 400 mg/kg/day for 5 consecutive days. The prevalence of coronary artery 
      abnormalities was 22.5% (18/80). The third group of 14 cases were treated with 
      aspirin and single high dose IVGG (2 gm/kg) for 10-12 hours. Coronary artery 
      abnormalities occurred in 3 cases (21.4%). IVGG, initiated within 10 days of the 
      onset of fever, in conjunction with aspirin decreased the prevalence of coronary 
      artery dilatation and aneurysms significantly in comparison with treatment by the 
      aspirin alone (p < 0.05). However, there was no difference in the prevalence of 
      coronary aneurysm between the groups of single high dose and multiple doses, 
      though the single high dose of IVGG can improve the clinical symptoms quickly and 
      shorten the duration of hospitalization.
FAU - Hwang, K P
AU  - Hwang KP
AD  - Department of Pediatrics, Kaohsiung Medical College, Kaohsiung City, Taiwan, 
      Republic of China.
FAU - Wu, J R
AU  - Wu JR
FAU - Huang, L Y
AU  - Huang LY
FAU - Liou, C C
AU  - Liou CC
FAU - Huang, T Y
AU  - Huang TY
LA  - chi
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China (Republic : 1949- )
TA  - Kaohsiung J Med Sci
JT  - The Kaohsiung journal of medical sciences
JID - 100960562
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/complications/*therapy
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
PST - ppublish
SO  - Kaohsiung J Med Sci. 1996 Mar;12(3):159-66.

PMID- 18651324
OWN - NLM
STAT- MEDLINE
DCOM- 20090123
LR  - 20131121
IS  - 1502-7686 (Electronic)
IS  - 0036-5513 (Linking)
VI  - 68
IP  - 8
DP  - 2008
TI  - Monitoring aspirin therapy with the Platelet Function Analyzer-100.
PG  - 786-92
LID - 10.1080/00365510802262680 [doi]
AB  - OBJECTIVE: Low platelet response to aspirin has been reported to be associated 
      with a high incidence of vascular events. The reported prevalence of aspirin 
      low-responsiveness varies, which may be explained by poor reproducibility of the 
      methods used to evaluate aspirin response and low compliance. The Platelet 
      Function Analyzer-100 (PFA-100) is a commonly used platelet function test. We 
      aimed to assess the reproducibility of the PFA-100 and the agreement with optical 
      platelet aggregometry (OPA) in healthy volunteers and in patients with coronary 
      artery disease (CAD) treated with low-dose aspirin. MATERIAL AND METHODS: 
      Twenty-one healthy volunteers and 43 patients with CAD took part in the study. 
      During treatment with aspirin 75 mg daily, all participants had platelet function 
      assessed in duplicate with the PFA-100 and OPA on 4 consecutive days. 
      Additionally, platelet function was assessed before aspirin treatment in healthy 
      subjects. Serum-thromboxane B(2) (S-TxB(2)) was measured to assess compliance. 
      RESULTS: In healthy volunteers not receiving aspirin, duplicate measurements 
      resulted in coefficients of variation (CV) of 7.9 % for the PFA-100 and 5.2 % for 
      OPA. During aspirin treatment, CVs were significantly higher (healthy volunteers: 
      PFA-100: 15.6 %, OPA: 19.2 %; patients: PFA-100: 26.6 %, OPA: 16.8 %). Two of the 
      64 participants were classified as aspirin low-responders with both methods, 
      indicating poor agreement (Kappa coefficient 0.05). Compliance was excellent, as 
      S-TxB(2) was completely inhibited in all participants. CONCLUSIONS: Aspirin 
      treatment affects the reproducibility of both PFA-100 and OPA. This imprecision 
      should be considered carefully if the methods are used for monitoring aspirin 
      treatment. Additionally, these methods do not identify the same individuals as 
      being aspirin low-responders.
FAU - Mortensen, Jette
AU  - Mortensen J
AD  - Department of Cardiology, Aarhus University Hospital Skejby, Aarhus, Denmark.
FAU - Poulsen, Tina Svenstrup
AU  - Poulsen TS
FAU - Grove, Erik Lerkevang
AU  - Grove EL
FAU - Refsgaard, Jens
AU  - Refsgaard J
FAU - Nielsen, Helle Ladefoged
AU  - Nielsen HL
FAU - Pedersen, Susanne Bendesgaard
AU  - Pedersen SB
FAU - Thygesen, Sofie Sommer
AU  - Thygesen SS
FAU - Hvas, Anne-Mette
AU  - Hvas AM
FAU - Kristensen, Steen Dalby
AU  - Kristensen SD
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/drug therapy
MH  - Female
MH  - Health
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Monitoring, Physiologic
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests/*instrumentation
EDAT- 2008/07/25 09:00
MHDA- 2009/01/24 09:00
CRDT- 2008/07/25 09:00
PHST- 2008/07/25 09:00 [pubmed]
PHST- 2009/01/24 09:00 [medline]
PHST- 2008/07/25 09:00 [entrez]
AID - 795276153 [pii]
AID - 10.1080/00365510802262680 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2008;68(8):786-92. doi: 10.1080/00365510802262680.

PMID- 1726215
OWN - NLM
STAT- MEDLINE
DCOM- 19920707
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 42 Suppl 5
DP  - 1991
TI  - Antiplatelet therapy in the prevention of stroke.
PG  - 39-50
AB  - Aspirin (acetylsalicylic acid) is effective in reducing vascular outcome events 
      in patients with atherosclerosis: a relative risk reduction of about 30% for 
      stroke, 22% for stroke and death, and 15% for vascular mortality. It is probable 
      that low and high dose aspirin are similar in efficacy. Complications are more 
      frequent with high dose aspirin than with low doses. Four randomised trials 
      evaluating sulfinpyrazone vs placebo, and 3 trials evaluating sulfinpyrazone vs 
      aspirin, showed more cerebrovascular events in the sulfinpyrazone group than in 
      the aspirin and placebo groups. One small trial comparing dipyridamole with 
      placebo in patients with cerebrovascular disease found no difference between the 
      2 groups in outcome. No other studies have compared dipyridamole alone with 
      placebo or aspirin. The European Stroke Prevention Study II is currently in 
      progress and is comparing dipyridamole + aspirin, dipyridamole, aspirin, and 
      placebo. In the first year, the Ticlopidine Aspirin Stroke Study (TASS) showed a 
      42% risk reduction for stroke and death using the efficacy analysis and a 47% 
      risk reduction for stroke and stroke death. Ticlopidine was more effective than 
      aspirin in reducing stroke in both males and females. Apart from a reversible 
      severe neutropenia in 0.86% of patients, ticlopidine-related adverse effects were 
      relatively benign and reversible. The Canadian-American Ticlopidine Study (CATS) 
      compared ticlopidine with placebo in patients with completed major strokes. The 
      cumulative event rates for the primary outcome events of stroke, myocardial 
      infarction and vascular death, using the efficacy approach, show clear evidence 
      of separation almost immediately after randomisation, consistent with a constant 
      risk reduction of about 30% in the ticlopidine group. These data provide strong 
      evidence that ticlopidine conveys a clinically important reduction in the risk of 
      thromboembolic events in patients with a history of completed thromboembolic 
      stroke. In conclusion, aspirin is effective in preventing atherothrombotic 
      morbidity and mortality. It reduces the overall vascular event rate by about 25%. 
      Sulfinpyrazone and dipyridamole appear to add nothing important over aspirin 
      alone. Ticlopidine is more effective than aspirin in preventing stroke. The 
      modest, reversible risk of neutropenia, affecting less than 1% of patients, makes 
      the benefit: risk ratio a reasonable one.
FAU - Easton, J D
AU  - Easton JD
AD  - Department of Neurology, Rhode Island Hospital-Brown University, Providence.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Sulfinpyrazone/therapeutic use
MH  - Ticlopidine/therapeutic use
RF  - 35
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.2165/00003495-199100425-00007 [doi]
PST - ppublish
SO  - Drugs. 1991;42 Suppl 5:39-50. doi: 10.2165/00003495-199100425-00007.

PMID- 16479097
OWN - NLM
STAT- MEDLINE
DCOM- 20060511
LR  - 20181201
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 21 Suppl 1
DP  - 2006
TI  - New modalities and aspects of antiplatelet therapy for stroke prevention.
PG  - 7-16
AB  - Antiplatelet therapy is indicated for secondary prevention of ischaemic stroke. 
      The first-line antiplatelet agent is aspirin. The effect of aspirin is, however, 
      very limited, and this limited effect of aspirin is argued with termed 'aspirin 
      resistance'. Strategies against aspirin resistance may include alternative use of 
      other antiplatelet agents, combination of aspirin with other antiplatelet agents 
      and investigation into molecular targets to develop novel antiplatelet agents. 
      Progress in antiplatelet therapy should be directed at further reducing the risk 
      of ischaemic events including ischaemic stroke without increasing the risk of 
      haemorrhagic events including haemorrhagic stroke.
CI  - Copyright (c) 2006 S. Karger AG, Basel.
FAU - Uchiyama, Shinichiro
AU  - Uchiyama S
AD  - Department of Neurology, Tokyo Women's Medical University School of Medicine, 
      Tokyo, Japan. suchiyam@nij.twmu.ac.jp
FAU - Nakamura, Tomomi
AU  - Nakamura T
FAU - Yamazaki, Masako
AU  - Yamazaki M
FAU - Kimura, Yumi
AU  - Kimura Y
FAU - Iwata, Makoto
AU  - Iwata M
LA  - eng
PT  - Journal Article
DEP - 20060213
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - A74586SNO7 (Clopidogrel)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cilostazol
MH  - Clopidogrel
MH  - Drug Design
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/*prevention & control
MH  - Tetrazoles/adverse effects/therapeutic use
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
EDAT- 2006/02/16 09:00
MHDA- 2006/05/12 09:00
CRDT- 2006/02/16 09:00
PHST- 2006/02/16 09:00 [pubmed]
PHST- 2006/05/12 09:00 [medline]
PHST- 2006/02/16 09:00 [entrez]
AID - 90357 [pii]
AID - 10.1159/000090357 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2006;21 Suppl 1:7-16. doi: 10.1159/000090357. Epub 2006 Feb 13.

PMID- 15575422
OWN - NLM
STAT- MEDLINE
DCOM- 20041209
LR  - 20131121
IS  - 0023-7205 (Print)
IS  - 0023-7205 (Linking)
VI  - 101
IP  - 45
DP  - 2004 Nov 4
TI  - [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism].
PG  - 3504-6, 3508-9
AB  - A review on the subject of aspirin resistance and its role in vascular diseases 
      is presented. Although the clinical diagnosis of aspirin resistance is frequently 
      made, little is known about its biochemical background. Only a few follow-up 
      studies, with varying design, have dealt with the possible association between an 
      aspirin resistant phenotype and clinical outcome in patients with 
      atherothrombosis. However, it was recently shown that ibuprofen acts as a 
      competitive inhibitor in the blockage of COX-1. This pharmacodynamic interaction 
      results in secondary aspirin resistance, which may have clinical significance in 
      patients taking both medicines. With the complex nature of vascular diseases in 
      mind, it is not surprising that aspirin used as a single preventive strategy 
      fails in many cases. At present, there is no clear evidence that treatment 
      failure is associated with a particular aspirin resistant phenotype.
FAU - Hillarp, Andreas
AU  - Hillarp A
AD  - Klinisk kemi, Universitetssjukhuset MAS, Malmö, Sweden. 
      andreas.hillarp@klkemi.mas.lu.se
LA  - swe
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Resistens mot acetylsalicylsyra--klinisk diagnos utan klarlagd mekanism.
PL  - Sweden
TA  - Lakartidningen
JT  - Lakartidningen
JID - 0027707
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/metabolism/*pharmacology
MH  - Bleeding Time
MH  - Cardiovascular Diseases/drug therapy/metabolism
MH  - Cyclooxygenase Inhibitors/metabolism/pharmacology
MH  - Drug Interactions
MH  - *Drug Resistance/genetics
MH  - *Drug Tolerance/genetics
MH  - Fibrinolytic Agents/metabolism/*pharmacology
MH  - Humans
MH  - Ibuprofen/metabolism/pharmacology
MH  - Phenotype
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/metabolism/*pharmacology
RF  - 35
EDAT- 2004/12/04 09:00
MHDA- 2004/12/16 09:00
CRDT- 2004/12/04 09:00
PHST- 2004/12/04 09:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/12/04 09:00 [entrez]
PST - ppublish
SO  - Lakartidningen. 2004 Nov 4;101(45):3504-6, 3508-9.

PMID- 15111370
OWN - NLM
STAT- MEDLINE
DCOM- 20040521
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 164
IP  - 8
DP  - 2004 Apr 26
TI  - Use of aspirin and ibuprofen compared with aspirin alone and the risk of 
      myocardial infarction.
PG  - 852-6
AB  - BACKGROUND: Laboratory investigations suggest that the simultaneous use of 
      aspirin and ibuprofen may attenuate the antiplatelet effect of aspirin, making it 
      less useful for cardioprotection. To determine if there is clinical evidence of 
      this potentially harmful interaction, we conducted a retrospective matched 
      case-control study. METHODS: All patients issued outpatient prescriptions for 
      aspirin or ibuprofen from January 1, 1990, to December 31, 2000, at the Durham 
      Veterans Affairs Medical Center pharmacy were included in the study. Patients who 
      used aspirin and ibuprofen concurrently were matched against those who used 
      aspirin only by race, sex, age within 10 years, and cholesterol levels (either 
      low-density lipoprotein or total cholesterol) to within 30 mg/dL (0.78 mmol/L). 
      The rate ratio of experiencing a myocardial infarction per patient-month of drug 
      exposure was then determined. RESULTS: Some 3859 patients received both aspirin 
      and ibuprofen, for a total of 52 139 patient-months of medication use. This group 
      experienced 138 infarctions. The 10 239 patients receiving aspirin only, for a 
      total of 156 417 patient-months of use, experienced 684 infarctions. The rate 
      ratio of having an infarction was 0.61 (95% confidence interval, 0.50-0.73) (P 
      <.001), favoring the group that took aspirin and ibuprofen simultaneously. An 
      analysis of diabetic patients found a rate ratio of 0.48 (95% confidence 
      interval, 0.34-0.66) (P <.001). An examination of patients who spent time in both 
      groups at different times resulted in a rate ratio of infarction during combined 
      use of 0.70 (95% confidence interval, 0.59-0.83) (P <.001). CONCLUSION: There 
      does not seem to be an increased risk of myocardial infarction among patients 
      simultaneously consuming aspirin and ibuprofen compared with aspirin alone.
FAU - Patel, Taral N
AU  - Patel TN
AD  - Department of Internal Medicine, Duke University Medical Center, Durham, NC 
      27710, USA.
FAU - Goldberg, Kenneth Charles
AU  - Goldberg KC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ibuprofen/*therapeutic use
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Retrospective Studies
EDAT- 2004/04/28 05:00
MHDA- 2004/05/22 05:00
CRDT- 2004/04/28 05:00
PHST- 2004/04/28 05:00 [pubmed]
PHST- 2004/05/22 05:00 [medline]
PHST- 2004/04/28 05:00 [entrez]
AID - 164/8/852 [pii]
AID - 10.1001/archinte.164.8.852 [doi]
PST - ppublish
SO  - Arch Intern Med. 2004 Apr 26;164(8):852-6. doi: 10.1001/archinte.164.8.852.

PMID- 11022121
OWN - NLM
STAT- MEDLINE
DCOM- 20001212
LR  - 20131121
IS  - 1148-5493 (Print)
IS  - 1148-5493 (Linking)
VI  - 11
IP  - 3
DP  - 2000 Sep
TI  - A short course of oral aspirin increases IL-18-induced interferon-gamma 
      production in whole blood cultures.
PG  - 379-82
AB  - The effect of aspirin on whole blood cytokine production was studied in six 
      healthy volunteers. Four days after cessation of a 3-day regimen of 650 mg of 
      oral aspirin, there was a 70% increase in interferon-gamma (IFN-gamma) 
      production, stimulated by a combination of interleukin-18 (IL-18) plus 
      lipopolysaccharide (p < 0.05). At this time, there was a 4-fold increase in the 
      production of tumor necrosis factor-alpha (TNF-alpha) compared to pre-aspirin 
      levels (p < 0.03). TNF-alpha and IFN-gamma production returned to pre-aspirin 
      levels one month after the discontinuation of aspirin. Short-term aspirin 
      treatment induces a significant increase in the production of these cytokines, 
      probably through inhibition of prostaglandins. These data suggest a novel pathway 
      through which long aspirin use reduces the risk of colon cancer, and may explain 
      the effects of aspirin in inflammatory bowel disease.
FAU - Netea, M G
AU  - Netea MG
AD  - Division of Infectious Diseases, B168, University of Colorado Health Sciences 
      Center, 4200 East Ninth Ave., Denver, CO 80262, USA.
FAU - Puren, A J
AU  - Puren AJ
FAU - Dinarello, C A
AU  - Dinarello CA
LA  - eng
GR  - AI 15614/AI/NIAID NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - France
TA  - Eur Cytokine Netw
JT  - European cytokine network
JID - 9100879
RN  - 0 (Interleukin-18)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 82115-62-6 (Interferon-gamma)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Cells/drug effects/*immunology
MH  - Cells, Cultured
MH  - Humans
MH  - Interferon-gamma/*biosynthesis/blood
MH  - Interleukin-18/*pharmacology
MH  - Lipopolysaccharides/pharmacology
MH  - Male
MH  - Tumor Necrosis Factor-alpha/biosynthesis
EDAT- 2000/10/07 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/07 11:00
PHST- 2000/10/07 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/07 11:00 [entrez]
PST - ppublish
SO  - Eur Cytokine Netw. 2000 Sep;11(3):379-82.

PMID- 2860740
OWN - NLM
STAT- MEDLINE
DCOM- 19850717
LR  - 20221207
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 16
IP  - 3
DP  - 1985 May-Jun
TI  - Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The 
      American-Canadian Co-Operative Study group.
PG  - 406-15
AB  - The Persantine Aspirin Trial focused on the question of whether the 
      administration of the combination of aspirin and dipyridamole (Persantine) would 
      result in a lower incidence of cerebral or retinal infarction or death than the 
      administration of aspirin alone for persons with a history of recent carotid 
      territory transient ischemic attacks (TIAs). Fifteen centers in the United States 
      and Canada participated and 890 individuals were admitted and randomly allocated 
      to either aspirin (325 mg) plus placebo or aspirin (325 mg) plus Persantine (75 
      mg) four times daily. Ninety eight percent of the subjects were followed for at 
      least one year; many were followed for four to five years. The results of life 
      table analysis indicate that the overall endpoint rates for the "aspirin only" 
      and "aspirin plus Persantine" groups are identical. Thus, for TIA patients taking 
      aspirin, the addition of Persantine contributes nothing. There was a clustering 
      of stroke endpoints during the first month after randomization. Deaths from all 
      causes were essentially equally divided between the two treatment groups.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Black People
MH  - Blindness/complications
MH  - Cerebrovascular Disorders/complications
MH  - Dipyridamole/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/complications/mortality/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/complications
MH  - Neoplasms/complications
MH  - White People
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
AID - 10.1161/01.str.16.3.406 [doi]
PST - ppublish
SO  - Stroke. 1985 May-Jun;16(3):406-15. doi: 10.1161/01.str.16.3.406.

PMID- 19458364
OWN - NLM
STAT- MEDLINE
DCOM- 20090601
LR  - 20220331
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 360
IP  - 21
DP  - 2009 May 21
TI  - Effect of dipyridamole plus aspirin on hemodialysis graft patency.
PG  - 2191-201
LID - 10.1056/NEJMoa0805840 [doi]
AB  - BACKGROUND: Arteriovenous graft stenosis leading to thrombosis is a major cause 
      of complications in patients undergoing hemodialysis. Procedural interventions 
      may restore patency but are costly. Although there is no proven pharmacologic 
      therapy, dipyridamole may be promising because of its known vascular 
      antiproliferative activity. METHODS: We conducted a randomized, double-blind, 
      placebo-controlled trial of extended-release dipyridamole, at a dose of 200 mg, 
      and aspirin, at a dose of 25 mg, given twice daily after the placement of a new 
      arteriovenous graft until the primary outcome, loss of primary unassisted patency 
      (i.e., patency without thrombosis or requirement for intervention), was reached. 
      Secondary outcomes were cumulative graft failure and death. Primary and secondary 
      outcomes were analyzed with the use of a Cox proportional-hazards regression with 
      adjustment for prespecified covariates. RESULTS: At 13 centers in the United 
      States, 649 patients were randomly assigned to receive dipyridamole plus aspirin 
      (321 patients) or placebo (328 patients) over a period of 4.5 years, with 6 
      additional months of follow-up. The incidence of primary unassisted patency at 1 
      year was 23% (95% confidence interval [CI], 18 to 28) in the placebo group and 
      28% (95% CI, 23 to 34) in the dipyridamole-aspirin group, an absolute difference 
      of 5 percentage points. Treatment with dipyridamole plus aspirin significantly 
      prolonged the duration of primary unassisted patency (hazard ratio, 0.82; 95% CI, 
      0.68 to 0.98; P=0.03) and inhibited stenosis. The incidences of cumulative graft 
      failure, death, the composite of graft failure or death, and serious adverse 
      events (including bleeding) did not differ significantly between study groups. 
      CONCLUSIONS: Treatment with dipyridamole plus aspirin had a significant but 
      modest effect in reducing the risk of stenosis and improving the duration of 
      primary unassisted patency of newly created grafts. (ClinicalTrials.gov number, 
      NCT00067119.)
CI  - 2009 Massachusetts Medical Society
FAU - Dixon, Bradley S
AU  - Dixon BS
AD  - University of Iowa College of Medicine and the Veterans Affairs Medical Center, 
      Iowa City, IA 52242-1081, USA. bradley-dixon@uiowa.edu
FAU - Beck, Gerald J
AU  - Beck GJ
FAU - Vazquez, Miguel A
AU  - Vazquez MA
FAU - Greenberg, Arthur
AU  - Greenberg A
FAU - Delmez, James A
AU  - Delmez JA
FAU - Allon, Michael
AU  - Allon M
FAU - Dember, Laura M
AU  - Dember LM
FAU - Himmelfarb, Jonathan
AU  - Himmelfarb J
FAU - Gassman, Jennifer J
AU  - Gassman JJ
FAU - Greene, Tom
AU  - Greene T
FAU - Radeva, Milena K
AU  - Radeva MK
FAU - Davidson, Ingemar J
AU  - Davidson IJ
FAU - Ikizler, T Alp
AU  - Ikizler TA
FAU - Braden, Gregory L
AU  - Braden GL
FAU - Fenves, Andrew Z
AU  - Fenves AZ
FAU - Kaufman, James S
AU  - Kaufman JS
FAU - Cotton, James R Jr
AU  - Cotton JR Jr
FAU - Martin, Kevin J
AU  - Martin KJ
FAU - McNeil, James W
AU  - McNeil JW
FAU - Rahman, Asif
AU  - Rahman A
FAU - Lawson, Jeffery H
AU  - Lawson JH
FAU - Whiting, James F
AU  - Whiting JF
FAU - Hu, Bo
AU  - Hu B
FAU - Meyers, Catherine M
AU  - Meyers CM
FAU - Kusek, John W
AU  - Kusek JW
FAU - Feldman, Harold I
AU  - Feldman HI
CN  - DAC Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT00067119
GR  - U01 DK058982/DK/NIDDK NIH HHS/United States
GR  - U01 DK058986/DK/NIDDK NIH HHS/United States
GR  - U01DK058978/DK/NIDDK NIH HHS/United States
GR  - U01DK058985/DK/NIDDK NIH HHS/United States
GR  - U01DK058986/DK/NIDDK NIH HHS/United States
GR  - U01 DK058973/DK/NIDDK NIH HHS/United States
GR  - U01DK058966/DK/NIDDK NIH HHS/United States
GR  - U01 DK058966/DK/NIDDK NIH HHS/United States
GR  - U01 DK058981/DK/NIDDK NIH HHS/United States
GR  - U01DK058982/DK/NIDDK NIH HHS/United States
GR  - U01 DK058968/DK/NIDDK NIH HHS/United States
GR  - U01DK058973/DK/NIDDK NIH HHS/United States
GR  - U01 DK058978/DK/NIDDK NIH HHS/United States
GR  - U01DK058981/DK/NIDDK NIH HHS/United States
GR  - U01 DK058985/DK/NIDDK NIH HHS/United States
GR  - U01DK058968/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2009 May 21;360(21):2240-2. PMID: 19458370
CIN - N Engl J Med. 2009 Aug 13;361(7):720; author reply 721. PMID: 19675337
CIN - N Engl J Med. 2009 Aug 13;361(7):720-1; author reply 721. PMID: 19681176
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Graft Occlusion, Vascular/epidemiology/*prevention & control
MH  - Humans
MH  - Incidence
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Proportional Hazards Models
MH  - *Renal Dialysis/adverse effects
MH  - Thrombosis/epidemiology/*prevention & control
PMC - PMC3929400
MID - NIHMS544210
COIS- No other potential conflict of interest relevant to this article was reported.
FIR - Dember, L
IR  - Dember L
FIR - Kaufman, J
IR  - Kaufman J
FIR - Hawley, M
IR  - Hawley M
FIR - Lauer, A
IR  - Lauer A
FIR - LeSage, P
IR  - LeSage P
FIR - Nathan, R
IR  - Nathan R
FIR - Holmberg, E
IR  - Holmberg E
FIR - Braden, G
IR  - Braden G
FIR - Ryan, M
IR  - Ryan M
FIR - Berkowitz, A
IR  - Berkowitz A
FIR - Rahman, A
IR  - Rahman A
FIR - Lucas, B Jr
IR  - Lucas B Jr
FIR - Santos, R
IR  - Santos R
FIR - Reyes, B
IR  - Reyes B
FIR - Greenberg, A
IR  - Greenberg A
FIR - Berkoben, M
IR  - Berkoben M
FIR - Kovalik, E
IR  - Kovalik E
FIR - Lawson, J
IR  - Lawson J
FIR - Middleton, J
IR  - Middleton J
FIR - Schwab, S
IR  - Schwab S
FIR - Schumm, D
IR  - Schumm D
FIR - Adams, S
IR  - Adams S
FIR - Gitter, K
IR  - Gitter K
FIR - Cantaffa, T
IR  - Cantaffa T
FIR - Quarles, A
IR  - Quarles A
FIR - Work, J
IR  - Work J
FIR - Rhodes, S
IR  - Rhodes S
FIR - Himmelfarb, J
IR  - Himmelfarb J
FIR - Whiting, J
IR  - Whiting J
FIR - Kane, J
IR  - Kane J
FIR - Freedman, S
IR  - Freedman S
FIR - Violette, R
IR  - Violette R
FIR - Cyr-Alves, H
IR  - Cyr-Alves H
FIR - Garrison, K
IR  - Garrison K
FIR - Martin, K
IR  - Martin K
FIR - Schmitz, P
IR  - Schmitz P
FIR - Jenkins, V
IR  - Jenkins V
FIR - Cotton, J Jr
IR  - Cotton J Jr
FIR - Husband, E
IR  - Husband E
FIR - Allon, M
IR  - Allon M
FIR - Robbin, M
IR  - Robbin M
FIR - Lockhart, M
IR  - Lockhart M
FIR - Casey, B
IR  - Casey B
FIR - Newsome, J
IR  - Newsome J
FIR - Dixon, B
IR  - Dixon B
FIR - Franzwa, B
IR  - Franzwa B
FIR - Hunsicker, L
IR  - Hunsicker L
FIR - Hoballah, J
IR  - Hoballah J
FIR - Katz, D
IR  - Katz D
FIR - Sharp, W
IR  - Sharp W
FIR - Kresowik, T
IR  - Kresowik T
FIR - Wu, Y
IR  - Wu Y
FIR - Rayhill, S
IR  - Rayhill S
FIR - Pflederer, T
IR  - Pflederer T
FIR - DuPage, K
IR  - DuPage K
FIR - Welch, K
IR  - Welch K
FIR - Darras, F
IR  - Darras F
FIR - Banqero, A
IR  - Banqero A
FIR - Ketel, B
IR  - Ketel B
FIR - Wounded Arrow, A
IR  - Wounded Arrow A
FIR - Grant, C
IR  - Grant C
FIR - Deeb, J
IR  - Deeb J
FIR - Pyszka, L
IR  - Pyszka L
FIR - Slavin, M
IR  - Slavin M
FIR - Wedeking, D
IR  - Wedeking D
FIR - Vazquez, M
IR  - Vazquez M
FIR - Davidson, I
IR  - Davidson I
FIR - Toto, R
IR  - Toto R
FIR - Littmon, L
IR  - Littmon L
FIR - Ying, C
IR  - Ying C
FIR - Lightfoot, T
IR  - Lightfoot T
FIR - Quinones, H
IR  - Quinones H
FIR - Saxena, R
IR  - Saxena R
FIR - Clagett, P
IR  - Clagett P
FIR - Valentine, J
IR  - Valentine J
FIR - Dolmatch, B
IR  - Dolmatch B
FIR - Thompson, J
IR  - Thompson J
FIR - Fenves, A
IR  - Fenves A
FIR - Pearl, G
IR  - Pearl G
FIR - Ikizler, A
IR  - Ikizler A
FIR - Egbert, P
IR  - Egbert P
FIR - McNeil, J
IR  - McNeil J
FIR - Holmes, D
IR  - Holmes D
FIR - Freiberger, W
IR  - Freiberger W
FIR - Delmez, J
IR  - Delmez J
FIR - Windus, D
IR  - Windus D
FIR - Coyne, D
IR  - Coyne D
FIR - Rothstein, M
IR  - Rothstein M
FIR - Shenoy, S
IR  - Shenoy S
FIR - Creaghan, R
IR  - Creaghan R
FIR - Lluka, B
IR  - Lluka B
FIR - Kusek, J
IR  - Kusek J
FIR - Meyers, C
IR  - Meyers C
FIR - Feldman, H
IR  - Feldman H
FIR - Beck, G
IR  - Beck G
FIR - Gassman, J
IR  - Gassman J
FIR - Greene, T
IR  - Greene T
FIR - Hu, B
IR  - Hu B
FIR - Bi, S
IR  - Bi S
FIR - Liu, A
IR  - Liu A
FIR - Radeva, M
IR  - Radeva M
FIR - Tuason, L
IR  - Tuason L
FIR - Weiss, B
IR  - Weiss B
FIR - Levin, N
IR  - Levin N
FIR - Besarab, A
IR  - Besarab A
FIR - Chertow, G
IR  - Chertow G
FIR - Diener-West, M
IR  - Diener-West M
FIR - Louis, T
IR  - Louis T
FIR - McClellan, W
IR  - McClellan W
FIR - Stehman-Breen, C
IR  - Stehman-Breen C
EDAT- 2009/05/22 09:00
MHDA- 2009/06/02 09:00
CRDT- 2009/05/22 09:00
PHST- 2009/05/22 09:00 [entrez]
PHST- 2009/05/22 09:00 [pubmed]
PHST- 2009/06/02 09:00 [medline]
AID - 360/21/2191 [pii]
AID - 10.1056/NEJMoa0805840 [doi]
PST - ppublish
SO  - N Engl J Med. 2009 May 21;360(21):2191-201. doi: 10.1056/NEJMoa0805840.

PMID- 19667414
OWN - NLM
STAT- MEDLINE
DCOM- 20091214
LR  - 20181201
IS  - 1550-8080 (Electronic)
IS  - 0091-7370 (Linking)
VI  - 39
IP  - 3
DP  - 2009 Summer
TI  - Prevalence and risk factors for aspirin and clopidogrel resistance in patients 
      with coronary artery disease or ischemic cerebrovascular disease.
PG  - 289-94
AB  - The objective of this study was to identify possible risk factors associated with 
      a lack of response to aspirin and clopidogrel treatments in patients with 
      coronary or cerebral ischemic artery disease. A point-of-care analyzer, VerifyNow 
      (Accumetrics, San Diego, CA), was used to measure adenosine-5-diphosphate and 
      platelet P2YI2 receptor blockage to investigate the responses of a group of 197 
      patients to aspirin and/ or clopidogrel therapies (aspirin therapy, 178; 
      clopidogrel therapy, 139; both drugs, 144). Of these 197 patients, 135 (68.5%) 
      had coronary artery disease and 72 (31.5%) had ischemic cerebrovascular disease. 
      Aspirin resistance was defined as an ARU (aspirin reaction units) > or =550, and 
      clopidogrel resistance was defined as platelet inhibition <20%. Twenty-five of 
      178 aspirin users (14.0%) were resistant to aspirin, and 54 of 139 (38.8%) 
      clopidogrel users were resistant to clopidogrel. The data indicate that low 
      hemoglobin (Hb) level in aspirin users and high systolic and diastolic blood 
      pressures in clopidogrel users are significantly related to treatment resistance 
      (p < 0.05). The latter finding is possibly due to the greater adhesiveness and 
      increased aggregability of platelets in hypertensive patients.
FAU - Kim, Hyunjung
AU  - Kim H
AD  - Department of Laboratory Medicine, College of Medicine, The Catholic University 
      of Korea, Seoul, Korea.
FAU - Lee, Hae Kyung
AU  - Lee HK
FAU - Han, Kyungja
AU  - Han K
FAU - Jeon, Hui-Kyung
AU  - Jeon HK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Clin Lab Sci
JT  - Annals of clinical and laboratory science
JID - 0410247
RN  - 0 (Hemoglobins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Blood Pressure/physiology
MH  - Cerebral Arterial Diseases/blood/*drug therapy
MH  - Clopidogrel
MH  - Coronary Artery Disease/blood/*drug therapy
MH  - *Drug Resistance
MH  - Female
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/therapeutic 
      use
MH  - Prevalence
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
EDAT- 2009/08/12 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/08/12 09:00
PHST- 2009/08/12 09:00 [entrez]
PHST- 2009/08/12 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 39/3/289 [pii]
PST - ppublish
SO  - Ann Clin Lab Sci. 2009 Summer;39(3):289-94.

PMID- 34767564
OWN - NLM
STAT- MEDLINE
DCOM- 20211223
LR  - 20211223
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 16
IP  - 11
DP  - 2021
TI  - Cost-effectiveness analysis of apixaban versus vitamin K antagonists for 
      antithrombotic therapy in patients with atrial fibrillation after acute coronary 
      syndrome or percutaneous coronary intervention in Spain.
PG  - e0259251
LID - 10.1371/journal.pone.0259251 [doi]
LID - e0259251
AB  - BACKGROUND/OBJECTIVE: AUGUSTUS trial demonstrated that, for patients with atrial 
      fibrillation (AF) having acute coronary syndrome (ACS) or undergoing percutaneous 
      coronary intervention (PCI), an antithrombotic regimen with apixaban and P2Y12 
      resulted in less bleeding, fewer hospitalizations, and similar ischemic events 
      than regimens including a vitamin K antagonist (VKA), aspirin, or both. This 
      study objective was to evaluate long-term health and economic outcomes and the 
      cost-effectiveness of apixaban over VKA, as a treatment option for patients with 
      AF having ACS/PCI. METHODS: A lifetime Markov cohort model was developed 
      comparing apixaban versus VKA across multiple treatment strategies (triple [with 
      P2Y12 + aspirin] or dual [with P2Y12] therapy followed by monotherapy [apixaban 
      or VKA]; triple followed by dual and then monotherapy; dual followed by 
      monotherapy). The model adopted the Spanish healthcare perspective, with a 
      3-month cycle length and costs and health outcomes discounted at 3%. RESULTS: 
      Treatment with apixaban resulted in total cost savings of €883 and higher life 
      years (LYs) and quality-adjusted LYs (QALYs) per patient than VKA (net 
      difference, LYs: 0.13; QALYs: 0.11). Bleeding and ischemic events (per 100 
      patients) were lower with apixaban than VKA (net difference, -13.9 and -1.8, 
      respectively). Incremental net monetary benefit for apixaban was €3,041, using a 
      willingness-to-pay threshold of €20,000 per QALY. In probabilistic sensitivity 
      analysis, apixaban was dominant in the majority of simulations (92.6%), providing 
      additional QALYs at lower costs than VKA. CONCLUSIONS: Apixaban was a dominant 
      treatment strategy than VKA from both the Spanish payer's and societal 
      perspectives, regardless of treatment strategy considered.
FAU - Rivolo, Simone
AU  - Rivolo S
AUID- ORCID: 0000-0002-8431-9611
AD  - Modeling and Simulation, Evidera PPD, Milan, Italy.
FAU - Di Fusco, Manuela
AU  - Di Fusco M
AD  - Pfizer Inc, New York, New York, United States of America.
FAU - Polanco, Carlos
AU  - Polanco C
AD  - Bristol Myers Squibb, Madrid, Spain.
FAU - Kang, Amiee
AU  - Kang A
AD  - Bristol Myers Squibb, Lawrenceville, New Jersey, United States of America.
FAU - Dhanda, Devender
AU  - Dhanda D
AD  - Bristol Myers Squibb, Lawrenceville, New Jersey, United States of America.
FAU - Savone, Mirko
AU  - Savone M
AD  - Pfizer Inc, New York, New York, United States of America.
FAU - Skandamis, Aristeidis
AU  - Skandamis A
AD  - Modeling and Simulation, Evidera, London, United Kingdom.
FAU - Kongnakorn, Thitima
AU  - Kongnakorn T
AD  - Modeling and Simulation, Evidera, London, United Kingdom.
FAU - Soto, Javier
AU  - Soto J
AD  - Pfizer, Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211112
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/complications/pathology
MH  - Aged
MH  - Aspirin/*economics/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - *Cost-Benefit Analysis
MH  - Female
MH  - Fibrinolytic Agents/*economics/therapeutic use
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Percutaneous Coronary Intervention/adverse effects
MH  - Pyrazoles/*economics/therapeutic use
MH  - Pyridones/*economics/therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Spain
PMC - PMC8589164
COIS- I have read the journal’s policy and the authors of this manuscript have the 
      following competing interests: AK is an employee and holds stock from BMS. CP is 
      an employee and holds stock from BMS. MDF is an employee and owner of stock at 
      Pfizer Inc. DD is an employee and holds stock from BMS. JS is an employee and 
      owner of stock at Pfizer Inc. MS is a Pfizer Inc. employee and owns stocks of 
      Pfizer Inc. SR, TK, and AS are salaried employees of Evidera and are not allowed 
      to accept remuneration from any clients for their services. Evidera received 
      funding from BMS/Pfizer Inc. to conduct the study and develop this manuscript. 
      This does not alter our adherence to all the PLOS ONE policies on sharing data 
      and materials.
EDAT- 2021/11/13 06:00
MHDA- 2021/12/24 06:00
CRDT- 2021/11/12 17:14
PHST- 2021/03/03 00:00 [received]
PHST- 2021/10/17 00:00 [accepted]
PHST- 2021/11/12 17:14 [entrez]
PHST- 2021/11/13 06:00 [pubmed]
PHST- 2021/12/24 06:00 [medline]
AID - PONE-D-21-07022 [pii]
AID - 10.1371/journal.pone.0259251 [doi]
PST - epublish
SO  - PLoS One. 2021 Nov 12;16(11):e0259251. doi: 10.1371/journal.pone.0259251. 
      eCollection 2021.

PMID- 24026319
OWN - NLM
STAT- MEDLINE
DCOM- 20131113
LR  - 20220317
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 159
IP  - 5
DP  - 2013 Sep 3
TI  - The ankle-brachial index for peripheral artery disease screening and 
      cardiovascular disease prediction among asymptomatic adults: a systematic 
      evidence review for the U.S. Preventive Services Task Force.
PG  - 333-41
LID - 10.7326/0003-4819-159-5-201309030-00007 [doi]
AB  - BACKGROUND: Screening for peripheral artery disease (PAD) may reduce morbidity 
      and mortality. PURPOSE: To review the evidence on the ability of the 
      ankle-brachial index (ABI) to predict cardiovascular disease (CVD) morbidity and 
      mortality independent of Framingham Risk Score (FRS) factors in asymptomatic 
      adults and on the benefits and harms of treating screen-detected adults with PAD. 
      DATA SOURCES: MEDLINE and the Cochrane Central Register of Controlled Trials 
      (1996 to September 2012), clinical trial registries, reference lists, and 
      experts. STUDY SELECTION: English-language, population-based prognostic studies 
      evaluating the ABI in addition to the FRS and treatment trials or studies of 
      treatment harms in screen-detected adults with PAD. DATA EXTRACTION: Dual quality 
      assessment and abstraction of relevant study details. DATA SYNTHESIS: One large 
      meta-analysis (n = 43 919) showed that the ABI could reclassify 10-year risk for 
      coronary artery disease (CAD), but it did not report measures of appropriate 
      reclassification (the net reclassification improvement [NRI]). Four heterogeneous 
      risk prediction studies showed that the magnitude of the NRI was probably small 
      when the ABI was added to the FRS to predict CAD or CVD events. Of 2 treatment 
      trials meeting inclusion criteria, 1 large trial (n = 3350) showed that low-dose 
      aspirin did not prevent CVD events in persons with a screen-detected low ABI but 
      may have increased the risk for major bleeding events. LIMITATIONS: Most 
      prognostic studies did not allow for calculation of a bias-corrected NRI. 
      Evidence on treatment benefits and harms was limited to aspirin and was scant. 
      CONCLUSION: Adding the ABI to the FRS probably has limited value for predicting 
      CAD or CVD. Treatment benefits for asymptomatic individuals with screen-detected 
      PAD are not established. PRIMARY FUNDING SOURCE: Agency for Healthcare Research 
      and Quality.
FAU - Lin, Jennifer S
AU  - Lin JS
FAU - Olson, Carin M
AU  - Olson CM
FAU - Johnson, Eric S
AU  - Johnson ES
FAU - Whitlock, Evelyn P
AU  - Whitlock EP
LA  - eng
GR  - HHSA 290-2007-10057/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2013 Sep 3;159(5):362-3. PMID: 24026321
MH  - Adult
MH  - *Ankle Brachial Index
MH  - Aspirin/adverse effects/therapeutic use
MH  - Asymptomatic Diseases
MH  - Cardiovascular Diseases/*epidemiology/mortality
MH  - Fibrinolytic Agents/adverse effects/therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Mass Screening/*methods
MH  - Peripheral Arterial Disease/*diagnosis/drug therapy
MH  - Predictive Value of Tests
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2013/09/13 06:00
MHDA- 2013/11/14 06:00
CRDT- 2013/09/13 06:00
PHST- 2013/09/13 06:00 [entrez]
PHST- 2013/09/13 06:00 [pubmed]
PHST- 2013/11/14 06:00 [medline]
AID - 1733278 [pii]
AID - 10.7326/0003-4819-159-5-201309030-00007 [doi]
PST - ppublish
SO  - Ann Intern Med. 2013 Sep 3;159(5):333-41. doi: 
      10.7326/0003-4819-159-5-201309030-00007.

PMID- 23007664
OWN - NLM
STAT- MEDLINE
DCOM- 20130419
LR  - 20211203
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 41
IP  - 6
DP  - 2012 Dec
TI  - Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery 
      of a novel aspirin, curcumin and sulforaphane drug combination regimen.
PG  - 2260-8
LID - 10.3892/ijo.2012.1636 [doi]
AB  - Pancreatic cancer is the fourth largest cause of cancer deaths in the Unites 
      States and the prognosis is grim with <5% survival chances upon diagnosis. The 
      objective of this study was to assess the combined chemopreventive effect of 
      solid lipid nanoparticle (SLN) encapsulated drugs aspirin (ASP), curcumin (CUR) 
      and free sulforaphane (SFN) for the chemoprevention of pancreatic cancer. 
      Experiments were carried out (1) to evaluate the feasibility of encapsulation of 
      these chemopreventive agents within solid lipid systems and (2) to measure the 
      synergistic effects of a combination of ASP with CUR in SLNs mixed with free SFN 
      against cell proliferation and apoptosis in pancreatic cancer cells, MIA PaCa-2 
      and Panc-1. The SLNs were prepared using a modified solvent evaporation technique 
      and were characterized for particle sizing, encapsulation efficiency and drug 
      release. ASP and CUR SLNs were formulated within the particle size range of 
      150‑250 nm and were found to have an encapsulation efficiency of 85 and 69%, 
      respectively. Sustained release of drugs over a 96 h period from SLNs was 
      observed. The SLNs were stable over a 3-month storage period at room temperature. 
      Cell viability studies demonstrated that combinations of low doses of ASP SLN (25 
      µM), CUR SLN (2.5 µM) and free SFN (5 µM) significantly reduced cell viability by 
      43.6 and 48.49% in MIAPaca-2 and Panc-1 cell lines, respectively. Furthermore, 
      increased apoptosis of 61.3 and 60.37% was found in MIA Paca-2 and Panc-1 cell 
      lines, respectively, in comparison to the individual doses administered. 
      Synergistic effects were demonstrated using MTS and apoptosis assays. Thus, this 
      study successfully demonstrated the feasibility of using a solid lipid 
      nanoparticulate system for the first time to deliver this novel combination 
      chemoprevention regimen, providing valuable evidence for the usability of 
      nanotechnology-based drug regimens towards pancreatic cancer chemoprevention.
FAU - Sutaria, Dhruvitkumar
AU  - Sutaria D
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Western University of 
      Health Sciences, Pomona, CA 91766, USA.
FAU - Grandhi, Balagangadhar Karthik
AU  - Grandhi BK
FAU - Thakkar, Arvind
AU  - Thakkar A
FAU - Wang, Jeffrey
AU  - Wang J
FAU - Prabhu, Sunil
AU  - Prabhu S
LA  - eng
GR  - R03 CA153812/CA/NCI NIH HHS/United States
GR  - 1R03CA153812-01A1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20120921
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Drug Combinations)
RN  - 0 (Isothiocyanates)
RN  - 0 (Lipids)
RN  - 0 (Nanocapsules)
RN  - 0 (Nanoconjugates)
RN  - 0 (Sulfoxides)
RN  - 0 (Thiocyanates)
RN  - GA49J4310U (sulforaphane)
RN  - IT942ZTH98 (Curcumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Aspirin/chemistry/*pharmacology
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Chemoprevention
MH  - Curcumin/chemistry/*pharmacology
MH  - Drug Combinations
MH  - Drug Stability
MH  - Drug Synergism
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Isothiocyanates
MH  - Lipids/*chemistry
MH  - Nanocapsules/*chemistry
MH  - Nanoconjugates/*chemistry
MH  - Pancreatic Neoplasms/drug therapy
MH  - Particle Size
MH  - Sulfoxides
MH  - Thiocyanates/chemistry/*pharmacology
PMC - PMC3583628
EDAT- 2012/09/26 06:00
MHDA- 2013/04/23 06:00
CRDT- 2012/09/26 06:00
PHST- 2012/07/07 00:00 [received]
PHST- 2012/08/16 00:00 [accepted]
PHST- 2012/09/26 06:00 [entrez]
PHST- 2012/09/26 06:00 [pubmed]
PHST- 2013/04/23 06:00 [medline]
AID - ijo-41-06-2260 [pii]
AID - 10.3892/ijo.2012.1636 [doi]
PST - ppublish
SO  - Int J Oncol. 2012 Dec;41(6):2260-8. doi: 10.3892/ijo.2012.1636. Epub 2012 Sep 21.

PMID- 14623265
OWN - NLM
STAT- MEDLINE
DCOM- 20040209
LR  - 20190612
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 311
IP  - 4
DP  - 2003 Nov 28
TI  - Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2.
PG  - 897-903
AB  - COX-2 is involved in inflammation and ischemic cardiovascular disease. As NO 
      regulates COX activity in various cells, we investigated the effect of NO-donors 
      and the novel NO-aspirin NC-4016 on human monocyte COX-2. Whole blood was 
      incubated with LPS and PGE(2) was measured in plasma as an index of monocyte 
      COX-2 activity. Serum TxB(2) was assessed as an index of platelet COX-1 activity. 
      SNP, DetaNONOate, and NO-aspirin inhibited dose-dependently PGE(2) production 
      while aspirin was ineffective. The guanylyl-cyclase inhibitor ODQ partially 
      reversed the suppression of COX-2 activity by NO-aspirin, demonstrating a role of 
      cGMP increase. NC-4016 and aspirin inhibited platelet COX-1 comparably while 
      NO-donors were ineffective. COX-2 expression was not affected by NO-donors or 
      NO-aspirin while aspirin or the selective COX-2-inhibitor DUP697 increased it. In 
      conclusion, Nitroaspirin inhibits monocyte COX-2 activity by a cGMP-dependent 
      mechanism. This might represent an advantage over aspirin, given the possible 
      detrimental role of COX-2 in cardiovascular disease.
FAU - Corazzi, Teresa
AU  - Corazzi T
AD  - Section of Internal and Cardiovascular Medicine, Department of Internal Medicine, 
      University of Perugia, Via Enrico dal Pozzo, 06126, Perugia, Italy.
FAU - Leone, Mario
AU  - Leone M
FAU - Roberti, Rita
AU  - Roberti R
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Gresele, Paolo
AU  - Gresele P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - 0 (Nitric Oxide Donors)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cells, Cultured
MH  - Cyclooxygenase 2
MH  - Dose-Response Relationship, Drug
MH  - Enzyme Activation
MH  - Humans
MH  - Isoenzymes/blood/*chemistry/*metabolism
MH  - Membrane Proteins
MH  - Monocytes/*drug effects/*metabolism
MH  - Nitric Oxide Donors/*pharmacology
MH  - Oxidation-Reduction
MH  - Prostaglandin-Endoperoxide Synthases/blood/*chemistry/*metabolism
EDAT- 2003/11/19 05:00
MHDA- 2004/02/11 05:00
CRDT- 2003/11/19 05:00
PHST- 2003/11/19 05:00 [pubmed]
PHST- 2004/02/11 05:00 [medline]
PHST- 2003/11/19 05:00 [entrez]
AID - S0006291X03021752 [pii]
AID - 10.1016/j.bbrc.2003.10.079 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2003 Nov 28;311(4):897-903. doi: 
      10.1016/j.bbrc.2003.10.079.

PMID- 424707
OWN - NLM
STAT- MEDLINE
DCOM- 19790523
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 109
IP  - 10
DP  - 1979 Mar 10
TI  - [Action mechanism and clinical indications for thrombocyte aggregation 
      inhibitors].
PG  - 348-53
AB  - The mechanisms of action of three most commonly used antiplatelet agents 
      (aspirin, sulfinpyrazone, dipyridamole) are briefly discussed. Aspirin inhibits 
      the prostaglandin synthetase of platelets irreversibly and thereby blocks the 
      production of prostaglandin endoperoxides and thromboxane A2, which stimulate 
      platelet aggregation. A daily aspirin dose of 200--300 mg is sufficient to 
      achieve this effect. Sulfinpyrazone appears to interfere with the adhesion of 
      platelets to subendothelial structures and atherosclerotic plaques. Dipyridamole 
      increases cyclic AMP in platelets and thus reduces platelet response to 
      aggregating agents. A few of the satisfactorily performed studies on the clinical 
      effectiveness of antiplatelet agents are mentioned. Sulfinpyrazone treatment of 
      patients with myocardial infarction (Killip--classification I and II), starting 
      25--35 days after the acute myocardial infarction, reduces cardiac mortality and 
      incidence of sudden death for a period of two years. The efficacy of aspirin 
      treatment in coronary artery disease is not yet definitely established. In 
      patients with transient ischemic attacks, particularly males with appropriate 
      carotid lesions, aspirin therapy reduces the frequency of transient ischemic 
      attacks and possibly the incidence of stroke and death. Sulfinpyrazone is 
      ineffective in these patients. Sulfinpyrazone and aspirin are of value in the 
      prevention of thrombosis in straight arterio-venous shunts. Aspirin reduces the 
      frequency of deep venous thrombosis after total hip replacement in males but not 
      in females. In patients with recurrent venous thrombosis, sulfinpyrazone 
      treatment is effective in preventing thrombosis.
FAU - Oelz, O
AU  - Oelz O
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Wirkungsmechanismus und klinische Indikationen der 
      Thrombozytenaggregationshemmer.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 0 (Anticoagulants)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Anticoagulants/*pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Coronary Disease/drug therapy
MH  - Dipyridamole/administration & dosage/pharmacology
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy
MH  - Myocardial Infarction/drug therapy
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Sulfinpyrazone/administration & dosage/pharmacology
MH  - Thrombophlebitis/prevention & control
MH  - Thrombosis/prevention & control
EDAT- 1979/03/10 00:00
MHDA- 1979/03/10 00:01
CRDT- 1979/03/10 00:00
PHST- 1979/03/10 00:00 [pubmed]
PHST- 1979/03/10 00:01 [medline]
PHST- 1979/03/10 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1979 Mar 10;109(10):348-53.

PMID- 1070998
OWN - NLM
STAT- MEDLINE
DCOM- 19770321
LR  - 20131121
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 6 Suppl 1
DP  - 1976
TI  - Does aspirin play a role in analgesic nephropathy?
PG  - Suppl 1:48-53
AB  - Using a compound analgesic mixture, it was found that renal pathology could be 
      produced in rats if the analgesic mixture was administered as a concentrated 
      aqueous suspension, but that development of renal pathology was not favored by 
      hot, dry environmental conditions. Determination of whole body total salicylate 
      concentrations in rats and humans receiving various doses of aspirin revealed 
      that twice daily doses of 24, 60 and 125 mg/kg aspirin in the rat were equivalent 
      to human doses of 8, 20 and (approximately) 40 ordinary 325 mg aspirin tablets 
      daily. These doses of aspirin were then employed in a subchronic study of the 
      nephrotoxicity of aspirin in the rat using the experimental design which 
      maximized the nephrotoxic effects of the compound analgesic mixture. Six groups 
      of ten male and ten female rats received aspirin orally at doses of 24,60 or 125 
      mg/kg twice a day five days a week for 12 weeks. Two additional groups of ten 
      male and ten female rats received only the vehicle, at a volume equivalent to 
      that received by the high dose group, and served as controls. Four groups (one 
      each, control, low, mid-, and high dose) were denied access to water for 16 hours 
      daily overnight. No pathologic renal changes were observed in any of the rats. 
      These findings are consistent with a growing body of evidence, from both animal 
      and human studies, that aspirin alone does not produce analgesic nephropathy.
FAU - Phillips, B M
AU  - Phillips BM
FAU - Hartnagel, R E
AU  - Hartnagel RE
FAU - Leeling, J L
AU  - Leeling JL
FAU - Gurtoo, H L
AU  - Gurtoo HL
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 0 (Drug Combinations)
RN  - 0 (Salicylates)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*toxicity
MH  - Caffeine/toxicity
MH  - Dehydration/complications
MH  - Drug Combinations
MH  - Female
MH  - Hot Temperature
MH  - Humidity
MH  - Kidney Diseases/*chemically induced
MH  - Kidney Papillary Necrosis/etiology
MH  - Male
MH  - Phenacetin/toxicity
MH  - Rats
MH  - Salicylates/blood
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Aust N Z J Med. 1976;6 Suppl 1:Suppl 1:48-53.

PMID- 32162875
OWN - NLM
STAT- MEDLINE
DCOM- 20201216
LR  - 20201216
IS  - 1433-6510 (Print)
IS  - 1433-6510 (Linking)
VI  - 66
IP  - 3
DP  - 2020 Mar 1
TI  - D-Dimer Assay May Guide LMWH Treatment in Repeated Biochemical Pregnancy Losses 
      in Women with Positive Antiphospholipid Antibody.
LID - 10.7754/Clin.Lab.2019.190637 [doi]
AB  - BACKGROUND: Do D-dimer levels influence the pregnancy outcomes after treatment 
      with low molecular weight heparin (LMWH) in women of recurrent miscarriage (RM), 
      repeated biochemical pregnancy losses (BPL), and a positive test for 
      antiphospholipid antibodies (aPLs)? METHODS: This study was a retrospective chart 
      review of 569 RM patients who were identified as having a history of BPL and a 
      positive aPL. These patients were grouped into three groups according to their 
      treatment plan including those who received low dose aspirin (LDA) alone (group 
      A), LDA plus LMWH after ovulation therapy (group B), and LDA plus LMWH after 
      pregnancy confirmation (group C). We hypothesized that the administration of LMWH 
      after ovulation increased the rates of live birth. D-dimer may predict the 
      pregnancy outcome after treatment. RESULTS: The live birth rate of group B and 
      group C is significantly higher than group A (86.96% and 66.80% vs. 52.89%, p < 
      0.0001, respectively). The live birth rate in group A, B, and C with elevated 
      D-dimer is 36.92%, 90.52%, and 61.60% respectively. However, there is no 
      significant difference in live birth rate among those who had normal baseline 
      D-dimer. CONCLUSIONS: These results suggest that LMWH therapy is more effective 
      in improving the live birth rate when given after ovulation than after pregnancy 
      confirmation. The plasma D-dimer assay can possibly guide LMWH treatment 
      appropriately.
FAU - Bao, Shi H
AU  - Bao SH
FAU - Frempong, Sophia T
AU  - Frempong ST
FAU - Ruan, Jia L
AU  - Ruan JL
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Lab
JT  - Clinical laboratory
JID - 9705611
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (fibrin fragment D)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abortion, Habitual/drug therapy/prevention & control
MH  - Antibodies, Antiphospholipid/*blood
MH  - Antiphospholipid Syndrome/drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/*analysis
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Live Birth/epidemiology
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/drug therapy
EDAT- 2020/03/13 06:00
MHDA- 2020/12/17 06:00
CRDT- 2020/03/13 06:00
PHST- 2020/03/13 06:00 [entrez]
PHST- 2020/03/13 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
AID - 10.7754/Clin.Lab.2019.190637 [doi]
PST - ppublish
SO  - Clin Lab. 2020 Mar 1;66(3). doi: 10.7754/Clin.Lab.2019.190637.

PMID- 29131238
OWN - NLM
STAT- MEDLINE
DCOM- 20180816
LR  - 20181202
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 21
IP  - 20
DP  - 2017 Oct
TI  - The role of prasugrel in the management of acute coronary syndromes: a systematic 
      review.
PG  - 4733-4743
LID - 13658 [pii]
AB  - OBJECTIVE: Dual antiplatelet therapy (DAPT) is the treatment of choice in the 
      medical management of patients with acute coronary syndrome (ACS). The 
      combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary 
      stent reduces the rate of stent thrombosis and the rates of major adverse 
      cardiovascular events. However, patients with acute coronary syndrome remain at 
      risk of recurrent cardiovascular events despite the advance of medical therapy. 
      The limitations of clopidogrel with variable antiplatelet effects and delayed 
      onset of action are well established and lead to the development of newer P2Y12 
      inhibitors. Prasugrel is a selective adenosine diphosphate (ADP) receptor 
      antagonist indicated for use in patients with ACS. Prasugrel provides greater 
      inhibition of platelet aggregation than clopidogrel and has a rapid onset of 
      action. We have conducted a systematic review to retrieve current evidence 
      regarding the role of prasugrel in the management of ACS. Evidence comparing 
      prasugrel, clopidogrel, and ticagrelor remain scant. MATERIALS AND METHODS: A 
      complete literature survey was performed using PubMed database search to gather 
      available information regarding management of acute coronary syndromes and 
      prasugrel. An explorative comparison of the safety and efficacy of prasugrel, 
      clopidogrel, and ticagrelor was also conducted. RESULTS: Prasugrel and ticagrelor 
      are more efficacious than clopidogrel in reducing the occurrence of non-fatal 
      myocardial infarction, stroke, or cardiovascular (CV) death but they have also an 
      increased risk of major bleeding in comparison to clopidogrel. CONCLUSIONS: 
      Prasugrel and ticagrelor are today the recommended first-line agents in patients 
      with ACS. The estimation of which drug is superior over the other cannot be 
      reliably established from the current trials.
FAU - Spartalis, M
AU  - Spartalis M
AD  - Division of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece. 
      mspartalis@icloud.com.
FAU - Tzatzaki, E
AU  - Tzatzaki E
FAU - Spartalis, E
AU  - Spartalis E
FAU - Damaskos, C
AU  - Damaskos C
FAU - Athanasiou, A
AU  - Athanasiou A
FAU - Moris, D
AU  - Moris D
FAU - Politou, M
AU  - Politou M
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/pathology
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prasugrel Hydrochloride/adverse effects/*therapeutic use
MH  - Thrombosis/therapy
MH  - Ticlopidine/analogs & derivatives/therapeutic use
EDAT- 2017/11/14 06:00
MHDA- 2018/08/17 06:00
CRDT- 2017/11/14 06:00
PHST- 2017/11/14 06:00 [entrez]
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2018/08/17 06:00 [medline]
AID - 13658 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4733-4743.

PMID- 19666941
OWN - NLM
STAT- MEDLINE
DCOM- 20100202
LR  - 20151119
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 15
IP  - 6
DP  - 2009 Dec
TI  - Use of heparin in women with early and late miscarriages with and without 
      thrombophilia.
PG  - 636-44
LID - 10.1177/1076029609335501 [doi]
AB  - OBJECTIVE: In women with a history of recurrent miscarriage, the risk of 
      miscarriage in a subsequent pregnancy is about 30% to 40%. In patients with 
      thrombophilia, the risk is even higher. Placental thrombosis has been found in 
      women with unexplained recurrent miscarriage independent of thrombophilia. In 
      addition, proinflammatory changes, for example, altered Th1 to Th2 cytokine ratio 
      and complement activation, have been repeatedly demonstrated in these women. 
      Because of the fact that heparin has both anticoagulative and anti-inflammatory 
      effects, the current study evaluated the efficacy of low-molecular-weight heparin 
      (LMWH) in unexplained abortions. STUDY DESIGN: A total of 164 women with 
      unexplained early and late miscarriages presented in our hemostaseological clinic 
      for thrombophilia screening. For these 164 women, 82 subsequent pregnancies in 79 
      patients were treated with subcutaneous LMWH independently of thrombophilia. In 
      54/82 unselected pregnancies, 100 mg aspirin was administered in addition to 
      LMWH. Two patients were excluded due to termination of pregnancy. RESULTS: 
      Overall, 83.8% (67/80) of pregnancies resulted in live births. In 22/79 women 
      (27.8%), thrombophilia markers were positive. Most noteworthy, patients with 
      thrombophilia markers had live births at a similar frequency as patients without 
      those parameters. No severe side effects of LMWH were seen. CONCLUSIONS: Our data 
      support the notion that LMWH is efficacious in patients with recurrent abortions 
      and thrombophilia. We demonstrated the same effect of LMWH in women with 
      unexplained abortions without thrombophilia. The potential mechanism of action of 
      LMWH in early and late abortions warrants further study.
FAU - Monien, Silke
AU  - Monien S
AD  - Department of Hemostaseology, Institute of Transfusion Medicine, Charité 
      University Hospital Berlin, Berlin, Germany. silke.monien@charite.de
FAU - Kadecki, Oliver
AU  - Kadecki O
FAU - Baumgarten, Susanne
AU  - Baumgarten S
FAU - Salama, Abdulgabar
AU  - Salama A
FAU - Dörner, Thomas
AU  - Dörner T
FAU - Kiesewetter, Holger
AU  - Kiesewetter H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20090809
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Biomarkers)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Abortion, Habitual/drug therapy/etiology/*prevention & control
MH  - Adult
MH  - Age Factors
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Biomarkers
MH  - Case-Control Studies
MH  - Dalteparin/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Live Birth
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Thrombophilia/*complications
MH  - Young Adult
EDAT- 2009/08/12 09:00
MHDA- 2010/02/03 06:00
CRDT- 2009/08/12 09:00
PHST- 2009/08/12 09:00 [entrez]
PHST- 2009/08/12 09:00 [pubmed]
PHST- 2010/02/03 06:00 [medline]
AID - 1076029609335501 [pii]
AID - 10.1177/1076029609335501 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2009 Dec;15(6):636-44. doi: 10.1177/1076029609335501. 
      Epub 2009 Aug 9.

PMID- 21821226
OWN - NLM
STAT- MEDLINE
DCOM- 20111129
LR  - 20181201
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 108
IP  - 8
DP  - 2011 Oct 15
TI  - Clinical and prognostic implications of the initial response to aspirin in 
      patients with acute coronary syndrome.
PG  - 1112-8
LID - 10.1016/j.amjcard.2011.06.013 [doi]
AB  - Increased platelet reactivity and decreased response to antiplatelet drugs may 
      result in recurrent ischemic events after acute coronary syndrome (ACS). We 
      evaluated laboratory response to aspirin in patients with ACS before and after 
      percutaneous coronary intervention (PCI) and assessed its effect on major adverse 
      clinical events. Sixty-three consecutive patients with ACS were tested for 
      response to aspirin by light transmittance aggregometry (LTA) and the IMPACT-R 
      test (with arachidonic acid) before and 2 to 4 days after PCI and clopidogrel 
      loading. Patients were followed for clinical events up to 15 months from PCI. 
      Response to aspirin improved significantly after PCI and clopidogrel treatment 
      (mean arachidonic acid-induced LTA decreased from 34.9 ± 3.35% before PCI to 15.2 
      ± 2.2% and surface coverage increased from 2.2 ± 0.27% to 6.2 ± 0.6%, p <0.0001 
      for the 2 methods). Improved response to aspirin after PCI correlated with 
      response to clopidogrel (LTA and IMPACT-R, p <0.01). Patients with good 
      laboratory response to aspirin before but not after PCI had a significantly lower 
      major cardiovascular event rate during 15-month follow-up in multivariate 
      analysis. In conclusion, laboratory response to aspirin is highly dynamic in 
      patients with ACS. Improved response to aspirin after PCI may result from 
      stabilization of coronary artery disease and/or clopidogrel treatment. Laboratory 
      response to aspirin before PCI and clopidogrel loading is a sensitive marker for 
      platelet reactivity that correlates with clinical outcome in patients with ACS.
CI  - Copyright © 2011 Elsevier Inc. All rights reserved.
FAU - Spectre, Galia
AU  - Spectre G
AD  - Hematology Department and Coagulation Unit, Hadassah Hebrew University Medical 
      Center, Jerusalem, Israel. galias@hadassah.org.il
FAU - Mosseri, Morris
AU  - Mosseri M
FAU - Abdelrahman, Nader M
AU  - Abdelrahman NM
FAU - Briskin, Elinor
AU  - Briskin E
FAU - Bulut, Atilla
AU  - Bulut A
FAU - Loncar, Sasa
AU  - Loncar S
FAU - Varon, David
AU  - Varon D
FAU - Alcalai, Ronny
AU  - Alcalai R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110806
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/blood/*drug therapy/physiopathology
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Electrocardiography/*drug effects
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Prospective Studies
MH  - Ticlopidine/analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2011/08/09 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/08/09 06:00
PHST- 2011/04/05 00:00 [received]
PHST- 2011/06/06 00:00 [revised]
PHST- 2011/06/06 00:00 [accepted]
PHST- 2011/08/09 06:00 [entrez]
PHST- 2011/08/09 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - S0002-9149(11)02002-9 [pii]
AID - 10.1016/j.amjcard.2011.06.013 [doi]
PST - ppublish
SO  - Am J Cardiol. 2011 Oct 15;108(8):1112-8. doi: 10.1016/j.amjcard.2011.06.013. Epub 
      2011 Aug 6.

PMID- 6220767
OWN - NLM
STAT- MEDLINE
DCOM- 19830610
LR  - 20131121
IS  - 0037-9026 (Print)
IS  - 0037-9026 (Linking)
VI  - 176
IP  - 5
DP  - 1982
TI  - [Effect of flurbiprofen and acetylsalicylic acid on the ultrastructure of blood 
      platelets].
PG  - 650-5
AB  - Flurbiprofene or acetylsalicylic acid did not change the structure of inactivated 
      platelets. With flurbiprofene 50% aggregation inhibition was obtained at 10(-6) 
      to 10(-5) M concentrations. To obtain the same result with acetylsalicylic acid, 
      10(-4) to 10(-3) M concentrations were necessary. With both agents, shape change 
      was inhibited. The platelets in the small aggregates did not have the normal 
      stretched dumb-bell shape but remained globulous and emitted a broad pseudopode 
      containing normally-repolymerized microtubules.
FAU - Le Menn, R
AU  - Le Menn R
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Effet du flurbiprofène et de l'acide acétylsalicylique sur l'ultrastructure des 
      plaquettes sanguines.
PL  - France
TA  - C R Seances Soc Biol Fil
JT  - Comptes rendus des seances de la Societe de biologie et de ses filiales
JID - 7505439
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/*ultrastructure
MH  - Flurbiprofen/*pharmacology
MH  - Humans
MH  - Microscopy, Electron
MH  - Propionates/*pharmacology
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - C R Seances Soc Biol Fil. 1982;176(5):650-5.

PMID- 19662979
OWN - NLM
STAT- MEDLINE
DCOM- 20100401
LR  - 20131121
IS  - 1002-1892 (Print)
IS  - 1002-1892 (Linking)
VI  - 23
IP  - 7
DP  - 2009 Jul
TI  - [Hidden blood loss after lumbar spinal stenosis operation].
PG  - 797-9
AB  - OBJECTIVE: To determine the total blood loss and hidden blood loss associated 
      with surgery for lumbar spinal stenosis and to identify risk factors for blood 
      loss. METHODS: From September 2002 to July 2006, the clinical data from 138 
      patients with lumbar spinal stenosis undergoing initial operation were analysed 
      prospectively. There were 44 males and 94 females, aging 56-78 years (mean 66.7 
      years). A simple posterior lumbar spinal decompression was used in 26 cases; 
      posterior spinal canal decompression, interbody distraction Cage, and bone graft 
      between transverse process was used in 54 cases; pedicle screw fixation, 
      posterior decompression and bone graft between transverse process was used in 32 
      cases; posterior decompression, pedicle screw fixation, interbody Cage, and graft 
      between transverse process was used in 26 cases. Before operation, 23 patients 
      took aspirin, and after operation 15 patients had gastrointestinal bleeding. 
      Intraoperative blood loss was calculated by the aspirator and observed blood loss 
      intraoperation. The whole estimated blood loss was calculated according to the 
      level of hemoglobin, blood volume and blood transfusion at the time of admission 
      and after 3 and 4 days of operation. RESULTS: The blood loss intraoperation was 
      (485.51 +/- 143.75) mL. The estimated blood loss was (1218.60 +/- 306.86) mL, 
      which was significantly higher than the intraoperational blood loss (P < 0.001). 
      There was significant difference between the estimated blood loss and observed 
      blood loss during surgeries (P < 0.001). There were significant differences in 
      the estimated blood loss and observed blood loss during surgery between patients 
      treated with aspirin and without aspirin (P < 0.001), between patients with 
      gastrointestinal bleeding and whiout gastrointestinal bleeding (P < 0.001). 
      CONCLUSION: The total blood loss after surgery for lumbar spinal stenosis is much 
      greater than that of observed intra-operation. The type of surgery, treatment 
      with aspirin and gastrointestinal bleeding or ulceration can all independently 
      increase blood loss.
FAU - Ju, Hongbin
AU  - Ju H
AD  - Department of Spine Surgery, Guangzhou 1st Municipal People Hospital, Affiliated 
      Guangzhou Medical College, Guangzhou Guangdong, 510180, P.R. China. 
      bin7810@126.com
FAU - Guo, Dongming
AU  - Guo D
FAU - Cai, Weishan
AU  - Cai W
FAU - Liu, Enzhi
AU  - Liu E
FAU - Zhong, Bofu
AU  - Zhong B
FAU - Yan, Han
AU  - Yan H
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
JT  - Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = 
      Chinese journal of reparative and reconstructive surgery
JID - 9425194
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects
MH  - *Blood Loss, Surgical
MH  - Female
MH  - Humans
MH  - *Lumbar Vertebrae
MH  - Male
MH  - Middle Aged
MH  - Postoperative Hemorrhage/*etiology
MH  - Prospective Studies
MH  - Spinal Stenosis/*surgery
EDAT- 2009/08/11 09:00
MHDA- 2010/04/02 06:00
CRDT- 2009/08/11 09:00
PHST- 2009/08/11 09:00 [entrez]
PHST- 2009/08/11 09:00 [pubmed]
PHST- 2010/04/02 06:00 [medline]
PST - ppublish
SO  - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009 Jul;23(7):797-9.

PMID- 12564293
OWN - NLM
STAT- MEDLINE
DCOM- 20030410
LR  - 20131121
IS  - 0028-2162 (Print)
IS  - 0028-2162 (Linking)
VI  - 147
IP  - 1
DP  - 2003 Jan 4
TI  - [Withdrawing the use of acetylsalicyclic acid prior to an operation usually not 
      necessary].
PG  - 21-5
AB  - Acetylsalicylic acid (aspirin) induces an irreversible inactivation of 
      cyclo-oxygenase in blood platelets which lasts for the entire period that the 
      platelets remain in the circulatory system, 7 to 10 days. In order to prevent 
      excessive bleeding, patients presenting for surgery are asked to stop using 
      aspirin 10 days before the procedure. Some studies have found that aspirin causes 
      increased peri-operative blood loss, whilst other studies have found that it does 
      not. All effect studies found in Medline (January 1966-May 2002) on surgery and 
      bleeding complications due to aspirin were analysed. The studies available were 
      assessed for methodological quality and the results were summarised in an 
      evidence table. No clinically relevant bleeding complications were reported for 
      cardiovascular, vascular and orthopaedic surgery and epidural anaesthesia. Most 
      studies reported an increase in clinically non-relevant bleeding induced by 
      aspirin. The literature contains too little information on cataract surgery, 
      dermatological surgery, gynaecological and abdominal surgery, ENT and dental 
      surgery, urological surgery, lung biopsy and endoscopic biopsy. In those types of 
      surgery in which even a minor bleeding leads to severe complications, e.g. 
      neurosurgery, aspirin should be withdrawn 5-10 days in advance. Also in patients 
      with coagulation disorders, aspirin should be withdrawn prior to the operation. 
      There is no scientific evidence for the withdrawal of aspirin in all patients, 
      5-10 days prior to surgery. Indeed for heart patients in particular, the 
      continued use of aspirin is recommended.
FAU - Fijnheer, R
AU  - Fijnheer R
AD  - Universitair Medisch Centrum, afd. Hematologie, Heidelberglaan 100, 3584 CX 
      Utrecht. r.fijnheer@azu.nl
FAU - Urbanus, R T
AU  - Urbanus RT
FAU - Nieuwenhuis, H K
AU  - Nieuwenhuis HK
LA  - dut
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Staken van gebruik van acetylsalicylzuur vóór een operatie meestal niet nodig.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ned Tijdschr Geneeskd. 2003 Mar 8;147(10):469; author reply 469. PMID: 12666521
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Loss, Surgical/*prevention & control
MH  - Cyclooxygenase Inhibitors/administration & dosage/*adverse effects
MH  - Humans
MH  - Incidence
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk Assessment
RF  - 38
EDAT- 2003/02/05 04:00
MHDA- 2003/04/11 05:00
CRDT- 2003/02/05 04:00
PHST- 2003/02/05 04:00 [pubmed]
PHST- 2003/04/11 05:00 [medline]
PHST- 2003/02/05 04:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2003 Jan 4;147(1):21-5.

PMID- 28004997
OWN - NLM
STAT- MEDLINE
DCOM- 20180501
LR  - 20180501
IS  - 2146-8427 (Electronic)
IS  - 1304-0855 (Linking)
VI  - 15
IP  - 4
DP  - 2017 Aug
TI  - Effect of Long-Term, Low-Dose Aspirin Therapy on Renal Graft Function.
PG  - 400-404
LID - 10.6002/ect.2016.0139 [doi]
AB  - OBJECTIVES: Despite improvements in immunosuppressive protocols for renal 
      transplant, long-term success of renal transplant is still limited by the 
      occurrence of interstitial fibrosis and tubular atrophy. Some studies have shown 
      that aspirin decreases the severity of kidney ischemia-reperfusion injury and the 
      development of tubular atrophy in animal models. This study aimed to assess the 
      effects of aspirin therapy started at the time of transplant on long-term graft 
      function. MATERIALS AND METHODS: We compared renal graft function of 82 patients 
      on low-dose aspirin 75 mg once daily who underwent renal transplant between 1 
      January 2000 and 31 December 2010 from a single center with 65 patients not 
      taking aspirin. For each patient, the following measurements were collected: age, 
      sex, creatinine level, type of donor, cold ischemia time, occurrence of acute 
      allograft rejections, number of HLA mismatches, first transplant, intake of 
      statins, number of antihypertensive medications, and number of days 
      posttransplant. Patients were excluded from the study who were on aspirin before 
      transplant or who had coronary artery disease. RESULTS: Multilevel modelling was 
      used to compare renal allograft function, as measured by serum creatinine levels, 
      between patients taking and not taking aspirin after kidney transplant. Aspirin 
      was not significantly associated with creatinine levels (P = .59) after adjusting 
      for other relevant variables. CONCLUSIONS: Low-dose aspirin started at the time 
      of transplant has a negligible effect on renal allograft function over the 
      15-year study period posttransplant.
FAU - Ali, Hatem
AU  - Ali H
AD  - From the Renal Department, Royal Preston Hospital, Lancashire Teaching Hospitals 
      NHS Foundation Trust, Preston, United Kingdom.
FAU - Shaaban, Ahmed
AU  - Shaaban A
FAU - Murtaza, Asam
AU  - Murtaza A
FAU - Howell, Laura E
AU  - Howell LE
FAU - Ahmed, Aimun
AU  - Ahmed A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20161222
PL  - Turkey
TA  - Exp Clin Transplant
JT  - Experimental and clinical transplantation : official journal of the Middle East 
      Society for Organ Transplantation
JID - 101207333
RN  - 0 (Biomarkers)
RN  - 0 (Cardiovascular Agents)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Biomarkers/blood
MH  - Cardiovascular Agents/*administration & dosage/adverse effects
MH  - Creatinine/blood
MH  - Female
MH  - Humans
MH  - Kidney/*drug effects/physiopathology/*surgery
MH  - Kidney Transplantation/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2016/12/23 06:00
MHDA- 2018/05/02 06:00
CRDT- 2016/12/23 06:00
PHST- 2016/12/23 06:00 [pubmed]
PHST- 2018/05/02 06:00 [medline]
PHST- 2016/12/23 06:00 [entrez]
AID - 10.6002/ect.2016.0139 [doi]
PST - ppublish
SO  - Exp Clin Transplant. 2017 Aug;15(4):400-404. doi: 10.6002/ect.2016.0139. Epub 
      2016 Dec 22.

PMID- 3664553
OWN - NLM
STAT- MEDLINE
DCOM- 19871217
LR  - 20201209
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 9
IP  - 5
DP  - 1987
TI  - Comparison of diflunisal and an aspirin-codeine combination in the management of 
      patients having one-visit endodontic therapy.
PG  - 500-11
AB  - One hundred seventy-nine patients with asymptomatic or mildly symptomatic 
      endodontic disease had single-visit therapy and were given either diflunisal (n = 
      94) or aspirin with codeine (n = 85) to control posttreatment pain. In this 
      open-label, randomized study, diflunisal was judged superior to the 
      aspirin-codeine combination in all major categories evaluated. Of patients 
      receiving diflunisal, 93.6% needed the medication for only one day. In contrast, 
      77.7% of patients receiving aspirin with codeine needed the medication for only 
      one day. Almost 64% of patients receiving diflunisal needed only one dose, while 
      32.9% of patients using aspirin with codeine needed only one dose. Four or more 
      doses were required by 5.3% of patients receiving diflunisal and by 23.5% of 
      patients receiving the aspirin-codeine combination. In patients receiving 
      diflunisal, 20.2% experienced side effects. In contrast, 29.4% of patients 
      receiving aspirin with codeine reported side effects. Thirty-five percent of 
      patients receiving diflunisal rated the analgesic as excellent; 5.3% rated it as 
      fair or poor. In contrast, 12.9% of patients receiving aspirin with codeine rated 
      the analgesic combination as excellent; another 12.9% rated it as fair or poor. 
      Diflunisal was found to be generally effective and well-tolerated, and superior 
      to aspirin with codeine in the management of pain from endodontic treatment.
FAU - Morse, D R
AU  - Morse DR
AD  - Department of Endodontology, Temple University School of Dentistry, Philadelphia, 
      Pennsylvania.
FAU - Furst, M L
AU  - Furst ML
FAU - Koren, L Z
AU  - Koren LZ
FAU - Bolanos, O R
AU  - Bolanos OR
FAU - Esposito, J V
AU  - Esposito JV
FAU - Yesilsoy, C
AU  - Yesilsoy C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Drug Combinations)
RN  - 0 (Salicylates)
RN  - 7C546U4DEN (Diflunisal)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Codeine/adverse effects/*therapeutic use
MH  - Diflunisal/adverse effects/*therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Prospective Studies
MH  - Random Allocation
MH  - *Root Canal Therapy
MH  - Salicylates/*therapeutic use
MH  - Time Factors
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1987;9(5):500-11.

PMID- 11927685
OWN - NLM
STAT- MEDLINE
DCOM- 20020923
LR  - 20190513
IS  - 0022-3751 (Print)
IS  - 1469-7793 (Electronic)
IS  - 0022-3751 (Linking)
VI  - 540
IP  - Pt 1
DP  - 2002 Apr 1
TI  - Vasodilatation in response to repeated anodal current application in the human 
      skin relies on aspirin-sensitive mechanisms.
PG  - 261-9
AB  - The vasodilatation resulting from prolonged square-wave monopolar current 
      application as used in iontophoresis is assumed to rely on an axon reflex. 
      Involvement of prostaglandins in the anodal current-induced vasodilatation 
      remains unclear. We tested the hypothesis that prostaglandins participate in a 
      sensitisation mechanism to current application rather than as direct 
      vasodilators. In healthy volunteers, laser Doppler flowmetry (LDF) was recorded 
      in the forearm during and following isolated or repeated 0.1 mA transcutaneous 
      anodal current applications, using deionised water as a vehicle. Segmented 
      current applications of 6 or 12 mC resulted in an LDF increase twice that 
      observed following current applications of comparable total charge delivered all 
      at once (P < 0.05). Following a 1 min anodal application, a slow and prolonged 
      LDF drift occurred (slope: 0.3 +/- 0.5 arbitrary units min(-1)). When the same 
      current application was repeated after intervals of 5 and 20 min, an abrupt 
      vasodilatation occurred, with maximal LDF amplitude of 53.5 +/- 34.0 and 48.2 +/- 
      19.1 arbitrary units, respectively. Pretreatment with 1 g oral aspirin abolished 
      the abrupt vasodilatation to repeated current application but not the initial 
      slow drift. We suggest that vasodilatation occurs through two parallel pathways: 
      (1) a slow progressive drift of LDF of limited amplitude insensitive to aspirin 
      pretreatment, and (2) an abrupt vasodilatation probably resulting from afferent 
      fibre activation, appearing if a preliminary sensitisation by current application 
      is performed. Sensitisation lasts for at least 20 min, and is blocked by aspirin, 
      suggesting participation of prostanoids.
FAU - Durand, S
AU  - Durand S
AD  - Laboratoire de Physiologie et Explorations Vasculaires, Centre hospitalier 
      universitaire, 49033 Angers cedex, France.
FAU - Fromy, B
AU  - Fromy B
FAU - Bouyé, Ph
AU  - Bouyé P
FAU - Saumet, J L
AU  - Saumet JL
FAU - Abraham, P
AU  - Abraham P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Physiol
JT  - The Journal of physiology
JID - 0266262
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Electric Stimulation
MH  - Humans
MH  - Laser-Doppler Flowmetry
MH  - Prostaglandins/physiology
MH  - Skin/*blood supply
MH  - Vasodilation/drug effects/*physiology
PMC - PMC2290218
EDAT- 2002/04/03 10:00
MHDA- 2002/09/24 06:00
CRDT- 2002/04/03 10:00
PHST- 2002/04/03 10:00 [pubmed]
PHST- 2002/09/24 06:00 [medline]
PHST- 2002/04/03 10:00 [entrez]
AID - PHY_13364 [pii]
AID - 10.1113/jphysiol.2001.013364 [doi]
PST - ppublish
SO  - J Physiol. 2002 Apr 1;540(Pt 1):261-9. doi: 10.1113/jphysiol.2001.013364.

PMID- 12211496
OWN - NLM
STAT- MEDLINE
DCOM- 20021120
LR  - 20220311
IS  - 0022-3492 (Print)
IS  - 0022-3492 (Linking)
VI  - 73
IP  - 8
DP  - 2002 Aug
TI  - The effect of aspirin on the periodontal parameter bleeding on probing.
PG  - 871-6
AB  - BACKGROUND: The absence or presence of bleeding on probing (BOP) is a sign of 
      periodontal health or disease, but the presence of BOP is not an accurate 
      predictor of disease progression. Aspirin is increasingly used in the prevention 
      of cerebrovascular and cardiovascular diseases and is a non-disease factor that 
      may modify bleeding indices given its antithrombolytic activity. The purpose of 
      this double-blind placebo-controlled randomized clinical trial was to study the 
      effect of short-term daily aspirin ingestion on the clinical parameter BOP. 
      METHODS: A total of 46 periodontally healthy subjects were included in this 
      study: 16 received placebo, 15 low-dose aspirin (81 mg), and 15 regular dose (325 
      mg) aspirin. Clinical parameters assessed included plaque index, periodontal 
      probing depth, and BOP using an automated pressure-sensitive probe. Measurements 
      were recorded before and after 7-day exposure to placebo and aspirin regimens. 
      RESULTS: A statistically significant difference in BOP was found in patients with 
      > or = 20% of bleeding sites during the visit prior to placebo or aspirin 
      exposure (n = 11). The group treated with 325 mg aspirin exhibited a moderate yet 
      statistically significant increase in BOP (12.4%) compared to the placebo group 
      (there was no significant difference between the 81 mg aspirin group and 
      placebo). The tendency to bleed was not statistically significant in the group 
      which exhibited <20% (n = 35) of bleeding sites during the visit prior to 
      exposure. CONCLUSION: Aspirin intake of 325 mg daily for 7 days moderately 
      increased the appearance of bleeding on probing in a population that had > or = 
      20% BOP sites.
FAU - Schrodi, Janet
AU  - Schrodi J
AD  - Departments of Pediatric Dentistry and Orthodontics, UCLA School of Dentistry, 
      Los Angeles, CA, USA.
FAU - Recio, Luisa
AU  - Recio L
FAU - Fiorellini, Joseph
AU  - Fiorellini J
FAU - Howell, Howard
AU  - Howell H
FAU - Goodson, Max
AU  - Goodson M
FAU - Karimbux, Nadeem
AU  - Karimbux N
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Periodontol
JT  - Journal of periodontology
JID - 8000345
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dental Plaque Index
MH  - Disease Progression
MH  - Double-Blind Method
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*pharmacology
MH  - Follow-Up Studies
MH  - Forecasting
MH  - Gingival Hemorrhage/classification/*physiopathology
MH  - Humans
MH  - Linear Models
MH  - Male
MH  - Matched-Pair Analysis
MH  - Multivariate Analysis
MH  - *Periodontal Index
MH  - Periodontal Pocket/classification/physiopathology
MH  - Placebos
EDAT- 2002/09/05 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/09/05 10:00
PHST- 2002/09/05 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/09/05 10:00 [entrez]
AID - 10.1902/jop.2002.73.8.871 [doi]
PST - ppublish
SO  - J Periodontol. 2002 Aug;73(8):871-6. doi: 10.1902/jop.2002.73.8.871.

PMID- 11558397
OWN - NLM
STAT- MEDLINE
DCOM- 20020212
LR  - 20151119
IS  - 0002-5151 (Print)
IS  - 0002-5151 (Linking)
VI  - 47
IP  - 6
DP  - 2000 Nov-Dec
TI  - [Respiratory function tests in aspirin-induced asthma].
PG  - 197-203
AB  - INTRODUCTION: Aspirin induced Asthma (AIA) is a syndrome, with typical clinical 
      features. Aspirin and Nsaids induced Asthma is its distinctive characteristic. 
      OBJECTIVE: Was to determine challenge and bronchodilator test usefulness, as well 
      as its complications, in patients with Aspirin induced Asthma. MATERIAL AND 
      METHODS: Prospective, open, transversal and comparative study of 20 patients 
      divided in two groups of ten people each one group with an Aspirin induced Asthma 
      antecedent, undertook a challenge and bronchodilator test, and the second group 
      was composed of patients with extrinsic asthma which were exposed to a challenge 
      test. All patients had a physical exam and laboratory test, besides paranasal and 
      chest X-ray, allergic skin test and spirometry. Criteria used to make diagnosis 
      of AIA were defined as a 15% decrease of FEV-1 in the both groups. Laboratory and 
      other paraclinic studies were made in order to assess diagnosis and/or 
      complications. RESULTS: In the first group it was observed a 15% statistically 
      significant decrease of FEV-1 and FEF 25-75 values (p < 0.05), on second group an 
      statistically significant increase in FEV-1 values of more than 15% was observed 
      in 7 patients (p < 0.05). In the control group no statistically significative 
      changes were observed in the patients. The more frequent complications after 
      challenge test were wheeze, dyspnea, cough and severe bronchospasm. Zero 
      defunctions were reported. CONCLUSION: The minimum dose to realize the diagnosis 
      of AIA are 100 mg of aspirin. The FEV-1 decrease depend of dose of aspirin in 
      patients with AIA. Patients with extrinsic asthma without an aspirin intolerance 
      history, have non adverse effects with aspirin ingestion. Severe bronchospasm was 
      the most severe complication in patients who underwent Aspirin challenge test who 
      had an idiosyncrasy history.
FAU - Machado Carrillo, F
AU  - Machado Carrillo F
AD  - Hospital Regional Lic. Adolfo López Mateos, ISSSTE Av. Universidad 1321-Colonia 
      Florida 01039 México, DF.
FAU - Orea Solano, M
AU  - Orea Solano M
FAU - Gómez Vera, J
AU  - Gómez Vera J
FAU - Flores, G
AU  - Flores G
LA  - spa
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Pruebas de función respiratoria en asma inducida por aspirina.
PL  - Mexico
TA  - Rev Alerg Mex
JT  - Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
JID - 9438824
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - *Aspirin/administration & dosage/adverse effects
MH  - Asthma/*chemically induced/*diagnosis/physiopathology
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Middle Aged
MH  - Prospective Studies
MH  - Respiratory Function Tests
MH  - Sensitivity and Specificity
EDAT- 2001/09/18 10:00
MHDA- 2002/02/13 10:01
CRDT- 2001/09/18 10:00
PHST- 2001/09/18 10:00 [pubmed]
PHST- 2002/02/13 10:01 [medline]
PHST- 2001/09/18 10:00 [entrez]
PST - ppublish
SO  - Rev Alerg Mex. 2000 Nov-Dec;47(6):197-203.

PMID- 17937086
OWN - NLM
STAT- MEDLINE
DCOM- 20071211
LR  - 20200923
IS  - 0390-6663 (Print)
IS  - 0390-6663 (Linking)
VI  - 34
IP  - 3
DP  - 2007
TI  - Safety and effectiveness of tinzaparin sodium in the management of recurrent 
      pregnancy loss.
PG  - 143-5
AB  - PURPOSE: To assess the safety and efficacy of tinzaparin sodium for the 
      management of recurrent pregnancy loss. METHODS: The study included 62 women with 
      a history of recurrent pregnancy loss and at least one factor of thrombophilic 
      disorder. Of these, 31 received 50 IU/kg of tinzaparin sodium daily (Group A), 
      and 33 received 100 mg of aspirin daily (Group B). RESULTS: Group A subjects 
      (receiving tinzaparin sodium) had six new abortions, whereas Group B subjects 
      (receiving aspirin) had 11 (significant difference). Cases of intrauterine growth 
      restriction (none in Group A and 2 in Group B), placental abruption (one in Group 
      A and 4 in Group B), and preeclampsia (one in Group A and 3 in Group B) were 
      comparable between the two groups. Finally coagulation disorders (none in Group A 
      and 6 in Group B) were significantly fewer in Group A. CONCLUSION: A 50 IU/kg 
      daily dose of tinzaparin sodium seems to be effective for the management of 
      recurrent abortion and has high standards of safety.
FAU - Dendrinos, S
AU  - Dendrinos S
AD  - 2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieion 
      Hospital, Athens, Greece.
FAU - Kalogirou, I
AU  - Kalogirou I
FAU - Makrakis, E
AU  - Makrakis E
FAU - Theodoridis, T
AU  - Theodoridis T
FAU - Mahmound, E A
AU  - Mahmound EA
FAU - Christopoulou-Cokkinou, V
AU  - Christopoulou-Cokkinou V
FAU - Creatsas, G
AU  - Creatsas G
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Singapore
TA  - Clin Exp Obstet Gynecol
JT  - Clinical and experimental obstetrics & gynecology
JID - 7802110
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 7UQ7X4Y489 (Tinzaparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*drug therapy
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Thrombophilia/drug therapy
MH  - Tinzaparin
EDAT- 2007/10/17 09:00
MHDA- 2007/12/12 09:00
CRDT- 2007/10/17 09:00
PHST- 2007/10/17 09:00 [pubmed]
PHST- 2007/12/12 09:00 [medline]
PHST- 2007/10/17 09:00 [entrez]
PST - ppublish
SO  - Clin Exp Obstet Gynecol. 2007;34(3):143-5.

PMID- 1741362
OWN - NLM
STAT- MEDLINE
DCOM- 19920325
LR  - 20190713
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 91
IP  - 3
DP  - 1992 Feb 15
TI  - Coronary artery disease. The latest on prevention.
PG  - 179-85
AB  - Because coronary artery disease is the most common cause of death in the United 
      States, much effort is being focused on research into prevention of this killer. 
      Dr. Lush reviews positive and negative aspects of recent trends and summarizes 
      the results of studies on the prophylactic potential of maintenance of normal 
      body weight, exercise, aspirin, fish oils, estrogens, and antioxidants.
FAU - Lush, D T
AU  - Lush DT
AD  - Division of General Medicine, Medical College of Pennsylvania, Philadelphia 
      19129.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Antioxidants)
RN  - 0 (Estrogens)
RN  - 0 (Fish Oils)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antioxidants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Body Weight
MH  - Coronary Disease/*prevention & control
MH  - Estrogens/therapeutic use
MH  - Exercise
MH  - Fish Oils/pharmacology
MH  - Humans
RF  - 19
EDAT- 1992/02/15 00:00
MHDA- 1992/02/15 00:01
CRDT- 1992/02/15 00:00
PHST- 1992/02/15 00:00 [pubmed]
PHST- 1992/02/15 00:01 [medline]
PHST- 1992/02/15 00:00 [entrez]
AID - 10.1080/00325481.1992.11701234 [doi]
PST - ppublish
SO  - Postgrad Med. 1992 Feb 15;91(3):179-85. doi: 10.1080/00325481.1992.11701234.

PMID- 9624789
OWN - NLM
STAT- MEDLINE
DCOM- 19980707
LR  - 20181201
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 52
IP  - 2
DP  - 1998 Mar
TI  - Antiplatelet drugs in secondary prevention of stroke.
PG  - 91-7
AB  - Stroke is a leading cause of long-term disability and death in developed 
      countries. The primary medical strategy for secondary prevention of stroke is 
      antiplatelet therapy. Although the clinical value of acetylsalicylic acid (ASA) 
      is well recognised for preventing secondary stroke, several questions remain. 
      What is the optimal dose of ASA to prevent stroke? Would combining ASA with 
      another antiplatelet drug increase efficacy? Do new agents currently under 
      development offer additional benefits? Many of the recent clinical trials address 
      these questions. This review article summarises the results of these trials in 
      the context of evolving strategies for stroke prevention, including the 
      management of recurrent transient ischaemic attacks (TIAs), side-effects of ASA, 
      and economic issues.
FAU - Diener, H C
AU  - Diener HC
AD  - Department of Neurology, University of Essen, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Clopidogrel
MH  - Dipyridamole/administration & dosage
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ischemic Attack, Transient/complications
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Ticlopidine/administration & dosage/analogs & derivatives
RF  - 36
EDAT- 1998/06/13 00:00
MHDA- 1998/06/13 00:01
CRDT- 1998/06/13 00:00
PHST- 1998/06/13 00:00 [pubmed]
PHST- 1998/06/13 00:01 [medline]
PHST- 1998/06/13 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pract. 1998 Mar;52(2):91-7.

PMID- 7264891
OWN - NLM
STAT- MEDLINE
DCOM- 19811029
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 3
DP  - 1981 Mar
TI  - Crystal structure and solid-state behavior of aspirin anhydride crystals.
PG  - 280-3
AB  - The crystal structure and solid-state behavior of aspirin anhydride were 
      determined using single-crystal X-ray techniques and microscopic examination of 
      the reacting crystals. The crystal structure and solid-state conformation of 
      aspirin anhydride were similar to those of related compounds. The crystal packing 
      of aspirin anhydride allows the initial product of the solid-state reaction to be 
      predicted; however, this prediction could not be tested because the thermal 
      degradation products reported in the literature appear to be those obtained from 
      reaction in a liquid state.
FAU - Byrn, S R
AU  - Byrn SR
FAU - Siew, P Y
AU  - Siew PY
LA  - eng
GR  - GM-21174/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Anhydrides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anhydrides
MH  - *Aspirin
MH  - Crystallization
MH  - Crystallography
MH  - Drug Stability
MH  - Molecular Conformation
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
AID - S0022-3549(15)43631-7 [pii]
AID - 10.1002/jps.2600700314 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Mar;70(3):280-3. doi: 10.1002/jps.2600700314.

PMID- 1657506
OWN - NLM
STAT- MEDLINE
DCOM- 19911223
LR  - 20190819
IS  - 0143-5221 (Print)
IS  - 0143-5221 (Linking)
VI  - 81
IP  - 4
DP  - 1991 Oct
TI  - Separation of the impairment of haemostasis by aspirin from mucosal injury in the 
      human stomach.
PG  - 565-73
AB  - 1. An increasing body of data suggests that the antihaemostatic as well as the 
      ulcerogenic actions of aspirin and other non-steroidal anti-inflammatory drugs 
      may be operative when patients present with haematemesis and melaena. 2. We 
      therefore developed methods to allow separate evaluation of the erosive and 
      anti-haemostatic actions of aspirin in the human gastric mucosa. Volunteer 
      subjects took 300 mg of aspirin daily in the morning or 600 mg of aspirin four 
      times a day for 5 days under blinded randomized conditions. Changes in 
      spontaneous gastric microbleeding, endoscopic signs of injury, spontaneous 
      bleeding per gastric erosion, biopsy-induced bleeding and eicosanoids were 
      studied. 3. Both doses of aspirin significantly inhibited gastric mucosal 
      synthesis of prostaglandin E2 and reduced the serum thromboxane concentration. 
      Erosions developed and regressed rapidly; compared with baseline 300 mg of 
      aspirin daily in the morning caused substantial numbers of gastric erosions to 
      develop (mean 5.3, 95% confidence limits 2.7-10.2) but this was significantly 
      less than that caused by 600 mg of aspirin four times a day (10.9, 7.2-16.5, P 
      less than 0.05). The presence of erosions was associated with enhanced 
      spontaneous bleeding, but only during aspirin administration. 4. Aspirin 
      significantly increased bleeding induced by mucosal biopsy and was associated 
      with significant enhancements in the rate of bleeding per gastric erosion. 
      Bleeding rate per erosion but not biopsy-induced bleeding showed a significant 
      dose-related increase with 600 mg of aspirin four times a day. Enteric coating 
      reduced endoscopic signs of injury, but did not affect the impaired haemostasis 
      caused by aspirin.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Hawkey, C J
AU  - Hawkey CJ
AD  - Department of Therapeutics, Queen's Medical Centre, University Hospital, 
      Nottingham, U.K.
FAU - Hawthorne, A B
AU  - Hawthorne AB
FAU - Hudson, N
AU  - Hudson N
FAU - Cole, A T
AU  - Cole AT
FAU - Mahida, Y R
AU  - Mahida YR
FAU - Daneshmend, T K
AU  - Daneshmend TK
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dinoprostone/biosynthesis
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Gastric Mucosa/*drug effects/metabolism/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Gastroscopy
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Stomach Ulcer/*chemically induced/pathology
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
AID - 10.1042/cs0810565 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 1991 Oct;81(4):565-73. doi: 10.1042/cs0810565.

PMID- 6681552
OWN - NLM
STAT- MEDLINE
DCOM- 19830225
LR  - 20190514
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 33
IP  - 1
DP  - 1983 Jan
TI  - Folate supplements and phenytoin-salicylate interaction.
PG  - 115-6
AB  - We found biphasic fluctuations of serum phenytoin level when aspirin was added to 
      chronic phenytoin therapy for an epileptic patient. The total serum phenytoin 
      level was lowered initially by addition of aspirin. However, after 4 months on 
      phenytoin-aspirin combination therapy, he showed elevated serum phenytoin levels, 
      mild nystagmus, and serum folate deficiency.
FAU - Inoue, F
AU  - Inoue F
FAU - Walsh, R J
AU  - Walsh RJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 6158TKW0C5 (Phenytoin)
RN  - 935E97BOY8 (Folic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Drug Interactions
MH  - Folic Acid
MH  - *Folic Acid Deficiency
MH  - Humans
MH  - Male
MH  - Phenytoin/*administration & dosage
MH  - Seizures/*drug therapy
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1212/wnl.33.1.115 [doi]
PST - ppublish
SO  - Neurology. 1983 Jan;33(1):115-6. doi: 10.1212/wnl.33.1.115.

PMID- 1785980
OWN - NLM
STAT- MEDLINE
DCOM- 19920319
LR  - 20131121
IS  - 0300-8495 (Print)
IS  - 0300-8495 (Linking)
VI  - 20
IP  - 11
DP  - 1991 Nov
TI  - Management of transient ischaemic attacks.
PG  - 1600-3
AB  - There have been major recent advances in the investigation and treatment of 
      transient ischaemic attacks, which represent an important prodrome of cerebral 
      infarction. Medical therapy with aspirin reduces stroke risk, while warfarin has 
      an important place in the prevention of cardiogenic cerebral embolism. Carotid 
      endarterectomy is of proven value in symptomatic patients with severe carotid 
      stenosis.
FAU - Davis, S
AU  - Davis S
AD  - Stroke Service, Royal Melbourne Hospital, Parkville, Victoria.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Aust Fam Physician
JT  - Australian family physician
JID - 0326701
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Diagnosis, Differential
MH  - Endarterectomy, Carotid
MH  - Humans
MH  - Ischemic Attack, Transient/diagnosis/etiology/*therapy
MH  - Warfarin/therapeutic use
RF  - 9
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
PST - ppublish
SO  - Aust Fam Physician. 1991 Nov;20(11):1600-3.

PMID- 21987079
OWN - NLM
STAT- MEDLINE
DCOM- 20120217
LR  - 20211020
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Print)
IS  - 0957-5243 (Linking)
VI  - 22
IP  - 12
DP  - 2011 Dec
TI  - Aspirin and NSAID use and lung cancer risk: a pooled analysis in the 
      International Lung Cancer Consortium (ILCCO).
PG  - 1709-20
LID - 10.1007/s10552-011-9847-z [doi]
AB  - PURPOSE: To investigate the hypothesis that non-steroidal anti-inflammatory drugs 
      (NSAIDs) lower lung cancer risk. METHODS: We analysed pooled individual-level 
      data from seven case-control and one cohort study in the International Lung 
      Cancer Consortium (ILCCO). Relative risks for lung cancer associated with 
      self-reported history of aspirin and other NSAID use were estimated within 
      individual studies using logistic regression or proportional hazards models, 
      adjusted for packyears of smoking, age, calendar period, ethnicity and education 
      and were combined using random effects meta-analysis. RESULTS: A total of 4,309 
      lung cancer cases (mean age at diagnosis 65 years, 45% adenocarcinoma and 22% 
      squamous-cell carcinoma) and 58,301 non-cases/controls were included. Amongst 
      controls, 34% had used NSAIDs in the past (81% of them used aspirin). After 
      adjustment for negative confounding by smoking, ever-NSAID use (affirmative 
      answer to the study-specific question on NSAID use) was associated with a 26% 
      reduction (95% confidence interval 8 to 41%) in lung cancer risk in men, but not 
      in women (3% increase (-11% to 30%)). In men, the association was stronger in 
      current and former smokers, and for squamous-cell carcinoma than for 
      adenocarcinomas, but there was no trend with duration of use. No differences were 
      found in the effects on lung cancer risk of aspirin and non-aspirin NSAIDs. 
      CONCLUSIONS: Evidence from ILCCO suggests that NSAID use in men confers a modest 
      protection for lung cancer, especially amongst ever-smokers. Additional 
      investigation is needed regarding the possible effects of age, duration, dose and 
      type of NSAID and whether effect modification by smoking status or sex exists.
FAU - McCormack, Valerie A
AU  - McCormack VA
AD  - Section of Environment and Radiation, International Agency for Research on 
      Cancer, 150 cours Albert Thomas, Lyon, France. mccormackv@iarc.fr
FAU - Hung, Rayjean J
AU  - Hung RJ
FAU - Brenner, Darren R
AU  - Brenner DR
FAU - Bickeböller, Heike
AU  - Bickeböller H
FAU - Rosenberger, Albert
AU  - Rosenberger A
FAU - Muscat, Joshua E
AU  - Muscat JE
FAU - Lazarus, Philip
AU  - Lazarus P
FAU - Tjønneland, Anne
AU  - Tjønneland A
FAU - Friis, Søren
AU  - Friis S
FAU - Christiani, David C
AU  - Christiani DC
FAU - Chun, Eun-Mi
AU  - Chun EM
FAU - Le Marchand, Loic
AU  - Le Marchand L
FAU - Rennert, Gad
AU  - Rennert G
FAU - Rennert, Hedy S
AU  - Rennert HS
FAU - Andrew, Angeline S
AU  - Andrew AS
FAU - Orlow, Irene
AU  - Orlow I
FAU - Park, Bernard
AU  - Park B
FAU - Boffetta, Paolo
AU  - Boffetta P
FAU - Duell, Eric J
AU  - Duell EJ
LA  - eng
GR  - P20 RR018787/RR/NCRR NIH HHS/United States
GR  - P20RR018787/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20111011
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*epidemiology
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Surveys and Questionnaires
PMC - PMC3852431
MID - NIHMS510206
EDAT- 2011/10/12 06:00
MHDA- 2012/02/18 06:00
CRDT- 2011/10/12 06:00
PHST- 2011/07/01 00:00 [received]
PHST- 2011/09/23 00:00 [accepted]
PHST- 2011/10/12 06:00 [entrez]
PHST- 2011/10/12 06:00 [pubmed]
PHST- 2012/02/18 06:00 [medline]
AID - 10.1007/s10552-011-9847-z [doi]
PST - ppublish
SO  - Cancer Causes Control. 2011 Dec;22(12):1709-20. doi: 10.1007/s10552-011-9847-z. 
      Epub 2011 Oct 11.

PMID- 7032379
OWN - NLM
STAT- MEDLINE
DCOM- 19820225
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 96
IP  - 1
DP  - 1982 Jan
TI  - Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic 
      thrombocytopenic purpura.
PG  - 27-33
AB  - Platelet-inhibiting drugs have been used widely in the treatment of thrombotic 
      thrombocytopenia purpura. Nineteen consecutive patients received various 
      treatments including platelet inhibitors, glucocorticoid drugs, whole blood or 
      plasma exchange transfusions, and splenectomy. During treatment with aspirin and 
      dipyridamole in 14 patients, five died, and only one had neither new neurologic 
      signs nor worsening thrombocytopenia. Prostacyclin in one patient was not 
      beneficial. Serious bleeding complications, including massive upper 
      gastrointestinal hemorrhage, epistaxes, or subarachnoid hemorrhage confirmed at 
      autopsy, occurred in five of the 19 patients and only during treatment with 
      aspirin and dipyridamole. We conclude that there is no evidence for the 
      effectiveness of aspirin and dipyridamole in the treatment of thrombotic 
      thrombocytopenic purpura and that these drugs may increase the risk of serious 
      bleeding complications.
FAU - Rosove, M H
AU  - Rosove MH
FAU - Ho, W G
AU  - Ho WG
FAU - Goldfinger, D
AU  - Goldfinger D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Glucocorticoids)
RN  - 64ALC7F90C (Dipyridamole)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Epistaxis/chemically induced
MH  - Epoprostenol/therapeutic use
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Purpura, Thrombotic Thrombocytopenic/*drug therapy/therapy
MH  - Subarachnoid Hemorrhage/chemically induced
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.7326/0003-4819-96-1-27 [doi]
PST - ppublish
SO  - Ann Intern Med. 1982 Jan;96(1):27-33. doi: 10.7326/0003-4819-96-1-27.

PMID- 10471421
OWN - NLM
STAT- MEDLINE
DCOM- 19991008
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 30
IP  - 9
DP  - 1999 Sep
TI  - Prospective study of aspirin use and risk of stroke in women.
PG  - 1764-71
AB  - BACKGROUND AND PURPOSE: In secondary prevention, aspirin reduces risk of ischemic 
      stroke. In primary prevention of stroke, however, the role of aspirin is 
      uncertain, especially in women. METHODS: In 1980, 79 319 women in the Nurses' 
      Health Study cohort, 34 to 59 years of age and free of diagnosed cardiovascular 
      disease, cancer, and rheumatoid arthritis, completed questionnaires that included 
      information on aspirin use. Data on aspirin use were updated in 1982, 1984, and 
      1988. By 1994, after 994 231 person-years of follow-up, 503 incident strokes (295 
      ischemic strokes, 100 subarachnoid hemorrhages, 52 intraparenchymal hemorrhages, 
      and 56 strokes of undetermined type) were documented. RESULTS: There was no clear 
      relationship between aspirin use and risk of total stroke; risk was slightly 
      reduced among women who took 1 to 6 aspirin per week and slightly increased among 
      women who took 7 or more aspirin per week. Women who took 1 to 6 aspirin per week 
      had a lower risk of large-artery occlusive infarction compared with women who 
      reported no aspirin use; after simultaneous adjustment for other cardiovascular 
      risk factors and selected nutrients, the multivariate relative risk was 0.50 (95% 
      CI 0.29 to 0.85, P=0.01). Women who took 15 or more aspirin per week had an 
      excess risk of subarachnoid hemorrhage; the multivariate relative risk was 2.02 
      (95% CI 1.04 to 3.91, P for trend=0.02). The reduction in large-artery occlusive 
      infarction with aspirin was of greater magnitude for older, hypertensive, or 
      smoking women than for younger, nonhypertensive, or nonsmoking women; the 
      elevation in subarachnoid hemorrhage with aspirin was also more apparent for 
      older or hypertensive women than for younger or nonhypertensive women. Aspirin 
      use was not associated with risk of other subtypes of stroke. CONCLUSIONS: These 
      prospective data indicate that women who take 1 to 6 aspirin per week have a 
      reduced risk of large-artery occlusive infarction, but those who use 15 or more 
      aspirin per week have an increased risk of subarachnoid hemorrhage. This 
      observational study suggests benefits of aspirin for ischemic stroke with low 
      frequency of use and hazards for hemorrhagic stroke with high frequency of use, 
      particularly among older or hypertensive women. Thus, the effect on total stroke 
      will depend on the dose of aspirin and the distribution of stroke subtypes and 
      risk factors in the population.
FAU - Iso, H
AU  - Iso H
AD  - Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, Mass 02115, USA.
FAU - Hennekens, C H
AU  - Hennekens CH
FAU - Stampfer, M J
AU  - Stampfer MJ
FAU - Rexrode, K M
AU  - Rexrode KM
FAU - Colditz, G A
AU  - Colditz GA
FAU - Speizer, F E
AU  - Speizer FE
FAU - Willett, W C
AU  - Willett WC
FAU - Manson, J E
AU  - Manson JE
LA  - eng
GR  - CA40356/CA/NCI NIH HHS/United States
GR  - HL34594/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/chemically induced/epidemiology/etiology/*prevention & 
      control
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Risk Factors
MH  - Subarachnoid Hemorrhage/epidemiology/etiology
EDAT- 1999/09/02 00:00
MHDA- 1999/09/02 00:01
CRDT- 1999/09/02 00:00
PHST- 1999/09/02 00:00 [pubmed]
PHST- 1999/09/02 00:01 [medline]
PHST- 1999/09/02 00:00 [entrez]
AID - 10.1161/01.str.30.9.1764 [doi]
PST - ppublish
SO  - Stroke. 1999 Sep;30(9):1764-71. doi: 10.1161/01.str.30.9.1764.

PMID- 18260128
OWN - NLM
STAT- MEDLINE
DCOM- 20080820
LR  - 20211020
IS  - 1097-4644 (Electronic)
IS  - 0730-2312 (Print)
IS  - 0730-2312 (Linking)
VI  - 104
IP  - 4
DP  - 2008 Jul 1
TI  - APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in 
      mice.
PG  - 1311-23
LID - 10.1002/jcb.21709 [doi]
AB  - Platelets contribute to the development of metastasis, the most common cause of 
      mortality in cancer patients, but the precise role that anti-platelet drugs play 
      in cancer treatment is not defined. Metastatic tumor cells can produce platelet 
      alphaIIb beta3 activators, such as ADP and thromboxane A(2) (TXA(2)). Inhibitors 
      of platelet beta3 integrins decrease bone metastases in mice but are associated 
      with significant bleeding. We examined the role of a novel soluble 
      apyrase/ADPase, APT102, and an inhibitor of TXA(2) synthesis, acetylsalicylic 
      acid (aspirin or ASA), in mouse models of experimental bone metastases. We found 
      that treatment with ASA and APT102 in combination (ASA + APT102), but not either 
      drug alone, significantly decreased breast cancer and melanoma bone metastases in 
      mice with fewer bleeding complications than observed with alphaIIb beta3 
      inhibition. ASA + APT102 diminished tumor cell induced platelet aggregation but 
      did not directly alter tumor cell viability. Notably, APT102 + ASA treatment did 
      not affect initial tumor cell distribution and similar results were observed in 
      beta3-/- mice. These results show that treatment with ASA + APT102 decreases bone 
      metastases without significant bleeding complications. Anti-platelet drugs such 
      as ASA + APT102 could be valuable experimental tools for studying the role of 
      platelet activation in metastasis as well as a therapeutic option for the 
      prevention of bone metastases.
CI  - 2008 Wiley-Liss, Inc.
FAU - Uluçkan, Ozge
AU  - Uluçkan O
AD  - Department of Medicine, Division of Oncology, Washington University School of 
      Medicine, St. Louis, Missouri 63110, USA.
FAU - Eagleton, Mark C
AU  - Eagleton MC
FAU - Floyd, Desiree H
AU  - Floyd DH
FAU - Morgan, Elizabeth A
AU  - Morgan EA
FAU - Hirbe, Angela C
AU  - Hirbe AC
FAU - Kramer, Matthew
AU  - Kramer M
FAU - Dowland, Nikki
AU  - Dowland N
FAU - Prior, Julie L
AU  - Prior JL
FAU - Piwnica-Worms, David
AU  - Piwnica-Worms D
FAU - Jeong, Soon Seog
AU  - Jeong SS
FAU - Chen, Ridong
AU  - Chen R
FAU - Weilbaecher, Katherine
AU  - Weilbaecher K
LA  - eng
GR  - P50 CA094056/CA/NCI NIH HHS/United States
GR  - 5-T32-GM-07200/GM/NIGMS NIH HHS/United States
GR  - T32 GM007200/GM/NIGMS NIH HHS/United States
GR  - R01 CA097250-01A1/CA/NCI NIH HHS/United States
GR  - 5-T32-HL07088-32/HL/NHLBI NIH HHS/United States
GR  - R01-CA097250/CA/NCI NIH HHS/United States
GR  - P50 CA94056/CA/NCI NIH HHS/United States
GR  - T32 HL007088/HL/NHLBI NIH HHS/United States
GR  - R01 CA097250/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cell Biochem
JT  - Journal of cellular biochemistry
JID - 8205768
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 3.6.1.5 (Apyrase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Apyrase/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Bone Neoplasms/*drug therapy/*secondary
MH  - Diagnostic Imaging
MH  - Melanoma, Experimental/drug therapy/pathology
MH  - Mice
MH  - Neoplasm Metastasis/*drug therapy
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Tumor Burden/drug effects
PMC - PMC2763643
MID - NIHMS111139
COIS- Dr. Jeong and Dr. Chen are employees of APT Therapeutics. All other authors have 
      no conflict of interest.
EDAT- 2008/02/09 09:00
MHDA- 2008/08/21 09:00
CRDT- 2008/02/09 09:00
PHST- 2008/02/09 09:00 [pubmed]
PHST- 2008/08/21 09:00 [medline]
PHST- 2008/02/09 09:00 [entrez]
AID - 10.1002/jcb.21709 [doi]
PST - ppublish
SO  - J Cell Biochem. 2008 Jul 1;104(4):1311-23. doi: 10.1002/jcb.21709.

PMID- 31865169
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20201215
IS  - 2210-7797 (Electronic)
IS  - 2210-7789 (Linking)
VI  - 19
DP  - 2020 Jan
TI  - Resistance of aspirin during and after pregnancy: A longitudinal cohort study.
PG  - 25-30
LID - S2210-7789(19)30468-4 [pii]
LID - 10.1016/j.preghy.2019.11.008 [doi]
AB  - OBJECTIVES: The objective of this study is to investigate possible changes in 
      aspirin resistance during and after pregnancy over time. STUDY DESIGN: A 
      longitudinal cohort study in obstetric high risk women with an indication for 
      aspirin usage during pregnancy to prevent placenta mediated pregnancy 
      complications. MAIN OUTCOME MEASURES: Aspirin resistance measured in the first, 
      second and third trimester of pregnancy and at least three months postpartum by 
      four complementary test: PFA-200, VerifyNow®, Chronolog light transmission 
      aggregometry (Chronolog LTA) and serum thromboxane B(2) (TxB(2)) level 
      measurements. Correlation between the devices was investigated. RESULTS: In 
      total, 23 pregnant women participated in the present study. Aspirin resistance 
      according to the PFA-200, VerifyNow®, Chronolog LTA and serum TxB(2), was 30.4%, 
      17.4%, 26.1% and 23.8% respectively. Resistance by any device was 69.6%. Aspirin 
      resistance measured by the VerifyNow®, Chronolog LTA, serum TxB(2) and aspirin 
      resistance by any device during pregnancy was demonstrated more frequently than 
      aspirin resistance after pregnancy. Correlation between the different devices was 
      weak. CONCLUSION: Aspirin resistance was found in a considerable part of the 
      participants. Considerable variation between participants, within participants 
      over time and between the different devices was found. Prevalence of aspirin 
      resistance during pregnancy differs from after pregnancy. More research on 
      aspirin resistance and clinical obstetric outcome is needed.
CI  - Copyright © 2019 International Society for the Study of Hypertension in 
      Pregnancy. Published by Elsevier B.V. All rights reserved.
FAU - Bij de Weg, Jeske M
AU  - Bij de Weg JM
AD  - Amsterdam UMC, location VUmc, Department of Obstetrics and Gynaecology, 
      Reproduction and Development, De Boelelaan 1117, Amsterdam, the Netherlands. 
      Electronic address: j.bijdeweg@amsterdamumc.nl.
FAU - Abheiden, Carolien N H
AU  - Abheiden CNH
AD  - Amsterdam UMC, location VUmc, Department of Obstetrics and Gynaecology, 
      Reproduction and Development, De Boelelaan 1117, Amsterdam, the Netherlands.
FAU - Fuijkschot, Wessel W
AU  - Fuijkschot WW
AD  - Amsterdam UMC, location VUmc, Department of Internal Medicine, Amsterdam 
      Cardiovascular Sciences, De Boelelaan 1117, Amsterdam, the Netherlands.
FAU - Harmsze, Ankie M
AU  - Harmsze AM
AD  - Amsterdam UMC, location VUmc, Department of Clinical Pharmacology and Pharmacy, 
      De Boelelaan 1117, Amsterdam, the Netherlands.
FAU - de Boer, Marjon A
AU  - de Boer MA
AD  - Amsterdam UMC, location VUmc, Department of Obstetrics and Gynaecology, 
      Reproduction and Development, De Boelelaan 1117, Amsterdam, the Netherlands.
FAU - Thijs, Abel
AU  - Thijs A
AD  - Amsterdam UMC, location VUmc, Department of Internal Medicine, Amsterdam 
      Cardiovascular Sciences, De Boelelaan 1117, Amsterdam, the Netherlands.
FAU - de Vries, Johanna I P
AU  - de Vries JIP
AD  - Amsterdam UMC, location VUmc, Department of Obstetrics and Gynaecology, 
      Reproduction and Development, De Boelelaan 1117, Amsterdam, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20191219
PL  - Netherlands
TA  - Pregnancy Hypertens
JT  - Pregnancy hypertension
JID - 101552483
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Cohort Studies
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/prevention & control
MH  - Longitudinal Studies
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests/methods
MH  - Pregnancy
MH  - Pregnancy Trimesters
OTO - NOTNLM
OT  - Aspirin
OT  - Drug resistance
OT  - HELLP
OT  - Pre-eclampsia
OT  - Pregnancy
OT  - Preventive therapy
EDAT- 2019/12/23 06:00
MHDA- 2020/12/16 06:00
CRDT- 2019/12/23 06:00
PHST- 2019/06/28 00:00 [received]
PHST- 2019/10/23 00:00 [revised]
PHST- 2019/11/25 00:00 [accepted]
PHST- 2019/12/23 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
PHST- 2019/12/23 06:00 [entrez]
AID - S2210-7789(19)30468-4 [pii]
AID - 10.1016/j.preghy.2019.11.008 [doi]
PST - ppublish
SO  - Pregnancy Hypertens. 2020 Jan;19:25-30. doi: 10.1016/j.preghy.2019.11.008. Epub 
      2019 Dec 19.

PMID- 3979467
OWN - NLM
STAT- MEDLINE
DCOM- 19850520
LR  - 20190816
IS  - 0014-4835 (Print)
IS  - 0014-4835 (Linking)
VI  - 40
IP  - 2
DP  - 1985 Feb
TI  - Aspirin prevents carbamylation of soluble lens proteins and prevents 
      cyanate-induced phase separation opacities in vitro: a possible mechanism by 
      which aspirin could prevent cataract.
PG  - 297-311
AB  - The carbamylation of lens proteins by cyanate causes conformational changes, and 
      cyanate causes cataract. There is some evidence that aspirin is beneficial to 
      cataract patients, so its effect on the carbamylation of lens proteins and on 
      opacification produced by cyanate in vitro was studied. Aspirin decreased the 
      phase separation temperature in lenses exposed to cyanate, and was found to 
      reduce the rate of carbamylation of most, if not all, soluble lens proteins. 
      Studies with radiolabelled aspirin lead to the conclusion that the drug achieves 
      this protection by chemically modifying the proteins. The nature of this 
      modification and the relevance of these results to human cataract is discussed.
FAU - Crompton, M
AU  - Crompton M
FAU - Rixon, K C
AU  - Rixon KC
FAU - Harding, J J
AU  - Harding JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 0 (Crystallins)
RN  - 0 (Cyanates)
RN  - G9C31TWN5M (potassium cyanate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cataract/*prevention & control
MH  - Cattle
MH  - Crystallins/*metabolism
MH  - Cyanates/pharmacology
MH  - In Vitro Techniques
MH  - Lens, Crystalline/*drug effects
MH  - Protein Conformation
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Temperature
MH  - Time Factors
EDAT- 1985/02/01 00:00
MHDA- 1985/02/01 00:01
CRDT- 1985/02/01 00:00
PHST- 1985/02/01 00:00 [pubmed]
PHST- 1985/02/01 00:01 [medline]
PHST- 1985/02/01 00:00 [entrez]
AID - 0014-4835(85)90014-4 [pii]
AID - 10.1016/0014-4835(85)90014-4 [doi]
PST - ppublish
SO  - Exp Eye Res. 1985 Feb;40(2):297-311. doi: 10.1016/0014-4835(85)90014-4.

PMID- 10502232
OWN - NLM
STAT- MEDLINE
DCOM- 19991026
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 138
IP  - 4 Pt 2
DP  - 1999 Oct
TI  - Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors.
PG  - 263-75
AB  - Antagonists of the platelet receptor glycoprotein (GP) IIb-IIIa are a novel class 
      of antithrombotic agents that provide more comprehensive platelet blockade than 
      the combination of aspirin and heparin. Studies in patients scheduled for 
      percutaneous coronary intervention and those with unstable angina or non-Q-wave 
      myocardial infarction have shown that a combination of intravenous GP IIb-IIIa 
      inhibitors with aspirin and heparin is associated with a reduction in death or 
      myocardial infarction compared with therapy with aspirin and heparin alone. As 
      with other antithrombotic agents, the principal safety issue with GP IIb-IIIa 
      inhibitors is bleeding, because the potent antiplatelet effect of these drugs may 
      adversely affect hemostasis. Increased risk of hemorrhage is of particular 
      concern for patients who subsequently require emergency or urgent bypass surgery 
      because the rate of bleeding complications in these patients is considerable even 
      in the absence of prior GP IIb-IIIa therapy. Additionally, antagonists of GP 
      IIb-IIIa may increase the risk of thrombocytopenia. The safety profiles of 
      various GP IIb-IIIa inhibitors are largely a function of their pharmacokinetic 
      and pharmacodynamic properties, most notably the reversibility of platelet 
      inhibition and the rate of plasma clearance. Knowledge of the pharmacokinetic and 
      pharmacodynamic properties of the GP IIb-IIIa inhibitors is critical for the 
      appropriate utilization of this new class of drugs.
FAU - Kleiman, N S
AU  - Kleiman NS
AD  - Division of Cardiology, Baylor College of Medicine, Texas, USA. 
      nkleiman@bcm.tmc.edu
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Anticoagulants)
RN  - 0 (Drug Combinations)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/pharmacokinetics/pharmacology
MH  - Aspirin/pharmacokinetics/pharmacology/therapeutic use
MH  - Drug Combinations
MH  - Fibrinolytic Agents/adverse effects/pharmacokinetics/pharmacology/therapeutic use
MH  - Hemorrhage/prevention & control
MH  - Hemostasis/drug effects
MH  - Heparin/pharmacokinetics/pharmacology/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse 
      effects/*pharmacokinetics/pharmacology/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
MH  - Safety
MH  - Thrombocytopenia/chemically induced
RF  - 67
EDAT- 1999/09/29 00:00
MHDA- 1999/09/29 00:01
CRDT- 1999/09/29 00:00
PHST- 1999/09/29 00:00 [pubmed]
PHST- 1999/09/29 00:01 [medline]
PHST- 1999/09/29 00:00 [entrez]
AID - a100459 [pii]
AID - 10.1053/hj.1999.v138.a100459 [doi]
PST - ppublish
SO  - Am Heart J. 1999 Oct;138(4 Pt 2):263-75. doi: 10.1053/hj.1999.v138.a100459.

PMID- 3368878
OWN - NLM
STAT- MEDLINE
DCOM- 19880613
LR  - 20131121
IS  - 0040-3709 (Print)
IS  - 0040-3709 (Linking)
VI  - 37
IP  - 3
DP  - 1988 Mar
TI  - Aspirin exposure during the first 20 weeks of gestation and IQ at four years of 
      age.
PG  - 249-55
AB  - The relationship between maternal aspirin use during the first 20 weeks of 
      pregnancy and the child's IQ at 4 years of age was investigated in 19,226 
      pregnancies occurring from 1959 to 1966 in the Collaborative Perinatal Project. 
      The mean IQ of children exposed to aspirin was 98.3, which was 2.1 points higher 
      (95% confidence interval = 1.7, 2.6; P less than 0.0001) than that of unexposed 
      children. Adjustment for multiple social, demographic, and other confounders 
      reduced this difference to less than one point in favor of the aspirin exposed 
      group, although statistical significance remained. Total days of exposure was 
      used as an index of dose, and no dose-response relationship between aspirin use 
      and IQ was found. The effect of prenatal aspirin exposure did not vary by infant 
      sex. It is concluded that an adverse effect of aspirin exposure on IQ is 
      unlikely.
FAU - Klebanoff, M A
AU  - Klebanoff MA
AD  - Prevention Research Program, National Institute of Child Health and Human 
      Development, Bethesda, Maryland 20892.
FAU - Berendes, H W
AU  - Berendes HW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Teratology
JT  - Teratology
JID - 0153257
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/*adverse effects
MH  - Data Collection/methods
MH  - Female
MH  - Humans
MH  - Intelligence/*drug effects
MH  - Male
MH  - Pregnancy
MH  - Pregnancy Trimester, First/*drug effects
MH  - Pregnancy Trimester, Second/*drug effects
MH  - *Prenatal Exposure Delayed Effects
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
AID - 10.1002/tera.1420370310 [doi]
PST - ppublish
SO  - Teratology. 1988 Mar;37(3):249-55. doi: 10.1002/tera.1420370310.

PMID- 16139122
OWN - NLM
STAT- MEDLINE
DCOM- 20051205
LR  - 20181201
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 46
IP  - 5
DP  - 2005 Sep 6
TI  - Long-term cost effectiveness of early and sustained dual oral antiplatelet 
      therapy with clopidogrel given for up to one year after percutaneous coronary 
      intervention results: from the Clopidogrel for the Reduction of Events During 
      Observation (CREDO) trial.
PG  - 761-9
AB  - OBJECTIVES: This study sought to evaluate the long-term cost effectiveness of a 
      clopidogrel loading strategy before percutaneous coronary intervention (PCI) 
      followed by continued treatment for one year. BACKGROUND: The Clopidogrel for the 
      Reduction of Events During Observation (CREDO) trial, a randomized trial of 2,116 
      patients, showed the effectiveness of antiplatelet therapy with clopidogrel 300 
      mg before PCI and 75 mg daily for one year afterward compared with placebo load 
      and placebo days 29 to 365 in reducing the combined risk of death, myocardial 
      infarction, and stroke. All patients received clopidogrel on days 1 to 28 and 
      aspirin on days 1 to 365. METHODS: All hospitalizations were assigned a 
      diagnosis-related group. Associated costs were estimated three ways (including 
      professional costs): 1) Medicare costs, 2) MEDSTAT costs, and 3) blend with 
      Medicare for those age > or = 65 years and MEDSTAT for those age <65 years. 
      Clopidogrel 75 mg cost 3.22 dollars. Life expectancy in trial survivors was 
      estimated using external data. Confidence intervals were assessed by bootstrap. 
      RESULTS: The primary composite end point occurred in 89 (8.45%) clopidogrel 
      patients and in 122 (11.48%) placebo patients (relative risk reduction [RRR] 
      26.9%; 95% confidence interval [CI] 3.9% to 44.4%). The number of life-years 
      gained (LYG) with clopidogrel was 0.1526 (95% CI 0.0263 to 0.2838) using 
      Framingham data and 0.1920 (95% CI 0.054 to 0.337) using Saskatchewan data. 
      Average total costs were 664 dollars higher for the clopidogrel arm (95% CI -461 
      dollars to 1,784 dollars). The incremental cost-effectiveness ratios (ICERs) 
      based on Framingham data ranged from 3,685 dollars/LYG to 4,353 dollars/LYG, with 
      over 97% of bootstrap-derived ICER estimates below 50,000 dollars/LYG. The ICERs 
      based on Saskatchewan data were 2,929 dollars/LYG to 3,460 dollars/LYG, with over 
      98% of estimates below 50,000 dollars/LYG. CONCLUSIONS: Platelet inhibition with 
      clopidogrel loading before PCI followed by therapy for one year is highly cost 
      effective.
FAU - Beinart, Sean C
AU  - Beinart SC
AD  - Emory University, Atlanta, Georgia, USA.
FAU - Kolm, Paul
AU  - Kolm P
FAU - Veledar, Emir
AU  - Veledar E
FAU - Zhang, Zefeng
AU  - Zhang Z
FAU - Mahoney, Elizabeth M
AU  - Mahoney EM
FAU - Bouin, Olivier
AU  - Bouin O
FAU - Gabriel, Sylvie
AU  - Gabriel S
FAU - Jackson, Joseph
AU  - Jackson J
FAU - Chen, Roland
AU  - Chen R
FAU - Caro, Jaime
AU  - Caro J
FAU - Steinhubl, Steven
AU  - Steinhubl S
FAU - Topol, Eric
AU  - Topol E
FAU - Weintraub, William S
AU  - Weintraub WS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/economics/*therapeutic use
MH  - *Cardiac Catheterization
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/economics/*prevention & control
MH  - Platelet Aggregation Inhibitors/economics/*therapeutic use
MH  - Stroke/*economics/prevention & control
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/economics/therapeutic 
      use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2005/09/06 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/09/06 09:00
PHST- 2004/12/27 00:00 [received]
PHST- 2005/03/03 00:00 [revised]
PHST- 2005/03/15 00:00 [accepted]
PHST- 2005/09/06 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/09/06 09:00 [entrez]
AID - S0735-1097(05)01272-6 [pii]
AID - 10.1016/j.jacc.2005.03.073 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2005 Sep 6;46(5):761-9. doi: 10.1016/j.jacc.2005.03.073.

PMID- 20961392
OWN - NLM
STAT- MEDLINE
DCOM- 20110411
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 8
IP  - 12
DP  - 2010 Dec
TI  - Redox-generated isoprostanes are associated with residual platelet activity in 
      aspirin-treated patients with stable coronary heart disease.
PG  - 2662-70
LID - 10.1111/j.1538-7836.2010.04117.x [doi]
AB  - AIM: Insufficient platelet inhibition by low-dose aspirin is associated with poor 
      prognosis in patients with coronary heart disease (CHD). We sought to investigate 
      the prevalence of this phenomenon in patients with stable CHD and to study 
      whether oxidative stress plays a role in its pathogenesis. METHODS AND RESULTS: 
      We studied the platelet response to long-term (≥ 6 months) low-dose (100 mg per 
      day) aspirin in 130 consecutive patients with stable CHD (age 66 ± 8 years, 83% 
      male). Among a wide distribution of platelet responses to collagen, ADP, and 
      arachidonic acid, the vast majority of patients in the highest tertile of 
      residual platelet activity (defined as 'aspirin low-responders') were 
      characterized by lack of platelet inhibition by aspirin in vitro, significantly 
      although not completely suppressed platelet TXB₂ production and COX-1 activity, 
      and significantly higher urinary 8-iso-prostaglandin F(2α) excretion [186 
      (147-230) vs. 230 (188-318) pg per mg creatinine; median (IQR), P < 0.001; 
      measured by GC-MS]. CONCLUSION: A relevant proportion of patients with CHD show 
      insufficient platelet inhibition by low-dose aspirin. Oxidative stress and lipid 
      peroxidation causing isoprostane formation may underlie inadequate platelet 
      inhibition in an aspirin-insensitive manner in patients with cardiovascular 
      disease.
CI  - © 2010 International Society on Thrombosis and Haemostasis.
FAU - Schwedhelm, E
AU  - Schwedhelm E
AD  - Institute of Experimental and Clinical Pharmacology and Toxicology, University 
      Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Bierend, A
AU  - Bierend A
FAU - Maas, R
AU  - Maas R
FAU - Trinks, R
AU  - Trinks R
FAU - Kom, G D
AU  - Kom GD
FAU - Tsikas, D
AU  - Tsikas D
FAU - Böger, R H
AU  - Böger RH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Isoprostanes)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/*pathology
MH  - Coronary Disease/drug therapy/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Isoprostanes/*biosynthesis/blood/urine
MH  - Male
MH  - Middle Aged
MH  - Oxidation-Reduction
MH  - Oxidative Stress
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Tandem Mass Spectrometry
EDAT- 2010/10/22 06:00
MHDA- 2011/04/13 06:00
CRDT- 2010/10/22 06:00
PHST- 2010/10/22 06:00 [entrez]
PHST- 2010/10/22 06:00 [pubmed]
PHST- 2011/04/13 06:00 [medline]
AID - S1538-7836(22)06664-8 [pii]
AID - 10.1111/j.1538-7836.2010.04117.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2010 Dec;8(12):2662-70. doi: 10.1111/j.1538-7836.2010.04117.x.

PMID- 24390889
OWN - NLM
STAT- MEDLINE
DCOM- 20140929
LR  - 20220318
IS  - 1558-7118 (Electronic)
IS  - 1557-2625 (Linking)
VI  - 27
IP  - 1
DP  - 2014 Jan-Feb
TI  - Effects of changing guidelines on prescribing aspirin for primary prevention of 
      cardiovascular events.
PG  - 78-86
LID - 10.3122/jabfm.2014.01.130030 [doi]
AB  - OBJECTIVE: The use of low-dose aspirin for primary prevention of cardiovascular 
      events in patients at elevated risk for cardiovascular disease (CVD) is 
      increasingly being questioned. Aspirin may not benefit this population and may 
      increase the risk of major bleeding events. Data support aspirin use in patients 
      with known CVD. METHODS: This is a secondary analysis of de-identified electronic 
      health record (EHR) data from 131,050 individuals with known CVD or elevated risk 
      for CVD as determined by diagnostic, demographic, and clinical data collected 
      from 33 primary care practices in 11 different clinical organizations across 6 
      states. The percentage of the population of each cohort with aspirin recorded on 
      their medication list, created through risk base analysis, was observed across 4 
      time periods. RESULTS: From 2007 to 2011, aspirin usage reflected in the EHR 
      increased for the entire population and for each individual high-risk diagnosis. 
      The percentage of the population initiating aspirin therapy for primary 
      prevention within a year of diagnosis of CVD risk factors or CVD "equivalency" 
      increased between 2007 and 2011. Among those with a new diagnosis of CVD, aspirin 
      usage also steadily increased over the 4-year period, indicating no negative 
      impact from new negative primary prevention studies. CONCLUSIONS: Primary care 
      clinicians have a central role in providing evidence-based preventive services 
      and should integrate revised information into their practice to improve outcomes. 
      Even with new evidence against the use of aspirin for primary prevention, it is 
      difficult to change beliefs about the effectiveness and safety of aspirin, as 
      reflected in the behavior of physicians and patients.
FAU - Hissett, Jennifer
AU  - Hissett J
AD  - the Louisiana State University Emergency Medicine Residency, New Orleans; the 
      Exempla St. Joseph Hospital Internal Medicine Residency, Denver, CO; and the 
      Department of Family Medicine, University of Colorado School of Medicine, Aurora.
FAU - Folks, Brittany
AU  - Folks B
FAU - Coombs, Letoynia
AU  - Coombs L
FAU - Leblanc, William
AU  - Leblanc W
FAU - Pace, Wilson D
AU  - Pace WD
LA  - eng
GR  - 5RC1HL101071-02/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Am Board Fam Med
JT  - Journal of the American Board of Family Medicine : JABFM
JID - 101256526
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Evidence-Based Medicine
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Practice Patterns, Physicians'/*trends
MH  - Primary Health Care/*trends
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular Diseases
OT  - Primary Prevention
EDAT- 2014/01/07 06:00
MHDA- 2014/09/30 06:00
CRDT- 2014/01/07 06:00
PHST- 2014/01/07 06:00 [entrez]
PHST- 2014/01/07 06:00 [pubmed]
PHST- 2014/09/30 06:00 [medline]
AID - 27/1/78 [pii]
AID - 10.3122/jabfm.2014.01.130030 [doi]
PST - ppublish
SO  - J Am Board Fam Med. 2014 Jan-Feb;27(1):78-86. doi: 10.3122/jabfm.2014.01.130030.

PMID- 17234129
OWN - NLM
STAT- MEDLINE
DCOM- 20100322
LR  - 20151119
IS  - 1944-7930 (Electronic)
IS  - 1539-6509 (Linking)
VI  - 6
IP  - 32
DP  - 2006 Apr
TI  - Genetic tools to tailor cancer prevention by NSAIDs.
PG  - 71-4
AB  - It was shown that NSAIDs, such as aspirin or Celebrex, are effective cancer 
      preventive agents when taken regularly. However, the long-term use of NSAIDs, the 
      cyclooxygenase (COX) inhibitors, may have significant adverse effects - primarily 
      on the gastrointestinal (inhibiting COX-1) and cardiovascular (inhibiting COX-2) 
      systems. Genetic analysis of enzymes (including COX) involved in the 
      prostaglandin synthesis should reveal and predict a person's benefits vs. 
      toxicity resulting from the NSAID treatment.
FAU - Ulrich, Cornelia M
AU  - Ulrich CM
AD  - Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA 
      98109, USA.
FAU - Bigler, Jeannette
AU  - Bigler J
FAU - Potter, John D
AU  - Potter JD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Discov Med
JT  - Discovery medicine
JID - 101250006
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology/therapeutic 
      use
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Cardiovascular System/*drug effects/enzymology
MH  - Celecoxib
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Cyclooxygenase Inhibitors/adverse effects/therapeutic use
MH  - Gastrointestinal Tract/*drug effects/enzymology
MH  - Humans
MH  - Models, Biological
MH  - Neoplasms/genetics/*prevention & control
MH  - Pyrazoles/adverse effects/pharmacology/therapeutic use
MH  - Sulfonamides/adverse effects/pharmacology/therapeutic use
EDAT- 2007/01/20 09:00
MHDA- 2010/03/23 06:00
CRDT- 2007/01/20 09:00
PHST- 2007/01/20 09:00 [pubmed]
PHST- 2010/03/23 06:00 [medline]
PHST- 2007/01/20 09:00 [entrez]
PST - ppublish
SO  - Discov Med. 2006 Apr;6(32):71-4.

PMID- 26881715
OWN - NLM
STAT- MEDLINE
DCOM- 20170208
LR  - 20190907
IS  - 1873-4294 (Electronic)
IS  - 1568-0266 (Linking)
VI  - 16
IP  - 19
DP  - 2016
TI  - An Insight into Drug Repositioning for the Development of Novel Anti-Cancer 
      Drugs.
PG  - 2156-68
AB  - Increased investments and development of new technologies in drug discovery have 
      barely improved the outcome of medicinal entities in the drug discovery market 
      from a long time. Minimal success rates of drug approvals, poor safety profiles, 
      and long development processes are some of many hurdles encountered in the drug 
      discovery field. Therefore, drug repurposing can provide an alternative approach 
      to meet the demands of the new, potent and safe anti-cancer agents in terms of 
      both economic cost and time efficiency. The common molecular pathways of 
      different diseases and secondary indications of most of the approved drugs, and 
      advances in genomics, informatics and biology, as well as the availability of 
      approved or safe drug libraries can certainly provide an improved and efficient 
      way of screening safer drugs for new indications. Promising results of drug 
      repurposing in different therapeutic areas have encouraged the scientific 
      community to discover new drugs for different diseases using this methodology. 
      Herein, we provide a general overview of structurally and functionally diverse 
      approved drugs that have been repurposed as anti-cancer drugs.
FAU - Bhattarai, Deepak
AU  - Bhattarai D
FAU - Singh, Sarbijt
AU  - Singh S
FAU - Jang, Yerin
AU  - Jang Y
FAU - Hyeon Han, Seung
AU  - Hyeon Han S
FAU - Lee, Kyeong
AU  - Lee K
AD  - Dongguk University-Seoul, Goyang, 410-820, Korea. kaylee@dongguk.edu.
FAU - Choi, Yongseok
AU  - Choi Y
AD  - Korea University, Seoul 136-713, Korea. ychoi@korea.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Top Med Chem
JT  - Current topics in medicinal chemistry
JID - 101119673
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Diphosphonates)
RN  - 304NUG5GF4 (Itraconazole)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 73K4184T59 (Digoxin)
RN  - 9100L32L2N (Metformin)
RN  - HO3OGH5D7I (Nelfinavir)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/chemistry/*pharmacology
MH  - Aspirin/chemistry/pharmacology
MH  - Digoxin/chemistry/pharmacology
MH  - Diphosphonates/chemistry/pharmacology
MH  - Drug Approval
MH  - Drug Discovery
MH  - Drug Repositioning/*methods
MH  - Humans
MH  - Itraconazole/chemistry/pharmacology
MH  - Metformin/chemistry/pharmacology
MH  - Nelfinavir/chemistry/pharmacology
MH  - Thalidomide/chemistry/pharmacology
EDAT- 2016/02/18 06:00
MHDA- 2017/02/09 06:00
CRDT- 2016/02/17 06:00
PHST- 2015/03/30 00:00 [received]
PHST- 2015/08/25 00:00 [revised]
PHST- 2015/10/05 00:00 [accepted]
PHST- 2016/02/17 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
AID - CTMC-EPUB-73745 [pii]
AID - 10.2174/1568026616666160216153618 [doi]
PST - ppublish
SO  - Curr Top Med Chem. 2016;16(19):2156-68. doi: 10.2174/1568026616666160216153618.

PMID- 28984005
OWN - NLM
STAT- MEDLINE
DCOM- 20180830
LR  - 20180830
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 44
IP  - 1
DP  - 2018 Jan
TI  - Influence of perinatal low-dose acetylsalicylic acid therapy on fetal 
      hemodynamics evaluated by determining the acceleration-time/ejection-time ratio 
      in the ductus arteriosus.
PG  - 87-92
LID - 10.1111/jog.13465 [doi]
AB  - AIM: Acceleration-time/ejection-time ratio (At/Et ratio) of Doppler waveform is 
      an established hemodynamic parameters that reflect proximal stenosis. Using this 
      parameter, we evaluated whether perinatal low-dose acetylsalicylic acid (ASA) 
      therapy could alter hemodynamics in the ductus arteriosus. METHODS: Pulse Doppler 
      measurements of the fetal ductus arteriosus were performed longitudinally from 20 
      to 37 gestational weeks in 106 healthy pregnant women (controls) and 65 pregnant 
      women taking daily low-dose ASA (80 or 100 mg/day) because of a history of 
      recurrent pregnancy loss. The At/Et ratio, pulsatility index (PI), and peak 
      systolic velocity were evaluated and statistically analyzed. RESULTS: The At/Et 
      ratio significantly increased with gestational age in both the ASA group 
      (r = 0.54) and the control group (r = 0.35), while the PI did not. Median peak 
      systolic velocities also increased with gestational age in both the ASA group 
      (r = 0.39) and the control group (r = 0.31). No significant differences in At/Et 
      ratio, PI, or peak systolic velocity were observed between the ASA group and the 
      control group. CONCLUSION: Administration of low-dose ASA during pregnancy did 
      not appear to alter hemodynamics in the fetal ductus arteriosus.
CI  - © 2017 Japan Society of Obstetrics and Gynecology.
FAU - Miyazaki, Miwa
AU  - Miyazaki M
AD  - Department of Obstetrics and Gynecology, Nippon Medical School, Tokyo, Japan.
FAU - Kuwabara, Yoshimitsu
AU  - Kuwabara Y
AUID- ORCID: 0000-0002-1622-4063
AD  - Department of Obstetrics and Gynecology, Nippon Medical School, Tokyo, Japan.
FAU - Takeshita, Toshiyuki
AU  - Takeshita T
AD  - Department of Obstetrics and Gynecology, Nippon Medical School, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20171006
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Ductus Arteriosus/*drug effects
MH  - Female
MH  - Gestational Age
MH  - Heart Rate/drug effects
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Longitudinal Studies
MH  - Pregnancy
MH  - Treatment Outcome
MH  - Ultrasonography, Prenatal/*drug effects/methods
OTO - NOTNLM
OT  - Doppler waveform
OT  - acceleration time
OT  - ductus arteriosus
OT  - low-dose acetylsalicylic acid therapy
EDAT- 2017/10/07 06:00
MHDA- 2018/08/31 06:00
CRDT- 2017/10/07 06:00
PHST- 2017/03/28 00:00 [received]
PHST- 2017/05/30 00:00 [revised]
PHST- 2017/07/11 00:00 [accepted]
PHST- 2017/10/07 06:00 [pubmed]
PHST- 2018/08/31 06:00 [medline]
PHST- 2017/10/07 06:00 [entrez]
AID - 10.1111/jog.13465 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2018 Jan;44(1):87-92. doi: 10.1111/jog.13465. Epub 2017 
      Oct 6.

PMID- 12541156
OWN - NLM
STAT- MEDLINE
DCOM- 20030805
LR  - 20181130
IS  - 0342-4642 (Print)
IS  - 0342-4642 (Linking)
VI  - 29
IP  - 3
DP  - 2003 Mar
TI  - DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" 
      multicenter study.
PG  - 378-85
AB  - OBJECTIVE: A major cause of death in patients with severe hemorrhagic shock 
      following trauma is the subsequent occurrence of multiple organ failure due to 
      tissue hypoxia. Early administration of an oxygen carrier may reduce the 
      occurrence of organ failures and improve survival. It may also reduce the need of 
      blood products. DESIGN AND SETTING: Prospective multicenter study in a university 
      clinic. PATIENTS: 121 patients with severe hemorrhagic shock. INTERVENTIONS: 
      Patients were randomly assigned "on-scene" to receive either up to 1000 ml of a 
      10% diaspirin cross-linked hemoglobin (DCLHb) solution or the study center's 
      standard therapy. MEASUREMENTS AND RESULTS: Demographic and physiological 
      characteristics of the two treatment groups at baseline were comparable. Organ 
      failures and survival rates until day 5 and day 28 showed no significant 
      differences. The sponsor therefore terminated this trial prematurely after an 
      interim evaluation of the data indicated no evidence of efficacy to offset 
      concerns raised about the safety of DCLHb. Median volumes of cumulative blood 
      products administered on 1 (1595 vs. 3716 ml) and 7 days (3139 vs. 4746 ml) after 
      admission were lower in the DCLHb group. CONCLUSIONS: The early application of an 
      oxygen carrier (DCLHb) to patients with severe hemorrhagic shock following trauma 
      had no significant effect on the occurrence of organ failure or on 5- and 28-day 
      survival in this abbreviated trial. However, early infusion of up to 1000 ml 
      DCLHb reduces the need for blood products without changing morbidity or survival.
FAU - Kerner, Thoralf
AU  - Kerner T
AD  - Klinik für Anästhesiologie und Operative Intensivmedizin, Campus 
      Virchow-Klinikum, Charité, Humboldt Universität, Augustenburger Platz 1, 13353 
      Berlin, Germany.
FAU - Ahlers, Olaf
AU  - Ahlers O
FAU - Veit, Siegfried
AU  - Veit S
FAU - Riou, Bruno
AU  - Riou B
FAU - Saunders, Michael
AU  - Saunders M
FAU - Pison, Ulrich
AU  - Pison U
CN  - European DCLHb Trauma Study Group
LA  - eng
PT  - Clinical Trial
PT  - Comment
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20030123
PL  - United States
TA  - Intensive Care Med
JT  - Intensive care medicine
JID - 7704851
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Intensive Care Med. 2003 Mar;29(3):347-9. PMID: 12710459
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*analogs & derivatives/*therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - European Union
MH  - Female
MH  - *Fluid Therapy
MH  - Hemoglobins/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Organ Failure/etiology/prevention & control
MH  - Prospective Studies
MH  - Shock, Hemorrhagic/complications/*drug therapy
MH  - Statistics, Nonparametric
MH  - Survival Rate
MH  - Trauma Severity Indices
MH  - Treatment Outcome
EDAT- 2003/01/24 04:00
MHDA- 2003/08/06 05:00
CRDT- 2003/01/24 04:00
PHST- 2002/02/01 00:00 [received]
PHST- 2002/11/29 00:00 [accepted]
PHST- 2003/01/24 04:00 [pubmed]
PHST- 2003/08/06 05:00 [medline]
PHST- 2003/01/24 04:00 [entrez]
AID - 10.1007/s00134-002-1622-x [doi]
PST - ppublish
SO  - Intensive Care Med. 2003 Mar;29(3):378-85. doi: 10.1007/s00134-002-1622-x. Epub 
      2003 Jan 23.

PMID- 10560261
OWN - NLM
STAT- MEDLINE
DCOM- 19991116
LR  - 20131121
IS  - 0030-6002 (Print)
IS  - 0030-6002 (Linking)
VI  - 140
IP  - 42
DP  - 1999 Oct 17
TI  - [The rate of acetylsalicylic acid non-respondents among patients hospitalized for 
      acute coronary disease, previously undergoing secondary salicylic acid 
      prophylaxis].
PG  - 2339-43
AB  - The authors determined the rate of acetylsalicylic acid (ASA) non-responders 
      among patients receiving secondary prevention due to cardiovascular diseases at 
      the appearance of acute coronary events. The non-responders were defined as: 
      patients who have been treated with ASA because of acute coronary syndrome, but 
      the subsequently performed platelet aggregation study did not confirmed an 
      appropriate platelet inhibition. Among the 75 patients being investigated (44 
      male, 31 female, average age: 61.3 ys) 21 were hospitalized due to acute 
      myocardial infarction and 54 for unstable angina, respectively. The daily doses 
      of ASA were 200-325 mg. The aggregation of platelets was measured within 24 h 
      after the admission. The investigations were performed with different amounts of 
      4 different inducers (ADP, arachidonic acid, epinephrine and collagen) taking 
      dose-response curves. The antiaggregatory treatment with ASA was considered to be 
      ineffective if the typical aggregation curves were obtained above the following 
      final concentrations of the inducers: ADP: > 5 microM, epinephrine: > 5 microM, 
      arachidonic acid: > 250 microM, collagen: > 2 micrograms/ml. These 
      upper-threshold concentrations of the inducers were determined with the help of 
      the data of healthy drug free volunteers. Twenty-six of the 75 patients (34%) 
      were found to be non-responder to ASA, whereas the antiaggregatory effect of ASA 
      was proven in 49 cases. No differences were found in gender. The compliance was 
      proven with the HPLC-determination of urinary metabolites of ASA performed 
      immediately after the upon admission. Seven patients (10.9%) showed a 
      non-compliance, not showing any traces of ASA-metabolites in their urine. The 
      authors emphasizing the importance of the laboratory control even of the 
      prophylactic ASA treatment in order to continue the effective antiaggregatory 
      therapy with other effective drugs.
FAU - Tarján, J
AU  - Tarján J
AD  - III. Belgyógyászati Osztály, Megyei Markusovszky Kórház, Szombathely.
FAU - Salamon, A
AU  - Salamon A
FAU - Jáger, R
AU  - Jáger R
FAU - Poór, F
AU  - Poór F
FAU - Barczi, V
AU  - Barczi V
FAU - Dinnyés, J
AU  - Dinnyés J
FAU - Hamvas, J
AU  - Hamvas J
FAU - Kinczel, A
AU  - Kinczel A
FAU - Pál, A
AU  - Pál A
FAU - Blaskó, G
AU  - Blaskó G
LA  - hun
PT  - English Abstract
PT  - Journal Article
TT  - Az acetilszalicilsav nonreszponderek gyakorisága akut coronaria-szindróma miatt 
      kórházba felvett, megelözöen acetilszalicilsav szekunder preventív kezelésben 
      részesült betegek körében.
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Angina, Unstable/*drug therapy/prevention & control
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Coronary Disease/*drug therapy/prevention & control
MH  - *Drug Resistance
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/prevention & control
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
PST - ppublish
SO  - Orv Hetil. 1999 Oct 17;140(42):2339-43.

PMID- 2339674
OWN - NLM
STAT- MEDLINE
DCOM- 19900621
LR  - 20190824
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 29
IP  - 3-4
DP  - 1990 Mar
TI  - Effects of pentazocine and acetylsalicylic acid on pain-rating, pain-related 
      evoked potentials and vigilance in relationship to pharmacokinetic parameters.
PG  - 342-59
AB  - Achieving objective and quantitative measurement of experimental pain in human 
      volunteers and establishing the impact of drugs remains a difficult task. This 
      problem may be overcome by employing a method which allows the simultaneous 
      measurement of pain ratings elicited by standardized stimulation of the nasal 
      mucosa by carbon dioxide, together with pain-related chemo-somatosensory evoked 
      potentials (CSSEP) and vigilance. We assessed the effect of pentazocine and 
      acetylsalicylic acid on these parameters in 14 human volunteers and related the 
      effects to the pharmacokinetic parameters of the drugs measured at the same time. 
      Pentazocine was found to reduce the pain ratings as well as the amplitudes of the 
      pain-related evoked potentials and to increase their latencies. Vigilance 
      (measured by EEG power spectra and performance of a tracking task) was also 
      significantly reduced. These effects were observed during the distribution phase 
      and the first period of the terminal elimination phase of the drug. 
      Acetylsalicylic acid had no significant effects on pain ratings, but reduced the 
      amplitudes of the event-related potentials when compared to placebo controls. At 
      the same time a slight, but significant, effect on vigilance (reduced performance 
      of the tracking task) was observed. These effects could not be related to the 
      presence of unmetabolized acetylsalicylic acid in the plasma. They appeared at 
      later times when only salicylic acid was left. It is concluded that chemical 
      stimuli of sufficient intensity produce pain which may be suppressed by opioid 
      analgesics such as pentazocine. The effect of acetylsalicylic acid on this 
      experimental pain did not reach significance for all measured parameters under 
      the experimental conditions chosen. The changes in vigilance and in the 
      amplitudes of pain-related chemo-somatosensory evoked potentials indicated as yet 
      unknown CNS-effects of this non-steroidal anti-inflammatory drug.
FAU - Kobal, G
AU  - Kobal G
AD  - Institut für Pharmakologie und Toxikologie, Universität Erlangen-Nürnberg, BRD.
FAU - Hummel, C
AU  - Hummel C
FAU - Nuernberg, B
AU  - Nuernberg B
FAU - Brune, K
AU  - Brune K
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - R16CO5Y76E (Aspirin)
RN  - RP4A60D26L (Pentazocine)
SB  - IM
MH  - Adult
MH  - *Analgesia
MH  - Arousal/drug effects
MH  - Aspirin/*pharmacokinetics/pharmacology
MH  - Cerebral Cortex/physiopathology
MH  - Electroencephalography
MH  - Evoked Potentials, Somatosensory/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain/*physiopathology
MH  - Pentazocine/*pharmacokinetics/pharmacology
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
AID - 10.1007/BF01966467 [doi]
PST - ppublish
SO  - Agents Actions. 1990 Mar;29(3-4):342-59. doi: 10.1007/BF01966467.

PMID- 6828390
OWN - NLM
STAT- MEDLINE
DCOM- 19830421
LR  - 20190713
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 73
IP  - 3
DP  - 1983 Mar
TI  - The emerging new arthritis drugs. A clinician's opinion.
PG  - 125-34
AB  - In the face of deficiencies in our present system of introducing new drugs, 
      clinicians must be committed to monitoring patients carefully. They must not be 
      caught up in the hyperbole and excitement of the latest new drug, but instead 
      should allow the crucible of time to teach them and the rest of the medical 
      community the ultimate truths about this drug in all situations. They must not 
      let the package circular be their only guide to therapy, for it reflects only 
      what has been accomplished under limited conditions. By knowing their patients 
      well and by learning to proficiently use selected drugs that they have become 
      familiar and comfortable with, conscientious practitioners will approach the 
      present state of the art in meeting the needs of their patients.
FAU - Roth, S H
AU  - Roth SH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Propionates)
RN  - 0 (Thiazines)
RN  - 0 (ortho-Aminobenzoates)
RN  - 13T4O6VMAM (Piroxicam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Arthritis/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Piroxicam
MH  - Propionates/therapeutic use
MH  - Thiazines/therapeutic use
MH  - ortho-Aminobenzoates/therapeutic use
EDAT- 1983/03/01 00:00
MHDA- 1983/03/01 00:01
CRDT- 1983/03/01 00:00
PHST- 1983/03/01 00:00 [pubmed]
PHST- 1983/03/01 00:01 [medline]
PHST- 1983/03/01 00:00 [entrez]
AID - 10.1080/00325481.1983.11697799 [doi]
PST - ppublish
SO  - Postgrad Med. 1983 Mar;73(3):125-34. doi: 10.1080/00325481.1983.11697799.

PMID- 6157974
OWN - NLM
STAT- MEDLINE
DCOM- 19801124
LR  - 20190821
IS  - 0306-9877 (Print)
IS  - 0306-9877 (Linking)
VI  - 6
IP  - 5
DP  - 1980 May
TI  - The pathomechanism of acetylsalicylic acid intolerance. A hypothesis.
PG  - 487-90
AB  - In a number of individuals suffering from chronic asthma or chronic urticaria, 
      acetylsalicylic acid and structurally unrelated non-steroidal anti-inflammatory 
      agents and other compounds, e.g. tartrazine, elicit an intolerance syndrome that 
      mimics the signs and symptoms of an immediate-type allergic (anaphylactic) 
      reaction. An immunological basis for this reaction could be excluded. It is 
      assumed that the eliciting agents activate complement and that the intolerant 
      individuals lack plasma carboxypeptidase B, that normally inactivates C3a and C5a 
      in statu nascendi. The anaphylatoxins, if not immediately inactivated, release 
      the endogenous mediators of the anaphylactic reaction from the tissue mast cells.
FAU - Kallós, P
AU  - Kallós P
FAU - Schlumberger, H D
AU  - Schlumberger HD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 9007-36-7 (Complement System Proteins)
RN  - EC 3.4.- (Carboxypeptidases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Carboxypeptidases/blood
MH  - Complement System Proteins/metabolism
MH  - Drug Tolerance
MH  - Histamine Release
MH  - Humans
EDAT- 1980/05/01 00:00
MHDA- 1980/05/01 00:01
CRDT- 1980/05/01 00:00
PHST- 1980/05/01 00:00 [pubmed]
PHST- 1980/05/01 00:01 [medline]
PHST- 1980/05/01 00:00 [entrez]
AID - 0306-9877(80)90100-0 [pii]
AID - 10.1016/0306-9877(80)90100-0 [doi]
PST - ppublish
SO  - Med Hypotheses. 1980 May;6(5):487-90. doi: 10.1016/0306-9877(80)90100-0.

PMID- 34126362
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
VI  - 30
IP  - 8
DP  - 2021 Aug
TI  - Big Data Analysis of the Risk of Intracranial Hemorrhage in Korean Populations 
      Taking Low-Dose Aspirin.
PG  - 105917
LID - S1052-3057(21)00320-7 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2021.105917 [doi]
AB  - OBJECTIVES: Aspirin has traditionally been used as an analgesic and 
      anti-inflammatory drug; however, low-dose aspirin is known to increase the risk 
      of gastrointestinal and intracranial hemorrhage. In this study, the risk of 
      intracranial hemorrhage in patients taking low-dose aspirin was assessed. 
      MATERIALS AND METHODS: We used the Standard Sample Cohort DB dataset from the 
      National Health Insurance Sharing Service of Korea. This dataset includes details 
      of medical care and prescriptions for patients who used hospital services during 
      a 14-year period throughout Korea. Of approximately 1 million total patients, 
      data from 746,703 adults over the age of 30 years were included for analysis. An 
      Χ(2) test was performed to assess the effect of low-dose aspirin on intracranial 
      hemorrhage. In addition, the relationship between use of low-dose aspirin and 
      intracranial hemorrhage was analyzed using multiple logistic regression with 
      consideration of all confounding variables. RESULTS: The results revealed no 
      significant positive correlations between the use of low-dose aspirin and 
      intracranial hemorrhage requiring hospitalization. CONCLUSIONS: Big data analysis 
      of 746,703 patients in Korea over a period of 14 years showed that serious 
      intracranial hemorrhage requiring hospitalization was unrelated to low-dose 
      aspirin use. Moreover, low-dose aspirin use reduced the risk of intracranial 
      hemorrhage in Korean populations.
CI  - Copyright © 2021 Elsevier Inc. All rights reserved.
FAU - Kim, Tae Gon
AU  - Kim TG
AD  - Department of Neurosurgery, CHA Bundang Medical Center, CHA University, School of 
      Medicine. Electronic address: yusso2012@daum.net.
FAU - Yu, Soyoung
AU  - Yu S
AD  - College of Nursing, CHA University, 120 Haeryong-ro, Pocheon-shi, Gyeongghi-do, 
      South Korea.
LA  - eng
PT  - Journal Article
DEP - 20210611
PL  - United States
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National 
      Stroke Association
JID - 9111633
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Big Data
MH  - Female
MH  - Humans
MH  - Intracranial Hemorrhages/*chemically induced/diagnosis/epidemiology/prevention & 
      control
MH  - Male
MH  - Middle Aged
MH  - Protective Factors
MH  - Republic of Korea/epidemiology
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Big data
OT  - Intracranial hemorrhage
OT  - Statistics
COIS- Declaration of Competing Interest None declared
EDAT- 2021/06/15 06:00
MHDA- 2021/07/27 06:00
CRDT- 2021/06/14 20:20
PHST- 2021/03/24 00:00 [received]
PHST- 2021/05/18 00:00 [revised]
PHST- 2021/05/21 00:00 [accepted]
PHST- 2021/06/15 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
PHST- 2021/06/14 20:20 [entrez]
AID - S1052-3057(21)00320-7 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2021.105917 [doi]
PST - ppublish
SO  - J Stroke Cerebrovasc Dis. 2021 Aug;30(8):105917. doi: 
      10.1016/j.jstrokecerebrovasdis.2021.105917. Epub 2021 Jun 11.

PMID- 35365165
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220405
IS  - 1749-8090 (Electronic)
IS  - 1749-8090 (Linking)
VI  - 17
IP  - 1
DP  - 2022 Apr 1
TI  - Degos disease complicated by constrictive pericarditis in remote phase: a case 
      report.
PG  - 59
LID - 10.1186/s13019-022-01810-0 [doi]
LID - 59
AB  - BACKGROUND: Degos disease, also known as malignant atrophic papulosis, is 
      characterised by cutaneous manifestations due to chronic thrombo-obliterative 
      vasculopathy. There have been reports of the rare late-onset Degos disease 
      complicated by constrictive pericarditis (CP). This study reports a case of CP 
      caused by Degos disease that developed 20 years after diagnosis. CASE 
      PRESENTATION: A 62-year-old woman who had been taking aspirin for 20 years for 
      Degos disease was hospitalised for worsening of heart failure. The patient was 
      diagnosed with CP and underwent pericardiectomy. Pathological findings suggested 
      the involvement of Degos disease. The postoperative course was uneventful, and 
      her heart failure and Degos disease did not worsen. CONCLUSIONS: The study 
      findings suggests that Degos disease can cause long-term CP. Aspirin effectively 
      inhibited the progression of Degos disease, and surgical treatment was necessary 
      when heart failure due to CP was refractory to treatment.
CI  - © 2022. The Author(s).
FAU - Tadokoro, Yuki
AU  - Tadokoro Y
AD  - Department of Cardiovascular Surgery, Kitasato University School of Medicine, 
      1-15-1 Kitasato, Minami, Sagamihara, Kanagawa, 252-0374, Japan. 
      ss598yaeshio@gmail.com.
FAU - Kitamura, Tadashi
AU  - Kitamura T
AD  - Department of Cardiovascular Surgery, Kitasato University School of Medicine, 
      1-15-1 Kitasato, Minami, Sagamihara, Kanagawa, 252-0374, Japan.
FAU - Horai, Tetsuya
AU  - Horai T
AD  - Department of Cardiovascular Surgery, Kitasato University School of Medicine, 
      1-15-1 Kitasato, Minami, Sagamihara, Kanagawa, 252-0374, Japan.
FAU - Miyaji, Kagami
AU  - Miyaji K
AD  - Department of Cardiovascular Surgery, Kitasato University School of Medicine, 
      1-15-1 Kitasato, Minami, Sagamihara, Kanagawa, 252-0374, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220401
PL  - England
TA  - J Cardiothorac Surg
JT  - Journal of cardiothoracic surgery
JID - 101265113
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Malignant Atrophic Papulosis/complications/diagnosis
MH  - Middle Aged
MH  - Pericardiectomy
MH  - *Pericarditis, Constrictive/complications/diagnosis
PMC - PMC8973571
OTO - NOTNLM
OT  - Constrictive pericarditis
OT  - Degos disease
OT  - Heart failure
COIS- The authors declare that they have no competing interests.
EDAT- 2022/04/03 06:00
MHDA- 2022/04/06 06:00
CRDT- 2022/04/02 05:22
PHST- 2021/07/21 00:00 [received]
PHST- 2022/03/19 00:00 [accepted]
PHST- 2022/04/02 05:22 [entrez]
PHST- 2022/04/03 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
AID - 10.1186/s13019-022-01810-0 [pii]
AID - 1810 [pii]
AID - 10.1186/s13019-022-01810-0 [doi]
PST - epublish
SO  - J Cardiothorac Surg. 2022 Apr 1;17(1):59. doi: 10.1186/s13019-022-01810-0.

PMID- 28556061
OWN - NLM
STAT- MEDLINE
DCOM- 20180417
LR  - 20210109
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Print)
IS  - 0014-2972 (Linking)
VI  - 47
IP  - 7
DP  - 2017 Jul
TI  - Acetylsalicylic acid in critically ill patients: a cross-sectional and a 
      randomized trial.
PG  - 504-512
LID - 10.1111/eci.12771 [doi]
AB  - BACKGROUND: Despite decades of clinical use, the pharmacokinetics and the effects 
      of acetylsalicylic acid (ASA) in critically ill patients remain ill-defined. We 
      aimed to investigate the pharmacokinetics and the effects of different ASA 
      formulations during critical illness. DESIGN: A cross-sectional study and a 
      randomized, parallel-group trial were performed. Critically ill patients under 
      chronic oral ASA treatment (100 mg enteric-coated) were screened for high 
      'on-treatment' platelet reactivity (HTPR) according to arachidonic acid-induced 
      whole-blood aggregometry. Thirty patients with HTPR were randomized to receive 
      100 mg ASA intravenously, 100 mg enteric-coated ASA bid (bis in die) or 81 mg 
      chewable ASA (n = 10 per group). Serum thromboxane B2 (TXB2) levels, ASA and 
      salicylic acid levels were quantified. RESULTS: Of 66 patients, 85% (95% 
      confidence intervals 74-93%) had HTPR. Compared to baseline infusion of 100 mg, 
      ASA significantly reduced platelet aggregation after 24 h to median 80% 
      (Quartiles: 66-84%). Intake of 81 mg chewable ASA significantly reduced platelet 
      aggregation to 75% (54-86%) after four hours, but increased it to 117% after 24 h 
      (81-163%). Treatment with 100 mg enteric-coated ASA bid decreased platelet 
      aggregation after 24 h to median 56% (52-113%). Baseline TXB2 levels were median 
      0·35 ng/mL (0·07-0·94). Infusion of ASA or intake of 100 mg ASA bid reduced TXB2 
      levels to 0·07-0·18 ng/mL after 24 h, respectively. Chewable ASA reduced TXB2 
      levels only transiently. Pharmacokinetic analysis revealed highly variable 
      absorption patterns of oral ASA formulations. CONCLUSION: There is a very high 
      prevalence of HTPR in critically ill patients on peroral ASA therapy, caused by 
      an incomplete suppression of TXB2 and/or by impaired absorption of ASA.
CI  - © 2017 The Authors. European Journal of Clinical Investigation published by John 
      Wiley & Sons Ltd on behalf of Stichting European Society for Clinical 
      Investigation Journal Foundation.
FAU - Schoergenhofer, Christian
AU  - Schoergenhofer C
AUID- ORCID: 0000-0002-2286-1077
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
FAU - Hobl, Eva-Luise
AU  - Hobl EL
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
FAU - Schwameis, Michael
AU  - Schwameis M
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
FAU - Gelbenegger, Georg
AU  - Gelbenegger G
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
FAU - Staudinger, Thomas
AU  - Staudinger T
AD  - Department of Internal Medicine I Oncology & Hematology, Medical University of 
      Vienna, Vienna, Austria.
FAU - Heinz, Gottfried
AU  - Heinz G
AD  - Department of Internal Medicine II Cardiology, Medical University of Vienna, 
      Vienna, Austria.
FAU - Speidl, Walter S
AU  - Speidl WS
AD  - Department of Internal Medicine II Cardiology, Medical University of Vienna, 
      Vienna, Austria.
FAU - Zauner, Christian
AU  - Zauner C
AD  - Department of Internal Medicine III Gastroenterology & Hepatology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Reiter, Birgit
AU  - Reiter B
AD  - Clinical Institute of Laboratory Medicine, Forensic Toxicology Unit, Medical 
      University of Vienna, Vienna, Austria.
FAU - Lang, Irene
AU  - Lang I
AD  - Department of Internal Medicine II Cardiology, Medical University of Vienna, 
      Vienna, Austria.
FAU - Jilma, Bernd
AU  - Jilma B
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170620
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Critical Illness/*therapy
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacokinetics
MH  - Thromboxane B2/metabolism
PMC - PMC5519937
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - critically ill
OT  - pharmacokinetics
OT  - platelet aggregation
OT  - thromboxane
EDAT- 2017/05/31 06:00
MHDA- 2018/04/18 06:00
CRDT- 2017/05/31 06:00
PHST- 2017/03/24 00:00 [received]
PHST- 2017/05/23 00:00 [accepted]
PHST- 2017/05/31 06:00 [pubmed]
PHST- 2018/04/18 06:00 [medline]
PHST- 2017/05/31 06:00 [entrez]
AID - ECI12771 [pii]
AID - 10.1111/eci.12771 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2017 Jul;47(7):504-512. doi: 10.1111/eci.12771. Epub 2017 Jun 
      20.

PMID- 7799510
OWN - NLM
STAT- MEDLINE
DCOM- 19950124
LR  - 20141120
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 44
IP  - 9
DP  - 1994 Sep
TI  - The effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the spontaneously 
      beating isolated auricles of the rabbit heart.
PG  - 216-9
AB  - The effects of NSAIDs (aspirin and indomethacin) on the isolated auricles of the 
      rabbit heart were studied by observing the effects of these drugs on 
      automaticity, excitability and contractility of the auricles. Aspirin (25,50,100 
      uM) produced concentration dependent depression in the automaticity of the SA 
      node while indomethacin (10 uM, 25 uM) has stimulant effects and 50 uM produced 
      depressant action. Only low concentration of indomethacin (10 uM) produced 
      significant effect. Aspirin (25,50,100 uM) and indomethacin (50 uM) have 
      significant depressant effects on the excitability of the auricles. Aspirin (100 
      uM) has suppressant effects (p < 0.05) on the normal contractility while the 
      adrenaline stimulated contractility is not suppressed by aspirin and indomethacin 
      significantly. The results obtained in this study with aspirin and indomethacin 
      on chronotropicity and inotropicity of the rabbit atria have been discussed in 
      the light of experimental work done by the workers regarding conventional 
      antiarrhythmic drugs.
FAU - Bhatti, A S
AU  - Bhatti AS
AD  - Department of Pharmacology and Therapeutics, Allama Iqbal Medical College, 
      Lahore.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/pharmacology
MH  - Atrial Function
MH  - Female
MH  - Heart Atria/*drug effects
MH  - In Vitro Techniques
MH  - Indomethacin/pharmacology
MH  - Male
MH  - Myocardial Contraction/*drug effects
MH  - Rabbits
MH  - Sinoatrial Node/drug effects/physiology
EDAT- 1994/09/01 00:00
MHDA- 1994/09/01 00:01
CRDT- 1994/09/01 00:00
PHST- 1994/09/01 00:00 [pubmed]
PHST- 1994/09/01 00:01 [medline]
PHST- 1994/09/01 00:00 [entrez]
AID - 4807 [pii]
PST - ppublish
SO  - J Pak Med Assoc. 1994 Sep;44(9):216-9.

PMID- 3653532
OWN - NLM
STAT- MEDLINE
DCOM- 19871105
LR  - 20180216
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 37
IP  - 3
DP  - 1987
TI  - Effect of ranitidine on the absorption of aspirin.
PG  - 178-83
AB  - Six healthy male volunteers received 1 week's pretreatment with ranitidine, 150 
      mg twice daily, and placebo in a double-blind cross-over trial. On the 8th day, 
      each volunteer received 1 g of aspirin in order to study the pharmacokinetics of 
      this nonsteroidal anti-inflammatory drug. The results of this study suggest that 
      ranitidine does not induce clinically significant alterations to the kinetics of 
      a single dose of aspirin in healthy males.
FAU - Corrocher, R
AU  - Corrocher R
AD  - Institute of Medical Pathology, University of Verona, Italy.
FAU - Bambara, L M
AU  - Bambara LM
FAU - Caramaschi, P
AU  - Caramaschi P
FAU - Testi, R
AU  - Testi R
FAU - Girelli, M
AU  - Girelli M
FAU - Pellegatti, M
AU  - Pellegatti M
FAU - Lomeo, A
AU  - Lomeo A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 884KT10YB7 (Ranitidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacokinetics
MH  - Biological Availability
MH  - Double-Blind Method
MH  - Half-Life
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Intestinal Absorption/drug effects
MH  - Male
MH  - Ranitidine/*pharmacology
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1159/000199497 [doi]
PST - ppublish
SO  - Digestion. 1987;37(3):178-83. doi: 10.1159/000199497.

PMID- 12050341
OWN - NLM
STAT- MEDLINE
DCOM- 20020611
LR  - 20181130
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 346
IP  - 23
DP  - 2002 Jun 6
TI  - Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of 
      coronary heart disease.
PG  - 1800-6
AB  - BACKGROUND: Both aspirin and clopidogrel reduce the rate of cardiovascular events 
      in patients with coronary heart disease. We estimated the cost effectiveness of 
      the increased use of aspirin, clopidogrel, or both for secondary prevention in 
      patients with coronary heart disease. METHODS: We used the Coronary Heart Disease 
      Policy Model, a computer simulation of the U.S. population, to estimate the 
      incremental cost effectiveness (in dollars per quality-adjusted years of life 
      gained) of four strategies in patients over 35 years of age with coronary disease 
      from 2003 to 2027: aspirin for all eligible patients (i.e., those who were not 
      allergic to or intolerant of aspirin), aspirin for all eligible patients plus 
      clopidogrel for patients who were ineligible for aspirin, clopidogrel for all 
      patients, and the combination of aspirin for all eligible patients plus 
      clopidogrel for all patients. RESULTS: The extension of aspirin therapy from the 
      current levels of use to all eligible patients for 25 years would have an 
      estimated cost-effectiveness ratio of about $11,000 per quality-adjusted year of 
      life gained. The addition of clopidogrel for the 5 percent of patients who are 
      ineligible for aspirin would cost about $31,000 per quality-adjusted year of life 
      gained. Clopidogrel alone in all patients or in routine combination with aspirin 
      had an incremental cost of more than $130,000 per quality-adjusted year of life 
      gained and remained financially unattractive across a wide range of assumptions. 
      However, clopidogrel alone or in combination with aspirin would cost less than 
      $50,000 per quality-adjusted year of life gained if its price were reduced by 70 
      to 82 percent, to $1.00 and $0.60 per day, respectively. CONCLUSIONS: Increased 
      prescription of aspirin for secondary prevention of coronary heart disease is 
      attractive from a cost-effectiveness perspective. Because clopidogrel is more 
      costly, its incremental cost effectiveness is currently unattractive, unless its 
      use is restricted to patients who are ineligible for aspirin.
FAU - Gaspoz, Jean-Michel
AU  - Gaspoz JM
AD  - Clinique de Médecine II and the Division of Cardiology, Hôpitaux Universitaires, 
      Geneva, Switzerland. jean-michel.gaspoz@hcuge.ch
FAU - Coxson, Pamela G
AU  - Coxson PG
FAU - Goldman, Paula A
AU  - Goldman PA
FAU - Williams, Lawrence W
AU  - Williams LW
FAU - Kuntz, Karen M
AU  - Kuntz KM
FAU - Hunink, M G Myriam
AU  - Hunink MG
FAU - Goldman, Lee
AU  - Goldman L
LA  - eng
GR  - R01 HL46315/HL/NHLBI NIH HHS/United States
GR  - R01 HS06258/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2002 Jun 6;346(23):1819-21. PMID: 12050345
CIN - J Fam Pract. 2002 Sep;51(9):789. PMID: 12366903
CIN - N Engl J Med. 2003 Feb 6;348(6):560-3; author reply 560-3. PMID: 12571267
CIN - N Engl J Med. 2003 Feb 6;348(6):560-3; author reply 560-3. PMID: 12572580
CIN - N Engl J Med. 2003 Feb 6;348(6):560-3; author reply 560-3. PMID: 12572582
CIN - N Engl J Med. 2003 Feb 6;348(6):560-3; author reply 560-3. PMID: 12572583
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*economics/therapeutic use
MH  - Clopidogrel
MH  - Computer Simulation
MH  - Coronary Disease/*drug therapy/economics
MH  - Cost-Benefit Analysis
MH  - Drug Costs/statistics & numerical data
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Middle Aged
MH  - Models, Econometric
MH  - Platelet Aggregation Inhibitors/*economics/*therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Ticlopidine/analogs & derivatives/*economics/therapeutic use
EDAT- 2002/06/07 10:00
MHDA- 2002/06/12 10:01
CRDT- 2002/06/07 10:00
PHST- 2002/06/07 10:00 [pubmed]
PHST- 2002/06/12 10:01 [medline]
PHST- 2002/06/07 10:00 [entrez]
AID - 346/23/1800 [pii]
AID - 10.1056/NEJM200206063462309 [doi]
PST - ppublish
SO  - N Engl J Med. 2002 Jun 6;346(23):1800-6. doi: 10.1056/NEJM200206063462309.

PMID- 9696555
OWN - NLM
STAT- MEDLINE
DCOM- 19980806
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 13
IP  - 4-5
DP  - 1995 Apr
TI  - A new salicylate ISFET for the determination of salicylic and acetylsalicylic 
      acid in drugs.
PG  - 449-57
AB  - A salicylate ISFET for the analysis of salicylic and acetylsalicylic acid in 
      drugs is described. It is based on a salicylate ion selective membrane coated on 
      the surface of the Si3N4 gate of the FET. The sensitive membrane consists of 
      tetra-dodecylammonium salicylate, polyvinyl chloride and a proper plasticizer. 
      The linearity range of the sensor is 5 x 10(-5)-1.5 x 10(-2) M for the salicylic 
      acid, and 7 x 10(-5)-1.5 x 10(-2) M for the acetylsalicylic acid, respectively. 
      The detection limit for the two compounds is 5 x 10(-5) M while the response time 
      is < or = 20 s. The effect of pH and different interfering ions was also studied. 
      The sensor was used to analyse the content of acetylsalicylic and salicylic acid 
      in some drugs, and the accuracy of the method was evaluated through recovery 
      tests. The results obtained with this method are well correlated either with 
      those obtained with a classical ISE employing the same sensitive membrane or with 
      the classical volumetric method.
FAU - Su, Y
AU  - Su Y
AD  - Institute of Soil Science, Academia Sinica, Nanjing, China.
FAU - Tomassetti, M
AU  - Tomassetti M
FAU - Sammartino, M P
AU  - Sammartino MP
FAU - Crescentini, G
AU  - Crescentini G
FAU - Campanella, L
AU  - Campanella L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Membranes, Artificial)
RN  - 0 (Ointments)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 9002-86-2 (Polyvinyl Chloride)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - *Ion-Selective Electrodes
MH  - Membranes, Artificial
MH  - Ointments
MH  - Polyvinyl Chloride
MH  - Potentiometry
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Tablets
MH  - *Transistors, Electronic
EDAT- 1995/04/01 00:00
MHDA- 1998/08/08 00:01
CRDT- 1995/04/01 00:00
PHST- 1995/04/01 00:00 [pubmed]
PHST- 1998/08/08 00:01 [medline]
PHST- 1995/04/01 00:00 [entrez]
AID - 0731-7085(95)01320-K [pii]
AID - 10.1016/0731-7085(95)01320-k [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1995 Apr;13(4-5):449-57. doi: 10.1016/0731-7085(95)01320-k.

PMID- 23950982
OWN - NLM
STAT- MEDLINE
DCOM- 20140303
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 8
DP  - 2013
TI  - Combining aspirin with cholecalciferol (vitamin D3)--a potential new tool for 
      controlling possum populations.
PG  - e70683
LID - 10.1371/journal.pone.0070683 [doi]
LID - e70683
AB  - The introduced Australian brushtail possum is a major vertebrate pest in New 
      Zealand, with impacts on conservation and agriculture being managed largely 
      through poisoning operations. Cholecalciferol (vitamin D3) is registered for use 
      in controlling possums and despite its many advantages it is expensive and 
      relatively inhumane. Combination of a high proportion of aspirin with a low 
      proportion of cholecalciferol was effective in killing high proportions of groups 
      of acclimatised, caged possums: this is attributed to both an unexpectedly high 
      toxicity of the type of cholecalciferol used, and a proposed synergistic 
      mechanism between the two compounds. Death was caused by localised damage to 
      heart ventricles by aspirin, and inhibition of tissue repair by both aspirin and 
      cholecalciferol. The observed toxicosis had lower impact on the welfare of 
      possums than either compound administered alone, particularly aspirin alone. 
      Residue analyses of bait remains in the GI tract suggested a low risk of 
      secondary poisoning by either compound. The combination of cholecalciferol and 
      aspirin has the potential to meet key requirements of cost-effectiveness and 
      humaneness in controlling possum populations, but the effect of the combination 
      in non-target species has yet to be tested.
FAU - Morgan, David R
AU  - Morgan DR
AD  - Landcare Research, Lincoln, Canterbury, New Zealand. 
      morgand@landcareresearch.co.nz
FAU - Arrow, Jane
AU  - Arrow J
FAU - Smith, Mark P
AU  - Smith MP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130809
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 1C6V77QF41 (Cholecalciferol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacokinetics/*toxicity
MH  - Body Weight/drug effects
MH  - Cholecalciferol/pharmacokinetics/*toxicity
MH  - Drug Synergism
MH  - Female
MH  - Gastrointestinal Tract/*drug effects
MH  - Introduced Species
MH  - Lethal Dose 50
MH  - Male
MH  - New Zealand
MH  - Pest Control/economics/*methods
MH  - Trichosurus/*physiology
PMC - PMC3739777
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2013/08/21 06:00
MHDA- 2014/03/04 06:00
CRDT- 2013/08/17 06:00
PHST- 2013/03/04 00:00 [received]
PHST- 2013/06/21 00:00 [accepted]
PHST- 2013/08/17 06:00 [entrez]
PHST- 2013/08/21 06:00 [pubmed]
PHST- 2014/03/04 06:00 [medline]
AID - PONE-D-13-10609 [pii]
AID - 10.1371/journal.pone.0070683 [doi]
PST - epublish
SO  - PLoS One. 2013 Aug 9;8(8):e70683. doi: 10.1371/journal.pone.0070683. eCollection 
      2013.

PMID- 7728622
OWN - NLM
STAT- MEDLINE
DCOM- 19950601
LR  - 20190830
IS  - 0954-7894 (Print)
IS  - 0954-7894 (Linking)
VI  - 25
IP  - 1
DP  - 1995 Jan
TI  - Early and late onset asthmatic responses following lysine-aspirin inhalation in 
      aspirin-sensitive asthmatic patients.
PG  - 38-40
AB  - Inhalation of aerosolized lysine-aspirin (L-ASA) has been described as an 
      alternative diagnostic method in aspirin-sensitive asthma. To further understand 
      the pathogenetic mechanism of aspirin-sensitive asthma, we performed L-ASA 
      (Inyesprin) bronchoprovocation test (BPT) in 51 asthmatic patients (45 non-atopic 
      and six atopic asthma). Twenty-six patients showed significant 
      bronchoconstriction after the inhalation of L-ASA. Bronchoprovocation test 
      produced immediate asthmatic responses in 13 cases as well as dual asthmatic 
      responses in four cases, whose late onset asthmatic response was noted at 4-7 h 
      after L-ASA inhalation. We conclude that L-ASA bronchoprovocation might be a 
      useful method for the diagnosis and investigation of aspirin-sensitive asthma. 
      However, L-ASA inhalation can also induce late onset asthmatic responses.
FAU - Park, H S
AU  - Park HS
AD  - Department of Internal Medicine, National Medical Center, Seoul, Korea.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
CIN - Clin Exp Allergy. 1995 Jan;25(1):1-3. PMID: 7728619
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/adverse effects/*analogs & derivatives
MH  - Asthma/*chemically induced/physiopathology
MH  - Bronchial Hyperreactivity/chemically induced
MH  - Bronchial Provocation Tests
MH  - Bronchoconstriction/drug effects
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Lysine/adverse effects/*analogs & derivatives
MH  - Male
MH  - Maximal Expiratory Flow Rate
MH  - Middle Aged
MH  - Nebulizers and Vaporizers
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1111/j.1365-2222.1995.tb01000.x [doi]
PST - ppublish
SO  - Clin Exp Allergy. 1995 Jan;25(1):38-40. doi: 10.1111/j.1365-2222.1995.tb01000.x.

PMID- 7968672
OWN - NLM
STAT- MEDLINE
DCOM- 19941220
LR  - 20190821
IS  - 0385-5600 (Print)
IS  - 0385-5600 (Linking)
VI  - 38
IP  - 6
DP  - 1994
TI  - Lidocaine hydrochloride and acetylsalicylate kill bacteria by disrupting the 
      bacterial membrane potential in different ways.
PG  - 429-34
AB  - Lidocaine hydrochloride (LH), a local anesthetic, and acetylsalicylate (AcSAL), 
      show antibacterial activity for both gram-negative and gram-positive bacteria. 
      Kinetic studies indicated that antibacterial activity of LH was different from 
      that of AcSAL. A subinhibitory concentration of LH and AcSAL enhanced the 
      sensitivity of Escherichia coli, Salmonella typhimurium, and Pseudomonas 
      aeruginosa to novobiocin and nalidixic acid. The synergistic effect of AcSAL with 
      novobiocin and nalidixic acid was higher than that of LH. The effect of both 
      drugs on the membrane potential of inner membrane was also studied using inverted 
      membrane vesicles of bacteria. Both LH and AcSAL depolarized the membrane 
      potential after the vesicles were energized with nicotinamide adenine 
      dinucleotide. However, unlike AcSAL, pre-treatment of vesicles with LH had no 
      effect on the generation of membrane potential. These results suggest that 
      depolarization of the cytoplasmic membrane, preceded by the permeabilization of 
      the outer membrane for gram-negative bacteria, is associated with antibacterial 
      activity of LH and AcSAL. The difference in actions of LH and AcSAL was 
      discussed.
FAU - Ohsuka, S
AU  - Ohsuka S
AD  - Department of Oral Surgery, Nagoya University School of Medicine, Aichi, Japan.
FAU - Ohta, M
AU  - Ohta M
FAU - Masuda, K
AU  - Masuda K
FAU - Arakawa, Y
AU  - Arakawa Y
FAU - Kaneda, T
AU  - Kaneda T
FAU - Kato, N
AU  - Kato N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Microbiol Immunol
JT  - Microbiology and immunology
JID - 7703966
RN  - 0 (Anti-Bacterial Agents)
RN  - 98PI200987 (Lidocaine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Bacterial Agents/pharmacology
MH  - Aspirin/*pharmacology
MH  - Bacteria/*drug effects/growth & development
MH  - *Bacterial Physiological Phenomena
MH  - Cell Membrane
MH  - Drug Synergism
MH  - Lidocaine/*pharmacology
MH  - Membrane Potentials/drug effects
MH  - Microbial Sensitivity Tests
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1111/j.1348-0421.1994.tb01803.x [doi]
PST - ppublish
SO  - Microbiol Immunol. 1994;38(6):429-34. doi: 10.1111/j.1348-0421.1994.tb01803.x.

PMID- 32940891
OWN - NLM
STAT- MEDLINE
DCOM- 20211213
LR  - 20211214
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 35
IP  - 1
DP  - 2021 Feb
TI  - Comparison of Antithrombotic Strategies in Chinese Patients in Sinus Rhythm after 
      Bioprosthetic Mitral Valve Replacement: Early Outcomes from a Multicenter 
      Registry in China.
PG  - 1-10
LID - 10.1007/s10557-020-07069-8 [doi]
AB  - OBJECTIVES: To compare antithrombotic strategies in Chinese patients undergoing 
      bioprosthetic mitral valve implantation discharged in normal sinus rhythm. 
      METHODS: At 28 hospitals in China, 1603 patients were followed for 2991.5 
      person-years. Adverse event and death rates during five postoperative time 
      intervals (≤ 30, 31-90, 91-180, 181-365, and 366-730 days) were calculated in 
      patients administered warfarin, aspirin, warfarin + aspirin, or neither 
      treatment. RESULTS: Thromboembolic and hemorrhagic events occurred in 22 
      (0.74/100 patient-years, 95%CI 0.43-1.05) and 28 (0.94/100 patient-years, 95%CI 
      0.59-1.29) patients, respectively. In the first 3 months post-surgery, 
      warfarin-treated patients had significantly lower rates of thromboembolic events 
      than the aspirin or untreated groups (P = 0.01, P<0.01), and a significantly 
      lower risk of bleeding than the aspirin + warfarin group (P = 0.02). From 91 to 
      180 days post-surgery, thromboembolism risk was significantly lower in 
      warfarin-treated patients relative to the aspirin-treated and untreated patients 
      (P = 0.04, P = 0.04), but bleeding and overall adverse event rates were similar 
      (P = 1.00). From 181 to 365 days, thromboembolic event rates did not differ 
      significantly between the untreated and anticoagulant-treated groups (P = 1.00). 
      CONCLUSION: Warfarin is the most effective intervention for preventing 
      thromboembolism within 6 months post-bioprosthetic MVR surgery in Chinese 
      patients in sinus rhythm. After 6 months, further warfarin therapy was 
      unnecessary, and aspirin should not be routinely administered.
FAU - Zhang, Heng
AU  - Zhang H
AD  - Department of Cardiovascular Surgery, West China Hospital of Sichuan University, 
      No. 37, Guoxue Alley, Chengdu, 610041, China.
FAU - Dong, Yijun
AU  - Dong Y
AD  - Department of Thoracic Neoplasm, West China Hospital of Sichuan University, 
      Chengdu, China.
FAU - Ao, Xuelian
AU  - Ao X
AD  - Department of Ultrasound West China Hospital of Sichuan University, Chengdu, 
      China.
FAU - Fu, Bo
AU  - Fu B
AD  - Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin, China.
FAU - Dong, Li
AU  - Dong L
AUID- ORCID: 0000-0001-7860-6510
AD  - Department of Cardiovascular Surgery, West China Hospital of Sichuan University, 
      No. 37, Guoxue Alley, Chengdu, 610041, China. donglikn199@163.com.
CN  - CLIATHVR (Chinese Low Intensity Anticoagulant Therapy After Heart Valve 
      Replacement) multicenter clinical study team
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200917
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - *Bioprosthesis
MH  - China
MH  - Comorbidity
MH  - Drug Therapy, Combination
MH  - Female
MH  - *Heart Valve Prosthesis
MH  - Heart Valve Prosthesis Implantation
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mortality
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sex Factors
MH  - Stroke/mortality/prevention & control
MH  - Thromboembolism/mortality/*prevention & control
MH  - Time Factors
MH  - Warfarin/administration & dosage/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - Antithrombotic strategies
OT  - Biological prostheses
OT  - Bleeding
OT  - Mitral valve replacement
OT  - Thromboembolism
EDAT- 2020/09/18 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/09/17 12:18
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/09/17 12:18 [entrez]
AID - 10.1007/s10557-020-07069-8 [pii]
AID - 10.1007/s10557-020-07069-8 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2021 Feb;35(1):1-10. doi: 10.1007/s10557-020-07069-8. Epub 
      2020 Sep 17.

PMID- 7406122
OWN - NLM
STAT- MEDLINE
DCOM- 19801027
LR  - 20190627
IS  - 0002-9610 (Print)
IS  - 0002-9610 (Linking)
VI  - 140
IP  - 2
DP  - 1980 Aug
TI  - The contralateral diseased but asymptomatic carotid artery: to operate or not? An 
      update.
PG  - 203-5
AB  - Bilaterally diseased carotid arteries were demonstrated in 147 patients in a 
      personal series of 535 carotid reconstructions. A general policy of operating 
      only on symptomatic patients was followed. Although stenotic and ulcerated 
      plaques were known to be present in the contralateral artery, they were not 
      repaired unless new symptoms occurred. No strokes were observed in these patients 
      in a 20 year follow-up period. Twelve percent of the patients became symptomatic, 
      leading to new arteriograms and a second artery repair. The patients at risk and 
      their families were carefully instructed to report any symptoms of 
      cerebrovascular insufficiency. If meticulous follow-up is carried out, the 
      prophylactic repair of a truly asymptomatic diseased carotid artery is not 
      believed necessary to prevent stroke.
FAU - Levin, S M
AU  - Levin SM
FAU - Sondheimer, F K
AU  - Sondheimer FK
FAU - Levin, J M
AU  - Levin JM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Surg
JT  - American journal of surgery
JID - 0370473
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/surgery
MH  - Aspirin/therapeutic use
MH  - Carotid Artery Diseases/*surgery/therapy
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Endarterectomy
MH  - Humans
EDAT- 1980/08/01 00:00
MHDA- 1980/08/01 00:01
CRDT- 1980/08/01 00:00
PHST- 1980/08/01 00:00 [pubmed]
PHST- 1980/08/01 00:01 [medline]
PHST- 1980/08/01 00:00 [entrez]
AID - 0002-9610(80)90005-7 [pii]
AID - 10.1016/0002-9610(80)90005-7 [doi]
PST - ppublish
SO  - Am J Surg. 1980 Aug;140(2):203-5. doi: 10.1016/0002-9610(80)90005-7.

PMID- 508615
OWN - NLM
STAT- MEDLINE
DCOM- 19800226
LR  - 20190704
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 43
IP  - 1
DP  - 1979 Sep
TI  - A modified non-radioisotope method for measurement of platelet production time.
PG  - 137-41
AB  - Platelet production time (PPT), based on the measurement of malondialdehyde (MDA) 
      production prior to and after the intake of acetylsalicylic acid (ASA), was 
      determined in 20 healthy subjects. High MDA levels were produced by stimulating 
      platelet lipid peroxidation with arachidonic acid, resulting in a reliable, 
      sensitive and accurate technique. PPT correlated well with platelet survival time 
      measured by 51Cr autologous labelled platelets when both methods were used 
      simultaneously in the same patients. This modified non-radioisotope method might 
      serve as a useful aid in the diagnosis of platelet disorders, thromboembolic 
      diseases associated with increased platelet consumption and for the evaluation of 
      drugs affecting platelet function.
FAU - de Haas, H A
AU  - de Haas HA
FAU - Clark, S E
AU  - Clark SE
FAU - Zahavi, J
AU  - Zahavi J
FAU - Kakkar, V V
AU  - Kakkar VV
FAU - White, A M
AU  - White AM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism
MH  - Blood Platelets/metabolism
MH  - Cell Survival
MH  - Hematopoiesis
MH  - Humans
MH  - Lipid Metabolism
MH  - Malondialdehyde/blood
MH  - Platelet Function Tests/*methods
MH  - Time Factors
EDAT- 1979/09/01 00:00
MHDA- 1979/09/01 00:01
CRDT- 1979/09/01 00:00
PHST- 1979/09/01 00:00 [pubmed]
PHST- 1979/09/01 00:01 [medline]
PHST- 1979/09/01 00:00 [entrez]
AID - 10.1111/j.1365-2141.1979.tb03728.x [doi]
PST - ppublish
SO  - Br J Haematol. 1979 Sep;43(1):137-41. doi: 10.1111/j.1365-2141.1979.tb03728.x.

PMID- 31159806
OWN - NLM
STAT- MEDLINE
DCOM- 20200224
LR  - 20200608
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 18
IP  - 1
DP  - 2019 Jun 3
TI  - Aspirin has potential benefits for primary prevention of cardiovascular outcomes 
      in diabetes: updated literature-based and individual participant data 
      meta-analyses of randomized controlled trials.
PG  - 70
LID - 10.1186/s12933-019-0875-4 [doi]
LID - 70
AB  - BACKGROUND: The clinical benefit of aspirin for the primary prevention of 
      cardiovascular disease (CVD) in diabetes remains uncertain. To evaluate the 
      efficacy and safety of aspirin for the primary prevention of cardiovascular 
      outcomes and all-cause mortality events in people with diabetes, we conducted an 
      updated meta-analysis of published randomised controlled trials (RCTs) and a 
      pooled analysis of individual participant data (IPD) from three trials. METHODS: 
      Randomised controlled trials of aspirin compared with placebo (or no treatment) 
      in participants with diabetes with no known CVD were identified from MEDLINE, 
      Embase, Cochrane Library, and manual search of bibliographies to January 2019. 
      Relative risks with 95% confidence intervals were used as the summary measures of 
      associations. RESULTS: We included 12 RCTs based on 34,227 participants with a 
      median treatment duration of 5.0 years. Comparing aspirin use with no aspirin, 
      there was a significant reduction in risk of major adverse cardiovascular events 
      (MACE)0.89 (0.83-0.95), with a number needed to treat (NNT)of 95 (95% CI 61 to 
      208) to prevent one MACE over 5 years average follow-up. Evidence was lacking of 
      heterogeneity and publication bias among contributing trials for MACE. Aspirin 
      use had no effect on other endpoints including all-cause mortality; however, 
      there was a significant reduction in stroke for aspirin dosage ≤ 100 mg/day 0.75 
      (0.59-0.95). There were no significant effects of aspirin use on major bleeding 
      and other bleeding events, though some of the estimates were imprecise. Pooled 
      IPD from the three trials (2306 participants) showed no significant evidence of 
      an effect of aspirin on any of the outcomes evaluated; however, aspirin reduced 
      the risk of MACE in non-smokers 0.70 (0.51-0.96) with a NNT of 33 (95% CI 20 to 
      246) to prevent one MACE. CONCLUSIONS: Aspirin has potential benefits in 
      cardiovascular primary prevention in diabetes. The use of low dose aspirin may 
      need to be individualised and based on each individual's baseline CVD and 
      bleeding risk. Systematic review registration PROSPERO: CRD42019122326.
FAU - Seidu, Samuel
AU  - Seidu S
AUID- ORCID: 0000-0002-8335-7018
AD  - Leicester Diabetes Centre, Leicester General Hospital, Gwendolen Road, Leicester, 
      LE5 4WP, UK. sis11@le.ac.uk.
AD  - Diabetes Research Centre, University of Leicester, Leicester General Hospital, 
      Gwendolen Road, Leicester, LE5 4WP, UK. sis11@le.ac.uk.
FAU - Kunutsor, Setor K
AU  - Kunutsor SK
AD  - National Institute for Health Research Bristol Biomedical Research Centre, 
      University Hospitals Bristol NHS Foundation Trust and University of Bristol, 
      Bristol, UK.
AD  - Translational Health Sciences, Bristol Medical School, Musculoskeletal Research 
      Unit, University of Bristol, Learning & Research Building (Level 1), Southmead 
      Hospital, Bristol, BS10 5NB, UK.
FAU - Sesso, Howard D
AU  - Sesso HD
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth 
      Avenue, East-3rd Floor, Boston, MA, 02215, USA.
AD  - Department of Medicine, Division of Aging, Brigham and Women's Hospital, 75 
      Francis Street, Boston, MA, 02115, USA.
FAU - Gaziano, J M
AU  - Gaziano JM
AD  - Department of Medicine, Division of Aging, Brigham and Women's Hospital, 75 
      Francis Street, Boston, MA, 02115, USA.
FAU - Buring, J E
AU  - Buring JE
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth 
      Avenue, East-3rd Floor, Boston, MA, 02215, USA.
FAU - Roncaglioni, Maria Carla
AU  - Roncaglioni MC
AD  - Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Milan, Italy.
FAU - Khunti, Kamlesh
AU  - Khunti K
AD  - Leicester Diabetes Centre, Leicester General Hospital, Gwendolen Road, Leicester, 
      LE5 4WP, UK.
AD  - Diabetes Research Centre, University of Leicester, Leicester General Hospital, 
      Gwendolen Road, Leicester, LE5 4WP, UK.
LA  - eng
GR  - U01 CA182913/CA/NCI NIH HHS/United States
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20190603
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Agents/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/diagnosis/mortality/*prevention & control
MH  - Diabetes Mellitus/diagnosis/*drug therapy/mortality
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC6547459
OTO - NOTNLM
OT  - All-cause mortality
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Diabetes
OT  - Meta-analysis
OT  - Primary prevention
COIS- The authors declare that they have no competing interests.
EDAT- 2019/06/05 06:00
MHDA- 2020/02/25 06:00
CRDT- 2019/06/05 06:00
PHST- 2019/04/20 00:00 [received]
PHST- 2019/05/25 00:00 [accepted]
PHST- 2019/06/05 06:00 [entrez]
PHST- 2019/06/05 06:00 [pubmed]
PHST- 2020/02/25 06:00 [medline]
AID - 10.1186/s12933-019-0875-4 [pii]
AID - 875 [pii]
AID - 10.1186/s12933-019-0875-4 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2019 Jun 3;18(1):70. doi: 10.1186/s12933-019-0875-4.

PMID- 10759689
OWN - NLM
STAT- MEDLINE
DCOM- 20000621
LR  - 20190513
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 49
IP  - 4
DP  - 2000 Apr
TI  - Interaction between the LMWH reviparin and aspirin in healthy volunteers.
PG  - 337-41
AB  - AIMS: To investigate potential interactions between reviparin and acetylsalicylic 
      acid (ASA 300 mg o.d. from day 1-5). METHODS: In an open, randomized, 
      three-way-cross over study nine healthy volunteers received reviparin (s.c. 
      injection of 6300 anti-Xa units) or placebo from days 3 to 5 and acetylsalicylic 
      acid (ASA 300 mg) or placebo from days 1 to 5. Assessments included bleeding time 
      (BT), collagen (1 microg ml-1) induced platelet aggregation (CAG), heptest, 
      plasma antifactor Xa-activity and activated partial thromboplastin time (aPTT). 
      RESULTS: Median bleeding time at day 5 was 5.5 min after reverparin alone and 
      after ASA alone and was 9.6 min after the combination of reviparin and ASA. ASA 
      treatment reduced CAG from 84% to 40 to 50% of Amax; values after combined 
      treatment of reviparin with ASA were not different from those after ASA alone. 
      aPTT was prolonged to 32 s after reviparin; this effect was not modified if 
      subjects received ASA. Combined treatment with ASA and reviparin had no effect on 
      plasma anti-Xa-activity and heptest compared with reviparin alone. CONCLUSIONS: 
      We could not entirely exclude a small interaction between reviparin and ASA on 
      bleeding time, but the effect is probably without clinical significance.
FAU - Klinkhardt, U
AU  - Klinkhardt U
AD  - Institute of Clinical Pharmacology of the J.W.Goethe University, Frankfurt/M, 
      Germany.
FAU - Breddin, H K
AU  - Breddin HK
FAU - Esslinger, H U
AU  - Esslinger HU
FAU - Haas, S
AU  - Haas S
FAU - Kalatzis, A
AU  - Kalatzis A
FAU - Harder, S
AU  - Harder S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 3.4.21.6 (Factor Xa)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/adverse effects/*pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Bleeding Time
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Factor Xa/metabolism
MH  - Female
MH  - Hemostasis/drug effects
MH  - Heparin, Low-Molecular-Weight/adverse effects/*pharmacology
MH  - Humans
MH  - Male
MH  - Partial Thromboplastin Time
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacology
MH  - Platelet Function Tests
PMC - PMC2014945
EDAT- 2000/04/12 09:00
MHDA- 2000/06/24 11:00
CRDT- 2000/04/12 09:00
PHST- 2000/04/12 09:00 [pubmed]
PHST- 2000/06/24 11:00 [medline]
PHST- 2000/04/12 09:00 [entrez]
AID - bcp173 [pii]
AID - 10.1046/j.1365-2125.2000.00173.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2000 Apr;49(4):337-41. doi: 
      10.1046/j.1365-2125.2000.00173.x.

PMID- 8584072
OWN - NLM
STAT- MEDLINE
DCOM- 19960315
LR  - 20131121
IS  - 0028-2804 (Print)
IS  - 0028-2804 (Linking)
VI  - 66
IP  - 12
DP  - 1995 Dec
TI  - [Aspirin dosage for prevention of cerebral infarct: arguments for low dosage].
PG  - 890-4; discussion 885
AB  - Acetylsalicylic acid (ASS) is one of the best examined substances used in 
      secondary prevention after TIA and stroke. Since different strategies and 
      measurement variables were used in numerous randomised, double-blind, 
      placebo-controlled studies (one end-variable, such as non-fatal stroke, 
      myocardium infarction and vascular mortality, or combined end-variables, such as 
      TIA, stroke and death), meta-analysis was necessary to prove that ASS resulted in 
      about 22% reduction of secondary stroke. There is disagreement over the optimal 
      dosage to prevent a stroke: earlier studies considered > or = 975 mg ASS per day, 
      sometimes in combination with other substances, while more recently, lower 
      dosages of about 300 mg per day or even as low as < or = 100 mg per day have been 
      proposed. Higher and lower dosages were effective compared with placebo but with 
      no significant difference in risk reduction, despite the trend towards a 
      transient but insignificant reduction of secondary events for the high dosage. 
      All available studies demonstrated a strictly dose-related gastro-intestinal 
      hemorrhagic bleeding complication rate. Since no data are available from a direct 
      comparison in a large sample size trial to prove the superiority of low-dose ASS 
      (< or = 300 mg per day) over high dosages (> or = 975 mg per day) in secondary 
      prevention of stroke, we believe that the lowest dosage of < or = 100 mg per day 
      should be recommended for safety reasons.
FAU - Hennerici, M G
AU  - Hennerici MG
AD  - Neurologische Universitätsklinik, Ruprecht-Karls-Universität Heidelberg, Klinikum 
      Mannheim.
FAU - Meairs, S
AU  - Meairs S
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - ASS-Dosierung zur Prävention zerebraler Insulte: Argumente für eine niedrige 
      Dosierung.
PL  - Germany
TA  - Nervenarzt
JT  - Der Nervenarzt
JID - 0400773
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cerebral Infarction/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Risk Factors
RF  - 38
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
PST - ppublish
SO  - Nervenarzt. 1995 Dec;66(12):890-4; discussion 885.

PMID- 16359503
OWN - NLM
STAT- MEDLINE
DCOM- 20060221
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 3
IP  - 12
DP  - 2005 Dec
TI  - Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least 
      inhibited by aspirin: a randomized crossover trial.
PG  - 2649-55
AB  - OBJECTIVE: We aimed to determine whether adding clopidogrel to aspirin in 
      patients at high risk of future cardiovascular events would suppress laboratory 
      measures of the antiplatelet effects of aspirin; and have greater platelet 
      inhibitory effects in patients with the least inhibition of platelets by aspirin. 
      METHODS: We performed a randomized, double-blind, placebo-controlled, crossover 
      trial, comparing clopidogrel 75 mg day(-1) versus placebo, in 36 aspirin-treated 
      patients with symptomatic objectively confirmed peripheral arterial disease. 
      RESULTS: The addition of clopidogrel to aspirin did not suppress platelet 
      aggregation induced by arachidonic acid, urinary 11 dehydro thromboxane B2 
      concentrations, or soluble markers of platelet activation markers (P-selectin, 
      CD40-ligand) and inflammation (high sensitivity serum C-reactive protein, 
      interleukin-6). Clopidogrel significantly inhibited platelet aggregation induced 
      by ADP (reduction 26.2%; 95% CI: 21.3-31.1%, P < 0.0001) and collagen (reduction 
      6.2%; 95% CI: 3.2-9.3%, P = 0.0003). The greatest inhibition of collagen-induced 
      platelet aggregation by clopidogrel was seen in patients with the least 
      inhibition of arachidonic acid induced aggregation by aspirin [lower tertile of 
      arachidonic acid-induced platelet aggregation: 2.8% (95% CI: -0.8 to 6.3%) 
      reduction in mean collagen-induced aggregation by clopidogrel; middle tertile: 
      4.0% (95% CI: 0.4-7.6%); upper tertile 12.6% (95% CI: 4.5-20.8%); P-value for 
      interaction 0.01]. CONCLUSIONS: The greatest platelet inhibitory effect of 
      clopidogrel occurs in patients with the least inhibition of arachidonic 
      acid-induced platelet aggregation by aspirin. This raises the possibility that 
      the clinical benefits of adding clopidogrel to aspirin may be greatest in 
      patients whose platelets are least inhibited by aspirin. Confirmation in clinical 
      outcome studies may allow these patients to be targeted with antiplatelet drugs 
      that inhibit the ADP receptor, thereby overcoming the problem of laboratory 
      aspirin resistance.
FAU - Eikelboom, J W
AU  - Eikelboom JW
AD  - Department of Medicine, HGH McMaster Clinic, McMaster University, Hamilton, 
      Ontario, Canada. eikelbj@mcmaster.ca
FAU - Hankey, G J
AU  - Hankey GJ
FAU - Thom, J
AU  - Thom J
FAU - Claxton, A
AU  - Claxton A
FAU - Yi, Q
AU  - Yi Q
FAU - Gilmore, G
AU  - Gilmore G
FAU - Staton, J
AU  - Staton J
FAU - Barden, A
AU  - Barden A
FAU - Norman, P E
AU  - Norman PE
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Thromb Haemost. 2006 Jul;4(7):1638-9; author reply 1639-40. PMID: 16839373
MH  - Adenosine Diphosphate
MH  - Aged
MH  - Arachidonic Acid
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Biomarkers/blood
MH  - Clopidogrel
MH  - Collagen
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nephelometry and Turbidimetry
MH  - Peripheral Vascular Diseases/blood/*drug therapy
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
EDAT- 2005/12/20 09:00
MHDA- 2006/02/24 09:00
CRDT- 2005/12/20 09:00
PHST- 2005/12/20 09:00 [pubmed]
PHST- 2006/02/24 09:00 [medline]
PHST- 2005/12/20 09:00 [entrez]
AID - S1538-7836(22)16759-0 [pii]
AID - 10.1111/j.1538-7836.2005.01640.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2005 Dec;3(12):2649-55. doi: 10.1111/j.1538-7836.2005.01640.x.

PMID- 1924010
OWN - NLM
STAT- MEDLINE
DCOM- 19911107
LR  - 20190713
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 90
IP  - 5
DP  - 1991 Oct
TI  - Aspirin sensitivity. A distressing reaction that is now often treatable.
PG  - 227-33
AB  - Aspirin-induced hypersensitivity affects a substantial number of people, 
      including 20% or more of asthmatic patients. A dramatic flare of symptoms occurs 
      after indigestion of aspirin or a nonsteroidal anti-inflammatory drug, and 
      symptoms can persist even after the agent is discontinued. Fortunately, aspirin 
      desensitization, as described by the authors, now appears to be a treatment 
      option.
FAU - Manning, M E
AU  - Manning ME
AD  - Scripps Clinic and Research Foundation, La Jolla, CA 92037.
FAU - Stevenson, D D
AU  - Stevenson DD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/diagnosis/*etiology/therapy
MH  - Humans
MH  - Respiratory Hypersensitivity/chemically induced/diagnosis/therapy
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
AID - 10.1080/00325481.1991.11701086 [doi]
PST - ppublish
SO  - Postgrad Med. 1991 Oct;90(5):227-33. doi: 10.1080/00325481.1991.11701086.

PMID- 17094675
OWN - NLM
STAT- MEDLINE
DCOM- 20070103
LR  - 20131121
IS  - 0001-6659 (Print)
IS  - 0001-6659 (Linking)
VI  - 76
IP  - 1
DP  - 2006
TI  - [Pharmaceutical chemistry of minor analgesics and non-steroidal antiinflammatory 
      agents].
PG  - 37-54
AB  - The paper represents the last (6th) part of a series about agents acting on the 
      central nervous system. This time the minor analgesics and the non-steroidal 
      antiinflammatory agents are surveyed. As previously, the material is divided into 
      chapters of history, preparation; structure-properties-activity; therapeutical 
      use; analysis.
FAU - Szász, György
AU  - Szász G
AD  - Semmelweis Egyetem Gyógyszerészi Kémiai Intézet, Budapest.
FAU - Takácsné Novák, Krisztina
AU  - Takácsné Novák K
LA  - hun
PT  - English Abstract
PT  - Journal Article
TT  - A minor analgetikumok és a nem-szteroid gyulladáscsökkentok gyógyszerészi 
      kémiája.
PL  - Hungary
TA  - Acta Pharm Hung
JT  - Acta pharmaceutica Hungarica
JID - 0414322
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/chemistry
MH  - Analgesics/*chemistry
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - Diclofenac/chemistry
MH  - Molecular Structure
MH  - Spectrophotometry, Infrared
EDAT- 2006/11/11 09:00
MHDA- 2007/01/04 09:00
CRDT- 2006/11/11 09:00
PHST- 2006/11/11 09:00 [pubmed]
PHST- 2007/01/04 09:00 [medline]
PHST- 2006/11/11 09:00 [entrez]
PST - ppublish
SO  - Acta Pharm Hung. 2006;76(1):37-54.

PMID- 380039
OWN - NLM
STAT- MEDLINE
DCOM- 19790917
LR  - 20131121
IS  - 0347-9994 (Print)
IS  - 0347-9994 (Linking)
VI  - 3
IP  - 2
DP  - 1979
TI  - A double blind single dose comparison between two analgesics, rimazolium and 
      acetylsalicylic acid in oral surgery outpatients.
PG  - 57-61
AB  - The relief of pain after extraction of a mandibular third molar by two 
      analgesics, rimazolium and acetylsalicylic acid (ASA) was studied in three groups 
      of patients, who received either of these analgesics or a placebo. A 
      questionnaire and careful instructions on its use were given to the patients. ASA 
      had a better effect than both rimazolium and placebo. The results are discussed 
      with regard to differences between analgesics with or without anti-inflammatory 
      properties.
FAU - Heimdahl, A
AU  - Heimdahl A
FAU - Dahlström, H
AU  - Dahlström H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Sweden
TA  - Swed Dent J
JT  - Swedish dental journal
JID - 7706129
RN  - 0 (Placebos)
RN  - 0 (Pyrimidinones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
MH  - Pyrimidinones/*therapeutic use
MH  - *Tooth Extraction
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Swed Dent J. 1979;3(2):57-61.

PMID- 23451245
OWN - NLM
STAT- MEDLINE
DCOM- 20140121
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 2
DP  - 2013
TI  - Dose-risk and duration-risk relationships between aspirin and colorectal cancer: 
      a meta-analysis of published cohort studies.
PG  - e57578
LID - 10.1371/journal.pone.0057578 [doi]
LID - e57578
AB  - BACKGROUND: In previous meta-analyses, aspirin use has been associated with 
      reduced risk of colorectal cancer. However, uncertainty remains on the exact 
      dose-risk and duration-risk relationships. METHODS: We identified studies by 
      searching several English and Chinese electronic databases and reviewing relevant 
      articles. The dose-response meta-analysis was performed by linear trend 
      regression and restricted cubic spline regression. Subgroup analyses were 
      conducted to explore possible heterogeneity among studies. Potential 
      heterogeneity was calculated as Q statistic and I(2) value. Publication bias was 
      evaluated using funnel plots and quantified by the Begg's and Egger's test. 
      RESULTS: Twelve studies were included in this meta-analysis. An inverse 
      association between aspirin use and colorectal cancer was observed in both the 
      overall group (RR = 0.74, 95% CI 0.64-0.83 for aspirin dose; RR = 0.80, 95% CI 
      0.75-0.85 for frequency of aspirin use; RR = 0.75, 95% CI 0.68-0.81 for years of 
      aspirin use) and subgroups stratified by sex and cancer site. The dose-response 
      meta-analysis showed that there was a 20% statistically significant decreased 
      risk of colorectal cancer for 325 mg aspirin per day increment, 18% decreased 
      risk for 7 times aspirin per week increment and 18% decreased risk for 10 years 
      aspirin increment. CONCLUSION: Long-term (>5 years), low-dose (75-325 mg per day) 
      and regular aspirin use (2-7 times per week) can effectively reduce the risk of 
      colorectal cancer.
FAU - Ye, Xiaohua
AU  - Ye X
AD  - School of Public Health and Tropical Medicine, Southern Medical University, 
      Guangzhou, Guangdong, China.
FAU - Fu, Jinjian
AU  - Fu J
FAU - Yang, Yi
AU  - Yang Y
FAU - Chen, Sidong
AU  - Chen S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20130225
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Cohort Studies
MH  - Colorectal Neoplasms/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Research Design
MH  - Risk
PMC - PMC3581483
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2013/03/02 06:00
MHDA- 2014/01/22 06:00
CRDT- 2013/03/02 06:00
PHST- 2012/10/10 00:00 [received]
PHST- 2013/01/22 00:00 [accepted]
PHST- 2013/03/02 06:00 [entrez]
PHST- 2013/03/02 06:00 [pubmed]
PHST- 2014/01/22 06:00 [medline]
AID - PONE-D-12-31110 [pii]
AID - 10.1371/journal.pone.0057578 [doi]
PST - ppublish
SO  - PLoS One. 2013;8(2):e57578. doi: 10.1371/journal.pone.0057578. Epub 2013 Feb 25.

PMID- 24767203
OWN - NLM
STAT- MEDLINE
DCOM- 20150212
LR  - 20140428
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 53
IP  - 3
DP  - 2014 Mar
TI  - [The incidence of aspirin resistance and relevant influencing factors in patients 
      on maintenance hemodialysis].
PG  - 178-83
AB  - OBJECTIVE: To explore aspirin resistance (AR) and its relevant influencing 
      factors in patients on maintenance hemodialysis (MHD). METHODS: Patients on MHD 
      who visited Beijing Chaoyang Hospital from June 1 to 30, 2011 were enrolled in 
      this study. A total of 150 age and gender matched individuals with normal renal 
      function were taken as control group. Anthropometric data, biochemistry 
      parameters, ultrasonography and thromboelastograph (TEG) were inspected in the 
      both groups. AR was defined as inhibiting rate of acetylsalicylic acid drugs 
      [MA(AA)]>50% by TEG. RESULTS: Among the total 391 patients on MHD, 
      hypercoagulation was found in 18 patients (4.6%), normal coagulation in 288 
      patients (73.7%) and hypocoagulation in 85 patients (21.7%). Pearson's 
      correlation analysis revealed that the reaction time (R) and the thrombus 
      maxithrombelastic degree (MA) values were not correlated with the levels of 
      hemoglobin and platelet in MHD patients. A total of 306 patients with 
      hypercoagulation and normal coagulation were chosen as the MHD group. Compared 
      with the control group, higher high sensitivity C reactive protein (hsCRP), 
      homocysteine (Hcy) and R value were observed in the MHD group (P < 0.05), while 
      MA was significantly lower in the MHD group. Statistically higher incidence of AR 
      was shown in the MHD group (48.0% vs 20.0%, P = 0.00). Patients in the MHD group 
      were divided into the AR group and the aspirin sensitive (AS) group by the result 
      of TEG. Compared with the AS group, patients in the AR group were found to be 
      older with a higher female/male ratio, longer dialysis sustained time, higher 
      ratio of diabetes history, higher hsCRP, Hcy and fasting blood glucose (FBG) and 
      MA. They also manifested a higher incidence of cardiovascular and cerebrovascular 
      diseases, peripheral vascular disease and arteriovenous fistulas with thrombosis 
      with more spots of carotid artery and higher intima thickness of carotid artery 
      (IMT) (all P values<0.05). Lower R value was shown in the AR group. Binary 
      logistic regressive analysis revealed that the ratio of diabetes history, age and 
      dialysis sustained time. Hcy and hsCRP were the independent risk factors for AR 
      in patients on MHD. A total of 289 patients on MHD with atherosclerosis were 
      followed up for the mean time of 18.0 months with no hemorrhage found in the 
      process. Cox proportional hazards regression modeling demonstrated that AR was 
      associated with the major adverse long-term outcome of the vascular events [HR = 
      0.40, 95%CI 0.29-0.72, P = 0.00]. CONCLUSIONS: The ratio of platelet activation 
      in patients on MHD is significantly lower than in those with normal renal 
      function. Small dose of aspirin could be prescribed for the patients on MHD with 
      atherosclerosis to prevent vascular events. The incidence of AR is 48.0% in the 
      MHD group and the independent risk factors for AR in MHD patients are the ratio 
      of diabetes history, age, dialysis sustained time, Hcy and hsCRP. AR is 
      associated with the major adverse long-term outcome of acute vascular events.
FAU - Zhang, Chunhua
AU  - Zhang C
AD  - Urology and Nephrology Center, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing 100020, China.
FAU - Cui, Taigen
AU  - Cui T
AD  - Urology and Nephrology Center, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing 100020, China. Email: andrewcui@sina.com.
FAU - Zhao, Sumei
AU  - Zhao S
AD  - Urology and Nephrology Center, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing 100020, China.
FAU - Wang, Shixiang
AU  - Wang S
AD  - Urology and Nephrology Center, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing 100020, China.
FAU - Zhang, Xiaodong
AU  - Zhang X
AD  - Urology and Nephrology Center, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing 100020, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Case-Control Studies
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Renal Dialysis/*adverse effects
MH  - Risk Factors
EDAT- 2014/04/29 06:00
MHDA- 2015/02/13 06:00
CRDT- 2014/04/29 06:00
PHST- 2014/04/29 06:00 [entrez]
PHST- 2014/04/29 06:00 [pubmed]
PHST- 2015/02/13 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2014 Mar;53(3):178-83.

PMID- 353274
OWN - NLM
STAT- MEDLINE
DCOM- 19780929
LR  - 20131121
IS  - 0024-7758 (Print)
IS  - 0024-7758 (Linking)
VI  - 20
IP  - 5
DP  - 1978 May
TI  - Ibuprofen therapy for dysmenorrhea.
PG  - 246-52
AB  - Thirty-three dysmenorrheic patients were given ibuprofen, aspirin and a placebo 
      in a double-blind crossover study, with each drug taken during one of three 
      successive menstrual cycles in random sequence. Paired drug comparisons 
      demonstrated the statistical superiority of ibuprofen, as compared with the other 
      two, for the relief of pain. Data evaluated according to patient drug preference 
      showed similar results. The role of nonsteroidal antiinflammatory drugs in 
      therapy for dysmenorrhea is discussed.
FAU - Corson, S L
AU  - Corson SL
FAU - Bolognese, R J
AU  - Bolognese RJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Reprod Med
JT  - The Journal of reproductive medicine
JID - 0173343
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Dysmenorrhea/*drug therapy
MH  - Female
MH  - Humans
MH  - Ibuprofen/*therapeutic use
MH  - Placebos
OID - PIP: 015697
OID - POP: 00120086
OAB - 40 women with regular menstrual cycles and who had experienced dysmenorrhea 
      requiring analgesic use for pain relief for at least 1 year and for each of 3 
      preceding cycles were evaluated. The protocol featured a double blind crossover 
      study of 2 medications and a placebo, each taken during 1 of 3 successive 
      menstrual cycles in random sequence. The medications used were ibuprofen (200 
      mg), aspirin (325 mg), and placebo made to appear grossly identical to the other 
      medications. The intended dosage was 2 tablets every 4 hours as necessary for 
      relief of menstrual pain. A propoxyphene preparation was allowed for those 
      receiving little or no relief of severe pain. A patient report card was used to 
      document the severity of pain, the quantity of medication taken, and the relief 
      of pain. At the termination of the 3 month study period, the patients were asked 
      to rank the preparations in order of effectiveness. 7 women dropped out of the 
      study, leaving 33 patients for evaluation. For 7 patients, the report forms 
      showed that during at least 1 cycle 1 rather than 2 tablets were taken on 1 or 
      more occasions. The data were analyzed with and without these 7 patients, and in 
      only 1 area, i.e., "ability to pursue normal daily functions," was a significant 
      difference noted. The data presented reflect the results from 33 patients unless 
      otherwise indicated. The patients' mean age was 24.7 years. 23 patients were 
      nulligravidas and 24 were nulliparas. The prestudy menstrual intervals averaged 
      29.8 days (23-33) and remained regular during the study period in 31 of 33 
      patients. The menstrual flow averaged 5.3 days (1-9), with most patients 
      reporting a "moderate" among (24), l "light," and 8 "heavy." 14 of the patients 
      used no contraceptive technique or were not sexually active; 5 used oral 
      contraceptives (OCs) and continued doing so throughout the study; 4 were IUD 
      wearers; 4 used a diaphragm; 3 had condom protected coitus; and 3 had had prior 
      laparoscopic sterilization. With the exception of IUD wearers, no pathology or 
      medical reason accounting for dysmenorrhea was obvious, and no patient had 
      physical findings suggestive of endometriosis. Most (18) symptoms started on day 
      0, but 13 patients suffered symptoms prior to the onset of menstrual bleeding. 
      The symptoms lasted an average of 2.6 days but as long as 7 days. The usual 
      severity of dysmenorrhea was reported as mild in 4, moderate in 18, and severe in 
      11. When paired comparisons were made of each of the 3 drug pairs, ibuprofen was 
      significantly more effective than either aspirin or the placebo. Aspirin was not 
      significantly superior to the placebo. Data evaluated according to patient drug 
      preference showed similar results.
OABL- eng
OTO - PIP
OT  - Age Factors
OT  - Americas
OT  - *Comparative Studies
OT  - Contraceptive Usage
OT  - Developed Countries
OT  - Diseases
OT  - *Dysmenorrhea
OT  - *Evaluation
OT  - *Menstruation Disorders
OT  - North America
OT  - Northern America
OT  - *Pain
OT  - Parity
OT  - Pennsylvania
OT  - Population Characteristics
OT  - Research Methodology
OT  - Signs And Symptoms
OT  - Studies
OT  - *Treatment
OT  - United States
GN  - PIP: TJ: JOURNAL OF REPRODUCTIVE MEDICINE.
EDAT- 1978/05/01 00:00
MHDA- 1978/05/01 00:01
CRDT- 1978/05/01 00:00
PHST- 1978/05/01 00:00 [pubmed]
PHST- 1978/05/01 00:01 [medline]
PHST- 1978/05/01 00:00 [entrez]
PST - ppublish
SO  - J Reprod Med. 1978 May;20(5):246-52.

PMID- 9021813
OWN - NLM
STAT- MEDLINE
DCOM- 19970415
LR  - 20191024
IS  - 0888-0018 (Print)
IS  - 0888-0018 (Linking)
VI  - 14
IP  - 1
DP  - 1997 Jan-Feb
TI  - Antipyretic effect of parenteral paracetamol (propacetamol) in pediatric 
      oncologic patients: a randomized trial.
PG  - 51-7
AB  - The antipyretic efficacy of propacetamol, an intravenous prodrug of paracetamol, 
      was evaluated in two pediatric prospective randomized studies. In the first, 
      we-compared one standard intravenous dose of propacetamol (30 mg/kg) to one 
      standard intravenous dose of acetylsalicylic acid (ASA, 15 mg/kg) in 10 
      nononcologic patients with bacterial illnesses. In the second study, we compared 
      two intravenous doses of propacetamol (30 mg/kg versus 15 mg/kg) in 24 oncologic 
      patients with fever and neutropenia. No statistically significant differences in 
      antipyretic efficacy were found between standard doses of propacetamol and ASA; 
      even when half-doses of propacetamol (15 mg/kg) were used, good antipyretic 
      efficacy was observed, which was not statistically different from that observed 
      with the full dose. The use of propacetamol seems promising for patients (such as 
      oncologic patients) who cannot receive enteral paracetamol formulas.
FAU - Reymond, D
AU  - Reymond D
AD  - Department of Paediatrics, University Hospital, Bern, Switzerland.
FAU - Birrer, P
AU  - Birrer P
FAU - Lüthy, A R
AU  - Lüthy AR
FAU - Rimensberger, P C
AU  - Rimensberger PC
FAU - Beck, M N
AU  - Beck MN
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Pediatr Hematol Oncol
JT  - Pediatric hematology and oncology
JID - 8700164
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/*therapeutic use
MH  - Analgesics, Non-Narcotic/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Bacterial Infections/complications
MH  - Child
MH  - Child, Preschool
MH  - Fever/*drug therapy/etiology
MH  - Humans
MH  - Infusions, Intravenous
MH  - Neoplasms/*complications
MH  - Neutropenia/drug therapy/etiology
MH  - Prospective Studies
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.3109/08880019709030884 [doi]
PST - ppublish
SO  - Pediatr Hematol Oncol. 1997 Jan-Feb;14(1):51-7. doi: 10.3109/08880019709030884.

PMID- 3909471
OWN - NLM
STAT- MEDLINE
DCOM- 19860128
LR  - 20201209
IS  - 0347-9994 (Print)
IS  - 0347-9994 (Linking)
VI  - 9
IP  - 5
DP  - 1985
TI  - Acetylsalicylic acid compared with acetylsalicylic acid plus codeine as 
      postoperative analgesics after removal of impacted mandibular third molars.
PG  - 207-12
AB  - In a multicenter, double blind clinical trial a combination of acetylsalicylic 
      acid 500 mg + codeine phosphate 30 mg has been compared with acetylsalicylic acid 
      500 mg as postoperative analgesics in patients with pain after surgical removal 
      of impacted mandibular third molars. Evaluation of the results from 129 patients 
      showed that the combination of acetylsalicylic acid and codeine provided better 
      pain relief and also the number of tablets used was smaller and the time 
      intervals between repeated doses were longer than with acetylsalicylic acid only. 
      Adverse effects were few and similar for both drugs. It may be concluded that the 
      combination of 500 mg acetylsalicylic acid and 30 mg codeine phosphate provides a 
      useful analgesic for more severe pain conditions in oral surgery.
FAU - Dahl, E
AU  - Dahl E
FAU - Feldmann, G
AU  - Feldmann G
FAU - Jönsson, E
AU  - Jönsson E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Sweden
TA  - Swed Dent J
JT  - Swedish dental journal
JID - 7706129
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Codeine/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Humans
MH  - Mandible
MH  - Molar, Third/*surgery
MH  - Pain, Postoperative/*drug therapy
MH  - Time Factors
MH  - Tooth Extraction/*adverse effects
MH  - Tooth, Impacted/*surgery
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Swed Dent J. 1985;9(5):207-12.

PMID- 17305650
OWN - NLM
STAT- MEDLINE
DCOM- 20070423
LR  - 20210503
IS  - 0954-6820 (Print)
IS  - 0954-6820 (Linking)
VI  - 261
IP  - 3
DP  - 2007 Mar
TI  - Prevention of serious vascular events by aspirin amongst patients with peripheral 
      arterial disease: randomized, double-blind trial.
PG  - 276-84
AB  - OBJECTIVE: To assess the prophylactic efficacy of aspirin and a high-dose 
      antioxidant vitamin combination in patients with peripheral arterial disease 
      (PAD) in terms of reduction of the risk of a first vascular event (myocardial 
      infarction, stroke, vascular death) and critical limb ischaemia. DESIGN: 
      Randomized, placebo-controlled, double-blind clinical trial with 2 x 2 factorial 
      design. SETTING: Thirty-seven European angiology/vascular medicine units. 
      SUBJECTS: A total of 366 outpatients with stage I-II PAD documented by 
      angiography or ultrasound, with ankle/brachial index <0.85 or toe index <0.6; 210 
      patients completed the follow-up. INTERVENTIONS: Four treatment groups: (i) oral 
      aspirin (100 mg daily), (ii) oral antioxidant vitamins (600 mg vitamin E, 250 mg 
      vitamin C and 20 mg beta-carotene daily), (iii) both or (iv) neither, given for 2 
      years. MAIN OUTCOME MEASURE: Major vascular events (cardiovascular death, 
      myocardial infarction or stroke) and critical leg ischaemia. RESULTS: Seven of 
      185 patients allocated aspirin and 20 of 181 allocated placebo suffered a major 
      vascular event (risk reduction 64%, P = 0.022); five and eight patients, 
      respectively, suffered critical leg ischaemia (total 12 vs. 28, P = 0.014). There 
      was no evidence that antioxidant vitamins were beneficial (16/185 vs. 11/181 
      vascular events). Neither treatment was associated with any significant increase 
      in adverse events. Inclusion of this trial in a meta-analysis of other randomized 
      trials of anti-platelet therapy in PAD makes the overall results highly 
      significant (P < 0.001) and suggests that low-dose aspirin reduces the incidence 
      of vascular events by 26%. CONCLUSIONS: For the first time direct evidence shows 
      that low-dose aspirin should routinely be considered for PAD patients, including 
      those with concomitant type 2 diabetes.
CN  - Critical Leg Ischaemia Prevention Study (CLIPS) Group
AD  - Research Centre on Vascular Diseases, University of Milan, L Sacco Hospital, 
      Italy. mariella.catalano@unimi.it
FAU - Catalano, M
AU  - Catalano M
FAU - Born, G
AU  - Born G
FAU - Peto, R
AU  - Peto R
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Ischemia/*prevention & control
MH  - Leg/*blood supply
MH  - Male
MH  - Peripheral Vascular Diseases/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Treatment Outcome
EDAT- 2007/02/20 09:00
MHDA- 2007/04/24 09:00
CRDT- 2007/02/20 09:00
PHST- 2007/02/20 09:00 [pubmed]
PHST- 2007/04/24 09:00 [medline]
PHST- 2007/02/20 09:00 [entrez]
AID - JIM1763 [pii]
AID - 10.1111/j.1365-2796.2006.01763.x [doi]
PST - ppublish
SO  - J Intern Med. 2007 Mar;261(3):276-84. doi: 10.1111/j.1365-2796.2006.01763.x.

PMID- 16687994
OWN - NLM
STAT- MEDLINE
DCOM- 20060629
LR  - 20191026
IS  - 0268-1315 (Print)
IS  - 0268-1315 (Linking)
VI  - 21
IP  - 4
DP  - 2006 Jul
TI  - Shortened onset of action of antidepressants in major depression using 
      acetylsalicylic acid augmentation: a pilot open-label study.
PG  - 227-31
AB  - Based on our preclinical data showing a potential accelerating effect of 
      acetylsalicylic acid (ASA) in combination with fluoxetine in an animal model of 
      depression, we examined the effect of ASA augmentation therapy on selective 
      reuptake inhibitors (SSRI) in major depressed non-responder patients. Twenty-four 
      non-responder patients having received at least 4 weeks of an adequate SSRI 
      treatment were included in a pilot open-label study. Participants were treated 
      openly during 4 weeks with 160 mg/day ASA in addition to their current 
      antidepressant treatment. The combination SSRI-ASA was associated with a response 
      rate of 52.4%. Remission was achieved in 43% of the total sample and 82% of the 
      responder sample. In the responder group, a significant improvement was observed 
      within week 1 (mean Hamilton Depression Rating Scale-21 items at day 
      0=29.3+/-4.5, at day 7=14.0+/-4.1; P<0.0001) and remained sustained until day 28. 
      Despite limitations due to the open nature of this study, our preliminary results 
      confirm our preclinical findings and are in favour of an accelerating effect of 
      ASA in combination with SSRIs in the treatment of major depression. Potential 
      physiological and biochemical mechanisms may involve an anti-inflammatory and/or 
      neurotrophic effect.
FAU - Mendlewicz, Julien
AU  - Mendlewicz J
AD  - Department of Psychiatry, Erasme Hospital, Free University of Brussels, Belgium. 
      jmendlew@ulb.ac.be
FAU - Kriwin, Philippe
AU  - Kriwin P
FAU - Oswald, Pierre
AU  - Oswald P
FAU - Souery, Daniel
AU  - Souery D
FAU - Alboni, Silvia
AU  - Alboni S
FAU - Brunello, Nicoletta
AU  - Brunello N
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antidepressive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Antidepressive Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Depressive Disorder, Major/*drug therapy
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2006/05/12 09:00
MHDA- 2006/06/30 09:00
CRDT- 2006/05/12 09:00
PHST- 2006/05/12 09:00 [pubmed]
PHST- 2006/06/30 09:00 [medline]
PHST- 2006/05/12 09:00 [entrez]
AID - 00004850-200607000-00005 [pii]
AID - 10.1097/00004850-200607000-00005 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 2006 Jul;21(4):227-31. doi: 
      10.1097/00004850-200607000-00005.

PMID- 11827382
OWN - NLM
STAT- MEDLINE
DCOM- 20020311
LR  - 20190822
IS  - 0003-2654 (Print)
IS  - 0003-2654 (Linking)
VI  - 127
IP  - 1
DP  - 2002 Jan
TI  - Quantitative determination of acetylsalicylic acid and acetaminophen in tablets 
      by FT-Raman spectroscopy.
PG  - 144-8
AB  - A procedure for quantitative determination of acetylsalicylic acid and 
      acetaminophen in pharmaceuticals by PLS (partial least squares) and PCR 
      (principal component regression) treatment of FT (Fourier transform)-Raman 
      spectroscopic data is proposed. The proposed method was tested on powdered 
      samples. Three chemometric models were built: the first, for samples consisting 
      of an active substance diluted by lactose, starch and talc; the second, in which 
      a simple inorganic salt was applied as an internal standard and additions were 
      not taken into account; and the third, in which a model was constructed for a 
      commercial pharmaceutical, where all constituents of the tablet were known. By 
      utilising selected spectral ranges and by changing the chemometric conditions it 
      is possible to carry out fast and precise analysis of the active component 
      content in medicines on the basis of the simplified chemometric models. The 
      proposed method was tested on five commercial tablets. The results were compared 
      with data obtained by intensity ratio and pharmacopoeial methods. To appraise the 
      quality of the models, the relative standard error of predictions (RSEPs) were 
      calculated for calibration and prediction data sets. These were 0.7-2.0% and 
      0.8-2.3%, respectively, for the different PLS models. Application of these models 
      to the Raman spectra of commercial tablets containing acetylsalicylic acid gave 
      RSEP values of 1.3-2.0% and a mean accuracy of 1.2-1.7% with a standard deviation 
      of 0.6-1.2%.
FAU - Szostak, Roman
AU  - Szostak R
AD  - Faculty of Chemistry, University of Wrocław, Poland. rsz@wchuwr.chem.uni.wroc.pl
FAU - Mazurek, Sylwester
AU  - Mazurek S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Analgesics, Non-Narcotic/*analysis
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis
MH  - Aspirin/*analysis
MH  - Spectrum Analysis, Raman/methods
MH  - Tablets
EDAT- 2002/02/06 10:00
MHDA- 2002/03/12 10:01
CRDT- 2002/02/06 10:00
PHST- 2002/02/06 10:00 [pubmed]
PHST- 2002/03/12 10:01 [medline]
PHST- 2002/02/06 10:00 [entrez]
AID - 10.1039/b108240j [doi]
PST - ppublish
SO  - Analyst. 2002 Jan;127(1):144-8. doi: 10.1039/b108240j.

PMID- 23386069
OWN - NLM
STAT- MEDLINE
DCOM- 20130729
LR  - 20181202
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 47
IP  - 2
DP  - 2013 Feb
TI  - Reinitiating aspirin therapy for primary prevention of cardiovascular events in a 
      patient post-aspirin-induced upper gastrointestinal bleed: a case report and 
      review of literature.
PG  - e8
LID - 10.1345/aph.1R570 [doi]
AB  - OBJECTIVE: To describe a case of continued aspirin use for primary prevention of 
      a cardiovascular event in a patient post-aspirin-induced upper gastrointestinal 
      (GI) bleed and evaluate published evidence to determine whether reinitiating 
      aspirin therapy for this patient was appropriate. CASE SUMMARY: A 65-year-old man 
      had been taking chronic low-dose (81 mg/day) aspirin therapy since 2002 for 
      primary prevention of a cardiovascular event. He developed an upper GI bleed with 
      lowered hemoglobin (9 mg/dL) and hematocrit (26.3%) after concomitantly taking 2 
      doses of naproxen (220 mg each). An objective causality assessment with the 
      Naranjo probability scale revealed a probable adverse reaction of an upper GI 
      bleed associated with concomitant naproxen and aspirin use. No further naproxen 
      was taken. Aspirin was discontinued and pantoprazole was started, with resolution 
      of the bleeding. Aspirin was restarted 2.5 months after pantoprazole was 
      initiated, and no further bleeding occurred. DISCUSSION: Upper GI bleeds 
      associated with aspirin therapy are well described in the literature. The 
      management of cardiovascular event prophylaxis after a GI bleed is often 
      controversial; consensus in regard to the optimal method of management does not 
      exist. We evaluated GI protection strategies for patients with a history of 
      aspirin-induced GI bleeding requiring cardiovascular prophylaxis. We found that 
      the benefit of aspirin for the primary prevention of cardiovascular events needs 
      to be carefully balanced with the risks associated with its use. The current 
      literature supports that the best approach to prevent recurrent aspirin-induced 
      GI bleeding is to administer a proton pump inhibitor with aspirin therapy. 
      CONCLUSIONS: The benefit of aspirin for primary prevention of cardiovascular 
      events needs to be carefully balanced with the risks associated with its use. 
      Based on the current literature, the best approach to preventing recurrent 
      aspirin-induced GI bleeds is to administer a proton pump inhibitor concomitantly 
      with aspirin therapy.
FAU - Adly, Gounathan
AU  - Adly G
AD  - St. Francis Hospital, The Heart Center, Roslyn, NY, USA. Gounathan.Adly@chsli.org
FAU - Plakogiannis, Roda
AU  - Plakogiannis R
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20130205
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 57Y76R9ATQ (Naproxen)
RN  - D8TST4O562 (Pantoprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects/therapeutic use
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cyclooxygenase Inhibitors/adverse effects
MH  - Drug Interactions
MH  - *Drug Monitoring
MH  - Gastrointestinal Hemorrhage/*chemically induced/therapy
MH  - Humans
MH  - Male
MH  - Naproxen/adverse effects
MH  - Pantoprazole
MH  - Proton Pump Inhibitors/adverse effects/therapeutic use
MH  - Treatment Outcome
EDAT- 2013/02/07 06:00
MHDA- 2013/07/31 06:00
CRDT- 2013/02/07 06:00
PHST- 2013/02/07 06:00 [entrez]
PHST- 2013/02/07 06:00 [pubmed]
PHST- 2013/07/31 06:00 [medline]
AID - aph.1R570 [pii]
AID - 10.1345/aph.1R570 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2013 Feb;47(2):e8. doi: 10.1345/aph.1R570. Epub 2013 Feb 5.

PMID- 8047812
OWN - NLM
STAT- MEDLINE
DCOM- 19940826
LR  - 20190814
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 29
IP  - 4
DP  - 1994 Apr
TI  - Can aspirin prevent gallstone recurrence after successful extracorporeal 
      shockwave lithotripsy?
PG  - 355-9
AB  - Extracorporeal shockwave lithotripsy (ESWL) is a feasible procedure for the 
      treatment of gallbladder stones in humans. Well-selected patients can achieve 
      stone-free rates in a high percentage. With the gallbladder in situ, these 
      patients are at risk of stone recurrence. There is considerable evidence that 
      aspirin prevents cholesterol gallstone formation in animal models and may prevent 
      gallstone recurrence in man. We attempted to clarify the risk of gallstone 
      recurrence after successful piezoelectric lithotripsy in patients taking either 
      low-dose aspirin or no medication. The first 45 patients shown to be completely 
      free from stones after ESWL were randomized into two groups. One group received 
      100 mg aspirin daily; the other group did not receive any further medical 
      therapy. Patients were further examined on an average of 19.6 months and 21.9 
      months, respectively. In the aspirin group the recurrence rate was 18.2%, whereas 
      21.7% of the patients in the control group developed recurrent stones. 
      Seventy-eight per cent of these patients also had a recurrence of biliary pain. 
      By life-table analysis we had, after a follow-up period of 24 months, a stone 
      recurrence rate of 25% (+/- 11) in the aspirin group and 34% (+/- 14) in the 
      control group. Our results indicate that recurrence prophylaxis remains one of 
      the central questions in ESWL. In this preliminary study, 100 mg of aspirin daily 
      was not able to reduce the recurrence rate after successful ESWL. Further studies 
      will have to show whether higher doses of aspirin or other ways of preventing 
      gallstone after ESWL are possible.
FAU - Adamek, H E
AU  - Adamek HE
AD  - Medical Dept. C, Municipal Hospital, Ludwigshafen/Rhein, Germany.
FAU - Buttmann, A
AU  - Buttmann A
FAU - Weber, J
AU  - Weber J
FAU - Riemann, J F
AU  - Riemann JF
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Cholelithiasis/*prevention & control/therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Life Tables
MH  - *Lithotripsy
MH  - Male
MH  - Middle Aged
MH  - Recurrence
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
AID - 10.3109/00365529409094849 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 1994 Apr;29(4):355-9. doi: 10.3109/00365529409094849.

PMID- 19233517
OWN - NLM
STAT- MEDLINE
DCOM- 20090715
LR  - 20131121
IS  - 1768-3254 (Electronic)
IS  - 0223-5234 (Linking)
VI  - 44
IP  - 6
DP  - 2009 Jun
TI  - Polycyclic cage structures as carrier molecules for neuroprotective non-steroidal 
      anti-inflammatory drugs.
PG  - 2577-82
LID - 10.1016/j.ejmech.2009.01.030 [doi]
AB  - The blood-brain barrier is formed by the brain capillary endothelium and plays 
      the predominant role in controlling the passage of substances between the blood 
      and the brain. Recent studies on polycyclic structures, i.e. 
      pentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecane and amantadine, indicated 
      favourable distribution thereof to the brain and it was concluded that these 
      polycyclic structures and their derivatives penetrate the blood-brain barrier 
      readily. A series of novel polycyclic prodrugs incorporating the well known 
      non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid and 
      ibuprofen, were synthesised and screened for blood-brain barrier permeability and 
      antioxidant activity. Increased levels of both NSAIDs were detected in the brain 
      tissue of C57BL/6 mice after administration of the synthesised prodrugs, 
      indicating favourable blood-brain barrier permeation. Results from a lipid 
      peroxidation assay indicated that the ester and amide prodrugs significantly 
      increased the ability of the drugs to attenuate lipid peroxidation. These novel 
      prodrugs thus readily penetrate the blood-brain barrier and exhibit increased 
      antioxidant activity when compared to the free NSAIDs.
FAU - Prins, Louis H A
AU  - Prins LH
AD  - Pharmaceutical Chemistry, School of Pharmacy, North-West University, 
      Potchefstroom 2520, South Africa.
FAU - du Preez, Jan L
AU  - du Preez JL
FAU - van Dyk, Sandra
AU  - van Dyk S
FAU - Malan, Sarel F
AU  - Malan SF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090205
PL  - France
TA  - Eur J Med Chem
JT  - European journal of medicinal chemistry
JID - 0420510
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Polycyclic Compounds)
RN  - 0 (Prodrugs)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemical 
      synthesis/chemistry/*pharmacology
MH  - Antioxidants/chemical synthesis/chemistry/pharmacology
MH  - Aspirin/chemical synthesis/chemistry/*pharmacology
MH  - Blood-Brain Barrier/drug effects
MH  - Drug Design
MH  - Drug Evaluation, Preclinical
MH  - Ibuprofen/chemical synthesis/chemistry/*pharmacology
MH  - Lipid Peroxidation/drug effects
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Molecular Structure
MH  - Neuroprotective Agents/chemical synthesis/chemistry/*pharmacology
MH  - Permeability/drug effects
MH  - Polycyclic Compounds/chemical synthesis/chemistry/*pharmacology
MH  - Prodrugs/chemical synthesis/chemistry/pharmacology
EDAT- 2009/02/24 09:00
MHDA- 2009/07/16 09:00
CRDT- 2009/02/24 09:00
PHST- 2008/04/22 00:00 [received]
PHST- 2008/07/23 00:00 [revised]
PHST- 2009/01/29 00:00 [accepted]
PHST- 2009/02/24 09:00 [entrez]
PHST- 2009/02/24 09:00 [pubmed]
PHST- 2009/07/16 09:00 [medline]
AID - S0223-5234(09)00048-8 [pii]
AID - 10.1016/j.ejmech.2009.01.030 [doi]
PST - ppublish
SO  - Eur J Med Chem. 2009 Jun;44(6):2577-82. doi: 10.1016/j.ejmech.2009.01.030. Epub 
      2009 Feb 5.

PMID- 33461467
OWN - NLM
STAT- MEDLINE
DCOM- 20220105
LR  - 20230209
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 19
IP  - 6
DP  - 2021
TI  - Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and 
      Warfarin for Thromboangiitis Obliterans (TAO).
PG  - 655-662
LID - 10.2174/1570161119666210118125424 [doi]
AB  - BACKGROUND: Thromboangiitis obliterans (TAO) is a chronic, non-atherosclerotic, 
      progressive inflammatory vascular disease affecting the small- and medium-size 
      arteries and veins of the extremities. OBJECTIVE: To evaluate whether long-term 
      anticoagulation with low-molecular-weight heparin (LMWH) and warfarin is 
      beneficial for treating the inflammation and symptoms associated with TAO. 
      METHODS: Patients with TAO who underwent anticoagulation as the mainstay of 
      treatment were included in this prospective study. Rest pain relief and healing 
      of trophic lesions (as the primary and secondary endpoint) were investigated at 
      Day 14 and after 6 months of follow-up. High sensitivity C-reactive protein 
      (hsCRP), monocyte count, and ankle-brachial index (ABI) were recorded, and the 
      difference was compared before and after 2-week anticoagulation. The Chi-square 
      test was used to compare the difference between anticoagulant and aspirin groups 
      (based on the literature). RESULTS: From 2014 to 2019, 18 patients were included. 
      Only 1 patient with wet gangrene received endo-therapy for a failing stent at the 
      start of treatment. After ~14 days, 12 of 13 (92%) patients showed complete ulcer 
      healing, and 17 of 18 (94%) patients showed complete relief from rest pain. 
      Monocyte-counts and hsCRP levels decreased significantly (p<0.001) after a 2-week 
      period of anticoagulation with LMWH. The mean follow-up was 2.6 years (range 
      0.5-5 years). At 6 months, all patients showed relief of rest pain and complete 
      healing of trophic lesions. All endpoints were significantly improved compared 
      with the aspirin group (p<0.01), and no rest pain or ulcer/gangrene recurred 
      during follow-up. CONCLUSION: Anticoagulant therapy may alleviate the 
      inflammation and symptoms of TAO.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Gao, Jiangping
AU  - Gao J
AD  - Department of Vascular Surgery, Chinese PLA General Hospital, Medical School of 
      China PLA, Beijing, China
AD  - Department of Vascular Surgery, Shijingshan Hospital, Beijing, China
FAU - Huang, Liuhuan
AU  - Huang L
AD  - Department of Vascular Surgery, Shijingshan Hospital, Beijing, China
FAU - Wang, Jianli
AU  - Wang J
AD  - Department of Vascular Surgery, Shijingshan Hospital, Beijing, China
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - C-Reactive Protein
MH  - Gangrene
MH  - *Heparin, Low-Molecular-Weight/adverse effects/therapeutic use
MH  - Humans
MH  - Inflammation
MH  - Pain
MH  - Prospective Studies
MH  - *Thromboangiitis Obliterans/drug therapy
MH  - Treatment Outcome
MH  - Ulcer
MH  - *Warfarin/adverse effects/therapeutic use
OTO - NOTNLM
OT  - Buerger's disease
OT  - Thromboangiitis obliterans
OT  - anticoagulation
OT  - critical limb ischaemia.
OT  - high-sensitivity C-reactive protein
OT  - inflammation
EDAT- 2021/01/20 06:00
MHDA- 2022/01/06 06:00
CRDT- 2021/01/19 05:37
PHST- 2020/09/29 00:00 [received]
PHST- 2020/12/10 00:00 [revised]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2021/01/20 06:00 [pubmed]
PHST- 2022/01/06 06:00 [medline]
PHST- 2021/01/19 05:37 [entrez]
AID - CVP-EPUB-113380 [pii]
AID - 10.2174/1570161119666210118125424 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2021;19(6):655-662. doi: 10.2174/1570161119666210118125424.

PMID- 29665554
OWN - NLM
STAT- MEDLINE
DCOM- 20181008
LR  - 20181008
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 103
DP  - 2018 Jul
TI  - Inhibition by non-steroidal anti-inflammatory drugs of compound action potentials 
      in frog sciatic nerve fibers.
PG  - 326-335
LID - S0753-3322(18)30396-2 [pii]
LID - 10.1016/j.biopha.2018.04.041 [doi]
AB  - AIMS: Although antinociception produced by non-steroidal anti-inflammatory drugs 
      (NSAIDs) is partly attributed to nerve conduction inhibition, this has not been 
      thoroughly examined yet. The aim of the present study was to reveal 
      quantitatively how various types of NSAIDs affect compound action potentials 
      (CAPs), a measure of nerve conduction. MAIN METHODS: CAPs were recorded from the 
      frog sciatic nerve by using the air-gap method. KEY FINDINGS: Soaking the sciatic 
      nerve with acetic acid-based NSAIDs (diclofenac and aceclofenac) reduced the peak 
      amplitude of CAP in a concentration-dependent manner; their IC(50) values were 
      0.94 and 0.47 mM, respectively. Other acetic acid-based NSAIDs (indomethacin, 
      acemetacin and etodolac) also inhibited CAPs [the extent of inhibition: some 40% 
      (1 mM), 40% (0.5 mM) and 15% (1 mM), respectively], except for sulindac and 
      felbinac at 1 mM that had no effects on CAP peak amplitudes. A similar inhibition 
      was produced by fenamic acid-based NSAIDs [tolfenamic acid (IC(50) = 0.29 mM), 
      meclofenamic acid (0.19 mM), flufenamic acid (0.22 mM) and mefenamic acid] which 
      are similar in chemical structure to diclofenac and aceclofenac; their 
      derivatives (2,6-dichlorodiphenylamine and N-phenylanthranilic acid) also 
      inhibited. On the other hand, salicylic acid-based (aspirin), propionic 
      acid-based (ketoprofen, naproxen, ibuprofen, loxoprofen and flurbiprofen) and 
      enolic acid-based (meloxicam and piroxicam) NSAIDs had no effects on CAP peak 
      amplitudes. SIGNIFICANCE: At least a part of antinociception produced by NSAIDs 
      used as a dermatological drug to alleviate pain may be attributed to their 
      inhibitory effects on nerve conduction, which depend on the chemical structures 
      of NSAIDs.
CI  - Copyright © 2018 Elsevier Masson SAS. All rights reserved.
FAU - Suzuki, Rika
AU  - Suzuki R
AD  - Department of Physiology, Saga Medical School, Nabeshima 5-1-1, Saga 849-8501, 
      Japan.
FAU - Fujita, Tsugumi
AU  - Fujita T
AD  - Department of Physiology, Saga Medical School, Nabeshima 5-1-1, Saga 849-8501, 
      Japan.
FAU - Mizuta, Kotaro
AU  - Mizuta K
AD  - Department of Physiology, Saga Medical School, Nabeshima 5-1-1, Saga 849-8501, 
      Japan.
FAU - Kumamoto, Eiichi
AU  - Kumamoto E
AD  - Department of Physiology, Saga Medical School, Nabeshima 5-1-1, Saga 849-8501, 
      Japan. Electronic address: kumamote@cc.saga-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20180424
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Action Potentials/*drug effects/physiology
MH  - Analgesics/classification/pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*classification/*pharmacology
MH  - Aspirin/classification/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Indomethacin/classification/pharmacology
MH  - Male
MH  - Naproxen/classification/pharmacology
MH  - Nerve Fibers/*drug effects/physiology
MH  - Ranidae
MH  - Sciatic Nerve/*drug effects/physiology
OTO - NOTNLM
OT  - Antinociception
OT  - Compound action potential
OT  - Conduction inhibition
OT  - Frog
OT  - NSAID
OT  - Sciatic nerve
EDAT- 2018/04/18 06:00
MHDA- 2018/10/09 06:00
CRDT- 2018/04/18 06:00
PHST- 2018/01/18 00:00 [received]
PHST- 2018/04/06 00:00 [revised]
PHST- 2018/04/06 00:00 [accepted]
PHST- 2018/04/18 06:00 [pubmed]
PHST- 2018/10/09 06:00 [medline]
PHST- 2018/04/18 06:00 [entrez]
AID - S0753-3322(18)30396-2 [pii]
AID - 10.1016/j.biopha.2018.04.041 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2018 Jul;103:326-335. doi: 10.1016/j.biopha.2018.04.041. 
      Epub 2018 Apr 24.

PMID- 8566836
OWN - NLM
STAT- MEDLINE
DCOM- 19960304
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 38
IP  - 1
DP  - 1996 Jan
TI  - Comparison of effects of calcium carbasalate and aspirin on gastroduodenal 
      mucosal damage in human volunteers.
PG  - 11-4
AB  - Calcium carbasalate is a therapeutically active salicylate which seems to cause 
      less gastroduodenal mucosal damage than aspirin in laboratory animals. This 
      endoscopist-blinded, randomised, cross over trial aimed to compare acute gastric 
      mucosal damage in 20 healthy volunteers treated with acetyl salicylic acid (ASA) 
      (650 mg three times daily) and effervescent calcium carbasalate (ECC) (826.8 mg 
      three times daily) bioequivalent to 650 mg ASA over a five day period. Endoscopy 
      was performed immediately before treatment and on day 5 of each treatment. Serum 
      salicylate, thromboxane B2, and gastric mucosal prostaglandin E2 (PGE2) 
      concentrations were measured after endoscopy. ECC caused fewer gastric mucosal 
      erosions than ASA. The total number of gastric erosions was 23.8 (16.1) in the 
      ASA treated subjects compared with 9.1 (8.7) in ECC treated subjects (p = 0.004). 
      Differences between ASA and ECC were significant for both the gastric antrum and 
      body, and for both haemorrhagic and non-haemorrhagic erosions. The mean gastric 
      body Lanza score for mucosal damage was lower after ECC than ASA (p = 0.003). The 
      visual analogue score for gastric body damage was lower for ECC (16.9 mm (15.9)) 
      than for ASA (32.7 mm (20.8)), p = 0.008. Serum salicylate concentrations were 
      similar after both preparations (ASA: 66 (23) mg/l, versus ECC: 58 (17) mg/l, 
      NS). Serum thromboxane B2 was similarly reduced using both preparations-97.2 
      (3.5)% inhibition with ASA, 95.2 (5.5)% inhibition with calcium carbasalate (NS). 
      Suppression of gastric mucosal PGE2 synthesis was similar with both preparations 
      (ASA: 83.4 (17.1)%; ECC 84.3 (12.9)%; NS). It is concluded that ECC causes 
      significantly less gastroduodenal mucosal damage than ASA administered at 
      bioequivalent doses as judged by serum salicylate, serum thromboxane, and mucosal 
      PGE2 values. ECC may therefore be a less harmful alternative treatment to plain 
      ASA.
FAU - Murray, F E
AU  - Murray FE
AD  - Department of Therapeutics, University Hospital, Nottingham.
FAU - Hudson, N
AU  - Hudson N
FAU - Atherton, J C
AU  - Atherton JC
FAU - Cole, A T
AU  - Cole AT
FAU - Scheck, F
AU  - Scheck F
FAU - Hawkey, C J
AU  - Hawkey CJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 8W8T17847W (Urea)
RN  - N667F17JP1 (carbaspirin calcium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analgesics/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Cross-Over Studies
MH  - Duodenum/*drug effects/pathology
MH  - Female
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastroscopy
MH  - Humans
MH  - Intestinal Mucosa/*drug effects/pathology
MH  - Male
MH  - Middle Aged
MH  - Urea/*analogs & derivatives/pharmacology
PMC - PMC1382971
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1136/gut.38.1.11 [doi]
PST - ppublish
SO  - Gut. 1996 Jan;38(1):11-4. doi: 10.1136/gut.38.1.11.

PMID- 25527016
OWN - NLM
STAT- MEDLINE
DCOM- 20150901
LR  - 20181202
IS  - 1532-9488 (Electronic)
IS  - 1043-0679 (Linking)
VI  - 26
IP  - 3
DP  - 2014 Autumn
TI  - Use of antiplatelet drugs after cardiac operations.
PG  - 223-30
LID - S1043-0679(14)00094-X [pii]
LID - 10.1053/j.semtcvs.2014.09.005 [doi]
AB  - Unfortunately, venous bypass grafts still have a prominent role in operative 
      coronary revascularization (coronary artery bypass graft [CABG]). Venous grafts 
      develop pathologically occlusive disease that limits the effectiveness of CABG, 
      and antiplatelet drugs following operation may limit this problem. The types and 
      indications of antiplatelet drugs following CABG generate some controversy in the 
      recent literature. This review surveys relevant evidence about the use of 
      antiplatelet drugs following CABG to identify the controversial issues, define 
      appropriate questions, and attempt to provide evidence-based interventions that 
      may be helpful in limiting graft occlusion after CABG. Evidence suggests that, in 
      most CABG patients, dual antiplatelet drugs (aspirin and clopidogrel), given 
      after operation, minimizes early (within 1 year) graft failure and improves 
      intermediate-term outcomes, better than single antiplatelet therapy with aspirin 
      alone. There are gaps in the knowledge base that supports this contention, and 
      future clinical trials will likely augment or alter this recommendation.
CI  - Copyright © 2014 Elsevier Inc. All rights reserved.
FAU - Ferraris, Victor A
AU  - Ferraris VA
AD  - Division of Cardiothoracic & Vascular Surgery, Chandler Medical Center, 
      University of Kentucky, Lexington, Kentucky. Electronic address: 
      ferraris@uky.edu.
FAU - Bolanos, Michael D
AU  - Bolanos MD
AD  - Division of Cardiothoracic & Vascular Surgery, Chandler Medical Center, 
      University of Kentucky, Lexington, Kentucky.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141023
PL  - United States
TA  - Semin Thorac Cardiovasc Surg
JT  - Seminars in thoracic and cardiovascular surgery
JID - 8917640
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - *Coronary Artery Bypass/adverse effects
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Graft Occlusion, Vascular/etiology/physiopathology/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vascular Patency/drug effects
OTO - NOTNLM
OT  - coronary artery bypass
OT  - coronary artery bypass grafting
OT  - dual antiplatelet therapy
OT  - graft occlusion
OT  - platelet aggregation inhibitors
OT  - saphenous vein grafts
EDAT- 2014/12/21 06:00
MHDA- 2015/09/02 06:00
CRDT- 2014/12/21 06:00
PHST- 2014/09/12 00:00 [accepted]
PHST- 2014/12/21 06:00 [entrez]
PHST- 2014/12/21 06:00 [pubmed]
PHST- 2015/09/02 06:00 [medline]
AID - S1043-0679(14)00094-X [pii]
AID - 10.1053/j.semtcvs.2014.09.005 [doi]
PST - ppublish
SO  - Semin Thorac Cardiovasc Surg. 2014 Autumn;26(3):223-30. doi: 
      10.1053/j.semtcvs.2014.09.005. Epub 2014 Oct 23.

PMID- 16371720
OWN - NLM
STAT- MEDLINE
DCOM- 20060314
LR  - 20170309
IS  - 1598-9992 (Print)
IS  - 1598-9992 (Linking)
VI  - 46
IP  - 6
DP  - 2005 Dec
TI  - [Characteristics of colon cancer diagnosed in patients taking aspirin or 
      warfarin].
PG  - 455-62
AB  - BACKGROUND/AIMS: Warfarin and aspirin are commonly used to prevent cardiovascular 
      diseases. Aspirin was recently found to have chemopreventive effects on colon 
      cancer and polyps by inhibiting cyclooxygenase-2. Therefore, we evaluated whether 
      the symptoms of bleeding related with aspirin or warfarin could be a clue in 
      early detection of colon cancer. We also assessed the effect of aspirin on the 
      development of synchronous polyps. METHODS: A total of forty-one and 16 patients 
      diagnosed as colon cancer, taking aspirin or warfarin respectively were enrolled. 
      In addition, 171 patients with colon cancers were age and gender matched as a 
      control group. We investigated the difference of clinical features and laboratory 
      findings among three groups. RESULTS: The incidence of bleeding was 81.3% 
      (warfarin), 53.7% (aspirin), 40.4% (control). Among three groups, location and 
      size of cancer, number of lymph nodes involvement and stages were not different, 
      but the number of patients in Duke stage D in warfarin group (n=1, 6.3%) were 
      less than that of the control (n=44, 25.7%) (p=0.049). The extent of 
      circumferential involvement by cancer was lower in aspirin group (67%) than in 
      the control group (80%) (p=0.035). The percentage of patients with synchronous 
      polyps and mean number of synchronous polyps in aspirin group (34.1%, 0.68, 
      respectively) was lower than that of control group (53.6%, 1.69, respectively) 
      (p=0.029, 0.008, respectively). CONCLUSIONS: Bleeding related with aspirin or 
      warfarin usage had no effect on the early diagnosis of colon cancer. However, 
      lower incidence of Duke stage D in warfarin group might be related to 
      anti-metastatic effect of warfarin. In addition, aspirin may have a role in 
      suppressing the development of synchronous polyps.
FAU - Shin, Sung Jae
AU  - Shin SJ
AD  - Department of Internal Medicine and Institute of Gastroenterology, Yonsei 
      University College of Medicine, Seoul, Korea.
FAU - Kim, Byung Chang
AU  - Kim BC
FAU - Park, Sooyoung
AU  - Park S
FAU - Kim, Sungai
AU  - Kim S
FAU - Kim, Tae Il
AU  - Kim TI
FAU - Kim, Won Ho
AU  - Kim WH
LA  - kor
PT  - English Abstract
PT  - Journal Article
PL  - Korea (South)
TA  - Korean J Gastroenterol
JT  - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JID - 101189416
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Colonic Neoplasms/*diagnosis/pathology
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2005/12/24 09:00
MHDA- 2006/03/15 09:00
CRDT- 2005/12/24 09:00
PHST- 2005/12/24 09:00 [pubmed]
PHST- 2006/03/15 09:00 [medline]
PHST- 2005/12/24 09:00 [entrez]
AID - 200512256 [pii]
PST - ppublish
SO  - Korean J Gastroenterol. 2005 Dec;46(6):455-62.

PMID- 33191392
OWN - NLM
STAT- MEDLINE
DCOM- 20211210
LR  - 20211214
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 85
IP  - 1
DP  - 2020 Dec 25
TI  - 1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y(12) 
      Receptor Inhibitor Monotherapy Using a Bioabsorbable Polymer Sirolimus-Eluting 
      Stent.
PG  - 19-26
LID - 10.1253/circj.CJ-20-0644 [doi]
AB  - BACKGROUND: This study evaluated the safety of 3-month dual antiplatelet therapy 
      (DAPT) after implantation of a bioresorbable polymer sirolimus-eluting stent 
      (BP-SES) and compared P2Y(12)inhibitor with aspirin monotherapy 3 months after 
      DAPT.Methods and Results:Patients who underwent percutaneous coronary 
      intervention using BP-SES were enrolled and followed for 1 year. Patients with a 
      history of stent thrombosis were excluded. The primary endpoint was a composite 
      of all-cause death, myocardial infarction, stroke (ischemic and hemorrhagic), 
      definite or probable stent thrombosis, and severe bleeding at 12 months. The 
      BP-SES arm of the CENTURY II trial was used as a conventional DAPT group for 
      comparison. After DAPT, patients were maintained on either aspirin (n=846) or a 
      P2Y(12)inhibitor (n=674 patients).In all, 1,695 patients were enrolled in the 
      study across 65 centers. The primary endpoint occurred in 4.3% of patients at 1 
      year. After propensity score adjustment, the incidence of the primary endpoint 
      was not inferior in those receiving DAPT for 3 months compared with conventional 
      DAPT (5.5%; P(non-inferiority)<0.0001). The incidence of the primary endpoint and 
      severe bleeding did not differ between the aspirin and P2Y(12)inhibitor 
      monotherapy groups. CONCLUSIONS: After adjustment, 3-month DAPT was not inferior 
      to longer DAPT after BP-SES implantation in terms of net adverse clinical events. 
      There was no difference in bleeding and thrombotic events between 
      P2Y(12)inhibitor and aspirin monotherapy after 3 months DAPT.
FAU - Kozuma, Ken
AU  - Kozuma K
AD  - Department of Cardiology, Teikyo University.
FAU - Kinoshita, Yoshihisa
AU  - Kinoshita Y
AD  - Department of Cardiology, Toyohashi Heart Center.
FAU - Hioki, Hirofumi
AU  - Hioki H
AD  - Department of Cardiology, Teikyo University.
FAU - Nanasato, Mamoru
AU  - Nanasato M
AD  - Department of Cardiology, Sakakibara Heart Institute.
FAU - Ito, Yoshiaki
AU  - Ito Y
AD  - Department of Cardiology, Saiseikai Yokohamashi Tobu Hospital.
FAU - Yamaguchi, Junichi
AU  - Yamaguchi J
AD  - Department of Cardiology, Tokyo Women's Medical University.
FAU - Shiode, Nobuo
AU  - Shiode N
AD  - Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital.
FAU - Hibi, Kiyoshi
AU  - Hibi K
AD  - Division of Cardiology, Yokohama City University Medical Center.
FAU - Tanabe, Kengo
AU  - Tanabe K
AD  - Division of Cardiology, Mitsui Memorial Hospital.
FAU - Ako, Junya
AU  - Ako J
AD  - Department of Cardiology, Kitazato University Hospital.
FAU - Morino, Yoshihiro
AU  - Morino Y
AD  - Department of Cardiology, Iwate Medical University.
FAU - Hirohata, Atsushi
AU  - Hirohata A
AD  - Department of Cardiology, The Sakakibara Heart Institute of Okayama.
FAU - Sonoda, Shinjo
AU  - Sonoda S
AD  - Department of Cardiology, Hospital of the University of Occupational and 
      Environmental Health.
FAU - Nakagawa, Yoshihisa
AU  - Nakagawa Y
AD  - Department of Cardiology, Shiga University of Medical Science Hospital.
FAU - Ikari, Yuji
AU  - Ikari Y
AD  - Department of Cardiology, Tokai University Hospital.
CN  - MODEL U-SES Study Investigators
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20201113
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polymers)
RN  - R16CO5Y76E (Aspirin)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Absorbable Implants
MH  - *Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Hemorrhage
MH  - Humans
MH  - Myocardial Infarction
MH  - *Percutaneous Coronary Intervention
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - Polymers
MH  - *Sirolimus/therapeutic use
MH  - Stroke
MH  - Thrombosis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Drug-eluting stent (DES)
OT  - Monotherapy
OT  - P2Y12 inhibitor
OT  - Short dual antiplatelet therapy (DAPT)
EDAT- 2020/11/17 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/11/16 05:57
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/11/16 05:57 [entrez]
AID - 10.1253/circj.CJ-20-0644 [doi]
PST - ppublish
SO  - Circ J. 2020 Dec 25;85(1):19-26. doi: 10.1253/circj.CJ-20-0644. Epub 2020 Nov 13.

PMID- 15187304
OWN - NLM
STAT- MEDLINE
DCOM- 20040702
LR  - 20190827
IS  - 0385-2407 (Print)
IS  - 0385-2407 (Linking)
VI  - 31
IP  - 5
DP  - 2004 May
TI  - Multiple NSAID intolerance in chronic idiopathic urticaria is correlated with 
      delayed, pronounced and prolonged autoreactivity.
PG  - 376-82
AB  - Autologous serum skin test (ASST) reactivity is positive in up to 60% of patients 
      with chronic idiopathic urticaria (CIU). About 21 to 30% of patients with CIU 
      have intolerance to acetyl salicylic acid (ASA) and/or other chemically unrelated 
      non-steroidal anti-inflammatory drugs (NSAIDs). To investigate the relationship 
      between ASA/NSAID intolerance and ASST reactivity, a case-control study was 
      performed in 110 patients with CIU and 60 healthy controls. A positive ASST was 
      defined as an erythematous wheal with a diameter of > 5 mm more than the 
      saline-induced response. Patients were assessed at 10-minute intervals for a 
      minimum of three hours. ASA/NSAID intolerance was ascertained by a placebo 
      controlled-provocation test with offending drug (s). Forty-two patients with CIU 
      (38.2%) had autoreactivity whereas only two of the controls (3.3%) displayed 
      early and weak skin responses (P<.0001). ASA/NSAID intolerance was demonstrated 
      in 30 (27.3%) patients with CIU. The prevalences of autoreactivity were 93.3% 
      (28/30) and 17.5% (14/80) in patients with and without ASA/NSAID intolerance, 
      respectively (P<.001). Thirteen of the 25 ASST-positive patients (52%) who had 
      single (n: 7) or multiple (n: 6) NSAID intolerance showed early (before or at 30 
      min) and mild autoreactivity of short duration, whereas 15 of the remaining 17 
      ASST-positive patients (88.2%) who all had multiple NSAID intolerance showed 
      delayed (later than 30 min) and prolonged autoreactivity (P<.05). These findings 
      suggest that a common mechanism may be responsible for the pathogeneses of both 
      delayed autoreactivity and multiple NSAID intolerance in CIU. It might be further 
      speculated that delayed, prolonged, and pronounced autoreactivity may be a 
      possible predictor for multiple NSAID sensitivity in CIU.
FAU - Erbagci, Zülal
AU  - Erbagci Z
AD  - Gaziantep University Medical Faculty, Department of Dermatology, Gaziantep, 
      Turkey.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Chronic Disease
MH  - Drug Hypersensitivity/*etiology/pathology
MH  - Female
MH  - Humans
MH  - Hypersensitivity, Delayed/*chemically induced/pathology
MH  - Male
MH  - *Urticaria
EDAT- 2004/06/10 05:00
MHDA- 2004/07/03 05:00
CRDT- 2004/06/10 05:00
PHST- 2003/08/20 00:00 [received]
PHST- 2004/01/14 00:00 [accepted]
PHST- 2004/06/10 05:00 [pubmed]
PHST- 2004/07/03 05:00 [medline]
PHST- 2004/06/10 05:00 [entrez]
AID - 031050376 [pii]
AID - 10.1111/j.1346-8138.2004.tb00688.x [doi]
PST - ppublish
SO  - J Dermatol. 2004 May;31(5):376-82. doi: 10.1111/j.1346-8138.2004.tb00688.x.

PMID- 14517527
OWN - NLM
STAT- MEDLINE
DCOM- 20031204
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 143
IP  - 3
DP  - 2003 Sep
TI  - Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic 
      fever: a randomized trial.
PG  - 399-401
AB  - We performed a prospective, randomized, open-label equivalence study comparing 
      the use of naproxen to aspirin in 33 patients with rheumatic fever. The mean time 
      until resolution of arthritis was 2.9+/-2.9 days in both groups. Liver enzyme 
      elevations were more frequent in the aspirin group (P=.002). We conclude that 
      naproxen is as effective, is easier to use, and is safer than aspirin in the 
      treatment of the arthritis of rheumatic fever.
FAU - Hashkes, Philip J
AU  - Hashkes PJ
AD  - Sieff Hospital, Safed, Israel.
FAU - Tauber, Tsivia
AU  - Tauber T
FAU - Somekh, Eli
AU  - Somekh E
FAU - Brik, Riva
AU  - Brik R
FAU - Barash, Judith
AU  - Barash J
FAU - Mukamel, Masza
AU  - Mukamel M
FAU - Harel, Liora
AU  - Harel L
FAU - Lorber, Abraham
AU  - Lorber A
FAU - Berkovitch, Matityahu
AU  - Berkovitch M
FAU - Uziel, Yosef
AU  - Uziel Y
CN  - Pediatric Rheumatlogy Study Group of Israel
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics/*therapeutic use
MH  - Aspirin/*pharmacokinetics/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Male
MH  - Naproxen/*pharmacokinetics/*therapeutic use
MH  - Prospective Studies
MH  - Rheumatic Fever/*drug therapy
MH  - Therapeutic Equivalency
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2003/10/01 05:00
MHDA- 2003/12/05 05:00
CRDT- 2003/10/01 05:00
PHST- 2003/10/01 05:00 [pubmed]
PHST- 2003/12/05 05:00 [medline]
PHST- 2003/10/01 05:00 [entrez]
AID - S0022347603003883 [pii]
AID - 10.1067/s0022-3476(03)00388-3 [doi]
PST - ppublish
SO  - J Pediatr. 2003 Sep;143(3):399-401. doi: 10.1067/s0022-3476(03)00388-3.

PMID- 33085967
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210809
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 41
IP  - 37
DP  - 2020 Oct 1
TI  - Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary 
      intervention in patients with non-ST-segment elevation acute coronary syndromes: 
      TWILIGHT-ACS.
PG  - 3533-3545
LID - 10.1093/eurheartj/ehaa670 [doi]
AB  - AIMS: The aim of this study was to determine the effect of ticagrelor monotherapy 
      on clinically relevant bleeding and major ischaemic events in relation to 
      clinical presentation with and without non-ST elevation acute coronary syndromes 
      (NSTE-ACS) among patients undergoing percutaneous coronary intervention (PCI) 
      with drug-eluting stents (DES). METHODS AND RESULTS: We conducted a pre-specified 
      subgroup analysis of The Ticagrelor With Aspirin or Alone in High Risk Patients 
      After Coronary Intervention (TWILIGHT) trial, which enrolled 9006 patients with 
      high-risk features undergoing PCI with DES. After 3 months of dual antiplatelet 
      therapy (DAPT) with ticagrelor plus aspirin, 7119 adherent and event-free 
      patients were randomized in a double-blind manner to ticagrelor plus placebo 
      versus ticagrelor plus aspirin for 12 months. The primary outcome was Bleeding 
      Academic Research Consortium (BARC) type 2, 3, or 5 bleeding while the composite 
      of all-cause death, myocardial infarction (MI), or stroke was the key secondary 
      outcome. Among patients with NSTE-ACS (n = 4614), ticagrelor monotherapy reduced 
      BARC 2, 3, or 5 bleeding by 53% [3.6% vs. 7.6%; hazard ratio (HR) 0.47; 95% 
      confidence interval (CI) 0.36-0.61; P < 0.001) and in stable patients (n = 2503) 
      by 24% (4.8% vs. 6.2%; HR 0.76; 95% CI 0.54-1.06; P = 0.11; nominal Pint = 0.03). 
      Rates of all-cause death, MI, or stroke among those with (4.3% vs. 4.4%; HR 0.97; 
      95% CI 0.74-1.28; P = 0.84) and without (3.1% vs. 3.2%; HR 0.96; 95% CI 
      0.61-1.49; P = 0.85) NSTE-ACS were similar between treatment arms irrespective of 
      clinical presentation (Pint = 0.96). CONCLUSION: Among patients with or without 
      NSTE-ACS who have completed an initial 3-month course of DAPT following PCI with 
      DES, ticagrelor monotherapy reduced clinically meaningful bleeding events without 
      increasing ischaemic risk as compared with ticagrelor plus aspirin. The benefits 
      of ticagrelor monotherapy with respect to bleeding events were more pronounced in 
      patients with NSTE-ACS. TRIAL REGISTRATION: Clinicaltrials.gov identifier: 
      NCT02270242.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved. © 
      The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
FAU - Baber, Usman
AU  - Baber U
AD  - Department of Cardiology, The University of Oklahoma Health Sciences Center, 
      Oklahoma City, OK 73104, USA.
AD  - Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular 
      Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, 
      NY 10029-6574, USA.
FAU - Dangas, George
AU  - Dangas G
AD  - Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular 
      Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, 
      NY 10029-6574, USA.
FAU - Angiolillo, Dominick Joseph
AU  - Angiolillo DJ
AD  - Department of Cardiology, University of Florida-Shands, Jacksonville, FL 32218, 
      USA.
FAU - Cohen, David Joel
AU  - Cohen DJ
AD  - Department of Cardiology, University of Missouri-Kansas CIty, Kansas City, MO 
      64110, USA.
FAU - Sharma, Samin Kumar
AU  - Sharma SK
AD  - Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular 
      Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, 
      NY 10029-6574, USA.
FAU - Nicolas, Johny
AU  - Nicolas J
AD  - Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular 
      Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, 
      NY 10029-6574, USA.
FAU - Briguori, Carlo
AU  - Briguori C
AD  - Department of Cardiology, Clinica Mediterranea, 80122 Napoli NA, Italy.
FAU - Cha, Jin Yu
AU  - Cha JY
AD  - Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular 
      Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, 
      NY 10029-6574, USA.
FAU - Collier, Timothy
AU  - Collier T
AD  - Department of Cardiology, London School of Hygiene and Tropical Medicine, Keppel 
      St, Bloomsbury, London WC1E 7HT, UK.
FAU - Dudek, Dariusz
AU  - Dudek D
AD  - The 2nd Department of Cardiology Jagiellonian University Medical College, Swietej 
      Anny 12, 31-008 Krakow, Poland.
FAU - Džavik, Vladimir
AU  - Džavik V
AD  - Department of Interventional Cardiology, Research and Innovation in 
      Interventional Cardiology and Cardiac Intensive Care, Peter Munk Cardiac Centre, 
      University Health Network, 200 Elizabeth St, Toronto, ON M5G 2CA, Canada.
FAU - Escaned, Javier
AU  - Escaned J
AD  - Department of Cardiology, Instituto de Investigacion Sanitaria del Hospital 
      Clinico San Carlos and Complutense University, Calle del Prof Martin Lagos, s/n, 
      28040 Madrid, Spain.
FAU - Gil, Robert
AU  - Gil R
AD  - Department of Invasive Cardiology, Center of Postgraduate Medical Education, 
      Central Clinical Hospital of the Ministry of Interior and Administration, 137 
      Woloska Str, 02-507 Warsaw, Poland.
FAU - Gurbel, Paul
AU  - Gurbel P
AD  - Department of Cardiology, Sinai Hospital of Baltimore System, Baltimore, MD 
      21215, USA.
FAU - Hamm, Christian W
AU  - Hamm CW
AD  - Department of Cardiology, Kerckhoff Clinic, Benekestrabe 2-8, 61231 Bad Nauheim, 
      Germany.
FAU - Henry, Timothy
AU  - Henry T
AD  - Department of Cardiology, The Carl and Edyth Lindner Center for Research and 
      Education at the Christ Hospital, Cincinnati, OH 45219, USA.
FAU - Huber, Kurt
AU  - Huber K
AD  - Department of Cardiology, Wilhelminenhospital, Montleartstrabe 37, 1160 Wien, 
      Austria.
FAU - Kastrati, Adnan
AU  - Kastrati A
AD  - Department of Cardiology, Deutsches Herzzentrum Munchen, Lazarettstrabe 36, 80636 
      Munchen, Germany.
FAU - Kaul, Upendra
AU  - Kaul U
AD  - Department of Cardiology, Batra Hospital and Medical Research Centre, New Delhi 
      110062, India.
FAU - Kornowski, Ran
AU  - Kornowski R
AD  - Department of Cardiology, Rabin Medical Center, Zeev Jabutinsky Rd 39, Petach 
      Tikva 49100, Israel.
FAU - Krucoff, Mitchell
AU  - Krucoff M
AD  - Department of Cardiology, Duke University Medical Center-Duke Clinical Research 
      Institute, Durham, NC 27710, USA.
FAU - Kunadian, Vijay
AU  - Kunadian V
AD  - Department of Cardiology, Institute of Cellular Medicine, Faculty of Medical 
      Sciences, Newcastle University, Freeman Road, High Heaton, NE7 7DN Newcastle upon 
      Tyne, UK.
AD  - Department of Cardiology, Cardiothoracic Centre, Freeman Hospital, Newcastle upon 
      Tyne Hospitals NHS Foundation Trust, Freeman Road, High Heaton, NE7 7DN Newcastle 
      upon Tyne, UK.
FAU - Marx, Steven Owen
AU  - Marx SO
AD  - Department of Cardiology, Columbia University Medical Center, New York, NY 10027, 
      USA.
FAU - Mehta, Shamir
AU  - Mehta S
AD  - Department of Cardiology, Hamilton Health Sciences, Hamilton, ON L8N 3Z5, Canada.
FAU - Moliterno, David
AU  - Moliterno D
AD  - Department of Cardiology, University of Kentucky, Lexington, KY 40506, USA.
FAU - Ohman, Erik Magnus
AU  - Ohman EM
AD  - Department of Cardiology, Duke University Medical Center-Duke Clinical Research 
      Institute, Durham, NC 27710, USA.
FAU - Oldroyd, Keith
AU  - Oldroyd K
AD  - Department of Cardiology, The West of Scotland Heart and Lung Centre, Golden 
      Jubilee National Hospital, Agamemnon St, Clydebank G81 4DY, UK.
FAU - Sardella, Gennaro
AU  - Sardella G
AD  - Department of Cardiology, Policlinico Umberto I University, 00161 Roma, Italy.
FAU - Sartori, Samantha
AU  - Sartori S
AD  - Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular 
      Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, 
      NY 10029-6574, USA.
FAU - Shlofmitz, Richard
AU  - Shlofmitz R
AD  - Department of Cardiology, St. Francis Hospital, Roslyn, 100 Port Washington Blvd, 
      Roslyn, NY 11576, USA.
FAU - Steg, Philippe Gabriel
AU  - Steg PG
AD  - Department of Cardiology, Groupe Hospitalier Bichat-Claude-Bernard, 46 Rue Henri 
      Huchard, 75018 Paris, France.
FAU - Weisz, Giora
AU  - Weisz G
AD  - Department of Cardiology, Montefiore Medical Center, The Bronx, NY 10467, USA.
FAU - Witzenbichler, Bernhard
AU  - Witzenbichler B
AD  - Department of Cardiology, Helios Amper-Klinikum, Krankenhausstrabe 15, 85221 
      Dachau, Germany.
FAU - Han, Ya-Ling
AU  - Han YL
AD  - Department of Cardiology, Shenyang North Hospital, Huanggu Qu, Shenyang Shi, 
      Liaoning Sheng, China.
FAU - Pocock, Stuart
AU  - Pocock S
AD  - Department of Cardiology, London School of Hygiene and Tropical Medicine, Keppel 
      St, Bloomsbury, London WC1E 7HT, UK.
FAU - Gibson, Charles Michael
AU  - Gibson CM
AD  - Department of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA 02215, 
      USA.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - Department of Cardiology, The Zena and Michael A. Wiener Cardiovascular 
      Institute, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, 
      NY 10029-6574, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02270242
GR  - CS/15/7/31679/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2020 Oct 1;41(37):3546-3548. PMID: 33085968
CIN - Eur Heart J. 2021 Jul 15;42(27):2708-2709. PMID: 33501975
CIN - Eur Heart J. 2021 Jul 15;42(27):2710-2711. PMID: 33615365
MH  - *Acute Coronary Syndrome/drug therapy
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Ticagrelor/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Bleeding
OT  - Ticagrelor
OT  -  Acute coronary syndrome
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 17:04
PHST- 2020/01/08 00:00 [received]
PHST- 2020/04/08 00:00 [revised]
PHST- 2020/07/29 00:00 [accepted]
PHST- 2020/10/21 17:04 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 5934642 [pii]
AID - 10.1093/eurheartj/ehaa670 [doi]
PST - ppublish
SO  - Eur Heart J. 2020 Oct 1;41(37):3533-3545. doi: 10.1093/eurheartj/ehaa670.

PMID- 3319716
OWN - NLM
STAT- MEDLINE
DCOM- 19880129
LR  - 20131121
IS  - 0011-8532 (Print)
IS  - 0011-8532 (Linking)
VI  - 31
IP  - 4
DP  - 1987 Oct
TI  - Pharmacologic rationale for the treatment of acute pain.
PG  - 675-94
AB  - This article reviews peripheral mechanisms involved in the production of dentinal 
      pain and acute inflammatory pain. The endogenous analgesic system, located in the 
      central nervous system, is also reviewed. The pharmacology of peripheral 
      analgesics (such as aspirin-like drugs), local anesthetics and central analgesics 
      (such as opiates) are discussed. Based on this information, a rational 
      therapeutic strategy, directed toward minimizing the perception of pain and the 
      experience of side effects, is presented.
FAU - Hargreaves, K M
AU  - Hargreaves KM
AD  - National Institute of Dental Research, National Institutes of Health, Bethesda, 
      Maryland.
FAU - Troullos, E S
AU  - Troullos ES
FAU - Dionne, R A
AU  - Dionne RA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Dent Clin North Am
JT  - Dental clinics of North America
JID - 0217440
RN  - 0 (Analgesics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Analgesics/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Facial Pain/*drug therapy
MH  - Humans
MH  - Nociceptors/drug effects
MH  - Toothache/drug therapy
RF  - 95
EDAT- 1987/10/01 00:00
MHDA- 1987/10/01 00:01
CRDT- 1987/10/01 00:00
PHST- 1987/10/01 00:00 [pubmed]
PHST- 1987/10/01 00:01 [medline]
PHST- 1987/10/01 00:00 [entrez]
PST - ppublish
SO  - Dent Clin North Am. 1987 Oct;31(4):675-94.

PMID- 7722147
OWN - NLM
STAT- MEDLINE
DCOM- 19950525
LR  - 20131121
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 25
IP  - 6
DP  - 1995 May
TI  - Effect of low dose aspirin on cardiorenal function and acute hemodynamic response 
      to enalaprilat in a canine model of severe heart failure.
PG  - 1445-50
AB  - OBJECTIVES: This study examined the effect of low dose aspirin on cardiorenal and 
      neurohumoral function and on the acute hemodynamic response to enalaprilat in a 
      canine model of heart failure. BACKGROUND: Low dose aspirin is frequently 
      prescribed for patients with systolic dysfunction who also benefit from 
      angiotensin-converting enzyme inhibition. Although high doses of potent 
      cyclo-oxygenase inhibitors cause fluid retention and vaso-constriction and 
      antagonize the effects of angiotensin-converting enzyme inhibitors, the effects 
      of low dose aspirin in heart failure are unknown. METHODS: A model of heart 
      failure was produced in 11 mongrel dogs by rapid ventricular pacing (250 
      beats/min for 12 to 14 days). Five dogs received 325 mg aspirin/day for the final 
      4 days of pacing before the acute experiment; six control dogs received no 
      aspirin. Cardiorenal and neurohumoral function was measured during chloralose 
      anesthesia. Hemodynamic and renal responses to enalaprilat were assessed. 
      RESULTS: Both groups demonstrated severe heart failure with decreased cardiac 
      output; increased atrial pressures and systemic resistance; activation of plasma 
      renin activity, aldosterone and atrial natriuretic factor; and sodium retention. 
      Low dose aspirin had no detrimental effect on cardiorenal or neurohumoral 
      function. Mean arterial pressure, pulmonary capillary wedge pressure and systemic 
      vascular resistance decreased to a similar degree with enalaprilat in both 
      groups. There was no difference between the groups with respect to renal response 
      to enalaprilat. CONCLUSIONS: The present study demonstrates that low dose aspirin 
      has no adverse effect on hemodynamic, neurohumoral or renal function in heart 
      failure. Furthermore, aspirin has no adverse effect on the acute response to 
      enalaprilat. These findings suggest that there is no contraindication to 
      concomitant treatment with low dose aspirin and angiotensin-converting enzyme 
      inhibitors in humans with heart failure.
FAU - Evans, M A
AU  - Evans MA
AD  - Cardiorenal Laboratory, Mayo Clinic, Rochester, Minnesota 55905, USA.
FAU - Burnett, J C Jr
AU  - Burnett JC Jr
FAU - Redfield, M M
AU  - Redfield MM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 4964P6T9RB (Aldosterone)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - EC 3.4.23.15 (Renin)
RN  - GV0O7ES0R3 (Enalaprilat)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aldosterone/blood
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Atrial Natriuretic Factor/blood
MH  - Disease Models, Animal
MH  - Dogs
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Enalaprilat/*pharmacology/therapeutic use
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Hemodynamics/*drug effects
MH  - Kidney/*drug effects
MH  - Renin/blood
MH  - Ventricular Dysfunction/drug therapy
EDAT- 1995/05/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
AID - 0735-1097(95)00006-P [pii]
AID - 10.1016/0735-1097(95)00006-P [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1995 May;25(6):1445-50. doi: 10.1016/0735-1097(95)00006-P.

PMID- 19887685
OWN - NLM
STAT- MEDLINE
DCOM- 20100304
LR  - 20131121
IS  - 0012-6543 (Print)
IS  - 0012-6543 (Linking)
VI  - 47
IP  - 11
DP  - 2009 Nov
TI  - Aspirin for primary prevention of cardiovascular disease?
PG  - 122-5
LID - 10.1136/dtb.2009.10.0045 [doi]
AB  - Cardiovascular disease (CVD) is a leading cause of mortality.1 For example, in 
      2000, it accounted directly for around 2 million deaths in the European Union. 
      Worldwide, many people take aspirin daily in the belief that doing so helps to 
      prevent CVD. This approach is established for the secondary prevention of 
      recurrent vascular events. However, there has been some uncertainty about the 
      place of aspirin for the primary prevention of cardiovascular events.6 In 
      particular, there have been doubts about whether any benefits of aspirin in 
      people with no history of CVD outweigh the risks (e.g. the fact that long-term 
      low-dose aspirin therapy almost doubles the likelihood of gastrointestinal 
      haemorrhage). Here we consider the place of low-dose aspirin in primary 
      prevention of CVD.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Drug Ther Bull. 2010 Feb;48(2):24
RPI - Evid Based Med. 2010 Feb;15(1):31-3. PMID: 20176886
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetic Angiopathies/prevention & control
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Off-Label Use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Sex Factors
EDAT- 2009/11/06 06:00
MHDA- 2010/03/05 06:00
CRDT- 2009/11/06 06:00
PHST- 2009/11/06 06:00 [entrez]
PHST- 2009/11/06 06:00 [pubmed]
PHST- 2010/03/05 06:00 [medline]
AID - 47/11/122 [pii]
AID - 10.1136/dtb.2009.10.0045 [doi]
PST - ppublish
SO  - Drug Ther Bull. 2009 Nov;47(11):122-5. doi: 10.1136/dtb.2009.10.0045.

PMID- 6886992
OWN - NLM
STAT- MEDLINE
DCOM- 19831028
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 72
IP  - 7
DP  - 1983 Jul
TI  - Influence of food on aspirin absorption from tablets and buffered solutions.
PG  - 819-21
AB  - After a standard meal, 12 normal volunteers received three aspirin dosage forms 
      in a single-dose, complete crossover study. The three dosage forms were an 
      unbuffered tablet, an effervescent solution with 16 meq of buffer, and an 
      effervescent solution with 34 meq of buffer. Plasma and urine aspirin, salicylic 
      acid, and salicyluric acid were measured for 10 hr. Significant differences in 
      the absorption kinetics of aspirin were observed, with aspirin from the two 
      solutions being absorbed faster than from the tablet. Urine pH and renal 
      clearance for all three acid compounds were influenced by the buffer during the 
      first 2 hr only. Area under the curve (AUC) and urine accumulation comparisons 
      suggest that 15-20% more aspirin reaches the general circulation after the 
      tablet, but that the total salicylate absorbed is not different. Comparison with 
      an earlier study indicates the solution with 34 meq of buffer is virtually 
      unaffected by the presence of the meal while the solution with 16 meq buffer and 
      the tablet are more slowly absorbed in the nonfasted state.
FAU - Mason, W D
AU  - Mason WD
FAU - Winer, N
AU  - Winer N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Buffers)
RN  - 0 (Salicylates)
RN  - 0 (Solutions)
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*metabolism
MH  - Buffers
MH  - *Food
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Salicylates/metabolism
MH  - Salicylic Acid
MH  - Solutions
MH  - Tablets
EDAT- 1983/07/01 00:00
MHDA- 1983/07/01 00:01
CRDT- 1983/07/01 00:00
PHST- 1983/07/01 00:00 [pubmed]
PHST- 1983/07/01 00:01 [medline]
PHST- 1983/07/01 00:00 [entrez]
AID - S0022-3549(15)44685-4 [pii]
AID - 10.1002/jps.2600720727 [doi]
PST - ppublish
SO  - J Pharm Sci. 1983 Jul;72(7):819-21. doi: 10.1002/jps.2600720727.

PMID- 18604019
OWN - NLM
STAT- MEDLINE
DCOM- 20101210
LR  - 20131121
IS  - 1812-2078 (Electronic)
IS  - 1812-2027 (Linking)
VI  - 5
IP  - 2
DP  - 2007 Apr-Jun
TI  - A study on the modification of anti-inflammatory and analgesic action of aspirin 
      by nifedipine.
PG  - 199-203
AB  - INTRODUCTION: Aspirin has been used as an analgesic from time immemorial. But the 
      recent advances on various aspects of it in reducing risk of various fatal and 
      non fatal diseases warrant a re-look. OBJECTIVE: This study has been undertaker 
      to assess the anti inflammatory and analgesic action of aspirin and Nifedipine 
      alone as well as in combination and their individual and synergistic effect as 
      anti-inflammatory and analgesic drug. MATERIALS AND METHODS: The anti - 
      inflammatory and anti - nociceptive effect of aspirin and nifedipine was studied 
      in a group of albino rats of Sprague Dowly strain. Anti - inflammatory action of 
      the drugs were tested in experimentally produced inflammatory model by injecting 
      turpentine oil in to the synovial cavity of knee joint of rats and anti - 
      nociceptive effect was studied by hot plate method. RESULTS: From the study it 
      was observed that nifedipine alone was a better anti - inflammatory drug causing 
      40.10 percent reduction of experimentally produced inflammation in the studied 
      rats on the 12th day of observation compared to aspirin alone (33.80 %) and 
      aspirin - nifedipine combination (39.82%) but as an analgesic nifedipine alone 
      (51.20%) was not found to be as effective as aspirin(88.96%) at 90 minutes of 
      observation. However, when nifedipine was combined with aspirin, it potentiated 
      the anti - nociceptive action of aspirin (107.64 %) at 90 minutes of observation 
      which was statistically significant (P<0.01). CONCLUSION: The above finding 
      demonstrated that the dose of Non Steroidal Anti - inflammatory Drugs (NSAIDs) 
      probably could be reduced when it is combined with Calcium Channel Blockers 
      (CCBs) and thus the adverse effect of NSAIDs could be reduced considerably. 
      Student's t test was applied for statistical analysis.
FAU - Patowary, S
AU  - Patowary S
AD  - Department of Clinical Pharmacology, College of Medical Sciences, Bharatpur, 
      Nepal. suspat@rediffmail.com
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Nepal
TA  - Kathmandu Univ Med J (KUMJ)
JT  - Kathmandu University medical journal (KUMJ)
JID - 101215359
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Calcium Channel Blockers)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/*administration & dosage/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*pharmacology
MH  - Aspirin/*administration & dosage/*pharmacology
MH  - Calcium Channel Blockers/*administration & dosage/*pharmacology
MH  - Drug Synergism
MH  - Female
MH  - Male
MH  - Nifedipine/*administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2008/07/08 09:00
MHDA- 2010/12/14 06:00
CRDT- 2008/07/08 09:00
PHST- 2008/07/08 09:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
PHST- 2008/07/08 09:00 [entrez]
PST - ppublish
SO  - Kathmandu Univ Med J (KUMJ). 2007 Apr-Jun;5(2):199-203.

PMID- 7994380
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Diaspirin cross-linked hemoglobin (DCLHB): involvement of adrenergic mechanisms 
      in the pressor effect.
PG  - 603-12
AB  - Diaspirin cross-linked Hemoglobin (DCLHb) (400 mg/kg, i.v.), a resuscitative 
      solution, produces a pressor effect in rats and several other species. Studies 
      were conducted to determine the role of the central nervous system and adrenal 
      medulla in the pressor effect of DCLHb in rats. Intravenous administration of 
      DCLHb produced an increase in blood pressure in cervical sectioned animals, which 
      was comparable to that observed in normal rats. This indicates that the pressor 
      effect of DCLHb was mediated through the peripheral vascular system rather than 
      through the central nervous system. DCLHb produced a pressor effect in bilateral 
      adrenal demedullated rats that was similar to normal rats, suggesting that the 
      pressor effect is not through the release of catecholamines or other pressor 
      substance from the adrenal medulla. The effects of DCLHb pretreatment on 
      norepinephrine (0.5 microgram/kg), phenylephrine (5 micrograms/kg) and clonidine 
      induced blood pressure and heart rate responses were also studied. DCLHb 
      significantly potentiated the pressor response to norepinephrine and 
      phenylephrine. Clonidine normally produces a fall in blood pressure by acting on 
      the central alpha-adrenoceptors, and a rise in blood pressure by stimulating the 
      peripheral vascular alpha-adrenoceptors. DCLHb produced a marked potentiation of 
      the pressor response to clonidine (75 micrograms/kg, i.v.), that masked the 
      central depressor effect. The specificity of the potentiation was confirmed by 
      using phenoxybenzamine, prazosin, and yohimbine. In order to exclude the 
      contribution of a centrally induced cardiovascular effect of clonidine, further 
      studies were carried out in cervical sectioned rats. DCLHb markedly potentiated 
      the pressor effect of clonidine (25 micrograms/kg, i.v.) in cervical sectioned 
      rats. This potentiation could be attenuated by prazosin and yohimbine.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Gulati, A
AU  - Gulati A
AD  - Department of Pharmacodynamics (m/c 865), University of Illinois at Chicago 
      60612-7231.
FAU - Rebello, S
AU  - Rebello S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Receptors, Adrenergic, alpha)
RN  - 1WS297W6MV (Phenylephrine)
RN  - 2Y49VWD90Q (Yohimbine)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - MN3L5RMN02 (Clonidine)
RN  - R16CO5Y76E (Aspirin)
RN  - XM03YJ541D (Prazosin)
SB  - IM
MH  - Adrenal Medulla/physiology
MH  - Adrenalectomy
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Blood Pressure/*drug effects/physiology
MH  - Blood Substitutes/administration & dosage/*pharmacology
MH  - Clonidine/administration & dosage
MH  - Drug Interactions
MH  - Hemoglobins/administration & dosage/*pharmacology
MH  - Male
MH  - Phenylephrine/administration & dosage
MH  - Prazosin/administration & dosage
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Adrenergic, alpha/drug effects/physiology
MH  - Yohimbine/administration & dosage
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117889 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):603-12. doi: 
      10.3109/10731199409117889.

PMID- 36546455
OWN - NLM
STAT- MEDLINE
DCOM- 20230404
LR  - 20230411
IS  - 1592-8721 (Electronic)
IS  - 0390-6078 (Print)
IS  - 0390-6078 (Linking)
VI  - 108
IP  - 4
DP  - 2023 Apr 1
TI  - Reduced platelet glycoprotein Ibα shedding accelerates thrombopoiesis and COX-1 
      recovery: implications for aspirin dosing regimen.
PG  - 1141-1157
LID - 10.3324/haematol.2022.281006 [doi]
AB  - Cardiovascular (CV) disease prevention with low-dose aspirin can be less 
      effective in patients with a faster recovery of platelet (PLT) cyclooxygenase 
      (COX)-1 activity during the 24-hour dosing interval. We previously showed that 
      incomplete suppression of TXA2 over 24 hours can be rescued by a twice daily 
      aspirin regimen. Here we show that reduced PLT glycoprotein (GP)Ibα shedding 
      characterizes patients with accelerated COX-1 recovery and may contribute to 
      higher thrombopoietin (TPO) production and higher rates of newly formed PLT, 
      escaping aspirin inhibition over 24 hours. Two hundred aspirin-treated patients 
      with high CV risk (100 with type 2 diabetes mellitus) were stratified according 
      to the kinetics of PLT COX-1 activity recovery during the 10- to 24-hour dosing 
      interval. Whole proteome analysis showed that PLT from patients with accelerated 
      COX-1 recovery were enriched in proteins involved in cell survival, inhibition of 
      apoptosis and cellular protrusion formation. In agreement, we documented 
      increased plasma TPO, megakaryocyte maturation and proplatelet formation, and 
      conversely increased PLT galactose and reduced caspase 3, phosphatidylserine 
      exposure and ADAM17 activation, translating into diminished GPIbα cleavage and 
      glycocalicin (GC) release. Treatment of HepG2 cells with recombinant GC led to a 
      dose-dependent reduction of TPO mRNA in the liver, suggesting that reduced GPIbα 
      ectodomain shedding may unleash thrombopoiesis. A cluster of clinical markers, 
      including younger age, non-alcoholic fatty liver disease, visceral obesity and 
      higher TPO/GC ratio, predicted with significant accuracy the likelihood of faster 
      COX-1 recovery and suboptimal aspirin response. Circulating TPO/GC ratio, 
      reflecting a dysregulation of PLT lifespan and production, may provide a simple 
      tool to identify patients amenable to more frequent aspirin daily dosing.
FAU - Simeone, Paola
AU  - Simeone P
AD  - Department of Medicine and Aging Sciences, Center for Advanced Studies and 
      Technology (CAST), University of Chieti.
FAU - Liani, Rossella
AU  - Liani R
AD  - Department of Medicine and Aging Sciences, Center for Advanced Studies and 
      Technology (CAST), University of Chieti.
FAU - Tripaldi, Romina
AU  - Tripaldi R
AD  - Department of Medicine and Aging Sciences, Center for Advanced Studies and 
      Technology (CAST), University of Chieti.
FAU - Ciotti, Sonia
AU  - Ciotti S
AD  - Department of Medicine and Aging Sciences, Center for Advanced Studies and 
      Technology (CAST), University of Chieti.
FAU - Recchiuti, Antonio
AU  - Recchiuti A
AD  - Department of Medical, Oral, and Biotechnological Science, Center for Advanced 
      Studies and Technology (CAST), Chieti.
FAU - Abbonante, Vittorio
AU  - Abbonante V
AD  - Department of Molecular Medicine, University of Pavia, Pavia, Italy; Department 
      of Health Sciences, Magna Graecia University of Catanzaro, Catanzaro.
FAU - Porro, Benedetta
AU  - Porro B
AD  - Centro Cardiologico Monzino IRCCS, Milan.
FAU - Del Boccio, Piero
AU  - Del Boccio P
AD  - Department of Pharmacy, Center for Advanced Studies and Technology (CAST), 
      Chieti.
FAU - Di Castelnuovo, Augusto
AU  - Di Castelnuovo A
AD  - Mediterranea Cardiocentro, Napoli.
FAU - Lanuti, Paola
AU  - Lanuti P
AD  - Department of Medicine and Aging Sciences, Center for Advanced Studies and 
      Technology (CAST), University of Chieti.
FAU - Camera, Marina
AU  - Camera M
AD  - Centro Cardiologico Monzino IRCCS, Milan; Department of Pharmaceutical Sciences, 
      Università degli Studi di Milano, Milan.
FAU - Pieragostino, Damiana
AU  - Pieragostino D
AD  - Department of Innovative Technologies in Medicine and Dentistry, Center for 
      Advanced Studies and Technology (CAST), Chieti.
FAU - Lee-Sundlov, Melissa
AU  - Lee-Sundlov M
AD  - Versiti Translational Glycomics Center and Versiti Blood Research Institute, 
      Milwaukee, WI.
FAU - Luongo, Myriam
AU  - Luongo M
AD  - Immunotransfusion Service, Clinical Haematology of Chieti University Hospital.
FAU - Auciello, Raffaella
AU  - Auciello R
AD  - Clinical Pathology of Chieti University Hospital.
FAU - Bologna, Giuseppina
AU  - Bologna G
AD  - Department of Medicine and Aging Sciences, Center for Advanced Studies and 
      Technology (CAST), University of Chieti.
FAU - Cufaro, Maria Concetta
AU  - Cufaro MC
AD  - Department of Innovative Technologies in Medicine and Dentistry, Center for 
      Advanced Studies and Technology (CAST), Chieti.
FAU - Tremoli, Elena
AU  - Tremoli E
AD  - Maria Cecilia Hospital, Cotignola.
FAU - Hoffmeister, Karin M
AU  - Hoffmeister KM
AD  - Versiti Translational Glycomics Center and Versiti Blood Research Institute, 
      Milwaukee, WI, USA; Departments of Biochemistry and Medicine, Medical College of 
      Wisconsin, Milwaukee, WI.
FAU - Cipollone, Francesco
AU  - Cipollone F
AD  - Department of Medicine and Aging Sciences, Center for Advanced Studies and 
      Technology (CAST), University of Chieti.
FAU - Balduini, Alessandra
AU  - Balduini A
AD  - Department of Molecular Medicine, University of Pavia, Pavia.
FAU - Santilli, Francesca
AU  - Santilli F
AD  - Department of Medicine and Aging Sciences, Center for Advanced Studies and 
      Technology (CAST), University of Chieti. francesca.santilli@unich.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230401
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Membrane Glycoproteins)
SB  - IM
MH  - Humans
MH  - Aspirin/pharmacology
MH  - Thrombopoiesis
MH  - *Diabetes Mellitus, Type 2/metabolism
MH  - Blood Platelets/metabolism
MH  - *Thrombocytopenia/metabolism
MH  - Platelet Membrane Glycoproteins/metabolism
PMC - PMC10071111
EDAT- 2022/12/23 06:00
MHDA- 2023/04/04 06:42
CRDT- 2022/12/22 05:44
PHST- 2022/03/10 00:00 [received]
PHST- 2023/04/04 06:42 [medline]
PHST- 2022/12/23 06:00 [pubmed]
PHST- 2022/12/22 05:44 [entrez]
AID - 10.3324/haematol.2022.281006 [doi]
PST - epublish
SO  - Haematologica. 2023 Apr 1;108(4):1141-1157. doi: 10.3324/haematol.2022.281006.

PMID- 27289249
OWN - NLM
STAT- MEDLINE
DCOM- 20170112
LR  - 20211025
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 104
DP  - 2016 Aug
TI  - The role of aspirin in colorectal cancer chemoprevention.
PG  - 87-90
LID - S1040-8428(16)30118-4 [pii]
LID - 10.1016/j.critrevonc.2016.05.011 [doi]
AB  - Considerable interest has emerged over the last decade regarding the role of 
      aspirin in prevention of colorectal cancer. This disease is one of the commonest 
      cancers in the Western World, therefore, the existence of a simple "everyday" 
      agent, which could have the ability to prevent the disease, represents an 
      invaluable opportunity clinicians may be able to exploit. Evidence from 
      case-control and cohort studies, and recent updates of randomised controlled 
      trials have been very encouraging-indicating benefit from long term use of 
      aspirin at low dose. Possible mechanisms of chemoprevention include inhibition of 
      the cyclooxygenase (COX) pathway, or COX-independent mechanisms, for example, the 
      PIK3CA pathway, or therapy-induced senescence of cancer cells. The most serious 
      side effect of prolonged aspirin treatment is haemorrhage, especially from the GI 
      tract. This is likely to be less of a problem with chemoprevention at lower 
      doses. One also needs to consider the impact if aspirin resistance, an 
      increasingly recognised clinical entity.
CI  - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Singh Ranger, Gurpreet
AU  - Singh Ranger G
AD  - Upper River Valley Hospital, 11300 Route 130, Waterville, New Brunswick, E7P 0A4, 
      Canada; Dalhousie Medical School, Halifax, Nova Scotia, Canada; Memorial 
      University, St. John's, Newfoundland, Canada. Electronic address: 
      gsinghranger@yahoo.co.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160526
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Chemoprevention
MH  - Colorectal Neoplasms/*prevention & control
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Humans
MH  - Observational Studies as Topic
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Aspirin
OT  - Chemoprevention
OT  - Colorectal cancer
OT  - Cyclooxygenase-1
OT  - Cyclooxygenase-2
OT  - Prostaglandins
EDAT- 2016/06/13 06:00
MHDA- 2017/01/14 06:00
CRDT- 2016/06/13 06:00
PHST- 2016/01/16 00:00 [received]
PHST- 2016/03/03 00:00 [revised]
PHST- 2016/05/25 00:00 [accepted]
PHST- 2016/06/13 06:00 [entrez]
PHST- 2016/06/13 06:00 [pubmed]
PHST- 2017/01/14 06:00 [medline]
AID - S1040-8428(16)30118-4 [pii]
AID - 10.1016/j.critrevonc.2016.05.011 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2016 Aug;104:87-90. doi: 
      10.1016/j.critrevonc.2016.05.011. Epub 2016 May 26.

PMID- 28911988
OWN - NLM
STAT- MEDLINE
DCOM- 20180205
LR  - 20181202
IS  - 1873-0183 (Electronic)
IS  - 1568-9972 (Linking)
VI  - 16
IP  - 11
DP  - 2017 Nov
TI  - Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: 
      Pro's and Con's.
PG  - 1103-1108
LID - S1568-9972(17)30227-6 [pii]
LID - 10.1016/j.autrev.2017.09.003 [doi]
AB  - Whether primary prophylaxis should be prescribed in individuals with 
      antiphospholipid antibodies (aPL) remains controversial due to the lack of 
      relevant evidence-based data. Indeed, it is unclear whether the benefit of LDA 
      outweighs the risk of major bleeding associated with LDA in a low-risk 
      population. On the contrary, stratification of aPL-positive subjects according to 
      their aPL profile (combination, isotype and titer), presence of other concomitant 
      risk factors for thrombosis and coexistence of an underling autoimmune disease is 
      essential to decide whether primary prophylactic therapy should be prescribed. 
      Additionally, the management of modifiable thrombotic risk factors is a necessary 
      strategy, and the use of transient prophylaxis is crucial during high-risk 
      periods. Specifically designed prospective trials are urgently needed to 
      determine the real prophylactic impact of aspirin, as well as of alternative or 
      concomitant therapeutic strategies such as hydroxychloroquine, statins or DOACS 
      in aPL positive patients.
CI  - Copyright © 2017. Published by Elsevier B.V.
FAU - Arnaud, Laurent
AU  - Arnaud L
AD  - Service de rhumatologie, Centre National de Référence des Maladies Autoimmunes et 
      Systémiques Rares, Université de Strasbourg, INSERM UMR-S 1109, F-67000 
      Strasbourg, France. Electronic address: Laurent.arnaud@chru-strasbourg.fr.
FAU - Conti, Fabrizio
AU  - Conti F
AD  - Rheumatology Unit, Department of Internal Medicine and Medical Specialties, 
      Sapienza University of Rome, Rome, Italy.
FAU - Massaro, Laura
AU  - Massaro L
AD  - Rheumatology Unit, Department of Internal Medicine and Medical Specialties, 
      Sapienza University of Rome, Rome, Italy.
FAU - Denas, Gentian
AU  - Denas G
AD  - Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, 
      Thrombosis Centre, University of Padova, Padova, Italy.
FAU - Chasset, François
AU  - Chasset F
AD  - Université Pierre et Marie Curie-Paris VI, Assistance Publique-Hôpitaux de Paris, 
      Service de Dermatologie-Allergologie, Hôpital Tenon, 4 rue de la Chine, 75020, 
      Paris, France.
FAU - Pengo, Vittorio
AU  - Pengo V
AD  - Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, 
      Thrombosis Centre, University of Padova, Padova, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20170911
PL  - Netherlands
TA  - Autoimmun Rev
JT  - Autoimmunity reviews
JID - 101128967
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antibodies, Antiphospholipid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Antibodies, Antiphospholipid/*therapeutic use
MH  - Antiphospholipid Syndrome/*complications
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Prognosis
MH  - Thrombosis/etiology/*prevention & control
OTO - NOTNLM
OT  - Antiphospholipid antibodies
OT  - Aspirin
OT  - Primary prophylaxis
OT  - Systematic review
OT  - Thrombosis
EDAT- 2017/09/16 06:00
MHDA- 2018/02/06 06:00
CRDT- 2017/09/16 06:00
PHST- 2017/07/14 00:00 [received]
PHST- 2017/07/19 00:00 [accepted]
PHST- 2017/09/16 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
PHST- 2017/09/16 06:00 [entrez]
AID - S1568-9972(17)30227-6 [pii]
AID - 10.1016/j.autrev.2017.09.003 [doi]
PST - ppublish
SO  - Autoimmun Rev. 2017 Nov;16(11):1103-1108. doi: 10.1016/j.autrev.2017.09.003. Epub 
      2017 Sep 11.

PMID- 541906
OWN - NLM
STAT- MEDLINE
DCOM- 19800627
LR  - 20190725
IS  - 0021-5198 (Print)
IS  - 0021-5198 (Linking)
VI  - 29
IP  - 6
DP  - 1979 Dec
TI  - Interaction between aspirin and prostaglandins in the isolated guinea-pig 
      tracheal muscle.
PG  - 865-75
AB  - The effects of PGE2 and PGF2 alpha on the tonus of isolated guinea-pig tracheal 
      chain were investigated and compared with those of histamine and acetylcholine. 
      PGE2 reduced tonus in normal resting state, but elevated tracheal tonus reduced 
      by aspirin. Such PGE2-induced contractions did not exceed the initial resting 
      tonus, and the magnitude and duration of the contractions progressively 
      diminished with increase of PGE2 concentrations. Aspirin produced neither 
      relaxation nor contraction in the presence of a low dose of PGE2. Unlike PGE2, 
      PGF2 alpha produced a dose-related contraction in the normal tracheal chain, and 
      the contractile response to PGF2 alpha was markedly potentiated by aspirin. In 
      the presence of PGF2 alpha, aspirin no longer produced tracheal relaxation but 
      produced a dose-related contraction. The contractile effect of histamine but not 
      of acetylcholine was also potentiated by aspirin, but there was a slight 
      difference between PGF2 alpha and histamine in that the potentiation of action of 
      PGF2 alpha by aspirin was more easily diminished by PGE2. These results suggest 
      that PGE2 plays an important role in the maintenance of the resting tonus of the 
      isolated guinea-pig tracheal chain, and in large doses it also acts as a tracheal 
      relaxant and attenuates the tracheal responses to PGF2 alpha and histamine.
FAU - Ono, T
AU  - Ono T
FAU - Motoyama, Y
AU  - Motoyama Y
FAU - Sakai, S
AU  - Sakai S
FAU - Yoneda, J
AU  - Yoneda J
FAU - Kumada, S
AU  - Kumada S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - Jpn J Pharmacol
JT  - Japanese journal of pharmacology
JID - 2983305R
RN  - 0 (Prostaglandins E)
RN  - 0 (Prostaglandins F)
RN  - 820484N8I3 (Histamine)
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylcholine/pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Drug Interactions
MH  - Histamine/pharmacology
MH  - In Vitro Techniques
MH  - Male
MH  - Muscle Tonus/*drug effects
MH  - Prostaglandins E/*pharmacology
MH  - Prostaglandins F/*pharmacology
MH  - Trachea/drug effects
EDAT- 1979/12/01 00:00
MHDA- 1979/12/01 00:01
CRDT- 1979/12/01 00:00
PHST- 1979/12/01 00:00 [pubmed]
PHST- 1979/12/01 00:01 [medline]
PHST- 1979/12/01 00:00 [entrez]
AID - 10.1254/jjp.29.865 [doi]
PST - ppublish
SO  - Jpn J Pharmacol. 1979 Dec;29(6):865-75. doi: 10.1254/jjp.29.865.

PMID- 16802846
OWN - NLM
STAT- MEDLINE
DCOM- 20060831
LR  - 20181201
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 24
IP  - 7
DP  - 2006
TI  - Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST 
      elevation acute coronary syndromes.
PG  - 709-26
AB  - Clopidogrel (Plavix) is a selective inhibitor of adenosine diphosphate-induced 
      platelet aggregation. In patients with acute coronary syndromes (ACS) [unstable 
      angina or non-ST-segment elevation myocardial infarction], clopidogrel plus 
      aspirin (acetylsalicylic acid) for up to 1 year significantly reduced the risk of 
      cardiovascular events relative to placebo plus aspirin in the well designed 
      clinical trial CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) 
      and its substudy in patients undergoing percutaneous coronary intervention (PCI) 
      [PCI-CURE]. In pharmacoeconomic evaluations based on data from these trials 
      conducted in a number of countries that used a variety of models, methods and/or 
      type of costs, clopidogrel plus aspirin was consistently predicted to be cost 
      effective relative to aspirin alone in the management of patients with ACS, 
      including those undergoing PCI. Clopidogrel plus aspirin in patients with ACS 
      reduced the incremental cost per cardiovascular event prevented and/or life-year 
      gained (LYG) relative to aspirin alone in analyses using within-trial data 
      (including longer-term analyses incorporating life-expectancy estimates) from the 
      CURE or PCI-CURE studies. In Markov models of cost effectiveness with a lifetime 
      horizon from a healthcare payer perspective based on the CURE trial, relative to 
      aspirin alone, clopidogrel plus aspirin for 1 year was predicted to have 
      incremental costs per LYG of 8132Euro in Spain (2003 values) and 1365Euro in 
      Sweden (2000 values). In similar Swedish analyses from a healthcare payer 
      perspective, clopidogrel plus aspirin for 1 year was predicted to have 
      incremental costs per LYG of 10,993Euro (2004 values) relative to aspirin alone 
      based on data from the PCI-CURE substudy. Broadly similar results have also been 
      reported in modelled analyses from other countries. Cost-utility analyses based 
      on the CURE trial suggest that, relative to lifelong aspirin alone, clopidogrel 
      plus aspirin for 1 year followed by aspirin alone is associated with incremental 
      costs per QALY gained that are below the traditional threshold of cost utility in 
      Spain, the UK and the US. In patients with ACS, including those undergoing PCI, 
      the addition of clopidogrel to standard therapy with aspirin is clinically 
      effective in preventing cardiovascular events. Available pharmacoeconomic data 
      from several countries, despite some inherent limitations, support the use of 
      clopidogrel plus aspirin for up to 1 year as a cost-effective treatment relative 
      to aspirin alone in this patient population.
FAU - Lyseng-Williamson, Katherine A
AU  - Lyseng-Williamson KA
AD  - Adis International Limited, Mairangi Bay, Auckland, New Zealand. 
      demail@adis.co.nz
FAU - Plosker, Greg L
AU  - Plosker GL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*economics/therapeutic 
      use
MH  - Aspirin/adverse effects/*economics/therapeutic use
MH  - Clopidogrel
MH  - Coronary Disease/*drug therapy/epidemiology
MH  - *Cost-Benefit Analysis
MH  - Economics, Pharmaceutical
MH  - Humans
MH  - Markov Chains
MH  - Platelet Aggregation Inhibitors/adverse effects/*economics/therapeutic use
MH  - Prescription Fees/*statistics & numerical data
MH  - Quality-Adjusted Life Years
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/adverse effects/*analogs & derivatives/economics/therapeutic use
RF  - 54
EDAT- 2006/06/29 09:00
MHDA- 2006/09/01 09:00
CRDT- 2006/06/29 09:00
PHST- 2006/06/29 09:00 [pubmed]
PHST- 2006/09/01 09:00 [medline]
PHST- 2006/06/29 09:00 [entrez]
AID - 2479 [pii]
AID - 10.2165/00019053-200624070-00009 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2006;24(7):709-26. doi: 10.2165/00019053-200624070-00009.

PMID- 20060783
OWN - NLM
STAT- MEDLINE
DCOM- 20100226
LR  - 20220318
IS  - 1474-4465 (Electronic)
IS  - 1474-4422 (Linking)
VI  - 9
IP  - 2
DP  - 2010 Feb
TI  - Early treatment with aspirin plus extended-release dipyridamole for transient 
      ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): 
      a randomised, open-label, blinded-endpoint trial.
PG  - 159-66
LID - 10.1016/S1474-4422(09)70361-8 [doi]
AB  - BACKGROUND: Little is known about the best antiplatelet treatment immediately 
      after ischaemic stroke or transient ischaemic attack (TIA). The EARLY trial aimed 
      to compare outcome in patients given aspirin plus extended-release dipyridamole 
      twice daily either within 24 h of stroke or TIA or after 7 days of aspirin 
      monotherapy. METHODS: In 46 stroke units in Germany, patients aged 18 years or 
      more who presented with symptoms of an acute ischaemic stroke that caused a 
      measurable neurological deficit (National Institutes of Health stroke scale score 
      < or =20) were randomly assigned to receive 25 mg aspirin plus 200 mg 
      extended-release dipyridamole open-label twice daily or 100 mg aspirin 
      monotherapy open-label once daily for 7 days. Patients were randomised by use of 
      a pseudorandom number generator. All patients were then given open-label aspirin 
      plus extended-release dipyridamole for up to 90 days. The primary endpoint was 
      modified Rankin scale score as recorded by centralised, blinded assessment by 
      telephone (tele-mRS) at 90 days. Vascular adverse events (non-fatal stroke, TIA, 
      non-fatal myocardial infarction, and major bleeding complications) and mortality 
      were assessed in a composite safety and efficacy endpoint. Patients were analysed 
      as treated. This trial is registered, number NCT00562588. FINDINGS: Between July, 
      2007, and February, 2009, 543 patients were treated: 283 received early aspirin 
      plus extended-release dipyridamole and 260 received aspirin plus extended-release 
      dipyridamole after 7 days on aspirin. At day 90, 154 (56%) patients in the 
      aspirin plus early extended-release dipyridamole group and 133 (52%) in the 
      aspirin plus later extended-release dipyridamole group had no or mild disability 
      (tele-mRS 0 or 1; difference 4.1%, 95% CI -4.5 to 12.6, p=0.45). 28 patients in 
      the early initiation group and 38 in the late initiation group reached the 
      composite endpoint (hazard ratio 0.73, 95% CI 0.44-1.19 p=0.20). INTERPRETATION: 
      Early initiation of aspirin plus extended-release dipyridamole within 24 h of 
      stroke onset is likely to be as safe and effective in preventing disability as is 
      later initiation after 7 days. FUNDING: Boehringer Ingelheim.
CI  - Copyright (c) 2010 Elsevier Ltd. All rights reserved.
FAU - Dengler, Reinhard
AU  - Dengler R
AD  - Department of Neurology, Medizinische Hochschule Hannover, Hannover, Germany. 
      dengler.reinhard@mhhannover.de
FAU - Diener, Hans-Christoph
AU  - Diener HC
FAU - Schwartz, Andreas
AU  - Schwartz A
FAU - Grond, Martin
AU  - Grond M
FAU - Schumacher, Helmut
AU  - Schumacher H
FAU - Machnig, Thomas
AU  - Machnig T
FAU - Eschenfelder, Christoph Cyrill
AU  - Eschenfelder CC
FAU - Leonard, Joachim
AU  - Leonard J
FAU - Weissenborn, Karin
AU  - Weissenborn K
FAU - Kastrup, Andreas
AU  - Kastrup A
FAU - Haberl, Roman
AU  - Haberl R
CN  - EARLY Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00562588
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100107
PL  - England
TA  - Lancet Neurol
JT  - The Lancet. Neurology
JID - 101139309
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Aspirin/*therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Dipyridamole/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Germany
MH  - Humans
MH  - Ischemic Attack, Transient/complications/*drug therapy
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Severity of Illness Index
MH  - Time Factors
FIR - Berrouschot, J
IR  - Berrouschot J
FIR - Stoll, A
IR  - Stoll A
FIR - Ickenstein, G W
IR  - Ickenstein GW
FIR - Westendorf, T
IR  - Westendorf T
FIR - Daffertshofer, M
IR  - Daffertshofer M
FIR - Lachenicht, B
IR  - Lachenicht B
FIR - Szponar-Wolf, A
IR  - Szponar-Wolf A
FIR - Krauseneck, P
IR  - Krauseneck P
FIR - Oschmann, P
IR  - Oschmann P
FIR - Pott, M
IR  - Pott M
FIR - Schultes, K
IR  - Schultes K
FIR - Wessel, K
IR  - Wessel K
FIR - Ahlers, A
IR  - Ahlers A
FIR - Nabavi, D G
IR  - Nabavi DG
FIR - Crome, O
IR  - Crome O
FIR - Endres, M
IR  - Endres M
FIR - Jungehülsing, J G
IR  - Jungehülsing JG
FIR - Ebke, M
IR  - Ebke M
FIR - Schröter, A
IR  - Schröter A
FIR - Odin, P
IR  - Odin P
FIR - von Mering, M
IR  - von Mering M
FIR - Heide, W
IR  - Heide W
FIR - Hanssen, J R
IR  - Hanssen JR
FIR - Schrader, J
IR  - Schrader J
FIR - Lüders, S
IR  - Lüders S
FIR - Rudel, G
IR  - Rudel G
FIR - Jander, S
IR  - Jander S
FIR - Siebler, M
IR  - Siebler M
FIR - Schellinger, P
IR  - Schellinger P
FIR - Berlit, P
IR  - Berlit P
FIR - Diener, H -C
IR  - Diener H-
FIR - Johansson, U
IR  - Johansson U
FIR - Weimer, C
IR  - Weimer C
FIR - Niesen, W D
IR  - Niesen WD
FIR - Schläger, A
IR  - Schläger A
FIR - Jacobs, A
IR  - Jacobs A
FIR - Hohmann, C
IR  - Hohmann C
FIR - Kastrup, A
IR  - Kastrup A
FIR - Gröschel, K
IR  - Gröschel K
FIR - Schnaudigel, S
IR  - Schnaudigel S
FIR - Wasser, K
IR  - Wasser K
FIR - Terborg, C
IR  - Terborg C
FIR - Urban, P P
IR  - Urban PP
FIR - Pohlman, C
IR  - Pohlman C
FIR - Kaczmarek, E
IR  - Kaczmarek E
FIR - Koehler, J
IR  - Koehler J
FIR - Müller-Jensen, A
IR  - Müller-Jensen A
FIR - Rosenkranz, M
IR  - Rosenkranz M
FIR - Dengler, R
IR  - Dengler R
FIR - Goldbecker, A
IR  - Goldbecker A
FIR - Worthmann, H
IR  - Worthmann H
FIR - Eicke, M
IR  - Eicke M
FIR - Witte, O W
IR  - Witte OW
FIR - Ringer, T
IR  - Ringer T
FIR - Müller, A
IR  - Müller A
FIR - Wöhrle, J
IR  - Wöhrle J
FIR - Sobesky, J
IR  - Sobesky J
FIR - Schneider, D
IR  - Schneider D
FIR - Michalski, D
IR  - Michalski D
FIR - Hobohm, C
IR  - Hobohm C
FIR - Seidel, G
IR  - Seidel G
FIR - Marx, J
IR  - Marx J
FIR - Klimpe, S
IR  - Klimpe S
FIR - Hamer, M
IR  - Hamer M
FIR - Haan, J
IR  - Haan J
FIR - Greif, G
IR  - Greif G
FIR - Al-Khalaf, A
IR  - Al-Khalaf A
FIR - Dichgans, M
IR  - Dichgans M
FIR - Mewald, Y
IR  - Mewald Y
FIR - Poppert, H
IR  - Poppert H
FIR - Schäbitz, W -R
IR  - Schäbitz W-
FIR - Nückel, M
IR  - Nückel M
FIR - Stark, E
IR  - Stark E
FIR - Schlachetzki, F
IR  - Schlachetzki F
FIR - Boy, S
IR  - Boy S
FIR - von Heinemann, P
IR  - von Heinemann P
FIR - Mühler, J
IR  - Mühler J
FIR - Fortwängler, T
IR  - Fortwängler T
FIR - Schmid, E
IR  - Schmid E
FIR - Menn, O
IR  - Menn O
FIR - Jauk, M
IR  - Jauk M
FIR - Luft, A
IR  - Luft A
FIR - Huber, R
IR  - Huber R
FIR - Müller, S
IR  - Müller S
FIR - Cepek, L
IR  - Cepek L
FIR - Dengler, R
IR  - Dengler R
FIR - Diener, H -C
IR  - Diener H-
FIR - Schwartz, A
IR  - Schwartz A
FIR - Grond, M
IR  - Grond M
FIR - Schumacher, H
IR  - Schumacher H
FIR - Machnig, T
IR  - Machnig T
FIR - Eschenfelder, C C
IR  - Eschenfelder CC
FIR - Leonard, J
IR  - Leonard J
FIR - Weissenborn, K
IR  - Weissenborn K
FIR - Kastrup, A
IR  - Kastrup A
FIR - Haberl, R
IR  - Haberl R
FIR - Dengler, R
IR  - Dengler R
FIR - Schumacher, H
IR  - Schumacher H
FIR - Leonard, J
IR  - Leonard J
FIR - Schumacher, H
IR  - Schumacher H
FIR - Machnig, T
IR  - Machnig T
FIR - Eschenfelder, C C
IR  - Eschenfelder CC
FIR - Leonard, J
IR  - Leonard J
FIR - Mateblowski, M
IR  - Mateblowski M
FIR - Grond, M
IR  - Grond M
FIR - Schenkel, J
IR  - Schenkel J
EDAT- 2010/01/12 06:00
MHDA- 2010/02/27 06:00
CRDT- 2010/01/12 06:00
PHST- 2010/01/12 06:00 [entrez]
PHST- 2010/01/12 06:00 [pubmed]
PHST- 2010/02/27 06:00 [medline]
AID - S1474-4422(09)70361-8 [pii]
AID - 10.1016/S1474-4422(09)70361-8 [doi]
PST - ppublish
SO  - Lancet Neurol. 2010 Feb;9(2):159-66. doi: 10.1016/S1474-4422(09)70361-8. Epub 
      2010 Jan 7.

PMID- 750827
OWN - NLM
STAT- MEDLINE
DCOM- 19790725
LR  - 20190814
IS  - 0024-4201 (Print)
IS  - 0024-4201 (Linking)
VI  - 13
IP  - 12
DP  - 1978 Dec
TI  - Incidence and severity of experimental allergic encephalomyelitis and cerebral 
      prostaglandin synthesis in essential fatty acid deficient and aspirin-treated 
      rats.
PG  - 867-72
AB  - Experimental allergic encephalomyelitis (EAE) was induced in rats of the Lewis 
      strain fed diets adequate or deficient in essential fatty acids (EFA). After 
      induction of the disease, the diets were supplemented with aspirin (3.75 g/kg 
      diet), and the effects of the drug on the course of EAE and on the synthesis of 
      prostaglandin F (PGF) by brain slices from diseased animals and their Freund 
      controls were examined. Aspirin supplementation delayed the onset of EAE in both 
      dietary groups. EFA-deficient rats experienced an incidence and severity of the 
      disease similar to that of aspirin-free, EFA-deficiet rats, while the 
      EFA-adequate group showed a greater severity but not an increased incidence, 
      compared to aspirin-free controls. Aspirin treatment led to an increased PGF 
      production by brain slices from rats on either diet and not subjected to an 
      immunochallenge. When the diet was deficient in EFA, challenge with antigen plus 
      adjuvant or adjuvant alone tended to decrease PGF synthesis by brain slices, and 
      when the diet was adequate in EFA, immunochallenge caused a marked depression on 
      PGF synthesis. It was concluded that the PG synthetase inhibitor aspirin can 
      alter the course of EAE in the rat, providing further evidence that PGs or 
      related metabolites may be involved in the immune response in this disease.
FAU - Weston, P G
AU  - Weston PG
FAU - Johnston, P V
AU  - Johnston PV
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Lipids
JT  - Lipids
JID - 0060450
RN  - 0 (Fatty Acids, Essential)
RN  - 0 (Prostaglandins F)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Brain/*metabolism
MH  - Brain Chemistry
MH  - Encephalomyelitis, Autoimmune, Experimental/drug therapy/*metabolism
MH  - Fatty Acids, Essential/*deficiency/metabolism
MH  - Male
MH  - Prostaglandins F/*biosynthesis
MH  - Rats
MH  - Salicylates/blood
EDAT- 1978/12/01 00:00
MHDA- 1978/12/01 00:01
CRDT- 1978/12/01 00:00
PHST- 1978/12/01 00:00 [pubmed]
PHST- 1978/12/01 00:01 [medline]
PHST- 1978/12/01 00:00 [entrez]
AID - 10.1007/BF02533841 [doi]
PST - ppublish
SO  - Lipids. 1978 Dec;13(12):867-72. doi: 10.1007/BF02533841.

PMID- 6812094
OWN - NLM
STAT- MEDLINE
DCOM- 19821202
LR  - 20191031
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 9
IP  - 2
DP  - 1982 Aug
TI  - The effect of aspirin pretreatment on the fate of arachidonic acid in hamster 
      isolated lungs.
PG  - 171-81
AB  - The fate of exogenous arachidonic acid (AA) was investigated in isolated perfused 
      lungs from hamsters, which were pretreated with aspirin in drinking water (0, 5, 
      50 or 500 mg/1) for one week. When 40 nmol of 14C-AA was infused in two minutes 
      into the pulmonary circulation, the perfusion pressure increased. This pressor 
      response was decreased by 50 mg/1 aspirin and was negligible after 500 mg/1. The 
      amount of radioactivity was increased by aspirin pretreatment in the perfused 
      lungs and decreased in the nonrecirculating perfusion effluent, which was 
      collected for 6 minutes after the beginning of the AA infusion. The amount of 
      unmetabolized free arachidonate was not changed significantly in the perfusion 
      effluent or in the perfused lungs. The perfusion effluent was extracted with 
      ethyl acetate first at pH 7.4 to extract unmetabolized AA, metabolites of 
      lipoxygenase and HHT and then at pH 3.5 for prostaglandins and thromboxanes. The 
      amounts of all arachidonate metabolites were decreased rather similarly by 
      aspirin pretreatment. In the perfused lung tissue the amount of 14C-AA was 
      increased by aspirin in phospholipids and in the triacylglycerol fraction of 
      neutral lipids.
FAU - Schalin, M
AU  - Schalin M
FAU - Uotila, P
AU  - Uotila P
LA  - eng
GR  - ES-01684-20/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Arachidonic Acids)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Phospholipids)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/*metabolism
MH  - Aspirin/*pharmacology
MH  - Chromatography, Thin Layer
MH  - Cricetinae
MH  - Fatty Acids, Nonesterified/analysis
MH  - Female
MH  - Lung/drug effects/*metabolism
MH  - Mesocricetus
MH  - Perfusion
MH  - Phospholipids/analysis
MH  - Tissue Distribution
EDAT- 1982/08/01 00:00
MHDA- 1982/08/01 00:01
CRDT- 1982/08/01 00:00
PHST- 1982/08/01 00:00 [pubmed]
PHST- 1982/08/01 00:01 [medline]
PHST- 1982/08/01 00:00 [entrez]
AID - 10.1016/0262-1746(82)90006-3 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1982 Aug;9(2):171-81. doi: 
      10.1016/0262-1746(82)90006-3.

PMID- 37148432
OWN - NLM
STAT- MEDLINE
DCOM- 20230717
LR  - 20230718
IS  - 1573-7365 (Electronic)
IS  - 0885-7490 (Linking)
VI  - 38
IP  - 6
DP  - 2023 Aug
TI  - Aspirin attenuates morphine antinociceptive tolerance in rats with diabetic 
      neuropathy by inhibiting apoptosis in the dorsal root ganglia.
PG  - 2145-2158
LID - 10.1007/s11011-023-01226-2 [doi]
AB  - Morphine is a drug used in chronic pain such as diabetic neuropathy, but the 
      development of tolerance to its antinociceptive effect is an important clinical 
      problem. Aspirin is an analgesic and antiapoptotic drug used in combination with 
      morphine as an adjuvant in diabetic neuropathy. Our aim in this study was to 
      investigate the effects of aspirin on morphine-induced neuronal apoptosis and 
      analgesic tolerance in rats with diabetic neuropathy. The antinociceptive effects 
      of aspirin (50 mg/kg) and morphine (5 mg/kg) were evaluated by thermal pain 
      tests. Streptozotocin (65 mg/kg) was injected intraperitoneally to induce 
      diabetic neuropathy. To evaluate apoptosis, ELISA kits were used to measure 
      caspase-3, Bax and Bcl-2 levels. Apoptotic cells were detected histologically by 
      terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) 
      method. Study results indicate that prior administration of aspirin to diabetic 
      rats significantly increased the antinociceptive efficacy of morphine compared to 
      morphine alone. Thermal pain tests showed that aspirin significantly reduced 
      morphine tolerance in rats with diabetic neuropathy. Biochemical analysis 
      revealed that aspirin significantly decreased the levels of pro-apoptotic 
      proteins, caspase-3 and Bax, while increasing the anti-apoptotic Bcl-2 in DRG 
      neurons. Semiquantitative scoring demonstrated that aspirin provided a 
      significant reduction in apoptotic cell counts in diabetic rats. In conclusion, 
      these data suggested that aspirin attenuated morphine antinociceptive tolerance 
      through anti-apoptotic activity in diabetic rat DRG neurons.
CI  - © 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Ozdemir, Ercan
AU  - Ozdemir E
AUID- ORCID: 0000-0001-8231-1053
AD  - Departments of Physiology, Sivas Cumhuriyet University School of Medicine, Sivas, 
      58140, Turkey. ercan_ozdemir@hotmail.com.
FAU - Avcı, Onur
AU  - Avcı O
AUID- ORCID: 0000-0003-0743-754X
AD  - Anesthesiology and Reanimation, Sivas Cumhuriyet University School of Medicine, 
      Sivas, Turkey.
FAU - Inan, Zeynep Deniz Sahin
AU  - Inan ZDS
AUID- ORCID: 0000-0002-0292-4448
AD  - Histology and Embryology, Sivas Cumhuriyet University School of Medicine, Sivas, 
      Turkey.
FAU - Taskiran, Ahmet Sevki
AU  - Taskiran AS
AUID- ORCID: 0000-0002-5810-8415
AD  - Departments of Physiology, Sivas Cumhuriyet University School of Medicine, Sivas, 
      58140, Turkey.
FAU - Gunes, Handan
AU  - Gunes H
AUID- ORCID: 0000-0003-3660-8264
AD  - Departments of Physiology, Sivas Cumhuriyet University School of Medicine, Sivas, 
      58140, Turkey.
FAU - Gursoy, Sinan
AU  - Gursoy S
AUID- ORCID: 0000-0003-0259-9750
AD  - Anesthesiology and Reanimation, Sivas Cumhuriyet University School of Medicine, 
      Sivas, Turkey.
LA  - eng
GR  - T-856/Sivas Cumhuriyet Üniversitesi/
PT  - Journal Article
DEP - 20230506
PL  - United States
TA  - Metab Brain Dis
JT  - Metabolic brain disease
JID - 8610370
RN  - 76I7G6D29C (Morphine)
RN  - R16CO5Y76E (Aspirin)
RN  - EC 3.4.22.- (Caspase 3)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 0 (Analgesics)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
SB  - IM
MH  - Rats
MH  - Animals
MH  - Morphine/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Caspase 3/metabolism
MH  - *Diabetic Neuropathies/drug therapy
MH  - *Diabetes Mellitus, Experimental/drug therapy
MH  - bcl-2-Associated X Protein
MH  - Ganglia, Spinal/metabolism
MH  - Apoptosis
MH  - Analgesics/pharmacology
MH  - Pain/drug therapy
MH  - Proto-Oncogene Proteins c-bcl-2/metabolism
OTO - NOTNLM
OT  - Apoptosis
OT  - Aspirin
OT  - Diabetic neuropathy
OT  - Dorsal root ganglion
OT  - Morphine tolerance
EDAT- 2023/05/06 19:42
MHDA- 2023/07/17 06:42
CRDT- 2023/05/06 14:53
PHST- 2022/10/12 00:00 [received]
PHST- 2023/04/27 00:00 [accepted]
PHST- 2023/07/17 06:42 [medline]
PHST- 2023/05/06 19:42 [pubmed]
PHST- 2023/05/06 14:53 [entrez]
AID - 10.1007/s11011-023-01226-2 [pii]
AID - 10.1007/s11011-023-01226-2 [doi]
PST - ppublish
SO  - Metab Brain Dis. 2023 Aug;38(6):2145-2158. doi: 10.1007/s11011-023-01226-2. Epub 
      2023 May 6.

PMID- 23413984
OWN - NLM
STAT- MEDLINE
DCOM- 20130905
LR  - 20131121
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 37
IP  - 7
DP  - 2013 Apr
TI  - The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid 
      clinicians in practice.
PG  - 738-48
LID - 10.1111/apt.12240 [doi]
AB  - BACKGROUND: Assessment of both GI and CV risks vs. the benefits of low-dose 
      aspirin for individual patients can be difficult in clinical practice. AIM: To 
      develop a tool to estimate CV and GI risks to facilitate the clinical 
      decision-making process. METHODS: We constructed risk-ratio estimations and 
      determined the incidence of CV events and upper GI complications according to the 
      presence of different risk factors. For upper GI complications we assumed a 
      baseline incidence of 1 case/1000-persons-year, a twofold increased risk with 
      low-dose aspirin, and estimated a 60% GI risk reduction with proton pump 
      inhibitors (PPI) co-therapy and a 60% risk reduction with H. pylori eradication 
      in patients with a history of peptic ulcer. RESULTS: The calculator can be found 
      at http://www.asariskcalculator.com. In patients with low CV risk the number of 
      GI complications induced by low-dose aspirin may be greater than the number of CV 
      events prevented. In patients with high CV risk, low-dose aspirin is recommended, 
      but the number of GI complications induced may still overcome the CV events 
      saved. The use of PPI reduces the number of complication events induced by 
      low-dose aspirin, but the number of CV events saved may still be offset by the 
      number of GI complications induced in patients at very high GI risk. CONCLUSIONS: 
      There are many clinical situations where the number of potential upper GI 
      complications induced by low-dose aspirin may exceed the number of potentially 
      prevented CV events. A risk calculator should guide physicians in choosing 
      appropriate therapy and maximise the aspirin benefit.
CI  - © 2013 Blackwell Publishing Ltd.
FAU - Lanas, A
AU  - Lanas A
AD  - Service of Digestive Diseases, University Hospital Lozano Blesa, University of 
      Zaragoza, IIS Aragón, Spain. alanas@unizar.es
FAU - Polo-Tomás, M
AU  - Polo-Tomás M
FAU - Casado-Arroyo, R
AU  - Casado-Arroyo R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130217
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Aliment Pharmacol Ther. 2013 Jun;37(11):1115. PMID: 23656421
CIN - Aliment Pharmacol Ther. 2013 Jun;37(11):1116. PMID: 23656423
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Algorithms
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/*chemically induced/prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/prevention & control
MH  - Gastrointestinal Tract/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Proton Pump Inhibitors/administration & dosage
MH  - Risk Assessment/methods
MH  - Risk Factors
MH  - Young Adult
EDAT- 2013/02/19 06:00
MHDA- 2013/09/06 06:00
CRDT- 2013/02/19 06:00
PHST- 2012/10/10 00:00 [received]
PHST- 2012/11/06 00:00 [revised]
PHST- 2013/01/21 00:00 [revised]
PHST- 2013/01/21 00:00 [accepted]
PHST- 2013/02/19 06:00 [entrez]
PHST- 2013/02/19 06:00 [pubmed]
PHST- 2013/09/06 06:00 [medline]
AID - 10.1111/apt.12240 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2013 Apr;37(7):738-48. doi: 10.1111/apt.12240. Epub 2013 
      Feb 17.

PMID- 21103659
OWN - NLM
STAT- MEDLINE
DCOM- 20110531
LR  - 20131121
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 105
IP  - 2
DP  - 2011 Feb
TI  - Thromboprophylaxis for recurrent miscarriage in women with or without 
      thrombophilia. HABENOX: a randomised multicentre trial.
PG  - 295-301
LID - 10.1160/TH10-05-0334 [doi]
AB  - Recurrent miscarriage affects 1-2% of women. In more than half of all recurrent 
      miscarriage the cause still remains uncertain. Thrombophilia has been identified 
      in about 50% of women with recurrent miscarriage and thromboprophylaxis has been 
      suggested as an option of treatment. A randomised double-blind (for aspirin) 
      multicentre trial was performed among 207 women with three or more consecutive 
      first trimester (<13 weeks) miscarriages, two or more second trimester (13-24 
      weeks) miscarriages or one third trimester fetal loss combined with one first 
      trimester miscarriage. Women were analysed for thrombophilia. After complete 
      work-up, women were randomly allocated before seven weeks' gestation to either 
      enoxaparin 40 mg and placebo (n=68), enoxaparin 40 mg and aspirin 100 mg (n=63) 
      or aspirin 100 mg (n=76). The primary outcome was live-birth rate. Secondary 
      outcomes were pregnancy complications, neonatal outcome and adverse effects. The 
      trial was ended prematurely because of slow recruitment. A live birth rate of 71% 
      [relative risk (RR) 1.17, 95% confidence interval (CI) 0.92-1.48] was found for 
      enoxaparin and placebo and 65% [RR 1.08, 95% CI 0.83-1.39] for enoxaparin and 
      aspirin when compared to aspirin alone (61%, reference group). In the whole study 
      group the live birth rate was 65% (95% CI 58.66-71.74) for women with three or 
      more miscarriages (n=204). No difference in pregnancy complications, neonatal 
      outcome or adverse effects was observed. No significant difference in live birth 
      rate was found with enoxaparin treatment versus aspirin or a combination of both 
      versus aspirin in women with recurrent miscarriage.
FAU - Visser, Jantien
AU  - Visser J
AD  - Department of Obstetrics, Gynaecology and Reproductive Medicine, Leiden 
      University Medical Center, Leiden, the Netherlands.
FAU - Ulander, Veli-Matti
AU  - Ulander VM
FAU - Helmerhorst, Frans M
AU  - Helmerhorst FM
FAU - Lampinen, Katja
AU  - Lampinen K
FAU - Morin-Papunen, Laure
AU  - Morin-Papunen L
FAU - Bloemenkamp, Kitty W M
AU  - Bloemenkamp KW
FAU - Kaaja, Risto J
AU  - Kaaja RJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20101123
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/etiology/*prevention & control
MH  - Adolescent
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Early Termination of Clinical Trials
MH  - Enoxaparin/adverse effects/*therapeutic use
MH  - Europe
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Gestational Age
MH  - Humans
MH  - Live Birth
MH  - Patient Selection
MH  - Pregnancy
MH  - Thrombophilia/complications/*drug therapy
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2010/11/26 06:00
MHDA- 2011/06/01 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/05/31 00:00 [received]
PHST- 2010/11/02 00:00 [accepted]
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2011/06/01 06:00 [medline]
AID - 10-05-0334 [pii]
AID - 10.1160/TH10-05-0334 [doi]
PST - ppublish
SO  - Thromb Haemost. 2011 Feb;105(2):295-301. doi: 10.1160/TH10-05-0334. Epub 2010 Nov 
      23.

PMID- 9539864
OWN - NLM
STAT- MEDLINE
DCOM- 19980416
LR  - 20190512
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 37
IP  - 1
DP  - 1998 Jan
TI  - Low-dose aspirin improves in vivo hemodynamics in conscious, chronically 
      infarcted rats.
PG  - 108-14
AB  - OBJECTIVE: The equivalent of the clinically used low (= antiplatelet)-dose 
      aspirin, inhibited collagen deposition in the non-infarcted myocardium in rats 
      with myocardial infarction. In the present study, the in vivo hemodynamic 
      consequences of this daily low-dose aspirin were investigated in conscious, 
      chronically instrumented, infarcted rats. METHODS: Rats, treated with 25 mg/kg 
      aspirin daily from 2 days before to 3 weeks after coronary artery ligation, were 
      chronically instrumented with an electromagnetic flow-probe and arterial and 
      venous catheters, to record cardiac output, and arterial and venous blood 
      pressure, respectively, in the conscious freely moving animal. In parallel, 
      isolated hearts were studied with regard to left ventricular stiffness 
      (pressure/volume relationships), maximal cardiac perfusion (adenosine), and in 
      vitro heart rate and beta-adrenergic responsiveness. Plasma catecholamine levels 
      were measured. RESULTS: Aspirin normalized the increased heart rate after 
      infarction, at a preserved cardiac output. This was accompanied by a 
      (non-significant) increase in stroke volume, at unchanged cardiac loading 
      conditions. The lower heart rate after aspirin was due to reduced intrinsic heart 
      rate rather than to lower sympathetic activation of the heart, since similar 
      effects were observed in isolated perfused hearts, while circulating levels of 
      catecholamines and beta-adrenergic responsiveness were not influenced. The 
      improved stroke volume was not explained by reduced left ventricular stiffness or 
      increased maximal perfusion after aspirin. CONCLUSION: In addition to the 
      antithrombotic action, effects of low-dose aspirin on cardiac remodeling could be 
      associated with favorable hemodynamic effects, as reflected by a lower heart rate 
      for the same cardiac output. Although the underlying mechanisms are still 
      unknown, it suggests a clinically relevant beneficial effect which deserves 
      further investigation.
FAU - Schoemaker, R G
AU  - Schoemaker RG
AD  - Department of Pharmacology, Faculty of Medicine and Health Sciences, Erasmus 
      University, Rotterdam, The Netherlands.
FAU - Saxena, P R
AU  - Saxena PR
FAU - Kalkman, E A
AU  - Kalkman EA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - L628TT009W (Isoproterenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Agonists/pharmacology
MH  - Animals
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Drug Administration Schedule
MH  - Heart Rate/*drug effects
MH  - Hemodynamics/drug effects
MH  - Isoproterenol/pharmacology
MH  - Male
MH  - Myocardial Infarction/*drug therapy/physiopathology
MH  - Perfusion
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Rats
MH  - Rats, Wistar
MH  - Stroke Volume/*drug effects
MH  - Ventricular Dysfunction, Left/drug therapy/physiopathology
EDAT- 1998/04/16 00:00
MHDA- 1998/04/16 00:01
CRDT- 1998/04/16 00:00
PHST- 1998/04/16 00:00 [pubmed]
PHST- 1998/04/16 00:01 [medline]
PHST- 1998/04/16 00:00 [entrez]
AID - S0008-6363(97)00208-3 [pii]
AID - 10.1016/s0008-6363(97)00208-3 [doi]
PST - ppublish
SO  - Cardiovasc Res. 1998 Jan;37(1):108-14. doi: 10.1016/s0008-6363(97)00208-3.

PMID- 2801550
OWN - NLM
STAT- MEDLINE
DCOM- 19891109
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 64
IP  - 14
DP  - 1989 Oct 15
TI  - Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave 
      myocardial infarction.
PG  - 840-4
AB  - The pivotal role of thrombosis in unstable angina and non-Q-wave myocardial 
      infarction has been established recently. To assess the value and safety of 
      thrombolytic therapy compared to conventional antithrombotic therapy (aspirin) in 
      arresting progression in this setting to recurrent ischemic end-points, 25 
      patients presenting with unstable angina and an electrocardiogram showing 
      subendocardial ischemia were randomized to receive either aspirin 325 mg daily, 
      or urokinase 3 x 10(6) U intravenously, over 30 minutes followed by heparin. 
      Incidence of endpoints (intractable ischemia requiring mechanical intervention, 
      new myocardial infarction or death) was determined over 7 days. Coronary 
      arteriography was performed at 24 to 72 hours to determine extent of coronary 
      artery disease and morphologic severity of the culprit lesion, graded by a 
      semiquantitative scoring system ranging from 4+ (definite thrombosis) to 0 
      (chronic lesion). In the first 24 hours, 7 of 13 aspirin versus 1 of 12 urokinase 
      patients exhibited ischemia progression (p less than 0.05). By 7 days, 
      progression to a primary ischemic endpoint occurred in 8 of 13 aspirin patients 
      (3 myocardial infarctions and 5 intractable ischemias) versus 3 of 12 urokinase 
      patients (2 intractable ischemias and 1 death) (p = 0.18). The apparent benefit 
      of urokinase followed by heparin compared to conventional aspirin therapy in 
      arresting early progression of unstable angina or non-Q-wave myocardial 
      infarction was not associated with enhanced culprit lesion morphology (mean 
      lesion severity score 2.7 +/- 1.5 vs 2.8 +/- 1.6 in aspirin-treated patients). 
      Large scale, randomized trials to assess the clinical utility of urokinase for 
      unstable angina are warranted.
FAU - Schreiber, T L
AU  - Schreiber TL
AD  - Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan.
FAU - Macina, G
AU  - Macina G
FAU - McNulty, A
AU  - McNulty A
FAU - Bunnell, P
AU  - Bunnell P
FAU - Kikel, M
AU  - Kikel M
FAU - Miller, D H
AU  - Miller DH
FAU - Devereux, R B
AU  - Devereux RB
FAU - Tenney, R
AU  - Tenney R
FAU - Cowley, M
AU  - Cowley M
FAU - Zola, B
AU  - Zola B
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina Pectoris
MH  - Angina, Unstable/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Coronary Angiography
MH  - Drug Therapy, Combination
MH  - Electrocardiography
MH  - Fibrinolysis/drug effects
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Random Allocation
MH  - Recurrence
MH  - Urokinase-Type Plasminogen Activator/adverse effects/*therapeutic use
EDAT- 1989/10/15 00:00
MHDA- 1989/10/15 00:01
CRDT- 1989/10/15 00:00
PHST- 1989/10/15 00:00 [pubmed]
PHST- 1989/10/15 00:01 [medline]
PHST- 1989/10/15 00:00 [entrez]
AID - 0002-9149(89)90828-X [pii]
AID - 10.1016/0002-9149(89)90828-x [doi]
PST - ppublish
SO  - Am J Cardiol. 1989 Oct 15;64(14):840-4. doi: 10.1016/0002-9149(89)90828-x.

PMID- 30679550
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20200722
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Jan 24
TI  - Search for efficient inhibitors of myotoxic activity induced by ophidian 
      phospholipase A(2)-like proteins using functional, structural and bioinformatics 
      approaches.
PG  - 510
LID - 10.1038/s41598-018-36839-6 [doi]
LID - 510
AB  - Ophidian accidents are considered an important neglected tropical disease by the 
      World Health Organization. Particularly in Latin America, Bothrops snakes are 
      responsible for the majority of the snakebite envenomings that are not 
      efficiently treated by conventional serum therapy. Thus, the search for simple 
      and efficient inhibitors to complement this therapy is a promising research area, 
      and a combination of functional and structural assays have been used to test 
      candidate ligands against specific ophidian venom compounds. Herein, we tested a 
      commercial drug (acetylsalicylic acid, ASA) and a plant compound with 
      antiophidian properties (rosmarinic acid, RA) using myographic, crystallographic 
      and bioinformatics experiments with a phospholipase A(2)-like toxin, MjTX-II. 
      MjTX-II/RA and MjTX-II/ASA crystal structures were solved at high resolution and 
      revealed the presence of ligands bound to different regions of the toxin. 
      However, in vitro myographic assays showed that only RA is able to prevent the 
      myotoxic effects of MjTX-II. In agreement with functional results, molecular 
      dynamics simulations showed that the RA molecule remains tightly bound to the 
      toxin throughout the calculations, whereas ASA molecules tend to dissociate. This 
      approach aids the design of effective inhibitors of PLA(2)-like toxins and, 
      eventually, may complement serum therapy.
FAU - Salvador, Guilherme H M
AU  - Salvador GHM
AD  - Depto. de Física e Biofísica, Instituto de Biociências, UNESP - Universidade 
      Estadual Paulista, Botucatu, SP, Brazil.
FAU - Cardoso, Fábio Florença
AU  - Cardoso FF
AD  - Depto. de Física e Biofísica, Instituto de Biociências, UNESP - Universidade 
      Estadual Paulista, Botucatu, SP, Brazil.
FAU - Gomes, Antoniel A
AU  - Gomes AA
AD  - Depto. de Física e Biofísica, Instituto de Biociências, UNESP - Universidade 
      Estadual Paulista, Botucatu, SP, Brazil.
FAU - Cavalcante, Walter L G
AU  - Cavalcante WLG
AD  - Depto. de Física e Biofísica, Instituto de Biociências, UNESP - Universidade 
      Estadual Paulista, Botucatu, SP, Brazil.
AD  - Depto. de Farmacologia, UFMG - Universidade Federal de Minas Gerais, Belo 
      Horizonte, MG, Brazil.
FAU - Gallacci, Márcia
AU  - Gallacci M
AD  - Depto. de Farmacologia, Instituto de Biociências, UNESP - Universidade Estadual 
      Paulista, Botucatu, SP, Brazil.
FAU - Fontes, Marcos R M
AU  - Fontes MRM
AUID- ORCID: 0000-0002-4634-6221
AD  - Depto. de Física e Biofísica, Instituto de Biociências, UNESP - Universidade 
      Estadual Paulista, Botucatu, SP, Brazil. marcos.fontes@unesp.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190124
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Cinnamates)
RN  - 0 (Crotalid Venoms)
RN  - 0 (Depsides)
RN  - EC 3.1.1.4 (Group II Phospholipases A2)
RN  - EC 3.1.1.4 (bothropstoxin II)
RN  - MQE6XG29YI (rosmarinic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Aspirin/chemistry/pharmacology
MH  - *Cinnamates/chemistry/pharmacology
MH  - *Crotalid Venoms/chemistry/toxicity
MH  - Crystallography, X-Ray
MH  - *Depsides/chemistry/pharmacology
MH  - *Group II Phospholipases A2/chemistry/toxicity
MH  - Male
MH  - Mice
MH  - *Molecular Dynamics Simulation
MH  - Protein Structure, Quaternary
PMC - PMC6346006
COIS- The authors declare no competing interests.
EDAT- 2019/01/27 06:00
MHDA- 2020/07/23 06:00
CRDT- 2019/01/26 06:00
PHST- 2018/10/29 00:00 [received]
PHST- 2018/11/29 00:00 [accepted]
PHST- 2019/01/26 06:00 [entrez]
PHST- 2019/01/27 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
AID - 10.1038/s41598-018-36839-6 [pii]
AID - 36839 [pii]
AID - 10.1038/s41598-018-36839-6 [doi]
PST - epublish
SO  - Sci Rep. 2019 Jan 24;9(1):510. doi: 10.1038/s41598-018-36839-6.

PMID- 27530
OWN - NLM
STAT- MEDLINE
DCOM- 19780915
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 62
IP  - 2
DP  - 1978 Aug
TI  - Effects of methylprednisolone on hydrogen ion absorption in the canine stomach.
PG  - 262-70
AB  - The effect of methylprednisolone (2 mg/kg per day given parenterally for 3 doses, 
      2 wk or 12 wk) on the permeability of mammalian gastric mucosa to hydrogen ion 
      (H(+)) was examined with denervated fundic pouches in dogs with antrectomies. 
      Transmucosal electric potential difference (PD) and net fluxes of H(+) and Na(+) 
      were determined for luminal [H(+)] from 20 to 160 mM and [Na(+)] from 1 to 140 mM 
      ([H(+)] and [Na(+)] were varied reciprocally). The PD was 50-60 mV lumen negative 
      and was constant over the entire range of Na(+) and H(+) concentration tested. 
      Net H(+) flux varied linearly with [H(+)]. Extrapolation indicated apparent H(+) 
      loss at zero luminal concentration, suggesting a basal HCO(3) (-) secretion. 
      Addition of acetylsalicylic acid (ASA) or taurocholate decreased the PD to 30-40 
      mV and increased threefold the slope of the relation between net H(+) flux and 
      [H(+)] (k(H)). Calculation of PD-independent permeability constants for H(+) 
      (P(H)) with the Goldman constant field equation indicated that this increase in 
      k(H) could not be attributed solely to the associated decrease in PD. 
      Prednisolone administered for 3 doses had no effect on either the basal mucosal 
      permeability to H(+) or the altered permeability induced by ASA or taurocholate. 
      Chronic administration induced a low rate of basal acid secretion (at 12 wk) but 
      had no effect on either PD or k(H). However, the increase in k(H) and P(H) that 
      developed upon addition of ASA or taurocholate in chronically treated dogs was 
      more than one and a half times that of controls. These data suggest that 
      prolonged treatment with glucocorticoids increases susceptibility of the gastric 
      mucosa to damage by agents that increase permeability to H(+).
FAU - Chung, R S
AU  - Chung RS
FAU - Field, M
AU  - Field M
FAU - Silen, W
AU  - Silen W
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 5E090O0G3Z (Taurocholic Acid)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Absorption
MH  - Animals
MH  - Aspirin/metabolism/pharmacology
MH  - Dogs
MH  - Gastric Mucosa/drug effects/*metabolism
MH  - Hydrogen-Ion Concentration
MH  - Membrane Potentials/drug effects
MH  - Methylprednisolone/*pharmacology
MH  - Permeability
MH  - Sodium/metabolism
MH  - Taurocholic Acid/metabolism/pharmacology
MH  - Time Factors
PMC - PMC371762
EDAT- 1978/08/01 00:00
MHDA- 1978/08/01 00:01
CRDT- 1978/08/01 00:00
PHST- 1978/08/01 00:00 [pubmed]
PHST- 1978/08/01 00:01 [medline]
PHST- 1978/08/01 00:00 [entrez]
AID - 10.1172/JCI109125 [doi]
PST - ppublish
SO  - J Clin Invest. 1978 Aug;62(2):262-70. doi: 10.1172/JCI109125.

PMID- 25804049
OWN - NLM
STAT- MEDLINE
DCOM- 20150504
LR  - 20191113
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 86
IP  - 12
DP  - 2014
TI  - [Antiplatelet therapy with acetylsalicylic acid: approaches to reducing the 
      frequency of gastrointenstinal adverse reactions].
PG  - 98-103
AB  - Acetylsalicylic acid (ASA) is highly effective in preventing cardiovascular 
      events, but associated with increased risk for digestive adverse reactions. The 
      paper provides an update on the epidemiology, mechanisms, and risk factors of 
      esophagogastroduodeno- and enteropathies during long-term low-dose ACA therapy. 
      It outlines the key principles of their prevention.
FAU - Onuchina, E V
AU  - Onuchina EV
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Gastrointestinal Diseases/*chemically induced/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Proton Pump Inhibitors/*therapeutic use
EDAT- 2014/01/01 00:00
MHDA- 2015/05/06 06:00
CRDT- 2015/03/26 06:00
PHST- 2015/03/26 06:00 [entrez]
PHST- 2014/01/01 00:00 [pubmed]
PHST- 2015/05/06 06:00 [medline]
AID - 10.17116/terarkh2014861298-103 [doi]
PST - ppublish
SO  - Ter Arkh. 2014;86(12):98-103. doi: 10.17116/terarkh2014861298-103.

PMID- 6701183
OWN - NLM
STAT- MEDLINE
DCOM- 19840426
LR  - 20190919
IS  - 0031-6989 (Print)
IS  - 0031-6989 (Linking)
VI  - 16
IP  - 1
DP  - 1984 Jan
TI  - Anti-inflammatory activity of amino acyl benzoates.
PG  - 9-20
AB  - Nineteen new piperazino or morpholino amino acyl benzoates were synthesized and 
      screened against carrageenin induced oedema in albino rats. Several compounds of 
      the series showed potent anti-inflammatory activity. Compound 10 was found to be 
      the most potent. This compound was further evaluated in detail and compared with 
      phenylbutazone for its relative anti-inflammatory potency and ulcerogenic 
      liability. The compound, in addition, was compared with acetyl salicylic acid for 
      its analgesic activity. This compound showed potent ant-inflammatory activity 
      with minimal ulcerogenic liability.
FAU - Verma, M
AU  - Verma M
FAU - Gujrati, V R
AU  - Gujrati VR
FAU - Sharma, M
AU  - Sharma M
FAU - Saxena, A K
AU  - Saxena AK
FAU - Bhalla, T N
AU  - Bhalla TN
FAU - Sinha, J N
AU  - Sinha JN
FAU - Bhargava, K P
AU  - Bhargava KP
FAU - Shanker, K
AU  - Shanker K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Pharmacol Res Commun
JT  - Pharmacological research communications
JID - 0236354
RN  - 0 (Aminobenzoates)
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Protease Inhibitors)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aminobenzoates/*pharmacology
MH  - Analgesics
MH  - Animals
MH  - *Anti-Inflammatory Agents
MH  - Aspirin/pharmacology
MH  - Chromatography, Thin Layer
MH  - Peptic Ulcer/chemically induced
MH  - Phenylbutazone/pharmacology
MH  - Protease Inhibitors
MH  - Rats
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1016/s0031-6989(84)80100-9 [doi]
PST - ppublish
SO  - Pharmacol Res Commun. 1984 Jan;16(1):9-20. doi: 10.1016/s0031-6989(84)80100-9.

PMID- 6890840
OWN - NLM
STAT- MEDLINE
DCOM- 19830107
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 32
IP  - 9
DP  - 1982
TI  - Analgesic activity of carprofen on human experimental dental pain.
PG  - 1146-9
AB  - 1. The effects of an orally administered single dose of placebo, acetylsalicyclic 
      acid (ASA) and (d,1)-6-chloro-a-methyl carbazole-2-acetic acid (carprofen) have 
      been evaluated on an experimental pain model by electrical stimulation of dental 
      pulp in man. 2. ASA and carprofen showed a significant analgesic action, while 
      placebo was ineffective. 3. Analgesic activity of ASA and carprofen was similar. 
      The two drugs were ineffective in modifying the pain threshold; on the contrary, 
      the tolerance to the strongest painful sensation was significantly increased.
FAU - Cruccu, G
AU  - Cruccu G
FAU - Bini, G
AU  - Bini G
FAU - Accornero, N
AU  - Accornero N
FAU - Berardelli, A
AU  - Berardelli A
FAU - Manfredi, M
AU  - Manfredi M
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Analgesics)
RN  - 0 (Carbazoles)
RN  - FFL0D546HO (carprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Analgesics
MH  - Aspirin/pharmacology
MH  - Carbazoles/*pharmacology
MH  - Dental Pulp/physiology
MH  - Electric Stimulation
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain/physiopathology
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1982;32(9):1146-9.

PMID- 965109
OWN - NLM
STAT- MEDLINE
DCOM- 19761121
LR  - 20190816
IS  - 0020-5915 (Print)
IS  - 0020-5915 (Linking)
VI  - 51
IP  - 5
DP  - 1976
TI  - Passive cutaneous anaphylaxis in guinea pigs elicited by gastric absorption of 
      dextran induced by acetylsalicylic acid.
PG  - 627-36
AB  - Passive cutaneous anaphylaxis (PCA) was elicited in guinea pigs sensitized with 
      rabbit antidextran by the absorption of dextran macromolecules from the stomach 
      induced by intragastric acetylsalicylic acid. The gastric contents had a pH 
      sufficiently low to maintain the acid mainly in the unionized form since it is 
      the latter which alters gastric permeability. The acid concentration required to 
      induce PCA was below that which caused mucosal cell loss or bleeding. The maximal 
      molecular weight of the absorbed dextran was approximately 25,000. Dextran was 
      chosen as antigen because of its well-characterized physical and immunological 
      properties. It is suggested that ingestion of acetylsalicylic acid may contribute 
      to sensitization and allergic reactions to antigenic food materials by 
      facilitating their absorption from the stomach.
FAU - Flemström, G
AU  - Flemström G
FAU - Marsden, N V
AU  - Marsden NV
FAU - Richter, W
AU  - Richter W
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int Arch Allergy Appl Immunol
JT  - International archives of allergy and applied immunology
JID - 0404561
RN  - 0 (Dextrans)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dextrans/*metabolism
MH  - Female
MH  - Gastric Mucosa/*metabolism
MH  - Guinea Pigs
MH  - Male
MH  - Molecular Weight
MH  - *Passive Cutaneous Anaphylaxis
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1159/000231640 [doi]
PST - ppublish
SO  - Int Arch Allergy Appl Immunol. 1976;51(5):627-36. doi: 10.1159/000231640.

PMID- 4461414
OWN - NLM
STAT- MEDLINE
DCOM- 19750826
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 3
IP  - 3
DP  - 1974
TI  - Platelet function tests in uraemia and under acetylsalicylic acid administration.
PG  - 129-36
AB  - Procollagen-induced platelet aggregation, platelet retention (Hellem II), and 
      platelet factor 3 availability (PF-3) were determinded in a group of healthy 
      volunteers,acetylsalicylic acid (ASA) treated patients and in uraemic patients. 
      ASA ingestion did not influence platelet retention and PF-3 availability. Uraemic 
      patients had apronounced decrease in platelet aggregation and retention and PF-3 
      availability revealed inconsistent alterations. The relevance of the tests and 
      the benefit of an ASA treatment for prophylaxis of thrombosis in Climino fistulae 
      are discussed.
FAU - Schöndoft, T H
AU  - Schöndoft TH
FAU - Hey, D
AU  - Hey D
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 37270-93-2 (Platelet Factor 3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelet Disorders/*etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Factor 3
MH  - Renal Dialysis
MH  - Thrombosis
MH  - Uremia/*complications
EDAT- 1974/01/01 00:00
MHDA- 1974/01/01 00:01
CRDT- 1974/01/01 00:00
PHST- 1974/01/01 00:00 [pubmed]
PHST- 1974/01/01 00:01 [medline]
PHST- 1974/01/01 00:00 [entrez]
AID - 10.1159/000214047 [doi]
PST - ppublish
SO  - Haemostasis. 1974;3(3):129-36. doi: 10.1159/000214047.

PMID- 857406
OWN - NLM
STAT- MEDLINE
DCOM- 19770622
LR  - 20131121
IS  - 0042-8809 (Print)
IS  - 0042-8809 (Linking)
IP  - 1
DP  - 1977 Jan-Feb
TI  - [Heparin-aspirin complex, its physico-chemical and physiologic properties].
PG  - 44-51
AB  - A method is developed for isolation of fibrinolytic and anticoagulant complex 
      heparin-aspirin. The complex possessed the highest activity when the ratio of 
      heparin to aspirin was 10 : 1. In vitro and in vivo the complex obtained showed 
      high anticoagulant and fibrinolytic activity with respect to unstabilized fibrin 
      both in absence and in presence of epsilon-aminocaproic acid as well as it had 
      the thrombolytic effect on the fresh thrombus. The total fibrinolytic activity, 
      nonenzymatic fibrinolysis and the anticoagulation activity in blood plasma were 
      increased after chronic administration per os and after repeated intramuscular 
      administration of the complex. The most distinct increase in fibrinolytic 
      properties of blood occurred after intravenous administration of the 
      heparin-aspirin complex.
FAU - Kudriashov, B A
AU  - Kudriashov BA
FAU - Liapina, L A
AU  - Liapina LA
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Kompleks geparin-aspirin, ego fiziko-khimicheskie i fiziologicheskie svoĭstva.
PL  - Russia (Federation)
TA  - Vopr Med Khim
JT  - Voprosy meditsinskoi khimii
JID - 0416601
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Fibrinolytic Agents)
RN  - 9001-31-4 (Fibrin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Anticoagulants
MH  - Antithrombins/blood
MH  - *Aspirin/pharmacology
MH  - Fibrin/analysis
MH  - *Fibrinolytic Agents
MH  - *Heparin/pharmacology
MH  - Male
MH  - Rats
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Vopr Med Khim. 1977 Jan-Feb;(1):44-51.

PMID- 29973709
OWN - NLM
STAT- MEDLINE
DCOM- 20190828
LR  - 20190828
IS  - 1759-5010 (Electronic)
IS  - 1759-5002 (Linking)
VI  - 15
IP  - 8
DP  - 2018 Aug
TI  - Aspirin-free strategies in cardiovascular disease and cardioembolic stroke 
      prevention.
PG  - 480-496
LID - 10.1038/s41569-018-0049-1 [doi]
AB  - In patients with manifestations of cardiovascular disease, acetylsalicylic acid 
      (popularly known as aspirin) has been the mainstay of treatment for decades owing 
      to its capacity to reduce the risk of ischaemic events. Accordingly, novel 
      antithrombotic therapies have been traditionally tested on a background of 
      acetylsalicylic acid therapy. Although the adjunctive use of such antithrombotic 
      therapies can potentially further reduce the risk of ischaemic events, these 
      agents are also inevitably associated with an increased risk of bleeding. 
      However, acetylsalicylic acid also increases the risk of bleeding, challenging 
      the paradigm that this agent should remain the cornerstone of antiplatelet 
      treatment when alternative antithrombotic agents are also used. Many 
      antithrombotic compounds are characterized by increased potency and consistent 
      efficacy, which might lessen the need for concomitant acetylsalicylic acid. 
      Accordingly, numerous investigations are testing the hypothesis that 
      acetylsalicylic acid-sparing regimens based on newer antithrombotic agents might 
      have an increased net benefit for individual patients owing to the reduction in 
      bleeding risk, without a trade-off in efficacy. This Review summarizes the state 
      of the art relating to antithrombotic approaches with and without acetylsalicylic 
      acid for the prevention of cardiovascular disease and cardioembolic stroke. 
      Discussion of the scientific rationale, from bench to bedside, for ongoing 
      studies of acetylsalicylic acid-free pharmacological strategies is included.
FAU - Capodanno, Davide
AU  - Capodanno D
AD  - Cardio-Thoracic-Vascular and Transplant Department, Azienda 
      Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 
      USA.
FAU - Valgimigli, Marco
AU  - Valgimigli M
AD  - Department of Cardiology, Bern University Hospital, Bern, Switzerland.
FAU - Baber, Usman
AU  - Baber U
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 
      USA.
FAU - Windecker, Stephan
AU  - Windecker S
AD  - Department of Cardiology, Bern University Hospital, Bern, Switzerland.
FAU - Vranckx, Pascal
AU  - Vranckx P
AD  - Department of Cardiology and Critical Care Medicine, Faculty of Medicine and Life 
      Sciences University of Hasselt, Hasselt, Belgium.
FAU - Dangas, George
AU  - Dangas G
AD  - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 
      USA.
FAU - Rollini, Fabiana
AU  - Rollini F
AD  - University of Florida, College of Medicine, Jacksonville, FL, USA.
FAU - Kimura, Takeshi
AU  - Kimura T
AD  - Department of Neurology, Asahikawa Medical Centre, National Hospital 
      Organization, Asahikawa, Hokkaido, Japan.
FAU - Collet, Jean-Philippe
AU  - Collet JP
AD  - Institut De Cardiologie and Action-Coeur Study Group (www.action-coeur.org), 
      Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.
FAU - Gibson, C Michael
AU  - Gibson CM
AD  - Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
FAU - Steg, Philippe Gabriel
AU  - Steg PG
AD  - Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Paris, France.
FAU - Lopes, Renato D
AU  - Lopes RD
AD  - Duke Clinical Research Institute, Durham, NC, USA.
FAU - Gwon, Hyeon-Cheol
AU  - Gwon HC
AD  - Department of Internal Medicine, Heart Vascular Stroke Institute, Seoul, Republic 
      of Korea.
FAU - Storey, Robert F
AU  - Storey RF
AD  - Department of Infection, Immunity and Cardiovascular Disease, University of 
      Sheffield, Sheffield, UK.
FAU - Franchi, Francesco
AU  - Franchi F
AD  - University of Florida, College of Medicine, Jacksonville, FL, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Department of Medicine, Brigham and Women's Hospital Heart & Vascular Center, 
      Boston, MA, USA.
FAU - Serruys, Patrick W
AU  - Serruys PW
AD  - Imperial College Healthcare NHS Trust, London, UK.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - University of Florida, College of Medicine, Jacksonville, FL, USA. 
      dominick.angiolillo@jax.ufl.edu.
LA  - eng
GR  - UL1 TR000064/TR/NCATS NIH HHS/United States
GR  - U01 HG007269/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Nat Rev Cardiol
JT  - Nature reviews. Cardiology
JID - 101500075
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Cardiovascular Diseases/drug therapy/prevention & control
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - *Stroke/drug therapy/prevention & control
EDAT- 2018/07/06 06:00
MHDA- 2019/08/29 06:00
CRDT- 2018/07/06 06:00
PHST- 2018/07/06 06:00 [pubmed]
PHST- 2019/08/29 06:00 [medline]
PHST- 2018/07/06 06:00 [entrez]
AID - 10.1038/s41569-018-0049-1 [pii]
AID - 10.1038/s41569-018-0049-1 [doi]
PST - ppublish
SO  - Nat Rev Cardiol. 2018 Aug;15(8):480-496. doi: 10.1038/s41569-018-0049-1.

PMID- 36067089
OWN - NLM
STAT- MEDLINE
DCOM- 20221021
LR  - 20221031
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Print)
IS  - 1524-6175 (Linking)
VI  - 24
IP  - 10
DP  - 2022 Oct
TI  - Comparative antiplatelet effects of chlorthalidone and hydrochlorothiazide.
PG  - 1310-1315
LID - 10.1111/jch.14564 [doi]
AB  - Chlorthalidone (CTD) may be superior to hydrochlorothiazide (HCTZ) in the 
      reduction of adverse cardiovascular events in hypertensive patients. The 
      mechanism of the potential benefit of CTD could be related to antiplatelet 
      effects. The objective of this study was to determine if CTD or HCTZ have 
      antiplatelet effects. This study was a prospective, double-blind, randomized, 
      three-way crossover comparison evaluating the antiplatelet effects of CTD, HCTZ, 
      and aspirin (ASA) in healthy volunteers. The effects of these treatments on 
      platelet activation and aggregation were assessed using a well-established method 
      with five standard platelet agonists. Thirty-four patients completed the 
      three-way crossover comparing pre- and post-treatment changes in platelet 
      activation and aggregation studies. There were statistically significant 
      antiplatelet effects with ASA but not with CTD or HCTZ. Hypokalemia occurred in 0 
      (0%), 10 (30%), and 6 (18%) of the ASA, CTD, and HCTZ patients, respectively. The 
      results of our study suggest that the benefits of CTD and HCTZ in reducing 
      adverse cardiovascular events in patients with hypertension is not a result of an 
      antiplatelet effect. In our study, hypokalemia with CTD was more prevalent than 
      that reported in a large outcome trial in patients with hypertension. The 
      clinical relevance of this finding is uncertain.
CI  - © 2022 The Authors. The Journal of Clinical Hypertension published by Wiley 
      Periodicals LLC.
FAU - Bashir, Khalid
AU  - Bashir K
AD  - Creighton University School of Medicine, Omaha, Nebraska, USA.
FAU - Burns, Tammy
AU  - Burns T
AD  - Mary Lanning Healthcare, Hastings, Nebraska, USA.
FAU - Pirruccello, Samuel J
AU  - Pirruccello SJ
AD  - University of Nebraska Medical Center, Omaha, Nebraska, USA.
FAU - Aurit, Sarah J
AU  - Aurit SJ
AD  - University of Nebraska-Lincoln, Lincoln, Nebraska, USA.
FAU - Hilleman, Daniel E
AU  - Hilleman DE
AUID- ORCID: 0000-0001-7593-3727
AD  - Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska, 
      USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02100462
GR  - Dialysis Clinic Inc., USA/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220906
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
RN  - Q0MQD1073Q (Chlorthalidone)
RN  - 0J48LPH2TH (Hydrochlorothiazide)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Diuretics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Chlorthalidone/adverse effects
MH  - Hydrochlorothiazide/adverse effects
MH  - *Hypertension
MH  - *Hypokalemia/chemically induced/epidemiology
MH  - Prospective Studies
MH  - Antihypertensive Agents/adverse effects
MH  - Blood Pressure
MH  - Diuretics/therapeutic use
MH  - Double-Blind Method
MH  - Aspirin/pharmacology/therapeutic use
MH  - Drug Therapy, Combination
PMC - PMC9581091
OTO - NOTNLM
OT  - antihypertensive therapy
OT  - clinical pharmacology
OT  - hypertension-general
OT  - pharmacologic (drug) therapy
OT  - potassium/hypertension
COIS- None of the authors have conflicts of interest.
EDAT- 2022/09/07 06:00
MHDA- 2022/10/22 06:00
CRDT- 2022/09/06 13:03
PHST- 2022/08/03 00:00 [revised]
PHST- 2022/07/05 00:00 [received]
PHST- 2022/08/06 00:00 [accepted]
PHST- 2022/09/07 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
PHST- 2022/09/06 13:03 [entrez]
AID - JCH14564 [pii]
AID - 10.1111/jch.14564 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2022 Oct;24(10):1310-1315. doi: 10.1111/jch.14564. 
      Epub 2022 Sep 6.

PMID- 34294337
OWN - NLM
STAT- MEDLINE
DCOM- 20211115
LR  - 20211115
IS  - 1879-1344 (Electronic)
IS  - 0144-8617 (Linking)
VI  - 269
DP  - 2021 Oct 1
TI  - Dual-drug delivery system based on the hydrogels of alginate and sodium 
      carboxymethyl cellulose for colorectal cancer treatment.
PG  - 118325
LID - S0144-8617(21)00712-8 [pii]
LID - 10.1016/j.carbpol.2021.118325 [doi]
AB  - To improve the efficacy of chemotherapy and relieve the pain associated with 
      colorectal cancer, a dual-drug delivery system (DDDS) is proposed. In this 
      system, methotrexate (MTX) loaded CaCO(3) (CaCO(3)/MTX) and aspirin (Asp) are 
      co-entrapped in the hydrogels of alginate (Alg) and sodium carboxymethyl 
      cellulose (CMC) crosslinked with Ca(2+). The hydrogels can protect the 
      anti-cancer drug of MTX from being absorbed in stomach and small intestine and 
      ensure their efficacy at the target site of colorectum. More importantly, dual 
      pH-responsive drug delivery can be achieved by the DDDS. Because the pH varies at 
      small intestine and colorectum of human body, dual pH-responsive delivery of Asp 
      and MTX can be achieved at the two organs, respectively, in response to ambient 
      pH. These finding are of significant importance for medical science and 
      pharmaceutics.
CI  - Copyright © 2021 Elsevier Ltd. All rights reserved.
FAU - Sheng, Yanshan
AU  - Sheng Y
AD  - Jiangsu Key Laboratory of Advanced Materials and Technology, School of 
      Petrochemical Engineering, Changzhou University, Changzhou 213164, China.
FAU - Gao, Jun
AU  - Gao J
AD  - Department of Orthopedics, Changzhou Municipal Hospital of Traditional Chinese 
      Medicine, Changzhou 213003, China. Electronic address: gaojungk@126.com.
FAU - Yin, Zheng-Zhi
AU  - Yin ZZ
AD  - College of Biological, Chemical Sciences and Engineering, Jiaxing University, 
      Jiaxing 314001, China. Electronic address: yinzhengzhi@zjxu.edu.cn.
FAU - Kang, Jing
AU  - Kang J
AD  - Jiangsu Key Laboratory of Advanced Materials and Technology, School of 
      Petrochemical Engineering, Changzhou University, Changzhou 213164, China.
FAU - Kong, Yong
AU  - Kong Y
AD  - Jiangsu Key Laboratory of Advanced Materials and Technology, School of 
      Petrochemical Engineering, Changzhou University, Changzhou 213164, China. 
      Electronic address: yzkongyong@cczu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20210610
PL  - England
TA  - Carbohydr Polym
JT  - Carbohydrate polymers
JID - 8307156
RN  - 0 (Alginates)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
RN  - 0 (Hydrogels)
RN  - H0G9379FGK (Calcium Carbonate)
RN  - K679OBS311 (Carboxymethylcellulose Sodium)
RN  - R16CO5Y76E (Aspirin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Alginates/chemistry
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/pharmacology
MH  - Antineoplastic Agents/chemistry/*pharmacology
MH  - Aspirin/chemistry/pharmacology
MH  - Calcium Carbonate/chemistry
MH  - Carboxymethylcellulose Sodium/chemistry
MH  - Cell Line, Tumor
MH  - Colorectal Neoplasms/*drug therapy
MH  - Drug Carriers/*chemistry
MH  - Drug Liberation
MH  - Humans
MH  - Hydrogels/*chemistry
MH  - Hydrogen-Ion Concentration
MH  - Methotrexate/chemistry/*pharmacology
OTO - NOTNLM
OT  - Alginate
OT  - Calcium carbonate microspheres
OT  - Dual pH-sensitivity
OT  - Dual-drug delivery system
OT  - Sodium carboxymethyl cellulose
EDAT- 2021/07/24 06:00
MHDA- 2021/11/16 06:00
CRDT- 2021/07/23 05:42
PHST- 2021/04/14 00:00 [received]
PHST- 2021/06/01 00:00 [revised]
PHST- 2021/06/07 00:00 [accepted]
PHST- 2021/07/23 05:42 [entrez]
PHST- 2021/07/24 06:00 [pubmed]
PHST- 2021/11/16 06:00 [medline]
AID - S0144-8617(21)00712-8 [pii]
AID - 10.1016/j.carbpol.2021.118325 [doi]
PST - ppublish
SO  - Carbohydr Polym. 2021 Oct 1;269:118325. doi: 10.1016/j.carbpol.2021.118325. Epub 
      2021 Jun 10.

PMID- 28409870
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20200721
IS  - 1097-4644 (Electronic)
IS  - 0730-2312 (Linking)
VI  - 120
IP  - 6
DP  - 2019 Jun
TI  - Comparative efficacy and safety of antiplatelet agents in cerebral ischemic 
      disease: A network meta-analysis.
PG  - 8919-8934
LID - 10.1002/jcb.26065 [doi]
AB  - We performed a network meta-analysis (NMA) to enhance the corresponding evidence 
      of the relative efficacy and safety of different antiplatelet agents in cerebral 
      ischemic disease. PubMed and EMBASE were searched systematically for relevant 
      studies. Outcomes were compared using odds ratios and 95% credible intervals. 
      Each agent was ranked according to the value of surface under the cumulative 
      ranking curve (SUCRA). Publication bias was evaluated by funnel plots, while 
      consistency between direct and indirect comparison was analyzed by node-splitting 
      and heat plots. Besides, the clustering technique was used to categorize similar 
      agents. A number of 44 eligible studies with 148 578 patients were included in 
      this NMA. In terms of efficacy (including mortality, recurrent stroke, and 
      vascular event), all six interventions were better than placebo. clopidogrel 
      (Clop) and aspirin (ASA)+Clop were the best two interventions from SUCRA. 
      However, the performance of ASA+Clop declined significantly when considering 
      safety (including myocardial infarction, all-cause withdrawal, and intracranial 
      hemorrhage), especially worse in intracranial hemorrhage. In conclusion, Clop was 
      potentially the most preferable treatment for preventing cerebral ischemic in 
      terms of efficacy and safety. However, the addition of ASA was associated with a 
      potential increase in intracranial hemorrhage, therefore, combination therapy of 
      ASA and Clop should be introduced with caution although it may be more effective 
      than the monotherapy of ASA.
CI  - © 2019 Wiley Periodicals, Inc.
FAU - Wa, Da
AU  - Wa D
AD  - Department of Neurosurgery, Shigatse People's Hospital, Shigatse, Xizang, China.
FAU - Zhu, Pa
AU  - Zhu P
AD  - Department of Neurosurgery, Shigatse People's Hospital, Shigatse, Xizang, China.
FAU - Long, Ziwen
AU  - Long Z
AUID- ORCID: 0000-0001-8784-9995
AD  - Department of Neurosurgery, Shigatse People's Hospital, Shigatse, Xizang, China.
AD  - Department of Gastric Cancer and Soft-Tissue Sarcoma Sugery, Fudan University 
      Shanghai Cancer Center, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20190310
PL  - United States
TA  - J Cell Biochem
JT  - Journal of cellular biochemistry
JID - 8205768
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/*drug therapy/mortality
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Humans
MH  - Network Meta-Analysis
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - antiplatelet agents
OT  - efficacy
OT  - ischemic stroke
OT  - network meta-analysis (NMA)
OT  - safety
EDAT- 2017/04/15 06:00
MHDA- 2020/07/22 06:00
CRDT- 2017/04/15 06:00
PHST- 2017/01/05 00:00 [received]
PHST- 2017/04/13 00:00 [accepted]
PHST- 2017/04/15 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
PHST- 2017/04/15 06:00 [entrez]
AID - 10.1002/jcb.26065 [doi]
PST - ppublish
SO  - J Cell Biochem. 2019 Jun;120(6):8919-8934. doi: 10.1002/jcb.26065. Epub 2019 Mar 
      10.

PMID- 24892779
OWN - NLM
STAT- MEDLINE
DCOM- 20150112
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 6
DP  - 2014
TI  - Preparation and characterization of a novel aspirin derivative with 
      anti-thrombotic and gastric mucosal protection properties.
PG  - e98513
LID - 10.1371/journal.pone.0098513 [doi]
LID - e98513
AB  - The use of acetylsalicylic acid (ASP) is limited by its adverse effects, 
      especially the effect on the gastric mucosa. To address this problem, we 
      synthesized a derivative form of ASP, prepared by modification of ASP with 
      nano-hydroxyapatite (a kind of inorganic particle containing Ca(2+)). The 
      derivative was named Ca-ASP. Structural study showed that Ca-ASP was a kind of 
      carboxylate containing intramolecular hydrogen bonds. Rats given a high dose of 
      Ca-ASP (5 mmol per kg body weight) showed similar anti-thrombotic activity as 
      those given the same dose of ASP, but had much lower gastric mucosal damage than 
      ASP (UI: 2 versus UI: 12.5). These rats also showed reduced expression of COX-2, 
      but their COX-1 expression was similar to that of control rats, but significantly 
      higher than that of ASP-administered rats. Furthermore, the level of 
      prostaglandin E2 (PGE2) was up-regulated in Ca-ASP-administered rats compared to 
      ASP-administered rats. Taken together, the results showed that Ca-ASP possessed 
      similar antithrombotic activity as ASP but without the side effect associated 
      with ASP, and the underlying mechanism may center on inhibiting COX-2 without 
      inhibiting COX-1, and thus favouring the production of PGE2, the prostaglandin 
      that plays a vital role in the suppression of platelet aggregation and 
      thrombosis, as well as in the repair of gastric damage.
FAU - Zhen, Xi-E
AU  - Zhen XE
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      China.
FAU - Zong, Ming
AU  - Zong M
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      China.
FAU - Gao, Sai-Nan
AU  - Gao SN
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      China.
FAU - Cao, Yong-Gang
AU  - Cao YG
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      China.
FAU - Jiang, Lei
AU  - Jiang L
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      China.
FAU - Chen, Shu-Xin
AU  - Chen SX
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      China.
FAU - Wang, Kuan
AU  - Wang K
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      China.
FAU - Sun, Shi-Qin
AU  - Sun SQ
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      China.
FAU - Peng, Hai-Sheng
AU  - Peng HS
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      China.
FAU - Bai, Yu-Hua
AU  - Bai YH
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      China.
FAU - Li, Sen
AU  - Li S
AD  - Department of Pharmaceutics, Daqing Branch, Harbin Medical University, Daqing, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140603
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Cyclooxygenase 1/genetics/metabolism
MH  - Cyclooxygenase 2/genetics/metabolism
MH  - Dinoprostone/genetics/metabolism
MH  - Female
MH  - Gastric Mucosa/drug effects/*metabolism
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Spectroscopy, Fourier Transform Infrared
PMC - PMC4043976
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/06/04 06:00
MHDA- 2015/01/13 06:00
CRDT- 2014/06/04 06:00
PHST- 2014/03/04 00:00 [received]
PHST- 2014/05/01 00:00 [accepted]
PHST- 2014/06/04 06:00 [entrez]
PHST- 2014/06/04 06:00 [pubmed]
PHST- 2015/01/13 06:00 [medline]
AID - PONE-D-14-08770 [pii]
AID - 10.1371/journal.pone.0098513 [doi]
PST - epublish
SO  - PLoS One. 2014 Jun 3;9(6):e98513. doi: 10.1371/journal.pone.0098513. eCollection 
      2014.

PMID- 11433179
OWN - NLM
STAT- MEDLINE
DCOM- 20010920
LR  - 20171116
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 7
IP  - 4
DP  - 2001 Jul-Aug
TI  - NCX4016 (NO-aspirin) inhibits thromboxane biosynthesis and tissue factor 
      expression and activity in human monocytes.
PG  - 573-7
AB  - BACKGROUND: NCX4016 (2 acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester, NicOx 
      S.A., France) is an antithrombotic agent chemically related to acetylsalicylic 
      acid (ASA). We hypothesised that NCX4016, being able to release nitric oxide (NO) 
      and to inhibit cyclo-oxygenase, might inhibit the prothrombotic function in human 
      monocytes. MATERIAL AND METHODS: The effects of NCX4016 and ASA on the release of 
      thromboxane (TX) B2 and tissue factor expression and activity were compared using 
      adherent human monocytes. The tested drugs were added before stimulation with 10 
      Kg/ml LPS and incubation lasted 6 hours. TXB2 concentration was measured by RIA 
      in the supernatant of cultured cells. Immunoreactive tissue factor (TF) 
      concentration was determined by enzyme-linked immunoassay and TF activity was 
      assayed by measuring the peptidyl activity of the tissue factor/ factor VII 
      complex. RESULTS: Both ASA and NCX4016 10-300 Kmol/L dose-dependently reduced 
      TXB2 release. NCX4016 activity was comparable to that of equimolar ASA. Part of 
      the activity of NCX4016 up to 100 Kmol/L was prevented by 10 Kml/L ODQ, inhibitor 
      of cGMP generation. Immunoreactive TF was dose-dependently inhibited by 300 
      Kmol/L NCX4016, but not by ASA. Also tissue TF activity was reduced by 300 Kmol/L 
      NCX4016, but not by ASA. CONCLUSIONS: The present results indicate that NCX4016 
      not only has anti-platelet effects but also inhibits prothrombotic activities in 
      human monocytes, partly via NO-dependent mechanisms. NCX4016 may prove effective 
      in the clinical setting of athero-thrombosis.
FAU - Minuz, P
AU  - Minuz P
AD  - Department of Biomedical and Surgical Sciences, University of Verona, Italy. 
      minuz@borgoroma.univr.it
FAU - Degan, M
AU  - Degan M
FAU - Gaino, S
AU  - Gaino S
FAU - Meneguzzi, A
AU  - Meneguzzi A
FAU - Zuliani, V
AU  - Zuliani V
FAU - Lechi Santonastaso, C
AU  - Lechi Santonastaso C
FAU - Del Soldato, P
AU  - Del Soldato P
FAU - Lechi, A
AU  - Lechi A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (NOC 18)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Nitroso Compounds)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 9035-58-9 (Thromboplastin)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Humans
MH  - Monocytes/*drug effects/metabolism
MH  - Nitric Oxide Donors/pharmacology
MH  - Nitroso Compounds/pharmacology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thromboplastin/*metabolism
MH  - Thromboxane B2/*antagonists & inhibitors/biosynthesis/metabolism
EDAT- 2001/07/04 10:00
MHDA- 2001/09/21 10:01
CRDT- 2001/07/04 10:00
PHST- 2001/07/04 10:00 [pubmed]
PHST- 2001/09/21 10:01 [medline]
PHST- 2001/07/04 10:00 [entrez]
AID - 2048 [pii]
PST - ppublish
SO  - Med Sci Monit. 2001 Jul-Aug;7(4):573-7.

PMID- 9358074
OWN - NLM
STAT- MEDLINE
DCOM- 19971125
LR  - 20191102
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 130
IP  - 4
DP  - 1997 Oct
TI  - Polycythemia vera: a retrospective and reprise.
PG  - 365-73
AB  - This article, by two of the late John H. Lawrence's fellows of the 1940s, traces 
      the development of the knowledge of polycythemia vera from Vaquez, who wrote the 
      first description of this disease, and Osler, who recognized it as "a new 
      clinical entity," through John H. Lawrence and the use of 32P as a treatment for 
      polycythemia vera, to the formation of French and Italian polycythemia study 
      groups. In particular, the history of polycythemia vera after the Second World 
      War, and its more recent history, can be traced through the development of an 
      algorithm for evaluating an elevated hematocrit and the development of the first 
      (O1) protocol of the Polycythemia Vera Study Group (PVSG), a randomized trial of 
      the efficacy of 32P, chlorambucil, and phlebotomy for treating polycythemia vera. 
      It was in 1948, only 9 years after the first use of 32P for treating polycythemia 
      vera, that Byron Hall reported the occurrence of acute leukemia following this 
      use of the isotope. This led to the formation of the PVSG. After completing 
      enrollment of patients in the first protocol of the PVSG, an attempt to find a 
      replacement for 32P as a myelosuppressive agent led to the testing of hydroxyurea 
      as a putative non-leukemogenic drug for this purpose. However, the use of 
      hydroxyurea for treating polycythemia vera is coming into question, as is the 
      ability to maintain patients with phlebotomy alone. The PVSG as such no longer 
      exists as an operational group; its files are maintained at the Mount Sinai 
      School of Medicine in New York City. However, the French group created for the 
      study of polycythemia vera has had a consensus conference, and the Italian group 
      has developed a low-dose aspirin protocol for treating the disease.
FAU - Berlin, N I
AU  - Berlin NI
AD  - Sylvester Cancer Center and the Department of Medicine, University of Miami, 
      Florida, USA.
FAU - Wasserman, L R
AU  - Wasserman LR
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Phosphorus Radioisotopes)
RN  - R16CO5Y76E (Aspirin)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Aspirin/history/therapeutic use
MH  - Blood Volume
MH  - Controlled Clinical Trials as Topic/history
MH  - Female
MH  - Hematocrit
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Hydroxyurea/history/therapeutic use
MH  - Male
MH  - Phlebotomy/history
MH  - Phosphorus Radioisotopes/history/therapeutic use
MH  - Polycythemia Vera/diagnosis/*history/mortality/therapy
EDAT- 1997/11/14 00:00
MHDA- 1997/11/14 00:01
CRDT- 1997/11/14 00:00
PHST- 1997/11/14 00:00 [pubmed]
PHST- 1997/11/14 00:01 [medline]
PHST- 1997/11/14 00:00 [entrez]
AID - S0022-2143(97)90035-4 [pii]
AID - 10.1016/s0022-2143(97)90035-4 [doi]
PST - ppublish
SO  - J Lab Clin Med. 1997 Oct;130(4):365-73. doi: 10.1016/s0022-2143(97)90035-4.

PMID- 17917525
OWN - NLM
STAT- MEDLINE
DCOM- 20090717
LR  - 20191110
IS  - 1751-7141 (Electronic)
IS  - 1520-037X (Linking)
VI  - 10 Suppl 4
DP  - 2007 Fall
TI  - PRO: Should aspirin be used in all women older than 65 years to prevent stroke?
PG  - 6-11
AB  - A number of studies have reported that aspirin is beneficial in the prevention of 
      cardiovascular disease. A meta-analysis of data from 3 studies of the 
      cardioprotective effect of aspirin in women has reported that use of aspirin 
      reduces the risk of coronary events mainly by reducing the risk of ischemic 
      stroke. Results of the Women's Health Study showed that although there is a risk 
      of bleeding events with aspirin use, overall this risk is outweighed by the 
      number of strokes prevented.
FAU - Hsia, Judith
AU  - Hsia J
AD  - Lipid Research Clinic, Washington, DC 20037, USA. jhsia@mfa.gwu.edu
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Prev Cardiol
JT  - Preventive cardiology
JID - 9813731
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Prev Cardiol. 2007 Fall;10 Suppl 4:12-8. PMID: 17917526
MH  - Age Factors
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/prevention & control
MH  - Cost of Illness
MH  - Evidence-Based Practice
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Incidence
MH  - *Patient Selection
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Risk Factors
MH  - Risk Reduction Behavior
MH  - Secondary Prevention
MH  - Stroke/epidemiology/*prevention & control
MH  - Treatment Outcome
MH  - *Women's Health
EDAT- 2007/12/06 09:00
MHDA- 2009/07/18 09:00
CRDT- 2007/12/06 09:00
PHST- 2007/12/06 09:00 [pubmed]
PHST- 2009/07/18 09:00 [medline]
PHST- 2007/12/06 09:00 [entrez]
AID - 10.1111/j.1520-037x.2007.07267.x [doi]
PST - ppublish
SO  - Prev Cardiol. 2007 Fall;10 Suppl 4:6-11. doi: 10.1111/j.1520-037x.2007.07267.x.

PMID- 6167117
OWN - NLM
STAT- MEDLINE
DCOM- 19810922
LR  - 20131121
IS  - 0001-5555 (Print)
IS  - 0001-5555 (Linking)
VI  - 61
IP  - 3
DP  - 1981
TI  - A randomized double blind comparison of an aspirin dipyridamole combination 
      versus a placebo in the treatment of necrobiosis lipoidica.
PG  - 270-1
AB  - Fourteen patients with a clinical and histological diagnosis of necrobiosis 
      lipoidica were treated in a double-blind control study with either an aspirin 
      dipyridamole combination or a matching placebo for an 8-week period. None of the 
      patients in the aspirin dipyridamole group showed a significant improvement.
FAU - Statham, B
AU  - Statham B
FAU - Finlay, A Y
AU  - Finlay AY
FAU - Marks, R
AU  - Marks R
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Sweden
TA  - Acta Derm Venereol
JT  - Acta dermato-venereologica
JID - 0370310
RN  - 0 (Drug Combinations)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyridamole/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Necrobiosis Lipoidica/*drug therapy
MH  - Random Allocation
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Derm Venereol. 1981;61(3):270-1.

PMID- 25981646
OWN - NLM
STAT- MEDLINE
DCOM- 20150723
LR  - 20150518
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 42
IP  - 5
DP  - 2015 May
TI  - [Chemoprevention of colorectal cancer for broad clinical use in the future].
PG  - 534-7
AB  - Establishment of preemptive medicine might be useful against the growing burden 
      among colorectal cancer patients. Currently, we are trying to develop effective 
      chemopreventive drugs not only for improving public health(i e, cancer morbidity 
      and mortality), but also for better health economics and medical services. We 
      have evaluated the suppressive effects of aspirin in subjects with a 
      moderate-to-high risk of developing colorectal cancer through a 
      randomized-controlled trial. For the first time, the efficacy of aspirin has been 
      shown in Asian patients with adenomatous polyposis and recurrent colorectal 
      tumors after endoscopic polypectomy. In this manuscript, we would like to show a 
      good example of drug repositioning in cancer-preventive clinical trials and to 
      discuss the future use of cancer-preventive agents.
FAU - Mutoh, Michihiro
AU  - Mutoh M
AD  - Epidemiology and Prevention Division, Research Center for Cancer Prevention and 
      Screening, National Cancer Center.
FAU - Ishikawa, Hideki
AU  - Ishikawa H
FAU - Wakabayashi, Keiji
AU  - Wakabayashi K
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Chemoprevention
MH  - Clinical Trials as Topic
MH  - Colorectal Neoplasms/*prevention & control
MH  - Humans
MH  - Risk Factors
EDAT- 2015/05/20 06:00
MHDA- 2015/07/24 06:00
CRDT- 2015/05/19 06:00
PHST- 2015/05/19 06:00 [entrez]
PHST- 2015/05/20 06:00 [pubmed]
PHST- 2015/07/24 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2015 May;42(5):534-7.

PMID- 27770326
OWN - NLM
STAT- MEDLINE
DCOM- 20170605
LR  - 20181113
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 24
IP  - 14
DP  - 2017 May
TI  - Aspirin and paracetamol removal using a commercial micro-sized TiO(2) catalyst in 
      deionized and tap water.
PG  - 12646-12654
LID - 10.1007/s11356-016-7781-z [doi]
AB  - Micro-sized TiO(2) catalyst was employed to degrade pharmaceutical compounds, 
      i.e. aspirin and paracetamol, two of the most widely used drugs, purchasable 
      without prescription. Their active agents, acetylsalicylic acid and 
      acetaminophen, are characterized by different substituent groups, linked to the 
      aromatic ring, which affect both the photodegradation and mineralization 
      processes. The experimental conditions highlight the relationship between the 
      nature of the pristine molecules, their degradation mechanisms, their mutual 
      interference and the water's role. The research started from model systems with a 
      single pollutant to the mixture of them and finally by moving from deionized 
      water to tap water.
FAU - Bianchi, Claudia L
AU  - Bianchi CL
AD  - Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133, 
      Milan, Italy.
AD  - Consorzio INSTM, via Giusti 9, 50121, Florence, Italy.
FAU - Sacchi, Benedetta
AU  - Sacchi B
AD  - Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133, 
      Milan, Italy. benedetta.sacchi@unimi.it.
AD  - Consorzio INSTM, via Giusti 9, 50121, Florence, Italy. benedetta.sacchi@unimi.it.
FAU - Pirola, Carlo
AU  - Pirola C
AD  - Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133, 
      Milan, Italy.
AD  - Consorzio INSTM, via Giusti 9, 50121, Florence, Italy.
FAU - Demartin, Francesco
AU  - Demartin F
AD  - Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133, 
      Milan, Italy.
FAU - Cerrato, Giuseppina
AU  - Cerrato G
AD  - Consorzio INSTM, via Giusti 9, 50121, Florence, Italy.
AD  - Dipartimento di Chimica and NIS, Inter-departmental Centre, Università degli 
      Studi di Torino, Via Giuria 7, 10125, Torino, Italy.
FAU - Morandi, Sara
AU  - Morandi S
AD  - Consorzio INSTM, via Giusti 9, 50121, Florence, Italy.
AD  - Dipartimento di Chimica and NIS, Inter-departmental Centre, Università degli 
      Studi di Torino, Via Giuria 7, 10125, Torino, Italy.
FAU - Capucci, Valentino
AU  - Capucci V
AD  - GranitiFiandre SpA, Via Radici Nord 112, 42014, Castellarano, Italy.
LA  - eng
PT  - Journal Article
DEP - 20161021
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Water Pollutants, Chemical)
RN  - 15FIX9V2JP (titanium dioxide)
RN  - 362O9ITL9D (Acetaminophen)
RN  - D1JT611TNE (Titanium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acetaminophen
MH  - *Aspirin
MH  - Catalysis
MH  - Titanium
MH  - Water Pollutants, Chemical
OTO - NOTNLM
OT  - Aspirin
OT  - By-products identification
OT  - Micro-sized TiO2
OT  - Paracetamol
OT  - Photocatalytic degradation
OT  - Titanium dioxide
EDAT- 2016/10/23 06:00
MHDA- 2017/06/06 06:00
CRDT- 2016/10/23 06:00
PHST- 2016/06/20 00:00 [received]
PHST- 2016/09/26 00:00 [accepted]
PHST- 2016/10/23 06:00 [pubmed]
PHST- 2017/06/06 06:00 [medline]
PHST- 2016/10/23 06:00 [entrez]
AID - 10.1007/s11356-016-7781-z [pii]
AID - 10.1007/s11356-016-7781-z [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2017 May;24(14):12646-12654. doi: 
      10.1007/s11356-016-7781-z. Epub 2016 Oct 21.

PMID- 8087230
OWN - NLM
STAT- MEDLINE
DCOM- 19941014
LR  - 20151119
IS  - 0002-5151 (Print)
IS  - 0002-5151 (Linking)
VI  - 41
IP  - 1
DP  - 1994 Jan-Feb
TI  - [Aspirin-induced asthma and arachidonic acid metabolites. In search of answers to 
      an enigma. Part 2].
PG  - 14-8
AB  - Acetylsalicylic acid is one of the most commonly used drugs and high on the list 
      of causes of drug reactions. Since early publication on 1902 by Hirschberg, a 
      great deal of information has emerged on aspirin sensitivity, including data on 
      epidemiology, further characterization of the two major subtypes of sensitivity 
      (bronchospastic and urticarial types), hereditary aspects, cross-reactions to 
      other nonsteroidal antiinflammatory drugs, and methods of desensitization. 
      Although the pathogenesis of aspirin-sensitive asthma remains unknown, several 
      theories has been proposed to explain the disease enigma.
FAU - Salazar Villa, R M
AU  - Salazar Villa RM
AD  - Div Allergy & Immunology, Scripps Clinic & Research Foundation, La Jolla, CA.
FAU - Zambrano Villa, S
AU  - Zambrano Villa S
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Asma inducida por aspirina y metabolitos del ácido araquidónico. En búsqueda de 
      respuestas a un enigma (segunda parte).
PL  - Mexico
TA  - Rev Alerg Mex
JT  - Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
JID - 9438824
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Arachidonic Acid/*metabolism
MH  - Aspirin/*adverse effects/pharmacology
MH  - Asthma/*chemically induced/diagnosis/immunology/metabolism/therapy
MH  - Desensitization, Immunologic
MH  - Genetic Predisposition to Disease
MH  - Inflammation/physiopathology
MH  - Models, Biological
MH  - Virus Diseases/complications
RF  - 17
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Alerg Mex. 1994 Jan-Feb;41(1):14-8.

PMID- 27636304
OWN - NLM
STAT- MEDLINE
DCOM- 20171120
LR  - 20181113
IS  - 1531-7056 (Electronic)
IS  - 0267-1379 (Print)
IS  - 0267-1379 (Linking)
VI  - 32
IP  - 6
DP  - 2016 Nov
TI  - An update in the nonendoscopic treatment of gastric cancer.
PG  - 501-506
AB  - PURPOSE OF REVIEW: This article reviews the recent seminal studies in 
      esophagogastric cancer. RECENT FINDINGS: Regular low aspirin use may reduce the 
      risk of esophagogastric cancer. Laparoscopic resection of locally advanced 
      gastric cancer appears equivalent to open resection. There is no survival benefit 
      for the addition of postoperative radiation therapy to adjuvant chemotherapy 
      after primary gastric cancer resection. For tumors of the esophagus and 
      gastroesophageal junction, the combination of preoperative radiation therapy with 
      concurrent chemotherapy may be required to ensure achievement of a negative 
      surgical margin and to reduce local tumor recurrence. Epirubicin may not add 
      benefit to fluorinated pyrimidine and platinum-based chemotherapy, either in the 
      preoperative setting or in the treatment of metastatic disease. The Her2-targeted 
      agents lapatinib and trastuzumab emtansine failed to improve outcome when either 
      added to or compared with chemotherapy. Immune checkpoint inhibition appears to 
      be active in metastatic gastric cancer. SUMMARY: Recent studies in 
      esophagogastric cancer help clarify the role of radiation therapy in surgical 
      management, as well as the role of chemotherapeutic and targeted agents.
FAU - Ilson, David H
AU  - Ilson DH
AD  - Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 
      Weill-Cornell Medical College, New York, New York, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Gastroenterol
JT  - Current opinion in gastroenterology
JID - 8506887
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticarcinogenic Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Esophagogastric Junction
MH  - Gastrectomy/methods
MH  - Humans
MH  - Molecular Targeted Therapy/methods
MH  - Neoplasm Metastasis
MH  - Radiotherapy, Adjuvant
MH  - Stomach Neoplasms/*therapy
PMC - PMC5678974
MID - NIHMS888260
EDAT- 2016/10/18 06:00
MHDA- 2017/11/29 06:00
CRDT- 2016/09/17 06:00
PHST- 2016/10/18 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2016/09/17 06:00 [entrez]
AID - 10.1097/MOG.0000000000000314 [doi]
PST - ppublish
SO  - Curr Opin Gastroenterol. 2016 Nov;32(6):501-506. doi: 
      10.1097/MOG.0000000000000314.

PMID- 2510490
OWN - NLM
STAT- MEDLINE
DCOM- 19891215
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 64
IP  - 18
DP  - 1989 Nov 15
TI  - Superior antiplatelet action of alternate day pulsed dosing versus split dose 
      administration of aspirin.
PG  - 1185-8
AB  - To explore the effect of timing on the antiplatelet action of aspirin, a constant 
      mean amount of 40 mg aspirin/day was administered either as a split regimen of 20 
      mg twice daily, a single dose of 40 mg or a doubled dose of 80 mg every other day 
      for 1 week each and compared to a current standard low dose regimen of 324 
      mg/day. Bleeding time, serum thromboxane, collagen-stimulated platelet 
      aggregation and associated thromboxane formation and excretion of thromboxane and 
      prostacyclin metabolites were measured both at peak and trough action of the 
      drug. The inhibitory effects on platelet aggregation and associated thromboxane 
      formation were significantly less marked with the split dose regimen, 
      intermediate with the single dose of 40 mg aspirin/day and best with the 
      alternate day doubled dose, but still inferior to the effects of 324 mg/day. 
      Thromboxane excretion was suppressed by greater than 80% with all regimens. 
      Prostacyclin metabolite excretion was similar for all 40 mg/day regimens with 
      about 40% suppression at trough and 60% at peak drug action, respectively. 
      Suppression was more pronounced after 324 mg/day. For best platelet inactivation 
      at comparable sparing of prostacyclin formation, low doses of aspirin should be 
      administered in pulsed rather than split regimens.
FAU - Lorenz, R L
AU  - Lorenz RL
AD  - Medizinische Klinik Innenstadt, Universitaet Muenchen, Munich, West Germany.
FAU - Boehlig, B
AU  - Boehlig B
FAU - Uedelhoven, W M
AU  - Uedelhoven WM
FAU - Weber, P C
AU  - Weber PC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Epoprostenol/*biosynthesis/urine
MH  - Humans
MH  - *Platelet Aggregation Inhibitors
MH  - Thromboxanes/*biosynthesis/blood/urine
EDAT- 1989/11/15 00:00
MHDA- 1989/11/15 00:01
CRDT- 1989/11/15 00:00
PHST- 1989/11/15 00:00 [pubmed]
PHST- 1989/11/15 00:01 [medline]
PHST- 1989/11/15 00:00 [entrez]
AID - 0002-9149(89)90875-8 [pii]
AID - 10.1016/0002-9149(89)90875-8 [doi]
PST - ppublish
SO  - Am J Cardiol. 1989 Nov 15;64(18):1185-8. doi: 10.1016/0002-9149(89)90875-8.

PMID- 373942
OWN - NLM
STAT- MEDLINE
DCOM- 19790716
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 25
IP  - 5 Pt 1
DP  - 1979 May
TI  - Pirprofen and aspirin in the treatment of rheumatoid arthritis.
PG  - 618-23
AB  - Pirprofen (800 mg/day) or aspirin (3,600 mg/day) was administered in double-blind 
      fashion for up to one year to 40 adult outpatients with rheumatoid arthritis, 
      after a short, single-blind placebo period. There were no statistically 
      significant differences in efficacy between pirprofen and aspirin, as evidenced 
      by patient opinion, observer opinion, grip strength, walking time, number of 
      tender joints, number of swollen joints, or erythrocyte sedimentation rate. 
      Clinically significant pain of gastrointestinal origin occurred in an equal 
      number of patients from each group. Audiologic evaluation revealed 3 
      pirprofen-treated patients and 5 aspirin-treated patients in whom sensorineural 
      hearing loss progressed during therapy and required either discontinuation or 
      reduction of drug dosage. Ophthalmologic evaluation disclosed a high prevalence 
      of lesions, the most common being decreased visual acuity and cataracts not 
      explained by previous antiarthritic therapy. The high prevalence of audiologic 
      and ophthalmologic pathology reported in the literature in patients with 
      rheumatoid arthritis makes it difficult to establish in our study whether 
      pirprofen or aspirin affected these organ systems.
FAU - Davis, J D
AU  - Davis JD
FAU - Struth, A G
AU  - Struth AG
FAU - Turner, R A
AU  - Turner RA
FAU - Pisko, E J
AU  - Pisko EJ
FAU - Ruchte, I R
AU  - Ruchte IR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyrroles)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/complications/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Eye Diseases/chemically induced
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Hearing Disorders/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenylpropionates/adverse effects/*therapeutic use
MH  - Pyrroles/adverse effects/*therapeutic use
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
AID - 10.1002/cpt1979255part1618 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1979 May;25(5 Pt 1):618-23. doi: 10.1002/cpt1979255part1618.

PMID- 25228722
OWN - NLM
STAT- MEDLINE
DCOM- 20150811
LR  - 20140917
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Linking)
VI  - 23
IP  - 12
DP  - 2014 Oct
TI  - Patient-health care provider relationship: how can it impact on APS (Hughes' 
      syndrome) adherence to treatment?
PG  - 1265-8
LID - 10.1177/0961203314536480 [doi]
AB  - Adherence to treatment is fundamental for its success. It comprises compliance 
      combined with persistency and should be constantly reassessed. This is true in 
      all medical situations. In antiphospholipid syndrome (or Hughes' syndrome), in 
      addition to taking the medication at the planned time so that its effect on blood 
      can be assessed and the dose adjusted if necessary, all patients must incorporate 
      healthy habits with a treatment that is lifelong and will be influenced by 
      dietary changes and the use of many other medications. Following a regime for the 
      treatment to be effective, and to avoid serious complications, often creates the 
      sensation of 'living on a tightrope' for both the patients and the health care 
      providers. Patient education along with constant monitoring using proper 
      communication settings and tools are certain to improve adherence and outcomes.
CI  - © The Author(s) 2014 Reprints and permissions: 
      sagepub.co.uk/journalsPermissions.nav.
FAU - Levy, R A
AU  - Levy RA
AD  - Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de 
      Janeiro, Brazil Centro de Imunoterapia de Ipanema - CITIPA, Rio de Janeiro, 
      Brazil rogeralevy@gmail.com.
FAU - Signorelli, F
AU  - Signorelli F
AD  - Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de 
      Janeiro, Rio de Janeiro, Brazil Hospital Universitário Pedro Ernesto, 
      Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antiphospholipid Syndrome/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - *Health Personnel
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - International Normalized Ratio
MH  - *Medication Adherence
MH  - *Physician-Patient Relations
MH  - Point-of-Care Systems
MH  - Pregnancy
OTO - NOTNLM
OT  - Treatment adherence
OT  - anticoagulation
OT  - antiphospholipid syndrome
EDAT- 2014/09/18 06:00
MHDA- 2015/08/12 06:00
CRDT- 2014/09/18 06:00
PHST- 2014/09/18 06:00 [entrez]
PHST- 2014/09/18 06:00 [pubmed]
PHST- 2015/08/12 06:00 [medline]
AID - 23/12/1265 [pii]
AID - 10.1177/0961203314536480 [doi]
PST - ppublish
SO  - Lupus. 2014 Oct;23(12):1265-8. doi: 10.1177/0961203314536480.

PMID- 8256630
OWN - NLM
STAT- MEDLINE
DCOM- 19940111
LR  - 20190914
IS  - 0374-5600 (Print)
IS  - 0374-5600 (Linking)
VI  - 35
IP  - 5
DP  - 1993 Oct
TI  - Non-steroidal anti-inflammatory drugs and slow-acting anti-rheumatic drugs in 
      juvenile rheumatoid arthritis.
PG  - 447-53
AB  - The preferred drugs for the initial treatment of juvenile rheumatoid arthritis 
      (JRA) are salicylates or other non-steroidal anti-inflammatory drugs (NSAID) such 
      as tolmetin or naproxen. If the disease activity does not respond adequately to 
      the treatment, slow-acting anti-rheumatic drugs (SAARD) such as oral gold agents, 
      low-dose D-penicillamine, or sulfasalazine should be given in addition to NSAID. 
      If the systemic manifestations are severe, corticosteroid therapy may be 
      commenced. Furthermore, if the joint destruction is progressive, 
      immunosuppressants such as methotrexate would be selected as the third-line drugs 
      of choice. The safety and efficacy of SAARD and immunosuppressants for the 
      treatment of children with JRA, however, have not yet been confirmed, as the 
      adverse effects such as bone marrow suppression, oncogenicity and mutagenicity 
      are sometimes intense. Consequently, the strict indications for use and new 
      therapeutic concepts for the management of JRA based on its pathogenesis are 
      required.
FAU - Fujikawa, S
AU  - Fujikawa S
AD  - Department of Pediatrics, Dokkyo University School of Medicine, Koshigaya 
      Hospital, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Acta Paediatr Jpn
JT  - Acta paediatrica Japonica : Overseas edition
JID - 0370357
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Humans
RF  - 68
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
AID - 10.1111/j.1442-200x.1993.tb03089.x [doi]
PST - ppublish
SO  - Acta Paediatr Jpn. 1993 Oct;35(5):447-53. doi: 
      10.1111/j.1442-200x.1993.tb03089.x.

PMID- 12030579
OWN - NLM
STAT- MEDLINE
DCOM- 20021119
LR  - 20190716
IS  - 0001-6489 (Print)
IS  - 0001-6489 (Linking)
VI  - 122
IP  - 3
DP  - 2002 Apr
TI  - High levels of nitric oxide synthase activity are associated with nasal polyp 
      tissue from aspirin-sensitive asthmatics.
PG  - 302-5
AB  - The pathogenesis of aspirin intolerance remains unclear. Inducible nitric oxide 
      synthase (iNOS) expression is upregulated in nasal polyp epithelium, implying a 
      role for nitric oxide (NO) in its formation. We decided to compare iNOS activity 
      in polyp tissue from patients with and without aspirin intolerance. Nasal polyp 
      tissue was collected from 15 patients undergoing routine nasal polypectomy. These 
      patients were classified into three groups: Group A comprised patients with nasal 
      polyps without asthma; Group B contained patients with nasal polyps and asthma; 
      and Group C comprised patients with nasal polyps, asthma and aspirin sensitivity. 
      All subjects in Group C had a history of aspirin-induced reaction and a 
      confirmatory intranasal challenge with lysine-aspirin. NOS activity was measured 
      by the ability of tissue homogenates to convert 3,4-L-arginine to L-citrulline in 
      an L-N(G)-nitro-L-arginine-inhibitable fashion. The iNOS activity (picomoles) in 
      polyp tissue from the 3 groups was: A, 248.72+/-220.79; B, 23.71+/-41.06; and C, 
      549.71+/-132.11. Thus, nasal polyps from patients with Samter's triad had a 
      significantly higher iNOS activity (p = 0.004; one-way ANOVA). This finding does 
      not correlate simply with disease severity or with the occurrence of asthma and 
      could indicate another important facet of aspirin-induced airways disease.
FAU - Parikh, A
AU  - Parikh A
AD  - Royal National Throat, Nose, and Ear Hospital, London, UK.
FAU - Scadding, G K
AU  - Scadding GK
FAU - Gray, P
AU  - Gray P
FAU - Belvisi, M G
AU  - Belvisi MG
FAU - Mitchell, J A
AU  - Mitchell JA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Otolaryngol
JT  - Acta oto-laryngologica
JID - 0370354
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.13.39 (NOS2 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology
MH  - Aspirin/*adverse effects/pharmacology
MH  - Asthma/complications/*physiopathology
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/complications/*enzymology
MH  - Nitric Oxide Synthase/*metabolism
MH  - Nitric Oxide Synthase Type II
EDAT- 2002/05/28 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/05/28 10:00
PHST- 2002/05/28 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/05/28 10:00 [entrez]
AID - 10.1080/000164802753648204 [doi]
PST - ppublish
SO  - Acta Otolaryngol. 2002 Apr;122(3):302-5. doi: 10.1080/000164802753648204.

PMID- 8236144
OWN - NLM
STAT- MEDLINE
DCOM- 19931126
LR  - 20181130
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 70
IP  - 2
DP  - 1993 Aug 2
TI  - Effect of diltiazem and low-dose aspirin on platelet aggregation and ATP release 
      induced by paired agonists.
PG  - 332-5
AB  - The authors studied the effects of diltiazem, administered alone and together 
      with low-dose aspirin, on the platelet response to paired agonists. After a 
      baseline period, 25 healthy volunteers were given oral diltiazem for 1 week (120, 
      240, or 360 mg/day), and then crossed over randomly between 1 week on diltiazem 
      plus aspirin (81 mg/day), and 1 week on aspirin (81 mg/day) alone. Platelet 
      function was tested on 2 consecutive days in each period. Synergistic platelet 
      aggregation and ATP release were obtained at baseline using a subthreshold 
      concentration of arachidonic acid combined with platelet activating factor, ADP, 
      or epinephrine. Diltiazem resulted in significant decrease from baseline in 
      platelet aggregation and ATP release using the arachidonic acid-epinephrine 
      combination (35% and 40% decrease, respectively, p < 0.01) and a significant 
      decrease in aggregation using the arachidonic acid-ADP combination (22% decrease, 
      p < 0.01). The effects were neither dose-related, nor accompanied by any 
      significant change in serum thromboxane B2 levels or bleeding times. There was no 
      significant difference between the effects of aspirin alone and aspirin plus 
      diltiazem on the synergistic platelet aggregation and ATP release induced by the 
      paired agonists, or on thromboxane B2 levels or bleeding times. Diltiazem 
      administered in vivo partially inhibits the synergistic platelet aggregation and 
      ATP release induced by paired agonists; however, in contrast to a previous in 
      vitro study it does not potentiate the platelet-inhibitory effect of aspirin.
FAU - Zucker, M L
AU  - Zucker ML
AD  - Department of Pathology, University of Kansas Medical Center, Kansas City.
FAU - Budd, S E
AU  - Budd SE
FAU - Dollar, L E
AU  - Dollar LE
FAU - Chernoff, S B
AU  - Chernoff SB
FAU - Altman, R
AU  - Altman R
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Activating Factor)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - EE92BBP03H (Diltiazem)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adenosine Triphosphate/*metabolism
MH  - Adult
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*metabolism
MH  - Diltiazem/*pharmacology
MH  - Drug Synergism
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Activating Factor/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
EDAT- 1993/08/02 00:00
MHDA- 1993/08/02 00:01
CRDT- 1993/08/02 00:00
PHST- 1993/08/02 00:00 [pubmed]
PHST- 1993/08/02 00:01 [medline]
PHST- 1993/08/02 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1993 Aug 2;70(2):332-5.

PMID- 6135989
OWN - NLM
STAT- MEDLINE
DCOM- 19830909
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 309
IP  - 7
DP  - 1983 Aug 18
TI  - Protective effects of aspirin against acute myocardial infarction and death in 
      men with unstable angina. Results of a Veterans Administration Cooperative Study.
PG  - 396-403
AB  - We conducted a multicenter, double-blind, placebo-controlled randomized trial of 
      aspirin treatment (324 mg in buffered solution daily) for 12 weeks in 1266 men 
      with unstable angina (625 taking aspirin and 641 placebo). The principal end 
      points were death and acute myocardial infarction diagnosed by the presence of 
      creatine kinase MB or pathologic Q-wave changes on electrocardiograms. The 
      incidence of death or acute myocardial infarction was 51 per cent lower in the 
      aspirin group than in the placebo group: 31 patients (5.0 per cent) as compared 
      with 65 (10.1 per cent); P = 0.0005. Nonfatal acute myocardial infarction was 51 
      per cent lower in the aspirin group: 21 patients (3.4 per cent) as compared with 
      44 (6.9 per cent); P = 0.005. The reduction in mortality in the aspirin group was 
      also 51 per cent--10 patients (1.6 per cent) as compared with 21 (3.3 per 
      cent)--although it was not statistically significant; P = 0.054. There was no 
      difference in gastrointestinal symptoms or evidence of blood loss between the 
      treatment and control groups. Our data show that aspirin has a protective effect 
      against acute myocardial infarction in men with unstable angina, and they suggest 
      a similar effect on mortality.
FAU - Lewis, H D Jr
AU  - Lewis HD Jr
FAU - Davis, J W
AU  - Davis JW
FAU - Archibald, D G
AU  - Archibald DG
FAU - Steinke, W E
AU  - Steinke WE
FAU - Smitherman, T C
AU  - Smitherman TC
FAU - Doherty, J E 3rd
AU  - Doherty JE 3rd
FAU - Schnaper, H W
AU  - Schnaper HW
FAU - LeWinter, M M
AU  - LeWinter MM
FAU - Linares, E
AU  - Linares E
FAU - Pouget, J M
AU  - Pouget JM
FAU - Sabharwal, S C
AU  - Sabharwal SC
FAU - Chesler, E
AU  - Chesler E
FAU - DeMots, H
AU  - DeMots H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Adrenergic beta-Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Angina, Unstable/complications/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - *Death, Sudden
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/mortality/*prevention & control
MH  - Patient Compliance
MH  - Pilot Projects
MH  - Random Allocation
EDAT- 1983/08/18 00:00
MHDA- 2001/03/28 10:01
CRDT- 1983/08/18 00:00
PHST- 1983/08/18 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1983/08/18 00:00 [entrez]
AID - 10.1056/NEJM198308183090703 [doi]
PST - ppublish
SO  - N Engl J Med. 1983 Aug 18;309(7):396-403. doi: 10.1056/NEJM198308183090703.

PMID- 23998607
OWN - NLM
STAT- MEDLINE
DCOM- 20140501
LR  - 20220408
IS  - 1009-2137 (Print)
IS  - 1009-2137 (Linking)
VI  - 21
IP  - 4
DP  - 2013 Aug
TI  - [Effect of aspirin on function of human umbilical cord blood-derived late 
      endothelial progenitor cells].
PG  - 1032-7
LID - 10.7534/j.issn.1009-2137.2013.04.042 [doi]
AB  - This study was aimed to investigate whether aspirin has effect on function of 
      late endothelial progenitor cells (EPC). Cord blood CD34(+) cells were purified 
      using the ficoll density gradient centrifugation and human CD34 positive 
      selection kit, then the cells were inoculated on fibronectin-coated culture 
      plate. After culture for 2 weeks, adherent cells were identified as EPC by flow 
      cytometry, immunofluorescence, RT-PCR, uptake of Dil-Ac-LDL and matrigel tube 
      formation assay. EPC were treated with different concentrations of aspirin (0.1, 
      1, 10, 100, 1 000, 10 000 µmol/L) for 24 h, then the proliferation, adhesion and 
      migration ability of these cells were analyzed by CCK-8 assay and transwell 
      methods. The results indicated that the low concentrations of aspirin (0.1 and 1 
      000 µmol/L) promoted late EPC adhesive and migratory capacity, but no obvious 
      effect on proliferation of late EPC were observed. On the other hand, the high 
      concentrations of aspirin (10 000 µmol/L) inhibited proliferation and migratory 
      capacity of EPC, but had no obvious effect on adhesive ability of EPC. It is 
      concluded that low concentration of aspirin promotes migration and adhesion of 
      late EPC, while the high concentration of aspirin decreases EPC proliferation and 
      migratory capacity of EPC.
FAU - Liu, Zhen-Zhen
AU  - Liu ZZ
AD  - Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow 
      University. Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      Suzhou 215006, Jiangsu Province, China.
FAU - Li, Guo-Qiang
AU  - Li GQ
FAU - Liu, Meng
AU  - Liu M
FAU - Sun, Sheng-Xuan
AU  - Sun SX
FAU - An, Guan-Yu
AU  - An GY
FAU - Dong, Ning-Zheng
AU  - Dong NZ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Shi Yan Xue Ye Xue Za Zhi
JT  - Zhongguo shi yan xue ye xue za zhi
JID - 101084424
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cell Adhesion/drug effects
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Endothelial Cells/cytology/*drug effects
MH  - Fetal Blood/*cytology
MH  - Humans
MH  - Stem Cells/cytology/*drug effects
EDAT- 2013/09/04 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/09/04 06:00
PHST- 2013/09/04 06:00 [entrez]
PHST- 2013/09/04 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - 1009-2137(2013)04-1032-06 [pii]
AID - 10.7534/j.issn.1009-2137.2013.04.042 [doi]
PST - ppublish
SO  - Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Aug;21(4):1032-7. doi: 
      10.7534/j.issn.1009-2137.2013.04.042.

PMID- 8457280
OWN - NLM
STAT- MEDLINE
DCOM- 19930428
LR  - 20131121
IS  - 0014-827X (Print)
IS  - 0014-827X (Linking)
VI  - 48
IP  - 1
DP  - 1993 Jan
TI  - Synthesis and some properties of two salsalate derivatives.
PG  - 95-103
AB  - The synthesis of esters of 2-hydroxy benzoic acid-2-carboxyphenyl ester 
      (salsalate) with guaiacol for the treatment of inflammatory bronchopneumopathies 
      is reported. The antiinflammatory, analgesic and antipyretic activities of these 
      derivatives were evaluated, together with their antioxidant, mucolytic and 
      broncho-bacteriostatic properties in comparison to acetylsalicylic acid.
FAU - Galzigna, L
AU  - Galzigna L
AD  - Department of Biological Chemistry - University of Padova.
FAU - Licit, L
AU  - Licit L
FAU - De Pieri, G F
AU  - De Pieri GF
FAU - Bonora, G M
AU  - Bonora GM
FAU - Signor, A
AU  - Signor A
LA  - eng
PT  - Journal Article
PL  - France
TA  - Farmaco
JT  - Farmaco (Societa chimica italiana : 1989)
JID - 8912641
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Antitussive Agents)
RN  - 0 (Expectorants)
RN  - 0 (Salicylates)
RN  - 0 (guaiacol-salsalate)
RN  - 6JKA7MAH9C (Guaiacol)
RN  - R16CO5Y76E (Aspirin)
RN  - T6EKB9V2O2 (guacetisal)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemical synthesis/pharmacology
MH  - Antioxidants/chemical synthesis/pharmacology
MH  - Antitussive Agents/*chemical synthesis/pharmacology/toxicity
MH  - Aspirin/*analogs & derivatives/chemical synthesis/pharmacology/toxicity
MH  - Chromatography, Thin Layer
MH  - Edema/chemically induced/prevention & control
MH  - Expectorants/chemical synthesis/pharmacology
MH  - Guaiacol/*analogs & derivatives/chemical synthesis/pharmacology/toxicity
MH  - Lethal Dose 50
MH  - Magnetic Resonance Spectroscopy
MH  - Male
MH  - Mice
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Rats, Wistar
MH  - Salicylates/*chemical synthesis/pharmacology/toxicity
MH  - Spectrophotometry, Ultraviolet
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Farmaco. 1993 Jan;48(1):95-103.

PMID- 15695141
OWN - NLM
STAT- MEDLINE
DCOM- 20050405
LR  - 20181201
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 95
IP  - 4
DP  - 2005 Feb 15
TI  - Rapid desensitization procedure for patients with aspirin hypersensitivity 
      undergoing coronary stenting.
PG  - 509-10
AB  - Some patients with imperative cardiologic indications for combination therapy 
      with aspirin and clopidogrel (stent placement and/or acute coronary syndrome) 
      have a history of allergy to aspirin. In other patients, symptoms of aspirin 
      hypersensitivity may develop in the days after stenting, at which time 
      discontinuation of aspirin carries a risk of catastrophic stent thrombosis. We 
      challenged 16 such patients using rapidly escalating low doses of aspirin. In 14 
      patients, reintroduction was immediately successful, and 11 underwent uneventful 
      stent placement. Two patients developed transient allergic reactions, 1 of whom 
      was successfully rechallenged 48 hours later. No late allergic reactions or 
      adverse cardiac events were seen after a mean follow-up of 14 months. A rapid 
      challenge-desensitization procedure may allow introduction of aspirin at 
      therapeutic doses within a few hours.
FAU - Silberman, Stéphane
AU  - Silberman S
AD  - Department of Cardiology, Hôpital Bichat, Paris, France.
FAU - Neukirch-Stoop, Catherine
AU  - Neukirch-Stoop C
FAU - Steg, Philippe Gabriel
AU  - Steg PG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Cardiol. 2006 Jan 15;97(2):294; author reply 294. PMID: 16442383
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clopidogrel
MH  - Coronary Artery Disease/therapy
MH  - Desensitization, Immunologic/*methods
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Hypersensitivity/*prevention & control
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - *Stents
MH  - Ticlopidine/administration & dosage/*analogs & derivatives
EDAT- 2005/02/08 09:00
MHDA- 2005/04/06 09:00
CRDT- 2005/02/08 09:00
PHST- 2004/07/14 00:00 [received]
PHST- 2004/10/07 00:00 [revised]
PHST- 2004/10/07 00:00 [accepted]
PHST- 2005/02/08 09:00 [pubmed]
PHST- 2005/04/06 09:00 [medline]
PHST- 2005/02/08 09:00 [entrez]
AID - S0002-9149(04)01700-X [pii]
AID - 10.1016/j.amjcard.2004.10.022 [doi]
PST - ppublish
SO  - Am J Cardiol. 2005 Feb 15;95(4):509-10. doi: 10.1016/j.amjcard.2004.10.022.

PMID- 15982932
OWN - NLM
STAT- MEDLINE
DCOM- 20060501
LR  - 20131121
IS  - 1567-1356 (Print)
IS  - 1567-1356 (Linking)
VI  - 5
IP  - 12
DP  - 2005 Dec
TI  - Metabolic aspects of aspirin-induced apoptosis in yeast.
PG  - 1207-13
AB  - We have previously shown that aspirin induces apoptosis in manganese superoxide 
      dismutase (MnSOD)-deficient Saccharomyces cerevisiae cells cultivated in ethanol 
      medium, and that it exhibits a significant antioxidant effect until the onset of 
      overt apoptosis. We here report that glucose-6-phosphate dehydrogenase activity 
      in these cells is not inhibited by aspirin. However, the reducing power, as 
      measured by the NADPH/NADP(+) concentration ratio, is significantly lower than in 
      wild-type cells. With aspirin, the levels of NADPH, NADP(+) and catalase in 
      MnSOD-deficient cells decrease significantly after 72 h of cultivation, without 
      significant decrease of the NADPH/NADP(+) ratio. This ratio is higher when the 
      cells are grown in glycerol or acetate medium. This seems to prevent loss in 
      viability and induction of apoptosis on treatment with aspirin. Additionally, the 
      glutathione (GSH) level is maintained, but the level of oxidized glutathione 
      (GSSG) increases, leading to a significant decrease in the GSH/GSSG ratio in 
      aspirin-treated cells. This decrease in the GSH/GSSG ratio is much less in cells 
      grown in glycerol medium, while there is an increase in the GSH/GSSG ratio of 
      cells grown in acetate medium. Consequently, the decreased reducing power may be 
      linked to apoptotic induction by aspirin. This occurs independently of the level 
      of reactive oxygen species which, as shown in our previous studies, do not play a 
      primary role in the apoptosis of cells exposed to aspirin. The protective effect 
      of MnSOD appears to be related to the cellular reducing power.
FAU - Sapienza, Karen
AU  - Sapienza K
AD  - Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, 
      University of Malta, Msida MSD 06, Malta.
FAU - Balzan, Rena
AU  - Balzan R
LA  - eng
PT  - Journal Article
DEP - 20050614
PL  - England
TA  - FEMS Yeast Res
JT  - FEMS yeast research
JID - 101085384
RN  - 0 (Culture Media)
RN  - 53-59-8 (NADP)
RN  - EC 1.1.1.49 (Glucosephosphate Dehydrogenase)
RN  - EC 1.11.1.6 (Catalase)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - GAN16C9B8O (Glutathione)
RN  - PDC6A3C0OX (Glycerol)
RN  - Q40Q9N063P (Acetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetic Acid/metabolism
MH  - *Apoptosis
MH  - Aspirin/metabolism/*pharmacology
MH  - Catalase/metabolism
MH  - Culture Media
MH  - Glucosephosphate Dehydrogenase/metabolism
MH  - Glutathione/metabolism
MH  - Glycerol/metabolism
MH  - NADP/metabolism
MH  - Oxidation-Reduction
MH  - Saccharomyces cerevisiae/*drug effects/metabolism/*physiology
MH  - Superoxide Dismutase/genetics/metabolism
EDAT- 2005/06/29 09:00
MHDA- 2006/05/02 09:00
CRDT- 2005/06/29 09:00
PHST- 2005/01/25 00:00 [received]
PHST- 2005/04/19 00:00 [revised]
PHST- 2005/05/03 00:00 [accepted]
PHST- 2005/06/29 09:00 [pubmed]
PHST- 2006/05/02 09:00 [medline]
PHST- 2005/06/29 09:00 [entrez]
AID - S1567-1356(05)00084-X [pii]
AID - 10.1016/j.femsyr.2005.05.001 [doi]
PST - ppublish
SO  - FEMS Yeast Res. 2005 Dec;5(12):1207-13. doi: 10.1016/j.femsyr.2005.05.001. Epub 
      2005 Jun 14.

PMID- 16267095
OWN - NLM
STAT- MEDLINE
DCOM- 20060503
LR  - 20171116
IS  - 0143-3334 (Print)
IS  - 0143-3334 (Linking)
VI  - 27
IP  - 4
DP  - 2006 Apr
TI  - NO-donating aspirin induces phase II enzymes in vitro and in vivo.
PG  - 803-10
AB  - Modulation of drug metabolizing enzymes, leading to facilitated elimination of 
      carcinogens represents a successful strategy for cancer chemoprevention. Nitric 
      oxide-donating aspirin (NO-ASA) is a promising agent for the prevention of colon 
      and other cancers. We studied the effect of NO-ASA on drug metabolizing enzymes 
      in HT-29 human colon adenocarcinoma and Hepa 1c1c7 mouse liver adenocarcinoma 
      cells and in Min mice treated with NO-ASA for 3 weeks. In these cell lines, 
      NO-ASA induced the activity and expression of NAD(P)H:quinone oxireductase (NQO) 
      and glutathione S-transferase (GST). Compared with untreated Min mice, NO-ASA 
      increased in the liver the activity (nmol/min/mg; mean+/-SEM for all) of NQO 
      (85+/-6 versus 128+/-11, P<0.05) and GST (2560+/-233 versus 4254+/-608, P<0.005) 
      and also in the intestine but not in the kidney; the expression of NQO1 and GST 
      P1-1 was also increased. NO-ASA had only a marginal effect on P450 1A1 and P450 
      2E1, two phase I enzymes. The release of NO from NO-ASA, determined with a 
      selective microelectrode was paralleled by the induction of NQO1 and abrogated by 
      NO scavengers; an exogenous NO donor also induced the expression of NQO1. NO-ASA 
      induced concentration-dependently the translocation of Nrf2 into the nucleus as 
      documented by immunofluorescence and immunoblotting; this paralleled the 
      induction of NQO1 and GST P1-1. Thus NO-ASA induces phase II enzymes, at least in 
      part, through the action of NO that it releases and by modulating the Keap1-Nrf2 
      pathway; this effect may be part of its mechanism of action against colon and 
      other cancers.
FAU - Gao, Jianjun
AU  - Gao J
AD  - Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, NY 
      11794, USA.
FAU - Kashfi, Khosrow
AU  - Kashfi K
FAU - Liu, Xiaoping
AU  - Liu X
FAU - Rigas, Basil
AU  - Rigas B
LA  - eng
GR  - CA92423/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20051102
PL  - England
TA  - Carcinogenesis
JT  - Carcinogenesis
JID - 8008055
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (KEAP1 protein, human)
RN  - 0 (Kelch-Like ECH-Associated Protein 1)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - 0 (Proteins)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.6.5.2 (NAD(P)H Dehydrogenase (Quinone))
RN  - EC 1.6.5.2 (NQO1 protein, human)
RN  - EC 2.5.1.18 (Glutathione Transferase)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenocarcinoma/*prevention & control
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Chemoprevention
MH  - Colonic Neoplasms/*prevention & control
MH  - Enzyme Induction
MH  - Female
MH  - Glutathione Transferase/*metabolism
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins
MH  - Kelch-Like ECH-Associated Protein 1
MH  - Liver Neoplasms/*prevention & control
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - NAD(P)H Dehydrogenase (Quinone)/*metabolism
MH  - NF-E2-Related Factor 2/physiology
MH  - Nitric Oxide/*pharmacology
MH  - Proteins/physiology
MH  - Transplantation, Heterologous
EDAT- 2005/11/04 09:00
MHDA- 2006/05/04 09:00
CRDT- 2005/11/04 09:00
PHST- 2005/11/04 09:00 [pubmed]
PHST- 2006/05/04 09:00 [medline]
PHST- 2005/11/04 09:00 [entrez]
AID - bgi262 [pii]
AID - 10.1093/carcin/bgi262 [doi]
PST - ppublish
SO  - Carcinogenesis. 2006 Apr;27(4):803-10. doi: 10.1093/carcin/bgi262. Epub 2005 Nov 
      2.

PMID- 30062853
OWN - NLM
STAT- MEDLINE
DCOM- 20190318
LR  - 20190318
IS  - 2041-1626 (Electronic)
IS  - 2041-1618 (Linking)
VI  - 9
IP  - 4
DP  - 2018 Nov
TI  - Effect of systemic long-term, low-dose aspirin on periodontal status and soluble 
      CD14 in gingival crevicular fluid: a case-control study.
PG  - e12353
LID - 10.1111/jicd.12353 [doi]
AB  - AIM: In the present study, we evaluated the effect of systemic long-term, 
      low-dose aspirin on the periodontal status and gingival crevicular fluid (GCF) 
      concentrations of aspirin-triggered lipoxins (ATL) and soluble CD14 (sCD14). 
      METHODS: The study group consisted of 45 patients who were on long-term, low-dose 
      aspirin therapy, and the control group included patients not on aspirin therapy. 
      Mean bleeding index, plaque index (PI), probing depth (PD), and clinical 
      attachment loss (CAL) were recorded. GCF samples were analyzed for concentrations 
      of ATL, and sCD14 using enzyme-linked immunosorbent assay method. RESULTS: The 
      means of PI, PD, and CAL were higher for the control group compared to the study 
      group. The mean concentration of ATL was significantly higher for the study group 
      (49.13 ± 37.39 ng/mL). The mean concentration of sCD14 was higher in the control 
      group (5.75 ± 3.91 μg/mL). There was a negative correlation in the study group 
      between concentrations of ATL with PD (r = -0.54) and CAL (r = -0.123). There was 
      a positive correlation between sCD14 and CAL (r = 0.047) in the study group. A 
      negative correlation was also observed between concentrations of sCD14 and ATL 
      (r = -0.134) in the study group. CONCLUSION: The results indicate better 
      periodontal status among long-term aspirin users compared to non-aspirin users.
CI  - © 2018 John Wiley & Sons Australia, Ltd.
FAU - Bali, Sumeet K
AU  - Bali SK
AD  - Department of Periodontics, M.R. Ambedkar Dental College and Hospital, Bangalore, 
      Karnataka, India.
FAU - Madaiah, Hemalata
AU  - Madaiah H
AD  - Department of Periodontics, M.R. Ambedkar Dental College and Hospital, Bangalore, 
      Karnataka, India.
FAU - Dharmapalan, Jayanthi
AU  - Dharmapalan J
AD  - Department of Periodontics, M.R. Ambedkar Dental College and Hospital, Bangalore, 
      Karnataka, India.
FAU - Janarthanam, Sanghamitra
AU  - Janarthanam S
AD  - Department of Periodontics, M.R. Ambedkar Dental College and Hospital, Bangalore, 
      Karnataka, India.
FAU - Tarannum, Fouzia
AU  - Tarannum F
AUID- ORCID: 0000-0002-1927-543X
AD  - Department of Periodontics, M.R. Ambedkar Dental College and Hospital, Bangalore, 
      Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20180730
PL  - Australia
TA  - J Investig Clin Dent
JT  - Journal of investigative and clinical dentistry
JID - 101524471
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Case-Control Studies
MH  - Chronic Periodontitis/*drug therapy/metabolism
MH  - Dental Plaque Index
MH  - Female
MH  - Gingival Crevicular Fluid/chemistry/*drug effects
MH  - Humans
MH  - Lipopolysaccharide Receptors/*analysis
MH  - Male
MH  - Middle Aged
MH  - Periodontal Attachment Loss/drug therapy
MH  - Periodontal Index
OTO - NOTNLM
OT  - clinical attachment loss
OT  - lipoxin
OT  - low-dose aspirin
OT  - periodontal status
OT  - soluble CD14
EDAT- 2018/08/01 06:00
MHDA- 2019/03/19 06:00
CRDT- 2018/08/01 06:00
PHST- 2018/03/02 00:00 [received]
PHST- 2018/05/18 00:00 [accepted]
PHST- 2018/08/01 06:00 [pubmed]
PHST- 2019/03/19 06:00 [medline]
PHST- 2018/08/01 06:00 [entrez]
AID - 10.1111/jicd.12353 [doi]
PST - ppublish
SO  - J Investig Clin Dent. 2018 Nov;9(4):e12353. doi: 10.1111/jicd.12353. Epub 2018 
      Jul 30.

PMID- 7267830
OWN - NLM
STAT- MEDLINE
DCOM- 19811014
LR  - 20191031
IS  - 0161-4630 (Print)
IS  - 0161-4630 (Linking)
VI  - 6
IP  - 6
DP  - 1981 Jun
TI  - Aspirin inhibits Ca2+-stimulated fatty acid release from human washed platelets.
PG  - 657-60
AB  - Ca2+ at 2mM concentration stimulates the release of saturated and unsaturated 
      fatty acids from intact washed platelets incubated at 37 degrees C with stirring. 
      Aspirin at a concentration of 0.4 mM inhibits both cyclo-oxygenase activity and 
      fatty acid efflux induced by Ca2+. Thus, in intact washed platelets, aspirin 
      reduces formation of cyclo-oxygenase products by direct inhibition of the enzyme 
      and by reducing the availability of precursor arachidonate.
FAU - Pilo, R
AU  - Pilo R
FAU - Raz, A
AU  - Raz A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Prostaglandins Med
JT  - Prostaglandins and medicine
JID - 7810330
RN  - 0 (Fatty Acids)
RN  - M4I0D6VV5M (Calcium Chloride)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*metabolism
MH  - Calcium/*antagonists & inhibitors
MH  - Calcium Chloride/antagonists & inhibitors
MH  - Fatty Acids/*blood
MH  - Humans
EDAT- 1981/06/01 00:00
MHDA- 1981/06/01 00:01
CRDT- 1981/06/01 00:00
PHST- 1981/06/01 00:00 [pubmed]
PHST- 1981/06/01 00:01 [medline]
PHST- 1981/06/01 00:00 [entrez]
AID - 10.1016/0161-4630(81)90128-2 [doi]
PST - ppublish
SO  - Prostaglandins Med. 1981 Jun;6(6):657-60. doi: 10.1016/0161-4630(81)90128-2.

PMID- 26369687
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 21
IP  - 35
DP  - 2015
TI  - Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction 
      Between H. pylori Infection and Low-Dose Aspirin Use.
PG  - 5056-65
AB  - Nowadays, low-dose aspirin is widely administered at low dose as an 
      antithrombotic drug for the prevention of cerebrovascular and cardiovascular 
      diseases. However, aspirin, even at a low dose, can induce varying degrees of 
      gastroduodenal mucosal injury (erosion, ulcer, ulcer bleeding). Hence, 
      co-prescription of proton pump inhibitors with low-dose aspirin is recommended 
      for those at high risk for adverse gastroduodenal events. At present, a history 
      of peptic ulcer, especially that of complicated ulcer, is the most important risk 
      factor for low-dose aspirin-associated gastroduodenal adverse events. 
      Additionally, concomitant use of non-steroidal anti-inflammatory drugs including 
      COX-2 selective inhibitors, anti-platelet agents, anti-coagulants, and oral 
      corticosteroid is recognized to increase the risk for adverse gastroduodenal 
      events in low-dose aspirin users. H. pylori infection could also be associated 
      with the increased risk for adverse gastroduodenal events in low-dose aspirin 
      users, especially in patients with histories of peptic ulcers. Therefore, 
      eradication therapy for such patients can prevent ulcer recurrence. However, the 
      efficacy of eradication therapy on low-dose aspirin-related gastroduodenal 
      lesions in unselected H. pylori-positive lowdose aspirin users without histories 
      of peptic ulcers remains to be clarified.
FAU - Iijima, Katsunori
AU  - Iijima K
AD  - Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 
      Seiryo-machi, Aobaku, Sendai 980-8574, Japan. kiijima@med.tohoku.ac.jp.
FAU - Shimosegawa, Tooru
AU  - Shimosegawa T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Diseases/*chemically induced/prevention & control
MH  - Helicobacter Infections/complications/drug therapy
MH  - Helicobacter pylori/isolation & purification
MH  - Humans
MH  - Peptic Ulcer/chemically induced/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Risk Factors
MH  - Upper Gastrointestinal Tract/*drug effects/pathology
EDAT- 2015/09/16 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/06/19 00:00 [received]
PHST- 2015/09/14 00:00 [accepted]
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - CPD-EPUB-70380 [pii]
AID - 10.2174/1381612821666150915105330 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2015;21(35):5056-65. doi: 10.2174/1381612821666150915105330.

PMID- 31203158
OWN - NLM
STAT- MEDLINE
DCOM- 20200305
LR  - 20200305
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 214
DP  - 2019 Aug
TI  - Rationale and design of the Onyx ONE global randomized trial: A randomized 
      controlled trial of high-bleeding risk patients after stent placement with 
      1 month of dual antiplatelet therapy.
PG  - 134-141
LID - S0002-8703(19)30106-1 [pii]
LID - 10.1016/j.ahj.2019.04.017 [doi]
AB  - BACKGROUND AND RATIONALE: Polymer-free drug-eluting stent (DES) implantation in 
      combination with 1-month dual antiplatelet therapy (DAPT) has shown superior 
      safety and efficacy outcomes compared with bare-metal stents among patients with 
      high-bleeding risk (HBR) treated with 1-month DAPT. The safety and efficacy of 
      the newer-generation durable-polymer DES Resolute Onyx compared with polymer-free 
      DES among HBR patients treated with 1-month DAPT is unknown. TRIAL DESIGN: The 
      Onyx ONE global randomized trial is an international, prospective, randomized, 
      blinded, controlled study enrolling HBR patients undergoing percutaneous coronary 
      intervention. The trial will randomize up to 2,000 patients in a 1:1 fashion to 
      receive either the durable-polymer Resolute Onyx DES or the polymer-free 
      Biosensors BioFreedom DES. After index procedure, patients in both arms will be 
      treated with 1 month of DAPT (aspirin and oral P2Y12 inhibitor), followed by 
      single antiplatelet therapy thereafter. The primary end point is the composite 
      end point of cardiac death, myocardial infarction, or stent thrombosis at 1-year 
      follow-up. The powered secondary end point is target lesion failure (defined as 
      the composite of cardiac death, target vessel myocardial infarction, or 
      clinically driven target lesion revascularization) at 1 year. Patient follow-up 
      is planned for 1, 2, and 6 months and 1 and 2 years after the procedure. 
      CONCLUSIONS: The Onyx ONE global randomized trial is the first study to directly 
      compare the safety and efficacy of a durable polymer DES (Resolute Onyx) with a 
      polymer-free DES (BioFreedom) in HBR patients treated with 1 month of DAPT.
CI  - Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Kedhi, Elvin
AU  - Kedhi E
AD  - Isala Hartcentrum, Zwolle, the Netherlands. Electronic address: e.kedhi@isala.nl.
FAU - Latib, Azeem
AU  - Latib A
AD  - Department of Cardiology, Montefiore Medical Center, New York, NY.
FAU - Abizaid, Alexandre
AU  - Abizaid A
AD  - Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
FAU - Kandzari, David
AU  - Kandzari D
AD  - Piedmont Atlanta Hospital, Atlanta, GA.
FAU - Kirtane, Ajay J
AU  - Kirtane AJ
AD  - Columbia University Medical Center/NewYork-Presbyterian Hospital and the 
      Cardiovascular Research Foundation, New York, NY.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - Department of Cardiology, Mount Sinai Medical Center, New York, NY.
FAU - Price, Matthew J
AU  - Price MJ
AD  - Department of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA.
FAU - Simon, Daniel
AU  - Simon D
AD  - University Hospitals Cleveland Medical Center, Cleveland, OH.
FAU - Worthley, Stephen
AU  - Worthley S
AD  - Royal Adelaide Hospital, Adelaide, Australia.
FAU - Zaman, Azfar
AU  - Zaman A
AD  - Freeman Hospital and Newcastle University, Newcastle upon Tyne, UK.
FAU - Brar, Sandeep
AU  - Brar S
AD  - Medtronic, Santa Rosa, CA.
FAU - Liu, Minglei
AU  - Liu M
AD  - Medtronic, Santa Rosa, CA.
FAU - Stone, Gregg W
AU  - Stone GW
AD  - Columbia University Medical Center/NewYork-Presbyterian Hospital and the 
      Cardiovascular Research Foundation, New York, NY.
FAU - Windecker, Stephan
AU  - Windecker S
AD  - Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, 
      Bern, Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT03344653
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20190506
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (P2RY12 protein, human)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Receptors, Purinergic P2Y12)
RN  - H4GXR80IZE (zotarolimus)
RN  - R16CO5Y76E (Aspirin)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Drug-Eluting Stents/*adverse effects
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Prosthesis Design
MH  - Receptors, Purinergic P2Y12
MH  - Research Design
MH  - Risk
MH  - Single-Blind Method
MH  - Sirolimus/analogs & derivatives/therapeutic use
MH  - Stents/adverse effects
MH  - Thrombosis/prevention & control
EDAT- 2019/06/17 06:00
MHDA- 2020/03/07 06:00
CRDT- 2019/06/17 06:00
PHST- 2019/01/05 00:00 [received]
PHST- 2019/04/26 00:00 [accepted]
PHST- 2019/06/17 06:00 [pubmed]
PHST- 2020/03/07 06:00 [medline]
PHST- 2019/06/17 06:00 [entrez]
AID - S0002-8703(19)30106-1 [pii]
AID - 10.1016/j.ahj.2019.04.017 [doi]
PST - ppublish
SO  - Am Heart J. 2019 Aug;214:134-141. doi: 10.1016/j.ahj.2019.04.017. Epub 2019 May 
      6.

PMID- 18574274
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20170602
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 133
IP  - 6 Suppl
DP  - 2008 Jun
TI  - Valvular and structural heart disease: American College of Chest Physicians 
      Evidence-Based Clinical Practice Guidelines (8th Edition).
PG  - 593S-629S
LID - S0012-3692(08)60126-9 [pii]
LID - 10.1378/chest.08-0724 [doi]
AB  - This chapter about antithrombotic therapy for valvular heart disease is part of 
      the American College of Chest Physicians Evidence-Based Clinical Practice 
      Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that 
      the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests 
      that individual patient values might lead to different choices (for a full 
      understanding of the grading see Guyatt et al, CHEST 2008; 133[suppl]:123S-131S). 
      Among the key recommendations in this chapter are the following: for patients 
      with rheumatic mitral valve disease complicated singly or in combination by the 
      presence of atrial fibrillation (AF), previous systemic embolism, or left atrial 
      thrombus, we recommend vitamin K antagonist (VKA) therapy (Grade 1A). For 
      patients with rheumatic mitral valve disease and normal sinus rhythm, without 
      left atrial enlargement, we do not suggest antithrombotic therapy unless a 
      separate indication exists (Grade 2C). For patients with mitral valve prolapse 
      (MVP), not complicated by AF, who have not had systemic embolism, unexplained 
      transient ischemic attacks, or ischemic stroke, we recommend against 
      antithrombotic therapy (Grade 1C). In patients with mitral annular calcification 
      complicated by systemic embolism or ischemic stroke, we recommend antiplatelet 
      agent (APA) therapy (Grade 1B). For patients with isolated calcific aortic valve 
      disease, we suggest against antithrombotic therapy (Grade 2C). But, for those 
      with aortic valve disease who have experienced ischemic stroke, we suggest APA 
      therapy (Grade 2C). For patients with stroke associated with aortic 
      atherosclerotic lesions, we recommend low-dose aspirin (ASA) therapy (Grade 1C). 
      For patients with cryptogenic ischemic stroke and a patent foramen ovale (PFO), 
      we recommend APA therapy (Grade 1A). For patients with mechanical heart valves, 
      we recommend VKA therapy (Grade 1A). For patients with mechanical heart valves 
      and history of vascular disease or who have additional risk factors for 
      thromboembolism, we recommend the addition of low-dose aspirin ASA to VKA therapy 
      (Grade 1B). We suggest ASA not be added to long-term VKA therapy in patients with 
      mechanical heart valves who are at particularly high risk of bleeding (Grade 2C). 
      For patients with bioprosthetic heart valves, we recommend ASA (Grade 1B). For 
      patients with bioprosthetic heart valves and additional risk factors for 
      thromboembolism, we recommend VKA therapy (Grade 1C). For patients with infective 
      endocarditis, we recommend against antithrombotic therapy, unless a separate 
      indication exists (Grade 1B).
FAU - Salem, Deeb N
AU  - Salem DN
AD  - Department of Medicine, Tufts-New England Medical Center, Boston, MA. Electronic 
      address: dsalem@tufts-nemc.org.
FAU - O'Gara, Patrick T
AU  - O'Gara PT
AD  - Department of Medicine, Tufts-New England Medical Center, Boston, MA.
FAU - Madias, Christopher
AU  - Madias C
AD  - Department of Medicine, Tufts-New England Medical Center, Boston, MA.
FAU - Pauker, Stephen G
AU  - Pauker SG
AD  - Department of Medicine, Tufts-New England Medical Center, Boston, MA.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Evidence-Based Medicine
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Heart Valve Diseases/complications/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Vitamin K/antagonists & inhibitors
EDAT- 2008/07/24 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/07/24 09:00
PHST- 2008/07/24 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/24 09:00 [entrez]
AID - S0012-3692(08)60126-9 [pii]
AID - 10.1378/chest.08-0724 [doi]
PST - ppublish
SO  - Chest. 2008 Jun;133(6 Suppl):593S-629S. doi: 10.1378/chest.08-0724.

PMID- 3897722
OWN - NLM
STAT- MEDLINE
DCOM- 19851007
LR  - 20131121
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 90
IP  - 3
DP  - 1985 Sep
TI  - Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary 
      bypass grafts. A double-blind, placebo-controlled, randomized trial.
PG  - 373-7
AB  - A total of 125 patients undergoing aorta-coronary bypass grafting for disabling 
      angina were randomized to receive either 330 mg of acetylsalicylic acid (aspirin) 
      plus 75 mg of dipyridamole three times daily or a placebo for 6 months 
      postoperatively. In addition, all patients were given warfarin for 3 months. 
      Repeat angiography was performed at 6 months in 103 patients. In the treatment 
      group 95 grafts were implanted in 48 patients, of which 87 were patent (91.6% 
      patency rate). This figure compares with 88 grafts patent out of 118 implanted in 
      55 patients in the placebo group (74.6% patency rate) (p less than 0.01). We 
      conclude that antiplatelet therapy improves the early patency of saphenous vein 
      aorta-coronary bypass grafts.
FAU - Rajah, S M
AU  - Rajah SM
FAU - Salter, M C
AU  - Salter MC
FAU - Donaldson, D R
AU  - Donaldson DR
FAU - Subba Rao, R
AU  - Subba Rao R
FAU - Boyle, R M
AU  - Boyle RM
FAU - Partridge, J B
AU  - Partridge JB
FAU - Watson, D A
AU  - Watson DA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Placebos)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Graft Occlusion, Vascular/*drug therapy
MH  - Humans
MH  - Middle Aged
MH  - Placebos
MH  - Random Allocation
EDAT- 1985/09/01 00:00
MHDA- 1985/09/01 00:01
CRDT- 1985/09/01 00:00
PHST- 1985/09/01 00:00 [pubmed]
PHST- 1985/09/01 00:01 [medline]
PHST- 1985/09/01 00:00 [entrez]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1985 Sep;90(3):373-7.

PMID- 3389069
OWN - NLM
STAT- MEDLINE
DCOM- 19880729
LR  - 20131121
IS  - 0300-9009 (Print)
IS  - 0300-9009 (Linking)
VI  - 88
IP  - 1
DP  - 1988 Jan-Feb
TI  - European stroke prevention study.
PG  - 14-8
AB  - The European Stroke Prevention Study showed: 1. That the association 
      Persantin-Aspirin reduces stroke and vascular death risks with 36,5% in a 
      population of 2500 patients. Risk reduction persisted during the two years 
      follow-up and was the same for men and women. 2. That this reduction is higher 
      than the reduction obtained in all other studies with anti-aggregation 
      prevention. 3. That studies with less than 600 patients cannot lead to 
      significant differences.
FAU - Lowenthal, A
AU  - Lowenthal A
AD  - Universitaire Instelling Antwerpen, Labo Neurochemie, Wilrijk, België.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Acta Neurol Belg
JT  - Acta neurologica Belgica
JID - 0247035
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cerebrovascular Disorders/drug therapy/mortality/*prevention & control
MH  - Dipyridamole/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Neurol Belg. 1988 Jan-Feb;88(1):14-8.

PMID- 14650215
OWN - NLM
STAT- MEDLINE
DCOM- 20040316
LR  - 20131121
IS  - 0869-2092 (Print)
IS  - 0869-2092 (Linking)
VI  - 66
IP  - 5
DP  - 2003 Sep-Oct
TI  - [Effect of acetylsalicylic and mefenamic acids on cytoarchitectonic of skin in 
      rats with acute local cryogenic trauma].
PG  - 45-7
AB  - The effect of acetylsalicylic (250 mg/kg) and mephenamic (50 mg/kg) acids on the 
      process of skin cytoarchitectonics restoration was studied in rats with acute 
      local cryogenic traumas induced by acting with a stream of ethyl chloride upon 
      epilated back skin area (1.5 cm2). The animals were killed under narcosis on the 
      12th day of post-treatment observation. Both acetylsalicylic and mephenamic acids 
      were administered per os twice per day over various periods after cryogenic 
      damage. The effect depended on the treatment duration. The normal skin 
      cytoarchitectonics was restored by acetylsalicylic acid in half, and by 
      mephenamic acid, in one-third of cases (for a "combined" administration scheme).
FAU - Nazarenko, N A
AU  - Nazarenko NA
AD  - Department of Pharmacology, Archangelsk State Medical Academy, Troitskii pr. 51, 
      Archangelsk, 163051 Russia.
FAU - Khodasevich, L S
AU  - Khodasevich LS
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Vliianie atsetilsalitsilovoĭ i mefenamovoĭ kislot na tsitoarkhitektoniku kozhi 
      krys pri ostroĭ lokal'noĭ kriotravme.
PL  - Russia (Federation)
TA  - Eksp Klin Farmakol
JT  - Eksperimental'naia i klinicheskaia farmakologiia
JID - 9215981
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 367589PJ2C (Mefenamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Disease Models, Animal
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Frostbite/*drug therapy
MH  - Male
MH  - Mefenamic Acid/administration & dosage/*therapeutic use
MH  - Rats
MH  - Skin/*drug effects/pathology
MH  - Wound Healing/*drug effects
EDAT- 2003/12/03 05:00
MHDA- 2004/03/17 05:00
CRDT- 2003/12/03 05:00
PHST- 2003/12/03 05:00 [pubmed]
PHST- 2004/03/17 05:00 [medline]
PHST- 2003/12/03 05:00 [entrez]
PST - ppublish
SO  - Eksp Klin Farmakol. 2003 Sep-Oct;66(5):45-7.

PMID- 12013090
OWN - NLM
STAT- MEDLINE
DCOM- 20021104
LR  - 20200923
IS  - 0390-6663 (Print)
IS  - 0390-6663 (Linking)
VI  - 29
IP  - 1
DP  - 2002
TI  - Liver and kidney ultrastructural changes caused by acetylsalicylic acid treatment 
      during pregnancy in rats.
PG  - 37-9
AB  - The worldwide use of acetylsalicylic acid (ASA) as an analgesic-antipyretic drug, 
      including during pregnancy, prompted us to investigate its potentially 
      deleterious effects in that condition. Pregnant rats were treated with ASA (1, 10 
      or 100 mg/kg once a day) from the first day up to term pregnancy. No histological 
      changes were noticed in maternal and fetal livers or kidneys when examined under 
      light microscopy, but some definite dose-dependent effects of ASA were observed 
      on electron microscopy examination. In livers and kidneys of pregnant rats 
      treated with the highest doses of ASA we observed cytoplasmic derangement, 
      mitochondrial cristolysis and abnormally shaped rough endoplasmic reticulum. 
      Similarly, in foetal livers and kidneys from this group we observed degenerative 
      cytoplasmic vacuoles and ballooned mitochondria with cristae derangement and 
      myelin figures. Our data point out the fact that both maternal and foetal tissues 
      can be importantly affected by ASA at the ultrastructural level, without overt 
      signs of toxicity.
FAU - Espiridião, S
AU  - Espiridião S
AD  - Fundação ABC School of Medicine, Brazil.
FAU - Oliveira-Filho, R M
AU  - Oliveira-Filho RM
FAU - Simões, M J
AU  - Simões MJ
FAU - Mamede, J A V
AU  - Mamede JA
FAU - Kulay, L Jr
AU  - Kulay L Jr
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - Clin Exp Obstet Gynecol
JT  - Clinical and experimental obstetrics & gynecology
JID - 7802110
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Kidney/*drug effects/embryology/*ultrastructure
MH  - Liver/*drug effects/embryology/*ultrastructure
MH  - Pregnancy
MH  - Rats
MH  - Rats, Wistar
EDAT- 2002/05/16 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/05/16 10:00
PHST- 2002/05/16 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/05/16 10:00 [entrez]
PST - ppublish
SO  - Clin Exp Obstet Gynecol. 2002;29(1):37-9.

PMID- 29139042
OWN - NLM
STAT- MEDLINE
DCOM- 20190829
LR  - 20190829
IS  - 1179-1926 (Electronic)
IS  - 0312-5963 (Linking)
VI  - 57
IP  - 6
DP  - 2018 Jun
TI  - Obesity and Altered Aspirin Pharmacology.
PG  - 663-672
LID - 10.1007/s40262-017-0611-8 [doi]
AB  - Obesity is an independent risk factor for cardiovascular morbidity and mortality 
      due to atherothrombotic events and represents a group of patients who are in need 
      of optimized antithrombotic therapy. Central to the obesity-related risk of 
      atherothrombosis is a pro-thrombotic state characterized by increased levels of 
      coagulation factors, impaired fibrinolysis, and platelet hyper-reactivity, which 
      results from the interaction among the features clustering in obesity: insulin 
      resistance, inflammation, oxidative stress, and endothelial dysfunction. Aspirin 
      is a cornerstone antiplatelet drug that has substantial interpatient variability 
      in pharmacodynamic response and a number of reports have demonstrated that 
      obesity is a risk factor for a reduced aspirin pharmacodynamic response. The 
      inflammatory state associated with obesity, particularly a metabolic endotoxemia, 
      may set in motion a number of mechanisms that increase platelet reactivity and 
      platelet turnover and decrease aspirin bioavailability, all contributing to a 
      poor aspirin response. A greater understanding of the mechanisms underlying 
      obesity-related high on-aspirin platelet reactivity will help in optimization of 
      antithrombotic therapy in this patient population.
FAU - Norgard, Nicholas B
AU  - Norgard NB
AUID- ORCID: 0000-0003-4612-0107
AD  - University of Missouri-Kansas City School of Medicine, M4-325, 2411 Holmes St, 
      Kansas City, MO, USA. norgardn@umkc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Clin Pharmacokinet
JT  - Clinical pharmacokinetics
JID - 7606849
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Humans
MH  - Obesity/metabolism/*physiopathology
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 2017/11/16 06:00
MHDA- 2019/08/30 06:00
CRDT- 2017/11/16 06:00
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2019/08/30 06:00 [medline]
PHST- 2017/11/16 06:00 [entrez]
AID - 10.1007/s40262-017-0611-8 [pii]
AID - 10.1007/s40262-017-0611-8 [doi]
PST - ppublish
SO  - Clin Pharmacokinet. 2018 Jun;57(6):663-672. doi: 10.1007/s40262-017-0611-8.

PMID- 11883156
OWN - NLM
STAT- MEDLINE
DCOM- 20020816
LR  - 20131121
IS  - 0019-5499 (Print)
IS  - 0019-5499 (Linking)
VI  - 45
IP  - 4
DP  - 2001 Oct
TI  - Aspirin modulates the anticonvulsant effect of diazepam and sodium valproate in 
      pentylenetetrazole and maximal electroshock induced seizures in mice.
PG  - 475-80
AB  - Release of prostaglandins in brain after spontaneous and experimentally induced 
      seizures, has been demonstrated. The possible role of prostaglandins in 
      modulation of seizure activity is still inconclusive. In the present study, the 
      effects of aspirin and its interaction with the anticonvulsants (diazepam and 
      sodium valproate) were studied in pentylenetetrazole (PTZ) and maximal 
      electroshock (MES) induced seizures in mice. Aspirin 50, 100, and 500 mg/kg, i.p. 
      was administered 45 min before the pentylenetetrazole (60 mg/kg, i.p.) and MES 
      (60 mA, 0.2 s duration via car clip electrodes) challenge. In MES seizures 
      significant protection was seen with aspirin 100 mg/kg where as higher dose of 
      aspirin 500 mg/kg was required to elicit maximum protection against PTZ seizures. 
      Sub anticonvulsant dose of sodium valproate 150 mg/kg, i.p. and aspirin 50 mg/kg 
      i.p. showed complete protection in MES seizures and the same dose of sodium 
      valproate offered superior protection in PTZ seizures than either drug used 
      alone. When mice were pretreated with combination of diazepam 0.5 mg/kg and 
      aspirin 50 mg/kg protection was significantly enhanced in PTZ seizures. However, 
      aspirin did not show any significant protection with subanticonvulsant dose of 
      diazepam against MES seizures. The present study suggests that prostaglandins may 
      have anticonvulsant potential and also may have modulatory effect on 
      anticonvulsant effect of conventional antiepileptic drugs.
FAU - Srivastava, A K
AU  - Srivastava AK
AD  - Neuropharmacology Laboratory, Department of Pharmacology, All India Institute Of 
      Medical Sciences, New Delhi-110 029.
FAU - Gupta, Y K
AU  - Gupta YK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Physiol Pharmacol
JT  - Indian journal of physiology and pharmacology
JID - 0374707
RN  - 0 (Anticonvulsants)
RN  - 0 (Prostaglandins)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - Q3JTX2Q7TU (Diazepam)
RN  - R16CO5Y76E (Aspirin)
RN  - WM5Z385K7T (Pentylenetetrazole)
SB  - IM
MH  - Animals
MH  - Anticonvulsants/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Diazepam/*pharmacology
MH  - Male
MH  - Mice
MH  - Pentylenetetrazole
MH  - Prostaglandins/*physiology
MH  - Seizures/prevention & control
MH  - Valproic Acid/*pharmacology
EDAT- 2002/03/09 10:00
MHDA- 2002/08/17 10:01
CRDT- 2002/03/09 10:00
PHST- 2002/03/09 10:00 [pubmed]
PHST- 2002/08/17 10:01 [medline]
PHST- 2002/03/09 10:00 [entrez]
PST - ppublish
SO  - Indian J Physiol Pharmacol. 2001 Oct;45(4):475-80.

PMID- 31801249
OWN - NLM
STAT- MEDLINE
DCOM- 20200423
LR  - 20200423
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 24
IP  - 23
DP  - 2019 Nov 30
TI  - Fiber-Array-Based Raman Hyperspectral Imaging for Simultaneous, 
      Chemically-Selective Monitoring of Particle Size and Shape of Active Ingredients 
      in Analgesic Tablets.
LID - 10.3390/molecules24234381 [doi]
LID - 4381
AB  - The particle shape, size and distribution of active pharmaceutical ingredients 
      (API) are relevant quality indicators of pharmaceutical tablets due to their high 
      impact on the manufacturing process. Furthermore, the bioavailability of the APIs 
      from the dosage form depends largely on these characteristics. Routinely, 
      particle size and shape are only analyzed in the powder form, without regard to 
      the effect of the formulation procedure on the particle characteristics. The 
      monitoring of these parameters improves the understanding of the process; 
      therefore, higher quality and better control over the biopharmaceutical profile 
      can be ensured. A new fiber-array-based Raman hyperspectral imaging technique is 
      presented for direct simultaneous in-situ monitoring of three different active 
      pharmaceutical ingredients- acetylsalicylic acid, acetaminophen and caffeine- in 
      analgesic tablets. This novel method enables a chemically selective, noninvasive 
      assessment of the distribution of the active ingredients down to 1 µm spatial 
      resolution. The occurrence of spherical and needle-like particles, as well as 
      agglomerations and the respective particle size ranges, were rapidly determined 
      for two commercially available analgesic tablet types. Subtle differences were 
      observed in comparison between these two tablets. Higher amounts of acetaminophen 
      were visible, more needle-shaped and bigger acetylsalicylic acid particles, and a 
      higher incidence of bigger agglomerations were found in one of the analgesic 
      tablets.
FAU - Frosch, Timea
AU  - Frosch T
AUID- ORCID: 0000-0001-8346-0253
AD  - Leibniz Institute of Photonic Technology, 07745 Jena, Germany.
FAU - Wyrwich, Elisabeth
AU  - Wyrwich E
AD  - Leibniz Institute of Photonic Technology, 07745 Jena, Germany.
FAU - Yan, Di
AU  - Yan D
AD  - Leibniz Institute of Photonic Technology, 07745 Jena, Germany.
FAU - Popp, Juergen
AU  - Popp J
AD  - Leibniz Institute of Photonic Technology, 07745 Jena, Germany.
AD  - Institute of Physical Chemistry, Friedrich Schiller University, 07743 Jena, 
      Germany.
AD  - Abbe Centre of Photonics, Friedrich Schiller University, 07745 code Jena, 
      Germany.
FAU - Frosch, Torsten
AU  - Frosch T
AUID- ORCID: 0000-0003-3358-8878
AD  - Leibniz Institute of Photonic Technology, 07745 Jena, Germany.
AD  - Institute of Physical Chemistry, Friedrich Schiller University, 07743 Jena, 
      Germany.
AD  - Abbe Centre of Photonics, Friedrich Schiller University, 07745 code Jena, 
      Germany.
LA  - eng
GR  - 2015 FE 9012/federal state of Thuringia/
PT  - Journal Article
DEP - 20191130
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Analgesics)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/chemistry
MH  - Analgesics/*analysis/*chemistry
MH  - Aspirin/chemistry
MH  - Chemical Phenomena
MH  - Particle Size
MH  - *Spectrum Analysis, Raman/methods
MH  - Tablets
PMC - PMC6930444
OTO - NOTNLM
OT  - API distribution
OT  - Raman spectroscopy
OT  - acetaminophen
OT  - acetylsalicylic acid
OT  - caffeine
OT  - chemical imaging
OT  - fiber sensing
OT  - fiber-array
OT  - hyperspectral imaging
OT  - particle shape
OT  - particle size
OT  - pharmaceutical spectroscopy
COIS- The authors declare no conflict of interest.
EDAT- 2019/12/06 06:00
MHDA- 2020/04/24 06:00
CRDT- 2019/12/06 06:00
PHST- 2019/09/12 00:00 [received]
PHST- 2019/11/17 00:00 [revised]
PHST- 2019/11/28 00:00 [accepted]
PHST- 2019/12/06 06:00 [entrez]
PHST- 2019/12/06 06:00 [pubmed]
PHST- 2020/04/24 06:00 [medline]
AID - molecules24234381 [pii]
AID - molecules-24-04381 [pii]
AID - 10.3390/molecules24234381 [doi]
PST - epublish
SO  - Molecules. 2019 Nov 30;24(23):4381. doi: 10.3390/molecules24234381.

PMID- 29204669
OWN - NLM
STAT- MEDLINE
DCOM- 20190606
LR  - 20190606
IS  - 1433-0385 (Electronic)
IS  - 0009-4722 (Linking)
VI  - 89
IP  - 2
DP  - 2018 Feb
TI  - [The use of platelet aggregation inhibitors in the perioperative period].
PG  - 90-94
LID - 10.1007/s00104-017-0525-x [doi]
AB  - Every year 16 million operations are performed in Germany. Many patients take 
      platelet aggregation inhibitors as a primary or secondary prevention to reduce 
      the risk of cardiovascular events. Especially during the perioperative period, 
      this risk reduction is relevant due to an increased risk for cardiac events (in 
      approximately 6.2% of operations). As a result of a presumed increased risk of 
      bleeding, platelet aggregation inhibitors are often paused perioperatively. Thus, 
      doctors must decide on a risk-adapted basis whether the medication can be 
      continued perioperatively and, if so, with what risks. If acetylsalicylic acid 
      (ASA) treatment is solely used as primary prevention it can be paused during the 
      perioperative period, whereas ASA treatment for secondary prevention should only 
      be paused for operations within narrow confines. When pausing ASA, a sufficient 
      time interval should be maintained before the operation. Furthermore, the ASA 
      withdrawal syndrome with an increased predisposition for clotting is an important 
      phenomenon to be considered. Additionally, the perioperative handling of dual 
      platelet aggregation inhibition needed after coronary stent implantation should 
      be addressed. Due to an increased risk for in-stent thrombosis, dual platelet 
      aggregation inhibition is only reluctantly paused. Emergency surgery must, if not 
      otherwise possible, be carried out even if the dual platelet aggregation 
      inhibition is not paused; however, if the risk for intraoperative bleeding is too 
      high and the risk of an in-stent thrombosis is lower in comparison, P2Y(12) 
      inhibitors (e.g. clopidogrel) should be paused and the operation carried out 
      solely with ASA therapy.
FAU - Wagner, J
AU  - Wagner J
AD  - Klinik für Allgemein‑, Viszeral‑, Gefäß- und Kinderchirurgie, 
      Universitätsklinikum Würzburg, Oberduerrbacherstr. 6, 97080, Würzburg, 
      Deutschland.
FAU - Lock, J F
AU  - Lock JF
AD  - Klinik für Allgemein‑, Viszeral‑, Gefäß- und Kinderchirurgie, 
      Universitätsklinikum Würzburg, Oberduerrbacherstr. 6, 97080, Würzburg, 
      Deutschland.
FAU - Luber, V
AU  - Luber V
AD  - Klinik für Innere Medizin II, Universitätsklinikum Würzburg, Würzburg, 
      Deutschland.
FAU - Dietz, U A
AU  - Dietz UA
AD  - Klinik für Allgemein‑, Viszeral‑, Gefäß- und Kinderchirurgie, 
      Universitätsklinikum Würzburg, Oberduerrbacherstr. 6, 97080, Würzburg, 
      Deutschland.
FAU - Lichthardt, S
AU  - Lichthardt S
AD  - Klinik für Allgemein‑, Viszeral‑, Gefäß- und Kinderchirurgie, 
      Universitätsklinikum Würzburg, Oberduerrbacherstr. 6, 97080, Würzburg, 
      Deutschland.
FAU - Matthes, N
AU  - Matthes N
AD  - Klinik für Allgemein‑, Viszeral‑, Gefäß- und Kinderchirurgie, 
      Universitätsklinikum Würzburg, Oberduerrbacherstr. 6, 97080, Würzburg, 
      Deutschland.
FAU - Krajinovic, K
AU  - Krajinovic K
AD  - Klinik für Allgemein‑, Viszeral‑, Gefäß- und Kinderchirurgie, 
      Universitätsklinikum Würzburg, Oberduerrbacherstr. 6, 97080, Würzburg, 
      Deutschland.
FAU - Germer, C-T
AU  - Germer CT
AD  - Klinik für Allgemein‑, Viszeral‑, Gefäß- und Kinderchirurgie, 
      Universitätsklinikum Würzburg, Oberduerrbacherstr. 6, 97080, Würzburg, 
      Deutschland.
AD  - Comprehensive Cancer Centre Mainfranken, Universitätsklinikum Würzburg, Würzburg, 
      Deutschland.
FAU - Knop, S
AU  - Knop S
AD  - Klinik für Innere Medizin II, Universitätsklinikum Würzburg, Würzburg, 
      Deutschland.
AD  - Comprehensive Cancer Centre Mainfranken, Universitätsklinikum Würzburg, Würzburg, 
      Deutschland.
FAU - Wiegering, A
AU  - Wiegering A
AD  - Klinik für Allgemein‑, Viszeral‑, Gefäß- und Kinderchirurgie, 
      Universitätsklinikum Würzburg, Oberduerrbacherstr. 6, 97080, Würzburg, 
      Deutschland. wiegering_a@ukw.de.
AD  - Institut für Biochemie und Molekularbiologie, Universität Würzburg, Würzburg, 
      Deutschland. wiegering_a@ukw.de.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Perioperativer Umgang mit Thrombozytenaggregationshemmern.
PL  - Germany
TA  - Chirurg
JT  - Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
JID - 16140410R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Clopidogrel/therapeutic use
MH  - Germany
MH  - Humans
MH  - *Perioperative Period
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - Secondary Prevention
OTO - NOTNLM
OT  - Acetylsalicylic acid withdrawal syndrome
OT  - Chronic medication
OT  - Dual platelet aggregation inhibitors
OT  - Perioperative bleeding risk
OT  - Platelet function measurement
EDAT- 2017/12/06 06:00
MHDA- 2019/06/07 06:00
CRDT- 2017/12/06 06:00
PHST- 2017/12/06 06:00 [pubmed]
PHST- 2019/06/07 06:00 [medline]
PHST- 2017/12/06 06:00 [entrez]
AID - 10.1007/s00104-017-0525-x [pii]
AID - 10.1007/s00104-017-0525-x [doi]
PST - ppublish
SO  - Chirurg. 2018 Feb;89(2):90-94. doi: 10.1007/s00104-017-0525-x.

PMID- 12907290
OWN - NLM
STAT- MEDLINE
DCOM- 20040308
LR  - 20191107
IS  - 0928-0987 (Print)
IS  - 0928-0987 (Linking)
VI  - 19
IP  - 5
DP  - 2003 Aug
TI  - Dissolution testing of acetylsalicylic acid by a channel flow method-correlation 
      to USP basket and intrinsic dissolution methods.
PG  - 395-401
AB  - A new modification of the channel flow dissolution method is introduced together 
      with the theoretical basis to extract the solubility and mass transfer parameters 
      from the dissolution experiments. Correlation of drug dissolution profiles in the 
      channel flow apparatus was evaluated with respect to USP basket and intrinsic 
      dissolution methods at pH 1.2 or 6.8. Acetylsalicylic acid (ASA) was studied as a 
      pure drug substance and as three simple tablet compositions with microcrystalline 
      cellulose (MCC) and/or lactose as excipients. The channel flow measurements of 
      100% ASA tablets correlated well with the results of intrinsic dissolution tests. 
      In the channel flow method as well as in the USP basket method the release of ASA 
      was fastest from the tablet compositions containing lactose, while the slowest 
      dissolution rate was observed with the composition containing MCC as the only 
      excipient. As presumed, the dissolution rate of the weak acid was decreased as 
      the pH of the medium was lowered, which was clearly confirmed also by the three 
      dissolution methods. MCC forms matrix tablets and in the USP basket method the 
      dissolution profiles followed square root of time kinetics indicating that 
      diffusion was the rate-controlling step of ASA dissolution. Also the channel flow 
      results indicated that the dissolution of ASA was controlled by mass transfer. 
      The swelling behaviour of the tablets is different in the channel flow method as 
      compared to the basket method: only one tablet surface is exposed to the 
      dissolution medium in the channel flow system. The contact between the tablet 
      surface and the dissolution medium is more similar between the channel flow and 
      intrinsic dissolution methods.
FAU - Peltonen, Leena
AU  - Peltonen L
AD  - Department of Pharmacy, Pharmaceutical Technology Division and Viikki Drug 
      Discovery Technology Center, University of Helsinki, Helsinki, Finland. 
      leena.peltonen@helsinki.fi
FAU - Liljeroth, Peter
AU  - Liljeroth P
FAU - Heikkilä, Tiina
AU  - Heikkilä T
FAU - Kontturi, Kyösti
AU  - Kontturi K
FAU - Hirvonen, Jouni
AU  - Hirvonen J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Buffers)
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - 9004-34-6 (Cellulose)
RN  - J2B2A4N98G (Lactose)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Aspirin/*chemistry
MH  - Buffers
MH  - Cellulose
MH  - Chemistry, Pharmaceutical
MH  - Drug Compounding
MH  - Excipients
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Lactose
MH  - Pharmacopoeias as Topic
MH  - Solubility
MH  - Tablets
MH  - United States
EDAT- 2003/08/09 05:00
MHDA- 2004/03/09 05:00
CRDT- 2003/08/09 05:00
PHST- 2003/08/09 05:00 [pubmed]
PHST- 2004/03/09 05:00 [medline]
PHST- 2003/08/09 05:00 [entrez]
AID - S0928098703001404 [pii]
AID - 10.1016/s0928-0987(03)00140-4 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2003 Aug;19(5):395-401. doi: 10.1016/s0928-0987(03)00140-4.

PMID- 11851991
OWN - NLM
STAT- MEDLINE
DCOM- 20021030
LR  - 20190822
IS  - 0025-7753 (Print)
IS  - 0025-7753 (Linking)
VI  - 118
IP  - 5
DP  - 2002 Feb 16
TI  - [Meta-analysis of the scientific evidence on the usefulness of sporadic intake of 
      acetylsalicylic acid in the prevention of coronary heart disease].
PG  - 166-9
AB  - BACKGROUND: The present study was aimed at determining whether the sporadic 
      intake of acetylsalicylic acid (ASA) shows a protective effect on the appearance 
      or attenuation of coronary disease events. METHODS: The analysis was based on 
      articles found in EMBASE, MEDLINE and the Cochrane Library. Scientific rigour was 
      further assessed. We looked for original articles with clinical trial, cohorts, 
      and case-control or cross-sectional study designs, where the effect could be 
      assessed by the odds ratio (OR). RESULTS: A meta-analysis showed a protective 
      effect of sporadic ASA intake on the prevention of acute myocardial infarction 
      (OR for fixed effects = 0.75, CI 95%, 0.63-0.88, p < 0.0006), which was more 
      important in men than in women, and on the prevention of cardiovascular mortality 
      (OR for fixed effects = 0.61, CI 95%, 0.59-0.64, p < 0.0001). However, overall 
      mortality was found to be higher in those groups receiving the drug (OR for fixed 
      effects = 1.20, CI 95%, 1.05-1.37, p = 0.0006). None of these effects was 
      significant when performing a random effect analysis. ASA also attenuated acute 
      coronary syndromes (OR for fixed effects = 0.34, CI 95%, 0.26-0.45, p < 0.0001). 
      CONCLUSIONS: These results suggest that the sporadic intake of ASA may have a 
      protective particularly in men and attenuating effect on acute myocardial 
      infarction, in addition to playing a role in preventing cardiovascular mortality 
      but not overall mortality. Further studies to confirm these effects are 
      warranted.
FAU - Pueyo, Gloria
AU  - Pueyo G
AD  - Química Farmacéutica Bayer S.A. Barcelona. Spain.
FAU - Elosua, Roberto
AU  - Elosua R
FAU - Marrugat, Jaume
AU  - Marrugat J
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
TT  - Metaanálisis de la evidencia científica sobre la utilidad de la toma esporádica 
      de ácido acetilsalicílico en la prevención de enfermedad coronaria.
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Coronary Disease/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
EDAT- 2002/02/20 10:00
MHDA- 2002/11/01 04:00
CRDT- 2002/02/20 10:00
PHST- 2002/02/20 10:00 [pubmed]
PHST- 2002/11/01 04:00 [medline]
PHST- 2002/02/20 10:00 [entrez]
AID - S0025-7753(02)72322-1 [pii]
AID - 10.1016/s0025-7753(02)72322-1 [doi]
PST - ppublish
SO  - Med Clin (Barc). 2002 Feb 16;118(5):166-9. doi: 10.1016/s0025-7753(02)72322-1.

PMID- 7009859
OWN - NLM
STAT- MEDLINE
DCOM- 19810528
LR  - 20151119
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 7
IP  - 6
DP  - 1980 Nov-Dec
TI  - A double-blind comparison of aspirin and pirprofen in the treatment of rheumatoid 
      arthritis.
PG  - 865-70
AB  - Pirprofen (600 mg, 800 mg) and aspirin (3,600 mg) were compared in 30 outpatients 
      (33-67 yr old) with definite or classical rheumatoid arthritis. After 10 wk of 
      treatment with either pirprofen dose, the number of painful joints, grip 
      strength, and the duration of morning stiffness improved significantly. Only the 
      number of painful joints improved significantly with aspirin. The erythrocyte 
      sedimentation rate decreased with aspirin and 600 mg pirprofen but increased 
      (significantly) with 800 mg pirprofen. The differences in improvement between the 
      3 treatment groups were not statistically significant. Gastrointestinal 
      disturbances were the most frequently reported side-effects in each treatment 
      group. Central nervous system effects and tinnitus were reported by more patients 
      in the aspirin group than in either of the pirprofen groups.
FAU - Singleton, C M
AU  - Singleton CM
FAU - Wild, J H
AU  - Wild JH
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyrroles)
RN  - R16CO5Y76E (Aspirin)
RN  - T7KN291890 (pirprofen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenylpropionates/*therapeutic use
MH  - Pyrroles/therapeutic use
EDAT- 1980/11/01 00:00
MHDA- 1980/11/01 00:01
CRDT- 1980/11/01 00:00
PHST- 1980/11/01 00:00 [pubmed]
PHST- 1980/11/01 00:01 [medline]
PHST- 1980/11/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1980 Nov-Dec;7(6):865-70.

PMID- 8534620
OWN - NLM
STAT- MEDLINE
DCOM- 19960206
LR  - 20190719
IS  - 0306-5456 (Print)
IS  - 0306-5456 (Linking)
VI  - 102
IP  - 11
DP  - 1995 Nov
TI  - Low dose aspirin in pregnancy and early childhood development: follow up of the 
      collaborative low dose aspirin study in pregnancy. CLASP collaborative group.
PG  - 861-8
AB  - OBJECTIVE: To determine any benefits or risks, expressed in early childhood, of 
      low dose aspirin treatment in pregnancies at high risk of complications due to 
      pre-eclampsia or intrauterine growth retardation. DESIGN: A questionnaire-based 
      follow-up at 12 and 18 months of age of cohorts of surviving children whose 
      mothers participated in a large randomised, double-blind placebo-controlled trial 
      of 60 mg aspirin. SETTING: United Kingdom and Ottawa, Canada. SUBJECTS: 4168 
      children assessed at 12 months through information provided by general 
      practitioners, and 4365 assessed at 18 months through a questionnaire to parents. 
      MAIN OUTCOME MEASURES: Hospital visits in the first 18 months for congenital 
      malformations, motor deficit, developmental delay, respiratory problems or 
      bleeding problems; height or weight below the third centile; and delayed 
      acquisition of certain developmental skills. RESULTS: There were no clear 
      differences in any of the main outcome measures, although some confidence 
      intervals were wide. CONCLUSIONS: Although an adverse effect can not be ruled 
      out, these findings are reassuring about the safety of low dose aspirin started 
      after the first trimester, at least in respect of congenital malformations, major 
      motor deficit, and severe neuromotor or developmental delay identifiable in early 
      childhood. They provide no clear evidence of benefit. Taking into account 
      evidence from large randomised controlled trials, the place of low-dose aspirin 
      in pregnancy appears to be limited, although it may be beneficial for women at 
      high risk of early onset pre-eclampsia; for them, evidence suggesting that it is 
      not harmful is important.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Obstet Gynaecol
JT  - British journal of obstetrics and gynaecology
JID - 7503752
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Body Height
MH  - Body Weight
MH  - Canada/epidemiology
MH  - Cohort Studies
MH  - Developmental Disabilities/*chemically induced/epidemiology
MH  - Double-Blind Method
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Follow-Up Studies
MH  - Hemorrhage/epidemiology
MH  - Hospitalization
MH  - Humans
MH  - Infant
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - *Prenatal Exposure Delayed Effects
MH  - Respiration Disorders/epidemiology
MH  - United Kingdom/epidemiology
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 10.1111/j.1471-0528.1995.tb10872.x [doi]
PST - ppublish
SO  - Br J Obstet Gynaecol. 1995 Nov;102(11):861-8. doi: 
      10.1111/j.1471-0528.1995.tb10872.x.

PMID- 24547895
OWN - NLM
STAT- MEDLINE
DCOM- 20141110
LR  - 20151119
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 13
IP  - 4
DP  - 2014 Apr
TI  - Does long-term aspirin use increase the risk of neovascular age-related macular 
      degeneration?
PG  - 421-9
LID - 10.1517/14740338.2014.889680 [doi]
AB  - INTRODUCTION: Aspirin is used regularly for rheumatoid pain management and 
      cardioprotection. However, aspirin has also been associated with significant 
      adverse events, such as cerebral and gastrointestinal bleeding. Recent findings 
      from several observational epidemiologic studies indicate that regular aspirin 
      use may also be associated with increased risks of some forms of age-related 
      macular degeneration (AMD). AREAS COVERED: In this report, we review recent 
      findings from observational epidemiologic studies suggesting a possible adverse 
      effect of regular aspirin use in AMD, and in particular, neovascular AMD. These 
      findings are considered in light of the relative strengths and limitations of 
      observational studies and randomized trials. EXPERT OPINION: While the findings 
      are important and warrant further investigation, the inherent limitations of 
      observational studies, most notably uncontrolled confounding, preclude an 
      interpretation of causality. Alternatively, the most reliable evidence with which 
      to evaluate the effects of regular aspirin use in AMD will derive from 
      well-designed randomized trials of sufficient size and duration. Such information 
      is unlikely to alter current recommendations for persons at high risk of 
      cardiovascular disease, but should help clarify the benefit-to-risk ratio of 
      regular aspirin use in the large majority of individuals at low-to-moderate risk.
FAU - Christen, William G
AU  - Christen WG
AD  - Brigham and Women's Hospital, Harvard Medical School, Division of Preventive 
      Medicine, Department of Medicine , Boston, MA , USA 
      wchristen@rics.bwh.harvard.edu.
FAU - Chew, Emily Y
AU  - Chew EY
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140219
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Expert Opin Drug Saf. 2014 Jun;13(6):691-3. PMID: 24773275
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Macular Degeneration/*chemically induced/*etiology
MH  - Observational Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Risk
MH  - Risk Factors
EDAT- 2014/02/20 06:00
MHDA- 2014/11/11 06:00
CRDT- 2014/02/20 06:00
PHST- 2014/02/20 06:00 [entrez]
PHST- 2014/02/20 06:00 [pubmed]
PHST- 2014/11/11 06:00 [medline]
AID - 10.1517/14740338.2014.889680 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2014 Apr;13(4):421-9. doi: 10.1517/14740338.2014.889680. 
      Epub 2014 Feb 19.

PMID- 16159063
OWN - NLM
STAT- MEDLINE
DCOM- 20051027
LR  - 20210105
IS  - 1541-6933 (Print)
IS  - 1541-6933 (Linking)
VI  - 2
IP  - 2
DP  - 2005
TI  - Oral clopidogrel load in aspirin-resistant capsular warning syndrome.
PG  - 183-4
AB  - INTRODUCTION: Capsular warning syndrome (CWS) carries a significant risk of 
      permanent stroke. There are no proven therapies for preventing completed stroke 
      in this unstable situation. METHODS: Clinical observation in two patients with 
      aspirin-resistant CWS treated with a loading dose of oral clopidogrel. RESULTS: 
      Both patients had excellent neurological outcome, although one sustained an 
      asymptomatic brain infarction. CONCLUSION: High-dose oral clopidogrel plus 
      aspirin merits formal evaluation in high-risk transient brain ischemia such as 
      CWS, preferably in a randomized trial compared to aspirin alone.
FAU - Fahey, Christopher D
AU  - Fahey CD
AD  - Ken and Ruth Davee Department of Neurology and Clinical Neurological Sciences, 
      Feinberg School of Medicine of Northwestern University, Chicago, IL 60611, USA.
FAU - Alberts, Mark J
AU  - Alberts MJ
FAU - Bernstein, Richard A
AU  - Bernstein RA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Neurocrit Care
JT  - Neurocritical care
JID - 101156086
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - *Internal Capsule
MH  - Ischemic Attack, Transient/complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Stroke/etiology/*prevention & control
MH  - Syndrome
MH  - Ticlopidine/administration & dosage/*analogs & derivatives
EDAT- 2005/09/15 09:00
MHDA- 2005/10/28 09:00
CRDT- 2005/09/15 09:00
PHST- 2005/09/15 09:00 [pubmed]
PHST- 2005/10/28 09:00 [medline]
PHST- 2005/09/15 09:00 [entrez]
AID - NCC:2:2:183 [pii]
AID - 10.1385/NCC:2:2:183 [doi]
PST - ppublish
SO  - Neurocrit Care. 2005;2(2):183-4. doi: 10.1385/NCC:2:2:183.

PMID- 31138859
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20210109
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 May 28
TI  - Long-Term Aspirin Administration Has No Effect on Erectile Function: Evidence 
      from Adult Rats and Ageing Rat Model.
PG  - 7941
LID - 10.1038/s41598-019-44386-x [doi]
LID - 7941
AB  - As the broad spectrum pharmacological action, aspirin has been one of the most 
      widely used medicines since its initial synthesis; however, the association 
      between aspirin and erectile function is still controversial. We aim to explore 
      whether long-term aspirin administration deteriorates or preserves erectile 
      function from adult rats and ageing rat model. Twenty adult rats (10 weeks of 
      age) and twenty ageing rats (80 weeks of age) were randomly divided into four 
      groups as follows: Adult-Control (normal saline [NS]), Adult-Aspirin (aspirin, 
      10 mg/kg/d), Ageing-Control (NS), and Ageing-Aspirin (aspirin, 10 mg/kg/d) groups 
      (n = 10 per group). For all rats, erectile function was assessed by maximum 
      intracavernous pressure (ICP), total area under ICP curve (AUC), ICP/mean 
      arterial pressure (MAP) ratio, and MAP. The total treatment duration was one 
      month. Protein expression levels of cyclooxygenase-1 (COX-1), COX-2, endothelial 
      nitric oxide synthase (eNOS), and nNOS of the corpus cavernosum were detected by 
      Western blot. ELISA kits were used to determine 6-keto PGF(1a), PGE(2), TXB(2), 
      cyclic adenosine monophosphate (cAMP), and cyclic guanosine monophosphate (cGMP) 
      levels. Total nitric oxide (NO) concentration was measured using a fluorometric 
      assay kit. As a result, Ageing-Control rats revealed significantly decreased ICP, 
      AUC, and ICP/MAP ratios compared to Adult-Control rats, and these effects were 
      accompanied by reduced eNOS protein expression and lower total NO and cGMP 
      levels; however, no difference was found in nNOS protein expression. For adult 
      rat groups, aspirin significantly inhibited the production of 6-keto PGF(1a), 
      PGE(2), and TXB(2); however, it neither changed the ICP, AUC, or ICP/ MAP ratios 
      nor altered the protein expression of eNOS, nNOS, COX-1, and COX-2. Meanwhile, 
      aspirin did not influence the concentrations of total NO, cAMP, or cGMP. The same 
      tendency was also found in the ageing rat model, which confirmed that aspirin did 
      not alter erectile function. Our data suggested that long-term aspirin 
      administration did not strengthen or weaken erectile function in adult rats or 
      ageing rat model. Thus, it had no impact on erectile function.
FAU - Li, Tao
AU  - Li T
AD  - The Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, 
      China.
FAU - Wu, Changjing
AU  - Wu C
AD  - The Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Fu, Fudong
AU  - Fu F
AD  - The Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Xiong, Wenfeng
AU  - Xiong W
AD  - The Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Qin, Feng
AU  - Qin F
AD  - The Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Yuan, Jiuhong
AU  - Yuan J
AD  - The Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China. jiuhongyuan2107@163.com.
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, 
      China. jiuhongyuan2107@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190528
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Membrane Proteins)
RN  - 0 (Prostaglandins)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (Ptgs1 protein, rat)
RN  - EC 1.14.99.1 (Ptgs2 protein, rat)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aging/drug effects
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cyclic GMP/analysis
MH  - Cyclooxygenase 1/analysis
MH  - Cyclooxygenase 2/analysis
MH  - Erectile Dysfunction/prevention & control
MH  - Humans
MH  - Male
MH  - Membrane Proteins/analysis
MH  - Nitric Oxide Synthase Type III/analysis
MH  - Penile Erection/*drug effects
MH  - Prostaglandins/analysis
MH  - Rats
MH  - Rats, Sprague-Dawley
PMC - PMC6538637
COIS- The authors declare no competing interests.
EDAT- 2019/05/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/05/30 06:00
PHST- 2018/11/22 00:00 [received]
PHST- 2019/05/08 00:00 [accepted]
PHST- 2019/05/30 06:00 [entrez]
PHST- 2019/05/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1038/s41598-019-44386-x [pii]
AID - 44386 [pii]
AID - 10.1038/s41598-019-44386-x [doi]
PST - epublish
SO  - Sci Rep. 2019 May 28;9(1):7941. doi: 10.1038/s41598-019-44386-x.

PMID- 10437688
OWN - NLM
STAT- MEDLINE
DCOM- 19991007
LR  - 20191024
IS  - 0020-6091 (Print)
IS  - 0020-6091 (Linking)
VI  - 38
IP  - 3
DP  - 1999 May-Jun
TI  - Effects of salicylates on evoked otoacoustic emissions and remote masking in 
      humans.
PG  - 174-9
AB  - The aim of this study was to evaluate, in young volunteer subjects, the effects 
      of salicylates on evoked otoacoustic emissions (EOAEs), which presumably reflect 
      an active mechanical process in the cochlea due to outer hair cell (OHC) 
      activity, and on remote masking (RM), which has been proposed as a useful tool in 
      the study of the non-linear cochlear distortion products generated by 
      high-frequency maskers. Data from the present research are consistent with the 
      literature showing a reversible effect of salicylate leading to elevated hearing 
      thresholds and reduced EOAE amplitudes. From the point of view of new findings, 
      the results demonstrate a reversible effect of salicylates on RM magnitude, which 
      decreases as serum salicylate concentration increases. As described previously by 
      other authors, salicylate selectivity inhibits OHC motility and, in consequence, 
      reduces the amplitude of the motion of the basilar membrane. According to these 
      data it is very likely that the observed reduction in RM magnitude after 
      salicylate administration is also the result of the decreased ability of the OHCs 
      to contract and of the reduced basilar membrane motion. The results are 
      consistent with the conclusion that the OHC system function plays a role in 
      producing RM.
FAU - Quaranta, A
AU  - Quaranta A
AD  - Department of Ophthalmology and Otolaryngology, University of Bari, Italy.
FAU - Portalatini, P
AU  - Portalatini P
FAU - Camporeale, M
AU  - Camporeale M
FAU - Sallustio, V
AU  - Sallustio V
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Audiology
JT  - Audiology : official organ of the International Society of Audiology
JID - 1273752
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acoustic Impedance Tests/instrumentation
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Basilar Membrane/*drug effects
MH  - Biomechanical Phenomena
MH  - Cyclooxygenase Inhibitors/blood/*pharmacology
MH  - Evoked Potentials, Auditory/*drug effects
MH  - Hair Cells, Auditory, Outer/drug effects
MH  - Humans
MH  - *Perceptual Masking
MH  - Time Factors
EDAT- 1999/08/07 00:00
MHDA- 1999/08/07 00:01
CRDT- 1999/08/07 00:00
PHST- 1999/08/07 00:00 [pubmed]
PHST- 1999/08/07 00:01 [medline]
PHST- 1999/08/07 00:00 [entrez]
AID - 10.3109/00206099909073019 [doi]
PST - ppublish
SO  - Audiology. 1999 May-Jun;38(3):174-9. doi: 10.3109/00206099909073019.

PMID- 6393976
OWN - NLM
STAT- MEDLINE
DCOM- 19850205
LR  - 20131121
IS  - 0232-766X (Print)
IS  - 0232-766X (Linking)
VI  - 43
IP  - 8-9
DP  - 1984
TI  - Reduced side effects by low dose of acetylsalicylic acid (ASA) in patients with 
      myocardial infarction; estimations of serum thromboxane B2 and PGF2 alpha.
PG  - S467-70
AB  - In a secondary prevention study 867 male and female patients with myocardial 
      infarction (MI) were divided 3 weeks after onset of MI into 4 treatment groups: I 
      - 273 patients received additionally to their common medication 1000 mg ASA/d; II 
      - 313 patients got 60 mg ASA/d; III - 208 patients 30 mg ASA/d resp.; IV - 73 
      patients received no ASA administration due to ASA contraindications. One year 
      after onset of MI the following parameters were checked: mortality, malignant 
      arrhythmia, exercise tolerance, gastrointestinal symptoms and hemorrhage as 
      typical side effects of ASA, formation of thromboxane B2 and PGF2 alpha in 
      clotting whole blood. The low dose of 30 mg ASA/d reśultes in a clear reduction 
      of ASA side effects (6,4% of patients with symptoms) in comparison to group I 
      (15,9% of patients with symptoms), in a tendency to decreased mortality, and in 
      unchanged frequency of malignant arrhythmias resp. Concerning the maximum 
      exercise tolerance no significant difference could be observed in all 4 groups 
      investigated. Estimations of serum thromboxane B2 by radioimmunoassay and gas 
      chromatography revealed strong inhibitions of the thromboxane formation in all 
      patients with ASA administrations; even the low dose of 30 mg ASA/d decreased 
      thromboxane B2 by more than 95%.
FAU - Hoffmann, W
AU  - Hoffmann W
FAU - Foerster, W
AU  - Foerster W
FAU - Mest, H J
AU  - Mest HJ
FAU - Taube, C
AU  - Taube C
FAU - Block, H U
AU  - Block HU
FAU - Braun, H
AU  - Braun H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Biomed Biochim Acta
JT  - Biomedica biochimica acta
JID - 8304435
RN  - 0 (Prostaglandins F)
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - B7IN85G1HY (Dinoprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Dinoprost
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Prostaglandins F/*blood
MH  - Thromboxane B2/*blood
MH  - Thromboxanes/*blood
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Biomed Biochim Acta. 1984;43(8-9):S467-70.

PMID- 8939179
OWN - NLM
STAT- MEDLINE
DCOM- 19961220
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 98
IP  - 5 Pt 2
DP  - 1996 Nov
TI  - Mast cell effector mechanisms.
PG  - S67-71; discussion S71-2
AB  - Several lines of evidence support the central role of the cysteinyl leukotrienes 
      in aspirin-sensitive asthma, although their cellular source is unknown. The two 
      most likely cells are the mast cell and eosinophil. Compared with 
      aspirin-tolerant patients with asthma, patients with aspirin-sensitive asthma 
      have been found to have a greater infiltration of mast cells and eosinophils in 
      bronchial biopsy samples, although proportions of activated eosinophils were 
      similar. Findings that support the involvement of mast cells include elevated 
      serum histamine and tryptase levels after aspirin challenge in sensitive 
      subjects, in line with a decrease in lung function and increased histamine and 
      leukotriene C4 levels in nasal secretions; release of high-molecular-weight 
      neutrophil chemotactic factor into serum after challenge; and prevention of 
      aspirin-induced bronchoconstriction by pretreatment with cromolyn sodium or 
      nedocromil sodium. These agents are also effective in protecting against 
      bronchoconstriction induced by hyperosmolar stimuli, a challenge that is not 
      associated with increased leukotriene E4 responsiveness but that is followed by 
      increased release of histamine and prostaglandin D2 into bronchoalveolar lavage 
      fluid. Antihistamines are poorly effective at inhibiting aspirin-induced 
      bronchoconstriction but have been shown to attenuate the bronchoconstrictor 
      response to hyperosmolar challenge. The main effector mechanism in 
      hyperosmolar-induced bronchoconstriction appears to be mast cell activation and 
      histamine release.
FAU - Lane, S J
AU  - Lane SJ
AD  - Department of Allergy and Respiratory Medicine, Guy's Hospital, London, United 
      Kingdom.
FAU - Lee, T H
AU  - Lee TH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects
MH  - Asthma/chemically induced
MH  - Asthma, Exercise-Induced/physiopathology
MH  - Humans
MH  - Mast Cells/*physiology
RF  - 40
EDAT- 1996/11/01 00:00
MHDA- 1996/11/01 00:01
CRDT- 1996/11/01 00:00
PHST- 1996/11/01 00:00 [pubmed]
PHST- 1996/11/01 00:01 [medline]
PHST- 1996/11/01 00:00 [entrez]
AID - S0091-6749(96)70019-2 [pii]
AID - 10.1016/s0091-6749(96)80131-x [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1996 Nov;98(5 Pt 2):S67-71; discussion S71-2. doi: 
      10.1016/s0091-6749(96)80131-x.

PMID- 19915994
OWN - NLM
STAT- MEDLINE
DCOM- 20100402
LR  - 20211020
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 29
IP  - 2
DP  - 2010 Feb
TI  - Combined warfarin-aspirin therapy: what is the evidence for benefit and harm and 
      which patients should (and should not) receive it?
PG  - 208-13
LID - 10.1007/s11239-009-0413-4 [doi]
AB  - Combined warfarin-aspirin therapy is currently used in about 1 million patients 
      in North America for the long-term primary and secondary prevention of 
      atherothrombotic and thromboembolic diseases. Despite a potentially complementary 
      action of anticoagulant and antiplatelet drugs on different components of the 
      thrombotic pathway, their combined use, typically with warfarin and aspirin, is 
      not based in many cases on compelling evidence of a net therapeutic benefit. In 
      the real-world management of patients, clinicians should combine the best 
      available evidence with clinical judgment, considering also that, in most 
      clinical scenarios, clinical practice guidelines may not provide strong or 
      prescriptive recommendations for patients who should (and should not) receive 
      combined aspirin-warfarin therapy. The objectives of this review are to describe 
      the characteristics of patients who are receiving combined warfarin-aspirin 
      therapy, to summarize the evidence for the therapeutic benefit and harm of 
      combined warfarin-aspirin, and to provide practical guidelines as to which 
      patients should (or should not) receive such treatment.
FAU - Donadini, Marco P
AU  - Donadini MP
AD  - Department of Medicine, McMaster University and St Joseph's Healthcare, Hamilton, 
      ON, L8N 4A6, Canada.
FAU - Douketis, James D
AU  - Douketis JD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Evidence-Based Medicine
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Risk Assessment
MH  - Thromboembolism/*prevention & control
MH  - Treatment Outcome
MH  - Warfarin/adverse effects/*therapeutic use
RF  - 14
EDAT- 2009/11/17 06:00
MHDA- 2010/04/03 06:00
CRDT- 2009/11/17 06:00
PHST- 2009/11/17 06:00 [entrez]
PHST- 2009/11/17 06:00 [pubmed]
PHST- 2010/04/03 06:00 [medline]
AID - 10.1007/s11239-009-0413-4 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2010 Feb;29(2):208-13. doi: 10.1007/s11239-009-0413-4.

PMID- 8229615
OWN - NLM
STAT- MEDLINE
DCOM- 19931203
LR  - 20190920
IS  - 0300-5577 (Print)
IS  - 0300-5577 (Linking)
VI  - 21
IP  - 3
DP  - 1993
TI  - Low dose aspirin in pregnancy: a clinical and biochemical study of effects on the 
      newborn.
PG  - 235-40
AB  - Low dose Aspirin in pregnancy reduces the incidence of intra uterine growth 
      retardation (IUGR) and pregnancy induced hypertension (PIH) in women at risk for 
      these complications. To investigate if this drug, even in a low dose, could 
      expose the newborn to hemorrhagic complications, we studied ten neonates whose 
      mothers had been taking 50 mg/day of Aspirin from the 12th week of pregnancy 
      until delivery and compared them with eight newborns whose mothers didn't take 
      the drug. No hemorrhagic complications (emathemesis, ecchymoses or petechiae, 
      subconjunctival hemorrhage, cephaloematomas etc.) were observed in the fetuses 
      exposed to Aspirin or in the control group. No hemorrhagic lesions were found by 
      ultrasound brain scan on the fourth day of life. Newborns exposed to Aspirin 
      showed a significantly lower thromboxane concentration on the first day of life 
      (median 73 ng/ml versus 217 ng/ml); however on the fourth day the level of serum 
      thromboxane in the cases exposed reached the values of the unexposed ones (median 
      146 ng/ml versus 143 ng/ml). In conclusion low dose Aspirin in pregnancy can be 
      considered a safe drug without and adverse effect on the newborn.
FAU - Valcamonico, A
AU  - Valcamonico A
AD  - Obstetrics and Gynecology Department, University of Brescia, Italy.
FAU - Foschini, M
AU  - Foschini M
FAU - Soregaroli, M
AU  - Soregaroli M
FAU - Tarantini, M
AU  - Tarantini M
FAU - Frusca, T
AU  - Frusca T
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Birth Weight
MH  - Cerebral Hemorrhage/*chemically induced
MH  - Female
MH  - Fetal Blood/metabolism
MH  - Fetal Growth Retardation/prevention & control
MH  - Gestational Age
MH  - Humans
MH  - Hypertension/prevention & control
MH  - Infant, Newborn
MH  - *Maternal-Fetal Exchange
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/prevention & control
MH  - Reference Values
MH  - Thromboxane B2/blood
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1515/jpme.1993.21.3.235 [doi]
PST - ppublish
SO  - J Perinat Med. 1993;21(3):235-40. doi: 10.1515/jpme.1993.21.3.235.

PMID- 28965180
OWN - NLM
STAT- MEDLINE
DCOM- 20190304
LR  - 20190304
IS  - 1573-6822 (Electronic)
IS  - 0742-2091 (Linking)
VI  - 34
IP  - 3
DP  - 2018 Jun
TI  - Effects of aspirin and clopidogrel on neural stem cells.
PG  - 219-232
LID - 10.1007/s10565-017-9412-y [doi]
AB  - Cerebral infarction causes severe morbidity and mortality. Most patients with 
      cerebral infarction should take antiplatelet drugs daily, so the effects of those 
      drugs on the regeneration of the brain need to be investigated. Aspirin and 
      clopidogrel are the most widely used antiplatelet drugs for the prevention of 
      ischemic stroke. We investigated the effects of aspirin and clopidogrel on neural 
      stem cells (NSCs). NSCs were dissociated from fetal rat cortex and cultured with 
      basic fibroblast growth factor and N2 medium. To measure the effects of aspirin 
      and clopidogrel on NSCs, NSCs were treated with several concentrations of 
      aspirin, clopidogrel bisulfate, and clopidogrel resinate for 24 h. After the 
      treatment, we measured cell viability by cell counting kit-8, MTT 
      (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, trypan blue 
      staining, flow cytometry, and lactate dehydrogenase assay. To evaluate their 
      effects on NSC proliferation, we performed BrdU cell proliferation assay and 
      colony-forming unit assay. We compared the intracellular protein level in the 
      NSCs treated with aspirin and two types of clopidogrel, by proteomics analysis. 
      Various viability tests showed that clopidogrel resinate and clopidogrel 
      bisulfate did not affect the viability and proliferation of NSCs whereas aspirin 
      decreased them even at low concentrations which are clinically relevant. 
      Moreover, through the proteomics, it was confirmed that the toxicity of aspirin 
      to NSCs might be associated with the alteration of several intracellular 
      proteins. Taken together, these results suggest that clopidogrel resinate and 
      clopidogrel bisulfate are safe but aspirin could be toxic to NSCs. Therefore, 
      when these antiplatelet agents are prescribed over the long-term, the finding 
      that aspirin could be toxic to NSCs should be considered.
FAU - Hwang, Mina
AU  - Hwang M
AD  - Department of Neurology, Hanyang University College of Medicine, 153 
      Gyeongchun-ro, Guri-Si, Gyeonggi-do, Seoul, 11923, South Korea.
FAU - Park, Hyun-Hee
AU  - Park HH
AD  - Department of Neurology, Hanyang University College of Medicine, 153 
      Gyeongchun-ro, Guri-Si, Gyeonggi-do, Seoul, 11923, South Korea.
FAU - Choi, Hojin
AU  - Choi H
AD  - Department of Neurology, Hanyang University College of Medicine, 153 
      Gyeongchun-ro, Guri-Si, Gyeonggi-do, Seoul, 11923, South Korea.
FAU - Lee, Kyu-Yong
AU  - Lee KY
AD  - Department of Neurology, Hanyang University College of Medicine, 153 
      Gyeongchun-ro, Guri-Si, Gyeonggi-do, Seoul, 11923, South Korea.
FAU - Lee, Young Joo
AU  - Lee YJ
AD  - Department of Neurology, Hanyang University College of Medicine, 153 
      Gyeongchun-ro, Guri-Si, Gyeonggi-do, Seoul, 11923, South Korea.
FAU - Koh, Seong-Ho
AU  - Koh SH
AUID- ORCID: 0000-0001-5419-5761
AD  - Department of Neurology, Hanyang University College of Medicine, 153 
      Gyeongchun-ro, Guri-Si, Gyeonggi-do, Seoul, 11923, South Korea. 
      ksh213@hanyang.ac.kr.
AD  - Department of Translational Medicine, Hanyang University Graduate School of 
      Biomedical Science and Engineering, , Hanyang University, Seoul, South Korea. 
      ksh213@hanyang.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170930
PL  - Switzerland
TA  - Cell Biol Toxicol
JT  - Cell biology and toxicology
JID - 8506639
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Aspirin/*pharmacology
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Clopidogrel/*pharmacology
MH  - Electrophoresis, Gel, Two-Dimensional
MH  - Neural Stem Cells/cytology/drug effects/*metabolism
MH  - Rats
OTO - NOTNLM
OT  - Aspirin
OT  - Clopidogrel bisulfate
OT  - Clopidogrel resinate
OT  - Neural stem cells
OT  - Proliferation
OT  - Viability
EDAT- 2017/10/02 06:00
MHDA- 2019/03/05 06:00
CRDT- 2017/10/02 06:00
PHST- 2017/05/28 00:00 [received]
PHST- 2017/09/01 00:00 [accepted]
PHST- 2017/10/02 06:00 [pubmed]
PHST- 2019/03/05 06:00 [medline]
PHST- 2017/10/02 06:00 [entrez]
AID - 10.1007/s10565-017-9412-y [pii]
AID - 10.1007/s10565-017-9412-y [doi]
PST - ppublish
SO  - Cell Biol Toxicol. 2018 Jun;34(3):219-232. doi: 10.1007/s10565-017-9412-y. Epub 
      2017 Sep 30.

PMID- 12166347
OWN - NLM
STAT- MEDLINE
DCOM- 20030116
LR  - 20191210
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 30
IP  - 3
DP  - 2002 May-Jun
TI  - Gastrointestinal tolerability of ibuprofen compared with paracetamol and aspirin 
      at over-the-counter doses.
PG  - 301-8
AB  - This multicentre, randomized, investigator-blinded, parallel-group study compared 
      the gastrointestinal (GI) tolerability of ibuprofen, paracetamol and aspirin at 
      over-the-counter doses for common pain indications. Patients (of whom 8633 were 
      evaluable) took either ibuprofen up to 1200 mg daily, or paracetamol or aspirin, 
      each up to 3000 mg daily, for 1-7 days. The main outcome was the proportion of 
      patients with GI adverse events. There were significantly more patients who 
      suffered GI adverse events, principally abdominal pain, dyspepsia, nausea and 
      diarrhoea, with aspirin (18.5%) than with ibuprofen (11.5%), but the difference 
      between ibuprofen and paracetamol (13.1%) was not significant. Significantly more 
      of those patients with a history of non-ulcer GI disease (n = 371) developed GI 
      adverse events than did those with no such history; the incidence of GI adverse 
      events in both groups was lowest with ibuprofen. More women than men experienced 
      GI adverse events (15.5% versus 12.8%). The higher incidence of GI adverse events 
      with aspirin was evident from the first day of treatment. In conclusion, the GI 
      tolerability of ibuprofen, at over-the-counter doses of up to 1200 mg daily for 
      up to 7 days, was at least as good as that of paracetamol and significantly 
      better than that of aspirin.
FAU - Rampal, P
AU  - Rampal P
AD  - Gastrointestinal Unit, Hôpital de l'Archet, Nice, France. rampal.p@chu-nice.fr
FAU - Moore, N
AU  - Moore N
FAU - Van Ganse, E
AU  - Van Ganse E
FAU - Le Parc, J M
AU  - Le Parc JM
FAU - Wall, R
AU  - Wall R
FAU - Schneid, H
AU  - Schneid H
FAU - Verrière, F
AU  - Verrière F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Digestive System/*drug effects
MH  - Female
MH  - Humans
MH  - Ibuprofen/*adverse effects
MH  - Male
MH  - Outcome Assessment, Health Care
EDAT- 2002/08/09 10:00
MHDA- 2003/01/17 04:00
CRDT- 2002/08/09 10:00
PHST- 2002/08/09 10:00 [pubmed]
PHST- 2003/01/17 04:00 [medline]
PHST- 2002/08/09 10:00 [entrez]
AID - 10.1177/147323000203000311 [doi]
PST - ppublish
SO  - J Int Med Res. 2002 May-Jun;30(3):301-8. doi: 10.1177/147323000203000311.

PMID- 3964778
OWN - NLM
STAT- MEDLINE
DCOM- 19850114
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 88
IP  - 1 Pt 2
DP  - 1985 Jan
TI  - Effect of 16,16-dimethyl prostaglandin E2 on the surface hydrophobicity of 
      aspirin-treated canine gastric mucosa.
PG  - 308-14
AB  - The canine gastric mucosa has a uniquely hydrophobic or nonwettable surface that 
      is rapidly disrupted by damaging agents such as aspirin. In this study we 
      investigated the effects of acidified aspirin on the wettability of the luminal 
      surface of gastric mucosae mounted in Ussing chambers in the presence of varying 
      concentrations of 16,16-dimethyl prostaglandin E2. It was determined that surface 
      hydrophobicity of the stomach, as measured by contact angle measurements, could 
      be reduced by 50% with an aspirin concentration of 5 mM in the mucosal bath and 
      that this change could be completely and significantly reversed by the addition 
      of 16,16-dimethyl prostaglandin E2 (1 microgram/ml) to the nutrient compartment. 
      16,16-Dimethyl prostaglandin E2 at this dose was less effective in restoring the 
      surface hydrophobicity in response to a higher concentration of aspirin (20 mM) 
      that abolished the nonwettable property of the tissue. The reduced surface 
      hydrophobicity in the presence of 5 mM aspirin could be increased in a dose 
      response relationship to the nutrient 16,16-dimethyl prostaglandin E2 
      concentration, with an effect being seen at doses as low as 1 ng/ml. These 
      results support the concept that prostaglandins may protect the stomach by the 
      maintenance of a nonwettable hydrophobic lining between damaging agents in the 
      lumen and the gastric epithelium.
FAU - Lichtenberger, L M
AU  - Lichtenberger LM
FAU - Richards, J E
AU  - Richards JE
FAU - Hills, B A
AU  - Hills BA
LA  - eng
GR  - AM33239/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Prostaglandins E, Synthetic)
RN  - M790V82VAC (16,16-Dimethylprostaglandin E2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 16,16-Dimethylprostaglandin E2/*pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Dogs
MH  - Gastric Mucosa/*drug effects/physiology
MH  - In Vitro Techniques
MH  - Prostaglandins E, Synthetic/*pharmacology
MH  - Surface Tension
OID - NASA: 85052440
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - S0016508585000427 [pii]
AID - 10.1016/s0016-5085(85)80185-2 [doi]
PST - ppublish
SO  - Gastroenterology. 1985 Jan;88(1 Pt 2):308-14. doi: 10.1016/s0016-5085(85)80185-2.

PMID- 580491
OWN - NLM
STAT- MEDLINE
DCOM- 19780617
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 39
IP  - 1
DP  - 1978 Feb 28
TI  - Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141) on rabbit 
      platelet aggregation in vitro and rat platelet retention.
PG  - 167-76
AB  - Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141) on rabbit 
      platelet aggregation in vitro and rat platelet retention investigated. In the in 
      vitro study, KC-6141 inhibited ADP-induced aggregation by 27% at 5 X 10(-4)M, 
      being more active than dipyridamole but much less than adenosine. Inhibition of 
      arachidonic acid- and collagen-induced aggregation by KC-6141 was more effective 
      than that of ADP-induced one and its ED50 was 2.1 X 10(-5) and 8 X 10(-5)M, 
      respectively. KC-6141 was 10 and 4 times more potent than aspirin in arachiodonic 
      acid- and collagen-induced aggregation, respectively. The dose-response curve of 
      KC-6141 was parallel to that of aspirin, suggesting it is an aspirin-like 
      compound. In the platelet retenion study, a method for determining platelet 
      retintion in rats was devised so that platelet retention can be measured with a 
      volume of blood as small as possible. By use of the method, effects of KC-6141, 
      aspirin and dipyridamole were compared. When deministered intraperitoneally at 
      100 mg/kg, KC-6141 indicated 54.8% inhibition of platelet retention, whereas 
      aspirin and dipyridamole showed only 23.5 and 5.2% inhibition, respectively. On 
      the oral administration at 200 mg/kg KC-6141 inhibited by 60.8% and its ED50 was 
      125 mg/kg. The activity lasted over 32 hr. The above results demonstrated that 
      KC-6141 is a compound with more potent action on the platelet aggregation, as 
      well as on the platelet retention than aspirin and dipyridamole-a known 
      antithrombotic drug.
FAU - Umetsu, T
AU  - Umetsu T
FAU - Kato, T
AU  - Kato T
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Imidazoles)
RN  - 0 (Pyridines)
RN  - 64ALC7F90C (Dipyridamole)
RN  - K72T3FS567 (Adenosine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine/pharmacology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Dipyridamole/pharmacology
MH  - Glass
MH  - Imidazoles/*pharmacology
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Pyridines/*pharmacology
MH  - Rabbits
MH  - Rats
EDAT- 1978/02/28 00:00
MHDA- 1978/02/28 00:01
CRDT- 1978/02/28 00:00
PHST- 1978/02/28 00:00 [pubmed]
PHST- 1978/02/28 00:01 [medline]
PHST- 1978/02/28 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1978 Feb 28;39(1):167-76.

PMID- 2910545
OWN - NLM
STAT- MEDLINE
DCOM- 19890222
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 79
IP  - 1
DP  - 1989 Jan
TI  - In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 alpha in humans 
      in response to a standardized vascular injury and the influence of aspirin.
PG  - 29-38
AB  - The effects of smoking, aspirin ingestion, and sex differences on bleeding times 
      and bleeding time thromboxane B2 and 6-keto-prostaglandin (PG)F1 alpha production 
      were examined. Nonsmoking men produced more thromboxane B2 (3.99 +/- 0.76 ng/ml) 
      than nonsmoking women (2.13 +/- 0.24 ng/ml). Female smokers produced more 
      thromboxane B2 (5.01 +/- 0.97 ng/ml) than nonsmoking women. Twenty-four hours 
      after a single dose of 600 mg aspirin, in vitro production of thromboxane B2 in 
      response to collagen fell by 95%, whereas in vivo production of thromboxane B2 
      and 6-keto-PGF1 alpha in bleeding time blood fell by 87% and 66%, respectively. 
      Subjects with the lowest absolute levels of thromboxane B2 24 hours after aspirin 
      were also those with the longest postaspirin bleeding times. Recovery of 
      6-keto-PGF1 alpha production was faster than recovery of thromboxane B2 
      production, but 6-keto-PGF1 alpha production for most subjects was still below 
      basal 72 hours after aspirin. The influence of two different doses of long-term 
      aspirin (80 mg every other day and 325 mg daily) on the in vivo production of 
      thromboxane B2 and 6-keto-PGF1 alpha was studied in normals and diabetics. After 
      14 days of 80 mg aspirin every other day, thromboxane B2 and 6-keto-PGF1 alpha 
      production were both substantially inhibited (93% and 78%, respectively). After 
      14 days of 325 mg aspirin daily, thromboxane B2 production was similarly 
      substantially inhibited (93%), whereas 6-keto-PGF1 alpha was significantly less 
      affected (only 45% inhibition). Study of a second group of five normal subjects 
      confirmed that 6-keto-PGF1 alpha production was significantly inhibited 24 hours 
      after the first dose of 325 mg aspirin but was not significantly less than basal 
      after 14 days of 325 mg aspirin. The results suggest that 325 mg aspirin daily is 
      more antithrombotic compared with 80 mg every other day due to the superior 
      preservation of prostacyclin production.
FAU - Gerrard, J M
AU  - Gerrard JM
AD  - Department of Pediatrics, University of Manitoba, Winnipeg, Canada.
FAU - Taback, S
AU  - Taback S
FAU - Singhroy, S
AU  - Singhroy S
FAU - Docherty, J C
AU  - Docherty JC
FAU - Kostolansky, I
AU  - Kostolansky I
FAU - McNicol, A
AU  - McNicol A
FAU - Kobrinsky, N L
AU  - Kobrinsky NL
FAU - McKenzie, J K
AU  - McKenzie JK
FAU - Rowe, R
AU  - Rowe R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 1990 Jan;81(1):392-4. PMID: 2105171
MH  - 6-Ketoprostaglandin F1 alpha/biosynthesis/*blood
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Diabetes Mellitus/blood
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Sex Characteristics
MH  - Smoking
MH  - Thromboxane B2/biosynthesis/*blood
MH  - Time Factors
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1161/01.cir.79.1.29 [doi]
PST - ppublish
SO  - Circulation. 1989 Jan;79(1):29-38. doi: 10.1161/01.cir.79.1.29.

PMID- 36584699
OWN - NLM
STAT- MEDLINE
DCOM- 20230211
LR  - 20230211
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 123
IP  - 2
DP  - 2023 Feb
TI  - Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An 
      Emerging Option for Antiplatelet Therapy De-escalation.
PG  - 159-165
LID - 10.1055/s-0042-1755330 [doi]
AB  - Antiplatelet therapy is considered essential for secondary prevention of ischemic 
      heart disease. After percutaneous coronary intervention (PCI), temporary dual 
      antiplatelet therapy (DAPT), a combination consisting of aspirin and an oral 
      P2Y12 receptor blocker, is recommended. In the long term, this strategy results 
      in more bleeding than antiplatelet therapy with aspirin alone. Therefore, to 
      reduce bleeding, an increasing trend has been to keep DAPT as short as clinically 
      acceptable, after which aspirin monotherapy is continued. Another option to 
      diminish bleeding is to discontinue aspirin at the moment of DAPT cessation after 
      PCI, and to continue on P2Y12 blocker monotherapy. This survey reviews the 
      evidence on P2Y12 blocker monotherapy. Some clinical guidance will be provided on 
      when and in whom P2Y12 inhibitor monotherapy may be applied after DAPT cessation 
      following PCI.
CI  - Thieme. All rights reserved.
FAU - Verheugt, Freek W A
AU  - Verheugt FWA
AUID- ORCID: 0000-0002-5831-6951
AD  - Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The 
      Netherlands.
FAU - Huber, Kurt
AU  - Huber K
AD  - 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminen 
      Hospital, Vienna, Austria.
AD  - Medical Faculty, Sigmund Freud University, Vienna, Austria.
FAU - Clemmensen, Peter
AU  - Clemmensen P
AD  - Department of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, 
      Hamburg, Germany.
AD  - Department of Medicine, Nykøbing F Hospital, Nykøbing Falster, Denmark.
FAU - Collet, Jean-Philippe
AU  - Collet JP
AD  - Sorbonne Université, ACTION Group, INSERM UMRS 1166, HÔpital Pitié-Salpêtrière 
      (AP-HP), Institut de Cardiologie, Paris, France.
FAU - Cuisset, Thomas
AU  - Cuisset T
AD  - Department of Cardiology, La Timone Hospital, Marseille, France.
FAU - Andreotti, Felicita
AU  - Andreotti F
AD  - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. 
      Gemelli IRCCS, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20221230
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - 0 (P2RY12 protein, human)
SB  - IM
MH  - Humans
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Dual Anti-Platelet Therapy/methods
MH  - Hemorrhage/prevention & control
MH  - *Percutaneous Coronary Intervention/methods
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
MH  - Treatment Outcome
COIS- F.W.A.V. has received honoraria for consulting and presentations from 
      AstraZeneca, Bayer Healthcare, and Daiichi-Sankyo. K.H. has received honoraria 
      for consulting and lectures from AstraZeneca, Chiesi, Daiichi Sankyo, and 
      Sanofi-Aventis. P.C. has received lecture fees, performed consulting, or been 
      involved in research contracts outside the context of the present work: Abbott, 
      AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol 
      Myers Squibb, Daiichi Sankyo, Eli-Lilly, Evolva, Fiberx, Janssen, Merck, Myogen, 
      Medtronic, Mitsubishi Pharma, The Medicines Company, Nycomed, Organon, Pfizer, 
      Pharmacia, Regado, Sanofi, Searle, Servier, ViFor Pharma. J.-P.C. does not report 
      any conflict of interest. T.C. has received consulting and lectures fees from 
      Abbott, Boston Scientific, Edwards, and Medtronic. F.A. reports honoraria for 
      consulting or lectures from Amgen, AstraZeneca, Bayer, BMS/Pfizer, and Daiichi 
      Sankyo.
EDAT- 2022/12/31 06:00
MHDA- 2023/02/10 06:00
CRDT- 2022/12/30 19:02
PHST- 2022/12/31 06:00 [pubmed]
PHST- 2023/02/10 06:00 [medline]
PHST- 2022/12/30 19:02 [entrez]
AID - 10.1055/s-0042-1755330 [doi]
PST - ppublish
SO  - Thromb Haemost. 2023 Feb;123(2):159-165. doi: 10.1055/s-0042-1755330. Epub 2022 
      Dec 30.

PMID- 16892516
OWN - NLM
STAT- MEDLINE
DCOM- 20060829
LR  - 20190911
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 22
IP  - 7
DP  - 2006 Jul
TI  - The dose of aspirin for the prevention of cardiovascular and cerebrovascular 
      events.
PG  - 1239-48
AB  - BACKGROUND: Low dose aspirin (ASA) (75-325 mg daily) is commonly used for the 
      secondary prevention of cardiovascular and cerebrovascular events, as recommended 
      by US national guidelines. Questions remain, however, as to whether there is a 
      difference in the efficacy and safety across this low dose range. SCOPE: 
      Double-blind controlled studies, meta-analyses, and observational analyses were 
      reviewed to assess the body of evidence regarding the safety and efficacy of 
      aspirin dosing. FINDINGS: Only one double-blind study directly compared two doses 
      of aspirin within the recommended low dose range. No difference in efficacy or 
      safety was observed, although there was a trend toward greater efficacy with ASA 
      325 mg vs. ASA 81 mg. Three meta-analyses did not find a difference in bleeding 
      events within the low dose range, while one found that higher doses were 
      associated with more events. One meta-analysis found ASA 75-150 mg was as 
      effective as ASA 160-325 mg. Observational analyses of low dose (75-325 mg) ASA 
      from two large controlled trials differed in their results. One study found no 
      difference in the number of cardiovascular/cerebrovascular events, and a 
      significant improvement in mortality with higher doses, while the other found 
      that higher doses were associated with more events. CONCLUSION: There does not 
      appear to be a difference in safety across the low dose range of 75-325 mg based 
      on randomized controlled trial data. Furthermore, ASA 325 mg daily appears to be 
      at least as effective as 75 mg daily. Since the optimal dose of ASA for primary 
      and secondary prevention of events in the broad population is uncertain, dosing 
      considerations should include an evaluation of a patient's individual clinical 
      status as well as an overall cardiovascular and cerebrovascular benefit vs. risk 
      assessment.
FAU - Fisher, Matt
AU  - Fisher M
AD  - Medical Affairs, Bayer HealthCare, Morristown, NJ 07962, USA. 
      matt.fisher.b@bayer.com
FAU - Knappertz, Volker
AU  - Knappertz V
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Curr Med Res Opin. 2006 Sep;22(9):1669; author reply 1669-70. PMID: 17007102
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Double-Blind Method
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
RF  - 58
EDAT- 2006/08/09 09:00
MHDA- 2006/08/30 09:00
CRDT- 2006/08/09 09:00
PHST- 2006/08/09 09:00 [pubmed]
PHST- 2006/08/30 09:00 [medline]
PHST- 2006/08/09 09:00 [entrez]
AID - 10.1185/030079906x112624 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2006 Jul;22(7):1239-48. doi: 10.1185/030079906x112624.

PMID- 3825983
OWN - NLM
STAT- MEDLINE
DCOM- 19870409
LR  - 20180330
IS  - 0002-9165 (Print)
IS  - 0002-9165 (Linking)
VI  - 45
IP  - 3
DP  - 1987 Mar
TI  - Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the 
      treatment of obesity.
PG  - 564-9
AB  - Chronic administration of aspirin to obese mice had no effect on energy balance 
      and body composition. In contrast, ephedrine increased energy expenditure by 9% 
      and reduced body weight and body fat by 18% and 50%, respectively: obesity, 
      however, was reduced but not reversed. In the presence of both ephedrine and 
      aspirin, increase in energy expenditure found during treatment with ephedrine 
      alone was doubled, and the obese group lost greater than 75% of body fat: obesity 
      was reversed. These studies indicate that although aspirin administered alone has 
      no influence on energy balance it can markedly potentiate thermogenic properties 
      of ephedrine, effects which led to a normalization of body composition of the 
      obese to that of the lean. Such ephedrine-aspirin mixtures, often found in 
      over-the-counter preparations for asthma and bronchial disorders, could be put to 
      new use as aids for treatment of human obesity.
FAU - Dulloo, A G
AU  - Dulloo AG
FAU - Miller, D S
AU  - Miller DS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
RN  - GN83C131XS (Ephedrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adipose Tissue/drug effects
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Body Temperature Regulation/*drug effects
MH  - Drug Therapy, Combination
MH  - Energy Metabolism/drug effects
MH  - Ephedrine/*therapeutic use
MH  - Mice
MH  - Obesity/*drug therapy
MH  - Oxygen Consumption/drug effects
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 10.1093/ajcn/45.3.564 [doi]
PST - ppublish
SO  - Am J Clin Nutr. 1987 Mar;45(3):564-9. doi: 10.1093/ajcn/45.3.564.

PMID- 1082165
OWN - NLM
STAT- MEDLINE
DCOM- 19760324
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 105
IP  - 47
DP  - 1975 Nov 22
TI  - [Adhesion and aggregation in the subendothelium: hereditary platelet function 
      disorder].
PG  - 1587-9
AB  - Platelet adhesion to a thrombogenic surface and adhesion-induced aggregation were 
      investigated using a perfusion system at a blood flow rate similar to that 
      observed in arteries. Morphometric measurements revealed diminished adhesion of 
      platelets but normal surface-induced aggregation with blood of patients with von 
      Willebrand's disease and with Bernard-Soulier syndrome. In contrast, 
      surface-induced aggregation was defective with blood of patients with storage 
      pool disease, thrombasthenia and with blood of healthy volunteers after Aspirin 
      ingestion. These findings may explain the defective hemostasis in these patients. 
      They suggest that platelet adhesion and aggregation are governed by different 
      mechanisms.
FAU - Tschopp, T B
AU  - Tschopp TB
FAU - Weiss, H J
AU  - Weiss HJ
FAU - Baumgartner, H R
AU  - Baumgartner HR
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Adhäsion und Aggregation am Subendothel: hereditäre Plättchenfunktionsstörungen.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 1404-55-3 (Ristocetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aorta
MH  - Aspirin/pharmacology
MH  - Endothelium
MH  - Humans
MH  - *Platelet Adhesiveness
MH  - *Platelet Aggregation/drug effects
MH  - Ristocetin
MH  - von Willebrand Diseases/blood
EDAT- 1975/11/22 00:00
MHDA- 1975/11/22 00:01
CRDT- 1975/11/22 00:00
PHST- 1975/11/22 00:00 [pubmed]
PHST- 1975/11/22 00:01 [medline]
PHST- 1975/11/22 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1975 Nov 22;105(47):1587-9.

PMID- 12409970
OWN - NLM
STAT- MEDLINE
DCOM- 20030529
LR  - 20190822
IS  - 0263-6352 (Print)
IS  - 0263-6352 (Linking)
VI  - 20
IP  - 11
DP  - 2002 Nov
TI  - Benefit and harm of low-dose aspirin in well-treated hypertensives at different 
      baseline cardiovascular risk.
PG  - 2301-7
AB  - BACKGROUND: The effects of aspirin in subjects without cardiovascular disease are 
      controversial. In the intensively treated patients of the Hypertension Optimal 
      Treatment (HOT) Study, randomization to low-dose aspirin (75 mg daily) versus 
      placebo significantly reduced cardiovascular events (-15%) and myocardial 
      infarction (-36%), but increased major bleedings (+65%). The present analyses of 
      HOT Study data aim at identifying subgroups of hypertensives with different 
      benefit-to-harm ratios from aspirin, in order to provide recommendations about 
      the use of aspirin in hypertension. METHODS: The 18 790 hypertensive patients 
      (aspirin 9399, placebo 9391; average treatment duration 3.8 years) were 
      stratified for global cardiovascular risk and for individual risk factors. 
      Subgroup-treatment interaction analyses (end points: cardiovascular events, 
      myocardial infarction, major bleedings) were performed by a Cox proportional 
      hazard model. Relative and absolute benefits and harms were calculated. RESULTS: 
      Interaction analyses indicated that of all subgroups, only patients with serum 
      creatinine > 1.3 mg/dl had a significantly greater reduction of cardiovascular 
      events and myocardial infarction (-13 and -7/1000 patient-years), while risk of 
      bleeding was not significantly different between subgroups. In addition to 
      patients with higher creatinine, a favourable balance between benefit and harm of 
      aspirin was found in subgroups of patients at higher global baseline risk and 
      baseline systolic pressure > or = 180 or diastolic pressure > or = 107 mmHg. 
      CONCLUSIONS: Low-dose aspirin should be recommended to well-treated hypertensive 
      patients with even moderate increase in serum creatinine. Aspirin may also be 
      recommended in well-treated hypertensives at higher global cardiovascular risk or 
      higher initial blood pressures.
FAU - Zanchetti, Alberto
AU  - Zanchetti A
AD  - Centro di Fisiologia Clinica e Ipertensione, University of Milan, Ospedale 
      Maggiore and Istituto Auxologico Italiano, Milan, Italy. 
      zanchett@mailserver.unimi.it
FAU - Hansson, Lennart
AU  - Hansson L
FAU - Dahlöf, Björn
AU  - Dahlöf B
FAU - Julius, Stevo
AU  - Julius S
FAU - Ménard, Joël
AU  - Ménard J
FAU - Warnold, Ingrid
AU  - Warnold I
FAU - Wedel, Hans
AU  - Wedel H
CN  - HOT Study Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Blood Pressure/drug effects
MH  - Humans
MH  - Hypertension/*drug therapy/epidemiology
MH  - Myocardial Infarction/drug therapy/epidemiology
MH  - Risk Factors
EDAT- 2002/11/01 04:00
MHDA- 2003/05/30 05:00
CRDT- 2002/11/01 04:00
PHST- 2002/11/01 04:00 [pubmed]
PHST- 2003/05/30 05:00 [medline]
PHST- 2002/11/01 04:00 [entrez]
AID - 10.1097/00004872-200211000-00031 [doi]
PST - ppublish
SO  - J Hypertens. 2002 Nov;20(11):2301-7. doi: 10.1097/00004872-200211000-00031.

PMID- 14671879
OWN - NLM
STAT- MEDLINE
DCOM- 20040114
LR  - 20191026
IS  - 1462-3935 (Print)
IS  - 1462-3935 (Linking)
VI  - 64
IP  - 11
DP  - 2003 Nov
TI  - Management of stroke: acute, rehabilitation and long-term care.
PG  - 666-72
AB  - Stroke is the major cause of disability in adults, resulting in much morbidity 
      and mortality in the west. Each year 120,000 people will suffer their first 
      stroke with a further 40,000 suffering a recurrent stroke and 40,000 a transient 
      ischaemic attack. The prevalence rises from 2/1000 population to 2/100 in those 
      over 85 years of age. Consequently stroke is seen as a problem of the elderly.
FAU - Smithard, David G
AU  - Smithard DG
AD  - William Harvey Hospital and Richard Stevens Stroke Unit, East Kent Hospitals, 
      Ashford, Kent TN24 0LZ.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Hosp Med
JT  - Hospital medicine (London, England : 1998)
JID - 9803882
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/therapeutic use
MH  - Clinical Protocols
MH  - Fibrinolytic Agents/therapeutic use
MH  - Heparin/therapeutic use
MH  - Hospitalization
MH  - Humans
MH  - Long-Term Care/methods
MH  - Referral and Consultation
MH  - *Stroke Rehabilitation
RF  - 27
EDAT- 2003/12/16 05:00
MHDA- 2004/01/15 05:00
CRDT- 2003/12/16 05:00
PHST- 2003/12/16 05:00 [pubmed]
PHST- 2004/01/15 05:00 [medline]
PHST- 2003/12/16 05:00 [entrez]
AID - 10.12968/hosp.2003.64.11.2349 [doi]
PST - ppublish
SO  - Hosp Med. 2003 Nov;64(11):666-72. doi: 10.12968/hosp.2003.64.11.2349.

PMID- 7787493
OWN - NLM
STAT- MEDLINE
DCOM- 19950727
LR  - 20181113
IS  - 0008-350X (Print)
IS  - 1715-5258 (Electronic)
IS  - 0008-350X (Linking)
VI  - 41
DP  - 1995 Apr
TI  - Hypertension in pregnancy.
PG  - 626-32
AB  - Hypertension occurs in 7% to 10% of pregnancies. It is associated with increased 
      risk of maternal and fetal complications. Early diagnosis in the office by 
      careful attention to signs and symptoms could result in adequate management. 
      Delivery provides the only care for this disease process. Recently, low-dose 
      acetylsalicylic acid has been used in high-risk situations to prevent the 
      development of preeclampsia.
FAU - Williams, K
AU  - Williams K
AD  - Department of Obstetrics and Gynaecology, University of British Columbia, 
      Vancouver.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Canada
TA  - Can Fam Physician
JT  - Canadian family physician Medecin de famille canadien
JID - 0120300
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Hypertension/complications/diagnosis/therapy
MH  - Pregnancy
MH  - *Pregnancy Complications, Cardiovascular/diagnosis/therapy
MH  - Prenatal Care
PMC - PMC2146515
EDAT- 1995/04/01 00:00
MHDA- 1995/04/01 00:01
CRDT- 1995/04/01 00:00
PHST- 1995/04/01 00:00 [pubmed]
PHST- 1995/04/01 00:01 [medline]
PHST- 1995/04/01 00:00 [entrez]
PST - ppublish
SO  - Can Fam Physician. 1995 Apr;41:626-32.

PMID- 6121895
OWN - NLM
STAT- MEDLINE
DCOM- 19820614
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 34
IP  - 3
DP  - 1982 Mar
TI  - Gastrointestinal and hepatic first-pass metabolism of aspirin in rats.
PG  - 176-80
AB  - The first-pass effect of aspirin was measured in male Wistar rats by comparing 
      the plasma concentration after intravenous, oral or intraportal administration 
      (10 mg kg-1) of the drug. Approximately 88 and 86% of the dose was excreted 
      mostly as salicylic acid and its conjugated forms, glucuronide and sulphate, in 
      urine within 48 h of i.v. or oral administration, respectively. This suggests 
      that the gastrointestinal absorption of aspirin was essentially complete in rats. 
      On the average, the area under the plasma concentration-time curve for unchanged 
      aspirin following oral dosing (AUCo) was 0.35 of that obtained following i.v. 
      administration (AUCi.v.) and 0.53 of that following intraportal administration 
      (AUCp). Therefore, orally administered aspirin is subject to first-pass 
      metabolism both in the gut and in the liver of rats. The gastrointestinal 
      first-pass effect is estimated to be relatively more important than the hepatic 
      effect.
FAU - Iwamoto, K
AU  - Iwamoto K
FAU - Takei, M
AU  - Takei M
FAU - Watanabe, J
AU  - Watanabe J
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Sulfates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*metabolism
MH  - Digestive System/*metabolism
MH  - Feces/analysis
MH  - Injections, Intravenous
MH  - Kinetics
MH  - Liver/*metabolism
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Sulfates/metabolism
EDAT- 1982/03/01 00:00
MHDA- 1982/03/01 00:01
CRDT- 1982/03/01 00:00
PHST- 1982/03/01 00:00 [pubmed]
PHST- 1982/03/01 00:01 [medline]
PHST- 1982/03/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1982.tb04216.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1982 Mar;34(3):176-80. doi: 
      10.1111/j.2042-7158.1982.tb04216.x.

PMID- 30817601
OWN - NLM
STAT- MEDLINE
DCOM- 20190314
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 9
DP  - 2019 Mar
TI  - Cerebral microbleeds in patients with ischemic cerebrovascular disease taking 
      aspirin or clopidogrel.
PG  - e14685
LID - 10.1097/MD.0000000000014685 [doi]
LID - e14685
AB  - Cerebral microbleeds (CMBs) may be markers of intracerebral bleeding risk in 
      patients receiving antithrombotic drugs. This study aimed to analyze CMBs and 
      white matter hyperintensities (WMHs) in patients taking aspirin or 
      clopidogrel.This retrospective study included patients with ischemic 
      cardiovascular disease administered 75 mg/day aspirin (n = 150) or clopidogrel 
      (n = 150, matched for age and gender) for >1 year (Affiliated Hospital of Inner 
      Mongolia Medical University, China, from July, 2010 to July, 2015). Patients 
      underwent T2-weighted imaging, T1-weighted imaging, diffusion-weighted imaging 
      (DWI) and enhanced T2*-weighted angiography (ESWAN) imaging (3.0-Tesla scanner). 
      Baseline vascular risk factors for CMBs and macroscopic bleeding (MB) were 
      evaluated using univariate and multivariate analyses.The aspirin and clopidogrel 
      groups did not differ significantly in baseline characteristics or prevalences of 
      CMBs or MB. The odds of MB were higher in patients with CMBs than in patients 
      without CMBs in both the aspirin (odds ratio, 95% confidence interval: 4.09, 
      1.93-8.68; P < .001) and clopidogrel (6.42, 2.83-14.57; P < .001) groups. The 
      odds of WMHs were also higher in patients with CMBs in both the aspirin (3.28, 
      1.60-6.71; P = .001) and clopidogrel (4.09, 1.91-8.75; P < .001) groups. Patients 
      receiving treatment for >5 years showed elevated risk of CMBs in the aspirin 
      (0.17; 0.09-0.36; P < .001) and clopidogrel (0.15, 0.07-0.33; P < .001) groups as 
      well as higher odds of MB in the aspirin (0.34, 0.16-0.71; P = .004) and 
      clopidogrel (0.37, 0.17-0.80; P = .010) groups.The WMHs and MB were associated 
      with CMBs in patients taking aspirin or clopidogrel for >1 year, and long-term 
      use increased the risks of CMB and bleeding.
FAU - Ge, Lihong
AU  - Ge L
AD  - Department of Magnetic Resonance.
FAU - Ouyang, Xuehui
AU  - Ouyang X
AD  - Department of Magnetic Resonance, Inner Mongolia Autonomous Region People's 
      Hospital, Hohhot, China.
FAU - Ban, Chao
AU  - Ban C
AD  - Department of Magnetic Resonance.
FAU - Yu, Haixia
AU  - Yu H
AD  - Department of Magnetic Resonance.
FAU - Wu, Qiong
AU  - Wu Q
AD  - Department of Magnetic Resonance.
FAU - Wu, Hui
AU  - Wu H
AD  - Department of Magnetic Resonance.
FAU - Liang, Junguo
AU  - Liang J
AD  - Department of Thoracic Surgery, the Affiliated Hospital of Inner Mongolia Medical 
      University.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cerebral Hemorrhage/*chemically induced
MH  - China
MH  - Clopidogrel/*adverse effects/therapeutic use
MH  - Diffusion Magnetic Resonance Imaging
MH  - Female
MH  - Humans
MH  - Leukoencephalopathies/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*chemically induced
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
PMC - PMC6831427
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/03/01 06:00
MHDA- 2019/03/15 06:00
CRDT- 2019/03/01 06:00
PHST- 2019/03/01 06:00 [entrez]
PHST- 2019/03/01 06:00 [pubmed]
PHST- 2019/03/15 06:00 [medline]
AID - 00005792-201903010-00041 [pii]
AID - MD-D-18-04945 [pii]
AID - 10.1097/MD.0000000000014685 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Mar;98(9):e14685. doi: 10.1097/MD.0000000000014685.

PMID- 18328841
OWN - NLM
STAT- MEDLINE
DCOM- 20080403
LR  - 20131121
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 101
IP  - 6
DP  - 2008 Mar 15
TI  - Aspirin desensitization in patients undergoing percutaneous coronary 
      interventions with stent implantation.
PG  - 786-9
LID - 10.1016/j.amjcard.2007.10.045 [doi]
AB  - The aim of this study was to test the safety and efficacy of a novel rapid 
      desensitization procedure in patients with acetylsalicylic acid sensitivity and 
      coronary artery disease who underwent cardiac catheterization and coronary stent 
      implantation. Aspirin plays a key role in the secondary prevention of 
      atherothrombotic events and thrombotic complications after stent implantation. 
      Aspirin sensitivity not only limits patients to benefit from the long-term use of 
      this antiplatelet agent but is also often an impediment to the implantation of 
      bare-metal and drug-eluting coronary stents. Of 1,014 patients admitted for 
      cardiac catheterization, 26 (2.6%) had histories of aspirin sensitivity 
      characterized by respiratory or cutaneous manifestations (none had previous 
      anaphylactic reactions); of these, 61.5% presented with acute coronary syndromes. 
      All patients underwent a novel rapid desensitization challenge procedure before 
      cardiac catheterization, except for those presenting with ST-elevation myocardial 
      infarctions (n = 4), who underwent desensitization before hospital discharge. The 
      desensitization procedure involved the oral administration of 6 sequential doses 
      of aspirin (1, 5, 10, 20, 40, and 100 mg) over 5.5 hours without the use of 
      corticosteroids or antihistamines. Patients were followed for 1 year to assess 
      compliance with aspirin therapy and adverse events. The desensitization procedure 
      was successful in 23 patients (88.5%). Percutaneous coronary intervention with 
      stent implantation was performed in 22 patients (1.8 stents/patient). 
      Drug-eluting stents were used in all patients except those who underwent primary 
      percutaneous coronary intervention (n = 3), in whom bare-metal stents were used. 
      Multivessel percutaneous coronary intervention was performed in 30.7% of 
      patients. At follow-up, all patients who successfully responded to the 
      desensitization procedure tolerated aspirin well, without developing allergic 
      reactions. Aspirin was withdrawn in only 1 patient, because of a peptic ulcer. In 
      conclusion, rapid desensitization is safe and highly effective in patients with 
      aspirin sensitivity and coronary artery disease who undergo coronary stent 
      implantation, including those who receive drug-eluting stents.
FAU - Rossini, Roberta
AU  - Rossini R
AD  - Divisione di Cardiologia, Dipartimento Cardiovascolare, Ospedali Riuniti di 
      Bergamo, Bergamo, Italy. roberta_rossini@yahoo.it
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
FAU - Musumeci, Giuseppe
AU  - Musumeci G
FAU - Scuri, PierMario
AU  - Scuri P
FAU - Invernizzi, Paolo
AU  - Invernizzi P
FAU - Bass, Theodore A
AU  - Bass TA
FAU - Mihalcsik, Laurian
AU  - Mihalcsik L
FAU - Gavazzi, Antonello
AU  - Gavazzi A
LA  - eng
PT  - Journal Article
DEP - 20080221
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Coated Materials, Biocompatible)
RN  - 0 (Metals)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary/*instrumentation
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiac Catheterization
MH  - Coated Materials, Biocompatible
MH  - Coronary Disease/diagnosis/*therapy
MH  - Desensitization, Immunologic/*methods
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/*prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Male
MH  - Metals
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - *Stents
MH  - Treatment Outcome
EDAT- 2008/03/11 09:00
MHDA- 2008/04/04 09:00
CRDT- 2008/03/11 09:00
PHST- 2007/08/29 00:00 [received]
PHST- 2007/10/21 00:00 [revised]
PHST- 2007/10/21 00:00 [accepted]
PHST- 2008/03/11 09:00 [pubmed]
PHST- 2008/04/04 09:00 [medline]
PHST- 2008/03/11 09:00 [entrez]
AID - S0002-9149(07)02228-X [pii]
AID - 10.1016/j.amjcard.2007.10.045 [doi]
PST - ppublish
SO  - Am J Cardiol. 2008 Mar 15;101(6):786-9. doi: 10.1016/j.amjcard.2007.10.045. Epub 
      2008 Feb 21.

PMID- 22542153
OWN - NLM
STAT- MEDLINE
DCOM- 20130320
LR  - 20181201
IS  - 1532-1916 (Electronic)
IS  - 1521-6918 (Linking)
VI  - 26
IP  - 2
DP  - 2012 Apr
TI  - Prevention of damage induced by aspirin in the GI tract.
PG  - 153-62
LID - 10.1016/j.bpg.2012.01.005 [doi]
AB  - Low-dose aspirin (325 mg or less) alone and in combination with other 
      antiplatelet agents is widely used for the management of cardiovascular disease. 
      Although the risk with low-dose aspirin alone is less than Nonsteroidal 
      anti-inflammatory drugs (NSAIDs), given widespread use, aspirin related toxicity 
      has become a substantial health care problem due to acute and chronic GI 
      bleeding. A variety of strategies are currently available to minimize the risk of 
      developing upper GI side effects of aspirin. Agents that have efficacy include 
      oral prostaglandin analogues, H2 receptor antagonists and proton pump inhibitors. 
      PPIs appear to be the most effective strategy, with the least side effects and 
      the convenience of once daily dosing. The substitution of another antiplatelet 
      agent such as clopidogrel for aspirin alone does not appear to provide a safer 
      alternative to low-dose aspirin for patients at GI risk. Small bowel injury can 
      occur with aspirin and can be assessed with capsule endoscopy; however, no 
      strategy is known to reduce this potential toxicity in clinical practice.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Scheiman, James M
AU  - Scheiman JM
AD  - Division of Gastroenterology, Department of Internal Medicine, University of 
      Michigan Medical Center, Ann Arbor, MI, USA. jscheima@umich.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Gastroenterol
JT  - Best practice & research. Clinical gastroenterology
JID - 101120605
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/chemically induced/drug therapy
MH  - Drug Substitution
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Histamine H2 Antagonists/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Proton Pump Inhibitors/therapeutic use
EDAT- 2012/05/01 06:00
MHDA- 2013/03/21 06:00
CRDT- 2012/05/01 06:00
PHST- 2011/08/15 00:00 [received]
PHST- 2012/01/08 00:00 [accepted]
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
AID - S1521-6918(12)00006-6 [pii]
AID - 10.1016/j.bpg.2012.01.005 [doi]
PST - ppublish
SO  - Best Pract Res Clin Gastroenterol. 2012 Apr;26(2):153-62. doi: 
      10.1016/j.bpg.2012.01.005.

PMID- 9640079
OWN - NLM
STAT- MEDLINE
DCOM- 19980728
LR  - 20170306
VI  - 98
IP  - 12
DP  - 1997 Dec
TI  - [Evaluation of platelet function and tissue plasminogen activator activity in 
      ischemic heart disease depending on concurrence with hyperlipoproteinemia and 
      aspirin therapy].
PG  - 510-9
AB  - Platelet activation, impairment of fibrinolysis and dyslipidemia are important 
      factors in the pathogenesis and progression of ischemic heart disease. Aspirin 
      therapy will reduce platelet activation both by its negative effect on platelet 
      aggregation (SPA) and by inhibition of granule release which liberates such 
      mediators as platelet factor 4 (PF4) and plasminogen activator inhibitor 1 
      (PAI-1). The present study was performed in 57 patients with ischemic heart 
      disease (IHD), divided into groups depending on coexistent hyperlipoproteinemia 
      (HLP) and aspirin treatment. The control group included 21 healthy individuals, 
      matched for age and sex. Parameters of hemostasis (SPA, PF4, PAI-1) and 
      concentration of lipid fractions (TC, TG, LDL, HDL) were measured in plasma. 
      Increased PF4 levels were found in all groups with IHD, irrespective of 
      hyperlipoproteinemia or aspirin treatment. Enhanced SPA and higher PAI-1 were 
      limited to group IHD-HLP without aspirin. Highest PAI-1 activities were observed 
      after stimulation of platelets in vitro. In conclusion, patients with IHD and 
      hyperlipoproteinemia presented most pronounced platelet activation and impairment 
      of fibrinolysis. Aspirin had a beneficial effect on these changes. Lower 
      activities of PAI-1, in patients treated with aspirin, can be ascribed to its 
      reduced release from platelets. Aspirin did not satisfactorily reduce the level 
      of PF4, although it strongly inhibited SPA.
FAU - Jastrzebska, M
AU  - Jastrzebska M
AD  - Zakład Biochemii Klinicznej i Diagnostyki Laboratoryjnej Pomorskiej Akademii 
      Medycznej, Szczecinie.
FAU - Torbus-Lisiecka, B
AU  - Torbus-Lisiecka B
FAU - Pieczul-Mróz, J
AU  - Pieczul-Mróz J
FAU - Chełstowski, K
AU  - Chełstowski K
LA  - pol
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Ocena funkcji płytek krwi i aktywności inhibitora aktywatora plazminogenu w 
      chorobie niedokrwiennej serca w zalezności od współistniejacej 
      hiperlipoproteinemii i leczenia aspiryna.
PL  - Poland
TA  - Pol Arch Med Wewn
JT  - Polskie Archiwum Medycyny Wewnetrznej
JID - 0401225
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 37270-94-3 (Platelet Factor 4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Fibrinolysis
MH  - Humans
MH  - Hyperlipoproteinemias/*complications/drug therapy/metabolism
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/complications/drug therapy/*metabolism
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Factor 4/analysis/drug effects
EDAT- 1998/06/26 00:00
MHDA- 1998/06/26 00:01
CRDT- 1998/06/26 00:00
PHST- 1998/06/26 00:00 [pubmed]
PHST- 1998/06/26 00:01 [medline]
PHST- 1998/06/26 00:00 [entrez]
PST - ppublish
SO  - Pol Arch Med Wewn. 1997 Dec;98(12):510-9.

PMID- 7313943
OWN - NLM
STAT- MEDLINE
DCOM- 19820212
LR  - 20161123
IS  - 0039-6060 (Print)
IS  - 0039-6060 (Linking)
VI  - 90
IP  - 6
DP  - 1981 Dec
TI  - Aspirin failure in symptomatic atherosclerotic carotid artery disease.
PG  - 1084-92
AB  - Over a 26-month period 27 urgent carotid endarterectomies were performed on 
      patients who had been taking antiplatelet aggregating drugs for 6 months to 2 
      years. Angiography confirmed an original diagnosis of symptomatic extracranial 
      carotid artery stenosis and ulceration in all patients. Nineteen had been started 
      on dosages of aspirin from 325 to 1,300 mg/day, and eight started on aspirin plus 
      persantine. Compliance to aspirin use appeared high. All had partial or total 
      resolution of the ischemic symptoms after aspirin therapy was instituted. On 
      readmission three patients had early stroke in evolution, and 24 had crescendo 
      transient ischemic attacks. Reevaluation included cerebral angiography which 
      confirmed progression of carotid artery disease to 90% or greater stenosis in 
      each instance. All patients underwent successful carotid endarterectomies. A 
      review of history of these 27 in the urgent group as opposed to the 45 
      symptomatic carotid patients who were electively operated on in the same time 
      period revealed no significant (P greater than 0.10) differences in incidence of 
      risk factors for atherosclerosis. However, none of the elective group had 
      regularly taken aspirin. It would appear that aspirin decreased ischemic symptoms 
      in the patients who underwent urgent operation by its antithromboxane effect, 
      inhibiting platelet aggregation and embolization. However, aspirin appeared to 
      have a deleterious effect on these patients by allowing their carotid disease to 
      progress to a dangerous state by eliminating the symptoms of progressive carotid 
      artery atherosclerosis or by accentuating the process of atherosclerosis possibly 
      by inhibition of arterial prostacyclin.
FAU - Carson, S N
AU  - Carson SN
FAU - Demling, R H
AU  - Demling RH
FAU - Esquivel, C O
AU  - Esquivel CO
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
RN  - 0 (Prostaglandin Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Carotid Artery Diseases/diagnostic imaging/*drug therapy/surgery
MH  - Emergencies
MH  - Endarterectomy
MH  - Humans
MH  - Intracranial Arteriosclerosis/diagnostic imaging/*drug therapy/surgery
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandin Antagonists
MH  - Radiography
EDAT- 1981/12/01 00:00
MHDA- 1981/12/01 00:01
CRDT- 1981/12/01 00:00
PHST- 1981/12/01 00:00 [pubmed]
PHST- 1981/12/01 00:01 [medline]
PHST- 1981/12/01 00:00 [entrez]
AID - 0039-6060(81)90405-0 [pii]
PST - ppublish
SO  - Surgery. 1981 Dec;90(6):1084-92.

PMID- 26108775
OWN - NLM
STAT- MEDLINE
DCOM- 20151215
LR  - 20190318
IS  - 1671-0274 (Print)
IS  - 1671-0274 (Linking)
VI  - 18
IP  - 6
DP  - 2015 Jun
TI  - [Association of long-term oral low-dose aspirin and survival in colorectal 
      cancer: a meta-analysis].
PG  - 589-92
AB  - OBJECTIVE: To examine the association between long-term oral low-dose aspirin and 
      overall survival in colorectal cancer patients after diagnosis. METHODS: The 
      literature databases, such as PubMed, Embase, Cochrane Library, Web of Science, 
      CBM, CNKI, and Wanfang database, were extensively searched to retrieve the 
      comparative studies about the association between low-dose aspirin use after 
      colorectal cancer diagnosis and overall survival published before June 2014. The 
      state 12.0 version software was used for meta-analysis. The quality of these 
      studies was assessed using the Newcastle-Ottawa scale. RESULTS: There were eight 
      studies meeting the inclusion criteria for meta-analysis. The total sample size 
      of these studies included 28 103 cases and the score of all the studies was more 
      than 6 points. Meta-analysis of the data using I(2) test showed significant 
      heterogeneity (I(2)=78.2%, P<0.01), therefore, a random effect model was 
      performed. Aspirin use after diagnosis was associated with longer overall 
      survival (HR=0.732, 95% CI:0.613-0.875, P<0.01). There were seven studies with 
      the same design or tumor stage in I-IIII period respectively for sensitivity 
      analysis. The results of studies showed that the sensitivity was low and accurate 
      (HR=0.687, 95% CI: 0.557-0.849, P<0.01; HR=0.682, 95% CI: 0.539-0.864, P<0.01). 
      CONCLUSION: Meta-analysis shows that long-term oral low-dose aspirin after 
      diagnosis of colorectal cancer is identified as a significant prognostic factor.
FAU - Ye, Hua
AU  - Ye H
AD  - Department of Gastrointestinal Surgery, Ningbo No.2 Hospital, Ningbo 315010, 
      China. nbchp@126.com.
FAU - Chen, Ping
AU  - Chen P
FAU - Dai, Wenyu
AU  - Dai W
FAU - Zheng, Qi
AU  - Zheng Q
FAU - Wu, Feng
AU  - Wu F
LA  - chi
PT  - Journal Article
PT  - Meta-Analysis
PL  - China
TA  - Zhonghua Wei Chang Wai Ke Za Zhi
JT  - Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
JID - 101177990
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - *Colorectal Neoplasms
MH  - Humans
EDAT- 2015/06/26 06:00
MHDA- 2015/12/17 06:00
CRDT- 2015/06/26 06:00
PHST- 2015/06/26 06:00 [entrez]
PHST- 2015/06/26 06:00 [pubmed]
PHST- 2015/12/17 06:00 [medline]
AID - 100001882012 [pii]
PST - ppublish
SO  - Zhonghua Wei Chang Wai Ke Za Zhi. 2015 Jun;18(6):589-92.

PMID- 7594043
OWN - NLM
STAT- MEDLINE
DCOM- 19951205
LR  - 20131121
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 26
IP  - 5
DP  - 1995 Nov 1
TI  - Immunosuppressive therapy prevents recurrent pericarditis.
PG  - 1276-9
AB  - OBJECTIVES: This study reviews the clinical outcome of a series of patients with 
      recurrent pericarditis before and after immunosuppressive therapy. BACKGROUND: 
      Despite anti-inflammatory treatment, some patients with acute pericarditis 
      experience repeated relapses of the disease. The use of steroids for the 
      treatment of recurrent pericarditis remains controversial. METHODS: Twelve 
      patients (4 women, 8 men; mean [+/- SD] age 35.9 +/- 17.2 years, range 15 to 65) 
      with recurrent pericarditis unrelated to any systemic disease were selected. All 
      12 patients previously received ineffective short-term courses of low dose 
      steroids and had a total of 39 relapses during a mean follow-up period of 14.2 
      months (range 4 to 50). A 3-month course of treatment with prednisone, at an 
      immunosuppressive dosage, was started (1 to 1.5 mg/kg body weight per day for 4 
      weeks, then gradually withdrawn). When prednisone reduction was undertaken, all 
      patients started a 5-month course of treatment with aspirin (1.6 g/day until 
      steroid suspension, then reduced to 0.8 g/day). RESULTS: During a mean follow-up 
      period of 41.6 months (range 7 to 104), immunosuppressive treatment with high 
      dose prednisone resulted in stable remission in all except one patient, who 
      experienced one relapse. In this patient, the addition of azathioprine to 
      prednisone induced a persistent remission, which remained after 1-year follow-up. 
      During treatment, three patients had severe steroid-related adverse effects that 
      in two patients required replacement of prednisone with azathioprine and 
      cyclophosphamide, respectively. This variation in the immunosuppressive regimen 
      did not modify the favorable clinical outcome. CONCLUSIONS: The dose and duration 
      of steroid treatment are critical factors in preventing recurrent pericarditis. 
      High dose prednisone with aspirin should be considered in the treatment of 
      recurrent pericarditis resistant to anti-inflammatory therapy. Cyclophosphamide 
      or azathioprine should be reserved for patients who do not respond to high dose 
      prednisone or who experience severe complications related to steroid therapy.
FAU - Marcolongo, R
AU  - Marcolongo R
AD  - Department of Clinical Medicine, Padua University School of Medicine, Italy.
FAU - Russo, R
AU  - Russo R
FAU - Laveder, F
AU  - Laveder F
FAU - Noventa, F
AU  - Noventa F
FAU - Agostini, C
AU  - Agostini C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Immunosuppressive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pericarditis/*prevention & control
MH  - Recurrence
MH  - Retrospective Studies
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 0735-1097(95)00302-9 [pii]
AID - 10.1016/0735-1097(95)00302-9 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1995 Nov 1;26(5):1276-9. doi: 10.1016/0735-1097(95)00302-9.

PMID- 11972262
OWN - NLM
STAT- MEDLINE
DCOM- 20020606
LR  - 20181130
IS  - 0890-5096 (Print)
IS  - 0890-5096 (Linking)
VI  - 16
IP  - 2
DP  - 2002 Mar
TI  - The role of platelets in peripheral arterial disease: therapeutic implications.
PG  - 246-58
AB  - Peripheral arterial disease (PAD) is associated with platelet hyperaggregability 
      as well as an increase in morbidity and mortality from myocardial infarction and 
      stroke. Enhanced platelet activation in PAD may substantially contribute to these 
      adverse outcomes. A relative resistance to aspirin therapy has been reported in 
      patients with PAD. Therefore, clopidogrel may be superior to aspirin in treatment 
      of PAD. Furthermore, the aspirin + clopidogrel combination could be more 
      effective than monotherapy but its risk-benefit ratio has yet to be evaluated. 
      Clopidogrel is preferable to ticlopidine because of its safer profile and the 
      convenience of once-daily administration. The glycoprotein (Gp) IIb/IIIa 
      inhibitors may also find a place as short-term therapy after peripheral 
      angioplasty. There is a need to consider the use of clopidogrel in patients who 
      cannot tolerate aspirin. Patients who have an event while taking aspirin also 
      present a problem. One possibility here is to substitute aspirin with clopidogrel 
      or to add clopidogrel to the aspirin. Although these options are currently not 
      evidence based in patients with PAD, there is emerging evidence showing that they 
      are realistic choices.
FAU - Matsagas, M I
AU  - Matsagas MI
AD  - Department of Clinical Biochemistry, Royal Free and University College Medical 
      School, University of London, London, UK.
FAU - Geroulakos, G
AU  - Geroulakos G
FAU - Mikhailidis, D P
AU  - Mikhailidis DP
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20020315
PL  - Netherlands
TA  - Ann Vasc Surg
JT  - Annals of vascular surgery
JID - 8703941
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Clopidogrel
MH  - Dipyridamole/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Peripheral Vascular Diseases/*drug therapy/physiopathology
MH  - Platelet Activation/drug effects/*physiology
MH  - Platelet Aggregation/drug effects/*physiology
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Ticlopidine/analogs & derivatives/pharmacology/*therapeutic use
RF  - 188
EDAT- 2002/04/25 10:00
MHDA- 2002/06/12 10:01
CRDT- 2002/04/25 10:00
PHST- 2002/04/25 10:00 [pubmed]
PHST- 2002/06/12 10:01 [medline]
PHST- 2002/04/25 10:00 [entrez]
AID - S0890-5096(07)60161-7 [pii]
AID - 10.1007/s10016-001-0159-8 [doi]
PST - ppublish
SO  - Ann Vasc Surg. 2002 Mar;16(2):246-58. doi: 10.1007/s10016-001-0159-8. Epub 2002 
      Mar 15.

PMID- 6339916
OWN - NLM
STAT- MEDLINE
DCOM- 19830505
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 308
IP  - 14
DP  - 1983 Apr 7
TI  - Differential inhibition by aspirin of vascular and platelet prostaglandin 
      synthesis in atherosclerotic patients.
PG  - 800-5
AB  - We studied the ability of a single oral dose of aspirin to inhibit prostacyclin 
      synthesis by human arterial and venous tissue and to inhibit thromboxane A2 
      synthesis by platelets in 70 patients who were undergoing aortocoronary bypass. A 
      dose of 40, 80, or 325 mg of aspirin was administered 12 to 16 hours before 
      surgery. The generation of thromboxane in serum--which provides an estimate of 
      platelet thromboxane production--was reduced from the control value by 77, 95, 
      and 99 per cent after single doses of 40, 80, and 325 mg of aspirin, 
      respectively. By contrast, prostacyclin production in aortic tissue that was 
      removed at operation was reduced by only 35, 38, and 75 per cent, respectively, 
      in response to these doses. Production of prostacyclin in saphenous-vein tissue 
      (not tested after 40 mg of aspirin) fell only slightly and not significantly 
      after 80 mg but was reduced by 85 per cent after 325 mg. These findings indicate 
      that a low dose of aspirin (40 to 80 mg) can largely inhibit platelet aggregation 
      and thromboxane synthesis but has much less effect on prostacyclin production in 
      arterial and venous endothelium.
FAU - Weksler, B B
AU  - Weksler BB
FAU - Pett, S B
AU  - Pett SB
FAU - Alonso, D
AU  - Alonso D
FAU - Richter, R C
AU  - Richter RC
FAU - Stelzer, P
AU  - Stelzer P
FAU - Subramanian, V
AU  - Subramanian V
FAU - Tack-Goldman, K
AU  - Tack-Goldman K
FAU - Gay, W A Jr
AU  - Gay WA Jr
LA  - eng
GR  - HL 18828/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Prostaglandins)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Arteries/metabolism
MH  - Arteriosclerosis/*metabolism
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/drug effects/*metabolism
MH  - Blood Vessels/drug effects/*metabolism
MH  - Culture Techniques
MH  - Epoprostenol/biosynthesis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandins/*biosynthesis
MH  - Thromboxane A2/biosynthesis
MH  - Veins/metabolism
EDAT- 1983/04/07 00:00
MHDA- 2001/03/28 10:01
CRDT- 1983/04/07 00:00
PHST- 1983/04/07 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1983/04/07 00:00 [entrez]
AID - 10.1056/NEJM198304073081402 [doi]
PST - ppublish
SO  - N Engl J Med. 1983 Apr 7;308(14):800-5. doi: 10.1056/NEJM198304073081402.

PMID- 7277181
OWN - NLM
STAT- MEDLINE
DCOM- 19811122
LR  - 20190913
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 3
IP  - 12
DP  - 1980 Dec
TI  - Interaction of indomethacin and aspirin or mepirizole in rats as shown by 
      gastrointestinal ulcerogenic and anti-inflammatory activities.
PG  - 659-66
AB  - The interaction of indomethacin and aspirin or mepirizole was studied in rats. 
      Concomitant oral administration of aspirin and indomethacin had no significant 
      influence on the gastro-ulcerogenicity of indomethacin alone, but caused 
      significantly less intestinal damage than an identical dose of indomethacin 
      alone. In proportion to the inhibitory activity of intestinal lesions, aspirin 
      also showed the activity that antagonized significantly the shortening of small 
      intestinal length, loss of body weight and delay of charcoal transport in the 
      intestine induced by indomethacin alone. Aspirin tended to reduce also the 
      anti-inflammatory and analgesic effects of indomethacin in combined 
      administration. On the other hand, mepirizole significantly reduced both gastric 
      and intestinal ulcerogenicities by indomethacin alone in concomitant oral 
      administration and inhibited dose-dependently the incidence and severity of those 
      lesions. The inhibitory activity of gastrointestinal lesions by mepirizole was in 
      proportion to the activities that antagonized the shortening of the small 
      intestine, loss of body weight and delay of charcoal transport by indomethacin. 
      Moreover, in contrast to aspirin, mepirizole exerted more potent 
      anti-inflammatory and analgesic effects in combined administration than in the 
      single administration of indomethacin. Therefore, aspirin reduced both the 
      intestinal side effect and the anti-inflammatory effect induced by indomethacin 
      in combination, while the combination of mepirizole reduced the gastrointestinal 
      side effects by indomethacin alone, but seemed to be additive in the 
      anti-inflammatory effect.
FAU - Tsurumi, K
AU  - Tsurumi K
FAU - Kyuki, K
AU  - Kyuki K
FAU - Fujimura, H
AU  - Fujimura H
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Pyrazoles)
RN  - 16291-96-6 (Charcoal)
RN  - 3B46O2FH8I (Epirizole)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Biological Transport/drug effects
MH  - Charcoal/metabolism
MH  - Drug Interactions
MH  - Edema/drug therapy
MH  - Epirizole/*administration & dosage
MH  - Indomethacin/*administration & dosage/adverse effects
MH  - Intestinal Diseases/*chemically induced
MH  - Male
MH  - Pain/drug therapy
MH  - Pyrazoles/*administration & dosage
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach Ulcer/*chemically induced
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
AID - 10.1248/bpb1978.3.659 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1980 Dec;3(12):659-66. doi: 10.1248/bpb1978.3.659.

PMID- 17277998
OWN - NLM
STAT- MEDLINE
DCOM- 20071105
LR  - 20220716
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 24
IP  - 1
DP  - 2007 Aug
TI  - Response to aspirin and clopidogrel in patients scheduled to undergo 
      cardiovascular surgery.
PG  - 15-21
AB  - BACKGROUND: Recent data indicate that among patients undergoing percutaneous 
      coronary intervention low platelet response to aspirin is associated with 
      clopidogrel low response. It is unclear whether these findings extend to other 
      patient populations. We, therefore, aimed to evaluate the relation between 
      response to aspirin and clopidogrel among patients scheduled to undergo cardiac 
      or vascular surgery. METHODS: Patients who were scheduled for cardiac or vascular 
      surgery and had taken aspirin 81-325 mg daily for at least a week and clopidogrel 
      75 mg daily for at least 3 days underwent blood testing for platelet function. 
      One hundred patients were included in the current analysis. Platelet function was 
      evaluated by the modified TEG platelet mapping assay with addition of ADP or 
      arachidonic acid (AA), and by the PFA-100 assay with collagen-epinephrine (CEPI) 
      or collagen-ADP (CADP) cartridges. Low response to aspirin or clopidogrel was 
      defined as inhibition < or =20% for TEG-AA or TEG-ADP, respectively. RESULTS: 
      Thirteen patients (13%) were low responders to aspirin and 34 (34%) were low 
      responders to clopidogrel. Eight patients were low responders to both drugs. 
      There were no differences in clinical characteristics between drug low responders 
      versus sensitive patients. Aspirin low responders had lower TEG-ADP inhibition 
      (19.5 +/- 6 vs. 35.8 +/- 3%, P = 0.03) and tended to have lower PFA-CADP time 
      (84.7 +/- 7 vs. 105.6 +/- 5 s, P = 0.1) than aspirin sensitive patients. 
      Clopidogrel low responders had lower TEG-AA inhibition (58 +/- 6 vs. 75.1 +/- 4%, 
      P = 0.01) and PFA-CEPI time (168 +/- 13 vs. 200.4 +/- 10 s, P = 0.07) than 
      clopidogrel sensitive patients. CONCLUSIONS: In patients scheduled to undergo 
      cardiovascular surgery low response to aspirin is associated with low response to 
      clopidogrel.
FAU - Lev, Eli I
AU  - Lev EI
AD  - Department of Cardiology, The Methodist Hospital Research Institute, The 
      Methodist DeBakey Heart Center, Houston, TX 77030, USA.
FAU - Ramchandani, Mahesh
AU  - Ramchandani M
FAU - Garg, Rajeev
AU  - Garg R
FAU - Wojciechowski, Zbigniew
AU  - Wojciechowski Z
FAU - Builes, Angela
AU  - Builes A
FAU - Vaduganathan, Muthiah
AU  - Vaduganathan M
FAU - Tripathy, Uttam
AU  - Tripathy U
FAU - Kleiman, Neal S
AU  - Kleiman NS
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20070203
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/blood/*therapeutic use
MH  - Cardiovascular Diseases/*surgery
MH  - Clopidogrel
MH  - Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/blood/*therapeutic use
MH  - Platelet Count
MH  - Preoperative Care
MH  - Ticlopidine/*analogs & derivatives/blood/therapeutic use
MH  - Treatment Outcome
EDAT- 2007/02/06 09:00
MHDA- 2007/11/06 09:00
CRDT- 2007/02/06 09:00
PHST- 2006/09/29 00:00 [received]
PHST- 2007/01/04 00:00 [accepted]
PHST- 2007/02/06 09:00 [pubmed]
PHST- 2007/11/06 09:00 [medline]
PHST- 2007/02/06 09:00 [entrez]
AID - 10.1007/s11239-007-0008-x [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2007 Aug;24(1):15-21. doi: 10.1007/s11239-007-0008-x. Epub 
      2007 Feb 3.

PMID- 359247
OWN - NLM
STAT- MEDLINE
DCOM- 19781220
LR  - 20190907
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 5
IP  - 7
DP  - 1978
TI  - A double-blind comparison of diflunisal and aspirin in the treatment of 
      post-operative pain after episiotomy.
PG  - 544-7
AB  - A double-blind randomized trial was carried out in 161 primiparous women 
      suffering from moderate to severe post-episiotomy pain to compare the analgesic 
      efficacy of single doses of diflunisal (125 mg, 250 mg, of 500 mg), aspirin (600 
      mg), and placebo. The results of pain rating assessments made before and at 
      hourly intervals after drug administration showed that both the active drugs were 
      more effective than placebo and produced similar pain relief over the first 4 
      hours. The analgesic efficacy of aspirin tailed off after 4 hours but pain relief 
      with 500 mg diflunisal was still evident after 8 hours. Over 65% of patients in 
      the diflunisal group had effective relief of pain at 8 hours whereas there was no 
      significant difference between the aspirin and placebo-treated groups by the 
      seventh and eighth hour.
FAU - De Vroey, P
AU  - De Vroey P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Analgesics)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analgesics/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Biphenyl Compounds/*therapeutic use
MH  - Clinical Trials as Topic
MH  - *Episiotomy
MH  - Female
MH  - Humans
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
MH  - Pregnancy
MH  - Time Factors
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1185/03007997809108998 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1978;5(7):544-7. doi: 10.1185/03007997809108998.

PMID- 8757361
OWN - NLM
STAT- MEDLINE
DCOM- 19960919
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 101
IP  - 2
DP  - 1996 Aug
TI  - Antiplatelet therapy.
PG  - 199-209
AB  - The major clinical indication for antiplatelet therapy has been the prevention of 
      arterial thrombosis. Arterial thrombi are composed of predominantly platelets 
      formed under conditions of elevated shear stress at sites of atherosclerotic 
      vascular injury and disturbed blood flow. Aspirin, the prototype antiplatelet 
      agent, has been in clinical use as an antithrombotic for almost a half century. 
      However, clinical trials have exposed the limitations of aspirin, and there has 
      been considerable recent progress in the development of more effective 
      antiplatelet agents. These newer agents are rationally based on interrupting 
      specific sites in the sequence of platelet activation. Inhibitors of the initial 
      step of platelet adhesion remain experimental. Inhibitors of specific platelet 
      agonist-receptor interactions include antithrombins, thromboxane A2 receptor 
      antagonists, and adenosine diphosphate (ADP) receptor blockers including 
      ticlopidine and clopidogrel. Inhibitors of arachidonic acid metabolism and 
      thromboxane A2 include omega-3 fatty acids, aspirin and other nonsteroidal 
      antiinflammatory drugs that inhibit cyclooxygenase, and thromboxane synthase 
      inhibitors. The clinical efficacy of many of these agents may be limited by their 
      actions, which are restricted to single, specific platelet receptors or metabolic 
      pathways. Global interruption of the final step of platelet aggregation can be 
      achieved with monoclonal antibodies and RGD (arginine-glycine-aspartic acid) 
      analogs that block ligand binding to the platelet glycoprotein IIb/IIIa complex. 
      Initial clinical trials with these novel agents have demonstrated superior 
      efficacy in preventing reocclusion and restenosis following coronary angioplasty 
      and atherectomy.
FAU - Schafer, A I
AU  - Schafer AI
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Thrombosis/*prevention & control
MH  - Ticlopidine/therapeutic use
RF  - 105
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - S0002-9343(96)80077-5 [pii]
AID - 10.1016/s0002-9343(96)80077-5 [doi]
PST - ppublish
SO  - Am J Med. 1996 Aug;101(2):199-209. doi: 10.1016/s0002-9343(96)80077-5.

PMID- 19558255
OWN - NLM
STAT- MEDLINE
DCOM- 20090902
LR  - 20181201
IS  - 1875-9114 (Electronic)
IS  - 0277-0008 (Linking)
VI  - 29
IP  - 7
DP  - 2009 Jul
TI  - Safety and tolerability of antiplatelet therapies for the secondary prevention of 
      atherothrombotic disease.
PG  - 812-21
LID - 10.1592/phco.29.7.812 [doi]
AB  - Aggressive secondary prevention is critical to improving long-term outcomes in 
      patients with ischemic coronary artery disease, cerebrovascular disease, and 
      peripheral artery disease. An essential component of successful secondary 
      prevention is antiplatelet therapy, which in most patient populations consists of 
      aspirin, clopidogrel, aspirin plus clopidogrel, or aspirin plus extended-release 
      dipyridamole. As is true for any pharmacologic agent, benefits must be balanced 
      with risks. For antiplatelet agents, the most important risk is excess bleeding, 
      especially as emerging evidence suggests that excess bleeding is associated with 
      adverse long-term outcomes; thus prevention and management of excess bleeding is 
      critically important. In addition, recommendations for avoidance and management 
      of minor adverse events are described so that patients maintain drug adherence. 
      Overall, aspirin, clopidogrel, aspirin plus clopidogrel, and aspirin plus 
      extended-release dipyridamole have favorable risk-versus-benefit profiles when 
      used as recommended in appropriate patient populations.
FAU - Spinler, Sarah A
AU  - Spinler SA
AD  - Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 
      Philadelphia, Pennsylvania 19104-4495, USA. s.spinle@usp.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/physiopathology/*prevention & control
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Dipyridamole/adverse effects/therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Secondary Prevention/*methods
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
RF  - 80
EDAT- 2009/06/30 09:00
MHDA- 2009/09/03 06:00
CRDT- 2009/06/30 09:00
PHST- 2009/06/30 09:00 [entrez]
PHST- 2009/06/30 09:00 [pubmed]
PHST- 2009/09/03 06:00 [medline]
AID - 10.1592/phco.29.7.812 [pii]
AID - 10.1592/phco.29.7.812 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2009 Jul;29(7):812-21. doi: 10.1592/phco.29.7.812.

PMID- 22449328
OWN - NLM
STAT- MEDLINE
DCOM- 20120717
LR  - 20131121
IS  - 1943-3530 (Electronic)
IS  - 0003-7028 (Linking)
VI  - 66
IP  - 4
DP  - 2012 Apr
TI  - Transmission fourier transform Raman spectroscopy of pharmaceutical tablet cores.
PG  - 451-7
LID - 10.1366/11-06538 [doi]
AB  - Transmission Fourier transform (FT) Raman spectroscopy of pharmaceutical tablet 
      cores is demonstrated using traditional, unmodified commercial instrumentation. 
      The benefits of improved precision over backscattering Raman spectroscopy due to 
      increased sample volume are demonstrated. Self-absorption effects on analyte band 
      ratios and sample probe volume are apparent, however. A survey of near-infrared 
      (NIR) absorption spectra in the FT-Raman spectral range (approximately 0 to 3500 
      wavenumber shift from 1064 nm, or 1064 to 1700 nm) of molecules with a wide range 
      of NIR-active functional groups shows that although absorption at the laser 
      wavelength (1064 nm) is relatively small, some regions of the Raman spectrum 
      coincide with NIR absorbances of 0.5 per cm or greater. Fortunately, the 
      pharmaceutically important regions of the Raman shift spectrum from 0 to 600 
      cm(-1) and from 1400 to 1900 cm(-1) exhibit low self-absorption for most organic 
      materials. A statistical analysis of transmission FT-Raman noise in spectra 
      collected from different regions of a pharmaceutical tablet provides insight into 
      both spectral distortion and reduced sampling volume caused by self-absorption.
CI  - © 2012 Society for Applied Spectroscopy
FAU - Pelletier, Michael J
AU  - Pelletier MJ
AD  - Analytical Technology, Pharmaceutical Sciences, Pfizer Worldwide Research and 
      Development, Eastern Point Road, Groton, Connecticut 06340, USA. 
      michael.pelletier@pfizer.com
FAU - Larkin, Peter
AU  - Larkin P
FAU - Santangelo, Matthew
AU  - Santangelo M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Appl Spectrosc
JT  - Applied spectroscopy
JID - 0372406
RN  - 0 (Drug Combinations)
RN  - 0 (Organic Chemicals)
RN  - 0 (Tablets)
RN  - 0 (acetaminophen, aspirin, caffeine drug combination)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Acetaminophen/chemistry
MH  - Aspirin/chemistry
MH  - Caffeine/chemistry
MH  - Drug Combinations
MH  - Fourier Analysis
MH  - Organic Chemicals/chemistry
MH  - Spectroscopy, Near-Infrared
MH  - Spectrum Analysis, Raman/*methods
MH  - Tablets/*chemistry
EDAT- 2012/03/28 06:00
MHDA- 2012/07/18 06:00
CRDT- 2012/03/28 06:00
PHST- 2012/03/28 06:00 [entrez]
PHST- 2012/03/28 06:00 [pubmed]
PHST- 2012/07/18 06:00 [medline]
AID - 10.1366/11-06538 [doi]
PST - ppublish
SO  - Appl Spectrosc. 2012 Apr;66(4):451-7. doi: 10.1366/11-06538.

PMID- 23732500
OWN - NLM
STAT- MEDLINE
DCOM- 20131223
LR  - 20181202
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 141
IP  - 2
DP  - 2013 Feb
TI  - [Rapid aspirin desensitization in patients with a history of aspirin 
      hypersensitivity requiring coronary angioplasty. Report of four cases].
PG  - 255-9
LID - S0034-98872013000200016 [pii]
LID - 10.4067/S0034-98872013000200016 [doi]
AB  - Aspirin use is necessary after a coronary angioplasty. It should not be used in 
      patients with a history of hypersensitivity. However, rapid desensitization 
      protocols have been reported to allow its use in such patients. One of these 
      protocols consists in the administration of progressive doses of aspirin, from 1 
      to 100 mg in a period of 5.5 hours, in a controlled environment. We report four 
      male patients aged 45,49, 59 and 73 years with a history of aspirin 
      hypersensitivity, who were subjected to a coronary angioplasty. In all, the rapid 
      aspirin desensitization protocol was successfully applied, allowing the use of 
      the drug after the intervention without problems.
FAU - Veas P, Nicolás
AU  - Veas P N
AD  - Departamento de Enfermedades Cardiovasculares, Pontificia Universidad Católica de 
      Chile, Chile. nicoveas@gmail.com
FAU - Martínez, Gonzalo
AU  - Martínez G
FAU - Jalil M, Jorge
AU  - Jalil M J
FAU - Martínez S, Alejandro
AU  - Martínez S A
FAU - Castro G, Pablo
AU  - Castro G P
LA  - spa
PT  - Case Reports
PT  - Journal Article
TT  - Desensibilización rápida en pacientes con hipersensibilidad a aspirina sometidos 
      a angioplastía coronaria. Reporte de cuatro casos.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/*methods
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clopidogrel
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Ticlopidine/administration & dosage/analogs & derivatives
MH  - Treatment Outcome
EDAT- 2013/06/05 06:00
MHDA- 2013/12/24 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/06/22 00:00 [received]
PHST- 2012/09/10 00:00 [accepted]
PHST- 2013/06/05 06:00 [entrez]
PHST- 2013/06/05 06:00 [pubmed]
PHST- 2013/12/24 06:00 [medline]
AID - S0034-98872013000200016 [pii]
AID - 10.4067/S0034-98872013000200016 [doi]
PST - ppublish
SO  - Rev Med Chil. 2013 Feb;141(2):255-9. doi: 10.4067/S0034-98872013000200016.

PMID- 8696902
OWN - NLM
STAT- MEDLINE
DCOM- 19960903
LR  - 20190920
IS  - 1078-5884 (Print)
IS  - 1078-5884 (Linking)
VI  - 12
IP  - 1
DP  - 1996 Jul
TI  - Aspirin increases tissue oedema after skeletal muscle ischaemia and reperfusion.
PG  - 76-80
AB  - PURPOSE: Skeletal muscle ischaemia reperfusion syndrome affects patients 
      following lower limb revascularisation. Aspirin has the potential to attenuate 
      these effects. METHODS: Using an established model of hind limb tourniquet 
      ischaemia, the effects of oral and intravenous aspirin administration were 
      observed after 6 h of ischaemia and 18 h reperfusion. Samples were obtained and 
      analysed for muscle viability and oedema, and lung neutrophil infiltration. 
      RESULTS: Aspirin, when compared to placebo and controls, significantly increased 
      muscle interstitial oedema when given orally and intravenously. It had no effect 
      on tissue viability or lung neutrophil infiltration. CONCLUSION: Aspirin 
      increases tissue oedema after ischaemia and reperfusion but has no effect on 
      tissue viability. Although its mechanism of action has not been clarified, 
      aspirin may influence the no-reflow component of ischaemia-reperfusion syndrome.
FAU - Braithwaite, B D
AU  - Braithwaite BD
AD  - Department of Vascular Surgery, University of California, UCLA School of Medicine 
      90024, USA.
FAU - Petrik, P V
AU  - Petrik PV
FAU - Moore, W S
AU  - Moore WS
FAU - Gelabert, H
AU  - Gelabert H
FAU - Pollen, D N
AU  - Pollen DN
FAU - Earnshaw, J J
AU  - Earnshaw JJ
FAU - Quinones-Baldrich, W J
AU  - Quinones-Baldrich WJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Vasc Endovasc Surg
JT  - European journal of vascular and endovascular surgery : the official journal of 
      the European Society for Vascular Surgery
JID - 9512728
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cell Movement/drug effects
MH  - Disease Models, Animal
MH  - Edema/*etiology
MH  - Hindlimb/blood supply
MH  - Infusions, Intravenous
MH  - Ischemia/*complications
MH  - Lung/drug effects/pathology
MH  - Male
MH  - Muscle, Skeletal/*blood supply
MH  - Muscular Diseases/*etiology
MH  - Neutrophils/drug effects/pathology
MH  - Placebos
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reperfusion/*adverse effects
MH  - Single-Blind Method
MH  - Tissue Survival
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
AID - S1078-5884(96)80279-6 [pii]
AID - 10.1016/s1078-5884(96)80279-6 [doi]
PST - ppublish
SO  - Eur J Vasc Endovasc Surg. 1996 Jul;12(1):76-80. doi: 
      10.1016/s1078-5884(96)80279-6.

PMID- 21829647
OWN - NLM
STAT- MEDLINE
DCOM- 20111227
LR  - 20211020
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 6
IP  - 8
DP  - 2011
TI  - Fatty acid binding protein 1 is related with development of aspirin-exacerbated 
      respiratory disease.
PG  - e22711
LID - 10.1371/journal.pone.0022711 [doi]
LID - e22711
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) refers to the 
      development of bronchoconstriction in asthmatics following the ingestion of 
      aspirin. Although alterations in eicosanoid metabolites play a role in AERD, 
      other immune or inflammatory mechanisms may be involved. We aimed to identify 
      proteins that were differentially expressed in nasal polyps between patients with 
      AERD and aspirin-tolerant asthma (ATA). METHODOLOGY/PRINCIPAL FINDINGS: 
      Two-dimensional electrophoresis was adopted for differential display proteomics. 
      Proteins were identified by liquid chromatography-tandem mass spectrometry 
      (LC-MS). Western blotting and immunohistochemical staining were performed to 
      compare the amount of fatty acid-binding protein 1 (FABP1) in the nasal polyps of 
      patients with AERD and ATA. Fifteen proteins were significantly up- (seven spots) 
      or down-regulated in the nasal polyps of patients with AERD (n = 5) compared to 
      those with ATA (n = 8). LC-MS revealed an increase in seven proteins expression 
      and a decrease in eight proteins expression in patients with AERD compared to 
      those with ATA (P = 0.003-0.045). FABP1-expression based on immunoblotting and 
      immunohistochemical analysis was significantly higher in the nasal polyps of 
      patients with AERD compared to that in patients with ATA. FABP1 was observed in 
      epithelial, eosinophils, macrophages, and the smooth-muscle cells of blood 
      vessels in the polyps. CONCLUSIONS/SIGNIFICANCE: Our results indicate that 
      alterations in 15 proteins, including FABP1, may be related to the development of 
      AERD.
FAU - Kim, Tae-Hoon
AU  - Kim TH
AD  - Genome Research Center for Allergy and Respiratory Disease, Soonchunhyang 
      University Bucheon Hospital, 1174, Jung-Dong, Wonmi-Gu, Bucheon, Gyeonggi-Do, 
      South Korea.
FAU - Lee, Ji-Yeon
AU  - Lee JY
FAU - Park, Jong-Sook
AU  - Park JS
FAU - Park, Sung-Woo
AU  - Park SW
FAU - Jang, An-Soo
AU  - Jang AS
FAU - Lee, Jae-Yong
AU  - Lee JY
FAU - Byun, Jang-Yul
AU  - Byun JY
FAU - Uh, Soo-Taek
AU  - Uh ST
FAU - Koh, Eun-Suk
AU  - Koh ES
FAU - Chung, Il Yup
AU  - Chung IY
FAU - Park, Choon-Sik
AU  - Park CS
LA  - eng
GR  - A010249/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20110804
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Fatty Acid-Binding Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Blotting, Western
MH  - Chromatography, Liquid
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Fatty Acid-Binding Proteins/*physiology
MH  - Humans
MH  - Immunohistochemistry
MH  - Respiratory Tract Diseases/*chemically induced/physiopathology
MH  - Tandem Mass Spectrometry
PMC - PMC3150373
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2011/08/11 06:00
MHDA- 2011/12/28 06:00
CRDT- 2011/08/11 06:00
PHST- 2011/04/04 00:00 [received]
PHST- 2011/06/28 00:00 [accepted]
PHST- 2011/08/11 06:00 [entrez]
PHST- 2011/08/11 06:00 [pubmed]
PHST- 2011/12/28 06:00 [medline]
AID - PONE-D-11-06277 [pii]
AID - 10.1371/journal.pone.0022711 [doi]
PST - ppublish
SO  - PLoS One. 2011;6(8):e22711. doi: 10.1371/journal.pone.0022711. Epub 2011 Aug 4.

PMID- 1863010
OWN - NLM
STAT- MEDLINE
DCOM- 19910905
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 42
IP  - 7
DP  - 1991 Jul
TI  - Physical training and antiplatelet treatment in stage II peripheral arterial 
      occlusive disease: alone or combined?
PG  - 513-21
AB  - The efficacy of physical training alone or combined with antiplatelet therapy 
      (dipyridamole and aspirin) was studied in 30 patients with stage II peripheral 
      arterial occlusive disease (PAOD). Patients were randomly allocated to one of the 
      following groups: Group A--dipyridamole 75 mg three times daily and aspirin 330 
      mg once daily: Group B--physical exercise; Group C--physical exercise and 
      dipyridamole 75 mg three time daily and aspirin 330 mg once daily. After six 
      months' treatment the pain-free walking time (PFWT) and the maximum walking time 
      (MWT) improved significantly (p less than 0.05) in all three groups. In group A 
      the PFWT lengthened by 35% (from 101.00 +/- 34.56 to 137.32 +/- 40.50 s) and the 
      MWT by 38% (from 150.34 +/- 55.60 to 207.26 +/- 60.67 s); in group B the PFWT 
      lengthened by 90% (from 90.65 +/- 40.54 to 171.45 +/- 55.60 s) and the MWT by 86% 
      (from 145.39 +/- 60.50 to 270.63 +/- 63.61 s). When physical exercise was 
      associated with drugs as in group C, the PFWT lengthened by 120% (from 89.51 +/- 
      43.89 to 196.72 +/- 51.73 s) and the MWT by 105% (from 160.43 +/- 59.84 to 329.05 
      +/- 63.96 s). No significant variations were observed at any stage of the study 
      in the ankle/arm pressure ratio at rest and after standard treadmill exercise, in 
      the plethysmographic rest and peak flows, or in the transcutaneous oxygen 
      pressure in basal conditions and in its half recovery time after an induced 
      ischemia. The results confirm the benefits of regular exercise in stage II PAOD 
      patients but suggest they may be enhanced by antiplatelet therapy.
FAU - Mannarino, E
AU  - Mannarino E
AD  - 2nd Dept. Internal Medicine, University of Perugia, Italy.
FAU - Pasqualini, L
AU  - Pasqualini L
FAU - Innocente, S
AU  - Innocente S
FAU - Scricciolo, V
AU  - Scricciolo V
FAU - Rignanese, A
AU  - Rignanese A
FAU - Ciuffetti, G
AU  - Ciuffetti G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Combined Modality Therapy
MH  - Dipyridamole/*therapeutic use
MH  - *Exercise Therapy
MH  - Female
MH  - Humans
MH  - Intermittent Claudication/rehabilitation/*therapy
MH  - Male
MH  - Middle Aged
MH  - Time Factors
MH  - Walking
EDAT- 1991/07/01 00:00
MHDA- 1991/07/01 00:01
CRDT- 1991/07/01 00:00
PHST- 1991/07/01 00:00 [pubmed]
PHST- 1991/07/01 00:01 [medline]
PHST- 1991/07/01 00:00 [entrez]
AID - 10.1177/000331979104200701 [doi]
PST - ppublish
SO  - Angiology. 1991 Jul;42(7):513-21. doi: 10.1177/000331979104200701.

PMID- 6812685
OWN - NLM
STAT- MEDLINE
DCOM- 19821221
LR  - 20210518
IS  - 0267-0623 (Print)
IS  - 0267-0623 (Linking)
VI  - 285
IP  - 6351
DP  - 1982 Nov 6
TI  - A regimen for low-dose aspirin?
PG  - 1299-302
AB  - The effects of different regimens of 40 mg aspirin on platelet thromboxane A2 
      synthesis and vascular prostacyclin synthesis were determined in patients who 
      were undergoing elective surgery for removal of varicose veins. Aspirin 40 mg 
      taken at intervals of 48 hours consistently reduced platelet thromboxane A2 
      synthesis to a level at which it failed to support platelet aggregation and the 
      associated release reaction. This effect lasted for at least 36 hours. In 
      contrast, aspirin 40 mg every 72 hours did not have the same consistent effect. 
      Both dose regimens led to a reduction in vascular prostacyclin synthesis 12 hours 
      after the last dose, but 36 or 72 hours after the last dose prostacyclin 
      synthesis was not reduced; thus the inhibition of prostacyclin synthesis was 
      short lived. If the balance between platelet thromboxane A2 and vascular 
      prostacyclin synthesis is important in thrombosis 40 mg aspirin every 48 hours 
      may have the maximum antithrombotic effect.
FAU - Hanley, S P
AU  - Hanley SP
FAU - Bevan, J
AU  - Bevan J
FAU - Cockbill, S R
AU  - Cockbill SR
FAU - Heptinstall, S
AU  - Heptinstall S
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br Med J (Clin Res Ed)
JT  - British medical journal (Clinical research ed.)
JID - 8302911
RN  - 333DO1RDJY (Serotonin)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Platelets/drug effects/metabolism
MH  - Drug Administration Schedule
MH  - Epoprostenol/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Malondialdehyde/blood
MH  - Middle Aged
MH  - Serotonin/blood
MH  - Thromboxane A2/blood
EDAT- 1982/11/06 00:00
MHDA- 1982/11/06 00:01
CRDT- 1982/11/06 00:00
PHST- 1982/11/06 00:00 [pubmed]
PHST- 1982/11/06 00:01 [medline]
PHST- 1982/11/06 00:00 [entrez]
AID - 10.1136/bmj.285.6351.1299 [doi]
PST - ppublish
SO  - Br Med J (Clin Res Ed). 1982 Nov 6;285(6351):1299-302. doi: 
      10.1136/bmj.285.6351.1299.

PMID- 1806734
OWN - NLM
STAT- MEDLINE
DCOM- 19920508
LR  - 20170126
IS  - 0022-4707 (Print)
IS  - 0022-4707 (Linking)
VI  - 31
IP  - 4
DP  - 1991 Dec
TI  - A double-blind, placebo-controlled study of acetylsalicylic acid (ASA) in trained 
      runners.
PG  - 561-4
AB  - Acetylsalicylic acid (ASA) is a short-acting oral inhibitor of the cyclooxygenase 
      enzyme. Ingestion of ASA is associated with a decrease in prostaglandins, 
      including those of the E2 series, as well as prostacyclin, and thromboxane. 
      Consumption of therapeutic doses is associated with decreased pain and 
      inflammation and is therefore used in a variety of inflammatory conditions. 
      Platelet aggregation is also inhibited. Because of these observations, and the 
      fact that platelet aggregation has been noted to be altered during exercise, the 
      effects of ASA on exercise tolerance was of interest. We studied 17 healthy male 
      volunteers who regularly ran as a source of exercise. During the study they 
      ingested either 650 mg of ASA or placebo 30 min before running 2 miles (3.2 km). 
      Outcome of the double-blind crossover study was measured by the time required to 
      run a 2-mile distance. No differences between ASA or placebo were noted in the 
      subjects. These data suggest that 650 mg of ASA as a premedication has little 
      effect on exercise performance in normal endurance runners. However, whether ASA 
      may affect pain after exercise or whether other dosage intervals would be more 
      beneficial needs further study.
FAU - Lisse, J R
AU  - Lisse JR
AD  - Department of Internal Medicine, University of Texas Medical Branch, Galveston.
FAU - MacDonald, K
AU  - MacDonald K
FAU - Thurmond-Anderle, M E
AU  - Thurmond-Anderle ME
FAU - Fuchs, J E Jr
AU  - Fuchs JE Jr
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Italy
TA  - J Sports Med Phys Fitness
JT  - The Journal of sports medicine and physical fitness
JID - 0376337
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/*pharmacology
MH  - Double-Blind Method
MH  - Exercise/*physiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - *Running
MH  - Time Factors
EDAT- 1991/12/11 19:15
MHDA- 2001/03/28 10:01
CRDT- 1991/12/11 19:15
PHST- 1991/12/11 19:15 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1991/12/11 19:15 [entrez]
PST - ppublish
SO  - J Sports Med Phys Fitness. 1991 Dec;31(4):561-4.

PMID- 21346577
OWN - NLM
STAT- MEDLINE
DCOM- 20110812
LR  - 20131121
IS  - 1531-6963 (Electronic)
IS  - 1040-8711 (Linking)
VI  - 23
IP  - 3
DP  - 2011 May
TI  - Heparin or aspirin or both in the treatment of recurrent abortions in women with 
      antiphospholipid antibody (syndrome).
PG  - 299-304
LID - 10.1097/BOR.0b013e328344c3f7 [doi]
AB  - PURPOSE OF REVIEW: Presence of antiphospholipid antibodies (aPL) is associated 
      with unsuccessful pregnancy outcome. Based on an early concept of aPL-induced 
      thrombophilia and placental thrombosis, antithrombotic interventions have been 
      used to reduce incidence of miscarriage in antiphospholipid antibody syndrome 
      (APS). The aim of this review is to summarize current knowledge on pathogenesis 
      of miscarriage in APS and the impact of different antithrombotic therapy 
      strategies. RECENT FINDINGS: Pathogenetic concepts on miscarriage in APS comprise 
      aPL-mediated cell activation, disturbance of coagulation along with increased 
      complement activation. There is increasing evidence that heparin exerts its 
      effect by inhibiting complement activation rather than by its anticoagulation 
      capacity. In this regard, the outcome of pregnancies in APS has considerably 
      improved by the invention of therapies using combinations of aspirin, 
      unfractionated heparin (UFH) and/or low molecular weight heparin (LMWH). However, 
      there is no clear evidence as to which treatment regimen should be preferred. 
      Some studies indicate superiority of aspirin plus heparin over aspirin-only. 
      Whether heparin-only treatment would confer equal effects and whether UFH and 
      LMWH were of comparable efficacy currently is unknown. SUMMARY: Treatment with 
      aspirin and heparin decreases the risk of miscarriages in APS. Well designed 
      trials as well as better patients-at-risk profiling are warranted that identify 
      which treatment strategy should be favored and whether detailed characterization 
      of aPL specificities could help in individualizing therapy.
FAU - Hoppe, Berthold
AU  - Hoppe B
AD  - Institute of Laboratory Medicine and Pathobiochemistry, Charité - 
      Universitätsmedizin Berlin, Germany. berthold.hoppe@charite.de
FAU - Burmester, Gerd-Rüdiger
AU  - Burmester GR
FAU - Dörner, Thomas
AU  - Dörner T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Rheumatol
JT  - Current opinion in rheumatology
JID - 9000851
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/blood/*drug therapy/*etiology/prevention & control
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Antiphospholipid Syndrome/blood/*complications/*drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Placenta/blood supply/drug effects
MH  - Pregnancy
MH  - Thrombosis/prevention & control
EDAT- 2011/02/25 06:00
MHDA- 2011/08/13 06:00
CRDT- 2011/02/25 06:00
PHST- 2011/02/25 06:00 [entrez]
PHST- 2011/02/25 06:00 [pubmed]
PHST- 2011/08/13 06:00 [medline]
AID - 10.1097/BOR.0b013e328344c3f7 [doi]
PST - ppublish
SO  - Curr Opin Rheumatol. 2011 May;23(3):299-304. doi: 10.1097/BOR.0b013e328344c3f7.

PMID- 15069114
OWN - NLM
STAT- MEDLINE
DCOM- 20040419
LR  - 20191210
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Linking)
VI  - 96
IP  - 7
DP  - 2004 Apr 7
TI  - Aspirin use and pancreatic cancer mortality in a large United States cohort.
PG  - 524-8
AB  - BACKGROUND: Results from some epidemiologic studies have suggested that aspirin 
      use may reduce risk of pancreatic cancer, but the evidence remains limited. 
      METHODS: We examined the association between aspirin use and pancreatic cancer 
      mortality among 987 590 U.S. adults in the Cancer Prevention Study II (CPS-II) 
      cohort. CPS-II participants completed a self-administered questionnaire in 1982 
      and were followed for mortality through 2000. During follow-up, there were 4577 
      deaths from pancreatic cancer (2434 in men and 2143 in women). We calculated rate 
      ratios (RR) adjusted for age, sex, race, body mass index, diabetes, and cigarette 
      smoking status. RESULTS: Aspirin use was not associated with pancreatic cancer 
      mortality. The rate ratio associated with aspirin use 30 or more times per month, 
      compared with no use, was 0.97 (95% confidence interval [CI] = 0.86 to 1.09). 
      Even participants who reported both frequent aspirin use (> or =30 times per 
      month) and use for 20 or more years were not at decreased risk compared with 
      nonusers (RR = 0.96, 95% CI = 0.69 to 1.33). We found no association between 
      aspirin use and pancreatic cancer mortality in subgroup analyses by follow-up 
      time, cigarette smoking status, or sex. CONCLUSION: Results from this large 
      prospective study do not support an important effect of aspirin use on pancreatic 
      cancer mortality.
FAU - Jacobs, Eric J
AU  - Jacobs EJ
AD  - Department of Epidemiology and Surveillance Research, American Cancer Society, 
      Atlanta, GA 30329, USA. eric.jacobs@cancer.org
FAU - Connell, Cari J
AU  - Connell CJ
FAU - Rodriguez, Carmen
AU  - Rodriguez C
FAU - Patel, Alpa V
AU  - Patel AV
FAU - Calle, Eugenia E
AU  - Calle EE
FAU - Thun, Michael J
AU  - Thun MJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*pharmacology
MH  - Aspirin/*administration & dosage/*pharmacology
MH  - Cohort Studies
MH  - Confounding Factors, Epidemiologic
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pancreatic Neoplasms/*mortality/*prevention & control
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Research Design
MH  - Surveys and Questionnaires
MH  - United States/epidemiology
EDAT- 2004/04/08 05:00
MHDA- 2004/04/20 05:00
CRDT- 2004/04/08 05:00
PHST- 2004/04/08 05:00 [pubmed]
PHST- 2004/04/20 05:00 [medline]
PHST- 2004/04/08 05:00 [entrez]
AID - 10.1093/jnci/djh084 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2004 Apr 7;96(7):524-8. doi: 10.1093/jnci/djh084.

PMID- 7646263
OWN - NLM
STAT- MEDLINE
DCOM- 19950921
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 88
IP  - 4
DP  - 1995 Apr
TI  - [Antiaggregants, aspirin, myocardial infarction and coronary deaths in the 
      Haute-Garonne area].
PG  - 459-63
AB  - The aim of this study was to determine changes in treatment of myocardial 
      infarction between 1986 and 1989 in the Haute-Garonne region and, in particular, 
      to assess the role of aspirin and antiaggregant therapy. The cases of 416 
      patients admitted to hospital for myocardial infarction in 1986 and 1989 were 
      reviewed. During this period the prescription of acetylsalicyclic acid during the 
      acute phase of myocardial infarction increased threefold (26.4 vs 72.9%; p < 
      0.001) and fivefold when associated with fibrinolytics, coronary bypass or 
      angioplasty. Similarly, the prescription of aspirin at the time of hospital 
      discharge doubled (from 32.6 to 69.5%; p < 0.001). The dosage of aspirin 
      decreased from 500 mg and more per day in 1986 to a dosage of 250 mg or 100 mg 
      per day in 1989. The most commonly prescribed preparation is lysine 
      acetylsalicylate. The hospital mortality in the Haute-Garonne between 1985 and 
      1989 has decreased as observed in the Haute-garonne centre of the MONICA project. 
      During the same period, the prescription of aspirin in association with 
      angioplasty, bypass surgery and fibrinolytics, has undergone a remarkable 
      increase. The changes observed during this period of observation are in perfect 
      accord with results already published of therapeutic trials of antithrombotic 
      agents in the acute phase or the post-infarction period (ISIS 2).
FAU - Cambou, J P
AU  - Cambou JP
AD  - Inserm U-326, ORSMIP, CHU Purpan, Toulouse.
FAU - Lablache-Combier, B
AU  - Lablache-Combier B
FAU - Marques-Vidal, P
AU  - Marques-Vidal P
FAU - Ruidavets, J B
AU  - Ruidavets JB
FAU - Ferrières, J
AU  - Ferrières J
FAU - Branchu, M P
AU  - Branchu MP
FAU - Richard, J L
AU  - Richard JL
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Antiagrégants, aspirine, infarctus du myocarde et décès coronaires en 
      Haute-Garonne.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Coronary Disease/epidemiology/*mortality/therapy
MH  - Drug Utilization
MH  - Female
MH  - France/epidemiology
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/epidemiology/*mortality/therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Retrospective Studies
EDAT- 1995/04/01 00:00
MHDA- 1995/04/01 00:01
CRDT- 1995/04/01 00:00
PHST- 1995/04/01 00:00 [pubmed]
PHST- 1995/04/01 00:01 [medline]
PHST- 1995/04/01 00:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 1995 Apr;88(4):459-63.

PMID- 371629
OWN - NLM
STAT- MEDLINE
DCOM- 19790524
LR  - 20190717
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 22
IP  - 4
DP  - 1979 Apr
TI  - Comparison of gastrointestinal effects of aspirin and fenoprofen. A double blind 
      crossover study.
PG  - 376-83
AB  - Sixteen men received 3904 mg of aspirin, 2400 mg of fenoprofen, or placebo daily 
      for 1 week in a double blind and crossover trial. Fecal blood loss was measured 
      by 51Cr labeled red cells; gastric and duodenal pathology were observed 
      endoscopically. There was more (P less than 0.05) blood loss (4.96 ml) after 
      aspirin than after fenoprofen (2.46 ml) or placebo (0.79 ml). By endoscopic 
      examination, aspirin induced more (P less than 0.05) gastrointestinal pathology 
      than fenoprofen or placebo, and there was a correlation of 0.70 between the two 
      methods used in this study.
FAU - Chernish, S M
AU  - Chernish SM
FAU - Rosenak, B D
AU  - Rosenak BD
FAU - Brunelie, R L
AU  - Brunelie RL
FAU - Crabtree, R
AU  - Crabtree R
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Phenylpropionates)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*toxicity
MH  - Clinical Trials as Topic
MH  - Duodenum/*drug effects
MH  - Endoscopy
MH  - Fenoprofen/administration & dosage/*toxicity
MH  - Gastric Mucosa/*drug effects
MH  - Gastritis/*chemically induced
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Gastroscopy
MH  - Humans
MH  - Intestinal Mucosa/*drug effects
MH  - Male
MH  - Middle Aged
MH  - Occult Blood
MH  - Phenylpropionates/*toxicity
MH  - Placebos
EDAT- 1979/04/01 00:00
MHDA- 1979/04/01 00:01
CRDT- 1979/04/01 00:00
PHST- 1979/04/01 00:00 [pubmed]
PHST- 1979/04/01 00:01 [medline]
PHST- 1979/04/01 00:00 [entrez]
AID - 10.1002/art.1780220410 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1979 Apr;22(4):376-83. doi: 10.1002/art.1780220410.

PMID- 24819018
OWN - NLM
STAT- MEDLINE
DCOM- 20140818
LR  - 20181202
IS  - 1873-3778 (Electronic)
IS  - 0021-9673 (Linking)
VI  - 1347
DP  - 2014 Jun 20
TI  - Multiple dual mode counter-current chromatography with variable duration of 
      alternating phase elution steps.
PG  - 87-95
LID - S0021-9673(14)00654-2 [pii]
LID - 10.1016/j.chroma.2014.04.064 [doi]
AB  - The multiple dual mode (MDM) counter-current chromatography separation processes 
      consist of a succession of two isocratic counter-current steps and are 
      characterized by the shuttle (forward and back) transport of the sample in 
      chromatographic columns. In this paper, the improved MDM method based on variable 
      duration of alternating phase elution steps has been developed and validated. The 
      MDM separation processes with variable duration of phase elution steps are 
      analyzed. Basing on the cell model, analytical solutions are developed for 
      impulse and non-impulse sample loading at the beginning of the column. Using the 
      analytical solutions, a calculation program is presented to facilitate the 
      simulation of MDM with variable duration of phase elution steps, which can be 
      used to select optimal process conditions for the separation of a given feed 
      mixture. Two options of the MDM separation are analyzed: 1 - with one-step solute 
      elution: the separation is conducted so, that the sample is transferred forward 
      and back with upper and lower phases inside the column until the desired 
      separation of the components is reached, and then each individual component 
      elutes entirely within one step; 2 - with multi-step solute elution, when the 
      fractions of individual components are collected in over several steps. It is 
      demonstrated that proper selection of the duration of individual cycles (phase 
      flow times) can greatly increase the separation efficiency of CCC columns. 
      Experiments were carried out using model mixtures of compounds from the GUESSmix 
      with solvent systems hexane/ethyl acetate/methanol/water. The experimental 
      results are compared to the predictions of the theory. A good agreement between 
      theory and experiment has been demonstrated.
CI  - Copyright © 2014 Elsevier B.V. All rights reserved.
FAU - Kostanyan, Artak E
AU  - Kostanyan AE
AD  - Kurnakov Institute of General & Inorganic Chemistry, Russian Academy of Sciences, 
      Leninsky Prospekt 31, Moscow 119991, Russia. Electronic address: 
      kost@igic.ras.ru.
FAU - Erastov, Andrey A
AU  - Erastov AA
AD  - Kurnakov Institute of General & Inorganic Chemistry, Russian Academy of Sciences, 
      Leninsky Prospekt 31, Moscow 119991, Russia.
FAU - Shishilov, Oleg N
AU  - Shishilov ON
AD  - Kurnakov Institute of General & Inorganic Chemistry, Russian Academy of Sciences, 
      Leninsky Prospekt 31, Moscow 119991, Russia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140430
PL  - Netherlands
TA  - J Chromatogr A
JT  - Journal of chromatography. A
JID - 9318488
RN  - 0 (Coumarins)
RN  - 3G6A5W338E (Caffeine)
RN  - A4VZ22K1WT (coumarin)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis
MH  - Caffeine/analysis
MH  - Coumarins/analysis
MH  - Countercurrent Distribution/*methods
MH  - Models, Theoretical
MH  - Salicylic Acid/analysis
OTO - NOTNLM
OT  - Impulse and non-impulse sample loading
OT  - Multi-dimensional liquid chromatography
OT  - Multiple dual mode counter-current chromatography
OT  - One- and multi-step solute elution
EDAT- 2014/05/14 06:00
MHDA- 2014/08/19 06:00
CRDT- 2014/05/14 06:00
PHST- 2014/01/29 00:00 [received]
PHST- 2014/03/17 00:00 [revised]
PHST- 2014/04/18 00:00 [accepted]
PHST- 2014/05/14 06:00 [entrez]
PHST- 2014/05/14 06:00 [pubmed]
PHST- 2014/08/19 06:00 [medline]
AID - S0021-9673(14)00654-2 [pii]
AID - 10.1016/j.chroma.2014.04.064 [doi]
PST - ppublish
SO  - J Chromatogr A. 2014 Jun 20;1347:87-95. doi: 10.1016/j.chroma.2014.04.064. Epub 
      2014 Apr 30.

PMID- 12885264
OWN - NLM
STAT- MEDLINE
DCOM- 20031205
LR  - 20181130
IS  - 0312-5963 (Print)
IS  - 0312-5963 (Linking)
VI  - 42
IP  - 10
DP  - 2003
TI  - Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention 
      of stroke.
PG  - 909-20
AB  - Stroke is one of the leading causes of death and debilitation. Several million 
      stroke survivors are alive throughout the world today. Prevention of recurrent 
      stroke is of major importance to stroke survivors. Several pharmacological agents 
      are currently available for use in secondary stroke prevention.Clopidogrel, the 
      combination of immediate-release aspirin and extended-release dipyridamole and 
      aspirin alone are the most widely recommended agents for use in the secondary 
      prevention of strokes. Clopidogrel has shown superiority over aspirin in the 
      combined endpoints of stroke, death and myocardial infarction. The 
      immediate-release aspirin/extended-release dipyridamole combination has shown 
      superiority to aspirin alone in the secondary prevention of stroke. Dipyridamole 
      has been studied as an antiplatelet agent for several decades. Early trials to 
      prove its efficacy compared with aspirin were not favourable, and patients often 
      experienced many adverse effects. Researchers began developing an 
      extended-release formulation in an effort to maintain therapeutic blood 
      concentrations with less frequent daily administration and better adverse effect 
      profile. Pharmacokinetic analysis of this new product showed it to have a more 
      consistent and reproducible absorption compared with immediate-release 
      dipyridamole. The rate of absorption of extended-release dipyridamole is 
      considerably slower than that of immediate-release dipyridamole, while similar 
      plasma concentrations are maintained to optimise antiplatelet efficacy. This 
      allows extended-release dipyridamole to be administered twice daily rather than 
      four times daily.A large-scale randomised trial was conducted with 
      extended-release dipyridamole 200mg in combination with immediate-release aspirin 
      25mg given twice daily. The combination product showed a greater efficacy at 
      preventing a recurring stroke then either agent administered alone. Indirect 
      comparisons with clopidogrel show that the combination of immediate-release 
      aspirin/extended-release dipyridamole may be more effective than clopidogrel at 
      preventing a recurring stroke.
FAU - Lenz, Thomas
AU  - Lenz T
AD  - Department of Pharmacy Practice, School of Pharmacy and Allied Health 
      Professions, Creighton University, 2500 California Plaza, Omaha, NE 68178, USA.
FAU - Wilson, Amy
AU  - Wilson A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Clin Pharmacokinet
JT  - Clinical pharmacokinetics
JID - 7606849
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacokinetics/*therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Dipyridamole/*administration & dosage/*pharmacokinetics/*therapeutic use
MH  - *Drug Combinations
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/*pharmacokinetics/*therapeutic use
MH  - Stroke/*prevention & control
MH  - Ticlopidine/*administration & dosage/*analogs & derivatives/*pharmacokinetics
RF  - 67
EDAT- 2003/07/30 05:00
MHDA- 2003/12/06 05:00
CRDT- 2003/07/30 05:00
PHST- 2003/07/30 05:00 [pubmed]
PHST- 2003/12/06 05:00 [medline]
PHST- 2003/07/30 05:00 [entrez]
AID - 42103 [pii]
AID - 10.2165/00003088-200342100-00003 [doi]
PST - ppublish
SO  - Clin Pharmacokinet. 2003;42(10):909-20. doi: 10.2165/00003088-200342100-00003.

PMID- 34429584
OWN - NLM
STAT- MEDLINE
DCOM- 20220113
LR  - 20220426
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 15
DP  - 2021
TI  - The Synergistic Effect of Ginkgo biloba Extract 50 and Aspirin Against Platelet 
      Aggregation.
PG  - 3543-3560
LID - 10.2147/DDDT.S318515 [doi]
AB  - PURPOSE: We aimed to investigate potential synergistic antiplatelet effects of 
      Ginkgo biloba extract (GBE50) in combination with aspirin using in vitro models. 
      METHODS: Arachidonic acid (AA), platelet activating factor (PAF), adenosine 
      5'-diphosphate (ADP) and collagen were used as inducers. The antiplatelet effects 
      of GBE50, aspirin and 1:1 combination of GBE50 and aspirin were detected by 
      microplate method using rabbit platelets. Synergy finder 2.0 was used to analyze 
      the synergistic antiplatelet effect. The compounds in GBE50 were identified by 
      UPLC-Q/TOF-MS analysis and the candidate compounds were screened by TCMSP 
      database. The targets of candidate compounds and aspirin were obtained in TCMSP, 
      CCGs, Swiss target prediction database and drugbank. Targets involving platelet 
      aggregation were obtained from GenCLiP database. Compound-target network was 
      constructed and GO and KEGG enrichment analyses were performed to identify the 
      critical biological processes and signaling pathways. The levels of thromboxane 
      B2 (TXB2), cyclic adenosine monophosphate (cAMP) and PAF receptor (PAFR) were 
      detected by ELISA to determine the effects of GBE50, aspirin and their 
      combination on these pathways. RESULTS: GBE50 combined with aspirin inhibited 
      platelet aggregation more effectively. The combination displayed synergistic 
      antiplatelet effects in AA-induced platelet aggregation, and additive 
      antiplatelet effects occurred in PAF, ADP and collagen induced platelet 
      aggregation. Seven compounds were identified as candidate compounds in GBE50. 
      Enrichment analyses revealed that GBE50 could interfere with platelet aggregation 
      via cAMP pathway, AA metabolism and calcium signaling pathway, and aspirin could 
      regulate platelet aggregation through AA metabolism and platelet activation. 
      ELISA experiments showed that GBE50 combined with aspirin could increase cAMP 
      levels in resting platelets, and decreased the levels of TXB2 and PAFR. 
      CONCLUSION: Our study indicated that GBE50 combined with aspirin could enhance 
      the antiplatelet effects. They exerted both synergistic and additive effects in 
      restraining platelet aggregation. The study highlighted the potential application 
      of GBE50 as a supplementary therapy to treat thrombosis-related diseases.
CI  - © 2021 Ke et al.
FAU - Ke, Jia
AU  - Ke J
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      People's Republic of China.
FAU - Li, Meng-Ting
AU  - Li MT
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      People's Republic of China.
FAU - Huo, Ya-Jing
AU  - Huo YJ
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      People's Republic of China.
FAU - Cheng, Yan-Qiong
AU  - Cheng YQ
AD  - Department of Pharmacology, School of Pharmacy, Second Military Medical 
      University, Shanghai, People's Republic of China.
FAU - Guo, Shu-Fen
AU  - Guo SF
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      People's Republic of China.
FAU - Wu, Yang
AU  - Wu Y
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      People's Republic of China.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional 
      Chinese and Western Medicine, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, People's Republic of China.
FAU - Ma, Jianpeng
AU  - Ma J
AD  - Multiscale Research Institute of Complex Systems, Fudan University, Shanghai, 
      People's Republic of China.
FAU - Liu, Ai-Jun
AU  - Liu AJ
AD  - Department of Pharmacology, School of Pharmacy, Second Military Medical 
      University, Shanghai, People's Republic of China.
FAU - Han, Yan
AU  - Han Y
AD  - Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210814
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Ginkgo biloba extract 50)
RN  - 0 (Plant Extracts)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Membrane Glycoproteins)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (platelet activating factor receptor)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - E0399OZS9N (Cyclic AMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Chromatography, High Pressure Liquid
MH  - Cyclic AMP/metabolism
MH  - Drug Synergism
MH  - Ginkgo biloba
MH  - Male
MH  - Mass Spectrometry
MH  - Plant Extracts/administration & dosage/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Membrane Glycoproteins/metabolism
MH  - Rabbits
MH  - Receptors, G-Protein-Coupled/metabolism
MH  - Thromboxane B2/metabolism
PMC - PMC8375244
OTO - NOTNLM
OT  - Chinese herb
OT  - Ginkgo biloba
OT  - antiplatelet
OT  - arachidonic acid
OT  - aspirin
OT  - synergistic effect
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/08/26 06:00
MHDA- 2022/01/14 06:00
CRDT- 2021/08/25 06:20
PHST- 2021/05/06 00:00 [received]
PHST- 2021/07/12 00:00 [accepted]
PHST- 2021/08/25 06:20 [entrez]
PHST- 2021/08/26 06:00 [pubmed]
PHST- 2022/01/14 06:00 [medline]
AID - 318515 [pii]
AID - 10.2147/DDDT.S318515 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2021 Aug 14;15:3543-3560. doi: 10.2147/DDDT.S318515. 
      eCollection 2021.

PMID- 5675432
OWN - NLM
STAT- MEDLINE
DCOM- 19681028
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 47
IP  - 9
DP  - 1968 Sep
TI  - The effect of salicylates on the hemostatic properties of platelets in man.
PG  - 2169-80
AB  - Ingestion of 1.5 g of aspirin, but not of sodium salicylate, produced a 
      significant prolongation of the bleeding time in six normal male subjects when 
      compared with the effects of a placebo. Similar differences in the effect of the 
      two drugs on platelets was also observed. Aspirin ingestion resulted in impaired 
      platelet aggregation by connective tissue and was associated with a decreased 
      release of platelet adenosine diphosphate (ADP); sodium salicylate had no effect 
      on these values. In vitro, incubation of platelet-rich plasma with an optimum 
      aspirin concentration of 0.50 mmole/liter (0.045 mg/ml) inhibited both the 
      adhesion of platelets to connective tissue and the release of ADP as well as the 
      secondary wave of platelet aggregation produced with ADP or epinephrine; sodium 
      salicylate had no effect on these reactions, which were also normal in patients 
      with von Willebrand's disease. The inhibitory effect produced by ingesting a 
      single 1.8 g dose of aspirin was detectable for 4-7 days at which time salicylate 
      was no longer detectable in the blood, which suggested an irreversible effect on 
      the platelet. Aspirin also inhibited the release of platelet adenosine 
      triphosphate (ATP), but had no effect on the platelet surface charge, available 
      platelet ATP or ADP, or the destruction of ADP by plasma ADPase. These studies 
      lend further support to the hypothesis that ingestion of aspirin, in contrast to 
      sodium salicylate, prolongs the bleeding time by inhibiting the release of 
      platelet ADP, perhaps reflecting the findings in other cell systems which suggest 
      that aspirin alters membrane permeability.
FAU - Weiss, H J
AU  - Weiss HJ
FAU - Aledort, L M
AU  - Aledort LM
FAU - Kochwa, S
AU  - Kochwa S
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Adenine Nucleotides)
RN  - 0 (Placebos)
RN  - 0 (Salicylates)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenine Nucleotides
MH  - Aspirin/pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Tests
MH  - Blood Platelets/*drug effects
MH  - Cell Membrane Permeability/drug effects
MH  - Culture Techniques
MH  - Electrophoresis
MH  - Humans
MH  - Male
MH  - Placebos
MH  - Salicylates/*pharmacology
MH  - Sodium
PMC - PMC297378
EDAT- 1968/09/01 00:00
MHDA- 1968/09/01 00:01
CRDT- 1968/09/01 00:00
PHST- 1968/09/01 00:00 [pubmed]
PHST- 1968/09/01 00:01 [medline]
PHST- 1968/09/01 00:00 [entrez]
AID - 10.1172/JCI105903 [doi]
PST - ppublish
SO  - J Clin Invest. 1968 Sep;47(9):2169-80. doi: 10.1172/JCI105903.

PMID- 26283758
OWN - NLM
STAT- MEDLINE
DCOM- 20151103
LR  - 20220408
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 85
IP  - 7
DP  - 2015 Aug 18
TI  - Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: 
      CHANCE substudy.
PG  - 573-9
LID - 10.1212/WNL.0000000000001844 [doi]
AB  - OBJECTIVE: We compared the effect of clopidogrel plus aspirin vs aspirin alone on 
      functional outcome and quality of life in the Clopidogrel in High-risk Patients 
      with Acute Non-disabling Cerebrovascular Events (CHANCE) trial of 
      aspirin-clopidogrel vs aspirin alone after acute minor stroke or TIA. METHODS: 
      Participants were assessed at 90 days for functional outcome using the modified 
      Rankin Scale (mRS) and quality of life using the EuroQol-5 Dimension (EQ-5D). 
      Poor functional outcome was defined as mRS score of 2-6 at 90 days and poor 
      quality of life as EQ-5D index score of 0.5 or less. RESULTS: Poor functional 
      outcome occurred in 254 patients (9.9%) in the clopidogrel-aspirin group, as 
      compared with 299 (11.6%) in the aspirin group (p = 0.046). Poor quality of life 
      occurred in 142 (5.5%) in the clopidogrel-aspirin group and in 175 (6.8%) in the 
      aspirin group (p = 0.06). Disabling stroke at 90 days occurred in 166 (6.5%) in 
      the clopidogrel-aspirin group and in 219 (8.5%) in the aspirin group (p = 0.01). 
      In stratified analysis by subsequent stroke, there was no difference in 90-day 
      functional outcome and quality of life between the 2 groups. CONCLUSIONS: In 
      patients with minor stroke or TIA, the combination of clopidogrel and aspirin 
      appears to be superior to aspirin alone in improving the 90-day functional 
      outcome, and this is consistent with a reduction in the rate of disabling stroke 
      in the dual antiplatelet arm. CLASSIFICATION OF EVIDENCE: This study provides 
      Class II evidence that for patients with acute minor stroke or TIA, clopidogrel 
      plus aspirin compared to aspirin alone improves 90-day functional outcome 
      (absolute reduction of poor outcome 1.70%, 95% confidence interval 0.03%-3.42%).
CI  - © 2015 American Academy of Neurology.
FAU - Wang, Xianwei
AU  - Wang X
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Zhao, Xingquan
AU  - Zhao X
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Johnston, S Claiborne
AU  - Johnston SC
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Xian, Ying
AU  - Xian Y
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Hu, Bo
AU  - Hu B
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Wang, Chunxue
AU  - Wang C
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Wang, David
AU  - Wang D
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Liu, Liping
AU  - Liu L
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Li, Hao
AU  - Li H
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Fang, Jiming
AU  - Fang J
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Meng, Xia
AU  - Meng X
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Wang, Anxin
AU  - Wang A
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Wang, Yongjun
AU  - Wang Y
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada.
FAU - Wang, Yilong
AU  - Wang Y
AD  - From the Department of Neurology (X.W., X.Z., C.W., L.L., H.L., X.M., A.W., 
      Yongjun Wang, Yilong Wang), Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; the Departments of Neurology and Epidemiology (S.C.J.), 
      University of California, San Francisco; Duke Clinical Research Institute (DCRI) 
      (Y.X.), Duke University, Durham, NC; the Department of Quantitative Health 
      Sciences (B.H.), Cleveland Clinic, OH; INI Stroke Network (D.W.), OSF Healthcare 
      System, University of Illinois College of Medicine, Peoria; and Institute for 
      Clinical Evaluative Sciences (J.F.), Toronto, Canada. yilong528@gmail.com 
      yongjunwang1962@gmail.com.
CN  - CHANCE investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150717
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Neurology. 2015 Aug 18;85(7):562-3. PMID: 26187224
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Clopidogrel
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - *Outcome Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Quality of Life
MH  - Stroke/*drug therapy
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
PMC - PMC4548281
EDAT- 2015/08/19 06:00
MHDA- 2015/11/04 06:00
CRDT- 2015/08/19 06:00
PHST- 2014/11/23 00:00 [received]
PHST- 2015/04/16 00:00 [accepted]
PHST- 2015/08/19 06:00 [entrez]
PHST- 2015/08/19 06:00 [pubmed]
PHST- 2015/11/04 06:00 [medline]
AID - WNL.0000000000001844 [pii]
AID - NEUROLOGY2014632117 [pii]
AID - 10.1212/WNL.0000000000001844 [doi]
PST - ppublish
SO  - Neurology. 2015 Aug 18;85(7):573-9. doi: 10.1212/WNL.0000000000001844. Epub 2015 
      Jul 17.

PMID- 8786556
OWN - NLM
STAT- MEDLINE
DCOM- 19960920
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 276
IP  - 3
DP  - 1996 Mar
TI  - Effects of intravenous nonsteroidal antiinflammatory drugs on a C-fiber reflex 
      elicited by a wide range of stimulus intensities in the rat.
PG  - 1232-43
AB  - A C-fiber reflex elicited by electrical stimulation within the territory of the 
      sural nerve, was recorded from the ipsilateral biceps femoris muscle in 
      anesthetized rats. The temporal evolution of the response was studied using a 
      constant stimulus intensity (3 x threshold) and recruitment curves were built by 
      varying stimulus intensity from 0 to 7 x threshold. The i.v. administration of 
      aspirin, indomethacin, ketoprofen, paracetamol (= acetaminophen) and lysine 
      clonixinate resulted in dose-dependent depressions of the C-fiber reflex by up to 
      30 to 40%. By contrast, saline was ineffective. High doses of the effective drugs 
      that produced large disturbances in heart rate and/or acid-base equilibrium were 
      not considered in the pharmacological analysis. When a constant level of 
      stimulation was used, different dose-dependent profiles of drug action were 
      observed. Aspirin induced a slow and gradual depression, although indomethacin, 
      ketoprofen and paracetamol produced a peak effect within the first 10-min period 
      and then reached a steady state phase for up to 30 min. The depressive effects of 
      lysine clonixinate appeared more stable. When recruitment curves were built with 
      a range of nociceptive stimulus intensities, all the drugs produced a 
      dose-dependent decrease in the slopes and the areas under the recruitment curves 
      without any major modification in the thresholds. The order of potency was the 
      same for both stimulation paradigms, e.g., aspirin < paracetamol < lysine 
      clonixinate = ketoprofen < indomethacin. It is concluded that NSAID elicit 
      significant antinociceptive effects at a central level, which do not depend on 
      the existence of a hyperalgesic or inflammatory state.
FAU - Bustamante, D
AU  - Bustamante D
AD  - INSERM U161, Paris, France.
FAU - Paeile, C
AU  - Paeile C
FAU - Willer, J C
AU  - Willer JC
FAU - Le Bars, D
AU  - Le Bars D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Electric Stimulation
MH  - Indomethacin/pharmacology
MH  - Injections, Intravenous
MH  - Nerve Fibers/*drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reflex/*drug effects
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1996 Mar;276(3):1232-43.

PMID- 6783576
OWN - NLM
STAT- MEDLINE
DCOM- 19810613
LR  - 20191031
IS  - 0300-9785 (Print)
IS  - 0300-9785 (Linking)
VI  - 9
IP  - 6
DP  - 1980 Dec
TI  - A clinical trial of Suprofen and aspirin in post-operative dental pain.
PG  - 477-9
AB  - A double-blind trial comparing the analgesic efficacy of Suprofen 200 mg with 
      aspirin 750 mg was carried out on 120 patients. There was no statistical 
      difference between the two, though Suprofen had fewer side effects and could be 
      used in circumstances where aspirin is contra-indicated.
FAU - Markus, A F
AU  - Markus AF
FAU - Gough, D
AU  - Gough D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Denmark
TA  - Int J Oral Surg
JT  - International journal of oral surgery
JID - 0334641
RN  - 0 (Phenylpropionates)
RN  - 988GU2F9PE (Suprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - Suprofen/*therapeutic use
MH  - Tooth Extraction
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
AID - 10.1016/s0300-9785(80)80079-2 [doi]
PST - ppublish
SO  - Int J Oral Surg. 1980 Dec;9(6):477-9. doi: 10.1016/s0300-9785(80)80079-2.

PMID- 24831287
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20211021
IS  - 1545-1151 (Electronic)
IS  - 1545-1151 (Linking)
VI  - 11
DP  - 2014 May 15
TI  - A 16-month community-based intervention to increase aspirin use for primary 
      prevention of cardiovascular disease.
PG  - E83
LID - 10.5888/pcd11.130378 [doi]
LID - E83
AB  - INTRODUCTION: Cardiovascular diseases are the leading causes of disability and 
      death in the United States. Primary prevention of these events may be achieved 
      through aspirin use. The ability of a community-based intervention to increase 
      aspirin use has not been evaluated. The objective of this study was to evaluate 
      an educational intervention implemented to increase aspirin use for primary 
      prevention of cardiovascular disease in a small city in Minnesota. METHODS: A 
      community-based intervention was implemented during 16 months in a medium-sized 
      community in Minnesota. Messages for aspirin use were disseminated to 
      individuals, health care professionals, and the general population. Independent 
      cross-sectional samples of residents (men aged 45-79, women aged 55-79) were 
      surveyed by telephone to identify candidates for primary prevention aspirin use, 
      examine their characteristics, and determine regular aspirin use at baseline and 
      after the campaign at 4 months and 16 months. RESULTS: In primary prevention 
      candidates, regular aspirin use rates increased from 36% at baseline to 54% at 4 
      months (odds ratio = 2.05; 95% confidence interval, 1.09-3.88); the increase was 
      sustained at 52% at 16 months (odds ratio = 1.89; 95% confidence interval, 
      1.02-3.49). The difference in aspirin use rates at 4 months and 16 months was not 
      significant (P = .77). CONCLUSION: Aspirin use rates for primary prevention 
      remain low. A combined public health and primary care approach can increase and 
      sustain primary prevention aspirin use in a community setting.
FAU - Oldenburg, Niki C
AU  - Oldenburg NC
AD  - Cardiovascular Division, University of Minnesota Medical School, MMC 508, 420 
      Delaware St SE, Minneapolis, MN 55455. E-mail: olden019@umn.edu.
FAU - Duval, Sue
AU  - Duval S
AD  - University of Minnesota, Minneapolis, Minnesota.
FAU - Luepker, Russell V
AU  - Luepker RV
AD  - University of Minnesota, Minneapolis, Minnesota.
FAU - Finnegan, John R
AU  - Finnegan JR
AD  - University of Minnesota, Minneapolis, Minnesota.
FAU - LaMarre, Heather
AU  - LaMarre H
AD  - University of Minnesota, Minneapolis, Minnesota.
FAU - Peterson, Kevin A
AU  - Peterson KA
AD  - University of Minnesota, Minneapolis, Minnesota.
FAU - Zantek, Nicole D
AU  - Zantek ND
AD  - University of Minnesota, Minneapolis, Minnesota.
FAU - Jacobs, Ginny
AU  - Jacobs G
AD  - University of Minnesota, Minneapolis, Minnesota.
FAU - Straka, Robert J
AU  - Straka RJ
AD  - University of Minnesota, Minneapolis, Minnesota.
FAU - Miller, Karen H
AU  - Miller KH
AD  - University of Minnesota, Minneapolis, Minnesota.
FAU - Hirsch, Alan T
AU  - Hirsch AT
AD  - University of Minnesota, Minneapolis, Minnesota.
LA  - eng
GR  - R01 HL126041/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140515
PL  - United States
TA  - Prev Chronic Dis
JT  - Preventing chronic disease
JID - 101205018
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Prev Chronic Dis. 2014;11:E172. PMID: 25299978
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - *Community Health Services
MH  - Cross-Sectional Studies
MH  - Drug Utilization
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Minnesota
MH  - Primary Prevention
MH  - Program Evaluation
PMC - PMC4023687
EDAT- 2014/05/17 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/05/17 06:00
PHST- 2014/05/17 06:00 [entrez]
PHST- 2014/05/17 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - E83 [pii]
AID - 13_0378 [pii]
AID - 10.5888/pcd11.130378 [doi]
PST - epublish
SO  - Prev Chronic Dis. 2014 May 15;11:E83. doi: 10.5888/pcd11.130378.

PMID- 21297996
OWN - NLM
STAT- MEDLINE
DCOM- 20110802
LR  - 20211020
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 6
IP  - 1
DP  - 2011 Jan 28
TI  - Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a 
      population-based nested case-control study.
PG  - e16412
LID - 10.1371/journal.pone.0016412 [doi]
LID - e16412
AB  - BACKGROUND: Despite strong laboratory evidence that non-steroidal 
      anti-inflammatory drugs (NSAIDs) could prevent prostate cancer, epidemiological 
      studies have so far reported conflicting results. Most studies were limited by 
      lack of information on dosage and duration of use of the different classes of 
      NSAIDs. METHODS: We conducted a nested case-control study using data from 
      Saskatchewan Prescription Drug Plan (SPDP) and Cancer Registry to examine the 
      effects of dose and duration of use of five classes of NSAIDs on prostate cancer 
      risk. Cases (N = 9,007) were men aged ≥40 years diagnosed with prostatic 
      carcinoma between 1985 and 2000, and were matched to four controls on age and 
      duration of SPDP membership. Detailed histories of exposure to prescription 
      NSAIDs and other drugs were obtained from the SPDP. RESULTS: Any use of 
      propionates (e.g., ibuprofen, naproxen) was associated with a modest reduction in 
      prostate cancer risk (Odds ratio = 0.90; 95%CI 0.84-0.95), whereas use of other 
      NSAIDs was not. In particular, we did not observe the hypothesized inverse 
      association with aspirin use (1.01; 0.95-1.07). There was no clear evidence of 
      dose-response or duration-response relationships for any of the examined NSAID 
      classes. CONCLUSIONS: Our findings suggest modest benefits of at least some 
      NSAIDs in reducing prostate cancer risk.
FAU - Mahmud, Salaheddin M
AU  - Mahmud SM
AD  - Department of Oncology, McGill University, Montreal, Canada. 
      Salah.mahmud@gmail.com
FAU - Franco, Eduardo L
AU  - Franco EL
FAU - Turner, Donna
AU  - Turner D
FAU - Platt, Robert W
AU  - Platt RW
FAU - Beck, Patricia
AU  - Beck P
FAU - Skarsgard, David
AU  - Skarsgard D
FAU - Tonita, Jon
AU  - Tonita J
FAU - Sharpe, Colin
AU  - Sharpe C
FAU - Aprikian, Armen G
AU  - Aprikian AG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20110128
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Propionates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Case-Control Studies
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Propionates/pharmacology/therapeutic use
MH  - Prostatic Neoplasms/*drug therapy/epidemiology/prevention & control
MH  - Risk
PMC - PMC3030588
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2011/02/08 06:00
MHDA- 2011/08/04 06:00
CRDT- 2011/02/08 06:00
PHST- 2010/11/02 00:00 [received]
PHST- 2010/12/14 00:00 [accepted]
PHST- 2011/02/08 06:00 [entrez]
PHST- 2011/02/08 06:00 [pubmed]
PHST- 2011/08/04 06:00 [medline]
AID - PONE-D-10-04518 [pii]
AID - 10.1371/journal.pone.0016412 [doi]
PST - epublish
SO  - PLoS One. 2011 Jan 28;6(1):e16412. doi: 10.1371/journal.pone.0016412.

PMID- 31090213
OWN - NLM
STAT- MEDLINE
DCOM- 20200806
LR  - 20210109
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 23
IP  - 7
DP  - 2019 Jul
TI  - Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 
      pathway.
PG  - 4514-4522
LID - 10.1111/jcmm.14332 [doi]
AB  - Colorectal cancer (CRC) is one of the most widespread malignant cancers, with a 
      high incidence and mortality all over the world. Aspirin (ASA) otherwise known as 
      acetylsalicylic acid, is a non-steroidal anti-inflammatory drug that has shown 
      promising results in the prevention of chronic diseases, including several 
      cancers. In previous studies, aspirin has been shown to reduce the incidence of 
      CRC. Immune checkpoint blockade of T cell Ig and ITIM domain receptor (TIGIT) 
      alone or combined with other immune checkpoint blockades moleculars has gained 
      impressive results in the treatment of the melanoma and glioblastoma. Here, we 
      found that TIGIT and Poliovirus receptor (PVR, CD155) are expressed in tumour 
      cells; the TIGIT and CD155 protein expression in cancer tissue has been found to 
      be significantly higher than that in the precancerous tissue. T cell Ig and ITIM 
      domain receptor and CD226 were expressed in the lymphocytes near the tumour 
      tissue and the adjacent tissues. Aspirin has been found to inhibit cancer cell 
      viability and promote CRC cell apoptosis.Similarly, aspirin has also been found 
      to increase pro-apoptotic protein Bax's expression. We found that the expression 
      of TIGIT decreased with an increase in the concentration of aspirin and that the 
      suppression of TIGIT can affect the effect of aspirin on cell proliferation. In 
      this paper, we found that aspirin attenuates cancer cell proliferation and 
      induces CRC cells apoptosis by down-regulating the expression of TIGIT, which 
      provides new evidence for the application of aspirin in cancer treatment.
CI  - © 2019 The Authors. Journal of Cellular and Molecular Medicine published by John 
      Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
FAU - Ma, Bin
AU  - Ma B
AD  - Department of Laboratory Medicine, College of Clinical Medicine, Ningxia Medical 
      University, Yinchuan, China.
AD  - Department of Oncology Surgery, The First People's Hospital of Yinchuan, 
      Yinchuan, China.
FAU - Duan, Xiangguo
AU  - Duan X
AD  - Department of Laboratory Medicine, College of Clinical Medicine, Ningxia Medical 
      University, Yinchuan, China.
AD  - Department of Laboratory Surgery, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Zhou, Qiunan
AU  - Zhou Q
AUID- ORCID: 0000-0002-9523-1973
AD  - Department of Laboratory Medicine, College of Clinical Medicine, Ningxia Medical 
      University, Yinchuan, China.
FAU - Liu, Juanxi
AU  - Liu J
AD  - Department of Laboratory Medicine, College of Clinical Medicine, Ningxia Medical 
      University, Yinchuan, China.
FAU - Yang, Xiaojuan
AU  - Yang X
AD  - Department of Laboratory Medicine, College of Clinical Medicine, Ningxia Medical 
      University, Yinchuan, China.
FAU - Zhang, Dong
AU  - Zhang D
AD  - Department of Colorectal Surgery, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Yang, Shaoqi
AU  - Yang S
AD  - Department of Gastroenterology, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Du, Yong
AU  - Du Y
AD  - Department of Laboratory Surgery, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Li, Hai
AU  - Li H
AD  - Department of Colorectal Surgery, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Su, Chunxia
AU  - Su C
AD  - Department of Pathogen Biology and Immunology, School of Basic Medical Science, 
      Ningxia Medical University, Yinchuan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190514
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (Antigens, Differentiation, T-Lymphocyte)
RN  - 0 (CD226 antigen)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, Virus)
RN  - 0 (TIGIT protein, human)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 0 (poliovirus receptor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antigens, Differentiation, T-Lymphocyte/metabolism
MH  - Apoptosis/drug effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cell Movement/drug effects
MH  - Cell Survival/drug effects
MH  - Colorectal Neoplasms/*drug therapy/pathology/*prevention & control
MH  - HT29 Cells
MH  - Humans
MH  - Lymphocytes/metabolism
MH  - Receptors, Immunologic/*metabolism
MH  - Receptors, Virus/*metabolism
MH  - *Signal Transduction/drug effects
MH  - bcl-2-Associated X Protein/metabolism
PMC - PMC6584546
OTO - NOTNLM
OT  - CD155
OT  - CD226
OT  - TIGIT
OT  - aspirin
OT  - cell proliferation
OT  - colorectal cancer
COIS- The authors declare no conflict of interest.
EDAT- 2019/05/16 06:00
MHDA- 2020/08/07 06:00
CRDT- 2019/05/16 06:00
PHST- 2018/11/29 00:00 [received]
PHST- 2019/03/25 00:00 [revised]
PHST- 2019/03/27 00:00 [accepted]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2020/08/07 06:00 [medline]
PHST- 2019/05/16 06:00 [entrez]
AID - JCMM14332 [pii]
AID - 10.1111/jcmm.14332 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2019 Jul;23(7):4514-4522. doi: 10.1111/jcmm.14332. Epub 2019 May 
      14.

PMID- 14551522
OWN - NLM
STAT- MEDLINE
DCOM- 20040621
LR  - 20131121
IS  - 0026-4725 (Print)
IS  - 0026-4725 (Linking)
VI  - 51
IP  - 5
DP  - 2003 Oct
TI  - The expanding role of antiplatelet agents in coronary artery disease. A current 
      review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines.
PG  - 531-46
AB  - The platelet has assumed an increasingly important role in cardiovascular 
      medicine as our understanding of the pathophysiology of acute coronary syndromes 
      (ACS) has evolved. Plaque rupture, platelet aggregation, and thrombus formation 
      occur as a result of complex interaction between the platelet, the endothelium, 
      and various inflammatory cells and circulating proteins. Aspirin continues to 
      form the foundation of any anti-ischemic regimen, but cardiologists have long 
      recognized the need for newer, more potent antiplatelet agents. Glycoprotein 
      IIb/IIIa receptor antagonists and thienopryidines have been developed over the 
      past decade and now serve as powerful complements to aspirin in the prevention 
      and treatment of coronary events. The paper will begin with a review of aspirin 
      as well as a discussion of the concept of aspirin resistance. The rapidly 
      expanding body of knowledge supporting the use of glycoprotein IIb/IIIa receptor 
      blockers and thienopyridines will then be addressed, with an emphasis on 
      reconciling recent controversies in the literature. Future advances in the 
      treatment of coronary artery disease will likely occur as we further refine the 
      role of these established antiplatelet drugs and develop agents that bind to 
      novel targets in the thrombotic cascade.
FAU - Hostetter, J C
AU  - Hostetter JC
AD  - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 
      44195, USA.
FAU - Bhatt, D L
AU  - Bhatt DL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Minerva Cardioangiol
JT  - Minerva cardioangiologica
JID - 0400725
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
MH  - Pyridines/*therapeutic use
RF  - 125
EDAT- 2003/10/11 05:00
MHDA- 2004/06/24 05:00
CRDT- 2003/10/11 05:00
PHST- 2003/10/11 05:00 [pubmed]
PHST- 2004/06/24 05:00 [medline]
PHST- 2003/10/11 05:00 [entrez]
PST - ppublish
SO  - Minerva Cardioangiol. 2003 Oct;51(5):531-46.

PMID- 8211029
OWN - NLM
STAT- MEDLINE
DCOM- 19931118
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 123
IP  - 38
DP  - 1993 Sep 25
TI  - [Therapy of acute salicylate poisoning].
PG  - 1775-83
AB  - Poisoning with salicylic acid and its derivatives is a quite common event, 
      leading to possibly life-threatening complications. A case of fatal intoxication 
      of a sixty-year old patient with acetylsalicylic acid is described and the 
      therapeutic options are discussed. In acute poisoning it is mandatory to initiate 
      simple and effective measures first. This gives time for discussing and planning 
      the more laborious procedures. The initial treatment of salicylate poisoning is 
      based on the prevention of further absorption by a sufficiently large quantity of 
      orally administered activated charcoal (approximately 1 g/kg b.w.). Given 
      repeatedly, activated charcoal may enhance non-renal clearance of salicylates. 
      Intravenously administered sodium bicarbonate counteracts the metabolic acidosis. 
      Moreover, bicarbonate therapy limits tissue distribution of the drug and enhances 
      its renal excretion. The availability of glycine for salicylic acid metabolism 
      may be limited in poisoning because glycine has been used for forming the 
      conjugation product salicyluric acid. Glycine may be administered orally to 
      overcome this bottleneck. Gastric lavage has been proven to be of limited 
      efficacy. This efficacy is further diminished if gastric lavage is performed late 
      after drug ingestion. When it is performed, however, activated charcoal should be 
      administered before and after gastric lavage. Whenever the more simple treatment 
      options fail, hemodialysis or hemoperfusion should be additionally considered 
      since these procedures are effective in removing salicylates from the body.
FAU - Herren, T
AU  - Herren T
AD  - Medizinische Universitätsklinik, Inselspital Bern.
FAU - Como, F
AU  - Como F
FAU - Krähenbühl, S
AU  - Krähenbühl S
FAU - Wyss, P A
AU  - Wyss PA
LA  - ger
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Die Therapie der akuten Salizylatintoxikation.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 0 (Salicylates)
RN  - 16291-96-6 (Charcoal)
RN  - 8MDF5V39QO (Sodium Bicarbonate)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Aspirin/metabolism/poisoning
MH  - Charcoal/therapeutic use
MH  - Coma/chemically induced
MH  - Fatal Outcome
MH  - Female
MH  - Fever/chemically induced
MH  - Gastric Lavage
MH  - Glycine/therapeutic use
MH  - Hemoperfusion
MH  - Humans
MH  - Middle Aged
MH  - Poisoning/therapy
MH  - Renal Dialysis
MH  - Salicylates/*poisoning
MH  - Sodium Bicarbonate/therapeutic use
RF  - 73
EDAT- 1993/09/25 00:00
MHDA- 1993/09/25 00:01
CRDT- 1993/09/25 00:00
PHST- 1993/09/25 00:00 [pubmed]
PHST- 1993/09/25 00:01 [medline]
PHST- 1993/09/25 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1993 Sep 25;123(38):1775-83.

PMID- 2509212
OWN - NLM
STAT- MEDLINE
DCOM- 19891208
LR  - 20190824
IS  - 0014-2972 (Print)
IS  - 0014-2972 (Linking)
VI  - 19
IP  - 3
DP  - 1989 Jun
TI  - Protection of the rat gastric mucosa against aspirin injury by arachidonic acid: 
      a dietary prostaglandin precursor fatty acid.
PG  - 278-90
AB  - We studied aspirin-induced injury to the gastric mucosa in control rats 
      pretreated with a solubilizer, pluronic F-68 (PL), and in rats pretreated with 
      solubilized arachidonic acid (AA). Fasted male rats were pretreated 
      intragastrically with 1 ml of either pluronic or AA and 1 h later acidified ASA 
      (1 ml suspension of 200 mg kg-1 body weight) was administered intragastrically. 
      Grossly apparent mucosal lesions developed 1 h after aspirin in 
      pluronic-pretreated rats, but were significantly reduced in AA-pretreated rats. 
      Histology, scanning and transmission electron microscopy demonstrated that AA 
      pretreatment did not prevent aspirin-induced initial damage to the surface 
      epithelium but did significantly reduce extent of aspirin-induced deep mucosal 
      necrosis at 1, 4 and 18 h after aspirin. Initial aspirin-induced surface 
      epithelial damage was rapidly restituted by two distinct types of 
      re-epithelialization - vertical and horizontal. While the vertical type of 
      re-epithelialization has been reported previously as the first stage of mucosal 
      repair following injury by various noxious agents such as concentrated ethanol, 
      the horizontal type of re-epithelialization, which is described for the first 
      time in this paper, seems to be specific for the repair of aspirin-induced 
      gastric mucosal injury. These studies suggest that dietary factors such as 
      essential fatty acids may play a role in gastric mucosal protection against 
      aspirin injury.
FAU - Tarnawski, A
AU  - Tarnawski A
AD  - Department of Medicine, VA Medical Center, Long Beach, CA 90822.
FAU - Hollander, D
AU  - Hollander D
FAU - Stachura, J
AU  - Stachura J
FAU - Krause, W J
AU  - Krause WJ
FAU - Gergely, H
AU  - Gergely H
LA  - eng
GR  - R0I AM 32856/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Arachidonic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acids/*pharmacology
MH  - Aspirin/*adverse effects
MH  - Gastric Mucosa/*drug effects
MH  - Microscopy, Electron
MH  - Microscopy, Electron, Scanning
MH  - Potentiometry
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Tissue Survival/drug effects
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2362.1989.tb00231.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 1989 Jun;19(3):278-90. doi: 
      10.1111/j.1365-2362.1989.tb00231.x.

PMID- 11827363
OWN - NLM
STAT- MEDLINE
DCOM- 20021018
LR  - 20191105
IS  - 1590-8658 (Print)
IS  - 1590-8658 (Linking)
VI  - 33 Suppl 2
DP  - 2001 Dec
TI  - Analgesia and cyclo-oxygenase inhibitors.
PG  - S8-11
AB  - Non-steroidal anti-inflammatory drugs are among the most commonly used 
      medications and they are a mainstay in the treatment of inflammatory diseases. 
      Non-steroidal anti-inflammatory drugs are widely used to reduce pain associated 
      with acute or chronic inflammation. Recently, a new class of inhibitors of the 
      inducible enzyme cyclo-oxygenase-2 have become available. These inhibitors 
      selectively target the inducible enzyme and have been shown to spare the 
      gastrointestinal tract. While a role of cyclo-oxygenase-2 in the development of 
      chronic inflammation has been well established, its role in pain perception is 
      still unclear. Recent experimental data led to the hypothesis that 
      cyclo-oxygenase-1 plays an important role in pain perception. This short review 
      addresses some recent preclinical data as well as some clinical evidence showing 
      that cyclo-oxygenase-1 is an important component of inflammatory pain.
FAU - Meli, R
AU  - Meli R
AD  - Department of Experimental Pharmacology, Federico II University of Naples, Italy.
FAU - Antonelli, E
AU  - Antonelli E
FAU - Cirino, G
AU  - Cirino G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (Analgesics)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*pharmacology/therapeutic use
MH  - Humans
MH  - Inflammation/drug therapy
MH  - Isoenzymes/*metabolism
MH  - Membrane Proteins
MH  - Pain/drug therapy
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
RF  - 6
EDAT- 2002/02/06 10:00
MHDA- 2002/10/19 04:00
CRDT- 2002/02/06 10:00
PHST- 2002/02/06 10:00 [pubmed]
PHST- 2002/10/19 04:00 [medline]
PHST- 2002/02/06 10:00 [entrez]
AID - S1590-8658(01)80153-5 [pii]
AID - 10.1016/s1590-8658(01)80153-5 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2001 Dec;33 Suppl 2:S8-11. doi: 10.1016/s1590-8658(01)80153-5.

PMID- 6433412
OWN - NLM
STAT- MEDLINE
DCOM- 19841022
LR  - 20161123
IS  - 0034-5288 (Print)
IS  - 0034-5288 (Linking)
VI  - 37
IP  - 1
DP  - 1984 Jul
TI  - Effect of lysine-acetylsalicylate and phenylbutazone premedication on the protein 
      content of secondary aqueous humour in the dog.
PG  - 26-9
AB  - Inhibitory effects of the anti-inflammatory agents lysine-acetylsalicylate (LAS) 
      and phenylbutazone (PBZ) on the breakdown of the blood-aqueous barrier by 
      paracentesis were studied in canine eyes using protein determination of ocular 
      fluid. In the untreated eyes the aqueous protein value was raised from 0.29 +/- 
      0.17 (mean +/- SD) g litre-1 at the initial paracentesis to 14.47 +/- 4.10 g 
      litre-1 at the second paracentesis. Pretreatment with LAS or PBZ had no 
      significant effect on the protein concentration of the primary aqueous humour. 
      However the secondary aqueous protein concentration was only 10.05 +/- 7.00 g 
      litre-1 with LAS and 5.80 +/- 3.83 g litre-1 with PBZ. With both drugs the 
      maximum inhibitory effect was observed on the gammaglobulins and albumin. These 
      results suggest that prostaglandins may be involved in the response of the canine 
      eye to paracentesis and that premedication with LAS or PBZ may be of value in 
      reducing postoperative ocular inflammation.
FAU - Regnier, A
AU  - Regnier A
FAU - Bonnefoi, M
AU  - Bonnefoi M
FAU - Lescure, F
AU  - Lescure F
LA  - eng
PT  - Journal Article
PL  - England
TA  - Res Vet Sci
JT  - Research in veterinary science
JID - 0401300
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Eye Proteins)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aqueous Humor/drug effects/*metabolism
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Dogs/metabolism/*surgery
MH  - Drainage/veterinary
MH  - Eye Proteins/*metabolism
MH  - Female
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
MH  - Phenylbutazone/*pharmacology
MH  - Premedication/*veterinary
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
PST - ppublish
SO  - Res Vet Sci. 1984 Jul;37(1):26-9.

PMID- 8999349
OWN - NLM
STAT- MEDLINE
DCOM- 19970123
LR  - 20131121
IS  - 0028-2162 (Print)
IS  - 0028-2162 (Linking)
VI  - 140
IP  - 49
DP  - 1996 Dec 7
TI  - [Colonic varices: an unusual cause of occult blood loss].
PG  - 2467-9
AB  - A man aged 81 known to suffer from atrial fibrillation - the treatment for which 
      included acetylsalicylic acid - and chronic obstructive pulmonary disease, was 
      hospitalized because of a respiratory infection. Since he had iron deficiency 
      anaemia and the case history mentioned "intestinal bleeding', supplementary 
      examinations were carried out. Endoscopy revealed colonic varices; because of the 
      absence of portal hypertension and other disorders related to colonic varices, 
      the varices were classified as idiopathic. In view of the extensiveness of the 
      lesions, it was decided to refrain from endoscopic sclerotherapy and to adopt an 
      expectative policy.
FAU - Loffeld, R J
AU  - Loffeld RJ
AD  - Afd. Interne Geneeskunde, Ziekenhuis De Heel, Zaandam.
FAU - van Bochove, A
AU  - van Bochove A
FAU - de Graaf, J C
AU  - de Graaf JC
LA  - dut
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Colonvarices: een zeldzame oorzaak van occult bloedverlies.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects
MH  - Colon/*blood supply
MH  - Humans
MH  - Male
MH  - Occult Blood
MH  - Varicose Veins/chemically induced/*diagnosis
EDAT- 1996/12/07 00:00
MHDA- 1996/12/07 00:01
CRDT- 1996/12/07 00:00
PHST- 1996/12/07 00:00 [pubmed]
PHST- 1996/12/07 00:01 [medline]
PHST- 1996/12/07 00:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 1996 Dec 7;140(49):2467-9.

PMID- 5551245
OWN - NLM
STAT- MEDLINE
DCOM- 19710526
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 1
IP  - 5751
DP  - 1971 Mar 27
TI  - Effect of aspirin on renal clearance of 125I-diatrizoate.
PG  - 707-8
AB  - Glomerular filtration rate was measured from the plasma disappearance curve after 
      a single injection of sodium (125)I-diatrizoate. A therapeutic dose of aspirin in 
      13 subjects produced a mean fall in glomerular filtration rate of 10.5%.
FAU - Beeley, L
AU  - Beeley L
FAU - Kendall, M J
AU  - Kendall MJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Iodine Isotopes)
RN  - 117-96-4 (Diatrizoate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Diatrizoate/*urine
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Iodine Isotopes
MH  - Kidney/drug effects/*metabolism
PMC - PMC1795500
EDAT- 1971/03/27 00:00
MHDA- 1971/03/27 00:01
CRDT- 1971/03/27 00:00
PHST- 1971/03/27 00:00 [pubmed]
PHST- 1971/03/27 00:01 [medline]
PHST- 1971/03/27 00:00 [entrez]
AID - 10.1136/bmj.1.5751.707 [doi]
PST - ppublish
SO  - Br Med J. 1971 Mar 27;1(5751):707-8. doi: 10.1136/bmj.1.5751.707.

PMID- 7469621
OWN - NLM
STAT- MEDLINE
DCOM- 19810413
LR  - 20201209
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 141
IP  - 3 Spec No
DP  - 1981 Feb 23
TI  - Aspirin and acetaminophen as constituents of analgesic combinations.
PG  - 293-300
AB  - Aspirin and acetaminophen are the mainstays of oral analgesic combinations. One 
      group of combinations is composed of antipyretic-analgesics combined with each 
      other. The superior efficacy of such combinations as compared with an optimal 
      dose of one of the constituents remains to be proved, and there is little 
      evidence that such combinations have less adverse-effect liability than a single 
      agent. On the other hand, there is substantial evidence that combinations of an 
      optimal dose of aspirin or acetaminophen with a narcotic (eg, codeine, 
      hydrocodone, or oxycodone) produce an additive analgesic effect greater than that 
      obtained by doubling the dose of either constituent administered alone. There is 
      also some evidence that the adverse effects produced by such combinations are 
      less than would be produced by an equianalgesic dose of a single constituent.
FAU - Beaver, W T
AU  - Beaver WT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Analgesics)
RN  - 0 (Drug Combinations)
RN  - 0 (Narcotics)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Acetaminophen/*administration & dosage
MH  - *Analgesics/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Caffeine/administration & dosage
MH  - Codeine/administration & dosage
MH  - Dextropropoxyphene/administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Humans
MH  - Narcotics/administration & dosage
EDAT- 1981/02/23 00:00
MHDA- 1981/02/23 00:01
CRDT- 1981/02/23 00:00
PHST- 1981/02/23 00:00 [pubmed]
PHST- 1981/02/23 00:01 [medline]
PHST- 1981/02/23 00:00 [entrez]
AID - 10.1001/archinte.141.3.293 [doi]
PST - ppublish
SO  - Arch Intern Med. 1981 Feb 23;141(3 Spec No):293-300. doi: 
      10.1001/archinte.141.3.293.

PMID- 2264023
OWN - NLM
STAT- MEDLINE
DCOM- 19910201
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 59
IP  - 6
DP  - 1990 Sep 15
TI  - The antiplatelet effect of daily low dose enteric-coated aspirin in man: a time 
      course of onset and recovery.
PG  - 995-1005
AB  - We have studied the onset and recovery of inhibition of platelet function by low 
      dose aspirin. Enteric-coated aspirin 50mg daily was administered to five human 
      volunteers for five weeks and then 100mg daily was given for a further five 
      weeks. We studied platelet aggregation and thromboxane formation in response to a 
      range of stimuli: ADP, adrenaline, arachidonate and collagen, and also measured 
      thromboxane formation after coagulation of whole blood (serum thromboxane). The 
      onset of inhibition of platelet aggregation was progressive over several days for 
      each of the four platelet stimuli, and was synchronous with the inhibition of 
      thromboxane formation. Maximum inhibition occurred by day three for the weak 
      stimuli ADP and adrenaline, by day five for the stronger stimuli arachidonate and 
      collagen, but did not occur until day eight for serum thromboxane. Further 
      inhibitory effects on both aggregation and thromboxane generation were observed 
      after 100mg daily. Two weeks after the cessation of aspirin the responses to 
      collagen and arachidonate and serum thromboxane had returned to normal. Platelet 
      aggregation in response to the weaker stimuli, ADP and adrenaline, still showed 
      detectable inhibition two weeks after cessation of aspirin, but had returned to 
      normal by four weeks. These experiments provided no evidence for an effect of 
      aspirin on platelets separate to its effect on cyclooxygenase. The onset and 
      recovery of inhibition of platelet function by low dose aspirin was dependent on 
      the strength of the stimulus studied.
FAU - Vanags, D
AU  - Vanags D
AD  - Department of Clinical and Experimental Pharmacology, University of Adelaide, 
      South Australia.
FAU - Rodgers, S E
AU  - Rodgers SE
FAU - Lloyd, J V
AU  - Lloyd JV
FAU - Bochner, F
AU  - Bochner F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - *Platelet Aggregation Inhibitors
MH  - Tablets, Enteric-Coated
MH  - Thromboxane B2/blood
EDAT- 1990/09/15 00:00
MHDA- 1990/09/15 00:01
CRDT- 1990/09/15 00:00
PHST- 1990/09/15 00:00 [pubmed]
PHST- 1990/09/15 00:01 [medline]
PHST- 1990/09/15 00:00 [entrez]
AID - 10.1016/0049-3848(90)90123-t [doi]
PST - ppublish
SO  - Thromb Res. 1990 Sep 15;59(6):995-1005. doi: 10.1016/0049-3848(90)90123-t.

PMID- 2874952
OWN - NLM
STAT- MEDLINE
DCOM- 19861022
LR  - 20200825
IS  - 0742-8413 (Print)
IS  - 0742-8413 (Linking)
VI  - 84
IP  - 2
DP  - 1986
TI  - Gastric mucus glycoprotein in different rat strains.
PG  - 359-61
AB  - The extent of gastric damage induced by aspirin was found to differ according to 
      rat strain. The occurrence of ulcers varied, from high to low, in the following 
      strain order: Donryu, Sprague-Dawley (SD) and Wistar. The content of corpus mucus 
      glycoprotein was essentially the same in all the strains: about 6 mg as hexose of 
      dry tissue. Antral mucus glycoprotein content increased in the order Wistar, SD 
      and Donryu: 7.1, 8.3 and 9.1 mg, respectively. Gastric mucus glycoprotein 
      carbohydrate composition was essentially the same in all three strains. The 
      relatively low proportions of N-acetylglucosamine, galactose and sialic acid from 
      the antrum was a characteristic feature in contrast to mucus glycoprotein from 
      the corpus which contained a high proportion of these sugars.
FAU - Tsurui, M
AU  - Tsurui M
FAU - Harada, Y
AU  - Harada Y
FAU - Ohara, S
AU  - Ohara S
FAU - Hotta, K
AU  - Hotta K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Comp Biochem Physiol C Comp Pharmacol Toxicol
JT  - Comparative biochemistry and physiology. C, Comparative pharmacology and 
      toxicology
JID - 8310013
RN  - 0 (Carbohydrates)
RN  - 0 (Glycoproteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Carbohydrates/analysis
MH  - Glycoproteins/*metabolism
MH  - Male
MH  - Mucus/drug effects/*metabolism
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Species Specificity
MH  - Stomach Ulcer/chemically induced
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1016/0742-8413(86)90105-2 [doi]
PST - ppublish
SO  - Comp Biochem Physiol C Comp Pharmacol Toxicol. 1986;84(2):359-61. doi: 
      10.1016/0742-8413(86)90105-2.

PMID- 16118381
OWN - NLM
STAT- MEDLINE
DCOM- 20050830
LR  - 20220317
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 294
IP  - 8
DP  - 2005 Aug 24
TI  - Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of 
      colorectal cancer.
PG  - 914-23
AB  - CONTEXT: Randomized trials of short-term aspirin use for prevention of recurrent 
      colorectal adenoma have provided compelling evidence of a causal relationship 
      between aspirin and colorectal neoplasia. However, data on long-term risk of 
      colorectal cancer according to dose, timing, or duration of therapy with aspirin 
      and other nonsteroidal anti-inflammatory drugs (NSAIDs) remain limited. 
      OBJECTIVE: To examine the influence of aspirin and NSAIDs in prevention of 
      colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study of 
      82 911 women enrolled in the Nurses' Health Study providing data on medication 
      use biennially since 1980 and followed up through June 1, 2000. MAIN OUTCOME 
      MEASURE: Incident colorectal cancer. RESULTS: Over a 20-year period, we 
      documented 962 cases of colorectal cancer. Among women who regularly used aspirin 
      (> or =2 standard [325-mg] tablets per week), the multivariate relative risk (RR) 
      for colorectal cancer was 0.77 (95% confidence interval [CI], 0.67-0.88) compared 
      with nonregular users. However, significant risk reduction was not observed until 
      more than 10 years of use (P< or =.001 for trend). The benefit appeared related 
      to dose: compared with women who reported no use, the multivariate RRs for cancer 
      were 1.10 (95% CI, 0.92-1.31) for women who used 0.5 to 1.5 standard aspirin 
      tablets per week, 0.89 (95% CI, 0.73-1.10) for 2 to 5 aspirin per week, 0.78 (95% 
      CI, 0.62-0.97) for 6 to 14 aspirin per week, and 0.68 (95% CI, 0.49-0.95) for 
      more than 14 aspirin per week (P<.001 for trend). Notably, women who used more 
      than 14 aspirin per week for longer than 10 years in the past had a multivariate 
      RR for cancer of 0.47 (95% CI, 0.31-0.71). A similar dose-response relationship 
      was found for nonaspirin NSAIDs (P = .007 for trend). The incidence of reported 
      major gastrointestinal bleeding events per 1000 person-years also appeared to be 
      dose-related: 0.77 among women who denied any aspirin use; 1.07 for 0.5 to 1.5 
      standard aspirin tablets per week; 1.07 for 2 to 5 aspirin per week; 1.40 for 6 
      to 14 aspirin per week; and 1.57 for more than 14 aspirin per week. CONCLUSIONS: 
      Regular, long-term aspirin use reduces risk of colorectal cancer. Nonaspirin 
      NSAIDs appear to have a similar effect. However, a significant benefit of aspirin 
      is not apparent until more than a decade of use, with maximal risk reduction at 
      doses greater than 14 tablets per week. These results suggest that optimal 
      chemoprevention for colorectal cancer requires long-term use of aspirin doses 
      substantially higher than those recommended for prevention of cardiovascular 
      disease, but the dose-related risk of gastrointestinal bleeding must also be 
      considered.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, 
      Boston, Mass 02114, USA. achan@partners.org
FAU - Giovannucci, Edward L
AU  - Giovannucci EL
FAU - Meyerhardt, Jeffrey A
AU  - Meyerhardt JA
FAU - Schernhammer, Eva S
AU  - Schernhammer ES
FAU - Curhan, Gary C
AU  - Curhan GC
FAU - Fuchs, Charles S
AU  - Fuchs CS
LA  - eng
GR  - CA107412/CA/NCI NIH HHS/United States
GR  - P01 CA087969/CA/NCI NIH HHS/United States
GR  - P01 CA055075/CA/NCI NIH HHS/United States
GR  - K07 CA107412/CA/NCI NIH HHS/United States
GR  - CA55075/CA/NCI NIH HHS/United States
GR  - CA 87969/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - CMAJ. 2005 Nov 8;173(10):1159-60. PMID: 16275965
CIN - JAMA. 2005 Dec 28;294(24):3090; author reply 3090-1. PMID: 16380587
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cohort Studies
MH  - Colorectal Neoplasms/epidemiology/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prospective Studies
MH  - Risk
MH  - Surveys and Questionnaires
PMC - PMC1550973
MID - NIHMS4906
EDAT- 2005/08/25 09:00
MHDA- 2005/09/01 09:00
CRDT- 2005/08/25 09:00
PHST- 2005/08/25 09:00 [pubmed]
PHST- 2005/09/01 09:00 [medline]
PHST- 2005/08/25 09:00 [entrez]
AID - 294/8/914 [pii]
AID - 10.1001/jama.294.8.914 [doi]
PST - ppublish
SO  - JAMA. 2005 Aug 24;294(8):914-23. doi: 10.1001/jama.294.8.914.

PMID- 36951435
OWN - NLM
STAT- MEDLINE
DCOM- 20230529
LR  - 20230821
IS  - 2641-7650 (Electronic)
IS  - 2641-7650 (Linking)
VI  - 4
IP  - 5
DP  - 2023 May 1
TI  - Effects of Aspirin on Kidney Biopsy Bleeding Complications: A Systematic Review 
      and Meta-Analysis (PROSPERO 2021 CRD42021261005).
PG  - 700-710
LID - 10.34067/KID.0000000000000091 [doi]
AB  - Postprocedural bleeding is the main complication of percutaneous kidney biopsy 
      (PKB). Therefore, aspirin is routinely withheld in patients undergoing PKB to 
      reduce the bleeding risk. The authors aimed to examine the association between 
      aspirin use and bleeding during PKB. This systematic review and meta-analysis was 
      performed according to the Preferred Reporting Items for Systematic Reviews and 
      Meta-Analyses guidelines. The article search was performed on MEDLINE and Scopus 
      using queries specific to each database. Article inclusion was limited to primary 
      studies. The meta-analysis compared the risk of major bleeding events between the 
      aspirin-exposed versus nonexposed group. Pooled effect estimate was examined 
      using random effects presented as odds ratio with 95% confidence intervals. 
      Heterogeneity was assessed through Cochrane I 2 test statistics. Sensitivity and 
      subgroup analyses were also performed according to kidney type. Ten studies were 
      included in the review and four studies were included in the meta-analysis, 
      reviewing a total of 34,067 PKBs. Definitions for significant aspirin exposure 
      were inconsistent between studies, limiting comparisons. Studies with broader 
      definitions for aspirin exposure mostly showed no correlation between aspirin use 
      and postbiopsy bleeding. Studies with strict definitions for aspirin exposure 
      found an increased risk of hemorrhagic events in the aspirin-exposed group. No 
      significant differences were found between the aspirin-exposed and comparison 
      groups regarding major bleeding events (odds ratio 1.72; 95% confidence interval 
      0.50 to 5.89, I 2 =84%). High-quality evidence on the effect of aspirin on the 
      bleeding risk is limited. Our meta-analysis did not show a significantly 
      increased risk of major bleeding complications in aspirin-exposed patients. 
      Further studies are needed to define a more comprehensive approach for clinical 
      practice.
CI  - Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of the American Society of Nephrology.
FAU - Relvas, Miguel
AU  - Relvas M
AUID- ORCID: 0000-0002-2947-1610
AD  - Nephrology Department, Centro Hospitalar Universitário de São João, Porto, 
      Portugal.
FAU - Gonçalves, Joana
AU  - Gonçalves J
AUID- ORCID: 0000-0001-7570-6022
AD  - Department of Medicine, Faculty of Medicine, University of Porto, Porto, 
      Portugal.
FAU - Castro, Inês
AU  - Castro I
AUID- ORCID: 0000-0001-7570-6022
AD  - Department of Medicine, Faculty of Medicine, University of Porto, Porto, 
      Portugal.
FAU - Diniz, Hugo
AU  - Diniz H
AUID- ORCID: 0000-0002-8476-1338
AD  - Nephrology Department, Centro Hospitalar Universitário de São João, Porto, 
      Portugal.
FAU - Mendonça, Luís
AU  - Mendonça L
AUID- ORCID: 0000-0003-1951-3941
AD  - Nephrology Department, Centro Hospitalar Universitário de São João, Porto, 
      Portugal.
AD  - Department of Surgery and Physiology, UnIC@RISE, Faculty of Medicine of the 
      University of Porto, Porto, Portugal.
FAU - Coentrão, Luís
AU  - Coentrão L
AUID- ORCID: 0000-0003-1124-5073
AD  - Nephrology Department, Centro Hospitalar Universitário de São João, Porto, 
      Portugal.
AD  - Department of Medicine, Faculty of Medicine, University of Porto, Porto, 
      Portugal.
AD  - Nephrology & Infectious Diseases R&D, i3S-Institute for Research & Innovation in 
      Health, Porto, Portugal.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230323
PL  - United States
TA  - Kidney360
JT  - Kidney360
JID - 101766381
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Aspirin/adverse effects
MH  - *Hemorrhage/chemically induced/epidemiology
MH  - Kidney
MH  - Biopsy/adverse effects
PMC - PMC10278841
COIS- H. Diniz reports the following: Consultancy: CSL and Vifor; Honoraria: 
      AstraZeneca; Patents or Royalties: Nephrology-applied Point-of-care Ultrasound 
      course—POCUSX, Braga, Portugal; Speakers Bureau: AstraZeneca, CSL, and Vifor; and 
      Other Interests or Relationships: Braga, POCUSX, Porto; Young Nephrologist 
      Platform—European Renal Association, Board member. L. Mendonça reports the 
      following: Honoraria: AstraZeneca; and Speakers Bureau: AstraZeneca. M. Relvas 
      reports the following: Ownership Interest: Biomarin Pharmaceutical and Viatris; 
      Honoraria: Sanofi; and Speakers Bureau: Sanofi. All remaining authors have 
      nothing to disclose.
EDAT- 2023/03/24 06:00
MHDA- 2023/05/29 06:42
CRDT- 2023/03/23 08:53
PHST- 2022/06/09 00:00 [received]
PHST- 2023/01/27 00:00 [accepted]
PHST- 2023/05/29 06:42 [medline]
PHST- 2023/03/24 06:00 [pubmed]
PHST- 2023/03/23 08:53 [entrez]
AID - 02200512-202305000-00020 [pii]
AID - K360-2023-000153 [pii]
AID - 10.34067/KID.0000000000000091 [doi]
PST - ppublish
SO  - Kidney360. 2023 May 1;4(5):700-710. doi: 10.34067/KID.0000000000000091. Epub 2023 
      Mar 23.

PMID- 36480246
OWN - NLM
STAT- MEDLINE
DCOM- 20230207
LR  - 20230227
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 20
IP  - 2
DP  - 2023 Feb 6
TI  - Relative Humidity Cycling: Implications on the Stability of Moisture-Sensitive 
      Drugs in Solid Pharmaceutical Products.
PG  - 1072-1085
LID - 10.1021/acs.molpharmaceut.2c00812 [doi]
AB  - The stability of a moisture-sensitive drug in tablet formulations depends 
      particularly on the environment's relative humidity (RH) and the products' prior 
      exposure to moisture. This study was designed to understand drug stability in 
      relation to the moisture interaction of the excipients, moisture history of the 
      tablets, and RH of the environment. The stability study was performed on tablets 
      containing acetylsalicylic acid (ASA), formulated with common pharmaceutical 
      excipients like native maize starch, microcrystalline cellulose (MCC), partially 
      pregelatinized maize starch (PGS), dicalcium phosphate dihydrate (DCP), lactose, 
      and mannitol. The tablets were subjected to storage conditions with RH cycling 
      alternating between 53% and 75%. Results were also compared to tablets stored at 
      a constant RH of 53% or 75%. The excipients demonstrated marked differences in 
      their interactions with moisture. They could be broadly grouped as excipients 
      with RH-dependent moisture content (native maize starch, MCC, and PGS) and 
      RH-independent moisture content (DCP, lactose, and mannitol). As each excipient 
      interacted differently with moisture, degradation of ASA in the tablets depended 
      on the excipients' ability to modulate the moisture availability for degradation. 
      The lowest ASA degradation was observed in tablets formulated with low moisture 
      content water-soluble excipients, such as lactose and mannitol. The impact of RH 
      cycling on ASA stability was apparent in tablets containing native maize starch, 
      MCC, PGS, or DCP. These findings suggested that the choice of excipients 
      influences the effect of moisture history on drug stability. The results from 
      studies investigating moisture interaction of excipients and drug stability are 
      valuable to understanding the inter-relationship between excipients, moisture 
      history, and drug stability.
FAU - Veronica, Natalia
AU  - Veronica N
AD  - GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, 
      National University of Singapore, 18 Science Drive 4, Singapore117543, Singapore.
FAU - Heng, Paul Wan Sia
AU  - Heng PWS
AD  - GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, 
      National University of Singapore, 18 Science Drive 4, Singapore117543, Singapore.
FAU - Liew, Celine Valeria
AU  - Liew CV
AUID- ORCID: 0000-0002-1752-2759
AD  - School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar 
      Sunway, 47500 Subang Jaya, Selangor, Malaysia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221208
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 0 (Excipients)
RN  - J2B2A4N98G (Lactose)
RN  - 9005-25-8 (Starch)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
RN  - 3OWL53L36A (Mannitol)
SB  - IM
MH  - *Excipients/chemistry
MH  - *Lactose
MH  - Humidity
MH  - Starch/chemistry
MH  - Tablets/chemistry
MH  - Aspirin/chemistry
MH  - Drug Stability
MH  - Mannitol/chemistry
OTO - NOTNLM
OT  - excipients
OT  - moisture history
OT  - moisture sorption
OT  - relative humidity cycling
OT  - stability
EDAT- 2022/12/09 06:00
MHDA- 2023/02/08 06:00
CRDT- 2022/12/08 14:53
PHST- 2022/12/09 06:00 [pubmed]
PHST- 2023/02/08 06:00 [medline]
PHST- 2022/12/08 14:53 [entrez]
AID - 10.1021/acs.molpharmaceut.2c00812 [doi]
PST - ppublish
SO  - Mol Pharm. 2023 Feb 6;20(2):1072-1085. doi: 10.1021/acs.molpharmaceut.2c00812. 
      Epub 2022 Dec 8.

PMID- 11109530
OWN - NLM
STAT- MEDLINE
DCOM- 20001228
LR  - 20131121
IS  - 0869-2092 (Print)
IS  - 0869-2092 (Linking)
VI  - 63
IP  - 5
DP  - 2000 Sep-Oct
TI  - [Effect of ammonium succinate on pharmacological effects of acetylsalicylic 
      acid].
PG  - 56-8
AB  - Ammonia succinate potentiates the main pharmacological properties and reduces the 
      toxic effects (ulcerogenic action and general toxicity) of acetylsalicylic acid. 
      The new preparation astam, representing a combination of acetylsalicylic acid 
      with ammonia succinate in a 2:1 ratio, is proposed. Astam exhibits antiexudative, 
      capillary-reinforcing, antiproliferative, pain-relieving, antipyretic, 
      antiaggregant, and antioxidant properties. In addition, the drug inhibits the 
      development of structural-metabolic disorders in the case of chronic immune 
      inflammation of joints and various internal organs.
FAU - Saratikov, A S
AU  - Saratikov AS
AD  - Pharmacology Department, Siberian Medical University, Tomsk, Russia.
FAU - Bulatnikov, A P
AU  - Bulatnikov AP
FAU - Vengerovskiĭ, A I
AU  - Vengerovskiĭ AI
FAU - Prishchep, T P
AU  - Prishchep TP
FAU - Sibileva, L A
AU  - Sibileva LA
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Vliianie ammoniia suktsinata na farmacologicheskie éffekty kisloty 
      atsetilsalitsilovoĭ.
PL  - Russia (Federation)
TA  - Eksp Klin Farmakol
JT  - Eksperimental'naia i klinicheskaia farmakologiia
JID - 9215981
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (aspirin, succinic acid drug combination)
RN  - AB6MNQ6J6L (Succinic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use/toxicity
MH  - Antioxidants/pharmacology/therapeutic use/toxicity
MH  - Arthritis, Experimental/drug therapy/metabolism
MH  - Aspirin/*pharmacology/therapeutic use/toxicity
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Female
MH  - Lethal Dose 50
MH  - Male
MH  - Mice
MH  - Peptic Ulcer/chemically induced
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use/toxicity
MH  - Rats
MH  - Succinic Acid/*pharmacology/therapeutic use/toxicity
MH  - Toxicity Tests, Acute
EDAT- 2000/12/08 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/12/08 11:00
PHST- 2000/12/08 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/12/08 11:00 [entrez]
PST - ppublish
SO  - Eksp Klin Farmakol. 2000 Sep-Oct;63(5):56-8.

PMID- 6420215
OWN - NLM
STAT- MEDLINE
DCOM- 19840312
LR  - 20190721
IS  - 0012-1606 (Print)
IS  - 0012-1606 (Linking)
VI  - 101
IP  - 2
DP  - 1984 Feb
TI  - Phenocritical times in the process of in vitro shoot organogenesis.
PG  - 382-90
AB  - Shoot organogenesis occurs when leaf explants of Convolvulus arvensis are 
      cultured on Murashige and Skoog salts, sucrose, vitamins, and 0.05 mg/liter IAA 
      with 7.0 mg/liter 2-isopentenyl adenine. Under the influence of this shoot 
      inducing medium (SIM), the explants become competent for the organogenic effects 
      of SIM and eventually become determined for shoot formation. The induction 
      process includes five separate transient sensitivities to inhibitors. Such 
      stage-specific inhibitions reflect phenocritical times in development rather than 
      general metabolic toxicities. The phenocopying agents are tri-iodobenzoic acid 
      (TIBA), sorbitol, ribose, ammonium ion, and acetylsalicylic acid. The process of 
      in vitro shoot organogenesis from leaf explants is now seen to include a series 
      of discrete steps which precede morphological differentiation. An initial 
      dedifferentiation process results in the formation of competent callus tissue 
      along the cut edges of the explant. Under the influence of the phytohormone 
      balance in SIM, shoot organogenic induction proceeds. This process involves a 
      time which is sensitive to inhibition by salicylates followed by a time sensitive 
      to TIBA which is followed in turn by a time sensitive to sorbitol and culminates 
      in cells or groups of cells determined for shoot formation. This process also 
      includes a time sensitive to inhibition by ribose, although its place in the 
      order of events is not yet firmly assigned. There is also a sensitivity to 
      ammonium ion (or lack of nitrate) at or near the time the explant becomes 
      determined for shoot production.
FAU - Christianson, M L
AU  - Christianson ML
FAU - Warnick, D A
AU  - Warnick DA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dev Biol
JT  - Developmental biology
JID - 0372762
RN  - 0 (Culture Media)
RN  - 0 (Quaternary Ammonium Compounds)
RN  - 0 (Triiodobenzoic Acids)
RN  - 506T60A25R (Sorbitol)
RN  - 681HV46001 (Ribose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Culture Media
MH  - Culture Techniques
MH  - *Plant Physiological Phenomena
MH  - Plants/drug effects
MH  - Quaternary Ammonium Compounds/pharmacology
MH  - Ribose/pharmacology
MH  - Sorbitol/pharmacology
MH  - Time Factors
MH  - Triiodobenzoic Acids/pharmacology
EDAT- 1984/02/01 00:00
MHDA- 1984/02/01 00:01
CRDT- 1984/02/01 00:00
PHST- 1984/02/01 00:00 [pubmed]
PHST- 1984/02/01 00:01 [medline]
PHST- 1984/02/01 00:00 [entrez]
AID - 0012-1606(84)90152-0 [pii]
AID - 10.1016/0012-1606(84)90152-0 [doi]
PST - ppublish
SO  - Dev Biol. 1984 Feb;101(2):382-90. doi: 10.1016/0012-1606(84)90152-0.

PMID- 7994376
OWN - NLM
STAT- MEDLINE
DCOM- 19950117
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 22
IP  - 3
DP  - 1994
TI  - Vasoconstrictor effects in isolated rabbit heart perfused with 
      bis(3,5-dibromosalicyl)fumarate cross-linked hemoglobin (alpha alpha Hb).
PG  - 565-75
AB  - To study the mechanism by which cell-free hemoglobin preparations may alter 
      coronary vascular reactivity, we investigated the effect of human hemoglobin 
      cross-linked between alpha chains with bis(3,5-dibromosalicyl)fumarate (alpha 
      alpha Hb) on the vasomotor response to acetylcholine (ACh) in isolated perfused 
      rabbit hearts. Dose-response curves were generated by monitoring the increase in 
      coronary pressure during serial addition of 0.2-10 microM ACh before, during and 
      after 20 min infusion of three test solutions: a) 0.1 g/dl alpha alpha Hb (62 
      microM heme); b) 0.1 g/dl alpha alpha Hb plus 60 microM deferoxamine (DFO); c) 50 
      microM NG-nitro-L-arginine methyl ester (L-NAME), a specific inhibitor of nitric 
      oxide (NO) synthase. We found that the sensitivity to ACh-induced 
      vasoconstriction was significantly potentiated in the presence of alpha alpha Hb 
      and L-NAME. In addition, this response was only partially reversed after removal 
      of alpha alpha Hb, except when DFO was simultaneously infused with the alpha 
      alpha Hb solution. These findings are consistent with the idea that both NO 
      binding to hemoglobin and iron-mediated oxygen free radical generation contribute 
      to an altered coronary vasomotor responsiveness induced by cell-free hemoglobin.
FAU - Macdonald, V W
AU  - Macdonald VW
AD  - Letterman Army Institute of Research Presidio of San Francisco, CA 94129-6800.
FAU - Motterlini, R
AU  - Motterlini R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (hemoglobin XL99alpha)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 94ZLA3W45F (Arginine)
RN  - J06Y7MXW4D (Deferoxamine)
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Acetylcholine/administration & dosage/pharmacology
MH  - Animals
MH  - Arginine/administration & dosage/analogs & derivatives/pharmacology
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Blood Pressure/drug effects
MH  - Blood Substitutes/administration & dosage/*pharmacology
MH  - Deferoxamine/administration & dosage/pharmacology
MH  - Drug Synergism
MH  - Heart/*drug effects
MH  - Hemoglobins/administration & dosage/*pharmacology
MH  - In Vitro Techniques
MH  - Male
MH  - NG-Nitroarginine Methyl Ester
MH  - Nitric Oxide/antagonists & inhibitors
MH  - Perfusion
MH  - Rabbits
MH  - Vasoconstriction/*drug effects
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/10731199409117885 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):565-75. doi: 
      10.3109/10731199409117885.

PMID- 9435549
OWN - NLM
STAT- MEDLINE
DCOM- 19980209
LR  - 20190522
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 273
IP  - 6
DP  - 1997 Dec
TI  - Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin 
      derivative: role of neutrophils.
PG  - G1246-51
LID - 10.1152/ajpgi.1997.273.6.G1246 [doi]
AB  - The gastric damage associated with hemorrhagic shock appears to occur, at least 
      in part, through neutrophil-dependent mechanisms. Nitric oxide (NO)-releasing 
      derivatives of aspirin have been shown to spare the gastrointestinal tract of 
      injury. As NO can inhibit neutrophil adherence, it is possible that such a 
      derivative of aspirin (NCX-4016) would exert inhibitory effects on neutrophil 
      adherence and therefore be capable of protecting the stomach against 
      shock-induced gastric damage. This hypothesis was tested in this study. Oral 
      administration of NCX-4016 or glyceryl trinitrate or depletion of circulating 
      neutrophils with antineutrophil serum significantly reduced the extent of gastric 
      damage induced by hemorrhagic shock, whereas aspirin had no effect. NCX-4016 and 
      antineutrophil serum pretreatment resulted in significant preservation of gastric 
      blood flow during the shock period. Moreover, NCX-4016, but not aspirin, was 
      capable of inhibiting N-formyl-Met-Leu-Phe-induced leukocyte adherence to 
      postcapillary mesenteric venules. These results suggest that an NO-releasing 
      aspirin derivative reduces the susceptibility of the stomach to shock-induced 
      damage through inhibitory effects on neutrophil adherence to the vascular 
      endothelium.
FAU - Wallace, J L
AU  - Wallace JL
AD  - Department of Pharmacology and Therapeutics, University of Calgary, Alberta, 
      Canada.
FAU - McKnight, W
AU  - McKnight W
FAU - Wilson, T L
AU  - Wilson TL
FAU - Del Soldato, P
AU  - Del Soldato P
FAU - Cirino, G
AU  - Cirino G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Cell Adhesion/drug effects
MH  - Gastric Mucosa/blood supply/drug effects/*pathology
MH  - Male
MH  - Neutrophils/drug effects/*physiology
MH  - Nitric Oxide/*pharmacology
MH  - Nitroglycerin/pharmacology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Regional Blood Flow/drug effects
MH  - Shock, Hemorrhagic/pathology/*physiopathology/*prevention & control
EDAT- 1998/01/22 00:00
MHDA- 1998/01/22 00:01
CRDT- 1998/01/22 00:00
PHST- 1998/01/22 00:00 [pubmed]
PHST- 1998/01/22 00:01 [medline]
PHST- 1998/01/22 00:00 [entrez]
AID - 10.1152/ajpgi.1997.273.6.G1246 [doi]
PST - ppublish
SO  - Am J Physiol. 1997 Dec;273(6):G1246-51. doi: 10.1152/ajpgi.1997.273.6.G1246.

PMID- 17304886
OWN - NLM
STAT- MEDLINE
DCOM- 20070313
LR  - 20131121
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 98
IP  - 2
DP  - 2007 Feb
TI  - Aspirin challenge and desensitization for aspirin-exacerbated respiratory 
      disease: a practice paper.
PG  - 172-4
AB  - Aspirin desensitization is indicated for patients who have aspirin-exacerbated 
      respiratory disease and whose asthma and/or rhinosinusitis is suboptimally 
      controlled with inhaled corticosteroids and leukotriene-modifying drugs. In this 
      practice paper, the general requirements for aspirin desensitization are 
      presented, the locations where desensitizations can be safely performed are 
      outlined, prechallenge patient preparation is discussed, an oral aspirin 
      challenge protocol is presented, treatment of adverse reactions is reviewed, and 
      maintenance of aspirin desensitization is discussed.
FAU - Macy, Eric
AU  - Macy E
AD  - SCPMG-Kaiser Permanente San Diego, California, USA.
FAU - Bernstein, Jonathan A
AU  - Bernstein JA
FAU - Castells, Mariana C
AU  - Castells MC
FAU - Gawchik, Sandra M
AU  - Gawchik SM
FAU - Lee, Tak H
AU  - Lee TH
FAU - Settipane, Russell A
AU  - Settipane RA
FAU - Simon, Ronald A
AU  - Simon RA
FAU - Wald, Jeffrey
AU  - Wald J
FAU - Woessner, Katharine M
AU  - Woessner KM
CN  - Aspirin Desensitization Joint Task Force
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Allergy Asthma Immunol. 2007 Aug;99(2):196; author reply 196-7. PMID: 
      17718110
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/immunology/*therapeutic 
      use
MH  - Aspirin/adverse effects/immunology/*therapeutic use
MH  - Asthma/chemically induced/drug therapy/prevention & control
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/*drug therapy/prevention & control
MH  - Humans
MH  - Rhinitis/chemically induced/drug therapy/prevention & control
MH  - Sinusitis/chemically induced/drug therapy/prevention & control
EDAT- 2007/02/20 09:00
MHDA- 2007/03/14 09:00
CRDT- 2007/02/20 09:00
PHST- 2007/02/20 09:00 [pubmed]
PHST- 2007/03/14 09:00 [medline]
PHST- 2007/02/20 09:00 [entrez]
AID - S1081-1206(10)60692-8 [pii]
AID - 10.1016/S1081-1206(10)60692-8 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2007 Feb;98(2):172-4. doi: 
      10.1016/S1081-1206(10)60692-8.

PMID- 22187066
OWN - NLM
STAT- MEDLINE
DCOM- 20120606
LR  - 20131121
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 107
IP  - 2
DP  - 2012 Feb
TI  - Use of aspirin in Chinese after recovery from primary intracranial haemorrhage.
PG  - 241-7
LID - 10.1160/TH11-06-0439 [doi]
AB  - Intracranial haemorrhage (ICH) accounts for ~35% of all strokes in Chinese. 
      Anti-platelet agent is often avoided after an index event due to the possibility 
      of recurrent ICH. This single-centered observational study included 440 
      consecutive Chinese patients with a first spontaneous ICH surviving the first 
      month performed during 1996-2010. The subjects were identified, and their 
      clinical characteristics, anti-platelet therapy after ICH, and outcomes including 
      recurrent ICH, ischaemic stroke, and acute coronary syndrome were checked from 
      hospital records. Of these 440 patients, 56 patients (12.7%) were prescribed 
      aspirin (312 patient-aspirin years). After a follow-up of 62.2 ± 1.8 months, 47 
      patients had recurrent ICH (10.7%, 20.6 per 1,000 patient years). Patients 
      prescribed aspirin did not have a higher risk of recurrent ICH compared with 
      those not prescribed aspirin (22.7 per 1,000 patient-aspirin years vs. 22.4 per 
      1,000 patient years, p=0.70). Multivariate analysis identified age > 60 years 
      (hazard ratio [HR]: 2.0, 95% confidence interval [CI]: 1.07-3.85, p=0.03) and 
      hypertension (HR: 2.0, 95% CI: 1.06-3.75, p=0.03) as independent predictors for 
      recurrent ICH. In a subgroup analysis including 127 patients with standard 
      indications for aspirin of whom 56 were prescribed aspirin, the incidence of 
      combined vascular events including recurrent ICH, ischaemic stroke, and acute 
      coronary syndrome was statistically lower in patients prescribed aspirin than 
      those not prescribed aspirin (52.4 per 1,000 patient-aspirin years, vs. 112.8 per 
      1,000 patient-years, p=0.04). In conclusion, we observed in a cohort of Chinese 
      post-ICH patients that aspirin use was not associated with an increased risk for 
      a recurrent ICH.
FAU - Chong, Boon-Hor
AU  - Chong BH
AD  - Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, the 
      University of Hong Kong, Hong Kong SAR, China.
FAU - Chan, Koon-Ho
AU  - Chan KH
FAU - Pong, Vincent
AU  - Pong V
FAU - Lau, Kui-Kai
AU  - Lau KK
FAU - Chan, Yap-Hang
AU  - Chan YH
FAU - Zuo, Ming-Liang
AU  - Zuo ML
FAU - Lui, Wai-Man
AU  - Lui WM
FAU - Leung, Gilberto Ka-Kit
AU  - Leung GK
FAU - Lau, Chu-Pak
AU  - Lau CP
FAU - Tse, Hung-Fat
AU  - Tse HF
FAU - Pu, Jenny Kan-Suen
AU  - Pu JK
FAU - Siu, Chung-Wah
AU  - Siu CW
LA  - eng
PT  - Journal Article
DEP - 20111221
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Intracranial Hemorrhages/drug therapy/*physiopathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Recurrence
MH  - Registries
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2011/12/22 06:00
MHDA- 2012/06/07 06:00
CRDT- 2011/12/22 06:00
PHST- 2011/06/29 00:00 [received]
PHST- 2011/11/04 00:00 [accepted]
PHST- 2011/12/22 06:00 [entrez]
PHST- 2011/12/22 06:00 [pubmed]
PHST- 2012/06/07 06:00 [medline]
AID - 11-06-0439 [pii]
AID - 10.1160/TH11-06-0439 [doi]
PST - ppublish
SO  - Thromb Haemost. 2012 Feb;107(2):241-7. doi: 10.1160/TH11-06-0439. Epub 2011 Dec 
      21.

PMID- 28039526
OWN - NLM
STAT- MEDLINE
DCOM- 20170329
LR  - 20181113
IS  - 1432-1971 (Electronic)
IS  - 0172-0643 (Linking)
VI  - 38
IP  - 2
DP  - 2017 Feb
TI  - Platelet Inhibition in Shunted Infants on Aspirin at Short and Midterm Follow-Up.
PG  - 401-409
LID - 10.1007/s00246-016-1529-x [doi]
AB  - There are few data to guide aspirin therapy to prevent shunt thrombosis in 
      infants. We aimed to determine if aspirin administered at conventional dosing in 
      shunted infants resulted in ≥50% arachidonic acid (AA) inhibition in short and 
      midterm follow-up using thromboelastography with platelet mapping (TEG-PM) and to 
      describe bleeding and thrombotic events during follow-up. We performed a 
      prospective observational study of infants on aspirin following Norwood 
      procedure, aortopulmonary shunt alone, or cavopulmonary shunt surgery. We 
      obtained TEG-PM preoperatively, after the third dose of aspirin, at the first 
      postoperative clinic visit, and 2-8 months after surgery. The primary outcome was 
      the proportion of subjects with ≥50% AA inhibition on aspirin. All bleeding and 
      thrombotic events were collected. Of 24 infants analyzed, 13% had ≥50% AA 
      inhibition at all designated time points after aspirin initiation; 38% had ≥50% 
      AA inhibition after the third aspirin dose of aspirin, 60% at the first 
      postoperative clinic visit, and 26% 2-8 months after surgery. Bleeding events 
      occurred in eight subjects, and two had a thrombotic event. Bleeding events were 
      associated with greater AA inhibition just prior to starting aspirin (p = 0.02) 
      and after the third dose of aspirin (p = 0.04), and greater ADP inhibition before 
      surgery (p = 0.03). The majority of infants failed to consistently have ≥50% AA 
      inhibition when checked longitudinally postoperatively. Preoperative TEG-PM may 
      be useful in identifying infants at higher risk of bleeding events on aspirin in 
      the early postoperative period. Further research is needed to guide antiplatelet 
      therapy in this population.
FAU - Truong, Dongngan T
AU  - Truong DT
AD  - Division of Cardiology, Department of Pediatrics, Primary Children's Hospital and 
      University of Utah, 81 North Mario Capecchi Drive, Salt Lake City, UT, 84113, 
      USA. dongngan.truong@hsc.utah.edu.
FAU - Johnson, Joyce T
AU  - Johnson JT
AD  - Division of Cardiology, Department of Pediatrics, Ann and Robert H. Lurie 
      Children's Hospital, Northwestern University Feinberg School of Medicine, 225 E. 
      Chicago Ave, Chicago, IL, 60611, USA.
FAU - Bailly, David K
AU  - Bailly DK
AD  - Division of Critical Care, Department of Pediatrics, Primary Children's Hospital 
      and University of Utah, 81 North Mario Capecchi Drive, Salt Lake City, UT, 84113, 
      USA.
FAU - Clawson, Jason R
AU  - Clawson JR
AD  - Division of Pediatric Neurosurgery, Department of Neurosurgery, Primary 
      Children's Hospital and University of Utah, 81 North Mario Capecchi Drive, Salt 
      Lake City, UT, 84113, USA.
FAU - Sheng, Xiaoming
AU  - Sheng X
AD  - Department of Pediatrics, Primary Children's Hospital and University of Utah, 81 
      North Mario Capecchi Drive, Salt Lake City, UT, 84113, USA.
FAU - Burch, Phillip T
AU  - Burch PT
AD  - Division of Pediatric Cardiothoracic Surgery, Department of Surgery, Primary 
      Children's Hospital and University of Utah, 81 North Mario Capecchi Drive, Salt 
      Lake City, UT, 84113, USA.
FAU - Witte, Madolin K
AU  - Witte MK
AD  - Division of Critical Care, Department of Pediatrics, Primary Children's Hospital 
      and University of Utah, 81 North Mario Capecchi Drive, Salt Lake City, UT, 84113, 
      USA.
FAU - LuAnn Minich, L
AU  - LuAnn Minich L
AD  - Division of Cardiology, Department of Pediatrics, Primary Children's Hospital and 
      University of Utah, 81 North Mario Capecchi Drive, Salt Lake City, UT, 84113, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20161230
PL  - United States
TA  - Pediatr Cardiol
JT  - Pediatric cardiology
JID - 8003849
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiac Surgical Procedures/*adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Defects, Congenital/*surgery
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Infant
MH  - Linear Models
MH  - Male
MH  - Pilot Projects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Prospective Studies
MH  - Thrombelastography
MH  - Thrombosis/*epidemiology/etiology/*prevention & control
OTO - NOTNLM
OT  - Blood
OT  - Coagulation/anticoagulation
OT  - Congenital heart disease
EDAT- 2017/01/01 06:00
MHDA- 2017/03/31 06:00
CRDT- 2017/01/01 06:00
PHST- 2016/05/27 00:00 [received]
PHST- 2016/11/11 00:00 [accepted]
PHST- 2017/01/01 06:00 [pubmed]
PHST- 2017/03/31 06:00 [medline]
PHST- 2017/01/01 06:00 [entrez]
AID - 10.1007/s00246-016-1529-x [pii]
AID - 10.1007/s00246-016-1529-x [doi]
PST - ppublish
SO  - Pediatr Cardiol. 2017 Feb;38(2):401-409. doi: 10.1007/s00246-016-1529-x. Epub 
      2016 Dec 30.

PMID- 2504081
OWN - NLM
STAT- MEDLINE
DCOM- 19890920
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 40
IP  - 9
DP  - 1989 Sep
TI  - Attenuation of reactive hyperemia caused by aspirin in canine coronary artery.
PG  - 824-9
AB  - Effects of intracoronary aspirin on coronary blood flow and reactive hyperemia 
      were evaluated in closed-chest, anesthetized dogs. In 18 dogs the left circumflex 
      coronary artery was cannulated and perfused by arterial blood at a constant 
      pressure. Coronary blood flow was measured by an electromagnetic flowmeter. 
      Intracoronary aspirin at doses of 5, 10, and 20 mg reduced coronary blood flow in 
      a dose-dependent manner. Injection of aspirin at doses of 10 to 25 mg also 
      inhibited reactive hyperemia following the coronary occlusion for fifteen 
      seconds. The mean peak flow ratio was reduced from 2.13 +/- 0.42 to 1.75 +/- 0.35 
      (p less than 0.005). The increment of coronary blood flow provoked by 
      intracoronary arachidonic acid at doses of 150 to 300 micrograms was almost 
      entirely inhibited by the pretreatment of the coronary artery with aspirin. The 
      authors conclude that aspirin increases coronary arterial resistance in a 
      dose-dependent manner and also restricts the maximal dilating capacity, possibly 
      by inhibition of prostacyclin synthesis.
FAU - Miyajima, S
AU  - Miyajima S
AD  - First Department of Internal Medicine, Niigata University School of Medicine 
      Japan.
FAU - Aizawa, Y
AU  - Aizawa Y
FAU - Shibata, A
AU  - Shibata A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Arachidonic Acids)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/antagonists & inhibitors/pharmacology
MH  - Aspirin/*pharmacology
MH  - Coronary Circulation/*drug effects
MH  - Depression, Chemical
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Hyperemia/*chemically induced/physiopathology
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
AID - 10.1177/000331978904000909 [doi]
PST - ppublish
SO  - Angiology. 1989 Sep;40(9):824-9. doi: 10.1177/000331978904000909.

PMID- 22551483
OWN - NLM
STAT- MEDLINE
DCOM- 20150413
LR  - 20181201
IS  - 2340-3284 (Electronic)
IS  - 0034-9356 (Linking)
VI  - 59
IP  - 4
DP  - 2012 Apr
TI  - [Low-dose aspirin doesn't increase surgical bleeding nor transfusion rate in 
      total knee arthroplasty].
PG  - 180-6
LID - 10.1016/j.redar.2012.02.006 [doi]
AB  - OBJECTIVES: Surgical bleeding. transfusion rate and cardiovascular complications 
      were analized in patients undergoing chronic treatment with low-doses aspirin and 
      scheduled to unilateral primary knee arthroplasty. PATIENTS AND METHODS: We 
      retrospectively studied 117 patients between 2005 and 2006 scheduled for elective 
      knee replacement that received antiplatelet therapy with aspirin (100mg/day). 
      Aspirin medication was maintained or discontinued preoperatively according to 
      medical criteria. We analyzed the biological, clinical and anesthetic data, 
      blood-saving techniques used, surgical bleeding, allogeneic blood transfusion 
      rate, cardiocirculatory complications (myocardial, cerebral or peripheral 
      ischemia), hospital stay and mortality. This population was compared with 190 
      patients (control group) who underwent the same operation at the same time 
      interval but did not receive aspirin therapy. RESULTS: The aspirin-treated group 
      was significantly older, with higher weight and poorer health state (higher 
      incidence of ischemic heart disease, cerebral ischemia and diabetes). The hidden 
      and external surgical bleeding and transfusion rate were similar if the aspirin 
      were interrupted or not, preoperatively. Bleeding and transfusion rates were 
      independent of time of interruption of the aspirin. Hospital mortality was zero 
      in the 2 groups. A acute myocardial infarction and a transient stroke happened in 
      two patients wich aspirin treatment was discontinued. CONCLUSIONS: Preoperative 
      treatment with low doses of aspirin does not increase surgical bleeding and 
      transfusion rate in total knee arthroplasty. Preoperative discontinuation can 
      cause severe cardiocirculatory complications.
CI  - Copyright © 2011 Sociedad Española de Anestesiología, Reanimación y Terapéutica 
      del Dolor. Published by Elsevier España. All rights reserved.
FAU - Castillo Monsegur, J
AU  - Castillo Monsegur J
AD  - Servicio de Anestesiología, Hospital Mar-Esperança, Parc de Salut Mar, Barcelona, 
      España.
FAU - Bisbe Vives, E
AU  - Bisbe Vives E
FAU - Santiveri Papiol, X
AU  - Santiveri Papiol X
FAU - López Bosque, R
AU  - López Bosque R
FAU - Ruiz, A
AU  - Ruiz A
LA  - spa
PT  - Journal Article
TT  - El tratamiento preoperatorio con aspirina a dosis bajas no aumenta la hemorragia 
      quirúrgica ni la tasa transfusional en la prótesis total de rodilla.
DEP - 20120501
PL  - Spain
TA  - Rev Esp Anestesiol Reanim
JT  - Revista espanola de anestesiologia y reanimacion
JID - 0134516
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Loss, Surgical/*statistics & numerical data
MH  - Blood Transfusion/*statistics & numerical data
MH  - Comorbidity
MH  - Elective Surgical Procedures
MH  - Female
MH  - Humans
MH  - Length of Stay/statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Operative Blood Salvage/statistics & numerical data
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Postoperative Complications/epidemiology
MH  - Postoperative Hemorrhage/*chemically induced/epidemiology
MH  - Preanesthetic Medication/adverse effects
MH  - Retrospective Studies
EDAT- 2012/05/04 06:00
MHDA- 2015/04/14 06:00
CRDT- 2012/05/04 06:00
PHST- 2011/01/03 00:00 [received]
PHST- 2012/02/15 00:00 [accepted]
PHST- 2012/05/04 06:00 [entrez]
PHST- 2012/05/04 06:00 [pubmed]
PHST- 2015/04/14 06:00 [medline]
AID - S0034-9356(12)00037-0 [pii]
AID - 10.1016/j.redar.2012.02.006 [doi]
PST - ppublish
SO  - Rev Esp Anestesiol Reanim. 2012 Apr;59(4):180-6. doi: 
      10.1016/j.redar.2012.02.006. Epub 2012 May 1.

PMID- 2979248
OWN - NLM
STAT- MEDLINE
DCOM- 19911218
LR  - 20190828
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 2
IP  - 3
DP  - 1988 Jun
TI  - Prophylaxis of aspirin-induced gastric mucosal bleeding with ranitidine.
PG  - 245-52
AB  - The ability of ranitidine to protect the human gastric mucosa against 
      aspirin-induced damage was investigated by timed measurements of blood loss 
      collected by gastric washing. Ranitidine (150 mg) 1 h or 5 h before 900 mg 
      aspirin (5 doses of each) over 48 h reduced subsequent mean bleeding from 7.7 
      microliters/10 min to 2.6 microliters/10 min or 3.4 microliters/10 min, 
      respectively. Both regimens were antisecretory at the time of aspirin 
      administration, as judged by a rise in the pH of the aspirated washings. The 
      prolonged protection against aspirin-induced bleeding achieved with twice daily 
      dosing with ranitidine has clinical potential in the management of patients 
      taking anti-inflammatory drugs.
FAU - Hawkey, C J
AU  - Hawkey CJ
AD  - Department of Therapeutics, University Hospital, Nottingham, UK.
FAU - Somerville, K W
AU  - Somerville KW
FAU - Marshall, S
AU  - Marshall S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 884KT10YB7 (Ranitidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Gastric Mucosa/drug effects
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Humans
MH  - Male
MH  - Ranitidine/*therapeutic use
EDAT- 1988/06/01 00:00
MHDA- 1988/06/01 00:01
CRDT- 1988/06/01 00:00
PHST- 1988/06/01 00:00 [pubmed]
PHST- 1988/06/01 00:01 [medline]
PHST- 1988/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2036.1988.tb00694.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 1988 Jun;2(3):245-52. doi: 
      10.1111/j.1365-2036.1988.tb00694.x.

PMID- 36602517
OWN - NLM
STAT- MEDLINE
DCOM- 20230310
LR  - 20230405
IS  - 1931-843X (Electronic)
IS  - 1540-9996 (Linking)
VI  - 32
IP  - 3
DP  - 2023 Mar
TI  - Aspirin and Risk of Specific Breast Cancer Subtype in Women with Diabetes.
PG  - 341-346
LID - 10.1089/jwh.2022.0055 [doi]
AB  - Purpose: Low-dose aspirin was associated with a reduced risk of breast cancer in 
      women with diabetes. However, whether the protective effect of aspirin varies as 
      a function of the hormone receptor status of breast cancer remained an unanswered 
      question. This study aims to explore the association between aspirin use and the 
      risk of specific breast cancer subtypes in women with diabetes. Methods: 
      Population-based retrospective cohort study of women with diabetes, using the 
      Taiwan National Health Insurance reimbursement database (year 1998 to 2011). 
      Patients diagnosed to have diabetes with new low-dose aspirin use (75-165 mg per 
      day) for at least 28 days of prescription were identified as the study 
      population, while patients without low-dose aspirin use were selected as 
      controls. The main outcome measure was breast cancer by aspirin use and hormone 
      receptor status. Results: We studied a total of 148,739 patients with diabetes. 
      Their mean (standard deviation) age was 63.3 (12.8) years. During follow-up, a 
      total of 849 breast cancers occurred, including 329 hormone receptor-positive and 
      529 hormone receptor-negative tumors. A total of 27,378 patients were taking 
      aspirin. The reduction in risk with aspirin use was seen among those with hormone 
      receptor-positive breast cancer (Hazard ratio [HR]: 0.73; 95% confidence interval 
      [CI]: 0.59-0.91) but not for women with hormone receptor-negative breast cancer 
      (HR: 0.88; 95% CI: 0.74-1.05). A cumulative dose of aspirin use of more than 
      8,600 mg was found to reduce the risk of hormone receptor-positive breast cancer 
      by 31% (HR: 0.69; 95% CI: 0.50-0.97). A cumulative dose of aspirin use of more 
      than 88,900 mg was found to reduce both the risk of hormone receptor-positive and 
      negative breast cancer. Conclusion: These data add to the growing evidence that 
      supports the use of low-dose aspirin as a potential chemopreventive agent for 
      specific subtypes of breast cancer. Further studies are necessary to confirm 
      these findings.
FAU - Yang, Yi-Sun
AU  - Yang YS
AUID- ORCID: 0000-0003-2456-0574
AD  - School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, Chung 
      Shan Medical University Hospital, Taichung, Taiwan.
FAU - Kornelius, Edy
AU  - Kornelius E
AD  - School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, Chung 
      Shan Medical University Hospital, Taichung, Taiwan.
FAU - Lo, Shih-Chan
AU  - Lo SC
AD  - School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, Chung 
      Shan Medical University Hospital, Taichung, Taiwan.
FAU - Wang, Yu-Hsun
AU  - Wang YH
AD  - Department of Medical Research, Chung Shan Medical University Hospital, Taichung, 
      Taiwan.
FAU - Huang, Chien-Ning
AU  - Huang CN
AD  - School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, Chung 
      Shan Medical University Hospital, Taichung, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230103
PL  - United States
TA  - J Womens Health (Larchmt)
JT  - Journal of women's health (2002)
JID - 101159262
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Hormones)
SB  - IM
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Aspirin/therapeutic use
MH  - *Breast Neoplasms/epidemiology
MH  - Retrospective Studies
MH  - *Triple Negative Breast Neoplasms
MH  - *Diabetes Mellitus/drug therapy/epidemiology
MH  - Hormones
OTO - NOTNLM
OT  - aspirin
OT  - breast cancer
OT  - diabetes
OT  - hormone-receptor
OT  - nationwide
EDAT- 2023/01/06 06:00
MHDA- 2023/03/11 06:00
CRDT- 2023/01/05 10:33
PHST- 2023/01/06 06:00 [pubmed]
PHST- 2023/03/11 06:00 [medline]
PHST- 2023/01/05 10:33 [entrez]
AID - 10.1089/jwh.2022.0055 [doi]
PST - ppublish
SO  - J Womens Health (Larchmt). 2023 Mar;32(3):341-346. doi: 10.1089/jwh.2022.0055. 
      Epub 2023 Jan 3.

PMID- 21718239
OWN - NLM
STAT- MEDLINE
DCOM- 20120502
LR  - 20190911
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Linking)
VI  - 12
IP  - 12
DP  - 2011 Nov
TI  - Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y12 inhibition 
      and thrombin receptor antagonists.
PG  - 1805-12
AB  - The platelet is central to the pathophysiology of acute coronary syndromes (ACS) 
      via its direct participation in the formation of the thrombotic occlusion and its 
      participation in the coagulation cascade that results in the formation of 
      thrombin. Antiplatelet therapy is a cornerstone of therapy in the setting of ACS. 
      Unfortunately, many patients who receive intensive antiplatelet therapy remain at 
      high risk for recurrent events. Current efforts to reduce this "residual risk" 
      include lifestyle modifications, cardiac rehabilitation, and intensive therapy 
      for dyslipidemia. Also being investigated are methods of individualizing and 
      intensifying antiplatelet therapy. Novel compounds that promise to reduce 
      recurrent ischemic events without an increase in bleeding events are being 
      evaluated in clinical trials. This review summarizes ongoing efforts to improve 
      the effectiveness of antiplatelet therapy among patients with ACS.
FAU - Bailey, Alison L
AU  - Bailey AL
AD  - Gill Heart Institute at University of Kentucky and Lexington Veterans 
      Administration Hospital, Lexington, KY, USA.
FAU - Campbell, Charles L
AU  - Campbell CL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - 0 (Receptors, Purinergic P2Y12)
RN  - 0 (Receptors, Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/prevention & control
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Coronary Artery Disease/drug therapy/prevention & control
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Receptors, Purinergic P2Y12/*chemistry
MH  - Receptors, Thrombin/*antagonists & inhibitors
MH  - Secondary Prevention
EDAT- 2011/07/02 06:00
MHDA- 2012/05/04 06:00
CRDT- 2011/07/02 06:00
PHST- 2010/09/08 00:00 [received]
PHST- 2011/01/08 00:00 [revised]
PHST- 2011/01/08 00:00 [accepted]
PHST- 2011/07/02 06:00 [entrez]
PHST- 2011/07/02 06:00 [pubmed]
PHST- 2012/05/04 06:00 [medline]
AID - BSP/CDT/E-Pub/0032 [pii]
AID - 10.2174/138945011797635830 [doi]
PST - ppublish
SO  - Curr Drug Targets. 2011 Nov;12(12):1805-12. doi: 10.2174/138945011797635830.

PMID- 21315430
OWN - NLM
STAT- MEDLINE
DCOM- 20110720
LR  - 20191210
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 127
IP  - 5
DP  - 2011 May
TI  - Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct 
      pattern in the aspirin-intolerant asthma phenotype.
PG  - 1141-7.e2
LID - 10.1016/j.jaci.2010.12.1108 [doi]
AB  - BACKGROUND: Eicosanoids, important signaling and inflammatory molecules, are 
      present in exhaled breath condensate (EBC) in very low concentrations, requiring 
      highly sensitive analytic methods for their quantification. OBJECTIVE: We sought 
      to assess a vast platform of eicosanoids in different asthma phenotypes, 
      including aspirin-intolerant asthma, by means of a recently developed analytic 
      approach based on mass spectrometry. METHODS: EBC from 115 adult asthmatic 
      subjects (62 with aspirin intolerance) and 38 healthy control subjects were 
      assessed quantitatively for 19 eicosanoids by using complementary HPLC, gas 
      chromatography-mass spectrometry, or both. Palmitic acid concentrations were used 
      as a marker for dilution of condensate samples. RESULTS: Asthma was characterized 
      by an increase in arachidonate lipoxygenase products and cysteinyl leukotrienes. 
      The COX pathway was also significantly upregulated in asthmatic subjects. 
      Subjects with aspirin-intolerant asthma were distinguished by a sharp increase in 
      the level of prostaglandin D(2) and E(2) metabolites; their 5- and 
      15-hydroxyeicosateraenoic acid levels were also higher than in aspirin-tolerant 
      subjects. A classical discriminant analysis permitted us to classify correctly 
      99% of asthmatic subjects within the study population; the specificity of the 
      analysis was 97%. The eicosanoid profiling allowed for 92% correct classification 
      of aspirin-intolerant subjects. CONCLUSIONS: The highly sensitive eicosanoid 
      profiling in EBC makes it possible to detect alterations in asthma, especially in 
      its distinct phenotype characterized by hypersensitivity to aspirin and other 
      nonsteroidal anti-inflammatory drugs. This permits us to discriminate asthmatic 
      subjects from healthy subjects, as well as to distinguish the 2 asthma phenotypes 
      based on the presence or absence of aspirin hypersensitivity.
CI  - Copyright © 2011 American Academy of Allergy, Asthma & Immunology. Published by 
      Mosby, Inc. All rights reserved.
FAU - Sanak, Marek
AU  - Sanak M
AD  - Department of Medicine, Jagiellonian University Medical College, Krakow, Poland.
FAU - Gielicz, Anna
AU  - Gielicz A
FAU - Bochenek, Grażyna
AU  - Bochenek G
FAU - Kaszuba, Marek
AU  - Kaszuba M
FAU - Niżankowska-Mogilnicka, Ewa
AU  - Niżankowska-Mogilnicka E
FAU - Szczeklik, Andrew
AU  - Szczeklik A
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110211
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Eicosanoids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*adverse effects/pharmacology
MH  - Asthma/*complications/diagnosis/drug therapy/*physiopathology
MH  - Bleeding Time
MH  - Breath Tests/*methods
MH  - Child
MH  - Child, Preschool
MH  - Chromatography, High Pressure Liquid
MH  - Drug Hypersensitivity/*etiology
MH  - Eicosanoids/*analysis/chemistry
MH  - Exhalation
MH  - Female
MH  - Gas Chromatography-Mass Spectrometry
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Sensitivity and Specificity
MH  - Young Adult
EDAT- 2011/02/15 06:00
MHDA- 2011/07/21 06:00
CRDT- 2011/02/15 06:00
PHST- 2010/10/22 00:00 [received]
PHST- 2010/12/22 00:00 [revised]
PHST- 2010/12/30 00:00 [accepted]
PHST- 2011/02/15 06:00 [entrez]
PHST- 2011/02/15 06:00 [pubmed]
PHST- 2011/07/21 06:00 [medline]
AID - S0091-6749(11)00035-2 [pii]
AID - 10.1016/j.jaci.2010.12.1108 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2011 May;127(5):1141-7.e2. doi: 
      10.1016/j.jaci.2010.12.1108. Epub 2011 Feb 11.

PMID- 15682258
OWN - NLM
STAT- MEDLINE
DCOM- 20050413
LR  - 20181201
IS  - 0027-2507 (Print)
IS  - 0027-2507 (Linking)
VI  - 72
IP  - 1
DP  - 2005 Jan
TI  - Combination antiplatelet agents in ischemic cerebrovascular disease.
PG  - 16-22
AB  - Combination antiplatelet agents with multiple mechanisms of action are being used 
      with increasing frequency for vascular disorders, including cerebrovascular 
      disease. Limited data exist regarding the efficacy of combination antiplatelet 
      therapy in the primary or secondary prevention of cerebral ischemia, and 
      combination therapies are often used without adequate evidence of efficacy. 
      However, over the last few years, several cerebrovascular and cardiovascular 
      trials have provided some preliminary information on the effectiveness of various 
      combination therapies in preventing cerebral ischemic disease. This article 
      reviews recently completed cerebrovascular and cardiovascular trials that tested 
      a combination antiplatelet regimen against aspirin alone, and that assessed 
      cerebral ischemia as an outcome measure. Controversies pertaining to these trials 
      and to the use of the various combination antiplatelet regimens are discussed. 
      Based on cardiovascular studies, clopidogrel in combination with aspirin has not 
      been proven superior to aspirin alone for the primary prevention of cerebral 
      ischemia. No data exists regarding the combination of clopidogrel and aspirin for 
      the secondary prevention of cerebrovascular disease. The combination of aspirin 
      plus extended-release dipyridamole (xrDP) appears to be superior to aspirin alone 
      in the secondary prevention of cerebral ischemia, but may compromise 
      cardiovascular protection in patients with coexisting coronary artery disease. 
      Combination therapy with aspirin and clopidogrel seems to increase the risk of 
      major hemorrhages, whereas aspirin plus xrDP does not. Ongoing trials are 
      expected to clarify the role of various combination antiplatelet regimens.
FAU - Moussouttas, Michael
AU  - Moussouttas M
AD  - Cerebrovascular Division, Department of Neurology, Seton Hall University, South 
      Orange, NJ, USA. arista1@pol.net
FAU - Papamitsakis, Nikolaos
AU  - Papamitsakis N
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Mt Sinai J Med
JT  - The Mount Sinai journal of medicine, New York
JID - 0241032
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Brain Ischemia/drug therapy/*prevention & control
MH  - Cardiovascular Diseases/complications
MH  - Clopidogrel
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/*therapeutic use
RF  - 49
EDAT- 2005/02/01 09:00
MHDA- 2005/04/14 09:00
CRDT- 2005/02/01 09:00
PHST- 2005/02/01 09:00 [pubmed]
PHST- 2005/04/14 09:00 [medline]
PHST- 2005/02/01 09:00 [entrez]
PST - ppublish
SO  - Mt Sinai J Med. 2005 Jan;72(1):16-22.

PMID- 24673112
OWN - NLM
STAT- MEDLINE
DCOM- 20141230
LR  - 20151119
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 44
IP  - 6
DP  - 2014 Jun
TI  - Impaired resolution of inflammation in human chronic heart failure.
PG  - 527-38
LID - 10.1111/eci.12265 [doi]
AB  - BACKGROUND: Lipoxins (LXs) are proresolving and anti-inflammatory eicosanoids 
      whose role in chronic heart failure (CHF) pathogenesis has never been 
      investigated. This study evaluated levels of LXs in CHF patients, its 
      relationship with disease severity and correlation with established CHF 
      biomarkers. The effect of low-dose aspirin [acetylsalicylic acid (ASA)] on the 
      levels of LXs was also studied. MATERIALS AND METHODS: Lipoxin A4 (LXA4 ), 
      15-epi-lipoxin A4 (15-epi-LXA4 ) and myeloperoxidase (MPO) concentration and 
      activity were evaluated by immunoenzymatic and spectrophotometric assays in 34 
      CHF patients [New York Heart Association (NYHA) functional class I to IV]. B-type 
      natriuretic peptide (BNP), troponin, myoglobin, C-reactive protein (CRP) and uric 
      acid (UA) were also analyzed. RESULTS: Patients were stratified into 
      mild-to-moderate CHF (NYHA, classes I and II) and severe CHF (NYHA classes III 
      and IV). Severe patients had lower plasma LXA4 (0·262 ± 0·034 vs. 
      0·362 ± 0·039 ng/mL, P < 0·05) and decreased urinary 15-epi-LXA4 levels 
      (2·28 ± 0·44 vs. 4·88 ± 1·03 μg/day, P < 0·05) besides exhibiting increased 
      plasma BNP (1464 ± 442 vs. 555 ± 162 pg/mL, P < 0·05) and MPO activity 
      (45·15 ± 11·56 vs. 15·90 ± 2·80 μmol/min/mg protein, P < 0·05). Plasma LXA4 was 
      inversely correlated with BNP, troponin, myoglobin, CRP, UA and MPO activity. ASA 
      treatment was associated with higher urinary excretion of 15-epi-LXA4 
      (7·70 ± 1·48 vs. 2·06 ± 0·30 μg/day, P < 0·05) in mild-to-moderate CHF patients 
      and lower BNP levels in both groups. CONCLUSIONS: Higher severity of CHF is 
      associated with reduced levels of LXs. Plasma LXA4 appears to be a valuable 
      marker for risk stratification in CHF. Furthermore, the ASA-related increase in 
      urinary 15-epi-LXA4 suggests enhanced renal synthesis of this eicosanoid and may 
      represent a disregarded benefit of ASA.
CI  - © 2014 Stichting European Society for Clinical Investigation Journal Foundation.
FAU - Reina-Couto, Marta
AU  - Reina-Couto M
AD  - Departamento de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade 
      do Porto, Porto, Portugal; MedInUP - Centro de Investigação Farmacológica e 
      Inovação Medicamentosa, Universidade do Porto, Porto, Portugal; Departamento de 
      Medicina Interna, Centro Hospitalar São João, Porto, Portugal.
FAU - Carvalho, Jorge
AU  - Carvalho J
FAU - Valente, Maria João
AU  - Valente MJ
FAU - Vale, Luís
AU  - Vale L
FAU - Afonso, Joana
AU  - Afonso J
FAU - Carvalho, Félix
AU  - Carvalho F
FAU - Bettencourt, Paulo
AU  - Bettencourt P
FAU - Sousa, Teresa
AU  - Sousa T
FAU - Albino-Teixeira, António
AU  - Albino-Teixeira A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140422
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Biomarkers/metabolism
MH  - Cardiovascular Diseases/etiology
MH  - Chronic Disease
MH  - Female
MH  - Glomerular Filtration Rate/physiology
MH  - Heart Failure/*etiology
MH  - Humans
MH  - Inflammation/physiopathology
MH  - Leukocyte Count
MH  - Lipoxins/*metabolism
MH  - Male
MH  - Peroxidase/metabolism
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - biomarkers
OT  - chronic heart failure
OT  - lipoxins
OT  - resolution of inflammation
EDAT- 2014/03/29 06:00
MHDA- 2014/12/31 06:00
CRDT- 2014/03/29 06:00
PHST- 2014/01/10 00:00 [received]
PHST- 2014/03/25 00:00 [accepted]
PHST- 2014/03/29 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/12/31 06:00 [medline]
AID - 10.1111/eci.12265 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2014 Jun;44(6):527-38. doi: 10.1111/eci.12265. Epub 2014 Apr 
      22.

PMID- 3867066
OWN - NLM
STAT- MEDLINE
DCOM- 19860224
LR  - 20191030
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 20
IP  - 3
DP  - 1985 Dec
TI  - Regression of lymphosarcoma by treatment with acetylsalicylic acid in rats.
PG  - 247-54
AB  - Increased synthesis of prostaglandins (PGs) may be an important promoting factor 
      in the development of lymphosarcoma. Thus, inhibition of PG synthesis may 
      represent a logical way of controlling the growth of lymphosarcomatous cells. In 
      order to verify this hypothesis, two groups of rats with lymphosarcoma have been 
      used: the test-group received acetyl salicylic acid (54 mg/animal/day) and the 
      control-group received the same quantity of physiological saline solution. After 
      4 days of treatment, the lymph nodes stopped growing in the test-group. 
      Microscopic and electron microscopic examinations of lymph node sections were 
      carried out after 11 days of treatment. These showed for the test-group the 
      disappearance of the characteristics of malignancy.
FAU - Popescu, M C
AU  - Popescu MC
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Antineoplastic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Antineoplastic Agents
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Lymphoma, Non-Hodgkin/*drug therapy/pathology
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1985/12/01 00:00
MHDA- 1985/12/01 00:01
CRDT- 1985/12/01 00:00
PHST- 1985/12/01 00:00 [pubmed]
PHST- 1985/12/01 00:01 [medline]
PHST- 1985/12/01 00:00 [entrez]
AID - 10.1016/0262-1746(85)90146-5 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1985 Dec;20(3):247-54. doi: 
      10.1016/0262-1746(85)90146-5.

PMID- 6786566
OWN - NLM
STAT- MEDLINE
DCOM- 19810810
LR  - 20190501
IS  - 0267-0623 (Print)
IS  - 0267-0623 (Linking)
VI  - 282
IP  - 6276
DP  - 1981 May 16
TI  - Analgesic effects of branding in treatment of headaches.
PG  - 1576-8
AB  - The effect of branding--that is, the labelling and marketing--of a well-known 
      proprietary analgesic used to treat headaches was studied in a sample of women 
      given a branded or unbranded form with either an inert or an active formulation. 
      The sample was also divided according to whether the subjects were regular users 
      of the brand or users of other brands. The findings showed that branded tablets 
      were overall significantly more effective than unbranded tablets in relieving 
      headaches. Differential effects were observed: the effects of branding were more 
      noticeable one hour after the tablets were taken compared with 30 minutes; in the 
      women given the placebo; and in the users of the brand compared with the users of 
      other brands. It is hypothesised that these effects are due to increased 
      confidence in obtaining relief with a well-known brand, and that branding has an 
      analgesic effect that interacts with the analgesic effects of placebos and active 
      ingredients.
FAU - Branthwaite, A
AU  - Branthwaite A
FAU - Cooper, P
AU  - Cooper P
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br Med J (Clin Res Ed)
JT  - British medical journal (Clinical research ed.)
JID - 8302911
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - *Drug Labeling
MH  - Female
MH  - Headache/*drug therapy/psychology
MH  - Humans
MH  - Random Allocation
MH  - Self Medication
MH  - Time Factors
PMC - PMC1505530
EDAT- 1981/05/16 00:00
MHDA- 1981/05/16 00:01
CRDT- 1981/05/16 00:00
PHST- 1981/05/16 00:00 [pubmed]
PHST- 1981/05/16 00:01 [medline]
PHST- 1981/05/16 00:00 [entrez]
AID - 10.1136/bmj.282.6276.1576 [doi]
PST - ppublish
SO  - Br Med J (Clin Res Ed). 1981 May 16;282(6276):1576-8. doi: 
      10.1136/bmj.282.6276.1576.

PMID- 2903874
OWN - NLM
STAT- MEDLINE
DCOM- 19881223
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 12
IP  - 6 Suppl A
DP  - 1988 Dec
TI  - Randomized trial of intravenous streptokinase, oral aspirin, both, or neither 
      among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 
      (Second International Study of Infarct Survival) Collaborative Group.
PG  - 3A-13A
AB  - 17,187 patients entering 417 hospitals up to 24 h (median 5 h) after the onset of 
      suspected acute myocardial infarction were randomized, with placebo control, 
      between i) a 1 h intravenous infusion of 1.5 million units of streptokinase; ii) 
      1 month of 160 mg/day enteric-coated aspirin; iii) both active treatments; or iv) 
      neither. Streptokinase alone and aspirin alone each produced a highly significant 
      reduction in 5 week vascular mortality: 791/8592 (9.2%) vascular deaths among 
      patients allocated streptokinase infusion versus 1029/8595 (12.0%) among those 
      allocated placebo infusion (odds reduction: 25% +/- 4; 2p less than 0.00001); 
      804/8587 (9.4%) vascular deaths among patients allocated aspirin tablets versus 
      1016/8600 (11.8%) among those allocated placebo tablets (odds reduction: 23% +/- 
      4; 2p less than 0.00001). The combination of streptokinase and aspirin was 
      significantly (2p less than 0.0001) better than either agent alone. Their 
      separate effects on vascular death appeared to be additive: 343/4292 (8.0%) among 
      patients allocated both active agents versus 568/4300 (13.2%) among those 
      allocated neither (odds reduction: 42% +/- 5; 95% confidence limits 34% to 50%). 
      There was evidence of benefit rom each agent even for patients treated late after 
      pain onset (odds reduction at 0-4, 5-12, and 13-24 h: 35% +/- 6, 16% +/- 7 and 
      21% +/- 12 for streptokinase alone; 25% +/- 7,21% +/- 7 and 21% +/- 12 for 
      aspirin alone; and 53% +/- 8,32% +/- 9 and 38% +/- 15 for the combination of 
      streptokinase and aspirin). Streptokinase was associated with an excess of bleeds 
      requiring transfusion (0.5% versus 0.2%) and of confirmed cerebral hemorrhage 
      (0.1% versus 0.0%), but with fewer other strokes (0.6% versus 0.8%). These 
      "other" strokes may have included a few undiagnosed cerebral hemorrhages, but 
      still there was no increase in total strokes (0.7% streptokinase versus 0.8% 
      placebo infusion). Aspirin significantly reduced nonfatal reinfarction (1.0% 
      versus 2.0%) and nonfatal stroke (0.3% versus 0.6%), and was not associated with 
      any significant increase in cerebral hemorrhage or in bleeds requiring 
      transfusion. An excess of nonfatal reinfarction was reported when streptokinase 
      was used alone, but this appeared to be entirely avoided by the addition of 
      aspirin. Those allocated the combination of streptokinase and aspirin had 
      significantly fewer reinfarctions (1.8% versus 2.9%), strokes (0.6% versus 1.1%), 
      and deaths (8.0% versus 13.2%) than those allocated neither.(ABSTRACT TRUNCATED 
      AT 250 WORDS)
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Follow-Up Studies
MH  - Humans
MH  - Infusions, Intravenous
MH  - Myocardial Infarction/*drug therapy/mortality
MH  - Random Allocation
MH  - Streptokinase/*administration & dosage/adverse effects
EDAT- 1988/12/01 00:00
MHDA- 1988/12/01 00:01
CRDT- 1988/12/01 00:00
PHST- 1988/12/01 00:00 [pubmed]
PHST- 1988/12/01 00:01 [medline]
PHST- 1988/12/01 00:00 [entrez]
AID - 10.1016/0735-1097(88)92635-6 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1988 Dec;12(6 Suppl A):3A-13A. doi: 
      10.1016/0735-1097(88)92635-6.

PMID- 299896
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20190630
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 237
IP  - 10
DP  - 1977 Mar 7
TI  - Gastrointestinal blood loss. Effect of aspirin, fenoprofen, and acetaminophen in 
      rheumatoid arthritis as determined by sequential gastroscopy and radioactive 
      fecal markers.
PG  - 976-81
AB  - The feasibility of determining the exact site and amount of drug-induced gastric 
      bleeding was tested. Fourteen patients with rheumatoid arthritis received 
      equivalent therapeutic doses of the antinflammatory drugs aspirin, 4 gm/day, and 
      fenoprofen calcium, 2.4 gm/day, in randomized order for seven days. Acetaminophen 
      was given for 14 days just prior to each of these periods. By fiberoptic 
      gastroscopy, antral ulceration and acute mucosal lesions were found in seven 
      patients following aspirin ingestion, in one taking fenoprofen, and in none 
      taking acetaminophen. Fecal blood loss in four-day stool collections, quantitated 
      by autologous chromium 51-labeled erythrocytes shed into the stool averaged 5.0 
      ml/day while taking aspirin, 2.2 ml/day while taking fenoprofen calcium, and 0.8 
      ml/day while taking acetaminophen. The mean blood loss was greater for those in 
      whom gastric lesions developed while taking aspirin than for those in whom 
      lesions did not develop. The short-term risk of erosive gastritis was greater for 
      aspirin than fenoprofen.
FAU - Loebl, D H
AU  - Loebl DH
FAU - Craig, R M
AU  - Craig RM
FAU - Culic, D D
AU  - Culic DD
FAU - Ridolfo, A S
AU  - Ridolfo AS
FAU - Falk, J
AU  - Falk J
FAU - Schmid, F R
AU  - Schmid FR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Phenylpropionates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Acetaminophen/*adverse effects/therapeutic use
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Autoradiography
MH  - Blood Specimen Collection
MH  - Female
MH  - Fenoprofen/*adverse effects/therapeutic use
MH  - Fiber Optic Technology
MH  - Gastritis/*chemically induced
MH  - Gastrointestinal Hemorrhage/*chemically induced/diagnostic imaging
MH  - Gastroscopes
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Occult Blood/*methods
MH  - Phenylpropionates/*adverse effects
MH  - Radiography
EDAT- 1977/03/07 00:00
MHDA- 1977/03/07 00:01
CRDT- 1977/03/07 00:00
PHST- 1977/03/07 00:00 [pubmed]
PHST- 1977/03/07 00:01 [medline]
PHST- 1977/03/07 00:00 [entrez]
AID - 10.1001/jama.237.10.976 [doi]
PST - ppublish
SO  - JAMA. 1977 Mar 7;237(10):976-81. doi: 10.1001/jama.237.10.976.

PMID- 10505996
OWN - NLM
STAT- MEDLINE
DCOM- 19991101
LR  - 20190813
IS  - 0009-9260 (Print)
IS  - 0009-9260 (Linking)
VI  - 54
IP  - 9
DP  - 1999 Sep
TI  - Management of patients treated with aspirin or warfarin and evaluation of 
      haemostasis prior to prostatic biopsy: a survey of current practice amongst 
      radiologists and urologists.
PG  - 598-603
AB  - AIM: To document current practice concerning the management of patients taking 
      aspirin or warfarin and the evaluation of haemostatic function prior to prostatic 
      biopsy. METHOD: A postal survey was performed with typed questionnaires being 
      sent to 275 urology and 275 radiology centres. RESULTS: A high proportion of 
      radiology departments in particular (83%) had protocols in place concerning the 
      management of aspirin or warfarin prior to prostatic biopsy. A significant 
      proportion of both radiologists and urologists have postponed biopsies due to 
      patients unexpectedly taking these medications. Few of the respondents reported 
      the use of pre-biopsy screening blood tests. Fifty-two percent of radiologists 
      and 27% of urologists terminated aspirin prior to prostatic biopsy, although the 
      urologists stopped aspirin for a long time period. Ninety-five percent of 
      radiologists and 84% of urologists terminated warfarin prior to prostatic biopsy, 
      although again the urologists stopped warfarin at an earlier stage. Most of those 
      respondents who stopped warfarin prior to biopsy, also checked the INR. The 
      urologists generally stated a higher threshold (INR) which would be considered 
      too high to proceed. CONCLUSION: There are wide variations in practice both 
      within and between the radiology and urology groups. This is unsurprising, since 
      there is conflicting advice in the relevant literature.
FAU - Connor, S E
AU  - Connor SE
AD  - Department of Clinical Radiology, City Hospital NHS Trust, Birmingham, UK.
FAU - Wingate, J P
AU  - Wingate JP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Radiol
JT  - Clinical radiology
JID - 1306016
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Biopsy
MH  - Health Care Surveys
MH  - Hemostasis
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Prostate/*pathology
MH  - *Radiology
MH  - *Urology
MH  - Warfarin/*administration & dosage/adverse effects
EDAT- 1999/10/03 00:00
MHDA- 1999/10/03 00:01
CRDT- 1999/10/03 00:00
PHST- 1999/10/03 00:00 [pubmed]
PHST- 1999/10/03 00:01 [medline]
PHST- 1999/10/03 00:00 [entrez]
AID - 10.1016/s0009-9260(99)90022-3 [doi]
PST - ppublish
SO  - Clin Radiol. 1999 Sep;54(9):598-603. doi: 10.1016/s0009-9260(99)90022-3.

PMID- 3100849
OWN - NLM
STAT- MEDLINE
DCOM- 19870317
LR  - 20190725
IS  - 0021-5198 (Print)
IS  - 0021-5198 (Linking)
VI  - 42
IP  - 4
DP  - 1986 Dec
TI  - Effects of a new anti-inflammatory imidazole derivative, fenflumizole, on 
      platelet aggregation in the rabbit.
PG  - 575-8
AB  - The antiplatelet effect of fenflumizole, compared with aspirin or ticlopidine, 
      was examined in in vitro, ex vivo and in vivo situations of the rabbit. Unlike 
      ticlopidine, fenflumizole and aspirin effectively inhibited in vitro the platelet 
      aggregation elicited by arachidonate and collagen. The activity of fenflumizole 
      was 350 times more potent than that of aspirin. Fenflumizole (0.3-3 mg/kg) given 
      p.o. was 4.2 and 8.1 times more potent than aspirin in inhibiting arachidonate- 
      and collagen-induced platelet aggregations, respectively. Ticlopidine (300 mg/kg, 
      p.o.) resulted in only weak effects on the aggregations. Fenflumizole (3 mg/kg) 
      as well as aspirin (10 mg/kg) given p.o., unlike ticlopidine (300 mg/kg), 
      effectively prevented the arachidonate-induced sudden death.
FAU - Aono, J
AU  - Aono J
FAU - Nabata, H
AU  - Nabata H
FAU - Sakai, K
AU  - Sakai K
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Jpn J Pharmacol
JT  - Japanese journal of pharmacology
JID - 2983305R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Imidazoles)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 9007-34-5 (Collagen)
RN  - PD0931191Q (fenflumizole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Arachidonic Acid
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/pharmacology
MH  - Collagen/pharmacology
MH  - Imidazoles/*pharmacology
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
EDAT- 1986/12/01 00:00
MHDA- 1986/12/01 00:01
CRDT- 1986/12/01 00:00
PHST- 1986/12/01 00:00 [pubmed]
PHST- 1986/12/01 00:01 [medline]
PHST- 1986/12/01 00:00 [entrez]
AID - 10.1254/jjp.42.575 [doi]
PST - ppublish
SO  - Jpn J Pharmacol. 1986 Dec;42(4):575-8. doi: 10.1254/jjp.42.575.

PMID- 18580734
OWN - NLM
STAT- MEDLINE
DCOM- 20090325
LR  - 20151119
IS  - 1541-8243 (Electronic)
IS  - 0038-4348 (Linking)
VI  - 101
IP  - 7
DP  - 2008 Jul
TI  - Aspirin for primary prevention of coronary heart disease: using the Framingham 
      Risk Score to improve utilization in a primary care clinic.
PG  - 725-9
LID - 10.1097/SMJ.0b013e318178e58e [doi]
AB  - OBJECTIVES: Coronary heart disease (CHD) is the number one cause of death in 
      adults in the industrialized world, and several large studies show that aspirin 
      is helpful for the primary prevention of this disease. Unfortunately, few 
      physicians are aware of its benefit, resulting in the underutilization of aspirin 
      for the primary prevention of CHD. The purpose of this study was to demonstrate 
      the underuse of aspirin for the primary prevention of CHD, and to improve 
      appropriate utilization by implementing an easy-to-use clinic tool that quickly 
      estimates a patient's risk. PATIENTS AND METHODS: This is a retrospective cohort 
      analysis conducted in the Internal Medicine Clinic in the Naval Medical Center in 
      San Diego, California. Random samples of 494 patients before and 593 after 
      intervention who were followed in the Internal Medicine Clinic were screened. 
      Inclusion criteria were a 10-year risk of myocardial infarction or coronary death 
      of more than 10%, or diabetes with one other cardiac risk factor. A poster was 
      placed in each clinic examination room showing the Framingham Risk Score, the 
      indications for aspirin use, and common contraindications to assist physicians in 
      determining if a patient warranted aspirin for primary prevention of CHD. A 
      physician documented regular use of aspirin, 81 to 325 mg per day. RESULTS: Age 
      and sex demographics were similar between the two measurement groups. Diabetics 
      comprised a significantly greater percentage of patients in the postintervention 
      group. There was a trend toward increase in utilization of aspirin from 63.5% to 
      72.8% (P = 0.054) after our intervention. In subgroup analysis, significant 
      improvement in appropriate aspirin use was found amongst males (P = 0.01) and 
      nondiabetics (P = 0.02). CONCLUSION: Aspirin has proven beneficial in the primary 
      prevention of CHD, but is clearly underutilized in this role. By implementing the 
      Framingham Risk Score to streamline the decision process, appropriate utilization 
      can be improved, and in turn, cardiac events can be reduced and patients can 
      benefit.
FAU - Romero, Steven C
AU  - Romero SC
AD  - Department of Internal Medicine and Cardiology, Naval Medical Center, San Diego, 
      CA, USA. steven.romero@med.navy.mil
FAU - Dela Rosa, Kristina M
AU  - Dela Rosa KM
FAU - Linz, Peter E
AU  - Linz PE
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - South Med J. 2008 Jul;101(7):679-80. PMID: 18580736
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Inservice Training
MH  - Male
MH  - *Medical Audit
MH  - Outpatient Clinics, Hospital
MH  - Practice Guidelines as Topic
MH  - *Practice Patterns, Physicians'
MH  - Retrospective Studies
EDAT- 2008/06/27 09:00
MHDA- 2009/03/26 09:00
CRDT- 2008/06/27 09:00
PHST- 2008/06/27 09:00 [pubmed]
PHST- 2009/03/26 09:00 [medline]
PHST- 2008/06/27 09:00 [entrez]
AID - 10.1097/SMJ.0b013e318178e58e [doi]
PST - ppublish
SO  - South Med J. 2008 Jul;101(7):725-9. doi: 10.1097/SMJ.0b013e318178e58e.

PMID- 32696878
OWN - NLM
STAT- MEDLINE
DCOM- 20200807
LR  - 20200807
IS  - 1806-9282 (Electronic)
IS  - 0104-4230 (Linking)
VI  - 66
IP  - 6
DP  - 2020 Jun
TI  - Incidence of aspirin resistance is higher in patients with acute coronary 
      syndrome and atrial fibrillation than without atrial fibrillation.
PG  - 800-805
LID - S0104-42302020000600800 [pii]
LID - 10.1590/1806-9282.66.6.800 [doi]
AB  - In patients with atrial fibrillation, standard anticoagulation with a vitamin K 
      antagonist plus dual antiplatelet therapy with a P2Y12 inhibitor and aspirin is 
      the standard of care after percutaneous coronary intervention (PCI). While this 
      therapy reduces the risk of thrombosis and stroke, it increases the risk of 
      bleeding. It is unclear whether the antiplatelet effect of aspirin and 
      clopidogrel may worsen atrial fibrillation (AF). OBJECTIVE Thus we aimed to 
      analyze platelet aspirin resistance (AR) and clopidogrel resistance (CR) in acute 
      coronary (ACS) patients based on sinus rhythm (SR) and AF. METHODS In this 
      prospective trial, we included 543 patients (mean age: 62± 12 years; range: 26 - 
      89 years) who were on aspirin and clopidogrel therapy after the diagnosis of 
      acute coronary syndrome. AR and CR were analyzed by a Multiplate® MP-0120 device 
      by using the method of whole blood aggregometry. RESULTS AF patients had 
      significantly higher age, mean platelet volume, and High-Sensitivity C-Reactive 
      Protein (p< 0.01 for each parameter). Similarly, Arachidonic-acid induced (ASPI) 
      aggregation was higher in AF patients compared to SR patients (666±218 vs. 
      187±179, p<0.001). Among the ACS patients, significantly more female patients had 
      AF (p<0.001). The incidence of hypertension in the AF group was higher compared 
      to the SR group (p<0.001). However, adenosine diphosphate levels were not at a 
      significant level in the two groups. CONCLUSION Our findings indicate that the 
      platelet inhibitory effect of Aspirin was worse for patients with AF, suggesting 
      that the effectiveness of aspirin may be less in the prophylaxis of 
      thromboembolism and more a bleeding risk.
FAU - Baş, Hasan Aydin
AU  - Baş HA
AD  - Department of Cardiology, Isparta City Hospital, Isparta, Turkey.
FAU - Aksoy, Fatih
AU  - Aksoy F
AD  - Department of Cardiology, Medical School, Suleyman Demirel University, Isparta, 
      Turkey.
FAU - Bağcı, Ali
AU  - Bağcı A
AD  - Department of Cardiology, Medical School, Suleyman Demirel University, Isparta, 
      Turkey.
FAU - Varol, Ercan
AU  - Varol E
AD  - Department of Cardiology, Medical School, Suleyman Demirel University, Isparta, 
      Turkey.
FAU - Altınbaş, Ahmet
AU  - Altınbaş A
AD  - Department of Cardiology, Medical School, Suleyman Demirel University, Isparta, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - Brazil
TA  - Rev Assoc Med Bras (1992)
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acute Coronary Syndrome
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants
MH  - Aspirin/*therapeutic use
MH  - *Atrial Fibrillation
MH  - Drug Resistance/*physiology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors
MH  - Prospective Studies
EDAT- 2020/07/23 06:00
MHDA- 2020/08/08 06:00
CRDT- 2020/07/23 06:00
PHST- 2020/01/01 00:00 [received]
PHST- 2020/01/19 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/08/08 06:00 [medline]
AID - S0104-42302020000600800 [pii]
AID - 10.1590/1806-9282.66.6.800 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras (1992). 2020 Jun;66(6):800-805. doi: 
      10.1590/1806-9282.66.6.800. Epub 2020 Jul 20.

PMID- 2590612
OWN - NLM
STAT- MEDLINE
DCOM- 19900116
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 28
IP  - 5
DP  - 1989 Nov
TI  - Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and 
      its reduction by ranitidine.
PG  - 581-5
AB  - 1. We evaluated injury to the human gastric mucosa caused by low doses of aspirin 
      and its prophylaxis by ranitidine. On two separate occasions, 30 subjects took 
      aspirin 300 mg daily for 12 days either with or without ranitidine 150 mg, 30 min 
      before aspirin. This dose of aspirin caused more than a 5 fold increase in 
      gastric bleeding, from control values of 0.5 microliters 10 min-1 (95% confidence 
      limits 0.3-0.8 microliters 10 min-1) to 2.8 microliters 10 min-1 (1.9-4.1 
      microliters 10 min-1, P less than 0.01) after 5 days of aspirin. Adaptation did 
      not occur and the gastric bleeding rates remained elevated at 3.4 microliters 10 
      min-1 (1.9-6.1 microliters 10 min-1) after 12 days of aspirin consumption (P less 
      than 0.01). 2. Coadministration of ranitidine significantly raised intragastric 
      pH and reduced aspirin induced bleeding to 1.5 microliters 10 min-1 (1.0-2.3 
      microliters 10 min-1) after 5 days and 1.6 (1.0-2.5 microliters 10 min-1) after 
      12 days (P less than 0.05). 3. Although these values were higher than control 
      levels our results raise the possibility that coadministration of ranitidine may 
      reduce the incidence of peptic ulceration and gastrointestinal haemorrhage which 
      is increasingly reported in some subjects taking low dose aspirin for vascular 
      prophylaxis.
FAU - Kitchingman, G K
AU  - Kitchingman GK
AD  - Department of Therapeutics, University Hospital, Nottingham.
FAU - Prichard, P J
AU  - Prichard PJ
FAU - Daneshmend, T K
AU  - Daneshmend TK
FAU - Walt, R P
AU  - Walt RP
FAU - Hawkey, C J
AU  - Hawkey CJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 884KT10YB7 (Ranitidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Gastric Acid/metabolism
MH  - Gastrointestinal Hemorrhage/*chemically induced/drug therapy
MH  - Humans
MH  - Male
MH  - Ranitidine/*therapeutic use
PMC - PMC1380019
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1989.tb03545.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1989 Nov;28(5):581-5. doi: 
      10.1111/j.1365-2125.1989.tb03545.x.

PMID- 3836859
OWN - NLM
STAT- MEDLINE
DCOM- 19860916
LR  - 20151119
IS  - 0378-6501 (Print)
IS  - 0378-6501 (Linking)
VI  - 11
IP  - 10
DP  - 1985
TI  - Evaluation of a new pharmaceutical form of nimesulide for the treatment of 
      influenza.
PG  - 739-43
AB  - In 39 outpatients suffering from a seasonal epidemic influenza, the antipyretic, 
      analgesic and anti-inflammatory activity of nimesulide granules was compared with 
      that of aspirin + vitamin C granules. The drugs were administered b.i.d., 
      dispensed in one-dose sachets containing either 100 mg of nimesulide or 500 mg 
      aspirin + 300 mg vitamin C. The efficacy of the two treatments was comparable: 
      both drugs brought about a rapid complete recovery in all treated patients. 
      However, nimesulide was better tolerated: only one case of slight gastralgia was 
      recorded in the nimesulide group vs the six cases of side-effects complained of 
      in the aspirin + vitamin C group.
FAU - Bernasconi, P
AU  - Bernasconi P
FAU - Massera, E
AU  - Massera E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Drugs Exp Clin Res
JT  - Drugs under experimental and clinical research
JID - 7802135
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Sulfonamides)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - V4TKW1454M (nimesulide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Ascorbic Acid/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Body Temperature/drug effects
MH  - Female
MH  - Humans
MH  - Influenza, Human/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Sulfonamides/*therapeutic use
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Drugs Exp Clin Res. 1985;11(10):739-43.

PMID- 681137
OWN - NLM
STAT- MEDLINE
DCOM- 19781025
LR  - 20131121
IS  - 0146-0404 (Print)
IS  - 0146-0404 (Linking)
VI  - 17
IP  - 8
DP  - 1978 Aug
TI  - Reduction by indomethacin of the degeneration increase in outflow facility after 
      superior cervical ganglionectomy in the rabbit.
PG  - 802-5
AB  - The effects of indomethacin and aspirin on the increase in facility of aqueous 
      outflow occurring 24 hr after removal of the the superior cervical ganglion from 
      rabbits have been studied. Both drugs were administered in the suppository from 1 
      hr prior to facility determinations. After pretreatment of rabbits with 
      indomethacin in this manner, the degeneration increase in outflow facility was 
      significantly reduced but not completely abolished. After pretreatment with 
      aspirin, on the other hand, outflow facility of the denervated eyes, although 
      showing a trend toward reduction from values for ganglionectomized eyes of 
      untreated rabbits, was not changed statistically. The effect of indomethacin may 
      be due to inhibition of porstaglandin or thromboxane synthesis. Because of the 
      results with aspirin, however, a special action of indomethacin in reducing the 
      elevated outflow facility must also be considered.
FAU - Colasanti, B K
AU  - Colasanti BK
FAU - Barany, E H
AU  - Barany EH
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Suppositories)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aqueous Humor/*drug effects/physiology
MH  - Aspirin/pharmacology
MH  - Eye/innervation
MH  - Ganglia, Autonomic/surgery
MH  - Indomethacin/*pharmacology
MH  - Intraocular Pressure/*drug effects
MH  - Male
MH  - Rabbits
MH  - Suppositories
EDAT- 1978/08/01 00:00
MHDA- 1978/08/01 00:01
CRDT- 1978/08/01 00:00
PHST- 1978/08/01 00:00 [pubmed]
PHST- 1978/08/01 00:01 [medline]
PHST- 1978/08/01 00:00 [entrez]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 1978 Aug;17(8):802-5.

PMID- 6508625
OWN - NLM
STAT- MEDLINE
DCOM- 19841231
LR  - 20190815
IS  - 0003-9977 (Print)
IS  - 0003-9977 (Linking)
VI  - 110
IP  - 12
DP  - 1984 Dec
TI  - Hydrophobic lining of the eustachian tube imparted by surfactant.
PG  - 779-82
AB  - The eustachian tubes were excised from nine rabbits and one pig, and the 
      hydrophobic nature of each luminal surface was determined by placing upon it a 
      drop of saline. Each surface resisted wetting, with the droplet "beading up" to 
      give a mean contact angle between the tissue-fluid and fluid-air interfaces of 
      50.1 degrees for the rabbits and 49 degrees for the pig. Each measurement was 
      determined by a goniometer. The hydrophobicity was eliminated by lipid solvents 
      and largely by aspirin, which desorb surface-active phospholipids. These results 
      are consistent with the hypothesis that surfactants identified in the eustachian 
      tubes are absorbed to the luminal surfaces as adhesives to oppose the strongly 
      adhesive nature of the proteins and thus maintain patency and ventilation of the 
      middle ear. This concept implies that an inadequate layer of adsorbed 
      phospholipid could lead to serous otitis.
FAU - Hills, B A
AU  - Hills BA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Otolaryngol
JT  - Archives of otolaryngology (Chicago, Ill. : 1960)
JID - 0376526
RN  - 0 (Phospholipids)
RN  - 0 (Surface-Active Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adhesiveness
MH  - Adsorption
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Epithelium/physiology
MH  - Eustachian Tube/analysis/drug effects/*physiology
MH  - Phospholipids/analysis/physiology
MH  - Rabbits
MH  - Surface Properties
MH  - Surface Tension
MH  - Surface-Active Agents/*pharmacology
MH  - Swine
OID - NASA: 85071742
EDAT- 1984/12/01 00:00
MHDA- 1984/12/01 00:01
CRDT- 1984/12/01 00:00
PHST- 1984/12/01 00:00 [pubmed]
PHST- 1984/12/01 00:01 [medline]
PHST- 1984/12/01 00:00 [entrez]
AID - 10.1001/archotol.1984.00800380009003 [doi]
PST - ppublish
SO  - Arch Otolaryngol. 1984 Dec;110(12):779-82. doi: 
      10.1001/archotol.1984.00800380009003.

PMID- 6694278
OWN - NLM
STAT- MEDLINE
DCOM- 19840302
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 251
IP  - 6
DP  - 1984 Feb 10
TI  - Reye's syndrome associated with long-term aspirin therapy.
PG  - 754-6
AB  - Reye's syndrome has been infrequently described in children receiving long-term 
      salicylate therapy. We report the clinical and laboratory findings of two 
      children in whom Reye's syndrome developed while taking salicylates for systemic 
      inflammatory disorders. Monitoring of hepatocellular function should be 
      considered in children who are receiving long-term salicylate therapy.
FAU - Young, R S
AU  - Young RS
FAU - Torretti, D
AU  - Torretti D
FAU - Williams, R H
AU  - Williams RH
FAU - Hendriksen, D
AU  - Hendriksen D
FAU - Woods, M
AU  - Woods M
LA  - eng
GR  - NS 18039/NS/NINDS NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*adverse effects
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Infant
MH  - Reye Syndrome/*chemically induced/diagnosis
EDAT- 1984/02/10 00:00
MHDA- 1984/02/10 00:01
CRDT- 1984/02/10 00:00
PHST- 1984/02/10 00:00 [pubmed]
PHST- 1984/02/10 00:01 [medline]
PHST- 1984/02/10 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1984 Feb 10;251(6):754-6.

PMID- 20970847
OWN - NLM
STAT- MEDLINE
DCOM- 20101223
LR  - 20220410
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 376
IP  - 9754
DP  - 2010 Nov 20
TI  - Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year 
      follow-up of five randomised trials.
PG  - 1741-50
LID - 10.1016/S0140-6736(10)61543-7 [doi]
AB  - BACKGROUND: High-dose aspirin (≥500 mg daily) reduces long-term incidence of 
      colorectal cancer, but adverse effects might limit its potential for long-term 
      prevention. The long-term effectiveness of lower doses (75-300 mg daily) is 
      unknown. We assessed the effects of aspirin on incidence and mortality due to 
      colorectal cancer in relation to dose, duration of treatment, and site of tumour. 
      METHODS: We followed up four randomised trials of aspirin versus control in 
      primary (Thrombosis Prevention Trial, British Doctors Aspirin Trial) and 
      secondary (Swedish Aspirin Low Dose Trial, UK-TIA Aspirin Trial) prevention of 
      vascular events and one trial of different doses of aspirin (Dutch TIA Aspirin 
      Trial) and established the effect of aspirin on risk of colorectal cancer over 20 
      years during and after the trials by analysis of pooled individual patient data. 
      RESULTS: In the four trials of aspirin versus control (mean duration of scheduled 
      treatment 6·0 years), 391 (2·8%) of 14 033 patients had colorectal cancer during 
      a median follow-up of 18·3 years. Allocation to aspirin reduced the 20-year risk 
      of colon cancer (incidence hazard ratio [HR] 0·76, 0·60-0·96, p=0·02; mortality 
      HR 0·65, 0·48-0·88, p=0·005), but not rectal cancer (0·90, 0·63-1·30, p=0·58; 
      0·80, 0·50-1·28, p=0·35). Where subsite data were available, aspirin reduced risk 
      of cancer of the proximal colon (0·45, 0·28-0·74, p=0·001; 0·34, 0·18-0·66, 
      p=0·001), but not the distal colon (1·10, 0·73-1·64, p=0·66; 1·21, 0·66-2·24, 
      p=0·54; for incidence difference p=0·04, for mortality difference p=0·01). 
      However, benefit increased with scheduled duration of treatment, such that 
      allocation to aspirin of 5 years or longer reduced risk of proximal colon cancer 
      by about 70% (0·35, 0·20-0·63; 0·24, 0·11-0·52; both p<0·0001) and also reduced 
      risk of rectal cancer (0·58, 0·36-0·92, p=0·02; 0·47, 0·26-0·87, p=0·01). There 
      was no increase in benefit at doses of aspirin greater than 75 mg daily, with an 
      absolute reduction of 1·76% (0·61-2·91; p=0·001) in 20-year risk of any fatal 
      colorectal cancer after 5-years scheduled treatment with 75-300 mg daily. 
      However, risk of fatal colorectal cancer was higher on 30 mg versus 283 mg daily 
      on long-term follow-up of the Dutch TIA trial (odds ratio 2·02, 0·70-6·05, 
      p=0·15). INTERPRETATION: Aspirin taken for several years at doses of at least 75 
      mg daily reduced long-term incidence and mortality due to colorectal cancer. 
      Benefit was greatest for cancers of the proximal colon, which are not otherwise 
      prevented effectively by screening with sigmoidoscopy or colonoscopy. FUNDING: 
      None.
CI  - Copyright © 2010 Elsevier Ltd. All rights reserved.
FAU - Rothwell, Peter M
AU  - Rothwell PM
AD  - Stroke Prevention Research Unit, Department of Clinical Neurology, University of 
      Oxford, Oxford, UK. peter.rothwell@clneuro.ox.ac.uk
FAU - Wilson, Michelle
AU  - Wilson M
FAU - Elwin, Carl-Eric
AU  - Elwin CE
FAU - Norrving, Bo
AU  - Norrving B
FAU - Algra, Ale
AU  - Algra A
FAU - Warlow, Charles P
AU  - Warlow CP
FAU - Meade, Tom W
AU  - Meade TW
LA  - eng
GR  - G0701113/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101021
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2010 Nov 20;376(9754):1713-4. PMID: 20970845
CIN - Nat Rev Clin Oncol. 2011 Mar;8(3):130-1. PMID: 21200396
CIN - Ann Intern Med. 2011 Mar 15;154(6):JC3-3. PMID: 21403066
CIN - Z Gastroenterol. 2011 Apr;49(4):532-3. PMID: 21476184
CIN - J Am Coll Surg. 2012 Jun;214(6):1023-6. PMID: 22626547
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Colonic Neoplasms/prevention & control
MH  - Colorectal Neoplasms/epidemiology/mortality/*prevention & control
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Randomized Controlled Trials as Topic
MH  - Thrombosis/prevention & control
EDAT- 2010/10/26 06:00
MHDA- 2010/12/25 06:00
CRDT- 2010/10/26 06:00
PHST- 2010/10/26 06:00 [entrez]
PHST- 2010/10/26 06:00 [pubmed]
PHST- 2010/12/25 06:00 [medline]
AID - S0140-6736(10)61543-7 [pii]
AID - 10.1016/S0140-6736(10)61543-7 [doi]
PST - ppublish
SO  - Lancet. 2010 Nov 20;376(9754):1741-50. doi: 10.1016/S0140-6736(10)61543-7. Epub 
      2010 Oct 21.

PMID- 9295821
OWN - NLM
STAT- MEDLINE
DCOM- 19971002
LR  - 20190706
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 25
IP  - 9
DP  - 1997 Sep
TI  - Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor 
      in critically ill patients.
PG  - 1480-8
AB  - OBJECTIVE: To evaluate the hemodynamic effects and any toxicologic effects of 
      diaspirin cross-linked hemoglobin (DCLHb) in critically ill patients. DESIGN: A 
      prospective, observational study. SETTING: A seven-bed intensive care unit (ICU) 
      in a University teaching hospital. PATIENTS: Fourteen critically ill patients 
      requiring vasopressor therapy to maintain adequate mean arterial pressure (MAP). 
      All patients had secondary organ dysfunction. INTERVENTIONS: Administration of 
      100 mL boluses of 10% diaspirin cross-linked hemoglobin, up to a maximum of 500 
      mL, given over 15 mins and separated by 60 to 90 mins. MEASUREMENTS AND MAIN 
      RESULTS: Hemodynamic parameters, norepinephrine and inotropic requirements, 
      arterial and mixed venous blood gases, urine output, and biochemical and 
      hematologic analyses were measured before diaspirin cross-linked hemoglobin 
      administration and at multiple time points up to 72 hrs. MAP was maintained at 
      approximately preinfusion values and the reduction in norepinephrine requirements 
      was used as the main end point to assess the efficacy of diaspirin cross-linked 
      hemoglobin as a vasopressor. Diaspirin cross-linked hemoglobin demonstrated a 
      marked vasopressor action, allowing norepinephrine requirements to be reduced 
      from 0.29 +/- 0.15 (SD) microgram/kg/min to 0.15 +/- 0.14 and 0.07 +/- 0.10 
      microgram/kg/min after the first (at 1.5 hrs, p < .001) and last (at 7.5 hrs, p < 
      .0001) boluses, respectively. These reductions in norepinephrine requirements 
      were maintained at 24, 48, and 72 hrs (p < .01 at all time points). These 
      hemodynamic changes began within 5 mins of starting the diaspirin cross-linked 
      hemoglobin infusion. MAP, heart rate, central venous pressure, pulmonary artery 
      occlusion pressure, mean pulmonary arterial pressure (MPAP), systemic vascular 
      resistance index, and urine output did not demonstrate any significant changes 
      from preinfusion values. Pulmonary vascular resistance index increased at 7.5 hrs 
      despite nonsignificant increases in MPAP. Cardiac index and oxygen delivery index 
      decreased significantly at 7.5 hrs and 24 hrs. Total plasma bilirubin increased 
      significantly from baseline at 24 and 48 hrs, before returning to baseline values 
      within 5 days. Platelet count was significantly reduced at 6 and 24 hrs. No other 
      biochemical or hematologic analyses were altered significantly post diaspirin 
      cross-linked hemoglobin. CONCLUSIONS: This preliminary study demonstrated that 
      diaspirin cross-linked hemoglobin is a potent vasopressor agent in critically ill 
      patients with septicemic shock or systemic inflammatory response syndrome. This 
      vasopressor characteristic of diaspirin cross-linked hemoglobin may have future 
      clinical applications.
FAU - Reah, G
AU  - Reah G
AD  - Anaesthetics Department, General Infirmary at Leeds, UK.
FAU - Bodenham, A R
AU  - Bodenham AR
FAU - Mallick, A
AU  - Mallick A
FAU - Daily, E K
AU  - Daily EK
FAU - Przybelski, R J
AU  - Przybelski RJ
LA  - eng
PT  - Case Reports
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Hemoglobins)
RN  - AYI8EX34EU (Creatinine)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Crit Care Med. 2000 Jul;28(7):2679-81. PMID: 10921632
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Creatinine/blood
MH  - Critical Illness
MH  - Drug Monitoring
MH  - Female
MH  - Hemodynamics/*drug effects
MH  - Hemoglobins/*therapeutic use
MH  - Humans
MH  - Hypotension/blood/*drug therapy/physiopathology
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/drug effects
MH  - Platelet Count/drug effects
MH  - Prospective Studies
MH  - Time Factors
EDAT- 1997/09/20 00:00
MHDA- 1997/09/20 00:01
CRDT- 1997/09/20 00:00
PHST- 1997/09/20 00:00 [pubmed]
PHST- 1997/09/20 00:01 [medline]
PHST- 1997/09/20 00:00 [entrez]
AID - 10.1097/00003246-199709000-00014 [doi]
PST - ppublish
SO  - Crit Care Med. 1997 Sep;25(9):1480-8. doi: 10.1097/00003246-199709000-00014.

PMID- 23799975
OWN - NLM
STAT- MEDLINE
DCOM- 20140206
LR  - 20130716
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 38
IP  - 4
DP  - 2013 Aug
TI  - The association between low-dose aspirin use and the incidence of colorectal 
      cancer: a nationwide cohort study.
PG  - 432-9
LID - 10.1111/apt.12388 [doi]
AB  - BACKGROUND: Considerable evidence suggests that aspirin has a chemopreventive 
      effect on colorectal cancer (CRC). However, optimal dose and treatment duration 
      have not been defined, and data on the effects of low-dose aspirin are 
      contradictory. AIM: To determine if the incidence of CRC in patients with 
      low-dose aspirin use was lower than in those without aspirin use. METHOD: From 
      Taiwan's National Health Insurance research database, aspirin users (n = 1985) 
      were defined as adults (age ≥20 years) with at least 3.5 years of regular 
      low-dose aspirin use (50-150 mg per day) between 1998 and 2002. Non-users (n = 
      7940) were those who did not use aspirin and were matched 4:1 with the user group 
      by age, gender, date of ambulatory care (index date), and presence of known risk 
      factors for cardiovascular disease (including hypertension, diabetes mellitus and 
      hyperlipidaemia). Follow-up of the two study groups was made until the end of 
      2010, and incidences and hazard ratios of colorectal cancer were determined. 
      RESULTS: During a median follow-up period of 8.9 years, 129 non-users and 14 
      users developed CRC, corresponding to incidence rates of 180.43 and 79.42 per 
      100,000 person-years respectively. Duration of aspirin use among users ranged 
      from 3.5 to 12.6 years (mean 8.7 years). The multivariate-adjusted hazard ratio 
      for CRC was 0.5 (95% confidence interval 0.28-0.87) among users as compared with 
      non-users. CONCLUSIONS: Long-term use of low-dose aspirin appears to be 
      associated with a lower incidence of CRC in patients with high cardiovascular 
      risk. Further randomised clinical trials are necessary to confirm these findings.
CI  - © 2013 John Wiley & Sons Ltd.
FAU - Huang, W-K
AU  - Huang WK
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung 
      Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, 
      Taiwan.
FAU - Chiou, M-J
AU  - Chiou MJ
FAU - Yu, K-H
AU  - Yu KH
FAU - Lin, Y-C
AU  - Lin YC
FAU - Yang, T-S
AU  - Yang TS
FAU - Chen, J-S
AU  - Chen JS
FAU - Kuo, C-F
AU  - Kuo CF
FAU - See, L-C
AU  - See LC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130625
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Aliment Pharmacol Ther. 2013 Sep;38(6):653-4. PMID: 23964734
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cohort Studies
MH  - Colorectal Neoplasms/*epidemiology/prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Taiwan
MH  - Time Factors
MH  - Young Adult
EDAT- 2013/06/27 06:00
MHDA- 2014/02/07 06:00
CRDT- 2013/06/27 06:00
PHST- 2013/04/27 00:00 [received]
PHST- 2013/04/29 00:00 [revised]
PHST- 2013/06/05 00:00 [revised]
PHST- 2013/06/05 00:00 [accepted]
PHST- 2013/06/27 06:00 [entrez]
PHST- 2013/06/27 06:00 [pubmed]
PHST- 2014/02/07 06:00 [medline]
AID - 10.1111/apt.12388 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2013 Aug;38(4):432-9. doi: 10.1111/apt.12388. Epub 2013 
      Jun 25.

PMID- 3919694
OWN - NLM
STAT- MEDLINE
DCOM- 19850410
LR  - 20190704
IS  - 0003-9950 (Print)
IS  - 0003-9950 (Linking)
VI  - 103
IP  - 1
DP  - 1985 Jan
TI  - Comparative in vivo inhibitory effects of nonsteroidal anti-inflammatory agents 
      on prostaglandin synthesis in rabbit ocular tissues.
PG  - 103-6
AB  - We have compared the effects of nonsteroidal anti-inflammatory agents (NSAIDs) 
      indomethacin, flurbiprofen, and aspirin administered either intraperitoneally 
      (IP) or topically on rabbit conjunctival and anterior uveal prostaglandin (PG) 
      synthesis. Doses of IP flurbiprofen and aspirin at or above 50 mg/kg almost 
      completely inhibited PG synthesis in the conjunctiva and anterior uvea. 
      Indomethacin at doses up to 100 mg/kg only partially inhibited PG synthesis in 
      rabbit anterior uvea. Although IP flurbiprofen and aspirin were better than IP 
      indomethacin in inhibiting PG synthesis in anterior uvea, 0.5% topical aspirin 
      almost completely inhibited PG synthesis in the conjunctiva and anterior uvea, 
      but 0.5% flurbiprofen and 0.5% indomethacin did not. A lower topical dose (0.01%) 
      of aspirin prevented the production of PGs in the anterior uvea.
FAU - Kulkarni, P S
AU  - Kulkarni PS
FAU - Srinivasan, B D
AU  - Srinivasan BD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Arch Ophthalmol
JT  - Archives of ophthalmology (Chicago, Ill. : 1960)
JID - 7706534
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Prostaglandins E)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Anti-Inflammatory Agents/administration & dosage/*pharmacology
MH  - Arachidonic Acid
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/administration & dosage/pharmacology
MH  - Conjunctiva/*metabolism
MH  - Dinoprostone
MH  - Flurbiprofen/administration & dosage/pharmacology
MH  - Indomethacin/administration & dosage/pharmacology
MH  - Injections, Intraperitoneal
MH  - Prostaglandins E/*biosynthesis
MH  - Rabbits
MH  - Uvea/*metabolism
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1001/archopht.1985.01050010109031 [doi]
PST - ppublish
SO  - Arch Ophthalmol. 1985 Jan;103(1):103-6. doi: 
      10.1001/archopht.1985.01050010109031.

PMID- 15040166
OWN - NLM
STAT- MEDLINE
DCOM- 20040415
LR  - 20131121
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 49
IP  - 12
DP  - 2003 Dec
TI  - [Therapeutic use of acetylsalicylic acid in diabetics].
PG  - 972-5
AB  - Aterosclerosis is a leading cause of morbidity and mortality in diabetics. 
      Macrovascular diseases--myocardial infarction, cerebral vascular accident, 
      ischemic lower extremities--start in persons with diabetes earlier and in a 
      bigger scope then in non-diabetics. Development of these changes is determined by 
      diabetic vasculopathy which is connected with endothelial dysfunction, 
      hypercoagulation state, and platelet abnormalities. Treatment of a patient with 
      diabetes is based on compensation of diabetes and management of hypertension and 
      dyslipidaemia. Drugs that inhibit platelets constitute an important part of 
      prevention of cardiovascular disabilities in diabetics.
FAU - Zácková, V
AU  - Zácková V
AD  - II. interní klinika Lékarské fakulty MU a FN u sv. Anny, Brno.
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Lécba kyselinou acetylsalicylovou u diabetiků.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Diabetes Mellitus, Type 2
MH  - Diabetic Angiopathies/drug therapy/*prevention & control
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2004/03/26 05:00
MHDA- 2004/04/16 05:00
CRDT- 2004/03/26 05:00
PHST- 2004/03/26 05:00 [pubmed]
PHST- 2004/04/16 05:00 [medline]
PHST- 2004/03/26 05:00 [entrez]
PST - ppublish
SO  - Vnitr Lek. 2003 Dec;49(12):972-5.

PMID- 1440951
OWN - NLM
STAT- MEDLINE
DCOM- 19921217
LR  - 20131121
IS  - 0041-4301 (Print)
IS  - 0041-4301 (Linking)
VI  - 34
IP  - 2
DP  - 1992 Apr-Jun
TI  - Kawasaki syndrome.
PG  - 115-20
AB  - Kawasaki syndrome, also known as mucocutaneous lymph node syndrome, is an acute 
      vasculitis of infants and young children. We describe a four-year-old girl who 
      presented with fever, a diffuse erythematous maculopapular rash, bilateral 
      nonpurulent bulbar conjunctivitis, dry, red, fissured lips, a tongue with a 
      strawberry "appearance", an erythematous pharynx, indurative erythema, and edema 
      and desquamation of the face, hands and feet. She probably developed mitral valve 
      prolapse during the course of the disease. The diagnosis of Kawasaki syndrome was 
      arrived at by excluding other diseases and by the presence of all the clinical 
      criteria for Kawasaki syndrome. Since this syndrome is rarely encountered in 
      Turkey, this case is presented and the literature regarding the syndrome is 
      reviewed.
FAU - Olgun, N
AU  - Olgun N
AD  - Department of Pediatrics, Dokuz Eylül University Faculty of Medicine, Izmir.
FAU - Ozkan, H
AU  - Ozkan H
FAU - Oren, H
AU  - Oren H
FAU - Erdem, N
AU  - Erdem N
FAU - Cevik, N
AU  - Cevik N
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Turkey
TA  - Turk J Pediatr
JT  - The Turkish journal of pediatrics
JID - 0417505
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/drug therapy
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
PST - ppublish
SO  - Turk J Pediatr. 1992 Apr-Jun;34(2):115-20.

PMID- 6719389
OWN - NLM
STAT- MEDLINE
DCOM- 19840618
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 51
IP  - 1
DP  - 1984 Feb 28
TI  - On a possible interaction between ADP and mechanical stimulation in platelet 
      activation.
PG  - 54-6
AB  - Freshly drawn blood with inhibited plasma coagulation, but normal 
      Ca++-concentration, was lightly centrifuged to produce platelet rich plasma 
      (PRP). In order to minimize mixing of the various parts of the blood during the 
      centrifugation, the red cells were centrifuged into a "cushion" of albumin in the 
      bottom of the tube. Platelets harvested from the different parts of the 
      centrifuge tube exhibited different degrees of activation, i.e. they possessed 
      different abilities to aggregate when tested afterwards in an aggregometer. 
      Complete ADP scavenging during the centrifugation inhibited the platelet 
      activation, and it was therefore assumed that ADP released from red cells during 
      the centrifugation was partly responsible for this. But as the ADP concentration 
      at hand could be significantly reduced enzymatically without reducing the 
      activation of the platelets by the centrifuge, mechanical stimulation during the 
      centrifugation was postulated as a contributing factor. Prostaglandin synthesis 
      inhibition during the centrifugation retarded the activation of the platelets in 
      the tube.
FAU - Aursnes, I
AU  - Aursnes I
FAU - Vikholm, V
AU  - Vikholm V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 73-89-2 (Phosphoenolpyruvate)
RN  - EC 2.7.1.40 (Pyruvate Kinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/*pharmacology
MH  - Aspirin/pharmacology
MH  - Cell Separation
MH  - Centrifugation
MH  - Humans
MH  - Phosphoenolpyruvate/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Pyruvate Kinase/metabolism
EDAT- 1984/02/28 00:00
MHDA- 1984/02/28 00:01
CRDT- 1984/02/28 00:00
PHST- 1984/02/28 00:00 [pubmed]
PHST- 1984/02/28 00:01 [medline]
PHST- 1984/02/28 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1984 Feb 28;51(1):54-6.

PMID- 7067257
OWN - NLM
STAT- MEDLINE
DCOM- 19820621
LR  - 20131121
IS  - 0009-921X (Print)
IS  - 0009-921X (Linking)
IP  - 163
DP  - 1982 Mar
TI  - Reflex sympathetic dystrophy in children.
PG  - 225-30
AB  - Six patients with reflex sympathetic dystrophy were investigated during the 
      period between 1973 and 1978. Children do not develop the severe, disabling pain 
      nor the patchy osteoporosis (Sudeck's atrophy) which are considered essential 
      features of reflex sympathetic dystrophy in adults. In contrast to the adult 
      variety, reflex sympathetic dystrophy in children is a self-limiting condition 
      which usually responds well to mild analgesics and physical therapy. Frequently 
      it may be necessary to administer the physical therapy in an intensive, inpatient 
      program, both to break the pain-disability cycle and to remove the patient from a 
      stressful family environment that may have initiated or prolonged the syndrome. 
      The use of steroids (dexamethasone) had no appreciable effect on the clinical 
      course in these children.
FAU - Ruggeri, S B
AU  - Ruggeri SB
FAU - Athreya, B H
AU  - Athreya BH
FAU - Doughty, R
AU  - Doughty R
FAU - Gregg, J R
AU  - Gregg JR
FAU - Das, M M
AU  - Das MM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Dexamethasone/therapeutic use
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Male
MH  - Physical Therapy Modalities/methods
MH  - Reflex Sympathetic Dystrophy/*diagnosis/rehabilitation
EDAT- 1982/03/01 00:00
MHDA- 1982/03/01 00:01
CRDT- 1982/03/01 00:00
PHST- 1982/03/01 00:00 [pubmed]
PHST- 1982/03/01 00:01 [medline]
PHST- 1982/03/01 00:00 [entrez]
PST - ppublish
SO  - Clin Orthop Relat Res. 1982 Mar;(163):225-30.

PMID- 6993677
OWN - NLM
STAT- MEDLINE
DCOM- 19800923
LR  - 20141120
IS  - 0380-0903 (Print)
IS  - 0380-0903 (Linking)
VI  - 6
DP  - 1980
TI  - Long-term treatment of symptomatic osteoarthritis with benoxaprofen. Double-blind 
      comparison with aspirin and ibuprofen.
PG  - 89-99
AB  - Benoxaprofen was compared to aspirin or to ibuprofen in 2 28-wk multiclinic 
      double-blind trials in patients with symptomatic osteoarthritis of the knees or 
      hips. The design of the study permitted such comparison even though aspirin and 
      ibuprofen were given in divided doses and benoxaprofen in a single dose. The 
      comparison of benoxaprofen with aspirin included 140 patients and that with 
      ibuprofen 143 patients. All 3 medications caused improvement in every measure of 
      joint disease after 1 wk of therapy and improvement was either increased or 
      maintained for the duration of treatment.
FAU - Alarcon-Segovia, D
AU  - Alarcon-Segovia D
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol Suppl
JT  - The Journal of rheumatology. Supplement
JID - 7806058
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Benzoxazoles)
RN  - 0 (Propionates)
RN  - 17SZX404IM (benoxaprofen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Benzoxazoles/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Hip Joint
MH  - Humans
MH  - Ibuprofen/adverse effects/*therapeutic use
MH  - Knee Joint
MH  - Male
MH  - Middle Aged
MH  - Movement/drug effects
MH  - Osteoarthritis/*drug therapy
MH  - Patient Compliance
MH  - Propionates/adverse effects/*therapeutic use
MH  - Time Factors
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol Suppl. 1980;6:89-99.

PMID- 11347721
OWN - NLM
STAT- MEDLINE
DCOM- 20010920
LR  - 20181113
IS  - 0114-5916 (Print)
IS  - 0114-5916 (Linking)
VI  - 24
IP  - 3
DP  - 2001
TI  - Interaction between aspirin and ACE inhibitors in patients with heart failure.
PG  - 167-82
AB  - Both aspirin (acetylsalicylic acid) and ACE inhibitors are often used 
      concomitantly, especially in patients with both heart failure and ischaemic heart 
      disease, which is the most common underlying cause of heart failure. The safety 
      of the association has been questioned because both drugs affect a related 
      prostaglandin-mediated pathway. Thanks to their vasodilating properties, 
      prostaglandins play an important role in heart failure where peripheral 
      vasoconstriction occurs. Some of the beneficial effects of ACE inhibitors might 
      be related to reduced degradation of bradykinin that enhances the synthesis of 
      prostaglandins, while aspirin, through inhibiting the enzyme cyclo-oxygenase, 
      inhibits the production of prostaglandins. To date no prospective study has been 
      conducted to investigate the effect of long term aspirin treatment in the 
      postinfarction period allowing the possible impact of the interaction between 
      aspirin and ACE inhibitors upon survival to be confirmed or negated. However, the 
      practitioner needs to know how to optimise the treatment of his or her patients. 
      In order to stimulate arguments for and against the use of aspirin in patients 
      with heart failure receiving ACE inhibitors, we searched MEDLINE from 1960 to 
      2000 using the key words heart failure, aspirin, and ACE inhibitors for English 
      language articles and conducted a review of the available data. We report on the 
      potential mechanisms of the interaction and the results of experimental studies 
      on haemodynamic parameters. Results of retrospective clinical studies, subgroup 
      analysis that were undertaken to evaluate the overall action upon haemodynamic 
      parameters and survival of the association are summarised. Conflicting 
      conclusions have been reported in the literature. Many explanations can be 
      advanced to try to understand these conflicting conclusions: differences in study 
      design (results of retrospective trials have to be interpreted with caution); 
      differences in the choice of the evaluation parameter (problem of the clinical 
      relevance of haemodynamic parameters); differences in the characteristics of the 
      patient (different underlying cardiopathy, e.g. heart failure, hypertension or 
      ischaemic cardiopathy); and differences in the type and the dosage of each 
      treatment (especially ACE inhibitors and aspirin since an interaction might occur 
      more often with dosage of aspirin greater than 250mg).
FAU - Mahé, I
AU  - Mahé I
AD  - Unité de Recherches Therapeutiques, Service de Medicine Interne A, H pital 
      Lariboisière, Paris, France. jf.bergmann@lrb.ap-hop-paris.fr
FAU - Meune, C
AU  - Meune C
FAU - Diemer, M
AU  - Diemer M
FAU - Caulin, C
AU  - Caulin C
FAU - Bergmann, J F
AU  - Bergmann JF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics/*therapeutic use
MH  - Animals
MH  - Aspirin/pharmacokinetics/*therapeutic use
MH  - Clinical Trials as Topic/methods
MH  - Cyclooxygenase Inhibitors/pharmacokinetics/*therapeutic use
MH  - Drug Interactions
MH  - Drug Monitoring/methods
MH  - Drug Therapy, Combination
MH  - Heart Failure/*drug therapy/metabolism
MH  - Humans
RF  - 91
EDAT- 2001/05/12 10:00
MHDA- 2001/09/21 10:01
CRDT- 2001/05/12 10:00
PHST- 2001/05/12 10:00 [pubmed]
PHST- 2001/09/21 10:01 [medline]
PHST- 2001/05/12 10:00 [entrez]
AID - 10.2165/00002018-200124030-00002 [doi]
PST - ppublish
SO  - Drug Saf. 2001;24(3):167-82. doi: 10.2165/00002018-200124030-00002.

PMID- 25109257
OWN - NLM
STAT- MEDLINE
DCOM- 20150601
LR  - 20220129
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 32
IP  - 4
DP  - 2014 Oct
TI  - Identification of aspirin analogues that repress NF-κB signalling and demonstrate 
      anti-proliferative activity towards colorectal cancer in vitro and in vivo.
PG  - 1670-80
LID - 10.3892/or.2014.3373 [doi]
AB  - Substantial evidence indicates that aspirin and related non-steroidal 
      anti-inflammatory drugs (NSAIDs) have potential as chemopreventative/therapeutic 
      agents. However, these agents cannot be universally recommended for prevention 
      purposes due to their potential side-effect profiles. Here, we compared the 
      growth inhibitory and mechanistic activity of aspirin to two novel analogues, 
      diaspirin (DiA) and fumaryl diaspirin (F-DiA). We found that the aspirin 
      analogues inhibited cell proliferation and induced apoptosis of colorectal cancer 
      cells at significantly lower doses than aspirin. Similar to aspirin, we found 
      that an early response to the analogues was a reduction in levels of cyclin D1 
      and stimulation of the NF-κB pathway. This stimulation was associated with a 
      significant reduction in basal levels of NF-κB transcriptional activity, in 
      keeping with previous data for aspirin. However, in contrast to aspirin, DiA and 
      F-DiA activity was not associated with nucleolar accumulation of RelA. For all 
      assays, F-DiA had a more rapid and significant effect than DiA, identifying this 
      agent as particularly active against colorectal cancer. Using a syngeneic 
      colorectal tumour model in mice, we found that, while both agents significantly 
      inhibited tumour growth in vivo, this effect was particularly pronounced for 
      F-DiA. These data identify two compounds that are active against colorectal 
      cancer in vitro and in vivo. They also identify a potential mechanism of action 
      of these agents and shed light on the chemical structures that may be important 
      for the antitumour effects of aspirin.
FAU - Claudius, Ann-Katrin
AU  - Claudius AK
AD  - Edinburgh Cancer Research Centre and MRC Human Genetics Unit, Institute of 
      Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.
FAU - Kankipati, Chandra S
AU  - Kankipati CS
AD  - The Research Institute in Healthcare Science, Faculty of Science and Engineering, 
      University of Wolverhampton, Wolverhampton WV1 1LY, UK.
FAU - Kilari, Rajagopal S
AU  - Kilari RS
AD  - The Research Institute in Healthcare Science, Faculty of Science and Engineering, 
      University of Wolverhampton, Wolverhampton WV1 1LY, UK.
FAU - Hassan, Sadiya
AU  - Hassan S
AD  - The Research Institute in Healthcare Science, Faculty of Science and Engineering, 
      University of Wolverhampton, Wolverhampton WV1 1LY, UK.
FAU - Guest, Kerry
AU  - Guest K
AD  - Life and Health Sciences, Aston Triangle, Aston University, Birmingham B4 7ET, 
      UK.
FAU - Russell, Steven T
AU  - Russell ST
AD  - Life and Health Sciences, Aston Triangle, Aston University, Birmingham B4 7ET, 
      UK.
FAU - Perry, Chris J
AU  - Perry CJ
AD  - The Research Institute in Healthcare Science, Faculty of Science and Engineering, 
      University of Wolverhampton, Wolverhampton WV1 1LY, UK.
FAU - Stark, Lesley A
AU  - Stark LA
AD  - Edinburgh Cancer Research Centre and MRC Human Genetics Unit, Institute of 
      Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.
FAU - Nicholl, Iain D
AU  - Nicholl ID
AD  - The Research Institute in Healthcare Science, Faculty of Science and Engineering, 
      University of Wolverhampton, Wolverhampton WV1 1LY, UK.
LA  - eng
GR  - 10-0158/AICR_/Worldwide Cancer Research/United Kingdom
GR  - ETM/154/CSO_/Chief Scientist Office/United Kingdom
GR  - MR/J001481/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140731
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclin D)
RN  - 0 (NF-kappa B)
RN  - 0 (Transcription Factor RelA)
RN  - 106044-07-9 (bis(2,3-dibromosalicyl)fumarate)
RN  - 578-19-8 (succinyldisalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Adenocarcinoma
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - *Colorectal Neoplasms
MH  - Cyclin D/drug effects/metabolism
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - NF-kappa B/*drug effects/metabolism
MH  - Signal Transduction/*drug effects
MH  - Transcription Factor RelA/drug effects/metabolism
MH  - Xenograft Model Antitumor Assays
EDAT- 2014/08/12 06:00
MHDA- 2015/06/02 06:00
CRDT- 2014/08/12 06:00
PHST- 2014/05/19 00:00 [received]
PHST- 2014/06/26 00:00 [accepted]
PHST- 2014/08/12 06:00 [entrez]
PHST- 2014/08/12 06:00 [pubmed]
PHST- 2015/06/02 06:00 [medline]
AID - 10.3892/or.2014.3373 [doi]
PST - ppublish
SO  - Oncol Rep. 2014 Oct;32(4):1670-80. doi: 10.3892/or.2014.3373. Epub 2014 Jul 31.

PMID- 12126819
OWN - NLM
STAT- MEDLINE
DCOM- 20020730
LR  - 20220309
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 360
IP  - 9327
DP  - 2002 Jul 13
TI  - Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a 
      randomised controlled trial.
PG  - 109-13
AB  - BACKGROUND: Antiplatelet treatment with aspirin and oral anticoagulants reduces 
      recurrence of ischaemic events after myocardial infarction. We aimed to 
      investigate which of these drugs is more effective in the long term after acute 
      coronary events, and whether the combination of aspirin and oral anticoagulants 
      offers greater benefit than either of these agents alone, without excessive risk 
      of bleeding. METHODS: In a randomised open-label trial in 53 sites, we randomly 
      assigned 999 patients to low-dose aspirin, high-intensity oral anticoagulation, 
      or combined low-dose aspirin and moderate intensity oral anticoagulation. 
      Patients were followed up for a maximum of 26 months. The primary composite 
      endpoint was first occurrence of myocardial infarction, stroke, or death. 
      FINDINGS: The primary endpoint was reached in 31 (9%) of 336 patients on aspirin, 
      in 17 (5%) of 325 on anticoagulants (hazard ratio 0.55 [95% CI 0.30-1.00], 
      p=0.0479), and in 16 (5%) of 332 on combination therapy (0.50 [0.27-0.92], 
      p=0.03). Major bleeding was recorded in three (1%) patients on aspirin, three 
      (1%) on anticoagulants (1.03 [0.21-5.08], p=1.0), and seven (2%) on combination 
      therapy (2.35 [0.61-9.10], p=0.2). Frequency of minor bleeding was 5%, 8% (1.68 
      [0.92-3.07], p=0.20), and 15% (3.13 [1.82-5.37], p=<0.0001), in the three groups, 
      respectively. 164 patients permanently discontinued the study drug. Analyses were 
      done by intention to treat. INTERPRETATION: In patients recently admitted with 
      acute coronary events, treatment with high-intensity oral anticoagulants or 
      aspirin with medium-intensity oral anticoagulants was more effective than aspirin 
      on its own in reduction of subsequent cardiovascular events and death.
FAU - van Es, Robert F
AU  - van Es RF
AD  - Julius Centre for General Practice and Patient Oriented Research, University 
      Medical Centre Utrecht, Netherlands.
FAU - Jonker, Jan J C
AU  - Jonker JJ
FAU - Verheugt, Freek W A
AU  - Verheugt FW
FAU - Deckers, Jaap W
AU  - Deckers JW
FAU - Grobbee, Diederick E
AU  - Grobbee DE
CN  - Antithrombotics in the Secondary Preventionof Events in Coronary Thrombosis-2 
      (ASPECT-2) Research Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2002 Dec 21-28;360(9350):2078; author reply 2078. PMID: 12504434
CIN - ACP J Club. 2003 Jan-Feb;138(1):9. PMID: 12511121
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/etiology/*prevention & control
MH  - Netherlands
MH  - Risk Factors
MH  - Stroke/etiology/*prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2002/07/20 10:00
MHDA- 2002/07/31 10:01
CRDT- 2002/07/20 10:00
PHST- 2002/07/20 10:00 [pubmed]
PHST- 2002/07/31 10:01 [medline]
PHST- 2002/07/20 10:00 [entrez]
AID - S0140-6736(02)09409-6 [pii]
AID - 10.1016/S0140-6736(02)09409-6 [doi]
PST - ppublish
SO  - Lancet. 2002 Jul 13;360(9327):109-13. doi: 10.1016/S0140-6736(02)09409-6.

PMID- 9914592
OWN - NLM
STAT- MEDLINE
DCOM- 19990223
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 180
IP  - 1 Pt 1
DP  - 1999 Jan
TI  - Effect of aspirin in pregnant women is dependent on increase in bleeding time.
PG  - 135-40
AB  - OBJECTIVES: Randomized trials with low-dose aspirin to prevent preeclampsia and 
      intrauterine growth restriction have yielded conflicting results. In particular, 
      3 recent large trials were not conclusive. Study designs, however, varied greatly 
      regarding selection of patients, dose of aspirin, and timing of treatment, all of 
      which can be determinants of the results. Retrospectively analyzing the 
      conditions associated with failure or success of aspirin may therefore help to 
      draw up new hypotheses and prepare for more specific randomized trials. STUDY 
      DESIGN: We studied a historical cohort of 187 pregnant women who were considered 
      at high risk for preeclampsia, intrauterine growth restriction, or both and were 
      therefore treated with low-dose aspirin between 1989 and 1994. Various 
      epidemiologic, clinical, and laboratory data were extracted from the files. 
      Univariate and multivariate analyses were performed to search for independent 
      parameters associated with the outcome of pregnancy. RESULTS: Age, parity, 
      weight, height, and race had no influence on the outcome. The success rate was 
      higher when treatment was given because of previous poor pregnancy outcomes than 
      when it was given for other indications, and the patients with successful therapy 
      had started aspirin earlier than had those with therapy failure (17.7 vs 20.0 
      weeks' gestation, P =.04). After multivariate analysis an increase in Ivy 
      bleeding time after 10 days of treatment by >2 minutes was an independent 
      predictor of a better outcome (odds ratio 0.22, 95% confidence interval 
      0.09-0.51). Borderline statistical significance was observed for aspirin 
      initiation before 17 weeks' gestation (odds ratio 0.44, 95% confidence interval 
      0.18-1. 08). Abnormal uterine artery Doppler velocimetric scan at 20-24 weeks' 
      gestation (odds ratio 3.31, 95% confidence interval 1.41-7.7), abnormal umbilical 
      artery Doppler velocimetric scan after 26 weeks' gestation (odds ratio 37.6, 95% 
      confidence interval 3.96-357), and use of antihypertensive therapy (odds ratio 
      6.06, 95% confidence interval 2.45-15) were independent predictors of poor 
      outcome. CONCLUSIONS: Efficacy of aspirin seems optimal when bleeding time 
      increases >/=2 minutes with treatment, indicating a more powerful antiplatelet 
      effect. This suggests that the dose of aspirin should be adjusted according to a 
      biologic marker of the antiplatelet effect. A prospective trial is warranted to 
      test this hypothesis.
FAU - Dumont, A
AU  - Dumont A
AD  - Departments of Obstetrics and Gynecology, Hôpital Tenon, Paris, France.
FAU - Flahault, A
AU  - Flahault A
FAU - Beaufils, M
AU  - Beaufils M
FAU - Verdy, E
AU  - Verdy E
FAU - Uzan, S
AU  - Uzan S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antihypertensive Agents/therapeutic use
MH  - Arteries/diagnostic imaging/physiopathology
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Bleeding Time
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fetal Growth Retardation/prevention & control
MH  - Gestational Age
MH  - Humans
MH  - Multivariate Analysis
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - Rheology
MH  - Treatment Outcome
MH  - Ultrasonography
MH  - Uterus/blood supply
EDAT- 1999/01/23 00:00
MHDA- 1999/01/23 00:01
CRDT- 1999/01/23 00:00
PHST- 1999/01/23 00:00 [pubmed]
PHST- 1999/01/23 00:01 [medline]
PHST- 1999/01/23 00:00 [entrez]
AID - S0002-9378(99)70163-8 [pii]
AID - 10.1016/s0002-9378(99)70163-8 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1999 Jan;180(1 Pt 1):135-40. doi: 
      10.1016/s0002-9378(99)70163-8.

PMID- 19100325
OWN - NLM
STAT- MEDLINE
DCOM- 20091215
LR  - 20220310
IS  - 1873-4596 (Electronic)
IS  - 0891-5849 (Linking)
VI  - 46
IP  - 5
DP  - 2009 Mar 1
TI  - Pharmacological profile of a novel H(2)S-releasing aspirin.
PG  - 586-92
LID - 10.1016/j.freeradbiomed.2008.11.013 [doi]
AB  - The pharmacological profile of a new, safe, and effective hydrogen sulfide 
      (H(2)S)-releasing derivative of aspirin (ACS14) is described. We report the 
      synthesis of ACS14, and of its deacetylated metabolite (ACS21), the preliminary 
      pharmacokinetics, and its in vivo metabolism, with the H(2)S plasma levels after 
      intravenous administration in the rat. ACS14 maintains the 
      thromboxane-suppressing activity of the parent compound, but seems to spare the 
      gastric mucosa, by affecting redox imbalance through increased H(2)S/glutathione 
      formation, heme oxygenase-1 promoter activity, and isoprostane suppression.
FAU - Sparatore, Anna
AU  - Sparatore A
AD  - Istituto di Chimica Farmaceutica e Tossicologica "Pietro Pratesi", University of 
      Milano, Italy. anna.sparatore@unimi.it
FAU - Perrino, Elena
AU  - Perrino E
FAU - Tazzari, Valerio
AU  - Tazzari V
FAU - Giustarini, Daniela
AU  - Giustarini D
FAU - Rossi, Ranieri
AU  - Rossi R
FAU - Rossoni, Giuseppe
AU  - Rossoni G
FAU - Erdmann, Kati
AU  - Erdmann K
FAU - Schröder, Henning
AU  - Schröder H
FAU - Del Soldato, Piero
AU  - Del Soldato P
LA  - eng
PT  - Journal Article
DEP - 20081206
PL  - United States
TA  - Free Radic Biol Med
JT  - Free radical biology & medicine
JID - 8709159
RN  - 0 (2-acetyloxybenzoic acid 4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl ester)
RN  - 0 (Disulfides)
RN  - 0 (Isoprostanes)
RN  - 0 (Thromboxanes)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
EIN - Free Radic Biol Med. 2009 Dec 15;47(12):1781. Erdman, Kati [corrected to Erdmann, 
      Kati]
MH  - 3T3 Cells
MH  - Animals
MH  - Aorta, Thoracic/enzymology/pathology
MH  - Aspirin/administration & dosage/*analogs & 
      derivatives/chemistry/*pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Disulfides/administration & dosage/chemistry/*pharmacokinetics
MH  - Gastric Mucosa/pathology
MH  - Glutathione/metabolism
MH  - Heme Oxygenase-1/*genetics
MH  - Hydrogen Sulfide/*blood
MH  - Isoprostanes/metabolism
MH  - Male
MH  - Mice
MH  - Myocardium/*enzymology/pathology
MH  - Promoter Regions, Genetic/genetics
MH  - Rats
MH  - Rats, Wistar
MH  - Thromboxanes/*antagonists & inhibitors/blood
MH  - Transcriptional Activation/drug effects
MH  - Transfection
EDAT- 2008/12/23 09:00
MHDA- 2009/12/16 06:00
CRDT- 2008/12/23 09:00
PHST- 2008/08/26 00:00 [received]
PHST- 2008/11/08 00:00 [revised]
PHST- 2008/11/12 00:00 [accepted]
PHST- 2008/12/23 09:00 [entrez]
PHST- 2008/12/23 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S0891-5849(08)00714-4 [pii]
AID - 10.1016/j.freeradbiomed.2008.11.013 [doi]
PST - ppublish
SO  - Free Radic Biol Med. 2009 Mar 1;46(5):586-92. doi: 
      10.1016/j.freeradbiomed.2008.11.013. Epub 2008 Dec 6.

PMID- 20229685
OWN - NLM
STAT- MEDLINE
DCOM- 20100420
LR  - 20190917
IS  - 0370-8179 (Print)
IS  - 0370-8179 (Linking)
VI  - 138 Suppl 1
DP  - 2010 Jan
TI  - Platelet function tests and resistance to antiplatelet therapy.
PG  - 59-63
AB  - The clinical efficacy of antiplatelet therapy (aspirin, P2Y12 and glycoprotein 
      IIb/IIIa receptor antagonists) to prevent occlusive arterial events in patients 
      with atherothrombotic disease is well established. Despite the proven benefits of 
      antiplatelet therapy, many patients continue to experience arterial events. Many 
      factors may influence the response of platelets to antiplatelet therapy and some 
      patients with adequate compliance to the treatment may exhibit failure of 
      platelet inhibition as determined by ex vivo laboratory tests, a phenomenon 
      termed "resistance" to antiplatelet therapy. Platelet function can be measured by 
      numerous platelet function tests, with which various parameters of platelet 
      activation, secretion, adhesion and aggregation can be determined. These tests 
      include light transmission (optical) and whole blood aggregometry, point-of-care 
      devices, such as platelet function analyzers PFA-100, and VerifyNow, flow 
      cytometry, serum thromboxane B2 and urinary levels of the thromboxane B2 
      metabolite 11-dehyro-thromboxane B2. Other tests, such as whole blood platelet 
      aggregation measured by platelet counting, thrombelastography and devices such as 
      the cone and plate(let) analyzer, Plateletworks and thrombotic status analyzer 
      have also been used to determine platelet inhibition by antiplatelet drugs, but 
      their use is not widespread and therefore experience is limited. Further studies 
      need to be carried out to answer basic questions on the clinical utility and 
      cost-effectiveness of laboratory monitoring of antiplatelet therapy before it can 
      be recommended in clinical practice.
FAU - Stegnar, Mojca
AU  - Stegnar M
AD  - Department of Vascular Diseases, University Medical Centre, Ljubljana, Slovenia. 
      mojca.stegnar@kclj.si
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Serbia
TA  - Srp Arh Celok Lek
JT  - Srpski arhiv za celokupno lekarstvo
JID - 0027440
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Platelet Function Tests
MH  - Ticlopidine/analogs & derivatives/therapeutic use
RF  - 31
EDAT- 2010/03/17 06:00
MHDA- 2010/04/21 06:00
CRDT- 2010/03/17 06:00
PHST- 2010/03/17 06:00 [entrez]
PHST- 2010/03/17 06:00 [pubmed]
PHST- 2010/04/21 06:00 [medline]
AID - 10.2298/sarh10s1059s [doi]
PST - ppublish
SO  - Srp Arh Celok Lek. 2010 Jan;138 Suppl 1:59-63. doi: 10.2298/sarh10s1059s.

PMID- 30819710
OWN - NLM
STAT- MEDLINE
DCOM- 20200327
LR  - 20200327
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 9
IP  - 2
DP  - 2019 Feb 27
TI  - Aspirin use in central retinal arterial occlusion to prevent ischaemic stroke: a 
      retrospective cohort study in Taiwan.
PG  - e025455
LID - 10.1136/bmjopen-2018-025455 [doi]
LID - e025455
AB  - OBJECTIVE: To understand the efficacy of aspirin use for preventing ischaemic 
      stroke after central retinal artery occlusion (CRAO). DESIGN: The retrospective 
      cohort study was conducted using the National Health Insurance Research Database 
      from 1998 to 2013. SETTING: A population-based study. PARTICIPANTS: A total of 
      9437 participants with newly diagnosed CRAO were identified. Participants who had 
      a previous stroke and/or retinal vascular occlusion, were aged <20 years and used 
      aspirin 3 months before the event were excluded. There were 3778 eligible 
      participants matched by propensity score, and they were divided into aspirin 
      (n=434) and aspirin-naive (n=1736) groups after the matching. METHODS: Cox 
      proportional hazard models and cumulative survival curves were used to assess 
      ischaemic stroke in the study groups, along with log-rank tests to compare group 
      differences. MAIN OUTCOME MEASURES: Incidence of ischaemic stroke in the aspirin 
      and aspirin-naive groups 1 year after CRAO. RESULTS: Of the 3778 patients with 
      newly diagnosed CRAO, 151 (4%) had a subsequent ischaemic stroke within 1 year. 
      The risk was especially high during the first week of the CRAO. No difference 
      between the aspirin and aspirin-naive groups was found in risk of ischaemic 
      stroke, haemorrhagic stroke, gastrointestinal bleeding, major bleeding, acute 
      coronary syndrome, retinal vein occlusion, new-onset glaucoma, undergoing 
      panretinal photocoagulation or all-cause mortality. Risk factors for ischaemic 
      stroke within 1 year of CRAO included male gender (p=0.031; HR=1.46) and age 
      (p=0.032; HR=1.14). CONCLUSIONS: Aspirin use after a CRAO showed no benefit on 
      attenuating the risk of ischaemic stroke. The risk of ischaemic stroke was 
      increased after CRAO especially during the first week. Male gender and age were 
      risk factors for ischaemic stroke after CRAO.
CI  - © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kang, Eugene Yu-Chuan
AU  - Kang EY
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, 
      Taoyuan, Taiwan.
AD  - Chang Gung University, College of Medicine, Taoyuan, Taiwan.
FAU - Lin, Yun-Hsuan
AU  - Lin YH
AD  - Chang Gung University, College of Medicine, Taoyuan, Taiwan.
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan.
FAU - Wang, Nan-Kai
AU  - Wang NK
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, 
      Taoyuan, Taiwan.
AD  - Chang Gung University, College of Medicine, Taoyuan, Taiwan.
AD  - Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia 
      University, New York, NY, USA.
FAU - Yeung, Ling
AU  - Yeung L
AD  - Chang Gung University, College of Medicine, Taoyuan, Taiwan.
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan.
FAU - Luo, Caesar
AU  - Luo C
AD  - Bay Area Retina Associates, Oakland, CA, USA.
FAU - Wu, Wei-Chi
AU  - Wu WC
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, 
      Taoyuan, Taiwan.
AD  - Chang Gung University, College of Medicine, Taoyuan, Taiwan.
FAU - Sun, Chi-Chin
AU  - Sun CC
AD  - Chang Gung University, College of Medicine, Taoyuan, Taiwan.
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan.
AD  - Biostatistical Consultation Center, Chang Gung Memorial Hospital, Keelung, 
      Taiwan.
FAU - Kang, Je-Ho
AU  - Kang JH
AD  - Department of Internal Medicine, Yang Ming Hospital, Taoyuan, Taiwan.
FAU - Hung, Ming-Jui
AU  - Hung MJ
AD  - Chang Gung University, College of Medicine, Taoyuan, Taiwan.
AD  - Department of Cardiology, Chang Gung Memorial Hospital, Keelung, Taiwan.
FAU - Chen, Tien-Hsing
AU  - Chen TH
AD  - Chang Gung University, College of Medicine, Taoyuan, Taiwan.
AD  - Biostatistical Consultation Center, Chang Gung Memorial Hospital, Keelung, 
      Taiwan.
AD  - Department of Cardiology, Chang Gung Memorial Hospital, Keelung, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190227
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cause of Death
MH  - Databases, Factual
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Mortality
MH  - Multivariate Analysis
MH  - Retinal Artery Occlusion/*drug therapy
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stroke/*prevention & control
MH  - Survival Analysis
MH  - Taiwan/epidemiology
MH  - Treatment Outcome
PMC - PMC6398622
OTO - NOTNLM
OT  - aspirin
OT  - central retinalarterial occlusion
OT  - ischemic stroke prevention
OT  - riskfactor
COIS- Competing interests: None declared.
EDAT- 2019/03/02 06:00
MHDA- 2020/03/28 06:00
CRDT- 2019/03/02 06:00
PHST- 2019/03/02 06:00 [entrez]
PHST- 2019/03/02 06:00 [pubmed]
PHST- 2020/03/28 06:00 [medline]
AID - bmjopen-2018-025455 [pii]
AID - 10.1136/bmjopen-2018-025455 [doi]
PST - epublish
SO  - BMJ Open. 2019 Feb 27;9(2):e025455. doi: 10.1136/bmjopen-2018-025455.

PMID- 36273575
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20221228
IS  - 1096-0007 (Electronic)
IS  - 0014-4835 (Linking)
VI  - 225
DP  - 2022 Dec
TI  - Differential effects of acetylsalicylic acid and mitomycin C on cytokine-induced 
      Tenon's capsule myofibroblast transdifferentiation and activity: Implications for 
      glaucoma surgery.
PG  - 109284
LID - S0014-4835(22)00365-7 [pii]
LID - 10.1016/j.exer.2022.109284 [doi]
AB  - Inflammation-driven scarring is a major contributor to surgical failure after 
      subconjunctival bleb forming glaucoma surgery. The current gold standard 
      anti-scarring adjuvant mitomycin C (MMC) has variable effectiveness and is 
      associated with significant risks. Acetylsalicylic acid (ASA), when delivered 
      locally, repurposes the typically pro-inflammatory cyclooxygenase (COX-2) 
      signaling for the resolution of inflammation and mitigating inflammation-mediated 
      fibrosis. The aim of this study is to compare the effects of ASA and MMC in an in 
      vitro model of subconjunctival scarring. Glaucoma patient-derived Tenon's capsule 
      fibroblasts (HTCFs) were treated with TGFβ1 (2 ng/mL) plus or minus ASA 
      (1600 μg/ml), or MMC (0.05, 0.1, 0.2 mg/mL). In vitro collagen contraction, MTT, 
      LDH, immunofluorescence, and Western blot assays were performed. To elucidate the 
      mechanistic effects of ASA in TGFβ1-induced HTCFs, liquid chromatography tandem 
      mass spectrometry (LC-MS/MS) was used to identify and measure pro-inflammatory 
      and pro-resolving lipid mediator secretion. ASA was at least as effective as MMC 
      in reducing TGFβ1-induced HTCF-mediated collagen contraction, metabolic activity, 
      and pro-fibrotic protein expression, with less cytotoxicity. Within 
      cytokine-activated HTCFs, ASA significantly impaired secretion of 
      pro-inflammatory lipid mediators prostaglandin E2 and 6-keto-prostaglandin F1α 
      and significantly increased secretion of the pro-resolving mediators 
      5-hydroxyeicosatetraenoic acid (HETE), 15-HETE and 18-hydroxyeicosapentaenoic 
      acid (HEPE). ASA reduces cytokine-induced myofibroblast transdifferentiation in 
      HTCFs, being non-inferior to MMC in vitro. ASA's effects are associated with a 
      unique lipid mediator expression profile, suggesting that the ASA-induced 
      resolution of inflammation may be a promising strategy to mitigate 
      inflammation-mediated scarring and could offer a novel alternative as a surgical 
      adjuvant.
CI  - Copyright © 2022 Elsevier Ltd. All rights reserved.
FAU - Vinokurtseva, Anastasiya
AU  - Vinokurtseva A
AD  - Department of Ophthalmology, Schulich School of Medicine and Dentistry, 
      University of Western Ontario, London, ON, Canada. Electronic address: 
      avinokurtseva2022@meds.uwo.ca.
FAU - Armstrong, James J
AU  - Armstrong JJ
AD  - Department of Ophthalmology, Schulich School of Medicine and Dentistry, 
      University of Western Ontario, London, ON, Canada; Ivey Eye Institute, St. 
      Joseph's Health Care, London, ON, Canada.
FAU - Liu, Hong
AU  - Liu H
AD  - Department of Ophthalmology, Schulich School of Medicine and Dentistry, 
      University of Western Ontario, London, ON, Canada; Department of Pathology and 
      Laboratory Medicine, Western University, London, ON, Canada.
FAU - Hutnik, Cindy M L
AU  - Hutnik CML
AD  - Department of Ophthalmology, Schulich School of Medicine and Dentistry, 
      University of Western Ontario, London, ON, Canada; Ivey Eye Institute, St. 
      Joseph's Health Care, London, ON, Canada; Department of Pathology and Laboratory 
      Medicine, Western University, London, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221021
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 50SG953SK6 (Mitomycin)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Cytokines)
RN  - 9007-34-5 (Collagen)
RN  - 0 (Lipids)
SB  - IM
MH  - Humans
MH  - *Tenon Capsule/metabolism
MH  - Mitomycin/pharmacology
MH  - Myofibroblasts/metabolism
MH  - Cell Transdifferentiation
MH  - Aspirin/pharmacology/metabolism
MH  - Cytokines/metabolism
MH  - Chromatography, Liquid
MH  - Tandem Mass Spectrometry
MH  - Fibroblasts/metabolism
MH  - *Glaucoma/metabolism
MH  - Cicatrix/metabolism
MH  - Collagen/metabolism
MH  - Fibrosis
MH  - Inflammation/metabolism
MH  - Lipids
MH  - Cells, Cultured
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Aspirin
OT  - Glaucoma
OT  - Human Tenon's capsule fibroblasts
OT  - Lipid mediator
OT  - Mitomycin C
OT  - Myofibroblasts
EDAT- 2022/10/24 06:00
MHDA- 2022/12/07 06:00
CRDT- 2022/10/23 19:33
PHST- 2022/07/11 00:00 [received]
PHST- 2022/09/08 00:00 [revised]
PHST- 2022/10/13 00:00 [accepted]
PHST- 2022/10/24 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/10/23 19:33 [entrez]
AID - S0014-4835(22)00365-7 [pii]
AID - 10.1016/j.exer.2022.109284 [doi]
PST - ppublish
SO  - Exp Eye Res. 2022 Dec;225:109284. doi: 10.1016/j.exer.2022.109284. Epub 2022 Oct 
      21.

PMID- 27555160
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20181202
IS  - 1873-4529 (Electronic)
IS  - 0952-8180 (Linking)
VI  - 33
DP  - 2016 Sep
TI  - A retrospective study showing the extent of compliance with perioperative 
      guidelines in patients with coronary stents with regard to double antiplatelet 
      therapy.
PG  - 179-84
LID - S0952-8180(16)00110-0 [pii]
LID - 10.1016/j.jclinane.2016.01.030 [doi]
AB  - STUDY OBJECTIVE: To evaluate perioperative dual antiplatelet therapy management 
      in patients with previously placed coronary stents. DESIGN: Retrospective medical 
      record review. SETTING: Academic medical center. PATIENTS: A total of 1891 
      surgical cases performed at Vanderbilt University Medical Center in 2012 were 
      evaluated using a perioperative database. Of these, 161 had complete data records 
      that were evaluated using 2 evidence-based and expert opinion-supported 
      protocols. INTERVENTIONS: N/A. MEASUREMENTS: This study is meant to evaluate 
      perioperative antiplatelet management decisions in patients with coronary stents. 
      MAIN RESULTS: Management decisions were consistent with guidelines regarding 
      antiplatelet therapy in 13% (21/161) of patients. Of the 87% (140/161) of cases 
      where decisions were not consistent, 88% (123/140) were due to discontinuing 
      aspirin preoperatively when there was not a high risk of surgical bleeding. 
      CONCLUSIONS: This study revealed suboptimal adherence to current perioperative 
      antiplatelet management guidelines in patients with coronary stents. The lack of 
      adherence to current guidelines is concerning and could be used to support the 
      notion of an anesthesiologist-led Perioperative Surgical Home.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Woolard, Austin A
AU  - Woolard AA
AD  - University of Tennessee Health Science Center, Memphis, TN. Electronic address: 
      awoolard@uthsc.edu.
FAU - Ehrenfeld, Jesse M
AU  - Ehrenfeld JM
AD  - Department of Anesthesiology, Vanderbilt University, Nashville, TN; Department of 
      Biomedical Informatics, Vanderbilt University, Nashville, TN; Department of 
      Surgery, Vanderbilt University, Nashville, TN.
FAU - Eagle, Susan S
AU  - Eagle SS
AD  - Department of Anesthesiology, Vanderbilt University, Nashville, TN.
FAU - Wanderer, Jonathan P
AU  - Wanderer JP
AD  - Department of Anesthesiology, Vanderbilt University, Nashville, TN; Department of 
      Biomedical Informatics, Vanderbilt University, Nashville, TN.
LA  - eng
PT  - Journal Article
DEP - 20160429
PL  - United States
TA  - J Clin Anesth
JT  - Journal of clinical anesthesia
JID - 8812166
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Case Management
MH  - Clopidogrel
MH  - *Coronary Vessels
MH  - Female
MH  - Guideline Adherence/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Perioperative Care/*standards/statistics & numerical data
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - *Stents
MH  - Ticlopidine/analogs & derivatives/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiplatelet agents
OT  - Coronary stents
OT  - Dual antiplatelet therapy
OT  - Perioperative Surgical Home
EDAT- 2016/08/25 06:00
MHDA- 2017/03/14 06:00
CRDT- 2016/08/25 06:00
PHST- 2014/02/22 00:00 [received]
PHST- 2016/01/16 00:00 [revised]
PHST- 2016/01/21 00:00 [accepted]
PHST- 2016/08/25 06:00 [entrez]
PHST- 2016/08/25 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
AID - S0952-8180(16)00110-0 [pii]
AID - 10.1016/j.jclinane.2016.01.030 [doi]
PST - ppublish
SO  - J Clin Anesth. 2016 Sep;33:179-84. doi: 10.1016/j.jclinane.2016.01.030. Epub 2016 
      Apr 29.

PMID- 30310118
OWN - NLM
STAT- MEDLINE
DCOM- 20191014
LR  - 20191014
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 8
IP  - 1
DP  - 2018 Oct 11
TI  - Effects of aspirin-loaded graphene oxide coating of a titanium surface on 
      proliferation and osteogenic differentiation of MC3T3-E1 cells.
PG  - 15143
LID - 10.1038/s41598-018-33353-7 [doi]
LID - 15143
AB  - Graphene oxide (GO) has attracted considerable attention for biomedical 
      applications such as drug delivery because of its two-dimensional structure, 
      which provides a large surface area on both sides of the nanosheet. Here, a new 
      method for titanium (Ti) surface modification involving a GO coating and aspirin 
      (A) loading (A/Ti-GO) was developed, and the bioactive effects on mouse 
      osteoblastic MC3T3-E1 cells were preliminarily studied. The X-ray photoelectron 
      spectrometry indicated new C-O-N, C-Si-O-C, and C-N=C bond formation upon GO 
      coating. Remarkably, the torsion test results showed stable bonding between the 
      GO coating and Ti under a torsional shear force found in clinical settings, in 
      that, there was no tearing or falling off of GO coating from the sample surface. 
      More importantly, through π-π stacking interactions, the release of aspirin 
      loaded on the surface of Ti-GO could sustain for 3 days. Furthermore, the A/Ti-GO 
      surface displayed a significantly higher proliferation rate and differentiation 
      of MC3T3-E1 cells into osteoblasts, which was confirmed by a water-soluble 
      tetrazolium salt-8 (WST-8) assay and alkaline phosphatase activity test. 
      Consequently, Ti surface modification involving GO coating and aspirin loading 
      might be a useful contribution to improve the success rate of Ti implants in 
      patients, especially in bone conditions.
FAU - Ren, Liping
AU  - Ren L
AD  - Department of Prosthodontics, The First Affiliated Hospital of Harbin Medical 
      University, No. 143 Yiman Street, Nangang District, Harbin, 150001, China.
FAU - Pan, Shuang
AU  - Pan S
AD  - Department of Endodontics, The First Affiliated Hospital of Harbin Medical 
      University, No. 143 Yiman Street, Nangang District, Harbin, 150001, China.
AD  - Oral Biomedical Research institute of Harbin Medical University, No. 143 Yiman 
      Street, Nangang District, Harbin, 150001, China.
FAU - Li, Haiqing
AU  - Li H
AD  - Department of Stomatology, Hospital of Heilongjiang Province, No. 82 Zhongshan 
      Street, Xiangfang District, Harbin, 150036, China.
FAU - Li, Yanping
AU  - Li Y
AD  - Department of Endodontics, The First Affiliated Hospital of Harbin Medical 
      University, No. 143 Yiman Street, Nangang District, Harbin, 150001, China.
FAU - He, Lina
AU  - He L
AD  - Department of Endodontics, The First Affiliated Hospital of Harbin Medical 
      University, No. 143 Yiman Street, Nangang District, Harbin, 150001, China.
FAU - Zhang, Shuang
AU  - Zhang S
AD  - Department of Endodontics, The First Affiliated Hospital of Harbin Medical 
      University, No. 143 Yiman Street, Nangang District, Harbin, 150001, China.
FAU - Che, Jingyi
AU  - Che J
AD  - Department of Endodontics, The First Affiliated Hospital of Harbin Medical 
      University, No. 143 Yiman Street, Nangang District, Harbin, 150001, China.
FAU - Niu, Yumei
AU  - Niu Y
AD  - Department of Endodontics, The First Affiliated Hospital of Harbin Medical 
      University, No. 143 Yiman Street, Nangang District, Harbin, 150001, China. 
      yumeiniu@163.com.
AD  - Oral Biomedical Research institute of Harbin Medical University, No. 143 Yiman 
      Street, Nangang District, Harbin, 150001, China. yumeiniu@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181011
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 7782-42-5 (Graphite)
RN  - D1JT611TNE (Titanium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*chemistry
MH  - *Cell Differentiation
MH  - Cell Line
MH  - *Cell Proliferation
MH  - Graphite/*chemistry
MH  - Mice
MH  - Osteoblasts/*cytology
MH  - Tissue Scaffolds/adverse effects/*chemistry
MH  - Titanium/*chemistry
PMC - PMC6181949
COIS- The authors declare no competing interests.
EDAT- 2018/10/13 06:00
MHDA- 2019/10/15 06:00
CRDT- 2018/10/13 06:00
PHST- 2018/05/03 00:00 [received]
PHST- 2018/09/27 00:00 [accepted]
PHST- 2018/10/13 06:00 [entrez]
PHST- 2018/10/13 06:00 [pubmed]
PHST- 2019/10/15 06:00 [medline]
AID - 10.1038/s41598-018-33353-7 [pii]
AID - 33353 [pii]
AID - 10.1038/s41598-018-33353-7 [doi]
PST - epublish
SO  - Sci Rep. 2018 Oct 11;8(1):15143. doi: 10.1038/s41598-018-33353-7.

PMID- 21303304
OWN - NLM
STAT- MEDLINE
DCOM- 20110928
LR  - 20131121
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 24
IP  - 7
DP  - 2011 Jul
TI  - Opinion & hypothesis could early aspirin prophylaxis prevent against preterm 
      birth?
PG  - 966-7
LID - 10.3109/14767058.2010.531319 [doi]
AB  - A growing body of evidence suggests that defective placentation may play a major 
      role in the genesis of preterm birth, indicating that preeclampsia, intra-uterine 
      growth restriction (IUGR), and spontaneous preterm birth can share a similar 
      mechanism of disease. A recent meta-analysis of low-dose aspirin trials for the 
      prevention of preeclampsia and IUGR in high-risk women demonstrated that, when 
      started early in gestation, aspirin could prevent more than half of preeclampsia 
      and IUGR cases but was also linked with a significant decrease of preterm births 
      (relative risk 0.22, 95% confidence interval: 0.10-0.49). Unfortunately, most 
      studies did not report specific data on the cause of preterm deliveries and, 
      therefore, we could not estimate the proportion of this effect that could be 
      related to spontaneous preterm births. Therefore, we hypothesize that low-dose 
      aspirin could become an additional weapon in the prevention of preterm births and 
      we suggest that further studies should be performed in this area of research.
FAU - Bujold, Emmanuel
AU  - Bujold E
AD  - Département d'obstétrique-gynécologie, Faculté de médecine, Université Laval, 
      Québec, QC, Canada. emmanuel.bujold@crchul.ulaval.ca
FAU - Roberge, Stéphanie
AU  - Roberge S
FAU - Tapp, Sylvie
AU  - Tapp S
FAU - Giguère, Yves
AU  - Giguère Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110209
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pregnancy
MH  - Premature Birth/*prevention & control
EDAT- 2011/02/10 06:00
MHDA- 2011/09/29 06:00
CRDT- 2011/02/10 06:00
PHST- 2011/02/10 06:00 [entrez]
PHST- 2011/02/10 06:00 [pubmed]
PHST- 2011/09/29 06:00 [medline]
AID - 10.3109/14767058.2010.531319 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2011 Jul;24(7):966-7. doi: 
      10.3109/14767058.2010.531319. Epub 2011 Feb 9.

PMID- 7973435
OWN - NLM
STAT- MEDLINE
DCOM- 19941212
LR  - 20190814
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 29
IP  - 8
DP  - 1994 Aug
TI  - Endogenous hypercholecystokininemia, but not aspirin, reduces the gallstone 
      incidence in the hamster model.
PG  - 740-3
AB  - BACKGROUND: Studies in humans and rodents indicate that gallstone development may 
      be prevented by inhibiting gallbladder mucus hypersecretion with non-steroidal 
      anti-inflammatory drugs or by preventing stasis of gallbladder bile with 
      administration of cholecystokinin. METHODS: The effect of oral aspirin and 
      pancreaticobiliary diversion with endogenous hypercholecystokininemia on crystal 
      and gallstone formation was studied in Syrian golden hamsters fed a lithogenic 
      diet for 8 weeks. RESULTS: None of the control animals fed a normal diet 
      developed gallstones or crystals in gallbladder bile. Gallstones developed in 67% 
      of the animals fed a lithogenic diet only. The gallstone prevalence did not 
      differ significantly in animals on a lithogenic diet and a daily aspirin dose of 
      6 mg/kg (gallstone prevalence, 60%) or 100 mg/kg (gallstone prevalence, 70%), 
      whereas it was significantly lower in animals with endogenous 
      hypercholecystokininemia on a lithogenic diet (gallstone prevalence, 29%). The 
      prevalence of crystals in gallbladder bile did not differ significantly between 
      any of the experimental groups. CONCLUSIONS: It is concluded that in hamsters on 
      a lithogenic diet, aspirin does not prevent gallstone formation, whereas 
      endogenous hypercholecystokininemia reduces the prevalence of stones without 
      affecting the occurrence of crystals in gallbladder bile.
FAU - Borch, K
AU  - Borch K
AD  - Dept. of Surgery, University Hospital of Linköping, Sweden.
FAU - Chu, M
AU  - Chu M
FAU - Kullman, E
AU  - Kullman E
FAU - Carlsson, B
AU  - Carlsson B
FAU - Rehfeld, J F
AU  - Rehfeld JF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 9011-97-6 (Cholecystokinin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Biliopancreatic Diversion
MH  - Cholecystokinin/blood/*physiology
MH  - Cholelithiasis/etiology/*prevention & control
MH  - Cricetinae
MH  - Diet
MH  - Male
MH  - Mesocricetus
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
AID - 10.3109/00365529409092503 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 1994 Aug;29(8):740-3. doi: 10.3109/00365529409092503.

PMID- 34039715
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220405
IS  - 2059-8696 (Electronic)
IS  - 2059-8688 (Linking)
VI  - 6
IP  - 4
DP  - 2021 Dec
TI  - Effects and safety of aspirin use in patients after cerebrovascular bypass 
      procedures.
PG  - 624-630
LID - 10.1136/svn-2020-000770 [doi]
AB  - OBJECT: Superficial temporal artery to middle cerebral artery (STA-MCA) bypass is 
      the most effective treatment for Moyamoya disease (MMD). In this study, we aimed 
      to assess whether aspirin improves STA-MCA bypass patency and is safe in patients 
      with MMD. METHODS: We performed a retrospective medical record review of patients 
      with ischaemic-onset MMD who had undergone STA-MCA bypass at two hospitals 
      between January 2011 and August 2018, to clarify the effects and safety of 
      aspirin following STA-MCA bypass. The neurological status at the last follow-up 
      (FU) was compared between patients with FU bypass patency and occlusion. Results 
      Among 217 identified patients (238 hemispheres), the mean age was 41.4±10.2 
      years, and 51.8% were male; the indications for STA-MCA bypass were stroke 
      (48.2%), followed by a transient ischaemic attack (44.0%). Immediate bypass 
      patency was confirmed in all cases. During the FU period (1.5±1.5 y), 15 cases 
      were occluded at FU imaging, resulting in an overall cumulative patency rate of 
      94%. The patency rates were 93% and 94% in the short-term FU group (n=131, mean 
      FU time 0.5±0.2 years) and long-term FU group (n=107, mean FU time 4.1±3.5 
      years), respectively. The STA-MCA bypass patency rate in the aspirin group was 
      higher than that in the non-aspirin group (98.7% vs 89.7%; HR 1.57; 95% CI 1.106 
      to 2.235; p=0.012). No significant difference in the FU haemorrhagic events was 
      observed between the aspirin and non-aspirin groups. CONCLUSIONS: Among adult 
      patients with ischaemic-onset MMD undergoing STA-MCA bypass procedures, aspirin 
      might increase the bypass patency rate, without increasing the bleeding risk. FU 
      bypass patency may be associated with a better outcome. Additional studies, 
      especially carefully designed prospective studies, are needed to address the role 
      of aspirin after bypass procedures.
CI  - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lu, Junlin
AU  - Lu J
AUID- ORCID: 0000-0003-4879-0729
AD  - Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 
      China.
FAU - Shi, Guangchao
AU  - Shi G
AD  - Neurosurgery, Peking University International Hospital, Beijing, China.
FAU - Zhao, Yuanli
AU  - Zhao Y
AD  - Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 
      China.
AD  - Neurosurgery, Peking University International Hospital, Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Stroke Center, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
AD  - Beijing Translational Engineering Enter for 3D Printer in Clinical Neuroscience, 
      Beijing, China.
FAU - Wang, Rong
AU  - Wang R
AD  - Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 
      China.
AD  - Neurosurgery, Peking University International Hospital, Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Stroke Center, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Zhang, Dong
AU  - Zhang D
AD  - Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Stroke Center, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Chen, Xiaolin
AU  - Chen X
AD  - Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Stroke Center, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
FAU - Wang, Hao
AU  - Wang H
AD  - Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 
      China cmu990103@163.com.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Stroke Center, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
AD  - Beijing Translational Engineering Enter for 3D Printer in Clinical Neuroscience, 
      Beijing, China.
FAU - Zhao, Ji Zong
AU  - Zhao JZ
AD  - Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
AD  - Stroke Center, Beijing Institute for Brain Disorders, Beijing, China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, 
      Beijing, China.
AD  - Beijing Translational Engineering Enter for 3D Printer in Clinical Neuroscience, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210526
PL  - England
TA  - Stroke Vasc Neurol
JT  - Stroke and vascular neurology
JID - 101689996
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects
MH  - *Cerebral Revascularization/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Moyamoya Disease
MH  - Prospective Studies
MH  - Retrospective Studies
PMC - PMC8717793
OTO - NOTNLM
OT  - artery
OT  - blood flow
OT  - drug
OT  - hemorrhage
OT  - stroke
COIS- Competing interests: None declared.
EDAT- 2021/05/28 06:00
MHDA- 2022/04/06 06:00
CRDT- 2021/05/27 05:51
PHST- 2020/11/28 00:00 [received]
PHST- 2021/04/07 00:00 [revised]
PHST- 2021/04/20 00:00 [accepted]
PHST- 2021/05/28 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
PHST- 2021/05/27 05:51 [entrez]
AID - svn-2020-000770 [pii]
AID - 10.1136/svn-2020-000770 [doi]
PST - ppublish
SO  - Stroke Vasc Neurol. 2021 Dec;6(4):624-630. doi: 10.1136/svn-2020-000770. Epub 
      2021 May 26.

PMID- 11957292
OWN - NLM
STAT- MEDLINE
DCOM- 20020604
LR  - 20151119
IS  - 0049-1101 (Print)
IS  - 0049-1101 (Linking)
VI  - 44
IP  - 2
DP  - 1999
TI  - [Fernand Widal syndrome: apropos of 2 cases].
PG  - 232-5
AB  - The Fernand Widal syndrome combines a nasal polyposis, an asthma and aspirin 
      sensitivity. It remains a nosological entity often unrecognized because of the 
      trivialization of aspirin in-take on the one hand the other its etiopathogenesis 
      which has not yet been clarified because of the inhibition of the 
      cyclo-oxygenase. In actual fact the aspirin molecule has yet to reveal all its 
      secrets (advantages and disadvantages). We report 2 cases of Fernand Widal 
      syndrome observed in 2 women in their thirties with a notion of atopy in one at 
      the Pneumophtisiology clinic at the Fann University Hospital in Dakar. The 
      confirmed diagnosis was based on oral provocative test in addition to suggestive 
      clinical signs which emphasize the classical triad with a chronological 
      appearance more or less typical. The best treatment could combine inhaled 
      corticotherapy, nasalization of sinus cavities, antihistaminics, no aspirin in 
      take and educating the patient.
FAU - Ndiaye, M
AU  - Ndiaye M
AD  - Service de Pneumophtisiologie C.H.U. de FANN BP: 5035 Dakar/Fann.
FAU - Hane, A A
AU  - Hane AA
FAU - Ndir, M
AU  - Ndir M
FAU - Ba, O
AU  - Ba O
FAU - Cissokho, S
AU  - Cissokho S
FAU - Kandji, M
AU  - Kandji M
FAU - Ndiaye, S
AU  - Ndiaye S
FAU - Diatta, A
AU  - Diatta A
FAU - Niang, A
AU  - Niang A
FAU - Dia, Y
AU  - Dia Y
FAU - Diouf, R
AU  - Diouf R
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Le syndrome de Fernand Widal: àpropos de deux cas.
PL  - Senegal
TA  - Dakar Med
JT  - Dakar medical
JID - 7907630
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Airway Obstruction/etiology
MH  - Aspirin/*adverse effects/pharmacology
MH  - Asthma/*chemically induced/etiology
MH  - Cyclooxygenase Inhibitors/*adverse effects
MH  - Female
MH  - Headache/etiology
MH  - Humans
MH  - Hypersensitivity, Immediate/*complications
MH  - Maxillary Sinusitis/complications
MH  - Nasal Polyps/*etiology
MH  - Rhinitis, Allergic, Perennial/complications
MH  - Sleep Initiation and Maintenance Disorders/complications
MH  - Syndrome
EDAT- 2002/04/18 10:00
MHDA- 2002/06/05 10:01
CRDT- 2002/04/18 10:00
PHST- 2002/04/18 10:00 [pubmed]
PHST- 2002/06/05 10:01 [medline]
PHST- 2002/04/18 10:00 [entrez]
PST - ppublish
SO  - Dakar Med. 1999;44(2):232-5.

PMID- 8301207
OWN - NLM
STAT- MEDLINE
DCOM- 19940310
LR  - 20181130
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 123
IP  - 2
DP  - 1994 Feb
TI  - Effect of diaspirin cross-linked hemoglobin and norepinephrine on systemic 
      hemodynamics and regional circulation in rats.
PG  - 299-308
AB  - Diaspirin cross-linked hemoglobin (DCLHb) (400 mg/kg, i.v.) produced a pressor 
      effect that was equal to that produced by norepinephrine (NE) (25 
      micrograms/kg/min i.v. infusion). Total peripheral resistance was increased by 
      DCLHb and more significantly by NE. Heart rate was not affected by DCLHb but was 
      significantly increased by NE. The cardiac output and stroke volume were 
      insignificantly increased by DCLHb but were significantly decreased by NE. DCLHb 
      and NE produced a significant increase in blood flow to the heart. The vascular 
      resistance in the heart was not affected by DCLHb but was decreased by NE. DCLHb 
      did not affect the renal and brain circulation, but NE in kidneys decreased the 
      blood flow and increased the vascular resistance, whereas in the brain it 
      increased the blood flow and decreased the vascular resistance. DCLHb increased 
      the blood flow to the stomach and small intestine. The vascular resistance was 
      not affected by DCLHb in the gastrointestinal tract. NE did not affect the blood 
      circulation in the gastrointestinal tract. Blood flow to the spleen was increased 
      by DCLHb, and there was no change in the vascular resistance. NE insignificantly 
      decreased the blood flow to the spleen and significantly increased the vascular 
      resistance. The blood circulation to the mesentery and pancreas was not affected 
      by DCLHb, whereas NE increased the blood flow without affecting the vascular 
      resistance. DCLHb produced a significant increase in the blood flow to the skin 
      without affecting the vascular resistance, whereas NE did not affect the blood 
      flow but increased the vascular resistance. DCLHb did not affect the blood flow 
      to the musculo-skeletal system but increased the vascular resistance, whereas NE 
      decreased the blood flow and increased the vascular resistance. In summary, 
      although the pressor effect of DCLHb and NE at the doses studied is equal, DCLHb 
      did not decrease the blood flow to any organ, whereas NE produced significant 
      decreases in blood flow to several organs. It is concluded that the blood flow to 
      most of the organs is either increased or not affected by DCLHb.
FAU - Sharma, A C
AU  - Sharma AC
AD  - Department of Pharmaceutics and Pharmacodynamics, University of Illinois, Chicago 
      Health Sciences Center 60612-7231.
FAU - Gulati, A
AU  - Gulati A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Circulation/*drug effects
MH  - Cardiac Output/drug effects
MH  - Cerebrovascular Circulation/drug effects
MH  - Coronary Circulation/drug effects
MH  - Digestive System/blood supply
MH  - Heart Rate/drug effects
MH  - Hemodynamics/*drug effects
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Muscles/blood supply
MH  - Norepinephrine/*pharmacology
MH  - Portal System/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Renal Circulation/drug effects
MH  - Skin/blood supply
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
PST - ppublish
SO  - J Lab Clin Med. 1994 Feb;123(2):299-308.

PMID- 26685215
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181113
IS  - 1557-3125 (Electronic)
IS  - 1541-7786 (Print)
IS  - 1541-7786 (Linking)
VI  - 14
IP  - 3
DP  - 2016 Mar
TI  - Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential 
      Role in Cancer Prevention.
PG  - 241-52
LID - 10.1158/1541-7786.MCR-15-0360 [doi]
AB  - Data emerging from the past 10 years have consolidated the rationale for 
      investigating the use of aspirin as a chemopreventive agent; however, the 
      mechanisms leading to its anticancer effects are still being elucidated. We 
      hypothesized that aspirin's chemopreventive actions may involve cell-cycle 
      regulation through modulation of the levels or activity of cyclin 
      A2/cyclin-dependent kinase-2 (CDK2). In this study, HT-29 and other diverse panel 
      of cancer cells were used to demonstrate that both aspirin and its primary 
      metabolite, salicylic acid, decreased cyclin A2 (CCNA2) and CDK2 protein and mRNA 
      levels. The downregulatory effect of either drugs on cyclin A2 levels was 
      prevented by pretreatment with lactacystin, an inhibitor of proteasomes, 
      suggesting the involvement of 26S proteasomes. In-vitro kinase assays showed that 
      lysates from cells treated with salicylic acid had lower levels of CDK2 activity. 
      Importantly, three independent experiments revealed that salicylic acid directly 
      binds to CDK2. First, inclusion of salicylic acid in naïve cell lysates, or in 
      recombinant CDK2 preparations, increased the ability of the anti-CDK2 antibody to 
      immunoprecipitate CDK2, suggesting that salicylic acid may directly bind and 
      alter its conformation. Second, in 8-anilino-1-naphthalene-sulfonate (ANS)-CDK2 
      fluorescence assays, preincubation of CDK2 with salicylic acid dose-dependently 
      quenched the fluorescence due to ANS. Third, computational analysis using 
      molecular docking studies identified Asp145 and Lys33 as the potential sites of 
      salicylic acid interactions with CDK2. These results demonstrate that aspirin and 
      salicylic acid downregulate cyclin A2/CDK2 proteins in multiple cancer cell 
      lines, suggesting a novel target and mechanism of action in chemoprevention. 
      IMPLICATIONS: Biochemical and structural studies indicate that the 
      antiproliferative actions of aspirin are mediated through cyclin A2/CDK2.
CI  - ©2015 American Association for Cancer Research.
FAU - Dachineni, Rakesh
AU  - Dachineni R
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy, Brookings, South Dakota.
FAU - Ai, Guoqiang
AU  - Ai G
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy, Brookings, South Dakota.
FAU - Kumar, D Ramesh
AU  - Kumar DR
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy, Brookings, South Dakota.
FAU - Sadhu, Satya S
AU  - Sadhu SS
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy, Brookings, South Dakota.
FAU - Tummala, Hemachand
AU  - Tummala H
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy, Brookings, South Dakota.
FAU - Bhat, G Jayarama
AU  - Bhat GJ
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      South Dakota State University College of Pharmacy, Brookings, South Dakota. 
      Jayarama.gunaje@sdstate.edu.
LA  - eng
GR  - R03 CA133061/CA/NCI NIH HHS/United States
GR  - 5R03CA133061-02/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151218
PL  - United States
TA  - Mol Cancer Res
JT  - Molecular cancer research : MCR
JID - 101150042
RN  - 0 (CCNA2 protein, human)
RN  - 0 (Cyclin A2)
RN  - EC 2.7.11.22 (CDK2 protein, human)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 2)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cyclin A2/genetics/*metabolism
MH  - Cyclin-Dependent Kinase 2/genetics/*metabolism
MH  - Down-Regulation
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - HCT116 Cells
MH  - HT29 Cells
MH  - Humans
MH  - MCF-7 Cells
MH  - Models, Molecular
MH  - Molecular Docking Simulation
MH  - Neoplasms/genetics/metabolism/*prevention & control
MH  - Protein Binding
MH  - Salicylic Acid/*pharmacology
PMC - PMC4794403
MID - NIHMS746264
EDAT- 2015/12/20 06:00
MHDA- 2016/12/15 06:00
PMCR- 2017/03/01
CRDT- 2015/12/20 06:00
PHST- 2015/08/25 00:00 [received]
PHST- 2015/12/03 00:00 [accepted]
PHST- 2017/03/01 00:00 [pmc-release]
PHST- 2015/12/20 06:00 [entrez]
PHST- 2015/12/20 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 1541-7786.MCR-15-0360 [pii]
AID - 10.1158/1541-7786.MCR-15-0360 [doi]
PST - ppublish
SO  - Mol Cancer Res. 2016 Mar;14(3):241-52. doi: 10.1158/1541-7786.MCR-15-0360. Epub 
      2015 Dec 18.

PMID- 2626744
OWN - NLM
STAT- MEDLINE
DCOM- 19900405
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 56
IP  - 5
DP  - 1989 Dec 1
TI  - In vitro bleeding test--a simple method for the detection of aspirin effects on 
      platelet function.
PG  - 593-602
AB  - We investigated platelet function of 21 healthy blood donors before, 4 hrs and 1 
      to 7 days after a single oral dose of 0.02 (n = 3), 0.05 (n = 3), 0.1 (n = 3), 
      0.5 (n = 2) and 1.0 g (n = 10) aspirin. Three additional donors received 0.02 g 
      aspirin/day for 5 days. A new and simple in vitro bleeding test (Thrombostat) 
      using whole blood was far more sensitive than all other tests for platelet 
      function (subaquatic bleeding time, thrombelastrogram, resonance-thrombogram, 
      platelet adherence, spreading and aggregation). With this method using 2mM CaCl2 
      as additional agent all donors showed significantly increased in vitro bleeding 
      volumes, for at least 2 days after ingestion of 0.1 to 1 g aspirin. In the 
      majority of cases the aspirin effect could be detected even after 5-6 days. In 2 
      of 3 donors even 0.05 g aspirin was detectable. There was already a definite 
      effect seen after 2 days in all 3 cases when 0.02 g was ingested daily. The new 
      in vitro bleeding test should be suitable for the control of low dose aspirin 
      prophylaxis of arterial thromboembolic disorders.
FAU - Kretschmer, V
AU  - Kretschmer V
AD  - Department of Transfusion Medicine and Coagulation Physiology, University 
      Clinics, Marburg, FRG.
FAU - Schikor, B
AU  - Schikor B
FAU - Söhngen, D
AU  - Söhngen D
FAU - Dietrich, G
AU  - Dietrich G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 1404-55-3 (Ristocetin)
RN  - M4I0D6VV5M (Calcium Chloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Calcium Chloride/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors
MH  - Platelet Function Tests/*methods
MH  - Ristocetin/pharmacology
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
AID - 0049-3848(89)90267-3 [pii]
AID - 10.1016/0049-3848(89)90267-3 [doi]
PST - ppublish
SO  - Thromb Res. 1989 Dec 1;56(5):593-602. doi: 10.1016/0049-3848(89)90267-3.

PMID- 499931
OWN - NLM
STAT- MEDLINE
DCOM- 19800128
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 8
IP  - 2
DP  - 1979
TI  - Deposition of human labeled platelets on damaged rabbit aorta before and after 
      ingestion of acetylsalicylic acid.
PG  - 99-105
AB  - Human blood platelets were labeled with 51Cr and whole blood was reconstituted. 
      The endothelium of rabbit abdominal aorta was removed with a balloon catheter and 
      the inverted aorta was placed on a Plexiglas rod in a perfusion chamber. The 
      reconstituted blood was perfused through the chamber of 10 min. Radioactivity of 
      the aorta was measured and found to be mainly caused by the labeled platelets. 
      The platelet deposition on the damaged aorta was measured before and after 
      ingestion of 0.5 g acetylsalicylic acid twice a day for 1 week, and was found to 
      be reduced after the use of this drug.
FAU - Jaeger, S
AU  - Jaeger S
FAU - Berntsen, H
AU  - Berntsen H
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Aorta, Abdominal/cytology
MH  - Ascorbic Acid/pharmacology
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1159/000214297 [doi]
PST - ppublish
SO  - Haemostasis. 1979;8(2):99-105. doi: 10.1159/000214297.

PMID- 34764212
OWN - NLM
STAT- MEDLINE
DCOM- 20220628
LR  - 20220722
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 108
IP  - 14
DP  - 2022 Jun 24
TI  - Aspirin and statin therapy for primary prevention of cardiovascular disease in 
      older adults.
PG  - 1090-1097
LID - 10.1136/heartjnl-2021-320154 [doi]
AB  - The value of primary preventative therapies for cardiovascular disease (CVD) in 
      older adults (age ≥75 years) is less certain than in younger patients. There is a 
      lack of quality evidence in older adults due to underenrolment in pivotal trials. 
      While aspirin is no longer recommended for routine use in primary prevention of 
      CVD in older adults, statins may be efficacious. However, it is unclear which 
      patient subgroups may benefit most, and guidelines differ between expert panels. 
      Three relevant geriatric conditions (cognitive impairment, functional impairment 
      and polypharmacy) may influence therapeutic decision making; for example, 
      baseline frailty may affect statin efficacy, and some have advocated for 
      deprescription in this scenario. Evidence regarding statins and incident 
      functional decline are mixed, and vigilance for adverse effects is important, 
      especially in the setting of polypharmacy. However, aspirin has not been shown to 
      affect incident cognitive or functional decline, and its lack of efficacy extends 
      to patients with baseline cognitive impairment or frailty. Ultimately, the 
      utility of primary preventative therapies for CVD in older adults depends on 
      potential lifetime benefit. Rather than basing treatment decisions on absolute 
      risk alone, consideration of comorbidities, polypharmacy and life expectancy 
      should play a significant role in decision making. Coronary calcium score and new 
      tools for risk stratification validated in older adults that account for the 
      competing risk of death may aid in evaluating potential benefits. Given the 
      complexity of therapeutic decisions in this context, shared decision making 
      provides an important framework.
CI  - © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Montgomery, Sophie
AU  - Montgomery S
AD  - NYU Grossman School of Medicine, NYU, New York, New York, USA.
FAU - Miedema, Michael D
AU  - Miedema MD
AD  - Nolan Center For Cardiovascular Health, Minneapolis Heart Institute and 
      Foundation, Minneapolis, Minnesota, USA.
FAU - Dodson, John A
AU  - Dodson JA
AUID- ORCID: 0000-0003-0163-3013
AD  - NYU Grossman School of Medicine, NYU, New York, New York, USA 
      John.Dodson@nyumc.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220624
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/drug therapy
MH  - *Frailty
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects
MH  - Primary Prevention
OTO - NOTNLM
OT  - atherosclerosis
OT  - clinical
OT  - pharmacology
COIS- Competing interests: None declared.
EDAT- 2021/11/13 06:00
MHDA- 2022/06/29 06:00
CRDT- 2021/11/12 06:01
PHST- 2021/08/09 00:00 [received]
PHST- 2021/09/29 00:00 [accepted]
PHST- 2021/11/13 06:00 [pubmed]
PHST- 2022/06/29 06:00 [medline]
PHST- 2021/11/12 06:01 [entrez]
AID - heartjnl-2021-320154 [pii]
AID - 10.1136/heartjnl-2021-320154 [doi]
PST - epublish
SO  - Heart. 2022 Jun 24;108(14):1090-1097. doi: 10.1136/heartjnl-2021-320154.

PMID- 2319839
OWN - NLM
STAT- MEDLINE
DCOM- 19900503
LR  - 20131121
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 12
IP  - 2
DP  - 1990 Mar
TI  - A rapid embedding procedure for the study of platelet interactions with 
      extracellular matrices in a flowing system. Effect of aspirin on platelet 
      activity.
PG  - 149-54
AB  - The cultured endothelial cell (EC) is currently used as a model for the study of 
      the interaction of platelets with the vascular wall. Described is a method for 
      rapid quantitative and qualitative evaluation of platelet interactions with 
      extracellular matrices (ECM) produced by human cultured ECs growing on plastic 
      coverslips. Morphometric calculations can be performed on the same perfused 
      coverslips. A very good correlation (r = 0.96) was found between results of a 
      morphometric method en face and those obtained from analysis of cross sections of 
      the perfused coverslips. A shear rate-dependent increase on platelet deposition 
      onto ECMs was observed with both morphometric procedures. The method is sensitive 
      enough to detect drug-related changes of platelet function. An impairment of the 
      interaction of platelets with the ECM was observed when blood obtained from 
      healthy volunteers who took 500 mg aspirin/day for five days was perfused. 
      Aspirin showed a marked effect, decreasing platelet spreading onto the 
      subendothelium (p less than 0.05). The embedding method described benefits from 
      the use of plastic coverslips that are easily detected from the glycol 
      methacrylate compound used for the embedding procedure. Quantitative analysis en 
      face (covered surface) and qualitative evaluation of platelet interactions 
      (contact, adhesive and aggregated platelets) in cross sections are performed on 
      the same coverslip. This embedding procedure provides a useful tool for the study 
      not only of platelet interactions with ECMs but also for the investigation of 
      interactions of blood elements with other cultured cells.
FAU - Aznar-Salatti, J
AU  - Aznar-Salatti J
AD  - Serv. Hemoterapia y Hemostasia, Hospital Clínico y Provincial, Barcelona, Spain.
FAU - Escolar, G
AU  - Escolar G
FAU - Antón, P
AU  - Antón P
FAU - Bastida, E
AU  - Bastida E
FAU - Ordinas, A
AU  - Ordinas A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cells, Cultured
MH  - Endothelium, Vascular/cytology/drug effects
MH  - Extracellular Space/drug effects/metabolism
MH  - Humans
MH  - Perfusion
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 1990 Mar;12(2):149-54.

PMID- 18406994
OWN - NLM
STAT- MEDLINE
DCOM- 20080701
LR  - 20181201
IS  - 0733-8651 (Print)
IS  - 0733-8651 (Linking)
VI  - 26
IP  - 2
DP  - 2008 May
TI  - Antiplatelet agents and arterial thrombosis.
PG  - 189-201, vi
LID - 10.1016/j.ccl.2007.12.007 [doi]
AB  - There is an increase in arterial thrombotic events in the elderly. Elderly 
      patients are more likely to have associated diseases, such as diabetes, 
      hypertension and hypercholesterolemia, and when age is confounded by these other 
      predisposing factors, the risk of an arterial ischemic event increases 
      disproportionately. Antithrombotic therapy for geriatric patients is underused, 
      even when one adjusts for potential drug contraindications. This article focuses 
      on the action of the currently available antiplatelet agents--aspirin, 
      clopidogrel, and glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists, and 
      assesses their effects in different disease states, with special attention to 
      data that examine the geriatric population.
FAU - Billett, Henny H
AU  - Billett HH
AD  - Albert Einstein College of Medicine, Thrombosis Prevention and Treatment Program, 
      Department of Medicine, Division of Hematology, Montefiore Medical Center, Bronx, 
      NY 10467, USA. hbillet@montefiore.org
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cardiol Clin
JT  - Cardiology clinics
JID - 8300331
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Thrombosis/prevention & control
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
MH  - Warfarin/administration & dosage/therapeutic use
RF  - 94
EDAT- 2008/04/15 09:00
MHDA- 2008/07/02 09:00
CRDT- 2008/04/15 09:00
PHST- 2008/04/15 09:00 [pubmed]
PHST- 2008/07/02 09:00 [medline]
PHST- 2008/04/15 09:00 [entrez]
AID - S0733-8651(07)00145-2 [pii]
AID - 10.1016/j.ccl.2007.12.007 [doi]
PST - ppublish
SO  - Cardiol Clin. 2008 May;26(2):189-201, vi. doi: 10.1016/j.ccl.2007.12.007.

PMID- 32761372
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20211021
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 77
IP  - 4
DP  - 2021 Apr
TI  - ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute 
      coronary syndrome: CARTHaGE-ACS trial.
PG  - 517-526
LID - 10.1007/s00228-020-02969-y [doi]
AB  - BACKGROUND: Diabetes is associated with a high rate of events after acute 
      coronary syndrome. It was recently reported that once-daily aspirin might not 
      provide stable biological efficacy in patients with diabetes. AIMS: We sought to 
      compare the biological efficacy of aspirin given once a day versus aspirin 
      divided twice per day in a population of diabetic patients with non-ST elevation 
      acute coronary syndrome (NSTE-ACS) as assessed by the thrombin generation test. 
      METHODS: We performed an open-label single-blind randomized study including 59 
      consecutive diabetic patients admitted for NSTE-ACS. Patients were randomly 
      treated with aspirin 100 mg once a day (GA100; n = 20), aspirin 160 mg once a day 
      (GA160; n = 19) or aspirin 100 mg twice a day (G2A100; n = 20). The primary 
      endpoint was endogenous thrombin potential (ETP) at discharge and after 6 months. 
      RESULTS: The mean age of our patients was 61.5 ± 9 years, and 73% were male. The 
      baseline characteristics were comparable between the three groups. In the GA100 
      group, there was no significant effect on ETP variation at 6 months 
      (1150.46 ± 504.84 vs. 1087.63 ± 454.18; p = 0.794). An increase in aspirin dose 
      with a second daily administration of 100 mg was associated with a significant 
      reduction in ETP at 6 months (1004.87 ± 196.2 vs. 1233.63 ± 333.5; p = 0.003). A 
      nonsignificant decrease in ETP was seen in the GA160 group (from 1173.8 ± 388.07 
      to 1053.64 ± 269.93 at 6 months, p = 0.117). CONCLUSION: Only the twice-daily 
      aspirin regimen led to better control of hypercoagulability in NSTE-ACS diabetic 
      patients. However, no thrombin generation normalization was reported.
FAU - Boussofara, Amine
AU  - Boussofara A
AD  - Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
FAU - Laroussi, Lobna
AU  - Laroussi L
AUID- ORCID: 0000-0002-1593-9593
AD  - Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia. 
      lobna_laroussi@hotmail.com.
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia. 
      lobna_laroussi@hotmail.com.
AD  - , Residence Diar Ons apartment B 2 1, Riadh El Andalos, 2058, Ariana, Tunisia. 
      lobna_laroussi@hotmail.com.
FAU - Baccouche, Hela
AU  - Baccouche H
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
AD  - Department of Hematology, Rabta Hospital, Tunis, Tunisia.
FAU - Bennour, Emna
AU  - Bennour E
AD  - Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
FAU - Kasbaoui, Sami
AU  - Kasbaoui S
AD  - Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
FAU - Triki, Hbib
AU  - Triki H
AD  - Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
FAU - Zied, Ibn El Haj
AU  - Zied EH
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
AD  - Taher Maamouri Hospital, Nabeul, Tunisia.
FAU - Kammoun, Ikram
AU  - Kammoun I
AD  - Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
FAU - Halima, Afef Ben
AU  - Halima AB
AD  - Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
FAU - Addad, Faouzi
AU  - Addad F
AD  - Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
FAU - Marrakchi, Sonia
AU  - Marrakchi S
AD  - Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
FAU - Romdhane, Neila Ben
AU  - Romdhane NB
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
AD  - Department of Hematology, Rabta Hospital, Tunis, Tunisia.
FAU - Kachboura, Salem
AU  - Kachboura S
AD  - Department of Cardiology, Abderrahmen Mami Hospital, Tunis, Tunisia.
AD  - Faculty of Medicine of Tunis- Tunis University El Manar, Tunis, Tunisia.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200806
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/blood/*drug therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Diabetes Mellitus/blood/*drug therapy
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Single-Blind Method
MH  - Thrombin/metabolism
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Aspirin
OT  - Diabetes
OT  - Thrombin generation
EDAT- 2020/08/08 06:00
MHDA- 2023/02/25 06:00
CRDT- 2020/08/08 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - 10.1007/s00228-020-02969-y [pii]
AID - 10.1007/s00228-020-02969-y [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2021 Apr;77(4):517-526. doi: 10.1007/s00228-020-02969-y. 
      Epub 2020 Aug 6.

PMID- 16159833
OWN - NLM
STAT- MEDLINE
DCOM- 20060221
LR  - 20220408
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 112
IP  - 9 Suppl
DP  - 2005 Aug 30
TI  - Preoperative aspirin therapy is associated with improved postoperative outcomes 
      in patients undergoing coronary artery bypass grafting.
PG  - I286-92
AB  - BACKGROUND: Aspirin is beneficial in the setting of atherosclerotic 
      cardiovascular disease. There are limited data evaluating preoperative aspirin 
      administration preceding coronary artery bypass grafting and associated 
      postoperative outcomes. METHODS AND RESULTS: Using prospectively collected data 
      from 1636 consecutive patients undergoing first-time isolated coronary artery 
      bypass surgery at our institution from January 2000 through December 2002, we 
      evaluated the association between aspirin usage within the 5 days preceding 
      coronary bypass surgery and risk of adverse in-hospital postoperative events. A 
      logistic regression model, which included propensity scores, was used to adjust 
      for remaining differences between groups. Overall, there were 36 deaths (2.2%) 
      and 48 adverse cerebrovascular events (2.9%) in the postoperative hospitalization 
      period. Patients receiving preoperative aspirin (n=1316) had significantly lower 
      postoperative in-hospital mortality compared with those not receiving 
      preoperative aspirin [1.7% versus 4.4%; adjusted odds ratio (OR), 0.34; 95% CI, 
      0.15 to 0.75; P=0.007]. Rates of postoperative cerebrovascular events were 
      similar between groups (2.7% versus 3.8%; adjusted OR, 0.67; 95% CI, 0.32 to 
      1.50; P=0.31). Preoperative aspirin therapy was not associated with an increased 
      risk of reoperation for bleeding (3.5% versus 3.4%; P=0.96) or requirement for 
      postoperative blood product transfusion (adjusted OR, 1.17; 95% CI, 0.88 to 1.54; 
      P=0.28). CONCLUSIONS: Aspirin usage within the 5 days preceding coronary artery 
      bypass surgery is associated with a lower risk of postoperative in-hospital 
      mortality and appears to be safe without an associated increased risk of 
      reoperation for bleeding or need for blood product transfusion.
FAU - Bybee, Kevin A
AU  - Bybee KA
AD  - Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, 
      USA.
FAU - Powell, Brian D
AU  - Powell BD
FAU - Valeti, Uma
AU  - Valeti U
FAU - Rosales, A Gabriela
AU  - Rosales AG
FAU - Kopecky, Stephen L
AU  - Kopecky SL
FAU - Mullany, Charles
AU  - Mullany C
FAU - Wright, R Scott
AU  - Wright RS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cohort Studies
MH  - Coronary Artery Bypass/*statistics & numerical data
MH  - Coronary Disease/surgery
MH  - Drug Administration Schedule
MH  - Drug Evaluation
MH  - Female
MH  - Hospital Mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/surgery
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Postoperative Complications/epidemiology
MH  - Preoperative Care
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Stroke/epidemiology
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2005/09/15 09:00
MHDA- 2006/02/24 09:00
CRDT- 2005/09/15 09:00
PHST- 2005/09/15 09:00 [pubmed]
PHST- 2006/02/24 09:00 [medline]
PHST- 2005/09/15 09:00 [entrez]
AID - 112/9_suppl/I-286 [pii]
AID - 10.1161/CIRCULATIONAHA.104.522805 [doi]
PST - ppublish
SO  - Circulation. 2005 Aug 30;112(9 Suppl):I286-92. doi: 
      10.1161/CIRCULATIONAHA.104.522805.

PMID- 78050
OWN - NLM
STAT- MEDLINE
DCOM- 19780828
LR  - 20190610
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 8077
DP  - 1978 Jun 17
TI  - Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents 
      by potentiating endogenous prostacyclin.
PG  - 1286-9
AB  - The antithrombotic effect of dipyridamole is through phosphodiesterase inhibition 
      and depends on stimulation of platelet cyclic A.M.P. by circulating prostacyclin 
      in the bloodstream. Low doses of aspirin selectively inhibit platelet 
      cyclooxygenase and potentiate the antithrombotic effects of dipyridamole and 
      theophylline. High doses of aspirin also prevent prostacyclin formation, thereby 
      abolishing the effects of dipyridamole. Thus, the antithrombotic effectiveness of 
      the combination of aspirin and dipyridamole depends critically on the doses used.
FAU - Moncada, S
AU  - Moncada S
FAU - Korbut, R
AU  - Korbut R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins)
RN  - 0 (Prostaglandins, Synthetic)
RN  - 64ALC7F90C (Dipyridamole)
RN  - C137DTR5RG (Theophylline)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology
MH  - Blood Platelets/enzymology
MH  - Cyclooxygenase Inhibitors
MH  - Depression, Chemical
MH  - Dipyridamole/administration & dosage/antagonists & inhibitors/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Epoprostenol/pharmacology/*physiology
MH  - *Fibrinolytic Agents
MH  - *Phosphodiesterase Inhibitors
MH  - Platelet Aggregation/*drug effects
MH  - Prostaglandin Antagonists
MH  - Prostaglandins/*physiology
MH  - Prostaglandins, Synthetic/pharmacology
MH  - Rabbits
MH  - Theophylline/pharmacology
MH  - Thrombosis/*prevention & control
EDAT- 1978/06/17 00:00
MHDA- 1978/06/17 00:01
CRDT- 1978/06/17 00:00
PHST- 1978/06/17 00:00 [pubmed]
PHST- 1978/06/17 00:01 [medline]
PHST- 1978/06/17 00:00 [entrez]
AID - S0140-6736(78)92046-9 [pii]
AID - 10.1016/s0140-6736(78)91269-2 [doi]
PST - ppublish
SO  - Lancet. 1978 Jun 17;1(8077):1286-9. doi: 10.1016/s0140-6736(78)91269-2.

PMID- 31076795
OWN - NLM
STAT- MEDLINE
DCOM- 20191015
LR  - 20200225
IS  - 1432-1289 (Electronic)
IS  - 0020-9554 (Linking)
VI  - 60
IP  - 6
DP  - 2019 Jun
TI  - [Drug-induced gastrointestinal bleeding].
PG  - 597-607
LID - 10.1007/s00108-019-0610-y [doi]
AB  - Gastrointestinal bleeding is a common and sometimes life-threatening event in 
      older people. There is often a drug-induced cause. Drugs that can lead to 
      gastrointestinal bleeding include non-steroidal anti-inflammatory drugs (NSAIDs) 
      like diclofenac and ibuprofen, platelet inhibitors such as acetylsalicylic acid 
      (ASS), clopidogrel and prasugrel, as well as anticoagulants like vitamin-K 
      antagonists, heparin or direct oral anticoagulants (DOAKs). Combination 
      antiplatelet therapy or combined medication with platelet inhibitor and 
      anticoagulants increase the risk of gastrointestinal bleeding compared to 
      monotherapy. Primary and secondary prevention options include Helicobacter pylori 
      eradication and co-medication with a proton pump inhibitor (PPI).
FAU - Fischbach, W
AU  - Fischbach W
AD  - Gastroenterologie und Innere Medizin Aschaffenburg, Elisenstraße 32, 63739, 
      Aschaffenburg, Deutschland. wuk.fischbach@gmail.com.
AD  - Ehemals Medizinische Klinik II, Klinikum Aschaffenburg-Alzenau, Akademisches 
      Krankenhaus der Universität Würzburg, Aschaffenburg, Deutschland. 
      wuk.fischbach@gmail.com.
LA  - ger
PT  - Journal Article
TT  - Medikamenteninduzierte gastrointestinale Blutung.
PL  - Germany
TA  - Internist (Berl)
JT  - Der Internist
JID - 0264620
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Helicobacter pylori
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Proton Pump Inhibitors/administration & dosage
MH  - Risk Factors
OTO - NOTNLM
OT  - Anti-inflammatory agents, non-steroidal
OT  - Anticoagulants
OT  - Gastrointestinal hemorrhage, primary prevention
OT  - Gastrointestinal hemorrhage, secondary prevention
OT  - Platelet aggregation inhibitors
EDAT- 2019/05/12 06:00
MHDA- 2019/10/16 06:00
CRDT- 2019/05/12 06:00
PHST- 2019/05/12 06:00 [pubmed]
PHST- 2019/10/16 06:00 [medline]
PHST- 2019/05/12 06:00 [entrez]
AID - 10.1007/s00108-019-0610-y [pii]
AID - 10.1007/s00108-019-0610-y [doi]
PST - ppublish
SO  - Internist (Berl). 2019 Jun;60(6):597-607. doi: 10.1007/s00108-019-0610-y.

PMID- 25600544
OWN - NLM
STAT- MEDLINE
DCOM- 20150928
LR  - 20150120
IS  - 1791-7549 (Electronic)
IS  - 0258-851X (Linking)
VI  - 29
IP  - 1
DP  - 2015 Jan-Feb
TI  - Acetylsalicylic acid resistance after renal transplantation.
PG  - 141-4
AB  - BACKGROUND: Cardiovascular diseases are a leading cause of mortality after kidney 
      transplantation. According to guidelines, acetylsalicylic acid (ASA) must be 
      given as preventive antiplatelet therapy, but resistance to this drug is also 
      well-known. PATIENTS AND METHODS: A total of 214 renal transplant patients were 
      included in our study and took 100 mg of ASA q.d. Aggregometry was performed to 
      determine resistance. Twenty-four variables were examined using logistic 
      regression analysis as possible causes of resistance. RESULTS: ASA resistance was 
      observed in 40.18% of the patients. Resistance reduced concomitant statin therapy 
      and significantly increased simultaneous cyclosporine therapy. CONCLUSION: Our 
      study assessed the post-transplant ASA resistance in a large population. 
      Clarification of this matter is crutial, since one of the major preventive 
      pharmacological therapies of cardiovascular mortality is not effective in a 
      significant number of patients.
CI  - Copyright © 2015 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Varga, Adam
AU  - Varga A
AD  - Department of Surgery, University of Pecs, School of Medicine, Pecs, Hungary.
FAU - Sandor, Barbara
AU  - Sandor B
AD  - First Department of Medicine, University of Pecs, School of Medicine, Pecs, 
      Hungary.
FAU - Nagy, Karoly Kalmar
AU  - Nagy KK
AD  - Department of Surgery, University of Pecs, School of Medicine, Pecs, Hungary.
FAU - Viola, Maria
AU  - Viola M
AD  - Department of Surgery, University of Pecs, School of Medicine, Pecs, Hungary.
FAU - Toth, Andras
AU  - Toth A
AD  - First Department of Medicine, University of Pecs, School of Medicine, Pecs, 
      Hungary.
FAU - Gombos, Katalin
AU  - Gombos K
AD  - Department of Public Health Medicine, University of Pecs, School of Medicine, 
      Pecs, Hungary.
FAU - Toth, Kalman
AU  - Toth K
AD  - First Department of Medicine, University of Pecs, School of Medicine, Pecs, 
      Hungary.
FAU - Szakaly, Peter
AU  - Szakaly P
AD  - Department of Surgery, University of Pecs, School of Medicine, Pecs, Hungary 
      drszakalyp@t-online.hu.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Cyclosporine/adverse effects/therapeutic use
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/therapeutic use
MH  - Kidney Transplantation/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Risk Factors
OTO - NOTNLM
OT  - Aggregometry
OT  - acetylsalicylic acid resistance
OT  - cardiovascular complication
OT  - platelet aggregation
OT  - transplantation
EDAT- 2015/01/21 06:00
MHDA- 2015/09/29 06:00
CRDT- 2015/01/21 06:00
PHST- 2015/01/21 06:00 [entrez]
PHST- 2015/01/21 06:00 [pubmed]
PHST- 2015/09/29 06:00 [medline]
AID - 29/1/141 [pii]
PST - ppublish
SO  - In Vivo. 2015 Jan-Feb;29(1):141-4.

PMID- 19465478
OWN - NLM
STAT- MEDLINE
DCOM- 20090928
LR  - 20220310
IS  - 0021-9258 (Print)
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
VI  - 284
IP  - 30
DP  - 2009 Jul 24
TI  - Binding modes of aromatic ligands to mammalian heme peroxidases with associated 
      functional implications: crystal structures of lactoperoxidase complexes with 
      acetylsalicylic acid, salicylhydroxamic acid, and benzylhydroxamic acid.
PG  - 20311-8
LID - 10.1074/jbc.M109.010280 [doi]
AB  - The binding and structural studies of bovine lactoperoxidase with three aromatic 
      ligands, acetylsalicylic acid (ASA), salicylhydoxamic acid (SHA), and 
      benzylhydroxamic acid (BHA) show that all the three compounds bind to 
      lactoperoxidase at the substrate binding site on the distal heme side. The 
      binding of ASA occurs without perturbing the position of conserved heme water 
      molecule W-1, whereas both SHA and BHA displace it by the hydroxyl group of their 
      hydroxamic acid moieties. The acetyl group carbonyl oxygen atom of ASA forms a 
      hydrogen bond with W-1, which in turn makes three other hydrogen-bonds, one each 
      with heme iron, His-109 N(epsilon2), and Gln-105 N(epsilon2). In contrast, in the 
      complexes of SHA and BHA, the OH group of hydroxamic acid moiety in both 
      complexes interacts with heme iron directly with Fe-OH distances of 3.0 and 3.2A 
      respectively. The OH is also hydrogen bonded to His-109 N(epsilon2) and 
      Gln-105N(epsilon2). The plane of benzene ring of ASA is inclined at 70.7 degrees 
      from the plane of heme moiety, whereas the aromatic planes of SHA and BHA are 
      nearly parallel to the heme plane with inclinations of 15.7 and 6.2 degrees , 
      respectively. The mode of ASA binding provides the information about the 
      mechanism of action of aromatic substrates, whereas the binding characteristics 
      of SHA and BHA indicate the mode of inhibitor binding.
FAU - Singh, Amit K
AU  - Singh AK
AD  - Department of Biophysics, All India Institute of Medical Sciences, New Delhi 110 
      029, India.
FAU - Singh, Nagendra
AU  - Singh N
FAU - Sinha, Mau
AU  - Sinha M
FAU - Bhushan, Asha
AU  - Bhushan A
FAU - Kaur, Punit
AU  - Kaur P
FAU - Srinivasan, Alagiri
AU  - Srinivasan A
FAU - Sharma, Sujata
AU  - Sharma S
FAU - Singh, Tej P
AU  - Singh TP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090522
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Hydroxamic Acids)
RN  - 0 (Salicylamides)
RN  - 42VZT0U6YR (Heme)
RN  - 8Q07182D0T (salicylhydroxamic acid)
RN  - EC 1.11.1.- (Lactoperoxidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry/*metabolism
MH  - Binding Sites
MH  - Cattle
MH  - Crystallography, X-Ray
MH  - Heme/chemistry/metabolism
MH  - Hydrogen Bonding
MH  - Hydroxamic Acids/chemistry/*metabolism
MH  - Lactoperoxidase/antagonists & inhibitors/*chemistry/isolation & 
      purification/*metabolism
MH  - Models, Molecular
MH  - Protein Binding
MH  - Protein Conformation
MH  - Salicylamides/chemistry/*metabolism
PMC - PMC2740456
EDAT- 2009/05/26 09:00
MHDA- 2009/09/29 06:00
CRDT- 2009/05/26 09:00
PHST- 2009/05/26 09:00 [entrez]
PHST- 2009/05/26 09:00 [pubmed]
PHST- 2009/09/29 06:00 [medline]
AID - S0021-9258(17)49314-8 [pii]
AID - M109.010280 [pii]
AID - 10.1074/jbc.M109.010280 [doi]
PST - ppublish
SO  - J Biol Chem. 2009 Jul 24;284(30):20311-8. doi: 10.1074/jbc.M109.010280. Epub 2009 
      May 22.

PMID- 1892362
OWN - NLM
STAT- MEDLINE
DCOM- 19911015
LR  - 20131121
IS  - 0364-5134 (Print)
IS  - 0364-5134 (Linking)
VI  - 29
IP  - 6
DP  - 1991 Jun
TI  - The European Stroke Prevention Study (ESPS): results by arterial distribution.
PG  - 596-600
AB  - The European Stroke Prevention Study was a multicenter study comparing the effect 
      of the combination of dipyridamole, 75 mg, and acetylsalicylic acid, 330 mg, 
      three times a day, to that of placebo in 2,500 patients in the secondary 
      prevention of stroke or death after one or more transient ischemic attacks, 
      reversible ischemic neurological deficits, or strokes of atherothrombotic origin. 
      The patients with vertebrobasilar events at entry comprised one-third of the 
      whole patient population. The overall total incidence of stroke or death (the end 
      points) during the 2-year follow-up in the placebo group was lower in the 
      vertebrobasilar group compared to the carotid group (14% versus 24%, 
      respectively). The combination therapy of dipyridamole and acetylsalicylic acid 
      caused a marked reduction in the incidence of stroke or death in patients with 
      vertebrobasilar (51%) and carotid (30%) events. When only stroke was considered 
      as the end point, dipyridamole and acetylsalicylic acid seemed to be more 
      effective in reducing the risk of transient ischemic attacks than stroke, and 
      more effective in men than in women.
FAU - Sivenius, J
AU  - Sivenius J
AD  - Department of Neurology, University of Kuopio, Finland.
FAU - Riekkinen, P J
AU  - Riekkinen PJ
FAU - Smets, P
AU  - Smets P
FAU - Laakso, M
AU  - Laakso M
FAU - Lowenthal, A
AU  - Lowenthal A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Ann Neurol
JT  - Annals of neurology
JID - 7707449
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Carotid Arteries
MH  - Cerebrovascular Disorders/drug therapy/epidemiology/*prevention & control
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Europe/epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Risk
MH  - Vertebrobasilar Insufficiency/*drug therapy
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
AID - 10.1002/ana.410290605 [doi]
PST - ppublish
SO  - Ann Neurol. 1991 Jun;29(6):596-600. doi: 10.1002/ana.410290605.

PMID- 31995818
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 1098-8947 (Electronic)
IS  - 0743-684X (Linking)
VI  - 36
IP  - 4
DP  - 2020 May
TI  - Effect of Simvastatin Use in Free Tissue Transfer: An Experimental Study in a Rat 
      Epigastric Free Flap Model.
PG  - 281-288
LID - 10.1055/s-0039-1701030 [doi]
AB  - BACKGROUND:  Statins are traditionally used in lowering cholesterol and 
      low-density lipoprotein biosynthesis, but recent reports show their beneficial 
      effect on microcirculation. The aim of this study was to investigate the effect 
      of simvastatin on the microcirculation and in conjunction with aspirin in a rat 
      free epigastric flap model. METHODS:  Thirty-six Sprague-Dawley rats were divided 
      into group A (control, n = 12), group B (simvastatin treated, n = 12), and group 
      C (simvastatin and aspirin, n = 12). Bilateral free epigastric skin flap was used 
      to evaluate the effect. At 48 hours, flaps biopsies were evaluated for 
      inflammatory activity, nitric oxide content, and thrombomodulin regulation in the 
      endothelial lining of microvessels. Flap survival was evaluated on day 7. 
      RESULTS:  The diameter of microvessels and nitric oxide activity in groups B and 
      C were significantly higher than in group A (p < 0.005 and 0.015, respectively). 
      The perivascular inflammatory cell infiltrates and intravascular adhesions were 
      predominant in group A compared with groups B and C (p < 0.005). Groups B and C 
      demonstrated significant higher degree of thrombomodulin expression. The flap 
      survival rate on day 7 was 70.8% for group A, and 87.5% and 91.7%, respectively, 
      for groups B and C without significance between the two (p = 0.675). CONCLUSION: 
       Simvastatin significantly improves the free flap survival by effective 
      anti-inflammatory, vasodilator, and anticoagulant activities. Combined therapy 
      did not have an antagonistic effect and further study is needed to see 
      synergistic action through different mechanisms.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Abdelfattah, Usama
AU  - Abdelfattah U
AD  - Department of Plastic and Reconstructive Surgery, Asan Medical Centre, Seoul, 
      Korea.
AD  - Department of Plastic and Reconstructive Surgery, Al-Azhar University Hospitals, 
      Cairo, Egypt.
FAU - Elbanoby, Tarek
AU  - Elbanoby T
AD  - Department of Plastic and Reconstructive Surgery, Al-Azhar University Hospitals, 
      Cairo, Egypt.
FAU - Kim, Eun Na
AU  - Kim EN
AD  - Department of Pathology, Asan Medical Centre, Seoul, Korea.
FAU - Park, Eun Jung
AU  - Park EJ
AD  - Department of Plastic and Reconstructive Surgery, Asan Medical Centre, Seoul, 
      Korea.
FAU - Suh, Hyunsuk Peter
AU  - Suh HP
AD  - Department of Plastic and Reconstructive Surgery, Asan Medical Centre, Seoul, 
      Korea.
FAU - Hong, Joon Pio Jp
AU  - Hong JPJ
AUID- ORCID: 0000-0002-6208-9704
AD  - Department of Plastic and Reconstructive Surgery, Asan Medical Centre, Seoul, 
      Korea.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial, Veterinary
DEP - 20200129
PL  - United States
TA  - J Reconstr Microsurg
JT  - Journal of reconstructive microsurgery
JID - 8502670
RN  - AGG2FN16EV (Simvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Epigastric Arteries/*transplantation
MH  - Free Tissue Flaps/*blood supply
MH  - *Graft Survival
MH  - Models, Animal
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Simvastatin/*pharmacology
COIS- None declared.
EDAT- 2020/01/30 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/01/30 06:00
PHST- 2020/01/30 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
PHST- 2020/01/30 06:00 [entrez]
AID - 10.1055/s-0039-1701030 [doi]
PST - ppublish
SO  - J Reconstr Microsurg. 2020 May;36(4):281-288. doi: 10.1055/s-0039-1701030. Epub 
      2020 Jan 29.

PMID- 17002069
OWN - NLM
STAT- MEDLINE
DCOM- 20061027
LR  - 20181201
IS  - 0035-2640 (Print)
IS  - 0035-2640 (Linking)
VI  - 56
IP  - 13
DP  - 2006 Sep 15
TI  - [Prevention of vascular events after transient ischemic attack or cerebral 
      infarct].
PG  - 1437-42
AB  - After a first cerebral ischemic event, secondary prevention should be started as 
      soon as possible, especially in transient ischemic attacks where the risk of 
      recurrence is the highest, especially during the first week, needing a diagnostic 
      workup in a short period of time, secondary prevention measures depending on the 
      presumed cause of the event. Secondary prevention of vascular events after 
      transient ischemic attack or cerebral infarct consists of 3 types of strategies: 
      1. treatment of risk factors for stroke, especially high blood pressure, high 
      cholesterol and smoking cessation; 2. aspirin (50 to 325 mg), or clopidogrel, or 
      association aspirine-dipyridamole in high-risk subjects, or warfarin in patients 
      with high-risk cardiopathies; and 3. carotid surgery in patients selected by 
      clinical and imaging criteria. Other strategies are currently partly under 
      evaluation: statins in normocholesterolemic ischemic stroke patients without 
      coronary event, angioplasty with stenting. Audits of practice are necessary to 
      determine whether patients are actually treated according to scientific evidence. 
      This is a crucial issue if we want the results of trials to be translated in the 
      true life, and really improve health at the community level.
FAU - Leys, Didier
AU  - Leys D
AD  - Equipe d'accueil EA 2691, Université Lille II), service de neurologie et 
      pathologie neurovasculaire, hôpital Roger-Salengro, 59037 Lille. 
      dleys@chru-lille.fr
FAU - Cordonnier, Charlotte
AU  - Cordonnier C
LA  - fre
PT  - Comparative Study
PT  - Journal Article
TT  - Prévenir les evénements vasculaires après l'AIT ou l'infarctus cérébral.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
RN  - 0 (Anticoagulants)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cerebral Infarction/drug therapy/*therapy
MH  - Clopidogrel
MH  - Dipyridamole/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypolipidemic Agents/administration & dosage/therapeutic use
MH  - Ischemic Attack, Transient/complications/drug therapy/prevention & 
      control/*therapy
MH  - Phosphodiesterase Inhibitors/administration & dosage/therapeutic use
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Recurrence
MH  - Risk Factors
MH  - Stents
MH  - Stroke/*prevention & control
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Warfarin/administration & dosage/therapeutic use
EDAT- 2006/09/28 09:00
MHDA- 2006/10/28 09:00
CRDT- 2006/09/28 09:00
PHST- 2006/09/28 09:00 [pubmed]
PHST- 2006/10/28 09:00 [medline]
PHST- 2006/09/28 09:00 [entrez]
PST - ppublish
SO  - Rev Prat. 2006 Sep 15;56(13):1437-42.

PMID- 36288911
OWN - NLM
STAT- MEDLINE
DCOM- 20230118
LR  - 20230118
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 49
IP  - 1
DP  - 2023 Jan
TI  - Combining curcumin and aspirin ameliorates preeclampsia-like symptoms by 
      inhibiting the placental TLR4/NF-κB signaling pathway in rats.
PG  - 128-140
LID - 10.1111/jog.15473 [doi]
AB  - AIM: Preeclampsia (PE) is a common medical complication of pregnancy 
      characterized by high blood pressure and proteinuria after the 20th gestational 
      week. This study aimed to investigate the potency of the combination of curcumin 
      and aspirin in the treatment of PE and explore the underlying mechanisms. 
      MATERIAL AND METHODS: The PE model was constructed in female rats by 
      administering 0.5 mg/mL N-nitro-L-arginine methyl ester from gestational days 
      (GDs) 6 to 16. The pregnant female rats were divided into five groups according 
      to the drug treatment. The curcumin or aspirin was given to the rats by tail vein 
      injection (0.36 mg/kg) or gavage treatment (1.5 mg/kg BW/day) from GD4 to GD18. 
      RESULTS: Treatment with curcumin and aspirin combination significantly reduced 
      the systolic blood pressure and proteinuria in the PE rats. Meanwhile, in 
      comparison to the PE rats treated with single-dose curcumin or aspirin, the rats 
      treated with combined curcumin and aspirin showed significantly decreased sFlt-1, 
      increased placental growth factor, and alleviated oxidative stress in both blood 
      and placental tissues, which are abnormal in no-treated PE rats. Furthermore, 
      dramatically decreased inflammatory cytokines secretion and TLR4 and NF-κB p65 
      expression in placental tissues were also observed in the PE rats with combined 
      treatment compared to those of no-treated, signal-dose curcumin or 
      aspirin-treated PE rats. CONCLUSIONS: Our results suggested that the combined 
      treatment of curcumin and aspirin significantly ameliorates the symptoms of PE in 
      rats, which is most likely due to the inhibition of the placental TLR4/NF-κB p65 
      signaling pathway.
CI  - © 2022 Japan Society of Obstetrics and Gynecology.
FAU - Ju, Yaru
AU  - Ju Y
AUID- ORCID: 0000-0002-5716-5290
AD  - Perinatal Center, The Fourth Hospital of Shijiazhuang, Shijiazhuang, China.
FAU - Feng, Yan
AU  - Feng Y
AD  - Department of Neurosurgery, The Second Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Yang, Yanjing
AU  - Yang Y
AD  - Perinatal Center, The Fourth Hospital of Shijiazhuang, Shijiazhuang, China.
FAU - Hou, Xiaolin
AU  - Hou X
AD  - Prenatal Diagnostic, The Fourth Hospital of Shijiazhuang, Shijiazhuang, China.
FAU - Zhang, Xiaofeng
AU  - Zhang X
AD  - Department of Obstetrics, The Fourth Hospital of Shijiazhuang, Shijiazhuang, 
      China.
FAU - Zhu, Xihui
AU  - Zhu X
AD  - Perinatal Center, The Fourth Hospital of Shijiazhuang, Shijiazhuang, China.
FAU - Wang, Yage
AU  - Wang Y
AD  - Department of Obstetrics, Gaocheng District Hospital of Traditional Chinese and 
      Western Medicine, Shijiazhuang, China.
FAU - Yang, Meiliu
AU  - Yang M
AD  - Department of Biology, Hengshui University, Hengshui, China.
LA  - eng
GR  - 20221677/The Medical Science Research Project of Hebei Province/
GR  - 20220112/The Medical Science Research Project of Hebei Province/
PT  - Journal Article
DEP - 20221026
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (NF-kappa B)
RN  - IT942ZTH98 (Curcumin)
RN  - 0 (Toll-Like Receptor 4)
RN  - 144589-93-5 (Placenta Growth Factor)
RN  - 0 (TLR4 protein, human)
RN  - 0 (Tlr4 protein, rat)
SB  - IM
MH  - Humans
MH  - Rats
MH  - Female
MH  - Pregnancy
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - NF-kappa B/metabolism
MH  - *Pre-Eclampsia
MH  - Placenta/metabolism
MH  - *Curcumin/pharmacology/metabolism/therapeutic use
MH  - Toll-Like Receptor 4/metabolism/therapeutic use
MH  - Placenta Growth Factor/metabolism
MH  - Signal Transduction
MH  - Proteinuria/drug therapy
OTO - NOTNLM
OT  - TLR4/NF-κB
OT  - aspirin
OT  - curcumin
OT  - inflammation
OT  - oxidative stress
OT  - preeclampsia
EDAT- 2022/10/27 06:00
MHDA- 2023/01/19 06:00
CRDT- 2022/10/26 21:02
PHST- 2022/10/06 00:00 [revised]
PHST- 2022/06/21 00:00 [received]
PHST- 2022/10/08 00:00 [accepted]
PHST- 2022/10/27 06:00 [pubmed]
PHST- 2023/01/19 06:00 [medline]
PHST- 2022/10/26 21:02 [entrez]
AID - 10.1111/jog.15473 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2023 Jan;49(1):128-140. doi: 10.1111/jog.15473. Epub 2022 
      Oct 26.

PMID- 30054611
OWN - NLM
STAT- MEDLINE
DCOM- 20180830
LR  - 20181202
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 320
IP  - 6
DP  - 2018 Aug 14
TI  - Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events 
      Among Patients at High Risk for Cardiovascular Events.
PG  - 593-594
LID - 10.1001/jama.2018.9641 [doi]
AB  - CLINICAL QUESTION: Among patients at high risk for or with established 
      cardiovascular disease (ie, history of peripheral artery disease, stroke, or 
      coronary artery disease without a coronary stent), is the addition of clopidogrel 
      to aspirin associated with lower risk of mortality and cardiovascular events 
      compared with aspirin alone? BOTTOM LINE: Clopidogrel plus aspirin is associated 
      with a reduced risk for myocardial infarction and ischemic stroke and an 
      increased risk for major bleeding compared with aspirin alone among patients at 
      high risk for or with an established cardiovascular disease but without a 
      coronary stent. However, combined therapy is not associated with lower mortality.
FAU - Donadini, Marco P
AU  - Donadini MP
AD  - Thrombosis and Haemostasis Center, Department of Clinical Medicine, Azienda Socio 
      Sanitaria Territoriale Sette Laghi, Ospedale di Circolo, Varese, Italy.
FAU - Bellesini, Marta
AU  - Bellesini M
AD  - Department of Medicine and Surgery, University of Insubria, Varese, Italy.
FAU - Squizzato, Alessandro
AU  - Squizzato A
AD  - Research Center on Thromboembolic Disorders and Antithrombotic Therapies, 
      Department of Medicine and Surgery, University of Insubria, Varese, Italy.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - JAMA. 2018 Sep 25;320(12):1288. PMID: 30264096
EIN - JAMA. 2019 Aug 6;322(5):469. PMID: 31386113
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Clopidogrel
MH  - Drug Therapy, Combination/adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Review Literature as Topic
MH  - Stroke/prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
EDAT- 2018/07/29 06:00
MHDA- 2018/08/31 06:00
CRDT- 2018/07/29 06:00
PHST- 2018/07/29 06:00 [pubmed]
PHST- 2018/08/31 06:00 [medline]
PHST- 2018/07/29 06:00 [entrez]
AID - 2695067 [pii]
AID - 10.1001/jama.2018.9641 [doi]
PST - ppublish
SO  - JAMA. 2018 Aug 14;320(6):593-594. doi: 10.1001/jama.2018.9641.

PMID- 21788962
OWN - NLM
STAT- MEDLINE
DCOM- 20120120
LR  - 20220321
IS  - 1759-5010 (Electronic)
IS  - 1759-5002 (Linking)
VI  - 8
IP  - 10
DP  - 2011 Jul 26
TI  - The role of aspirin for stroke prevention in atrial fibrillation.
PG  - 602-6
LID - 10.1038/nrcardio.2011.112 [doi]
AB  - Atrial fibrillation (AF) is a major cause of stroke and thromboembolism, 
      resulting in substantial morbidity and mortality. For the majority of patients 
      with AF, aspirin has a limited role in stroke prevention, being an inferior 
      strategy and not necessarily safer than the anticoagulant warfarin, especially in 
      the elderly. Novel oral anticoagulant drugs, such as oral direct thrombin 
      inhibitors and oral factor Xa inhibitors, might further diminish the role of 
      aspirin for stroke prevention in AF. Nonetheless, aspirin use should continue in 
      the early stages following presentation of a patient with AF and acute coronary 
      syndrome, and after stenting, in combination with oral anticoagulant drugs and 
      clopidogrel, as appropriate. Notably, aspirin combined with clopidogrel shows 
      only modest benefit in stroke prevention compared with aspirin monotherapy in 
      patients with AF who refuse oral anticoagulant drugs (including warfarin), or in 
      those individuals who have difficulties in anticoagulation monitoring, and can be 
      used where bleeding risk is not excessive.
FAU - Lip, Gregory Y H
AU  - Lip GY
AD  - University of Birmingham Centre for Cardiovascular Sciences, City Hospital, 
      Dudley Road, Birmingham B18 7QH, UK.g.y.h.lip@bham.ac.uk
LA  - eng
PT  - Review
DEP - 20110726
PL  - England
TA  - Nat Rev Cardiol
JT  - Nature reviews. Cardiology
JID - 101500075
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Drug Therapy, Combination
MH  - Evidence-Based Medicine
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Primary Prevention/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Stroke/etiology/*prevention & control
EDAT- 2011/07/27 06:00
MHDA- 2012/01/21 06:00
CRDT- 2011/07/27 06:00
PHST- 2011/07/27 06:00 [entrez]
PHST- 2011/07/27 06:00 [pubmed]
PHST- 2012/01/21 06:00 [medline]
AID - nrcardio.2011.112 [pii]
AID - 10.1038/nrcardio.2011.112 [doi]
PST - epublish
SO  - Nat Rev Cardiol. 2011 Jul 26;8(10):602-6. doi: 10.1038/nrcardio.2011.112.

PMID- 9768401
OWN - NLM
STAT- MEDLINE
DCOM- 19981116
LR  - 20220317
IS  - 0886-3350 (Print)
IS  - 0886-3350 (Linking)
VI  - 24
IP  - 9
DP  - 1998 Sep
TI  - Effect of aspirin intake on bleeding during cataract surgery.
PG  - 1243-6
AB  - PURPOSE: To study the association between chronic intake of aspirin and 
      intraoperative bleeding during cataract surgery and the effect of discontinuing 
      the medication before surgery. SETTING: Department of Ophthalmology, Meir 
      Hospital, Sapir Medical Center, Kfar-Saba, Israel. METHODS: Sixty-one patients 
      having cataract surgery and receiving aspirin to prevent thromboembolic events 
      were divided into 3 groups: Group A, continuation of the medication; Group B, 
      cessation of aspirin intake for 2 to 5 days before surgery; Group C, cessation of 
      medication for 7 to 10 days before surgery. Blood tests of coagulation 
      parameters, a detailed questionnaire, and 1 day and 1 week follow-up were 
      evaluated. RESULTS: There were no significant differences in blood tests and the 
      amount and incidence of intraoperative bleeding among the 3 groups. Diathermy was 
      used somewhat more in Group A; however, there was no difficulty stopping the 
      bleeding in any case and discontinuation of the medication had no effect on the 
      intraoperative course or postoperative outcome. CONCLUSIONS: Aspirin intake was 
      not associated with significant intraoperative bleeding; thus, discontinuation of 
      aspirin is usually not indicated. Clear corneal phacoemulsification is 
      advantageous in patients receiving antiplatelet therapy.
FAU - Assia, E I
AU  - Assia EI
AD  - Department of Ophthalmology, Meir Hospital, Sapir Medical Center, Kfar-Saba, 
      Israel.
FAU - Raskin, T
AU  - Raskin T
FAU - Kaiserman, I
AU  - Kaiserman I
FAU - Rotenstreich, Y
AU  - Rotenstreich Y
FAU - Segev, F
AU  - Segev F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Cataract Refract Surg
JT  - Journal of cataract and refractive surgery
JID - 8604171
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Cataract Refract Surg. 1999 Mar;25(3):301. PMID: 10079425
CIN - J Cataract Refract Surg. 1999 Mar;25(3):301-2. PMID: 10079426
MH  - Aspirin/*administration & dosage/adverse effects
MH  - *Blood Loss, Surgical
MH  - *Cataract Extraction
MH  - Eye Hemorrhage/chemically induced/epidemiology
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Follow-Up Studies
MH  - Hematocrit
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Incidence
MH  - Lens Implantation, Intraocular
MH  - Partial Thromboplastin Time
MH  - Prospective Studies
MH  - Prothrombin Time
MH  - Surveys and Questionnaires
EDAT- 1998/10/13 00:00
MHDA- 1998/10/13 00:01
CRDT- 1998/10/13 00:00
PHST- 1998/10/13 00:00 [pubmed]
PHST- 1998/10/13 00:01 [medline]
PHST- 1998/10/13 00:00 [entrez]
AID - S0886-3350(98)80020-5 [pii]
AID - 10.1016/s0886-3350(98)80020-5 [doi]
PST - ppublish
SO  - J Cataract Refract Surg. 1998 Sep;24(9):1243-6. doi: 
      10.1016/s0886-3350(98)80020-5.

PMID- 28882113
OWN - NLM
STAT- MEDLINE
DCOM- 20180503
LR  - 20181113
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Sep 7
TI  - New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: 
      a nested case-control study in UK general practice.
PG  - 637
LID - 10.1186/s12885-017-3594-9 [doi]
LID - 637
AB  - BACKGROUND: Evidence from clinical trial populations suggests low-dose aspirin 
      reduces the risk of colorectal cancer (CRC). Part of this reduction in risk might 
      be due to protection against metastatic disease. METHODS: We investigated the 
      risk of CRC among new-users of low-dose aspirin (75-300 mg), including risk by 
      stage at diagnosis. Using The Health Improvement Network, we conducted a cohort 
      study with nested case-control analysis. Two cohorts (N = 170,336 each) aged 
      40-89 years from 2000 to 2009 and free of cancer were identified: i) new-users of 
      low-dose aspirin, ii) non-users of low-dose aspirin, at start of follow-up, 
      matched by age, sex and previous primary care practitioner visits. Patients were 
      followed for up to 12 years to identify incident CRC. 10,000 frequency-matched 
      controls were selected by incidence density sampling where the odds ratio is an 
      unbiased estimator of the incidence rate ratio (RR). RRs with 95% confidence 
      intervals were calculated. Low-dose aspirin use was classified 'as-treated' 
      independent from baseline exposure status to account for changes in exposure 
      during follow-up. RESULTS: Current users of low-dose aspirin (use on the index 
      date or in the previous 90 days) had a significantly reduced risk of CRC, RR 0.66 
      (95% CI 0.60-0.74). The reduction in risk was apparent across all age groups, and 
      was unrelated to dose, indication, gender, CRC location or case-fatality status. 
      Reduced risks occurred throughout treatment duration and with all low-dose 
      aspirin doses. RRs by aspirin indication were 0.71 (0·63-0·79) and 0.60 
      (0.53-0.68) for primary and secondary cardiovascular protection, respectively. 
      Among cases with staging information (n = 1421), RRs for current use of low-dose 
      aspirin were 0.94 (0.66-1.33) for Dukes Stage A CRC, 0.54 (0.42-0.68) for Dukes 
      B, 0.71 (0.56-0.91) for Dukes C, and 0.60 (0.48-0.74) for Dukes D. After 5 years' 
      therapy, the RR for Dukes Stage A CRC was 0.53 (0.24-1.19). CONCLUSIONS: Patients 
      starting low-dose aspirin therapy have a reduced risk of Stages B-D CRC, 
      suggesting a role for low-dose aspirin in the progression of established CRC; a 
      substantial reduction in the risk of Dukes A CRC may occur after 5 years' 
      therapy.
FAU - García Rodríguez, Luis A
AU  - García Rodríguez LA
AD  - Spanish Centre for Pharmacoepidemiologic Research, c/ Almirante 28, 2°, 28004, 
      Madrid, Spain.
FAU - Soriano-Gabarró, Montse
AU  - Soriano-Gabarró M
AD  - Epidemiology, Bayer AG, Müllerstr. 178, 13353, Berlin, Germany. 
      montse.soriano-gabarro@bayer.com.
FAU - Bromley, Susan
AU  - Bromley S
AD  - EpiMed Communications Ltd, Abingdon, Oxford, OX14 1QS, UK.
AD  - London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, UK.
FAU - Lanas, Angel
AU  - Lanas A
AD  - Servicio de Aparato Digestivo, Hospital Clínico, University of Zaragoza, IIS 
      Aragón, Zaragoza, Spain.
AD  - CIBERehd, Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0, 28029, Madrid, 
      Spain.
FAU - Cea Soriano, Lucía
AU  - Cea Soriano L
AD  - Spanish Centre for Pharmacoepidemiologic Research, c/ Almirante 28, 2°, 28004, 
      Madrid, Spain.
AD  - Department of Preventive Medicine and Public Health, Faculty of Medicine, 
      Complutense University of Madrid, Av. Séneca, 2, 28040, Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20170907
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Colorectal Neoplasms/*epidemiology/*etiology/pathology
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Odds Ratio
MH  - Population Surveillance
MH  - Risk
MH  - United Kingdom/epidemiology
PMC - PMC5590216
OTO - NOTNLM
OT  - Aspirin
OT  - Chemoprevention
OT  - Colorectal cancer
OT  - Diagnosis
OT  - Nested case-control studies
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study protocol was reviewed and 
      approved by an independent scientific review committee for THIN (reference number 
      14–080), which ensured that data were to be analysed and interpreted 
      appropriately. Data collection for THIN was approved by the South East 
      Multicentre Research Ethics Committee in 2003 and individual studies using THIN 
      data do not require separate ethical approval if only anonymized THIN data is 
      used (CSD Health Research. MREC. http://www.thin-uk.com/mrec.htm. Accessed 10 
      October 2016). CONSENT FOR PUBLICATION: Not Applicable. COMPETING INTERESTS: MS-G 
      is a salaried, full-time employee of Bayer AG. LCS and LAGR work for CEIFE, which 
      has received a research grant from Bayer AG. LAGR has also served as an advisory 
      board member for Bayer AG. SB has received funding from Bayer AG for 
      epidemiological research and medical writing services. AL has received a research 
      grant from Bayer AG and has served as an advisory board member for Bayer AG and 
      Bayer HealthCare. PUBLISHER’S NOTE: Springer Nature remains neutral with regard 
      to jurisdictional claims in published maps and institutional affiliations.
EDAT- 2017/09/09 06:00
MHDA- 2018/05/04 06:00
CRDT- 2017/09/09 06:00
PHST- 2016/10/04 00:00 [received]
PHST- 2017/08/23 00:00 [accepted]
PHST- 2017/09/09 06:00 [entrez]
PHST- 2017/09/09 06:00 [pubmed]
PHST- 2018/05/04 06:00 [medline]
AID - 10.1186/s12885-017-3594-9 [pii]
AID - 3594 [pii]
AID - 10.1186/s12885-017-3594-9 [doi]
PST - epublish
SO  - BMC Cancer. 2017 Sep 7;17(1):637. doi: 10.1186/s12885-017-3594-9.

PMID- 30232399
OWN - NLM
STAT- MEDLINE
DCOM- 20200331
LR  - 20210415
IS  - 1476-5527 (Electronic)
IS  - 0950-9240 (Linking)
VI  - 33
IP  - 1
DP  - 2019 Jan
TI  - Aspirin in the prevention of preeclampsia: the conundrum of how, who and when.
PG  - 1-9
LID - 10.1038/s41371-018-0113-7 [doi]
AB  - Aspirin is widely used in preventing early onset preeclampsia in women who are 
      identified as being high risk. Although the benefit of aspirin is increasingly 
      evident and acknowledged, there remains many unanswered questions with regards to 
      its optimal application in pregnancy. The issues mainly centre around the 
      relatively modest risk reduction that is observed with the use of aspirin 
      prophylactically. We aim to explore the reasons behind the conservative rate of 
      benefit and aim to explore factors that are likely to influence the outcomes with 
      the use of aspirin.
FAU - Shanmugalingam, Renuka
AU  - Shanmugalingam R
AUID- ORCID: 0000-0002-2255-8369
AD  - Department of Renal Medicine, South Western Sydney Local Health District, Sydney, 
      NSW, Australia. renuka.shanmugalingam@health.nsw.gov.au.
AD  - School of Medicine, Western Sydney University, Sydney, NSW, Australia. 
      renuka.shanmugalingam@health.nsw.gov.au.
FAU - Hennessy, Annemarie
AU  - Hennessy A
AD  - Department of Renal Medicine, South Western Sydney Local Health District, Sydney, 
      NSW, Australia.
AD  - School of Medicine, Western Sydney University, Sydney, NSW, Australia.
FAU - Makris, Angela
AU  - Makris A
AD  - Department of Renal Medicine, South Western Sydney Local Health District, Sydney, 
      NSW, Australia.
AD  - School of Medicine, Western Sydney University, Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20180919
PL  - England
TA  - J Hum Hypertens
JT  - Journal of human hypertension
JID - 8811625
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
EDAT- 2018/09/21 06:00
MHDA- 2020/04/01 06:00
CRDT- 2018/09/21 06:00
PHST- 2018/07/26 00:00 [received]
PHST- 2018/08/28 00:00 [accepted]
PHST- 2018/09/21 06:00 [pubmed]
PHST- 2020/04/01 06:00 [medline]
PHST- 2018/09/21 06:00 [entrez]
AID - 10.1038/s41371-018-0113-7 [pii]
AID - 10.1038/s41371-018-0113-7 [doi]
PST - ppublish
SO  - J Hum Hypertens. 2019 Jan;33(1):1-9. doi: 10.1038/s41371-018-0113-7. Epub 2018 
      Sep 19.

PMID- 3582476
OWN - NLM
STAT- MEDLINE
DCOM- 19870716
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 32
IP  - 2
DP  - 1987
TI  - Studies on performance with aspirin and paracetamol and with the centrally acting 
      analgesics meptazinol and pentazocine.
PG  - 135-9
AB  - Effects of aspirin (325 and 650 mg) and paracetamol (500 and 1000 mg), and of the 
      centrally acting analgesics meptazinol (100 and 200 mg) and pentazocine (25 and 
      50 mg) on visuo-motor coordination and dynamic visual acuity, together with 
      critical flicker fusion, digit symbol substitution, complex reaction time and 
      subjective assessments of mood, were studied from 0.75-2.0 h after ingestion by 
      seven healthy female adults. The study was double-blind and placebo controlled, 
      and triprolidine (10 mg) was used as the active control. No effects of meptazinol 
      and paracetamol on performance were observed. Pentazocine (25 mg) impaired 
      performance on digit symbol substitution (p less than 0.05) and aspirin (650 mg) 
      appeared to have shortened complex reaction time (p less than 0.05). Meptazinol 
      (100 mg) increased the component of mood assessments related to wakefulness (p 
      less than 0.05). Impaired performance with pentazocine may involve opioid 
      receptor activity, while the apparent alerting effect of meptazinol may relate to 
      its cholinergic activity. The possible effect of aspirin on reaction time needs 
      to be confirmed.
FAU - Bradley, C M
AU  - Bradley CM
FAU - Nicholson, A N
AU  - Nicholson AN
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Azepines)
RN  - 18Y7S5JKZD (Meptazinol)
RN  - 2L8T9S52QM (Triprolidine)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - RP4A60D26L (Pentazocine)
SB  - IM
MH  - Acetaminophen/adverse effects/*pharmacology
MH  - Adult
MH  - Aspirin/adverse effects/*pharmacology
MH  - Azepines/*pharmacology
MH  - Emotions/drug effects
MH  - Female
MH  - Flicker Fusion/drug effects
MH  - Humans
MH  - Meptazinol/adverse effects/*pharmacology
MH  - Pentazocine/adverse effects/*pharmacology
MH  - Psychomotor Performance/*drug effects
MH  - Reaction Time/drug effects
MH  - Triprolidine/pharmacology
MH  - Visual Acuity/drug effects
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1007/BF00542185 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1987;32(2):135-9. doi: 10.1007/BF00542185.

PMID- 2664523
OWN - NLM
STAT- MEDLINE
DCOM- 19890822
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 321
IP  - 6
DP  - 1989 Aug 10
TI  - Effect of low-dose aspirin on fetal and maternal generation of thromboxane by 
      platelets in women at risk for pregnancy-induced hypertension.
PG  - 357-62
AB  - There is evidence that aspirin in low doses favorably influences the course of 
      pregnancy-induced hypertension, but the mechanism, although assumed to involve 
      suppression of the production of thromboxane by platelets, has not been 
      established. We performed a randomized study of the effect of the long-term daily 
      administration of 60 mg of aspirin (n = 17) or placebo (n = 16) on platelet 
      thromboxane A2 and vascular prostacyclin in women at risk for pregnancy-induced 
      hypertension. Low doses of aspirin were associated with a longer pregnancy and 
      increased weight of newborns. Serum levels of thromboxane B2, a stable product of 
      thromboxane A2, were almost completely (greater than 90 percent) inhibited by low 
      doses of aspirin. The urinary excretion of immunoreactive thromboxane B2 was 
      significantly reduced without changes in the level of 6-keto-prostaglandin F1 
      alpha, a product of prostacyclin. Mass spectrometric analysis showed that aspirin 
      reduced the excretion of the 2,3-dinor-thromboxane B2 metabolite--mainly of 
      platelet origin--by 81 percent and of thromboxane B2, probably chiefly of renal 
      origin, by 59 percent. The urinary excretion of 6-keto-prostaglandin F1 alpha and 
      of its metabolite 2,3-dinor-6-keto-prostaglandin F1 alpha was not affected. Low 
      doses of aspirin only partially (63 percent) reduced neonatal serum thromboxane 
      B2. No hemorrhagic complications were observed in the newborns. Thus, in women at 
      risk for pregnancy-induced hypertension, low doses of aspirin selectively 
      suppressed maternal platelet thromboxane B2 while sparing vascular prostacyclin, 
      but only partially suppressed neonatal platelet thromboxane B2, allowing 
      hemostatic competence in the fetus and newborn.
FAU - Benigni, A
AU  - Benigni A
AD  - Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
FAU - Gregorini, G
AU  - Gregorini G
FAU - Frusca, T
AU  - Frusca T
FAU - Chiabrando, C
AU  - Chiabrando C
FAU - Ballerini, S
AU  - Ballerini S
FAU - Valcamonico, A
AU  - Valcamonico A
FAU - Orisio, S
AU  - Orisio S
FAU - Piccinelli, A
AU  - Piccinelli A
FAU - Pinciroli, V
AU  - Pinciroli V
FAU - Fanelli, R
AU  - Fanelli R
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Blood Platelets/*metabolism
MH  - Epoprostenol/biosynthesis
MH  - Female
MH  - Fetus/*metabolism
MH  - Humans
MH  - Hypertension/*blood/drug therapy/metabolism
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*blood/drug therapy/metabolism
MH  - Random Allocation
MH  - Thromboxane A2/biosynthesis
MH  - Thromboxane B2/blood
MH  - Thromboxanes/*biosynthesis
EDAT- 1989/08/10 00:00
MHDA- 1989/08/10 00:01
CRDT- 1989/08/10 00:00
PHST- 1989/08/10 00:00 [pubmed]
PHST- 1989/08/10 00:01 [medline]
PHST- 1989/08/10 00:00 [entrez]
AID - 10.1056/NEJM198908103210604 [doi]
PST - ppublish
SO  - N Engl J Med. 1989 Aug 10;321(6):357-62. doi: 10.1056/NEJM198908103210604.

PMID- 3665615
OWN - NLM
STAT- MEDLINE
DCOM- 19871209
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 92
IP  - 5
DP  - 1987 Nov
TI  - Severe restrictive pulmonary defect in a patient with adult-onset Still's 
      disease.
PG  - 939-40
AB  - Adult-onset Still's disease is characterized by seronegative arthritis, fever, 
      and an evanescent skin rash. Earlier reports have described pneumonitis and 
      pleuritis as manifestations of this disease. We report a patient with adult-onset 
      Still's disease with severe restrictive ventilatory impairment and evidence of 
      respiratory muscle weakness who responded to corticosteroid and aspirin therapy.
FAU - Cantor, J P
AU  - Cantor JP
AD  - Department of Internal Medicine (Rheumatology and Pulmonary Diseases), University 
      of Texas Health Science Center, Dallas.
FAU - Pitcher, W D
AU  - Pitcher WD
FAU - Hurd, E
AU  - Hurd E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Arthritis, Juvenile/*complications
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Lung Diseases/*complications/drug therapy/physiopathology
MH  - Male
MH  - Prednisone/therapeutic use
MH  - Respiratory Function Tests
EDAT- 1987/11/01 00:00
MHDA- 1987/11/01 00:01
CRDT- 1987/11/01 00:00
PHST- 1987/11/01 00:00 [pubmed]
PHST- 1987/11/01 00:01 [medline]
PHST- 1987/11/01 00:00 [entrez]
AID - S0012-3692(16)30875-3 [pii]
AID - 10.1378/chest.92.5.939 [doi]
PST - ppublish
SO  - Chest. 1987 Nov;92(5):939-40. doi: 10.1378/chest.92.5.939.

PMID- 31093885
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20201006
IS  - 1868-4297 (Electronic)
IS  - 1868-4297 (Linking)
VI  - 35
IP  - 2
DP  - 2020 Apr
TI  - A prospective interventional registry of short-term dual-antiplatelet treatment 
      after implantation of drug-eluting stents in patients with atrial fibrillation 
      requiring oral anticoagulation therapy.
PG  - 150-161
LID - 10.1007/s12928-019-00589-7 [doi]
AB  - There are limited data regarding the use of antithrombotic therapy in patients 
      with atrial fibrillation (AF) who underwent percutaneous coronary intervention 
      (PCI) with drug-eluting stents (DES). In this prospective interventional study, 
      we evaluated the feasibility of short-term dual-antiplatelet therapy (DAPT) after 
      DES implantation in AF patients treated with oral anticoagulation (OAC). The 
      antithrombotic regimen in the present study was 1-month DAPT, followed by 
      single-antiplatelet therapy with OAC. A total of 285 consecutive patients were 
      enrolled between 2015 and 2017. The mean CHA2DS2-VASc score was 3.91 ± 1.51. The 
      duration of DAPT was 28.5 ± 11.5 days. At 1-year follow-up, serious bleeding 
      complications, defined as Bleeding Academic Research Consortium type ≥ 2, were 
      observed in 27 patients (9.5%). Multivariate analysis showed that previous 
      history of bleeding episodes (P = 0.009) and continuation of aspirin (P = 0.003) 
      were independent predictors for the serious bleeding complications. High ORBIT 
      (P = 0.008) and PRECISE-DAPT (P = 0.002) scores were associated with the bleeding 
      complications, and the cut-off values were 5.00 and 49.0, respectively. No 
      definite stent thrombosis occurred in any of the patients. Short-term DAPT is 
      feasible in AF patients treated with OAC after undergoing PCI with DES. The 
      previous history of bleeding episodes and long-term aspirin use were associated 
      with their 1-year serious bleeding events.
FAU - Horie, Kazunori
AU  - Horie K
AUID- ORCID: 0000-0002-8614-7729
AD  - Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, 
      Sendai Kousei Hospital, 4-15 Hirose-cho, Aoba-ku, Sendai, Miyagi, 980-0873, 
      Japan. horihori1015@gmail.com.
FAU - Matsumoto, Takashi
AU  - Matsumoto T
AD  - Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, 
      Sendai Kousei Hospital, 4-15 Hirose-cho, Aoba-ku, Sendai, Miyagi, 980-0873, 
      Japan.
FAU - Mizutani, Yukiko
AU  - Mizutani Y
AD  - Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, 
      Sendai Kousei Hospital, 4-15 Hirose-cho, Aoba-ku, Sendai, Miyagi, 980-0873, 
      Japan.
FAU - Tada, Norio
AU  - Tada N
AD  - Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, 
      Sendai Kousei Hospital, 4-15 Hirose-cho, Aoba-ku, Sendai, Miyagi, 980-0873, 
      Japan.
FAU - Osai, Norichika
AU  - Osai N
AD  - Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, 
      Sendai Kousei Hospital, 4-15 Hirose-cho, Aoba-ku, Sendai, Miyagi, 980-0873, 
      Japan.
FAU - Isawa, Tsuyoshi
AU  - Isawa T
AD  - Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, 
      Sendai Kousei Hospital, 4-15 Hirose-cho, Aoba-ku, Sendai, Miyagi, 980-0873, 
      Japan.
FAU - Taguri, Masataka
AU  - Taguri M
AD  - Department of Biostatics, Yokohama City University School of Medicine, Yokohama, 
      Kanagawa, Japan.
FAU - Kato, Shigeaki
AU  - Kato S
AD  - Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, 
      Sendai Kousei Hospital, 4-15 Hirose-cho, Aoba-ku, Sendai, Miyagi, 980-0873, 
      Japan.
FAU - Honda, Taku
AU  - Honda T
AD  - Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, 
      Sendai Kousei Hospital, 4-15 Hirose-cho, Aoba-ku, Sendai, Miyagi, 980-0873, 
      Japan.
FAU - Ootomo, Tatsushi
AU  - Ootomo T
AD  - Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, 
      Sendai Kousei Hospital, 4-15 Hirose-cho, Aoba-ku, Sendai, Miyagi, 980-0873, 
      Japan.
FAU - Inoue, Naoto
AU  - Inoue N
AD  - Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, 
      Sendai Kousei Hospital, 4-15 Hirose-cho, Aoba-ku, Sendai, Miyagi, 980-0873, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20190515
PL  - Japan
TA  - Cardiovasc Interv Ther
JT  - Cardiovascular intervention and therapeutics
JID - 101522043
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects
MH  - Atrial Fibrillation/*therapy
MH  - Clopidogrel/therapeutic use
MH  - *Drug-Eluting Stents
MH  - *Dual Anti-Platelet Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Multivariate Analysis
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Prospective Studies
MH  - Registries
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - Atrial fibrillation
OT  - Drug-eluting stents
OT  - Oral anticoagulation
OT  - Percutaneous coronary intervention
EDAT- 2019/05/17 06:00
MHDA- 2020/10/07 06:00
CRDT- 2019/05/17 06:00
PHST- 2019/02/28 00:00 [received]
PHST- 2019/05/10 00:00 [accepted]
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
PHST- 2019/05/17 06:00 [entrez]
AID - 10.1007/s12928-019-00589-7 [pii]
AID - 10.1007/s12928-019-00589-7 [doi]
PST - ppublish
SO  - Cardiovasc Interv Ther. 2020 Apr;35(2):150-161. doi: 10.1007/s12928-019-00589-7. 
      Epub 2019 May 15.

PMID- 28216620
OWN - NLM
STAT- MEDLINE
DCOM- 20170922
LR  - 20181113
IS  - 1745-7254 (Electronic)
IS  - 1671-4083 (Print)
IS  - 1671-4083 (Linking)
VI  - 38
IP  - 4
DP  - 2017 Apr
TI  - Aspirin alleviates cardiac fibrosis in mice by inhibiting autophagy.
PG  - 488-497
LID - 10.1038/aps.2016.143 [doi]
AB  - Aspirin (ASA) is a cardioprotective drug with anti-cardiac fibrosis action in 
      vivo. This study was aimed to clarify the anti-cardiac fibrosis action of ASA and 
      the underlying mechanisms. Two heart injury models (injection of isoproterenol 
      and ligation of the left anterior descending branch) were used in mice to induce 
      cardiac fibrosis. The animals were treated with ASA (10 mg·kg(-1)·d(-1), ig) for 
      21 and 14 d, respectively. ASA administration significantly improved cardiac 
      function, and ameliorated heart damage and fibrosis in the mice. The mechanisms 
      underlying ASA's anti-fibrotic effect were further analyzed in neonatal cardiac 
      fibroblasts (CFs) exposed to hypoxia in vitro. ASA (0.5-5 mmol/L) 
      dose-dependently inhibited the proliferation and Akt phosphorylation in the CFs. 
      In addition, ASA significantly inhibited CF apoptosis, and decreased the levels 
      of apoptosis markers (cleaved caspase 3 and Parp1), which might serve as a side 
      effect of anti-fibrotic effect of ASA. Furthermore, ASA dose-dependently 
      inhibited the autophagy in the CFs, as evidenced by the reduced levels of 
      autophagy marker LC3-II. The autophagy inhibitor Pepstatin A (PepA) promoted the 
      inhibitory effect of ASA on CF proliferation, whereas the autophagy inducer 
      rapamycin rescued ASA-caused inhibition of CF proliferation, suggesting an 
      autophagy-dependent anti-proliferative effect of ASA. Both p38 inhibitor SB203580 
      and ROS scavenger N-acetyl-cysteine (NAC) significantly decreased Akt 
      phosphorylation in CFs in the basal and hypoxic situations, but they both 
      significantly increased LC3-II levels in the CFs. Our results suggest that an 
      autophagy- and p38/ROS-dependent pathway mediates the anti-cardiac fibrosis 
      effect of ASA in CFs. As PepA and SB203580 did not affect ASA-caused inhibition 
      of CF apoptosis, the drug combination will enhance ASA's therapeutic effects.
FAU - Liu, Ping-Ping
AU  - Liu PP
AD  - Medical College of Shandong University, Ji-nan 250100, China.
FAU - Liu, Hong-Hong
AU  - Liu HH
AD  - Institute of Developmental Biology, School of Life Science, Shandong University, 
      Ji-nan 250100, China.
FAU - Sun, Shu-Hong
AU  - Sun SH
AD  - Animal Science Department, Shandong Agriculture University, Tai-an 271018, China.
FAU - Shi, Xing-Xing
AU  - Shi XX
AD  - Institute of Developmental Biology, School of Life Science, Shandong University, 
      Ji-nan 250100, China.
FAU - Yang, Wan-Cheng
AU  - Yang WC
AD  - Institute of Developmental Biology, School of Life Science, Shandong University, 
      Ji-nan 250100, China.
FAU - Su, Guo-Hai
AU  - Su GH
AD  - Jinan central hospital affiliated to Shandong University, Ji-nan 250100, China.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Institute of Developmental Biology, School of Life Science, Shandong University, 
      Ji-nan 250100, China.
LA  - eng
PT  - Journal Article
DEP - 20170220
PL  - United States
TA  - Acta Pharmacol Sin
JT  - Acta pharmacologica Sinica
JID - 100956087
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Imidazoles)
RN  - 0 (Pyridines)
RN  - 0 (Reactive Oxygen Species)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - OU13V1EYWQ (SB 203580)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Autophagy/*drug effects
MH  - Cardiomyopathies/*drug therapy/pathology/physiopathology
MH  - Cardiotonic Agents/pharmacology/*therapeutic use
MH  - Cell Hypoxia
MH  - Fibroblasts/drug effects/pathology
MH  - Fibrosis/drug therapy/pathology
MH  - Imidazoles/pharmacology
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Pyridines/pharmacology
MH  - Reactive Oxygen Species/metabolism
MH  - p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
PMC - PMC5386311
EDAT- 2017/02/22 06:00
MHDA- 2017/09/25 06:00
CRDT- 2017/02/21 06:00
PHST- 2016/06/29 00:00 [received]
PHST- 2016/11/07 00:00 [accepted]
PHST- 2017/02/22 06:00 [pubmed]
PHST- 2017/09/25 06:00 [medline]
PHST- 2017/02/21 06:00 [entrez]
AID - aps2016143 [pii]
AID - 10.1038/aps.2016.143 [doi]
PST - ppublish
SO  - Acta Pharmacol Sin. 2017 Apr;38(4):488-497. doi: 10.1038/aps.2016.143. Epub 2017 
      Feb 20.

PMID- 24187901
OWN - NLM
STAT- MEDLINE
DCOM- 20131203
LR  - 20190907
IS  - 1028-8880 (Print)
IS  - 1028-8880 (Linking)
VI  - 15
IP  - 10
DP  - 2012 May 15
TI  - A randomized controlled clinical trial investigating the effect of calcium 
      supplement plus low-dose aspirin on hs-CRP, oxidative stress and insulin 
      resistance in pregnant women at risk for pre-eclampsia.
PG  - 469-76
AB  - Increased levels of pro-inflammatory factors, markers of oxidative stress and 
      insulin resistance during pregnancy have been associated with the development of 
      pre-eclampsia. There is some evidence to suggest that calcium supplement and 
      aspirin can reduce the risk of the disorder. To our knowledge, no reports are 
      available indicating the effects of consumed calcium supplement plus aspirin on 
      high sensitivity C-reactive protein (hs-CRP), oxidative stress parameters and 
      insulin resistance in pregnant women at risk for pre-eclampsia. This study was 
      designed to investigate the effects of consumed calcium supplement plus low-dose 
      aspirin on hs-CRP, oxidative stress parameters and insulin resistance among 
      Iranian pregnant women at risk for pre-eclampsia. This randomized single-blind 
      controlled clinical trial was carried out among 42 pregnant women at risk for 
      pre-eclampsia, primigravida, aged 18-40 year old who were carrying singleton 
      pregnancy at their third trimester. Subjects were randomly assigned to received 
      either the placebo (n = 22) or calcium supplement plus low-dose aspirin (n = 20) 
      for 9 weeks. Calcium supplement plus low-dose aspirin were containing 500 mg 
      carbonate calcium plus 80 mg aspirin. Fasting blood samples were taken at 
      baseline and after 9 weeks intervention to measure serum hs-CRP, oxidative stress 
      parameters including plasma Total Antioxidant Capacity (TAC) and Total 
      Glutathione (GSH), Fasting Plasma Glucose (FPG), serum insulin and HOMA-IR score. 
      Consumption of calcium supplement plus low-dose aspirin resulted in a significant 
      difference serum hs-CRP levels as compared to the placebo (102.87 vs. 3227.75 ng 
      mL(-1), p = 0.01). Also, mean changes for plasma TAC (68.96 vs. -74.46 mmol 
      L(-1), p = 0.04) and total GSH levels (304.33 vs. -39.33 micromol L(-1), p = 
      0.03) were significantly different between the two groups. No significant 
      differences were found comparing calcium supplement plus low-dose aspirin and 
      placebo in terms of their effects on FPG, serum insulin levels and HOMA-IR. 
      Within-group differences in the placebo group revealed a significant increase in 
      serum hs-CRP levels (3227.75 ng mL(-1), p = 0.008) and marginally significant 
      increase in plasma total GSH levels (304.33 micromol L(-1), p = 0.07). In 
      conclusion, consumption calcium supplement plus low-dose aspirin during pregnancy 
      for 9 weeks in pregnant women at risk for pre-eclampsia resulted in a significant 
      difference serum hs-CRP and increased levels of plasma TAC and total GSH as 
      compared to the placebo group, but could not affect serum insulin levels and 
      HOMA-IR score.
FAU - Asemi, Z
AU  - Asemi Z
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, School of 
      Medicine, Kashan University of Medical Sciences, Kashan, Iran.
FAU - Samimi, M
AU  - Samimi M
FAU - Heidarzadeh, Z
AU  - Heidarzadeh Z
FAU - Khorrammian, H
AU  - Khorrammian H
FAU - Tabassi, Z
AU  - Tabassi Z
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Pakistan
TA  - Pak J Biol Sci
JT  - Pakistan journal of biological sciences : PJBS
JID - 101247723
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Glucose/analysis
MH  - C-Reactive Protein/*analysis
MH  - Calcium/administration & dosage/*pharmacology
MH  - *Dietary Supplements
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Glutathione/blood
MH  - Humans
MH  - Insulin/blood
MH  - *Insulin Resistance
MH  - Iran
MH  - Oxidative Stress/*drug effects
MH  - Pre-Eclampsia/*metabolism
MH  - Pregnancy
MH  - Risk Factors
EDAT- 2012/05/15 00:00
MHDA- 2013/12/16 06:00
CRDT- 2013/11/06 06:00
PHST- 2013/11/06 06:00 [entrez]
PHST- 2012/05/15 00:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 10.3923/pjbs.2012.469.476 [doi]
PST - ppublish
SO  - Pak J Biol Sci. 2012 May 15;15(10):469-76. doi: 10.3923/pjbs.2012.469.476.

PMID- 2104767
OWN - NLM
STAT- MEDLINE
DCOM- 19900222
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 75
IP  - 2
DP  - 1990 Jan 15
TI  - Platelet aggregation in flowing blood at a site of injury to an endothelial cell 
      monolayer: quantitation and real-time imaging with the TAB monoclonal antibody.
PG  - 390-8
AB  - Epifluorescence videomicroscopy permits real-time imaging of platelet 
      adhesion/aggregation to a defined microinjury of a monolayer of endothelial cells 
      exposed to flowing blood. The fluorescent label is the TAB murine monoclonal 
      antibody directed against human platelet GP IIB, together with a 
      fluorescein-conjugated goat F(ab')2 against murine immunoglobulin. The 
      combination assures specificity for platelet membranes, yet leaves platelet 
      function intact. TAB is first added to gently mixed, citrated human blood; the 
      second antibody is added 1 hour after the first, mixing continuing for a second 
      hour. Bovine aortic endothelial cell monolayers (ECMs), grown on rectangular 
      cover glasses precoated with microfibrillar collagen, comprise one wall of a flow 
      chamber mounted on a vertical microscope stage. A loop of 6-0 sterile suture is 
      drawn across the ECM in order to create microinjuries of width 70 +/- 15 microns 
      (mean +/- SD) oriented in a direction transverse to flow. Platelet 
      adhesion/aggregation is virtually absent on intact and confluent regions of the 
      monolayer. On micro-injury sites and at shear rates of 60 to 1,080 sec-1, 
      however, computer-enhanced images obtained by means of videomicroscopy show 
      arrival and adherence of single platelets resulting in the formation of platelet 
      aggregates elongated in the flow direction. When the monolayers are pretreated 
      with 1.0 mmol/L lysine acetylsalicylate, the mean aggregate thickness increases 
      (2P less than .05) to 260 +/- 58% (mean +/- SE, N = 6) of control, aggregates are 
      regularly shed downstream, and the surface area of the injury site covered by 
      platelets is augmented (2P less than .05) from 14.8 +/- 3.9% to 49.2 +/- 4.7% 
      (mean +/- SE, N = 6). Donor ingestion of aspirin, on the other hand, leads to an 
      increase (2P less than .01) in percent surface coverage to 42.7 +/- 8.5 without a 
      concomitant increase in mean aggregate thickness. In parallel with the above, 
      outflow levels of serum thromboxane and prostacyclin are measured by 
      radioimmunoassays (RIAs) for thromboxane B2 and 6-Keto-PGF1 alpha, respectively. 
      Thromboxane B2 is increased (2P less than .01) by monolayer pretreatment with 
      lysine acetylsalicylate from 5.08 +/- 1.47 to 9.35 +/- 2.42, but decreased (2P 
      less than .05) after oral aspirin to 1.21 +/- 0.38 ng/mL (mean +/- SE, N = 6). 
      Levels of 6-Keto-PGF1 alpha were reduced (2P less than .05) by monolayer 
      pretreatment from 0.48 +/- 0.046 to 0.36 +/- 0.016 ng/mL. Platelet 
      adhesion/aggregation at a site of injury to an endothelial cell monolayer, 
      therefore, can be imaged in flowing blood in real time using a monoclonal 
      antibody approach.(ABSTRACT TRUNCATED AT 400 WORDS)
FAU - Grabowski, E F
AU  - Grabowski EF
AD  - Department of Pediatrics, Cornell University Medical Center, New York, New York 
      10021.
LA  - eng
GR  - HL33095/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Platelet Membrane Glycoproteins)
RN  - 54397-85-2 (Thromboxane B2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/immunology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cattle
MH  - Endothelium, Vascular/*physiology
MH  - Epoprostenol/metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Lysine/analogs & derivatives/pharmacology
MH  - *Platelet Adhesiveness
MH  - *Platelet Aggregation
MH  - Platelet Membrane Glycoproteins/immunology
MH  - Rheology
MH  - Stress, Mechanical
MH  - Thromboxane B2/metabolism
MH  - Video Recording
EDAT- 1990/01/15 00:00
MHDA- 1990/01/15 00:01
CRDT- 1990/01/15 00:00
PHST- 1990/01/15 00:00 [pubmed]
PHST- 1990/01/15 00:01 [medline]
PHST- 1990/01/15 00:00 [entrez]
AID - S0006-4971(20)85786-3 [pii]
PST - ppublish
SO  - Blood. 1990 Jan 15;75(2):390-8.

PMID- 19410194
OWN - NLM
STAT- MEDLINE
DCOM- 20090518
LR  - 20220225
IS  - 1474-5488 (Electronic)
IS  - 1470-2045 (Linking)
VI  - 10
IP  - 5
DP  - 2009 May
TI  - Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an 
      international consensus statement.
PG  - 501-7
LID - 10.1016/S1470-2045(09)70035-X [doi]
AB  - Evidence clearly shows a chemopreventive effect for aspirin and other 
      non-steroidal anti-inflammatory drugs (NSAIDs) on colorectal cancer and probably 
      other cancer types; however, data on the risk-benefit profile for cancer 
      prevention are insufficient and no definitive recommendations can be made. 
      Aspirin has emerged as the most likely NSAID for use in chemoprevention because 
      of its known cardiovascular benefit and available safety and efficacy data. Other 
      traditional NSAIDs, particularly sulindac, and selective COX-2 inhibitors are now 
      given to patients at high risk of colorectal cancer, although these drugs do not 
      provide cardioprotection. More studies of aspirin and cancer prevention are 
      needed to define the lowest effective dose, the age at which to initiate therapy, 
      the optimum treatment duration, and the subpopulations for which the benefits of 
      chemoprevention outweigh the risks of adverse side-effects. Although it might be 
      possible to answer some of these questions with longer follow-up of existing 
      clinical trials, randomised controlled trials with new study designs will be 
      needed. Future projects should investigate the effects of aspirin treatment on 
      multiple organ systems. Cancers of interest are colorectal, breast, prostate, 
      lung, stomach, and oesophageal. The main side-effect of aspirin is peptic ulcers; 
      therefore coadministration of aspirin with a proton-pump inhibitor is an 
      attractive option and is under investigation in the AspECT trial.
FAU - Cuzick, Jack
AU  - Cuzick J
AD  - Cancer Research UK Centre for Epidemiology, Mathematics, and Statistics, Queen 
      Mary University of London, London UK. j.cuzick@qmul.ac.uk
FAU - Otto, Florian
AU  - Otto F
FAU - Baron, John A
AU  - Baron JA
FAU - Brown, Powel H
AU  - Brown PH
FAU - Burn, John
AU  - Burn J
FAU - Greenwald, Peter
AU  - Greenwald P
FAU - Jankowski, Janusz
AU  - Jankowski J
FAU - La Vecchia, Carlo
AU  - La Vecchia C
FAU - Meyskens, Frank
AU  - Meyskens F
FAU - Senn, Hans Jörg
AU  - Senn HJ
FAU - Thun, Michael
AU  - Thun M
LA  - eng
GR  - G0100496/MRC_/Medical Research Council/United Kingdom
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Review
PL  - England
TA  - Lancet Oncol
JT  - The Lancet. Oncology
JID - 100957246
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Breast Neoplasms/prevention & control
MH  - Colorectal Neoplasms/prevention & control
MH  - Digestive System Neoplasms/prevention & control
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/prevention & control
MH  - Neoplasms/*prevention & control
MH  - Ovarian Neoplasms/prevention & control
MH  - Risk
RF  - 66
EDAT- 2009/05/05 09:00
MHDA- 2009/05/19 09:00
CRDT- 2009/05/05 09:00
PHST- 2009/05/05 09:00 [entrez]
PHST- 2009/05/05 09:00 [pubmed]
PHST- 2009/05/19 09:00 [medline]
AID - S1470-2045(09)70035-X [pii]
AID - 10.1016/S1470-2045(09)70035-X [doi]
PST - ppublish
SO  - Lancet Oncol. 2009 May;10(5):501-7. doi: 10.1016/S1470-2045(09)70035-X.

PMID- 16914369
OWN - NLM
STAT- MEDLINE
DCOM- 20070508
LR  - 20181201
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 9
IP  - 2
DP  - 2007 Feb
TI  - Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in 
      patients with heart failure receiving ACE inhibitors.
PG  - 197-201
AB  - BACKGROUND: By inhibiting prostaglandins, aspirin may be deleterious in heart 
      failure (HF) and/or may counteract angiotensin-converting enzyme (ACE) inhibitor 
      efficacy. Conversely, clopidogrel has no effect on prostaglandin metabolism. AIM: 
      To investigate the effect of aspirin and clopidogrel on brain natriuretic peptide 
      (BNP) levels in HF patients treated with ACE inhibitors. METHODS: 36 patients 
      with stable HF (65+/-13 years, 24 males/12 females, NYHA class II to IV, ejection 
      fraction <40%, 13 with coronary disease, all treated with ACE inhibitors) were 
      enrolled in this prospective, double-blind study and randomised to aspirin 325 
      mg/day or clopidogrel 75 mg/day for 14 days. BNP was determined at day 0 and day 
      14. RESULTS: 19 patients were randomised to aspirin and 17 to clopidogrel. 
      Baseline characteristics were similar in both groups. BNP levels increased in the 
      aspirin group from day 0 to day 14 (107+/-103 to 144+/-149 pg/ml, p=0.04) whereas 
      clopidogrel had no effect (104+/-107 and 97+/-99 pg/ml respectively, p=0.61). 
      CONCLUSION: This study demonstrates an adverse effect of aspirin 325 mg/day on 
      BNP plasma levels in HF patients treated with ACE inhibitors. In contrast 
      clopidogrel 75 mg/day had no effect.
FAU - Meune, Christophe
AU  - Meune C
AD  - Department of Cardiology, Cochin Hospital, Paris, France. 
      christophe.meune@cch.ap-hop-paris.fr
FAU - Wahbi, Karim
AU  - Wahbi K
FAU - Fulla, Yvonne
AU  - Fulla Y
FAU - Cohen-Solal, Alain
AU  - Cohen-Solal A
FAU - Duboc, Denis
AU  - Duboc D
FAU - Mahé, Isabelle
AU  - Mahé I
FAU - Simoneau, Guy
AU  - Simoneau G
FAU - Bergmann, Jean-François
AU  - Bergmann JF
FAU - Weber, Simon
AU  - Weber S
FAU - Mouly, Stéphane
AU  - Mouly S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20060817
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Angiotensins)
RN  - 0 (Prostaglandins)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Angiotensins/drug effects
MH  - Aspirin/adverse effects/*pharmacology
MH  - Clopidogrel
MH  - Female
MH  - Heart Failure/*blood/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood/drug effects
MH  - Prostaglandins
MH  - Ticlopidine/*analogs & derivatives/pharmacology
EDAT- 2006/08/18 09:00
MHDA- 2007/05/09 09:00
CRDT- 2006/08/18 09:00
PHST- 2005/06/30 00:00 [received]
PHST- 2006/01/18 00:00 [revised]
PHST- 2006/06/12 00:00 [accepted]
PHST- 2006/08/18 09:00 [pubmed]
PHST- 2007/05/09 09:00 [medline]
PHST- 2006/08/18 09:00 [entrez]
AID - S1388-9842(06)00185-1 [pii]
AID - 10.1016/j.ejheart.2006.06.003 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2007 Feb;9(2):197-201. doi: 10.1016/j.ejheart.2006.06.003. Epub 
      2006 Aug 17.

PMID- 18205662
OWN - NLM
STAT- MEDLINE
DCOM- 20080225
LR  - 20131121
IS  - 1523-5378 (Electronic)
IS  - 1083-4389 (Linking)
VI  - 13
IP  - 1
DP  - 2008 Feb
TI  - Effects of aspirin on the development of Helicobacter pylori-induced gastric 
      inflammation and heterotopic proliferative glands in Mongolian gerbils.
PG  - 20-9
LID - 10.1111/j.1523-5378.2008.00585.x [doi]
AB  - BACKGROUND: Helicobacter pylori infection is a major cause of gastritis and 
      gastric carcinoma. Aspirin has anti-inflammatory and antineoplastic activity. The 
      aim of the present study was to determine the effects of aspirin on H. 
      pylori-induced gastritis and the development of heterotopic proliferative glands. 
      METHODS: H. pylori strain SS1 was inoculated into the stomachs of Mongolian 
      gerbils. Two weeks after inoculation, the animals were fed with the powder diets 
      containing 0 p.p.m. (n = 10), 150 p.p.m. (n = 10), or 500 p.p.m. (n = 10) 
      aspirin. Mongolian gerbils were killed after 36 weeks of infection. Uninfected 
      Mongolian gerbils (n = 10) were used as controls. Histologic changes, epithelial 
      cell proliferation and apoptosis, and prostaglandin E(2) (PGE(2)) levels of 
      gastric tissue were determined. RESULTS: H. pylori infection induced gastric 
      inflammation. Administration of aspirin did not change H. pylori-induced 
      gastritis, but alleviated H. pylori-induced hyperplasia and the development of 
      heterotopic proliferative glands. Administration of aspirin accelerated H. 
      pylori-associated apoptosis but decreased H. pylori-associated cell 
      proliferation. In addition, the increased gastric PGE(2) levels due to H. pylori 
      infection were suppressed by treatment with aspirin, especially at the dose of 
      500 p.p.m. CONCLUSIONS: Aspirin alleviates H. pylori-induced hyperplasia and the 
      development of heterotopic proliferative glands. Moreover, aspirin increases H. 
      pylori-induced apoptosis. We demonstrated the antineoplastic activities of 
      aspirin in H. pylori-related gastric carcinogenesis.
FAU - Li, Guo Qing
AU  - Li GQ
AD  - Department of Medicine, The First Affiliated Hospital of Sun Yat-Sen University, 
      Guangzhou, China.
FAU - Xia, Harry H X
AU  - Xia HH
FAU - Chen, Min Hu
AU  - Chen MH
FAU - Tsukamoto, Tetsuya
AU  - Tsukamoto T
FAU - Tatematsu, Masae
AU  - Tatematsu M
FAU - Gu, Qing
AU  - Gu Q
FAU - Qiao, Liang
AU  - Qiao L
FAU - Cho, C H
AU  - Cho CH
FAU - So, Wallace H L
AU  - So WH
FAU - Yuen, M F
AU  - Yuen MF
FAU - Hu, Pin Jin
AU  - Hu PJ
FAU - Liang, Ying Jie
AU  - Liang YJ
FAU - Lin, Han Liang
AU  - Lin HL
FAU - Chan, Annie O O
AU  - Chan AO
FAU - Wong, Benjamin C Y
AU  - Wong BC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (Anti-Inflammatory Agents)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/administration & dosage/*pharmacology
MH  - Apoptosis
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Choristoma/pathology/*prevention & control
MH  - Dinoprostone/analysis
MH  - Epithelial Cells/pathology
MH  - Gastric Mucosa/chemistry/*drug effects/pathology
MH  - Gerbillinae
MH  - Helicobacter Infections/microbiology/*pathology
MH  - Helicobacter pylori/*physiology
MH  - Hyperplasia/prevention & control
MH  - Inflammation/pathology/*prevention & control
MH  - Male
EDAT- 2008/01/22 09:00
MHDA- 2008/02/26 09:00
CRDT- 2008/01/22 09:00
PHST- 2008/01/22 09:00 [pubmed]
PHST- 2008/02/26 09:00 [medline]
PHST- 2008/01/22 09:00 [entrez]
AID - HEL585 [pii]
AID - 10.1111/j.1523-5378.2008.00585.x [doi]
PST - ppublish
SO  - Helicobacter. 2008 Feb;13(1):20-9. doi: 10.1111/j.1523-5378.2008.00585.x.

PMID- 31261711
OWN - NLM
STAT- MEDLINE
DCOM- 20191206
LR  - 20200225
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 20
IP  - 13
DP  - 2019 Jun 28
TI  - Cellular Metabolomics Reveal the Mechanism Underlying the Anti-Atherosclerotic 
      Effects of Aspirin Eugenol Ester on Vascular Endothelial Dysfunction.
LID - 10.3390/ijms20133165 [doi]
LID - 3165
AB  - Aspirin eugenol ester (AEE) possesses anti-thrombotic, anti-atherosclerotic and 
      anti-oxidative effects. The study aims to clarify the mechanism underlying the 
      anti-atherosclerotic effects of AEE on vascular endothelial dysfunction. Both the 
      high-fat diet (HFD)-induced atherosclerotic rat model and the H(2)O(2)-induced 
      human umbilical vein endothelial cells (HUVECs) model were used to investigate 
      the effects of AEE on vascular endothelial dysfunction. UPLC/QTOF-MS coupled with 
      a multivariate data analysis method were used to profile the variations in the 
      metabolites of HUVECs in response to different treatments. Pretreatment of HUVECs 
      with AEE significantly ameliorated H(2)O(2)-induced apoptosis, the overexpression 
      of E-selectin and VCAM-1, and the adhesion of THP-1 cells. Putative endogenous 
      biomarkers associated with the inhibition of endothelial dysfunction were 
      identified in HUVECs pretreated with AEE in the absence or presence of H(2)O(2), 
      and these biomarkers were involved in important metabolic pathways, including 
      amino acid metabolism, carbohydrate metabolism, and glutathione metabolism. 
      Moreover, in vivo, AEE also significantly reduced vascular endothelial 
      dysfunction and decreased the overexpression of VCAM-1 and E-selectin. Based on 
      our findings, the mechanism underlying the anti-atherosclerotic effects of AEE 
      might be related to a reduction in vascular endothelial dysfunction mediated by 
      ameliorating alterations in metabolism, inhibiting oxidative stress, and 
      decreasing the expression of adhesion molecules.
FAU - Huang, Mei-Zhou
AU  - Huang MZ
AUID- ORCID: 0000-0003-2538-0217
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China.
FAU - Lu, Xiao-Rong
AU  - Lu XR
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China.
FAU - Yang, Ya-Jun
AU  - Yang YJ
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China.
FAU - Liu, Xi-Wang
AU  - Liu XW
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China.
FAU - Qin, Zhe
AU  - Qin Z
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China.
FAU - Li, Jian-Yong
AU  - Li JY
AUID- ORCID: 0000-0003-3317-0666
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China. 
      lijy1971@163.com.
LA  - eng
GR  - 31572573 and 31872518/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20190628
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (E-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Apoptosis
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Cell Line
MH  - Cells, Cultured
MH  - Diet, High-Fat/adverse effects
MH  - E-Selectin/metabolism
MH  - Endothelium, Vascular/*drug effects/metabolism
MH  - Eugenol/*analogs & derivatives/pharmacology/therapeutic use
MH  - Human Umbilical Vein Endothelial Cells/drug effects/metabolism
MH  - Humans
MH  - Male
MH  - Metabolome
MH  - Plaque, Atherosclerotic/*drug therapy
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Vascular Cell Adhesion Molecule-1/metabolism
PMC - PMC6651823
OTO - NOTNLM
OT  - aspirin eugenol ester
OT  - cell metabolomics
OT  - vascular endothelium
COIS- The authors declare no conflict of interest.
EDAT- 2019/07/03 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/07/03 06:00
PHST- 2019/06/18 00:00 [received]
PHST- 2019/06/26 00:00 [accepted]
PHST- 2019/07/03 06:00 [entrez]
PHST- 2019/07/03 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
AID - ijms20133165 [pii]
AID - ijms-20-03165 [pii]
AID - 10.3390/ijms20133165 [doi]
PST - epublish
SO  - Int J Mol Sci. 2019 Jun 28;20(13):3165. doi: 10.3390/ijms20133165.

PMID- 22871195
OWN - NLM
STAT- MEDLINE
DCOM- 20121218
LR  - 20131121
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 8
IP  - 4
DP  - 2012 Jul
TI  - Aspirin sensitivity and coronary artery disease: implications for the practicing 
      cardiologist.
PG  - 555-62
LID - 10.2217/fca.12.38 [doi]
AB  - Aspirin is the most commonly used antiplatelet agent in patients with coronary 
      artery disease (CAD). It continues to play a key role as an antiplatelet agent 
      given its long-term safety, efficacy and low cost. Aspirin or NSAID 
      hypersensitivity is not an uncommon occurrence and can vary from generalized 
      urticaria and angioedema to exacerbation of upper and lower respiratory tract 
      reactions. It is not uncommon for clinicians to avoid using aspirin and 
      alternative agents when encountering aspirin hypersensitivity among CAD patients. 
      However, given the critical role of aspirin in CAD patients, particularly among 
      those who receive the drug-eluting stents, aspirin desensitization can be useful. 
      This article highlights the importance of aspirin desensitization, the mechanism 
      and the process involved. We draw attention to recently described rapid 
      desensitization protocols and how they can be more useful than the old procedure.
FAU - Pattanaik, Debendra
AU  - Pattanaik D
AD  - Department of Medicine, Division of Allergy & Immunology, University of Tennessee 
      Health Science Center, 956 Court Avenue, Memphis, TN, USA.
FAU - Lieberman, Phil
AU  - Lieberman P
FAU - Das, Pranab
AU  - Das P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/adverse effects/*immunology
MH  - Asthma/chemically induced
MH  - Chronic Disease
MH  - Coronary Artery Disease/*drug therapy/prevention & control
MH  - Cyclooxygenase Inhibitors/administration & dosage/adverse effects/*immunology
MH  - Desensitization, Immunologic/methods
MH  - Drug Hypersensitivity/classification/prevention & control
MH  - Graft Occlusion, Vascular/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors
MH  - Stents
MH  - Urticaria/chemically induced
EDAT- 2012/08/09 06:00
MHDA- 2012/12/19 06:00
CRDT- 2012/08/09 06:00
PHST- 2012/08/09 06:00 [entrez]
PHST- 2012/08/09 06:00 [pubmed]
PHST- 2012/12/19 06:00 [medline]
AID - 10.2217/fca.12.38 [doi]
PST - ppublish
SO  - Future Cardiol. 2012 Jul;8(4):555-62. doi: 10.2217/fca.12.38.

PMID- 3463186
OWN - NLM
STAT- MEDLINE
DCOM- 19861007
LR  - 20151119
IS  - 0379-0363 (Print)
IS  - 0379-0363 (Linking)
VI  - 19
DP  - 1986
TI  - Pyrazolones in the treatment of postoperative pain.
PG  - 331-7
AB  - The aim pursued in postoperative analgesia is to mobilize patients, to prevent 
      thrombo-embolism, to improve subjective well-being, and to reduce the stress 
      reaction caused by pain. In sufficiently high doses, metamizol is equally as 
      suitable for the treatment of postoperative traumatic pain as are opioids. 
      Comparative studies provide evidence that metamizol is no less potent in its 
      action than pethidine, and that in cases of pain in the head and neck region it 
      is superior to buprenorphine in its usual dose. It can also be used to supplement 
      opioid medication where this does not produce satisfactory analgesia. In patients 
      with a history of drug abuse, metamizol is in fact the drug of choice for 
      immediate postoperative analgesic treatment.
FAU - Hempel, V
AU  - Hempel V
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions Suppl
JT  - Agents and actions. Supplements
JID - 7801014
RN  - 01704YP3MO (Aminopyrine)
RN  - 6429L0L52Y (Dipyrone)
RN  - 8008-60-4 (Opium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aminopyrine/*analogs & derivatives
MH  - Aspirin/therapeutic use
MH  - Dipyrone/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Opium/therapeutic use
MH  - Pain, Postoperative/*drug therapy
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Agents Actions Suppl. 1986;19:331-7.

PMID- 848356
OWN - NLM
STAT- MEDLINE
DCOM- 19770520
LR  - 20131121
IS  - 0001-6101 (Print)
IS  - 0001-6101 (Linking)
VI  - 201
IP  - 3
DP  - 1977
TI  - Leucocyte migration inhibitory activity of concanavalin-A-stimulated lymphocytes. 
      In vivo and in vitro modifications with dipyridamole and acetylsalicylic acid.
PG  - 197-201
AB  - Lymphocytes from 14 patients treated with a combination of acetylsalicylic acid 
      (ASA) and dipyridamole (DIPY) showed a decreased ability to produce leucocyte 
      migration inhibitory activity (LMIA) when stimulated with concanavalin-A (ConA). 
      The combined treatment also produced a decrease of leucocyte response to a 
      standard LMIA-containing culture supernatant. Treatment with only one of the two 
      drugs did not cause detectable alteration of the lymphocyte response to Con-A or 
      the leucocyte response to LMIA. In vitro, both DIPY and ASA were independently 
      effective in decreasing the LMIA production of Con-A-stimulated lymphocytes and 
      the leucocyte response to a standard LMIA-containing culture supernatant.
FAU - Coeugniet, E
AU  - Coeugniet E
FAU - Bendtzen, K
AU  - Bendtzen K
FAU - Soeberg, B
AU  - Soeberg B
FAU - Bendixen, G
AU  - Bendixen G
LA  - eng
PT  - Journal Article
PL  - Sweden
TA  - Acta Med Scand
JT  - Acta medica Scandinavica
JID - 0370330
RN  - 11028-71-0 (Concanavalin A)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - *Cell Migration Inhibition
MH  - Concanavalin A/*pharmacology
MH  - Dipyridamole/*pharmacology
MH  - Female
MH  - Humans
MH  - Lymphocytes/*immunology
MH  - Male
MH  - Time Factors
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Med Scand. 1977;201(3):197-201.

PMID- 32830272
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 59
IP  - 12
DP  - 2020 Dec 1
TI  - The role of aspirin in the primary prevention of accelerated atherosclerosis in 
      systemic autoimmune rheumatic diseases.
PG  - 3593-3602
LID - 10.1093/rheumatology/keaa335 [doi]
AB  - Aspirin is the most commonly used medication worldwide. Beside its well-known 
      anti-inflammatory effects, a role has emerged in the prevention of cardiovascular 
      events. However, a significant benefit has been demonstrated in secondary 
      cardiovascular prevention only, while there is limited evidence supporting a role 
      in primary prevention. This discrepancy might depend on the that so far, the 
      high-risk populations that will achieve the greatest benefits yet experiencing 
      minimal harmful side effects have not been identified. Patients with autoimmune 
      systemic rheumatic diseases have an increased risk of cardiovascular 
      complications compared with the general population, which makes aspirin of 
      potential value in these subjects. Moving from general aspects of aspirin 
      pharmacology and specific issues in general population, the aim of this study is 
      to review the evidence about the role of low-dose aspirin in primary 
      cardiovascular prevention in autoimmune systemic rheumatic diseases.
CI  - © The Author(s) 2020. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology. All rights reserved. For permissions, please 
      email: journals.permissions@oup.com.
FAU - Fasano, Serena
AU  - Fasano S
AD  - Rheumatology Unit, University of Campania 'Luigi Vanvitelli', Naples, Italy.
FAU - Iacono, Daniela
AU  - Iacono D
AD  - Rheumatology Unit, University of Campania 'Luigi Vanvitelli', Naples, Italy.
FAU - Riccardi, Antonella
AU  - Riccardi A
AD  - Rheumatology Unit, University of Campania 'Luigi Vanvitelli', Naples, Italy.
FAU - Ciccia, Francesco
AU  - Ciccia F
AD  - Rheumatology Unit, University of Campania 'Luigi Vanvitelli', Naples, Italy.
FAU - Valentini, Gabriele
AU  - Valentini G
AD  - Rheumatology Unit, University of Campania 'Luigi Vanvitelli', Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atherosclerosis/*etiology/*prevention & control
MH  - Autoimmune Diseases/*complications
MH  - Disease Progression
MH  - Humans
MH  - *Primary Prevention
MH  - Rheumatic Diseases/*complications
MH  - Time Factors
OTO - NOTNLM
OT  - cardiovascular prevention
OT  - low-dose acetylsalicylic acid
OT  - systemic autoimmune rheumatic diseases
EDAT- 2020/08/25 06:00
MHDA- 2021/01/29 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/05/17 00:00 [revised]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 5896263 [pii]
AID - 10.1093/rheumatology/keaa335 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2020 Dec 1;59(12):3593-3602. doi: 
      10.1093/rheumatology/keaa335.

PMID- 2935327
OWN - NLM
STAT- MEDLINE
DCOM- 19860306
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 73
IP  - 2
DP  - 1986 Feb
TI  - Reduction of indium-111 platelet deposition on Dacron vascular grafts in humans 
      by aspirin plus dipyridamole.
PG  - 325-30
AB  - Aspirin plus dipyridamole reduces platelet accumulation on short-term Dacron 
      vascular grafts in man. To determine whether drug inhibition of platelet 
      deposition is sustained on older grafts, we studied 18 men aged 41 to 87 years 
      who had Dacron aortic bifurcation grafts in place a mean of 43.4 months (range 
      9.8 to 121.0) before and during short-term therapy with aspirin (325 mg tid) plus 
      dipyridamole (75 mg tid). During both the baseline and drug studies, indium-111 
      (111In) platelet deposition was quantitated by two techniques, standard planar 
      imaging performed at 24, 48, and 72 hr after injection of platelets and single 
      photon emission computed tomographic imaging performed at 24 and 72 hr after 
      injection. All analyses were performed in a blinded fashion. On both the planar 
      and tomographic images, platelet accumulation on the graft was quantitated by a 
      graft/blood ratio that compared activity in the graft to simultaneously collected 
      whole blood 111In platelet activity. Aspirin plus dipyridamole reduced the 
      tomographic graft/blood ratio at 24 hr (20.6 +/- 3.5 vs 17.3 +/- 2.5) (+/-SEM) 
      and at 72 hr (29.0 +/- 4.8 vs 25.0 +/- 4.1) after injection of platelets (p = 
      .02). Dacron vascular grafts. Similarly, the planar graft/blood ratio was reduced 
      at 24 hr (2.7 +/- 0.5 vs 2.4 +/- 0.5), 48 hr (3.7 +/- 0.9 vs 3.1 +/- 0.7), and 72 
      hr (4.0 +/- 0.9 vs 3.6 +/- 0.8) (p = .04). We conclude that aspirin (325 mg tid) 
      plus dipyridamole (75 mg tid) reduces platelet accumulation on long-term Dacron 
      vascular grafts.
FAU - Stratton, J R
AU  - Stratton JR
FAU - Ritchie, J L
AU  - Ritchie JL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Polyethylene Terephthalates)
RN  - 0 (Radioisotopes)
RN  - 045A6V3VFX (Indium)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*physiopathology
MH  - Dipyridamole/*therapeutic use
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Indium
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Terephthalates
MH  - Radioisotopes
MH  - Tomography, Emission-Computed
EDAT- 1986/02/01 00:00
MHDA- 1986/02/01 00:01
CRDT- 1986/02/01 00:00
PHST- 1986/02/01 00:00 [pubmed]
PHST- 1986/02/01 00:01 [medline]
PHST- 1986/02/01 00:00 [entrez]
AID - 10.1161/01.cir.73.2.325 [doi]
PST - ppublish
SO  - Circulation. 1986 Feb;73(2):325-30. doi: 10.1161/01.cir.73.2.325.

PMID- 8951777
OWN - NLM
STAT- MEDLINE
DCOM- 19970320
LR  - 20190116
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 22 Suppl 1
DP  - 1996 Sep
TI  - Aspirin in polycythemia vera and essential thrombocythemia: current facts and 
      perspectives.
PG  - 83-6
AB  - The role of aspirin in the antithrombotic strategy of patients with polycythemia 
      vera (PV) and essential thrombocythemia (ET) is highly controversial. Long 
      considered unsafe on the basis of a single clinical trial testing very high doses 
      in PV patients, aspirin is being increasingly used at lower dosage. The rationale 
      for the use of aspirin in patients with PV and ET is provided by the efficacy of 
      this agent in the treatment of microcirculatory disturbances of thrombocythemic 
      states associated with myeloproliferative disorders and by recent evidence that 
      asymptomatic PV and ET patients have persistently increased thromboxane (TX) 
      A2-biosynthesis. This increase, which most likely reflects enhanced platelet 
      activation in vivo, is independent of the platelet mass and blood viscosity and 
      largely supressed by a short term low-dose aspirin regimen (50 mg/day for 7 
      days). Since enhanced TXA2 biosynthesis may play a role in transducing the 
      increased thrombotic risk associated with PV and ET, long-term low-dose aspirin 
      administration has been proposed as a possible antithombotic strategy in these 
      subjects. The safety of this treatment in PV patients has been recently 
      reassessed by the Gruppo Italiano per lo Studio della Policitemia Vera (GISP) 
      which has followed for over one year 112 patients randomized to receive 40 mg/day 
      aspirin or placebo. In the same study, serum TXB2 measurements provided evidence 
      that the low-dose aspirin regimen tested was fully effective in inhibiting 
      platelet cyclooxygenase activity. On this basis, a large scale trial aimed at 
      assessing the antithrombotic efficacy of this approach is currently being 
      organized. In patients with ET both the minimal aspirin dose required for 
      complete inhibition of platelet cyclooxygenase and the safety of long-term 
      aspirin administration need to be established prior to extensive clinical 
      evaluation of this strategy.
FAU - Landolfi, R
AU  - Landolfi R
AD  - Department of Internal Medicine, Catholic University School of Medicine, Rome, 
      Italy.
FAU - Patrono, C
AU  - Patrono C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Review
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Cyclooxygenase Inhibitors/administration & dosage/pharmacology/*therapeutic use
MH  - Erythromelalgia/drug therapy/etiology
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Polycythemia Vera/*drug therapy
MH  - Thrombocythemia, Essential/complications/*drug therapy
MH  - Thromboxane A2/biosynthesis
RF  - 22
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - 10.3109/10428199609074365 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 1996 Sep;22 Suppl 1:83-6. doi: 10.3109/10428199609074365.

PMID- 3552295
OWN - NLM
STAT- MEDLINE
DCOM- 19870601
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 75
IP  - 5
DP  - 1987 May
TI  - Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at 
      the site of plug formation in man in vivo.
PG  - 1025-9
AB  - In a double-blind placebo-controlled crossover study, we investigated in seven 
      healthy male volunteers the effect of a low-dose aspirin regimen (35 mg 
      acetylsalicylate per day for 7 days) on the formation of thromboxane A2 (TxA2) 
      and prostacyclin (PGI2) in blood emerging from a standardized injury of the 
      microvasculature made to determine skin bleeding time. When subjects were treated 
      with placebo, there was rapid and substantial generation of TxA2 and PGI2 at the 
      site of platelet-vessel wall interaction within the first 2 min after vascular 
      injury. This was reflected by a greater than 100-fold and greater than 10-fold 
      increase in thromboxane B2 (TxB2) and 6-keto-prostaglandin F1 alpha (6-keto-PGF1 
      alpha) in blood obtained from incisions made to determine bleeding time as 
      compared with the corresponding plasma values. Low-dose aspirin caused a 
      significant inhibition of both TxA2 and PGI2 generation in blood sampled from the 
      skin incisions, represented by a 85% and 92% and 81% and 84% inhibition of TxB2 
      and 6-keto-PGF1 alpha, respectively, as compared with controls. We therefore 
      conclude that rapid activation of both platelet prostaglandin metabolism and 
      vascular PGI2 biosynthesis occurs at the site of platelet-vessel wall 
      interaction, and low-dose aspirin results in a significant inhibition of both 
      platelet and vascular cyclooxygenase activity. Thus, our data fail to confirm the 
      concept of a differential effect of low-dose aspirin on platelet and vascular 
      prostaglandin synthesis in man in vivo.
FAU - Kyrle, P A
AU  - Kyrle PA
FAU - Eichler, H G
AU  - Eichler HG
FAU - Jäger, U
AU  - Jäger U
FAU - Lechner, K
AU  - Lechner K
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/drug effects
MH  - Blood Vessels/drug effects
MH  - Double-Blind Method
MH  - Epoprostenol/*antagonists & inhibitors
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Thrombosis/prevention & control
MH  - Thromboxane A2/*antagonists & inhibitors
MH  - Thromboxane B2/blood
EDAT- 1987/05/01 00:00
MHDA- 1987/05/01 00:01
CRDT- 1987/05/01 00:00
PHST- 1987/05/01 00:00 [pubmed]
PHST- 1987/05/01 00:01 [medline]
PHST- 1987/05/01 00:00 [entrez]
AID - 10.1161/01.cir.75.5.1025 [doi]
PST - ppublish
SO  - Circulation. 1987 May;75(5):1025-9. doi: 10.1161/01.cir.75.5.1025.

PMID- 35664643
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220716
IS  - 1748-6718 (Electronic)
IS  - 1748-670X (Print)
IS  - 1748-670X (Linking)
VI  - 2022
DP  - 2022
TI  - Analysis of Adverse Reactions of Aspirin in Prophylaxis Medication Based on FAERS 
      Database.
PG  - 7882277
LID - 10.1155/2022/7882277 [doi]
LID - 7882277
AB  - OBJECTIVE: As the most commonly used drug in the world, aspirin has shown 
      benefits for myocardial infarction, stroke, and vascular death in many secondary 
      prevention trials and their meta-analysis. The purpose of this study was to 
      evaluate the association between aspirin and its adverse reactions as a 
      preventive drug using the FDA adverse event reporting system (FAERS). METHODS: 
      The FAERS database was queried for the adverse drug events (ADE) reported from 
      the first quarter of 2004 to the second quarter of 2021. We counted and trended 
      reports to FAERS in which aspirin was associated with anaphylaxis or anaphylaxis 
      followed by death. RESULTS: The search retrieved 858 aspirin-associated cases 
      within the reporting period; 108 AE pairs with significant disproportionality 
      were retained. The top 10 AE pairs associated with using aspirin for prophylaxis 
      were melaena, duodenal ulcer, gastritis erosive, gastric ulcer hemorrhage, etc. 
      The top 10 AE pairs for thrombosis prophylaxis were melaena, duodenal ulcer, 
      microcytic anemia, lip erosion, vascular stent thrombosis, etc. The screened 
      adverse event reports are classified and counted according to the system organ 
      class (SOC); it mainly focuses on gastrointestinal disorders, general disorders, 
      and administration site conditions. Among the 858 cases of aspirin used as 
      prophylaxis medication in the FAERS database, the reporting areas were mainly in 
      Europe and the Americas. CONCLUSION: Adverse drug reactions may occur in the 
      clinical use of aspirin. It should strengthen patient medication education, pay 
      close attention to adverse reactions, and adjust the administration method in 
      time to ensure the safety of medication.
CI  - Copyright © 2022 Weidong Ren et al.
FAU - Ren, Weidong
AU  - Ren W
AUID- ORCID: 0000-0003-0600-4697
AD  - Department of Neurosurgery, Mengyin People's Hospital, Linyi City 276200, 
      Shandong Province, China.
FAU - Wang, Weihua
AU  - Wang W
AUID- ORCID: 0000-0002-7051-7887
AD  - Pharmacy Department, Chengyang People's Hospital, Qingdao City 266000, Shandong 
      Province, China.
FAU - Guo, Yanli
AU  - Guo Y
AUID- ORCID: 0000-0002-0866-2725
AD  - Department of Neurology, Jinnan Nanjiao Hospital, Jinan City 250000, Shandong 
      Province, China.
LA  - eng
PT  - Journal Article
DEP - 20220526
PL  - United States
TA  - Comput Math Methods Med
JT  - Computational and mathematical methods in medicine
JID - 101277751
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Adverse Drug Reaction Reporting Systems
MH  - Anaphylaxis/chemically induced/epidemiology
MH  - *Aspirin/adverse effects
MH  - Duodenal Ulcer
MH  - Humans
MH  - Melena
MH  - United States/epidemiology
PMC - PMC9162824
COIS- The authors declare that they have no competing interests.
EDAT- 2022/06/07 06:00
MHDA- 2022/06/09 06:00
CRDT- 2022/06/06 14:17
PHST- 2022/03/17 00:00 [received]
PHST- 2022/03/30 00:00 [revised]
PHST- 2022/03/31 00:00 [accepted]
PHST- 2022/06/06 14:17 [entrez]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
AID - 10.1155/2022/7882277 [doi]
PST - epublish
SO  - Comput Math Methods Med. 2022 May 26;2022:7882277. doi: 10.1155/2022/7882277. 
      eCollection 2022.

PMID- 7002354
OWN - NLM
STAT- MEDLINE
DCOM- 19810226
LR  - 20131121
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 62
IP  - 6 Pt 2
DP  - 1980 Dec
TI  - The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction 
      Study (PARIS) research group.
PG  - V85-8
AB  - The efficacy and safety of a combination of Persantine and aspirin, of aspirin 
      alone and of a placebo as a regimen for preventing reinfarction were compared in 
      2026 patients who had recovered from a documented acute myocardial infarction 
      (MI) that had occurred 8 weeks to 5 years previously. Baseline variables were 
      comparable, and almost all surviving patients were treated for 3 years. There was 
      a trend toward improved survival rates both for the combination and single drug 
      compared with placebo. Coronary incidence was significantly lower in the 
      combination group compared with placebo at each 4-month interval during the first 
      24 months of treatment, whereas significant reductions in the aspirin group 
      occurred only at 8 and 24 months. Gastric and renal side effects were more common 
      in the treated groups. To confirm the above results and the findings that the 
      group of patients enrolled within 6 months of last MI had the largest reduction 
      in mortality in the combination group, another study has been designed to compare 
      the combination with a placebo in a large group of patients.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Placebos)
RN  - 268B43MJ25 (Uric Acid)
RN  - 64ALC7F90C (Dipyridamole)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Blood Urea Nitrogen
MH  - Cerebrovascular Disorders/diagnosis
MH  - Clinical Trials as Topic
MH  - Coronary Disease/mortality
MH  - Creatinine/blood
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Heart Failure/diagnosis
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Placebos
MH  - Random Allocation
MH  - Uric Acid/blood
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
PST - ppublish
SO  - Circulation. 1980 Dec;62(6 Pt 2):V85-8.

PMID- 2281997
OWN - NLM
STAT- MEDLINE
DCOM- 19910312
LR  - 20190828
IS  - 0160-564X (Print)
IS  - 0160-564X (Linking)
VI  - 14
IP  - 6
DP  - 1990 Dec
TI  - Detection of microemboli by constant-pressure filtration during in vitro 
      circulation of bovine and human blood.
PG  - 466-70
AB  - The constant-pressure filtration (CPF) method has been developed to assess blood 
      microemboli (BME) in terms of their ability to occlude microvascular flow. 
      Previous reports suggest that the method is sensitive to the effects of platelet 
      stimulation and to blood-pumping conditions. BME production and heparin activity 
      were studied in bovine and human blood pumped by a Pellethane ventricle with 
      Pellethane molded valves connected via smooth quick-connects to a Pellethane 
      horseshoe-shaped reservoir. In each experiment, blood was collected into heparin 
      by cardiac puncture from a stunned animal or by venepuncture from a human donor. 
      The blood from each donor was filled into three ventricle-reservoir systems (50 
      cc ventricle and 1,500 cc reservoir for the bovine blood, and 20 cc ventricle and 
      150 cc reservoir for the human blood). One of the systems received aspirin (ASA; 
      25 mg/dl) shortly after the onset of pumping, whereas the other two served as 
      pumping and non-pumping controls. The blood was pumped in a full-fill/full-eject 
      mode for up to 10 h. BME concentration was measured by the CPF method in which 
      the blood was filtered through 20-microns pore filters at 20 mm Hg for 10 s, and 
      the flowrate curves were evaluated from occlusion model. Heparin activity was 
      measured by the activated partial thromboplastin time (APTT) test. In the early 
      period after the onset of pumping, the BME concentration increased, whereas the 
      APTT decreased from an initial value of greater than 250 s, with the relative 
      rate of change for both the BME and the APTT being the following: pumping control 
      greater than pumping ASA blood greater than quiescent control.(ABSTRACT TRUNCATED 
      AT 250 WORDS)
FAU - Solen, K A
AU  - Solen KA
AD  - Department of Chemical Engineering, Brigham Young University, Provo, Utah 84602.
FAU - Mohammad, S F
AU  - Mohammad SF
FAU - Pijl, A J
AU  - Pijl AJ
FAU - Swier, P
AU  - Swier P
FAU - Monson, R D
AU  - Monson RD
FAU - Olsen, D B
AU  - Olsen DB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Artif Organs
JT  - Artificial organs
JID - 7802778
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Cattle
MH  - Embolism/*blood
MH  - Filtration/*methods
MH  - *Heart-Assist Devices
MH  - Heparin/blood
MH  - In Vitro Techniques
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
AID - 10.1111/j.1525-1594.1990.tb03005.x [doi]
PST - ppublish
SO  - Artif Organs. 1990 Dec;14(6):466-70. doi: 10.1111/j.1525-1594.1990.tb03005.x.

PMID- 30451948
OWN - NLM
STAT- MEDLINE
DCOM- 20191213
LR  - 20191217
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 8
IP  - 1
DP  - 2018 Nov 19
TI  - Perioperative aspirin and long-term survival in patients undergoing coronary 
      artery bypass graft.
PG  - 17051
LID - 10.1038/s41598-018-35208-7 [doi]
LID - 17051
AB  - This study aimed to examine association between perioperative uses of aspirin and 
      long-term survival in patients undergoing CABG. A retrospective cohort study was 
      performed in 9,584 consecutive patients receiving cardiac surgery from three 
      tertiary hospitals. Of all the patients, 4,132 patients undergoing CABG met 
      inclusion criteria and were divided into four groups: with or without 
      preoperative or postoperative aspirin respectively. 30-day postoperative and 
      long-term mortality were compared with the use of propensity scores and inverse 
      probability weighting adjustment to reduce the treatment-selection bias. The 
      patients taking preoperative aspirin presented significantly more with 
      comorbidities. However, the results of this study showed that preoperative 
      aspirin (vs. no preoperative aspirin) was associated with significantly reduced 
      the risk of 30-day mortality in the patients undergoing CABG. Further, the 
      results of long-term mortality showed that the patients taking preoperative 
      aspirin and postoperative aspirin (vs. not taking) were associated with 
      significantly reduced the risk of 4-year mortality (14.8% vs. 18.1%, RR: 0.82, 
      95% CI: 0.75-0.89, P = 0.005; 10.7% vs. 16.2%, RR: 0.66, 95% CI: 0.50-0.82, 
      P = 0.003). In conclusion, this cohort study showed that perioperative (before 
      and after surgery) use of aspirin was associated with significant reduction in 
      30-day mortality without significant bleeding complications, also improved 
      long-term survival in patients undergoing CABG.
FAU - Ding, Qian
AU  - Ding Q
AD  - Department of Anesthesiology, Thomas Jefferson University, Philadelphia, PA, 
      19107, USA. 250848637@qq.com.
AD  - Anesthesiology and Critical Care, Tangdu Hospital, The Fourth Military Medical 
      University, Xian, 710038, P. R. China. 250848637@qq.com.
FAU - Liu, Hong
AU  - Liu H
AD  - Department of Anesthesiology and Pain Medicine, University of California Davis 
      Medical Center, Sacramento, CA, 95817, USA.
FAU - Zhang, Zugui
AU  - Zhang Z
AD  - Department of Section of Cardiology, Center for Outcomes Research, Christiana 
      Care Health System, Newark, DE, USA.
FAU - Goldhammer, Jordan
AU  - Goldhammer J
AD  - Department of Anesthesiology, Thomas Jefferson University, Philadelphia, PA, 
      19107, USA.
FAU - Yuen, Eric
AU  - Yuen E
AD  - Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 
      19107, USA.
FAU - Li, Zhongmin
AU  - Li Z
AD  - Department of Internal Medicine, University of California Davis Medical Center, 
      Sacramento, CA, 95817, USA.
FAU - Yao, Linong
AU  - Yao L
AD  - Anesthesiology and Critical Care, Tangdu Hospital, The Fourth Military Medical 
      University, Xian, 710038, P. R. China.
FAU - Young, Nilas
AU  - Young N
AD  - Division of Cardiothoracic Surgery, University of California Davis Medical 
      Center, Sacramento, CA, 95817, USA.
FAU - Boyd, Douglas
AU  - Boyd D
AD  - Division of Cardiothoracic Surgery, University of California Davis Medical 
      Center, Sacramento, CA, 95817, USA.
FAU - Weintraub, William
AU  - Weintraub W
AD  - Department of Section of Cardiology, Center for Outcomes Research, Christiana 
      Care Health System, Newark, DE, USA.
FAU - Morris, Rohinton
AU  - Morris R
AD  - Division of Cardiothoracic Surgery, Thomas Jefferson University, Philadelphia, 
      PA, 19107, USA.
FAU - Sun, Jianzhong
AU  - Sun J
AD  - Department of Anesthesiology, Thomas Jefferson University, Philadelphia, PA, 
      19107, USA. jian-zhong.sun@jefferson.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181119
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Cohort Studies
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Perioperative Care
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - *Survival Analysis
PMC - PMC6242822
COIS- The authors declare no competing interests.
EDAT- 2018/11/20 06:00
MHDA- 2019/12/18 06:00
CRDT- 2018/11/20 06:00
PHST- 2018/01/09 00:00 [received]
PHST- 2018/10/31 00:00 [accepted]
PHST- 2018/11/20 06:00 [entrez]
PHST- 2018/11/20 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
AID - 10.1038/s41598-018-35208-7 [pii]
AID - 35208 [pii]
AID - 10.1038/s41598-018-35208-7 [doi]
PST - epublish
SO  - Sci Rep. 2018 Nov 19;8(1):17051. doi: 10.1038/s41598-018-35208-7.

PMID- 25665880
OWN - NLM
STAT- MEDLINE
DCOM- 20160321
LR  - 20150618
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 20
IP  - 4
DP  - 2015 Jul
TI  - Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications 
      of Metabolic Bioactivation.
PG  - 370-7
LID - 10.1177/1074248415571456 [doi]
AB  - Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist remains a 
      mainstay in the prevention of ischemic events following coronary stent placement. 
      Significant controversy exists regarding the optimal management of high platelet 
      reactivity despite antiplatelet therapy; however this finding has been 
      consistently associated with poor clinical outcomes including greater risk of 
      stent thrombosis and myocardial infarction. Variability in antiplatelet effects 
      of clopidogrel and prasugrel has been linked to genetic polymorphisms and 
      potential drug-drug interactions. Both of these factors have significant 
      influence on the cytochrome P-450 enzyme system activity of the liver responsible 
      for their biotransformation to the active form of both drugs. Very little has 
      been publicized regarding differences in antiplatelet effects which may be 
      associated with conditions in which the functional capacity of the liver may be 
      temporarily compromised. Patients who present with cardiogenic shock due to acute 
      coronary syndromes have evidence of multiorgan dysfunction including liver 
      dysfunction that may affect the activity of these drugs. This review aims to 
      explore existing evidence and propose additional considerations to the selection 
      of antiplatelet therapy in patients with cardiogenic shock who receive 
      catheter-based revascularization and stent placement.
CI  - © The Author(s) 2015.
FAU - Weeks, Phillip A
AU  - Weeks PA
AD  - Department of Pharmacy, Memorial Hermann-Texas Medical Center, Houston, TX, USA 
      phillip.weeks@memorialhermann.org.
FAU - Sieg, Adam
AU  - Sieg A
AD  - Department of Pharmacy, Memorial Hermann-Texas Medical Center, Houston, TX, USA.
FAU - Paruthi, Christina
AU  - Paruthi C
AD  - Center for Advanced Heart Failure, University of Texas Health Science Center, 
      Houston, TX, USA.
FAU - Rajapreyar, Indranee
AU  - Rajapreyar I
AD  - Center for Advanced Heart Failure, University of Texas Health Science Center, 
      Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150208
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/complications
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Myocardial Ischemia/complications
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/therapeutic use
MH  - Shock, Cardiogenic/etiology/*therapy
MH  - *Stents
OTO - NOTNLM
OT  - P2Y12 receptor antagonist
OT  - cardiogenic shock
OT  - clopidogrel
OT  - prasugrel
OT  - ticagrelor
EDAT- 2015/02/11 06:00
MHDA- 2016/03/22 06:00
CRDT- 2015/02/11 06:00
PHST- 2014/11/04 00:00 [received]
PHST- 2015/01/07 00:00 [accepted]
PHST- 2015/02/11 06:00 [entrez]
PHST- 2015/02/11 06:00 [pubmed]
PHST- 2016/03/22 06:00 [medline]
AID - 1074248415571456 [pii]
AID - 10.1177/1074248415571456 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2015 Jul;20(4):370-7. doi: 10.1177/1074248415571456. 
      Epub 2015 Feb 8.

PMID- 16988315
OWN - NLM
STAT- MEDLINE
DCOM- 20070322
LR  - 20181113
IS  - 1472-0213 (Electronic)
IS  - 1472-0205 (Print)
IS  - 1472-0205 (Linking)
VI  - 23
IP  - 10
DP  - 2006 Oct
TI  - Towards evidence-based emergency medicine: best BETs from the Manchester Royal 
      Infirmary. Use of aspirin in acute stroke.
PG  - 804-5
AB  - A short-cut review was carried out to establish whether the administration of 
      aspirin before computed tomography scanning improved outcome in patients with 
      symptoms suggestive of stroke. In all, 866 papers were found using the reported 
      searches, two of which presented the best evidence to answer the clinical 
      question. The author group, date and country of publication, patient group 
      studied, study type, relevant outcomes, results and study weaknesses of these 
      best papers are tabulated. If a computed tomography scan is to be carried out 
      within 48 h of onset of symptoms, then it is prudent to await the result before 
      starting aspirin.
FAU - Ferguson, Craig
AU  - Ferguson C
AD  - Manchester Royal Infirmary, Manchester, UK.
FAU - Body, Richard
AU  - Body R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Emerg Med J
JT  - Emergency medicine journal : EMJ
JID - 100963089
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Emergencies
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/diagnostic imaging/*drug therapy
MH  - Tomography, X-Ray Computed
PMC - PMC2579607
EDAT- 2006/09/22 09:00
MHDA- 2007/03/23 09:00
CRDT- 2006/09/22 09:00
PHST- 2006/09/22 09:00 [pubmed]
PHST- 2007/03/23 09:00 [medline]
PHST- 2006/09/22 09:00 [entrez]
AID - 23/10/804 [pii]
AID - em41103 [pii]
AID - 10.1136/emj.2006.041103 [doi]
PST - ppublish
SO  - Emerg Med J. 2006 Oct;23(10):804-5. doi: 10.1136/emj.2006.041103.

PMID- 17716716
OWN - NLM
STAT- MEDLINE
DCOM- 20080225
LR  - 20181201
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 121
IP  - 1
DP  - 2008 Jan
TI  - An economic analysis of aspirin desensitization in aspirin-exacerbated 
      respiratory disease.
PG  - 81-7
AB  - BACKGROUND: Aspirin desensitization is an effective therapy for 
      moderate-to-severe aspirin-exacerbated respiratory disease (AERD). 
      Desensitization also allows the use of aspirin for secondary cardiovascular 
      prevention. OBJECTIVE: We sought to investigate the cost-effectiveness of aspirin 
      desensitization with subsequent aspirin therapy in patients with AERD. METHODS: 
      The Healthcare Cost and Utilization Project was used, together with average 
      reimbursements from a large Midwestern health care plan, to model the costs of 
      aspirin desensitization for therapeutic and prophylactic use in patients with 
      AERD. Event probabilities were based on the published literature. RESULTS: 
      Ambulatory desensitization for AERD cost $6768 per quality-adjusted life year 
      (QALY) saved ($18.54 per additional symptom-free day). Aspirin desensitization 
      for AERD remained cost-effective (<$50,000 per QALY saved) across a wide range of 
      assumptions. When secondary cardiovascular prophylaxis was considered, ambulatory 
      aspirin desensitization was less expensive than an alternative antiplatelet 
      agent, clopidogrel. Clopidogrel cost $106,453 per incremental QALY saved when 
      compared with desensitization. CONCLUSIONS: Aspirin desensitization is a 
      cost-effective therapeutic intervention in patients with moderate-to-severe AERD. 
      Although the incremental cost-effectiveness of clopidogrel in individuals with 
      aspirin allergy is marginal, if available, ambulatory desensitization remains a 
      less-expensive option for secondary cardiovascular prophylaxis.
FAU - Shaker, Marcus
AU  - Shaker M
AD  - Section of Allergy and Clinical Immunology, Department of Pediatrics and 
      Community and Family Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 
      03756, USA. Marcus.Shaker@dartmouth.edu
FAU - Lobb, Ano
AU  - Lobb A
FAU - Jenkins, Pamela
AU  - Jenkins P
FAU - O'Rourke, Daniel
AU  - O'Rourke D
FAU - Takemoto, Steve K
AU  - Takemoto SK
FAU - Sheth, Salil
AU  - Sheth S
FAU - Burroughs, Thomas
AU  - Burroughs T
FAU - Dykewicz, Mark S
AU  - Dykewicz MS
LA  - eng
PT  - Journal Article
DEP - 20070822
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/economics/therapeutic use
MH  - Aspirin/*adverse effects/economics/therapeutic use
MH  - Asthma/etiology/therapy
MH  - Cardiovascular Diseases/prevention & control
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Desensitization, Immunologic/*economics/methods
MH  - Drug Hypersensitivity/etiology/*therapy
MH  - Humans
MH  - Markov Chains
MH  - Middle Aged
MH  - Models, Biological
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Respiration Disorders/etiology/*therapy
MH  - Ticlopidine/analogs & derivatives/economics/therapeutic use
EDAT- 2007/08/25 09:00
MHDA- 2008/02/26 09:00
CRDT- 2007/08/25 09:00
PHST- 2006/12/11 00:00 [received]
PHST- 2007/06/22 00:00 [revised]
PHST- 2007/06/26 00:00 [accepted]
PHST- 2007/08/25 09:00 [pubmed]
PHST- 2008/02/26 09:00 [medline]
PHST- 2007/08/25 09:00 [entrez]
AID - S0091-6749(07)01386-3 [pii]
AID - 10.1016/j.jaci.2007.06.047 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2008 Jan;121(1):81-7. doi: 10.1016/j.jaci.2007.06.047. 
      Epub 2007 Aug 22.

PMID- 12518657
OWN - NLM
STAT- MEDLINE
DCOM- 20030408
LR  - 20131121
IS  - 0034-0634 (Print)
IS  - 0034-0634 (Linking)
VI  - 119
IP  - 2
DP  - 2002
TI  - [Neuroprotection by aspirin in cerebrovascular pathology].
PG  - 311-20; discussion 320-6
AB  - Aspirin reduces the size of infarcts after ischaemic stroke. Although this fact 
      has been attributed to its antiplatelet actions, direct neuroprotective effects 
      have been also reported. We have demonstrated that aspirin is neuroprotective by 
      inhibiting glutamate release in "in vitro" models of brain ischaemia. A 
      pharmacological dissection of the components involved, using cell cortical 
      culture exposed to oxygen-glucose deprivation, indicated that aspirin selectively 
      inhibits the increase in extracellular glutamate concentration which results from 
      reversal of the glutamate transporter, a component of release which is due to ATP 
      depletion. Moreover, the neuroprotection afforded by aspirin occurred in parallel 
      to a lesser decay in ATP levels after OGD. Aspirin not only elevated ATP levels 
      in intact cortical neurones, but also in isolated brain mitochondria. On the 
      other hand, using a whole-animal model of permanent focal brain ischaemia (MCAO; 
      middle cerebral artery occlusion), wed have also demonstrated that aspirin (30 
      mg/Kg i.p. administered 2 h before the occlusion) produced a significant 
      reduction in infarct volume, effect that correlated with the inhibition caused by 
      aspirin on ischaemia-induced increase in brain and serum glutamate concentrations 
      after the onset of the ischaemia. Aspirin also inhibited ischaemia-induced 
      decrease in brain ATP levels. Finally, clinical studies showed that prior 
      treatment with aspirin was associated with a lower risk of neurological 
      deterioration after acute ischemic stroke which was related to a reduction of 
      glutamate release. Our present findings show a novel mechanism for the 
      neuroprotective effects of aspirin, that takes place at concentrations in the 
      antiaggregant-analgesic range, useful in the management of patients with risk of 
      ischaemic events.
FAU - Lorenzo Fernández, Pedro
AU  - Lorenzo Fernández P
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Neuroprotección por Aspirina en patología cerebrovascular.
PL  - Spain
TA  - An R Acad Nac Med (Madr)
JT  - Anales de la Real Academia Nacional de Medicina
JID - 7505188
RN  - 0 (Amino Acid Transport System X-AG)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Salicylates)
RN  - 3KX376GY7L (Glutamic Acid)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adenosine Triphosphate/antagonists & inhibitors/metabolism
MH  - Algorithms
MH  - Amino Acid Transport System X-AG/drug effects/metabolism
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Brain Ischemia/drug therapy
MH  - Cell Death/drug effects
MH  - Cerebrovascular Disorders/*drug therapy
MH  - Clinical Trials as Topic
MH  - Disease Models, Animal
MH  - Glucose/metabolism
MH  - Glutamic Acid/drug effects/metabolism
MH  - Humans
MH  - Indomethacin/pharmacology/therapeutic use
MH  - Mitochondria/drug effects
MH  - Neuroprotective Agents/*therapeutic use
MH  - Oxygen/metabolism
MH  - Salicylates/pharmacology/therapeutic use
EDAT- 2003/01/10 04:00
MHDA- 2003/04/09 05:00
CRDT- 2003/01/10 04:00
PHST- 2003/01/10 04:00 [pubmed]
PHST- 2003/04/09 05:00 [medline]
PHST- 2003/01/10 04:00 [entrez]
PST - ppublish
SO  - An R Acad Nac Med (Madr). 2002;119(2):311-20; discussion 320-6.

PMID- 32394295
OWN - NLM
STAT- MEDLINE
DCOM- 20211005
LR  - 20211005
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jan
TI  - Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: 
      Systematic Review and Meta-Analysis.
PG  - 63-71
LID - 10.1007/s40256-020-00409-x [doi]
AB  - BACKGROUND: Acetylsalicylic acid (ASA) is a frequently used antiplatelet agent, 
      although some individuals have reduced antiplatelet responses on ASA, with 
      recurrent ischemic events. It has been proposed that shortening the ASA dosing 
      interval may overcome the time-dependent renewal of the drug target, leading to a 
      greater antiplatelet effect. We conducted a systematic review of randomized 
      controlled trials (RCTs) to determine the efficacy of once- versus twice-daily 
      ASA in conditions with increased platelet turnover. METHODS: We conducted a 
      systematic review and meta-analysis by searching the CENTRAL, MEDLINE, and Embase 
      databases for RCTs assessing once- versus twice-daily ASA. Data were screened, 
      extracted, and appraised by two independent reviewers, and were pooled using a 
      random-effects model. The primary outcomes were major adverse cardiovascular 
      events (MACEs) and serum thromboxane B2 (TxB2). Other pharmacodynamic measures 
      were retrieved as secondary outcomes. Results were reported as mean differences 
      with corresponding 95% confidence intervals (CIs). We followed the Preferred 
      Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 
      RESULTS: Seven RCTs were included, enrolling 379 participants overall. None of 
      the studies reported clinical outcomes. Pooled results showed that compared with 
      once-daily ASA, twice-daily ASA was associated with a decrease in mean TxB2 of 
      1.42 ng/mL (95% CI - 2.71 to - 0.13; I(2 )= 66%). We found no differences in 
      subgroup analyses based on disease subtype, trial blinding, or trial design. A 
      greater antiplatelet activity of the twice-daily regimen was also found when 
      using PFA-100-ADP methods, although not when using the VerifyNow, LTA-AA, and 
      multiplate methods. CONCLUSIONS: Twice-daily ASA was associated with a greater 
      antiplatelet effect compared with standard once-daily ASA.
FAU - Mainoli, Beatrice
AU  - Mainoli B
AUID- ORCID: 0000-0002-5295-4346
AD  - Laboratório de Farmacologia Clínica E Terapêutica, Faculdade de Medicina, 
      Universidade de Lisboa. Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
AD  - IMM, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 
      1649-028, Lisbon, Portugal.
FAU - Duarte, Gonçalo S
AU  - Duarte GS
AD  - Laboratório de Farmacologia Clínica E Terapêutica, Faculdade de Medicina, 
      Universidade de Lisboa. Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
AD  - IMM, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 
      1649-028, Lisbon, Portugal.
AD  - Centro de Estudos de Medicina Baseada Na Evidência, Faculdade de Medicina, 
      Universidade de Lisboa, Lisbon, Portugal.
FAU - Costa, João
AU  - Costa J
AD  - Laboratório de Farmacologia Clínica E Terapêutica, Faculdade de Medicina, 
      Universidade de Lisboa. Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
AD  - IMM, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 
      1649-028, Lisbon, Portugal.
AD  - Centro de Estudos de Medicina Baseada Na Evidência, Faculdade de Medicina, 
      Universidade de Lisboa, Lisbon, Portugal.
FAU - Ferreira, Joaquim
AU  - Ferreira J
AD  - Laboratório de Farmacologia Clínica E Terapêutica, Faculdade de Medicina, 
      Universidade de Lisboa. Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
AD  - IMM, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 
      1649-028, Lisbon, Portugal.
AD  - CNS, Campus Neurológico Sénior, Torres Vedras, Portugal.
FAU - Caldeira, Daniel
AU  - Caldeira D
AD  - Laboratório de Farmacologia Clínica E Terapêutica, Faculdade de Medicina, 
      Universidade de Lisboa. Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal. 
      dgcaldeira@hotmail.com.
AD  - IMM, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 
      1649-028, Lisbon, Portugal. dgcaldeira@hotmail.com.
AD  - Serviço de Cardiologia, Faculdade de Medicina, Hospital Universitário de Santa 
      Maria (CHULN), CAML, Centro Cardiovascular da Universidade de Lisboa, CCUL, 
      Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal. 
      dgcaldeira@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drug Administration Schedule
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Thrombosis/*prevention & control
MH  - Thromboxane B2/blood
EDAT- 2020/05/13 06:00
MHDA- 2021/10/06 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/10/06 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1007/s40256-020-00409-x [pii]
AID - 10.1007/s40256-020-00409-x [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2021 Jan;21(1):63-71. doi: 10.1007/s40256-020-00409-x.

PMID- 16321425
OWN - NLM
STAT- MEDLINE
DCOM- 20071212
LR  - 20151119
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 118
IP  - 4
DP  - 2006
TI  - Aspirin overprescription in primary cardiovascular prevention.
PG  - 471-7
AB  - INTRODUCTION: Aspirin overprescription is of some concern, especially in 
      still-healthy individuals, and estimates of the magnitude of this problem are 
      lacking. We evaluated the inappropriateness of aspirin prescription by primary 
      care physicians in primary cardiovascular prevention. MATERIALS AND METHODS: Out 
      of 20,599 patients screened by 16 primary care physicians in the Abruzzi region, 
      central Italy, 400 patients were on treatment with aspirin for primary 
      prevention. For each such patient, the absolute cardiovascular and coronary risks 
      were assessed according to the Italian Cardiovascular Risk Chart for Primary 
      Prevention and the European Society of Cardiology Coronary Risk Chart, 
      respectively. Patients with a cardiovascular and/or coronary risk <1.0 event/100 
      patients/year were considered as treated inappropriately (aspirin 
      overprescription), on the basis of previous literature. RESULTS: Overall, as many 
      as 12% and 18% of patients had a cardiovascular and/or coronary risk <1.0 
      event/100 patients/year according to the European and the Italian charts, 
      respectively, and therefore were defined as treated inappropriately. Patients 
      with and without inappropriate treatment were similar with respect to smoking 
      habits, family history and body max index. However, inappropriately treated 
      patients had significantly lower levels of blood pressure and total cholesterol, 
      and were more likely to be female, younger and non-diabetic than patients 
      appropriately treated. CONCLUSIONS: A non-negligible proportion-up to 18%-of 
      subjects in primary prevention is currently more likely to derive harm than 
      benefit from inappropriate aspirin use. A wider use of Cardiovascular Risk Charts 
      should guide primary care physicians in prescribing aspirin for primary 
      prevention.
FAU - Manes, Costantina
AU  - Manes C
AD  - Institute of Cardiology, G d'Annunzio University-Chieti, Italy.
FAU - Giacci, Luciano
AU  - Giacci L
FAU - Sciartilli, Adolfo
AU  - Sciartilli A
FAU - D'Alleva, Alberto
AU  - D'Alleva A
FAU - De Caterina, Raffaele
AU  - De Caterina R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Blood Pressure
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Cholesterol/blood
MH  - *Drug Utilization Review
MH  - Female
MH  - Follow-Up Studies
MH  - *Health Care Surveys
MH  - Health Services Misuse
MH  - Humans
MH  - Italy
MH  - Male
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Primary Health Care/*standards
MH  - Primary Prevention/methods/*standards
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Treatment Outcome
EDAT- 2005/12/03 09:00
MHDA- 2007/12/13 09:00
CRDT- 2005/12/03 09:00
PHST- 2005/06/08 00:00 [received]
PHST- 2005/09/28 00:00 [revised]
PHST- 2005/09/28 00:00 [accepted]
PHST- 2005/12/03 09:00 [pubmed]
PHST- 2007/12/13 09:00 [medline]
PHST- 2005/12/03 09:00 [entrez]
AID - S0049-3848(05)00417-2 [pii]
AID - 10.1016/j.thromres.2005.09.013 [doi]
PST - ppublish
SO  - Thromb Res. 2006;118(4):471-7. doi: 10.1016/j.thromres.2005.09.013.

PMID- 8111770
OWN - NLM
STAT- MEDLINE
DCOM- 19940330
LR  - 20181130
IS  - 0008-6312 (Print)
IS  - 0008-6312 (Linking)
VI  - 83
IP  - 5-6
DP  - 1993
TI  - Effect of single oral dose of aspirin on human platelet functions and plasma 
      plasminogen activator inhibitor-1.
PG  - 367-73
AB  - Previous reports documented the inhibitory efficacy of different doses of aspirin 
      on arachidonic acid (AA)-induced platelet aggregation, however, the sensitivity 
      of platelets toward other agonists as well as the effects of aspirin on platelet 
      and plasma plasminogen activator inhibitor-1 (PAI-1) release and levels were not 
      investigated. Hence, the present study was undertaken to investigate the effect 
      and duration of action of a single oral dose (650 mg) of aspirin on human 
      platelet functions (n = 34, normal healthy male and female volunteers) including 
      aggregation, fibrinogen binding and PAI-1 release, and on the plasma level of 
      PAI-1. Aspirin demonstrated a rapid onset of action (at 2 h after ingestion) in 
      specifically inhibiting ex vivo AA-mediated functions including (a) fibrinogen 
      binding to gel-purified platelets, (b) platelet aggregation, and (c) platelet 
      PAI-1 release. A peak reduction of plasma PAI-1 level at 2 h was demonstrated as 
      well. The effect of aspirin on the ex vivo AA-mediated effects (a-c) was shown to 
      last for up to 4 days. However, aspirin treatment resulted in a rebound effect in 
      platelet function (a-c) to other platelet agonists such as adenosine diphosphate 
      or the combination of agonists including adenosine diphosphate, epinephrine, and 
      AA. In conclusion, a single oral dose of aspirin has long-acting effects on 
      AA-induced platelet activation and reduces plasma levels of PAI-1 as 
      well.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Mousa, S A
AU  - Mousa SA
AD  - DuPont Merck Pharmaceutical Company, Cardiovascular Diseases Division, 
      Wilmington, DE 19880-0400.
FAU - Forsythe, M S
AU  - Forsythe MS
FAU - Bozarth, J M
AU  - Bozarth JM
FAU - Reilly, T M
AU  - Reilly TM
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Arachidonic Acid/pharmacology/physiology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Fibrinogen/metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Plasminogen Activator Inhibitor 1/blood/*metabolism
MH  - Platelet Aggregation/drug effects
MH  - Time Factors
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1159/000175993 [doi]
PST - ppublish
SO  - Cardiology. 1993;83(5-6):367-73. doi: 10.1159/000175993.

PMID- 15528453
OWN - NLM
STAT- MEDLINE
DCOM- 20050405
LR  - 20181201
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 312
IP  - 3
DP  - 2005 Mar
TI  - Positional isomerism markedly affects the growth inhibition of colon cancer cells 
      by nitric oxide-donating aspirin in vitro and in vivo.
PG  - 978-88
AB  - NO-donating aspirin (NO-ASA), a novel pharmacological agent currently undergoing 
      clinical testing, consists of ASA to which a nitrate group is covalently linked 
      via a spacer molecule. We synthesized the three positional isomers of NO-ASA with 
      respect to the -CH(2)ONO(2) group (ortho, meta, and para) and examined whether 
      this isomerism affects the biological activity of NO-ASA on HT-29 human colon 
      cancer cells. The ortho- and para-isomers showed similar IC(50) values (1-5 
      microM) for cell growth inhibition over 72 h, whereas the IC(50) of the 
      meta-isomer was 200 to 500 microM. The ortho- and para-isomers inhibited cell 
      proliferation more potently than the meta-isomer. All three induced apoptosis but 
      the ortho- and para-isomers also induced atypical cells (they maintain their 
      shape but have diminished or absent nuclear material). Treatment for 3 weeks of 
      Min (Apc(min)(/+)) mice, a model of intestinal cancer, with equimolar amounts of 
      meta- and para-NO-ASA decreased the number of tumors in the small intestine by 36 
      and 59% (P < 0.01), respectively, compared with vehicle-treated controls, thus 
      confirming their in vitro differences in potency. A structure-activity study of 
      the three isomers revealed that substituting an aliphatic for the aromatic spacer 
      or removing the -ONO(2) group profoundly diminished NO-ASA's ability to inhibit 
      cell growth, whereas removal of the acetyl group on the ASA moiety did not affect 
      cell growth inhibition. Thus, positional isomerism is critical for the 
      pharmacological properties of NO-ASA against colon cancer and it should be taken 
      into consideration in rational drug design.
FAU - Kashfi, Khosrow
AU  - Kashfi K
AD  - Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, Stony 
      Brook, NY 11794-8160, USA.
FAU - Borgo, Simona
AU  - Borgo S
FAU - Williams, Jennie L
AU  - Williams JL
FAU - Chen, Jie
AU  - Chen J
FAU - Gao, Jianjun
AU  - Gao J
FAU - Glekas, Athanasios
AU  - Glekas A
FAU - Benedini, Francesca
AU  - Benedini F
FAU - Del Soldato, Piero
AU  - Del Soldato P
FAU - Rigas, Basil
AU  - Rigas B
LA  - eng
GR  - CA92423/CA/NCI NIH HHS/United States
GR  - CA92423-S1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20041104
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Growth Inhibitors)
RN  - 0 (N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 
      4-(nitrooxy)butyl ester)
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Cell Proliferation/drug effects
MH  - Colonic Neoplasms/*drug therapy/pathology
MH  - Dose-Response Relationship, Drug
MH  - Growth Inhibitors/*pharmacology
MH  - HT29 Cells
MH  - Humans
MH  - Isomerism
MH  - Nitrates/*pharmacology
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Donors/*pharmacology
MH  - Proliferating Cell Nuclear Antigen/analysis
MH  - Structure-Activity Relationship
EDAT- 2004/11/06 09:00
MHDA- 2005/04/06 09:00
CRDT- 2004/11/06 09:00
PHST- 2004/11/06 09:00 [pubmed]
PHST- 2005/04/06 09:00 [medline]
PHST- 2004/11/06 09:00 [entrez]
AID - jpet.104.075994 [pii]
AID - 10.1124/jpet.104.075994 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2005 Mar;312(3):978-88. doi: 10.1124/jpet.104.075994. Epub 
      2004 Nov 4.

PMID- 6480878
OWN - NLM
STAT- MEDLINE
DCOM- 19841120
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 24
IP  - 8-9
DP  - 1984 Aug-Sep
TI  - Zomepirac--aspirin interactions in man.
PG  - 371-80
AB  - The pharmacokinetic interaction between zomepirac and aspirin was studied in 12 
      healthy males who received a single dose of 100 mg zomepirac sodium on days 1 and 
      5 and 975 mg aspirin every 6 hours on days 2 to 5. The results indicated that in 
      the presence of salicylate, the peak concentration of zomepirac was depressed; 
      peak time, AUC(0-24 hr), and clearance of total drug remained unchanged. 
      Percentage unbound zomepirac was increased twofold. In the presence of zomepirac, 
      the peak concentration and AUC of salicylate were increased and clearance 
      decreased. The data suggest that zomepirac and salicylate compete with each other 
      for the enzymes and/or cofactors involved in glucuronidation. This competition 
      for metabolic clearance offsets the consequences of the zomepirac-salicylate 
      interactions at the plasma protein binding sites. However, in light of increased 
      unbound zomepirac as well as decreased clearance of unbound drug, concomitant 
      therapy of zomepirac and aspirin is not advised.
FAU - Desiraju, R K
AU  - Desiraju RK
FAU - Nayak, R K
AU  - Nayak RK
FAU - Pritchard, J F
AU  - Pritchard JF
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Blood Proteins)
RN  - 0 (Hippurates)
RN  - 0 (Pyrroles)
RN  - 0 (Salicylates)
RN  - 487-54-7 (salicylurate)
RN  - 822G987U9J (zomepirac)
RN  - D8K2JPN18B (Tolmetin)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*pharmacology
MH  - Blood Proteins/metabolism
MH  - Drug Interactions
MH  - Hippurates/blood
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Protein Binding
MH  - Pyrroles/*pharmacology
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Tolmetin/analogs & derivatives/blood/*pharmacology
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1984.tb02789.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1984 Aug-Sep;24(8-9):371-80. doi: 
      10.1002/j.1552-4604.1984.tb02789.x.

PMID- 657826
OWN - NLM
STAT- MEDLINE
DCOM- 19780828
LR  - 20190907
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 5
IP  - 5
DP  - 1978
TI  - Sigma SR, a new method of measuring erythrocyte sedimentation rate. Its value in 
      studying the action and interactions of non-steroidal anti-inflammatory agents.
PG  - 412-7
AB  - Sigma SR is a new method of measuring erythrocyte sedimentation rate (ESR) and is 
      characterized by an unvarying haematocrit, routinely corrected to 35%, and the 
      sum of 4 sedimentation levels at 20, 30, 40, and 50 minutes. Two studies were 
      carried out in patients with inflammatory arthritic disorders; the first in 25 
      patients treated with 1800 mg ibuprofen daily for 7 days, and the second in 31 
      patients treated either with indomethacin alone (150 mg/day) or combined with 
      aspirin (1500 mg/day) for 5 days. In addition to the assessment of clinical 
      parameters, the ESR was measured using the classical Westergren and the sigma SR 
      methods. The results showed that there were little or no changes from baseline 
      values in the ESR using the Westergren method. With the sigma SR method, however, 
      statistically significant changes were recorded after treatment and these 
      correlated with the clinical findings which demonstrated the anti-inflammatory 
      action of ibuprofen and the reduction in activity of indomethacin by aspirin.
FAU - Pawlotsky, Y
AU  - Pawlotsky Y
FAU - Chales, G
AU  - Chales G
FAU - Grosbois, B
AU  - Grosbois B
FAU - Louboutin, Y B
AU  - Louboutin YB
FAU - Lenoir, P
AU  - Lenoir P
FAU - Bourel, M
AU  - Bourel M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/pharmacology
MH  - Blood Sedimentation/*methods
MH  - Body Temperature/drug effects
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Ibuprofen/pharmacology
MH  - Indomethacin/pharmacology
MH  - Male
MH  - Middle Aged
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1185/03007997809111907 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1978;5(5):412-7. doi: 10.1185/03007997809111907.

PMID- 7469134
OWN - NLM
STAT- MEDLINE
DCOM- 19810413
LR  - 20131121
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 46
IP  - 2
DP  - 1981 Feb
TI  - Tartrazine (FD & C yellow #5) anaphylaxis: a case report.
PG  - 81-2
AB  - Tartrazine dye has been implicated in a variety of adverse reactions. There is a 
      high correlation between aspirin sensitivity and tartrazine sensitivity but the 
      reverse is exceedingly rare. Herewith is presented a case where repeated occult 
      exposures to tartrazine yellow dye in a patient who could take aspirin with 
      impunity was uncovered by a deduction. The ubiquitous nature and protean 
      manifestations of dye sensitivity are discussed.
FAU - Desmond, R E
AU  - Desmond RE
FAU - Trautlein, J J
AU  - Trautlein JJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - 0 (Azo Compounds)
RN  - 0 (Coloring Agents)
RN  - I753WB2F1M (Tartrazine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anaphylaxis/*chemically induced
MH  - Aspirin/adverse effects
MH  - Azo Compounds/*adverse effects
MH  - Coloring Agents/adverse effects
MH  - Drug Hypersensitivity/*etiology
MH  - Humans
MH  - Male
MH  - Tartrazine/*adverse effects
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1981 Feb;46(2):81-2.

PMID- 8159037
OWN - NLM
STAT- MEDLINE
DCOM- 19940516
LR  - 20171218
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 107
IP  - 4
DP  - 1994 Apr
TI  - Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft 
      patency one year after coronary artery bypass grafting.
PG  - 1146-53
AB  - Saphenous vein coronary artery bypass graft patency can be increased by 
      antiplatelet therapy. Aspirin plus dipyridamole are effective but are associated 
      with tolerability problems. Indobufen is a possible alternative antiplatelet 
      agent that may be better tolerated. A prospective, randomized, double-blind, 
      parallel-group study was undertaken to compare the efficacy and safety of 
      indobufen 200 mg twice daily with aspirin 300 mg thrice daily plus dipyridamole 
      75 mg thrice daily in preventing occlusion of autologous saphenous vein coronary 
      artery bypass grafts. A total of 803 patients were randomized in the study, of 
      whom 552 had a follow-up coronary angiogram approximately 1 year after operation. 
      All anastomoses were patent in 56% of indobufen-treated patients and 59% of 
      aspirin-dipyridamole recipients (p = 0.384). The percentage of all anastomoses 
      patent was 82% in the indobufen group and 83% in the aspirin-dipyridamole group 
      (p = 0.297). Mean postoperative blood loss was significantly less in the 
      indobufen group (p = 0.043). Patients who received indobufen also had 
      significantly fewer adverse events considered to be treatment-related compared 
      with aspirin-dipyridamole recipients (p = 0.02). At the doses tested indobufen 
      was as effective as aspirin plus dipyridamole in preventing occlusion of 
      saphenous vein grafts and was better tolerated. Because indobufen was associated 
      with less postoperative blood loss it may be used before operation in coronary 
      artery bypass grafting.
FAU - Rajah, S M
AU  - Rajah SM
AD  - Killingbeck Hospital, Leeds, United Kingdom.
FAU - Nair, U
AU  - Nair U
FAU - Rees, M
AU  - Rees M
FAU - Saunders, N
AU  - Saunders N
FAU - Walker, D
AU  - Walker D
FAU - Williams, G
AU  - Williams G
FAU - Critchley, A
AU  - Critchley A
FAU - Beton, D
AU  - Beton D
FAU - Campbell, C
AU  - Campbell C
FAU - Lawson, R A
AU  - Lawson RA
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 6T9949G4LZ (indobufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - *Coronary Artery Bypass/statistics & numerical data
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/epidemiology/*prevention & control
MH  - Humans
MH  - Isoindoles
MH  - Male
MH  - Middle Aged
MH  - Phenylbutyrates/adverse effects/*therapeutic use
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - *Postoperative Care/statistics & numerical data
MH  - Prospective Studies
MH  - Time Factors
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
AID - S0022-5223(94)70392-2 [pii]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1994 Apr;107(4):1146-53.

PMID- 7901582
OWN - NLM
STAT- MEDLINE
DCOM- 19931209
LR  - 20170920
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 342
IP  - 8882
DP  - 1993 Nov 20
TI  - Secondary prevention in non-rheumatic atrial fibrillation after transient 
      ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study 
      Group.
PG  - 1255-62
AB  - Several studies have established the value of anticoagulation for primary 
      prevention of thromboembolic events in patients with non-rheumatic atrial 
      fibrillation (NRAF). However, in patients with a recent transient ischaemic 
      attack (TIA) or minor ischaemic stroke the preventive benefit of anticoagulation 
      or aspirin remains unclear. Physicians in 108 centres from 13 countries 
      collaborated to study this question. 1007 NRAF patients with a recent TIA or 
      minor ischaemic stroke were randomised to open anticoagulation or double-blind 
      treatment with either 300 mg aspirin per day or placebo (group 1, 669). Patients 
      with contraindications to anticoagulation were randomised to receive aspirin or 
      placebo (group 2,338). The measure of outcome was death from vascular disease, 
      any stroke, myocardial infarction, or systemic embolism. During mean follow-up of 
      2.3 years, the annual rate of outcome events was 8% in patients assigned to 
      anticoagulants vs 17% in placebo-treated patients in group 1 (hazard ratio [HR] 
      0.53; 95% confidence interval [CI] 0.36-0.79). The risk of stroke alone was 
      reduced from 12% to 4% per year (HR 0.34; 95% CI 0.20-0.57). Among all patients 
      assigned to aspirin (groups 1 and 2), the annual incidence of outcome events was 
      15%, against 19% in those on placebo (HR 0.83; 95% CI 0.65-1.05). Anticoagulation 
      was significantly more effective than aspirin (HR 0.60; 95% CI 0.41-0.87). The 
      incidence of major bleeding events was low, both on anticoagulation (2.8% per 
      year) and on aspirin (0.9% per year). No intracranial bleeds were identified in 
      patients assigned to anticoagulation. We conclude that anticoagulation is 
      effective in reducing the risk of recurrent vascular events in NRAF patients with 
      a recent TIA or minor ischaemic stroke. In absolute terms: 90 vascular events 
      (mainly strokes) are prevented if 1000 patients are treated with anticoagulation 
      for one year. Aspirin is a safe, though less effective, alternative when 
      anticoagulation is contraindicated; it prevents 40 vascular events each year for 
      every 1000 treated patients.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 1994 May-Jun;120 Suppl 3:74
CIN - Lancet. 1993 Nov 20;342(8882):1251-2. PMID: 7901577
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Cerebrovascular Disorders/epidemiology/etiology/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/etiology
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology
MH  - Recurrence
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Vascular Diseases/epidemiology/mortality
EDAT- 1993/11/20 00:00
MHDA- 1993/11/20 00:01
CRDT- 1993/11/20 00:00
PHST- 1993/11/20 00:00 [pubmed]
PHST- 1993/11/20 00:01 [medline]
PHST- 1993/11/20 00:00 [entrez]
AID - 0140-6736(93)92358-Z [pii]
PST - ppublish
SO  - Lancet. 1993 Nov 20;342(8882):1255-62.

PMID- 11284783
OWN - NLM
STAT- MEDLINE
DCOM- 20010517
LR  - 20190831
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 15
IP  - 4
DP  - 2001 Apr
TI  - Effect of nabumetone and aspirin on colonic mucosal bleeding time.
PG  - 539-42
AB  - BACKGROUND: The management of patients taking aspirin or non-steroidal 
      anti-inflammatory drugs (NSAIDs) who require colonoscopy remains controversial 
      because of concerns over bleeding after biopsy or polypectomy. AIM: To determine 
      whether patients using the NSAID nabumetone, a non-acidic prodrug with mixed 
      activity against cyclooxygenase-1 (COX-1) and COX-2, exhibited prolonged mucosal 
      bleeding times and how this might compare with mucosal bleeding times in patients 
      using aspirin. METHODS: We assessed triplicate mucosal bleeding times in patients 
      undergoing screening flexible sigmoidoscopy. We compared 90 patients who had 
      taken no aspirin or NSAIDs within the previous 2 weeks, to 60 patients who had 
      received nabumetone 1 g b.d. by mouth for the previous 2 weeks, and 30 patients 
      who had taken 325 mg aspirin daily for the previous 2 weeks. In each case, the 
      investigator performing the study was blinded to the patient's medication. 
      RESULTS: Mucosal bleeding times did not differ significantly among control or 
      nabumetone-using patients. However, the patients receiving aspirin exhibited 
      significant prolongation. Mucosal bleeding time correlated statistically 
      significantly, but weakly, with skin bleeding time. CONCLUSIONS: Nabumetone does 
      not appear to prolong mucosal bleeding time after mucosal pinch biopsy, and skin 
      bleeding time does not reliably screen for prolonged mucosal bleeding time.
FAU - Basson, M D
AU  - Basson MD
AD  - Wayne State University Medical School, Detroit, MI, USA. marc.basson@med.ua.gov
FAU - Panzini, L
AU  - Panzini L
FAU - Palmer, R H
AU  - Palmer RH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Butanones)
RN  - LW0TIW155Z (Nabumetone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Biopsy
MH  - Butanones/adverse effects/*pharmacology
MH  - Colonic Polyps/surgery
MH  - Forecasting
MH  - Gastrointestinal Hemorrhage/*chemically induced/prevention & control
MH  - Humans
MH  - Intestinal Mucosa/*drug effects/pathology
MH  - Male
MH  - Nabumetone
MH  - Sigmoidoscopy
MH  - Skin/pathology
EDAT- 2001/04/04 10:00
MHDA- 2001/05/18 10:01
CRDT- 2001/04/04 10:00
PHST- 2001/04/04 10:00 [pubmed]
PHST- 2001/05/18 10:01 [medline]
PHST- 2001/04/04 10:00 [entrez]
AID - apt948 [pii]
AID - 10.1046/j.1365-2036.2001.00948.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2001 Apr;15(4):539-42. doi: 
      10.1046/j.1365-2036.2001.00948.x.

PMID- 34702067
OWN - NLM
STAT- MEDLINE
DCOM- 20220107
LR  - 20221202
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 52
IP  - 12
DP  - 2021 Dec
TI  - Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke 
      With Aspirin Treatment Failure.
PG  - e777-e781
LID - 10.1161/STROKEAHA.121.034622 [doi]
AB  - BACKGROUND AND PURPOSE: Many older patients presenting with acute ischemic stroke 
      were already taking aspirin before admission. However, the management strategy 
      for patients with aspirin treatment failure has not been fully established. 
      METHODS: We used data from the American Heart Association Get With The Guidelines 
      Stroke Registry to describe discharge antithrombotic treatment patterns among 
      Medicare beneficiaries with ischemic stroke who were taking aspirin before their 
      stroke and were discharged alive from 1734 hospitals in the United States between 
      October 2012 and December 2017. RESULTS: Of 261 634 ischemic stroke survivors, 
      100 016 (38.2%) were taking aspirin monotherapy before stroke. Among them, 44.4% 
      of patients remained on aspirin monotherapy at discharge (20.9% 81 mg, 18.2% 325 
      mg, 5.3% other or unknown dose). The next most common therapy choice was dual 
      antiplatelet therapy (24.6%), followed by clopidogrel monotherapy (17.8%). The 
      remaining 13.2% of patients were discharged on either aspirin/dipyridamole, 
      warfarin, or nonvitamin K antagonist oral anticoagulants with or without 
      antiplatelet, or no antithrombotic therapy at all. CONCLUSIONS: Nearly half of 
      patients with ischemic stroke while on preventive therapy with aspirin are 
      discharged on aspirin monotherapy without changing antithrombotic class, while 
      the other half are discharged on clopidogrel monotherapy, dual antiplatelet 
      therapy, or other less common agents. These findings emphasize the need for 
      future research to identify best management strategies for this very common and 
      complex clinical scenario.
FAU - Lusk, Jay B
AU  - Lusk JB
AUID- ORCID: 0000-0002-5728-8872
AD  - Duke University School of Medicine, Durham, NC (J.B.L.).
FAU - Xu, Haolin
AU  - Xu H
AUID- ORCID: 0000-0003-1069-9567
AD  - Duke Clinical Research Institute, Durham, NC (H.X., R.M.).
FAU - Peterson, Eric D
AU  - Peterson ED
AUID- ORCID: 0000-0002-5415-4721
AD  - Division of Cardiology (E.D.P.), University of Texas Southwestern Medical Center, 
      Dallas, TX.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AUID- ORCID: 0000-0002-1278-6245
AD  - Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, 
      Boston, MA (D.L.B.).
FAU - Fonarow, Gregg C
AU  - Fonarow GC
AUID- ORCID: 0000-0002-3192-8093
AD  - Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA 
      (G.C.F.).
FAU - Smith, Eric E
AU  - Smith EE
AUID- ORCID: 0000-0003-3956-1668
AD  - Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of 
      Calgary, Alberta, Canada (E.E.S.).
FAU - Matsouaka, Roland
AU  - Matsouaka R
AUID- ORCID: 0000-0002-0271-5400
AD  - Duke Clinical Research Institute, Durham, NC (H.X., R.M.).
AD  - Department of Biostatistics and Bioinformatics, Duke University, Durham NC 
      (R.M.).
FAU - Schwamm, Lee H
AU  - Schwamm LH
AUID- ORCID: 0000-0003-0592-9145
AD  - Department of Neurology, Massachusetts General Hospital, Boston (L.H.S.).
FAU - Xian, Ying
AU  - Xian Y
AUID- ORCID: 0000-0002-1237-1162
AD  - Department of Neurology (Y.X.), University of Texas Southwestern Medical Center, 
      Dallas, TX.
LA  - eng
GR  - P50 NS051343/NS/NINDS NIH HHS/United States
GR  - R01 AG062770/AG/NIA NIH HHS/United States
GR  - U24 NS107243/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20211027
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Dual Anti-Platelet Therapy/methods
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Ischemic Stroke/*prevention & control
MH  - Male
MH  - Secondary Prevention/*methods
MH  - *Treatment Failure
PMC - PMC8608737
MID - NIHMS1746653
OTO - NOTNLM
OT  - anticoagulants
OT  - aspirin
OT  - cardiovascular disease
OT  - clopidogrel
OT  - warfarin
EDAT- 2021/10/28 06:00
MHDA- 2022/01/08 06:00
CRDT- 2021/10/27 05:31
PHST- 2021/10/28 06:00 [pubmed]
PHST- 2022/01/08 06:00 [medline]
PHST- 2021/10/27 05:31 [entrez]
AID - 10.1161/STROKEAHA.121.034622 [doi]
PST - ppublish
SO  - Stroke. 2021 Dec;52(12):e777-e781. doi: 10.1161/STROKEAHA.121.034622. Epub 2021 
      Oct 27.

PMID- 16168278
OWN - NLM
STAT- MEDLINE
DCOM- 20051222
LR  - 20220311
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 46
IP  - 6
DP  - 2005 Sep 20
TI  - Aspirin administered at bedtime, but not on awakening, has an effect on 
      ambulatory blood pressure in hypertensive patients.
PG  - 975-83
AB  - OBJECTIVES: The purpose of this research was to investigate in untreated 
      hypertensive patients the effects on ambulatory blood pressure (BP) of aspirin 
      (ASA) administered at different times of the day. BACKGROUND: Previous studies 
      have shown that ASA produces an administration time-dependent inhibition of 
      angiotensin II. Low-dose ASA has also been shown to reduce BP when administered 
      before bedtime, as opposed to upon awakening, in normotensive and hypertensive 
      volunteers, and in pregnant women at high risk for preeclampsia. METHODS: We 
      studied 328 untreated patients with grade 1 hypertension, 44.0 +/- 12.6 years of 
      age, randomly divided into three groups: nonpharmacological hygienic-dietary 
      recommendations, the same recommendations and ASA (100 mg/day) on awakening, or 
      the same recommendations and ASA before bedtime. Blood pressure was measured 
      every 20 min during the day and every 30 min at night for 48 consecutive h before 
      and after 3 months of intervention. RESULTS: After three months of 
      nonpharmacological intervention, there was a small and nonsignificant reduction 
      of BP (<0.2 mm Hg; p = 0.648). Blood pressure was slightly elevated after aspirin 
      on awakening (2.6/1.6 mm Hg in the 24-h mean of systolic/diastolic BP; p = 
      0.002). A significant BP reduction, however, was observed in the patients who 
      received aspirin before bedtime (6.8/4.6 mm Hg in systolic/diastolic BP; p < 
      0.001). CONCLUSIONS: This prospective trial documents a significant 
      administration time-dependent effect of low-dose ASA on BP in untreated 
      hypertensive patients. The timed administration of low-dose ASA could provide a 
      valuable approach, beyond the secondary prevention of cardiovascular disease, in 
      the added BP control of patients with mild essential hypertension.
FAU - Hermida, Ramón C
AU  - Hermida RC
AD  - Department of Bioengineering and Chronobiology Laboratories, University of Vigo, 
      Campus Universitario, Vigo, Spain. rhermida@tsc.uvigo.es
FAU - Ayala, Diana E
AU  - Ayala DE
FAU - Calvo, Carlos
AU  - Calvo C
FAU - López, José E
AU  - López JE
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2005 Sep 20;46(6):984-5. PMID: 16168279
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - *Blood Pressure Monitoring, Ambulatory
MH  - Circadian Rhythm
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
EDAT- 2005/09/20 09:00
MHDA- 2005/12/24 09:00
CRDT- 2005/09/20 09:00
PHST- 2004/06/23 00:00 [received]
PHST- 2004/08/20 00:00 [revised]
PHST- 2004/08/23 00:00 [accepted]
PHST- 2005/09/20 09:00 [pubmed]
PHST- 2005/12/24 09:00 [medline]
PHST- 2005/09/20 09:00 [entrez]
AID - S0735-1097(05)01560-3 [pii]
AID - 10.1016/j.jacc.2004.08.071 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2005 Sep 20;46(6):975-83. doi: 10.1016/j.jacc.2004.08.071.

PMID- 35076678
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20220726
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 327
IP  - 4
DP  - 2022 Jan 25
TI  - Aspirin Use for Preeclampsia Prevention Among Women With Prepregnancy Diabetes, 
      Obesity, and Hypertension.
PG  - 388-390
LID - 10.1001/jama.2021.22749 [doi]
AB  - This study estimates aspirin use for preeclampsia prevention in pregnant women 
      with prepregnancy diabetes, obesity, chronic hypertension, and combinations of 
      these factors in 2018-2020.
FAU - Ray, Joel G
AU  - Ray JG
AD  - Department of Medicine, St Michael's Hospital, Toronto, Ontario, Canada.
FAU - Abdulaziz, Kasim E
AU  - Abdulaziz KE
AD  - Better Outcomes Registry and Network Ontario, Ottawa, Canada.
FAU - Berger, Howard
AU  - Berger H
AD  - Department of Obstetrics and Gynaecology, St Michael's Hospital, Toronto, 
      Ontario, Canada.
CN  - DOH-NET (Diabetes, Obesity, and Hypertension in Pregnancy Research Network)
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - *Hypertension
MH  - Length of Stay
MH  - *Obesity
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - *Pregnancy in Diabetics
MH  - Premature Birth/epidemiology
PMC - PMC8790661
COIS- Conflict of Interest Disclosures: None reported.
EDAT- 2022/01/26 06:00
MHDA- 2022/02/03 06:00
CRDT- 2022/01/25 12:20
PHST- 2022/01/25 12:20 [entrez]
PHST- 2022/01/26 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
AID - 2788362 [pii]
AID - jld210082 [pii]
AID - 10.1001/jama.2021.22749 [doi]
PST - ppublish
SO  - JAMA. 2022 Jan 25;327(4):388-390. doi: 10.1001/jama.2021.22749.

PMID- 21921460
OWN - NLM
STAT- MEDLINE
DCOM- 20120917
LR  - 20190918
IS  - 1882-0654 (Electronic)
IS  - 0009-918X (Linking)
VI  - 50
IP  - 11
DP  - 2010 Nov
TI  - [Results of the Cilostazol Stroke Prevention Study II (CSPS II): a randomized 
      controlled trial for the comparison of cilostazol and aspirin in stroke 
      patients].
PG  - 832-4
AB  - We compared the efficacy and safety of cilostazol and aspirin in 2,672 Japanese 
      patients with non-cardioembolic ischemic stroke. The patients were randomized to 
      be allocated either on cilostazol (200 mg/day) group or aspirin (81 mg/day) 
      group, and were followed up for one to five years (average 29 months). The 
      primary endpoint was any stroke, and safety endpoint was hemorrhagic stroke or 
      hemorrhage requiring hospitalization. Annual incidence of stroke was 
      significantly lower in the cilostazol group (2.76%) than in the aspirin group 
      (3.71%) (relative risk reduction [RRR] 25.7%, p=0.0357) and annual incidence of 
      hemorrhagic stroke or hemorrhage requiring hospitalization was 0.77% in the 
      cilostazol group and 1.77% in the aspirin group (RRR 54.2%, p=0.0004). The 
      sub-analyses between subtypes of ischemic stroke showed that annual incidence of 
      hemorrhagic stroke was much lower in the cilostazol group (0.36%) than in the 
      aspirin group (1.20%) among patients with lacunar stroke (p=0.003). The results 
      suggest that cilostazol has a favorable risk-benefit profile alternative to 
      aspirin for secondary stroke prevention in patients with non-cardioembolic 
      ischemic stroke, particularly in patients with lacunar stroke, who are at high 
      risk of hemorrhagic stroke.
FAU - Uchiyama, Shinichiro
AU  - Uchiyama S
AD  - Department of Neurology, Tokyo Women's Medical University.
LA  - jpn
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Rinsho Shinkeigaku
JT  - Rinsho shinkeigaku = Clinical neurology
JID - 0417466
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cilostazol
MH  - Gastrointestinal Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Japan/epidemiology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - *Randomized Controlled Trials as Topic
MH  - Stroke/epidemiology/*prevention & control
MH  - Tetrazoles/*administration & dosage/adverse effects
EDAT- 2011/09/17 06:00
MHDA- 2012/09/18 06:00
CRDT- 2011/09/17 06:00
PHST- 2011/09/17 06:00 [entrez]
PHST- 2011/09/17 06:00 [pubmed]
PHST- 2012/09/18 06:00 [medline]
AID - JST.JSTAGE/clinicalneurol/50.832 [pii]
AID - 10.5692/clinicalneurol.50.832 [doi]
PST - ppublish
SO  - Rinsho Shinkeigaku. 2010 Nov;50(11):832-4. doi: 10.5692/clinicalneurol.50.832.

PMID- 7466856
OWN - NLM
STAT- MEDLINE
DCOM- 19810421
LR  - 20190819
IS  - 0378-4274 (Print)
IS  - 0378-4274 (Linking)
VI  - 5
IP  - 3-4
DP  - 1980 Mar
TI  - Renal toxicity of aspirin to rats pre-treated with ethinyl oestradiol.
PG  - 269-74
AB  - Castrated rats receiving aspirin at a dose level of 1000 mg/kg showed necrosis of 
      the proximal convoluted tubules, similar to that seen in female rats, and the 
      extent of this lesion was increased by oestrogen pre-treatment. Urinary 
      gamma-glutamyl transpeptidase activity was a useful indicator of the necrotic 
      changes induced.
FAU - Owen, R A
AU  - Owen RA
FAU - Heywood, R
AU  - Heywood R
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Toxicol Lett
JT  - Toxicology letters
JID - 7709027
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Castration
MH  - Ethinyl Estradiol/pharmacology
MH  - Female
MH  - Kidney/*drug effects/enzymology
MH  - Male
MH  - Rats
MH  - Urine/analysis
EDAT- 1980/03/01 00:00
MHDA- 1980/03/01 00:01
CRDT- 1980/03/01 00:00
PHST- 1980/03/01 00:00 [pubmed]
PHST- 1980/03/01 00:01 [medline]
PHST- 1980/03/01 00:00 [entrez]
AID - 0378-4274(80)90071-5 [pii]
AID - 10.1016/0378-4274(80)90071-5 [doi]
PST - ppublish
SO  - Toxicol Lett. 1980 Mar;5(3-4):269-74. doi: 10.1016/0378-4274(80)90071-5.

PMID- 1149792
OWN - NLM
STAT- MEDLINE
DCOM- 19751107
LR  - 20190623
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 31
IP  - 2
DP  - 1975 Apr
TI  - Inhibition of prostaglandin biosynthesis as the mechanism of analgesia of 
      aspirin-like drugs in the dog knee joint.
PG  - 250-60
AB  - A method has been developed to measure the analgesic action of aspirin-like drugs 
      in knee joints of anaesthetized dogs. Bradykinin, injected into the joint cavity, 
      induced a reflex rise in blood pressure which was dose-dependent; this was used 
      as a measure of nociceptive activity. The joint cavity became more sensitive to 
      bradykinin as the experiment proceeded, or when a low concentration of 
      prostaglandin E1 or E2 was infused locally. The increase in sensitivity with time 
      was prevented by local injection of aspirin or indomethacin, but that induced by 
      exogenous prostaglandin infusion was not. Injections of carrageenin into dog knee 
      joints increased the prostaglandin E2 content of synovial fluid by up to 160 ng 
      per joint; indomethacin prevented this increase. These experiments support our 
      previous conclusion that local biosynthesis of a prostaglandin (induced by mild 
      trauma) sensitizes pain receptors to mechanical or chemical stimuli. Aspirin-like 
      drugs are analgesic because they prevent prostaglandin biosynthesis, thereby 
      preventing this sensitization.
FAU - Moncada, S
AU  - Moncada S
FAU - Ferreira, S H
AU  - Ferreira SH
FAU - Vane, J R
AU  - Vane JR
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Prostaglandins)
RN  - 0 (Prostaglandins E)
RN  - 9000-07-1 (Carrageenan)
RN  - 98PI200987 (Lidocaine)
RN  - R16CO5Y76E (Aspirin)
RN  - S8TIM42R2W (Bradykinin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - *Analgesia
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Bradykinin/pharmacology
MH  - Carrageenan
MH  - Depression, Chemical
MH  - Dogs
MH  - Female
MH  - Indomethacin/pharmacology
MH  - Inflammation/chemically induced/drug therapy
MH  - Knee Joint/drug effects/*metabolism
MH  - Lidocaine/pharmacology
MH  - Male
MH  - Prostaglandins/*biosynthesis
MH  - Prostaglandins E/biosynthesis/pharmacology
MH  - Reflex/drug effects
EDAT- 1975/04/01 00:00
MHDA- 1975/04/01 00:01
CRDT- 1975/04/01 00:00
PHST- 1975/04/01 00:00 [pubmed]
PHST- 1975/04/01 00:01 [medline]
PHST- 1975/04/01 00:00 [entrez]
AID - 0014-2999(75)90047-3 [pii]
AID - 10.1016/0014-2999(75)90047-3 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1975 Apr;31(2):250-60. doi: 10.1016/0014-2999(75)90047-3.

PMID- 27907814
OWN - NLM
STAT- MEDLINE
DCOM- 20170413
LR  - 20170817
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 149
DP  - 2017 Jan
TI  - Platelet function one and three months after coronary bypass surgery in relation 
      to once or twice daily dosing of acetylsalicylic acid.
PG  - 64-69
LID - S0049-3848(16)30630-2 [pii]
LID - 10.1016/j.thromres.2016.11.018 [doi]
AB  - INTRODUCTION: Current guidelines recommend acetylsalicylic acid (ASA) treatment 
      after coronary artery bypass grafting (CABG) to reduce thrombotic vein graft 
      occlusion. The optimal dosage of ASA is not known. MATERIALS AND METHODS: 
      Forty-two patients undergoing elective CABG were randomized to receive either ASA 
      75mg or 160mg once daily (OD) or 75mg twice daily (BID) after the operation. 
      Platelet function testing was performed before, and one and three months after 
      the operation. RESULTS: White blood cell counts increased during the initial 
      postoperative days whereas platelet counts were initially slightly reduced after 
      the operation but increased after one month without any major changes of mean 
      platelet volumes. Serum thromboxane B(2) was more effectively suppressed at one 
      and three months after the operation with ASA 75mg BID or 160mg OD than with 75mg 
      OD (p<0.001). ASA 75mg BID and 160mg OD were equally effective. Adenosine 
      diphosphate stimulated platelet aggregation in whole blood (Multiplate®) was 
      increased one and three months after the operation, and this was counteracted by 
      ASA 75mg BID but not by 75 or 160mg OD. Arachidonic acid-induced aggregation was 
      more effectively inhibited by 75mg BID or 160mg OD compared to 75mg OD at three 
      months. CONCLUSIONS: Less effective inhibition of platelet activation was 
      obtained with ASA 75mg OD than with ASA 160mg OD or 75mg BID up to three months 
      after CABG. Especially the latter dose is of interest for further studies of 
      efficacy and clinical outcomes after CABG.
CI  - Copyright © 2016 Elsevier Ltd. All rights reserved.
FAU - Ivert, Torbjörn
AU  - Ivert T
AD  - Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University 
      Hospital and Department of Molecular Medicine and Surgery, Karolinska Institutet, 
      Stockholm, Sweden. Electronic address: torbjorn.ivert@ki.se.
FAU - Dalén, Magnus
AU  - Dalén M
AD  - Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University 
      Hospital and Department of Molecular Medicine and Surgery, Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Ander, Charlotte
AU  - Ander C
AD  - Department of Clinical Pharmacology, Karolinska University Hospital and 
      Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
FAU - Stålesen, Ragnhild
AU  - Stålesen R
AD  - Department of Clinical Pharmacology, Karolinska University Hospital and 
      Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
FAU - Näsman, Per
AU  - Näsman P
AD  - Center for Safety Research, KTH Royal Institute of Technology, Stockholm, Sweden.
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
AD  - Faculté de pharmacie, Université de Montréal and Research Center, Montreal Heart 
      Institute, Montréal, Québec, Canada.
FAU - Hjemdahl, Paul
AU  - Hjemdahl P
AD  - Department of Clinical Pharmacology, Karolinska University Hospital and 
      Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20161121
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Coronary Artery Bypass/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Thrombosis/blood/*etiology/*prevention & control
MH  - Thromboxane B2/blood
OTO - NOTNLM
OT  - Aspirin
OT  - Coronary artery bypass grafting
OT  - Individualized therapy
OT  - Platelet function
OT  - Thromboxane
EDAT- 2016/12/03 06:00
MHDA- 2017/04/14 06:00
CRDT- 2016/12/02 06:00
PHST- 2016/09/07 00:00 [received]
PHST- 2016/10/21 00:00 [revised]
PHST- 2016/11/20 00:00 [accepted]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2017/04/14 06:00 [medline]
PHST- 2016/12/02 06:00 [entrez]
AID - S0049-3848(16)30630-2 [pii]
AID - 10.1016/j.thromres.2016.11.018 [doi]
PST - ppublish
SO  - Thromb Res. 2017 Jan;149:64-69. doi: 10.1016/j.thromres.2016.11.018. Epub 2016 
      Nov 21.

PMID- 27464285
OWN - NLM
STAT- MEDLINE
DCOM- 20170314
LR  - 20170817
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 141
IP  - 15
DP  - 2016 Jul
TI  - [Bleeding in patients receiving dual antiplatelet therapy after acute coronary 
      syndrome - significance, prevention and interdisciplinary management].
PG  - 1107-11
LID - 10.1055/s-0042-106944 [doi]
AB  - For secondary prevention of acute coronary syndrome, guidelines recommend dual 
      antiplatelet therapy with acetylsalicylic acid and a P2Y12 receptor antagonist 
      such as clopidogrel, prasugrel or ticagrelor for a period of 12 months. Premature 
      discontinuation of dual antiplatelet therapy is associated with an increased risk 
      of ischaemic events. However, antiplatelet therapy is also associated with an 
      increased risk of bleeding that should not be under- or overestimated. To ensure 
      an optimal care of patients receiving dual antiplatelet therapy after an acute 
      coronary syndrome, an interdisciplinary group of experienced experts in the 
      fields of cardiology, cardiac surgery, gastroenterology, anaesthesiology, 
      intensive care and haemostaseology gathered bleeding-related information and 
      developed recommendations relevant to daily clinical practice. These include the 
      significance of bleeding events in the course of treatment, measures for bleeding 
      prevention and the adequate care of patients with bleedings.
CI  - © Georg Thieme Verlag KG Stuttgart · New York.
FAU - Zeymer, U
AU  - Zeymer U
FAU - Koscielny, J
AU  - Koscielny J
FAU - von Heymann, C
AU  - von Heymann C
FAU - Spannagl, M
AU  - Spannagl M
FAU - Labenz, J
AU  - Labenz J
FAU - Cremer, J
AU  - Cremer J
FAU - Giannitsis, E
AU  - Giannitsis E
FAU - Darius, H
AU  - Darius H
FAU - Goss, F
AU  - Goss F
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Interdisziplinäres Management von Blutungen unter dualer antithrombozytärer 
      Therapie nach akutem Koronarsyndrom.
DEP - 20160727
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*complications/*drug therapy
MH  - Aspirin/administration & dosage/adverse effects
MH  - Evidence-Based Medicine
MH  - Hemorrhage/*etiology/*therapy
MH  - Humans
MH  - Patient Care Team/organization & administration
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*adverse effects
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/adverse effects
MH  - Treatment Outcome
EDAT- 2016/07/28 06:00
MHDA- 2017/03/16 06:00
CRDT- 2016/07/28 06:00
PHST- 2016/07/28 06:00 [entrez]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/03/16 06:00 [medline]
AID - 10.1055/s-0042-106944 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2016 Jul;141(15):1107-11. doi: 10.1055/s-0042-106944. Epub 
      2016 Jul 27.

PMID- 7528480
OWN - NLM
STAT- MEDLINE
DCOM- 19950125
LR  - 20131121
IS  - 0201-7563 (Print)
IS  - 0201-7563 (Linking)
IP  - 4
DP  - 1994 Jul-Aug
TI  - [Current principles of the clinical use of central-action analgesics].
PG  - 16-20
AB  - The author analyzes the results of experimental and clinical studies of various 
      central action analgesics used for total anesthesia, postoperative analgesia, and 
      chronic pain relief in cancer patients. General shortcomings of all opioid 
      analgesics were revealed: analgesias not always full-value because of different 
      individual sensitivity to opioids, and side effects were often serious. The 
      latest progress of the fundamental sciences in research of the mechanisms of pain 
      and body responses related to pain helped improve the available and develop new 
      more effective methods for total anesthesia and postoperative analgesia on the 
      basis of opioid analgesics with the use of special nonopiate components 
      compensating for the defects of opiate analgesia: clofelin, an adreno-positive 
      agent; acelysin and contrykal, prostaglandin and kinin synthesis inhibitors. 
      Synthetic opioids of the latest generation (buprenorphine, tramadol) were found 
      preferable in the treatment of chronic pain in cancer vs. morphine and its 
      analogs; an alternative scheme of drug therapy of chronic pain on the basis of 
      these drugs is offered which is highly effective and causes the minimal side 
      effects.
FAU - Osipova, N A
AU  - Osipova NA
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Sovremennye printsipy klinicheskogo primeneniia analgetikov tsentral'nogo 
      deĭstviia.
PL  - Russia (Federation)
TA  - Anesteziol Reanimatol
JT  - Anesteziologiia i reanimatologiia
JID - 7705399
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Drug Combinations)
RN  - 0 (acetylsalicylate, glycine, lysine drug combination)
RN  - 76I7G6D29C (Morphine)
RN  - 9087-70-1 (Aprotinin)
RN  - K3Z4F929H6 (Lysine)
RN  - MN3L5RMN02 (Clonidine)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Analgesics/therapeutic use
MH  - Analgesics, Opioid/*therapeutic use
MH  - Animals
MH  - Aprotinin/therapeutic use
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Chronic Disease
MH  - Clonidine/therapeutic use
MH  - Drug Combinations
MH  - Glycine/therapeutic use
MH  - Humans
MH  - Lysine/analogs & derivatives/therapeutic use
MH  - Mice
MH  - Morphine/therapeutic use
MH  - Pain/drug therapy
MH  - Pain, Postoperative/drug therapy
RF  - 38
EDAT- 1994/07/01 00:00
MHDA- 1994/07/01 00:01
CRDT- 1994/07/01 00:00
PHST- 1994/07/01 00:00 [pubmed]
PHST- 1994/07/01 00:01 [medline]
PHST- 1994/07/01 00:00 [entrez]
PST - ppublish
SO  - Anesteziol Reanimatol. 1994 Jul-Aug;(4):16-20.

PMID- 8857034
OWN - NLM
STAT- MEDLINE
DCOM- 19970206
LR  - 20131121
IS  - 0367-0643 (Print)
IS  - 0367-0643 (Linking)
VI  - 32
IP  - 3-4
DP  - 1994
TI  - [The relationship between resorption and the morphological changes in the gastric 
      mucosa of rats after acute and chronic exposures to acetylsalicylic acid].
PG  - 69-79
AB  - The effect of acute and chronic ASA administration on stomach and duodenal mucosa 
      was studied on white male Wistar rats. ASA (250 mg/kg b.w.) was administered by 
      esophageal intubation in a single dose, and the rats were sacrificed at 2, 6, 24 
      hours, or after two, three, ten and twenty days, 24 hours after the last ASA 
      application. Two types of erosions were found in the first 24 hours: superficial 
      and deep. Superficial erosions showed advanced healing by the 24th hour. Deep 
      erosions appearing between 6 and 24 hours from the beginning of experiment became 
      deeper, after two and three days ASA application. They had morphological features 
      of chronic ones by the 10-20th day. ASA resorbtion was most expressed by the 3rd 
      day from the experimental onset (plasma concentration 0.348 +/- 0.052 g/l). The 
      resorbtion was decreased in chronic experiment, and plasma concentration (0.236 
      +/- 0.046 g/l, 0.244 +/- 0.045 g/l) showed statistically reliable lower values.
FAU - Tsaneva, M
AU  - Tsaneva M
AD  - Department of Pathology, Higher Medical School, Stara Zagora.
FAU - Tolekova, A
AU  - Tolekova A
FAU - Ilieva, G
AU  - Ilieva G
FAU - Logofetov, A
AU  - Logofetov A
LA  - bul
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Zavisimost mezhdu rezorbtsiiata i morfologichnite promeni v stomashnata ligavitsa 
      na plukhove sled ostro i khronichno vuzdeistvie s atsetilsalitsilova kiselina.
PL  - Bulgaria
TA  - Eksp Med Morfol
JT  - Eksperimentalna meditsina i morfologiia
JID - 0007506
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Analysis of Variance
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/blood/*pharmacology
MH  - Aspirin/blood/*pharmacology
MH  - Gastric Mucosa/*drug effects/metabolism/pathology
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Time Factors
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Eksp Med Morfol. 1994;32(3-4):69-79.

PMID- 27438118
OWN - NLM
STAT- MEDLINE
DCOM- 20180626
LR  - 20181202
IS  - 2380-6591 (Electronic)
IS  - 2380-6583 (Print)
VI  - 1
IP  - 3
DP  - 2016 Jun 1
TI  - Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An 
      Overview of Systematic Reviews.
PG  - 341-9
LID - 10.1001/jamacardio.2016.0218 [doi]
AB  - IMPORTANCE: The Million Hearts initiative emphasizes ABCS (aspirin for high-risk 
      patients, blood pressure [BP] control, cholesterol level management, and smoking 
      cessation). Evidence of the effects of drugs used to achieve ABCS has not been 
      synthesized comprehensively in the prevention of primary atherosclerotic 
      cardiovascular disease (ASCVD). OBJECTIVE: To compare the efficacy and safety of 
      aspirin, BP-lowering therapy, statins, and tobacco cessation drugs for fatal and 
      nonfatal ASCVD outcomes in primary ASCVD prevention. EVIDENCE REVIEW: Structured 
      search of the Cochrane Database of Systematic Reviews, Database of Abstracts of 
      Reviews of Effects (DARE), Health Technology Assessment Database (HTA), MEDLINE, 
      EMBASE, and PROSPERO International Prospective Systematic Review Trial Register 
      to identify systematic reviews published from January 1, 2005, to June 17, 2015, 
      that reported the effect of aspirin, BP-lowering therapy, statin, or tobacco 
      cessation drugs on ASCVD events in individuals without prevalent ASCVD. 
      Additional studies were identified by searching the reference lists of included 
      systematic reviews, meta-analyses, and health technology assessment reports. 
      Reviews were selected according to predefined criteria and appraised for 
      methodologic quality using the Assessment of Multiple Systematic Reviews (AMSTAR) 
      tool (range, 0-11). Studies were independently reviewed for key participant and 
      intervention characteristics. Outcomes that were meta-analyzed in each included 
      review were extracted. Qualitative synthesis was performed, and data were 
      analyzed from July 2 to August 13, 2015. FINDINGS: From a total of 1967 reports, 
      35 systematic reviews of randomized clinical trials were identified, including 15 
      reviews of aspirin, 4 reviews of BP-lowering therapy, 12 reviews of statins, and 
      4 reviews of tobacco cessation drugs. Methodologic quality varied, but 30 reviews 
      had AMSTAR ratings of 5 or higher. Compared with placebo, aspirin (relative risk 
      [RR], 0.90; 95% CI, 0.85-0.96) and statins (RR, 0.75; 95% CI, 0.70-0.81) reduced 
      the risk for ASCVD. Compared with placebo, BP-lowering therapy reduced the risk 
      for coronary heart disease (RR, 0.84; 95% CI, 0.79-0.90) and stroke (RR, 0.64; 
      95% CI, 0.56-0.73). Tobacco cessation drugs increased the odds of continued 
      abstinence at 6 months (odds ratio range, 1.82 [95% CI, 1.60-2.06] to 2.88 [95% 
      CI, 2.40-3.47]), but the direct effects on ASCVD were poorly reported. Aspirin 
      increased the risk for major bleeding (RR, 1.54; 95% CI, 1.30-1.82), and statins 
      did not increase overall risk for adverse effects (RR, 1.00; 95% CI, 0.97-1.03). 
      Adverse effects of BP-lowering therapy and tobacco cessation drugs were poorly 
      reported. CONCLUSIONS AND RELEVANCE: This overview demonstrates high-quality 
      evidence to support aspirin, BP-lowering therapy, and statins for primary ASCVD 
      prevention and tobacco cessation drugs for smoking cessation. Treatment effects 
      of each drug can be used to enrich discussions between health care professionals 
      and patients in primary ASCVD prevention.
FAU - Karmali, Kunal N
AU  - Karmali KN
AD  - Division of Epidemiology, Department of Preventive Medicine, Northwestern 
      University Feinberg School of Medicine, Chicago, Illinois2Division of Cardiology, 
      Department of Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois.
FAU - Lloyd-Jones, Donald M
AU  - Lloyd-Jones DM
AD  - Division of Epidemiology, Department of Preventive Medicine, Northwestern 
      University Feinberg School of Medicine, Chicago, Illinois2Division of Cardiology, 
      Department of Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois.
FAU - Berendsen, Mark A
AU  - Berendsen MA
AD  - Galter Health Sciences Library, Northwestern University Feinberg School of 
      Medicine, Chicago, Illinois.
FAU - Goff, David C Jr
AU  - Goff DC Jr
AD  - Colorado School of Public Health, University of Colorado Anschutz Medical Center, 
      Aurora.
FAU - Sanghavi, Darshak M
AU  - Sanghavi DM
AD  - Center for Medicare & Medicaid Services, Baltimore, Maryland.
FAU - Brown, Nina C
AU  - Brown NC
AD  - Center for Medicare & Medicaid Services, Baltimore, Maryland.
FAU - Korenovska, Liliya
AU  - Korenovska L
AD  - The MITRE Corporation, McLean, Virginia.
FAU - Huffman, Mark D
AU  - Huffman MD
AD  - Division of Epidemiology, Department of Preventive Medicine, Northwestern 
      University Feinberg School of Medicine, Chicago, Illinois2Division of Cardiology, 
      Department of Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois7Asso.
LA  - eng
GR  - T32 HL069771/HL/NHLBI NIH HHS/United States
GR  - UL1 TR001422/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - JAMA Cardiol
JT  - JAMA cardiology
JID - 101676033
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - JAMA Cardiol. 2017 Apr 1;2(4):461. PMID: 28146229
MH  - Aspirin/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Coronary Artery Disease/drug therapy
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Tobacco Use Cessation
PMC - PMC5053397
MID - NIHMS817182
COIS- Disclosures: All authors have completed and submitted the ICMJE Form for 
      Disclosure of Potential Conflicts of Interest.
EDAT- 2016/07/22 06:00
MHDA- 2018/06/27 06:00
CRDT- 2016/07/21 06:00
PHST- 2016/07/21 06:00 [entrez]
PHST- 2016/07/22 06:00 [pubmed]
PHST- 2018/06/27 06:00 [medline]
AID - 2517393 [pii]
AID - 10.1001/jamacardio.2016.0218 [doi]
PST - ppublish
SO  - JAMA Cardiol. 2016 Jun 1;1(3):341-9. doi: 10.1001/jamacardio.2016.0218.

PMID- 15821823
OWN - NLM
STAT- MEDLINE
DCOM- 20050727
LR  - 20191109
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 11
IP  - 2
DP  - 2005 Apr
TI  - A protocol for the use of enoxaparin during pregnancy: results from 85 
      pregnancies including 13 multiple gestation pregnancies.
PG  - 171-81
AB  - Many practitioners consider low-molecular-weight heparin (LMWH) an alternative to 
      unfractionated heparin, although there are limited safety data regarding maternal 
      and fetal outcomes in patients using an LMWH during pregnancy. A retrospective 
      chart review was performed on 72 patients with thrombophilia exposed to the LMWH, 
      enoxaparin, during pregnancy. Eighty-five pregnancies resulted in 93 of 99 
      potential live births. Eleven of 12 twin pregnancies and one triplet pregnancy 
      were successful. One preterm live birth infant of 33 weeks' gestation did not 
      survive. Three patients with thrombophilia spontaneously aborted. A patient 
      receiving injectable fertility treatment had spontaneously aborted one twin at 5 
      weeks' gestation. One patient terminated the pregnancy after discovering the 
      presence of Down's syndrome. The mean maximum dose required to achieve a 
      therapeutic anti-Xa level of 0.2-0.4 IU/mL at 5 to 6 hours following 
      administration, was 38.1 mg every 12 hours (median 35 mg, range 30-75 mg every 12 
      hours). The mean anti-Xa level was 0.28 IU/mL (median 0.3, range 0.05-0.8 IU/mL). 
      A total of nine patients experienced bleeding events, two requiring 
      discontinuation of enoxaparin for the remainder of the pregnancy. Two patients 
      experienced injection site reactions requiring discontinuation of enoxaparin. 
      Three patients developed preeclampsia, two placenta abruptio, and one placenta 
      previa. No thromboembolic complications or osteoporotic fractures had occurred. 
      Enoxaparin was safe and effective for preventing thromboembolism and adverse 
      obstetrical complications in our patients, including 12 of 13 multiple gestation 
      pregnancies.
FAU - Huxtable, Lindsay M
AU  - Huxtable LM
AD  - Midwestern University College of Pharmacy-Glendale, Department of Pharmacy 
      Practice, Arizona 85308, USA. lhuxta@midwestern.edu
FAU - Tafreshi, Mohammad J
AU  - Tafreshi MJ
FAU - Ondreyco, Sharon M
AU  - Ondreyco SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Enoxaparin)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacology
MH  - Clinical Protocols
MH  - Dose-Response Relationship, Drug
MH  - Drug Monitoring
MH  - Enoxaparin/administration & dosage/adverse effects/*pharmacology
MH  - Female
MH  - Fetus
MH  - Hemorrhage
MH  - Heparin, Low-Molecular-Weight/pharmacology
MH  - Humans
MH  - Middle Aged
MH  - Pregnancy/*drug effects/physiology
MH  - Pregnancy Outcome
MH  - Pregnancy, Multiple/*drug effects/physiology
MH  - Risk Factors
EDAT- 2005/04/12 09:00
MHDA- 2005/07/28 09:00
CRDT- 2005/04/12 09:00
PHST- 2005/04/12 09:00 [pubmed]
PHST- 2005/07/28 09:00 [medline]
PHST- 2005/04/12 09:00 [entrez]
AID - 10.1177/107602960501100206 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2005 Apr;11(2):171-81. doi: 10.1177/107602960501100206.

PMID- 9471923
OWN - NLM
STAT- MEDLINE
DCOM- 19980218
LR  - 20131121
IS  - 1427-440X (Print)
IS  - 1427-440X (Linking)
VI  - 43
DP  - 1997
TI  - [The effect of exercise on the pharmacokinetics of acetaminophen and 
      acetylsalicylic acid].
PG  - 57-66
AB  - The influence of exercise on the pharmacokinetics of drugs is not sufficiently 
      apparent. Therefore the purpose of my study was to evaluate the influence of 
      standardized exercise on pharmacokinetics of acetaminophen and acetylsalicylic 
      acid (ASA) and also to establish whether moderate (submaximal) exercise demands 
      modification involving the doses of these drugs. That was studied in 20 healthy 
      young (ranging in age 22-42 years) male subjects receiving acetaminophen or ASA, 
      1 g orally. All subjects were non-smokers who abstained from using caffeine and 
      alcohol 2 weeks before and in the period of study, which consisted of two parts: 
      resting trials and exercise trials. Exercise trials: treadmill walking--3 mph 
      (4.8 km/h), 20 minutes per half an hour for 3 hours (50% VO2max). On the rest day 
      volunteers stayed in the supine or sitting position for the same period. Blood 
      samples were collected from a forearm (antecubital) vein through an indwelling 
      cannula. Acetaminophen and ASA plasma concentrations were determined by FPIA. The 
      plasma level-time curves were fitted according to one compartment open 
      pharmacokinetic model. Plasma concentrations measured (7 days) before and after 
      the physical exercise, did not demonstrate statistically significant differences 
      (Fig. 1, 2). The results of this study indicate that the pharmacokinetics of 
      single doses of acetaminophen and ASA are independent of submaximal physical 
      exercise. There were no significant differences between the rest and the exercise 
      day in the pharmacokinetic parameters of acetaminophen and ASA (Fig. 3). Since 
      both drugs belong to the group whose elimination is not due to the liver flow, it 
      is not surprising that its total body clearance, and its half-life of elimination 
      were unaffected by physical exercise. The minor changes in haematocrit, plasma 
      protein, free fatty acids, levels which were reported are probably not sufficient 
      to modify the disposition of these drugs. Therefore, there is no need for dose 
      adjustment in patient who moderately exercises (50% VO2max). A little change in 
      pharmacokinetics parameters of acetaminophen and ASA could arise due to some 
      differences of its physical and chemical properties. Without further studies on 
      this subject, the explanation of that finding remains very much speculative.
FAU - Sawrymowicz, M
AU  - Sawrymowicz M
AD  - Z Katedry Farmakologii Klinicznej i Toksykologii Pomorskiej Akademii Medycznej w 
      Szczecinie, Szczecin.
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Wpływ wysiłku fizycznego na farmakokinetyke acetaminofenu i kwasu 
      acetylosalicylowego.
PL  - Poland
TA  - Ann Acad Med Stetin
JT  - Annales Academiae Medicae Stetinensis
JID - 7506854
RN  - 0 (Blood Proteins)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/*blood
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*blood
MH  - Blood Proteins/analysis/drug effects
MH  - Exercise/*physiology
MH  - Fatty Acids, Nonesterified/blood
MH  - Half-Life
MH  - Hematocrit
MH  - Humans
MH  - Male
MH  - Reference Values
EDAT- 1997/01/01 00:00
MHDA- 1998/02/21 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1998/02/21 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Ann Acad Med Stetin. 1997;43:57-66.

PMID- 3913724
OWN - NLM
STAT- MEDLINE
DCOM- 19860505
LR  - 20131121
IS  - 0025-7850 (Print)
IS  - 0025-7850 (Linking)
VI  - 16
IP  - 4
DP  - 1985
TI  - The analgesic effects of aspirin and placebo on experimentally induced tooth pulp 
      pain.
PG  - 417-28
AB  - We examined the relative analgesic potency of aspirin and placebo in a 
      within-subject-repeated-measure experiment using a precision tooth pulp 
      stimulation technique with long-term stability (r = 0.93) for more than two 
      months between measures. The attenuation of pain perception was evaluated using a 
      standardized magnitude estimation procedure and constructing an individual 
      psychophysical function for each trial. The data were fit equally well by either 
      a straight line (Y = mX + b) or a power function (Y = mXa + b). Using the line 
      fit and distribution insensitive conservative statistical tests, the effect of 
      each treatment was compared to baseline and the treatments were compared to each 
      other. In randomized, double-blind trials we found reliable effects of both 
      aspirin (p less than 0.001) and placebo (p less than 0.001) but no difference (p 
      = 0.08) between these two treatments. However, on an individual basis, 12 of 17 
      subjects displayed a larger analgesic response to aspirin than to placebo (p less 
      than 0.05).
FAU - Lee, M H
AU  - Lee MH
FAU - Zarestsky, H H
AU  - Zarestsky HH
FAU - Ernst, M
AU  - Ernst M
FAU - Dworkin, B
AU  - Dworkin B
FAU - Jonas, R
AU  - Jonas R
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med
JT  - Journal of medicine
JID - 7505566
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analgesia
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dental Pulp Diseases/*drug therapy
MH  - Female
MH  - Humans
MH  - Placebos
MH  - Random Allocation
MH  - Regression Analysis
MH  - Toothache/*drug therapy
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - J Med. 1985;16(4):417-28.

PMID- 10480755
OWN - NLM
STAT- MEDLINE
DCOM- 19991007
LR  - 20190921
IS  - 0785-3890 (Print)
IS  - 0785-3890 (Linking)
VI  - 31
IP  - 4
DP  - 1999 Aug
TI  - Chronic hypertension in pregnancy.
PG  - 246-52
AB  - Pregnancies in women with chronic hypertension are at increased risk of 
      superimposed pre-eclampsia, abruptio placentae, fetal growth retardation and 
      prematurity. The frequencies of these complications are increased in those women 
      who have high-risk chronic hypertension, ie severe hypertension or pre-existing 
      cardiovascular or renal diseases, as well as in those with target organ damage. 
      Such women should receive antihypertensive therapy and close management to 
      improve maternal and fetal outcome. In women with low-risk chronic hypertension, 
      antihypertensive treatments do not improve pregnancy outcome. Prophylactic 
      low-dose acetylsalicylic acid treatment does not reduce the frequency of 
      superimposed pre-eclampsia nor does it improve perinatal outcome in these 
      pregnancies.
FAU - Haddad, B
AU  - Haddad B
AD  - Department of Obstetrics and Gynecology, University of Tennessee, Memphis 38103, 
      USA.
FAU - Sibai, B M
AU  - Sibai BM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abruptio Placentae/etiology
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Chronic Disease
MH  - Female
MH  - Fetal Growth Retardation/etiology
MH  - Humans
MH  - Hypertension/*complications/prevention & control
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Pre-Eclampsia/etiology
MH  - Pregnancy
MH  - *Pregnancy Complications, Cardiovascular/prevention & control
MH  - Pregnancy Outcome
MH  - Risk Factors
RF  - 47
EDAT- 1999/09/10 00:00
MHDA- 1999/09/10 00:01
CRDT- 1999/09/10 00:00
PHST- 1999/09/10 00:00 [pubmed]
PHST- 1999/09/10 00:01 [medline]
PHST- 1999/09/10 00:00 [entrez]
AID - 10.3109/07853899908995887 [doi]
PST - ppublish
SO  - Ann Med. 1999 Aug;31(4):246-52. doi: 10.3109/07853899908995887.

PMID- 26680524
OWN - NLM
STAT- MEDLINE
DCOM- 20160923
LR  - 20181113
IS  - 1476-5446 (Electronic)
IS  - 1462-0049 (Linking)
VI  - 16
IP  - 4
DP  - 2015 Dec
TI  - No evidence for stopping long-term aspirin therapy before tooth extraction.
PG  - 118-9
LID - 10.1038/sj.ebd.6401137 [doi]
AB  - DATA SOURCES: PubMed, ScienceDirect and EBSCOhost databases. STUDY SELECTION: 
      Prospective randomised controlled trials (RCTs) or controlled trials. DATA 
      EXTRACTION AND SYNTHESIS: Two independent investigators extracted data. The 
      primary measured outcomes were rates of haemorrhage and bleeding time. 
      Disagreements were clarified with a third investigator. Relevant authors were 
      contacted if any relevant data was missing. The Grades of Recommendation, 
      Assessment, Development and Evaluation (GRADE) system was used to evaluate the 
      overall quality of evidence. The authors used standardised mean difference or 
      relative risk to evaluate each outcome. RESULTS: Ten studies were included, three 
      randomised controlled trials and seven controlled trials. A total of 1752 
      patients were enrolled in the meta-analysis; the study group comprised 529 
      patients on long-term aspirin therapy, and the control group comprised 1223 
      patients. The risk of post-operative haemorrhage was significantly higher in 
      patients on aspirin therapy (relative risk=2.46; 95% confidence interval: 
      1.45-4.81) but bleeding time was not significantly different between the two 
      groups (standardised mean difference=0.63; 95% CI: - 0.04 to 1.31). CONCLUSIONS: 
      Increased rates of haemorrhage are observed in patients on long-term aspirin 
      therapy. The authors recommend not stopping long-term aspirin prior to dental 
      extraction, and local measures for haemostasis should be enhanced when required.
FAU - Halley, Daphne
AU  - Halley D
AD  - Dublin Dental University Hospital, Dublin, Ireland.
FAU - Weld-Moore, Robert
AU  - Weld-Moore R
AD  - Dublin Dental University Hospital, Dublin, Ireland.
FAU - Duane, Brett
AU  - Duane B
AD  - Dublin Dental University Hospital, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Evid Based Dent
JT  - Evidence-based dentistry
JID - 100883603
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Evidence-Based Dentistry
MH  - Hemostasis, Surgical
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Postoperative Hemorrhage/*etiology/*prevention & control
MH  - *Tooth Extraction
MH  - Withholding Treatment
EDAT- 2015/12/19 06:00
MHDA- 2016/09/24 06:00
CRDT- 2015/12/19 06:00
PHST- 2015/12/19 06:00 [entrez]
PHST- 2015/12/19 06:00 [pubmed]
PHST- 2016/09/24 06:00 [medline]
AID - 6401137 [pii]
AID - 10.1038/sj.ebd.6401137 [doi]
PST - ppublish
SO  - Evid Based Dent. 2015 Dec;16(4):118-9. doi: 10.1038/sj.ebd.6401137.

PMID- 17875111
OWN - NLM
STAT- MEDLINE
DCOM- 20071207
LR  - 20181201
IS  - 0269-4727 (Print)
IS  - 0269-4727 (Linking)
VI  - 32
IP  - 5
DP  - 2007 Oct
TI  - Possible case of potentiation of the antiplatelet effect of cilostazol by 
      grapefruit juice.
PG  - 457-9
AB  - We present a case of purpura associated with concomitant ingestion of cilostazol, 
      aspirin and grapefruit juice. A 79-year-old man with atherosclerosis obliterans, 
      taking cilostazol and aspirin, complained of purpura. Interview by a pharmacist 
      revealed that he had been taking grapefruit juice for a month. His purpura 
      disappeared upon cessation of grapefruit juice, although his medication was not 
      altered. The most probable cause of his purpura is an increase in the blood level 
      of cilostazol because of the inhibition of cilostazol metabolism by components of 
      grapefruit juice. Aspirin may possibly have potentiated the risk of purpura. 
      Grapefruit juice should be avoided in patients taking cilostazol, especially in 
      patients being concomitantly treated with other anticoagulants.
FAU - Taniguchi, K
AU  - Taniguchi K
AD  - Nara Kouseikai Hospital, Nara, Japan.
FAU - Ohtani, H
AU  - Ohtani H
FAU - Ikemoto, T
AU  - Ikemoto T
FAU - Miki, A
AU  - Miki A
FAU - Hori, S
AU  - Hori S
FAU - Sawada, Y
AU  - Sawada Y
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/pharmacokinetics
MH  - Beverages
MH  - Cilostazol
MH  - *Citrus
MH  - *Food-Drug Interactions
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*adverse effects/blood/pharmacokinetics
MH  - Purpura/chemically induced
MH  - Tetrazoles/*adverse effects/blood/pharmacokinetics
EDAT- 2007/09/19 09:00
MHDA- 2007/12/08 09:00
CRDT- 2007/09/19 09:00
PHST- 2007/09/19 09:00 [pubmed]
PHST- 2007/12/08 09:00 [medline]
PHST- 2007/09/19 09:00 [entrez]
AID - JCP844 [pii]
AID - 10.1111/j.1365-2710.2007.00844.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2007 Oct;32(5):457-9. doi: 10.1111/j.1365-2710.2007.00844.x.

PMID- 9161655
OWN - NLM
STAT- MEDLINE
DCOM- 19970721
LR  - 20170214
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 31
IP  - 5
DP  - 1997 May
TI  - Nitroprusside treatment of erythromelalgia in an adolescent female.
PG  - 590-2
AB  - OBJECTIVE: To report a case of erythromelalgia in an adolescent patient 
      successfully treated with nitroprusside. CASE SUMMARY: A 15-year-old girl with 
      erythromelalgia resistant to aspirin therapy received an infusion of 
      nitroprusside. The response of the erythromelalgia to nitroprusside was dramatic, 
      with complete pain resolution within 17 hours after the start of therapy. No 
      relapse of erythromelalgia was seen when nitroprusside was discontinued and the 
      patient remained well after 6 months. DISCUSSION: This case adds to existing 
      literature substantiating the benefit of nitroprusside for the treatment of 
      erythromelalgia in pediatric patients. Erythromelalgia in children may represent 
      a different disease entity than that seen in adults, which is commonly responsive 
      to aspirin therapy. The pathogenesis of erythromelalgia is unclear and precludes 
      formulating a proposed mechanism by which nitroprusside has benefit in children. 
      CONCLUSIONS: Nitroprusside is valuable for erythromelalgia resistant to aspirin 
      therapy in pediatric patients. Because of unanswered questions regarding the 
      disease, aspirin remains the agent of first choice in all patients with this rare 
      disease.
FAU - Stone, J D
AU  - Stone JD
AD  - Community Medical Center, Missoula, MT, USA.
FAU - Rivey, M P
AU  - Rivey MP
FAU - Allington, D R
AU  - Allington DR
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Vasodilator Agents)
RN  - 169D1260KM (Nitroprusside)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Analgesics, Non-Narcotic/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Erythromelalgia/*drug therapy/rehabilitation
MH  - Female
MH  - Humans
MH  - Nitroprusside/*therapeutic use
MH  - Vasodilator Agents/*therapeutic use
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - 10.1177/106002809703100513 [doi]
PST - ppublish
SO  - Ann Pharmacother. 1997 May;31(5):590-2. doi: 10.1177/106002809703100513.

PMID- 3788816
OWN - NLM
STAT- MEDLINE
DCOM- 19870114
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 58
IP  - 13
DP  - 1986 Dec 1
TI  - Effects of dipyridamole and low-dose aspirin therapy on platelet adhesion to 
      vascular subendothelium.
PG  - 1261-4
AB  - The effect on platelet function of low-dose aspirin (ASA) and dipyridamole alone 
      or in combination was evaluated after repeated dosing in 5 healthy volunteers. 
      The subjects were treated according to a randomized, single-blind, crossover 
      design with 150 mg of dipyridamole, 25 mg of ASA, the 2 drugs together or placebo 
      twice a day for 3 days. Platelet adhesin was evaluated using an experimental 
      model of adhesion to rat aorta subendothelium under controlled hemodynamic 
      conditions in the presence of red blood cells. Dipyridamole significantly reduced 
      platelet adhesion both alone and in combination with ASA. ASA by itself did not 
      significantly modify platelet adhesion, but completely blocked serum thromboxane 
      production and platelet aggregation by arachidonic acid. Thus, low-dose ASA and 
      dipyridamole may have a complementary action, modifying at the same time 2 
      platelet functions, adhesion and aggregation, both relevant in the pathogenesis 
      of thrombosis.
FAU - Lauri, D
AU  - Lauri D
FAU - Zanetti, A
AU  - Zanetti A
FAU - Dejana, E
AU  - Dejana E
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Drug Combinations)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Vessels/cytology/*drug effects
MH  - Dipyridamole/*pharmacology
MH  - Drug Combinations
MH  - Endothelium/cytology/drug effects
MH  - Humans
MH  - Male
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/drug effects
EDAT- 1986/12/01 00:00
MHDA- 1986/12/01 00:01
CRDT- 1986/12/01 00:00
PHST- 1986/12/01 00:00 [pubmed]
PHST- 1986/12/01 00:01 [medline]
PHST- 1986/12/01 00:00 [entrez]
AID - 0002-9149(86)90394-2 [pii]
AID - 10.1016/0002-9149(86)90394-2 [doi]
PST - ppublish
SO  - Am J Cardiol. 1986 Dec 1;58(13):1261-4. doi: 10.1016/0002-9149(86)90394-2.

PMID- 2022012
OWN - NLM
STAT- MEDLINE
DCOM- 19910606
LR  - 20201209
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 83
IP  - 5
DP  - 1991 May
TI  - Combined administration of aspirin and a specific thrombin inhibitor in man.
PG  - 1510-8
AB  - BACKGROUND: Heparin is of limited value as an antithrombotic drug in the presence 
      of platelet activation and residual thrombus. Greater anticoagulant activity can 
      be achieved in vivo with more specific thrombin inhibitors. Heparin may also 
      increase the risk of bleeding by an effect on platelets that is independent of 
      its thrombin inhibitory activity. METHODS AND RESULTS: The pharmacodynamic and 
      pharmacokinetic effects of a novel thrombin inhibitor, argatroban, were examined 
      alone and in combination with aspirin in normal male volunteers. Argatroban 
      induced a dose-dependent prolongation of the thrombin time and the activated 
      partial thromboplastin time (aPTT). aPTT had returned to its pretreatment value 1 
      hour after stopping the infusion of argatroban. Six male subjects received an 
      infusion of 1 micrograms/kg/min argatroban after the administration of two doses 
      of 162.5 mg aspirin or a matching placebo. At this dose, aspirin decreased serum 
      thromboxane B2 by a mean of 99% and prolonged the bleeding time (230 +/- 52 
      versus 320 +/- 113 seconds, p less than 0.01). Argatroban given alone increased 
      thrombin time by 454 +/- 18% and aPTT by 160 +/- 3%. Steady-state plasma 
      concentrations were achieved at 1 hour and declined exponentially with an 
      elimination half-life of 24 +/- 4 minutes. Neither the anticoagulant effects nor 
      the plasma concentrations of argatroban were altered by aspirin. Furthermore, 
      argatroban did not increase the bleeding time when given alone and did not 
      further prolong the bleeding time when combined with aspirin. CONCLUSION: The 
      combination of aspirin and argatroban may prove to be an effective therapeutic 
      strategy in the prevention of coronary thrombosis.
FAU - Clarke, R J
AU  - Clarke RJ
AD  - Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN 37232.
FAU - Mayo, G
AU  - Mayo G
FAU - FitzGerald, G A
AU  - FitzGerald GA
FAU - Fitzgerald, D J
AU  - Fitzgerald DJ
LA  - eng
GR  - HL-30400/HL/NHLBI NIH HHS/United States
GR  - HL-40056/HL/NHLBI NIH HHS/United States
GR  - TWO462/TW/FIC NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Antithrombins)
RN  - 0 (Drug Combinations)
RN  - 0 (Pipecolic Acids)
RN  - 0 (Sulfonamides)
RN  - 94ZLA3W45F (Arginine)
RN  - IY90U61Z3S (argatroban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 1991 May;83(5):1815-7. PMID: 2022032
MH  - Adult
MH  - Antithrombins/*pharmacology
MH  - Arginine/analogs & derivatives
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Humans
MH  - Male
MH  - Pipecolic Acids/*pharmacology
MH  - Sulfonamides
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
AID - 10.1161/01.cir.83.5.1510 [doi]
PST - ppublish
SO  - Circulation. 1991 May;83(5):1510-8. doi: 10.1161/01.cir.83.5.1510.

PMID- 16815474
OWN - NLM
STAT- MEDLINE
DCOM- 20061103
LR  - 20131121
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 79
IP  - 19
DP  - 2006 Oct 4
TI  - Antioxidative enzyme and glutathione S-transferase activities in diabetic rats 
      exposed to long-term ASA treatment.
PG  - 1804-11
AB  - Low-dose acetylsalicylic acid (ASA) treatment is a standard therapeutic approach 
      in diabetes mellitus for prevention of long-term vascular complications. The aim 
      of the present work was to investigate the effect of long-term ASA administration 
      in experimental diabetes on activities of some liver enzymes: glutathione 
      peroxidase (GSHPx), catalase, glucose-6-phosphate dehydrogenase (G6PDH) and 
      glutathione S-transferase (GST). Blood glucose, glycated hemoglobin, as well as 
      plasma ALT and AST activities increased in rats with streptozotocin-induced 
      experimental diabetes. The long-term hyperglycemia resulted in decreased 
      activities of GSHPx (by 26%), catalase (by 34%), GST (by 38%) and G6PDH (by 27%) 
      in diabetic animals. We did not observe increased accumulation of membrane lipid 
      peroxidation products or altered levels of reduced glutathione in livers. The 
      linear correlation between blood glucose and glycated hemoglobin in diabetic 
      animals was distorted upon ASA treatment, which was likely due to a chemical 
      competition between nonenzymatic protein glycosylation and protein acetylation. 
      The long-term ASA administration partially reversed the decrease in GSHPx 
      activity, but did not influence the activities of catalase and GST in diabetic 
      rats. Otherwise, some decrease in these parameters was noted in ASA-treated 
      nondiabetic animals. Increased ASA-induced G6PDH activity was recorded in both 
      diabetic and nondiabetic rats. While both glycation due to diabetic hyperglycemia 
      and ASA-mediated acetylation had very similar effects on the activities of all 
      studied enzymes but G6PDH, we conclude that non-enzymatic modification by either 
      glucose or ASA may be a common mechanism of the observed convergence.
FAU - Lapshina, E A
AU  - Lapshina EA
AD  - Institute of Biochemistry, National Academy of Sciences of Belarus, BLK-50, 
      Grodno, Belarus.
FAU - Sudnikovich, E Ju
AU  - Sudnikovich EJ
FAU - Maksimchik, Ju Z
AU  - Maksimchik JZ
FAU - Zabrodskaya, S V
AU  - Zabrodskaya SV
FAU - Zavodnik, L B
AU  - Zavodnik LB
FAU - Kubyshin, V L
AU  - Kubyshin VL
FAU - Nocun, M
AU  - Nocun M
FAU - Kazmierczak, P
AU  - Kazmierczak P
FAU - Dobaczewski, M
AU  - Dobaczewski M
FAU - Watala, C
AU  - Watala C
FAU - Zavodnik, I B
AU  - Zavodnik IB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060615
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Antioxidants)
RN  - 0 (Blood Glucose)
RN  - 0 (Hemoglobins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 2.5.1.18 (Glutathione Transferase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antioxidants/*metabolism
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Blood Glucose/analysis
MH  - *Diabetes Mellitus, Experimental/complications/drug therapy/enzymology
MH  - Diabetic Angiopathies/enzymology/etiology/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Glutathione Transferase/*metabolism
MH  - Hemoglobins/analysis
MH  - Lipid Peroxidation/drug effects
MH  - Liver/drug effects/enzymology
MH  - Male
MH  - Oxidative Stress/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Rats
MH  - Rats, Wistar
EDAT- 2006/07/04 09:00
MHDA- 2006/11/04 09:00
CRDT- 2006/07/04 09:00
PHST- 2005/11/05 00:00 [received]
PHST- 2006/05/21 00:00 [revised]
PHST- 2006/06/09 00:00 [accepted]
PHST- 2006/07/04 09:00 [pubmed]
PHST- 2006/11/04 09:00 [medline]
PHST- 2006/07/04 09:00 [entrez]
AID - S0024-3205(06)00456-5 [pii]
AID - 10.1016/j.lfs.2006.06.008 [doi]
PST - ppublish
SO  - Life Sci. 2006 Oct 4;79(19):1804-11. doi: 10.1016/j.lfs.2006.06.008. Epub 2006 
      Jun 15.

PMID- 10598619
OWN - NLM
STAT- MEDLINE
DCOM- 19991230
LR  - 20190628
IS  - 0003-3022 (Print)
IS  - 0003-3022 (Linking)
VI  - 91
IP  - 6
DP  - 1999 Dec
TI  - Diaspirin cross-linked hemoglobin effectively restores pancreatic 
      microcirculatory failure in hemorrhagic shock.
PG  - 1754-62
AB  - BACKGROUND: Microvascular reperfusion failure of splanchnic organs is a crucial 
      hallmark in organ damage induced by hemorrhagic shock, which should be prevented 
      by a resuscitation solution. Because the vasoactive properties of the 
      hemoglobin-based oxygen carrier diaspirin cross-linked hemoglobin (DCLHb) could 
      adversely influence restoration of pancreatic capillary perfusion during 
      resuscitation, the authors investigated its effects on the microcirculation of 
      the rat pancreas in comparison with whole blood and 6% hydroxyethylstarch 
      resuscitation from severe hemorrhagic shock. METHODS: Twenty-eight 
      pentobarbital-anaesthetized rats were bled to a mean arterial pressure (MAP) of 
      40 mmHg and maintained at this level for 1 h. Using an intravital microscope, 
      mean arterial pressure, the length of erythrocyte-perfused pancreatic capillaries 
      per observation area (functional capillary density), the adherence of leukocytes 
      in postcapillary venules, and pancreatic lipid peroxidation, measured as 
      thiobarbituric acid-reactive material in pancreatic tissue, were determined in 
      animals resuscitated by volumes of hydroxyethylstarch, DCLHb, and whole blood 
      (WB) equivalent to the shed blood volume or in control animals without shock 
      induction for a period of 2 h after resuscitation. RESULTS: Compared with control 
      animals (366+/-28 cm(-1)), animals resuscitated with DCLHb (294+/-45 cm(-1)), WB 
      (306+/-11 cm(-1)), and hydroxyethylstarch (241+/-34 cm(-1)) showed a significant 
      reduction of functional capillary density after 2 h of resuscitation. DCLHb was 
      as effective as WB and superior to hydroxyethylstarch in restoring functional 
      capillary density and mean arterial pressure. Leukocyte adherence in 
      postcapillary venules was not enhanced by DCLHb (369+/-148/mm2) infusion when 
      compared with hydroxyethylstarch- (615+/-283/mm2) and WB-treated (510+/-415/mm2) 
      animals. Lipid peroxidation of pancreatic tissue was significantly elevated after 
      treatment with both oxygen-carrying solutions compared with hydroxyethylstarch. 
      CONCLUSION: DCLHb is as effective as WB for preservation of the pancreatic 
      microcirculation.
FAU - von Dobschuetz, E
AU  - von Dobschuetz E
AD  - Institute for Surgical Research, Klinikum Grosshadern 
      Ludwig-Maximilians-University, Munich, Germany. edobschu@icf.med.uni-muenchen.de
FAU - Hoffmann, T
AU  - Hoffmann T
FAU - Messmer, K
AU  - Messmer K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesthesiology
JT  - Anesthesiology
JID - 1300217
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Thiobarbituric Acid Reactive Substances)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 578-19-8 (succinyldisalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acid-Base Equilibrium/drug effects
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Blood Substitutes/chemistry/*pharmacology
MH  - Cell Adhesion/drug effects
MH  - Cross-Linking Reagents/*pharmacology
MH  - Endothelium, Vascular/drug effects/physiology
MH  - Hematocrit
MH  - Hemoglobins/chemistry/*pharmacology
MH  - Lactic Acid/blood
MH  - Leukocytes/drug effects/physiology
MH  - Lipid Peroxidation/drug effects
MH  - Male
MH  - Microcirculation/drug effects
MH  - Pancreas/*blood supply/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/drug effects
MH  - Shock, Hemorrhagic/*chemically induced/physiopathology
MH  - Thiobarbituric Acid Reactive Substances/metabolism
EDAT- 1999/12/22 00:00
MHDA- 1999/12/22 00:01
CRDT- 1999/12/22 00:00
PHST- 1999/12/22 00:00 [pubmed]
PHST- 1999/12/22 00:01 [medline]
PHST- 1999/12/22 00:00 [entrez]
AID - 10.1097/00000542-199912000-00029 [doi]
PST - ppublish
SO  - Anesthesiology. 1999 Dec;91(6):1754-62. doi: 10.1097/00000542-199912000-00029.

PMID- 8556139
OWN - NLM
STAT- MEDLINE
DCOM- 19960226
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 23
IP  - 6
DP  - 1995
TI  - Diaspirin crosslinked hemoglobin (DCLHb) attenuates bacterial translocation in 
      rats.
PG  - 647-64
AB  - Intestinal barrier function is compromised following severe hemorrhage which may 
      allow bacterial translocation (BT) to occur and subsequently initiate a systemic 
      response leading to multiple system organ failure (MSOF). This study compared BT 
      following hemorrhage and resuscitation with lactated Ringer's solution (LR) or 
      diaspirin crosslinked hemoglobin solution (DCLHb). Rats (250-350 grams) were 
      hemorrhaged to a base deficit of 15 +/- 2 mmol/L and immediately resuscitated 
      with either 3:1 LR or 1:1 DCLHb based on shed blood volume. Four hours following 
      resuscitation, the mesenteric lymph node complex was harvested, homogenized and 
      plated onto MacConkey and Columbia CNA agar culture media. Facultative anaerobic 
      and obligate aerobic bacteria were identified 48 hours later in 11/22 (50%) 
      LR-treated rats and in 4/21 (19%) DCLHb-treated rats (p < or = 0.05). Following 
      resuscitation, base excess (BE) and central venous oxygen saturation (SvO2) were 
      not only restored to baseline but were significantly greater (p < or = 0.05) in 
      DCLHb-treated rats than in LR-treated rats. In a separate group of rats subjected 
      to the same hemorrhage and resuscitation protocol, mean arterial pressure in 
      DCLHb-treated rats, but not LR-treated rats, was restored to baseline by 15 
      minutes and remained at or above baseline for up to 4 hrs. Twenty-four hour 
      survival was 50% in LR-treated rats and 77% in DCLHb-treated rats (p > 0.05). 
      These data suggest that DCLHb is superior to LR in restoring tissue oxygen 
      delivery, as judged by BE and SvO2. Furthermore, since DCLHb restores oxygen 
      delivery and attenuates BT, early resuscitation with DCLHb may limit gut ischemia 
      and subsequent gut barrier failure and hence prevent the development of sepsis, 
      MSOF and subsequent death.
FAU - Schultz, S C
AU  - Schultz SC
AD  - Department of Surgery, Uniformed Services University of the Health Sciences, 
      Bethesda, Maryland, USA.
FAU - Powell, C C
AU  - Powell CC
FAU - Bernard, E
AU  - Bernard E
FAU - Malcolm, D S
AU  - Malcolm DS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - *Bacteria/isolation & purification
MH  - Biological Transport/drug effects
MH  - Blood Substitutes/*pharmacology/therapeutic use
MH  - Depression, Chemical
MH  - Hemoglobins/*pharmacology/therapeutic use
MH  - Immunocompromised Host
MH  - Intestinal Mucosa/*drug effects/microbiology
MH  - Lymph Nodes/microbiology
MH  - Male
MH  - Mesentery/microbiology
MH  - Multiple Organ Failure/etiology/prevention & control
MH  - Oxygen/blood
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Resuscitation
MH  - Sepsis/etiology/prevention & control
MH  - Shock, Hemorrhagic/blood/*complications/microbiology
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.3109/10731199509117978 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1995;23(6):647-64. doi: 
      10.3109/10731199509117978.

PMID- 34314517
OWN - NLM
STAT- MEDLINE
DCOM- 20220414
LR  - 20220414
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 157
IP  - 2
DP  - 2022 May
TI  - Low-dose aspirin improves blood perfusion of endometrium of unexplained recurrent 
      biochemical pregnancy loss.
PG  - 418-423
LID - 10.1002/ijgo.13838 [doi]
AB  - OBJECTIVE: To assess the differences in Doppler parameters of endometrial 
      receptivity in unexplained recurrent biochemical pregnancy loss (URBPL) and the 
      therapeutic effect of low-dose aspirin (LDA). METHODS: A retrospective study was 
      conducted at Ren Ji Hospital, Shanghai, PR China, from January 2017 to January 
      2019. Doppler parameters of endometrium and uterus were recorded as the 
      evaluation of the endometrial receptivity. Receiver operating characteristic 
      (ROC) curve was managed to predict the risk of URBPL. Ultrasonography tests were 
      repeated after 2 months of treatment with LDA. RESULTS: Biochemical pregnancies 
      did not correlate with maternal age. The resistance of endometrial perfusion 
      (pulsatility index, resistive index, and systolic-to-diastolic ratio) was 
      significantly higher in URBPLs (P < 0.001) and had predictive values (0.739, 
      0.779, and 0.760, respectively). Endometrial thickness and impedance to uterine 
      blood flow showed no statistically significant difference (P > 0.05). After 
      treatment with LDA, patients with URBPL improved the blood perfusion of 
      endometrium significantly (P < 0.01). CONCLUSION: There was no relation between 
      BPL and maternal age. Patients with URBPL had inappropriate endometrial blood 
      velocity. Doppler indices are capable of predicting the risk of URBPL. LDA exerts 
      the therapeutic effect on improving blood perfusion of endometrium in URBPL.
CI  - © 2021 International Federation of Gynecology and Obstetrics.
FAU - Zhang, Xiaoxin
AU  - Zhang X
AD  - Department of Obstetrics and Gynecology, School of Medicine, Ren Ji Hospital, 
      Shanghai JiaoTong University, Shanghai, PR China.
AD  - Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, PR China.
FAU - Guo, Feng
AU  - Guo F
AD  - Department of Obstetrics and Gynecology, School of Medicine, Ren Ji Hospital, 
      Shanghai JiaoTong University, Shanghai, PR China.
FAU - Wang, Qiaohong
AU  - Wang Q
AD  - Department of Obstetrics and Gynecology, School of Medicine, Ren Ji Hospital, 
      Shanghai JiaoTong University, Shanghai, PR China.
FAU - Bai, Wenxin
AU  - Bai W
AD  - Department of Obstetrics and Gynecology, School of Medicine, Ren Ji Hospital, 
      Shanghai JiaoTong University, Shanghai, PR China.
FAU - Zhao, Aimin
AU  - Zhao A
AD  - Department of Obstetrics and Gynecology, School of Medicine, Ren Ji Hospital, 
      Shanghai JiaoTong University, Shanghai, PR China.
AD  - Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, PR China.
LA  - eng
GR  - 08140901500/Science and Technology Commission Foundation of Shanghai, China/
GR  - 81270715/National Natural Science Foundation of China/
GR  - 81302295/National Natural Science Foundation of China/
GR  - 2017ZZ02016/Shanghai Municipal Commission of Health and Family Planning/
PT  - Journal Article
DEP - 20210806
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abortion, Habitual/drug therapy/prevention & control
MH  - Aspirin/therapeutic use
MH  - China
MH  - *Endometrium/diagnostic imaging
MH  - Female
MH  - Humans
MH  - Perfusion
MH  - Pregnancy
MH  - Retrospective Studies
MH  - Uterus
OTO - NOTNLM
OT  - endometrial receptivity
OT  - endometrium
OT  - lose-dose aspirin
OT  - unexplained recurrent biochemical pregnancy loss
OT  - uterine artery
EDAT- 2021/07/28 06:00
MHDA- 2022/04/15 06:00
CRDT- 2021/07/27 17:22
PHST- 2021/06/22 00:00 [revised]
PHST- 2021/04/02 00:00 [received]
PHST- 2021/07/21 00:00 [accepted]
PHST- 2021/07/28 06:00 [pubmed]
PHST- 2022/04/15 06:00 [medline]
PHST- 2021/07/27 17:22 [entrez]
AID - 10.1002/ijgo.13838 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2022 May;157(2):418-423. doi: 10.1002/ijgo.13838. Epub 
      2021 Aug 6.

PMID- 35843503
OWN - NLM
STAT- MEDLINE
DCOM- 20220929
LR  - 20221005
IS  - 1098-8823 (Print)
IS  - 1098-8823 (Linking)
VI  - 162
DP  - 2022 Oct
TI  - Aspirin attenuates the expression of adhesion molecules, risk of obesity, and 
      adipose tissue inflammation in high-fat diet-induced obese mice.
PG  - 106664
LID - S1098-8823(22)00054-5 [pii]
LID - 10.1016/j.prostaglandins.2022.106664 [doi]
AB  - The prevalence of obesity is increasing at an alarming rate and keeps on being 
      one of the significant challenges of this century. Obesity promotes adipose 
      tissue hypertrophy and causes the release of different pro-inflammatory 
      cytokines, playing a significant role in the pathophysiology of metabolic 
      syndrome. Aspirin is known as a potent anti-inflammatory drug, but its role in 
      adipogenesis, adipocyte-specific inflammation, and metabolic syndrome is not well 
      characterized. Thus, in this experiment, we aimed to determine the effect of 
      low-dose aspirin on obesity, obesity-induced inflammation, and metabolic 
      syndrome. High-fat diet-induced obese female mice (Swiss Albino) were used in our 
      study. Mice were fed on a normal diet, a high-fat diet, and a low dose of aspirin 
      (LDA) in the presence of a high-fat diet for 11 weeks. Body weight, lipid 
      profile, adipose tissue size, and inflammatory status were analyzed after that 
      period. The ∆∆CT method was used to calculate the relative mRNA expression of 
      target genes. Treatment with a low dose of aspirin resulted in a significant 
      reduction of body weight, visceral fat mass and serum total cholesterols, serum 
      and adipose tissue triglycerides, and blood glucose levels in high-fat 
      diet-induced obese mice compared to the untreated obese group. Consistent with 
      these biochemical results, a significant reduction in mRNA expression of 
      different genes like PPARγ, GLUT4, IL-6, TNFα, MCP-1, ICAM-I, and VCAM-I 
      associated with adipogenesis and inflammation were noticed. Overall, current 
      study findings indicate that low-dose aspirin reduces obesity, hyperlipidemia, 
      adipocyte-specific inflammation, and metabolic syndrome in high-fat diet-induced 
      obese mice.
CI  - Copyright © 2022 Elsevier Inc. All rights reserved.
FAU - Roy, Sourav
AU  - Roy S
AD  - Department of Pharmacy, Noakhali Science and Technology University, 
      Noakhlai 3814, Bangladesh.
FAU - Bhowmik, Dipty Rani
AU  - Bhowmik DR
AD  - Department of Pharmacy, Noakhali Science and Technology University, 
      Noakhlai 3814, Bangladesh.
FAU - Begum, Rahima
AU  - Begum R
AD  - Department of Pharmacy, Noakhali Science and Technology University, 
      Noakhlai 3814, Bangladesh.
FAU - Amin, Mohammad Tohidul
AU  - Amin MT
AD  - Department of Pharmacy, Noakhali Science and Technology University, 
      Noakhlai 3814, Bangladesh.
FAU - Islam, Md Aminul
AU  - Islam MA
AD  - Department of Microbiology, Noakahli Science and Technology University, Noakhali 
      3814, Bangladesh.
FAU - Ahmed, Firoz
AU  - Ahmed F
AD  - Department of Microbiology, Noakahli Science and Technology University, Noakhali 
      3814, Bangladesh.
FAU - Hossain, Mohammad Salim
AU  - Hossain MS
AD  - Department of Pharmacy, Noakhali Science and Technology University, 
      Noakhlai 3814, Bangladesh. Electronic address: pharmasalim@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20220714
PL  - United States
TA  - Prostaglandins Other Lipid Mediat
JT  - Prostaglandins & other lipid mediators
JID - 9808648
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Interleukin-6)
RN  - 0 (PPAR gamma)
RN  - 0 (RNA, Messenger)
RN  - 0 (Triglycerides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adipose Tissue/metabolism
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Glucose/metabolism
MH  - Body Weight
MH  - *Diet, High-Fat
MH  - Female
MH  - Inflammation/metabolism
MH  - Interleukin-6/metabolism
MH  - *Metabolic Syndrome/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Obese
MH  - Obesity/metabolism
MH  - PPAR gamma/metabolism
MH  - RNA, Messenger/metabolism
MH  - Triglycerides/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - Anti-inflammation
OT  - Aspirin
OT  - Cholesterol
OT  - IL-6
OT  - MCP-1
OT  - Obesity
OT  - PPARγ
OT  - TNFα
OT  - Triglyceride
COIS- Competing Interests The author declares no competing interest.
EDAT- 2022/07/18 06:00
MHDA- 2022/09/30 06:00
CRDT- 2022/07/17 19:27
PHST- 2022/04/06 00:00 [received]
PHST- 2022/06/30 00:00 [revised]
PHST- 2022/07/07 00:00 [accepted]
PHST- 2022/07/18 06:00 [pubmed]
PHST- 2022/09/30 06:00 [medline]
PHST- 2022/07/17 19:27 [entrez]
AID - S1098-8823(22)00054-5 [pii]
AID - 10.1016/j.prostaglandins.2022.106664 [doi]
PST - ppublish
SO  - Prostaglandins Other Lipid Mediat. 2022 Oct;162:106664. doi: 
      10.1016/j.prostaglandins.2022.106664. Epub 2022 Jul 14.

PMID- 32996349
OWN - NLM
STAT- MEDLINE
DCOM- 20220907
LR  - 20220907
IS  - 1758-1109 (Electronic)
IS  - 1357-633X (Linking)
VI  - 28
IP  - 9
DP  - 2022 Oct
TI  - Efficacy of a WeChat-based intervention for adherence to secondary prevention 
      therapies in patients undergoing coronary artery bypass graft in China: A 
      randomized controlled trial.
PG  - 653-661
LID - 10.1177/1357633X20960639 [doi]
AB  - INTRODUCTION: We assessed whether the social media-based (WeChat) intervention 
      integrated with follow-up care could improve adherence to drugs, lifestyle 
      changes and clinical risk markers in patients undergoing coronary artery bypass 
      graft (CABG) in China. METHODS: We randomized patients at hospital discharge 
      following CABG to intervention group or control care in China. The intervention 
      is a structured programme of cardiac health education, medication reminders and 
      cardiologist-based follow-up service using WeChat platform. The control group 
      maintains a routine practice pattern. The primary outcome is adherence to 
      cardioprotective medications measured for 12 months after discharge. We also 
      evaluated the lifestyle modifications and clinical risk markers at 12 months. 
      RESULTS: A total of 164 participants completed the trial for analysis. The 
      intervention group had significantly greater adherence to statins use 98.6% vs. 
      75.0% (p < 0.01), beta-blockers 93.4% vs. 69.3% (p < 0.01) and aspirin 98.8% vs. 
      87.8% (p < 0.001). The intervention group had significantly greater adherence to 
      regular physical activity (64.2% vs. 48.2%; p < 0.039). Furthermore, intervention 
      versus standard group at 12 months had significantly lower mean systolic blood 
      pressure and low-density lipoprotein cholesterol (p < 0.05). DISCUSSION: A 
      WeChat-based intervention strategy in post-CABG patients improved adherence to 
      medications, including statin, aspirin and beta-blockers, and regular physical 
      activity and resulted in an improvement in systolic blood pressure and 
      low-density lipoprotein cholesterol level.
FAU - Wang, Jinwen
AU  - Wang J
AUID- ORCID: 0000-0002-7594-1310
AD  - Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart 
      Lung and Blood Vessel Disease, People's Republic of China.
FAU - Zeng, Zhechun
AU  - Zeng Z
AD  - Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart 
      Lung and Blood Vessel Disease, People's Republic of China.
FAU - Dong, Ran
AU  - Dong R
AD  - Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical 
      University, People's Republic of China.
FAU - Sheng, Juanjuan
AU  - Sheng J
AD  - Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical 
      University, People's Republic of China.
FAU - Lai, Yongqiang
AU  - Lai Y
AD  - Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical 
      University, People's Republic of China.
FAU - Yu, Jianbo
AU  - Yu J
AD  - Department of Cardiac Surgery, Beijing An Zhen Hospital, Capital Medical 
      University, People's Republic of China.
FAU - Zuo, Huijuan
AU  - Zuo H
AD  - Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart 
      Lung and Blood Vessel Disease, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200930
PL  - England
TA  - J Telemed Telecare
JT  - Journal of telemedicine and telecare
JID - 9506702
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipoproteins, LDL)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cholesterol
MH  - *Coronary Artery Bypass
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Lipoproteins, LDL
MH  - Medication Adherence
MH  - Secondary Prevention/methods
OTO - NOTNLM
OT  - CABG
OT  - Social media
OT  - cardiology
OT  - medication adherence
OT  - randomized controlled trial
OT  - telehealth
EDAT- 2020/10/01 06:00
MHDA- 2022/09/08 06:00
CRDT- 2020/09/30 08:41
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2022/09/08 06:00 [medline]
PHST- 2020/09/30 08:41 [entrez]
AID - 10.1177/1357633X20960639 [doi]
PST - ppublish
SO  - J Telemed Telecare. 2022 Oct;28(9):653-661. doi: 10.1177/1357633X20960639. Epub 
      2020 Sep 30.

PMID- 15659723
OWN - NLM
STAT- MEDLINE
DCOM- 20050127
LR  - 20220310
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 352
IP  - 3
DP  - 2005 Jan 20
TI  - Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
PG  - 238-44
AB  - BACKGROUND: Concurrent therapy with a proton-pump inhibitor is a standard 
      treatment for patients receiving aspirin who are at risk for ulcer. Current U.S. 
      guidelines also recommend clopidrogel for patients who have major 
      gastrointestinal intolerance of aspirin. We compared clopidogrel with aspirin 
      plus esomeprazole for the prevention of recurrent bleeding from ulcers in 
      high-risk patients. METHODS: We studied patients who took aspirin to prevent 
      vascular diseases and who presented with ulcer bleeding. After the ulcers had 
      healed, we randomly assigned patients who were negative for Helicobacter pylori 
      to receive either 75 mg of clopidogrel daily plus esomeprazole placebo twice 
      daily or 80 mg of aspirin daily plus 20 mg of esomeprazole twice daily for 12 
      months. The end point was recurrent ulcer bleeding. RESULTS: We enrolled 320 
      patients (161 patients assigned to receive clopidogrel and 159 to receive aspirin 
      plus esomeprazole). Recurrent ulcer bleeding occurred in 13 patients receiving 
      clopidogrel and 1 receiving aspirin plus esomeprazole. The cumulative incidence 
      of recurrent bleeding during the 12-month period was 8.6 percent (95 percent 
      confidence interval, 4.1 to 13.1 percent) among patients who received clopidogrel 
      and 0.7 percent (95 percent confidence interval, 0 to 2.0 percent) among those 
      who received aspirin plus esomeprazole (difference, 7.9 percentage points; 95 
      percent confidence interval for the difference, 3.4 to 12.4; P=0.001). 
      CONCLUSIONS: Among patients with a history of aspirin-induced ulcer bleeding 
      whose ulcers had healed before they received the study treatment, aspirin plus 
      esomeprazole was superior to clopidogrel in the prevention of recurrent ulcer 
      bleeding. Our finding does not support the current recommendation that patients 
      with major gastrointestinal intolerance of aspirin be given clopidogrel.
CI  - Copyright 2005 Massachusetts Medical Society.
FAU - Chan, Francis K L
AU  - Chan FK
AD  - Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese 
      University of Hong Kong, Shatin, Hong Kong, China. fklchan@cuhk.edu.hk
FAU - Ching, Jessica Y L
AU  - Ching JY
FAU - Hung, Lawrence C T
AU  - Hung LC
FAU - Wong, Vincent W S
AU  - Wong VW
FAU - Leung, Vincent K S
AU  - Leung VK
FAU - Kung, Nelson N S
AU  - Kung NN
FAU - Hui, Aric J
AU  - Hui AJ
FAU - Wu, Justin C Y
AU  - Wu JC
FAU - Leung, Wai K
AU  - Leung WK
FAU - Lee, Vivian W Y
AU  - Lee VW
FAU - Lee, Kenneth K C
AU  - Lee KK
FAU - Lee, Yuk T
AU  - Lee YT
FAU - Lau, James Y W
AU  - Lau JY
FAU - To, Ka F
AU  - To KF
FAU - Chan, Henry L Y
AU  - Chan HL
FAU - Chung, S C Sydney
AU  - Chung SC
FAU - Sung, Joseph J Y
AU  - Sung JJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - N3PA6559FT (Esomeprazole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2005 Jan 20;352(3):287-9. PMID: 15659730
CIN - J Fam Pract. 2005 Apr;54(4):308-9. PMID: 15833219
CIN - N Engl J Med. 2005 Apr 21;352(16):1716-8; author reply 1716-8. PMID: 15843675
CIN - N Engl J Med. 2005 Apr 21;352(16):1716-8; author reply 1716-8. PMID: 15846857
CIN - N Engl J Med. 2005 Apr 21;352(16):1716-8; author reply 1716-8. PMID: 15846858
CIN - ACP J Club. 2005 Jul-Aug;143(1):9. PMID: 15989297
CIN - Gastroenterology. 2005 Jul;129(1):386-8. PMID: 16705774
MH  - Aged
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Clopidogrel
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Esomeprazole/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Peptic Ulcer Hemorrhage/chemically induced/*prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Proton Pump Inhibitors
MH  - Secondary Prevention
MH  - Ticlopidine/*analogs & derivatives/*therapeutic use
EDAT- 2005/01/22 09:00
MHDA- 2005/01/28 09:00
CRDT- 2005/01/22 09:00
PHST- 2005/01/22 09:00 [pubmed]
PHST- 2005/01/28 09:00 [medline]
PHST- 2005/01/22 09:00 [entrez]
AID - 352/3/238 [pii]
AID - 10.1056/NEJMoa042087 [doi]
PST - ppublish
SO  - N Engl J Med. 2005 Jan 20;352(3):238-44. doi: 10.1056/NEJMoa042087.

PMID- 4590669
OWN - NLM
STAT- MEDLINE
DCOM- 19740402
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 1
IP  - 5900
DP  - 1974 Feb 2
TI  - Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin.
PG  - 176-80
AB  - Fenoprofen, a compound with analgesic, anti-inflammatory, and antipyretic 
      properties in animals, has been compared with placebo in a double-blind 
      cross-over trial in 60 patients with rheumatoid arthritis. There was a 
      statistically highly significant reduction in pain, duration of morning 
      stiffness, analgesic requirements, and articular index, with increase in grip 
      strength. There was no significant reduction in joint size or temperature. In a 
      subsequent double-blind group-comparative study fenoprofen proved to be as 
      effective as aspirin in relieving the symptoms of rheumatoid arthritis, with 
      strikingly fewer side effects. Almost half of the patients taking aspirin were 
      unable to tolerate the drug in adequate dosage for six months. The remainder were 
      able to take on average only 4 g daily, and at this dose almost half still 
      complained of tinnitus and deafness.Fenoprofen is likely to be useful for 
      patients who cannot tolerate aspirin and other more toxic anti-inflammatory drugs 
      or whose disease is not of sufficient severity to justify their use.
FAU - Huskisson, E C
AU  - Huskisson EC
FAU - Wojtulewski, J A
AU  - Wojtulewski JA
FAU - Berry, H
AU  - Berry H
FAU - Scott, J
AU  - Scott J
FAU - Hart, F D
AU  - Hart FD
FAU - Balme, H W
AU  - Balme HW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Placebos)
RN  - 0 (Propionates)
RN  - 268B43MJ25 (Uric Acid)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 8W8T17847W (Urea)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Aspirin/adverse effects/blood/*therapeutic use
MH  - Body Temperature
MH  - Clinical Trials as Topic
MH  - Deafness/chemically induced
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Movement
MH  - Pain/drug therapy
MH  - Placebos
MH  - Propionates/adverse effects/blood/*therapeutic use
MH  - Tinnitus/chemically induced
MH  - Urea/blood
MH  - Uric Acid/blood
MH  - Wrist/physiopathology
PMC - PMC1633047
EDAT- 1974/02/02 00:00
MHDA- 1974/02/02 00:01
CRDT- 1974/02/02 00:00
PHST- 1974/02/02 00:00 [pubmed]
PHST- 1974/02/02 00:01 [medline]
PHST- 1974/02/02 00:00 [entrez]
AID - 10.1136/bmj.1.5900.176 [doi]
PST - ppublish
SO  - Br Med J. 1974 Feb 2;1(5900):176-80. doi: 10.1136/bmj.1.5900.176.

PMID- 21766899
OWN - NLM
STAT- MEDLINE
DCOM- 20110830
LR  - 20211020
IS  - 1178-1653 (Print)
IS  - 1178-1653 (Linking)
VI  - 4
IP  - 2
DP  - 2011
TI  - Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic 
      Acid: a quantitative study in patients with cardiovascular risk.
PG  - 103-13
LID - 10.2165/11589200-000000000-00000 [doi]
AB  - BACKGROUND: Low-dose acetylsalicylic acid (ASA; 75-325 mg) is a mainstay of 
      therapy for patients at high risk of cardiovascular (CV) events. However, in some 
      patients, such treatment is associated with upper gastrointestinal (GI) adverse 
      effects, e.g. dyspeptic symptoms, peptic ulceration, and GI bleeding, that may 
      interfere with adequate adherence to, and continuation of, low-dose ASA for CV 
      protection. OBJECTIVE: The objective of this study was to explore the extent of, 
      and drivers for, poor adherence to, and discontinuation of, low-dose ASA 
      treatment for CV protection among a representative sample of patients in the US 
      with GI problems. METHODS: An online questionnaire was completed by eligible US 
      adult patients (aged ≥20 years) who had been recommended low-dose ASA by a 
      healthcare professional for secondary CV prevention or high-risk primary CV 
      prevention (defined as diabetes mellitus or three or more risk factors for CV 
      disease) and had experience of upper GI problems. Participants were asked 
      questions about their demographic profile, general health, and attitudes towards 
      low-dose ASA use. Patients were classified as 'lapsers' if they reported no 
      longer regularly taking low-dose ASA; patients were also asked if they ever took 
      deliberate, short-term breaks from their low-dose ASA regimen ('breakers'). 
      Statistical analysis was descriptive. RESULTS: From 56 296 invitation emails that 
      were sent out, 1007 questionnaires were completed in full and were eligible for 
      the analysis. The main reason for ineligible responses was unread emails. 
      Respondents had a mean age of 52 years and 59% were women. Some 57% of patients 
      were categorized as being at high primary CV risk and 43% were categorized as 
      secondary CV prevention patients. A total of 67% of all patients used ASA at a 
      daily dose of 81 mg. Overall, 28% of patients were considered to be poorly 
      adherent through lapsing and/or taking deliberate, short-term breaks, and those 
      receiving low-dose ASA for secondary CV prevention were more likely to be poorly 
      adherent than were high-risk primary CV prevention patients (32% vs 25%). Of the 
      overall population, 15% were lapsers (12% of secondary and 18% of high-risk 
      primary CV prevention patients). The most common spontaneously reported reasons 
      for lapse of low-dose ASA therapy were contraindicated combinations of 
      medications and 'stomach problems'. Deliberate, short-term breaks from treatment 
      were reported by 19% of all patients (24% of secondary and 15% of high-risk 
      primary CV prevention). The most common spontaneously reported reasons for breaks 
      were 'stomach problems' and preparation for surgery. Overall, 88% of patients 
      reported experiencing heartburn or acid reflux symptoms. Self-reported rates of 
      GI problems were greater in secondary than in high-risk primary CV prevention 
      patients. CONCLUSION: Among the US cohort studied (i.e. low-dose ASA users with 
      experience of upper GI problems), poor adherence to low-dose ASA treatment for 
      both secondary and high-risk primary CV prevention was common.
FAU - Moberg, Christina
AU  - Moberg C
AD  - AstraZeneca RD, Mlndal, Sweden.
FAU - Naesdal, Jørgen
AU  - Naesdal J
FAU - Svedberg, Lars-Erik
AU  - Svedberg LE
FAU - Duchateau, Delphine
AU  - Duchateau D
FAU - Harte, Nicola
AU  - Harte N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Patient
JT  - The patient
JID - 101309314
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/epidemiology/prevention & control
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced/*epidemiology
MH  - Humans
MH  - Internet
MH  - Male
MH  - Medication Adherence/*psychology/*statistics & numerical data
MH  - Middle Aged
MH  - Nonprescription Drugs
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - United States/epidemiology
MH  - Young Adult
EDAT- 2011/07/20 06:00
MHDA- 2011/08/31 06:00
CRDT- 2011/07/20 06:00
PHST- 2011/07/20 06:00 [entrez]
PHST- 2011/07/20 06:00 [pubmed]
PHST- 2011/08/31 06:00 [medline]
AID - 4 [pii]
AID - 10.2165/11589200-000000000-00000 [doi]
PST - ppublish
SO  - Patient. 2011;4(2):103-13. doi: 10.2165/11589200-000000000-00000.

PMID- 24108232
OWN - NLM
STAT- MEDLINE
DCOM- 20160204
LR  - 20150228
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 21
IP  - 3
DP  - 2015 Apr
TI  - Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for 
      Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial.
PG  - 235-40
LID - 10.1177/1076029613507335 [doi]
AB  - BACKGROUND: The AVERROES trial name is the following: The Apixaban Versus 
      Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who 
      Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial 
      demonstrated that apixaban reduced the risk of stroke relative to aspirin, 
      without significantly increasing major bleeding risk in patients with atrial 
      fibrillation (AF) considered unsuitable for warfarin therapy. Based on AVERROES 
      trial results, this study compared the medical costs for clinical end points 
      among patients with AF treated with either apixaban or aspirin. METHODS: Medical 
      costs per patient-year for clinical events were determined. Based on clinical 
      event rates for patients in the AVERROES trial, medical costs excluding drug 
      costs were estimated for apixaban- and aspirin-treated patient groups. RESULTS 
      AND CONCLUSIONS: Based on AVERROES trial results, among patients with AF 
      unsuitable for warfarin therapy, apixaban use was estimated to be associated with 
      a mean medical cost avoidance of US$735 in a patient-year relative to aspirin. 
      The primary driver was the significant reduction in ischemic stroke rate. The 
      medical cost reduction associated with apixaban use was consistent in sensitivity 
      analyses.
CI  - © The Author(s) 2013.
FAU - Amin, Alpesh
AU  - Amin A
AD  - Department of Medicine, Hospitalist Program, School of Medicine, University of 
      California, Irvine, CA, USA anamin@uci.edu.
FAU - Deitelzweig, Steve
AU  - Deitelzweig S
AD  - Medical Affairs, Ochsner Clinic Foundation, New Orleans, LA, USA.
FAU - Jing, Yonghua
AU  - Jing Y
AD  - Medical Affairs, Bristol-Myers Squibb, Plainsboro, NJ, USA.
FAU - Makenbaeva, Dinara
AU  - Makenbaeva D
AD  - Medical Affairs, Bristol-Myers Squibb, Plainsboro, NJ, USA.
FAU - Wiederkehr, Daniel
AU  - Wiederkehr D
AD  - Medical Affairs, Pfizer, New York City, NY, USA.
FAU - Lin, Jay
AU  - Lin J
AD  - Health Economics and Outcomes Research, Novosys Health, Flemington, NJ, USA.
FAU - Graham, John
AU  - Graham J
AD  - Medical Affairs, Bristol-Myers Squibb, Plainsboro, NJ, USA.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20131009
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Anticoagulants)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anticoagulants/administration & dosage/economics
MH  - *Aspirin/administration & dosage/economics
MH  - *Atrial Fibrillation/drug therapy/economics
MH  - Costs and Cost Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - *Pyrazoles/administration & dosage/economics
MH  - *Pyridones/administration & dosage/economics
MH  - *Warfarin/administration & dosage/economics
EDAT- 2013/10/11 06:00
MHDA- 2016/02/05 06:00
CRDT- 2013/10/11 06:00
PHST- 2013/10/11 06:00 [entrez]
PHST- 2013/10/11 06:00 [pubmed]
PHST- 2016/02/05 06:00 [medline]
AID - 1076029613507335 [pii]
AID - 10.1177/1076029613507335 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2015 Apr;21(3):235-40. doi: 10.1177/1076029613507335. 
      Epub 2013 Oct 9.

PMID- 7934246
OWN - NLM
STAT- MEDLINE
DCOM- 19941108
LR  - 20190830
IS  - 0140-0118 (Print)
IS  - 0140-0118 (Linking)
VI  - 32
IP  - 3
DP  - 1994 May
TI  - Electrocatalytic glucose sensor.
PG  - 247-52
AB  - An electrocatalytic glucose sensor for in vivo application has been developed. 
      The sensor is a flow-through cell with three electrodes and can be integrated 
      into a blood vessel. The principle of measurement is based on the direct 
      electrochemical oxidation of glucose at a membrane-covered noble-metal electrode. 
      To test the potential long-term in vivo function of the sensor, it was implanted 
      in the carotid artery of a sheep. Thus, the sensor performance was verified over 
      a period of 71 days. During this time, a nearly constant blood flow through the 
      cell was achieved, which indicates good blood compatibility of the materials 
      used. It was possible to set up a calibration that was valid over 24 days (mean 
      error 2.3 mmol l-1). The tested cross-sensitivity of the sensor towards cysteine, 
      acetyl salicylic acid and other small molecules shows tolerable effects on this 
      type of glucose measurement. Only high concentrations of lactate and ethanol 
      require a special adaptation of the calibration to suppress their influence. 
      Minor cross-sensitivity and promising long-term stability recommend this type of 
      sensor for in vivo monitoring of blood sugar level. However, for intravasal 
      application, it is necessary to modify the present sensor design to a 
      catheter-type construction.
FAU - Lager, W
AU  - Lager W
AD  - Siemens AG, Erlangen, Germany.
FAU - von Lucadou, I
AU  - von Lucadou I
FAU - Preidel, W
AU  - Preidel W
FAU - Ruprecht, L
AU  - Ruprecht L
FAU - Saeger, S
AU  - Saeger S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Biol Eng Comput
JT  - Medical & biological engineering & computing
JID - 7704869
RN  - 0 (Blood Glucose)
RN  - 3K9958V90M (Ethanol)
RN  - K848JZ4886 (Cysteine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - *Biosensing Techniques
MH  - Blood Glucose/*analysis/drug effects
MH  - Cysteine/pharmacology
MH  - Electrochemistry
MH  - Electrodes, Implanted
MH  - Ethanol/pharmacology
MH  - Sheep
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
AID - 10.1007/BF02512518 [doi]
PST - ppublish
SO  - Med Biol Eng Comput. 1994 May;32(3):247-52. doi: 10.1007/BF02512518.

PMID- 6127692
OWN - NLM
STAT- MEDLINE
DCOM- 19821221
LR  - 20181212
IS  - 0950-1193 (Print)
IS  - 0950-1193 (Linking)
VI  - 214
IP  - 1197
DP  - 1982 Mar 22
TI  - Effect of removing sialic acids from endothelium on the adherence of circulating 
      platelets in arteries in vivo.
PG  - 471-80
AB  - The contribution of the net negative charge excess due to sialic acids on 
      endothelium in preventing adhesion of circulating platelets in vivo was 
      investigated in anaesthetized rabbits. Platelets in the rabbit's circulation were 
      selectively labelled with radioactive 5-hydroxytryptamine in vivo. Segments of 
      carotid arteries temporarily isolated from the circulation were perfused with one 
      or other of two commercial preparations of neuraminidase; the opposite carotid 
      artery was perfused similarly without the enzyme, as control. A neuraminidase 
      preparation from Behringwerke free of proteolytic activity released sialic acid 
      into the perfusate with a peak concentration after 10-15 min which decreased 
      gradually later. A neuraminidase preparation from Sigma that contained 
      demonstrable proteolytic activity released sialic acid similarly during the first 
      hour and thereafter more sialic acid in a second peak. After blood flow through 
      the carotids had been restored the adhesion of labelled platelets in the artery 
      perfused with neuraminidase was compared with that in the artery perfused without 
      the enzyme. The radioactivities were significantly higher in carotids that had 
      been perfused with neuraminidase than in those that had been perfused without the 
      enzyme. Neuraminidase perfusion had no effect on the production of prostacyclin 
      by the carotids. Perfusion with acetylsalicylic acid before neuraminidase 
      increased the adhesion of platelets significantly. It is concluded that 
      diminution in electrostatic repulsion between circulating platelets and vascular 
      endothelium from which the net negative charge excess due to sialic acids has 
      been removed increases the adhesion of circulating platelets, irrespective of the 
      production of prostacyclin by the arterial walls, and that inhibition of 
      prostacyclin production augments this adhesion of platelets.
FAU - Görög, P
AU  - Görög P
FAU - Schraufstätter, I
AU  - Schraufstätter I
FAU - Born, G V
AU  - Born GV
LA  - eng
PT  - Journal Article
PL  - England
TA  - Proc R Soc Lond B Biol Sci
JT  - Proceedings of the Royal Society of London. Series B, Biological sciences
JID - 7505889
RN  - 0 (Sialic Acids)
RN  - EC 3.2.1.18 (Neuraminidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteries/*physiology
MH  - Aspirin/pharmacology
MH  - Endothelium/*physiology
MH  - Neuraminidase/metabolism
MH  - *Platelet Adhesiveness/drug effects
MH  - Rabbits
MH  - Sialic Acids/*physiology
EDAT- 1982/03/22 00:00
MHDA- 1982/03/22 00:01
CRDT- 1982/03/22 00:00
PHST- 1982/03/22 00:00 [pubmed]
PHST- 1982/03/22 00:01 [medline]
PHST- 1982/03/22 00:00 [entrez]
AID - 10.1098/rspb.1982.0022 [doi]
PST - ppublish
SO  - Proc R Soc Lond B Biol Sci. 1982 Mar 22;214(1197):471-80. doi: 
      10.1098/rspb.1982.0022.

PMID- 7743538
OWN - NLM
STAT- MEDLINE
DCOM- 19950615
LR  - 20180215
IS  - 0008-6312 (Print)
IS  - 0008-6312 (Linking)
VI  - 85 Suppl 1
DP  - 1994
TI  - Use and abuse of clinical trials. Is the timing of treatment critical?
PG  - 7-12
AB  - The timing of treatment for any condition is dependent on the underlying 
      pathophysiology. One of the issues to consider is whether decreasing the time to 
      intervention can be translated into recognisable benefits. Key data have been 
      generated over the last 10 years which are relevant to the treatment of acute 
      myocardial infarction (MI), including results of the large-scale 'mega-trials' in 
      broad population groups. The therapeutic interventions which will be considered 
      here are beta blockers, aspirin, thrombolytics and angiotensin-converting enzyme 
      (ACE) inhibitors. Of these, aspirin seems to be the least time-dependent, 
      provided it is administered within 12-24 h of symptom onset. Mortality benefits 
      associated with beta blocker therapy increase as the time of administration from 
      symptom onset is reduced and the extent to which thrombolytic therapy is 
      beneficial is also clearly time dependent. The results from GISSI-3 and ISIS-4, 
      which recruited a broader patient population than in previous trials, were 
      concordant, showing a significant improvement in survival after five to six 
      weeks' treatment. The message from GISSI-3 was that administration of ACE 
      inhibitors within 24 h of symptom onset will improve survival and left 
      ventricular function provided patients are hemodynamically stable, are not 
      hypotensive and have no renal dysfunction; 76 lives were saved (representing an 
      11% risk reduction in mortality) after six weeks' lisinopril treatment, 54 of 
      which were saved in the first five days.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Tognoni, G
AU  - Tognoni G
AD  - Laboratory of Clinical Pharmacology, Mario Negri Institute, Milan, Italy.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Clinical Trials as Topic
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Thrombolytic Therapy
MH  - Time Factors
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1159/000176750 [doi]
PST - ppublish
SO  - Cardiology. 1994;85 Suppl 1:7-12. doi: 10.1159/000176750.

PMID- 2600123
OWN - NLM
STAT- MEDLINE
DCOM- 19900206
LR  - 20161026
IS  - 0021-9509 (Print)
IS  - 0021-9509 (Linking)
VI  - 30
IP  - 6
DP  - 1989 Nov-Dec
TI  - Aspirin improves the patency rate of seeded vena cava grafts.
PG  - 936-41
AB  - The purpose of this study was to evaluate the effectiveness of aspirin (ASA) and 
      porcine endothelial cell seeding in improving the patency rate of vena cava 
      grafts. Thirty-nine dogs underwent infrarenal vena cava replacement by 10 cm 
      lengths of 8 mm I.D. ringed polytetrafluoroethylene grafts. Thirty-one grafts 
      were seeded with 1-1.5 x 10(6) porcine aortic endothelial cells while eight were 
      not (GIII). Of the seeded group, 16 animals received no ASA (GI), while 15 others 
      (GII) were given ASA (325 mg) daily starting two days preoperatively and 
      continuing until sacrifice. Venograms were performed on the fourth postoperative 
      day. Grafts were harvested 32 days after insertion and evaluated for patency rate 
      and endothelialized surfaces. The 32-day patency rate was significantly higher 
      for GII than for GI and III animals (67% vs. 13 and 25% respectively). 
      Endothelialized surface was higher in GII than Gi and III (67% vs. 16% and 18% 
      respectively). We conclude that endothelial cell seeding alone does not prevent 
      graft closure and that a combination of ASA and cell seeding significantly 
      increases the patency rate of vena cava grafts.
FAU - Vo, N M
AU  - Vo NM
AD  - Department of Surgery, East Tennessee State University, Johnson City.
FAU - Arbogast, L Y
AU  - Arbogast LY
FAU - Friedlander, E
AU  - Friedlander E
FAU - Stanton, P E
AU  - Stanton PE
FAU - Arbogast, B
AU  - Arbogast B
LA  - eng
GR  - HL 37449/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Italy
TA  - J Cardiovasc Surg (Torino)
JT  - The Journal of cardiovascular surgery
JID - 0066127
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - *Blood Vessel Prosthesis
MH  - Dogs
MH  - Endothelium, Vascular/cytology
MH  - Graft Occlusion, Vascular
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Swine
MH  - *Vascular Patency
MH  - Venae Cavae/*surgery
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
PST - ppublish
SO  - J Cardiovasc Surg (Torino). 1989 Nov-Dec;30(6):936-41.

PMID- 899874
OWN - NLM
STAT- MEDLINE
DCOM- 19771020
LR  - 20190812
IS  - 0001-6101 (Print)
IS  - 0001-6101 (Linking)
VI  - 202
IP  - 1-2
DP  - 1977
TI  - Bioavailability of D-propoxyphene, acetyl salicylic acid, and phenazone in a 
      combination tablet (Doleron): interindividual variation and influence of food 
      intake.
PG  - 119-24
AB  - The influence of food intake on the bioavailability of three analgesic 
      compounds--propoxyphene chloride, acetyl salicylic acid and phenazone--in a 
      combination tablet, Doleron, has been examined in eight healthy volunteers. A 
      single oral dose was given both on an empty stomach and together with a 
      standardized breakfast meal. The plasma concentrations of propoxyphene, its major 
      metabolite norpropoxyphene, salicylic acid and phenazone were determined by mass 
      fragmentography, spectrofluorimetry and gas chromatography. Concomitant food 
      intake had no consistent influence on the bioavailability of any of the 
      components. Hence, doleron may be taken together with meals as well as between 
      meals. Large interindividual variations in propoxyphene and phenazone 
      concentrations were found, indicating that an optimal effect will not always be 
      obtained by standard doses.
FAU - Melander, A
AU  - Melander A
FAU - Berlin-Wahlén, A
AU  - Berlin-Wahlén A
FAU - Bodin, N O
AU  - Bodin NO
FAU - Danielson, K
AU  - Danielson K
FAU - Gustafsson, B
AU  - Gustafsson B
FAU - Lindgren, S
AU  - Lindgren S
FAU - Westerlund, D
AU  - Westerlund D
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Sweden
TA  - Acta Med Scand
JT  - Acta medica Scandinavica
JID - 0370330
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
RN  - T3CHA1B51H (Antipyrine)
SB  - IM
MH  - Adult
MH  - Antipyrine/*metabolism
MH  - Aspirin/*metabolism
MH  - Biological Availability
MH  - Dextropropoxyphene/*metabolism
MH  - Drug Combinations
MH  - Fasting
MH  - Female
MH  - *Food
MH  - Humans
MH  - Male
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1111/j.0954-6820.1977.tb16796.x [doi]
PST - ppublish
SO  - Acta Med Scand. 1977;202(1-2):119-24. doi: 10.1111/j.0954-6820.1977.tb16796.x.

PMID- 6158390
OWN - NLM
STAT- MEDLINE
DCOM- 19801218
LR  - 20190825
IS  - 0305-1870 (Print)
IS  - 0305-1870 (Linking)
VI  - 7
IP  - 4
DP  - 1980 Jul
TI  - The action of aspirin on plasma kininogen and other plasma proteins in rheumatoid 
      patients: relationship to disease activity.
PG  - 347-54
AB  - 1. When six female seropositive rheumatoid patients were given placebo therapy 
      for 48 h, their plasma kininogen level, 9.2 +/- 0.7 microgram bradykinin 
      equivalents (bk eq) per ml, was found to be 59% greater than that of a group of 
      eight healthy female volunteers (5.8 +/- 0.5 microgram/ml). 2. When the 
      rheumatoid patients received aspirin therapy for 1 week, their mean plasma 
      kininogen concentration fell by 31% to 6.3 +/- 0.8 microgram Bk eq/ml. This was 
      accompanied by a 20.4% fall in mean plasma alpha 2-globulin level. Haematocrit 
      and total plasma protein were not significantly altered (P > 0.05). 3. The fall 
      in kininogen was very rapid, the main reduction occurring within the first hour. 
      4. Aspirin therapy greatly reduced the pain assessments but had no effect on 
      plasma concentrations of IgG, IgA, IgM, complement component C3, nor on ESR, 
      haemoglobin, leucocyte count, nor ring size. Left hand grip strength was 
      increased while right hand grip strength was unchanged. 5. The action of aspirin 
      on plasma kininogen and alpha 2-globulin was similar to that of indomethacin. 
      Plasma kininogen has been considered to be an acute phase reactant. The possible 
      diagnostic value of plasma kininogen estimation is discussed.
FAU - Sharma, J N
AU  - Sharma JN
FAU - Zeitlin, I J
AU  - Zeitlin IJ
FAU - Brooks, P M
AU  - Brooks PM
FAU - Buchanan, W W
AU  - Buchanan WW
FAU - Dick, W C
AU  - Dick WC
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Alpha-Globulins)
RN  - 0 (Blood Proteins)
RN  - 0 (Complement C3)
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Kininogens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alpha-Globulins/analysis
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Proteins/*metabolism
MH  - Complement C3/analysis
MH  - Female
MH  - Humans
MH  - Immunoglobulin A/analysis
MH  - Immunoglobulin G/analysis
MH  - Immunoglobulin M/analysis
MH  - Kininogens/*blood
MH  - Middle Aged
EDAT- 1980/07/01 00:00
MHDA- 1980/07/01 00:01
CRDT- 1980/07/01 00:00
PHST- 1980/07/01 00:00 [pubmed]
PHST- 1980/07/01 00:01 [medline]
PHST- 1980/07/01 00:00 [entrez]
AID - 10.1111/j.1440-1681.1980.tb00082.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 1980 Jul;7(4):347-54. doi: 
      10.1111/j.1440-1681.1980.tb00082.x.

PMID- 19187640
OWN - NLM
STAT- MEDLINE
DCOM- 20090522
LR  - 20220317
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 122
IP  - 2
DP  - 2009 Jan 20
TI  - The utilization status of aspirin for the secondary prevention of ischemic 
      stroke.
PG  - 165-8
AB  - BACKGROUND: The present study was aimed to investigate the usage of aspirin for 
      the secondary prevention of ischemic stroke, evaluate the correlated factors, and 
      analyze the reasons for not taking and irregularly taking aspirin. METHODS: The 
      patients in this group were all stroke survivors who have formerly been diagnosed 
      with a cerebral infarction or transient ischemic attack (TIA) in our hospital. We 
      investigated their use of aspirin over a three-year period following their 
      hospitalization. According to the patients' aspirin usage, they were divided into 
      treatment and non-treatment groups. In addition, the reasons for not taking or 
      irregularly taking aspirin were analyzed in the two groups. RESULTS: A total of 
      1240 patients were studied, including 367 (29.60%) in the treatment group and 873 
      (70.40%) cases in the non-treatment group. In addition, 201 (16.20%) cases in the 
      treatment group had been regularly taking aspirin (50 - 325 mg of aspirin daily) 
      for 1 to 3 years or longer. The results demonstrated that the main reasons for 
      not taking aspirin in this study were related to patients' concerns regarding the 
      side effects of taking aspirin (46.45%), as well as the doctors' inadequacy in 
      informing their patients to take aspirin (38.71%). The major reasons for patients 
      to irregularly take aspirin were that the doctors did not notify the length of 
      aspirin usage to their patients (41.57%), and that doctors did not prescribe 
      aspirin upon the patients' follow-up visit (26.51%). CONCLUSION: The most 
      effective way to increase patient's compliance for aspirin consumption is to 
      promote the guidelines for stroke treatment and to relay these advances in stroke 
      therapy to the patient.
FAU - Ke, Xian-jun
AU  - Ke XJ
AD  - Department of Neurology, People's Hospital of East and West Lake District, Wuhan, 
      Hubei 430040, China. kxj2688@163.com
FAU - Yu, Yong-fei
AU  - Yu YF
FAU - Guo, Zhen-li
AU  - Guo ZL
FAU - Xu, Kang
AU  - Xu K
FAU - Hai, Hong
AU  - Hai H
FAU - Zhang, Ai-he
AU  - Zhang AH
FAU - Jiang, Hong
AU  - Jiang H
FAU - Peng, Hong
AU  - Peng H
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Chin Med J (Engl). 2009 May 5;122(9):1119. PMID: 19493454
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Retrospective Studies
MH  - Secondary Prevention/*methods
MH  - Stroke/*prevention & control/psychology
EDAT- 2009/02/04 09:00
MHDA- 2009/05/23 09:00
CRDT- 2009/02/04 09:00
PHST- 2009/02/04 09:00 [entrez]
PHST- 2009/02/04 09:00 [pubmed]
PHST- 2009/05/23 09:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2009 Jan 20;122(2):165-8.

PMID- 1505815
OWN - NLM
STAT- MEDLINE
DCOM- 19920923
LR  - 20180217
IS  - 0378-7346 (Print)
IS  - 0378-7346 (Linking)
VI  - 33
IP  - 4
DP  - 1992
TI  - Maternal hemorrhagic complications following prophylactic low-dose aspirin and 
      dipyridamole therapy.
PG  - 241-3
AB  - A case is reported of a severe postpartum maternal hemorrhagic complication, 
      which was related to prophylactic antithrombotic therapy with daily low-dose 
      aspirin (75 mg) combined with dipyridamole (225 mg) for the prevention of 
      preeclampsia. The postpartum course was complicated by recurrent episiotomy site 
      hematomas of nonclotted blood and prolonged bleeding time. Transfusion of 
      platelet concentrates was necessary to control the bleeding. This case report 
      draws attention to maternal hemorrhagic complications which may be associated 
      with prophylactic low-dose aspirin and dipyridamole in pregnancy.
FAU - Reubinoff, B E
AU  - Reubinoff BE
AD  - Department of Obstetrics and Gynecology, Hadassah University Hospital, Jerusalem, 
      Israel.
FAU - Eldor, A
AU  - Eldor A
FAU - Laufer, N
AU  - Laufer N
FAU - Sadovsky, E
AU  - Sadovsky E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Switzerland
TA  - Gynecol Obstet Invest
JT  - Gynecologic and obstetric investigation
JID - 7900587
RN  - 0 (Hemoglobins)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Bleeding Time
MH  - Blood Component Transfusion
MH  - Blood Transfusion
MH  - Dipyridamole/administration & dosage/*adverse effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Postpartum Hemorrhage/blood/*chemically induced/therapy
MH  - Pre-Eclampsia/*drug therapy/prevention & control
MH  - Pregnancy
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1159/000294893 [doi]
PST - ppublish
SO  - Gynecol Obstet Invest. 1992;33(4):241-3. doi: 10.1159/000294893.

PMID- 2362094
OWN - NLM
STAT- MEDLINE
DCOM- 19900806
LR  - 20190817
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 12
IP  - 3
DP  - 1990 Jun
TI  - Chronic beta-carotene supplementation does not alter the gastric mucosal response 
      to acute aspirin ingestion.
PG  - 267-70
AB  - Carotenoids and retinoids have been reported to reduce gastrointestinal mucosa 
      damage from a variety of irritants. We performed double-blind, placebo-controlled 
      endoscopic trial to evaluate the effect of chronic beta-carotene supplementation 
      upon the gastric mucosal response to acute aspirin injury. Six subjects taking 
      chronic beta-carotene and six taking placebo each ingested 650 mg of aspirin 
      after an endoscopy confirmed normal gastric mucosa. Three hours later, mucosal 
      lesions were counted at repeat endoscopy. beta-Carotene did not prevent acute 
      mucosal injury better than placebo.
FAU - Moses, F M
AU  - Moses FM
AD  - Gastroenterology Service, Walter Reed Army Medical Center, Washington, D.C. 
      20307-5001.
FAU - Kikendall, J W
AU  - Kikendall JW
FAU - Bowen, P
AU  - Bowen P
FAU - Young, T R
AU  - Young TR
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 01YAE03M7J (beta Carotene)
RN  - 36-88-4 (Carotenoids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Carotenoids/administration & dosage/*pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Stomach Ulcer/prevention & control
MH  - beta Carotene
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
AID - 10.1097/00004836-199006000-00006 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 1990 Jun;12(3):267-70. doi: 
      10.1097/00004836-199006000-00006.

PMID- 36942800
OWN - NLM
STAT- MEDLINE
DCOM- 20230725
LR  - 20230805
IS  - 1866-0452 (Electronic)
IS  - 1866-0452 (Linking)
VI  - 120
IP  - 18
DP  - 2023 May 5
TI  - Acute Chest Pain.
PG  - 317-323
LID - arztebl.m2023.0065 [pii]
LID - 10.3238/arztebl.m2023.0065 [doi]
AB  - BACKGROUND: Acute chest pain (aCP) can be a symptom of life-threatening diseases 
      such as acute coronary or aortic syndrome, but often has a non-cardiac cause. The 
      recommendations regarding pre-hospital drug treatment of patients with aCP are 
      ambiguous. METHODS: A retrospective cohort study was conducted of 822 patients 
      with aCP who were attended by emergency physicians. The cause of aCP was 
      classified as follows: acute coronary syndrome without ST-segment elevation 
      (NSTE-ACS), acute aortic syndrome, hypertensive crisis, cardiac arrhythmias, 
      musculoskeletal, or other. The suspected and discharge diagnoses were compared, 
      and the pre-hospital administration of acetylsalicylic acid (ASA) and 
      unfractionated heparin (UFH) was analyzed. Furthermore, the parameters that 
      improved diagnostic accuracy were investigated. RESULTS: The positive predictive 
      value of the diagnosis assigned by the emergency physician (EP diagnosis) was 
      39.7%. NSTEACS was the most commonly suspected cause of aCP (74.7%), but was 
      confirmed after hospital admission in only 26.3% of patients. ASA was 
      administered in 51%, UFH in 55%, and both substances in 46.4% of cases. A large 
      proportion of patients received anticoagulants in the pre-hospital setting 
      although the discharge diagnosis was not NSTE-ACS: ASA 62.9%, UFH 66.0%, both 
      substances 56.5%. CONCLUSION: ASA and UFH are often given to EP-accompanied 
      patients with aCP despite the low accuracy of diagnosis in the pre-hospital 
      setting. Pre-hospital measurement of high-sensitivity troponin T (hs Trop-T) 
      might improve discrimination between NSTE-ACS and other causes of aCP. This is 
      important, as the current guidelines contain no clear recommendations for 
      prehospital drug treatment in NSTE-ACS.
FAU - Braumann, Simon
AU  - Braumann S
AD  - Medical Faculty, University of Cologne, and Department of Internal Medicine III, 
      Cologne University Hospital; Department of Internal Medicine, Evangelical 
      Hospital Cologne-Weyertal; Medical Faculty, University of Cologne, and Institute 
      for Medical Statistics, Cologne University Hospital; Medical Faculty, University 
      of Cologne, and Clinical Acute and Emergency Medicine Team, Cologne University 
      Hospital; Medical Faculty, University of Cologne, and Department of Internal 
      Medicine II, Cologne University Hospital.
FAU - Faber-Zameitat, Christian
AU  - Faber-Zameitat C
FAU - Macherey-Meyer, Sascha
AU  - Macherey-Meyer S
FAU - Tichelbäcker, Tobias
AU  - Tichelbäcker T
FAU - Meertens, Max
AU  - Meertens M
FAU - Heyne, Sebastian
AU  - Heyne S
FAU - Nießen, Franz
AU  - Nießen F
FAU - Nies, Richard Julius
AU  - Nies RJ
FAU - Nettersheim, Felix
AU  - Nettersheim F
FAU - Reuter, Hannes
AU  - Reuter H
FAU - Pfister, Roman
AU  - Pfister R
FAU - Hellmich, Martin
AU  - Hellmich M
FAU - Burst, Volker
AU  - Burst V
FAU - Baldus, Stephan
AU  - Baldus S
FAU - Lee, Samuel
AU  - Lee S
FAU - Adler, Christoph
AU  - Adler C
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Dtsch Arztebl Int
JT  - Deutsches Arzteblatt international
JID - 101475967
RN  - 9005-49-6 (Heparin)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Heparin/therapeutic use
MH  - Retrospective Studies
MH  - *Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Chest Pain/diagnosis/etiology
PMC - PMC10398374
EDAT- 2023/03/22 06:00
MHDA- 2023/07/25 06:42
CRDT- 2023/03/21 07:32
PHST- 2022/09/20 00:00 [received]
PHST- 2022/09/20 00:00 [revised]
PHST- 2023/03/07 00:00 [accepted]
PHST- 2023/07/25 06:42 [medline]
PHST- 2023/03/22 06:00 [pubmed]
PHST- 2023/03/21 07:32 [entrez]
AID - arztebl.m2023.0065 [pii]
AID - 10.3238/arztebl.m2023.0065 [doi]
PST - ppublish
SO  - Dtsch Arztebl Int. 2023 May 5;120(18):317-323. doi: 10.3238/arztebl.m2023.0065.

PMID- 24751924
OWN - NLM
STAT- MEDLINE
DCOM- 20150120
LR  - 20220318
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 4
DP  - 2014
TI  - Effect of heparin on prevention of flap loss in microsurgical free flap transfer: 
      a meta-analysis.
PG  - e95111
LID - 10.1371/journal.pone.0095111 [doi]
LID - e95111
AB  - The effectiveness of heparin for thromboprophylaxis during microvascular free 
      flap transfer is uncertain. The purpose of this meta-analysis was to determine 
      the effect of heparin on the prevention of flap loss in microsurgical free flap 
      transfer.A search of PubMed, Cochrane databases, and Google Scholar using 
      combinations of the search terms heparin, free flap, flap loss, free tissue 
      transfer was conducted on March 15, 2013. Inclusion criteria were: 1) Prospective 
      randomized trials. 2) Retrospective, non-randomized studies. 3) Patients received 
      free tissue transfer. Flap loss rate was used to evaluate treatment efficacy. 
      Odds ratios (ORs) with 95% confidence intervals (CI) were calculated and compared 
      between therapies. Four studies meet the criteria for analysis and were included. 
      Two studiescompared aspirin and heparin, and the ORs of the 2 studies were 1.688 
      and 2.087. The combined OR of 2.003 (95% CI 0.976-4.109, p = 0.058) did not 
      indicate any significant difference between heparin and aspirin therapies. Two 
      studiescompared high and low doses of dalteparin/heparin therapies, and the ORs 
      of the 2 studies were 4.691 and 11.00. The combined OR of 7.810 (95% CI 
      1.859-32.808, p = 0.005) revealed a significant difference indicating that high 
      dose dalteparin or heparin therapy is associated with a greater flap loss rate 
      than low dose therapy. Heparin and aspirin prophylaxis are associated with 
      similar flap loss rates after free flap transfer, and high dose dalteparin or 
      heparin therapy is associated with a greater flap loss rate than low dose 
      therapy.
FAU - Pan, Xuan-Liang
AU  - Pan XL
AD  - Department of Burns, Second Affiliated Hospital of Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang, China.
FAU - Chen, Guo-Xian
AU  - Chen GX
AD  - Department of Burns, Second Affiliated Hospital of Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang, China.
FAU - Shao, Hua-Wei
AU  - Shao HW
AD  - Department of Burns, Second Affiliated Hospital of Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang, China.
FAU - Han, Chun-Mao
AU  - Han CM
AD  - Department of Burns, Second Affiliated Hospital of Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang, China.
FAU - Zhang, Li-Ping
AU  - Zhang LP
AD  - Department of Burns, Second Affiliated Hospital of Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang, China.
FAU - Zhi, Li-Zhu
AU  - Zhi LZ
AD  - Department of Burns, Second Affiliated Hospital of Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20140421
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Dalteparin/pharmacology
MH  - Free Tissue Flaps/*pathology
MH  - Heparin/*pharmacology
MH  - Humans
MH  - Odds Ratio
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC3994018
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/04/23 06:00
MHDA- 2015/01/21 06:00
CRDT- 2014/04/23 06:00
PHST- 2013/12/08 00:00 [received]
PHST- 2014/03/24 00:00 [accepted]
PHST- 2014/04/23 06:00 [entrez]
PHST- 2014/04/23 06:00 [pubmed]
PHST- 2015/01/21 06:00 [medline]
AID - PONE-D-13-51403 [pii]
AID - 10.1371/journal.pone.0095111 [doi]
PST - epublish
SO  - PLoS One. 2014 Apr 21;9(4):e95111. doi: 10.1371/journal.pone.0095111. eCollection 
      2014.

PMID- 21422675
OWN - NLM
STAT- MEDLINE
DCOM- 20120214
LR  - 20190606
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 50
IP  - 6
DP  - 2011
TI  - Gastric mucosal damage evaluated by transnasal endoscopy and QOL assessments in 
      ischemic heart disease patients receiving low-dose aspirin.
PG  - 539-44
AB  - OBJECTIVE: Transnasal endoscopy was conducted to examine gastric mucosal damage 
      in Japanese patients with ischemic heart disease who were receiving low-dose 
      aspirin for preventing the onset or recurrence of cardiovascular disease. 
      PATIENTS AND METHODS: An endoscopist assessed gastric mucosal damage. 
      Furthermore, the MOS 36-Item Short-Form Health Survey (SF-36(®)) and the 
      Gastrointestinal Symptom-Rating Scale (GSRS) were used to assess the outcomes of 
      their quality of life (QOL) and the possible presence of gastric cancer and H. 
      pylori infection. RESULTS: Seventy-five patients were studied; and 24 (32.0%) and 
      16 (21.3%) of them concurrently received antithrombotic drugs other than aspirin 
      and antiulcer drugs, respectively. Regarding gastric mucosal damage, 15 (20.0%) 
      and 8 (10.7%) of the patients were endoscopically diagnosed with ulcer and 
      hemorrhagic gastritis, respectively. Furthermore, 5 patients (6.7%) were found to 
      have esophageal or gastric cancer. The positivity rate of Helicobacter pylori (H. 
      pylori) was 45.3%. Patients receiving low-dose aspirin showed a decreased QOL. 
      Consequently, no significant differences were found among the groups. Regarding 
      endoscopic findings, no differences were found in the scores of both SF-36(®) and 
      GSRS with respect to the presence or absence of gastric ulcer, hemorrhagic 
      gastritis, and H. pylori infection. CONCLUSION: Transnasal endoscopy was possible 
      to perform during the oral intake of low-dose aspirin without causing any 
      hemorrhagic complications. Many patients with gastric mucosal lesions showed no 
      subjective symptom, and patients receiving aspirin were strongly recommended to 
      undergo regular transnasal endoscopy, regardless of the presence or absence of 
      symptoms.
FAU - Watanabe, Masataka
AU  - Watanabe M
AD  - Department of Cardiology, Tokyo Medical University, Japan. w-mac@xg7.so-net.ne.jp
FAU - Kawai, Takashi
AU  - Kawai T
FAU - Takata, Yoshifumi
AU  - Takata Y
FAU - Yamashina, Akira
AU  - Yamashina A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110315
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - *Endoscopy, Digestive System/methods
MH  - Female
MH  - Gastric Mucosa/drug effects/*pathology
MH  - Health Surveys/methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/complications/drug therapy/*psychology
MH  - Nasal Cavity
MH  - Quality of Life/*psychology
MH  - Stomach Ulcer/chemically induced/diagnosis
MH  - Surveys and Questionnaires
EDAT- 2011/03/23 06:00
MHDA- 2012/02/15 06:00
CRDT- 2011/03/23 06:00
PHST- 2011/03/23 06:00 [entrez]
PHST- 2011/03/23 06:00 [pubmed]
PHST- 2012/02/15 06:00 [medline]
AID - JST.JSTAGE/internalmedicine/50.4361 [pii]
AID - 10.2169/internalmedicine.50.4361 [doi]
PST - ppublish
SO  - Intern Med. 2011;50(6):539-44. doi: 10.2169/internalmedicine.50.4361. Epub 2011 
      Mar 15.

PMID- 37385747
OWN - NLM
STAT- MEDLINE
DCOM- 20230703
LR  - 20230704
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 13
IP  - 6
DP  - 2023 Jun 29
TI  - Multicentre, randomised, double-blind, parallel controlled trial to investigate 
      timing of platelet inhibition after coronary artery bypass grafting: TOP-CABG 
      trial study.
PG  - e070823
LID - 10.1136/bmjopen-2022-070823 [doi]
LID - e070823
AB  - INTRODUCTION: Dual antiplatelet therapy (DAPT), referred to as the combination of 
      aspirin and P2Y(12) receptor antagonist (clopidogrel or ticagrelor), potentially 
      improves patency of saphenous vein grafts (SVG) after coronary artery bypass 
      grafting (CABG), while it is further proposed that DAPT potentially increases 
      bleeding risk. Compared with DAPT, de-escalated DAPT (De-DAPT) is an effective 
      antiplatelet strategy for acute coronary syndrome treatment, which significantly 
      reduces the risk of bleeding without increasing the incidence of major adverse 
      cardiovascular events. However, insufficient evidence is available to determine 
      the timing of DAPT after CABG. METHODS AND ANALYSIS: ETHICS AND DISSEMINATION: 
      The Ethics Committee in Fuwai hospital approved this study (2022-1774). Fifteen 
      centres agreed to participate the TOP-CABG trial, and the study has been approved 
      in these 15 centres by whose ethics committee. The results of the trial will be 
      submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: 
      NCT05380063.
CI  - © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yuan, Xin
AU  - Yuan X
AD  - State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre 
      for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, People's Republic of China.
AD  - Department of Cardiac Surgery, Fuwai Hospital, Chinese Academy of Medical Science 
      and Peking Union Medical College, Beijing, People's Republic of China.
FAU - Chu, Qing
AU  - Chu Q
AUID- ORCID: 0000-0001-5022-2945
AD  - State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre 
      for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, People's Republic of China.
AD  - Department of Cardiac Surgery, Fuwai Hospital, Chinese Academy of Medical Science 
      and Peking Union Medical College, Beijing, People's Republic of China.
FAU - Chen, Kai
AU  - Chen K
AD  - State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre 
      for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, People's Republic of China.
AD  - Department of Cardiac Surgery, Fuwai Hospital, Chinese Academy of Medical Science 
      and Peking Union Medical College, Beijing, People's Republic of China.
FAU - Wang, Yang
AU  - Wang Y
AUID- ORCID: 0000-0002-5040-2492
AD  - National Clinical Research Centre of Cardiovascular Diseases, State Key 
      Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for 
      Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, People's Republic of China.
FAU - Zhang, Lihua
AU  - Zhang L
AD  - National Clinical Research Centre of Cardiovascular Diseases, State Key 
      Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for 
      Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, People's Republic of China.
FAU - Zheng, Yingli
AU  - Zheng Y
AD  - Department of Pharmacy, Fuwai Hospital, Chinese Academy of Medical Science and 
      Peking Union Medical College, Beijing, People's Republic of China.
FAU - Hu, Shengshou
AU  - Hu S
AD  - State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre 
      for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, People's Republic of China shengshouhu@yahoo.com.
AD  - Department of Cardiac Surgery, Fuwai Hospital, Chinese Academy of Medical Science 
      and Peking Union Medical College, Beijing, People's Republic of China.
LA  - eng
SI  - ClinicalTrials.gov/NCT05380063
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20230629
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - Double-Blind Method
MH  - Coronary Artery Bypass
MH  - *Acute Coronary Syndrome/drug therapy/surgery
MH  - Aspirin/therapeutic use
PMC - PMC10314523
OTO - NOTNLM
OT  - Adult cardiology
OT  - Coronary heart disease
OT  - Myocardial infarction
COIS- Competing interests: None declared.
EDAT- 2023/06/30 01:06
MHDA- 2023/07/03 06:41
CRDT- 2023/06/29 21:22
PHST- 2023/07/03 06:41 [medline]
PHST- 2023/06/30 01:06 [pubmed]
PHST- 2023/06/29 21:22 [entrez]
AID - bmjopen-2022-070823 [pii]
AID - 10.1136/bmjopen-2022-070823 [doi]
PST - epublish
SO  - BMJ Open. 2023 Jun 29;13(6):e070823. doi: 10.1136/bmjopen-2022-070823.

PMID- 31442298
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20201112
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 107
IP  - 2
DP  - 2020 Feb
TI  - Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity 
      and Coagulation Activation: A Randomized Trial in Healthy Volunteers.
PG  - 415-422
LID - 10.1002/cpt.1616 [doi]
AB  - Dual antiplatelet therapy (DAPT) is standard in acute coronary heart disease but 
      confers a bleeding risk. To compare the effects of ticagrelor-monotherapy with 
      ticagrelor-based DAPT on hemostatic system activation, we conducted a randomized 
      controlled trial in 44 volunteers using a loading-dose regimen and measured 
      platelet-aggregometry triggered by adenosine diphosphate (multiple electrode 
      aggregometry (MEA)-ADP) and arachidonic acid (MEA-AA), the vasodilator-stimulated 
      phosphoprotein (VASP), prothrombin fragment 1.2 (f1.2), and d-Dimer. 
      Ticagrelor-based DAPT and ticagrelor-monotherapy significantly decreased MEA-ADP 
      (Δmean: -51.4 (-56.9; -45.8) and -46.2 (-51.7; -40.7)) and VASP (Δmean: -70.3 
      (-76.2; -64.4) and -69.6 (-75.5; -63.7)) at 2 hours and over 24 hours. MEA-AA was 
      reduced significantly by both treatments (Δmean: -72.9 (-80.6; -65.3) and -25.7 
      (-33.3; -18.0)) at 2 hours, and stronger by ticagrelor-based DAPT over 24 hours. 
      Both treatments decreased f1.2 (geometric mean ratio (GMR): 0.92 (0.84; 1.01) and 
      0.88 (0.80; 0.96)) and d-Dimer (GMR: 0.89 (0.86; 0.92) and 0.91 (0.88; 0.94)) at 
      2 hours and d-Dimer over 24 hours. Ticagrelor-monotherapy and ticagrelor-based 
      DAPT comparably affect hemostatic system activation.
CI  - © 2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley 
      Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and 
      Therapeutics.
FAU - Traby, Ludwig
AU  - Traby L
AUID- ORCID: 0000-0003-2861-5771
AD  - Department of Medicine I, Medical University of Vienna, Vienna, Austria.
FAU - Kollars, Marietta
AU  - Kollars M
AD  - Department of Medicine I, Medical University of Vienna, Vienna, Austria.
FAU - Kaider, Alexandra
AU  - Kaider A
AD  - Center for Medical Statistics, Informatics and Intelligent Systems, Medical 
      University of Vienna, Vienna, Austria.
FAU - Siller-Matula, Jolanta M
AU  - Siller-Matula JM
AD  - Department of Medicine II, Medical University of Vienna, Vienna, Austria.
FAU - Wolkersdorfer, Martin F
AU  - Wolkersdorfer MF
AD  - Landesapotheke Salzburg, Salzburg, Austria.
FAU - Wolzt, Michael
AU  - Wolzt M
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
FAU - Kyrle, Paul A
AU  - Kyrle PA
AD  - Department of Medicine I, Medical University of Vienna, Vienna, Austria.
FAU - Eichinger, Sabine
AU  - Eichinger S
AD  - Department of Medicine I, Medical University of Vienna, Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190928
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Ticagrelor/*pharmacology
MH  - Young Adult
PMC - PMC7006887
COIS- Jolanta M. Siller‐Matula reports lecture or consultant fees from Bayer, Astra 
      Zeneca, Eli Lilly, Daiichi‐Sankyo, and Roche. All other authors declared no 
      competing interests for this work.
EDAT- 2019/08/24 06:00
MHDA- 2020/11/13 06:00
CRDT- 2019/08/24 06:00
PHST- 2019/06/12 00:00 [received]
PHST- 2019/07/29 00:00 [accepted]
PHST- 2019/08/24 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
PHST- 2019/08/24 06:00 [entrez]
AID - CPT1616 [pii]
AID - 10.1002/cpt.1616 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2020 Feb;107(2):415-422. doi: 10.1002/cpt.1616. Epub 2019 
      Sep 28.

PMID- 33594652
OWN - NLM
STAT- MEDLINE
DCOM- 20220414
LR  - 20220612
IS  - 2196-8837 (Electronic)
IS  - 2196-8837 (Linking)
VI  - 9
IP  - 2
DP  - 2022 Apr
TI  - Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among 
      Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across 
      the Life Span (HANDLS) Study.
PG  - 538-545
LID - 10.1007/s40615-021-00984-y [doi]
AB  - OBJECTIVE: Guideline-directed medical therapy (GDMT) has been shown to improve 
      outcomes for people with cardiovascular disease (CVD). Our goal was to assess 
      racial and socioeconomic differences in GDMT use among a diverse population. 
      METHODS: We examined the cross-sectional association of race and poverty status 
      with GDMT among 441 participants with CVD in a longitudinal cohort of 
      urban-dwelling Black and White adults in Baltimore City, Maryland, using 
      multivariable logistic regression. CVD status and GDMT were self-reported. 
      RESULTS: The participants' mean age was 60.5 (SD 8.5) years, with 61.7% women, 
      64.4% Black, and 46.9% living below poverty. Of the 126 participants with 
      coronary artery disease (CAD), 37.3%, 54.8%, and 62.7% were on aspirin, 
      antiplatelets, and statins, respectively. Black participants with CAD were less 
      likely to be on aspirin, OR 0.29 (95% CI 0.13-0.67), and on combination GDMT 
      (antiplatelet and statin), OR 0.36 (0.16-0.78) compared to Whites. There were no 
      differences by poverty status in GDMT for CAD. Fully, 222 participants reported 
      atrial fibrillation (AF), but only 10.5% were on anticoagulation with no 
      significant difference by race or poverty status. The use of GDMT for heart 
      failure and stroke was also low overall, but there were no differences by race or 
      poverty status. CONCLUSIONS: Among an urban-dwelling population of adults, the 
      use of secondary prevention of CVD was low, with lower aspirin and combination 
      GDMT for Black participants with CAD. Efforts to improve GDMT use at the patient 
      and provider levels may be needed to improve morbidity and mortality and reduce 
      disparities in CVD.
CI  - © 2021. W. Montague Cobb-NMA Health Institute.
FAU - Mathews, Lena
AU  - Mathews L
AUID- ORCID: 0000-0003-3780-7572
AD  - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, 
      MD, USA. lmathew6@jhmi.edu.
AD  - Division of Cardiology, Johns Hopkins School of Medicine, 600 North Wolfe Street 
      Blalock 524D, Baltimore, MD, USA. lmathew6@jhmi.edu.
FAU - Han, Dingfen
AU  - Han D
AD  - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, 
      MD, USA.
FAU - Evans, Michele K
AU  - Evans MK
AD  - Laboratory of Epidemiology and Population Sciences, National Institute on Aging 
      Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
FAU - Zonderman, Alan B
AU  - Zonderman AB
AD  - Laboratory of Epidemiology and Population Sciences, National Institute on Aging 
      Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
FAU - Ndumele, Chiadi E
AU  - Ndumele CE
AD  - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, 
      MD, USA.
AD  - Division of Cardiology, Johns Hopkins School of Medicine, 600 North Wolfe Street 
      Blalock 524D, Baltimore, MD, USA.
AD  - Johns Hopkins Center for Health Equity, Johns Hopkins Bloomberg School of Public 
      Health, Baltimore, MD, USA.
FAU - Crews, Deidra C
AU  - Crews DC
AD  - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, 
      MD, USA.
AD  - Johns Hopkins Center for Health Equity, Johns Hopkins Bloomberg School of Public 
      Health, Baltimore, MD, USA.
LA  - eng
GR  - K24 HL148181/HL/NHLBI NIH HHS/United States
GR  - HHSN268201700002I/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210216
PL  - Switzerland
TA  - J Racial Ethn Health Disparities
JT  - Journal of racial and ethnic health disparities
JID - 101628476
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Baltimore/epidemiology
MH  - *Cardiovascular Diseases
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Healthy Aging
MH  - Humans
MH  - Longevity
MH  - Male
MH  - Middle Aged
MH  - Prevalence
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Guideline-directed medical therapy
OT  - Socioeconomic status
EDAT- 2021/02/18 06:00
MHDA- 2022/04/15 06:00
CRDT- 2021/02/17 06:00
PHST- 2020/06/26 00:00 [received]
PHST- 2021/01/28 00:00 [accepted]
PHST- 2021/01/27 00:00 [revised]
PHST- 2021/02/18 06:00 [pubmed]
PHST- 2022/04/15 06:00 [medline]
PHST- 2021/02/17 06:00 [entrez]
AID - 10.1007/s40615-021-00984-y [pii]
AID - 10.1007/s40615-021-00984-y [doi]
PST - ppublish
SO  - J Racial Ethn Health Disparities. 2022 Apr;9(2):538-545. doi: 
      10.1007/s40615-021-00984-y. Epub 2021 Feb 16.

PMID- 17724837
OWN - HSR
STAT- MEDLINE
DCOM- 20070830
LR  - 20131121
IS  - 1167-7422 (Print)
IS  - 1167-7422 (Linking)
VI  - 16
IP  - 90
DP  - 2007 Aug
TI  - Clopidogrel: new indication. In combination with aspirin: marginal additional 
      benefits.
PG  - 146
AB  - In patients with myocardial infarction who are not eligible for angioplasty, 
      adding clopidogrel to aspirin reduces the overall 15-day mortality rate, but the 
      subsequent outcome is not known.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Prescrire Int
JT  - Prescrire international
JID - 9439295
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & 
      derivatives/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2007/08/30 09:00
MHDA- 2007/08/31 09:00
CRDT- 2007/08/30 09:00
PHST- 2007/08/30 09:00 [pubmed]
PHST- 2007/08/31 09:00 [medline]
PHST- 2007/08/30 09:00 [entrez]
PST - ppublish
SO  - Prescrire Int. 2007 Aug;16(90):146.

PMID- 6141262
OWN - NLM
STAT- MEDLINE
DCOM- 19840323
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 36
IP  - 1
DP  - 1984 Jan
TI  - The influence of agitation intensity, particle size and pH of dissolution fluid 
      on the in-vitro release of drug from hard gelatin capsules.
PG  - 42-4
AB  - The influence of agitation intensity on the in-vitro release of controlled 
      particle size fractions of acetylsalicylic acid from hard gelatin capsules into 
      buffered dissolution fluids has been investigated employing a dissolution 
      technique. The value of T50 decreased as the stirring rate increased from 120 to 
      320 rev min-1 for all particle size fractions and pH values. A further increase 
      in the stirring rate had a limited effect on the value of T50 and the changes 
      were particle size dependent. The influence of the drug solubility, induced by 
      changing the pH of the dissolution fluid, was decreased by increased agitation. 
      When the capsules were filled at bulk densities above the maximum tapped bulk 
      density, the value of T50 was increased, the extent of increase being greater the 
      smaller the particle size of the drug. The kinetics of the solution process were 
      influenced by agitation intensity and particle packing.
FAU - Newton, J M
AU  - Newton JM
FAU - Muhammad, N A
AU  - Muhammad NA
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Capsules)
RN  - 9000-70-8 (Gelatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - *Capsules
MH  - Gelatin
MH  - Hydrogen-Ion Concentration
MH  - Particle Size
MH  - Solubility
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1984.tb02984.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1984 Jan;36(1):42-4. doi: 10.1111/j.2042-7158.1984.tb02984.x.

PMID- 17760507
OWN - NLM
STAT- MEDLINE
DCOM- 20071207
LR  - 20171116
IS  - 1523-0864 (Print)
IS  - 1523-0864 (Linking)
VI  - 9
IP  - 11
DP  - 2007 Nov
TI  - Nitroaspirin (NCX-4016), an NO donor, is antiangiogenic through induction of loss 
      of redox-dependent viability and cytoskeletal reorganization in endothelial 
      cells.
PG  - 1837-49
AB  - We recently reported that NCX-4016, a derivative of aspirin containing a nitro 
      moiety that releases nitric oxide (NO) in a sustained fashion in biologic 
      systems, is a potent cytotoxic agent inhibiting the proliferation of 
      cisplatin-resistant human ovarian cancer cells. Therefore, we hypothesize that 
      NCX-4016 possesses antiangiogenic properties. Our study with the bovine lung 
      microvascular endothelial cells (BLMVECs) revealed that NCX-4016 significantly 
      induced the loss of redox-dependent cell viability in a dose- and time-dependent 
      manner, as assayed by the redox-sensitive Alamar blue cell viability assay. 
      Fluorescence microscopy of cells labeled with NO-specific fluorophore (DAF-FM) 
      confirmed that NCX-4016 generated significant levels of intracellular NO. NO 
      donors, including S-nitroso-N-acetylpenicillamine, spermine NONOate, and 
      isosorbide dinitrite, were less effective in causing loss of cell viability. 
      Thiol-protectant, N-acetylcysteine, significantly attenuated the NCX-4016-induced 
      loss of cell viability, suggesting the role of alteration of thiol-redox status 
      therein. NCX-4016 also suppressed oxygen consumption, decreased transendothelial 
      electrical resistance (EC barrier dysfunction), and induced actin cytoskeletal 
      reorganization in BLMVECs. The in vitro assay with human umbilical vein ECs and 
      BLMVECs revealed that NCX-4016, in a dose-dependent manner, significantly 
      inhibited angiogenesis with almost complete inhibition at a 100-microM 
      concentration, suggesting that NCX-4016 can act as an antiangiogenic drug.
FAU - Parinandi, Narasimham L
AU  - Parinandi NL
AD  - Department of Internal Medicine, Divisions of Cardiology and Pulmonary, Critical 
      Care, and Sleep Medicine, Dorothy M. Davis Heart and Lung Research Institute, 
      College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA. 
      kuppusamy.1@osu.edu
FAU - Sharma, Ashish
AU  - Sharma A
FAU - Eubank, Timothy D
AU  - Eubank TD
FAU - Kaufman, Bruce F
AU  - Kaufman BF
FAU - Kutala, Vijay Kumar
AU  - Kutala VK
FAU - Marsh, Clay B
AU  - Marsh CB
FAU - Ignarro, Louis J
AU  - Ignarro LJ
FAU - Kuppusamy, Periannan
AU  - Kuppusamy P
LA  - eng
GR  - CA102264/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Antioxid Redox Signal
JT  - Antioxidants & redox signaling
JID - 100888899
RN  - 0 (Antioxidants)
RN  - 0 (Nitric Oxide Donors)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antioxidants/pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Capillaries/cytology
MH  - Cattle
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Cytoskeleton/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Endothelial Cells/*cytology/metabolism
MH  - Endothelium, Vascular/cytology
MH  - Humans
MH  - Hydrogen Peroxide/pharmacology
MH  - Lung/blood supply
MH  - Microscopy, Fluorescence
MH  - Neovascularization, Physiologic/*drug effects
MH  - Nitric Oxide Donors/*pharmacology
MH  - Oxidation-Reduction
MH  - Umbilical Veins/cytology
EDAT- 2007/09/01 09:00
MHDA- 2007/12/08 09:00
CRDT- 2007/09/01 09:00
PHST- 2007/09/01 09:00 [pubmed]
PHST- 2007/12/08 09:00 [medline]
PHST- 2007/09/01 09:00 [entrez]
AID - 10.1089/ars.2007.1603 [doi]
PST - ppublish
SO  - Antioxid Redox Signal. 2007 Nov;9(11):1837-49. doi: 10.1089/ars.2007.1603.

PMID- 16311970
OWN - NLM
STAT- MEDLINE
DCOM- 20060317
LR  - 20181203
IS  - 0171-6425 (Print)
IS  - 0171-6425 (Linking)
VI  - 53
IP  - 6
DP  - 2005 Dec
TI  - Aspirin and clopidogrel taken until 2 days prior to coronary artery bypass graft 
      surgery is associated with increased postoperative drainage loss.
PG  - 341-5
AB  - OBJECTIVE: Platelet aggregation inhibitors, such as aspirin and clopidogrel, are 
      associated with increased bleeding in patients undergoing cardiac surgery with 
      cardiopulmonary bypass. We investigated the impact of time between the last 
      intake of aspirin and clopidogrel before CABG surgery and drainage loss, 
      transfusion requirements and rate of reoperation. PATIENTS AND METHODS: The 
      records of patients who had coronary artery bypass graft surgery (CABG) were 
      reviewed for intake of aspirin and clopidogrel within 7 days prior to surgery. 
      Drainage loss, transfusion requirements and rate of reoperation for bleeding 
      within 5 days after the operation, were recorded. RESULTS: Out of 261 analysed 
      patients, 225 patients (86.2 %) had no anti-platelet medication and 36 patients 
      (13.8 %) were on aspirin and clopidogrel. Aspirin and clopidogrel, taken all 
      until 2 days prior to operation, were associated with a significantly higher 
      postoperative blood loss (1840 mL [1230 - 3710] vs. 280 mL [185 - 765], p = 0.005 
      for one day and 850 mL [345 - 1725] vs. 277 mL [165 - 778], p = 0.026, for 2 days 
      prior to surgery). The trend showed that patients in the study group received 
      more platelet concentrates (PC: 5.3 % vs. 13.9 %, p = 0.067). The rate of 
      reoperation for bleeding was not different ( p = 0.25). CONCLUSION: Aspirin and 
      clopidogrel up to 2 days prior to CABG were associated with a significantly 
      higher postoperative drainage loss.
FAU - von Heymann, C
AU  - von Heymann C
AD  - Department of Anesthesiology and Intensive Care Medicine, Charité - University 
      Hospital Berlin, Berlin, Germany. christian.von_heymann@charite.de
FAU - Redlich, U
AU  - Redlich U
FAU - Moritz, M
AU  - Moritz M
FAU - Sander, M
AU  - Sander M
FAU - Vargas Hein, O
AU  - Vargas Hein O
FAU - Grubitzsch, H
AU  - Grubitzsch H
FAU - Konertz, W F
AU  - Konertz WF
FAU - Spies, C
AU  - Spies C
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thorac Cardiovasc Surg
JT  - The Thoracic and cardiovascular surgeon
JID - 7903387
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Transfusion
MH  - Clopidogrel
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Reoperation
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
EDAT- 2005/11/29 09:00
MHDA- 2006/03/18 09:00
CRDT- 2005/11/29 09:00
PHST- 2005/11/29 09:00 [pubmed]
PHST- 2006/03/18 09:00 [medline]
PHST- 2005/11/29 09:00 [entrez]
AID - 10.1055/s-2005-865760 [doi]
PST - ppublish
SO  - Thorac Cardiovasc Surg. 2005 Dec;53(6):341-5. doi: 10.1055/s-2005-865760.

PMID- 11122547
OWN - NLM
STAT- MEDLINE
DCOM- 20010322
LR  - 20191104
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 10
IP  - 3
DP  - 2000 Dec
TI  - Ticlopidine and aspirin fail to suppress the increased platelet aggregability 
      that follows percutaneous coronary interventions.
PG  - 265-9
AB  - Previous studies indicate that percutaneous transluminal coronary angioplasty 
      (PTCA) is associated with platelet activation. It is not well-established whether 
      enhanced platelet aggregability after PTCA is prevented by the association of 
      ticlopidine with aspirin. The aim of this study was to evaluate whole blood 
      platelet aggregability before and after elective PTCA in patients with chronic 
      stable angina receiving ticlopidine and aspirin. We studied 16 patients referred 
      for elective PTCA, treated for > or = 72 hours with oral aspirin and ticlopidine 
      (group 1), and 10 patients referred for diagnostic coronary angiography, treated 
      with oral aspirin alone (group 2). An intravenous bolus of heparin was 
      administered at the start of PTCA. In both groups, platelet aggregability was 
      assessed at baseline and 24 hours after the procedure, using the PFA 100(R) 
      system. This method measures the time required for flowing whole blood to occlude 
      a collagen and adenosine diphosphate (ADP)-coated ring, shorter times indicating 
      greater aggregability. In both groups, platelet aggregability after the procedure 
      was significantly increased compared with baseline: 104+/-30 seconds before 
      versus 88+/-24 seconds at 24 hours in group 1 (p=0.03) and 84+/-16 seconds before 
      versus 69+/-14 seconds at 24 hours in group 2 (p=0.004). Group 1 patients, 
      compared with group 2, showed a trend toward reduced aggregability at baseline 
      (p=0.06) and significantly lower aggregability 24 hours after the procedure 
      (p=0.03). Ticlopidine and aspirin reduce whole-blood platelet aggregability 
      compared with aspirin alone but fail to suppress the increased aggregability that 
      occurs 24 hours after PTCA.
FAU - Fischetti, D
AU  - Fischetti D
AD  - Institute of Cardiology, Catholic University, Rome, Italy. dfischetti@libero.it
FAU - Sciahbasi, A
AU  - Sciahbasi A
FAU - Leone, A M
AU  - Leone AM
FAU - Niccoli, G
AU  - Niccoli G
FAU - Schiavoni, G
AU  - Schiavoni G
FAU - Trani, C
AU  - Trani C
FAU - Mazzari, M A
AU  - Mazzari MA
FAU - Andreotti, F
AU  - Andreotti F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/drug therapy/surgery
MH  - Angioplasty, Balloon/*adverse effects
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Coagulation Tests/instrumentation/methods
MH  - Coronary Angiography
MH  - Drug Evaluation
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Ticlopidine/administration & dosage/*pharmacology
EDAT- 2000/12/21 11:00
MHDA- 2001/03/27 10:01
CRDT- 2000/12/21 11:00
PHST- 2000/12/21 11:00 [pubmed]
PHST- 2001/03/27 10:01 [medline]
PHST- 2000/12/21 11:00 [entrez]
AID - 10.1023/a:1026551409350 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2000 Dec;10(3):265-9. doi: 10.1023/a:1026551409350.

PMID- 3932082
OWN - NLM
STAT- MEDLINE
DCOM- 19851218
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 116
IP  - 1-2
DP  - 1985 Oct 8
TI  - Gastric ulcer formation and cyclo-oxygenase inhibition in cat antrum follows 
      parenteral administration of aspirin but not salicylate.
PG  - 153-7
AB  - The ulcerogenic actions of aspirin and sodium salicylate in cat gastric antrum 
      following intravenous injection, and their effects on the synthesis of two major 
      cyclo-oxygenase products by antral mucosa have been determined. Near-maximal 
      rates of gastric acid secretion were stimulated by histamine, infused i.v. for 1 
      h prior to bolus injection of aspirin or salicylate and throughout the subsequent 
      4 h. The area of lesions in the cat gastric antrum were then assessed 
      macroscopically and the generation of both 6-oxo-PGF1 alpha and PGE2 from strips 
      of antral mucosal tissue following 1 min vortex-incubation was determined by 
      radioimmunoassay. The plasma and mucosal-tissue levels of both aspirin and 
      salicylate were determined using HPLC techniques. Aspirin (0.2 mmol. kg-1 i.v.) 
      induced substantial deep antral ulceration during the 4 h histamine infusion, 
      whereas sodium salicylate (0.2 mmol. kg-1 i.v.) caused no significant macroscopic 
      damage. Sodium salicylate likewise caused no significant inhibition in the ex 
      vivo generation of either 6-oxo-PGF1 alpha or PGE2, whereas aspirin induced 92 
      +/- 3 and 97 +/- 1% inhibition of generation of these prostanoids respectively. 
      The levels of total salicylate in plasma and mucosal tissue were comparable 
      following bolus i.v. injection of aspirin or sodium salicylate. These 
      observations support the concept that cyclo-oxygenase inhibition is an important 
      mechanism underlying deep gastric ulceration induced by aspirin, when 
      administered parenterally in the cat.
FAU - Whittle, B J
AU  - Whittle BJ
FAU - Hansen, D
AU  - Hansen D
FAU - Salmon, J A
AU  - Salmon JA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandins E)
RN  - 0 (Salicylates)
RN  - 820484N8I3 (Histamine)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/blood/*toxicity
MH  - Cats
MH  - *Cyclooxygenase Inhibitors
MH  - Dinoprostone
MH  - Epoprostenol/metabolism
MH  - Female
MH  - Histamine/metabolism
MH  - Infusions, Parenteral
MH  - Male
MH  - Prostaglandins E/metabolism
MH  - Salicylates/administration & dosage/blood/*toxicity
MH  - Salicylic Acid
MH  - Stomach Ulcer/*chemically induced/metabolism
EDAT- 1985/10/08 00:00
MHDA- 1985/10/08 00:01
CRDT- 1985/10/08 00:00
PHST- 1985/10/08 00:00 [pubmed]
PHST- 1985/10/08 00:01 [medline]
PHST- 1985/10/08 00:00 [entrez]
AID - 0014-2999(85)90196-7 [pii]
AID - 10.1016/0014-2999(85)90196-7 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1985 Oct 8;116(1-2):153-7. doi: 10.1016/0014-2999(85)90196-7.

PMID- 6487359
OWN - NLM
STAT- MEDLINE
DCOM- 19841102
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 33
IP  - 19
DP  - 1984 Oct 1
TI  - Difference in hepatic uptake kinetics of aspirin and salicylamide in rats.
PG  - 3089-95
AB  - Immediately after intraportal administration to rats, the ratio of liver to 
      plasma concentrations for total aspirin was close to unity, whereas that for 
      total salicylamide ranged from about 3 to 7. The hepatic accumulation of 
      salicylamide appeared to be capacity-limited because the ratio decreased with 
      increases in the dose. In vitro experiments with isolated hepatocytes indicated 
      that aspirin was slowly transported into the hepatocytes by an apparently linear 
      process only, while salicylamide was taken up very rapidly by both saturable and 
      apparently linear transport processes. The cell to medium concentration ratio 
      estimated for the initially net transported component of the unchanged drug was 
      significantly larger with salicylamide, which give ratios from 3.5 to 19, than 
      with aspirin which gave an almost constant value lower than 2 despite wide 
      variations in the initial concentration. For the capacity-limited uptake process 
      of salicylamide, the kinetic parameters were estimated as Vmax = 0.325 nmole X 
      (mg cellular protein)-1 X sec-1 and Km = 201 microM. Among various metabolic 
      inhibitors, 2,4-dinitrophenol (50 microM) inhibited the uptake of salicylamide 
      most extensively. The present comparison of the in vivo and in vitro data for 
      aspirin with those for salicylamide confirmed the previously reported difference 
      in the hepatic first-pass effect of these two drugs.
FAU - Iwamoto, K
AU  - Iwamoto K
FAU - Furune, Y
AU  - Furune Y
FAU - Watanabe, J
AU  - Watanabe J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Dinitrophenols)
RN  - 0 (Salicylamides)
RN  - Q13SKS21MN (2,4-Dinitrophenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2,4-Dinitrophenol
MH  - Animals
MH  - Aspirin/*metabolism
MH  - Dinitrophenols/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - In Vitro Techniques
MH  - Liver/*metabolism
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Salicylamides/*metabolism
MH  - Time Factors
EDAT- 1984/10/01 00:00
MHDA- 1984/10/01 00:01
CRDT- 1984/10/01 00:00
PHST- 1984/10/01 00:00 [pubmed]
PHST- 1984/10/01 00:01 [medline]
PHST- 1984/10/01 00:00 [entrez]
AID - 0006-2952(84)90614-2 [pii]
AID - 10.1016/0006-2952(84)90614-2 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1984 Oct 1;33(19):3089-95. doi: 10.1016/0006-2952(84)90614-2.

PMID- 574128
OWN - NLM
STAT- MEDLINE
DCOM- 19800128
LR  - 20131121
IS  - 0340-0026 (Print)
IS  - 0340-0026 (Linking)
VI  - 17
IP  - 10
DP  - 1979 Oct
TI  - Time dependent changes in the pharmacokinetics of aspirin.
PG  - 409-11
AB  - In an experiment carried out on six volunteers, measurement of total serum 
      salicylate concentration was used to describe aspirin kinetics after a single 
      1500 mg oral dose. The availability of the drug was significantly better when it 
      was administered at 6(00) than at 18(00) or 22(00). Also a significant 
      time-dependence was found between the morning and evening values of both the 
      serum half-life time of salicylate and kel. The possible relation between these 
      results and the appearance of undesirable side effects in patients should be 
      examined.
FAU - Markiewicz, A
AU  - Markiewicz A
FAU - Semenowicz, K
AU  - Semenowicz K
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Biopharm
JT  - International journal of clinical pharmacology and biopharmacy
JID - 7505527
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*metabolism
MH  - Circadian Rhythm
MH  - Half-Life
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Salicylates/blood
MH  - Time Factors
EDAT- 1979/10/01 00:00
MHDA- 1979/10/01 00:01
CRDT- 1979/10/01 00:00
PHST- 1979/10/01 00:00 [pubmed]
PHST- 1979/10/01 00:01 [medline]
PHST- 1979/10/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Biopharm. 1979 Oct;17(10):409-11.

PMID- 25281530
OWN - NLM
STAT- MEDLINE
DCOM- 20150626
LR  - 20181202
IS  - 1527-3288 (Electronic)
IS  - 0147-9563 (Linking)
VI  - 44
IP  - 1
DP  - 2015 Jan-Feb
TI  - Time to treatment in patients of suspected acute coronary syndrome in Pakistan: a 
      clinical audit.
PG  - 63-7
LID - S0147-9563(14)00327-6 [pii]
LID - 10.1016/j.hrtlng.2014.08.007 [doi]
AB  - OBJECTIVE: Evaluate time to treatment (TT) in suspected acute coronary syndrome 
      (ACS) patients in the Emergency Department (ED) in Pakistan. METHODS: In this 
      clinical audit, medical records of adult patients with suspicion of ACS visiting 
      the ED of a tertiary care facility in Karachi from January to March of 2012 were 
      reviewed and evaluated according to benchmarks from American College of 
      Cardiology/American Heart Association guidelines. RESULTS: Study included 230 
      patients, of which 62.6% were males (n = 144). Physicians saw most patients 
      (74.1%) in ≤10 min (min) of ED triage. ECG was performed in ≤10 min in 93 (47.7%) 
      patients. Of the 207 patients being prescribed Aspirin, 41.9% received it in 
      ≤10 min. Of 155 patients who were prescribed anti-coagulants (e.g., heparin), 
      32.9% received them in 10 min. Half of the patients requiring primary coronary 
      intervention underwent the procedure within 90 min. CONCLUSION: Findings warrant 
      exploring interventions to improve TT for ACS care in resource-limited settings.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Khursheed, Munawar
AU  - Khursheed M
AD  - Department of Emergency Medicine, Aga Khan University, Karachi, Pakistan. 
      Electronic address: munawar.khursheed@aku.edu.
FAU - Fayyaz, Jabeen
AU  - Fayyaz J
AD  - Department of Emergency Medicine, Aga Khan University, Karachi, Pakistan.
FAU - Feroze, Asher
AU  - Feroze A
AD  - Department of Emergency Medicine, Aga Khan University, Karachi, Pakistan.
FAU - Shakeel, Nishi
AU  - Shakeel N
AD  - Department of Emergency Medicine, Aga Khan University, Karachi, Pakistan.
FAU - Bhatti, Junaid A
AU  - Bhatti JA
AD  - Department of Emergency Medicine, Aga Khan University, Karachi, Pakistan; 
      Sunnybrook Health Sciences Centre Research Institute, Toronto, Canada.
LA  - eng
PT  - Journal Article
DEP - 20141001
PL  - United States
TA  - Heart Lung
JT  - Heart & lung : the journal of critical care
JID - 0330057
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Clinical Audit
MH  - Emergency Service, Hospital
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pakistan
MH  - Retrospective Studies
MH  - Time-to-Treatment
MH  - *Triage
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Audit
OT  - Emergency department
OT  - Pakistan
OT  - Quality improvement
EDAT- 2014/10/05 06:00
MHDA- 2015/06/27 06:00
CRDT- 2014/10/05 06:00
PHST- 2013/09/26 00:00 [received]
PHST- 2014/08/24 00:00 [revised]
PHST- 2014/08/25 00:00 [accepted]
PHST- 2014/10/05 06:00 [entrez]
PHST- 2014/10/05 06:00 [pubmed]
PHST- 2015/06/27 06:00 [medline]
AID - S0147-9563(14)00327-6 [pii]
AID - 10.1016/j.hrtlng.2014.08.007 [doi]
PST - ppublish
SO  - Heart Lung. 2015 Jan-Feb;44(1):63-7. doi: 10.1016/j.hrtlng.2014.08.007. Epub 2014 
      Oct 1.

PMID- 31420920
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Print)
IS  - 1742-7835 (Linking)
VI  - 127
IP  - 2
DP  - 2020 Aug
TI  - Aspirin for the prevention and treatment of pre-eclampsia: A matter of COX-1 
      and/or COX-2 inhibition?
PG  - 132-141
LID - 10.1111/bcpt.13308 [doi]
AB  - Since the 1970s, we have known that aspirin can reduce the risk of pre-eclampsia. 
      However, the underlying mechanisms explaining this risk reduction are poorly 
      understood. Both cyclooxygenase (COX)-1- and COX-2-dependent effects might be 
      involved. As a consequence of this knowledge hiatus, the optimal dose and timing 
      of initiation of aspirin therapy are not clear. Here, we review how (COX-1 versus 
      COX-2 inhibition) and when (prevention versus treatment) aspirin therapy may 
      interfere with the mechanisms implicated in the pathogenesis of pre-eclampsia. 
      The available evidence suggests that both COX-1- and COX-2-dependent effects play 
      important roles in the early stage of aberrant placental development and in the 
      next phase leading to the clinical syndrome of pre-eclampsia. Collectively, these 
      data suggest that high-dose (dual COX inhibition) aspirin may be superior to 
      standard low-dose (selective COX-1 inhibition) aspirin for the prevention and 
      also treatment of pre-eclampsia. Therefore, we conclude that more functional and 
      biochemical tests are needed to unravel the contribution of prostanoids in the 
      mechanisms implicated in the pathogenesis of pre-eclampsia and the potential of 
      dual COX and/or selective COX-2 inhibition for the prevention and treatment of 
      pre-eclampsia. This information is vital if we are to deduce the suitability, 
      optimal timing and dose of aspirin and/or a specific COX-2 inhibitor (most likely 
      using modified forms that do not cross the placenta) that can then be tested in a 
      randomized, controlled trial instead of the current practice of empirical dosing 
      regimens.
CI  - © 2019 The Authors. Basic & Clinical Pharmacology & Toxicology published by John 
      Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT 
      (former Nordic Pharmacological Society).
FAU - Mirabito Colafella, Katrina M
AU  - Mirabito Colafella KM
AD  - Cardiovascular Disease Program, Monash Biomedicine Discovery Institute, Monash 
      University, Melbourne, Vic, Australia.
AD  - Department of Physiology, Monash University, Melbourne, Vic, Australia.
AD  - Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, 
      Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
FAU - Neuman, Rugina I
AU  - Neuman RI
AD  - Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, 
      Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
AD  - Division of Obstetrics and Perinatal Medicine, Department of Obstetrics and 
      Gynecology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
FAU - Visser, Willy
AU  - Visser W
AD  - Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, 
      Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
AD  - Division of Obstetrics and Perinatal Medicine, Department of Obstetrics and 
      Gynecology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
FAU - Danser, A H Jan
AU  - Danser AHJ
AD  - Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, 
      Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
FAU - Versmissen, Jorie
AU  - Versmissen J
AD  - Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, 
      Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
LA  - eng
GR  - GNT1112125/National Health and Medical Research Council (NHMRC) of Australia/
PT  - Journal Article
PT  - Review
DEP - 20190911
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cyclooxygenase 1/*metabolism
MH  - Cyclooxygenase 2/*metabolism
MH  - Cyclooxygenase 2 Inhibitors/therapeutic use
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/drug therapy/enzymology/*prevention & control
MH  - Pregnancy
PMC - PMC7496715
OTO - NOTNLM
OT  - Prostaglandin-Endoperoxide Synthases
OT  - aspirin
OT  - hypertension
OT  - pre-eclampsia
COIS- The authors declare that they have nothing to disclose.
EDAT- 2019/08/20 06:00
MHDA- 2021/03/30 06:00
CRDT- 2019/08/18 06:00
PHST- 2019/06/08 00:00 [received]
PHST- 2019/08/11 00:00 [accepted]
PHST- 2019/08/20 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PHST- 2019/08/18 06:00 [entrez]
AID - BCPT13308 [pii]
AID - 10.1111/bcpt.13308 [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2020 Aug;127(2):132-141. doi: 10.1111/bcpt.13308. 
      Epub 2019 Sep 11.

PMID- 33423282
OWN - NLM
STAT- MEDLINE
DCOM- 20210727
LR  - 20210727
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 110
IP  - 1
DP  - 2021 Jul
TI  - Pharmacological Interventions for the Prevention of Fetal Growth Restriction: A 
      Systematic Review and Network Meta-Analysis.
PG  - 189-199
LID - 10.1002/cpt.2164 [doi]
AB  - The prevention of fetal growth restriction (FGR) is challenging in clinical 
      practice. To date, no meta-analysis summarized evidence on the relative benefits 
      and harms of pharmacological interventions for FGR prevention. We performed a 
      systematic review and network meta-analysis (NetMA), searching PubMed, Embase, 
      Cochrane Library, and ClinicalTrials.gov from inception until November 2019. We 
      included clinical trials and observational studies on singleton gestating women 
      evaluating antiplatelet, anticoagulant, or other treatments, compared between 
      each other or with controls (placebo or no treatment), and considering the 
      pregnancy outcome FGR (primary outcome of the NetMA). Secondary efficacy outcomes 
      included preterm birth, placental abruption, and fetal or neonatal death. Safety 
      outcomes included bleeding and thrombocytopenia. Network meta-analyses using a 
      frequentist framework were conducted to derive odds ratios (ORs) and 95% 
      confidence intervals (CIs). Of 18,780 citations, we included 30 studies on 4,326 
      patients. Low molecular weight heparin (LMWH), alone or associated with low-dose 
      aspirin (LDA), appeared more efficacious than controls in preventing FGR (OR 
      2.00, 95% CI 1.27-3.16 and OR 2.67, 95% CI 1.21-5.89 for controls vs. LMWH and 
      LDA + LMWH, respectively). No difference between active treatments emerged in 
      terms of FGR prevention, but estimates for treatments other than LMWH +/- LDA 
      were imprecise. Only the confidence in the evidence regarding LMWH vs. controls 
      was judged as moderate, according to the Confidence in Network Meta-Analysis 
      framework. No treatment was associated with an increased risk of bleeding, 
      although estimates were precise enough only for LMWH. These results should inform 
      clinicians on the benefits of active pharmacological prophylaxis for FGR 
      prevention.
CI  - © 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley 
      Periodicals LLC on behalf of American Society for Clinical Pharmacology and 
      Therapeutics.
FAU - Bettiol, Alessandra
AU  - Bettiol A
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health, 
      University of Florence, Florence, Italy.
FAU - Avagliano, Laura
AU  - Avagliano L
AD  - Department of Health Sciences, San Paolo Hospital Medical School, University of 
      Milan, Milan, Italy.
FAU - Lombardi, Niccolò
AU  - Lombardi N
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health, 
      University of Florence, Florence, Italy.
FAU - Crescioli, Giada
AU  - Crescioli G
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health, 
      University of Florence, Florence, Italy.
AD  - PeaRL Perinatal Research Laboratory, University of Florence, CiaoLapo Foundation 
      for Perinatal Health, Prato, Italy.
FAU - Emmi, Giacomo
AU  - Emmi G
AD  - Department of Experimental and Clinical Medicine, University of Florence, 
      Florence, Italy.
FAU - Urban, Maria Letizia
AU  - Urban ML
AD  - Department of Experimental and Clinical Medicine, University of Florence, 
      Florence, Italy.
FAU - Virgili, Gianni
AU  - Virgili G
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health, 
      University of Florence, Florence, Italy.
AD  - Centre for Public Health, Queen's University Belfast, Belfast, UK.
FAU - Ravaldi, Claudia
AU  - Ravaldi C
AD  - PeaRL Perinatal Research Laboratory, University of Florence, CiaoLapo Foundation 
      for Perinatal Health, Prato, Italy.
AD  - Department of Health Sciences, University of Florence, Florence, Italy.
FAU - Vannacci, Alfredo
AU  - Vannacci A
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health, 
      University of Florence, Florence, Italy.
AD  - PeaRL Perinatal Research Laboratory, University of Florence, CiaoLapo Foundation 
      for Perinatal Health, Prato, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210226
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Heparin, Low-Molecular-Weight/administration & dosage/adverse effects
MH  - Humans
MH  - Infant, Newborn
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Pregnancy
EDAT- 2021/01/11 06:00
MHDA- 2021/07/28 06:00
CRDT- 2021/01/10 20:51
PHST- 2020/09/30 00:00 [received]
PHST- 2020/12/04 00:00 [accepted]
PHST- 2021/01/11 06:00 [pubmed]
PHST- 2021/07/28 06:00 [medline]
PHST- 2021/01/10 20:51 [entrez]
AID - 10.1002/cpt.2164 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2021 Jul;110(1):189-199. doi: 10.1002/cpt.2164. Epub 2021 
      Feb 26.

PMID- 28431474
OWN - NLM
STAT- MEDLINE
DCOM- 20180322
LR  - 20181202
IS  - 1743-1328 (Electronic)
IS  - 0161-6412 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Previous hypertensive hemorrhage increases the risk for bleeding and ischemia for 
      PCI patients on dual antiplatelet therapy.
PG  - 516-520
LID - 10.1080/01616412.2017.1316041 [doi]
AB  - OBJECTIVES: The use of antiplatelet therapy after intracerebral hemorrhage 
      remains controversial, while the use of dual antiplatelet therapy (DAPT) is 
      required after cardiac stenting. In this study, we examine the risk of bleeding 
      and ischemic events for PCI patients with a history of hypertensive hemorrhage on 
      DAPT. METHODS: A total of 128 cases and 153 controls were selected from Chinese 
      patients with cardiac stenting on dual anti-platelet therapy for a single-center 
      retrospective case-control study. Patients with a history of hypertensive 
      hemorrhage were selected for the case group, while patients with a history of 
      hypertension were chosen as control. All patients were on aspirin 100 mg and 
      clopidogrel 75 mg after cardiac stenting, and were followed for a duration of 
      12-48 months. The primary outcomes were intracerebral hemorrhage, major bleeding, 
      and major adverse cardiovascular and cerebrovascular events. RESULTS: A history 
      of previous hypertensive hemorrhage was not found to be a risk factor for 
      intracerebral hemorrhage and major bleeding while on dual anti-platelet therapy. 
      However, a history of either hypertensive hemorrhage or coronary artery disease 
      was independently found to be risk factors for major adverse cardiovascular and 
      cerebrovascular events. On sub-group analysis, patients with a history of 
      hypertensive hemorrhage within 12 months were found to be at higher risk for 
      bleeding on dual anti-platelet therapy, while patients with history of 
      hypertensive hemorrhage outside of 12 months on dual anti-platelet therapy did 
      not have the same increased risk. CONCLUSION: A history of hypertensive 
      hemorrhage and coronary heart disease were two independent risk factors for major 
      adverse cardiovascular and cerebrovascular events in PCI patients taking DAPT. A 
      history of hypertensive hemorrhage less than 12 months had an increased risk for 
      recurrent intracerebral hemorrhage and major bleeding in PCI patients taking 
      DAPT.
FAU - Qiao, Manli
AU  - Qiao M
AD  - a Department of General Practice Medicine , Beijing Anzhen Hospital, Capital 
      Medical University , Beijing , China.
FAU - Bi, Qi
AU  - Bi Q
AD  - b Department of Neurology , Beijing Anzhen Hospital, Capital Medical University , 
      Beijing , China.
FAU - Fu, Paul
AU  - Fu P
AD  - c Department of Neurology , Yale New Haven Hospital , New Haven , CT , USA.
FAU - Wang, Yixin
AU  - Wang Y
AD  - a Department of General Practice Medicine , Beijing Anzhen Hospital, Capital 
      Medical University , Beijing , China.
FAU - Song, Zhe
AU  - Song Z
AD  - b Department of Neurology , Beijing Anzhen Hospital, Capital Medical University , 
      Beijing , China.
FAU - Guo, Fang
AU  - Guo F
AD  - a Department of General Practice Medicine , Beijing Anzhen Hospital, Capital 
      Medical University , Beijing , China.
LA  - eng
PT  - Journal Article
DEP - 20170421
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/*complications/therapy
MH  - Humans
MH  - Ischemia/complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Cardiovascular diseases
OT  - PCI
OT  - dual antiplatelet therapy
OT  - hypertensive hemorrhage
OT  - platelet aggregation inhibitors
EDAT- 2017/04/23 06:00
MHDA- 2018/03/23 06:00
CRDT- 2017/04/23 06:00
PHST- 2017/04/23 06:00 [pubmed]
PHST- 2018/03/23 06:00 [medline]
PHST- 2017/04/23 06:00 [entrez]
AID - 10.1080/01616412.2017.1316041 [doi]
PST - ppublish
SO  - Neurol Res. 2017 Jun;39(6):516-520. doi: 10.1080/01616412.2017.1316041. Epub 2017 
      Apr 21.

PMID- 27074368
OWN - NLM
STAT- MEDLINE
DCOM- 20170508
LR  - 20181202
IS  - 1476-4431 (Electronic)
IS  - 1476-4431 (Linking)
VI  - 26
IP  - 4
DP  - 2016 Jul
TI  - Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed 
      primary immune-mediated hemolytic anemia.
PG  - 488-94
LID - 10.1111/vec.12480 [doi]
AB  - OBJECTIVE: To evaluate the safety and tolerability of rivaroxaban (RIV), an oral 
      direct factor Xa inhibitory drug, in dogs with presumed primary immune-mediated 
      hemolytic anemia (pIMHA). DESIGN: Prospective, multicenter, positive-controlled, 
      unblinded clinical trial. Client-owned dogs were enrolled between October 2012 
      and March 2014. SETTING: Private referral centers. ANIMALS: Twenty-four 
      client-owned dogs with pIMHA. Enrolled dogs were randomized in 2 treatment groups 
      to receive by mouth RIV or clopidogrel (CL) and low-dose aspirin (LDA). All dogs 
      were monitored for 90 days from the enrollment in the study. INTERVENTIONS: 
      Enrolled dogs were given a standardized immunosuppressive protocol and RIV or CL 
      and LDA. MEASUREMENTS AND MAIN RESULTS: There was no identifiable adverse drug 
      reaction, evidence of hemorrhage, significant prolongation of prothrombin time or 
      activated partial thromboplastin time, or increase in transfusion requirements 
      associated with RIV therapy compared to CL and LDA in dogs with pIMHA. There was 
      no significant difference between treatment groups with respect to thrombotic 
      events, survival rates to discharge, at 1 month and 3 months from diagnosis. 
      CONCLUSIONS: This study suggests that RIV at a median dose of 0.89 mg/kg by mouth 
      once daily was safe and well tolerated in a small group of dogs with presumed 
      pIMHA able to tolerate oral medications and treated with a standardized 
      immunosuppressive treatment protocol. Conclusions regarding the relative efficacy 
      of RIV as compared to CL and LDA cannot be made due to the small size of the 
      treatment groups and because pharmacodynamic effects were not assessed.
CI  - © Veterinary Emergency and Critical Care Society 2016.
FAU - Morassi, Alice
AU  - Morassi A
AD  - Internal Medicine Department, College of Veterinary Medicine, Washington State 
      University, Pullman, WA, 99165.
FAU - Bianco, Domenico
AU  - Bianco D
AD  - Internal Medicine Department, Advanced Critical Care Emergency and Specialty 
      Services, Woodland Hills, CA, 91364.
FAU - Park, Ed
AU  - Park E
AD  - Emergency and Critical Care Department, Fresno Veterinary Specialty and Emergency 
      Center, Fresno, CA, 93719.
FAU - Nakamura, Reid K
AU  - Nakamura RK
AD  - Cardiology Department, Southern California Veterinary Specialty Hospital, Irvine, 
      CA, 92614.
FAU - White, George A
AU  - White GA
AD  - Emergency and Critical Care Department, Fresno Veterinary Specialty and Emergency 
      Center, Fresno, CA, 93719.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20160413
PL  - United States
TA  - J Vet Emerg Crit Care (San Antonio)
JT  - Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
JID - 101152804
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anemia, Hemolytic, Autoimmune/drug therapy/*veterinary
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - California
MH  - Dog Diseases/*drug therapy
MH  - Dogs
MH  - Drug Therapy, Combination
MH  - Female
MH  - Male
MH  - Prospective Studies
MH  - Rivaroxaban/administration & dosage/*therapeutic use
MH  - Treatment Outcome
MH  - Washington
OTO - NOTNLM
OT  - IMHA
OT  - anticoagulant
OT  - fXa inhibitor
OT  - pulmonary thromboembolism
EDAT- 2016/04/14 06:00
MHDA- 2017/05/10 06:00
CRDT- 2016/04/14 06:00
PHST- 2014/11/29 00:00 [accepted]
PHST- 2014/05/19 00:00 [received]
PHST- 2014/11/16 00:00 [revised]
PHST- 2016/04/14 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2017/05/10 06:00 [medline]
AID - 10.1111/vec.12480 [doi]
PST - ppublish
SO  - J Vet Emerg Crit Care (San Antonio). 2016 Jul;26(4):488-94. doi: 
      10.1111/vec.12480. Epub 2016 Apr 13.

PMID- 19258246
OWN - NLM
STAT- MEDLINE
DCOM- 20090505
LR  - 20131121
IS  - 0030-6002 (Print)
IS  - 0030-6002 (Linking)
VI  - 150
IP  - 11
DP  - 2009 Mar 15
TI  - [A new possible strategy for prevention and preventive treatment of age-related 
      macular degeneration resting on recent clinical and pathophysiological 
      observations].
PG  - 503-12
LID - 10.1556/OH.2009.28524 [doi]
AB  - The beneficial effect achieved by the treatment of endothelial dysfunction in 
      chronic cardiovascular diseases is already an evidence belonging to the basic 
      treatment of the disease. Given the fact that the vascular system is uniform and 
      consubstantial both physiologically, pathophysiologically and in terms of 
      therapy, and that it plays a key role in age-related macular degeneration 
      (AMD)--a disease leading to tragic loss of vision with its etiology and therapy 
      being unknown--endothelial dysfunction should be treated. The pleiotropic effects 
      of ACE-inhibitors, AR-blockers and statins and third generation beta blockers 
      help to restitute the balance between vasodilators and vasoconstrictors in 
      endothelial dysfunction caused by oxidative stress, the balance of growth factors 
      and their inhibitors, pro- and anti-inflammatory substances and prothrombotic and 
      fibrinolytic factors, inhibit the formation of oxidative stress and its harmful 
      effects; while aspirin with its pleiotropic effects acting as an antiaggregation 
      substance on platelets helps to set the endothelial layer back to its normal 
      balance regarding its vasodilating, antithrombotic, antiadhesive and 
      anti-inflammatory functions; trimetazidine as an adjuvant agent helps to 
      normalize, to restore the disturbed metabolism of the retinal tissue functioning 
      insufficiently, in the end. The angiotensin II receptor blocker telmisartan with 
      its peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist effect 
      inhibits the development of choroidal neovascularisation (CNV) and improves it 
      clinically favourably. The third generation beta adrenergic receptor blocker 
      carvedilol and nebivolol as well as the peroxisome proliferator-activated 
      receptor-gamma agonist pioglitazone elicit their antioxidant vascular protective 
      effects mitochondrially. For the above reasons it is suggested that, as a part of 
      long term primary and/or secondary prevention, the following groups of patients 
      with AMD receive--taking into consideration all possible side 
      effects--ACE-inhibitor and/or AR blocker and statin and aspirin treatment, and 
      trimetazidine as adjuvant medicine, and third generation beta adrenergic receptor 
      blockers: 1. those without macular degeneration but being above the age of 50 and 
      having risk factors inducing endothelial dysfunction; 2. those, who already 
      developed AMD in one eye as a prevention in the second, unaffected eye; and 3. 
      those patients who developed AMD in both eyes in order to ameliorate or merely 
      slow the progression of the disease. Besides, it is advisory and important to 
      eliminate AMD risk factors (cardiovascular risk factors also) inducing oxidative 
      stress with consecutive endothelial dysfunction.
FAU - Fischer, Tamás
AU  - Fischer T
AD  - t.fischer.med@gmail.com
LA  - hun
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Az idoskori maculadegeneráció megelozésének és preventív terápiájának az újabb 
      kórélettani és klinikai észlelésekre alapozott lehetséges stratégiája.
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Receptors, Adrenergic)
RN  - R16CO5Y76E (Aspirin)
RN  - VBE72MCP5L (acetylsalicylsalicylic acid)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Endothelium, Vascular/drug effects/physiopathology
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Macular Degeneration/drug therapy/*physiopathology/*prevention & control
MH  - Oxidative Stress
MH  - Primary Prevention/*methods
MH  - Receptors, Adrenergic/drug effects
MH  - Risk Factors
MH  - Secondary Prevention/methods
RF  - 86
EDAT- 2009/03/05 09:00
MHDA- 2009/05/06 09:00
CRDT- 2009/03/05 09:00
PHST- 2009/03/05 09:00 [entrez]
PHST- 2009/03/05 09:00 [pubmed]
PHST- 2009/05/06 09:00 [medline]
AID - 0U75H4125387V801 [pii]
AID - 10.1556/OH.2009.28524 [doi]
PST - ppublish
SO  - Orv Hetil. 2009 Mar 15;150(11):503-12. doi: 10.1556/OH.2009.28524.

PMID- 16795055
OWN - NLM
STAT- MEDLINE
DCOM- 20060921
LR  - 20181201
IS  - 0361-8609 (Print)
IS  - 0361-8609 (Linking)
VI  - 81
IP  - 9
DP  - 2006 Sep
TI  - Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy 
      in patients with chronic myeloproliferative disorders.
PG  - 676-83
AB  - Twenty-seven patients with chronic myeloproliferative disorders and in vitro 
      evidence of platelet hyperactivity on whole blood platelet lumi-aggregometry were 
      commenced on anti-platelet therapy comprising aspirin, clopidogrel, and/or 
      odorless garlic and the studies were repeated to assess the efficacy of the 
      therapeutic agent(s). Only 8 patients showed clear evidence of anti-platelet 
      effect while receiving the standard low-dose (100 mg/day) aspirin therapy. 
      Thirteen patients required a higher dosage of aspirin and/or an additional 
      anti-platelet agent to achieve therapeutic adequacy. Lumi-aggregometry also 
      proved useful to optimize therapy in the 6 patients who received clopidogrel or 
      odorless garlic because of aspirin intolerance.
CI  - (c) 2006 Wiley-Liss, Inc.
FAU - Manoharan, A
AU  - Manoharan A
AD  - Department of Clinical Haematology , St George Hospital, Sydney, Australia. 
      a.manoharan@unsw.edu.au
FAU - Gemmell, R
AU  - Gemmell R
FAU - Hartwell, T
AU  - Hartwell T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Chronic Disease
MH  - Clopidogrel
MH  - Dietary Supplements
MH  - Dose-Response Relationship, Drug
MH  - Garlic
MH  - Humans
MH  - Luminescent Measurements/methods
MH  - Myeloproliferative Disorders/blood/*drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Function Tests/methods
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
EDAT- 2006/06/24 09:00
MHDA- 2006/09/22 09:00
CRDT- 2006/06/24 09:00
PHST- 2006/06/24 09:00 [pubmed]
PHST- 2006/09/22 09:00 [medline]
PHST- 2006/06/24 09:00 [entrez]
AID - 10.1002/ajh.20698 [doi]
PST - ppublish
SO  - Am J Hematol. 2006 Sep;81(9):676-83. doi: 10.1002/ajh.20698.

PMID- 3712471
OWN - NLM
STAT- MEDLINE
DCOM- 19860627
LR  - 20181113
IS  - 0027-9684 (Print)
IS  - 0027-9684 (Linking)
VI  - 78
IP  - 4
DP  - 1986 Apr
TI  - Gastrocolic fistula.
PG  - 330-2
AB  - Peptic ulcer disease is a less common cause of gastrocolic fistula than either 
      carcinoma of the stomach or colon. However, use of steroids or aspirin appear to 
      make this a more common complication of benign disease. The typical symptoms are 
      pain, diarrhea, weight loss, foul eructation, and feculent vomiting. The most 
      accurate method of diagnosis is with barium enema. The treatment is surgical.
FAU - Casey, J
AU  - Casey J
FAU - Lorenzo, G
AU  - Lorenzo G
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Natl Med Assoc
JT  - Journal of the National Medical Association
JID - 7503090
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects
MH  - Colonic Diseases/*etiology
MH  - Female
MH  - Gastric Fistula/*etiology
MH  - Humans
MH  - Intestinal Fistula/*etiology
MH  - Stomach Ulcer/*complications
PMC - PMC2571285
EDAT- 1986/04/01 00:00
MHDA- 1986/04/01 00:01
CRDT- 1986/04/01 00:00
PHST- 1986/04/01 00:00 [pubmed]
PHST- 1986/04/01 00:01 [medline]
PHST- 1986/04/01 00:00 [entrez]
PST - ppublish
SO  - J Natl Med Assoc. 1986 Apr;78(4):330-2.

PMID- 36327
OWN - NLM
STAT- MEDLINE
DCOM- 19790901
LR  - 20131121
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 77
IP  - 2
DP  - 1979 Aug
TI  - Protection by histamine receptor antagonists and prostaglandin against gastric 
      mucosal barrier disruption in the rat.
PG  - 303-8
AB  - This study was undertaken to determine if the cytoprotective effect of 
      prostaglandin and the H2 histamine receptor antagonist cimetidine involves 
      protection against disruption of the gastric mucosal barrier. Groups of 
      anesthetized, vagotomized rats received one of the following parenterally: saline 
      (control), mepyramine--an H1 histamine receptor antagonist, cimetidine, 
      cimetidine and mepyramine, or 16,16 dimethyl prostaglandin E2. Parameters of 
      barrier disruption were then determined before and after exposure of the gastric 
      mucosa to 40mM acetylsalicylic acid. At the end of the study, gastric lesions 
      were scored according to size and number. Lesion score and fall in potential 
      difference were significantly lower in rats receiving cimetidine, cimetidine and 
      mepyramine, and prostaglandin. Other parameters of barrier disruption--H+ back 
      diffusion, Na+ and K+ influx, and protein outpouring--exhibited the same pattern 
      and correlated with change in potential difference. We conclude that both 
      prostaglandin and cimetidine, but not mepyramine, protect against barrier 
      disruption by topical aspirin, and this may be a factor in the mechanism of their 
      cytoprotective action.
FAU - Bommelaer, G
AU  - Bommelaer G
FAU - Guth, P H
AU  - Guth PH
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Drug Combinations)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Prostaglandins E, Synthetic)
RN  - 80061L1WGD (Cimetidine)
RN  - 9NEZ333N27 (Sodium)
RN  - HPE317O9TL (Pyrilamine)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Aspirin/administration & dosage/metabolism/*toxicity
MH  - Cimetidine/administration & dosage/therapeutic use
MH  - Drug Combinations
MH  - Gastric Juice/metabolism
MH  - Gastric Mucosa/*drug effects/metabolism
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Injections, Intraperitoneal
MH  - Membrane Potentials/drug effects
MH  - Potassium/metabolism
MH  - Prostaglandins E, Synthetic/administration & dosage/therapeutic use
MH  - Pyrilamine/administration & dosage/therapeutic use
MH  - Rats
MH  - Sodium/metabolism
MH  - Stomach Ulcer/*chemically induced/prevention & control
EDAT- 1979/08/01 00:00
MHDA- 1979/08/01 00:01
CRDT- 1979/08/01 00:00
PHST- 1979/08/01 00:00 [pubmed]
PHST- 1979/08/01 00:01 [medline]
PHST- 1979/08/01 00:00 [entrez]
AID - S0016508579001360 [pii]
PST - ppublish
SO  - Gastroenterology. 1979 Aug;77(2):303-8.

PMID- 12432935
OWN - NLM
STAT- MEDLINE
DCOM- 20030710
LR  - 20191106
IS  - 1098-8823 (Print)
IS  - 1098-8823 (Linking)
VI  - 68-69
DP  - 2002 Aug
TI  - Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in 
      anti-inflammation and pro-resolution.
PG  - 433-55
AB  - Lipoxins (LX) are trihydroxytetraene-containing eicosanoids that are generated 
      within the vascular lumen during platelet-leukocyte interactions and at mucosal 
      surfaces via leukocyte-epithelial cell interactions. Recent findings have given 
      several new concepts that are reviewed here regarding the generation of LX and 15 
      epi-LX and their impact in the resolution of acute inflammation and organ 
      protection from leukocyte-mediated injury. During cell-cell interactions, 
      transcellular biosynthetic pathways are used as major LX biosynthetic routes, and 
      thus, in humans, LX are formed in vivo during multicellular responses such as 
      inflammation, and asthma. This branch of the eicosanoid cascade generates 
      specific tetraene-containing products that serve as neutrophil "stop signals," in 
      that they regulate key steps in leukocyte trafficking and prevent 
      neutrophil-mediated acute tissue injury. In addition, aspirin's mechanism of 
      action also involves the triggering of carbon 15 epimers of lipoxins or 
      15-epi-lipoxins that mimic the bioactions of native LX. An overview of these 
      recent developments is presented with a focus on the cellular and molecular 
      interactions of these novel anti-inflammatory lipid mediators that also appear to 
      facilitate the resolution of acute inflammatory responses.
FAU - Serhan, Charles N
AU  - Serhan CN
AD  - Department of Anesthesiology, Center for Experimental Therapeutics and 
      Reperfusion Injury, Perioperative and Pain Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, Boston, MA 02115, USA.
LA  - eng
GR  - DK50305/DK/NIDDK NIH HHS/United States
GR  - GM38765/GM/NIGMS NIH HHS/United States
GR  - P01-DE13499/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Prostaglandins Other Lipid Mediat
JT  - Prostaglandins & other lipid mediators
JID - 9808648
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - 0 (Leukotrienes)
RN  - 0 (Prostaglandins)
RN  - EC 1.13.11.34 (Arachidonate 5-Lipoxygenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism
MH  - Arachidonate 5-Lipoxygenase/metabolism
MH  - Aspirin/*metabolism
MH  - Asthma/metabolism
MH  - Cell Adhesion/physiology
MH  - Humans
MH  - Hydroxyeicosatetraenoic Acids/*chemistry/*immunology/metabolism
MH  - Inflammation/*metabolism
MH  - Leukocytes/immunology/metabolism
MH  - Leukotrienes/metabolism
MH  - Molecular Structure
MH  - Prostaglandins/metabolism
RF  - 115
EDAT- 2002/11/16 04:00
MHDA- 2003/07/11 05:00
CRDT- 2002/11/16 04:00
PHST- 2002/11/16 04:00 [pubmed]
PHST- 2003/07/11 05:00 [medline]
PHST- 2002/11/16 04:00 [entrez]
AID - S0090-6980(02)00047-3 [pii]
AID - 10.1016/s0090-6980(02)00047-3 [doi]
PST - ppublish
SO  - Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:433-55. doi: 
      10.1016/s0090-6980(02)00047-3.

PMID- 15477397
OWN - NLM
STAT- MEDLINE
DCOM- 20050706
LR  - 20220317
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 110
IP  - 16
DP  - 2004 Oct 19
TI  - Impact of prior use or recent withdrawal of oral antiplatelet agents on acute 
      coronary syndromes.
PG  - 2361-7
AB  - BACKGROUND: Oral antiplatelet agents (OAAs) can prevent further vascular events 
      in cardiovascular disease. How prior use or recent discontinuation of OAA affects 
      clinical presentation of acute coronary syndromes (ACS) and clinical outcomes 
      (death, myocardial infarction [MI]) is unclear. METHODS AND RESULTS: We studied 
      and followed up for up to 30 days a cohort of 1358 consecutive patients admitted 
      for a suspected ACS; of these, 930 were nonusers, 355 were prior users of OAA, 
      and 73 had recently withdrawn OAA. Nonusers were at lower risk, more frequently 
      presented with ST-elevation MI on admission, and more frequently had Q-wave MI at 
      discharge than prior users (36.6% versus 17.5%, P<0.001; and 47.8% versus 28.2%, 
      P<0.001, respectively). However, there was no difference regarding the incidence 
      of death or MI at 30 days between nonusers and prior users (10.3% versus 12.4%, 
      P=NS). In addition, prior users experienced more major bleeds within 30 days 
      compared with nonusers (3.4% versus 1.4%, respectively; P=0.04). Recent 
      withdrawers were admitted on average 11.9+/-0.8 days after OAA withdrawal. 
      Interruption was primarily a physician decision for scheduled surgery (n=47 of 
      73). Despite a similar cardiovascular risk profile, recent withdrawers had higher 
      30-day rates of death or MI (21.9% versus 12.4%, P=0.04) and bleedings (13.7% 
      versus 5.9%, P=0.03) than prior users. After multivariate analysis, OAA 
      withdrawal was found to be an independent predictor of both mortality and 
      bleedings at 30 days. CONCLUSIONS: Among ACS patients, prior users represent a 
      higher-risk population and present more frequently with non-ST-elevation ACS than 
      nonusers. Although patients with a recent interruption of OAA resemble those 
      chronically treated by OAA, they display worse clinical outcomes.
FAU - Collet, J P
AU  - Collet JP
AD  - Institute of Cardiology, Pitié-Salpêtrière Hospital, Paris, France.
FAU - Montalescot, G
AU  - Montalescot G
FAU - Blanchet, B
AU  - Blanchet B
FAU - Tanguy, M L
AU  - Tanguy ML
FAU - Golmard, J L
AU  - Golmard JL
FAU - Choussat, R
AU  - Choussat R
FAU - Beygui, F
AU  - Beygui F
FAU - Payot, L
AU  - Payot L
FAU - Vignolles, N
AU  - Vignolles N
FAU - Metzger, J P
AU  - Metzger JP
FAU - Thomas, D
AU  - Thomas D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20041011
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Agents/therapeutic use
MH  - Cohort Studies
MH  - Drug Therapy, Combination
MH  - Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology/etiology
MH  - Myocardial Ischemia/epidemiology/*etiology
MH  - Paris/epidemiology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Prospective Studies
MH  - Risk Factors
MH  - Syndrome
MH  - Thrombosis/prevention & control
MH  - Treatment Outcome
MH  - *Withholding Treatment
EDAT- 2004/10/13 09:00
MHDA- 2005/07/07 09:00
CRDT- 2004/10/13 09:00
PHST- 2004/10/13 09:00 [pubmed]
PHST- 2005/07/07 09:00 [medline]
PHST- 2004/10/13 09:00 [entrez]
AID - 01.CIR.0000145171.89690.B4 [pii]
AID - 10.1161/01.CIR.0000145171.89690.B4 [doi]
PST - ppublish
SO  - Circulation. 2004 Oct 19;110(16):2361-7. doi: 10.1161/01.CIR.0000145171.89690.B4. 
      Epub 2004 Oct 11.

PMID- 7458524
OWN - NLM
STAT- MEDLINE
DCOM- 19810327
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 141
IP  - 2
DP  - 1981 Feb
TI  - Fever caused by hydroxyurea.
PG  - 260-1
AB  - Hydroxyurea has been rarely implicated as a cause of drug fever. In this report, 
      we describe a patient who was highly febrile while receiving hydroxyurea for 
      psoriasis. The fever disappeared after discontinuation of therapy with this drug; 
      however, the fever recurred when the patient received hydroxyurea again.
FAU - Bauman, J L
AU  - Bauman JL
FAU - Shulruff, S
AU  - Shulruff S
FAU - Hasegawa, G R
AU  - Hasegawa GR
FAU - Roden, R
AU  - Roden R
FAU - Hartsough, N
AU  - Hartsough N
FAU - Bauernfeind, R A
AU  - Bauernfeind RA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - R16CO5Y76E (Aspirin)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Fever/*chemically induced/drug therapy
MH  - Humans
MH  - Hydroxyurea/*adverse effects/therapeutic use
MH  - Middle Aged
MH  - Psoriasis/*drug therapy
MH  - Recurrence
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1981 Feb;141(2):260-1.

PMID- 12959636
OWN - NLM
STAT- MEDLINE
DCOM- 20040414
LR  - 20181113
IS  - 0312-5963 (Print)
IS  - 0312-5963 (Linking)
VI  - 42
IP  - 12
DP  - 2003
TI  - Pharmacokinetic and pharmacodynamic differences between two low dosages of 
      aspirin may affect therapeutic outcomes.
PG  - 1059-70
AB  - BACKGROUND: Meta-analyses of the prevention of major vascular events by aspirin 
      suggest therapeutic equivalence of all dosages. However, the optimal dosage still 
      remains problematic, and a recent trial found aspirin 160 mg/day to be more 
      effective than 80 mg/day for secondary prevention of ischaemic stroke. OBJECTIVE: 
      To evaluate two low dosages of aspirin in terms of pharmacokinetics and 
      pharmacodynamics (inhibition of platelet thromboxane generation and urinary 
      excretion of thromboxane and prostacyclin metabolites). DESIGN AND PARTICIPANTS: 
      A randomised cross-over study was performed in 16 healthy volunteers (9 women and 
      7 men, 33.8 +/- 5.1 years old) given enteric-coated aspirin 80 or 160 mg/day for 
      7 days. METHODS: Plasma concentrations of salicylate and aspirin were measured by 
      high-performance liquid chromatography (HPLC) after both the first and the last 
      dose (days 1 and 7). The usual pharmacokinetic parameters were then derived. 
      Serum thromboxane B2 (TxB2) was measured by radioimmunoassay. The urinary 
      excretion of 11-dehydro-TxB2 and 2,3-dinor-6-keto-prostaglandin F1alpha were 
      measured on 8-hour urine samples by immunoassay after extraction and HPLC 
      separation, both before and after 7 days of drug administration. RESULTS: With 
      the 160 mg dosage, but not with the 80 mg dosage, higher concentrations of 
      aspirin were found at day 7 compared with day 1. For aspirin 80 mg/day, 24-hour 
      area under the concentration-time curve (AUC24) was similar on days 1 and 7 (569 
      +/- 339 vs 605 +/- 377 microg. h/L), but increased from 904 +/- 356 microg. h/L 
      on day 1 to 1355 +/- 883 microg. h/L on day 7 with the higher dosage. Similarly, 
      the AUC24 for salicylate was similar on days 1 and 7 with the lower dosage, but 
      significantly increased from day 1 to day 7 after the higher dosage. This 
      paralleled inhibition of serum TxB2 levels (99% vs 95% average inhibition by 160 
      and 80 mg/day) and of urinary excretion of thromboxane metabolite (77% vs 61% 
      average inhibition by 160 and 80 mg/day), without altering the excretion of 
      prostacyclin metabolite. CONCLUSIONS: Inhibition of serum TxB2 generation and of 
      thromboxane metabolite urinary excretion by the lower dosage of aspirin, although 
      substantial, still appeared incomplete. The small but significant further 
      increase of serum TxB2 inhibition by the higher dosage was accompanied by an even 
      greater inhibition of urinary excretion. We suggest that in some instances this 
      difference would translate into a greater clinical benefit with the higher 
      aspirin dosage. Our findings may also contribute to better definition of the 
      recent concept of 'aspirin resistance'.
FAU - Cerletti, Chiara
AU  - Cerletti C
AD  - Centre for High Technology Research and Education in Biomedical Sciences, 
      Catholic University, Campobasso, Italy. ccerletti@rm.unicatt.it
FAU - Dell'Elba, Giuseppe
AU  - Dell'Elba G
FAU - Manarini, Stefano
AU  - Manarini S
FAU - Pecce, Romina
AU  - Pecce R
FAU - Di Castelnuovo, Augusto
AU  - Di Castelnuovo A
FAU - Scorpiglione, Nicola
AU  - Scorpiglione N
FAU - Feliziani, Vincenzo
AU  - Feliziani V
FAU - de Gaetano, Giovanni
AU  - de Gaetano G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Clin Pharmacokinet
JT  - Clinical pharmacokinetics
JID - 7606849
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Blood Platelets/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Epoprostenol/urine
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*pharmacokinetics
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacokinetics
MH  - Salicylates/blood
MH  - Tablets, Enteric-Coated
MH  - Thromboxane B2/biosynthesis
MH  - Treatment Outcome
EDAT- 2003/09/10 05:00
MHDA- 2004/04/15 05:00
CRDT- 2003/09/10 05:00
PHST- 2003/09/10 05:00 [pubmed]
PHST- 2004/04/15 05:00 [medline]
PHST- 2003/09/10 05:00 [entrez]
AID - 42124 [pii]
AID - 10.2165/00003088-200342120-00004 [doi]
PST - ppublish
SO  - Clin Pharmacokinet. 2003;42(12):1059-70. doi: 10.2165/00003088-200342120-00004.

PMID- 3154685
OWN - NLM
STAT- MEDLINE
DCOM- 19910426
LR  - 20190912
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 2
IP  - 1
DP  - 1988 May
TI  - Which role for antiplatelet and anticoagulant drugs in unstable angina pectoris?
PG  - 103-6
AB  - Two large placebo-controlled, randomized, double-blind clinical trials have 
      demonstrated the benefit of aspirin therapy in preventing myocardial infarction 
      and death in patients with unstable angina. The Veterans Administration 
      Cooperative Study of 1266 men hospitalized with unstable angina showed that 324 
      mg of aspirin daily for 12 weeks reduced the incidence of myocardial infarction 
      by 51% (p = 0.001), and the data suggested a similar reduction in mortality. The 
      Canadian McMaster University multicenter trial of 555 patients showed that 
      treatment with 1300 mg of aspirin per day for a mean of 18 months reduced the 
      incidence of cardiac death and nonfatal myocardial infarction together by 51% (p 
      = 0.008). The reduction in death alone was 71% (p = 0.004). In the Canadian study 
      there was no observed benefit of sulfinpyrazone. The Canadian trial confirmed the 
      results of the VA Cooperative Study and showed statistical significance for 
      reduction by aspirin of death as well as of myocardial infarction. It showed 
      similar benefits in women as in men with unstable angina. The life-table curves 
      for aspirin-treated and control patients continued to separate throughout the 
      2-year study period, demonstrating the value of continued treatment. The VA study 
      showed no evidence of gastrointestinal side effects from 324 mg of aspirin daily 
      administered in a buffered solution. Heparin therapy for unstable angina has 
      appeared promising, but no properly conducted randomized trial has been 
      accomplished.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Lewis, H D Jr
AU  - Lewis HD Jr
AD  - Veterans Administration Medical Center, Kansas City, Missouri 64128.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/*drug therapy/physiopathology
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 7
EDAT- 1988/05/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
AID - 10.1007/BF00054259 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 1988 May;2(1):103-6. doi: 10.1007/BF00054259.

PMID- 11586268
OWN - NLM
STAT- MEDLINE
DCOM- 20011101
LR  - 20131121
IS  - 0022-5347 (Print)
IS  - 0022-5347 (Linking)
VI  - 166
IP  - 5
DP  - 2001 Nov
TI  - Effects of the nuclear factor-kappaB inhibitors 
      2-hydroxy-4-trifluoromethylbenzoic acid and aspirin on micturition in rats with 
      normal and inflamed bladder.
PG  - 1962-8
AB  - PURPOSE: We examined the effects of intravenous administration of the 2 nuclear 
      factor-kappaB inhibitors aspirin and 2-hydroxy-4-trifluoromethylbenzoic acid 
      (HTB) on bladder filling and voiding in anesthetized and conscious rats. 
      MATERIALS AND METHODS: Disappearance of isovolumic bladder contractions after 
      intravenous administration of different doses of aspirin and HTB in anesthetized, 
      transurethrally catheterized rats was evaluated. Cystometry was performed in 
      conscious rats during bladder infusion with saline or diluted acetic acid as well 
      as in those with cyclophosphamide induced cystitis. Changes in bladder capacity 
      and voiding pressure were evaluated after intravenous administration of test 
      compounds. RESULTS: Aspirin induced a dose dependent disappearance of isovolumic 
      bladder contractions in anesthetized rats with an extrapolated dose of 2.1 
      mg./kg. inducing 10 minutes of bladder quiescence. HTB was practically inactive, 
      inducing a dose independent block of 3 to 4 minutes after intravenous 
      administration of 1 to 10 mg./kg. In conscious rats with a bladder infused with 
      saline aspirin was poorly active on bladder capacity, inducing a 20% increase 60 
      minutes after intravenous administration of 30 and 100 mg./kg. In rats with a 
      bladder infused with acetic acid aspirin was much more active when injected at 
      the initiation of inflammation and after 1 hour of irritant infusion. In this 
      latter situation aspirin increased bladder capacity up to 60% after intravenous 
      administration of 30 and 100 mg./kg. Similar results were obtained in rats with 
      cyclophosphamide induced cystitis in which the bladder was infused with saline. 
      In these cystometrography models 30 mg./kg. HTB intravenously was completely 
      inactive. CONCLUSIONS: The results show that HTB is devoid of significant effects 
      on the micturition reflex in the absence or presence of bladder inflammation, 
      suggesting that acute inhibition of nuclear factor-kappaB does not influence 
      bladder urodynamics in rats. In contrast, aspirin, which is a cyclooxygenase and 
      nuclear factor-kappaB inhibitor, was always effective, indicating the important 
      role of cyclooxygenase enzymes.
FAU - Velasco, C
AU  - Velasco C
AD  - Pharmaceutical Research and Development Division, Recordati S. p. A., Milano, 
      Italy.
FAU - Angelico, P
AU  - Angelico P
FAU - Guarneri, L
AU  - Guarneri L
FAU - Leonardi, A
AU  - Leonardi A
FAU - Clarke, D E
AU  - Clarke DE
FAU - Testa, R
AU  - Testa R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (NF-kappa B)
RN  - 0 (Salicylates)
RN  - 328-90-5 (4-trifluoromethylsalicylic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cyclooxygenase Inhibitors/pharmacology/therapeutic use
MH  - Cystitis/*physiopathology
MH  - Female
MH  - Male
MH  - NF-kappa B/antagonists & inhibitors
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Salicylates/*pharmacology/therapeutic use
MH  - Urination/*drug effects
MH  - Urodynamics/drug effects
EDAT- 2001/10/05 10:00
MHDA- 2001/11/03 10:01
CRDT- 2001/10/05 10:00
PHST- 2001/10/05 10:00 [pubmed]
PHST- 2001/11/03 10:01 [medline]
PHST- 2001/10/05 10:00 [entrez]
AID - S0022-5347(05)65728-X [pii]
PST - ppublish
SO  - J Urol. 2001 Nov;166(5):1962-8.

PMID- 21813335
OWN - NLM
STAT- MEDLINE
DCOM- 20120515
LR  - 20131121
IS  - 1938-0690 (Electronic)
IS  - 1525-7304 (Linking)
VI  - 13
IP  - 1
DP  - 2012 Jan
TI  - Meta-analysis on the association between nonsteroidal anti-inflammatory drug use 
      and lung cancer risk.
PG  - 44-51
LID - 10.1016/j.cllc.2011.06.009 [doi]
AB  - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs), especially aspirin, 
      have emerged as the most potential chemopreventive agents. However, epidemiologic 
      studies reported a controversial association between NSAID use and lung cancer 
      risk. We conducted a meta-analysis to summarize the evidence for such 
      relationship. METHODS: Eligible studies were identified by searching the 
      electronic literature PubMed, Medline, Embase, and ScienceDirect databases for 
      relevant reports and bibliographies. Studies were included if they designed as 
      cohort study, case-control study, or clinical trial on the NSAID exposure and 
      lung cancer with sufficient raw data to analyzes. Relative risk (RR) or odds 
      ratio (OR) was used to evaluate the association between NSAIDs and lung cancer. 
      Stratified analysis was also performed. RESULTS: A total of 19 studies including 
      20,266 lung cancer cases met the inclusion criteria. To the effect of aspirin on 
      lung cancer, the combined RR for cohort studies was 0.96 (95%confidence interval 
      [CI]: 0.78-1.19) and OR for case-control studies was 0.87 (95%CI: 0.69-1.09). 
      When restricted in exposure of aspirin use to 7 tablets per week, the OR was 0.80 
      (95%CI: 0.67-0.95). The summary risk estimates showed no significant association 
      between non-aspirin NSAID or overall NSAID use and lung cancer risk. CONCLUSIONS: 
      Aspirin use with a dose of 7 tablets per week can significantly reduce lung 
      cancer risk, whereas non-aspirin NSAIDs showed no chemopreventive value. Greater 
      attention should be paid to identifying appropriate individuals for this new 
      indication of aspirin and the optimal dose and duration as a chemopreventive 
      agent.
CI  - Copyright © 2012 Elsevier Inc. All rights reserved.
FAU - Xu, Jiali
AU  - Xu J
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Yin, Zhiqiang
AU  - Yin Z
FAU - Gao, Wen
AU  - Gao W
FAU - Liu, Lingxiang
AU  - Liu L
FAU - Wang, Rongsheng
AU  - Wang R
FAU - Huang, Puwen
AU  - Huang P
FAU - Yin, Yongmei
AU  - Yin Y
FAU - Liu, Ping
AU  - Liu P
FAU - Yu, Rongbin
AU  - Yu R
FAU - Shu, Yongqian
AU  - Shu Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20110802
PL  - United States
TA  - Clin Lung Cancer
JT  - Clinical lung cancer
JID - 100893225
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenocarcinoma/*prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Humans
MH  - Lung Neoplasms/*prevention & control
MH  - Risk Factors
EDAT- 2011/08/05 06:00
MHDA- 2012/05/16 06:00
CRDT- 2011/08/05 06:00
PHST- 2011/03/22 00:00 [received]
PHST- 2011/06/12 00:00 [revised]
PHST- 2011/06/18 00:00 [accepted]
PHST- 2011/08/05 06:00 [entrez]
PHST- 2011/08/05 06:00 [pubmed]
PHST- 2012/05/16 06:00 [medline]
AID - S1525-7304(11)00159-8 [pii]
AID - 10.1016/j.cllc.2011.06.009 [doi]
PST - ppublish
SO  - Clin Lung Cancer. 2012 Jan;13(1):44-51. doi: 10.1016/j.cllc.2011.06.009. Epub 
      2011 Aug 2.

PMID- 3287907
OWN - NLM
STAT- MEDLINE
DCOM- 19880627
LR  - 20201209
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 84
IP  - 5A
DP  - 1988 May 20
TI  - Analgesic efficacy of piroxicam in the treatment of postoperative pain.
PG  - 16-22
AB  - Two randomized, double-blind, single-dose studies were conducted to assess the 
      analgesic efficacy and safety of piroxicam for the treatment of moderate or 
      severe postoperative pain. Study 1 evaluated the analgesic efficacy of piroxicam 
      20 mg compared with that of codeine sulfate 60 mg and placebo. A final patient 
      population of 149 subjects rated pain intensity and pain relief at one half hour 
      and one hour following treatment and then hourly for six hours, with a global 
      assessment made at the completion of 24 hours. Piroxicam 20 mg was significantly 
      more efficacious than placebo for all analgesic variables, including the sum of 
      the pain intensity differences (SPID), total pain relief (TOTAL), percent SPID, 
      duration of effect, and time to remedication. Codeine 60 mg was significantly 
      superior to placebo for percent SPID and some hourly measures. Piroxicam 20 mg 
      was significantly more effective than codeine 60 mg for percent SPID and a few 
      hourly measures including time to remedication. Study 2 assessed the efficacy of 
      piroxicam 20 mg or 40 mg compared with aspirin 648 mg and placebo. Sixty patients 
      rated their pain intensity and relief hourly for 12 hours and at 24 hours after 
      administration of study medication. Both doses of piroxicam were significantly 
      more effective than placebo from Hours 2 to 12 for pain intensity difference 
      (PID) and relief scores, as well as for SPID and TOTAL. Aspirin was significantly 
      more effective than placebo from Hours 2 to 8 for relief and Hours 2 to 10 for 
      PID as well as SPID and TOTAL. Piroxicam 40 mg was significantly more effective 
      than aspirin 648 mg for SPID, TOTAL, and hourly measures beginning with Hour 6 
      through Hour 12. Piroxicam 20 mg was significantly better than aspirin for a few 
      hourly measures: Hours 7 to 9 for relief and Hour 7 for PID. In addition, effects 
      of piroxicam 20 mg had a significantly longer duration than aspirin. Similarly, 
      piroxicam 20 mg had a significantly longer time to remedication compared with 
      aspirin and placebo. The results of these studies provide evidence in support of 
      the longer duration of analgesic efficacy of piroxicam compared with codeine or 
      aspirin in patients with postoperative pain.
FAU - Sunshine, A
AU  - Sunshine A
AD  - New York University Medical Center, New York.
FAU - Roure, C
AU  - Roure C
FAU - Colon, A
AU  - Colon A
FAU - Olson, N Z
AU  - Olson NZ
FAU - Gonzalez, L
AU  - Gonzalez L
FAU - Siegel, C
AU  - Siegel C
FAU - Laska, E
AU  - Laska E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Analgesics)
RN  - 13T4O6VMAM (Piroxicam)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Analgesics/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Codeine/therapeutic use
MH  - Humans
MH  - Pain, Postoperative/*drug therapy
MH  - Piroxicam/*therapeutic use
MH  - Time Factors
EDAT- 1988/05/20 00:00
MHDA- 1988/05/20 00:01
CRDT- 1988/05/20 00:00
PHST- 1988/05/20 00:00 [pubmed]
PHST- 1988/05/20 00:01 [medline]
PHST- 1988/05/20 00:00 [entrez]
AID - 0002-9343(88)90472-X [pii]
AID - 10.1016/0002-9343(88)90472-x [doi]
PST - ppublish
SO  - Am J Med. 1988 May 20;84(5A):16-22. doi: 10.1016/0002-9343(88)90472-x.

PMID- 2734719
OWN - NLM
STAT- MEDLINE
DCOM- 19890725
LR  - 20131121
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 44
IP  - 1
DP  - 1989 Jan-Feb
TI  - [Prolonged effect of an antacid treatment on changes in gastric potential 
      difference induced by aspirin in man].
PG  - 39-42
AB  - In ten healthy volunteers, we evaluated the effects of a 6 days antacid treatment 
      (Rocgel) on the aspirin induced changes in gastric potential difference (PD). In 
      this placebo controlled cross-over study, PD was measured twelve hours after the 
      last take of the antacid. Aspirin induced drop of PD was less pronounced after 
      antacid compared to placebo; maximal fall of PD and area upper the curve 
      decreased (p less than 0.001). This effect was observed twelve hours after the 
      last take of the antacid. It may suggested a long-term protective effect on the 
      gastric mucosa.
FAU - Bergmann, J F
AU  - Bergmann JF
FAU - Simoneau, G
AU  - Simoneau G
FAU - Dorf, G
AU  - Dorf G
FAU - Caulin, C
AU  - Caulin C
FAU - Segrestaa, J M
AU  - Segrestaa JM
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Effect prolongé d'un traitement anti-acide sur les modifications de la différence 
      de potential gastrique induites par l'asprine chez l'homme.
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Antacids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Action Potentials/drug effects
MH  - Adult
MH  - Antacids/*pharmacology
MH  - Aspirin/*antagonists & inhibitors
MH  - Female
MH  - Humans
MH  - Male
MH  - Random Allocation
MH  - Stomach/*drug effects/physiology
MH  - Time Factors
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Therapie. 1989 Jan-Feb;44(1):39-42.

PMID- 7446146
OWN - NLM
STAT- MEDLINE
DCOM- 19810224
LR  - 20131121
IS  - 0044-6033 (Print)
IS  - 0044-6033 (Linking)
VI  - 31
IP  - 3
DP  - 1980 May-Jun
TI  - Comparative investigations of aspirin and indomethacin effects on blood flow in 
      the vascular bed of skeletal muscles at rest and during muscle contractions in 
      dogs and cats.
PG  - 297-303
AB  - The effecs of two different inhibitors of prostaglandin synthesis--aspirin and 
      indomethacin--on the blood flow in the vascular bed of the hindleg of vagotomized 
      animals were studied before, during and after muscular activity of this limb. The 
      responses of resistance and capacitance vessels were recorded simultaneously. 
      Muscular contractions were evoked stimulating electrically (4 impulses/second) 
      the peripheral part of the sciatic nerve. It was found that both inhibitors 
      reduced exercise hyperaemia and postexercise hyperaemia. The response of the 
      capacitance vessels was also reduced during muscular contractions. The obtained 
      results confirmed that endogenous prostaglandins participate in the vascular 
      response during exercise in the precapillary and postcapillary sections of 
      microcirculation in the muscles. The particularly important effect of aspirin on 
      postexercise hyperaemia in dogs in relation to cats is stressed.
FAU - Janczewska, H
AU  - Janczewska H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Poland
TA  - Acta Physiol Pol
JT  - Acta physiologica Polonica
JID - 2985166R
RN  - 0 (Vasoconstrictor Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Capillaries/*drug effects
MH  - Cats
MH  - Dogs
MH  - Female
MH  - Hindlimb/blood supply
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - *Microcirculation
MH  - Muscle Contraction
MH  - Muscles/*blood supply
MH  - Regional Blood Flow/drug effects
MH  - Rest
MH  - Vasoconstrictor Agents
EDAT- 1980/05/01 00:00
MHDA- 1980/05/01 00:01
CRDT- 1980/05/01 00:00
PHST- 1980/05/01 00:00 [pubmed]
PHST- 1980/05/01 00:01 [medline]
PHST- 1980/05/01 00:00 [entrez]
PST - ppublish
SO  - Acta Physiol Pol. 1980 May-Jun;31(3):297-303.

PMID- 1008020
OWN - NLM
STAT- MEDLINE
DCOM- 19770216
LR  - 20191210
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 6
IP  - 6
DP  - 1976 Nov
TI  - Anti-inflammatory activity of isoxicam in combination with aspirin or 
      D-propoxyphene.
PG  - 748-54
AB  - Unlike several arylacetic acid derivatives (indomethacin, fenoprofen, ibuprofen, 
      flurbiprofen and naproxen), the anti-arthritic activity of isoxicam is not 
      reduced in the adjuvant-induced polyarthritis assay by the concomitant 
      administration of aspirin or D-propoxyphene.
FAU - DiPasquale, G
AU  - DiPasquale G
FAU - Rassaert, C
AU  - Rassaert C
FAU - Welaj, P
AU  - Welaj P
FAU - Tripp, L
AU  - Tripp L
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Isoxazoles)
RN  - 0 (Oxazoles)
RN  - 0 (Thiazines)
RN  - 13T4O6VMAM (Piroxicam)
RN  - 8XU734C4NG (isoxicam)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
SB  - IM
MH  - Animals
MH  - *Anti-Inflammatory Agents
MH  - Arthritis, Experimental/drug therapy/prevention & control
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Body Weight
MH  - Dextropropoxyphene/*administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Isoxazoles/*administration & dosage/therapeutic use
MH  - Male
MH  - Organ Size
MH  - Oxazoles/*administration & dosage
MH  - Piroxicam/analogs & derivatives
MH  - Rats
MH  - Thiazines/*administration & dosage/therapeutic use
EDAT- 1976/11/01 00:00
MHDA- 1976/11/01 00:01
CRDT- 1976/11/01 00:00
PHST- 1976/11/01 00:00 [pubmed]
PHST- 1976/11/01 00:01 [medline]
PHST- 1976/11/01 00:00 [entrez]
AID - 10.1007/BF02026098 [doi]
PST - ppublish
SO  - Agents Actions. 1976 Nov;6(6):748-54. doi: 10.1007/BF02026098.

PMID- 37011853
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20230515
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
VI  - 870
DP  - 2023 Jun 20
TI  - Aspirin-Exacerbated Respiratory Disease Polymorphisms; a review study.
PG  - 147326
LID - S0378-1119(23)00167-1 [pii]
LID - 10.1016/j.gene.2023.147326 [doi]
AB  - Aspirin exacerbated respiratory disease (AERD) is a condition caused by increased 
      bronchoconstriction in people with asthma after taking aspirin or another NSAID. 
      Molecular analysis of the human genome has opened up new perspectives on human 
      polymorphisms and disease. This study was conducted to identify the genetic 
      factors that influence this disease due to its unknown genetic factors. We 
      evaluated research studies, letters, comments, editorials, eBooks, and reviews. 
      PubMed/MEDLINE, Web of Sciences, Cochrane Library, and Scopus were searched for 
      information. We used the keywords polymorphisms, aspirin-exacerbated respiratory 
      disease, asthma, allergy as search terms. This study included 38 studies. AERD 
      complications were associated with polymorphisms in ALOX15, EP2, ADRB2, SLC6A12, 
      CCR3, CRTH2, CysLTs, DPCR1, DPP10, FPR2, HSP70, IL8, IL1B, IL5RA, IL-13, IL17RA, 
      ILVBL, TBXA2R, TLR3, HLA-DRB and HLA-DQ, HLA-DR7, HLA-DP. AERD was associated 
      with heterogeneity in gene polymorphisms, making it difficult to pinpoint 
      specific gene changes. Therefore, diagnosing and treating AERD may be facilitated 
      by examining common variants involving the disease.
CI  - Copyright © 2023 Elsevier B.V. All rights reserved.
FAU - Fathollahpour, Aida
AU  - Fathollahpour A
AD  - Iran Universuty of Medical Science, Tehran, Iran.
FAU - Abyaneh, Fahimeh Abdi
AU  - Abyaneh FA
AD  - Kashan University of Medical Sciences, Kashan, Iran.
FAU - Darabi, Behzad
AU  - Darabi B
AD  - Allergist and Clinical Immunologist, Department of Pediaterics, Faculty of 
      Medicine, Ilam University of Medical Sciences, Ilam, Iran.
FAU - Ebrahimi, Mohsen
AU  - Ebrahimi M
AD  - Neonatal and Children's Health Research Center, Golestan University of Medical 
      Sciences, Gorgan, Iran.
FAU - Kooti, Wesam
AU  - Kooti W
AD  - Lung Diseases & Allergy Research Center, Research Institute for Health 
      Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
FAU - Kalmarzi, Rasoul Nasiri
AU  - Kalmarzi RN
AD  - Lung Diseases & Allergy Research Center, Research Institute for Health 
      Development, Kurdistan University of Medical Sciences, Sanandaj, Iran. Electronic 
      address: rasool_nsr@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230401
PL  - Netherlands
TA  - Gene
JT  - Gene
JID - 7706761
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
SB  - IM
MH  - Humans
MH  - *Asthma, Aspirin-Induced/genetics
MH  - Polymorphism, Genetic
MH  - Aspirin/adverse effects
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - *Asthma
OTO - NOTNLM
OT  - Allergy
OT  - Aspirin-Exacerbated Respiratory Disease
OT  - Asthma
OT  - Polymorphisms
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/04/04 06:00
MHDA- 2023/05/15 06:42
CRDT- 2023/04/03 19:24
PHST- 2022/09/26 00:00 [received]
PHST- 2023/02/22 00:00 [revised]
PHST- 2023/02/27 00:00 [accepted]
PHST- 2023/05/15 06:42 [medline]
PHST- 2023/04/04 06:00 [pubmed]
PHST- 2023/04/03 19:24 [entrez]
AID - S0378-1119(23)00167-1 [pii]
AID - 10.1016/j.gene.2023.147326 [doi]
PST - ppublish
SO  - Gene. 2023 Jun 20;870:147326. doi: 10.1016/j.gene.2023.147326. Epub 2023 Apr 1.

PMID- 31228190
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201111
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 40
IP  - 41
DP  - 2019 Nov 1
TI  - Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies 
      cardiovascular disease prevention effects of aspirin.
PG  - 3385-3392
LID - 10.1093/eurheartj/ehz384 [doi]
AB  - AIMS: Efficacy of aspirin in primary prevention of cardiovascular disease (CVD) 
      may be influenced by a common allele in guanylate cyclase GUCY1A3, which has been 
      shown to modify platelet function and increase CVD risk. METHODS AND RESULTS: We 
      investigated whether homozygotes of the GUCY1A3 rs7692387 risk (G) allele 
      benefited from aspirin in two long-term, randomized placebo-controlled trials of 
      aspirin in primary CVD prevention: the Women's Genome Health Study (WGHS, 
      N = 23 294) and a myocardial infarction (MI, N = 550) and stroke (N = 382) 
      case-control set from the Physician's Health Study (PHS, N = 22 071). Bleeding 
      risk was evaluated in the WGHS. In the placebo group of the WGHS, the GUCY1A3 
      risk (G) allele was confirmed to increase CVD risk [hazard ratio 1.38; 95% 
      confidence interval (CI) 1.08-1.78; P = 0.01]. Random-effects meta-analysis of 
      the WGHS and PHS revealed that aspirin reduced CVD events among risk allele 
      homozygotes [G/G: odds ratio (OR) 0.79; 95% CI 0.65-0.97; P = 0.03] but increased 
      CVD events among non-risk allele carriers (e.g. G/A: OR 1.39; 95% CI 1.03-1.87; 
      P = 0.03) thus implying an interaction between genotype stratum and aspirin 
      intake (Pinteraction = 0.01). Bleeding associated with aspirin increased in all 
      genotype groups, with higher risks in heterozygotes. CONCLUSION: In two 
      randomized placebo-controlled trials in the setting of primary prevention, 
      aspirin reduced the incidence of CVD events in individuals homozygous for the 
      GUCY1A3 risk (G) allele, whereas heterozygote individuals had more events when 
      taking aspirin.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved. © 
      The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.
FAU - Hall, Kathryn T
AU  - Hall KT
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02146, USA.
FAU - Kessler, Thorsten
AU  - Kessler T
AD  - Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, 
      Technische Universität München, Deutsches Zentrum für Herz- und 
      Kreislauf-Forschung (DZHK) e.V., Partner Site Munich Heart Alliance, 
      Lazarettstrasse 36, 80636 Munich, Germany.
FAU - Buring, Julie E
AU  - Buring JE
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02146, USA.
FAU - Passow, Dani
AU  - Passow D
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02146, USA.
FAU - Sesso, Howard D
AU  - Sesso HD
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02146, USA.
FAU - Zee, Robert Y L
AU  - Zee RYL
AD  - Department of Pediatric Dentistry, Tufts University School of Dental Medicine, 
      Boston, MA, USA.
FAU - Ridker, Paul M
AU  - Ridker PM
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02146, USA.
FAU - Chasman, Daniel I
AU  - Chasman DI
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02146, USA.
FAU - Schunkert, Heribert
AU  - Schunkert H
AD  - Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, 
      Technische Universität München, Deutsches Zentrum für Herz- und 
      Kreislauf-Forschung (DZHK) e.V., Partner Site Munich Heart Alliance, 
      Lazarettstrasse 36, 80636 Munich, Germany.
LA  - eng
GR  - K01 HL130625/HL/NHLBI NIH HHS/United States
GR  - R01 CA047988/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (GUCY1A1 protein, human)
RN  - EC 4.6.1.2 (Soluble Guanylyl Cyclase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2019 Nov 1;40(41):3393-3396. PMID: 31280284
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aspirin/adverse effects/therapeutic use
MH  - *Cardiovascular Diseases/drug therapy/epidemiology/genetics/prevention & control
MH  - *Coronary Artery Disease/epidemiology/genetics
MH  - Female
MH  - Genetic Predisposition to Disease/epidemiology/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Primary Prevention
MH  - Soluble Guanylyl Cyclase/*genetics
PMC - PMC6933533
OTO - NOTNLM
OT  - GUCY1A3
OT  - Aspirin
OT  - Coronary artery disease risk gene
OT  - Guanylate cyclase
OT  - Primary prevention
OT  - rs7692387
EDAT- 2019/06/23 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/06/23 06:00
PHST- 2018/08/22 00:00 [received]
PHST- 2019/02/26 00:00 [revised]
PHST- 2019/05/22 00:00 [accepted]
PHST- 2019/06/23 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/06/23 06:00 [entrez]
AID - 5521149 [pii]
AID - ehz384 [pii]
AID - 10.1093/eurheartj/ehz384 [doi]
PST - ppublish
SO  - Eur Heart J. 2019 Nov 1;40(41):3385-3392. doi: 10.1093/eurheartj/ehz384.

PMID- 94870
OWN - NLM
STAT- MEDLINE
DCOM- 19800815
LR  - 20131121
IS  - 0323-4347 (Print)
IS  - 0323-4347 (Linking)
VI  - 106
IP  - 5-6
DP  - 1979
TI  - [Clinical-experimental studies on the inhibition of thrombocyte function with 
      acetylsalicylic acid and with indobufen].
PG  - 783-96
AB  - The mode of action of two inhibitors of platelet function is reported. At low 
      doses both substances inhibit platelet aggregation, at higher doses they inhibit 
      the availability of platelet factor 3 and liberation of platelet factor 4. 
      Acetylsalicylic acid, however, possesses a long-lasting effect produced by 
      irreversible acetylation of platelet membrane. This was demonstrated in a series 
      of clinico-experimental studies in which 14C-labelled ASA was used. Indobufen was 
      found to cause transitory changes of platelet function. It is easily washed out 
      from platelets and binds loosely to cytosol proteins of platelets, as shown in 
      studies with 14-C-labelled indobufen. In contrast to ASA, it exerts an effect on 
      platelets lasting for a few hours only.
FAU - Vinazzer, H
AU  - Vinazzer H
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Klinisch-experimentelle Studien zur Hemmung der Thrombozytenfunktion mit 
      Azetylsalizylsäure und mit Indobufen.
PL  - Germany
TA  - Folia Haematol Int Mag Klin Morphol Blutforsch
JT  - Folia haematologica (Leipzig, Germany : 1928)
JID - 0374615
RN  - 0 (Indoles)
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 37270-93-2 (Platelet Factor 3)
RN  - 37270-94-3 (Platelet Factor 4)
RN  - 6T9949G4LZ (indobufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Indoles/pharmacology
MH  - Isoindoles
MH  - Phenylbutyrates/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Factor 3/analysis
MH  - Platelet Factor 4/analysis
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):783-96.

PMID- 23306328
OWN - NLM
STAT- MEDLINE
DCOM- 20130311
LR  - 20211021
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 44
IP  - 2
DP  - 2013 Feb
TI  - Effect of low-dose aspirin on functional outcome from cerebral vascular events in 
      women.
PG  - 432-6
LID - 10.1161/STROKEAHA.112.672451 [doi]
AB  - BACKGROUND AND PURPOSE: Although aspirin is effective in prevention of stroke, 
      fewer studies have examined the impact of aspirin on stroke morbidity. METHODS: 
      The Women's Health Study is a completed randomized, placebo-controlled trial 
      designed to test the effect of low-dose aspirin and vitamin E in the primary 
      prevention of cardiovascular disease and cancer, which enrolled 39 876 women. We 
      used multinomial logistic regression to evaluate the relationship between 
      randomized aspirin assignment and functional outcomes from stroke. Possible 
      functional outcomes were neither stroke nor transient ischemic attack (TIA), 
      modified Rankin scale (mRS) score 0 to 1, 2 to 3, and 4 to 6. RESULTS: After a 
      mean of 9.9 years of follow-up, 460 confirmed strokes (366 ischemic, 90 
      hemorrhagic, and 4 unknown type) and 405 confirmed TIAs occurred. With regard to 
      total and ischemic stroke, women who were randomized to aspirin had a 
      nonsignificant decrease in risk of any outcome compared to women not randomized 
      to aspirin. This decrease in risk only reached statistical significance for those 
      experiencing TIA compared to participants without stroke or TIA (odds ratio=0.77; 
      95% confidence interval, 0.63-0.94). For hemorrhagic stroke, a nonsignificant 
      increase in the risk of achieving an mRS score 2 to 3 or 4 to 6 compared with no 
      stroke or TIA was observed for the women randomized to aspirin compared to those 
      randomized to placebo. CONCLUSIONS: Results from this large randomized clinical 
      trial provide evidence that 100 mg of aspirin every other day may reduce the risk 
      of ischemic cerebral vascular events but does not have differential effects on 
      functional outcomes from stroke.
FAU - Rist, Pamela M
AU  - Rist PM
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women’s 
      Hospital, Harvard Medical School, Boston, MA 02215, USA. prist@partners.org
FAU - Buring, Julie E
AU  - Buring JE
FAU - Kase, Carlos S
AU  - Kase CS
FAU - Kurth, Tobias
AU  - Kurth T
LA  - eng
GR  - AG-00158/AG/NIA NIH HHS/United States
GR  - R01 HL043851/HL/NHLBI NIH HHS/United States
GR  - CA-047988/CA/NCI NIH HHS/United States
GR  - T32 AG000158/AG/NIA NIH HHS/United States
GR  - HL-043851/HL/NHLBI NIH HHS/United States
GR  - R01 CA047988/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20130110
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cerebrovascular Disorders/*epidemiology/physiopathology/*prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/epidemiology/physiopathology/prevention & control
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic/trends
MH  - Recovery of Function/*drug effects/physiology
MH  - Treatment Outcome
PMC - PMC3552068
MID - NIHMS427438
EDAT- 2013/01/12 06:00
MHDA- 2013/03/12 06:00
CRDT- 2013/01/12 06:00
PHST- 2013/01/12 06:00 [entrez]
PHST- 2013/01/12 06:00 [pubmed]
PHST- 2013/03/12 06:00 [medline]
AID - STROKEAHA.112.672451 [pii]
AID - 10.1161/STROKEAHA.112.672451 [doi]
PST - ppublish
SO  - Stroke. 2013 Feb;44(2):432-6. doi: 10.1161/STROKEAHA.112.672451. Epub 2013 Jan 
      10.

PMID- 27590185
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20181202
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 16
IP  - 1
DP  - 2016 Sep 2
TI  - Adverse clinical outcomes associated with a low dose and a high dose of aspirin 
      following percutaneous coronary intervention: a systematic review and 
      meta-analysis.
PG  - 169
LID - 10.1186/s12872-016-0347-7 [doi]
LID - 169
AB  - BACKGROUND: Guidelines from the American Heart Association/American College of 
      Cardiology recommend a higher dosage of aspirin daily following Percutaneous 
      Coronary Intervention (PCI), whereas guidelines from the European Society of 
      Cardiology recommend a lower dosage. This study aimed to compare the adverse 
      clinical outcomes associated with a low dose and a high dose of aspirin following 
      PCI. METHODS: Electronic databases were searched for studies comparing a low dose 
      with a high dose aspirin following PCI. Adverse clinical outcomes were considered 
      as the endpoints in this study. We calculated Odds Ratios (OR) with 95 % 
      Confidence Intervals (CIs) for categorical variables. The pooled analyses were 
      performed with RevMan 5.3 software. RESULTS: A total number of 25,083 patients 
      were included. Results from this analysis showed that the combination of 
      Cardiovascular (CV) death/Myocardial Infarction (MI) or stroke was not 
      significantly different between a low and high dose of aspirin with OR: 1.08, 
      95 % CI: 0.98-1.18; P = 0.11. Mortality and MI were also not significantly 
      different between these two treatment regimens following PCI with OR: 0.95, 95 % 
      CI: 0.74-1.23; P = 0.71 and OR: 1.17, 95 % CI: 0.97-1.41; P = 0.09 respectively. 
      However, a high dose of aspirin was associated with a significantly higher rate 
      of Major Adverse Cardiac Events (MACEs) with OR: 1.20, 95 % CI: 1.02-1.41; 
      P = 0.03. Thrombolysis In Myocardial Infarction (TIMI) defined minor bleeding was 
      also significantly higher with a high dose aspirin with OR: 1.22, 95 % CI: 
      1.02-1.47; P = 0.03. When Stent thrombosis (ST) was compared, no significant 
      difference was found with OR: 1.28, 95 % CI: 0.59-2.58; P = 0.53. Even if TIMI 
      defined major bleeding favored a low dose of aspirin, with OR: 1.42, 95 % CI: 
      0.95-2.13; P = 0.09, or even if major bleeding was insignificantly higher with a 
      high dose aspirin, with OR: 1.78, 95 % CI: 1.01-3.13; P = 0.05; I(2) = 94 %, 
      higher levels of heterogeneity observed in these subgroups could not be 
      considered significant to any extent. CONCLUSION: According to the results of 
      this analysis, a high dose of aspirin following PCI was not associated with any 
      significantly higher rate of CV death/MI/stroke, mortality or MI. However, MACEs 
      significantly favored a low dose of aspirin. In addition, TIMI defined minor 
      bleeding was significantly higher with a high dose of aspirin whereas the results 
      for the major bleeding outcomes were not statistically significant. However, due 
      to limited data availability and since the subgroups analyzing major bleeding 
      were highly heterogeneous, further studies are recommended to completely solve 
      this issue.
FAU - Bundhun, Pravesh Kumar
AU  - Bundhun PK
AD  - Institute of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi 
      Medical University, Nanning, Guangxi, 530027, People's Republic of China.
FAU - Janoo, Girish
AU  - Janoo G
AD  - Guangxi Medical University, Nanning, Guangxi, 530027, People's Republic of China.
FAU - Teeluck, Abhishek Rishikesh
AU  - Teeluck AR
AD  - Guangxi Medical University, Nanning, Guangxi, 530027, People's Republic of China.
FAU - Huang, Wei-Qiang
AU  - Huang WQ
AD  - Institute of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi 
      Medical University, Nanning, Guangxi, 530027, People's Republic of China. 
      huangwq1029@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160902
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Coronary Artery Disease/drug therapy/*surgery
MH  - Global Health
MH  - Humans
MH  - Incidence
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - *Postoperative Care
MH  - Postoperative Hemorrhage/*chemically induced/epidemiology
MH  - Survival Rate/trends
PMC - PMC5009703
OTO - NOTNLM
OT  - Aspirin
OT  - Bleeding
OT  - Cardiovascular death
OT  - Major adverse cardiac events
OT  - Meta-analysis
OT  - Percutaneous coronary intervention
EDAT- 2016/09/04 06:00
MHDA- 2017/06/22 06:00
CRDT- 2016/09/04 06:00
PHST- 2016/07/13 00:00 [received]
PHST- 2016/08/16 00:00 [accepted]
PHST- 2016/09/04 06:00 [entrez]
PHST- 2016/09/04 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - 10.1186/s12872-016-0347-7 [pii]
AID - 347 [pii]
AID - 10.1186/s12872-016-0347-7 [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2016 Sep 2;16(1):169. doi: 10.1186/s12872-016-0347-7.

PMID- 6859071
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 74
IP  - 6A
DP  - 1983 Jun 14
TI  - Distribution of salicylate in lens and intraocular fluids and its effect on 
      cataract formation.
PG  - 83-90
AB  - Retrospective studies on cataract development in patients with rheumatoid 
      arthritis or osteoarthritis revealed a retardant effect of aspirin on diabetic 
      and non-diabetic cataracts. The effect of aspirin is dose-dependent. The 
      correlation coefficient between years delay for various cataracts subcategories 
      versus aspirin taken (in tablets per day X years of intake) was 0.69. The ocular 
      pharmacokinetics of 14C acetylsalicylic acid or salicylate were determined after 
      intravenous or intraperitoneal administration to rabbits. 14C acetylsalicylic 
      acid penetrates rapidly into rabbit lens and aqueous humor after intravenous 
      administration. After intraperitoneal administration, salicylate levels in rabbit 
      plasma, similar to those of humans receiving four to six aspirin tablets (325 mg 
      each), result in accumulation of salicylate by lens (mean +/- SD) of 405 +/- 72 
      mumoles/g and 620 +/- 30 mumoles/g at two and four hours, respectively. At those 
      dosages, salicylate is cleared in 24 hours from rabbit plasma and intraocular 
      fluids, but retained by lens. Penetration of salicylate into rabbit lens and rat 
      lens is dose-dependent. The retardant aspirin effect in diabetic cataracts is 
      linked to inhibition of tissue aldose reductase and lens protein glycosylation. 
      Deceleration of galactose cataract formation in rats occurs after daily 
      salicylate intraperitoneal injections of 100 mg/kg a day.
FAU - Cotlier, E
AU  - Cotlier E
FAU - Sharma, Y R
AU  - Sharma YR
FAU - Niven, T
AU  - Niven T
FAU - Brescia, M
AU  - Brescia M
LA  - eng
GR  - EY02490/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Crystallins)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
RN  - X2RN3Q8DNE (Galactose)
SB  - IM
MH  - Animals
MH  - Aqueous Humor/*metabolism
MH  - Aspirin/metabolism/therapeutic use
MH  - Cataract/etiology/*prevention & control
MH  - Crystallins/metabolism
MH  - Diabetes Complications
MH  - Galactose
MH  - Humans
MH  - Lens, Crystalline/*metabolism
MH  - Rabbits
MH  - Rats
MH  - Salicylates/metabolism/*therapeutic use
MH  - Sodium Salicylate/metabolism/therapeutic use
MH  - Vitreous Body/*metabolism
EDAT- 1983/06/14 00:00
MHDA- 1983/06/14 00:01
CRDT- 1983/06/14 00:00
PHST- 1983/06/14 00:00 [pubmed]
PHST- 1983/06/14 00:01 [medline]
PHST- 1983/06/14 00:00 [entrez]
AID - 0002-9343(83)90534-X [pii]
AID - 10.1016/0002-9343(83)90534-x [doi]
PST - ppublish
SO  - Am J Med. 1983 Jun 14;74(6A):83-90. doi: 10.1016/0002-9343(83)90534-x.

PMID- 32671928
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 11
IP  - 2
DP  - 2021 Feb
TI  - Major complications of aspirin desensitization and maintenance therapy in 
      aspirin-exacerbated respiratory disease.
PG  - 115-119
LID - 10.1002/alr.22643 [doi]
AB  - BACKGROUND: Treatment of aspirin-exacerbated respiratory disease (AERD) includes 
      endoscopic sinus surgery (ESS) and aspirin desensitization (AD) with aspirin 
      therapy after desensitization (ATAD). The objective of this study was to 
      determine the rate of major complications associated with aspirin use that 
      resulted in the discontinuation of aspirin therapy. METHODS: This study was a 
      retrospective chart review of patients with AERD who underwent ESS, AD, and ATAD 
      at a single AERD tertiary center between July 2016 and February 2019. 
      Complications associated with aspirin that resulted in the discontinuation of 
      aspirin therapy were analyzed via analysis of variance and logistic regression. 
      RESULTS: In total, 109 AERD patients underwent ESS with subsequent AD. Ten 
      patients (9.2%) discontinued therapy after AD, before starting ATAD. Eight 
      patients (7.3%) discontinued therapy after starting ATAD. There were 91 patients 
      (83.5%) with no complications throughout ATAD. Reasons for discontinuation 
      included gastritis, upper gastrointestinal (GI) bleed, anaphylaxis, persistent 
      sinonasal symptoms, recurrent epistaxis, asthma exacerbation, and a nummular 
      rash. There was no significant correlation between complication rate and (1) 
      aspirin doses (analysis of variance [ANOVA] F: 0.69; p = 0.51), (2) gender (odds 
      ratio [OR] 0.56; 95% confidence interval [CI], 0.19 to 1.65; p = 0.30), (3) age 
      (OR 1.04; 95% CI, 0.96 to 1.09; p = 0.06), or (4) race/ethnicity (OR 1.12; 95% 
      CI, 0.88 to 1.44; p = 0.36). CONCLUSION: AD with ATAD was associated with only a 
      0.92% incidence of a clinically significant GI bleed, and only a 0.92% incidence 
      of anaphylaxis. A remaining 16 patients (14.7%) discontinued aspirin therapy due 
      to minor clinical sequelae. These findings demonstrate that the majority of AERD 
      patients tolerate AD with ATAD without any major complications.
CI  - © 2020 ARS-AAOA, LLC.
FAU - Sweis, Auddie M
AU  - Sweis AM
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
FAU - Locke, Tran B
AU  - Locke TB
AUID- ORCID: 0000-0002-3838-3890
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
FAU - Ig-Izevbekhai, Kevin I
AU  - Ig-Izevbekhai KI
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
FAU - Lin, Theodore C
AU  - Lin TC
AUID- ORCID: 0000-0001-5280-0286
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
AD  - Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
FAU - Gleeson, Patrick K
AU  - Gleeson PK
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
FAU - Civantos, Alyssa M
AU  - Civantos AM
AUID- ORCID: 0000-0003-1226-6634
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
FAU - Kumar, Ankur
AU  - Kumar A
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
FAU - Corr, Andrew M
AU  - Corr AM
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
FAU - Kohanski, Michael A
AU  - Kohanski MA
AUID- ORCID: 0000-0001-8399-364X
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
FAU - Palmer, James N
AU  - Palmer JN
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
FAU - Bosso, John V
AU  - Bosso JV
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
FAU - Adappa, Nithin D
AU  - Adappa ND
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA.
LA  - eng
PT  - Journal Article
DEP - 20200716
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Asthma, Aspirin-Induced
MH  - Desensitization, Immunologic
MH  - Humans
MH  - *Nasal Polyps/therapy
MH  - Retrospective Studies
MH  - *Sinusitis/drug therapy
OTO - NOTNLM
OT  - asthma
OT  - chronic rhinosinusitis
OT  - eosinophilic rhinitis and nasal polyposis
OT  - medical therapy of chronic rhinosinusitis
OT  - therapeutics
EDAT- 2020/07/17 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/07/17 06:00 [entrez]
AID - 10.1002/alr.22643 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2021 Feb;11(2):115-119. doi: 10.1002/alr.22643. Epub 
      2020 Jul 16.

PMID- 864100
OWN - NLM
STAT- MEDLINE
DCOM- 19770729
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 59
IP  - 6
DP  - 1977 Jun
TI  - Bronchial response to inhaled prostaglandin F2alpha in patients with common or 
      aspirin-sensitive asthma.
PG  - 414-9
AB  - The effect of aerosolized prostaglandin F2alpha (PGF2alpha) on specific airway 
      resistance (SRaw) has been measured in patients with common (n = 10) or 
      aspirin-sensitive asthma (n = 5). In all subjects PGF2alpha caused a dose-related 
      increase in SRaw, but considerable individual differences in sensitivity were 
      observed. The patients with aspirin intolerance did not differ from regular 
      asthmatics in terms of their response to PGF2alpha. Two types of reactions to 
      PGF2alpha could be distinguished from their time-course: immediate and 
      short-lasting (3 cases) or delayed and long-lasting (12 cases). Inhalation of a 
      beta-adrenergic drug rapidly and completely reversed the effect of PGF2alpha, 
      suggesting that the increase in SRaw was due to bronchospasm. In 7 subjects the 
      inhalation of an anticholinergic drug (SCH 1000) prior to PGF2alpha inhibited to 
      a large extent the effect of the latter, suggesting that the cholinergic system 
      played an important role in the bronchial response to PGF2alpha. In 9 subjects no 
      correlation was found between the bronchial sensitivity to carbachol and 
      PGF2alpha.
FAU - Orehek, J
AU  - Orehek J
FAU - Gayrard, P
AU  - Gayrard P
FAU - Grimaud, C
AU  - Grimaud C
FAU - Charpin, J
AU  - Charpin J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Aerosols)
RN  - 0 (Prostaglandins F)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aerosols
MH  - Airway Resistance/drug effects
MH  - *Aspirin/pharmacology
MH  - Asthma/*physiopathology
MH  - Bronchi/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Tolerance
MH  - Humans
MH  - Prostaglandins F/*pharmacology
EDAT- 1977/06/01 00:00
MHDA- 1977/06/01 00:01
CRDT- 1977/06/01 00:00
PHST- 1977/06/01 00:00 [pubmed]
PHST- 1977/06/01 00:01 [medline]
PHST- 1977/06/01 00:00 [entrez]
AID - 0091-6749(77)90003-3 [pii]
AID - 10.1016/0091-6749(77)90003-3 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1977 Jun;59(6):414-9. doi: 10.1016/0091-6749(77)90003-3.

PMID- 10853626
OWN - NLM
STAT- MEDLINE
DCOM- 20000928
LR  - 20190915
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 20
IP  - 6
DP  - 2000 Jun
TI  - Update on the interaction between aspirin and angiotensin-converting enzyme 
      inhibitors.
PG  - 698-710
AB  - We summarized recent published literature regarding the significance of an 
      interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors in 
      patients with various cardiovascular diseases. A MEDLINE search (January 
      1998-July 1999) was performed and abstracts from the 1999 American College of 
      Cardiology and 1998 American Heart Association annual scientific sessions were 
      reviewed to identify pertinent studies. Material for discussion was identified 
      through a MEDLINE search from January 1996-July 1999 and through cited 
      references. The results of several studies added to our understanding of the 
      clinical ramifications of an aspirin-ACE inhibitor interaction, but also 
      introduced questions. These studies are largely contradictory, but do reiterate 
      the possibility of an interaction, if only in certain subsets of patients. Low 
      dosages (< or = 100 mg/day) of aspirin appear to be safer in this regard than 
      higher dosages. The frequency and severity of the interaction and possible 
      predisposing factors await future research.
FAU - Nawarskas, J J
AU  - Nawarskas JJ
AD  - Department of Pharmacy Practice, University of New Mexico College of Pharmacy, 
      Albuquerque 87131-5691, USA.
FAU - Spinler, S A
AU  - Spinler SA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/*adverse effects
MH  - Clinical Trials as Topic
MH  - Coronary Disease/drug therapy
MH  - Drug Interactions
MH  - Heart Failure/drug therapy
MH  - Humans
MH  - Hypertension/drug therapy
RF  - 59
EDAT- 2000/06/15 09:00
MHDA- 2000/09/30 11:01
CRDT- 2000/06/15 09:00
PHST- 2000/06/15 09:00 [pubmed]
PHST- 2000/09/30 11:01 [medline]
PHST- 2000/06/15 09:00 [entrez]
AID - 10.1592/phco.20.7.698.35168 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2000 Jun;20(6):698-710. doi: 10.1592/phco.20.7.698.35168.

PMID- 2868549
OWN - NLM
STAT- MEDLINE
DCOM- 19860306
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 17
IP  - 1
DP  - 1986 Jan-Feb
TI  - Persantine aspirin trial in cerebral ischemia--Part III: Risk factors for stroke. 
      The American-Canadian Co-Operative Study Group.
PG  - 12-8
AB  - This third paper from the Persantine Aspirin Trial examines the data to identify 
      risk factors for stroke in persons with a history of carotid territory transient 
      ischemic attacks (TIAs) Fifteen centers in the United States and Canada 
      participated, and 890 subjects were admitted and randomly allocated to either 
      aspirin plus placebo or aspirin plus dipyridamole (Persantine). Persons with the 
      following characteristics were in greater jeopardy for stroke, retinal 
      infarction, or death: older age, history of heart disease, history of peripheral 
      vascular disease, and persisting neurologic deficit from a recent event. Elevated 
      diastolic blood pressure, diabetes, use of estrogen, and smoking were not found 
      to be risk factors. Elevated systolic blood pressure was a risk factor primarily 
      in subjects with a history of heart disease. Estrogen use may actually have had a 
      protective effect for women. This cannot be considered as a report of the natural 
      history of TIA patients; it does identify risk factors in a specific cohort of 
      subjects under treatment.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Brain Ischemia/*drug therapy
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retinal Vessels/drug effects
MH  - Risk
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1161/01.str.17.1.12 [doi]
PST - ppublish
SO  - Stroke. 1986 Jan-Feb;17(1):12-8. doi: 10.1161/01.str.17.1.12.

PMID- 19556719
OWN - NLM
STAT- MEDLINE
DCOM- 20091021
LR  - 20190608
IS  - 1880-3873 (Electronic)
IS  - 1340-3478 (Linking)
VI  - 16
IP  - 3
DP  - 2009 Jun
TI  - Circadian variations of gastrointestinal mucosal damage detected with transnasal 
      endoscopy in apparently healthy subjects treated with low-dose aspirin (ASA) for 
      a short period.
PG  - 155-63
AB  - AIM: In this study, transnasal endoscopy was used to observe the time-course 
      changes of gastrointestinal mucosa with low-dose aspirin (ASA), and the 
      preventive effect of rebamipide was compared with placebo. METHODS: Twenty 
      healthy H.pylori-negative subjects were divided between those receiving 100 mg 
      aspirin with placebo, and those receiving 100 mg aspirin+300 mg rebamipide for 7 
      days daily. Transnasal endoscopy was performed at 0, 2, 6 and 24 hrs on the first 
      day, and then on the third and seventh days. RESULTS: Ulcers, in the duodenum at 
      24 hrs and in the antrum at 72 hrs, improved with continuous ASA. Erosions were 
      mainly observed in the duodenum; erosions amounted to 14 at 3 days and 19 at 7 
      days in the placebo group. No ulcers and some erosions were mainly observed in 
      the duodenum; erosions amounted to 5 at 3 days and 3 at 7 days in the rebamipide 
      group. CONCLUSION: In short-term gastrointestinal damage induced by ASA, damage 
      was observed in the duodenum most frequently, and peak damage was at 24 hrs and 
      72 hrs. Almost all damage improved gradually in spite of continuous ASA. 
      Rebamipide reduced the damage of low-dose aspirin-induced GI complications.
FAU - Kawai, Takashi
AU  - Kawai T
AD  - Endoscopy Center, Tokyo Medical University Hospital, Tokyo 160-0023, Japan. 
      t-kawai@tokyo-med.ac.jp
FAU - Yamagishi, Tetsuya
AU  - Yamagishi T
FAU - Goto, Shinya
AU  - Goto S
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20090625
PL  - Japan
TA  - J Atheroscler Thromb
JT  - Journal of atherosclerosis and thrombosis
JID - 9506298
RN  - 0 (Quinolones)
RN  - LR583V32ZR (rebamipide)
RN  - OF5P57N2ZX (Alanine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Alanine/administration & dosage/analogs & derivatives/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - *Circadian Rhythm
MH  - Double-Blind Method
MH  - Endoscopy
MH  - Female
MH  - Gastric Mucosa/drug effects/*pathology
MH  - Humans
MH  - Intestinal Mucosa/drug effects/*pathology
MH  - Male
MH  - Quinolones/administration & dosage/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ulcer/chemically induced/drug therapy
MH  - Young Adult
EDAT- 2009/06/27 09:00
MHDA- 2009/10/22 06:00
CRDT- 2009/06/27 09:00
PHST- 2009/06/27 09:00 [entrez]
PHST- 2009/06/27 09:00 [pubmed]
PHST- 2009/10/22 06:00 [medline]
AID - JST.JSTAGE/jat/E615 [pii]
AID - 10.5551/jat.e615 [doi]
PST - ppublish
SO  - J Atheroscler Thromb. 2009 Jun;16(3):155-63. doi: 10.5551/jat.e615. Epub 2009 Jun 
      25.

PMID- 3726873
OWN - NLM
STAT- MEDLINE
DCOM- 19860818
LR  - 20190727
IS  - 0041-008X (Print)
IS  - 0041-008X (Linking)
VI  - 84
IP  - 3
DP  - 1986 Jul
TI  - Metabolism of aspirin and procaine in mice pretreated with O-4-nitrophenyl 
      methyl(phenyl)phosphinate or O-4-nitrophenyl diphenylphosphinate.
PG  - 523-32
AB  - Concentrations of [carboxyl-14C]procaine in blood of mice were increased 
      threefold for 27 min by exposure to O-4-nitrophenyl diphenylphosphinate 2 hr 
      prior to [carboxyl-14C]procaine injection ip, while there was no effect of 
      O-4-nitrophenyl methyl(phenyl)phosphinate pretreatment. There was no effect of 
      either organophosphinate on the primary hydrolysis of [acetyl-l-14C]aspirin when 
      assessed by the expiration of [14C]carbon dioxide; however, O-4-nitrophenyl 
      diphenylphosphinate pretreatment produced transient increases in blood 
      concentrations of both [carboxyl-14C]aspirin and [carboxyl-14C]salicylic acid 
      following administration of [carboxyl-14C]aspirin. Liver carboxylesterase 
      activity in O-4-nitrophenyl diphenylphosphinate pretreated mice was 11% of 
      control activity. These results indicate the potential for drug interaction with 
      O-4-nitrophenyl diphenylphosphinate but not with O-4-nitrophenyl 
      methyl(phenyl)phosphinate. It appears that liver carboxylesterase activity has a 
      minor role in hydrolysis of aspirin in vivo, but may be more important in 
      procaine metabolism.
FAU - Joly, J M
AU  - Joly JM
FAU - Brown, T M
AU  - Brown TM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Toxicol Appl Pharmacol
JT  - Toxicology and applied pharmacology
JID - 0416575
RN  - 0 (Carbon Radioisotopes)
RN  - 0 (Nitrobenzenes)
RN  - 0 (Organophosphorus Compounds)
RN  - 10259-20-8 (O-4-(nitrophenyl)diphenyl phosphinate)
RN  - 35691-25-9 (O-4-(nitrophenyl)methylphenyl phosphinate)
RN  - 4Z8Y51M438 (Procaine)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/*metabolism
MH  - Carbon Radioisotopes
MH  - Carboxylic Ester Hydrolases/*antagonists & inhibitors
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Hydrolysis
MH  - Injections, Intramuscular
MH  - Lethal Dose 50
MH  - Liver/*drug effects/metabolism
MH  - Male
MH  - Mice
MH  - Nitrobenzenes/*toxicity
MH  - Organophosphorus Compounds/*toxicity
MH  - Procaine/blood/*metabolism
MH  - Sex Factors
EDAT- 1986/07/01 00:00
MHDA- 1986/07/01 00:01
CRDT- 1986/07/01 00:00
PHST- 1986/07/01 00:00 [pubmed]
PHST- 1986/07/01 00:01 [medline]
PHST- 1986/07/01 00:00 [entrez]
AID - 10.1016/0041-008x(86)90257-7 [doi]
PST - ppublish
SO  - Toxicol Appl Pharmacol. 1986 Jul;84(3):523-32. doi: 10.1016/0041-008x(86)90257-7.

PMID- 1070995
OWN - NLM
STAT- MEDLINE
DCOM- 19770321
LR  - 20131121
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 6 Suppl 1
DP  - 1976
TI  - Pathology, aetiology and pathogenesis of analgesic nephropathy.
PG  - Suppl 1:33-7
AB  - 1. The initial site of damage in analgesic abuse is the renal medulla and the 
      characteristic lesion is renal papillary necrosis. The papillary necrosis appears 
      to be an ischaemic infarct. The cortical lesion of chronic interstial nephritis 
      is a non-specific change and secondary to obstruction to tubules in the necrotic 
      medulla. 2. Medullary perfusion and the concentration mechanism appear to be 
      important factors in the genesis of renal papillary necrosis. 3. Experimental and 
      clinical studies suggest that abuse of compound analgesics containing aspirin, 
      phenacetin and caffeine result in renal papillary necrosis and the clinical 
      syndrome of analgesic nephropathy. In the APC mixture aspirin appears to be the 
      major nephrotoxic agent while phenacetin plays a synergistic but secondary role 
      in the renal nephrotoxicity.
FAU - Nanra, R S
AU  - Nanra RS
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 0 (Drug Combinations)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arthritis, Rheumatoid/complications
MH  - Aspirin/*adverse effects/toxicity
MH  - Drug Combinations
MH  - Humans
MH  - Kidney Cortex/pathology
MH  - Kidney Medulla/pathology
MH  - Kidney Papillary Necrosis/*chemically induced/complications/pathology
MH  - Phenacetin/*adverse effects/toxicity
MH  - Rats
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Aust N Z J Med. 1976;6 Suppl 1:Suppl 1:33-7.

PMID- 28045119
OWN - NLM
STAT- MEDLINE
DCOM- 20181018
LR  - 20190109
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 7
DP  - 2017 Jan 3
TI  - The Molecular Structure of Human Red Blood Cell Membranes from Highly Oriented, 
      Solid Supported Multi-Lamellar Membranes.
PG  - 39661
LID - 10.1038/srep39661 [doi]
LID - 39661
AB  - We prepared highly oriented, multi-lamellar stacks of human red blood cell (RBC) 
      membranes applied on silicon wafers. RBC ghosts were prepared by hemolysis and 
      applied onto functionalized silicon chips and annealed into multi-lamellar RBC 
      membranes. High resolution X-ray diffraction was used to determine the molecular 
      structure of the stacked membranes. We present direct experimental evidence that 
      these RBC membranes consist of nanometer sized domains of integral coiled-coil 
      peptides, as well as liquid ordered (l(o)) and liquid disordered (l(d)) lipids. 
      Lamellar spacings, membrane and hydration water layer thicknesses, areas per 
      lipid tail and domain sizes were determined. The common drug aspirin was added to 
      the RBC membranes and found to interact with RBC membranes and preferably 
      partition in the head group region of the l(o) domain leading to a fluidification 
      of the membranes, i.e., a thinning of the bilayers and an increase in lipid tail 
      spacing. Our results further support current models of RBC membranes as patchy 
      structures and provide unprecedented structural details of the molecular 
      organization in the different domains.
FAU - Himbert, Sebastian
AU  - Himbert S
AD  - Department of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.
AD  - Department of Experimental Physics, Saarland University, Saarbrücken, Germany.
FAU - Alsop, Richard J
AU  - Alsop RJ
AD  - Department of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.
FAU - Rose, Markus
AU  - Rose M
AD  - Department of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.
FAU - Hertz, Laura
AU  - Hertz L
AD  - Research Center for Molecular Imaging and Screening, Saarland University, 
      Homburg/Saar, Germany.
FAU - Dhaliwal, Alexander
AU  - Dhaliwal A
AD  - Department of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.
FAU - Moran-Mirabal, Jose M
AU  - Moran-Mirabal JM
AD  - Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, 
      Canada.
FAU - Verschoor, Chris P
AU  - Verschoor CP
AD  - Department of Pathology and Molecular Medicine, McMaster University, Hamilton, 
      Canada.
AD  - McMaster Immunology Research Center, McMaster University, Hamilton, Canada.
AD  - Michael G. DeGroote Institute for Infectious Disease Research, McMaster 
      University, Hamilton, Canada.
FAU - Bowdish, Dawn M E
AU  - Bowdish DM
AD  - Department of Pathology and Molecular Medicine, McMaster University, Hamilton, 
      Canada.
AD  - McMaster Immunology Research Center, McMaster University, Hamilton, Canada.
AD  - Michael G. DeGroote Institute for Infectious Disease Research, McMaster 
      University, Hamilton, Canada.
FAU - Kaestner, Lars
AU  - Kaestner L
AD  - Research Center for Molecular Imaging and Screening, Saarland University, 
      Homburg/Saar, Germany.
AD  - Department of Experimental Physics, Saarland University, Saarbrücken, Germany.
FAU - Wagner, Christian
AU  - Wagner C
AD  - Department of Experimental Physics, Saarland University, Saarbrücken, Germany.
FAU - Rheinstädter, Maikel C
AU  - Rheinstädter MC
AD  - Department of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170103
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - R16CO5Y76E (Aspirin)
RN  - Z4152N8IUI (Silicon)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - Erythrocyte Membrane/*chemistry/drug effects
MH  - Humans
MH  - Molecular Structure
MH  - Silicon/chemistry
MH  - X-Ray Diffraction
PMC - PMC5206716
EDAT- 2017/01/04 06:00
MHDA- 2018/10/20 06:00
CRDT- 2017/01/04 06:00
PHST- 2016/10/11 00:00 [received]
PHST- 2016/11/24 00:00 [accepted]
PHST- 2017/01/04 06:00 [entrez]
PHST- 2017/01/04 06:00 [pubmed]
PHST- 2018/10/20 06:00 [medline]
AID - srep39661 [pii]
AID - 10.1038/srep39661 [doi]
PST - epublish
SO  - Sci Rep. 2017 Jan 3;7:39661. doi: 10.1038/srep39661.

PMID- 2260148
OWN - NLM
STAT- MEDLINE
DCOM- 19910129
LR  - 20161122
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 21
IP  - 12 Suppl
DP  - 1990 Dec
TI  - Aspirin reduces the growth of medial and neointimal thickenings in 
      balloon-injured rat carotid arteries.
PG  - IV44-5
AB  - We analyzed the effect of Aspirin on the growth of experimentally induced 
      vascular thickenings in rat carotid arteries. Vascular thickenings were induced 
      by denudation of the endothelium in the left carotid artery with a balloon 
      catheter. Administration of Aspirin-rich food (17.4 g/kg body wt/day) was started 
      1 week before and continued 2 weeks after injury. Nine rats were used. A control 
      group of equal size received normal food. Sizes of the tunica media, the 
      neointima, and the open vessel lumen were measured on cross sections of carotid 
      segments with the aid of a videomorphometry system. The results show that in the 
      Aspirin group, neointimal lesions are significantly smaller than in the control 
      group (0.14 mm2 versus 0.23 mm2; p less than 0.5). Thickenings of the tunica 
      media are also reduced (0.11 mm2 versus 0.12 mm2; p less than 0.5). It is 
      suggested that Aspirin reduces both medial hypertrophy and neointimal outgrowth 
      in injury-induced atherosclerosis.
FAU - Völker, W
AU  - Völker W
AD  - Institute for Arteriosclerosis Research, University of Münster, FRG.
FAU - Faber, V
AU  - Faber V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Carotid Arteries/pathology
MH  - Carotid Artery Diseases/pathology/*prevention & control
MH  - *Carotid Artery Injuries
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
PST - ppublish
SO  - Stroke. 1990 Dec;21(12 Suppl):IV44-5.

PMID- 10868447
OWN - NLM
STAT- MEDLINE
DCOM- 20001205
LR  - 20190814
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 35
IP  - 5
DP  - 2000 May
TI  - Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy 
      volunteers. A gastroscopic study.
PG  - 464-9
AB  - BACKGROUND: Clopidogrel is a new antiplatelet agent that offers increased 
      protection over aspirin in preventing vascular ischaemic events in patients with 
      symptomatic atherosclerosis. In a large, randomized, international study of 
      clopidogrel and aspirin (n = 19,185 patients) clopidogrel was associated with a 
      lower incidence of gastrointestinal adverse events, including gastrointestinal 
      haemorrhage and hospitalizations because of gastrointestinal haemorrhage. The aim 
      of the study was to determine whether macroscopic differences in the gastric 
      mucosa between aspirin- and clopidogrel-treated subjects could be detected by 
      gastroscopy after short-term treatment. METHODS: Thirty-six healthy volunteers 
      were randomized in a double-blind, double-dummy, parallel design, to 75 mg/day of 
      clopidogrel or 325 mg/day of aspirin for 8 days. Gastroscopy was performed at 
      base line before administration of study drug and directly after treatment 
      completion. Gastroduodenal effects were measured in accordance with a modified 
      Lanza scale. RESULTS: At base line no difference between the groups was detected 
      (median Lanza score, 0.0 in both groups). At the end of treatment the aspirin 
      group showed a median score of 7.5, and the clopidogrel group showed an unchanged 
      median score of 0.0 (P < 0.001). In the aspirin group 13 individuals reported 19 
      adverse events versus 8 individuals and 13 adverse events for clopidogrel, with 
      approximately half of the adverse events being gastrointestinal in each group. No 
      serious adverse events were reported. CONCLUSION: In contrast to aspirin, 
      short-term treatment with clopidogrel does not induce macroscopic changes in the 
      gastroduodenal mucosa. The study results show that in patients without 
      gastroduodenal disease clopidogrel, but not aspirin, does not induce any 
      gastroscopically evident erosions during short-term treatment.
FAU - Fork, F T
AU  - Fork FT
AD  - Dept. of Diagnostic Radiology, and Sanofi Winthrop, Stockholm, Sweden.
FAU - Lafolie, P
AU  - Lafolie P
FAU - Tóth, E
AU  - Tóth E
FAU - Lindgärde, F
AU  - Lindgärde F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Double-Blind Method
MH  - Drug Hypersensitivity/etiology
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastritis/chemically induced
MH  - Gastroscopy
MH  - Humans
MH  - Intestinal Mucosa/*drug effects/pathology
MH  - Male
MH  - Patient Compliance
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
EDAT- 2000/06/27 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/06/27 11:00
PHST- 2000/06/27 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/06/27 11:00 [entrez]
AID - 10.1080/003655200750023705 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2000 May;35(5):464-9. doi: 10.1080/003655200750023705.

PMID- 22440946
OWN - NLM
STAT- MEDLINE
DCOM- 20120514
LR  - 20220410
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 379
IP  - 9826
DP  - 2012 Apr 28
TI  - Short-term effects of daily aspirin on cancer incidence, mortality, and 
      non-vascular death: analysis of the time course of risks and benefits in 51 
      randomised controlled trials.
PG  - 1602-12
LID - 10.1016/S0140-6736(11)61720-0 [doi]
AB  - BACKGROUND: Daily aspirin reduces the long-term risk of death due to cancer. 
      However, the short-term effect is less certain, especially in women, effects on 
      cancer incidence are largely unknown, and the time course of risk and benefit in 
      primary prevention is unclear. We studied cancer deaths in all trials of daily 
      aspirin versus control and the time course of effects of low-dose aspirin on 
      cancer incidence and other outcomes in trials in primary prevention. METHODS: We 
      studied individual patient data from randomised trials of daily aspirin versus no 
      aspirin in prevention of vascular events. Death due to cancer, all non-vascular 
      death, vascular death, and all deaths were assessed in all eligible trials. In 
      trials of low-dose aspirin in primary prevention, we also established the time 
      course of effects on incident cancer, major vascular events, and major 
      extracranial bleeds, with stratification by age, sex, and smoking status. 
      RESULTS: Allocation to aspirin reduced cancer deaths (562 vs 664 deaths; odds 
      ratio [OR] 0·85, 95% CI 0·76-0·96, p=0·008; 34 trials, 69,224 participants), 
      particularly from 5 years onwards (92 vs 145; OR 0·63, 95% CI 0·49-0·82, 
      p=0·0005), resulting in fewer non-vascular deaths overall (1021 vs 1173; OR 0·88, 
      95% CI 0·78-0·96, p=0·003; 51 trials, 77,549 participants). In trials in primary 
      prevention, the reduction in non-vascular deaths accounted for 87 (91%) of 96 
      deaths prevented. In six trials of daily low-dose aspirin in primary prevention 
      (35,535 participants), aspirin reduced cancer incidence from 3 years onwards (324 
      vs 421 cases; OR 0·76, 95% CI 0·66-0·88, p=0·0003) in women (132 vs 176; OR 0·75, 
      95% CI 0·59-0·94, p=0·01) and in men (192 vs 245; OR 0·77, 95% CI 0·63-0·93, 
      p=0·008). The reduced risk of major vascular events on aspirin was initially 
      offset by an increased risk of major bleeding, but effects on both outcomes 
      diminished with increasing follow-up, leaving only the reduced risk of cancer 
      (absolute reduction 3·13 [95% CI 1·44-4·82] per 1000 patients per year) from 3 
      years onwards. Case-fatality from major extracranial bleeds was also lower on 
      aspirin than on control (8/203 vs 15/132; OR 0·32, 95% CI 0·12-0·83, p=0·009). 
      INTERPRETATION: Alongside the previously reported reduction by aspirin of the 
      long-term risk of cancer death, the short-term reductions in cancer incidence and 
      mortality and the decrease in risk of major extracranial bleeds with extended 
      use, and their low case-fatality, add to the case for daily aspirin in prevention 
      of cancer. FUNDING: None.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Rothwell, Peter M
AU  - Rothwell PM
AD  - Stroke Prevention Research Unit, Nuffield Department of Clinical Neuroscience, 
      University of Oxford, UK. peter.rothwell@clneuro.ox.ac.uk
FAU - Price, Jacqueline F
AU  - Price JF
FAU - Fowkes, F Gerald R
AU  - Fowkes FG
FAU - Zanchetti, Alberto
AU  - Zanchetti A
FAU - Roncaglioni, Maria Carla
AU  - Roncaglioni MC
FAU - Tognoni, Gianni
AU  - Tognoni G
FAU - Lee, Robert
AU  - Lee R
FAU - Belch, Jill F F
AU  - Belch JF
FAU - Wilson, Michelle
AU  - Wilson M
FAU - Mehta, Ziyah
AU  - Mehta Z
FAU - Meade, Tom W
AU  - Meade TW
LA  - eng
GR  - 095626/Wellcome Trust/United Kingdom
GR  - G9534799/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120321
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2012 Apr 28;379(9826):1569-71. PMID: 22440945
CIN - Ann Intern Med. 2012 Jul 17;157(2):JC2-2, JC2-3. PMID: 22801694
CIN - Gastroenterology. 2012 Oct;143(4):1110-2. PMID: 22917866
CIN - Natl Med J India. 2012 Sep-Oct;25(5):284-6. PMID: 23448629
CIN - Urologe A. 2013 May;52(5):718. PMID: 23657775
MH  - Antineoplastic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Neoplasms/*epidemiology/mortality/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
EDAT- 2012/03/24 06:00
MHDA- 2012/05/15 06:00
CRDT- 2012/03/24 06:00
PHST- 2012/03/24 06:00 [entrez]
PHST- 2012/03/24 06:00 [pubmed]
PHST- 2012/05/15 06:00 [medline]
AID - S0140-6736(11)61720-0 [pii]
AID - 10.1016/S0140-6736(11)61720-0 [doi]
PST - ppublish
SO  - Lancet. 2012 Apr 28;379(9826):1602-12. doi: 10.1016/S0140-6736(11)61720-0. Epub 
      2012 Mar 21.

PMID- 15948729
OWN - NLM
STAT- MEDLINE
DCOM- 20050927
LR  - 20131121
IS  - 0919-8172 (Print)
IS  - 0919-8172 (Linking)
VI  - 12
IP  - 4
DP  - 2005 Apr
TI  - Antiplatelet therapy and spontaneous perirenal hematoma.
PG  - 398-400
AB  - This case report clarifies an adverse reaction of antiplatelet therapy which has 
      been a standard prophylactic method for patients harboring significant risks of 
      thromboembolic events. A 71-year-old Japanese man who had been taking aspirin 
      tablets (81 mg) for a year presented with sudden colic pain in the left flank 
      region. An abdominal computed tomography scan revealed a significant perirenal 
      hematoma of the left kidney. There were no pathological kidney conditions, such 
      as renal tumors, calculi or vascular diseases, found by magnetic resonance 
      imaging examination. After cessation of aspirin administration followed by 
      conservative management, the hematoma completely disappeared 6 months later. This 
      is the first documented case of spontaneous perirenal hematoma secondary to 
      low-dose aspirin treatment. While such unpleasant events occur extraordinarily, 
      this should be noted as a severe risk of antiplatelet therapy.
FAU - Yamamoto, Keisuke
AU  - Yamamoto K
AD  - Urology Service, Seikeikai Hospital and Clinics, Osaka, Japan.
FAU - Yasunaga, Yutaka
AU  - Yasunaga Y
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Australia
TA  - Int J Urol
JT  - International journal of urology : official journal of the Japanese Urological 
      Association
JID - 9440237
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdominal Pain/diagnosis/etiology
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Diagnosis, Differential
MH  - Follow-Up Studies
MH  - Hematoma/*chemically induced/complications/diagnosis
MH  - Humans
MH  - Ischemic Attack, Transient/prevention & control
MH  - Kidney Diseases/*chemically induced/complications/diagnosis
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Perineum
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Radiography, Abdominal
MH  - Rupture, Spontaneous
MH  - Tomography, X-Ray Computed
MH  - Urography
EDAT- 2005/06/14 09:00
MHDA- 2005/09/28 09:00
CRDT- 2005/06/14 09:00
PHST- 2005/06/14 09:00 [pubmed]
PHST- 2005/09/28 09:00 [medline]
PHST- 2005/06/14 09:00 [entrez]
AID - IJU1059 [pii]
AID - 10.1111/j.1442-2042.2005.01059.x [doi]
PST - ppublish
SO  - Int J Urol. 2005 Apr;12(4):398-400. doi: 10.1111/j.1442-2042.2005.01059.x.

PMID- 7469626
OWN - NLM
STAT- MEDLINE
DCOM- 19810413
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 141
IP  - 3 Spec No
DP  - 1981 Feb 23
TI  - Effects of aspirin and acetaminophen in pregnancy and in the newborn.
PG  - 358-63
AB  - Inhibitors of prostaglandin synthesis are increasingly recommended for delaying 
      premature delivery. However, such inhibitors--eg, aspirin, indomethacin, or 
      naproxen--may interfere with uterine contractility, with maternal, fetal, and 
      neonatal platelet function, and especially with fetal circulation and postnatal 
      adaptation. The instillation of aspirin (50 to 90 mg/kg of fetal body weight) 
      into the rumina of fetal lambs resulted in significant increase of pulmonary 
      arterial pressure, which was directly related to constriction of the ductus 
      arteriosus. Such pressure elevation may act as a stimulus to increased muscular 
      development in the small vessels of the lung, which, in turn, could interfere 
      with the rapid reduction in pulmonary vascular resistance normally occurring 
      after birth. The effects of acetaminophen in pregnancy and in the newborn have 
      not been studied extensively; when ingested in usual therapeutic doses, the 
      available data have shown no adverse effects.
FAU - Rudolph, A M
AU  - Rudolph AM
LA  - eng
GR  - HL 06285/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Prostaglandins)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Abnormalities, Drug-Induced/etiology
MH  - Acetaminophen/*adverse effects
MH  - Animals
MH  - Aspirin/*adverse effects/metabolism
MH  - Blood Platelets/drug effects
MH  - Female
MH  - Fetus/*drug effects
MH  - Humans
MH  - Hypertension, Pulmonary/chemically induced/congenital
MH  - Indomethacin/adverse effects
MH  - Infant, Newborn
MH  - Infant, Newborn, Diseases/chemically induced
MH  - Placenta/metabolism
MH  - Pregnancy/*drug effects
MH  - Prostaglandins/biosynthesis
MH  - Pulmonary Circulation/drug effects
MH  - Rabbits
MH  - Rats
EDAT- 1981/02/23 00:00
MHDA- 1981/02/23 00:01
CRDT- 1981/02/23 00:00
PHST- 1981/02/23 00:00 [pubmed]
PHST- 1981/02/23 00:01 [medline]
PHST- 1981/02/23 00:00 [entrez]
AID - 10.1001/archinte.141.3.358 [doi]
PST - ppublish
SO  - Arch Intern Med. 1981 Feb 23;141(3 Spec No):358-63. doi: 
      10.1001/archinte.141.3.358.

PMID- 36041069
OWN - NLM
STAT- MEDLINE
DCOM- 20221103
LR  - 20221128
IS  - 1945-1474 (Electronic)
IS  - 1062-2551 (Linking)
VI  - 44
IP  - 6
DP  - 2022 Nov-Dec 01
TI  - Standardizing Screening for Preeclampsia Risk Factors to Improve Prescribing of 
      Low-Dose Aspirin.
PG  - 324-330
LID - 10.1097/JHQ.0000000000000362 [doi]
AB  - Preeclampsia is a serious health condition and leading cause of perinatal and 
      neonatal morbidity and mortality. Research supports the use of low-dose aspirin 
      therapy to prevent preeclampsia in high-risk pregnant people. This quality 
      improvement project outlines the implementation of a preeclampsia risk screen in 
      the electronic health record to ensure standardized screening for, and provision 
      of, low-dose aspirin therapy consistent with professional guidelines. Two 
      thousand three hundred seventy-one patients were seen between March and November 
      2020 at 13 OB/GYN and family practice offices at a large health system in our 
      state. Provider screening and prescribing rates were evaluated at the first 
      prenatal visit, and at 3-month intervals using an analytics dashboard built in 
      the EHR. In the first 3 months after rollout visits at all offices in our system 
      (March to May 2020), the average screening rate during first prenatal visits at 
      all offices was 74.2% (n = 561), 41% (n = 230) had a positive screen, and 81.3% 
      (n = 187) of those who screened high risk were prescribed aspirin as recommended. 
      At 9 months after rollout, the screening rate during first prenatal visits at all 
      offices improved to 95.6% (n = 782), 39.6% (n = 310) of those screened, screened 
      positive, and 97.1% (n = 301) were prescribed low-dose aspirin therapy 
      appropriately.
CI  - Copyright © 2022 National Association for Healthcare Quality.
FAU - Burgess, Adriane
AU  - Burgess A
FAU - Dalke, Kara
AU  - Dalke K
FAU - Wheeling, Julia
AU  - Wheeling J
FAU - Clark, Kelley
AU  - Clark K
LA  - eng
PT  - Journal Article
DEP - 20220830
PL  - United States
TA  - J Healthc Qual
JT  - Journal for healthcare quality : official publication of the National Association 
      for Healthcare Quality
JID - 9202994
RN  - R16CO5Y76E (Aspirin)
MH  - Pregnancy
MH  - Female
MH  - Infant, Newborn
MH  - Humans
MH  - *Pre-Eclampsia/diagnosis/drug therapy/prevention & control
MH  - Aspirin/therapeutic use
MH  - Risk Factors
MH  - Mass Screening
COIS- The authors declare no conflicts of interest.
EDAT- 2022/08/31 06:00
MHDA- 2022/11/04 06:00
CRDT- 2022/08/30 15:02
PHST- 2022/08/31 06:00 [pubmed]
PHST- 2022/11/04 06:00 [medline]
PHST- 2022/08/30 15:02 [entrez]
AID - 01445442-202212000-00003 [pii]
AID - 10.1097/JHQ.0000000000000362 [doi]
PST - ppublish
SO  - J Healthc Qual. 2022 Nov-Dec 01;44(6):324-330. doi: 10.1097/JHQ.0000000000000362. 
      Epub 2022 Aug 30.

PMID- 26025549
OWN - NLM
STAT- MEDLINE
DCOM- 20160419
LR  - 20160512
IS  - 1618-2650 (Electronic)
IS  - 1618-2642 (Linking)
VI  - 407
IP  - 19
DP  - 2015 Jul
TI  - Unfolded partial least squares/residual bilinearization combined with the 
      Successive Projections Algorithm for interval selection: enhanced 
      excitation-emission fluorescence data modeling in the presence of the inner 
      filter effect.
PG  - 5649-59
LID - 10.1007/s00216-015-8745-8 [doi]
AB  - The use of the successive projections algorithm (SPA) for elimination of 
      uninformative variables in interval selection, and unfold partial least squares 
      regression (U-PLS) modeling of excitation-emission matrices (EEM), when under the 
      inner filter effect (IFE) is reported for first time. Post-calibration residual 
      bilinearization (RBL) was employed against events of unknown components in the 
      test samples. The inner filter effect can originate changes in both the shape and 
      intensity of analyte spectra, leading to trilinearity losses in both modes, and 
      thus invalidating most multiway calibration methods. The algorithm presented in 
      this paper was named iSPA-U-PLS/RBL. Both simulated and experimental data sets 
      were used to compare the prediction capability during: (1) simulated EEM; and (2) 
      quantitation of phenylephrine (PHE) in the presence of paracetamol (PAR) (or 
      acetaminophen) in water samples. Test sets containing unexpected components were 
      built in both systems [a single interference was taken into account in the 
      simulated data set, while water samples were added with varying amounts of 
      ibuprofen (IBU), and acetyl salicylic acid (ASA)]. The prediction results and 
      figures of merit obtained with the new algorithm were compared with those 
      obtained with U-PLS/RBL (without intervals selection), and with the well-known 
      parallel factors analysis (PARAFAC). In all cases, U-PLS/RBL displayed better EEM 
      handling capability in the presence of the inner filter effect compared with 
      PARAFAC. In addition, iSPA-U-PLS/RBL improved the results obtained with the full 
      U-PLS/RBL model, in this case demonstrating the potential of variable selection.
FAU - Gomes, Adriano de Araújo
AU  - Gomes Ade A
AD  - Departamento de Química, Laboratório de Automação e Instrumentação em Química 
      Analítica e Quimiometria (LAQA) Universidade Federal da Paraíba, CCEN, Caixa 
      Postal 5093, CEP, 58051-970, João Pessoa, PB, Brasil.
FAU - Schenone, Agustina V
AU  - Schenone AV
FAU - Goicoechea, Héctor C
AU  - Goicoechea HC
FAU - de Araújo, Mario Cesar U
AU  - de Araújo MC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150530
PL  - Germany
TA  - Anal Bioanal Chem
JT  - Analytical and bioanalytical chemistry
JID - 101134327
RN  - 1WS297W6MV (Phenylephrine)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/analysis
MH  - *Algorithms
MH  - Aspirin/analysis
MH  - Fluorescence
MH  - Ibuprofen/analysis
MH  - Least-Squares Analysis
MH  - *Models, Chemical
MH  - Phenylephrine/analysis
EDAT- 2015/05/31 06:00
MHDA- 2016/04/20 06:00
CRDT- 2015/05/31 06:00
PHST- 2014/12/17 00:00 [received]
PHST- 2015/04/27 00:00 [accepted]
PHST- 2015/03/31 00:00 [revised]
PHST- 2015/05/31 06:00 [entrez]
PHST- 2015/05/31 06:00 [pubmed]
PHST- 2016/04/20 06:00 [medline]
AID - 10.1007/s00216-015-8745-8 [doi]
PST - ppublish
SO  - Anal Bioanal Chem. 2015 Jul;407(19):5649-59. doi: 10.1007/s00216-015-8745-8. Epub 
      2015 May 30.

PMID- 17551995
OWN - NLM
STAT- MEDLINE
DCOM- 20071129
LR  - 20131121
IS  - 1053-8569 (Print)
IS  - 1053-8569 (Linking)
VI  - 16
IP  - 10
DP  - 2007 Oct
TI  - The impact of pharmaceuticals on the decline of cardiovascular mortality in 
      Germany.
PG  - 1167-76
AB  - PURPOSE: The effect of innovative medicines and surgical interventions on the 
      decline of (cardiovascular) mortality is often called into question. The increase 
      in general economic prosperity is often seen as the main reason for the 
      continuous increase in life expectancy. The purpose of this study is to 
      investigate the extent to which mortality from cardiovascular diseases has been 
      affected by pharmaceuticals and other medical interventions over the last 30 
      years in Germany. METHODS: Main outcome measures were the time series of direct 
      method death rates (DMDR) of cardiovascular and non-cardiovascular mortalities. 
      To control for socioeconomic and secular trends the difference between both time 
      series was calculated. The impact of interventions on mortality was analysed by 
      developing two linear regression models: The onset model analyses whether the 
      introduction of interventions influences mortality or not. The consumption model 
      estimates the quantitative impact of interventions in two phases. RESULTS: 
      Cardiovascular mortality as a percentage of total mortality fell from 40 to 38% 
      over the study period. All investigated interventions had statistically 
      significant effects on the decline of cardiovascular diseases, which is expressed 
      by the standardised regression coefficient: onset model: preventive behaviour 
      index (PBI) -8.3, angioplasty/CABG -0.6, antithrombotic agents -1.5, diuretics 
      -0.9, beta-blockers -1.0, calcium channel blockers -0.8 and ACE inhibitors -1.1 
      (all interventions p < 0.01); consumption model: innovative drugs phase I -7.5 (p 
      = 0.017), innovative drugs phase II -6.9 (p < 0.01), PBI -13.1 (p < 0.01) and 
      angioplasty/CABG -9.9 (p < 0.01). CONCLUSIONS: All innovative drug classes and 
      surgical interventions had a positive effect on the decline of cardiovascular 
      mortality.
FAU - Häussler, Bertram
AU  - Häussler B
AD  - IGES--institut für Gesundheits- und Sozialforschung GmbH, Berlin, Germany. 
      bh@iges.de
FAU - Schiffhorst, Guido
AU  - Schiffhorst G
FAU - Gothe, Holger
AU  - Gothe H
FAU - Hempel, Elke
AU  - Hempel E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Agents/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*mortality/surgery
MH  - Germany/epidemiology
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
EDAT- 2007/06/07 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/06/07 09:00
PHST- 2007/06/07 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/06/07 09:00 [entrez]
AID - 10.1002/pds.1428 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1167-76. doi: 10.1002/pds.1428.

PMID- 10591389
OWN - NLM
STAT- MEDLINE
DCOM- 19991214
LR  - 20190701
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 282
IP  - 21
DP  - 1999 Dec 1
TI  - Oral anticoagulant therapy in patients with coronary artery disease: a 
      meta-analysis.
PG  - 2058-67
AB  - CONTEXT: Despite years of use in coronary artery disease (CAD) and several 
      studies of its effectiveness, the role of oral anticoagulants (OAs) remains 
      controversial. OBJECTIVE: To determine the effects of long-term OA therapy, 
      stratified by the intensities of anticoagulation and aspirin therapy, on outcomes 
      in patients with CAD. DATA SOURCES: Studies were identified by MEDLINE, EMBASE, 
      and CURRENT CONTENTS searches (1960-July 1999) and by reviewing reference lists 
      and inquiring with experts and pharmaceutical companies. STUDY SELECTION: Studies 
      were included if they were published between 1960 and July 1999, were randomized, 
      had recruited patients with CAD, who had used OA therapy for at least 3 months. 
      Of 43 articles identified, 30 articles (31 trials) were analyzed. DATA 
      EXTRACTION: Information on type, duration, and method of monitoring OA therapy, 
      as well as rates of death, myocardial infarction (MI), thromboembolic 
      complications, stroke, and bleeding were abstracted by 2 independent observers. 
      DATA SYNTHESIS: With high-intensity (international normalized ratio [INR], 
      2.8-4.8) OAs vs control (16 trials, 10056 patients), clear reductions in 
      mortality (odds reduction [ORed], 22%; 95% confidence interval [CI], 13%-31%), 
      MIs (ORed, 42%; 95% CI, 34%-48%), and thromboembolic complications including 
      stroke (ORed, 63%; 95% CI, 53-71%) were observed, but were associated with a 
      6.0-fold (95% CI, 4.4- to 8.2-fold) increase in major bleeding. For moderate OAs 
      (INR, 2-3) vs control (4 trials, 1365 patients) the ORed for death was 18% (95% 
      CI, -6% to 37%); for MI, 52% (95% CI, 37%-64%); and for stroke, 53% (95% CI, 
      19%-73%), but it increased bleeding by 7.7-fold (95% CI, 3.3- to 18-fold). For 
      moderate- to high-intensity OAs (INR, > or =2) vs aspirin (7 trials, 3457 
      patients), no reduction in death, MI, or stroke was observed, and it was 
      associated with a 2.4-fold (95% CI, 1.6- to 3.6-fold) increase in major bleeding. 
      For moderate- to high-intensity OAs and aspirin vs aspirin alone (3 trials, 480 
      patients), the ORed for death, MI, or stroke was 56% (95% CI, 17%-77%) and major 
      bleeding increased by 1.9-fold (0.6- to 6.0-fold). For low-intensity OAs (INR, 
      <2.0) and aspirin vs aspirin alone (3 trials, 8435 patients), no significant 
      reduction in death, MI, or stroke was observed, and major bleeding increased by 
      1.3-fold (95% CI, 1.0- to 1.8-fold). CONCLUSIONS: Among patients with CAD, 
      high-intensity and moderate-intensity OA are effective in reducing MI and stroke 
      but increase the risk of bleeding. In the presence of aspirin, low-intensity OA 
      does not appear to be superior to aspirin alone, while moderate- to 
      high-intensity OA and aspirin vs aspirin alone appears promising and the bleeding 
      risk is modest, but this requires confirmation from ongoing trials.
FAU - Anand, S S
AU  - Anand SS
AD  - Program of Preventive Cardiology and Therapeutics, Hamilton Civic Hospitals 
      Research Centre, McMaster University, Ontario, Canada. anands@fhs.mcmaster.ca
FAU - Yusuf, S
AU  - Yusuf S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - JAMA 2000 Jul 5;284(1):45
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Disease/*drug therapy/physiopathology
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Myocardial Infarction/epidemiology/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk
MH  - Stroke/epidemiology/prevention & control
EDAT- 1999/12/11 09:00
MHDA- 2001/08/14 10:01
CRDT- 1999/12/11 09:00
PHST- 1999/12/11 09:00 [pubmed]
PHST- 2001/08/14 10:01 [medline]
PHST- 1999/12/11 09:00 [entrez]
AID - jma90015 [pii]
AID - 10.1001/jama.282.21.2058 [doi]
PST - ppublish
SO  - JAMA. 1999 Dec 1;282(21):2058-67. doi: 10.1001/jama.282.21.2058.

PMID- 23126042
OWN - NLM
STAT- MEDLINE
DCOM- 20121120
LR  - 20181202
IS  - 1330-0164 (Print)
IS  - 1330-0164 (Linking)
VI  - 65 Suppl 1
DP  - 2011 Sep
TI  - [Antiaggregation therapy after percutaneous coronary intervention in a patient 
      with thrombocytopenia: case report].
PG  - 139-42
AB  - Dual antiaggregation (antiplatelet) therapy is mandatory in patients having 
      received a stent during percutaneous coronary intervention. This therapy usually 
      consists of acetylsalicylic acid (100 mg per day) and clopidogrel (75 mg per day) 
      for at least 6 to 12 months (depending on the type of stent). Such therapy has 
      been shown to reduce significantly unwanted clinical events, although slightly 
      increasing the risk of bleeding. Coronary stents must rarely be implanted in 
      patients who have or develop thrombocytopenia. In such patients, the risk of 
      bleeding is increased manifold. On the other hand, the risk of potentially fatal 
      thrombotic events is unknown. In this case report, we present a patient who 
      developed thrombocytopenia shortly (one month) after the stent had been 
      implanted. After thorough clinical workup, we could not find the remediable cause 
      of thrombocytopenia. Because of the potential of acetylsalicylic acid to induce 
      thrombocytopenia, it was excluded from therapy and a double dose of clopidogrel 
      (150 mg per day) was introduced. Then we decided to evaluate platelet function 
      with the ADP aggregation test (which indicates the degree to which the function 
      of platelets is blocked by clopidogrel) and aspirin resistance test (which 
      indicates the degree to which the function of platelets is blocked by 
      acetylsalicylic acid). In the first set of tests, the patient was shown to be 
      hyperreactive to both substances. We then lowered the dose of clopidogrel to the 
      standard dose and evaluated the function of platelets with the same tests two 
      weeks later and the results were the same. Because the patient was without 
      obvious and laboratory signs of bleeding, we decided not to change the prescribed 
      antiplatelet therapy because of fear from potentially fatal thrombotic events. 
      The use of dual antiplatelet therapy in patients with thrombocytopenia is 
      particularly challenging. We believe that in such patients, firstly, the cause of 
      thrombocytopenia should be sought for by thorough clinical investigation. If not 
      found, as in our patient, tailoring of such therapy should be done using 
      currently available aggregation tests. In such a way, patients could be protected 
      from both excessive bleeding and potentially devastating thrombotic events. 
      Unfortunately, this is a sole example and definite conclusions could only be made 
      on larger studies.
FAU - Jerkić, Helena
AU  - Jerkić H
AD  - Merkur University Hospital, Department of Medicine, Division of Cardiology, 
      Zagreb, Croatia. helena.jerkic@zg.t-com.hr
FAU - Letilović, Tomislav
AU  - Letilović T
FAU - Skorić, Kristina Narancić
AU  - Skorić KN
FAU - Skorić, Bosko
AU  - Skorić B
FAU - Mestrović, Ivica Premuzić
AU  - Mestrović IP
FAU - Pocanić, Darko
AU  - Pocanić D
FAU - Kozmar, Damir
AU  - Kozmar D
FAU - Kranjcević, Stjepan
AU  - Kranjcević S
LA  - hrv
PT  - Case Reports
PT  - Journal Article
TT  - Antiagregacijska terapija nakon perkutane koronarne intervencije kod bolesnika s 
      trombocitopenijom--prikaz bolesnika.
PL  - Croatia
TA  - Acta Med Croatica
JT  - Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti
JID - 9208249
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clopidogrel
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - *Stents
MH  - Thrombocytopenia/*blood/etiology
MH  - Ticlopidine/administration & dosage/*analogs & derivatives
EDAT- 2011/09/01 00:00
MHDA- 2012/12/10 06:00
CRDT- 2012/11/07 06:00
PHST- 2012/11/07 06:00 [entrez]
PHST- 2011/09/01 00:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
PST - ppublish
SO  - Acta Med Croatica. 2011 Sep;65 Suppl 1:139-42.

PMID- 26479580
OWN - NLM
STAT- MEDLINE
DCOM- 20160929
LR  - 20220331
IS  - 1360-0451 (Electronic)
IS  - 0954-0121 (Print)
IS  - 0954-0121 (Linking)
VI  - 28
IP  - 4
DP  - 2016
TI  - Coronary artery disease risk reduction in HIV-infected persons: a comparative 
      analysis.
PG  - 475-82
LID - 10.1080/09540121.2015.1099602 [doi]
AB  - Despite an increased risk of coronary artery disease (CAD) in persons infected 
      with human immunodeficiency virus (HIV), few data are available on primary 
      prevention of CAD in this population. In this retrospective cohort study, 
      HIV-infected patients treated in an academic medical center HIV Specialty Clinic 
      between 1996 and 2010 were matched by age, gender, and ethnicity to a cohort of 
      presumed uninfected persons followed in an academic medical center Internal 
      Medicine primary care clinic. We compared CAD primary prevention care practices 
      between the two clinics, including use of aspirin, HMG-CoA reductase inhibitors 
      ("statins"), and anti-hypertensive drugs. CAD risk between the two groups was 
      assessed with 10-year Framingham CAD risk scores. In the comparative analysis, 
      890 HIV-infected persons were compared to 807 controls. Ten-year Framingham CAD 
      Risk Scores were similar in the two groups (median, 3; interquartile range [IQR], 
      0-5). After adjusting for relevant risk factors, HIV-infected persons were less 
      likely to be prescribed aspirin (odds ratio [OR] 0.53; 95% confidence interval 
      [CI], 0.40-0.71), statins (OR, 0.70; 95% CI, 0.53-0.92), and anti-hypertensive 
      drugs (OR, 0.63; 95% CI, 0.50-0.79) than persons in the control group. In 
      summary, when compared to demographically similar uninfected persons, 
      HIV-infected persons treated in an HIV specialty clinic were less likely to be 
      prescribed medications appropriate for CAD risk reduction. Improving primary 
      preventative CAD care in HIV specialty clinic populations is an important step 
      toward diminishing risk of heart disease in HIV-infected persons.
FAU - Okeke, Nwora Lance
AU  - Okeke NL
AD  - a Division of Infectious Diseases, Department of Medicine , Duke University 
      Medical Center , Durham , NC , USA.
FAU - Chin, Tammy
AU  - Chin T
AD  - b School of Medicine , The University of North Carolina , Chapel Hill , NC , USA.
FAU - Clement, Meredith
AU  - Clement M
AD  - a Division of Infectious Diseases, Department of Medicine , Duke University 
      Medical Center , Durham , NC , USA.
FAU - Chow, Shein-Chung
AU  - Chow SC
AD  - c Department of Biostatistics and Bioinformatics , Duke University School of 
      Medicine , Durham , NC , USA.
FAU - Hicks, Charles B
AU  - Hicks CB
AD  - d Division of Infectious Diseases, Department of Medicine , University of 
      California , San Diego , CA , USA.
LA  - eng
GR  - P30 AI064518/AI/NIAID NIH HHS/United States
GR  - T32 AI007392/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20151019
PL  - England
TA  - AIDS Care
JT  - AIDS care
JID - 8915313
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Case-Control Studies
MH  - Coronary Artery Disease/*prevention & control
MH  - Drug Prescriptions/*statistics & numerical data
MH  - Female
MH  - HIV Infections/*complications/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - *Practice Patterns, Physicians'
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Risk Reduction Behavior
PMC - PMC4784685
MID - NIHMS732665
OTO - NOTNLM
OT  - HIV
OT  - cardiovascular disease
OT  - clinical outcomes research
OT  - coronary artery disease
OT  - primary care
EDAT- 2015/10/20 06:00
MHDA- 2016/09/30 06:00
CRDT- 2015/10/20 06:00
PHST- 2015/10/20 06:00 [entrez]
PHST- 2015/10/20 06:00 [pubmed]
PHST- 2016/09/30 06:00 [medline]
AID - 10.1080/09540121.2015.1099602 [doi]
PST - ppublish
SO  - AIDS Care. 2016;28(4):475-82. doi: 10.1080/09540121.2015.1099602. Epub 2015 Oct 
      19.

PMID- 14502454
OWN - NLM
STAT- MEDLINE
DCOM- 20040212
LR  - 20181130
IS  - 0171-6425 (Print)
IS  - 0171-6425 (Linking)
VI  - 51
IP  - 4
DP  - 2003 Aug
TI  - Urgent or emergent coronary revascularization using bilateral internal thoracic 
      artery after previous clopidogrel antiplatelet therapy.
PG  - 185-9
AB  - BACKGROUND: Clopidogrel application before diagnostic or therapeutical 
      percutaneous coronary intervention has become the standard for stent thrombosis 
      prevention. Irreversible platelet inhibition causes increasing bleeding 
      complications if urgent coronary artery bypass grafting is necessary. This study 
      evaluates the effect on bleeding complications of clopidogrel in urgent CABG 
      using bilateral internal thoracic artery (ITA) and saphenous veins in all 
      patients. METHODS: We retrospectively analyzed 128 patients (operated between 
      January 2000 and September 2002) undergoing urgent or emergent CABG using both 
      ITAs, and compared 64 patients with previous clopidogrel and aspirin application 
      (within 5 days) to 64 patients without clopidogrel. We evaluated chest tube 
      output, re-exploration rate and necessity of blood products, ventilation time and 
      ICU stay. RESULTS: Both groups were comparable in age, gender, number of 
      performed anastomoses (mean 4/patient). Chest tube output (24 h) was higher in 
      the clopidogrel group at 977+/-628 ml vs. 788+/-389 ml (p=0.046), as was 
      re-exploration rate with 7.81% (5 of 64) vs. 0% (0 of 64) (p<0.005). The number 
      of blood products amounted to 2.7+/-1.9 U in the clopidogrel group vs. 1.9+/-1.6 
      U (p=0.013) for red cells, 0.05+/-0.9 U vs. 0.03+/-0.25 (p=0.0003) for platelets, 
      and 0.5+/-1.3 U vs. 0.2+/-1.0 U (p=0.14) for fresh frozen plasma. Mechanical 
      ventilation time was 11.9+/-9.7 h vs. 9.6+/-5.9 h (p=0.10), ICU stay 32.6+/-22.1 
      h vs. 27.8+/-18.2 h (p=0.19). CONCLUSIONS: Previous application of clopidogrel in 
      combination with aspirin before urgent CABG induces increased chest tube output, 
      re-exploration rate and necessity of blood products, especially platelets. 
      Nevertheless, routine use of both ITAs in patients after clopidogrel exposure can 
      be performed with acceptable bleeding complications.
FAU - Gansera, B
AU  - Gansera B
AD  - Department of Cardiovascular Surgery, Klinikum Bogenhausen, Munich, Germany. 
      herzchirurgie@kh-bogenhausen.de
FAU - Schmidtler, F
AU  - Schmidtler F
FAU - Spiliopoulos, K
AU  - Spiliopoulos K
FAU - Angelis, I
AU  - Angelis I
FAU - Neumaier-Prauser, P
AU  - Neumaier-Prauser P
FAU - Kemkes, B M
AU  - Kemkes BM
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thorac Cardiovasc Surg
JT  - The Thoracic and cardiovascular surgeon
JID - 7903387
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Transfusion
MH  - Chest Tubes
MH  - Clopidogrel
MH  - *Coronary Artery Bypass
MH  - Emergencies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Postoperative Hemorrhage/chemically induced
MH  - Reoperation
MH  - Retrospective Studies
MH  - Ticlopidine/adverse effects/*analogs & derivatives/*therapeutic use
EDAT- 2003/09/23 05:00
MHDA- 2004/02/13 05:00
CRDT- 2003/09/23 05:00
PHST- 2003/09/23 05:00 [pubmed]
PHST- 2004/02/13 05:00 [medline]
PHST- 2003/09/23 05:00 [entrez]
AID - 10.1055/s-2003-42260 [doi]
PST - ppublish
SO  - Thorac Cardiovasc Surg. 2003 Aug;51(4):185-9. doi: 10.1055/s-2003-42260.

PMID- 35041575
OWN - NLM
STAT- MEDLINE
DCOM- 20220503
LR  - 20220510
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 57
IP  - 5
DP  - 2022 May
TI  - Discontinuing low-dose acetylsalicylic acid after gastrointestinal bleeding is 
      associated with increased mortality.
PG  - 618-624
LID - 10.1080/00365521.2022.2026461 [doi]
AB  - BACKGROUND: Gastrointestinal bleeding is a common clinical problem in patients 
      using low-dose acetylsalicylic acid (ASA). It is uncertain whether aspirin should 
      continue to be used in patients who develop acute gastrointestinal bleeding 
      during low-dose ASA therapy. AIMS: To assess whether ASA should be continued in 
      patients who develop GI bleeding during low-dose ASA. METHODS: All patients 
      admitted to an academic hospital for acute gastrointestinal bleeding between 2009 
      and 2011 were reviewed retrospectively. Clinical characteristics, comorbidities, 
      medications and treatments were recorded from the patient records. Patients were 
      divided into two groups based on continuing or discontinuing ASA after discharge. 
      RESULTS: A total of 548 patients were included. ASA was continued in 282 (51.5%) 
      (ASAc group) and discontinued in 266 (48.5%) patients (ASAd group). ASAc patients 
      had more often coronary artery disease (57.8% vs. 42.5%, p < .001) and peripheral 
      artery disease (17.4% vs. 9.0%, p = .004) than ASAd patients, whereas no 
      differences were found in other comorbidities. There was no difference in 30-day 
      all-cause mortality between ASAd and ASAc groups. However, after adjustment for 
      age, gender and comorbidities, one-year all-cause mortality was double in the 
      ASAd group (hazard ratio 2.16, 95% confidence interval 1.39-3.35). ASAd and ASAc 
      groups did not differ with respect to cardiovascular mortality (4.9% vs. 5.3%, 
      p = .811, respectively) or re-bleeding (10.2% vs. 9.2%, p = .713, respectively). 
      CONCLUSION: Continuing low-dose ASA after gastrointestinal bleeding was 
      associated with lower all-cause mortality during the first year without 
      increasing the risk of re-bleeding.
FAU - Miilunpohja, Sami
AU  - Miilunpohja S
AUID- ORCID: 0000-0002-4631-9709
AD  - Heart Centre, Kuopio University Hospital, Kuopio, Finland.
AD  - Emergency Department, Kuopio University Hospital, Kuopio, Finland.
FAU - Jyrkkä, Johanna
AU  - Jyrkkä J
AD  - Assessment of Pharmacotherapies, Finnish Medicines Agency, Kuopio, Finland.
FAU - Kärkkäinen, Jussi M
AU  - Kärkkäinen JM
AD  - Heart Centre, Kuopio University Hospital, Kuopio, Finland.
AD  - Department of Surgery, Kuopio University Hospital, Kuopio, Finland.
FAU - Kastarinen, Helena
AU  - Kastarinen H
AD  - Insurance Medicine Unit, The Social Insurance Institution of Finland, Kuopio, 
      Finland.
FAU - Heikkinen, Markku
AU  - Heikkinen M
AD  - Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
FAU - Paajanen, Hannu
AU  - Paajanen H
AD  - Department of Surgery, Kuopio University Hospital, Kuopio, Finland.
AD  - Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, 
      University of Eastern Finland, Kuopio, Finland.
FAU - Rantanen, Tuomo
AU  - Rantanen T
AD  - Department of Surgery, Kuopio University Hospital, Kuopio, Finland.
AD  - Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, 
      University of Eastern Finland, Kuopio, Finland.
FAU - Hartikainen, Juha
AU  - Hartikainen J
AUID- ORCID: 0000-0003-0847-107X
AD  - Heart Centre, Kuopio University Hospital, Kuopio, Finland.
AD  - Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, 
      University of Eastern Finland, Kuopio, Finland.
LA  - eng
PT  - Journal Article
DEP - 20220118
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/adverse effects
MH  - Proportional Hazards Models
MH  - Retrospective Studies
OTO - NOTNLM
OT  - ASA
OT  - GI-bleeding
OT  - acetylsalicylic acid
OT  - morbidity
OT  - mortality
EDAT- 2022/01/19 06:00
MHDA- 2022/05/04 06:00
CRDT- 2022/01/18 17:19
PHST- 2022/01/19 06:00 [pubmed]
PHST- 2022/05/04 06:00 [medline]
PHST- 2022/01/18 17:19 [entrez]
AID - 10.1080/00365521.2022.2026461 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2022 May;57(5):618-624. doi: 
      10.1080/00365521.2022.2026461. Epub 2022 Jan 18.

PMID- 22326145
OWN - NLM
STAT- MEDLINE
DCOM- 20120720
LR  - 20131121
IS  - 1768-3254 (Electronic)
IS  - 0223-5234 (Linking)
VI  - 50
DP  - 2012 Apr
TI  - Assessment of antiplatelet activity of 2-aminopyrimidines.
PG  - 428-32
LID - 10.1016/j.ejmech.2012.01.035 [doi]
AB  - A series of 4,6-diaryl-2-aminopyrimidines was developed as antiplatelet agents 
      and their potency was evaluated by in vitro assay. Compound 14k was found to be 
      two times more potent than aspirin. These encouraging results could be helpful 
      for the development of new antiplatelet compounds.
CI  - Copyright Â© 2012 Elsevier Masson SAS. All rights reserved.
FAU - Giridhar, Rajani
AU  - Giridhar R
AD  - Pharmacy Department, Faculty of Technology and Engineering, Kalabhavan, The M. S. 
      University of Baroda, Vadodara 390 001, India. rajanimsu@rediffmail.com
FAU - Tamboli, Riyaj S
AU  - Tamboli RS
FAU - Ramajayam, R
AU  - Ramajayam R
FAU - Prajapati, Dhaval G
AU  - Prajapati DG
FAU - Yadav, M R
AU  - Yadav MR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120124
PL  - France
TA  - Eur J Med Chem
JT  - European journal of medicinal chemistry
JID - 0420510
RN  - 0 (4-(2'-hydroxy-4'-methoxyphenyl)-6-(2'',4''-dichlorophenyl)-2-aminopyrimidine)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 109-12-6 (2-aminopyrimidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Humans
MH  - Molecular Structure
MH  - Platelet Aggregation Inhibitors/chemical synthesis/*pharmacology
MH  - Pyrimidines/chemical synthesis/*chemistry/*pharmacology
MH  - Structure-Activity Relationship
EDAT- 2012/02/14 06:00
MHDA- 2012/07/21 06:00
CRDT- 2012/02/14 06:00
PHST- 2010/08/11 00:00 [received]
PHST- 2012/01/16 00:00 [revised]
PHST- 2012/01/17 00:00 [accepted]
PHST- 2012/02/14 06:00 [entrez]
PHST- 2012/02/14 06:00 [pubmed]
PHST- 2012/07/21 06:00 [medline]
AID - S0223-5234(12)00050-5 [pii]
AID - 10.1016/j.ejmech.2012.01.035 [doi]
PST - ppublish
SO  - Eur J Med Chem. 2012 Apr;50:428-32. doi: 10.1016/j.ejmech.2012.01.035. Epub 2012 
      Jan 24.

PMID- 8750402
OWN - NLM
STAT- MEDLINE
DCOM- 19961021
LR  - 20190920
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 17
IP  - 6
DP  - 1995 Nov-Dec
TI  - Gastrointestinal blood loss induced by bromfenac sodium, aspirin, and placebo.
PG  - 1110-7
AB  - The effects of bromfenac sodium, aspirin, and placebo on gastrointestinal (GI) 
      blood loss were compared. In a 22-day, randomized study, healthy men received 
      treatment with either bromfenac sodium 300 mg/d, aspirin 3900 mg/d, or placebo 
      for 10 days. On days 3 through 9 and days 20 through 22, all patients received 
      placebo. Fecal blood was measured using the chromium 51-labeled red blood cell 
      technique. Thirty-seven subjects entered the treatment period (13 in the aspirin 
      group, 12 in the bromfenac sodium group, and 12 in the placebo group). The mean 
      change in fecal blood loss during the treatment period compared with the baseline 
      period was significantly greater in the aspirin group (8.00 +/- 4.17 mL/d) than 
      in the bromfenac sodium group (1.63 +/- 1.01 mL/d). Blood loss in both the 
      aspirin and bromfenac sodium groups was significantly greater than in the placebo 
      group (-0.12 +/- 0.25 mL/d). It is concluded that bromfenac sodium 300 mg/d, a 
      higher daily dose than the proposed daily dose, causes significantly less GI 
      blood loss than aspirin 3900 mg/d.
FAU - Cohen, A
AU  - Cohen A
AD  - Peninsular Testing Corporation, Miami, Florida, USA.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Benzophenones)
RN  - 0 (Bromobenzenes)
RN  - 864P0921DW (bromfenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analgesics/administration & dosage/*adverse effects/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/blood/therapeutic use
MH  - Benzophenones/administration & dosage/*adverse effects/therapeutic use
MH  - Bromobenzenes/administration & dosage/*adverse effects/therapeutic use
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Occult Blood
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 0149-2918(95)80089-1 [pii]
AID - 10.1016/0149-2918(95)80089-1 [doi]
PST - ppublish
SO  - Clin Ther. 1995 Nov-Dec;17(6):1110-7. doi: 10.1016/0149-2918(95)80089-1.

PMID- 28621087
OWN - NLM
STAT- MEDLINE
DCOM- 20170915
LR  - 20181202
IS  - 2791-6421 (Electronic)
IS  - 0041-4301 (Linking)
VI  - 58
IP  - 5
DP  - 2016
TI  - The efficacy and safety of naproxen in acute rheumatic fever: The comparative 
      results of 11-year experience with acetylsalicylic acid and naproxen.
PG  - 473-479
LID - 1632 [pii]
LID - 10.24953/turkjped.2016.05.003 [doi]
AB  - The objective was to compare the efficacy and safety of naproxen (NXN) to 
      acetylsalicylic acid (ASA) in the treatment of acute rheumatic fever (ARF). The 
      data of 338 children were retrospectively analyzed. The patients were grouped 
      according to joint and valve involvement and also drug chosen [methyl 
      prednisolone (mPSL), ASA or NXN]. The treatment results and adverse events in 
      each group were compared. The mean age was 10.3 years and the median follow-up 
      was 62 months. Median time for normalization of acute phase reactants was 1 week 
      in patients given steroids and 2 weeks in patients given ASA or NXN. ASA was 
      replaced with NXN in 18 patients (10.2%) due to hepatic toxicity. The rate of 
      rebound, recurrence and the prevalence of rheumatic valve disease were not 
      different in patients given NXN, ASA or mPSL. In conclusion, NXN is a safe and 
      effective alternative to ASA in the treatment of ARF in children.
FAU - Çetin, İbrahim İlker
AU  - Çetin İİ
AD  - Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric 
      Cardiology Clinic, Ankara, Turkey.
FAU - Ekici, Filiz
AU  - Ekici F
AD  - Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric 
      Cardiology Clinic, Ankara, Turkey.
FAU - Kocabaş, Abdullah
AU  - Kocabaş A
AD  - Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric 
      Cardiology Clinic, Ankara, Turkey.
FAU - Çevik, Berna Şaylan
AU  - Çevik BŞ
AD  - Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric 
      Cardiology Clinic, Ankara, Turkey.
FAU - Eminoğlu, Sancar
AU  - Eminoğlu S
AD  - Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric 
      Cardiology Clinic, Ankara, Turkey.
FAU - Azak, Emine
AU  - Azak E
AD  - Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric 
      Cardiology Clinic, Ankara, Turkey.
FAU - Kibar, Ayşe Esin
AU  - Kibar AE
AD  - Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric 
      Cardiology Clinic, Ankara, Turkey.
FAU - Arı, Mehmet Emre
AU  - Arı ME
AD  - Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric 
      Cardiology Clinic, Ankara, Turkey.
FAU - Sürücü, Murat
AU  - Sürücü M
AD  - Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric 
      Cardiology Clinic, Ankara, Turkey.
FAU - Orgun, Ali
AU  - Orgun A
AD  - Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric 
      Cardiology Clinic, Ankara, Turkey.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Turkey
TA  - Turk J Pediatr
JT  - The Turkish journal of pediatrics
JID - 0417505
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Naproxen/adverse effects/*therapeutic use
MH  - Recurrence
MH  - Retrospective Studies
MH  - Rheumatic Fever/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - acute rheumatic fever
OT  - adverse events
OT  - efficacy
OT  - naproxen
EDAT- 2016/01/01 00:00
MHDA- 2017/09/16 06:00
CRDT- 2017/06/17 06:00
PHST- 2017/06/17 06:00 [entrez]
PHST- 2016/01/01 00:00 [pubmed]
PHST- 2017/09/16 06:00 [medline]
AID - 1632 [pii]
AID - 10.24953/turkjped.2016.05.003 [doi]
PST - ppublish
SO  - Turk J Pediatr. 2016;58(5):473-479. doi: 10.24953/turkjped.2016.05.003.

PMID- 9724312
OWN - NLM
STAT- MEDLINE
DCOM- 19981001
LR  - 20190308
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 275
IP  - 3
DP  - 1998 Sep
TI  - Acellular hemoglobin-mediated oxidative stress toward endothelium: a role for 
      ferryl iron.
PG  - H1046-53
LID - 10.1152/ajpheart.1998.275.3.H1046 [doi]
AB  - We tested the hypothesis that chemical modifications used to produce stable, 
      oxygen-carrying, Hb-based blood substitutes can induce cytotoxicity in 
      endothelial cells in culture because of altered redox activity. We examined the 
      interaction of hydrogen peroxide with nonmodified hemoglobin (HbA0) and two 
      chemically modified hemoglobins, alpha-cross-linked hemoglobin (alpha-DBBF) and 
      its polymerized form (poly-alpha-DBBF). Hydrogen peroxide-induced cell death (as 
      assessed by lactate dehydrogenase release) in bovine aortic endothelial cells 
      (BAEC) was completely inhibited by all three hemoglobin preparations, consistent 
      with their known pseudoperoxidase activity [hemoglobin consumes peroxide as it 
      cycles between ferric (Fe3+) and ferryl (Fe4+) hemes]. However, reaction of the 
      modified hemoglobins, but not HbA0, with hydrogen peroxide induced apoptotic cell 
      death (as assessed by morphological changes and DNA fragmentation) that 
      correlated with the formation of a long-lived ferrylhemoglobin. A preparation of 
      ferryl-alpha-DBBF free of residual peroxide rapidly induced morphological changes 
      and DNA fragmentation in BAEC, indicative of apoptotic cell death. Redox cycling 
      of chemically modified hemoglobins by peroxide yielded a persistent ferryl iron 
      that was cytotoxic to endothelial cells.
FAU - Goldman, D W
AU  - Goldman DW
AD  - Laboratory of Cellular Hematology, Center for Biologics Evaluation and Research, 
      Food and Drug Administration, Bethesda, Maryland 20892, USA.
FAU - Breyer, R J 3rd
AU  - Breyer RJ 3rd
FAU - Yeh, D
AU  - Yeh D
FAU - Brockner-Ryan, B A
AU  - Brockner-Ryan BA
FAU - Alayash, A I
AU  - Alayash AI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Iron Compounds)
RN  - 0 (Polymers)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 54651-57-9 (hemoglobin A(0))
RN  - 9034-51-9 (Hemoglobin A)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta
MH  - Apoptosis/drug effects
MH  - Aspirin/analogs & derivatives/chemistry
MH  - Cattle
MH  - Cell Death
MH  - Cross-Linking Reagents
MH  - DNA Fragmentation
MH  - Endothelium, Vascular/*metabolism
MH  - Hemoglobin A/metabolism/pharmacology
MH  - Hemoglobins/chemistry/*metabolism/pharmacology
MH  - Hydrogen Peroxide/pharmacology
MH  - Iron Compounds/*metabolism
MH  - L-Lactate Dehydrogenase/metabolism
MH  - *Oxidative Stress
MH  - Polymers
EDAT- 1998/09/02 05:27
MHDA- 1998/09/02 05:28
CRDT- 1998/09/02 05:27
PHST- 1998/09/02 05:27 [pubmed]
PHST- 1998/09/02 05:28 [medline]
PHST- 1998/09/02 05:27 [entrez]
AID - 10.1152/ajpheart.1998.275.3.H1046 [doi]
PST - ppublish
SO  - Am J Physiol. 1998 Sep;275(3):H1046-53. doi: 10.1152/ajpheart.1998.275.3.H1046.

PMID- 15028353
OWN - NLM
STAT- MEDLINE
DCOM- 20040406
LR  - 20191210
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 43
IP  - 6
DP  - 2004 Mar 17
TI  - Inhibition of platelet aggregation by aspirin progressively decreases in 
      long-term treated patients.
PG  - 979-84
AB  - OBJECTIVES: We sought to investigate, during a two-year follow-up period, the 
      effects of aspirin on platelet aggregation. BACKGROUND: The platelets of patients 
      given aspirin may be less sensitive to antiplatelet treatment, although the 
      extent of such phenomenon over long-term follow-up is unclear. METHODS: Adenosine 
      diphosphate (ADP) and collagen-induced platelet aggregation was periodically 
      monitored before and after 2, 6, 12, and 24 months of treatment with aspirin (n = 
      150) or ticlopidine (n = 80) in patients matched for gender, age, and risk 
      factors for atherothrombosis. RESULTS: Compared with baseline values, two months 
      of aspirin treatment significantly inhibited platelet aggregation; thereafter, 
      this inhibitory effect progressively decreased. At 24-month follow-up, 
      collagen-induced platelet aggregation was significantly higher than that observed 
      at two months (p < 0.05); a more pronounced difference was observed when 
      collagen-induced lag phase was considered (p < 0.01). Restoration of platelet 
      aggregation was less evident when ADP was used as an agonist. Conversely, the 
      inhibition induced by ticlopidine was constant throughout follow-up with both 
      agonists. CONCLUSIONS: The study demonstrates that a long-term treatment with 
      aspirin is associated with a progressive reduction in platelet sensitivity to 
      this drug.
FAU - Pulcinelli, Fabio M
AU  - Pulcinelli FM
AD  - Department of Experimental Medicine and Pathology, University La Sapienza, Viale 
      Regina Elena 324, 00161 Rome, Italy. fabio.pulcinelli@uniroma1.it
FAU - Pignatelli, Pasquale
AU  - Pignatelli P
FAU - Celestini, Andrea
AU  - Celestini A
FAU - Riondino, Silvia
AU  - Riondino S
FAU - Gazzaniga, Pier Paolo
AU  - Gazzaniga PP
FAU - Violi, Francesco
AU  - Violi F
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Collagen
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Ticlopidine/*pharmacology
EDAT- 2004/03/19 05:00
MHDA- 2004/04/07 05:00
CRDT- 2004/03/19 05:00
PHST- 2003/05/26 00:00 [received]
PHST- 2003/07/11 00:00 [revised]
PHST- 2003/08/05 00:00 [accepted]
PHST- 2004/03/19 05:00 [pubmed]
PHST- 2004/04/07 05:00 [medline]
PHST- 2004/03/19 05:00 [entrez]
AID - S0735109703017145 [pii]
AID - 10.1016/j.jacc.2003.08.062 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2004 Mar 17;43(6):979-84. doi: 10.1016/j.jacc.2003.08.062.

PMID- 28910463
OWN - NLM
STAT- MEDLINE
DCOM- 20171221
LR  - 20220603
IS  - 1553-9768 (Print)
IS  - 1553-9768 (Linking)
VI  - 17
IP  - 3
DP  - 2017 Fall
TI  - Use of Acetylsalicylic Acid in the Prehospital Setting for Suspected Acute 
      Ischemic Stroke.
PG  - 21-23
LID - YR2M-G4N4 [pii]
LID - 10.55460/YR2M-G4N4 [doi]
AB  - Acute ischemic stroke (AIS) treatment guidelines include various recommendations 
      for treatment once the patient arrives at the hospital. Prehospital care 
      recommendations, however, are limited to expeditious transport to a qualified 
      hospital and supportive care. The literature has insufficiently considered 
      prehospital antiplatelet therapy. An otherwise healthy 30-year-old black man 
      presented with headache for about 3 hours, left-sided facial and upper extremity 
      numbness, slurred speech, miosis, lacrimation, and general fatigue and malaise. 
      The presentation occurred at a time and location where appropriate resources to 
      manage potential AIS were limited. The patient received a thorough physical 
      examination and electrocardiogram. Acetylsalicylic acid (ASA) 325mg was 
      administered within 15 minutes of history and examination. A local host-nation 
      ambulance arrived approximately 30 minutes after presentation. The patient's 
      neurologic symptoms had abated by the time the ambulance arrived. The patient did 
      not undergo magnetic resonance imaging (MRI) until 72 hours after being admitted, 
      owing to lack of neurology staff over the weekend. The MRI showed evidence of a 
      left-sided, posteriorinferior cerebellar artery stroke. The patient was then 
      taken to a different hospital, where he received care for his acute stroke. The 
      patient eventually was prescribed a statin, ASA, and an angiotensin-converting 
      enzyme inhibitor. The patient has no lingering symptoms or neurologic deficits.
CI  - 2017.
FAU - Levri, John M
AU  - Levri JM
FAU - Ocon, Armando
AU  - Ocon A
FAU - Schunk, Paul
AU  - Schunk P
FAU - Cunningham, Cord W
AU  - Cunningham CW
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Spec Oper Med
JT  - Journal of special operations medicine : a peer reviewed journal for SOF medical 
      professionals
JID - 101158402
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Diagnosis, Differential
MH  - *Emergency Medical Services
MH  - Humans
MH  - Male
MH  - Military Personnel
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/diagnosis/*drug therapy
EDAT- 2017/09/15 06:00
MHDA- 2017/12/22 06:00
CRDT- 2017/09/15 06:00
PHST- 2017/09/01 00:00 [accepted]
PHST- 2017/09/15 06:00 [entrez]
PHST- 2017/09/15 06:00 [pubmed]
PHST- 2017/12/22 06:00 [medline]
AID - YR2M-G4N4 [pii]
AID - 10.55460/YR2M-G4N4 [doi]
PST - ppublish
SO  - J Spec Oper Med. 2017 Fall;17(3):21-23. doi: 10.55460/YR2M-G4N4.

PMID- 23142450
OWN - NLM
STAT- MEDLINE
DCOM- 20130930
LR  - 20220410
IS  - 1532-8406 (Electronic)
IS  - 0883-5403 (Linking)
VI  - 28
IP  - 4
DP  - 2013 Apr
TI  - Safety and efficacy of multimodal thromboprophylaxis following total knee 
      arthroplasty: a comparative study of preferential aspirin vs. routine coumadin 
      chemoprophylaxis.
PG  - 575-9
LID - S0883-5403(12)00572-4 [pii]
LID - 10.1016/j.arth.2012.08.004 [doi]
AB  - Multimodal thromboprophylaxis encompasses preoperative VTE risk stratification, 
      regional anesthesia, mechanical prophylaxis, and early mobilization. We 
      determined if aspirin can be safely used for adjuvant chemoprophylaxis in 
      patients who have a low thromboembolic risk. 1016 consecutive patients undergoing 
      TKA received multimodal thromboprophylaxis. Aspirin was used in 67% of patients 
      and Coumadin 33% (high risk patients, or who were on Coumadin before surgery). 
      This study group was compared to 1001 consecutive patients who received 
      multimodal thromboprophylaxis and routine Coumadin chemoprophylaxis. There was no 
      significant difference in rates of VTE, PE, bleeding, complications, readmission 
      and 90-day mortality between the two groups. There was a significantly higher 
      rate of wound related complications in the control group (p=0.03). Multimodal 
      thromboprophylaxis with aspirin given to the majority of patients at a low VTE 
      risk is safe and effective in patients undergoing primary TKA.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Gesell, Mark W
AU  - Gesell MW
AD  - Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY 
      10021, USA.
FAU - González Della Valle, Alejandro
AU  - González Della Valle A
FAU - Bartolomé García, Sergio
AU  - Bartolomé García S
FAU - Memtsoudis, Stavros G
AU  - Memtsoudis SG
FAU - Ma, Yan
AU  - Ma Y
FAU - Haas, Steven B
AU  - Haas SB
FAU - Salvati, Eduardo A
AU  - Salvati EA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20121108
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Chemoprevention
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Thromboembolism/*etiology/*prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2012/11/13 06:00
MHDA- 2013/10/01 06:00
CRDT- 2012/11/13 06:00
PHST- 2012/03/12 00:00 [received]
PHST- 2012/06/05 00:00 [revised]
PHST- 2012/08/05 00:00 [accepted]
PHST- 2012/11/13 06:00 [entrez]
PHST- 2012/11/13 06:00 [pubmed]
PHST- 2013/10/01 06:00 [medline]
AID - S0883-5403(12)00572-4 [pii]
AID - 10.1016/j.arth.2012.08.004 [doi]
PST - ppublish
SO  - J Arthroplasty. 2013 Apr;28(4):575-9. doi: 10.1016/j.arth.2012.08.004. Epub 2012 
      Nov 8.

PMID- 14675099
OWN - NLM
STAT- MEDLINE
DCOM- 20040220
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 1
IP  - 12
DP  - 2003 Dec
TI  - Safety of plasmin in the setting of concomitant aspirin and heparin 
      administration in an animal model of bleeding.
PG  - 2621-5
AB  - Plasmin is a direct thrombolytic which has been shown to have a strikingly 
      favorable benefit to risk profile in comparison with plasminogen activators, 
      notably tissue plasminogen activator (t-PA). As heparin is known to increase the 
      risk of hemorrhage when co-administered with a plasminogen activator, we asked 
      whether adjunct antithrombotic agents such as aspirin and heparin would affect 
      the safety of plasmin. Three groups of rabbits were administered plasmin at a 
      dose (4 mg kg-1) designed to induce significant decreases in antiplasmin, 
      fibrinogen and factor (F)VIII, to about 25, 40 and 40%, respectively, of baseline 
      values, but not cause prolongation of the ear puncture bleeding time. In a 
      blinded and randomized trial, the results show that an intravenous aspirin bolus 
      plus heparin administered as a bolus followed by a maintenance continuous 
      infusion did not significantly prolong the bleeding time during plasmin infusion. 
      These data indicate that in the rabbit, concomitant use of aspirin plus heparin 
      does not affect the safety of a therapeutic dose of plasmin.
FAU - Sadeghi, S
AU  - Sadeghi S
AD  - Vascular Medicine Program, Los Angeles Orthopedic Hospital, and David Geffen 
      School of Medicine at University of California Los Angeles, Los Angeles, 
      California 90007, USA.
FAU - Marder, V J
AU  - Marder VJ
FAU - Stewart, D
AU  - Stewart D
FAU - Kong, M
AU  - Kong M
FAU - Humphries, J
AU  - Humphries J
FAU - Baumbach, G A
AU  - Baumbach GA
FAU - Jesmok, G
AU  - Jesmok G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.7 (Fibrinolysin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/adverse effects
MH  - Bleeding Time
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Fibrinolysin/administration & dosage/adverse effects
MH  - Fibrinolytic Agents/*administration & dosage/*adverse effects
MH  - Hemorrhage/*chemically induced
MH  - Heparin/administration & dosage/adverse effects
MH  - Models, Animal
MH  - Rabbits
MH  - Thrombolytic Therapy/adverse effects
EDAT- 2003/12/17 05:00
MHDA- 2004/02/21 05:00
CRDT- 2003/12/17 05:00
PHST- 2003/12/17 05:00 [pubmed]
PHST- 2004/02/21 05:00 [medline]
PHST- 2003/12/17 05:00 [entrez]
AID - S1538-7836(22)15630-8 [pii]
AID - 10.1046/j.1538-7836.2003.00441.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2003 Dec;1(12):2621-5. doi: 10.1046/j.1538-7836.2003.00441.x.

PMID- 11798395
OWN - NLM
STAT- MEDLINE
DCOM- 20020313
LR  - 20131121
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 12
IP  - 8
DP  - 2001 Dec
TI  - Measurement of primary haemostasis using a pressure clamp technique.
PG  - 462-70
AB  - With the PFA-100 a sensitive and specific screening test for primary haemostasis 
      has recently become available. An important part of the device is a capillary, 
      providing a defined haemodynamic resistance for the perfusion of the aperture. A 
      modified method to measure platelet function (VCP2) is presented in which the 
      capillary essentially is replaced with an 'electronic capillary' by clamping the 
      pressure/flow relationship. RESULTS AND CONCLUSION: Closure time (CT) and blood 
      volume (BV) as determined by PFA-100 and VCP2 correlated well within (r = 0.922 - 
      0.952) and between the two methods (r = 0.86). The test variability (CV) of CT 
      could be significantly reduced in the VCP2 method (collagen/epi 3.9 vs. 5.9%, 
      p<0.05; collagen/ADP 3.3 vs. 6.9%, p<0.001), thus considerably increasing test 
      reliability and reducing test variance. In preliminary clinical studies the VCP2 
      system showed comparable sensitivity for vWD and slightly less sensitivity 
      regarding ASA ingestion. The test spectrum of VCP2 could be extended to more 
      thrombocytopenic samples (< or =20 000/microl) even in combination with low 
      haematocrit levels (20%), thus perhaps permitting the determination of the 
      bleeding risk in bone marrow hypoplasia. Additionally, the sensitivity and 
      applicability can easily be adapted to the desired need only by software 
      modifications.
FAU - Kretschmer, V
AU  - Kretschmer V
AD  - Department of Transfusion Medicine and Haemostaseology, University Hospital, 
      Marburg, Germany. kretschv@mailer.uni-marburg.de
FAU - Bade, S
AU  - Bade S
FAU - Weippert-Kretschmer, M
AU  - Weippert-Kretschmer M
FAU - Kratzer, M A
AU  - Kratzer MA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - R16CO5Y76E (Aspirin)
RN  - VBE72MCP5L (acetylsalicylsalicylic acid)
SB  - IM
MH  - Aspirin/*analogs & derivatives/analysis
MH  - Bleeding Time/instrumentation/*methods
MH  - Blood Platelets/*pathology/*physiology
MH  - Bone Marrow Diseases/blood
MH  - Capillaries
MH  - Female
MH  - Hematocrit
MH  - Hematologic Diseases/*blood
MH  - Hemostasis/*physiology
MH  - Humans
MH  - Male
MH  - Reproducibility of Results
MH  - Thrombocytopenia/blood
MH  - von Willebrand Diseases/blood
EDAT- 2002/01/19 10:00
MHDA- 2002/03/14 10:01
CRDT- 2002/01/19 10:00
PHST- 2002/01/19 10:00 [pubmed]
PHST- 2002/03/14 10:01 [medline]
PHST- 2002/01/19 10:00 [entrez]
AID - 10.1080/09537100120093965 [doi]
PST - ppublish
SO  - Platelets. 2001 Dec;12(8):462-70. doi: 10.1080/09537100120093965.

PMID- 8595061
OWN - NLM
STAT- MEDLINE
DCOM- 19960411
LR  - 20181212
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 45
IP  - 10
DP  - 1995 Oct
TI  - Metabolic fate of the new antithrombotic agent aspalatone in rats. In vivo and in 
      vitro study.
PG  - 1071-4
AB  - In order to determine whether aspalatone ([3-(2-methyl-4-pyronyl)]-2- 
      acetyloxybenzoate, CAS 147249-33-0), a new antiplatelet agent, behaves as a 
      prodrug of acetylsalicylic acid (ASA), metabolism studies in rats were carried 
      out in vivo and in vitro using the whole animal and tissue homogenates. The ASA 
      molecule was not detected in the plasma samples taken after oral administration 
      of aspalatone at 80 mg/kg. Instead, salicylic acid maltol ester (SM), the 
      deacetylated metabolite of aspalatone, was detected in the plasma and it was 
      rapidly hydrolyzed to salicylic acid. In in vitro experiments with rat serum, 
      intestinal fluid, liver and gastric mucosal homogenates, SM was the only compound 
      formed after 4 min incubation at 37 degrees C. From these results it was 
      concluded that aspalatone does not behave as a prodrug of ASA in rats. In 
      addition, the results of experiments using certain esterase inhibitors, suggested 
      the major contribution of B-esterase(s) in the metabolism of aspalatone to SM 
      particularly in serum and intestinal fluid.
FAU - Suh, D Y
AU  - Suh DY
AD  - Natural Products Research Institute, Seoul National University, Korea.
FAU - Yang, H O
AU  - Yang HO
FAU - Kim, Y C
AU  - Kim YC
FAU - Han, B H
AU  - Han BH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prodrugs)
RN  - 0 (Salicylates)
RN  - 0 (salicylic acid maltol ester)
RN  - A233M007P0 (aspalatone)
RN  - EC 3.1.- (Esterases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacokinetics
MH  - Biotransformation
MH  - Chromatography, High Pressure Liquid
MH  - Dealkylation
MH  - Esterases/antagonists & inhibitors
MH  - Fibrinolytic Agents/*pharmacokinetics
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Aggregation Inhibitors/*pharmacokinetics
MH  - Prodrugs
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Salicylates/metabolism
MH  - Spectrophotometry, Ultraviolet
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1995 Oct;45(10):1071-4.

PMID- 3097760
OWN - NLM
STAT- MEDLINE
DCOM- 19870107
LR  - 20190824
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 32
IP  - 3
DP  - 1986 Sep
TI  - Platelet aggregation and thromboxane release induced by arachidonic acid, 
      collagen, ADP and platelet-activating factor following low dose acetylsalicylic 
      acid in man.
PG  - 415-23
AB  - The present study was undertaken in order to characterize the dose-dependent 
      nature of acetylsalicylic acid (ASA) on platelet aggregation and plasma 
      thromboxane B2 (TXB2) release in healthy volunteers. Volunteers received either 
      25, 50, 100 or 500 mg daily for five consecutive days. At the end of the five day 
      period, all dosages of ASA were capable of completely suppressing TXB2 production 
      and arachidonic acid-induced platelet aggregation. At that time, the second phase 
      of ADP-induced aggregation was also blocked. However, while the inhibition 
      following 500 mg ASA was complete after 24 hours, total inhibition with 100, 50 
      and 25 mg was attained only after two, three and four days, respectively, 
      indicating the cumulative effect of ASA on platelets. Aggregation induced by 
      collagen was also inhibited dose-dependently- yet slower and at no time complete. 
      ASA had no inhibitory effect on aggregation by platelet-activating factor (PAF). 
      It is concluded that a daily dose of 50 mg ASA would suffice in blocking platelet 
      TXA2 production and aggregation induced by most physiological agents.
FAU - Küster, L J
AU  - Küster LJ
FAU - Frölich, J C
AU  - Frölich JC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Arachidonic Acids)
RN  - 0 (Platelet Activating Factor)
RN  - 0 (Thromboxanes)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/*pharmacology
MH  - Adolescent
MH  - Adult
MH  - Arachidonic Acid
MH  - Arachidonic Acids/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Collagen/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Activating Factor/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane B2/blood
MH  - Thromboxanes/*blood
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
AID - 0090-6980(86)90009-2 [pii]
AID - 10.1016/0090-6980(86)90009-2 [doi]
PST - ppublish
SO  - Prostaglandins. 1986 Sep;32(3):415-23. doi: 10.1016/0090-6980(86)90009-2.

PMID- 29478986
OWN - NLM
STAT- MEDLINE
DCOM- 20180601
LR  - 20180601
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 70
IP  - 6 pt 1
DP  - 2017
TI  - [high on-treatment platelet reactivity in patients with chronic renal failure 
      using acetylsalicylic acid].
PG  - 1102-1107
AB  - Cardiovascular diseases (CVD) are the most common cause of mortality in the 
      world. Acetylsalicylic acid (ASA) is a widely used medicine in primary and 
      secondary prevention of cardiovascular diseases. About 1-60% patients taking 
      aspirin have high platelet reactivity (HOPR) despite aspirin treatment. HOPR is 
      significantly more frequent in patients with chronic kidney disease (CKD) and it 
      increases the risk of adverse cardiovascular events in these patients. The cause 
      of HOPR in patients with CKD may be oxidative stress and inflammation. To the 
      risk factors belong diabetes, female sex or decreased HDL cholesterol level.
FAU - Horyniecki, Maciej
AU  - Horyniecki M
AD  - Katedra i Klinika Neurologii W Zabrzu, Śląski Uniwersytet Medyczny w Katowicach, 
      Zabrze, Polska.
FAU - Łącka-Gaździk, Beata
AU  - Łącka-Gaździk B
AD  - Katedra i Klinika Chorób Wewnętrznych, Diabetologii i Nefrologii, Śląski 
      Uniwersytet Medyczny w Katowicach, Katowice, Polska.
FAU - Dworaczek, Wojciech
AU  - Dworaczek W
AD  - III Oddział Psychiatrii, Szpital Psychiatryczny w Toszku, Toszek, Polska.
FAU - Śnit, Mirosław
AU  - Śnit M
AD  - Katedra i Klinika Chorób Wewnętrznych, Diabetologii i Nefrologii, Śląski 
      Uniwersytet Medyczny w Katowicach, Katowice, Polska.
FAU - Łabuz-Roszak, Beata
AU  - Łabuz-Roszak B
AD  - Katedra I Zakład Podstawowych Nauk Medycznych, Wydział Zdrowia Publicznego w 
      Bytomiu, Śląski Uniwersytet Medyczny w Katowicach, Bytom, Polska.
LA  - pol
PT  - Journal Article
PT  - Review
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Platelets/*physiology
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus, Type 2/complications
MH  - Female
MH  - Humans
MH  - Inflammation/complications
MH  - Kidney Failure, Chronic/complications
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Renal Insufficiency, Chronic/complications
MH  - Secondary Prevention/methods
OTO - NOTNLM
OT  - aspirin
OT  - chronic kidney disease
OT  - high on treatment platelet reactivity
EDAT- 2018/02/27 06:00
MHDA- 2018/06/02 06:00
CRDT- 2018/02/27 06:00
PHST- 2018/02/27 06:00 [entrez]
PHST- 2018/02/27 06:00 [pubmed]
PHST- 2018/06/02 06:00 [medline]
PST - ppublish
SO  - Wiad Lek. 2017;70(6 pt 1):1102-1107.

PMID- 12827329
OWN - NLM
STAT- MEDLINE
DCOM- 20040123
LR  - 20181113
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 59
IP  - 4
DP  - 2003 Aug
TI  - Does aspirin protect against Alzheimer's dementia? A study in a Swedish 
      population-based sample aged > or =80 years.
PG  - 313-9
AB  - OBJECTIVE: It has been reported that aspirin and other non-steroidal 
      anti-inflammatory drugs (NSAID) may protect against dementia of Alzheimer's type 
      and/or vascular dementia. However, co-morbidity and the dose of aspirin may be 
      critical. A major indication for low-dose aspirin is prophylaxis after stroke and 
      transient ischaemic attacks, conditions that may obscure an anti-dementia effect 
      by the drug. Alternatively, low-dose aspirin may be insufficient if the 
      protective effect is due to an anti-inflammatory mechanism. The aim of this study 
      was to assess whether high-dose or low-dose aspirin may protect against 
      Alzheimer's dementia in subjects aged > or =80 years. For comparison, effects of 
      (other) NSAID, paracetamol and D-propoxyphene were studied. METHODS: Global, 
      cross-sectional, and longitudinal (1991-2000) epidemiological analyses of 
      clinical, cognitive and drug treatment data on 702 individuals 80 years old or 
      more (351 twin pairs of same sex), all alive at inclusion: mean age 83.9 years 
      (80-99 years). Calculations were made with logistic regression of associations 
      between use of various analgesics and cognitive function, after adjustment for 
      age, gender, and cardiovascular and cerebrovascular diseases. RESULTS: Users of 
      high-dose aspirin had significantly lower prevalence of Alzheimer's dementia and 
      better-maintained cognitive function than non-users. There were numerically 
      similar but not significant associations with use of low-dose aspirin and other 
      NSAID. There were no such associations with use of either paracetamol or 
      D-propoxyphene. CONCLUSION: Aspirin might protect against Alzheimer's disease, 
      but controlled trials are warranted.
FAU - Nilsson, Sven E
AU  - Nilsson SE
AD  - Institute of Gerontology, School of Health Sciences, Jönköping University, 
      Jönköping, Sweden.
FAU - Johansson, Boo
AU  - Johansson B
FAU - Takkinen, Sanna
AU  - Takkinen S
FAU - Berg, Stig
AU  - Berg S
FAU - Zarit, Steven
AU  - Zarit S
FAU - McClearn, Gerald
AU  - McClearn G
FAU - Melander, Arne
AU  - Melander A
LA  - eng
GR  - AG 08861/AG/NIA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20030625
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*prevention & control
MH  - Analgesics, Non-Narcotic/therapeutic use
MH  - Analgesics, Opioid/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Cognition/drug effects
MH  - Cross-Sectional Studies
MH  - Dextropropoxyphene/therapeutic use
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Neuropsychological Tests
MH  - Sweden
MH  - Twins
EDAT- 2003/06/27 05:00
MHDA- 2004/01/24 05:00
CRDT- 2003/06/27 05:00
PHST- 2002/11/18 00:00 [received]
PHST- 2003/05/07 00:00 [accepted]
PHST- 2003/06/27 05:00 [pubmed]
PHST- 2004/01/24 05:00 [medline]
PHST- 2003/06/27 05:00 [entrez]
AID - 10.1007/s00228-003-0618-y [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2003 Aug;59(4):313-9. doi: 10.1007/s00228-003-0618-y. Epub 
      2003 Jun 25.

PMID- 16103468
OWN - NLM
STAT- MEDLINE
DCOM- 20050831
LR  - 20220309
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 143
IP  - 4
DP  - 2005 Aug 16
TI  - Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: 
      meta-analysis with estimates of risk and benefit.
PG  - 241-50
AB  - BACKGROUND: After the acute coronary syndrome, adding warfarin to standard 
      aspirin therapy decreases myocardial infarction and stroke but increases major 
      bleeding. PURPOSE: To quantify the risks and benefits of warfarin therapy after 
      the acute coronary syndrome. DATA SOURCES: MEDLINE from 1990 to October 2004. 
      Additional data were obtained from study authors. Clinical risk factors were used 
      to classify hypothetical patients into cardiovascular and bleeding risk groups on 
      the basis of published data. STUDY SELECTION: Randomized trials comparing 
      intensive warfarin therapy (international normalized ratio > 2.0) plus aspirin 
      with aspirin alone after the acute coronary syndrome. DATA EXTRACTION: Two 
      reviewers independently selected studies and extracted data on study design; 
      quality; and clinical outcomes, including myocardial infarction, stroke, 
      revascularization, death, and major and minor bleeding. Rate ratios for outcomes 
      were calculated and pooled by using the method of DerSimonian and Laird. DATA 
      SYNTHESIS: Ten trials involving a total of 5938 patients (11,334 patient-years) 
      met the study criteria. Compared with aspirin alone, warfarin plus aspirin was 
      associated with a decrease in the annual rate of myocardial infarction (0.022 vs. 
      0.041; rate ratio, 0.56 [95% CI, 0.46 to 0.69]), ischemic stroke (0.004 vs. 
      0.008; rate ratio, 0.46 [CI, 0.27 to 0.77]), and revascularization (0.115 vs. 
      0.135; rate ratio, 0.80 [CI, 0.67 to 0.95]). Warfarin was associated with an 
      increase in major bleeding (0.015 vs. 0.006; rate ratio, 2.5 [CI, 1.7 to 3.7]). 
      Mortality did not differ. LIMITATIONS: Two large studies provided most of the 
      data. Studies did not include coronary stenting, and results should not be 
      applied to patients with stents. Relative risk reductions may not be consistent 
      across risk groups. CONCLUSIONS: For patients with the acute coronary syndrome 
      who are at low or intermediate risk for bleeding, the cardiovascular benefits of 
      warfarin outweigh the bleeding risks.
FAU - Rothberg, Michael B
AU  - Rothberg MB
AD  - Division of General Medicine and Geriatrics, Baystate Medical Center, 
      Springfield, Massachusetts 01199, USA. Michael.Rothberg@bhs.org
FAU - Celestin, Carmel
AU  - Celestin C
FAU - Fiore, Louis D
AU  - Fiore LD
FAU - Lawler, Elizabeth
AU  - Lawler E
FAU - Cook, James R
AU  - Cook JR
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- Ann Intern Med. 2005 Aug 16;143(4):I14. PMID: 16103464
CIN - Evid Based Med. 2006 Apr;11(2):43. PMID: 17213073
MH  - Acute Disease
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Coronary Disease/*prevention & control
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Risk Assessment
MH  - Secondary Prevention
MH  - Syndrome
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2005/08/17 09:00
MHDA- 2005/09/01 09:00
CRDT- 2005/08/17 09:00
PHST- 2005/08/17 09:00 [pubmed]
PHST- 2005/09/01 09:00 [medline]
PHST- 2005/08/17 09:00 [entrez]
AID - 143/4/241 [pii]
AID - 10.7326/0003-4819-143-4-200508160-00005 [doi]
PST - ppublish
SO  - Ann Intern Med. 2005 Aug 16;143(4):241-50. doi: 
      10.7326/0003-4819-143-4-200508160-00005.

PMID- 33902301
OWN - NLM
STAT- MEDLINE
DCOM- 20220105
LR  - 20220105
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 52
IP  - 6
DP  - 2021 Jun
TI  - Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient 
      Ischemic Attack: Meta-Analysis of Randomized Controlled Trials.
PG  - e217-e223
LID - 10.1161/STROKEAHA.120.033033 [doi]
AB  - BACKGROUND AND PURPOSE: Antiplatelet therapy is key for preventing thrombotic 
      events after transient ischemic attack or ischemic stroke. Although the role of 
      aspirin is well established, there is emerging evidence for the role of 
      short-term dual antiplatelet therapy (DAPT) in preventing recurrent stroke. 
      METHODS: We conducted a systematic review and study-level meta-analyses of 
      randomized controlled trials comparing outcomes of early initiation of short-term 
      DAPT (aspirin+P2Y12 inhibitor for up to 3 months) versus aspirin alone in 
      patients with acute stroke or transient ischemic attack. Primary efficacy outcome 
      was risk of recurrent stroke and primary safety outcome was incidence of major 
      bleeding. Secondary outcomes studied were risk of any ischemic stroke, 
      hemorrhagic stroke, major adverse cardiovascular events, and all-cause death. 
      Pooled risk ratios (RRs) and CIs were calculated using a random-effects model. 
      RESULTS: Four trials with a total of 21 459 patients were included. As compared 
      to aspirin alone, DAPT had a lower risk of recurrent stroke (RR, 0.76 [95% CI, 
      0.68–0.83]; P<0.001; I2=0%) but a higher risk of major bleeding events (RR, 2.22 
      [95% CI, 1.14–4.34], P=0.02, I2=46.5%). Patients receiving DAPT had a lower risk 
      of major adverse cardiovascular events (RR, 0.76 [95% CI, 0.69–0.84], P<0.001, 
      I2=0%) and recurrent ischemic events (RR, 0.74 [95% CI, 0.67–0.82], P<0.001, 
      I2=0%). CONCLUSIONS: As compared to aspirin alone, short-term DAPT within 24 
      hours of high-risk transient ischemic attack or mild-moderate ischemic stroke 
      reduces the risk of recurrent stroke at the expense of higher risk of major 
      bleeding.
FAU - Bhatia, Kirtipal
AU  - Bhatia K
AD  - Department of Medicine, Icahn School of Medicine at Mount Sinai, NY (K.B.).
FAU - Jain, Vardhmaan
AU  - Jain V
AD  - Department of Medicine, Cleveland Clinic, Cleveland, OH (V.J.).
FAU - Aggarwal, Devika
AU  - Aggarwal D
AD  - Department of Medicine, Beaumont Hospital, Royal Oak, MI (D.A.).
FAU - Vaduganathan, Muthiah
AU  - Vaduganathan M
AD  - Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, MA (M.V.).
FAU - Arora, Sameer
AU  - Arora S
AD  - Cardiovascular Division, University of North Carolina School of Medicine, Chapel 
      Hill (S.A.).
FAU - Hussain, Zeeshan
AU  - Hussain Z
FAU - Uberoi, Guneesh
AU  - Uberoi G
AD  - Division of Cardiology, Loyola University School of Medicine, Maywood, IL. 
      Department of Medicine, Emory University School of Medicine, Atlanta, GA (G.U.).
FAU - Tafur, Alfonso
AU  - Tafur A
AD  - Section of Interventional Cardiology and Vascular Medicine, NorthShore University 
      Health System, Evanston, IL (A.T., M.R., A.Q.).
FAU - Zhang, Cen
AU  - Zhang C
AD  - Department of Neurology, New York University Grossman School of Medicine (C.Z.).
FAU - Ricciardi, Mark
AU  - Ricciardi M
AD  - Section of Interventional Cardiology and Vascular Medicine, NorthShore University 
      Health System, Evanston, IL (A.T., M.R., A.Q.).
FAU - Qamar, Arman
AU  - Qamar A
AD  - Section of Interventional Cardiology and Vascular Medicine, NorthShore University 
      Health System, Evanston, IL (A.T., M.R., A.Q.).
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210427
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dual Anti-Platelet Therapy/adverse effects/*methods
MH  - Hemorrhage/chemically induced/diagnosis
MH  - Humans
MH  - Ischemic Attack, Transient/diagnosis/*drug therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic/*methods
MH  - Stroke/diagnosis/*drug therapy
MH  - Time-to-Treatment
OTO - NOTNLM
OT  - aspirin
OT  - hemorrhage
OT  - incidence
OT  - ischemic attack, transient
OT  - ischemic stroke
EDAT- 2021/04/28 06:00
MHDA- 2022/01/06 06:00
CRDT- 2021/04/27 05:31
PHST- 2021/04/28 06:00 [pubmed]
PHST- 2022/01/06 06:00 [medline]
PHST- 2021/04/27 05:31 [entrez]
AID - 10.1161/STROKEAHA.120.033033 [doi]
PST - ppublish
SO  - Stroke. 2021 Jun;52(6):e217-e223. doi: 10.1161/STROKEAHA.120.033033. Epub 2021 
      Apr 27.

PMID- 29796686
OWN - NLM
STAT- MEDLINE
DCOM- 20181024
LR  - 20181114
IS  - 2737-5935 (Electronic)
IS  - 0037-5675 (Print)
IS  - 0037-5675 (Linking)
VI  - 59
IP  - 5
DP  - 2018 May
TI  - Traditional Chinese medicine: herb-drug interactions with aspirin.
PG  - 230-239
LID - 10.11622/smedj.2018051 [doi]
AB  - Traditional Chinese medicine (TCM)-based herbal therapies have gained increasing 
      popularity worldwide, raising concerns of its efficacy, safety profile and 
      potential interactions with Western medications. Antithrombotic agents are among 
      the most common prescription drugs involved in herb-drug interactions, and this 
      article focused on aspirin, one of the most widely used antiplatelet agents 
      worldwide. We discussed herbs that have potential interactions by exploring 
      Western and TCM approaches to thrombotic events. Common TCM indications for these 
      herbs were also highlighted, including possible scenarios of their concurrent 
      usage with aspirin. With greater awareness and understanding of potential 
      herb-drug interactions, TCM and Western physicians may collaborate more closely 
      to identify, treat and, most importantly, prevent adverse drug events.
CI  - Copyright: © Singapore Medical Association.
FAU - Lim, Jia Wei
AU  - Lim JW
AD  - University Medicine Cluster, National University Health System, Singapore.
FAU - Chee, Siow Xian
AU  - Chee SX
AD  - Eu Yan Sang Integrative Health Pte Ltd, Singapore.
FAU - Wong, Wen Jun
AU  - Wong WJ
AD  - Eu Yan Sang Integrative Health Pte Ltd, Singapore.
FAU - He, Qiu Ling
AU  - He QL
AD  - Eu Yan Sang Integrative Health Pte Ltd, Singapore.
FAU - Lau, Tang Ching
AU  - Lau TC
AD  - University Medicine Cluster, National University Health System, Singapore.
AD  - Division of Rheumatology, University Medicine Cluster, National University Health 
      System, Singapore.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Singapore Med J
JT  - Singapore medical journal
JID - 0404516
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Carthamus
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - *Herb-Drug Interactions
MH  - Humans
MH  - Medicine, Chinese Traditional
MH  - Panax
MH  - Physicians
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Salvia
MH  - Thrombosis/drug therapy
PMC - PMC5966631
OTO - NOTNLM
OT  - antiplatelet
OT  - aspirin
OT  - herb-drug interactions
OT  - traditional Chinese medicine
EDAT- 2018/05/26 06:00
MHDA- 2018/10/26 06:00
CRDT- 2018/05/26 06:00
PHST- 2018/05/26 06:00 [entrez]
PHST- 2018/05/26 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
AID - j59/5/230 [pii]
AID - SMJ-59-230 [pii]
AID - 10.11622/smedj.2018051 [doi]
PST - ppublish
SO  - Singapore Med J. 2018 May;59(5):230-239. doi: 10.11622/smedj.2018051.

PMID- 19434864
OWN - NLM
STAT- MEDLINE
DCOM- 20090720
LR  - 20191027
IS  - 0210-5705 (Print)
IS  - 0210-5705 (Linking)
VI  - 31 Suppl 4
DP  - 2008 Oct
TI  - [Update on gastrointestinal disorders associated with non-steroidal 
      anti-inflammatory drugs].
PG  - 35-41
AB  - The most recent studies presented at Digestive Disease Week 2008 on non-steroidal 
      anti-inflammatory drugs (NSAIDs) and aspirin have revealed the growing interest 
      of investigators in the adverse effects of these drugs in the lower 
      gastrointestinal (GI) tract. Some studies have shown that there is an increasing 
      time trend of lower GI events and a decreasing time trend of upper GI events, and 
      that the number of events associated with NSAIDs and/or aspirin located in the 
      lower GI tract is approaching that of events located in the upper GI tract. 
      Another area of growing research interest is the lack of appropriate 
      gastroprotective therapy in patients with risk factors who received NSAIDS or 
      aspirin. Several studies have investigated diverse aspects related to this area 
      and most indicate that at least 50% of at-risk patients treated with NSAIDs (or 
      aspirin) do not receive appropriate gastroprotective therapy. A personal analysis 
      of the data suggests that the risk factor most frequently associated with lack of 
      gastroprotection is age. Knowledge of risk factors and potential therapeutic 
      measures are appropriate among senior residents, but is not subsequently 
      translated into clinical practice. There is no easy solution to this problem 
      since, even within the best conditions of a mega-trial (MEDAL trial) with free 
      available gastroprotection and intervention during the trial, investigators could 
      not reach reasonable gastroprotection rates in at-risk patients.One potential 
      solution may come from combination pills (e.g., NSAID+proton pump inhibitor). One 
      study showed that this combination was associated with fewer gastroduodenal 
      lesions and could avoid the need to prescribe a gastroprotective agent and poor 
      compliance.
FAU - Lanas, Angel
AU  - Lanas A
AD  - Servicio de Aparato Digestivo, Hospital Clinico Universitario Lozano Blesa, 
      CIBEREHD, IACS, Universidad de Zaragoza, Zaragoza, España. angel.lanas@gmail.com
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Actualizació en enfermedad gastrointestinal relacionada con antiinflamatorios no 
      esteroideos.
PL  - Spain
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/therapeutic use
MH  - Gastrointestinal Diseases/*chemically induced/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Factors
EDAT- 2009/05/13 09:00
MHDA- 2009/07/21 09:00
CRDT- 2009/05/13 09:00
PHST- 2009/05/13 09:00 [entrez]
PHST- 2009/05/13 09:00 [pubmed]
PHST- 2009/07/21 09:00 [medline]
AID - S0210-5705(08)76627-5 [pii]
AID - 10.1016/s0210-5705(08)76627-5 [doi]
PST - ppublish
SO  - Gastroenterol Hepatol. 2008 Oct;31 Suppl 4:35-41. doi: 
      10.1016/s0210-5705(08)76627-5.

PMID- 8575110
OWN - NLM
STAT- MEDLINE
DCOM- 19960312
LR  - 20190825
IS  - 0305-1870 (Print)
IS  - 0305-1870 (Linking)
VI  - 22
IP  - 10
DP  - 1995 Oct
TI  - Effects of dietary fibre on dimethylhydrazine-induced changes in prostanoid 
      concentrations in rat colonic mucosa.
PG  - 739-42
AB  - 1. This study was designed to elucidate the effects of guar gum, a dietary fibre, 
      on changes in prostanoid contents induced by 1,2-dimethylhydrazine, a 
      carcinogenic agent, in rat colonic mucosa. 2. Prostanoid contents were determined 
      using high performance liquid chromatography; five prostanoids, namely 
      6-keto-prostaglandin F1 alpha, prostaglandin F2 alpha, prostaglandin E2, 
      prostaglandin D2 and thromboxane B2, were detected. 3. Four subcutaneous 
      injections of dimethylhydrazine, 60 mg/kg every 6 days, increased the mucosal 
      concentrations of prostaglandin E2 and thromboxane B2 by approximately 50%. Other 
      prostanoids did not change significantly throughout the experiments. 4. In rats 
      treated with dimethylhydrazine and a fibre diet a significant increase in 
      thromboxane B2 content was not observed, although a significant increase in 
      prostaglandin E2 content was observed. These effects were observed in rats fed 
      with fibre diet over 20 days but not observed in rats fed with fibre diet over 10 
      days. 5. From these results and the report that aspirin use at low doses is 
      effective in the reduction of the risk of fatal colonic cancer, inhibiting 
      thromboxane B2 synthesis by fibre diet might be involved in the protective effect 
      against the occurrence of colonic cancer.
FAU - Kanamori, S
AU  - Kanamori S
AD  - Department of Internal Medicine, Faculty of Medicine, University of Nagoya, 
      Japan.
FAU - Sugiyama, S
AU  - Sugiyama S
FAU - Goto, H
AU  - Goto H
FAU - Hayakawa, T
AU  - Hayakawa T
FAU - Shimomura, Y
AU  - Shimomura Y
FAU - Ozawa, T
AU  - Ozawa T
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Carcinogens)
RN  - 0 (Dietary Fiber)
RN  - 0 (Dimethylhydrazines)
RN  - 0 (Galactans)
RN  - 0 (Mannans)
RN  - 0 (Plant Gums)
RN  - 0 (Prostaglandins)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - E89I1637KE (guar gum)
RN  - IX068S9745 (1,2-Dimethylhydrazine)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - RXY07S6CZ2 (Prostaglandin D2)
SB  - IM
MH  - 1,2-Dimethylhydrazine
MH  - 6-Ketoprostaglandin F1 alpha/metabolism
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Carcinogens/administration & dosage/*pharmacology
MH  - Chromatography, High Pressure Liquid
MH  - Colon/chemistry/*drug effects
MH  - Colonic Neoplasms/prevention & control
MH  - Dietary Fiber/*pharmacology
MH  - Dimethylhydrazines/*pharmacology
MH  - Dinoprostone/metabolism
MH  - Galactans/*pharmacology
MH  - Injections, Subcutaneous
MH  - Intestinal Mucosa/chemistry/drug effects
MH  - Male
MH  - Mannans/*pharmacology
MH  - Plant Gums
MH  - Prostaglandin D2/metabolism
MH  - Prostaglandins/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thromboxane B2/metabolism
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - 10.1111/j.1440-1681.1995.tb01928.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 1995 Oct;22(10):739-42. doi: 
      10.1111/j.1440-1681.1995.tb01928.x.

PMID- 7361450
OWN - NLM
STAT- MEDLINE
DCOM- 19800523
LR  - 20131121
IS  - 0145-6296 (Print)
IS  - 0145-6296 (Linking)
VI  - 22
IP  - 1
DP  - 1980 Feb
TI  - Relative efficacy and palatability of three activated charcoal mixtures.
PG  - 6-9
AB  - The addition of bentonite with or without chocolate syrup improved the 
      palatability of activated charcoal preparations. Furthermore, bentonite did not 
      significantly reduce the efficacy of charcoal to absorb aspirin. Chocolate syrup 
      reduced the adsorption effectiveness significantly. The mixtures have a reduced 
      shelf-life when premixed with water. However, the dry ingredients can be 
      pre-weighed and sealed in a large jar. Water can be added just prior to 
      administration.
FAU - Navarro, R P
AU  - Navarro RP
FAU - Navarro, K R
AU  - Navarro KR
FAU - Krenzelok, E P
AU  - Krenzelok EP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Vet Hum Toxicol
JT  - Veterinary and human toxicology
JID - 7704194
RN  - 0 (Flavoring Agents)
RN  - 1302-78-9 (Bentonite)
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Adult
MH  - Aspirin/metabolism
MH  - Bentonite
MH  - Cacao
MH  - Charcoal/*administration & dosage/pharmacology
MH  - Flavoring Agents
MH  - Humans
MH  - Male
MH  - Taste
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
PST - ppublish
SO  - Vet Hum Toxicol. 1980 Feb;22(1):6-9.

PMID- 26422851
OWN - NLM
STAT- MEDLINE
DCOM- 20151030
LR  - 20171116
IS  - 1300-0144 (Print)
IS  - 1300-0144 (Linking)
VI  - 45
IP  - 4
DP  - 2015
TI  - The effects of aspirin, flurbiprofen, and NO-donating acetylsalicylic acid (NCX 
      4016) on mice models of endotoxic and septic shock.
PG  - 812-9
AB  - BACKGROUND/AIM: Nitric oxide-donating nonsteroidal antiinflammatory drugs 
      (NO-NSAIDs) are a promising new class of antiinflammatory agents, which are 
      obtained by adding NO-donating moieties to the existing conventional NSAID 
      molecules. The aim of this study was to investigate the effects of aspirin, 
      flurbiprofen, and NO-donating acetylsalicylic acid (NCX 4016) on cecal ligation 
      and puncture (CLP) and endotoxin-induced septic shock (LPS) models in mice. 
      MATERIALS AND METHODS: Overall survival and spleen and liver weights were 
      monitored in LPS and CLP models. Histopathological examinations of liver and 
      spleen were performed at the end of the experimental protocols. RESULTS: NCX 4016 
      was able to reverse the increased spleen weight in CLP-operated animals, whereas 
      aspirin or flurbiprofen did not. Similar to the results of the CLP model, none of 
      the drugs modified the survival rates in the LPS model. Flurbiprofen in 
      particular produced significant histopathological damage in spleens and livers, 
      which was less significant with aspirin. NCX 4016 did not cause any liver damage. 
      CONCLUSION: NCX 4016 has the potential to be used in septic states, while special 
      attention has to be paid to the effects of aspirin and flurbiprofen on the liver 
      and spleen.
FAU - Ulu, Nadir
AU  - Ulu N
FAU - Iskit, Alper Bektaş
AU  - Iskit AB
FAU - Sökmensüer, Cenk
AU  - Sökmensüer C
FAU - Güç, Mustafa Oğuz
AU  - Güç MO
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Turkey
TA  - Turk J Med Sci
JT  - Turkish journal of medical sciences
JID - 9441758
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - *Disease Models, Animal
MH  - Flurbiprofen/*pharmacology
MH  - *Liver/drug effects/pathology
MH  - Male
MH  - Mice
MH  - *Shock, Septic/drug therapy/etiology/metabolism/mortality/pathology
MH  - *Spleen/drug effects/pathology
MH  - Treatment Outcome
EDAT- 2015/10/02 06:00
MHDA- 2015/10/31 06:00
CRDT- 2015/10/02 06:00
PHST- 2015/10/02 06:00 [entrez]
PHST- 2015/10/02 06:00 [pubmed]
PHST- 2015/10/31 06:00 [medline]
PST - ppublish
SO  - Turk J Med Sci. 2015;45(4):812-9.

PMID- 9184720
OWN - NLM
STAT- MEDLINE
DCOM- 19970728
LR  - 20131121
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 31
IP  - 6
DP  - 1997 Jun
TI  - Ticlopidine and aspirin therapy following implantation of coronary artery stents.
PG  - 770-2
AB  - A number of studies evaluated the pharmacologic management of patients with 
      coronary artery stents. Four studies demonstrated a low subacute thrombosis rate 
      with antiplatelet therapy without implementation of anticoagulant therapy. 
      However, in three of these trials conflicting results were reported regarding the 
      relative efficacy of various antiplatelet therapies. Given the limitations of 
      these studies, well-designed, randomized studies are necessary to assess the 
      relative superiority of antiplatelet regimens to determine the safest and most 
      effective treatment. Two clinical studies evaluated antiplatelet therapy compared 
      with anticoagulant therapy in patients receiving coronary artery stents. Compared 
      with conventional anticoagulant therapy, combined antiplatelet therapy with 
      ticlopidine and aspirin appears to reduce clinical cardiovascular events, stent 
      thrombosis, and hemorrhagic complications. Despite the potential benefits of 
      therapy with ticlopidine observed in these studies, hematologic monitoring is 
      required to detect neutropenia that may occur during ticlopidine therapy. In 
      addition, the potential benefits of combination therapy with ticlopidine and 
      aspirin apply only to patients at low risk as defined by the ACCP and ACC expert 
      panels. Until further data become available, high-risk patients should be managed 
      with conventional anticoagulation regimens. Studies are needed to determine 
      whether antiplatelet therapy is effective in high-risk patients and the optimal 
      antiplatelet therapy (ticlopidine, aspirin, or ticlopidine/aspirin) for the 
      management of patients with coronary artery stents.
FAU - Hobson, A G
AU  - Hobson AG
AD  - School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN, 
      USA.
FAU - Sowinski, K M
AU  - Sowinski KM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary/*adverse effects
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/therapy
MH  - Coronary Thrombosis/etiology/*prevention & control
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Stents/*adverse effects
MH  - Ticlopidine/*administration & dosage/therapeutic use
RF  - 16
EDAT- 1997/06/01 00:00
MHDA- 1997/06/01 00:01
CRDT- 1997/06/01 00:00
PHST- 1997/06/01 00:00 [pubmed]
PHST- 1997/06/01 00:01 [medline]
PHST- 1997/06/01 00:00 [entrez]
PST - ppublish
SO  - Ann Pharmacother. 1997 Jun;31(6):770-2.

PMID- 8088892
OWN - NLM
STAT- MEDLINE
DCOM- 19941020
LR  - 20131121
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 99
DP  - 1994 Jun
TI  - Mechanism of aspirin induced neural tube defect in chick embryo.
PG  - 289-94
AB  - The effect of acetyl salicylic acid (aspirin) on neural tube development in chick 
      embryo was studied, using the chick embryo blastoderm model. Aspirin was injected 
      in four different doses sub-blastodermally into fresh embryonated eggs. The role 
      of PGE1 and PGE2 alpha in the defect induced by aspirin on neural tube 
      development in chick embryo was studied. PGE1 (5 micrograms) given after aspirin 
      (30 micrograms) treatment was found to produce greater defect in development. All 
      the four doses of aspirin used (i.e., 6, 30, 60 and 120 micrograms/embryo) 
      produced significant changes (P < 0.01) in the neural tube development of chick 
      embryo. Pre-treatment with PGE1 did not modify the defect induced by aspirin, 
      whereas pre-treatment with PGF2 alpha prevented neural tube defects induced by 
      aspirin. It appears that aspirin (in the doses used) affects neural tube 
      formation by decreasing PGF2 alpha synthesis in chick embryo blastoderm.
FAU - Kotwani, A
AU  - Kotwani A
AD  - Department of Pharmacology, Maulana Azad Medical College, New Delhi.
FAU - Mehta, V L
AU  - Mehta VL
FAU - Iyengar, B
AU  - Iyengar B
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - B7IN85G1HY (Dinoprost)
RN  - F5TD010360 (Alprostadil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alprostadil/pharmacology
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Chick Embryo
MH  - Dinoprost/pharmacology
MH  - Neural Tube Defects/*chemically induced/embryology
EDAT- 1994/06/01 00:00
MHDA- 1994/06/01 00:01
CRDT- 1994/06/01 00:00
PHST- 1994/06/01 00:00 [pubmed]
PHST- 1994/06/01 00:01 [medline]
PHST- 1994/06/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Med Res. 1994 Jun;99:289-94.

PMID- 6631686
OWN - NLM
STAT- MEDLINE
DCOM- 19831217
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 72
IP  - 9
DP  - 1983 Sep
TI  - Stability of aspirin in different media.
PG  - 1024-6
AB  - Aspirin rapidly hydrolyzes in various aqueous, organic, and biological media. The 
      purpose of this investigation was to study the decomposition of aspirin in the 
      media that comes in contact with it during analysis in biological fluids for 
      pharmacokinetic studies. These media included water, water-polyethylene glycol 
      400, water-methanol-acetic acid, phosphate buffer, freshly drawn blood and plasma 
      from control rats and rats deprived of water for 36 hr, and blood precipitated 
      with acetonitrile. Studies were also conducted to determine the decomposition as 
      a function of temperature and pH. Of the various solvent systems studied, aspirin 
      was found most stable in water-polyethylene glycol (4:1, v/v),which provides an 
      excellent medium for preparation of intravenous dosage forms. Phosphate buffer 
      showed significant catalysis of aspirin hydrolysis. A more than fivefold increase 
      in the hydrolysis of aspirin was noted when the temperature was raised to 37 
      degrees from 22.5 degrees. The hydrolysis of aspirin in rat blood was 13 times 
      faster than that in plasma, with an average half-life in blood of approximately 
      13 min. This creates significant problems in aspirin disposition kinetic studies. 
      Mixing the blood sample immediately after collection with twice the volume of 
      acetonitrile and thn en centrifuging gives a plasma-acetonitrile mixture in which 
      no lysis of blood cells is observed.
FAU - Bakar, S K
AU  - Bakar SK
FAU - Niazi, S
AU  - Niazi S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Solvents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Aspirin
MH  - Drug Stability
MH  - Half-Life
MH  - Hydrolysis
MH  - Rats
MH  - Solvents
EDAT- 1983/09/01 00:00
MHDA- 1983/09/01 00:01
CRDT- 1983/09/01 00:00
PHST- 1983/09/01 00:00 [pubmed]
PHST- 1983/09/01 00:01 [medline]
PHST- 1983/09/01 00:00 [entrez]
AID - S0022-3549(15)44751-3 [pii]
AID - 10.1002/jps.2600720914 [doi]
PST - ppublish
SO  - J Pharm Sci. 1983 Sep;72(9):1024-6. doi: 10.1002/jps.2600720914.

PMID- 19122933
OWN - NLM
STAT- MEDLINE
DCOM- 20090430
LR  - 20220311
IS  - 2737-5935 (Electronic)
IS  - 0037-5675 (Linking)
VI  - 49
IP  - 12
DP  - 2008 Dec
TI  - Spontaneous spinal epidural haematoma associated with aspirin intake.
PG  - e353-5
AB  - Spontaneous spinal epidural haematoma (SSEH) is rare. No identifiable cause is 
      found in the majority of cases, while anticoagulation accounts for up to 17 
      percent of cases. Aspirin-associated SSEH, however, has rarely been described in 
      literature. A 62-year-old man on prophylactic aspirin presented with symptoms of 
      acute cord compression due to spinal epidural haematoma that was confirmed on 
      magnetic resonance imaging. An emergency decompression laminectomy was performed 
      ten hours after the onset of his symptoms. No vascular anomaly was detected. Our 
      patient recovered well and regained full motor and sensory function. Aspirin is 
      unlikely to be the direct cause of SSEH but may predispose to it, with the 
      underlying cause being a locus minoris resistentiae, consisting of a network of 
      weakened epidural veins. Early diagnosis and treatment are essential for a 
      successful outcome.
FAU - Oh, J Y L
AU  - Oh JY
AD  - Department of Orthopaedic Surgery, Alexandra Hospital, 378 Alexandra Road, 
      Singapore 159964. jacob_oh@yahoo.com
FAU - Lingaraj, K
AU  - Lingaraj K
FAU - Rahmat, R
AU  - Rahmat R
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - India
TA  - Singapore Med J
JT  - Singapore medical journal
JID - 0404516
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Emergencies
MH  - Hematoma, Epidural, Spinal/*chemically induced/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2009/01/06 09:00
MHDA- 2009/05/01 09:00
CRDT- 2009/01/06 09:00
PHST- 2009/01/06 09:00 [entrez]
PHST- 2009/01/06 09:00 [pubmed]
PHST- 2009/05/01 09:00 [medline]
PST - ppublish
SO  - Singapore Med J. 2008 Dec;49(12):e353-5.

PMID- 15306054
OWN - NLM
STAT- MEDLINE
DCOM- 20040916
LR  - 20151119
IS  - 1431-9276 (Print)
IS  - 1431-9276 (Linking)
VI  - 10
IP  - 2
DP  - 2004 Apr
TI  - Atomic force microscopy studies on DNA structural changes induced by vincristine 
      sulfate and aspirin.
PG  - 286-90
AB  - We report that atomic force microscopy (AFM) studies on structural variations of 
      a linear plasmid DNA interact with various concentrations of vincristine sulfate 
      and aspirin. The different binding images show that vincrinstine sulfate binding 
      DNA chains caused some loops and cleavages of the DNA fragments, whereas aspirin 
      interaction caused the width changes and conformational transition of the DNA 
      fragments. Two different DNA structural alternations could be explained by the 
      different mechanisms of the interactions with these two components. Our work 
      indicates that the AFM is a powerful tool in studying the interaction between DNA 
      and small molecules.
FAU - Zhu, Yi
AU  - Zhu Y
AD  - Laboratory of Molecular and Biomolecular Electronics, Southeast University, 
      Nanjing 210096, P.R. China.
FAU - Zeng, Hu
AU  - Zeng H
FAU - Xie, Jianming
AU  - Xie J
FAU - Ba, Long
AU  - Ba L
FAU - Gao, Xiang
AU  - Gao X
FAU - Lu, Zuhong
AU  - Lu Z
LA  - eng
PT  - Journal Article
PL  - England
TA  - Microsc Microanal
JT  - Microscopy and microanalysis : the official journal of Microscopy Society of 
      America, Microbeam Analysis Society, Microscopical Society of Canada
JID - 9712707
RN  - 5J49Q6B70F (Vincristine)
RN  - 9007-49-2 (DNA)
RN  - EC 3.1.21.4 (Deoxyribonucleases, Type II Site-Specific)
RN  - EC 3.1.21.4 (GATATC-specific type II deoxyribonucleases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - DNA/*chemistry/*drug effects/*ultrastructure
MH  - Deoxyribonucleases, Type II Site-Specific
MH  - Microscopy, Atomic Force
MH  - Nucleic Acid Conformation
MH  - Plasmids/drug effects/*ultrastructure
MH  - Vincristine/*pharmacology
EDAT- 2004/08/13 05:00
MHDA- 2004/09/17 05:00
CRDT- 2004/08/13 05:00
PHST- 2002/10/29 00:00 [received]
PHST- 2004/08/13 05:00 [pubmed]
PHST- 2004/09/17 05:00 [medline]
PHST- 2004/08/13 05:00 [entrez]
AID - S1431927604040127 [pii]
AID - 10.1017/S1431927604040127 [doi]
PST - ppublish
SO  - Microsc Microanal. 2004 Apr;10(2):286-90. doi: 10.1017/S1431927604040127.

PMID- 487958
OWN - NLM
STAT- MEDLINE
DCOM- 19791220
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 18
IP  - 2
DP  - 1979 Aug
TI  - Role of antiplatelet agents in cerebrovascular disease.
PG  - 150-5
AB  - It is now generally accepted by neurologists that most transient ischaemic 
      attacks, particularly in the carotid artery territory, have a thromboembolic 
      basis. These emboli are, for the most part, fibrin-platelet aggregates. Others 
      which contain atheromatous debris are more likely to produce longer lasting 
      neurological deficits. If one assumes this hypothesis then it is reasonable to 
      employ drugs which interfere with platelet aggregation in order to prevent 
      cerebrovascular symptoms and signs. Acetylsalicylic acid (aspirin) prevents 
      aggregation by inhibiting the 'release reaction' initiated by thromboxane A2. 
      This inhibition lasts for the life of the affected platelets. Recent trials in 
      the United States and Canada have demonstrated a positive clinical benefit from 
      the employment of aspirin in patients suffering from transient cerebral ischaemic 
      attacks and amaurosis fugax. There was a reduction or cessation of the attacks in 
      both males and females and a 50% reduction of stroke morbidity and mortality in 
      males.
FAU - Fields, W S
AU  - Fields WS
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Fibrinolytic Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Blood Platelets/physiopathology
MH  - Cerebrovascular Disorders/*drug therapy/prevention & control
MH  - Dipyridamole/therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation
EDAT- 1979/08/01 00:00
MHDA- 1979/08/01 00:01
CRDT- 1979/08/01 00:00
PHST- 1979/08/01 00:00 [pubmed]
PHST- 1979/08/01 00:01 [medline]
PHST- 1979/08/01 00:00 [entrez]
AID - 10.2165/00003495-197918020-00007 [doi]
PST - ppublish
SO  - Drugs. 1979 Aug;18(2):150-5. doi: 10.2165/00003495-197918020-00007.

PMID- 19531172
OWN - NLM
STAT- MEDLINE
DCOM- 20091001
LR  - 20181201
IS  - 1749-4486 (Electronic)
IS  - 1749-4478 (Linking)
VI  - 34
IP  - 3
DP  - 2009 Jun
TI  - Clopidogrel versus low-dose aspirin as risk factors for epistaxis.
PG  - 232-5
LID - 10.1111/j.1749-4486.2009.01926.x [doi]
AB  - OBJECTIVES: To quantify the relative risk of epistaxis for patients taking 
      low-dose aspirin or clopidogrel compared to patients taking neither drug. DESIGN: 
      Case-control study. SETTING: Primary care. PARTICIPANTS: 10,241 patients from 
      three GP practices in the West Midlands. MAIN OUTCOME MEASURES: Epistaxis 
      resulting in presentation to the GP, attendance at Accident & Emergency, or 
      referral to ENT outpatients. RESULTS: There was a significant difference in the 
      proportion of patients with epistaxis across the three groups (chi(2) = 84.1; 2 
      degrees of freedom; P < 0.000001). Relative risk of epistaxis was increased in 
      both the aspirin (RR = 9.04; 95% CI = 5.13-15.96) and clopidogrel (RR = 6.40; 95% 
      CI = 2.33-17.56) groups compared to the no drug group. There was no increased 
      risk of epistaxis with aspirin compared to clopidogrel (RR = 1.4; 95% CI = 
      0.6-3.4). CONCLUSION: There is an increased risk of troublesome epistaxis in 
      patients taking aspirin or clopidogrel. There is no significant difference in 
      risk of epistaxis between the two drug groups.
FAU - Rainsbury, J W
AU  - Rainsbury JW
AD  - ENT Department, Russells Hall Hospital, Dudley, West Midlands, UK. 
      j_rainsbury@yahoo.co.uk
FAU - Molony, N C
AU  - Molony NC
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Otolaryngol
JT  - Clinical otolaryngology : official journal of ENT-UK ; official journal of 
      Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
JID - 101247023
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clopidogrel
MH  - Dose-Response Relationship, Drug
MH  - Epistaxis/*chemically induced/epidemiology
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Myocardial Ischemia/prevention & control
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Risk Factors
MH  - Ticlopidine/adverse effects/*analogs & derivatives
EDAT- 2009/06/18 09:00
MHDA- 2009/10/02 06:00
CRDT- 2009/06/18 09:00
PHST- 2009/06/18 09:00 [entrez]
PHST- 2009/06/18 09:00 [pubmed]
PHST- 2009/10/02 06:00 [medline]
AID - COA1926 [pii]
AID - 10.1111/j.1749-4486.2009.01926.x [doi]
PST - ppublish
SO  - Clin Otolaryngol. 2009 Jun;34(3):232-5. doi: 10.1111/j.1749-4486.2009.01926.x.

PMID- 9853178
OWN - NLM
STAT- MEDLINE
DCOM- 19990303
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 21
IP  - 12
DP  - 1998 Dec
TI  - Salutary effects of aspirin in coronary artery disease are not limited to its 
      platelet inhibitory effects.
PG  - 879-84
AB  - Aspirin is widely used in the treatment and prevention of coronary artery disease 
      (CAD). However, other platelet inhibitory agents, which inhibit platelet 
      activation, have not been found to be effective or as effective as aspirin. The 
      discrepancy between the efficacy of these compounds and aspirin suggests that the 
      therapeutic efficacy of aspirin may not be limited to its platelet inhibitory 
      effect. In this review, the basis for a unique place for aspirin in the therapy 
      of patients with CAD is discussed. The author believes that the 
      nonplatelet-mediated effects of aspirin could be more important than the platelet 
      inhibitory effect, or at least may complement the platelet inhibitory effects of 
      aspirin in patients with acute myocardial ischemia and in others undergoing 
      intracoronary procedures.
FAU - Mehta, J L
AU  - Mehta JL
AD  - Division of Cardiology, University of Florida College of Medicine, Gainesville 
      32610-0277, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Clin Cardiol. 1999 Jun;22(6):A27. PMID: 10376172
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/*drug therapy/*prevention & control
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
PMC - PMC6655515
EDAT- 1998/12/16 00:00
MHDA- 1998/12/16 00:01
CRDT- 1998/12/16 00:00
PHST- 1998/12/16 00:00 [pubmed]
PHST- 1998/12/16 00:01 [medline]
PHST- 1998/12/16 00:00 [entrez]
AID - CLC4960211204 [pii]
AID - 10.1002/clc.4960211204 [doi]
PST - ppublish
SO  - Clin Cardiol. 1998 Dec;21(12):879-84. doi: 10.1002/clc.4960211204.

PMID- 7644046
OWN - NLM
STAT- MEDLINE
DCOM- 19950920
LR  - 20220317
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 45
IP  - 8
DP  - 1995 Aug
TI  - The Warfarin-Aspirin Symptomatic Intracranial Disease Study.
PG  - 1488-93
AB  - We conducted a retrospective, multicenter study to compare the efficacy of 
      warfarin with aspirin for the prevention of major vascular events (ischemic 
      stroke, myocardial infarction, or sudden death) in patients with symptomatic 
      stenosis of a major intracranial artery. Patients with 50 to 99% stenosis of an 
      intracranial artery (carotid; anterior, middle, or posterior cerebral; vertebral; 
      or basilar) were identified by reviewing the results of consecutive angiograms 
      performed at participating centers between 1985 and 1991. Only patients with TIA 
      or stroke in the territory of the stenotic artery qualified for inclusion in the 
      study. Patients were prescribed warfarin or aspirin according to local physician 
      preference and were followed by chart review and personal or telephone interview. 
      Seven centers enrolled 151 patients; 88 were treated with warfarin and 63 were 
      treated with aspirin. Median follow-up was 14.7 months (warfarin group) and 19.3 
      months (aspirin group). Vascular risk factors and mean percent stenosis of the 
      symptomatic artery were similar in the two groups, yet the rates of major 
      vascular events were 18.1 per 100 patient-years of follow-up in the aspirin group 
      (stroke rate, 10.4/100 patient-years; myocardial infarction or sudden death rate, 
      7.7/100 patient-years) compared with 8.4 per 100 patient-years of follow-up in 
      the warfarin group (stroke rate, 3.6/100 patient-years; myocardial infarction or 
      sudden death rate, 4.8/100 patient-years). Kaplan-Meier analysis showed a 
      significantly higher percentage of patients free of major vascular events among 
      patients treated with warfarin (p = 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Chimowitz, M I
AU  - Chimowitz MI
AD  - Department of Neurology, University of Michigan Medical Center, Ann Arbor, USA.
FAU - Kokkinos, J
AU  - Kokkinos J
FAU - Strong, J
AU  - Strong J
FAU - Brown, M B
AU  - Brown MB
FAU - Levine, S R
AU  - Levine SR
FAU - Silliman, S
AU  - Silliman S
FAU - Pessin, M S
AU  - Pessin MS
FAU - Weichel, E
AU  - Weichel E
FAU - Sila, C A
AU  - Sila CA
FAU - Furlan, A J
AU  - Furlan AJ
AU  - et al.
LA  - eng
GR  - NS23393/NS/NINDS NIH HHS/United States
GR  - NS27517/NS/NINDS NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebral Angiography
MH  - Cerebral Hemorrhage/chemically induced
MH  - Cerebrovascular Disorders/*complications/diagnostic imaging/*drug therapy
MH  - Cohort Studies
MH  - Constriction, Pathologic
MH  - Female
MH  - Guinea Pigs
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Vascular Diseases/*prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
AID - 10.1212/wnl.45.8.1488 [doi]
PST - ppublish
SO  - Neurology. 1995 Aug;45(8):1488-93. doi: 10.1212/wnl.45.8.1488.

PMID- 2310475
OWN - NLM
STAT- MEDLINE
DCOM- 19900424
LR  - 20131121
IS  - 0397-9148 (Print)
IS  - 0397-9148 (Linking)
VI  - 22
IP  - 2
DP  - 1990 Feb
TI  - [Therapeutic approach for nasal sinus polyposis].
PG  - 45-9
AB  - The multiple etiologies of bilateral naso-ethmoidal polyposis (PNE) make a 
      precise and regulated therapeutic decision difficult. The treatment is chosen 
      after a clinical history, radiology and complete biological investigation. 
      Medical and surgical treatments share the indications. Medical treatment is 
      dominated by local corticotherapy. Its failures and recurrence following its end 
      may suggest general corticotherapy, an efficacious remedy but which carries well 
      known risks. The choice of treatment is guided by whether the characteristics of 
      the polyposis are invalidating or not. The localised forms often respond to local 
      medical treatment. Invalidating polyposis continues to be difficult to treat, 
      especially where there is intolerance to aspirin. Corticotherapy by the general 
      route, even sequential, remains insufficient to be sure of long asymptomatic 
      periods. We suggest for these patients a clear ethmoidal once or twice under 
      local anaesthetic with diazanalgesia. The local treatments associated with 
      corticotherapy and anti histamines help the healing of the operated cavity. 
      Crenotherapy is an useful aid after having obtained clean, permeable nasal 
      fossae. The choice remains empirical and is a function of the group, but it must 
      not include iatrogenic risks greater than those of the illness itself. We report 
      our actual experience.
FAU - Klossek, J M
AU  - Klossek JM
AD  - Praticien Hospitalo-Universitaire Service ORL, Hôpital Jean Bernard, CHU 
      Poitiers.
FAU - Feger, B
AU  - Feger B
FAU - Fontanel, J P
AU  - Fontanel JP
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Approche thérapeutique de la polypose naso-sinusienne.
PL  - France
TA  - Allerg Immunol (Paris)
JT  - Allergie et immunologie
JID - 0245775
RN  - 0 (Adrenal Cortex Hormones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Endoscopy
MH  - Ethmoid Sinusitis/diagnosis/*therapy
MH  - Humans
MH  - Nasal Polyps/diagnosis/*therapy
EDAT- 1990/02/01 00:00
MHDA- 1990/02/01 00:01
CRDT- 1990/02/01 00:00
PHST- 1990/02/01 00:00 [pubmed]
PHST- 1990/02/01 00:01 [medline]
PHST- 1990/02/01 00:00 [entrez]
PST - ppublish
SO  - Allerg Immunol (Paris). 1990 Feb;22(2):45-9.

PMID- 6487934
OWN - NLM
STAT- MEDLINE
DCOM- 19841217
LR  - 20190829
IS  - 0263-7103 (Print)
IS  - 0263-7103 (Linking)
VI  - 23
IP  - 4
DP  - 1984 Nov
TI  - A pharmacokinetic comparison of choline magnesium trisalicylate and soluble 
      aspirin.
PG  - 288-91
AB  - Claims that twice-daily dosage of choline magnesium trisalicylate (CMT) may alter 
      salicylate disposal kinetics and result in sustained plasma levels were examined. 
      Plasma levels, urine excretion and pharmacokinetics of salicylate were estimated 
      in six men following the recommended twice-daily dose of CMT and a smaller dose 
      of soluble aspirin. The plasma salicylate levels achieved with CMT were lower 
      than those seen in previous studies but this probably reflected differences of 
      methodology. Salicylate levels were not sustained between doses and elimination 
      rates and half-life were similar for both preparations. No major alteration of 
      disposal kinetics could be demonstrated for CMT with the dose used in the present 
      study.
FAU - Helliwell, M
AU  - Helliwell M
FAU - Gibson, T
AU  - Gibson T
FAU - Berry, D
AU  - Berry D
FAU - Volans, G
AU  - Volans G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Br J Rheumatol
JT  - British journal of rheumatology
JID - 8302415
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Salicylates)
RN  - DJJ95FJP1H (choline magnesium trisalicylate)
RN  - N91BDP6H0X (Choline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Aspirin/administration & dosage/*metabolism/pharmacology
MH  - Choline/administration & dosage/*analogs & derivatives/metabolism/pharmacology
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - Salicylates/administration & dosage/blood/*metabolism/pharmacology/urine
MH  - Statistics as Topic
EDAT- 1984/11/01 00:00
MHDA- 1984/11/01 00:01
CRDT- 1984/11/01 00:00
PHST- 1984/11/01 00:00 [pubmed]
PHST- 1984/11/01 00:01 [medline]
PHST- 1984/11/01 00:00 [entrez]
AID - 10.1093/rheumatology/23.4.288 [doi]
PST - ppublish
SO  - Br J Rheumatol. 1984 Nov;23(4):288-91. doi: 10.1093/rheumatology/23.4.288.

PMID- 32317171
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20210113
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 157
IP  - 3
DP  - 2020 Jun
TI  - Common medications and survival in women with ovarian cancer: A systematic review 
      and meta-analysis.
PG  - 678-685
LID - S0090-8258(20)30253-5 [pii]
LID - 10.1016/j.ygyno.2020.03.028 [doi]
AB  - OBJECTIVES: Ovarian cancer is usually diagnosed at an advanced stage when 
      five-year relative survival is <50%. Therefore, strategies to improve survival 
      are required. Studies suggest associations between common chronic disease 
      medications such as metformin, statins, beta-blockers, aspirin and non-aspirin 
      non-steroidal anti-inflammatory drugs (NA-NSAIDs) and improved cancer survival. 
      We aimed to review the evidence for a possible relation between these medications 
      and survival among women with ovarian cancer. METHODS: We conducted four 
      systematic reviews and evaluated the risk of bias in the included studies. Where 
      possible, we calculated pooled hazard ratios (pHR) and 95% confidence intervals 
      (CI), excluding studies considered to have the potential for immortal time bias 
      (ITB) which, in practice, was the major source of bias. RESULTS: We identified 36 
      studies evaluating one or more of the medications (metformin n = 8, statins 
      n = 12, beta-blockers n = 11, aspirin and/or NA-NSAIDs n = 9). We rated 21 
      studies as ITB-free. The meta-analysis of the ITB-free studies suggested improved 
      survival in statin users compared to non-users (pHR: 0.76, 95%CI: 0.68-0.85), but 
      no overall survival benefit associated with use of metformin, beta-blockers, 
      aspirin or NA-NSAIDs. The pooled result of two studies did, however, suggest a 
      possible association between perioperative beta-blocker use and improved 
      survival. Studies considered to have potential ITB were more likely to report 
      survival benefits associated with these medications. CONCLUSION: Statin use is 
      associated with better ovarian cancer survival but further study, preferably a 
      clinical trial, is required. There are insufficient data to draw conclusions 
      regarding metformin, beta-blockers, aspirin and NA-NSAIDs.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Majidi, Azam
AU  - Majidi A
AD  - Population Health Department, QIMR Berghofer Medical Research Institute, 
      Brisbane, Australia; School of Public Health, University of Queensland, Brisbane, 
      Australia.
FAU - Na, Renhua
AU  - Na R
AD  - Population Health Department, QIMR Berghofer Medical Research Institute, 
      Brisbane, Australia.
FAU - Dixon-Suen, Suzanne
AU  - Dixon-Suen S
AD  - Population Health Department, QIMR Berghofer Medical Research Institute, 
      Brisbane, Australia; Cancer Epidemiology Division, Cancer Council Victoria, 
      Melbourne, Australia.
FAU - Jordan, Susan J
AU  - Jordan SJ
AD  - Population Health Department, QIMR Berghofer Medical Research Institute, 
      Brisbane, Australia; School of Public Health, University of Queensland, Brisbane, 
      Australia.
FAU - Webb, Penelope M
AU  - Webb PM
AD  - Population Health Department, QIMR Berghofer Medical Research Institute, 
      Brisbane, Australia; School of Public Health, University of Queensland, Brisbane, 
      Australia. Electronic address: penny.webb@qimrberghofer.edu.au.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200418
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/*therapeutic use
MH  - Metformin/pharmacology/*therapeutic use
MH  - Ovarian Neoplasms/*drug therapy/mortality
MH  - Risk Factors
MH  - Survival Analysis
OTO - NOTNLM
OT  - Aspirin
OT  - Beta-blocker
OT  - Metformin
OT  - NSAID
OT  - Ovarian cancer survival
OT  - Statin
COIS- Declaration of competing interest The authors have declared that there are no 
      conflicts of interest.
EDAT- 2020/04/23 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/02/11 00:00 [received]
PHST- 2020/03/21 00:00 [accepted]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - S0090-8258(20)30253-5 [pii]
AID - 10.1016/j.ygyno.2020.03.028 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2020 Jun;157(3):678-685. doi: 10.1016/j.ygyno.2020.03.028. Epub 
      2020 Apr 18.

PMID- 25957325
OWN - NLM
STAT- MEDLINE
DCOM- 20160906
LR  - 20191210
IS  - 1758-1052 (Electronic)
IS  - 0956-4624 (Linking)
VI  - 27
IP  - 6
DP  - 2016 May
TI  - Use of aspirin and statins for the primary prevention of myocardial infarction 
      and stroke in patients with human immunodeficiency virus infection.
PG  - 447-52
LID - 10.1177/0956462415585448 [doi]
AB  - This retrospective, cross-sectional study evaluated whether HIV-infected patients 
      received aspirin and statins for the primary prevention of myocardial infarction 
      and stroke. Among the 258 patients included, 50.4% (n = 130/258) of the patients 
      had a high risk of myocardial infarction and 14% (n = 36/258) of stroke. Overall, 
      43.1% (n = 56/130) and 50% (n = 18/36) of the patients were prescribed aspirin 
      for the primary prevention of myocardial infarction and stroke, respectively. 
      Among the patients who required statin therapy, 42.5% (n = 34/80) and 37.1% 
      (n = 13/35) of patients received it for the primary prevention of myocardial 
      infarction and stroke, respectively. The patients who had hypertension (odds 
      ratio 3.8, 95% confidence interval 1.5-10.9) and diabetes mellitus (odds ratio 
      5.6, 95% confidence interval 2.6-12.4) were more likely to receive aspirin. 
      Interventions are needed to improve provider awareness of the use of aspirin and 
      statins in the primary prevention of myocardial infarction and stroke in 
      HIV-infected patients.
CI  - © The Author(s) 2016.
FAU - Park, Tae Eun
AU  - Park TE
AD  - School of Pharmacy, Fairleigh Dickinson University, NJ, USA.
FAU - Yusuff, Jameela
AU  - Yusuff J
AD  - SUNY Downstate College of Medicine, Brooklyn, NY, USA.
FAU - Sharma, Roopali
AU  - Sharma R
AD  - Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, 
      NY, USA rsharma@downstate.edu.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20150507
PL  - England
TA  - Int J STD AIDS
JT  - International journal of STD & AIDS
JID - 9007917
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Female
MH  - HIV Infections/*complications
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Outcome Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Primary Prevention
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stroke/*prevention & control
OTO - NOTNLM
OT  - AIDS
OT  - HIV
OT  - Human immunodeficiency virus
OT  - aspirin
OT  - cardiovascular disease
OT  - myocardial infarction
OT  - prevention
OT  - statins
OT  - stroke
EDAT- 2015/05/10 06:00
MHDA- 2016/09/07 06:00
CRDT- 2015/05/10 06:00
PHST- 2015/01/09 00:00 [received]
PHST- 2015/03/29 00:00 [accepted]
PHST- 2015/05/10 06:00 [entrez]
PHST- 2015/05/10 06:00 [pubmed]
PHST- 2016/09/07 06:00 [medline]
AID - 0956462415585448 [pii]
AID - 10.1177/0956462415585448 [doi]
PST - ppublish
SO  - Int J STD AIDS. 2016 May;27(6):447-52. doi: 10.1177/0956462415585448. Epub 2015 
      May 7.

PMID- 3927512
OWN - NLM
STAT- MEDLINE
DCOM- 19850904
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 39
IP  - 2
DP  - 1985 Jul 15
TI  - The tachyphylactic effect of arachidonic acid on in-vivo ADP induced arterial 
      platelet thrombosis.
PG  - 231-6
AB  - The continuous superfusion of arachidonic acid over a branch of the mesenteric 
      artery in an animal in-vivo model results in an initial increase followed by a 
      decrease to control values of ADP induced platelet thrombogenesis. This 
      phenomenon is observed in normal rats as well as in rats submitted to the 
      intravenous administration of ASA three hours prior to the investigation. In the 
      latter group the cyclooxygenase of the platelets is permanently affected while 
      the cyclooxygenase of the endothelial cells is regenerated at the time the 
      investigation is started. The tachyphylactic-like phenomenon observed with 
      arachidonic acid is probably related to the dynamics of the enzymatic reactions 
      of the arachidonate cascade involving the platelets and the endothelial cells 
      surrounding the local de-endothelialized area.
FAU - Bourgain, R H
AU  - Bourgain RH
FAU - Andries, R
AU  - Andries R
FAU - Deby, C
AU  - Deby C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Arachidonic Acids)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Drug Synergism
MH  - Rats
MH  - Thrombosis/*chemically induced
EDAT- 1985/07/15 00:00
MHDA- 1985/07/15 00:01
CRDT- 1985/07/15 00:00
PHST- 1985/07/15 00:00 [pubmed]
PHST- 1985/07/15 00:01 [medline]
PHST- 1985/07/15 00:00 [entrez]
AID - 0049-3848(85)90111-2 [pii]
AID - 10.1016/0049-3848(85)90111-2 [doi]
PST - ppublish
SO  - Thromb Res. 1985 Jul 15;39(2):231-6. doi: 10.1016/0049-3848(85)90111-2.

PMID- 3893039
OWN - NLM
STAT- MEDLINE
DCOM- 19850806
LR  - 20131121
IS  - 0231-424X (Print)
IS  - 0231-424X (Linking)
VI  - 65
IP  - 3
DP  - 1985
TI  - Effect of acetylsalicylic acid on prostacyclin production in trophoblast.
PG  - 379-82
AB  - In attempt to elucidate whether acetylsalicylic acid (ASA) has an in vivo effect 
      on prostacyclin (PGI2)-like activity released from trophoblast we have evaluated 
      PGI2-like activity in pregnant women scheduled for pregnancy termination after 
      ASA ingestion. Following subjects were studied: Group I: 7 healthy pregnant women 
      who were treated with 1.5 g ASA for two days; Group II: 18 control pregnant women 
      who received placebo for two days. Trophoblast specimens were obtained by legal 
      abortions; PGI2-like activity in trophoblast was measured by the method of 
      Moncada. In normal pregnant women (8-10 weeks gestation) treated with ASA the 
      mean PGI2-like activity of trophoblast significantly decreased compared to the 
      controls. These data indicate that treatment with ASA of early pregnant women 
      might have a harmful effect on trophoblast and the problem should be further 
      explored before allowing the administration of cyclooxygenase inhibiting drugs 
      during early pregnancy.
FAU - Rákóczi, I
AU  - Rákóczi I
FAU - Tihanyi, K
AU  - Tihanyi K
FAU - Demeter, J
AU  - Demeter J
FAU - Gáti, I
AU  - Gáti I
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Hungary
TA  - Acta Physiol Hung
JT  - Acta physiologica Hungarica
JID - 8309201
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Epoprostenol/*biosynthesis
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Trophoblasts/*metabolism
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Physiol Hung. 1985;65(3):379-82.

PMID- 28065801
OWN - NLM
STAT- MEDLINE
DCOM- 20170804
LR  - 20171205
IS  - 1534-4436 (Electronic)
IS  - 1081-1206 (Linking)
VI  - 118
IP  - 3
DP  - 2017 Mar
TI  - Frequency and severity of reactions to a 325-mg aspirin dose during 
      desensitization.
PG  - 333-338.e1
LID - S1081-1206(16)31355-2 [pii]
LID - 10.1016/j.anai.2016.11.021 [doi]
AB  - BACKGROUND: The frequency with which patients with aspirin-exacerbated 
      respiratory disease (AERD) react to 325 mg of aspirin during aspirin 
      desensitization, or fail to react at all, is not fully known. OBJECTIVE: To 
      determine the rate and type of reaction at 325 mg of aspirin during 
      desensitization. METHODS: A retrospective study of 104 patients who underwent 
      aspirin desensitization from 2010 to 2016 was performed. A standard 
      desensitization protocol (starting at 20-40 mg, progressing through 325 mg, and 
      extinguishing reactions by dose repetition) was used. Reactions were defined by 
      upper respiratory tract symptoms, lower respiratory tract symptoms, and/or forced 
      expiratory volume in 1 second decrease of 15% or greater. Patients who did and 
      did not react were compared by logistic regression. RESULTS: Eighty-four patients 
      reacted (81%) and 20 did not (19%). Seventy-seven patients who had a provoking 
      reaction at 162 mg of aspirin or less subsequently extinguished their reactions 
      before they reached a dose of 325 mg and had no problems at that dose; one 
      subsequent 325-mg reaction occurred during a protocol violation. One initial 
      provoking reaction to 325 mg occurred. Both 325-mg reactions were mild, and 
      neither met the forced expiratory volume in 1 second criterion for a clinically 
      meaningful change. The remaining 5 patients could not complete the protocol 
      because of persistent reactions or social reasons. Reactors were more likely to 
      have had asthma for more than 10 years than nonreactors (odds ratio, 3.2; 95% 
      confidence interval, 1.0-10.3; P = .05). CONCLUSION: During aspirin 
      desensitization for AERD, provoking reactions at the 325-mg dose are rare (1%) 
      and mild. Patients who react at 162 mg or less and extinguish their reactions may 
      be able to administer the 325-mg dose at home.
CI  - Copyright © 2016 American College of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Schuler, Charles F 4th
AU  - Schuler CF 4th
AD  - Department of Internal Medicine, University of Michigan Health System, Ann Arbor, 
      Michigan. Electronic address: schulerc@med.umich.edu.
FAU - Baldwin, James L
AU  - Baldwin JL
AD  - Division of Allergy and Immunology, Department of Internal Medicine, University 
      of Michigan Health System, Ann Arbor, Michigan.
FAU - Baptist, Alan P
AU  - Baptist AP
AD  - Division of Allergy and Immunology, Department of Internal Medicine, University 
      of Michigan Health System, Ann Arbor, Michigan.
LA  - eng
PT  - Journal Article
DEP - 20170105
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/administration & dosage/therapeutic use
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - *Desensitization, Immunologic/methods
MH  - Drug Hypersensitivity/*diagnosis/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Respiratory Function Tests
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2017/01/10 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/01/10 06:00
PHST- 2016/10/08 00:00 [received]
PHST- 2016/11/18 00:00 [revised]
PHST- 2016/11/26 00:00 [accepted]
PHST- 2017/01/10 06:00 [pubmed]
PHST- 2017/08/05 06:00 [medline]
PHST- 2017/01/10 06:00 [entrez]
AID - S1081-1206(16)31355-2 [pii]
AID - 10.1016/j.anai.2016.11.021 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2017 Mar;118(3):333-338.e1. doi: 
      10.1016/j.anai.2016.11.021. Epub 2017 Jan 5.

PMID- 15107602
OWN - NLM
STAT- MEDLINE
DCOM- 20040914
LR  - 20190917
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 17
IP  - 5-6
DP  - 2003 Sep-Nov
TI  - The role of clopidogrel in the management of patients with ischemic heart 
      disease.
PG  - 467-77
AB  - Antiplatelet therapy plays a pivotal role in the treatment of patients across the 
      entire spectrum of coronary artery disease. Platelets are believed to be 
      integrally involved in both the development and progression of atherosclerotic 
      heart disease, as well as in its acute thrombotic complications. While aspirin 
      remains the traditional antiplatelet agent in patients with CAD, adverse vascular 
      events continue to occur in patients on aspirin therapy. Clopidogrel is a 
      relatively new antiplatelet agent and is currently one of the most widely 
      prescribed drugs for the treatment of symptomatic coronary artery disease. As a 
      member of the class of drugs known as the thienopyridines, clopidogrel 
      irreversibly prevents platelet activation by blocking one of the three known 
      adenosine 5'-diphosphate (ADP) receptors on its surface. The findings of a number 
      of seminal clinical trials have expanded the indications for the use of 
      clopidogrel in patients with coronary artery disease. When used in conjunction 
      with aspirin, these studies have demonstrated an incremental benefit of 
      clopidogrel above and beyond that of aspirin alone. This article reviews the data 
      supporting the use of clopidogrel in patients with atherosclerotic heart disease, 
      and makes recommendations for its use based on the available evidence.
FAU - Chopra, V
AU  - Chopra V
AD  - Department of Medicine, Bronx Veterans Affairs Medical Center and The Mount Sinai 
      School of Medicine, New York, NY, USA.
FAU - Marmur, J D
AU  - Marmur JD
FAU - Cavusoglu, E
AU  - Cavusoglu E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Brachytherapy
MH  - Clopidogrel
MH  - Coronary Artery Disease/prevention & control
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stents/adverse effects
MH  - Thrombosis/prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/*therapeutic use
RF  - 56
EDAT- 2004/04/27 05:00
MHDA- 2004/09/15 05:00
CRDT- 2004/04/27 05:00
PHST- 2004/04/27 05:00 [pubmed]
PHST- 2004/09/15 05:00 [medline]
PHST- 2004/04/27 05:00 [entrez]
AID - 5264040 [pii]
AID - 10.1023/b:card.0000015862.62649.c8 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):467-77. doi: 
      10.1023/b:card.0000015862.62649.c8.

PMID- 10354521
OWN - NLM
STAT- MEDLINE
DCOM- 19990702
LR  - 20190610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1454
IP  - 1
DP  - 1999 May 31
TI  - The mechanism of inhibition of beta-oxidation by aspirin metabolites in skin 
      fibroblasts from Reye's syndrome patients and controls.
PG  - 115-25
AB  - The effects of aspirin metabolites on beta-oxidation were studied in skin 
      fibroblasts from eight typical Reye's syndrome (RS) patients and controls. RS 
      patients' cells did not differ from controls in rates of palmitate oxidation or 
      in the three component activities of the mitochondrial trifunctional enzyme 
      (MTE), indicating no inherited beta-oxidation defect. Aspirin metabolites 
      salicylate, hydroxyhippurate and gentisate, but not aspirin, directly inhibited 
      palmitate oxidation in control and RS cells. RS cells were significantly more 
      sensitive to inhibition than controls at 0.5 to 5 mM salicylate. Inhibition was 
      concentration-dependent and reversible. Inhibition did not occur in fibroblasts 
      lacking activity of the long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) 
      activity of MTE. Salicylate was therefore inhibiting beta-oxidation at this step. 
      Hydroxyhippurate and salicylate reversibly inhibited HAD activities in extracts 
      of control and RS cells. Studies with pure short-chain HAD and LCHAD (MTE) showed 
      hydroxyhippurate and salicylate were competitive inhibitors of the former but 
      mixed (not competitive) inhibitors of the latter. Both compounds inhibited the 
      combined, three-step, MTE reaction measured in the physiological direction. We 
      conclude that (1) salicylate and hydroxyhippurate decrease beta-oxidation in 
      intact cells by reversible inhibition of LCHAD activity of the MTE, and (2) 
      beta-oxidation in RS cells is inherently more sensitive to inhibition by low 
      concentrations of salicylate than controls.
FAU - Glasgow, J F
AU  - Glasgow JF
AD  - Nuffield Department of Child Health, The Queen's University of Belfast, Royal 
      Belfast Hospital for Sick Children, Belfast BT12 6BA, UK.
FAU - Middleton, B
AU  - Middleton B
FAU - Moore, R
AU  - Moore R
FAU - Gray, A
AU  - Gray A
FAU - Hill, J
AU  - Hill J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Antioxidants)
RN  - 0 (Multienzyme Complexes)
RN  - 0 (Palmitates)
RN  - 10028-17-8 (Tritium)
RN  - EC 1.1.1.- (3-Hydroxyacyl CoA Dehydrogenases)
RN  - EC 2.3.1.16 (Mitochondrial Trifunctional Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 3-Hydroxyacyl CoA Dehydrogenases/*antagonists & inhibitors/deficiency
MH  - Antioxidants/*pharmacology
MH  - Aspirin/metabolism/*pharmacology
MH  - Catalysis
MH  - Child
MH  - Fibroblasts/drug effects/enzymology
MH  - Humans
MH  - Mitochondrial Trifunctional Protein
MH  - Multienzyme Complexes/*antagonists & inhibitors
MH  - Oxidation-Reduction/drug effects
MH  - Palmitates/metabolism
MH  - Reye Syndrome/*metabolism
MH  - Skin/*drug effects/enzymology
MH  - Structure-Activity Relationship
MH  - Tritium
EDAT- 1999/06/04 00:00
MHDA- 1999/06/04 00:01
CRDT- 1999/06/04 00:00
PHST- 1999/06/04 00:00 [pubmed]
PHST- 1999/06/04 00:01 [medline]
PHST- 1999/06/04 00:00 [entrez]
AID - S0925-4439(99)00025-3 [pii]
AID - 10.1016/s0925-4439(99)00025-3 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 1999 May 31;1454(1):115-25. doi: 
      10.1016/s0925-4439(99)00025-3.

PMID- 29673465
OWN - NLM
STAT- MEDLINE
DCOM- 20190729
LR  - 20201229
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 71
IP  - 16
DP  - 2018 Apr 24
TI  - Effect of Aspirin Coadministration on the Safety of Celecoxib, 
      Naproxen, or Ibuprofen.
PG  - 1741-1751
LID - S0735-1097(18)33316-3 [pii]
LID - 10.1016/j.jacc.2018.02.036 [doi]
AB  - BACKGROUND: The safety of nonsteroidal anti-inflammatory drug (NSAID) and aspirin 
      coadministration is uncertain. OBJECTIVES: The aim of this study was to compare 
      the safety of combining NSAIDs with low-dose aspirin. METHODS: This analysis of 
      the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety 
      Versus Ibuprofen or Naproxen) trial included 23,953 patients with osteoarthritis 
      or rheumatoid arthritis at increased cardiovascular risk randomized to celecoxib, 
      ibuprofen, or naproxen. The on-treatment population was used for this study. 
      Outcomes included composite major adverse cardiovascular events, 
      noncardiovascular death, gastrointestinal or renal events, and components of the 
      composite. Cox proportional hazards models compared outcomes among NSAIDs 
      stratified by aspirin use following propensity score adjustment. Kaplan-Meier 
      analysis was used to compare the cumulative probability of events. RESULTS: When 
      taken without aspirin, naproxen or ibuprofen had greater risk for the primary 
      composite endpoint compared with celecoxib (hazard ratio [HR]: 1.52; 95% 
      confidence interval [CI]: 1.22 to 1.90, p <0.001; and HR: 1.81; 95% CI: 1.46 to 
      2.26; p <0.001, respectively). Compared with celecoxib, ibuprofen had more major 
      adverse cardiovascular events (p < 0.05), and both ibuprofen and naproxen had 
      more gastrointestinal (p < 0.001) and renal (p < 0.05) events. Taken with 
      aspirin, ibuprofen had greater risk for the primary composite endpoint compared 
      with celecoxib (HR: 1.27; 95% CI: 1.06 to 1.51; p < 0.01); this was not 
      significantly higher with naproxen (HR: 1.18; 95% CI: 0.98 to 1.41; p = 0.08). 
      Among patients on aspirin, major adverse cardiovascular events were similar among 
      NSAIDs, and compared with celecoxib, ibuprofen had more gastrointestinal and 
      renal events (p < 0.05), while naproxen had more gastrointestinal events (p < 
      0.05), without a difference in renal events. Similar results were seen on 
      adjusted Kaplan-Meier analysis. CONCLUSIONS: Celecoxib has a more favorable 
      overall safety profile than naproxen or ibuprofen when taken without aspirin. 
      Adding aspirin attenuates the safety advantage of celecoxib, although celecoxib 
      is still associated with fewer gastrointestinal events than ibuprofen or naproxen 
      and fewer renal events than ibuprofen. (Prospective Randomized Evaluation of 
      Celecoxib Integrated Safety vs Ibuprofen or Naproxen [PRECISION]; NCT00346216).
CI  - Copyright © 2018 American College of Cardiology Foundation. All rights reserved.
FAU - Reed, Grant W
AU  - Reed GW
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; 
      Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, 
      Cleveland, Ohio.
FAU - Abdallah, Mouin S
AU  - Abdallah MS
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; 
      Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, 
      Cleveland, Ohio.
FAU - Shao, Mingyuan
AU  - Shao M
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
FAU - Wolski, Kathy
AU  - Wolski K
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
FAU - Wisniewski, Lisa
AU  - Wisniewski L
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
FAU - Yeomans, Neville
AU  - Yeomans N
AD  - University of Melbourne Department of Medicine, Austin Health, Melbourne, 
      Victoria, and Western Sydney University, Campbelltown, New South Wales, 
      Australia.
FAU - Lüscher, Thomas F
AU  - Lüscher TF
AD  - Royal Brompton & Harefield Hospitals Trust and Imperial College, London, United 
      Kingdom.
FAU - Borer, Jeffrey S
AU  - Borer JS
AD  - Schiavone Cardiovascular Translational Research Institute, State University of 
      New York, Downstate Medical Center and College of Medicine, Brooklyn and New 
      York, New York.
FAU - Graham, David Y
AU  - Graham DY
AD  - Baylor College of Medicine, Veterans Affairs Medical Center, Houston, Texas.
FAU - Husni, M Elaine
AU  - Husni ME
AD  - Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, 
      Ohio.
FAU - Solomon, Daniel H
AU  - Solomon DH
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Libby, Peter
AU  - Libby P
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Menon, Venu
AU  - Menon V
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; 
      Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, 
      Cleveland, Ohio.
FAU - Lincoff, A Michael
AU  - Lincoff AM
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; 
      Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, 
      Cleveland, Ohio.
FAU - Nissen, Steven E
AU  - Nissen SE
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; 
      Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, 
      Cleveland, Ohio. Electronic address: nissens@ccf.org.
LA  - eng
SI  - ClinicalTrials.gov/NCT00346216
GR  - P30 DK056338/DK/NIDDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
CIN - J Am Coll Cardiol. 2018 Apr 24;71(16):1752-1754. PMID: 29673466
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Arthritis/*complications
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*complications
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Propensity Score
OTO - NOTNLM
OT  - aspirin
OT  - celecoxib
OT  - ibuprofen
OT  - naproxen
OT  - nonsteroidal anti-inflammatory drugs
EDAT- 2018/04/21 06:00
MHDA- 2019/07/30 06:00
CRDT- 2018/04/21 06:00
PHST- 2018/01/15 00:00 [received]
PHST- 2018/02/06 00:00 [accepted]
PHST- 2018/04/21 06:00 [entrez]
PHST- 2018/04/21 06:00 [pubmed]
PHST- 2019/07/30 06:00 [medline]
AID - S0735-1097(18)33316-3 [pii]
AID - 10.1016/j.jacc.2018.02.036 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2018 Apr 24;71(16):1741-1751. doi: 10.1016/j.jacc.2018.02.036.

PMID- 9381256
OWN - NLM
STAT- MEDLINE
DCOM- 19971031
LR  - 20131121
IS  - 0036-4355 (Print)
IS  - 0036-4355 (Linking)
VI  - 42
IP  - 3
DP  - 1997 Jun
TI  - [Comparative efficiency of 1 direct and 2 indirect methods for the detection of 
      differences in erythrocyte aggregation, in normal blood and in blood with 
      echinocytosis].
PG  - 165-9
AB  - BACKGROUND: There are many different methods for assessing red cell aggregation, 
      but they have been evaluated in isolated form. The aim of this work was to 
      compare the efficacy and reliability of three different methods for evaluating 
      red cell aggregation. MATERIAL AND METHODS: Blood was drawn on trisodium citrate, 
      and after removal of platelet-rich plasma, the red cell were washed with sodium 
      chloride, and blood was reconstituted until a haematocrit of 40% was achieved. 
      Aspirin or dipyridamole were added, the latter for inducing echinocyte formation. 
      Three methods of assessment of red cell aggregation were used; two of them, 
      indirect, were based upon blood viscosimetry under shear rates indices, and 
      sedimentation rate of centrifuged blood. The third, direct method was based on 
      microscope observation of aggregation and digital analysis of its images for 
      statistical evaluation. Both descriptive methods and analysis of variance were 
      used. RESULTS: The addition of aspirin and dipyridamole increased blood viscosity 
      with respect to the control (p < 0.001 and p < 0.005, respectively), thus showing 
      increased red cell aggregation. Sedimentation rate was also increased, with, 
      statistical significance in the case of dipyridamole (p < 0.05). Digital analysis 
      of images showed significant increase of red cell aggregation with aspirin (37.48 
      +/- 2.16 vs 27.99 +/- 1.55 in controls, p < 0.05). The presence of 
      dipyridamole-induced echinocytes impeded an adequate evaluation of red cell 
      aggregation indices. CONCLUSION: It was included from these studies that blood 
      viscosimetry proved to be as efficient as digital analysis of images for 
      assessing the differences in red cell aggregation. Nevertheless, microscope 
      examination was necessary for a correct evaluation of this phenomenon, and the 
      presence of echinocytes invalidated any attempt to compare red cell aggregation 
      with respect to normal blood.
FAU - Bozzo, J
AU  - Bozzo J
AD  - Servei Hemotèrapia i Hemostàsia, Hospital Clinic i Provincial, Barcelona.
FAU - Hernández, M R
AU  - Hernández MR
FAU - Ordinas, A
AU  - Ordinas A
LA  - spa
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Eficacia comparada de un método directo y dos indirectos en la detección de 
      diferencias de agregación eritrocitaria, en sangre normal y en sangre con 
      equinocitosis.
PL  - Spain
TA  - Sangre (Barc)
JT  - Sangre
JID - 0404373
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Sedimentation
MH  - Blood Viscosity
MH  - Centrifugation
MH  - Dipyridamole/pharmacology
MH  - *Erythrocyte Aggregation/drug effects
MH  - *Erythrocytes, Abnormal/drug effects
MH  - Hematology/methods
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Microscopy
EDAT- 1997/06/01 00:00
MHDA- 1998/02/12 00:01
CRDT- 1997/06/01 00:00
PHST- 1997/06/01 00:00 [pubmed]
PHST- 1998/02/12 00:01 [medline]
PHST- 1997/06/01 00:00 [entrez]
PST - ppublish
SO  - Sangre (Barc). 1997 Jun;42(3):165-9.

PMID- 3134810
OWN - NLM
STAT- MEDLINE
DCOM- 19880812
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 116
IP  - 1 Pt 1
DP  - 1988 Jul
TI  - The effect of aspirin on the hemodynamic response to nitroglycerin.
PG  - 77-84
AB  - The role of prostaglandins in mediating the hemodynamic response to nitroglycerin 
      in vivo is controversial. To determine the effect of inhibiting prostaglandin 
      production on the response to nitroglycerin, either placebo or aspirin (650 mg) 
      was administered 1 hour prior to the administration of nitroglycerin (432 
      micrograms) sublingually to 40 healthy volunteers in a double-blind, randomized, 
      cross-over study. Prior to nitroglycerin administration, blood pressure and pulse 
      rate were determined noninvasively every 2 minutes until stable conditions were 
      reached, and then after nitroglycerin administration determinations were made 
      every 1 minute for the first 10 minutes, every 2 minutes for the next 10 minutes, 
      and every 5 minutes until 30 minutes had elapsed. At peak response in the placebo 
      study, nitroglycerin lowered systolic pressure from 117 +/- 10 to 111 +/- 10 mm 
      Hg (p less than 0.0001). Unexpectedly, nitroglycerin increased diastolic pressure 
      from 75 +/- 8 to 80 +/- 7 mm Hg (p less than 0.005), thus reducing pulse pressure 
      significantly. Pulse rate after nitroglycerin increased from 72 +/- 11 to 85 +/- 
      14 (p less than 0.001). Aspirin slightly modified the pattern of response at 1 
      minute but altered neither the peak hemodynamic responses nor the areas under the 
      time-pressure and time-pulse curves. Thus nitroglycerin-induced prostaglandin 
      production does not play a major role in the systemic hemodynamic response to 
      nitroglycerin in vivo.
FAU - Levin, R I
AU  - Levin RI
AD  - Cardiology Section, New York University School of Medicine, NY 10016.
FAU - Feit, F
AU  - Feit F
LA  - eng
GR  - K08 HL00748/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Prostaglandin Antagonists)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Middle Aged
MH  - Nitroglycerin/*pharmacology
MH  - Prostaglandin Antagonists
MH  - Random Allocation
MH  - Reference Values
MH  - Time Factors
EDAT- 1988/07/01 00:00
MHDA- 1988/07/01 00:01
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 1988/07/01 00:01 [medline]
PHST- 1988/07/01 00:00 [entrez]
AID - 0002-8703(88)90252-9 [pii]
AID - 10.1016/0002-8703(88)90252-9 [doi]
PST - ppublish
SO  - Am Heart J. 1988 Jul;116(1 Pt 1):77-84. doi: 10.1016/0002-8703(88)90252-9.

PMID- 31081778
OWN - NLM
STAT- MEDLINE
DCOM- 20200102
LR  - 20200102
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 32
IP  - 2
DP  - 2019 Mar
TI  - Frequency of aspirin non responsiveness in patients of ischemic heart disease.
PG  - 647-650
AB  - Aspirin is widely used as an antiplatelet agent . Many patients have been noticed 
      with recurrence of major ischemic events in- spite of antiplatelet therapy. The 
      objective of this study was to determine frequency of aspirin non-responsiveness 
      /resistance in patients of ischemic heart disease. Seventy one patients of IHD 
      were selected from out-patient department of Punjab Institute of Cardiology 
      Lahore. Whole Blood Platelet aggregation studies were performed on Diamed Impact 
      R. Aspirin response assay was performed with DiaChidon (Arachidoinc Acid 
      16mmol/L). Non responders to aspirin were assessed on the basis of software 
      generated results: Surface covered (SC) >2.5% was considered as response to 
      aspirin and SC <2.5% was considered as no response (or resistance) to Aspirin. 
      Chi-square test was applied to measure statistical significance. Non-response to 
      Aspirin was observed in 11% (8 out of 71). There was significant association 
      (p=0.045) between resistance to aspirin and Diabetes mellitus. Treatment 
      resistance was also significantly associated with female gender (p=0.015). We 
      concluded that non response to Aspirin is seen in significant number of patients 
      of IHD. Diabetes mellitus and female gender are strong risk factors of developing 
      failure to aspirin therapy.
FAU - Rizvi, Syed Khizar Abbas
AU  - Rizvi SKA
AD  - Department of Pathology, Ch. Pervaiz Elahi Institute of Cardiology, Abdali Road, 
      Multan, Pakistan.
FAU - Mohsin, Shahida
AU  - Mohsin S
AD  - Department of Hematology, University of Health Sciences Lahore, Pakistan.
FAU - Saeed, Tahir
AU  - Saeed T
AD  - Department of Pathology, Sharif Medical and Dental College, Lahore, Pakistan.
FAU - Ahmad, Saeed
AU  - Ahmad S
AD  - Hussani Blood Transfusion Centre, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Drug Resistance/drug effects
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Ischemia/blood/*drug therapy
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
EDAT- 2019/05/14 06:00
MHDA- 2020/01/03 06:00
CRDT- 2019/05/14 06:00
PHST- 2019/05/14 06:00 [entrez]
PHST- 2019/05/14 06:00 [pubmed]
PHST- 2020/01/03 06:00 [medline]
PST - ppublish
SO  - Pak J Pharm Sci. 2019 Mar;32(2):647-650.

PMID- 33736523
OWN - NLM
STAT- MEDLINE
DCOM- 20220706
LR  - 20220706
IS  - 1531-1937 (Electronic)
IS  - 0897-1900 (Linking)
VI  - 35
IP  - 4
DP  - 2022 Aug
TI  - Preventive Cardiovascular Care in Patients With HIV Infection in an Outpatient 
      Clinic.
PG  - 612-616
LID - 10.1177/08971900211000700 [doi]
AB  - BACKGROUND: People/patients living with human immunodeficiency virus (PLWH) are 
      at an increased risk for atherosclerotic cardiovascular disease due to normal 
      disease processes, antiretroviral medication adverse effects, and age-related 
      comorbid conditions. Preventive cardiovascular (CV) screenings such as the need 
      for statin, low-dose aspirin, or smoking cessation counseling are not well 
      studied in PLWH. OBJECTIVES: To investigate whether there are differences in 
      preventive CV care offered to patients with and without human immunodeficiency 
      virus (HIV) infection in 1 outpatient clinic. METHODS: This retrospective study 
      enrolled 150 consecutive patients if they had at least 4 appointments in 2 years 
      and they did not have a history and they do not have a history of CV events. A 
      randomly selected sample of patients without HIV infection receiving primary care 
      services in the same clinic were used as the control group and were enrolled 
      using the same inclusion criteria. RESULTS: More patients met statin criteria and 
      were prescribed it in the HIV-negative arm [(70% vs. 24.67%; p < 0.0001); (89.52% 
      vs. 54.05%; p < 0.0001)]. More patients in the HIV-negative arm met aspirin 
      criteria and were prescribed it [(10.67% vs. 8.16%; p = 0.46); (50% vs. 33.3%; p 
      = 0.33)]. There were more current smokers in the HIV-positive arm and a slightly 
      greater number that received smoking cessation counseling [(38% vs. 11.33%; p < 
      0.0001); (82.46% vs. 76.47%; p = 0.58)]. CONCLUSION: Our results found that PLWH 
      receive less preventive CV care compared to non-HIV-infected patients in the same 
      outpatient clinic. Increased efforts are needed to ensure PLWH are receiving 
      primary preventive CV care they need.
FAU - Özdener-Poyraz, Ayşe Elif
AU  - Özdener-Poyraz AE
AUID- ORCID: 0000-0002-0797-193X
AD  - Department of Pharmacy Practice, Fairleigh Dickinson University, School of 
      Pharmacy and Health Sciences, Florham Park, NJ, USA.
FAU - Vaidean, Georgeta
AU  - Vaidean G
AD  - Department of Pharmacy Practice, Fairleigh Dickinson University, School of 
      Pharmacy and Health Sciences, Florham Park, NJ, USA.
LA  - eng
PT  - Journal Article
DEP - 20210319
PL  - United States
TA  - J Pharm Pract
JT  - Journal of pharmacy practice
JID - 8900945
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ambulatory Care Facilities
MH  - Aspirin/therapeutic use
MH  - *HIV Infections/drug therapy
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Retrospective Studies
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular
OT  - human immunodeficiency virus
OT  - primary prevention
OT  - statin
EDAT- 2021/03/20 06:00
MHDA- 2022/07/07 06:00
CRDT- 2021/03/19 05:43
PHST- 2021/03/20 06:00 [pubmed]
PHST- 2022/07/07 06:00 [medline]
PHST- 2021/03/19 05:43 [entrez]
AID - 10.1177/08971900211000700 [doi]
PST - ppublish
SO  - J Pharm Pract. 2022 Aug;35(4):612-616. doi: 10.1177/08971900211000700. Epub 2021 
      Mar 19.

PMID- 26056971
OWN - NLM
STAT- MEDLINE
DCOM- 20160607
LR  - 20171116
IS  - 1872-7077 (Electronic)
IS  - 1382-6689 (Linking)
VI  - 40
IP  - 1
DP  - 2015 Jul
TI  - Effect of tocopherol and acetylsalicylic acid on the biochemical indices of blood 
      in dioxin-exposed rats.
PG  - 1-11
LID - S1382-6689(15)00110-6 [pii]
LID - 10.1016/j.etap.2015.04.017 [doi]
AB  - New sources of dioxins and increased dioxin concentrations in the environment, 
      coupled with their increased bioavailability along the food chain and 
      accumulation in adipose tissues, contribute to various adverse long-term 
      biological effects. The purpose of the study was to determine whether tocopherol 
      protects the CNS by decreasing the pro-inflammatory influence of free radicals 
      generated by TCDD; whether acetylsalicylic acid inhibits the production of 
      inflammatory mediators; and whether the combined administration of tocopherol and 
      acetylsalicylic acid to TCDD-exposed rats has a potential CNS-protective effect. 
      The study included 117 rats divided into 8 groups: 75 female and 12 male Buffalo 
      rats aged 8-10 weeks, weighing 140-160 g; as well as 30 female rats aged 6 weeks 
      and weighing 120 g, which were the offspring of females from each study group. In 
      the experiment, the following substances were used: 
      2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), dosed at 5 μg/kg BW and 12.5 μg/kg 
      BW, diluted in a 1% DMSO solution at the concentration of 1 μg/ml; α-tocopherol 
      acetate, dosed at 30 mg/kg BW, in 0.2 ml of oil solution; and acetylsalicylic 
      acid, 50mg/kg BW, suspended in 0.5 ml of starch solution, administered orally 
      using a feeding tube. Pleurisy was induced by an injection of 0.15 ml of 1% 
      carrageenin solution. The use of tocopherol reduces the adverse effects of the 
      inflammatory reaction induced by TCDD. Administering tocopherol improves protein 
      metabolism by reducing protein catabolism, and raises γ-globulin fraction levels. 
      Combined acetylsalicylic acid and tocopherol suppress catabolic processes 
      accompanying inflammation.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Rosińczuk, Joanna
AU  - Rosińczuk J
AD  - Department of Nervous System Diseases, The Faculty of Health Science, Wroclaw 
      Medical University, Bartla 5 Street, 51-618 Wrocław, Poland. Electronic address: 
      joanna.rosinczuk@umed.wroc.pl.
FAU - Całkosiński, Ireneusz
AU  - Całkosiński I
AD  - Department of Nervous System Diseases, The Faculty of Health Science, Wroclaw 
      Medical University, Bartla 5 Street, 51-618 Wrocław, Poland. Electronic address: 
      ireneusz.calkosinski@umed.wroc.pl.
LA  - eng
PT  - Journal Article
DEP - 20150516
PL  - Netherlands
TA  - Environ Toxicol Pharmacol
JT  - Environmental toxicology and pharmacology
JID - 9612020
RN  - 0 (Polychlorinated Dibenzodioxins)
RN  - R0ZB2556P8 (Tocopherols)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood
MH  - Female
MH  - Male
MH  - Polychlorinated Dibenzodioxins/*toxicity
MH  - Rats
MH  - Tocopherols/*pharmacology
OTO - NOTNLM
OT  - Ascorbic acid
OT  - Biochemical parameters
OT  - Dioxin
OT  - Inflammatory reaction
OT  - Tocopherol
EDAT- 2015/06/10 06:00
MHDA- 2016/06/09 06:00
CRDT- 2015/06/10 06:00
PHST- 2015/02/20 00:00 [received]
PHST- 2015/04/21 00:00 [revised]
PHST- 2015/04/28 00:00 [accepted]
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - S1382-6689(15)00110-6 [pii]
AID - 10.1016/j.etap.2015.04.017 [doi]
PST - ppublish
SO  - Environ Toxicol Pharmacol. 2015 Jul;40(1):1-11. doi: 10.1016/j.etap.2015.04.017. 
      Epub 2015 May 16.

PMID- 3803702
OWN - NLM
STAT- MEDLINE
DCOM- 19870227
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 14
IP  - 6
DP  - 1986
TI  - Effect of esaprazole on gastric mucosal potential difference after oral 
      administration of aspirin (ASA).
PG  - 321-4
AB  - The potential protective properties of esaprazole on the gastric mucosa following 
      administration of aspirin were evaluated by measurement of the potential 
      difference across the gastric mucosa. Twelve patients with non-ulcer dyspepsia 
      were admitted to the study and were divided into two groups of six patients each. 
      In association with a randomized double-blind scheme the two groups of patients 
      underwent two tests, with placebo and esaprazole 600 or 900 mg. After 30 min of 
      basal recording of the potential difference, patients received either esaprazole 
      or placebo i.v. and recording was continued for a further 30 min. Afterwards, 600 
      mg of unbuffered aspirin was instilled into the stomach through a naso-gastric 
      tube and the potential difference was measured for 60 min. Esaprazole 600 mg did 
      not prevent the fall in the potential difference across the gastric mucosa caused 
      by aspirin. A higher dose of esaprazole, however, did significantly (p less than 
      0.05) reduce the fall. These results suggest that esaprazole exerts a 
      dose-dependent cytoprotective effect on the gastric mucosa in man.
FAU - Ardizzone, S
AU  - Ardizzone S
FAU - Sangaletti, O
AU  - Sangaletti O
FAU - Ghirardosi, C
AU  - Ghirardosi C
FAU - Bianchi Porro, G
AU  - Bianchi Porro G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Piperazines)
RN  - 38QSU0IB5L (esaprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*antagonists & inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Piperazines/*pharmacology
MH  - Random Allocation
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1177/030006058601400607 [doi]
PST - ppublish
SO  - J Int Med Res. 1986;14(6):321-4. doi: 10.1177/030006058601400607.

PMID- 20502298
OWN - NLM
STAT- MEDLINE
DCOM- 20100701
LR  - 20220410
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 115
IP  - 6
DP  - 2010 Jun
TI  - Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a 
      systematic review and meta-analysis.
PG  - 1256-1262
LID - 10.1097/AOG.0b013e3181deba40 [doi]
AB  - OBJECTIVE: To estimate the effect of combined heparin and aspirin compared with 
      aspirin monotherapy in pregnant women with antiphospholipid syndrome and 
      recurrent pregnancy loss. DATA SOURCES: We searched the PubMed database up to 
      December 2009 for English-language studies using the key words "aspirin AND 
      (heparin OR low molecular weight heparin), (antiphospholipid OR anticardiolipin 
      OR aPL) AND pregnancy." METHODS OF STUDY SELECTION: Two hundred ninety- two 
      studies were initially screened. Randomized controlled trials comparing the 
      effect of heparin (unfractionated heparin or low molecular weight heparin) plus 
      aspirin compared with aspirin alone on the live-birth rate in women with a 
      history of at least two miscarriages and antiphospholipid antibodies were 
      eligible. TABULATION, INTEGRATION, AND RESULTS: The pooled effect of 
      unfractionated heparin and low molecular weight heparin was evaluable in three 
      and two randomized controlled studies, respectively, with regard to live births, 
      which was the major outcome. Overall, treatment effects were in favor of heparin 
      against first-trimester losses (odd ratio [OR] 0.39, 95% confidence interval [CI] 
      0.24-0.65, number needed to treat 6). More specifically, unfractionated heparin 
      displayed a significant effect (OR 0.26, 95% CI 0.14-0.48, number needed to treat 
      4), while the pooled effect of low molecular weight heparin was insignificant (OR 
      0.70, 95% CI 0.34-1.45). Combination therapy of either unfractionated heparin or 
      low molecular weight heparin with aspirin failed to display any significant 
      effect in the prevention of late-pregnancy losses. No significant differences 
      were observed between treatment and control groups for any other outcomes. 
      CONCLUSION: The combination of unfractionated heparin and aspirin confers a 
      significant benefit in live births. However, the efficacy of low molecular weight 
      heparin plus aspirin remains unproven, highlighting the urgent need for large 
      controlled trials.
FAU - Ziakas, Panayiotis D
AU  - Ziakas PD
AD  - From the Department of Pathophysiology, Medical School, University of Athens, 
      Greece.
FAU - Pavlou, Matthaios
AU  - Pavlou M
FAU - Voulgarelis, Michael
AU  - Voulgarelis M
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Obstet Gynecol. 2010 Oct;116(4):997-8; author reply 998. PMID: 20859172
MH  - Abortion, Habitual/etiology/*prevention & control
MH  - Antiphospholipid Syndrome/complications/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Pregnancy
RF  - 42
EDAT- 2010/05/27 06:00
MHDA- 2010/07/02 06:00
CRDT- 2010/05/27 06:00
PHST- 2010/05/27 06:00 [entrez]
PHST- 2010/05/27 06:00 [pubmed]
PHST- 2010/07/02 06:00 [medline]
AID - 00006250-201006000-00023 [pii]
AID - 10.1097/AOG.0b013e3181deba40 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2010 Jun;115(6):1256-1262. doi: 10.1097/AOG.0b013e3181deba40.

PMID- 2491826
OWN - NLM
STAT- MEDLINE
DCOM- 19890207
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 96
IP  - 2 Pt 2 Suppl
DP  - 1989 Feb
TI  - Aspirin-induced gastric mucosal injury: lessons learned from animal models.
PG  - 606-14
AB  - This review of the mechanisms by which aspirin causes gastric mucosal damage 
      points to the involvement of two potential mechanisms. Aspirin, which inhibits 
      cyclooxygenase, is rapidly deacetylated to salicylate. Salicylate is toxic to 
      cells and affects mucosal barrier function, reduces cytosolic adenosine 
      triphosphate, stimulates sodium transport, and increases proton dissipation from 
      surface epithelial cells. Cyclooxygenase inhibition makes the gastric mucosa more 
      susceptible to injury, inhibits mucus and bicarbonate secretion, alters the 
      physicochemical nature of mucus, stimulates fundic but not antral [3H]thymidine 
      incorporation, and reduces epithelial surface hydrophobicity. No single mechanism 
      seems to be involved. It is likely, instead, that the toxic effects of salicylate 
      and the effect of cyclooxygenase inhibition work in concert to render the mucosa 
      more susceptible to injury, resulting in mucosal damage.
FAU - Kauffman, G
AU  - Kauffman G
AD  - Department of Surgery, Milton S. Hershey Medical Center, Pennsylvania State 
      University, Hershey.
LA  - eng
GR  - R01 DK38198/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacokinetics/*toxicity
MH  - Cyclooxygenase Inhibitors
MH  - Disease Models, Animal
MH  - Gastric Mucosa/blood supply/*drug effects/enzymology
MH  - Prostaglandins/biosynthesis
MH  - Regional Blood Flow
MH  - Stomach Ulcer/chemically induced/metabolism/*physiopathology
RF  - 49
EDAT- 1989/02/01 00:00
MHDA- 1989/02/01 00:01
CRDT- 1989/02/01 00:00
PHST- 1989/02/01 00:00 [pubmed]
PHST- 1989/02/01 00:01 [medline]
PHST- 1989/02/01 00:00 [entrez]
AID - S0016-5085(89)80056-3 [pii]
AID - 10.1016/s0016-5085(89)80056-3 [doi]
PST - ppublish
SO  - Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):606-14. doi: 
      10.1016/s0016-5085(89)80056-3.

PMID- 117424
OWN - NLM
STAT- MEDLINE
DCOM- 19800226
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 64
IP  - 6
DP  - 1979 Dec
TI  - A circulating inhibitor of platelet aggregation in Bartter's syndrome.
PG  - 939-41
AB  - Aggregation studies were performed on platelets from five patients with Bartter's 
      syndrome. Epinephrine failed to induce aggregation in all five patients. 
      Adenosine 5'-diphosphate (ADP) produced a single reversible phase of aggregation, 
      and there was depressed sensitivity to collagen. Response to ristocetin was 
      normal. There was a dose-related inhibition of ADP-induced platelet aggregation 
      when plasma from the patients was addeded to normal platelet-rich plasma. This 
      inhibition was diminished or absent when patients were receiving aspirin. Washed 
      platelets from two patients who were no longer undergoing aspirin therapy, showed 
      a normal response to epinephrine in normal platelet-poor plasma. Bleeding time 
      was reduced from 23 minutes to 12 minutes in one patient while on aspirin 
      therapy. These studies suggest that a circulating inhibitor of platelet 
      aggregation, probably of prostaglandin origin, is present in the plasma of 
      patients with Bartter's syndrome.
FAU - O'Reagan, S O
AU  - O'Reagan SO
FAU - Rivard, G E
AU  - Rivard GE
FAU - Mongeau, J G
AU  - Mongeau JG
FAU - Robitaille, P O
AU  - Robitaille PO
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adolescent
MH  - Adult
MH  - Aspirin/pharmacology/therapeutic use
MH  - Bartter Syndrome/*blood/drug therapy
MH  - Bleeding Time
MH  - Collagen/pharmacology
MH  - Cyclooxygenase Inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Epinephrine/pharmacology
MH  - Humans
MH  - Hyperaldosteronism/*blood
MH  - Infant
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
EDAT- 1979/12/01 00:00
MHDA- 1979/12/01 00:01
CRDT- 1979/12/01 00:00
PHST- 1979/12/01 00:00 [pubmed]
PHST- 1979/12/01 00:01 [medline]
PHST- 1979/12/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1979 Dec;64(6):939-41.

PMID- 7288383
OWN - NLM
STAT- MEDLINE
DCOM- 19811215
LR  - 20131121
IS  - 0022-104X (Print)
IS  - 0022-104X (Linking)
VI  - 216
IP  - 1
DP  - 1981 Apr
TI  - Aspirin-induced teratogenesis: a unique pattern of cell death and subsequent 
      polydactyly in the rat.
PG  - 107-12
AB  - Offspring of pregnant rats treated with a high dose of aspirin on day 11 of 
      gestation frequently had predominantly right-sided polydactyly of the hindlimbs 
      at term. Aspirin-treated embryos removed on day 12 exhibited a unique pattern of 
      preaxial mesodermal cell death in the hindlimb buds. In addition, these embryos 
      had a delay of the normal episode of cells death in the preaxial apical 
      ectodermal ridge and an absence of cell death in a zone of physiological necrosis 
      in the preaxial mesoderm thought to be instrumental in controlling preaxial digit 
      formation. The role of cell death in the pathogenesis of polydactyly is 
      discussed.
FAU - Klein, K L
AU  - Klein KL
FAU - Scott, W J
AU  - Scott WJ
FAU - Wilson, J G
AU  - Wilson JG
LA  - eng
GR  - HD09951/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Exp Zool
JT  - The Journal of experimental zoology
JID - 0375365
RN  - 0 (Teratogens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced/*pathology
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Cell Survival/drug effects
MH  - Culture Techniques
MH  - Ectoderm/drug effects
MH  - Female
MH  - Hindlimb/*abnormalities/embryology
MH  - Mesoderm/drug effects
MH  - Pregnancy
MH  - Rats
MH  - *Teratogens
EDAT- 1981/04/01 00:00
MHDA- 1981/04/01 00:01
CRDT- 1981/04/01 00:00
PHST- 1981/04/01 00:00 [pubmed]
PHST- 1981/04/01 00:01 [medline]
PHST- 1981/04/01 00:00 [entrez]
AID - 10.1002/jez.1402160111 [doi]
PST - ppublish
SO  - J Exp Zool. 1981 Apr;216(1):107-12. doi: 10.1002/jez.1402160111.

PMID- 33404873
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 0942-0940 (Electronic)
IS  - 0001-6268 (Linking)
VI  - 163
IP  - 5
DP  - 2021 May
TI  - Effects of aspirin and heparin treatment on perioperative outcomes in patients 
      with Moyamoya disease.
PG  - 1485-1491
LID - 10.1007/s00701-020-04668-0 [doi]
AB  - BACKGROUND: When superficial temporal artery-middle cerebral artery bypass is 
      combined with indirect methods (e.g., revascularization surgery) to treat 
      Moyamoya disease (MMD), antiplatelet treatment can impact bypass patency, 
      infarction, or hemorrhage complications. Recently, heparin has been proposed as 
      an anticoagulant treatment against white thrombus at the anastomosis site. The 
      study aims to evaluate the effect of aspirin on the perioperative outcomes and 
      investigate the results of heparin treatment for white thrombus. METHODS: This 
      retrospective study included 74 procedures of combined revascularization surgery 
      for MMD patients who either received or did not receive aspirin. Perioperative 
      outcomes were compared between the two groups. In addition, the effects of 
      heparin treatment for white thrombus were evaluated. RESULTS: The rate of white 
      thrombus at the anastomosis site was significantly higher in the non-aspirin 
      medication group (univariate: p = 0.032, multivariate: p = 0.044) and, 
      accordingly, initial bypass patency was lower in the non-aspirin medication group 
      (p = 0.049). Of the 17 patients with white thrombus development, five received 
      heparin injections, and all white thrombi disappeared; however, there was one 
      case of epidural hematoma and another of subdural hematoma. The risk of 
      hemorrhagic complications was significantly higher in the surgical procedures 
      that received heparin injections (p = 0.021). CONCLUSIONS: In MMD patients who 
      received combined revascularization surgery, aspirin medication lowered the 
      occurrence of white thrombus. Heparin injections help to treat white thrombus but 
      can enhance the risk of hemorrhagic complications.
FAU - Kanamori, Fumiaki
AU  - Kanamori F
AUID- ORCID: 0000-0001-7899-5149
AD  - Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 
      Tsurumai, Showa-ku, Nagoya, Aichi, 466-8550, Japan. 
      kanamori.fumiaki@f.mbox.nagoya-u.ac.jp.
FAU - Araki, Yoshio
AU  - Araki Y
AD  - Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 
      Tsurumai, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
FAU - Yokoyama, Kinya
AU  - Yokoyama K
AD  - Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 
      Tsurumai, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
FAU - Uda, Kenji
AU  - Uda K
AD  - Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 
      Tsurumai, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
FAU - Mamiya, Takashi
AU  - Mamiya T
AD  - Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 
      Tsurumai, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
FAU - Nishihori, Masahiro
AU  - Nishihori M
AD  - Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 
      Tsurumai, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
FAU - Izumi, Takashi
AU  - Izumi T
AD  - Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 
      Tsurumai, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
FAU - Okamoto, Sho
AU  - Okamoto S
AD  - Aichi Rehabilitation Hospital, Nishio, Japan.
FAU - Natsume, Atsushi
AU  - Natsume A
AD  - Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 
      Tsurumai, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210106
PL  - Austria
TA  - Acta Neurochir (Wien)
JT  - Acta neurochirurgica
JID - 0151000
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebral Revascularization/adverse effects/*methods
MH  - Heparin/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Middle Cerebral Artery/surgery
MH  - Moyamoya Disease/drug therapy/*surgery
MH  - Postoperative Complications/*epidemiology
MH  - Temporal Arteries/surgery
OTO - NOTNLM
OT  - Anticoagulant treatment
OT  - Antiplatelet treatment
OT  - Moyamoya disease
OT  - Surgical revascularization
EDAT- 2021/01/07 06:00
MHDA- 2021/07/09 06:00
CRDT- 2021/01/06 12:19
PHST- 2020/09/04 00:00 [received]
PHST- 2020/12/01 00:00 [accepted]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2021/01/06 12:19 [entrez]
AID - 10.1007/s00701-020-04668-0 [pii]
AID - 10.1007/s00701-020-04668-0 [doi]
PST - ppublish
SO  - Acta Neurochir (Wien). 2021 May;163(5):1485-1491. doi: 
      10.1007/s00701-020-04668-0. Epub 2021 Jan 6.

PMID- 36055271
OWN - NLM
STAT- MEDLINE
DCOM- 20221020
LR  - 20221020
IS  - 1098-9064 (Electronic)
IS  - 0094-6176 (Linking)
VI  - 48
IP  - 7
DP  - 2022 Oct
TI  - The Applicability of Thromboelastography in Acute Ischemic Stroke: A Literature 
      Review.
PG  - 842-849
LID - 10.1055/s-0042-1753529 [doi]
AB  - Acute ischemic stroke (AIS) due to cerebral artery occlusion is often treated by 
      thrombolytics or antithrombotic drugs. Thromboelastography (TEG) is a noninvasive 
      test that provides a dynamic overview of the coagulation process. TEG may help 
      guide thrombolytic and antithrombotic therapy in AIS. This article aims to 
      highlight the potential use of TEG in AIS patients by reviewing available 
      studies. We conducted a literature review, including PubMed and Cochrane library 
      databases. The following keywords were used to find relevant studies: 
      thromboelastography, TEG, acute ischemic stroke, stroke, coagulopathy, 
      antiplatelet, and anticoagulant treatment. We identified 142 papers and after 
      abstract review, we included 24 studies in this report. TEG identified a 
      hypercoagulable state in AIS patients represented by short R, K, and greater α: 
      angle in all papers included. Modification of TEG parameters induced by 
      intravenous thrombolysis was inconsistent but prolonged lysis (increased LY30) 
      and weaker clots (lower maximum amplitude) were most frequent. TEG detected 
      hypo-coagulopathy induced by dual antiplatelet therapy as well as antiplatelet 
      drug resistance, with ticagrelor and aspirin having greater inhibition of 
      platelet activity. A prolonged R-value seems to be the most reliable TEG 
      parameter in detecting the anticoagulant effect of factor Xa inhibitor treatment. 
      TEG might represent a useful point-of-care test for emergency decision-making in 
      AIS patients and a tool for individualized treatment options. This hypothesis 
      needs validation in a large cohort of prospectively studied AIS patients.
CI  - Thieme. All rights reserved.
FAU - Pîrlog, Bianca O
AU  - Pîrlog BO
AD  - Department of Neurology, County Emergency Hospital, Cluj-Napoca, Romania.
AD  - University of Medicine and Pharmacy "Iuliu Hațieganu" Cluj-Napoca, Romania.
FAU - Grotta, James C
AU  - Grotta JC
AD  - Memorial Hermann Hospital-Texas Medical Center, Houston, Texas.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220902
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - GLH0314RVC (Ticagrelor)
RN  - 0 (Factor Xa Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Thrombelastography
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Fibrinolytic Agents/therapeutic use
MH  - *Ischemic Stroke
MH  - Ticagrelor
MH  - Factor Xa Inhibitors
MH  - Aspirin/therapeutic use
MH  - *Blood Coagulation Disorders/drug therapy
COIS- J.C.G. serves on the Scientific Advisory Council for Haemonetics, the 
      manufacturer of TEG equipment.
EDAT- 2022/09/03 06:00
MHDA- 2022/10/21 06:00
CRDT- 2022/09/02 18:52
PHST- 2022/09/03 06:00 [pubmed]
PHST- 2022/10/21 06:00 [medline]
PHST- 2022/09/02 18:52 [entrez]
AID - 10.1055/s-0042-1753529 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2022 Oct;48(7):842-849. doi: 10.1055/s-0042-1753529. Epub 
      2022 Sep 2.

PMID- 475592
OWN - NLM
STAT- MEDLINE
DCOM- 19791024
LR  - 20190902
IS  - 0340-5761 (Print)
IS  - 0340-5761 (Linking)
VI  - 42
IP  - 3
DP  - 1979 Jul 11
TI  - The effects of aspirin on the development of the mouse third molar. A potential 
      screening system for weak teratogens.
PG  - 185-90
AB  - Aspirin is teratogenic at high doses in rodents. A dose related effect is shown 
      at much lower levels in an animal testing system which permits subthreshold 
      effects on development to be measured. This system, which depends on changes in 
      tooth size in the mouse, has advantages in assessing weak or cumulative 
      teratogens.
FAU - Berry, C L
AU  - Berry CL
FAU - Nickols, C D
AU  - Nickols CD
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arch Toxicol
JT  - Archives of toxicology
JID - 0417615
RN  - 0 (Teratogens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical/*methods
MH  - Female
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Molar/*drug effects/growth & development
MH  - *Teratogens
EDAT- 1979/07/11 00:00
MHDA- 1979/07/11 00:01
CRDT- 1979/07/11 00:00
PHST- 1979/07/11 00:00 [pubmed]
PHST- 1979/07/11 00:01 [medline]
PHST- 1979/07/11 00:00 [entrez]
AID - 10.1007/BF00353710 [doi]
PST - ppublish
SO  - Arch Toxicol. 1979 Jul 11;42(3):185-90. doi: 10.1007/BF00353710.

PMID- 8246728
OWN - NLM
STAT- MEDLINE
DCOM- 19931230
LR  - 20131121
IS  - 0025-7680 (Print)
IS  - 0025-7680 (Linking)
VI  - 53
IP  - 1
DP  - 1993
TI  - [Antipyretic effect of indomethacin vs aspirin in fever of tumor origin].
PG  - 35-8
AB  - Fever is frequently a symptom in patients suffering from cancer and in most cases 
      it is related to infections or complications of the treatment. Some cancers can 
      also be the direct cause of fever. A total of 28 episodes of fever in 8 patients 
      with cancer were studied. The diagnoses were: 3 patients with lung cancer, 1 
      patient with chronic myelogenous leukemia, 1 patient with kidney cancer, 2 
      patients with non-Hodgkin lymphoma, and 1 patient with Hodgkin's disease. Were 
      included cancer diagnosed patients of any age and sex, with three or more 
      episodes of fever of more than 37.5 C (with a case of 38.5 C or more) after 
      having eliminated any infectious etiology or fever caused by drugs. Were not 
      excluded any patients who had received whole blood or blood derivative 
      transfusions, chemotherapy or antibiotic treatment up to 48 hs before the fever 
      peak. The patients were given intramuscularly 500 mg of aspirin or 50 mg of 
      indomethacin. The first response in the temperature curve was evaluated while 
      checking the axillary temperature six hours after drug administration and 48 hs 
      later if the fever persisted. The patients who were given aspirin at first, were 
      then given indomethacin and vice versa, using the same criteria to evaluate the 
      response. In patients treated with indomethacin the temperature diminished 
      quickly and completely (Fig. 1), unlike the effect achieved with the use of 
      aspirin (Fig. 2). All patients treated with indomethacin also showed a remarkable 
      clinical improvement which was not observed when aspirin was used.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Berbotto, G A
AU  - Berbotto GA
AD  - Servicio de Clínica Médica, Hospital Provincial, Rosario, Argentina.
FAU - Asef, S G
AU  - Asef SG
FAU - Elias, G
AU  - Elias G
FAU - Ostoich, M T
AU  - Ostoich MT
FAU - Teglia, O
AU  - Teglia O
LA  - spa
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Efecto antipirético de la indometacina versus aspirina en la fiebre de origen 
      tumoral.
PL  - Argentina
TA  - Medicina (B Aires)
JT  - Medicina
JID - 0204271
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Body Temperature
MH  - Female
MH  - Fever/*drug therapy/etiology
MH  - Humans
MH  - Indomethacin/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*complications
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Medicina (B Aires). 1993;53(1):35-8.

PMID- 7048482
OWN - NLM
STAT- MEDLINE
DCOM- 19820910
LR  - 20131121
IS  - 0035-3787 (Print)
IS  - 0035-3787 (Linking)
VI  - 138
IP  - 1
DP  - 1982
TI  - [Controlled cooperative trial. Secondary prevention of atherosclerosis-related 
      cerebral ischemic accidents by aspirin dipyridamole. 2: Description of subjects 
      at the beginning of the trial].
PG  - 1-15
AB  - This paper is the second devoted to the controlled trial "A.I.C.L.A." comparing 
      aspirin, aspirin + dipyridamole and placebo in the secondary prevention of 
      athero-thrombotic cerebral ischaemic events. It presents the description and 
      distribution of baseline characteristics at entry. Six hundred and four patients 
      (men: 70 p. 100, mean age : 63) were entered. Risk factors were distributed as 
      follows: arterial hypertension: 63 p. 100, Diabetes: 24 p. 100, High blood 
      lipids: 26 p. 100, high uric acid: 20 p. 100, hematocrit greater than 46 p. 100: 
      34 p. 100, cigarette smoking: 64 p. 100, angina pectoris and myocardial 
      infarction: 15 p. 100, peripheral vascular disease: 7 p. 100, 37 p. 100 of 
      patients had a stroke prior to entry. The ischemic event at entry occurred not 
      more than one year prior to randomization and less than 3 months in 77 p. 100. It 
      was much more often a completed stroke (84 p. 100) than a transient ischaemic 
      attack (16 p. 100) and was referrable either to the carotid (46 p. 100) or the 
      vertebrobasilar circulation (50 p. 100). On the whole patients are older and 
      strokes more severe than in other similar studies. Randomization produced 
      remarkably comparable treatment groups since almost no significant difference was 
      observed between the 3 groups.
FAU - Bousser, M G
AU  - Bousser MG
FAU - Eschwege, E
AU  - Eschwege E
FAU - Haguenau, M
AU  - Haguenau M
FAU - Lefauconnier, J M
AU  - Lefauconnier JM
FAU - Thibult, N
AU  - Thibult N
FAU - Touboul, D
AU  - Touboul D
FAU - Touboul, P J
AU  - Touboul PJ
LA  - fre
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Essai coopératif contrôlé "A.I.C.L.A." Prévention secondaire des accidents 
      ischémiques cérébraux liés à l'athérosclérose par l'aspirine et le dipyridamole. 
      2e partie: Description des sujets à l'entrée dans l'essai.
PL  - France
TA  - Rev Neurol (Paris)
JT  - Revue neurologique
JID - 2984779R
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Brain Ischemia/diagnosis/*prevention & control
MH  - Cerebral Infarction/diagnosis/*prevention & control
MH  - Clinical Trials as Topic
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Intracranial Arteriosclerosis/*complications/diagnosis
MH  - Male
MH  - Middle Aged
MH  - Risk
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Neurol (Paris). 1982;138(1):1-15.

PMID- 15651282
OWN - NLM
STAT- MEDLINE
DCOM- 20050304
LR  - 20131121
IS  - 0009-918X (Print)
IS  - 0009-918X (Linking)
VI  - 44
IP  - 11
DP  - 2004 Nov
TI  - [Primary prevention of thrombosis for patients with atrial fibrillation].
PG  - 752-5
AB  - Clinical importance of antithrombotic prophylaxis strategy for patients with 
      atrial fibrillation has been focused because of the high prevalence of severe 
      cerebral embolism especially in elderly patients. Several multicenter, randomized 
      clinical trials for prevention of thromboemblolism performed in the Western 
      countries have revealed efficacy of the anticoagulation therapy with warfarin 
      over the anti-platelet aggregation therapy with aspirin. Therapeutic guideline 
      for thromboembolism in patients with atrial fibrillation has been established 
      based on these observations. However, special attentions should be paid for 
      applying the guideline for Japanese patients since bleeding risk in 
      antithrombotic treatment seems to be high in Japanese. Recently, therapeutic 
      guideline for thromboembolism in Japanese patients with atrial fibrillation has 
      been established. In this guideline, treatment with warfarin is also recommended 
      for patients with atrial fibrillation. However treatment target of warfarin, ie, 
      PT-INR, is designated rather low in Japanese patients, especially in eldely 
      patients over 75 years old. Usage of antiplatelet treatment with aspirin is also 
      described in this guideline for Japanese, however, the evidence suggesting the 
      usefulness for prophylaxis with aspirin is not sufficiently obtained in Japanese 
      patients. Further clinical studies for antithrombotic treatment are needed for 
      Japanese patients with atrial fibrillation.
FAU - Hori, Masatsugu
AU  - Hori M
AD  - Department of Internal Medicine and Therapeutics, Osaka University Graduate 
      School of Medicine.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Shinkeigaku
JT  - Rinsho shinkeigaku = Clinical neurology
JID - 0417466
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Humans
MH  - Intracranial Thrombosis/*prevention & control
MH  - Japan
MH  - Practice Guidelines as Topic
MH  - Warfarin/therapeutic use
EDAT- 2005/01/18 09:00
MHDA- 2005/03/05 09:00
CRDT- 2005/01/18 09:00
PHST- 2005/01/18 09:00 [pubmed]
PHST- 2005/03/05 09:00 [medline]
PHST- 2005/01/18 09:00 [entrez]
PST - ppublish
SO  - Rinsho Shinkeigaku. 2004 Nov;44(11):752-5.

PMID- 7143483
OWN - NLM
STAT- MEDLINE
DCOM- 19830119
LR  - 20131121
IS  - 0098-4108 (Print)
IS  - 0098-4108 (Linking)
VI  - 10
IP  - 2
DP  - 1982 Aug
TI  - Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 
      and Wistar strains.
PG  - 297-305
AB  - The Fischer 344 rat is being used increasingly in toxicology studies. There have 
      been few reports in which rats of this strain were used in teratology and 
      reproduction studies, but comparison of teratologic data with other toxic and 
      points and kinetic information would be greatly facilitated by using the same 
      strain. Therefore, the embryotoxic effects of two positive teratogens, aspirin 
      and hydroxyurea, were compared in Fischer rats and in the commonly used Wistar 
      rats. Aspirin was administered in single oral doses of 500 and 625 mg/kg on d 10; 
      hydroxyurea was injected ip at 500 mg/kg on d 11. Dams were sacrificed on d 20 
      and fetuses examined for skeletal and visceral defects. Male and female fetal 
      weights and lengths were significantly reduced in treated groups in both strains. 
      Both teratogens caused a significant increase in resorptions in Wistar and 
      Fischer rats. A wide variety of skeletal alterations were induced by both 
      teratogens in both strains. These included extra ribs, fused or missing ribs, 
      extra thoracic and lumbar vertebrae, split vertebral centra, and missing 
      vertebrae. Only a small number of Fischer fetuses exhibited visceral 
      malformations such as hydrocephaly and cleft palate. The frequency of soft-tissue 
      malformations, including cleft palate and severe cardiac anomalies, was much 
      higher in Wistar fetuses.
FAU - DePass, L R
AU  - DePass LR
FAU - Weaver, E V
AU  - Weaver EV
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Toxicol Environ Health
JT  - Journal of toxicology and environmental health
JID - 7513622
RN  - 0 (Teratogens)
RN  - R16CO5Y76E (Aspirin)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Abnormalities, Drug-Induced/physiopathology
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Female
MH  - Hydroxyurea/*toxicity
MH  - Pregnancy
MH  - Rats
MH  - Rats, Inbred F344
MH  - Rats, Inbred Strains
MH  - Species Specificity
MH  - *Teratogens
EDAT- 1982/08/01 00:00
MHDA- 1982/08/01 00:01
CRDT- 1982/08/01 00:00
PHST- 1982/08/01 00:00 [pubmed]
PHST- 1982/08/01 00:01 [medline]
PHST- 1982/08/01 00:00 [entrez]
AID - 10.1080/15287398209530252 [doi]
PST - ppublish
SO  - J Toxicol Environ Health. 1982 Aug;10(2):297-305. doi: 10.1080/15287398209530252.

PMID- 22059476
OWN - NLM
STAT- MEDLINE
DCOM- 20120710
LR  - 20220408
IS  - 1471-2474 (Electronic)
IS  - 1471-2474 (Linking)
VI  - 12
DP  - 2011 Nov 7
TI  - Bleeding and first-year mortality following hip fracture surgery and preoperative 
      use of low-dose acetylsalicylic acid: an observational cohort study.
PG  - 254
LID - 10.1186/1471-2474-12-254 [doi]
AB  - BACKGROUND: Hip fracture is associated with high mortality. Cardiovascular 
      disease and other comorbidities requiring long-term anticoagulant medication are 
      common in these mostly elderly patients. The objective of our observational 
      cohort study of patients undergoing surgery for hip fracture was to study the 
      association between preoperative use of low-dose acetylsalicylic acid (LdAA) and 
      intraoperative blood loss, blood transfusion and first-year all-cause mortality. 
      METHODS: An observational cohort study was conducted on patients with hip 
      fracture (cervical requiring hemiarthroplasty or pertrochanteric or 
      subtrochanteric requiring internal fixation) participating in a randomized trial 
      that found lack of efficacy of a compression bandage in reducing postoperative 
      bleeding. The participants were 255 patients (≥50 years) of whom 118 (46%) were 
      using LdAA (defined as ≤320 mg daily) preoperatively. Bleeding variables in 
      patients with and without LdAA treatment at time of fracture were measured and 
      blood transfusions given were compared using logistic regression. The association 
      between first-year mortality and preoperative use of LdAA was analyzed with Cox 
      regression adjusting for age, sex, type of fracture, baseline renal dysfunction 
      and baseline cardiovascular and/or cerebrovascular disease. RESULTS: Blood 
      transfusions were given postoperatively to 74 (62.7%) LdAA-treated and 76 (54%) 
      non-treated patients; the adjusted odds ratio was 1.8 (95% CI 1.04 to 3.3). 
      First-year mortality was significantly higher in LdAA-treated patients; the 
      adjusted hazard ratio (HR) was 2.35 (95% CI 1.23 to 4.49). The mortality was also 
      higher with baseline cardiovascular and/or cerebrovascular disease, adjusted HR 
      2.78 (95% CI 1.31 to 5.88). Patients treated with LdAA preoperatively were 
      significantly more likely to suffer thromboembolic events (5.7% vs. 0.7%, P = 
      0.03). CONCLUSIONS: In patients with hip fracture (cervical treated with 
      hemiarthroplasty or pertrochanteric or subtrochanteric treated with internal 
      fixation) preoperative use of low-dose acetylsalicylic acid was associated with 
      significantly increased need for postoperative blood transfusions and 
      significantly higher all-cause mortality during one year after surgery.
FAU - Kragh, Annika M
AU  - Kragh AM
AD  - Department of Orthopedics, Hässleholm Hospital, SE-281 25 Hässleholm, Sweden. 
      annikakragh@gmail.com
FAU - Waldén, Markus
AU  - Waldén M
FAU - Apelqvist, Anna
AU  - Apelqvist A
FAU - Wagner, Philippe
AU  - Wagner P
FAU - Atroshi, Isam
AU  - Atroshi I
LA  - eng
PT  - Journal Article
DEP - 20111107
PL  - England
TA  - BMC Musculoskelet Disord
JT  - BMC musculoskeletal disorders
JID - 100968565
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Loss, Surgical/*mortality
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hip Fractures/*mortality/*surgery
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Preoperative Care
MH  - Randomized Controlled Trials as Topic
PMC - PMC3220640
EDAT- 2011/11/09 06:00
MHDA- 2012/07/11 06:00
CRDT- 2011/11/09 06:00
PHST- 2011/05/28 00:00 [received]
PHST- 2011/11/07 00:00 [accepted]
PHST- 2011/11/09 06:00 [entrez]
PHST- 2011/11/09 06:00 [pubmed]
PHST- 2012/07/11 06:00 [medline]
AID - 1471-2474-12-254 [pii]
AID - 10.1186/1471-2474-12-254 [doi]
PST - epublish
SO  - BMC Musculoskelet Disord. 2011 Nov 7;12:254. doi: 10.1186/1471-2474-12-254.

PMID- 9095107
OWN - NLM
STAT- MEDLINE
DCOM- 19970501
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 42
IP  - 3
DP  - 1997 Mar
TI  - Resuscitation from hemorrhagic shock with diaspirin cross-linked hemoglobin, 
      blood, or hetastarch.
PG  - 406-12; discussion 412-4
AB  - BACKGROUND: An oxygen-transporting hemoglobin solution should be more effective 
      than a nonhemoglobin solution for resuscitation from hemorrhagic shock. A way to 
      evaluate this effectiveness is to determine whether a hemoglobin solution can 
      reverse the base deficit accumulated during hemorrhage at a faster rate than a 
      nonhemoglobin solution. Using this criterion, we compared the resuscitative 
      powers of autologous blood, hetastarch (Het), and diaspirin cross-linked 
      hemoglobin (DCLHb). METHODS: Fifteen sedated, spontaneously breathing sheep (37.5 
      +/- 10.2 kg) were bled until base deficits fell to -5 to -10 mEq/L, and plasma 
      lactate concentrations rose to 6 to 9 mg/L. The animals were resuscitated with 
      autologous blood (n = 5), Het (n = 5), or DCLHb (n = 5) (3.5-4.0 mL/kg every 15 
      minutes) until base deficits returned to prehemorrhage baseline. RESULTS: 
      Exsanguination to target base deficits required removal of an average of 41.4 +/- 
      5.5 mL blood/kg (estimated total blood volume, 80 mL/kg). Resuscitation required 
      18 +/- 3, 38 +/- 2 (different from blood), and 35 +/- 1 (different from blood) 
      mL/kg of autologous blood, Het and DCLHb, respectively, over periods of 78 +/- 8, 
      163 +/- 10 (different from blood), and 129 +/- 9 minutes (different from blood 
      and different from Het (p < or = 0.05)). Based on regression analysis, autologous 
      blood, Het, and DCLHb corrected the base deficit at rates of, respectively, 0.074 
      (different from Het (p < or = 0.05)), 0.016, and 0.056 (different from Het (P < 
      or = 0.05)) mEq/L/min. CONCLUSIONS: Based on the rate of base deficit correction 
      and the volume of solution required, autologous blood was the most effective 
      resuscitation solution. However, DCLHb was more effective than Het. DCLHb may be 
      an attractive alternative to blood for resuscitation from hemorrhagic shock.
FAU - DeAngeles, D A
AU  - DeAngeles DA
AD  - Department of Surgery, University of Wisconsin-Madison Medical School, USA.
FAU - Scott, A M
AU  - Scott AM
FAU - McGrath, A M
AU  - McGrath AM
FAU - Korent, V A
AU  - Korent VA
FAU - Rodenkirch, L A
AU  - Rodenkirch LA
FAU - Conhaim, R L
AU  - Conhaim RL
FAU - Harms, B A
AU  - Harms BA
LA  - eng
GR  - HL46236/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Hydroxyethyl Starch Derivatives)
RN  - 0 (Lactates)
RN  - 0 (Plasma Substitutes)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Gas Analysis
MH  - Blood Substitutes/*therapeutic use
MH  - *Blood Transfusion, Autologous
MH  - Hemodynamics
MH  - Hemoglobins/analysis/*therapeutic use
MH  - Hydroxyethyl Starch Derivatives/*therapeutic use
MH  - Lactates/blood
MH  - Oxygen/blood
MH  - Oxygen Consumption
MH  - Plasma Substitutes/*therapeutic use
MH  - Regression Analysis
MH  - Sheep
MH  - Shock, Hemorrhagic/physiopathology/*therapy
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
AID - 10.1097/00005373-199703000-00007 [doi]
PST - ppublish
SO  - J Trauma. 1997 Mar;42(3):406-12; discussion 412-4. doi: 
      10.1097/00005373-199703000-00007.

PMID- 12659201
OWN - NLM
STAT- MEDLINE
DCOM- 20031010
LR  - 20190717
IS  - 0003-2700 (Print)
IS  - 0003-2700 (Linking)
VI  - 75
IP  - 6
DP  - 2003 Mar 15
TI  - A metal nebulizer capillary electrophoresis/Fourier transform infrared 
      spectrometric interface.
PG  - 1393-9
AB  - A capillary electrophoretic (CE) system has been successfully interfaced to a 
      Fourier transform infrared spectrometer. The advantage of such an interface is 
      that analytes may be detected and often unequivocally identified without analyte 
      derivatization. The interface consists of a stainless steel tube in which the CE 
      capillary is placed and the two are held in contact with the use of a metal tee. 
      A solvent elimination approach is used with the interface, so that analytes are 
      deposited onto an infrared transparent window, that is, CaF2, and measured with 
      the use of an infrared microscope. A critical component of this design is to 
      provide an electrical connection at the end of the CE column to permit stable 
      separations that allow for efficient transport of the sample onto the window. The 
      interface produces an aerosol that is directed at the surface of the infrared 
      transparent window. The use of a volatile electrolyte, along with the flow of 
      helium, allows for partial evaporation of the electrolyte in flight and complete 
      evaporation of the solvent and electrolyte on the surface of the window to 
      produce a "dry", or neat, analyte deposit.
FAU - Todebush, Richard A
AU  - Todebush RA
AD  - University of Georgia, Department of Chemistry, Athens, Georgia 30602-2556, USA.
FAU - He, Lin-Tao
AU  - He LT
FAU - de Haseth, James A
AU  - de Haseth JA
LA  - eng
GR  - 2P41-RR-05351/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
RN  - 0 (Quaternary Ammonium Compounds)
RN  - 3G6A5W338E (Caffeine)
RN  - KM15WK8O5T (Acetylgalactosamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylgalactosamine/analysis
MH  - Aspirin/analysis
MH  - Caffeine/analysis
MH  - Electrophoresis, Capillary/*instrumentation
MH  - Equipment Design
MH  - Methods
MH  - Nebulizers and Vaporizers
MH  - Quaternary Ammonium Compounds/analysis
MH  - Spectroscopy, Fourier Transform Infrared/*instrumentation
EDAT- 2003/03/28 05:00
MHDA- 2003/10/11 05:00
CRDT- 2003/03/28 05:00
PHST- 2003/03/28 05:00 [pubmed]
PHST- 2003/10/11 05:00 [medline]
PHST- 2003/03/28 05:00 [entrez]
AID - 10.1021/ac025858g [doi]
PST - ppublish
SO  - Anal Chem. 2003 Mar 15;75(6):1393-9. doi: 10.1021/ac025858g.

PMID- 6820297
OWN - NLM
STAT- MEDLINE
DCOM- 19830610
LR  - 20190511
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 68
IP  - 3
DP  - 1980 Mar
TI  - The effect of sodium salicylate on cerebral blood flow and metabolism.
PG  - 407-11
AB  - 1 The effect of intravenous sodium salicylate on cerebral oxygen consumption and 
      cerebral blood flow and its response to hypercapnia was measured by the 133Xenon 
      intracarotid injection technique in ten baboons. 2 After an initial peak, the 
      plasma salicylate level maintained a stable value for 2 h of 1 mmol/l with 50 
      mg/kg sodium salicylate and 2.5 mmol/l with 200 mg/kg sodium salicylate. 3 Sodium 
      salicylate (50 mg/kg) produced no change in baseline cerebral blood flow (CBF) or 
      cerebral oxygen consumption (CMRO2) but the CBF response to hypercapnia was 
      reduced by 41% during the first hour. During the second hour after salicylate 
      administration, CMRO2 increased by 26%, CBF at normocapnia increased by 31% and 
      the CBF response to hypercapnia was 67% of the baseline value. 4 Sodium 
      salicylate (200 mg/kg) increased CMRO2 by 65%. There was no significant change in 
      CBF at normocapnia or hypercapnia. 5 These results confirm that inhibitors of 
      prostaglandin synthesis, which can cross the blood brain barrier in sufficient 
      quantity, reduce the response of the cerebral circulation to hypercapnia. The 
      difficulties in interpreting changes in the CBF CO2 response in the presence of 
      increases in CMRO2 are discussed. It is suggested that the respiratory 
      stimulation seen in salicylate intoxication is the result of a central metabolic 
      stimulation.
FAU - Pickard, J D
AU  - Pickard JD
FAU - Rose, J E
AU  - Rose JE
FAU - Shaw, M D
AU  - Shaw MD
FAU - Strathdee, A
AU  - Strathdee A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 142M471B3J (Carbon Dioxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Body Temperature/drug effects
MH  - Brain/*metabolism
MH  - Carbon Dioxide/pharmacology
MH  - Cerebrovascular Circulation/*drug effects
MH  - Female
MH  - Male
MH  - Oxygen Consumption/*drug effects
MH  - Papio
PMC - PMC2044200
EDAT- 1980/03/01 00:00
MHDA- 1980/03/01 00:01
CRDT- 1980/03/01 00:00
PHST- 1980/03/01 00:00 [pubmed]
PHST- 1980/03/01 00:01 [medline]
PHST- 1980/03/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1980.tb14554.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1980 Mar;68(3):407-11. doi: 10.1111/j.1476-5381.1980.tb14554.x.

PMID- 29341525
OWN - NLM
STAT- MEDLINE
DCOM- 20190429
LR  - 20190429
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 14
IP  - 590
DP  - 2018 Jan 17
TI  - [General internal medicine : 2017 scientific breakthroughs in ambulatory care].
PG  - 130-134
AB  - Bariatric surgery improves glycemic control in obese patients with diabetes type 
      2. Dual antiplatelet therapy can be maintained beyond 12 months after a 
      myocardial infarction. Levothyroxine is not beneficial among patients ≥ 65 years 
      that have subclinical hypothyroidism. Prophylactic anticoagulation in lower limb 
      immobilisation should be reserved only for patients with a high risk of 
      thromboembolism. A diagnosis of asthma should be initially confirmed by a 
      spirometry if clinically suspected. A proton pump inhibitor is indicated for 
      patients ≥ 65 years that are treated with aspirin. Beta-lactams should not be 
      avoided in patients with a previous history of non-severe allergy. General 
      internists overestimate harms and benefits of common medical tests and 
      treatments.
FAU - Gouveia, Alexandre
AU  - Gouveia A
AD  - Policlinique médicale universitaire, Rue du Bugnon 44, 1011 Lausanne.
FAU - De Alencastro, Lionel
AU  - De Alencastro L
AD  - Policlinique médicale universitaire, Rue du Bugnon 44, 1011 Lausanne.
FAU - Fierz, Yvonne
AU  - Fierz Y
AD  - Policlinique médicale universitaire, Rue du Bugnon 44, 1011 Lausanne.
FAU - Koehli, Lionel
AU  - Koehli L
AD  - Policlinique médicale universitaire, Rue du Bugnon 44, 1011 Lausanne.
FAU - Béguelin, Alexandre
AU  - Béguelin A
AD  - Policlinique médicale universitaire, Rue du Bugnon 44, 1011 Lausanne.
FAU - Pasche, Olivier
AU  - Pasche O
AD  - Policlinique médicale universitaire, Rue du Bugnon 44, 1011 Lausanne.
FAU - Selby, Kevin
AU  - Selby K
AD  - Policlinique médicale universitaire, Rue du Bugnon 44, 1011 Lausanne.
FAU - Bodenmann, Patrick
AU  - Bodenmann P
AD  - Policlinique médicale universitaire, Rue du Bugnon 44, 1011 Lausanne.
LA  - fre
PT  - Journal Article
TT  - Médecine interne générale ambulatoire : avancées scientifiques en 2017.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - Q51BO43MG4 (Thyroxine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Ambulatory Care/trends
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Internal Medicine/trends
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Thyroxine
COIS- Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
EDAT- 2018/01/18 06:00
MHDA- 2019/04/30 06:00
CRDT- 2018/01/18 06:00
PHST- 2018/01/18 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2019/04/30 06:00 [medline]
AID - RMS0590-003 [pii]
PST - ppublish
SO  - Rev Med Suisse. 2018 Jan 17;14(590):130-134.

PMID- 1458181
OWN - NLM
STAT- MEDLINE
DCOM- 19930111
LR  - 20181130
IS  - 0869-2092 (Print)
IS  - 0869-2092 (Linking)
VI  - 55
IP  - 4
DP  - 1992 Jul-Aug
TI  - [The enhanced efficacy of the pharmacological regulation of the processes of 
      blood cell activation and interaction in the flow by polymer additives decreasing 
      the hydrodynamic resistance of the blood].
PG  - 25-8
AB  - The increase of blood cell auto- and interactivation and the decrease of aspirin 
      antiaggregant effect were demonstrated under hemodynamic conditions of a stenotic 
      zone in a model maximally approached to the real blood circulation. The lowering 
      of platelet activation, of the release of active agents from platelets, and of 
      platelet-leukocyte interactivation was attained under the conditions of the flow 
      modified by the drag-reducing polymer solution. The recovery of aspirin 
      antiaggregant activity and aspirin-induced reduction of the total platelet 
      release of platelet- and leukocyte-activating agents were demonstrated under the 
      influence of the polymer.
FAU - Akopov, S E
AU  - Akopov SE
FAU - Konorova, I L
AU  - Konorova IL
FAU - Grigorian, M R
AU  - Grigorian MR
FAU - Gabrielian, E S
AU  - Gabrielian ES
FAU - Gannushkina, I V
AU  - Gannushkina IV
LA  - rus
PT  - Journal Article
TT  - Povyshenie éffektivnosti farmakologicheskoĭ reguliatsii protsessov aktivatsii i 
      vzaimodeĭstviia kletok krovi v potoke polimernymi dobavkami, snizhaiushchimi 
      gidrodinamicheskoe soprotivlenie krovi.
PL  - Russia (Federation)
TA  - Eksp Klin Farmakol
JT  - Eksperimental'naia i klinicheskaia farmakologiia
JID - 9215981
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - 9007-34-5 (Collagen)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Blood Flow Velocity/*drug effects
MH  - Blood Viscosity/*drug effects
MH  - Cell Communication/*drug effects
MH  - Collagen/pharmacology
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Lymphocyte Activation/*drug effects
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Models, Structural
MH  - N-Formylmethionine Leucyl-Phenylalanine/pharmacology
MH  - Neutrophils/*drug effects/physiology
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Polyethylene Glycols/*pharmacology
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
PST - ppublish
SO  - Eksp Klin Farmakol. 1992 Jul-Aug;55(4):25-8.

PMID- 12390104
OWN - NLM
STAT- MEDLINE
DCOM- 20030131
LR  - 20190901
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 16
IP  - 11
DP  - 2002 Nov
TI  - Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for 
      the prevention of cardiovascular diseases.
PG  - 1945-53
AB  - BACKGROUND: Most patients with vascular-occlusive diseases benefit from low-dose 
      aspirin (75-325 mg/day). However, they have an increased risk of upper 
      gastrointestinal bleeding (UGIB). AIMS: To analyse the incidence and factors 
      influencing the occurrence of UGIB in patients taking low-dose aspirin for the 
      prevention of cardiovascular diseases outside clinical trials. METHODS: We 
      studied 903 consecutive patients discharged on low-dose aspirin from the 
      Cardiology Department of a general hospital. Data were collected from medical 
      charts and structured telephone interviews. RESULTS: Forty-one patients (4.5%) 
      presented with UGIB requiring hospitalization during follow-up (45 +/- 22 
      months). The incidence of UGIB was uniform during follow-up (1.2 UGIB per 100 
      patient years). Multivariate analysis showed that a history of peptic ulcer or 
      UGIB [risk ratio: 3.1, 95% CI: (1.5-6.5)] and aspirin dose (per 100 mg/day) [1.8 
      (1.5-2.9)] was associated with higher risk of UGIB. On the other hand, 
      antisecretory [0.22 (0.07-0.75)] and nitrovasodilator drugs [0.73 (0.55-0.96)] 
      were associated with a decreased risk. CONCLUSIONS: Cardiovascular patients on 
      long-term low-dose aspirin have a stable risk of major UGIB, which is higher than 
      published controlled clinical trials. Antisecretory and nitrovasodilator drugs 
      protect from UGIB, whereas previous peptic ulcer or UGIB and higher doses of 
      aspirin increase the risk.
FAU - Serrano, P
AU  - Serrano P
AD  - Service of Cardiology, Hospital Clínico Universitario 'Lozano Blesa', Zaragoza, 
      Spain.
FAU - Lanas, A
AU  - Lanas A
FAU - Arroyo, M T
AU  - Arroyo MT
FAU - Ferreira, I J
AU  - Ferreira IJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Hemorrhage/*chemically induced/microbiology
MH  - Helicobacter Infections/complications
MH  - Helicobacter pylori
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2002/10/23 04:00
MHDA- 2003/02/01 04:00
CRDT- 2002/10/23 04:00
PHST- 2002/10/23 04:00 [pubmed]
PHST- 2003/02/01 04:00 [medline]
PHST- 2002/10/23 04:00 [entrez]
AID - 1355 [pii]
AID - 10.1046/j.1365-2036.2002.01355.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2002 Nov;16(11):1945-53. doi: 
      10.1046/j.1365-2036.2002.01355.x.

PMID- 7752308
OWN - NLM
STAT- MEDLINE
DCOM- 19950620
LR  - 20190920
IS  - 0140-7783 (Print)
IS  - 0140-7783 (Linking)
VI  - 18
IP  - 1
DP  - 1995 Feb
TI  - The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy 
      cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid.
PG  - 61-7
AB  - Ceftiofur sodium is a third-generation cephalosporin antibiotic. It is possible 
      that non-steroidal anti-inflammatory drugs such as acetyl salicylate (aspirin) 
      may be used concomitantly with ceftiofur sodium in dairy cattle. Therefore this 
      study evaluated potential pharmacokinetic interactions between ceftiofur sodium 
      and aspirin. In addition, this study evaluated the potential for interaction 
      between ceftiofur and its active metabolites and the organic anion transporter. 
      The organic anion transporter substrate used in this evaluation was probenecid. 
      Ten healthy, non-pregnant, non-lactating dairy cows were used in a randomized 
      complete three-way crossover design. In repeated experiments all cows were 
      administered: (1) 2 mg of ceftiofur sodium per kg body weight by intravenous 
      bolus or (2) 10 mg of probenecid per kg body weight by intravenous bolus, 
      followed immediately by 2 mg of ceftiofur sodium per kg body weight by 
      intravenous bolus or (3) 26 mg of aspirin per kg body weight by intravenous 
      bolus, followed immediately by 2 mg of ceftiofur sodium per kg body weight by 
      intravenous bolus. For treatment with ceftiofur sodium alone, the mean volume of 
      distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of 
      distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence 
      time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) 
      was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and 
      elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard 
      deviation). No statistically significant changes were detected as a result of 
      preceding treatment with aspirin.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Whittem, T
AU  - Whittem T
AD  - Department of Veterinary Clinical Sciences, Massey University, Palmerston North, 
      New Zealand.
FAU - Freeman, D A
AU  - Freeman DA
FAU - Hanlon, D
AU  - Hanlon D
FAU - Parton, K
AU  - Parton K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - 0 (Cephalosporins)
RN  - 83JL932I1C (ceftiofur)
RN  - PO572Z7917 (Probenecid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cattle
MH  - Cephalosporins/administration & dosage/blood/*pharmacokinetics
MH  - Cross-Over Studies
MH  - Drug Interactions
MH  - Female
MH  - Half-Life
MH  - Injections, Intravenous/veterinary
MH  - Ion Transport/drug effects
MH  - Probenecid/administration & dosage/*pharmacology
MH  - Tissue Distribution
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
AID - 10.1111/j.1365-2885.1995.tb00552.x [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 1995 Feb;18(1):61-7. doi: 
      10.1111/j.1365-2885.1995.tb00552.x.

PMID- 31424359
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 2146-8427 (Electronic)
IS  - 1304-0855 (Linking)
VI  - 18
IP  - 2
DP  - 2020 Apr
TI  - Low-Dose Aspirin Reduces the Rate of Renal Allograft Thrombosis in Pediatric 
      Renal Transplant Recipients.
PG  - 157-163
LID - 10.6002/ect.2018.0358 [doi]
AB  - OBJECTIVES: Renal allograft thrombosis is an important cause of early renal 
      allograft loss. A previous study from our unit showed thrombosis rates in 
      patients who received heparin that were similar to those who did not receive any 
      thromboprophylaxis. This study evaluated the impact of aspirin prophylaxis on 
      renal allograft thrombosis rates in pediatric renal transplant recipients. 
      MATERIALS AND METHODS: We conducted a retrospective study of 456 consecutive 
      pediatric allografts from deceased and living related donors over age 22 years in 
      a single center. Routine perioperative heparin was introduced in 1994 and was 
      subsequently changed to aspirin prophylaxis in 2000. Group 1 comprised 126 
      patients who did not receive any thromboprophylaxis, group 2 comprised 128 
      patients who received heparin, and group 3 comprised 202 patients who received 
      aspirin therapy. Variables associated with increased risk of renal allograft loss 
      were examined using multivariable logistic regression. RESULTS: Thrombosis 
      occurred in 11% (14/126) of grafts in group 1, 9% (11/128) of grafts in group 2, 
      and 1% (2/202) of grafts in group 3 (odds ratio for aspirin group = 0.38, 95% 
      confidence interval, 0.22-0.64; P = .02). In patients who received aspirin (group 
      3), there was only one renal allograft loss secondary to hemorrhage, and no 
      grafts were lost in patients younger than 5 years of age. CONCLUSIONS: After our 
      center introduced a change from heparin to aspirin prophylaxis, the thrombosis 
      rate in pediatric renal allografts fell from 9% to 1%. Although there are a 
      number of possible confounding variables, the introduction of aspirin has led to 
      a reduced rate of renal allograft thrombosis.
FAU - Al Midani, Ammar
AU  - Al Midani A
AD  - >From the Department of Renal Transplantation, Royal Free Hospital NHS Trust, 
      London, UK.
FAU - Rudarakanchana, Nung
AU  - Rudarakanchana N
AD  - >From the Department of Renal Transplantation, Royal Free Hospital NHS Trust, 
      London, UK.
FAU - Nagra, Arvind
AU  - Nagra A
AD  - From the Regional Paediatric Nephro-Urology Service, Southampton University 
      Hospitals NHS Trust, Southampton, UK
FAU - Fidan, Kibriya
AU  - Fidan K
AD  - From the Department of Paediatric Nephrology, Gazi University, Ankara, Turkey
FAU - Tugtepe, Halil
AU  - Tugtepe H
AD  - From the Department of Paediatric Nephrology, Great Ormond Street Hospital for 
      Children NHS Foundation Trust, London, UK
FAU - Matthias, Mary
AU  - Matthias M
AD  - From the Department of Haematology, Great Ormond Street Hospital for Children NHS 
      Foundation Trust, London, UK
FAU - Ridout, Deborah
AU  - Ridout D
AD  - From the University College London, Great Ormond Street Institute of Child 
      Health, London, UK
FAU - Kessaris, Nicos
AU  - Kessaris N
AD  - From the Department of Transplantation, Guy’s and St Thomas’NHS Foundation Trust, 
      London, UK
FAU - Marks, Stephen D
AU  - Marks SD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190819
PL  - Turkey
TA  - Exp Clin Transplant
JT  - Experimental and clinical transplantation : official journal of the Middle East 
      Society for Organ Transplantation
JID - 101207333
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Humans
MH  - Infant
MH  - Kidney Transplantation/*adverse effects
MH  - Male
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Thrombosis/diagnosis/etiology/*prevention & control
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2019/08/20 06:00
MHDA- 2021/08/17 06:00
CRDT- 2019/08/20 06:00
PHST- 2019/08/20 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2019/08/20 06:00 [entrez]
AID - 10.6002/ect.2018.0358 [doi]
PST - ppublish
SO  - Exp Clin Transplant. 2020 Apr;18(2):157-163. doi: 10.6002/ect.2018.0358. Epub 
      2019 Aug 19.

PMID- 15222006
OWN - NLM
STAT- MEDLINE
DCOM- 20040716
LR  - 20151119
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 101
IP  - 1
DP  - 2004 Jul 1
TI  - The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors 
      for colorectal carcinoma chemoprevention in healthy individuals.
PG  - 189-97
AB  - BACKGROUND: Aspirin therapy is accepted widely for secondary prevention in 
      patients with documented cardiovascular disease, but there is a growing trend 
      among healthy individuals to use aspirin as primary chemoprevention for both 
      cardiovascular and oncologic diseases. Accruing evidence suggests that 
      cyclooxygenase-2-selective inhibitors (coxibs) may be effective for colorectal 
      carcinoma (CRC) chemoprevention but would not provide the primary cardiac benefit 
      of aspirin. METHODS: A computer-based Markov model simulated hypothetical cohorts 
      of healthy men age 50 years who took either 325 mg of enteric-coated aspirin 
      daily or celecoxib at a dose of 400 mg twice a day. Patients in both cohorts 
      could develop drug-related complications that would lead to its discontinuation. 
      The aspirin group also was modeled to have a decreased rate of coronary ischemic 
      events; however, decreased CRC mortality was not modeled in either group based on 
      the assumption that the two treatments were effective equally in this regard. 
      Data sources included published literature and the Centers for Medicare and 
      Medicaid Services. Endpoints used to compare the two strategies included 
      quality-adjusted life years (QALYs), mortality and complication rates, and cost. 
      The analysis was from a societal perspective with a time horizon of 10 years from 
      age 50 years. Extensive sensitivity analyses were performed. RESULTS: Aspirin 
      therapy resulted in 0.03 more QALYs and cost $23,000 less than coxib therapy over 
      a 10-year period. Compared with the aspirin group, the coxib group had 3.877% 
      more complications and 0.17% more deaths. Alternatively stated, coxib therapy 
      resulted in 1 patient complication or death for every 26 or 588 patients treated 
      with coxibs, respectively. CONCLUSIONS: Assuming equal efficacy in CRC prevention 
      over a 10-year period, aspirin was both more effective and less costly than coxib 
      therapy when used for primary chemoprevention of CRC.
CI  - Copyright 2004 American Cancer Society.
FAU - Hur, Chin
AU  - Hur C
AD  - Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac 
      Street, 10th Floor, Boston, MA 02114, USA. chur@mgh-ita.org
FAU - Simon, Lee S
AU  - Simon LS
FAU - Gazelle, G Scott
AU  - Gazelle GS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*economics/therapeutic 
      use
MH  - Aspirin/adverse effects/*economics/therapeutic use
MH  - Celecoxib
MH  - Colorectal Neoplasms/*prevention & control
MH  - *Computer Simulation
MH  - Cost-Benefit Analysis
MH  - Cyclooxygenase Inhibitors/adverse effects/*economics/therapeutic use
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Pyrazoles
MH  - Quality-Adjusted Life Years
MH  - Sulfonamides/adverse effects/*economics/therapeutic use
EDAT- 2004/06/29 05:00
MHDA- 2004/07/17 05:00
CRDT- 2004/06/29 05:00
PHST- 2004/06/29 05:00 [pubmed]
PHST- 2004/07/17 05:00 [medline]
PHST- 2004/06/29 05:00 [entrez]
AID - 10.1002/cncr.20329 [doi]
PST - ppublish
SO  - Cancer. 2004 Jul 1;101(1):189-97. doi: 10.1002/cncr.20329.

PMID- 10802407
OWN - NLM
STAT- MEDLINE
DCOM- 20000627
LR  - 20190910
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 199
IP  - 2
DP  - 2000 Apr 20
TI  - An investigation into the use of stepwise isothermal high sensitivity DSC as a 
      means of detecting drug-excipient incompatibility.
PG  - 141-50
AB  - The use of stepwise isothermal high sensitivity differential scanning calorimetry 
      (HSDSC) as a novel means of detecting excipient incompatibility is described 
      using aspirin mixes with magnesium stearate and stearic acid as model systems. 
      Aspirin, magnesium stearate and stearic acid alone and as mixes were studied in 
      scanning mode using conventional DSC and were then subjected to a stepwise 
      heating programme using HSDSC, whereby the samples were heated to temperatures 
      between 45 and 70 degrees C and held for 1 h, during which the heat flow to or 
      from the sample was measured. The data indicated that while no thermal events 
      were detected for the individual components or mixes with stearic acid other than 
      melting of stearic acid, 50% w/w mixes of magnesium stearate showed a marked 
      endothermic response at temperatures above 55 degrees C. The data were fitted to 
      an adaptation of an existing kinetic model for the degradation process and a 
      reasonable correlation found. Mixes of the drug with the two excipients were then 
      studied at 60 degrees C over 6 h at concentrations between 1 and 50% w/w. 
      Incompatibilities with magnesium stearate concentrations as low as 1% w/w could 
      be detected using this approach. Compacts of magnesium stearate and aspirin were 
      also studied, with considerably more pronounced thermal events taking place 
      compared to the powder mixes. It is concluded from these studies that while the 
      study has highlighted certain limitations of the approach, stepwise isothermal 
      DSC represents a potentially highly useful means of detecting excipient 
      incompatibilities.
FAU - Wissing, S
AU  - Wissing S
AD  - Centre for Materials Science, School of Pharmacy, University of London, 29-39 
      Brunswick Square, London, UK.
FAU - Craig, D Q
AU  - Craig DQ
FAU - Barker, S A
AU  - Barker SA
FAU - Moore, W D
AU  - Moore WD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Excipients)
RN  - 0 (Stearic Acids)
RN  - 4ELV7Z65AP (stearic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - Calorimetry, Differential Scanning
MH  - *Drug Compounding
MH  - *Excipients
MH  - Models, Chemical
MH  - Stearic Acids
EDAT- 2000/05/10 09:00
MHDA- 2000/07/06 11:00
CRDT- 2000/05/10 09:00
PHST- 2000/05/10 09:00 [pubmed]
PHST- 2000/07/06 11:00 [medline]
PHST- 2000/05/10 09:00 [entrez]
AID - S037851730000380X [pii]
AID - 10.1016/s0378-5173(00)00380-x [doi]
PST - ppublish
SO  - Int J Pharm. 2000 Apr 20;199(2):141-50. doi: 10.1016/s0378-5173(00)00380-x.

PMID- 20122592
OWN - NLM
STAT- MEDLINE
DCOM- 20100617
LR  - 20131121
IS  - 1873-4529 (Electronic)
IS  - 0952-8180 (Linking)
VI  - 21
IP  - 8
DP  - 2009 Dec
TI  - Atypical presentation of an epidural hematoma in a patient receiving aspirin and 
      low molecular weight heparin. Was epidural analgesia the right choice?
PG  - 595-8
LID - 10.1016/j.jclinane.2008.12.022 [doi]
AB  - A case of postoperative epidural hematoma with an atypical presentation and an 
      excellent outcome in an 80 year-old woman who received both prophylactic aspirin 
      and enoxaparin following a primary total knee arthroplasty, is presented. She 
      developed lower limb neurological symptoms, fully recovered, and then 
      deteriorated again. The hematoma was surgically evacuated, resulting in full 
      neurological recovery. Epidural analgesia may not be the best choice for pain 
      management in patients who require the combined use of aspirin and low-molecular 
      weight heparin postoperatively.
FAU - Kasodekar, Shilpa V
AU  - Kasodekar SV
AD  - Department of Anesthesia and Pain Management, Mount Sinai Hospital, Ontario, 
      Canada.
FAU - Goldszmidt, Eric
AU  - Goldszmidt E
FAU - Davies, Sharon R
AU  - Davies SR
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Clin Anesth
JT  - Journal of clinical anesthesia
JID - 8812166
RN  - 0 (Enoxaparin)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged, 80 and over
MH  - Analgesia, Patient-Controlled/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Enoxaparin/administration & dosage/*adverse effects
MH  - Female
MH  - Hematoma, Epidural, Spinal/*chemically induced
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*adverse effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Postoperative Care
MH  - Treatment Outcome
EDAT- 2010/02/04 06:00
MHDA- 2010/06/18 06:00
CRDT- 2010/02/04 06:00
PHST- 2007/05/14 00:00 [received]
PHST- 2008/12/02 00:00 [revised]
PHST- 2008/12/04 00:00 [accepted]
PHST- 2010/02/04 06:00 [entrez]
PHST- 2010/02/04 06:00 [pubmed]
PHST- 2010/06/18 06:00 [medline]
AID - S0952-8180(09)00260-8 [pii]
AID - 10.1016/j.jclinane.2008.12.022 [doi]
PST - ppublish
SO  - J Clin Anesth. 2009 Dec;21(8):595-8. doi: 10.1016/j.jclinane.2008.12.022.

PMID- 27440202
OWN - NLM
STAT- MEDLINE
DCOM- 20180329
LR  - 20220311
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 116
IP  - 4
DP  - 2016 Sep 27
TI  - Comparison of current platelet functional tests for the assessment of aspirin and 
      clopidogrel response. A review of the literature.
PG  - 638-50
LID - 10.1160/TH15-11-0870 [doi]
AB  - The two most widely used antiplatelet drugs in the world are aspirin and 
      clopidogrel. However, some patients on aspirin and/or clopidogrel therapy do not 
      respond appropriately to either aspirin or clopidogrel. This phenomenon is 
      usually called "aspirin/clopidogrel resistance". Several platelet function tests 
      have been used in various studies for the assessment of aspirin and clopidogrel 
      resistance in healthy individuals and patients admitted in cardiology 
      departments. An accurate assessment of platelet response to aspirin/clopidogrel 
      could benefit patients by proposing tailored-antiplatelet therapy based on test 
      results. However, there is a clear lack of standardisation of such techniques and 
      their analytical variability may induce misinterpretation. After a quick report 
      of the mechanisms responsible for aspirin/clopidogrel resistance, we describe the 
      pre-analytical aspects and the analytical performances of current platelet 
      function tests (Light-transmission aggregometry, whole-blood aggregometry, 
      VerifyNow®, Platelet Function Analyzer®, thromboelastography, VASP assay) that 
      are used for the assessment of aspirin/clopidogrel resistance in clinical 
      studies. Considering the different variables that have to be taken into account 
      with each of the platelet function tests, a particular attention should be paid 
      when interpreting results.
FAU - Le Quellec, Sandra
AU  - Le Quellec S
AD  - Sandra Le Quellec, Unité d'hémostase clinique, Université Lyon I-Hospices Civils 
      de Lyon, 59 Boulevard Pinel, 69677 Bron, France, Tel.: +33 472118810, Fax: +33 
      472118817, E-mail: sandra.le-quellec@chu-lyon.fr.
FAU - Bordet, Jean-Claude
AU  - Bordet JC
FAU - Negrier, Claude
AU  - Negrier C
FAU - Dargaud, Yesim
AU  - Dargaud Y
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160721
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Platelet Function Tests
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - *Antiplatelet agents
OT  - *aggregometry
OT  - *aspirin resistance
OT  - *clopidogrel resistance
OT  - *platelet function test
EDAT- 2016/07/22 06:00
MHDA- 2018/03/30 06:00
CRDT- 2016/07/22 06:00
PHST- 2015/11/13 00:00 [received]
PHST- 2016/06/29 00:00 [accepted]
PHST- 2016/07/22 06:00 [entrez]
PHST- 2016/07/22 06:00 [pubmed]
PHST- 2018/03/30 06:00 [medline]
AID - 15-11-0870 [pii]
AID - 10.1160/TH15-11-0870 [doi]
PST - ppublish
SO  - Thromb Haemost. 2016 Sep 27;116(4):638-50. doi: 10.1160/TH15-11-0870. Epub 2016 
      Jul 21.

PMID- 28125435
OWN - NLM
STAT- MEDLINE
DCOM- 20180109
LR  - 20220409
IS  - 1473-5660 (Electronic)
IS  - 0342-5282 (Linking)
VI  - 40
IP  - 2
DP  - 2017 Jun
TI  - Efficacy of mesotherapy using drugs versus normal saline solution in chronic 
      spinal pain: a retrospective study.
PG  - 171-174
LID - 10.1097/MRR.0000000000000214 [doi]
AB  - Mesotherapy, or intradermal therapy, is a therapeutic approach that is gaining 
      popularity, but there is still a significant lack of information on its 
      mechanisms of action or the pharmacokinetics of the therapeutic regimens. This 
      retrospective study on 220 records compared the short-term and long-term effects 
      of mesotherapy using a mixture of drugs versus normal saline solution in the 
      treatment of patients with chronic spinal pain (CSP). At the end of treatment, 
      outcome measures showed a significant improvement (P<0.003) in both groups, which 
      persisted at the follow-up assessments. At 12 weeks of follow-up, the improvement 
      was significantly greater in patients treated with the drug cocktail than with 
      the saline solution (P<0.05). Mesotherapy was effective in patients affected by 
      CSP, with high patient satisfaction reported irrespective of the agent used. 
      Considering the risks and costs of drugs, normal saline solution appears to be 
      the best agent in cost-benefit terms for treating localized pain by mesotherapy 
      in CSP.
FAU - Ferrara, Paola E
AU  - Ferrara PE
AD  - aDepartment of Physical Medicine and Rehabilitation, Teaching Hospital Foundation 
      'Agostino Gemelli', Catholic University of Sacred Heart bDepartment of Physical 
      Medicine and Rehabilitation, Clinical Sciences and Translational Medicine, Tor 
      Vergata University, Rome cDepartment of Physical and Rehabilitative Medicine, 
      Scientific Institute of Lissone MB, Istituti Clinici Scientifici Maugeri, IRCCS, 
      Lissone MB, Italy dDepartment of Physical Therapy and Sports Medicine, University 
      of Craiova, Craiova, Romania.
FAU - Ronconi, Gianpaolo
AU  - Ronconi G
FAU - Viscito, Rossella
AU  - Viscito R
FAU - Pascuzzo, Romina
AU  - Pascuzzo R
FAU - Rosulescu, Eugenia
AU  - Rosulescu E
FAU - Ljoka, Concetta
AU  - Ljoka C
FAU - Maggi, Loredana
AU  - Maggi L
FAU - Ferriero, Giorgio
AU  - Ferriero G
FAU - Foti, Calogero
AU  - Foti C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Int J Rehabil Res
JT  - International journal of rehabilitation research. Internationale Zeitschrift fur 
      Rehabilitationsforschung. Revue internationale de recherches de readaptation
JID - 7805421
RN  - 0 (Analgesics)
RN  - 0 (Anesthetics, Local)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - 98PI200987 (Lidocaine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Analgesics/therapeutic use
MH  - Anesthetics, Local/therapeutic use
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Back Pain/*therapy
MH  - Chronic Pain/*therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lidocaine/therapeutic use
MH  - Lysine/analogs & derivatives/therapeutic use
MH  - Male
MH  - Mesotherapy/*methods
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Retrospective Studies
MH  - Sodium Chloride/administration & dosage
MH  - Visual Analog Scale
EDAT- 2017/01/27 06:00
MHDA- 2018/01/10 06:00
CRDT- 2017/01/27 06:00
PHST- 2017/01/27 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
PHST- 2017/01/27 06:00 [entrez]
AID - 10.1097/MRR.0000000000000214 [doi]
PST - ppublish
SO  - Int J Rehabil Res. 2017 Jun;40(2):171-174. doi: 10.1097/MRR.0000000000000214.

PMID- 27995463
OWN - NLM
STAT- MEDLINE
DCOM- 20180409
LR  - 20181202
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 18
IP  - 4
DP  - 2017 May
TI  - Effect of Formulation and Process Parameters on Chitosan Microparticles Prepared 
      by an Emulsion Crosslinking Technique.
PG  - 1084-1094
LID - 10.1208/s12249-016-0677-x [doi]
AB  - There are many studies about the synthesis of chitosan microparticles; however, 
      most of them have very low production rate, have wide size distribution, are 
      difficult to reproduce, and use harsh crosslinking agents. Uniform microparticles 
      are necessary to obtain repeatable drug release behavior. The main focus of this 
      investigation was to study the effect of the process and formulation parameters 
      during the preparation of chitosan microparticles in order to produce particles 
      with narrow size distribution. The technique evaluated during this study was 
      emulsion crosslinking technique. Chitosan is a biocompatible and biodegradable 
      material but lacks good mechanical properties; for that reason, chitosan was 
      ionically crosslinked with sodium tripolyphosphate (TPP) at three different 
      ratios (32, 64, and 100%). The model drug used was acetylsalicylic acid (ASA). 
      During the preparation of the microparticles, chitosan was first mixed with ASA 
      and then dispersed in oil containing an emulsifier. The evaporation of the 
      solvents hardened the hydrophilic droplets forming microparticles with spherical 
      shape. The process and formulation parameters were varied, and the microparticles 
      were characterized by their morphology, particle size, drug loading efficiency, 
      and drug release behavior. The higher drug loading efficiency was achieved by 
      using 32% mass ratio of TPP to chitosan. The average microparticle size was 
      18.7 μm. The optimum formulation conditions to prepare uniform spherical 
      microparticles were determined and represented by a region in a triangular phase 
      diagram. The drug release analyses were evaluated in phosphate buffer solution at 
      pH 7.4 and were mainly completed at 24 h.
FAU - Rodriguez, Lidia B
AU  - Rodriguez LB
AD  - Department of Bioengineering, University of Toledo, Toledo, Ohio, 43606, USA. 
      Lidia.Rodriguez@utoledo.edu.
FAU - Avalos, Abraham
AU  - Avalos A
AD  - Department of Bioengineering, University of Toledo, Toledo, Ohio, 43606, USA.
FAU - Chiaia, Nicholas
AU  - Chiaia N
AD  - Department of Neurosciences, University of Toledo, Toledo, Ohio, 43614, USA.
FAU - Nadarajah, Arunan
AU  - Nadarajah A
AD  - Department of Bioengineering, University of Toledo, Toledo, Ohio, 43606, USA.
LA  - eng
PT  - Journal Article
DEP - 20161219
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Biocompatible Materials)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Emulsifying Agents)
RN  - 0 (Emulsions)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polyphosphates)
RN  - 9012-76-4 (Chitosan)
RN  - NU43IAG5BC (triphosphoric acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage/pharmacokinetics
MH  - Biocompatible Materials/chemistry/pharmacology
MH  - *Chitosan/chemistry/pharmacology
MH  - Cross-Linking Reagents/chemistry
MH  - Drug Delivery Systems
MH  - Drug Liberation
MH  - Emulsifying Agents/chemistry/pharmacology
MH  - Emulsions
MH  - Microspheres
MH  - Models, Chemical
MH  - Particle Size
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacokinetics
MH  - Polyphosphates
OTO - NOTNLM
OT  - chitosan
OT  - drug delivery
OT  - emulsion
OT  - microparticles
EDAT- 2016/12/21 06:00
MHDA- 2018/04/10 06:00
CRDT- 2016/12/21 06:00
PHST- 2016/07/11 00:00 [received]
PHST- 2016/11/28 00:00 [accepted]
PHST- 2016/12/21 06:00 [pubmed]
PHST- 2018/04/10 06:00 [medline]
PHST- 2016/12/21 06:00 [entrez]
AID - 10.1208/s12249-016-0677-x [pii]
AID - 10.1208/s12249-016-0677-x [doi]
PST - ppublish
SO  - AAPS PharmSciTech. 2017 May;18(4):1084-1094. doi: 10.1208/s12249-016-0677-x. Epub 
      2016 Dec 19.

PMID- 26547790
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20170821
IS  - 1989-2284 (Electronic)
IS  - 0211-6995 (Linking)
VI  - 35
IP  - 6
DP  - 2015 Nov-Dec
TI  - Hyperbaric index in the primary prevention of hypertensive complications in 
      high-risk pregnancy.
PG  - 572-7
LID - S0211-6995(15)00168-X [pii]
LID - 10.1016/j.nefro.2015.10.001 [doi]
AB  - INTRODUCTION: Preeclampsia (PE) is a major cause of fetal morbidity and 
      mortality. In the Western World, PE affects 2-7% of pregnancies and is 
      responsible for 50,000 deaths annually. Early detection is a priority as it can 
      change the clinical course, but there are no biomarkers or instrumental methods 
      with high sensitivity and specificity. Only the hyperbaric index has a 
      sensitivity and specificity of 99% for early identification of pregnant women at 
      risk of developing PE, but its use is not widespread. OBJECTIVE: To assess the 
      usefulness of the hyperbaric index in the primary prevention of hypertensive 
      pregnancy complications in a public healthcare area. MATERIAL AND METHODS: This 
      is a retrospective study of pregnancies that occurred in our area during the 
      period 2007-2012 (N=11,784). The diagnosis was established by the hyperbaric 
      index and pregnant women at risk were treated with ASA at night. RESULTS: In 
      pregnant patients referred to the nephrology clinic (38.2%), diagnosed as 
      high-risk for PE, and treated with 100mg ASA/night (from week 17), the incidence 
      of PE episodes was reduced by 96.94.
CI  - Copyright © 2015 Sociedad Española de Nefrología. Published by Elsevier España, 
      S.L.U. All rights reserved.
FAU - Otero González, Alfonso
AU  - Otero González A
AD  - Servicio de Nefrología, Centro Hospitalario Universitario de Ourense, Ourense, 
      España. Electronic address: alfonso.otero.gonzalez@sergas.es.
FAU - Uribe Moya, Silvia
AU  - Uribe Moya S
AD  - Servicio de Nefrología, Centro Hospitalario Universitario de Ourense, Ourense, 
      España.
FAU - Arenas Moncaleano, Ivan Gilberto
AU  - Arenas Moncaleano IG
AD  - Servicio de Nefrología, Centro Hospitalario Universitario de Ourense, Ourense, 
      España.
FAU - Borrajo Prol, María Paz
AU  - Borrajo Prol MP
AD  - Servicio de Nefrología, Centro Hospitalario Universitario de Ourense, Ourense, 
      España.
FAU - García García, María Jesús
AU  - García García MJ
AD  - Servicio de Nefrología, Centro Hospitalario Universitario de Ourense, Ourense, 
      España.
FAU - López Sánchez, Luis
AU  - López Sánchez L
AD  - Documentación Clínica, Centro Hospitalario Universitario de Ourense, Ourense, 
      España.
LA  - eng
LA  - spa
PT  - Journal Article
DEP - 20151105
PL  - Spain
TA  - Nefrologia
JT  - Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
JID - 8301215
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/therapeutic use
MH  - *Blood Pressure
MH  - Blood Pressure Monitoring, Ambulatory
MH  - Drug Administration Schedule
MH  - Early Diagnosis
MH  - Female
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/diagnosis/physiopathology/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Pregnancy, High-Risk/*physiology
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - Embarazo
OT  - Hipertensión
OT  - Hyperbaric index
OT  - Hypertension
OT  - Pregnancy
OT  - Índice hiperbárico
EDAT- 2015/11/09 06:00
MHDA- 2017/08/22 06:00
CRDT- 2015/11/09 06:00
PHST- 2014/12/23 00:00 [received]
PHST- 2015/04/15 00:00 [accepted]
PHST- 2015/11/09 06:00 [entrez]
PHST- 2015/11/09 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - S0211-6995(15)00168-X [pii]
AID - 10.1016/j.nefro.2015.10.001 [doi]
PST - ppublish
SO  - Nefrologia. 2015 Nov-Dec;35(6):572-7. doi: 10.1016/j.nefro.2015.10.001. Epub 2015 
      Nov 5.

PMID- 25535147
OWN - NLM
STAT- MEDLINE
DCOM- 20150824
LR  - 20181202
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 18
IP  - 23
DP  - 2014
TI  - Effects of N-acetyl-cysteine and acetylsalicylic acid on the tonsil bacterial 
      biofilm tissues by light and electron microscopy.
PG  - 3720-5
LID - 8178 [pii]
AB  - OBJECTIVE: The present study aimed to investigate the effects of the bacterial 
      biofilm formation on the tonsil surface exposed N-acetyl-cysteine (NAC) and 
      acetylsalicylic acid (ASA) of patients undergoing tonsillectomy by light and 
      electron microscopy. The general process of biofilm formation comprises adhesion 
      of free-living or planktonic bacteria to a surface, which subsequently develop 
      into microcolonies and form a biofilm. Based on studies that have shown the 
      presence of biofilms in common sites of chronic infections, it has become clear 
      that bacteria may persist on mucosal surfaces through formation of biofilms. 
      PATIENTS AND METHODS: Ten patients between 4 and 39 years of age (mean, 11.9 ± 
      11.2 years). In all cases, periodic acide Schiff (PAS) staining was found to be 
      an accurate predictor of the presence or absence of biofilm using light 
      microscopy as a control standard. Therapeutic doses of NAC and ASA were 
      identificated as the effective on the tonsil bacterial biofilm using light and 
      electron microscopy. RESULTS: Biofilm formation was detected on all samples. 
      Tonsils removed from patients with ASA-10 had showed higher-grade inhibitory 
      effect at the biofilm formation than the other group (p ≤ 0.0001). The 
      correlation was found between drug dose and decrease at the biofilm formation. 
      CONCLUSIONS: In chronic or recurrent tonsillitis patients, decrease on the 
      tonsils surface biofilm formation may be associated with ASA dose. Whether effect 
      on the tonsils surface biofilm formation of other agent have a role is not known. 
      Key Words: Acetylsalicylic acid, Chronic tonsillitis, In vitro, Mucosal biofilm, 
      N-Acetyl-cysteine.
FAU - Bulut, F
AU  - Bulut F
AD  - Ear Nose and Throat Nose Diseases, Memorial Hospital, Diyarbakır, Turkey. 
      yusufnergiz21@gmail.com.
FAU - Meric, F
AU  - Meric F
FAU - Yorgancilar, E
AU  - Yorgancilar E
FAU - Nergiz, Y
AU  - Nergiz Y
FAU - Akkus, M
AU  - Akkus M
FAU - Nergiz, S
AU  - Nergiz S
FAU - Nasir, Y
AU  - Nasir Y
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - R16CO5Y76E (Aspirin)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/*pharmacology/therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Biofilms/*drug effects
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Male
MH  - Microscopy, Electron/methods
MH  - Microscopy, Polarization/methods
MH  - Palatine Tonsil/*drug effects/microbiology/*pathology
MH  - Tonsillitis/diagnosis/drug therapy
MH  - Young Adult
EDAT- 2014/12/24 06:00
MHDA- 2015/08/25 06:00
CRDT- 2014/12/24 06:00
PHST- 2014/12/24 06:00 [entrez]
PHST- 2014/12/24 06:00 [pubmed]
PHST- 2015/08/25 06:00 [medline]
AID - 8178 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2014;18(23):3720-5.

PMID- 21708383
OWN - NLM
STAT- MEDLINE
DCOM- 20111011
LR  - 20131121
IS  - 1873-3778 (Electronic)
IS  - 0021-9673 (Linking)
VI  - 1218
IP  - 35
DP  - 2011 Sep 2
TI  - Method development and validation for optimised separation of salicylic, acetyl 
      salicylic and ascorbic acid in pharmaceutical formulations by hydrophilic 
      interaction chromatography and response surface methodology.
PG  - 5995-6003
LID - 10.1016/j.chroma.2011.06.009 [doi]
AB  - This paper introduces a design of experiments (DOE) approach for method 
      optimisation in hydrophilic interaction chromatography (HILIC). An optimisation 
      strategy for the separation of acetylsalicylic acid, its major impurity salicylic 
      acid and ascorbic acid in pharmaceutical formulations by HILIC is presented, with 
      the aid of response surface methodology (RSM) and Derringer's desirability 
      function. A Box-Behnken experimental design was used to build the mathematical 
      models and then to choose the significant parameters for the optimisation by 
      simultaneously taking both resolution and retention time as the responses. The 
      refined model had a satisfactory coefficient (R²>0.92, n=27). The four 
      independent variables studied simultaneously were: acetonitrile content of the 
      mobile phase, pH and concentration of buffer and column temperature each at three 
      levels. Of these, the concentration of buffer and its cross-product with pH had a 
      significant, positive influence on all studied responses. For the test compounds, 
      the best separation conditions were: acetonitrile/22 mM ammonium acetate, pH 4.4 
      (82:18, v/v) as the mobile phase and column temperature of 28°C. The methodology 
      also captured the interaction between variables which enabled exploration of the 
      retention mechanism involved. It would be inferred that the retention is governed 
      by a compromise between hydrophilic partitioning and ionic interaction. The 
      optimised method was further validated according to the ICH guidelines with 
      respect to linearity and range, precision, accuracy, specificity and sensitivity. 
      The robustness of the method was also determined and confirmed by overlying 
      counter plots of responses which were derived from the experimental design 
      utilised for method optimisation.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Hatambeygi, Nader
AU  - Hatambeygi N
AD  - Kimiafaam Pharmaceutical Co., Tehran 11458, Iran.
FAU - Abedi, Ghazaleh
AU  - Abedi G
FAU - Talebi, Mohammad
AU  - Talebi M
LA  - eng
PT  - Journal Article
DEP - 20110612
PL  - Netherlands
TA  - J Chromatogr A
JT  - Journal of chromatography. A
JID - 9318488
RN  - 0 (Acetates)
RN  - 0 (Acetonitriles)
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - RRE756S6Q2 (ammonium acetate)
RN  - Z072SB282N (acetonitrile)
SB  - IM
MH  - Acetates/chemistry
MH  - Acetonitriles/chemistry
MH  - Analysis of Variance
MH  - Ascorbic Acid/analysis/*isolation & purification
MH  - Aspirin/analysis/*isolation & purification
MH  - Chromatography, Liquid/*methods
MH  - Drug Contamination
MH  - Hydrogen-Ion Concentration
MH  - *Hydrophobic and Hydrophilic Interactions
MH  - Least-Squares Analysis
MH  - Models, Chemical
MH  - Reproducibility of Results
MH  - Salicylic Acid/analysis/*isolation & purification
MH  - Sensitivity and Specificity
MH  - Tablets/chemistry
MH  - Temperature
EDAT- 2011/06/29 06:00
MHDA- 2011/10/12 06:00
CRDT- 2011/06/29 06:00
PHST- 2010/04/20 00:00 [received]
PHST- 2011/05/31 00:00 [revised]
PHST- 2011/06/02 00:00 [accepted]
PHST- 2011/06/29 06:00 [entrez]
PHST- 2011/06/29 06:00 [pubmed]
PHST- 2011/10/12 06:00 [medline]
AID - S0021-9673(11)00805-3 [pii]
AID - 10.1016/j.chroma.2011.06.009 [doi]
PST - ppublish
SO  - J Chromatogr A. 2011 Sep 2;1218(35):5995-6003. doi: 10.1016/j.chroma.2011.06.009. 
      Epub 2011 Jun 12.

PMID- 11441981
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20191210
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 7
IP  - 3
DP  - 2001 Jul
TI  - Individual dosing of ASA prophylaxis by controlling platelet aggregation.
PG  - 209-13
AB  - Acetylsalicylic acid is widely used in the primary and secondary prevention of 
      cardiovascular diseases. In the current study, we used platelet aggregation ex 
      vivo in platelet-rich plasma induced with arachidonic acid as a routine method 
      for the determination of the individual dose of acetylsalicylic acid necessary to 
      inhibit platelet aggregation in 108 patients with cardiovascular diseases. In 40% 
      of all patients studied, a dose of 30 mg/day was sufficient to block the 
      arachidonic acid-induced platelet aggregation nearly completely. In 50% of all 
      patients, a dose of 100 mg/day was necessary. In 10% of all patients, the dose 
      had to be further increased to 300 mg/day or even to 500 mg/day to inhibit 
      platelet aggregation nearly completely. These results demonstrate that platelet 
      aggregation can be used as a simple routine laboratory method to control 
      acetylsalicylic acid treatment in patients with cardiovascular diseases and to 
      determine individual doses of acetylsalicylic acid for a nearly complete 
      inhibition of platelet aggregation. With a standard dose of 100 mg/day, 10% of 
      the patients were nonresponders.
FAU - Syrbe, G
AU  - Syrbe G
AD  - Department of Internal Medicine, District Hospital of Stadtroda/Thuringia, 
      Germany. helgeredlich@t-online.de
FAU - Redlich, H
AU  - Redlich H
FAU - Weidlich, B
AU  - Weidlich B
FAU - Ludwig, J
AU  - Ludwig J
FAU - Kopitzsch, S
AU  - Kopitzsch S
FAU - Göckefitz, A
AU  - Göckefitz A
FAU - Herzog, T
AU  - Herzog T
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/complications
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - *Platelet Function Tests
MH  - Thrombophilia/blood/complications/*drug therapy
EDAT- 2001/07/10 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/07/10 10:00
PHST- 2001/07/10 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/07/10 10:00 [entrez]
AID - 10.1177/107602960100700305 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2001 Jul;7(3):209-13. doi: 10.1177/107602960100700305.

PMID- 3714210
OWN - NLM
STAT- MEDLINE
DCOM- 19860724
LR  - 20131121
IS  - 0030-5898 (Print)
IS  - 0030-5898 (Linking)
VI  - 17
IP  - 2
DP  - 1986 Apr
TI  - Conservative treatment of patellofemoral pain.
PG  - 269-72
AB  - The vast majority of patients with patellofemoral pain respond to conservative 
      treatment. Nonoperative management consists of rest and avoidance of activities 
      producing increased patellofemoral pressure, combined with quadriceps 
      strengthening exercises with the knee extended. Anti-inflammatory drugs and 
      special braces may assist in the treatment program.
FAU - Fisher, R L
AU  - Fisher RL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Orthop Clin North Am
JT  - The Orthopedic clinics of North America
JID - 0254463
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/therapeutic use
MH  - Braces
MH  - Cartilage Diseases/complications/drug therapy
MH  - *Femur
MH  - Humans
MH  - *Knee Joint
MH  - *Pain Management
MH  - *Patella
MH  - Patient Education as Topic
MH  - Physical Exertion
MH  - Rest
EDAT- 1986/04/01 00:00
MHDA- 1986/04/01 00:01
CRDT- 1986/04/01 00:00
PHST- 1986/04/01 00:00 [pubmed]
PHST- 1986/04/01 00:01 [medline]
PHST- 1986/04/01 00:00 [entrez]
PST - ppublish
SO  - Orthop Clin North Am. 1986 Apr;17(2):269-72.

PMID- 10494706
OWN - NLM
STAT- MEDLINE
DCOM- 19991104
LR  - 20190125
IS  - 0001-5555 (Print)
IS  - 0001-5555 (Linking)
VI  - 79
IP  - 5
DP  - 1999 Sep
TI  - Microdialysis vs. suction blister technique for in vivo sampling of 
      pharmacokinetics in the human dermis.
PG  - 338-42
AB  - Our aim was to simultaneously investigate 2 techniques for in vivo sampling of 
      peripheral compartment pharmacokinetics after systemic administration of 
      acetylsalicylic acid. Ten volunteers were given 2 g acetylsalicylic acid orally. 
      Blood samples and dialysates from 4 microdialysis probes inserted in the dermis 
      of the forearm were collected for 5 h and suction blisters were raised 1-3 h 
      after dosing. In microdialysates, both acetylsalicylic acid and the metabolite 
      salicylic acid were measurable in the absence of hydrolysing enzymes. The mean 
      Cmax (maximum concentration) of total, unbound salicylic acid was 9.5 microg/ml 
      in microdialysates, 13.2 microg/ml in suction blister fluid and 56.5 microg/ml in 
      plasma. Mean Tmax (time to Cmax) for salicylic acid was 188 and 161 min in plasma 
      and microdialysates, respectively. The dermis-to-plasma Cmax ratio was 
      0.16+/-0.04 (mean +/- SD) by microdialysis sampling and 0.25+/-0.09 by the 
      suction blister fluid method. Close correlations (p<0.01) were found between Cmax 
      of salicylic acid in microdialysates and plasma, and between Cmax of salicylic 
      acid in suction blister fluid and plasma. The 2 techniques were in excellent 
      accordance with even closer correlation between maximum concentrations obtained 
      by microdialysis and suction blister fluid sampling (p<0.001). However, comparing 
      the tolerability of the sampling procedure, ease of analysis, and detail in 
      chronology, microdialysis is superior for sampling in vivo pharmacokinetics in 
      the dermis.
FAU - Benfeldt, E
AU  - Benfeldt E
AD  - Department of Dermatology, University of Copenhagen, Gentofte Hospital, Hellerup, 
      Denmark.
FAU - Serup, J
AU  - Serup J
FAU - Menné, T
AU  - Menné T
LA  - eng
PT  - Journal Article
PL  - Sweden
TA  - Acta Derm Venereol
JT  - Acta dermato-venereologica
JID - 0370310
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/blood/*pharmacokinetics
MH  - Aspirin/blood/*pharmacokinetics
MH  - Blister
MH  - Dermis/*metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Microdialysis
MH  - Middle Aged
MH  - Protein Binding
MH  - Reference Values
MH  - Reproducibility of Results
MH  - Specimen Handling/*methods
EDAT- 1999/09/24 00:00
MHDA- 1999/09/24 00:01
CRDT- 1999/09/24 00:00
PHST- 1999/09/24 00:00 [pubmed]
PHST- 1999/09/24 00:01 [medline]
PHST- 1999/09/24 00:00 [entrez]
AID - 10.1080/000155599750010210 [doi]
PST - ppublish
SO  - Acta Derm Venereol. 1999 Sep;79(5):338-42. doi: 10.1080/000155599750010210.

PMID- 9812322
OWN - NLM
STAT- MEDLINE
DCOM- 19990125
LR  - 20191210
IS  - 1121-7138 (Print)
IS  - 1121-7138 (Linking)
VI  - 21
IP  - 4
DP  - 1998 Oct
TI  - In vitro activity of acetylsalicylic acid on replication of varicella-zoster 
      virus.
PG  - 397-401
AB  - Topical application of a mixture of acetylsalicylic acid (ASA) and diethyl ether 
      is effective in the treatment of acute herpes zoster and postherpetic neuralgia. 
      To study whether the other-than-analgesic effects of that treatment could be due 
      to an antiviral activity of ASA the effects of the drug on the replication of 
      varicella zoster virus (VZV) were assessed by the fluorescent focus assay on MRC5 
      and Vero cells. ASA caused a marked reduction in the spread of infection in MRC5 
      monolayers while in growing Vero cells the effective dose proved toxic. ASA 
      concentrations (5-10 mM) which were effective in vitro against VZV are higher 
      than the plasma concentrations attained in the standard treatment of chronic 
      inflammatory states, but are consistent with the skin concentration attained by 
      topical application of ASA/diethyl ether mixture. These data support similar 
      findings relating the antiviral activity of acetylsalicylic acid to influenza 
      virus, CMV, and HIV.
FAU - Primache, V
AU  - Primache V
AD  - Institute of Virology, University of Milan, Italy.
FAU - Binda, S
AU  - Binda S
FAU - De Benedittis, G
AU  - De Benedittis G
FAU - Barbi, M
AU  - Barbi M
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - New Microbiol
JT  - The new microbiologica
JID - 9516291
RN  - 0 (Anti-Infective Agents, Local)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0F5N573A2Y (Ether)
RN  - J4Z741D6O5 (Gentian Violet)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Infective Agents, Local/chemistry
MH  - Antibodies, Monoclonal
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cell Line
MH  - Chlorocebus aethiops
MH  - Colorimetry
MH  - Cytopathogenic Effect, Viral/immunology
MH  - Ether/pharmacology/therapeutic use
MH  - Fluorescent Antibody Technique, Indirect
MH  - Gentian Violet/chemistry
MH  - Herpes Zoster/*drug therapy/virology
MH  - Herpesvirus 3, Human/drug effects/*physiology
MH  - Humans
MH  - Regression Analysis
MH  - Vero Cells
MH  - Virus Replication/*drug effects
EDAT- 1998/11/13 00:00
MHDA- 1998/11/13 00:01
CRDT- 1998/11/13 00:00
PHST- 1998/11/13 00:00 [pubmed]
PHST- 1998/11/13 00:01 [medline]
PHST- 1998/11/13 00:00 [entrez]
PST - ppublish
SO  - New Microbiol. 1998 Oct;21(4):397-401.

PMID- 7017917
OWN - NLM
STAT- MEDLINE
DCOM- 19810810
LR  - 20190909
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 10
IP  - 2
DP  - 1981
TI  - Additive clinical effect of indomethacin suppositories during salicylate therapy 
      in rheumatoid patients.
PG  - 69-75
AB  - Twelve rheumatic patients were given 2.0 and 4.5 g acetylsalicylic acid daily in 
      two 3-week periods. On days 13 and 20 of each period the patients took a 
      suppository containing either placebo or 50 mg of indomethacin. The study was 
      performed double-blind. Indomethacin had a significant additive effect during ASA 
      therapy with 2 g daily as estimated by articular index and subjective ratings of 
      pain and morning stiffness. On the 4.5 g ASA dose there was a significant 
      improvement only for articular index. The patients experienced less pain during 
      maintenance therapy with 4.5 g of ASA compared with 2.0 g daily. Both ASA doses 
      induced complete inhibition of prostaglandin PGF2 alpha release from platelets. 
      Thus the suppression of PGF2 alpha release does not reflect the therapeutic 
      response of these drugs. Side effects observed comprised tinnitus, dizziness and 
      gastritis. In 2 of the patients the aminotransferase levels increased, indicating 
      hepatotoxicity. The protein binding of salicylate decreased with increasing 
      salicylate concentration. As the dose was increased from 2.0 to 4.5 g/day the 
      unbound concentration increased 5 to 24 times. This reflects the combined effect 
      of capacity-limited metabolism and capacity-limited protein binding of 
      salicylate.
FAU - Ekstrand, R
AU  - Ekstrand R
FAU - Alván, G
AU  - Alván G
FAU - Magnusson, A
AU  - Magnusson A
FAU - Oliw, E
AU  - Oliw E
FAU - Palmér, L
AU  - Palmér L
FAU - Rane, A
AU  - Rane A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Prostaglandins F)
RN  - 0 (Suppositories)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Aspirin/blood/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Indomethacin/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prostaglandins F/blood
MH  - Suppositories
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.3109/03009748109095275 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 1981;10(2):69-75. doi: 10.3109/03009748109095275.

PMID- 7179223
OWN - NLM
STAT- MEDLINE
DCOM- 19830225
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 28
IP  - 3
DP  - 1982 Nov 1
TI  - Platelet aggregation in laminar flow. II. Shear rate and ADP-dependent effects of 
      acetylsalicylic acid and indomethacin.
PG  - 379-87
AB  - The relative contributions of physiologic activators and shear rates (G) on the 
      formation and stability of platelet aggregates arising from platelets treated 
      with widely clinically used non-steroidal anti-inflammatory drugs such as 
      acetylsalicylic acid (ASA) need to be characterized for conditions of low G 
      believed to be important in vivo. In Part I of these studies it was found that 
      platelets in human citrated platelet-rich plasma (PRP) undergo ADP-induced 
      aggregation in laminar flow by apparently two distinct processes: a low 
      ADP-dependent process, generating large visible aggregates stably only at low 
      shear rates, and a higher ADP-threshold-dependent process yielding more complete 
      and shear-resistant large aggregate formation. Similar studies of both 
      macroaggregation (TA) and actual % aggregation (%PA) were made with ADP 
      injections into PRP in the cone-in-plate device as a function of G and 
      pre-treatments with ASA (200 microM) and indomethacin (10 microM). These drugs 
      reduced %PA in part and yielded only reversible macro-aggregation for studies 
      conducted at the higher [ADP] (4-6 microM) and at high G (greater than or 
      approximately 120-150 sec-1), with no significant effects at low G (less than or 
      approximately 20 sec-1). The results are discussed in terms of a platelet 
      stickiness factor 's', ascribed to changes in fibrinogen binding sites reported 
      for these drug actions, and related to in vivo flow and variable platelet 
      activation conditions.
FAU - Yung, W
AU  - Yung W
FAU - Frojmovic, M M
AU  - Frojmovic MM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Aspirin/*pharmacology
MH  - *Environment, Controlled
MH  - Humans
MH  - Indomethacin/*pharmacology
MH  - Nephelometry and Turbidimetry
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Time Factors
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
AID - 0049-3848(82)90119-0 [pii]
AID - 10.1016/0049-3848(82)90119-0 [doi]
PST - ppublish
SO  - Thromb Res. 1982 Nov 1;28(3):379-87. doi: 10.1016/0049-3848(82)90119-0.

PMID- 31345167
OWN - NLM
STAT- MEDLINE
DCOM- 20200406
LR  - 20200408
IS  - 1471-2296 (Electronic)
IS  - 1471-2296 (Linking)
VI  - 20
IP  - 1
DP  - 2019 Jul 25
TI  - Assessing quality improvement capacity in primary care practices.
PG  - 103
LID - 10.1186/s12875-019-1000-1 [doi]
LID - 103
AB  - BACKGROUND: Healthy Hearts Northwest (H2N) is a study of external support 
      strategies to build quality improvement (QI) capacity in primary care with a 
      focus on cardiovascular risk factors: appropriate aspirin use, blood pressure 
      control, and tobacco screening/cessation. METHODS: To guide practice facilitator 
      support, experts in practice transformation identified seven domains of QI 
      capacity and mapped items from a previously validated medical home assessment 
      tool to them. A practice facilitator (PF) met with clinicians and staff in each 
      practice to discuss each item on the Quality Improvement Capacity Assessment 
      (QICA) resulting in a practice-level response to each item. We examined the 
      association between the QICA total and sub-scale scores, practice 
      characteristics, a measure of prior experience with managing practice change, and 
      performance on clinical quality measures (CQMs) for the three cardiovascular risk 
      factors. RESULTS: The QICA score was associated with prior experience managing 
      change and moderately associated with two of the three CQMs: aspirin use 
      (r = 0.16, p = 0.049) and blood pressure control (r = 0.18, p = 0.013). Rural 
      practices and those with 2-5 clinicians had lower QICA scores.. CONCLUSIONS: The 
      QICA is useful for assessing QI capacity within a practice and may serve as a 
      guide for both facilitators and primary care practices in efforts to build this 
      capacity and improve measures of clinical quality. TRIAL REGISTRATION: This trial 
      is registered with www.clinicaltrials.gov Identifier# NCT02839382, 
      retrospectively registered on July 21, 2016.
FAU - Parchman, Michael L
AU  - Parchman ML
AUID- ORCID: 0000-0001-7129-2889
AD  - Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave Ste 1600, 
      Seattle, WA, 98101, USA. michael.x.parchman@kp.org.
FAU - Anderson, Melissa L
AU  - Anderson ML
AD  - Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave Ste 1600, 
      Seattle, WA, 98101, USA.
FAU - Coleman, Katie
AU  - Coleman K
AD  - Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave Ste 1600, 
      Seattle, WA, 98101, USA.
FAU - Michaels, Le Ann
AU  - Michaels LA
AD  - Oregon Rural Practice Research Network, Oregon Health Sciences University, 
      Portland, OR, USA.
FAU - Schuttner, Linnaea
AU  - Schuttner L
AD  - VA Puget Sound Healthcare System, Seattle, WA, USA.
FAU - Conway, Cullen
AU  - Conway C
AD  - Oregon Rural Practice Research Network, Oregon Health Sciences University, 
      Portland, OR, USA.
FAU - Hsu, Clarissa
AU  - Hsu C
AD  - Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave Ste 1600, 
      Seattle, WA, 98101, USA.
FAU - Fagnan, Lyle J
AU  - Fagnan LJ
AD  - Oregon Rural Practice Research Network, Oregon Health Sciences University, 
      Portland, OR, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02839382
GR  - UL1 TR002319/TR/NCATS NIH HHS/United States
GR  - R18HS023908/Agency for Healthcare Research &amp; Quality/International
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20190725
PL  - England
TA  - BMC Fam Pract
JT  - BMC family practice
JID - 100967792
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Hypertension/prevention & control
MH  - Idaho
MH  - Oregon
MH  - Patient-Centered Care
MH  - Primary Health Care/*standards
MH  - Program Evaluation
MH  - *Quality Improvement
MH  - Tobacco Use Cessation
MH  - Washington
PMC - PMC6657073
OTO - NOTNLM
OT  - Patient care team
OT  - Primary health care
OT  - Process assessment
OT  - Quality improvement
COIS- The authors declare that they have no competing interests.
EDAT- 2019/07/28 06:00
MHDA- 2020/04/09 06:00
CRDT- 2019/07/27 06:00
PHST- 2019/05/13 00:00 [received]
PHST- 2019/07/18 00:00 [accepted]
PHST- 2019/07/27 06:00 [entrez]
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
AID - 10.1186/s12875-019-1000-1 [pii]
AID - 1000 [pii]
AID - 10.1186/s12875-019-1000-1 [doi]
PST - epublish
SO  - BMC Fam Pract. 2019 Jul 25;20(1):103. doi: 10.1186/s12875-019-1000-1.

PMID- 21567303
OWN - NLM
STAT- MEDLINE
DCOM- 20120504
LR  - 20211020
IS  - 1556-0961 (Electronic)
IS  - 1541-6933 (Linking)
VI  - 15
IP  - 3
DP  - 2011 Dec
TI  - Aspirin use or reduced platelet activity predicts craniotomy after intracerebral 
      hemorrhage.
PG  - 442-6
LID - 10.1007/s12028-011-9557-0 [doi]
AB  - BACKGROUND: Craniotomy is potentially life-saving in selected patients with 
      intracerebral hemorrhage (ICH). Aside from specific scenarios (cerebellar 
      hemorrhage with hydrocephalus, midline shift from an accessible lesion, etc.) the 
      indications for surgical decompression are controversial. Based on the earlier 
      work that aspirin and reduced platelet activity are associated with larger 
      hemorrhage size and hemorrhage growth, we tested the hypothesis that aspirin or 
      reduced platelet activity would be associated with increased odds of craniotomy, 
      likely through hemorrhage growth. METHODS: We prospectively identified patients 
      with spontaneous ICH and routinely measured platelet activity on admission. 
      Patients were prospectively tracked, and outcomes were obtained with the modified 
      Rankin Scale (mRS). RESULTS: There were 187 patients in the sample. Craniotomy 
      (N = 32, 17%) was associated with a higher initial ICH volume (37.9 [20-63] vs. 
      12 [5-24] ml, P < 0.001) and location (P = 0.005). In multivariate logistic 
      regression, after controlling for ICH volume and location, any known aspirin use 
      (OR 3.4, 95% CI 1.1-10.4, P = 0.03), platelet activity ≤550 aspirin reaction 
      units (OR 3.1, 95% CI 1.05-9.3, P = 0.04), or an elevated PFA-EPI closure time 
      (OR 3.2, 95% CI 1.02-10.3, P = 0.04) were associated with increased odds of 
      craniotomy. Craniotomy was not associated with mRS at 14 days, 28 days, or 
      3 months. CONCLUSIONS: After correction for ICH volume and location, aspirin use 
      or reduced platelet activity was associated with similar increased odds for 
      craniotomy.
FAU - Naidech, Andrew M
AU  - Naidech AM
AD  - Department of Neurology, Northwestern University Feinberg School of Medicine, 
      Chicago, IL 60611, USA. a-naidech@northwestern.edu
FAU - Rosenberg, Neil F
AU  - Rosenberg NF
FAU - Bernstein, Richard A
AU  - Bernstein RA
FAU - Batjer, H Hunt
AU  - Batjer HH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurocrit Care
JT  - Neurocritical care
JID - 101156086
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cerebral Hemorrhage/blood/*chemically induced/*surgery
MH  - *Craniotomy
MH  - Decompression, Surgical
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*adverse effects/*therapeutic use
MH  - Prospective Studies
EDAT- 2011/05/14 06:00
MHDA- 2012/05/05 06:00
CRDT- 2011/05/14 06:00
PHST- 2011/05/14 06:00 [entrez]
PHST- 2011/05/14 06:00 [pubmed]
PHST- 2012/05/05 06:00 [medline]
AID - 10.1007/s12028-011-9557-0 [doi]
PST - ppublish
SO  - Neurocrit Care. 2011 Dec;15(3):442-6. doi: 10.1007/s12028-011-9557-0.

PMID- 34396883
OWN - NLM
STAT- MEDLINE
DCOM- 20220112
LR  - 20220112
IS  - 1541-2563 (Electronic)
IS  - 1541-2563 (Linking)
VI  - 18
IP  - 4
DP  - 2021 Aug
TI  - Effectiveness of Aspirin in COPD: Biases in the Observational Studies.
PG  - 449-455
LID - 10.1080/15412555.2021.1963696 [doi]
AB  - Several observational studies report decreased incidence of mortality and of 
      exacerbations with aspirin use in patients with chronic obstructive pulmonary 
      disease (COPD), with calls for a large randomized trial. Aspirin does have local 
      and systemic pulmonary mechanisms of action that could make this drug beneficial 
      in the treatment of COPD. However, the potential for biases in the observational 
      studies has not been examined. We searched the literature for all observational 
      studies reporting on the effect of aspirin in COPD patients on exacerbation and 
      mortality. We reviewed the studies for the presence of time-related and other 
      biases. We identified eight observational studies reporting an overall reduction 
      in all-cause mortality or exacerbation with aspirin use of 21% (pooled rate ratio 
      (RR) 0.79; 95% CI 0.71-0.86). We found two studies affected by immortal time bias 
      (pooled RR 0.81; 95% CI 0.74-0.89), three studies affected by 
      collider-stratification bias (pooled RR 0.66; 95% CI 0.55-0.79) and three that 
      involved some exposure misclassification (pooled RR 0.85; 95% CI 0.78-0.92). 
      Moreover, while adjusting for cardiovascular factors, six of the eight studies 
      did not adjust for important markers of COPD severity and thus remain susceptible 
      to confounding bias. In conclusion, all observational studies reporting on the 
      effectiveness of aspirin on major outcomes of COPD are affected by biases known 
      to exaggerate the effectiveness of a drug. As these studies cannot be used to 
      support a beneficial effect for aspirin in COPD, it would be premature to 
      consider a randomized trial to investigate this question until methodologically 
      rigorous studies are available.
FAU - Bakshi, Anirudh
AU  - Bakshi A
AD  - Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital; 
      Departments of Epidemiology and Biostatistics, and Medicine, McGill University, 
      Montreal, Quebec, Canada.
FAU - Suissa, Samy
AU  - Suissa S
AD  - Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital; 
      Departments of Epidemiology and Biostatistics, and Medicine, McGill University, 
      Montreal, Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210816
PL  - England
TA  - COPD
JT  - COPD
JID - 101211769
RN  - 0 (Respiratory System Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Bias
MH  - Epidemiologic Factors
MH  - Humans
MH  - Observational Studies as Topic
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy/mortality
MH  - Respiratory System Agents/*therapeutic use
OTO - NOTNLM
OT  - COPD exacerbations
OT  - Observational research
OT  - biases
OT  - cardiovascular disease
OT  - mortality
OT  - real-world evidence
EDAT- 2021/08/17 06:00
MHDA- 2022/01/13 06:00
CRDT- 2021/08/16 08:44
PHST- 2021/08/17 06:00 [pubmed]
PHST- 2022/01/13 06:00 [medline]
PHST- 2021/08/16 08:44 [entrez]
AID - 10.1080/15412555.2021.1963696 [doi]
PST - ppublish
SO  - COPD. 2021 Aug;18(4):449-455. doi: 10.1080/15412555.2021.1963696. Epub 2021 Aug 
      16.

PMID- 11303325
OWN - NLM
STAT- MEDLINE
DCOM- 20010614
LR  - 20170306
VI  - 104
IP  - 1
DP  - 2000 Jul
TI  - [Use of platelet function analyzer PFA-100 and whole blood aggregometry to 
      monitor blood platelet sensitivity to acetylsalicylic acid (aspirin). Is it 
      possible to reliably monitor antiplatelet treatment using routine laboratory 
      diagnostic methods?].
PG  - 355-61
AB  - Introduction of the antiplatelet agents of new generations and the occurrence of 
      the phenomenon of "aspirin-resistance" triggered the search for better, simpler 
      and more reliable routine diagnostic methods to monitor platelet reactivity. Our 
      objective was to evaluate the usefulness and reliability of two simple methods: 
      platelet function analyzer (PFA-100) and whole blood platelet aggregometry for 
      monitoring of platelet function in 18 healthy blood donors and 35 patients with 
      ischaemic heart disease (IHD) subjected to small doses/75 mg and 150 mg a day) of 
      acetylsalicylic acid (aspirin). In 50% of healthy blood donors the intake of 75 
      mg ASA a day resulted in the prolongation of PFA-100 collagen/epinephrine closure 
      time (CEPI = (relevant to reduced platelet reactivity) of over 150 s, whereas 75% 
      donors responded to 150 mg ASA-. Otherwise, the daily dose of 150 mg ASA resulted 
      in a prolonged CEPI merely in 23% of in IHD patients. At both doses ASA 
      completely inhibited the arachidonic acid-induced whole blood platelet 
      aggregation in all healthy donors and in all but 3 IHD patients. Collagen-induced 
      platelet aggregation was only negligibly affected by either dose of ASA. Our 
      results point that the simultaneous monitoring of the PFA-100 
      collagen/epinephrine closure time and whole blood platelet aggregometry 
      (Chrono-Log) enables to reliably evaluate the inhibition of platelet function by 
      ASA and discriminate the partial or complete platelet insensitivity to aspirin. 
      The phenomenon of more frequent platelet aspirin-resistance in IHD patients 
      requires to be verified in randomised clinical prospective studies.
FAU - Golański, J
AU  - Golański J
AD  - Samodzielna Pracownia Zaburzeń Krzepniecia Krwi Katedry Diagnostyki 
      Laboratoryjnej Akademii Medycznej w Łodzi.
FAU - Chizyński, K
AU  - Chizyński K
FAU - Golański, R
AU  - Golański R
FAU - Watała, C
AU  - Watała C
LA  - pol
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Zastosowanie analizatora funkcji płytek PFA-100 oraz metody agregacji we krwi 
      pełnej do oceny wrazliwości płytek krwi na działanie kwasu acetylosalicylowego 
      (aspiryny). Czy mozliwa jest wiarygodna laboratoryjna weryfikacja leczenia 
      przeciwpłytkowego?
PL  - Poland
TA  - Pol Arch Med Wewn
JT  - Polskie Archiwum Medycyny Wewnetrznej
JID - 0401225
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic/methods
MH  - Myocardial Ischemia/blood/*drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Reproducibility of Results
EDAT- 2001/04/17 10:00
MHDA- 2001/06/23 10:01
CRDT- 2001/04/17 10:00
PHST- 2001/04/17 10:00 [pubmed]
PHST- 2001/06/23 10:01 [medline]
PHST- 2001/04/17 10:00 [entrez]
PST - ppublish
SO  - Pol Arch Med Wewn. 2000 Jul;104(1):355-61.

PMID- 10560451
OWN - NLM
STAT- MEDLINE
DCOM- 19991124
LR  - 20210501
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 171
IP  - 6
DP  - 1999 Sep 20
TI  - Warfarin or aspirin: both or others?
PG  - 321-6
AB  - In general, aspirin is indicated to prevent thrombosis in conditions associated 
      with high shear rates (i.e., atherosclerosis) and warfarin is indicated to 
      prevent thrombosis in conditions associated with stasis (i.e., atrial 
      fibrillation). While aspirin and warfarin should generally not be used together, 
      their combined use is beneficial in selected patients (e.g., some patients with 
      mechanical valve prostheses). Aspirin in a dose of 75-150 mg per day is indicated 
      to prevent vascular events in patients with ischaemic heart disease and also in 
      patients at high risk of ischaemic heart disease. All patients with atrial 
      fibrillation should be considered for oral anticoagulant therapy, with the 
      decision for its use based on an assessment of the balance between the risk of 
      thromboembolism and bleeding. The recommended therapeutic INR (international 
      normalised ratio) range in non-valvular atrial fibrillation is 2.0-3.0. Warfarin 
      is contraindicated in pregnancy, particularly during the first trimester; 
      however, it may still need to be used in the second and third trimesters in 
      patients with mechanical valve prostheses.
FAU - Peverill, R E
AU  - Peverill RE
AD  - Department of Medicine, Monash Medical Centre, and Monash University, Melbourne, 
      VIC. roger.peverill@med.monash.edu.au
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Embolism/etiology/*prevention & control
MH  - Female
MH  - Heart Diseases/*complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/drug therapy
MH  - Risk Factors
MH  - Thrombosis/etiology/*prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
AID - 10.5694/j.1326-5377.1999.tb123671.x [doi]
PST - ppublish
SO  - Med J Aust. 1999 Sep 20;171(6):321-6. doi: 10.5694/j.1326-5377.1999.tb123671.x.

PMID- 1761336
OWN - NLM
STAT- MEDLINE
DCOM- 19920213
LR  - 20190816
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 33
IP  - 3
DP  - 1991 Dec
TI  - Increased occurrence of exercise-induced silent ischemia after treatment with 
      aspirin in patients admitted for suspected acute myocardial infarction.
PG  - 413-7
AB  - Patients admitted for suspected acute myocardial infarction within 6 hours (mean 
      3 hours 42 minutes) after onset of symptoms were randomised to double-blind 
      treatment with low-dose oral aspirin or placebo. Early exercise ischemic 
      responses, exercise capacity and resting left ventricular ejection fraction 
      (radionuclide ventriculography) were estimated in 77 survivors 2-4 weeks later. 
      Exercise performance and ejection fraction in patients with confirmed acute 
      myocardial infarction were equal in the two groups. During exercise, patients 
      treated with aspirin had significantly more silent ischemia (ST depression 
      without chest pain) compared to placebo (28% versus 6%; P = 0.015). The 
      occurrence of positive exercise tests (chest pain or ST-segment depression), 
      however, was similar in the two groups. The results indicate that the 
      administration of aspirin early after acute myocardial infarction increases the 
      occurrence of silent ischemia but has no effect on left ventricular function.
FAU - Rønnevik, P K
AU  - Rønnevik PK
AD  - Department of Medicine, University Clinic Haukeland Hospital, Bergen, Norway.
FAU - Følling, M
AU  - Følling M
FAU - Pedersen, D
AU  - Pedersen D
FAU - Rodt, S A
AU  - Rodt SA
FAU - von der Lippe, G
AU  - von der Lippe G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Coronary Disease/*chemically induced/complications/diagnosis
MH  - Double-Blind Method
MH  - Electrocardiography
MH  - *Exercise Test
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/complications/diagnosis/*drug therapy
MH  - Radionuclide Ventriculography
MH  - Stroke Volume/drug effects
MH  - Ventricular Function, Left/drug effects
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
AID - 0167-5273(91)90071-V [pii]
AID - 10.1016/0167-5273(91)90071-v [doi]
PST - ppublish
SO  - Int J Cardiol. 1991 Dec;33(3):413-7. doi: 10.1016/0167-5273(91)90071-v.

PMID- 24777030
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20140617
IS  - 1364-548X (Electronic)
IS  - 1359-7345 (Linking)
VI  - 50
IP  - 56
DP  - 2014 Jul 18
TI  - The ligation of aspirin to cisplatin demonstrates significant synergistic effects 
      on tumor cells.
PG  - 7427-30
LID - 10.1039/c4cc00419a [doi]
AB  - Asplatin, a fusion of aspirin and cisplatin, exhibits significant cytotoxicity in 
      tumor cells and almost fully overcomes the drug resistance of cisplatin resistant 
      cells. Asplatin is highly accumulated in cancer cells and is activated upon the 
      reduction by ascorbic acid.
FAU - Cheng, Qinqin
AU  - Cheng Q
AD  - CAS Key Laboratory of Soft Matter Chemistry, CAS High Magnetic Field Laboratory, 
      Department of Chemistry, University of Science and Technology of China, Hefei, 
      Anhui 230026, China. liuyz@ustc.edu.cn.
FAU - Shi, Hongdong
AU  - Shi H
FAU - Wang, Hongxia
AU  - Wang H
FAU - Min, Yuanzeng
AU  - Min Y
FAU - Wang, Jun
AU  - Wang J
FAU - Liu, Yangzhong
AU  - Liu Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Chem Commun (Camb)
JT  - Chemical communications (Cambridge, England)
JID - 9610838
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Combinations)
RN  - Q20Q21Q62J (Cisplatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*chemistry
MH  - Antineoplastic Agents/administration & dosage/*chemistry
MH  - Aspirin/administration & dosage/*chemistry
MH  - Cell Line, Tumor
MH  - Cisplatin/administration & dosage/*chemistry
MH  - Drug Combinations
MH  - Drug Synergism
MH  - Hep G2 Cells
MH  - Humans
MH  - MCF-7 Cells
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Tumor Burden/*drug effects
MH  - Xenograft Model Antitumor Assays/methods
EDAT- 2014/04/30 06:00
MHDA- 2015/05/12 06:00
CRDT- 2014/04/30 06:00
PHST- 2014/04/30 06:00 [entrez]
PHST- 2014/04/30 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - 10.1039/c4cc00419a [doi]
PST - ppublish
SO  - Chem Commun (Camb). 2014 Jul 18;50(56):7427-30. doi: 10.1039/c4cc00419a.

PMID- 36625733
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20230509
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 57
IP  - 6
DP  - 2023 Mar
TI  - Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin 
      and metformin.
PG  - 600-609
LID - 10.1111/apt.17371 [doi]
AB  - BACKGROUND: Emerging data suggest that statins, aspirin and metformin may protect 
      against hepatocellular carcinoma (HCC) development. However, prior meta-analyses 
      were limited by heterogeneity and inclusion of studies without adequate 
      adjustment for baseline risks. AIM: To examine by an updated meta-analysis the 
      association between these medications and HCC risk. METHODS: Medline and Embase 
      databases were searched from inception to March 2022 for studies that balanced 
      baseline risks between study groups via propensity score matching or inverse 
      probability of treatment weighting, that reported the impact of statins, aspirin 
      or metformin on HCC risk. Multivariable-adjusted hazard ratios (HRs) for HCC were 
      pooled using a random effects model. RESULTS: Statin use was associated with 
      reduced HCC risk overall (HR: 0.52; 95% CI: 0.37-0.72) (10 studies, 1,774,476), 
      and in subgroup analyses for cirrhosis, hepatitis B/C, non-alcoholic fatty liver 
      disease, studies accounting for concurrent aspirin and metformin consumption and 
      lipophilic statins. Aspirin use was associated with reduced HCC risk overall (HR: 
      0.48; 95% CI: 0.27-0.87) (11 studies, 2,190,285 patients) but not in studies 
      accounting for concurrent statin and metformin use. Metformin use was not 
      associated with reduced HCC risk overall (HR: 0.57; 95% CI: 0.31-1.06) (3 
      studies, 125,458 patients). Most analyses had moderate/substantial heterogeneity, 
      except in follow-up <60 months for aspirin (I(2)  = 0%). CONCLUSION: Although 
      statin and aspirin use were associated with reduced HCC risk, only statin use was 
      significant in subgroup analyses accounting for concurrent medications. Metformin 
      use was not associated with reduced HCC risk. These data have implications for 
      future clinical trial design.
CI  - © 2023 John Wiley & Sons Ltd.
FAU - Zeng, Rebecca W
AU  - Zeng RW
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Yong, Jie Ning
AU  - Yong JN
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Tan, Darren J H
AU  - Tan DJH
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Fu, Clarissa E
AU  - Fu CE
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Lim, Wen Hui
AU  - Lim WH
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Xiao, Jieling
AU  - Xiao J
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Chan, Kai En
AU  - Chan KE
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Tan, Caitlyn
AU  - Tan C
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Goh, Xin Lei
AU  - Goh XL
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Chee, Douglas
AU  - Chee D
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, National 
      University Hospital, Singapore, Singapore.
FAU - Syn, Nicholas
AU  - Syn N
AUID- ORCID: 0000-0002-6343-176X
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Tan, Eunice X
AU  - Tan EX
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, National 
      University Hospital, Singapore, Singapore.
AD  - National University Centre for Organ Transplantation, National University Health 
      System, Singapore, Singapore.
FAU - Muthiah, Mark D
AU  - Muthiah MD
AUID- ORCID: 0000-0002-9724-4743
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, National 
      University Hospital, Singapore, Singapore.
AD  - National University Centre for Organ Transplantation, National University Health 
      System, Singapore, Singapore.
FAU - Ng, Cheng Han
AU  - Ng CH
AUID- ORCID: 0000-0002-8297-1569
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Tamaki, Nobuharu
AU  - Tamaki N
AD  - Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 
      Tokyo, Japan.
FAU - Lee, Sung Won
AU  - Lee SW
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      College of Medicine, The Catholic University of Korea, Seoul, Korea.
AD  - The Catholic University Liver Research Centre, Seoul, Korea.
FAU - Kim, Beom Kyung
AU  - Kim BK
AUID- ORCID: 0000-0002-5363-2496
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Republic of Korea.
AD  - Yonsei Liver Center, Severance Hospital, Yonsei University Health System, Seoul, 
      Republic of Korea.
FAU - Nguyen, Mindie H
AU  - Nguyen MH
AUID- ORCID: 0000-0002-6275-4989
AD  - Division of Gastroenterology and Hepatology, Stanford University Medical Center, 
      Palo Alto, California, USA.
FAU - Loomba, Rohit
AU  - Loomba R
AUID- ORCID: 0000-0002-4845-9991
AD  - NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of 
      Medicine, University of California at San Diego, San Diego, California, USA.
FAU - Huang, Daniel Q
AU  - Huang DQ
AUID- ORCID: 0000-0002-5165-5061
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, National 
      University Hospital, Singapore, Singapore.
AD  - National University Centre for Organ Transplantation, National University Health 
      System, Singapore, Singapore.
AD  - NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of 
      Medicine, University of California at San Diego, San Diego, California, USA.
LA  - eng
GR  - P01 HL147835/HL/NHLBI NIH HHS/United States
GR  - R01 DK124318/DK/NIDDK NIH HHS/United States
GR  - R01 DK121378/DK/NIDDK NIH HHS/United States
GR  - P30 DK120515/DK/NIDDK NIH HHS/United States
GR  - R01 DK106419/DK/NIDDK NIH HHS/United States
GR  - U01 DK061734/DK/NIDDK NIH HHS/United States
GR  - U01 DK130190/DK/NIDDK NIH HHS/United States
GR  - UL1 TR001442/TR/NCATS NIH HHS/United States
GR  - P42 ES010337/ES/NIEHS NIH HHS/United States
GR  - U01 AA029019/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20230110
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - *Liver Neoplasms/drug therapy
MH  - Aspirin/therapeutic use
MH  - *Metformin
MH  - Chemoprevention
OTO - NOTNLM
OT  - hepatoma
OT  - incidence
OT  - liver cancer
OT  - prevention
EDAT- 2023/01/11 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/01/10 10:07
PHST- 2022/11/12 00:00 [revised]
PHST- 2022/10/26 00:00 [received]
PHST- 2022/12/11 00:00 [accepted]
PHST- 2023/01/11 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2023/01/10 10:07 [entrez]
AID - 10.1111/apt.17371 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2023 Mar;57(6):600-609. doi: 10.1111/apt.17371. Epub 2023 
      Jan 10.

PMID- 25956227
OWN - NLM
STAT- MEDLINE
DCOM- 20160222
LR  - 20150605
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 112
DP  - 2015 Aug 10
TI  - Determination of counterfeit medicines by Raman spectroscopy: Systematic study 
      based on a large set of model tablets.
PG  - 70-8
LID - S0731-7085(15)00229-0 [pii]
LID - 10.1016/j.jpba.2015.04.001 [doi]
AB  - In the last decade, counterfeit pharmaceutical products have become a widespread 
      issue for public health. Raman spectroscopy which is easy, non-destructive and 
      information-rich is particularly suitable as screening method for fast 
      characterization of chemicals and pharmaceuticals. Combined with chemometric 
      techniques, it provides a powerful tool for the analysis and determination of 
      counterfeit medicines. Here, for the first time, a systematic study of the 
      benefits and limitations of Raman spectroscopy for the analysis of pharmaceutical 
      samples on a large set of model tablets, varying with respect to chemical and 
      physical properties, was performed. To discriminate between the different 
      mixtures, a combination of dispersive Raman spectroscopy performing in 
      backscattering mode and principal component analysis was used. The discrimination 
      between samples with different coatings, a varying amount of active 
      pharmaceutical ingredients and a diversity of excipients were possible. However, 
      it was not possible to distinguish between variations of the press power, mixing 
      quality and granulation. As a showcase, the change in Raman signals of commercial 
      acetylsalicylic acid effervescent tablets due to five different storage 
      conditions was monitored. It was possible to detect early small chemical changes 
      caused by inappropriate storage conditions. These results demonstrate that Raman 
      spectroscopy combined with multivariate data analysis provides a powerful 
      methodology for the fast and easy characterization of genuine and counterfeit 
      medicines.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Neuberger, Sabine
AU  - Neuberger S
AD  - Aalen University, Aalen, Germany.
FAU - Neusüß, Christian
AU  - Neusüß C
AD  - Aalen University, Aalen, Germany. Electronic address: 
      christian.neusuess@hs-aalen.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150417
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Counterfeit Drugs)
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Counterfeit Drugs/*analysis/*chemistry
MH  - Excipients/chemistry
MH  - Multivariate Analysis
MH  - Principal Component Analysis/methods
MH  - Spectrum Analysis, Raman/methods
MH  - Tablets/*analysis/*chemistry
OTO - NOTNLM
OT  - Counterfeit
OT  - Model tablets
OT  - PCA
OT  - Raman spectroscopy
OT  - Screening method
EDAT- 2015/05/10 06:00
MHDA- 2016/02/24 06:00
CRDT- 2015/05/10 06:00
PHST- 2014/11/24 00:00 [received]
PHST- 2015/03/30 00:00 [revised]
PHST- 2015/04/02 00:00 [accepted]
PHST- 2015/05/10 06:00 [entrez]
PHST- 2015/05/10 06:00 [pubmed]
PHST- 2016/02/24 06:00 [medline]
AID - S0731-7085(15)00229-0 [pii]
AID - 10.1016/j.jpba.2015.04.001 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2015 Aug 10;112:70-8. doi: 10.1016/j.jpba.2015.04.001. Epub 
      2015 Apr 17.

PMID- 19162515
OWN - NLM
STAT- MEDLINE
DCOM- 20090331
LR  - 20220309
IS  - 1532-2165 (Electronic)
IS  - 1078-5884 (Linking)
VI  - 37
IP  - 3
DP  - 2009 Mar
TI  - Combined intermittent pneumatic leg compression and pharmacological prophylaxis 
      for prevention of venous thrombo-embolism in high-risk patients.
PG  - 364-5
LID - 10.1016/j.ejvs.2008.11.033 [doi]
AB  - BACKGROUND: It has been suggested that combined modalities (methods of treatment) 
      are more effective than single modalities in preventing venous thrombo-embolism 
      (defined as deep vein thrombosis and pulmonary embolism, or both) in high-risk 
      patients. OBJECTIVES: To assess the efficacy of intermittent pneumatic leg 
      compression combined with pharmacological prophylaxis versus single modalities in 
      preventing venous thrombo-embolism in high-risk patients. SEARCH STRATEGY: The 
      Cochrane Peripheral Vascular Diseases (PVD) Group searched the reference lists of 
      their Specialised Register (last searched 17 July 2007) and the Cochrane Central 
      Register of Controlled Trials (CENTRAL) (last searched The Cochrane Library 2008, 
      issue 3) for relevant articles to identify additional trials. SELECTION CRITERIA: 
      Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) of 
      combined intermittent pneumatic leg compression and pharmacological interventions 
      used to prevent venous thrombo-embolism in high-risk patients. DATA COLLECTION 
      AND ANALYSIS: Data extraction was undertaken independently by two review authors 
      using data extraction sheets.
FAU - Kakkos, S K
AU  - Kakkos SK
AD  - Division of Vascular Surgery, Department of Surgery, Detroit, USA. 
      kakkos@upatras.gr
FAU - Caprini, J A
AU  - Caprini JA
FAU - Geroulakos, G
AU  - Geroulakos G
FAU - Nicolaides, A N
AU  - Nicolaides AN
FAU - Stansby, G P
AU  - Stansby GP
FAU - Reddy, D J
AU  - Reddy DJ
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090121
PL  - England
TA  - Eur J Vasc Endovasc Surg
JT  - European journal of vascular and endovascular surgery : the official journal of 
      the European Society for Vascular Surgery
JID - 9512728
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - *Intermittent Pneumatic Compression Devices
MH  - Pulmonary Embolism/*prevention & control
MH  - Venous Thrombosis/*prevention & control
RF  - 0
EDAT- 2009/01/24 09:00
MHDA- 2009/04/01 09:00
CRDT- 2009/01/24 09:00
PHST- 2008/10/21 00:00 [received]
PHST- 2008/11/18 00:00 [accepted]
PHST- 2009/01/24 09:00 [entrez]
PHST- 2009/01/24 09:00 [pubmed]
PHST- 2009/04/01 09:00 [medline]
AID - S1078-5884(08)00652-7 [pii]
AID - 10.1016/j.ejvs.2008.11.033 [doi]
PST - ppublish
SO  - Eur J Vasc Endovasc Surg. 2009 Mar;37(3):364-5. doi: 10.1016/j.ejvs.2008.11.033. 
      Epub 2009 Jan 21.

PMID- 29259292
OWN - NLM
STAT- MEDLINE
DCOM- 20181105
LR  - 20181105
IS  - 1476-5608 (Electronic)
IS  - 1365-7852 (Linking)
VI  - 21
IP  - 1
DP  - 2018 Apr
TI  - Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs 
      (NSAIDs) and prostate cancer risk.
PG  - 147-152
LID - 10.1038/s41391-017-0021-x [doi]
AB  - BACKGROUND: Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) may 
      have a preventive effect against prostate cancer. However, evidence is limited 
      and still controversial, especially considering non-aspirin non-steroidal 
      anti-inflammatory drugs (NSAIDs). METHODS: Swedish nationwide population-based 
      cohort study including all long-term (≥180 days) adult male users of aspirin 
      (n = 419,931) or NSAIDs (n = 223,437) followed from the first dispense date until 
      the first cancer diagnosis, death or 31 December 2012, whichever occurred first. 
      The risk of prostate cancer was measured as standardized incidence ratios (SIR) 
      and 95% confidence intervals (CI), assessing duration of use, age and concomitant 
      statins intake, comparing to the general male background population of the same 
      age in Sweden. RESULTS: The overall SIR suggests that maintenance use of aspirin 
      decreases the risk of prostate cancer (SIR = 0.87, 95% CI 0.85-0.88), in 
      particular if used ≥5 years (SIR = 0.31, 95% CI 0.30-0.32). The overall risk was 
      decreased (SIR = 0.87, 95% CI 0.85-0.90) among other NSAIDs users, and again in 
      particular among longer-term users (≥3 years) with SIR = 0.58 (95% CI 0.53-0.63). 
      When statins users were excluded from all aspirin users, there was no remaining 
      association with prostate cancer (SIR = 0.99, 95% CI 0.96-1.02), only if taken ≥5 
      years (SIR = 0.31, 95% CI 0.29-0.34). For non-aspirin NSAIDs users, the 
      protective effect remained after exclusion of statins users (SIR = 0.92, 95% CI 
      0.88-0.95). CONCLUSIONS: This population-based cohort study provides evidence for 
      a protective effect of aspirin and other NSAIDs against prostate cancer, in 
      particular for longer durations of use, yet concomitant use of statins strongly 
      influences the risk among aspirin users.
FAU - Ma, Yuanjun
AU  - Ma Y
AD  - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. 
      yuanjun.ma@ki.se.
FAU - Brusselaers, Nele
AU  - Brusselaers N
AD  - Centre for Translational Microbiome Research, Department of Microbiology, Tumor 
      and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
AD  - Science for Life Laboratory (SciLifeLab), Stockholm, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20171219
PL  - England
TA  - Prostate Cancer Prostatic Dis
JT  - Prostate cancer and prostatic diseases
JID - 9815755
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/*drug therapy/epidemiology/pathology
MH  - Risk Factors
MH  - Sweden/epidemiology
MH  - Young Adult
EDAT- 2017/12/21 06:00
MHDA- 2018/11/06 06:00
CRDT- 2017/12/21 06:00
PHST- 2017/07/18 00:00 [received]
PHST- 2017/09/16 00:00 [accepted]
PHST- 2017/12/21 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
PHST- 2017/12/21 06:00 [entrez]
AID - 10.1038/s41391-017-0021-x [pii]
AID - 10.1038/s41391-017-0021-x [doi]
PST - ppublish
SO  - Prostate Cancer Prostatic Dis. 2018 Apr;21(1):147-152. doi: 
      10.1038/s41391-017-0021-x. Epub 2017 Dec 19.

PMID- 3041973
OWN - NLM
STAT- MEDLINE
DCOM- 19880830
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 38
IP  - 4
DP  - 1988 Apr
TI  - [Therapy of common cold with a homeopathic combination preparation in comparison 
      with acetylsalicylic acid. A controlled, randomized double-blind study].
PG  - 578-82
AB  - A clinical test was carried out on 170 West German army soldiers suffering from 
      common cold. The test was conducted on a monocentric, randomized, non-sequential, 
      and inter-individual basis; the research workers were kept blind on the identity 
      of the medication. The purpose of testing was to compare the effectiveness of a 
      combination homeopathic preparation (Gripp-Heel) with that of acetylsalicylic 
      acid. On the 4th and 10th treatment days, no significant difference was 
      determined with respect to changes in clinical findings, subjectively assessed 
      complaints, or length of time the patients were unable to work. Thus the two 
      preparations possess comparative effectiveness in the treatment of the common 
      cold.
FAU - Maiwald, V L
AU  - Maiwald VL
AD  - Medizinischen Universitäts-Klinik Würzburg.
FAU - Weinfurtner, T
AU  - Weinfurtner T
FAU - Mau, J
AU  - Mau J
FAU - Connert, W D
AU  - Connert WD
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Therapie des grippalen Infekts mit einem homöopathischen Kombinationspräparat im 
      Vergleich zu Acetylsalicylsäure. Kontrollierte, randomisierte Einfachblindstudie.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Common Cold/*drug therapy
MH  - Double-Blind Method
MH  - *Homeopathy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
EDAT- 1988/04/01 00:00
MHDA- 1988/04/01 00:01
CRDT- 1988/04/01 00:00
PHST- 1988/04/01 00:00 [pubmed]
PHST- 1988/04/01 00:01 [medline]
PHST- 1988/04/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1988 Apr;38(4):578-82.

PMID- 9214056
OWN - NLM
STAT- MEDLINE
DCOM- 19970710
LR  - 20131121
IS  - 0041-5782 (Print)
IS  - 0041-5782 (Linking)
VI  - 159
IP  - 24
DP  - 1997 Jun 9
TI  - [NSAID and ulcer complications. An analysis of risk factors].
PG  - 3787-91
AB  - Use of NSAIDs is recognized as an important cause of peptic ulcer complications. 
      The aim of this nested case-control study was to identify risk factors for 
      NSAID-related ulcer complications. Cases were consecutive NSAID users admitted 
      with an ulcer complication (n = 94), and controls were a random sample of all 
      NSAID users without ulcer complication identified by a pharmaco-epidemiological 
      database (n = 324). Risk factors for patients at start of NSAID-therapy were: 
      high age: 60-75 yr; Odds Ratio (OR) 3.5 (95% CI: 1.8-7.0); > 75 yr: OR 8.8 
      (4.3-18.1); male sex: OR 1.7 (1.0-3.0); ulcer history: OR 2.5 (1.2-5.1); steroid 
      treatment: OR 2.0 (0.8-4.6); smoking: OR 1.6 (0.9-2.7); alcohol use: OR 1.8 
      (0.9-3.6). Risk factors for patients on NSAID-therapy were: high age, male sex, 
      ulcer history, and smoking, and furthermore dyspepsia: OR 2.1 (1.0-4.2), 
      especially NSAID-related dyspepsia: OR 8.9 (4.1-19.2). Risk was lower for 
      patients treated more than three months. In conclusion, risk measured from this 
      design can be shown to correlate strongly with the rate difference, a measure 
      that is more clinically relevant than conventional relative risk estimates. 
      Strong risk factors for NSAID-related ulcer complication are high age, male sex, 
      ulcer history, and dyspepsia related to the NSAID therapy.
FAU - Hansen, J M
AU  - Hansen JM
AD  - Medicinsk gastroenterologisk afdeling S, Odense Universitetshospital.
FAU - Hallas, J
AU  - Hallas J
FAU - Lauritsen, J M
AU  - Lauritsen JM
FAU - Bytzer, P
AU  - Bytzer P
LA  - dan
PT  - English Abstract
PT  - Journal Article
TT  - NSAID og ulcuskomplikationer. En analyse af risikofaktorer.
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Databases, Factual
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer Hemorrhage/chemically induced
MH  - Pharmacoepidemiology
MH  - Stomach Ulcer/*chemically induced
EDAT- 1997/06/09 00:00
MHDA- 1997/06/09 00:01
CRDT- 1997/06/09 00:00
PHST- 1997/06/09 00:00 [pubmed]
PHST- 1997/06/09 00:01 [medline]
PHST- 1997/06/09 00:00 [entrez]
PST - ppublish
SO  - Ugeskr Laeger. 1997 Jun 9;159(24):3787-91.

PMID- 11576200
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190901
IS  - 0017-8748 (Print)
IS  - 0017-8748 (Linking)
VI  - 41
IP  - 8
DP  - 2001 Sep
TI  - Reduction in the intensity of abortive migraine drug use during coumarin therapy.
PG  - 768-73
AB  - OBJECTIVE: To investigate the impact of coumarin therapy on migraine attack 
      frequency. BACKGROUND: Sporadic case reports and clinical studies have described 
      beneficial effects of coumarin therapy on migraine severity. DESIGN AND METHODS: 
      A retrospective follow-up study based on a prescription database covering a 
      population of 450 000 was conducted. All patients using an abortive migraine drug 
      (ergotamine or sumatriptan) and subsequently treated with either coumarin (index 
      group) or low-dose acetylsalicylic acid (control group) were analyzed. The impact 
      of coumarin and low-dose acetylsalicylic acid on the frequency of migraine 
      attacks was assessed by measuring the intensity of ergotamine and sumatriptan 
      use, in defined daily doses per month per patient, before and during coumarin or 
      acetylsalicylic acid treatment. In addition, a "therapeutic intensity reduction" 
      was determined for each patient. RESULTS: The study population consisted of 92 
      patients; 35% had been prescribed coumarin and 65% had been prescribed low-dose 
      acetylsalicylic acid after the initiation of ergotamine or sumatriptan. Two 
      thirds of the study population was treated with ergotamine. Overall, ergotamine 
      and sumatriptan use for the coumarin cohort decreased from 6.4 defined daily 
      doses per month prior to coumarin treatment to 3.0 defined daily doses during 
      coumarin treatment, compared with a reduction from 5.2 defined daily doses per 
      month to 4.4 defined daily doses per month for the low-dose acetylsalicylic acid 
      cohort (P>.05). The therapeutic intensity of ergotamine and sumatriptan use was 
      significantly decreased by 40% for the coumarin cohort, compared with 4.7% for 
      the low-dose acetylsalicylic acid cohort (P=.004). CONCLUSIONS: We observed that 
      coumarin treatment was clearly associated with a reduction in the therapeutic 
      intensity of abortive migraine drug use in comparison with low-dose aspirin 
      treatment. This suggests that, overall, the coumarin cohort had experienced a 
      substantial reduction in the frequency of migraine attacks during anticoagulation 
      treatment. Our findings, as well as those of others, justify a controlled 
      clinical trial to further establish the effects of coumarin therapy on migraine 
      severity and its possible role in the prophylactic management of patients 
      suffering from migraine.
FAU - Rahimtoola, H
AU  - Rahimtoola H
AD  - Department of Pharmacy Practice Research, SIR Institute, Leiden, The Netherlands.
FAU - Egberts, A C
AU  - Egberts AC
FAU - Buurma, H
AU  - Buurma H
FAU - Tijssen, C C
AU  - Tijssen CC
FAU - Leufkens, H G
AU  - Leufkens HG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - 0 (Anticoagulants)
RN  - 0 (Coumarins)
RN  - 0 (Vasoconstrictor Agents)
RN  - 8R78F6L9VO (Sumatriptan)
RN  - A4VZ22K1WT (coumarin)
RN  - PR834Q503T (Ergotamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Coumarins/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Ergotamine/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy/*physiopathology
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Sumatriptan/*therapeutic use
MH  - Vasoconstrictor Agents/*therapeutic use
EDAT- 2001/09/29 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/09/29 10:00
PHST- 2001/09/29 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/09/29 10:00 [entrez]
AID - hed01141 [pii]
AID - 10.1046/j.1526-4610.2001.01141.x [doi]
PST - ppublish
SO  - Headache. 2001 Sep;41(8):768-73. doi: 10.1046/j.1526-4610.2001.01141.x.

PMID- 28906358
OWN - NLM
STAT- MEDLINE
DCOM- 20170922
LR  - 20220410
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 37
DP  - 2017 Sep
TI  - Efficacy evaluation of low-dose aspirin in IVF/ICSI patients evidence from 13 
      RCTs: A systematic review and meta-analysis.
PG  - e7720
LID - 10.1097/MD.0000000000007720 [doi]
LID - e7720
AB  - BACKGROUND: We conducted a systematic review and meta-analysis of existing 
      literature to evaluate the different outcomes of low-dose aspirin on patients 
      undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI), 
      including clinical pregnancy rate, implantation rate, live birth rate, 
      miscarriage rate, fertilization rate, number of oocytes retrieved, and so forth. 
      METHODS: Electronic databases including PubMed, MEDLINE, and Embase were searched 
      between 1997 and March 2016 to identity eligible studies. The following 
      comparisons between treatment groups were included: aspirin versus placebo; 
      aspirin versus control group; aspirin versus aspirin + prednisolone + control. 
      RESULTS: Thirteen randomized controlled trials which included 3104 participants 
      were selected. There were no significant differences in implantation rate 
      (RR = 1.15; 95% CI = 0.78-1.70), live birth rate (RR = 1.06; 95% CI = 0.93-1.21), 
      miscarriage rate (RR = 1.28; 95% CI = 0.93-1.77), fertilization rate (RR = 0.91; 
      95% CI = 0.75-1.11), and endometrial thickness (WMD = 0.15; 95% CI = -0.38-0.67). 
      But the research showed that aspirin treatment may improve the clinical pregnancy 
      rate (RR = 1.16; 95% CI = 1.04-1.28) compared to placebo or no treatment, and 
      reduce the number of oocytes retrieved (WMD = -0.68; 95% CI = -0.91-0.46). 
      CONCLUSIONS: Our findings suggest that low-dose aspirin may improve the pregnancy 
      rate in IVF/ICSI, with the recommended clinical use dose of 100 mg/day. 
      Considering the limitation of included studies, further well-designed 
      large-scaled RCTs are necessary to clarify whether aspirin may improve assisted 
      reproduction outcomes in IVF/ICSI patients.
FAU - Wang, Liping
AU  - Wang L
AD  - Department of Biobank, Clinical Medical College,Yangzhou University, Northern 
      Jiangsu Province Hospital, Yangzhou Department of Obstetrical, the First 
      Affiliated Hospital of Jinan University, Guangzhou, Guangdong Reproductive 
      Medicine Center, Department of Obstetrics and Gynecology, Clinical Medical 
      College, Yangzhou University, Northern Jiangsu Province Hospital, Yangzhou, China 
      The University of Texas MD Anderson Cancer Center, Department of Anesthesiology & 
      Perioperative Medicine, Houston, TX.
FAU - Huang, Xiaman
AU  - Huang X
FAU - Li, Xueli
AU  - Li X
FAU - Lv, Fang
AU  - Lv F
FAU - He, Xiao
AU  - He X
FAU - Pan, Yu
AU  - Pan Y
FAU - Wang, Li
AU  - Wang L
FAU - Zhang, Xiaomei
AU  - Zhang X
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Fertility Agents, Female)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fertility Agents, Female/*administration & dosage
MH  - *Fertilization in Vitro
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - *Sperm Injections, Intracytoplasmic
MH  - Treatment Outcome
PMC - PMC5604627
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2017/09/15 06:00
MHDA- 2017/09/25 06:00
CRDT- 2017/09/15 06:00
PHST- 2017/09/15 06:00 [entrez]
PHST- 2017/09/15 06:00 [pubmed]
PHST- 2017/09/25 06:00 [medline]
AID - 00005792-201709150-00010 [pii]
AID - MD-D-16-07348 [pii]
AID - 10.1097/MD.0000000000007720 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Sep;96(37):e7720. doi: 10.1097/MD.0000000000007720.

PMID- 27094089
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20170817
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 27
IP  - 7
DP  - 2016 Nov
TI  - Evaluation of platelet function using PFA-100® in patients treated with 
      Acetylsalicylic acid and qualified for Trauma and Orthopedic surgery procedures.
PG  - 680-686
AB  - The phenomenon of high on-acetylsalicylic acid (ASA) treatment platelet (PLT) 
      reactivity - HATPR - and its clinical implications have not been fully 
      understood. Little data is available on assessing PLT activity based on the 
      severity of intra- and postoperative bleeding in a population of orthopedic 
      patients with normal closure time (CT) measured by a PLT function analyzer 
      PFA-100®, despite being given long-term ASA therapy. The aim is to assess PLT 
      function using PFA-100® in patients with ASA therapy and qualified for trauma and 
      orthopedic surgery procedures. The retrospective analysis covered 384 patients 
      whose PLT reactivity was assessed using PFA-100®. Out of those, 198 had been 
      taking ASA with a 75 mg dose until hospital admission. In addition, a group of 70 
      patients with a proximal femoral fracture surgically treated using the dynamic 
      hip screw (DHS) was selected, in whom severity of bleeding was assessed by HIP 
      ASA (+). The reference group comprised 52 patients (without ASA therapy) who were 
      operated on due to the same indications. Normal CT was found in 37% of 
      ASA-receiving patients. Patients with normal CT, despite ASA therapy, exhibited 
      significantly more intense bleeding after DHS surgery. A similar number of 
      patients required red blood cells (RBCs) transfusion in HIP ASA (+) and HIP ASA 
      (-). Increased risk of complications in HIP ASA (+) group was not found. 
      CONCLUSIONS: Normal PLT function assessed using PFA-100® is a common phenomenon 
      in patients with long-term ASA treatment and who are qualified for trauma and 
      orthopedic surgery procedures. In many cases, it seems that inadequate response 
      to ASA is only a laboratory phenomenon.
FAU - Kurak, J
AU  - Kurak J
AD  - a Department of Trauma and Orthopaedics , District Trauma and Orthopaedic 
      Hospital , Piekary Sląskie , Poland.
FAU - Zając, P
AU  - Zając P
AD  - a Department of Trauma and Orthopaedics , District Trauma and Orthopaedic 
      Hospital , Piekary Sląskie , Poland.
FAU - Czyżewski, D
AU  - Czyżewski D
AD  - b Department of Thoracic Surgery, SMDZ in Zabrze , Medical University of Silesia 
      , Katowice , Poland.
FAU - Kucharski, R
AU  - Kucharski R
AD  - a Department of Trauma and Orthopaedics , District Trauma and Orthopaedic 
      Hospital , Piekary Sląskie , Poland.
FAU - Grzanka, R
AU  - Grzanka R
AD  - c Department of Internal Diseases, Dermatology and Allergology in Zabrze, SMDZ in 
      Zabrze , Medical University of Silesia , Katowice , Poland.
FAU - Kasperska-Zajac, A
AU  - Kasperska-Zajac A
AD  - c Department of Internal Diseases, Dermatology and Allergology in Zabrze, SMDZ in 
      Zabrze , Medical University of Silesia , Katowice , Poland.
FAU - Koczy, B
AU  - Koczy B
AD  - a Department of Trauma and Orthopaedics , District Trauma and Orthopaedic 
      Hospital , Piekary Sląskie , Poland.
LA  - eng
PT  - Journal Article
DEP - 20160420
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Coagulation Tests
MH  - Blood Platelets/*drug effects/*metabolism
MH  - Clinical Decision-Making
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Operative Time
MH  - Orthopedic Procedures/adverse effects/methods
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests/*methods/standards
MH  - Preoperative Care
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Wounds and Injuries/blood/diagnosis/drug therapy/surgery
MH  - Young Adult
OTO - NOTNLM
OT  - PFA-100®
OT  - aspirin resistance
OT  - high on-acetylsalicylic acid treatment platelet reactivity
OT  - platelet
OT  - trauma and orthopedic surgery procedures
EDAT- 2016/11/05 06:00
MHDA- 2017/03/14 06:00
CRDT- 2016/04/21 06:00
PHST- 2016/11/05 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
PHST- 2016/04/21 06:00 [entrez]
AID - 10.3109/09537104.2016.1158401 [doi]
PST - ppublish
SO  - Platelets. 2016 Nov;27(7):680-686. doi: 10.3109/09537104.2016.1158401. Epub 2016 
      Apr 20.

PMID- 29872260
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20220317
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 12
DP  - 2018
TI  - Immature platelets and antiplatelet therapy response to aspirin in Kawasaki 
      disease.
PG  - 1353-1362
LID - 10.2147/DDDT.S163705 [doi]
AB  - INTRODUCTION: Kawasaki disease is a kind of systemic vasculitis that mainly 
      damages moderate and small-sized blood vessels, and is a leading cause of 
      coronary artery lesions (CAL). Antiplatelet therapy is a routine component of 
      Kawasaki disease treatment strategies. So it is important to evaluate the 
      antiplatelet effect of aspirin because of the individual biological variability 
      of antiplatelet effect of aspirin. The immature platelet fraction (IPF) has 
      attracted particular attention as it may influence the antiplatelet effect of 
      aspirin. This study investigated the prognostic factors for evaluating the degree 
      of vasculitis and the effect of antiplatelet therapy in children with Kawasaki 
      disease. MATERIALS AND METHODS: Blood samples were collected from 44 patients 
      with Kawasaki disease before aspirin treatment and 7 to 10 days after treatment. 
      The IPF counts, percentage of the IPF, and highly fluorescent IPF were detected 
      by a Sysmex XE-5000 instrument. The levels of 11-dehydrothromboxane B(2) 
      (11-DH-TXB(2)), soluble CD40 ligand (sCD40L), and soluble P-selectin 
      (sP-selectin) were measured by ELISA. The correlation between the measured 
      factors and the degree of coronary artery damage in Kawasaki disease was 
      analyzed. RESULTS: We found that 11-DH-TXB(2), sP-selectin, and sCD40L levels 
      were much more elevated in the CAL group than in the non-coronary artery lesions 
      (NCAL) group before aspirin treatment. The concentrations of 11-DH-TXB(2), 
      sCD40L, sP-selectin, and IPF were reduced after aspirin treatment in the NCAL 
      group but not the CAL group. This is related to the degree of coronary artery 
      damage in Kawasaki disease patients. Additionally, 11-DH-TXB(2), sCD40L, 
      sP-selectin, and IPF were positively correlated with the degree of coronary 
      artery damage in Kawasaki disease patients. CONCLUSION: The current study 
      suggests that the presence of high plasma concentrations of 11-DH-TXB(2), sCD40L, 
      sP-selectin, and IPF can be considered a risk factor and experimental biomarker 
      for CAL in Kawasaki disease patients.
FAU - Pi, Lei
AU  - Pi L
AD  - Department of Clinical Biological Resource Bank, Guangzhou Institute of 
      Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical 
      University, Guangzhou, China.
FAU - Che, Di
AU  - Che D
AD  - Department of Clinical Biological Resource Bank, Guangzhou Institute of 
      Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical 
      University, Guangzhou, China.
FAU - Long, Haifeng
AU  - Long H
AD  - Department of Clinical Laboratory, Guangzhou Women and Children's Medical Center, 
      Guangzhou Medical University, Guangzhou, China.
AD  - Department of Clinical Laboratory, The First Clinical Medical College, Jinan 
      University, Guangzhou, China.
FAU - Fang, Zhenzhen
AU  - Fang Z
AD  - Program of Molecular Medicine, Guangzhou Women and Children's Hospital, Zhongshan 
      School of Medicine, Sun Yat-Sen University, Guangzhou, China.
FAU - Li, Jiawen
AU  - Li J
AD  - Department of Clinical Biological Resource Bank, Guangzhou Institute of 
      Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical 
      University, Guangzhou, China.
FAU - Lin, Shuyi
AU  - Lin S
AD  - Department of Clinical Laboratory, Guangzhou Women and Children's Medical Center, 
      Guangzhou Medical University, Guangzhou, China.
FAU - Liu, Yunfeng
AU  - Liu Y
AD  - Department of Clinical Laboratory, Guangzhou Women and Children's Medical Center, 
      Guangzhou Medical University, Guangzhou, China.
FAU - Li, Meiai
AU  - Li M
AD  - Department of Clinical Laboratory, Guangzhou Women and Children's Medical Center, 
      Guangzhou Medical University, Guangzhou, China.
FAU - Bao, Lijuan
AU  - Bao L
AD  - Department of Clinical Laboratory, Guangzhou Women and Children's Medical Center, 
      Guangzhou Medical University, Guangzhou, China.
FAU - Li, Wenli
AU  - Li W
AD  - Department of Clinical Laboratory, Guangzhou Women and Children's Medical Center, 
      Guangzhou Medical University, Guangzhou, China.
FAU - Zhang, Yuan
AU  - Zhang Y
AD  - Department of Clinical Laboratory, Guangzhou Women and Children's Medical Center, 
      Guangzhou Medical University, Guangzhou, China.
FAU - Deng, Qiulian
AU  - Deng Q
AD  - Department of Clinical Laboratory, Guangzhou Women and Children's Medical Center, 
      Guangzhou Medical University, Guangzhou, China.
FAU - Liu, Techang
AU  - Liu T
AD  - Department of Cardiology, Guangzhou Women and Children's Medical Center, 
      Guangzhou Medical University, Guangzhou, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Cardiology, Guangzhou Women and Children's Medical Center, 
      Guangzhou Medical University, Guangzhou, China.
FAU - Gu, Xiaoqiong
AU  - Gu X
AD  - Department of Clinical Biological Resource Bank, Guangzhou Institute of 
      Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical 
      University, Guangzhou, China.
AD  - Department of Clinical Laboratory, Guangzhou Women and Children's Medical Center, 
      Guangzhou Medical University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20180523
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 147205-72-9 (CD40 Ligand)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - CD40 Ligand/analysis
MH  - Child
MH  - Child, Preschool
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/blood/*drug therapy
MH  - P-Selectin/analysis
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Thromboxane B2/analogs & derivatives/analysis
PMC - PMC5973383
OTO - NOTNLM
OT  - Kawasaki disease
OT  - aspirin
OT  - coronary artery lesions
OT  - immature platelet fraction
COIS- Disclosure The authors report no conflicts of interest.
EDAT- 2018/06/07 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/06/07 06:00
PHST- 2018/06/07 06:00 [entrez]
PHST- 2018/06/07 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
AID - dddt-12-1353 [pii]
AID - 10.2147/DDDT.S163705 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2018 May 23;12:1353-1362. doi: 10.2147/DDDT.S163705. 
      eCollection 2018.

PMID- 32358315
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Linking)
VI  - 27
IP  - 5
DP  - 2020 May
TI  - Aspirin for primary prevention of cardiovascular disease in women.
PG  - 605-606
LID - 10.1097/GME.0000000000001547 [doi]
AB  - For primary prevention, low-dose aspirin should be considered in women aged 40 to 
      70 years with a 10-year cardiovascular risk of 20% or more or in women with 
      diabetes and a 10-year cardiovascular risk of 10% or more. The risk of bleeding 
      outweighs the benefits in low-risk women and in women aged 70 years and older.
FAU - Shufelt, Chrisandra L
AU  - Shufelt CL
AD  - The Barbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai 
      Medical Center, Los Angeles, California.
FAU - Manson, JoAnn E
AU  - Manson JE
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
LA  - eng
GR  - K23 HL127262/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/prevention & control
MH  - *Diabetes Mellitus
MH  - Female
MH  - Hemorrhage
MH  - Humans
MH  - Middle Aged
MH  - Primary Prevention
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2020/05/03 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 00042192-202005000-00016 [pii]
AID - 10.1097/GME.0000000000001547 [doi]
PST - ppublish
SO  - Menopause. 2020 May;27(5):605-606. doi: 10.1097/GME.0000000000001547.

PMID- 16421012
OWN - NLM
STAT- MEDLINE
DCOM- 20060411
LR  - 20181203
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 17
IP  - 2
DP  - 2006 Mar
TI  - Effect of combined administration of clopidogrel and lysine acetylsalicylate 
      versus clopidogrel and aspirin on platelet aggregation and activated GPIIb/IIIa 
      expression in healthy volunteers.
PG  - 105-7
AB  - Platelet activation contributes to thrombotic events in cardiovascular disease. 
      Acetylsalicylic acid (ASA) is used in combination with clopidogrel to reduce 
      cardiovascular events. Lysine acetylsalicylate (L-ASA), also inhibits platelet 
      activation with fewer gastrointestinal side effects than ASA. Dual therapy with 
      L-ASA and clopidogrel may result in an antiplatelet effect with fewer side 
      effects. We compared the antiplatelet effect of combined ASA/clopidogrel versus 
      L-ASA/clopidogrel in healthy subjects. Fourteen volunteers (seven men and seven 
      women, aged 25-45 years) received antiplatelet therapy during 14-day periods in 
      the following sequence: 75 mg ASA; 160 mg L-ASA; 75 mg clopidogrel; 160 mg L-ASA 
      plus 75 mg clopidogrel, and 75 mg ASA plus 75 mg clopidogrel. We evaluated 
      platelet aggregation and glycoprotein IIb/IIIa activation. Our results show that 
      administration of L-ASA/clopidogrel is as effective as ASA/clopidogrel 
      combination.
FAU - Majluf-Cruz, Abraham
AU  - Majluf-Cruz A
AD  - Unidad de Investigacion Medica en Trombosis, Hemostasia y Aterogenesis, Hospital 
      General Regional Gabriel Mancera, Instituto Mexicano del Seguro Social, Mexico 
      City, Mexico. amajlufc@prodigy.net.mx
FAU - Chavez-Ochoa, Adriana Ruiz de
AU  - Chavez-Ochoa AR
FAU - Majluf-Cruz, Karim
AU  - Majluf-Cruz K
FAU - Coria-Ramirez, Erika
AU  - Coria-Ramirez E
FAU - Pineda Del Aguila, Ignacio
AU  - Pineda Del Aguila I
FAU - Treviño-Perez, Sandra
AU  - Treviño-Perez S
FAU - Matías-Aguilar, Lisneth
AU  - Matías-Aguilar L
FAU - López-Armenta, Julio César
AU  - López-Armenta JC
FAU - Corona de la Peña, Norma
AU  - Corona de la Peña N
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - A74586SNO7 (Clopidogrel)
RN  - K3Z4F929H6 (Lysine)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/*analogs & derivatives/therapeutic use
MH  - Blood Platelets/*drug effects/physiology
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*biosynthesis/*drug effects/physiology
MH  - Reference Values
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
EDAT- 2006/01/20 09:00
MHDA- 2006/04/12 09:00
CRDT- 2006/01/20 09:00
PHST- 2006/01/20 09:00 [pubmed]
PHST- 2006/04/12 09:00 [medline]
PHST- 2006/01/20 09:00 [entrez]
AID - U7415VP21V122821 [pii]
AID - 10.1080/09537100500438156 [doi]
PST - ppublish
SO  - Platelets. 2006 Mar;17(2):105-7. doi: 10.1080/09537100500438156.

PMID- 19910291
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20151119
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 96
IP  - 5
DP  - 2010 Mar
TI  - The antiplatelet effect of aspirin is reduced by proton pump inhibitors in 
      patients with coronary artery disease.
PG  - 368-71
LID - 10.1136/hrt.2009.181107 [doi]
AB  - OBJECTIVE: To evaluate the effect of proton pump inhibitors (PPIs) on the 
      platelet response to aspirin in patients with coronary artery disease (CAD). 
      DESIGN: Case-control study. PATIENTS: 418 stable patients with CAD, 54 of whom 
      were treated with PPIs. All patients were treated with non-enteric coated aspirin 
      75 mg/day and received no other antithrombotic drugs. MAIN OUTCOME MEASURES: 
      Platelet aggregation was measured by Multiplate (Dynabyte, Munich, Germany) whole 
      blood aggregometry induced by arachidonic acid 1.0 mmol/l and expressed as area 
      under the aggregation curve (aggregation units*min). Platelet activation was 
      assessed by soluble serum P-selectin. Compliance was confirmed by serum 
      thromboxane B(2) levels. RESULTS: The distribution of age, sex, body mass index, 
      blood pressure, family history of ischaemic heart disease, smoking, diabetes and 
      the number of previous ischaemic events did not differ between groups. All 
      patients were compliant with aspirin treatment according to serum thromboxane 
      B(2) levels. Platelet aggregation (median 180 (interquartile range 119-312) vs 
      152 (84-226) aggregation units*min, p=0.003) and soluble serum P-selectin levels 
      (88.5 (65.2-105.8) vs 75.4 (60.0-91.5) ng/ml, p=0.005) were significantly higher 
      in patients treated with PPIs. Furthermore, these patients had significantly 
      higher serum thromboxane B(2) levels (geometric mean 1.29 (95% CI 0.96 to 1.72) 
      vs 0.92 (0.84 to 1.01) ng/ml, p=0.01). CONCLUSIONS: Patients with CAD treated 
      with PPIs had a reduced platelet response to aspirin, as shown by increased 
      residual platelet aggregation and platelet activation, compared with patients 
      with CAD not taking PPIs. Concomitant use of aspirin and PPIs might reduce the 
      cardiovascular protection by aspirin.
FAU - Würtz, Morten
AU  - Würtz M
AD  - Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.
FAU - Grove, Erik L
AU  - Grove EL
FAU - Kristensen, Steen D
AU  - Kristensen SD
FAU - Hvas, Anne-Mette
AU  - Hvas AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091111
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Biomarkers)
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Heart. 2010 Oct;96(20):1684; author reply 1684. PMID: 20736199
MH  - Aged
MH  - Aspirin/antagonists & inhibitors/*therapeutic use
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Coronary Artery Disease/*drug therapy
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - P-Selectin/blood
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Proton Pump Inhibitors/pharmacology/*therapeutic use
MH  - *Registries
MH  - Thromboxane B2/blood
EDAT- 2009/11/17 06:00
MHDA- 2010/06/16 06:00
CRDT- 2009/11/14 06:00
PHST- 2009/11/14 06:00 [entrez]
PHST- 2009/11/17 06:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
AID - hrt.2009.181107 [pii]
AID - 10.1136/hrt.2009.181107 [doi]
PST - ppublish
SO  - Heart. 2010 Mar;96(5):368-71. doi: 10.1136/hrt.2009.181107. Epub 2009 Nov 11.

PMID- 7485340
OWN - NLM
STAT- MEDLINE
DCOM- 19951205
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 173
IP  - 4
DP  - 1995 Oct
TI  - The effect of low-dose aspirin on pregnancies complicated by elevated human 
      chorionic gonadotropin levels.
PG  - 1292-6
AB  - OBJECTIVE: Our purpose was to determine whether elevated second-trimester human 
      chorionic gonadotropin levels identify women likely to benefit from low-dose 
      aspirin therapy. STUDY DESIGN: We evaluated second-trimester human chorionic 
      gonadotropin levels obtained from healthy nulliparous women before screening for 
      participation in a double-blind randomized trial of aspirin therapy: 262 women 
      took 60 mg of aspirin daily and 420 did not. RESULTS: Among women who did not 
      take aspirin, those with human chorionic gonadotropin levels > or = 2.0 multiples 
      of the median had a significantly lower mean birth weight (2859 vs 3159 gm, p = 
      0.04) than did those with normal human chorionic gonadotropin levels. All women 
      who took aspirin had a higher mean birth weight than women who did not, but women 
      with human chorionic gonadotropin levels > or = 2.0 multiples of the median had 
      the greatest increase (416.2 gm higher in those with human chorionic gonadotropin 
      levels > or = 2.0 multiples of the median, p = 0.02; 96 gm higher in those with 
      human chorionic gonadotropin levels > or 2.0 multiples of the median, p = 0.04). 
      Regression analysis suggested that the higher birth weight was partly explained 
      by a higher gestational age at delivery and partly by increased weight 
      independent of gestational age. CONCLUSIONS: Aspirin therapy increased birth 
      weight in all women, especially in women with high human chorionic gonadotropin 
      levels, partly by increasing gestational age at delivery. This observation needs 
      to be confirmed by further studies.
FAU - Wenstrom, K D
AU  - Wenstrom KD
AD  - Department of Obstetrics and Gynecology, University of Alabama at Birmingham 
      35233-7333, USA.
FAU - Hauth, J C
AU  - Hauth JC
FAU - Goldenberg, R L
AU  - Goldenberg RL
FAU - DuBard, M B
AU  - DuBard MB
FAU - Lea, C
AU  - Lea C
LA  - eng
GR  - 282-92-0055/PHS HHS/United States
GR  - R01-HD24496-01/HD/NICHD NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Chorionic Gonadotropin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Birth Weight/drug effects
MH  - Chi-Square Distribution
MH  - Chorionic Gonadotropin/*blood
MH  - Double-Blind Method
MH  - Female
MH  - Fetal Growth Retardation/prevention & control
MH  - Gestational Age
MH  - Humans
MH  - Infant, Newborn
MH  - Linear Models
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications/blood/*drug therapy
MH  - Pregnancy Trimester, Second
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - 0002-9378(95)91373-4 [pii]
AID - 10.1016/0002-9378(95)91373-4 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1995 Oct;173(4):1292-6. doi: 10.1016/0002-9378(95)91373-4.

PMID- 23288416
OWN - NLM
STAT- MEDLINE
DCOM- 20130118
LR  - 20211021
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 308
IP  - 23
DP  - 2012 Dec 19
TI  - Long-term use of aspirin and age-related macular degeneration.
PG  - 2469-78
LID - 10.1001/jama.2012.65406 [doi]
AB  - CONTEXT: Aspirin is widely used for relief of pain and for cardioprotective 
      effects. Its use is of concern to ophthalmologists when ocular surgery is being 
      considered and also in the presence of age-related macular degeneration (AMD). 
      OBJECTIVE: To examine the association of regular aspirin use with incidence of 
      AMD. DESIGN, SETTING, AND PARTICIPANTS: The Beaver Dam Eye Study, a longitudinal 
      population-based study of age-related eye diseases conducted in Wisconsin. 
      Examinations were performed every 5 years over a 20-year period (1988-1990 
      through 2008-2010). Study participants (N = 4926) were aged 43 to 86 years at the 
      baseline examination. At subsequent examinations, participants were asked if they 
      had regularly used aspirin at least twice a week for more than 3 months. MAIN 
      OUTCOME MEASURE: Incidence of early AMD, late AMD, and 2 subtypes of late AMD 
      (neovascular AMD and pure geographic atrophy), assessed in retinal photographs 
      according to the Wisconsin Age-Related Maculopathy Grading System. RESULTS: The 
      mean duration of follow-up was 14.8 years. There were 512 incident cases of early 
      AMD (of 6243 person-visits at risk) and 117 incident cases of late AMD (of 8621 
      person-visits at risk) over the course of the study. Regular aspirin use 10 years 
      prior to retinal examination was associated with late AMD (hazard ratio [HR], 
      1.63 [95% CI, 1.01-2.63]; P = .05), with estimated incidence of 1.76% (95% CI, 
      1.17%-2.64%) in regular users and 1.03% (95% CI, 0.70%-1.51%) in nonusers. For 
      subtypes of late AMD, regular aspirin use 10 years prior to retinal examination 
      was significantly associated with neovascular AMD (HR, 2.20 [95% CI, 1.20-4.15]; 
      P = .01) but not pure geographic atrophy (HR, 0.66 [95% CI, 0.25-1.95]; P = .45). 
      Aspirin use 5 years (HR, 0.86 [95% CI, 0.71-1.05]; P = .13) or 10 years (HR, 0.86 
      [95% CI, 0.65-1.13]; P = .28) prior to retinal examination was not associated 
      with incident early AMD. CONCLUSIONS: Among an adult cohort, aspirin use 5 years 
      prior to observed incidence was not associated with incident early or late AMD. 
      However, regular aspirin use 10 years prior was associated with a small but 
      statistically significant increase in the risk of incident late and neovascular 
      AMD.
FAU - Klein, Barbara E K
AU  - Klein BE
AD  - Department of Ophthalmology and Visual Sciences, University of Wisconsin School 
      of Medicine and Public Health, Madison 53726-2336, USA. kleinb@epi.ophth.wisc.edu
FAU - Howard, Kerri P
AU  - Howard KP
FAU - Gangnon, Ronald E
AU  - Gangnon RE
FAU - Dreyer, Jennifer O
AU  - Dreyer JO
FAU - Lee, Kristine E
AU  - Lee KE
FAU - Klein, Ronald
AU  - Klein R
LA  - eng
GR  - U10 EY006594/EY/NEI NIH HHS/United States
GR  - EY06594/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2013 Mar 27;309(12):1226. PMID: 23532230
CIN - JAMA. 2013 Mar 27;309(12):1227. PMID: 23532231
CIN - JAMA. 2013 Mar 27;309(12):1227-8. PMID: 23532232
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cohort Studies
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Macular Degeneration/classification/*epidemiology
MH  - Male
MH  - Middle Aged
MH  - Risk
MH  - Time Factors
MH  - Wisconsin/epidemiology
PMC - PMC3630794
MID - NIHMS438110
COIS- Conflict of Interest Disclosures: All authors have completed and submitted the 
      ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. R. Klein 
      reported serving as a consultant to Pfizer. All other authors reported no 
      potential conflicts of interest.
EDAT- 2013/01/05 06:00
MHDA- 2013/01/19 06:00
CRDT- 2013/01/05 06:00
PHST- 2013/01/05 06:00 [entrez]
PHST- 2013/01/05 06:00 [pubmed]
PHST- 2013/01/19 06:00 [medline]
AID - 1486830 [pii]
AID - 10.1001/jama.2012.65406 [doi]
PST - ppublish
SO  - JAMA. 2012 Dec 19;308(23):2469-78. doi: 10.1001/jama.2012.65406.

PMID- 33037951
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Linking)
VI  - 22
IP  - 12
DP  - 2020 Oct 10
TI  - Management of Patients with Acute Coronary Syndrome and Cancer.
PG  - 159
LID - 10.1007/s11886-020-01409-8 [doi]
AB  - Cancer patients with acute coronary syndrome (ACS) have significantly greater 
      mortality compared with non-cancer patients. This risk is partly directly 
      attributable to the malignancy; however these patients are frequently 
      undertreated with respect to guideline recommended treatments for ACS due to 
      higher bleeding risks from anemia and thrombocytopenia. Due to exclusion from 
      large clinical trials, there is a paucity of data regarding how to best treat 
      these complex and high-risk patients. PURPOSE OF REVIEW: To review the literature 
      and identify risk factors among cancer patients associated with poor outcomes, 
      pathophysiology of chemotherapy and radiation therapy contributing to accelerated 
      coronary artery disease and ACS, and data regarding outcomes with medical therapy 
      and invasive management. RECENT FINDINGS: Despite an elevated bleeding risk, many 
      cancer patients may benefit from ACC/AHA guideline-directed management for ACS 
      including aspirin, P2Y(12) inhibitor, statin, and beta-blocker therapies. Cancer 
      patients with ACS are a uniquely vulnerable population who are often 
      undertreated, and with improved cancer treatments, this population is expected to 
      increase. These patients should be included in future randomized trials to better 
      understand how to balance the complexities of increased bleeding and thrombosis 
      risks during ACS.
FAU - Moran, Tyler B
AU  - Moran TB
AUID- ORCID: 0000-0002-3157-2584
AD  - Section of Cardiology, Department of Internal Medicine, Baylor College of 
      Medicine, 7200 Cambridge St., Houston, TX, 77030, USA. tyler.moran@bcm.edu.
FAU - Plana, Juan Carlos
AU  - Plana JC
AD  - Section of Cardiology, Department of Internal Medicine, Baylor College of 
      Medicine, 7200 Cambridge St., Houston, TX, 77030, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201010
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acute Coronary Syndrome/complications/therapy
MH  - Aspirin/therapeutic use
MH  - *Coronary Artery Disease
MH  - Humans
MH  - *Neoplasms/complications/therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Factors
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Cancer
OT  - Chemotherapy
OT  - Coronary artery disease
EDAT- 2020/10/11 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/10/10 12:04
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/10/10 12:04 [entrez]
PHST- 2020/10/11 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - 10.1007/s11886-020-01409-8 [pii]
AID - 10.1007/s11886-020-01409-8 [doi]
PST - epublish
SO  - Curr Cardiol Rep. 2020 Oct 10;22(12):159. doi: 10.1007/s11886-020-01409-8.

PMID- 3253119
OWN - NLM
STAT- MEDLINE
DCOM- 19890825
LR  - 20191022
IS  - 0950-821X (Print)
IS  - 0950-821X (Linking)
VI  - 2
IP  - 6
DP  - 1988 Dec
TI  - The influence of endothelial seeding and platelet inhibition on the patency of 
      ePTFE grafts used to replace small arteries--an experimental study.
PG  - 365-70
AB  - Previous studies on the influence of endothelial seeding on graft patency have 
      shown that significant improvement has only been achieved with Dacron and an 
      experimental, porous PTFE graft. Methods of assessing patency or showing 
      statistical significance could be questioned in some of these studies. To 
      determine if the combination of endothelial cell seeding and antiplatelet agents 
      would improve patency in small-diameter, commercially available expanded 
      polytetrafluorethylene (ePTFE) grafts, we placed ePTFE grafts into the left 
      carotid position in two groups of mongrel dogs. All grafts were 4 mm internal 
      diameter and 60 mm long, and were interposed in an end-to-end fashion. Both 
      groups received aspirin (80 mg daily) and dipyridamole (25 mg daily) for 14 days, 
      beginning immediately prior to surgery. In Group I (n = 12), the grafts were 
      seeded with enzymatically harvested autogenous endothelium just prior to 
      implantation; in Group II (n = 10) the grafts were not seeded. All grafts were 
      removed at 30 days. Seven of 12 (58%) seeded grafts, but only one control graft 
      (10%) remained patent (P = 0.03). Six of the seven seeded grafts exhibited 
      surface endothelium, but the single patent control graft did not. The inner 
      capsule of the seeded grafts consisted of a monolayer of endothelium and a thin 
      acellular subendothelial matrix with an average thickness of 8 mu. We conclude 
      that a 14-day course of anti-platelet agents combined with endothelial seeding of 
      ePTFE resulted in significantly improved patency compared to controls, with most 
      patent, seeded grafts developing an endothelial lining in 30 days.
FAU - Campbell, J B
AU  - Campbell JB
AD  - Louisiana State University Medical Center, Shreveport.
FAU - Glover, J L
AU  - Glover JL
FAU - Herring, B
AU  - Herring B
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Vasc Surg
JT  - European journal of vascular surgery
JID - 8709440
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteries/surgery
MH  - Aspirin/pharmacology
MH  - *Blood Vessel Prosthesis
MH  - Dogs
MH  - Endothelium, Vascular/*cytology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Polytetrafluoroethylene
MH  - *Prosthesis Design
MH  - Vascular Patency/*drug effects
EDAT- 1988/12/01 00:00
MHDA- 1988/12/01 00:01
CRDT- 1988/12/01 00:00
PHST- 1988/12/01 00:00 [pubmed]
PHST- 1988/12/01 00:01 [medline]
PHST- 1988/12/01 00:00 [entrez]
AID - 10.1016/s0950-821x(88)80013-6 [doi]
PST - ppublish
SO  - Eur J Vasc Surg. 1988 Dec;2(6):365-70. doi: 10.1016/s0950-821x(88)80013-6.

PMID- 23455869
OWN - NLM
STAT- MEDLINE
DCOM- 20140218
LR  - 20130508
IS  - 1742-2051 (Electronic)
IS  - 1742-2051 (Linking)
VI  - 9
IP  - 6
DP  - 2013 Jun
TI  - Prediction of human genes and diseases targeted by xenobiotics using predictive 
      toxicogenomic-derived models (PTDMs).
PG  - 1316-25
LID - 10.1039/c3mb25309k [doi]
AB  - New technologies for systems-level determinants of human exposure to drugs, 
      industrial chemicals, pesticides, and other environmental agents provide an 
      invaluable opportunity to extend the understanding of human health and potential 
      environmental hazards. We report here the development of a new 
      computational-systems toxicology framework, called predictive 
      toxicogenomics-derived models (PTDMs). PTDMs integrate three networks of 
      chemical-gene interactions (CGIs), chemical-disease associations (CDAs) and 
      gene-disease associations (GDAs) to infer chemical hazard profiles, identify 
      exposure data gaps and to incorporate genes and disease networks into chemical 
      safety evaluations. Three comprehensive networks addressing CGI, CDA and GDA 
      extracted from the comparative toxicogenomics database (CTD) were constructed. 
      The areas under the receiver operating characteristics curve ranged from 0.85 to 
      0.97 and were yielded using our methodology using a 10-fold cross validation by a 
      simulation carried out 100 times. As the illustrated examples show, we predicted 
      new potential target genes and diseases for bisphenol A and aspirin. The 
      molecular hypothesis and experimental evidence from published literature for 
      these predictions were provided. The results demonstrated that our method has 
      potential applications for chemical profiling in human health exposure and 
      environmental hazard assessment.
FAU - Cheng, Feixiong
AU  - Cheng F
AD  - Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China 
      University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
FAU - Li, Weihua
AU  - Li W
FAU - Zhou, Yadi
AU  - Zhou Y
FAU - Li, Jie
AU  - Li J
FAU - Shen, Jie
AU  - Shen J
FAU - Lee, Philip W
AU  - Lee PW
FAU - Tang, Yun
AU  - Tang Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130301
PL  - England
TA  - Mol Biosyst
JT  - Molecular bioSystems
JID - 101251620
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Hazardous Substances)
RN  - 0 (Phenols)
RN  - 0 (Xenobiotics)
RN  - MLT3645I99 (bisphenol A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arrhythmias, Cardiac/drug therapy
MH  - Aspirin/adverse effects/metabolism/therapeutic use
MH  - Benzhydryl Compounds/metabolism/toxicity
MH  - Bradycardia/drug therapy
MH  - Computer Simulation
MH  - Databases, Chemical
MH  - Databases, Genetic
MH  - Diabetes Mellitus, Type 2/chemically induced
MH  - Dyslipidemias/chemically induced
MH  - Environmental Exposure
MH  - Genes
MH  - Hallucinations/chemically induced
MH  - Hazardous Substances/toxicity
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Nephritis/chemically induced
MH  - Nervous System Diseases/chemically induced
MH  - Phenols/metabolism/toxicity
MH  - Quantitative Structure-Activity Relationship
MH  - ROC Curve
MH  - *Toxicogenetics
MH  - Tremor/chemically induced
MH  - Xenobiotics/metabolism/*toxicity
EDAT- 2013/03/05 06:00
MHDA- 2014/02/19 06:00
CRDT- 2013/03/05 06:00
PHST- 2013/03/05 06:00 [entrez]
PHST- 2013/03/05 06:00 [pubmed]
PHST- 2014/02/19 06:00 [medline]
AID - 10.1039/c3mb25309k [doi]
PST - ppublish
SO  - Mol Biosyst. 2013 Jun;9(6):1316-25. doi: 10.1039/c3mb25309k. Epub 2013 Mar 1.

PMID- 27920074
OWN - NLM
STAT- MEDLINE
DCOM- 20170503
LR  - 20170503
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 134
IP  - 23
DP  - 2016 Dec 6
TI  - A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?
PG  - 1881-1906
AB  - Aspirin represents the sine qua non for antiplatelet pharmacotherapy in patients 
      with cardiovascular diseases because of its well-established role in secondary 
      prevention and its widespread availability and affordability. Historical studies, 
      conducted in an era that bears little resemblance to contemporary clinical 
      practice, demonstrated large reductions in thrombotic risk when aspirin was 
      compared with placebo, thus forming the evidence base promulgated in practice 
      guidelines and recommendations. P2Y(12) inhibitors have mostly been studied in 
      addition to aspirin; dual-antiplatelet therapy proved superiority compared with 
      aspirin monotherapy for the prevention of ischemic events, despite increased 
      bleeding risks. An alternative approach currently under investigation includes 
      evaluation of single-antiplatelet therapy with P2Y(12) inhibitors alone versus 
      dual-antiplatelet therapy after acute coronary syndromes or coronary stent 
      implantation. As the availability of more effective antiplatelet agents 
      increases, it is time to revisit the existing and long-standing paradigm 
      supporting aspirin use for secondary prevention of atherothrombotic events. 
      Ongoing trials will provide new evidence whether the less-is-more strategy is 
      justified.
CI  - © 2016 American Heart Association, Inc.
FAU - Gargiulo, Giuseppe
AU  - Gargiulo G
AD  - From Department of Cardiology, Bern University Hospital, University of Bern, 
      Switzerland (G.G., S.W., M.V.); Department of Advanced Biomedical Sciences, 
      Federico II University of Naples, Italy (G.G.); Department of Cardiology and 
      Critical Care Medicine, Hartcentrum Hasselt, Belgium (P.V.); Division of 
      Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.); The Zena 
      and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount 
      Sinai, New York, NY (R.M.); and Thoraxcenter, Erasmus Medical Center, Rotterdam, 
      The Netherlands (M.V.).
FAU - Windecker, Stephan
AU  - Windecker S
AD  - From Department of Cardiology, Bern University Hospital, University of Bern, 
      Switzerland (G.G., S.W., M.V.); Department of Advanced Biomedical Sciences, 
      Federico II University of Naples, Italy (G.G.); Department of Cardiology and 
      Critical Care Medicine, Hartcentrum Hasselt, Belgium (P.V.); Division of 
      Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.); The Zena 
      and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount 
      Sinai, New York, NY (R.M.); and Thoraxcenter, Erasmus Medical Center, Rotterdam, 
      The Netherlands (M.V.).
FAU - Vranckx, Pascal
AU  - Vranckx P
AD  - From Department of Cardiology, Bern University Hospital, University of Bern, 
      Switzerland (G.G., S.W., M.V.); Department of Advanced Biomedical Sciences, 
      Federico II University of Naples, Italy (G.G.); Department of Cardiology and 
      Critical Care Medicine, Hartcentrum Hasselt, Belgium (P.V.); Division of 
      Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.); The Zena 
      and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount 
      Sinai, New York, NY (R.M.); and Thoraxcenter, Erasmus Medical Center, Rotterdam, 
      The Netherlands (M.V.).
FAU - Gibson, Charles Michael
AU  - Gibson CM
AD  - From Department of Cardiology, Bern University Hospital, University of Bern, 
      Switzerland (G.G., S.W., M.V.); Department of Advanced Biomedical Sciences, 
      Federico II University of Naples, Italy (G.G.); Department of Cardiology and 
      Critical Care Medicine, Hartcentrum Hasselt, Belgium (P.V.); Division of 
      Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.); The Zena 
      and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount 
      Sinai, New York, NY (R.M.); and Thoraxcenter, Erasmus Medical Center, Rotterdam, 
      The Netherlands (M.V.).
FAU - Mehran, Roxana
AU  - Mehran R
AD  - From Department of Cardiology, Bern University Hospital, University of Bern, 
      Switzerland (G.G., S.W., M.V.); Department of Advanced Biomedical Sciences, 
      Federico II University of Naples, Italy (G.G.); Department of Cardiology and 
      Critical Care Medicine, Hartcentrum Hasselt, Belgium (P.V.); Division of 
      Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.); The Zena 
      and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount 
      Sinai, New York, NY (R.M.); and Thoraxcenter, Erasmus Medical Center, Rotterdam, 
      The Netherlands (M.V.).
FAU - Valgimigli, Marco
AU  - Valgimigli M
AD  - From Department of Cardiology, Bern University Hospital, University of Bern, 
      Switzerland (G.G., S.W., M.V.); Department of Advanced Biomedical Sciences, 
      Federico II University of Naples, Italy (G.G.); Department of Cardiology and 
      Critical Care Medicine, Hartcentrum Hasselt, Belgium (P.V.); Division of 
      Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.); The Zena 
      and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount 
      Sinai, New York, NY (R.M.); and Thoraxcenter, Erasmus Medical Center, Rotterdam, 
      The Netherlands (M.V.). marco.valgimigli@insel.ch.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 2017 May 9;135(19):e1035-e1036. PMID: 28483836
CIN - Circulation. 2017 May 9;135(19):e1037-e1038. PMID: 28483837
MH  - Acute Coronary Syndrome/drug therapy
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
MH  - Secondary Prevention
OTO - NOTNLM
OT  - aspirin
OT  - percutaneous coronary intervention
OT  - platelet aggregation inhibitors
OT  - purinergic P2Y receptor antagonists
OT  - secondary prevention
EDAT- 2016/12/07 06:00
MHDA- 2017/05/04 06:00
CRDT- 2016/12/07 06:00
PHST- 2016/12/07 06:00 [entrez]
PHST- 2016/12/07 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
AID - CIRCULATIONAHA.116.023952 [pii]
AID - 10.1161/CIRCULATIONAHA.116.023952 [doi]
PST - ppublish
SO  - Circulation. 2016 Dec 6;134(23):1881-1906. doi: 
      10.1161/CIRCULATIONAHA.116.023952.

PMID- 24691365
OWN - NLM
STAT- MEDLINE
DCOM- 20141209
LR  - 20181202
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 128
DP  - 2014 Jul 15
TI  - Comparative study of three modified numerical spectrophotometric methods: an 
      application on pharmaceutical ternary mixture of aspirin, atorvastatin and 
      clopedogrel.
PG  - 514-21
LID - S1386-1425(14)00166-8 [pii]
LID - 10.1016/j.saa.2014.02.002 [doi]
AB  - Three novel numerical methods were developed for the spectrophotometric 
      multi-component analysis of capsules and synthetic mixtures of aspirin, 
      atorvastatin and clopedogrel without any chemical separation. The subtraction 
      method is based on the relationship between the difference in absorbance at four 
      wavelengths and corresponding concentration of analyte. In this method, the 
      linear determination ranges were 0.8-40 μg mL(-1) aspirin, 0.8-30 μg mL(-1) 
      atorvastatin and 0.5-30 μg mL(-1) clopedogrel. In the quotient method, 0.8-40 μg 
      mL(-1) aspirin, 0.8-30 μg mL(-1) atorvastatin and 1.0-30 μg mL(-1) clopedogrel 
      were determine from spectral data at the wavelength pairs that show the same 
      ratio of absorbance for other two species. Standard addition method was used for 
      resolving ternary mixture of 1.0-40 μg mL(-1) aspirin, 0.8-30 μg mL(-1) 
      atorvastatin and 2.0-30 μg mL(-1) clopedogrel. The proposed methods were 
      validated. The reproducibility and repeatability were found satisfactory which 
      evidence was by low values of relative standard deviation (<2%). Recovery was 
      found to be in the range (99.6-100.8%). By adopting these methods, the time taken 
      for analysis was reduced as these methods involve very limited steps. The 
      developed methods were applied for simultaneous analysis of aspirin, atorvastatin 
      and clopedogrel in capsule dosage forms and results were in good concordance with 
      alternative liquid chromatography.
CI  - Copyright © 2014 Elsevier B.V. All rights reserved.
FAU - Issa, Mahmoud Mohamed
AU  - Issa MM
AD  - Pharmaceutical Analytical Chemistry, Department of Chemistry, Alaqsa University, 
      P.O. Box 4051, Gaza, Palestine.
FAU - Nejem, R'afat Mahmoud
AU  - Nejem RM
AD  - Analytical Chemistry, Department of Chemistry, Alaqsa University, P.O. Box 4051, 
      Gaza, Palestine. Electronic address: rafat_nejem@yahoo.com.
FAU - Shanab, Alaa Abu
AU  - Shanab AA
AD  - Inorganic Analytical Chemistry, Department of Chemistry, Alaqsa University, P.O. 
      Box 4051, Gaza, Palestine.
FAU - Hegazy, Nahed Diab
AU  - Hegazy ND
AD  - R and D Department, Middle East Pharmaceuticals and Cosmetics Laboratories, Gaza, 
      Palestine.
FAU - Stefan-van Staden, Raluca-Ioana
AU  - Stefan-van Staden RI
AD  - National Institute of Research for Electrochemistry and Condensed Matter, 
      Bucharest, Romania. Electronic address: iustinavanstaden@yahoo.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20140221
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 0 (Heptanoic Acids)
RN  - 0 (Pyrroles)
RN  - A0JWA85V8F (Atorvastatin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Atorvastatin
MH  - Clopidogrel
MH  - Heptanoic Acids/*analysis
MH  - Pyrroles/*analysis
MH  - Spectrophotometry/methods
MH  - Ticlopidine/*analogs & derivatives/analysis
OTO - NOTNLM
OT  - Aspirin
OT  - Atorvastatin
OT  - Clopidgrel
OT  - Quotient
OT  - Standard addition
OT  - Subtraction
EDAT- 2014/04/03 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/04/03 06:00
PHST- 2013/11/24 00:00 [received]
PHST- 2014/01/30 00:00 [revised]
PHST- 2014/02/02 00:00 [accepted]
PHST- 2014/04/03 06:00 [entrez]
PHST- 2014/04/03 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - S1386-1425(14)00166-8 [pii]
AID - 10.1016/j.saa.2014.02.002 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2014 Jul 15;128:514-21. doi: 
      10.1016/j.saa.2014.02.002. Epub 2014 Feb 21.

PMID- 18473234
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20190923
IS  - 1520-5762 (Electronic)
IS  - 0363-9045 (Linking)
VI  - 34
IP  - 5
DP  - 2008 May
TI  - Swelling and aspirin release study: cross-linked pH-sensitive vinyl 
      acetate-co-acrylic acid (VAC-co-AA) hydrogels.
PG  - 512-21
LID - 10.1080/03639040701744079 [doi]
AB  - The objective of this work was to develop new pH-sensitive hydrogels to deliver 
      gastric mucosal irritating drugs to the lower part of the gastrointestinal tract. 
      For this purpose, cross-linked vinyl acetate-co-acrylic acid (VAC-co-AA) 
      hydrogels were synthesized by using N, N, methylene bisacrylamide (MBAAm) as a 
      cross-linking agent. Different ratios of 90:10, 70:30, 50:50, 30:70, and 10:90 of 
      VAC-co-AA were synthesized. All of the compositions were cross-linked using 0.15, 
      0.30, 0.45, and 0.60 mol percent MBAAm. Swelling and aspirin release were studied 
      for 8 hour period. The drug release data were fitted into various kinetic models 
      like the zero-order, first-order, Higuchi, and Peppas. Hydrogels were 
      characterized by Fourier transform infrared spectroscopy and scanning electron 
      microscopy. In addition to the above, these hydrogels were loaded with 2%, 8% and 
      14% w/v aspirin solutions, keeping the monomeric composition and degree of 
      cross-linking constant. In conclusion, it can be said that aspirin can be 
      successfully incorporated into cross-linked VAC/AA hydrogels and its swelling and 
      drug release can be modulated by changing the mole fraction of the acid component 
      in the gels.
FAU - Ranjha, Nazar Mohammad
AU  - Ranjha NM
AD  - Department of Pharmacy, Faculty of Pharmacy, Bahauddin Zakariya University, 
      Multan, Pakistan. nazar_ranjha@hotmail.com
FAU - Mudassir, Jahanzeb
AU  - Mudassir J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - 0 (Acrylates)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Carriers)
RN  - 0 (Hydrogels)
RN  - 0 (Polymers)
RN  - 0 (Vinyl Compounds)
RN  - J94PBK7X8S (acrylic acid)
RN  - L9MK238N77 (vinyl acetate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acrylates/*chemistry
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Cross-Linking Reagents
MH  - Crystallization
MH  - Delayed-Action Preparations
MH  - Drug Carriers
MH  - Hydrogels
MH  - Hydrogen-Ion Concentration
MH  - Microscopy, Electron, Scanning
MH  - Polymers
MH  - Solubility
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Vinyl Compounds/*chemistry
EDAT- 2008/05/14 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/05/14 09:00
PHST- 2008/05/14 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/05/14 09:00 [entrez]
AID - 793099249 [pii]
AID - 10.1080/03639040701744079 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 2008 May;34(5):512-21. doi: 10.1080/03639040701744079.

PMID- 3287910
OWN - NLM
STAT- MEDLINE
DCOM- 19880627
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 84
IP  - 5A
DP  - 1988 May 20
TI  - Analgesic efficacy of piroxicam in postoperative dental pain.
PG  - 35-41
AB  - The severity of postoperative dental pain can be variable depending on the type 
      of procedure. Both centrally acting and peripherally acting analgesics, such as 
      nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, and acetaminophen are 
      used. NSAIDs are generally better suited to ambulatory outpatients. The most 
      commonly used postoperative dental pain model includes patients who have 
      undergone surgical removal of impacted third molar teeth. The analgesic efficacy 
      of piroxicam in this pain model was studied both in the United States and in 
      foreign centers. The foreign studies suggest that piroxicam at 20-mg doses 
      produces analgesia in patients with postoperative dental pain. Seven single-dose, 
      randomized, double-blind trials of 798 patients in the United States more clearly 
      evaluated the efficacy of piroxicam. These studies used various doses of 
      piroxicam (5, 10, 20, and 40 mg), aspirin 648 mg, and placebo. Safety results 
      showed that a wide range of piroxicam doses were safe when administered in single 
      doses. Although neither piroxicam 5 mg nor 10 mg produced clinically significant 
      analgesia, 20-mg and 40-mg doses were significantly superior to placebo and both 
      were comparable with aspirin 648 mg over the initial six hours. Piroxicam 20 mg 
      and 40 mg, however, produced significantly longer durations of analgesia than 
      aspirin 648 mg, and it appears that the analgesic effect of piroxicam may extend 
      for up to 24 hours in a substantial proportion of patients.
FAU - Desjardins, P J
AU  - Desjardins PJ
AD  - Department of Biodental Sciences, University of Medicine and Dentistry of New 
      Jersey-New Jersey Dental School, Newark 07103-2425.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Analgesics)
RN  - 13T4O6VMAM (Piroxicam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Pain Measurement
MH  - Pain, Postoperative/*drug therapy
MH  - Piroxicam/*therapeutic use
MH  - *Surgery, Oral
MH  - Time Factors
MH  - Tooth Extraction
EDAT- 1988/05/20 00:00
MHDA- 1988/05/20 00:01
CRDT- 1988/05/20 00:00
PHST- 1988/05/20 00:00 [pubmed]
PHST- 1988/05/20 00:01 [medline]
PHST- 1988/05/20 00:00 [entrez]
AID - 0002-9343(88)90475-5 [pii]
AID - 10.1016/0002-9343(88)90475-5 [doi]
PST - ppublish
SO  - Am J Med. 1988 May 20;84(5A):35-41. doi: 10.1016/0002-9343(88)90475-5.

PMID- 3881108
OWN - NLM
STAT- MEDLINE
DCOM- 19850318
LR  - 20220330
IS  - 0007-0769 (Print)
IS  - 0007-0769 (Linking)
VI  - 53
IP  - 2
DP  - 1985 Feb
TI  - Randomised placebo controlled trial of aspirin and dipyridamole in the prevention 
      of coronary vein graft occlusion.
PG  - 201-7
AB  - Treatment with the combination of aspirin and dipyridamole is believed to reduce 
      the incidence of coronary vein graft occlusion. A double blind randomised 
      controlled trial was carried out in which aspirin 990 mg and dipyridamole 225 mg 
      daily or placebo were added to the routine postoperative management (warfarin for 
      three months) of 320 patients undergoing coronary bypass grafting. The trial 
      treatment was given for 12 months, after which the results were assessed by 
      coronary and graft angiography. The two randomised groups, each of 160 patients, 
      were comparable in age, sex, symptomatic state, angiographic findings, and 
      operative procedure. Repeat coronary arteriography was carried out on 266 
      patients, 133 in each group. All grafts and distal anastomoses were patent in 68% 
      (91/133) of the placebo patients and in 75% (100/133) of those receiving active 
      treatment. Overall graft patency was 87% (306/352) and 89% (342/385) 
      respectively. Retrospective subgroup analysis showed patency rates of 72% (26/36) 
      and 78% (39/50) of grafts to vessels requiring preliminary endarterectomy, and 
      80% (36/45) and 91% (40/44) of distal anastomoses to vessels measured at 
      operation to have a diameter of less than or equal to 1 mm. None of these 
      differences was significant at the 5% level. Thus in this group of patients with 
      high graft patency rates, treatment with aspirin and dipyridamole conferred no 
      appreciable advantage.
FAU - Brooks, N
AU  - Brooks N
FAU - Wright, J
AU  - Wright J
FAU - Sturridge, M
AU  - Sturridge M
FAU - Pepper, J
AU  - Pepper J
FAU - Magee, P
AU  - Magee P
FAU - Walesby, R
AU  - Walesby R
FAU - Layton, C
AU  - Layton C
FAU - Honey, M
AU  - Honey M
FAU - Balcon, R
AU  - Balcon R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br Heart J
JT  - British heart journal
JID - 0370634
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
PMC - PMC481740
EDAT- 1985/02/01 00:00
MHDA- 1985/02/01 00:01
CRDT- 1985/02/01 00:00
PHST- 1985/02/01 00:00 [pubmed]
PHST- 1985/02/01 00:01 [medline]
PHST- 1985/02/01 00:00 [entrez]
AID - 10.1136/hrt.53.2.201 [doi]
PST - ppublish
SO  - Br Heart J. 1985 Feb;53(2):201-7. doi: 10.1136/hrt.53.2.201.

PMID- 612125
OWN - NLM
STAT- MEDLINE
DCOM- 19780612
LR  - 20141120
IS  - 0323-9950 (Print)
IS  - 0323-9950 (Linking)
VI  - 3
IP  - 3
DP  - 1977
TI  - Influence of indomethacin and aspirin on the contractile effects of prostaglandin 
      F2alpha (PGF2alpha) at different Ca++ concentrations (experiments on guinea-pig 
      ileum).
PG  - 18-23
AB  - The direct effect of the prostaglandine synthetase inhibitors indomethacin and 
      aspirin on the contractile effects of PGF2alpha at different Ca++ concentrations 
      (1.5, 2.5 and 3.5 mM) in the Krebs solution was studied on isolated segments of 
      guinea-pig ileum. It is established that after contact with indomethacin (3 X 
      10(-5) M) for 1-5 min the contractile effect of PGF2alpha (1 X 10(-7) M) 
      decreases by 20-60%. Higher Ca++ content in the Krebs solution weakens the direct 
      inhibitory effect of indomethacin. Unlike indomethacin, aspirin has no 
      significant direct effect on prostaglandine contractions. Increase of Ca++ in the 
      Krebs solution by 1 mM in itself does not change significantly the effect of 
      PGF2alpha. Having in mind analogous results obtained in previous experiments with 
      PGE1, it is concluded that indomethacin but not aspirin exercises a direct 
      antagonistic action to the contractile effects of PGF2alpha and PGE1 on the 
      guinea-pig ileum. The degree of this antagonistic action is in a definite 
      dependence on the concentration of extracellular Ca++. Discussing the possible 
      mechanisms of direct inhibitory action of indomethacin on the PGE1 and PGF2alpha 
      effects on guinea-pig ileum, assumptions are made concerning the effect of 
      indomethacin on the utilization of external Ca++ and the noncompetitive 
      antagonistic action of indomethacin as a result of the interaction with 
      allosteric (allotopic) sites of the prostaglandine receptor system.
FAU - Petkov, V
AU  - Petkov V
FAU - Radomirov, R
AU  - Radomirov R
LA  - eng
PT  - Journal Article
PL  - Bulgaria
TA  - Acta Physiol Pharmacol Bulg
JT  - Acta physiologica et pharmacologica Bulgarica
JID - 7512568
RN  - 0 (Cations, Divalent)
RN  - 0 (Prostaglandins F)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Calcium/*pharmacology
MH  - Cations, Divalent
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Guinea Pigs
MH  - Ileum
MH  - In Vitro Techniques
MH  - Indomethacin/*pharmacology
MH  - Muscle Contraction/*drug effects
MH  - Muscle, Smooth/drug effects
MH  - Prostaglandins F/*pharmacology
MH  - Time Factors
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Physiol Pharmacol Bulg. 1977;3(3):18-23.

PMID- 1199905
OWN - NLM
STAT- MEDLINE
DCOM- 19760209
LR  - 20131121
IS  - 0002-838X (Print)
IS  - 0002-838X (Linking)
VI  - 12
IP  - 5
DP  - 1975 Nov
TI  - Intolerance to aspirin.
PG  - 119-22
AB  - The aspirin intolerance syndrome is characterized by rhinitis and/or sinusitis, 
      nasal polyposis and asthma, with or without a history of adverse reactions, 
      following aspirin ingestion. The frequency of this syndrome in a total population 
      of patients with asthma and/or rhinitis has recently been estimated to be 2.4 
      percent. Aspirin-intolerant individuals can tolerate sodium salicylate and 
      acetaminophen but indomethacin, morphine, codeine and certain pharmaceutical dyes 
      may cause adverse reactions. The mechanism of aspirin intolerance is as yet 
      unclear but does not appear to be on an immunologic basis. Treatment includes 
      strict avoidance of aspirin and symptomatic therapy of rhinitis and asthma.
FAU - Casterline, C L
AU  - Casterline CL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Fam Physician
JT  - American family physician
JID - 1272646
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced
MH  - Drug Hypersensitivity/etiology
MH  - Humans
MH  - Nasal Polyps/*chemically induced
MH  - Rhinitis/*chemically induced
EDAT- 1975/11/01 00:00
MHDA- 1975/11/01 00:01
CRDT- 1975/11/01 00:00
PHST- 1975/11/01 00:00 [pubmed]
PHST- 1975/11/01 00:01 [medline]
PHST- 1975/11/01 00:00 [entrez]
PST - ppublish
SO  - Am Fam Physician. 1975 Nov;12(5):119-22.

PMID- 25212871
OWN - NLM
STAT- MEDLINE
DCOM- 20160506
LR  - 20220318
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 22
IP  - 1
DP  - 2015 Jan
TI  - Clopidogrel plus aspirin versus aspirin alone for preventing early neurological 
      deterioration in patients with acute ischemic stroke.
PG  - 83-6
LID - S0967-5868(14)00482-2 [pii]
LID - 10.1016/j.jocn.2014.05.038 [doi]
AB  - Recent studies have suggested that combination antiplatelet therapy may be 
      superior to monotherapy in the treatment of acute stroke. However, additional 
      prospective studies are needed to confirm this finding. The present trial 
      compared the efficacy and safety of clopidogrel plus aspirin versus aspirin alone 
      in the treatment of non-cardioembolic ischemic stroke within 72 hours of onset. 
      Six hundred and ninety patients aged ⩾ 40 years with minor stroke or transient 
      ischemic attack (TIA) were identified for enrollment. Experienced physicians 
      determined baseline National Institutes of Health Stroke Scale scores at the time 
      of admission. All patients were randomly allocated (1:1) to receive aspirin alone 
      (300 mg/day) or clopidogrel (300 mg for the first day, 75 mg/day thereafter) plus 
      aspirin (100mg/day). The main endpoints were neurological deterioration, 
      recurrent stroke, and development of stroke in patients with TIA within 14 days 
      of admission. After 43 patients were excluded, 321 patients in the dual therapy 
      group and 326 patients in the monotherapy group completed the treatment. Baseline 
      characteristics were similar between groups. During the 2 week period, stroke 
      deterioration occurred in nine patients in the dual therapy group and 19 patients 
      in the monotherapy group. Stroke occurred after TIA in one patient in the dual 
      therapy group and three patients in the monotherapy group. Similar numbers of 
      adverse events occurred in both groups. This study showed that early dual 
      antiplatelet treatment reduced early neurological deterioration in patients with 
      acute ischemic stroke, compared with antiplatelet monotherapy. These results 
      imply that dual antiplatelet therapy is superior to monotherapy in the early 
      treatment of acute ischemic stroke.
CI  - Copyright © 2014 Elsevier Ltd. All rights reserved.
FAU - He, Fan
AU  - He F
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, 83 Wen 
      Hua Road, Shen He District, Shen Yang 110840, PR China.
FAU - Xia, Cheng
AU  - Xia C
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, 83 Wen 
      Hua Road, Shen He District, Shen Yang 110840, PR China.
FAU - Zhang, Jing-Hua
AU  - Zhang JH
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, 83 Wen 
      Hua Road, Shen He District, Shen Yang 110840, PR China.
FAU - Li, Xiao-Qiu
AU  - Li XQ
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, 83 Wen 
      Hua Road, Shen He District, Shen Yang 110840, PR China.
FAU - Zhou, Zhong-He
AU  - Zhou ZH
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, 83 Wen 
      Hua Road, Shen He District, Shen Yang 110840, PR China.
FAU - Li, Feng-Peng
AU  - Li FP
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, 83 Wen 
      Hua Road, Shen He District, Shen Yang 110840, PR China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, 83 Wen 
      Hua Road, Shen He District, Shen Yang 110840, PR China.
FAU - Lv, Yan
AU  - Lv Y
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, 83 Wen 
      Hua Road, Shen He District, Shen Yang 110840, PR China.
FAU - Chen, Hui-Sheng
AU  - Chen HS
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, 83 Wen 
      Hua Road, Shen He District, Shen Yang 110840, PR China. Electronic address: 
      chszh@aliyun.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140910
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Prospective Studies
MH  - Stroke/*drug therapy
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Treatment Outcome
MH  - United States
OTO - NOTNLM
OT  - Acute ischemic stroke
OT  - Antiplatelet
OT  - Deterioration of stroke
EDAT- 2014/09/13 06:00
MHDA- 2016/05/07 06:00
CRDT- 2014/09/13 06:00
PHST- 2013/07/04 00:00 [received]
PHST- 2014/05/19 00:00 [revised]
PHST- 2014/05/25 00:00 [accepted]
PHST- 2014/09/13 06:00 [entrez]
PHST- 2014/09/13 06:00 [pubmed]
PHST- 2016/05/07 06:00 [medline]
AID - S0967-5868(14)00482-2 [pii]
AID - 10.1016/j.jocn.2014.05.038 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2015 Jan;22(1):83-6. doi: 10.1016/j.jocn.2014.05.038. Epub 2014 
      Sep 10.

PMID- 8759084
OWN - NLM
STAT- MEDLINE
DCOM- 19961211
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 94
IP  - 3
DP  - 1996 Aug 1
TI  - Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet 
      activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin 
      and aspirin.
PG  - 425-31
AB  - BACKGROUND: Previous studies have demonstrated increased markers of 
      thrombogenesis in patients with atrial fibrillation (AF), suggesting the presence 
      of a hypercoagulable or prothrombotic state. The objective of this study was to 
      determine the effects of introducing ultra-low-dose warfarin (1 mg), conventional 
      warfarin, and aspirin. (300 mg) therapy on thrombogenesis and platelet activation 
      in AF. METHODS AND RESULTS: We measured sequential changes in plasma fibrin 
      D-dimer (an index of thrombogenesis) and beta-thromboglobulin (beta-TG, a measure 
      of platelet activation) in 51 patients with chronic AF before and at 2 and 6 
      weeks after randomization to either 1 mg warfarin or 300 mg aspirin (phase 1). 
      Then all patients were started on conventional warfarin therapy (phase 2) with 
      samples taken 2 and 6 weeks later. Pretreatment results were compared with those 
      from 26 healthy control subjects in sinus rhythm. Baseline (pretreatment) beta-TG 
      and D-dimer levels in patients with AF were elevated compared with those of 
      control subjects (P < .001). In phase 1, there were no significant changes in 
      median levels of fibrin D-dimer or beta-TG, despite warfarin 1 mg or aspirin 300 
      mg. With standard warfarin therapy (phase 2), there was a reduction in median 
      beta-TG at 6 weeks (P = .025) and a sequential reduction in median D-dimer levels 
      at 2 (P = .001) and 6 (P < .001) weeks compared with baseline levels. 
      CONCLUSIONS: Patients with AF have increased intravascular thrombogenesis and 
      platelet activation compared with patients in sinus rhythm. Introduction of 
      ultra-low-dose warfarin (1 mg) or aspirin 300 mg does not significantly alter 
      these markers, although conventional warfarin therapy reduces beta-TG and fibrin 
      D-dimer levels. This is consistent with the beneficial effect of full-dose 
      warfarin in preventing stroke and thromboembolism in AF and suggests that 
      ultra-low-dose warfarin and aspirin may not exert similar beneficial effects.
FAU - Lip, G Y
AU  - Lip GY
AD  - Department of Medicine, City Hospital, Birmingham, England, UK.
FAU - Lip, P L
AU  - Lip PL
FAU - Zarifis, J
AU  - Zarifis J
FAU - Watson, R D
AU  - Watson RD
FAU - Bareford, D
AU  - Bareford D
FAU - Lowe, G D
AU  - Lowe GD
FAU - Beevers, D G
AU  - Beevers DG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (beta-Thromboglobulin)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 1997 Aug 5;96(3):1053-4; author reply 1055-6. PMID: 9264527
CIN - Circulation. 1997 Aug 5;96(3):1054-6. PMID: 9264528
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Atrial Fibrillation/*complications/*physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/*metabolism
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Prospective Studies
MH  - Thrombosis/*etiology
MH  - Warfarin/*administration & dosage/therapeutic use
MH  - beta-Thromboglobulin/*metabolism
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - 10.1161/01.cir.94.3.425 [doi]
PST - ppublish
SO  - Circulation. 1996 Aug 1;94(3):425-31. doi: 10.1161/01.cir.94.3.425.

PMID- 33743316
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20221207
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 95
DP  - 2021 Jun
TI  - Aspirin alleviates skin inflammation and angiogenesis in rosacea.
PG  - 107558
LID - S1567-5769(21)00194-6 [pii]
LID - 10.1016/j.intimp.2021.107558 [doi]
AB  - Rosacea is a chronic, relapsing inflammatory skin disease featured by abnormal 
      activation of immune responses, vascular dysfunction and prominent permeability 
      barrier alterations. Aspirin, as the first nonsteroidal anti-inflammatory drug 
      (NSAID), is widely used for various inflammatory conditions due to its 
      anti-inflammatory and anti-angiogenic properties. However, its effects on rosacea 
      are unclear. In this study, we demonstrated that aspirin dramatically improved 
      pathological phenotypes in LL37-induced rosacea-like mice. The RNA-sequencing 
      analysis revealed that aspirin alleviated rosacea-like skin dermatitis mainly via 
      modulating immune responses. Mechanically, we showed that aspirin decreased the 
      production of chemokines and cytokines associated with rosacea, and suppressed 
      the Th1- and Th17-polarized immune responses in LL37-induced rosacea-like mice. 
      Besides, aspirin administration decreased the microvessels density and the VEGF 
      expression in rosacea-like skin. We further demonstrated that aspirin inhibited 
      the activation of NF-κB signaling and the release of its downstream 
      pro-inflammatory cytokines. Collectively we showed that aspirin exerts a curative 
      effect on rosacea by attenuating skin inflammation and angiogenesis, suggesting a 
      promising therapeutic candidate for the treatment of rosacea.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Deng, Zhili
AU  - Deng Z
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central 
      South University, Changsha, China; National Clinical Research Center for 
      Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 
      China; Key Laboratory of Molecular Radiation Oncology Hunan Province, Changsha, 
      Hunan, China; Key Laboratory of Organ Injury, Aging and Regenerative Medicine of 
      Hunan Province, Central South University, Changsha, Hunan, China.
FAU - Xu, San
AU  - Xu S
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central 
      South University, Changsha, China; National Clinical Research Center for 
      Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 
      China; Key Laboratory of Molecular Radiation Oncology Hunan Province, Changsha, 
      Hunan, China; Key Laboratory of Organ Injury, Aging and Regenerative Medicine of 
      Hunan Province, Central South University, Changsha, Hunan, China.
FAU - Peng, Qinqin
AU  - Peng Q
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya 
      Hospital, Central South University, Changsha, Hunan, China.
FAU - Sha, Ke
AU  - Sha K
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya 
      Hospital, Central South University, Changsha, Hunan, China.
FAU - Xiao, Wenqin
AU  - Xiao W
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya 
      Hospital, Central South University, Changsha, Hunan, China.
FAU - Liu, Tangxiele
AU  - Liu T
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya 
      Hospital, Central South University, Changsha, Hunan, China.
FAU - Zhang, Yiya
AU  - Zhang Y
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central 
      South University, Changsha, China; Key Laboratory of Molecular Radiation Oncology 
      Hunan Province, Changsha, Hunan, China.
FAU - Wang, Ben
AU  - Wang B
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central 
      South University, Changsha, China; Key Laboratory of Molecular Radiation Oncology 
      Hunan Province, Changsha, Hunan, China.
FAU - Xie, Hongfu
AU  - Xie H
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central 
      South University, Changsha, China; National Clinical Research Center for 
      Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 
      China; Key Laboratory of Molecular Radiation Oncology Hunan Province, Changsha, 
      Hunan, China.
FAU - Chen, Mengting
AU  - Chen M
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central 
      South University, Changsha, China; National Clinical Research Center for 
      Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 
      China; Key Laboratory of Molecular Radiation Oncology Hunan Province, Changsha, 
      Hunan, China; Key Laboratory of Organ Injury, Aging and Regenerative Medicine of 
      Hunan Province, Central South University, Changsha, Hunan, China. Electronic 
      address: cmt0702@csu.edu.cn.
FAU - Li, Ji
AU  - Li J
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central 
      South University, Changsha, China; National Clinical Research Center for 
      Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 
      China; Key Laboratory of Molecular Radiation Oncology Hunan Province, Changsha, 
      Hunan, China; Key Laboratory of Organ Injury, Aging and Regenerative Medicine of 
      Hunan Province, Central South University, Changsha, Hunan, China; Department of 
      Dermatology, The Second Affiliated Hospital of Xinjiang Medical University, 
      Urumqi, China. Electronic address: liji_xy@csu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20210317
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antimicrobial Cationic Peptides)
RN  - 0 (NF-kappa B)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Cathelicidins)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Antimicrobial Cationic Peptides
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Dermatitis/*drug therapy/immunology/pathology
MH  - Female
MH  - Keratinocytes/drug effects/immunology
MH  - Mice, Inbred BALB C
MH  - NF-kappa B/immunology
MH  - Neovascularization, Pathologic/*drug therapy/immunology/pathology
MH  - Rosacea/chemically induced/*drug therapy/immunology/pathology
MH  - Skin/drug effects/pathology
MH  - Cathelicidins
OTO - NOTNLM
OT  - Angiogenesis
OT  - Aspirin
OT  - Inflammation
OT  - LL37
OT  - NF-κB
OT  - Rosacea
EDAT- 2021/03/21 06:00
MHDA- 2021/06/05 06:00
CRDT- 2021/03/20 20:09
PHST- 2020/12/13 00:00 [received]
PHST- 2021/02/18 00:00 [revised]
PHST- 2021/03/01 00:00 [accepted]
PHST- 2021/03/21 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
PHST- 2021/03/20 20:09 [entrez]
AID - S1567-5769(21)00194-6 [pii]
AID - 10.1016/j.intimp.2021.107558 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2021 Jun;95:107558. doi: 10.1016/j.intimp.2021.107558. Epub 
      2021 Mar 17.

PMID- 30204698
OWN - NLM
STAT- MEDLINE
DCOM- 20190920
LR  - 20200309
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 132
IP  - 4
DP  - 2018 Oct
TI  - Maternal Outcomes Associated With Lower Range Stage 1 Hypertension.
PG  - 843-849
LID - 10.1097/AOG.0000000000002870 [doi]
AB  - OBJECTIVE: To evaluate maternal and neonatal outcomes in healthy, nulliparous 
      women classified with stage 1 hypertension under the revised American College of 
      Cardiology and American Heart Association Guidelines and to evaluate the effects 
      of low-dose aspirin on maternal and neonatal outcomes in this population. 
      METHODS: We conducted a secondary analysis of data from a multicenter randomized, 
      double-blind, placebo-controlled trial of low-dose aspirin for prevention of 
      preeclampsia in nulliparous, low-risk women recruited between 13 and 25 weeks of 
      gestation. Of the 3,134 nulliparous women enrolled in the original study, 2,947 
      women with singleton pregnancies and without missing data were included in this 
      analysis. Blood pressure was measured at enrollment between 13 and 25 weeks of 
      gestation and outcomes were adjudicated from the medical record. RESULTS: One 
      hundred sixty-four participants were identified with lower range stage 1 
      hypertension (5.6%), systolic blood pressure 130-135 mm Hg, diastolic blood 
      pressure 80-85 mm Hg, or both by the new American College of Cardiology-American 
      Heart Association guidelines. Within the placebo group (n=1,482), women with 
      stage 1 hypertension had a significantly increased incidence of preeclampsia 
      compared with normotensive women, 15.3% (15/98) vs 5.4% (75/1,384) (relative risk 
      2.66, 95% CI 1.56-4.54, P<.001). Moreover, women with stage 1 hypertension had an 
      increased incidence of gestational diabetes mellitus (6.1% vs 2.5%, P=.03) and 
      more indicated preterm deliveries (4.2% vs 1.1%, P=.01). Comparing women with 
      stage 1 hypertension and normotensive women receiving low-dose aspirin during 
      pregnancy (n=1,465), no differences in rates of preeclampsia (7.6% vs 4.4%, 
      respectively, P=.2), gestational diabetes mellitus, or indicated preterm 
      deliveries were observed. Rates of placenta abruption, small for gestational age, 
      and spontaneous preterm birth did not differ significantly between groups. 
      CONCLUSION: Application of the new American College of Cardiology-American Heart 
      Association guidelines in a pregnant population identifies a cohort of women who 
      are at increased risk for preeclampsia, gestational diabetes mellitus, and 
      preterm birth.
FAU - Sutton, Elizabeth F
AU  - Sutton EF
AD  - Magee-Womens Research Institute, and the Department of Obstetrics, Gynecology and 
      Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania.
FAU - Hauspurg, Alisse
AU  - Hauspurg A
FAU - Caritis, Steve N
AU  - Caritis SN
FAU - Powers, Robert W
AU  - Powers RW
FAU - Catov, Janet M
AU  - Catov JM
LA  - eng
GR  - R01 HL103825/HL/NHLBI NIH HHS/United States
GR  - U01 HD019897/HD/NICHD NIH HHS/United States
GR  - U10 HD021410/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Obstet Gynecol. 2019 Jan;133(1):190. PMID: 30575662
CIN - Obstet Gynecol. 2019 Jan;133(1):190-191. PMID: 30575663
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Infant, Newborn
MH  - Pregnancy
MH  - Pregnancy Complications/*etiology/prevention & control
MH  - Prehypertension/*complications
MH  - Young Adult
PMC - PMC6331002
MID - NIHMS997169
COIS- Financial Disclosure The authors did not report any potential conflicts of 
      interest.
EDAT- 2018/09/12 06:00
MHDA- 2019/09/21 06:00
CRDT- 2018/09/12 06:00
PHST- 2018/09/12 06:00 [pubmed]
PHST- 2019/09/21 06:00 [medline]
PHST- 2018/09/12 06:00 [entrez]
AID - 10.1097/AOG.0000000000002870 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2018 Oct;132(4):843-849. doi: 10.1097/AOG.0000000000002870.

PMID- 29668690
OWN - NLM
STAT- MEDLINE
DCOM- 20180716
LR  - 20220204
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 4
DP  - 2018
TI  - Aspirin use and long-term rates of sepsis: A population-based cohort study.
PG  - e0194829
LID - 10.1371/journal.pone.0194829 [doi]
LID - e0194829
AB  - OBJECTIVE: Sepsis is the syndrome of life-threatening organ dysfunction resulting 
      from dysregulated host response to infection. Aspirin, an anti-inflammatory 
      agent, may play a role in attenuating the inflammatory response during infection. 
      We evaluated the association between aspirin use and long-term rates of sepsis as 
      well as sepsis outcomes. METHODS: We analyzed data from 30,239 adults ≥45 years 
      old in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) 
      cohort. The primary exposure was aspirin use, identified via patient interview. 
      The primary outcome was sepsis hospitalization, defined as admission for 
      infection with two or more systemic inflammatory response syndrome criteria. We 
      fit Cox proportional hazards models assessing the association between aspirin use 
      and rates of sepsis, adjusted for participant demographics, health behaviors, 
      chronic medical conditions, medication adherence, and biomarkers. We used a 
      propensity-matched analysis and a series of sensitivity analyses to assess the 
      robustness of our results. We also examined risk of organ dysfunction and 
      hospital mortality during hospitalization for sepsis. RESULTS: Among 29,690 
      REGARDS participants with follow-up data available, 43% reported aspirin use (n = 
      12,869). Aspirin users had higher sepsis rates (hazard ratio 1.35; 95% CI: 
      1.22-1.49) but this association was attenuated following adjustment for potential 
      confounders (adjusted HR 0.99; 95% CI: 0.88-1.12). We obtained similar results in 
      propensity-matched and sensitivity analyses. Among sepsis hospitalizations, 
      aspirin use was not associated with organ dysfunction or hospital death. 
      CONCLUSIONS: In the REGARDS cohort, baseline aspirin use was not associated with 
      long-term rates of sepsis.
FAU - Hsu, Joann
AU  - Hsu J
AD  - University of Alabama School of Medicine, Birmingham, Alabama, United States of 
      America.
FAU - Donnelly, John P
AU  - Donnelly JP
AD  - Department of Emergency Medicine, University of Alabama School of Medicine, 
      Birmingham, Alabama, United States of America.
AD  - Division of Preventive Medicine, Department of Medicine, University of Alabama 
      School of Medicine, Birmingham, Alabama, United States of America.
AD  - Department of Epidemiology, University of Alabama at Birmingham, Birmingham, 
      Alabama, United States of America.
FAU - Chaudhary, Ninad S
AU  - Chaudhary NS
AD  - Department of Emergency Medicine, University of Alabama School of Medicine, 
      Birmingham, Alabama, United States of America.
AD  - Department of Epidemiology, University of Alabama at Birmingham, Birmingham, 
      Alabama, United States of America.
FAU - Moore, Justin X
AU  - Moore JX
AD  - Department of Emergency Medicine, University of Alabama School of Medicine, 
      Birmingham, Alabama, United States of America.
AD  - Department of Epidemiology, University of Alabama at Birmingham, Birmingham, 
      Alabama, United States of America.
FAU - Safford, Monika M
AU  - Safford MM
AD  - Department of Medicine, Weill Cornell Medical College, New York, NY, United 
      States of America.
FAU - Kim, Junghyun
AU  - Kim J
AD  - Department of Emergency Medicine, University of Texas Health Science Center at 
      Houston, Houston, Texas, United States of America.
FAU - Wang, Henry E
AU  - Wang HE
AUID- ORCID: 0000-0002-4738-0093
AD  - Department of Emergency Medicine, University of Alabama School of Medicine, 
      Birmingham, Alabama, United States of America.
AD  - Department of Emergency Medicine, University of Texas Health Science Center at 
      Houston, Houston, Texas, United States of America.
LA  - eng
GR  - TL1 TR001418/TR/NCATS NIH HHS/United States
GR  - R01 NR012726/NR/NINR NIH HHS/United States
GR  - R25 CA047888/CA/NCI NIH HHS/United States
GR  - UL1 TR001417/TR/NCATS NIH HHS/United States
GR  - F31 GM122180/GM/NIGMS NIH HHS/United States
GR  - U01 NS041588/NS/NINDS NIH HHS/United States
GR  - UL1 RR025777/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180418
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cohort Studies
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Population Surveillance
MH  - Proportional Hazards Models
MH  - Sepsis/*epidemiology/*etiology
MH  - Socioeconomic Factors
MH  - Southeastern United States/epidemiology
MH  - Time Factors
PMC - PMC5905958
COIS- Competing Interests: Dr. Safford reports the following potential conflicts of 
      interest: Amgen—salary support to study patterns of statin use in Medicare and 
      other large databases; diaDexus—salary support for a research grant on lipids and 
      CAD outcomes; diaDexus—consulting to help with FDA application; NIH, AHRQ—salary 
      support for research grants. Dr. Wang – methodological consultant for Shire, Inc.
EDAT- 2018/04/19 06:00
MHDA- 2018/07/17 06:00
CRDT- 2018/04/19 06:00
PHST- 2017/08/11 00:00 [received]
PHST- 2018/03/09 00:00 [accepted]
PHST- 2018/04/19 06:00 [entrez]
PHST- 2018/04/19 06:00 [pubmed]
PHST- 2018/07/17 06:00 [medline]
AID - PONE-D-17-29857 [pii]
AID - 10.1371/journal.pone.0194829 [doi]
PST - epublish
SO  - PLoS One. 2018 Apr 18;13(4):e0194829. doi: 10.1371/journal.pone.0194829. 
      eCollection 2018.

PMID- 329172
OWN - NLM
STAT- MEDLINE
DCOM- 19770922
LR  - 20190712
IS  - 0030-4220 (Print)
IS  - 0030-4220 (Linking)
VI  - 44
IP  - 1
DP  - 1977 Jul
TI  - Harmful effects of "aspirin compounds".
PG  - 64-70
AB  - "Aspirin" is the most widely used medication which is considered to be safe and 
      effective, and which can be obtained universally without prescription. A review 
      of the literature and clinical experience reveal that many complications can be 
      attributed to the prolonged use of it. Some of these complications involve damage 
      to various tissues and organs (particularly the gastric mucosa, the renal 
      papilla, red blood cells, and the inner ear) and to coagulation and body 
      temperature control. Hemorrhagic gastritis may result with as little as 600 mg. 
      of salicylate four times a day for 5 days. Papillitis of the renal system may 
      result from a comparable dosage of aspirin compound mediates with phenacetin. The 
      purpose of this article has been to call attention to some of the important 
      complications which may result from salicylate abuse. It is hoped that many of 
      these complications may be avoided by proper and effective indoctrination of 
      patients to the hazards associated with prolonged or indiscriminate intake of 
      salicylates.
FAU - Najjar, T A
AU  - Najjar TA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Oral Surg Oral Med Oral Pathol
JT  - Oral surgery, oral medicine, and oral pathology
JID - 0376406
RN  - 0 (Salicylates)
RN  - 142M471B3J (Carbon Dioxide)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acid-Base Equilibrium/drug effects
MH  - Aspirin/*adverse effects/blood
MH  - Blood Coagulation/drug effects
MH  - Blood Platelets/drug effects
MH  - Carbon Dioxide/metabolism
MH  - Digestive System/drug effects
MH  - Ear, Inner/drug effects
MH  - Fever/chemically induced
MH  - Gastric Mucosa/drug effects
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Homeostasis/drug effects
MH  - Humans
MH  - Kidney/drug effects
MH  - Kidney Papillary Necrosis/chemically induced
MH  - Phenacetin/adverse effects
MH  - Salicylates/pharmacology
RF  - 231
EDAT- 1977/07/01 00:00
MHDA- 1977/07/01 00:01
CRDT- 1977/07/01 00:00
PHST- 1977/07/01 00:00 [pubmed]
PHST- 1977/07/01 00:01 [medline]
PHST- 1977/07/01 00:00 [entrez]
AID - 10.1016/0030-4220(77)90245-6 [doi]
PST - ppublish
SO  - Oral Surg Oral Med Oral Pathol. 1977 Jul;44(1):64-70. doi: 
      10.1016/0030-4220(77)90245-6.

PMID- 2339203
OWN - NLM
STAT- MEDLINE
DCOM- 19900619
LR  - 20190824
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 39
IP  - 3
DP  - 1990 Mar
TI  - Unresponsiveness of forearm hemodynamics to omega-3 polyunsaturated fatty acids 
      and aspirin.
PG  - 339-47
AB  - Prostaglandin synthesis has been reported to change with aspirin ingestion via 
      cyclooxygenase enzyme inhibition and with marine oil supplementation via an 
      increase in the metabolism of 3-series eicosanoids. This study investigated the 
      effects of pharmacological manipulations of prostaglandin metabolism on forearm 
      hemodynamics and blood pressure. The agents studied were omega-3 fatty acids and 
      aspirin. In the omega-3 fatty acid study, two groups of normal volunteers (N = 
      10/group) supplemented their diets with either marine oil capsules or placebo. 
      Hemodynamic variables (Mercury-in-Silastic forearm plethysmography) were measured 
      initially and weekly for 4 weeks. There were no significant differences between 
      the two groups in blood pressure, forearm blood flow, venous capacitance, or 
      forearm vascular resistance. Parallel changes occurred for forearm blood flow and 
      venous capacitance. Six normal volunteers took daily dosages of aspirin, 
      increasing from 162 to 2600 mg. Hemodynamic measurements, ADP-induced platelet 
      aggregation, and serum salicylate levels were obtained daily. Maximum inhibition 
      of platelet aggregation occurred after 162 mg. (serum salicylate = 17.7 +/- 6.4 
      mg/l). Though serum salicylate levels rose to 165.0 +/- 20.0 mg/l, no significant 
      changes occurred in blood pressure or forearm blood flow. Even at aspirin levels 
      16-fold greater than those required to impair platelet aggregation, the changes 
      in forearm vascular resistance were not found to be significant. These results 
      suggest that under resting conditions in normotensive males, neither 
      pharmacological inhibition nor stimulation of vascular prostaglandin metabolism 
      alters forearm vascular resistance or arterial blood pressure.
FAU - Ryu, J
AU  - Ryu J
AD  - Department of Medicine, University of Tennessee, Memphis 38163.
FAU - Lerner, J
AU  - Lerner J
FAU - Sullivan, J M
AU  - Sullivan JM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Fatty Acids, Omega-3/*pharmacology
MH  - Forearm/blood supply
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Male
MH  - Prostaglandins/metabolism
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
AID - 0090-6980(90)90051-V [pii]
AID - 10.1016/0090-6980(90)90051-v [doi]
PST - ppublish
SO  - Prostaglandins. 1990 Mar;39(3):339-47. doi: 10.1016/0090-6980(90)90051-v.

PMID- 12010380
OWN - NLM
STAT- MEDLINE
DCOM- 20020816
LR  - 20190901
IS  - 0017-8748 (Print)
IS  - 0017-8748 (Linking)
VI  - 42
IP  - 4
DP  - 2002 Apr
TI  - Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled 
      study.
PG  - 249-55
AB  - OBJECTIVE: To compare the efficacy of mouth-dispersible aspirin 900 mg and 
      placebo in the treatment of migraine. BACKGROUND: Aspirin is widely accepted as 
      an effective therapy for migraine. Previous studies have indicated that gastric 
      stasis and delayed gastric emptying, which occur during migraine attacks, delay 
      aspirin absorption. Mouth-dispersible formulations are considered to be more 
      quickly absorbed than solid formulations and, therefore, may be more effective in 
      treating migraine. DESIGN: Randomized, double-blind, placebo-controlled, 
      crossover study in four specialized migraine clinics in the United Kingdom. 
      METHODS: One hundred one patients diagnosed with migraine (according to the 
      International Headache Society diagnostic criteria) participated in the study. 
      Patients received either single doses of mouth-dispersible aspirin (3 x 300 mg) 
      or placebo for moderate pain in the treatment of two migraine attacks. Rescue 
      medication could be taken after 2 hours, if required. The primary efficacy 
      parameter was response to therapy at 2 hours posttreatment. Other efficacy 
      parameters were response to treatment, pain-free, and pain intensity at all other 
      time points. Functional disability, nausea, vomiting, photophobia, phonophobia, 
      symptom relief, patient and investigator global evaluation, use of rescue 
      medication, headache recurrence, and palatability and convenience were also 
      recorded. RESULTS: Of 101 patients, 73 took both treatments. At 2 hours, 48% of 
      patients taking mouth-dispersible aspirin responded, compared to only 19% taking 
      placebo (P =.0005). Mouth-dispersible aspirin was significantly better than 
      placebo for response to treatment (P<.05) and pain intensity difference (P<.01) 
      at all time points from 30 minutes posttreatment; for pain-free (P<.05) and use 
      of rescue medication (P<.01) from 3 hours posttreatment; for headache recurrence 
      (P<.05); and for patients' and investigators' global evaluations of efficacy (P 
      =.0001 in both cases). CONCLUSIONS: Mouth-dispersible aspirin 900 mg is effective 
      compared with placebo for the treatment of moderate migraine head pain, with 
      relief seen from as early as 30 minutes after taking medication.
FAU - MacGregor, E Anne
AU  - MacGregor EA
AD  - City of London Migraine Clinic, UK.
FAU - Dowson, Andrew
AU  - Dowson A
FAU - Davies, Paul T G
AU  - Davies PT
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdominal Pain/chemically induced
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Nausea/chemically induced
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vomiting/chemically induced
EDAT- 2002/05/16 10:00
MHDA- 2002/08/17 10:01
CRDT- 2002/05/16 10:00
PHST- 2002/05/16 10:00 [pubmed]
PHST- 2002/08/17 10:01 [medline]
PHST- 2002/05/16 10:00 [entrez]
AID - hed02076 [pii]
AID - 10.1046/j.1526-4610.2002.02076.x [doi]
PST - ppublish
SO  - Headache. 2002 Apr;42(4):249-55. doi: 10.1046/j.1526-4610.2002.02076.x.

PMID- 19931667
OWN - NLM
STAT- MEDLINE
DCOM- 20091214
LR  - 20220330
IS  - 1097-685X (Electronic)
IS  - 0022-5223 (Linking)
VI  - 138
IP  - 6
DP  - 2009 Dec
TI  - Aspirin and clopidogrel use in the early postoperative period following on-pump 
      and off-pump coronary artery bypass grafting.
PG  - 1377-84
LID - 10.1016/j.jtcvs.2009.07.027 [doi]
AB  - OBJECTIVE: Preoperative use of clopidogrel increases the risk of bleeding, but 
      its postoperative use has not been studied. We studied early postoperative 
      clopidogrel use in on-pump and off-pump coronary artery bypass grafting. METHODS: 
      Data were obtained from the University HealthSystem Consortium database. We 
      conducted a retrospective analysis of data of 15,067 adults who had coronary 
      artery bypass grafting between 2003 and 2006 and received perioperative aspirin 
      alone or in combination with clopidogrel, with the latter administered within 2 
      days after coronary artery bypass grafting. Logistic regression was used to 
      analyze in-hospital mortality, 30-day readmission, ischemic or thrombotic events, 
      and bleeding events, with propensity score adjustment for clopidogrel treatment. 
      RESULTS: Combined aspirin and clopidogrel were used in 3268 patients (22%). 
      Compared with aspirin alone, aspirin plus clopidogrel was associated with 
      reductions of in-hospital mortality (0.95% vs 1.78%; adjusted odds ratio: 0.50; 
      95% confidence interval: 0.25, 0.99) and bleeding events (4.19% vs 5.17%; 
      adjusted odds ratio: 0.70; 95% confidence interval: 0.51, 0.97). Ischemic or 
      thrombotic events were not significantly different (1.29% vs 1.53%; adjusted odds 
      ratio, 0.99; 95% confidence interval: 0.59, 1.64). The relative effect of 
      combined treatment did not differ between on-pump and off-pump coronary artery 
      bypass grafting. CONCLUSIONS: Early postoperative clopidogrel combined with 
      aspirin may be safe and beneficial compared with perioperative aspirin treatment 
      alone, in both on-pump and off-pump coronary artery bypass grafting. However, a 
      possibility of selection bias calls for randomized controlled trials to confirm 
      our findings.
FAU - Kim, Dae Hyun
AU  - Kim DH
AD  - Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. 
      dkim2@bidmc.harvard.edu
FAU - Daskalakis, Constantine
AU  - Daskalakis C
FAU - Silvestry, Scott C
AU  - Silvestry SC
FAU - Sheth, Mital P
AU  - Sheth MP
FAU - Lee, Andrew N
AU  - Lee AN
FAU - Adams, Suzanne
AU  - Adams S
FAU - Hohmann, Sam
AU  - Hohmann S
FAU - Medvedev, Sofia
AU  - Medvedev S
FAU - Whellan, David J
AU  - Whellan DJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Thorac Cardiovasc Surg. 2011 Mar;141(3):850-1; author reply 851-2. PMID: 
      21335142
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - *Coronary Artery Bypass/mortality
MH  - *Coronary Artery Bypass, Off-Pump/mortality
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/prevention & control
MH  - Postoperative Period
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
EDAT- 2009/11/26 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/11/26 06:00
PHST- 2008/11/13 00:00 [received]
PHST- 2009/05/20 00:00 [revised]
PHST- 2009/07/06 00:00 [accepted]
PHST- 2009/11/26 06:00 [entrez]
PHST- 2009/11/26 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S0022-5223(09)00938-6 [pii]
AID - 10.1016/j.jtcvs.2009.07.027 [doi]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 2009 Dec;138(6):1377-84. doi: 
      10.1016/j.jtcvs.2009.07.027.

PMID- 25150382
OWN - NLM
STAT- MEDLINE
DCOM- 20151019
LR  - 20221207
IS  - 1096-0260 (Electronic)
IS  - 0091-7435 (Linking)
VI  - 69
DP  - 2014 Dec
TI  - Non-melanoma skin cancer and NSAID use in women with a history of skin cancer in 
      the Women's Health Initiative.
PG  - 8-12
LID - S0091-7435(14)00315-6 [pii]
LID - 10.1016/j.ypmed.2014.08.024 [doi]
AB  - OBJECTIVE: Evidence for the effect of non-steroidal anti-inflammatory drugs 
      (NSAIDs) on non-melanoma skin cancer (NMSC) risk is inconsistent. We 
      prospectively examined whether regular, inconsistent, or no/low-use of NSAIDs is 
      associated with lower NMSC risk among 54,728 postmenopausal Caucasian women in 
      the Women's Health Initiative Observational Study enrolled between 1993 and 1998. 
      METHODS: Logistic regression models were used to assess odds of NMSC after 
      adjusting for skin type, sun exposure history and indication for NSAID use. 
      RESULTS: There were 7652 incident cases of NMSC (median follow-up: 6.9years). 
      There was no association between regular NSAID-use and NMSC risk relative to 
      no/low-users. However, in a subgroup analysis of 5325 women with a history of 
      skin cancer (incident NMSC: 1897), odds of NMSC were lower among regular NSAID 
      users whether <5years (OR 0.82, 95% CI: 0.70-0.95) or ≥5years (OR 0.82, 95% CI: 
      0.69-0.98) of use compared to no/low-users. Inconsistent NSAID use and 
      acetaminophen use were not associated with NMSC risk. CONCLUSION: Overall, NSAID 
      use was not associated with NMSC risk. However, in women with a history of skin 
      cancer, regular NSAID use was associated with 18% lower odds of NMSC. Future 
      studies on potential chemopreventative effects of NSAIDs should focus on subjects 
      with prior history of NMSC.
CI  - Copyright © 2014 Elsevier Inc. All rights reserved.
FAU - Wysong, Ashley
AU  - Wysong A
AD  - University of Southern California, Keck School of Medicine, Department of 
      Dermatology, Los Angeles, CA, United States; Stanford University, Department of 
      Dermatology, Redwood City, CA, United States. Electronic address: 
      awysong@usc.edu.
FAU - Ally, Mina S
AU  - Ally MS
AD  - Stanford University, Department of Dermatology, Redwood City, CA, United States.
FAU - Gamba, Christina S
AU  - Gamba CS
AD  - Stanford University School of Medicine and Cancer Institute, Stanford, CA, United 
      States.
FAU - Desai, Manisha
AU  - Desai M
AD  - Stanford University School of Medicine and Cancer Institute, Stanford, CA, United 
      States.
FAU - Swetter, Susan M
AU  - Swetter SM
AD  - Stanford University, Department of Dermatology, Redwood City, CA, United States; 
      Stanford University School of Medicine and Cancer Institute, Stanford, CA, United 
      States; VA Palo Alto Health Care System, Palo Alto, CA, United States.
FAU - Seiffert-Sinha, Kristina
AU  - Seiffert-Sinha K
AD  - Department of Dermatology, University at Buffalo, Buffalo, NY, United States.
FAU - Sinha, Animesh A
AU  - Sinha AA
AD  - Department of Dermatology, University at Buffalo, Buffalo, NY, United States.
FAU - Stefanick, Marcia L
AU  - Stefanick ML
AD  - Stanford University School of Medicine and Cancer Institute, Stanford, CA, United 
      States.
FAU - Tang, Jean Y
AU  - Tang JY
AD  - Stanford University, Department of Dermatology, Redwood City, CA, United States; 
      Stanford University School of Medicine and Cancer Institute, Stanford, CA, United 
      States.
LA  - eng
GR  - HHSN271201100004C/PHS HHS/United States
GR  - HHSN268201100001C/PHS HHS/United States
GR  - HHSN268201100003C/PHS HHS/United States
GR  - HHSN268201100004C/PHS HHS/United States
GR  - HHSN268201100046C/PHS HHS/United States
GR  - HHSN268201100002C/PHS HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
DEP - 20140820
PL  - United States
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Skin Neoplasms/chemically induced/*prevention & control
MH  - Surveys and Questionnaires
MH  - White People
MH  - Women's Health
OTO - NOTNLM
OT  - Anti-inflammatory drugs
OT  - Aspirin
OT  - Female
OT  - Non-melanoma skin cancer
OT  - Non-steroidal
EDAT- 2014/08/26 06:00
MHDA- 2015/10/20 06:00
CRDT- 2014/08/25 06:00
PHST- 2014/04/24 00:00 [received]
PHST- 2014/06/28 00:00 [revised]
PHST- 2014/08/12 00:00 [accepted]
PHST- 2014/08/25 06:00 [entrez]
PHST- 2014/08/26 06:00 [pubmed]
PHST- 2015/10/20 06:00 [medline]
AID - S0091-7435(14)00315-6 [pii]
AID - 10.1016/j.ypmed.2014.08.024 [doi]
PST - ppublish
SO  - Prev Med. 2014 Dec;69:8-12. doi: 10.1016/j.ypmed.2014.08.024. Epub 2014 Aug 20.

PMID- 20095898
OWN - NLM
STAT- MEDLINE
DCOM- 20100405
LR  - 20161125
IS  - 1365-2931 (Electronic)
IS  - 1364-5706 (Linking)
VI  - 19
IP  - 1
DP  - 2010
TI  - Endoscopic application of hemostatic thrombin-gelatin matrix (FloSeal) in 
      anticoagulated pigs.
PG  - 48-51
LID - 10.3109/13645700903516585 [doi]
AB  - Flexible endoscopy is the method of choice for the diagnosis and therapy of upper 
      gastrointestinal bleeding, but there are still problems during therapy of 
      patients with coagulation disorders. FloSeal((R)) is a hemostatic matrix largely 
      independent of the body's own clotting system. A newly developed endoscopic 
      applicator for FloSeal((R)) was tested in a survival study on pigs with impaired 
      clotting. In a total of eight pigs ulcerous lesions Forrest Ib were induced and 
      the bleeding stopped by applying FloSeal((R)). Thirty minutes before intervention 
      six pigs were given full weight-adjusted heparinization or a maximum dose of ASS 
      in advance. The Hb course was monitored over the next 48 hours and a postmortem 
      examination was performed. In each case, FloSeal((R)) was successfully applied 
      and all bleedings could be stopped. In both groups (except the control group) 
      spontaneous extraintestinal bleeding occurred, but in only one case in the ASS 
      group a gastrointestinal bleeding happened. The Hb course was stable in all other 
      animals. FloSeal((R)) can also be used endoscopically using the applicator being 
      presented here for the first time. It is suited for primary hemostasis of 
      excavated sources of bleeding especially in situations where coagulation is 
      impaired.
FAU - Hammes, C
AU  - Hammes C
AD  - Department of Surgery, University Hospital Mannheim, Ruprechts-Karls-Universität 
      Heidelberg, Germany.
FAU - Moersdorf, G
AU  - Moersdorf G
FAU - Refeidi, A
AU  - Refeidi A
FAU - Post, S
AU  - Post S
FAU - Kaehler, G
AU  - Kaehler G
LA  - eng
PT  - Journal Article
PL  - England
TA  - Minim Invasive Ther Allied Technol
JT  - Minimally invasive therapy & allied technologies : MITAT : official journal of 
      the Society for Minimally Invasive Therapy
JID - 9612996
RN  - 0 (Anticoagulants)
RN  - 0 (FloSeal Matrix)
RN  - 0 (Hemostatics)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Anticoagulants/administration & dosage
MH  - Aspirin/administration & dosage/analogs & derivatives
MH  - Blood Coagulation Disorders/therapy
MH  - Disease Models, Animal
MH  - Endoscopy/*methods
MH  - Gastrointestinal Hemorrhage/*therapy
MH  - Gelatin Sponge, Absorbable/*administration & dosage
MH  - Hemostatics/*administration & dosage
MH  - Heparin/administration & dosage
MH  - Lysine/administration & dosage/analogs & derivatives
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Swine
EDAT- 2010/01/26 06:00
MHDA- 2010/04/07 06:00
CRDT- 2010/01/26 06:00
PHST- 2010/01/26 06:00 [entrez]
PHST- 2010/01/26 06:00 [pubmed]
PHST- 2010/04/07 06:00 [medline]
AID - 10.3109/13645700903516585 [doi]
PST - ppublish
SO  - Minim Invasive Ther Allied Technol. 2010;19(1):48-51. doi: 
      10.3109/13645700903516585.

PMID- 17364875
OWN - NLM
STAT- MEDLINE
DCOM- 20070416
LR  - 20190516
IS  - 1071-7544 (Print)
IS  - 1071-7544 (Linking)
VI  - 14
IP  - 2
DP  - 2007 Feb
TI  - Antibacterial activity of dipeptide constructs of acetylsalicylic acid and 
      nicotinic acid.
PG  - 105-9
AB  - Two dipeptide drugs are synthesized utilizing an acetylsalicylic acid or 
      nicotinic acid molecule for the framework. A D-alanine-D-alanine dipeptide moiety 
      is attached to the carbonyl carbon of acetylsalicylic acid (I) and nicotinic acid 
      (II). Dipeptide derivatives (I) and (II) showed significant reduction of 
      Escherichia coli (E. coli) bacterial growth and colony-forming units. A mixture 
      of (I) and (II) induced growth inhibition of 8%, 17.5%, 28%, and 42.5% at 
      concentrations of 100, 200, 300, and 400 microg/mL, respectively. Ampicillin 
      demonstrated much less growth inhibition of this penicillin-resistant E. coli 
      bacteria. Derivatives (I) and (II) showed significant reduction of colony-forming 
      units at concentrations higher than 200 microg/mL, whereas ampicillin showed no 
      significant affect on colony-forming units. Both (I) and (II) produced no 
      violations of the Rule of 5, indicating favorable characteristics for 
      bioavailability. Molecular properties were determined and showed (I) to have a 
      Log Kow of -0.22 with aqueous solubility of 683.8 mg/L, whereas (II) had a Log 
      Kow of -1.00 and aqueous solubility of 6859 mg/L. A mixture of the parent 
      compounds acetyl salicylic acid and nicotinic acid demonstrated some 
      antibacterial activity.
FAU - Bartzatt, Ronald
AU  - Bartzatt R
AD  - Durham Science Center, Laboratory of Pharmaceutical Studies, Department of 
      Chemistry, University of Nebraska, Omaha, Nebraska 68182, USA. 
      bartzatt@mail.unomaha.edu
FAU - Cirillo, Suat L G
AU  - Cirillo SL
FAU - Cirillo, Jeffrey D
AU  - Cirillo JD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Drug Deliv
JT  - Drug delivery
JID - 9417471
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Dipeptides)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Penicillins)
RN  - 2679MF687A (Niacin)
RN  - 7C782967RD (Ampicillin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ampicillin/chemistry/pharmacology
MH  - Anti-Bacterial Agents/chemical synthesis/*pharmacology
MH  - Aspirin/chemistry/*pharmacology
MH  - Chemistry, Pharmaceutical
MH  - Colony Count, Microbial
MH  - Dipeptides/chemical synthesis/*pharmacology
MH  - Escherichia coli/drug effects/growth & development
MH  - Indicators and Reagents
MH  - Microbial Sensitivity Tests
MH  - Niacin/chemistry/*pharmacology
MH  - Penicillin Resistance
MH  - Penicillins/chemistry/pharmacology
EDAT- 2007/03/17 09:00
MHDA- 2007/04/17 09:00
CRDT- 2007/03/17 09:00
PHST- 2007/03/17 09:00 [pubmed]
PHST- 2007/04/17 09:00 [medline]
PHST- 2007/03/17 09:00 [entrez]
AID - 770392624 [pii]
AID - 10.1080/10717540600740128 [doi]
PST - ppublish
SO  - Drug Deliv. 2007 Feb;14(2):105-9. doi: 10.1080/10717540600740128.

PMID- 15327368
OWN - NLM
STAT- MEDLINE
DCOM- 20041103
LR  - 20211203
IS  - 0929-8665 (Print)
IS  - 0929-8665 (Linking)
VI  - 11
IP  - 4
DP  - 2004 Aug
TI  - Chemically modified porcine hemoglobins and their biological properties.
PG  - 353-60
AB  - Hemoglobin cross-linked with small molecular modifiers turns out to be more 
      stable. Modifications of proteins with polyethylene glycol (PEG) have been proven 
      to enlarge the molecular size of proteins, to prolong their retention time in the 
      circulation as well as blunt immune reactions. In the present study, the optimal 
      conditions for porcine hemoglobin (pHb) modification with bis (3, 
      5-dibromosalicyl) fumarate (DBBF) and PEG were evaluated. The derivative of DBBF 
      cross-linked pHb (DBBF-pHb) showed improved oxygen affinity and the ability to 
      resist the dissociation of the alpha2beta2 tetramer compared with the natural 
      protein. DBBF-pHb was then bound to the activated PEG. The results indicated that 
      the pHb modified with DBBF and PEG had more stable tetrameric conformation with a 
      molecular weight of 107000. Their oxygen half-saturation pressure (P50) is around 
      3.33 kPa, which approximates the physiological P50 of human red blood cells. Both 
      routine and reinforced immunizing methods were adopted to study the 
      immunogenicity of modified products and the results showed that the products had 
      very low immunogenicity evaluated by enzyme-linked immunoadsordent assay (ELISA). 
      Somewhat beneficial effects were shown in the treatment of hemorrhagic shock 
      where modified hemoglobin solutions were used as resuscitation fluids in the 
      hemorrhagic shock Sprague-Dawley (SD) rats model.
FAU - Jin, Cai
AU  - Jin C
AD  - College of Material and Chemical Engineering, Zhejiang University, Hangzhou 
      310027, China.
FAU - Wen-Fang, Meng
AU  - Wen-Fang M
FAU - Min, Hong
AU  - Min H
FAU - Pei-Lin, Cen
AU  - Pei-Lin C
FAU - Zhong-Yi, Yuan
AU  - Zhong-Yi Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Protein Pept Lett
JT  - Protein and peptide letters
JID - 9441434
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (PHB protein, human)
RN  - 0 (Phb protein, rat)
RN  - 0 (Prohibitins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Allosteric Regulation
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*chemistry
MH  - Blood Substitutes/chemistry/metabolism
MH  - Cross-Linking Reagents/chemistry
MH  - Disease Models, Animal
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Hemoglobins/*chemistry/*metabolism
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Molecular Weight
MH  - Oxygen/metabolism
MH  - Polyethylene Glycols/*chemistry
MH  - Prohibitins
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Shock, Hemorrhagic/pathology
MH  - *Swine
EDAT- 2004/08/26 05:00
MHDA- 2004/11/04 09:00
CRDT- 2004/08/26 05:00
PHST- 2004/08/26 05:00 [pubmed]
PHST- 2004/11/04 09:00 [medline]
PHST- 2004/08/26 05:00 [entrez]
AID - 10.2174/0929866043406797 [doi]
PST - ppublish
SO  - Protein Pept Lett. 2004 Aug;11(4):353-60. doi: 10.2174/0929866043406797.

PMID- 10540937
OWN - NLM
STAT- MEDLINE
DCOM- 19991124
LR  - 20191103
IS  - 0905-4383 (Print)
IS  - 0905-4383 (Linking)
VI  - 15
IP  - 5
DP  - 1999 Oct
TI  - The photoprotective effect of ascorbic acid, acetylsalicylic acid, and 
      indomethacin evaluated by the photo hen's egg test.
PG  - 166-70
AB  - The aim of the present study was to evaluate the supposed photoprotective effects 
      of ascorbic acid, acetylsalicylic acid, and indomethacin by the photo hen's egg 
      test, a recently developed new model for phototoxicity. Therefore, in three 
      independent experimental settings the blood vessel system of the embryo's yolk 
      sac of 24 incubated hens' eggs (2 test groups) were exposed to 60 mJ/cm2 
      ultraviolet B (UVB) to induce severe phototoxic damage. Before UVB irradiation, 
      one of these test groups was exposed additionally to one of the test substances 
      and the other one to 0.9% sodium solution alone. To exclude plain toxic 
      reactions, two additional test groups were exposed only to 0.9% sodium chloride 
      solution or to one of the test substances alone. Over a test observation period 
      of 24 h, the embryo lethality as well as the morphological changes of the yolk 
      sac blood vessel system were observed. Ascorbic acid led to a significant and 
      remarkable reduction of the UVB-induced damage. Acetylsalicylic acid also showed 
      a significant but lower photoprotective capacity. In contrast, indomethacin 
      showed no photoprotective effects in the photo hen's egg test.
FAU - Neumann, N J
AU  - Neumann NJ
AD  - Department of Dermatology, Heinrich-Heine-University, Düsseldorf, Germany.
FAU - Hölzle, E
AU  - Hölzle E
FAU - Wallerand, M
AU  - Wallerand M
FAU - Vierbaum, S
AU  - Vierbaum S
FAU - Ruzicka, T
AU  - Ruzicka T
FAU - Lehmann, P
AU  - Lehmann P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Photodermatol Photoimmunol Photomed
JT  - Photodermatology, photoimmunology & photomedicine
JID - 9013641
RN  - 0 (Sunscreening Agents)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Ascorbic Acid/*pharmacology/toxicity
MH  - Aspirin/*pharmacology/toxicity
MH  - Blood Vessels/radiation effects
MH  - Chick Embryo
MH  - Indomethacin/*pharmacology/toxicity
MH  - Sunscreening Agents/*pharmacology
MH  - Ultraviolet Rays/*adverse effects
MH  - Yolk Sac/blood supply/radiation effects
EDAT- 1999/11/30 00:00
MHDA- 1999/11/30 00:01
CRDT- 1999/11/30 00:00
PHST- 1999/11/30 00:00 [pubmed]
PHST- 1999/11/30 00:01 [medline]
PHST- 1999/11/30 00:00 [entrez]
AID - 10.1111/j.1600-0781.1999.tb00078.x [doi]
PST - ppublish
SO  - Photodermatol Photoimmunol Photomed. 1999 Oct;15(5):166-70. doi: 
      10.1111/j.1600-0781.1999.tb00078.x.

PMID- 7744314
OWN - NLM
STAT- MEDLINE
DCOM- 19950612
LR  - 20190825
IS  - 0891-5849 (Print)
IS  - 0891-5849 (Linking)
VI  - 18
IP  - 2
DP  - 1995 Feb
TI  - Effects of intra- and intermolecular crosslinking on the free radical reactions 
      of bovine hemoglobins.
PG  - 295-301
AB  - Chemical modifications of human or bovine hemoglobins are designed to produce 
      proteins that can act as oxygen-carrying blood substitutes. Concerns about the 
      redox reactivity of cell-free hemoglobin and its contribution to tissue-damaging 
      oxygen free radicals has not been fully established. We determined that bovine 
      hemoglobins intra- or intermolecularly crosslinked differ in their ability to 
      generate or interact with reactive oxygen species. These differences do not 
      correlate with their oxygen affinities. We compared HbBv-FMDA, produced by the 
      reaction of bovine hemoglobin with fumaryl-monodiaspirin and Poly HbBv, a 
      glutaraldehyde polymerized bovine hemoglobin, with unmodified bovine hemoglobin 
      (HbBv). Superoxide radicals are produced during the spontaneous oxidation of 
      hemoglobin. Relative to the other two proteins. Poly HbBv was found to be more 
      susceptible to autoxidation. Spectral changes indicative of protein modification 
      and ferrylhemoglobin formation during the enzymatic peroxidation of these 
      hemoglobins differ qualitatively and occur at an increasing order, poly HbBv > 
      HbBv > HbBv-FMDA. The proteins also differ in the rate of hemoglobin catalyzed 
      NADPH oxidation and aniline hydroxylation, reactions mediated by reactive oxygen 
      species. Taken together, our results and those reported previously on modified 
      human hemoglobins, suggest that redox and oxygen-carrying functions of hemoglobin 
      can be experimentally manipulated as independently selectable parameters that may 
      ultimately aid in the design of a safer reperfusion agent.
FAU - Alayash, A I
AU  - Alayash AI
AD  - Center for Biologics Evaluation and Research, Food and Drug Administration, 
      Bethesda, MD, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Free Radic Biol Med
JT  - Free radical biology & medicine
JID - 8709159
RN  - 0 (Aniline Compounds)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Ferric Compounds)
RN  - 0 (Ferrous Compounds)
RN  - 0 (Free Radicals)
RN  - 0 (Hemoglobins)
RN  - 11062-77-4 (Superoxides)
RN  - 53-59-8 (NADP)
RN  - 93705-06-7 (mono(3,5-dibromosalicyl)fumarate)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
RN  - SIR7XX2F1K (aniline)
RN  - T3C89M417N (Glutaral)
SB  - IM
MH  - Aniline Compounds/metabolism
MH  - Animals
MH  - Aspirin/analogs & derivatives/chemistry
MH  - Cattle
MH  - *Cross-Linking Reagents
MH  - Ferric Compounds/chemistry
MH  - Ferrous Compounds/chemistry
MH  - Free Radicals
MH  - Glutaral/chemistry
MH  - Hemoglobins/*chemistry/*metabolism
MH  - Humans
MH  - Kinetics
MH  - NADP/metabolism
MH  - Oxidation-Reduction
MH  - Oxygen/blood
MH  - Superoxides/metabolism
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
AID - 0891584994E01426 [pii]
AID - 10.1016/0891-5849(94)e0142-6 [doi]
PST - ppublish
SO  - Free Radic Biol Med. 1995 Feb;18(2):295-301. doi: 10.1016/0891-5849(94)e0142-6.

PMID- 22428607
OWN - NLM
STAT- MEDLINE
DCOM- 20121129
LR  - 20211021
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 166
IP  - 7
DP  - 2012 Aug
TI  - Safety and efficacy of targeting platelet proteinase-activated receptors in 
      combination with existing anti-platelet drugs as antithrombotics in mice.
PG  - 2188-97
LID - 10.1111/j.1476-5381.2012.01944.x [doi]
AB  - BACKGROUND AND PURPOSE: Developing novel anti-platelet strategies is fundamental 
      to reducing the impact of thrombotic diseases. Thrombin activates platelets via 
      proteinase-activated receptors (PARs), and PAR antagonists are being evaluated in 
      clinical trials for prevention of arterial thrombosis. However, one such trial 
      was recently suspended due to increased bleeding in patients receiving a PAR₁ 
      antagonist in addition to anti-platelet drugs that most often included both 
      aspirin and clopidogrel. Therefore, it remains unclear how to best manipulate 
      PARs for safe antithrombotic activity. To address this, we have examined 
      potential interactions between existing anti-platelet drugs and strategies that 
      target PARs. EXPERIMENTAL APPROACH: We used in vivo mouse models in which 
      interactions between various anti-platelet strategies could be evaluated. We 
      examined the effects on thrombosis and haemostasis in PAR₄ -/- mice (platelets 
      unresponsive to thrombin) treated with therapeutic doses of either aspirin or 
      clopidogrel. KEY RESULTS: Using a model in which occlusive thrombosis occurred in 
      PAR₄ -/- mice or wild-type mice treated with aspirin or clopidogrel, PAR₄ -/- 
      mice treated with either anti-platelet agent showed marked protection against 
      thrombosis. This antithrombotic effect occurred without any effect on haemostasis 
      with aspirin, but not clopidogrel. Furthermore, specifically targeting 
      thrombin-induced platelet activation (via PARs) improved the therapeutic window 
      of non-specifically inhibiting thrombin functions (via anticoagulants). 
      CONCLUSIONS AND IMPLICATIONS: Our results indicate that PAR antagonists used in 
      combination with aspirin provide a potent yet safe antithrombotic strategy in 
      mice and provide insights into the safety and efficacy of using PAR antagonists 
      for the prevention of acute coronary syndromes in humans.
CI  - © 2012 The Authors. British Journal of Pharmacology © 2012 The British 
      Pharmacological Society.
FAU - Lee, H
AU  - Lee H
AD  - Australian Centre for Blood Diseases, Monash University, Melbourne, Australia.
FAU - Sturgeon, S A
AU  - Sturgeon SA
FAU - Mountford, J K
AU  - Mountford JK
FAU - Jackson, S P
AU  - Jackson SP
FAU - Hamilton, J R
AU  - Hamilton JR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Receptors, Proteinase-Activated)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Clopidogrel
MH  - Disease Models, Animal
MH  - Fibrinolytic Agents/pharmacology/*therapeutic use
MH  - Hemostasis/drug effects
MH  - Mice
MH  - Mice, Knockout
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Receptors, Proteinase-Activated/*antagonists & inhibitors/physiology
MH  - Thrombosis/*drug therapy/physiopathology
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
PMC - PMC3402781
EDAT- 2012/03/21 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/03/21 06:00
PHST- 2012/03/21 06:00 [entrez]
PHST- 2012/03/21 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.1111/j.1476-5381.2012.01944.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 2012 Aug;166(7):2188-97. doi: 10.1111/j.1476-5381.2012.01944.x.

PMID- 20698055
OWN - NLM
STAT- MEDLINE
DCOM- 20101108
LR  - 20191027
IS  - 1473-5709 (Electronic)
IS  - 0959-8278 (Linking)
VI  - 19
IP  - 5
DP  - 2010 Sep
TI  - Aspirin and risk of endometrial cancer: a case-control study from Italy.
PG  - 401-3
AB  - Data on the role of aspirin on endometrial cancer risk are scanty. Here we 
      provide additional information on the issue, using data from a multicentric 
      Italian case-control study. The study was conducted between 1992 and 2006 in 
      three Italian areas, on 442 cases with histologically confirmed endometrial 
      cancer and 676 control women admitted to the same hospitals as cases for a wide 
      spectrum of acute, non-neoplastic, non-gynaecological, non-hormone-related 
      conditions, providing information on aspirin use. Odds ratios (OR) of endometrial 
      cancer and corresponding 95% confidence intervals were calculated using multiple 
      logistic regression models, including terms for sociodemographic characteristics, 
      body mass index and hormonal and reproductive factors. Regular aspirin use was 
      reported by 28 (6.3%) cases and 46 (6.8%) controls, corresponding to a 
      multivariate OR of 0.65 (95% confidence interval 0.37-1.11). There was no 
      consistent pattern of risk with duration of use, nor with age at first use, time 
      since first use or time since last use. Further, there was no difference in risk 
      estimates across strata of body mass index. This study--the first one from a 
      population outside North America--adds relevant information on the absence of a 
      consistent association between aspirin use and endometrial cancer risk, even in 
      high-risk overweight and obese women.
FAU - Bosetti, Cristina
AU  - Bosetti C
AD  - Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa, Milan, 
      Italy.
FAU - Bravi, Francesca
AU  - Bravi F
FAU - Talamini, Renato
AU  - Talamini R
FAU - Montella, Maurizio
AU  - Montella M
FAU - Negri, Eva
AU  - Negri E
FAU - La Vecchia, Carlo
AU  - La Vecchia C
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Eur J Cancer Prev
JT  - European journal of cancer prevention : the official journal of the European 
      Cancer Prevention Organisation (ECP)
JID - 9300837
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Endometrial Neoplasms/*chemically induced/diagnosis
MH  - Female
MH  - Humans
MH  - Italy
MH  - Middle Aged
MH  - Odds Ratio
MH  - Risk
MH  - Young Adult
EDAT- 2010/08/11 06:00
MHDA- 2010/11/09 06:00
CRDT- 2010/08/11 06:00
PHST- 2010/08/11 06:00 [entrez]
PHST- 2010/08/11 06:00 [pubmed]
PHST- 2010/11/09 06:00 [medline]
AID - 10.1097/cej.0b013e32833b4871 [doi]
PST - ppublish
SO  - Eur J Cancer Prev. 2010 Sep;19(5):401-3. doi: 10.1097/cej.0b013e32833b4871.

PMID- 17957573
OWN - NLM
STAT- MEDLINE
DCOM- 20080123
LR  - 20181201
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 18
IP  - 7
DP  - 2007 Nov
TI  - To adjust or not to adjust the platelet count in light transmission aggregometry 
      in patients receiving dual aspirin/clopidogrel treatment.
PG  - 550-3
AB  - We evaluated whether the results of light transmittance aggregometry (LTA) differ 
      when "native" platelet-rich plasma (PRP) or adjusted (to a standard platelet 
      count of 250.000/microL) PRP is used in patients on dual antiplatelet therapy 
      with aspirin and clopidogrel. LTA has been performed on the blood of 142 stable 
      angina pectoris patients who were adequately pretreated with aspirin and 
      clopidogrel. Platelet aggregation was significant higher in native PRP as 
      compared to platelet count adjusted PRP (P<0.0001) for all four concentrations of 
      adenosine-5'-diphosphate (ADP) (2, 5, 10 and 20 micromol/L). The interindividual 
      variability was significantly higher in platelet count adjusted PRP as compared 
      to native PRP when stimulated with 10 and 20 micromol/L of ADP. The absolute 
      magnitude of aggregation in non-adjusted PRP is clearly dependent on platelet 
      number. These observations are important since several studies have used 
      empirically defined cut-off levels to segregate non-responders from responders to 
      clopidogrel therapy.
FAU - van der Stelt, Cornelia A K
AU  - van der Stelt CA
AD  - Department of Cardiology, St Antonius Hospital, Niuwegein, The Netherlands.
FAU - van Werkum, Jochem W
AU  - van Werkum JW
FAU - Seesing, Toine H
AU  - Seesing TH
FAU - Berg, Jurriën M Ten
AU  - Berg JM
FAU - Hackeng, Christian M
AU  - Hackeng CM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Platelet Count/methods
MH  - Platelet Function Tests/*methods
MH  - Platelet-Rich Plasma/*cytology
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
EDAT- 2007/10/25 09:00
MHDA- 2008/01/24 09:00
CRDT- 2007/10/25 09:00
PHST- 2007/10/25 09:00 [pubmed]
PHST- 2008/01/24 09:00 [medline]
PHST- 2007/10/25 09:00 [entrez]
AID - 783324164 [pii]
AID - 10.1080/09537100701326721 [doi]
PST - ppublish
SO  - Platelets. 2007 Nov;18(7):550-3. doi: 10.1080/09537100701326721.

PMID- 9008269
OWN - NLM
STAT- MEDLINE
DCOM- 19970325
LR  - 20191024
IS  - 0142-2782 (Print)
IS  - 0142-2782 (Linking)
VI  - 18
IP  - 1
DP  - 1997 Jan
TI  - Effect of portal vein ligation and silymarin treatment on aspirin metabolism and 
      disposition in rats.
PG  - 53-64
AB  - The influence of portal hypertension on the metabolism and pharmacokinetics of 
      aspirin was evaluated after the administration of a single oral dose of 
      acetylsalicylic acid (20 mgkg(-1)) in portal-vein-ligated (PVL) rats. Experiments 
      were also performed in control (sham-operated rats) and in rats that received an 
      oral daily dose (150 mgkg(-1)) of silymarin from the tenth day after surgery for 
      7 d. Plasma concentration profiles of all groups exhibited monoexponential decay 
      but with important changes in pharmacokinetic parameters. The aspirin elimination 
      constant (k) for PVL rats was lower than for control rats, whereas the plasma 
      half-life and area under the curve were greater than those in the control group. 
      However, Cmax was comparable with that of the control rats. Urinary excretion of 
      the metabolites (salicylic acid and glucuronides) was significantly altered in 
      PVL rats: the urinary glucuronides were reduced and urinary salicylic acid was 
      increased. The activities of plasma and liver esterases were increased 
      significantly in PVL rats, while the activity of p-nitroanisole-O-demethylase was 
      not affected. Depletion of cytochrome P 450 was also noted in the same group of 
      rats. Silymarin markedly reversed the alterations found in the PVL group.
FAU - Favari, L
AU  - Favari L
AD  - Departamento de Farmacologia y Toxicologia, Cinvestav-I.P.N., Mexico.
FAU - Soto, C
AU  - Soto C
FAU - Mourelle, M
AU  - Mourelle M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biopharm Drug Dispos
JT  - Biopharmaceutics & drug disposition
JID - 7911226
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Silymarin)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism/pharmacokinetics
MH  - Area Under Curve
MH  - Aspirin/*metabolism/pharmacokinetics
MH  - Cytochrome P-450 Enzyme System/metabolism
MH  - Half-Life
MH  - Hypertension, Portal/*metabolism
MH  - Ligation
MH  - Liver/drug effects/enzymology
MH  - Liver Function Tests
MH  - Male
MH  - *Portal Vein
MH  - Rats
MH  - Rats, Wistar
MH  - Silymarin/*pharmacology
EDAT- 1997/01/01 00:00
MHDA- 2000/06/20 09:00
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1002/(SICI)1099-081X(199701)18:1<53::AID-BDD3>3.0.CO;2-9 [pii]
AID - 10.1002/(sici)1099-081x(199701)18:1<53::aid-bdd3>3.0.co;2-9 [doi]
PST - ppublish
SO  - Biopharm Drug Dispos. 1997 Jan;18(1):53-64. doi: 
      10.1002/(sici)1099-081x(199701)18:1<53::aid-bdd3>3.0.co;2-9.

PMID- 1500806
OWN - NLM
STAT- MEDLINE
DCOM- 19920915
LR  - 20131121
IS  - 0300-9165 (Print)
IS  - 0300-9165 (Linking)
VI  - 44
IP  - 7
DP  - 1992 Jul
TI  - [A trial of low-dose aspirin therapy in high-risk pregnancy].
PG  - 845-52
AB  - Intra-uterine growth retardation, intra-uterine fetal death and pre-eclampsia 
      have common abnormalities: A reduction of uteroplacental perfusion, lack of 
      vasodilation of spiral arteries and subsequent thrombosis. These physiological 
      processes have been explained by an imbalance between prostacyclin and 
      thromboxane A2 production. Many studies have suggested that treatment with 
      low-dose aspirin and steroids is effective in preventing pregnancy loss or 
      pre-eclampsia, but the mechanism has not been established. We evaluated the 
      effectiveness of these therapies in patients at risk for pregnancy loss with the 
      aspect of intracellular ionized calcium mobilization. Low-dose aspirin directs 
      the prostacyclin/thromboxane A2 balance to the dominance of prostacyclin and 
      steroids suppress the activities of lupus anticoagulant or antiphospholipid 
      antibodies. The intracellular ionized calcium concentration in platelets is 
      decreased significantly after these therapies. Concerning the pathological 
      examination of placenta, there were deposits of fibrin in only 2 out of 8 cases 
      and there were no abnormal findings in the other 6 cases. These data show that 
      the aggregation of platelets is suppressed in microvascular circulations. These 
      therapies do not cause any adverse effect on the mother or fetus. It is concluded 
      that low-dose aspirin therapy with steroids is useful for patients with a poor 
      obstetrical history.
FAU - Takashima, M
AU  - Takashima M
AD  - Department of Obstetrics and Gynecology, Kobe University School of Medicine.
FAU - Yamasaki, M
AU  - Yamasaki M
FAU - Ohashi, M
AU  - Ohashi M
FAU - Morikawa, H
AU  - Morikawa H
FAU - Mochizuki, M
AU  - Mochizuki M
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Sanka Fujinka Gakkai Zasshi
JT  - Nihon Sanka Fujinka Gakkai zasshi
JID - 7505749
RN  - 0 (Lupus Coagulation Inhibitor)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Calcium/blood
MH  - Female
MH  - Fetal Death
MH  - Fetal Growth Retardation
MH  - Humans
MH  - Lupus Coagulation Inhibitor/analysis
MH  - Placenta/pathology
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications/*prevention & control
MH  - Thromboxane B2/blood
MH  - Treatment Outcome
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
PST - ppublish
SO  - Nihon Sanka Fujinka Gakkai Zasshi. 1992 Jul;44(7):845-52.

PMID- 17239863
OWN - NLM
STAT- MEDLINE
DCOM- 20070312
LR  - 20141120
IS  - 0014-5793 (Print)
IS  - 0014-5793 (Linking)
VI  - 581
IP  - 3
DP  - 2007 Feb 6
TI  - Aspirin prevents adhesion of T lymphoblasts to vascular smooth muscle cells.
PG  - 427-32
AB  - In the development of atherosclerosis, inflammatory cells adhere to and migrate 
      into the vascular walls by interacting with vascular smooth muscle cells. To 
      investigate the mechanism of aspirin's anti-atherogenic activity, we examined 
      whether aspirin inhibits the adhesion of lymphocytes to human aortic smooth 
      muscle cells (AoSMC). Aspirin inhibited T-cell adhesion to AoSMC activated by 
      interleukin 1beta (IL-1beta) in a dose-dependent manner. Antibodies to the 
      adhesion molecules ICAM-1 or VCAM-1, but not to E-selectin, prevented T-cell 
      adhesion. ICAM-1 and VCAM-1 expression stimulated by IL-1beta was reduced by the 
      treatment with aspirin, whereas the expression of E-selectin was unaffected. 
      Nuclear factor kappaB (NF-kappaB) activity was enhanced by IL-1beta and reduced 
      by aspirin, indicating that decreased ICAM-1 and VCAM-1 expression was due to 
      reduced NF-kappaB activity.Thus, aspirin inhibits the adhesion of Jurkat T cells 
      to IL-1beta-activated AoSMC by reducing NF-kappaB activity and decreasing 
      expression of ICAM-1 and VCAM-1, and may prevent the development of 
      atherosclerosis.
FAU - Yotsui, Takamori
AU  - Yotsui T
AD  - Department of Geriatric Medicine, Osaka University Graduate School of Medicine, 
      2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
FAU - Yasuda, Osamu
AU  - Yasuda O
FAU - Kawamoto, Hidenobu
AU  - Kawamoto H
FAU - Higuchi, Masayoshi
AU  - Higuchi M
FAU - Chihara, Yukana
AU  - Chihara Y
FAU - Umemoto, Eiji
AU  - Umemoto E
FAU - Tanaka, Toshiyuki
AU  - Tanaka T
FAU - Miyasaka, Masayuki
AU  - Miyasaka M
FAU - Rakugi, Hiromi
AU  - Rakugi H
FAU - Ogihara, Toshio
AU  - Ogihara T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070112
PL  - England
TA  - FEBS Lett
JT  - FEBS letters
JID - 0155157
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (NF-kappa B)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Monoclonal/pharmacology
MH  - Aspirin/*pharmacology
MH  - Atherosclerosis/prevention & control
MH  - Cell Adhesion/*drug effects
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Humans
MH  - In Vitro Techniques
MH  - Intercellular Adhesion Molecule-1/physiology
MH  - Jurkat Cells
MH  - Muscle, Smooth, Vascular/cytology/*drug effects/physiology
MH  - Myocytes, Smooth Muscle/cytology/*drug effects/physiology
MH  - NF-kappa B/metabolism
MH  - T-Lymphocytes/cytology/*drug effects/physiology
MH  - Vascular Cell Adhesion Molecule-1/physiology
EDAT- 2007/01/24 09:00
MHDA- 2007/03/14 09:00
CRDT- 2007/01/24 09:00
PHST- 2006/11/24 00:00 [received]
PHST- 2006/12/21 00:00 [revised]
PHST- 2006/12/22 00:00 [accepted]
PHST- 2007/01/24 09:00 [pubmed]
PHST- 2007/03/14 09:00 [medline]
PHST- 2007/01/24 09:00 [entrez]
AID - S0014-5793(07)00021-X [pii]
AID - 10.1016/j.febslet.2006.12.052 [doi]
PST - ppublish
SO  - FEBS Lett. 2007 Feb 6;581(3):427-32. doi: 10.1016/j.febslet.2006.12.052. Epub 
      2007 Jan 12.

PMID- 2035005
OWN - NLM
STAT- MEDLINE
DCOM- 19910627
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 121
IP  - 14
DP  - 1991 Apr 6
TI  - [Thrombolysis in acute myocardial infarct. An established therapy with open 
      questions].
PG  - 493-500
AB  - Intravenous thrombolysis is an established form of therapy within the first 4-6 
      hours of acute myocardial infarction. In numerous randomized controlled trials it 
      has been shown to be effective in restoring myocardial perfusion, reducing 
      mortality and improving ventricular function. The data so far available do not 
      allow conclusions regarding the best lytic substance. The complication rate is 
      surprisingly low. As adjunctive therapy, aspirin exerts an additive effect and 
      heparin should be given for the first 48 hours. Its exact role is still under 
      investigation. Several ongoing studies are designed to answer the remaining 
      questions: (1.) Which patients with symptoms of more than 6 hours' duration could 
      benefit from thrombolysis? (2.) Should patients with unstable angina be given 
      this treatment? (3.) To minimize delay, it might be beneficial to start 
      thrombolysis in the prehospital phase, but the problems of information and 
      organization need to be solved. (4.) Attempts are being made to further improve 
      thrombolytic and adjunctive therapy.
FAU - Baumann, P C
AU  - Baumann PC
AD  - Departement für Innere Medizin, Universitätsspital Zürich.
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Thrombolyse beim akuten Myokardinfarkt. Eine etablierte Therapie mit offenen 
      Fragen.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Myocardial Reperfusion
MH  - *Thrombolytic Therapy/adverse effects
MH  - Time Factors
RF  - 52
EDAT- 1991/04/06 00:00
MHDA- 1991/04/06 00:01
CRDT- 1991/04/06 00:00
PHST- 1991/04/06 00:00 [pubmed]
PHST- 1991/04/06 00:01 [medline]
PHST- 1991/04/06 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1991 Apr 6;121(14):493-500.

PMID- 7775710
OWN - NLM
STAT- MEDLINE
DCOM- 19950713
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 25
IP  - 7 Suppl
DP  - 1995 Jun
TI  - Antithrombotic therapy for acute myocardial infarction.
PG  - 23S-29S
AB  - Antithrombotic therapy is clearly beneficial in the treatment of acute myocardial 
      infarction, but the optimal regimen is controversial. Treatment with aspirin 
      leads to substantial and significant reductions in rates of mortality, 
      reinfarction and stroke in patients with acute myocardial infarction, and the 
      benefits are additive with those of thrombolytic therapy. It is unclear whether 
      heparin confers additional net benefits over aspirin alone. In patients receiving 
      aspirin and thrombolytic therapy, there is no mortality benefit from adding 
      delayed subcutaneous heparin, no consistent patency benefit from adding immediate 
      intravenous heparin and no reduction in mortality from adding immediate 
      intravenous heparin, at least for patients treated with streptokinase. However, 
      heparin is consistently associated with increased rates of intracranial and other 
      serious bleeding events when used with both aspirin and thrombolytic therapy. 
      Existing data support the need for further large-scale trials of current and 
      newer antithrombotic regimens in acute myocardial infarction to assess the 
      balance of benefits and risks of these regimens compared with that for aspirin 
      alone. In patients not receiving thrombolytic therapy, randomized trial data are 
      currently insufficient to adequately compare the benefits and risks of adding 
      heparin to aspirin alone. The First American Study of Infarct Survival (ASIS-1) 
      will directly compare the balance of risks and benefits of aspirin alone, aspirin 
      plus intravenous heparin and aspirin plus intravenous hirudin in patients with 
      acute myocardial infarction not receiving thrombolytic therapy.
FAU - O'Donnell, C J
AU  - O'Donnell CJ
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 
      02215, USA.
FAU - Ridker, P M
AU  - Ridker PM
FAU - Hebert, P R
AU  - Hebert PR
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/therapeutic use
MH  - Heparin/therapeutic use
MH  - Hirudin Therapy
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - *Thrombolytic Therapy
RF  - 36
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
AID - 0735-1097(95)00105-D [pii]
AID - 10.1016/0735-1097(95)00105-d [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1995 Jun;25(7 Suppl):23S-29S. doi: 
      10.1016/0735-1097(95)00105-d.

PMID- 8087259
OWN - NLM
STAT- MEDLINE
DCOM- 19941020
LR  - 20131121
IS  - 0966-8519 (Print)
IS  - 0966-8519 (Linking)
VI  - 3
IP  - 3
DP  - 1994 May
TI  - Acute coronary embolism complicating aortic valve endocarditis treated with 
      streptokinase and aspirin. A case report.
PG  - 245-6
AB  - Bacterial endocarditis may present with acute chest pain due to coronary 
      embolization and mimics acute myocardial infarction secondary to coronary 
      atherosclerosis. We present the first case report of coronary embolization 
      secondary to aortic valve endocarditis treated with standard doses of 
      streptokinase and aspirin. The patient survived but sustained a large myocardial 
      infarction and a major gastrointestinal bleed. Infective endocarditis should be 
      considered in all patients presenting with acute chest pain. When myocardial 
      infarction is due to coronary embolism from endocarditic valves standard 
      thrombolysis regimes should be avoided.
FAU - Connolly, D L
AU  - Connolly DL
AD  - Department of Cardiology, Papworth Hospital, Cambridge, United Kingdom.
FAU - Dardas, P S
AU  - Dardas PS
FAU - Crowley, J J
AU  - Crowley JJ
FAU - Kenny, A
AU  - Kenny A
FAU - Petch, M C
AU  - Petch MC
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Heart Valve Dis
JT  - The Journal of heart valve disease
JID - 9312096
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aortic Valve
MH  - Aspirin/adverse effects/therapeutic use
MH  - Embolism/etiology
MH  - Endocarditis, Bacterial/*complications
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Heart Valve Diseases/complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/*etiology
MH  - Streptococcal Infections/complications
MH  - Streptokinase/adverse effects/therapeutic use
MH  - *Thrombolytic Therapy/adverse effects
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
PST - ppublish
SO  - J Heart Valve Dis. 1994 May;3(3):245-6.

PMID- 23639707
OWN - NLM
STAT- MEDLINE
DCOM- 20131118
LR  - 20131121
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 33
IP  - 2
DP  - 2013 May
TI  - Genetics of hypersensitivity to aspirin and nonsteroidal anti-inflammatory drugs.
PG  - 177-94
LID - S0889-8561(12)00114-2 [pii]
LID - 10.1016/j.iac.2012.10.003 [doi]
AB  - Various hypersensitivity reactions have been reported with aspirin and 
      nonsteroidal anti-inflammatory drugs. Hypersensitivity can occur regardless of a 
      chemical drug structure or its therapeutic potency. Allergic conditions include 
      aspirin-exacerbated respiratory disease (AERD or aspirin-induced asthma), 
      aspirin-induced urticaria/angioedema (AIU), and anaphylaxis. Several genetic 
      studies on aspirin hypersensitivity have been performed to discover the genetic 
      predisposition to aspirin hypersensitivity and to gain insight into the 
      phenotypic diversity. This article updates data on the genetic mechanisms that 
      govern AERD and AIU and summarizes recent findings on the molecular genetic 
      mechanism of aspirin hypersensitivity.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Kim, Seung-Hyun
AU  - Kim SH
AD  - Department of Allergy & Clinical Immunology, Ajou University School of Medicine, 
      Youngtonggu, Suwon, Republic of Korea.
FAU - Sanak, Marek
AU  - Sanak M
FAU - Park, Hae-Sim
AU  - Park HS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20121031
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Drug Hypersensitivity/*genetics/immunology
MH  - Humans
EDAT- 2013/05/04 06:00
MHDA- 2013/11/19 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/05/04 06:00 [entrez]
PHST- 2013/05/04 06:00 [pubmed]
PHST- 2013/11/19 06:00 [medline]
AID - S0889-8561(12)00114-2 [pii]
AID - 10.1016/j.iac.2012.10.003 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2013 May;33(2):177-94. doi: 
      10.1016/j.iac.2012.10.003. Epub 2012 Oct 31.

PMID- 7128192
OWN - NLM
STAT- MEDLINE
DCOM- 19821216
LR  - 20190909
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 8
IP  - 3
DP  - 1982
TI  - Night-time indomethacin in rheumatoid arthritis.
PG  - 197-9
AB  - Indomethacin is commonly prescribed at night to relieve morning stiffness in 
      patients with rheumatoid arthritis. Pharmacokinetic and pharmacodynamic 
      interactions are frequently described with non-steroidal anti-inflammatory drugs, 
      and the rationale of using more than one of these agents at the same time is 
      questionable. A randomized crossover trial was carried out in 14 patients to 
      compare the effects of 100 mg indomethacin at night with those of placebo when 
      added to a baseline regimen of stabilized salicylate therapy with a slow-release 
      preparation. Each treatment was given for 2 weeks. The results suggest that the 
      addition of indomethacin produced no significant benefit in terms of reduction in 
      the duration of morning stiffness or on the overall daily pain score.
FAU - Carr, G
AU  - Carr G
FAU - Dougan, M
AU  - Dougan M
FAU - Brooks, P M
AU  - Brooks PM
FAU - Maycock, S
AU  - Maycock S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Delayed-Action Preparations)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage
MH  - Delayed-Action Preparations
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Indomethacin/*therapeutic use
MH  - Middle Aged
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1185/03007998209112383 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1982;8(3):197-9. doi: 10.1185/03007998209112383.

PMID- 35657357
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220608
IS  - 1538-9766 (Electronic)
IS  - 1042-895X (Linking)
VI  - 45
IP  - 3
DP  - 2022 May-Jun 01
TI  - The American College of Gastroenterology's 2021 Colorectal Cancer Screening 
      Guidelines: A Summary for Gastroenterology Nurses & Associates.
PG  - 184-187
LID - 10.1097/SGA.0000000000000638 [doi]
AB  - Colorectal cancer ranks third for both men and women as the most common cause of 
      cancer death in the United States. Screening allows for removal of polyps before 
      they turn to cancer or by identifying early-stage colorectal cancers, which are 
      most treatable. The American College of Gastroenterology recently released an 
      update of their 2009 recommendations, which includes average risk individuals 
      between ages 45 and 49 years due to the increased incidence of early-onset 
      colorectal cancers. They consider screening two types of screening options: (1) 
      one-step colonoscopy, which is both diagnostic and therapeutic and (2) two-step 
      options, all of which require a follow-up colonoscopy when the first step is 
      positive. They added the recommendation of daily aspirin for some people aged 50 
      to 69 years. However, the recommendations for screening remain the same when 
      people do take aspirin. They recommend endoscopists measure cecal intubation 
      rates, adenoma detection rates, and withdrawal times to reduce postcolonoscopy 
      cancers due to missed lesions. They also propose strategies to promote screening 
      adherence and suggest health systems adopt them. These are important updates of 
      which the gastroenterology nurse should be aware and assist with their 
      implementation.
CI  - Copyright © 2022 Society of Gastroenterology Nurses and Associates.
FAU - Morrow, Linda
AU  - Morrow L
AD  - Linda Morrow, DNP, MSN, MBA, NE-BC, CPHQ, CNOR, RN, is Program Director, Nursing 
      Management and Executive Leadership, Clinical Associate Professor of Nursing, Dr. 
      Susan L. Davis & Richard J. Henley College of Nursing, Sacred Heart University, 
      Fairfield, Connecticut.
AD  - Beverly Greenwald, PhD, MSN, APRN, FNP-BC, NP-C, CGRN, RN, is Professor of 
      Nursing, Department of Nursing, Archer College of Health and Human Services, 
      Angelo State University, San Angelo, Texas.
FAU - Greenwald, Beverly
AU  - Greenwald B
AD  - Linda Morrow, DNP, MSN, MBA, NE-BC, CPHQ, CNOR, RN, is Program Director, Nursing 
      Management and Executive Leadership, Clinical Associate Professor of Nursing, Dr. 
      Susan L. Davis & Richard J. Henley College of Nursing, Sacred Heart University, 
      Fairfield, Connecticut.
AD  - Beverly Greenwald, PhD, MSN, APRN, FNP-BC, NP-C, CGRN, RN, is Professor of 
      Nursing, Department of Nursing, Archer College of Health and Human Services, 
      Angelo State University, San Angelo, Texas.
LA  - eng
PT  - Journal Article
DEP - 20220228
PL  - United States
TA  - Gastroenterol Nurs
JT  - Gastroenterology nursing : the official journal of the Society of 
      Gastroenterology Nurses and Associates
JID - 8915377
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/therapeutic use
MH  - Cecum
MH  - Colonoscopy
MH  - *Colorectal Neoplasms/prevention & control
MH  - Early Detection of Cancer
MH  - Female
MH  - *Gastroenterology
MH  - Humans
MH  - Male
MH  - Mass Screening
MH  - United States
COIS- The authors declare no conflicts of interest.
EDAT- 2022/06/04 06:00
MHDA- 2022/06/09 06:00
CRDT- 2022/06/03 10:43
PHST- 2021/04/02 00:00 [received]
PHST- 2021/07/28 00:00 [accepted]
PHST- 2022/06/03 10:43 [entrez]
PHST- 2022/06/04 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
AID - 00001610-202205000-00006 [pii]
AID - 10.1097/SGA.0000000000000638 [doi]
PST - ppublish
SO  - Gastroenterol Nurs. 2022 May-Jun 01;45(3):184-187. doi: 
      10.1097/SGA.0000000000000638. Epub 2022 Feb 28.

PMID- 15667550
OWN - NLM
STAT- MEDLINE
DCOM- 20050808
LR  - 20131121
IS  - 1443-9611 (Print)
IS  - 1443-9573 (Linking)
VI  - 6
IP  - 1
DP  - 2005
TI  - Should we eradicate Helicobacter pylori infection in patients receiving 
      nonsteroidal anti-inflammatory drugs or low-dose aspirin?
PG  - 1-5
AB  - Whether Helicobacter pylori infection alters the risk of ulcer disease in 
      patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs) or low-dose 
      aspirin is one of the most controversial topics in peptic ulcer research. This is 
      an important management issue, particularly in countries where peptic ulcer 
      disease is common and the prevalence of H. pylori infection is high. Current 
      evidence shows that H. pylori infection increases the ulcer risk associated with 
      NSAIDs or low-dose aspirin. Eradication of H. pylori reduces the subsequent risk 
      of endoscopic and complicated ulcers in patients who are about to start long-term 
      NSAIDs. Among patients with H. pylori infection and a history of ulcer bleeding 
      who continue to use low-dose aspirin, 1 week of eradication therapy prevents 
      recurrent ulcer bleeding. Failure of eradication and concomitant use of NSAIDs, 
      however, account for most cases of recurrent bleeding with low-dose aspirin. The 
      apparent protective effect of H. pylori in long-term NSAIDs users reported in 
      some studies was actually the weeding out of susceptible patients who were 
      intolerant to NSAIDs. There is no convincing evidence that eradication of H. 
      pylori has any clinically important adverse effect on the healing and prevention 
      of ulcers in NSAIDs users.
FAU - Chan, Francis K L
AU  - Chan FK
AD  - Division of Gastroenterology & Hepatology, Department of Medicine & Therapeutics, 
      The Chinese University of Hong Kong, Hong Kong, China. fklchan@cuhk.edu.hk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Chin J Dig Dis
JT  - Chinese journal of digestive diseases
JID - 101088612
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Helicobacter Infections/*complications/*drug therapy
MH  - Helicobacter pylori/*pathogenicity
MH  - Humans
MH  - Patient Selection
MH  - Risk Factors
MH  - Stomach Ulcer/*chemically induced/*microbiology/prevention & control
RF  - 32
EDAT- 2005/01/26 09:00
MHDA- 2005/08/09 09:00
CRDT- 2005/01/26 09:00
PHST- 2005/01/26 09:00 [pubmed]
PHST- 2005/08/09 09:00 [medline]
PHST- 2005/01/26 09:00 [entrez]
AID - CDD192 [pii]
AID - 10.1111/j.1443-9573.2005.00192.x [doi]
PST - ppublish
SO  - Chin J Dig Dis. 2005;6(1):1-5. doi: 10.1111/j.1443-9573.2005.00192.x.

PMID- 902454
OWN - NLM
STAT- MEDLINE
DCOM- 19771125
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 22
IP  - 4
DP  - 1977 Oct
TI  - Patterns of plasma concentrations and urinary excretion of salicylate in 
      rheumatoid arthritis.
PG  - 410-20
AB  - Intersubject differences in the volume of distribution, whole body clearance, and 
      steady-state plasma concentrations of salicylic acid (SA) were studied in a 
      series of patients with rheumatoid arthritis and healthy control subjects. The 
      measurement of the plasma concentration of SA 12 hr after an oral dose of 1.2 gm 
      aspirin appears predictive of the success of long-term dosage of aspirin. 
      Concentrations below 5 microgram/ml in this single-dose test were associated with 
      failure to achieve therapeutic plasma concentrations of SA (above 150 
      microgram/ml during long-term therapy with approximately 4.8 gm aspirin per day. 
      Conversely, plasma concentrations above 10 microgram/ml in the single-dose test 
      were associated with levels above 150 microgram/ml during long-term therapy. The 
      volume of distribution of SA correlated poorly with body weight (r = 0.51, p less 
      than 0.01) and did not correlate significantly with plasma albumin levels. 
      Corticosteroids appear to induce the metabolism of SA and most subjects dosed 
      with oral corticosteroids and aspirin 4.8 gm/day did not attain plasma levels of 
      SA above 150 microgram/ml. The clearance of SA was greater in male than in female 
      patients. The difference appears to be of clinical significance since fewer men 
      than women achieved therapeutic plasma concentrations of SA.
FAU - Graham, G G
AU  - Graham GG
FAU - Champion, G D
AU  - Champion GD
FAU - Day, R O
AU  - Day RO
FAU - Paull, P D
AU  - Paull PD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adrenal Cortex Hormones/pharmacology
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*metabolism
MH  - Aspirin/administration & dosage/metabolism
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - Salicylates/blood/*metabolism/urine
MH  - Sex Factors
MH  - Time Factors
EDAT- 1977/10/01 00:00
MHDA- 1977/10/01 00:01
CRDT- 1977/10/01 00:00
PHST- 1977/10/01 00:00 [pubmed]
PHST- 1977/10/01 00:01 [medline]
PHST- 1977/10/01 00:00 [entrez]
AID - 0009-9236(77)90174-6 [pii]
AID - 10.1002/cpt1977224410 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1977 Oct;22(4):410-20. doi: 10.1002/cpt1977224410.

PMID- 15953335
OWN - NLM
STAT- MEDLINE
DCOM- 20051025
LR  - 20131121
IS  - 1034-4810 (Print)
IS  - 1034-4810 (Linking)
VI  - 41
IP  - 5-6
DP  - 2005 May-Jun
TI  - Reye's syndrome developing in an infant on treatment of Kawasaki syndrome.
PG  - 303-4
AB  - Aspirin is commonly used as an anti-inflammatory therapy for Kawasaki syndrome. 
      Early initiation with high dose aspirin (80 to > 100 mg/kg per day), followed by 
      low-dose therapy at the afebrile stage, has been often used to reduce morbidity 
      and mortality in coronary complications. We report a 10-month-old infant who was 
      diagnosed with Kawasaki syndrome. Sudden onset of poor activity, poor appetite, 
      lethargy, tachycardia, tachypnea, hepatomegaly, increased AST/ALT, coagulopathy 
      and hyperammonemia developed 3 days after the high-dose aspirin therapy. His 
      histopathological and ultrastructural findings from the liver biopsy were 
      compatible with Reye's syndrome. He recovered completely, and there was no 
      recurrence.
FAU - Wei, Chih-Ming
AU  - Wei CM
AD  - Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Chen, Huey-Ling
AU  - Chen HL
FAU - Lee, Ping-Ing
AU  - Lee PI
FAU - Chen, Chong-Ming
AU  - Chen CM
FAU - Ma, Chun-Yi
AU  - Ma CY
FAU - Hwu, Wuh-Liang
AU  - Hwu WL
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Australia
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Humans
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/complications/*drug therapy
MH  - Reye Syndrome/*etiology/physiopathology
MH  - Taiwan
EDAT- 2005/06/15 09:00
MHDA- 2005/10/26 09:00
CRDT- 2005/06/15 09:00
PHST- 2005/06/15 09:00 [pubmed]
PHST- 2005/10/26 09:00 [medline]
PHST- 2005/06/15 09:00 [entrez]
AID - JPC617 [pii]
AID - 10.1111/j.1440-1754.2005.00617.x [doi]
PST - ppublish
SO  - J Paediatr Child Health. 2005 May-Jun;41(5-6):303-4. doi: 
      10.1111/j.1440-1754.2005.00617.x.

PMID- 4080802
OWN - NLM
STAT- MEDLINE
DCOM- 19860207
LR  - 20141120
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 40
IP  - 8
DP  - 1985 Aug
TI  - Effect of certain additives on the diffusion characteristics through a cellophane 
      membrane of acetylsalicylic acid, salicylamide and phenacetin. Part 1: Effect of 
      certain surface active agents.
PG  - 557-8
AB  - The diffusion rate (D. R.) of certain ionic and non-ionic surfactant 
      concentrations through a standard cellophane membrane was studied. D. R. of 
      acetylsalicylic acid significantly increased in the presence of 0.1% w/v Brij 35, 
      Tween 20 or 40 respectively. The other tested surfactants slightly increased D. 
      R. of acetylsalicylic acid, while that of salicylamide increased in presence of 
      0.1% w/v of either Tween 20, 40, 60 or 80; Myrj 52 or 59; Brij 58; benzalkonium 
      chloride, cetrimide or sodium lauryl sulphate. The highest D. R. of phenacetin 
      was observed in presence of either 0.01% w/v Tween 20 or 0.001% w/v Brij 35.
FAU - el-Sourady, H A
AU  - el-Sourady HA
FAU - Habib, F S
AU  - Habib FS
FAU - Mohamed, S I
AU  - Mohamed SI
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Analgesics)
RN  - 0 (Excipients)
RN  - 0 (Membranes, Artificial)
RN  - 0 (Salicylamides)
RN  - 0 (Surface-Active Agents)
RN  - 9005-81-6 (Cellophane)
RN  - EM8BM710ZC (salicylamide)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/*analysis
MH  - Aspirin/analysis
MH  - *Cellophane
MH  - Chemistry, Pharmaceutical
MH  - Diffusion
MH  - Excipients
MH  - Kinetics
MH  - Membranes, Artificial
MH  - Phenacetin/analysis
MH  - Salicylamides/analysis
MH  - Surface-Active Agents/*pharmacology
EDAT- 1985/08/01 00:00
MHDA- 1985/08/01 00:01
CRDT- 1985/08/01 00:00
PHST- 1985/08/01 00:00 [pubmed]
PHST- 1985/08/01 00:01 [medline]
PHST- 1985/08/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1985 Aug;40(8):557-8.

PMID- 6973990
OWN - NLM
STAT- MEDLINE
DCOM- 19811014
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 31
IP  - 5a
DP  - 1981
TI  - Antipyretic activity of fluproquazone in man.
PG  - 934-5
AB  - A multicentric, double-blind, randomized, parallel-group study was performed in 
      patients with fever of diverse origin to test the tolerance and the antipyretic 
      activity of single oral doses of 
      4-(p-fluorophenyl)-1-isopropyl-7-methyl-2(1H)-quinazolinone (fluproquazone) (200 
      mg, n = 18), acetylsalicylic acid (ASA) (1000 mg, n = 22) and placebo (n = 19). 
      Whereas with placebo mean rectal temperature remained constant, a continuous fall 
      was recorded with both active medications over the whole 3-h study period. With 
      fluproquazone normalization of body temperature was nearly reached. Fluproquazone 
      was more effective than placebo (p less than 0.001) and ASA (p less than 0.1), 
      which in turn was more active than placebo (p less than 0.0001). No specific 
      side-effects occurred.
FAU - Fankhauser, S
AU  - Fankhauser S
FAU - Laube, W
AU  - Laube W
FAU - Marti, H R
AU  - Marti HR
FAU - Schultheiss, H R
AU  - Schultheiss HR
FAU - Vögtlin, J
AU  - Vögtlin J
FAU - von Graffenried, B
AU  - von Graffenried B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Quinazolines)
RN  - 0 (Quinazolinones)
RN  - R16CO5Y76E (Aspirin)
RN  - U4K85O58HD (fluproquazone)
SB  - IM
MH  - Adult
MH  - *Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/therapeutic use
MH  - Body Temperature
MH  - Female
MH  - Fever/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Quinazolines/*therapeutic use
MH  - Quinazolinones
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1981;31(5a):934-5.

PMID- 728321
OWN - NLM
STAT- MEDLINE
DCOM- 19790313
LR  - 20190509
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 6
IP  - 6
DP  - 1978 Dec
TI  - Evaluation of effect of acetylsalicylic acid using electrical stimulation on the 
      forefinger of healthy volunteers.
PG  - 521-4
AB  - 1 In order to determine the optimal level of electrical stimulation, the degree 
      of pain sensitivity produced by electrical stimulation on the volar side of 
      terminal phalange of the right forefinger was studied in 22 male and female 
      volunteers between the ages of 20 and 27 years. 2 A stimulation frequency of 400 
      Hz, width of 0.1 ms and electrical potential of 55 V was found to be optimal for 
      study fo analgesics. 3 The effect of acetylsalicylic acid was studied in 40 
      healthy male volunteers between the ages of 20 and 25 years. Electrical 
      stimulation was applied for 5 s under a single-blind method at a frequency of 400 
      Hz, width of 0.1 ms and electrical potential of 25, 35 and 55 V. Placebo, 250 mg, 
      500 mg and 1 000 mg of acetylsalicyclic acid were administered orally under 
      double-blind method conditions. 4 As a result of this study, it was found that 
      acetslsalicylic acid in a dose of 500 and 1 000 mg, was effective in relieving 
      pain with statistically significant differences from a placebo.
FAU - Seki, T
AU  - Seki T
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Double-Blind Method
MH  - Electric Stimulation
MH  - Female
MH  - Fingers/physiology
MH  - Humans
MH  - Male
MH  - Pain/*physiopathology
MH  - Placebos
MH  - Time Factors
PMC - PMC1429705
EDAT- 1978/12/01 00:00
MHDA- 1978/12/01 00:01
CRDT- 1978/12/01 00:00
PHST- 1978/12/01 00:00 [pubmed]
PHST- 1978/12/01 00:01 [medline]
PHST- 1978/12/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1978.tb00876.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1978 Dec;6(6):521-4. doi: 
      10.1111/j.1365-2125.1978.tb00876.x.

PMID- 32777683
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 171
DP  - 2020 Sep
TI  - Platelets in chronic obstructive pulmonary disease: An update on pathophysiology 
      and implications for antiplatelet therapy.
PG  - 106098
LID - S0954-6111(20)30238-9 [pii]
LID - 10.1016/j.rmed.2020.106098 [doi]
AB  - Platelets are essential mediators of inflammation and thrombosis. Chronic 
      obstructive pulmonary disease (COPD) is a heterogeneous multisystem disease, 
      causing significant morbidity and mortality worldwide. Recent evidence suggests 
      that the lung is an important organ for platelet biogenesis. Cigarette smoking 
      has been shown to induce platelet aggregation and decrease the capacity of 
      mitochondrial electron transport system in platelets. Preclinical and clinical 
      studies have suggested that platelets may contribute to the development of COPD 
      through the breakdown of lung elastin by platelet factor 4, platelet activation 
      and formation of platelet aggregates, and modulation of hypoxia signaling 
      pathways. Recent large population studies have produced encouraging results 
      indicating a potential role for aspirin in preventing exacerbations and delaying 
      disease progression in patients with COPD. This review summarizes the information 
      about the lung as an organ for platelet production, pathophysiological functions 
      of platelets and platelet mediators in the development of COPD, and the most 
      updated evidence on the utility of aspirin in patients with COPD.
CI  - Copyright © 2020 Elsevier Ltd. All rights reserved.
FAU - Mallah, Haneen
AU  - Mallah H
AD  - Department of Internal Medicine, Texas Tech University Health Sciences Center, 
      Lubbock, TX, USA.
FAU - Ball, Somedeb
AU  - Ball S
AD  - Department of Internal Medicine, Texas Tech University Health Sciences Center, 
      Lubbock, TX, USA. Electronic address: somedeb.ball@ttuhsc.edu.
FAU - Sekhon, Jasmine
AU  - Sekhon J
AD  - Department of Internal Medicine, Texas Tech University Health Sciences Center, 
      Lubbock, TX, USA.
FAU - Parmar, Kanak
AU  - Parmar K
AD  - Department of Internal Medicine, Texas Tech University Health Sciences Center, 
      Lubbock, TX, USA.
FAU - Nugent, Kenneth
AU  - Nugent K
AD  - Division of Pulmonary and Critical Care Medicine, Texas Tech University Health 
      Sciences Center, Lubbock, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200730
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 37270-94-3 (Platelet Factor 4)
RN  - 9007-58-3 (Elastin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Platelets/metabolism/*physiology
MH  - Disease Progression
MH  - Elastin/metabolism
MH  - Electron Transport
MH  - Humans
MH  - Inflammation
MH  - Lung/cytology/metabolism
MH  - Megakaryocytes
MH  - Mitochondria/metabolism
MH  - Mitochondrial Diseases
MH  - *Platelet Activation
MH  - *Platelet Aggregation
MH  - *Platelet Aggregation Inhibitors
MH  - Platelet Factor 4/physiology
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy/*etiology
MH  - Smoking/adverse effects
MH  - Thrombosis
OTO - NOTNLM
OT  - Aspirin
OT  - COPD
OT  - Emphysema
OT  - Hypoxia
OT  - Megakaryocytes
OT  - Platelet aggregates
EDAT- 2020/08/11 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/04/12 00:00 [received]
PHST- 2020/06/14 00:00 [revised]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - S0954-6111(20)30238-9 [pii]
AID - 10.1016/j.rmed.2020.106098 [doi]
PST - ppublish
SO  - Respir Med. 2020 Sep;171:106098. doi: 10.1016/j.rmed.2020.106098. Epub 2020 Jul 
      30.

PMID- 25521726
OWN - NLM
STAT- MEDLINE
DCOM- 20150810
LR  - 20220409
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 29 Suppl 4
DP  - 2014 Dec
TI  - Comparison of teprenone and famotidine against gastroduodenal mucosal damage in 
      patients taking low-dose aspirin.
PG  - 11-5
LID - 10.1111/jgh.12768 [doi]
AB  - BACKGROUND AND AIM: Proton-pump inhibitors are known to be effective in the 
      treatment and prevention of ulcers related to low-dose aspirin (LDA), but few 
      reports address H2 -receptor antagonists (H2RAs) and gastroprotective agents 
      (GPs). This study was intended to compare the therapeutic effects of an H2RA and 
      a GP against gastroduodenal mucosal injuries in patients taking LDA. METHODS: The 
      subjects consisted of patients requiring continuous LDA treatment, in whom no 
      peptic ulcer was found on endoscopy at enrollment. The patients were randomized 
      to either famotidine 20 mg/day (group F) or teprenone 150 mg/day (group T). The 
      study medication was administered for 12 weeks. The patients underwent endoscopy 
      after administration of the study medication in order to obtain a Lanza score. 
      RESULTS: A total of 66 patients (38 in group F, 28 in group T) were included in 
      the efficacy analysis population. The Lanza score changed as follows: in group F, 
      it improved significantly, from 0.89±1.03 (mean±standard deviation) before 
      medication to 0.39±0.75 after medication (P=0.006); in group T, no significant 
      difference was observed: 0.75±0.93 before medication and 0.68±0.82 after 
      medication. CONCLUSION: Famotidine is better than teprenone in terms of reducing 
      the number of the erosions under use of LDA.
CI  - © 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing 
      Asia Pty Ltd.
FAU - Takeuchi, Toshihisa
AU  - Takeuchi T
AD  - 2nd Department of Internal Medicine, Osaka Medical College, Osaka, Japan.
FAU - Ota, Kazuhiro
AU  - Ota K
FAU - Harada, Satoshi
AU  - Harada S
FAU - Kojima, Yuichi
AU  - Kojima Y
FAU - Inoue, Takuya
AU  - Inoue T
FAU - Iwakiri, Ryuichi
AU  - Iwakiri R
FAU - Sakata, Yasuhisa
AU  - Sakata Y
FAU - Fujimoto, Kazuma
AU  - Fujimoto K
FAU - Fujita, Tsuyoshi
AU  - Fujita T
FAU - Azuma, Takeshi
AU  - Azuma T
FAU - Higuchi, Kazuhide
AU  - Higuchi K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Diterpenes)
RN  - 0 (Histamine H2 Antagonists)
RN  - 5QZO15J2Z8 (Famotidine)
RN  - R16CO5Y76E (Aspirin)
RN  - S8S8451A4O (geranylgeranylacetone)
SB  - IM
MH  - Aged
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Diterpenes/*administration & dosage
MH  - Famotidine/*administration & dosage
MH  - Female
MH  - Histamine H2 Antagonists/*administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*chemically induced/*drug therapy/pathology/prevention & control
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - famotidine
OT  - gastroduodenal injury
OT  - low-dose aspirin
OT  - teprenone
EDAT- 2014/12/19 06:00
MHDA- 2015/08/11 06:00
CRDT- 2014/12/19 06:00
PHST- 2014/12/19 06:00 [entrez]
PHST- 2014/12/19 06:00 [pubmed]
PHST- 2015/08/11 06:00 [medline]
AID - 10.1111/jgh.12768 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2014 Dec;29 Suppl 4:11-5. doi: 10.1111/jgh.12768.

PMID- 10910377
OWN - NLM
STAT- MEDLINE
DCOM- 20000803
LR  - 20190717
IS  - 0002-9629 (Print)
IS  - 0002-9629 (Linking)
VI  - 320
IP  - 1
DP  - 2000 Jul
TI  - An uncommon case of fluid retention simulating a congestive heart failure after 
      aspirin consumption.
PG  - 72-4
AB  - Nonsteroidal anti-inflammatory drugs are widely used and relatively safe 
      medications. We report here an uncommon case of fluid retention simulating acute 
      congestive heart failure, secondary to aspirin consumption, promptly reversible 
      after discontinuation of therapy, and triggered again by pharmacological 
      challenge test.
FAU - Manfredini, R
AU  - Manfredini R
AD  - First Institute of Internal Medicine, Department of Clinical and Experimental 
      Medicine, University of Ferrara School of Medicine, Italy. mfr@unife.it
FAU - Ricci, L
AU  - Ricci L
FAU - Giganti, M
AU  - Giganti M
FAU - La Cecilia, O
AU  - La Cecilia O
FAU - Kuwornu Afi, H
AU  - Kuwornu Afi H
FAU - Chierici, F
AU  - Chierici F
FAU - Gallerani, M
AU  - Gallerani M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Heart Failure/*chemically induced
MH  - Humans
MH  - Water-Electrolyte Imbalance/*chemically induced
EDAT- 2000/07/26 11:00
MHDA- 2000/08/06 11:00
CRDT- 2000/07/26 11:00
PHST- 2000/07/26 11:00 [pubmed]
PHST- 2000/08/06 11:00 [medline]
PHST- 2000/07/26 11:00 [entrez]
AID - S0002-9629(15)40801-8 [pii]
AID - 10.1097/00000441-200007000-00012 [doi]
PST - ppublish
SO  - Am J Med Sci. 2000 Jul;320(1):72-4. doi: 10.1097/00000441-200007000-00012.

PMID- 7462305
OWN - NLM
STAT- MEDLINE
DCOM- 19810424
LR  - 20161026
IS  - 0021-9509 (Print)
IS  - 0021-9509 (Linking)
VI  - 21
IP  - 6
DP  - 1980 Nov-Dec
TI  - Lillehei-Kaster prosthesis in the aortic position with and without 
      anticoagulants.
PG  - 669-74
AB  - Sixty-two patients after aortic valve replacement were given aspirin in place of 
      anticoagulants post operatively. This group is compared with another of 125 
      patients receiving anticoagulants. In the former group there was one instance of 
      valve thrombosis, five of transient embolic episodes and six late deaths. In the 
      latter group there were two instances of valve thrombosis--both occurring when 
      the anticoagulation was inadequate, one embolic episode and six late deaths. 
      Anticoagulant therapy is recommended for all patients with the Lillehei-Kaster 
      prosthesis. However, where anticoagulants cannot be used control with aspirin is 
      nearly as effective, but with a somewhat higher risk. Long-term results with 
      Lillehei-Kaster valves as regards survival and thromboembolism compare favourably 
      with all contemporary mechanical prostheses and porcine heterografts.
FAU - Thevenet, A
AU  - Thevenet A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Italy
TA  - J Cardiovasc Surg (Torino)
JT  - The Journal of cardiovascular surgery
JID - 0066127
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - *Aortic Valve
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - *Heart Valve Prosthesis/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Care
MH  - Postoperative Complications/prevention & control
MH  - Thromboembolism/prevention & control
EDAT- 1980/11/01 00:00
MHDA- 1980/11/01 00:01
CRDT- 1980/11/01 00:00
PHST- 1980/11/01 00:00 [pubmed]
PHST- 1980/11/01 00:01 [medline]
PHST- 1980/11/01 00:00 [entrez]
PST - ppublish
SO  - J Cardiovasc Surg (Torino). 1980 Nov-Dec;21(6):669-74.

PMID- 32570670
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20200819
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 270
DP  - 2020 Jun 16
TI  - Safety and Drugs: How Do We Record Medication Consumption and Prescription in 
      Electronic Medical Records? A Look on Aspirin.
PG  - 1383-1384
LID - 10.3233/SHTI200453 [doi]
AB  - BACKGROUND: documentation of aspirin consumption is usually not complete and 
      clear, probably because it's a cheap drug that can be easily acquired. OBJECTIVE: 
      To evaluate the quality of the record of aspirin consumption documented in the 
      electronic medical records (EMRs) of a Private University Hospital of Argentina. 
      DESIGN: Qualitative and quantitative descriptive exploratory study. RESULTS: 
      principal findings were that 86 % of the notes mentioned aspirin as a chronic 
      prescription. 12% mentioned its temporary suspension. Numerous EMRs mentioned the 
      use of an "antiplatelet" drug without specifying which, and didn't specify 
      abbreviations, consumed dose or when to start or stop aspirin. CONCLUSIONS: 
      overall quality of aspirin related information registration in EMRs was poor. 
      This is concerning since it's a frequently prescribed drug, not exempt from 
      adverse events.
FAU - Volpi, Mercedes
AU  - Volpi M
AD  - Family and Community Medicine Division, Hospital Italiano, Buenos Aires, 
      Argentina.
FAU - Esteban, Santiago
AU  - Esteban S
AD  - Family and Community Medicine Division, Hospital Italiano, Buenos Aires, 
      Argentina.
FAU - Terrasa, Sergio
AU  - Terrasa S
AD  - Family and Community Medicine Division, Hospital Italiano, Buenos Aires, 
      Argentina.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
RN  - R16CO5Y76E (Aspirin)
MH  - Argentina
MH  - Aspirin
MH  - Documentation
MH  - *Electronic Health Records
MH  - Prescriptions
OTO - NOTNLM
OT  - Aspirin
OT  - EMR
OT  - consumption
OT  - record
EDAT- 2020/06/24 06:00
MHDA- 2020/08/20 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
AID - SHTI200453 [pii]
AID - 10.3233/SHTI200453 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Jun 16;270:1383-1384. doi: 10.3233/SHTI200453.

PMID- 27868071
OWN - NLM
STAT- MEDLINE
DCOM- 20170518
LR  - 20190723
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2016
DP  - 2016
TI  - Mean Daily Dosage of Aspirin and the Risk of Incident Alzheimer's Dementia in 
      Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study 
      in Taiwan.
PG  - 9027484
LID - 9027484
AB  - Background. Type 2 diabetes mellitus patients are known to have higher risk of 
      developing dementia while aspirin use has been shown to prevent incident 
      dementia. This study was conducted to evaluate the potential benefits of aspirin 
      use on dementia in patients with type 2 diabetes mellitus and identify the 
      appropriate dosage of aspirin that provides the most benefit. Method. A Taiwan 
      nationwide, population-based retrospective 8-year study was employed to analyze 
      the association between the use of aspirin and incidence of dementia including 
      Alzheimer's disease and non-Alzheimer's dementia using multivariate 
      Cox-proportional hazards regression model and adjusting for several potential 
      confounders. Results. Regular aspirin use in mean daily dosage of within 40 mg 
      was associated with a decreased risk of developing incident Alzheimer's dementia 
      in patients with type 2 diabetes mellitus (adjusted HR of 0.51 with 95% CI of 
      0.27-0.97, p value 0.041). Conclusion. A mean daily dosage of aspirin use within 
      40 mg might decrease the risk of developing Alzheimer's disease in patients with 
      type 2 diabetes mellitus.
FAU - Chang, Cheng-Wei
AU  - Chang CW
AUID- ORCID: 0000-0002-8103-4995
AD  - Department of Endocrinology and Metabolism, Tungs' Taichung MetroHarbor Hospital, 
      Taichung 435, Taiwan; Department of Information Management, Hsing Wu University, 
      New Taipei City, Taiwan.
FAU - Horng, Jorng-Tzong
AU  - Horng JT
AD  - Department of Biomedical Informatics, Asia University, Taichung 413, Taiwan; 
      Department of Computer Science and Information Engineering, National Central 
      University, Chungli, Taiwan.
FAU - Hsu, Chi-Chang
AU  - Hsu CC
AD  - Department of Computer Science and Information Engineering, National Central 
      University, Chungli, Taiwan.
FAU - Chen, Jui-Ming
AU  - Chen JM
AUID- ORCID: 0000-0003-4198-4192
AD  - Department of Endocrinology and Metabolism, Tungs' Taichung MetroHarbor Hospital, 
      Taichung 435, Taiwan; Department of Biomedical Informatics, Asia University, 
      Taichung 413, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20161027
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Protective Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*epidemiology/etiology/prevention & control
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Protective Agents/*administration & dosage/therapeutic use
MH  - Retrospective Studies
MH  - Risk
MH  - Taiwan/epidemiology
PMC - PMC5102734
EDAT- 2016/11/22 06:00
MHDA- 2017/05/19 06:00
CRDT- 2016/11/22 06:00
PHST- 2016/07/11 00:00 [received]
PHST- 2016/09/29 00:00 [accepted]
PHST- 2016/11/22 06:00 [entrez]
PHST- 2016/11/22 06:00 [pubmed]
PHST- 2017/05/19 06:00 [medline]
AID - 10.1155/2016/9027484 [doi]
PST - ppublish
SO  - J Diabetes Res. 2016;2016:9027484. doi: 10.1155/2016/9027484. Epub 2016 Oct 27.

PMID- 1874875
OWN - NLM
STAT- MEDLINE
DCOM- 19910924
LR  - 20190629
VI  - 565
IP  - 1-2
DP  - 1991 Apr 19
TI  - Novel direct high-performance liquid chromatographic method for determination of 
      salicylate glucuronide conjugates in human urine.
PG  - 309-20
AB  - A novel direct high-performance liquid chromatographic (HPLC) assay for the 
      simultaneous determination of three salicylate glucuronide conjugates and other 
      salicylate metabolites in human urine has been developed. Salicylate glucuronide 
      conjugates were purified by HPLC from the urine of a volunteer after oral 
      administration of aspirin and identified by selective hydrolysis with 
      beta-glucuronidase and with sodium hydroxide. This method gave high 
      reproducibility with coefficients of variation less than 10%. The total urinary 
      recovery of salicylic acid after a single 1.2-g dose of soluble aspirin was 
      greater than 90%. This assay has been successfully used to re-evaluate the 
      capacity-limited pharmacokinetics of salicylic acid in humans.
FAU - Shen, J J
AU  - Shen JJ
AD  - Department of Pharmacy, University of Otago Medical School, Dunedin, New Zealand.
FAU - Wanwimolruk, S
AU  - Wanwimolruk S
FAU - Roberts, M S
AU  - Roberts MS
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Chromatogr
JT  - Journal of chromatography
JID - 0427043
RN  - 0 (Glucuronates)
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 29315-53-5 (salicylacyl glucuronide)
RN  - 487-54-7 (salicylurate)
RN  - 7695-70-7 (1-salicylate glucuronide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/metabolism
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Glucuronates/*urine
MH  - Hippurates/*urine
MH  - Humans
MH  - Salicylates/metabolism/*urine
EDAT- 1991/04/19 00:00
MHDA- 1991/04/19 00:01
CRDT- 1991/04/19 00:00
PHST- 1991/04/19 00:00 [pubmed]
PHST- 1991/04/19 00:01 [medline]
PHST- 1991/04/19 00:00 [entrez]
AID - 10.1016/0378-4347(91)80392-p [doi]
PST - ppublish
SO  - J Chromatogr. 1991 Apr 19;565(1-2):309-20. doi: 10.1016/0378-4347(91)80392-p.

PMID- 9444297
OWN - NLM
STAT- MEDLINE
DCOM- 19980204
LR  - 20131121
IS  - 0828-282X (Print)
IS  - 0828-282X (Linking)
VI  - 13
IP  - 12
DP  - 1997 Dec
TI  - Survey of cardiac surgeons' perceptions of the addition of ASA to warfarin for 
      patients with mechanical heart valves.
PG  - 1162-5
AB  - Evidence suggests that the addition of acetylsalicylic acid (ASA) to warfarin 
      therapy among patients with mechanical heart valves may reduce mortality, at a 
      slightly higher bleeding risk. A survey was conducted of North American cardiac 
      surgeons to assess whether they routinely use ASA in conjunction with 
      anticoagulants among such patients. From a list of 142 cardiac surgeons and 
      centres, questionnaires were successfully transmitted by fax to 137. Respondents 
      were surveyed about their prescribing habits of both warfarin and ASA among 
      patients with mechanical heart valves. Information collected included the target 
      international normalized ratio (INR) and reasons for not routinely prescribing 
      ASA, when applicable. One hundred and eighteen cardiac surgeons (86%) returned 
      the questionnaire: 75% were American and 25% Canadian. All surgeons (100%) stated 
      that they use warfarin for patients with mechanical valves, but there was little 
      consensus about the target INR. Only 25 respondents (21%) routinely used ASA in 
      conjunction with anticoagulants, while 90 (76%) said they would not. The most 
      common reason cited for withholding ASA was the perceived increased risk of 
      bleeding (49% of nonusers), while another 23% felt that there is no benefit. Of 
      the 90 surgeons who would not routinely prescribe ASA, 50 (55%) would on 
      occasion. The most commonly used dose of ASA was 80 to 100 mg daily (79%). Low 
      dose ASA, in conjunction with warfarin, is underused by North American cardiac 
      surgeons for the prevention of systemic thromboembolism among patients with 
      mechanical heart valves. Most surgeons avoid ASA out of concern for the increased 
      risk of hemorrhage and a belief that there is no benefit. These perceptions are 
      not supported by recent scientific data, however.
FAU - Ray, J G
AU  - Ray JG
AD  - Department of Medicine, McMaster University, Hamilton, Ontario. 
      rayjg@fhs.mcmaster.ca
FAU - Turpie, A G
AU  - Turpie AG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Canada
MH  - Female
MH  - *Heart Valve Prosthesis Implantation
MH  - Humans
MH  - Male
MH  - Medicine
MH  - Postoperative Care
MH  - Specialization
MH  - *Thoracic Surgery
MH  - United States
MH  - Warfarin/therapeutic use
EDAT- 1998/01/28 00:00
MHDA- 1998/01/28 00:01
CRDT- 1998/01/28 00:00
PHST- 1998/01/28 00:00 [pubmed]
PHST- 1998/01/28 00:01 [medline]
PHST- 1998/01/28 00:00 [entrez]
PST - ppublish
SO  - Can J Cardiol. 1997 Dec;13(12):1162-5.

PMID- 6800979
OWN - NLM
STAT- MEDLINE
DCOM- 19820521
LR  - 20190904
IS  - 0018-2214 (Print)
IS  - 0018-2214 (Linking)
VI  - 14
IP  - 1
DP  - 1982 Jan
TI  - Studies of platelets with heavy metal impregnation techniques.
PG  - 73-86
AB  - Various methods of heavy metal impregnations were performed on human platelets. 
      The optimal technique consisted of glutaraldehyde fixation, incubation in warm 
      uranyl acetate at a pH of 3.5, followed by a double solution of lead and copper, 
      and finally overnight immersion in cold osmium tetroxide. Semi-thin sections, 
      viewed at 90 kV, revealed three types of platelets: (1) 'reticular' cells, with a 
      prominent tubular network and very dark granules in a pale cytoplasm; (2) 'dark' 
      cells, with an electron-dense cytoplasm; and (3) 'pale' cells, with microvesicles 
      and non-staining granules. Pre-treatments with EGTA, aspirin and various platelet 
      activators altered the appearances and proportions of the three cell types. A 
      cell-partitioning two-phase polymer system showed that the sub-grouping is 
      related to surface membrane properties, the cells retained in the top phase being 
      exclusively type 2 'dark' cells. The changes in cell type distribution produced 
      by activation show that metal impregnation may be a useful method for studying 
      structure-function correlations in platelets.
FAU - Yarom, R
AU  - Yarom R
FAU - More, R
AU  - More R
FAU - Havivi, Y
AU  - Havivi Y
FAU - Lijovetzky, G
AU  - Lijovetzky G
FAU - Meyer, S
AU  - Meyer S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Histochem J
JT  - The Histochemical journal
JID - 0163161
RN  - 0 (Indicators and Reagents)
RN  - 2P299V784P (Lead)
RN  - 4OC371KSTK (Uranium)
RN  - 526U7A2651 (Egtazic Acid)
RN  - 789U1901C5 (Copper)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets/drug effects/*ultrastructure
MH  - Copper
MH  - Egtazic Acid/pharmacology
MH  - Humans
MH  - Indicators and Reagents
MH  - Lead
MH  - Microscopy, Electron
MH  - Uranium
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1007/BF01041131 [doi]
PST - ppublish
SO  - Histochem J. 1982 Jan;14(1):73-86. doi: 10.1007/BF01041131.

PMID- 8396534
OWN - NLM
STAT- MEDLINE
DCOM- 19931008
LR  - 20161123
IS  - 0903-1936 (Print)
IS  - 0903-1936 (Linking)
VI  - 6
IP  - 7
DP  - 1993 Jul
TI  - The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by 
      inhaled lysine-aspirin in aspirin-sensitive asthmatics.
PG  - 1018-26
AB  - Drugs which block the action or formation of the cysteinyl leukotrienes (LTC4, 
      LTD4 and LTE4) inhibit asthmatic responses evoked by allergen, exercise and cold 
      dry air. The purpose of this study was to determine whether the specific 
      leukotriene-receptor antagonist MK-0679 could block the airway obstruction 
      induced by aspirin (acetylsalicylic acid (ASA)) in aspirin-intolerant asthmatics. 
      Eight asthmatics (mean age 45 yrs), with an average history of asthma and 
      ASA-sensitivity of about 10 yrs duration, were subjected to bronchial provocation 
      with lysine-ASA. Baseline ASA-sensitivity was first determined in an open 
      prestudy session by inhalation of cumulative doses of lysine-ASA to establish the 
      dose of ASA decreasing forced expiratory volume in one second (FEV1) by 20% 
      (PD20). Rechallenge with lysine-ASA was performed on two different occasions, 1 h 
      after oral administration of placebo, or 750 mg of MK-0679, under double-blind 
      conditions, in a randomized, cross-over design. Leukotriene formation was 
      estimated by the measurement of urinary LTE4. The lysine-ASA challenge was highly 
      reproducible (geometric mean for group PD20 being identical for the open prestudy 
      and the placebo session), and was associated with a post-challenge increase in 
      urinary LTE4. In contrast, after MK-0679, there was a rightward shift in the dose 
      response relationship for all eight subjects (median shift being 4.4 fold), with 
      three of the subjects failing to produce a 20% decrease in FEV1 despite 
      inhalation of the highest dose of lysine-ASA feasible to deliver.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Dahlén, B
AU  - Dahlén B
AD  - Dept of Thoracic Medicine, Karolinska Hospital, Stockholm, Sweden.
FAU - Kumlin, M
AU  - Kumlin M
FAU - Margolskee, D J
AU  - Margolskee DJ
FAU - Larsson, C
AU  - Larsson C
FAU - Blomqvist, H
AU  - Blomqvist H
FAU - Williams, V C
AU  - Williams VC
FAU - Zetterström, O
AU  - Zetterström O
FAU - Dahlén, S E
AU  - Dahlén SE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Leukotriene Antagonists)
RN  - 0 (Leukotrienes)
RN  - 0 (Propionates)
RN  - 0 (Quinolines)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, Leukotriene)
RN  - 5Q9O54P0H7 (verlukast)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aspirin/*analogs & derivatives/antagonists & inhibitors
MH  - Asthma/diagnosis/*physiopathology
MH  - *Bronchial Provocation Tests
MH  - Bronchoconstriction/drug effects/physiology
MH  - Bronchodilator Agents/*pharmacology
MH  - Female
MH  - Humans
MH  - *Leukotriene Antagonists
MH  - Leukotrienes/physiology
MH  - Lysine/*analogs & derivatives/antagonists & inhibitors
MH  - Male
MH  - Middle Aged
MH  - Propionates/*pharmacology
MH  - Quinolines/*pharmacology
MH  - Receptors, Immunologic/*antagonists & inhibitors
MH  - Receptors, Leukotriene
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
PST - ppublish
SO  - Eur Respir J. 1993 Jul;6(7):1018-26.

PMID- 8319788
OWN - NLM
STAT- MEDLINE
DCOM- 19930803
LR  - 20190909
IS  - 0902-4441 (Print)
IS  - 0902-4441 (Linking)
VI  - 50
IP  - 5
DP  - 1993 May
TI  - Influence of aspirin on human megakaryocyte prostaglandin synthesis.
PG  - 264-8
AB  - To evaluate whether currently popular aspirin regimens have an effect on the 
      prostaglandin synthesis in human megakaryocytes we measured thromboxane B2 (TXB2) 
      synthesis in response to thrombin stimulation in human megakaryocytes ex vivo. 
      Human megakaryocytes were purified by Counterflow Centrifugal Elutriation from 
      bone marrow punctures, taken from volunteers before and 2 hours after ingestion 
      of one dose of 500 mg (n = 4), 80 mg (n = 4) or 40 mg (n = 2) aspirin. 
      Subsequently, megakaryocytes were purified before and 12 h after ingestion of 80 
      mg (n = 3) aspirin twice daily for 1 week and 12 h after 500 mg (n = 3) aspirin. 
      On average, 140 +/- 102 x 10(3) (mean +/- 1 SD) megakaryocytes were recovered. We 
      found that aspirin inhibits megakaryocyte cyclooxygenase in a dose-dependent 
      manner. Two hours after 500 mg of aspirin, TXB2 synthesis in megakaryocytes was 
      inhibited by 96.8 +/- 2%, whereas one dose of 80 and 40 mg aspirin showed an 
      inhibition of 79.4 +/- 13.7% and 80 +/- 6.2% respectively. However, the 
      inhibition of TXB2 synthesis seems not to be long-lasting since, 12 h after the 
      ingestion of aspirin, an increase of megakaryocyte TXB2 production could be 
      observed which reached significance after the 500 mg aspirin dosage (p < 0.048). 
      We conclude that human megakaryocyte cyclooxygenase is sensitive to aspirin 
      inhibition and that low doses of aspirin (40 and 80 mg) enter the systemic 
      circulation and are able to inhibit megakaryocyte cyclooxygenase, but this 
      inhibition is incomplete and megakaryocyte cyclooxygenase seems to recover within 
      12 h after ingestion of aspirin.
FAU - van Pampus, E C
AU  - van Pampus EC
AD  - Department of Haematology, Free University Hospital, Amsterdam, The Netherlands.
FAU - Huijgens, P C
AU  - Huijgens PC
FAU - Zevenbergen, A
AU  - Zevenbergen A
FAU - Twaalfhoven, H
AU  - Twaalfhoven H
FAU - van Kamp, G J
AU  - van Kamp GJ
FAU - Langenhuijsen, M M
AU  - Langenhuijsen MM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Bone Marrow Cells
MH  - Humans
MH  - In Vitro Techniques
MH  - Megakaryocytes/drug effects/*metabolism
MH  - Thrombin/pharmacology
MH  - Thromboxane B2/*biosynthesis
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1993.tb00160.x [doi]
PST - ppublish
SO  - Eur J Haematol. 1993 May;50(5):264-8. doi: 10.1111/j.1600-0609.1993.tb00160.x.

PMID- 796938
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20191028
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - Suppl
DP  - 1976
TI  - Ketoprofen in the treatment of rheumatoid arthritis.
PG  - 34-6
AB  - A double-blind cross-over trial of ketoprofen (200 mg daily) compared with 
      placebo and aspirin (4 g daily) was carried out in 24 patients with rheumatoid 
      arthritis. Ketoprofen was shown to be significantly more effective than placebo 
      in terms of pain relief, degree and duration of morning stiffness, articular 
      index and patients' assessment of improvement. No significant differences were 
      noted between ketoprofen and aspirin, although side-effects were less with 
      ketoprofen.
FAU - Kennedy, A C
AU  - Kennedy AC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Benzophenones)
RN  - 0 (Placebos)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Anti-Inflammatory Agents
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Benzophenones/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Ketoprofen/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Placebos
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1093/rheumatology/15.5.34 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1976;Suppl:34-6. doi: 10.1093/rheumatology/15.5.34.

PMID- 33515330
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210915
IS  - 1432-5195 (Electronic)
IS  - 0341-2695 (Linking)
VI  - 45
IP  - 3
DP  - 2021 Mar
TI  - Retrospective high volume comparative study suggests that patients on aspirin 
      could have immediate surgery for hip fractures without significant blood loss.
PG  - 543-549
LID - 10.1007/s00264-021-04941-6 [doi]
AB  - PURPOSE: This study aimed to investigate the effects of aspirin on peri-operative 
      hidden blood loss during hip fracture surgery by adjusting for possible factors 
      affecting blood loss using a propensity score matching method. METHODS: We 
      retrospectively collected data from a cohort of isolated hip fracture patients 
      (aged ≥ 65 years)who underwent surgery from January 2010 to December 2019. The 
      study's primary outcome was blood loss from admission to the day after surgery in 
      the aspirin and control groups. We estimated the hidden blood loss, calculated 
      based on patient's blood volume, haemoglobin measurements, and blood 
      transfusions. The secondary outcome focused on the requirement for blood 
      transfusion. We adjusted for possible factors affecting blood loss using a 
      propensity score matching method and statistically examined the effects of 
      aspirin on hip fracture surgery. RESULTS: We enrolled 806 patients of whom 271 
      (34%) were taking anticoagulant and antiplatelet drugs, while 114 (14%) were 
      taking only aspirin (aspirin group). A total of 535 patients were not taking 
      antiplatelets and anticoagulants (control group). In propensity score matching, 
      103 patients were matched. Aspirin was not associated with a significantly higher 
      risk of hidden blood loss (aspirin group; median 598 mL [410-783 mL] vs control 
      group; median 556 ml [321-741 mL], p = 0.14) and higher risk of blood transfusion 
      requirement (aspirin group; 49 patients [48%] vs control group; 39 patients 
      [38%], p = 0.21). CONCLUSION: Aspirin did not affect peri-operative blood loss in 
      hip fracture surgery. We concluded that patients taking aspirin can safely 
      undergo hip fracture surgery without delay.
FAU - Ohmori, Takao
AU  - Ohmori T
AUID- ORCID: 0000-0003-0103-5558
AD  - Department of Orthopaedic Surgery, Japanese Red Cross Kobe Hospital, Kobe, Japan. 
      takao771577157715@yahoo.co.jp.
FAU - Toda, Kazukiyo
AU  - Toda K
AD  - Department of Orthopaedic Surgery, Japanese Red Cross Kobe Hospital, Kobe, Japan.
FAU - Kanazawa, Tomoko
AU  - Kanazawa T
AD  - Department of Orthopaedic Surgery, Japanese Red Cross Kobe Hospital, Kobe, Japan.
FAU - Tada, Keitaro
AU  - Tada K
AD  - Department of Orthopaedic Surgery, Hyogo Emergency Medical Center, Kobe, Japan.
FAU - Yagata, Yukihisa
AU  - Yagata Y
AD  - Department of Orthopaedic Surgery, Hyogo Emergency Medical Center, Kobe, Japan.
FAU - Ito, Yasuo
AU  - Ito Y
AD  - Department of Orthopaedic Surgery, Japanese Red Cross Kobe Hospital, Kobe, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210130
PL  - Germany
TA  - Int Orthop
JT  - International orthopaedics
JID - 7705431
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Int Orthop. 2021 Aug;45(8):2169-2170. PMID: 33774698
MH  - Aged
MH  - *Aspirin/adverse effects
MH  - Blood Loss, Surgical/prevention & control
MH  - *Hip Fractures/surgery
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Aspirin
OT  - Blood loss
OT  - Blood transfusion requirement
OT  - Hip fracture surgery
OT  - Peri-operative
EDAT- 2021/01/31 06:00
MHDA- 2021/04/24 06:00
CRDT- 2021/01/30 12:06
PHST- 2020/10/13 00:00 [received]
PHST- 2021/01/07 00:00 [accepted]
PHST- 2021/01/31 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
PHST- 2021/01/30 12:06 [entrez]
AID - 10.1007/s00264-021-04941-6 [pii]
AID - 10.1007/s00264-021-04941-6 [doi]
PST - ppublish
SO  - Int Orthop. 2021 Mar;45(3):543-549. doi: 10.1007/s00264-021-04941-6. Epub 2021 
      Jan 30.

PMID- 36871000
OWN - NLM
STAT- MEDLINE
DCOM- 20230307
LR  - 20230307
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 24
IP  - 1
DP  - 2023 Mar 4
TI  - Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A 
      Study of Cardiovascular Events iN Diabetes) randomized controlled trial.
PG  - 166
LID - 10.1186/s13063-023-07198-z [doi]
LID - 166
AB  - BACKGROUND: Aspirin is widely used for cardioprotection with its antiplatelet 
      effects due to the blocking of thromboxane A2 production. However, it has been 
      suggested that platelet abnormalities in those with diabetes prevent adequate 
      suppression with once daily aspirin. METHODS: In the ASCEND randomized 
      double-blind trial of aspirin 100 mg once daily versus placebo in participants 
      with diabetes but no history of cardiovascular disease, suppression was assessed 
      by measuring 11-dehydro-thromboxane B2 excretion in urine (U-TXM) in a randomly 
      selected sample of 152 participants (76 aspirin arm, 74 placebo arm), plus 198 
      (93 aspirin arm, 105 placebo arm) adherent to study drugs and selected to 
      maximize the numbers ingesting their last tablet 12-24 h before urine sampling. 
      U-TXM was assayed using a competitive ELISA assay in samples mailed a mean of 
      2 years after randomization, with time since taking last aspirin/placebo tablet 
      recorded at the time of sample provision. Effective suppression 
      (U-TXM < 1500 pg/mg creatinine) and percentage reductions in U-TXM by aspirin 
      allocation were compared. RESULTS: In the random sample, U-TXM was 71% (95% CI 
      64-76%) lower among aspirin vs placebo-allocated participants. Among adherent 
      participants in the aspirin arm, U-TXM was 72% (95% CI 69-75%) lower than in the 
      placebo arm and 77% achieved effective suppression overall. Suppression was 
      similar among those who ingested their last tablet more than 12 h before urine 
      sampling with levels in the aspirin arm 72% (95% CI 67-77%) lower than in the 
      placebo arm and 70% achieving effective suppression. CONCLUSIONS: Daily aspirin 
      significantly reduces U-TXM in participants with diabetes, including at 12-24 h 
      after ingestion. TRIAL REGISTRATION: ISRCTN ISRCTN60635500. Registered on 1 Sept 
      2005; ClinicalTrials.gov NCT00135226. Registered on 24 Aug 2005.
CI  - © 2023. The Author(s).
FAU - Parish, Sarah
AU  - Parish S
AUID- ORCID: 0000-0003-3532-0832
AD  - MRC Population Health Research Unit, Nuffield Department of Population Health, 
      University of Oxford, Big Data Institute, Old Road Campus, Roosevelt Drive, 
      Oxford, OX3 7LF, UK. sarah.parish@ndph.ox.ac.uk.
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK. 
      sarah.parish@ndph.ox.ac.uk.
FAU - Buck, Georgina
AU  - Buck G
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Aung, Theingi
AU  - Aung T
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Mafham, Marion
AU  - Mafham M
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Clark, Sarah
AU  - Clark S
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Hill, Michael R
AU  - Hill MR
AD  - MRC Population Health Research Unit, Nuffield Department of Population Health, 
      University of Oxford, Big Data Institute, Old Road Campus, Roosevelt Drive, 
      Oxford, OX3 7LF, UK.
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Collins, Rory
AU  - Collins R
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Bowman, Louise
AU  - Bowman L
AD  - MRC Population Health Research Unit, Nuffield Department of Population Health, 
      University of Oxford, Big Data Institute, Old Road Campus, Roosevelt Drive, 
      Oxford, OX3 7LF, UK.
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
FAU - Armitage, Jane
AU  - Armitage J
AD  - MRC Population Health Research Unit, Nuffield Department of Population Health, 
      University of Oxford, Big Data Institute, Old Road Campus, Roosevelt Drive, 
      Oxford, OX3 7LF, UK.
AD  - Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department 
      of Population Health, University of Oxford, Oxford, UK.
CN  - ASCEND Study Collaborative Group
LA  - eng
SI  - ClinicalTrials.gov/NCT00135226
GR  - SP/03/002/BHF_/British Heart Foundation/United Kingdom
GR  - SP/08/010/25939/BHF_/British Heart Foundation/United Kingdom
GR  - SP/14/3/31114/BHF_/British Heart Foundation/United Kingdom
GR  - PG/05/013/18296/BHF_/British Heart Foundation/United Kingdom
GR  - MC_UU_00017/3/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_00017/5/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20230304
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
RN  - 54397-85-2 (Thromboxane B2)
SB  - IM
MH  - Humans
MH  - Aspirin
MH  - *Diabetes Mellitus
MH  - Thromboxane B2
MH  - *Cardiovascular Diseases
PMC - PMC9985834
OTO - NOTNLM
OT  - 11-Dehydro-thromboxane B2
OT  - Daily low-dose aspirin
OT  - Diabetes
OT  - Randomized placebo-controlled trial
COIS- SP, MM, GB, SC, MRH, RC, LB, and JA work in the Clinical Trial Service Unit & 
      Epidemiological Studies Unit (CTSU) of the Nuffield Department of Population 
      Health at the University of Oxford. The Clinical Trial Service Unit & 
      Epidemiological Studies Unit has a staff policy of not taking any personal 
      payments directly or indirectly from industry (with reimbursement sought only for 
      the costs of travel and accommodation to attend scientific meetings). CTSU has 
      received research grants from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, 
      GlaxoSmithKline, The Medicines Company, Merck, Mylan, Novartis, Pfizer, Roche, 
      Schering, and Solvay, which are governed by University of Oxford contracts that 
      protect the researchers’ independence. SP and RC are co-inventors of a genetic 
      test for statin-related myopathy risk but receive no income from it.
EDAT- 2023/03/05 06:00
MHDA- 2023/03/08 06:00
CRDT- 2023/03/04 23:35
PHST- 2022/09/30 00:00 [received]
PHST- 2023/02/21 00:00 [accepted]
PHST- 2023/03/04 23:35 [entrez]
PHST- 2023/03/05 06:00 [pubmed]
PHST- 2023/03/08 06:00 [medline]
AID - 10.1186/s13063-023-07198-z [pii]
AID - 7198 [pii]
AID - 10.1186/s13063-023-07198-z [doi]
PST - epublish
SO  - Trials. 2023 Mar 4;24(1):166. doi: 10.1186/s13063-023-07198-z.

PMID- 34234075
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20221207
IS  - 1349-3299 (Electronic)
IS  - 1349-2365 (Linking)
VI  - 62
IP  - 4
DP  - 2021 Jul 30
TI  - Efficacy and Safety of Aspirin Combined with Low-Dose P2Y12 Receptor Antagonists 
      in East Asian Patients Undergoing PCI.
PG  - 742-751
LID - 10.1536/ihj.20-772 [doi]
AB  - Previous studies have indicated that low-dose new generation of P2Y12 receptor 
      antagonists may be more suitable compared with clopidogrel at a standard dose for 
      the dual antiplatelet therapy (DAPT) for East Asian patients receiving 
      percutaneous coronary intervention (PCI). However, there remains no consensus in 
      clinical practice. Thus, in this study, we aimed to determine the efficacy and 
      safety of low-dose P2Y12 receptor antagonists, compared to clopidogrel at a 
      standard dose, in DAPT in East Asian patients after PCI. We systematically 
      searched literatures for randomized controlled trials (RCT) comparing low-dose 
      P2Y12 receptor antagonists with standard-dose clopidogrel for the treatment of 
      East Asian patients undergoing PCI. The endpoints of efficacy include major 
      adverse cardiac events (MACEs), all-cause mortality, and the number of target 
      vessel revascularization. The indicators of safety include major and minor 
      bleeding events. Heterogeneity was evaluated by I(2) statistic test. Begg's and 
      Egger's tests were used to evaluate publication bias. In total, 2,747 subjects 
      from 8 RCT studies were included. Low-dose new P2Y12 receptor antagonists, that 
      is, ticagrelor or prasugrel, showed significantly lower incidence of MACEs, as 
      compared with standard-dose clopidogrel, in the East Asian patients who are in 
      DAPT after undergoing PCI. Further, no difference was noted for the risk of major 
      and minor bleeding events. In East Asian patients undergoing PCI and receiving 
      DAPT, the use of low-dose P2Y12 receptor antagonists, ticagrelor or prasugrel, 
      has been determined to be superior than clopidogrel at standard dose; this has 
      been evidenced by a lower incidence of MACEs without increasing the risk of 
      bleeding.
FAU - Hu, Xiankang
AU  - Hu X
AD  - Department of Cardiology, The First Affiliated Hospital of Chongqing Medical 
      University.
FAU - Zhao, Weibo
AU  - Zhao W
AD  - Department of Endocrinology, Diabetes Center of People's Liberation Army, 
      Strategic Support Force Medical Center.
FAU - Zhang, Qiongyue
AU  - Zhang Q
AD  - Department of Nephrology, The First Affiliated Hospital of Chongqing Medical 
      University.
FAU - Hu, Houyuan
AU  - Hu H
AD  - Department of Cardiology, Southwest Hospital, Third Military Medical University 
      (Army Medical University).
FAU - Luo, Suxin
AU  - Luo S
AD  - Department of Cardiology, The First Affiliated Hospital of Chongqing Medical 
      University.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210706
PL  - Japan
TA  - Int Heart J
JT  - International heart journal
JID - 101244240
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Asia, Eastern
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Humans
MH  - Percutaneous Coronary Intervention/*adverse effects
MH  - Purinergic P2Y Receptor Antagonists/*administration & dosage/adverse effects
MH  - Thrombosis/etiology/*prevention & control
OTO - NOTNLM
OT  - Dual antiplatelet therapy
OT  - Major adverse cardiac events
OT  - Percutaneous coronary intervention
EDAT- 2021/07/09 06:00
MHDA- 2021/08/07 06:00
CRDT- 2021/07/08 05:52
PHST- 2021/07/09 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
PHST- 2021/07/08 05:52 [entrez]
AID - 10.1536/ihj.20-772 [doi]
PST - ppublish
SO  - Int Heart J. 2021 Jul 30;62(4):742-751. doi: 10.1536/ihj.20-772. Epub 2021 Jul 6.

PMID- 2062511
OWN - NLM
STAT- MEDLINE
DCOM- 19910806
LR  - 20131121
IS  - 0161-6420 (Print)
IS  - 0161-6420 (Linking)
VI  - 98
IP  - 5 Suppl
DP  - 1991 May
TI  - Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. 
      Early Treatment Diabetic Retinopathy Study Research Group.
PG  - 757-65
AB  - Aspirin treatment did not alter the course of diabetic retinopathy in patients 
      enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS). In this 
      randomized clinical trial supported by the National Eye Institute, 3711 patients 
      with mild-to-severe nonproliferative or early proliferative diabetic retinopathy 
      were assigned randomly to either aspirin (650 mg per day) or placebo. Aspirin did 
      not prevent the development of high-risk proliferative retinopathy and did not 
      reduce the risk of visual loss, nor did it increase the risk of vitreous 
      hemorrhage. This was true both for eyes assigned randomly to deferral of 
      photocoagulation and for eyes assigned randomly to early argon laser 
      photocoagulation. The ETDRS results indicate that for patients with 
      mild-to-severe non-proliferative or early proliferative diabetic retinopathy, it 
      is likely that aspirin has no clinically important beneficial effects on the 
      progression of retinopathy. The data also show that aspirin 650 mg per day had no 
      clinically important harmful effects for diabetic patients with retinopathy. 
      These findings suggest there are no ocular contraindications to aspirin when 
      required for cardiovascular disease or other medical indications.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Ophthalmology
JT  - Ophthalmology
JID - 7802443
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Diabetic Retinopathy/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Life Tables
MH  - Macular Edema/complications
MH  - Male
MH  - Middle Aged
MH  - Placebos
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
AID - S0161-6420(13)38010-5 [pii]
PST - ppublish
SO  - Ophthalmology. 1991 May;98(5 Suppl):757-65.

PMID- 7834325
OWN - NLM
STAT- MEDLINE
DCOM- 19950224
LR  - 20150514
IS  - 0002-5151 (Print)
IS  - 0002-5151 (Linking)
VI  - 41
IP  - 6
DP  - 1994 Nov-Dec
TI  - [Asthma induced by aspirin and arachidonic acid metabolites. II. The role of 
      leukotrienes (part four)].
PG  - 147-52
AB  - Although the mechanism of aspirin-induced asthma is unknown, it has be suggested 
      that adverse nasal and bronchial reactions are caused by an increased production 
      of lipoxygenase products. We have measured the release of urinary LTE4, TXB2 and 
      11-dehydro-TXB2 of aspirin induced asthmatics and controls by radioimmunoassay 
      and HPLC methods during aspirin challenge and after desensitization. The 
      overproduction demonstration of urinary LTE4 during aspirin challenge and the 
      decrease after desensitization in inversal direct proportion manner with TXB2 
      suggest a "shunting" of the arachidonic acid metabolites of the target cells. 
      Whichever theory is to be pursued further, it must also accommodate the clinical 
      effect of aspirin densitization.
FAU - Salazar Villa, R M
AU  - Salazar Villa RM
AD  - Div Allergy and Immunology, Scripps Clinic & Research Foundation, La Jolla, CA 
      92037.
FAU - Zambrano Villa, S
AU  - Zambrano Villa S
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Asma inducida por aspirina y metabolitos del ácido araquidónico. II. La 
      participación de los leucotrienos (cuarta parte).
PL  - Mexico
TA  - Rev Alerg Mex
JT  - Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
JID - 9438824
RN  - 0 (Leukotrienes)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced
MH  - Humans
MH  - Leukotrienes/metabolism
RF  - 28
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
PST - ppublish
SO  - Rev Alerg Mex. 1994 Nov-Dec;41(6):147-52.

PMID- 365211
OWN - NLM
STAT- MEDLINE
DCOM- 19790313
LR  - 20190515
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 38
IP  - 4
DP  - 1978 Oct
TI  - Mechanism of inhibition of tumour growth by aspirin and indomethacin.
PG  - 503-12
AB  - The growth of a 3-methylcholanthrene-induced fibrosarcoma of C3H mice was 
      inhibited by aspirin and indomethacin. While the tumour contained relatively high 
      concentrations of PGE2-like material, that were markedly diminished by 
      indomethacin treatment, our results did not confirm the recently proposed 
      hypothesis that the anti-tumour effect arises from a restoration of depressed 
      immune function. For example, mice that had completely eliminated their tumours 
      under indomethacin administration were not immune to rechallenge. The 
      tumour-bearing animals were not non-specifically immunodepressed, as their 
      splenic PFC responses against SRBC were enhanced. However, while indomethacin 
      augmented the PFC response in normal mice, this adjuvant effect was depressed in 
      tumour-bearing animals. The spleen-cell PHA responses of tumour bearers were 
      severely depressed, and such cells suppressed the PHA response of normal cells. 
      Only after prolonged indomethacin treatment did animals (with comparable tumour 
      burdens) show weak PHA responses and somewhat diminished suppressive activity. 
      Possible alternative mechanisms, such as direct cytotoxicity, or inhibition of 
      inflammation, phosphodiesterase activity, blood coagulation or calcium 
      availability were not implicated (nor definitively excluded) in the anti-tumour 
      effect.
FAU - Lynch, N R
AU  - Lynch NR
FAU - Castes, M
AU  - Castes M
FAU - Astoin, M
AU  - Astoin M
FAU - Salomon, J C
AU  - Salomon JC
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Immunosuppressive Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Antibodies, Neoplasm/biosynthesis
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Female
MH  - Fibrosarcoma/*drug therapy/immunology/pathology
MH  - Hemolytic Plaque Technique
MH  - Immunosuppressive Agents
MH  - Indomethacin/*pharmacology/therapeutic use
MH  - Male
MH  - Mice
MH  - Sarcoma, Experimental/drug therapy/immunology/pathology
PMC - PMC2009769
EDAT- 1978/10/01 00:00
MHDA- 1978/10/01 00:01
CRDT- 1978/10/01 00:00
PHST- 1978/10/01 00:00 [pubmed]
PHST- 1978/10/01 00:01 [medline]
PHST- 1978/10/01 00:00 [entrez]
AID - 10.1038/bjc.1978.237 [doi]
PST - ppublish
SO  - Br J Cancer. 1978 Oct;38(4):503-12. doi: 10.1038/bjc.1978.237.

PMID- 9851736
OWN - NLM
STAT- MEDLINE
DCOM- 19981230
LR  - 20191102
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 132
IP  - 6
DP  - 1998 Dec
TI  - Focused antithrombotic therapy: novel anti-platelet salicylates with reduced 
      ulcerogenic potential and higher first-pass detoxification than aspirin in rats.
PG  - 469-77
AB  - The use of aspirin as an anti-platelet drug is limited by its propensity to 
      induce gastric injury and by its adverse effect on vascular prostacyclin 
      formation. Two phenolic non-steroidal anti-inflammatory drugs (salicylic acid and 
      diflunisal) were modified by esterification with a series of O-acyl moieties. The 
      short-term ulcerogenic in vitro and in vivo anti-platelet properties, 
      pharmacodynamic profiles, and extent of hepatic extraction of these phenolic 
      esters were compared with aspirin (acetylsalicylic acid). The more lipophilic 
      esters (longer carbon chain length in O-acyl group) show significantly less 
      gastrotoxicity in stressed rats than does aspirin after a single oral dose. The 
      in vitro and in vivo anti-platelet studies show that these phenolic esters 
      inhibited (1) arachidonate-triggered human platelet aggregation and (2) 
      thrombin-stimulated rat serum thromboxane A2 production by platelets in the 
      clotting process almost as effectively as aspirin. The hepatic extractions of 
      these O-acyl derivatives are significantly higher than those of aspirin. The 
      pharmacodynamic studies show that these O-acyl derivatives of salicylic acid and 
      diflunisal probably bind to, or combine with, the same site on the platelet 
      cyclooxygenase as aspirin. Replacing the O-acetyl group with longer chain O-acyl 
      moiety in this series of phenolic esters markedly reduced the potential of these 
      agents to induce short-term gastric injury but did not lessen their activity as 
      inhibitors of platelet aggregation. These non-acetyl salicylates may therefore 
      represent a novel class of anti-platelet drugs with less ulcerogenic potential.
FAU - Hung, D Y
AU  - Hung DY
AD  - Department of Medicine, The University of Queensland, Princess Alexandra 
      Hospital, Woolloongabba, Australia.
FAU - Mellick, G D
AU  - Mellick GD
FAU - Masci, P P
AU  - Masci PP
FAU - Whitaker, A N
AU  - Whitaker AN
FAU - Whitehouse, M W
AU  - Whitehouse MW
FAU - Roberts, M S
AU  - Roberts MS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Steroids)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 7C546U4DEN (Diflunisal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Lab Clin Med. 1998 Dec;132(6):446-7. PMID: 9851731
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Arthritis, Experimental/chemically induced/pathology
MH  - Aspirin/analogs & derivatives/pharmacokinetics/*pharmacology
MH  - Blood Platelets/drug effects/metabolism
MH  - Diflunisal/analogs & derivatives/pharmacokinetics/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrinolytic Agents/*pharmacology
MH  - Gastric Mucosa/*drug effects/pathology
MH  - In Vitro Techniques
MH  - Inactivation, Metabolic
MH  - Liver/*metabolism
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Steroids
MH  - Stomach Ulcer/*prevention & control
MH  - Thromboxane A2/metabolism
EDAT- 1998/12/16 00:00
MHDA- 1998/12/16 00:01
CRDT- 1998/12/16 00:00
PHST- 1998/12/16 00:00 [pubmed]
PHST- 1998/12/16 00:01 [medline]
PHST- 1998/12/16 00:00 [entrez]
AID - S0022-2143(98)90124-X [pii]
AID - 10.1016/s0022-2143(98)90124-x [doi]
PST - ppublish
SO  - J Lab Clin Med. 1998 Dec;132(6):469-77. doi: 10.1016/s0022-2143(98)90124-x.

PMID- 6389409
OWN - NLM
STAT- MEDLINE
DCOM- 19850124
LR  - 20131121
IS  - 0020-8167 (Print)
IS  - 0020-8167 (Linking)
VI  - 24
IP  - 4
DP  - 1984 Winter
TI  - The diabetic retinopathy study and the early treatment diabetic retinopathy 
      study.
PG  - 13-29
AB  - The DRS showed that the benefit of panretinal photocoagulation outweighed the 
      risks of therapy in eyes with high-risk characteristics. The ETDRS will 
      demonstrate if photocoagulation earlier in the course of diabetic retinopathy is 
      safe and efficacious. Criteria will be developed for determining which eyes with 
      macular edema are responsive to photocoagulation. The data collected on the 
      different laser treatments should establish which techniques are most effective 
      and least harmful. Systemic aspirin therapy to retard or reverse retinopathy will 
      be investigated in a controlled manner.
FAU - Cantrill, H L
AU  - Cantrill HL
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Int Ophthalmol Clin
JT  - International ophthalmology clinics
JID - 0374731
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Diabetic Retinopathy/classification/drug therapy/surgery/*therapy
MH  - Edema/surgery
MH  - Follow-Up Studies
MH  - Humans
MH  - Laser Therapy
MH  - Light Coagulation/adverse effects/methods
MH  - Macula Lutea
MH  - Random Allocation
MH  - Retinal Diseases/surgery
MH  - Time Factors
MH  - Visual Acuity
RF  - 22
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Int Ophthalmol Clin. 1984 Winter;24(4):13-29.

PMID- 31765070
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Linking)
VI  - 126
IP  - 5
DP  - 2020 May
TI  - A model to predict the risk of aspirin/non-steroidal anti-inflammatory 
      drugs-related upper gastrointestinal bleeding for the individual patient.
PG  - 437-443
LID - 10.1111/bcpt.13370 [doi]
AB  - Upper gastrointestinal bleeding is a feared complication of using non-steroidal 
      anti-inflammatory drugs (NSAIDs) or aspirin. Studies predicting the incidence 
      rate for individuals with a given set of characteristics are lacking. The aim of 
      this study was to develop a risk model to predict the incidence rate of upper 
      gastrointestinal bleeding (UGIB) in users of aspirin/NSAID based on presence of 
      well-defined risk factors for the individual patient. METHODS: The model was 
      developed from data from a case-control study, sampled from a well-defined source 
      population, residents of the Funen County 1995-2006. All cases and controls were 
      characterized in terms of factors known to affect the risk of UGIB. By using 
      census data, we rescaled the control group, so their composition accurately 
      reflected age and sex distribution of the source population. Only persons using 
      NSAIDs or/and aspirin and no PPI were included in the analysis. As reference 
      group, we chose 80- to 89-year-old women with no ulcer history, using NSAID, but 
      neither aspirin, other platelet inhibitors, vitamin K antagonists, selective 
      serotonin reuptake inhibitors nor corticosteroids. RESULTS: We identified 1388 
      cases among non-users of PPIs. We found a modelled baseline incidence rate of 
      10.7 per 1000 person-years for the reference group. The strongest associations 
      were found for ADP inhibitors (OR 5.80), followed by anticoagulants treatment (OR 
      2.62) and prior ulcer (OR 2.68). The model performed well in terms of calibration 
      and discriminatory power. CONCLUSION: This study is the first to describe a 
      model, which estimates the incidence rate of UGIB for patients using 
      aspirin/NSAID, based on the specific combination of risk factors. Risk of upper 
      gastrointestinal bleeding for a given patient can be accurately estimated using 
      this model.
CI  - © 2019 Nordic Association for the Publication of BCPT (former Nordic 
      Pharmacological Society).
FAU - Petersen, Jóhanna
AU  - Petersen J
AD  - Department of Medical Gastroenterology, Odense University Hospital, Odense, 
      Denmark.
FAU - Møller Hansen, Jane
AU  - Møller Hansen J
AD  - Department of Medical Gastroenterology, Odense University Hospital, Odense, 
      Denmark.
FAU - de Muckadell, Ove B Schaffalitzky
AU  - de Muckadell OBS
AD  - Department of Medical Gastroenterology, Odense University Hospital, Odense, 
      Denmark.
FAU - Dall, Michael
AU  - Dall M
AD  - Department of Clinical Pharmacology and Pharmacy, University of Southern Denmark, 
      Odense, Denmark.
FAU - Hallas, Jesper
AU  - Hallas J
AD  - Department of Clinical Pharmacology and Pharmacy, University of Southern Denmark, 
      Odense, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20191219
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Models, Statistical
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2019/11/26 06:00
MHDA- 2021/02/13 06:00
CRDT- 2019/11/26 06:00
PHST- 2019/09/04 00:00 [received]
PHST- 2019/11/20 00:00 [accepted]
PHST- 2019/11/26 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
PHST- 2019/11/26 06:00 [entrez]
AID - 10.1111/bcpt.13370 [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2020 May;126(5):437-443. doi: 10.1111/bcpt.13370. 
      Epub 2019 Dec 19.

PMID- 29490066
OWN - NLM
STAT- MEDLINE
DCOM- 20200110
LR  - 20200110
IS  - 1524-4040 (Electronic)
IS  - 0148-396X (Linking)
VI  - 84
IP  - 1
DP  - 2019 Jan 1
TI  - Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial 
      Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive 
      Patients With Unruptured Aneurysms.
PG  - 77-83
LID - 10.1093/neuros/nyy002 [doi]
AB  - BACKGROUND: Dual antiplatelet therapy (DAPT) associating aspirin + clopidogrel is 
      commonly utilized in neurovascular interventions despite unpredictable 
      clopidogrel efficacy with 4% to 50% of patients considered nonresponders. 
      Ticagrelor is an antiplatelet agent with low resistance rates but unknown 
      efficacy and safety in neurovascular patients. OBJECTIVE: To evaluate frequency 
      of ischemic and hemorrhagic events in patients treated with aspirin and 
      ticagrelor when associated with perioperative heparin bolus for unruptured 
      aneurysms treated with intracranial stents. METHODS: One hundred fifty-four 
      consecutive patients with unruptured intracranial aneurysms treated by stent 
      procedures (113 = flow diverter stent [FDS], 41 = stent-assisted coiling) were 
      retrospectively analyzed. All patients received aspirin and ticagrelor without 
      platelet function testing. Patients were separated in 2 groups following 
      perioperative heparin dose: group I = 70 U/kg; group II = 50 U/kg. FDS versus 
      stent-assisted coiling procedures were also separately analyzed. RESULTS: Nine 
      patients (5.8%) presented symptomatic neurological complications poststenting (3 
      ischemic, 6 hemorrhagic): 8 patients received 70 U/kg of heparin (11.1%) and 1 
      patient received 50 U/kg (1.2%; P < .009). Four patients died (2.6%) during the 
      3-mo follow-up period-all deaths were correlated to intracranial hemorrhage: 3 at 
      group I and 1 at group II (P < .251). No difference in complications or death was 
      observed considering separately FDS and stent-assisted coiling procedures. 
      CONCLUSION: This study did not find more neurological complications than in 
      previous neurointerventional reports using DAPT with aspirin + ticagrelor or 
      aspirin + clopidogrel. Overall number of neurological complications was lower 
      when a lower dose of heparin was administered. Neurovascular studies comparing 
      clopidogrel to ticagrelor and different doses of heparin are necessary to 
      demonstrate which association is more efficient with lower complication rates.
FAU - Narata, Ana Paula
AU  - Narata AP
AD  - Department of Radiology and Neu-roradiology, University Hospital of Tours, Tours, 
      France.
FAU - Amelot, Aymeric
AU  - Amelot A
AD  - Department of Neurosurgery, University Hospital of Tours, Tours, France.
FAU - Bibi, Richard
AU  - Bibi R
AD  - Department of Radiology and Neu-roradiology, University Hospital of Tours, Tours, 
      France.
FAU - Herbreteau, Denis
AU  - Herbreteau D
AD  - Department of Radiology and Neu-roradiology, University Hospital of Tours, Tours, 
      France.
FAU - Angoulvant, Denis
AU  - Angoulvant D
AD  - Department of Cardiology, University Hospital of Tours, Tours, France.
FAU - Gruel, Yves
AU  - Gruel Y
AD  - Department of Hematology, University Hospital of Tours, Tours, France.
FAU - Janot, Kevin
AU  - Janot K
AD  - Department of Radiology and Neu-roradiology, University Hospital of Tours, Tours, 
      France.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects/therapeutic use
MH  - *Dual Anti-Platelet Therapy/adverse effects/statistics & numerical data
MH  - Humans
MH  - *Intracranial Aneurysm/drug therapy/surgery
MH  - *Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Retrospective Studies
MH  - Stents/adverse effects/statistics & numerical data
MH  - *Ticagrelor/adverse effects/therapeutic use
MH  - Vascular Surgical Procedures/adverse effects/methods
EDAT- 2018/03/01 06:00
MHDA- 2020/01/11 06:00
CRDT- 2018/03/01 06:00
PHST- 2017/08/21 00:00 [received]
PHST- 2018/01/05 00:00 [accepted]
PHST- 2018/03/01 06:00 [pubmed]
PHST- 2020/01/11 06:00 [medline]
PHST- 2018/03/01 06:00 [entrez]
AID - 4911477 [pii]
AID - 10.1093/neuros/nyy002 [doi]
PST - ppublish
SO  - Neurosurgery. 2019 Jan 1;84(1):77-83. doi: 10.1093/neuros/nyy002.

PMID- 21698778
OWN - NLM
STAT- MEDLINE
DCOM- 20120416
LR  - 20160511
IS  - 1942-7611 (Electronic)
IS  - 1942-7603 (Linking)
VI  - 3
IP  - 6
DP  - 2011 Jun
TI  - Early drug discovery and the rise of pharmaceutical chemistry.
PG  - 337-44
LID - 10.1002/dta.301 [doi]
AB  - Studies in the field of forensic pharmacology and toxicology would not be 
      complete without some knowledge of the history of drug discovery, the various 
      personalities involved, and the events leading to the development and 
      introduction of new therapeutic agents. The first medicinal drugs came from 
      natural sources and existed in the form of herbs, plants, roots, vines and fungi. 
      Until the mid-nineteenth century nature's pharmaceuticals were all that were 
      available to relieve man's pain and suffering. The first synthetic drug, chloral 
      hydrate, was discovered in 1869 and introduced as a sedative-hypnotic; it is 
      still available today in some countries. The first pharmaceutical companies were 
      spin-offs from the textiles and synthetic dye industry and owe much to the rich 
      source of organic chemicals derived from the distillation of coal (coal-tar). The 
      first analgesics and antipyretics, exemplified by phenacetin and acetanilide, 
      were simple chemical derivatives of aniline and p-nitrophenol, both of which were 
      byproducts from coal-tar. An extract from the bark of the white willow tree had 
      been used for centuries to treat various fevers and inflammation. The active 
      principle in white willow, salicin or salicylic acid, had a bitter taste and 
      irritated the gastric mucosa, but a simple chemical modification was much more 
      palatable. This was acetylsalicylic acid, better known as Aspirin®, the first 
      blockbuster drug. At the start of the twentieth century, the first of the 
      barbiturate family of drugs entered the pharmacopoeia and the rest, as they say, 
      is history.
CI  - Copyright © 2011 John Wiley & Sons, Ltd.
FAU - Jones, Alan Wayne
AU  - Jones AW
AD  - Department of Forensic Genetics and Forensic Toxicology, National Board of 
      Forensic Medicine, Artillerigatan, Linköping, Sweden. wayne.jones@RMV.SE
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - England
TA  - Drug Test Anal
JT  - Drug testing and analysis
JID - 101483449
RN  - 0 (Alkaloids)
RN  - 0 (Analgesics)
RN  - 0 (Antipyretics)
RN  - 0 (Barbiturates)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Plant Preparations)
RN  - 418M5916WG (Chloral Hydrate)
RN  - 7V31YC746X (Chloroform)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alkaloids/analysis/history/isolation & purification
MH  - Analgesics/chemical synthesis/history/therapeutic use
MH  - Antipyretics/chemical synthesis/history/therapeutic use
MH  - Aspirin/chemical synthesis/history/therapeutic use
MH  - Barbiturates/chemical synthesis/history/therapeutic use
MH  - Chemistry, Organic/history
MH  - Chemistry, Pharmaceutical/*history
MH  - Chloral Hydrate/chemical synthesis/history/therapeutic use
MH  - Chloroform/chemical synthesis/history/therapeutic use
MH  - Drug Discovery/*history
MH  - Drug Industry/history
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, Ancient
MH  - Humans
MH  - Pharmaceutical Preparations/chemical synthesis/history
MH  - Pharmacology/history
MH  - Plant Preparations/chemistry/history/isolation & purification/therapeutic use
MH  - Toxicology/history
EDAT- 2011/06/24 06:00
MHDA- 2012/04/17 06:00
CRDT- 2011/06/24 06:00
PHST- 2011/06/24 06:00 [entrez]
PHST- 2011/06/24 06:00 [pubmed]
PHST- 2012/04/17 06:00 [medline]
AID - 10.1002/dta.301 [doi]
PST - ppublish
SO  - Drug Test Anal. 2011 Jun;3(6):337-44. doi: 10.1002/dta.301.

PMID- 23816610
OWN - NLM
STAT- MEDLINE
DCOM- 20140327
LR  - 20181202
IS  - 1421-9786 (Electronic)
IS  - 1015-9770 (Linking)
VI  - 35
IP  - 6
DP  - 2013
TI  - Discontinuation of antiplatelet study medication and risk of recurrent stroke and 
      cardiovascular events: results from the PRoFESS study.
PG  - 538-43
LID - 10.1159/000351144 [doi]
AB  - BACKGROUND: Several case control studies have reported an increased risk of 
      cardiovascular events following discontinuation of antiplatelet agents in 
      high-risk patients. We therefore sought to investigate the risk of recurrent 
      stroke and cardiovascular events following discontinuation of antiplatelet study 
      medication in the Prevention Regimen for Effectively Avoiding Second Strokes 
      (PRoFESS) trial, a large randomized secondary stroke prevention study. METHODS: 
      The recurrent stroke and cardiovascular event rates following discontinuation of 
      aspirin plus extended-release dipyridamole (ASA + ERDP) or clopidogrel were 
      compared to the event rates in the on-treatment populations (patients who had 
      discontinued their antiplatelet medication due to an outcome event were kept in 
      the on-treatment population in order not to underestimate the on-treatment stroke 
      rate). RESULTS: In 7,212 treated ASA + ERDP patients, the stroke incidence rate 
      for the on-treatment group was 729 strokes with an average exposure of 17,048 
      person-years (0.12 per 1,000 person-days). For 7,864 treated clopidogrel 
      patients, the stroke incidence rate for the on-treatment group was 737 strokes 
      with an average exposure of 18,715 person-years (0.11 per 1,000 person-days). ASA 
      + ERDP was discontinued in 2,843 patients (in 57.7% due to an adverse event, 
      28.2% noncompliance, 1.4% loss to follow-up, 4.5% withdrawal of consent and 8.1% 
      other/nonspecified reasons) and clopidogrel was permanently discontinued in 2,176 
      patients (49.0% due to an adverse event, 34.2% noncompliance, 1.8% loss to 
      follow-up, 5.3% withdrawal of consent and 9.7% other/nonspecified reasons). 
      Within 30 days, a recurrent stroke occurred in 31 patients (0.37 per 1,000 
      person-days) after discontinuation of ASA + ERDP and in 15 patients (0.24 per 
      1,000 person-days) after discontinuation of clopidogrel. This corresponds to an 
      absolute excess risk of 0.77% within 30 days after discontinuation of ASA + ERDP 
      and 0.40% within 30 days after discontinuation of clopidogrel compared with the 
      on-treatment study populations. A combined vascular endpoint (stroke, myocardial 
      infarction, vascular death) occurred in 68 patients (0.82 per 1,000 person-days) 
      within 30 days after discontinuation of ASA + ERDP and in 47 patients (0.75 per 
      1,000 person-days) within 30 days after discontinuation of clopidogrel. This 
      corresponds to an absolute excess risk of 2.02% within 30 days after 
      discontinuation of ASA + ERDP and 1.83% within 30 days after discontinuation of 
      clopidogrel compared with the on-treatment study populations. CONCLUSION: 
      Discontinuation of antiplatelet medication after ischemic stroke should be 
      advocated only when the risk and severity of bleeding clearly outweigh the risk 
      of cardiovascular events.
CI  - Copyright © 2013 S. Karger AG, Basel.
FAU - Weimar, Christian
AU  - Weimar C
AD  - Department of Neurology, University of Duisburg-Essen, Essen, Germany. 
      christian.weimar@uk-essen.de
FAU - Cotton, Dan
AU  - Cotton D
FAU - Sha, Nanshi
AU  - Sha N
FAU - Sacco, Ralph L
AU  - Sacco RL
FAU - Bath, Philip M W
AU  - Bath PM
FAU - Weber, Ralph
AU  - Weber R
FAU - Diener, Hans Christoph
AU  - Diener HC
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130625
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Clopidogrel
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Risk
MH  - Secondary Prevention
MH  - Stroke/*drug therapy/prevention & control
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2013/07/03 06:00
MHDA- 2014/03/29 06:00
CRDT- 2013/07/03 06:00
PHST- 2012/12/07 00:00 [received]
PHST- 2013/03/25 00:00 [accepted]
PHST- 2013/07/03 06:00 [entrez]
PHST- 2013/07/03 06:00 [pubmed]
PHST- 2014/03/29 06:00 [medline]
AID - 000351144 [pii]
AID - 10.1159/000351144 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2013;35(6):538-43. doi: 10.1159/000351144. Epub 2013 Jun 25.

PMID- 14504182
OWN - NLM
STAT- MEDLINE
DCOM- 20031103
LR  - 20220330
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 108
IP  - 14
DP  - 2003 Oct 7
TI  - Effects of aspirin dose when used alone or in combination with clopidogrel in 
      patients with acute coronary syndromes: observations from the Clopidogrel in 
      Unstable angina to prevent Recurrent Events (CURE) study.
PG  - 1682-7
AB  - BACKGROUND: We studied the benefits and risks of adding clopidogrel to different 
      doses of aspirin in the treatment of patients with acute coronary syndrome (ACS). 
      METHODS AND RESULTS: In the Clopidogrel in Unstable angina to prevent Recurrent 
      Events (CURE) trial, 12 562 patients with ACS using aspirin, 75 to 325 mg daily, 
      were randomized to clopidogrel or placebo for up to 1 year. In this analysis, 
      patients were divided into the following 3 aspirin dose groups: < or =100 mg, 101 
      through 199 mg, and > or =200 mg. The combined incidence of cardiovascular death, 
      myocardial infarction, or stroke was reduced by clopidogrel regardless of aspirin 
      dose, as follows: < or =100 mg, 10.5% versus 8.6% (relative risk [RR], 0.81 [95% 
      CI, 0.68 to 0.97]); 101 to 199 mg, 9.8% versus 9.5% (RR, 0.97 [95% CI 0.77 to 
      1.22]); and > or =200 mg, 13.6% versus 9.8% (RR, 0.71 [95% CI, 0.59 to 0.85]). 
      The incidence of major bleeding increased with increasing aspirin dose both in 
      the placebo group (1.9%, 2.8%, and 3.7%, respectively; P=0.0001) and the 
      clopidogrel group (3.0%, 3.4%, and 4.9%, respectively; P=0.0009); thus, the 
      excess risk with clopidogrel was 1.1%, 1.2%, and 1.2%, respectively. The adjusted 
      hazard ratio for major bleeding for the highest versus the lowest dose of aspirin 
      was 1.9 (95% CI 1.29 to 2.72) in the placebo group, 1.6 (95% CI 1.19 to 2.23) in 
      the clopidogrel group, and 1.7 (95% CI 1.36 to 2.20) in the combined group. 
      CONCLUSIONS: In patients with ACS, adding clopidogrel to aspirin is beneficial 
      regardless of aspirin dose. Bleeding risks increase with increasing aspirin dose, 
      with or without clopidogrel, without any increase in efficacy. Our findings 
      suggest that the optimal daily dose of aspirin may be between 75 and 100 mg, with 
      or without clopidogrel.
FAU - Peters, Ron J G
AU  - Peters RJ
AD  - Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
FAU - Mehta, Shamir R
AU  - Mehta SR
FAU - Fox, Keith A A
AU  - Fox KA
FAU - Zhao, Feng
AU  - Zhao F
FAU - Lewis, Basil S
AU  - Lewis BS
FAU - Kopecky, Steven L
AU  - Kopecky SL
FAU - Diaz, Rafael
AU  - Diaz R
FAU - Commerford, Patrick J
AU  - Commerford PJ
FAU - Valentin, Vicent
AU  - Valentin V
FAU - Yusuf, Salim
AU  - Yusuf S
CN  - Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial 
      Investigators
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20030922
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Angina, Unstable/*drug therapy/mortality/therapy
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/epidemiology/etiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Myocardial Infarction/epidemiology
MH  - Myocardial Revascularization
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Stroke/epidemiology
MH  - Syndrome
MH  - Ticlopidine/analogs & derivatives/*therapeutic use
MH  - Treatment Outcome
EDAT- 2003/09/25 05:00
MHDA- 2003/11/05 05:00
CRDT- 2003/09/25 05:00
PHST- 2003/09/25 05:00 [pubmed]
PHST- 2003/11/05 05:00 [medline]
PHST- 2003/09/25 05:00 [entrez]
AID - 01.CIR.0000091201.39590.CB [pii]
AID - 10.1161/01.CIR.0000091201.39590.CB [doi]
PST - ppublish
SO  - Circulation. 2003 Oct 7;108(14):1682-7. doi: 10.1161/01.CIR.0000091201.39590.CB. 
      Epub 2003 Sep 22.

PMID- 12738997
OWN - NLM
STAT- MEDLINE
DCOM- 20030811
LR  - 20171116
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 22
IP  - 6
DP  - 2003 Jun
TI  - NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant 
      antiproliferative effect and alters cell cycle progression in human colon 
      adenocarcinoma cell lines.
PG  - 1297-302
AB  - Nitric oxide-releasing non-steroidal antiinflammatory drugs (NO-NSAIDs) are safer 
      than NSAIDs due to their ability to reduce gastric toxicity. We assessed the 
      cytotoxic activity of a new aspirin derivative, NCX 4016, after different 
      exposure schedules, in three human colon adenocarcinoma cell lines. All the lines 
      were positive for COX-1 protein and mRNA, as evaluated by Western blot and 
      RT-PCR, respectively, while only one was positive for COX-2. The cytostatic and 
      cytocidal activity was determined by sulforhodamine B assay and evaluated 
      according to Monks' model. Cytostatic activity was observed after a 24-h drug 
      exposure and 50% growth inhibition was reached at concentrations ranging from 165 
      to 250 micro M in all cell lines, whereas with aspirin the IC50 was never 
      reached, even at the maximum concentration tested (500 micro M), and was 
      independent of COX-1 or COX-2 status. Cytocidal activity was observed only at the 
      highest concentrations and persisted for a long time after drug removal. Flow 
      cytometric analysis showed that the NO-aspirin compound induced a persistent 
      accumulation of cells in G2-M phase in all the cell lines after at least 48 h 
      exposure. Specifically, the block pertained mainly to G2 phase, whereas mitotic 
      index was not affected at all. Our results indicate that NCX 4016 has an in vitro 
      cytostatic activity superior to that of its parental aspirin compound, which 
      makes it a potentially important tumor preventive agent. Furthermore, the 
      cytocidal effect observed at the highest concentrations and the induction of a 
      specific block in G2 phase renders it a promising candidate for drug combination 
      treatments.
FAU - Tesei, Anna
AU  - Tesei A
AD  - Istituto Oncologico Romagnolo, Pierantoni Hospital, Forlì, Italy.
FAU - Ricotti, Luca
AU  - Ricotti L
FAU - Ulivi, Paola
AU  - Ulivi P
FAU - Medri, Laura
AU  - Medri L
FAU - Amadori, Dino
AU  - Amadori D
FAU - Zoli, Wainer
AU  - Zoli W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenocarcinoma/pathology
MH  - Anticarcinogenic Agents/*pharmacology
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Cell Cycle/*drug effects
MH  - Cell Division/*drug effects
MH  - Cell Survival/drug effects
MH  - Colonic Neoplasms/pathology
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Gene Expression Regulation, Enzymologic/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Isoenzymes/genetics/metabolism
MH  - Kinetics
MH  - Membrane Proteins
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/genetics/metabolism
MH  - Tumor Cells, Cultured
EDAT- 2003/05/10 05:00
MHDA- 2003/08/12 05:00
CRDT- 2003/05/10 05:00
PHST- 2003/05/10 05:00 [pubmed]
PHST- 2003/08/12 05:00 [medline]
PHST- 2003/05/10 05:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2003 Jun;22(6):1297-302.

PMID- 8164813
OWN - NLM
STAT- MEDLINE
DCOM- 19940524
LR  - 20190514
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 44
IP  - 4
DP  - 1994 Apr
TI  - A follow-up survey of clinical practices for the use of heparin, warfarin, and 
      aspirin.
PG  - 618-21
AB  - OBJECTIVE: To determine whether anticoagulation practices have changed when 
      heparin and warfarin are used to treat cerebrovascular disease, and to determine 
      the dosage of aspirin used to treat carotid territory transient ischemic attacks 
      (TIAs). BACKGROUND: A 1987 study documented that neurologists and neurology house 
      officers were using excessive amounts of heparin and warfarin. Recent studies 
      have demonstrated the efficacy and safety of low-intensity anticoagulation for 
      preventing strokes, but no data are available on how these findings have affected 
      the treatment practices of clinicians. DESIGN/METHODS: Questionnaires were sent 
      to neurology staff at 10 medical centers. The questions dealt with the use of 
      heparin, warfarin, and aspirin in stroke/transient ischemic attack patients. The 
      nonparametric Wilcoxon rank sum test was used for analyzing the responses. 
      RESULTS: Ninety-three physicians responded compared with 52 in the prior study. 
      Most (56 of 92; 61%) did not use an IV heparin bolus. The mean partial 
      thromboplastin time (PTT) was 55 seconds, which was significantly less than the 
      mean PTT of 62 seconds (p = 0.006) in the prior study. The mean prothrombin time 
      (PT) fell to 16.0 seconds (range, 12.5 to 20.0) compared with a mean of 19.9 
      seconds (range, 15.0 to 27.0; p < 0.001) in the earlier study. There was a 
      significant fall in the mean PT ratio from 1.74 (range, 1.20 to 2.25) to 1.49 
      (range, 1.12 to 2.50; p < 0.001). Most respondents used 325 mg qd of aspirin for 
      treating TIAs. CONCLUSIONS: At the centers studied, neurologists and neurology 
      house officers are using less intense anticoagulation when treating stroke 
      patients now than in 1986. This concurs with recent studies demonstrating the 
      efficacy and safety of low-intensity anticoagulation in some clinical settings. 
      The use of 325 mg/d of aspirin is common, although the data supporting its 
      efficacy compared with higher doses are unclear.
FAU - Alberts, M J
AU  - Alberts MJ
AD  - Department of Medicine, Duke University Medical Center, Durham, NC 27710.
FAU - Dawson, D V
AU  - Dawson DV
FAU - Massey, E W
AU  - Massey EW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Carotid Artery Diseases/drug therapy
MH  - Cerebrovascular Disorders/drug therapy
MH  - Data Collection
MH  - Follow-Up Studies
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy
MH  - Neurology
MH  - Practice Patterns, Physicians'
MH  - Surveys and Questionnaires
MH  - Warfarin/administration & dosage/*therapeutic use
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
AID - 10.1212/wnl.44.4.618 [doi]
PST - ppublish
SO  - Neurology. 1994 Apr;44(4):618-21. doi: 10.1212/wnl.44.4.618.

PMID- 8492320
OWN - NLM
STAT- MEDLINE
DCOM- 19930616
LR  - 20190512
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 85
IP  - 11
DP  - 1993 Jun 2
TI  - Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention 
      Study Group.
PG  - 912-6
AB  - BACKGROUND: Epidemiological studies have indicated that aspirin consumption can 
      lower the risk of large-bowel cancer. These studies are not entirely consistent, 
      however, and their interpretation has been complicated by the possibility that 
      cancer symptoms may have led patients to avoid aspirin or that aspirin may have 
      influenced cancer diagnosis and treatment. PURPOSE: Our purpose was to determine 
      the effect of aspirin on risk of large-bowel neoplasms in a study in which 
      aspirin use would not be expected to affect tumor detection and tumor-related 
      symptoms would not likely influence aspirin use. A less complicated assessment of 
      the relationship between aspirin and large-bowel tumors should thus be possible. 
      METHODS: We studied 793 patients enrolled in a clinical trial of nutrient 
      supplements to prevent large-bowel adenomas. Unlike invasive cancers, adenomas 
      usually do not cause symptoms or detectable gastrointestinal bleeding; thus, 
      adenomas are unlikely to influence aspirin use. Each patient had at least one 
      large-bowel adenoma diagnosed and removed shortly before study entry and had been 
      judged to be free of further tumors by colonoscopy. Use of aspirin was assessed 
      by responses on questionnaires administered 6 and 12 months after enrollment. We 
      performed complete colonoscopies on all patients 1 year after they entered the 
      study and removed all polyps. RESULTS: Patients who reported taking aspirin on 
      both questionnaires (consistent users) had a lower risk of new adenomas at their 
      1-year follow-up colonoscopy (odds ratio = 0.52; 95% confidence interval = 
      0.31-0.89) compared with patients who did not report using aspirin on either of 
      the questionnaires. The apparent protective effect of consistent aspirin use was 
      present among both men and women and did not appear to be influenced by the 
      number of prior adenomas. CONCLUSIONS: These data further support the hypothesis 
      that aspirin has an antineoplastic effect in the large bowel. Nevertheless, the 
      question of whether aspirin should be used to prevent large-bowel tumors would be 
      best answered by a randomized controlled clinical trial specifically designed to 
      address this issue.
FAU - Greenberg, E R
AU  - Greenberg ER
AD  - Department of Community and Family Medicine, Dartmouth Medical School, Hanover, 
      N.H. 03755-3861.
FAU - Baron, J A
AU  - Baron JA
FAU - Freeman, D H Jr
AU  - Freeman DH Jr
FAU - Mandel, J S
AU  - Mandel JS
FAU - Haile, R
AU  - Haile R
LA  - eng
GR  - CA-23108/CA/NCI NIH HHS/United States
GR  - CA-37287/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/*prevention & control
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Colonic Neoplasms/*prevention & control
MH  - Colonoscopy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Surveys and Questionnaires
EDAT- 1993/06/02 00:00
MHDA- 2001/03/28 10:01
CRDT- 1993/06/02 00:00
PHST- 1993/06/02 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1993/06/02 00:00 [entrez]
AID - 10.1093/jnci/85.11.912 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 1993 Jun 2;85(11):912-6. doi: 10.1093/jnci/85.11.912.

PMID- 32354366
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 1868-7083 (Electronic)
IS  - 1868-7075 (Print)
IS  - 1868-7075 (Linking)
VI  - 12
IP  - 1
DP  - 2020 Apr 30
TI  - Cord blood DNA methylation reflects cord blood C-reactive protein levels but not 
      maternal levels: a longitudinal study and meta-analysis.
PG  - 60
LID - 10.1186/s13148-020-00852-2 [doi]
LID - 60
AB  - BACKGROUND: Prenatal inflammation has been proposed as an important mediating 
      factor in several adverse pregnancy outcomes. C-reactive protein (CRP) is an 
      inflammatory cytokine easily measured in blood. It has clinical value due to its 
      reliability as a biomarker for systemic inflammation and can indicate cellular 
      injury and disease severity. Elevated levels of CRP in adulthood are associated 
      with alterations in DNA methylation. However, no studies have prospectively 
      investigated the relationship between maternal CRP levels and newborn DNA 
      methylation measured by microarray in cord blood with reasonable epigenome-wide 
      coverage. Importantly, the timing of inflammation exposure during pregnancy may 
      also result in different effects. Thus, our objective was to evaluate this 
      prospective association of CRP levels measured during multiple periods of 
      pregnancy and in cord blood at delivery which was available in one cohort (i.e., 
      Effects of Aspirin in Gestation and Reproduction trial), and also to conduct a 
      meta-analysis with available data at one point in pregnancy from three other 
      cohorts from the Pregnancy And Childhood Epigenetics consortium (PACE). 
      Secondarily, the impact of maternal randomization to low dose aspirin prior to 
      pregnancy on methylation was assessed. RESULTS: Maternal CRP levels were not 
      associated with newborn DNA methylation regardless of gestational age of 
      measurement (i.e., CRP at approximately 8, 20, and 36 weeks among 358 newborns in 
      EAGeR). There also was no association in the meta-analyses (all p > 0.5) with a 
      larger sample size (n = 1603) from all participating PACE cohorts with available 
      CRP data from first trimester (< 18 weeks gestation). Randomization to aspirin 
      was not associated with DNA methylation. On the other hand, newborn CRP levels 
      were significantly associated with DNA methylation in the EAGeR trial, with 33 
      CpGs identified (FDR corrected p < 0.05) when both CRP and methylation were 
      measured at the same time point in cord blood. The top 7 CpGs most strongly 
      associated with CRP resided in inflammation and vascular-related genes. 
      CONCLUSIONS: Maternal CRP levels measured during each trimester were not 
      associated with cord blood DNA methylation. Rather, DNA methylation was 
      associated with CRP levels measured in cord blood, particularly in gene regions 
      predominately associated with angiogenic and inflammatory pathways. TRIAL 
      REGISTRATION: Clinicaltrials.gov, NCT00467363, Registered April 30, 2007, 
      http://www.clinicaltrials.gov/ct2/show/NCT00467363.
FAU - Yeung, Edwina H
AU  - Yeung EH
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 6710B 
      Rockledge Dr, MSC 7004, Bethesda, MD, 20817, USA. yeungedw@mail.nih.gov.
FAU - Guan, Weihua
AU  - Guan W
AD  - Division of Biostatistics, School of Public Health, University of Minnesota, A460 
      Mayo Building, MMC 303, 420 Delaware St. SE, Minneapolis, MN, 55455, USA.
FAU - Zeng, Xuehuo
AU  - Zeng X
AD  - Glotech, Inc., Bethesda, MD, 20817, USA.
FAU - Salas, Lucas A
AU  - Salas LA
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth College, 
      Lebanon, NH, 03766, USA.
FAU - Mumford, Sunni L
AU  - Mumford SL
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 6710B 
      Rockledge Dr, MSC 7004, Bethesda, MD, 20817, USA.
FAU - de Prado Bert, Paula
AU  - de Prado Bert P
AD  - ISGlobal, 08003, Barcelona, Spain.
AD  - Universitat Pompeu Fabra (UPF), 08003, Barcelona, Spain.
AD  - CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
FAU - van Meel, Evelien R
AU  - van Meel ER
AD  - The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, 
      P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
AD  - Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, P.O. 
      Box 2040, 3000 CA, Rotterdam, The Netherlands.
FAU - Malmberg, Anni
AU  - Malmberg A
AD  - Department of Psychology and Logopedics, Faculty of Medicine, University of 
      Helsinki, Helsinki, Finland.
FAU - Sunyer, Jordi
AU  - Sunyer J
AD  - ISGlobal, 08003, Barcelona, Spain.
AD  - Universitat Pompeu Fabra (UPF), 08003, Barcelona, Spain.
AD  - CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
AD  - IMIM (Hospital del Mar Medical Research Institute), 08003, Barcelona, Spain.
FAU - Duijts, Liesbeth
AU  - Duijts L
AD  - The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, 
      P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
AD  - Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, P.O. 
      Box 2040, 3000 CA, Rotterdam, The Netherlands.
FAU - Felix, Janine F
AU  - Felix JF
AD  - The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, 
      P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
AD  - Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, P.O. 
      Box 2040, 3000 CA, Rotterdam, The Netherlands.
FAU - Czamara, Darina
AU  - Czamara D
AD  - Department of Translational Research in Psychiatry, Max-Planck-Institute of 
      Psychiatry, Munich, Germany.
FAU - Hämäläinen, Esa
AU  - Hämäläinen E
AD  - University of Eastern Finland, Kuopio, Finland.
FAU - Binder, Elisabeth B
AU  - Binder EB
AD  - Department of Translational Research in Psychiatry, Max-Planck-Institute of 
      Psychiatry, Munich, Germany.
AD  - Department of Psychiatry and Behavioral Sciences, Emory University School of 
      Medicine, Atlanta, USA.
FAU - Räikkönen, Katri
AU  - Räikkönen K
AD  - Department of Psychology and Logopedics, Faculty of Medicine, University of 
      Helsinki, Helsinki, Finland.
FAU - Lahti, Jari
AU  - Lahti J
AD  - Department of Psychology and Logopedics, Faculty of Medicine, University of 
      Helsinki, Helsinki, Finland.
FAU - London, Stephanie J
AU  - London SJ
AD  - Division of Intramural Research, National Institute of Environmental Health 
      Sciences, National Institutes of Health, Department of Health and Human Services, 
      Research Triangle Park, Durham, NC, 27709, USA.
FAU - Silver, Robert M
AU  - Silver RM
AD  - University of Utah, Salt Lake City, 50 N Medical Dr, Salt Lake City, UT, 84132, 
      USA.
FAU - Schisterman, Enrique F
AU  - Schisterman EF
AD  - Epidemiology Branch, Division of Intramural Population Health Research, Eunice 
      Kennedy Shriver National Institute of Child Health and Human Development, 6710B 
      Rockledge Dr, MSC 7004, Bethesda, MD, 20817, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00467363
GR  - MR/S03658X/1/MRC_/Medical Research Council/United Kingdom
GR  - HHSN272201300023I/AI/NIAID NIH HHS/United States
GR  - R01 HD068437/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200430
PL  - Germany
TA  - Clin Epigenetics
JT  - Clinical epigenetics
JID - 101516977
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - C-Reactive Protein/*metabolism
MH  - CpG Islands/drug effects
MH  - *DNA Methylation/drug effects
MH  - Epigenesis, Genetic/drug effects
MH  - Female
MH  - Fetal Blood/*chemistry
MH  - Gestational Age
MH  - Humans
MH  - Longitudinal Studies
MH  - Maternal Age
MH  - Oligonucleotide Array Sequence Analysis/*methods
MH  - Pregnancy
MH  - Pregnancy Trimesters/*blood/drug effects
MH  - Prospective Studies
PMC - PMC7193358
OTO - NOTNLM
OT  - C-reactive protein
OT  - DNA methylation
OT  - Developmental programming
OT  - Inflammation
OT  - Newborn
OT  - Pregnancy
COIS- The authors report no competing interests.
EDAT- 2020/05/02 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/01/03 00:00 [received]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
AID - 10.1186/s13148-020-00852-2 [pii]
AID - 852 [pii]
AID - 10.1186/s13148-020-00852-2 [doi]
PST - epublish
SO  - Clin Epigenetics. 2020 Apr 30;12(1):60. doi: 10.1186/s13148-020-00852-2.

PMID- 15026612
OWN - NLM
STAT- MEDLINE
DCOM- 20040713
LR  - 20131121
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 17
IP  - 4
DP  - 2004
TI  - What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane 
      production after a transient ischemic attack or ischemic stroke?
PG  - 296-302
AB  - BACKGROUND: There is still worldwide disagreement about the optimal lowest dose 
      of aspirin to be used in patients after a transient ischemic attack (TIA) or 
      nondisabling stroke. We measured the urinary 11-dehydro-thromboxane-B(2) 
      (uTXB(2)) excretion to compare the degree of suppression of in vivo platelet 
      activation by various low doses of aspirin. METHODS: 60 patients were randomly 
      allocated to treatment with either 30, 50, 75 or 325 mg of aspirin. All patients 
      received a 413-mg loading dose of carbasalate calcium (equivalent to 325 mg of 
      aspirin) on day 0. The study population was stratified into a subgroup with acute 
      ischemic stroke (AIS; n = 20; onset of symptoms <48 h) and a subgroup with a 
      recent TIA or minor stroke (TIA/mS; n = 40) with onset of symptoms beyond 30 
      days, but less than a year previously. Urine samples were collected on day 0, 1, 
      5, 11 and 28 in patients with AIS, and on day 0, 11 and 28 in the patients with a 
      TIA/mS. RESULTS: On day 28, mean uTXB(2) levels were 241, 130, 217 and 187 
      pmol/mmol creatinine in the four treatment groups (ANOVA, p = 0.43). In the AIS 
      subgroup, uTXB(2) remained suppressed on days 5 and 11 in all except the patients 
      with the lowest dose (mean uTXB(2) on days 5 and 11: 475 and 392 pmol/mmol 
      creatinine; log-transformed ANOVA, p = 0.05). CONCLUSION: In patients with a TIA 
      or nondisabling stroke, a daily dose of 30 mg of aspirin provides sufficient 
      suppression of thromboxane synthesis. No indication of a dose-effect relationship 
      was found. However, whether such a low dose adequately suppresses thromboxane 
      synthesis in patients with acute stroke is uncertain.
CI  - Copyright 2004 S. Karger AG, Basel
FAU - Dippel, Diederik W J
AU  - Dippel DW
AD  - Departments of Neurology and Hematology, Erasmus Medical Center, Rotterdam, The 
      Netherlands. d.dippel@erasmusmc.nl
FAU - Van Kooten, Fop
AU  - Van Kooten F
FAU - Leebeek, Frank W G
AU  - Leebeek FW
FAU - van Vliet, Huub H D M
AU  - van Vliet HH
FAU - Mehicevic, Ajnira
AU  - Mehicevic A
FAU - Li, Simon S C
AU  - Li SS
FAU - Koudstaal, Peter J
AU  - Koudstaal PJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20040315
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*therapeutic use
MH  - Risk Factors
MH  - Stroke/*therapy
MH  - Thromboxane B2/*analogs & derivatives/urine
MH  - Thromboxanes/*antagonists & inhibitors
MH  - Treatment Outcome
EDAT- 2004/03/18 05:00
MHDA- 2004/07/14 05:00
CRDT- 2004/03/18 05:00
PHST- 2003/04/10 00:00 [received]
PHST- 2003/10/20 00:00 [accepted]
PHST- 2004/03/18 05:00 [pubmed]
PHST- 2004/07/14 05:00 [medline]
PHST- 2004/03/18 05:00 [entrez]
AID - 77340 [pii]
AID - 10.1159/000077340 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2004;17(4):296-302. doi: 10.1159/000077340. Epub 2004 Mar 15.

PMID- 26213876
OWN - NLM
STAT- MEDLINE
DCOM- 20170117
LR  - 20170117
IS  - 1542-538X (Electronic)
IS  - 0744-6020 (Linking)
VI  - 34
IP  - 4
DP  - 2015 Jul-Aug
TI  - Impact of a Focused Approach for Discharge Teaching Regarding the Use of Aspirin 
      as Anticoagulant After Joint Replacement Surgery.
PG  - 211-20; quiz 221-2
LID - 10.1097/NOR.0000000000000160 [doi]
AB  - BACKGROUND: Patient education for the use and administration of aspirin (ASA) as 
      an anticoagulant may be deficient. PURPOSE: To pilot a knowledge assessment tool 
      regarding the use of aspirin (ASA) as an anticoagulant and to evaluate the impact 
      of a focused approach for discharge teaching. DESIGN: One-group pretest-posttest 
      pilot study. SAMPLE: Convenience sample of patients hospitalized for total knee 
      and total hip arthroplasty. MEASURE: Researcher developed ASA quiz. INTERVENTION: 
      Focused education on aspirin as an anticoagulant. RESULTS: There was a 
      statistically significant improvement in knowledge (Wilcoxon rank sum test Z = 
      3.880, p < .001).
FAU - Wittig-Wells, Deborah
AU  - Wittig-Wells D
AD  - Deborah Wittig-Wells, PhD, MSN, RN, BC-NE, Director of Nursing Research, Emory 
      University Orthopedic and Spine Hospital, Tucker, GA. Melinda Higgins, PhD, 
      Senior Biostatistician, Emory University School of Nursing, Atlanta, GA. Erica 
      Davis, BSN, RN, Staff Nurse, Emory University Orthopedic and Spine Hospital, 
      Tucker, GA. Ifeya Johnson, AAN, RN, Staff Nurse, Emory University Orthopedic and 
      Spine Hospital, Tucker, GA. Latalya Louis, BSN, RN, Staff Nurse, Emory University 
      Orthopedic and Spine Hospital, Tucker, GA. Olga Mason, BSN, RN, Staff Nurse, 
      Emory University Orthopedic and Spine Hospital, Tucker, GA. Jacqueline 
      Samms-McPherson, Staff Nurse, Emory University Orthopedic and Spine Hospital, 
      Tucker, GA. Sandra Sims, MSN, RN, Staff Nurse, Emory University Orthopedic and 
      Spine Hospital, Tucker, GA. Ani Jacob, BSN, RN, Staff Nurse, Emory University 
      Orthopedic and Spine Hospital, Tucker, GA.
FAU - Higgins, Melinda
AU  - Higgins M
FAU - Davis, Erica
AU  - Davis E
FAU - Johnson, Ifeya
AU  - Johnson I
FAU - Louis, Latalya
AU  - Louis L
FAU - Mason, Olga
AU  - Mason O
FAU - Samms-McPherson, Jacqueline
AU  - Samms-McPherson J
FAU - Sims, Sandra
AU  - Sims S
FAU - Jacob, Ani
AU  - Jacob A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Orthop Nurs
JT  - Orthopedic nursing
JID - 8409486
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
MH  - Anticoagulants/*administration & dosage
MH  - *Arthroplasty, Replacement, Hip
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/*administration & dosage
MH  - Education, Nursing, Continuing
MH  - Female
MH  - Humans
MH  - Male
MH  - *Patient Discharge
MH  - Pilot Projects
EDAT- 2015/07/28 06:00
MHDA- 2017/01/18 06:00
CRDT- 2015/07/28 06:00
PHST- 2015/07/28 06:00 [entrez]
PHST- 2015/07/28 06:00 [pubmed]
PHST- 2017/01/18 06:00 [medline]
AID - 00006416-201507000-00011 [pii]
AID - 10.1097/NOR.0000000000000160 [doi]
PST - ppublish
SO  - Orthop Nurs. 2015 Jul-Aug;34(4):211-20; quiz 221-2. doi: 
      10.1097/NOR.0000000000000160.

PMID- 33860685
OWN - NLM
STAT- MEDLINE
DCOM- 20211026
LR  - 20211026
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 10
IP  - 8
DP  - 2021 Apr 20
TI  - Aspirin Alone Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve 
      Implantation: A Systematic Review and Patient-Level Meta-Analysis.
PG  - e019604
LID - 10.1161/JAHA.120.019604 [doi]
LID - e019604
AB  - Background In patients undergoing transcatheter aortic valve implantation without 
      an indication for oral anticoagulation, it is unclear whether single or dual 
      antiplatelet therapy (DAPT) is necessary to minimize both the bleeding and 
      thromboembolic risk. In this patient-level meta-analysis, we further investigate 
      the effect of aspirin alone compared with DAPT for preventing both thromboembolic 
      and bleeding events after transcatheter aortic valve implantation. Methods and 
      Results We conducted a systematic review of all available randomized controlled 
      trials comparing aspirin with DAPT. In total, 1086 patients were included across 
      4 eligible trials. The primary outcomes were the composite of all-cause 
      mortality, major or life-threatening bleeding, stroke or myocardial infarction 
      (first composite outcome), and the same composite excluding bleeding (second 
      composite outcome), both tested at 30 days and 3 months. The first composite 
      outcome occurred significantly less in the aspirin-alone group at 30 days (10.3% 
      versus 14.7%, odds ratio [OR], 0.67; 95% CI, 0.46-0.97, P=0.034) and 3 months 
      (11.0% versus 16.5%, hazard ratio [HR], 0.66; 95% CI, 0.47-0.94, P=0.02), 
      compared with the DAPT group. The second composite outcome occurred in 5.5% and 
      6.6% at 30 days (OR, 0.83; 95% CI, 0.50-1.38, P=0.47) and in 6.9% and 8.5% at 
      3 months in the aspirin-alone group compared with the DAPT group (HR, 0.82; 95% 
      CI, 0.52-1.29, P=0.39), respectively. Conclusions In patients without an 
      indication for oral anticoagulation undergoing transcatheter aortic valve 
      implantation, aspirin alone significantly reduced the composite of thromboembolic 
      and bleeding events, and does not increase the composite of thromboembolic events 
      after transcatheter aortic valve implantation, compared with DAPT.
FAU - Brouwer, Jorn
AU  - Brouwer J
AD  - Department of Cardiology St. Antonius Hospital Nieuwegein The Netherlands.
FAU - Nijenhuis, Vincent J
AU  - Nijenhuis VJ
AD  - Department of Cardiology St. Antonius Hospital Nieuwegein The Netherlands.
FAU - Rodés-Cabau, Josep
AU  - Rodés-Cabau J
AD  - Department of Cardiology Quebec Heart & Lung Institute Laval University Quebec 
      City Quebec Canada.
FAU - Stabile, Eugenio
AU  - Stabile E
AD  - Department of Advanced Biomedical Sciences University "Federico II" Naples Italy.
FAU - Barbanti, Marco
AU  - Barbanti M
AD  - Department of Cardiology A.O.U. Policlinico "G. Rodolico - San Marco" Catania 
      Italy.
FAU - Costa, Giuliano
AU  - Costa G
AD  - Department of Cardiology A.O.U. Policlinico "G. Rodolico - San Marco" Catania 
      Italy.
FAU - Mahmoodi, Bakhtawar K
AU  - Mahmoodi BK
AD  - Department of Cardiology St. Antonius Hospital Nieuwegein The Netherlands.
FAU - Ten Berg, Jurrien M
AU  - Ten Berg JM
AD  - Department of Cardiology St. Antonius Hospital Nieuwegein The Netherlands.
AD  - Cardiovascular Research Institute Maastricht (CARIM) Maastricht The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210416
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aortic Valve Stenosis/*surgery
MH  - Aspirin/*therapeutic use
MH  - Dual Anti-Platelet Therapy/*methods
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Thrombosis/*prevention & control
MH  - Transcatheter Aortic Valve Replacement/*adverse effects
PMC - PMC8174170
OTO - NOTNLM
OT  - aspirin
OT  - dual antiplatelet therapy
OT  - transcatheter aortic valve implantation
COIS- None.
EDAT- 2021/04/17 06:00
MHDA- 2021/10/27 06:00
CRDT- 2021/04/16 08:38
PHST- 2021/04/17 06:00 [pubmed]
PHST- 2021/10/27 06:00 [medline]
PHST- 2021/04/16 08:38 [entrez]
AID - JAH36168 [pii]
AID - 10.1161/JAHA.120.019604 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2021 Apr 20;10(8):e019604. doi: 10.1161/JAHA.120.019604. Epub 
      2021 Apr 16.

PMID- 19614796
OWN - NLM
STAT- MEDLINE
DCOM- 20090924
LR  - 20211020
IS  - 1559-4572 (Electronic)
IS  - 1559-4564 (Linking)
VI  - 4
IP  - 2
DP  - 2009 Spring
TI  - Utility of aspirin therapy in patients with the cardiometabolic syndrome and 
      diabetes.
PG  - 96-101
LID - 10.1111/j.1559-4572.2008.00037.x [doi]
AB  - Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly 
      growing health problem in the United States. There is a 3-fold increase in the 
      prevalence of coronary heart disease, myocardial infarction, and stroke due to 
      the coagulation, hemodynamic, and metabolic abnormalities seen in these 
      individuals. The use of aspirin for secondary prevention and, to a lesser degree, 
      primary prevention of cardiovascular events is a well-established standard of 
      care. However, in patients with diabetes or the cardiometabolic syndrome, the 
      role of aspirin in prevention of cardiovascular events remains controversial. In 
      this review, the authors examine the clinical trial data on the use of aspirin in 
      diabetes and the cardiometabolic syndrome for cardiovascular protection. They 
      also explore, in addition to aspirin's effects on platelet aggregation, some of 
      the mechanisms by which aspirin may favorably alter the course of 
      atherosclerosis, effects on endothelial function, and glycemia.
FAU - Gardner, Michael
AU  - Gardner M
AD  - Diabetes and Cardiovascular Center, University of Missouri School of Medicine and 
      Truman VA Hospital, Columbia, MO 65212, USA. gardnermj@health.missouri.edu
FAU - Palmer, John
AU  - Palmer J
FAU - Manrique, Camila
AU  - Manrique C
FAU - Lastra, Guido
AU  - Lastra G
FAU - Gardner, David W
AU  - Gardner DW
FAU - Sowers, James R
AU  - Sowers JR
LA  - eng
GR  - I01 BX001981/BX/BLRD VA/United States
GR  - R01 HL073101/HL/NHLBI NIH HHS/United States
GR  - R01 HL73101-01A1/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - United States
TA  - J Cardiometab Syndr
JT  - Journal of the cardiometabolic syndrome
JID - 101284690
RN  - 0 (Blood Glucose)
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Blood Glucose/metabolism
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Agents/*therapeutic use
MH  - Cardiovascular Diseases/blood/etiology/*prevention & control
MH  - Diabetes Complications/blood/etiology/*prevention & control
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Endothelium, Vascular/drug effects
MH  - Humans
MH  - Metabolic Syndrome/blood/complications/*drug therapy
MH  - Treatment Outcome
RF  - 39
EDAT- 2009/07/21 09:00
MHDA- 2009/09/25 06:00
CRDT- 2009/07/21 09:00
PHST- 2009/07/21 09:00 [entrez]
PHST- 2009/07/21 09:00 [pubmed]
PHST- 2009/09/25 06:00 [medline]
AID - CMS037 [pii]
AID - 10.1111/j.1559-4572.2008.00037.x [doi]
PST - ppublish
SO  - J Cardiometab Syndr. 2009 Spring;4(2):96-101. doi: 
      10.1111/j.1559-4572.2008.00037.x.

PMID- 30575949
OWN - NLM
STAT- MEDLINE
DCOM- 20191028
LR  - 20191028
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 145
IP  - 1
DP  - 2019 Jul 1
TI  - Long-term use of low-dose aspirin for cancer prevention: A 10-year population 
      cohort study in Hong Kong.
PG  - 267-273
LID - 10.1002/ijc.32083 [doi]
AB  - Aspirin, commonly used for prevention of cardiovascular and cerebrovascular 
      diseases, has been found to possess protective effects against cancer development 
      in the Western populations. Such effects among Asian populations remain 
      uncertain. The objective of this study is to investigate the use of aspirin on 
      prevention of different cancers among Chinese users. This population-based study 
      utilized database from the Hong Kong Hospital Authority; adults with aspirin 
      prescription for at least 6 months between 2000 and 2004 were included and 
      followed up until 2013. Aspirin users were age-sex matched with non-aspirin users 
      at a 1:2 ratio. Incidences of cancer were the primary outcome measured by 
      relative risk (RR). A total of 204,170 aspirin users and 408,339 non-aspirin 
      users were included, with the mean age 67.5 years, 7.7 years average duration of 
      aspirin prescription and 80 mg as the median dose of aspirin. Cancer incidences 
      were found in 26,929 (13.2%) aspirin users and 70,755 (17.3%) non-aspirin users. 
      Compared with patients who had not been prescribed aspirin, aspirin usage led to 
      significant reduction of cancers in liver (RR: 0.49), stomach (RR: 0.42), 
      colorectum (RR: 0.71), lung (RR: 0.65), pancreas (RR: 0.54), oesophagus (RR: 
      0.59) and leukaemia (RR: 0.67). There was no demonstrable reduction of kidney 
      cancer, bladder cancer, prostate cancer and multiple myeloma in association with 
      the usage of aspirin. Risk of breast cancer was shown to marginally increase (RR: 
      1.14) with aspirin usage. This study demonstrated that the long-term use of 
      low-dose aspirin is associated with the reduction in risk of various cancers but 
      not for breast cancer. Further investigation is needed before promoting aspirin 
      as a primary chemoprotective agent.
CI  - © 2018 UICC.
FAU - Tsoi, Kelvin K F
AU  - Tsoi KKF
AUID- ORCID: 0000-0001-5580-7686
AD  - Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of 
      Hong Kong, Shatin, Hong Kong.
AD  - Jockey Club School of Public Health and Primary Care, The Chinese University of 
      Hong Kong, Shatin, Hong Kong.
FAU - Ho, Jason M W
AU  - Ho JMW
AD  - Jockey Club School of Public Health and Primary Care, The Chinese University of 
      Hong Kong, Shatin, Hong Kong.
FAU - Chan, Felix C H
AU  - Chan FCH
AD  - Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of 
      Hong Kong, Shatin, Hong Kong.
FAU - Sung, Joseph J Y
AU  - Sung JJY
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Shatin, Hong Kong.
LA  - eng
PT  - Journal Article
DEP - 20190107
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hong Kong/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*epidemiology/prevention & control
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Chinese
OT  - Hong Kong
OT  - aspirin
OT  - cancer incidence
OT  - long-term
EDAT- 2018/12/24 06:00
MHDA- 2019/10/29 06:00
CRDT- 2018/12/22 06:00
PHST- 2018/06/26 00:00 [received]
PHST- 2018/11/29 00:00 [revised]
PHST- 2018/12/13 00:00 [accepted]
PHST- 2018/12/24 06:00 [pubmed]
PHST- 2019/10/29 06:00 [medline]
PHST- 2018/12/22 06:00 [entrez]
AID - 10.1002/ijc.32083 [doi]
PST - ppublish
SO  - Int J Cancer. 2019 Jul 1;145(1):267-273. doi: 10.1002/ijc.32083. Epub 2019 Jan 7.

PMID- 25222879
OWN - NLM
STAT- MEDLINE
DCOM- 20150708
LR  - 20141016
IS  - 1520-5207 (Electronic)
IS  - 1520-5207 (Linking)
VI  - 118
IP  - 41
DP  - 2014 Oct 16
TI  - Elucidating the origin of the esterase activity of human serum albumin using 
      QM/MM calculations.
PG  - 11886-94
LID - 10.1021/jp506629y [doi]
AB  - Human serum albumin (HSA) is a critical transport plasma protein accounting for 
      ∼60% of the total protein content in blood. Remarkably, this protein is also 
      found to display esterase activity. In this study, we apply theoretical studies 
      to elucidate the origin of the esterase-like activity arising from the Sudlow 
      site I. Using MD and QM/MM calculations, we investigate which active site 
      residues are involved in the reaction, and the precise mechanistic sequence of 
      events. Our results suggest Lys199, His242, and Arg257 help give rise to the 
      esterase activity and that the most catalytically efficient active site 
      configuration requires that both Lys199 and Aspirin are in their neutral forms. 
      The abundance of HSA in the body suggests the protein might be a suitable target 
      for the computational guided design of acetyl based pro-drugs of acidic molecules 
      that often displayed limited oral exposure due to their unmasked ionizable 
      substituent.
FAU - Phuangsawai, Oraphan
AU  - Phuangsawai O
AD  - Department of Chemistry, Faculty of Science, Kasetsart University , 50 Ngam Wong 
      Wan Road, Chatuchak, Bangkok 10900, Thailand.
FAU - Hannongbua, Supa
AU  - Hannongbua S
FAU - Gleeson, M Paul
AU  - Gleeson MP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141007
PL  - United States
TA  - J Phys Chem B
JT  - The journal of physical chemistry. B
JID - 101157530
RN  - 0 (Protons)
RN  - 0 (Serum Albumin)
RN  - EC 3.1.1.7 (Acetylcholinesterase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylcholinesterase/chemistry
MH  - Aspirin/chemistry
MH  - Catalytic Domain
MH  - Computer Simulation
MH  - Humans
MH  - Models, Molecular
MH  - Protons
MH  - Quantum Theory
MH  - Serum Albumin/*chemistry/genetics
EDAT- 2014/09/16 06:00
MHDA- 2015/07/15 06:00
CRDT- 2014/09/16 06:00
PHST- 2014/09/16 06:00 [entrez]
PHST- 2014/09/16 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - 10.1021/jp506629y [doi]
PST - ppublish
SO  - J Phys Chem B. 2014 Oct 16;118(41):11886-94. doi: 10.1021/jp506629y. Epub 2014 
      Oct 7.

PMID- 29319605
OWN - NLM
STAT- MEDLINE
DCOM- 20180917
LR  - 20220330
IS  - 1532-8651 (Electronic)
IS  - 1098-7339 (Linking)
VI  - 43
IP  - 3
DP  - 2018 Apr
TI  - Epidural Hematoma Following Interlaminar Epidural Injection in Patient Taking 
      Aspirin.
PG  - 310-312
LID - 10.1097/AAP.0000000000000730 [doi]
AB  - OBJECTIVE: We present a case report of a patient who developed an epidural 
      hematoma following an interlaminar epidural steroid injection with no risk 
      factors aside from old age and aspirin use for secondary prevention. CASE REPORT: 
      A 79-year-old man developed an epidural hematoma requiring surgical treatment 
      following an uncomplicated interlaminar epidural steroid injection performed for 
      neurogenic claudication. In the periprocedural period, he continued aspirin for 
      secondary prophylaxis following a myocardial infarction. CONCLUSIONS: For 
      patients taking aspirin for primary or secondary prophylaxis, the American 
      Society of Regional Anesthesia and Pain Medicine antiplatelet and anticoagulation 
      guidelines for spine and pain procedures recommend a shared assessment and risk 
      stratification when deciding to hold the medication for intermediate-risk 
      neuraxial procedures. Cases such as this serve to highlight the importance of 
      giving careful consideration to medical optimization of a patient even when a 
      low- or intermediate-risk procedure is planned.
FAU - Sanders, Rebecca A
AU  - Sanders RA
AD  - From the Pain Division, Mayo Clinic Department of Anesthesiology and 
      Perioperative Medicine, Rochester, MN.
FAU - Bendel, Markus A
AU  - Bendel MA
FAU - Moeschler, Susan M
AU  - Moeschler SM
FAU - Mauck, William D
AU  - Mauck WD
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Reg Anesth Pain Med
JT  - Regional anesthesia and pain medicine
JID - 9804508
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Steroids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Reg Anesth Pain Med. 2018 Jul;43(5):557. PMID: 29927847
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Hematoma, Epidural, Spinal/*chemically induced/diagnostic imaging
MH  - Humans
MH  - Injections, Epidural/adverse effects
MH  - Low Back Pain/diagnosis/*drug therapy/physiopathology
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk Factors
MH  - *Secondary Prevention
MH  - Steroids/*administration & dosage
MH  - Treatment Outcome
EDAT- 2018/01/11 06:00
MHDA- 2018/09/18 06:00
CRDT- 2018/01/11 06:00
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2018/09/18 06:00 [medline]
PHST- 2018/01/11 06:00 [entrez]
AID - 10.1097/AAP.0000000000000730 [doi]
PST - ppublish
SO  - Reg Anesth Pain Med. 2018 Apr;43(3):310-312. doi: 10.1097/AAP.0000000000000730.

PMID- 12784086
OWN - NLM
STAT- MEDLINE
DCOM- 20031126
LR  - 20171101
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 68
IP  - 3
DP  - 2003 Jul
TI  - Effects of nonsteroidal anti-inflammatory drugs on prostacyclin and thromboxane 
      in the kidney.
PG  - 147-53
AB  - Dose-response curves were obtained relating the effects of increasing amounts of 
      aspirin, a nonselective cyclooxygenase (COX) inhibitor, and celecoxib, a 
      selective cyclooxygenase 2 (COX-2) inhibitor, on the concentrations of 
      prostacyclin and thromboxane in renal cortex and medulla of rabbits. The 
      concentrations of the two agonists (aspirin and celecoxib) which elicit a 
      half-maximal response on the prostanoid concentration (EC(50)) were compared. 
      Additionally, controls for prostacyclin and thromboxane were related to values 
      for the experimental groups. The EC(50) values for celecoxib were considerably 
      lower than those for aspirin, indicating that celecoxib was more effective in 
      suppressing prostanoid production. There were also significant differences 
      between the majority of experimental groups and their respective controls, 
      further evidence for the greater inhibitory activity of celecoxib on 
      prostacyclin. Celecoxib lowered the ratio prostacyclin/thromboxane in the renal 
      medulla; mercuric chloride further diminished the concentration of prostacyclin 
      in the renal medulla. The results confirm that in the normal rabbit kidney, both 
      nonselective and specific COX inhibitors interfere with renal prostanoid 
      synthesis, but that a selective COX-2 inhibitor is more effective.
CI  - Copyright 2003 S. Karger AG, Basel
FAU - Lomnicka, Magdalena
AU  - Lomnicka M
AD  - Department of Experimental Cardiology, Huntington Medical Research Institutes, 
      Pasadena, California 91101, USA.
FAU - Karouni, Katayoun
AU  - Karouni K
FAU - Sue, Michele
AU  - Sue M
FAU - Wessel, Lauren A
AU  - Wessel LA
FAU - Bing, Richard J
AU  - Bing RJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - 0 (Thromboxanes)
RN  - 53GH7MZT1R (Mercuric Chloride)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Celecoxib
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Epoprostenol/*metabolism
MH  - Kidney/*drug effects/*metabolism
MH  - Mercuric Chloride/administration & dosage/pharmacology
MH  - Pyrazoles
MH  - Rabbits
MH  - Sulfonamides/administration & dosage/pharmacology
MH  - Thromboxanes/*metabolism
EDAT- 2003/06/05 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/06/05 05:00
PHST- 2002/10/24 00:00 [received]
PHST- 2003/01/21 00:00 [accepted]
PHST- 2003/06/05 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/06/05 05:00 [entrez]
AID - 70172 [pii]
AID - 10.1159/000070172 [doi]
PST - ppublish
SO  - Pharmacology. 2003 Jul;68(3):147-53. doi: 10.1159/000070172.

PMID- 984064
OWN - NLM
STAT- MEDLINE
DCOM- 19770103
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 61
IP  - 5
DP  - 1976 Nov
TI  - The effect of anti-inflammatory agents and inflammation on granulocyte adherence. 
      Evidence for regulation by plasma factors.
PG  - 597-607
AB  - Significant inhibition of granulocyte adherence to nylon fiber columns followed 
      the administration of alcohol, aspirin, sodium salicylate, acetaminophen, 
      indomethacin, phenylbutazone, colchicine or prednisone to normal subjects. The 
      addition of salicylates and glucocorticoids to blood in vitro had no effect on 
      adherence, but plasma from volunteer subjects treated with either drug contained 
      a factor which inhibited the adherence of normal granulocytes. The factor is heat 
      stable, nondialyzable and not present in serum; it produces a linear dose 
      response in normal cells. When mixed with the adherence-increasing factor found 
      in inflammatory diseases, it neutralizes the augmenting effect and normal 
      granulocyte adherence results. The effect of anti-inflammatory therapy on 
      inflammatory disease was studied in aspirin-treated patients with rheumatoid 
      arthritis. Their granulocyte adherence fell into two categories based on the 
      clinical control of their disease; patients in good control had only slightly 
      increased granulocyte adherence, but those in poor control had an average 
      adherence more than twice normal. Mean blood aspirin levels were equivalent for 
      the two groups (11.0 mg/100 ml for the well controlled and 13.4 mg/100 ml for 
      those poorly controlled). Thus, clinical response to anti-inflammatory therapy 
      correlates well with granulocyte adherence, not with aspirin levels. The 
      potential pathogenetic role of adherence-modifying factors in inflammatory 
      diseases remains to be determined.
FAU - MacGregor, R R
AU  - MacGregor RR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adhesiveness
MH  - Adult
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Arthritis, Rheumatoid/physiopathology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Depression, Chemical
MH  - Dialysis
MH  - Drug Administration Schedule
MH  - Female
MH  - Granulocytes/drug effects/*physiology
MH  - Hot Temperature
MH  - Humans
MH  - Inflammation/*physiopathology
MH  - Leukocytes/*physiology
MH  - Male
MH  - Methods
MH  - Peritonitis/physiopathology
MH  - Plasma/*physiology
MH  - Prednisone/administration & dosage/pharmacology
MH  - Rabbits
MH  - Time Factors
EDAT- 1976/11/01 00:00
MHDA- 1976/11/01 00:01
CRDT- 1976/11/01 00:00
PHST- 1976/11/01 00:00 [pubmed]
PHST- 1976/11/01 00:01 [medline]
PHST- 1976/11/01 00:00 [entrez]
AID - 0002-9343(76)90137-6 [pii]
AID - 10.1016/0002-9343(76)90137-6 [doi]
PST - ppublish
SO  - Am J Med. 1976 Nov;61(5):597-607. doi: 10.1016/0002-9343(76)90137-6.

PMID- 37504320
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230731
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 30
IP  - 7
DP  - 2023 Jun 27
TI  - In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in 
      Colorectal Adenocarcinoma Cells.
PG  - 6197-6219
LID - 10.3390/curroncol30070460 [doi]
AB  - Although remarkable progress has been made, colorectal cancer remains a 
      significant global health issue. One of the most challenging aspects of cancer 
      treatment is the resistance of tumor cells to classical chemotherapy. 
      Conventional therapy for colorectal cancer often involves the use of 
      5-fluorouracil as a chemotherapeutic agent. Aspirin, a drug used primarily to 
      prevent cardiovascular complications, became a focus of attention due to its 
      potential use as an antitumor agent. The purpose of the study was to evaluate the 
      potential synergistic cytotoxic effects of aspirin and 5-fluorouracil on 
      colorectal adenocarcinoma cells. The viability of cells, the impact on the 
      morphology and nuclei of cells, the potential antimigratory effect, and the 
      impact on the expression of the major genes associated with cell apoptosis 
      (Bcl-2, Bax, Bad), as well as caspases 3 and 8, were evaluated. The results 
      indicated that the two compounds exerted a synergistic effect, causing a 
      reduction in cell viability accompanied by changes characteristic of the 
      apoptosis process-the condensation of nuclei and the reorganization of actin 
      filaments in cells, the reduction in the expression of the Bcl-2 gene, and the 
      increase in the expression of Bax and Bad genes, along with caspases 3 and 8. 
      Considering all these findings, it appears that aspirin may be investigated in 
      depth in order to be used in conjunction with 5-fluorouracil to increase 
      antitumor activity.
FAU - Susan, Monica
AU  - Susan M
AD  - Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy from 
      Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
FAU - Macasoi, Ioana
AU  - Macasoi I
AUID- ORCID: 0000-0002-9890-2277
AD  - Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy from 
      Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
AD  - Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, 
      "Victor Babes" University of Medicine and Pharmacy from Timisoara, Eftimie Murgu 
      Square No. 2, 300041 Timisoara, Romania.
FAU - Pinzaru, Iulia
AU  - Pinzaru I
AUID- ORCID: 0000-0003-2295-1926
AD  - Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy from 
      Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
AD  - Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, 
      "Victor Babes" University of Medicine and Pharmacy from Timisoara, Eftimie Murgu 
      Square No. 2, 300041 Timisoara, Romania.
FAU - Dehelean, Cristina
AU  - Dehelean C
AD  - Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy from 
      Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
AD  - Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, 
      "Victor Babes" University of Medicine and Pharmacy from Timisoara, Eftimie Murgu 
      Square No. 2, 300041 Timisoara, Romania.
FAU - Ilia, Iosif
AU  - Ilia I
AUID- ORCID: 0000-0002-0036-239X
AD  - Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy from 
      Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
FAU - Susan, Razvan
AU  - Susan R
AUID- ORCID: 0000-0003-3531-3974
AD  - Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy from 
      Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
FAU - Ionita, Ioana
AU  - Ionita I
AUID- ORCID: 0000-0002-6840-9553
AD  - Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy from 
      Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
LA  - eng
PT  - Journal Article
DEP - 20230627
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
RN  - U3P01618RT (Fluorouracil)
RN  - 0 (bcl-2-Associated X Protein)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Antineoplastic Agents)
RN  - EC 3.4.22.- (Caspases)
SB  - IM
MH  - Humans
MH  - Fluorouracil/pharmacology/therapeutic use
MH  - bcl-2-Associated X Protein/genetics/metabolism/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Antineoplastic Agents/therapeutic use
MH  - *Colorectal Neoplasms/drug therapy/pathology
MH  - *Adenocarcinoma/drug therapy
MH  - Caspases/metabolism/therapeutic use
PMC - PMC10377900
OTO - NOTNLM
OT  - 5-fluorouracil
OT  - aspirin
OT  - bcl-2 proteins
OT  - caspases
OT  - colorectal adenocarcinoma
OT  - immunofluorescence staining
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/28 13:10
MHDA- 2023/07/31 11:41
CRDT- 2023/07/28 08:35
PHST- 2023/05/08 00:00 [received]
PHST- 2023/06/22 00:00 [revised]
PHST- 2023/06/25 00:00 [accepted]
PHST- 2023/07/31 11:41 [medline]
PHST- 2023/07/28 13:10 [pubmed]
PHST- 2023/07/28 08:35 [entrez]
AID - curroncol30070460 [pii]
AID - curroncol-30-00460 [pii]
AID - 10.3390/curroncol30070460 [doi]
PST - epublish
SO  - Curr Oncol. 2023 Jun 27;30(7):6197-6219. doi: 10.3390/curroncol30070460.

PMID- 27473898
OWN - NLM
STAT- MEDLINE
DCOM- 20170206
LR  - 20220330
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
VI  - 34
IP  - 6
DP  - 2016 Dec
TI  - Adherence to therapies for secondary prevention of cardiovascular disease: a 
      focus on aspirin.
PG  - 415-422
LID - 10.1111/1755-5922.12211 [doi]
AB  - AIM: Suboptimal adherence to medications taken chronically for secondary 
      prevention of cardiovascular disease (CVD, e.g., aspirin) continues to burden the 
      healthcare system despite the well-established benefits of prevention. We 
      conducted a literature search to examine patient adherence to medications for 
      secondary prevention of CVD-as evaluated by prescription refill data, electronic 
      medication monitors, pill counts, and physiologic markers-to better identify an 
      unmet need for measures to improve patient adherence to these therapies. METHODS: 
      English-language articles were obtained from the PubMed database using the 
      following key words or combinations thereof "adherence," "compliance," "secondary 
      prevention," and "cardiovascular disease." Publications that provided adherence 
      data only for primary prevention, lacked data on medication adherence (e.g., 
      focus on guideline adherence), emphasized quality-of-care outcomes, or focused on 
      outcomes of acute interventions were excluded. RESULTS: Multiple patient-, 
      disease-, and treatment-related factors may contribute to poor adherence to 
      treatment regimens, and therefore, a multifactorial approach will likely be 
      needed to improve compliance with prescribed treatments for CVD. Although no 
      magic bullet exists to assure full adherence, adherence programs coupled with 
      patient counseling and education (inclusive of over-the-counter therapies), along 
      with treatments that are less complex or avoid bothersome adverse effects, are 
      more likely to be associated with successful outcomes. CONCLUSION: Given the 
      burden of CVD to the community and the healthcare system, nonadherence to 
      CVD-preventative medications such as aspirin remains a substantial area of unmet 
      need and represents a key opportunity for the development of quality-of-care 
      enhancement programs to improve health outcomes in this patient population.
CI  - © 2016 John Wiley & Sons Ltd.
FAU - Packard, Kathleen A
AU  - Packard KA
AD  - Department of Pharmacy Practice, Creighton University School of Pharmacy and 
      Health Professions, Omaha, NE, USA.
FAU - Hilleman, Daniel E
AU  - Hilleman DE
AD  - Department of Pharmacy Practice, Creighton University School of Pharmacy and 
      Health Professions, Omaha, NE, USA.
AD  - The Cardiac Center of Creighton University School of Medicine, Omaha, NE, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Agents/*therapeutic use
MH  - Cardiovascular Diseases/diagnosis/epidemiology/*prevention & control
MH  - Humans
MH  - *Medication Adherence
MH  - Recurrence
MH  - Risk Factors
MH  - Secondary Prevention/*methods
MH  - Treatment Outcome
OTO - NOTNLM
OT  - adherence
OT  - aspirin
OT  - cardiovascular disease
OT  - diabetes mellitus
OT  - morbidity and mortality
OT  - over-the-counter
EDAT- 2016/07/31 06:00
MHDA- 2017/02/07 06:00
CRDT- 2016/07/31 06:00
PHST- 2016/07/31 06:00 [pubmed]
PHST- 2017/02/07 06:00 [medline]
PHST- 2016/07/31 06:00 [entrez]
AID - 10.1111/1755-5922.12211 [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2016 Dec;34(6):415-422. doi: 10.1111/1755-5922.12211.

PMID- 25212403
OWN - NLM
STAT- MEDLINE
DCOM- 20150910
LR  - 20181023
IS  - 0256-9574 (Print)
VI  - 104
IP  - 9
DP  - 2014 Jul 22
TI  - The pharmacoeconomics of routine postoperative troponin surveillance to prevent 
      and treat myocardial infarction after non-cardiac surgery.
PG  - 619-23
LID - 10.7196/samj.7654 [doi]
AB  - BACKGROUND: A postoperative troponin leak that was previously considered 
      clinically insignificant has been independently associated with 30-day mortality 
      in unselected surgical patients ≥45 years of age following non-cardiac surgery. 
      OBJECTIVES: To determine whether routine troponin surveillance following 
      non-cardiac surgery and initiation of aspirin and statin therapy in 
      troponin-positive patients is cost-effective. METHODS: Pharmacoeconomic analysis 
      to determine the cost-effectiveness of routine postoperative surveillance for 
      patients aged ≥45 years undergoing non-cardiac surgery. We compared the total 
      expected cost of hospital care of patients who received routine troponin 
      surveillance and subsequent introduction of statin and aspirin therapy for 30 
      days in troponin-positive patients with the cost of hospital care of patients who 
      did not receive troponin surveillance. We estimated a 25% relative risk reduction 
      following statin and aspirin therapy for postoperative vascular mortality and 
      non-fatal myocardial infarction. RESULTS: Routine troponin surveillance with 
      initiation of aspirin and statin therapy was cost-effective, with an incremental 
      cost of -R16,724 per event avoided. CONCLUSION: Routine postoperative troponin 
      surveillance in non-cardiac surgical patients ≥45 years of age requiring a 
      postoperative night in hospital is potentially cost-effective.
FAU - Torborg, Alex
AU  - Torborg A
AD  - Perioperative Research Group, Department of Anaesthetics, Nelson R Mandela School 
      of Medicine, College of Health Sciences, University of KwaZulu-Natal and Inkosi 
      Albert Luthuli Central Hospital, Durban, South Africa. alexandra@iafrica.com.
FAU - Ryan, Lisa
AU  - Ryan L
FAU - Kantor, Gary
AU  - Kantor G
FAU - Biccard, Bruce M
AU  - Biccard BM
LA  - eng
PT  - Journal Article
DEP - 20140722
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Troponin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/economics/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Economics, Pharmaceutical
MH  - Hospital Costs
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/economics/*therapeutic use
MH  - Middle Aged
MH  - Myocardial Infarction/economics/*prevention & control
MH  - Postoperative Complications/economics/*prevention & control
MH  - Risk
MH  - Troponin/*analysis/economics
EDAT- 2014/09/13 06:00
MHDA- 2015/09/12 06:00
CRDT- 2014/09/13 06:00
PHST- 2013/10/25 00:00 [received]
PHST- 2014/04/30 00:00 [accepted]
PHST- 2014/09/13 06:00 [entrez]
PHST- 2014/09/13 06:00 [pubmed]
PHST- 2015/09/12 06:00 [medline]
AID - 10.7196/samj.7654 [doi]
PST - epublish
SO  - S Afr Med J. 2014 Jul 22;104(9):619-23. doi: 10.7196/samj.7654.

PMID- 19356003
OWN - NLM
STAT- MEDLINE
DCOM- 20090604
LR  - 20191027
IS  - 1570-1611 (Print)
IS  - 1570-1611 (Linking)
VI  - 7
IP  - 2
DP  - 2009 Apr
TI  - Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and 
      clopidogrel resistance.
PG  - 198-208
AB  - Cardiovascular diseases are the most common cause of mortality and morbidity 
      accounting for more than 40% of total mortality in Western countries, most of 
      which is due to acute coronary syndromes (ACS), including ST and non-ST elevation 
      myocardial infarction. An optimal pharmacological approach in these patients is 
      of major importance with a particular emphasis on the antiplatelet regimen, which 
      remains the cornerstone of the initial ACS treatment at hospital admission and 
      during percutaneous coronary interventions (PCI). This review briefly discusses 
      the pathogenesis of ACS, and updates the available pharmacological antithrombotic 
      strategies with a particular focus on aspirin and clopidogrel resistance, which 
      has caused major concern, especially in the modern era of interventional 
      cardiology. Persistent platelet reactivity despite aspirin or clopidogrel intake 
      is probably a risk factor for the recurrence of ischemic events. Despite a lack 
      of uniformly accepted definitions of aspirin and clopidogrel resistance, we 
      provide an objective description of what is already proved and what remains to be 
      established. In clopidogrel poor-responders, preliminary data suggest that 
      increasing the loading dose might be beneficial prior to PCI, while trials on the 
      potential benefit of an increased maintenance dose after PCI are ongoing. 
      Overall, data on the mechanisms and the management of platelet hyperactivity or 
      antiplatelet drug biological resistance are still scarce and further studies are 
      needed.
FAU - Bonvini, Robert F
AU  - Bonvini RF
AD  - Angiology Division, Heart Center, Bad Krozingen, Germany. Robert.Bonvini@hcuge.ch
FAU - Reny, Jean-Luc
AU  - Reny JL
FAU - Mach, François
AU  - Mach F
FAU - Zeller, Thomas
AU  - Zeller T
FAU - Fontana, Pierre
AU  - Fontana P
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/physiopathology/therapy
MH  - Angioplasty, Balloon, Coronary/methods
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Fibrinolytic Agents/pharmacology/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Risk Factors
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
RF  - 101
EDAT- 2009/04/10 09:00
MHDA- 2009/06/06 09:00
CRDT- 2009/04/10 09:00
PHST- 2009/04/10 09:00 [entrez]
PHST- 2009/04/10 09:00 [pubmed]
PHST- 2009/06/06 09:00 [medline]
AID - 10.2174/157016109787455662 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2009 Apr;7(2):198-208. doi: 10.2174/157016109787455662.

PMID- 1286550
OWN - NLM
STAT- MEDLINE
DCOM- 19930317
LR  - 20131121
IS  - 0278-2677 (Print)
IS  - 0278-2677 (Linking)
VI  - 11
IP  - 12
DP  - 1992 Dec
TI  - Antipyretic therapy in the febrile child.
PG  - 1005-21
AB  - General principles of thermoregulation, the pathophysiology of fever, 
      controversies concerning the use of antipyretic therapy, and nonpharmacologic and 
      pharmacologic treatments commonly used for antipyresis in the pediatric 
      population are reviewed. Several arguments can be made for not ameliorating the 
      febrile response. Fever is an important diagnostic and prognostic clinical sign 
      that may have beneficial effects for the host. In addition, body temperatures of 
      < or = 41 degrees C (105.8 degrees F) are relatively harmless. Reasons for 
      treating fever include patient discomfort, the potential for adverse sequelae, 
      the possibility of seizures, and the possibility that fever could affect the 
      pharmacokinetic profiles of drugs. Nonpharmacologic treatment for fever includes 
      environmental measures to enhance dissipation of body heat and sponging. Aspirin 
      and acetaminophen are the agents used most frequently for antipyresis in 
      pediatric patients. However, aspirin use in children with a viral illness has 
      been associated with development of Reye's syndrome. As a result, its use in 
      children has declined in the United States. Acetaminophen is relatively free of 
      adverse effects and is considered first-line pharmacologic antipyresis therapy. 
      Ibuprofen suspension should be considered as second-line antipyretic therapy. 
      Combination therapy with acetaminophen and aspirin may be considered if the 
      patient fails to respond to other nonpharmacologic and pharmacologic therapies; 
      however, combination therapy may result in increased risk of drug toxicity, 
      increased probability of adverse reactions, and increased risk of intoxication. 
      Aspirin, acetaminophen, and ibuprofen are equally effective for antipyresis in 
      pediatric patients. However, because acetaminophen is the safest medication, it 
      is currently the therapy of choice.
FAU - Drwal-Klein, L A
AU  - Drwal-Klein LA
AD  - Department of Pharmacy Practice, Massachusetts College of Pharmacy and Allied 
      Health Sciences, Boston 02115.
FAU - Phelps, S J
AU  - Phelps SJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Clin Pharm
JT  - Clinical pharmacy
JID - 8207437
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/pharmacokinetics/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics/*therapeutic use
MH  - Aspirin/pharmacokinetics/therapeutic use
MH  - Child, Preschool
MH  - Drug Therapy, Combination
MH  - Fever/*drug therapy/physiopathology/therapy
MH  - Humans
MH  - Ibuprofen/pharmacokinetics/therapeutic use
MH  - Infant
RF  - 244
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
PST - ppublish
SO  - Clin Pharm. 1992 Dec;11(12):1005-21.

PMID- 22715138
OWN - NLM
STAT- MEDLINE
DCOM- 20131223
LR  - 20191210
IS  - 1522-7243 (Electronic)
IS  - 1522-7235 (Linking)
VI  - 28
IP  - 3
DP  - 2013 May-Jun
TI  - Simultaneous determination of methocarbamol and aspirin by RP-HPLC using 
      fluorescence detection with time programming: its application to pharmaceutical 
      dosage form.
PG  - 332-8
LID - 10.1002/bio.2386 [doi]
AB  - A new simple, rapid and sensitive reversed-phase liquid chromatographic method 
      was developed and validated for the simultaneous determination of methocarbamol 
      (MET) and aspirin (ASP) in their combined dosage form. The separation of these 
      compounds was achieved within 6.0 min on a CLC Shim-pack C8 column (250 × 4.6 mm, 
      5 µm particle size) using isocratic mobile phase consisting of acetonitrile and 
      0.02 M dihydrogenphosphate buffer (30:70, v/v) at pH = 5.0. The analysis was 
      performed at a flow rate of 1.0 mL/min with fluorescence detection at 277/313 nm 
      for MET and 298/410 nm for ASP using real-time programming. The selectivity, 
      linearity of calibration, accuracy, inter- and intra-day precision and recovery 
      were examined as parts of the method validation. The concentration-response 
      relationship was linear over concentration ranges of 0.02-0.20 and 0.02-0.40 
      µg/mL for MET and ASP, respectively, with a limit of detection of 6 and 32 ng/mL 
      for MET and ASP, respectively. The proposed method was successfully applied for 
      the analysis of both MET and ASP in prepared tablets with average recoveries of 
      99.88 ± 0.65% for MET and 100.44 ± 0.78% for ASP. The results were favourably 
      compared to those obtained by a reference method.
CI  - Copyright © 2012 John Wiley & Sons, Ltd.
FAU - El-Din, M Sharaf
AU  - El-Din MS
AD  - Department of Analytical Chemistry, Faculty of Pharmacy, University of Mansoura, 
      Mansoura, 35516, Egypt.
FAU - Eid, M
AU  - Eid M
FAU - Zeid, A M
AU  - Zeid AM
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20120620
PL  - England
TA  - Luminescence
JT  - Luminescence : the journal of biological and chemical luminescence
JID - 100889025
RN  - 0 (Dosage Forms)
RN  - 125OD7737X (Methocarbamol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid/instrumentation/*methods
MH  - Chromatography, Reverse-Phase/instrumentation/methods
MH  - Dosage Forms
MH  - Fluorescence
MH  - Methocarbamol/*analysis
EDAT- 2012/06/21 06:00
MHDA- 2013/12/24 06:00
CRDT- 2012/06/21 06:00
PHST- 2012/01/14 00:00 [received]
PHST- 2012/04/23 00:00 [revised]
PHST- 2012/04/30 00:00 [accepted]
PHST- 2012/06/21 06:00 [entrez]
PHST- 2012/06/21 06:00 [pubmed]
PHST- 2013/12/24 06:00 [medline]
AID - 10.1002/bio.2386 [doi]
PST - ppublish
SO  - Luminescence. 2013 May-Jun;28(3):332-8. doi: 10.1002/bio.2386. Epub 2012 Jun 20.

PMID- 24880196
OWN - NLM
STAT- MEDLINE
DCOM- 20141209
LR  - 20181202
IS  - 1872-6976 (Electronic)
IS  - 0167-4943 (Linking)
VI  - 59
IP  - 2
DP  - 2014 Sep-Oct
TI  - High prevalence of aspirin resistance in elderly patients with cardiovascular 
      disease (CVD) and hyperhomocysteinaemia.
PG  - 491-5
LID - S0167-4943(14)00051-X [pii]
LID - 10.1016/j.archger.2014.04.005 [doi]
AB  - Although aspirin resistance is well reported in CVD, little is known about 
      aspirin response in elderly patients with hyperhomocysteinaemia. The aim of the 
      present study was to explore the prevalence of aspirin resistance in elderly 
      patients with CVD and hyperhomocysteinaemia. A total of 370 elderly patients with 
      CVD were recruited. The study included 216 patients with hyperhomocysteinaemia 
      and 154 patients with normohomocysteinaemia receiving daily aspirin therapy (≥ 75 
      mg) over 1 month. The effect of aspirin was assessed using by light transmission 
      aggregometry (LTA). Aspirin resistance was defined as ≥ 20% arachidonic acid 
      induced aggregation according to LTA. Aspirin resistance was defined in 48 
      (13.0%) of 370 patients. The prevalence of aspirin resistance was higher in 
      hyperhomocysteinaemic patients than normohomocysteinaemic patients (16.7% vs. 
      7.8%, odds ratio (OR)=2.367; 95% confidence interval (CI)=1.188-4.715, p=0.012). 
      In the multivariate logistic regression analysis, hyperhomocysteinaemia 
      (OR=2.406, 95% CI=1.201-4.820, p=0.013) was a significant risk factor for aspirin 
      resistance. A significant number of CVD patients with hyperhomocysteinemia are 
      resistant to aspirin therapy. Hyperhomocysteinemia is a significant risk factor 
      for aspirin resistance in elderly patients with CVD.
CI  - Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
FAU - Zhang, Huaxin
AU  - Zhang H
AD  - Department of Clinical Laboratory of South Building, Chinese PLA General 
      Hospital, Beijing, China.
FAU - Chen, Xiuying
AU  - Chen X
AD  - Pharmacy Department, Hospital of Chinese Peoples Armed Police Forces, Beijing 
      100039, PR China.
FAU - Liu, Lin
AU  - Liu L
AD  - Department of Respiratory Disease of South Building, Chinese PLA General 
      Hospital, Beijing, China.
FAU - Fan, Li
AU  - Fan L
AD  - First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, 
      China. Electronic address: calvin301@163.com.
FAU - Cao, Jian
AU  - Cao J
AD  - First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, 
      China. Electronic address: calvinisbest@hotmail.com.
FAU - Li, Xiaoli
AU  - Li X
AD  - First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, 
      China.
FAU - Hu, Guoliang
AU  - Hu G
AD  - First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, 
      China.
FAU - Hu, Yixin
AU  - Hu Y
AD  - First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, 
      China.
FAU - Zhu, Bingpo
AU  - Zhu B
AD  - First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, 
      China.
FAU - Liu, Xianfeng
AU  - Liu X
AD  - First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, 
      China.
FAU - Gao, Yan
AU  - Gao Y
AD  - First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, 
      China.
FAU - Ma, Cong
AU  - Ma C
AD  - First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, 
      China.
FAU - Leng, Wenxiu
AU  - Leng W
AD  - Second Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140510
PL  - Netherlands
TA  - Arch Gerontol Geriatr
JT  - Archives of gerontology and geriatrics
JID - 8214379
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - Homocysteinemia
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - China
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Hyperhomocysteinemia/*drug therapy
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prevalence
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin resistance
OT  - Cardiovascular disease
OT  - Hyperhomocysteinaemia
EDAT- 2014/06/02 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/06/02 06:00
PHST- 2012/04/27 00:00 [received]
PHST- 2014/04/16 00:00 [revised]
PHST- 2014/04/24 00:00 [accepted]
PHST- 2014/06/02 06:00 [entrez]
PHST- 2014/06/02 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - S0167-4943(14)00051-X [pii]
AID - 10.1016/j.archger.2014.04.005 [doi]
PST - ppublish
SO  - Arch Gerontol Geriatr. 2014 Sep-Oct;59(2):491-5. doi: 
      10.1016/j.archger.2014.04.005. Epub 2014 May 10.

PMID- 16214916
OWN - NLM
STAT- MEDLINE
DCOM- 20051229
LR  - 20161025
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 14
IP  - 10
DP  - 2005 Oct
TI  - Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs 
      and the risk of colorectal adenomas.
PG  - 2353-8
AB  - BACKGROUND: Calcium and aspirin have both been found to be chemopreventive 
      against colorectal neoplasia. However, the joint effect of the two agents has not 
      been well investigated. METHODS: To explore the separate and joint effects of 
      calcium and aspirin/nonsteroidal anti-inflammatory drugs (NSAID), we used data 
      from two large randomized clinical trials among patients with a recent history of 
      colorectal adenomas. In the Calcium Polyp Prevention Study, 930 eligible subjects 
      were randomized to receive placebo or 1,200 mg of elemental calcium daily for 4 
      years. In the Aspirin/Folate Polyp Prevention Study, 1,121 eligible subjects were 
      assigned to take placebo, 81 mg of aspirin, or 325 mg of aspirin daily for 3 
      years. In each study, subjects completed a validated food frequency questionnaire 
      at enrollment and were asked periodically about medications and supplements used. 
      Recurrent adenomas and advanced adenomas were the end points considered. We used 
      generalized linear models to assess the separate and combined effects of aspirin 
      (or NSAIDs) and calcium supplementation (or dietary calcium) and the interactions 
      between these exposures. RESULTS: In the Calcium Trial, subjects randomized to 
      calcium who also were frequent users of NSAIDs had a reduction of risk for 
      advanced adenomas of 65% [adjusted risk ratio (RR), 0.35; 95% confidence interval 
      (95% CI), 0.13-0.96], and there was a highly significant statistical interaction 
      between calcium treatment and frequent NSAID use (P(interaction) = 0.01). 
      Similarly, in the Aspirin Trial, 81 mg aspirin and calcium supplement use 
      together conferred a risk reduction of 80% for advanced adenomas (adjusted RR, 
      0.20; 95% CI, 0.05-0.81); there was a borderline significant statistical 
      interaction between the two treatments (P(interaction) = 0.09). In this trial, we 
      found similar trends when we considered baseline dietary calcium intake instead 
      of calcium supplements. For all adenomas considered together, the interactive 
      patterns were not consistent. CONCLUSION: Data from two different randomized 
      clinical trials suggest that calcium and NSAIDs may act synergistically to lower 
      the risk of advanced colorectal neoplastic polyps.
FAU - Grau, Maria V
AU  - Grau MV
AD  - Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, 
      New Hamsphire, USA. maria.grau.sepulveda@dartmouth.edu
FAU - Baron, John A
AU  - Baron JA
FAU - Barry, Elizabeth L
AU  - Barry EL
FAU - Sandler, Robert S
AU  - Sandler RS
FAU - Haile, Robert W
AU  - Haile RW
FAU - Mandel, Jack S
AU  - Mandel JS
FAU - Cole, Bernard F
AU  - Cole BF
LA  - eng
GR  - R01 CA059005/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Calcium, Dietary)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Adenoma/*prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Calcium/administration & dosage/*therapeutic use
MH  - Calcium, Dietary/administration & dosage/*therapeutic use
MH  - Colorectal Neoplasms/*prevention & control
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
EDAT- 2005/10/11 09:00
MHDA- 2005/12/31 09:00
CRDT- 2005/10/11 09:00
PHST- 2005/10/11 09:00 [pubmed]
PHST- 2005/12/31 09:00 [medline]
PHST- 2005/10/11 09:00 [entrez]
AID - 14/10/2353 [pii]
AID - 10.1158/1055-9965.EPI-05-0003 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2353-8. doi: 
      10.1158/1055-9965.EPI-05-0003.

PMID- 3769380
OWN - NLM
STAT- MEDLINE
DCOM- 19861211
LR  - 20190511
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 40
IP  - 5
DP  - 1986 Nov
TI  - Rates of sensitivity reactions to aspirin: problems in interpreting the data.
PG  - 494-505
AB  - This work was done to determine the reasons for variation in the reported 
      rates--ranging from less than 1% to greater than 50%--of sensitivity to aspirin 
      and cross-reactivity to acetaminophen and ibuprofen. In 47 studies that reported 
      rates of sensitivity and in 23 reports that contained series of sensitive 
      patients, we examined the research setting, source of patients, clinical 
      attributes of the study group, admission process, and selection, operational 
      definition, and method of determining sensitivity reactions. In five studies with 
      reasonably well-specified methods, the reported sensitivity rates to aspirin were 
      lowest (0.3% to 0.9%) for patients without allergic tendencies, higher in 
      asthmatics, and highest if patients had nasal polyps or severe atopy. Although 
      not determined in any of these studies, the rate of sensitivity in a general 
      (nonclinical) population would doubtlessly be substantially lower than the rate 
      of three per 1000 reported for nonallergic patients. The admixture of different 
      clinical groups, varying definitions, and ascertainment of a sensitivity reaction 
      seem to be responsible for the variations in the reported rates of sensitivity 
      and cross-reactivity.
FAU - Kwoh, C K
AU  - Kwoh CK
FAU - Feinstein, A R
AU  - Feinstein AR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/adverse effects
MH  - Aspirin/*adverse effects
MH  - Drug Hypersensitivity/*etiology
MH  - Humans
MH  - Ibuprofen/adverse effects
MH  - *Research Design
EDAT- 1986/11/01 00:00
MHDA- 1986/11/01 00:01
CRDT- 1986/11/01 00:00
PHST- 1986/11/01 00:00 [pubmed]
PHST- 1986/11/01 00:01 [medline]
PHST- 1986/11/01 00:00 [entrez]
AID - 0009-9236(86)90061-5 [pii]
AID - 10.1038/clpt.1986.214 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1986 Nov;40(5):494-505. doi: 10.1038/clpt.1986.214.

PMID- 30057104
OWN - NLM
STAT- MEDLINE
DCOM- 20180924
LR  - 20220716
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 392
IP  - 10145
DP  - 2018 Aug 4
TI  - Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial 
      trial.
PG  - 400-408
LID - S0140-6736(18)31388-6 [pii]
LID - 10.1016/S0140-6736(18)31388-6 [doi]
AB  - BACKGROUND: Oesophageal adenocarcinoma is the sixth most common cause of cancer 
      death worldwide and Barrett's oesophagus is the biggest risk factor. We aimed to 
      evaluate the efficacy of high-dose esomeprazole proton-pump inhibitor (PPI) and 
      aspirin for improving outcomes in patients with Barrett's oesophagus. METHODS: 
      The Aspirin and Esomeprazole Chemoprevention in Barrett's metaplasia Trial had a 
      2 × 2 factorial design and was done at 84 centres in the UK and one in Canada. 
      Patients with Barrett's oesophagus of 1 cm or more were randomised 1:1:1:1 using 
      a computer-generated schedule held in a central trials unit to receive high-dose 
      (40 mg twice-daily) or low-dose (20 mg once-daily) PPI, with or without aspirin 
      (300 mg per day in the UK, 325 mg per day in Canada) for at least 8 years, in an 
      unblinded manner. Reporting pathologists were masked to treatment allocation. The 
      primary composite endpoint was time to all-cause mortality, oesophageal 
      adenocarcinoma, or high-grade dysplasia, which was analysed with accelerated 
      failure time modelling adjusted for minimisation factors (age, Barrett's 
      oesophagus length, intestinal metaplasia) in all patients in the 
      intention-to-treat population. This trial is registered with EudraCT, number 
      2004-003836-77. FINDINGS: Between March 10, 2005, and March 1, 2009, 2557 
      patients were recruited. 705 patients were assigned to low-dose PPI and no 
      aspirin, 704 to high-dose PPI and no aspirin, 571 to low-dose PPI and aspirin, 
      and 577 to high-dose PPI and aspirin. Median follow-up and treatment duration was 
      8·9 years (IQR 8·2-9·8), and we collected 20 095 follow-up years and 99·9% of 
      planned data. 313 primary events occurred. High-dose PPI (139 events in 1270 
      patients) was superior to low-dose PPI (174 events in 1265 patients; time ratio 
      [TR] 1·27, 95% CI 1·01-1·58, p=0·038). Aspirin (127 events in 1138 patients) was 
      not significantly better than no aspirin (154 events in 1142 patients; TR 1·24, 
      0·98-1·57, p=0·068). If patients using non-steroidal anti-inflammatory drugs were 
      censored at the time of first use, aspirin was significantly better than no 
      aspirin (TR 1·29, 1·01-1·66, p=0·043; n=2236). Combining high-dose PPI with 
      aspirin had the strongest effect compared with low-dose PPI without aspirin (TR 
      1·59, 1·14-2·23, p=0·0068). The numbers needed to treat were 34 for PPI and 43 
      for aspirin. Only 28 (1%) participants reported study-treatment-related serious 
      adverse events. INTERPRETATION: High-dose PPI and aspirin chemoprevention 
      therapy, especially in combination, significantly and safely improved outcomes in 
      patients with Barrett's oesophagus. FUNDING: Cancer Research UK, AstraZeneca, 
      Wellcome Trust, and Health Technology Assessment.
CI  - Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access 
      article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights 
      reserved.
FAU - Jankowski, Janusz A Z
AU  - Jankowski JAZ
AD  - Gastroenterology Unit, Morecambe Bay University Hospitals NHS Trust, Lancaster, 
      UK; National Institute for Health and Care Excellence, London, UK. Electronic 
      address: janusz.jankowski@nice.org.uk.
FAU - de Caestecker, John
AU  - de Caestecker J
AD  - Digestive Diseases Centre, University Hospitals of Leicester, Leicester, UK; 
      College of Medicine, Biological Sciences and Psychology, University of Leicester, 
      Leicester, UK.
FAU - Love, Sharon B
AU  - Love SB
AD  - Centre for Statistics in Medicine, University of Oxford, Oxford, UK; MRC Clinical 
      Trials Unit at University College London, London, UK.
FAU - Reilly, Gavin
AU  - Reilly G
AD  - Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
FAU - Watson, Peter
AU  - Watson P
AD  - Queens University, Belfast, UK.
FAU - Sanders, Scott
AU  - Sanders S
AD  - South Warwickshire NHS Foundation Trust, Warwick, UK.
FAU - Ang, Yeng
AU  - Ang Y
AD  - Wrightington, Wigan & Leigh NHS Foundation Trust, Wigan, UK; GI Science, Salford 
      Royal NHS Foundation Trust and University of Manchester, Manchester, UK.
FAU - Morris, Danielle
AU  - Morris D
AD  - Queen Elizabeth II Hospital, Welwyn Garden City, UK.
FAU - Bhandari, Pradeep
AU  - Bhandari P
AD  - Queen Alexandra Hospital, Portsmouth, UK.
FAU - Brooks, Claire
AU  - Brooks C
AD  - Oncology Clinical Trials Office, University of Oxford, Oxford, UK.
FAU - Attwood, Stephen
AU  - Attwood S
AD  - School of Medicine, Pharmacy and Health, Durham University, Durham, UK.
FAU - Harrison, Rebecca
AU  - Harrison R
AD  - Department of Pathology, University Hospitals of Leicester, Leicester, UK.
FAU - Barr, Hugh
AU  - Barr H
AD  - Gloucester Royal Hospital, Gloucester, UK.
FAU - Moayyedi, Paul
AU  - Moayyedi P
AD  - Department of Medicine, McMaster University Ontario, Hamilton, ON, Canada.
CN  - AspECT Trial Team
LA  - eng
GR  - MC_UU_12023/28/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180726
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Proton Pump Inhibitors)
RN  - N3PA6559FT (Esomeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2018 Aug 4;392(10145):362-364. PMID: 30057101
CIN - Ann Intern Med. 2018 Nov 20;169(10):JC54. PMID: 30452561
EIN - Lancet. 2018 Dec 15;392(10164):2552. PMID: 30563642
CIN - Gastroenterology. 2019 Apr;156(5):1228-1231. PMID: 30849313
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Barrett Esophagus/*drug therapy
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Esomeprazole/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/administration & dosage/*therapeutic use
MH  - Young Adult
PMC - PMC6083438
FIR - Ragunath, Krish
IR  - Ragunath K
FIR - Rameh, Bashir
IR  - Rameh B
FIR - Fullarton, Grant
IR  - Fullarton G
FIR - Tucker, Art
IR  - Tucker A
FIR - Penman, Ian
IR  - Penman I
FIR - Rodgers, Colin
IR  - Rodgers C
FIR - Neale, James
IR  - Neale J
FIR - Edwards, Cathryn
IR  - Edwards C
FIR - Wise, Adelyn
IR  - Wise A
FIR - Jones, Stephen
IR  - Jones S
FIR - Church, Nicholas
IR  - Church N
FIR - Vaidya, Kishor
IR  - Vaidya K
FIR - Balata, Sherzad
IR  - Balata S
FIR - Todd, John
IR  - Todd J
FIR - Gibbons, Michael
IR  - Gibbons M
FIR - Johnston, David
IR  - Johnston D
FIR - Anderson, Mark
IR  - Anderson M
FIR - Davies, Gareth
IR  - Davies G
FIR - Dickey, William
IR  - Dickey W
FIR - Murdock, Andrew
IR  - Murdock A
FIR - Turner, Graham
IR  - Turner G
FIR - Goddard, Andrew
IR  - Goddard A
FIR - Gore, Stephen
IR  - Gore S
FIR - Haigh, Chris
IR  - Haigh C
FIR - Harding, Timothy
IR  - Harding T
FIR - Jackson, Lucina
IR  - Jackson L
FIR - Murray, Iain
IR  - Murray I
FIR - Worthingon, Joy
IR  - Worthingon J
FIR - Lee, Thomas
IR  - Lee T
FIR - Lim, Peik Loon
IR  - Lim PL
FIR - McLoughlin, James
IR  - McLoughlin J
FIR - Macdonald, Christopher
IR  - Macdonald C
FIR - Mairs, Philip
IR  - Mairs P
FIR - Monk, David
IR  - Monk D
FIR - Preston, Sean
IR  - Preston S
FIR - Pugh, Stirling
IR  - Pugh S
FIR - Smart, Howard
IR  - Smart H
FIR - Soliman, Ashraf
IR  - Soliman A
FIR - Isaacs, Peter
IR  - Isaacs P
FIR - Aldulaimi, David
IR  - Aldulaimi D
FIR - Trudgill, Nigel
IR  - Trudgill N
FIR - Teare, Julian
IR  - Teare J
FIR - Benhamida, Abduljalil
IR  - Benhamida A
FIR - Bell, Andrew
IR  - Bell A
FIR - Boulton-Jones, Robert
IR  - Boulton-Jones R
FIR - Daneshmend, Tawfique
IR  - Daneshmend T
FIR - Suzuki, Hisaharu
IR  - Suzuki H
FIR - Cullen, Sue
IR  - Cullen S
FIR - Fitzgerald, Rebecca
IR  - Fitzgerald R
FIR - Ransford, Rupert
IR  - Ransford R
FIR - Rahman, Mohammad Mesbahur
IR  - Rahman MM
FIR - Tebala, Giovanni Domenico
IR  - Tebala GD
FIR - Hallissey, Michael
IR  - Hallissey M
FIR - Kelly, Carrie
IR  - Kelly C
FIR - Hickish, Tamas
IR  - Hickish T
FIR - Taha, Ali
IR  - Taha A
FIR - Rademaker, Johan
IR  - Rademaker J
FIR - Whitehead, Mark
IR  - Whitehead M
FIR - Kelly, Sean
IR  - Kelly S
FIR - Phull, Perminder
IR  - Phull P
FIR - Sharma, Naveen
IR  - Sharma N
FIR - Perry, Ian
IR  - Perry I
FIR - Sankara-Raman, Vankatraman
IR  - Sankara-Raman V
FIR - Ali, Haythem
IR  - Ali H
FIR - Khan, Iqbal
IR  - Khan I
FIR - Curtis, Howard
IR  - Curtis H
FIR - Wadley, Martin
IR  - Wadley M
FIR - Stone, Adam
IR  - Stone A
FIR - Sukumaran, Sumesh
IR  - Sukumaran S
FIR - Higham, Andrew
IR  - Higham A
FIR - Lewis, Stephen
IR  - Lewis S
FIR - Haycock, Adam
IR  - Haycock A
FIR - Usselmann, Bernhard
IR  - Usselmann B
FIR - Johnston, Simon Douglas
IR  - Johnston SD
FIR - Tham, Tony
IR  - Tham T
FIR - Campbell, Stewart
IR  - Campbell S
FIR - Douds, Andrew
IR  - Douds A
FIR - Dunn, Jason
IR  - Dunn J
FIR - Sargeant, Ian
IR  - Sargeant I
FIR - Narain, Mark
IR  - Narain M
FIR - Maynard, Nick
IR  - Maynard N
FIR - Chilton, Andrew
IR  - Chilton A
FIR - Green, Susi
IR  - Green S
FIR - Loft, Duncan
IR  - Loft D
FIR - Decadt, Bart
IR  - Decadt B
FIR - Mendall, Michael
IR  - Mendall M
FIR - Heydtmann, Mathis
IR  - Heydtmann M
FIR - Fisher, Neil
IR  - Fisher N
EDAT- 2018/07/31 06:00
MHDA- 2018/09/25 06:00
CRDT- 2018/07/31 06:00
PHST- 2018/05/30 00:00 [received]
PHST- 2018/06/11 00:00 [revised]
PHST- 2018/06/12 00:00 [accepted]
PHST- 2018/07/31 06:00 [pubmed]
PHST- 2018/09/25 06:00 [medline]
PHST- 2018/07/31 06:00 [entrez]
AID - S0140-6736(18)31388-6 [pii]
AID - 10.1016/S0140-6736(18)31388-6 [doi]
PST - ppublish
SO  - Lancet. 2018 Aug 4;392(10145):400-408. doi: 10.1016/S0140-6736(18)31388-6. Epub 
      2018 Jul 26.

PMID- 30577986
OWN - NLM
STAT- MEDLINE
DCOM- 20200102
LR  - 20200102
IS  - 1879-1476 (Electronic)
IS  - 0385-8146 (Linking)
VI  - 46
IP  - 4
DP  - 2019 Aug
TI  - Objective and subjective sinonasal and pulmonary outcomes in aspirin 
      desensitization therapy: A prospective cohort study.
PG  - 526-532
LID - S0385-8146(18)30314-6 [pii]
LID - 10.1016/j.anl.2018.12.002 [doi]
AB  - OBJECTIVE: Aspirin exacerbated respiratory disease (AERD) patients are 
      challenging to manage with sinonasal and pulmonary symptoms refractory to maximal 
      medical and surgical therapies. Our objective was to comprehensively examine 
      objective and validated, disease-specific subjective sinonasal and pulmonary 
      outcomes of aspirin (ASA) desensitization therapy in this patient population. 
      METHODS: Prospective cohort study at an academic tertiary center. AERD patients 
      with a history of chronic rhinosinusitis with nasal polyposis (CRSwNP), prior 
      diagnosis of asthma, and a history of ASA sensitivity were eligible for 
      inclusion. Patients underwent ASA desensitization using an established 
      institutional protocol and continued on a 650mg twice daily maintenance dose. 
      Baseline Sinonasal Outcome Test (SNOT-22) and Asthma Control Questionnaire (ACQ) 
      responses, acoustic rhinometry, peak flow readings, and endoscopic scoring of 
      nasal polyps were recorded prior to desensitization and after 6months of 
      maintenance therapy. RESULTS: Twelve patients were recruited for participation 
      and underwent desensitization. Eight patients continued maintenance therapy and 
      follow up at 6months. Prior to desensitization, patients reported bothersome 
      sinonasal symptoms with a median SNOT-22 score of 30.0±34.5 (interquartile range 
      (IQR)). There was significant improvement after 6months of maintenance therapy to 
      a median SNOT-22 score of 18.5±17.3 (p=0.025, Wilcoxon signed rank test). 
      Acoustic rhinometry, endoscopic scores, ACQ and forced expiratory volume values 
      remained stable at 6months. CONCLUSIONS: AERD patients may benefit from ASA 
      desensitization with subjective sinonasal symptom improvement at 6months and 
      stable asthma and objective sinonasal measures. Further discussion is needed in 
      the otolaryngology community regarding ASA desensitization in AERD management.
CI  - Copyright © 2019. Published by Elsevier B.V.
FAU - Cooper, Timothy
AU  - Cooper T
AD  - Division of Otolaryngology - Head and Neck Surgery, Department of Surgery, 
      University of Alberta, 1E4 University of Alberta Hospital, Edmonton, AB, Canada, 
      T6G 2B7. Electronic address: tcooper@ualberta.ca.
FAU - Greig, Samuel R
AU  - Greig SR
AD  - Division of Otolaryngology - Head and Neck Surgery, Department of Surgery, 
      University of Alberta, 1E4 University of Alberta Hospital, Edmonton, AB, Canada, 
      T6G 2B7. Electronic address: gresa1@yahoo.co.nz.
FAU - Zhang, Han
AU  - Zhang H
AD  - Division of Otolaryngology - Head and Neck Surgery, Department of Surgery, 
      McMaster University, Room G811, 50 Charlton Ave, Hamilton, ON, Canada L8N 4A6. 
      Electronic address: hanzhang@stjosham.on.ca.
FAU - Seemann, Robert
AU  - Seemann R
AD  - Division of Otolaryngology - Head and Neck Surgery, Department of Surgery, 
      University of Alberta, 1E4 University of Alberta Hospital, Edmonton, AB, Canada, 
      T6G 2B7. Electronic address: r_see_00@yahoo.ca.
FAU - Wright, Erin D
AU  - Wright ED
AD  - Division of Otolaryngology - Head and Neck Surgery, Department of Surgery, 
      University of Alberta, 1E4 University of Alberta Hospital, Edmonton, AB, Canada, 
      T6G 2B7. Electronic address: erin.wright@ualberta.ca.
FAU - Vliagoftis, Harissios
AU  - Vliagoftis H
AD  - Division of Pulmonary Medicine, Department of Medicine, University of Alberta, 
      3-105 Central Services Building, Edmonton, AB, Canada. Electronic address: 
      hari@ualberta.ca.
FAU - Côté, David W J
AU  - Côté DWJ
AD  - Division of Otolaryngology - Head and Neck Surgery, Department of Surgery, 
      University of Alberta, 1E4 University of Alberta Hospital, Edmonton, AB, Canada, 
      T6G 2B7. Electronic address: cote@ualberta.ca.
LA  - eng
PT  - Journal Article
DEP - 20181219
PL  - Netherlands
TA  - Auris Nasus Larynx
JT  - Auris, nasus, larynx
JID - 7708170
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Asthma, Aspirin-Induced/etiology/*therapy
MH  - Chronic Disease
MH  - Cohort Studies
MH  - *Desensitization, Immunologic
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/chemically induced/*therapy
MH  - Prospective Studies
MH  - Rhinitis/chemically induced/*therapy
MH  - Rhinometry, Acoustic
MH  - Sino-Nasal Outcome Test
MH  - Sinusitis/chemically induced/*therapy
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirin exacerbated respiratory disease
OT  - Asthma
OT  - Chronic rhinosinusitis
OT  - Nasal polyposis
OT  - Samter’s triad
EDAT- 2018/12/24 06:00
MHDA- 2020/01/03 06:00
CRDT- 2018/12/23 06:00
PHST- 2018/05/19 00:00 [received]
PHST- 2018/11/19 00:00 [revised]
PHST- 2018/12/02 00:00 [accepted]
PHST- 2018/12/24 06:00 [pubmed]
PHST- 2020/01/03 06:00 [medline]
PHST- 2018/12/23 06:00 [entrez]
AID - S0385-8146(18)30314-6 [pii]
AID - 10.1016/j.anl.2018.12.002 [doi]
PST - ppublish
SO  - Auris Nasus Larynx. 2019 Aug;46(4):526-532. doi: 10.1016/j.anl.2018.12.002. Epub 
      2018 Dec 19.

PMID- 30797761
OWN - NLM
STAT- MEDLINE
DCOM- 20200115
LR  - 20200115
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 220
IP  - 6
DP  - 2019 Jun
TI  - Aspirin delays the development of preeclampsia.
PG  - 580.e1-580.e6
LID - S0002-9378(19)30386-2 [pii]
LID - 10.1016/j.ajog.2019.02.034 [doi]
AB  - BACKGROUND: In the Combined Multimarker Screening and Randomized Patient 
      Treatment with Aspirin for Evidence-Based Preeclampsia Prevention trial, risks of 
      preterm preeclampsia were obtained from the competing risk model. Consenting 
      women with risks of greater than 1 in 100 were randomized to treatment with 
      aspirin or placebo. The trial showed strong evidence of an effect (odds ratio, 
      0.38, 95% confidence interval, 0.20-0.74) on the incidence of preterm 
      preeclampsia, which was the primary outcome of Aspirin for Evidence-Based 
      Preeclampsia Prevention. There was a small and insignificant effect on the 
      incidence of term preeclampsia, which was a secondary outcomes (odds ratio, 0.95, 
      95% confidence interval, 0.64-1.39). These differential effects on term and 
      preterm preeclampsia could reflect a mechanism in which the action of aspirin is 
      to delay the delivery with preeclampsia, thereby converting what would be, 
      without treatment, preterm preeclampsia to term preeclampsia. OBJECTIVE: The 
      objective of the study was to examine the hypothesis that the effect of aspirin 
      is to delay the time of delivery in women who have preeclampsia. STUDY DESIGN: 
      This was an unplanned exploratory analysis of data from the Aspirin for 
      Evidence-Based Preeclampsia Prevention trial. The delay hypothesis predicts that 
      in groups for which preterm preeclampsia, without aspirin, were infrequent 
      relative to term preeclampsia, a reduction in term preeclampsia would be expected 
      because few cases of preterm preeclampsia would be converted to term 
      preeclampsia. In contrast, in groups for which preterm preeclampsia were frequent 
      relative to term preeclampsia, the conversion of preterm preeclampsia to term 
      preeclampsia by aspirin would reduce or even reverse any effect on the incidence 
      term preeclampsia. This is examined using the Aspirin for Evidence-Based 
      Preeclampsia Prevention trial data by analysis of the effect of aspirin on the 
      incidence of term preeclampsia stratified according to the risk of preterm 
      preeclampsia at randomization. Given that women were included in Aspirin for 
      Evidence-Based Preeclampsia Prevention with risks of preterm preeclampsia >1 in 
      100, a risk cutoff if 1 in 50 was used to define higher risk and lower risk 
      strata. A statistical model in which the effect of aspirin is to delay the 
      gestational age at delivery was fitted to the Aspirin for Evidence-Based 
      Preeclampsia Prevention trial data and the consistency of the predictions from 
      this model with the observed incidence was demonstrated. RESULTS: In the 
      lower-risk group (<1 in 50), there was a reduction in the incidence of term 
      preeclampsia (odds ratio, 0.62, 95% confidence interval, 0.29-1.30). In contrast, 
      in the higher risk group (≥1 in 50) there was a small increase in the incidence 
      of term- preeclampsia (odds ratio 1.11, 95% confidence interval, 0.71- .75). 
      Although these effects fail to achieve significance, they are consistent with the 
      delay hypothesis. Within the framework of the aspirin-related delay hypothesis, 
      the effect of aspirin was to delay the gestational age at delivery with 
      preeclampsia by an estimated 4.4 weeks (95% confidence interval, 1.4-7.1 weeks) 
      for those that in the placebo group would be delivered at 24 weeks and the effect 
      decreased by an estimated 0.23 weeks (95% confidence interval, 0.021-0.40 weeks) 
      for each week of gestation so that at 40(+0) weeks, the estimated delay was by 
      0.8 weeks (95% confidence interval, -0.03 to 1.7 weeks). CONCLUSION: The Aspirin 
      for Evidence-Based Preeclampsia Prevention trial data are consistent with the 
      hypothesis that aspirin delays the gestational age at delivery with preeclampsia.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Wright, David
AU  - Wright D
AD  - Institute of Health Research, University of Exeter, Exeter, United Kingdom.
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College, London, 
      United Kingdom. Electronic address: kypros@fetalmedicine.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190221
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Premature Birth/*epidemiology
MH  - Time Factors
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin for Evidence-Based Preeclampsia Prevention trial
OT  - aspirin
OT  - competing risks model
OT  - first-trimester screening
OT  - preeclampsia
OT  - pregnancy
OT  - preterm delivery
OT  - pyramid of pregnancy care
OT  - term delivery
EDAT- 2019/02/25 06:00
MHDA- 2020/01/16 06:00
CRDT- 2019/02/25 06:00
PHST- 2018/11/19 00:00 [received]
PHST- 2019/02/14 00:00 [revised]
PHST- 2019/02/15 00:00 [accepted]
PHST- 2019/02/25 06:00 [pubmed]
PHST- 2020/01/16 06:00 [medline]
PHST- 2019/02/25 06:00 [entrez]
AID - S0002-9378(19)30386-2 [pii]
AID - 10.1016/j.ajog.2019.02.034 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2019 Jun;220(6):580.e1-580.e6. doi: 
      10.1016/j.ajog.2019.02.034. Epub 2019 Feb 21.

PMID- 2069096
OWN - NLM
STAT- MEDLINE
DCOM- 19910809
LR  - 20191029
IS  - 0379-0363 (Print)
IS  - 0379-0363 (Linking)
VI  - 32
DP  - 1991
TI  - Antipyretic activity of tebufelone (NE-11740) in man.
PG  - 45-9
AB  - Tebufelone (formerly NE-11740) is a member of the new class of 
      di-tert-butyl-phenol anti-inflammatory agents. It has previously been reported 
      that this new agent has potent analgesic, antipyretic, and anti-inflammatory 
      effects using in vitro, in vivo, and ex vivo experimental models. A randomized, 
      active- and placebo- controlled double-blinded study in 120 healthy males, 20 to 
      55 years old, was conducted to clinically assess tebufelone's antipyretic 
      activity. Subjects received a single peroral dose of placebo, 650 mg aspirin 
      (ASA), or tebufelone at doses of 25, 50, 100, or 200 mg. Thirty minutes later, E. 
      coli endotoxin (2 ng/kg) was administered intravenously. Oral temperatures were 
      recorded at 15 minute intervals from 30 minutes post dosing to 8 hours post 
      endotoxin administration. Areas under the temperature curves (AUCs), adjusted for 
      baseline, were significantly lower than placebo for ASA and all but the 25 mg 
      tebufelone groups. An AUC dose-response equation estimates 60 mg tebufelone as 
      equivalent to 650 mg ASA, with 50 mg tebufelone not significantly greater than 
      650 mg ASA. Side effects, attributable to the endotoxin, included mild flu-like 
      symptoms and were worse in the placebo group and the non-efficacious 25 mg 
      tebufelone group. Doses of 100 and 200 mg tebufelone had onset characteristics 
      indistinguishable from 650 mg ASA, whereas 50 mg tebufelone showed significantly 
      slower onset while suppressing temperature for a longer period than ASA. These 
      results provide an important early demonstration of tebufelone's biological 
      activity in man.
FAU - Powell, J H
AU  - Powell JH
AD  - Procter & Gamble Co., Miami Valley Laboratories Cincinnati, Ohio.
FAU - Meredith, M P
AU  - Meredith MP
FAU - Vargas, R
AU  - Vargas R
FAU - McMahon, F G
AU  - McMahon FG
FAU - Jain, A K
AU  - Jain AK
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Agents Actions Suppl
JT  - Agents and actions. Supplements
JID - 7801014
RN  - 0 (Alkynes)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Phenols)
RN  - O048K9ZFHO (tebufelone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Alkynes/*pharmacology
MH  - *Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/pharmacology
MH  - Body Temperature/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - Phenols/*pharmacology
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1007/978-3-0348-7405-2_5 [doi]
PST - ppublish
SO  - Agents Actions Suppl. 1991;32:45-9. doi: 10.1007/978-3-0348-7405-2_5.

PMID- 21370214
OWN - NLM
STAT- MEDLINE
DCOM- 20110616
LR  - 20131121
IS  - 1098-9064 (Electronic)
IS  - 0094-6176 (Linking)
VI  - 37
IP  - 2
DP  - 2011 Mar
TI  - Antiplatelet agents for the prevention of pre-eclampsia.
PG  - 137-40
LID - 10.1055/s-0030-1270340 [doi]
AB  - Pre-eclampsia (P-EC) remains a significant problem in modern obstetrics occurring 
      in 2 to 4% of women. The disease is still responsible for 60,000 maternal deaths 
      worldwide annually. An increased understanding of the underlying pathophysiology 
      has resulted in a more scientific approach to prophylaxis and prevention, yet the 
      underlying disease mechanisms are not fully understood. The role of combining 
      good prediction with prevention has yet to be established but has the potential 
      to target health resources far more efficiently. Good prediction may also impact 
      on tailoring antenatal care appropriately, with prophylactic measures for 
      high-risk women becoming the highly preferred management option. Antiplatelet 
      agents reduce the incidence and complications of P-EC and should be considered 
      prophylactically in those at high risk of the disease.
CI  - © Thieme Medical Publishers.
FAU - Duhig, Kate E
AU  - Duhig KE
AD  - Maternal and Fetal Research Unit, Department of Reproduction and Endocrinology, 
      King's College London, St Thomas' Hospital, Westminster Bridge Road, SE1 7EH 
      London, United Kingdom.
FAU - Shennan, Andrew H
AU  - Shennan AH
LA  - eng
PT  - Journal Article
DEP - 20110302
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/physiopathology/*prevention & control
MH  - Pregnancy
MH  - Prenatal Care
MH  - Randomized Controlled Trials as Topic
EDAT- 2011/03/04 06:00
MHDA- 2011/06/17 06:00
CRDT- 2011/03/04 06:00
PHST- 2011/03/04 06:00 [entrez]
PHST- 2011/03/04 06:00 [pubmed]
PHST- 2011/06/17 06:00 [medline]
AID - 10.1055/s-0030-1270340 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2011 Mar;37(2):137-40. doi: 10.1055/s-0030-1270340. Epub 
      2011 Mar 2.

PMID- 15853174
OWN - NLM
STAT- MEDLINE
DCOM- 20050610
LR  - 20190906
IS  - 0891-1150 (Print)
IS  - 0891-1150 (Linking)
VI  - 72 Suppl 1
DP  - 2005 Apr
TI  - Prevention of venous thromboembolism in medical and surgical patients.
PG  - S7-13
AB  - Prophylaxis against venous thromboembolism (VTE) should be considered in all 
      hospitalized patients, as VTE is a significant cause of morbidity and mortality 
      in the hospital. Although VTE risk is greatest and VTE prophylaxis is more 
      established in surgical patients, most hospitalized medical patients have one or 
      more risk factors for VTE and are candidates for prophylaxis. Selection of a 
      prophylaxis strategy should be guided by the patient's risk factors for VTE and 
      the risks associated with prophylaxis options. This review surveys evidence and 
      recommendations for various VTE prophylaxis methods in medical and surgical 
      patients.
FAU - Kaboli, Peter J
AU  - Kaboli PJ
AD  - Center for Research in the Implementation of Innovative Strategies in Practice, 
      Iowa City VA Medical Center, Iowa, USA. peter-kaboli@uiowa.edu
FAU - Brenner, Adam
AU  - Brenner A
FAU - Dunn, Andrew S
AU  - Dunn AS
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - United States
TA  - Cleve Clin J Med
JT  - Cleveland Clinic journal of medicine
JID - 8703441
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Bandages
MH  - Chemoprevention
MH  - Early Ambulation
MH  - Hospitalization
MH  - Humans
MH  - Risk Factors
MH  - *Surgical Procedures, Operative
MH  - Thromboembolism/*prevention & control
MH  - Venous Thrombosis/*prevention & control
RF  - 48
EDAT- 2005/04/28 09:00
MHDA- 2005/06/11 09:00
CRDT- 2005/04/28 09:00
PHST- 2005/04/28 09:00 [pubmed]
PHST- 2005/06/11 09:00 [medline]
PHST- 2005/04/28 09:00 [entrez]
AID - 10.3949/ccjm.72.suppl_1.s7 [doi]
PST - ppublish
SO  - Cleve Clin J Med. 2005 Apr;72 Suppl 1:S7-13. doi: 10.3949/ccjm.72.suppl_1.s7.

PMID- 10065951
OWN - NLM
STAT- MEDLINE
DCOM- 19990603
LR  - 20131121
IS  - 0173-0835 (Print)
IS  - 0173-0835 (Linking)
VI  - 20
IP  - 1
DP  - 1999 Jan
TI  - Gradient elution capillary electrochromatography and hyphenation with nuclear 
      magnetic resonance.
PG  - 3-8
AB  - Coupling of gradient capillary electrochromatography (gradient CEC) and capillary 
      zone electrophoresis (CZE) with nuclear magnetic resonance spectroscopy (NMR) was 
      performed using a recently developed capillary NMR interface. This technique was 
      applied for the analysis of pharmaceuticals and food. An analgesic was 
      investigated using isocratic and gradient continuous-flow CEC-NMR. Comparison of 
      the results demonstrated the superiority of gradient CEC over isocratic CEC. 
      Aspartame and caffeine, both ingredients of soft beverages, were separated and 
      analyzed by continuous flow CZE-NMR. The order of elution could be reversed by 
      altering the pH. This reversal led to an increased sample concentration in the 
      NMR detection cell, thus allowing the acquisition of a totally correlated 
      spectroscopy (TOCSY) two-dimensional (2-D) spectrum of the synthetic peptide 
      aspartame.
FAU - Gfrörer, P
AU  - Gfrörer P
AD  - University of Tübingen, Institute of Organic Chemistry, Germany.
FAU - Schewitz, J
AU  - Schewitz J
FAU - Pusecker, K
AU  - Pusecker K
FAU - Tseng, L H
AU  - Tseng LH
FAU - Albert, K
AU  - Albert K
FAU - Bayer, E
AU  - Bayer E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Electrophoresis
JT  - Electrophoresis
JID - 8204476
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Analgesics, Non-Narcotic/*analysis
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Chromatography, Liquid/*methods
MH  - Electrophoresis, Capillary/*methods
MH  - Magnetic Resonance Spectroscopy/*methods
MH  - Molecular Structure
EDAT- 1999/03/05 03:03
MHDA- 2000/08/12 11:00
CRDT- 1999/03/05 03:03
PHST- 1999/03/05 03:03 [pubmed]
PHST- 2000/08/12 11:00 [medline]
PHST- 1999/03/05 03:03 [entrez]
AID - 10.1002/(SICI)1522-2683(19990101)20:1<3::AID-ELPS3>3.0.CO;2-U [pii]
AID - 10.1002/(SICI)1522-2683(19990101)20:1<3::AID-ELPS3>3.0.CO;2-U [doi]
PST - ppublish
SO  - Electrophoresis. 1999 Jan;20(1):3-8. doi: 
      10.1002/(SICI)1522-2683(19990101)20:1<3::AID-ELPS3>3.0.CO;2-U.

PMID- 7014570
OWN - NLM
STAT- MEDLINE
DCOM- 19810723
LR  - 20161026
IS  - 0021-9509 (Print)
IS  - 0021-9509 (Linking)
VI  - 22
IP  - 2
DP  - 1981 Mar-Apr
TI  - Prevention of early reocclusion by dipyridamole and ASA in arterial 
      reconstructive surgery.
PG  - 141-4
AB  - In this prospective study 364 patients were subjected to different types of 
      arterial reconstructive surgery. The patients were randomly divided into four 
      groups according to the type of antithrombotic medication given. During the 
      hospitalization period there were no reocclusions in the dipyridamole/ASA group 
      of 93 patients compared with 12 reocclusions in the control group of 86 patients. 
      The difference was statistically highly significant. The difference between the 
      control group and the given dipyridamole or ASA was not statistically 
      significant. Dipyridamole and ASA were tolerated well by the patients in this 
      clinical trial. This was the first clinical investigation to prove the 
      effectiveness of dipyridamole and ASA medication in the prevention of 
      reocclusions in arterial reconstructive bypass surgery.
FAU - Harajola, P T
AU  - Harajola PT
FAU - Meurala, H
AU  - Meurala H
FAU - Frick, M H
AU  - Frick MH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Italy
TA  - J Cardiovasc Surg (Torino)
JT  - The Journal of cardiovascular surgery
JID - 0066127
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/*prevention & control/surgery
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyridamole/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
MH  - Recurrence
MH  - *Vascular Surgical Procedures
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
PST - ppublish
SO  - J Cardiovasc Surg (Torino). 1981 Mar-Apr;22(2):141-4.

PMID- 9727545
OWN - NLM
STAT- MEDLINE
DCOM- 19980917
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 98
IP  - 8
DP  - 1998 Aug 25
TI  - Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results 
      of a double-blind, randomized comparative trial.
PG  - 757-65
AB  - BACKGROUND: Coprescription of aspirin and ACE inhibitors is frequent in heart 
      failure caused by coronary artery disease. Negative interaction between aspirin 
      and enalapril has been reported, presumably through inhibition by aspirin of ACE 
      inhibitor-induced prostaglandin synthesis. Ticlopidine is a potent antiplatelet 
      agent without interaction with prostaglandin synthesis. METHODS AND RESULTS: The 
      objective of this study was to compare the influence of a coadministration of 
      ticlopidine or aspirin on the hemodynamic effects of an ACE inhibitor (enalapril) 
      in patients with chronic heart failure. Twenty patients with severe heart failure 
      were enrolled in a double-blind comparative trial and allocated to ticlopidine 
      (500 mg daily, 12 patients) or aspirin (325 mg daily, 8 patients). Hemodynamic 
      evaluation was performed after 7 days of treatment, every hour for 4 hours after 
      an oral administration of 10 mg of enalapril. Significant reductions in systemic 
      vascular resistance were observed in the ticlopidine group, in contrast to no 
      significant decrease in the aspirin group. A significant (P=0.03) 
      time-by-treatment interaction indicated significant aspirin-enalapril drug 
      interaction. Total pulmonary resistance decreased significantly in both groups, 
      with no difference between patients assigned to aspirin or ticlopidine. 
      CONCLUSIONS: Enalapril reduced systemic vascular resistance more effectively when 
      given in combination with ticlopidine than with aspirin. In contrast, the 
      reduction in total pulmonary resistance is similar when enalapril is administered 
      in combination with aspirin or ticlopidine. Negative aspirin-enalapril 
      interaction on prostaglandin synthesis presumably alters vasodilatation in 
      systemic vessels, whereas prostaglandin-independent actions of ACE inhibition 
      such as pulmonary arterial vasodilatation are maintained.
FAU - Spaulding, C
AU  - Spaulding C
AD  - Department of Cardiology, Cochin Hospital, René Descartes University, Paris, 
      France. christian.spaulding@cch.ap-hop-paris.fr
FAU - Charbonnier, B
AU  - Charbonnier B
FAU - Cohen-Solal, A
AU  - Cohen-Solal A
FAU - Juillière, Y
AU  - Juillière Y
FAU - Kromer, E P
AU  - Kromer EP
FAU - Benhamda, K
AU  - Benhamda K
FAU - Cador, R
AU  - Cador R
FAU - Weber, S
AU  - Weber S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 69PN84IO1A (Enalapril)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 1999 Dec 21;100(25):e141-2. PMID: 10604908
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Double-Blind Method
MH  - Enalapril/therapeutic use
MH  - Female
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/therapeutic use
EDAT- 1998/09/04 02:34
MHDA- 2000/04/15 09:00
CRDT- 1998/09/04 02:34
PHST- 1998/09/04 02:34 [pubmed]
PHST- 2000/04/15 09:00 [medline]
PHST- 1998/09/04 02:34 [entrez]
AID - 10.1161/01.cir.98.8.757 [doi]
PST - ppublish
SO  - Circulation. 1998 Aug 25;98(8):757-65. doi: 10.1161/01.cir.98.8.757.

PMID- 322520
OWN - NLM
STAT- MEDLINE
DCOM- 19770525
LR  - 20190627
IS  - 0002-9610 (Print)
IS  - 0002-9610 (Linking)
VI  - 133
IP  - 4
DP  - 1977 Apr
TI  - Prevention of postoperative thrombosis by aspirin.
PG  - 420-2
AB  - In a random double-blind trial monitored by 125I-fibrinogen leg scan, impedance 
      plethysmography, and contrast phleobograms if impedance became abnormal, 
      hydroxycholoroquine was shown to be no more effective than placebo for prevention 
      of venous thrombosis after total hip replacement. Subsequently, the combination 
      of hydroxychloroquine with aspirin was shown to be not significantly better than 
      aspirin alone. Although the two parts of the trial were performed in an identical 
      manner, comparison of the two sequential parts of this investigation, which 
      provided a significant tread favoring aspirin, must be interpreted with caution. 
      Further study including concurrent controls is needed.
FAU - Hume, M
AU  - Hume M
FAU - Bierbaum, B
AU  - Bierbaum B
FAU - Kuriakose, T X
AU  - Kuriakose TX
FAU - Surprenant, J
AU  - Surprenant J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Surg
JT  - American journal of surgery
JID - 0370473
RN  - 0 (Placebos)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Evaluation
MH  - Hip Joint/surgery
MH  - Humans
MH  - Hydroxychloroquine/therapeutic use
MH  - Joint Prosthesis
MH  - Placebos
MH  - Postoperative Complications/*prevention & control
MH  - Thrombophlebitis/*prevention & control
EDAT- 1977/04/01 00:00
MHDA- 1977/04/01 00:01
CRDT- 1977/04/01 00:00
PHST- 1977/04/01 00:00 [pubmed]
PHST- 1977/04/01 00:01 [medline]
PHST- 1977/04/01 00:00 [entrez]
AID - 0002-9610(77)90125-8 [pii]
AID - 10.1016/0002-9610(77)90125-8 [doi]
PST - ppublish
SO  - Am J Surg. 1977 Apr;133(4):420-2. doi: 10.1016/0002-9610(77)90125-8.

PMID- 1151653
OWN - NLM
STAT- MEDLINE
DCOM- 19751030
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 64
IP  - 5
DP  - 1975 May
TI  - Effect of aspirin on fate of 14C-acetaminophen in guinea pigs.
PG  - 819-21
AB  - The interaction of 14C-acetaminophen, 150 mg/kg (20 muCi/kg), and orally 
      administered aspirin, 200 mg/kg, was studied in male guinea pigs. 
      Aspirin-pretreated animals possessed higher 14C blood levels than controls. Paper 
      chromatography of 0-6 hr urines demonstrated that pretreated animals excreted 
      significantly greater amounts of mercapturate than controls; however, it was only 
      a minor metabolite, accounting for 1-3% of the counts in the urine. The major 
      metabolite, the glucuronide, accounted for 90% of the counts, with free 
      acetaminophen and its sulfate responsible for the remaining counts. Tissue 
      distribution studies indicated that blood plasma and kidneys from 
      aspirin-pretreated animals possessed statistically higher 14C levels than did 
      control tissues. Bile duct and ureter cannulation experiments indicated that 
      aspirin inhibited the concentrating processes into the urine and bile.
FAU - Whitehouse, L W
AU  - Whitehouse LW
FAU - Paul, C J
AU  - Paul CJ
FAU - Thomas, B H
AU  - Thomas BH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Carbon Radioisotopes)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*metabolism
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bile/metabolism
MH  - Bile Ducts/physiology
MH  - Carbon Radioisotopes
MH  - Guinea Pigs
MH  - Intestinal Absorption
MH  - Kidney/metabolism
MH  - Liver/metabolism
MH  - Time Factors
MH  - Ureter/physiology
EDAT- 1975/05/01 00:00
MHDA- 1975/05/01 00:01
CRDT- 1975/05/01 00:00
PHST- 1975/05/01 00:00 [pubmed]
PHST- 1975/05/01 00:01 [medline]
PHST- 1975/05/01 00:00 [entrez]
AID - S0022-3549(15)40182-0 [pii]
AID - 10.1002/jps.2600640519 [doi]
PST - ppublish
SO  - J Pharm Sci. 1975 May;64(5):819-21. doi: 10.1002/jps.2600640519.

PMID- 373954
OWN - NLM
STAT- MEDLINE
DCOM- 19790716
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 25
IP  - 5 Pt 2
DP  - 1979 May
TI  - Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction 
      Study.
PG  - 681-4
AB  - Both the Coronary Drug Project (CDP) and the Aspirin Myocardial Infarction Study 
      (AMIS) were successfully able to recruit adequate members of postmyocardial 
      infarction patients to long-term multicenter clinical trials in the secondary 
      prevention of coronary heart disease. Aggressive efforts to achieve the 
      recruitment within an acceptable time limit were found to be neccessary. A direct 
      approach to the general public via the mass media and painstaking search of 
      hospital records proved to be the most effective methods. Referral from 
      physicians was not an effective way to recruit participants for the most part. 
      Both the general public and the medical profession are generally supportive of 
      this type of research.
FAU - Schoenberger, J A
AU  - Schoenberger JA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/*prevention & control
MH  - Drug Evaluation/*methods
MH  - *Human Experimentation
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Research Design
MH  - United States
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
AID - 10.1002/cpt1979255part2681 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1979 May;25(5 Pt 2):681-4. doi: 10.1002/cpt1979255part2681.

PMID- 31704207
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20200615
IS  - 1532-1932 (Electronic)
IS  - 1521-6934 (Linking)
VI  - 64
DP  - 2020 Apr
TI  - Antiphospholipid syndrome: Diagnosis and management in the obstetric patient.
PG  - 31-40
LID - S1521-6934(19)30137-3 [pii]
LID - 10.1016/j.bpobgyn.2019.10.001 [doi]
AB  - Antiphospholipid syndrome (APS) is a rare condition clinically characterized by 
      thrombotic events or pregnancy complications and confirmed by one or more 
      repeatedly positive antiphospholipid antibodies on two or more occasions at least 
      12 weeks apart. Several factors are thought to have roles in the pathogenesis of 
      adverse obstetric events related to APS, including platelet and endothelial cell 
      activation, complement activation, and ultimate activation of the thrombotic 
      pathway. Despite standard treatment with a heparin agent and low-dose aspirin, 
      30% of women with definite APS cannot achieve a successful pregnancy outcome. 
      Additional treatment options are still controversial, and prospective trials with 
      appropriate controls are needed to investigate the efficiency of alternative 
      treatments. In this chapter, we discuss diagnostic, clinical, and therapeutic 
      approaches in the treatment of APS syndrome in pregnancy.
CI  - Copyright © 2019. Published by Elsevier Ltd.
FAU - Arslan, Erol
AU  - Arslan E
AD  - University of Utah Health, Salt Lake City, UT, USA.
FAU - Branch, D Ware
AU  - Branch DW
AD  - University of Utah Health, Salt Lake City, UT, USA. Electronic address: 
      ware.branch@hsc.utah.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191017
PL  - Netherlands
TA  - Best Pract Res Clin Obstet Gynaecol
JT  - Best practice & research. Clinical obstetrics & gynaecology
JID - 101121582
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Antiphospholipid/blood
MH  - Antiphospholipid Syndrome/*diagnosis/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - *Pregnancy Complications
OTO - NOTNLM
OT  - Antiphospholipid antibodies
OT  - Antiphospholipid syndrome
OT  - Aspirin
OT  - Heparin
OT  - Preeclampsia
OT  - Pregnancy loss
COIS- Declaration of Competing Interest The authors have no conflict of interest.
EDAT- 2019/11/11 06:00
MHDA- 2020/06/17 06:00
CRDT- 2019/11/10 06:00
PHST- 2019/09/16 00:00 [received]
PHST- 2019/10/03 00:00 [revised]
PHST- 2019/10/06 00:00 [accepted]
PHST- 2019/11/11 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2019/11/10 06:00 [entrez]
AID - S1521-6934(19)30137-3 [pii]
AID - 10.1016/j.bpobgyn.2019.10.001 [doi]
PST - ppublish
SO  - Best Pract Res Clin Obstet Gynaecol. 2020 Apr;64:31-40. doi: 
      10.1016/j.bpobgyn.2019.10.001. Epub 2019 Oct 17.

PMID- 15951873
OWN - NLM
STAT- MEDLINE
DCOM- 20060823
LR  - 20131121
IS  - 0379-5284 (Print)
IS  - 0379-5284 (Linking)
VI  - 26
IP  - 5
DP  - 2005 May
TI  - Decreased proinflammatory cytokine production by peripheral blood mononuclear 
      cells from vitiligo patients following aspirin treatment.
PG  - 799-805
AB  - OBJECTIVE: Limited studies have shown that treatment of cells with aspirin 
      modulates their cytokine production. Consequently, the aim of the present study 
      is to investigate the pattern of important proinflammatory cytokines production 
      by stimulated peripheral blood mononuclear cells (PBMC) from patients with active 
      vitiligo following long-term treatment with low-dose oral aspirin. METHODS: The 
      study was conducted at the Vitiligo Unit, King Abdul-Aziz University Medical 
      Center, Jeddah, Kingdom of Saudi Arabia between March and October 2003. 
      Thirty-two patients (18 females and 14 males) with non-segmental vitiligo were 
      divided into 2 equal groups, one group received a daily single dose of oral 
      aspirin (300 mg) and the other group received placebo for a period of 12 weeks. 
      The concentrations of interleukin (IL)-1beta, IL-6, IL-8 and tumor necrosis 
      factor-alpha (TNF-alpha) were determined in the supernatant of isolated cultured 
      PMBC after being stimulated with bacterial lipopolysaccharide (LPS), before the 
      start of aspirin treatment and at end of treatment period. Cytokine levels were 
      measured using the quantitative sandwich enzyme-linked immunosorbent assay 
      (ELISA) technique, utilizing commercially available kits. RESULTS: The 
      proinflammatory cytokine production by the PBMC of patients with active vitiligo 
      was significantly increased compared to normal controls. Thus, the relative 
      percentage increase in the production of IL-1beta, IL-6, IL-8 and TNF-alpha was: 
      39.4%, 110.5% (p<0.05), 91.5% (p<0.01), and 37% (p<0.05). At the end of 
      treatment, proinflammatory cytokine production in the aspirin-treated group of 
      active vitiligo patients was significantly decreased compared to the placebo 
      group. Thus, the relative percentage decrease in the production of IL-1beta IL-6, 
      IL-8 and TNF-alpha was: 42.5%, 45.2% (p<0.05), 30.8% (p<0.01), and 50.6% 
      (p<0.05). The vitiligo activity was arrested in all aspirin-treated patients, 
      while 2 patients demonstrated significant repigmentation. CONCLUSION: Chronic 
      administration of low-dose oral aspirin can down-regulate the PBMC 
      proinflammatory cytokine production in active vitiligo with concomitant arrest of 
      disease activity.
FAU - Zailaie, Mohammad Z
AU  - Zailaie MZ
AD  - The Vitiligo Unit, King Abdul-Aziz University Medical Center, PO Box 80170, 
      Jeddah 21589, Kingdom of Saudi Arabia. mzailaie@kaau.edu.sa
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Saudi Arabia
TA  - Saudi Med J
JT  - Saudi medical journal
JID - 7909441
RN  - 0 (Cytokines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cytokines/*analysis/*biosynthesis
MH  - Female
MH  - Humans
MH  - Leukocytes, Mononuclear/*metabolism
MH  - Male
MH  - Saudi Arabia
MH  - Vitiligo/*drug therapy
EDAT- 2005/06/14 09:00
MHDA- 2006/08/24 09:00
CRDT- 2005/06/14 09:00
PHST- 2005/06/14 09:00 [pubmed]
PHST- 2006/08/24 09:00 [medline]
PHST- 2005/06/14 09:00 [entrez]
AID - 20050024' [pii]
PST - ppublish
SO  - Saudi Med J. 2005 May;26(5):799-805.

PMID- 8426506
OWN - NLM
STAT- MEDLINE
DCOM- 19930303
LR  - 20190825
IS  - 0023-852X (Print)
IS  - 0023-852X (Linking)
VI  - 103
IP  - 2
DP  - 1993 Feb
TI  - Easy bruisability, aspirin intolerance, and response to DDAVP.
PG  - 156-9
AB  - Easy bruisability raises the issue of bleeding during otolaryngological surgery. 
      Ten female patients with easy bruisability were evaluated by aspirin challenge; 
      clinical history and screening coagulation studies in these patients had revealed 
      no evidence of a bleeding disorder. The baseline Ivy bleeding time (BT) test (4.5 
      to 9.5 minutes) was found to be normal in 6 patients and prolonged in 4 patients. 
      Following treatment with aspirin, the bleeding time prolonged significantly in 
      the three groups evaluated: normal controls (6.0 +/- 1.5 minutes vs. 8.4 +/- 2.0 
      minutes), patients with easy bruisability and a normal baseline (7.8 +/- 1.3 
      minutes vs. 12.0 +/- 1.6 minutes), and patients with easy bruisability and an 
      abnormal baseline (11.0 +/- 0.7 minutes vs. 14.5 +/- 0.9 minutes). Administration 
      of DDAVP (desmopressin acetate) 0.3 microgram/kg normalized the prolonged 
      bleeding times in all groups after 7 days of daily aspirin therapy. Performing 
      bleeding times before aspirin challenge, after aspirin challenge, and after DDAVP 
      therapy following aspirin challenge is both a useful way of confirming aspirin 
      sensitivity in patients with easy bruisability as well as a useful way of 
      documenting improved hemostasis after DDAVP administration.
FAU - Lekas, M D
AU  - Lekas MD
AD  - Department of Surgery, Brown University School of Medicine, Providence, RI.
FAU - Crowley, J P
AU  - Crowley JP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - *Bleeding Time
MH  - Deamino Arginine Vasopressin/*pharmacology
MH  - Female
MH  - Hemorrhage/blood/*chemically induced
MH  - Humans
MH  - Middle Aged
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
AID - 10.1002/lary.5541030206 [doi]
PST - ppublish
SO  - Laryngoscope. 1993 Feb;103(2):156-9. doi: 10.1002/lary.5541030206.

PMID- 20664119
OWN - NLM
STAT- MEDLINE
DCOM- 20110808
LR  - 20200219
IS  - 2561-8741 (Electronic)
IS  - 2561-8741 (Linking)
VI  - 17
IP  - 2
DP  - 2010 Summer
TI  - A multi-case report of acute renal failure in patients treated with Aggrenox.
PG  - e262-8
AB  - BACKGROUND: Aggrenox is used in the secondary prevention of stroke. Acute renal 
      failure, potentially associated with Aggrenox, has been observed in several 
      patients. OBJECTIVE: The objective of this study was to determine if Aggrenox was 
      associated with acute renal failure and to determine whether it was 
      acetylsalicylic acid, dipyridamole or the combination that led to decline in 
      renal function. METHODS: A case series of three patients suffering severe nausea, 
      vomiting, diarrhea, renal dysfunction and clinical decline during Aggrenox 
      therapy was examined. Serum creatinine and Blood Urea Nitrogen (BUN) were 
      measured to evaluate renal function. RESULTS: Analysis of this patient group 
      revealed that Patient 1 experienced nausea, emesis, anorexia, diarrhea and 
      significant clinical decline during treatment with Aggrenox. Patients 2 and 3 
      also presented with complaints of nausea and emesis. Lab measurements along with 
      clinical symptoms indicated that all three patients experienced acute renal 
      failure, having increases in serum creatinine of 186%, 144% and 249%, 
      respectively. Symptoms and lab work returned to baseline following 
      discontinuation of Aggrenox. CONCLUSION: It is biologically plausible that 
      Aggrenox may contribute to renal dysfunction in patients under certain 
      pathophysiological circumstances.
FAU - Joy, Kerry
AU  - Joy K
AD  - St. Joseph's Care Group, Thunder Bay, Ontario, Canada. joyk@tbh.net
FAU - Dubois, Sacha
AU  - Dubois S
FAU - Gibbons, Carrie
AU  - Gibbons C
FAU - Hargadon, John
AU  - Hargadon J
FAU - Bédard, Michel
AU  - Bédard M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100706
PL  - Australia
TA  - J Popul Ther Clin Pharmacol
JT  - Journal of population therapeutics and clinical pharmacology = Journal de la 
      therapeutique des populations et de la pharmacologie clinique
JID - 101530023
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 64ALC7F90C (Dipyridamole)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Kidney Injury/blood/*chemically induced/*diagnosis
MH  - Aspirin/*adverse effects
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Creatinine/blood
MH  - Dipyridamole/*adverse effects
MH  - Drug Combinations
MH  - Humans
EDAT- 2010/07/29 06:00
MHDA- 2011/08/09 06:00
CRDT- 2010/07/29 06:00
PHST- 2010/07/29 06:00 [entrez]
PHST- 2010/07/29 06:00 [pubmed]
PHST- 2011/08/09 06:00 [medline]
PST - ppublish
SO  - J Popul Ther Clin Pharmacol. 2010 Summer;17(2):e262-8. Epub 2010 Jul 6.

PMID- 33762229
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 11
IP  - 3
DP  - 2021 Mar 24
TI  - PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic 
      trial protocol comparing aspirin versus low-molecular-weight heparin for blood 
      clot prevention in orthopaedic trauma patients.
PG  - e041845
LID - 10.1136/bmjopen-2020-041845 [doi]
LID - e041845
AB  - INTRODUCTION: Patients who sustain orthopaedic trauma are at an increased risk of 
      venous thromboembolism (VTE), including fatal pulmonary embolism (PE). Current 
      guidelines recommend low-molecular-weight heparin (LMWH) for VTE prophylaxis in 
      orthopaedic trauma patients. However, emerging literature in total joint 
      arthroplasty patients suggests the potential clinical benefits of VTE prophylaxis 
      with aspirin. The primary aim of this trial is to compare aspirin with LMWH as a 
      thromboprophylaxis in fracture patients. METHODS AND ANALYSIS: PREVENT CLOT is a 
      multicentre, randomised, pragmatic trial that aims to enrol 12 200 adult patients 
      admitted to 1 of 21 participating centres with an operative extremity fracture, 
      or any pelvis or acetabular fracture. The primary outcome is all-cause mortality. 
      We will evaluate non-inferiority by testing whether the intention-to-treat 
      difference in the probability of dying within 90 days of randomisation between 
      aspirin and LMWH is less than our non-inferiority margin of 0.75%. Secondary 
      efficacy outcomes include cause-specific mortality, non-fatal PE and deep vein 
      thrombosis. Safety outcomes include bleeding complications, wound complications 
      and deep surgical site infections. ETHICS AND DISSEMINATION: The PREVENT CLOT 
      trial has been approved by the ethics board at the coordinating centre (Johns 
      Hopkins Bloomberg School of Public Health) and all participating sites. 
      Recruitment began in April 2017 and will continue through 2021. As both study 
      medications are currently in clinical use for VTE prophylaxis for orthopaedic 
      trauma patients, the findings of this trial can be easily adopted into clinical 
      practice. The results of this large, patient-centred pragmatic trial will help 
      guide treatment choices to prevent VTE in fracture patients. TRIAL REGISTRATION 
      NUMBER: NCT02984384.
CI  - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - O'Toole, Robert V
AU  - O'Toole RV
AUID- ORCID: 0000-0003-0537-3474
AD  - Department of Orthopaedics, University of Maryland Baltimore, Baltimore, 
      Maryland, USA ROtoole@som.umaryland.edu.
FAU - Stein, Deborah M
AU  - Stein DM
AD  - Department of Surgery, University of California in San Francisco, San Francisco, 
      California, USA.
FAU - Frey, Katherine P
AU  - Frey KP
AD  - METRC Coordinating Center, Johns Hopkins University Bloomberg School of Public 
      Health, Baltimore, Maryland, USA.
FAU - O'Hara, Nathan N
AU  - O'Hara NN
AUID- ORCID: 0000-0003-0537-3474
AD  - Department of Orthopaedics, University of Maryland Baltimore, Baltimore, 
      Maryland, USA.
FAU - Scharfstein, Daniel O
AU  - Scharfstein DO
AD  - Department of Population Health Sciences, University of Utah, Salt Lake City, 
      Utah, USA.
FAU - Slobogean, Gerard P
AU  - Slobogean GP
AD  - Department of Orthopaedics, University of Maryland Baltimore, Baltimore, 
      Maryland, USA.
FAU - Taylor, Tara J
AU  - Taylor TJ
AD  - METRC Coordinating Center, Johns Hopkins University Bloomberg School of Public 
      Health, Baltimore, Maryland, USA.
FAU - Haac, Bryce E
AU  - Haac BE
AD  - Department of Surgery, University of Maryland School of Medicine, Baltimore, 
      Maryland, USA.
FAU - Carlini, Anthony R
AU  - Carlini AR
AD  - METRC Coordinating Center, Johns Hopkins University Bloomberg School of Public 
      Health, Baltimore, Maryland, USA.
FAU - Manson, Theodore T
AU  - Manson TT
AD  - Department of Orthopaedics, University of Maryland Baltimore, Baltimore, 
      Maryland, USA.
FAU - Sudini, Kuladeep
AU  - Sudini K
AD  - METRC Coordinating Center, Johns Hopkins University Bloomberg School of Public 
      Health, Baltimore, Maryland, USA.
FAU - Mullins, C Daniel
AU  - Mullins CD
AD  - Department of Pharmaceutical Health Services Research, University of Maryland 
      School of Pharmacy, Baltimore, Maryland, USA.
FAU - Wegener, Stephen T
AU  - Wegener ST
AD  - Department of Physical Medicine and Rehabilitation, Johns Hopkins University 
      School of Medicine, Baltimore, Maryland, USA.
FAU - Firoozabadi, Reza
AU  - Firoozabadi R
AD  - Department of Orthopaedic Surgery and Sports Medicine, University of Washington - 
      Harborview Medical Center, Seattle, Washington, USA.
FAU - Haut, Elliott R
AU  - Haut ER
AD  - Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, 
      USA.
FAU - Bosse, Michael J
AU  - Bosse MJ
AD  - Department of Orthopaedic Surgery, Atrium Health, Charlotte, North Carolina, USA.
FAU - Seymour, Rachel B
AU  - Seymour RB
AD  - Department of Orthopaedic Surgery, Atrium Health, Charlotte, North Carolina, USA.
FAU - Holden, Martha B
AU  - Holden MB
AD  - Department of Orthopaedic Surgery, Wake Forest Baptist Medical Center, 
      Winston-Salem, North Carolina, USA.
FAU - Gitajn, Ida Leah
AU  - Gitajn IL
AD  - Department of Orthopaedics, Dartmouth-Hitchcock Medical Center, Lebanon, New 
      Hampshire, USA.
FAU - Goldhaber, Samuel Z
AU  - Goldhaber SZ
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
FAU - Eastman, Alexander L
AU  - Eastman AL
AD  - Department of Surgery, University of Texas Southwestern Medical School, Dallas, 
      Texas, USA.
FAU - Jurkovich, Gregory J
AU  - Jurkovich GJ
AD  - Department of Surgery, University of California Davis, Davis, California, USA.
FAU - Vallier, Heather A
AU  - Vallier HA
AD  - Department of Orthopaedics, MetroHealth System, Cleveland, Ohio, USA.
FAU - Gary, Joshua L
AU  - Gary JL
AD  - Department of Orthopedic Surgery, University of Texas McGovern Medical School, 
      Houston, Texas, USA.
FAU - Kleweno, Conor P
AU  - Kleweno CP
AD  - Department of Orthopaedic Surgery and Sports Medicine, University of Washington - 
      Harborview Medical Center, Seattle, Washington, USA.
FAU - Cuschieri, Joseph
AU  - Cuschieri J
AD  - Department of Surgery, University of Washington - Harborview Medical Center, 
      Seattle, Washington, USA.
FAU - Marvel, Debra
AU  - Marvel D
AD  - PREVENT CLOT Stakeholder Committee, Baltimore, Maryland, USA.
FAU - Castillo, Renan C
AU  - Castillo RC
AD  - METRC Coordinating Center, Johns Hopkins University Bloomberg School of Public 
      Health, Baltimore, Maryland, USA.
CN  - METRC
LA  - eng
SI  - ClinicalTrials.gov/NCT02984384
GR  - R21 HL129028/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20210324
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Orthopedics
MH  - Randomized Controlled Trials as Topic
MH  - *Thrombosis
MH  - *Venous Thromboembolism/prevention & control
PMC - PMC7993181
OTO - NOTNLM
OT  - orthopaedic & trauma surgery
OT  - thromboembolism
OT  - trauma management
COIS- Competing interests: CDM has received grant funding as PI from Merck and receives 
      consulting income from AstraZeneca, Bayer Pharmaceuticals, Janssen/J&J, Merck and 
      Pfizer. ERH is/was the primary investigator of contracts from The Patient-Centred 
      Outcomes Research Institute (PCORI) entitled 'Preventing Venous Thromboembolism: 
      Empowering Patients and Enabling Patient-Centred Care via Health Information 
      Technology' (CE-12-11-4489) and 'Preventing Venous Thromboembolism (VTE): 
      Engaging Patients to Reduce Preventable Harm from Missed/Refused Doses of VTE 
      Prophylaxis' (DI-1603-34596); is the primary investigator of a grant from the 
      Agency for Healthcare Research and Quality (AHRQ) (1R01HS024547) entitled 
      'Individualised Performance Feedback on Venous Thromboembolism Prevention 
      Practice,' and is a co-investigator on a grant from the NIH/NHLBI (R21HL129028) 
      entitled 'Analysis of the Impact of Missed Doses of Venous Thromboembolism 
      Prophylaxis'; receives research grant support from the DOD/Army Medical Research 
      Acquisition Activity and has received grant support from the Henry M. Jackson 
      Foundation for the Advancement of Military Medicine (HJF); receives book 
      royalties from Lippincott, Williams, Wilkins; and is a paid consultant to Vizient 
      for their HIIN Venous Thromboembolism (VTE) Prevention Action Network.
FIR - Altman, Gregory T
IR  - Altman GT
FIR - Christmas, A Britton
IR  - Christmas AB
FIR - Hymes, Robert A
IR  - Hymes RA
FIR - Gaski, Greg E
IR  - Gaski GE
FIR - Natoli, Roman M
IR  - Natoli RM
FIR - Velmahos, George C
IR  - Velmahos GC
FIR - Weaver, Michael J
IR  - Weaver MJ
FIR - Cotton, Bryan A
IR  - Cotton BA
FIR - Johal, Herman
IR  - Johal H
FIR - Sne, Niv
IR  - Sne N
FIR - Hayda, Roman
IR  - Hayda R
FIR - Evans, Andrew R
IR  - Evans AR
FIR - Osborn, Patrick M
IR  - Osborn PM
FIR - Rivera, Jessica C
IR  - Rivera JC
FIR - Boulton, Christina L
IR  - Boulton CL
FIR - Joseph, Bellal
IR  - Joseph B
FIR - Schneider, Prism S
IR  - Schneider PS
FIR - Degani, Yasmin
IR  - Degani Y
FIR - Rattan, Rishi
IR  - Rattan R
FIR - Bergin, Patrick F
IR  - Bergin PF
FIR - Kutcher, Matthew E
IR  - Kutcher ME
FIR - Croce, Martin A
IR  - Croce MA
FIR - Weinlein, John C
IR  - Weinlein JC
FIR - Whiting, Paul S
IR  - Whiting PS
FIR - Obremskey, William
IR  - Obremskey W
FIR - Guillamondegui, Oscar D
IR  - Guillamondegui OD
FIR - Carroll, Eben A
IR  - Carroll EA
FIR - Miller, Preston R
IR  - Miller PR
EDAT- 2021/03/26 06:00
MHDA- 2021/05/20 06:00
CRDT- 2021/03/25 05:49
PHST- 2021/03/25 05:49 [entrez]
PHST- 2021/03/26 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - bmjopen-2020-041845 [pii]
AID - 10.1136/bmjopen-2020-041845 [doi]
PST - epublish
SO  - BMJ Open. 2021 Mar 24;11(3):e041845. doi: 10.1136/bmjopen-2020-041845.

PMID- 8250352
OWN - NLM
STAT- MEDLINE
DCOM- 19931227
LR  - 20131121
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 71
IP  - 5
DP  - 1993 Nov
TI  - Nonsteroidal antiinflammatory drug desensitization using flurbiprofen (Ansaid).
PG  - 459-60
AB  - Nonsteroidal antiinflammatory drug (NSAID) and aspirin reactions remain 
      commonplace. Specific recommendations and standardized approaches to the use of 
      NSAIDs in patients with known hypersensitivity to these agents are evolving. 
      Cross reactivity and sensitization are frequent within this group of agents. The 
      advent of newer synthetic nonsteroidal antiinflammatory drugs may offer a means 
      of lowering reaction rates. Flurbiprofen (Ansaid) is a new NSAID for the 
      treatment of rheumatoid arthritis and osteoarthritis. We report successful 
      flurbiprofen desensitization with incremental oral challenge in a patient using 
      this agent.
FAU - Douglas, D M
AU  - Douglas DM
AD  - Department of Internal Medicine, Madigan Army Medical Center, Tacoma, Washington.
FAU - Ward, L
AU  - Ward L
FAU - Brown, J S
AU  - Brown JS
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Allergy. 1993 Nov;71(5):417-8. PMID: 8250345
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/immunology
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/*adverse effects/immunology
MH  - Cross Reactions
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/etiology
MH  - Drug Tolerance
MH  - Female
MH  - Flurbiprofen/*immunology/therapeutic use
MH  - Humans
MH  - Osteoarthritis/drug therapy
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1993 Nov;71(5):459-60.

PMID- 25895638
OWN - NLM
STAT- MEDLINE
DCOM- 20160308
LR  - 20220410
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 760
DP  - 2015 Aug 5
TI  - Lipoxins and aspirin-triggered lipoxins in resolution of inflammation.
PG  - 49-63
LID - S0014-2999(15)00329-5 [pii]
LID - 10.1016/j.ejphar.2015.03.083 [doi]
AB  - The resolution of the inflammatory response is highly regulated by the timely 
      biosynthesis of a number of endogenous lipid mediators. Among these, lipoxins 
      (LX) and their 15-epimers, aspirin triggered lipoxins (ATL) derived by the 
      lipoxygenase (LO) route of arachidonic acid metabolism. In particular, they are 
      formed and released by cells expressing 5-, 12- and 15-LO such as leukocytes, 
      platelets, vascular endothelium and epithelium, alone or during transcellular 
      interactions. ATL biosynthesis requires cyclooxygenase-2 acetylation by aspirin. 
      LX and ATL exert potent bioactions on leukocytes, vascular and epithelial cells 
      to stop inflammation and promote resolution. They have shown to be beneficial in 
      a broad spectrum of preclinical models of disease as well as in some clinical 
      trials. Counter-regulatory signaling by LXA4 and 15-epi-LXA4 follows the 
      activation of a G protein-coupled receptor, termed ALX/FPR2, which is emerging as 
      a key anti-inflammatory receptor.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Romano, Mario
AU  - Romano M
AD  - Department of Medical, Oral and Biotechnological Sciences, G. d׳Annunzio 
      University of Chieti-Pescara, Chieti, Italy; Center of Excellence on Aging, G. 
      d׳Annunzio University of Chieti-Pescara, Chieti, Italy. Electronic address: 
      mromano@unich.it.
FAU - Cianci, Eleonora
AU  - Cianci E
AD  - Medicine and Aging Sciences, G. d׳Annunzio University of Chieti-Pescara, Chieti, 
      Italy; Center of Excellence on Aging, G. d׳Annunzio University of Chieti-Pescara, 
      Chieti, Italy.
FAU - Simiele, Felice
AU  - Simiele F
AD  - Department of Medical, Oral and Biotechnological Sciences, G. d׳Annunzio 
      University of Chieti-Pescara, Chieti, Italy; Center of Excellence on Aging, G. 
      d׳Annunzio University of Chieti-Pescara, Chieti, Italy.
FAU - Recchiuti, Antonio
AU  - Recchiuti A
AD  - Department of Medical, Oral and Biotechnological Sciences, G. d׳Annunzio 
      University of Chieti-Pescara, Chieti, Italy; Center of Excellence on Aging, G. 
      d׳Annunzio University of Chieti-Pescara, Chieti, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150418
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Inflammation Mediators)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Humans
MH  - Inflammation/chemically induced/metabolism
MH  - Inflammation Mediators/*metabolism
MH  - Lipoxins/*metabolism
MH  - Signal Transduction/drug effects/physiology
OTO - NOTNLM
OT  - Efferocytosis
OT  - Inflammation
OT  - Lipoxin
OT  - Lipoxygenase
OT  - Polymorphysm
OT  - Promoter
OT  - Receptor
OT  - Resolution
OT  - microRNA
EDAT- 2015/04/22 06:00
MHDA- 2016/03/10 06:00
CRDT- 2015/04/22 06:00
PHST- 2015/01/27 00:00 [received]
PHST- 2015/03/27 00:00 [revised]
PHST- 2015/03/30 00:00 [accepted]
PHST- 2015/04/22 06:00 [entrez]
PHST- 2015/04/22 06:00 [pubmed]
PHST- 2016/03/10 06:00 [medline]
AID - S0014-2999(15)00329-5 [pii]
AID - 10.1016/j.ejphar.2015.03.083 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2015 Aug 5;760:49-63. doi: 10.1016/j.ejphar.2015.03.083. Epub 
      2015 Apr 18.

PMID- 12030663
OWN - NLM
STAT- MEDLINE
DCOM- 20020530
LR  - 20181113
IS  - 0960-1643 (Print)
IS  - 0960-1643 (Linking)
VI  - 52
IP  - 476
DP  - 2002 Mar
TI  - Thrombosis prevention trial: follow-up study of practical implications.
PG  - 208-9
AB  - The impact of randomised controlled trials on subsequent practice has only 
      occasionally been assessed. Doing so is particularly necessary when unusual and 
      possibly controversial treatments are being used. The aim of this study was to 
      assess the practical implications of the results of the placebo-controlled 
      primary prevention thrombosis prevention trial, in which the active treatment 
      regimens were combined warfarin and aspirin, warfarin alone, and aspirin alone. 
      Both active agents were given in low doses. Decisions on post-trial management 
      were sought about men who continued with randomly-allocated treatment until the 
      trial ended. The results of the trial appeared to have influenced decisions about 
      future management. While aspirin was clearly the most frequent choice, a regimen 
      involving warfarin was also used for a substantial proportion of men. Prior 
      experience of acceptability, effectiveness, and safety probably played a 
      significant part in decisions to continue with or switch to a warfarin-containing 
      regimen. The findings may provide a measure of reassurance about the value of 
      oral anticoagulation in other settings, particularly atrial fibrillation where, 
      despite the results of trials showing major reductions in stroke, anticoagulation 
      is underused.
FAU - Fasey, N
AU  - Fasey N
AD  - MRC Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, 
      London.
FAU - Brennan, P J
AU  - Brennan PJ
FAU - Meade, T W
AU  - Meade TW
CN  - MRC General Practice Research Framework. Medical Research Council
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of 
      General Practitioners
JID - 9005323
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Family Practice
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thrombosis/*prevention & control
MH  - Warfarin/*therapeutic use
PMC - PMC1314240
EDAT- 2002/05/28 10:00
MHDA- 2002/05/31 10:01
CRDT- 2002/05/28 10:00
PHST- 2002/05/28 10:00 [pubmed]
PHST- 2002/05/31 10:01 [medline]
PHST- 2002/05/28 10:00 [entrez]
PST - ppublish
SO  - Br J Gen Pract. 2002 Mar;52(476):208-9.

PMID- 9670622
OWN - NLM
STAT- MEDLINE
DCOM- 19980804
LR  - 20131121
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 107
DP  - 1998 May
TI  - Efficacy of pentoxifylline with aspirin in the treatment of frostbite in rats.
PG  - 239-45
AB  - The efficacy of pentoxifylline--a haemorrheologic agent along with aspirin--an 
      analgesic agent was evaluated in the amelioration of the tissue damage due to 
      experimentally induced frostbite in 5 groups (20 each) of rats with body weights 
      ranging between 175 and 200 g. Frostbite was produced experimentally in the hind 
      limbs by exposing the animals to -15 +/- 1 degrees C for 1 h using the harness 
      technique, with simultaneous recording of rectal and environmental temperatures. 
      The degree of tissue damage was assessed on the basis of tissue necrosis after 15 
      days. Administration of pentoxifylline (40 mg/kg bw) 30 min before and 30 min 
      after the cold exposure followed by two doses of the same daily for the next 5 
      days along with aspirin (5 mg/kg bw) twice daily for the same duration only after 
      cold exposure, resulted in significant improvement in the degree of tissue 
      preservation. The findings of this preliminary study have brought to light the 
      potential usefulness of these drugs in the treatment of frostbite. The combined 
      pharmacological properties of these two drugs might have altered the 
      haemorrheologic status of blood and produced the curative beneficial effect in 
      improving tissue survival following experimentally induced frostbite in rats.
FAU - Purkayastha, S S
AU  - Purkayastha SS
AD  - Department of Cold Physiology, Defence Institute of Physiology & Allied Sciences, 
      Delhi.
FAU - Roy, A
AU  - Roy A
FAU - Chauhan, S K
AU  - Chauhan SK
FAU - Verma, S S
AU  - Verma SS
FAU - Selvamurthy, W
AU  - Selvamurthy W
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Cold Temperature
MH  - Drug Therapy, Combination
MH  - Female
MH  - Frostbite/*drug therapy
MH  - Male
MH  - Necrosis
MH  - Pentoxifylline/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Vasodilator Agents/*therapeutic use
EDAT- 1998/07/22 00:00
MHDA- 1998/07/22 00:01
CRDT- 1998/07/22 00:00
PHST- 1998/07/22 00:00 [pubmed]
PHST- 1998/07/22 00:01 [medline]
PHST- 1998/07/22 00:00 [entrez]
PST - ppublish
SO  - Indian J Med Res. 1998 May;107:239-45.

PMID- 1398237
OWN - NLM
STAT- MEDLINE
DCOM- 19921029
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 33
IP  - 8
DP  - 1992 Aug
TI  - Mucus glycoprotein biosynthesis in the human gall bladder: inhibition by aspirin.
PG  - 1109-12
AB  - Aspirin, which inhibits mucin secretion in the gastrointestinal tract prevents 
      gall stone formation in animals and may reduce gall stone recurrence in man. This 
      study examines the effect of aspirin on mucin synthesis in human gall bladder 
      explants. Two hundred explants were cultured with 3H-glucosamine (74 kBq/ml) for 
      24 hours at 37 degrees C. Mucin and other glycoproteins were isolated by papain 
      digestion (72 hours) and exhaustive dialysis (144 hours) to remove 
      non-incorporated radioactivity and digested protein. 3H-glucosamine was readily 
      incorporated into glycoprotein. Pooled gall bladder explants were fractionated on 
      a CsCl density gradient and by gel filtration on Sepharose 2B and 4B to confirm 
      that >90% radioactivity was incorporated into mucin. Acetylsalicylic acid 
      (230-666 micrograms/ml) significantly reduced total 3H-glucosamine incorporation 
      (43-89%), p<0.01 (unpaired t test). Diclofenac (125-1250 micrograms/ml), 
      similarly reduced incorporation by 45-97% p<0.001 (unpaired t test). Inhibition 
      of mucin glycoprotein biosynthesis was irreversible with both drugs. Analysis of 
      pooled samples on Sepharose 4B showed abolition of radioactive incorporation into 
      mucin but no effect on incorporation into low molecular weight glycoprotein 
      material (10% of total incorporation). This study provides a method for measuring 
      human gall bladder mucin synthesis and shows its irreversible inhibition by 
      acetylsalicylic acid and diclofenac at concentrations compatible with a 
      therapeutic dose.
FAU - Rhodes, M
AU  - Rhodes M
AD  - Department of Surgery, University of Newcastle upon Tyne.
FAU - Allen, A
AU  - Allen A
FAU - Lennard, T W
AU  - Lennard TW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Glycoproteins)
RN  - 144O8QL0L1 (Diclofenac)
RN  - N08U5BOQ1K (Glucosamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Depression, Chemical
MH  - Diclofenac/pharmacology
MH  - Gallbladder/drug effects/*metabolism
MH  - Glucosamine/metabolism
MH  - Glycoproteins/*biosynthesis
MH  - Humans
MH  - In Vitro Techniques
MH  - Mucus/*metabolism
PMC - PMC1379452
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
AID - 10.1136/gut.33.8.1109 [doi]
PST - ppublish
SO  - Gut. 1992 Aug;33(8):1109-12. doi: 10.1136/gut.33.8.1109.

PMID- 9457092
OWN - NLM
STAT- MEDLINE
DCOM- 19980219
LR  - 20220408
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 351
IP  - 9098
DP  - 1998 Jan 24
TI  - Thrombosis prevention trial: randomised trial of low-intensity oral 
      anticoagulation with warfarin and low-dose aspirin in the primary prevention of 
      ischaemic heart disease in men at increased risk. The Medical Research Council's 
      General Practice Research Framework.
PG  - 233-41
AB  - BACKGROUND: We aimed to evaluate low intensity oral anticoagulation with warfarin 
      and low-dose aspirin in the primary prevention of ischaemic heart disease (IHD). 
      METHODS: 5499 men aged between 45 years and 69 years at high risk of IHD were 
      recruited from 108 practices in the UK that belong to the Medical Research 
      Council's General Practice Research Framework. Initially, warfarin or placebo was 
      randomly allocated to 1427 men; 1013 of these men later moved to a factorial 
      stage of the trial, retaining their warfarin or placebo warfarin allocation and 
      adding randomly allocated active or placebo aspirin. Another 4072 men entered 
      directly into the factorial stage making a total of 5085 men. The four factorial 
      treatment groups were: active warfarin and active aspirin (WA, n = 1277), active 
      warfarin and placebo aspirin (W, n = 1268), and placebo warfarin and active 
      aspirin (A, n = 1268), and placebo warfarin and placebo aspirin (P, n = 1272). 
      The primary end-point was all IHD defined as the sum of coronary death and fatal 
      and non-fatal myocardial infarction (MI). FINDINGS: The mean International 
      Normalised Ratio (INR) of those on active warfarin was 1.47. The mean warfarin 
      dose was 4.1 mg a day (range 0.5 mg-12.5 mg). There were 410 IHD events (142 
      fatal, 268 non-fatal). The main effect of warfarin (i.e., WA and W vs A and P) 
      was a reduction in all IHD of 21% (95% CI 4-35, p = 0.02) chiefly due to a 39% 
      reduction (15-57, p = 0.003) in fatal events so that warfarin reduced the death 
      rate from all causes by 17% (1-30, p = 0.04). The main effect of aspirin (i.e., 
      WA and A vs W and P) was a reduction in all IHD of 20% (1-35, p = 0.04) almost 
      entirely due to a 32% reduction (12-48, p = 0.004) in non-fatal events. Absolute 
      reductions in all IHD due to warfarin or aspirin were 2.6 and 2.3 per 1000 person 
      years, respectively. WA reduced all IHD by 34% (11-51, p = 0.006) compared with 
      P. WA increased haemorrhagic and fatal strokes. Ruptured aortic or dissecting 
      aneurysms occurred in 15 of those who were or had been on warfarin compared with 
      three of those who had not (p = 0.01). INTERPRETATION: These results add to 
      evidence that aspirin reduces non-fatal IHD. Warfarin reduced all IHD chiefly 
      because of an effect on fatal events. Combined treatment with warfarin and 
      aspirin is more effective in the reduction of IHD than either agent on its own.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 1998 Jul-Aug;129(1):4
CIN - Lancet. 1998 Jan 24;351(9098):227-8. PMID: 9457087
CIN - Lancet. 1998 Apr 18;351(9110):1204; author reply 1206-7. PMID: 9643712
CIN - Lancet. 1998 Apr 18;351(9110):1204-5; author reply 1206-7. PMID: 9643713
CIN - Lancet. 1998 Apr 18;351(9110):1205; author reply 1206-7. PMID: 9643714
CIN - Lancet. 1998 Apr 18;351(9110):1205; author reply 1206-7. PMID: 9643715
CIN - Lancet. 1998 Apr 18;351(9110):1205-6; author reply 1206-7. PMID: 9643716
CIN - Lancet. 1998 Apr 18;351(9110):1206; author reply 1206-7. PMID: 9643717
CIN - Lancet. 1998 Apr 18;351(9110):1206-7. PMID: 9643718
CIN - Lancet. 1999 Jan 9;353(9147):148-50. PMID: 10023923
CIN - Lancet. 1999 Oct 23;354(9188):1472. PMID: 10543693
MH  - Administration, Oral
MH  - Aged
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/chemically induced/epidemiology
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Factor Analysis, Statistical
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/mortality/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Primary Prevention
MH  - Risk Factors
MH  - Thrombosis/*prevention & control
MH  - Warfarin/administration & dosage/adverse effects/*therapeutic use
EDAT- 1998/02/11 00:00
MHDA- 1998/02/11 00:01
CRDT- 1998/02/11 00:00
PHST- 1998/02/11 00:00 [pubmed]
PHST- 1998/02/11 00:01 [medline]
PHST- 1998/02/11 00:00 [entrez]
AID - S0140673697114751 [pii]
PST - ppublish
SO  - Lancet. 1998 Jan 24;351(9098):233-41.

PMID- 25295482
OWN - NLM
STAT- MEDLINE
DCOM- 20150603
LR  - 20211021
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 15
IP  - 10
DP  - 2014 Oct 7
TI  - Platelets: still a therapeutical target for haemostatic disorders.
PG  - 17901-19
LID - 10.3390/ijms151017901 [doi]
AB  - Platelets are cytoplasmatic fragments from bone marrow megakaryocytes present in 
      blood. In this work, we review the basis of platelet mechanisms, their 
      participation in syndromes and in arterial thrombosis, and their potential as a 
      target for designing new antithrombotic agents. The option of new 
      biotechnological sources is also explored.
FAU - Geraldo, Reinaldo Barros
AU  - Geraldo RB
AD  - Programa de Pós-graduação em Ciências e Biotecnologia, Instituto de Biologia, 
      Universidade Federal Fluminense (UFF), Niterói CEP 24210-130, RJ, Brazil. 
      reinaldobgeraldo@yahoo.com.br.
FAU - Sathler, Plínio Cunha
AU  - Sathler PC
AD  - Programa de Pós-graduação em Patologia, Departamento de Patologia, Hospital 
      Universitário Antônio Pedro (HUAP), Universidade Federal Fluminense (UFF), 
      Niterói CEP 24030-215, RJ, Brazil. pliniocs@yahoo.com.br.
FAU - Lourenço, André Luiz
AU  - Lourenço AL
AD  - Programa de Pós-graduação em Patologia, Departamento de Patologia, Hospital 
      Universitário Antônio Pedro (HUAP), Universidade Federal Fluminense (UFF), 
      Niterói CEP 24030-215, RJ, Brazil. andrebiouff@gmail.com.
FAU - Saito, Max Seidy
AU  - Saito MS
AD  - Programa de Pós-graduação em Patologia, Departamento de Patologia, Hospital 
      Universitário Antônio Pedro (HUAP), Universidade Federal Fluminense (UFF), 
      Niterói CEP 24030-215, RJ, Brazil. maxs@yahoo.com.br.
FAU - Cabral, Lucio M
AU  - Cabral LM
AD  - LabTIF, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro (UFRJ), Rio 
      de Janeiro CEP 21941-590, RJ, Brazil. pliniocs@yahoo.com.br.
FAU - Rampelotto, Pabulo Henrique
AU  - Rampelotto PH
AD  - Interdisciplinary Center for Biotechnology Research, Federal University of Pampa, 
      Antônio Trilha Avenue, P.O. Box 1847, São Gabriel/RS 97300-000, Brazil. 
      pabulo@lacesm.ufsm.br.
FAU - Castro, Helena Carla
AU  - Castro HC
AD  - Programa de Pós-graduação em Ciências e Biotecnologia, Instituto de Biologia, 
      Universidade Federal Fluminense (UFF), Niterói CEP 24210-130, RJ, Brazil. 
      hcastrorangel@yahoo.com.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20141007
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Integrins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/*metabolism
MH  - Hemostatic Disorders/metabolism/*pathology
MH  - Humans
MH  - Integrins/genetics/metabolism
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Platelet Storage Pool Deficiency/metabolism/pathology
MH  - Thrombosis/drug therapy/pathology
PMC - PMC4227196
EDAT- 2014/10/09 06:00
MHDA- 2015/06/04 06:00
CRDT- 2014/10/09 06:00
PHST- 2014/06/19 00:00 [received]
PHST- 2014/08/26 00:00 [revised]
PHST- 2014/09/23 00:00 [accepted]
PHST- 2014/10/09 06:00 [entrez]
PHST- 2014/10/09 06:00 [pubmed]
PHST- 2015/06/04 06:00 [medline]
AID - ijms151017901 [pii]
AID - ijms-15-17901 [pii]
AID - 10.3390/ijms151017901 [doi]
PST - epublish
SO  - Int J Mol Sci. 2014 Oct 7;15(10):17901-19. doi: 10.3390/ijms151017901.

PMID- 15839851
OWN - NLM
STAT- MEDLINE
DCOM- 20050811
LR  - 20161124
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 25
IP  - 5
DP  - 2005 May
TI  - Effects of symptomatic treatments on cutaneous hyperalgesia and laser evoked 
      potentials during migraine attack.
PG  - 359-68
AB  - Previously an amplitude enhancement of laser evoked potentials (LEPs) was 
      detected during migraine attack: we further examined pain threshold to CO2 laser 
      stimuli and LEPs during attacks, evaluating the effect of almotriptan, 
      lysine-acetylsalicylate and placebo treatment on cutaneous hyperalgesia to 
      thermal stimuli delivered by CO2 laser and on LEP components. Eighteen patients 
      suffering from migraine without aura were analysed. They were divided into three 
      groups of six patients each, randomly assigned to lysine acetyl-salicylate, 
      almotriptan or placebo treatments. The supraorbital zones and the dorsum of the 
      hand were stimulated on both the symptomatic and not symptomatic side in all 
      patients. The LEPs were recorded by 25 scalp electrodes. During attacks, the P2 
      wave was significantly enhanced; the amplitude of the P2 component obtained by 
      the stimulation of the supraorbital zone during the attack on the side of the 
      headache was significantly correlated with the intensity of pain and the 
      frequency of headache. Both almotriptan and lysine acetyl-salicylate 
      significantly reduced the P2 amplitude but they showed no effects on hyperalgesia 
      to laser stimulation; headache relief following therapy was correlated with the 
      reduction of the P2 amplitude. The cortical elaboration of laser-induced 
      experimental pain seemed increased during migraine attack, and the severity of 
      headache was mainly related to the increase of the later LEPs components 
      expressing the attentive and emotive compounds of suffering. Reversion of this 
      process appeared to be primarily responsible for the efficacy of drugs in 
      treating migraine, though both almotriptan and lysine-acetil salicilate seemed to 
      have no effect in reducing sensitization at second and third order nociceptive 
      neurons.
FAU - de Tommaso, M
AU  - de Tommaso M
AD  - Laboratory of Clinical Neurophysiology and Pain, Department of Neurologic and 
      Psychiatric Sciences, University of Bari, Policlinico, Piazza Giulio Cesare, Bari 
      Italy. m.detommaso@neurol.uniba.it
FAU - Losito, L
AU  - Losito L
FAU - Libro, G
AU  - Libro G
FAU - Guido, M
AU  - Guido M
FAU - Di Fruscolo, O
AU  - Di Fruscolo O
FAU - Sardaro, M
AU  - Sardaro M
FAU - Sciruicchio, V
AU  - Sciruicchio V
FAU - Lamberti, P
AU  - Lamberti P
FAU - Livrea, P
AU  - Livrea P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Indoles)
RN  - 0 (Tryptamines)
RN  - 1O4XL5SN61 (almotriptan)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Evoked Potentials/drug effects/*physiology
MH  - Female
MH  - *Hot Temperature
MH  - Humans
MH  - Hyperalgesia/diagnosis/*drug therapy/physiopathology
MH  - Indoles/therapeutic use
MH  - *Lasers
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Middle Aged
MH  - Migraine Disorders/diagnosis/*drug therapy/physiopathology
MH  - Tryptamines
EDAT- 2005/04/21 09:00
MHDA- 2005/08/12 09:00
CRDT- 2005/04/21 09:00
PHST- 2005/04/21 09:00 [pubmed]
PHST- 2005/08/12 09:00 [medline]
PHST- 2005/04/21 09:00 [entrez]
AID - CHA866 [pii]
AID - 10.1111/j.1468-2982.2004.00866.x [doi]
PST - ppublish
SO  - Cephalalgia. 2005 May;25(5):359-68. doi: 10.1111/j.1468-2982.2004.00866.x.

PMID- 6316860
OWN - NLM
STAT- MEDLINE
DCOM- 19840107
LR  - 20181130
IS  - 0003-9780 (Print)
IS  - 0003-9780 (Linking)
VI  - 265
IP  - 1
DP  - 1983 Sep
TI  - Prejunctional alpha-adrenoceptor mediated prostaglandin releasing effect of 
      clonidine in the isolated perfused rabbit kidney.
PG  - 138-49
AB  - The effects of clonidine (CLO) were assessed in the isolated perfused rabbit 
      kidney on responses to periarterial stimulation (PS) and intraarterially injected 
      noradrenaline (NA). Changes in perfusion pressure (PP) and responses of venous 
      outflow-superfused assay organs to PS and NA were considered as parameters. 
      Graded increases in PP and contractions of venous outflow-superfused rabbit 
      aortic strips were elicited by PS at frequencies of 5-10 Hz and intraarterially 
      injected NA at concentrations of 10(-8) - 10(-7) M. CLO added to the perfusion 
      medium caused concentration-dependent reductions of PP and of aorta contractions 
      to PS. The inhibitory effect of CLO was reversed by acetylsalicylic acid (ASA). 
      The responses to venous outflow-superfused rat stomach fundus strip to PS and 
      exogenous NA were biphasic. The first relaxation phase to PS was reduced but the 
      second contractile phase was enhanced by CLO. Responses to exogenous NA in PP and 
      venous outflow-superfused organs were not affected by CLO. The relaxation of 
      submaximally contracted and kidney venous effluent-superfused cat tracheal muscle 
      to PS was reduced whereas the responses to NA was unaffected by CLO. The 
      inhibitory effect of CLO on PS in the cat tracheal muscle was prevented by 
      yohimbine (YOH). YOH, however, caused a further decrease in PP in response to 
      both PS and exogenous NA. From these results it was concluded that CLO may act on 
      presynaptic alpha-adrenoceptors in the kidney resulting in a reduction on the 
      release of NA and enhancement of the synthesis of prostaglandins (PGs).
FAU - Ercan, Z S
AU  - Ercan ZS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Belgium
TA  - Arch Int Pharmacodyn Ther
JT  - Archives internationales de pharmacodynamie et de therapie
JID - 0405353
RN  - 0 (Prostaglandins)
RN  - 0 (Receptors, Adrenergic, alpha)
RN  - 1WS297W6MV (Phenylephrine)
RN  - 2Y49VWD90Q (Yohimbine)
RN  - K3Z4F929H6 (Lysine)
RN  - MN3L5RMN02 (Clonidine)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W3ENH1CV (Norepinephrine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Clonidine/*pharmacology
MH  - Electric Stimulation
MH  - Female
MH  - In Vitro Techniques
MH  - Kidney/*metabolism
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Norepinephrine/pharmacology
MH  - Phenylephrine/pharmacology
MH  - Prostaglandins/*metabolism
MH  - Rabbits
MH  - Receptors, Adrenergic, alpha/drug effects/*physiology
MH  - Yohimbine/pharmacology
EDAT- 1983/09/01 00:00
MHDA- 1983/09/01 00:01
CRDT- 1983/09/01 00:00
PHST- 1983/09/01 00:00 [pubmed]
PHST- 1983/09/01 00:01 [medline]
PHST- 1983/09/01 00:00 [entrez]
PST - ppublish
SO  - Arch Int Pharmacodyn Ther. 1983 Sep;265(1):138-49.

PMID- 30096648
OWN - NLM
STAT- MEDLINE
DCOM- 20190107
LR  - 20190107
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 160
DP  - 2018 Oct 25
TI  - Quantitative analysis of a pharmaceutical formulation: Performance comparison of 
      different handheld near-infrared spectrometers.
PG  - 179-186
LID - S0731-7085(18)31364-5 [pii]
LID - 10.1016/j.jpba.2018.07.048 [doi]
AB  - Notwithstanding the first developments of miniaturized vibrational spectrometers 
      more than a decade ago, only recently real handheld near-infrared (NIR) 
      spectrometers (<200 g) became commercially available at significantly reduced 
      costs compared to other portable systems. While on the one hand this development 
      was driven by the consumer request for every-day-life applications by 
      non-experts, on the manufacturer side it was supported by the availability and 
      potential of new technologies such as micro-electromechanical systems (MEMS). In 
      the present communication calibration spectra of a solid pharmaceutical 
      formulation consisting of two excipients and three active ingredients, 
      acetylsalicylic acid (ASA), ascorbic acid (ASC) and caffeine (CAF), have been 
      measured with four handheld NIR spectrometers based on different monochromator 
      principles and have subsequently been used to develop partial least squares (PLS) 
      models for the quantitative determination of the active ingredients. Taking into 
      account the instrumental and spectral peculiarities of the four instruments and 
      the three analytes, respectively, the detailed analysis of the calibration 
      parameters and the prediction accuracy for a test sample set then allowed to 
      compare the performance of the different spectrometers for the analytical problem 
      under investigation.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Yan, Hui
AU  - Yan H
AD  - School of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang, 
      China; Department of Physical Chemistry, University of Duisburg-Essen, Essen, 
      Germany. Electronic address: yanh1006@163.com.
FAU - Siesler, Heinz W
AU  - Siesler HW
AD  - Department of Physical Chemistry, University of Duisburg-Essen, Essen, Germany.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20180730
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 3G6A5W338E (Caffeine)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/analysis
MH  - Aspirin/analysis
MH  - Caffeine/analysis
MH  - Calibration
MH  - Drug Compounding/*statistics & numerical data
MH  - *Evaluation Studies as Topic
MH  - Spectroscopy, Near-Infrared/*instrumentation/methods
OTO - NOTNLM
OT  - Analytical performance
OT  - Handheld NIR spectrometers
OT  - Partial least squares (PLS) calibration
OT  - Pharmaceutical formulation
OT  - Quantitative NIR analysis
EDAT- 2018/08/11 06:00
MHDA- 2019/01/08 06:00
CRDT- 2018/08/11 06:00
PHST- 2018/06/09 00:00 [received]
PHST- 2018/07/20 00:00 [revised]
PHST- 2018/07/29 00:00 [accepted]
PHST- 2018/08/11 06:00 [pubmed]
PHST- 2019/01/08 06:00 [medline]
PHST- 2018/08/11 06:00 [entrez]
AID - S0731-7085(18)31364-5 [pii]
AID - 10.1016/j.jpba.2018.07.048 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2018 Oct 25;160:179-186. doi: 10.1016/j.jpba.2018.07.048. 
      Epub 2018 Jul 30.

PMID- 7740291
OWN - NLM
STAT- MEDLINE
DCOM- 19950608
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 125
IP  - 15
DP  - 1995 Apr 15
TI  - [Treatment of chronic virus hepatitis with acetylsalicylic acid].
PG  - 755-7
AB  - The treatment of chronic hepatitis B and C with recombinant interferon (IFN) has 
      only poor durable response rates. In the past only the lack of any prior 
      effective therapy regimen could justify the use of this expensive agent. Dose 
      escalating or prolonged treatment courses did not enhance the rate of sustained 
      remissions. Pre- or cotreatment with antiviral (e.g. acyclovir, ribavirin, 
      isoprenosin) or immunomodulating (e.g. prednisone, gamma IFN) drugs have not 
      influenced the resistance to exogenous (IFN) of many patients. The mechanisms 
      underlying resistance to this drug remain unknown. Some hypotheses focus on IFN 
      antibodies, down regulation of IFN receptors or defects in the postreceptor 
      response of cells to IFN. In 1991 Hannigan and Williams (Science 1991; 251: 
      204-207) described a synergistic signal transduction effect in human fibroblasts 
      after exposure to IFN. Arachidonic acid (AA) activation from membrane 
      phospholipid pools is common to many receptors and can be followed by 
      metabolization of AA by cyclooxygenase to prostanoids, thromboxanes and 
      eicosanoids and by lipoxygenase to leukotrienes; inhibition of these AA oxidation 
      pathways by addition of inhibitors of these enzymes (e.g. indomethacin) resulted 
      in marked amplification of the IFN signal, possibly by using the epoxygenase 
      enzyme family as an alternative pathway. Our data are taken from the pretreatment 
      part of a current study for evaluation of pre- and combination treatment with 
      acetylsalicylic acid (ASA) as cyclooxygenase inhibitor and IFN in chronic 
      hepatitis C. 27 patients with histologically proven chronic active hepatitis C 
      were divided into two groups. Group A (16 patients) were treated with a daily 
      dose of 100 mg ASA orally, and the 11 patients in group B served as untreated 
      controls.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Heinrich, D
AU  - Heinrich D
AD  - Fachbereich Gastroenterologie, Städtische Krankenanstalten Esslingen a.N.
FAU - Maier, K P
AU  - Maier KP
LA  - ger
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Behandlung der chronsichen Virus-hepatitis mit Azetylsalizylsäure.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Hepatitis C/*drug therapy
MH  - Hepatitis, Chronic/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1995/04/15 00:00
MHDA- 1995/04/15 00:01
CRDT- 1995/04/15 00:00
PHST- 1995/04/15 00:00 [pubmed]
PHST- 1995/04/15 00:01 [medline]
PHST- 1995/04/15 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1995 Apr 15;125(15):755-7.

PMID- 26283278
OWN - NLM
STAT- MEDLINE
DCOM- 20160906
LR  - 20150924
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 494
IP  - 1
DP  - 2015 Oct 15
TI  - Silk fibroin/copolymer composite hydrogels for the controlled and sustained 
      release of hydrophobic/hydrophilic drugs.
PG  - 264-70
LID - S0378-5173(15)30132-0 [pii]
LID - 10.1016/j.ijpharm.2015.08.035 [doi]
AB  - In the present study, a composite system for the controlled and sustained release 
      of hydrophobic/hydrophilic drugs is described. Composite hydrogels were prepared 
      by blending silk fibroin (SF) with PLA-PEG-PLA copolymer under mild aqueous 
      condition. Aspirin and indomethacin were incorporated into SF/Copolymer hydrogels 
      as two model drugs with different water-solubility. The degradation of composite 
      hydrogels during the drug release was mainly caused by the hydrolysis of 
      copolymers. SF with stable β-sheet-rich structure was not easily degraded which 
      maintained the mechanical integrity of composite hydrogel. The 
      hydrophobic/hydrophilic interactions of copolymers with model drugs would 
      significantly alter the morphological features of composite hydrogels. Various 
      parameters such as drug load, concentration ratio, and composition of copolymer 
      were considered in vitro drug release. Aspirin as a hydrophilic drug could be 
      controlled release from composite hydrogel at a constant rate for 5 days. Its 
      release was mainly driven by diffusion-based mechanism. Hydrophobic indomethacin 
      could be encapsulated in copolymer nanoparticles distributing in the composite 
      hydrogel. Its sustained release was mainly degradation controlled which could 
      last up to two weeks. SF/Copolymer hydrogel has potential as a useful composite 
      system widely applying for controlled and sustained release of various drugs.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Zhong, Tianyi
AU  - Zhong T
AD  - College of Textile and Clothing Engineering, Soochow University, National 
      Engineering Laboratory for Modern Silk, Suzhou Jiangsu, PR China.
FAU - Jiang, Zhijuan
AU  - Jiang Z
AD  - College of Textile and Clothing Engineering, Soochow University, National 
      Engineering Laboratory for Modern Silk, Suzhou Jiangsu, PR China.
FAU - Wang, Peng
AU  - Wang P
AD  - College of Textile and Clothing Engineering, Soochow University, National 
      Engineering Laboratory for Modern Silk, Suzhou Jiangsu, PR China.
FAU - Bie, Shiyu
AU  - Bie S
AD  - College of Textile and Clothing Engineering, Soochow University, National 
      Engineering Laboratory for Modern Silk, Suzhou Jiangsu, PR China.
FAU - Zhang, Feng
AU  - Zhang F
AD  - Medical College of Soochow University, Jiangsu Province Key Laboratory of Stem 
      Cell Research, Suzhou Jiangsu, PR China.
FAU - Zuo, Baoqi
AU  - Zuo B
AD  - College of Textile and Clothing Engineering, Soochow University, National 
      Engineering Laboratory for Modern Silk, Suzhou Jiangsu, PR China. Electronic 
      address: bqzuo@suda.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150814
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Carriers)
RN  - 0 (Hydrogels)
RN  - 0 (Polymers)
RN  - 9007-76-5 (Fibroins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Delayed-Action Preparations/*chemistry
MH  - Drug Carriers/*chemistry
MH  - *Drug Liberation
MH  - Fibroins/*chemistry
MH  - Hydrogels/*chemistry
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Indomethacin/chemistry
MH  - Polymers/*chemistry
OTO - NOTNLM
OT  - Composite system
OT  - Controlled release
OT  - Copolymers
OT  - Hydrogel
OT  - Silk fibroin
EDAT- 2015/08/19 06:00
MHDA- 2016/09/07 06:00
CRDT- 2015/08/19 06:00
PHST- 2015/03/26 00:00 [received]
PHST- 2015/07/21 00:00 [revised]
PHST- 2015/08/12 00:00 [accepted]
PHST- 2015/08/19 06:00 [entrez]
PHST- 2015/08/19 06:00 [pubmed]
PHST- 2016/09/07 06:00 [medline]
AID - S0378-5173(15)30132-0 [pii]
AID - 10.1016/j.ijpharm.2015.08.035 [doi]
PST - ppublish
SO  - Int J Pharm. 2015 Oct 15;494(1):264-70. doi: 10.1016/j.ijpharm.2015.08.035. Epub 
      2015 Aug 14.

PMID- 7470372
OWN - NLM
STAT- MEDLINE
DCOM- 19810526
LR  - 20190512
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 10
IP  - 6
DP  - 1980 Dec
TI  - 'MacDope': a simulation of drug disposition in the human body: applications in 
      clinical pharmacokinetics.
PG  - 591-602
AB  - 1 We have described a novel approach to absorption, distribution, metabolism and 
      elimination of drugs in which the patient is described using 23 Patient Factors 
      and drugs by up to 50 Drug Factors. Kinetic behavior of a drug results from the 
      interaction of patient and drug factors according to equations describing an 
      eight compartment model. In this model non-linear processes (protein binding, 
      hepatic drug metabolism and renal tubular transport) are handled by derivations 
      of the law of mass action which have been generalised to permit the consequences 
      of multiple drugs interacting at single macromolecular sites to be correctly 
      calculated. 2 The mathematical description of this model is provided in a 
      companion paper and solution of the equations is only possible using a digital 
      computer. The computer programme is provided with an interactional format which 
      makes operation independent of mathematical skills. Patients are defined by age, 
      sex, height and weight with, or without, organ dysfunction; the programme then 
      generates appropriate factors. Drug enters the system when a prescription is type 
      on the keyboard and required Drug Factors are then retrieved from the disc flies. 
      Drug concentrations in plasma or body fluids are given as simple graphs as a 
      function of time, or in tabular form. 3 Any of the Patient or Drug Factors may be 
      altered before, or during a run and up to three drugs may be simulated at one 
      time thus permitting certain kinetic interactions to be examined. The scope of 
      the simulator is illustrated using aspirin: pH dependent gastric absorption, 
      first-order conversion of aspirin to salicylate, partly first order and partly 
      saturable hepatic metabolism of salicylate, and the complex renal handling of 
      this drug are all represented. Interaction of phenytoin with salicylate has been 
      examined quantitatively to suggest limited clinical relevance for the observed 
      displacement of phenytoin from serum albumin. The use of the simulator in a short 
      course of pharmacokinetics is briefly described.
FAU - Bloch, R
AU  - Bloch R
FAU - Sweeney, G
AU  - Sweeney G
FAU - Ahmed, K
AU  - Ahmed K
FAU - Dickinson, C J
AU  - Dickinson CJ
FAU - Ingram, D
AU  - Ingram D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Pharmaceutical Preparations)
RN  - 6158TKW0C5 (Phenytoin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism
MH  - Drug Interactions
MH  - Humans
MH  - Intestinal Absorption
MH  - Kinetics
MH  - Liver/metabolism
MH  - Male
MH  - *Models, Biological
MH  - Pharmaceutical Preparations/*metabolism
MH  - Phenytoin/metabolism
MH  - Protein Binding
PMC - PMC1430214
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1980.tb00515.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1980 Dec;10(6):591-602. doi: 
      10.1111/j.1365-2125.1980.tb00515.x.

PMID- 32049589
OWN - NLM
STAT- MEDLINE
DCOM- 20210609
LR  - 20210609
IS  - 1931-8448 (Electronic)
IS  - 1076-6294 (Linking)
VI  - 26
IP  - 8
DP  - 2020 Aug
TI  - Aspirin Causes Lipid Accumulation and Damage to Cell Membrane by Regulating 
      DCI1/OLE1 in Saccharomyces cerevisiae.
PG  - 857-868
LID - 10.1089/mdr.2019.0200 [doi]
AB  - Aspirin is one of the most commonly used nonsteroidal anti-inflammatory drugs. 
      Various potential pharmacological effects of aspirin, such as anticancer, 
      antibacterial activity, and prolonging life expectancy have been discovered. 
      However, the mechanism of aspirin is not fully elucidated. Herein, the effects of 
      aspirin on fatty acid metabolism in yeast cell model Saccharomyces cerevisiae 
      were studied. The results showed that aspirin can induce lipid accumulation and 
      reduce the unsaturated fat index in cells. The assessment of cell membrane 
      integrity demonstrated that aspirin caused damage to the cell membrane. These 
      effects of aspirin were attributed to the alterations of the expression of DCI1 
      and OLE1. Similarly, aspirin was able to cause lipid accumulation and damage to 
      the cell membrane by interfering with the expression of OLE1 in Candida albicans. 
      These findings are expected to improve current understanding of the mode of 
      action of aspirin and provide a novel strategy for antifungal drug design. 
      Graphical abstract [Figure: see text].
FAU - Zhu, Pan
AU  - Zhu P
AD  - State Key Laboratory of Bioreactor Engineering, East China University of Science 
      and Technology, Shanghai, China.
FAU - Li, Ming
AU  - Li M
AD  - State Key Laboratory of Bioreactor Engineering, East China University of Science 
      and Technology, Shanghai, China.
FAU - Yan, Chongjia
AU  - Yan C
AD  - State Key Laboratory of Bioreactor Engineering, East China University of Science 
      and Technology, Shanghai, China.
FAU - Sun, Jing
AU  - Sun J
AD  - Qinghai Key Laboratory of Qinghai-Tibet Plateau Biological Resources, Northwest 
      Institute of Plateau Biology, the Chinese Academy of Sciences, Xining, Qinghai, 
      China.
FAU - Peng, Min
AU  - Peng M
AD  - Qinghai Key Laboratory of Qinghai-Tibet Plateau Biological Resources, Northwest 
      Institute of Plateau Biology, the Chinese Academy of Sciences, Xining, Qinghai, 
      China.
FAU - Huang, Zhiwei
AU  - Huang Z
AD  - Key Lab of Eco-Textile, Ministry of Education, College of Chemistry, Chemical 
      Engineering and Biotechnology, Donghua University, Shanghai, China.
FAU - Shi, Ping
AU  - Shi P
AD  - State Key Laboratory of Bioreactor Engineering, East China University of Science 
      and Technology, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20200212
PL  - United States
TA  - Microb Drug Resist
JT  - Microbial drug resistance (Larchmont, N.Y.)
JID - 9508567
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Fatty Acids)
RN  - 0 (Membrane Proteins)
RN  - 0 (Saccharomyces cerevisiae Proteins)
RN  - EC 1.14.19.1 (Stearoyl-CoA Desaturase)
RN  - EC 1.14.99.- (delta-9 fatty acid desaturase)
RN  - EC 5.3.3.- (Carbon-Carbon Double Bond Isomerases)
RN  - EC 5.3.3.- (DCI1 protein, S cerevisiae)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Carbon-Carbon Double Bond Isomerases/drug effects
MH  - Cell Membrane/*drug effects
MH  - Fatty Acids/*metabolism
MH  - Lipid Metabolism/drug effects
MH  - Membrane Proteins/drug effects
MH  - Saccharomyces cerevisiae/*drug effects
MH  - Saccharomyces cerevisiae Proteins/drug effects
MH  - Stearoyl-CoA Desaturase/drug effects
OTO - NOTNLM
OT  - DCI1
OT  - OLE1
OT  - Saccharomyces cerevisiae
OT  - aspirin
OT  - fatty acid metabolism
EDAT- 2020/02/13 06:00
MHDA- 2021/06/10 06:00
CRDT- 2020/02/13 06:00
PHST- 2020/02/13 06:00 [pubmed]
PHST- 2021/06/10 06:00 [medline]
PHST- 2020/02/13 06:00 [entrez]
AID - 10.1089/mdr.2019.0200 [doi]
PST - ppublish
SO  - Microb Drug Resist. 2020 Aug;26(8):857-868. doi: 10.1089/mdr.2019.0200. Epub 2020 
      Feb 12.

PMID- 1534906
OWN - NLM
STAT- MEDLINE
DCOM- 19920713
LR  - 20190912
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 45
IP  - 4
DP  - 1992 Apr
TI  - The diminished extracellular matrix production induced by isradipine, a calcium 
      channel blocker, is completely abolished by cyclooxygenase inhibition.
PG  - 289-91
AB  - Collagen and glycosaminoglycan synthesis are well known to be enhanced during 
      early atherogenesis. In this experimental study the synthesis of collagen was 
      determined using 14C proline incorporation, the glycosaminoglycan production by 
      means of 35S-sulphate incorporation and subsequent quantification by means of 
      autoradiography. Isradipine, a new calcium channel blocker of the dihydropyridine 
      family at a dose of 0.3 mg/kg significantly (p less than 0.01) decreased the 
      incorporation of both the radioactive precursors. This effect was abolished by a 
      concomitant aspirin treatment, while aspirin alone did not exert any significant 
      effect on the precursor incorporation. These data suggest that isradipine, which 
      is known to stimulate PGI2 synthesis, may exert this antiatherosclerotic 
      inhibitory action on extracellular matrix production via the endogenous 
      liberation of PGI2.
FAU - Fitscha, P
AU  - Fitscha P
AD  - 2nd Department of Internal Medicine, Policlinic Vienna, Austria.
FAU - Keiler, A
AU  - Keiler A
FAU - Rauscha, F
AU  - Rauscha F
FAU - O'Grady, J
AU  - O'Grady J
FAU - Sinzinger, H
AU  - Sinzinger H
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Dihydropyridines)
RN  - 0 (Glycosaminoglycans)
RN  - 9007-34-5 (Collagen)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - YO1UK1S598 (Isradipine)
SB  - IM
MH  - Animals
MH  - Arteriosclerosis/prevention & control
MH  - Aspirin/administration & dosage/pharmacology
MH  - Calcium Channel Blockers/pharmacology
MH  - Collagen/biosynthesis
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Dihydropyridines/administration & dosage/*pharmacology
MH  - Drug Interactions
MH  - Epoprostenol/biosynthesis
MH  - Extracellular Matrix/*drug effects/metabolism
MH  - Glycosaminoglycans/biosynthesis
MH  - Isradipine
MH  - Male
MH  - Rabbits
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
AID - 10.1016/0952-3278(92)90085-w [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 1992 Apr;45(4):289-91. doi: 
      10.1016/0952-3278(92)90085-w.

PMID- 25995130
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20191210
IS  - 1179-2027 (Electronic)
IS  - 1170-7690 (Linking)
VI  - 33
IP  - 10
DP  - 2015 Oct
TI  - Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin 
      for Secondary Prevention of Ischemic Stroke.
PG  - 1091-100
LID - 10.1007/s40273-015-0289-4 [doi]
AB  - BACKGROUND: Low-dose aspirin (ASA) is effective for secondary prevention of 
      ischemic stroke but can increase the risks of hemorrhagic stroke, upper 
      gastrointestinal bleeding (UGIB), and dyspepsia. Prophylactic administration of 
      proton pump inhibitors (PPIs) reduces the risks of these digestive symptoms. We 
      investigated the cost effectiveness of adding a PPI to ASA therapy for ischemic 
      stroke patients in Japan. METHODS: A Markov state-transition model was developed 
      to compare the cost effectiveness of ASA monotherapy with ASA plus PPI co-therapy 
      in patients with histories of upper gastrointestinal ulcers and ischemic stroke. 
      The model takes into account ASA adherence rate and adverse effects due to ASA, 
      including hemorrhagic stroke and UGIB. The analysis was performed from the 
      perspective of healthcare payers in 2013. RESULTS: In the base case, total 
      life-years by PPI co-therapy and monotherapy were 16.005 and 15.932, 
      respectively. The difference in duration of no therapy (no ASA or PPI) between 
      the therapies was 558.5 days, which would prevent 30.3 recurrences of ischemic 
      stroke per 1000 person-years. The incremental cost-effectiveness ratio of PPI 
      co-therapy relative to monotherapy was ¥1,191,665 (US$11,458) per life-year 
      gained. In a one-way sensitivity analysis, PPI co-therapy was consistently cost 
      effective at a willingness to pay of ¥5,000,000 (US$48,077) per life-year gained. 
      In a probabilistic sensitivity analysis, the probability that PPI co-therapy was 
      cost effective was 89.74% at the willingness to pay. CONCLUSIONS: Co-therapy with 
      ASA plus PPI appears to be cost-effective compared with ASA monotherapy. The 
      addition of PPI also appeared to prolong the duration of ASA therapy, thereby 
      reducing the risk of ischemic stroke.
FAU - Takabayashi, Nobuyoshi
AU  - Takabayashi N
AD  - Department of Pharmacoepidemiology, Graduate School of Medicine and Public 
      Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
AD  - Takeda Pharmaceutical Company, Limited, Osaka, Japan.
FAU - Murata, Kyoko
AU  - Murata K
AD  - Department of Pharmacoepidemiology, Graduate School of Medicine and Public 
      Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
FAU - Tanaka, Shiro
AU  - Tanaka S
AD  - Department of Pharmacoepidemiology, Graduate School of Medicine and Public 
      Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
FAU - Kawakami, Koji
AU  - Kawakami K
AD  - Department of Pharmacoepidemiology, Graduate School of Medicine and Public 
      Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan. 
      kawakami.koji.4e@kyoto-u.ac.jp.
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Hemorrhage/economics/prevention & control
MH  - Humans
MH  - Incidence
MH  - Japan
MH  - Markov Chains
MH  - Models, Economic
MH  - Outcome Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Proton Pump Inhibitors/administration & dosage/*economics/therapeutic use
MH  - *Quality-Adjusted Life Years
MH  - Secondary Prevention/*economics/methods
MH  - Stroke/economics/mortality/*prevention & control
EDAT- 2015/05/23 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/05/22 06:00
PHST- 2015/05/22 06:00 [entrez]
PHST- 2015/05/23 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1007/s40273-015-0289-4 [pii]
AID - 10.1007/s40273-015-0289-4 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2015 Oct;33(10):1091-100. doi: 10.1007/s40273-015-0289-4.

PMID- 12132827
OWN - NLM
STAT- MEDLINE
DCOM- 20020808
LR  - 20131121
IS  - 1059-1052 (Print)
IS  - 1059-1052 (Linking)
VI  - 10
IP  - 3
DP  - 2001 Fall
TI  - Thromboembolism after total knee arthroplasty: intermittent pneumatic compression 
      and aspirin prophylaxis.
PG  - 155-63; discussion 163
AB  - This is a study of two consecutive antithromboembolism regimens after total knee 
      arthroplasty. In group 1, 131 patients were given aspirin prophylaxis alone (650 
      mg by mouth twice a day). In group 2, 123 patients were treated with aspirin, 
      knee-high compression stockings, and intermittent knee-high pneumatic compression 
      devices, which were started intraoperatively. The prevalence of deep vein 
      thrombosis in group 1 was 15.9% (21 of 131 patients). One patient had a possible 
      symptomatic nonfatal pulmonary embolism, and one patient had a symptomatic calf 
      thrombus. Asymptomatic thrombi were detected in calf veins in 9 patients, 
      popliteal vein in 6 patients, and femoral vein in 5 patients. In Group 2, the 
      prevalence was 7.4% (9 of 123 patients). Asymptomatic thrombi were located in 
      calf veins in 6 patients, popliteal vein in 1 patient, and femoral vein in 2 
      patients. There was a significant difference in the prevalence of deep vein 
      thrombosis between the two groups. A history of previous thromboembolism was a 
      significant risk factor for a new thrombus. The prevalence after bilateral 
      one-stage knee arthroplasty was 24.3% for group 1 and 12.5% for group 2. Aspirin 
      and knee-high intermittent pneumatic compression together are more effective than 
      aspirin alone for prevention of deep vein thrombosis after primary and revision 
      knee arthroplasty.
FAU - Larson, C M
AU  - Larson CM
AD  - Department of Orthopaedic Surgery, University of North Carolina School of 
      Medicine, Chapel Hill 27599-7055, USA.
FAU - MacMillan, D P
AU  - MacMillan DP
FAU - Lachiewicz, P F
AU  - Lachiewicz PF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J South Orthop Assoc
JT  - Journal of the Southern Orthopaedic Association
JID - 9211289
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/*therapeutic use
MH  - *Bandages
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
MH  - Pressure
MH  - Prospective Studies
MH  - Thromboembolism/*etiology
EDAT- 2002/07/23 10:00
MHDA- 2002/08/09 10:01
CRDT- 2002/07/23 10:00
PHST- 2002/07/23 10:00 [pubmed]
PHST- 2002/08/09 10:01 [medline]
PHST- 2002/07/23 10:00 [entrez]
PST - ppublish
SO  - J South Orthop Assoc. 2001 Fall;10(3):155-63; discussion 163.

PMID- 35750510
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20220923
IS  - 1465-3931 (Electronic)
IS  - 0031-3025 (Linking)
VI  - 54
IP  - 6
DP  - 2022 Oct
TI  - A pilot study assessing the implementation of 96-well plate-based aggregometry 
      (Optimul) in Australia.
PG  - 746-754
LID - S0031-3025(22)00168-4 [pii]
LID - 10.1016/j.pathol.2022.03.012 [doi]
AB  - Identification of disordered platelet function is important to guide 
      peri-operative bleeding management as well as long term treatment and prognostic 
      strategies in individuals with platelet bleeding disorders. Light transmission 
      aggregometry (LTA), the current gold standard diagnostic test of platelet 
      function is a time consuming technique almost exclusively performed in 
      specialised laboratories and almost universally unavailable in regional centres 
      in Australia, where there is an unmet need for access to specialised platelet 
      function diagnostic services. 96-well plate-based aggregometry (Optimul, UK), has 
      been utilised in research laboratories as a novel platform to investigate 
      platelet function. We evaluated the Optimul assay at two centres in Australia, 
      one regional and one tertiary metropolitan, to assess its feasibility as a 
      screening test applicable to remote regional centres. Concentration-response 
      curves were established from 45 healthy volunteers at the participating regional 
      hospital and from 31 healthy volunteers at the tertiary institution. Optimul 
      successfully detected anti-platelet effects in individuals taking aspirin (n=4), 
      NSAID (n=2), clopidogrel (n=2) and dual therapy with aspirin and clopidogrel 
      (n=1). When tested in parallel to LTA in individuals referred for the evaluation 
      of abnormal bleeding symptoms there was overall a very good level of agreement 
      between Optimul and LTA [Cohen's kappa (k(2))=0.84], supporting its role as a 
      useful screening tool in the assessment of platelet function. Optimul assay 
      performance was quick and the methodology simple, requiring no specialised 
      training or resources to be implemented at either the regional or metropolitan 
      laboratory. Widespread implementation, particularly in regional laboratories 
      within Australia where specialised platelet function testing is unavailable, has 
      the potential to drastically improve the inequity of access to such services.
CI  - Copyright © 2022 Royal College of Pathologists of Australasia. Published by 
      Elsevier B.V. All rights reserved.
FAU - Hsu, Hannah
AU  - Hsu H
AD  - Prince of Wales Hospital, Sydney, NSW, Australia.
FAU - Chan, Melissa V
AU  - Chan MV
AD  - Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen 
      Mary University of London, London, UK; National Heart, Blood and Lung Institute, 
      Population Sciences Branch, Framingham, MA, USA.
FAU - Armstrong, Paul C
AU  - Armstrong PC
AD  - Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen 
      Mary University of London, London, UK.
FAU - Crescente, Marilena
AU  - Crescente M
AD  - Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen 
      Mary University of London, London, UK.
FAU - Donikian, Dea
AU  - Donikian D
AD  - Haematology NSW Health Pathology Randwick, Sydney, NSW, Australia.
FAU - Kondo, Mayuko
AU  - Kondo M
AD  - Haematology NSW Health Pathology Randwick, Sydney, NSW, Australia.
FAU - Brighton, Timothy
AU  - Brighton T
AD  - Haematology NSW Health Pathology Randwick, Sydney, NSW, Australia; Prince of 
      Wales Hospital, Sydney, NSW, Australia.
FAU - Chen, Vivien
AU  - Chen V
AD  - Haematology, Concord Repatriation General Hospital and NSW Health Pathology, 
      Sydney, NSW, Australia; ANZAC Research Institute and University of Sydney, 
      Sydney, NSW, Australia.
FAU - Chen, Qiang
AU  - Chen Q
AD  - Northern Blood Research Centre, Kolling Institute, University of Sydney, Sydney, 
      NSW, Australia; Department of Haematology and Transfusion Medicine, Royal North 
      Shore Hospital, Sydney, NSW, Australia.
FAU - Connor, David
AU  - Connor D
AD  - St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia; St 
      Vincent's Clinical School, University of New South Wales, Sydney, Australia.
FAU - Joseph, Joanne
AU  - Joseph J
AD  - St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia; St 
      Vincent's Clinical School, University of New South Wales, Sydney, Australia; St 
      Vincent's Hospital, Sydney, NSW, Australia.
FAU - Morel-Kopp, Marie-Christine
AU  - Morel-Kopp MC
AD  - Northern Blood Research Centre, Kolling Institute, University of Sydney, Sydney, 
      NSW, Australia; Department of Haematology and Transfusion Medicine, Royal North 
      Shore Hospital, Sydney, NSW, Australia.
FAU - Stevenson, William S
AU  - Stevenson WS
AD  - Northern Blood Research Centre, Kolling Institute, University of Sydney, Sydney, 
      NSW, Australia; Department of Haematology and Transfusion Medicine, Royal North 
      Shore Hospital, Sydney, NSW, Australia.
FAU - Ward, Christopher
AU  - Ward C
AD  - Northern Blood Research Centre, Kolling Institute, University of Sydney, Sydney, 
      NSW, Australia; Department of Haematology and Transfusion Medicine, Royal North 
      Shore Hospital, Sydney, NSW, Australia.
FAU - Warner, Timothy D
AU  - Warner TD
AD  - Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen 
      Mary University of London, London, UK.
FAU - Rabbolini, David J
AU  - Rabbolini DJ
AD  - Northern Blood Research Centre, Kolling Institute, University of Sydney, Sydney, 
      NSW, Australia; Northern Clinical School and the Rural Clinical School (Northern 
      Rivers), Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 
      Australia; Lismore Base Hospital, Lismore, NSW, Australia. Electronic address: 
      david.rabbolini@sydney.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20220621
PL  - England
TA  - Pathology
JT  - Pathology
JID - 0175411
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/pharmacology
MH  - *Blood Platelet Disorders/diagnosis
MH  - Clopidogrel/pharmacology
MH  - Humans
MH  - Pilot Projects
MH  - *Platelet Aggregation
MH  - Platelet Function Tests/methods
OTO - NOTNLM
OT  - Optimul
OT  - platelet bleeding disorders
OT  - platelet function testing
EDAT- 2022/06/25 06:00
MHDA- 2022/09/24 06:00
CRDT- 2022/06/24 22:03
PHST- 2021/12/18 00:00 [received]
PHST- 2022/03/09 00:00 [revised]
PHST- 2022/03/21 00:00 [accepted]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/06/24 22:03 [entrez]
AID - S0031-3025(22)00168-4 [pii]
AID - 10.1016/j.pathol.2022.03.012 [doi]
PST - ppublish
SO  - Pathology. 2022 Oct;54(6):746-754. doi: 10.1016/j.pathol.2022.03.012. Epub 2022 
      Jun 21.

PMID- 20091603
OWN - NLM
STAT- MEDLINE
DCOM- 20100416
LR  - 20211203
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 1
DP  - 2010 Jan 20
TI  - Chuanxiong preparations for preventing stroke.
PG  - CD006765
LID - 10.1002/14651858.CD006765.pub2 [doi]
AB  - BACKGROUND: Stroke is a major healthcare problem and is one of the leading causes 
      of death and serious long-term disability. Prevention of stroke is considered an 
      important strategy. Chuanxiong is traditionally used in China in the treatment 
      and prevention of stroke. In recent years, Chinese researchers have developed new 
      patented Chuanxiong preparations. OBJECTIVES: To assess the effects and safety of 
      Chuanxiong preparations in preventing stroke in high-risk adults. SEARCH 
      STRATEGY: We searched the Cochrane Central Register of Controlled Trials 
      (CENTRAL) (2008, Issue 1), MEDLINE (1950 to March 2008), EMBASE (1980 to March 
      2008), AMED (1985 to March 2008), Chinese Biomedical Database (CBM) (1975 to 
      March 2008), China National Knowledge Infrastructure (CNKI) (1994 to March 2008), 
      and the VIP Database (1989 to March 2008). Trials registers were searched for 
      ongoing studies. No language restrictions were applied. SELECTION CRITERIA: 
      Randomised controlled trials (RCTs) studying the effects of Chuanxiong 
      preparations in preventing stroke were included. DATA COLLECTION AND ANALYSIS: 
      Three reviewers independently selected studies for inclusion and two reviewers 
      independently extracted data. Authors of identified RCTs were telephoned to 
      confirm the randomisation procedure. Outcomes assessed included: stroke, 
      composite cardiovascular outcomes, changes in cardiovascular and cerebrovascular 
      haemodynamic indices and adverse events. Peto odds ratio (OR) with 95% confidence 
      intervals (CI) were calculated for dichotomous variables and mean differences for 
      continuous outcomes. MAIN RESULTS: Three RCTs (5042 participants) were included. 
      One higher quality study (4415 participants) compared Nao-an capsule with aspirin 
      for primary prevention in high-risk stroke populations. Nao-an capsule appeared 
      to reduce the incidence of stroke compared with aspirin (OR 0.56 95% CI 0.33 to 
      0.96). One study of low methodological quality indicated that a self-prepared 
      Xifenwan tablet reduced the incidence of stroke in people with transient 
      ischaemia attack (TIA) (OR 0.18, 95% CI 0.04 to 0.78). The remaining low quality 
      study indicated that "apoplexy 2 preventing dry ointment powder" appeared to 
      reduce both fatal stroke and incidence of stroke (OR 0.21, 95% CI 0.10 to 0.43, 
      and OR 0.28, 95% CI 0.16 to 0.49, respectively). AUTHORS' CONCLUSIONS: Nao-an 
      capsule may be a choice for the primary prevention of stroke. However, the design 
      of the study providing this evidence means that there was potential for results 
      to have been affected by bias from the way participants may have been selected, 
      or from investigators' conflicts of interests. There was a lack of description of 
      the methodology in the two other studies therefore evidence from these was 
      considered too weak to draw any firm conclusions. Further high quality research 
      is required.
FAU - Yang, Xunzhe
AU  - Yang X
AD  - West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 
      China, 610041.
FAU - Zeng, Xiaoxi
AU  - Zeng X
FAU - Wu, Taixiang
AU  - Wu T
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20100120
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (naoan)
RN  - R16CO5Y76E (Aspirin)
RN  - RR83T99U97 (chuangxiong extract)
SB  - IM
UIN - Cochrane Database Syst Rev. 2016;(6):CD006765. PMID: 27258581
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Ligusticum
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/*prevention & control
RF  - 47
EDAT- 2010/01/22 06:00
MHDA- 2010/04/17 06:00
CRDT- 2010/01/22 06:00
PHST- 2010/01/22 06:00 [entrez]
PHST- 2010/01/22 06:00 [pubmed]
PHST- 2010/04/17 06:00 [medline]
AID - 10.1002/14651858.CD006765.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006765. doi: 
      10.1002/14651858.CD006765.pub2.

PMID- 29031392
OWN - NLM
STAT- MEDLINE
DCOM- 20180531
LR  - 20220310
IS  - 1532-2823 (Electronic)
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 126
DP  - 2017 Nov
TI  - Effects of aspirin in combination with EPA and DHA on HDL-C cholesterol and ApoA1 
      exchange in individuals with type 2 diabetes mellitus.
PG  - 25-31
LID - S0952-3278(17)30058-3 [pii]
LID - 10.1016/j.plefa.2017.08.016 [doi]
AB  - BACKGROUND/SYNOPSIS: Low-dose aspirin is an effective drug for the prevention of 
      cardiovascular disease (CVD) events but individuals with diabetes mellitus can be 
      subject to 'aspirin resistance'. Thus, aspirin's effect in these individuals is 
      controversial. Higher blood levels of seafood-derived omega-3 polyunsaturated 
      fatty acids (ω3) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also 
      have beneficial effects in reducing risk of CVD events but few studies have 
      examined the interaction of plasma EPA and DHA with aspirin ingestion. 
      OBJECTIVE/PURPOSE: Our study examined the combinatory effects of EPA, DHA, and 
      aspirin ingestion on HDL-cholesterol (HDL-C) and apoA-I exchange (shown to be 
      associated with CVD event risk). METHODS: 30 adults with Type 2 diabetes mellitus 
      ingested aspirin (81mg/day) for 7 consecutive days, EPA+DHA (2.6g/day) for 28 
      days, then both for 7 days. Plasma was collected at baseline and at 5 subsequent 
      visits including 4h after each aspirin ingestion. Mixed model methods were used 
      to determine HDL-C-concentrations and apoA-I exchange compared to the baseline 
      visit values. LOWESS curves were used for non-linear analyses of outcomes to help 
      discern change patterns, which was followed by piecewise linear functions for 
      formal testing of curvilinear relationships. RESULTS: Significant changes (p < 
      0.05) compared to baseline in both HDL-C-concentrations and apoA-I exchange were 
      present at different times. After 7 days of aspirin-only ingestion, apoA-I 
      exchange was significantly modified by increasing levels of DHA concentration, 
      with increased apoA-I exchange observed up until log(DHA) of 4.6 and decreased 
      exchange thereafter (p = 0.03). These LOWESS curve effects were not observed for 
      EPA or HDL-C (p > 0.05). Aspirin's effects on apoA-I exchange were the greatest 
      when EPA or DHA concentrations were moderate compared to high or low. Comparison 
      of EPA, DHA, and EPA+DHA LOWESS curves, demonstrated that the majority of the 
      effect is due to DHA. CONCLUSION: Our results strongly suggest that plasma 
      concentrations of EPA and DHA influence aspirin effects on lipid mediators of CVD 
      event risk where their concentrations are most beneficial when moderate, not high 
      or low. These effects on HDL-C cholesterol and apoA-I exchange are novel. 
      Personalized dosing of DHA in those who take aspirin may be a beneficial option 
      for patients with type 2 diabetes mellitus.
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - Block, Robert C
AU  - Block RC
AD  - Department of Public Health Sciences, University of Rochester School of Medicine 
      and Dentistry, Rochester, NY, United States. Electronic address: 
      robert_block@urmc.rochester.edu.
FAU - Holub, Ashley
AU  - Holub A
AD  - Department of Public Health Sciences, University of Rochester School of Medicine 
      and Dentistry, Rochester, NY, United States.
FAU - Abdolahi, Amir
AU  - Abdolahi A
AD  - Department of Acute Care Solutions, Philips Research North America, United 
      States.
FAU - Tu, Xin M
AU  - Tu XM
AD  - Division of Biostatistics & Bioinformatics in the Department of Family Medicine 
      and Public Health, University of California School of Medicine, San Diego, CA, 
      United States.
FAU - Mousa, Shaker A
AU  - Mousa SA
AD  - Pharmaceutical Research Institute, Albany College of Pharmacy and Health 
      Sciences, Albany, NY, United States.
FAU - Oda, Michael N
AU  - Oda MN
AD  - Children's Hospital Oakland Research Institute, Oakland, CA, United States.
LA  - eng
GR  - KL2 RR024136/RR/NCRR NIH HHS/United States
GR  - T32 HL007937/HL/NHLBI NIH HHS/United States
GR  - UL1 TR001442/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20170909
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (APOA1 protein, human)
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Triglycerides)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Apolipoprotein A-I/*blood
MH  - Aspirin/*administration & dosage
MH  - Cholesterol, HDL/*blood
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/pathology
MH  - Docosahexaenoic Acids/administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Eicosapentaenoic Acid/administration & dosage
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Triglycerides/blood
PMC - PMC5683419
MID - NIHMS906422
OTO - NOTNLM
OT  - ApoA
OT  - Aspirin
OT  - Diabetes mellitus
OT  - Docosahexaenoic acid
OT  - Eicosapentaenoic acid
OT  - High density lipoprotein
EDAT- 2017/10/17 06:00
MHDA- 2018/06/01 06:00
CRDT- 2017/10/17 06:00
PHST- 2017/02/22 00:00 [received]
PHST- 2017/08/29 00:00 [revised]
PHST- 2017/08/30 00:00 [accepted]
PHST- 2017/10/17 06:00 [entrez]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2018/06/01 06:00 [medline]
AID - S0952-3278(17)30058-3 [pii]
AID - 10.1016/j.plefa.2017.08.016 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2017 Nov;126:25-31. doi: 
      10.1016/j.plefa.2017.08.016. Epub 2017 Sep 9.

PMID- 856231
OWN - NLM
STAT- MEDLINE
DCOM- 19770622
LR  - 20190718
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 27
IP  - 1
DP  - 1977 May
TI  - Inhibition of platelet adhesion to rabbit aorta by sulphinpyrazone and 
      acetylsalicylic acid.
PG  - 89-95
AB  - A technique for the isolation of rabbit thoracic aorta in a form in which it can 
      withstand normal pressure and a new in vitro system in which it was tested is 
      described. Segments of aorta were selectively damaged with a balloon catheter by 
      the Baumgartneer technique and supensions of washed platelets, labelled with 
      51Cr, were perfused through them. More platelets adhered to the damaged surface 
      than to the undamaged surface. Suophinpyrazone was more effective than aspirin in 
      inhibiting platelet adherence to both the damaged and undamaged surface.
FAU - Essien, E M
AU  - Essien EM
FAU - Mustard, J F
AU  - Mustard JF
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Animals
MH  - *Aorta/ultrastructure
MH  - Aspirin/*pharmacology
MH  - Collagen/pharmacology
MH  - Microscopy, Electron, Scanning
MH  - Perfusion
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
MH  - Sulfinpyrazone/*pharmacology
EDAT- 1977/05/01 00:00
MHDA- 1977/05/01 00:01
CRDT- 1977/05/01 00:00
PHST- 1977/05/01 00:00 [pubmed]
PHST- 1977/05/01 00:01 [medline]
PHST- 1977/05/01 00:00 [entrez]
AID - 0021-9150(77)90028-4 [pii]
AID - 10.1016/0021-9150(77)90028-4 [doi]
PST - ppublish
SO  - Atherosclerosis. 1977 May;27(1):89-95. doi: 10.1016/0021-9150(77)90028-4.

PMID- 21449163
OWN - NLM
STAT- MEDLINE
DCOM- 20110504
LR  - 20131121
IS  - 0033-2674 (Print)
IS  - 0033-2674 (Linking)
VI  - 44
IP  - 6
DP  - 2010 Nov-Dec
TI  - [Gender and presence of profound psychological traumas versus comorbidity of 
      panic disorder and depression in difficult and aspirin-induced asthma].
PG  - 785-99
AB  - AIM: The author examined psychiatrically a group of 106 patients with difficult 
      asthma and 100 patients with aspirin-induced asthma. The special interest of the 
      study was the careful analysis of the time, context and content of different 
      psychological traumas that the patients from both groups had throughout their 
      lives. METHODS: 106 consecutive adults with confirmed, physician-diagnosed 
      difficult asthma and 100 patients with aspirin-induced asthma underwent 
      psychiatric interview and assessment using M.I.N.I 5.0, Beck Depression Inventory 
      (BDI) and Panic And Agoraphobia Scale (PAS). Psychiatric assessment was performed 
      by an experienced liaison psychiatrist according to ICD-10 and DSM-IV diagnosis. 
      In the difficult asthma group, there were 78 women (74%) and 28 men (26%). The 
      average age was 51.3 (SD = 14.5) for women and 47.5 (SD = 12.7) for men. In the 
      aspirin induced asthma group, there were 66 women (66%) and 34 men (34%). The 
      average age was 52.7 (SD = 12.3) for women and 48.8 (SD = 13.0) for men. RESULTS: 
      In both groups of asthmatic patients women were majority (74% with difficult 
      asthma and 66% with aspirin-induced asthma) with a higher level of anxiety and 
      depressive symptoms than men. It may be due to specific trauma of suffering 
      and/or death of an emotionally close person, which occurred in adulthood. This 
      kind of trauma may have impact on the aetiology of both panic disorder and 
      depression. Women are more exposed to this sort of trauma due to their social 
      role. CONCLUSIONS: It is possible, that psychological trauma affects the 
      development, course and severity of anxiety and depressive symptoms in asthmatic 
      patients. It may play a special role in development of difficult asthma.
FAU - Potoczek, Anna
AU  - Potoczek A
AD  - Klinika Psychiatrii Dorosłych Katedry Psychiatrii UJ CM.
LA  - pol
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Pleć i obecność doznanych urazów psychicznych a współwystepowanie zespołu leku 
      napadowego i depresji w astmie ciezkiej i trudnej oraz w astmie aspirynowej.
PL  - Poland
TA  - Psychiatr Pol
JT  - Psychiatria polska
JID - 0103314
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*epidemiology
MH  - Asthma, Aspirin-Induced/*epidemiology/physiopathology/psychology
MH  - Comorbidity
MH  - Depression/*epidemiology
MH  - Female
MH  - Humans
MH  - Interpersonal Relations
MH  - Male
MH  - Mental Health
MH  - Middle Aged
MH  - Panic Disorder/diagnosis/*epidemiology
MH  - Poland
MH  - Prevalence
MH  - Severity of Illness Index
MH  - Sex Factors
EDAT- 2011/04/01 06:00
MHDA- 2011/05/05 06:00
CRDT- 2011/04/01 06:00
PHST- 2011/04/01 06:00 [entrez]
PHST- 2011/04/01 06:00 [pubmed]
PHST- 2011/05/05 06:00 [medline]
PST - ppublish
SO  - Psychiatr Pol. 2010 Nov-Dec;44(6):785-99.

PMID- 6143803
OWN - NLM
STAT- MEDLINE
DCOM- 19840601
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 36
IP  - 2
DP  - 1984 Feb
TI  - Suppression of laxative action of phenolphthalein by orally-administered 
      indomethacin or aspirin.
PG  - 132-3
AB  - Oral administration of phenolphthalein produced a dose-dependent increase of wet 
      faeces excreted by mice. The response to phenolphthalein was reduced by 
      pretreatment with indomethacin, aspirin or polyphloretin phosphate (PPP), but not 
      with benoxaprofen. These findings support the view that the effect of 
      phenolphthalein may be suppressed by PG synthetase inhibitors (indomethacin, 
      aspirin) and by PPP.
FAU - Capasso, F
AU  - Capasso F
FAU - Mascolo, N
AU  - Mascolo N
FAU - Autore, G
AU  - Autore G
FAU - Duraccio, M R
AU  - Duraccio MR
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Cathartics)
RN  - 0 (Phenolphthaleins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cathartics/*antagonists & inhibitors/pharmacology
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Mice
MH  - Phenolphthaleins/*antagonists & inhibitors/pharmacology
EDAT- 1984/02/01 00:00
MHDA- 1984/02/01 00:01
CRDT- 1984/02/01 00:00
PHST- 1984/02/01 00:00 [pubmed]
PHST- 1984/02/01 00:01 [medline]
PHST- 1984/02/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1984.tb03013.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1984 Feb;36(2):132-3. doi: 10.1111/j.2042-7158.1984.tb03013.x.

PMID- 1131582
OWN - NLM
STAT- MEDLINE
DCOM- 19750905
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 2
IP  - 5965
DP  - 1975 May 3
TI  - Aspirin and coronary heart disease: findings of a prospective study.
PG  - 269-71
AB  - Over 1 000 000 men and women answered a confidential questionnaire and were 
      traced for up to six years afterwards. Among other questions each person was 
      asked how often he or she took aspirin-"never", "seldom," or "often." Coronary 
      heart disease death rates were no lower among people who took aspirin often than 
      among those who did not do so.
FAU - Hammond, E C
AU  - Hammond EC
FAU - Garfinkel, L
AU  - Garfinkel L
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Arthritis/drug therapy
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Prospective Studies
MH  - Sex Factors
MH  - Smoking
MH  - Surveys and Questionnaires
PMC - PMC1673278
EDAT- 1975/05/03 00:00
MHDA- 1975/05/03 00:01
CRDT- 1975/05/03 00:00
PHST- 1975/05/03 00:00 [pubmed]
PHST- 1975/05/03 00:01 [medline]
PHST- 1975/05/03 00:00 [entrez]
AID - 10.1136/bmj.2.5965.269 [doi]
PST - ppublish
SO  - Br Med J. 1975 May 3;2(5965):269-71. doi: 10.1136/bmj.2.5965.269.

PMID- 17221333
OWN - NLM
STAT- MEDLINE
DCOM- 20070417
LR  - 20181113
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 23
IP  - 2
DP  - 2007 Apr
TI  - Tissue factor and nitric oxide: a controversial relationship!
PG  - 129-33
AB  - Tissue factor (TF) is the primary physiological initiator of blood coagulation. 
      TF has a high-affinity for factor (F) VII resulting in the formation of 
      (TF:FVII:FVIIa) bimolecular complex which, in the presence of Ca(2+), increases 
      the enzymatic activity of FVIIa towards its natural substrates, FIX and FX, 
      generating their active forms FIXa and FXa, respectively. This eventually leads 
      to thrombin generation and a fibrin clot formation. Up-regulation of TF in 
      injured blood vessels and atherosclerotic plaque can lead to undesirable vascular 
      thrombosis. Nitric oxide (NO) is a free radical synthesized from L-arginine and 
      molecular oxygen by nitric oxide synthases (NOS). NO participates in diverse 
      physiological and pathophysiological process as an intra or extracellular 
      messenger. A relationship between TF and NO has been proposed. Thus, models of TF 
      regulation by NO has been studied in different cells and experimental animal 
      models, but the results have been conflicting. The premise that NO donors can 
      prevent TF expression in vivo has provided the foundation for a broad field of 
      pharmacotherapeutics in vascular medicine. A new class of drugs combining a 
      statin (inhibitors of coenzyme A reductase) with an NO-donating moiety has been 
      described. The resulting drug, nitrostatin, has been suggested to increase the 
      antithrombotic effects of native statin. However, it is questionable if NO 
      release from these drugs had any significant role on TF inhibition. In summary, 
      care must be taken in drawing conclusions about the relationship between NO and 
      TF. Interpretation of NO studies must take several factors into consideration, 
      including NO bioavailability, its half-life and inactivation, as well as the cell 
      type and experimental model used.
FAU - Dusse, Luci Maria SantAna
AU  - Dusse LM
AD  - University of Southampton, Southampton, UK.
FAU - Cooper, Alan J
AU  - Cooper AJ
FAU - Lwaleed, Bashir A
AU  - Lwaleed BA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20070113
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 
      (1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic 
      acid 4-(nitrooxy)butyl ester)
RN  - 0 (Anticoagulants)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Nitrates)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 9035-58-9 (Thromboplastin)
RN  - EH04H13L6B (nitroaspirin)
RN  - KXO2KT9N0G (Pravastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/*pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Blood Coagulation/physiology
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology
MH  - Nitrates/*pharmacology
MH  - Nitric Oxide/*metabolism/pharmacology
MH  - Pravastatin/*analogs & derivatives/pharmacology
MH  - Thromboplastin/*drug effects/metabolism
MH  - Up-Regulation
RF  - 44
EDAT- 2007/01/16 09:00
MHDA- 2007/04/18 09:00
CRDT- 2007/01/16 09:00
PHST- 2006/11/07 00:00 [received]
PHST- 2006/12/11 00:00 [accepted]
PHST- 2007/01/16 09:00 [pubmed]
PHST- 2007/04/18 09:00 [medline]
PHST- 2007/01/16 09:00 [entrez]
AID - 10.1007/s11239-006-0001-9 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2007 Apr;23(2):129-33. doi: 10.1007/s11239-006-0001-9. 
      Epub 2007 Jan 13.

PMID- 14575023
OWN - NLM
STAT- MEDLINE
DCOM- 20040226
LR  - 20131121
IS  - 0033-2240 (Print)
IS  - 0033-2240 (Linking)
VI  - 60
IP  - 3
DP  - 2003
TI  - [Exacerbation of aspirin-induced asthma associated with RSV infection].
PG  - 185-7
AB  - We report the case of a 60 year old woman, suffering for 8 years from 
      aspirin-induced asthma, having an airway infection of RSV-respiratory syncytial 
      virus. New methods of molecular biology were used to identify the virus in the 
      lung bioptate (RT-PCR, reverse transcription polymerase chain reaction and nested 
      PCR). The role of viruses, especially RNA, is still unknown in pathogenesis of 
      asthma. The reported case could help to explain their participation in this 
      disease.
FAU - Filipowicz, Elzbieta
AU  - Filipowicz E
AD  - II Katedra Chorób Wewnetrznych Collegium Medicum Uniwersytet Jagielloński, 31-066 
      Kraków, ul. Skawińska 8.
FAU - Sanak, Marek
AU  - Sanak M
LA  - pol
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Zaostrzenie astmy aspirynowej zwiazane z zakazeniem RSV.
PL  - Poland
TA  - Przegl Lek
JT  - Przeglad lekarski
JID - 19840720R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (RNA, Viral)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*virology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - RNA, Viral
MH  - Respiratory Syncytial Virus Infections/genetics/*virology
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
MH  - Severity of Illness Index
EDAT- 2003/10/25 05:00
MHDA- 2004/02/27 05:00
CRDT- 2003/10/25 05:00
PHST- 2003/10/25 05:00 [pubmed]
PHST- 2004/02/27 05:00 [medline]
PHST- 2003/10/25 05:00 [entrez]
PST - ppublish
SO  - Przegl Lek. 2003;60(3):185-7.

PMID- 6368649
OWN - NLM
STAT- MEDLINE
DCOM- 19840511
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 73
IP  - 4
DP  - 1984 Apr
TI  - Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of 
      treatment with aspirin.
PG  - 500-7
AB  - Twenty-five ASA-sensitive patients with rhinosinusitis asthma underwent oral ASA 
      challenges followed by desensitization to the adverse respiratory effects of ASA. 
      We then compared the efficacy of continuous ASA treatment for their respiratory 
      tract disease to that of a placebo treatment during a double-blind crossover 
      study. For this group of 25 patients, there was significant improvement in nasal 
      symptoms and a reduction in use of nasal beclomethasone during the months when 
      they received ASA treatment. Lower respiratory tract symptoms, values of FEV1, 
      and the use of antiasthmatic medications including prednisone were not 
      significantly changed during ASA treatment. Desensitization to ASA followed by 
      ASA treatment appears to significantly alleviate symptoms of rhinosinusitis. 
      However, only half the patients experienced improvement in their asthma symptoms 
      during ASA treatment.
FAU - Stevenson, D D
AU  - Stevenson DD
FAU - Pleskow, W W
AU  - Pleskow WW
FAU - Simon, R A
AU  - Simon RA
FAU - Mathison, D A
AU  - Mathison DA
FAU - Lumry, W R
AU  - Lumry WR
FAU - Schatz, M
AU  - Schatz M
FAU - Zeiger, R S
AU  - Zeiger RS
LA  - eng
GR  - AI-10386/AI/NIAID NIH HHS/United States
GR  - RR-00833/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Asthma/*chemically induced/immunology
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Hypersensitivity/etiology/*immunology
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Hypersensitivity, Delayed/immunology
MH  - Placebos
MH  - Rhinitis/drug therapy/immunology
MH  - Sinusitis/drug therapy/immunology
EDAT- 1984/04/01 00:00
MHDA- 1984/04/01 00:01
CRDT- 1984/04/01 00:00
PHST- 1984/04/01 00:00 [pubmed]
PHST- 1984/04/01 00:01 [medline]
PHST- 1984/04/01 00:00 [entrez]
AID - 0091-6749(84)90361-0 [pii]
AID - 10.1016/0091-6749(84)90361-0 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1984 Apr;73(4):500-7. doi: 10.1016/0091-6749(84)90361-0.

PMID- 35183905
OWN - NLM
STAT- MEDLINE
DCOM- 20220415
LR  - 20220415
IS  - 1877-783X (Electronic)
IS  - 1877-7821 (Linking)
VI  - 77
DP  - 2022 Apr
TI  - Non-aspirin NSAIDs and head and neck cancer mortality in a Danish nationwide 
      cohort study.
PG  - 102121
LID - S1877-7821(22)00026-1 [pii]
LID - 10.1016/j.canep.2022.102121 [doi]
AB  - BACKGROUND: Evidence suggests that non-aspirin non-steroidal anti-inflammatory 
      drugs (NSAIDs) have antineoplastic properties of potential importance for 
      survival of head and neck cancer. METHODS: We conducted a nationwide cohort study 
      including all individuals with primary head and neck squamous cell carcinoma in 
      Denmark during 2000-2016 at age 30-84 years, with no history of cancer (except 
      non-melanoma skin cancer), and alive at 1 year after diagnosis. Nationwide 
      registries provided information on drug use, causes of death and potential 
      confounders, and additional clinical information was obtained for a 
      subpopulation. We conducted Cox proportional hazards regression to estimate 
      multivariable-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) 
      for the association between post-diagnosis non-aspirin NSAID use (defined as ≥1 
      filled prescription within first year after diagnosis) and cancer-specific 
      mortality. RESULTS: Among 10,770 head and neck cancer 1-year survivors, the HR 
      for cancer-specific mortality with non-aspirin NSAID use was 1.68 at 1 year after 
      diagnosis, but declined and stabilized around 1.15 (95% CI 1.02-1.29) at 2 years 
      after diagnosis. Among 2-year survivors, the HRs for cancer-specific mortality 
      with non-aspirin NSAID use remained slightly increased in analyses stratified by 
      age, sex, stage, and pre-diagnosis non-aspirin NSAID use. Similar results were 
      seen in the subpopulation (n = 1029) with additional clinical information, and 
      among 5-year survivors with additional non-aspirin NSAID exposure assessment. 
      CONCLUSION: In this nationwide cohort of patients with head and neck cancer, use 
      of non-aspirin NSAIDs was associated with a slightly increased mortality risk, 
      warranting further evaluation.
CI  - Copyright © 2022 Elsevier Ltd. All rights reserved.
FAU - de la Cour, Cecilie D
AU  - de la Cour CD
AD  - Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 
      Strandboulevarden 49, Copenhagen 2100, Denmark. Electronic address: 
      cecilie.de.la.cour@regionh.dk.
FAU - Dehlendorff, Christian
AU  - Dehlendorff C
AD  - Statistics and Data Analysis, Danish Cancer Society Research Center, 
      Strandboulevarden 49, Copenhagen 2100, Denmark.
FAU - von Buchwald, Christian
AU  - von Buchwald C
AD  - Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, 
      Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen 2100, 
      Denmark.
FAU - Garset-Zamani, Martin
AU  - Garset-Zamani M
AD  - Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, 
      Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen 2100, 
      Denmark.
FAU - Grønhøj, Christian
AU  - Grønhøj C
AD  - Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, 
      Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen 2100, 
      Denmark.
FAU - Carlander, Amanda-Louise F
AU  - Carlander AF
AD  - Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, 
      Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen 2100, 
      Denmark.
FAU - Friis, Søren
AU  - Friis S
AD  - Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Society Research 
      Center, Strandboulevarden 49, Copenhagen 2100, Denmark.
FAU - Kjaer, Susanne K
AU  - Kjaer SK
AD  - Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 
      Strandboulevarden 49, Copenhagen 2100, Denmark; Department of Gynecology, 
      Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen 2100, 
      Denmark. Electronic address: susanne@cancer.dk.
LA  - eng
PT  - Journal Article
DEP - 20220217
PL  - Netherlands
TA  - Cancer Epidemiol
JT  - Cancer epidemiology
JID - 101508793
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - *Aspirin/therapeutic use
MH  - Cohort Studies
MH  - Denmark/epidemiology
MH  - *Head and Neck Neoplasms/drug therapy
MH  - Humans
MH  - Middle Aged
MH  - Risk Factors
OTO - NOTNLM
OT  - Head and neck cancer
OT  - Human papillomavirus
OT  - Non-steroidal anti-inflammatory drugs
OT  - Oropharyngeal cancer
OT  - Survival
EDAT- 2022/02/21 06:00
MHDA- 2022/04/16 06:00
CRDT- 2022/02/20 20:34
PHST- 2021/10/12 00:00 [received]
PHST- 2022/01/12 00:00 [revised]
PHST- 2022/02/10 00:00 [accepted]
PHST- 2022/02/21 06:00 [pubmed]
PHST- 2022/04/16 06:00 [medline]
PHST- 2022/02/20 20:34 [entrez]
AID - S1877-7821(22)00026-1 [pii]
AID - 10.1016/j.canep.2022.102121 [doi]
PST - ppublish
SO  - Cancer Epidemiol. 2022 Apr;77:102121. doi: 10.1016/j.canep.2022.102121. Epub 2022 
      Feb 17.

PMID- 15354902
OWN - NLM
STAT- MEDLINE
DCOM- 20041004
LR  - 20190709
IS  - 0002-8177 (Print)
IS  - 0002-8177 (Linking)
VI  - 135
IP  - 7
DP  - 2004 Jul
TI  - Tooth erosion caused by chewing aspirin.
PG  - 911-4
AB  - BACKGROUND: Although the effects of aspirin on the oral mucosa are 
      well-documented, there is little documentation of the effects of aspirin-chewing 
      on the enamel and dentin. CASE DESCRIPTION: The authors present two cases of 
      patients with damage to their tooth enamel and dentin. Both patients had similiar 
      symptoms, but had not been told that chewing aspirin could harm tooth structure. 
      The authors identify clinical signs and symptoms and discuss ways to prevent 
      erosion. CLINICAL IMPLICATIONS: The common factor in these cases is that aspirin 
      was the only possible cause of the tooth erosion. Dentists should be aware of the 
      effects of aspirin-chewing on tooth structure and advise their patients 
      accordingly.
FAU - Grace, Edward G
AU  - Grace EG
AD  - Department of Health Promotion and Policy, and Brotman Facial Pain Center, 
      University of Maryland Dental School, Baltimore 21201, USA. 
      egg001@dental.umaryland.edu
FAU - Sarlani, Eleni
AU  - Sarlani E
FAU - Kaplan, Sarit
AU  - Kaplan S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Mastication
MH  - Middle Aged
MH  - Tooth Erosion/*chemically induced
EDAT- 2004/09/10 05:00
MHDA- 2004/10/05 09:00
CRDT- 2004/09/10 05:00
PHST- 2004/09/10 05:00 [pubmed]
PHST- 2004/10/05 09:00 [medline]
PHST- 2004/09/10 05:00 [entrez]
AID - S0002-8177(14)61356-8 [pii]
AID - 10.14219/jada.archive.2004.0337 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 2004 Jul;135(7):911-4. doi: 10.14219/jada.archive.2004.0337.

PMID- 313330
OWN - NLM
STAT- MEDLINE
DCOM- 19790925
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 24
IP  - 7
DP  - 1979 Jul
TI  - A procedure for measuring gastric bleeding caused by drugs.
PG  - 525-8
AB  - Seven subjects were given one day's treatment with full doses of either aspirin, 
      ibuprofen, or placebo, and then their stomachs were washed out three times at 
      intervals of 10 min, for five successive days. The blood in the recoveries was 
      estimated chemically. After compensating for gastric emptying, the rate of 
      bleeding was expressed as ml blood per day. Relative to placebo, one day's 
      treatment with aspirin increased the rate of blood loss significantly at day 1, 
      median 2.7 ml/day, and not thereafter. A corresponding dose of ibuprofen did not 
      produce any significant bleeding. The procedure gives specific information about 
      gastric bleeding. It can measure rates of bleeding down to 0.01 ml/day.
FAU - Hunt, J N
AU  - Hunt JN
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Gastric Mucosa/*pathology
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Ibuprofen/*adverse effects
MH  - Male
MH  - Methods
EDAT- 1979/07/01 00:00
MHDA- 1979/07/01 00:01
CRDT- 1979/07/01 00:00
PHST- 1979/07/01 00:00 [pubmed]
PHST- 1979/07/01 00:01 [medline]
PHST- 1979/07/01 00:00 [entrez]
AID - 10.1007/BF01489320 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1979 Jul;24(7):525-8. doi: 10.1007/BF01489320.

PMID- 29642568
OWN - NLM
STAT- MEDLINE
DCOM- 20180905
LR  - 20181202
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 19
IP  - 4
DP  - 2018 Apr 10
TI  - Irradiation-Induced Cardiac Connexin-43 and miR-21 Responses Are Hampered by 
      Treatment with Atorvastatin and Aspirin.
LID - 10.3390/ijms19041128 [doi]
LID - 1128
AB  - Radiation of the chest during cancer therapy is deleterious to the heart, mostly 
      due to oxidative stress and inflammation related injury. A single sub-lethal dose 
      of irradiation has been shown to result in compensatory up-regulation of the 
      myocardial connexin-43 (Cx43), activation of the protein kinase C (PKC) signaling 
      along with the decline of microRNA (miR)-1 and an increase of miR-21 levels in 
      the left ventricle (LV). We investigated whether drugs with antioxidant, 
      anti-inflammatory or vasodilating properties, such as aspirin, atorvastatin, and 
      sildenafil, may affect myocardial response in the LV and right ventricle (RV) 
      following chest irradiation. Adult, male Wistar rats were subjected to a single 
      sub-lethal dose of chest radiation at 25 Gy and treated with aspirin (3 mg/day), 
      atorvastatin (0.25 mg/day), and sildenafil (0.3 mg/day) for six weeks. Cx43, PKCε 
      and PKCδ proteins expression and levels of miR-1 as well as miR-21 were 
      determined in the LV and RV. Results showed that the suppression of miR-1 was 
      associated with an increase of total and phosphorylated forms of Cx43 as well as 
      PKCε expression in the LV while having no effect in the RV post-irradiation as 
      compared to the non-irradiated rats. Treatment with aspirin and atorvastatin 
      prevented an increase in the expression of Cx43 and PKCε without change in the 
      miR-1 levels. Furthermore, treatment with aspirin, atorvastatin, and sildenafil 
      completely prevented an increase of miR-21 in the LV while having partial effect 
      in the RV post irradiation. The increase in pro-apoptotic PKCδ was not affected 
      by any of the used treatment. In conclusion, irradiation and drug-induced changes 
      were less pronounced in the RV as compared to the LV. Treatment with aspirin and 
      atorvastatin interfered with irradiation-induced compensatory changes in 
      myocardial Cx43 protein and miR-21 by preventing their elevation, possibly via 
      amelioration of oxidative stress and inflammation.
FAU - Viczenczova, Csilla
AU  - Viczenczova C
AD  - Institute for Heart Research, Center of Experimental Medicine, Slovak Academy of 
      Sciences, Bratislava 841 04, Slovak Republic. viczencz.csilla@gmail.com.
FAU - Kura, Branislav
AU  - Kura B
AD  - Institute for Heart Research, Center of Experimental Medicine, Slovak Academy of 
      Sciences, Bratislava 841 04, Slovak Republic. branislav.kura@savba.sk.
FAU - Egan Benova, Tamara
AU  - Egan Benova T
AD  - Institute for Heart Research, Center of Experimental Medicine, Slovak Academy of 
      Sciences, Bratislava 841 04, Slovak Republic. tamara.benova@savba.sk.
FAU - Yin, Chang
AU  - Yin C
AD  - Division of Cardiology, Medical College of Virginia, Virginia Commonwealth 
      University, Richmond, VA 23298, USA. rakesh@vcu.edu.
FAU - Kukreja, Rakesh C
AU  - Kukreja RC
AD  - Division of Cardiology, Medical College of Virginia, Virginia Commonwealth 
      University, Richmond, VA 23298, USA. rakesh.kukreja@vcuhealth.org.
FAU - Slezak, Jan
AU  - Slezak J
AD  - Institute for Heart Research, Center of Experimental Medicine, Slovak Academy of 
      Sciences, Bratislava 841 04, Slovak Republic. jan.slezak@savba.sk.
FAU - Tribulova, Narcis
AU  - Tribulova N
AD  - Institute for Heart Research, Center of Experimental Medicine, Slovak Academy of 
      Sciences, Bratislava 841 04, Slovak Republic. narcisa.tribulova@savba.sk.
FAU - Szeiffova Bacova, Barbara
AU  - Szeiffova Bacova B
AD  - Institute for Heart Research, Center of Experimental Medicine, Slovak Academy of 
      Sciences, Bratislava 841 04, Slovak Republic. barbara.bacova@savba.sk.
LA  - eng
PT  - Journal Article
DEP - 20180410
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antioxidants)
RN  - 0 (Connexin 43)
RN  - 0 (MicroRNAs)
RN  - 0 (mirn21 microRNA, rat)
RN  - A0JWA85V8F (Atorvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antioxidants/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Atorvastatin/*pharmacology/therapeutic use
MH  - Connexin 43/*metabolism
MH  - Heart/*radiation effects
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Myocardium/metabolism
MH  - Radiation Injuries/drug therapy/*metabolism
MH  - Radiation, Ionizing
MH  - Rats
MH  - Rats, Wistar
PMC - PMC5979305
OTO - NOTNLM
OT  - aspirin
OT  - atorvastatin
OT  - connexin-43
OT  - heart
OT  - irradiation
OT  - miR-1
OT  - miR-21
COIS- The authors declare no conflict of interest.
EDAT- 2018/04/13 06:00
MHDA- 2018/09/06 06:00
CRDT- 2018/04/13 06:00
PHST- 2018/03/09 00:00 [received]
PHST- 2018/03/31 00:00 [revised]
PHST- 2018/04/05 00:00 [accepted]
PHST- 2018/04/13 06:00 [entrez]
PHST- 2018/04/13 06:00 [pubmed]
PHST- 2018/09/06 06:00 [medline]
AID - ijms19041128 [pii]
AID - ijms-19-01128 [pii]
AID - 10.3390/ijms19041128 [doi]
PST - epublish
SO  - Int J Mol Sci. 2018 Apr 10;19(4):1128. doi: 10.3390/ijms19041128.

PMID- 15823962
OWN - NLM
STAT- MEDLINE
DCOM- 20050711
LR  - 20191109
IS  - 1061-186X (Print)
IS  - 1026-7158 (Linking)
VI  - 13
IP  - 2
DP  - 2005 Feb
TI  - Aspirin induces its anti-inflammatory effects through its specific binding to 
      phospholipase A2: crystal structure of the complex formed between phospholipase 
      A2 and aspirin at 1.9 angstroms resolution.
PG  - 113-9
AB  - Phospholipase A2 is potentially an important target for structure-based rational 
      drug design. In order to determine the involvement of phospholipase A2 in the 
      action of non-steroidal anti-inflammatory drugs (NSAIDs), the crystal structure 
      of the complex formed between phospholipase A2 and aspirin has been determined at 
      1.9 angstroms resolution. The structure contains 915 protein atoms, 1 calcium 
      ion, 13 atoms of aspirin and 105 water molecules. The observed electron density 
      of the aspirin molecule in the structure was of very high quality thus allowing 
      the precise determination of its atomic coordinates leading to the clear 
      description of its interactions with the enzyme. The structure of the complex 
      clearly shows that aspirin is literally embedded in the hydrophobic environment 
      of PLA2. It is so placed in the substrate binding channel that it forms several 
      important attractive interactions with calcium ion, His 48 and Asp 49. Thus, the 
      structure of the complex clearly shows that aspirin occupies a favourable place 
      in the specific binding site of PLA2. The binding studies have shown that acetyl 
      salicylate (aspirin) binds to PLA2 enzyme specifically with a dissociation 
      constant of 6.4 x 10(-6) M. The structural details and binding data suggest that 
      the inhibition of PLA2 by aspirin is of pharmacological
FAU - Singh, Rajendra Kumar
AU  - Singh RK
AD  - Department of Biophysics, All India Institute of Medical Sciences, Ansari Nagar, 
      New Delhi 110 029, India.
FAU - Ethayathulla, A S
AU  - Ethayathulla AS
FAU - Jabeen, Talat
AU  - Jabeen T
FAU - Sharma, Sujata
AU  - Sharma S
FAU - Kaur, Punit
AU  - Kaur P
FAU - Singh, Tej P
AU  - Singh TP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Drug Target
JT  - Journal of drug targeting
JID - 9312476
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Elapid Venoms)
RN  - EC 3.1.1.32 (Phospholipases A)
RN  - EC 3.1.1.4 (Phospholipases A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Binding Sites
MH  - Crystallography, X-Ray
MH  - Elapid Venoms/chemistry
MH  - Kinetics
MH  - Models, Molecular
MH  - Phospholipases A/*chemistry/isolation & purification
MH  - Phospholipases A2
MH  - Protein Binding
EDAT- 2005/04/13 09:00
MHDA- 2005/07/12 09:00
CRDT- 2005/04/13 09:00
PHST- 2005/04/13 09:00 [pubmed]
PHST- 2005/07/12 09:00 [medline]
PHST- 2005/04/13 09:00 [entrez]
AID - M80774406655HX84 [pii]
AID - 10.1080/10611860400024078 [doi]
PST - ppublish
SO  - J Drug Target. 2005 Feb;13(2):113-9. doi: 10.1080/10611860400024078.

PMID- 2185679
OWN - NLM
STAT- MEDLINE
DCOM- 19900601
LR  - 20181113
IS  - 0035-8843 (Print)
IS  - 1478-7083 (Electronic)
IS  - 0035-8843 (Linking)
VI  - 72
IP  - 2
DP  - 1990 Mar
TI  - Surgery offers no more than medical treatment in the management of transient 
      ischaemic attack.
PG  - 114-8
AB  - This paper debates the motion that 'Surgery offers no more than medical treatment 
      in the management of transient ischaemic attack' (TIA). The arguments in support 
      of this motion are that surgical treatment has a high morbidity and mortality, 
      and that even the investigation of patients by angiography prior to surgery 
      entails a risk of stroke; that TIA is a marker of generalised vascular disease, 
      and that medical treatment can reduce the incidence of stroke after TIA. The 
      counter arguments are that TIA is associated with an increased risk of stroke and 
      this risk can be reduced by surgery; that recent surgical results show an 
      acceptable complication rate, and that modern methods of investigation permit 
      accurate non-invasive assessment of patients at risk of stroke.
FAU - Thompson, J
AU  - Thompson J
AD  - Department of Surgery, Royal South Hants Hospital.
FAU - McDonald, P J
AU  - McDonald PJ
FAU - Johnson, C D
AU  - Johnson CD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Ann R Coll Surg Engl
JT  - Annals of the Royal College of Surgeons of England
JID - 7506860
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/etiology
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/*surgery
MH  - Risk Factors
PMC - PMC2499110
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
PST - ppublish
SO  - Ann R Coll Surg Engl. 1990 Mar;72(2):114-8.

PMID- 3781418
OWN - NLM
STAT- MEDLINE
DCOM- 19870106
LR  - 20190829
IS  - 0278-6915 (Print)
IS  - 0278-6915 (Linking)
VI  - 24
IP  - 6-7
DP  - 1986 Jun-Jul
TI  - Application of the post-implantation rat embryo culture system to in vitro 
      teratogenicity testing.
PG  - 623-6
AB  - Originally developed for studying basic mechanisms in developmental biology, the 
      post-implantation embryo culture system has been extended and applied to the 
      testing of chemicals in the field of prenatal toxicology. The endpoints used in a 
      procedure that has been developed for the routine short-term assessment of 
      teratogenicity in vitro are growth (crown-rump length), differentiation (somite 
      number) and morphology (together with measurement of yolk-sac growth and 
      vascularization) in rat embryos explanted on day 9.5 of gestation and cultured 
      for 48 hr in 100% homologous rat serum containing the test compound. Studies 
      involving exposure to trichlorophenoxyacetic acid and to acetylsalicylic acid 
      demonstrate the ability of this system to distinguish between non-specific 
      toxicity and specific effects on development.
FAU - Schmid, B P
AU  - Schmid BP
FAU - Cicurel, L
AU  - Cicurel L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Food Chem Toxicol
JT  - Food and chemical toxicology : an international journal published for the British 
      Industrial Biological Research Association
JID - 8207483
RN  - 9Q963S4YMX (2,4,5-Trichlorophenoxyacetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2,4,5-Trichlorophenoxyacetic Acid/toxicity
MH  - Abnormalities, Drug-Induced/*etiology
MH  - Animals
MH  - Aspirin/toxicity
MH  - Embryo, Mammalian/*drug effects
MH  - Female
MH  - Male
MH  - Organ Culture Techniques
MH  - Rats
EDAT- 1986/06/01 00:00
MHDA- 1986/06/01 00:01
CRDT- 1986/06/01 00:00
PHST- 1986/06/01 00:00 [pubmed]
PHST- 1986/06/01 00:01 [medline]
PHST- 1986/06/01 00:00 [entrez]
AID - 0278-6915(86)90137-7 [pii]
AID - 10.1016/0278-6915(86)90137-7 [doi]
PST - ppublish
SO  - Food Chem Toxicol. 1986 Jun-Jul;24(6-7):623-6. doi: 10.1016/0278-6915(86)90137-7.

PMID- 33471648
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210122
IS  - 1530-891X (Print)
IS  - 1530-891X (Linking)
VI  - 26
IP  - 7
DP  - 2020 Jul
TI  - A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent 
      Cardiovascular Thrombosis.
PG  - 787-793
LID - S1530-891X(20)36021-3 [pii]
LID - 10.4158/EP-2020-0023 [doi]
AB  - OBJECTIVE: Cardiovascular disease is the leading metabolic cause of mortality in 
      the United States. Among current therapies, low-dose aspirin has been shown to 
      reduce cardiovascular thrombosis. However, aspirin also causes major 
      complications (hemorrhagic stroke and gastrointestinal bleeding). The American 
      Heart Association recommends that aspirin only be prescribed for "high-risk" 
      individuals. No guidelines are available as to the duration of aspirin therapy. 
      METHODS: A reasonable approach to aspirin administration is to determine the 
      appropriateness of aspirin therapy based on the pathophysiology of coronary 
      artery thrombosis. It suggests that the coronary artery calcium (CAC) score be 
      used as the basis for determining "high risk." This score was shown to accurately 
      predict future cardiovascular events. The greater the CAC score, the greater the 
      extent of coronary artery atherosclerotic plaque and future cardiovascular risk. 
      RESULTS: A CAC score >400 places an individual at very-high 10-year risk for an 
      atherosclerotic event. Since aggressive medical therapy initiates stabilization 
      of unstable atherosclerotic plaques within 1 month and reversal within 2 years, 
      this treatment significantly reduces the risk of the individual for a 
      cardiovascular event. Thus, most individuals aged <75 years with a CAC score of 
      >400 should receive aspirin therapy for a maximum of 2 years. CONCLUSION: 
      Utilization of a CAC score greatly simplifies the decision of whom to treat with 
      aspirin and for what duration. Importantly, focusing on two factors (hemorrhage 
      and plaque stabilization) is easily understood by both the physician and the 
      patient. ABBREVIATIONS: CAC = coronary artery calcium; CVD = cardiovascular 
      disease; LDL = low-density lipoprotein; OCT = optical coherence tomography.
CI  - © 2020 American Association of Clinical Endocrinologists. Published by Elsevier, 
      Inc. All rights reserved.
FAU - Schade, David S
AU  - Schade DS
AD  - University of New Mexico Health Sciences Center, Department of Internal Medicine, 
      Division of Endocrinology. Electronic address: dschade@salud.unm.edu.
FAU - Burchiel, Scott
AU  - Burchiel S
AD  - University of New Mexico Health Sciences Center, Department of Pharmaceutical 
      Sciences, Albuquerque, New Mexico.
FAU - Eaton, R Philip
AU  - Eaton RP
AD  - University of New Mexico Health Sciences Center, Department of Internal Medicine, 
      Division of Endocrinology.
LA  - eng
PT  - Journal Article
DEP - 20201124
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/epidemiology/prevention & control
MH  - *Coronary Artery Disease
MH  - Humans
MH  - *Plaque, Atherosclerotic/diagnostic imaging
MH  - Primary Prevention
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Thrombosis/prevention & control
MH  - United States
MH  - *Vascular Calcification
EDAT- 2021/01/21 06:00
MHDA- 2021/01/23 06:00
CRDT- 2021/01/20 17:09
PHST- 2020/01/21 00:00 [received]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2021/01/20 17:09 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
AID - S1530-891X(20)36021-3 [pii]
AID - 10.4158/EP-2020-0023 [doi]
PST - ppublish
SO  - Endocr Pract. 2020 Jul;26(7):787-793. doi: 10.4158/EP-2020-0023. Epub 2020 Nov 
      24.

PMID- 18035244
OWN - NLM
STAT- MEDLINE
DCOM- 20080108
LR  - 20141120
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
VI  - 16
IP  - 6
DP  - 2007 Nov-Dec
TI  - New developments in secondary stroke prevention: impact of the 
      European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on 
      clinical management.
PG  - 263-7
AB  - Secondary stroke prevention is an important goal of poststroke patient treatment. 
      Various pharmacologic approaches have been advocated, but the relative efficacy 
      and safety of these regimens has remained the subject of much debate. Recently 
      released data from the European/Australasian Stroke Prevention in Reversible 
      Ischemia Trial (ESPRIT) indicated that combination therapy with aspirin and 
      extended-release dipyridamole was more effective than aspirin monotherapy, and 
      probably more effective than anticoagulants, for the prevention of 
      cerebrovascular events after a stroke or transient ischemic attack. When viewed 
      in light of results of earlier trials, these findings confirmed that combination 
      aspirin plus extended-release dipyridamole therapy improved outcomes in these 
      patients and is a recommended option for poststroke patient treatment.
FAU - Lutsep, Helmi L
AU  - Lutsep HL
AD  - Department of Neurology, Oregon Health and Science University, Oregon Stroke 
      Center, Portland, OR 97239, USA. lutseph@ohsu.edu
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National 
      Stroke Association
JID - 9111633
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - J Stroke Cerebrovasc Dis. 2008 Sep;17(5):330
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Australasia
MH  - Brain Ischemia/*complications/drug therapy
MH  - Delayed-Action Preparations
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Europe
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Secondary Prevention
MH  - Stroke/*drug therapy/etiology/prevention & control
MH  - Treatment Outcome
EDAT- 2007/11/24 09:00
MHDA- 2008/01/09 09:00
CRDT- 2007/11/24 09:00
PHST- 2007/02/26 00:00 [received]
PHST- 2007/07/14 00:00 [revised]
PHST- 2007/07/26 00:00 [accepted]
PHST- 2007/11/24 09:00 [pubmed]
PHST- 2008/01/09 09:00 [medline]
PHST- 2007/11/24 09:00 [entrez]
AID - S1052-3057(07)00107-3 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2007.07.005 [doi]
PST - ppublish
SO  - J Stroke Cerebrovasc Dis. 2007 Nov-Dec;16(6):263-7. doi: 
      10.1016/j.jstrokecerebrovasdis.2007.07.005.

PMID- 31780809
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20210110
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Nov 28
TI  - Clopidogrel plus Aspirin Use is Associated with Worse Long-Term Outcomes, but 
      Aspirin Use Alone is Safe in Patients with Vasospastic Angina: Results from the 
      VA-Korea Registry, A Prospective Multi-Center Cohort.
PG  - 17783
LID - 10.1038/s41598-019-54390-w [doi]
LID - 17783
AB  - Anti-platelet agents are commonly used in vasospastic angina (VA) patients with 
      comorbidity like coronary artery disease. However, long-term clinical outcomes in 
      the use of aspirin, clopidogrel or the two agents together have rarely been 
      investigated in VA patients. In a prospective study, we enrolled 2960 patients 
      who received coronary angiography and ergonovine provocation test at 11 
      university hospitals in Korea. Among them, 1838 patients were diagnosed either 
      with definite (n = 680) or intermediate (n = 1212) VA, using the criteria of 
      chest pain, ECG changes and ergonovine provocation test results. They were 
      analyzed according to their use of aspirin, clopidogrel or both, or no 
      anti-platelet agent at all. The primary outcome was time to composite events of 
      death from any cause, acute coronary syndrome (ACS) and symptomatic arrhythmia 
      during a 3-year follow-up. A primary composite outcome was significantly more 
      common in the aspirin plus clopidogrel group, at 10.8% (14/130), as compared with 
      the non-antiplatelet group, at 4.4% (44/1011), (hazard ratio [HR] 2.41, 95% 
      confidence interval [CI], 1.32-4.40, p = 0.004). With regard to the person-time 
      event rate, similar results were shown, with the highest rate in the aspirin plus 
      clopidogrel user at 4.72/1000 person months (95% CI, 2.79-7.96, log-rank test for 
      primary outcome p = 0.016). The person-time event of the ACS rate was also 
      highest in that group, at 2.81 (95% CI, 1.46-5.40, log-rank test for ACS 
      p = 0.116). Kaplan-Meier survival analysis demonstrated poor prognosis in primary 
      outcomes and ACS in aspirin plus clopidogrel users (log-rank test, p = 0.005 and 
      p = 0.0392, respectively). Cox-proportional hazard regression analysis, adjusting 
      for age, sex, history of coronary heart disease, hypertension, diabetes, presence 
      or not of definite spasm, use of calcium channel blocker, demonstrated that the 
      use of aspirin plus clopidogrel is an independent risk for the primary outcome 
      (HR 2.01, CI: 1.07-3.81, p = 0.031). The aspirin-alone group had a similar 
      primary and individual event rate compared to the no-antiplatelet agent group (HR 
      0.96, CI, 0.59-1.55, p = 0.872). Smokers using aspirin plus clopidogrel had 
      poorer outcomes than non-smokers, with HR 6.36 (CI 2.31-17.54, p = 0.045 for 
      interaction). In conclusion, among VA patients, aspirin plus clopidogrel use is 
      associated with a poor clinical outcome at 3 years, especially in ACS. Aspirin 
      alone appears to be safe for use in those patients.
FAU - Cho, Seong-Sik
AU  - Cho SS
AD  - Department of Occupational and Environmental Medicine, College of Medicine, 
      Dong-A University, Busan, Korea.
FAU - Jo, Sang-Ho
AU  - Jo SH
AUID- ORCID: 0000-0002-2063-1542
AD  - Division of Cardiology, Department of Internal Medicine, Hallym University Sacred 
      Heart Hospital, Anyang-si, Gyeonggi-do, Korea. sophi5neo@gmail.com.
FAU - Han, Seung Hwan
AU  - Han SH
AD  - Department of Cardiovascular Medicine, Gil Medical Center, Gachon University, 
      Incheon, South Korea.
FAU - Lee, Kwan Yong
AU  - Lee KY
AD  - Department of Cardiovascular Medicine, Incheon St. Mary's Hospital, The Catholic 
      University of Korea, Incheon, South Korea.
FAU - Her, Sung-Ho
AU  - Her SH
AD  - Department of Cardiovascular Medicine, Daejeon St. Mary's Hospital, The Catholic 
      University of Korea, Daejeon, South Korea.
FAU - Lee, Min-Ho
AU  - Lee MH
AUID- ORCID: 0000-0003-0748-7766
AD  - Department of Cardiovascular Medicine, Soonchunhyang Seoul Hospital, Seoul, South 
      Korea.
FAU - Seo, Won-Woo
AU  - Seo WW
AD  - Department of Cardiovascular Medicine Hallym University Kangdong Hospital, Seoul, 
      South Korea.
FAU - Kim, Sung Eun
AU  - Kim SE
AD  - Department of Cardiovascular Medicine Hallym University Kangdong Hospital, Seoul, 
      South Korea.
FAU - Yang, Tae-Hyun
AU  - Yang TH
AD  - Department of Cardiovascular Medicine, Busan Paik Hospital, Inje University, 
      Busan, South Korea.
FAU - Park, Keun-Ho
AU  - Park KH
AD  - Department of Cardiovascular Medicine, Chosun Medical Center, Gwangju, South 
      Korea.
FAU - Suh, Jung-Won
AU  - Suh JW
AD  - Department of Cardiovascular Medicine, Bundang Hospital, Seoul National 
      University, Seongnam, South Korea.
FAU - Lee, Byoung-Kwon
AU  - Lee BK
AD  - Department of Cardiovascular Medicine, Gangnam Severance Hospital, Yonsei 
      University, Seoul, South Korea.
FAU - Rha, Seung-Woon
AU  - Rha SW
AD  - Department of Cardiovascular Medicine, Guro Hospital, Korea University, Seoul, 
      South Korea.
FAU - Gwon, Hyeon-Cheol
AU  - Gwon HC
AD  - Department of Cardiovascular Medicine, Samsung Medical Center, Sungkyunkwan 
      University, Seoul, South Korea.
FAU - Baek, Sang Hong
AU  - Baek SH
AD  - Department of Cardiovascular Medicine, Seoul St. Mary's Hospital, The Catholic 
      University of Korea, Seoul, South Korea.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20191128
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris, Variant/*drug therapy/epidemiology
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clopidogrel/*adverse effects/therapeutic use
MH  - Drug Therapy, Combination/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Prospective Studies
MH  - Republic of Korea/epidemiology
MH  - Treatment Outcome
PMC - PMC6883054
COIS- The authors declare no competing interests.
EDAT- 2019/11/30 06:00
MHDA- 2020/11/11 06:00
CRDT- 2019/11/30 06:00
PHST- 2019/06/19 00:00 [received]
PHST- 2019/11/12 00:00 [accepted]
PHST- 2019/11/30 06:00 [entrez]
PHST- 2019/11/30 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1038/s41598-019-54390-w [pii]
AID - 54390 [pii]
AID - 10.1038/s41598-019-54390-w [doi]
PST - epublish
SO  - Sci Rep. 2019 Nov 28;9(1):17783. doi: 10.1038/s41598-019-54390-w.

PMID- 15804471
OWN - NLM
STAT- MEDLINE
DCOM- 20050601
LR  - 20131121
IS  - 1072-7515 (Print)
IS  - 1072-7515 (Linking)
VI  - 200
IP  - 4
DP  - 2005 Apr
TI  - Duration of increased bleeding tendency after cessation of aspirin therapy.
PG  - 564-73; quiz A59-61
AB  - BACKGROUND: Aspirin has a significant effect on hemostasis, so it is often 
      recommended that patients taking aspirin discontinue treatment before elective 
      surgery. While off aspirin, these patients may be at risk of thrombosis. The 
      optimum period of time that aspirin should be withheld is controversial. The aim 
      of this study was to establish the duration of the antihemostatic effect of 
      prolonged aspirin therapy. STUDY DESIGN: In a prospective study, 51 healthy 
      volunteers were randomly assigned into 3 groups, each receiving an identical 
      tablet for 14 days. One group received a placebo tablet; individuals in the other 
      two groups received either 75 mg or 300 mg of aspirin once a day. Template 
      bleeding times and specific platelet function testing (using the PFA-100; Dade 
      Behring) were carried out on subjects before therapy and again after its 
      completion until they returned to baseline. RESULTS: Thirty-eight volunteers 
      complied sufficiently with the protocol to provide useful results. All bleeding 
      times normalized within 96 hours and all platelet function tests within 144 hours 
      after stopping aspirin. There was no demonstrable hemostatic defect in any 
      volunteer persisting by or beyond the sixth day after treatment cessation. There 
      was no apparent difference in duration of effect between those taking either 75 
      mg or 300 mg of aspirin. CONCLUSIONS: This study uses sensitive measures of 
      platelet function to demonstrate the duration of increased bleeding tendency 
      after withdrawal of aspirin therapy. It supports discontinuation of aspirin 
      therapy 5 days before elective surgery (with the operation being performed on the 
      sixth day).
FAU - Cahill, Ronan A
AU  - Cahill RA
AD  - Department of Surgery, NUI (Cork), Cork University Hospital, Cork, Ireland.
FAU - McGreal, Gerard T
AU  - McGreal GT
FAU - Crowe, Basil H
AU  - Crowe BH
FAU - Ryan, Damien A
AU  - Ryan DA
FAU - Manning, Brian J
AU  - Manning BJ
FAU - Cahill, Mary R
AU  - Cahill MR
FAU - Redmond, H Paul
AU  - Redmond HP
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Am Coll Surg
JT  - Journal of the American College of Surgeons
JID - 9431305
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - *Bleeding Time
MH  - Double-Blind Method
MH  - Female
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Platelet Function Tests
MH  - Prospective Studies
EDAT- 2005/04/05 09:00
MHDA- 2005/06/02 09:00
CRDT- 2005/04/05 09:00
PHST- 2004/10/16 00:00 [received]
PHST- 2004/11/02 00:00 [revised]
PHST- 2004/11/02 00:00 [accepted]
PHST- 2005/04/05 09:00 [pubmed]
PHST- 2005/06/02 09:00 [medline]
PHST- 2005/04/05 09:00 [entrez]
AID - S1072-7515(04)01363-8 [pii]
AID - 10.1016/j.jamcollsurg.2004.11.002 [doi]
PST - ppublish
SO  - J Am Coll Surg. 2005 Apr;200(4):564-73; quiz A59-61. doi: 
      10.1016/j.jamcollsurg.2004.11.002.

PMID- 33725352
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1286
DP  - 2021
TI  - Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.
PG  - 145-161
LID - 10.1007/978-3-030-55035-6_11 [doi]
AB  - Aging is a biological process with effects at the molecular, cellular, tissue, 
      organ, system, and organismal levels and is characterized by decline in physical 
      function and higher risks of age-related diseases. The use of anti-aging drugs 
      for disease prevention has become a high priority for science and is a new 
      biomedicine trend. Geroprotectors are compounds which slow aging and increase 
      lifespan of the organism in question. The common painkiller aspirin, a member of 
      the non-steroidal anti-inflammatory drug (NSAID) family, is one of the potential 
      geroprotective agents. Aspirin is often used in treatment of mild to moderate 
      pain. It has anti-inflammatory and anti-pyretic properties and acts as an 
      inhibitor of cyclooxygenase which results in inhibition of prostaglandin. 
      Acetylsalicylic acid as an active compound of aspirin also inhibits platelet 
      aggregation and is used in the prevention of arterial and venous thrombosis. 
      Aspirin has shown life-extending effects in numerous model organisms. This 
      chapter reviews the evidence for clinical efficacy of aspirin including 
      cardiovascular disease prevention, anti-cancer effects, and improvement of 
      cognitive function. However, there are some limitations of these therapies, 
      including the risk of excessive bleeding. We have also summarized numerous 
      experimental and analytical data that support health and longevity benefits of 
      aspirin treatment by affecting pro-longevity pathways.
FAU - Lushchak, Oleh
AU  - Lushchak O
AD  - Department of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian 
      National University, Ivano-Frankivsk, Ukraine. oleh.lushchak@pnu.edu.ua.
FAU - Piskovatska, Veronika
AU  - Piskovatska V
AD  - Clinic for Heart Surgery, University clinic of Martin Luther University, Halle, 
      Germany.
FAU - Strilbytska, Olha
AU  - Strilbytska O
AD  - Department of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian 
      National University, Ivano-Frankivsk, Ukraine.
FAU - Kindrat, Iryna
AU  - Kindrat I
AD  - Medical University, Ivano-Frankivsk, Ukraine.
FAU - Stefanyshyn, Nadya
AU  - Stefanyshyn N
AD  - Department of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian 
      National University, Ivano-Frankivsk, Ukraine.
FAU - Koliada, Alexander
AU  - Koliada A
AD  - Laboratory of Epigenetics, D.F. Chebotarev Institute of Gerontology, NAMS, Kyiv, 
      Ukraine.
FAU - Bubalo, Volodymyr
AU  - Bubalo V
AD  - Laboratory of Experimental Toxicology and Mutagenesis L.I. Medved's Research 
      Center of Preventive Toxicology, Food and Chemical Safety, MHU, Kyiv, Ukraine.
FAU - Storey, Kenneth B
AU  - Storey KB
AD  - Department of Biology, Carleton University, Ottawa, Canada.
FAU - Vaiserman, Alexander
AU  - Vaiserman A
AD  - Laboratory of Epigenetics, D.F. Chebotarev Institute of Gerontology, NAMS, Kyiv, 
      Ukraine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents
MH  - *Anti-Inflammatory Agents, Non-Steroidal
MH  - *Aspirin
MH  - Cyclooxygenase 2
MH  - Platelet Aggregation
OTO - NOTNLM
OT  - Age-related diseases
OT  - Aging
OT  - Aspirin
OT  - Geroprotector
OT  - Geroscience
OT  - NSAID
EDAT- 2021/03/17 06:00
MHDA- 2021/03/19 06:00
CRDT- 2021/03/16 17:41
PHST- 2021/03/16 17:41 [entrez]
PHST- 2021/03/17 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - 10.1007/978-3-030-55035-6_11 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2021;1286:145-161. doi: 10.1007/978-3-030-55035-6_11.

PMID- 22088425
OWN - NLM
STAT- MEDLINE
DCOM- 20120604
LR  - 20221207
IS  - 1878-3562 (Electronic)
IS  - 1590-8658 (Linking)
VI  - 44
IP  - 3
DP  - 2012 Mar
TI  - Association of SLCO1B1 1b with peptic ulcer amongst Japanese patients taking 
      low-dose aspirin.
PG  - 201-5
LID - 10.1016/j.dld.2011.10.005 [doi]
AB  - BACKGROUND: In the recent case-control study, we showed an inverse association 
      between peptic ulcer and angiotensin type 1 receptor (AT1R) blockers (ARBs) or 
      HMG-Co A reductase inhibitors (statins). The aim was to evaluate whether the 
      genotypes of uptake and efflux transporters of ARBs and statins relate to the 
      presence of peptic ulcer and/or ulcer bleeding associated with aspirin use. 
      METHODS: Patients taking 100mg of enteric-coated aspirin for cardiovascular 
      diseases who also participated in endoscopic surveillance were studied. SLCO1B, 
      ABCC2, ABCG2, and MDR1 genotypes were determined by PCR or PCR-RFLP. RESULTS: 492 
      patients enrolled including 78 with peptic ulcer. The frequencies of the SLCO1B1 
      521TT genotype were significantly higher in the ulcer group (p=0.006) compared to 
      the controls. After adjustment for significant factors, the SLCO1B1 1b haplotype 
      was significantly associated with peptic ulcer (OR, 3.64; 95% CI, 1.81-7.29). 
      CONCLUSIONS: SLCO1B1 1b haplotype may identify patients at increased risk for 
      aspirin-induced peptic ulcer.
CI  - Copyright © 2011 Editrice Gastroenterologica Italiana S.r.l. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Shiotani, Akiko
AU  - Shiotani A
AD  - Department of Internal Medicine, Kawasaki Medical School, Okayama, Japan. 
      shiotani@med.kawasaki-m.ac.jp
FAU - Murao, Takahisa
AU  - Murao T
FAU - Sakakibara, Takashi
AU  - Sakakibara T
FAU - Tarumi, Ken-Ichi
AU  - Tarumi K
FAU - Manabe, Noriaki
AU  - Manabe N
FAU - Kamada, Tomoari
AU  - Kamada T
FAU - Kusunoki, Hiroaki
AU  - Kusunoki H
FAU - Haruma, Ken
AU  - Haruma K
LA  - eng
PT  - Journal Article
DEP - 20111115
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (ABCC2 protein, human)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Liver-Specific Organic Anion Transporter 1)
RN  - 0 (Multidrug Resistance-Associated Protein 2)
RN  - 0 (Organic Anion Transporters)
RN  - 0 (SLCO1B1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Asian People
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Female
MH  - Gene Frequency
MH  - Genotype
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects
MH  - Japan
MH  - Liver-Specific Organic Anion Transporter 1
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multidrug Resistance-Associated Protein 2
MH  - Organic Anion Transporters/*genetics
MH  - Peptic Ulcer/chemically induced/*genetics
MH  - Polymorphism, Single Nucleotide
EDAT- 2011/11/18 06:00
MHDA- 2012/06/05 06:00
CRDT- 2011/11/18 06:00
PHST- 2011/06/03 00:00 [received]
PHST- 2011/09/07 00:00 [revised]
PHST- 2011/10/07 00:00 [accepted]
PHST- 2011/11/18 06:00 [entrez]
PHST- 2011/11/18 06:00 [pubmed]
PHST- 2012/06/05 06:00 [medline]
AID - S1590-8658(11)00383-5 [pii]
AID - 10.1016/j.dld.2011.10.005 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2012 Mar;44(3):201-5. doi: 10.1016/j.dld.2011.10.005. Epub 2011 
      Nov 15.

PMID- 16685632
OWN - NLM
STAT- MEDLINE
DCOM- 20060612
LR  - 20181201
IS  - 0012-0472 (Print)
IS  - 0012-0472 (Linking)
VI  - 131
IP  - 19
DP  - 2006 May 12
TI  - [Dual antithrombotic therapy after implantation of coronary stents].
PG  - 1105-10
AB  - Dual antiplatelet-aggregation treatment with aspirin and clopidogrel after 
      coronary stent implantation is nowadays standard peri-interventional practice, 
      although its use is not yet licensed for this indication in many European 
      countries. Clopidogrel administration is initiated before PCI with a loading dose 
      of 300 mg when given at least 6 hours before PCI, otherwise 600 mg. The required 
      duration of combined (aspirin + clopidogrel) antiplatelet-aggregation treatment 
      after coronary stent implantation depends on the type of stent and the 
      pre-existing disease. After bare-metal stent implantation dual antiplatelet 
      medication is needed for at least 3-4 weeks, after drug-eluting stent 
      implantation 6 months, after coronary brachytherapy 12 months, and 9 months after 
      an acute coronary syndrome. These time intervals should also be respected before 
      any elective surgical intervention. Early operations, because postponement is 
      impossible, should be performed under antiplatelet-aggregation treatment after 
      assessment of bleeding risk in the individual case. Premature termination of this 
      treatment carries an increased risk of serious cardiovascular events, especially 
      stent thrombosis and myocardial infarction. Prolonged antiplatelet-aggregation 
      treatment is of benefit especially in patients with a high risk of serious 
      cardiovascular events. Patients with an indication for long-term anticoagulation 
      may require, during the period of highest risk of stent thrombosis after stent 
      implantation, administration of combined aspirin, clopidogrel and anticoagulants 
      with an INR target value in the lower therapeutic range. The increased risk of 
      bleeding must be weighed up against the potential benefit.
FAU - Schneider, H
AU  - Schneider H
AD  - Universität Rostock, Klinik und Poliklinik für Innere Medizin, Abteilung für 
      Kardiologie.
FAU - Weber, F
AU  - Weber F
FAU - Holzhausen, C
AU  - Holzhausen C
FAU - Körber, T
AU  - Körber T
FAU - Ince, H
AU  - Ince H
FAU - Rehders, T
AU  - Rehders T
FAU - Nienaber, C A
AU  - Nienaber CA
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Duale antiaggregatorische Therapie nach Implantation von Koronarstents.
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Coronary Stenosis/*drug therapy/*prevention & control/surgery
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - *Stents
MH  - Thrombosis/*prevention & control
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
RF  - 31
EDAT- 2006/05/11 09:00
MHDA- 2006/06/13 09:00
CRDT- 2006/05/11 09:00
PHST- 2006/05/11 09:00 [pubmed]
PHST- 2006/06/13 09:00 [medline]
PHST- 2006/05/11 09:00 [entrez]
AID - 10.1055/s-2006-941730 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2006 May 12;131(19):1105-10. doi: 10.1055/s-2006-941730.

PMID- 12100305
OWN - NLM
STAT- MEDLINE
DCOM- 20020919
LR  - 20190822
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 57
IP  - 7
DP  - 2002 Jul
TI  - Nasal provocation test (NPT) with aspirin: a sensitive and safe method to 
      diagnose aspirin-induced asthma (AIA).
PG  - 632-5
AB  - BACKGROUND: We have aimed to determine the sensitivity and specificity of a 
      simpler technique with less risk than oral provocation to diagnose 
      aspirin-induced asthma (AIA). METHODS: We studied a group of 20 AIA patients 
      compared to a control group with 40 aspirin-tolerant patients (confirmed by oral 
      provocation test): 10 asthmatic patients and 30 healthy subjects. A nasal 
      provocation test (NPT) with lysine acetylsalicylic acid (L-ASA) was carried out. 
      Nasal and pulmonary functions were monitored with anterior active rhinomanometry 
      (AAR) and spirometry. An L-ASA solution (900 mg/ml L-ASA, equivalent to 500 mg/ml 
      acetylsalicylic acid) was diluted with saline solution. We administered four 
      increasing doses: 5, 25, 50 and 100 mg/ml acetylsalicylic acid (ASA) with saline 
      solution control. Nasal and pulmonary functions were monitored with 
      rhinomanometry and spirometry. The patients were controlled for nasal inspiratory 
      peak flow and expiratory peak flow. RESULTS: The results showed high sensitivity 
      and specificity: 80% and 92.5%, respectively, with an 84.2% positive predictive 
      value and an 89.2% negative predictive value. The patients had no bronchial or 
      systemic symptoms, and no decreases over 20% were recorded in the FEV1. 
      CONCLUSION: NPT has a high sensitivity and specificity in the diagnosis of AIA. 
      An oral provocation should be performed to confirm the result whenever the 
      clinical situation of the patient permits it.
FAU - Alonso-Llamazares, A
AU  - Alonso-Llamazares A
AD  - Allergy Department, Hospital Clínico San Carlos, Madrid, Spain.
FAU - Martinez-Cócera, C
AU  - Martinez-Cócera C
FAU - Domínguez-Ortega, J
AU  - Domínguez-Ortega J
FAU - Robledo-Echarren, T
AU  - Robledo-Echarren T
FAU - Cimarra-Alvarez, M
AU  - Cimarra-Alvarez M
FAU - Mesa del Castillo, M
AU  - Mesa del Castillo M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Allergy. 2002 Jul;57(7):562-5. PMID: 12100294
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/immunology
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/*chemically induced/*diagnosis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Provocation Tests/adverse effects/*methods
MH  - Predictive Value of Tests
MH  - Rhinomanometry
MH  - Sensitivity and Specificity
MH  - Spirometry
EDAT- 2002/07/09 10:00
MHDA- 2002/09/20 10:01
CRDT- 2002/07/09 10:00
PHST- 2002/07/09 10:00 [pubmed]
PHST- 2002/09/20 10:01 [medline]
PHST- 2002/07/09 10:00 [entrez]
AID - 1s3447 [pii]
AID - 10.1034/j.1398-9995.2002.t01-1-13447.x [doi]
PST - ppublish
SO  - Allergy. 2002 Jul;57(7):632-5. doi: 10.1034/j.1398-9995.2002.t01-1-13447.x.

PMID- 3257680
OWN - NLM
STAT- MEDLINE
DCOM- 19880308
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 148
IP  - 2
DP  - 1988 Feb
TI  - Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and 
      other nonnarcotic analgesics.
PG  - 281-5
AB  - In a hospital-based case-control study, the risk of a first episode of major 
      upper gastrointestinal tract bleeding in subjects now known to be predisposed was 
      assessed in relation to the use of nonnarcotic analgesics. For aspirin use within 
      the week before the onset of symptoms, the rate ratio estimates, adjusted for 
      potential confounding, were 15 (95% confidence interval, 6.4 to 34) for regular 
      use (at least four days a week) and 5.6 (confidence interval, 2.7 to 12) for 
      occasional use. For aspirin use discontinued at least one week earlier, the 
      estimate was 1.6 (confidence interval, 0.6 to 4.2). There was no evidence that 
      acetaminophen use increased the risk. For the regular use of other analgesics in 
      the week before onset, the adjusted rate ratio estimate was 9.1 (confidence 
      interval, 2.7 to 31); there were insufficient data to evaluate occasional use. 
      The findings suggest that the risk of bleeding is increased substantially by 
      aspirin, even when used occasionally. With the exception of acetaminophen, other 
      nonnarcotic analgesics may also increase the risk, but they remain to be 
      evaluated individually.
FAU - Levy, M
AU  - Levy M
AD  - Department of Medicine A, Hadassah University Hospital, Jerusalem.
FAU - Miller, D R
AU  - Miller DR
FAU - Kaufman, D W
AU  - Kaufman DW
FAU - Siskind, V
AU  - Siskind V
FAU - Schwingl, P
AU  - Schwingl P
FAU - Rosenberg, L
AU  - Rosenberg L
FAU - Strom, B
AU  - Strom B
FAU - Shapiro, S
AU  - Shapiro S
LA  - eng
GR  - 223-76-3016/PHS HHS/United States
GR  - 223-80-3001/PHS HHS/United States
GR  - 226-82-0007/PHS HHS/United States
GR  - etc.
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Analgesics)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/adverse effects
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Analgesics/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Regression Analysis
MH  - Retrospective Studies
MH  - Risk Factors
EDAT- 1988/02/01 00:00
MHDA- 1988/02/01 00:01
CRDT- 1988/02/01 00:00
PHST- 1988/02/01 00:00 [pubmed]
PHST- 1988/02/01 00:01 [medline]
PHST- 1988/02/01 00:00 [entrez]
AID - 10.1001/archinte.148.2.281 [doi]
PST - ppublish
SO  - Arch Intern Med. 1988 Feb;148(2):281-5. doi: 10.1001/archinte.148.2.281.

PMID- 33914148
OWN - NLM
STAT- MEDLINE
DCOM- 20211220
LR  - 20211220
IS  - 1436-5073 (Electronic)
IS  - 0026-3672 (Linking)
VI  - 188
IP  - 5
DP  - 2021 Apr 29
TI  - Core-shell MOF@COFs used as an adsorbent and matrix for the detection of 
      nonsteroidal anti-inflammatory drugs by MALDI-TOF MS.
PG  - 179
LID - 10.1007/s00604-021-04832-y [doi]
AB  - A core-shell material (UiO@TapbTp) has been developed as an adsorbent and matrix 
      to detect nonsteroidal anti-inflammatory drugs (NSAIDS) by matrix laser 
      desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in complex 
      samples. The hybrid material is prepared by growing covalent organic framework 
      (COF, TapbTp) layers in situ on an amino-modified metal-organic framework (MOF, 
      UiO-66-NH(2)). The combination of the MOF and COF overcomes their individual 
      shortcomings and integrates both of their advantages. Compared with the bare COF 
      and MOF, the core-shell composite exhibits improved enrichment ability and matrix 
      performance. With the help of pre-enrichment under optimized conditions, the 
      limits of detection (LODs) for ketoprofen, naproxen, and aspirin are reduced by 
      nearly 1000 times, with values of 0.001 mg L(-1), 0.010 mg L(-1), and 
      0.001 mg L(-1), respectively, and the relative standard deviations (RSDs) are all 
      below 12.35%. The good recoveries (84.8-118%) in (spiked) saliva and 
      environmental water sample further verify the applicability of the method in 
      complex samples.
FAU - Zheng, Ruijuan
AU  - Zheng R
AD  - Research Center for Analytical Sciences, State Key Laboratory of Medicinal 
      Chemical Biology, and Tianjin Key Laboratory of Biosensing and Molecular 
      Recognition, College of Chemistry, Nankai University, 94 Weijin Road, Tianjin, 
      300071, China.
FAU - Yang, Yingchen
AU  - Yang Y
AD  - Research Center for Analytical Sciences, State Key Laboratory of Medicinal 
      Chemical Biology, and Tianjin Key Laboratory of Biosensing and Molecular 
      Recognition, College of Chemistry, Nankai University, 94 Weijin Road, Tianjin, 
      300071, China.
FAU - Yang, Chang
AU  - Yang C
AD  - Research Center for Analytical Sciences, State Key Laboratory of Medicinal 
      Chemical Biology, and Tianjin Key Laboratory of Biosensing and Molecular 
      Recognition, College of Chemistry, Nankai University, 94 Weijin Road, Tianjin, 
      300071, China.
FAU - Xia, Yan
AU  - Xia Y
AUID- ORCID: 0000-0002-8390-8414
AD  - Research Center for Analytical Sciences, State Key Laboratory of Medicinal 
      Chemical Biology, and Tianjin Key Laboratory of Biosensing and Molecular 
      Recognition, College of Chemistry, Nankai University, 94 Weijin Road, Tianjin, 
      300071, China. nkxiayan@nankai.edu.cn.
AD  - Central Laboratory, Nankai University, Tianjin, 300071, China. 
      nkxiayan@nankai.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210429
PL  - Austria
TA  - Mikrochim Acta
JT  - Mikrochimica acta
JID - 7808782
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drinking Water)
RN  - 0 (Metal-Organic Frameworks)
RN  - 0 (Water Pollutants, Chemical)
RN  - 57Y76R9ATQ (Naproxen)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis/chemistry
MH  - Aspirin/*analysis/chemistry
MH  - Drinking Water/analysis
MH  - Ketoprofen/*analysis/chemistry
MH  - Lakes/analysis
MH  - Limit of Detection
MH  - Metal-Organic Frameworks/*chemistry
MH  - Naproxen/*analysis/chemistry
MH  - Saliva/chemistry
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods
MH  - Water Pollutants, Chemical/analysis/chemistry
OTO - NOTNLM
OT  - Core-shell composite
OT  - Drug pollutants
OT  - Enrichment
OT  - Nonsteroidal anti-inflammatory drugs
EDAT- 2021/04/30 06:00
MHDA- 2021/12/21 06:00
CRDT- 2021/04/29 12:29
PHST- 2021/02/09 00:00 [received]
PHST- 2021/04/19 00:00 [accepted]
PHST- 2021/04/29 12:29 [entrez]
PHST- 2021/04/30 06:00 [pubmed]
PHST- 2021/12/21 06:00 [medline]
AID - 10.1007/s00604-021-04832-y [pii]
AID - 10.1007/s00604-021-04832-y [doi]
PST - epublish
SO  - Mikrochim Acta. 2021 Apr 29;188(5):179. doi: 10.1007/s00604-021-04832-y.

PMID- 15523870
OWN - NLM
STAT- MEDLINE
DCOM- 20041222
LR  - 20131121
IS  - 1115-2613 (Print)
IS  - 1115-2613 (Linking)
VI  - 13
IP  - 4
DP  - 2004 Oct-Dec
TI  - An assessment of aspirin use in a Nigerian diabetes outpatient clinic.
PG  - 405-6
AB  - BACKGROUND: We have conducted this study to assess the use of aspirin among adult 
      diabetic outpatients in our hospital. METHODS: The records of all patients 
      attending the weekly Diabetes clinic of the Wesley Guild Hospital (WGH), Ilesa, 
      Osun state, Nigeria over one month were reviewed and aspirin use evaluated in 
      light of the American Diabetes Association position statement (2003) on aspirin 
      therapy in diabetes. RESULTS: Eighty-two patients in all were studied. Fourty 
      three (52.4%) were males, 39 (47.6%) were females. Their mean age was 59.1 +/- 
      10.7 yrs (range 31-81). All were type 2 and had been diabetic for a mean of 5.2 
      +/- 5.7 yrs (1-26yrs). Concurrent hypertension, another major risk factor for 
      cardiovascular disease was found in 71.9% and 12.2% were obese. Aspirin use was 
      contraindicated in 1.2%. All other patients had at least one indication for the 
      use of aspirin based on the ADA criteria but only 39% were taking aspirin 
      regularly. CONCLUSION: The results of this present study suggest that aspirin is 
      still grossly under utilised in clinic patients with diabetes despite proven 
      benefits. There is need to stimulate awareness amongst health care providers.
FAU - Kolawole, B A
AU  - Kolawole BA
AD  - Department of Medicine, Obafemi Awolowo University Teaching Hospital, Ile-Ife, 
      Nigeria.
FAU - Adebayo, R A
AU  - Adebayo RA
FAU - Aloba, O O
AU  - Aloba OO
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - Niger J Med
JT  - Nigerian journal of medicine : journal of the National Association of Resident 
      Doctors of Nigeria
JID - 100888321
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Diabetic Angiopathies/*drug therapy
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Nigeria
MH  - Outpatient Clinics, Hospital
EDAT- 2004/11/05 09:00
MHDA- 2004/12/23 09:00
CRDT- 2004/11/05 09:00
PHST- 2004/11/05 09:00 [pubmed]
PHST- 2004/12/23 09:00 [medline]
PHST- 2004/11/05 09:00 [entrez]
PST - ppublish
SO  - Niger J Med. 2004 Oct-Dec;13(4):405-6.

PMID- 22366248
OWN - NLM
STAT- MEDLINE
DCOM- 20120508
LR  - 20131121
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 419
IP  - 3
DP  - 2012 Mar 16
TI  - NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing 
      hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a 
      xenograft mouse model.
PG  - 523-8
LID - 10.1016/j.bbrc.2012.02.051 [doi]
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) are prototypical anti-cancer 
      agents. However, their long-term use is associated with adverse gastrointestinal 
      effects. Recognition that endogenous gaseous mediators, nitric oxide (NO) and 
      hydrogen sulfide (H(2)S) can increase mucosal defense mechanisms has led to the 
      development of NO- and H(2)S-releasing NSAIDs with increased safety profiles. 
      Here we report on a new hybrid, NOSH-aspirin, which is an NO- and H(2)S-releasing 
      agent. NOSH-aspirin inhibited HT-29 colon cancer growth with IC(50)s of 45.5 ± 
      2.5, 19.7 ± 3.3, and 7.7 ± 2.2 nM at 24, 48, and 72 h, respectively. This is the 
      first NSAID based agent with such high degree of potency. NOSH-aspirin inhibited 
      cell proliferation, induced apoptosis, and caused G(0)/G(1) cell cycle block. 
      Reconstitution and structure-activity studies representing a fairly close 
      approximation to the intact molecule showed that NOSH-aspirin was 9000-fold more 
      potent than the sum of its parts towards growth inhibition. NOSH-aspirin 
      inhibited ovine COX-1 more than ovine COX-2. NOSH-ASA treatment of mice bearing a 
      human colon cancer xenograft caused a reduction in volume of 85%. Taken together, 
      these results demonstrate that NOSH-aspirin has strong anti-cancer potential and 
      merits further evaluation.
CI  - Copyright Â© 2012 Elsevier Inc. All rights reserved.
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
AD  - Department of Physiology, Pharmacology, and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, NY 10031, USA.
FAU - Kodela, Ravinder
AU  - Kodela R
FAU - Olson, Kenneth R
AU  - Olson KR
FAU - Kashfi, Khosrow
AU  - Kashfi K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20120216
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Disulfides)
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Cell Cycle/drug effects
MH  - Cell Proliferation/drug effects
MH  - Colonic Neoplasms/enzymology/*metabolism
MH  - Cyclooxygenase Inhibitors/chemistry/*pharmacology
MH  - Disulfides/chemistry/*pharmacology
MH  - HT29 Cells
MH  - Humans
MH  - Hydrogen Sulfide/*metabolism
MH  - Mice
MH  - Mice, Nude
MH  - Nitrates/chemistry/*pharmacology
MH  - Nitric Oxide/*metabolism
MH  - Nitric Oxide Donors/chemistry/*pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Rats
MH  - Xenograft Model Antitumor Assays
EDAT- 2012/03/01 06:00
MHDA- 2012/05/09 06:00
CRDT- 2012/02/28 06:00
PHST- 2012/01/25 00:00 [received]
PHST- 2012/02/08 00:00 [accepted]
PHST- 2012/02/28 06:00 [entrez]
PHST- 2012/03/01 06:00 [pubmed]
PHST- 2012/05/09 06:00 [medline]
AID - S0006-291X(12)00284-7 [pii]
AID - 10.1016/j.bbrc.2012.02.051 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2012 Mar 16;419(3):523-8. doi: 
      10.1016/j.bbrc.2012.02.051. Epub 2012 Feb 16.

PMID- 21448174
OWN - NLM
STAT- MEDLINE
DCOM- 20110526
LR  - 20220129
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 104
IP  - 7
DP  - 2011 Mar 29
TI  - Current misconception 3: that subgroup-specific trial mortality results often 
      provide a good basis for individualising patient care.
PG  - 1057-8
LID - 10.1038/bjc.2011.79 [doi]
AB  - Misconceptions and ill-founded theories can arise in all areas of science. 
      However, the apparent accessibility of many epidemiology findings and popular 
      interest in the subject can lead to additional misunderstandings. The article 
      below is the third in an occasional series of short editorials highlighting some 
      current misinterpretations of epidemiological findings. Invited authors will be 
      given wide scope in judging the prevalence of the misconception under discussion. 
      We hope that this series will prove instructive to cancer researchers in other 
      disciplines as well as to students of epidemiology. Adrian L Harris and Leo 
      Kinlen.
FAU - Peto, R
AU  - Peto R
LA  - eng
GR  - MC_U137686857/MRC_/Medical Research Council/United Kingdom
PT  - Editorial
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic/*mortality
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Precision Medicine
PMC - PMC3068511
EDAT- 2011/03/31 06:00
MHDA- 2011/05/27 06:00
CRDT- 2011/03/31 06:00
PHST- 2011/03/31 06:00 [entrez]
PHST- 2011/03/31 06:00 [pubmed]
PHST- 2011/05/27 06:00 [medline]
AID - bjc201179 [pii]
AID - 10.1038/bjc.2011.79 [doi]
PST - ppublish
SO  - Br J Cancer. 2011 Mar 29;104(7):1057-8. doi: 10.1038/bjc.2011.79.

PMID- 15327322
OWN - NLM
STAT- MEDLINE
DCOM- 20041104
LR  - 20211203
IS  - 0002-7863 (Print)
IS  - 0002-7863 (Linking)
VI  - 126
IP  - 34
DP  - 2004 Sep 1
TI  - Supramolecular assemblies based on copolymers of PEG600 and functionalized 
      aromatic diesters for drug delivery applications.
PG  - 10640-4
AB  - A chemoenzymatic approach has been developed to synthesize poly(ethylene 
      glycol)-based amphiphilic copolymers under mild reaction conditions that 
      self-assemble in aqueous media to form polymeric nanomicelles in the range of 
      20-50 nm. The supramolecular organization of polymeric nanomicelles was studied 
      by 1H NMR longitudinal relaxation time (T1) and light scattering techniques 
      (static and dynamic). Interestingly, the enzyme novozyme-435 plays an important 
      role in controlling the polymerization and distribution of polymer chains, which 
      is critical for the formation of nanomicelles with unimodal distributions. The 
      methodology developed is highly flexible as it allows the introduction of various 
      functionalities in the polymeric nanomicelles. These self-organized nanomicelles 
      are highly efficient drug delivery vehicles for hydrophobic and partially 
      hydrophilic drugs, both transdermally and orally, as they have the ability to 
      encapsulate guest molecules during self-organization. In vivo studies by 
      encapsulating anti-inflammatory agents (aspirin and naproxen) in these polymeric 
      nanomicelles and by applying topically resulted in significant reduction in 
      inflammation. The % reduction in inflammation using polymeric nanomicelles 
      containing aspirin and naproxen was 62 and 64%, respectively.
CI  - Copyright 2004 American Chemical Society
FAU - Kumar, Rajesh
AU  - Kumar R
AD  - Institute for Nano-Science and Engineering Technology and Center for Advanced 
      Materials, Department of Chemistry, University of Massachusetts, Lowell, 
      Massachusetts 01854, USA.
FAU - Chen, Ming-Hsiung
AU  - Chen MH
FAU - Parmar, Virinder S
AU  - Parmar VS
FAU - Samuelson, Lynne A
AU  - Samuelson LA
FAU - Kumar, Jayant
AU  - Kumar J
FAU - Nicolosi, Robert
AU  - Nicolosi R
FAU - Yoganathan, Subbiah
AU  - Yoganathan S
FAU - Watterson, Arthur C
AU  - Watterson AC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Chem Soc
JT  - Journal of the American Chemical Society
JID - 7503056
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Enzymes, Immobilized)
RN  - 0 (Fungal Proteins)
RN  - 0 (Micelles)
RN  - 0 (Polyesters)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - EC 3.1.1.- (Novozyme 435)
RN  - EC 3.1.1.3 (Lipase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/chemistry
MH  - Aspirin/administration & dosage/*chemistry
MH  - Chemistry, Pharmaceutical
MH  - Drug Delivery Systems/*methods
MH  - Enzymes, Immobilized
MH  - Fungal Proteins
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Inflammation/drug therapy
MH  - Lipase/chemistry
MH  - Mice
MH  - Micelles
MH  - Nanotechnology
MH  - Polyesters/*chemical synthesis/chemistry
MH  - Polyethylene Glycols/*chemical synthesis/chemistry
MH  - Spectrophotometry, Ultraviolet
EDAT- 2004/08/26 05:00
MHDA- 2004/11/05 09:00
CRDT- 2004/08/26 05:00
PHST- 2004/08/26 05:00 [pubmed]
PHST- 2004/11/05 09:00 [medline]
PHST- 2004/08/26 05:00 [entrez]
AID - 10.1021/ja039651w [doi]
PST - ppublish
SO  - J Am Chem Soc. 2004 Sep 1;126(34):10640-4. doi: 10.1021/ja039651w.

PMID- 1344081
OWN - NLM
STAT- MEDLINE
DCOM- 19940426
LR  - 20131121
IS  - 1058-2819 (Print)
IS  - 1058-2819 (Linking)
VI  - 1
IP  - 1
DP  - 1992 Jan-Feb
TI  - Use of antiplatelet medication for prevention of myocardial infarction and 
      stroke.
PG  - 2-3
AB  - Patients who suffer a heart attack can reduce the risk of another attack by 20% 
      by taking 325 mg aspirin daily or every other day. The risk of stroke can be 
      reduced by 50% in patients who experience atrial fibrillation or transient 
      ischemic attacks. Although the benefit of aspirin use in women is controversial, 
      data that suggest that women benefit as well as men are emerging. Antiplatelet 
      drugs should be used only as adjunctive therapy and should not divert one's 
      attention from the more important task of reducing major risk factors, such as 
      smoking, hypertension.
FAU - Rakel, R E
AU  - Rakel RE
AD  - Department of Family Medicine, Baylor College of Medicine, Houston, Texas.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Heart Dis Stroke
JT  - Heart disease and stroke : a journal for primary care physicians
JID - 9210156
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/therapeutic use
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Heart Dis Stroke. 1992 Jan-Feb;1(1):2-3.

PMID- 12197802
OWN - NLM
STAT- MEDLINE
DCOM- 20021009
LR  - 20220316
IS  - 1072-4710 (Print)
IS  - 1072-4710 (Linking)
VI  - 156
IP  - 9
DP  - 2002 Sep
TI  - The effectiveness of child-resistant packaging for aspirin.
PG  - 929-33
AB  - OBJECTIVE: To evaluate the effectiveness of child-resistant packaging in reducing 
      the mortality rate from the unintentional ingestion of aspirin for children 
      younger than 5 years. DESIGN: Estimates of the annual aspirin-related mortality 
      rate for children younger than 5 years in the United States were developed for 
      the 1958-1990 study period. A multivariate negative binomial regression model was 
      then used to estimate the independent effect of the packaging requirements on the 
      child mortality rate during the postintervention period. The analysis controlled 
      for changes in the per capita use of aspirin, long-term safety trends, and other 
      extraneous and potentially confounding factors that may have affected the 
      aspirin-related child mortality rate. MAIN OUTCOME MEASURE: Estimated percentage 
      reduction in the child mortality rate associated with the use of child-resistant 
      packaging. RESULTS: After controlling for covariates, the use of child-resistant 
      packaging was associated with a 34% reduction in the aspirin-related child 
      mortality rate. This mortality rate reduction equates to the prevention of about 
      90 child deaths during the 1973-1990 postregulatory study period. CONCLUSIONS: 
      Child-resistant packaging has been effective in reducing aspirin-related child 
      poisonings. However, because its effectiveness is only partial, further poison 
      prevention strategies should be developed and instituted.
FAU - Rodgers, Gregory B
AU  - Rodgers GB
AD  - Directorate for Economic Analysis, US Consumer Product Safety Commission, 
      Washington, DC 20207, USA. grodgers@cpsc.gov
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Arch Pediatr Adolesc Med
JT  - Archives of pediatrics & adolescent medicine
JID - 9422751
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*poisoning
MH  - Child, Preschool
MH  - *Drug Packaging
MH  - Humans
MH  - Infant
MH  - Multivariate Analysis
MH  - Poisoning/mortality/prevention & control
MH  - *Protective Devices
MH  - Regression Analysis
MH  - United States
EDAT- 2002/08/29 10:00
MHDA- 2002/10/10 04:00
CRDT- 2002/08/29 10:00
PHST- 2002/08/29 10:00 [pubmed]
PHST- 2002/10/10 04:00 [medline]
PHST- 2002/08/29 10:00 [entrez]
AID - poa10352 [pii]
AID - 10.1001/archpedi.156.9.929 [doi]
PST - ppublish
SO  - Arch Pediatr Adolesc Med. 2002 Sep;156(9):929-33. doi: 
      10.1001/archpedi.156.9.929.

PMID- 31881040
OWN - NLM
STAT- MEDLINE
DCOM- 20200401
LR  - 20200401
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 12
DP  - 2019
TI  - Optimising medication data collection in a large-scale clinical trial.
PG  - e0226868
LID - 10.1371/journal.pone.0226868 [doi]
LID - e0226868
AB  - OBJECTIVE: Pharmaceuticals play an important role in clinical care. However, in 
      community-based research, medication data are commonly collected as unstructured 
      free-text, which is prohibitively expensive to code for large-scale studies. The 
      ASPirin in Reducing Events in the Elderly (ASPREE) study developed a two-pronged 
      framework to collect structured medication data for 19,114 individuals. ASPREE 
      provides an opportunity to determine whether medication data can be 
      cost-effectively collected and coded, en masse from the community using this 
      framework. METHODS: The ASPREE framework of type-to-search box with automated 
      coding and linked free text entry was compared to traditional method of free-text 
      only collection and post hoc coding. Reported medications were classified 
      according to their method of collection and analysed by Anatomical Therapeutic 
      Chemical (ATC) group. Relative cost of collecting medications was determined by 
      calculating the time required for database set up and medication coding. RESULTS: 
      Overall, 122,910 participant structured medication reports were entered using the 
      type-to-search box and 5,983 were entered as free-text. Free-text data 
      contributed 211 unique medications not present in the type-to-search box. 
      Spelling errors and unnecessary provision of additional information were among 
      the top reasons why medications were reported as free-text. The cost per 
      medication using the ASPREE method was approximately USD $0.03 compared with USD 
      $0.20 per medication for the traditional method. CONCLUSION: Implementation of 
      this two-pronged framework is a cost-effective alternative to free-text only data 
      collection in community-based research. Higher initial set-up costs of this 
      combined method are justified by long term cost effectiveness and the scientific 
      potential for analysis and discovery gained through collection of detailed, 
      structured medication data.
FAU - Lockery, Jessica E
AU  - Lockery JE
AUID- ORCID: 0000-0001-6664-1239
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Rigby, Jason
AU  - Rigby J
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Collyer, Taya A
AU  - Collyer TA
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Stewart, Ashley C
AU  - Stewart AC
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
AD  - School of Public Health, Curtin University, Perth, Western Australia, Australia.
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - Department of Pharmacy Practice and Science, College of Pharmacy and Department 
      of Family Medicine, Carver College of Medicine, The University of Iowa, Iowa 
      City, Iowa, United States of America.
CN  - ASPREE Investigator Group
LA  - eng
SI  - ISRCTN/ISRCTN83772183
SI  - ClinicalTrials.gov/NCT01038583
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U19 AG062682/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20191227
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pharmaceutical Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Data Collection/economics/*methods
MH  - Databases, Factual/economics
MH  - Drug Therapy
MH  - Humans
MH  - Pharmaceutical Preparations/administration & dosage
MH  - Pharmaceutical Research/economics/*methods
PMC - PMC6934269
COIS- The authors have declared that no competing interests exist.
EDAT- 2019/12/28 06:00
MHDA- 2020/04/02 06:00
CRDT- 2019/12/28 06:00
PHST- 2019/09/13 00:00 [received]
PHST- 2019/12/08 00:00 [accepted]
PHST- 2019/12/28 06:00 [entrez]
PHST- 2019/12/28 06:00 [pubmed]
PHST- 2020/04/02 06:00 [medline]
AID - PONE-D-19-25763 [pii]
AID - 10.1371/journal.pone.0226868 [doi]
PST - epublish
SO  - PLoS One. 2019 Dec 27;14(12):e0226868. doi: 10.1371/journal.pone.0226868. 
      eCollection 2019.

PMID- 32921373
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 2211-7466 (Electronic)
IS  - 2211-7458 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Oct
TI  - The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The 
      Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary 
      Intervention Clinical Trial Experience.
PG  - 489-498
LID - S2211-7458(20)30044-4 [pii]
LID - 10.1016/j.iccl.2020.06.003 [doi]
AB  - Traditionally, aspirin has played a significant role in both primary and 
      secondary prevention of cardiovascular disease. However, emerging antithrombotic 
      regimens with better efficacy and safety have challenged the foundation of 
      aspirin. Aspirin-free strategies consisting of P2Y12 inhibitor monotherapy 
      following percutaneous coronary intervention (PCI) have now been tested in 
      several large randomized controlled trials. In this article, we provide a 
      contemporary overview of these data and suggest an algorithm to inform clinical 
      decision with respect to antiplatelet pharmacotherapy after PCI.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Asad, Zain Ul Abideen
AU  - Asad ZUA
AD  - Cardiovascular Disease Section, Department of Medicine, University of Oklahoma 
      Health Sciences Center, Andrews Academic Tower, Suite 5400, 800 Stanton L. Young 
      Boulevard, Oklahoma City, OK 73104, USA.
FAU - Baber, Usman
AU  - Baber U
AD  - Cardiovascular Disease Section, Department of Medicine, University of Oklahoma 
      Health Sciences Center, Andrews Academic Tower, Suite 5400, 800 Stanton L. Young 
      Boulevard, Oklahoma City, OK 73104, USA. Electronic address: 
      Usman-baber@ouhsc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Interv Cardiol Clin
JT  - Interventional cardiology clinics
JID - 101615153
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Artery Disease/*therapy
MH  - Drug Therapy, Combination
MH  - Hemorrhage/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Secondary Prevention/*methods
MH  - Ticagrelor/*therapeutic use
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Aspirin
OT  - P2Y(12) inhibitors
OT  - Percutaneous coronary intervention
OT  - Stable ischemic heart disease
COIS- Disclosure Z.U.A. Asad has no financial disclosures. U. Baber discloses honoraria 
      from Astra Zeneca, Boston Scientific, and Amgen.
EDAT- 2020/09/15 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/14 05:33
PHST- 2020/09/14 05:33 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - S2211-7458(20)30044-4 [pii]
AID - 10.1016/j.iccl.2020.06.003 [doi]
PST - ppublish
SO  - Interv Cardiol Clin. 2020 Oct;9(4):489-498. doi: 10.1016/j.iccl.2020.06.003.

PMID- 8217999
OWN - NLM
STAT- MEDLINE
DCOM- 19931222
LR  - 20190719
IS  - 0306-5456 (Print)
IS  - 0306-5456 (Linking)
VI  - 100
IP  - 9
DP  - 1993 Sep
TI  - Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and 
      prostacyclin-thromboxane balance in mother and newborn.
PG  - 809-15
AB  - OBJECTIVE: To study the effect of daily treatment with 50 mg of aspirin (ASA) on 
      the hypertensive pregnancy complications and on the production prostacyclin 
      (PGI2) and thromboxane A2 (TxA2) in high risk pregnant women and their infants. 
      DESIGN: Placebo controlled prospective study. SETTING: Departments of Obstetrics 
      and Gynaecology, University of Helsinki, University of Oulu and Central Hospital 
      of Middle Finland, Finland. SUBJECTS: Two hundred and eight pregnant women with 
      pre-existing hypertension or a history of severe preeclampsia in their previous 
      pregnancy. Prostanoids were studied in a subgroup of 18 women. INTERVENTIONS: The 
      women were randomised to receive ASA (50 mg/day, n = 103) or placebo (n = 105) 
      from the mean of 15 weeks gestational age to delivery. The exacerbation of 
      pre-existing hypertension or the appearance of hypertension in previously 
      normotensive women, the appearance of proteinuria and fetal growth were the main 
      end points, but some other clinical characteristics were also recorded. Urinary 
      excretion of PGI2 and TxA2 metabolites by mothers and infants and their 
      production in umbilical arteries in vitro were also studied. RESULTS: Two women 
      (one in both groups) had miscarriages, and one pregnancy was terminated for fetal 
      anencephaly (ASA group). In addition, seven women discontinued the treatment due 
      to urticaria (two women in ASA group), increased activity of aspartate amino 
      transferase in serum (one woman in both groups), or increased bleeding time (one 
      woman in ASA group, two women in placebo group), and one woman in the placebo 
      group was lost from follow-up. Thus the end points could be assessed in 97 women 
      taking ASA and 100 women taking placebo. ASA did not diminish the rate of the 
      rise of blood pressure without (12 vs 14, respectively) or with proteinuria (9 vs 
      11), but fetal haemodynamic disturbances as assessed by Doppler equipment (1/44 
      vs 6/45 women studied, P = 0.05) and need for treatment in neonatal intensive 
      care unit (10 vs 21, P = 0.04) were more rare in ASA group. ASA tended to 
      increase the birthweight of the newborn (3348 +/- 707 g vs 3170 +/- 665 g, mean 
      +/- SD, P = 0.07), but two perinatal deaths occurred in ASA group. ASA prolonged 
      the bleeding time of the mother (435 s, 210-998 s (geometric mean, range) vs 349 
      s, 210-690 s, P = 0.02), but caused no extra blood loss during delivery, nor 
      affected neonatal hemostasis. In a subgroup of mothers (ASA, n = 10; placebo, n = 
      8), ASA inhibited more than 90% of platelet TxA2-production, and caused a 65 to 
      80% decrease in the urinary excretion of TxA2 metabolites, but no decrease in the 
      urinary excretion of PGI2 metabolites. CONCLUSIONS: ASA did not prevent the rise 
      of maternal hypertension, but improved fetal haemodynamic performance and reduced 
      the need of intensive neonatal care. It inhibited strongly maternal thromboxane 
      A2 but not PGI2 production and thus shifted the balance between PGI2/TxA2 to the 
      dominance of the vasodilatory, anti-aggregatory side.
FAU - Viinikka, L
AU  - Viinikka L
AD  - Children's Hospital, University of Helsinki, Department of Obstetrics and 
      Gynaecology, Finland.
FAU - Hartikainen-Sorri, A L
AU  - Hartikainen-Sorri AL
FAU - Lumme, R
AU  - Lumme R
FAU - Hiilesmaa, V
AU  - Hiilesmaa V
FAU - Ylikorkala, O
AU  - Ylikorkala O
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Obstet Gynaecol
JT  - British journal of obstetrics and gynaecology
JID - 7503752
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/metabolism
MH  - Drug Administration Schedule
MH  - Epoprostenol/*metabolism
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy/metabolism
MH  - Pre-Eclampsia/drug therapy/metabolism
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*drug therapy/metabolism
MH  - Pregnancy Outcome
MH  - Prospective Studies
MH  - Thromboxane A2/*metabolism
MH  - Time Factors
EDAT- 1993/09/01 00:00
MHDA- 1993/09/01 00:01
CRDT- 1993/09/01 00:00
PHST- 1993/09/01 00:00 [pubmed]
PHST- 1993/09/01 00:01 [medline]
PHST- 1993/09/01 00:00 [entrez]
AID - 10.1111/j.1471-0528.1993.tb14304.x [doi]
PST - ppublish
SO  - Br J Obstet Gynaecol. 1993 Sep;100(9):809-15. doi: 
      10.1111/j.1471-0528.1993.tb14304.x.

PMID- 32854760
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Aug 27
TI  - Aspirin mediates histone methylation that inhibits inflammation-related stemness 
      gene expression to diminish cancer stemness via COX-independent manner.
PG  - 370
LID - 10.1186/s13287-020-01884-4 [doi]
LID - 370
AB  - BACKGROUND: The widely recognized anti-cancer potential of aspirin has created a 
      broad interest to explore the clinical benefits of aspirin in cancer therapy. 
      However, the current understanding of the molecular mechanisms involved in the 
      anti-cancer potential of aspirin remains limited. METHODS: Cancer stemness assays 
      which contained ALDH, side population, chemo-resistance, sphere formation, and 
      tumorigenesis were performed to validate aspirin function in vitro and in vivo. 
      Histone modification assay was performed to check the effect of aspirin on 
      histone methylation as well as the activity of HDAC and KDM6A/B. Inhibitor in 
      vivo assay was performed to evaluate therapeutic effects of various inhibitor 
      combination manners. RESULTS: In regards to in vitro studies, aspirin diminishes 
      cancer cell stemness properties which include reducing the ALDH+ subpopulation, 
      side population, chemo-resistance, and sphere formation in three cancer types. In 
      regards to in vivo studies, aspirin decreases tumor growth and metastasis and 
      prolongs survival. In addition, our results showed that aspirin inhibits 
      inflammation-related stemness gene expression (especially ICAM3) identified by a 
      high-throughput siRNA platform. In regards to the underlying molecular mechanism 
      of action, aspirin reduces histone demethylase (KDM6A/B) expression that mediates 
      histone methylation and suppresses gene expression via a COX-independent manner. 
      In regards to therapeutic strategies, aspirin combined HDM inhibitors, ICAM3 
      downstream signaling Src/PI3K inhibitors, or ICAM3 inhibitor Lifitigrast prevents 
      cancer progression in vivo. CONCLUSIONS: The aforementioned findings suggest a 
      molecular model that explains how aspirin diminishes cancer cell stemness 
      properties. These findings may provide novel targets for therapeutic strategies 
      involving aspirin in the prevention of cancer progression.
FAU - Zhang, Xiaoyuan
AU  - Zhang X
AD  - Department of Pathology and Institute of Precision Medicine, Jining Medical 
      University, 133 Hehua Road, Jining, 272067, China.
FAU - Du, Renle
AU  - Du R
AD  - Department of Immunology, School of Medicine, Nankai University, Tianjin, 300071, 
      China.
FAU - Luo, Na
AU  - Luo N
AD  - Department of Immunology, School of Medicine, Nankai University, Tianjin, 300071, 
      China.
FAU - Xiang, Rong
AU  - Xiang R
AD  - Department of Immunology, School of Medicine, Nankai University, Tianjin, 300071, 
      China.
AD  - 2011 Project Collaborative Innovation Center for Biotherapy of Ministry of 
      Education, 94 Weijin Road, Tianjin, 300071, China.
FAU - Shen, Wenzhi
AU  - Shen W
AUID- ORCID: 0000-0002-4251-6035
AD  - Department of Pathology and Institute of Precision Medicine, Jining Medical 
      University, 133 Hehua Road, Jining, 272067, China. shenwenzhi2011@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200827
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
RN  - 0 (Histones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacology
MH  - Cell Line, Tumor
MH  - Gene Expression
MH  - Histones/genetics/metabolism
MH  - Humans
MH  - Inflammation
MH  - Methylation
MH  - *Neoplasms
MH  - Neoplastic Stem Cells/metabolism
MH  - Phosphatidylinositol 3-Kinases
PMC - PMC7450956
OTO - NOTNLM
OT  - Aspirin
OT  - COX
OT  - Cancer stemness
OT  - Histone methylation
OT  - ICAM3
OT  - Therapeutic strategies
COIS- The authors declare no potential conflicts of interest.
EDAT- 2020/08/29 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/08/29 06:00
PHST- 2019/12/07 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/07/01 00:00 [revised]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13287-020-01884-4 [pii]
AID - 1884 [pii]
AID - 10.1186/s13287-020-01884-4 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2020 Aug 27;11(1):370. doi: 10.1186/s13287-020-01884-4.

PMID- 23135381
OWN - NLM
STAT- MEDLINE
DCOM- 20130416
LR  - 20181202
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 23
IP  - 8
DP  - 2012 Dec
TI  - Short-term effects of aspirin and clopidogrel on mean platelet volume among 
      patients with acute coronary syndromes. A single-center prospective study.
PG  - 756-9
LID - 10.1097/MBC.0b013e328358e941 [doi]
AB  - Mean platelet volume (MPV) has been correlated with platelet reactivity, thus its 
      changes might be used to monitor the effects of antiplatelet therapy. However, no 
      data have been reported on platelet remodelling after antiplatelet therapy. The 
      aim of the current study was to investigate the short-term effects of oral 
      antiplatelet therapy on MPV. Our population is represented by 62 consecutive 
      patients with acute coronary syndrome (ACS), who did not receive GpIIb-IIIa 
      inhibitors. We measured MPV before starting dual antiplatelet therapy, at day 1, 
      day 2, and day 3-5 from starting adjunctive antiplatelet therapy. We additionally 
      analyzed the relationship between platelet aggregation and MPV at admission by 
      Multiplate in patients who were on chronic aspirin therapy. We observed a 
      significant paradoxical increase in MPV, with a reduction in platelet count. We 
      observed at all time intervals a significant inverse relationship between MPV and 
      platelet count (T0: r = -0.44, P < 0.0001; T1: r = -0.36, P = 0.006; T2: r = 
      -0.3, P = 0.026; T3-5: r = -0.29, P = 0.046). No relationship was observed 
      between MPV and the extent of platelet aggregation inhibition by aspirin. This 
      study showed a paradoxical increase in MPV after starting antiplatelet therapy. 
      In addition, we did not observe any relationship between baseline MPV and the 
      extent of platelet aggregation inhibition by aspirin. Thus, larger MPV does not 
      imply higher platelet reactivity and may not be considered to monitor platelet 
      reactivity and the efficacy of antiplatelet therapies.
FAU - De Luca, Giuseppe
AU  - De Luca G
AD  - Division of Cardiology, Maggiore della Carità Hospital, University of Eastern 
      Piedmont, Novara, Italy. giuseppe.deluca@maggioreosp.novara.it
FAU - Secco, Gioel G
AU  - Secco GG
FAU - Iorio, Sergio
AU  - Iorio S
FAU - Verdoia, Monica
AU  - Verdoia M
FAU - Bellomo, Giorgio
AU  - Bellomo G
FAU - Marino, Paolo
AU  - Marino P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*blood/*drug therapy
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*drug effects/pathology
MH  - Cell Size/*drug effects
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Count
MH  - Prospective Studies
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Treatment Outcome
EDAT- 2012/11/09 06:00
MHDA- 2013/04/17 06:00
CRDT- 2012/11/09 06:00
PHST- 2012/11/09 06:00 [entrez]
PHST- 2012/11/09 06:00 [pubmed]
PHST- 2013/04/17 06:00 [medline]
AID - 00001721-201212000-00014 [pii]
AID - 10.1097/MBC.0b013e328358e941 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2012 Dec;23(8):756-9. doi: 
      10.1097/MBC.0b013e328358e941.

PMID- 19106007
OWN - NLM
STAT- MEDLINE
DCOM- 20100726
LR  - 20220318
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 140
IP  - 3
DP  - 2010 Apr 30
TI  - A cost-utility analysis of clopidogrel in patients with ST elevation acute 
      coronary syndromes in the UK.
PG  - 315-22
LID - 10.1016/j.ijcard.2008.11.105 [doi]
AB  - OBJECTIVE: To assess the long-term cost effectiveness of treatment for 1 month, 
      and for 1 year with clopidogrel in addition to standard therapy (including 
      aspirin) compared with standard therapy alone, in patients diagnosed with ST 
      elevation acute myocardial infarction (STEMI) in the UK. DESIGN: Cost utility 
      analysis using a cohort Markov model, incorporating clinical data from two 
      pivotal clinical trials (the COMMIT/CCS-2 and CLARITY-TIMI 28 trials) and data 
      from UK and non-UK observational studies. SETTING: Health economic evaluation 
      carried out from the perspective of the UK NHS. PATIENTS: A representative cohort 
      of 1000 UK patients aged 60 years, diagnosed with STEMI. INTERVENTIONS: 75 mg/day 
      clopidogrel, with and without a 300 mg loading dose, in addition to standard 
      therapy (including aspirin, 75-325 mg/day) for 1 month, and for 1 year, followed 
      by standard therapy alone for their remaining lifetime, or standard therapy alone 
      (including aspirin, 75-325 mg/day) for their remaining lifetime. MAIN OUTCOME 
      MEASURES: Incremental cost per quality-adjusted life-year (QALY) gained (ICER). 
      RESULTS: For the 1-month treatment option both the COMMIT/CCS-2 and CLARITY-TIMI 
      28 trials have ICERs below 2500 pounds. For the 1-year treatment option both 
      trials have ICERs below 4000 pounds. Extensive univariate and probabilistic 
      sensitivity analyses showed these results to be robust. CONCLUSIONS: In 
      combination with previous economic analyses of clopidogrel in NSTEMI patients, 
      this paper demonstrates that clopidogrel appears to offer a cost-effective 
      treatment option for all ACS patients.
CI  - Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved.
FAU - Karnon, Jonathan
AU  - Karnon J
AD  - School of Population Health and Clinical Practice, University of Adelaide, 
      Adelaide, Australia. jonathan.karnon@adelaide.edu.au
FAU - Holmes, Mike W
AU  - Holmes MW
FAU - Williams, Robert
AU  - Williams R
FAU - Bakhai, Ameet
AU  - Bakhai A
FAU - Brennan, Alan
AU  - Brennan A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20081223
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/economics/therapeutic use
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - *Drug Costs
MH  - Follow-Up Studies
MH  - Humans
MH  - Markov Chains
MH  - Middle Aged
MH  - Models, Econometric
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/*economics/therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Survival Analysis
MH  - Ticlopidine/*analogs & derivatives/economics/therapeutic use
MH  - United Kingdom
EDAT- 2008/12/25 09:00
MHDA- 2010/07/27 06:00
CRDT- 2008/12/25 09:00
PHST- 2008/06/04 00:00 [received]
PHST- 2008/11/16 00:00 [accepted]
PHST- 2008/12/25 09:00 [entrez]
PHST- 2008/12/25 09:00 [pubmed]
PHST- 2010/07/27 06:00 [medline]
AID - S0167-5273(08)01264-3 [pii]
AID - 10.1016/j.ijcard.2008.11.105 [doi]
PST - ppublish
SO  - Int J Cardiol. 2010 Apr 30;140(3):315-22. doi: 10.1016/j.ijcard.2008.11.105. Epub 
      2008 Dec 23.

PMID- 10981955
OWN - NLM
STAT- MEDLINE
DCOM- 20001130
LR  - 20190915
IS  - 0731-3810 (Print)
IS  - 0731-3810 (Linking)
VI  - 38
IP  - 5
DP  - 2000
TI  - Gastrointestinal decontamination for enteric-coated aspirin overdose: what to do 
      depends on who you ask.
PG  - 465-70
AB  - CONTEXT: Overdoses with enteric-coated preparation are common. The optimal means 
      by which to limit drug absorption in such cases is controversial. OBJECTIVE: To 
      describe the recommendations for gastrointestinal decontamination issued by North 
      American poison control centers for a hypothetical patient, (an adult male with 
      normal vital signs), presenting 1 hour after ingesting 500 mg/kg of 
      enteric-coated aspirin. DESIGN: Telephone survey of 76 poison control centers in 
      North America. Seven toxicologists who contributed to the American Academy of 
      Clinical Toxicology/European Association of Poison Centres and Clinical 
      Toxicologists position statements on gastrointestinal decontamination were also 
      surveyed for informal comparison. RESULTS: Most poison control centers (99%) and 
      all of the toxicologists (100%) participated in the survey. Four centers (5 %) 
      recommended syrup of ipecac and 38 (51%) recommended gastric lavage, compared 
      with 0% and 0% of toxicologists, respectively. Seventy-three centers (97%) 
      recommended at least one dose of activated charcoal, compared with 6 
      toxicologists (86%). Twenty-one poison centers (28%) recommended whole-bowel 
      irrigation, compared with 3 toxicologists (43%). A total of 36 different courses 
      of action were suggested by respondents at the poison centers. Some of these 
      recommendations were potentially harmful. CONCLUSIONS: Considerable variability 
      exists in the recommendations of North American poison control centers for the 
      gastrointestinal decontamination of patients with large, acute overdoses of 
      enteric-coated aspirin.
FAU - Juurlink, D N
AU  - Juurlink DN
AD  - Division of Clinical Pharmacology and Toxicology, University of Toronto, Ontario, 
      Canada. david.juurlink@ices.on.ca
FAU - McGuigan, M A
AU  - McGuigan MA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Toxicol Clin Toxicol
JT  - Journal of toxicology. Clinical toxicology
JID - 8213460
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Emetics)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 16291-96-6 (Charcoal)
RN  - 8012-96-2 (Ipecac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Toxicol Clin Toxicol. 2000;38(7):689-90. PMID: 11192453
CIN - J Toxicol Clin Toxicol. 2000;38(7):691-2. PMID: 11192454
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*poisoning
MH  - Aspirin/pharmacokinetics/*poisoning
MH  - Charcoal/therapeutic use
MH  - Decontamination/*methods
MH  - Digestive System/metabolism
MH  - Drug Overdose
MH  - Emetics/therapeutic use
MH  - Enterosorption/methods
MH  - Gastric Lavage
MH  - Health Care Surveys
MH  - Humans
MH  - Intestinal Absorption/drug effects
MH  - Ipecac/therapeutic use
MH  - Male
MH  - Poison Control Centers
MH  - Tablets, Enteric-Coated
EDAT- 2000/09/12 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/12 11:00
PHST- 2000/09/12 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/12 11:00 [entrez]
AID - 10.1081/clt-100102004 [doi]
PST - ppublish
SO  - J Toxicol Clin Toxicol. 2000;38(5):465-70. doi: 10.1081/clt-100102004.

PMID- 2083410
OWN - NLM
STAT- MEDLINE
DCOM- 19910514
LR  - 20190828
IS  - 0954-7894 (Print)
IS  - 0954-7894 (Linking)
VI  - 20
IP  - 6
DP  - 1990 Nov
TI  - Plasmapheresis in a patient with severe asthma associated with auto-antibodies to 
      platelets.
PG  - 707-12
AB  - Although the pathogenesis of aspirin-sensitive asthma remains to be specified, it 
      is known that in the presence of acetylsalicylic acid or non-steroidal 
      anti-inflammatory drugs, platelets from aspirin-sensitive asthmatics have been 
      described as generating cytocidal mediators that killed parasite targets such as 
      Schistosoma mansoni larvae. Here we report, in a patient with 
      corticosteroid-dependent asthma associated with aspirin sensitivity, the presence 
      of circulating IgE antibodies against 55 kD and 68 kD platelet antigens. In 
      addition, the serum from this patient was shown to contain a factor able to 
      trigger the release of cytocidal mediators from his platelets as well as from 
      normal individual platelets. This platelet stimulatory activity was presumably 
      supported by IgE antibodies or immune complexes. After informed consent the 
      patient was submitted to plasma exchanges. Plasma removal induced clinical 
      improvement, anti-platelet antibody decrease, and the reduction of the platelet 
      stimulatory activity. All clinical symptoms disappeared within 2 weeks. The 
      disease remained quiescent for 2 months, and daily requirements for prednisone 
      (20-5 mg), and beta-agonist (10-16 to 0-1 inhalations) could be kept at a low 
      level follow-up. The plasma exchanges were delayed by 3 mg kg-1 azathioprine with 
      the maintenance of clinical improvement. A relapse occurred after the arrest of 
      immunosuppressive therapy with the reappearance of both asthma attacks and 
      anti-platelet antibodies, as well as the increase of the platelet stimulatory 
      activity.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Lassalle, P
AU  - Lassalle P
AD  - Centre d'Immunologie et de Biologie Parasitaire, Institut Pasteur, Lille, France.
FAU - Joseph, M
AU  - Joseph M
FAU - Ramon, P
AU  - Ramon P
FAU - Dracon, M
AU  - Dracon M
FAU - Tonnel, A B
AU  - Tonnel AB
FAU - Capron, A
AU  - Capron A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - 0 (Autoantibodies)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/immunology
MH  - Asthma/etiology/immunology/*therapy
MH  - Autoantibodies/*blood
MH  - Blood Platelets/*immunology
MH  - Drug Hypersensitivity/immunology
MH  - Humans
MH  - Immunoglobulin E/metabolism
MH  - Male
MH  - Plasma Exchange
MH  - *Plasmapheresis
EDAT- 1990/11/01 00:00
MHDA- 1990/11/01 00:01
CRDT- 1990/11/01 00:00
PHST- 1990/11/01 00:00 [pubmed]
PHST- 1990/11/01 00:01 [medline]
PHST- 1990/11/01 00:00 [entrez]
AID - 10.1111/j.1365-2222.1990.tb02712.x [doi]
PST - ppublish
SO  - Clin Exp Allergy. 1990 Nov;20(6):707-12. doi: 10.1111/j.1365-2222.1990.tb02712.x.

PMID- 27652589
OWN - NLM
STAT- MEDLINE
DCOM- 20180402
LR  - 20181113
IS  - 2160-7648 (Electronic)
IS  - 2160-763X (Print)
IS  - 2160-763X (Linking)
VI  - 6
IP  - 4
DP  - 2017 Jul
TI  - Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in 
      Combination With Aspirin in Healthy Japanese Subjects.
PG  - 398-407
LID - 10.1002/cpdd.308 [doi]
AB  - We evaluated the pharmacokinetics and pharmacodynamics of prasugrel used in 
      combination with aspirin in healthy Japanese subjects. All subjects received 
      aspirin 100 mg/day. Subsequently, in the single-administration study, 23 subjects 
      also received prasugrel 20 or 30 mg, and in the multiple-administration study, 20 
      subjects received a loading dose of prasugrel 20 or 30 mg on day 1, followed by a 
      maintenance dose of prasugrel 5 or 7.5 mg/day, respectively, on days 2-5. In both 
      studies, the plasma concentration of the active metabolite of prasugrel, 
      R-138727, reached a maximum 0.5 hours after administration and rapidly decreased 
      within 4 hours. In the single-administration study, the inhibitory effect on 
      adenosine diphosphate-induced platelet aggregation was significantly higher in 
      the prasugrel 20- and 30-mg groups than in the placebo group at all times 
      (1-144 hours) after administration. In the multiple-administration study, a 
      similar antiplatelet effect was found after both the loading dose and the 
      maintenance dose and was maintained for 3-6 days after the last administration. 
      There were study drug-related adverse events; however, all were mild, and none 
      was clinically significant.
CI  - © 2016 The Authors. Clinical Pharmacology in Drug Development Published by Wiley 
      Periodicals, Inc. on behalf of The American College of Clinical Pharmacology.
FAU - Umemura, Kazuo
AU  - Umemura K
AD  - Department of Pharmacology, Hamamatsu University School of Medicine, 
      Hamamatsu-shi, Shizuoka, Japan.
FAU - Ikeda, Yasuhiko
AU  - Ikeda Y
AD  - Department of Pharmacology, Hamamatsu University School of Medicine, 
      Hamamatsu-shi, Shizuoka, Japan.
AD  - Shin-nakagawa Hospital, Yokohama-shi, Kanagawa, Japan.
FAU - Matsushima, Nobuko
AU  - Matsushima N
AD  - Translational Medicine and Clinical Pharmacology Department, Daiichi Sankyo Co., 
      Ltd, Shinagawa-ku, Tokyo, Japan.
AD  - Clinical Pharmacology Department, Janssen Pharmaceutical K.K. , Chiyoda-ku, 
      Tokyo, Japan.
FAU - Kondo, Kazunao
AU  - Kondo K
AD  - Department of Pharmacology, Fujita Health University School of Medicine, 
      Toyoake-shi, Aichi, Japan.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20161026
PL  - United States
TA  - Clin Pharmacol Drug Dev
JT  - Clinical pharmacology in drug development
JID - 101572899
RN  - 0 (Piperazines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (R-138727)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Healthy Volunteers
MH  - Humans
MH  - Japan
MH  - Piperazines/blood
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacokinetics
MH  - Platelet Function Tests
MH  - Prasugrel Hydrochloride/administration & dosage/*pharmacokinetics
MH  - Young Adult
PMC - PMC5516194
OTO - NOTNLM
OT  - aspirin
OT  - healthy Japanese subjects
OT  - inhibition of platelet aggregation
OT  - pharmacokinetics
OT  - prasugrel
EDAT- 2016/10/28 06:00
MHDA- 2018/04/03 06:00
CRDT- 2016/09/23 06:00
PHST- 2016/05/25 00:00 [received]
PHST- 2016/09/12 00:00 [accepted]
PHST- 2016/10/28 06:00 [pubmed]
PHST- 2018/04/03 06:00 [medline]
PHST- 2016/09/23 06:00 [entrez]
AID - CPDD308 [pii]
AID - 10.1002/cpdd.308 [doi]
PST - ppublish
SO  - Clin Pharmacol Drug Dev. 2017 Jul;6(4):398-407. doi: 10.1002/cpdd.308. Epub 2016 
      Oct 26.

PMID- 24140966
OWN - NLM
STAT- MEDLINE
DCOM- 20140815
LR  - 20131126
IS  - 1873-6351 (Electronic)
IS  - 0278-6915 (Linking)
VI  - 62
DP  - 2013 Dec
TI  - Genotoxic evaluation of aspirin eugenol ester using the Ames test and the mouse 
      bone marrow micronucleus assay.
PG  - 805-9
LID - S0278-6915(13)00685-6 [pii]
LID - 10.1016/j.fct.2013.10.010 [doi]
AB  - Aspirin eugenol ester (AEE) is a promising drug candidate for treatment of 
      inflammation, pain and fever and prevention of cardiovascular diseases with less 
      side effects and it is important to characterize its genotoxicity. In this study, 
      the genotoxicity of AEE was assessed with two standard genotoxicity assays of the 
      Salmonella typhimurium mutagenicity assay (Ames test) and the mouse bone marrow 
      micronucleus assay. In the Ames test, Salmonella strains TA97, TA98, TA100, TA102 
      and TA1535 were treated with or without the metabolic activation with a S9 
      fraction from Acroclor-induced rat liver. The doses of AEE were 5 mg/plate, 2.5 
      mg/plate, 1.25 mg/plate, 0.625 mg/plate and 0.3125 mg/plate, respectively. In the 
      above tested strains, mutagenicity with or without the S-9 mixture was not 
      detected. In the mammalian erythrocyte micronucleus assay, fifty mice were 
      divided into five groups evenly and the AEE dose at 5000 mg/kg, 2500 mg/kg and 
      1250 mg/kg and the cyclophosphamide dose at 40 mg/kg as a positive control, the 
      0.5% of CMC-Na as negative control were administered. The results showed that AEE 
      did not induce any significant increase in micronucleated erythrocytes after 24 h 
      (p<0.01). Our results suggested that AEE was non-genotoxic in vivo or in vitro.
CI  - Copyright © 2013 Elsevier Ltd. All rights reserved.
FAU - Li, Jianyong
AU  - Li J
AD  - Key Lab of New Animal Drug Project, Gansu Province, Key Lab of Veterinary Drug 
      Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and 
      Pharmaceutical Sciences of CAAS, Lanzhou 730050, China. Electronic address: 
      lijy1971@163.com.
FAU - Kong, Xiaojun
AU  - Kong X
FAU - Li, Xiwang
AU  - Li X
FAU - Yang, Yajun
AU  - Yang Y
FAU - Zhang, Jiyu
AU  - Zhang J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131016
PL  - England
TA  - Food Chem Toxicol
JT  - Food and chemical toxicology : an international journal published for the British 
      Industrial Biological Research Association
JID - 8207483
RN  - 0 (aspirin eugenol ester)
RN  - 3T8H1794QW (Eugenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/toxicity
MH  - Biotransformation
MH  - Bone Marrow/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Erythrocytes/drug effects
MH  - Eugenol/*analogs & derivatives/toxicity
MH  - Female
MH  - Male
MH  - Mice
MH  - Micronucleus Tests/methods
MH  - Mutagenicity Tests/*methods
MH  - Rats
MH  - Salmonella typhimurium/drug effects/genetics
OTO - NOTNLM
OT  - Ames test
OT  - Aspirin eugenol ester
OT  - Mammalian erythrocyte micronucleus
EDAT- 2013/10/22 06:00
MHDA- 2014/08/16 06:00
CRDT- 2013/10/22 06:00
PHST- 2013/07/08 00:00 [received]
PHST- 2013/09/14 00:00 [revised]
PHST- 2013/10/08 00:00 [accepted]
PHST- 2013/10/22 06:00 [entrez]
PHST- 2013/10/22 06:00 [pubmed]
PHST- 2014/08/16 06:00 [medline]
AID - S0278-6915(13)00685-6 [pii]
AID - 10.1016/j.fct.2013.10.010 [doi]
PST - ppublish
SO  - Food Chem Toxicol. 2013 Dec;62:805-9. doi: 10.1016/j.fct.2013.10.010. Epub 2013 
      Oct 16.

PMID- 34796411
OWN - NLM
STAT- MEDLINE
DCOM- 20220719
LR  - 20220819
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 67
IP  - 8
DP  - 2022 Aug
TI  - Antiplatelet Monotherapy Is Associated with an Increased Risk of Bleeding After 
      Endoscopic Sphincterotomy.
PG  - 4161-4169
LID - 10.1007/s10620-021-07302-w [doi]
AB  - BACKGROUND: Clinical guidelines recommend continuing antiplatelet monotherapy 
      with aspirin and, in certain situations, other antiplatelet agents in patients 
      undergoing endoscopic retrograde cholangiopancreatography (ERCP) with 
      sphincterotomy. AIMS: Given the scant evidence supporting this recommendation, 
      our primary objective was to determine if the risk of post-sphincterotomy 
      bleeding was increased in patients on antiplatelet monotherapy. METHODS: We 
      performed a systematic search of Cochrane Library, Ovid Embase, Ovid Medline, 
      Pubmed, Scopus, and Web of Science Core Collection databases. Inclusion criteria 
      were adult patients undergoing ERCP and sphincterotomy on antiplatelet 
      monotherapy with the comparator of no antithrombotic therapy. Our primary outcome 
      was post-sphincterotomy bleeding. Methodological quality was assessed with the 
      ROBINS-I tool and the Newcastle-Ottawa Scale. Meta-analysis with random-effects 
      model was performed. RESULTS: The search identified 4676 unique citations, with 
      six cohort studies meeting our inclusion criteria. Post-sphincterotomy bleeding 
      was increased in patients on antiplatelet monotherapy: OR = 1.53 (95% CI 
      1.03-2.28) without substantial heterogeneity (I(2) = 0%). The number needed to 
      harm (the number of patients who would have to receive antiplatelet monotherapy 
      for one additional patient to have a post-sphincterotomy bleeding episode) was 
      185(95% CI 80-2272). All included studies had methodological shortcomings. 
      CONCLUSION: Antiplatelet monotherapy was associated with a modestly increased 
      risk of post-sphincterotomy bleeding in our systematic review and meta-analysis. 
      More high-quality studies are needed to improve certainty regarding the estimated 
      effect size. REGISTRATION: PROSPERO CRD42020153019.
CI  - © 2021. This is a U.S. government work and not under copyright protection in the 
      U.S.; foreign copyright protection may apply.
FAU - Zakko, Alan
AU  - Zakko A
AD  - Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
FAU - Zakko, Liam
AU  - Zakko L
AD  - Connecticut Clinical Research Institute, Connecticut GI, Bristol, CT, USA.
FAU - Grimshaw, Alyssa A
AU  - Grimshaw AA
AD  - Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT, 
      USA.
FAU - Laine, Loren
AU  - Laine L
AUID- ORCID: 0000-0002-4296-7901
AD  - Department of Medicine, Yale School of Medicine, New Haven, CT, USA. 
      Loren.Laine@yale.edu.
AD  - VA Connecticut Healthcare System, West Haven, CT, USA. Loren.Laine@yale.edu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20211118
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects
MH  - Cholangiopancreatography, Endoscopic Retrograde
MH  - *Hemorrhage/chemically induced
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/adverse effects
MH  - *Sphincterotomy, Endoscopic
OTO - NOTNLM
OT  - Antiplatelet agents
OT  - Aspirin
OT  - ERCP
OT  - Gastrointestinal hemorrhage
EDAT- 2021/11/20 06:00
MHDA- 2022/07/20 06:00
CRDT- 2021/11/19 07:04
PHST- 2021/07/13 00:00 [received]
PHST- 2021/10/21 00:00 [accepted]
PHST- 2021/11/20 06:00 [pubmed]
PHST- 2022/07/20 06:00 [medline]
PHST- 2021/11/19 07:04 [entrez]
AID - 10.1007/s10620-021-07302-w [pii]
AID - 10.1007/s10620-021-07302-w [doi]
PST - ppublish
SO  - Dig Dis Sci. 2022 Aug;67(8):4161-4169. doi: 10.1007/s10620-021-07302-w. Epub 2021 
      Nov 18.

PMID- 21718553
OWN - NLM
STAT- MEDLINE
DCOM- 20160422
LR  - 20211020
IS  - 1752-8526 (Electronic)
IS  - 1462-3846 (Linking)
VI  - 2011
DP  - 2011 Feb 1
TI  - Recurrent miscarriage.
LID - 1409 [pii]
AB  - INTRODUCTION: Recurrent miscarriage is the spontaneous loss of three or more 
      consecutive pregnancies with the same biological father in the first trimester, 
      and affects 1% to 2% of women, half of whom have no identifiable cause. Overall, 
      75% of affected women will have a successful subsequent pregnancy, but this rate 
      falls for older mothers and with increasing number of miscarriages. 
      Antiphospholipid syndrome, with anticardiolipin or lupus anticoagulant 
      antibodies, is present in 15% of women with recurrent first and second trimester 
      miscarriage. METHODS AND OUTCOMES: We conducted a systematic review and aimed to 
      answer the following clinical questions: What are the effects of treatments for 
      unexplained recurrent miscarriage? What are the effects of treatments for 
      recurrent miscarriage caused by antiphospholipid syndrome? We searched: Medline, 
      Embase, The Cochrane Library, and other important databases up to January 2010 
      (Clinical Evidence reviews are updated periodically, please check our website for 
      the most up-to-date version of this review). We included harms alerts from 
      relevant organisations such as the US Food and Drug Administration (FDA) and the 
      UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 
      14 systematic reviews, RCTs, or observational studies that met our inclusion 
      criteria. We performed a GRADE evaluation of the quality of evidence for 
      interventions. CONCLUSIONS: In this systematic review we present information 
      relating to the effectiveness and safety of the following interventions: aspirin 
      (low dose), bed-rest, corticosteroids, early scanning in subsequent pregnancies, 
      heparin plus low-dose aspirin, human chorionic gonadotrophin, intravenous 
      immunoglobulin treatment, lifestyle adaptation, oestrogen, paternal white cell 
      immunisation, progesterone, trophoblastic membrane infusion, and vitamin 
      supplementation.
FAU - Duckitt, Kirsten
AU  - Duckitt K
AD  - Campbell River Hospital, Campbell River, BC, Canada.
FAU - Qureshi, Aysha
AU  - Qureshi A
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20110201
PL  - England
TA  - BMJ Clin Evid
JT  - BMJ clinical evidence
JID - 101294314
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abortion, Habitual/drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Antiphospholipid Syndrome
MH  - Aspirin/administration & dosage
MH  - *Heparin/administration & dosage
MH  - Humans
PMC - PMC3275302
EDAT- 2011/07/02 06:00
MHDA- 2016/04/23 06:00
CRDT- 2011/07/02 06:00
PHST- 2011/07/02 06:00 [entrez]
PHST- 2011/07/02 06:00 [pubmed]
PHST- 2016/04/23 06:00 [medline]
AID - 1409 [pii]
PST - epublish
SO  - BMJ Clin Evid. 2011 Feb 1;2011:1409.

PMID- 34010070
OWN - NLM
STAT- MEDLINE
DCOM- 20211220
LR  - 20230412
IS  - 1477-0377 (Electronic)
IS  - 1358-863X (Print)
IS  - 1358-863X (Linking)
VI  - 26
IP  - 6
DP  - 2021 Dec
TI  - Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19.
PG  - 626-632
LID - 10.1177/1358863X211012754 [doi]
AB  - Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral 
      pandemic marked by increased risk of thrombotic events. However, the role of 
      platelets in the elevated observed thrombotic risk in COVID-19 and utility of 
      antiplatelet agents in attenuating thrombosis is unknown. We aimed to determine 
      if the antiplatelet effect of aspirin may mitigate risk of myocardial infarction, 
      cerebrovascular accident, and venous thromboembolism in COVID-19. We evaluated 
      22,072 symptomatic patients tested for COVID-19. Propensity-matched analyses were 
      performed to determine if treatment with aspirin or nonsteroidal 
      anti-inflammatory drugs (NSAIDs) affected thrombotic outcomes in COVID-19. 
      Neither aspirin nor NSAIDs affected mortality in COVID-19. Thus, aspirin does not 
      appear to prevent thrombosis and death in COVID-19. The mechanisms of thrombosis 
      in COVID-19, therefore, appear distinct and the role of platelets as direct 
      mediators of SARS-CoV-2-mediated thrombosis warrants further investigation.
FAU - Sahai, Aditya
AU  - Sahai A
AD  - Section of Vascular Medicine, Department of Cardiovascular Medicine; Heart, 
      Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - Bhandari, Rohan
AU  - Bhandari R
AUID- ORCID: 0000-0003-1063-6291
AD  - Section of Vascular Medicine, Department of Cardiovascular Medicine; Heart, 
      Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
AD  - Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - Godwin, Matthew
AU  - Godwin M
AD  - Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - McIntyre, Thomas
AU  - McIntyre T
AD  - Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - Chung, Mina K
AU  - Chung MK
AD  - Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
AD  - Department of Cardiovascular Medicine; Heart, Vascular & Thoracic Institute, 
      Cleveland Clinic, Cleveland, OH, USA.
FAU - Iskandar, Jean-Pierre
AU  - Iskandar JP
AD  - Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
FAU - Kamran, Hayaan
AU  - Kamran H
AD  - Section of Vascular Medicine, Department of Cardiovascular Medicine; Heart, 
      Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - Hariri, Essa
AU  - Hariri E
AD  - Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
FAU - Aggarwal, Anu
AU  - Aggarwal A
AD  - Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - Burton, Robert
AU  - Burton R
AD  - Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
FAU - Kalra, Ankur
AU  - Kalra A
AD  - Section of Vascular Medicine, Department of Cardiovascular Medicine; Heart, 
      Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - Bartholomew, John R
AU  - Bartholomew JR
AD  - Section of Vascular Medicine, Department of Cardiovascular Medicine; Heart, 
      Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - McCrae, Keith R
AU  - McCrae KR
AD  - Department of Cardiovascular Medicine; Heart, Vascular & Thoracic Institute, 
      Cleveland Clinic, Cleveland, OH, USA.
AD  - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - Elbadawi, Ayman
AU  - Elbadawi A
AUID- ORCID: 0000-0002-4248-781X
AD  - Division of Cardiovascular Medicine, University of Texas Medical Branch, 
      Galveston, TX, USA.
FAU - Bena, James
AU  - Bena J
AD  - Department of Quantitative Health Science, Cleveland Clinic, Cleveland, OH, USA.
FAU - Svensson, Lars G
AU  - Svensson LG
AD  - Section of Vascular Medicine, Department of Cardiovascular Medicine; Heart, 
      Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - Kapadia, Samir
AU  - Kapadia S
AD  - Section of Vascular Medicine, Department of Cardiovascular Medicine; Heart, 
      Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - Cameron, Scott J
AU  - Cameron SJ
AUID- ORCID: 0000-0002-9616-1540
AD  - Section of Vascular Medicine, Department of Cardiovascular Medicine; Heart, 
      Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
AD  - Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
AD  - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
LA  - eng
GR  - L30 HL120200/HL/NHLBI NIH HHS/United States
GR  - K08 HL128856/HL/NHLBI NIH HHS/United States
GR  - R01 HL111314/HL/NHLBI NIH HHS/United States
GR  - U01 HL143402/HL/NHLBI NIH HHS/United States
GR  - R01 HL158669/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20210519
PL  - England
TA  - Vasc Med
JT  - Vascular medicine (London, England)
JID - 9610930
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - COVID-19/*complications
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - *Inpatients
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - SARS-CoV-2
MH  - Thrombosis/*prevention & control/virology
PMC - PMC8137864
OTO - NOTNLM
OT  - ACE2
OT  - COVID-19
OT  - SARS-CoV-2
OT  - TMPRSS2
OT  - platelets
OT  - thrombosis
COIS- Declaration of conflicting interests: The authors declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2021/05/20 06:00
MHDA- 2021/12/21 06:00
CRDT- 2021/05/19 17:21
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2021/12/21 06:00 [medline]
PHST- 2021/05/19 17:21 [entrez]
AID - 10.1177_1358863X211012754 [pii]
AID - 10.1177/1358863X211012754 [doi]
PST - ppublish
SO  - Vasc Med. 2021 Dec;26(6):626-632. doi: 10.1177/1358863X211012754. Epub 2021 May 
      19.

PMID- 11674857
OWN - NLM
STAT- MEDLINE
DCOM- 20020308
LR  - 20131121
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 12
IP  - 7
DP  - 2001 Nov
TI  - Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet 
      activation and aggregation.
PG  - 406-14
AB  - Ticlopidine, recently classified as a P2Y(12) ADP receptor blockade, is known to 
      be an effective antiplatelet agent preventing arterial thrombosis, e.g., 
      myocardial infarction or cerebral infarction, but the mechanism of the in vivo 
      antithrombotic effects of ticlopidine is not fully understood. Blood was drawn 
      from seven normal volunteers before and 7 days after consecutive intake of 
      ticlopidine, and 1 day after oral intake of aspirin after 7 days of ticlopidine 
      wash-out period. Effects of drug intake on shear-induced von Willebrand factor 
      (vWF) binding to platelets, platelet activation evidenced by P-selectin surface 
      expression and translocation of GP Ibalpha, and vWF-mediated platelet 
      aggregation, were investigated by using an optically modified cone-plate 
      viscometer and quantitative flow cytometry. The maximum extent of platelet 
      aggregation occurring under a high shear rate of 10800 s(-1), presumably mediated 
      by vWF, was not significantly influenced by either ticlopidine or aspirin. 
      However, significant dissociation of once aggregated platelets occurred in 
      samples obtained after ticlopidine intake (25.4 +/- 9.3%, P = 0.00030) and less 
      significantly after aspirin intake (15.9 +/- 5.7%, P = 0.0013), while only 
      insignificant and modest dissociation occurred in controls (6.3 +/- 4.4%, n.s.). 
      Binding experiments also revealed that the shear-induced vWF binding to platelets 
      was significantly inhibited by ticlopidine, and less significantly by aspirin, 
      although other indicators of platelet activation, such as shear-induced 
      P-selectin expression and GP Ibalpha translocation were not influenced by either 
      ticlopidine or aspirin. We demonstrate here that platelet aggregation mediated by 
      von Willebrand factor (vWF) under a high shear rate of 10800 s(-1) cannot be 
      stabilized and that dissociation occurs readily when ADP receptor stimulation is 
      blocked by continuous intake of ticlopidine, indicating that these effects on 
      platelet thrombus formation may contribute to the in vivo antithrombotic effects 
      of ticlopidine.
FAU - Goto, S
AU  - Goto S
AD  - Division of Cardiology, Department of Medicine, Tokai University School of 
      Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. 
      shinichi@is.icc.u-tokai.ac.jp
FAU - Tamura, N
AU  - Tamura N
FAU - Sakakibara, M
AU  - Sakakibara M
FAU - Ikeda, Y
AU  - Ikeda Y
FAU - Handa, S
AU  - Handa S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Membrane Proteins)
RN  - 0 (P2RY12 protein, human)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2 Receptor Antagonists)
RN  - 0 (Receptors, Purinergic P2Y12)
RN  - 0 (von Willebrand Factor)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacology
MH  - Blood Platelets/drug effects/metabolism
MH  - Hemorheology
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - *Membrane Proteins
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Protein Binding/drug effects
MH  - Purinergic P2 Receptor Antagonists
MH  - Receptors, Purinergic P2Y12
MH  - Stress, Mechanical
MH  - Ticlopidine/administration & dosage/*pharmacology
MH  - von Willebrand Factor/metabolism/*pharmacology
EDAT- 2001/10/25 10:00
MHDA- 2002/03/09 10:01
CRDT- 2001/10/25 10:00
PHST- 2001/10/25 10:00 [pubmed]
PHST- 2002/03/09 10:01 [medline]
PHST- 2001/10/25 10:00 [entrez]
AID - 10.1080/09537100120078377 [doi]
PST - ppublish
SO  - Platelets. 2001 Nov;12(7):406-14. doi: 10.1080/09537100120078377.

PMID- 8983933
OWN - NLM
STAT- MEDLINE
DCOM- 19970107
LR  - 20181113
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 20
IP  - 4
DP  - 1995 Oct-Dec
TI  - Effects of acetysal, dexamethasone and their combination on drug metabolizing 
      enzyme systems in rat liver microsomes.
PG  - 281-6
AB  - After 4 days of acetysal treatment (160 mg/kg body weight orally), the following 
      were established: a higher acute toxicity of acetysal, an inducing effect on 
      amidopyrin N-demethylase and analgin N-demethylase activity and increases in 
      cytochrome P-450 and cytochrome b5 content. Aniline hydroxylase activity 
      decreased, thiopental sleeping time was prolonged and UDP-glucuronyltransferase 
      activity was not changed. Dexamethasone, at a dose of 5 mg/kg body weight p.o. 
      for 4 days, did not change acetysal acute toxicity but at a dose of 100 mg/kg 
      i.p. increased it. Thiopental sleeping time was shortened by dexamethasone (100 
      mg/kg i.p.) but was not changed by dexamethasone at 5 mg/kg p.o., alone or in 
      combination. Dexamethasone at 5 mg/kg increased analgin N-demethylase and 
      UDP-glucuronyltransferase activities, did not change cytochrome P-450 content and 
      decreased aniline hydroxylase activity. The combination with 5 mg/kg 
      dexamethasone increased the activity of amidopyrin N-demethylase, analgin 
      N-demethylase and UDP-glucuronyltransferase and decreased those of amitriptyllin 
      N-demethylase and aniline hydroxylase and cytochrome P-450 content. Ethylmorphine 
      N-demethylase, benzphetamine N-demethylase, NADPH-cytochrome c reductase and 
      glutathione S-transferase activities were not affected significantly by acetysal, 
      dexamethasone or their combination. Hepatic carboxyl esterase was depressed by 
      dexamethasone (5 mg/kg) and was increased by the combination. Lipid peroxidation 
      was not changed by dexamethasone (5 mg/kg) but was decreased by acetysal and the 
      combination.
FAU - Tantcheva, L P
AU  - Tantcheva LP
AD  - Department of Drug Toxicology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
FAU - Rangelova, D S
AU  - Rangelova DS
FAU - Stoytchev, T S
AU  - Stoytchev TS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Glucocorticoids)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/poisoning
MH  - Aspirin/*pharmacology/poisoning
MH  - Dexamethasone/*pharmacology
MH  - Drug Interactions
MH  - Glucocorticoids/*pharmacology
MH  - Lipid Peroxidation/*drug effects/physiology
MH  - Male
MH  - Microsomes, Liver/*drug effects/metabolism
MH  - Rats
MH  - Rats, Wistar
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - 10.1007/BF03190245 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 1995 Oct-Dec;20(4):281-6. doi: 
      10.1007/BF03190245.

PMID- 2648792
OWN - NLM
STAT- MEDLINE
DCOM- 19890511
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 63
IP  - 13
DP  - 1989 Apr 15
TI  - Effect of low dose acetylsalicylic acid on the frequency and hematologic activity 
      of left ventricular thrombus in anterior wall acute myocardial infarction.
PG  - 917-20
AB  - In this prospective, randomized, placebo-controlled trial the effect of 100 mg 
      acetylsalicylic acid (ASA) once daily on the incidence, hematologic activity and 
      embolic potential of left ventricular (LV) thrombosis was studied in 100 
      consecutive patients with a first anterior wall acute myocardial infarction 
      (AMI). Patients were randomized to ASA or placebo less than 12 hours after onset 
      of symptoms. Heparin, 5,000 IU subcutaneously twice daily, was given to all 
      patients during immobilization. Echocardiography was performed less than 24 
      hours, 48 to 72 hours and 1, 2, and 12 weeks after AMI. LV thrombosis was 
      detected by echocardiography in 30 (33%) of the 92 evaluable patients (15 
      patients given ASA and 15 given placebo). Indium-111 platelet scintigraphy was 
      done in 17 of the 22 patients with an LV thrombus at the second week 
      echocardiogram. Among 7 ASA-treated patients, 4 had positive images; among 10 
      placebo patients, 5 had positive images. LV thrombus resolution was noted in 3 of 
      9 patients with a positive scan and in 5 of 8 patients with a negative platelet 
      scan. In 7 of 10 ASA-treated patients and 5 of 12 placebo-treated patients 
      thrombus resolution was observed (difference not significant). Systemic embolism 
      occurred in 2 patients, both given ASA, during the first week after AMI. Thus, 
      low dose ASA has no effect on the incidence, hematologic activity and embolic 
      potential of LV thrombosis in anterior wall AMI.
FAU - Küpper, A J
AU  - Küpper AJ
AD  - Department of Cardiology, Free University Hospital, Amsterdam, the Netherlands.
FAU - Verheugt, F W
AU  - Verheugt FW
FAU - Peels, C H
AU  - Peels CH
FAU - Galema, T W
AU  - Galema TW
FAU - den Hollander, W
AU  - den Hollander W
FAU - Roos, J P
AU  - Roos JP
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Indium Radioisotopes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Platelets
MH  - Clinical Trials as Topic
MH  - Echocardiography
MH  - Heart/diagnostic imaging
MH  - Humans
MH  - Indium Radioisotopes
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*pathology/physiopathology
MH  - Prospective Studies
MH  - Radionuclide Imaging
MH  - Random Allocation
MH  - Thrombosis/complications/diagnostic imaging/pathology/*prevention & control
EDAT- 1989/04/15 00:00
MHDA- 1989/04/15 00:01
CRDT- 1989/04/15 00:00
PHST- 1989/04/15 00:00 [pubmed]
PHST- 1989/04/15 00:01 [medline]
PHST- 1989/04/15 00:00 [entrez]
AID - 0002-9149(89)90139-2 [pii]
AID - 10.1016/0002-9149(89)90139-2 [doi]
PST - ppublish
SO  - Am J Cardiol. 1989 Apr 15;63(13):917-20. doi: 10.1016/0002-9149(89)90139-2.

PMID- 6809296
OWN - NLM
STAT- MEDLINE
DCOM- 19821012
LR  - 20190904
IS  - 0008-2856 (Print)
IS  - 0008-2856 (Linking)
VI  - 29
IP  - 4
DP  - 1982 Jul
TI  - Inhibition of the cardiovascular effects of lysine acetylsalicylate by 
      propranolol in dogs during halothane anaesthesia.
PG  - 349-54
AB  - The cardiovascular effects of lysine acetylsalicylate and/or propranolol were 
      studied in 26 dogs. All animals were maintained under anaesthesia with halothane 
      0.75 per cent, supplemented by the intravenous administration of succinylcholine 
      to allow controlled ventilation during a two hour period of monitoring. Cardiac 
      output, stroke volume, heart rate, mean arterial pressure, pulse pressure, 
      central venous pressure, total peripheral resistance, pH, Paco2, pao2 and base 
      deficit were measured in each dog. Lysine acetylsalicylate 50 mg . kg-1, 
      administered alone as a single bolus, significantly (P less than 0.05) increased 
      the cardiac output and stroke volume and significantly decreased the heart rate, 
      central venous pressure and total peripheral resistance in dogs under halothane 
      anaesthesia. Propranolol hydrochloride 0.5 mg . kg-1 as a single intravenous 
      bolus was followed by a significant decrease in cardiac output, heart rate and 
      mean arterial pressure and a significant increase in central venous pressure and 
      total peripheral resistance. The administration of propranolol prior to lysine 
      acetylsalicylate resulted in a significant decrease in cardiac output and heart 
      rate. Pretreatment with propranolol was effective in inhibiting the positive 
      inotropic effect of lysine acetylsalicylate.
FAU - Lee, D C
AU  - Lee DC
FAU - Lee, M O
AU  - Lee MO
FAU - Clifford, D H
AU  - Clifford DH
LA  - eng
GR  - 5-S01-RR-05700-10/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Canada
TA  - Can Anaesth Soc J
JT  - Canadian Anaesthetists' Society journal
JID - 0371163
RN  - 9Y8NXQ24VQ (Propranolol)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - UQT9G45D1P (Halothane)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - *Anesthesia, General
MH  - Animals
MH  - Aspirin/*analogs & derivatives/antagonists & inhibitors
MH  - Blood Pressure/drug effects
MH  - Cardiac Output/drug effects
MH  - Dogs
MH  - *Halothane
MH  - Heart Rate/drug effects
MH  - Hemodynamics/*drug effects
MH  - Lysine/*analogs & derivatives/antagonists & inhibitors
MH  - Propranolol/*pharmacology
MH  - Stroke Volume/drug effects
MH  - Vascular Resistance/drug effects
EDAT- 1982/07/01 00:00
MHDA- 1982/07/01 00:01
CRDT- 1982/07/01 00:00
PHST- 1982/07/01 00:00 [pubmed]
PHST- 1982/07/01 00:01 [medline]
PHST- 1982/07/01 00:00 [entrez]
AID - 10.1007/BF03007524 [doi]
PST - ppublish
SO  - Can Anaesth Soc J. 1982 Jul;29(4):349-54. doi: 10.1007/BF03007524.

PMID- 3746043
OWN - NLM
STAT- MEDLINE
DCOM- 19861008
LR  - 20131121
IS  - 0148-916X (Print)
IS  - 0148-916X (Linking)
VI  - 54
IP  - 3
DP  - 1986 Sep
TI  - Analgesic use by leprosy patients.
PG  - 399-402
AB  - We questioned 235 subjects with leprosy regarding the consumption of analgesic 
      preparations, and 46 subjects (19.5%) admitted to having consumed more than 2 kg 
      of analgesics; the main reason for consumption was neuritic pain. The commonly 
      consumed analgesics are paracetamol (acetaminophen) and local proprietary 
      compound analgesics containing aspirin, phenacetin, and caffeine. Intravenous 
      urograms were done on 28 of the 46 subjects, but none showed evidence of renal 
      papillary necrosis. The reasons for this lack of renal papillary necrosis are 
      postulated. Excessive ingestion of analgesics may be a contributory factor in the 
      development of interstitial nephritis in patients with leprosy.
FAU - Segasothy, M
AU  - Segasothy M
FAU - Muhaya, H M
AU  - Muhaya HM
FAU - Musa, A
AU  - Musa A
FAU - Rajagopalan, K
AU  - Rajagopalan K
FAU - Lim, K J
AU  - Lim KJ
FAU - Fatimah, Y
AU  - Fatimah Y
FAU - Kamal, A
AU  - Kamal A
FAU - Ahmad, K S
AU  - Ahmad KS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Lepr Other Mycobact Dis
JT  - International journal of leprosy and other mycobacterial diseases : official 
      organ of the International Leprosy Association
JID - 8505819
RN  - 0 (Analgesics)
RN  - 362O9ITL9D (Acetaminophen)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/therapeutic use
MH  - Adult
MH  - Aged
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Kidney Papillary Necrosis/chemically induced
MH  - Leprosy/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Nephritis, Interstitial/chemically induced
MH  - Phenacetin/adverse effects/therapeutic use
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
PST - ppublish
SO  - Int J Lepr Other Mycobact Dis. 1986 Sep;54(3):399-402.

PMID- 23864173
OWN - NLM
STAT- MEDLINE
DCOM- 20130923
LR  - 20220311
IS  - 1535-1386 (Electronic)
IS  - 0021-9355 (Linking)
VI  - 95
IP  - 14
DP  - 2013 Jul 17
TI  - Cost-effectiveness of low-molecular-weight heparin compared with aspirin for 
      prophylaxis against venous thromboembolism after total joint arthroplasty.
PG  - 1256-64
LID - 10.2106/JBJS.L.00400 [doi]
AB  - BACKGROUND: There is controversy regarding the most appropriate strategy to 
      prevent venous thromboembolism following total joint arthroplasty. Our objective 
      was to estimate the lifetime costs, quality-adjusted life-years (QALYs), and 
      costs per QALY gained using low-molecular-weight heparin compared with low-dose 
      aspirin for two weeks after total knee or total hip arthroplasty in patients with 
      no history of venous thromboembolism. METHODS: We used a Markov cohort model with 
      health states of healthy after surgery, no postphlebitic syndrome after venous 
      thromboembolism, postphlebitic syndrome after venous thromboembolism, and 
      survival after intracranial hemorrhage to compare treatment with 
      low-molecular-weight heparin or aspirin (160 mg) for fourteen days after total 
      knee arthroplasty or total hip arthroplasty in patients with an age of 
      fifty-five, sixty, sixty-five, seventy, seventy-five, eighty, or eighty-five 
      years. We estimated lifetime costs, QALYs gained, and costs per QALY gained for 
      both strategies, and applied a cost-effectiveness threshold of $100,000 (2010 
      U.S. dollars) per QALY gained. RESULTS: For patients undergoing total hip 
      arthroplasty at the ages of fifty-five and seventy years, costs per QALY gained 
      for low-molecular-weight heparin compared with aspirin were $315,000 and $1.4 
      million, respectively. For those undergoing total hip arthroplasty at the age of 
      eighty or eighty-five years, aspirin cost less and saved more QALYs than 
      low-molecular-weight heparin. For patients undergoing total knee arthroplasty at 
      the ages of fifty-five, seventy, and eighty-five years, costs per QALY gained 
      with low-molecular-weight heparin were $36,000, $112,000, and $448,000, 
      respectively. Probabilistic sensitivity analyses confirmed a low probability of 
      low-molecular-weight heparin being cost-effective for patients undergoing total 
      hip arthroplasty and for those with an age of eighty years or older undergoing 
      total knee arthroplasty. For individuals younger than eighty years of age 
      undergoing total knee arthroplasty, the cost-effectiveness of 
      low-molecular-weight heparin compared with aspirin is uncertain. CONCLUSIONS: For 
      patients with no history of venous thromboembolism, aspirin is a cost-effective 
      choice for venous thromboembolism prophylaxis following total hip arthroplasty, 
      but the preferred choice following total knee arthroplasty depends on age and is 
      uncertain for those younger than eighty years old.
FAU - Schousboe, John T
AU  - Schousboe JT
AD  - Park Nicollet Institute for Research & Education, 3800 Park Nicollet Boulevard, 
      Minneapolis, MN 55416, USA. john.schousboe@parknicollet.com
FAU - Brown, Gregory A
AU  - Brown GA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Bone Joint Surg Am. 2013 Jul 17;95(14):e102 1-2. PMID: 23864185
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/economics/therapeutic use
MH  - Arthroplasty, Replacement/adverse effects/*economics
MH  - Aspirin/*economics/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Fibrinolytic Agents/*economics/therapeutic use
MH  - Heparin, Low-Molecular-Weight/*economics/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Quality-Adjusted Life Years
MH  - Venous Thromboembolism/drug therapy/economics/etiology/*prevention & control
EDAT- 2013/07/19 06:00
MHDA- 2013/09/24 06:00
CRDT- 2013/07/19 06:00
PHST- 2013/07/19 06:00 [entrez]
PHST- 2013/07/19 06:00 [pubmed]
PHST- 2013/09/24 06:00 [medline]
AID - 1705132 [pii]
AID - 10.2106/JBJS.L.00400 [doi]
PST - ppublish
SO  - J Bone Joint Surg Am. 2013 Jul 17;95(14):1256-64. doi: 10.2106/JBJS.L.00400.

PMID- 8391726
OWN - NLM
STAT- MEDLINE
DCOM- 19930805
LR  - 20161123
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 69
IP  - 5
DP  - 1993 May 3
TI  - Comparative effects of enoxaparin and heparin on arterial and venous clot lysis 
      with alteplase in dogs.
PG  - 454-9
AB  - The effects of Enoxaparin with a specific anti-thrombin (anti-IIa) activity of 32 
      U/mg and a specific anti-factor-XA (anti-Xa) activity of 96 U/mg, and of heparin 
      with a specific anti-IIa and anti-Xa activity of 192 U/mg, on thrombolysis with 
      alteplase (Actilyse) were compared in a randomized blinded study using a combined 
      arterial and venous thrombosis model in the dog. All dogs received an intravenous 
      bolus of 5 mg/kg lysine-acetyl salicylate and 0.5 mg/kg alteplase over 60 min. 
      Twenty-eight dogs were randomly assigned to seven treatment groups: placebo, 
      Enoxaparin 1.5, 3 or 6 mg/kg, or heparin 0.5, 1 or 2 mg/kg, given as a 50% 
      intravenous bolus and a 50% infusion over 2 h. Steady-state plasma levels ranged 
      from 0.37 to 1.0 anti-IIa U/ml and 0.9 to 3.1 anti-Xa U/ml for Enoxaparin and 
      from 0.4 to 2.3 anti-IIa U/ml and 0.42 to 3.2 anti-Xa U/ml for heparin. The 
      activated thromboplastin time with 6 mg/kg Enoxaparin prolonged to 94 +/- 19 s 
      and with 2 mg/kg heparin to > 150 s. The time to reflow was 120 +/- 36 min with 
      placebo, 19 +/- 5 min with 6 mg/kg Enoxaparin (p = 0.03 vs control), and 22 +/- 5 
      min with 2 mg/kg of heparin (p = 0.03 vs control). Arterial patency, expressed in 
      min reflow during the 180 min observation period correlated significantly with 
      the dose of anticoagulant given (r = 0.73, p = 0.003 for Enoxaparin and r = 0.61, 
      p = 0.012 for heparin).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Stassen, J M
AU  - Stassen JM
AD  - Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
FAU - Rapold, H J
AU  - Rapold HJ
FAU - Vanlinthout, I
AU  - Vanlinthout I
FAU - Collen, D
AU  - Collen D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Dogs
MH  - Drug Synergism
MH  - *Femoral Artery
MH  - *Femoral Vein
MH  - Hemostasis/drug effects
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Lysine/analogs & derivatives/therapeutic use
MH  - Random Allocation
MH  - Single-Blind Method
MH  - *Thrombolytic Therapy
MH  - Thrombosis/*drug therapy
MH  - Tissue Plasminogen Activator/*therapeutic use
EDAT- 1993/05/03 00:00
MHDA- 1993/05/03 00:01
CRDT- 1993/05/03 00:00
PHST- 1993/05/03 00:00 [pubmed]
PHST- 1993/05/03 00:01 [medline]
PHST- 1993/05/03 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1993 May 3;69(5):454-9.

PMID- 6401878
OWN - NLM
STAT- MEDLINE
DCOM- 19830311
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 14
IP  - 1
DP  - 1983 Jan-Feb
TI  - "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention 
      of athero-thrombotic cerebral ischemia.
PG  - 5-14
AB  - 604 Patients with atherothrombotic cerebral ischemic events (transient, 16%: or 
      completed, 84%) referrable either to the carotid or to the vertebral-basilar 
      circulation were entered into a double blind randomized clinical trial (AICLA) to 
      determine whether aspirin (A) (1 g/day) or aspirin (1 g/day) + Dipyridamole (225 
      mg/day) (AD) would produce a significant reduction in the subsequent (3 years) 
      occurrence of fatal and nonfatal cerebral infarction. Randomization produced 
      remarkably comparable treatment groups and this good comparability was maintained 
      throughout the study. Adherence to the protocol and drug compliance were 
      excellent. Side effects, particularly symptoms of peptic ulcer and hemorrhagic 
      events were significantly (p less than 0.03) more frequent in the two treatment 
      groups containing aspirin. With the exception of patients who withdrew from the 
      study, each patient was followed for 3 years. At the end of the study, the number 
      of fatal and nonfatal cerebral infarctions was 31 in the placebo (P) group, 17 in 
      the A group and 18 in the AD group. Taking into account the duration of follow-up 
      for each patient, these figures correspond to cumulative rates of 18% in the P 
      group and 10.5% in each of the 2 active treatment groups. Analysis with the 
      Mantel Method showed: 1)--A difference at the 6% level between the 3 groups and 
      between P and AD; 2)--A difference at the 5% level between P and A; 3)--No 
      difference between (A and AD; 4)--A difference at the 2% level between the P 
      group and the two treated groups taken together (A + AD). Among other diseases 
      occurring during the trial, the only significant difference concerned myocardial 
      infarction, which was less frequent in the 2 treated groups (P less than 0.05). 
      Subgroup analysis failed to show a significant sex difference in the efficacy of 
      aspirin. It is concluded that, in patients comparable to those defined in the 
      protocol, Aspirin (1 g) has a significantly beneficial effect in the secondary 
      prevention of atherothrombotic cerebral infarction.
FAU - Bousser, M G
AU  - Bousser MG
FAU - Eschwege, E
AU  - Eschwege E
FAU - Haguenau, M
AU  - Haguenau M
FAU - Lefaucconnier, J M
AU  - Lefaucconnier JM
FAU - Thibult, N
AU  - Thibult N
FAU - Touboul, D
AU  - Touboul D
FAU - Touboul, P J
AU  - Touboul PJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Placebos)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arteriosclerosis/complications/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebral Infarction/*drug therapy/etiology
MH  - Clinical Trials as Topic
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy
MH  - Long-Term Care
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Placebos
MH  - Risk
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1161/01.str.14.1.5 [doi]
PST - ppublish
SO  - Stroke. 1983 Jan-Feb;14(1):5-14. doi: 10.1161/01.str.14.1.5.

PMID- 14959953
OWN - NLM
STAT- MEDLINE
DCOM- 20040831
LR  - 20191108
IS  - 1594-0667 (Print)
IS  - 1594-0667 (Linking)
VI  - 15
IP  - 6
DP  - 2003 Dec
TI  - The risk of upper gastrointestinal bleeding in elderly users of aspirin and other 
      non-steroidal anti-inflammatory drugs: the role of gastroprotective drugs.
PG  - 494-9
AB  - BACKGROUND AND AIMS: Although the administration of gastroprotective drugs may 
      reduce the risk of gastrointestinal (GI) bleeding due to intake of non-steroidal 
      anti-inflammatory drugs (NSAIDs) and aspirin during chronic treatment, no 
      consensus exists as to whether such co-therapy is effective in short-term 
      prevention, particularly in old age. The aim of our study was to evaluate the 
      risk of bleeding associated with acute and chronic NSAID or aspirin therapy in 
      elderly subjects, and the influence of gastroprotective treatment on such a risk. 
      METHODS: The study included 467 elderly NSAID or aspirin users and 1784 
      non-users, who consecutively underwent upper GI endoscopy. The use of NSAIDs 
      and/or aspirin as well as gastroprotective drugs (misoprostol, H2-blockers, 
      proton pump inhibitors) was evaluated during a structured interview. Upper GI 
      tract bleeding was diagnosed on the basis of symptoms and endoscopic signs of 
      recent hemorrhage. RESULTS: 54.2% of patients were acute and 45.8% chronic users 
      of NSAIDs or aspirin. The risk of bleeding was higher in acute [odds ratio (OR) 
      4.14, 95% CI 2.97-5.78] than chronic users (OR 1.71, 95% CI 1.1-2.67). The risk 
      of bleeding, adjusted for age, gender, Helicobacter (H) pylori infection, and 
      gastroprotective drug use were 7.87 (CI 4.90-12.60) in acute users and 3.97 (95% 
      CI 2.27-6.96) in chronic users of NSAIDs and/or aspirin. The risk of bleeding was 
      significantly associated with acute but not chronic use of regular-dose aspirin 
      (OR 5.53, 95% CI 2.29-13.3), diclofenac (OR 4.44, 95% CI 2.21-8.93), ketorolac 
      (OR 4.81, 95% CI 2.13-10.9), naproxen (OR 14.9, 95% CI 4.23-52.4) or nimesulide 
      (OR 4.06, 95% CI 1.2-13.8). Piroxicam increased the risk of bleeding in both 
      acute (OR 5.36, 95% CI 1.94-14.8) and chronic therapy (OR 5.53, 95% CI 
      1.23-24.9). In acute users, concomitant therapy with proton pump inhibitors 
      reduced the risk of bleeding compared with non-users (OR 1.05, 95% CI 0.19-5.65), 
      whereas co-treatment with H2-blockers was associated with a significantly higher 
      risk of bleeding than in non-users (OR 3.40, 95% CI 1.28-9.02). Chronic users of 
      NSAIDs or aspirin co-treated with proton pump inhibitors had a lower risk of 
      bleeding (OR 1.12, 95% CI 0.21-6.07) than those treated with misoprostol (OR 
      1.91, 95% CI 0.33-10.9) or H2 blockers (OR 2.26, 95% CI 0.81-6.36). CONCLUSIONS: 
      The risk of upper GI bleeding is significantly higher in elderly acute vs chronic 
      users of NSAIDs or regular-dose aspirin. In acute NSAID or aspirin users, 
      co-treatment with proton pump inhibitors, but not with H2-blockers, may reduce 
      the risk of bleeding compared with non-users.
FAU - Pilotto, Alberto
AU  - Pilotto A
AD  - Division of Geriatrics, IRCCS Casa Sollievo della Sofferenza, San Giovanni 
      Rotondo (Foggia), Italy. alberto.pilotto@libero.it
FAU - Franceschi, Marilisa
AU  - Franceschi M
FAU - Leandro, Gioacchino
AU  - Leandro G
FAU - Paris, Francesco
AU  - Paris F
FAU - Niro, Valeria
AU  - Niro V
FAU - Longo, Maria Grazia
AU  - Longo MG
FAU - D'Ambrosio, Luigi Piero
AU  - D'Ambrosio LP
FAU - Andriulli, Angelo
AU  - Andriulli A
FAU - Di Mario, Francesco
AU  - Di Mario F
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Aging Clin Exp Res
JT  - Aging clinical and experimental research
JID - 101132995
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0E43V0BB57 (Misoprostol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/*prevention & control
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Male
MH  - Misoprostol/*therapeutic use
MH  - *Proton Pump Inhibitors
MH  - Risk Assessment
EDAT- 2004/02/13 05:00
MHDA- 2004/09/01 05:00
CRDT- 2004/02/13 05:00
PHST- 2004/02/13 05:00 [pubmed]
PHST- 2004/09/01 05:00 [medline]
PHST- 2004/02/13 05:00 [entrez]
AID - 10.1007/BF03327372 [doi]
PST - ppublish
SO  - Aging Clin Exp Res. 2003 Dec;15(6):494-9. doi: 10.1007/BF03327372.

PMID- 7508071
OWN - NLM
STAT- MEDLINE
DCOM- 19940308
LR  - 20171218
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 107
IP  - 2
DP  - 1994 Feb
TI  - Aprotinin significantly decreases bleeding and transfusion requirements in 
      patients receiving aspirin and undergoing cardiac operations.
PG  - 554-61
AB  - BACKGROUND: Patients with heart disease are frequently maintained on a regimen of 
      aspirin because of its ability to decrease thrombotic complications and reduce 
      the prevalence of unstable angina and myocardial infarction. Aspirin-induced 
      platelet acetylation also increases bleeding caused by impairment of platelet 
      function during cardiac surgery. METHODS: Between October 1990 and November 1991 
      this double-blind, randomized, placebo-controlled, parallel group interventional 
      study examined the efficacy of high-dose aprotinin administration (up to 7 
      million KIU) to decrease blood loss and transfusion requirements in patients 
      receiving aspirin within 48 hours of undergoing coronary bypass or valvular heart 
      operations. Primary outcome measures in this study were total volume of blood 
      loss (intraoperative blood loss plus postoperative chest tube drainage) and 
      volume of transfusion during hospitalization. RESULTS: Patients treated with 
      aprotinin (n = 29) had significantly lower total blood loss (1409 +/- 232 ml 
      versus 2765 +/- 248 ml; p = 0.0002), intraoperative blood loss (503 +/- 53 ml 
      versus 1055 +/- 199 ml; p = 0.0001), postoperative blood loss (906 +/- 204 ml 
      versus 1710 +/- 202 ml; p = 0.0074), and prevalence of transfusion (59% versus 
      88% of patients; p = 0.016) than the placebo group (n = 25). The prevalence of 
      complications including myocardial infarction was similar in the two groups. 
      CONCLUSIONS: High-dose aprotinin significantly reduces blood loss and red blood 
      cell transfusions in patients receiving aspirin who undergo cardiac operations.
FAU - Murkin, J M
AU  - Murkin JM
AD  - Department of Anaesthesia, University Hospital, University of Western Ontario, 
      London, Canada.
FAU - Lux, J
AU  - Lux J
FAU - Shannon, N A
AU  - Shannon NA
FAU - Guiraudon, G M
AU  - Guiraudon GM
FAU - Menkis, A H
AU  - Menkis AH
FAU - McKenzie, F N
AU  - McKenzie FN
FAU - Novick, R J
AU  - Novick RJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 9087-70-1 (Aprotinin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aprotinin/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Blood Loss, Surgical/*prevention & control
MH  - Blood Transfusion
MH  - Blood Volume
MH  - *Cardiac Surgical Procedures
MH  - Double-Blind Method
MH  - Female
MH  - Hemostasis, Surgical/*methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction
MH  - Postoperative Complications
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
AID - S0022-5223(94)70102-4 [pii]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1994 Feb;107(2):554-61.

PMID- 33581359
OWN - NLM
STAT- MEDLINE
DCOM- 20210906
LR  - 20210906
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
VI  - 19
IP  - 7
DP  - 2021 Jul
TI  - AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert 
      Review.
PG  - 1327-1336
LID - S1542-3565(21)00148-8 [pii]
LID - 10.1016/j.cgh.2021.02.014 [doi]
AB  - DESCRIPTION: The purpose of this expert review is to describe the role of 
      medications for the chemoprevention of colorectal neoplasia. Neoplasia is defined 
      as precancerous lesions (e.g., adenoma and sessile serrated lesion) or cancer. 
      The scope of this review excludes dietary factors and high-risk individuals with 
      hereditary syndromes or inflammatory bowel disease. METHODS: The best practice 
      advice statements are based on a review of the literature to provide practical 
      advice. A formal systematic review and rating of the quality of evidence or 
      strength of recommendation were not performed. BEST PRACTICE ADVICE 1: In 
      individuals at average risk for CRC who are (1) younger than 70 years with a life 
      expectancy of at least 10 years, (2) have a 10-year cardiovascular disease risk 
      of at least 10%, and (3) not at high risk for bleeding, clinicians should use 
      low-dose aspirin to reduce CRC incidence and mortality. BEST PRACTICE ADVICE 2: 
      In individuals with a history of CRC, clinicians should consider using aspirin to 
      prevent recurrent colorectal neoplasia. BEST PRACTICE ADVICE 3: In individuals at 
      average risk for CRC, clinicians should not use non-aspirin NSAIDs to prevent 
      colorectal neoplasia because of a substantial risk of cardiovascular and 
      gastrointestinal adverse events. BEST PRACTICE ADVICE 4: In individuals with type 
      2 diabetes, clinicians may consider using metformin to prevent colorectal 
      neoplasia. BEST PRACTICE ADVICE 5: In individuals with CRC and type 2 diabetes, 
      clinicians may consider using metformin to reduce mortality. BEST PRACTICE ADVICE 
      6: Clinicians should not use calcium or vitamin D (alone or together) to prevent 
      colorectal neoplasia. BEST PRACTICE ADVICE 7: Clinicians should not use folic 
      acid to prevent colorectal neoplasia. BEST PRACTICE ADVICE 8: In individuals at 
      average risk for CRC, clinicians should not use statins to prevent colorectal 
      neoplasia. BEST PRACTICE ADVICE 9: In individuals with a history of CRC, 
      clinicians should not use statins to reduce mortality.
CI  - Published by Elsevier Inc.
FAU - Liang, Peter S
AU  - Liang PS
AD  - NYU Langone Health, New York, New York; VA New York Harbor Health Care System, 
      New York, New York. Electronic address: Peter.Liang@nyulangone.org.
FAU - Shaukat, Aasma
AU  - Shaukat A
AD  - University of Minnesota, Minneapolis, Minnesota; Minneapolis VA Health Care 
      System, Minneapolis, Minnesota.
FAU - Crockett, Seth D
AU  - Crockett SD
AD  - University of North Carolina School of Medicine, Chapel Hill, North Carolina.
LA  - eng
PT  - Practice Guideline
PT  - Review
DEP - 20210210
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal 
      of the American Gastroenterological Association
JID - 101160775
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Chemoprevention
MH  - *Colorectal Neoplasms/epidemiology/prevention & control
MH  - *Diabetes Mellitus, Type 2
MH  - Humans
MH  - Neoplasm Recurrence, Local
OTO - NOTNLM
OT  - Cancer
OT  - Chemoprevention
OT  - Colorectal
OT  - Neoplasia
EDAT- 2021/02/14 06:00
MHDA- 2021/09/07 06:00
CRDT- 2021/02/13 20:10
PHST- 2020/10/05 00:00 [received]
PHST- 2021/02/02 00:00 [revised]
PHST- 2021/02/08 00:00 [accepted]
PHST- 2021/02/14 06:00 [pubmed]
PHST- 2021/09/07 06:00 [medline]
PHST- 2021/02/13 20:10 [entrez]
AID - S1542-3565(21)00148-8 [pii]
AID - 10.1016/j.cgh.2021.02.014 [doi]
PST - ppublish
SO  - Clin Gastroenterol Hepatol. 2021 Jul;19(7):1327-1336. doi: 
      10.1016/j.cgh.2021.02.014. Epub 2021 Feb 10.

PMID- 31732119
OWN - NLM
STAT- MEDLINE
DCOM- 20200724
LR  - 20200724
IS  - 1531-5037 (Electronic)
IS  - 0022-3468 (Linking)
VI  - 55
IP  - 2
DP  - 2020 Feb
TI  - Anti-coagulation management in pediatric traumatic vascular injuries.
PG  - 324-330
LID - S0022-3468(19)30744-4 [pii]
LID - 10.1016/j.jpedsurg.2019.10.009 [doi]
AB  - BACKGROUND: Pediatric traumatic vascular injuries are rare. Given the paucity of 
      data to guide anti-coagulation (AC) management of these injuries in children, who 
      have a lower overall risk for thrombosis compared to their adult counterparts, we 
      sought to examine and summarize our recent experience. METHOD: We conducted a 
      retrospective review of all patients (<18 years old) who sustained traumatic 
      vascular injuries between 2010-2018 at a Level 1 and Level 2 Pediatric Trauma 
      Center. RESULTS: Ninety-nine patients had traumatic vascular injuries. 
      Eighty-four patients sustained a major arterial injury, 26 had a major venous 
      injury, and 11 had both arterial and venous injuries. The arterial injury cohort 
      had a median age of 13.3 years. Most of the arterial injury patients (65/84, 77%) 
      required vascular repair. In-hospital AC management for the arterial injury 
      patients consisted of a post-operative heparin drip (18%, 15/84), aspirin (39%, 
      26/84), enoxaparin (23%, 19/84), or none (42%, 43/84). Approximately one-half of 
      the patients with arterial injuries (54%, 45/84) were discharged home on AC 
      therapy, most commonly aspirin. Fifty-six patients (66%) followed up post-injury, 
      of which 25% (14/56) had experienced complications. CONCLUSION: Pediatric 
      traumatic arterial injuries that require surgical intervention other than 
      ligation should be considered for discharge AC - most commonly aspirin - in the 
      absence of contraindications. Pediatric patients with vascular injuries to the 
      aorta, carotid artery, inferior vena cava, portal vein, or lower extremities that 
      are managed non-operatively should also be considered for AC. The preferred AC 
      for pediatric venous injuries is enoxaparin, in the absence of contraindications. 
      STUDY TYPE: Treatment Study LEVEL OF EVIDENCE: IV.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Shahi, Niti
AU  - Shahi N
AD  - Division of Pediatric Surgery, Children's Hospital Colorado, Aurora, CO, USA; 
      Department of Surgery, University of Colorado School of Medicine, Aurora, CO, 
      USA. Electronic address: niti.shahi@childrenscolorado.org.
FAU - Phillips, Ryan
AU  - Phillips R
AD  - Division of Pediatric Surgery, Children's Hospital Colorado, Aurora, CO, USA; 
      Department of Surgery, University of Colorado School of Medicine, Aurora, CO, 
      USA.
FAU - Meier, Maxene
AU  - Meier M
AD  - The Center for Research in Outcomes for Children's Surgery, University of 
      Colorado School of Medicine, Aurora, CO, USA.
FAU - Nehler, Mark
AU  - Nehler M
AD  - Department of Surgery, University of Colorado School of Medicine, Aurora, CO, 
      USA.
FAU - Jacobs, Donald
AU  - Jacobs D
AD  - Department of Surgery, University of Colorado School of Medicine, Aurora, CO, 
      USA.
FAU - Recicar, John
AU  - Recicar J
AD  - Division of Pediatric Surgery, Children's Hospital Colorado, Aurora, CO, USA.
FAU - Bensard, Denis
AU  - Bensard D
AD  - Department of Surgery, University of Colorado School of Medicine, Aurora, CO, 
      USA; Department of Surgery, Denver Health Medical Center, Denver, CO, USA.
FAU - Moulton, Steven
AU  - Moulton S
AD  - Division of Pediatric Surgery, Children's Hospital Colorado, Aurora, CO, USA; 
      Department of Surgery, University of Colorado School of Medicine, Aurora, CO, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20191031
PL  - United States
TA  - J Pediatr Surg
JT  - Journal of pediatric surgery
JID - 0052631
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Postoperative Care
MH  - Retrospective Studies
MH  - Vascular System Injuries/*drug therapy/surgery
OTO - NOTNLM
OT  - Anti-coagulation
OT  - Antiplatelet therapy
OT  - Pediatric trauma
OT  - Vascular graft
OT  - Vascular injury
EDAT- 2019/11/17 06:00
MHDA- 2020/07/25 06:00
CRDT- 2019/11/17 06:00
PHST- 2019/10/16 00:00 [received]
PHST- 2019/10/17 00:00 [accepted]
PHST- 2019/11/17 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
PHST- 2019/11/17 06:00 [entrez]
AID - S0022-3468(19)30744-4 [pii]
AID - 10.1016/j.jpedsurg.2019.10.009 [doi]
PST - ppublish
SO  - J Pediatr Surg. 2020 Feb;55(2):324-330. doi: 10.1016/j.jpedsurg.2019.10.009. Epub 
      2019 Oct 31.

PMID- 27258204
OWN - NLM
STAT- MEDLINE
DCOM- 20170426
LR  - 20181202
IS  - 1875-8622 (Electronic)
IS  - 1386-0291 (Linking)
VI  - 65
IP  - 1
DP  - 2017
TI  - The effects of oral acetylsalicylic acid on blood fluidity and infusion speed 
      in the cancer patients with PICC.
PG  - 11-22
LID - 10.3233/CH-162068 [doi]
AB  - OBJECTIVE: This study aimed to examine the influence of oral acetylsalicylic acid 
      on blood fluidity and infusion speed in the cancer patients with Peripherally 
      Inserted Central Catheter (PICC). BACKGROUND: PICC is placed for prolonged 
      chemotherapy of cancer patients. The fibrin sheaths, which consist of cellular 
      substance and non-cellular substance, generate at the place of insertion and grow 
      down all over the catheter. Finally they cover the vent of the catheter and lead 
      to catheter dysfunctions such as the decrease of infusion speed. In addition, the 
      high viscosity status of cancer patients could lead to acute embolization, which 
      adds to the high risk of death. DESIGN: Randomized controlled trial. METHODS: 
      This research was carried out between April 2013 and January 2014 in the second 
      hospital of Xiangya, Central South University in Changsha, China. Initially 96 
      cancer participants with PICC were chosen and randomly allocated to experimental 
      and control group. The participants of the experimental group were conducted 
      route PICC maintain technique and took acetylsalicylic acid 100 mg per day after 
      dinner, while the control group received route PICC maintain technique only. The 
      infusion speed and hemorheology indexes of the two groups were tested before our 
      study and at the end of the 2nd and 4th months with several instruments. RESULTS: 
      Repeated measures analysis of variance indicated that taking acetylsalicylic acid 
      orally had significant main effect on high shear blood viscosity and red blood 
      cell deformability index (P < 0.05), and it also had significant main effect as 
      well as time effect on plasma viscosity (P < 0.05); and time had significant main 
      effect as well as interaction effect with oral acetylsalicylic acid on low shear 
      blood viscosity and red blood cell aggregation index (P < 0.05). Repeated 
      measures ANOVA also showed that taking acetylsalicylic acid orally had 
      significant main effect, time effect and interaction effect on infusion speed 
      (P < 0.01). CONCLUSION: Oral acetylsalicylic acid could improve hemorheology 
      condition and the infusion speed related to fibrin sheath in the cancer patients.
FAU - Ma, Lili
AU  - Ma L
AD  - School of Nursing, Henan University of Science and Technology, Luoyang, Henan, 
      China.
FAU - Xia, Chunfang
AU  - Xia C
AD  - The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
FAU - Sun, Xin
AU  - Sun X
AD  - School of Nursing, Central South University, Changsha, Hunan, China.
FAU - Zuo, Yulan
AU  - Zuo Y
AD  - The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
FAU - Zhao, Liping
AU  - Zhao L
AD  - The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/*therapeutic use
MH  - Catheterization, Peripheral/*instrumentation/methods
MH  - Female
MH  - Hemorheology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*therapy
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Peripherally Inserted Central Catheter (PICC)
OT  - cancer patients
OT  - fibrin sheaths
OT  - hemorheology
OT  - infusion speed
EDAT- 2016/06/04 06:00
MHDA- 2017/04/27 06:00
CRDT- 2016/06/04 06:00
PHST- 2016/06/04 06:00 [pubmed]
PHST- 2017/04/27 06:00 [medline]
PHST- 2016/06/04 06:00 [entrez]
AID - CH2068 [pii]
AID - 10.3233/CH-162068 [doi]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 2017;65(1):11-22. doi: 10.3233/CH-162068.

PMID- 27796503
OWN - NLM
STAT- MEDLINE
DCOM- 20170612
LR  - 20190320
IS  - 1613-7671 (Electronic)
IS  - 0043-5325 (Linking)
VI  - 128
IP  - Suppl 7
DP  - 2016 Dec
TI  - Spontaneous pulmonary hematoma in a patient with sepsis treated with dual 
      antiplatelet therapy.
PG  - 553-556
AB  - A 72-year-old patient was admitted to the medical intensive care unit due to 
      a right-sided, hospital-acquired pneumonia and septic shock with respiratory 
      failure and deterioration of chronic renal failure. During hospitalization the 
      patient required hemodynamic support with norepinephrine and dobutamine, 
      mechanical ventilation and hemodialysis. The patient suffered a non-ST segment 
      elevation myocardial infarction (NSTEMI) and received dual antiplatelet therapy. 
      After 14 days an acute intrapulmonary infiltrate of unknown origin developed, 
      accompanied by fever and a significant increase of the C‑reactive protein (CRP) 
      level. Chest radiography and a computed tomography (CT) scan showed 
      a well-defined, round, high-attenuation lesion in the lungs and a suspected 
      infected pulmonary hematoma, which was confirmed by percutaneous aspiration 
      biopsy. There was no evidence of trauma and it is believed that the hematoma 
      occurred spontaneously, probably because of the dual antiplatelet therapy. Double 
      antibiotic treatment was started but no surgery was performed after consultation 
      with a thoracic surgeon. The antiplatelet drugs were temporarily withdrawn until 
      the size of the hematoma showed no further increase and then antiplatelet therapy 
      was continued. After stabilization the patient was discharged from hospital and 6 
      months later a follow-up chest X‑ray showed almost complete resolution of the 
      hematoma.
FAU - Vlaović, Janko
AU  - Vlaović J
AUID- ORCID: 0000-0002-7275-8422
AD  - Department of Intensive Internal Medicine, General Hospital Celje, Oblakova 
      ulica 5, 3000, Celje, Slovenia. janko.vlaovic@gmail.com.
FAU - Voga, Gorazd
AU  - Voga G
AD  - Department of Intensive Internal Medicine, General Hospital Celje, Oblakova 
      ulica 5, 3000, Celje, Slovenia.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20161028
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Diagnosis, Differential
MH  - Hematoma/*chemically induced/diagnosis/therapy
MH  - Humans
MH  - Lung Diseases/*chemically induced/diagnosis/therapy
MH  - Male
MH  - Platelet Aggregation Inhibitors/*adverse effects/*therapeutic use
MH  - Shock, Septic/*complications/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Dual antiplatelet therapy
OT  - Hematoma
OT  - Lungs
EDAT- 2016/11/01 06:00
MHDA- 2019/03/21 06:00
CRDT- 2016/11/01 06:00
PHST- 2016/07/09 00:00 [received]
PHST- 2016/10/04 00:00 [accepted]
PHST- 2016/11/01 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
PHST- 2016/11/01 06:00 [entrez]
AID - 10.1007/s00508-016-1107-5 [pii]
AID - 10.1007/s00508-016-1107-5 [doi]
PST - ppublish
SO  - Wien Klin Wochenschr. 2016 Dec;128(Suppl 7):553-556. doi: 
      10.1007/s00508-016-1107-5. Epub 2016 Oct 28.

PMID- 21745179
OWN - NLM
STAT- MEDLINE
DCOM- 20121207
LR  - 20191112
IS  - 1875-6220 (Electronic)
IS  - 1570-1638 (Linking)
VI  - 9
IP  - 3
DP  - 2012 Sep
TI  - Crosslinked, polymerized, and PEG-conjugated hemoglobin-based oxygen carriers: 
      clinical safety and efficacy of recent and current products.
PG  - 158-65
AB  - Blood substitutes, especially hemoglobin based oxygen carriers (HBOC) have been 
      widely studied and reviewed over the past 30 years. The development of HBOCs was 
      highlighted by crosslinking to minimize adverse effects. However, even early 
      attempts at single crosslinking using alpha-alpha crosslinks or diaspirin 
      crosslinking failed clinical trials due to renal morbidity and increased 
      mortality. In fact, preclinical trials may have predicted failure of this first 
      generation product, DCLHb (diaspirin-crosslinked Hb) (HemAssist ®, Baxter). In 
      the 1980's, three small biopharmaceutical companies developed "second generation" 
      HBOCs, the first being Hemosol with their raffinose crosslinked HBOC, hemoglobin- 
      raffimer. The other two development programs modified the HBOC using 
      glutaraldehyde polymerization, in an attempt to further alleviate the toxicities 
      of the "first" generation HBOCs. This paper will review the definitive clinical 
      trials of the two polymerized HBOCs, Biopure's hemoglobin glutamer-250 (bovine) 
      and Northfield's polymerized human Hb, pegylated HBOC and Sangart's 
      peg-conjugated HBOC, with an introductory brief review of Hemosol's 
      hemoglobinraffimer. The paper will then introduce the newest polymerized 
      hemoglobin, zero-linked hemoglobin polymer, which has not yet undergone clinical 
      trials but has undergone some preclinical work that will be discussed in a 
      section on this product. As a new generation HBOC, zero-linked hemoglobin polymer 
      may begin to address the issues presented by the first two generations of HBOCs, 
      and may hold promise as a universally applicable HBOC.
FAU - Jahr, Jonathan S
AU  - Jahr JS
AD  - David Geffen School of Medicine at UCLA, Ronald Reagan UCLA Medical Center, 757 
      Westwood Plaza, Los Angeles, CA 90095, USA. jsjahr@mednet.ucla.edu
FAU - Akha, Arezou Sadighi
AU  - Akha AS
FAU - Holtby, Randall J
AU  - Holtby RJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Discov Technol
JT  - Current drug discovery technologies
JID - 101157212
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 0 (Maleimides)
RN  - 0 (OxyVita)
RN  - 0 (PEG-hemoglobin)
RN  - 0 (maleimide-polyethylene glycol-modified hemoglobin, MP4)
RN  - 1XQE66T19H (HBOC 201)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Blood Substitutes/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Hemoglobins/*metabolism/therapeutic use
MH  - Humans
MH  - Maleimides/therapeutic use
MH  - Oxygen/*blood
MH  - Polyethylene Glycols/*metabolism/therapeutic use
EDAT- 2011/07/13 06:00
MHDA- 2012/12/12 06:00
CRDT- 2011/07/13 06:00
PHST- 2010/11/30 00:00 [received]
PHST- 2011/02/17 00:00 [revised]
PHST- 2011/07/01 00:00 [accepted]
PHST- 2011/07/13 06:00 [entrez]
PHST- 2011/07/13 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
AID - BSP/CDDT/E-Pub/00078 [pii]
AID - 10.2174/157016312802650742 [doi]
PST - ppublish
SO  - Curr Drug Discov Technol. 2012 Sep;9(3):158-65. doi: 10.2174/157016312802650742.

PMID- 8008719
OWN - NLM
STAT- MEDLINE
DCOM- 19940721
LR  - 20190904
IS  - 0901-9928 (Print)
IS  - 0901-9928 (Linking)
VI  - 74
IP  - 3
DP  - 1994 Mar
TI  - Low dose acetylsalicylic acid in the antithrombotic treatment of patients with 
      stable angina pectoris and acute coronary syndromes (unstable angina pectoris and 
      acute myocardial infarction).
PG  - 141-7
AB  - Acetylsalicylic acid has an antithrombotic effect by inhibition of thromboxane A2 
      synthesis in platelets. Thromboxane A2 is a potent stimulator of platelet 
      aggregation and vasoconstriction and synthesis may be completely inhibited by a 
      single oral dose of 150 mg acetylsalicylic acid or an intravenous dose of 100 mg. 
      A daily maintenance dose of 75 mg acetylsalicylic acid is sufficient to 
      effectively inhibit thromboxane A2 synthesis in long-term treatment. 
      Acetylsalicylic acid therapy reduces acute myocardial infarction and sudden death 
      in patients with stable angina pectoris and the drug is equally effective in 
      patients with symptomatic and 'silent' angina pectoris. Early intervention with 
      acetylsalicylic acid in patients with unstable angina pectoris reduces the risk 
      of acute myocardial infarction and death. In patients with acute myocardial 
      infarction, acute therapy with acetylsalicylic acid significantly reduces 
      mortality both in monotherapy and in combination with thrombolytics. In the 
      secondary prophylaxis following acute myocardial infarction, acetylsalicylic acid 
      reduces the incidence of reinfarction and coronary death. Treatment of 100 
      patients with acute coronary syndrome (unstable angina pectoris or acute 
      myocardial infarction) for 2 years may hinder the development of 3-4 fatal and 4 
      non-fatal vascular events. The risk of gastrointestinal side-effects and bleeding 
      during acetylsalicylic acid therapy is dose-dependent and the incidence is low 
      with a daily dose of 75-150 mg.
FAU - Winther, K
AU  - Winther K
AD  - Department of Clinical Chemistry, Glostrup Hospital, University of Copenhagen, 
      Denmark.
FAU - Husted, S E
AU  - Husted SE
FAU - Vissinger, H
AU  - Vissinger H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Denmark
TA  - Pharmacol Toxicol
JT  - Pharmacology & toxicology
JID - 8702180
RN  - 0 (Antithrombins)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Angina Pectoris/*drug therapy
MH  - Antithrombins/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Myocardial Infarction/*drug therapy
MH  - Thromboxane A2/antagonists & inhibitors
RF  - 54
EDAT- 1994/03/01 00:00
MHDA- 1994/03/01 00:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 1994/03/01 00:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
AID - 10.1111/j.1600-0773.1994.tb01089.x [doi]
PST - ppublish
SO  - Pharmacol Toxicol. 1994 Mar;74(3):141-7. doi: 10.1111/j.1600-0773.1994.tb01089.x.

PMID- 34147883
OWN - NLM
STAT- MEDLINE
DCOM- 20211213
LR  - 20211214
IS  - 2210-7797 (Electronic)
IS  - 2210-7789 (Linking)
VI  - 25
DP  - 2021 Aug
TI  - Informational needs related to aspirin prophylactic therapy amongst pregnant 
      women at risk of preeclampsia - A qualitative study.
PG  - 161-168
LID - S2210-7789(21)00067-2 [pii]
LID - 10.1016/j.preghy.2021.06.006 [doi]
AB  - OBJECTIVE: Despite being key to reducing the occurrence of pre-eclampsia in 
      high-risk women, adherence to aspirin prophylaxis is low, reflecting 
      multifactorial challenges faced by pregnant women. It is therefore important to 
      understand the barriers and facilitators of aspirin adherence in pregnancy. This 
      sub-analysis of a qualitative study conducted to better understand barriers and 
      facilitators of aspirin adherence was set to describe informational needs related 
      to aspirin use in pregnancy. STUDY DESIGN: A qualitative study was conducted with 
      14 postnatal women from North-East of England, who declared various levels of 
      non-adherence to aspirin (0-5/7 prescribed). A thematic framework analysis of 
      semi-structured interviews was used. OUTCOME MEASURES: Emerging themes associated 
      with informational needs about aspirin use in pregnancy. RESULTS: Main themes 
      identified a) Informational needs, b) Nature of the information seeking behaviour 
      (active vs passive), c) Sources of information, d) Preferred format of 
      information, e) Partners seeking knowledge. Not all women actively seek 
      information; some choose not to pursue it as they find thinking of hypothetical 
      risks disturbing. When information is accessed, women use a wide range of 
      informational resources from scientific articles and National Health Services 
      website to social media sources and word-of-mouth. Women admit that reading 
      leaflets can be difficult, preferring to receive information in interactive ways. 
      Although partners seek information about risks and risk reduction strategies, 
      they are often not included in conversations with health care professionals. 
      CONCLUSION: New interactive and accessible informational resources are needed to 
      engage pregnant women and their partners in aspirin prophylactic therapy.
CI  - Copyright © 2021. Published by Elsevier B.V.
FAU - Vinogradov, Raya
AU  - Vinogradov R
AD  - Research Directorate, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK. 
      Electronic address: raya.vinogradov@ncl.ac.uk.
FAU - Smith, Vikki Joanne
AU  - Smith VJ
AD  - Nursing, Midwifery & Health Department, Northumbria University, UK.
FAU - Robson, Stephen Courtenay
AU  - Robson SC
AD  - Women's Services, Newcastle upon Tyne Hospitals NHS Foundation Trust and 
      Population Health Sciences, Reproductive and Vascular Biology Group, Newcastle 
      University, UK.
FAU - Araujo-Soares, Vera
AU  - Araujo-Soares V
AD  - University of Twente, BMS Faculty, Health Technology and Services Research 
      (HTSR), Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20210612
PL  - Netherlands
TA  - Pregnancy Hypertens
JT  - Pregnancy hypertension
JID - 101552483
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - *Patient Compliance
MH  - *Patient Education as Topic
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - *Prenatal Care
MH  - Qualitative Research
MH  - State Medicine
MH  - Young Adult
OTO - NOTNLM
OT  - Adherence to medication in pregnancy
OT  - Aspirin
OT  - Information needs
OT  - Knowledge
EDAT- 2021/06/21 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/06/20 20:48
PHST- 2020/11/10 00:00 [received]
PHST- 2021/05/25 00:00 [revised]
PHST- 2021/06/08 00:00 [accepted]
PHST- 2021/06/21 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/06/20 20:48 [entrez]
AID - S2210-7789(21)00067-2 [pii]
AID - 10.1016/j.preghy.2021.06.006 [doi]
PST - ppublish
SO  - Pregnancy Hypertens. 2021 Aug;25:161-168. doi: 10.1016/j.preghy.2021.06.006. Epub 
      2021 Jun 12.

PMID- 2055420
OWN - NLM
STAT- MEDLINE
DCOM- 19910731
LR  - 20190824
IS  - 0306-3623 (Print)
IS  - 0306-3623 (Linking)
VI  - 22
IP  - 2
DP  - 1991
TI  - Does the association dipyridamole-aspirin only act by a functional synergism?
PG  - 271-4
AB  - 1. Some of the antiplatelet effects of the dipyridamole-aspirin association may 
      be explained by a functional (additive) synergism, but other effects by a 
      potentiation synergism. 2. Platelet adhesivity and aggregation induced by ADP, 
      adrenaline and collagen, and malondialdehyde production, are tests in which 
      dipyridamole and aspirin shows a potentiation synergism.
FAU - De la Cruz, J P
AU  - De la Cruz JP
AD  - Department of Pharmacology and Therapeutics, School of Medicine, University of 
      Málaga, Spain.
FAU - Sanchez de la Cuesta, F
AU  - Sanchez de la Cuesta F
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gen Pharmacol
JT  - General pharmacology
JID - 7602417
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/metabolism
MH  - Dipyridamole/*pharmacology
MH  - Drug Combinations
MH  - Drug Synergism
MH  - Humans
MH  - In Vitro Techniques
MH  - Malondialdehyde/blood
MH  - Platelet Adhesiveness
MH  - Platelet Aggregation/drug effects
MH  - *Platelet Aggregation Inhibitors
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 0306-3623(91)90446-D [pii]
AID - 10.1016/0306-3623(91)90446-d [doi]
PST - ppublish
SO  - Gen Pharmacol. 1991;22(2):271-4. doi: 10.1016/0306-3623(91)90446-d.

PMID- 1124868
OWN - NLM
STAT- MEDLINE
DCOM- 19750702
LR  - 20131121
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 34
IP  - 5
DP  - 1975 May
TI  - Induced bleeding changes with aspirin in various tolerant and intolerant patient 
      groups.
PG  - 315-22
AB  - The advantages of aspirin as a first stage anti-hemostatic agent, combined with 
      its relatively low cost, ease of administration and simplicity of control, have 
      led to its use in prophylaxis for atherosclerotic and thromboembolic disease 
      processes, in addition to its long established employment as an analgesic and 
      antipyretic agent. However, adverse reactions in aspirin-hypersensitive patients 
      have led to reappraisal of the risks involved in its casual administration. A 
      method to reduce such risks is proposed.
FAU - Fisherman, E W
AU  - Fisherman EW
FAU - Cohen, G N
AU  - Cohen GN
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - 0 (Iodides)
RN  - 0 (Polysorbates)
RN  - 1P9D0Z171K (Butylated Hydroxytoluene)
RN  - 25013-16-5 (Butylated Hydroxyanisole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Blood Coagulation Tests
MH  - Butylated Hydroxyanisole
MH  - Butylated Hydroxytoluene
MH  - Diabetes Mellitus
MH  - Drug Hypersensitivity/immunology
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Immune Tolerance
MH  - Iodides
MH  - Polysorbates
EDAT- 1975/05/01 00:00
MHDA- 1975/05/01 00:01
CRDT- 1975/05/01 00:00
PHST- 1975/05/01 00:00 [pubmed]
PHST- 1975/05/01 00:01 [medline]
PHST- 1975/05/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1975 May;34(5):315-22.

PMID- 7574228
OWN - NLM
STAT- MEDLINE
DCOM- 19951107
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 123
IP  - 9
DP  - 1995 Nov 1
TI  - Medical compared with surgical treatment of asymptomatic carotid artery stenosis.
PG  - 720-2
AB  - The Asymptomatic Carotid Atherosclerosis Study (ACAS) results suggest that 
      carotid endarterectomy combined with aspirin and risk factor reduction is 
      superior to aspirin and risk factor reduction is superior to aspirin and risk 
      factor reduction alone in preventing ipsilateral stroke in asymptomatic patients 
      with diameter stenosis of the carotid artery of 60% or more. The absolute risk 
      reduction over 5 years conferred by surgical therapy is modest (5.9%) compared 
      with the risk reduction conferred by surgical therapy for symptomatic carotid 
      disease but compares favorably with the degree of stroke prevention shown for 
      antihypertensive therapy in the elderly. For prevention of stroke in women and 
      for prevention of major stroke, the ACAS results favoring surgery did not reach 
      statistical significance. The combined arteriographic and perioperative 
      surgery-related mortality and stroke rates achieved by the carefully selected 
      surgical teams was low (2.3%). Accordingly, carotid endarterectomy can be 
      recommended for preventing stroke in the setting of hemodynamically significant 
      stenosis when the arteriographic and surgical complication rates can be kept low.
FAU - Brott, T
AU  - Brott T
AD  - University of Cincinnati Medical Center, Ohio, USA.
FAU - Toole, J F
AU  - Toole JF
LA  - eng
GR  - NS22611/NS/NINDS NIH HHS/United States
PT  - Comment
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 1995 Nov 1;123(9):649-55. PMID: 7574219
CON - Ann Intern Med. 1995 Nov 1;123(9):649-55. PMID: 7574219
CON - Ann Intern Med. 1995 Nov 1;123(9):729. PMID: 7574232
MH  - Aspirin/therapeutic use
MH  - Carotid Stenosis/surgery/*therapy
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Combined Modality Therapy
MH  - Endarterectomy, Carotid
MH  - Female
MH  - Humans
MH  - Male
MH  - Risk Factors
RF  - 21
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 10.7326/0003-4819-123-9-199511010-00011 [doi]
PST - ppublish
SO  - Ann Intern Med. 1995 Nov 1;123(9):720-2. doi: 
      10.7326/0003-4819-123-9-199511010-00011.

PMID- 12519590
OWN - NLM
STAT- MEDLINE
DCOM- 20030221
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 4
DP  - 2002
TI  - Anticoagulants versus antiplatelet agents for acute ischaemic stroke.
PG  - CD003242
AB  - BACKGROUND: Antiplatelet agents produce a small, but worthwhile benefit in 
      long-term functional outcome and survival, and have become standard treatment for 
      acute ischaemic stroke. Anticoagulants are often used as an alternative 
      treatment, despite evidence that they are ineffective in producing long-term 
      benefits. We wanted to review trials which have directly compared anticoagulants 
      and antiplatelet agents, to assess whether any anticoagulant regimen offers net 
      advantages over antiplatelet agents, overall or in some particular category of 
      patients (e.g. patients with atrial fibrillation). OBJECTIVES: a) To assess the 
      effectiveness of anticoagulants compared with antiplatelet agents in acute 
      ischaemic stroke b) To assess whether the addition of anticoagulants to 
      antiplatelet agents offers any net advantage over antiplatelet agents alone. 
      SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register, the 
      Cochrane Controlled Trials Register (Central/CCTR), the trials register held by 
      the Antithrombotic Therapy Trialists' Collaboration, MEDLINE (1966-2000), and 
      EMBASE (1980-2000). All searches were performed during April and May 2001. 
      SELECTION CRITERIA: Truly unconfounded, randomised-controlled trials comparing 
      anticoagulants with antiplatelet agents, or anticoagulants and antiplatelet 
      agents with antiplatelet agents alone, given within 14 days of onset of presumed 
      or confirmed ischaemic stroke. DATA COLLECTION AND ANALYSIS: Both reviewers 
      independently selected trials for inclusion in the review, assessed trial quality 
      and extracted data. MAIN RESULTS: A total of 16,558 patients from four trials 
      contributed to the analyses. The methodological quality was high in all four 
      trials. The anticoagulants tested were unfractionated heparin (UFH) and low 
      molecular-weight heparin. Aspirin was used as control in all trials. Overall, 
      there was no evidence that anticoagulants were superior to aspirin in reducing 
      'death or dependency' at long-term follow-up (odds ratio [OR] 1.07, 95% 
      confidence interval [95% CI] 0.98-1.15). Compared with aspirin, anticoagulants 
      were associated with a small but significant increase in the number of deaths at 
      the end of follow-up (OR 1.10, 95% CI 1.01-1.29), equivalent to 20 more deaths 
      (95% CI 0-30) per 1000 patients treated; a significant increased risk of 
      symptomatic intracranial haemorrhage (OR 2.35, 95% CI 1.49-3.46); and a 
      non-significant increased risk of 'any recurrent stroke' during treatment (OR 
      1.20, 95% CI 0.99-1.46). These neutral or adverse effects outweighed a small, but 
      significant effect on symptomatic deep vein thrombosis (OR 1.20, 95% CI 
      0.07-0.58), equivalent to 10 fewer (95% CI 0-30) DVTs by 14 days per 1000 
      patients treated with anticoagulants instead of aspirin. Subgroup analysis could 
      not identify any type, dose, or route of administration of anticoagulants 
      associated with net benefit, or any benefit in patients with atrial fibrillation. 
      Overall, the combination of UFH and aspirin did not appear to be associated with 
      a net advantage over aspirin alone. A subgroup analysis showed that, compared 
      with aspirin, the combination of low-dose UFH and aspirin was associated with a 
      marginally significant reduced risk of 'any recurrent stroke' (OR 0.75, 95% CI 
      0.56-1.03) and a marginally significant reduced risk of death at 14 days (OR 
      0.84, 95% CI 0.69-1.01), and with no clear adverse effect on death at end of 
      follow-up (OR 0.98, 95% CI 0.85-1.12). REVIEWER'S CONCLUSIONS: Anticoagulants 
      offered no net advantages over antiplatelet agents in acute ischaemic stroke. The 
      combination of low-dose UFH and aspirin appeared in a subgroup analysis to be 
      associated with net benefits compared with aspirin alone, and this merits further 
      research.
FAU - Berge, E
AU  - Berge E
AD  - Dept of Internal Medicine, Ullevål University Hospital, N-0407 Oslo, Norway. 
      eivind.berge@ioks.uio.no
FAU - Sandercock, P
AU  - Sandercock P
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 2003 Jul-Aug;139(1):5. PMID: 12841709
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Cerebral Infarction/*drug therapy
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
RF  - 33
EDAT- 2003/01/10 04:00
MHDA- 2003/02/22 04:00
CRDT- 2003/01/10 04:00
PHST- 2003/01/10 04:00 [pubmed]
PHST- 2003/02/22 04:00 [medline]
PHST- 2003/01/10 04:00 [entrez]
AID - 10.1002/14651858.CD003242 [doi]
PST - ppublish
SO  - Cochrane Database Syst Rev. 2002;(4):CD003242. doi: 10.1002/14651858.CD003242.

PMID- 6660269
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20190627
IS  - 0002-9394 (Print)
IS  - 0002-9394 (Linking)
VI  - 96
IP  - 6
DP  - 1983 Dec
TI  - Aspirin and recurrent hyphema after blunt ocular trauma.
PG  - 797-801
AB  - Recurrent hyphema after traumatic blunt injury to the eye is associated with a 
      more serious prognosis than that occurring from the initial trauma, resulting in 
      a higher risk of glaucoma, corneal staining, surgical intervention, poor visual 
      acuity, and enucleation. Risk factors associated with the development of 
      recurrent bleeding are not well defined, but recent evidence suggests a high 
      association with concurrent aspirin ingestion. Of 25 consecutive patients with 
      hyphemas (20 males and five females, ranging in age from 2 to 53 years), 12 took 
      aspirin after the initial trauma and seven had recurrent hyphemas. Platelet 
      aggregation determinations in these seven patients showed defects associated with 
      aspirin. Only one of 13 patients without aspirin intake had recurrent bleeding.
FAU - Ganley, J P
AU  - Ganley JP
FAU - Geiger, J M
AU  - Geiger JM
FAU - Clement, J R
AU  - Clement JR
FAU - Rigby, P G
AU  - Rigby PG
FAU - Levy, G J
AU  - Levy GJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Eye Injuries/*complications
MH  - Female
MH  - Humans
MH  - Hyphema/*chemically induced
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Wounds, Nonpenetrating/*complications
EDAT- 1983/12/01 00:00
MHDA- 1983/12/01 00:01
CRDT- 1983/12/01 00:00
PHST- 1983/12/01 00:00 [pubmed]
PHST- 1983/12/01 00:01 [medline]
PHST- 1983/12/01 00:00 [entrez]
AID - S0002-9394(14)71926-9 [pii]
AID - 10.1016/s0002-9394(14)71926-9 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 1983 Dec;96(6):797-801. doi: 10.1016/s0002-9394(14)71926-9.

PMID- 57733
OWN - NLM
STAT- MEDLINE
DCOM- 19760706
LR  - 20131121
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 36
IP  - 4
DP  - 1976 Apr
TI  - A serum factor in aspirin intolerance disease.
PG  - 250-62
AB  - Direct and indirect intradermal serum challenge with aspirin intolerant sera in 
      both aspirin tolerant and intolerant patients demonstrated a heat, cold and 
      storage stable serum factor capable of inducing acute anti-hemostatic effects and 
      in some aspirin intolerant patients exacerbation of brief induced clinical 
      symptoms. The data supports a hypothesis for possible induced, conformationally 
      altered gamma globulin resulting from low molecular weight chemical exposures 
      such as aspirin with ensuing recognition by a genetically determined 
      subpopulation of B-lymphocytes with surface membrane receptors avid for the Fc 
      portion of altered gamma globulin or some conformationally altered gamma globulin 
      fraction leading to immune and/or interprotein complexes with subsequent 
      alterations of adrenergic, cholinergic and/or metabolic pharmacologic pathways.
FAU - Fisherman, E W
AU  - Fisherman EW
FAU - Cohen, G N
AU  - Cohen GN
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - 0 (Serum Albumin)
RN  - 0 (gamma-Globulins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Blood Coagulation/drug effects
MH  - Blood Coagulation Tests
MH  - Drug Hypersensitivity/*blood/physiopathology
MH  - Drug Tolerance
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Serum Albumin
MH  - gamma-Globulins
EDAT- 1976/04/01 00:00
MHDA- 1976/04/01 00:01
CRDT- 1976/04/01 00:00
PHST- 1976/04/01 00:00 [pubmed]
PHST- 1976/04/01 00:01 [medline]
PHST- 1976/04/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1976 Apr;36(4):250-62.

PMID- 26517138
OWN - NLM
STAT- MEDLINE
DCOM- 20160912
LR  - 20221207
IS  - 1482-1826 (Electronic)
IS  - 1482-1826 (Linking)
VI  - 18
IP  - 3
DP  - 2015
TI  - The Implication of the Polymorphisms of COX-1, UGT1A6, and CYP2C9 among 
      Cardiovascular Disease (CVD) Patients Treated with Aspirin.
PG  - 474-83
AB  - PURPOSE:   Enzymes potentially responsible for the pharmacokinetic variations of 
      aspirin include cyclooxygenase-1 (COX-1), UDP-glucuronosyltransferase (UGT1A6) 
      and P450 (CYP) (CYP2C9). We therefore aimed to determine the types and 
      frequencies of variants of COX-1 (A-842G), UGT1A6 (UGT1A6*2; A541G and UGT1A6*3; 
      A522C) and CYP2C9 (CYP2C9*3; A1075C) in the three major ethnic groups in 
      Malaysia. In addition, the role of these polymorphisms on aspirin-induced 
      gastritis among the patients was investigated. METHODS: A total of 165 patients 
      with cardiovascular disease who were treated with 75-150 mg daily dose of aspirin 
      and 300 healthy volunteers were recruited. DNA was extracted from the blood 
      samples and genotyped for COX-1 (A-842G), UGT1A6 (UGT1A6*2 and UGT1A6*3) and 
      CYP2C9 (CYP2C9*3; A1075C) using allele specific polymerase chain reaction 
      (AS-PCR). RESULTS: Variants UGT1A6*2,*3 and CYP2C9*3 were detected in relatively 
      high percentage of 22.83%, 30.0% and 6.50%, respectively; while COX-1 (A-842G) 
      was absent. The genotype frequencies for UGT1A6*2 and *3 were significantly 
      different between Indians and Malays or Chinese. The level of bilirubin among 
      patients with different genotypes of UGT1A6 was significantly different (p-value 
      &lt; 0.05). In addition, CYP2C9*3 was found to be associated with gastritis with 
      an odd ratio of 6.8 (95 % Cl OR: 1.39 - 33.19; P = 0.033). CONCLUSION: Screening 
      of patients with defective genetic variants of UGT1A6 and CYP2C9*3 helps in 
      identifying patients at risk of aspirin induced gastritis. However, a randomised 
      clinical study of bigger sample size would be needed before it is translated to 
      clinical use.
FAU - Jalil, Nur Jalinna Abdul
AU  - Jalil NJ
AD  - Integrative Pharmacogenomics Institute (iPROMISE), Universiti Teknologi MARA, 
      Selangor, Malaysia.
FAU - Bannur, Zakaria
AU  - Bannur Z
FAU - Derahman, A
AU  - Derahman A
FAU - Maskon, O
AU  - Maskon O
FAU - Darinah, Noor
AU  - Darinah N
FAU - Hamidi, Hamat
AU  - Hamidi H
FAU - Gunasekaran, Osama Ali
AU  - Gunasekaran OA
FAU - Rafizi, Mohd
AU  - Rafizi M
FAU - Azreen, Nur Izatul
AU  - Azreen NI
FAU - Kek, Teh Lay
AU  - Kek TL
FAU - Salleh, Mohd Zaki
AU  - Salleh MZ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - J Pharm Pharm Sci
JT  - Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian 
      Society for Pharmaceutical Sciences, Societe canadienne des sciences 
      pharmaceutiques
JID - 9807281
RN  - EC 1.14.13.- (CYP2C9 protein, human)
RN  - EC 1.14.13.- (Cytochrome P-450 CYP2C9)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 2.4.1.- (UDP-glucuronosyltransferase, UGT1A6)
RN  - EC 2.4.1.17 (Glucuronosyltransferase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Asian People/genetics
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*genetics
MH  - Cyclooxygenase 1/*genetics
MH  - Cytochrome P-450 CYP2C9/*genetics
MH  - Female
MH  - Gastritis/chemically induced/genetics
MH  - Glucuronosyltransferase/*genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic/*genetics
MH  - Treatment Outcome
MH  - White People/genetics
MH  - Young Adult
EDAT- 2015/11/01 06:00
MHDA- 2016/09/13 06:00
CRDT- 2015/10/31 06:00
PHST- 2015/10/31 06:00 [entrez]
PHST- 2015/11/01 06:00 [pubmed]
PHST- 2016/09/13 06:00 [medline]
AID - 10.18433/j3fc7f [doi]
PST - ppublish
SO  - J Pharm Pharm Sci. 2015;18(3):474-83. doi: 10.18433/j3fc7f.

PMID- 24054359
OWN - NLM
STAT- MEDLINE
DCOM- 20131114
LR  - 20131121
IS  - 1534-4436 (Electronic)
IS  - 1081-1206 (Linking)
VI  - 111
IP  - 4
DP  - 2013 Oct
TI  - Use of nasal inspiratory flow rates in the measurement of aspirin-induced 
      respiratory reactions.
PG  - 252-5
LID - S1081-1206(13)00488-2 [pii]
LID - 10.1016/j.anai.2013.07.009 [doi]
AB  - BACKGROUND: Nasal ketorolac challenge with modified oral aspirin challenge is a 
      safe and effective alternative for desensitizing patients with 
      aspirin-exacerbated respiratory disease. In addition to clinical judgment, 
      objective tests assessing nasal flow may help in diagnosing nasal reactions. 
      OBJECTIVE: To evaluate the feasibility of peak nasal inspiratory flow (PNIF) as 
      an objective measurement in the assessment of a reaction to nasal ketorolac and 
      to determine changes in PNIF that have adequate sensitivity and specificity. 
      METHODS: One hundred fifty-one patients referred to the Scripps Clinic for 
      aspirin challenge and desensitization and 14 healthy controls participated in the 
      study. Percentages of decrease in PNIF during reactions were compared with the 
      nonreactors' measurements. A receiver operating characteristic curve was 
      constructed to assess the diagnostic performance of PNIF measurement during a 
      clinically positive nasal challenge. RESULTS: A total of 165 subjects 
      participated in the study. One hundred fourteen patients (69.1%) clinically 
      reacted to the nasal ketorolac challenge. There was no statistical difference 
      between nasal reactors and nonreactors regarding sex, baseline forced expiratory 
      volume in 1 second, and use of systemic steroid before challenge. The mean 
      percentage of decrease in PNIF was significantly higher in the reactor group 
      (-0.30 ± 0.29 vs -0.07 ± 0.16, P < .001). A cutoff value of 25% decrease in PNIF 
      had the maximum sensitivity and specificity (56.1% and 94.1%). CONCLUSION: The 
      high specificity of a 25% decrease in PNIF found in receiver operating 
      characteristic curve analysis indicated that PNIF measurements can be useful for 
      assessing nasal reactions during nasal ketorolac challenges in the diagnosis of 
      aspirin-exacerbated respiratory disease.
CI  - Copyright © 2013. Published by Elsevier Inc.
FAU - Celikel, Serhat
AU  - Celikel S
AD  - Department of Pulmonary, Istanbul Medical University School of Medicine, 
      Istanbul, Turkey.
FAU - Stevenson, Donald
AU  - Stevenson D
FAU - Erkorkmaz, Unal
AU  - Erkorkmaz U
FAU - White, Andrew A
AU  - White AA
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20130802
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - YZI5105V0L (Ketorolac)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Inhalation
MH  - Ketorolac/administration & dosage/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Nose/physiopathology
MH  - Respiratory Function Tests
MH  - Respiratory Tract Diseases/chemically induced/*diagnosis/physiopathology
MH  - *Rhinomanometry
EDAT- 2013/09/24 06:00
MHDA- 2013/11/15 06:00
CRDT- 2013/09/24 06:00
PHST- 2013/03/20 00:00 [received]
PHST- 2013/07/08 00:00 [revised]
PHST- 2013/07/10 00:00 [accepted]
PHST- 2013/09/24 06:00 [entrez]
PHST- 2013/09/24 06:00 [pubmed]
PHST- 2013/11/15 06:00 [medline]
AID - S1081-1206(13)00488-2 [pii]
AID - 10.1016/j.anai.2013.07.009 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2013 Oct;111(4):252-5. doi: 
      10.1016/j.anai.2013.07.009. Epub 2013 Aug 2.

PMID- 30852971
OWN - NLM
STAT- MEDLINE
DCOM- 20200108
LR  - 20210503
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 50
IP  - 4
DP  - 2019 Apr
TI  - Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient 
      Ischemic Attack.
PG  - 947-953
LID - 10.1161/STROKEAHA.118.023978 [doi]
AB  - Background and Purpose- The role of aspirin plus clopidogrel (A+C) therapy 
      compared with aspirin monotherapy in patients presenting with acute ischemic 
      stroke (IS) or transient ischemic attack remains uncertain. We conducted this 
      study to determine the optimal period of efficacy and safety of A+C compared with 
      aspirin monotherapy. Methods- Ten randomized controlled trials (15 434 patients) 
      were selected using MEDLINE, EMBASE, and the Cochrane Central Register of 
      Controlled Trials (CENTRAL) (inception June 2018) comparing A+C with aspirin 
      monotherapy in patients with transient ischemic attack or IS. The primary 
      efficacy outcome was recurrent IS, and the primary safety outcome was major 
      bleeding. The secondary outcomes were major adverse cardiovascular events 
      (composite of stroke, myocardial infarction, and cardiovascular mortality) and 
      all-cause mortality. We stratified analysis based on the short- (≤1 month), 
      intermediate- (≤3 month), and long-term (>3 month) A+C therapy. Effects were 
      estimated as relative risk (RR) with 95% CI. Results- A+C significantly reduced 
      the risk of recurrent IS at short-term (RR, 0.53; 95% CI, 0.37-0.78) and 
      intermediate-term (RR, 0.72; 95% CI, 0.58-0.90) durations. Similarly, major 
      adverse cardiovascular event was significantly reduced by short-term (RR, 0.68; 
      95% CI, 0.60-0.78) and intermediate-term (RR, 0.76; 95% CI, 0.61-0.94) A+C 
      therapy. However, long-term A+C did not yield beneficial effect in terms of 
      recurrent IS (RR, 0.81; 95% CI, 0.63-1.04) and major adverse cardiovascular 
      events (RR, 0.87; 95% CI, 0.71-1.07). Intermediate-term (RR, 2.58; 95% CI, 
      1.19-5.60) and long-term (RR, 1.87; 95% CI, 1.36-2.56) A+C regimens significantly 
      increased the risk of major bleeding as opposed to short-term A+C (RR, 1.82; 95% 
      CI, 0.91-3.62). Excessive all-cause mortality was limited to long-term A+C (RR, 
      1.45; 95% CI, 1.10-1.93). Conclusions- Short-term A+C is more effective and 
      equally safe in comparison to aspirin alone in patients with acute IS or 
      transient ischemic attack.
FAU - Rahman, Hammad
AU  - Rahman H
AD  - From the Department of Medicine (H.R., F.N., E.K.), Guthrie Health System/Robert 
      Packer Hospital, Sayre, PA.
FAU - Khan, Safi U
AU  - Khan SU
AD  - Department of Medicine, West Virginia University, Morgantown (S.U.K.).
FAU - Nasir, Fahad
AU  - Nasir F
AD  - From the Department of Medicine (H.R., F.N., E.K.), Guthrie Health System/Robert 
      Packer Hospital, Sayre, PA.
FAU - Hammad, Tehseen
AU  - Hammad T
AD  - Department of Medicine, Services Hospital, Lahore, Pakistan (T.H.).
FAU - Meyer, Michael A
AU  - Meyer MA
AD  - Division of Neurology (M.A.M.), Guthrie Health System/Robert Packer Hospital, 
      Sayre, PA.
FAU - Kaluski, Edo
AU  - Kaluski E
AD  - From the Department of Medicine (H.R., F.N., E.K.), Guthrie Health System/Robert 
      Packer Hospital, Sayre, PA.
AD  - Division of Cardiology, Rutgers New Jersey Medical School, Newark (E.K.).
AD  - Division of Cardiology, The Geisinger Commonwealth Medical College, Scranton, PA 
      (E.K.).
LA  - eng
GR  - U54 GM104942/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2019 Aug 20;171(4):JC14. PMID: 31426057
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Brain Ischemia/*drug therapy/prevention & control
MH  - Clopidogrel/*administration & dosage/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/prevention & control
MH  - Secondary Prevention
MH  - Stroke/*drug therapy/prevention & control
PMC - PMC7457746
MID - NIHMS1620976
OTO - NOTNLM
OT  - aspirin
OT  - clopidogrel
OT  - stroke
OT  - transient ischemic attack
EDAT- 2019/03/12 06:00
MHDA- 2020/01/09 06:00
CRDT- 2019/03/12 06:00
PHST- 2019/03/12 06:00 [pubmed]
PHST- 2020/01/09 06:00 [medline]
PHST- 2019/03/12 06:00 [entrez]
AID - 10.1161/STROKEAHA.118.023978 [doi]
PST - ppublish
SO  - Stroke. 2019 Apr;50(4):947-953. doi: 10.1161/STROKEAHA.118.023978.

PMID- 8140394
OWN - NLM
STAT- MEDLINE
DCOM- 19940425
LR  - 20190821
IS  - 0036-5513 (Print)
IS  - 0036-5513 (Linking)
VI  - 53
IP  - 8
DP  - 1993 Dec
TI  - Comparison of three independent methods as estimates of platelet inhibition after 
      a single dose of acetylsalicylic acid.
PG  - 835-41
AB  - In order to assess the ability of three different (one in vivo, one ex vivo and 
      one in vitro) methods to estimate platelet function, 10 healthy volunteers were 
      given a single oral dose of 160 mg ASA. Platelet function was assessed before, 4, 
      24, 48 and 72 h after dosing by urinary excretion of thromboxane B2, 
      filtragometry and collagen-based whole blood aggregometry. Further, in order to 
      study mechanisms for platelet aggregation in filtragometry, platelet activation 
      was assessed by measurements of beta-thromboglobulin at three different places 
      within the filtragometer test unit in another nine healthy subjects. Four hours 
      after ASA, the aggregation time during filtragometry increased by 213 +/- 133% (p 
      < 0.001) and was parallelled by a decrease in impedance 85 +/- 7% (p < 0.001) 
      indicating an inhibition of platelet aggregability in both tests. A subsequent 
      gradual recovery was observed with both methods. The excretion of thromboxane B2 
      followed the aggregability pattern being maximally reduced by 72 +/- 6% (p < 
      0.01) 24 h after ASA and then gradually recovering. All three methods indicated 
      that platelet function was still decreased 72 h after dosing. The urinary 
      excretion of prostacyclin did not change significantly. The results of 
      filtragometry and impedance aggregometry correlated to the logarithm of 
      thromboxane B2 excretion (r = 0.60; p < 0.01 and r = 0.49; p < 0.01, 
      respectively) and to each other (r = 0.70; p < 0.001). In filtragometry 
      beta-thromboglobulin increased significantly (p < 0.05) over the filter.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Karlberg, K E
AU  - Karlberg KE
AD  - Department of Medicine, Huddinge Hospital, Sweden.
FAU - Chen, J
AU  - Chen J
FAU - Egberg, N
AU  - Egberg N
FAU - Nowak, J
AU  - Nowak J
FAU - Sylvén, C
AU  - Sylvén C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (beta-Thromboglobulin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Time Factors
MH  - beta-Thromboglobulin/analysis
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
AID - 10.3109/00365519309086496 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 1993 Dec;53(8):835-41. doi: 10.3109/00365519309086496.

PMID- 1318982
OWN - NLM
STAT- MEDLINE
DCOM- 19920721
LR  - 20141120
IS  - 0022-9032 (Print)
IS  - 0022-9032 (Linking)
VI  - 36
IP  - 3
DP  - 1992 Mar
TI  - [Evaluation of the antithrombotic effects of pentoxifylline, acetylsalicylic acid 
      and low molecular weight heparin in the laser model of thrombosis].
PG  - 142-5
AB  - Antithrombotic effects of different agents including acetylsalicylic acid 
      (Asprocol/Polfa PL/), pentoxifylline (Agapurin/Spofa CS/) and low molecular 
      weight heparin (Antixarin B. Braun, Melsungen, FRG) were studied in the 
      laser-induced rat thrombosis model. The investigations were carried out on male 
      Wistar rats weighing 200-300 g. Thrombus formation was induced in small 
      mesenteric arteries 25-30 microns; using argon laser. An interference contrast 
      system based on a Leitz Orthoplan microscope for the evaluation of thrombus 
      formation was used. The number of laser injuries needed to induce a defined 
      thrombus proved to be a useful way to quantitate the results in this thrombosis 
      mode. All agents showed dose dependent antithrombotic effect in our laser model. 
      Acetylsalicylic acid (ASA) 2 hours after oral administration markedly inhibited 
      thrombus formation in minimal dose 50 mg/kg, pentoxifylline in dose 10 mg/kg 30 
      min after i.v. injection and low molecular weight heparin (Antixarin) in dose 0.1 
      mg/kg, 2 hours, after s.c. injection. Antithrombotic effect of administration of 
      minimal effective doses of ASA (orally) and pentoxifylline (i.v.) lasted longer 
      than 4 hours but less then 6 hours. LMW heparin (Antixarin) in minimal effective 
      dose 0.1 mg/kg after s.c. injection inhibited thrombus formation in small 
      mesenteric vessels for more than 12 hours but less than 24 hours.
FAU - Krupiński, K
AU  - Krupiński K
AD  - Klinika Hematologii Akademii Medycznej Białymstoku.
FAU - Breddin, H K
AU  - Breddin HK
FAU - Bielawiec, M
AU  - Bielawiec M
FAU - Płonowski, A
AU  - Płonowski A
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Ocena przeciwzakrzepowych właściwości pentoksyfiliny,kwasu acetylsalicylowego 
      oraz drobnoczasteczkowej heparyny na laserowym modelu zakrzepowym.
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Disease Models, Animal
MH  - Heparin, Low-Molecular-Weight/*pharmacology
MH  - In Vitro Techniques
MH  - Lasers
MH  - Male
MH  - Pentoxifylline/*pharmacology
MH  - Splanchnic Circulation/drug effects
MH  - *Thrombolytic Therapy
MH  - Thrombosis/*drug therapy
EDAT- 1992/03/01 00:00
MHDA- 1992/03/01 00:01
CRDT- 1992/03/01 00:00
PHST- 1992/03/01 00:00 [pubmed]
PHST- 1992/03/01 00:01 [medline]
PHST- 1992/03/01 00:00 [entrez]
PST - ppublish
SO  - Kardiol Pol. 1992 Mar;36(3):142-5.

PMID- 31591940
OWN - NLM
STAT- MEDLINE
DCOM- 20200804
LR  - 20200804
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 54
IP  - 10
DP  - 2019 Oct
TI  - Teprenone for the prevention of low-dose aspirin-induced gastric mucosal injury 
      in Helicobacter pylori-negative patients.
PG  - 1199-1204
LID - 10.1080/00365521.2019.1672781 [doi]
AB  - Objectives: Low-dose aspirin is the standard treatment for the prevention of 
      cardiovascular events in at-risk patients. We performed a randomized, 
      placebo-controlled study to determine the efficacy of teprenone for primary 
      prevention of gastrointestinal injury in patients taking LDA for vascular 
      protection.Methods: Patients were eligible for enrollment if they required 
      aspirin 100 mg/day. Aspirin- naïve patients without gastroduodenal ulcer and 
      Helicobacter pylori infection were randomized to receive teprenone 150 mg/day or 
      placebo for 12 weeks. Primary outcome was assessed by the incidence rate of 
      gastroduodenal ulcer. Secondary outcomes were assessed by the incidence rate of 
      gastric mucosal injury, the improvement in modified Lanza score (MLS), 
      gastrointestinal symptom rating scale (GSRS) and the change of gastric 
      immunohistochemical expression for COX-1.Results: Total of 130 patients were 
      randomized, 64 in teprenone group and 66 in placebo group. There was no incidence 
      of ulcer after 12 weeks in both groups. Incidence of gastric mucosal injury was 
      higher in placebo group than in teprenone group (40.0 vs. 13.38%, p = .039). Mean 
      change of MLS was higher in placebo group than in teprenone group (0.767 ± 0.467 
      vs. 0.271 ± 0.158, p = .003). Scores of mucosal edema, hyperemia and hemorrhage 
      and the change of GSRS were not different between the two groups. Change of COX-1 
      immunoreactive score was higher in placebo group than in teprenone group 
      (2.433 ± 1.476 vs. 1.233 ± 0.955, p = .001). There were no treatment-related 
      adverse events.Conclusions: Teprenone is effective in preventing gastric mucosal 
      injury in patients taking LDA. Preventive effects of teprenone on LDA-related 
      gastroduodenal ulcers require further investigation.
FAU - Chitapanarux, Taned
AU  - Chitapanarux T
AUID- ORCID: 0000-0002-9908-3680
AD  - Gastrohepatology Unit, Department of Internal Medicine, Faculty of Medicine, 
      Chiang Mai University, Chiang Mai, Thailand.
AD  - Northern Thai Research Group of Radiation Oncology (NTRG-RO), Faculty of 
      Medicine, Chiang Mai University, Chiang Mai, Thailand.
FAU - Lertprasertsuke, Nirush
AU  - Lertprasertsuke N
AD  - Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 
      Thailand.
FAU - Kongnak, Acharaporn
AU  - Kongnak A
AD  - Gastrohepatology Unit, Department of Internal Medicine, Faculty of Medicine, 
      Chiang Mai University, Chiang Mai, Thailand.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20191008
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Diterpenes)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - S8S8451A4O (geranylgeranylacetone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged, 80 and over
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Diterpenes/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Helicobacter Infections
MH  - Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*chemically induced/*prevention & control
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Teprenone
OT  - gastric mucosal injury
OT  - gastroduodenal ulcer
OT  - low-dose aspirin
EDAT- 2019/10/09 06:00
MHDA- 2020/08/05 06:00
CRDT- 2019/10/09 06:00
PHST- 2019/10/09 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
PHST- 2019/10/09 06:00 [entrez]
AID - 10.1080/00365521.2019.1672781 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2019 Oct;54(10):1199-1204. doi: 
      10.1080/00365521.2019.1672781. Epub 2019 Oct 8.

PMID- 16954814
OWN - NLM
STAT- MEDLINE
DCOM- 20061207
LR  - 20181201
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 48
IP  - 2
DP  - 2006 Aug
TI  - Resveratrol inhibits aggregation of platelets from high-risk cardiac patients 
      with aspirin resistance.
PG  - 1-5
AB  - Up to 20% of serious vascular events in high-risk vascular patients is 
      attributable to a failure of aspirin (ASA) to suppress platelet aggregation. 
      Resveratrol is a cardioprotective phytoestrogen that can inhibit platelet 
      aggregation in animal models. We hypothesized that resveratrol can also inhibit 
      aggregation of platelets from ASA-resistant (ASA-R) patients. Thus, platelet-rich 
      plasma was isolated from ASA-sensitive (ASA-S) and ASA-R patients (aspirin 
      resistance was defined as higher-than-expected aggregation to collagen and 
      epinephrine [>/=40%] after oral treatment with 100 mg/d ASA). Aggregation to 
      adenosine diphosphate (ADP; 5 and 10 mumol/L), collagen (2 mug/mL), and 
      epinephrine (10 mumol/L) in the absence and presence of resveratrol (10 mol/L) 
      was measured by optical aggregometry. Maximal aggregation to 5 mumol/L ADP was 
      only slightly affected by resveratrol. Similar results were obtained using 10 
      mumol/L ADP. Maximal aggregation of ASA-R platelets to collagen was significantly 
      decreased by resveratrol, whereas resveratrol had only marginal effects in ASA-S 
      platelets. Similar results were obtained with epinephrine as well. Collectively, 
      resveratrol effectively inhibited collagen- and epinephrine-induced aggregation 
      of platelets from ASA-R patients, which may contribute to its cardioprotective 
      effects in high-risk cardiac patients.
FAU - Stef, Gyorgyi
AU  - Stef G
AD  - State Hospital for Cardiology, Balatonfured, Hungary.
FAU - Csiszar, Anna
AU  - Csiszar A
FAU - Lerea, Kenneth
AU  - Lerea K
FAU - Ungvari, Zoltan
AU  - Ungvari Z
FAU - Veress, Gabor
AU  - Veress G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Stilbenes)
RN  - Q369O8926L (Resveratrol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Drug Resistance
MH  - Female
MH  - Heart Diseases/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Resveratrol
MH  - Stilbenes/*pharmacology
EDAT- 2006/09/07 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/09/07 09:00
PHST- 2006/09/07 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/09/07 09:00 [entrez]
AID - 00005344-200608000-00001 [pii]
AID - 10.1097/01.fjc.0000238592.67191.ab [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2006 Aug;48(2):1-5. doi: 
      10.1097/01.fjc.0000238592.67191.ab.

PMID- 22608535
OWN - NLM
STAT- MEDLINE
DCOM- 20120904
LR  - 20131121
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 125
IP  - 7
DP  - 2012 Jul
TI  - Pheidippides redux: reducing risk for acute cardiac events during marathon 
      running.
PG  - 630-5
LID - 10.1016/j.amjmed.2011.11.008 [doi]
AB  - Prolonged strenuous exercise such as marathon running transiently increases the 
      absolute and relative risk for sudden cardiac death. A 17-fold increase in the 
      latter over resting baseline in previously sedentary middle-aged men is reduced 
      due to cardioprotection from training in experienced marathon runners. Exertional 
      rhabdomyolysis as a common occurrence during the race is accompanied by 
      neutrophilia and elevated biomarkers of inflammation, including interleukin-6 and 
      C-reactive protein. A hemostatic imbalance with prothrombotic effects includes in 
      vivo platelet activation during the race. Suggesting a pathogenic role for these 
      findings, plaque rupture due to atherothrombosis triggers acute exertional 
      cardiac events, including sudden death, in low-risk runners as in high-risk 
      patients such as those with diabetes mellitus. Strategies including prophylactic 
      aspirin are considered to decrease the risk for acute cardiac events.
CI  - Copyright © 2012 Elsevier Inc. All rights reserved.
FAU - Siegel, Arthur J
AU  - Siegel AJ
AD  - Department of Medicine, McLean Hospital, Belmont, MA, USA. asiegel@partners.org
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120518
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Med. 2013 Mar;126(3):e19. PMID: 23410574
CIN - Am J Med. 2013 Mar;126(3):e21. PMID: 23410575
CIN - Am J Med. 2013 Mar;126(3):e23. PMID: 23410576
CIN - Am J Med. 2013 Mar;126(3):e25-6. PMID: 23410577
MH  - Aspirin/therapeutic use
MH  - Death, Sudden, Cardiac/etiology/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Factors
MH  - *Running
EDAT- 2012/05/23 06:00
MHDA- 2012/09/05 06:00
CRDT- 2012/05/22 06:00
PHST- 2011/10/14 00:00 [received]
PHST- 2011/11/10 00:00 [revised]
PHST- 2011/11/10 00:00 [accepted]
PHST- 2012/05/22 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2012/09/05 06:00 [medline]
AID - S0002-9343(11)00945-4 [pii]
AID - 10.1016/j.amjmed.2011.11.008 [doi]
PST - ppublish
SO  - Am J Med. 2012 Jul;125(7):630-5. doi: 10.1016/j.amjmed.2011.11.008. Epub 2012 May 
      18.

PMID- 8237407
OWN - NLM
STAT- MEDLINE
DCOM- 19931208
LR  - 20131121
IS  - 0253-9756 (Print)
IS  - 0253-9756 (Linking)
VI  - 14
IP  - 3
DP  - 1993 May
TI  - [Effect of quercetin on chemiluminescence of human platelets induced by 
      arachidonic acid].
PG  - 263-5
AB  - Arachidonic acid (AA)-induced platelet chemiluminescence (CL) was measured with a 
      lumiphotometer. Quercetin remarkably inhibited the CL, the IC50 of quercetin was 
      3 mumol.L-1. When quercetin plus aspirin, which inhibits only cyclooxygenase, was 
      added, the inhibitory rate of platelet-CL obviously increased (P < 0.01). On the 
      other hand, the quercetin had a scavenging effect on superoxide anion radical 
      using alkaline sodium dithionite solution generation. The IC50 was 20.9 
      mumol.L-1. In addition, superoxide dismutase of 0.1 mg.ml-1 inhibited the 
      platelet-CL by 97.8%, while mannitol, a hydroxyl radical scavenger, only by 43.3% 
      at a concentration of 80 mg.ml-1. These results suggest that the mechanism of the 
      inhibiting AA-induced platelet-CL by quercetin was associated with scavenging the 
      superoxide anion radical directly and with inhibiting the cyclooxygenase.
FAU - Gu, Z L
AU  - Gu ZL
AD  - Department of Pharmacology, Suzhou Medical College, China.
FAU - Xie, M L
AU  - Xie ML
FAU - Qian, Z N
AU  - Qian ZN
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Yao Li Xue Bao
JT  - Zhongguo yao li xue bao = Acta pharmacologica Sinica
JID - 8100330
RN  - 0 (Free Radical Scavengers)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 3OWL53L36A (Mannitol)
RN  - 9IKM0I5T1E (Quercetin)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Drug Synergism
MH  - Free Radical Scavengers
MH  - Humans
MH  - Luminescent Measurements
MH  - Mannitol/pharmacology
MH  - Quercetin/*pharmacology
MH  - Superoxide Dismutase/pharmacology
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
PST - ppublish
SO  - Zhongguo Yao Li Xue Bao. 1993 May;14(3):263-5.

PMID- 937351
OWN - NLM
STAT- MEDLINE
DCOM- 19760823
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 60
IP  - 7
DP  - 1976 Jun
TI  - Thrombotic thrombocytopenic purpura in a previously splenectomized patient.
PG  - 1061-3
AB  - Idiopathic thrombocytopenic purpura was diagnosed in a 26 year old man who had 
      rectal bleeding and marked thrombocytopenia (10,000 platelets/mm3). Complete 
      recovery followed treatment with steroids and splenectomy. There was no clinical, 
      laboratory or histopathologic evidence of thrombotic thrombocytopenic purpura. 
      Several months later typical thrombotic thrombocytopenic purpura developed; 
      recovery followed treatment with steroids, aspirin and dipyridamole. The presence 
      of Howell-Jolly bodies and a negative scan indicated that an accessory spleen was 
      not present. Since thrombotic thrombocytopenic purpura developed in the absence 
      of a spleen in this case, it may be that in some, if not all, instances of 
      thrombotic thrombocytopenic purpura the spleen is not importantly related to the 
      pathogenesis of thrombotic thrombocytopenic purpura; this is in contrast to the 
      situation in idiopathic thrombocytopenic purpura. Benefits attributed to 
      splenectomy in thrombotic thrombocytopenic purpura, therefore, may in fact be due 
      to the platelet inhibitory properties of common anesthetic agents, or to some 
      other factor in the surgical procedure rather than to removal of the spleen per 
      se.
FAU - Zacharski, L R
AU  - Zacharski LR
FAU - Lusted, D
AU  - Lusted D
FAU - Glick, J L
AU  - Glick JL
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Male
MH  - Prednisone/therapeutic use
MH  - Spleen/physiopathology
MH  - *Splenectomy
MH  - Thrombocytopenia/drug therapy/*physiopathology
EDAT- 1976/06/01 00:00
MHDA- 1976/06/01 00:01
CRDT- 1976/06/01 00:00
PHST- 1976/06/01 00:00 [pubmed]
PHST- 1976/06/01 00:01 [medline]
PHST- 1976/06/01 00:00 [entrez]
AID - 0002-9343(76)90581-7 [pii]
AID - 10.1016/0002-9343(76)90581-7 [doi]
PST - ppublish
SO  - Am J Med. 1976 Jun;60(7):1061-3. doi: 10.1016/0002-9343(76)90581-7.

PMID- 6304182
OWN - NLM
STAT- MEDLINE
DCOM- 19830708
LR  - 20190817
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 5
IP  - 2
DP  - 1983 Apr
TI  - 1,300 mg of aspirin daily does not cause positive fecal hemoccult tests.
PG  - 123-5
AB  - Americans 50 years of age and older are advised to test their stools for occult 
      blood to detect colorectal neoplasms. Many will be taking 1,300 mg of aspirin 
      daily because of cerebrovascular disease or smaller amounts for cardiovascular 
      disease. To determine if 1,300 mg of aspirin causes positive hemoccult II tests, 
      27 healthy volunteers ate a red meat-free, high-fiber diet. Their stools were 
      negative for occult blood during a 3-day control period and remained negative 
      while they took 1,300 mg aspirin daily for an additional 7 days. This indicates 
      that 1,300 mg aspirin daily for 1 week does not cause positive hemoccult II 
      testing. Those taking this dose of aspirin probably need not interrupt therapy to 
      perform hemoccult II testing.
FAU - Norfleet, R G
AU  - Norfleet RG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Dietary Fiber)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Dietary Fiber/administration & dosage
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Occult Blood
MH  - Time Factors
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 10.1097/00004836-198304000-00006 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 1983 Apr;5(2):123-5. doi: 10.1097/00004836-198304000-00006.

PMID- 16882099
OWN - NLM
STAT- MEDLINE
DCOM- 20061121
LR  - 20131121
IS  - 0269-4727 (Print)
IS  - 0269-4727 (Linking)
VI  - 31
IP  - 4
DP  - 2006 Aug
TI  - Efficacy and safety of over-the-counter analgesics in the treatment of common 
      cold and flu.
PG  - 309-19
AB  - RATIONALE: Common cold and flu are the most common human illnesses, and 
      over-the-counter (OTC) analgesics are widely used to treat the pain and fever 
      symptoms. Despite the every day use of these analgesic there is little 
      information available in the literature on the efficacy and safety of these 
      medicines in treating colds and flu symptoms. The aim of this review was to 
      determine the safety and efficacy of the analgesics, aspirin, paracetamol and 
      aspirin for the treatment of colds and flu. METHODS: Electronic databases and a 
      personal database were searched and the information retrieved together with 
      information from relevant textbooks has been integrated in the review. RESULTS: 
      The literature search established that there is relatively little information on 
      the use of analgesics in treating colds and flu and that much of the safety and 
      efficacy data must be related to other pain and fever models. The review 
      establishes that aspirin, paracetamol and ibuprofen are safe in OTC doses and 
      that there is no evidence for any difference between the medicines as regards 
      efficacy and safety for treatment of colds and flu (except in certain cases such 
      as the use of aspirin in feverish children). There is also no evidence that these 
      medicines prolong the course of colds and flu by any effect on the immune system 
      or by reducing fever. CONCLUSION: Despite the lack of clinical data on the safety 
      and efficacy of analgesics for the treatment of colds and flu symptoms a case can 
      be made that these medicines are safe and effective for treatment of these common 
      illnesses.
FAU - Eccles, R
AU  - Eccles R
AD  - Common Cold Centre, Cardiff School of Biosciences, Cardiff University, Cardiff, 
      UK. eccles@cardiff.ac.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Common Cold/*drug therapy
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Fever/drug therapy
MH  - Humans
MH  - Ibuprofen/*therapeutic use
MH  - Infant
MH  - Influenza, Human/*drug therapy
MH  - Nonprescription Drugs/adverse effects/*therapeutic use
MH  - Pain/drug therapy
RF  - 63
EDAT- 2006/08/03 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/08/03 09:00
PHST- 2006/08/03 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/08/03 09:00 [entrez]
AID - JCP754 [pii]
AID - 10.1111/j.1365-2710.2006.00754.x [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2006 Aug;31(4):309-19. doi: 10.1111/j.1365-2710.2006.00754.x.

PMID- 377449
OWN - NLM
STAT- MEDLINE
DCOM- 19790816
LR  - 20191028
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - 18
IP  - 2
DP  - 1979 May
TI  - Clinical comparative evaluation of choline magnesium trisalicylate and 
      acetylsalicylic acid in rheumatoid arthritis.
PG  - 119-24
AB  - A multicentre double-blind comparison of choline magnesium trisalicylate (CMT) 
      and acetylsalicylic acid (ACSA) compared the two medications for seven weeks in 
      rheumatoid arthritis patients. Investigators measured the number of painful and 
      swollen joints and the duration of morning stiffness, and assessed the overall 
      condition of each patient. Both medications were highly effective in 
      significantly reducing the severity of symptoms flaring after interruption of 
      prior therapy. CMT achieved a greater reduction in the number of swollen joints 
      than did ACSA (P less than 0.05). The incidence of adverse side-effects per 
      patient was significantly less with CMT (P less than 0.05) (ACSA 32.1%; CMT, 
      16.3%. A larger percentage of ACSA patients (50.8%) reported adverse side-effects 
      than did CMT patients 28.4%) (P less than 0.02).
FAU - Blechman, W J
AU  - Blechman WJ
FAU - Lechner, B L
AU  - Lechner BL
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - N91BDP6H0X (Choline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Choline/*analogs & derivatives/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/administration & dosage/adverse effects/*therapeutic use
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
AID - 10.1093/rheumatology/18.2.119 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1979 May;18(2):119-24. doi: 10.1093/rheumatology/18.2.119.

PMID- 2456076
OWN - NLM
STAT- MEDLINE
DCOM- 19880831
LR  - 20131121
IS  - 0397-9148 (Print)
IS  - 0397-9148 (Linking)
VI  - 18
IP  - 3
DP  - 1986 Mar
TI  - [Interpretation of reactions to acetylsalicylic acid and glaphenine].
PG  - 17-20
AB  - Challenge test puts in evidence the responsibility of a drug. The biological 
      checking by plasmatic histamine leads to distinguish between a specific 
      histamine-release reaction and a non-specific one. Thus, glafenine has proved to 
      be a non specific histamine release where as in some cases, acetyl-salicylic-acid 
      (A.S.A.) behaves like a specific histamine release.
FAU - Sabbah, A
AU  - Sabbah A
AD  - Laboratoire d'Immuno-allergologie, C.H.U., Angers, France.
FAU - Drouet, M
AU  - Drouet M
FAU - Bonneau, J C
AU  - Bonneau JC
FAU - Heulin, M
AU  - Heulin M
FAU - Le Sellin, J
AU  - Le Sellin J
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Interprétation des réactions à l'acide acétyl-salicylique et à la glafénine.
PL  - France
TA  - Allerg Immunol (Paris)
JT  - Allergie et immunologie
JID - 0245775
RN  - 0 (ortho-Aminobenzoates)
RN  - 46HL4I09AH (Glafenine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anaphylaxis/chemically induced
MH  - Angioedema/chemically induced
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Hypersensitivity/*diagnosis
MH  - Glafenine/administration & dosage/*adverse effects
MH  - Histamine Release
MH  - Humans
MH  - Urticaria/chemically induced
MH  - ortho-Aminobenzoates/*adverse effects
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
PST - ppublish
SO  - Allerg Immunol (Paris). 1986 Mar;18(3):17-20.

PMID- 3179610
OWN - NLM
STAT- MEDLINE
DCOM- 19881221
LR  - 20190510
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 94
IP  - 3
DP  - 1988 Jul
TI  - Age and the antihypertensive effect of aspirin in rats.
PG  - 755-8
AB  - 1. We previously showed that chronic exposure to aspirin (100 mg kg-1 daily, by 
      mouth) is effective in preventing the onset of hypertension in young (28-84 day 
      old) spontaneously hypertensive rats (SHRs). This is contrary to what others have 
      reported using older SHRs. 2. Renal prostaglandin F2 alpha was also reduced in 
      young SHRs and Wistar-Okamoto strain rats (WKYs) exposed to aspirin. 3. In the 
      present study we extended the period of aspirin treatment in young rats to beyond 
      84 days of age. We found that aspirin lost its antihypertensive effect in SHR and 
      WKY rats at 110 +/- 7 days of age regardless of whether the exposure to aspirin 
      had begun at age 28, 49 or 87 days. 4. We conclude that the loss of 
      antihypertensive effect of aspirin in the SHR and in older WKY rats, is 
      determined by some factor(s) probably not related to prostaglandin F2 alpha, 
      which reaches full expression in the 110 +/- 7 day old rat, or is fully 
      dissipated at this age. 5. The anti-PGF2 alpha activity of aspirin in the SHR and 
      WKY rat was short-lived and apparently unrelated in time to the antihypertensive 
      effect of aspirin.
FAU - Tuttle, R S
AU  - Tuttle RS
AD  - Masonic Medical Research Laboratory, Utica, NY 13501-1787.
FAU - Yager, J
AU  - Yager J
FAU - Northrup, N
AU  - Northrup N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Antihypertensive Agents)
RN  - B7IN85G1HY (Dinoprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aging/*physiology
MH  - Animals
MH  - *Antihypertensive Agents
MH  - Aspirin/*pharmacology
MH  - Dinoprost/metabolism
MH  - Kidney/drug effects/metabolism
MH  - Male
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Rats, Inbred WKY
PMC - PMC1854040
EDAT- 1988/07/01 00:00
MHDA- 1988/07/01 00:01
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 1988/07/01 00:01 [medline]
PHST- 1988/07/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1988.tb11585.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1988 Jul;94(3):755-8. doi: 10.1111/j.1476-5381.1988.tb11585.x.

PMID- 22490487
OWN - NLM
STAT- MEDLINE
DCOM- 20120803
LR  - 20181201
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 125
IP  - 4
DP  - 2012 Feb
TI  - Earlier application of loading doses of aspirin and clopidogrel decreases rate of 
      recurrent cardiovascular ischemic events for patients undergoing percutaneous 
      coronary intervention.
PG  - 631-8
AB  - BACKGROUND: Aspirin and clopidogrel resistance plays a significant role in the 
      development of cardiovascular ischemic events for ninety patients undergoing 
      percutaneous coronary intervention. Recent studies have indicated that increasing 
      the dose of antiplatelet drugs maybe a potent method to improve the inhibition of 
      platelet aggregation. METHODS: Thrombelastograph (TEG) determinations were used 
      to evaluate the effect of antiplatelet therapy. According to the results, 90 
      patients were divided into three groups and given different doses of aspirin and 
      clopidogrel. Thirty patients with both an inhibition rate of aspirin > 50% and an 
      inhibition rate of clopidogrel > 50% were defined as the control group. Sixty 
      patients with an inhibition rate for aspirin < 50% and an inhibition rate for 
      clopidogrel < 50% were defined as the resistance group. Patients in resistance 
      group were randomly assigned to be given a routine dose (100 mg aspirin plus 75 
      mg clopidogrel per day, which we called a resistance plus routine dose group, R + 
      R) and a loading dose (200 mg aspirin and 150 mg clopidogrel per day, which we 
      called resistance plus loading dose group, R + L) of antiplatelet therapy. A 
      12-month follow-up was observed to examine the change of inhibition rate of 
      antiplatelet therapy and to estimate the relationship between inhibition rate and 
      the occurrence of cardiovascular ischemic events. RESULTS: After 6 months of 
      antiplatelet therapy, the inhibition rate of aspirin in the R + L group increased 
      from (31.4 ± 3.7)% to (68.6 ± 7.1)%, which was significantly higher than that in 
      R + R group, (51.9 ± 8.2)% (P < 0.01). The inhibition rate of clopidogrel in the 
      R + L group increased from (22.1 ± 3.8)% to (60.2 ± 7.4)%, which was 
      significantly higher than in the R + R group, (45.9 ± 4.3)% (P < 0.01). The 
      occurrence rates of cardiovascular ischemic events, stent thrombosis, recurrent 
      unstable angina and myocardial infarction in the R + R group were 20%, 36% and 
      17%, respectively. Occurrence was significantly increased compared with that in 
      the control group, 3%, 10% and 1%, respectively (P < 0.01). In contrast, the 
      occurrence rates in the R + L group (10%, 23% and 6%, respectively) were 
      attenuated compared with those in the R + R group (P < 0.01), although still 
      higher than in the control group (P < 0.01). CONCLUSIONS: Almost all of the 
      cardiovascular ischemic events occurred in the first six months after 
      percutaneous coronary intervention. According to the result of TEG 
      determinations, earlier application of a loading dose of aspirin and clopidogrel 
      can decrease the rate of recurrent cardiovascular ischemic events.
FAU - Tang, Fa-kuan
AU  - Tang FK
AD  - Departments of Cardiology, 309th Hospital of Chinese People's Liberation Army, 
      Beijing, China. TFK616@yahoo.com.cn
FAU - Lin, Le-jian
AU  - Lin LJ
FAU - Hua, Ning
AU  - Hua N
FAU - Lu, Hong
AU  - Lu H
FAU - Qi, Zhi
AU  - Qi Z
FAU - Tang, Xue-zheng
AU  - Tang XZ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/*adverse effects
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/prevention & control
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Prospective Studies
MH  - Thrombelastography
MH  - Thrombosis/prevention & control
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2012/04/12 06:00
MHDA- 2012/08/04 06:00
CRDT- 2012/04/12 06:00
PHST- 2012/04/12 06:00 [entrez]
PHST- 2012/04/12 06:00 [pubmed]
PHST- 2012/08/04 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2012 Feb;125(4):631-8.

PMID- 29349624
OWN - NLM
STAT- MEDLINE
DCOM- 20180820
LR  - 20211007
IS  - 1573-6776 (Electronic)
IS  - 0141-5492 (Linking)
VI  - 40
IP  - 3
DP  - 2018 Mar
TI  - Combined effects of aspirin and vitamin D3 on two OSCC cell lines: a preliminary 
      study.
PG  - 551-559
LID - 10.1007/s10529-018-2508-5 [doi]
AB  - OBJECTIVES: We evaluated the potential effects of aspirin combined with vitamin 
      D3 on cell proliferation and apoptosis in oral cancer cells. RESULTS: Compared to 
      the untreated control or individual drug, the combinations of aspirin and vitamin 
      D3 significantly decreased the rates of cell proliferation by CCK-8 assay, and 
      caused higher rates of cell apoptosis in both CAL-27 and SCC-15 cells by Annexin 
      V-FITC apoptosis assay and flow cytometry. Remarkably, the combined treatment 
      with aspirin and vitamin D3 significantly suppressed the expression of Bcl-2 
      protein and p-Erk1/2 protein, examined by western blot analysis. CONCLUSIONS: Our 
      study demonstrates that aspirin and vitamin D3 have biological activity against 
      two human OSCC cell lines and their activity is synergistic or additive when two 
      drugs used in combination with therapeutic concentrations. The combination of 
      aspirin and vitamin D3 may be an effective approach for inducing cell death in 
      OSCC.
FAU - Xiao, Ting-Ting
AU  - Xiao TT
AD  - Department of Oral and Maxillofacial Surgery, Stomatological Hospital of 
      Chongqing Medical University, Chongqing, People's Republic of China.
AD  - Chongqing Key Laboratory of Oral Disease and Biomedical Sciences, Chongqing, 
      People's Republic of China.
FAU - Li, Xian
AU  - Li X
AD  - Department of Oral and Maxillofacial Surgery, Stomatological Hospital of 
      Chongqing Medical University, Chongqing, People's Republic of China.
AD  - Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher 
      Education, Chongqing, People's Republic of China.
FAU - Feng, Jia-Li
AU  - Feng JL
AD  - Chongqing Key Laboratory of Oral Disease and Biomedical Sciences, Chongqing, 
      People's Republic of China.
AD  - Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher 
      Education, Chongqing, People's Republic of China.
FAU - Li, Yong
AU  - Li Y
AUID- ORCID: 0000-0002-2087-8326
AD  - Department of Oral and Maxillofacial Surgery, Stomatological Hospital of 
      Chongqing Medical University, Chongqing, People's Republic of China. 
      13062363130@163.com.
AD  - Chongqing Key Laboratory of Oral Disease and Biomedical Sciences, Chongqing, 
      People's Republic of China. 13062363130@163.com.
AD  - Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher 
      Education, Chongqing, People's Republic of China. 13062363130@163.com.
LA  - eng
GR  - NO CXTDG201602006/Program for Innovation Team Building at Institutions of Higher 
      Education in Chongqing in 2016/
GR  - 2017ZDXM019/the Scientific and Technological Research Program of Health and 
      Family planning Commission of Chongqing Province/
PT  - Journal Article
DEP - 20180118
PL  - Netherlands
TA  - Biotechnol Lett
JT  - Biotechnology letters
JID - 8008051
RN  - 1C6V77QF41 (Cholecalciferol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Aspirin/*pharmacology
MH  - Carcinoma, Squamous Cell/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cholecalciferol/*pharmacology
MH  - Humans
MH  - Mouth Neoplasms/*metabolism
OTO - NOTNLM
OT  - Apoptosis
OT  - Aspirin
OT  - B-cell lymphoma-2
OT  - Erk phosphorylation
OT  - Oral squamous cell carcinoma
OT  - Vitamin D3
EDAT- 2018/01/20 06:00
MHDA- 2018/08/21 06:00
CRDT- 2018/01/20 06:00
PHST- 2017/08/29 00:00 [received]
PHST- 2018/01/08 00:00 [accepted]
PHST- 2018/01/20 06:00 [pubmed]
PHST- 2018/08/21 06:00 [medline]
PHST- 2018/01/20 06:00 [entrez]
AID - 10.1007/s10529-018-2508-5 [pii]
AID - 10.1007/s10529-018-2508-5 [doi]
PST - ppublish
SO  - Biotechnol Lett. 2018 Mar;40(3):551-559. doi: 10.1007/s10529-018-2508-5. Epub 
      2018 Jan 18.

PMID- 1804553
OWN - NLM
STAT- MEDLINE
DCOM- 19920504
LR  - 20190705
IS  - 0009-2363 (Print)
IS  - 0009-2363 (Linking)
VI  - 39
IP  - 9
DP  - 1991 Sep
TI  - Preparation and evaluation of oral dosage form using acylglycerols. II. Effect of 
      food ingestion on dissolution and absorption of aspirin from the granules 
      prepared by acylglycerols in human subjects.
PG  - 2391-4
AB  - The dissolution behavior of the aspirin enteric granule prepared using 
      acylglycerols, glyceryl monostearate (GMS) and glyceryl trilaurate (GTL), was 
      investigated in vitro and in human subjects in a fasting or non-fasting state. 
      Aspirin was slowly released from the granule in vitro at pH 1.2. No acceleration 
      of the aspirin dissolution rate in the medium without lipase and cholic acid was 
      observed when the pH level of the medium increased to a neutral region (pH 6.4). 
      However, the dissolution of aspirin was significantly increased by increasing the 
      concentrations of lipase and cholic acid in the medium. Lipase appears to play an 
      essential role in the dissolution process of aspirin granules. In human subjects, 
      the average levels of the cumulative amount of total salicylate excreted in a 
      urine-time curve, and the mean residence time (MRT) obtained after oral 
      administration of a granule in the fasting state were markedly delayed in 
      comparison with the results observed using an aqueous solution and a crystalline 
      form of aspirin. In comparing the fasting condition with the non-fasting 
      condition (after food ingestion), no significant difference was recognized in the 
      total amount of salicylate excreted in urine to an infinite time (Ae(infinity)), 
      whether the MRT was obtained by granule, crystalline form or aqueous solution. It 
      can be concluded that aspirin granule prepared by GMS and GTL has a property of 
      pancreatic lipase-sensitive dissolution, and its bioavailability is unaffected by 
      food intake.
FAU - Watanabe, Y
AU  - Watanabe Y
AD  - Department of Pharmaceutics, Showa College of Pharmaceutical Sciences, Tokyo, 
      Japan.
FAU - Suda, M
AU  - Suda M
FAU - Matsumoto, Y
AU  - Matsumoto Y
FAU - Takayama, K
AU  - Takayama K
FAU - Matsumoto, M
AU  - Matsumoto M
FAU - Zhao, W
AU  - Zhao W
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - 0 (Dosage Forms)
RN  - PDC6A3C0OX (Glycerol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*pharmacokinetics
MH  - Chemistry, Pharmaceutical
MH  - Dosage Forms
MH  - Food
MH  - Glycerol/*pharmacokinetics
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
AID - 10.1248/cpb.39.2391 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 1991 Sep;39(9):2391-4. doi: 10.1248/cpb.39.2391.

PMID- 7088753
OWN - NLM
STAT- MEDLINE
DCOM- 19820826
LR  - 20190501
IS  - 0032-5473 (Print)
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 58
IP  - 675
DP  - 1982 Jan
TI  - A comparison of antrafenine and aspirin on platelet aggregation and 
      frusemide-induced diuresis.
PG  - 17-9
AB  - The effects of antrafenine were compared with aspirin and placebo on platelet 
      aggregation and on the diuretic action of frusemide in normal volunteers. Aspirin 
      significantly reduced platelet aggregation at 3 and 6 hr after administration, 
      but antrafenine only at 3 hr. Only aspirin significantly reduced the increase in 
      urine sodium and potassium produced by frusemide.
FAU - Hassan, S M
AU  - Hassan SM
FAU - Olivesi, A
AU  - Olivesi A
FAU - Fish, A
AU  - Fish A
FAU - Turner, P
AU  - Turner P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - 0 (Analgesics)
RN  - 0 (Piperazines)
RN  - 0 (Placebos)
RN  - 21FS93Y6OE (antrafenine)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analgesics/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Diuresis/*drug effects
MH  - Female
MH  - Furosemide/*antagonists & inhibitors
MH  - Humans
MH  - Male
MH  - Piperazines/*pharmacology
MH  - Placebos
MH  - Platelet Aggregation/*drug effects
PMC - PMC2426228
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1136/pgmj.58.675.17 [doi]
PST - ppublish
SO  - Postgrad Med J. 1982 Jan;58(675):17-9. doi: 10.1136/pgmj.58.675.17.

PMID- 10318654
OWN - NLM
STAT- MEDLINE
DCOM- 19990526
LR  - 20220408
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 99
IP  - 18
DP  - 1999 May 11
TI  - Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in 
      preventing stent thrombosis after coronary stent implantation.
PG  - 2364-6
AB  - BACKGROUND: Ticlopidine has been shown to reduce the incidence of stent 
      thrombosis compared with warfarin, but it may cause serious hematological side 
      effects. Clopidogrel, a new thienopyridine derivative, may be a safe alternative 
      to ticlopidine. The aim of this study was to compare the safety and efficacy of 
      clopidogrel and aspirin with those of ticlopidine and aspirin in patients 
      undergoing coronary stent implantation. METHODS AND RESULTS: The population of 
      this study consisted of 2 groups: patients who underwent coronary stenting and 
      were treated with ticlopidine and aspirin (TA group, n=1406), and patients who 
      underwent coronary stenting followed by treatment with clopidogrel and aspirin 
      (CA group, n=283). At 1-month follow-up, there was no difference in stent 
      thrombosis (1.5% versus 1.4%, P=1.0) or major adverse cardiac events (3.1% versus 
      2.4%, P=0. 85) between the TA and CA groups, respectively. The probability of any 
      side effect (neutropenia, diarrhea, rash) was significantly higher in the TA 
      group (10.6% versus 5.3%, P=0.006; relative risk, 0. 53; CI, 0.32 to 0.86). 
      CONCLUSIONS: These data suggest that clopidogrel may be an effective 
      pharmacological regimen after coronary stent implantation. Furthermore, the 
      simpler dosing regimen, the absence of neutropenia, and the lower frequency of 
      other side effects make it a safe alternative to ticlopidine.
FAU - Moussa, I
AU  - Moussa I
AD  - Lenox Hill Hospital, New York, NY, USA.
FAU - Oetgen, M
AU  - Oetgen M
FAU - Roubin, G
AU  - Roubin G
FAU - Colombo, A
AU  - Colombo A
FAU - Wang, X
AU  - Wang X
FAU - Iyer, S
AU  - Iyer S
FAU - Maida, R
AU  - Maida R
FAU - Collins, M
AU  - Collins M
FAU - Kreps, E
AU  - Kreps E
FAU - Moses, J W
AU  - Moses JW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Coronary Angiography
MH  - Coronary Disease/*surgery
MH  - Coronary Thrombosis/*prevention & control
MH  - Diarrhea/chemically induced
MH  - Drug Eruptions/etiology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neutropenia/chemically induced
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Safety
MH  - *Stents
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/*therapeutic use
MH  - Treatment Outcome
EDAT- 1999/05/11 00:00
MHDA- 1999/05/11 00:01
CRDT- 1999/05/11 00:00
PHST- 1999/05/11 00:00 [pubmed]
PHST- 1999/05/11 00:01 [medline]
PHST- 1999/05/11 00:00 [entrez]
AID - 10.1161/01.cir.99.18.2364 [doi]
PST - ppublish
SO  - Circulation. 1999 May 11;99(18):2364-6. doi: 10.1161/01.cir.99.18.2364.

PMID- 25176250
OWN - NLM
STAT- MEDLINE
DCOM- 20141107
LR  - 20191210
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 27
IP  - 5 Spec no
DP  - 2014 Sep
TI  - Simultaneous quantitation of aspirin, amlodipine and simvastatin in a fixed dose 
      combination of encapsulated tablet formulation by HPLC-UV method.
PG  - 1553-8
AB  - A high-pressure liquid chromatography (HPLC-UV) based simple and specific method 
      for simultaneous quantitative determination of aspirin, amlodipine besylate and 
      simvastatin in a capsule formulation has been developed and validated according 
      to ICH guidelines. Chromatographic separation of the three drugs was carried out 
      by aSpherisorbODS2 reverse phase column (4.6 x 250 mm; 5 μm) using amobile phase, 
      which consisted of 70: 30 (v/v) mixture of acetonitrile and triethylamine 
      phosphate buffer (pH 3; 0.015 M) with final pH adjusted to 2.5 using dilute 
      ortho-phosphoric acid, at a flow rate of 1mL/min. The eluents were detected at UV 
      wavelength of 237 nm and the retention times for aspirin, amlodipine besylate and 
      simvastatin were ~2.7 mins, ~6.1 mins and ~10.5mins, respectively. This method is 
      suitable and specific for the three drugs and was found to be linear (R2>0.995), 
      accurate, specific, reproducible and robust in the concentration range of 375 to 
      1125mcg/ml for aspirin, 25 to 75mcg/ml for amlodipine besylate and 50 to 
      150mcg/ml for simvastatin. This simple and convenient method could be easily 
      utilized for the characterization and quantitation of the three drugs in a single 
      formulation for combination therapy of cardiovascular diseases.
FAU - Sultan, Faisal
AU  - Sultan F
AD  - Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, 
      Pakistan.
FAU - Shoaib, Muhammad Harris
AU  - Shoaib MH
AD  - Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, 
      Pakistan.
FAU - Yousuf, Rabia Ismail
AU  - Yousuf RI
AD  - Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, 
      Pakistan.
FAU - Ahmed, Farrukh Rafiq
AU  - Ahmed FR
AD  - Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, 
      Pakistan.
FAU - Salam, Faseeh A
AU  - Salam FA
AD  - Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, 
      Pakistan.
FAU - Nasiri, Muhammad Iqbal
AU  - Nasiri MI
AD  - Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, 
      Pakistan.
FAU - Khan, Muhammad Atif
AU  - Khan MA
AD  - Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, 
      Pakistan.
FAU - Manzoor, Saeed
AU  - Manzoor S
AD  - Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, 
      Pakistan.
LA  - eng
PT  - Journal Article
PT  - Validation Study
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 1J444QC288 (Amlodipine)
RN  - AGG2FN16EV (Simvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amlodipine/*analysis
MH  - Aspirin/*analysis
MH  - Cardiovascular Agents/*analysis
MH  - Chemistry, Pharmaceutical
MH  - *Chromatography, High Pressure Liquid
MH  - Chromatography, Reverse-Phase
MH  - Drug Combinations
MH  - Limit of Detection
MH  - Reproducibility of Results
MH  - Simvastatin/*analysis
MH  - *Spectrophotometry, Ultraviolet
MH  - Tablets
MH  - Technology, Pharmaceutical/*methods
EDAT- 2014/09/02 06:00
MHDA- 2014/11/08 06:00
CRDT- 2014/09/02 06:00
PHST- 2014/09/02 06:00 [entrez]
PHST- 2014/09/02 06:00 [pubmed]
PHST- 2014/11/08 06:00 [medline]
PST - ppublish
SO  - Pak J Pharm Sci. 2014 Sep;27(5 Spec no):1553-8.

PMID- 23384979
OWN - NLM
STAT- MEDLINE
DCOM- 20130801
LR  - 20131121
IS  - 1873-4243 (Electronic)
IS  - 1093-3263 (Linking)
VI  - 40
DP  - 2013 Mar
TI  - Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as 
      predicted by QM/MM calculations.
PG  - 99-109
LID - S1093-3263(13)00003-X [pii]
LID - 10.1016/j.jmgm.2012.12.013 [doi]
AB  - Acetylsalicylic acid (aspirin) suppresses the generation of prostaglandin H2, 
      which is the precursor of thromboxane A2. Aspirin acts as an acetylating agent in 
      which its acetyl group is covalently attached to a serine residue (S530) in the 
      active site of the cyclooxygenase-1 enzyme. The exact reaction mechanism has not 
      been revealed by experimental methods. In this study the putative structure of 
      human cyclooxygenase-1 was constructed from ovine cyclooxygenase-1 by homology 
      modeling, and the acetylsalicylic acid was docked into the arachidonic acid 
      binding cavity of the enzyme. To characterize the shape of the potential energy 
      surface of the acetylating reaction and to determine the relative energies of the 
      stationary points on the surface, a series of ONIOM-type quantum 
      mechanical/molecular mechanical (QM/MM) calculations were carried out at 
      different QM levels of theories applying electronic embedding approximations. The 
      acetylsalicylic acid and the surrounding amino acids were included in these 
      calculations. Frequency analyses were performed to prove the existence of first 
      order saddle points (representing transition states) and local minima on the 
      potential energy surface. It was found that all levels of theories predicted 
      similar transition state geometries. The activation energy values, however, 
      demonstrated significant dependence on the methods that were applied. All the 
      applied "dependable" ab initio and DFT methods predicted that the breakage of the 
      S530 Oγ--Hγ and formation of the Oγ--C(acetylsalicylic acid carbonyl) bonds occur 
      in a single elementary step.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Tóth, L
AU  - Tóth L
AD  - Clinical Research Center, Medical and Health Science Center, University of 
      Debrecen, Debrecen, Hungary.
FAU - Muszbek, L
AU  - Muszbek L
FAU - Komáromi, I
AU  - Komáromi I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130109
PL  - United States
TA  - J Mol Graph Model
JT  - Journal of molecular graphics & modelling
JID - 9716237
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Aspirin/*chemistry
MH  - Binding Sites
MH  - Cyclooxygenase 1/*chemistry
MH  - Cyclooxygenase Inhibitors/*chemistry
MH  - Humans
MH  - Kinetics
MH  - Models, Molecular
MH  - Molecular Sequence Data
MH  - Protein Binding
MH  - Protein Structure, Secondary
MH  - *Quantum Theory
MH  - Sequence Alignment
EDAT- 2013/02/07 06:00
MHDA- 2013/08/02 06:00
CRDT- 2013/02/07 06:00
PHST- 2012/08/21 00:00 [received]
PHST- 2012/12/27 00:00 [revised]
PHST- 2012/12/28 00:00 [accepted]
PHST- 2013/02/07 06:00 [entrez]
PHST- 2013/02/07 06:00 [pubmed]
PHST- 2013/08/02 06:00 [medline]
AID - S1093-3263(13)00003-X [pii]
AID - 10.1016/j.jmgm.2012.12.013 [doi]
PST - ppublish
SO  - J Mol Graph Model. 2013 Mar;40:99-109. doi: 10.1016/j.jmgm.2012.12.013. Epub 2013 
      Jan 9.

PMID- 9456592
OWN - NLM
STAT- MEDLINE
DCOM- 19980218
LR  - 20131121
IS  - 0029-2001 (Print)
IS  - 0029-2001 (Linking)
VI  - 117
IP  - 30
DP  - 1997 Dec 10
TI  - [Acetylsalicylic acid in the treatment of cardiovascular and cerebrovascular 
      diseases].
PG  - 4432-6
AB  - This year acetylsalicylic acid (aspirin) celebrates its 100-year anniversary. 
      While the drug was previously used mainly as an antipyretic and a pain-killer, 
      aspirin has, during the last 10-15 years, become one of the most important agents 
      in the treatment of cardiovascular and cerebrovascular diseases. In addition to 
      being one of our oldest drugs, aspirin is one of the most interesting and widely 
      used remedies. The antithrombotic property of aspirin is mainly related to its 
      irreversible inhibition of the production of platelet-derived thromboxane A2, 
      which possesses aggregatory and vasoconstrictive properties. Aspirin reduces the 
      risk in patients with overt cardiovascular and cerebrovascular diseases, i.e. 
      chronic stable and unstable angina pectoris. It also reduces the risk in the 
      acute phase of and following a myocardial infarction and after a transient 
      ischemic attack or stroke. The use of the drug is controversial in primary 
      cardiovascular prevention. Overall mortality is not reduced, and side-effects, 
      such as increased bleeding tendency, may be serious. This side-effect is 
      dose-dependent, and smaller doses (75-160 mg) which have the same effect as 
      higher doses should be preferred.
FAU - Landmark, K
AU  - Landmark K
AD  - Institutt for farmakoterapi, Oslo.
LA  - nor
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Acetylsalisylsyre i behandlingen av kardiovaskulaere og cerebrovaskulaere 
      sykdommer.
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny 
      raekke
JID - 0413423
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Cerebrovascular Disorders/*drug therapy/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage
RF  - 45
EDAT- 1998/02/11 00:00
MHDA- 1998/02/11 00:01
CRDT- 1998/02/11 00:00
PHST- 1998/02/11 00:00 [pubmed]
PHST- 1998/02/11 00:01 [medline]
PHST- 1998/02/11 00:00 [entrez]
PST - ppublish
SO  - Tidsskr Nor Laegeforen. 1997 Dec 10;117(30):4432-6.

PMID- 35730631
OWN - NLM
STAT- MEDLINE
DCOM- 20220725
LR  - 20220919
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 11
IP  - 13
DP  - 2022 Jul 5
TI  - Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With 
      COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-COVID-19 
      Registry.
PG  - e024530
LID - 10.1161/JAHA.121.024530 [doi]
LID - e024530
AB  - Background COVID-19 is an infectious illness, featured by an increased risk of 
      thromboembolism. However, no standard antithrombotic therapy is currently 
      recommended for patients hospitalized with COVID-19. The aim of this study was to 
      evaluate safety and efficacy of additional therapy with aspirin over prophylactic 
      anticoagulation (PAC) in patients hospitalized with COVID-19 and its impact on 
      survival. Methods and Results A total of 8168 patients hospitalized for COVID-19 
      were enrolled in a multicenter-international prospective registry (HOPE 
      COVID-19). Clinical data and in-hospital complications, including mortality, were 
      recorded. Study population included patients treated with PAC or with PAC and 
      aspirin. A comparison of clinical outcomes between patients treated with PAC 
      versus PAC and aspirin was performed using an adjusted analysis with propensity 
      score matching. Of 7824 patients with complete data, 360 (4.6%) received PAC and 
      aspirin and 2949 (37.6%) PAC. Propensity-score matching yielded 298 patients from 
      each group. In the propensity score-matched population, cumulative incidence of 
      in-hospital mortality was lower in patients treated with PAC and aspirin versus 
      PAC (15% versus 21%, Log Rank P=0.01). At multivariable analysis in propensity 
      matched population of patients with COVID-19, including age, sex, hypertension, 
      diabetes, kidney failure, and invasive ventilation, aspirin treatment was 
      associated with lower risk of in-hospital mortality (hazard ratio [HR], 0.62; 
      [95% CI 0.42-0.92], P=0.018). Conclusions Combination PAC and aspirin was 
      associated with lower mortality risk among patients hospitalized with COVID-19 in 
      a propensity score matched population compared to PAC alone.
FAU - Santoro, Francesco
AU  - Santoro F
AUID- ORCID: 0000-0001-9909-6513
AD  - Department of Medical and Surgical Sciences University of Foggia Italy.
FAU - Núñez-Gil, Ivan J
AU  - Núñez-Gil IJ
AD  - Hospital Clinico San Carlos Madrid Spain.
FAU - Vitale, Enrica
AU  - Vitale E
AD  - Department of Medical and Surgical Sciences University of Foggia Italy.
FAU - Viana-Llamas, María C
AU  - Viana-Llamas MC
AUID- ORCID: 0000-0002-9523-1631
AD  - Hospital Universitario Guadalajara Guadalajara Spain.
FAU - Romero, Rodolfo
AU  - Romero R
AUID- ORCID: 0000-0002-3777-2050
AD  - Universidad Europea Madrid Spain.
FAU - Maroun Eid, Charbel
AU  - Maroun Eid C
AUID- ORCID: 0000-0001-7684-868X
AD  - Hospital Universitario de la Paz Madrid Spain.
FAU - Feltes Guzman, Gisela
AU  - Feltes Guzman G
AD  - Department of Cardiology Hospital Nuestra Señora de America Madrid Spain.
FAU - Becerra-Muñoz, Victor Manuel
AU  - Becerra-Muñoz VM
AUID- ORCID: 0000-0001-6454-7644
AD  - Servicio de Cardiología Hospital Universitario Virgen de la VictoriaIBIMA Málaga 
      Spain.
FAU - Fernández Rozas, Inmaculada
AU  - Fernández Rozas I
AD  - Hospital Universitario Severo Ochoa Leganés Spain.
FAU - Uribarri, Aitor
AU  - Uribarri A
AUID- ORCID: 0000-0002-6911-7480
AD  - Department of Cardiology Hospital Clinico Universitario de Valladolid Spain.
FAU - Alfonso-Rodriguez, Emilio
AU  - Alfonso-Rodriguez E
AUID- ORCID: 0000-0003-1063-9898
AD  - Institute of Cardiology and Cardiovascular Surgery Havana Cuba.
FAU - García Aguado, Marcos
AU  - García Aguado M
AD  - Hospital Puerta de Hierro de Majadahonda Majadahonda, Madrid Spain.
FAU - Huang, Jia
AU  - Huang J
AD  - The Second Affiliated Hospital of Southern University of Science and Technology 
      Shenzhen China.
FAU - Castro Mejía, Alex Fernando
AU  - Castro Mejía AF
AUID- ORCID: 0000-0003-4208-1681
AD  - Hospital General del Norte de Guayaquil IESS, Los Ceibos Guayaquil Ecuador.
FAU - Garcia Prieto, Juan Fortunato
AU  - Garcia Prieto JF
AD  - Department of Emergency Medicine Hospital de Manises Valencia Spain.
FAU - Elola, Javier
AU  - Elola J
AUID- ORCID: 0000-0002-4473-5864
AD  - IMAS Foundation Madrid Spain.
FAU - Ugo, Fabrizio
AU  - Ugo F
AD  - Department of Cardiology Sant'Andrea Hospital Vercelli Italy.
FAU - Cerrato, Enrico
AU  - Cerrato E
AUID- ORCID: 0000-0002-1260-7534
AD  - San Luigi Gonzaga University Hospital Orbassano Italy.
AD  - Rivoli Infermi Hospital Rivoli Italy.
FAU - Signes-Costa, Jaime
AU  - Signes-Costa J
AD  - Department of Lung Disease Hospital Clinico Valencia Spain.
FAU - Raposeiras Roubin, Sergio
AU  - Raposeiras Roubin S
AUID- ORCID: 0000-0002-6462-4715
AD  - University Hospital Alvaro Cunqueiro Vigo Spain.
FAU - Jativa Mendez, Jorge Luis
AU  - Jativa Mendez JL
AUID- ORCID: 0000-0003-3338-607X
AD  - Department of Cardiology Hospital De Especialidades De Las Fuerzas Armadas Quito 
      Ecuador.
FAU - Espejo Paeres, Carolina
AU  - Espejo Paeres C
AD  - Department of Cardiology Hospital Universitario Principe de Asturias Madrid 
      Spain.
FAU - López Masjuan, Alvaro
AU  - López Masjuan A
AD  - Department of Cardiology Hospital Universitario Juan Ramon Jimenez Huelva Spain.
FAU - Marin, Francisco
AU  - Marin F
AD  - IMIB-Arrixaca CIBERCV Hospital Clínico Universitario Virgen de la 
      ArrixacaUniversidad de Murcia Spain.
FAU - Guerra, Federico
AU  - Guerra F
AUID- ORCID: 0000-0001-5394-1312
AD  - Cardiology and Arrhythmology Clinic Ospedali Riuniti "Umberto I - Lancisi - 
      Salesi" Università Politecnica delle Marche Ancona Italy.
FAU - El-Battrawy, Ibrahim
AU  - El-Battrawy I
AUID- ORCID: 0000-0002-0139-1045
AD  - First Department of Medicine Faculty of Medicine University of Mannheim Mannheim 
      Germany.
FAU - Cortese, Bernardo
AU  - Cortese B
AUID- ORCID: 0000-0002-5808-7810
AD  - San Carlo Clinic Milano Italy.
FAU - Ramakrishna, Harish
AU  - Ramakrishna H
AUID- ORCID: 0000-0001-8785-5092
AD  - Department of Anesthesiology Mayo Clinic Rochester MN.
FAU - Perez-Villacastín, Julian
AU  - Perez-Villacastín J
AUID- ORCID: 0000-0002-4867-3912
AD  - Hospital Clinico San Carlos Madrid Spain.
FAU - Fernandez-Ortiz, Antonio
AU  - Fernandez-Ortiz A
AUID- ORCID: 0000-0002-3239-1910
AD  - Hospital Clinico San Carlos Madrid Spain.
FAU - Brunetti, Natale Daniele
AU  - Brunetti ND
AUID- ORCID: 0000-0001-9610-7408
AD  - Department of Medical and Surgical Sciences University of Foggia Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220622
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects
MH  - Aspirin/therapeutic use
MH  - *COVID-19
MH  - Cohort Studies
MH  - Humans
MH  - Propensity Score
MH  - Registries
MH  - Retrospective Studies
PMC - PMC9333361
OTO - NOTNLM
OT  - COVID‐19
OT  - anticoagulation
OT  - antiplatelet therapy
OT  - aspirin
OT  - prognosis
OT  - risk prediction
EDAT- 2022/06/23 06:00
MHDA- 2022/07/26 06:00
CRDT- 2022/06/22 06:42
PHST- 2022/06/23 06:00 [pubmed]
PHST- 2022/07/26 06:00 [medline]
PHST- 2022/06/22 06:42 [entrez]
AID - JAH37551 [pii]
AID - 10.1161/JAHA.121.024530 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2022 Jul 5;11(13):e024530. doi: 10.1161/JAHA.121.024530. Epub 
      2022 Jun 22.

PMID- 24002913
OWN - NLM
STAT- MEDLINE
DCOM- 20141009
LR  - 20220321
IS  - 1432-2218 (Electronic)
IS  - 0930-2794 (Linking)
VI  - 28
IP  - 1
DP  - 2014 Jan
TI  - Risks and complications of transurethral resection of bladder tumor among 
      patients taking antiplatelet agents for cardiovascular disease.
PG  - 116-21
LID - 10.1007/s00464-013-3136-8 [doi]
AB  - BACKGROUND: Urologists have not reached a consensus regarding the pre-, intra-, 
      and postoperative management of patients taking antiplatelet agents. This study 
      aimed to evaluate the clinical course of patients receiving antithrombotic 
      monotherapy with acetylsalicylic acid (ASA) 100 mg who underwent transurethral 
      resection of bladder cancer. METHODS: This study was designed to compare the 
      surgical outcomes for 108 transurethral resections of bladder cancer performed 
      for patients taking antiplatelet therapy and for 105 procedures performed for 
      patients who had never taken antiplatelet agents before surgery. Antiaggregant 
      therapy was maintained according to criteria evaluated by a urologist, surgeon, 
      anesthesiologist, and cardiologist. Variables were described using the mean as 
      the location index and using standard deviation as a dispersion index if 
      continuous percentages were used elsewhere. Group comparisons were performed 
      using the t test or the chi-square test for categorical data, and Fisher's exact 
      test was used where appropriate. RESULTS: The mean operative time for patients 
      taking ASA was 31 min (range 10-65 min), whereas it was 26 min (range 5-60 min) 
      for control subjects. The difference between pre- and postoperative hemoglobin 
      values was -0.6 g/dl in the group receiving antiplatelet therapy and -0.8 g/dl in 
      the control group (p = 0.0720). Transfusional support was required during four 
      procedures performed for patients taking antiplatelet therapy and during two 
      procedures for the control group (p = 0.242). No adverse cardiac events or 
      anesthesia-related complications occurred. Three patients in the treatment group 
      and two patients in the control group required reintervention to ensure 
      hemostasis during the postoperative period. None of the patients in either group 
      underwent rehospitalization for hematuria after leaving the hospital. CONCLUSION: 
      The current results suggest that continued use of anti-aggregant monotherapy does 
      not increase the risk of overall bleeding or reintervention for patients 
      undergoing transurethral resection of bladder neoplasms and that suspending 
      aspirin before such a procedure is therefore unnecessary.
FAU - Picozzi, Stefano
AU  - Picozzi S
AD  - Urology Department, IRCCS Policlinico San Donato, University of Milan, Via 
      Morandi 30, 20097, San Donato Milanese, Milan, Italy, stepico@tin.it.
FAU - Marenghi, Carlo
AU  - Marenghi C
FAU - Ricci, Cristian
AU  - Ricci C
FAU - Bozzini, Giorgio
AU  - Bozzini G
FAU - Casellato, Stefano
AU  - Casellato S
FAU - Carmignani, Luca
AU  - Carmignani L
LA  - eng
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20130904
PL  - Germany
TA  - Surg Endosc
JT  - Surgical endoscopy
JID - 8806653
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Blood Transfusion
MH  - Cardiovascular Diseases/*complications/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/*chemically induced/prevention & control
MH  - Humans
MH  - Male
MH  - Operative Time
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Postoperative Care
MH  - Risk Assessment
MH  - Urinary Bladder Neoplasms/*complications/*surgery
MH  - Urologic Surgical Procedures/*adverse effects
EDAT- 2013/09/05 06:00
MHDA- 2014/10/10 06:00
CRDT- 2013/09/05 06:00
PHST- 2013/01/13 00:00 [received]
PHST- 2013/07/22 00:00 [accepted]
PHST- 2013/09/05 06:00 [entrez]
PHST- 2013/09/05 06:00 [pubmed]
PHST- 2014/10/10 06:00 [medline]
AID - 10.1007/s00464-013-3136-8 [doi]
PST - ppublish
SO  - Surg Endosc. 2014 Jan;28(1):116-21. doi: 10.1007/s00464-013-3136-8. Epub 2013 Sep 
      4.

PMID- 16316558
OWN - NLM
STAT- MEDLINE
DCOM- 20061106
LR  - 20181203
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 44
IP  - 11
DP  - 2005 Nov
TI  - [Effects of cilostazol on long-term clinical outcomes after coronary stenting].
PG  - 814-7
AB  - OBJECTIVE: To evaluate the effects of cilostazol on long-term clinical outcomes 
      in patients underwent coronary stent implantation. METHODS: One hundred patients 
      who underwent coronary stenting were randomly assigned to receive cilostazol 200 
      mg/d for 6 months (n = 50) or ticlopidine 500 mg/d for 1 month (n = 50). Aspirin 
      100 mg/d was administrated concomitantly with cilostazol or ticlopidine. 
      Angiographic follow-up was carried out at 6 months and clinical follow-up for 3 
      years after stenting. RESULTS: Angiographic restenosis occurred in 5 of 34 
      patients (14.7%) in cilostazol group and 10 of 37 patients (27.0%) in ticlopidine 
      group (P = 0.204). At the end of three-year follow-up, the incidence of major 
      adverse cardiac and cerebral events (MACCE) was greatly reduced in cilostazol 
      group compared with ticlopidine group (16% vs 36%, P = 0.023). Changes of Seattle 
      angina questionnaire (SAQ) physical limitation score showed no significant 
      difference between two groups (21.8 +/- 12.3 vs 16.8 +/- 15.9, P = 0.086). 
      However, changes the improvement of angina frequency score much more was 
      significant in cilostazol group (22.6 +/- 12.7) compared with that in ticlopidine 
      group (16.1 +/- 13.3, P = 0.015). Recurrent angina occurred in 38% of patients in 
      cilostazol group and 54% in ticlopidine group, respectively (P = 0.105). 
      Readmission due to cardiac and cerebral vascular diseases was much less in 
      cilostazol group than that in ticlopidine group (20% vs 40%, P = 0.029). 
      CONCLUSIONS: Cilostazol treatment significantly reduced MACCE and improved the 
      quality of life pf patients in three-year clinical follow-up after coronary 
      stenting.
FAU - Han, Ya-ling
AU  - Han YL
AD  - Department of Cardiology, Shenyang General Hospital, Cardiovascular Research 
      Institute of PLA, Shenyang 110016, China. hanyal@mail.sy.ln.cn
FAU - Wang, Shou-li
AU  - Wang SL
FAU - Li, Yi
AU  - Li Y
FAU - Jing, Quan-min
AU  - Jing QM
FAU - Ma, Ying-yan
AU  - Ma YY
FAU - Deng, Jie
AU  - Deng J
FAU - Yang, Gui-tang
AU  - Yang GT
FAU - Yu, Hai-bo
AU  - Yu HB
FAU - Ge, Jun-bo
AU  - Ge JB
LA  - chi
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cilostazol
MH  - Coronary Disease/*therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - *Stents
MH  - Tetrazoles/administration & dosage/*therapeutic use
MH  - Ticlopidine/administration & dosage/therapeutic use
MH  - Treatment Outcome
EDAT- 2005/12/01 09:00
MHDA- 2006/11/07 09:00
CRDT- 2005/12/01 09:00
PHST- 2005/12/01 09:00 [pubmed]
PHST- 2006/11/07 09:00 [medline]
PHST- 2005/12/01 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2005 Nov;44(11):814-7.

PMID- 17713271
OWN - NLM
STAT- MEDLINE
DCOM- 20090526
LR  - 20171116
IS  - 1001-5515 (Print)
IS  - 1001-5515 (Linking)
VI  - 24
IP  - 3
DP  - 2007 Jun
TI  - [The drug release properties of poly 
      (acrylamide-co-itaconate-vinylbenzylglycosylallylamide) hydrogels].
PG  - 603-6
AB  - Sugar-containing monomer vinylbenzylglycosylallyamide (VBG) was synthesized by 
      vinylbenzyl amine and delta-gluconolactone in dimethylformamide(DMF) solution. 
      The sugar-based hydrogel was prepared by free radical crosslinking 
      copolymerization of VBG, itaconic acid (IA) and acrylamide (AM). The release 
      properties of Aspirin from xerogels matrices and from hydrogel in different pH 
      solutions and different concentration NaCl solutions were studied respectively. 
      The release mechanism of Aspirin was further confirmed by evaluating the n value 
      in Peppas equation. The results indicated that the drug release increased with 
      the increase of pH values and with the decrease of NaCl concentration.
FAU - Xi, Yanwei
AU  - Xi Y
AD  - Department of Pharmacy, Shandong University, Ji'nan 250012, China.
FAU - Li, Lingbing
AU  - Li L
FAU - Tan, Yebang
AU  - Tan Y
FAU - Xu, Zhenqin
AU  - Xu Z
FAU - Li, Ying
AU  - Li Y
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
JT  - Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = 
      Shengwu yixue gongchengxue zazhi
JID - 9426398
RN  - 0 (Acrylic Resins)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Succinates)
RN  - 0 (Vinyl Compounds)
RN  - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate)
RN  - 9003-05-8 (polyacrylamide)
RN  - Q4516562YH (itaconic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acrylic Resins/*chemistry
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/chemistry
MH  - Aspirin/*administration & dosage/chemistry
MH  - Delayed-Action Preparations/chemical synthesis/chemistry
MH  - Humans
MH  - Hydrogel, Polyethylene Glycol Dimethacrylate/*chemical synthesis/chemistry
MH  - Hydrogen-Ion Concentration
MH  - Succinates/*chemistry
MH  - Vinyl Compounds/*chemistry
EDAT- 2007/08/24 09:00
MHDA- 2009/05/27 09:00
CRDT- 2007/08/24 09:00
PHST- 2007/08/24 09:00 [pubmed]
PHST- 2009/05/27 09:00 [medline]
PHST- 2007/08/24 09:00 [entrez]
PST - ppublish
SO  - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2007 Jun;24(3):603-6.

PMID- 12716445
OWN - NLM
STAT- MEDLINE
DCOM- 20031105
LR  - 20191107
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 5
IP  - 1
DP  - 2003
TI  - COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 
      selective inhibitors at recommended dosages in appropriate patients.
PG  - 28-31
AB  - Cyclooxygenase (COX)-2 selective inhibitors have been shown to have comparable 
      efficacy to nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in the 
      treatment of patients with osteoarthritis (OA) and rheumatoid arthritis (RA). 
      Large outcome studies have shown that patients with OA and RA not taking low-dose 
      aspirin have fewer symptomatic and complicated upper GI events when treated with 
      COX-2 selective inhibitors than with nonselective NSAIDs. When used in 
      recommended dosages, there is no convincing evidence that patients treated with 
      COX-2 selective inhibitors have an increased incidence of cardiovascular 
      thrombotic events, including non-fatal myocardial infarction, than patients 
      treated with either placebo or nonselective NSAIDs other than naproxen. 
      Co-therapy with low-dose aspirin is recommended in patients with OA and RA at 
      increased risk for cardiovascular events; the need for gastroprotective therapy 
      in such patients is controversial.
FAU - Hochberg, Marc C
AU  - Hochberg MC
AD  - Division of Rheumatology and Clinical Immunology, University of Maryland School 
      of Medicine, Baltimore, Maryland, USA. mhochber@umaryland.edu
LA  - eng
PT  - Editorial
DEP - 20021211
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis/*drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*administration & dosage/therapeutic use/toxicity
MH  - Digestive System/drug effects
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Isoenzymes/*antagonists & inhibitors/physiology
MH  - Membrane Proteins
MH  - Prostaglandin-Endoperoxide Synthases/physiology
PMC - PMC154435
EDAT- 2003/04/30 05:00
MHDA- 2003/11/06 05:00
CRDT- 2003/04/30 05:00
PHST- 2002/10/31 00:00 [received]
PHST- 2002/11/14 00:00 [accepted]
PHST- 2003/04/30 05:00 [pubmed]
PHST- 2003/11/06 05:00 [medline]
PHST- 2003/04/30 05:00 [entrez]
AID - ar617 [pii]
AID - 10.1186/ar617 [doi]
PST - ppublish
SO  - Arthritis Res Ther. 2003;5(1):28-31. doi: 10.1186/ar617. Epub 2002 Dec 11.

PMID- 6617735
OWN - NLM
STAT- MEDLINE
DCOM- 19831123
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 91
IP  - 1
DP  - 1983 Jul 15
TI  - Omeprazole provides protection against experimentally induced gastric mucosal 
      lesions.
PG  - 111-4
AB  - Omeprazole, given orally to rats, protects the gastric mucosa against various 
      necrotizing agents, in doses (ED50 values 12-40 mumol/kg) which inhibit acid 
      secretion. However, the protection is due to reduced acid secretion since 
      omeprazole given intravenously in doses which completely inhibit acid secretion 
      is not protective. The mechanism of the protective effect of omeprazole is 
      unknown, but does not seem to be due to stimulation of the endogenous synthesis 
      of prostaglandins since the effect was not blocked by indomethacin.
FAU - Mattsson, H
AU  - Mattsson H
FAU - Andersson, K
AU  - Andersson K
FAU - Larsson, H
AU  - Larsson H
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 3K9958V90M (Ethanol)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Anti-Ulcer Agents
MH  - Aspirin/pharmacology
MH  - Benzimidazoles/*pharmacology
MH  - Ethanol/pharmacology
MH  - Female
MH  - Injections, Intravenous
MH  - Omeprazole
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach Ulcer/*prevention & control
MH  - Time Factors
EDAT- 1983/07/15 00:00
MHDA- 1983/07/15 00:01
CRDT- 1983/07/15 00:00
PHST- 1983/07/15 00:00 [pubmed]
PHST- 1983/07/15 00:01 [medline]
PHST- 1983/07/15 00:00 [entrez]
AID - 0014-2999(83)90370-9 [pii]
AID - 10.1016/0014-2999(83)90370-9 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1983 Jul 15;91(1):111-4. doi: 10.1016/0014-2999(83)90370-9.

PMID- 28705190
OWN - NLM
STAT- MEDLINE
DCOM- 20180419
LR  - 20181113
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Jul 14
TI  - Low dose aspirin in the prevention of recurrent spontaneous preterm labour - the 
      APRIL study: a multicenter randomized placebo controlled trial.
PG  - 223
LID - 10.1186/s12884-017-1338-0 [doi]
LID - 223
AB  - BACKGROUND: Preterm birth (birth before 37 weeks of gestation) is a major problem 
      in obstetrics and affects an estimated 15 million pregnancies worldwide annually. 
      A history of previous preterm birth is the strongest risk factor for preterm 
      birth, and recurrent spontaneous preterm birth affects more than 2.5 million 
      pregnancies each year. A recent meta-analysis showed possible benefits of the use 
      of low dose aspirin in the prevention of recurrent spontaneous preterm birth. We 
      will assess the (cost-)effectiveness of low dose aspirin in comparison with 
      placebo in the prevention of recurrent spontaneous preterm birth in a randomized 
      clinical trial. METHODS/DESIGN: Women with a singleton pregnancy and a history of 
      spontaneous preterm birth in a singleton pregnancy (22-37 weeks of gestation) 
      will be asked to participate in a multicenter, randomized, double blinded, 
      placebo controlled trial. Women will be randomized to low dose aspirin (80 mg 
      once daily) or placebo, initiated from 8 to 16 weeks up to maximal 36 weeks of 
      gestation. The primary outcome measure will be preterm birth, defined as birth at 
      a gestational age (GA) < 37 weeks. Secondary outcomes will be a composite of 
      adverse neonatal outcome and maternal outcomes, including subgroups of 
      prematurity, as well as intrauterine growth restriction (IUGR) and costs from a 
      healthcare perspective. Preterm birth will be analyzed as a group, as well as 
      separately for spontaneous or indicated onset. Analysis will be performed by 
      intention to treat. In total, 406 pregnant women have to be randomized to show a 
      reduction of 35% in preterm birth from 36 to 23%. If aspirin is effective in 
      preventing preterm birth, we expect that there will be cost savings, because of 
      the low costs of aspirin. To evaluate this, a cost-effectiveness analysis will be 
      performed comparing preventive treatment with aspirin with placebo. DISCUSSION: 
      This trial will provide evidence as to whether or not low dose aspirin is (cost-) 
      effective in reducing recurrence of spontaneous preterm birth. TRIAL 
      REGISTRATION: Clinical trial registration number of the Dutch Trial Register: NTR 
      5675 . EudraCT-registration number: 2015-003220-31.
FAU - Visser, Laura
AU  - Visser L
AD  - Department of Obstetrics and Gynecology, VU University Medical Center, De 
      Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands.
FAU - de Boer, Marjon A
AU  - de Boer MA
AD  - Department of Obstetrics and Gynecology, VU University Medical Center, De 
      Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands.
FAU - de Groot, Christianne J M
AU  - de Groot CJM
AD  - Department of Obstetrics and Gynecology, VU University Medical Center, De 
      Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands.
FAU - Nijman, Tobias A J
AU  - Nijman TAJ
AD  - Department of Obstetrics and Gynecology, Birth Centre Wilhelmina Children 
      Hospital, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, 
      Utrecht, The Netherlands.
FAU - Hemels, Marieke A C
AU  - Hemels MAC
AD  - Department of Neonatology, Isala Clinic, Dokter van Heesweg 2, 8025 AB, Zwolle, 
      The Netherlands.
FAU - Bloemenkamp, Kitty W M
AU  - Bloemenkamp KWM
AD  - Department of Obstetrics and Gynecology, Birth Centre Wilhelmina Children 
      Hospital, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, 
      Utrecht, The Netherlands.
FAU - Bosmans, Judith E
AU  - Bosmans JE
AD  - Department of Health Sciences and the EMGO Institute for Health and Care 
      Research, Faculty of Earth and Life Sciences, Vrije Universiteit Amsterdam, De 
      Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands.
FAU - Kok, Marjolein
AU  - Kok M
AD  - Department of Obstetrics and Gynecology, Academic Medical Center, Meibergdreef 9, 
      1105 AZ, Amsterdam, The Netherlands.
FAU - van Laar, Judith O
AU  - van Laar JO
AD  - Department of Obstetrics and Gynecology, Maxima Medical Center in Veldhoven, De 
      Run 4600, 5504 DB, Veldhoven, The Netherlands.
FAU - Sueters, Marieke
AU  - Sueters M
AD  - Department of Obstetrics and Gynecology, Leiden University Medical Center, 
      Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
FAU - Scheepers, Hubertina
AU  - Scheepers H
AD  - Department of Obstetrics and Gynecology, Maastricht University Medical Center, P. 
      Debyelaan 25, 6229 HX, Maastricht, The Netherlands.
FAU - van Drongelen, Joris
AU  - van Drongelen J
AD  - Department of Obstetrics and Gynecology, Radboud University Medical Center, Geert 
      Grooteplein-Zuid 10, 6525 GA, Nijmegen, The Netherlands.
FAU - Franssen, Maureen T M
AU  - Franssen MTM
AD  - Department of Obstetrics and Gynecology, University Medical Center Groningen, 
      Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
FAU - Sikkema, J Marko
AU  - Sikkema JM
AD  - Department of Obstetrics and Gynecology, Hospital Group Twente, Zilvermeeuw 1, 
      7609 PP, Almelo, The Netherlands.
FAU - Duvekot, Hans J J
AU  - Duvekot HJJ
AD  - Department of Obstetrics and Gynecology, Erasmus Medical Center, 's- 
      Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
FAU - Bekker, Mireille N
AU  - Bekker MN
AD  - Department of Obstetrics and Gynecology, Birth Centre Wilhelmina Children 
      Hospital, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, 
      Utrecht, The Netherlands.
FAU - van der Post, Joris A M
AU  - van der Post JAM
AD  - Department of Obstetrics and Gynecology, Academic Medical Center, Meibergdreef 9, 
      1105 AZ, Amsterdam, The Netherlands.
FAU - Naaktgeboren, Christiana
AU  - Naaktgeboren C
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center 
      Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
FAU - Mol, Ben W J
AU  - Mol BWJ
AD  - Department of Obstetrics and Gynecology, Robinson Research Institute, University 
      of Adelaide, 72 King William St, North Adelaide, SA 5006, Australia.
FAU - Oudijk, Martijn A
AU  - Oudijk MA
AD  - Department of Obstetrics and Gynecology, Academic Medical Center, Meibergdreef 9, 
      1105 AZ, Amsterdam, The Netherlands. m.a.oudijk@amc.uva.nl.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20170714
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/economics
MH  - Cost-Benefit Analysis
MH  - Double-Blind Method
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Obstetric Labor, Premature/economics/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/economics
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Prenatal Care/economics/*methods
MH  - Recurrence
MH  - Secondary Prevention/economics/*methods
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC5513323
OTO - NOTNLM
OT  - ASA
OT  - Acetylsalicylic acid
OT  - Aspirin
OT  - PTB
OT  - Pregnancy
OT  - Preterm birth
OT  - Preterm labour
OT  - Prevention
OT  - Reduction
OT  - SPTB
OT  - ‘Spontaneous recurrent preterm birth’
EDAT- 2017/07/15 06:00
MHDA- 2018/04/20 06:00
CRDT- 2017/07/15 06:00
PHST- 2017/02/14 00:00 [received]
PHST- 2017/05/19 00:00 [accepted]
PHST- 2017/07/15 06:00 [entrez]
PHST- 2017/07/15 06:00 [pubmed]
PHST- 2018/04/20 06:00 [medline]
AID - 10.1186/s12884-017-1338-0 [pii]
AID - 1338 [pii]
AID - 10.1186/s12884-017-1338-0 [doi]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2017 Jul 14;17(1):223. doi: 10.1186/s12884-017-1338-0.

PMID- 8560344
OWN - NLM
STAT- MEDLINE
DCOM- 19960227
LR  - 20190727
IS  - 0362-2436 (Print)
IS  - 0362-2436 (Linking)
VI  - 20
IP  - 17
DP  - 1995 Sep 1
TI  - Is there a link between acute spinal epidural hematoma and aspirin?
PG  - 1931-2
AB  - STUDY DESIGN: This is a report of a patient with acute spinal epidural hematoma 
      taking aspirin, 250 mg/day. OBJECTIVE: To describe the association of spinal 
      epidural hematoma and aspirin. SUMMARY OF BACKGROUND DATA: In about 50% of 
      patients, the cause of acute spinal epidural hematoma is obscure. Analysis of 
      possible mechanisms is necessary. METHODS: Diagnostic lumbar puncture, 
      suboccipital myelography, and surgical removal of the hematoma was performed. 
      RESULTS: Increased bleeding was noticed during these procedures. Bleeding time 
      was normal 6 days after discontinuance of aspirin. CONCLUSION: Because aspirin is 
      widely used, its role in causing spinal epidural hematoma will remain 
      conjectural. For the present patient, however, it was postulated that aspirin had 
      a major impact on the extent of the epidural bleeding. There should be awareness 
      of a possible link between aspirin and spinal epidural hematoma.
FAU - Heye, N
AU  - Heye N
AD  - Neurologische Klinik, St. Josef Hospital, Ruhr Universität Bochum, Bochum, 
      Germany.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Spine (Phila Pa 1976)
JT  - Spine
JID - 7610646
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Hematoma, Epidural, Cranial/*chemically induced
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*adverse effects
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
AID - 10.1097/00007632-199509000-00017 [doi]
PST - ppublish
SO  - Spine (Phila Pa 1976). 1995 Sep 1;20(17):1931-2. doi: 
      10.1097/00007632-199509000-00017.

PMID- 22044036
OWN - NLM
STAT- MEDLINE
DCOM- 20160519
LR  - 20191112
IS  - 2212-4063 (Electronic)
IS  - 1871-529X (Linking)
VI  - 11
IP  - 2
DP  - 2011
TI  - Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently 
      Available Agents and What the Future Holds.
PG  - 79-86
AB  - Dual anti-platelet therapy remains a cornerstone in the management of patients 
      suffering from acute coronary syndromes (ACS). The combination of aspirin and 
      clopidogrel has been shown to result in significant reductions in cardiovascular 
      end points including recurrent infarction and death in several randomised control 
      trial of patients with ACS. However, many patients still experience ischaemic 
      events on the combination of aspirin and clopidogrel. Aspirin is a relatively 
      weak anti platelet agent. Clopidogrel is a pro drug that required activation by 
      hepatic metabolism and hence its onset of action is delayed; there is genetic 
      variation in the clinical response to the drug, the platelet inhibition is 
      irreversible and no intravenous form is available. Consequently new anti-platelet 
      agents have been developed to address the short falls of this combination 
      therapy. This paper discusses existing anti-platelet regimes and focuses on novel 
      antiplatelet agents that are currently under clinical evaluation.
FAU - Syed, F A
AU  - Syed FA
AD  - The Prince Charles Hospital, Brisbane, Queensland, Australia. sfarhan5@yahoo.com.
FAU - Bett, J H N
AU  - Bett JH
FAU - Walters, D L
AU  - Walters DL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Cardiovasc Hematol Disord Drug Targets
JT  - Cardiovascular & hematological disorders drug targets
JID - 101269160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2011/11/03 06:00
MHDA- 2016/05/20 06:00
CRDT- 2011/11/03 06:00
PHST- 2011/11/03 06:00 [entrez]
PHST- 2011/11/03 06:00 [pubmed]
PHST- 2016/05/20 06:00 [medline]
AID - BSP/CHDDT/E-Pub/00045 [pii]
AID - 10.2174/187152911798347007 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Disord Drug Targets. 2011;11(2):79-86. doi: 
      10.2174/187152911798347007.

PMID- 28642210
OWN - NLM
STAT- MEDLINE
DCOM- 20180507
LR  - 20181202
IS  - 1559-2030 (Electronic)
IS  - 1551-7144 (Linking)
VI  - 60
DP  - 2017 Sep
TI  - Rationale and Design for a Randomized Comparison of Efficacy and Safety between 
      Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: 
      CESAC-AF trial.
PG  - 51-55
LID - S1551-7144(17)30160-X [pii]
LID - 10.1016/j.cct.2017.06.011 [doi]
AB  - BACKGROUND: Atrial fibrillation (AF) increases the risk of thromboembolic stroke. 
      An oral anticoagulant should be administrated to prevent stroke in patients with 
      moderate stroke risk (ie, CHA(2)DS(2)-VASc score>2). If the stroke risk is low 
      (i.e. the score=1), however, antiplatelet agent such as aspirin is widely used. 
      Aspirin can cause peptic ulcer disease (PUD) while its alternative, clopidogrel, 
      theoretically does not. OBJECTIVE: To elucidate the efficacy and safety between 
      aspirin and clopidogrel, a multicenter randomized controlled trial was designed 
      in AF patients with low stroke risk. METHODS: According to sample size estimation 
      based on previous literature, a total of 1560 AF patients with low stroke risk 
      will be randomly assigned into 4 different groups dependent upon initial 
      esophagogastroduodenoscopy (EGD) results: two mono-antiplatelet treatment groups 
      with either aspirin 100mg or clopidogrel 75mg for 1year; two antiplatelet agent 
      and proton pump inhibitor (PPI) combination groups. Follow-up EGD will be 
      performed at 1year. RESULTS: The clinical follow-up will be performed for 1year 
      after enrollment. The primary efficacy endpoint is to compare the annual stroke 
      rate between aspirin and clopidogrel treatment groups. The primary safety 
      endpoint is to compare the prevalence of drug-induced gastrointestinal (GI) and 
      intracranial hemorrhage and upper-GI response including PUD based on EGD after 
      1year. CONCLUSIONS: This trial will determine whether clopidogrel is noninferior 
      in stroke prevention and superior in reduction of GI events including PUD to 
      aspirin in AF patients with low stroke risk. (ClinicalTrials.gov: NCT02960126).
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Park, Sang Min
AU  - Park SM
AD  - Cardiovascular Center, Chuncheon Sacred Heart Hospital, Hallym University College 
      of Medicine, Chuncheon, Republic of Korea; Department of Medicine, the Graduate 
      School of Yonsei University, Seoul, Republic of Korea. Electronic address: 
      samipark@hanmail.net.
FAU - Jeong, Haemin
AU  - Jeong H
AD  - Cardiovascular Center, Chuncheon Sacred Heart Hospital, Hallym University College 
      of Medicine, Chuncheon, Republic of Korea.
FAU - Jung, Mi-Hyang
AU  - Jung MH
AD  - Cardiovascular Center, Chuncheon Sacred Heart Hospital, Hallym University College 
      of Medicine, Chuncheon, Republic of Korea.
FAU - Hong, Kyung Soon
AU  - Hong KS
AD  - Cardiovascular Center, Chuncheon Sacred Heart Hospital, Hallym University College 
      of Medicine, Chuncheon, Republic of Korea.
FAU - Hong, Myeong-Ki
AU  - Hong MK
AD  - Division of Cardiology, Yonsei Cardiovascular Center, Yonsei University College 
      of Medicine, Seoul, Republic of Korea.
FAU - Bang, Chang Seok
AU  - Bang CS
AD  - Division of Gastroenterology, Department of Internal Medicine, Hallym University 
      College of Medicine, Chuncheon, Republic of Korea.
FAU - Kim, Christopher Y
AU  - Kim CY
AD  - Utah Cardiology, Layton, UT, United States.
LA  - eng
SI  - ClinicalTrials.gov/NCT02960126
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20170619
PL  - United States
TA  - Contemp Clin Trials
JT  - Contemporary clinical trials
JID - 101242342
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*complications/*drug therapy
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Endoscopy, Digestive System
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Proton Pump Inhibitors/administration & dosage
MH  - Research Design
MH  - Risk Factors
MH  - Stroke/*prevention & control
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
OTO - NOTNLM
OT  - Atrial fibrillation
OT  - Bleeding
OT  - Esophagogastroduodenoscopy
OT  - Stroke
EDAT- 2017/06/24 06:00
MHDA- 2018/05/08 06:00
CRDT- 2017/06/24 06:00
PHST- 2017/03/01 00:00 [received]
PHST- 2017/06/12 00:00 [revised]
PHST- 2017/06/16 00:00 [accepted]
PHST- 2017/06/24 06:00 [pubmed]
PHST- 2018/05/08 06:00 [medline]
PHST- 2017/06/24 06:00 [entrez]
AID - S1551-7144(17)30160-X [pii]
AID - 10.1016/j.cct.2017.06.011 [doi]
PST - ppublish
SO  - Contemp Clin Trials. 2017 Sep;60:51-55. doi: 10.1016/j.cct.2017.06.011. Epub 2017 
      Jun 19.

PMID- 26105589
OWN - NLM
STAT- MEDLINE
DCOM- 20160519
LR  - 20160606
IS  - 1878-3562 (Electronic)
IS  - 1590-8658 (Linking)
VI  - 47
IP  - 9
DP  - 2015 Sep
TI  - Proton pump inhibitors are associated with lower gastrointestinal tract bleeding 
      in low-dose aspirin users with ischaemic heart disease.
PG  - 757-62
LID - S1590-8658(15)00349-7 [pii]
LID - 10.1016/j.dld.2015.05.020 [doi]
AB  - BACKGROUND: Impact of acid suppressants on lower gastrointestinal bleeding 
      remains unclear in low-dose aspirin users; we aimed to investigate this 
      relationship. METHODS: Retrospective cohort study of low-dose aspirin users who 
      underwent coronary angiography for ischaemic heart disease in our institution 
      between October 2005 and December 2006; patients were evaluated for upper or 
      lower gastrointestinal bleedings within 3 years post-angiography. RESULTS: 538 
      patients were enrolled (males, 74.4%; mean age 67.4±10.6 years). Risk for upper 
      gastrointestinal bleeding decreased with concomitant use of statins (HR, 0.37; 
      95% CI, 0.15-0.89), calcium channel blockers (HR, 0.29; 95% CI, 0.10-0.85), and 
      histamine-2 receptor antagonists (HR, 0.26; 95% CI, 0.08-0.89). Concomitant use 
      of proton pump inhibitors tended to decrease risk of upper gastrointestinal 
      bleeding (HR, 0.27; 95% CI, 0.06-1.18). Risk for lower gastrointestinal bleeding 
      increased with both concomitant use of warfarin (HR, 15.68; 95% CI, 4.43-55.53) 
      and proton pump inhibitors (HR, 6.55; 95% CI, 2.01-21.32), but not with 
      histamine-2 receptor antagonists. Hyperuricemia lowered risk for lower 
      gastrointestinal bleeding (HR, 0.12; 95% CI, 0.02-0.88). CONCLUSIONS: In low-dose 
      aspirin users, concomitant use of proton pump inhibitors increased lower 
      gastrointestinal bleeding risk, independent from effects on upper 
      gastrointestinal bleeding.
CI  - Copyright © 2015 Editrice Gastroenterologica Italiana S.r.l. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Miyake, Kazumasa
AU  - Miyake K
AD  - Department of Gastroenterology, Nippon Medical School, Tokyo, Japan. Electronic 
      address: km366@nms.ac.jp.
FAU - Akimoto, Teppei
AU  - Akimoto T
AD  - Department of Gastroenterology, Nippon Medical School, Tokyo, Japan.
FAU - Hanada, Yuriko
AU  - Hanada Y
AD  - Department of Gastroenterology, Nippon Medical School, Tokyo, Japan.
FAU - Nagoya, Hiroyuki
AU  - Nagoya H
AD  - Department of Gastroenterology, Nippon Medical School, Tokyo, Japan.
FAU - Kodaka, Yasuhiro
AU  - Kodaka Y
AD  - Department of Gastroenterology, Nippon Medical School, Tokyo, Japan.
FAU - Ueki, Nobue
AU  - Ueki N
AD  - Department of Gastroenterology, Nippon Medical School, Tokyo, Japan.
FAU - Kusunoki, Masafumi
AU  - Kusunoki M
AD  - Department of Gastroenterology, Nippon Medical School, Tokyo, Japan.
FAU - Kawagoe, Tetsuro
AU  - Kawagoe T
AD  - Department of Gastroenterology, Nippon Medical School, Tokyo, Japan.
FAU - Futagami, Seiji
AU  - Futagami S
AD  - Department of Gastroenterology, Nippon Medical School, Tokyo, Japan.
FAU - Takahashi, Yasuhiro
AU  - Takahashi Y
AD  - Department of Cardiology, Nippon Medical School, Tokyo, Japan.
FAU - Takano, Hitoshi
AU  - Takano H
AD  - Department of Cardiology, Nippon Medical School, Tokyo, Japan.
FAU - Sakamoto, Choitsu
AU  - Sakamoto C
AD  - Department of Gastroenterology, Nippon Medical School, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20150602
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Dig Liver Dis. 2016 Feb;48(2):211. PMID: 26699825
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastrointestinal Hemorrhage/*etiology/prevention & control
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myocardial Ischemia/complications/*drug therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Proportional Hazards Models
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - Gastrointestinal bleeding
OT  - Histamine-2 receptor antagonists
OT  - Low-dose aspirin
OT  - Oroton pump inhibitors
EDAT- 2015/06/25 06:00
MHDA- 2016/05/20 06:00
CRDT- 2015/06/25 06:00
PHST- 2014/12/10 00:00 [received]
PHST- 2015/05/21 00:00 [revised]
PHST- 2015/05/26 00:00 [accepted]
PHST- 2015/06/25 06:00 [entrez]
PHST- 2015/06/25 06:00 [pubmed]
PHST- 2016/05/20 06:00 [medline]
AID - S1590-8658(15)00349-7 [pii]
AID - 10.1016/j.dld.2015.05.020 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2015 Sep;47(9):757-62. doi: 10.1016/j.dld.2015.05.020. Epub 2015 
      Jun 2.

PMID- 20593231
OWN - NLM
STAT- MEDLINE
DCOM- 20101208
LR  - 20181201
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 24
IP  - 3
DP  - 2010 Jun
TI  - Role of dual antiplatelet therapy in symptomatic patients with established 
      vascular disease: putting the CHARISMA trial into therapeutic perspective.
PG  - 207-16
LID - 10.1007/s10557-010-6245-9 [doi]
AB  - INTRODUCTION: The CHARISMA (Clopidogrel for High Atherothrombotic Risk and 
      Ischemic Stabilization, Management, and Avoidance) trial has spurred debate over 
      subgroup analysis interpretation and prompted renewed consideration of the 
      long-term role of dual aspirin and clopidogrel therapy (DAPT) in patients with 
      established vascular disease. DISCUSSION: Previous DAPT studies consistently 
      demonstrated greater efficacy but an increased risk of bleeding compared with 
      aspirin alone in patients with acute coronary syndromes or undergoing 
      percutaneous coronary intervention. However, CHARISMA data were inconclusive and 
      difficult to interpret. The principal subgroup analysis showed a significant 
      benefit for clopidogrel plus aspirin in the 80% of patients with documented 
      vascular disease, but unexpectedly showed potential harm in the approximately 20% 
      of asymptomatic patients. CONCLUSIONS: Hypothesizing that dual antiplatelet 
      therapy would provide benefit across the broad spectrum of atherothrombotic 
      disease was plausible. In retrospect, it is apparent that by combining such a 
      heterogeneous population, CHARISMA failed to show a clear treatment effect for 
      DAPT and potentially masked important benefits in specific populations. Given the 
      inherent clinical and biological variability among patients and disease states, 
      difficult-to-interpret clinical data should not be dismissed. The current 
      challenge is identifying clinically useful data from CHARISMA to determine the 
      role of DAPT in contemporary clinical practice.
FAU - Boden, William E
AU  - Boden WE
AD  - Buffalo General Hospital and SUNY, University at Buffalo School of Medicine and 
      Biomedical Sciences, Buffalo, NY, USA. wboden@kaleidahealth.org
FAU - Flather, Marcus D
AU  - Flather MD
FAU - Bhatt, Deepak L
AU  - Bhatt DL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Randomized Controlled Trials as Topic/*methods
MH  - Retrospective Studies
MH  - Risk
MH  - Thrombosis/prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Vascular Diseases/drug therapy
EDAT- 2010/07/02 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/07/02 06:00
PHST- 2010/07/02 06:00 [entrez]
PHST- 2010/07/02 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.1007/s10557-010-6245-9 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2010 Jun;24(3):207-16. doi: 10.1007/s10557-010-6245-9.

PMID- 2145839
OWN - NLM
STAT- MEDLINE
DCOM- 19901108
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 40
IP  - 7
DP  - 1990 Oct 1
TI  - Platelet thromboxane A2/prostaglandin H2 receptors in human volunteers on low 
      doses of aspirin.
PG  - 1559-61
AB  - Administration of aspirin (81 mg/day for 2-3 weeks) in nine healthy volunteers 
      (out of an initial ten subjects, only nine qualified) resulted in a greater than 
      95% decrease of thromboxane B2 production by thrombin-stimulated platelets. At 
      the same time, ligand binding studies with a thromboxane A2 antagonist, 
      125I-PTA-OH, measurements of shape change, and aggregation of platelets 
      stimulated with U46619, a prostaglandin H2 analogue, indicated that 
      administration of aspirin to normal human subjects does not result in the 
      up-regulation of platelet thromboxane A2/prostaglandin H2 receptors.
FAU - Covatto, R H
AU  - Covatto RH
AD  - Department of Physiology, Temple University School of Medicine, Philadelphia, PA 
      19140.
FAU - Niewiarowski, S
AU  - Niewiarowski S
LA  - eng
GR  - HL15226/HL/NHLBI NIH HHS/United States
GR  - HL36579/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Prostaglandin Endoperoxides, Synthetic)
RN  - 0 (Receptors, Prostaglandin)
RN  - 0 (Receptors, Thromboxane)
RN  - 0 (Receptors, Thromboxane A2, Prostaglandin H2)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 97228-80-3 (I-PTA-OH)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandin Endoperoxides, Synthetic/pharmacology
MH  - Receptors, Prostaglandin/*metabolism
MH  - Receptors, Thromboxane
MH  - Receptors, Thromboxane A2, Prostaglandin H2
MH  - Thrombin
MH  - Thromboxane A2/analogs & derivatives/antagonists & inhibitors/pharmacology
MH  - Thromboxane B2/metabolism
EDAT- 1990/10/01 00:00
MHDA- 1990/10/01 00:01
CRDT- 1990/10/01 00:00
PHST- 1990/10/01 00:00 [pubmed]
PHST- 1990/10/01 00:01 [medline]
PHST- 1990/10/01 00:00 [entrez]
AID - 0006-2952(90)90454-S [pii]
AID - 10.1016/0006-2952(90)90454-s [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1990 Oct 1;40(7):1559-61. doi: 10.1016/0006-2952(90)90454-s.

PMID- 21334823
OWN - NLM
STAT- MEDLINE
DCOM- 20110722
LR  - 20151119
IS  - 1879-1409 (Electronic)
IS  - 0305-4179 (Linking)
VI  - 37
IP  - 4
DP  - 2011 Jun
TI  - Influence of anti-inflammatory and vasoactive drugs on microcirculation and 
      angiogenesis after burn in mice.
PG  - 656-64
LID - 10.1016/j.burns.2011.01.004 [doi]
AB  - OBJECTIVE: The treatment of burns remains a challenge. Besides the administration 
      of physiological saline, local disinfection and symptomatic medications, no 
      causal therapy is known to accelerate angiogenesis and wound healing. The aim of 
      this study was to investigate the influences of dilatative and anti-inflammatory 
      acting drugs on microcirculation, angiogenesis and leukocyte behavior, which had 
      shown positive effects in former burn studies. METHODS: The ears of male hairless 
      mice (n=47) were inflicted with full thickness burns using a hot air jet. Then 
      the affects of five intraperitoneal injections of either acetylsalicylic acid 
      (ASA), isosorbide dinitrate, prostaglandin E1 (PGE1) or sodium chloride (each 
      administered to one of four corresponding study groups), on microcirculation, 
      leukocyte-endothelial interaction and angiogenesis were investigated over a 12 
      day period using intravital fluorescent microscopy. RESULTS: Angiogenesis was 
      slightly improved by PGE1 (0.3 vs. 1.3% non-perfused area in other groups on day 
      12, p=0.029). Additionally, blood flow increased and rolling leukocytes decreased 
      compared to other groups. The ASA-group showed best functional vessel density and 
      lowest leukocyte-adhesion. The often described posttraumatic expansion of tissue 
      damage could not be observed in either group. CONCLUSION: Prostaglandin E1 
      improved angiogenesis, increased the blood flow and reduced the number of rolling 
      leukocytes. ASA had positive influences on functional vessel density, edema 
      formation and the number of sticking leukocytes. However, it reduced the blood 
      flow. Overall, out of all the drugs tested, prostaglandin seems to have the 
      greatest positive impact on microcirculation and angiogenesis in burns.
CI  - Copyright © 2011 Elsevier Ltd and ISBI. All rights reserved.
FAU - Goertz, O
AU  - Goertz O
AD  - Department of Plastic and Hand Surgery, Burn Center, BG-University Hospital 
      Bergmannsheil, Ruhr-University Bochum, Bochum, Germany. ole.goertz@rub.de
FAU - Ring, A
AU  - Ring A
FAU - Buschhaus, B
AU  - Buschhaus B
FAU - Hirsch, T
AU  - Hirsch T
FAU - Daigeler, A
AU  - Daigeler A
FAU - Steinstraesser, L
AU  - Steinstraesser L
FAU - Steinau, H-U
AU  - Steinau HU
FAU - Langer, S
AU  - Langer S
LA  - eng
PT  - Journal Article
DEP - 20110222
PL  - Netherlands
TA  - Burns
JT  - Burns : journal of the International Society for Burn Injuries
JID - 8913178
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Prostaglandins)
RN  - 0 (Vasodilator Agents)
RN  - 0 (isosorbide diaspirinate)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - R16CO5Y76E (Aspirin)
RN  - WXR179L51S (Isosorbide)
SB  - IM
CIN - Burns. 2011 Nov;37(7):1272; author reply 1272-3. PMID: 21821361
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Burns/*drug therapy/physiopathology
MH  - Disease Models, Animal
MH  - Endothelium/pathology
MH  - Injections, Intraperitoneal
MH  - Isosorbide/analogs & derivatives/pharmacology
MH  - Leukocytes/pathology
MH  - Mice
MH  - Mice, Hairless
MH  - Microcirculation/*drug effects
MH  - Neovascularization, Pathologic/*drug therapy
MH  - Prostaglandins/pharmacology
MH  - Skin/*blood supply/pathology
MH  - Sodium Chloride/pharmacology
MH  - Vasodilator Agents/*pharmacology
EDAT- 2011/02/22 06:00
MHDA- 2011/07/23 06:00
CRDT- 2011/02/22 06:00
PHST- 2010/06/08 00:00 [received]
PHST- 2010/12/31 00:00 [revised]
PHST- 2011/01/05 00:00 [accepted]
PHST- 2011/02/22 06:00 [entrez]
PHST- 2011/02/22 06:00 [pubmed]
PHST- 2011/07/23 06:00 [medline]
AID - S0305-4179(11)00007-6 [pii]
AID - 10.1016/j.burns.2011.01.004 [doi]
PST - ppublish
SO  - Burns. 2011 Jun;37(4):656-64. doi: 10.1016/j.burns.2011.01.004. Epub 2011 Feb 22.

PMID- 14601968
OWN - NLM
STAT- MEDLINE
DCOM- 20041220
LR  - 20191210
IS  - 1083-7450 (Print)
IS  - 1083-7450 (Linking)
VI  - 8
IP  - 4
DP  - 2003
TI  - Influence of the aqueous film coating process on the properties and stability of 
      tablets containing a moisture-labile drug.
PG  - 443-51
AB  - The effects of an aqueous film coating process on the morphology and storage 
      stability of hydroxypropyl methylcellulose-coated tablets containing a 
      moisture-labile model drug (acetylsalicylic acid, ASA) were evaluated using an 
      instrumented side-vented tablet pan coater. Coating parameters studied were inlet 
      air absolute humidity 5 g/m3 and 12 g/m3, spraying air pressure 100 kPa and 500 
      kPa, pan air temperature 35 degrees C and 55 degrees C, and coating solution flow 
      rate 2.2 g/min and 7.8 g/min. The surface roughness of the coatings was measured 
      with a laser profilometer and the chemical hydrolysis of the model drug ASA with 
      an UV-spectrophotometer. The film-coated tablets were stored at 25 degrees C/60% 
      RH and 40 degrees C/75% RH for three months. The high absolute humidity of the 
      inlet air increased the residual water content and surface roughness of the 
      coated tablets. Using a lower coating solution flow rate, higher spraying air 
      pressure and pan temperature the coatings were smooth and homogeneous. In both 
      ambient and accelerated storage conditions, the roughness of the coatings and the 
      hydrolysis of ASA increased, but this was independent of the film coating 
      process. Uniform and smooth hydroxypropyl methylcellulose coatings can be 
      achieved by improved control of process parameters related to the application of 
      the coating solution and water evaporation of the tablet surface.
FAU - Ruotsalainen, Mirja
AU  - Ruotsalainen M
AD  - Pharmaceutical Technology Division, Department of Pharmacy, University of 
      Helsinki, Finland. mirja.ruotsalainen@helsinki.fi
FAU - Heinämäki, Jyrki
AU  - Heinämäki J
FAU - Taipale, Krista
AU  - Taipale K
FAU - Yliruusi, Jouko
AU  - Yliruusi J
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Pharm Dev Technol
JT  - Pharmaceutical development and technology
JID - 9610932
RN  - 0 (Coated Materials, Biocompatible)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 059QF0KO0R (Water)
RN  - 9004-67-5 (Methylcellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Air Movements
MH  - Aspirin/analysis/pharmacokinetics
MH  - Chemistry, Pharmaceutical
MH  - Coated Materials, Biocompatible/analysis/pharmacokinetics
MH  - Drug Stability
MH  - Drug Storage
MH  - Humidity/adverse effects
MH  - Methylcellulose/chemistry/pharmacokinetics
MH  - Pharmaceutical Preparations
MH  - *Tablets, Enteric-Coated/analysis/pharmacokinetics
MH  - Water
EDAT- 2003/11/07 05:00
MHDA- 2004/12/21 09:00
CRDT- 2003/11/07 05:00
PHST- 2003/11/07 05:00 [pubmed]
PHST- 2004/12/21 09:00 [medline]
PHST- 2003/11/07 05:00 [entrez]
AID - 10.1081/pdt-120024697 [doi]
PST - ppublish
SO  - Pharm Dev Technol. 2003;8(4):443-51. doi: 10.1081/pdt-120024697.

PMID- 35158155
OWN - NLM
STAT- MEDLINE
DCOM- 20220527
LR  - 20230602
IS  - 2210-7797 (Electronic)
IS  - 2210-7789 (Print)
IS  - 2210-7789 (Linking)
VI  - 28
DP  - 2022 Jun
TI  - Association between aspirin use during pregnancy and cardiovascular risk factors 
      2-7 years after delivery: The nuMoM2b Heart Health Study.
PG  - 28-34
LID - S2210-7789(22)00014-9 [pii]
LID - 10.1016/j.preghy.2022.01.012 [doi]
AB  - OBJECTIVES: To evaluate the association between aspirin use during first 
      pregnancy and later maternal cardiovascular risk. STUDY DESIGN: In this secondary 
      analysis of a prospective cohort, we included participants who carried their 
      first pregnancy to 20 + weeks, had data regarding aspirin use, and attended a 
      study visit 2-7 years following delivery. The exposure was aspirin use during the 
      first pregnancy. We calculated aspirin use propensity scores from logistic 
      regression models including baseline variables associated with aspirin use in 
      pregnancy and cardiovascular risk. Outcomes of interest were incident 
      cardiovascular-related diagnoses 2-7 years following delivery. Robust Poisson 
      regression calculated the risk of outcomes by aspirin exposure, adjusting for the 
      aspirin use propensity score. MAIN OUTCOME MEASURES: The primary outcome was a 
      composite of incident cardiovascular diagnoses at the time of the study visit: 
      cardiovascular events, chronic hypertension, metabolic syndrome, prediabetes or 
      type 2 diabetes, dyslipidemia, and chronic kidney disease. RESULTS: Of 4,480 
      women included, 84 (1.9%) reported taking aspirin during their first pregnancy. 
      52.6% of participants in the aspirin-exposed group and 43.0% in the unexposed 
      group had the primary outcome. After adjusting for the aspirin use propensity 
      scores, aspirin use during the first pregnancy was not associated with any of the 
      outcomes. CONCLUSION: We did not detect an association between aspirin use during 
      the first pregnancy and cardiovascular-related diagnoses 2-7 years later. Our 
      study was only powered to detect a large difference in relative risk, so we 
      cannot rule out a smaller difference that may be clinically meaningful.
CI  - Copyright © 2022 International Society for the Study of Hypertension in 
      Pregnancy. All rights reserved.
FAU - Theilen, Lauren H
AU  - Theilen LH
AD  - University of Utah School of Medicine, 30 N 1900 E, Salt Lake City, UT 84132, 
      United States. Electronic address: lauren.theilen@hsc.utah.edu.
FAU - Greenland, Philip
AU  - Greenland P
AD  - Northwestern University Feinberg School of Medicine, 680 N Lakeshore Dr, Chicago, 
      IL 60611, United States. Electronic address: p-greenland@northwestern.edu.
FAU - Varagic, Jasmina
AU  - Varagic J
AD  - National Heart, Lung, and Blood Institute, 31 Center Drive, Bethesda, MD 20892, 
      United States. Electronic address: jasmina.varagic@nih.gov.
FAU - Catov, Janet
AU  - Catov J
AD  - University of Pittsburgh, 300 Halket Street, Pittsburgh, PA 15213, United States. 
      Electronic address: catovjm@upmc.edu.
FAU - Shanks, Anthony
AU  - Shanks A
AD  - Indiana University School of Medicine, 720 Eskenazi Avenue, Indianapolis, IN 
      46202, United States. Electronic address: ashanks@iupui.edu.
FAU - Thorsten, Vanessa
AU  - Thorsten V
AD  - RTI International, United States. Electronic address: vthorsten@rti.org.
FAU - Parker, Corette B
AU  - Parker CB
AD  - RTI International, United States. Electronic address: rette@rti.org.
FAU - McNeil, Rebecca
AU  - McNeil R
AD  - RTI International, United States. Electronic address: rmcneil@rti.org.
FAU - Mercer, Brian
AU  - Mercer B
AD  - MetroHealth, 2500 MetroHealth Drive, G267, Cleveland, OH 44109, United States. 
      Electronic address: bmercer@metrohealth.org.
FAU - Hoffman, Matthew
AU  - Hoffman M
AD  - Christiana Care, 4755 Ogletown Stanton Road, Newark, DE 19718, United States. 
      Electronic address: mhoffman@christianacare.org.
FAU - Wapner, Ronald
AU  - Wapner R
AD  - Columbia University, 622 West 168(th) Street, New York, NY 10032, United States. 
      Electronic address: rw2191@cumc.columbia.edu.
FAU - Haas, David
AU  - Haas D
AD  - Indiana University School of Medicine, 720 Eskenazi Avenue, Indianapolis, IN 
      46202, United States. Electronic address: dahaas@iu.edu.
FAU - Simhan, Hyagriv
AU  - Simhan H
AD  - University of Pittsburgh, 300 Halket Street, Pittsburgh, PA 15213, United States. 
      Electronic address: hsimhan@upmc.edu.
FAU - Grobman, William
AU  - Grobman W
AD  - Northwestern University Feinberg School of Medicine, 680 N Lakeshore Dr, Chicago, 
      IL 60611, United States. Electronic address: w-grobman@northwestern.edu.
FAU - Chung, Judith H
AU  - Chung JH
AD  - University of California, Irvine, 333 City Tower West, Suite 1400, Orange, CA 
      92868, United States. Electronic address: judithc@hs.uci.edu.
FAU - Levine, Lisa D
AU  - Levine LD
AD  - University of Pennsylvania Perelman School of Medicine, 3400 Spruce Street, 2 
      Silverstein, Philadelphia, PA 19104, United States. Electronic address: 
      lisa.levine@pennmedicine.upenn.edu.
FAU - Barnes, Shannon
AU  - Barnes S
AD  - Indiana University School of Medicine, 720 Eskenazi Avenue, Indianapolis, IN 
      46202, United States. Electronic address: shanbarn@iupui.edu.
FAU - Bairey Merz, Noel
AU  - Bairey Merz N
AD  - Cedars Sinai Smidt Heart Institute, 127 S San Vicente Blvd #A3600, Los Angeles, 
      CA 90048, United States. Electronic address: noel.baireymerz@cshs.org.
FAU - Saade, George
AU  - Saade G
AD  - University of Texas Medical Branch, 1005 Harborside Drive, Galveston, TX 77555, 
      United States. Electronic address: gsaade@utmb.edu.
FAU - Silver, Robert M
AU  - Silver RM
AD  - University of Utah School of Medicine, 30 N 1900 E, Salt Lake City, UT 84132, 
      United States. Electronic address: bob.silver@hsc.utah.edu.
LA  - eng
GR  - U10 HL120006/HL/NHLBI NIH HHS/United States
GR  - U10 HL119991/HL/NHLBI NIH HHS/United States
GR  - U10 HL120018/HL/NHLBI NIH HHS/United States
GR  - U10 HD063037/HD/NICHD NIH HHS/United States
GR  - UL1 TR000439/TR/NCATS NIH HHS/United States
GR  - U01 HL145358/HL/NHLBI NIH HHS/United States
GR  - UL1 TR001414/TR/NCATS NIH HHS/United States
GR  - U10 HL119993/HL/NHLBI NIH HHS/United States
GR  - U10 HL119992/HL/NHLBI NIH HHS/United States
GR  - U10 HD063053/HD/NICHD NIH HHS/United States
GR  - U10 HL120034/HL/NHLBI NIH HHS/United States
GR  - U10 HL120019/HL/NHLBI NIH HHS/United States
GR  - UL1 TR002548/TR/NCATS NIH HHS/United States
GR  - U10 HD063036/HD/NICHD NIH HHS/United States
GR  - U10 HL119989/HL/NHLBI NIH HHS/United States
GR  - U10 HD063046/HD/NICHD NIH HHS/United States
GR  - U10 HD063072/HD/NICHD NIH HHS/United States
GR  - U10 HD063048/HD/NICHD NIH HHS/United States
GR  - UL1 TR000124/TR/NCATS NIH HHS/United States
GR  - U10 HD063047/HD/NICHD NIH HHS/United States
GR  - U10 HL119990/HL/NHLBI NIH HHS/United States
GR  - UL1 TR001108/TR/NCATS NIH HHS/United States
GR  - U10 HD063041/HD/NICHD NIH HHS/United States
GR  - U10 HD063020/HD/NICHD NIH HHS/United States
GR  - UL1 TR000153/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20220204
PL  - Netherlands
TA  - Pregnancy Hypertens
JT  - Pregnancy hypertension
JID - 101552483
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/epidemiology/prevention & control
MH  - *Diabetes Mellitus, Type 2
MH  - Female
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - *Pre-Eclampsia
MH  - Pregnancy
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC9133043
MID - NIHMS1780060
OTO - NOTNLM
OT  - Adverse pregnancy outcomes
OT  - Cardiovascular prevention
OT  - Maternal health
OT  - Pregnancy as a window to future health
OT  - Pregnancy complications
EDAT- 2022/02/15 06:00
MHDA- 2022/05/28 06:00
CRDT- 2022/02/14 20:12
PHST- 2021/08/13 00:00 [received]
PHST- 2022/01/08 00:00 [revised]
PHST- 2022/01/31 00:00 [accepted]
PHST- 2022/02/15 06:00 [pubmed]
PHST- 2022/05/28 06:00 [medline]
PHST- 2022/02/14 20:12 [entrez]
AID - S2210-7789(22)00014-9 [pii]
AID - 10.1016/j.preghy.2022.01.012 [doi]
PST - ppublish
SO  - Pregnancy Hypertens. 2022 Jun;28:28-34. doi: 10.1016/j.preghy.2022.01.012. Epub 
      2022 Feb 4.

PMID- 22918746
OWN - NLM
STAT- MEDLINE
DCOM- 20130110
LR  - 20131121
IS  - 0171-2004 (Print)
IS  - 0171-2004 (Linking)
IP  - 210
DP  - 2012
TI  - Antiplatelet therapy in peripheral artery disease.
PG  - 547-63
LID - 10.1007/978-3-642-29423-5_22 [doi]
AB  - Peripheral artery disease (PAD) is a term that relates to atherosclerosis and 
      narrowing of the arteries in the lower extremities. The prevalence of PAD is 
      approximately 12% of the adult population. Despite the low rate of peripheral 
      complications and amputation, PAD is complicated by a high rate of cardiovascular 
      events including myocardial infarction, stroke, and vascular death with an annual 
      incidence of about 5%.The detection of PAD is initially based on the appearance 
      of typical symptoms (claudication and critical limb ischemia) related to 
      peripheral arterial insufficiency. However, PAD may also be present in the 
      absence of clinical symptoms (asymptomatic PAD). Accordingly, asymptomatic 
      disease may occur in up to 50% of all patients with PAD. Ankle brachial index 
      (ABI) is a diagnostic test used to evaluate the presence of PAD, defined by an 
      ABI ≤0.90. The ABI is also demonstrated to be useful in the assessment of 
      vascular risk in asymptomatic and symptomatic patients. Antiplatelet therapy 
      remains a key intervention to reduce cardiovascular risk in PAD. Data from 
      Antithrombotic Trialists' Collaboration showed that antiplatelet treatment was 
      associated with a 23% risk reduction of vascular events in overall population 
      with PAD. However, closer scrutiny of these data reveals that nonaspirin 
      antiplatelet drugs, including ticlopidine, clopidogrel, picotamide, and 
      dipyridamole largely drove the benefits in the PAD subgroup. It remains an open 
      issue if PAD represents an atherosclerotic clinical model where aspirin, 
      differently from coronary heart disease, is less effective in reducing 
      atherosclerotic progression. Based on the reported results further trials with 
      aspirin should be done in asymptomatic (ABI ≤0.90) and symptomatic PAD patients. 
      Finally, the role of new antiplatelet drugs such as prasugrel and ticagrelor has 
      not yet been studied in PAD.
FAU - Violi, Francesco
AU  - Violi F
AD  - Prima Clinica Medica, Sapienza-University of Rome, Rome, Italy. 
      Francesco.Violi@uniroma1.it
FAU - Basili, Stefania
AU  - Basili S
FAU - Berger, Jeffrey S
AU  - Berger JS
FAU - Hiatt, William R
AU  - Hiatt WR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Handb Exp Pharmacol
JT  - Handbook of experimental pharmacology
JID - 7902231
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ankle Brachial Index
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Peripheral Arterial Disease/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
EDAT- 2012/08/25 06:00
MHDA- 2013/01/11 06:00
CRDT- 2012/08/25 06:00
PHST- 2012/08/25 06:00 [entrez]
PHST- 2012/08/25 06:00 [pubmed]
PHST- 2013/01/11 06:00 [medline]
AID - 10.1007/978-3-642-29423-5_22 [doi]
PST - ppublish
SO  - Handb Exp Pharmacol. 2012;(210):547-63. doi: 10.1007/978-3-642-29423-5_22.

PMID- 19069453
OWN - NLM
STAT- MEDLINE
DCOM- 20090109
LR  - 20131121
IS  - 0023-2149 (Print)
IS  - 0023-2149 (Linking)
VI  - 86
IP  - 10
DP  - 2008
TI  - [Correction of the disturbed coagulation circadian rhythm in patients with type 1 
      diabetes mellitus treated by aspirin chronotherapy].
PG  - 17-23
AB  - Circadian rhythms of hemostasis were studied in 20 healthy subjects and 30 
      patients with type 1 diabetes mellitus before and after conventional therapy (CT) 
      with aspirin (125 mg thrice daily) and chronotherapy (ChN) with aspirin taken 
      once daily at 22.00 (i.e., two hours before the acrophase of the blood 
      coagulation activity revealed during a chronobiological study of hemostasis 
      pripor to the initiation of the treatment). The parameters measured in the study 
      included results of the auticoagulation test, hemolysate of the aggregation test, 
      thrombin time, fibrinogen level, fibrinolytic activity, fibrinolygase activity, 
      and antithrombin III level at 07 h 00 min, 11 hr 00 min, 15 hr 00 min, 19 hr 00 
      min, 23 hr 00 min, and 03 hr 00 min in 20 healthy subjects and 30 patients with 
      type 1 diabetes mellitus. The data obtained were treated by cosinor analysis as 
      described by F. Halberg. The results suggest internal and external 
      synchronization of circadian rhythms and hemostatic parameters in healthy 
      subjects. Coagulation activity, platelet aggregation in daytime, and blood 
      anticoagulative potential at night increased. In diabetic patients, circadian 
      patterns of hemostasis were disturbed by a combination of enhanced coagulation 
      activity and platelet aggregation with a decrease of anticoagulative potential 
      throughout 24 hours. The maximum disturbance (acrophase) occurred at night. 
      Combined CT with aspirin and insulin therapy caused mean daily levels of plasma 
      and platelet hemostasis to decrease in the absence of normalization of their 
      circadian rhythms. CT not only decreased these parameters and increased 
      anticoagulation activity but also tended to improve chronobiological structure of 
      hemostasis. This effect was reached using thrice lower doses of aspirin.
FAU - Zaslavskaia, R M
AU  - Zaslavskaia RM
FAU - Tulemisov, E U
AU  - Tulemisov EU
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Russia (Federation)
TA  - Klin Med (Mosk)
JT  - Klinicheskaia meditsina
JID - 2985204R
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Coagulation/drug effects/*physiology
MH  - Circadian Rhythm/*physiology
MH  - Diabetes Mellitus, Type 1/*blood/complications
MH  - Diabetic Angiopathies/blood/*drug therapy/etiology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - Prognosis
MH  - Young Adult
EDAT- 2008/12/17 09:00
MHDA- 2009/01/10 09:00
CRDT- 2008/12/17 09:00
PHST- 2008/12/17 09:00 [entrez]
PHST- 2008/12/17 09:00 [pubmed]
PHST- 2009/01/10 09:00 [medline]
PST - ppublish
SO  - Klin Med (Mosk). 2008;86(10):17-23.

PMID- 18586338
OWN - NLM
STAT- MEDLINE
DCOM- 20100308
LR  - 20181201
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 135
IP  - 3
DP  - 2009 Jul 10
TI  - Long-term cost-effectiveness of clopidogrel in STEMI patients.
PG  - 353-60
LID - 10.1016/j.ijcard.2008.04.011 [doi]
AB  - BACKGROUND: The COMMIT trial demonstrated that clopidogrel produced a 9% relative 
      reduction in death, reinfarction or stroke (9.2% vs. 10.1%, 95% CI: 0.86-0.97) in 
      ST-elevated myocardial infarction (STEMI) patients. METHODS: Between 08/1999 and 
      05/2005, 45,852 STEMI patients were randomized to clopidogrel (n=22,961) or 
      matching placebo (n=22,891) in addition to aspirin. The rate of initial 
      hospitalizations for death, non-fatal myocardial infarction with/without major 
      complications and PCI within 28 days was calculated based on the COMMIT clinical 
      paper. Three CURE papers, concerning non-STEMI patients, were used to estimate 
      the event rates between 29 days and 1 year. Hospitalizations were assigned a 
      diagnosis-related group (DRG). Costs for each DRG were estimated from the 
      Medicare reimbursement rate. Clopidogrel was assumed to be given for 1 year, 
      priced at $4.22/day. Life expectancy gain as a result of the prevention of death, 
      myocardial infarction, and stroke was estimated using Framingham data. RESULTS: 
      Within 28 days, adding clopidogrel to aspirin is likely a dominant strategy, 
      lowering the event rate (9.2% vs. 10.1%) without an increase in cost ($7791 vs. 
      $7797). Over a lifetime, treating for 1 year with clopidogrel-plus-aspirin 
      produced a gain of 0.1187 life years at an incremental cost of $1269 compared to 
      aspirin alone, resulting in an incremental cost-effectiveness ratio (ICER) of 
      $10,691/life year gained. Sensitivity analyses showed that ICERs for clopidogrel 
      are well below the common benchmark ceiling ratio of $50,000/life year gained. 
      CONCLUSIONS: Addition of clopidogrel to aspirin, given up to 1 year, in the 
      setting of STEMI is a highly cost-effective strategy.
FAU - Zhang, Zefeng
AU  - Zhang Z
AD  - School of Public Health, Nantong University, PR China. zzhang2@emory.edu
FAU - Kolm, Paul
AU  - Kolm P
FAU - Mosse, Frederique
AU  - Mosse F
FAU - Jackson, Joseph
AU  - Jackson J
FAU - Zhao, Liping
AU  - Zhao L
FAU - Weintraub, William S
AU  - Weintraub WS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080630
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/economics/therapeutic use
MH  - Clopidogrel
MH  - Cost-Benefit Analysis/economics
MH  - Decision Trees
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/*economics/mortality
MH  - Ticlopidine/*analogs & derivatives/economics/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2008/07/01 09:00
MHDA- 2010/03/10 06:00
CRDT- 2008/07/01 09:00
PHST- 2007/08/17 00:00 [received]
PHST- 2008/04/01 00:00 [accepted]
PHST- 2008/07/01 09:00 [pubmed]
PHST- 2010/03/10 06:00 [medline]
PHST- 2008/07/01 09:00 [entrez]
AID - S0167-5273(08)00559-7 [pii]
AID - 10.1016/j.ijcard.2008.04.011 [doi]
PST - ppublish
SO  - Int J Cardiol. 2009 Jul 10;135(3):353-60. doi: 10.1016/j.ijcard.2008.04.011. Epub 
      2008 Jun 30.

PMID- 16710082
OWN - NLM
STAT- MEDLINE
DCOM- 20061006
LR  - 20131121
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 22
IP  - 2-3
DP  - 2006
TI  - Aspirin or anticoagulants in stenosis of the middle cerebral artery: A randomized 
      trial.
PG  - 162-9
AB  - BACKGROUND: We report the results of an open, randomized, multicenter trial that 
      compared the efficacy of aspirin to oral anticoagulants (OA) for the prevention 
      of vascular events in patients with symptomatic stenosis of the middle cerebral 
      artery (MCA). METHODS: Participants were randomly assigned to receive 300 mg/day 
      of aspirin or a dose of OA (target INR 2-3). The MCA stenosis was demonstrated by 
      conventional angiography or by at least two noninvasive examinations. Patients 
      had either transient ischemic attack or cerebral infarct (CI) attributable to the 
      MCA stenosis within 90 days before inclusion. The primary endpoint was: nonfatal 
      CI, nonfatal acute myocardial infarct, vascular death and major hemorrhage. The 
      patients were followed-up for a minimum of 1 year and a maximum of 3 years. 
      RESULTS: The study included 28 patients (14 in each treatment group); the average 
      age was 67 +/- 9.9 years. Men constituted 68% of the patients. After a mean 
      follow-up of 23.1 +/- 10.9 months, there were no recurrences of CI in both 
      groups. No endpoint was reported in the aspirin group, but 2 patients in the OA 
      group (14.3%) exhibited vascular events: 1 acute myocardial infarct and 1 
      intracerebral hemorrhage). However, this difference was not statistically 
      significant (p = 0.48). CONCLUSIONS: Our study suggests that aspirin is the 
      treatment of choice for the prevention of vascular events in patients with 
      symptomatic MCA stenosis.
CI  - Copyright 2006 S. Karger AG, Basel.
FAU - Martí-Fàbregas, J
AU  - Martí-Fàbregas J
AD  - Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 
      jmarti@santpau.es
FAU - Cocho, D
AU  - Cocho D
FAU - Martí-Vilalta, J-L
AU  - Martí-Vilalta JL
FAU - Gich, I
AU  - Gich I
FAU - Belvís, R
AU  - Belvís R
FAU - Bravo, Y
AU  - Bravo Y
FAU - Millán, M
AU  - Millán M
FAU - Castellanos, M
AU  - Castellanos M
FAU - Rodríguez-Campello, A
AU  - Rodríguez-Campello A
FAU - Egido, J
AU  - Egido J
FAU - Geffner, D
AU  - Geffner D
FAU - Gil-Núñez, A
AU  - Gil-Núñez A
FAU - Marta, J
AU  - Marta J
FAU - Navarro, R
AU  - Navarro R
FAU - Obach, V
AU  - Obach V
FAU - Palomeras, E
AU  - Palomeras E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20060519
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Anticoagulants)
RN  - 0 (Coumarins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A4VZ22K1WT (coumarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cerebral Arterial Diseases/complications/*drug therapy/pathology
MH  - Cerebrovascular Disorders/etiology/*prevention & control
MH  - Constriction, Pathologic
MH  - Coumarins/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Cerebral Artery/*drug effects/pathology
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Treatment Outcome
EDAT- 2006/05/20 09:00
MHDA- 2006/10/07 09:00
CRDT- 2006/05/20 09:00
PHST- 2005/09/07 00:00 [received]
PHST- 2006/01/30 00:00 [accepted]
PHST- 2006/05/20 09:00 [pubmed]
PHST- 2006/10/07 09:00 [medline]
PHST- 2006/05/20 09:00 [entrez]
AID - 93450 [pii]
AID - 10.1159/000093450 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2006;22(2-3):162-9. doi: 10.1159/000093450. Epub 2006 May 19.

PMID- 11216981
OWN - NLM
STAT- MEDLINE
DCOM- 20010301
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 37
IP  - 2
DP  - 2001 Feb
TI  - Risks and benefits of adding anti-platelet therapy to warfarin among patients 
      with prosthetic heart valves: a meta-analysis.
PG  - 569-78
AB  - OBJECTIVES: The objective of this study was to compare the effectiveness and 
      safety of adding dipyridamole or aspirin to warfarin among patients with 
      prosthetic heart valves using meta-analytic techniques. BACKGROUND: Patients with 
      prosthetic heart valves are at increased risk for valve thrombosis and arterial 
      thromboembolism. Oral anticoagulation alone, or the addition of antiplatelet 
      drugs, has been used to minimize this risk. An important issue is the 
      effectiveness and safety of the latter strategy. METHODS: A combined MEDLINE and 
      manual search was made for relevant articles from 1966 to November 1999. Standard 
      meta-analysis techniques were used. RESULTS: Ten studies involving 2,199 subjects 
      met the inclusion criteria. Compared with anticoagulation alone, the addition of 
      an antiplatelet agent reduced the risk of thromboembolic events (odds ratio [OR]: 
      0.41, p < 0.001) and total mortality (OR: 0.49, p < 0.001). The risk of major 
      bleeding was increased when antiplatelet agents were added (OR: 1.50, p = 0.033). 
      For major bleeding, the comparison of trials performed before and after 1990 (OR: 
      2.23 and 0.88, respectively) showed that the chi-square test for heterogeneity 
      was significant (p = 0.025). The latter trials used low-dose aspirin, suggesting 
      that the risk of bleeding may be lower with contemporary low-dose (100 mg daily) 
      aspirin. CONCLUSIONS: Adding antiplatelet therapy, especially low-dose aspirin, 
      to warfarin decreases the risk of systemic embolism or death among patients with 
      prosthetic heart valves. The risk of major bleeding is slightly increased with 
      antiplatelet therapy. Nonetheless, the risk of bleeding appears to have 
      diminished with the lower doses of aspirin used in the more recent trials, 
      resulting in a favorable risk-to-benefit profile.
FAU - Massel, D
AU  - Massel D
AD  - Department of Medicine, London Health Sciences Center, University of Western 
      Ontario, Canada. dmassel@lhsc.on.ca
FAU - Little, S H
AU  - Little SH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 2001 Sep-Oct;135(2):58
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dipyridamole/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Thromboembolism/*prevention & control
MH  - Treatment Outcome
MH  - Warfarin/*administration & dosage/adverse effects
EDAT- 2001/02/24 12:00
MHDA- 2001/03/07 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/03/07 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
AID - S0735-1097(00)01135-9 [pii]
AID - 10.1016/s0735-1097(00)01135-9 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2001 Feb;37(2):569-78. doi: 10.1016/s0735-1097(00)01135-9.

PMID- 10875825
OWN - NLM
STAT- MEDLINE
DCOM- 20000804
LR  - 20190504
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 321
IP  - 7252
DP  - 2000 Jul 1
TI  - Determination of who may derive most benefit from aspirin in primary prevention: 
      subgroup results from a randomised controlled trial.
PG  - 13-7
AB  - OBJECTIVE: To determine which groups of patients may derive particular benefit or 
      experience harm from the use of low dose aspirin for the primary prevention of 
      coronary heart disease. DESIGN: Randomised controlled trial. SETTING: 108 group 
      practices in the Medical Research Council's general practice research framework 
      who were taking part in the thrombosis prevention trial. PARTICIPANTS: 5499 men 
      aged between 45 and 69 years at entry who were at increased risk of coronary 
      heart disease. MAIN OUTCOME MEASURES: Myocardial infarction, coronary death, and 
      stroke. RESULTS: Aspirin reduced coronary events by 20%. This benefit, mainly for 
      non-fatal events, was significantly greater the lower the systolic blood pressure 
      at entry (interaction P=0.0015), the relative risk at pressures 130 mm Hg being 
      0.55 compared with 0.94 at pressures >145 mm Hg. Aspirin also reduced strokes at 
      low but not high pressures, the relative risks being 0.41 and 1.42 (P=0.006) 
      respectively. The relative risk of all major cardiovascular events-that is, the 
      sum of coronary heart disease and stroke-was 0.59 at pressures <130 mm Hg 
      compared with 1.08 at pressures >145 mm Hg (P=0.0001). CONCLUSION: Even with the 
      limitations of subgroup analyses the evidence suggests that the benefit of low 
      dose aspirin in primary prevention may occur mainly in those with lower systolic 
      blood pressures, although it is not clear even in these men that the benefit 
      outweighs the potential hazards. Men with higher pressures may be exposed to the 
      risks of bleeding while deriving no benefit through reductions in coronary heart 
      disease and stroke.
FAU - Meade, T W
AU  - Meade TW
AD  - MRC Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, 
      London, EC1M 6BQ. t.w.meade@mds.qmw.ac.uk
FAU - Brennan, P J
AU  - Brennan PJ
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 2001 Jan 20;322(7279):171. PMID: 11159585
CIN - BMJ. 2000 Dec 9;321(7274):1472. PMID: 11187950
CIN - BMJ. 2000 Dec 9;321(7274):1472-3. PMID: 11187951
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Death, Sudden, Cardiac/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/physiopathology/*prevention & control
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Stroke/physiopathology/*prevention & control
PMC - PMC27417
EDAT- 2000/06/30 11:00
MHDA- 2000/08/12 11:00
CRDT- 2000/06/30 11:00
PHST- 2000/06/30 11:00 [pubmed]
PHST- 2000/08/12 11:00 [medline]
PHST- 2000/06/30 11:00 [entrez]
AID - 10.1136/bmj.321.7252.13 [doi]
PST - ppublish
SO  - BMJ. 2000 Jul 1;321(7252):13-7. doi: 10.1136/bmj.321.7252.13.

PMID- 17396230
OWN - NLM
STAT- MEDLINE
DCOM- 20071217
LR  - 20181113
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 24
IP  - 2
DP  - 2007 Oct
TI  - The thrombolytic effect of aspirin in animal model.
PG  - 123-9
AB  - BACKGROUND: The aspirin induced platelet aggregation has been reported to be 
      mediated through the inhibition of platelet prostaglandin synthesis. This 
      compound has also been recently reported to stimulate nitric oxide synthesis in 
      platelets. Since nitric oxide has been reported to produce 
      fibrinogen/fibrinolytic effect, investigation was carried out to determine 
      fibrinolytic effect of in vivo exposure of platelets to aspirin in normal 
      volunteers on the fibrinolysis of the clotted platelet-rich plasma in vitro. The 
      thrombolytic effect of aspirin in situ was also carried out by injecting aspirin 
      solution in the mice with ADP induced formed thrombi in the coronary artery. 
      METHODS AND RESULTS: It was found that the clotted platelet-rich plasma prepared 
      from the volunteers (n = 10, F = 5, M = 5) who ingested 150 mg aspirin, began to 
      undergo spontaneous and progressive fibrinolysis for 200 min at 37 degrees C with 
      the generation of fibrin degradation products in the lysate. No such fibrinolysis 
      could be seen in control experiments. When platelet thrombi were produced in the 
      coronary artery of mice by injecting ADP, and these animals subsequently received 
      intravenous injection of aspirin (4 muM final), they not only survived (P < 
      0.0001, n = 10) the thrombogenic assault but the lysis of the platelet thrombi 
      was also noted in the post mortem examination. The thrombolytic effect of aspirin 
      was found to be comparable to that of streptokinase in these animals. 
      CONCLUSIONS: Aspirin, through the stimulation of NO synthesis, may produce 
      thrombolysis in vivo.
FAU - Karmohapatra, Soumendra K
AU  - Karmohapatra SK
AD  - Sinha Institute of Medical Science and Technology, Garia, Calcutta 700084, India.
FAU - Kahn, Nighat N
AU  - Kahn NN
FAU - Sinha, Asru K
AU  - Sinha AK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070331
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Animals
MH  - Aspirin/*administration & dosage
MH  - Disease Models, Animal
MH  - Female
MH  - Fibrinolysis/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet-Rich Plasma
MH  - *Thrombolytic Therapy
MH  - Thrombosis/drug therapy
EDAT- 2007/03/31 09:00
MHDA- 2007/12/18 09:00
CRDT- 2007/03/31 09:00
PHST- 2006/12/18 00:00 [received]
PHST- 2007/02/27 00:00 [accepted]
PHST- 2007/03/31 09:00 [pubmed]
PHST- 2007/12/18 09:00 [medline]
PHST- 2007/03/31 09:00 [entrez]
AID - 10.1007/s11239-007-0023-y [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2007 Oct;24(2):123-9. doi: 10.1007/s11239-007-0023-y. Epub 
      2007 Mar 31.

PMID- 30876584
OWN - NLM
STAT- MEDLINE
DCOM- 20190408
LR  - 20190408
IS  - 1873-3573 (Electronic)
IS  - 0039-9140 (Linking)
VI  - 198
DP  - 2019 Jun 1
TI  - Thermogravimetry coupled to an atmospheric pressure photo ionization quadrupole 
      mass spectrometry for the product control of pharmaceutical formulations and the 
      analysis of plasticizers in polymers.
PG  - 440-446
LID - S0039-9140(19)30069-4 [pii]
LID - 10.1016/j.talanta.2019.01.118 [doi]
AB  - The development of a thermogravimetry coupled to an atmospheric pressure 
      photoionization mass spectrometry (TG-APPI-MS) with a high temperature and 
      flexible transfer line is presented. A method was developed to analyze 
      plasticizers in solution which consist of a solvent evaporation step and 
      subsequent evaporation of the analyte. These solutions of dibutyl phthalate (DBP) 
      in hexane were used to investigate the repeatability (RSD: 3.6%) and linearity 
      (R(2): 0.9995) of the new developed system. With the new device the detection of 
      different phthalates in a standardized PVC (polyvinyl chloride) polymer is shown. 
      On the example of ASA, the degradation of a pharmaceutical drug is investigated. 
      The dimerization and the possible trimerization of ASA during the thermal 
      degradation is shown. Ten tablets of different ASA manufacturers were analyzed 
      with the new developed analysis platform. The active substance was found in every 
      tablet. Differences in mass spectral data as well as the studying of the pack 
      insert were used to assign the tablets to companies and their subsidiaries. A 
      unique formulation of ASA was found to have a different mass pattern when 
      analyzed with TG-APPI-qMS. The developed device is a promising tool for the 
      product control and the identification of falsified drugs.
CI  - Copyright © 2019 Elsevier B.V. All rights reserved.
FAU - Brecht, Dominik
AU  - Brecht D
AD  - Department of Applied Analytical Chemistry, University of Duisburg-Essen, 
      Universitaetsstrasse 5, 45141 Essen, Germany.
FAU - Uteschil, Florian
AU  - Uteschil F
AD  - Department of Applied Analytical Chemistry, University of Duisburg-Essen, 
      Universitaetsstrasse 5, 45141 Essen, Germany.
FAU - Schmitz, Oliver J
AU  - Schmitz OJ
AD  - Department of Applied Analytical Chemistry, University of Duisburg-Essen, 
      Universitaetsstrasse 5, 45141 Essen, Germany. Electronic address: 
      oliver.schmitz@uni-due.de.
LA  - eng
PT  - Journal Article
DEP - 20190210
PL  - Netherlands
TA  - Talanta
JT  - Talanta
JID - 2984816R
RN  - 0 (Phthalic Acids)
RN  - 0 (Plasticizers)
RN  - 9002-86-2 (Polyvinyl Chloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - *Atmospheric Pressure
MH  - Drug Compounding
MH  - Mass Spectrometry
MH  - Phthalic Acids/*analysis
MH  - Plasticizers/*analysis
MH  - Polyvinyl Chloride/*chemistry
MH  - Temperature
MH  - Thermogravimetry
OTO - NOTNLM
OT  - Atmospheric pressure photo ionization (APPI)
OT  - Differential thermo analysis (DTA)
OT  - Polymer analysis
OT  - Product control pharmaceuticals
OT  - Thermal analysis (TA)
OT  - Thermogravimetry (TG)
OT  - Thermogravimetry mass spectrometry (TG-MS)
EDAT- 2019/03/17 06:00
MHDA- 2019/04/09 06:00
CRDT- 2019/03/17 06:00
PHST- 2018/11/21 00:00 [received]
PHST- 2019/01/14 00:00 [revised]
PHST- 2019/01/17 00:00 [accepted]
PHST- 2019/03/17 06:00 [entrez]
PHST- 2019/03/17 06:00 [pubmed]
PHST- 2019/04/09 06:00 [medline]
AID - S0039-9140(19)30069-4 [pii]
AID - 10.1016/j.talanta.2019.01.118 [doi]
PST - ppublish
SO  - Talanta. 2019 Jun 1;198:440-446. doi: 10.1016/j.talanta.2019.01.118. Epub 2019 
      Feb 10.

PMID- 2293357
OWN - NLM
STAT- MEDLINE
DCOM- 19910411
LR  - 20190918
IS  - 0036-5580 (Print)
IS  - 0036-5580 (Linking)
VI  - 24
IP  - 3
DP  - 1990
TI  - Effect of dipyridamole (Persantin) on blood flow and patency of aortocoronary 
      vein bypass grafts.
PG  - 191-6
AB  - The effect of dipyridamole was investigated in 360 patients undergoing coronary 
      bypass surgery. They were randomly allocated to receive dipyridamole (100 mg 
      orally q.i.d. for 2 days preoperatively, 5 mg/kg body weight/24 h i.v. 
      peroperatively and 100 mg orally q.i.d. for 1 year postoperatively) or placebo. 
      Withdrawn from the study were 48 patients on dipyridamole and 57 on placebo. 
      Cardiovascular and/or cerebrovascular events or need for anticoagulant treatment 
      were the reasons for withdrawal in 22 (13%) of the dipyridamole, and 34 (18%) of 
      the placebo group. Logistic regression analysis of risk factors influencing graft 
      patency showed significant relation to peroperatively measured coronary blood 
      flow. A positive trend of treatment was observed (p = 0.08). Vein graft blood 
      flow measured during bypass surgery (245 patients) was significantly greater in 
      the dipyridamole group (p less than 0.01). The occlusion rate was lower in 
      vessels with peroperative blood flow greater than 30 ml/min (vein-marginal p less 
      than 0.01, vein-dexter p less than 0.05, vein-diagonal 0.05 less than p less than 
      0.1). Dipyridamole increases coronary blood flow and graft patency following 
      coronary bypass surgery.
FAU - Ekeström, S A
AU  - Ekeström SA
AD  - Department of Thoracic Surgery, Karolinska Hospital, Stockholm, Sweden.
FAU - Gunnes, S
AU  - Gunnes S
FAU - Brodin, U B
AU  - Brodin UB
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Sweden
TA  - Scand J Thorac Cardiovasc Surg
JT  - Scandinavian journal of thoracic and cardiovascular surgery
JID - 0121343
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Blood Flow Velocity/drug effects
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications
MH  - Risk Factors
MH  - Vascular Patency/*drug effects
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.3109/14017439009098068 [doi]
PST - ppublish
SO  - Scand J Thorac Cardiovasc Surg. 1990;24(3):191-6. doi: 10.3109/14017439009098068.

PMID- 1166387
OWN - NLM
STAT- MEDLINE
DCOM- 19751212
LR  - 20131121
IS  - 0039-6087 (Print)
IS  - 0039-6087 (Linking)
VI  - 141
IP  - 4
DP  - 1975 Oct
TI  - The source and removal of microaggregates in aged human blood and human blood 
      components.
PG  - 582-6
AB  - Microaggregates are formed during the storage of human blood and are composed 
      largely of platelets and leukocytes. These microparticles reside in the buffy 
      coat fraction of blood. The formation of microaggregates can be successfully 
      prevented by removal of the buffy coat or by treatment of blood with drugs which 
      inhibit platelet function prior to storage. Once formed, the volumes of 
      microaggregates in aged blood can be significantly reduced by washing, 
      centrifugation or treatment with urokinase or streptokinase. Glycerol frozen red 
      blood cells and blood components--packed red blood cells and plasma--are free of 
      microaggregates, and they can be infused without fear of embolic consequence.
FAU - Gervin, A S
AU  - Gervin AS
FAU - Mason, K G
AU  - Mason KG
FAU - Buckman, R F
AU  - Buckman RF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Surg Gynecol Obstet
JT  - Surgery, gynecology & obstetrics
JID - 0101370
RN  - EC 3.4.- (Streptokinase)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - *Blood Preservation
MH  - Centrifugation
MH  - Filtration
MH  - Freezing
MH  - Humans
MH  - *Platelet Aggregation/drug effects
MH  - Streptokinase/pharmacology
MH  - Urokinase-Type Plasminogen Activator/pharmacology
EDAT- 1975/10/01 00:00
MHDA- 1975/10/01 00:01
CRDT- 1975/10/01 00:00
PHST- 1975/10/01 00:00 [pubmed]
PHST- 1975/10/01 00:01 [medline]
PHST- 1975/10/01 00:00 [entrez]
PST - ppublish
SO  - Surg Gynecol Obstet. 1975 Oct;141(4):582-6.

PMID- 31220426
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 1872-6240 (Electronic)
IS  - 0006-8993 (Linking)
VI  - 1720
DP  - 2019 Oct 1
TI  - Aspirin in stroke patients modifies the immunomodulatory interactions of marrow 
      stromal cells and monocytes.
PG  - 146298
LID - S0006-8993(19)30344-0 [pii]
LID - 10.1016/j.brainres.2019.06.017 [doi]
AB  - BACKGROUND AND OBJECTIVE: Most stroke patients are prescribed aspirin (ASA) to 
      adjust blood coagulability. Marrow stromal cells (MSCs) are being tested in 
      clinical trials for stroke patients who likely are prescribed aspirin. One of the 
      principal mechanisms of action of MSCs and ASA is modulation of the inflammatory 
      response, including those mediated by monocytes (Mo). Thus, here we tested if 
      aspirin can modify anti-inflammatory properties of MSCs or Mo alone, and in 
      combination. METHODS: Mo were isolated at 24 h of stroke onset from ischemic 
      stroke patients with NIHSS ranging from 11 to 20 or from healthy controls. Human 
      bone marrow-derived MSCs from healthy subjects were used at passage 3. Mo, MSCs, 
      and MSCs-Mo co-cultures were exposed to ASA at clinically relevant doses. The 
      secretome profile of inflammatory mediators was measured using Magpix multiplex 
      cytokine array. Viability was measured using MTT assay. Linear mixed effect model 
      was used for statistical analysis. RESULTS: Overall Mo from control subjects 
      exposed to ASA showed increased secretion of IL-1RA, IL-8, MCP-1, and TNF-α and 
      Mo from stroke patients showed greater release of IL-1RA and MCP-1. In MSCs-Mo 
      co-cultures, ASA added to co-cultures of control Mo reduced fractalkine secretion 
      while it increased the fractalkine secretion when added to Mo from stroke 
      patients. In addition, in co-cultures independent of Mo origin, ASA reduced IL-6, 
      IL-8, MCP-1, and TNF-α. CONCLUSIONS: Aspirin in acute stroke patients may 
      modulate the secretome profile of Mo and MSCs, thus potentially modulating immune 
      and inflammatory responses associated with stroke. Our results suggest that 
      stroke trials involving the use of intravenous MSCs should consider the effect of 
      aspirin as a confounding factor.
CI  - Copyright © 2019 Elsevier B.V. All rights reserved.
FAU - Satani, Nikunj
AU  - Satani N
AD  - Institute for Stroke and Cerebrovascular Diseases, The University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA. 
      Electronic address: Nikunj.B.Satani@uth.tmc.edu.
FAU - Giridhar, Kaavya
AU  - Giridhar K
AD  - Institute for Stroke and Cerebrovascular Diseases, The University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA.
FAU - Cai, Chunyan
AU  - Cai C
AD  - Institute for Stroke and Cerebrovascular Diseases, The University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA; 
      Department of Internal Medicine, The University of Texas Health Science Center at 
      Houston, McGovern Medical School, Houston, TX 77030, USA; Center for Clinical and 
      Translational Sciences, The University of Texas Health Science Center at Houston, 
      McGovern Medical School, Houston, TX 77030, USA.
FAU - Wewior, Natalia
AU  - Wewior N
AD  - Institute for Stroke and Cerebrovascular Diseases, The University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA.
FAU - Norris, Dominique D
AU  - Norris DD
AD  - Institute for Stroke and Cerebrovascular Diseases, The University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA.
FAU - Olson, Scott D
AU  - Olson SD
AD  - Department of Pediatric Surgery, The University of Texas Health Science Center at 
      Houston, McGovern Medical School at UTHealth, Houston, TX, USA.
FAU - Aronowski, Jaroslaw
AU  - Aronowski J
AD  - Institute for Stroke and Cerebrovascular Diseases, The University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA.
FAU - Savitz, Sean I
AU  - Savitz SI
AD  - Institute for Stroke and Cerebrovascular Diseases, The University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA.
LA  - eng
PT  - Journal Article
DEP - 20190617
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cytokines)
RN  - 0 (IL1RN protein, human)
RN  - 0 (Interleukin 1 Receptor Antagonist Protein)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/metabolism/*therapeutic use
MH  - Bone Marrow
MH  - Chemokine CCL2
MH  - Coculture Techniques
MH  - Cytokines
MH  - Female
MH  - Humans
MH  - Immunomodulation/*drug effects
MH  - Interleukin 1 Receptor Antagonist Protein
MH  - Male
MH  - Mesenchymal Stem Cells/drug effects/metabolism
MH  - Middle Aged
MH  - Monocytes/drug effects/metabolism
MH  - Stroke/*drug therapy/metabolism
MH  - Stromal Cells/drug effects/metabolism
MH  - Tumor Necrosis Factor-alpha
OTO - NOTNLM
OT  - Cell interactions
OT  - Fractalkine
OT  - IL-1RA
OT  - Immunomodulation
OT  - Mesenchymal stromal cells
OT  - Monocytes
EDAT- 2019/06/21 06:00
MHDA- 2020/09/25 06:00
CRDT- 2019/06/21 06:00
PHST- 2019/05/24 00:00 [received]
PHST- 2019/06/14 00:00 [revised]
PHST- 2019/06/15 00:00 [accepted]
PHST- 2019/06/21 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2019/06/21 06:00 [entrez]
AID - S0006-8993(19)30344-0 [pii]
AID - 10.1016/j.brainres.2019.06.017 [doi]
PST - ppublish
SO  - Brain Res. 2019 Oct 1;1720:146298. doi: 10.1016/j.brainres.2019.06.017. Epub 2019 
      Jun 17.

PMID- 22621626
OWN - NLM
STAT- MEDLINE
DCOM- 20120531
LR  - 20220409
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 366
IP  - 21
DP  - 2012 May 24
TI  - Aspirin for preventing the recurrence of venous thromboembolism.
PG  - 1959-67
LID - 10.1056/NEJMoa1114238 [doi]
AB  - BACKGROUND: About 20% of patients with unprovoked venous thromboembolism have a 
      recurrence within 2 years after the withdrawal of oral anticoagulant therapy. 
      Extending anticoagulation prevents recurrences but is associated with increased 
      bleeding. The benefit of aspirin for the prevention of recurrent venous 
      thromboembolism is unknown. METHODS: In this multicenter, investigator-initiated, 
      double-blind study, patients with first-ever unprovoked venous thromboembolism 
      who had completed 6 to 18 months of oral anticoagulant treatment were randomly 
      assigned to aspirin, 100 mg daily, or placebo for 2 years, with the option of 
      extending the study treatment. The primary efficacy outcome was recurrence of 
      venous thromboembolism, and major bleeding was the primary safety outcome. 
      RESULTS: Venous thromboembolism recurred in 28 of the 205 patients who received 
      aspirin and in 43 of the 197 patients who received placebo (6.6% vs. 11.2% per 
      year; hazard ratio, 0.58; 95% confidence interval [CI], 0.36 to 0.93) (median 
      study period, 24.6 months). During a median treatment period of 23.9 months, 23 
      patients taking aspirin and 39 taking placebo had a recurrence (5.9% vs. 11.0% 
      per year; hazard ratio, 0.55; 95% CI, 0.33 to 0.92). One patient in each 
      treatment group had a major bleeding episode. Adverse events were similar in the 
      two groups. CONCLUSIONS: Aspirin reduced the risk of recurrence when given to 
      patients with unprovoked venous thromboembolism who had discontinued 
      anticoagulant treatment, with no apparent increase in the risk of major bleeding. 
      (Funded by the University of Perugia and others; WARFASA ClinicalTrials.gov 
      number, NCT00222677.).
FAU - Becattini, Cecilia
AU  - Becattini C
AD  - Division of Internal and Cardiovascular Medicine and Stroke Unit, Department of 
      Internal Medicine, University of Perugia, Perugia, Italy. 
      cecilia.becattini@unipg.it
FAU - Agnelli, Giancarlo
AU  - Agnelli G
FAU - Schenone, Alessandro
AU  - Schenone A
FAU - Eichinger, Sabine
AU  - Eichinger S
FAU - Bucherini, Eugenio
AU  - Bucherini E
FAU - Silingardi, Mauro
AU  - Silingardi M
FAU - Bianchi, Marina
AU  - Bianchi M
FAU - Moia, Marco
AU  - Moia M
FAU - Ageno, Walter
AU  - Ageno W
FAU - Vandelli, Maria Rita
AU  - Vandelli MR
FAU - Grandone, Elvira
AU  - Grandone E
FAU - Prandoni, Paolo
AU  - Prandoni P
CN  - WARFASA Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00222677
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - N Engl J Med. 2012 Oct 18;367(16):1573
CIN - N Engl J Med. 2012 May 24;366(21):2028-30. PMID: 22621631
CIN - Nat Rev Cardiol. 2012 Aug;9(8):433. PMID: 22688533
CIN - N Engl J Med. 2012 Sep 13;367(11):1067; author reply 1068-9. PMID: 22970958
CIN - N Engl J Med. 2012 Sep 13;367(11):1067; author reply 1068-9. PMID: 22970959
CIN - N Engl J Med. 2012 Sep 13;367(11):1067-8; author reply 1068-9. PMID: 22970960
CIN - Praxis (Bern 1994). 2012 Oct 3;101(20):1331-2. PMID: 23032500
CIN - Ann Intern Med. 2012 Oct 16;157(8):JC4-3. PMID: 23070505
CIN - N Engl J Med. 2012 Nov 22;367(21):2039-41. PMID: 23121404
CIN - Evid Based Nurs. 2013 Jul;16(3):92-3. PMID: 23178311
CIN - J Fam Pract. 2012 Nov;61(11):673-4. PMID: 23256098
CIN - J Mal Vasc. 2013 Feb;38(1):4-5. PMID: 23317999
CIN - J Mal Vasc. 2013 Feb;38(1):2-3. PMID: 23347567
CIN - Rev Clin Esp (Barc). 2013 Jan-Feb;213(1):59. PMID: 23565544
CIN - Ann Intern Med. 2013 Apr 16;158(8):615-9. PMID: 23579948
CIN - Internist (Berl). 2013 Nov;54(11):1393-6. PMID: 24045645
MH  - Aged
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Pulmonary Embolism/prevention & control
MH  - Secondary Prevention
MH  - Venous Thromboembolism/drug therapy/*prevention & control
MH  - Venous Thrombosis/prevention & control
MH  - Vitamin K/antagonists & inhibitors
FIR - Agnelli, G
IR  - Agnelli G
FIR - Becattini, C
IR  - Becattini C
FIR - Prandoni, P
IR  - Prandoni P
FIR - Becattini, Cecilia
IR  - Becattini C
FIR - Agnelli, Giancarlo
IR  - Agnelli G
FIR - Prandoni, Paolo
IR  - Prandoni P
FIR - Ageno, Walter
IR  - Ageno W
FIR - Cimminiello, Claudio
IR  - Cimminiello C
FIR - Eichinger, Sabine
IR  - Eichinger S
FIR - Duranti, M
IR  - Duranti M
FIR - Radicchia, S
IR  - Radicchia S
FIR - Guercini, F
IR  - Guercini F
FIR - Vedovati, M C
IR  - Vedovati MC
FIR - Tormene, D
IR  - Tormene D
FIR - Perlati, M
IR  - Perlati M
FIR - Barbar, S
IR  - Barbar S
FIR - Poggio, R
IR  - Poggio R
FIR - Leischer, L
IR  - Leischer L
FIR - Bucherini, E
IR  - Bucherini E
FIR - Galimberti, D
IR  - Galimberti D
FIR - Leone, M F
IR  - Leone MF
FIR - Beretta, A
IR  - Beretta A
FIR - Carugati, A
IR  - Carugati A
FIR - Braham, S
IR  - Braham S
FIR - Romualdi, E
IR  - Romualdi E
FIR - Tiscia, G
IR  - Tiscia G
FIR - Colaizzo, D
IR  - Colaizzo D
FIR - Grilli, M
IR  - Grilli M
FIR - Siragusa, S
IR  - Siragusa S
FIR - Salvi, R
IR  - Salvi R
FIR - Miccio, M
IR  - Miccio M
FIR - Ria, L
IR  - Ria L
FIR - Zanatta, N
IR  - Zanatta N
FIR - Poli, D
IR  - Poli D
FIR - Camporese, G
IR  - Camporese G
FIR - Verlato, F
IR  - Verlato F
FIR - Salvi, A
IR  - Salvi A
FIR - Nitti, C
IR  - Nitti C
FIR - Santi, R
IR  - Santi R
FIR - Cimminiello, C
IR  - Cimminiello C
FIR - Scannapieco, G
IR  - Scannapieco G
FIR - Barillari, G
IR  - Barillari G
FIR - Pasca, S
IR  - Pasca S
FIR - De Gaudenzi, E
IR  - De Gaudenzi E
FIR - Cappelli, R
IR  - Cappelli R
FIR - Di Minno, G
IR  - Di Minno G
FIR - Tufano, A
IR  - Tufano A
FIR - Frausini, G
IR  - Frausini G
FIR - Bova, C
IR  - Bova C
FIR - Pogliani, E
IR  - Pogliani E
FIR - Signorelli, S S
IR  - Signorelli SS
FIR - Testa, S
IR  - Testa S
FIR - Alatri, A
IR  - Alatri A
FIR - Mancuso, G
IR  - Mancuso G
FIR - Grifoni, S
IR  - Grifoni S
FIR - Lodigiani, C
IR  - Lodigiani C
EDAT- 2012/05/25 06:00
MHDA- 2012/06/01 06:00
CRDT- 2012/05/25 06:00
PHST- 2012/05/25 06:00 [entrez]
PHST- 2012/05/25 06:00 [pubmed]
PHST- 2012/06/01 06:00 [medline]
AID - 10.1056/NEJMoa1114238 [doi]
PST - ppublish
SO  - N Engl J Med. 2012 May 24;366(21):1959-67. doi: 10.1056/NEJMoa1114238.

PMID- 18278165
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20181201
IS  - 0720-9355 (Print)
IS  - 0720-9355 (Linking)
VI  - 28
IP  - 1-2
DP  - 2008 Feb
TI  - [Methods to evaluate aspirin and clopidogrel resistance].
PG  - 66-71
AB  - Based on the concept that the so-called resistance to anti-platelet drugs is 
      meant to describe a phenomenon where the drug does not hit its direct 
      pharmacodynamic target, assays, used to evaluated the effects of anti-platelet 
      drugs, should as closely as possible measure the direct pharmacodynamic effect of 
      a particular drug. Thus, for the detection of aspirin effects, thromboxane 
      concentrations or arachidonic acid-induced responses (light aggregometry, 
      whole-blood aggregometry) should be measured. For the detection of clopidogrel 
      actions, VASP phosphorylation (flow cytometry) or ADP-induced responses (light 
      aggregometry, whole blood aggregometry) should be analysed.
FAU - Weber, A-A
AU  - Weber AA
AD  - Institut für Pharmakologie, Universität Duisburg-Essen, Universitätsklinikum 
      Essen, Hufelandstr. 55, 45122 Essen, Germany. artur.weber@uk-essen.de
FAU - Adamzik, M
AU  - Adamzik M
FAU - Bachmann, H S
AU  - Bachmann HS
FAU - Görlinger, K
AU  - Görlinger K
FAU - Grandoch, M
AU  - Grandoch M
FAU - Leineweber, K
AU  - Leineweber K
FAU - Müller-Beissenhirtz, H
AU  - Müller-Beissenhirtz H
FAU - Wenzel, F
AU  - Wenzel F
FAU - Naber, C
AU  - Naber C
CN  - für die interdisziplinäre Studiengruppe Clinical Pharmacology of Haemostasis
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Methoden zur Messung der Azetylsalizylsäure- bzw. Clopidogrelresistenz.
PL  - Germany
TA  - Hamostaseologie
JT  - Hamostaseologie
JID - 8204531
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
RF  - 54
EDAT- 2008/02/19 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/02/19 09:00
PHST- 2008/02/19 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/02/19 09:00 [entrez]
AID - 08010066 [pii]
PST - ppublish
SO  - Hamostaseologie. 2008 Feb;28(1-2):66-71.

PMID- 4582051
OWN - NLM
STAT- MEDLINE
DCOM- 19731130
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 2
IP  - 5868
DP  - 1973 Jun 23
TI  - Method for assessing therapeutic potential of anti-inflammatory antirheumatic 
      drugs in rheumatoid arthritis.
PG  - 685-8
AB  - A 14-day, single-blind trial of prednisone, aspirin, and placebo was carried out 
      in 128 patients suffering from rheumatoid arthritis, using subjective criteria 
      only (severity of pain daily on a pain chart and assessment of the drug for 
      effectiveness). The average treated pain rating, mean patient satisfaction 
      rating, and mean number of days withdrawn from each drug all showed significant 
      differences between prednisone, aspirin, and placebo. Of various pretreatment 
      observations, only the initial pain score and articular index of joint tenderness 
      were significantly related to the average treated pain rating.The trial method is 
      simple and allows many patients to participate without being time consuming for 
      patient or physician. The method seems to have potential in comparing the 
      comparative effectiveness of anti-inflammatory analgesics used in the treatment 
      of patients with rheumatoid arthritis.
FAU - Lee, P
AU  - Lee P
FAU - Webb, J
AU  - Webb J
FAU - Anderson, J
AU  - Anderson J
FAU - Buchanan, W W
AU  - Buchanan WW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Methods
MH  - Pain
MH  - Placebos
MH  - Prednisone/therapeutic use
MH  - Self Concept
PMC - PMC1589743
EDAT- 1973/06/23 00:00
MHDA- 1973/06/23 00:01
CRDT- 1973/06/23 00:00
PHST- 1973/06/23 00:00 [pubmed]
PHST- 1973/06/23 00:01 [medline]
PHST- 1973/06/23 00:00 [entrez]
AID - 10.1136/bmj.2.5868.685 [doi]
PST - ppublish
SO  - Br Med J. 1973 Jun 23;2(5868):685-8. doi: 10.1136/bmj.2.5868.685.

PMID- 689492
OWN - NLM
STAT- MEDLINE
DCOM- 19781118
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 7
IP  - 5
DP  - 1978
TI  - Acetylsalicylic acid and the cardiovascular effects of ADP in the rat.
PG  - 294-7
AB  - Acetylsalicylic acid (ASA) did not prevent the arrhythmias induced in rats by a 
      bolus intravenous injection of ADP, an effect independent of platelets. ASA was 
      also unable to protect the rats from the platelet-mediated cardiovascular effects 
      and myocardial ischaemia induced by a prolonged ADP infusion. It is suggested 
      that the release of vasoactive substances inhibited by ASA does not play a major 
      role in the cardiovascular effects of ADP in rats.
FAU - Dejana, E
AU  - Dejana E
FAU - Bonaccorsi, A
AU  - Bonaccorsi A
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/*pharmacology
MH  - Animals
MH  - Arrhythmias, Cardiac/*etiology
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Coronary Disease/etiology
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Rats
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1159/000214271 [doi]
PST - ppublish
SO  - Haemostasis. 1978;7(5):294-7. doi: 10.1159/000214271.

PMID- 22440112
OWN - NLM
STAT- MEDLINE
DCOM- 20120626
LR  - 20220331
IS  - 1474-5488 (Electronic)
IS  - 1470-2045 (Linking)
VI  - 13
IP  - 5
DP  - 2012 May
TI  - Effects of regular aspirin on long-term cancer incidence and metastasis: a 
      systematic comparison of evidence from observational studies versus randomised 
      trials.
PG  - 518-27
LID - 10.1016/S1470-2045(12)70112-2 [doi]
AB  - BACKGROUND: Long-term follow-up of randomised trials of aspirin in prevention of 
      vascular events showed that daily aspirin reduced the incidence of colorectal 
      cancer and several other cancers and reduced metastasis. However, statistical 
      power was inadequate to establish effects on less common cancers and on cancers 
      in women. Observational studies could provide this information if results can be 
      shown to be reliable. We therefore compared effects of aspirin on risk and 
      outcome of cancer in observational studies versus randomised trials. METHODS: For 
      this systematic review, we searched for case-control and cohort studies published 
      from 1950 to 2011 that reported associations between aspirin use and risk or 
      outcome of cancer. Associations were pooled across studies by meta-analysis and 
      stratified by duration, dose, and frequency of aspirin use and by stage of 
      cancer. We compared associations from observational studies with the effect of 
      aspirin on 20-year risk of cancer death and on metastasis in the recent reports 
      of randomised trials. FINDINGS: In case-control studies, regular use of aspirin 
      was associated with reduced risk of colorectal cancer (pooled odds ratio [OR] 
      0·62, 95% CI 0·58-0·67, p(sig)<0·0001, 17 studies), with little heterogeneity 
      (p(het)=0·13) in effect between studies, and good agreement with the effect of 
      daily aspirin use on 20-year risk of death due to colorectal cancer from the 
      randomised trials (OR 0·58, 95% CI 0·44-0·78, p(sig)=0·0002, p(het)=0·45). 
      Similarly consistent reductions were seen in risks of oesophageal, gastric, 
      biliary, and breast cancer. Overall, estimates of effect of aspirin on individual 
      cancers in case-control studies were highly correlated with those in randomised 
      trials (r(2)=0·71, p=0·0006), with largest effects on risk of gastrointestinal 
      cancers (case-control studies, OR 0·62, 95% CI 0·55-0·70, p<0·0001, 41 studies; 
      randomised trials, OR 0·54, 95% CI 0·42-0·70, p<0·0001). Estimates of effects in 
      cohort studies were similar when analyses were stratified by frequency and 
      duration of aspirin use, were based on updated assessments of use during 
      follow-up, and were appropriately adjusted for baseline characteristics. Although 
      fewer observational studies stratified analyses by the stage of cancer at 
      diagnosis, regular use of aspirin was associated with a reduced proportion of 
      cancers with distant metastasis (OR 0·69, 95% CI 0·57-0·83, p(sig)<0·0001, 
      p(het)=0·89, five studies), but not with any reduction in regional spread (OR 
      0·98, 95% CI 0·88-1·09, p(sig)=0·71, p(het)=0·88, seven studies), consistent 
      again with the findings in randomised trials. INTERPRETATION: Observational 
      studies show that regular use of aspirin reduces the long-term risk of several 
      cancers and the risk of distant metastasis. Results of methodologically rigorous 
      studies are consistent with those obtained from randomised controlled trials, but 
      sensitivity is particularly dependent on appropriately detailed recording and 
      analysis of aspirin use. FUNDING: None.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Algra, Annemijn M
AU  - Algra AM
AD  - Stroke Prevention Research Unit, University Department of Clinical Neurology, 
      University of Oxford, Oxford, UK.
FAU - Rothwell, Peter M
AU  - Rothwell PM
LA  - eng
GR  - 095626/Wellcome Trust/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20120321
PL  - England
TA  - Lancet Oncol
JT  - The Lancet. Oncology
JID - 100957246
RN  - 0 (Antineoplastic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Humans
MH  - Incidence
MH  - Neoplasm Metastasis/prevention & control
MH  - Neoplasms/epidemiology/*prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
EDAT- 2012/03/24 06:00
MHDA- 2012/06/27 06:00
CRDT- 2012/03/24 06:00
PHST- 2012/03/24 06:00 [entrez]
PHST- 2012/03/24 06:00 [pubmed]
PHST- 2012/06/27 06:00 [medline]
AID - S1470-2045(12)70112-2 [pii]
AID - 10.1016/S1470-2045(12)70112-2 [doi]
PST - ppublish
SO  - Lancet Oncol. 2012 May;13(5):518-27. doi: 10.1016/S1470-2045(12)70112-2. Epub 
      2012 Mar 21.

PMID- 9385337
OWN - NLM
STAT- MEDLINE
DCOM- 19971218
LR  - 20161025
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 102
IP  - 5
DP  - 1997 Nov
TI  - Pharmacologic therapy for acute myocardial infarction. Which agent, how much, how 
      soon, how long?
PG  - 143-5, 148-50, 152-4 passim
AB  - Is there any good reason to give intravenous nitroglycerin during evolving acute 
      myocardial infarction? How about a beta blocker? Should an ACE inhibitor be 
      started routinely within the first 24 hours of infarction? When is aspirin useful 
      for suspected acute myocardial infarction? Is it safe in patients with 
      contraindications to thrombolytic therapy? In this article, Dr Rapaport answers 
      these and many more questions by summarizing findings of important studies and 
      describing conclusions he has come to on the basis of his own clinical 
      experience.
FAU - Rapaport, E
AU  - Rapaport E
AD  - University of California, San Francisco, School of Medicine, USA. 
      erapapor@sfghdean.ucsf.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Postgrad Med 1998 Jul;104(1):32
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Nitroglycerin/therapeutic use
MH  - Platelet Aggregation Inhibitors/therapeutic use
RF  - 17
EDAT- 1997/12/31 00:00
MHDA- 1997/12/31 00:01
CRDT- 1997/12/31 00:00
PHST- 1997/12/31 00:00 [pubmed]
PHST- 1997/12/31 00:01 [medline]
PHST- 1997/12/31 00:00 [entrez]
AID - 10.3810/pgm.1997.11.364 [doi]
PST - ppublish
SO  - Postgrad Med. 1997 Nov;102(5):143-5, 148-50, 152-4 passim. doi: 
      10.3810/pgm.1997.11.364.

PMID- 984037
OWN - NLM
STAT- MEDLINE
DCOM- 19770103
LR  - 20190819
IS  - 0361-8609 (Print)
IS  - 0361-8609 (Linking)
VI  - 1
IP  - 1
DP  - 1976
TI  - The effect of thrombin on the uptake and transformation of arachidonic acid by 
      human platelets.
PG  - 59-70
AB  - Washed human platelets take up arachidonic acid from plasma and incorporate the 
      fatty acid into the major classes of complex lipids. Thrombin impairs net 
      incorporation. It activates endogenous phospholipases which liberate arachidonic 
      acid from phospholipids. As a consequence of thrombin induced aggregation 
      platelets release arachidonic acid intermediates formed by the action of platelet 
      fatty acid cyclooxygenase and by platelet fatty acid lipoxygenase. 
      Cyclooxygenase, but not lipoxygenase, is inhibited by aspirin and indomethicin. 
      Analysis of the pathways of arachidonic acid metabolism may furnish new insight 
      into platelet function and into disorders of primary hemostasis.
FAU - Russell, F A
AU  - Russell FA
FAU - Deykin, D
AU  - Deykin D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (Arachidonic Acids)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Lipids)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Arachidonic Acids/*metabolism
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*metabolism
MH  - Fatty Acids, Unsaturated/pharmacology
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Lipids/biosynthesis
MH  - Thrombin/*pharmacology
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1002/ajh.2830010107 [doi]
PST - ppublish
SO  - Am J Hematol. 1976;1(1):59-70. doi: 10.1002/ajh.2830010107.

PMID- 594394
OWN - NLM
STAT- MEDLINE
DCOM- 19780218
LR  - 20190823
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 14
IP  - 5
DP  - 1977 Nov
TI  - Radioimmunoassay of main urinary metabolite of prostaglandin F2alpha in normal 
      subjects.
PG  - 961-5
AB  - Radioimmunoassay of 5alpha, 7alpha-dihydroxy-11-keto-tetranor-prosta-1,16-dioic 
      acid, main urinary metabolite of prostaglandin F2alpha (PGF2alpha-MUM), was 
      performed in normal subjects. Twenty-four hours secretion of PGF2alpha-MUM were 
      29.04 +/- 9.73 microgram in males and 18.22 +/- 5.88 microgram in females on an 
      average. And an oral administration of aspirin resulted in the remarkable 
      decrease of PGF2alpha-MUM in both sexes.
FAU - Kitamura, S
AU  - Kitamura S
FAU - Ishihara, Y
AU  - Ishihara Y
FAU - Kosaka, K
AU  - Kosaka K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Prostaglandins F)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Prostaglandins F/metabolism/*urine
MH  - Radioimmunoassay
MH  - Sex Factors
EDAT- 1977/11/01 00:00
MHDA- 1977/11/01 00:01
CRDT- 1977/11/01 00:00
PHST- 1977/11/01 00:00 [pubmed]
PHST- 1977/11/01 00:01 [medline]
PHST- 1977/11/01 00:00 [entrez]
AID - 0090-6980(77)90310-0 [pii]
AID - 10.1016/0090-6980(77)90310-0 [doi]
PST - ppublish
SO  - Prostaglandins. 1977 Nov;14(5):961-5. doi: 10.1016/0090-6980(77)90310-0.

PMID- 33691498
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 1945-8932 (Electronic)
IS  - 1945-8932 (Linking)
VI  - 35
IP  - 6
DP  - 2021 Nov
TI  - Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease Based on the 
      12-Item Short Form Survey.
PG  - 790-797
LID - 10.1177/19458924211001640 [doi]
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is optimally managed 
      by endoscopic sinus surgery (ESS) followed by aspirin therapy after 
      desensitization (ATAD). Most AERD quality of life (QOL) studies use the 22-item 
      Sinonasal Outcomes Test (SNOT-22), which focuses predominantly on sinonasal 
      outcomes. OBJECTIVE: This study seeks to assess QOL outcomes in AERD patients 
      after ESS and ATAD via the 12-item Short Form Survey (SF-12), a well-validated 
      QOL measure for general health status of chronic conditions. METHODS: 
      Retrospective review of 112 AERD patients who underwent ESS followed by ATAD at 
      our institution between 2016 and 2019. SF-12 was collected preoperatively, 
      postoperatively/pre-AD, and serially post-AD (1-3, 4-6, 7-12, and >12 months). 
      Optum® PRO CoRE software was used to compare data to national norms. ANOVA was 
      performed comparing physical component summary (PCS), mental component summary 
      (MCS) and eight health domains (physical functioning, role physical, general 
      health, bodily pain, vitality, social functioning, role emotional, and mental 
      health). RESULTS: AERD patients showed improvement in PCS scores across all 
      timepoints after ESS and ATAD (p = 0.004). When stratified by gender, women 
      demonstrated an improvement in PCS scores (p = 0.004). Within the domains, there 
      were significant improvements in social functioning (SF), role physical (RP), and 
      bodily pain (BP) at all timepoints (SF: p = 0.006; RP: p = 0.005; BP: p < 0.001). 
      CONCLUSIONS: AERD patients undergoing ESS and ATAD show improvement in physical 
      QOL and 3 of the 8 health domains as measured by the SF-12. Future studies can 
      use the SF-12 to study the impact of AERD treatment versus other chronic diseases 
      and health demographics.
FAU - Locke, Tran B
AU  - Locke TB
AUID- ORCID: 0000-0002-3838-3890
AD  - Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, 
      Houston, Texas.
FAU - Sweis, Auddie M
AU  - Sweis AM
AD  - Division of Otolaryngology-Head and Neck Surgery, NorthShore University Health 
      System, The University of Chicago, Pritzker School of Medicine, Evanston, 
      Illinois.
FAU - Douglas, Jennifer E
AU  - Douglas JE
AUID- ORCID: 0000-0002-3634-2067
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Ig-Izevbekhai, Kevin I
AU  - Ig-Izevbekhai KI
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Stevens, Elizabeth M
AU  - Stevens EM
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Civantos, Alyssa M
AU  - Civantos AM
AUID- ORCID: 0000-0003-1226-6634
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - McCarty, Elizabeth B
AU  - McCarty EB
AUID- ORCID: 0000-0001-5186-9150
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Kumar, Ankur
AU  - Kumar A
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Kohanski, Michael A
AU  - Kohanski MA
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Kennedy, David W
AU  - Kennedy DW
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Palmer, James N
AU  - Palmer JN
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Bosso, John V
AU  - Bosso JV
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Adappa, Nithin D
AU  - Adappa ND
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of 
      Pennsylvania, Philadelphia, Pennsylvania.
LA  - eng
PT  - Journal Article
DEP - 20210310
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Asthma, Aspirin-Induced/epidemiology
MH  - Female
MH  - Humans
MH  - *Quality of Life
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - 12-item Short Form survey
OT  - aspirin desensitization
OT  - aspirin-exacerbated respiratory disease
OT  - endoscopic sinus surgery
OT  - quality of life
EDAT- 2021/03/12 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/03/11 05:39
PHST- 2021/03/12 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/03/11 05:39 [entrez]
AID - 10.1177/19458924211001640 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2021 Nov;35(6):790-797. doi: 10.1177/19458924211001640. Epub 
      2021 Mar 10.

PMID- 25641745
OWN - NLM
STAT- MEDLINE
DCOM- 20151201
LR  - 20181202
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 751
DP  - 2015 Mar 15
TI  - High on-treatment platelet reactivity in transcatheter aortic valve implantation 
      patients.
PG  - 24-7
LID - S0014-2999(15)00061-8 [pii]
LID - 10.1016/j.ejphar.2015.01.028 [doi]
AB  - Dual antiplatelet therapy (DAPT) is recommended early after transcatheter aortic 
      valve implantation (TAVI) procedure at the moment despite the lack of evidence. 
      Two small randomized trials failed to demonstrate DAPT to be superior to aspirin 
      alone in TAVI patients. However, it is known that there are substantial response 
      variabilities to antiplatelet medication. We aimed to investigate high 
      on-treatment platelet reactivity (HTPR), low on-treatment platelet reactivity 
      (LTPR) to clopidogrel as well as HTPR to aspirin in patients undergoing TAVI 
      procedure. We analyzed data of 140 TAVI patients in a real world observational 
      study. Platelet function assays (clopidogrel-vasodilator-stimulated protein 
      phosphorylation assay; aspirin-light-transmission aggregometry) have been 
      performed during hospital course. Clinical complications were investigated during 
      30 days follow-up and defined using the valve academic research consortium 
      standardized criteria. HTPR to clopidogrel occurred in 87 (62%) patients and LTPR 
      in 9 (6.4%) patients. Aspirin antiplatelet effects were insufficient in 25 (18%) 
      patients. Clinical complications were observed in 35 (25%) patients. Ischemic 
      events occurred in 6 (4%), bleeding complications in 28 (20%) patients. There 
      were no differences regarding the incidence of HTPR/LTPR in patients with overall 
      complications, ischemic events or bleeding events. HTPR to clopidogrel is very 
      frequent in TAVI patients. However bleeding complications are frequent and 
      ischemic events are rare. Therefore, future clinical trials investigating the 
      optimal antithrombotic regiment in TAVI patients should consider this high 
      incidence of HTPR to clopidogrel and monitor clopidogrel antiplatelet effects 
      carefully.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Polzin, Amin
AU  - Polzin A
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany. Electronic address: 
      Amin.polzin@med.uni-duesseldorf.de.
FAU - Schleicher, Mathias
AU  - Schleicher M
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Seidel, Holger
AU  - Seidel H
AD  - Department of Experimental and Clinical Hemostasis, Hemotherapy, and Transfusion 
      Medicine, Heinrich Heine University Medical Center Düsseldorf, Düsseldorf, 
      Germany.
FAU - Scharf, Rüdiger E
AU  - Scharf RE
AD  - Department of Experimental and Clinical Hemostasis, Hemotherapy, and Transfusion 
      Medicine, Heinrich Heine University Medical Center Düsseldorf, Düsseldorf, 
      Germany.
FAU - Merx, Marc W
AU  - Merx MW
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Kelm, Malte
AU  - Kelm M
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Zeus, Tobias
AU  - Zeus T
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20150129
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/pharmacology
MH  - Blood Platelets/drug effects/*physiology
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Ischemia/etiology/physiopathology
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology
MH  - Ticlopidine/adverse effects/analogs & derivatives/pharmacology
MH  - Transcatheter Aortic Valve Replacement/*adverse effects
OTO - NOTNLM
OT  - Aspirin - ACETYLSALICYLIC ACID (PubChem CID: 2244)
OT  - Clopidogrel (PubChem CID: 60606)
OT  - HTPR
OT  - TAVI
EDAT- 2015/02/03 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/02/03 06:00
PHST- 2014/12/16 00:00 [received]
PHST- 2015/01/12 00:00 [revised]
PHST- 2015/01/16 00:00 [accepted]
PHST- 2015/02/03 06:00 [entrez]
PHST- 2015/02/03 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S0014-2999(15)00061-8 [pii]
AID - 10.1016/j.ejphar.2015.01.028 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2015 Mar 15;751:24-7. doi: 10.1016/j.ejphar.2015.01.028. Epub 
      2015 Jan 29.

PMID- 10654888
OWN - NLM
STAT- MEDLINE
DCOM- 20000217
LR  - 20190714
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 55
IP  - 1
DP  - 2000 Jan
TI  - Clinical significance of gross hematuria and its evaluation in patients receiving 
      anticoagulant and aspirin treatment.
PG  - 22-4
AB  - OBJECTIVES: To investigate the results of evaluations in patients presenting with 
      gross hematuria while receiving anticoagulant or aspirin treatment and to compare 
      the source of bleeding in these respective groups. METHODS: We retrospectively 
      studied all patients admitted because of gross hematuria while receiving warfarin 
      or aspirin treatment between 1990 and 1998. The degree of anticoagulation was 
      evaluated in patients taking anticoagulation medication. Almost all patients were 
      evaluated by cystoscopy and either excretory urography or ultrasound. RESULTS: 
      Patients taking warfarin had a normal evaluation almost twice as often as those 
      taking aspirin: 38% versus 22%, respectively. The leading pathologic findings in 
      both groups were a bleeding benign prostate and a tumor in the urinary tract, in 
      similar proportions. Overall, a tumor was diagnosed in one quarter of patients, 
      and other treatable pathologic findings were diagnosed about half the time. In 
      the 11 patients receiving excessive anticoagulation medication, two tumors were 
      found (18%). Hemorrhagic cystitis was diagnosed in 12 patients. All 12 were 
      taking aspirin. CONCLUSIONS: A normal evaluation was more prevalent in the 
      warfarin group. A tumor was diagnosed in about one quarter of the patients. The 
      prevalence of hemorrhagic cystitis in patients taking aspirin may point to a 
      specific bleeding diathesis in the urothelium of these patients. In light of 
      these findings, a full evaluation is warranted in patients receiving aspirin or 
      warfarin therapy, and the presence of excessive anticoagulation should not impede 
      a full evaluation.
FAU - Avidor, Y
AU  - Avidor Y
AD  - Department of Urology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel-Aviv University, Israel.
FAU - Nadu, A
AU  - Nadu A
FAU - Matzkin, H
AU  - Matzkin H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Hematuria/diagnosis/*etiology
MH  - Humans
MH  - Male
MH  - Retrospective Studies
MH  - Warfarin/*therapeutic use
EDAT- 2000/02/02 00:00
MHDA- 2000/02/19 00:00
CRDT- 2000/02/02 00:00
PHST- 2000/02/02 00:00 [pubmed]
PHST- 2000/02/19 00:00 [medline]
PHST- 2000/02/02 00:00 [entrez]
AID - S0090-4295(99)00388-X [pii]
AID - 10.1016/s0090-4295(99)00388-x [doi]
PST - ppublish
SO  - Urology. 2000 Jan;55(1):22-4. doi: 10.1016/s0090-4295(99)00388-x.

PMID- 23955035
OWN - NLM
STAT- MEDLINE
DCOM- 20140225
LR  - 20130819
IS  - 1600-5775 (Electronic)
IS  - 0909-0495 (Linking)
VI  - 20
IP  - Pt 5
DP  - 2013 Sep
TI  - Determination of nanostructure of liposomes containing two model drugs by X-ray 
      scattering from a synchrotron source.
PG  - 721-8
LID - 10.1107/S0909049513020074 [doi]
AB  - Small-angle X-ray scattering has been employed to study how the introduction of 
      paracetamol and acetylsalicylic acid into a liposome bilayer system affects the 
      system's nanostructure. An X-ray scattering model, developed for multilamellar 
      liposome systems [Pabst et al. (2000), Phys. Rev. E, 62, 4000-4009], has been 
      used to fit the experimental data and to extract information on how structural 
      parameters, such as the number and thickness of the bilayers of the liposomes, 
      thickness of the water layer in between the bilayers, size and volume of the head 
      and tail groups, are affected by the drugs and their concentration. Even though 
      the experimental data reveal a complicated picture of the drug-bilayer 
      interaction, they clearly show a correlation between nanostructure, drug and 
      concentration in some aspects. The localization of the drugs in the bilayers is 
      discussed.
FAU - Nasedkin, Alexandr
AU  - Nasedkin A
AD  - Department of Chemistry, Ångström Laboratory, Uppsala University, Lagerhyddsvägen 
      1, S-75120 Uppsala, Sweden.
FAU - Davidsson, Jan
AU  - Davidsson J
FAU - Kumpugdee-Vollrath, Mont
AU  - Kumpugdee-Vollrath M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130808
PL  - United States
TA  - J Synchrotron Radiat
JT  - Journal of synchrotron radiation
JID - 9888878
RN  - 0 (Lipid Bilayers)
RN  - 0 (Liposomes)
RN  - 0 (Phospholipids)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*chemistry
MH  - Aspirin/*chemistry
MH  - Lipid Bilayers
MH  - Liposomes/*chemistry
MH  - Models, Theoretical
MH  - Nanostructures
MH  - Phospholipids/*chemistry
MH  - Scattering, Small Angle
MH  - Synchrotrons
MH  - X-Ray Diffraction/*methods
OTO - NOTNLM
OT  - SAXS
OT  - WAXS
OT  - acetylsalicylic acid
OT  - drug-loaded liposomes
OT  - paracetamol
EDAT- 2013/08/21 06:00
MHDA- 2014/02/26 06:00
CRDT- 2013/08/20 06:00
PHST- 2013/01/04 00:00 [received]
PHST- 2013/07/20 00:00 [accepted]
PHST- 2013/08/20 06:00 [entrez]
PHST- 2013/08/21 06:00 [pubmed]
PHST- 2014/02/26 06:00 [medline]
AID - S0909049513020074 [pii]
AID - 10.1107/S0909049513020074 [doi]
PST - ppublish
SO  - J Synchrotron Radiat. 2013 Sep;20(Pt 5):721-8. doi: 10.1107/S0909049513020074. 
      Epub 2013 Aug 8.

PMID- 3413736
OWN - NLM
STAT- MEDLINE
DCOM- 19881012
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 51
IP  - 1
DP  - 1988 Jul 1
TI  - Detection of small inhibitory effects of acetylsalicylic acid (ASA) by platelet 
      impedance aggregometry in whole blood.
PG  - 55-62
AB  - Our investigations have demonstrated on 10 volunteers receiving either 500 mg or 
      100 mg acetylsalicylic acid (ASA) that a low collagen concentration (1 
      microgram/ml) can best detect the aggregation defect caused by ASA. With the 
      impedance aggregometry the mean inhibition reaches 82% and 52% with 500 mg and 
      100 mg ASA, respectively. Collagen at higher concentration (3 micrograms/ml) as 
      well as ADP 10 and 25 mumol/l are less sensitive, less than 25% inhibition was 
      recorded. These results suggest that a 1 microgram/ml concentration of collagen 
      is adequate for the control of the ASA effect up to 6 days after intake of 100 
      mg. Furthermore, the von Willebrand factor (vWF) dependent platelet aggregation 
      induced by 0.6 and 1.0 mg/ml ristocetin was clearly diminished after ASA. 
      Therefore, a ristocetin screening test in whole blood for vWF disorder is 
      possibly distorted when the test is performed within 6 days from ASA 
      administration.
FAU - Sathiropas, P
AU  - Sathiropas P
AD  - Coagulation and Fibrinolysis Laboratory, Kantonsspital, Basel, Switzerland.
FAU - Marbet, G A
AU  - Marbet GA
FAU - Sahaphong, S
AU  - Sahaphong S
FAU - Duckert, F
AU  - Duckert F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 1404-55-3 (Ristocetin)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Collagen/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Ristocetin/pharmacology
EDAT- 1988/07/01 00:00
MHDA- 1988/07/01 00:01
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 1988/07/01 00:01 [medline]
PHST- 1988/07/01 00:00 [entrez]
AID - 0049-3848(88)90282-4 [pii]
AID - 10.1016/0049-3848(88)90282-4 [doi]
PST - ppublish
SO  - Thromb Res. 1988 Jul 1;51(1):55-62. doi: 10.1016/0049-3848(88)90282-4.

PMID- 701483
OWN - NLM
STAT- MEDLINE
DCOM- 19781229
LR  - 20190206
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 62
IP  - 4
DP  - 1978 Oct
TI  - Effect of aspirin on thrombin-induced adherence of platelets to cultured cells 
      from the blood vessel wall.
PG  - 847-56
AB  - An in vitro method was used to detect adherence of (51)Cr-labeled platelets to 
      monolayers of cultured human endothelial, fibroblast, and smooth muscle cells. 
      Washed platelets did not adhere to untreated or aspirin-treated endothelial 
      monolayers in the absence of thrombin. In contrast, thrombin-induced platelet 
      aggregates adhered to all of the monolayers but adherence to endothelium was 
      significantly less than to the other cells. Additional evidence for adherence of 
      platelets to the endothelium was provided by scanning and transmission electron 
      microscopy. Thrombin-induced platelet adherence to endothelium was inhibited by 
      hirudin. Platelet adherence induced by thrombin was enhanced significantly by 
      treatment of the endothelial monolayer with 1-2 mM aspirin. This increase in 
      adherence was seen even when aspirin-treated platelets were used; adherence 
      values approached those seen with fibroblasts and smooth muscle cells. An aspirin 
      concentration of 0.1 mM was sufficient to block thrombin-induced malonaldehyde 
      production in platelets but it did not interfere with the inhibitory effect of 
      the endothelium against platelet adherence. The effect of aspirin on the 
      endothelium was temporary and inhibitory activity of the endothelium was restored 
      1 h after aspirin had been removed from the incubation system. The ability of 
      thrombin to cause adherence of platelets to undamaged endothelium, and the 
      potential for aspirin to enhance this adherence have implications for mechanisms 
      which operate in platelet interaction with the blood vessel wall.
FAU - Czervionke, R L
AU  - Czervionke RL
FAU - Hoak, J C
AU  - Hoak JC
FAU - Fry, G L
AU  - Fry GL
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Vessels/cytology/*physiology
MH  - Cells, Cultured
MH  - Endothelium/physiology
MH  - Fibroblasts/physiology
MH  - Muscle, Smooth/physiology
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Thrombin/metabolism
PMC - PMC371837
EDAT- 1978/10/01 00:00
MHDA- 1978/10/01 00:01
CRDT- 1978/10/01 00:00
PHST- 1978/10/01 00:00 [pubmed]
PHST- 1978/10/01 00:01 [medline]
PHST- 1978/10/01 00:00 [entrez]
AID - 10.1172/JCI109197 [doi]
PST - ppublish
SO  - J Clin Invest. 1978 Oct;62(4):847-56. doi: 10.1172/JCI109197.

PMID- 32369856
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20200824
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 120
IP  - 5
DP  - 2020 May
TI  - Cilostazol for Chinese Patients with Aspirin Intolerance after Coronary 
      Drug-Eluting Stent Implantation.
PG  - 857-865
LID - 10.1055/s-0040-1709520 [doi]
AB  - BACKGROUND:  Cilostazol-based dual antiplatelet therapy (DAPT) is widely used in 
      patients with aspirin intolerance after coronary drug-eluting stent (DES) 
      implantation in China. However, this empirical strategy is not recommended or 
      even mentioned in Chinese or international guidelines due to a lack of evidence 
      from large-scale studies. We aimed to explore the efficacy and safety of 
      cilostazol-based DAPT in this special population. METHODS:  In this cohort study, 
      patients were grouped according to the DAPT strategy that they received after 
      coronary DES implantation. The primary efficacy endpoint was major adverse 
      cardiovascular and cerebrovascular events (MACCEs). Angiographic follow-up and 
      major bleeding events were also recorded. RESULTS:  A total of 918 patients 
      receiving cilostazol-based DAPT due to aspirin intolerance were enrolled, matched 
      with 918 patients receiving aspirin-based DAPT. After 15-month prospective 
      follow-up, the cilostazol group had lower risk of MACCE (5.1% vs. 7.6%, 
      propensity score adjusted hazard ratio = 0.671 [95% confidence interval 
      0.462-0.974], p = 0.036) compared with the aspirin group. Lower rate of coronary 
      lesion progression was also found through follow-up angiography in the cilostazol 
      group (17.4% vs. 23.6%, p = 0.022), especially in nontarget lesions (12.1% vs. 
      17.6%, p = 0.019). The two groups had the same risk of major bleeding events 
      (0.8% vs. 0.4%, p = 0.364). CONCLUSION:  In the current study, cilostazol is a 
      good substitute for aspirin in patients who have aspirin intolerance but need 
      DAPT after coronary DES implantation in China. However, large-scale randomized 
      controlled trials were still required to further confirm its efficacy and safety.
CI  - Georg Thieme Verlag KG Stuttgart · New York.
FAU - Dai, Chunfeng
AU  - Dai C
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Chen, Zhangwei
AU  - Chen Z
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Fu, Jiayu
AU  - Fu J
AD  - Shanghai Medical College, Fudan University, Shanghai, China.
FAU - Qian, Juying
AU  - Qian J
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Ge, Junbo
AU  - Ge J
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
LA  - eng
GR  - National Natural Science Foundation of China/81970295/
GR  - National Natural Science Foundation of China/81870267/
GR  - National Natural Science Foundation of China/81570314/
GR  - National Natural Science Foundation of China/81670318/
GR  - Grant of Shanghai Municipal Commission of Health and Family Planning/2017YQ057/
GR  - Grant of Shanghai Science and Technology Committee/17411962300/
GR  - National Program on Key Basic Research Project of China/2014CBA02003/
GR  - Program for Outstanding Medical Academic Leader/2015-Weijiwei-24/
GR  - Grant of Zhongshan Hospital Affiliated to Fudan University/2015ZSYXGG07/
GR  - Grant of Zhongshan Hospital Affiliated to Fudan University/2017ZSYQ08/
GR  - VG Funding of Clinical Trials/2017-CCA-VG-036/
GR  - Merck Funding/Xinxin-merck-fund-051/
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20200505
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - China
MH  - Cilostazol/adverse effects/*therapeutic use
MH  - Coronary Artery Disease/diagnostic imaging/*therapy
MH  - *Drug-Eluting Stents
MH  - *Dual Anti-Platelet Therapy
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/adverse effects/*instrumentation
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
COIS- None declared.
EDAT- 2020/05/06 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1055/s-0040-1709520 [doi]
PST - ppublish
SO  - Thromb Haemost. 2020 May;120(5):857-865. doi: 10.1055/s-0040-1709520. Epub 2020 
      May 5.

PMID- 8169680
OWN - NLM
STAT- MEDLINE
DCOM- 19940601
LR  - 20131121
IS  - 0743-8346 (Print)
IS  - 0743-8346 (Linking)
VI  - 14
IP  - 1
DP  - 1994 Jan-Feb
TI  - Multiple thromboses in a premature infant associated with maternal phospholipid 
      antibody syndrome.
PG  - 66-70
AB  - Phospholipid antibodies (lupus anticoagulant, cardiolipin) are associated with a 
      syndrome of repeated fetal loss. Mothers with phospholipid antibodies are 
      currently being treated with either prednisone, aspirin, or heparin to prevent 
      fetal death. We describe a neonate whose mother had cardiolipin antibody and 
      recurrent fetal loss and was treated with prednisone and aspirin. Thrombosis was 
      noted in placental fetal vessels. Thromboses developed in the infant's aorta, 
      left renal artery, middle cerebral artery, and superior sagittal sinus. Infants 
      of phospholipid-positive mothers may have vascular thrombosis and should be 
      carefully monitored for signs of thromboembolism.
FAU - Tabbutt, S
AU  - Tabbutt S
AD  - Department of Pediatrics, University of California School of Medicine, Children's 
      Hospital and Health Center, San Diego.
FAU - Griswold, W R
AU  - Griswold WR
FAU - Ogino, M T
AU  - Ogino MT
FAU - Mendoza, A E
AU  - Mendoza AE
FAU - Allen, J B
AU  - Allen JB
FAU - Reznik, V M
AU  - Reznik VM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Perinatol
JT  - Journal of perinatology : official journal of the California Perinatal 
      Association
JID - 8501884
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - *Antiphospholipid Syndrome/diagnosis/drug therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - *Infant, Premature, Diseases/diagnosis
MH  - Male
MH  - Prednisone/therapeutic use
MH  - Pregnancy
MH  - *Pregnancy Complications/diagnosis/drug therapy
MH  - *Thrombosis/diagnosis
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - J Perinatol. 1994 Jan-Feb;14(1):66-70.

PMID- 19573471
OWN - NLM
STAT- MEDLINE
DCOM- 20091013
LR  - 20181201
IS  - 2046-4924 (Electronic)
IS  - 1366-5278 (Linking)
VI  - 13
IP  - 31
DP  - 2009 Jun
TI  - The effect of different treatment durations of clopidogrel in patients with 
      non-ST-segment elevation acute coronary syndromes: a systematic review and value 
      of information analysis.
PG  - iii-iv, ix-xi, 1-77
LID - 10.3310/hta13310 [doi]
AB  - OBJECTIVE: To update the previous systematic review of the use of clopidogrel in 
      combination with aspirin for patients with non-ST-elevation acute coronary 
      syndrome (NSTE-ACS), investigating the optimal duration of treatment and effects 
      of withdrawal from treatment. DATA SOURCES: Ten electronic databases and internet 
      resources were searched from 2003 to February 2007, including MEDLINE, MEDLINE 
      In-Process, EMBASE, BIOSIS, CENTRAL and CINAHL. REVIEW METHODS: Randomised 
      controlled trials (RCTs) of clopidogrel plus aspirin compared with aspirin alone 
      were used to evaluate clinical effectiveness and safety. Inclusion criteria 
      included any comparator trial for duration of treatment studies, and any study 
      design conducted in patients with NSTE-ACS, percutaneous coronary intervention 
      (PCI), stroke, peripheral artery disease (PAD) or ST-elevation myocardial 
      infarction (STEMI) for evidence of rebound on withdrawal of treatment. The 
      existing model was updated to provide a more robust approach to evaluating the 
      cost-effectiveness of alternative durations of clopidogrel and to assess the 
      potential value of further research using value of information approaches. 
      RESULTS: Two RCTs were included for the review of clinical effectiveness and 
      safety. The only RCTs identified that evaluated different durations of 
      clopidogrel treatments were conducted in patients with stroke, PAD, STEMI or PCI. 
      Two small RCTs and one uncontrolled retrospective cohort study were identified 
      for the review of rebound after thienopyridine withdrawal in patients with 
      medically-treated NSTE-ACS. On broadening the criteria, five RCTs, two 
      observational cohorts, nine case series and 33 case reports were identified in 
      patients post-PCI, and two case series and two case reports were identified in 
      patients with stroke, PAD or STEMI. The CURE trial reported that the proportion 
      of patients experiencing cardiovascular death, myocardial infarction or stroke 
      was lower in the clopidogrel group at 30 days [relative risk (RR) 0.79; 95% 
      confidence interval (CI) 0.67-0.92] and from 30 days to 12 months (RR 0.82; 95% 
      CI 0.70-0.95). Clopidogrel seems to be effective in reducing adverse 
      cardiovascular events in patients with NSTE-ACS at intermediate and high risk of 
      ischaemic events, and appears to increase the risk of bleeding when compared with 
      aspirin in patients with intermediate risk of ischaemic events. In terms of the 
      cost-effectiveness of alternative durations of clopidogrel, the updated model 
      reinforced the conclusions from the earlier analysis, i.e. a policy of 12 months 
      of clopidogrel for patients with NSTE-ACS appears to be cost-effective in both 
      'average' patients and higher-risk patients. The incremental cost-effectiveness 
      (ICER) of 12 months' duration ranged from 13,380 pounds to 20,661 pounds per 
      additional quality-adjusted life-year (QALY) across the different scenarios. For 
      lower-risk patients, treatment beyond 3 months does not appear to be 
      cost-effective. The ICER of 12 months' treatment with clopidogrel varied between 
      49,436 pounds and 58,691 pounds per QALY. Estimates of expected value of perfect 
      information (EVPI) were higher for the combined analysis and for analysis of 
      high-risk patients alone (between 48.69 million pounds and 108.4 million pounds 
      at a threshold of 30,000 pounds per QALY). At a threshold of 20,000 pounds-30,000 
      pounds per QALY, total EVPI ranged between 3.27 million pounds and 20.38 million 
      pounds in the lower-risk group. CONCLUSIONS: The review was limited by the lack 
      of available data. There is considerable variation in the costs of uncertainty 
      surrounding the different scenarios and populations considered. The validity of 
      these may also be less reliable in the higher-risk groups owing to changes in 
      clinical practice. An adequately powered, well-conducted RCT that directly 
      compares different durations of clopidogrel treatment in patients with NSTE-ACS 
      would ideally be required to provide more robust evidence in relation to the 
      impact of clopidogrel withdrawal.
FAU - Rogowski, W
AU  - Rogowski W
AD  - Helmholtz Zentrum München, German Research Center for Environmental Health, 
      Institute of Health Economics and Health Care Management, Neuherberg.
FAU - Burch, J
AU  - Burch J
FAU - Palmer, S
AU  - Palmer S
FAU - Craigs, C
AU  - Craigs C
FAU - Golder, S
AU  - Golder S
FAU - Woolacott, N
AU  - Woolacott N
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Health Technol Assess
JT  - Health technology assessment (Winchester, England)
JID - 9706284
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/epidemiology/etiology/physiopathology
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & 
      dosage/economics/pharmacology/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/administration & dosage/*analogs & 
      derivatives/economics/pharmacology/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - United Kingdom/epidemiology
MH  - Withholding Treatment
MH  - Young Adult
RF  - 122
EDAT- 2009/07/04 09:00
MHDA- 2009/10/14 06:00
CRDT- 2009/07/04 09:00
PHST- 2009/07/04 09:00 [entrez]
PHST- 2009/07/04 09:00 [pubmed]
PHST- 2009/10/14 06:00 [medline]
AID - 10.3310/hta13310 [doi]
PST - ppublish
SO  - Health Technol Assess. 2009 Jun;13(31):iii-iv, ix-xi, 1-77. doi: 
      10.3310/hta13310.

PMID- 29392866
OWN - NLM
STAT- MEDLINE
DCOM- 20190409
LR  - 20190409
IS  - 1447-0594 (Electronic)
IS  - 1447-0594 (Linking)
VI  - 18
IP  - 6
DP  - 2018 Jun
TI  - Population-based study examining the utilization of preventive medicines by older 
      people in the last year of life.
PG  - 892-898
LID - 10.1111/ggi.13273 [doi]
AB  - AIM: To examine the patterns of preventive medicines (PM) use in the last year of 
      life of older adults. METHODS: This study cohort included individuals (n = 99 
      809) aged ≥75 years who were in their last year of life. PM examined in this 
      study included low-dose aspirin (≤325 mg/day), clopidogrel, dipyridamole, 
      warfarin, dabigatran, statins and bisphosphonates. Logistic regression models 
      examined the influence of age, sex, multimorbidity, socioeconomic status, and a 
      diagnosis of cancer on the number and type of PM prescribed from 2007 to 2012. 
      RESULTS: The number of PM prescribed was higher for men compared with women (OR 
      1.11, 95% CI 1.08-1.14). Increasing age did not have an effect on the number of 
      PM prescribed. The use of clopidogrel increased almost threefold from 2007 to 
      2012 (OR 5.53, 95% CI 4.61-6.65). In contrast, bisphosphonates use decreased 
      significantly during the same period (OR 0.35, 95% CI 0.32-0.39). Individuals 
      with a diagnosis of cancer had increased odds of PM utilization for 
      antiplatelets, aspirin monotherapy and statins, which had remarkably high odds 
      (OR 4.11, 95% CI 3.88-4.34, P < 0.001). CONCLUSIONS: The present explorative 
      study highlighted that some PM, such as statins, continue to be prescribed until 
      death, particularly those that might have been beneficial earlier in life, but 
      have an uncertain or unfavorable risk-benefit ratio towards the end-of-life. 
      Geriatr Gerontol Int 2018; 18: 892-898.
CI  - © 2018 Japan Geriatrics Society.
FAU - Narayan, Sujita W
AU  - Narayan SW
AUID- ORCID: 0000-0001-8706-2113
AD  - School of Pharmacy, University of Otago, Dunedin, New Zealand.
FAU - Nishtala, Prasad S
AU  - Nishtala PS
AD  - School of Pharmacy, University of Otago, Dunedin, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20180202
PL  - Japan
TA  - Geriatr Gerontol Int
JT  - Geriatrics & gerontology international
JID - 101135738
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Cohort Studies
MH  - Drug Prescriptions/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Male
MH  - *Terminal Care
MH  - Warfarin/therapeutic use
OTO - NOTNLM
OT  - cancer
OT  - drug utilization
OT  - limited life expectancy
OT  - older people
OT  - preventive medicines
EDAT- 2018/02/03 06:00
MHDA- 2019/04/10 06:00
CRDT- 2018/02/03 06:00
PHST- 2017/12/02 00:00 [revised]
PHST- 2017/12/21 00:00 [accepted]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2019/04/10 06:00 [medline]
PHST- 2018/02/03 06:00 [entrez]
AID - 10.1111/ggi.13273 [doi]
PST - ppublish
SO  - Geriatr Gerontol Int. 2018 Jun;18(6):892-898. doi: 10.1111/ggi.13273. Epub 2018 
      Feb 2.

PMID- 11565855
OWN - NLM
STAT- MEDLINE
DCOM- 20020312
LR  - 20191210
IS  - 0739-1102 (Print)
IS  - 0739-1102 (Linking)
VI  - 19
IP  - 1
DP  - 2001 Aug
TI  - The effects of anions on the solution structure of Na,K-ATPase.
PG  - 95-102
AB  - Anions interact with protein to induce structural changes at ligand binding 
      sites. The effects of anion complexation include structural stabilization and 
      promote cation-protein interaction. This study was designed to examine the 
      interaction of aspirin and ascorbate anions with the Na+, K+-dependent adenosine 
      triphosphatase (Na,K-ATPase) in H2O and D2O solutions at physiological pH, using 
      anion concentrations of 0.1 microM to 1 mM with final protein concentration of 
      0.5 to 1 mg/ml. Absorption spectra and Fourier transform infrared (FTIR) 
      difference spectroscopy with its self-deconvolution, second derivative resolution 
      enhancement and curve-fitting procedures were applied to characterize the anion 
      binding mode, binding constant, and the protein secondary structure in the 
      anion-ATPase complexes. Spectroscopic evidence showed that the anion interaction 
      is mainly through the polypeptide C=O and C-N groups with minor perturbation of 
      the lipid moiety. Evidence for this came from major spectral changes (intensity 
      variations) of the protein amide I and amide II vibrations at 1651 and 1550 
      cm(-1). respectively. The anion-ATPase binding constants were K=6.45 x 10(3) 
      M(-1) for aspirin and K=1.04 x 10(4) M(-1) for ascorbate complexes. The anion 
      interaction resulted in major protein secondary structural changes from that of 
      the alpha-helix 19.8%; beta-pleated sheet 25.6%; turn 9.1%; beta-antiparallel 
      7.5% and random 38% in the free Na,K-ATPase to that of the alpha-helix 24-26%; 
      beta-pleated 17-18%; turn 8%; beta-antiparallel 5-3% and random 45.0% in the 
      anion-ATPase complexes.
FAU - Neault, J F
AU  - Neault JF
AD  - Department of Chemistry-Biology, University of Québec at Trois-Rivières, Canada.
FAU - Benkiran, A
AU  - Benkiran A
FAU - Malonga, H
AU  - Malonga H
FAU - Tajmir-Riahi, H A
AU  - Tajmir-Riahi HA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Biomol Struct Dyn
JT  - Journal of biomolecular structure & dynamics
JID - 8404176
RN  - 0 (Anions)
RN  - 0 (Macromolecular Substances)
RN  - 0 (Solutions)
RN  - EC 7.2.2.13 (Sodium-Potassium-Exchanging ATPase)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anions
MH  - Ascorbic Acid/chemistry
MH  - Aspirin/chemistry
MH  - Binding Sites
MH  - Guinea Pigs
MH  - In Vitro Techniques
MH  - Macromolecular Substances
MH  - Protein Structure, Secondary
MH  - Sodium-Potassium-Exchanging ATPase/*chemistry
MH  - Solutions
MH  - Spectrophotometry
MH  - Spectroscopy, Fourier Transform Infrared
EDAT- 2001/09/22 10:00
MHDA- 2002/03/13 10:01
CRDT- 2001/09/22 10:00
PHST- 2001/09/22 10:00 [pubmed]
PHST- 2002/03/13 10:01 [medline]
PHST- 2001/09/22 10:00 [entrez]
AID - 10.1080/07391102.2001.10506723 [doi]
PST - ppublish
SO  - J Biomol Struct Dyn. 2001 Aug;19(1):95-102. doi: 10.1080/07391102.2001.10506723.

PMID- 8620270
OWN - NLM
STAT- MEDLINE
DCOM- 19960619
LR  - 20220317
IS  - 1063-3987 (Print)
IS  - 1063-3987 (Linking)
VI  - 5
IP  - 5
DP  - 1996 May
TI  - Adherence to single daily dose of aspirin in a chemoprevention trial. An 
      evaluation of self-report and microelectronic monitoring.
PG  - 297-300
AB  - A consecutive sample of 64 healthy adults (33 female and 31 male) were recruited 
      at the University of Michigan Medical Center, Ann Arbor. Data were available for 
      analysis on 57 subjects. The participants were asked to take a single daily dose 
      of aspirin ranging from 0 to 640 mg. Adherence to the daily aspirin ingestion was 
      measured by self-report and the Medication Event Monitoring System (MEMS, Aprex 
      Corp, Fremont, Calif); adherence rate for the study population was 35%. The 
      adherence rates for all dosing errors between self-report and Medication Event 
      Monitoring System were significantly different (P = .002). There was no 
      significant gender difference in adherence rates. Adherence to regular aspirin 
      ingestion was poor in healthy, paid subjects despite explicit, written and verbal 
      instructions. Patient self-report alone is not a reliable measure of adherence.
FAU - Burney, K D
AU  - Burney KD
AD  - Department of Internal Medicine, University of Michigan Medical School, Ann 
      Arbor, USA.
FAU - Krishnan, K
AU  - Krishnan K
FAU - Ruffin, M T
AU  - Ruffin MT
FAU - Zhang, D
AU  - Zhang D
FAU - Brenner, D E
AU  - Brenner DE
LA  - eng
GR  - CN-25429/CN/NCI NIH HHS/United States
GR  - MO1-RR00042/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Fam Med
JT  - Archives of family medicine
JID - 9300357
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Colorectal Neoplasms/*prevention & control
MH  - Drug Administration Schedule
MH  - Drug Packaging
MH  - Electronics
MH  - Female
MH  - Humans
MH  - Male
MH  - *Patient Compliance
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 10.1001/archfami.5.5.297 [doi]
PST - ppublish
SO  - Arch Fam Med. 1996 May;5(5):297-300. doi: 10.1001/archfami.5.5.297.

PMID- 23469911
OWN - NLM
STAT- MEDLINE
DCOM- 20130826
LR  - 20181202
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 11
IP  - 3
DP  - 2013 Mar
TI  - Dual antiplatelet therapy in patients with diabetes mellitus: special 
      considerations.
PG  - 307-17
LID - 10.1586/erc.13.3 [doi]
AB  - Diabetes mellitus (DM) is associated with higher rates of ischemic events in 
      patients suffering from an acute coronary syndrome and/or undergoing percutaneous 
      coronary intervention, thereby underscoring the need to develop more effective 
      and specific strategies toward mitigation of the cardiovascular burden associated 
      with DM. Platelet hyper-reactivity associated with DM is a central contributor to 
      this high risk, since platelets are the key players in the processes underpinning 
      atherothrombotic complications, thereby representing a specific therapeutic 
      target. Oral dual antiplatelet therapy comprising the combination of aspirin 
      (75-100 mg) and clopidogrel (75 mg) has been, for years, the standard 
      antithrombotic treatment for patients with acute coronary syndrome and/or 
      undergoing percutaneous coronary intervention. However, despite the use of this 
      therapy, high rates of cardiovascular events continue to occur, especially within 
      the cohort of patients with DM. These observations could be in part explained by 
      an inadequate clopidogrel-induced platelet inhibition, which has been associated 
      with impaired clinical outcomes. In particular, DM is associated with a higher 
      prevalence of reduced responsiveness to standard dual antiplatelet therapy, which 
      may contribute to the higher rates of ischemic events seen in this population. 
      These findings have prompted the identification of alternative dual antiplatelet 
      treatment regimens to optimize platelet inhibition. The present review aims to 
      describe benefits and limitations of oral dual antiplatelet therapy with aspirin 
      and clopidogrel (75 mg) and to appraise the evidence regarding alternative oral 
      dual antiplatelet therapy regimens, which include higher doses of aspirin and 
      clopidogrel or the combination of prasugrel or ticagrelor with aspirin, focusing 
      on patients with DM.
FAU - Capranzano, Piera
AU  - Capranzano P
AD  - Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, 
      Italy.
FAU - Capodanno, Davide
AU  - Capodanno D
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blood Platelets/drug effects/metabolism
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Clopidogrel
MH  - Diabetes Mellitus/drug therapy/*physiopathology
MH  - Diabetic Angiopathies/prevention & control
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
EDAT- 2013/03/09 06:00
MHDA- 2013/08/27 06:00
CRDT- 2013/03/09 06:00
PHST- 2013/03/09 06:00 [entrez]
PHST- 2013/03/09 06:00 [pubmed]
PHST- 2013/08/27 06:00 [medline]
AID - 10.1586/erc.13.3 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2013 Mar;11(3):307-17. doi: 10.1586/erc.13.3.

PMID- 19116178
OWN - NLM
STAT- MEDLINE
DCOM- 20090609
LR  - 20161229
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 104
IP  - 3
DP  - 2009 Mar
TI  - Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent 
      abortion associated with antiphospholipid antibody syndrome.
PG  - 223-5
LID - 10.1016/j.ijgo.2008.11.010 [doi]
AB  - OBJECTIVE: To compare low-molecular-weight (LMW) heparin plus low-dose aspirin 
      with intravenous immunoglobulin (IVIG) in the treatment of antiphospholipid 
      antibody syndrome in women with recurrent spontaneous abortions before 10 weeks 
      of gestation. METHOD: This prospective, multicenter trial conducted between 2002 
      and 2006 included 85 patients aged 18-39 years. The women were allocated randomly 
      to receive LMW heparin plus low-dose aspirin, or IVIG. Data were compared using 
      the t test and Fisher exact test. RESULTS: The women treated with LMW heparin 
      plus low-dose aspirin had a higher rate of live births than those treated with 
      IVIG (P=0.003). Of those who completed the study, 29/40 (72.5%) and 15/38 
      (39.5%), respectively, had live births. Intent-to-treat analysis revealed a 
      significant difference between the 2 groups (OR 1.802; 95%CI, 1.14-2.84; 
      P=0.007). CONCLUSIONS: LMW heparin plus low-dose aspirin resulted in a higher 
      live birth rate than IVIG in the treatment of antiphospholipid antibody syndrome 
      in women with recurrent abortion.
FAU - Dendrinos, Spiros
AU  - Dendrinos S
AD  - 2nd Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, 
      University of Athens, Athens, Greece.
FAU - Sakkas, Evangelos
AU  - Sakkas E
FAU - Makrakis, Evangelos
AU  - Makrakis E
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20081229
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/etiology/immunology/*prevention & control
MH  - Adolescent
MH  - Adult
MH  - Anticoagulants/*therapeutic use
MH  - Antiphospholipid Syndrome/complications/*drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gestational Age
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy/immunology
MH  - Pregnancy Outcome
MH  - Pregnancy, High-Risk
MH  - Prospective Studies
MH  - Young Adult
EDAT- 2009/01/01 09:00
MHDA- 2009/06/10 09:00
CRDT- 2009/01/01 09:00
PHST- 2008/07/13 00:00 [received]
PHST- 2008/10/28 00:00 [revised]
PHST- 2008/11/07 00:00 [accepted]
PHST- 2009/01/01 09:00 [entrez]
PHST- 2009/01/01 09:00 [pubmed]
PHST- 2009/06/10 09:00 [medline]
AID - S0020-7292(08)00516-X [pii]
AID - 10.1016/j.ijgo.2008.11.010 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2009 Mar;104(3):223-5. doi: 10.1016/j.ijgo.2008.11.010. 
      Epub 2008 Dec 29.

PMID- 16240817
OWN - NLM
STAT- MEDLINE
DCOM- 20060601
LR  - 20190516
IS  - 0001-4966 (Print)
IS  - 0001-4966 (Linking)
VI  - 118
IP  - 3 Pt 1
DP  - 2005 Sep
TI  - Effects of aspirin on distortion product otoacoustic emission suppression in 
      human adults: a comparison with neonatal data.
PG  - 1566-75
AB  - One of the distortion product otoacoustic emission (DPOAE) paradigms used to 
      study cochlear function is DPOAE (2f1-f2) ipsilateral suppression. Newborns do 
      not have adultlike DPOAE suppression. At 6000 Hz, infants show excessively narrow 
      DPOAE suppression tuning and shallow growth of suppression for low-frequency 
      suppressor tones. The source of this immaturity is not known but the outer hair 
      cell (OHC) is one possible locus. In the present study, DPOAE suppression was 
      measured at f2 = 1500 and 6000 Hz from two groups with impaired OHC function in 
      an attempt to model the observed immaturity in neonates: adults with 
      aspirin-induced OHC dysfunction and subjects with sensorineural hearing loss 
      (SNHL). Their DPOAE suppression results were compared to those obtained from a 
      group of term newborns to address whether infant DPOAE suppression resembles 
      suppression from individuals with known OHC dysfunction. Results indicate that 
      aspirin systematically alters DPOAE suppression in adults at f2 = 6000 Hz, but 
      not 1500 Hz. However, neither aspirin-induced OHC dysfunction nor naturally 
      occurring SNHL produces "neonatal-like" DPOAE suppression at either test 
      frequency. This finding does not support the hypothesis that non-adultlike DPOAE 
      suppression characterizing newborns can be explained by minor impairments or 
      alterations of OHC function.
FAU - Abdala, Carolina
AU  - Abdala C
AD  - House Ear Institute, 2100 West Third Street, Children's Auditory Research and 
      Evaluation Center, Los Angeles, California 90057, USA. CAbdala@hei.org
LA  - eng
GR  - R01 DC003552-6/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Acoust Soc Am
JT  - The Journal of the Acoustical Society of America
JID - 7503051
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acoustic Stimulation
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Case-Control Studies
MH  - Child
MH  - Cochlea/drug effects/*physiology
MH  - Female
MH  - Hearing Loss, Sensorineural/chemically induced/*physiopathology
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Multivariate Analysis
MH  - Otoacoustic Emissions, Spontaneous/*drug effects
EDAT- 2005/10/26 09:00
MHDA- 2006/06/02 09:00
CRDT- 2005/10/26 09:00
PHST- 2005/10/26 09:00 [pubmed]
PHST- 2006/06/02 09:00 [medline]
PHST- 2005/10/26 09:00 [entrez]
AID - 10.1121/1.1985043 [doi]
PST - ppublish
SO  - J Acoust Soc Am. 2005 Sep;118(3 Pt 1):1566-75. doi: 10.1121/1.1985043.

PMID- 21703110
OWN - NLM
STAT- MEDLINE
DCOM- 20110726
LR  - 20181201
IS  - 1479-1072 (Print)
IS  - 1479-1064 (Linking)
VI  - 19
IP  - 1
DP  - 2011
TI  - The prevalence of co-administration of clopidogrel and proton pump inhibitors.
PG  - 35-42
AB  - BACKGROUND: Recent studies have suggested that proton pump inhibitors (PPIs) may 
      inhibit the antiplatelet activity of clopidogrel, increasing the risk of major 
      cardiovascular events in patients taking clopidogrel and PPIs together. AIM: The 
      primary aim of this study was to determine the prevalence of co-prescription of 
      clopidogrel and PPIs amongst residents of aged-care facilities in New South 
      Wales, Australia. METHODS: One-year prescription records of 791 aged-care 
      residents were analysed for prevalence of co-prescribing of clopidogrel and PPIs, 
      and aspirin with clopidogrel and PPIs. Prevalence of co-prescribing of 
      clopidogrel, aspirin and PPI in diabetic patients and clopidogrel with various 
      CYP2C19 inhibitors was also examined. RESULTS: Of the 791 residents studied, 60 
      were prescribed clopidogrel, 248 were on aspirin and 326 were prescribed a PPI. 
      Among residents who were prescribed PPIs, 155 were prescribed omeprazole, 72 
      pantoprazole, 15 lansoprazole, 44 esomeprazole and 51 rabeprazole. Eleven of 
      these residents had taken more than one PPI during the study period. Thirty-nine 
      residents took a combination of clopidogrel and a PPI (any PPI) for a mean 203 
      days (SD 12). Thirteen residents were on the combination of aspirin and 
      clopidogrel for a mean of 202 days (SD 111). Nine residents took the combination 
      of clopidogrel, aspirin and a PPI (any PPI) for a mean of 173 days (SD 81). Only 
      one patient on clopidogrel was receiving a CYP2C19 inhibitor in addition to a 
      PPI. CONCLUSIONS: A significant number of residents in this cohort were taking a 
      combination of clopidogrel and a PPI, mainly omeprazole. Residents who were on 
      the combination of clopidogrel and a PPI, with or without aspirin, were on these 
      combinations for a significantly long duration, which could increase their risk 
      of adverse cardiovascular events.
FAU - Shrestha, Kajal
AU  - Shrestha K
AD  - School of Pharmacy, Curtin University of Technology and Curtin Health Innovation 
      and Research Institute, Perth, Australia.
FAU - Hughes, Jeffery David
AU  - Hughes JD
FAU - Lee, Ya Ping
AU  - Lee YP
FAU - Parsons, Richard
AU  - Parsons R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Qual Prim Care
JT  - Quality in primary care
JID - 101182136
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*etiology/prevention & control
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Drug Therapy, Combination/statistics & numerical data
MH  - Drug Utilization Review
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Humans
MH  - Male
MH  - New South Wales
MH  - Nursing Homes/statistics & numerical data
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/therapeutic use
MH  - Proton Pump Inhibitors/*administration & dosage/adverse effects/therapeutic use
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
EDAT- 2011/06/28 06:00
MHDA- 2011/07/27 06:00
CRDT- 2011/06/28 06:00
PHST- 2011/06/28 06:00 [entrez]
PHST- 2011/06/28 06:00 [pubmed]
PHST- 2011/07/27 06:00 [medline]
PST - ppublish
SO  - Qual Prim Care. 2011;19(1):35-42.

PMID- 14675084
OWN - NLM
STAT- MEDLINE
DCOM- 20040220
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 1
IP  - 12
DP  - 2003 Dec
TI  - Heterologous cell-cell interactions: thromboregulation, cerebroprotection and 
      cardioprotection by CD39 (NTPDase-1).
PG  - 2497-509
AB  - Blood platelets maintain vascular integrity and promote primary and secondary 
      hemostasis following interruption of vessel continuity. Biochemical or physical 
      damage to the coronary, carotid or peripheral arteries is followed by excessive 
      platelet activation and recruitment culminating in vascular occlusion and tissue 
      ischemia. Currently inadequate therapeutic approaches to stroke and coronary 
      artery disease are a public health issue. Following our demonstration of 
      neutrophil leukotriene production from arachidonate released from activated 
      aspirin-treated platelets, we studied interactions between platelets and other 
      blood cells, leading to concepts of transcellular metabolism and 
      thromboregulation. Thrombosis has a proinflammatory component whereby 
      biologically active substances are synthesized by interactions between different 
      cell types that could not individually synthesize the product(s). Endothelial 
      cells control platelet reactivity via three biochemical systems-autacoids leading 
      to production of prostacyclin and nitric oxide, and endothelial 
      ecto-ADPase/CD39/NTPDase-1. The autacoids are fluid-phase reactants, not produced 
      by tissues in the basal state. They are only synthesized intracellularly and 
      released upon interactions of cells with an agonist. When released, autacoids 
      exert fleeting actions in the immediate milieu, and are rapidly inactivated. CD39 
      is an integral component of the endothelial cell surface and is 
      substrate-activated. It maintains vascular fluidity in the complete absence of 
      prostacyclin and nitric oxide, indicating that they are ancillary components of 
      hemostasis. Therapeutic implications for the autacoids have not been compelling 
      because of their transient, local and fleeting action, and limited potency. 
      Conversely, CD39, acting solely on the platelet releasate, is efficacious in 
      three different animal models. It metabolically neutralizes a prothrombotic 
      platelet releasate via deletion of ADP--the major recruiting agent responsible 
      for formation of an occlusive thrombus. In addition, solCD39 reduced ATP- and 
      ischemia-induced norepinephrine release in the heart. This reduction can prevent 
      fatal arrhythmia. Moreover, solCD39 ameliorated the sequelae of stroke in CD39 
      null mice. CD39 represents the next generation of cardioprotective and 
      cerebroprotective molecules.
FAU - Marcus, A J
AU  - Marcus AJ
AD  - Department of Medicine, Weill Medical College of Cornell University, and Medical 
      Service/Hematology-Oncology, VA New York Harbor Healthcare System, New York, NY 
      10010, USA. ajmarcus@med.cornell.edu
FAU - Broekman, M J
AU  - Broekman MJ
FAU - Drosopoulos, J H F
AU  - Drosopoulos JH
FAU - Islam, N
AU  - Islam N
FAU - Pinsky, D J
AU  - Pinsky DJ
FAU - Sesti, C
AU  - Sesti C
FAU - Levi, R
AU  - Levi R
LA  - eng
GR  - HL 46403/HL/NHLBI NIH HHS/United States
GR  - HL 47073/HL/NHLBI NIH HHS/United States
GR  - HL34215/HL/NHLBI NIH HHS/United States
GR  - HL59488/HL/NHLBI NIH HHS/United States
GR  - HL69448/HL/NHLBI NIH HHS/United States
GR  - NS 41462/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Antigens, CD)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - EC 3.6.1.- (Adenosine Triphosphatases)
RN  - EC 3.6.1.5 (Apyrase)
RN  - EC 3.6.1.5 (CD39 antigen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - J Thromb Haemost. 2004 Apr;2(4):682
MH  - Adenosine Diphosphate/metabolism
MH  - Adenosine Triphosphatases/genetics/metabolism/*physiology
MH  - Animals
MH  - Antigens, CD/genetics/metabolism/*physiology
MH  - Apyrase
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cell Communication/drug effects/*physiology
MH  - Endothelial Cells/enzymology/metabolism
MH  - Hemostasis
MH  - Humans
MH  - Thrombosis/blood/drug therapy
RF  - 59
EDAT- 2003/12/17 05:00
MHDA- 2004/02/21 05:00
CRDT- 2003/12/17 05:00
PHST- 2003/12/17 05:00 [pubmed]
PHST- 2004/02/21 05:00 [medline]
PHST- 2003/12/17 05:00 [entrez]
AID - S1538-7836(22)15644-8 [pii]
AID - 10.1111/j.1538-7836.2003.00479.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2003 Dec;1(12):2497-509. doi: 10.1111/j.1538-7836.2003.00479.x.

PMID- 19482214
OWN - NLM
STAT- MEDLINE
DCOM- 20090612
LR  - 20220410
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 373
IP  - 9678
DP  - 2009 May 30
TI  - Aspirin in the primary and secondary prevention of vascular disease: 
      collaborative meta-analysis of individual participant data from randomised 
      trials.
PG  - 1849-60
LID - 10.1016/S0140-6736(09)60503-1 [doi]
AB  - BACKGROUND: Low-dose aspirin is of definite and substantial net benefit for many 
      people who already have occlusive vascular disease. We have assessed the benefits 
      and risks in primary prevention. METHODS: We undertook meta-analyses of serious 
      vascular events (myocardial infarction, stroke, or vascular death) and major 
      bleeds in six primary prevention trials (95,000 individuals at low average risk, 
      660,000 person-years, 3554 serious vascular events) and 16 secondary prevention 
      trials (17,000 individuals at high average risk, 43,000 person-years, 3306 
      serious vascular events) that compared long-term aspirin versus control. We 
      report intention-to-treat analyses of first events during the scheduled treatment 
      period. FINDINGS: In the primary prevention trials, aspirin allocation yielded a 
      12% proportional reduction in serious vascular events (0.51% aspirin vs 0.57% 
      control per year, p=0.0001), due mainly to a reduction of about a fifth in 
      non-fatal myocardial infarction (0.18%vs 0.23% per year, p<0.0001). The net 
      effect on stroke was not significant (0.20%vs 0.21% per year, p=0.4: haemorrhagic 
      stroke 0.04%vs 0.03%, p=0.05; other stroke 0.16%vs 0.18% per year, p=0.08). 
      Vascular mortality did not differ significantly (0.19%vs 0.19% per year, p=0.7). 
      Aspirin allocation increased major gastrointestinal and extracranial bleeds 
      (0.10%vs 0.07% per year, p<0.0001), and the main risk factors for coronary 
      disease were also risk factors for bleeding. In the secondary prevention trials, 
      aspirin allocation yielded a greater absolute reduction in serious vascular 
      events (6.7%vs 8.2% per year, p<0.0001), with a non-significant increase in 
      haemorrhagic stroke but reductions of about a fifth in total stroke (2.08%vs 
      2.54% per year, p=0.002) and in coronary events (4.3%vs 5.3% per year, p<0.0001). 
      In both primary and secondary prevention trials, the proportional reductions in 
      the aggregate of all serious vascular events seemed similar for men and women. 
      INTERPRETATION: In primary prevention without previous disease, aspirin is of 
      uncertain net value as the reduction in occlusive events needs to be weighed 
      against any increase in major bleeds. Further trials are in progress. FUNDING: UK 
      Medical Research Council, British Heart Foundation, Cancer Research UK, and the 
      European Community Biomed Programme.
CN  - Antithrombotic Trialists' (ATT) Collaboration
AD  - CTSU, Oxford University, Oxford, UK. colin.baigent@ctsu.ox.ac.uk
FAU - Baigent, Colin
AU  - Baigent C
FAU - Blackwell, Lisa
AU  - Blackwell L
FAU - Collins, Rory
AU  - Collins R
FAU - Emberson, Jonathan
AU  - Emberson J
FAU - Godwin, Jon
AU  - Godwin J
FAU - Peto, Richard
AU  - Peto R
FAU - Buring, Julie
AU  - Buring J
FAU - Hennekens, Charles
AU  - Hennekens C
FAU - Kearney, Patricia
AU  - Kearney P
FAU - Meade, Tom
AU  - Meade T
FAU - Patrono, Carlo
AU  - Patrono C
FAU - Roncaglioni, Maria Carla
AU  - Roncaglioni MC
FAU - Zanchetti, Alberto
AU  - Zanchetti A
LA  - eng
GR  - G9534799/MRC_/Medical Research Council/United Kingdom
GR  - BHF_/British Heart Foundation/United Kingdom
GR  - MC_U137686861/MRC_/Medical Research Council/United Kingdom
GR  - G0701113/MRC_/Medical Research Council/United Kingdom
GR  - MC_U137686849/MRC_/Medical Research Council/United Kingdom
GR  - CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2009 May 30;373(9678):1821-2. PMID: 19482200
CIN - Lancet. 2009 Sep 12;374(9693):877-8; author reply 879. PMID: 19748390
CIN - Lancet. 2009 Sep 12;374(9693):877; author reply 879. PMID: 19748391
CIN - Lancet. 2009 Sep 12;374(9693):878; author reply 879. PMID: 19748392
CIN - Lancet. 2009 Sep 12;374(9693):878-9; author reply 879. PMID: 19748393
CIN - Ann Intern Med. 2009 Sep 15;151(6):JC3-4, JC3-5. PMID: 19755350
CIN - Evid Based Med. 2009 Dec;14(6):172-3. PMID: 19949174
CIN - Br J Gen Pract. 2019 Nov 28;69(689):590-591. PMID: 31780468
MH  - Aspirin/adverse effects/*therapeutic use
MH  - *Cardiovascular Diseases/drug therapy/mortality/prevention & control
MH  - Cause of Death
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Patient Selection
MH  - Practice Guidelines as Topic
MH  - Primary Prevention/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Risk Assessment
MH  - Risk Factors
MH  - Risk Reduction Behavior
MH  - Secondary Prevention/*methods
MH  - Sex Distribution
MH  - Treatment Outcome
PMC - PMC2715005
FIR - Collins, Rory
IR  - Collins R
FIR - Peto, Richard
IR  - Peto R
FIR - Hennekens, Charles
IR  - Hennekens C
FIR - Doll, Richard
IR  - Doll R
FIR - Bubes, Vadim
IR  - Bubes V
FIR - Buring, Julie
IR  - Buring J
FIR - Dushkesas, Rimma
IR  - Dushkesas R
FIR - Gaziano, Michael
IR  - Gaziano M
FIR - Hennekens, Charles
IR  - Hennekens C
FIR - Brennan, Patrick
IR  - Brennan P
FIR - Meade, Tom
IR  - Meade T
FIR - Rudnicka, Alicja
IR  - Rudnicka A
FIR - Hansson, Lennart
IR  - Hansson L
FIR - Warnold, Ingrid
IR  - Warnold I
FIR - Zanchetti, Alberto
IR  - Zanchetti A
FIR - Avanzini, Fausto
IR  - Avanzini F
FIR - Roncaglioni, Maria Carla
IR  - Roncaglioni MC
FIR - Tognoni, Gianni
IR  - Tognoni G
FIR - Buring, Julie
IR  - Buring J
FIR - Chown, Marilyn
IR  - Chown M
FIR - Gaziano, Michael
IR  - Gaziano M
FIR - Hennekens, Charles
IR  - Hennekens C
FIR - Baigent, Colin
IR  - Baigent C
FIR - Barton, Ian
IR  - Barton I
FIR - Baxter, Alex
IR  - Baxter A
FIR - Bhala, Neeraj
IR  - Bhala N
FIR - Blackwell, Lisa
IR  - Blackwell L
FIR - Boreham, Jill
IR  - Boreham J
FIR - Bowman, Louise
IR  - Bowman L
FIR - Buck, Georgina
IR  - Buck G
FIR - Collins, Rory
IR  - Collins R
FIR - Emberson, Jonathan
IR  - Emberson J
FIR - Godwin, Jon
IR  - Godwin J
FIR - Halls, Heather
IR  - Halls H
FIR - Holland, Lisa
IR  - Holland L
FIR - Kearney, Patricia
IR  - Kearney P
FIR - Peto, Richard
IR  - Peto R
FIR - Reith, Christina
IR  - Reith C
FIR - Wilson, Kate
IR  - Wilson K
EDAT- 2009/06/02 09:00
MHDA- 2009/06/13 09:00
CRDT- 2009/06/02 09:00
PHST- 2009/06/02 09:00 [entrez]
PHST- 2009/06/02 09:00 [pubmed]
PHST- 2009/06/13 09:00 [medline]
AID - S0140-6736(09)60503-1 [pii]
AID - LANCET60503 [pii]
AID - 10.1016/S0140-6736(09)60503-1 [doi]
PST - ppublish
SO  - Lancet. 2009 May 30;373(9678):1849-60. doi: 10.1016/S0140-6736(09)60503-1.

PMID- 6021671
OWN - NLM
STAT- MEDLINE
DCOM- 19670531
LR  - 20181113
IS  - 0035-9157 (Print)
IS  - 0035-9157 (Linking)
VI  - 60
IP  - 4
DP  - 1967 Apr
TI  - Experimental pain in general practice.
PG  - 415-7
AB  - Dr Robert Smith discusses the relationship between pain and emotional disturbance 
      and describes experiments which he has undertaken in general practice, using a 
      pressure algometer. Amongst other findings, he shows that aspirin did not relieve 
      pressure pain but did delay or even suppress the onset of ultraviolet light 
      burns.Dr K D Keele describes experiments to define individual pain thresholds and 
      correlates these with the pain of cardiac infarction, and the morphine 
      requirements in that condition.Professor C A Keele considers the chemistry of 
      pain production and describes his technique for applying chemical algogens to 
      experimentally induced blisters. He further considers the similarity between such 
      substances and those contained in animal and plant venoms and speculates as to an 
      even closer relationship between these and painful medical conditions.
FAU - Smith, R
AU  - Smith R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Proc R Soc Med
JT  - Proceedings of the Royal Society of Medicine
JID - 7505890
RN  - 76I7G6D29C (Morphine)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Morphine/pharmacology
MH  - Pain/*chemically induced
MH  - *Pain Management
MH  - Physician-Patient Relations
MH  - Potassium/pharmacology
MH  - *Psychosomatic Medicine
PMC - PMC1901725
EDAT- 1967/04/01 00:00
MHDA- 1967/04/01 00:01
CRDT- 1967/04/01 00:00
PHST- 1967/04/01 00:00 [pubmed]
PHST- 1967/04/01 00:01 [medline]
PHST- 1967/04/01 00:00 [entrez]
PST - ppublish
SO  - Proc R Soc Med. 1967 Apr;60(4):415-7.

PMID- 4817161
OWN - NLM
STAT- MEDLINE
DCOM- 19740517
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 1
IP  - 5906
DP  - 1974 Mar 16
TI  - Aspirin and anaemia in childhood.
PG  - 491-2
AB  - Chronic aspirin ingestion in childhood is not uncommon, often goes undetected, 
      and may cause serious anaemia from occult blood loss. Five cases are described.
FAU - Heggarty, H
AU  - Heggarty H
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Hemoglobins)
RN  - E1UOL152H7 (Iron)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anemia/*chemically induced
MH  - Aspirin/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Infant
MH  - Iron/therapeutic use
MH  - Male
MH  - Occult Blood
MH  - Pallor
MH  - Public Opinion
MH  - Substance-Related Disorders
PMC - PMC1633516
EDAT- 1974/03/16 00:00
MHDA- 1974/03/16 00:01
CRDT- 1974/03/16 00:00
PHST- 1974/03/16 00:00 [pubmed]
PHST- 1974/03/16 00:01 [medline]
PHST- 1974/03/16 00:00 [entrez]
AID - 10.1136/bmj.1.5906.491 [doi]
PST - ppublish
SO  - Br Med J. 1974 Mar 16;1(5906):491-2. doi: 10.1136/bmj.1.5906.491.

PMID- 20446587
OWN - NLM
STAT- MEDLINE
DCOM- 20100527
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 5
DP  - 2010 May
TI  - [Investigation of the effects of low dose aspirin therapy on primary and 
      secondary prevention of cardiovascular disease].
PG  - 882-6
AB  - We examined the efficacy of low-dose aspirin for the primary prevention of 
      atherosclerotic events in patients with type 2 diabetes. Multicenter, 
      prospective, randomized, open -label, blinded end-point trial enrolled 2,539 
      patients with type 2 diabetes. A total of 154 atherosclerotic events occurred: 68 
      in the aspirin group and 86 in the nonaspirin group (log -rank test, p = 0.16). 
      The multicenter study was performed to find out whether aspirin or trapidil would 
      improve clinical outcome. The study was a multicenter, open-label, randomized 
      controlled trial of aspirin 81 mg/day, trapidil 300 mg/day, and no antiplatelets 
      in patients with acute myocardial infarction (AMI) admitted within 1 month from 
      the onset of symptoms. Long-term use of aspirin reduced the incidence of 
      recurrent AMI (p = 0.0045).
FAU - Soejima, Hirofumi
AU  - Soejima H
AD  - Health Care Center, Kumamoto University.
FAU - Ogawa, Hisao
AU  - Ogawa H
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EYG5Y6355E (Trapidil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Angiopathies/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Trapidil/therapeutic use
EDAT- 2010/05/08 06:00
MHDA- 2010/05/28 06:00
CRDT- 2010/05/08 06:00
PHST- 2010/05/08 06:00 [entrez]
PHST- 2010/05/08 06:00 [pubmed]
PHST- 2010/05/28 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 May;68(5):882-6.

PMID- 309931
OWN - NLM
STAT- MEDLINE
DCOM- 19790226
LR  - 20131121
IS  - 0022-3255 (Print)
IS  - 0022-3255 (Linking)
VI  - 36
IP  - 12
DP  - 1978 Dec
TI  - Clinical effects of aspirin and acetaminophen on hemostasis after exodontics.
PG  - 944-7
AB  - The effects of aspirin and acetaminophen on postextraction hemostasis were 
      evaluated in a double-blind study in a group of 43 patients; 20 received aspirin 
      and 23 received acetaminophen. No significant difference was found in the 
      observed postsurgical alveolus bleeding times or the patients' reported length of 
      postoperative bleeding. However, Ivy bleeding times taken after the ingestion of 
      80 grains of medication showed an elevation in 75% of the aspirin users and in 
      60% of the acetaminophen group; the mean change in bleeding times was 2.75 times 
      greater in the aspirin group.
FAU - Pawlak, D F
AU  - Pawlak DF
FAU - Itkin, A B
AU  - Itkin AB
FAU - Lapeyrolerie, F M
AU  - Lapeyrolerie FM
FAU - Zweig, B
AU  - Zweig B
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Oral Surg
JT  - Journal of oral surgery (American Dental Association : 1965)
JID - 8302454
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Blood Coagulation Tests
MH  - Blood Platelets/drug effects
MH  - Double-Blind Method
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Oral Hemorrhage/physiopathology
MH  - *Tooth Extraction
EDAT- 1978/12/01 00:00
MHDA- 1978/12/01 00:01
CRDT- 1978/12/01 00:00
PHST- 1978/12/01 00:00 [pubmed]
PHST- 1978/12/01 00:01 [medline]
PHST- 1978/12/01 00:00 [entrez]
PST - ppublish
SO  - J Oral Surg. 1978 Dec;36(12):944-7.

PMID- 25471265
OWN - NLM
STAT- MEDLINE
DCOM- 20150921
LR  - 20181202
IS  - 1364-5528 (Electronic)
IS  - 0003-2654 (Linking)
VI  - 140
IP  - 3
DP  - 2015 Feb 7
TI  - In situ investigation of supercritical CO2 assisted impregnation of drugs into a 
      polymer by high pressure FTIR micro-spectroscopy.
PG  - 869-79
LID - 10.1039/c4an01130a [doi]
AB  - An original experimental set-up combining a FTIR micro-spectrometer with a high 
      pressure cell has been built in order to analyze in situ the impregnation of a 
      solute into microscopic polymer samples, such as fibers or films, subjected to 
      supercritical CO2. Thanks to this experimental set-up, key factors governing the 
      impregnation process can be simultaneously followed such as the swelling of the 
      polymeric matrix, the CO2 sorption, the kinetics of impregnation and the drug 
      loading into the matrix. Moreover, the solute/polymer interactions and the 
      speciation of the solute can be analyzed. We have monitored in situ the 
      impregnation of aspirin and ketoprofen into PEO (Polyethylene Oxide) platelets at 
      T = 40 °C and P = 5; 10 and 15 MPa. The kinetics of impregnation of aspirin was 
      quicker than the one of ketoprofen and the final drug loading was also higher in 
      the case of aspirin. Whereas the CO2 sorption and the PEO swelling remain 
      constant when PEO is just subjected to CO2 under isobaric conditions, we noticed 
      that both parameters can increase while the drug impregnates PEO. Coupling these 
      results with DSC measurements, we underlined the plasticizing effect of the drug 
      that also leads to a decrease in the crystallinity of PEO in situ thus favoring 
      the sorption of CO2 molecules into the matrix and the swelling of the matrix. The 
      plasticizing effect increases with the drug loading. Finally, the speciation of 
      drugs was investigated considering the shift of the carboxyl bands of the drugs. 
      Both drugs were found to be mainly homogeneously dispersed into PEO.
FAU - Champeau, M
AU  - Champeau M
AD  - Institut des Sciences Moléculaires, UMR 5255 CNRS, Université de Bordeaux, 351 
      cours de la Libération, 33405 TALENCE Cedex, France. 
      t.tassaing@ism.u-bordeaux1.fr.
FAU - Thomassin, J-M
AU  - Thomassin JM
FAU - Jérôme, C
AU  - Jérôme C
FAU - Tassaing, T
AU  - Tassaing T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - 0 (Plasticizers)
RN  - 0 (Polymers)
RN  - 142M471B3J (Carbon Dioxide)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Calorimetry, Differential Scanning
MH  - Carbon Dioxide/*chemistry
MH  - Ketoprofen/*chemistry
MH  - Plasticizers/chemistry
MH  - Polyethylene Glycols/*chemistry
MH  - Polymers/*chemistry
MH  - Pressure
MH  - Spectroscopy, Fourier Transform Infrared/*methods
MH  - Thermodynamics
EDAT- 2014/12/05 06:00
MHDA- 2015/09/22 06:00
CRDT- 2014/12/05 06:00
PHST- 2014/12/05 06:00 [entrez]
PHST- 2014/12/05 06:00 [pubmed]
PHST- 2015/09/22 06:00 [medline]
AID - 10.1039/c4an01130a [doi]
PST - ppublish
SO  - Analyst. 2015 Feb 7;140(3):869-79. doi: 10.1039/c4an01130a.

PMID- 17288680
OWN - NLM
STAT- MEDLINE
DCOM- 20070315
LR  - 20151119
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 23
IP  - 2
DP  - 2007 Feb
TI  - ESPRIT study design and outcomes--a critical appraisal.
PG  - 271-3
AB  - Evidence is needed to guide therapeutic decisions on patients who had ischaemic 
      cerebral events. The recently published European/Australasian Stroke Prevention 
      in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled 
      study, compared long-term treatment of patients randomised to aspirin 30-325 mg 
      daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily. The 
      study found the combination to be superior to aspirin alone (13% vs. 16% events 
      in a composite endpoint of vascular death, non-fatal stroke, non-fatal myocardial 
      infarction, or major bleeding; hazard ratio 0.8; 95% confidence interval 
      0.66-0.98). In the interpretation of the results, criticism has been raised 
      related to the study design (open-label, change during the study), the study 
      conduct (half of the aspirin patients underdosed, 33% drop-out rate in the 
      combination group, missing information on potential confounders such as 
      protective concomitant medication), and the outcomes (lack of differences in the 
      efficacy outcomes between the intent-to-treat and the on-treatment populations, 
      lack of differences in minor bleedings between treatment groups, borderline 
      statistical significance of primary study endpoint). Further studies are needed 
      to determine the place of aspirin/dipyridamole combinations in the secondary 
      prevention of stroke.
FAU - Einhäupl, Karl
AU  - Einhäupl K
AD  - Department of Neurology, Medical School, Charité, Berlin, Germany. 
      karl.einhaeupl@charite.de
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Biomarkers)
RN  - 0 (Fibrinolytic Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Biomarkers
MH  - Brain Ischemia/epidemiology/prevention & control
MH  - Dipyridamole/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Myocardial Infarction/epidemiology/prevention & control
MH  - Patient Dropouts/statistics & numerical data
MH  - Prospective Studies
MH  - Research Design
MH  - Stroke/epidemiology/*prevention & control
MH  - Treatment Outcome
MH  - Vascular Diseases/mortality
EDAT- 2007/02/10 09:00
MHDA- 2007/03/16 09:00
CRDT- 2007/02/10 09:00
PHST- 2007/02/10 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2007/02/10 09:00 [entrez]
AID - 10.1185/030079906X167291 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2007 Feb;23(2):271-3. doi: 10.1185/030079906X167291.

PMID- 31233627
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201023
IS  - 1472-8206 (Electronic)
IS  - 0767-3981 (Linking)
VI  - 34
IP  - 1
DP  - 2020 Feb
TI  - Evaluation of antitumor effects of aspirin and LGK974 drugs on cellular signaling 
      pathways, cell cycle and apoptosis in colorectal cancer cell lines compared to 
      oxaliplatin drug.
PG  - 51-64
LID - 10.1111/fcp.12492 [doi]
AB  - Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies. 
      Despite recent advances in the treatment for CRC, resistance to chemotherapy 
      drugs and recurrence of the tumor are among the main problems for treatment in 
      this cancer. The MTT assay was performed to assess the cytotoxic effects of drugs 
      on CRC cell lines (SW742 and SW480) and normal colon cells. Three-dimensional 
      culture (spheroid) was also used to evaluate the effect of drugs on tumor cell 
      masses. The rate of expression of genes was also evaluated using Real-Time PCR. 
      The analysis of the results demonstrated that aspirin and LGK974 have cytotoxic 
      effects on CRC cell lines, and in the IC50 dose, they disintegrate the cancerous 
      cell masses. These drugs reduce the invasion and increase apoptosis in SW742 and 
      SW480 cell lines. A decrease in the expression of WNT, AXIN, TCF and APC genes 
      and an increase in the expression of β-catenin gene in the WNT signaling pathway 
      were revealed. The genes involved in the MAPK signaling pathway such as ERK, JNK, 
      KRAS and MEK showed a decrease in expression and a increase in expression of RAF 
      gene. In the apoptotic pathway, increased expression of BAX and decreased 
      expression of BCL-2 were reported. Also, decreased expression of P53, cyclin D1 
      and COX-2 was observed. This study demonstrates that aspirin and LGK974 could be 
      effective in inhibiting the signaling pathways of WNT and MAPK, arresting cell 
      cycle and inducing apoptosis in CRC cell lines.
CI  - © 2019 Société Française de Pharmacologie et de Thérapeutique.
FAU - Bagheri, Malihe
AU  - Bagheri M
AD  - Department of Biotechnology, School of Medicine, Arak University of Medical 
      Sciences, Arak, 38481-7-6941, Iran.
FAU - Tabatabae Far, Mohamad Amin
AU  - Tabatabae Far MA
AD  - Department of Genetics, School of Medicine, Isfahan University of Medical 
      Sciences, Isfahan, 8415683111, Iran.
FAU - Mirzaei, Hamed
AU  - Mirzaei H
AUID- ORCID: 0000-0002-9399-8281
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, 87159-88141, Iran.
FAU - Ghasemi, Faezeh
AU  - Ghasemi F
AUID- ORCID: 0000-0003-0647-6651
AD  - Molecular and Medicine Research Centre, Faculty of Medicine, Arak University of 
      Medical Sciences, Arak, 38481-7-6941, Iran.
AD  - Blood Transfusion Research Center, High Institute for Research and Education in 
      Transfusion Medicine, Next to Milad Tower, Tehran, 1497716316, Iran.
LA  - eng
GR  - 2826/Arak University of Medical Science/
PT  - Comparative Study
PT  - Journal Article
DEP - 20190716
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyrazines)
RN  - 0 (Pyridines)
RN  - 04ZR38536J (Oxaliplatin)
RN  - R16CO5Y76E (Aspirin)
RN  - U27F40013Q (LGK974)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Colorectal Neoplasms/*drug therapy/pathology
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - MAP Kinase Signaling System/drug effects
MH  - Oxaliplatin/*administration & dosage/pharmacology
MH  - Pyrazines/*administration & dosage/pharmacology
MH  - Pyridines/*administration & dosage/pharmacology
MH  - Wnt Signaling Pathway/drug effects
OTO - NOTNLM
OT  - LGK974
OT  - aspirin
OT  - colorectal cancer
EDAT- 2019/06/25 06:00
MHDA- 2020/10/24 06:00
CRDT- 2019/06/25 06:00
PHST- 2019/01/27 00:00 [received]
PHST- 2019/06/10 00:00 [revised]
PHST- 2019/06/19 00:00 [accepted]
PHST- 2019/06/25 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
PHST- 2019/06/25 06:00 [entrez]
AID - 10.1111/fcp.12492 [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2020 Feb;34(1):51-64. doi: 10.1111/fcp.12492. Epub 2019 
      Jul 16.

PMID- 10714217
OWN - NLM
STAT- MEDLINE
DCOM- 20000404
LR  - 20180227
IS  - 0070-4113 (Print)
IS  - 0070-4113 (Linking)
VI  - 83
DP  - 1999
TI  - [Aspirin suppresses microsatellite instability].
PG  - 240-6
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) exhibit cancer preventive effects 
      and have been shown to induce regression of adenomas in FAP patients. In order to 
      elucidate the probable underlying mechanism, the effect of NSAIDs on mismatch 
      repair related microsatellite instability was investigated. Six colorectal cancer 
      cell lines all but one deficient for human mismatch repair (MMR) genes were 
      examined for microsatellite instability (MSI) prior and after treatment with 
      Aspirin or Sulindac. For rapid in vitro analysis of MSI a microcloning assay was 
      developed by combining Laser microdissection and random (PEP-) PCR prior to 
      specific MSI-PCR. Effects of NSAIDs on cell cycle and apoptosis were 
      systematically investigated by using flow cytometry and cell-sorting. MSI 
      frequency in cells deficient of MMR genes (hMSH2, hMLH1, hMSH6) was markedly 
      reduced after long-term (> 10 weeks) NSAID treatment. This effect was reversible, 
      time- and concentration dependent. However, in the hPMS2 deficient endometrial 
      cancer cell line (HEC-1-A) the MSI phenotype kept unchanged. According to cell 
      sorting, non-apoptotic cells were stable and apoptotic cells were unstable. These 
      results suggest that aspirin/sulindac induces a genetic selection for 
      microsatellite stability in a subset of MMR-deficient cells and may thus provide 
      an effective prophylactic therapy for HNPCC related colorectal carcinomas.
FAU - Wallinger, S
AU  - Wallinger S
AD  - Institut für Pathologie, Universität Regensburg.
FAU - Dietmaier, W
AU  - Dietmaier W
FAU - Beyser, K
AU  - Beyser K
FAU - Bocker, T
AU  - Bocker T
FAU - Hofstädter, F
AU  - Hofstädter F
FAU - Fishel, R
AU  - Fishel R
FAU - Rüschoff, J
AU  - Rüschoff J
LA  - ger
GR  - R01 CA067007/CA/NCI NIH HHS/United States
PT  - English Abstract
PT  - Journal Article
TT  - Aspirin supprimiert Mikrosatelliten-Instabilität.
PL  - Germany
TA  - Verh Dtsch Ges Pathol
JT  - Verhandlungen der Deutschen Gesellschaft fur Pathologie
JID - 7503704
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*pharmacology
MH  - Base Pair Mismatch
MH  - Colorectal Neoplasms
MH  - Flow Cytometry
MH  - Humans
MH  - Microsatellite Repeats/*drug effects
MH  - Polymerase Chain Reaction
MH  - Tumor Cells, Cultured
EDAT- 2000/03/14 00:00
MHDA- 2000/03/14 00:01
CRDT- 2000/03/14 00:00
PHST- 2000/03/14 00:00 [pubmed]
PHST- 2000/03/14 00:01 [medline]
PHST- 2000/03/14 00:00 [entrez]
PST - ppublish
SO  - Verh Dtsch Ges Pathol. 1999;83:240-6.

PMID- 11200792
OWN - NLM
STAT- MEDLINE
DCOM- 20010322
LR  - 20161124
IS  - 0393-5264 (Print)
IS  - 0393-5264 (Linking)
VI  - 15 Suppl 3
DP  - 2000
TI  - The effectiveness of combined oral lysine acetylsalicylate and metoclopramide 
      (Migpriv) in the treatment of migraine attacks. Comparison with placebo and oral 
      sumatriptan.
PG  - 196-201
AB  - In two, double-blind, randomised, clinical, trials (RCTs), oral lysine 
      acetylsalicylate (1620 mg, equivalent to 900 mg aspirin) combined with 
      metoclopramide (10 mg) (LAS + MTC) was compared with placebo, and with oral 
      sumatriptan (100 mg) in one of these RCTs. In both RCTs the LAS + MTC combination 
      was superior to placebo with therapeutic gains (percentage relief after active 
      treatment minus percentage relief after placebo) of 30% and 31% for the first 
      treated attack. These therapeutic gains are in the same range as those found for 
      100 mg oral sumatriptan, and in the comparative RCT the LAS + MTC combination was 
      quite comparable to 100 mg sumatriptan, with success rates for the first attack 
      of 57% and 53%, respectively.
FAU - Tfelt-Hansen, P
AU  - Tfelt-Hansen P
AD  - Department of Neurology, Glostrup Hospital, University of Copenhagen, Glostrup, 
      DK-2600 Glostrup, Denmark.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Review
PL  - Italy
TA  - Funct Neurol
JT  - Functional neurology
JID - 8707746
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Drug Combinations)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 8R78F6L9VO (Sumatriptan)
RN  - K3Z4F929H6 (Lysine)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/*therapeutic use
MH  - Dopamine Antagonists/administration & dosage/*therapeutic use
MH  - Drug Combinations
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives/*therapeutic use
MH  - Metoclopramide/administration & dosage/*therapeutic use
MH  - Migraine Disorders/complications/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Serotonin Receptor Agonists/*therapeutic use
MH  - Sumatriptan/*therapeutic use
RF  - 19
EDAT- 2001/02/24 12:00
MHDA- 2001/03/27 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/03/27 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
PST - ppublish
SO  - Funct Neurol. 2000;15 Suppl 3:196-201.

PMID- 20424852
OWN - NLM
STAT- MEDLINE
DCOM- 20100830
LR  - 20211020
IS  - 1435-702X (Electronic)
IS  - 0721-832X (Linking)
VI  - 248
IP  - 8
DP  - 2010 Aug
TI  - Safety and feasibility of a novel intravitreal tamponade using a silicone 
      oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first 
      results of the Austrian Clinical Multicenter Study.
PG  - 1193-8
LID - 10.1007/s00417-010-1389-7 [doi]
AB  - BACKGROUND: The safety and efficacy of a new surgical method of intravitreal 
      tamponade using silicone oil suspended with aspirin (acetylsalicylic acid) was 
      investigated for the treatment of proliferative vitreoretinopathy. METHODS: The 
      study was designed as a prospective, randomized, controlled, double-blind 
      multicenter study. A total of 29 patients were included; 15 patients were treated 
      with the silicone oil suspended with aspirin, and 14 patients represented the 
      control group receiving only silicone oil. A standard three-port pars plana 
      vitrectomy was performed in 29 eyes of 29 patients. In cases in which the natural 
      lens was present, simultaneous phacoemulsification was required. The control 
      group received as standard therapy a vitreous tamponade with pure 5000 mPas 
      silicone oil and the treatment group received silicone oil containing 0.2 mg/ml 
      aspirin (AS SiO). At 6 months after surgery, the tamponade was removed from all 
      eyes. The main outcome measure was the incidence of retinal redetachment 
      requiring reoperation. Secondary outcome measures were visual acuity and 
      ophthalmic examination results. RESULTS: The rate of redetachment, defined as the 
      primary outcome parameter, was the same for both groups. The AS SiO was well 
      tolerated and remained clear during the 6-month study period. Clinical 
      examination revealed no signs of local or systemic adverse effects. The visual 
      acuities were well matched before inclusion in the study and there were no 
      significant differences during the follow-up period and in the final visual 
      outcome between the two groups. CONCLUSIONS: Aspirin delivery by intravitreal 
      silicone oil in the human eye is safe and also may provide a delivery vehicle for 
      other antiproliferative agents to the posterior pole.
FAU - Kralinger, Martina Theresa
AU  - Kralinger MT
AD  - Department of Ophthalmology, Innsbruck Medical University, Innsbruck, Austria. 
      martina.kralinger@i-med.ac.at
FAU - Stolba, Ulrike
AU  - Stolba U
FAU - Velikay, Michaela
AU  - Velikay M
FAU - Egger, Stefan
AU  - Egger S
FAU - Binder, Susanne
AU  - Binder S
FAU - Wedrich, Andreas
AU  - Wedrich A
FAU - Haas, Anton
AU  - Haas A
FAU - Parel, Jean-Marie
AU  - Parel JM
FAU - Kieselbach, Gerhard Franz
AU  - Kieselbach GF
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100428
PL  - Germany
TA  - Graefes Arch Clin Exp Ophthalmol
JT  - Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
      Graefes Archiv fur klinische und experimentelle Ophthalmologie
JID - 8205248
RN  - 0 (Drug Combinations)
RN  - 0 (Silicone Oils)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Austria
MH  - Double-Blind Method
MH  - Drainage
MH  - Drug Combinations
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phacoemulsification
MH  - Prognosis
MH  - Prospective Studies
MH  - Recurrence
MH  - Retinal Detachment/physiopathology/*surgery
MH  - Silicone Oils/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Visual Acuity/physiology
MH  - Vitrectomy
MH  - Vitreoretinopathy, Proliferative/physiopathology/*surgery
MH  - Young Adult
EDAT- 2010/04/29 06:00
MHDA- 2010/08/31 06:00
CRDT- 2010/04/29 06:00
PHST- 2010/01/22 00:00 [received]
PHST- 2010/04/02 00:00 [accepted]
PHST- 2010/03/22 00:00 [revised]
PHST- 2010/04/29 06:00 [entrez]
PHST- 2010/04/29 06:00 [pubmed]
PHST- 2010/08/31 06:00 [medline]
AID - 10.1007/s00417-010-1389-7 [doi]
PST - ppublish
SO  - Graefes Arch Clin Exp Ophthalmol. 2010 Aug;248(8):1193-8. doi: 
      10.1007/s00417-010-1389-7. Epub 2010 Apr 28.

PMID- 1987387
OWN - NLM
STAT- MEDLINE
DCOM- 19910220
LR  - 20131121
IS  - 0741-5214 (Print)
IS  - 0741-5214 (Linking)
VI  - 13
IP  - 1
DP  - 1991 Jan
TI  - Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial.
PG  - 150-61; discussion 161-2
AB  - To evaluate the influence of antiplatelet drugs on patency in femoropopliteal 
      vein bypasses, 48 vascular surgeons recruited 549 patients to a randomized 
      double-blind trial of aspirin (300 mg) + dipyridamole (150 mg) or placebo twice 
      daily starting 2 days before surgery and continuing indefinitely. Graft occlusion 
      measured objectively by independent coordinators and cardiovascular events 
      (myocardial infarction or stroke) were studied, expressed by life table, and 
      analyzed statistically by log rank and confidence intervals (95% CI). 
      Randomization achieved comparable groups with 60% of grafts inserted for rest 
      pain or gangrene. Operative complications on aspirin plus dipyridamole included 
      18 reoperations for bleeding and 12 hematomas compared with 9 and 14, 
      respectively, on placebo (NS). Most of the 172 graft failures occurred early with 
      failure rates of 43/1000 patient-months in the first 3 months, reducing to 
      17/1000 at 6 to 12 months, and under 10/1000 in subsequent years. Cumulative 
      graft patency on placebo was 72%, 62%, and 60% at 1, 2, and 3 years, 
      respectively, compared with 78%, 70%, and 61% on aspirin plus dipyridamole. The 
      difference in patency of 6.1% (95% CI, -3% to 15.5%) at 1 year and 8.0% (95% CI, 
      -5% to 21%) at 2 years failed to achieve significance (p = 0.43). On mean 
      follow-up of 34 months, 53 (132/1000 patient-years) cardiovascular events 
      (myocardial infarction or cerebrovascular accident) occurred in patients on 
      placebo compared with only 35 (73/1000) on aspirin plus dipyridamole, a 
      significant difference of 59/1000 (p = 0.004). Antiplatelet therapy had little 
      influence on femoropopliteal vein patency, but subsequent myocardial infarction 
      and stroke was reduced in these patients with peripheral vascular disease.
FAU - McCollum, C
AU  - McCollum C
AD  - Department of Surgery, University of Manchester, United Kingdom.
FAU - Alexander, C
AU  - Alexander C
FAU - Kenchington, G
AU  - Kenchington G
FAU - Franks, P J
AU  - Franks PJ
FAU - Greenhalgh, R
AU  - Greenhalgh R
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Dipyridamole/adverse effects/therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Femoral Artery/*surgery
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/epidemiology/mortality/prevention & control
MH  - Humans
MH  - Patient Compliance
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Popliteal Artery/*surgery
MH  - Postoperative Complications/epidemiology/mortality/prevention & control
MH  - Saphenous Vein/*transplantation
MH  - Vascular Patency/drug effects
EDAT- 1991/01/01 00:00
MHDA- 2001/09/06 10:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 2001/09/06 10:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 0741-5214(91)90022-M [pii]
PST - ppublish
SO  - J Vasc Surg. 1991 Jan;13(1):150-61; discussion 161-2.

PMID- 3698619
OWN - NLM
STAT- MEDLINE
DCOM- 19860606
LR  - 20190706
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 14
IP  - 5
DP  - 1986 May
TI  - Transient ischemic attacks at high altitude.
PG  - 517-8
AB  - The precise etiology of transient neurologic deficits at high altitude is 
      unclear, particularly since the subjects are not investigated as they would be 
      had the events occurred in an urban environment. This report describes two 
      subjects who experienced transient ischemic attacks (TIAs) while ascending the 
      northeast ridge route of Mt. Everest during the Ultima Thule Everest Expedition, 
      and a third subject with TIAs during three separate high-altitude climbs. 
      Possible etiologies and treatment for TIAs at high altitude are suggested.
FAU - Wohns, R N
AU  - Wohns RN
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Altitude Sickness/*complications
MH  - Aspirin/therapeutic use
MH  - Fluid Therapy
MH  - Humans
MH  - Hypoxia/*complications
MH  - Ischemic Attack, Transient/*etiology/therapy
MH  - Male
MH  - Middle Aged
MH  - Mountaineering
MH  - Recurrence
EDAT- 1986/05/01 00:00
MHDA- 1986/05/01 00:01
CRDT- 1986/05/01 00:00
PHST- 1986/05/01 00:00 [pubmed]
PHST- 1986/05/01 00:01 [medline]
PHST- 1986/05/01 00:00 [entrez]
AID - 10.1097/00003246-198605000-00020 [doi]
PST - ppublish
SO  - Crit Care Med. 1986 May;14(5):517-8. doi: 10.1097/00003246-198605000-00020.

PMID- 6732270
OWN - NLM
STAT- MEDLINE
DCOM- 19840709
LR  - 20190501
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Print)
IS  - 0003-9888 (Linking)
VI  - 59
IP  - 5
DP  - 1984 May
TI  - Treatment choice in acute rheumatic carditis.
PG  - 410-3
AB  - A trial was conducted using sequential analysis by pairs to compare the efficacy 
      of corticosteroids and salicylates in the treatment of acute rheumatic carditis. 
      The results show a significantly favourable effect of steroid treatment both in 
      clinical response and in reduction of the erythrocyte sedimentation rate. In 
      addition, patients receiving steroids usually had a shorter hospital stay. The 
      use of steroids in acute rheumatic fever with carditis is recommended.
FAU - Human, D G
AU  - Human DG
FAU - Hill, I D
AU  - Hill ID
FAU - Fraser, C B
AU  - Fraser CB
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/*therapeutic use
MH  - Blood Sedimentation
MH  - Child
MH  - Humans
MH  - Length of Stay
MH  - Myocarditis/*drug therapy
MH  - Prednisone/*therapeutic use
MH  - Rheumatic Heart Disease/*drug therapy
PMC - PMC1628489
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
AID - 10.1136/adc.59.5.410 [doi]
PST - ppublish
SO  - Arch Dis Child. 1984 May;59(5):410-3. doi: 10.1136/adc.59.5.410.

PMID- 967765
OWN - NLM
STAT- MEDLINE
DCOM- 19761121
LR  - 20190501
IS  - 0032-5473 (Print)
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 52
IP  - 609
DP  - 1976 Jul
TI  - Primary and secondary prevention trials in coronary heart disease.
PG  - 464-9
AB  - Trials in primary and secondary prevention of coronary heart disease (CHD) are 
      reviewed. The results of completed primary prevention trials suggest that dietary 
      changes in middle-aged men may lower the incidence of CHD. Multifactorial trials 
      may achieve an even greater reduction in CHD. Secondary prevention trials 
      indicate that stopping smoking and the use of beta-blocking agents are effective 
      in reducing recurrence rates.
FAU - Shaper, A G
AU  - Shaper AG
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Coronary Disease/mortality/*prevention & control
MH  - Diet
MH  - Diet, Atherogenic
MH  - Evaluation Studies as Topic
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - United Kingdom
MH  - United States
PMC - PMC2496410
EDAT- 1976/07/01 00:00
MHDA- 1976/07/01 00:01
CRDT- 1976/07/01 00:00
PHST- 1976/07/01 00:00 [pubmed]
PHST- 1976/07/01 00:01 [medline]
PHST- 1976/07/01 00:00 [entrez]
AID - 10.1136/pgmj.52.609.464 [doi]
PST - ppublish
SO  - Postgrad Med J. 1976 Jul;52(609):464-9. doi: 10.1136/pgmj.52.609.464.

PMID- 19167894
OWN - NLM
STAT- MEDLINE
DCOM- 20090916
LR  - 20131121
IS  - 1464-3391 (Electronic)
IS  - 0968-0896 (Linking)
VI  - 17
IP  - 4
DP  - 2009 Feb 15
TI  - Importance of surface properties of affinity resin for capturing a target 
      protein, cyclooxygenase-1.
PG  - 1587-99
LID - 10.1016/j.bmc.2008.12.066 [doi]
AB  - We have prepared affinity resins based on two kinds of solid phases, including a 
      commercially available solid phase, to re-realize the importance of surface 
      properties of affinity resins such as controlled ligand density as well as 
      existential surroundings of the ligand. Affinity resins were prepared using 
      non-steroidal anti-inflammatory drugs, such as Ketoprofen, Ibuprofen, and 
      Aspirin, having different activities as ligands. The ligand density was 
      controlled through two different strategies: one strategy was that the solid 
      phases having different amino group densities (20, 60, 100, 125 micromol/ml) were 
      utilized then, Ketoprofen was fully immobilized through condensation reaction to 
      amino groups; another strategy was that a solid phase having amino group density 
      (125 micromol/ml) was utilized then, each ligand was immobilized with controlled 
      immobilization rate. In addition, a typical hydrophobic group, stearoyl group 
      (C(18) group), was immobilized on the affinity resin with controlled ligand 
      immobilization rate to change the existential surroundings of the ligand. 
      Affinity tests were performed for Cyclooxgenase-1 (COX-1) as it was the target 
      protein in this work. The amount of captured COX-1 was evaluated utilizing each 
      affinity resin. It was suggested that the density of surface ligand tends to 
      relate to the amount of captured COX-1 on our solid phase-based affinity resins; 
      however, several exceptions occurred according to the surface properties of 
      affinity resins in the case of commercial one.
FAU - Mori, Tomoko
AU  - Mori T
AD  - Graduate School of Environmental Studies, Tohoku University, Aramaki, Sendai, 
      Japan.
FAU - Kubo, Takuya
AU  - Kubo T
FAU - Kaya, Kunimitsu
AU  - Kaya K
FAU - Hosoya, Ken
AU  - Hosoya K
LA  - eng
PT  - Journal Article
DEP - 20090106
PL  - England
TA  - Bioorg Med Chem
JT  - Bioorganic & medicinal chemistry
JID - 9413298
RN  - 0 (Ligands)
RN  - 0 (Proteins)
RN  - 0 (Resins, Synthetic)
RN  - 90Y4QC304K (Ketoprofen)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry
MH  - Chromatography, Affinity
MH  - Cyclooxygenase 1/*chemistry
MH  - Ibuprofen/chemistry
MH  - Ketoprofen/chemistry
MH  - Ligands
MH  - Protein Binding
MH  - Proteins/*chemistry
MH  - Rats
MH  - Resins, Synthetic/*chemistry
MH  - Surface Properties
EDAT- 2009/01/27 09:00
MHDA- 2009/09/17 06:00
CRDT- 2009/01/27 09:00
PHST- 2008/11/25 00:00 [received]
PHST- 2008/12/29 00:00 [revised]
PHST- 2008/12/30 00:00 [accepted]
PHST- 2009/01/27 09:00 [entrez]
PHST- 2009/01/27 09:00 [pubmed]
PHST- 2009/09/17 06:00 [medline]
AID - S0968-0896(08)01241-8 [pii]
AID - 10.1016/j.bmc.2008.12.066 [doi]
PST - ppublish
SO  - Bioorg Med Chem. 2009 Feb 15;17(4):1587-99. doi: 10.1016/j.bmc.2008.12.066. Epub 
      2009 Jan 6.

PMID- 1496851
OWN - NLM
STAT- MEDLINE
DCOM- 19920910
LR  - 20131121
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 81
IP  - 6
DP  - 1992 Jun
TI  - [Prostacyclin in hypertension].
PG  - 303-9
AB  - Prostacyclin (PGI2) is known to cause vasorelaxation and inhibit platelet 
      aggregation by receptor-mediated mechanisms. While cyclic (c) AMP is known to act 
      as a second messenger for inhibition of platelet aggregation, vasorelaxation by 
      hyperpolarization has been described only recently and may provide an 
      explanation, in addition to stimulation of cAMP for the PGI2 mechanism of action 
      on blood vessels. When PGI2 is infused into healthy volunteers it reduces blood 
      pressure only at infusion rates that also cause significant side-effects, 
      primarily, nausea, emesis, flushing, diaphoresis, and restlessness. In 
      hypertensive patients blood-pressure responses are complex and are influenced to 
      some extent by renin secretion. PGI2 stimulates renin secretion by a direct 
      effect on the juxtaglomerular apparatus, and it also has an indirect effect by 
      activating the sympathetic nervous system. Thus, it is useless as an 
      antihypertensive agent even apart from its debilitating side-effects. Vascular 
      PGI2 is synthesized endogenously by both the endothelial cells and the muscularis 
      of arteries. While the endothelial cells undoubtedly synthesize large amounts of 
      PGI2, the muscularis comprises a much larger tissue mass so that the overall 
      synthesis is about equally distributed between the endothelial and muscle cells. 
      In patients with pregnancy-induced hypertension and some patients with essential 
      hypertension endogenous synthesis of PGI2 has been evaluated by measuring 
      2,3-dinor-6-keto-PGF1 alpha and has proved to be greatly reduced. Some drugs 
      (thiazides, propranolol) have been shown to stimulate PGI2 synthesis, and 
      inhibition of cyclooxygenase has been shown to reduce their antihypertensive 
      effects. The effects of low- and high-dose aspirin on prostacyclin and 
      thromboxane synthesis are discussed.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Frölich, J C
AU  - Frölich JC
AD  - Abt. Klinische Pharmakologie, Medizinische Hochschule Hannover.
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Prostazyklin bei Hypertonie.
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Epoprostenol/*physiology
MH  - Humans
MH  - Hypertension/drug therapy/*physiopathology
MH  - Vascular Resistance/drug effects/physiology
MH  - Vasodilation/drug effects/physiology
RF  - 71
EDAT- 1992/06/01 00:00
MHDA- 1992/06/01 00:01
CRDT- 1992/06/01 00:00
PHST- 1992/06/01 00:00 [pubmed]
PHST- 1992/06/01 00:01 [medline]
PHST- 1992/06/01 00:00 [entrez]
PST - ppublish
SO  - Z Kardiol. 1992 Jun;81(6):303-9.

PMID- 16821537
OWN - NLM
STAT- MEDLINE
DCOM- 20060913
LR  - 20161124
IS  - 0030-6657 (Print)
IS  - 0030-6657 (Linking)
VI  - 60
IP  - 1
DP  - 2006
TI  - [Nasal provocation test with lysine-aspirin in diagnosis of nonallergic rhinitis 
      with eosinophilia].
PG  - 25-31
AB  - Nonallergic rhinitis with eosinophilia is characterized by persistent nasal 
      symptoms without allergy and by a marked eosinophil recruitment in the nasal 
      cavities. The incidence of it is more than 15% among all types of rhinitis. A 
      part of them is caused by nonsteroidal anti-inflammatory drugs hypersensivity. 
      For this study 114 patients were selected on the basis of perennial rhinitis, the 
      absence of allergy and with an eosinophil count higher than 10% of total 
      leukocytes in nasal cytology. In all of them the nasal provocation test with 
      lysine-aspirin was made. The clinical response was evaluated based on nasal 
      symptoms (sneezes, itching, secretion and blockage). The nasal response was 
      measured by acoustic rhinometry. The results of the test was positive in 19 
      cases, mostly in patients with nasal polyps, bronchial asthma and higher level of 
      nasal eosinophilia (differences statistically significant). The count of nasal 
      eosinophilia corresponded better with the decrease of nasal volume in acoustic 
      rhinometry (r = 0,84) then with the clinical score (r = 0,52). The nasal 
      challenge was well tolerated by almost all subjects. We conclude that the nasal 
      challenge with lysine-aspirin is safe and can be helpful as a diagnostic test in 
      patients with nonallergic rhinitis with eosinophilia.
FAU - Modrzyński, Marek
AU  - Modrzyński M
AD  - Poradnia Alergologiczna NZOZ Euromedica w Grudziadzu. euromedica@lekarz.net
FAU - Mazurek, Henryk
AU  - Mazurek H
FAU - Zawisza, Edward
AU  - Zawisza E
LA  - pol
PT  - Clinical Trial
PT  - Journal Article
TT  - Ocena przydatności testu donosowej prowokacji z aspiryna lizynowa w diagnostyce 
      przewlekłych eozynofilowych niezytów nosa.
PL  - Poland
TA  - Otolaryngol Pol
JT  - Otolaryngologia polska = The Polish otolaryngology
JID - 0404453
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Intranasal
MH  - Adult
MH  - Aged
MH  - *Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/adverse effects/*analogs & derivatives
MH  - Asthma/complications
MH  - Dose-Response Relationship, Drug
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Eosinophilia/*diagnosis/etiology
MH  - Female
MH  - Humans
MH  - Lysine/adverse effects/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/complications
MH  - Nasal Provocation Tests/*methods
MH  - Rhinitis/*diagnosis/etiology
EDAT- 2006/07/11 09:00
MHDA- 2006/09/14 09:00
CRDT- 2006/07/11 09:00
PHST- 2006/07/11 09:00 [pubmed]
PHST- 2006/09/14 09:00 [medline]
PHST- 2006/07/11 09:00 [entrez]
PST - ppublish
SO  - Otolaryngol Pol. 2006;60(1):25-31.

PMID- 12395741
OWN - NLM
STAT- MEDLINE
DCOM- 20021114
LR  - 20220309
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 31
IP  - 31
DP  - 2002 Sep 28
TI  - [Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and 
      gastroduodenal lesions].
PG  - 1469-75
AB  - NSAID CATEGORIES: Contrary to classical NSAIDs, which inhibit the 2 isoforms of 
      cyclo-oxygenase (COX), coxibs do not affect COX-1, which catalyses the synthesis 
      of cytoprotective prostaglandins in the stomach. ULCER COMPLICATIONS: The 
      probability of developing a symptomatic, uncomplicated or complicated 
      (perforation, gastric outlet obstruction, bleeding) gastroduodenal ulcer is 
      significantly lower with a COX-2 selective inhibitor (Celecoxib, rofecoxib) than 
      with a traditional NSAIDs, with a reduction in absolute risk of around 1-1.5 for 
      100 patient-years in clinical trials. The gastrointestinal toxicity of coxibs is 
      greater than that of a placebo. THE INFLUENCE OF A CO-PRESCRIPTION OF ASPIRIN: 
      Patients for whom low-dose aspirin is indicated to offset known thrombotic risk 
      must continue this therapy if a COX-2 selective inhibitor is introduced. In that 
      case, however, coxibs expose the patient to almost the same risk of severe 
      gastroduodenal complications as with classical NSAIDs. TARGET POPULATION: In view 
      of the lesser ulcerogenic potential of coxibs, patients at risk of 
      gastrointestinal complications are the population of choice for these drugs. In 
      the case of concomitant ingestion of aspirin for prevention of thrombosis, some 
      authors prefer the association of classical NSAIs with proton pump inhibitors 
      (omeprazole, lansoprazole) or misoprostol.
FAU - Bannwarth, Bernard
AU  - Bannwarth B
AD  - Service de rhumatologie, Groupe hospitalier Pellegrin & Laboratoire de 
      thérapeutique, EA 525, Université Victor Segalen, Bordeaux (33). 
      bernard.bannwarth@u-bordeaux2.fr
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Anti-inflammatoires non stéroïdiens inhibiteurs sélectifs de la cyclo-oxygénase 2 
      et lésions gastroduodénales.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Presse Med. 2002 Sep 28;31(31):1461. PMID: 12395739
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/*adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Peptic Ulcer/*chemically induced/prevention & control
MH  - Risk Factors
MH  - Structure-Activity Relationship
RF  - 40
EDAT- 2002/10/25 04:00
MHDA- 2002/11/26 04:00
CRDT- 2002/10/25 04:00
PHST- 2002/10/25 04:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/10/25 04:00 [entrez]
PST - ppublish
SO  - Presse Med. 2002 Sep 28;31(31):1469-75.

PMID- 11689471
OWN - NLM
STAT- MEDLINE
DCOM- 20011205
LR  - 20211203
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Linking)
VI  - 15
IP  - 13
DP  - 2001 Nov
TI  - Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) 
      and inhibit its ATPase activity in human fibroblasts.
PG  - 2463-70
AB  - Salicylic acid (SA), an endogenous signaling molecule of plants, possesses 
      anti-inflammatory and anti-neoplastic actions in human. Its derivative, aspirin, 
      is the most commonly used anti-inflammatory and analgesic drug. Aspirin and 
      sodium salicylate (salicylates) have been reported to have multiple 
      pharmacological actions. However, it is unclear whether they bind to a cellular 
      protein. Here, we report for the first time the purification from human 
      fibroblasts of a approximately 78 kDa salicylate binding protein with sequence 
      identity to immunoglobulin heavy chain binding protein (BiP). The Kd values of SA 
      binding to crude extract and to recombinant BiP were 45.2 and 54.6 microM, 
      respectively. BiP is a chaperone protein containing a polypeptide binding site 
      recognizing specific heptapeptide sequence and an ATP binding site. A 
      heptapeptide with the specific sequence displaced SA binding in a 
      concentration-dependent manner whereas a control heptapeptide did not. 
      Salicylates inhibited ATPase activity stimulated by this specific heptapeptide 
      but did not block ATP binding or induce BiP expression. These results indicate 
      that salicylates bind specifically to the polypeptide binding site of BiP in 
      human cells that may interfere with folding and transport of proteins important 
      in inflammation.
FAU - Deng, W G
AU  - Deng WG
AD  - Vascular Biology Research Center and Division of Hematology, Department of 
      Internal Medicine, University of Texas-Houston Medical School, Houston, Texas 
      77030, USA.
FAU - Ruan, K H
AU  - Ruan KH
FAU - Du, M
AU  - Du M
FAU - Saunders, M A
AU  - Saunders MA
FAU - Wu, K K
AU  - Wu KK
LA  - eng
GR  - HL-50675/HL/NHLBI NIH HHS/United States
GR  - NS-23327/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (Carbon Radioisotopes)
RN  - 0 (Carrier Proteins)
RN  - 0 (Endoplasmic Reticulum Chaperone BiP)
RN  - 0 (Heat-Shock Proteins)
RN  - 0 (Molecular Chaperones)
RN  - 0 (Oligopeptides)
RN  - 0 (Proteins)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - EC 3.6.1.- (Adenosine Triphosphatases)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Adenosine Triphosphatases/*metabolism
MH  - Adenosine Triphosphate/metabolism
MH  - Amino Acid Sequence
MH  - Aspirin/metabolism/*pharmacology
MH  - Binding, Competitive/drug effects
MH  - Carbon Radioisotopes
MH  - Carrier Proteins/*metabolism
MH  - Cell-Free System/metabolism
MH  - Cells, Cultured
MH  - Endoplasmic Reticulum Chaperone BiP
MH  - Fibroblasts/cytology/*drug effects/metabolism
MH  - *Heat-Shock Proteins
MH  - Humans
MH  - Male
MH  - Molecular Chaperones/*metabolism
MH  - Oligopeptides/chemical synthesis/pharmacology
MH  - Protein Binding/drug effects
MH  - Proteins/isolation & purification/metabolism
MH  - Sodium Salicylate/*pharmacology
EDAT- 2001/11/02 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/02 10:00
PHST- 2001/11/02 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/02 10:00 [entrez]
AID - 15/13/2463 [pii]
AID - 10.1096/fj.01-0259com [doi]
PST - ppublish
SO  - FASEB J. 2001 Nov;15(13):2463-70. doi: 10.1096/fj.01-0259com.

PMID- 7414289
OWN - NLM
STAT- MEDLINE
DCOM- 19801125
LR  - 20131121
IS  - 0586-5581 (Print)
IS  - 0586-5581 (Linking)
IP  - 3
DP  - 1980
TI  - SEM of the ciliary processes after paracentesis.
PG  - 441-7
AB  - Corneal perforation and withdrawal of aqueous humor (paracentesis) represents a 
      practical means for producing controlled trauma to the eye. The sequence of 
      events triggered by paracentesis has been carefully studied by in vivo and in 
      vitro microscopy and other means. These observations have proven especially 
      helpful in elucidating the physiology and pharmacology of ocular trauma. Scanning 
      electron microscopy of the ciliary processes of the rabbit has proven a sensitive 
      indicator of the response to prostaglandin, a mediator of the paracentesis 
      reaction. We used SEM to invetigate changes in the ciliary processes induced by 
      paracentesis. We also examined the opposite eye for a consensual response. The 
      effect of prior treatment with aspirin or nerve block was assessed in both the 
      traumatized eye and the fellow eye. In an untreated animal, a consensual response 
      to trauma was present and demonstrable by scanning electron microscopy. The 
      direct response was more effectively blocked by aspirin than by local anesthesia. 
      Both pretreatments were effective in reducing the consensual reaction.
FAU - Dueker, D K
AU  - Dueker DK
FAU - Chaudhry, H A
AU  - Chaudhry HA
LA  - eng
GR  - 5-RO1-EY01750/EY/NEI NIH HHS/United States
GR  - EY00089/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Scan Electron Microsc
JT  - Scanning electron microscopy
JID - 0371617
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Ciliary Body/pathology/*ultrastructure
MH  - Disease Models, Animal
MH  - *Eye Injuries
MH  - Female
MH  - Functional Laterality
MH  - Male
MH  - Microscopy, Electron, Scanning
MH  - Prostaglandins/physiology
MH  - Rabbits
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Scan Electron Microsc. 1980;(3):441-7.

PMID- 24482
OWN - NLM
STAT- MEDLINE
DCOM- 19780508
LR  - 20131121
IS  - 0306-042X (Print)
IS  - 0306-042X (Linking)
VI  - 5
IP  - 3
DP  - 1978 Mar
TI  - Mass spectrometry of medicines. Quantitative determination by direct probe inlet 
      system mass chromatography.
PG  - 192-7
AB  - A fundamental study was performed to establish a method of quantitative analysis 
      using mass chromatography by the direct inlet system. The samples were aspirin, 
      phenacetin and caffeine, which are often used as cold medicines, and barbital, 
      allobarbital, phenobarbital and phenytoin which are difficult to analyse by gas 
      chromatography in their intact states. N-acetylsulfamine and ethyl 
      p-aminobenzoate were used as internal standards. Direct inlet mass chromatography 
      was performed by an on-line system of the Shimadzu LKB-9000 and the GC-MSPAC 300. 
      The ratio of the cumulative ions of certain peaks of sample and the internal 
      standard was studied. It was found that, whether the sample is a pure reagent or 
      a mixture, the ratio of cumulative ions of a peak specific to the sample and of a 
      selected peak of the internal standard is proportional to the sample size, the 
      error being less than +/- 3.5% for aspirin, phenacetin and caffeine, and less 
      than +/- 2.7% for barbital, allobarbital and phenobarbital. The same relationship 
      was observed for the phenobarbital and phenytoin mixed in rat plasma, the error 
      being less than +/- 2.0%. It can be concluded that this method is applicable to 
      the quantiative determination of medicines in urine, body fluids and other 
      biological samples.
FAU - Tatematsu, A
AU  - Tatematsu A
FAU - Yoshizumi, H
AU  - Yoshizumi H
FAU - Nadai, T
AU  - Nadai T
FAU - Kubodera, T
AU  - Kubodera T
FAU - Asai, S
AU  - Asai S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biomed Mass Spectrom
JT  - Biomedical mass spectrometry
JID - 0430246
RN  - 0 (Barbiturates)
RN  - 0 (Pharmaceutical Preparations)
RN  - 3G6A5W338E (Caffeine)
RN  - 5WZ53ENE2P (Barbital)
RN  - 6158TKW0C5 (Phenytoin)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
RN  - YQE403BP4D (Phenobarbital)
SB  - IM
MH  - Aspirin/analysis
MH  - Barbital/analysis
MH  - Barbiturates/analysis
MH  - Caffeine/analysis
MH  - Mass Spectrometry/*methods
MH  - Pharmaceutical Preparations/*analysis
MH  - Phenacetin/analysis
MH  - Phenobarbital/analysis
MH  - Phenytoin/analysis
EDAT- 1978/03/01 00:00
MHDA- 1978/03/01 00:01
CRDT- 1978/03/01 00:00
PHST- 1978/03/01 00:00 [pubmed]
PHST- 1978/03/01 00:01 [medline]
PHST- 1978/03/01 00:00 [entrez]
AID - 10.1002/bms.1200050306 [doi]
PST - ppublish
SO  - Biomed Mass Spectrom. 1978 Mar;5(3):192-7. doi: 10.1002/bms.1200050306.

PMID- 26252306
OWN - NLM
STAT- MEDLINE
DCOM- 20151028
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 94
IP  - 31
DP  - 2015 Aug
TI  - A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus 
      Placebo/Control for Treating Peripheral Artery Disease.
PG  - e1293
LID - 10.1097/MD.0000000000001293 [doi]
LID - e1293
AB  - Effect of aspirin (antiplatelet agents) in patients with peripheral artery 
      disease (PAD) was still controversial. Varying studies reported varying results. 
      Therefore, we did this meta-analysis to investigate if aspirin could reduce 
      cardiovascular events in patients with PAD.A comprehensive literature search 
      (PubMed, CCTR, Embase, Web of Science, CNKI, CBM-disc, and relevant websites) was 
      conducted from 1990 to September 2014. The key search terms ("aspirin," "PAD," 
      "peripheral arterial occlusive diseases," and "claudication") produced 9 
      high-quality randomized controlled trials (RCTs) of aspirin versus 
      placebo/control. Mantel-Haenszel random-effects model was used to analysis of the 
      9 RCTs. The primary outcome was the cardiovascular events.Nine RCTs, composed of 
      9526 patients (4786 aspirin-treated and 4740 placebo or control-treated 
      patients), were meta-analyzed. The results indicated that compared to 
      placebo/control, aspirin could not significantly reduce the cardiovascular events 
      (OR = 0.81, 95% CI = 0.56-1.15). Moreover, aspirin could not produce better 
      effect on prevention of nonfatal myocardial infarction (OR = 0.98, 95% 
      CI = 0.52-1.84), nonfatal stroke (OR = 0.89, 95% CI = 0.69-1.14), cardiovascular 
      death (OR = 0.97, 95% CI = 0.68-1.38), any death (OR = 1.05, 95% CI = 0.85-1.30), 
      and major bleeding (OR = 1.16, 95% CI = 0.82-1.65) than placebo/control. But 
      aspirin, as monotherapy therapy, did significantly reduce the risk of nonfatal 
      stroke (OR = 0.42, 95% CI = 0.21-0.84).Aspirin, as monotherapy or combination 
      therapy, did not result in a significant decrease in the cardiovascular events. 
      But aspirin, as monotherapy therapy, did significantly reduce the risk of 
      nonfatal stroke. Our conclusion might help clinicians in clinical treating PAD. 
      Future studies are needed to draw firm conclusions about the clinical benefit and 
      risks of aspirin and other antiplatelet agents.
FAU - Qian, Jun
AU  - Qian J
AD  - From the Department of Tumor Interventional Radiology, Dadong District, Shenyang, 
      Liaoning Province, China.
FAU - Yang, Xiao Hong
AU  - Yang XH
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Peripheral Arterial Disease/complications/*drug therapy/mortality
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
PMC - PMC4616615
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2015/08/08 06:00
MHDA- 2015/10/29 06:00
CRDT- 2015/08/08 06:00
PHST- 2015/08/08 06:00 [entrez]
PHST- 2015/08/08 06:00 [pubmed]
PHST- 2015/10/29 06:00 [medline]
AID - 00005792-201508010-00040 [pii]
AID - 10.1097/MD.0000000000001293 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2015 Aug;94(31):e1293. doi: 10.1097/MD.0000000000001293.

PMID- 33588594
OWN - NLM
STAT- MEDLINE
DCOM- 20211210
LR  - 20221207
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 52
IP  - 3
DP  - 2021 Mar
TI  - Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined 
      Source: RE-SPECT ESUS Subgroup Analysis.
PG  - 1069-1073
LID - 10.1161/STROKEAHA.120.031891 [doi]
AB  - BACKGROUND AND PURPOSE: We assessed the outcomes of dabigatran versus aspirin in 
      a prespecified subgroup analysis of East Asian patients with embolic stroke of 
      undetermined source in the RE-SPECT ESUS trial (Randomized, Double-Blind, 
      Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of 
      the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in 
      Patients With Embolic Stroke of Undetermined Source). METHODS: Patients with a 
      recent embolic stroke of undetermined source were randomized to dabigatran (150 
      or 110 mg BID) or aspirin (100 mg QD). The primary efficacy outcome was recurrent 
      stroke; the primary safety outcome was major bleeding. The East Asia cohort was 
      compared with patients from all other countries (non-East Asia cohort). RESULTS: 
      Overall, 988 of 5390 patients (18%) were randomized in East Asia. During a median 
      follow-up of 18.8 months, there was no statistically significant difference in 
      recurrent stroke (hazard ratio, 0.65 [95% CI, 0.41-1.03]) or major bleeding 
      (hazard ratio, 1.04 [95% CI, 0.57-1.91]) in East Asian patients receiving 
      dabigatran versus aspirin. Death from any cause occurred more often in the 
      dabigatran versus the aspirin group (hazard ratio, 3.98 [95% CI, 1.32-12.01]). 
      CONCLUSIONS: The treatment effect of dabigatran versus aspirin was consistent 
      between cohorts, with no apparent superiority for dabigatran over aspirin in 
      preventing recurrent stroke in patients with embolic stroke of undetermined 
      source. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: 
      NCT02239120.
FAU - Uchiyama, Shinichiro
AU  - Uchiyama S
AD  - Clinical Research Centre for Medicine, International University of Health and 
      Welfare, Tokyo, Japan (S.U.).
FAU - Toyoda, Kazunori
AU  - Toyoda K
AD  - Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular 
      Center, Suita, Japan (K.T.).
FAU - Lee, Byung-Chul
AU  - Lee BC
AD  - Department of Neurology, Hallym Neurological Institute, Hallym University College 
      of Medicine, Seoul, South Korea (B.-C.L.).
FAU - Liou, Chia-Wei
AU  - Liou CW
AD  - Department of Neurology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung 
      University College of Medicine, Taiwan (C.-W.L.).
FAU - Wong, Lawrence Ka Sing
AU  - Wong LKS
AD  - Division of Neurology, Department of Medicine and Therapeutics, The Chinese 
      University of Hong Kong, Shatin (L.K.S.W.).
FAU - Grauer, Claudia
AU  - Grauer C
AD  - Clinical Operations Global, Boehringer Ingelheim Pharma GmbH K.G., Biberach, 
      Germany (C.G.).
FAU - Brueckmann, Martina
AU  - Brueckmann M
AD  - Department of Cardiometabolic Medicine, Boehringer Ingelheim International GmbH, 
      Ingelheim am Rhein, Germany (M.B.).
FAU - Taniguchi, Atsushi
AU  - Taniguchi A
AD  - Biostatistics and Data Sciences (A.T.), Nippon Boehringer Ingelheim Co, Ltd, 
      Tokyo, Japan.
FAU - Urano, Yasuhisa
AU  - Urano Y
AD  - Primary Care Medicine (Y.U.), Nippon Boehringer Ingelheim Co, Ltd, Tokyo, Japan.
FAU - Easton, J Donald
AU  - Easton JD
AD  - Department of Neurology, University of California, San Francisco (J.D.E.).
CN  - RE-SPECT ESUS Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT02239120
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20210216
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - I0VM4M70GC (Dabigatran)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Asian People
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cohort Studies
MH  - Dabigatran/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Embolic Stroke/*drug therapy/etiology/mortality
MH  - Asia, Eastern
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Recurrence
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Far East
OT  - cohort studies
OT  - dabigatran
OT  - follow-up studies
OT  - hemorrhage
OT  - stroke
EDAT- 2021/02/17 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/02/16 05:41
PHST- 2021/02/17 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/02/16 05:41 [entrez]
AID - 10.1161/STROKEAHA.120.031891 [doi]
PST - ppublish
SO  - Stroke. 2021 Mar;52(3):1069-1073. doi: 10.1161/STROKEAHA.120.031891. Epub 2021 
      Feb 16.

PMID- 25855099
OWN - NLM
STAT- MEDLINE
DCOM- 20160324
LR  - 20220408
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 70
IP  - 7
DP  - 2015 Jul
TI  - NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, 
      mean provocative dose of aspirin and increased asthma morbidity.
PG  - 828-35
LID - 10.1111/all.12629 [doi]
AB  - BACKGROUND: The prevalence and mean provocative dose of oral aspirin (MPDA) 
      triggering respiratory reactions in people with asthma have been inconsistently 
      reported, and the relationship between NSAID-exacerbated respiratory disease 
      (NERD) and asthma morbidity was less well quantified. METHODS: A systematic 
      review was performed by identifying studies diagnosing NERD using blinded, 
      placebo-controlled oral provocation challenge tests (OPCTs) or by self-reported 
      history in people with asthma. Data were extracted, and effect estimates for 
      changes in respiratory function, MPDA and asthma morbidity were pooled using 
      random-effects meta-analysis. RESULTS: The prevalence of NERD in adults with 
      asthma was 9.0% (95% CI 6-12%) using OPCTs and 9.9% (95% CI 9.4-10.5%) using 
      self-reported history from questionnaires. The MPDA in adults with NERD was 85.8 
      mg (95% CI 73.9-97.6). In people with NERD, the risk of: uncontrolled asthma was 
      increased twofold (RR 1.96 (95% CI 1.25-3.07)); severe asthma and asthma attacks 
      was increased by 60% (RR 1.58 (95% CI 1.15-2.16) and RR 1.59 (95% CI 1.21-2.09), 
      respectively); emergency room visits was increased by 80% (RR 1.79 (95% CI 
      1.29-2.49)); and asthma hospitalization was increased by 40% (RR 1.37 (95% CI 
      1.12-1.67)) compared to people with NSAID-tolerant asthma. CONCLUSIONS: 
      Respiratory reactions triggered by oral aspirin in people with asthma are 
      relatively common. At the population level, the prevalence of NERD was similar 
      when measured using appropriately conducted OPCTs or by self-reported history. On 
      average, respiratory reactions were triggered by clinically relevant doses of 
      oral aspirin. Asthma morbidity was significantly increased in people with NERD 
      who potentially require more intensive monitoring and follow-up.
CI  - © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Morales, D R
AU  - Morales DR
AD  - Quality, Safety & Informatics Group, Division of Population Health Sciences, 
      Medical Research Institute, University of Dundee, Dundee, UK.
FAU - Guthrie, B
AU  - Guthrie B
AD  - Quality, Safety & Informatics Group, Division of Population Health Sciences, 
      Medical Research Institute, University of Dundee, Dundee, UK.
FAU - Lipworth, B J
AU  - Lipworth BJ
AD  - Scottish Centre for Respiratory Research, Medical Research Institute, University 
      of Dundee, Dundee, UK.
FAU - Jackson, C
AU  - Jackson C
AD  - School of Medicine, University of Central Lancashire, Preston, UK.
FAU - Donnan, P T
AU  - Donnan PT
AD  - Dundee Epidemiology and Biostatistics Unit, Division of Population Health 
      Sciences, Medical Research Institute, University of Dundee, Dundee, UK.
FAU - Santiago, V H
AU  - Santiago VH
AD  - Quality, Safety & Informatics Group, Division of Population Health Sciences, 
      Medical Research Institute, University of Dundee, Dundee, UK.
LA  - eng
GR  - CAF/11/07/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20150507
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Asthma/epidemiology/etiology
MH  - Bronchial Provocation Tests
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Morbidity
MH  - Prevalence
MH  - Publication Bias
MH  - Respiratory Tract Diseases/*diagnosis/epidemiology/*etiology
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - NSAID-exacerbated respiratory disease
OT  - aspirin
OT  - aspirin-exacerbated respiratory disease
OT  - asthma
OT  - pharmacoepidemiology
EDAT- 2015/04/10 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/04/10 06:00
PHST- 2015/04/03 00:00 [accepted]
PHST- 2015/04/10 06:00 [entrez]
PHST- 2015/04/10 06:00 [pubmed]
PHST- 2016/03/25 06:00 [medline]
AID - 10.1111/all.12629 [doi]
PST - ppublish
SO  - Allergy. 2015 Jul;70(7):828-35. doi: 10.1111/all.12629. Epub 2015 May 7.

PMID- 15223902
OWN - NLM
STAT- MEDLINE
DCOM- 20040810
LR  - 20220318
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 77
IP  - 12
DP  - 2004 Jun 27
TI  - Low-dose aspirin therapy is associated with improved allograft function and 
      prolonged allograft survival after kidney transplantation.
PG  - 1848-53
AB  - BACKGROUND: Aspirin treatment has an undoubted beneficial impact on the 
      progression of cardiovascular diseases. We hypothesized that aspirin also 
      protects allograft function and survival in the context of chronic renal 
      allograft dysfunction, which displays decisive pathophysiologic features that are 
      similar to those involved in atherogenesis. METHODS: A retrospective, 
      multivariate analysis was performed to assess the effect of low-dose aspirin 
      treatment (100 mg/day) on allograft function and survival of 830 renal transplant 
      recipients. Allograft function was evaluated by serum creatinine levels, urine 
      protein levels, and the presence of hematuria. RESULTS: Median allograft survival 
      time was significantly longer in patients receiving low-dose aspirin therapy 
      compared with patients receiving no aspirin treatment (n=205, 13.8 +/- 2.6 vs. 
      7.8 +/- 0.3 years, n=625; adjusted relative risk=0.443, 95% confidence interval 
      [0.323-0.608], P<0.0001). Statin treatment and a recent time point of 
      transplantation, reflecting the qualitative advances of the applied 
      immunosuppressive therapy, were further positive determinants of renal allograft 
      survival. The number of antihypertensive agents, representing the extent of 
      hypertension, was a negative determinant of allograft survival. Transplant 
      function was better preserved in aspirin-treated patients, who displayed a slower 
      increase of serum creatinine and less proteinuria and hematuria during the 
      observation period. The duration of aspirin treatment was positively associated 
      with better allograft function. CONCLUSIONS: Low-dose aspirin therapy 
      substantially improves renal allograft function and allograft survival. These 
      findings suggest that aspirin should be considered to complement long-term 
      posttransplant medical treatment regimens.
FAU - Grotz, Wolfgang
AU  - Grotz W
AD  - Department of Nephrology, Albert-Ludwigs-University, Freiburg, Germany. 
      wolfgang.grotz@krupp-krankenhaus.de
FAU - Siebig, Sylvia
AU  - Siebig S
FAU - Olschewski, Manfred
AU  - Olschewski M
FAU - Strey, Christoph W
AU  - Strey CW
FAU - Peter, Karlheinz
AU  - Peter K
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Transplantation. 2005 Jan 27;79(2):253-4. PMID: 15665784
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Graft Survival/*physiology
MH  - Humans
MH  - Kidney Transplantation/*physiology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Postoperative Complications/classification/epidemiology
MH  - Reoperation/statistics & numerical data
MH  - Retrospective Studies
MH  - Transplantation, Homologous/physiology
EDAT- 2004/06/30 05:00
MHDA- 2004/08/11 05:00
CRDT- 2004/06/30 05:00
PHST- 2004/06/30 05:00 [pubmed]
PHST- 2004/08/11 05:00 [medline]
PHST- 2004/06/30 05:00 [entrez]
AID - 00007890-200406270-00012 [pii]
AID - 10.1097/01.tp.0000129407.31494.45 [doi]
PST - ppublish
SO  - Transplantation. 2004 Jun 27;77(12):1848-53. doi: 
      10.1097/01.tp.0000129407.31494.45.

PMID- 30861647
OWN - NLM
STAT- MEDLINE
DCOM- 20190607
LR  - 20190607
IS  - 0529-5815 (Print)
IS  - 0529-5815 (Linking)
VI  - 57
IP  - 3
DP  - 2019 Mar 1
TI  - [Impact of discontinuation of aspirin and clopidogrel before off-pump coronary 
      artery bypass grafting on postoperative bleeding and transfusion requirement].
PG  - 187-193
LID - 10.3760/cma.j.issn.0529-5815.2019.03.006 [doi]
AB  - Objective: To investigate the influence of different discontinuation time of 
      aspirin and clopidogrel before off-pump coronary artery bypass grafting (OPCABG) 
      on postoperative bleeding and blood products transfusion requirement. Methods: 
      Three hundred and fifty-three coronary artery disease patients who underwent 
      OPCABG from January 2017 to January 2018 at Department of Cardiac Surgery, 
      Zhongshan Hospital, Fudan University were retrospectively analysed. There were 
      268 males and 85 females, aged (66.0±9.1)years. All patients were divided into 
      three groups: (1) guideline-recommended group: patients who discontinued 
      clopidogrel for >5 days without discontinuing aspirin before surgery; (2) without 
      discontinuing group: patients who discontinued clopidogrel for ≤5 days without 
      discontinuing aspirin before surgery; (3) discontinuing group: patients who 
      discontinued clopidogrel for >5 days with discontinuing aspirin before surgery. 
      Postoperative bleeding recorded as chest tube drainage (CTD) volume and blood 
      products transfusion requirement and perioperative complications were recorded. 
      CTD volumes within 12 hours after surgery between groups were compared by 
      Mann-Whitney U tests, CTD volumes after 12 hours postoperatively were compared by 
      repeated measures analysis of variance and blood products transfusion and 
      complications incidence were compared by χ(2) test or Fisher's precise test. 
      Results: The 12 hours CTD volumes of guideline-recommended group, without 
      discontinuing group, discontinuing group after surgery were 280(153) ml 
      (M(Q(R))), 291(229) ml, 225(161) ml, respectively. There were no significant 
      differences in postoperative 12 hours CTD volumes (P=0.865), red blood cells 
      transfusion incidence (χ(2)=2.626, P=0.149) and fresh frozen plasma (FFP) 
      transfusion incidence (χ(2)=1.258, P=0.324) between guideline-recommended group 
      and without discontinuing group. However, the 12 hours CTD volumes were 
      significantly higher in guideline-recommended group patients compared with 
      disconutinuing group patients (U=5 247, P=0.002). No significant differences were 
      observed in red blood cells (χ(2)=0.182, P=0.757) and FFP (χ(2)=0.083, P=0.839) 
      transfusion rate between these two groups. Repeated measures analysis of variance 
      indicated that when patients began to take antiplatelet drugs (aspirin and 
      clopidogrel) after 12 hours postoperatively, the change of CTD volumes beyond 12 
      hours after surgery didn't differ either between guideline-recommended group and 
      without discontinuing group (F=0.019, P=0.941) or between guideline-recommended 
      group and discontinuing group (F=2.447,P=0.113). Besides, the incidence of 
      perioperative arrhythmia was significantly higher in guideline-recommended group 
      patients compared with without discontinuing group patients (4.8% vs. 0, 
      χ(2)=5.073, P=0.038). Conclusions: OPCABG patients who discontinued aspirin 
      before surgery had lower postoperative 12 hours CTD volumes but similar blood 
      products transfusion rate and CTD volumes beyond 12 hours postoperatively 
      compared with patients adhering to the current guideline-recommended protocol. 
      And for patients who discontinued clopidogrel for ≤5 days, postoperative CTD 
      volumes and blood products transfusion requirement were similar but the incidence 
      of perioperative arrhythmia was significantly lower compared with 
      guideline-treated patients.
FAU - Wang, Z
AU  - Wang Z
AD  - Department of Clinical Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 
      200032, China.
FAU - Xia, L M
AU  - Xia LM
AD  - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, China.
FAU - Song, K
AU  - Song K
AD  - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, China.
FAU - Li, X Y
AU  - Li XY
AD  - Department of Clinical Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 
      200032, China.
FAU - Lyu, Q Z
AU  - Lyu QZ
AD  - Department of Clinical Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 
      200032, China.
FAU - Shen, J Q
AU  - Shen JQ
AD  - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, China.
LA  - chi
GR  - 2018ZSLC30/Clinical Research Fund of Zhongshan Hospital, Fudan University/
PT  - Journal Article
PL  - China
TA  - Zhonghua Wai Ke Za Zhi
JT  - Zhonghua wai ke za zhi [Chinese journal of surgery]
JID - 0153611
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Blood Transfusion
MH  - Clopidogrel/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Hemorrhage/*drug therapy
MH  - Retrospective Studies
MH  - Ticlopidine
OTO - NOTNLM
OT  - Aspirin
OT  - Clopidogrel
OT  - Coronary artery bypass, off-pump
OT  - Hemorrhage
EDAT- 2019/03/14 06:00
MHDA- 2019/06/08 06:00
CRDT- 2019/03/13 06:00
PHST- 2019/03/13 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/06/08 06:00 [medline]
AID - 10.3760/cma.j.issn.0529-5815.2019.03.006 [doi]
PST - ppublish
SO  - Zhonghua Wai Ke Za Zhi. 2019 Mar 1;57(3):187-193. doi: 
      10.3760/cma.j.issn.0529-5815.2019.03.006.

PMID- 31854295
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20200716
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 58
IP  - 4
DP  - 2020 Apr
TI  - Influence of co-initiation of antiulcer drugs on persistence and adherence to 
      low-dose aspirin: A retrospective cohort study using a Japanese claims database .
PG  - 214-222
LID - 10.5414/CP203634 [doi]
AB  - OBJECTIVE: The purpose of this study was to examine whether co-initiation of 
      antiulcer drugs (AUDs) and low-dose aspirin (LDA) therapy is beneficial for good 
      adherence to LDA therapy. MATERIALS AND METHODS: A retrospective cohort study was 
      conducted using the JMDC claims database. Patients for whom LDA therapy was newly 
      initiated between January 2005 and April 2016 were selected from the JMDC 
      database. The selected patients were divided into LDA and LDA+AUD groups and were 
      followed up from the first prescription of LDA or LDA+AUD until the earliest of 
      the following events: discontinuation or the end of the observation period. 
      Unadjusted and multivariable Cox proportional hazards models controlling for all 
      demographic and clinical characteristics were applied to examine whether the 
      addition of an AUD to LDA improved adherence. A 1 : 1 propensity score matching 
      analysis was conducted to balance confounders between the two groups. RESULTS: 
      After the propensity score matching analysis, 4,089 patients were matched in each 
      therapy group. The Kaplan-Meier curves for the rate of LDA continuation showed a 
      sharp decline just after the initiation of LDA therapy. A significant difference 
      was observed in the incidence of LDA therapy discontinuation between the LDA+AUD 
      and LDA groups (HR: 0.87, 95% CI: 0.82 - 0.92), and the median duration of LDA 
      therapy in the LDA+AUD and LDA groups were 18 and 11 months (log-rank test: 
      p < 0.0001), respectively. CONCLUSION: The therapy persistence rate in the 
      LDA+AUD group was significantly higher than that in the LDA group.
FAU - Iwasawa, Makiko
AU  - Iwasawa M
FAU - Sagami, Keiko
AU  - Sagami K
FAU - Yokoyama, Satoshi
AU  - Yokoyama S
FAU - Hosomi, Kouichi
AU  - Hosomi K
FAU - Takada, Mitsutaka
AU  - Takada M
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Anti-Ulcer Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Databases, Factual
MH  - Humans
MH  - Japan
MH  - *Medication Adherence
MH  - Retrospective Studies
EDAT- 2019/12/20 06:00
MHDA- 2020/07/17 06:00
CRDT- 2019/12/20 06:00
PHST- 2020/03/18 00:00 [accepted]
PHST- 2019/12/20 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2019/12/20 06:00 [entrez]
AID - 186125 [pii]
AID - 10.5414/CP203634 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2020 Apr;58(4):214-222. doi: 10.5414/CP203634.

PMID- 19740038
OWN - NLM
STAT- MEDLINE
DCOM- 20101012
LR  - 20131121
IS  - 1520-5762 (Electronic)
IS  - 0363-9045 (Linking)
VI  - 36
IP  - 4
DP  - 2010 Apr
TI  - Influence of fulvic acid and hydroxy propyl-beta-cyclodextrin on aspirin 
      degradation.
PG  - 428-30
LID - 10.3109/03639040903225091 [doi]
AB  - OBJECTIVE: The degradation of aspirin (ASA) was investigated to reveal 
      information about the influence of complexation with fulvic acid (FA), as a new 
      complexing agent and compared with hydroxy propyl-beta-cyclodextrin complex. 
      MATERIALS AND METHODS: ASA was complexed with FA in the molar ratio 1:0.5, 1:1, 
      and 1:2 by different methods through lyophilization, solvent evaporation, and 
      spray drying. Spray-dried (1:1) ASA-hydroxy propyl-beta-cyclodextrin complex was 
      prepared and compared with optimized complex of FA. All the complexes and ASA 
      alone were packaged in well-labeled sealed polythene-lined aluminum pouches and 
      stored in stability chamber at 40 +/- 2 degrees C and 75 +/- 5% relative humidity 
      for 120 days. Samples were analyzed for salicylic acid content at 0, 30, 60, 90, 
      and 120 days. RESULTS: Overall 4.31% salicylic acid was formed in 1:1 ASA-FA 
      spray-dried complex, which was optimized stable complex among other complexes of 
      FA prepared by different methods in different molar ratios. However, 2.35% 
      salicylic acid was measured with 1:1 spray-dried ASA-hydroxy 
      propyl-beta-cyclodextrin complex. Stability of ASA increased more when complexed 
      with hydroxy propyl-beta-cyclodextrin as compared to FA. CONCLUSIONS: A novel 
      complexing agent in the form of FA was investigated to increase the stability of 
      ASA. A marked improvement in stability of ASA was observed when complexed with 
      hydroxy propyl-beta-cyclodextrin (1:1) by spray drying as compared to 1:1 
      spray-dried ASA-FA complex.
FAU - Anwer, Mohammad Khalid
AU  - Anwer MK
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, 
      India. mkanwer2002@yahoo.co.in
FAU - Agarwal, Suraj Prakash
AU  - Agarwal SP
FAU - Ali, Asgar
AU  - Ali A
FAU - Sultana, Yasmin
AU  - Sultana Y
LA  - eng
PT  - Journal Article
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Benzopyrans)
RN  - 0 (Excipients)
RN  - 0 (beta-Cyclodextrins)
RN  - R16CO5Y76E (Aspirin)
RN  - XII14C5FXV (fulvic acid)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry
MH  - Aspirin/*chemistry
MH  - Benzopyrans/*chemistry
MH  - Chemistry, Pharmaceutical
MH  - Drug Compounding
MH  - Drug Stability
MH  - Excipients
MH  - Solubility
MH  - Technology, Pharmaceutical/*methods
MH  - beta-Cyclodextrins/*chemistry
EDAT- 2009/09/11 06:00
MHDA- 2010/10/13 06:00
CRDT- 2009/09/11 06:00
PHST- 2009/09/11 06:00 [entrez]
PHST- 2009/09/11 06:00 [pubmed]
PHST- 2010/10/13 06:00 [medline]
AID - 10.3109/03639040903225091 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 2010 Apr;36(4):428-30. doi: 10.3109/03639040903225091.

PMID- 24161294
OWN - NLM
STAT- MEDLINE
DCOM- 20140721
LR  - 20131203
IS  - 1769-6623 (Electronic)
IS  - 0750-7658 (Linking)
VI  - 32
IP  - 11
DP  - 2013 Nov
TI  - [Aspirin and its danger: Reye syndrome in young adult].
PG  - 814-6
LID - S0750-7658(13)01122-2 [pii]
LID - 10.1016/j.annfar.2013.08.009 [doi]
AB  - We describe the case of a 19-year-old male diagnosed with Reye syndrome within 
      the context of viral pericarditis and salicylate ingestion. He presented a fatal 
      brain oedema without liver failure. Brain biopsies obtained during a 
      decompressive craniectomy led to the diagnosis.
CI  - Copyright © 2013 Société française d’anesthésie et de réanimation (Sfar). 
      Published by Elsevier SAS. All rights reserved.
FAU - Selves, A
AU  - Selves A
AD  - Pôle d'anesthésie-réanimation, hôpital Rangueil, CHU de Toulouse, 1, avenue du 
      Professeur-Jean-Poulhes TSA 50032, 31059 Toulouse cedex 9, France.
FAU - Ruiz, S
AU  - Ruiz S
FAU - Crognier, L
AU  - Crognier L
FAU - Conil, J-M
AU  - Conil JM
FAU - Bonneville, F
AU  - Bonneville F
FAU - Georges, B
AU  - Georges B
FAU - Dupuy, M
AU  - Dupuy M
FAU - Fourcade, O
AU  - Fourcade O
FAU - Geeraerts, T
AU  - Geeraerts T
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - L'aspirine et ses dangers: syndrome de Reye chez un adulte jeune.
DEP - 20131023
PL  - France
TA  - Ann Fr Anesth Reanim
JT  - Annales francaises d'anesthesie et de reanimation
JID - 8213275
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antiviral Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - X4HES1O11F (Acyclovir)
SB  - IM
MH  - Acyclovir/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Antiviral Agents/therapeutic use
MH  - Aspirin/*adverse effects
MH  - Brain Edema/etiology/therapy
MH  - Coma/etiology/therapy
MH  - Decompressive Craniectomy
MH  - Fatal Outcome
MH  - Glasgow Coma Scale
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Pericarditis/complications
MH  - Resuscitation
MH  - Reye Syndrome/*surgery
MH  - Seizures/etiology/therapy
MH  - Virus Diseases/complications
MH  - Young Adult
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Acide acétylsalicylique
OT  - Adult
OT  - Adulte
OT  - Encephalitis
OT  - Encéphalite
OT  - H1N1
OT  - Reye syndrome
OT  - Syndrome de Reye
EDAT- 2013/10/29 06:00
MHDA- 2014/07/22 06:00
CRDT- 2013/10/29 06:00
PHST- 2013/06/04 00:00 [received]
PHST- 2013/08/20 00:00 [accepted]
PHST- 2013/10/29 06:00 [entrez]
PHST- 2013/10/29 06:00 [pubmed]
PHST- 2014/07/22 06:00 [medline]
AID - S0750-7658(13)01122-2 [pii]
AID - 10.1016/j.annfar.2013.08.009 [doi]
PST - ppublish
SO  - Ann Fr Anesth Reanim. 2013 Nov;32(11):814-6. doi: 10.1016/j.annfar.2013.08.009. 
      Epub 2013 Oct 23.

PMID- 19678849
OWN - NLM
STAT- MEDLINE
DCOM- 20110311
LR  - 20131121
IS  - 1472-8206 (Electronic)
IS  - 0767-3981 (Linking)
VI  - 24
IP  - 3
DP  - 2010 Jun
TI  - Aspirin in the secondary prevention of cardiovascular disease: an update of the 
      APTC meta-analysis.
PG  - 385-91
LID - 10.1111/j.1472-8206.2009.00769.x [doi]
AB  - We updated the 2002 Antiplatelet Trialists' Collaboration meta-analysis of 
      antiplatelet therapy to assess the effects of aspirin alone in the secondary 
      prevention of different types of thrombotic arterial disease. Results of 
      randomized, placebo-controlled trials of aspirin in patients with confirmed 
      cardiovascular disease were abstracted and synthesized by the Mantel-Haenszel 
      method. We defined three cardiovascular disease groups according to the 
      qualifying disease at entry: coronary artery disease (CAD), cerebrovascular 
      disease (CRVD), and peripheral arterial disease (PAD). Results are given as odds 
      ratios (OR) and 95% confidence intervals (95% CI). Compared with placebo, aspirin 
      decreased significantly the risk of all-cause death in CAD and CRVD (OR = 0.80, 
      95% CI 0.75-0.86 and 0.91, 95% CI 0.85-0.98, respectively), and of vascular 
      events in CAD, CRVD, and PAD (OR = 0.71, 95% CI 0.67-0.76, 0.87, 95% CI 
      0.82-0.93, and 0.50, 95% CI 0.29-0.88, respectively). The risk of non-fatal 
      stroke was decreased in the CAD, CRVD, and PAD (OR = 0.64, 95% CI 0.50-0.83, 
      0.81, 95% CI 0.74-0.89, and 0.26, 95% CI 0.07-0.94, respectively). The risk of 
      non-fatal myocardial infarction was decreased significantly in the CAD and CRVD 
      (OR = 0.59, 95% CI 0.53-0.67, and 0.63, 95% CI 0.48-0.84, respectively), but not 
      in the PAD (OR = 0.43, 95% CI 0.15-1.25). Aspirin nearly doubled the risk of 
      major bleeds (OR = 1.87, 95% CI 1.51-2.32 for all clinical conditions). This 
      meta-analysis confirms that aspirin decreases the risk of thrombotic events in 
      patients with confirmed disease of the coronary, cerebrovascular, or peripheral 
      artery beds.
FAU - Lièvre, Michel
AU  - Lièvre M
AD  - Université Claude Bernard Lyon 1, UMR5558, service de pharmacologie clinique, 
      Faculté de Médecine, Rue Guillaume Paradin, F-69008 Lyon, France. 
      ml@upcl.univ-lyon1.fr
FAU - Cucherat, Michel
AU  - Cucherat M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20090812
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/metabolism/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic/methods
MH  - Risk Factors
MH  - Secondary Prevention/*methods
EDAT- 2009/08/15 09:00
MHDA- 2011/03/12 06:00
CRDT- 2009/08/15 09:00
PHST- 2009/08/15 09:00 [entrez]
PHST- 2009/08/15 09:00 [pubmed]
PHST- 2011/03/12 06:00 [medline]
AID - FCP769 [pii]
AID - 10.1111/j.1472-8206.2009.00769.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2010 Jun;24(3):385-91. doi: 
      10.1111/j.1472-8206.2009.00769.x. Epub 2009 Aug 12.

PMID- 16509516
OWN - NLM
STAT- MEDLINE
DCOM- 20060320
LR  - 20181201
IS  - 0028-2200 (Print)
IS  - 0028-2200 (Linking)
VI  - 113
IP  - 2
DP  - 2006 Feb
TI  - [Cardiological (pharmaco)therapy and dental practice].
PG  - 75-81
AB  - In recent years much progress has been made in the treatment of acute coronary 
      syndromes, heart failure and cardiac rhythm disturbances. Polypharmacy including 
      two antiplatelet drugs (aspirin and clopidogrel) is common in many patients after 
      a percutaneous coronary intervention using a 'stent'. Discontinuation of these 
      drugs for invasive dental treatment may result in coronary rethrombosis. However, 
      in many patients with coronary artery disease, a temporal pause in the use of 
      aspirin appears safe and may decrease the risk of bleeding after a dental 
      procedure. An increasing number of patients with heart failure and/or life 
      threatening rhythm disturbances receive an implantable cardioverter defibrillator 
      (ICD). Such a device, equipped with a left ventricular lead, also stimulates the 
      left ventricle in case of delayed electrical conduction (e.g. a left bundle 
      branch block). This so called cardiac resynchronization therapy decreases 
      morbidity and mortality in selected patients. ICDs are safe in the dental office 
      even in case of discharge. In patients with prosthetic heart valves, endocarditis 
      prophylaxis according to the current guidelines is recommended before invasive 
      dental treatment. Dentists are advised to contact the Dutch Thrombosis Service to 
      discuss the dose of oral ancicoagulants and the required INR value. In case of 
      urgent and/or extended dental procedures, admittence to a hospital must be 
      considered to secure optimal therapy.
FAU - Brügemann, J
AU  - Brügemann J
AD  - Cardiologie, Universitair Medisch Centrum Groningen. j.brugemann@thorax.umcg.nl
FAU - van Gelder, I C
AU  - van Gelder IC
FAU - van der Meer, J
AU  - van der Meer J
FAU - Zijlstra, F
AU  - Zijlstra F
LA  - dut
PT  - Journal Article
PT  - Review
TT  - Cardiologie en tandheelkunde.
PL  - Netherlands
TA  - Ned Tijdschr Tandheelkd
JT  - Nederlands tijdschrift voor tandheelkunde
JID - 0400771
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clopidogrel
MH  - Coronary Thrombosis/*etiology/prevention & control
MH  - Defibrillators, Implantable
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Oral Surgical Procedures/*adverse effects
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
RF  - 28
EDAT- 2006/03/03 09:00
MHDA- 2006/03/21 09:00
CRDT- 2006/03/03 09:00
PHST- 2006/03/03 09:00 [pubmed]
PHST- 2006/03/21 09:00 [medline]
PHST- 2006/03/03 09:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Tandheelkd. 2006 Feb;113(2):75-81.

PMID- 16462062
OWN - NLM
STAT- MEDLINE
DCOM- 20060417
LR  - 20190706
IS  - 0009-2363 (Print)
IS  - 0009-2363 (Linking)
VI  - 54
IP  - 2
DP  - 2006 Feb
TI  - Control release effects of binders used in pills of traditional Chinese medicine 
      herbs.
PG  - 188-95
AB  - This research investigated the effects of control release of binders that are 
      used in the pills of Chinese herbal medicine, namely, as processed honey, starch 
      paste, beeswax, or mixtures thereof. Aspirin and baicalin were used as the active 
      pharmaceutical ingredients (API). The processed honey was heated to 110 degrees 
      C, 120 degrees C, or 130 degrees C. In these pills, the binders were the only 
      excipients. The pills were prepared by the stir method using a mixer at 80 
      degrees C without pressure. The differential thermal analysis (DTA) showed that 
      the melting points of aspirin and baicalin were changed by the binders. The 
      Fourier Transform infrared spectra (FT-IR) of aspirin and baicalin suggest that 
      there are different non-covalent molecular interactions between the API and the 
      binders, such as C-H-pi and hydrogen bond interaction. The dissolution profiles 
      indicate that changing the ratio of the binders altered the patterns of 
      dissolution of the API; thus, this ration may be used to control the release of 
      API from the pills.
FAU - Yang, Zhijun
AU  - Yang Z
AD  - School of Chinese Medicine, Hong Kong Baptist University, Kowloon. 
      yzhijun@hkbu.edu.hk
FAU - Wong, Chi Sun
AU  - Wong CS
FAU - Yang, Chun
AU  - Yang C
FAU - Jiang, Zhi-Hong
AU  - Jiang ZH
FAU - Zhao, Zhongzhen
AU  - Zhao Z
FAU - Liu, Liang
AU  - Liu L
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Chem Pharm Bull (Tokyo)
JT  - Chemical & pharmaceutical bulletin
JID - 0377775
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Dextrins)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Excipients)
RN  - 0 (Flavonoids)
RN  - 0 (Tablets)
RN  - 0 (Waxes)
RN  - 2ZA36H0S2V (beeswax)
RN  - 347Q89U4M5 (baicalin)
RN  - 9005-25-8 (Starch)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/chemistry
MH  - Aspirin/administration & dosage/chemistry
MH  - Chemistry, Pharmaceutical
MH  - Delayed-Action Preparations
MH  - Dextrins
MH  - Differential Thermal Analysis
MH  - Drug Compounding
MH  - Drugs, Chinese Herbal/*administration & dosage/*chemistry
MH  - Excipients
MH  - Flavonoids/administration & dosage/chemistry
MH  - Honey
MH  - Solubility
MH  - Spectrophotometry, Infrared
MH  - Spectrophotometry, Ultraviolet
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Starch
MH  - Tablets
MH  - Waxes
EDAT- 2006/02/08 09:00
MHDA- 2006/04/18 09:00
CRDT- 2006/02/08 09:00
PHST- 2006/02/08 09:00 [pubmed]
PHST- 2006/04/18 09:00 [medline]
PHST- 2006/02/08 09:00 [entrez]
AID - JST.JSTAGE/cpb/54.188 [pii]
AID - 10.1248/cpb.54.188 [doi]
PST - ppublish
SO  - Chem Pharm Bull (Tokyo). 2006 Feb;54(2):188-95. doi: 10.1248/cpb.54.188.

PMID- 11512189
OWN - NLM
STAT- MEDLINE
DCOM- 20010920
LR  - 20131121
IS  - 0303-8173 (Print)
IS  - 0303-8173 (Linking)
VI  - 26
IP  - 5
DP  - 1999
TI  - [Platelet aggregation inhibitors in diabetes mellitus].
PG  - 137-41
AB  - Major cardiovascular complications and ischemic events occur more frequently in 
      diabetic than nondiabetic patients. Platelets of diabetic patients are found in a 
      permanent prethrombotic state. Platelet activation and aggregation with resultant 
      arterial thrombus formation, are the central mechanisms in the pathophysiology of 
      acute coronary syndromes. Over the past two decades aspirin was the leading 
      antithrombotic agent for reduction of thrombotic events and efficacy was proven 
      in many studies. The main study concerning the aspirin question was the 
      "Antiplatelet Trialist's Collaboration-Study", where a successful risk reduction 
      for vascular events of 25%-34% was observed with daily dosis between 75 and 325 
      mg. In the last years some new, very effective drugs have been developed. 
      Clopidogrel, a thienopyridine was studied in the CAPRIE trial and compared with 
      aspirin. A small advantage could be proved for clopidogrel. The development of 
      inhibitors of fibrinogen, binding to the platelet glykoprotein IIb/IIIa receptor 
      has expanded the therapeutic spectrum for the treatment of thrombotic disorders. 
      Especially in diabetic patients a significant benefit of these new drugs was 
      demonstrated in various clinical indications. The newest results show the clear 
      advantage of combining thrombolytic agents with the glycoprotein IIb/IIIa 
      receptor antagonists in reperfusion after myocardial infarction. In conclusion 
      the main message is, that diabetic patients do need antithrombotic therapy 
      earlier than nondiabetic patients, that efficient drugs are available and that a 
      primary prevention should be considered in this special patient group.
FAU - Abrahamian, H
AU  - Abrahamian H
AD  - Medizinische Abteilung für Stoffwechselerkrankungen und Nephrologie, Krankenhaus 
      der Stadt Wien-Lainz, Wolkersbergenstrasse 1, A-1130 Wien. 
      abh@3me.khl.magwien.gv.at
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aggregationshemmer bei Diabetes mellitus.
PL  - Austria
TA  - Acta Med Austriaca
JT  - Acta medica Austriaca
JID - 7501997
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - Diabetes Mellitus/blood/*drug therapy
MH  - Diabetic Angiopathies/blood/drug therapy
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
RF  - 20
EDAT- 2001/08/22 10:00
MHDA- 2001/09/21 10:01
CRDT- 2001/08/22 10:00
PHST- 2001/08/22 10:00 [pubmed]
PHST- 2001/09/21 10:01 [medline]
PHST- 2001/08/22 10:00 [entrez]
PST - ppublish
SO  - Acta Med Austriaca. 1999;26(5):137-41.

PMID- 9179433
OWN - NLM
STAT- MEDLINE
DCOM- 19970718
LR  - 20131121
IS  - 0954-7894 (Print)
IS  - 0954-7894 (Linking)
VI  - 27
IP  - 5
DP  - 1997 May
TI  - Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes.
PG  - 574-7
AB  - BACKGROUND: Aspirin-induced asthma (AIA) affects one in 10 individuals with 
      adult-onset asthma. It is not known if aspirin sensitivity is due to immune 
      mechanisms or to interference with biochemical pathways. OBJECTIVE: The study 
      aimed to test for possible involvement of the genes of the Major 
      Histocompatibility Complex (MHC) in AIA. METHODS: HLA-DPB1 and HLA-DRB1 
      genotyping was carried out by DNA methods in 59 patients with positive challenge 
      tests for AIA and in 48 normal and 57 asthmatic controls. RESULTS: The DPB1*0301 
      frequency was increased in AIA patients when compared with normal controls (19.5% 
      vs 5.2%, Odds Ratio = 4.4, 95% Confidence Interval (CI) 1.6-12.1, P = 0.002), and 
      compared with asthmatic controls (4.4%, OR = 5.3, 95% CI = 1.9-14.4, P = 0.0001). 
      The frequency of DPB1*0401 in AIA subjects was decreased when compared with 
      normal controls (28.8% vs 49.0%, OR = 0.42, 95% CI = 0.24-0.74, P = 0.003) and 
      asthmatic controls (45.6%, OR = 0.48, 95% CI = 0.28-0.83, P = 0.008). The results 
      remained significant when corrected for multiple comparisons. There were no 
      significant HLA-DRB1 associations with AIA. CONCLUSION: The presence of an HLA 
      association suggests that immune recognition of an unknown antigen may be part of 
      the aetiology of AIA.
FAU - Dekker, J W
AU  - Dekker JW
AD  - Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK.
FAU - Nizankowska, E
AU  - Nizankowska E
FAU - Schmitz-Schumann, M
AU  - Schmitz-Schumann M
FAU - Pile, K
AU  - Pile K
FAU - Bochenek, G
AU  - Bochenek G
FAU - Dyczek, A
AU  - Dyczek A
FAU - Cookson, W O
AU  - Cookson WO
FAU - Szczeklik, A
AU  - Szczeklik A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - 0 (Allergens)
RN  - 0 (HLA-DP Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alleles
MH  - Allergens/immunology
MH  - Aspirin/immunology/pharmacology
MH  - Asthma/*chemically induced/*genetics
MH  - Bronchial Provocation Tests
MH  - Female
MH  - HLA-DP Antigens/*genetics
MH  - HLA-DR Antigens/*genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Polymerase Chain Reaction
MH  - Skin Tests
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Allergy. 1997 May;27(5):574-7.

PMID- 2299107
OWN - NLM
STAT- MEDLINE
DCOM- 19900308
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 85
IP  - 1 Pt 1
DP  - 1990 Jan
TI  - Long-term effects of aspirin desensitization--treatment for aspirin-sensitive 
      rhinosinusitis-asthma.
PG  - 59-65
AB  - One hundred seven known aspirin (ASA)-sensitive patients with 
      rhinosinusitis-asthma were studied from 1975 to 1988. Forty-two of the patients 
      avoided ASA and served as the control group. Thirty-five patients were 
      desensitized to ASA and treated with daily ASA treatment (Rx) for as long as 8 
      years (mean, 3.75 years) to May 1988 and were designated the continuous group. 
      Thirty patients, initially desensitized to ASA and treated with daily ASA, who 
      stopped Rx permanently after a mean duration of 2 years, were designated the 
      discontinued group. Retrospective analyses of baselines revealed that both 
      continuous and discontinued groups during ASA Rx demonstrated statistically 
      significant reduction in number of hospitalizations per year, emergency room 
      visits per year, outpatient visits per year, upper respiratory 
      infections-sinusitis-antibiotics per year, need for nasal polypectomies and 
      additional sinus operations, and improvement in sense of smell compared to the 
      control group. Simultaneously, the ASA-Rx groups were able to significantly 
      reduce systemic corticosteroid dosage, corticosteroid bursts per year, and, in 
      the continuous group only, significantly reduce inhaled corticosteroids. All 
      three groups maintained control of respiratory symptoms. ASA desensitization 
      followed by long-term daily ASA Rx appears to improve ASA-sensitive 
      rhinosinusitis-asthma and concomitantly allows reduction of systemic 
      corticosteroids.
FAU - Sweet, J M
AU  - Sweet JM
AD  - Department of Basic and Clinical Research, Scripps Clinic and Research 
      Foundation, La Jolla, Calif 92037.
FAU - Stevenson, D D
AU  - Stevenson DD
FAU - Simon, R A
AU  - Simon RA
FAU - Mathison, D A
AU  - Mathison DA
LA  - eng
GR  - AI-10386/AI/NIAID NIH HHS/United States
GR  - M01 RR 00833/RR/NCRR NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Adrenal Cortex Hormones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/chemically induced/*therapy
MH  - Combined Modality Therapy
MH  - *Desensitization, Immunologic/methods
MH  - Drug Therapy, Combination
MH  - Follow-Up Studies
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Rhinitis/chemically induced/*therapy
MH  - Sinusitis/chemically induced/*therapy
MH  - Time Factors
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 0091-6749(90)90222-P [pii]
AID - 10.1016/0091-6749(90)90222-p [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1990 Jan;85(1 Pt 1):59-65. doi: 
      10.1016/0091-6749(90)90222-p.

PMID- 401278
OWN - NLM
STAT- MEDLINE
DCOM- 19900226
LR  - 20131121
IS  - 0071-8041 (Print)
IS  - 0071-8041 (Linking)
VI  - 29
DP  - 1978
TI  - Preventing the prostaglandin effect on dermal ischemia in the burn wound.
PG  - 603-5
AB  - The eventual depth of tissue necrosis after burning is not immediately apparent. 
      In all burn wounds, there exists a zone of stasis which shows progressive 
      microvascular deterioration. These progressive changes have been prevented by 
      methylprednisolone acetate, indomethacin, and ASA. All of these agents are known 
      to inhibit prostaglandin synthesis. These data suggest that prostaglandins have a 
      role in the progressive dermal ischemia after thermal trauma and that their 
      effect can be prevented by specific antiprostaglandins.
FAU - Del Beccaro, E J
AU  - Del Beccaro EJ
AD  - Section of Plastic and Reconstructive Surgery, University of Chicago Pritzker 
      School of Medicine.
FAU - Heggers, J P
AU  - Heggers JP
FAU - Robson, M C
AU  - Robson MC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Surg Forum
JT  - Surgical forum
JID - 0337723
RN  - 0 (Prostaglandin Antagonists)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W7ZR7023 (Methylprednisolone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Burns/*drug therapy/pathology
MH  - Female
MH  - Guinea Pigs
MH  - Indomethacin/pharmacology
MH  - Ischemia/prevention & control
MH  - Methylprednisolone/pharmacology
MH  - Prostaglandin Antagonists/*therapeutic use
MH  - Skin/*blood supply
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
PST - ppublish
SO  - Surg Forum. 1978;29:603-5.

PMID- 2410340
OWN - NLM
STAT- MEDLINE
DCOM- 19850827
LR  - 20131121
IS  - 0323-4347 (Print)
IS  - 0323-4347 (Linking)
VI  - 112
IP  - 2
DP  - 1985
TI  - [The effect of selected drugs on the interpretation of hemostasis- related study 
      results].
PG  - 311-8
AB  - By applying in vitro and additional in vivo investigations of analysing 
      coagulation in human beings with the routine methods TPZW, PTT and TZ it was 
      possible to exclude influences of hemostasis described in literature and often 
      uncritically generalised in papers and articles as well as assumed influences for 
      such medicaments as acetylsalicylic acid, ascorbic acid, chlorpromazine, 
      fluphenazine, gentamycin, haloperidol, lincomycin, methyldopa, sodium fluoride 
      and penicillin G in therapeutic doses or concentrations in vitro respectively 
      which correspond to therapeutic or toxic doses. For such solutions of infusion as 
      infucoll 6% and gelafusal there exist these influences in the sense of an 
      acceleration of coagulation in vitro. They can be regarded as shiftings within 
      the normal range of methods which have no clinical relevance. Infucoll M 40 will 
      to a concentration of 0.25 mmol/l of blood which corresponds to therapeutic 
      conditions, to a shortening of Tz falling below the normal range of the method. 
      These findings correlate with data in literature and could be identified even in 
      lower concentrations by excluding the effect of dilution. According to literature 
      these relations are identical with those in vivo some minutes after infusion.
FAU - Steps, G
AU  - Steps G
FAU - Böhme, H R
AU  - Böhme HR
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Uber den Einfluss ausgewählter Arzneimittel auf die Interpretation 
      hämostaseologischer Untersuchungsergebnisse.
PL  - Germany
TA  - Folia Haematol Int Mag Klin Morphol Blutforsch
JT  - Folia haematologica (Leipzig, Germany : 1928)
JID - 0374615
RN  - 0 (Gentamicins)
RN  - BOD072YW0F (Lincomycin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Tests
MH  - Female
MH  - Gentamicins/pharmacology
MH  - Humans
MH  - Lincomycin/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Thrombin Time
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Folia Haematol Int Mag Klin Morphol Blutforsch. 1985;112(2):311-8.

PMID- 6102409
OWN - NLM
STAT- MEDLINE
DCOM- 19800514
LR  - 20191031
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - 19
IP  - 1
DP  - 1980 Feb
TI  - A placebo-controlled trial of floctafenine (idarac) against enteric-coated 
      acetylsalicylic acid in osteoarthritic patients.
PG  - 52-9
AB  - A double-blind placebo-controlled trial was carried out in 30 out-patients with 
      osteoarthritis of knee and hip. The therapeutic value of flactafenine 1.2 g 
      daily, a new oral non-narcotic analgesic agent, was compared with that of 
      enteric-coated acetylsalicylic acid (ACSA) (Rougier Inc.--enteric-coated 
      acetylsalicylic acid, tablets of 650 mg) 2.6 g daily. Every patient successively 
      received the three medications for six weeks according to a Latin-square design. 
      An objective index of improvement of hips and knees was developed and applied to 
      this study. In both objective and subjective assessments of the disease, 
      floctafenine was found to be approximately equivalent to or superior to ACSA and 
      superior to placebo. Both drugs were clinically well tolerated. A consistant but 
      slight decrease in both haemoglobin and red-blood-cell count under floctafenine 
      and ASA was found to be statistically but not clinically significant.
FAU - Lussier, A
AU  - Lussier A
FAU - Elie, R
AU  - Elie R
FAU - Gareau, J
AU  - Gareau J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Placebos)
RN  - 0 (ortho-Aminobenzoates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*drug therapy
MH  - Placebos
MH  - ortho-Aminobenzoates/*therapeutic use
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
AID - 10.1093/rheumatology/19.1.52 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1980 Feb;19(1):52-9. doi: 10.1093/rheumatology/19.1.52.

PMID- 508556
OWN - NLM
STAT- MEDLINE
DCOM- 19800228
LR  - 20190509
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 8
IP  - 5
DP  - 1979 Nov
TI  - The interaction of varying doses of dipyridamole and acetyl salicylic acid on the 
      inhibition of platelet functions and their effect on bleeding time.
PG  - 483-9
AB  - 1 In normal volunteers maximum reductions in platelet functions, collagen 
      aggregation, adhesion and PF4 availability, were achieved using combined doses of 
      50 mg three times daily dipyridamole + 180 mg ASA or 75 mg three times daily 
      dipyridamole + 120 mg ASA daily. 2 These doses did not prolong the bleeding time. 
      3 A synergistic effect has been demonstrated with 25 mg dipyridamole three times 
      daily and 60 mg ASA. 4 At higher doses the effects on platelet functions were 
      additive up to the maximal response. 5 The effect of low doses of ASA on platelet 
      function was cumulative. 6 As lower doses of ASA in the combination studied 
      inhibit platelet functions maximally without altering the bleeding time and 
      probably without inhibiting prostacyclin, we suggest that these combinations of 
      dipyridamole and ASA merit consideration in future clinical trials.
FAU - Rajah, S M
AU  - Rajah SM
FAU - Penny, A F
AU  - Penny AF
FAU - Crow, M J
AU  - Crow MJ
FAU - Pepper, M D
AU  - Pepper MD
FAU - Watson, D A
AU  - Watson DA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation/*drug effects
MH  - Blood Platelets/*drug effects
MH  - Dipyridamole/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
PMC - PMC1429809
EDAT- 1979/11/01 00:00
MHDA- 1979/11/01 00:01
CRDT- 1979/11/01 00:00
PHST- 1979/11/01 00:00 [pubmed]
PHST- 1979/11/01 00:01 [medline]
PHST- 1979/11/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1979.tb01031.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1979 Nov;8(5):483-9. doi: 
      10.1111/j.1365-2125.1979.tb01031.x.

PMID- 35281068
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20221128
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Low-Molecular-Weight Heparin Versus Aspirin in Early Management of Acute Ischemic 
      Stroke: A Systematic Review and Meta-Analysis.
PG  - 823391
LID - 10.3389/fimmu.2022.823391 [doi]
LID - 823391
AB  - OBJECTIVES: To evaluate the difference between low-molecular-weight heparin 
      (LMWH) and aspirin in preventing early neurological deterioration (END) and 
      recurrent ischemic stroke (RIS), post-recovery independence, and safety outcomes 
      in acute ischemic stroke. MATERIALS AND METHODS: We performed systematic searches 
      of the PubMed, Embase, Web of Science, and Cochrane Library databases for 
      full-text articles of randomized controlled trials (RCTs) of LMWH vs. aspirin in 
      the early management of acute ischemic stroke. Information on study design, 
      eligibility criteria, baseline information, and outcomes was extracted. 
      Synthesized relative risks (RRs) with 95% confidence intervals (CIs) are used to 
      present the differences between the two treatments based on fixed-effects models. 
      RESULTS: Five RCTs were retrieved from the online databases. The results showed 
      no significant difference in efficacy outcomes between the two groups among 
      unselected patients. Subgroup analysis showed that LMWH was significantly related 
      to a lower incidence of END events [relative risk (RR): 0.44, 95% confidence 
      interval (CI): 0.35-0.56] and reduced occurrence of RIS during treatment (OR: 
      0.34, 95% CI: 0.16-0.75) in non-cardioembolic stroke. LMWH significantly 
      increased the number of patients with a modified Rankin scale (mRS) score of 0-1 
      at 6 months in patients with large-artery occlusive disease (LAOD) (RR: 0.50, 95% 
      CI: 0.27-0.91). LMWH had a similar effect on symptomatic intracranial hemorrhage 
      (sICH) and major extracranial hemorrhage during treatment to that of aspirin, 
      except that LMWH was related to an increased likelihood of extracranial 
      hemorrhage. CONCLUSIONS: In patients with acute non-cardioembolic ischemic 
      stroke, especially that with large-artery stenosis, LMWH treatment significantly 
      reduced the incidence of END and RIS, and improved the likelihood of independence 
      (mRS 0-1) at 6 months compared with those with aspirin treatment. LMWH was 
      related to an increased likelihood of extracranial hemorrhage among all patients; 
      however, the difference in major extracranial hemorrhage and sICH was not 
      significant. Choosing the appropriate patients and paying attention to the start 
      time and duration of treatment are very important in the use of anticoagulation. 
      SYSTEMATIC REVIEW REGISTRATION: http://www.crd.york.ac.uk/PROSPERO, identifier 
      CRD42020185446.
CI  - Copyright © 2022 Xia, Wang, Tian, Liu and Zhou.
FAU - Xia, Hui
AU  - Xia H
AD  - Department of Neurology, China-Japan Friendship Hospital, Beijing, China.
FAU - Wang, Ziyao
AU  - Wang Z
AD  - Department of Neurology, China-Japan Friendship Hospital, Beijing, China.
FAU - Tian, Min
AU  - Tian M
AD  - Department of Neurology, China-Japan Friendship Hospital, Beijing, China.
FAU - Liu, Zunjing
AU  - Liu Z
AD  - Department of Neurology, China-Japan Friendship Hospital, Beijing, China.
FAU - Zhou, Zhenhua
AU  - Zhou Z
AD  - Department of Neurology, Southwest Hospital, Third Military Medical University 
      (Army Medical University), Chongqing, China.
LA  - eng
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20220224
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Front Immunol. 2022 Nov 10;13:1052766. PMID: 36439122
MH  - Anticoagulants/adverse effects
MH  - Aspirin/adverse effects
MH  - Hemorrhage
MH  - *Heparin, Low-Molecular-Weight/adverse effects
MH  - Humans
MH  - *Ischemic Stroke/drug therapy
PMC - PMC8908308
OTO - NOTNLM
OT  - aspirin
OT  - ischemic stroke
OT  - large-artery stenosis
OT  - low-molecular-weight heparin
OT  - stroke subtype
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/15 06:00
MHDA- 2022/05/03 06:00
CRDT- 2022/03/14 05:17
PHST- 2021/11/27 00:00 [received]
PHST- 2022/02/03 00:00 [accepted]
PHST- 2022/03/14 05:17 [entrez]
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
AID - 10.3389/fimmu.2022.823391 [doi]
PST - epublish
SO  - Front Immunol. 2022 Feb 24;13:823391. doi: 10.3389/fimmu.2022.823391. eCollection 
      2022.

PMID- 12834179
OWN - NLM
STAT- MEDLINE
DCOM- 20031003
LR  - 20211203
IS  - 0301-0430 (Print)
IS  - 0301-0430 (Linking)
VI  - 59
IP  - 6
DP  - 2003 Jun
TI  - Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced 
      thrombocytopenia in a hemodialysis patient.
PG  - 458-62
AB  - We report on the management of a 36-year-old hemodialysis patient with 
      heparin-induced thrombocytopenia (HIT, type II) and clot formation in 
      extracorporeal circulation. Platelet aggregation test and measurement of 
      anti-platelet factor 4/heparin complex antibody by enzyme-linked immunosorbent 
      assay revealed to us that our patient had developed HIT. Instead of heparin, we 
      used nafamostat mesilate (NM) as an anticoagulant during hemodialysis, but could 
      not completely prevent HIT-induced thrombocytopenia or clot formation in the 
      extracorporeal circuit. Combined use of NM and aspirin completely inhibited 
      platelet aggregation, decrease in platelet count and clot formation in the 
      extracorporeal circuit.
FAU - Takahashi, H
AU  - Takahashi H
AD  - Department of Nephrology, Jichi Medical School, Tochigi, Japan.
FAU - Muto, S
AU  - Muto S
FAU - Nakazawa, E
AU  - Nakazawa E
FAU - Yanagiba, S
AU  - Yanagiba S
FAU - Masunaga, Y
AU  - Masunaga Y
FAU - Miyata, Y
AU  - Miyata Y
FAU - Tamba, K
AU  - Tamba K
FAU - Kusano, E
AU  - Kusano E
FAU - Matsuo, M
AU  - Matsuo M
FAU - Matsuo, T
AU  - Matsuo T
FAU - Asano, Y
AU  - Asano Y
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Germany
TA  - Clin Nephrol
JT  - Clinical nephrology
JID - 0364441
RN  - 0 (Anticoagulants)
RN  - 0 (Benzamidines)
RN  - 0 (Guanidines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - Y25LQ0H97D (nafamostat)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Benzamidines
MH  - Extracorporeal Circulation
MH  - Guanidines/*therapeutic use
MH  - Heparin/*adverse effects/therapeutic use
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Renal Dialysis
MH  - Thrombocytopenia/*prevention & control
EDAT- 2003/07/02 05:00
MHDA- 2003/10/04 05:00
CRDT- 2003/07/02 05:00
PHST- 2003/07/02 05:00 [pubmed]
PHST- 2003/10/04 05:00 [medline]
PHST- 2003/07/02 05:00 [entrez]
AID - 10.5414/cnp59458 [doi]
PST - ppublish
SO  - Clin Nephrol. 2003 Jun;59(6):458-62. doi: 10.5414/cnp59458.

PMID- 30413815
OWN - NLM
STAT- MEDLINE
DCOM- 20190723
LR  - 20230216
IS  - 1530-0307 (Electronic)
IS  - 0023-6837 (Print)
IS  - 0023-6837 (Linking)
VI  - 99
IP  - 2
DP  - 2019 Feb
TI  - Sex-associated preventive effects of low-dose aspirin on obesity and 
      non-alcoholic fatty liver disease in mouse offspring with over-nutrition in 
      utero.
PG  - 244-259
LID - 10.1038/s41374-018-0144-2 [doi]
AB  - Aspirin has been found to diminish hypertriglyceridemia and hyperglycemia in both 
      obese rodents and patients with type 2 diabetes mellitus. We aimed to test 
      whether low-dose aspirin can prevent obesity and the progression of non-alcoholic 
      fatty liver disease (NAFLD) in high-risk subjects. We used offspring mice with 
      maternal over-nutrition as a high-risk model of obesity and NAFLD. The offspring 
      were given postnatal HF-diet and diethylnitrosamine (DEN) to induce obesity and 
      NAFLD, and were treated with or without a low dose of aspirin for 12 weeks (ASP 
      or CTL groups). Aspirin treatment reduced body weight gain, reversed glucose 
      intolerance, and depressed hepatic lipid accumulation in female, but not in male 
      mice. Female mice displayed re-sensitized insulin/Akt signaling and overactivated 
      AMPK signaling, with enhanced level of hepatic PPAR-γ, Glut4, and Glut2, while 
      male mice only enhanced hepatic PPAR-α and PPAR-γ levels. The female ASP mice had 
      inhibited p44/42 MAPK activity and enhanced Pten expression, while male displayed 
      activated p38 MAPK signaling. Furthermore, the female but not the male ASP mice 
      reduced Wnt-signaling activity via both the epigenetic regulation of Apc 
      expression and the post-transcriptional regulation of β-catenin degradation. In 
      summary, our study demonstrates a sex-associated effect of low-dose aspirin on 
      obesity and NAFLD prevention in female but not in male mice.
FAU - Zhou, Yi
AU  - Zhou Y
AD  - Tongji Hospital, Huazhong University of Science and Technology, 430030, Wuhan, 
      Hubei, China.
AD  - Department of Nutrition and Food Sciences, Texas A&M University, College Station, 
      TX, 77843, USA.
FAU - Peng, Hui
AU  - Peng H
AD  - Tongji Hospital, Huazhong University of Science and Technology, 430030, Wuhan, 
      Hubei, China.
AD  - Department of Nutrition and Food Sciences, Texas A&M University, College Station, 
      TX, 77843, USA.
FAU - Liu, Zhimin
AU  - Liu Z
AD  - Department of Nutrition and Food Sciences, Texas A&M University, College Station, 
      TX, 77843, USA.
AD  - Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen 
      University (Gastrointestinal and Anal Hospital), 510655, Guangzhou, China.
FAU - Zhang, Ke K
AU  - Zhang KK
AD  - Department of Nutrition and Food Sciences, Texas A&M University, College Station, 
      TX, 77843, USA.
AD  - Department of Pathology, University of North Dakota, Grand Forks, ND, 58202, USA.
AD  - Center for Epigenetics & Disease Prevention, Institute of Biosciences & 
      Technology, College of Medicine, Texas A&M University, Houston, TX, 77030, USA.
FAU - Jendrusch, Chelsea
AU  - Jendrusch C
AD  - Department of Nutrition and Food Sciences, Texas A&M University, College Station, 
      TX, 77843, USA.
FAU - Drake, Madeline
AU  - Drake M
AD  - Department of Nutrition and Food Sciences, Texas A&M University, College Station, 
      TX, 77843, USA.
FAU - Hao, Yi
AU  - Hao Y
AD  - Department of Microbiology, Tongji Medical College, Huazhong University of 
      Science and Technology, 430030, Wuhan, Hubei, China.
FAU - Xie, Linglin
AU  - Xie L
AD  - Department of Nutrition and Food Sciences, Texas A&M University, College Station, 
      TX, 77843, USA. Linglin.xie@tamu.edu.
LA  - eng
GR  - R01 DK112368/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20181109
PL  - United States
TA  - Lab Invest
JT  - Laboratory investigation; a journal of technical methods and pathology
JID - 0376617
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Body Weight/*drug effects
MH  - Diet, High-Fat
MH  - Female
MH  - Glucose Intolerance/metabolism
MH  - Lipid Metabolism/drug effects
MH  - Male
MH  - Maternal Nutritional Physiological Phenomena
MH  - Mice
MH  - Non-alcoholic Fatty Liver Disease/*metabolism/prevention & control
MH  - Obesity/*metabolism
MH  - Overnutrition/metabolism
MH  - Signal Transduction/drug effects
PMC - PMC6354253
MID - NIHMS1504981
COIS- COMPETING FIANCIAL INTERESTS No potential conflicts of interest relevant to this 
      article were reported.
EDAT- 2018/11/11 06:00
MHDA- 2019/07/25 06:00
CRDT- 2018/11/11 06:00
PHST- 2018/06/04 00:00 [received]
PHST- 2018/08/23 00:00 [accepted]
PHST- 2018/08/16 00:00 [revised]
PHST- 2018/11/11 06:00 [pubmed]
PHST- 2019/07/25 06:00 [medline]
PHST- 2018/11/11 06:00 [entrez]
AID - S0023-6837(22)01057-1 [pii]
AID - 10.1038/s41374-018-0144-2 [doi]
PST - ppublish
SO  - Lab Invest. 2019 Feb;99(2):244-259. doi: 10.1038/s41374-018-0144-2. Epub 2018 Nov 
      9.

PMID- 26702085
OWN - NLM
STAT- MEDLINE
DCOM- 20160913
LR  - 20190110
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 4
IP  - 12
DP  - 2015 Dec 23
TI  - Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980-2009: 
      The Minnesota Heart Survey.
LID - 10.1161/JAHA.115.002320 [doi]
LID - e002320
AB  - BACKGROUND: Daily low-dose aspirin is recommended for primary prevention of 
      myocardial infarction and stroke in higher-risk patients. Population trends in 
      aspirin use for cardiovascular disease (CVD) prevention in an urban population 
      (Minneapolis/St. Paul, 2010 population 2.85 million) from 1980 to 2009 were 
      evaluated. METHODS AND RESULTS: Surveys of randomly selected adults aged 25 to 74 
      years were collected at 5-year intervals. Self-reports of regular aspirin use for 
      CVD prevention and history of CVD were obtained. Six cross-sectional surveys 
      included 12 281 men and 14 258 women. Age-adjusted aspirin use for primary 
      prevention increased during this period from 1% to 21% among men and 1% to 12% 
      among women. Aspirin use was highest in those aged 65 to 74 years. For secondary 
      prevention, age-adjusted aspirin use increased from 19% to 74% among men and 11% 
      to 64% among women. While data are based on self-report, a substudy using a 
      biochemical indicator of aspirin use (serum thromboxane B2) supports the validity 
      of self-report. CONCLUSIONS: Aspirin for CVD prevention is commonly used by a 
      large and growing portion of the general population. It is not known if this is 
      based on professional advice or self-prescribed use. It is also likely that many 
      who would benefit do not use aspirin and others use aspirin inappropriately.
CI  - © 2015 The Authors. Published on behalf of the American Heart Association, Inc., 
      by Wiley Blackwell.
FAU - Luepker, Russell V
AU  - Luepker RV
AD  - Division of Epidemiology and Community Health, School of Public Health, 
      University of Minnesota, Minneapolis, MN (R.V.L., L.M.S., X.Z., A.T.H.) Lillehei 
      Heart Institute and Cardiovascular Division, University of Minnesota Medical 
      School, Minneapolis, MN (R.V.L., S.D., A.T.H.).
FAU - Steffen, Lyn M
AU  - Steffen LM
AD  - Division of Epidemiology and Community Health, School of Public Health, 
      University of Minnesota, Minneapolis, MN (R.V.L., L.M.S., X.Z., A.T.H.).
FAU - Duval, Sue
AU  - Duval S
AD  - Lillehei Heart Institute and Cardiovascular Division, University of Minnesota 
      Medical School, Minneapolis, MN (R.V.L., S.D., A.T.H.).
FAU - Zantek, Nicole D
AU  - Zantek ND
AD  - Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 
      (N.D.Z.).
FAU - Zhou, Xia
AU  - Zhou X
AD  - Division of Epidemiology and Community Health, School of Public Health, 
      University of Minnesota, Minneapolis, MN (R.V.L., L.M.S., X.Z., A.T.H.).
FAU - Hirsch, Alan T
AU  - Hirsch AT
AD  - Division of Epidemiology and Community Health, School of Public Health, 
      University of Minnesota, Minneapolis, MN (R.V.L., L.M.S., X.Z., A.T.H.) Lillehei 
      Heart Institute and Cardiovascular Division, University of Minnesota Medical 
      School, Minneapolis, MN (R.V.L., S.D., A.T.H.).
LA  - eng
GR  - R01 HL126041/HL/NHLBI NIH HHS/United States
GR  - 5R01HL023727-28/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20151223
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Heart Assoc. 2015 Dec;4(12). pii: e002927. doi: 10.1161/JAHA.115.002927. 
      PMID: 26702080
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Minnesota/epidemiology
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Sex Factors
MH  - Surveys and Questionnaires
PMC - PMC4845283
OTO - NOTNLM
OT  - aspirin
OT  - epidemiology
OT  - prevention
EDAT- 2015/12/25 06:00
MHDA- 2016/09/14 06:00
CRDT- 2015/12/25 06:00
PHST- 2015/12/25 06:00 [entrez]
PHST- 2015/12/25 06:00 [pubmed]
PHST- 2016/09/14 06:00 [medline]
AID - JAHA.115.002320 [pii]
AID - JAH31203 [pii]
AID - 10.1161/JAHA.115.002320 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2015 Dec 23;4(12):e002320. doi: 10.1161/JAHA.115.002320.

PMID- 7126359
OWN - NLM
STAT- MEDLINE
DCOM- 19821221
LR  - 20131121
IS  - 0037-8771 (Print)
IS  - 0037-8771 (Linking)
VI  - 58
IP  - 13
DP  - 1982 Jul 15
TI  - [In vitro effect of culture fluids from neoplastic tissues on platelet 
      aggregation. II. Experimental tumors].
PG  - 854-9
AB  - We have investigated the effects on platelet function of culture media from 2 
      sublines of a benzopyrene-induced murine sarcoma (mFS6). Platelet aggregation was 
      investigated according to Born's method. The cell line with greater "in vivo" 
      invasiveness showed higher aggregating activity and higher increase on 
      ADP-induced aggregation; these effects were inhibited by the preincubation of 
      platelets with Aspirin (0,1 mM). These results suggest the role of platelets in 
      metastasis formation; the possibility to inhibit pharmacologically the 
      interactions between platelets and tumour cells could have important implications 
      from both speculative and practical viewpoints.
FAU - Pacchiarini, L
AU  - Pacchiarini L
FAU - Serra, L
AU  - Serra L
FAU - Grignani, G
AU  - Grignani G
FAU - Gamba, G
AU  - Gamba G
FAU - Gorini, M
AU  - Gorini M
LA  - ita
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Azione in vitro sull'aggregazione piastrinica dei liquidi di coltura di tessuti 
      neoplastici. II) Tumori sperimentali.
PL  - Italy
TA  - Boll Soc Ital Biol Sper
JT  - Bollettino della Societa italiana di biologia sperimentale
JID - 7506962
RN  - 0 (Culture Media)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Culture Media/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Mice
MH  - Platelet Aggregation/*drug effects
MH  - Sarcoma, Experimental/*analysis
EDAT- 1982/07/15 00:00
MHDA- 1982/07/15 00:01
CRDT- 1982/07/15 00:00
PHST- 1982/07/15 00:00 [pubmed]
PHST- 1982/07/15 00:01 [medline]
PHST- 1982/07/15 00:00 [entrez]
PST - ppublish
SO  - Boll Soc Ital Biol Sper. 1982 Jul 15;58(13):854-9.

PMID- 6176388
OWN - NLM
STAT- MEDLINE
DCOM- 19820719
LR  - 20170214
IS  - 0009-9228 (Print)
IS  - 0009-9228 (Linking)
VI  - 21
IP  - 5
DP  - 1982 May
TI  - Parents' conception of their use of over-the-counter medicines.
PG  - 298-301
AB  - To explore their hypothetical responses to management of fever or nasal 
      congestion in their children, 109 patients were interviewed in a clinic 
      waiting-room area. Most parents said they would medicate their children in these 
      situations without first consulting a health professional. Parents were more 
      willing to administer a drug product for fever than for nasal congestion, 
      especially to children under 2 years of age. Although most parents selected 
      appropriate medications for these situations, many were poorly informed about 
      these drugs and falsely attributed germicidal and decongestant properties to 
      aspirin and Tylenol. Younger, less educated, indigent parents in lower-status 
      occupations were the least well informed. Pediatricians need to prepare parents 
      for their role as health care providers.
FAU - Ames, J T
AU  - Ames JT
FAU - Hayden, G F
AU  - Hayden GF
FAU - Campbell, R E
AU  - Campbell RE
FAU - Lohr, J A
AU  - Lohr JA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Pediatr (Phila)
JT  - Clinical pediatrics
JID - 0372606
RN  - 0 (Nasal Decongestants)
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Child, Preschool
MH  - Fever/drug therapy
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Nasal Decongestants/therapeutic use
MH  - Nonprescription Drugs/*therapeutic use
MH  - Parents/*education
MH  - Socioeconomic Factors
EDAT- 1982/05/01 00:00
MHDA- 1982/05/01 00:01
CRDT- 1982/05/01 00:00
PHST- 1982/05/01 00:00 [pubmed]
PHST- 1982/05/01 00:01 [medline]
PHST- 1982/05/01 00:00 [entrez]
AID - 10.1177/000992288202100506 [doi]
PST - ppublish
SO  - Clin Pediatr (Phila). 1982 May;21(5):298-301. doi: 10.1177/000992288202100506.

PMID- 23029468
OWN - NLM
STAT- MEDLINE
DCOM- 20130221
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 7
IP  - 9
DP  - 2012
TI  - H(2)S-releasing aspirin protects against aspirin-induced gastric injury via 
      reducing oxidative stress.
PG  - e46301
LID - 10.1371/journal.pone.0046301 [doi]
LID - e46301
AB  - The aim of this study was to examine the effect of ACS14, a hydrogen sulfide 
      (H(2)S)-releasing derivative of aspirin (Asp), on Asp-induced gastric injury. 
      Gastric hemorrhagic lesions were induced by intragastric administration of Asp 
      (200 mg/kg, suspended in 0.5% carboxymethyl cellulose solutions) in a volume of 1 
      ml/100 g body weight. ACS14 (1, 5 or 10 mg/kg) was given 30 min before the Asp 
      administration. The total area of gastric erosions, H(2)S concentration and 
      oxidative stress in gastric tissues were measured three hours after 
      administration of Asp. Treatment with Asp (200 mg/kg), but not ACS14 (430 mg/kg, 
      at equimolar doses to 200 mg/kg Asp), for 3 h significantly increased gastric 
      mucosal injury. The damage caused by Asp was reversed by ACS14 at 1-10 mg/kg in a 
      concentration-dependent manner. ACS14 abrogated Asp-induced upregulation of COX-2 
      expression, but had no effect on the reduced PGE(2) level. ACS14 reversed the 
      decreased H(2)S concentrations and blood flow in the gastric tissue in 
      Asp-treated rats. Moreover, ACS14 attenuated Asp-suppressed superoxide 
      dismutase-1 (SOD-1) expression and GSH activity, suggesting that ACS14 may 
      stimulate antioxidants in the gastric tissue. ACS14 also obviously inhibited 
      Asp-induced upregulation of protein expression of oxidases including XOD, 
      p47(phox) and p67(phox). In conclusion, ACS14 protects Asp induced gastric 
      mucosal injury by inhibiting oxidative stress in the gastric tissue.
FAU - Liu, Lei
AU  - Liu L
AD  - Department of Physiology, Xuzhou Medical College, Xuzhou, Jiangsu, People's 
      Republic of China.
FAU - Cui, Jie
AU  - Cui J
FAU - Song, Cheng-Jie
AU  - Song CJ
FAU - Bian, Jin-Song
AU  - Bian JS
FAU - Sparatore, Anna
AU  - Sparatore A
FAU - Soldato, Piero Del
AU  - Soldato PD
FAU - Wang, Xin-Yu
AU  - Wang XY
FAU - Yan, Chang-Dong
AU  - Yan CD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120928
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (2-acetyloxybenzoic acid 4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl ester)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Disulfides)
RN  - 0 (Phosphoproteins)
RN  - 0 (neutrophil cytosol factor 67K)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (Ptgs2 protein, rat)
RN  - EC 1.15.1.1 (Sod1 protein, rat)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - EC 1.15.1.1 (Superoxide Dismutase-1)
RN  - EC 1.17.3.2 (Xanthine Oxidase)
RN  - EC 1.6.3.- (NADPH Oxidases)
RN  - EC 1.6.3.1 (neutrophil cytosolic factor 1)
RN  - GAN16C9B8O (Glutathione)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology/therapeutic use
MH  - Cyclooxygenase 2/genetics/metabolism
MH  - Delayed-Action Preparations/chemistry/pharmacology/*therapeutic use
MH  - Dinoprostone/metabolism
MH  - Disulfides/chemistry/pharmacology/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/drug effects/metabolism/pathology
MH  - Gene Expression Regulation/drug effects
MH  - Glutathione/metabolism
MH  - Hydrogen Sulfide/*chemistry
MH  - Male
MH  - NADPH Oxidases/genetics/metabolism
MH  - Oxidative Stress/*drug effects
MH  - Phosphoproteins/genetics/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Stomach Ulcer/chemically induced/*drug therapy/metabolism
MH  - Superoxide Dismutase/genetics/metabolism
MH  - Superoxide Dismutase-1
MH  - Xanthine Oxidase/genetics/metabolism
PMC - PMC3460860
COIS- Competing Interests: Dr. Piero Del Soldato is a shareholder and employee of CTG 
      Pharma, Milan, Italy. This company has patent on ACS14 used in this study. There 
      are no further patents, products in development or marketed products to declare. 
      This does not alter the authors' adherence to all the PLOS ONE policies on 
      sharing data and materials, as detailed online in the guide for authors.
EDAT- 2012/10/03 06:00
MHDA- 2013/02/22 06:00
CRDT- 2012/10/03 06:00
PHST- 2012/06/06 00:00 [received]
PHST- 2012/08/29 00:00 [accepted]
PHST- 2012/10/03 06:00 [entrez]
PHST- 2012/10/03 06:00 [pubmed]
PHST- 2013/02/22 06:00 [medline]
AID - PONE-D-12-16816 [pii]
AID - 10.1371/journal.pone.0046301 [doi]
PST - ppublish
SO  - PLoS One. 2012;7(9):e46301. doi: 10.1371/journal.pone.0046301. Epub 2012 Sep 28.

PMID- 2873067
OWN - NLM
STAT- MEDLINE
DCOM- 19860813
LR  - 20131121
IS  - 0011-8532 (Print)
IS  - 0011-8532 (Linking)
VI  - 30
IP  - 3
DP  - 1986 Jul
TI  - Pharmacotherapeutics in urgent dental care.
PG  - 399-420
AB  - A frequent requisite to urgent dental care is the use of pharmacotherapeutic 
      agents as part of the treatment protocol. Anxiolytics, anesthetics, analgesics, 
      and antibiotics are prescribed as dictated by particular clinical situations.
FAU - Terezhalmy, G T
AU  - Terezhalmy GT
FAU - Bowen, L L
AU  - Bowen LL
FAU - Rye, L A
AU  - Rye LA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Dent Clin North Am
JT  - Dental clinics of North America
JID - 0217440
RN  - 0 (Aminophenols)
RN  - 0 (Anesthetics, Local)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Barbiturates)
RN  - 0 (Histamine H1 Antagonists)
RN  - 0 (Narcotics)
RN  - 12794-10-4 (Benzodiazepines)
RN  - R16CO5Y76E (Aspirin)
RN  - R7P8FRP05V (4-aminophenol)
SB  - IM
MH  - Aminophenols/metabolism/pharmacology/therapeutic use
MH  - Anesthetics, Local
MH  - Anti-Bacterial Agents/pharmacology/therapeutic use
MH  - Anti-Inflammatory Agents/metabolism/pharmacology/therapeutic use
MH  - Anxiety/prevention & control
MH  - Aspirin/metabolism/pharmacology/therapeutic use
MH  - Bacterial Infections/drug therapy
MH  - Barbiturates/metabolism/pharmacology/therapeutic use
MH  - Benzodiazepines/metabolism/pharmacology/therapeutic use
MH  - *Dental Care/psychology
MH  - *Drug Therapy
MH  - Emergencies
MH  - Histamine H1 Antagonists/therapeutic use
MH  - Humans
MH  - Kinetics
MH  - Narcotics/metabolism/pharmacology/therapeutic use
MH  - Pain/drug therapy
RF  - 49
EDAT- 1986/07/01 00:00
MHDA- 1986/07/01 00:01
CRDT- 1986/07/01 00:00
PHST- 1986/07/01 00:00 [pubmed]
PHST- 1986/07/01 00:01 [medline]
PHST- 1986/07/01 00:00 [entrez]
PST - ppublish
SO  - Dent Clin North Am. 1986 Jul;30(3):399-420.

PMID- 6727549
OWN - NLM
STAT- MEDLINE
DCOM- 19840709
LR  - 20190701
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 34
IP  - 20
DP  - 1984 May 14
TI  - The effects of aspirin and dimethyl sulphoxide on the latency of lysosomes in a 
      cell-free system.
PG  - 1967-75
AB  - Lysosomal preparations were exposed to various concentrations of 
      dimethylsulphoxide (DMSO) and aspirin singularly and in combination. Acid 
      phosphatase and beta-glucuronidase activities were measured and utilized as an 
      indication of lysosomal membrane stability under experimental conditions in the 
      presence and absence of these drugs. Extremely low concentrations of each drug 
      were employed in an attempt to mimic the levels which might be feasible in vivo. 
      There was a significant decrease of enzyme activity (increased structure-linked 
      latency) in the presence of DMSO. Aspirin had no significant effect on the 
      latency of the lysosomes. There was no indication of synergism between DMSO and 
      aspirin. It was concluded that some of the therapeutic advantages attributed to 
      DMSO in the treatment of arthritis and other musculoskeletal diseases may come 
      from the stabilization of lysosomes in cells that contribute to the pathological 
      condition. Aspirin did not seem to exert a therapeutic effect through this 
      mechanism.
FAU - Zodrow, J
AU  - Zodrow J
FAU - Rogers, S H
AU  - Rogers SH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - EC 3.1.3.2 (Acid Phosphatase)
RN  - EC 3.2.1.31 (Glucuronidase)
RN  - R16CO5Y76E (Aspirin)
RN  - YOW8V9698H (Dimethyl Sulfoxide)
SB  - IM
MH  - Acid Phosphatase/analysis
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cell-Free System
MH  - Dimethyl Sulfoxide/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Glucuronidase/analysis
MH  - Lysosomes/*drug effects/enzymology
MH  - Mice
EDAT- 1984/05/14 00:00
MHDA- 1984/05/14 00:01
CRDT- 1984/05/14 00:00
PHST- 1984/05/14 00:00 [pubmed]
PHST- 1984/05/14 00:01 [medline]
PHST- 1984/05/14 00:00 [entrez]
AID - 0024-3205(84)90128-0 [pii]
AID - 10.1016/0024-3205(84)90128-0 [doi]
PST - ppublish
SO  - Life Sci. 1984 May 14;34(20):1967-75. doi: 10.1016/0024-3205(84)90128-0.

PMID- 22497730
OWN - NLM
STAT- MEDLINE
DCOM- 20130718
LR  - 20181202
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 24
IP  - 2
DP  - 2013
TI  - Impaired responsiveness to clopidogrel and aspirin in patients with recurrent 
      stent thrombosis following percutaneous intervention for peripheral artery 
      disease.
PG  - 151-5
LID - 10.3109/09537104.2012.676220 [doi]
AB  - Patients with peripheral artery disease (PAD) following peripheral percutaneous 
      transluminal angioplasty (PTA) with stent implantation are prone to stent 
      thrombosis despite treatment with aspirin and clopidogrel. Impaired clopidogrel 
      responsiveness is associated with increased risk of ischemic events in patients 
      following coronary stent implantation. We sought to assess platelet 
      responsiveness to clopidogrel and aspirin in patients with PAD and recurrent 
      stent thrombosis. Platelet aggregation induced by 5 and 20 µmol/l adenosine 
      diphosphate (ADP) and 0.5 mmol/l arachidonic acid (AA), together with platelet 
      reactivity index (PRI) and serum thromboxane B(2) (TXB(2)), were determined in 11 
      patients with PAD and a history of stent thrombosis (mean, 3.1 ± 1.14) after PTA 
      and in 15 patients with PAD with no such history, also in 11 controls with 
      coronary artery disease (CAD) and previous stent thrombosis. Platelet aggregation 
      to 5 µmol/l ADP was higher in subjects with PAD and stent thrombosis than in 
      those without stent thrombosis (p = 0.0003) and CAD subjects (p = 0.002). 
      Aggregation induced by 20 µmol/l ADP was higher in PAD group with stent 
      thrombosis than in PAD subjects without thrombosis (p = 0.004). The PAD group 
      with stent thrombosis had higher AA-induced platelet aggregation than CAD 
      controls (p = 0.007) and serum TXB(2) concentrations higher than PAD group 
      without thrombosis (p = 0.002) and CAD group (p = 0.02). Concluding, platelet 
      responsiveness to clopidogrel and aspirin is impaired in patients with PAD and 
      recurrent stent thrombosis following PTA, as compared with similar individuals 
      with CAD, and PAD with no history of stent thrombosis. This indicates that 
      atherosclerosis burden affects platelet function and might contribute to stent 
      thrombosis following percutaneous intervention in peripheral arteries.
FAU - Mazur, Piotr
AU  - Mazur P
AD  - Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland.
FAU - Frołow, Marzena
AU  - Frołow M
FAU - Niżankowski, Rafał
AU  - Niżankowski R
FAU - Sadowski, Jerzy
AU  - Sadowski J
FAU - Undas, Anetta
AU  - Undas A
LA  - eng
PT  - Journal Article
DEP - 20120413
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angioplasty/adverse effects
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/*physiology
MH  - Clopidogrel
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peripheral Arterial Disease/therapy
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Risk Factors
MH  - Stents
MH  - Thrombosis/drug therapy/etiology
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2012/04/14 06:00
MHDA- 2013/07/19 06:00
CRDT- 2012/04/14 06:00
PHST- 2012/04/14 06:00 [entrez]
PHST- 2012/04/14 06:00 [pubmed]
PHST- 2013/07/19 06:00 [medline]
AID - 10.3109/09537104.2012.676220 [doi]
PST - ppublish
SO  - Platelets. 2013;24(2):151-5. doi: 10.3109/09537104.2012.676220. Epub 2012 Apr 13.

PMID- 6541932
OWN - NLM
STAT- MEDLINE
DCOM- 19841212
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 34
IP  - 9A
DP  - 1984
TI  - Some aspects of pain measurement in man.
PG  - 1093-5
AB  - Methods of clinical and experimental algesimetry are described that have been 
      used to evaluate effects of peripherally and centrally acting analgesics. Since 
      pain is a complex psychophysical phenomenon, algesimetry has a lot of inherent 
      problems which are discussed.
FAU - Handwerker, H O
AU  - Handwerker HO
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Neurons/physiology
MH  - Nociceptors/physiology
MH  - Pain/drug therapy/*physiopathology
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1984;34(9A):1093-5.

PMID- 9038687
OWN - NLM
STAT- MEDLINE
DCOM- 19970311
LR  - 20190503
IS  - 1355-6037 (Print)
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 77
IP  - 1
DP  - 1997 Jan
TI  - Ticlopidine and aspirin interactions.
PG  - 11-2
AB  - The risk-benefit balance when aspirin is compared with aspirin combined with 
      ticlopidine is being investigated in several multicentre trials (MUSIC and WEST 
      II versus TASTE, MUST, and STARS respectively). Cardiologists follow one of two 
      strategies. Some prefer a more aggressive antiplatelet regimen, disregarding the 
      risk of neutropenia (0.7%) because they want to avoid lessening the therapeutic 
      effect of vessel patency obtained with stent implantation. Others give only 
      aspirin (a money saving approach) confident that IVUS inspection (an expensive 
      approach) will allow an adequate evaluation of full stent expansion and lesion 
      coverage, despite a more pronounced activation of the coagulation cascade. Our 
      impression so far is that the combination of ticlopidine and aspirin has a more 
      favourable risk-effect balance.
FAU - Gregorini, L
AU  - Gregorini L
AD  - Clinica Medica Generale, Università di Milano, Ospedale Maggiore IRCCS, Italy.
FAU - Marco, J
AU  - Marco J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/*prevention & control/therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Recurrence
MH  - Ticlopidine/*therapeutic use
PMC - PMC484627
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1136/hrt.77.1.11 [doi]
PST - ppublish
SO  - Heart. 1997 Jan;77(1):11-2. doi: 10.1136/hrt.77.1.11.

PMID- 11009265
OWN - NLM
STAT- MEDLINE
DCOM- 20001005
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 86
IP  - 5
DP  - 2000 Sep 1
TI  - Effects of cilostazol on angiographic restenosis after coronary stent placement.
PG  - 499-503
AB  - This study evaluates the impact of cilostazol on post-stenting restenosis. 
      Cilostazol is a potent antiplatelet agent with antiproliferative properties. Few 
      data are available about the effect of cilostazol on poststenting restenosis. 
      Four hundred nine patients (494 lesions) who were scheduled for elective stenting 
      were randomized to receive aspirin plus ticlopidine (group I, n = 201, 240 
      lesions) or aspirin plus cilostazol (group II, n = 208, 254 lesions), starting 2 
      days before stenting. Ticlopidine was given for 1 month and cilostazol for 6 
      months. Follow-up angiography was performed at 6 months, and clinical evaluation 
      at regular intervals. Baseline characteristics were similar between the 2 groups. 
      The procedural success rate was 99.6% in group I and 100% in group II. There were 
      no cases of stent thrombosis after stenting. Angiographic follow-up was performed 
      in 380 of the 494 eligible lesions and the angiographic restenosis rate was 27% 
      in group I and 22.9% in group II (p = NS). However, diffuse type in-stent 
      restenosis was more common in group I than in group II (54.2% vs 26.8%, 
      respectively, p <0.05). In diabetic patients, the angiographic restenosis rate 
      was 50% in group I and 21.7% in group II (p <0.05). Clinical events during 
      follow-up did not differ between the 2 groups. In conclusion, aspirin plus 
      cilostazol seems to be an effective antithrombotic regimen with comparable 
      results to aspirin plus ticlopidine, but it does not reduce the overall 
      angiographic restenosis rate after elective coronary stenting.
FAU - Park, S W
AU  - Park SW
AD  - Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea.
FAU - Lee, C W
AU  - Lee CW
FAU - Kim, H S
AU  - Kim HS
FAU - Lee, N H
AU  - Lee NH
FAU - Nah, D Y
AU  - Nah DY
FAU - Hong, M K
AU  - Hong MK
FAU - Kim, J J
AU  - Kim JJ
FAU - Park, S J
AU  - Park SJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cilostazol
MH  - Coronary Angiography
MH  - Coronary Disease/therapy
MH  - Disease-Free Survival
MH  - Drug Therapy, Combination
MH  - Follow-Up Studies
MH  - Humans
MH  - Phosphodiesterase Inhibitors/adverse effects/therapeutic use
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Recurrence
MH  - *Stents
MH  - Tetrazoles/adverse effects/*therapeutic use
MH  - Ticlopidine/adverse effects/therapeutic use
EDAT- 2000/09/29 11:00
MHDA- 2000/10/07 11:01
CRDT- 2000/09/29 11:00
PHST- 2000/09/29 11:00 [pubmed]
PHST- 2000/10/07 11:01 [medline]
PHST- 2000/09/29 11:00 [entrez]
AID - S0002-9149(00)01001-8 [pii]
AID - 10.1016/s0002-9149(00)01001-8 [doi]
PST - ppublish
SO  - Am J Cardiol. 2000 Sep 1;86(5):499-503. doi: 10.1016/s0002-9149(00)01001-8.

PMID- 2647494
OWN - NLM
STAT- MEDLINE
DCOM- 19890511
LR  - 20220330
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 10
IP  - 2
DP  - 1989 Feb
TI  - Prevention of aortocoronary vein-graft attrition with low-dose aspirin and 
      triflusal, both associated with dipyridamole: a randomized, double-blind, 
      placebo-controlled trial.
PG  - 159-67
AB  - A randomized, double-blind, placebo-controlled trial was performed in 209 
      patients to evaluate the efficacy of a low dose of aspirin plus dipyridamole or 
      that of a new antiplatelet agent (triflusal) plus dipyridamole in the prevention 
      of aortocoronary vein-graft occlusion. An angiographic control performed in 161 
      patients 9 days after surgery showed no significant differences between groups, 
      but a new control on 138 of those patients 6 months later did show significant 
      linear trends towards fewer distal anastomosis occlusions (P = 0.027) from the 
      placebo (24%, 22/91) to the aspirin (16%, 17/106) and to the trifusal groups 
      (12%, 10/86), and towards fewer new occlusions (P = 0.056) from 12% (9/78) to 10% 
      (10/99) and to 2.6% (2/78), respectively, in the same groups. A multivariate 
      logistic regression model, used to determine the effect of 33 variables on distal 
      anastomosis occlusion at 6 months control, demonstrated that diameter of distal 
      bed (P = 0.006), moderately to severely atherosclerotic distal bed (P = 0.003) 
      and the interactions between poor distal bed and triflusal (P = 0.005) were 
      independent predictors of occlusion. Thus, triflusal plus dipyridamole appeared 
      superior to low-dose aspirin plus dipyridamole in the prevention of vein-graft 
      occlusion, independently of coronary and vein-graft determinants of occlusion.
FAU - Guiteras, P
AU  - Guiteras P
AD  - Cardiac Catheterization and Invasive Cardiology Unit, Hospital de la Santa Creu i 
      Sant Pau, Barcelona, Spain.
FAU - Altimiras, J
AU  - Altimiras J
FAU - Arís, A
AU  - Arís A
FAU - Augé, J M
AU  - Augé JM
FAU - Bassons, T
AU  - Bassons T
FAU - Bonal, J
AU  - Bonal J
FAU - Caralps, J M
AU  - Caralps JM
FAU - Castellarnau, C
AU  - Castellarnau C
FAU - Crexells, C
AU  - Crexells C
FAU - Masotti, M
AU  - Masotti M
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Salicylates)
RN  - 1Z0YFI05OO (triflusal)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clinical Trials as Topic
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/*administration & dosage
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Prospective Studies
MH  - Random Allocation
MH  - Salicylates/*administration & dosage/adverse effects
MH  - Vascular Patency/*drug effects
EDAT- 1989/02/01 00:00
MHDA- 1989/02/01 00:01
CRDT- 1989/02/01 00:00
PHST- 1989/02/01 00:00 [pubmed]
PHST- 1989/02/01 00:01 [medline]
PHST- 1989/02/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.eurheartj.a059456 [doi]
PST - ppublish
SO  - Eur Heart J. 1989 Feb;10(2):159-67. doi: 
      10.1093/oxfordjournals.eurheartj.a059456.

PMID- 2012762
OWN - NLM
STAT- MEDLINE
DCOM- 19910516
LR  - 20190704
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 77
IP  - 3
DP  - 1991 Mar
TI  - Primary thrombocythaemia in pregnancy.
PG  - 371-4
AB  - Nine pregnancies in six patients with primary thrombocythaemia are reported. 
      Eight pregnancies resulted in the delivery of normal infants. One pregnancy ended 
      in spontaneous abortion at 7 weeks gestation. One pregnancy was complicated by 
      superficial thrombophlebitis and a postpartum haemorrhage. We suggest that 
      pregnancy in patients with primary thrombocythaemia can have a favourable 
      outcome, but requires close monitoring. Administration of aspirin during 
      pregnancy may be of benefit.
FAU - Beard, J
AU  - Beard J
AD  - Division of Haematology, United Medical School, St Thomas' Hospital, London.
FAU - Hillmen, P
AU  - Hillmen P
FAU - Anderson, C C
AU  - Anderson CC
FAU - Lewis, S M
AU  - Lewis SM
FAU - Pearson, T C
AU  - Pearson TC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Incomplete/etiology
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - *Pregnancy Complications, Hematologic
MH  - Pregnancy Outcome
MH  - Thrombocythemia, Essential/*complications/drug therapy
RF  - 33
EDAT- 1991/03/01 00:00
MHDA- 1991/03/01 00:01
CRDT- 1991/03/01 00:00
PHST- 1991/03/01 00:00 [pubmed]
PHST- 1991/03/01 00:01 [medline]
PHST- 1991/03/01 00:00 [entrez]
AID - 10.1111/j.1365-2141.1991.tb08586.x [doi]
PST - ppublish
SO  - Br J Haematol. 1991 Mar;77(3):371-4. doi: 10.1111/j.1365-2141.1991.tb08586.x.

PMID- 21389863
OWN - NLM
STAT- MEDLINE
DCOM- 20110721
LR  - 20220318
IS  - 1473-5687 (Electronic)
IS  - 0954-691X (Linking)
VI  - 23
IP  - 4
DP  - 2011 Apr
TI  - Anticoagulant or aspirin treatment does not affect the positive predictive value 
      of an immunological fecal occult blood test in patients undergoing colorectal 
      cancer screening: results from a nested in a cohort case-control study.
PG  - 323-6
LID - 10.1097/MEG.0b013e3283438aac [doi]
AB  - BACKGROUND AND AIM: The immunochemical fecal occult blood test (i-FOBT) is widely 
      used as a recommended screening strategy for colorectal cancer (CRC). A growing 
      number of patients potentially targeted by CRC screening programs are on oral 
      anticoagulant or chronic low-dose aspirin therapy, mainly for primary or 
      secondary cardiovascular prophylaxis. This study aims at evaluating whether the 
      use of these medications may impact on the diagnostic performances of i-FOBT for 
      CRC screening. METHODS: All i-FOBT-positive patients on anticoagulant or chronic 
      low-dose aspirin therapy recorded in a regional mass screening program database 
      were enrolled as cases. Control groups were derived from the same database and 
      included drug-naive i-FOBT-positive patients, matched in a ratio of 1 : 2 for age 
      (± 3 years of age), sex, date of colonoscopy, and practice site. Information 
      about the use of medications was collected by cross-checking patients' interview 
      before colonoscopy and data recorded in the provincial electronic registry of 
      medical prescriptions. The positive predictive value of i-FOBT for significant 
      neoplasia (high-risk adenoma and CRC) was calculated in the case and control 
      groups. RESULTS: In a 2-year study period, 2376 patients were recorded in the 
      regional database. Of these patients, 53 (2%) were on anticoagulation (control 
      group of 106 patients) and 172 (6.6%) were on chronic low-dose aspirin treatment 
      (control group of 344 patients). Significant neoplasia was detected in 15 (28.3%) 
      patients on anticoagulants and in 37 (34.9%) corresponding controls (P=0.45). 
      Significant neoplasia was detected in 50 (29.1%) patients on chronic low-dose 
      aspirin and in 107 (31.1%) corresponding controls (P=0.64). CONCLUSION: The 
      positive predictive value of i-FOBT for significant neoplasia is not affected by 
      ongoing anticoagulant or chronic low-dose aspirin therapy. This finding suggests 
      that there is no need to interrupt these treatments before i-FOBT for CRC 
      screening.
FAU - Mandelli, Giovanna
AU  - Mandelli G
AD  - Gastroenterology Unit, Valduce Hospital, Como, Italy.
FAU - Radaelli, Franco
AU  - Radaelli F
FAU - Paggi, Silvia
AU  - Paggi S
FAU - Terreni, Natalia
AU  - Terreni N
FAU - Gola, Gemma
AU  - Gola G
FAU - Gramegna, Maria
AU  - Gramegna M
FAU - Bonaffini, Antonino
AU  - Bonaffini A
FAU - Terruzzi, Vittorio
AU  - Terruzzi V
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Colorectal Neoplasms/*diagnosis
MH  - Early Detection of Cancer
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Occult Blood
MH  - Predictive Value of Tests
EDAT- 2011/03/11 06:00
MHDA- 2011/07/22 06:00
CRDT- 2011/03/11 06:00
PHST- 2011/03/11 06:00 [entrez]
PHST- 2011/03/11 06:00 [pubmed]
PHST- 2011/07/22 06:00 [medline]
AID - 10.1097/MEG.0b013e3283438aac [doi]
PST - ppublish
SO  - Eur J Gastroenterol Hepatol. 2011 Apr;23(4):323-6. doi: 
      10.1097/MEG.0b013e3283438aac.

PMID- 7959941
OWN - NLM
STAT- MEDLINE
DCOM- 19941221
LR  - 20131121
IS  - 0019-5189 (Print)
IS  - 0019-5189 (Linking)
VI  - 32
IP  - 8
DP  - 1994 Aug
TI  - Biochemical evaluation of acetyl salicylic acid in relation to different diets.
PG  - 577-80
AB  - Effect of aspirin on some biochemical and nutritional parameters was studied in 
      rats fed with high fat, low fat, high protein or low protein diets. Two doses of 
      aspirin (50 and 150 mg/kg rat body weight) were tested. The experiment continued 
      for 10 days. Results showed that, when rats fed high fat diet, high dose of 
      aspirin significantly decreased body weight gain, food efficiency ratio, plasma 
      high density lipoproteins-cholesterol and its ratio to total cholesterol. Low 
      dose of aspirin significantly reduced plasma total lipids. Low aspirin dose 
      significantly increased plasma glucose level, when low fat diet was fed. Feeding 
      high protein diet during administration of both doses of aspirin significantly 
      reduced plasma total lipids and albumin/globulin ratio, while both doses 
      significantly elevated plasma globulins. Low aspirin dose reduced plasma HDL-ch 
      and significantly elevated plasma total proteins. In rats fed low protein diet, 
      both aspirin doses significantly increased plasma triglycerides. The high dose 
      significantly increased albumin/globulin ratio.
FAU - Hamdy, M A
AU  - Hamdy MA
AD  - Biochemistry Department, Faculty of Pharmacy, Cairo University, Egypt.
FAU - Metwalli, O M
AU  - Metwalli OM
FAU - al-Okbi, S Y
AU  - al-Okbi SY
FAU - el-Said, E M
AU  - el-Said EM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - India
TA  - Indian J Exp Biol
JT  - Indian journal of experimental biology
JID - 0233411
RN  - 0 (Dietary Fats)
RN  - 0 (Dietary Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dietary Fats/*administration & dosage
MH  - Dietary Proteins/*administration & dosage
MH  - Evaluation Studies as Topic
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Exp Biol. 1994 Aug;32(8):577-80.

PMID- 7291963
OWN - NLM
STAT- MEDLINE
DCOM- 19811222
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 111
IP  - 39
DP  - 1981 Sep 26
TI  - [Acetylsalicylic acid and food additive intolerance in urticaria, bronchial 
      asthma and rhinopathy].
PG  - 1445-50
AB  - Adverse reactions (urticaria, angio-edema, bronchoconstriction, purpura) to 
      Aspirin (ASS) and food-and-drug additives such as the yellow dye tartrazine and 
      the preservative benzoate are observed all over the world. Since the exact 
      pathogenetic mechanisms of this condition is unknown, it is described as 
      intolerance or pseudo-allergy and has been related to an imbalance of 
      prostaglandin synthesis. Among 620 patients with urticaria, bronchial asthma or 
      chronic rhinitis, oral provocation tests with ASS, tartrazine or benzoic acid 
      revealed in 165 (26.6%) intolerance to ASS or additives. Frequency of intolerance 
      to tartrazine varied between 6.1% in urticaria (n=308), 7.3% in asthma (n=96) and 
      14.5% in urticaria and asthma patients, while intolerance to benzoate varied from 
      2.5% in rhinitis (n=40) to 11.5% in asthma. More than two thirds of the 
      intolerant patients were improved by an elimination diet and by the avoidance of 
      "aspirin-like" drugs. More than one third of chronic urticaria patients became 
      symptomfree. In Switzerland exact declaration of all food additives is urgently 
      needed. Moreover, azo-dyes must no longer be used for colouring of drugs.
FAU - Wüthrich, B
AU  - Wüthrich B
FAU - Fabro, L
AU  - Fabro L
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Acetylsalicylsäure- und Lebensmitteladditiva-Intoleranz bei Urtikaria, Asthma 
      bronchiale und chronischer Rhinopathie.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 0 (Food Additives)
RN  - I753WB2F1M (Tartrazine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/etiology
MH  - Child
MH  - Drug Hypersensitivity/*complications
MH  - Female
MH  - Food Additives/*adverse effects/immunology
MH  - Food Hypersensitivity/*complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rhinitis, Allergic, Seasonal/etiology
MH  - Tartrazine/adverse effects/immunology
MH  - Urticaria/etiology
EDAT- 1981/09/26 00:00
MHDA- 1981/09/26 00:01
CRDT- 1981/09/26 00:00
PHST- 1981/09/26 00:00 [pubmed]
PHST- 1981/09/26 00:01 [medline]
PHST- 1981/09/26 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1981 Sep 26;111(39):1445-50.

PMID- 8088292
OWN - NLM
STAT- MEDLINE
DCOM- 19941018
LR  - 20190813
IS  - 0340-6199 (Print)
IS  - 0340-6199 (Linking)
VI  - 153
IP  - 6
DP  - 1994 Jun
TI  - Treatment of fever in childhood.
PG  - 394-402
AB  - Although the need for routine antipyretic therapy in children has often been 
      questioned, there are no data to contra-indicate this. Not all fevers need to be 
      treated but many physicians do so to relieve parental concern. The most commonly 
      used antipyretic drugs are acetylsalicylic acid (ASA), paracetamol 
      (acetaminophen) and dipyrone (metamizol). Paracetamol and ASA have been 
      extensively evaluated but there are few clinical trials on dipyrone. In the last 
      decade a strong statistical association has been observed between salicylates and 
      Reye syndrome. Paracetamol is the most common cause of acute hepatic failure. 
      Dipyrone has been associated with agranulocytosis. In the light of these findings 
      the extensive use of antipyretics drugs has been seriously questioned.
FAU - Adam, D
AU  - Adam D
AD  - Department of Antimicrobial Therapy and Immunology of Infections, Children 
      Hospital, University of Munich, Germany.
FAU - Stankov, G
AU  - Stankov G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Eur J Pediatr
JT  - European journal of pediatrics
JID - 7603873
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/pharmacology
MH  - Child
MH  - Dipyrone/pharmacology
MH  - Fever/*drug therapy/therapy
MH  - Humans
RF  - 119
EDAT- 1994/06/01 00:00
MHDA- 1994/06/01 00:01
CRDT- 1994/06/01 00:00
PHST- 1994/06/01 00:00 [pubmed]
PHST- 1994/06/01 00:01 [medline]
PHST- 1994/06/01 00:00 [entrez]
AID - 10.1007/BF01983400 [doi]
PST - ppublish
SO  - Eur J Pediatr. 1994 Jun;153(6):394-402. doi: 10.1007/BF01983400.

PMID- 34053277
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210607
IS  - 2049-4408 (Electronic)
IS  - 2049-4394 (Linking)
VI  - 103-B
IP  - 6 Supple A
DP  - 2021 Jun
TI  - 2021 John N. Insall Award: Aspirin is effective in preventing propagation of 
      infrapopliteal deep venous thrombosis following total knee arthroplasty.
PG  - 18-22
LID - 10.1302/0301-620X.103B6.BJJ-2020-2436.R1 [doi]
AB  - AIMS: The optimal management of an infrapopliteal deep venous thrombosis (IDVT) 
      following total knee arthroplasty (TKA) remains unknown. The risk of DVT 
      propagation and symptom progression must be balanced against potential 
      haemorrhagic complications associated with administration of anticoagulation 
      therapy. The current study reports on a cohort of patients diagnosed with IDVT 
      following TKA who were treated with aspirin, followed closely for development of 
      symptoms, and scanned with ultrasound to determine resolution of IDVT. METHODS: 
      Among a cohort of 5,078 patients undergoing TKA, 532 patients (695 TKAs, 12.6%) 
      developed an IDVT between 1 January 2014 to 31 December 2019 at a single 
      institution, as diagnosed using Doppler ultrasound at the first postoperative 
      visit. Of the entire cohort of 532 patients with IDVT, 91.4% (486/532) were 
      treated with aspirin (325 mg twice daily) and followed closely. Repeat lower limb 
      ultrasound was performed four weeks later to evaluate the status of IDVT. 
      RESULTS: Follow-up Doppler ultrasound was performed on 459/486 (94.4%) patients 
      and demonstrated resolution of IDVT in 445/459 cases (96.9%). Doppler diagnosed 
      propagation of IDVT to the popliteal vein had occurred in 10/459 (2.2%) cases. 
      One patient with an IDVT developed a pulmonary embolus six weeks postoperatively. 
      CONCLUSION: The results of this study demonstrate a low rate of IDVT propagation 
      in patients managed with aspirin. Additionally, no significant bleeding episodes, 
      wound-related complications, or other adverse events were noted from aspirin 
      therapy. Cite this article: Bone Joint J 2021;103-B(6 Supple A):18-22.
FAU - Omari, Ali M
AU  - Omari AM
AUID- ORCID: 0000-0001-5806-6377
AD  - Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, USA.
FAU - Parcells, Bertrand W
AU  - Parcells BW
AUID- ORCID: 0000-0003-0884-2272
AD  - Seaview Orthopaedic and Medical Associates, Ocean, New Jersey, USA.
FAU - Levine, Harlan B
AU  - Levine HB
AUID- ORCID: 0000-0002-3784-0260
AD  - Hackensack University Medical Center, Hackensack, New Jersey, USA.
AD  - Rothman Orthopaedic Institute, Montvale, New Jersey, USA.
FAU - Seidenstein, Ari
AU  - Seidenstein A
AUID- ORCID: 0000-0002-1134-9879
AD  - Hackensack University Medical Center, Hackensack, New Jersey, USA.
AD  - Rothman Orthopaedic Institute, Montvale, New Jersey, USA.
FAU - Parvizi, Javad
AU  - Parvizi J
AUID- ORCID: 0000-0002-6985-5870
AD  - Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, 
      Pennsylvania, USA.
FAU - Klein, Gregg R
AU  - Klein GR
AUID- ORCID: 0000-0001-8811-4106
AD  - Hackensack University Medical Center, Hackensack, New Jersey, USA.
AD  - Rothman Orthopaedic Institute, Montvale, New Jersey, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Bone Joint J
JT  - The bone & joint journal
JID - 101599229
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/*therapeutic use
MH  - Awards and Prizes
MH  - Female
MH  - Humans
MH  - Male
MH  - *Popliteal Vein
MH  - Postoperative Complications/*prevention & control
MH  - Ultrasonography, Doppler
MH  - Venous Thromboembolism/diagnostic imaging/*prevention & control
OTO - NOTNLM
OT  - Anticoagulation
OT  - Aspirin
OT  - Deep venous thrombosis
OT  - Infrapopliteal DVT
OT  - Venous thromboembolism
EDAT- 2021/06/01 06:00
MHDA- 2021/06/08 06:00
CRDT- 2021/05/31 05:24
PHST- 2021/05/31 05:24 [entrez]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
AID - 10.1302/0301-620X.103B6.BJJ-2020-2436.R1 [doi]
PST - ppublish
SO  - Bone Joint J. 2021 Jun;103-B(6 Supple A):18-22. doi: 
      10.1302/0301-620X.103B6.BJJ-2020-2436.R1.

PMID- 34643829
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220405
IS  - 1437-2320 (Electronic)
IS  - 0344-5607 (Linking)
VI  - 45
IP  - 2
DP  - 2022 Apr
TI  - Aspirin does not affect hematoma growth in severe spontaneous intracranial 
      hematoma.
PG  - 1491-1499
LID - 10.1007/s10143-021-01675-2 [doi]
AB  - Hematoma growth (HG) affects the prognosis of patients with spontaneous 
      intracranial hematoma (ICH), but there is still a lack of evidence about the 
      effects of aspirin (acetylsalicylic acid, ASA) on HG in patients with severe ICH. 
      This study retrospectively analyzed patients with severe ICH who met the 
      inclusion and exclusion criteria in Beijing Tiantan Hospital, Capital Medical 
      University, between January 1, 2015, and July 31, 2019. Severe ICH patients were 
      divided into ASA group and nASA groups according to ASA usage, and the incidence 
      of HG between the groups was compared. Univariate analysis was performed by the 
      Mann-Whitney U test, chi-square test, or Fisher exact test. Multivariate logistic 
      regression analysis was used to analyze the impact of ASA on HG and to screen for 
      risk factors of HG. In total, 221 patients with severe ICH were consecutively 
      enrolled in this study. There were 72 (32.6%) patients in the ASA group and 149 
      patients in the nASA group. Although the incidence of HG in the nASA group was 
      higher than that in the ASA group (34.9% VS 22.2%, p = 0.056), ASA did not 
      significantly affect the occurrence of HG (p = 0.285) after adjusting for initial 
      hematoma volume, high blood pressure at admission, coronary heart disease, and 
      GCS at admission. In addition, we found that high blood pressure at admission was 
      a risk factor for HG. Prior ASA does not increase the incidence of HG in severe 
      ICH patients, and high blood pressure at admission is a risk factor for HG.
CI  - © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Yang, Junhua
AU  - Yang J
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Mo, Shaohua
AU  - Mo S
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Wang, Kaiwen
AU  - Wang K
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Liu, Qingyuan
AU  - Liu Q
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Wu, Jun
AU  - Wu J
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Yang, Shuzhe
AU  - Yang S
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Guo, Rui
AU  - Guo R
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Yang, Yi
AU  - Yang Y
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Zhang, Jiaming
AU  - Zhang J
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Jiang, Pengjun
AU  - Jiang P
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Cao, Yong
AU  - Cao Y
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China.
FAU - Wang, Shuo
AU  - Wang S
AUID- ORCID: 0000-0003-4919-5390
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      No. 119 Nansihuanxilu, Fengtai District, Beijing, 100160, People's Republic of 
      China. captain9858@126.com.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China. captain9858@126.com.
AD  - Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's 
      Republic of China. captain9858@126.com.
AD  - Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, 
      Beijing, People's Republic of China. captain9858@126.com.
LA  - eng
GR  - 81471210/National Natural Science Foundation of China/
GR  - 81671129/National Natural Science Foundation of China/
GR  - 2016YFC1301800/Major special projects in the 13th five-year plan/
PT  - Journal Article
DEP - 20211013
PL  - Germany
TA  - Neurosurg Rev
JT  - Neurosurgical review
JID - 7908181
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - Cerebral Hemorrhage/etiology
MH  - Hematoma/complications
MH  - Humans
MH  - *Hypertension/complications
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Antiplatelet
OT  - Aspirin
OT  - Hematoma growth
OT  - Intracerebral hemorrhage
OT  - Stroke
EDAT- 2021/10/14 06:00
MHDA- 2022/04/06 06:00
CRDT- 2021/10/13 12:28
PHST- 2021/05/10 00:00 [received]
PHST- 2021/10/05 00:00 [accepted]
PHST- 2021/08/20 00:00 [revised]
PHST- 2021/10/14 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
PHST- 2021/10/13 12:28 [entrez]
AID - 10.1007/s10143-021-01675-2 [pii]
AID - 10.1007/s10143-021-01675-2 [doi]
PST - ppublish
SO  - Neurosurg Rev. 2022 Apr;45(2):1491-1499. doi: 10.1007/s10143-021-01675-2. Epub 
      2021 Oct 13.

PMID- 10575906
OWN - NLM
STAT- MEDLINE
DCOM- 19991209
LR  - 20190214
IS  - 0029-6643 (Print)
IS  - 0029-6643 (Linking)
VI  - 57
IP  - 10
DP  - 1999 Oct
TI  - Vitamin E, a modifier of platelet function: rationale and use in cardiovascular 
      and cerebrovascular disease.
PG  - 306-9
AB  - Vitamin E has emerged as a major factor in the prevention and inhibition of 
      cardiovascular disease. The inhibition of platelet function, especially adhesion, 
      which is an important event in the development and propagation of cardiovascular 
      disease, plays a crucial role in the beneficial effect that vitamin E exerts on 
      such diseases. Although it is best known for its antioxidant activity, vitamin E 
      interferes with platelet adhesion via a mechanism that is independent of this 
      action. Vitamin E-induced inhibition of protein kinase C leads to decreased 
      platelet pseudopodia formation upon stimulation by agonists, a process that is 
      instrumental in reducing platelet adhesion. In conjunction with potent inhibitors 
      of platelet aggregation, vitamin E has become a widely applied treatment regimen 
      for this group of diseases. Increased bleeding, especially when vitamin E is 
      combined with a potent platelet aggregation inhibitor, has to be considered a 
      side effect of its mechanism of action, but should not detract from the potential 
      benefits for the majority of patients who take this vitamin.
FAU - Steiner, M
AU  - Steiner M
AD  - Division of Hematology/Oncology, East Carolina School of Medicine, Greenville, NC 
      27858-4354, USA.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Nutr Rev
JT  - Nutrition reviews
JID - 0376405
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 1406-18-4 (Vitamin E)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Blood Platelets/*drug effects/physiology
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Double-Blind Method
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Ischemic Attack, Transient/prevention & control
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Protein Kinase C/antagonists & inhibitors/physiology
MH  - Recurrence
MH  - Time Factors
MH  - Vitamin E/administration & dosage/adverse effects/pharmacology/*therapeutic use
EDAT- 1999/11/27 00:00
MHDA- 1999/11/27 00:01
CRDT- 1999/11/27 00:00
PHST- 1999/11/27 00:00 [pubmed]
PHST- 1999/11/27 00:01 [medline]
PHST- 1999/11/27 00:00 [entrez]
AID - 10.1111/j.1753-4887.1999.tb06903.x [doi]
PST - ppublish
SO  - Nutr Rev. 1999 Oct;57(10):306-9. doi: 10.1111/j.1753-4887.1999.tb06903.x.

PMID- 9385588
OWN - NLM
STAT- MEDLINE
DCOM- 19971219
LR  - 20181201
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 19
IP  - 6
DP  - 1997 Jul-Aug
TI  - Interaction of dexamethasone with acetylsalicylic acid in mice.
PG  - 387-94
AB  - The effect of acetylsalicylic acid (ASA, 160 mg/kg b.wt.) and dexamethasone (DEX, 
      15 mg/kg b.wt.) on ASA antinociception and toxicity when administered orally 
      alone or in combination for 4 consecutive days was studied in male albino mice. 
      ASA antinociception decreased after repeated ASA administration. Bleeding time 
      was prolonged and the intestinal ASA esterase activity was increased, which was 
      probably related to the increased ASA general toxicity in ASA-treated animals. 
      There were no changes in the blood alkaline content, in the ulcerogenic or 
      hepatotoxic effect of ASA, nor in the hepatic monooxygenase activity 
      (ethylmorphine N-demethylase and aniline hydroxylase and the cytochrome P450 and 
      b-5 content). DEX administered alone exerted a significant antinociceptive 
      effect, increased both acute ASA toxicity and aniline hydroxylase activity and 
      decreased body growth. However, DEX did not change the bleeding time, the 
      alkaline blood content nor the intestinal esterase activity. The combination of 
      ASA and DEX did not increase the ASA antinociceptive effect nor the general and 
      specific toxicity of ASA. DEX in combination even abolished the effect of ASA on 
      intestinal ASA esterase and on bleeding time. DEX also increased the hepatic 
      cytochrome P450 content and did not change the ulcerogenic effect of ASA nor the 
      alkaline blood content.
FAU - Tantcheva, L
AU  - Tantcheva L
AD  - Department of Drug Toxicology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
FAU - Stoytchev, T
AU  - Stoytchev T
FAU - Rangelova, D
AU  - Rangelova D
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - EC 3.1.- (Esterases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents/administration & dosage/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/metabolism/*toxicity
MH  - Aspirin/administration & dosage/metabolism/*toxicity
MH  - Bleeding Time
MH  - Dexamethasone/administration & dosage/*pharmacology
MH  - Drug Combinations
MH  - Drug Interactions
MH  - Esterases/metabolism
MH  - Intestinal Mucosa/metabolism
MH  - Intestines/enzymology
MH  - Liver/drug effects/enzymology
MH  - Male
MH  - Mice
MH  - Pain/*prevention & control
EDAT- 1997/07/01 00:00
MHDA- 1997/12/31 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/12/31 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 1997 Jul-Aug;19(6):387-94.

PMID- 793958
OWN - NLM
STAT- MEDLINE
DCOM- 19770226
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 5
IP  - 3
DP  - 1976
TI  - Ionophore a 23187: some effects on platelet aggregation and clot retraction.
PG  - 176-88
AB  - The ionophore for divalent cations, A 23187, induces plate aggregation and clot 
      retraction. Acetylsalicyclic acid has a potentiating effect on the aggregation 
      induced by A 23187 in platelet-rich plasma, while it inhibits the aggregation of 
      washed platelets. Acetylation of plasma proteins could be the reason of the 
      increased platelet aggregation induced by A 23187 in the presence of 
      acetylsalicyclic acid. Platelet aggregation by A 23187 is probably activated by 
      the passage of Ca2+ through the platelet membrane(s); the aggation, clot 
      retraction by A 23187 requires increased availability in the intracellular space 
      of both Ca2+ and Mg2+.
FAU - Bottecchia, D
AU  - Bottecchia D
FAU - Fantin, G
AU  - Fantin G
FAU - Gruppo, F
AU  - Gruppo F
FAU - Nassuato, G
AU  - Nassuato G
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Anti-Bacterial Agents)
RN  - 37H9VM9WZL (Calcimycin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Aspirin/pharmacology
MH  - Calcimycin/antagonists & inhibitors/*pharmacology
MH  - *Clot Retraction
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Rats
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1159/000214133 [doi]
PST - ppublish
SO  - Haemostasis. 1976;5(3):176-88. doi: 10.1159/000214133.

PMID- 11825303
OWN - NLM
STAT- MEDLINE
DCOM- 20020926
LR  - 20190916
IS  - 1465-6566 (Print)
IS  - 1465-6566 (Linking)
VI  - 2
IP  - 10
DP  - 2001 Oct
TI  - Antiplatelet therapy in secondary stroke prevention.
PG  - 1609-13
AB  - Stroke is the third leading cause of death in the United States. Antiplatelet 
      agents are the mainstays of ischaemic stroke prevention. The therapies 
      recommended for initial therapy include aspirin (50 - 325 mg) daily, the 
      combination of aspirin (25 mg) and extended-release dipyridamole (200 mg) b.i.d., 
      or clopidogrel (75 mg) daily. Ticlopidine 250 mg b.i.d. is approved for stroke 
      prevention but is no longer a first-line therapy. This article reviews the 
      literature on antiplatelet agents for secondary stroke prevention.
FAU - Crawford, K M
AU  - Crawford KM
AD  - College of Pharmacy, University of Texas at Austin and Department of Medicine, 
      University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, 
      San Antonio, Texas 78229-3900, USA. talbert@uthscsa.edu
FAU - Talbert, R L
AU  - Talbert RL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Stroke/*prevention & control
RF  - 36
EDAT- 2002/02/05 10:00
MHDA- 2002/09/27 06:00
CRDT- 2002/02/05 10:00
PHST- 2002/02/05 10:00 [pubmed]
PHST- 2002/09/27 06:00 [medline]
PHST- 2002/02/05 10:00 [entrez]
AID - 10.1517/14656566.2.10.1609 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2001 Oct;2(10):1609-13. doi: 
      10.1517/14656566.2.10.1609.

PMID- 652049
OWN - NLM
STAT- MEDLINE
DCOM- 19780715
LR  - 20190725
IS  - 0028-1298 (Print)
IS  - 0028-1298 (Linking)
VI  - 302
IP  - 1
DP  - 1978 Mar
TI  - In vivo method for quantitation for anti-platelet potency of drugs.
PG  - 25-30
AB  - Aortic strips from atherosclerotic rabbits or Achilles tendons from healthy 
      rabbits were superfused with blood (3 ml/min) from anaesthetized and heparinized 
      cats, while blood was returned to the venous system of animals. The superfused 
      tissues gained in weight because of deposition of platelet thrombi on their 
      surface. This gain in weight was continuously monitored and quantified. Forty 
      minutes after intravenous administration of indomethacin (14 mg/kg), aspirin (7 
      mg/kg) or nictindole (2 mg/kg) the formation of platelet depostis was reduced by 
      half. Three hours after i.v. administration of each drug at a dose of 20 m;/kg 
      the remaining anti-platelet activities were 92% for aspirin, 59% for indomethacin 
      and 18% for nictindole as compared to their antithrombotic action, which was 
      recorded 40 min after their administration. Thrombogenesis was also prevented by 
      a direct infusion of nictindole (50 ng/ml) or indomethacin (2000 ng/ml) into a 
      stream of superfusing blood. Thereby our method enables us to quantify in vivo 
      anti-aggregating potency of drug, to estimate the duration of this action, and to 
      compare their in vitro and in vivo aggregation-inhibitory activities.
FAU - Gryglewski, R J
AU  - Gryglewski RJ
FAU - Korbut, R
AU  - Korbut R
FAU - Ocetkiewicz, A
AU  - Ocetkiewicz A
FAU - Stachura, J
AU  - Stachura J
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyridines)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Cats
MH  - Fibrinolytic Agents/*pharmacology
MH  - In Vitro Techniques
MH  - Indoles/pharmacology
MH  - Indomethacin/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Pyridines/pharmacology
MH  - Rabbits
MH  - Time Factors
EDAT- 1978/03/16 00:00
MHDA- 1978/03/16 00:01
CRDT- 1978/03/16 00:00
PHST- 1978/03/16 00:00 [pubmed]
PHST- 1978/03/16 00:01 [medline]
PHST- 1978/03/16 00:00 [entrez]
AID - 10.1007/BF00586592 [doi]
PST - ppublish
SO  - Naunyn Schmiedebergs Arch Pharmacol. 1978 Mar;302(1):25-30. doi: 
      10.1007/BF00586592.

PMID- 3985922
OWN - NLM
STAT- MEDLINE
DCOM- 19850517
LR  - 20190903
IS  - 0300-8428 (Print)
IS  - 0300-8428 (Linking)
VI  - 80
IP  - 1
DP  - 1985 Jan-Feb
TI  - Cyclical coronary flow reductions in conscious dogs equipped with ameroid 
      constrictors to produce severe coronary narrowing.
PG  - 100-6
AB  - In conscious dogs equipped with ameroid constrictors to produce gradual coronary 
      occlusion, coronary flow velocity was monitored prior to complete occlusion when 
      coronary constriction was severe (resting flow velocity reduced by 10-50% from 
      control recordings made days after ameroid implantation). In six of the ten dogs, 
      we observed spontaneous cyclical variations in coronary flow velocity, 
      characterized by gradual reduction in flow followed by very abrupt restoration of 
      flow. The cyclic coronary flow reductions were observed between 20 and 31 days 
      after ameroid implantation. These changes in flow bear striking similarity to 
      those observed by previous investigators using anesthetized, open-chest canine 
      preparations, in which the role of platelets was clearly demonstrated. 
      Consequently, we hypothesize that spontaneous platelet aggregation and 
      de-aggregation within the severely narrowed coronary lumen (enclosed by the 
      ameroid constrictors) could account for our observations.
FAU - Gallagher, K P
AU  - Gallagher KP
FAU - Osakada, G
AU  - Osakada G
FAU - Kemper, W S
AU  - Kemper WS
FAU - Ross, J Jr
AU  - Ross J Jr
LA  - eng
GR  - HL-17682/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Basic Res Cardiol
JT  - Basic research in cardiology
JID - 0360342
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - *Coronary Circulation/drug effects
MH  - Coronary Disease/*physiopathology
MH  - Coronary Vessels/physiopathology
MH  - Disease Models, Animal
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Platelet Aggregation/drug effects
EDAT- 1985/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1007/BF01906748 [doi]
PST - ppublish
SO  - Basic Res Cardiol. 1985 Jan-Feb;80(1):100-6. doi: 10.1007/BF01906748.

PMID- 31790409
OWN - NLM
STAT- MEDLINE
DCOM- 20200323
LR  - 20200323
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 12
DP  - 2019
TI  - Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular 
      events among patients with type 2 diabetes in China.
PG  - e0224580
LID - 10.1371/journal.pone.0224580 [doi]
LID - e0224580
AB  - The use of aspirin for primary prevention of cardiovascular disease (CVD) in 
      patients with diabetes mellitus (DM) is associated with lower rates of 
      cardiovascular events but increased risks of bleeding complications. We aimed to 
      examine the cost-effectiveness of aspirin therapy for primary prevention of CVD 
      in Chinese DM patients. A life-long Markov model was developed to compare aspirin 
      therapy (100mg daily) versus no use of aspirin in DM patients with no history of 
      CVD. Model validation was conducted by comparing the simulated event rates with 
      data reported in a clinical trial. Direct medical costs and quality-adjusted 
      life-years gained (QALYs) were the primary outcomes from the perspective of 
      healthcare system in China. Sensitivity analyses were performed to examine the 
      uncertainty of model inputs. Base-case analysis showed aspirin therapy was more 
      costly (USD1,086 versus USD819) with higher QALYs gained (11.94 versus 11.86 
      QALYs) compared to no use of aspirin. The base-case results were sensitive to the 
      odds ratio of all-cause death in aspirin therapy versus no use of aspirin. 
      Probabilistic sensitivity analysis found that aspirin therapy gained an 
      additional 0.066 QALYs (95% CI: -0.167 QALYs-0.286 QALYs) at higher cost by 
      USD352 (95% CI: USD130-644)). Using 30,000 USD/QALY as willingness-to-pay 
      threshold, aspirin therapy and no use of aspirin were the preferred option in 
      68.71% and 31.29% of 10,000 Monte Carlo simulations, respectively. In conclusion, 
      aspirin therapy appears to be cost-effective compared with no use of aspirin in 
      primary prevention of CVD in Chinese DM patients.
FAU - Jiang, Minghuan
AU  - Jiang M
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, 
      Xi'an Jiaotong University, Xi'an, China.
AD  - Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, 
      China.
FAU - Li, Pengchao
AU  - Li P
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, 
      Xi'an Jiaotong University, Xi'an, China.
AD  - Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, 
      China.
FAU - You, Joyce Hoi-Sze
AU  - You JH
AD  - School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 
      Shatin, N.T, Hong Kong, China SAR.
FAU - Zheng, Xinglong
AU  - Zheng X
AD  - Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, China.
FAU - Deng, Jizhao
AU  - Deng J
AD  - Department of Cardiovascular Medicine, Shaanxi Provincial People's Hospital, 
      Xi'an, China.
FAU - Zhao, Mingyue
AU  - Zhao M
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, 
      Xi'an Jiaotong University, Xi'an, China.
AD  - Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, 
      China.
FAU - Feng, Liuxin
AU  - Feng L
AD  - Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Fang, Yu
AU  - Fang Y
AUID- ORCID: 0000-0003-3187-2007
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, 
      Xi'an Jiaotong University, Xi'an, China.
AD  - Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191202
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology
MH  - Cardiovascular Diseases/*complications/economics/*prevention & control
MH  - China
MH  - *Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention/*economics
PMC - PMC6886850
COIS- The authors have declared that no competing interests exist.
EDAT- 2019/12/04 06:00
MHDA- 2020/03/24 06:00
CRDT- 2019/12/03 06:00
PHST- 2019/05/29 00:00 [received]
PHST- 2019/10/16 00:00 [accepted]
PHST- 2019/12/03 06:00 [entrez]
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2020/03/24 06:00 [medline]
AID - PONE-D-19-15215 [pii]
AID - 10.1371/journal.pone.0224580 [doi]
PST - epublish
SO  - PLoS One. 2019 Dec 2;14(12):e0224580. doi: 10.1371/journal.pone.0224580. 
      eCollection 2019.

PMID- 11511984
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190906
IS  - 0931-041X (Print)
IS  - 0931-041X (Linking)
VI  - 16
IP  - 9
DP  - 2001 Sep
TI  - The renal hemodynamic effects of Aspirin in newborn and young adult rabbits.
PG  - 713-8
AB  - A group of neonatal (n=10) and 12-week-old (n=12) anesthetized, ventilated New 
      Zealand white rabbits received an acute i.v. dose (40 mg/kg body weight) of 
      acetylsalicylic acid (ASA, Aspirin). In the neonatal animals, i.v. ASA caused 
      within 20 min a significant (P<0.01) fall in renal blood flow and glomerular 
      filtration rate (GFR), with an equally significant (P<0.01) increase in 
      filtration fraction and renal vascular resistance. The latter indicates greatly 
      augmented renal vasconstriction or more precisely reduction in intrarenal 
      vasodilatation by inhibition of vasodilatory prostaglandin (PG) synthesis. Urine 
      volume decreased. The 12-week-old young adult animals responded in a similar, but 
      significantly attenuated fashion. These experiments demonstrate that inhibition 
      of PG synthesis in neonatal animals causes very rapid, reversible 
      vasoconstriction, with a reduction in GFR. In addition, this study confirms 
      previous observations that the renal hemodynamic response to the inhibition of PG 
      synthesis is far more pronounced in neonatal animals than in (young) adult 
      rabbits.
FAU - Drukker, A
AU  - Drukker A
AD  - Department of Pediatrics, University Medical Center (CHUV), CH-1011 Lausanne, 
      Switzerland.
FAU - Mosig, D
AU  - Mosig D
FAU - Guignard, J P
AU  - Guignard JP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Pediatr Nephrol
JT  - Pediatric nephrology (Berlin, Germany)
JID - 8708728
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Animals
MH  - Animals, Newborn
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Glomerular Filtration Rate/drug effects
MH  - Hemodynamics/*drug effects
MH  - Kidney/*drug effects/physiology
MH  - Prostaglandins/*physiology
MH  - Rabbits
EDAT- 2001/08/21 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/08/21 10:00
PHST- 2001/12/11 00:00 [received]
PHST- 2001/04/24 00:00 [accepted]
PHST- 2001/08/21 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/08/21 10:00 [entrez]
AID - 10.1007/s004670100641 [doi]
PST - ppublish
SO  - Pediatr Nephrol. 2001 Sep;16(9):713-8. doi: 10.1007/s004670100641.

PMID- 17163268
OWN - NLM
STAT- MEDLINE
DCOM- 20070316
LR  - 20181113
IS  - 1173-2563 (Print)
IS  - 1173-2563 (Linking)
VI  - 26
IP  - 6
DP  - 2006
TI  - Use of unfractionated heparin and a low-molecular-weight heparin following 
      thrombolytic therapy for acute ST-segment elevation myocardial infarction.
PG  - 341-9
AB  - BACKGROUND: Acute myocardial infarction (AMI) is one of the most serious 
      cardiovascular diseases, with acute ST-segment elevation myocardial infarction 
      (STEMI) showing a higher mortality rate than non-ST-segment elevation myocardial 
      infarction (NSTEMI). There is evidence that low-molecular-weight heparin (LMWH) 
      shows greater efficacy than unfractionated heparin (UFH). This open-label, 
      single-centre, randomised study was conducted to compare the efficacy and safety 
      of parnaparin sodium, a LMWH, with UFH in patients with STEMI. PATIENTS AND 
      METHODS: Patients with STEMI were randomised to receive either parnaparin sodium 
      (4250IU aXa subcutaneously every 12 hours for 7 days, initiated 12 hours after 
      thrombolysis) or UFH (100 U/kg intravenous bolus, initiated 12 hours after 
      thrombolytic therapy, followed by 1000 U/hour as a continuous infusion for 3 
      days, then 7500U subcutaneously every 12 hours for 4 days). Patients were 
      followed up for 45 days (> or =14 days in hospital). RESULTS: In total, 186 
      patients were randomised to receive parnaparin sodium (n = 96) or UFH (n = 90). A 
      significantly greater reduction in the composite primary endpoint (sum of all 
      deaths, first occurrence of recurrent MI, and first occurrence of emergency 
      revascularisation) was seen with parnaparin sodium compared with UFH at day 45 
      (27.08% vs 42.22%; p = 0.03). A lower incidence of composite endpoint was seen as 
      early as day 2 with parnaparin sodium, but this did not reach significance versus 
      UFH. The rate of individual endpoint events (death, first occurrence of non-fatal 
      recurrent MI and first occurrence of emergency revascularisation) was lower in 
      the parnaparin sodium group than the UFH group at 2, 7, 14 and 45 days, but the 
      differences were not statistically significant. At day 7, the incidences of any 
      bleeding and heparin-induced thrombocytopenia were also lower in the parnaparin 
      sodium group compared with the UFH group (3.13% vs 10.0%; p = 0.06 and 0% vs 
      3.33%; p = 0.07, respectively). CONCLUSION: The results of this study indicate 
      that parnaparin sodium is more effective than UFH in reducing composite cardiac 
      events in patients with STEMI following thrombolytic therapy. There was also a 
      lower incidence of bleeding and heparin-induced thrombocytopenia with parnaparin 
      sodium than with UFH. In view of these findings, parnaparin sodium represents an 
      effective, convenient and well tolerated alternative to UFH.
FAU - Wang, Xu-Kai
AU  - Wang XK
AD  - Daping Hospital, Third Military Medical University, Chongqing, China. 
      wangxuk@163.com
FAU - Zhang, Ye
AU  - Zhang Y
FAU - Yang, Cheng-Ming
AU  - Yang CM
FAU - Wang, Yan
AU  - Wang Y
FAU - Liu, Guang-Yao
AU  - Liu GY
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - M316WT19D8 (parnaparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Electrocardiography
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Heparin/administration & dosage/adverse effects/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/physiopathology
MH  - Partial Thromboplastin Time/methods
MH  - Platelet Count/methods
MH  - Thrombocytopenia/chemically induced
MH  - *Thrombolytic Therapy
MH  - Time Factors
MH  - Tomography Scanners, X-Ray Computed
MH  - Treatment Outcome
EDAT- 2006/12/14 09:00
MHDA- 2007/03/17 09:00
CRDT- 2006/12/14 09:00
PHST- 2006/12/14 09:00 [pubmed]
PHST- 2007/03/17 09:00 [medline]
PHST- 2006/12/14 09:00 [entrez]
AID - 2665 [pii]
AID - 10.2165/00044011-200626060-00005 [doi]
PST - ppublish
SO  - Clin Drug Investig. 2006;26(6):341-9. doi: 10.2165/00044011-200626060-00005.

PMID- 33453025
OWN - NLM
STAT- MEDLINE
DCOM- 20210531
LR  - 20210531
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 28
IP  - 20
DP  - 2021 May
TI  - Removal of aspirin from aqueous solution using electroactive bacteria induced by 
      alternating current.
PG  - 25327-25338
LID - 10.1007/s11356-020-11365-z [doi]
AB  - This study aims to improve bacterial laccase enzyme activity (LEA) and 
      dehydrogenase activity (DHA) affecting acetylsalicylic acid (ASA) biodegradation 
      using an alternating current (AC). A microbial consortium was inoculated in an 
      electroactive bioreactor supplied with an AC by a function generator under 
      operating conditions of amplitude (AMPL) = 2-10 peak-to-peak voltage (V(pp)), 
      optical fiber splice tray (OFST) = 0.1 V, and sine wave frequency = 10 Hz. The 
      obtained results revealed that at an applied voltage of 8 V(pp) and an OFST of 
      0.1 for 12 h, the maximum bacterial LEA and DHA were 30.6 U/mL and 75.5 micro 
      grTF/cm(2).gr biomass; respectively. Cell viability and permeability were equal 
      to 95.7% and 0.3%; respectively, at the voltage of 8 V(pp). Moreover, liquid 
      chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry 
      (GC-MS) analyses showed that by-products had lower intensity at 8 V(pp) compared 
      with that of 2 V(pp) voltage. Finally, the results demonstrated an optimum 
      applied voltage of the AC, which could stimulate and promote bacterial LEA and 
      DHA. Therefore, an electroactive bioreactor supplied with an AC can be a novel 
      system for stimulation of enzyme activities in the process of ASA biodegradation.
FAU - Moghiseh, Zohreh
AU  - Moghiseh Z
AD  - Department of Environmental Health Engineering, Faculty of Medical Sciences, 
      Tarbiat Modares University, Tehran, Iran.
FAU - Rezaee, Abbas
AU  - Rezaee A
AUID- ORCID: 0000-0001-5042-2963
AD  - Department of Environmental Health Engineering, Faculty of Medical Sciences, 
      Tarbiat Modares University, Tehran, Iran. rezaee@mdoares.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20210116
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - Bacteria
MH  - Biodegradation, Environmental
MH  - *Bioreactors
MH  - Electricity
OTO - NOTNLM
OT  - Applied current
OT  - Biostimulation
OT  - Dehydrogenase activity
OT  - Emerging contaminant
OT  - Laccase
OT  - Wastewater
EDAT- 2021/01/17 06:00
MHDA- 2021/06/01 06:00
CRDT- 2021/01/16 12:06
PHST- 2020/02/15 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2021/01/17 06:00 [pubmed]
PHST- 2021/06/01 06:00 [medline]
PHST- 2021/01/16 12:06 [entrez]
AID - 10.1007/s11356-020-11365-z [pii]
AID - 10.1007/s11356-020-11365-z [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2021 May;28(20):25327-25338. doi: 
      10.1007/s11356-020-11365-z. Epub 2021 Jan 16.

PMID- 36050471
OWN - NLM
STAT- MEDLINE
DCOM- 20220908
LR  - 20221107
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Sep 1
TI  - Low dose aspirin associated with greater bone mineral density in older adults.
PG  - 14887
LID - 10.1038/s41598-022-19315-0 [doi]
LID - 14887
AB  - The use of low-dose aspirin in older adults is increasing as is the prevalence of 
      osteoporosis. Aspirin has been shown in numerous studies to affect bone 
      metabolism. However, there is no clear link between low-dose aspirin use and bone 
      mineral density (BMD). This study examined differences in bone mineral density 
      between low-dose aspirin users and non-aspirin users in adults aged 50-80 years. 
      We conducted a cross-sectional study of 15,560 participants who participated in 
      the National Health and Nutrition Examination Survey (NHANES) 2017-March 2020. We 
      used a multivariate logistic regression model to evaluate the relationship 
      between low-dose aspirin and femoral neck BMD, femoral total BMD, 
      intertrochanteric BMD, and the first lumbar vertebra BMD (L1 BMD) in patients 
      aged 50 to 80 years. A total of 1208 (Group 1: femoral neck BMD, total femur BMD, 
      and intertrochanter BMD) and 1228 (Group 2: L1 BMD) adults were included in this 
      study. In both group 1 and group 2, BMD was higher in the low-dose aspirin group 
      than in the non-aspirin group (Total femur BMD β = 0.019, 95% CI 0.004-0.034; 
      Femoral neck BMD β = 0.017, 95% CI 0.002-0.032; Intertrochanter BMD β = 0.025, 
      95% CI 0.007-0.043; L1 BMD β = 0.026, 95% CI 0.006-0.046). In subgroup analyses 
      stratified by gender, this positive association existed in both gender after 
      adjusting for confounders. On subgroup analyses stratified by age, this positive 
      association existed in three different age groups after adjusting for 
      confounders. To test whether the effect of low-dose aspirin on BMD was affected 
      by gender and age, the interaction P value was greater than 0.05. These findings 
      from a human study looking into the relationship between low-dose aspirin use and 
      BMD suggest that regular low-dose aspirin may be associated with a higher BMD. 
      The association between low-dose aspirin and BMD did not differ by age group or 
      gender.
CI  - © 2022. The Author(s).
FAU - Liu, Hongzhan
AU  - Liu H
AD  - Department of Joint Surgery, Hengyang Medical School, The Chenzhou Affiliated 
      Hospital, University of South China, Hengyang, 421001, Hunan, China.
FAU - Xiao, Xungang
AU  - Xiao X
AD  - Department of Joint Surgery, Chenzhou No.1 People's Hospital, Chenzhou, 423000, 
      Hunan, China. xxg8088@163.com.
FAU - Shi, Qiaojing
AU  - Shi Q
AD  - Department of Oncology, Affiliated Hospital of Xiangnan University, Chenzhou, 
      423000, Hunan, China.
FAU - Tang, Xianzhe
AU  - Tang X
AD  - Department of Joint Surgery, Chenzhou No.1 People's Hospital, Chenzhou, 423000, 
      Hunan, China.
FAU - Tian, Yun
AU  - Tian Y
AD  - Department of Joint Surgery, Chenzhou No.1 People's Hospital, Chenzhou, 423000, 
      Hunan, China.
LA  - eng
PT  - Journal Article
DEP - 20220901
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorptiometry, Photon
MH  - Aged
MH  - Aspirin/adverse effects
MH  - *Bone Density
MH  - Cross-Sectional Studies
MH  - *Femur Neck/diagnostic imaging
MH  - Humans
MH  - Lumbar Vertebrae/diagnostic imaging
MH  - Nutrition Surveys
PMC - PMC9436986
COIS- The authors declare no competing interests.
EDAT- 2022/09/02 06:00
MHDA- 2022/09/09 06:00
CRDT- 2022/09/01 23:31
PHST- 2022/03/24 00:00 [received]
PHST- 2022/08/26 00:00 [accepted]
PHST- 2022/09/01 23:31 [entrez]
PHST- 2022/09/02 06:00 [pubmed]
PHST- 2022/09/09 06:00 [medline]
AID - 10.1038/s41598-022-19315-0 [pii]
AID - 19315 [pii]
AID - 10.1038/s41598-022-19315-0 [doi]
PST - epublish
SO  - Sci Rep. 2022 Sep 1;12(1):14887. doi: 10.1038/s41598-022-19315-0.

PMID- 6122281
OWN - NLM
STAT- MEDLINE
DCOM- 19820624
LR  - 20191031
IS  - 0270-3211 (Print)
IS  - 0270-3211 (Linking)
VI  - 2
IP  - 1
DP  - 1982
TI  - Aspirin-induced psychoteratogenesis in rats as a function of embryonic age.
PG  - 77-84
AB  - Gravid Wistar rats were treated with either 625 mg/kg of aspirin (acetylsalicylic 
      acid) or vehicle alone on either gestational Day 11 or 12, and their progeny were 
      evaluated postnatally using a standardized series of neurobehavioral tests and 
      physical measurements. The results showed that aspirin given on Day 11 produced 
      maternal and offspring growth deficits not seen when given on Day 12. In 
      addition, aspirin on Day 11 reduced behavioral performance in the progeny on 
      tests of pivoting locomotion, negative geotaxis orientation, home scent 
      (olfactory) orientation, and swimming performance. Further analysis revealed that 
      some of the behavioral effects of aspirin on Day 11 significantly covaried with 
      the body weight reductions noted in this group, such as negative geotaxis, 
      whereas other results showed only minor associations with weight, such as 
      pivoting and swimming. Interestingly, the olfactory orientation results were more 
      apparent after body weight differences were factored out. These data demonstrate 
      that (1) aspirin causes marked differences both in behavior and postnatal growth 
      with only a 24-hr difference in embryonic age at the time of treatment; (2) 
      behavioral tests are differentially affected by differences in body weight; and 
      (3) behavioral tests appear to be measuring phenomena not reflected by growth, 
      survival, or physical landmarks of development and, as such, add significant 
      information about the toxicological effects of aspirin.
FAU - Vorhees, C V
AU  - Vorhees CV
FAU - Klein, K L
AU  - Klein KL
FAU - Scott, W J
AU  - Scott WJ
LA  - eng
GR  - HD-05221/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Teratog Carcinog Mutagen
JT  - Teratogenesis, carcinogenesis, and mutagenesis
JID - 8100917
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Behavior, Animal/*drug effects
MH  - Female
MH  - Fetus/*drug effects
MH  - Gestational Age
MH  - Litter Size/drug effects
MH  - Pregnancy
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Swimming
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1002/1520-6866(1990)2:1<77::aid-tcm1770020108>3.0.co;2-c [doi]
PST - ppublish
SO  - Teratog Carcinog Mutagen. 1982;2(1):77-84. doi: 
      10.1002/1520-6866(1990)2:1<77::aid-tcm1770020108>3.0.co;2-c.

PMID- 21354678
OWN - NLM
STAT- MEDLINE
DCOM- 20110719
LR  - 20131121
IS  - 1532-1681 (Electronic)
IS  - 0268-960X (Linking)
VI  - 25
IP  - 3
DP  - 2011 May
TI  - Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a 
      critical review of the evidence from randomized controlled trials.
PG  - 123-9
LID - 10.1016/j.blre.2011.01.007 [doi]
AB  - Antiplatelet and anticoagulant drugs are effective for the prevention of arterial 
      and venous thrombosis but patients continue to experience major cardiovascular 
      events despite their use. Strategies to improve the effectiveness of 
      antithrombotic therapies include selecting the optimal drug and dosing regimen, 
      the use of combinations of antiplatelet and anticoagulant drugs and the 
      development of new more effective drugs to replace existing therapies. Evidence 
      from randomized controlled trials indicates that the combination of aspirin and 
      an anticoagulant is more effective than aspirin alone for the prevention of 
      recurrent cardiovascular events in patients with acute coronary syndrome and is 
      more effective than anticoagulation alone for the prevention of thromboembolic 
      events in patients with mechanical heart valves, but at a cost of increased 
      bleeding. Randomized controlled trials provide no evidence for improved 
      effectiveness of combination therapy compared with antiplatelet therapy alone for 
      the prevention of recurrent cardiovascular events in patients with 
      non-cardioembolic stroke or peripheral artery disease, or compared with 
      anticoagulant therapy alone for the prevention of stroke in patients with atrial 
      fibrillation. Despite lack of evaluation in randomized controlled trials, 
      combination therapy is commonly used in patients with separate indications for 
      antiplatelet therapy (e.g., acute coronary syndrome, recent coronary artery 
      stent) and anticoagulant therapy (e.g., atrial fibrillation with at least one 
      additional risk factor for stroke). Randomized trials are urgently required to 
      evaluate the effectiveness and safety of combining antiplatelet and anticoagulant 
      therapy in these settings.
CI  - Copyright © 2011 Elsevier Ltd. All rights reserved.
FAU - Paikin, Jeremy S
AU  - Paikin JS
AD  - Cardiology Fellow, Hamilton General Hospital, McMaster University, Hamilton, 
      Ontario, Canada. paikinjs@mcmaster.ca
FAU - Wright, Doug S
AU  - Wright DS
FAU - Eikelboom, John W
AU  - Eikelboom JW
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20110226
PL  - England
TA  - Blood Rev
JT  - Blood reviews
JID - 8708558
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
EDAT- 2011/03/01 06:00
MHDA- 2011/07/20 06:00
CRDT- 2011/03/01 06:00
PHST- 2011/03/01 06:00 [entrez]
PHST- 2011/03/01 06:00 [pubmed]
PHST- 2011/07/20 06:00 [medline]
AID - S0268-960X(11)00008-7 [pii]
AID - 10.1016/j.blre.2011.01.007 [doi]
PST - ppublish
SO  - Blood Rev. 2011 May;25(3):123-9. doi: 10.1016/j.blre.2011.01.007. Epub 2011 Feb 
      26.

PMID- 24969230
OWN - NLM
STAT- MEDLINE
DCOM- 20150819
LR  - 20221015
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 23
IP  - 7
DP  - 2014 Jul
TI  - Case-control study of aspirin use and risk of pancreatic cancer.
PG  - 1254-63
LID - 10.1158/1055-9965.EPI-13-1284 [doi]
AB  - BACKGROUND: Pancreas-cancer prognosis is dismal, with 5-year survival less than 
      5%. Significant relationships between aspirin use and decreased pancreas-cancer 
      incidence and mortality have been shown in four of 13 studies. METHODS: To 
      evaluate further a possible association between aspirin use and risk of 
      pancreatic cancer, we used data from a population-based Connecticut study 
      conducted from January 2005 to August 2009, of 362 pancreas-cancer cases 
      frequency matched to 690 randomly sampled controls. RESULTS: Overall, regular use 
      of aspirin was associated with reduced risk of pancreatic cancer [odds ratio 
      (OR), 0.52; 95% confidence interval (CI), 0.39-0.69]. Increments of decreasing 
      risk of pancreatic cancer were observed for each year of low-dose or regular-dose 
      aspirin use (OR, 0.94; 95% CI, 0.91-0.98 and OR, 0.98; 95% CI, 0.96-1.01, 
      respectively) and for increasing years in the past that low-dose or regular-dose 
      aspirin use had started (OR, 0.95; 95% CI, 0.92-0.99 and OR, 0.98; 95% CI, 
      0.96-1.00, respectively). Reduced risk of pancreatic cancer was seen in most 
      categories of calendar time period of aspirin use, for both low-dose aspirin and 
      regular-dose aspirin use. Relative to continuing use at the time of interview, 
      termination of aspirin use within 2 years of interview was associated with 
      increased risk of pancreatic cancer (OR, 3.24; 95% CI, 1.58-6.65). CONCLUSIONS: 
      Our results provide some support that a daily aspirin regimen may reduce risk of 
      developing pancreatic cancer. IMPACT: Long-term aspirin use has benefits for both 
      cardiovascular disease and cancer, but appreciable bleeding complications that 
      necessitate risk-benefit analysis for individual applications.
CI  - ©2014 American Association for Cancer Research.
FAU - Streicher, Samantha A
AU  - Streicher SA
AD  - Authors' Affiliations: Department of Chronic Disease Epidemiology, Yale School of 
      Public Health;
FAU - Yu, Herbert
AU  - Yu H
AD  - Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, 
      Hawaii.
FAU - Lu, Lingeng
AU  - Lu L
AD  - Authors' Affiliations: Department of Chronic Disease Epidemiology, Yale School of 
      Public Health;
FAU - Kidd, Mark S
AU  - Kidd MS
AD  - Department of Surgery, Yale School of Medicine, New Haven, Connecticut; and.
FAU - Risch, Harvey A
AU  - Risch HA
AD  - Authors' Affiliations: Department of Chronic Disease Epidemiology, Yale School of 
      Public Health; harvey.risch@yale.edu.
LA  - eng
GR  - F31 CA177153/CA/NCI NIH HHS/United States
GR  - R01 CA098870/CA/NCI NIH HHS/United States
GR  - 5R01 CA 098870/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Pancreatic Neoplasms/*epidemiology
PMC - PMC4091763
MID - NIHMS592026
COIS- Disclosures: There were no apparent or real conflicts of interest for any of the 
      authors.
EDAT- 2014/06/28 06:00
MHDA- 2015/08/20 06:00
CRDT- 2014/06/28 06:00
PHST- 2014/06/28 06:00 [entrez]
PHST- 2014/06/28 06:00 [pubmed]
PHST- 2015/08/20 06:00 [medline]
AID - 1055-9965.EPI-13-1284 [pii]
AID - 10.1158/1055-9965.EPI-13-1284 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1254-63. doi: 
      10.1158/1055-9965.EPI-13-1284.

PMID- 16099399
OWN - NLM
STAT- MEDLINE
DCOM- 20051215
LR  - 20131121
IS  - 1098-8823 (Print)
IS  - 1098-8823 (Linking)
VI  - 77
IP  - 1-4
DP  - 2005 Sep
TI  - Targeted chiral lipidomics analysis.
PG  - 141-57
AB  - Genomics, transcriptomics, and proteomics are proving to be very useful 
      techniques, which have impacted significantly on our understanding mechanisms of 
      human disease. However, this systems biology approach has several drawbacks than 
      can be overcome by the integration of metabonomics and lipidomics. We have 
      developed a targeted lipidomics approach that makes it possible to directly 
      analyze chiral lipids generated in cellular systems. Bioactive lipids are usually 
      present in trace amounts as enanatiomers and regioisomers that require separation 
      before they can be analyzed by mass spectrometry. Normal phase chiral 
      chromatography is generally used to resolve bioactive lipid enanatiomers. 
      However, conventional electrospray and atmospheric pressure chemical 
      ionization/tandem mass spectrometry have limited sensitivity when normal phase 
      solvents are used, which makes it difficult to conduct studies when only trace 
      amounts of the bioactive lipids are present. The use of electron capture 
      atmospheric pressure chemical ionization/tandem mass spectrometry overcomes this 
      problem. Enantiomers and regioisomers of targeted bioactive lipids can be 
      quantified using stable isotope dilution methodology coupled with normal phase 
      chiral chromatography and electron capture atmospheric chemical ionization/tandem 
      mass spectrometry. A targeted lipidomics profile from rat epithelial cells 
      transfected with cyclooxygenase-2 and maintained in culture was obtained. 
      Inhibition with the non-selective cyclooxygenase inhibitor aspirin increased the 
      formation of 15(R)-hydroxyeicosatetraenoic acid in the cells although it 
      completely inhibited formation of the 15(S)-enantiomer and prostaglandin E2. New 
      mass spectrometry instrumentation with an improved atmospheric pressure chemical 
      ionization source was found to be an order of magnitude more sensitive than 
      existing instruments for analysis of bioactive lipids using electron capture 
      methodology. This type of mass spectrometer will permit a more detailed analysis 
      of cellular bioactive lipid production than has been possible previously. It will 
      also permit in vivo targeted lipidomics studies to be conducted using biological 
      fluids derived from animal models and human subjects.
FAU - Lee, Seon Hwa
AU  - Lee SH
AD  - Center for Cancer Pharmacology, University of Pennsylvania School of Medicine, 
      1254 BRB II/III, 421 Curie Boulevard Philadelphia, PA 19104-6160, USA.
FAU - Williams, Michelle V
AU  - Williams MV
FAU - Blair, Ian A
AU  - Blair IA
LA  - eng
GR  - R01 CA91016/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Prostaglandins Other Lipid Mediat
JT  - Prostaglandins & other lipid mediators
JID - 9808648
RN  - 0 (15-hydroxyeicosatetraenoic acid receptor)
RN  - 0 (Ions)
RN  - 0 (Lipids)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Receptors, Eicosanoid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Chromatography
MH  - Electrons
MH  - Epithelial Cells/metabolism
MH  - Humans
MH  - Ions
MH  - Lipids/*chemistry
MH  - Mass Spectrometry
MH  - Models, Chemical
MH  - Rats
MH  - Reactive Oxygen Species
MH  - Receptors, Eicosanoid/chemistry
MH  - Spectrometry, Mass, Electrospray Ionization
MH  - Stereoisomerism
MH  - Time Factors
RF  - 74
EDAT- 2005/08/16 09:00
MHDA- 2005/12/16 09:00
CRDT- 2005/08/16 09:00
PHST- 2004/01/10 00:00 [received]
PHST- 2004/01/11 00:00 [accepted]
PHST- 2005/08/16 09:00 [pubmed]
PHST- 2005/12/16 09:00 [medline]
PHST- 2005/08/16 09:00 [entrez]
AID - S1098-8823(05)00077-8 [pii]
AID - 10.1016/j.prostaglandins.2004.01.009 [doi]
PST - ppublish
SO  - Prostaglandins Other Lipid Mediat. 2005 Sep;77(1-4):141-57. doi: 
      10.1016/j.prostaglandins.2004.01.009.

PMID- 25110930
OWN - NLM
STAT- MEDLINE
DCOM- 20150417
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 8
DP  - 2014
TI  - Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among 
      high vascular risk patients: a meta-analysis of randomized controlled trials.
PG  - e104402
LID - 10.1371/journal.pone.0104402 [doi]
LID - e104402
AB  - OBJECTIVES: Whether clopidogrel should be added to aspirin for stroke prevention 
      remained controversial for the risk of hemorrhagic complications. This 
      meta-analysis was aimed to assess the efficacy and safety of adding clopidogrel 
      to aspirin on stroke prevention in high vascular risk patients, and to provide 
      evidence for a suitable duration of dual antiplatelet therapy. METHODS: We 
      searched PubMed, EMBase, OVID and Cochrane Central Register of Controlled Trials 
      (up to June, 2013) for randomized controlled trials evaluating the efficacy and 
      safety of clopidogrel plus aspirin versus aspirin alone in high vascular risk 
      patients. Comparisons of stroke and hemorrhagic complications between treatment 
      groups were expressed by the pooled Relative Risks (RRs) with 95% Confidence 
      Intervals (CIs). RESULTS: Fifteen trials with a total of 97692 intention-to-treat 
      participants were included with duration of follow-up ranging from 7 days to 3.6 
      years. Dual antiplatelet therapy reduced all stroke by 21% (RR: 0.79, 95% CI: 
      0.73-0.85) with no evidence of heterogeneity across the trials (P = 0.27, 
      I2 = 17%).The effects were consistent between short-term subgroup (≤1 month, RR: 
      0.76, 95% CI: 0.67-0.85) and long-term subgroup (≥3 months, RR: 0.81, 95% CI: 
      0.73-0.89). The risk of major bleeding was not significantly increased by dual 
      antiplatelet therapy in short-term subgroup (RR: 1.11, 95% CI: 0.91-1.36), while 
      significantly increased in long-term subgroup (RR: 1.52, 95% CI: 1.36-1.69). 
      Long-term dual antiplatelet therapy substantially increased the risk of 
      intracranial bleeding (RR: 1.76, 95% CI: 1.22-2.54). CONCLUSIONS: This 
      meta-analysis demonstrates that short-term combination of clopidogrel and aspirin 
      is effective and safe for stroke prevention in high vascular risk patients. 
      Long-term combination therapy substantially increases the risk of major bleeding 
      and intracranial bleeding.
FAU - Chen, Shuying
AU  - Chen S
AD  - Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, Guangdong Province, China.
FAU - Shen, Qingyu
AU  - Shen Q
AD  - Department of Neurology, Affiliated Boji Hospital, Sun Yat-Sen University, 
      Guangzhou, Guangdong Province, China.
FAU - Tang, Yamei
AU  - Tang Y
AD  - Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, Guangdong Province, China.
FAU - He, Lei
AU  - He L
AD  - Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, Guangdong Province, China.
FAU - Li, Yi
AU  - Li Y
AD  - Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, Guangdong Province, China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Neurology, Guangdong General Hospital, Guangzhou, Guangdong 
      Province, China.
FAU - Li, Mei
AU  - Li M
AD  - Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, Guangdong Province, China.
FAU - Peng, Ying
AU  - Peng Y
AD  - Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, Guangdong Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20140811
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/*pharmacology
MH  - Clopidogrel
MH  - Hemorrhage/chemically induced/complications
MH  - Humans
MH  - Randomized Controlled Trials as Topic/*methods
MH  - Risk
MH  - *Safety
MH  - Stroke/complications/*prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/pharmacology
PMC - PMC4128803
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/08/12 06:00
MHDA- 2015/04/18 06:00
CRDT- 2014/08/12 06:00
PHST- 2013/11/04 00:00 [received]
PHST- 2014/07/13 00:00 [accepted]
PHST- 2014/08/12 06:00 [entrez]
PHST- 2014/08/12 06:00 [pubmed]
PHST- 2015/04/18 06:00 [medline]
AID - PONE-D-13-45093 [pii]
AID - 10.1371/journal.pone.0104402 [doi]
PST - epublish
SO  - PLoS One. 2014 Aug 11;9(8):e104402. doi: 10.1371/journal.pone.0104402. 
      eCollection 2014.

PMID- 22632777
OWN - NLM
STAT- MEDLINE
DCOM- 20130212
LR  - 20131121
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 319
IP  - 1-2
DP  - 2012 Aug 15
TI  - No significant association of aspirin use with cerebral microbleeds in the 
      asymptomatic elderly.
PG  - 56-8
LID - 10.1016/j.jns.2012.05.017 [doi]
AB  - BACKGROUND AND PURPOSE: Cerebral microbleeds (CMBs) may predict future risk for 
      intracerebral hemorrhage (ICH). ICH is one of the most important complications of 
      aspirin use. The association between aspirin use and CMBs is still controversial. 
      In this context, we sought to investigate whether aspirin use is associated with 
      CMBs in subjects without previous history of stroke. METHODS: Asymptomatic 
      elderly subjects (n=1452; age ≥ 65 years) who visited for routine health 
      check-ups were included in this study. CMBs were evaluated through T2*-weighted 
      gradient-recalled echo MRI. Information about aspirin or warfarin use was 
      obtained using a structured questionnaire. RESULTS: A total of 138 subjects 
      (9.5%) were found to have CMBs. In the group of aspirin use, 43 subjects (11.2%) 
      had CMBs; among them 9 (2.3%) had strictly lobar microbleeds and 34 (8.9%) had 
      deep or infratentorial microbleeds. Compared with the non-use group, the risk for 
      CMBs did not increase in the group of aspirin use (adjusted odds ratio, 1.10; 95% 
      confidence interval, 0.73-1.66). For the group of aspirin use above 5 years, the 
      proportion of CMBs (11.1%) did not increase compared with the group of short-term 
      use (≤ 5 years, 9.5%, p=0.99) and non-use group (8.9%, p=0.66). CONCLUSIONS: We 
      found that the prevalence of CMBs did not increase in the group of aspirin use, 
      and the presence of CMBs was not associated with the duration of aspirin use in 
      asymptomatic elderly subjects without a history of stroke or transient ischemic 
      attack.
CI  - Copyright © 2012 Elsevier B.V. All rights reserved.
FAU - Kim, Chi Kyung
AU  - Kim CK
AD  - Department of Neurology, Seoul National University Hospital, Seoul, Republic of 
      Korea.
FAU - Kwon, Hyuk Tae
AU  - Kwon HT
FAU - Kwon, Hyung-Min
AU  - Kwon HM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120524
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Humans
MH  - Intracranial Hemorrhages/*chemically induced
MH  - Male
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Risk Factors
EDAT- 2012/05/29 06:00
MHDA- 2013/02/13 06:00
CRDT- 2012/05/29 06:00
PHST- 2012/03/22 00:00 [received]
PHST- 2012/04/20 00:00 [revised]
PHST- 2012/05/04 00:00 [accepted]
PHST- 2012/05/29 06:00 [entrez]
PHST- 2012/05/29 06:00 [pubmed]
PHST- 2013/02/13 06:00 [medline]
AID - S0022-510X(12)00228-6 [pii]
AID - 10.1016/j.jns.2012.05.017 [doi]
PST - ppublish
SO  - J Neurol Sci. 2012 Aug 15;319(1-2):56-8. doi: 10.1016/j.jns.2012.05.017. Epub 
      2012 May 24.

PMID- 36681456
OWN - NLM
STAT- MEDLINE
DCOM- 20230126
LR  - 20230202
IS  - 1523-1755 (Electronic)
IS  - 0085-2538 (Linking)
VI  - 103
IP  - 2
DP  - 2023 Feb
TI  - TIPS to decide whether to prescribe aspirin for the primary prevention of 
      cardiovascular events in chronic kidney disease.
PG  - 261-263
LID - S0085-2538(22)00943-7 [pii]
LID - 10.1016/j.kint.2022.10.018 [doi]
AB  - Aspirin effectively prevents subsequent cardiovascular events. A post hoc 
      subgroup analysis of the International Polycap Study 3 (TIPS-3) trial suggests 
      that patients with chronic kidney disease might also benefit from aspirin for 
      primary prevention. We consider the merits of doing so in practice.
CI  - Copyright © 2022 International Society of Nephrology. Published by Elsevier Inc. 
      All rights reserved.
FAU - Roshanov, Pavel S
AU  - Roshanov PS
AD  - Department of Medicine, Western University, London, Ontario, Canada; Department 
      of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. 
      Electronic address: pavel.roshanov@lhsc.on.ca.
FAU - Garg, Amit X
AU  - Garg AX
AD  - Department of Medicine, Western University, London, Ontario, Canada; Department 
      of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/etiology/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Primary Prevention
MH  - *Renal Insufficiency, Chronic/complications
EDAT- 2023/01/22 06:00
MHDA- 2023/01/25 06:00
CRDT- 2023/01/21 21:01
PHST- 2022/10/20 00:00 [received]
PHST- 2022/10/26 00:00 [accepted]
PHST- 2023/01/21 21:01 [entrez]
PHST- 2023/01/22 06:00 [pubmed]
PHST- 2023/01/25 06:00 [medline]
AID - S0085-2538(22)00943-7 [pii]
AID - 10.1016/j.kint.2022.10.018 [doi]
PST - ppublish
SO  - Kidney Int. 2023 Feb;103(2):261-263. doi: 10.1016/j.kint.2022.10.018.

PMID- 25518419
OWN - NLM
STAT- MEDLINE
DCOM- 20150120
LR  - 20141218
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 72
IP  - 9
DP  - 2014 Sep
TI  - [Thromboprophylaxis in patients with coronary aneurysms caused by Kawasaki 
      disease].
PG  - 1659-63
AB  - Patients with coronary artery aneurysms caused by Kawasaki disease are at 
      increased risk of coronary thrombosis and ischemia. To prevent coronary 
      thrombosis, long term thromboprophylaxis using anti-platelet drugs, such as 
      aspirin, dipyridamole, ticlopidine, clopidogrel, and abciximab, with or without 
      warfarin is recommended by official guidelines. In fact, aspirin or aspirin with 
      warfarin are the most frequently administered regimen in these patients with 
      coronary aneurysms. However, still there has been paucity of data and no 
      randomized controlled study to determine the efficacy of these drugs. This short 
      article describes the currently accepted practice of thromboprophylaxis in 
      patients with coronary aneurysms caused by Kawasaki disease.
FAU - Suda, Kenii
AU  - Suda K
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Coronary Aneurysm/*etiology
MH  - Coronary Thrombosis/*prevention & control
MH  - Humans
MH  - Mucocutaneous Lymph Node Syndrome/*complications
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Warfarin/therapeutic use
EDAT- 2014/12/19 06:00
MHDA- 2015/01/21 06:00
CRDT- 2014/12/19 06:00
PHST- 2014/12/19 06:00 [entrez]
PHST- 2014/12/19 06:00 [pubmed]
PHST- 2015/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2014 Sep;72(9):1659-63.

PMID- 14499730
OWN - NLM
STAT- MEDLINE
DCOM- 20031219
LR  - 20191108
IS  - 1297-9589 (Print)
IS  - 1297-9589 (Linking)
VI  - 31
IP  - 9
DP  - 2003 Sep
TI  - [Treatment of recurrent spontaneous abortion associated with the antiphospholipid 
      antibody syndrome].
PG  - 789-93
AB  - Treatment of repeated foetal loss associated with antiphospholipid syndrome was 
      initially based on immunomodulating therapy such as corticosteroids or 
      intravenous immunoglobulins. More recently aspirin and heparin have been assessed 
      because of the thrombotic mechanisms involved in foetal losses. Randomized 
      controlled trials have demonstrated that the association of aspirin and heparin 
      is superior to aspirin alone in the prevention of recurrence of pregnancy loss.
FAU - Carbonne, B
AU  - Carbonne B
AD  - Groupe Arpège, hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 
      Paris, France. bruno.carbonne@sat.ap-hop-paris.fr
FAU - Lejeune, V
AU  - Lejeune V
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Modalités thérapeutiques d'une maladie abortive d'origine dysimmunitaire 
      (syndrome des antiphospholipides primitif).
PL  - France
TA  - Gynecol Obstet Fertil
JT  - Gynecologie, obstetrique & fertilite
JID - 100936305
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*immunology/*prevention & control
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Antiphospholipid Syndrome/*complications
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Pregnancy
RF  - 18
EDAT- 2003/09/23 05:00
MHDA- 2003/12/20 05:00
CRDT- 2003/09/23 05:00
PHST- 2003/09/23 05:00 [pubmed]
PHST- 2003/12/20 05:00 [medline]
PHST- 2003/09/23 05:00 [entrez]
AID - S1297958903002108 [pii]
AID - 10.1016/s1297-9589(03)00210-8 [doi]
PST - ppublish
SO  - Gynecol Obstet Fertil. 2003 Sep;31(9):789-93. doi: 10.1016/s1297-9589(03)00210-8.

PMID- 19055515
OWN - NLM
STAT- MEDLINE
DCOM- 20100202
LR  - 20220311
IS  - 1463-1318 (Electronic)
IS  - 1462-8910 (Linking)
VI  - 11
IP  - 9
DP  - 2009 Nov
TI  - The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis 
      of randomized controlled trials.
PG  - 893-901
LID - 10.1111/j.1463-1318.2008.01746.x [doi]
AB  - PURPOSE: Colorectal adenomas are precursors of most colorectal cancers and are 
      important targets for chemoprevention. Aspirin is thought to play an important 
      role in chemoprevention. However, the role of aspirin in preventing recurrence of 
      adenomas is controversial. We performed a systematic review and meta-analysis to 
      evaluate the effect of aspirin in preventing the recurrence of colorectal 
      adenoma. METHOD: Trials were located through Medline, Embase and the Cochrane 
      Central Register of Controlled Trials (CENTRAL). From 14 articles screened, three 
      were identified as randomized controlled trials and were included for data 
      extraction. Main outcome measures were the recurrence of any new adenoma and 
      advanced adenoma. The meta-analysis was performed with the fixed-effects model. 
      RESULTS: A total of 2338 participants were enrolled in the three studies and 2175 
      of them completed the follow-up colonoscopy. We found that the relative risks of 
      any adenoma (when compared with the placebo group) were 0.859 in the high dose of 
      aspirin groups (95% confidence interval (CI), 0.756-0.976, P = 0.019), 0.826 in 
      the low dose of aspirin groups (95% CI 0.706-0.965, P = 0.016) and 0.836 in the 
      both aspirin combined groups (95% CI 0.746-0.937, P = 0.002). For the recurrence 
      of advanced adenoma, the relative risk (when compared with the placebo group) was 
      0.655 (95% CI 0.513-0.837, P = 0.001) in the aspirin groups without considering 
      the dose. CONCLUSION: This meta-analysis suggests that aspirin prevents recurrent 
      colorectal adenomas among patients with a history of colorectal adenomas.
FAU - Gao, F
AU  - Gao F
AD  - Departments of Colorectal and Anal Surgery, First Affiliated Hospital, Guangxi 
      Medical University, Nanning, Guangxi, P.R. China. doctorgao0771@hotmail.com
FAU - Liao, C
AU  - Liao C
FAU - Liu, L
AU  - Liu L
FAU - Tan, A
AU  - Tan A
FAU - Cao, Y
AU  - Cao Y
FAU - Mo, Z
AU  - Mo Z
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20091114
PL  - England
TA  - Colorectal Dis
JT  - Colorectal disease : the official journal of the Association of Coloproctology of 
      Great Britain and Ireland
JID - 100883611
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Humans
MH  - Neoplasm Recurrence, Local/*prevention & control
RF  - 53
EDAT- 2008/12/06 09:00
MHDA- 2010/02/03 06:00
CRDT- 2008/12/06 09:00
PHST- 2008/12/06 09:00 [pubmed]
PHST- 2010/02/03 06:00 [medline]
PHST- 2008/12/06 09:00 [entrez]
AID - CDI1746 [pii]
AID - 10.1111/j.1463-1318.2008.01746.x [doi]
PST - ppublish
SO  - Colorectal Dis. 2009 Nov;11(9):893-901. doi: 10.1111/j.1463-1318.2008.01746.x. 
      Epub 2009 Nov 14.

PMID- 559478
OWN - NLM
STAT- MEDLINE
DCOM- 19770718
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 137
IP  - 6
DP  - 1977 Jun
TI  - Platelet-latelet-.
PG  - 735-7
AB  - Two patients with thrombotic thrombocytopenic purpura were seen. Aspirin, 
      dipyridamole, and sulfinpyrazone were administered to patient 1 after 
      splenectomy, and administration of high-dose prednisone and methylprednisolone 
      failed to induce remission. The platelet count rose, but the patient had a 
      relapse when the dipyridamole dose was tapered. This condition responded to an 
      increase of the drug, and the patient obtained a long-lasting remission. A 
      splenectomy was not performed on patient 2, and all three platelet-inhibiting 
      drugs, together with prednisone, were given. This resulted in a prompt remission 
      that has been sustained for 29 weeks. Morphologic changes in the peripheral blood 
      smear remained for several weeks after other features of the disease had 
      resolved. Thus, in both cases, platelet-inhibiting drugs appeared to induce a 
      remission.
FAU - Eckel, R H
AU  - Eckel RH
FAU - Crowell, E B
AU  - Crowell EB
FAU - Waterhouse, B E
AU  - Waterhouse BE
FAU - Bozdech, M J
AU  - Bozdech MJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
RN  - VB0R961HZT (Prednisone)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Depression, Chemical
MH  - Dipyridamole/*pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Methylprednisolone/therapeutic use
MH  - Middle Aged
MH  - Prednisone/therapeutic use
MH  - Purpura, Thrombotic Thrombocytopenic/*blood/drug therapy
MH  - Remission, Spontaneous
MH  - Sulfinpyrazone/*pharmacology/therapeutic use
EDAT- 1977/06/01 00:00
MHDA- 1977/06/01 00:01
CRDT- 1977/06/01 00:00
PHST- 1977/06/01 00:00 [pubmed]
PHST- 1977/06/01 00:01 [medline]
PHST- 1977/06/01 00:00 [entrez]
AID - 10.1001/archinte.137.6.735 [doi]
PST - ppublish
SO  - Arch Intern Med. 1977 Jun;137(6):735-7. doi: 10.1001/archinte.137.6.735.

PMID- 28880838
OWN - NLM
STAT- MEDLINE
DCOM- 20180518
LR  - 20181113
IS  - 1545-1151 (Electronic)
IS  - 1545-1151 (Linking)
VI  - 14
DP  - 2017 Sep 7
TI  - Aspirin for Prevention of Cardiovascular Disease.
PG  - E77
LID - 10.5888/pcd14.170171 [doi]
LID - E77
AB  - We used data from the 2013 Mississippi Behavioral Risk Factor Surveillance System 
      to examine aspirin use for the prevention of primary and secondary cardiovascular 
      disease (CVD), based on the 2009 US Preventive Services Task Force (USPSTF) 
      guidelines, among Mississippi men (aged 45-79 y) and women (aged 55-79 y) and to 
      explore differences in aspirin use by sociodemographic characteristics. Among 
      those without CVD, 39.1% of men and 45.9% of women reported taking aspirin, and 
      among those with CVD, 85.9% of men and 85.1% of women reported taking aspirin. 
      Data on preventive use of aspirin by sociodemographic characteristics yielded 
      mixed results.
FAU - Mendy, Vincent L
AU  - Mendy VL
AD  - Office of Health Data and Research, Mississippi State Department of Health, 570 
      East Woodrow Wilson Drive, Jackson, MS 39215. Email: vincent.mendy@msdh.ms.gov.
FAU - Vargas, Rodolfo
AU  - Vargas R
AD  - Office of Health Data and Research, Mississippi State Department of Health, 
      Jackson, Mississippi.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Office of Health Data and Research, Mississippi State Department of Health, 
      Jackson, Mississippi.
LA  - eng
GR  - U50 DP003088/DP/NCCDPHP CDC HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20170907
PL  - United States
TA  - Prev Chronic Dis
JT  - Preventing chronic disease
JID - 101205018
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mississippi/epidemiology
PMC - PMC5590489
EDAT- 2017/09/08 06:00
MHDA- 2018/05/19 06:00
CRDT- 2017/09/08 06:00
PHST- 2017/09/08 06:00 [entrez]
PHST- 2017/09/08 06:00 [pubmed]
PHST- 2018/05/19 06:00 [medline]
AID - E77 [pii]
AID - 17_0171 [pii]
AID - 10.5888/pcd14.170171 [doi]
PST - epublish
SO  - Prev Chronic Dis. 2017 Sep 7;14:E77. doi: 10.5888/pcd14.170171.

PMID- 22743731
OWN - NLM
STAT- MEDLINE
DCOM- 20121126
LR  - 20190608
IS  - 2329-0358 (Electronic)
IS  - 1425-9524 (Linking)
VI  - 17
IP  - 2
DP  - 2012 Apr-Jun
TI  - Successful liver transplantation with continued dual antiplatelet therapy.
PG  - 127-30
AB  - BACKGROUND: Liver transplantation in patients with dual antiplatelet therapy is 
      considered high-risk procedure due to possible bleeding complications. However, 
      withdrawal of antiplatelet therapy can lead to major adverse cardiac events such 
      as stent thrombosis and even fatal myocardial infarction. CASE REPORT: We report 
      on a 61-year-old male patient with nutritive toxic liver cirrhosis who underwent 
      liver transplantation at our hospital in March 2010. Following two strokes he 
      received secondary prophylaxis with aspirin and clopidogrel, which was continued 
      at time of liver transplantation. The transplantation was performed successfully 
      without withdrawal of the antiplatelet therapy. No cardiac event and no major 
      bleeding complication occurred. CONCLUSIONS: This is, to our knowledge, the first 
      report of a liver transplantation under dual antiplatelet therapy with aspirin 
      and clopidogrel. It shows that even major procedures such as liver 
      transplantation, with its associated high risk of surgical bleeding, can be 
      safely performed with an appropriate risk.
FAU - Spieker, Henning
AU  - Spieker H
AD  - Department of Visceral, Transplantation, Thoracic and Vascular Surgery, 
      University Hospital Leipzig, Germany. henning.spieker@medizin.uni-leipzig.de
FAU - Benckert, Christoph
AU  - Benckert C
FAU - Quante, Markus
AU  - Quante M
FAU - Thelen, Armin
AU  - Thelen A
FAU - Gaebelein, Gereon
AU  - Gaebelein G
FAU - Kaisers, Udo
AU  - Kaisers U
FAU - Jonas, Sven
AU  - Jonas S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Transplant
JT  - Annals of transplantation
JID - 9802544
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Liver Cirrhosis/*surgery
MH  - Liver Transplantation/*methods
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Stroke/drug therapy/*prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
EDAT- 2012/06/30 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/06/30 06:00
PHST- 2012/06/30 06:00 [entrez]
PHST- 2012/06/30 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 883231 [pii]
AID - 10.12659/aot.883231 [doi]
PST - ppublish
SO  - Ann Transplant. 2012 Apr-Jun;17(2):127-30. doi: 10.12659/aot.883231.

PMID- 24109
OWN - NLM
STAT- MEDLINE
DCOM- 19780417
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 30
IP  - 2
DP  - 1978 Feb
TI  - Gastric erosions induced by analgesic drug mixtures in the rat.
PG  - 84-7
AB  - Gastric erosions after oral administration of analgesics separately and in 
      admixture have been examined in adult rats. After administration of 
      acetylsalicylic acid (aspirin), phenacetin, paracetamol and caffeine as single 
      drugs, gastric erosions were only observed with aspirin. The combination of 
      aspirin with phenacetin did not change, that of aspirin with caffeine 
      significantly increased, and aspirin with paracetamol significantly decreased the 
      incidence of gastric lesions compared with aspirin alone. The results for aspirin 
      with paracetamol did not differ from those for the vehicle. Addition of caffeine 
      to the combination of aspirin and phenacetin caused a significant increase in 
      erosions, but when given with aspirin and paracetamol no erosions occurred. The 
      mechanisms underlying the effects of these drugs on aspirin-induced erosions are 
      discussed.
FAU - Seegers, A J
AU  - Seegers AJ
FAU - Jager, L P
AU  - Jager LP
FAU - Van Noordwijk, J
AU  - Van Noordwijk J
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Caffeine/*pharmacology
MH  - Drug Combinations
MH  - Female
MH  - Lethal Dose 50
MH  - Phenacetin/*pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach Ulcer/*chemically induced
MH  - Time Factors
EDAT- 1978/02/01 00:00
MHDA- 1978/02/01 00:01
CRDT- 1978/02/01 00:00
PHST- 1978/02/01 00:00 [pubmed]
PHST- 1978/02/01 00:01 [medline]
PHST- 1978/02/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1978.tb13167.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1978 Feb;30(2):84-7. doi: 10.1111/j.2042-7158.1978.tb13167.x.

PMID- 7234307
OWN - NLM
STAT- MEDLINE
DCOM- 19810723
LR  - 20131121
IS  - 0001-5989 (Print)
IS  - 0001-5989 (Linking)
VI  - 37
IP  - 4
DP  - 1980
TI  - Experimental evidence for cytoprotective effect of atropine on the rat gastric 
      mucosa.
PG  - 401-5
AB  - The inhibitory effect of atropine on the gastric mucosal damage produced by 
      topical aspirin has been studied in the rat, in the presence and in the absence 
      of intragastrically applied 160 mmole/l HCl. The gastric mucosal damage was 
      produced by aspirin given intragastrically in doses of 192 mg/kg. The topical 
      application was done alone or in the presence of 160 mmole/l HCl. The ulcer 
      incidence, the number and size of gastric mucosal damage were studied during 4 h. 
      The aspirin solutions were administered with or without atropine (in doses of 4 
      and 10 mg/kg). The atropine was added immediately after the administration of 
      aspirin. The results were as follows 1. A dose-dependent inhibition of ulcer 
      incidence, number and size of gastric mucosal damage was produced by atropine in 
      both groups of animals, when the aspirin was given alone or together with 160 
      mmole/l HCl; 2. The inhibitory effect of atropine was significantly weaker in the 
      group treated with aspirin plus 160 mmole/l HCl than in th aspirin-treated group. 
      It has been concluded the ulcer-preventing effect of atropine is mediated partly 
      through the inhibition of gastric H+ secretion, and partly some "cytoprotective 
      effect"; the extent of the "cytoprotective effect" of atropine was about half 
      that on gastric H+ secretion.
FAU - Mózsik, G
AU  - Mózsik G
FAU - Lovász, L
AU  - Lovász L
FAU - Kutor, G
AU  - Kutor G
FAU - Nagy, L
AU  - Nagy L
FAU - Tárnok, F
AU  - Tárnok F
LA  - eng
PT  - Journal Article
PL  - Hungary
TA  - Acta Med Acad Sci Hung
JT  - Acta medica Academiae Scientiarum Hungaricae
JID - 0370323
RN  - 7C0697DR9I (Atropine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/toxicity
MH  - Atropine/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Male
MH  - Rats
MH  - Stomach Ulcer/prevention & control
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Med Acad Sci Hung. 1980;37(4):401-5.

PMID- 15858933
OWN - NLM
STAT- MEDLINE
DCOM- 20050527
LR  - 20191109
IS  - 1349-2365 (Print)
IS  - 1349-2365 (Linking)
VI  - 46
IP  - 1
DP  - 2005 Jan
TI  - Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent 
      thrombosis and platelet function in acute myocardial infarction patients with 
      percutaneous coronary intervention.
PG  - 13-22
AB  - We compared the effects of ticlopidine and cilostazol on the prevention of 
      subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients 
      with stenting. We also analyzed the cause of the difference by measuring platelet 
      aggregation activity. Consecutive patients who underwent successful stenting for 
      AMI between March 2001 and March 2004 were analyzed. In addition to aspirin (100 
      mg/day), cilostazol (200 mg/day) was administered to 99 cases between March 2001 
      and May 2002 and ticlopidine (200 mg/day) was administered to 85 cases between 
      June 2002 and February 2004. The incidence of SAT within four weeks after 
      stenting was analyzed. Thirty-eight AMI patients were randomized and their 
      platelet aggregation activity was measured using a laser-scattered aggregometer 
      (18 cases in the cilostazol group and 20 cases in the ticlopidine group). SAT did 
      not occur in the ticlopidine group while 5 cases (5.1%) of SAT occurred in the 
      cilostazol group (P < 0.05). The inhibitory activity of cilostazol for 
      ADP-induced platelet aggregation was lower than that of ticlopidine (P < 0.05). 
      Cilostazol with aspirin after stenting in AMI patients showed more frequent SAT 
      than ticlopidine with aspirin. One of the causes for this difference was 
      speculated to be the weaker inhibitory activity of cilostazol for ADP-induced 
      platelet aggregation.
FAU - Kawata, Masahito
AU  - Kawata M
AD  - Department of Cardiology, Akashi Medical Center, Hyogo, Japan.
FAU - Kuramoto, Emi
AU  - Kuramoto E
FAU - Kataoka, Toshio
AU  - Kataoka T
FAU - Saito, Atsushi
AU  - Saito A
FAU - Adachi, Kazumasa
AU  - Adachi K
FAU - Matsuura, Akira
AU  - Matsuura A
FAU - Sakamoto, Susumu
AU  - Sakamoto S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Japan
TA  - Int Heart J
JT  - International heart journal
JID - 101244240
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cilostazol
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Myocardial Infarction/*therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - *Stents
MH  - Tetrazoles/administration & dosage/*therapeutic use
MH  - Thrombosis/epidemiology/*prevention & control
MH  - Ticlopidine/administration & dosage/*therapeutic use
EDAT- 2005/04/30 09:00
MHDA- 2005/05/28 09:00
CRDT- 2005/04/30 09:00
PHST- 2005/04/30 09:00 [pubmed]
PHST- 2005/05/28 09:00 [medline]
PHST- 2005/04/30 09:00 [entrez]
AID - 10.1536/ihj.46.13 [doi]
PST - ppublish
SO  - Int Heart J. 2005 Jan;46(1):13-22. doi: 10.1536/ihj.46.13.

PMID- 17489072
OWN - NLM
STAT- MEDLINE
DCOM- 20070724
LR  - 20191110
IS  - 0003-4509 (Print)
IS  - 0003-4509 (Linking)
VI  - 65
IP  - 3
DP  - 2007 May
TI  - [Interindividual variability in the laboratory response to the 
      aspirin-clopidogrel combination: are patients with stent occlusion "resistant" to 
      treatment?].
PG  - 169-73
AB  - Interindividual variability of biological response to antiplatelet agents is an 
      opened question, which constitute the purpose of recent publications. Indeed, a 
      wide interindividual variability in the laboratory response to antiplatelet 
      agents such as aspirin and/or clopidogrel has been shown. However, only few 
      clinical data are available to demonstrate the relationship between a poor 
      laboratory response to antiplatelet treatment and the occurrence of stent 
      thrombosis. The aim of this study is to compare photometric platelet aggregation 
      profiles of two groups of patients who had undergone percutaneous coronary 
      intervention with stent implantation (one group with at least one subacute 
      thrombotic event following stent implantation and one historical control group 
      free of thrombotic events) to determine whether there is a parameter which could 
      be useful in identifying patients with a risk of having a thrombotic event 
      related to poor response to antiplatelet treatment. We found some differences 
      between the two groups regarding the maximal light transmission after stimulation 
      with arachidonic acid (1,39 mM) or collagen at low concentration (Horm, 2 
      microg/mL) but not after stimulation with ADP irrespective of the concentration 
      studied (10, 5 and 2,5 microM). However, platelet inhibition response to ADP 
      could be assessed with another parameter, the disaggregation percentage, which 
      was significantly lower in patients with than without thrombosis, and may be used 
      as marker to distinguish patients with a higher risk of thrombosis.
FAU - Hacquard, M
AU  - Hacquard M
AD  - Service d'Hématologie Biologique, Chu Nancy, Allée du Morvan, 54500 
      Vandoeuvre-lès-Nancy. m.toussaint-hacquard@chu-nancy.fr
FAU - Angioï, M
AU  - Angioï M
FAU - Lecompte, T
AU  - Lecompte T
FAU - Vigneron, C
AU  - Vigneron C
LA  - fre
PT  - Journal Article
TT  - Existe-t-il une "résistance" biologique au traitement antiplaquettaire associant 
      aspirine et clopidogrel chez les patients ayant présenté une occlusion de stent?
PL  - France
TA  - Ann Pharm Fr
JT  - Annales pharmaceutiques francaises
JID - 2985176R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - Collagen
MH  - Coronary Restenosis/*drug therapy/prevention & control
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Predictive Value of Tests
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2007/05/10 09:00
MHDA- 2007/07/25 09:00
CRDT- 2007/05/10 09:00
PHST- 2007/05/10 09:00 [pubmed]
PHST- 2007/07/25 09:00 [medline]
PHST- 2007/05/10 09:00 [entrez]
AID - MDOI-APF-05-2007-65-3-0003-4509-101019-200609740 [pii]
AID - 10.1016/s0003-4509(07)90032-2 [doi]
PST - ppublish
SO  - Ann Pharm Fr. 2007 May;65(3):169-73. doi: 10.1016/s0003-4509(07)90032-2.

PMID- 31898611
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20210114
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 9
IP  - 4
DP  - 2019 Oct-Dec
TI  - Revisiting the expanded use of hyperbaric oxygen therapy for treatment of 
      resistant migraines.
PG  - 238-240
LID - 10.4103/2045-9912.273963 [doi]
AB  - There are currently 13 indications approved by the U.S. Food and Drug 
      Administration for use of hyperbaric oxygen therapy. The European Consensus 
      Conference on Hyperbaric Medicine has 28 indications approved for its use. 
      However, neither includes the use of hyperbaric oxygen therapy for neurological 
      conditions such as migraines with aura. Recent research has made the attempt to 
      fully understand the use of hyperbaric therapy in treatment of neurological 
      conditions, but results have so far been inconclusive. We report a 23-year-old 
      female with an 11-year history of migraines with aura who has received inadequate 
      pharmacological treatment for her migraines since she began having them. 
      Migraines have led her to significant loss of function. The patient underwent 
      treatment at 1.5 absolute atmospheres in a hyperbaric chamber Monday through 
      Friday for 1 hour each day for a total of 40 sessions but reported missing a few 
      sessions over the 8-week period. No more than 1 session during a given week was 
      missed and the patient received no other treatments for her migraines throughout 
      this time period. By her 24(th) treatment, the patient had only experienced a 
      single migraine with aura but without debilitating pain. The patient stated she 
      had never had a migraine with such little intensity prior to initiation of 
      hyperbaric treatment and did not have to take any days off from work or school. 
      Follow-up at the end of her 40-day treatment period revealed a highly-satisfied 
      patient who had only experienced the single episode of a mild migraine during the 
      entire course of treatment. Thus, we believe that further research needs to be 
      done to realize the full potential of hyperbaric oxygen therapy in the treatment 
      of neurological conditions as this case highlights the potential for using 
      hyperbaric oxygen therapy as prophylaxis against attacks in patients with 
      treatment resistant migraines with aura.
FAU - Matera, David V
AU  - Matera DV
AD  - Department of General Surgery, Geisinger Wyoming Valley Medical Center, 
      Wilkes-Barre, PA, USA.
FAU - Smith, Brian
AU  - Smith B
AD  - Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA.
FAU - Lam, Benjamin
AU  - Lam B
AD  - Division of Plastic and Reconstructive Surgery, Philadelphia College of 
      Osteopathic Medicine, Philadelphia, PA, USA.
LA  - eng
PT  - Case Reports
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 0 (Drug Combinations)
RN  - 0 (acetaminophen, aspirin, caffeine drug combination)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Caffeine/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - *Hyperbaric Oxygenation
MH  - Migraine Disorders/diagnosis/*therapy
MH  - Young Adult
PMC - PMC7802418
OTO - NOTNLM
OT  - aura
OT  - hyperbaric chambers
OT  - hyperbaric oxygen therapy
OT  - indications for hyperbaric oxygen
OT  - migraine with aura
OT  - migraines
OT  - vascular headaches
OT  - vasoconstriction
COIS- Conflicts of interest None.
EDAT- 2020/01/04 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/01/04 06:00
PHST- 2020/01/04 06:00 [entrez]
PHST- 2020/01/04 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - MedGasRes_2019_9_4_238_273963 [pii]
AID - MGR-9-238 [pii]
AID - 10.4103/2045-9912.273963 [doi]
PST - ppublish
SO  - Med Gas Res. 2019 Oct-Dec;9(4):238-240. doi: 10.4103/2045-9912.273963.

PMID- 8764364
OWN - NLM
STAT- MEDLINE
DCOM- 19960923
LR  - 20171116
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 278
IP  - 1
DP  - 1996 Jul
TI  - Antinociceptive action of 2-(4-bromobenzoyl)-3-methyl-4,6-dimethoxy benzofuran, a 
      novel xanthoxyline derivative on chemical and thermal models of nociception in 
      mice.
PG  - 304-12
AB  - The antinociceptive effect of the novel xanthoxyline derivative 
      2-(4-bromobenzoyl)-3-methyl-4-6-dimethoxy benzofuran) (BMDB), given i.p., p.o., 
      s.c., subplantarly, intrathecally or by i.c.v. routes was assessed in five models 
      of chemical and thermal nociception in mice, namely acetic acid-induced abdominal 
      constriction, formalin and capsaicin-induced licking, hot-plate and tail-flick 
      tests. BMDB given by i.p., s.c., subplantarly or by i.c.v. routes elicited 
      dose-related and long-lasting (4 hr) antinociception, but had no significant 
      effect by p.o. route. At the ID50 level, this compound was about 15- to 100-fold 
      more potent than aspirin and acetaminophen, but it was about 2- to 50-fold less 
      potent than morphine. Its analgesic action was not influenced by naloxone, 
      L-arginine, antagonist of alpha-1 adrenoceptor, prazosin, tau -aminobutyric acid 
      (B) antagonist, phaclofen, after adrenalectomy, but was reversed in part by 
      p-chlorophenylalanine methyl ester. Its analgesic action was not secondary to an 
      anti-inflammatory effect, or was it associated with nonspecific effect such as 
      muscle relaxant or sedative actions of animals. We conclude that BMDB produces 
      dose-dependent spinal and supraspinal antinociception as evaluated in several 
      algesic models in mice, including the neurogenic nociception responses induced by 
      formalin and capsaicin. Its antinociceptive effect was insensitive to naloxone, 
      suggesting the lack of involvement of endogenous opioid, was not modulated by 
      adrenal glands and does not involve interaction with the L-arginine-nitric oxide 
      pathway, activation of alpha-1 adrenoceptors or tau-aminobutyric acidB receptors, 
      but requires, at least in part, the serotoninergic pathway.
FAU - Vaz, Z R
AU  - Vaz ZR
AD  - Department of Pharmacology, CCB, Universidade Federal de Santa Catarina, 
      Florianópolls, Brazil.
FAU - Filho, V C
AU  - Filho VC
FAU - Yunes, R A
AU  - Yunes RA
FAU - Calixto, J B
AU  - Calixto JB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (2-(4-bromobenzoyl)-3-methyl-4,6-dimethoxybenzofuran)
RN  - 0 (Acetophenones)
RN  - 0 (Benzofurans)
RN  - 0 (Parasympatholytics)
RN  - R16CO5Y76E (Aspirin)
RN  - Z8RSY5TZPA (xanthoxyline)
SB  - IM
MH  - Acetophenones/*pharmacology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Behavior, Animal/*drug effects
MH  - Benzofurans/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Models, Biological
MH  - Pain Measurement
MH  - Parasympatholytics/*pharmacology
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1996 Jul;278(1):304-12.

PMID- 713891
OWN - NLM
STAT- MEDLINE
DCOM- 19790126
LR  - 20190819
IS  - 0306-9877 (Print)
IS  - 0306-9877 (Linking)
VI  - 4
IP  - 4
DP  - 1978 Jul-Aug
TI  - Nelson-Town anti virus theory.
PG  - 340-52
AB  - For any virus that causes a biological change in the body, there is a substance 
      that will prevent this virus from causing this biological change. We will call 
      this substance an anti virus substance. Reasons for proposing this theory along 
      with reasons for the prediction of 3 properties of an anti virus will be 
      presented. Also to be presented is an anti virus circular diagram, a mechanism 
      where when vitamin C is present the body can more easily manufacture the anti 
      virus, other mechanisms, and the comparison of properties of humoral antibodies 
      and interferon with suspected properties of anti viruses.
FAU - Nelson, V A
AU  - Nelson VA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (Antiviral Agents)
RN  - 789U1901C5 (Copper)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Antiviral Agents/isolation & purification/physiology
MH  - Ascorbic Acid/physiology
MH  - Aspirin/pharmacology
MH  - Body Temperature/drug effects
MH  - Copper/physiology
MH  - Female
MH  - Humans
MH  - *Models, Biological
MH  - Pregnancy
EDAT- 1978/07/01 00:00
MHDA- 1978/07/01 00:01
CRDT- 1978/07/01 00:00
PHST- 1978/07/01 00:00 [pubmed]
PHST- 1978/07/01 00:01 [medline]
PHST- 1978/07/01 00:00 [entrez]
AID - 0306-9877(78)90069-5 [pii]
AID - 10.1016/0306-9877(78)90069-5 [doi]
PST - ppublish
SO  - Med Hypotheses. 1978 Jul-Aug;4(4):340-52. doi: 10.1016/0306-9877(78)90069-5.

PMID- 833413
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20190709
IS  - 0002-8614 (Print)
IS  - 0002-8614 (Linking)
VI  - 25
IP  - 2
DP  - 1977 Feb
TI  - Medication procedures in a nursing home: abuse of PRN orders.
PG  - 83-4
AB  - Nursing home patients often receive more drugs than needed. Drug 
      incompatibilities frequently are found, and PRN orders are apt to be overused. 
      Regulatory agencies require periodic physician review in the hope of eliminating 
      these loose prescribing habits. A study was made of the drugs prescribed for 98 
      patients in a proprietary nursing home. The principal findings were that PRN 
      orders can indeed be inappropriate and indiscriminately followed, and that the 
      multiplicity of drugs often prescribed can lead to drug incompatibilities and to 
      additional illness of the patient. Concern is expressed about the medication 
      review process currently in vogue in nursing homes.
FAU - Howard, J B
AU  - Howard JB
FAU - Strong, K E Sr
AU  - Strong KE Sr
FAU - Strong, K E Jr
AU  - Strong KE Jr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - 0 (Analgesics)
RN  - 0 (Cathartics)
RN  - 0 (Psychotropic Drugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Analgesics/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Cathartics/therapeutic use
MH  - Drug Therapy/*standards
MH  - Humans
MH  - Medication Systems/*standards
MH  - Nursing Homes/*standards
MH  - Psychotropic Drugs/therapeutic use
EDAT- 1977/02/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1977/02/01 00:00
PHST- 1977/02/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1977/02/01 00:00 [entrez]
AID - 10.1111/j.1532-5415.1977.tb00235.x [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 1977 Feb;25(2):83-4. doi: 10.1111/j.1532-5415.1977.tb00235.x.

PMID- 3260568
OWN - NLM
STAT- MEDLINE
DCOM- 19880812
LR  - 20171228
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 95
IP  - 2
DP  - 1988 Aug
TI  - Gastric adaptation. Studies in humans during continuous aspirin administration.
PG  - 327-33
AB  - To study the process of gastric mucosal adaptation to aspirin administration, 14 
      normal men underwent a study with continued administration of aspirin. Endoscopic 
      assessment, biopsies, and gastric wash collections for acid, mucus, and 
      deoxyribonucleic acid recovery were performed weekly; aspirin was continued until 
      the endoscopy showed minimal damage. Six subjects took 650 mg of aspirin b.i.d., 
      and 8 took 650 mg q.i.d.; adaptation and resolution took longer with the higher 
      dose (median 4.5 wk vs. 1 wk, p less than 0.01). Despite improvement in mucosal 
      appearance, gastric microbleeding remained elevated throughout aspirin 
      administration. In contrast, deoxyribonucleic acid recovery (a marker for 
      cellular exfoliation and regeneration) increased significantly just before the 
      time of resolution, when, on average, it more than doubled. As no other 
      biochemical or histologic changes could be associated with the resolution of 
      damages, we conclude that gastric adaptation to chronic injury may involve 
      increased cellular regeneration.
FAU - Graham, D Y
AU  - Graham DY
AD  - Department of Medicine, Veterans Administration Medical Center, Houston, Texas.
FAU - Smith, J L
AU  - Smith JL
FAU - Spjut, H J
AU  - Spjut HJ
FAU - Torres, E
AU  - Torres E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adaptation, Physiological
MH  - Adult
MH  - Aspirin/*toxicity
MH  - Cell Division
MH  - Gastric Mucosa/*drug effects
MH  - Gastrointestinal Contents/analysis
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Time Factors
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
AID - 0016-5085(88)90487-8 [pii]
PST - ppublish
SO  - Gastroenterology. 1988 Aug;95(2):327-33.

PMID- 17404419
OWN - NLM
STAT- MEDLINE
DCOM- 20070925
LR  - 20160919
IS  - 1469-0667 (Print)
IS  - 1469-0667 (Linking)
VI  - 12
IP  - 5
DP  - 2006
TI  - Determination of dissociation constants of cyclodextrin-ligand inclusion 
      complexes by electrospray ionization mass spectrometry.
PG  - 291-9
AB  - The inclusion complexes of four ligands binding to cyclodextrins (CDs) were 
      studied by electrospray ionization mass spectrometry (ESI-MS) and the 
      dissociation constants of the complexes were obtained. The 1:1 stoichiometric 
      inclusion complex was found in the system of CD and fenbufen or aspirin. The 
      obtained KD values of the inclusion complexes of fenbufen binding to alpha-CD and 
      to beta-CD are 4.38x10(-4) mol L(-1) and 2.12x10(-4) mol L(-1), respectively. The 
      KD values of the inclusion complexes of alpha-CD-aspirin and beta-CD-aspirin are 
      3.33x10(-4) mol L(-1) and 1.83x10(-4) mol L(-1), respectively. A non-linear least 
      squares regression method was applied to validate the results which were 
      consistent with each other. For the system of tetracycline hydrochloride and CD, 
      the 1:1 and 1:2 stoichiometric inclusion complexes were found in the mass 
      spectra. The KD,1 and KD,2 values of the 1:1 and 1:2 stoichiometric inclusion 
      complexes of alpha-CD and tetracycline hydrochloride are 4.47x10(-4) mol L(-1) 
      and 6.51x10(-4) mol L(-1), respectively, and those of beta-CD and tetracycline 
      hydrochloride are 2.26x10(-4) mol L(-1) and 8.57x10(-4) mol L(-1), respectively. 
      For the system of norfloxacin and CD, besides the 1:1 and 1:2 inclusion 
      complexes, the 1:3 stoichiometric inclusion complex was also found. The KD,1, 
      KD,2 and KD,3 of alpha-CD and norfloxacin inclusion complexes are 4.61x10(-4) mol 
      L(-1), 6.05x10(-4) mol L(-1) and 1.45x10(-3) mol L(-1), respectively. The three 
      KD values of beta-CD and norfloxacin are 1.96x10(-4) mol L(-1), 4.93x10(-4) mol 
      L(-1) and 1.15x10(-3) mol L(-1), respectively.
FAU - Zhang, Huarong
AU  - Zhang H
AD  - College of Chemistry, Jilin University, 2699 Qianjin Street, Changchun 130012, PR 
      China.
FAU - Zhang, Hanqi
AU  - Zhang H
FAU - Jin, Weiqun
AU  - Jin W
FAU - Ding, Lan
AU  - Ding L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Mass Spectrom (Chichester)
JT  - European journal of mass spectrometry (Chichester, England)
JID - 101124748
RN  - 0 (Cyclodextrins)
RN  - 0 (Ligands)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Phenylbutyrates)
RN  - 9815R1WR9B (fenbufen)
RN  - F8VB5M810T (Tetracycline)
RN  - N0F8P22L1P (Norfloxacin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Binding Sites
MH  - Cyclodextrins/*chemistry
MH  - Ligands
MH  - Norfloxacin/chemistry
MH  - Pharmaceutical Preparations/*chemistry
MH  - Phenylbutyrates/chemistry
MH  - Spectrometry, Mass, Electrospray Ionization/*methods
MH  - Tetracycline/chemistry
MH  - Thermodynamics
EDAT- 2007/04/04 09:00
MHDA- 2007/09/26 09:00
CRDT- 2007/04/04 09:00
PHST- 2007/04/04 09:00 [pubmed]
PHST- 2007/09/26 09:00 [medline]
PHST- 2007/04/04 09:00 [entrez]
AID - 10.1255/ejms.818 [doi]
PST - ppublish
SO  - Eur J Mass Spectrom (Chichester). 2006;12(5):291-9. doi: 10.1255/ejms.818.

PMID- 15663612
OWN - NLM
STAT- MEDLINE
DCOM- 20050630
LR  - 20161124
IS  - 0017-8748 (Print)
IS  - 0017-8748 (Linking)
VI  - 45
IP  - 1
DP  - 2005 Jan
TI  - Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid 
      in acute migraine attacks.
PG  - 42-6
AB  - OBJECTIVE: The study compared efficacy and tolerability of intravenous valproate 
      (iVPA) with intravenous lysine-acetylsalicylic acid (iLAS) in acute migraine 
      attacks. Background.-iLAS has been proven to be a highly effective treatment in 
      acute migraine attacks, but it is not available in many countries and 
      contraindicated in patients with asthma or peptic ulcers. Current data suggest 
      that iVPA may be effective in the treatment of acute migraine attacks. 
      DESIGN/METHODS: In this randomized, double-blind, parallel-group phase-II study, 
      40 patients with acute migraine attacks (onset <5 hours, severe or moderate 
      headache on a four-point IHS scale) alternately received iVPA 800 mg or iLAS 1000 
      mg. Primary outcome criteria were the percentage of patients reporting pain 
      relief after 1 hour and patients who remained sustained pain free for 24 hours 
      following drug administration. Secondary outcome criteria were relief of pain and 
      associated migrainous symptoms (nausea, photophobia, and phonophobia) at 1, 2, 
      24, and 48 hours following drug administration. RESULTS: There were no 
      significant differences in demographic and clinical features between both 
      treatment groups. Percentage of pain relief after 1 hour in the iVPA and iLAS 
      groups were 25% and 30%, respectively, and of sustained pain free for 24 hours 
      were 20% and 30%, respectively, without significant differences (P = 1 and P= 
      .72, respectively). Both drugs improved associated migrainous symptoms without 
      significant differences at the different time points, but again with a trend in 
      favor of iLAS. No adverse events were observed. CONCLUSION: Both drugs were 
      effective in acute migraine attacks with a trend in favor of iLAS. As both drugs 
      were well tolerated, further studies with higher doses of iVPA for the treatment 
      of acute migraine attacks are recommended.
FAU - Leniger, Tobias
AU  - Leniger T
AD  - Department of Neurology, University of Essen, Hufelandstr.55, 45122 Essen, 
      Germany.
FAU - Pageler, Lutz
AU  - Pageler L
FAU - Stude, Philipp
AU  - Stude P
FAU - Diener, Hans Christoph
AU  - Diener HC
FAU - Limmroth, Volker
AU  - Limmroth V
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - 0 (Analgesics)
RN  - 0 (GABA Agents)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acute Disease
MH  - Analgesics/*administration & dosage
MH  - Aspirin/*administration & dosage/*analogs & derivatives
MH  - Double-Blind Method
MH  - GABA Agents/*administration & dosage
MH  - Humans
MH  - Infusions, Intravenous
MH  - Lysine/*administration & dosage/*analogs & derivatives
MH  - Migraine Disorders/*drug therapy
MH  - Treatment Outcome
MH  - Valproic Acid/*administration & dosage
EDAT- 2005/01/25 09:00
MHDA- 2005/07/01 09:00
CRDT- 2005/01/25 09:00
PHST- 2005/01/25 09:00 [pubmed]
PHST- 2005/07/01 09:00 [medline]
PHST- 2005/01/25 09:00 [entrez]
AID - HED5009 [pii]
AID - 10.1111/j.1526-4610.2005.05009.x [doi]
PST - ppublish
SO  - Headache. 2005 Jan;45(1):42-6. doi: 10.1111/j.1526-4610.2005.05009.x.

PMID- 18997198
OWN - NLM
STAT- MEDLINE
DCOM- 20081118
LR  - 20220410
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 300
IP  - 18
DP  - 2008 Nov 12
TI  - Low-dose aspirin for primary prevention of atherosclerotic events in patients 
      with type 2 diabetes: a randomized controlled trial.
PG  - 2134-41
LID - 10.1001/jama.2008.623 [doi]
AB  - CONTEXT: Previous trials have investigated the effects of low-dose aspirin on 
      primary prevention of cardiovascular events, but not in patients with type 2 
      diabetes. OBJECTIVE: To examine the efficacy of low-dose aspirin for the primary 
      prevention of atherosclerotic events in patients with type 2 diabetes. DESIGN, 
      SETTING, AND PARTICIPANTS: Multicenter, prospective, randomized, open-label, 
      blinded, end-point trial conducted from December 2002 through April 2008 at 163 
      institutions throughout Japan, which enrolled 2539 patients with type 2 diabetes 
      without a history of atherosclerotic disease and had a median follow-up of 4.37 
      years. INTERVENTIONS: Patients were assigned to the low-dose aspirin group (81 or 
      100 mg per day) or the nonaspirin group. MAIN OUTCOME MEASURES: Primary end 
      points were atherosclerotic events, including fatal or nonfatal ischemic heart 
      disease, fatal or nonfatal stroke, and peripheral arterial disease. Secondary end 
      points included each primary end point and combinations of primary end points as 
      well as death from any cause. RESULTS: A total of 154 atherosclerotic events 
      occurred: 68 in the aspirin group (13.6 per 1000 person-years) and 86 in the 
      nonaspirin group (17.0 per 1000 person-years) (hazard ratio [HR], 0.80; 95% 
      confidence interval [CI], 0.58-1.10; log-rank test, P = .16). The combined end 
      point of fatal coronary events and fatal cerebrovascular events occurred in 1 
      patient (stroke) in the aspirin group and 10 patients (5 fatal myocardial 
      infarctions and 5 fatal strokes) in the nonaspirin group (HR, 0.10; 95% CI, 
      0.01-0.79; P = .0037). A total of 34 patients in the aspirin group and 38 
      patients in the nonaspirin group died from any cause (HR, 0.90; 95% CI, 
      0.57-1.14; log-rank test, P = .67). The composite of hemorrhagic stroke and 
      significant gastrointestinal bleeding was not significantly different between the 
      aspirin and nonaspirin groups. CONCLUSION: In this study of patients with type 2 
      diabetes, low-dose aspirin as primary prevention did not reduce the risk of 
      cardiovascular events. TRIAL REGISTRATION: clinicaltrials.gov Identifier: 
      NCT00110448.
FAU - Ogawa, Hisao
AU  - Ogawa H
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kumamoto University, 1-1-1 Honjo, Kumamoto City, 860-8556, Japan. 
      ogawah@kumamoto-u.ac.jp
FAU - Nakayama, Masafumi
AU  - Nakayama M
FAU - Morimoto, Takeshi
AU  - Morimoto T
FAU - Uemura, Shiro
AU  - Uemura S
FAU - Kanauchi, Masao
AU  - Kanauchi M
FAU - Doi, Naofumi
AU  - Doi N
FAU - Jinnouchi, Hideaki
AU  - Jinnouchi H
FAU - Sugiyama, Seigo
AU  - Sugiyama S
FAU - Saito, Yoshihiko
AU  - Saito Y
CN  - Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) 
      Trial Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00110448
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20081109
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - JAMA. 2009 May 13;301(18):1882
EIN - JAMA. 2012 Nov 14;308(18):1861
CIN - JAMA. 2008 Nov 12;300(18):2180-1. PMID: 18997199
CIN - Nat Rev Endocrinol. 2009 Apr;5(4):188-90. PMID: 19352314
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Atherosclerosis/epidemiology/etiology/*prevention & control
MH  - Cardiovascular Diseases/epidemiology/etiology/prevention & control
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Diabetic Angiopathies/epidemiology/etiology/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
FIR - Ogawa, Hisao
IR  - Ogawa H
FIR - Saito, Yoshihiko
IR  - Saito Y
FIR - Nakayama, Masafumi
IR  - Nakayama M
FIR - Kanauchi, Masao
IR  - Kanauchi M
FIR - Uemura, Shiro
IR  - Uemura S
FIR - Morimoto, Takeshi
IR  - Morimoto T
FIR - Masuda, Izuru
IR  - Masuda I
FIR - Nakayama, Masafumi
IR  - Nakayama M
FIR - Kanauchi, Masao
IR  - Kanauchi M
FIR - Ueshima, Hirotsugu
IR  - Ueshima H
FIR - Imura, Hiroo
IR  - Imura H
FIR - Kimura, Kazuo
IR  - Kimura K
FIR - Ohtorii, Makiko
IR  - Ohtorii M
FIR - Miyake, Eri
IR  - Miyake E
FIR - Jinnouchi, Hideaki
IR  - Jinnouchi H
FIR - Hanaoka, Yoichi
IR  - Hanaoka Y
FIR - Waki, Masako
IR  - Waki M
FIR - Kawamura, Kyousuke
IR  - Kawamura K
FIR - Shimabukuro, Michio
IR  - Shimabukuro M
FIR - Nishiura, Kimiaki
IR  - Nishiura K
FIR - Kawano, Takahiro
IR  - Kawano T
FIR - Kyoda, Yusuke
IR  - Kyoda Y
FIR - Hashiguchi, Jun
IR  - Hashiguchi J
FIR - Kagoshima, Tadashi
IR  - Kagoshima T
FIR - Hanatani, Masakazu
IR  - Hanatani M
FIR - Matsumura, Norihiko
IR  - Matsumura N
FIR - Doi, Naofumi
IR  - Doi N
FIR - Nakai, Kenji
IR  - Nakai K
FIR - Kobayashi, Yoshiyuki
IR  - Kobayashi Y
FIR - Suzuki, Megumi
IR  - Suzuki M
FIR - Soeda, Tsuneari
IR  - Soeda T
FIR - Morikawa, Yoshinobu
IR  - Morikawa Y
FIR - Horimoto, Masashi
IR  - Horimoto M
FIR - Hasegawa, Atsushi
IR  - Hasegawa A
FIR - Yamano, Shigeru
IR  - Yamano S
FIR - Matsuo, Syuichi
IR  - Matsuo S
FIR - Sakamoto, Yasuhiro
IR  - Sakamoto Y
FIR - Masuda, Izuru
IR  - Masuda I
FIR - Yasuno, Akiko
IR  - Yasuno A
FIR - Fujinaga, Yuriko
IR  - Fujinaga Y
FIR - Horii, Kazuko
IR  - Horii K
FIR - Koga, Takeshi
IR  - Koga T
FIR - Ogawa, Hiroshi
IR  - Ogawa H
FIR - Ozaki, Ken
IR  - Ozaki K
FIR - Ikemura, Makoto
IR  - Ikemura M
FIR - Hayashi, Motomu
IR  - Hayashi M
FIR - Yabuta, Ikuo
IR  - Yabuta I
FIR - Sughihara, Kiyotaka
IR  - Sughihara K
FIR - Yazaki, Akihiro
IR  - Yazaki A
FIR - Masuda, Joji
IR  - Masuda J
FIR - Nishitani, Yoshiharu
IR  - Nishitani Y
FIR - Naito, Masaki
IR  - Naito M
FIR - Ote, Shigenobu
IR  - Ote S
FIR - Yamada, Kazuhiko
IR  - Yamada K
FIR - Wakabayashi, Chikashi
IR  - Wakabayashi C
FIR - Fukuoka, Yoshiaki
IR  - Fukuoka Y
FIR - Mahara, Keiji
IR  - Mahara K
FIR - Kan, Hirofumi
IR  - Kan H
FIR - Oshima, Eiji
IR  - Oshima E
FIR - Sutani, Toshio
IR  - Sutani T
FIR - Hoda, Koichi
IR  - Hoda K
FIR - Sawai, Koryo
IR  - Sawai K
FIR - Yamaga, Kenichi
IR  - Yamaga K
FIR - Nakamura, Tomoki
IR  - Nakamura T
FIR - Okamoto, Shinya
IR  - Okamoto S
FIR - Horie, Hiroaki
IR  - Horie H
FIR - Ashihara, Kenichi
IR  - Ashihara K
FIR - Miki, Hiroshi
IR  - Miki H
FIR - Makino, Hisaharu
IR  - Makino H
FIR - Odo, Takafumi
IR  - Odo T
FIR - Iseri, Yoshihisa
IR  - Iseri Y
FIR - Tanaka, Hiroyuki
IR  - Tanaka H
FIR - Marutsuka, Kousuke
IR  - Marutsuka K
FIR - Nakatani, Akira
IR  - Nakatani A
FIR - Murakami, Hironori
IR  - Murakami H
FIR - Shioya, Yoshiko
IR  - Shioya Y
FIR - Horio, Yutaka
IR  - Horio Y
FIR - Ikeda, Tsuneo
IR  - Ikeda T
FIR - Machii, Kazuo
IR  - Machii K
FIR - Kamura, Masanori
IR  - Kamura M
FIR - Ban, Keiichiro
IR  - Ban K
FIR - Fujii, Yoshihiro
IR  - Fujii Y
FIR - Nishimoto, Kazuo
IR  - Nishimoto K
FIR - Misugi, Susumu
IR  - Misugi S
FIR - Munakata, Tetsuo
IR  - Munakata T
FIR - Yoshimura, Katsutoshi
IR  - Yoshimura K
FIR - Minami, Shigetoshi
IR  - Minami S
FIR - Nakashima, Takao
IR  - Nakashima T
FIR - Ogata, Hirofumi
IR  - Ogata H
FIR - Hifumi, Atuko
IR  - Hifumi A
FIR - Sakurai, Nobuko
IR  - Sakurai N
FIR - Tsurusaki, Ryuichiro
IR  - Tsurusaki R
FIR - Yamanaka, Yoshito
IR  - Yamanaka Y
FIR - Yokota, Hiromitsu
IR  - Yokota H
FIR - Ichihara, Seishi
IR  - Ichihara S
FIR - Yoshinari, Motoki
IR  - Yoshinari M
FIR - Sawada, Yoko
IR  - Sawada Y
FIR - Kawashima, Eiji
IR  - Kawashima E
FIR - Goto, Kazuo
IR  - Goto K
FIR - Kinoshita, Yoshimi
IR  - Kinoshita Y
FIR - Kikukawa, Masao
IR  - Kikukawa M
FIR - Yamada, Hiroharu
IR  - Yamada H
FIR - Tanaka, Yuya
IR  - Tanaka Y
FIR - Kiyota, Mayumi
IR  - Kiyota M
FIR - Kimura, Yoshihiro
IR  - Kimura Y
FIR - Morikami, Yasuhiro
IR  - Morikami Y
FIR - Fukuda, Masahiro
IR  - Fukuda M
FIR - Takami, Takeshi
IR  - Takami T
FIR - Nakatani, Fumihiko
IR  - Nakatani F
FIR - Naomi, Shojiro
IR  - Naomi S
FIR - Nasu, Toshiaki
IR  - Nasu T
FIR - Sawada, Tomohiro
IR  - Sawada T
FIR - Minagawa, Fuyuki
IR  - Minagawa F
FIR - Haraguchi, Osamu
IR  - Haraguchi O
FIR - Kondo, Norifumi
IR  - Kondo N
FIR - Shono, Hiroyuki
IR  - Shono H
FIR - Sugiyama, Hiromichi
IR  - Sugiyama H
FIR - Matsuo, Takeshi
IR  - Matsuo T
FIR - Takaoka, Minoru
IR  - Takaoka M
FIR - Nakajima, Tamio
IR  - Nakajima T
FIR - Toihata, Masamitsu
IR  - Toihata M
FIR - Matsuyama, Kozaburo
IR  - Matsuyama K
FIR - Komori, Kenichi
IR  - Komori K
FIR - Tsubokura, Toshio
IR  - Tsubokura T
FIR - Taguchi, Madoka
IR  - Taguchi M
FIR - Hiramori, Yuko
IR  - Hiramori Y
FIR - Okubo, Hiroto
IR  - Okubo H
FIR - Iemura, Akihiro
IR  - Iemura A
FIR - Doi, Osamu
IR  - Doi O
FIR - Ogihara, Masayuki
IR  - Ogihara M
FIR - Misumi, Kenji
IR  - Misumi K
FIR - Seo, Koji
IR  - Seo K
FIR - Iwai, Ken
IR  - Iwai K
FIR - Naito, Masatoshi
IR  - Naito M
FIR - Ozawa, Seiji
IR  - Ozawa S
FIR - Minoda, Kotaro
IR  - Minoda K
FIR - Fujii, Hiromi
IR  - Fujii H
FIR - Miwa, Kimiaki
IR  - Miwa K
FIR - Egusa, Genshi
IR  - Egusa G
FIR - Yasuda, Isao
IR  - Yasuda I
FIR - Ueda, Michiaki
IR  - Ueda M
FIR - Miyata, Junichi
IR  - Miyata J
FIR - Yoshimura, Midori
IR  - Yoshimura M
FIR - Uemyama, Masakuni
IR  - Uemyama M
FIR - Watanabe, Katumi
IR  - Watanabe K
FIR - Haraguchi, Yoshikuni
IR  - Haraguchi Y
FIR - Tanazawa, Satoshi
IR  - Tanazawa S
FIR - Osamura, Yoshiaki
IR  - Osamura Y
FIR - Shibata, Junji
IR  - Shibata J
FIR - Ono, Takashi
IR  - Ono T
FIR - Kamijikkoku, Syuichi
IR  - Kamijikkoku S
FIR - Yoshimoto, Kazumi
IR  - Yoshimoto K
FIR - Kinuwaki, Etsuo
IR  - Kinuwaki E
FIR - Kozuma, Kazuo
IR  - Kozuma K
FIR - Onoue, Kenji
IR  - Onoue K
FIR - Nakano, Yukitaka
IR  - Nakano Y
FIR - Abe, Nanami
IR  - Abe N
FIR - Araki, Haruo
IR  - Araki H
FIR - Takaoka, Kyoji
IR  - Takaoka K
FIR - Imamoto, Chieko
IR  - Imamoto C
FIR - Suefuji, Hisakazu
IR  - Suefuji H
FIR - Sugimoto, Keisuke
IR  - Sugimoto K
FIR - Matsunaga, Terufumi
IR  - Matsunaga T
FIR - Oya, Akiko
IR  - Oya A
FIR - Onishi, Yoko
IR  - Onishi Y
FIR - Kajiwara, Keizo
IR  - Kajiwara K
FIR - Ikuno, Tetsuo
IR  - Ikuno T
FIR - Doi, Michiaki
IR  - Doi M
FIR - Igaki, Toshiro
IR  - Igaki T
FIR - Bando, Hiroshi
IR  - Bando H
FIR - Ogura, Tateo
IR  - Ogura T
FIR - Doijiri, Kenichi
IR  - Doijiri K
FIR - Iwaoka, Taisuke
IR  - Iwaoka T
FIR - Akahoshi, Kazunobu
IR  - Akahoshi K
FIR - Obata, Kenji
IR  - Obata K
FIR - Shimono, Hisashi
IR  - Shimono H
FIR - Tsuda, Kaoru
IR  - Tsuda K
FIR - Yumoto, Shinya
IR  - Yumoto S
FIR - Oka, Keishiro
IR  - Oka K
FIR - Hasegawa, Hironori
IR  - Hasegawa H
FIR - Fujimoto, Hisao
IR  - Fujimoto H
FIR - Atsumi, Toshiya
IR  - Atsumi T
FIR - Matsutani, Akira
IR  - Matsutani A
FIR - Katsuyama, Yohiyuki
IR  - Katsuyama Y
FIR - Fukami, Ryo
IR  - Fukami R
FIR - Iseri, Yoshihisa
IR  - Iseri Y
FIR - Ishibashi, Yutaka
IR  - Ishibashi Y
FIR - Kudou, Kiyotaka
IR  - Kudou K
FIR - Kuwahara, Tetsuo
IR  - Kuwahara T
FIR - Maeda, Kazutaka
IR  - Maeda K
FIR - Maki, Akira
IR  - Maki A
FIR - Manda, Naoki
IR  - Manda N
FIR - Yasue, Hirofumi
IR  - Yasue H
FIR - Mizuno, Yuji
IR  - Mizuno Y
FIR - Momosaki, Sueo
IR  - Momosaki S
FIR - Tokube, Koji
IR  - Tokube K
FIR - Tomita, Fumishi
IR  - Tomita F
FIR - Tsuchiya, Tatsuaki
IR  - Tsuchiya T
FIR - Yabuta, Matahiro
IR  - Yabuta M
FIR - Yamada, Hidei
IR  - Yamada H
FIR - Sugiyama, Seigo
IR  - Sugiyama S
EDAT- 2008/11/11 09:00
MHDA- 2008/11/19 09:00
CRDT- 2008/11/11 09:00
PHST- 2008/11/11 09:00 [pubmed]
PHST- 2008/11/19 09:00 [medline]
PHST- 2008/11/11 09:00 [entrez]
AID - 2008.623 [pii]
AID - 10.1001/jama.2008.623 [doi]
PST - ppublish
SO  - JAMA. 2008 Nov 12;300(18):2134-41. doi: 10.1001/jama.2008.623. Epub 2008 Nov 9.

PMID- 8510013
OWN - NLM
STAT- MEDLINE
DCOM- 19930714
LR  - 20181130
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 265
IP  - 3
DP  - 1993 Jun
TI  - The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid 
      secretion and prevents gastrointestinal damage induced by aspirin, ethanol and 
      cysteamine in the rat.
PG  - 1348-54
AB  - L-365,260, a nonpeptide antagonist of gastrin/CCK-B receptors, was evaluated in 
      receptor binding, antisecretory and gastrointestinal damage assays. L-365,260 
      binds potently and stereo-selectively to gastrin and CCK-B sites in guinea pig 
      tissue. In contrast, L-365,260 binds to the isolated canine parietal cell gastrin 
      receptor weakly, and without stereoselectivity. In the pylorus-ligated rat, low 
      doses of L-365,260, given i.v., attenuated pentagastrin-stimulated acid 
      secretion, whereas higher doses were required to inhibit both 
      histamine-stimulated and basal acid secretion. In an aspirin-induced gastric 
      damage model, L-365,260 was 2.4-fold less potent than the standard histamine H2 
      antagonist cimetidine in preventing gastric damage when given i.v., and was 
      8.3-fold less potent than cimetidine when given p.o. Moreover, the ED50 value for 
      L-365,260, given i.v., in prevention of aspirin-induced gastric damage (11.5 
      mg/kg) agreed well with its ED50 value for inhibition of basal acid secretion 
      (12.6 mg/kg). At doses as great as 100 mg/kg p.o., neither L-365,260 nor 
      cimetidine had an effect on ethanol-induced gastric damage. L-365,260, although 
      p.o. less bioavailable relative to cimetidine in the aspirin gastric damage 
      model, was as potent as cimetidine in the prevention of cysteamine-induced 
      duodenal ulcers in the rat. We conclude that the gastrin/CCK-B receptor 
      antagonist L-365,260, at doses supramaximal for the inhibition of 
      pentagastrin-stimulated secretory responses in vivo, inhibits gastrointestinal 
      damage in models of peptic ulcer disease by an antisecretory mechanism of action.
FAU - Pendley, C E
AU  - Pendley CE
AD  - Department of Pharmacology, Rhône-Poulenc Rorer Central Research, Collegeville, 
      Pennsylvania.
FAU - Fitzpatrick, L R
AU  - Fitzpatrick LR
FAU - Ewing, R W
AU  - Ewing RW
FAU - Molino, B F
AU  - Molino BF
FAU - Martin, G E
AU  - Martin GE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Benzodiazepinones)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Receptors, Cholecystokinin)
RN  - 370JHF4586 (L 365260)
RN  - 3K9958V90M (Ethanol)
RN  - 5UX2SD1KE2 (Cysteamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*antagonists & inhibitors
MH  - Benzodiazepinones/*pharmacology
MH  - Cysteamine/adverse effects/*antagonists & inhibitors
MH  - Digestive System/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Ethanol/adverse effects/*antagonists & inhibitors
MH  - Gastric Acid/*metabolism
MH  - Guinea Pigs
MH  - In Vitro Techniques
MH  - Male
MH  - *Phenylurea Compounds
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Cholecystokinin/*antagonists & inhibitors
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1993 Jun;265(3):1348-54.

PMID- 7934089
OWN - NLM
STAT- MEDLINE
DCOM- 19941110
LR  - 20190830
IS  - 0378-8741 (Print)
IS  - 0378-8741 (Linking)
VI  - 42
IP  - 3
DP  - 1994 May
TI  - Preliminary screening of methanolic extracts of Celastrus paniculatus and 
      Tecomella undulata for analgesic and anti-inflammatory activities.
PG  - 193-8
AB  - Flowers of Celastrus paniculatus and whole plant of Tecomella undulata were 
      extracted individually in absolute methanol. Using the hot water tail immersion 
      test in mice and carrageenan induced pedal edema in rats, both extracts were 
      tested for their oral analgesic and anti-inflammatory potentials. Results showed 
      that C. paniculatus had both analgesic and anti-inflammatory activities, while T. 
      undulata had only analgesic potential when compared with aspirin.
FAU - Ahmad, F
AU  - Ahmad F
AD  - Department of Pharmacology, Faculty of Pharmacy, University of Karachi, Pakistan.
FAU - Khan, R A
AU  - Khan RA
FAU - Rasheed, S
AU  - Rasheed S
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Plant Extracts)
RN  - R16CO5Y76E (Aspirin)
RN  - Y4S76JWI15 (Methanol)
SB  - IM
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/pharmacology
MH  - Edema/drug therapy
MH  - Female
MH  - Male
MH  - Methanol
MH  - Mice
MH  - Plant Extracts/chemistry/*pharmacology
MH  - Plants, Medicinal/*chemistry
MH  - Rats
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
AID - 0378-8741(94)90085-X [pii]
AID - 10.1016/0378-8741(94)90085-x [doi]
PST - ppublish
SO  - J Ethnopharmacol. 1994 May;42(3):193-8. doi: 10.1016/0378-8741(94)90085-x.

PMID- 1023834
OWN - NLM
STAT- MEDLINE
DCOM- 19770520
LR  - 20131121
IS  - 0020-3785 (Print)
VI  - 46
IP  - 6
DP  - 1976 Nov-Dec
TI  - [Long term prevention of thromboembolic accidents with acetylsalicylic acid in 
      auricular fibrillation patients].
PG  - 764-9
AB  - For the past few years various authors have reported the antiplatelet action and 
      prolongation of bleeding time with the use of acetyl-salicilic acid. In the 
      present work, we review the frequency of thromboembolism in a group of patients 
      with rheumatic or sclerotic heart disease with atrial fibrillation, in which the 
      treatment with coumarins was suspended and substituted for 1 gram of aspirin P.O. 
      daily. The results were compared with a similar group studied by Cárdenas and 
      col. During the time of the observation 10 patients had 14 thromboembolic 
      accidents, slightly predominated by the emboli in the inferior members and in the 
      cerebral vascular territory. The mortality was 2.5% and in 9 patients hemorrhages 
      of little importance appeared, which could have been caused by the ASA, although 
      it can not be proven. In comparing the results of this work with the above 
      mentioned of Cárdenas, it appeared that the number of thromboemboli, of deaths, 
      and secondary accidents in the group treated with ASA was less than in the group 
      which received coumarin or which were maintained without treatment. Based on the 
      results, it can be concluded that it is possible to substitute the coumarins with 
      acetyl-salicilic acid in the prevention of thromboembolism, in patient with 
      rheumatic or sclerotic heart disease with atrial fibrillation.
FAU - Buen Abad, L H
AU  - Buen Abad LH
FAU - Elizalde Galván, J A
AU  - Elizalde Galván JA
FAU - Cárdenas, M
AU  - Cárdenas M
LA  - spa
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Prevención a largo plazo de accidentes tromboembólicos con ácido 
      acetil-salicílico en pacientes con fibrilación auricular.
PL  - Mexico
TA  - Arch Inst Cardiol Mex
JT  - Archivos del Instituto de Cardiologia de Mexico
JID - 0400463
RN  - 0 (Coumarins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Coronary Disease/prevention & control
MH  - Coumarins/therapeutic use
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Thromboembolism/*prevention & control
EDAT- 1976/11/01 00:00
MHDA- 1976/11/01 00:01
CRDT- 1976/11/01 00:00
PHST- 1976/11/01 00:00 [pubmed]
PHST- 1976/11/01 00:01 [medline]
PHST- 1976/11/01 00:00 [entrez]
PST - ppublish
SO  - Arch Inst Cardiol Mex. 1976 Nov-Dec;46(6):764-9.

PMID- 6112411
OWN - NLM
STAT- MEDLINE
DCOM- 19810720
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 8228
DP  - 1981 May 9
TI  - Intrasynovial orgotein therapy in rheumatoid arthritis.
PG  - 1015-7
AB  - 30 patients with active classical rheumatoid arthritis affecting the knee took 
      part in a 12-week double-blind trial in which intra-articular injections of 
      orgotein (4 mg/week for 6 weeks) were compared with intra-articular aspirin 4 
      mg/week for 6 weeks. After 12 weeks clinical and biochemical assessments showed 
      that orgotein was superior to aspirin. Clinical response was measured in terms of 
      the cumulative rheumatoid activity index (RAI) which was based on scores for 
      morning stiffness, range of flexion, pain and 25-foot (7.5 m) walking time. 
      Treatment with orgotein resulted in significant improvement of the RAI; the 
      improvement correlated with findings on knee-joint scanning which showed reduced 
      mean uptake of 99mTc-pyrophosphate. After intra-articular orgotein injections, 
      synovial fluid IgM and IgG rheumatoid factor levels fell significantly; so did 
      prostaglandin E2 formation and lactate dehydrogenase activity. The changes in the 
      synovial fluid suggest that the anti-inflammatory properties of orgotein may lie 
      in its effect on proliferating synovia.
FAU - Goebel, K M
AU  - Goebel KM
FAU - Storck, U
AU  - Storck U
FAU - Neurath, F
AU  - Neurath F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Metalloproteins)
RN  - PKE82W49V1 (orgotein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Injections, Intra-Articular
MH  - Metalloproteins/*therapeutic use
MH  - Middle Aged
MH  - Synovial Membrane/drug effects
EDAT- 1981/05/09 00:00
MHDA- 1981/05/09 00:01
CRDT- 1981/05/09 00:00
PHST- 1981/05/09 00:00 [pubmed]
PHST- 1981/05/09 00:01 [medline]
PHST- 1981/05/09 00:00 [entrez]
AID - S0140-6736(81)92185-1 [pii]
AID - 10.1016/s0140-6736(81)92185-1 [doi]
PST - ppublish
SO  - Lancet. 1981 May 9;1(8228):1015-7. doi: 10.1016/s0140-6736(81)92185-1.

PMID- 34033814
OWN - NLM
STAT- MEDLINE
DCOM- 20211215
LR  - 20211215
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 906
DP  - 2021 Sep 5
TI  - Aspirin inhibits prostaglandins to prevents colon tumor formation via 
      down-regulating Wnt production.
PG  - 174173
LID - S0014-2999(21)00326-5 [pii]
LID - 10.1016/j.ejphar.2021.174173 [doi]
AB  - According to numerous epidemiological studies, aspirin is a non-steroidal 
      anti-inflammatory drug (NSAID) that reduces the occurrence and mortality of 
      colorectal cancer (CRC). However, the underlying mechanisms are not well 
      identified. In an effort to fill these gaps, we administered aspirin on mice one 
      day before induction in an azoxymethane (AOM)/dextran sulfate sodium (DSS) 
      induced CRC model. In this study, we assessed the effects of aspirin on 
      tumorigenesis and tumor cell proliferation. Multi-layer analyses were carried out 
      to identify changes in cytokines, metabolites, level of gene expressions, and 
      proteins associated with tumorigenesis and aspirin treatment. The results showed 
      that aspirin-treated mice developed fewer colon tumors in response to AOM/DSS, 
      and aspirin can actively block cyclooxygenase (COX) metabolism and reduce levels 
      of pro-inflammatory cytokines. In addition, the transcriptomic and proteomic 
      analyses both indicated that aspirin has an inhibitory effect on the Wnt pathway. 
      The in vitro results further indicated that aspirin inhibits WNT6 production, 
      possibly by suppressing its transcription factor NR4A2, which in turn is 
      regulated by prostaglandin E2, thereby ultimately inhibiting the Wnt pathway. 
      These findings improve our understanding of the mechanisms behind aspirin's 
      chemoprevention effect on CRC.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Feng, Yaqian
AU  - Feng Y
AD  - School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus 
      Chemistry and Chemical Biology (Ministry of Education), Tsinghua University, 
      Beijing, 100084, China; Advanced Innovation Center for Human Brain Protection, 
      Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
FAU - Tao, Lei
AU  - Tao L
AD  - School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus 
      Chemistry and Chemical Biology (Ministry of Education), Tsinghua University, 
      Beijing, 100084, China; Collaborative Innovation Center for Biotherapy, State Key 
      Laboratory of Biotherapy and Cancer Center, West China Hospital, West China 
      Medical School, Sichuan University, Chengdu, 610041, China; Advanced Innovation 
      Center for Human Brain Protection, Beijing Tiantan Hospital, Capital Medical 
      University, Beijing, 100070, China.
FAU - Wang, Guoqiang
AU  - Wang G
AD  - School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus 
      Chemistry and Chemical Biology (Ministry of Education), Tsinghua University, 
      Beijing, 100084, China; Advanced Innovation Center for Human Brain Protection, 
      Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
FAU - Li, Zhen
AU  - Li Z
AD  - School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus 
      Chemistry and Chemical Biology (Ministry of Education), Tsinghua University, 
      Beijing, 100084, China.
FAU - Yang, Mingming
AU  - Yang M
AD  - School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus 
      Chemistry and Chemical Biology (Ministry of Education), Tsinghua University, 
      Beijing, 100084, China; Advanced Innovation Center for Human Brain Protection, 
      Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
FAU - He, Weishen
AU  - He W
AD  - Boston College, 140 Commonwealth Ave, Chestnut Hill, MA 02467, USA.
FAU - Zhong, Xincheng
AU  - Zhong X
AD  - School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus 
      Chemistry and Chemical Biology (Ministry of Education), Tsinghua University, 
      Beijing, 100084, China.
FAU - Zhang, Yong
AU  - Zhang Y
AD  - Advanced Biotechnology and Application Research Center, School of Chemistry and 
      Biological Engineering, University of Science and Technology Beijing, Beijing, 
      100024, China.
FAU - Yang, Jinliang
AU  - Yang J
AD  - Collaborative Innovation Center for Biotherapy, State Key Laboratory of 
      Biotherapy and Cancer Center, West China Hospital, West China Medical School, 
      Sichuan University, Chengdu, 610041, China.
FAU - Cheung, Shinghu
AU  - Cheung S
AD  - Bayer Healthcare Company Ltd., Beijing, 100020, China. Electronic address: 
      shinghu.cheung@bayer.com.
FAU - McDonald, Fiona
AU  - McDonald F
AD  - Bayer AG, Research & Development Pharmaceuticals, Berlin, 13342, Germany. 
      Electronic address: fiona.mcdonald@bayer.com.
FAU - Chen, Ligong
AU  - Chen L
AD  - School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus 
      Chemistry and Chemical Biology (Ministry of Education), Tsinghua University, 
      Beijing, 100084, China; Collaborative Innovation Center for Biotherapy, State Key 
      Laboratory of Biotherapy and Cancer Center, West China Hospital, West China 
      Medical School, Sichuan University, Chengdu, 610041, China; Advanced Innovation 
      Center for Human Brain Protection, Beijing Tiantan Hospital, Capital Medical 
      University, Beijing, 100070, China. Electronic address: 
      ligongchen@tsinghua.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20210523
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Nr4a2 protein, mouse)
RN  - 0 (Nuclear Receptor Subfamily 4, Group A, Member 2)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Wnt Proteins)
RN  - 0 (Wnt6 protein, mouse)
RN  - 9042-14-2 (Dextran Sulfate)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - MO0N1J0SEN (Azoxymethane)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Azoxymethane/administration & dosage/toxicity
MH  - Cell Transformation, Neoplastic/drug effects/genetics
MH  - Colitis/chemically induced/*drug therapy/pathology
MH  - Colitis-Associated Neoplasms/pathology/*prevention & control
MH  - Dextran Sulfate/administration & dosage/toxicity
MH  - Dinoprostone/*antagonists & inhibitors/genetics/metabolism
MH  - Disease Models, Animal
MH  - Down-Regulation/drug effects
MH  - Humans
MH  - Male
MH  - Mice
MH  - Nuclear Receptor Subfamily 4, Group A, Member 2/antagonists & 
      inhibitors/metabolism
MH  - Proteomics
MH  - Proto-Oncogene Proteins/metabolism
MH  - Wnt Proteins/metabolism
MH  - Wnt Signaling Pathway/drug effects
OTO - NOTNLM
OT  - Aspirin
OT  - Colorectal cancer
OT  - Multi-layer analyses
OT  - Prostaglandins
OT  - Wnt signaling pathway
EDAT- 2021/05/26 06:00
MHDA- 2021/12/16 06:00
CRDT- 2021/05/25 20:10
PHST- 2020/12/11 00:00 [received]
PHST- 2021/04/15 00:00 [revised]
PHST- 2021/05/11 00:00 [accepted]
PHST- 2021/05/26 06:00 [pubmed]
PHST- 2021/12/16 06:00 [medline]
PHST- 2021/05/25 20:10 [entrez]
AID - S0014-2999(21)00326-5 [pii]
AID - 10.1016/j.ejphar.2021.174173 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2021 Sep 5;906:174173. doi: 10.1016/j.ejphar.2021.174173. Epub 
      2021 May 23.

PMID- 21794076
OWN - NLM
STAT- MEDLINE
DCOM- 20120210
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 9
IP  - 10
DP  - 2011 Oct
TI  - Aspirin has little additional anti-platelet effect in healthy volunteers 
      receiving prasugrel.
PG  - 2050-6
LID - 10.1111/j.1538-7836.2011.04450.x [doi]
AB  - BACKGROUND: Strong P2Y(12) blockade, as can be achieved with novel anti-platelet 
      agents such as prasugrel, has been shown in vitro to inhibit both ADP and 
      thromboxane A(2) -mediated pathways of platelet aggregation, calling into 
      question the need for the concomitant use of aspirin. OBJECTIVE: The present 
      study investigated the hypothesis that aspirin provides little additional 
      anti-aggregatory effect in a group of healthy volunteers taking prasugrel. STUDY 
      PARTICIPANTS/METHODS: In all, 9 males, aged 18 to 40 years, enrolled into the 
      21-day study. Prasugrel was loaded at 60 mg on day 1 and maintained at 10 mg 
      until day 21. At day 8, aspirin 75 mg was introduced and the dose increased to 
      300 mg on day 15. On days 0, 7, 14 and 21, platelet function was assessed by 
      aggregometry, response to treatments was determined by VerifyNow and urine 
      samples were collected for quantification of prostanoid metabolites. RESULTS: At 
      day 7, aggregation responses to a range of platelet agonists were reduced and 
      there was only a small further inhibition of aggregation to TRAP-6, collagen and 
      epinephrine at days 14 and 21, when aspirin was included with prasugrel. Urinary 
      prostanoid metabolites were unaffected by prasugrel, and were reduced by the 
      addition of aspirin, independent of dose. CONCLUSIONS: In healthy volunteers, 
      prasugrel produces a strong anti-aggregatory effect, which is little enhanced by 
      the addition of aspirin. The addition of aspirin as a dual-therapy with potent 
      P2Y(12) receptor inhibitors warrants further investigation.
CI  - © 2011 International Society on Thrombosis and Haemostasis.
FAU - Leadbeater, P D M
AU  - Leadbeater PD
AD  - Department of Cardiothoracic Pharmacology, Imperial College London, National 
      Heart and Lung Institute, London, UK.
FAU - Kirkby, N S
AU  - Kirkby NS
FAU - Thomas, S
AU  - Thomas S
FAU - Dhanji, A-R
AU  - Dhanji AR
FAU - Tucker, A T
AU  - Tucker AT
FAU - Milne, G L
AU  - Milne GL
FAU - Mitchell, J A
AU  - Mitchell JA
FAU - Warner, T D
AU  - Warner TD
LA  - eng
GR  - Wellcome Trust/United Kingdom
GR  - 085255/Wellcome Trust/United Kingdom
GR  - 085255/Z/08/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Piperazines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - 0 (Thiophenes)
RN  - 0 (Thromboxanes)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Male
MH  - Piperazines/*pharmacology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Prasugrel Hydrochloride
MH  - Purinergic P2Y Receptor Antagonists/*pharmacology
MH  - Thiophenes/*pharmacology
MH  - Thromboxanes/biosynthesis
PMC - PMC3338354
MID - UKMS47791
OID - NLM: UKMS47791
EDAT- 2011/07/29 06:00
MHDA- 2012/02/11 06:00
CRDT- 2011/07/29 06:00
PHST- 2011/07/29 06:00 [entrez]
PHST- 2011/07/29 06:00 [pubmed]
PHST- 2012/02/11 06:00 [medline]
AID - S1538-7836(22)07370-6 [pii]
AID - 10.1111/j.1538-7836.2011.04450.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2011 Oct;9(10):2050-6. doi: 10.1111/j.1538-7836.2011.04450.x.

PMID- 25369051
OWN - NLM
STAT- MEDLINE
DCOM- 20150626
LR  - 20201217
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 11
DP  - 2014
TI  - Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer 
      growth both in vitro and in vivo by a redox-dependent effect.
PG  - e111720
LID - 10.1371/journal.pone.0111720 [doi]
LID - e111720
AB  - Phospho-aspirin (PA-2) is a novel aspirin derivative that exhibits promising 
      anticancer properties and is considerably safer than conventional aspirin. In 
      this study, we investigated the chemotherapeutic efficacy of PA-2 in preclinical 
      models of estrogen receptor positive (ER+) breast cancer and elucidated its 
      mechanism of action. PA-2 inhibited the growth of ER+ cells more potently than 
      aspirin in vitro, and exerted a triple cytokinetic effect that includes induction 
      of apoptosis and cell cycle arrest as well as the inhibition of cell 
      proliferation. PA-2 is highly efficacious in vivo, as treatment of established 
      MCF7 xenografts with PA-2 induced tumor stasis (98.2% inhibition, p<0.01). PA-2 
      triggered the activation of p53-dependent apoptosis via two distinct mechanisms: 
      1) acetylation of p53 (at K373), which disrupts its interaction with its 
      transcription repressor MDM2, and 2) translocation of p53 to the mitochondria 
      leading to the dissipation of mitochondrial transmembrane potential (ΔΨ(m)). 
      Consistent with these observations, both the RNAi-mediated knockdown of p53 and 
      forced deactylation via HDAC1 over-expression attenuated the anticancer effect of 
      PA-2 in MCF7 cells. An upstream mediator of the signaling effects of PA-2 is 
      RONS. PA-2 induced oxidative stress in vitro and in mice bearing MCF7 xenografts; 
      its induction effect appears to be tumor-specific. Crucially, administration of 
      N-acetylcysteine, a ROS scavenger, abrogated the effect of PA-2 on p53 
      acetylation and mitochondria translocation, thus identifying RONS as proximal 
      molecules mediating the anticancer effect of PA-2. In summary, our findings 
      demonstrate that PA-2 is a promising antineoplastic compound against ER+ breast 
      cancer, warranting further evaluation as an anticancer agent.
FAU - Huang, Liqun
AU  - Huang L
AD  - Division of Cancer Prevention, Department of Medicine, Stony Brook University, 
      Stony Brook, New York, United States of America.
FAU - Wong, Chi C
AU  - Wong CC
AD  - Division of Cancer Prevention, Department of Medicine, Stony Brook University, 
      Stony Brook, New York, United States of America.
FAU - Cheng, Ka W
AU  - Cheng KW
AD  - Division of Cancer Prevention, Department of Medicine, Stony Brook University, 
      Stony Brook, New York, United States of America.
FAU - Rigas, Basil
AU  - Rigas B
AD  - Division of Cancer Prevention, Department of Medicine, Stony Brook University, 
      Stony Brook, New York, United States of America; Medicon Pharmaceuticals, Inc, 
      Setauket, New York, United States of America.
LA  - eng
GR  - N01CN43302/CA/NCI NIH HHS/United States
GR  - R01CA13945402/CA/NCI NIH HHS/United States
GR  - 1N01CN43302WA22/CN/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20141104
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation/drug effects
MH  - Animals
MH  - Antineoplastic Agents/*chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*analogs & derivatives/*therapeutic use
MH  - Breast/*drug effects/metabolism/pathology
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Cell Proliferation/drug effects
MH  - Female
MH  - Humans
MH  - MCF-7 Cells
MH  - Mice
MH  - Oxidation-Reduction/drug effects
MH  - Oxidative Stress/drug effects
MH  - Receptors, Estrogen/analysis
MH  - Tumor Suppressor Protein p53/metabolism
PMC - PMC4219766
COIS- Competing Interests: The authors have nothing to disclose except for BR, who has 
      an equity position in Medicon Pharmaceuticals, Inc. This does not alter the 
      authors' adherence to PLOS ONE policies on sharing data and materials.
EDAT- 2014/11/05 06:00
MHDA- 2015/06/27 06:00
CRDT- 2014/11/05 06:00
PHST- 2014/05/20 00:00 [received]
PHST- 2014/10/01 00:00 [accepted]
PHST- 2014/11/05 06:00 [entrez]
PHST- 2014/11/05 06:00 [pubmed]
PHST- 2015/06/27 06:00 [medline]
AID - PONE-D-14-22499 [pii]
AID - 10.1371/journal.pone.0111720 [doi]
PST - epublish
SO  - PLoS One. 2014 Nov 4;9(11):e111720. doi: 10.1371/journal.pone.0111720. 
      eCollection 2014.

PMID- 17636787
OWN - NLM
STAT- MEDLINE
DCOM- 20071018
LR  - 20210105
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 3
DP  - 2007 Jul 18
TI  - Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular 
      disease.
PG  - CD005158
AB  - BACKGROUND: Aspirin is the prophylactic antiplatelet drug of choice for people 
      with cardiovascular disease. However, protection with antiplatelet therapy in 
      people with a high risk of cardiovascular disease is unsatisfactory in absolute 
      terms. Adding a second antiplatelet drug to aspirin may produce additional 
      benefit for those at high risk and those with established cardiovascular disease. 
      OBJECTIVES: To quantify the effects (both benefit and harm) of adding clopidogrel 
      to standard long-term aspirin therapy for preventing cardiovascular events in 
      people at high risk of cardiovascular disease and those with established 
      cardiovascular disease. SEARCH STRATEGY: CENTRAL (Issue 2 2006), MEDLINE (2002 to 
      May 2006) and EMBASE (2002 to May 2006) were searched. Online registers of 
      ongoing trials and reference lists from original articles and reviews were 
      checked. SELECTION CRITERIA: All randomized controlled trials comparing long term 
      (>30 days) use of aspirin plus clopidogrel with aspirin plus placebo or aspirin 
      alone in patients with coronary disease, ischemic cerebrovascular disease, 
      peripheral arterial disease, or at high risk of atherothrombotic disease (with 
      data for at least one of the outcomes) were included. DATA COLLECTION AND 
      ANALYSIS: Data were collected on the following outcomes and analysed where 
      appropriate: mortality (from myocardial infarction, stroke, cardiovascular 
      causes, all-causes), non-fatal myocardial infarction, non-fatal stroke, unstable 
      angina, heart failure, revascularizations, major and minor bleeding, and all 
      adverse events. Quantitative analysis of outcome was based on an 
      intention-to-treat principle. The overall treatment effect was estimated by the 
      pooled odds ratio (OR) with 95% confidence interval (CI) using a fixed-effect 
      model (Mantel-Haenszel). MAIN RESULTS: Two RCTs were found. Patients enrolled in 
      the CHARISMA study were at high risk for cardiovascular events, either with or 
      without an established cardiovascular disease. Patients enrolled in the CURE 
      study had a recent non-ST segment elevation acute coronary syndrome. The use of 
      clopidogrel plus aspirin, compared with placebo plus aspirin, was associated with 
      a lower risk of cardiovascular events (OR: 0.87, 95% CI 0.81 to 0.94; P<0.01) and 
      a higher risk of major bleeding (OR 1.34, 95% CI 1.14 to 1.57; P<0.01). Overall, 
      we would expect 13 cardiovascular events to be prevented for every 1000 patients 
      treated with the combination, but 6 major bleeds would be caused. Treatment 
      effects differed in the two trials: the CURE trial, confined to people with acute 
      non-ST segment coronary syndromes, showed definite evidence of benefit from 
      treatment. For every 1000 people treated for an average of 9 months, 23 events 
      would be avoided and 10 major bleeds would be caused. In the CHARISMA trial that 
      randomized people at high cardiovascular risk defined either in terms of 
      pre-existing cardiovascular diseases or risk factors, the effects of treatment 
      were less marked and were consistent with the play of chance. For every 1000 
      people treated for an average of 28 months, 5 cardiovascular events would be 
      avoided and 3 major bleeds would be caused. AUTHORS' CONCLUSIONS: The available 
      evidence demonstrates that the use of clopidogrel plus aspirin is associated with 
      a reduction in the risk of cardiovascular events compared with aspirin alone in 
      patients with acute non-ST coronary syndrome. In patients at high risk of 
      cardiovascular disease but not presenting acutely, there is only weak evidence of 
      benefit and hazards of treatment almost match any benefit obtained.
FAU - Keller, T T
AU  - Keller TT
FAU - Squizzato, A
AU  - Squizzato A
FAU - Middeldorp, S
AU  - Middeldorp S
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20070718
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UIN - Cochrane Database Syst Rev. 2011;(1):CD005158. PMID: 21249668
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
RF  - 40
EDAT- 2007/07/20 09:00
MHDA- 2007/10/19 09:00
CRDT- 2007/07/20 09:00
PHST- 2007/07/20 09:00 [pubmed]
PHST- 2007/10/19 09:00 [medline]
PHST- 2007/07/20 09:00 [entrez]
AID - 10.1002/14651858.CD005158.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005158. doi: 
      10.1002/14651858.CD005158.pub2.

PMID- 3127431
OWN - NLM
STAT- MEDLINE
DCOM- 19880428
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 28
IP  - 1
DP  - 1988 Jan
TI  - Effect of rioprostil on aspirin-induced gastrointestinal mucosal changes in 
      normal volunteers.
PG  - 76-80
AB  - Rioprostil, a 15-deoxy-16-methyl prostaglandin E1, was evaluated for its effect 
      on aspirin-induced gastrointestinal mucosal changes in normal volunteers. 
      Fifty-six normal male volunteers were evaluated by endoscopy in a double-blind, 
      placebo-controlled study. Aspirin was given at a dose of 975 mg four times per 
      day. Rioprostil was given at doses of 60, 120, and 300 micrograms four times per 
      day. Rioprostil, at both antisecretory and subantisecretory doses, prevented or 
      reduced aspirin-induced injury. Increased stool frequency was the most common 
      side effect and appeared to be a dose-related effect of rioprostil occurring at 
      only antisecretory doses.
FAU - Tolman, K G
AU  - Tolman KG
AD  - Department of Internal Medicine, University of Utah School of Medicine, Salt Lake 
      City 84132.
FAU - Detweiler, M K
AU  - Detweiler MK
FAU - Harrison, C A
AU  - Harrison CA
FAU - Rollins, D E
AU  - Rollins DE
FAU - Simon, D A
AU  - Simon DA
FAU - Brady, C
AU  - Brady C
FAU - McCormack, G H
AU  - McCormack GH
FAU - Bryant, E C
AU  - Bryant EC
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Prostaglandins E)
RN  - 7JL402PVQR (Rioprostil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Ulcer Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Double-Blind Method
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Intestinal Mucosa/*drug effects
MH  - Male
MH  - Prostaglandins E/*pharmacology
MH  - Rioprostil
MH  - Time Factors
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1988.tb03104.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1988 Jan;28(1):76-80. doi: 10.1002/j.1552-4604.1988.tb03104.x.

PMID- 26587983
OWN - NLM
STAT- MEDLINE
DCOM- 20160627
LR  - 20181202
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 11
DP  - 2015
TI  - Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of 
      Thromboembolic Disease: A Systematic Review and Meta-Analysis.
PG  - e0143252
LID - 10.1371/journal.pone.0143252 [doi]
LID - e0143252
AB  - BACKGROUND: Patients who have had an unprovoked deep venous thrombosis (DVT) or 
      pulmonary embolus (PE) are at a high risk for recurrent venous thromboembolism 
      (VTE). Extended "life-long" anticoagulation has been recommended in these 
      patients. However, the risk benefit ratio of this approach is controversial and 
      the role of the direct oral anticoagulants (DOACs) and aspirin is unclear. 
      Furthermore, in some patients with a "weak provoking factor" there is clinical 
      equipoise regarding continuation or cessation of anticoagulant therapy after 
      treatment of the acute VTE event. OBJECTIVE: A systematic review and 
      meta-analysis to determine the risks (major bleeding) and benefits (recurrent VTE 
      and mortality) of extended anticoagulation with vitamin k antagonists (VKA), 
      DOACs and aspirin in patients with an unprovoked VTE and in those patients with 
      clinical equipoise regarding continuation or cessation of anticoagulant therapy. 
      In addition, we sought to determine the risk of recurrent VTE events once 
      extended anti-thrombotic therapy was discontinued. DATA SOURCES: MEDLINE, 
      Cochrane Register of Controlled Trials, citation review of relevant primary and 
      review articles. STUDY SELECTION: Randomized placebo-controlled trials (RCTs) 
      that compared the risk of recurrent VTE in patients with an unprovoked DVT or PE 
      who had been treated for at least 3 months with a VKA or a DOAC and were then 
      randomized to receive an oral anti-thrombotic agent or placebo for at least 6 
      additional months. We included studies that included patients in whom clinical 
      equipoise existed regarding the continuation or cessation of anticoagulant 
      therapy. DATA EXTRACTION: Independent extraction of articles by both authors 
      using predefined data fields, including study quality indicators. Data were 
      abstracted on study size, study setting, initial event (DVT or PE), percentage of 
      patients where the initial VTE event was unprovoked, the number of recurrent VTE 
      events, major bleeds and mortality during the period of extended anticoagulation 
      in the active treatment and placebo arms. In addition, we recorded the event rate 
      once extended treatment was stopped. Meta-analytic techniques were used to 
      summarize the data. Studies were grouped according to the type of anti-thrombotic 
      agent. DATA SYNTHESIS: Seven studies which enrolled 6778 patients met our 
      inclusion criteria; two studies evaluated the extended use of Coumadin, three 
      studies evaluated a DOAC and two studies evaluated the use of aspirin. The 
      duration of followup varied from 6 to 37 months. In the Coumadin and aspirin 
      studies 100% of the randomized patients had an unprovoked VTE, while in the DOAC 
      studies between 73.5% and 93.2% of the VTE events were unprovoked. In the control 
      group recurrent VTE occurred in 9.7% of patients compared to 2.8% in the active 
      treatment group (OR 0.21; 95% CI 0.11-0.42, p<0.0001). VKA, DOACs and aspirin 
      significantly reduced the risk of recurrent VTE, with VKA and DOACs being 
      significantly more effective than aspirin. Major bleeding events occurred in 12 
      patients in the control group (0.4%) and 25 of 3815 (0.6%) patients in the active 
      treatment group (OR 1.64; 95% CI 0.69-3.90, NS). There were 39 (1.3%) deaths in 
      control patients and 33 (0.9%) deaths in the anti-thrombotic group during the 
      treatment period (OR 0.73; 95% CI 0.40-1.33, NS). Patients whose initial VTE 
      event was a PE were more likely to have a recurrent PE than a DVT. The annualized 
      event rate after discontinuation of extended antithrombotic therapy was 4.4% in 
      the control group and 6.5% in the active treatment arm. CONCLUSIONS: VKA, DOACs 
      and aspirin significantly reduced the risk of recurrent VTE, with DOACs and VKA 
      being more effective than aspirin. The decision regarding life-long 
      anticoagulation following an unprovoked DVT or PE should depend on the patients' 
      risk for recurrent PE as well as the patients' values and preferences.
FAU - Marik, Paul E
AU  - Marik PE
AD  - Division of Pulmonary and Critical Care Medicine, Eastern Virginia Medical 
      School, Norfolk, Virginia, United States of America.
FAU - Cavallazzi, Rodrigo
AU  - Cavallazzi R
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of 
      Louisville, Louisville, Kentucky, United States of America.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20151120
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*adverse effects/*therapeutic use
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Data Collection
MH  - Drug Administration Schedule
MH  - Female
MH  - Hemorrhage/prevention & control
MH  - Humans
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Risk Factors
MH  - Sex Factors
MH  - Thromboembolism/*prevention & control
MH  - Treatment Outcome
MH  - Vitamin K/antagonists & inhibitors
MH  - Warfarin/adverse effects/therapeutic use
PMC - PMC4654552
COIS- Competing Interests: Dr Marik is on the speaker’s bureau for 
      Boehringer-Ingelheim, who manufacture and market dabigatran. Dr Cavallazzi has no 
      conflict of interest to declare.
EDAT- 2015/11/21 06:00
MHDA- 2016/06/28 06:00
CRDT- 2015/11/21 06:00
PHST- 2015/08/26 00:00 [received]
PHST- 2015/11/02 00:00 [accepted]
PHST- 2015/11/21 06:00 [entrez]
PHST- 2015/11/21 06:00 [pubmed]
PHST- 2016/06/28 06:00 [medline]
AID - PONE-D-15-37509 [pii]
AID - 10.1371/journal.pone.0143252 [doi]
PST - epublish
SO  - PLoS One. 2015 Nov 20;10(11):e0143252. doi: 10.1371/journal.pone.0143252. 
      eCollection 2015.

PMID- 26763863
OWN - NLM
STAT- MEDLINE
DCOM- 20161226
LR  - 20181202
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 6
DP  - 2016 Jan 14
TI  - Stabilizing Off-pathway Oligomers by Polyphenol Nanoassemblies for IAPP 
      Aggregation Inhibition.
PG  - 19463
LID - 10.1038/srep19463 [doi]
LID - 19463
AB  - Experimental studies have shown that many naturally occurring polyphenols have 
      inhibitory effect on the aggregation of several proteins. Here, we use discrete 
      molecular dynamics (DMD) simulations and high-throughput dynamic light scattering 
      (DLS) experiments to study the anti-aggregation effects of two polyphenols, 
      curcumin and resveratrol, on the aggregation of islet amyloid polypeptide (IAPP 
      or amylin). Our DMD simulations suggest that the aggregation inhibition is caused 
      by stabilization of small molecular weight IAPP off-pathway oligomers by the 
      polyphenols. Our analysis indicates that IAPP-polyphenol hydrogen bonds and π-π 
      stacking combined with hydrophobic interactions are responsible for the 
      stabilization of oligomers. The presence of small oligomers is confirmed with DLS 
      measurements in which nanometer-sized oligomers are found to be stable for up to 
      7.5 hours, the time frame within which IAPP aggregates in the absence of 
      polyphenols. Our study offers a general anti-aggregation mechanism for 
      polyphenols, and further provides a computational framework for the future design 
      of anti-amyloid aggregation therapeutics.
FAU - Nedumpully-Govindan, Praveen
AU  - Nedumpully-Govindan P
AD  - Department of Physics and Astronomy, Clemson University, Clemson, SC 29634, USA.
FAU - Kakinen, Aleksandr
AU  - Kakinen A
AD  - ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash 
      Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, 
      Parkville, VIC 3052, Australia.
FAU - Pilkington, Emily H
AU  - Pilkington EH
AD  - ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash 
      Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, 
      Parkville, VIC 3052, Australia.
FAU - Davis, Thomas P
AU  - Davis TP
AD  - ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash 
      Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, 
      Parkville, VIC 3052, Australia.
AD  - Department of Chemistry, University of Warwick, Gibbet Hill, Coventry, CV4 7AL, 
      United Kingdom.
FAU - Chun Ke, Pu
AU  - Chun Ke P
AD  - ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash 
      Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, 
      Parkville, VIC 3052, Australia.
FAU - Ding, Feng
AU  - Ding F
AD  - Department of Physics and Astronomy, Clemson University, Clemson, SC 29634, USA.
LA  - eng
GR  - R15 ES022766/ES/NIEHS NIH HHS/United States
GR  - R15ES022766-01A/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160114
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Islet Amyloid Polypeptide)
RN  - 0 (Polyphenols)
RN  - 0 (Protein Aggregates)
RN  - 0 (Stilbenes)
RN  - IT942ZTH98 (Curcumin)
RN  - Q369O8926L (Resveratrol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry/pharmacology
MH  - Curcumin/chemistry/pharmacology
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Islet Amyloid Polypeptide/*chemistry/metabolism
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Nanostructures/*chemistry
MH  - Polyphenols/*chemistry/*pharmacology
MH  - Protein Aggregates/*drug effects
MH  - *Protein Aggregation, Pathological/drug therapy/metabolism
MH  - Protein Binding
MH  - Resveratrol
MH  - Stilbenes/chemistry/pharmacology
PMC - PMC4725907
EDAT- 2016/01/15 06:00
MHDA- 2016/12/27 06:00
CRDT- 2016/01/15 06:00
PHST- 2015/08/21 00:00 [received]
PHST- 2015/12/14 00:00 [accepted]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/12/27 06:00 [medline]
AID - srep19463 [pii]
AID - 10.1038/srep19463 [doi]
PST - epublish
SO  - Sci Rep. 2016 Jan 14;6:19463. doi: 10.1038/srep19463.

PMID- 17955898
OWN - NLM
STAT- MEDLINE
DCOM- 20071126
LR  - 20211020
IS  - 0830-9000 (Print)
IS  - 0830-9000 (Linking)
VI  - 71
IP  - 4
DP  - 2007 Oct
TI  - Monitoring blood glucose levels in female mink during the reproductive cycle: 2. 
      Effects of short-term fish oil, chromium picolinate, and acetylsalicylic acid 
      supplementation during late lactation.
PG  - 249-55
AB  - Mink nursing sickness is a metabolic disorder characterized by hyperglycemia that 
      is similar to the metabolic syndrome associated with type 2, or 
      non-insulin-dependent, diabetes mellitus. This research studied the effects of 
      short-term administration of antidiabetic supplements on the blood glucose 
      concentration in female mink during late lactation. Female mink that had blood 
      glucose levels < 5.5 mmol/L (normoglycemic [NG]) or > or = 5.5 mmol/L 
      (hyperglycemic [HG]) early in lactation were given daily supplements of various 
      combinations of herring oil (HerO, 3% in diet), chromium picolinate (CrPic, 200 
      microg), and acetylsalicylic acid (ASA, 100 mg) for 1 wk starting at day 21 post 
      partum. In the NG mink, most of the treatments did not significantly change the 
      blood glucose concentration from day 28 to 42 post partum. However, treatment 
      with ASA alone and treatment with the combination HerO-CrPic-ASA elevated the 
      blood glucose levels when compared with those of the control group, which had 
      received just the basal diet. In the HG mink, all treatment combinations except 
      CrPic alone and ASA alone, reduced the blood glucose concentration. Thus, in 
      lactating mink with hyperglycemia, the blood glucose concentration may be 
      effectively lowered by dietary antidiabetic supplementation; however, because 
      hyperglycemia also occurs before nursing, preventive measures are recommended 
      throughout the year.
FAU - Hynes, Amber M J
AU  - Hynes AM
AD  - Nova Scotia Agricultural College, Department of Plant and Animal Sciences and 
      Canadian Centre for Fur Animal Research, PO Box 550, Truro, Nova Scotia B2N 5E3.
FAU - Rouvinen-Watt, Kirsti
AU  - Rouvinen-Watt K
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - Can J Vet Res
JT  - Canadian journal of veterinary research = Revue canadienne de recherche 
      veterinaire
JID - 8607793
RN  - 0 (Blood Glucose)
RN  - 0 (Fish Oils)
RN  - 0 (Picolinic Acids)
RN  - QZV2W997JQ (picolinic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animal Nutritional Physiological Phenomena/*physiology
MH  - Animals
MH  - Aspirin/administration & dosage/metabolism
MH  - Blood Glucose/*metabolism
MH  - Dietary Supplements
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fish Oils/administration & dosage/metabolism
MH  - Hyperglycemia/prevention & control/*veterinary
MH  - Lactation/*metabolism
MH  - Mink/metabolism/*physiology
MH  - Picolinic Acids/administration & dosage/metabolism
MH  - Postpartum Period
MH  - Treatment Outcome
PMC - PMC1940271
EDAT- 2007/10/25 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/10/25 09:00
PHST- 2007/10/25 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/10/25 09:00 [entrez]
AID - cjvr71_pg249 [pii]
PST - ppublish
SO  - Can J Vet Res. 2007 Oct;71(4):249-55.

PMID- 25243161
OWN - NLM
STAT- MEDLINE
DCOM- 20150604
LR  - 20211021
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2014
DP  - 2014
TI  - Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene 
      promoter and clinical factors on the development of peptic ulcer during 
      cardiovascular prophylaxis with low-dose aspirin.
PG  - 616018
LID - 10.1155/2014/616018 [doi]
LID - 616018
AB  - AIMS: To investigate the impact of blood type, functional polymorphism (T-1676C) 
      of the COX-1 gene promoter, and clinical factors on the development of peptic 
      ulcer during cardiovascular prophylaxis with low-dose aspirin. METHODS: In a 
      case-control study including 111 low-dose aspirin users with peptic ulcers and 
      109 controls (asymptomatic aspirin users), the polymorphism (T-1676C) of the 
      COX-1 gene promoter was genotyped, and blood type, H pylori status, and clinical 
      factors were assessed. RESULTS: Univariate analysis showed no significant 
      differences in genotype frequencies of the COX-1 gene at position -1676 between 
      the peptic ulcer group and control group. Multivariate analysis revealed that 
      blood type O, advanced age, history of peptic ulcer, and concomitant use of NSAID 
      were the independent risk factors for the development of peptic ulcer with the 
      odds ratios of the 2.1, 3.1, 27.6, and 2.9, respectively. CONCLUSION: The C-1676T 
      polymorphism in the COX-1 gene promoter is not a risk factor for ulcer formation 
      during treatment with low-dose aspirin. Blood type O, advanced age, history of 
      peptic ulcer, and concomitant use of NSAID are of independent significance in 
      predicting peptic ulcer development during treatment with low-dose aspirin.
FAU - Wang, Pin-Yao
AU  - Wang PY
AD  - Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 804, 
      Taiwan.
FAU - Chen, Hsiu-Ping
AU  - Chen HP
AD  - Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 804, 
      Taiwan.
FAU - Chen, Angela
AU  - Chen A
AD  - Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 804, 
      Taiwan.
FAU - Tsay, Feng-Woei
AU  - Tsay FW
AD  - Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans 
      General Hospital, 386 Ta Chung 1st Road, Kaohsiung 813, Taiwan ; School of 
      Medicine, National Yang-Ming University, Taipei 112, Taiwan.
FAU - Lai, Kwok-Hung
AU  - Lai KH
AUID- ORCID: 0000-0002-3085-6534
AD  - Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans 
      General Hospital, 386 Ta Chung 1st Road, Kaohsiung 813, Taiwan ; School of 
      Medicine, National Yang-Ming University, Taipei 112, Taiwan.
FAU - Kao, Sung-Shuo
AU  - Kao SS
AD  - Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans 
      General Hospital, 386 Ta Chung 1st Road, Kaohsiung 813, Taiwan ; School of 
      Medicine, National Yang-Ming University, Taipei 112, Taiwan.
FAU - Chen, Wen-Chi
AU  - Chen WC
AUID- ORCID: 0000-0002-7572-4201
AD  - Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans 
      General Hospital, 386 Ta Chung 1st Road, Kaohsiung 813, Taiwan ; School of 
      Medicine, National Yang-Ming University, Taipei 112, Taiwan ; Department of 
      Chemistry, College of Science, National Kaohsiung Normal University, Kaohsiung 
      802, Taiwan.
FAU - Kuo, Chao-Hung
AU  - Kuo CH
AUID- ORCID: 0000-0002-6027-8296
AD  - Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical 
      University Hospital, Kaohsiung 807, Taiwan.
FAU - Peng, Nan-Jing
AU  - Peng NJ
AD  - School of Medicine, National Yang-Ming University, Taipei 112, Taiwan ; 
      Department of Nuclear Medicine, Kaohsiung Veterans General Hospital and National 
      Yang-Ming University, Kaohsiung 813, Taiwan.
FAU - Tseng, Hui-Hwa
AU  - Tseng HH
AD  - Department of Pathology, Kaohsiung Veterans General Hospital, Kaohsiung 813, 
      Taiwan.
FAU - Hsu, Ping-I
AU  - Hsu PI
AD  - Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans 
      General Hospital, 386 Ta Chung 1st Road, Kaohsiung 813, Taiwan ; School of 
      Medicine, National Yang-Ming University, Taipei 112, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140827
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (ABO Blood-Group System)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - ABO Blood-Group System/*physiology
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/drug therapy/prevention & control
MH  - Case-Control Studies
MH  - Cyclooxygenase 1/*genetics
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/chemically induced/*epidemiology/genetics
MH  - Polymorphism, Genetic/*genetics
MH  - Promoter Regions, Genetic/*genetics
MH  - Risk Factors
PMC - PMC4163467
EDAT- 2014/09/23 06:00
MHDA- 2015/06/05 06:00
CRDT- 2014/09/23 06:00
PHST- 2014/05/24 00:00 [received]
PHST- 2014/07/09 00:00 [accepted]
PHST- 2014/09/23 06:00 [entrez]
PHST- 2014/09/23 06:00 [pubmed]
PHST- 2015/06/05 06:00 [medline]
AID - 10.1155/2014/616018 [doi]
PST - ppublish
SO  - Biomed Res Int. 2014;2014:616018. doi: 10.1155/2014/616018. Epub 2014 Aug 27.

PMID- 25463991
OWN - NLM
STAT- MEDLINE
DCOM- 20150625
LR  - 20220410
IS  - 1527-3792 (Electronic)
IS  - 0022-5347 (Linking)
VI  - 193
IP  - 4
DP  - 2015 Apr
TI  - The use of aspirin and the risk of mortality in patients with prostate cancer.
PG  - 1220-5
LID - S0022-5347(14)04863-0 [pii]
LID - 10.1016/j.juro.2014.11.018 [doi]
AB  - PURPOSE: The association between the use of aspirin and mortality in patients 
      with prostate cancer remains uncertain. We determine whether the use of aspirin 
      in patients with prostate cancer is associated with a decreased risk of prostate 
      cancer mortality and all cause mortality. MATERIALS AND METHODS: Using the United 
      Kingdom National Cancer Data Repository, Clinical Practice Research Datalink and 
      associated databases, we identified a cohort of men with nonmetastatic prostate 
      cancer between 1998 and 2009, followed until 2012. Cox proportional hazards 
      models were used to estimate adjusted HRs with 95% CIs of mortality outcomes 
      associated with post-diagnostic use of aspirin defined as a time-varying 
      exposure. Effect modification by pre-diagnostic aspirin use was also assessed. 
      RESULTS: The cohort included 11,779 men followed for 5.4 years (SD 2.9). 
      Post-diagnostic aspirin use was associated with an increased risk of prostate 
      cancer mortality (HR 1.46, 95% CI 1.29-1.65) and all cause mortality (HR 1.37, 
      95% CI 1.26-1.50). These increased risks were restricted to patients initiating 
      aspirin after the prostate cancer diagnosis (HR 1.84, 95% CI 1.59-2.12, and HR 
      1.70, 95% CI 1.53-1.88, respectively), and not in patients who were already 
      exposed to aspirin before the diagnosis (HR 0.97, 95% CI 0.81-1.16 and HR 0.98, 
      95% CI 0.87-1.18, respectively). CONCLUSIONS: The post-diagnostic use of aspirin 
      is not associated with a decreased risk of prostate cancer outcomes. Increased 
      risks were restricted to patients initiating these drugs after their diagnosis, 
      suggesting a noncausal association.
CI  - Copyright © 2015 American Urological Association Education and Research, Inc. 
      Published by Elsevier Inc. All rights reserved.
FAU - Assayag, Jonathan
AU  - Assayag J
AD  - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 
      McGill University, Montreal, Quebec, Canada; Department of Experimental Medicine, 
      McGill University, Montreal, Quebec, Canada.
FAU - Pollak, Michael N
AU  - Pollak MN
AD  - Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada; 
      Department of Oncology, McGill University, Montreal, Quebec, Canada.
FAU - Azoulay, Laurent
AU  - Azoulay L
AD  - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 
      McGill University, Montreal, Quebec, Canada; Department of Oncology, McGill 
      University, Montreal, Quebec, Canada. Electronic address: 
      laurent.azoulay@mcgill.ca.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20141114
PL  - United States
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cause of Death
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/*mortality
MH  - Risk
OTO - NOTNLM
OT  - aspirin
OT  - mortality
OT  - prognosis
OT  - prostatic neoplasms
EDAT- 2014/12/03 06:00
MHDA- 2015/06/26 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/11/06 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/06/26 06:00 [medline]
AID - S0022-5347(14)04863-0 [pii]
AID - 10.1016/j.juro.2014.11.018 [doi]
PST - ppublish
SO  - J Urol. 2015 Apr;193(4):1220-5. doi: 10.1016/j.juro.2014.11.018. Epub 2014 Nov 
      14.

PMID- 36260615
OWN - NLM
STAT- MEDLINE
DCOM- 20221021
LR  - 20221129
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 10
DP  - 2022
TI  - Low-dose aspirin to prevent preeclampsia and growth restriction in nulliparous 
      women identified by uterine artery Doppler as at high risk of preeclampsia: A 
      double blinded randomized placebo-controlled trial.
PG  - e0275129
LID - 10.1371/journal.pone.0275129 [doi]
LID - e0275129
AB  - INTRODUCTION: This trial evaluates whether daily low-dose aspirin initiated 
      before 16 weeks of gestation can reduce preeclampsia and fetal growth restriction 
      in nulliparous women identified by first-trimester uterine artery Dopplers as at 
      high risk of preeclampsia. METHODS: This randomized, blinded, placebo-controlled, 
      parallel-group trial took place in 17 French obstetric departments providing 
      antenatal care. Pregnant nulliparous women aged ≥ 18 years with a singleton 
      pregnancy at a gestational age < 16 weeks of gestation with a lowest pulsatility 
      index ≥ 1.7 or a bilateral protodiastolic notching for both uterine arteries on 
      an ultrasound performed between 11+0 and 13+6 weeks by a certified sonographer 
      were randomized at a 1:1 ratio to 160 mg of low-dose aspirin or to placebo to be 
      taken daily from inclusion to their 34th week of gestation. The main outcome was 
      preeclampsia or a birthweight ≤ 5th percentile. Other outcomes included 
      preeclampsia, severe preeclampsia, preterm preeclampsia, preterm delivery before 
      34 weeks, mode of delivery, type of anesthesia, birthweight ≤ 5th percentile and 
      perinatal death. RESULTS: The trial was interrupted due to recruiting 
      difficulties. Between June 2012 and June 2016, 1104 women were randomized, two 
      withdrew consent, and two had terminations of pregnancies. Preeclampsia or a 
      birthweight ≤ 5th percentile occurred in 88 (16.0%) women in the low-dose aspirin 
      group and in 79 (14.4%) in the placebo group (proportion difference 1.6 [-2.6; 
      5.9] p = 0.45). The two groups did not differ significantly for the secondary 
      outcomes. CONCLUSION: Low-dose aspirin was not associated with a lower rate of 
      either preeclampsia or birthweight ≤ 5th percentile in women identified by their 
      first-trimester uterine artery Doppler as at high risk of preeclampsia. TRIAL 
      REGISTRATION: (NCT0172946).
FAU - Diguisto, Caroline
AU  - Diguisto C
AUID- ORCID: 0000-0002-1176-0991
AD  - Pôle de Gynécologie Obstétrique, Médecine Fœtale, Médecine et Biologie de la 
      Reproduction, Centre Olympe de Gouges, CHRU de Tours, Tours, France.
AD  - Université de Tours, Tours, France.
AD  - Université de Paris, CRESS, Obstetrical Perinatal and Pediatric Epidemiology 
      Research Team, EPOPé, INSERM, INRAE,F, Paris, France.
FAU - Le Gouge, Amelie
AU  - Le Gouge A
AD  - INSERM CIC1415, CHRU de Tours, Tours, France.
FAU - Marchand, Marie-Sara
AU  - Marchand MS
AD  - Service de Pharmacovigilance CHU Tours, Tours, France.
FAU - Megier, Pascal
AU  - Megier P
AD  - Department of Gynaecology and Obstetrics, Centre Hospitalier Régional d'Orléans, 
      Orleans, France.
FAU - Ville, Yves
AU  - Ville Y
AD  - Centre de Dépistage PRIMA FACIE Université de Paris, Paris, France.
AD  - Maternité, AP-HP, Hôpital Necker, Paris, France.
FAU - Haddad, Georges
AU  - Haddad G
AD  - Cabinet Mosaïque Santé, La Chaussée Saint Victor, France.
FAU - Winer, Norbert
AU  - Winer N
AUID- ORCID: 0000-0001-9897-8493
AD  - Department of Obstetrics and Gynecology, University Hospital of Nantes, Nantes, 
      NUN, INRAE, UMR 1280, PhAN, Université de Nantes, Nantes, France.
FAU - Arthuis, Chloé
AU  - Arthuis C
AD  - Department of Obstetrics and Gynecology, University Hospital of Nantes, Nantes, 
      NUN, INRAE, UMR 1280, PhAN, Université de Nantes, Nantes, France.
FAU - Doret, Muriel
AU  - Doret M
AD  - Service de Gynécologie-Obstétrique, HFME, Hospices Civils de Lyon, Lyon, France.
FAU - Debarge, Veronique Houfflin
AU  - Debarge VH
AD  - Department of Obstetrics, CHU Lille, Univ. Lille, ULR 2694-METRICS: Évaluation 
      des Technologies de Santé et des Pratiques Médicales, Lille, France.
FAU - Flandrin, Anaig
AU  - Flandrin A
AD  - Service de Gynécologie-Obstétrique, Hôpital Arnaud de Villeneuve, CHRU de 
      Montpellier, Montpellier, France.
FAU - Delmas, Hélène Laurichesse
AU  - Delmas HL
AD  - Service de Gynécologie-Obstétrique, Hôpital d'Estaing, CHU de Clermont-Ferrand, 
      Maternité Clermont Ferrand, Clermont-Ferrand, France.
FAU - Gallot, Denis
AU  - Gallot D
AD  - Service de Gynécologie-Obstétrique, Hôpital d'Estaing, CHU de Clermont-Ferrand, 
      Maternité Clermont Ferrand, Clermont-Ferrand, France.
FAU - Mares, Pierre
AU  - Mares P
AD  - Département de Gynécologie Obstétrique, Centre Hospitalo-Universitaire Caremeau, 
      Nîmes, France.
AD  - École de Maïeutique, Université de Montpellier, Site de Nîmes, Nîmes, France.
FAU - Vayssiere, Christophe
AU  - Vayssiere C
AD  - Department of Obstetrics and Gynaecology, Paule de Viguier Hospital, Toulouse 
      University Hospital Center, Toulouse, France.
AD  - Centre for Epidemiology and Population Health Research, Team SPHERE, Toulouse III 
      University, Toulouse, France.
FAU - Sentilhes, Loïc
AU  - Sentilhes L
AD  - Service de Gynécologie-Obstétrique, Groupe Hospitalier Pellegrin, CHRU de 
      Bordeaux, Talence, France.
FAU - Cheve, Marie-Therese
AU  - Cheve MT
AD  - Service de Gynécologie-Obstétrique, CHR Le Mans, Le Mans, France.
FAU - Paumier, Anne
AU  - Paumier A
AD  - Service de Gynécologie-Obstétrique, Polyclinique de l'Atlantique, Saint-Herblain, 
      France.
FAU - Durin, Luc
AU  - Durin L
AD  - Service de Gynécologie-Obstétrique, Polyclinique du Parc, Caen, France.
FAU - Schaub, Bruno
AU  - Schaub B
AD  - Service de Gynécologie-Obstétrique, Maison de la Femme, de la Mère et de 
      l'Enfant, CHU Martinique, Fort-de-France, Martinique, France.
FAU - Equy, Veronique
AU  - Equy V
AD  - Service de Gynécologie-Obstétrique, Hôpital Couple Enfant, CHRU de Grenoble, La 
      Tronche, France.
FAU - Giraudeau, Bruno
AU  - Giraudeau B
AD  - Université de Tours, Tours, France.
AD  - INSERM CIC1415, CHRU de Tours, Tours, France.
FAU - Perrotin, Franck
AU  - Perrotin F
AD  - Pôle de Gynécologie Obstétrique, Médecine Fœtale, Médecine et Biologie de la 
      Reproduction, Centre Olympe de Gouges, CHRU de Tours, Tours, France.
AD  - Université de Tours, Tours, France.
CN  - Groupe de Recherche en Obstétrique et Gynécologie (GROG)
LA  - eng
SI  - ClinicalTrials.gov/NCT01729468
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20221019
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Infant, Newborn
MH  - Female
MH  - Pregnancy
MH  - Humans
MH  - Male
MH  - *Uterine Artery/diagnostic imaging
MH  - *Pre-Eclampsia/prevention & control/drug therapy
MH  - Birth Weight
MH  - Aspirin/therapeutic use
MH  - Pregnancy Trimester, First
PMC - PMC9581352
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/10/20 06:00
MHDA- 2022/10/22 06:00
CRDT- 2022/10/19 13:43
PHST- 2022/04/06 00:00 [received]
PHST- 2022/09/08 00:00 [accepted]
PHST- 2022/10/19 13:43 [entrez]
PHST- 2022/10/20 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
AID - PONE-D-22-07025 [pii]
AID - 10.1371/journal.pone.0275129 [doi]
PST - epublish
SO  - PLoS One. 2022 Oct 19;17(10):e0275129. doi: 10.1371/journal.pone.0275129. 
      eCollection 2022.

PMID- 27683033
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20181202
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 45
DP  - 2016 Nov 8
TI  - A novel co-drug of aspirin and ursolic acid interrupts adhesion, invasion and 
      migration of cancer cells to vascular endothelium via regulating EMT and 
      EGFR-mediated signaling pathways: multiple targets for cancer metastasis 
      prevention and treatment.
PG  - 73114-73129
LID - 10.18632/oncotarget.12232 [doi]
AB  - Metastasis currently remains the predominant cause of breast carcinoma treatment 
      failure. The effective targeting of metastasis-related-pathways in cancer holds 
      promise for a new generation of therapeutics. In this study, we developed an 
      novel Asp-UA conjugate, which was composed of classical "old drug" aspirin and 
      low toxicity natural product ursolic acid for targeting breast cancer metastasis. 
      Our results showed that Asp-UA could attenuate the adhesion, migration and 
      invasion of breast cancer MCF-7 and MDA-MB-231 cells in a more safe and effective 
      manner in vitro. Molecular and cellular study demonstrated that Asp-UA 
      significantly down-regulated the expression of cell adhesion and invasion 
      molecules including integrin α6β1, CD44 ,MMP-2, MMP-9, COX-2, EGFR and ERK 
      proteins, and up-regulated the epithelial markers "E-cadherin" and "β-catenin", 
      and PTEN proteins. Furthermore, Asp-UA (80 mg/kg) reduced lung metastasis in a 
      4T1 murine breast cancer metastasis model more efficiently, which was associated 
      with a decrease in the expression of CD44. More importantly, we did not detect 
      side effects with Asp-UA in mice such as weight loss and main viscera tissues 
      toxicity. Overall, our research suggested that co-drug Asp-UA possessed potential 
      metastasis chemoprevention abilities via influencing EMT and EGFR-mediated 
      pathways and could be a more promising drug candidate for the prevention and/or 
      treatment of breast cancer metastasis.
FAU - Tang, Qiao
AU  - Tang Q
AD  - Cancer Metastasis Alert and Prevention Center, Pharmaceutical Photocatalysis of 
      State Key Laboratory of Photocatalysis on Energy and Environment, College of 
      Chemistry, Fuzhou University, Fuzhou, China.
AD  - Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention, Fuzhou 
      University, Fuzhou, China.
FAU - Liu, Yajun
AU  - Liu Y
AD  - Cancer Metastasis Alert and Prevention Center, Pharmaceutical Photocatalysis of 
      State Key Laboratory of Photocatalysis on Energy and Environment, College of 
      Chemistry, Fuzhou University, Fuzhou, China.
AD  - Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention, Fuzhou 
      University, Fuzhou, China.
FAU - Li, Tao
AU  - Li T
AD  - Cancer Metastasis Alert and Prevention Center, Pharmaceutical Photocatalysis of 
      State Key Laboratory of Photocatalysis on Energy and Environment, College of 
      Chemistry, Fuzhou University, Fuzhou, China.
AD  - Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention, Fuzhou 
      University, Fuzhou, China.
FAU - Yang, Xiang
AU  - Yang X
AD  - Cancer Metastasis Alert and Prevention Center, Pharmaceutical Photocatalysis of 
      State Key Laboratory of Photocatalysis on Energy and Environment, College of 
      Chemistry, Fuzhou University, Fuzhou, China.
AD  - Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention, Fuzhou 
      University, Fuzhou, China.
FAU - Zheng, Guirong
AU  - Zheng G
AD  - Cancer Metastasis Alert and Prevention Center, Pharmaceutical Photocatalysis of 
      State Key Laboratory of Photocatalysis on Energy and Environment, College of 
      Chemistry, Fuzhou University, Fuzhou, China.
AD  - Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention, Fuzhou 
      University, Fuzhou, China.
FAU - Chen, Hongning
AU  - Chen H
AD  - Cancer Metastasis Alert and Prevention Center, Pharmaceutical Photocatalysis of 
      State Key Laboratory of Photocatalysis on Energy and Environment, College of 
      Chemistry, Fuzhou University, Fuzhou, China.
AD  - Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention, Fuzhou 
      University, Fuzhou, China.
FAU - Jia, Lee
AU  - Jia L
AD  - Cancer Metastasis Alert and Prevention Center, Pharmaceutical Photocatalysis of 
      State Key Laboratory of Photocatalysis on Energy and Environment, College of 
      Chemistry, Fuzhou University, Fuzhou, China.
AD  - Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention, Fuzhou 
      University, Fuzhou, China.
FAU - Shao, Jingwei
AU  - Shao J
AD  - Cancer Metastasis Alert and Prevention Center, Pharmaceutical Photocatalysis of 
      State Key Laboratory of Photocatalysis on Energy and Environment, College of 
      Chemistry, Fuzhou University, Fuzhou, China.
AD  - Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention, Fuzhou 
      University, Fuzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Biomarkers)
RN  - 0 (RNA, Messenger)
RN  - 0 (Triterpenes)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - P3M2575F3F (ursolic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry/*pharmacology
MH  - Biomarkers
MH  - Cell Adhesion/drug effects
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Survival/drug effects
MH  - Disease Models, Animal
MH  - Endothelium, Vascular/*metabolism
MH  - Epithelial-Mesenchymal Transition/*drug effects
MH  - ErbB Receptors/*metabolism
MH  - Female
MH  - Gene Expression
MH  - Heterografts
MH  - Humans
MH  - Mice
MH  - Models, Biological
MH  - Neoplasm Metastasis
MH  - Neoplasms/drug therapy/metabolism/pathology
MH  - RNA, Messenger/genetics/metabolism
MH  - Rats
MH  - Signal Transduction/*drug effects
MH  - Triterpenes/chemistry/*pharmacology
PMC - PMC5341967
OTO - NOTNLM
OT  - EGFR
OT  - EMT
OT  - aspirin
OT  - cancer metastatic chemoprevention
OT  - ursolic acid
COIS- CONFLICTS OF INTEREST The authors declare no competing financial interests.
EDAT- 2016/09/30 06:00
MHDA- 2018/02/27 06:00
CRDT- 2016/09/30 06:00
PHST- 2016/05/27 00:00 [received]
PHST- 2016/09/16 00:00 [accepted]
PHST- 2016/09/30 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
PHST- 2016/09/30 06:00 [entrez]
AID - 12232 [pii]
AID - 10.18632/oncotarget.12232 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Nov 8;7(45):73114-73129. doi: 10.18632/oncotarget.12232.

PMID- 27499621
OWN - NLM
STAT- MEDLINE
DCOM- 20170227
LR  - 20211204
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 11
DP  - 2016
TI  - Preclinical systemic toxicity evaluation of chitosan-solid lipid 
      nanoparticle-encapsulated aspirin and curcumin in combination with free 
      sulforaphane in BALB/c mice.
PG  - 3265-76
LID - 10.2147/IJN.S106736 [doi]
AB  - Our previous studies have established the efficacy of chemopreventive regimens of 
      aspirin and curcumin (CUR) encapsulated within solid lipid nanoparticles (SLNs) 
      in combination with free sulforaphane (ACS combination) to prevent or delay the 
      initiation and progression of pancreatic cancer, classified as one of the 
      deadliest diseases with very low chances of survival upon diagnosis. Although 
      toxicity of individual drugs and SLN has been studied previously, there are no 
      studies in current literature that evaluate the potential toxicity of a combined 
      regimen of ACS, especially when encapsulated within chitosan-SLNs (c-SLNs). 
      Hence, objective of the current study was to investigate the potential toxic 
      effects of ACS c-SLN combined chemopreventive regimens following acute (3 days), 
      subacute (28 days), and subchronic (90 days) administrations by oral gavage in 
      BALB/c mice. Mice were administered the following regimens: saline, blank c-SLN, 
      low-dose ACS c-SLN (2+4.5+0.16 mg/kg), medium-dose ACS c-SLN (20+45+1.6 mg/kg), 
      and high-dose ACS c-SLN (60+135+4.8 mg/kg). The potential toxicity was evaluated 
      based on animal survival, body weight, hematology, blood chemistry, and organ 
      histopathology. During 3-day, 28-day, and 90-day study periods, no animal deaths 
      were observed. Treatment with ACS c-SLNs did not cause alteration in complete 
      blood counts and blood chemistry data. Histopathological examination of various 
      organ sections (pancreas, heart, liver, kidney, and brain) appeared normal. Based 
      on the results of this study, no signs of toxicity in acute, subacute, and 
      subchronic studies following oral administration of ACS c-SLNs were found 
      indicating that the oral dosing regimens were safe at the levels tested for 
      long-term administration to prevent the onset of pancreatic cancer.
FAU - Thakkar, Arvind
AU  - Thakkar A
AD  - Department of Pharmaceutical Sciences, College of Pharmacy.
FAU - Chenreddy, Sushma
AU  - Chenreddy S
AD  - Department of Pharmaceutical Sciences, College of Pharmacy.
FAU - Thio, Astrid
AU  - Thio A
AD  - Department of Pharmaceutical Sciences, College of Pharmacy.
FAU - Khamas, Wael
AU  - Khamas W
AD  - College of Veterinary Medicine, Western University of Health Sciences, Pomona, 
      CA, USA.
FAU - Wang, Jeffrey
AU  - Wang J
AD  - Department of Pharmaceutical Sciences, College of Pharmacy.
FAU - Prabhu, Sunil
AU  - Prabhu S
AD  - Department of Pharmaceutical Sciences, College of Pharmacy.
LA  - eng
GR  - R15 CA182834/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20160720
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (Isothiocyanates)
RN  - 0 (Lipids)
RN  - 0 (Sulfoxides)
RN  - 9012-76-4 (Chitosan)
RN  - GA49J4310U (sulforaphane)
RN  - IT942ZTH98 (Curcumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Body Weight/drug effects
MH  - Chitosan/*toxicity
MH  - Curcumin/administration & dosage/*pharmacology
MH  - Drug Liberation
MH  - Female
MH  - Isothiocyanates/administration & dosage/*pharmacology
MH  - Lipids/*toxicity
MH  - Mice, Inbred BALB C
MH  - Nanoparticles/*toxicity
MH  - Particle Size
MH  - Static Electricity
MH  - Sulfoxides
MH  - *Toxicity Tests
PMC - PMC4959578
OTO - NOTNLM
OT  - aspirin
OT  - chitosan-solid lipid nanoparticle
OT  - curcumin
OT  - pancreatic cancer
OT  - sulforaphane
OT  - toxicity
EDAT- 2016/08/09 06:00
MHDA- 2017/02/28 06:00
CRDT- 2016/08/09 06:00
PHST- 2016/08/09 06:00 [entrez]
PHST- 2016/08/09 06:00 [pubmed]
PHST- 2017/02/28 06:00 [medline]
AID - ijn-11-3265 [pii]
AID - 10.2147/IJN.S106736 [doi]
PST - epublish
SO  - Int J Nanomedicine. 2016 Jul 20;11:3265-76. doi: 10.2147/IJN.S106736. eCollection 
      2016.

PMID- 23897511
OWN - NLM
STAT- MEDLINE
DCOM- 20150113
LR  - 20181202
IS  - 1432-086X (Electronic)
IS  - 0174-1551 (Linking)
VI  - 37
IP  - 3
DP  - 2014 Jun
TI  - High on-treatment platelet reactivity in peripheral endovascular procedures.
PG  - 559-71
LID - 10.1007/s00270-013-0707-y [doi]
AB  - The use of aspirin is considered the "gold standard" for the decrease of major 
      adverse cardiovascular events in patients with atherosclerosis, including 
      peripheral arterial disease (PAD), whereas a dual-antiplatelet regimen with 
      aspirin and clopidogrel is usually indicated for such patients after angioplasty 
      and stent deployment. However, a substantial number of subsequent adverse events 
      still occur, even in patients who receive double-antiplatelet therapy. The "high 
      on-treatment platelet reactivity" (HTPR) phenomenon has been lately recognized 
      and plays a major role in the management of patients with PAD. Greater and more 
      rapid inhibition of platelet aggregation has become the goal for new antiplatelet 
      agents with the expectation of further improving outcomes for percutaneous 
      intervention for PAD. The purpose of this review article is to highlight current 
      evidence regarding the prevalence, aetiology, and clinical implications of HTPR 
      in PAD as well as to discuss the possibilities of novel alternative antiplatelet 
      regiments.
FAU - Spiliopoulos, Stavros
AU  - Spiliopoulos S
AD  - Department of Radiology, Patras University Hospital, Rio, Greece.
FAU - Kassimis, George
AU  - Kassimis G
FAU - Hatzidakis, Adam
AU  - Hatzidakis A
FAU - Krokidis, Miltiadis
AU  - Krokidis M
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130730
PL  - United States
TA  - Cardiovasc Intervent Radiol
JT  - Cardiovascular and interventional radiology
JID - 8003538
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacokinetics/*therapeutic use
MH  - Atherosclerosis/*therapy
MH  - Blood Platelets/drug effects
MH  - Clopidogrel
MH  - *Endovascular Procedures/adverse effects
MH  - Humans
MH  - Peripheral Arterial Disease/*therapy
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/pharmacokinetics/therapeutic use
EDAT- 2013/07/31 06:00
MHDA- 2015/01/15 06:00
CRDT- 2013/07/31 06:00
PHST- 2013/04/24 00:00 [received]
PHST- 2013/07/10 00:00 [accepted]
PHST- 2013/07/31 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2015/01/15 06:00 [medline]
AID - 10.1007/s00270-013-0707-y [doi]
PST - ppublish
SO  - Cardiovasc Intervent Radiol. 2014 Jun;37(3):559-71. doi: 
      10.1007/s00270-013-0707-y. Epub 2013 Jul 30.

PMID- 21334119
OWN - NLM
STAT- MEDLINE
DCOM- 20110606
LR  - 20131121
IS  - 1768-3254 (Electronic)
IS  - 0223-5234 (Linking)
VI  - 46
IP  - 4
DP  - 2011 Apr
TI  - Carbaboranes as pharmacophores: similarities and differences between aspirin and 
      asborin.
PG  - 1131-9
LID - 10.1016/j.ejmech.2011.01.030 [doi]
AB  - In medicinal chemistry carbaboranes have been used almost exclusively as boron 
      carriers for boron neutron capture therapy (BNCT). Recent developments extended 
      the carrier approach and use carbaboranes as scaffolds for radiodiagnostic or 
      therapeutic agents. Most recent studies, however, focus on carbaboranes as modern 
      hydrophobic pharmacophores. This research employs preferably meta- and 
      para-carbaborane, because these isomers are extremely hydrophobic and very 
      stable. In this paper we therefore investigated the pharmacophoric behavior of 
      the ortho isomer as putative phenyl mimetic by comparing aspirin to asborin, its 
      ortho-carbaborane analogue. Special emphasis is placed on the impact of the 
      cluster properties on the pharmacological profile. Subjects under study are the 
      mode of cyclooxygenase (COX) inhibition, stability, and toxicity. The 
      straightforward syntheses of the corresponding nido compounds as well as their 
      contribution to the pharmacology of the closo precursors will be highlighted. 
      Finally, proof will be given that the ortho-carbaborane core of asborin merits 
      the designation "pharmacophore" by definition and is a multifunctional group 
      rather than just a hydrophobic, bulky spectator.
CI  - Copyright © 2011 Elsevier Masson SAS. All rights reserved.
FAU - Scholz, Matthias
AU  - Scholz M
AD  - Institut für Anorganische Chemie der Universität Leipzig, Johannisallee 29, 04103 
      Leipzig, Germany. hey@rz.uni-leipzig.de
FAU - Kaluđerović, Goran N
AU  - Kaluđerović GN
FAU - Kommera, Harish
AU  - Kommera H
FAU - Paschke, Reinhard
AU  - Paschke R
FAU - Will, Joanna
AU  - Will J
FAU - Sheldrick, William S
AU  - Sheldrick WS
FAU - Hey-Hawkins, Evamarie
AU  - Hey-Hawkins E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110128
PL  - France
TA  - Eur J Med Chem
JT  - European journal of medicinal chemistry
JID - 0420510
RN  - 0 (Acetates)
RN  - 0 (Boron Compounds)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Rhodamines)
RN  - 0 (asborin)
RN  - 12008-78-5 (dodecaborate)
RN  - 2609-88-3 (lissamine rhodamine B)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 3.4.22.- (Caspases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/*chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*chemistry/*pharmacology
MH  - Boron Compounds/*chemistry/*pharmacology
MH  - Caspases/metabolism
MH  - Catalytic Domain
MH  - Cell Line, Tumor
MH  - Cyclooxygenase 1/chemistry/metabolism
MH  - Cyclooxygenase 2/chemistry/metabolism
MH  - Cyclooxygenase 2 Inhibitors/*chemistry/*pharmacology
MH  - Drug Discovery
MH  - Humans
MH  - Hydrolysis
MH  - Isomerism
MH  - Models, Molecular
MH  - Rhodamines/metabolism
EDAT- 2011/02/22 06:00
MHDA- 2011/06/07 06:00
CRDT- 2011/02/22 06:00
PHST- 2010/11/25 00:00 [received]
PHST- 2011/01/05 00:00 [revised]
PHST- 2011/01/17 00:00 [accepted]
PHST- 2011/02/22 06:00 [entrez]
PHST- 2011/02/22 06:00 [pubmed]
PHST- 2011/06/07 06:00 [medline]
AID - S0223-5234(11)00052-3 [pii]
AID - 10.1016/j.ejmech.2011.01.030 [doi]
PST - ppublish
SO  - Eur J Med Chem. 2011 Apr;46(4):1131-9. doi: 10.1016/j.ejmech.2011.01.030. Epub 
      2011 Jan 28.

PMID- 3769383
OWN - NLM
STAT- MEDLINE
DCOM- 19861211
LR  - 20190511
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 40
IP  - 5
DP  - 1986 Nov
TI  - Toxic interaction between acetazolamide and salicylate: case reports and a 
      pharmacokinetic explanation.
PG  - 518-24
AB  - Two elderly patients, who were chronically receiving aspirin, developed lethargy, 
      incontinence, and confusion after dosing with acetazolamide. Unbound plasma 
      acetazolamide concentrations were elevated and plasma protein binding was 
      reduced, suggesting an interaction with aspirin. In vitro studies demonstrated a 
      concentration-dependent effect of salicylate on acetazolamide binding to serum 
      proteins. At a therapeutic serum acetazolamide level of 8.0 micrograms/ml, the 
      unbound percentage of acetazolamide in serum was 3.3% and increased to 11.0% and 
      30.0%, with serum salicylate levels of 200 and 386 micrograms/ml, respectively. 
      Furthermore, the apparent association constant of acetazolamide for binding to 
      serum proteins was decreased by 58% and 86% of its control value at these 
      respective salicylate concentrations. The maximal binding capacity of serum for 
      acetazolamide was not affected by salicylate. Pharmacokinetic studies in four 
      volunteers showed that the plasma protein binding and renal clearance of 
      acetazolamide were significantly reduced during chronic salicylate dosing. 
      Salicylate appears to competitively inhibit the plasma protein binding of 
      acetazolamide and simultaneously to inhibit acetazolamide renal tubular 
      secretion. Caution is advised when acetazolamide and salicylate are used 
      concurrently.
FAU - Sweeney, K R
AU  - Sweeney KR
FAU - Chapron, D J
AU  - Chapron DJ
FAU - Brandt, J L
AU  - Brandt JL
FAU - Gomolin, I H
AU  - Gomolin IH
FAU - Feig, P U
AU  - Feig PU
FAU - Kramer, P A
AU  - Kramer PA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Blood Proteins)
RN  - 0 (Salicylates)
RN  - O3FX965V0I (Acetazolamide)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Clin Pharmacol Ther 1987 Jan;41(1):67
MH  - Acetazolamide/adverse effects/*metabolism
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/metabolism
MH  - Blood Proteins/metabolism
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Metabolic Clearance Rate/drug effects
MH  - Protein Binding/drug effects
MH  - Salicylates/adverse effects/*metabolism
MH  - Salicylic Acid
EDAT- 1986/11/01 00:00
MHDA- 1986/11/01 00:01
CRDT- 1986/11/01 00:00
PHST- 1986/11/01 00:00 [pubmed]
PHST- 1986/11/01 00:01 [medline]
PHST- 1986/11/01 00:00 [entrez]
AID - 10.1038/clpt.1986.217 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1986 Nov;40(5):518-24. doi: 10.1038/clpt.1986.217.

PMID- 15899631
OWN - NLM
STAT- MEDLINE
DCOM- 20050614
LR  - 20131121
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 91 Suppl 2
DP  - 2004 May
TI  - [Cyclooxygenase 2 inhibitors and adenomatous polyposis coli].
PG  - S85-8
AB  - Prolonged use of aspirin and\or non-steroidal anti-inflammatory drugs induces a 
      partial regression of either sporadic adenomas or adenomas in adenomatous 
      polyposis coli (APC), but also their emergence and colonic cancer development in 
      sporadic adenomas. Specific inhibitors of cyclooxygenase of type 2 (Cox2) induce 
      less upper and lower digestive tract adverse events that non-specific 
      anti-inflammatory drugs. This better tolerance might allow a long-lasting use in 
      patients with APC. At time, we don't know if such treatments are able to prevent 
      the development of cancer in the rectum or duodenum of these patients. In this 
      paper we will discuss the scientific proofs and potential interest of Cox2 
      inhibitors in the treatment of PAF.
FAU - Florent, Christian
AU  - Florent C
AD  - Gastro-entérologie, Hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 
      75012 Paris.
FAU - Meary, Nathalie
AU  - Meary N
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Inhibiteurs spécifiques de la cyclo-oxygénase 2 et polypose adénomateuse 
      familiale.
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenomatous Polyposis Coli/*prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cyclooxygenase Inhibitors/adverse effects/*therapeutic use
MH  - Humans
RF  - 14
EDAT- 2005/05/19 09:00
MHDA- 2005/06/15 09:00
CRDT- 2005/05/19 09:00
PHST- 2005/05/19 09:00 [pubmed]
PHST- 2005/06/15 09:00 [medline]
PHST- 2005/05/19 09:00 [entrez]
PST - ppublish
SO  - Bull Cancer. 2004 May;91 Suppl 2:S85-8.

PMID- 30183988
OWN - NLM
STAT- MEDLINE
DCOM- 20181018
LR  - 20181202
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Print)
IS  - 0066-782X (Linking)
VI  - 111
IP  - 2
DP  - 2018 Aug
TI  - Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, 
      Evidence and Potentialities - Systematic Review.
PG  - 205-212
LID - S0066-782X2018001400205 [pii]
LID - 10.5935/abc.20180138 [doi]
AB  - Breast cancer is the most frequently diagnosed tumor in women worldwide, with a 
      significant impact on morbidity and mortality. Chemotherapy and hormone therapy 
      have significantly reduced mortality; however, the adverse effects are 
      significant. Aspirin has been incorporated into clinical practice for over 100 
      years at a low cost, making it particularly attractive as a potential agent in 
      breast cancer prevention and as an adjunct treatment to endocrine therapy in the 
      prophylaxis of cardiovascular complications. The objective of this study was to 
      evaluate the role of aspirin in reducing the incidence of breast cancer and to 
      evaluate the impact of its use on morbidity and mortality and reduction of 
      cardiovascular events as adjuvant therapy during breast cancer treatment with 
      selective estrogen receptor modulators. A systematic review was performed using 
      the PRISMA methodology and PICO criteria, based on the MEDLINE, EMBASE and LILACS 
      databases. The original articles of clinical trials, cohort, case-control studies 
      and meta-analyses published from January 1998 to June 2017, were considered. Most 
      studies showed an association between the use of selective estrogen receptor 
      modulators and the increase in thromboembolic events. The studies suggest a 
      protective effect of aspirin for cardiovascular events during its concomitant use 
      with selective estrogen receptor modulators and in the prevention of breast 
      cancer. This systematic review suggests that aspirin therapy combines the benefit 
      of protection against cardiovascular events with the potential reduction in 
      breast cancer risk, and that the evaluation of the benefits of the interaction of 
      endocrine therapy with aspirin should be further investigated.
FAU - Leite, Andréa de Melo
AU  - Leite AM
AD  - Programa de Pós-graduação em Ciências Cardiovasculares da Universidade Federal 
      Fluminense (UFF), Niterói, RJ - Brazil.
AD  - Rede D'Or São Luiz, Rio de Janeiro, RJ - Brazil.
FAU - Macedo, Ariane Vieira Scarlatelli
AU  - Macedo AVS
AD  - Grupo Oncoclínicas do Brasil, Belo Horizonte, MG - Brazil.
FAU - Jorge, Antonio José Lagoeiro
AU  - Jorge AJL
AD  - Programa de Pós-graduação em Ciências Cardiovasculares da Universidade Federal 
      Fluminense (UFF), Niterói, RJ - Brazil.
FAU - Martins, Wolney de Andrade
AU  - Martins WA
AD  - Programa de Pós-graduação em Ciências Cardiovasculares da Universidade Federal 
      Fluminense (UFF), Niterói, RJ - Brazil.
LA  - eng
LA  - por
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - Brazil
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents, Hormonal/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Breast Neoplasms/*drug therapy
MH  - Evidence-Based Medicine
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
PMC - PMC6122903
COIS- Potential Conflict of Interest No potential conflict of interest relevant to this 
      article was reported.
EDAT- 2018/09/06 06:00
MHDA- 2018/10/20 06:00
CRDT- 2018/09/06 06:00
PHST- 2017/10/25 00:00 [received]
PHST- 2018/06/12 00:00 [accepted]
PHST- 2018/09/06 06:00 [entrez]
PHST- 2018/09/06 06:00 [pubmed]
PHST- 2018/10/20 06:00 [medline]
AID - S0066-782X2018001400205 [pii]
AID - 10.5935/abc.20180138 [doi]
PST - ppublish
SO  - Arq Bras Cardiol. 2018 Aug;111(2):205-212. doi: 10.5935/abc.20180138.

PMID- 28463766
OWN - NLM
STAT- MEDLINE
DCOM- 20181015
LR  - 20181015
IS  - 1095-7103 (Electronic)
IS  - 0021-9797 (Linking)
VI  - 501
DP  - 2017 Sep 1
TI  - One-step synthesis of porous copper oxide for electrochemical sensing of 
      acetylsalicylic acid in the real sample.
PG  - 350-356
LID - S0021-9797(17)30491-5 [pii]
LID - 10.1016/j.jcis.2017.04.074 [doi]
AB  - A Facile approach of one-step synthesis was employed to prepare porous CuO at 
      different annealing temperature and characterized by using numerous analytical 
      techniques. Moreover, the electrochemical sensing application of CuO modified 
      glassy carbon electrode was studied and recorded using various electrochemical 
      techniques. From the results, it was interpreted that the CuO prepared at 350°C 
      exhibits satisfactorily electrochemical determination of Acetylsalicylic acid 
      (ASA) with unique sensitivity, linear range and limit of detection of about 
      831.65µA mM(-1)cm(-2), 0.1-714µM and 0.037µM respectively. The proposed sensor 
      also shows good electrocatalytic performance in real sample analysis with 
      acceptable results.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Sivakumar, Mani
AU  - Sivakumar M
AD  - Electroanalysis and Bioelectrochemistry Lab, Department of Chemical Engineering 
      and Biotechnology, National Taipei University of Technology, Taipei 10608, 
      Taiwan.
FAU - Sakthivel, Mani
AU  - Sakthivel M
AD  - Electroanalysis and Bioelectrochemistry Lab, Department of Chemical Engineering 
      and Biotechnology, National Taipei University of Technology, Taipei 10608, 
      Taiwan.
FAU - Chen, Shen-Ming
AU  - Chen SM
AD  - Electroanalysis and Bioelectrochemistry Lab, Department of Chemical Engineering 
      and Biotechnology, National Taipei University of Technology, Taipei 10608, 
      Taiwan. Electronic address: smchen78@ms15.hinet.net.
FAU - Cheng, Yi-Hui
AU  - Cheng YH
AD  - Electroanalysis and Bioelectrochemistry Lab, Department of Chemical Engineering 
      and Biotechnology, National Taipei University of Technology, Taipei 10608, 
      Taiwan.
FAU - Pandi, Karuppiah
AU  - Pandi K
AD  - Electroanalysis and Bioelectrochemistry Lab, Department of Chemical Engineering 
      and Biotechnology, National Taipei University of Technology, Taipei 10608, 
      Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20170425
PL  - United States
TA  - J Colloid Interface Sci
JT  - Journal of colloid and interface science
JID - 0043125
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets)
RN  - 7440-44-0 (Carbon)
RN  - 789U1901C5 (Copper)
RN  - R16CO5Y76E (Aspirin)
RN  - T8BEA5064F (cuprous oxide)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis
MH  - Aspirin/*analysis
MH  - Carbon/chemistry
MH  - Chemistry Techniques, Synthetic
MH  - Copper/*chemistry
MH  - Electrochemical Techniques/instrumentation/*methods
MH  - Electrodes
MH  - Equipment Design
MH  - Hot Temperature
MH  - Porosity
MH  - Tablets
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Electrochemical sensor
OT  - Glucose
OT  - Porous CuO
EDAT- 2017/05/04 06:00
MHDA- 2018/10/16 06:00
CRDT- 2017/05/03 06:00
PHST- 2017/03/11 00:00 [received]
PHST- 2017/04/20 00:00 [revised]
PHST- 2017/04/24 00:00 [accepted]
PHST- 2017/05/04 06:00 [pubmed]
PHST- 2018/10/16 06:00 [medline]
PHST- 2017/05/03 06:00 [entrez]
AID - S0021-9797(17)30491-5 [pii]
AID - 10.1016/j.jcis.2017.04.074 [doi]
PST - ppublish
SO  - J Colloid Interface Sci. 2017 Sep 1;501:350-356. doi: 10.1016/j.jcis.2017.04.074. 
      Epub 2017 Apr 25.

PMID- 6692512
OWN - NLM
STAT- MEDLINE
DCOM- 19840314
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 69
IP  - 3
DP  - 1984 Mar
TI  - The incidence and natural history of pericardial effusion after cardiac 
      surgery--an echocardiographic study.
PG  - 506-11
AB  - One hundred twenty-two consecutive patients (104 men; 18 women) were studied to 
      determine the incidence and natural history of pericardial effusion occurring 2, 
      5, 10, and 20 to 50 days after cardiac surgery. Three patients had pericardial 
      effusions before and 103 patients (91 men; three women) had effusions after 
      surgery. Effusions were first recorded on the second postoperative day in 72 
      patients, on the fifth postoperative day in 29 patients, and on the tenth 
      postoperative day in two patients. In 96 of these patients, effusions reached 
      their maximum size by postoperative day 10. Of the 103 patients with effusions, 
      66 (64%) were followed to complete resolution. A specific pattern was observed in 
      most resolving effusions. The echo-free space diagnostic of pericardial effusion 
      became progressively more echo-dense as the effusion diminished in size. As the 
      effusion became echo-dense, the posterior pericardium, which had been motionless, 
      resumed its normal systolic anterior motion. One patient developed cardiac 
      tamponade on postoperative day 3. We conclude that pericardial effusion occurs 
      frequently after cardiac surgery, but that associated complications are rare.
FAU - Weitzman, L B
AU  - Weitzman LB
FAU - Tinker, W P
AU  - Tinker WP
FAU - Kronzon, I
AU  - Kronzon I
FAU - Cohen, M L
AU  - Cohen ML
FAU - Glassman, E
AU  - Glassman E
FAU - Spencer, F C
AU  - Spencer FC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - *Cardiac Surgical Procedures
MH  - Echocardiography
MH  - Female
MH  - Humans
MH  - Indomethacin/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Pericardial Effusion
MH  - Postoperative Care
MH  - Postoperative Complications
MH  - Prednisone/therapeutic use
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
AID - 10.1161/01.cir.69.3.506 [doi]
PST - ppublish
SO  - Circulation. 1984 Mar;69(3):506-11. doi: 10.1161/01.cir.69.3.506.

PMID- 6787630
OWN - NLM
STAT- MEDLINE
DCOM- 19810810
LR  - 20191031
IS  - 0161-4630 (Print)
IS  - 0161-4630 (Linking)
VI  - 6
IP  - 2
DP  - 1981 Feb
TI  - Salicylic acid inhibition of the irreversible effect of acetylsalicyclic aicd on 
      prostaglandin synthetase may be due to competition for the enzyme cationic 
      binding site.
PG  - 161-4
AB  - Salicylic acid (SA), a weak inhibitor of the prostaglandin endoperoxide 
      synthetase or fatty acid cyclooxygenase enzyme, is known to prevent irreversible 
      enzyme inhibition by acetylsalicylic acid (ASA). The interaction of arachidonic 
      acid with ferrous sulfate was used as a model to study the reaction of the fatty 
      acid with the postulated enzymic cationic binding site on Fe2+-heme. SA was as 
      potent as ASA in inhibiting the cooxygenation of arachidonic acid and ferrous 
      sulfate. The results suggests that SA could complete effectively for the enzyme 
      cationic site with ASA. Thus SA may block ASA acetylation of the cyclooxygenase 
      by preventing ASA from binding to this site.
FAU - Peterson, D A
AU  - Peterson DA
FAU - Gerrard, J M
AU  - Gerrard JM
FAU - Rao, G H
AU  - Rao GH
FAU - White, J G
AU  - White JG
LA  - eng
GR  - AM-06317/AM/NIADDK NIH HHS/United States
GR  - HL-06314/HL/NHLBI NIH HHS/United States
GR  - HL-11880/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Prostaglandins Med
JT  - Prostaglandins and medicine
JID - 7810330
RN  - 0 (Arachidonic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Ferrous Compounds)
RN  - 0 (Salicylates)
RN  - 39R4TAN1VT (ferrous sulfate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acids
MH  - Aspirin/*antagonists & inhibitors
MH  - Binding, Competitive
MH  - Chemical Phenomena
MH  - Chemistry
MH  - *Cyclooxygenase Inhibitors
MH  - Ferrous Compounds
MH  - Models, Chemical
MH  - Salicylates/*pharmacology
MH  - Spectrophotometry
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
AID - 10.1016/0161-4630(81)90087-2 [doi]
PST - ppublish
SO  - Prostaglandins Med. 1981 Feb;6(2):161-4. doi: 10.1016/0161-4630(81)90087-2.

PMID- 33956420
OWN - NLM
STAT- MEDLINE
DCOM- 20210827
LR  - 20220520
IS  - 1944-8252 (Electronic)
IS  - 1944-8244 (Print)
IS  - 1944-8244 (Linking)
VI  - 13
IP  - 19
DP  - 2021 May 19
TI  - Modulating Mechanical and Shape-Memory Properties while Mitigating 
      Degradation-Induced Inflammation of Polylactides by Pendant Aspirin 
      Incorporation.
PG  - 22271-22281
LID - 10.1021/acsami.1c06178 [doi]
AB  - Synergistically modulating mechanical properties and improving shape-memory 
      performance while mitigating degradation-induced chronic inflammation of 
      polylactide (PLA)-based implants for biomedical applications remain elusive. We 
      test the hypothesis that copolymerizing aspirin-functionalized glycolide with 
      d,l-lactide could enhance the thermal processing, toughness, and shape-memory 
      efficiency of the copolymer while mitigating local inflammatory responses upon 
      its degradation. The content of pendant aspirin was readily modulated by monomer 
      feeds during ring-opening polymerization, and the copolymers with ∼10% or less 
      aspirin pendants exhibited gigapascal-tensile moduli at body temperature and 
      significantly improved fracture toughness and energy dissipation that positively 
      correlated with the aspirin pendant content. The copolymers also exhibited 
      excellent thermal-healing and shape-memory efficacy, achieving a >97% temporary 
      shape fixing ratio at room temperature and facile shape recovery at 50-65 °C. 
      These drastic improvements were attributed to the dynamic hydrophobic 
      aggregations among aspirin pendants that strengthen glassy-state physical 
      entanglement of PLA while readily dissociating under stress/thermal activation. 
      When subcutaneously implanted, the copolymers mitigated degradation-induced 
      inflammation due to concomitant hydrolytic release of aspirin without suppressing 
      early acute inflammatory responses. The incorporation of aspirin pendants in PLA 
      represents a straightforward and innovative strategy to enhance the toughness, 
      shape-memory performance, and in vivo safety of this important class of 
      thermoplastics for biomedical applications.
FAU - Xu, Xiaowen
AU  - Xu X
AUID- ORCID: 0000-0003-1404-6619
AD  - Department of Orthopedics & Physical Rehabilitation, University of Massachusetts 
      Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01655, United 
      States.
FAU - Zhang, Jing
AU  - Zhang J
AUID- ORCID: 0000-0003-0541-7721
AD  - Department of Orthopedics & Physical Rehabilitation, University of Massachusetts 
      Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01655, United 
      States.
FAU - Filion, Tera M
AU  - Filion TM
AD  - Department of Orthopedics & Physical Rehabilitation, University of Massachusetts 
      Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01655, United 
      States.
FAU - Akalin, Ali
AU  - Akalin A
AD  - Department of Pathology, University of Massachusetts Medical School, 55 Lake 
      Avenue North, Worcester, Massachusetts 01655, United States.
FAU - Song, Jie
AU  - Song J
AUID- ORCID: 0000-0001-7554-5564
AD  - Department of Orthopedics & Physical Rehabilitation, University of Massachusetts 
      Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01655, United 
      States.
LA  - eng
GR  - R01 AR055615/AR/NIAMS NIH HHS/United States
GR  - R01 GM088678/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20210506
PL  - United States
TA  - ACS Appl Mater Interfaces
JT  - ACS applied materials & interfaces
JID - 101504991
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Polyesters)
RN  - 459TN2L5F5 (poly(lactide))
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/*chemistry
MH  - Calorimetry, Differential Scanning
MH  - Carbon-13 Magnetic Resonance Spectroscopy
MH  - Cells, Cultured
MH  - Inflammation/drug therapy/*metabolism
MH  - Male
MH  - Mechanical Phenomena
MH  - Polyesters/*chemistry
MH  - Proton Magnetic Resonance Spectroscopy
MH  - Rats
MH  - Rats, Sprague-Dawley
PMC - PMC8151694
MID - NIHMS1700301
OTO - NOTNLM
OT  - bone tissue engineering
OT  - inflammatory response
OT  - nonsteroidal anti-inflammatory drug
OT  - polylactic acid
OT  - shape memory
OT  - thermal healing
EDAT- 2021/05/07 06:00
MHDA- 2021/08/28 06:00
CRDT- 2021/05/06 17:23
PHST- 2021/05/07 06:00 [pubmed]
PHST- 2021/08/28 06:00 [medline]
PHST- 2021/05/06 17:23 [entrez]
AID - 10.1021/acsami.1c06178 [doi]
PST - ppublish
SO  - ACS Appl Mater Interfaces. 2021 May 19;13(19):22271-22281. doi: 
      10.1021/acsami.1c06178. Epub 2021 May 6.

PMID- 6195479
OWN - NLM
STAT- MEDLINE
DCOM- 19831220
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 5
IP  - 5
DP  - 1983 Sep-Oct
TI  - Influence of aspirin on the hemodynamic effects of sublingual nitroglycerin.
PG  - 874-7
AB  - We studied the possible interaction between aspirin and nitroglycerin (NTG) in 
      seven healthy volunteers. Effects of NTG (0.8 mg sublingual spray) were assessed 
      by the decrease in diastolic arterial pressure, increase in heart rate, and 
      decrease in M-mode echocardiographic end-diastolic and end-systolic diameters of 
      the left ventricle. Measurements were performed before and during 30 min after 
      NTG. Plasma levels of NTG were monitored during the experimental procedure. Each 
      of the following trials was repeated three times, in random order, in each 
      volunteer: NTG without aspirin pretreatment, NTG 1 h after 1 g of oral aspirin, 
      and NTG after 8 days of aspirin, 500 mg every 48 h. Aspirin at the 1-g dose level 
      significantly increased the effects of NTG on diastolic blood pressure (p less 
      than 0.05) and left ventricular end-diastolic (p less than 0.001) and 
      end-systolic (p less than 0.001) diameters. Aspirin (1 g) significantly increased 
      (p less than 0.01) mean NTG plasma levels from 0.24 +/- 0.13 ng . ml-1 (control) 
      to 0.37 +/- 0.26 ng . ml-1. We conclude that pretreatment with 1 g of aspirin 
      increases NTG plasma levels and therefore significantly enhances the 
      pharmacodynamic effects of NTG.
FAU - Weber, S
AU  - Weber S
FAU - Rey, E
AU  - Rey E
FAU - Pipeau, C
AU  - Pipeau C
FAU - Lutfalla, G
AU  - Lutfalla G
FAU - Richard, M O
AU  - Richard MO
FAU - Daoud-El-Assaf, H
AU  - Daoud-El-Assaf H
FAU - Olive, G
AU  - Olive G
FAU - Degeorges, M
AU  - Degeorges M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Drug Interactions
MH  - Echocardiography
MH  - Heart Rate/drug effects
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Male
MH  - Nitroglycerin/administration & dosage/*blood
EDAT- 1983/09/01 00:00
MHDA- 1983/09/01 00:01
CRDT- 1983/09/01 00:00
PHST- 1983/09/01 00:00 [pubmed]
PHST- 1983/09/01 00:01 [medline]
PHST- 1983/09/01 00:00 [entrez]
AID - 10.1097/00005344-198309000-00026 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1983 Sep-Oct;5(5):874-7. doi: 
      10.1097/00005344-198309000-00026.

PMID- 14614633
OWN - NLM
STAT- MEDLINE
DCOM- 20031223
LR  - 20131121
IS  - 1300-4948 (Print)
IS  - 1300-4948 (Linking)
VI  - 14
IP  - 2
DP  - 2003 Jun
TI  - The effects of ursodeoxycholic acid alone and ursodeoxycholic acid plus low-dose 
      acetylsalicylic acid on radiolucent gallstones.
PG  - 91-6
AB  - BACKGROUND/AIMS: Mucin, a high molecular weight glycoprotein secreted by the 
      gallbladder and biliary duct epithelium, is a pronucleating agent in experimental 
      and human gallstone disease. Blockage of mucin release with aspirin inhibits the 
      formation of primary gallstones in animal models. The aim of this study was to 
      compare the effects of ursodeoxycholic acid alone and plus low-dose aspirin on 
      dissolution of solitary or multiple gallstones. METHODS: There were three 
      treatment groups comprising 43 patients with cholesterol gallstones: Group I 
      (n=16, 13 females, three males) was given ursodeoxycholic acid (15 mg. kg. day) 
      alone and Group II (n=14, 12 females, two males) was treated with aspirin (100 
      mg/day) in addition to ursodeoxycholic acid cholic. Group III was a control group 
      of 13 cases (11 females, two males) who were monitored without medical treatment. 
      Stone dissolution rates were evaluated sonographically in all patients at three 
      month intervals during the treatment period. RESULTS: After 12 months of 
      treatment, stone dissolution was found in six (37.5%) of the patients in Group I 
      and six (42.8%) of the patients in Group II. The difference in both treatment 
      groups was significant compared to controls (p<0.05) but there was no significant 
      difference between the two treatment groups (p>0.05). Of the cases in whom 
      dissolution was achieved, all patients had multiple gallstones except for one 
      with a solitary stone in Group I. Gallstones were not dissolved of any subject of 
      group III. CONCLUSIONS: The results showed that ursodeoxycholic acid cholic 
      therapy is more effective in the dissolution of multiple gallstones than of 
      solitary ones. Combination with aspirin did not potentiate the efficacy of 
      ursodeoxycholic acid cholic.
FAU - Tuncer, Ilyas
AU  - Tuncer I
AD  - Department of Gastroenterology, Yuzuncu Yil University Medical Faculty, Van, 
      Turkey. iltuncer@yahoo.com
FAU - Harman, Mustafa
AU  - Harman M
FAU - Mercan, Ridvan
AU  - Mercan R
FAU - Oztürk, Mustafa
AU  - Oztürk M
FAU - Arslan, Ismail
AU  - Arslan I
FAU - Meral, Cezmi
AU  - Meral C
FAU - Türkdoğan, M Kürşat
AU  - Türkdoğan MK
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Turk J Gastroenterol
JT  - The Turkish journal of gastroenterology : the official journal of Turkish Society 
      of Gastroenterology
JID - 9515841
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cholagogues and Choleretics)
RN  - 724L30Y2QR (Ursodeoxycholic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cholagogues and Choleretics/*therapeutic use
MH  - Cholecystolithiasis/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ursodeoxycholic Acid/*therapeutic use
EDAT- 2003/11/14 05:00
MHDA- 2003/12/24 05:00
CRDT- 2003/11/14 05:00
PHST- 2003/11/14 05:00 [pubmed]
PHST- 2003/12/24 05:00 [medline]
PHST- 2003/11/14 05:00 [entrez]
PST - ppublish
SO  - Turk J Gastroenterol. 2003 Jun;14(2):91-6.

PMID- 9760006
OWN - NLM
STAT- MEDLINE
DCOM- 19981211
LR  - 20131121
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 36
IP  - 9
DP  - 1998 Sep
TI  - Long-term therapy with policosanol improves treadmill exercise-ECG testing 
      performance of coronary heart disease patients.
PG  - 469-73
AB  - This study examined the effects of long-term lipid-lowering therapy with 
      policosanol on the clinical evolution, and exercise-ECG testing responses of 45 
      coronary heart disease (CHD) patients with myocardial ischemia, documented by 
      exercise 201T1-myocardial perfusion scintigraphy, in an overall randomized, 
      double-blind, placebo-controlled trial, made for different test endpoints. 
      Fifteen patients were treated with 5 mg of policosanol twice daily; another 15 
      patients were administered the same drug dose plus 125 mg aspirin; and the other 
      15 patients received placebo plus equal aspirin dose. They were followed for 20 
      months, previous baseline observations, with treadmill exercise-ECG, besides 
      serum lipid test. Beneficial changes on proportions among the 2 policosanol 
      groups and the placebo group, showed an increment on functional capacity class, a 
      decrement on rest and exercise angina, and a significant decrease in cardiac 
      events, and in ischemic ST segment response, especially in the policosanol plus 
      aspirin group (p = 0.05, X2(2df) = 5.8; p = 0.04, p = 0.02; Fisher). After 
      treatment, sets of mean changes revealed an increase on maximum oxygen uptake, 
      and a decline on double product simultaneously in both policosanol groups (p < or 
      = 0.02, p < or = 0.002; Pillais, Hotellings' T2), while the placebo group was 
      impaired. Aerobic functional capacity percent showed an increment in policosanol 
      groups (p < or = 0.05, paired T). Lipid levels improved as other endpoints 
      already reported. A supposed ergogenic effect of octacosanol, policosanol's main 
      active compound, was not detected with this design. These results show that 
      policosanol-treated CHD patients improved clinical evolution, and exercise-ECG 
      responses, owing to the amelioration of myocardial ischemia, even more when 
      administered with aspirin.
FAU - Stüsser, R
AU  - Stüsser R
AD  - Clinical Research Center, Havana University, Playa, Cuba.
FAU - Batista, J
AU  - Batista J
FAU - Padrón, R
AU  - Padrón R
FAU - Sosa, F
AU  - Sosa F
FAU - Pereztol, O
AU  - Pereztol O
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Fatty Alcohols)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 142583-61-7 (policosanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticholesteremic Agents/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - *Exercise Test/drug effects
MH  - Fatty Alcohols/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
EDAT- 1998/10/06 00:00
MHDA- 1998/10/06 00:01
CRDT- 1998/10/06 00:00
PHST- 1998/10/06 00:00 [pubmed]
PHST- 1998/10/06 00:01 [medline]
PHST- 1998/10/06 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 1998 Sep;36(9):469-73.

PMID- 9496933
OWN - NLM
STAT- MEDLINE
DCOM- 19980319
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 114
IP  - 3
DP  - 1998 Mar
TI  - Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal 
      adenomas.
PG  - 441-7
AB  - BACKGROUND & AIMS: Aspirin and nonsteroidal anti-inflammatory drugs have been 
      reported to protect against the development of colorectal cancer. Because 
      adenomas are precursors to most colorectal cancers, the aim of this study was to 
      examine the relationship of these medications to the risk for colorectal adenomas 
      in a colonoscopy-based case-control study. METHODS: Study participants were drawn 
      from patients who underwent colonoscopy at the University of North Carolina 
      Hospitals. Medication use was assessed by telephone using a comprehensive list of 
      prescription and nonprescription drugs as well as questions about dietary and 
      lifestyle factors that might be relevant for adenoma development. RESULTS: There 
      were 210 patients with adenomas and 169 adenoma-free controls. After adjusting 
      for potential confounders, regular users were half as likely to currently have 
      adenomas compared with nonusers (adjusted odds ratio, 0.56; 95% confidence 
      interval, 0.34-0.92). Regular users who stopped medication at least 1 year before 
      colonoscopy were still protected (adjusted odds ratio, 0.59; 95% confidence 
      interval, 0.21-1.67), although small numbers make this conclusion tentative. The 
      protective effects of aspirin and the nonaspirin nonsteroidal anti-inflammatory 
      drugs were similar. CONCLUSIONS: The results suggest that aspirin and 
      nonsteroidal anti-inflammatory drugs cause early disruption of the 
      adenoma-carcinoma sequence. The challenge for the future will be to learn more 
      about dose, duration, and mechanism of action.
FAU - Sandler, R S
AU  - Sandler RS
AD  - Center for Gastrointestinal Biology and Disease, and Department of Epidemiology, 
      University of North Carolina at Chapel Hill, 27599-7080, USA.
FAU - Galanko, J C
AU  - Galanko JC
FAU - Murray, S C
AU  - Murray SC
FAU - Helm, J F
AU  - Helm JF
FAU - Woosley, J T
AU  - Woosley JT
LA  - eng
GR  - P30 DK34987/DK/NIDDK NIH HHS/United States
GR  - R01 CA44684/CA/NCI NIH HHS/United States
GR  - R01 CA66635/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 1998 Sep-Oct;129(2):49
MH  - Adenoma/*prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Colorectal Neoplasms/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk
EDAT- 1998/03/13 00:00
MHDA- 1998/03/13 00:01
CRDT- 1998/03/13 00:00
PHST- 1998/03/13 00:00 [pubmed]
PHST- 1998/03/13 00:01 [medline]
PHST- 1998/03/13 00:00 [entrez]
AID - S0016508598002121 [pii]
AID - 10.1016/s0016-5085(98)70526-8 [doi]
PST - ppublish
SO  - Gastroenterology. 1998 Mar;114(3):441-7. doi: 10.1016/s0016-5085(98)70526-8.

PMID- 10605601
OWN - NLM
STAT- MEDLINE
DCOM- 20000113
LR  - 20131121
IS  - 0365-8341 (Print)
IS  - 0365-8341 (Linking)
VI  - 206
DP  - 1999
TI  - In vivo microdialysis for the investigation of drug levels in the dermis and the 
      effect of barrier perturbation on cutaneous drug penetration. Studies in hairless 
      rats and human subjects.
PG  - 1-59
AB  - The thesis opens with review chapters concerning theoretical and practical 
      aspects of the investigation of drug contents in the skin. A discussion of the 
      advantages and limitations of the established methods as well as the relatively 
      new sampling method of microdialysis, which is employed in the experimental 
      section, is given. Factors influencing the barrier function of the normal human 
      skin are described as are the alterations in skin barrier function found in 
      diseased and experimentally barrier perturbed skin. The microdialysis technique 
      consists of introducing an ultra thin, semipermeable tube, a so-called probe, in 
      the dermis. The tube is connected to a precision pump, which provides a steady 
      flow of a tissue-compatible fluid through the probe at a very low flow. Smaller 
      molecules in the tissue, among them the non-protein bound fraction of the drug 
      content in the extracellular fluid, will passively diffuse across the surface of 
      the membrane and thus enter the flow of the perfusate, which is sampled at 
      regular intervals and analysed. Microdialysis is used for the determination of 
      drug levels in the skin after topical as well as systemic drug delivery in the 
      experimental part of the thesis. The method is not applicable to the 
      investigation of all drugs or compounds, as we have shown that it is not feasible 
      to sample highly protein-bound drugs or very lipophilic drugs by microdialysis 
      without further development of the method. The investigation of topical drug 
      administration consists of 2 studies of cutaneous penetration of a model drug, 
      salicylic acid, initially investigated in hairless rats and subsequently in human 
      volunteers. In both studies, barrier perturbation of the skin was undertaken by 
      physical (removal of the stratum corneum by repeated tape stripping) or chemical 
      (treatment with acetone) methods or by provocation of irritative dermatitis (by 
      application of sodium lauryl sulphate, a detergent). Prior to the penetration 
      experiment, the barrier damage inflicted was quantified by non-invasive 
      measurements of transepidermal, water loss and erythema. The penetration of 
      salicylic acid, applied in an ethanol solution in chambers glued to the skin in 
      the barrier perturbed areas, was measured by microdialysis sampling of the drug 
      level in the underlying dermis. At the end of the experiment, probe depth in the 
      dermis and skin thickness were measured by ultrasound scanning. In humans and 
      hairless rats alike, the cutaneous drug penetration was highly increased in tape 
      stripped skin (157- and 170-fold increased, respectively, in comparison to the 
      penetration in unmodified skin) and in skin with irritative dermatitis (46- and 
      80-fold increased). Delipidization by acetone led to a doubling of the 
      penetration in humans but had no effect on penetration in hairless rats. In both 
      studies a close correlation between the measurements of barrier perturbation by 
      non-invasive methods and the cutaneous drug penetration in the same area was 
      found. In the human study, the barrier perturbation in the acetone treated area 
      was not measurable by non-invasive methods, whereas drug penetration, measured by 
      microdialysis sampling, was significantly increased, indicating that the 
      microdialysis method possesses high sensitivity in the detection and 
      quantification of perturbed skin barrier function. In the human study, a 
      dose-response relationship between the concentration of detergent used for the 
      induction of irritant dermatitis and the ensuing increase in drug penetration 
      across the skin could be demonstrated. In the hairless rat study a correlation 
      between probe depth in the dermis and drug penetration was found, demonstrating 
      that the more superficially a probe was placed, the earlier it would be reached 
      by the influx of drug across the skin. Systemic drug distribution was studied in 
      healthy volunteers following oral administration of 2 g acetylsalicylic acid. 
      (ABSTRACT TRUNCATED)
FAU - Benfeldt, E
AU  - Benfeldt E
AD  - Department of Dermatology, Gentofte Hospital, University of Copenhagen, Hellerup, 
      Denmark.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Norway
TA  - Acta Derm Venereol Suppl (Stockh)
JT  - Acta dermato-venereologica. Supplementum
JID - 0370311
RN  - 0 (Keratolytic Agents)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Cutaneous
MH  - Administration, Oral
MH  - Adult
MH  - Animals
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/analysis/*pharmacokinetics
MH  - Female
MH  - Forearm
MH  - Humans
MH  - Keratolytic Agents/administration & dosage/analysis/*pharmacokinetics
MH  - Male
MH  - *Microdialysis/methods
MH  - Middle Aged
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reference Values
MH  - Salicylic Acid/administration & dosage/analysis/*pharmacokinetics
MH  - Skin/blood supply/*metabolism
MH  - Skin Absorption
MH  - Time Factors
EDAT- 1999/12/22 00:00
MHDA- 1999/12/22 00:01
CRDT- 1999/12/22 00:00
PHST- 1999/12/22 00:00 [pubmed]
PHST- 1999/12/22 00:01 [medline]
PHST- 1999/12/22 00:00 [entrez]
PST - ppublish
SO  - Acta Derm Venereol Suppl (Stockh). 1999;206:1-59.

PMID- 24896242
OWN - NLM
STAT- MEDLINE
DCOM- 20150306
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 6
DP  - 2014
TI  - Hydrogen sulfide releasing aspirin, ACS14, attenuates high glucose-induced 
      increased methylglyoxal and oxidative stress in cultured vascular smooth muscle 
      cells.
PG  - e97315
LID - 10.1371/journal.pone.0097315 [doi]
LID - e97315
AB  - Hydrogen sulfide is a gasotransmitter with vasodilatory and anti-inflammatory 
      properties. Aspirin is an irreversible cyclooxygenase inhibitor anti-inflammatory 
      drug. ACS14 is a novel synthetic hydrogen sulfide releasing aspirin which 
      inhibits cyclooxygenase and has antioxidant effects. Methylglyoxal is a 
      chemically active metabolite of glucose and fructose, and a major precursor of 
      advanced glycation end products formation. Methylglyoxal is harmful when produced 
      in excess. Plasma methylglyoxal levels are significantly elevated in diabetic 
      patients. Our aim was to investigate the effects of ACS14 on methylglyoxal levels 
      in cultured rat aortic vascular smooth muscle cells. We used cultured rat aortic 
      vascular smooth muscle cells for the study. Methylglyoxal was measured by HPLC 
      after derivatization, and nitrite+nitrate with an assay kit. Western blotting was 
      used to determine NADPH oxidase 4 (NOX4) and inducible nitric oxide synthase 
      (iNOS) protein expression. Dicholorofluorescein assay was used to measure 
      oxidative stress. ACS14 significantly attenuated elevation of intracellular 
      methylglyoxal levels caused by incubating cultured vascular smooth muscle cells 
      with methylglyoxal (30 µM) and high glucose (25 mM). ACS14, but not aspirin, 
      caused a significant attenuation of increase in nitrite+nitrate levels caused by 
      methylglyoxal or high glucose. ACS14, aspirin, and sodium hydrogen sulfide (NaHS, 
      a hydrogen sulfide donor), all attenuated the increase in oxidative stress caused 
      by methylglyoxal and high glucose in cultured cells. ACS14 prevented the increase 
      in NOX4 expression caused by incubating the cultured VSMCs with MG (30 µM). 
      ACS14, aspirin and NaHS attenuated the increase in iNOS expression caused by high 
      glucose (25 mM). In conclusion, ACS14 has the novel ability to attenuate an 
      increase in methylglyoxal levels which in turn can reduce oxidative stress, 
      decrease the formation of advanced glycation end products and prevent many of the 
      known deleterious effects of elevated methylglyoxal. Thus, ACS14 has the 
      potential to be especially beneficial for diabetic patients pending further in 
      vivo studies.
FAU - Huang, Qian
AU  - Huang Q
AD  - Department of Pharmacology, College of Medicine, University of Saskatchewan, 
      Saskatoon, Saskatchewan, Canada; King's Lab, School of Pharmacy, Shanghai Jiao 
      Tong University, Shanghai, China.
FAU - Sparatore, Anna
AU  - Sparatore A
AD  - Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Milan, 
      Italy.
FAU - Del Soldato, Piero
AU  - Del Soldato P
AD  - CTG Pharma, Milan, Italy.
FAU - Wu, Lingyun
AU  - Wu L
AD  - Department of Health Sciences, Lakehead University, Thunder Bay, Ontario, Canada; 
      Thunder Bay Regional Research Institute, Thunder Bay, Ontario, Canada.
FAU - Desai, Kaushik
AU  - Desai K
AD  - Department of Pharmacology, College of Medicine, University of Saskatchewan, 
      Saskatoon, Saskatchewan, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140604
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (2-acetyloxybenzoic acid 4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl ester)
RN  - 0 (Disulfides)
RN  - 722KLD7415 (Pyruvaldehyde)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.6.3.- (NADPH Oxidase 4)
RN  - EC 1.6.3.- (NADPH Oxidases)
RN  - EC 1.6.3.- (Nox4 protein, rat)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta/drug effects/metabolism
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cell Line
MH  - Cells, Cultured
MH  - Disulfides/*pharmacology
MH  - Glucose/*pharmacology
MH  - Muscle, Smooth, Vascular/*drug effects/metabolism
MH  - Myocytes, Smooth Muscle/*drug effects/metabolism
MH  - NADPH Oxidase 4
MH  - NADPH Oxidases/metabolism
MH  - Nitric Oxide Synthase Type II/metabolism
MH  - Oxidative Stress/*drug effects/physiology
MH  - Pyruvaldehyde/*metabolism
MH  - Rats
PMC - PMC4045575
COIS- Competing Interests: At the time of the study, Dr. Piero Del Soldato was a 
      shareholder of CTG Pharma, Milan, Italy. Professor Anna Sparatore received a 
      grant from CTG Pharma. This company had patents on reagents used in this study. 
      CTG Pharma ceased operations and is now closed, The patent on ACS 14 has been 
      abandoned. This does not alter the authors' adherence to all PLOS ONE policies on 
      sharing data and materials.
EDAT- 2014/06/05 06:00
MHDA- 2015/03/07 06:00
CRDT- 2014/06/05 06:00
PHST- 2013/11/22 00:00 [received]
PHST- 2014/04/18 00:00 [accepted]
PHST- 2014/06/05 06:00 [entrez]
PHST- 2014/06/05 06:00 [pubmed]
PHST- 2015/03/07 06:00 [medline]
AID - PONE-D-13-49331 [pii]
AID - 10.1371/journal.pone.0097315 [doi]
PST - epublish
SO  - PLoS One. 2014 Jun 4;9(6):e97315. doi: 10.1371/journal.pone.0097315. eCollection 
      2014.

PMID- 23625286
OWN - NLM
STAT- MEDLINE
DCOM- 20131126
LR  - 20211203
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 58
IP  - 9
DP  - 2013 Sep
TI  - Colonic 15-PGDH levels are stable across distance and time and are not perturbed 
      by aspirin intervention.
PG  - 2615-22
LID - 10.1007/s10620-013-2670-5 [doi]
AB  - BACKGROUND AND AIMS: 15-Hydroxprostaglandin dehydrogenase (15-PGDH) mediates a 
      colon neoplasia suppressor pathway, acting through metabolic antagonism of 
      cyclooxygenase-mediated colon carcinogenesis. To determine whether the colon 
      tumor prevention activity of 15-PGDH acts as a constant or variable effect among 
      individuals, we determined whether 15-PGDH levels remain stable over subsite and 
      time in the human colon, determined the extent of differences in 15-PGDH levels 
      between different individuals, and determined whether 15-PGDH modulation mediates 
      any part of the anti-colon tumor effect of aspirin. METHODS: Using real-time PCR, 
      we measured 15-PGDH mRNA to determine the correlation of 15-PGDH level in 
      replicate colon biopsies, in biopsies from throughout the length of the colon, in 
      repeat biopsies taken 4 months apart, and in paired biopsies of individuals taken 
      before and after aspirin treatment, and by Western-blot for 15-PGDH protein in 
      mice. RESULTS: Colonic 15-PGDH levels varied 4.4-fold across the human 
      population. Within individuals, 15-PGDH levels proved highly reproducible (r=0.81 
      in duplicate biopsies) and stable along the length of the colon, with average 
      15-PGDH levels deviating by only 17% from rectum to cecum. An individual's 
      15-PGDH levels are also highly stable over time, with a median coefficient of 
      variation over a 4-month interval of only 12%. Last, colonic 15-PGDH levels 
      proved resistant to alteration by aspirin, with only a 10% difference in 15-PGDH 
      levels measured before and after aspirin treatment. CONCLUSIONS: 15-PGDH levels 
      vary across the population in a stable and reproducible manner, and are resistant 
      to alteration by aspirin. 15-PGDH represents an independent target for modulation 
      by candidate colon tumor chemopreventive agents.
FAU - Fink, Stephen P
AU  - Fink SP
AD  - Department of Medicine, Case Western Reserve University and Case Medical Center, 
      10900 Euclid Ave., Wolstein Research Building, Rm 3-128, Cleveland, OH 
      44106-7285, USA. stephen.fink@case.edu
FAU - Yang, Dong-Hoon
AU  - Yang DH
FAU - Barnholtz-Sloan, Jill S
AU  - Barnholtz-Sloan JS
FAU - Ryu, Yeon-Mi
AU  - Ryu YM
FAU - Mikkola, Debra
AU  - Mikkola D
FAU - Potter, John D
AU  - Potter JD
FAU - Lampe, Johanna W
AU  - Lampe JW
FAU - Markowitz, Sanford D
AU  - Markowitz SD
FAU - Myung, Seung-Jae
AU  - Myung SJ
LA  - eng
GR  - 1P50CA150964/CA/NCI NIH HHS/United States
GR  - R01 CA094954/CA/NCI NIH HHS/United States
GR  - R01-CA94954/CA/NCI NIH HHS/United States
GR  - P50 CA150964/CA/NCI NIH HHS/United States
GR  - P30 CA043703/CA/NCI NIH HHS/United States
GR  - P30-CA043703/CA/NCI NIH HHS/United States
GR  - U01 CA152756/CA/NCI NIH HHS/United States
GR  - 1U01 CA152756-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130427
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Transforming Growth Factor beta)
RN  - EC 1.1.1.- (Hydroxyprostaglandin Dehydrogenases)
RN  - EC 1.1.1.141 (15-hydroxyprostaglandin dehydrogenase)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Chemoprevention
MH  - Colon/drug effects/*enzymology
MH  - Colonic Neoplasms/*prevention & control
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Female
MH  - Humans
MH  - Hydroxyprostaglandin Dehydrogenases/*metabolism
MH  - Male
MH  - Protein Serine-Threonine Kinases/metabolism
MH  - RNA, Messenger/metabolism
MH  - Receptor, Transforming Growth Factor-beta Type II
MH  - Receptors, Transforming Growth Factor beta/metabolism
MH  - Rectum/enzymology
PMC - PMC3769508
MID - NIHMS473320
COIS- Disclosure of potential conflicts of interest: No potential conflicts of interest 
      are present.
EDAT- 2013/04/30 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/12/11 00:00 [received]
PHST- 2013/03/27 00:00 [accepted]
PHST- 2013/04/30 06:00 [entrez]
PHST- 2013/04/30 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 10.1007/s10620-013-2670-5 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2013 Sep;58(9):2615-22. doi: 10.1007/s10620-013-2670-5. Epub 2013 
      Apr 27.

PMID- 22724441
OWN - NLM
STAT- MEDLINE
DCOM- 20130225
LR  - 20211021
IS  - 1540-8183 (Electronic)
IS  - 0896-4327 (Print)
IS  - 0896-4327 (Linking)
VI  - 25
IP  - 5
DP  - 2012 Oct
TI  - Safety of temporary and permanent suspension of antiplatelet therapy after drug 
      eluting stent implantation in contemporary "real-world" practice.
PG  - 482-92
LID - 10.1111/j.1540-8183.2012.00746.x [doi]
AB  - OBJECTIVES: To define the incidence of stent thrombosis (ST) and/or AMI (ST/AMI) 
      associated with temporary or permanent suspension of dual antiplatelet therapy 
      (DAPT) after coronary drug-eluting stent (DES) implantation in "real-world" 
      patients, and additional factors influencing these events. BACKGROUND: Adherence 
      to DAPT is critical for avoiding ST following DES implantation. However, the 
      outcomes of patients undergoing antiplatelet therapy withdrawal following DES 
      implantation remain to be clearly described. METHODS: Patients receiving DES from 
      05/01/2003 to 05/01/2008 were identified from a single-center registry. Complete 
      follow-up data were available for 5,681 patients (67% male, age 66 ± 11 years, 
      duration 1,108 ± 446 days) who were included in this analysis. RESULTS: 
      Uninterrupted DAPT was maintained in 4,070/5,681 (71.6%) patients, with an annual 
      ST/AMI rate of 0.43%. Antiplatelet therapy was commonly ceased for 
      gastrointestinal-related issues, dental procedures or 
      noncardiac/nongastrointestinal surgery. Temporary DAPT suspension occurred in 
      593/5,681 (10.4%) patients for 17.6 ± 74.1 days, with 6/593 (1.0%) experiencing 
      ST/AMI during this period. Of patients permanently ceasing aspirin (n = 187, mean 
      338 ± 411 days poststenting), clopidogrel (n = 713, mean 614 ± 375 days) or both 
      agents (n = 118, mean 459 ± 408 days), ST/AMI was uncommon with an annual rate of 
      0.1-0.2%. Overall, independent predictors of ST/AMI were unstable initial 
      presentation, uninterrupted DAPT and lower left ventricular ejection fraction. 
      Factors predicting uninterrupted DAPT included diabetes, unstable presentation, 
      prior MI, left main coronary PCI, and multivessel coronary disease. CONCLUSIONS: 
      In real-world practice, rates of ST/AMI following DES implantation are low, but 
      not insignificant, following aspirin and/or clopidogrel cessation. Use of 
      uninterrupted DAPT appears more common in high-risk patients.
CI  - ©2012, Wiley Periodicals, Inc.
FAU - Kovacic, Jason C
AU  - Kovacic JC
AD  - Cardiac Catheterization Laboratory, Cardiovascular Institute, Mount Sinai 
      Hospital, New York, New York, USA.
FAU - Lee, Paul
AU  - Lee P
FAU - Karajgikar, Rucha
AU  - Karajgikar R
FAU - Baber, Usman
AU  - Baber U
FAU - Narechania, Birju
AU  - Narechania B
FAU - Suleman, Javed
AU  - Suleman J
FAU - Moreno, Pedro R
AU  - Moreno PR
FAU - Sharma, Samin K
AU  - Sharma SK
FAU - Kini, Annapoorna S
AU  - Kini AS
LA  - eng
GR  - K08 HL111330/HL/NHLBI NIH HHS/United States
GR  - T32 HL007824/HL/NHLBI NIH HHS/United States
GR  - 1K08HL111330-01/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20120622
PL  - United States
TA  - J Interv Cardiol
JT  - Journal of interventional cardiology
JID - 8907826
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Coronary Artery Disease/*drug therapy/mortality/therapy
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Health Status Indicators
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Practice Patterns, Physicians'
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & 
      derivatives/therapeutic use
MH  - Time Factors
PMC - PMC3757924
MID - NIHMS501452
EDAT- 2012/06/26 06:00
MHDA- 2013/02/26 06:00
CRDT- 2012/06/26 06:00
PHST- 2012/06/26 06:00 [entrez]
PHST- 2012/06/26 06:00 [pubmed]
PHST- 2013/02/26 06:00 [medline]
AID - 10.1111/j.1540-8183.2012.00746.x [doi]
PST - ppublish
SO  - J Interv Cardiol. 2012 Oct;25(5):482-92. doi: 10.1111/j.1540-8183.2012.00746.x. 
      Epub 2012 Jun 22.

PMID- 3106134
OWN - NLM
STAT- MEDLINE
DCOM- 19870615
LR  - 20190824
IS  - 0306-3623 (Print)
IS  - 0306-3623 (Linking)
VI  - 18
IP  - 2
DP  - 1987
TI  - The search for ideal antidote treatment in Gramoxone intoxication.
PG  - 129-32
AB  - The herbicide Gramoxone (the active ingredient is paraquat) actively accumulates 
      in the lung in the mammalian organism, where it exerts its toxic effect through 
      the generation of oxygen radicals. Efforts were made to counteract the toxic 
      effect in experiments in mice. Its penetration into the cells was blocked with 
      the diamines putrescine and cadaverine. The synthesis of the prostaglandins, 
      which are supposed by responsible for the acute symptoms, was inhibited with 
      Aspisol. Accumulation inhibition with biogenic amines is considered the most 
      effective.
FAU - Barabás, K
AU  - Barabás K
FAU - Szabó, L
AU  - Szabó L
FAU - Matkovics, B
AU  - Matkovics B
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gen Pharmacol
JT  - General pharmacology
JID - 7602417
RN  - 0 (Antidotes)
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - K3Z4F929H6 (Lysine)
RN  - L90BEN6OLL (Cadaverine)
RN  - PLG39H7695 (Paraquat)
RN  - R16CO5Y76E (Aspirin)
RN  - V10TVZ52E4 (Putrescine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Antidotes/*pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cadaverine/pharmacology
MH  - Kidney/metabolism
MH  - Lung/metabolism
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Mice
MH  - Paraquat/antagonists & inhibitors/metabolism/*poisoning
MH  - Prostaglandin Antagonists/pharmacology
MH  - Prostaglandins/biosynthesis
MH  - Putrescine/pharmacology
MH  - Superoxide Dismutase/metabolism
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 0306-3623(87)90238-2 [pii]
AID - 10.1016/0306-3623(87)90238-2 [doi]
PST - ppublish
SO  - Gen Pharmacol. 1987;18(2):129-32. doi: 10.1016/0306-3623(87)90238-2.

PMID- 22513195
OWN - NLM
STAT- MEDLINE
DCOM- 20120716
LR  - 20131121
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 125
IP  - 6
DP  - 2012 Jun
TI  - Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials.
PG  - 560-7
LID - 10.1016/j.amjmed.2012.01.017 [doi]
AB  - OBJECTIVE: Low-dose aspirin is a common strategy for preventing cardiovascular 
      disease and associated mortality. A recent individual patient data meta-analysis 
      of 8 trials of low- and high-dose aspirin, with long-term follow-up, found 
      important reductions in cancer mortality. We aimed to determine whether cancer 
      mortality also is reduced by low-dose aspirin in the shorter term. METHODS: We 
      conducted a comprehensive search of 10 electronic databases up to December 2011. 
      We conducted a meta-analysis using data from all randomized clinical trials 
      evaluating low-dose (75-325 mg) daily aspirin. We extracted data on 
      non-cardiovascular disease mortality and cancer mortality. We pooled studies 
      using a random-effects model and conducted a meta-regression. We supplemented 
      this with a cumulative meta-analysis and trial sequential monitoring analysis. 
      RESULTS: Twenty-three randomized studies reported on nonvascular death. There 
      were 944 nonvascular deaths of 41,398 (2.28%) patients receiving low-dose aspirin 
      and 1074 nonvascular deaths of 41,470 (2.58%) patients not receiving aspirin 
      therapy. The relative risk of nonvascular death was 0.88 (95% confidence interval 
      [CI], 0.81-0.96, I(2) = 0%). Eleven trials included data evaluating cancer 
      mortality involving 16,066 patients. There were 162 of 7998 (2.02%) and 210 of 
      8068 (2.60%) cancer deaths among low-dose aspirin users versus non-aspirin users, 
      respectively, reported over an average follow-up of 2.8 years. The relative risk 
      of cancer mortality was 0.77 (95% CI, 0.63-0.95, I(2) = 0%). Studies demonstrated 
      a significant treatment effect after approximately 4 years of follow-up. The 
      optimal information size analysis showed that a sufficient number of patients had 
      been randomized to provide convincing evidence of a preventive role of low-dose 
      aspirin in nonvascular deaths. CONCLUSION: Nonvascular deaths, including cancer 
      deaths, are reduced with low-dose aspirin.
CI  - Copyright © 2012 Elsevier Inc. All rights reserved.
FAU - Mills, Edward J
AU  - Mills EJ
AD  - Faculty of Health Sciences, University of Ottawa, Ontario, Canada. 
      Edward.mills@uottawa.ca
FAU - Wu, Ping
AU  - Wu P
FAU - Alberton, Mark
AU  - Alberton M
FAU - Kanters, Steve
AU  - Kanters S
FAU - Lanas, Angel
AU  - Lanas A
FAU - Lester, Richard
AU  - Lester R
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20120417
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Med. 2013 Feb;126(2):e11. PMID: 23331451
CIN - Am J Med. 2013 Feb;126(2):e13. PMID: 23331452
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Drug Administration Schedule
MH  - Humans
MH  - Neoplasms/*mortality
MH  - Randomized Controlled Trials as Topic
MH  - Risk
EDAT- 2012/04/20 06:00
MHDA- 2012/07/17 06:00
CRDT- 2012/04/20 06:00
PHST- 2011/11/18 00:00 [received]
PHST- 2012/01/06 00:00 [revised]
PHST- 2012/01/12 00:00 [accepted]
PHST- 2012/04/20 06:00 [entrez]
PHST- 2012/04/20 06:00 [pubmed]
PHST- 2012/07/17 06:00 [medline]
AID - S0002-9343(12)00094-0 [pii]
AID - 10.1016/j.amjmed.2012.01.017 [doi]
PST - ppublish
SO  - Am J Med. 2012 Jun;125(6):560-7. doi: 10.1016/j.amjmed.2012.01.017. Epub 2012 Apr 
      17.

PMID- 33620886
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1473-656X (Electronic)
IS  - 1040-872X (Linking)
VI  - 33
IP  - 2
DP  - 2021 Apr 1
TI  - Low-dose aspirin in pregnancy: who? when? how much? and why?
PG  - 65-71
LID - 10.1097/GCO.0000000000000694 [doi]
AB  - PURPOSE OF REVIEW: The use of low dose aspirin (LDA) has become routine in 
      prenatal care for a variety of diagnoses, most importantly in women with a 
      history of preeclampsia and associated poor pregnancy outcomes. Although LDA is 
      currently indicated in patients considered to be at risk for development of 
      preeclampsia, optimal dosing, timing of treatment initiation, and persons of 
      benefit are under investigation. Several studies have also looked at LDA 
      treatment and its effect on other maternal and fetal outcomes. This review 
      summarizes the current guidelines for the use of LDA, incorporating the most 
      recent research findings, and offers possible future implications of LDA 
      treatment. RECENT FINDINGS: Over 10 years ago, the American College of 
      Obstetricians and Gynecologists, the World Health Organization, and the United 
      States Preventive Service Task Force began publishing guidelines focused on the 
      use of LDA in pregnancy. Since the release of these guidelines, several large 
      studies have re-evaluated the use of LDA with a focus on initiation of treatment 
      and dosing. The combined results of these studies suggest a decreased rate of 
      preeclampsia at aspirin doses >100 mg when treatment is initiated prior to 
      16 weeks of gestation. SUMMARY: Overall, early initiation of LDA has been shown 
      to decrease the development of preeclampsia in patients considered at increased 
      risk. Current literature suggests increasing the recommended dose to >100 mg to 
      optimize these risk reductions. Although LDA use seems promising for other 
      outcomes like preterm delivery and intrauterine growth restriction, further 
      studies to strengthen recommendations are warranted.
CI  - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Mather, Andrew R
AU  - Mather AR
AD  - Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, 
      University of Rochester Medical Center, Rochester, New York, USA.
FAU - Dom, Aaron M
AU  - Dom AM
FAU - Thorburg, Loralei L
AU  - Thorburg LL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Obstet Gynecol
JT  - Current opinion in obstetrics & gynecology
JID - 9007264
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - Female
MH  - Fetal Growth Retardation
MH  - Humans
MH  - Infant, Newborn
MH  - *Pre-Eclampsia/drug therapy/prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Prenatal Care
EDAT- 2021/02/24 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/02/23 15:07
PHST- 2021/02/23 15:07 [entrez]
PHST- 2021/02/24 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - 00001703-202104000-00002 [pii]
AID - 10.1097/GCO.0000000000000694 [doi]
PST - ppublish
SO  - Curr Opin Obstet Gynecol. 2021 Apr 1;33(2):65-71. doi: 
      10.1097/GCO.0000000000000694.

PMID- 7977015
OWN - NLM
STAT- MEDLINE
DCOM- 19941227
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 128
IP  - 6 Pt 2
DP  - 1994 Dec
TI  - Platelet inhibitors and antioxidant vitamins in cardiovascular disease.
PG  - 1333-6
AB  - Considerable research attention has focused on the possible roles of platelet 
      inhibition, principally using aspirin, and antioxidant vitamins in reducing the 
      risks of cardiovascular disease. Data from large-scale randomized trials indicate 
      that aspirin reduces subsequent vascular events among patients with prior 
      myocardial infarction, stroke, transient ischemic attacks, or unstable angina, as 
      well as among patients with acute evolving myocardial infarction. In primary 
      prevention trials, the Physicians' Health Study showed a clear benefit in 
      decreasing risk of a first myocardial infarction in men; the data on stroke and 
      total number of deaths from vascular causes are inadequate. The Women's Health 
      Study, a trial now under way among apparently healthy women, will provide direct 
      evidence on the balance of risks and benefits of aspirin in primary prevention. 
      Antioxidant vitamins are hypothesized to decrease cardiovascular disease risk by 
      several mechanisms, including inhibition of oxidation of low-density lipoprotein 
      cholesterol and decreasing uptake into the coronary endothelium. Promising 
      results have emerged from observational studies, which show that people with high 
      intakes of antioxidant vitamins through diet or supplements have lowered risks of 
      cardiovascular disease; however, unknown or unmeasured factors associated with 
      high antioxidant vitamin intake may explain all or part of the observed 
      associations. Randomized trials to provide reliable data are now ongoing among 
      apparently healthy men and women, as well as among survivors of prior 
      cardiovascular disease events.
FAU - Hennekens, C H
AU  - Hennekens CH
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Antioxidants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vitamins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antioxidants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/prevention & control
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Vitamins/*therapeutic use
RF  - 22
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
AID - 0002-8703(94)90256-9 [pii]
AID - 10.1016/0002-8703(94)90256-9 [doi]
PST - ppublish
SO  - Am Heart J. 1994 Dec;128(6 Pt 2):1333-6. doi: 10.1016/0002-8703(94)90256-9.

PMID- 24799357
OWN - NLM
STAT- MEDLINE
DCOM- 20150416
LR  - 20140721
IS  - 1097-0223 (Electronic)
IS  - 0197-3851 (Linking)
VI  - 34
IP  - 7
DP  - 2014 Jul
TI  - Low-dose aspirin for prevention of adverse outcomes related to abnormal 
      placentation.
PG  - 642-8
LID - 10.1002/pd.4403 [doi]
AB  - Meta-analysis of randomized studies on the use of low-dose aspirin in women at 
      high risk of preeclampsia (PE) has demonstrated that if treatment is initiated at 
      ≤16 weeks' gestation, there is significant reduction in the risk of PE [relative 
      risk (RR) 0.47, 95% confidence interval (CI) 0.36-0.62], fetal growth restriction 
      (RR 0.46, 95% CI 0.33-0.64), preterm birth (RR 0.35, 95% CI 0.22-0.57) and 
      perinatal death (RR 0.41, 95% CI 0.19-0.92), whereas the effect of treatment 
      after 16 weeks is substantially less (RR 0.78, 95% CI 0.61-0.99; RR 0.98, 95% CI 
      0.88-1.08; RR 0.90, 95% CI 0.83-0.97; and RR 0.93, 95% CI 0.73-1.19, 
      respectively). Moreover, the decrease in the risk of PE from early onset 
      treatment seems to be related to the dose of aspirin, and a dose of >80 mg daily 
      should be considered for optimal benefits.
CI  - © 2014 John Wiley & Sons, Ltd.
FAU - Bujold, Emmanuel
AU  - Bujold E
AD  - Department of Obstetrics and Gynecology & Department of Social and Preventive 
      Medicine, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
FAU - Roberge, Stéphanie
AU  - Roberge S
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140529
PL  - England
TA  - Prenat Diagn
JT  - Prenatal diagnosis
JID - 8106540
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Placenta Diseases/*drug therapy
MH  - Placentation/physiology
MH  - Pregnancy
MH  - Pregnancy Complications/*prevention & control
MH  - Pregnancy Outcome
MH  - Randomized Controlled Trials as Topic
EDAT- 2014/05/07 06:00
MHDA- 2015/04/17 06:00
CRDT- 2014/05/07 06:00
PHST- 2014/03/06 00:00 [received]
PHST- 2014/04/28 00:00 [revised]
PHST- 2014/04/28 00:00 [accepted]
PHST- 2014/05/07 06:00 [entrez]
PHST- 2014/05/07 06:00 [pubmed]
PHST- 2015/04/17 06:00 [medline]
AID - 10.1002/pd.4403 [doi]
PST - ppublish
SO  - Prenat Diagn. 2014 Jul;34(7):642-8. doi: 10.1002/pd.4403. Epub 2014 May 29.

PMID- 6468632
OWN - NLM
STAT- MEDLINE
DCOM- 19840924
LR  - 20190908
IS  - 0014-4800 (Print)
IS  - 0014-4800 (Linking)
VI  - 41
IP  - 1
DP  - 1984 Aug
TI  - Model system to study interaction of platelets with damaged arterial wall. I. 
      Inhibition of platelet adhesion to subendothelium by aspirin and dipyridamole.
PG  - 141-52
AB  - An experimental model system has been developed to study the interaction of 
      platelets with a damaged vessel wall, in vivo, without deep surgical 
      intervention. Endothelium of the central ear artery of an anesthetized rabbit is 
      damaged by placing artery forceps on the ear directly over the vessel. Forceps 
      are removed 30 min later and blood flow resumes. After 30 min, blood is washed 
      out with Tyrode's solution and the vessel is perfused with 1% glutaraldehyde 
      solution. Tissue containing the vessel is then removed and further prepared for 
      scanning and transmission electron microscopy. Damage to the endothelium observed 
      by scanning electron microscopy included separation of adjacent endothelial cells 
      (EC); partial destruction and lifting up of some EC, exposing subendothelium; and 
      denudation of larger areas of endothelium. Disc-shaped platelets were seen 
      clinging to some damaged endothelial cells. Platelets adhered, formed pseudopods, 
      and spread over the surface of some areas of exposed subendothelium. The extent 
      of platelet adhesion to exposed subendothelium was estimated by eight "blind" 
      evaluators and the average taken. Aspirin (8 mg/kg, ip) significantly inhibited 
      adhesion (P less than 0.05) when compared to controls. No other agent tested gave 
      significant inhibition after a single treatment. Dipyridamole (1.5 mg/kg, ip) 
      given five times on 3 successive days, inhibited adhesion significantly (P less 
      than 0.001). Heparin (800 U/kg, iv) or dipyridamole (0.7 mg/kg, ip) enhanced the 
      inhibitory effect of aspirin (8 mg/kg, ip), with either combined treatment giving 
      P less than 0.001.
FAU - Silver, M J
AU  - Silver MJ
FAU - Ingerman-Wojenski, C M
AU  - Ingerman-Wojenski CM
FAU - Sedar, A W
AU  - Sedar AW
FAU - Smith, M
AU  - Smith M
LA  - eng
GR  - HL-14890/HL/NHLBI NIH HHS/United States
GR  - T32-HL07371/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Exp Mol Pathol
JT  - Experimental and molecular pathology
JID - 0370711
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteries/*physiology/ultrastructure
MH  - Aspirin/*pharmacology
MH  - Dipyridamole/*pharmacology
MH  - Endothelium/physiology
MH  - Heparin/pharmacology
MH  - Male
MH  - Microscopy, Electron
MH  - Platelet Adhesiveness/*drug effects
MH  - Rabbits
MH  - Vascular Diseases/blood
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 0014-4800(84)90014-5 [pii]
AID - 10.1016/0014-4800(84)90014-5 [doi]
PST - ppublish
SO  - Exp Mol Pathol. 1984 Aug;41(1):141-52. doi: 10.1016/0014-4800(84)90014-5.

PMID- 21512184
OWN - NLM
STAT- MEDLINE
DCOM- 20110805
LR  - 20220302
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 42
IP  - 6
DP  - 2011 Jun
TI  - Cost effectiveness of warfarin versus aspirin in patients older than 75 years 
      with atrial fibrillation.
PG  - 1717-21
LID - 10.1161/STROKEAHA.110.600767 [doi]
AB  - BACKGROUND AND PURPOSE: Oral anticoagulants are effective at reducing stroke 
      compared with aspirin in atrial fibrillation patients older than 75 years. 
      Although the benefits of reduced stroke risk outweigh the risks of bleeding, the 
      cost effectiveness of warfarin in this patient population has not yet been 
      established. METHODS: An economic evaluation was conducted alongside a 
      randomized, controlled trial; 973 patients ≥75 years of age with atrial 
      fibrillation were recruited from primary care and randomly assigned to either 
      take warfarin or aspirin. Follow-up was for a mean of 2.7 years. Costs of 
      thrombotic and hemorrhagic events, anticoagulation clinic visits, and primary 
      care utilization were determined. Clinical benefits were expressed in terms of a 
      primary event avoided: fatal/nonfatal disabling stroke, intracranial hemorrhage, 
      or systemic embolism. A cost-utility analysis was performed using 
      quality-adjusted life years as the benefit measure. RESULTS: Total costs over 4 
      years were lower in the warfarin group (difference, -£165; 95% CI, -£452-£89), 
      primarily driven by the difference in primary event costs. The primary event rate 
      over 4 years was lower in the warfarin group (0.049 versus 0.099), and the 
      quality-adjusted life years score was higher (difference, 0.02; 95% CI, 
      -0.07-0.11). With lower costs and a higher quality-adjusted life years score, 
      warfarin is the dominant treatment, but the differences in both costs and effects 
      are small. CONCLUSIONS: Warfarin is cost-effective compared with aspirin in 
      atrial fibrillation patients age ≥75 years. These data support the anticoagulant 
      therapy option in this high-risk patient population. However, the small 
      differences in costs and effects indicate the importance of exploring patient 
      preferences.
FAU - Jowett, Sue
AU  - Jowett S
AD  - Health Economics Unit, Public Health Building, University of Birmingham, 
      Edgbaston, Birmingham, B15 2TT, UK. s.jowett@bham.ac.uk
FAU - Bryan, Stirling
AU  - Bryan S
FAU - Mant, Jonathan
AU  - Mant J
FAU - Fletcher, Kate
AU  - Fletcher K
FAU - Roalfe, Andrea
AU  - Roalfe A
FAU - Fitzmaurice, David
AU  - Fitzmaurice D
FAU - Lip, Gregory Y H
AU  - Lip GY
FAU - Hobbs, F D Richard
AU  - Hobbs FD
LA  - eng
GR  - G9900264/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110421
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Anticoagulants/economics/therapeutic use
MH  - *Aspirin/economics/therapeutic use
MH  - *Atrial Fibrillation/drug therapy/economics
MH  - *Cost-Benefit Analysis
MH  - Humans
MH  - International Normalized Ratio/economics
MH  - Quality-Adjusted Life Years
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Stroke/drug therapy/economics
MH  - Treatment Outcome
MH  - *Warfarin/economics/therapeutic use
EDAT- 2011/04/23 06:00
MHDA- 2011/08/06 06:00
CRDT- 2011/04/23 06:00
PHST- 2011/04/23 06:00 [entrez]
PHST- 2011/04/23 06:00 [pubmed]
PHST- 2011/08/06 06:00 [medline]
AID - STROKEAHA.110.600767 [pii]
AID - 10.1161/STROKEAHA.110.600767 [doi]
PST - ppublish
SO  - Stroke. 2011 Jun;42(6):1717-21. doi: 10.1161/STROKEAHA.110.600767. Epub 2011 Apr 
      21.

PMID- 16479039
OWN - NLM
STAT- MEDLINE
DCOM- 20071213
LR  - 20191109
IS  - 1349-2365 (Print)
IS  - 1349-2365 (Linking)
VI  - 47
IP  - 1
DP  - 2006 Jan
TI  - Impact of aspirin treatment on long-term outcome (over 10 years) after 
      percutaneous coronary intervention.
PG  - 37-45
AB  - Aspirin has been shown to reduce cardiovascular morbidity and mortality following 
      percutaneous coronary intervention (PCI). However, its effects on long-term (over 
      10 years) mortality have not been fully elucidated. This retrospective study 
      recorded the patient characteristics and admission medication for all patients 
      undergoing PCI over an 8-year period from 1984 to 1992. Follow-up information was 
      available for 748 patients (100%) for a mean of 143.6 +/- 43.4 months. A 
      propensity analysis was performed to adjust for presumed selection biases in the 
      administration of aspirin. The baseline clinical characteristics were similar 
      between the group that received aspirin and the group that did not, except for 
      the administration of statins and PCI procedural success rate. Of the 748 
      patients, 535 (71.5%) received aspirin treatment at the time of PCI. During the 
      12-year follow-up, 54 patients died from any cause and 20 patients from cardiac 
      death. Kaplan-Meier analysis showed that aspirin treatment led to a significant 
      reduction in all cause mortality (10% versus 16.4%; P = 0.01) and cardiac death 
      (3.7% versus 8.0%; P = 0.02) compared to other antiplatelet drugs. The hazard 
      ratio (HR) for the total mortality and cardiac mortality rates was adjusted using 
      the Cox-proportional hazard model for confounding variables and propensity score. 
      The all cause (HR, 0.49; 95%CI [0.29-0.80], P = 0.005) and cardiac mortality 
      rates (HR, 0.32; 95%CI [0.14-0.72], P = 0.006) for patients receiving aspirin 
      remained lower than for those not receiving aspirin. Aspirin treatment at the 
      time of PCI significantly reduced the risk of death from any cause and cardiac 
      death. The administration of aspirin had a positive impact on the over 10-year 
      long-term outcomes of patients who underwent PCI.
FAU - Njaman, Widi
AU  - Njaman W
AD  - Department of Cardiology, Juntendo University School of Medicine, Tokyo, Japan.
FAU - Miyauchi, Katsumi
AU  - Miyauchi K
FAU - Kasai, Takatoshi
AU  - Kasai T
FAU - Kurata, Takeshi
AU  - Kurata T
FAU - Satoh, Hitoshi
AU  - Satoh H
FAU - Ohta, Hiroshi
AU  - Ohta H
FAU - Okazaki, Shinya
AU  - Okazaki S
FAU - Yokoyama, Ken
AU  - Yokoyama K
FAU - Kojima, Takahiko
AU  - Kojima T
FAU - Akimoto, Yoshinori
AU  - Akimoto Y
FAU - Daida, Hiroyuki
AU  - Daida H
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Int Heart J
JT  - International heart journal
JID - 101244240
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2006/02/16 09:00
MHDA- 2007/12/14 09:00
CRDT- 2006/02/16 09:00
PHST- 2006/02/16 09:00 [pubmed]
PHST- 2007/12/14 09:00 [medline]
PHST- 2006/02/16 09:00 [entrez]
AID - JST.JSTAGE/ihj/47.37 [pii]
AID - 10.1536/ihj.47.37 [doi]
PST - ppublish
SO  - Int Heart J. 2006 Jan;47(1):37-45. doi: 10.1536/ihj.47.37.

PMID- 17581318
OWN - NLM
STAT- MEDLINE
DCOM- 20071227
LR  - 20131121
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 18
IP  - 5
DP  - 2007 Jul
TI  - Utility of the PFA-100 as a screening test of platelet function: an audit of 
      haemostasis laboratories in Australia and New Zealand.
PG  - 441-8
AB  - The PFA-100 is a relatively new laboratory instrument, first described in 1995. 
      There have since been numerous studies assessing its utility as a screening tool 
      for platelet dysfunction and/or von Willebrand's disease (VWD). The PFA-100 
      displays variable sensitivity to different types of platelet disorders, as well 
      as to antiplatelet medication (e.g. aspirin), with similar caveats for monitoring 
      of primary haemostasis-promoting therapies in platelet dysfunction. There is 
      therefore considerable uncertainty regarding its utility within this context, and 
      we have accordingly performed an audit of usage among participants of the Royal 
      College of Pathologists of Australasia Quality Assurance Program. Of 105 
      laboratories surveyed, 40 responded that they performed platelet function 
      testing, with 26 (65%) further indicating they utilized the PFA-100. We report a 
      wide variety of laboratory usage among these users, including numbers of tests 
      performed [annual median (range) = 270 (15-6000)], sources of requests (clinical 
      sources and localities), testing criteria and follow-up action. Most tests were 
      completed within 4 h of collection, as recommended by the manufacturer, and most 
      tests were performed as a replacement, or as a preliminary screen of platelet 
      function (i.e. classical aggregation). Most abnormal findings, however, were 
      attributed to antiplatelet medication such as aspirin.
FAU - Favaloro, Emmanuel J
AU  - Favaloro EJ
AD  - Department of Haematology and Royal College of Pathologists of Australasia 
      Quality Assurance Program, Institute of Clinical Pathology and Medical Research, 
      Westmead Hospital, New South Wales, Australia. emmanuel@icpmr.wsahs.nsw.gov.au
FAU - Bonar, Roslyn
AU  - Bonar R
FAU - Duncan, Elizabeth
AU  - Duncan E
FAU - Rodgers, Susan
AU  - Rodgers S
FAU - Marsden, Katherine
AU  - Marsden K
CN  - Royal College of Pathologists of Australasia Quality Assurance Program in 
      Haematology
LA  - eng
PT  - Journal Article
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Australia
MH  - *Commission on Professional and Hospital Activities
MH  - *Hemostasis
MH  - Humans
MH  - *Laboratories, Hospital/standards
MH  - *Monitoring, Physiologic/instrumentation/standards
MH  - New Zealand
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Platelet Function Tests/instrumentation/standards
MH  - von Willebrand Diseases/*blood/drug therapy
EDAT- 2007/06/22 09:00
MHDA- 2007/12/28 09:00
CRDT- 2007/06/22 09:00
PHST- 2007/06/22 09:00 [pubmed]
PHST- 2007/12/28 09:00 [medline]
PHST- 2007/06/22 09:00 [entrez]
AID - 00001721-200707000-00008 [pii]
AID - 10.1097/MBC.0b013e328136c178 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2007 Jul;18(5):441-8. doi: 
      10.1097/MBC.0b013e328136c178.

PMID- 35837782
OWN - NLM
STAT- MEDLINE
DCOM- 20220718
LR  - 20220718
IS  - 1672-7347 (Print)
IS  - 1672-7347 (Linking)
VI  - 47
IP  - 6
DP  - 2022 Jun 28
TI  - A young patient with recurrent myocardial infarction within a half month.
PG  - 809-813
LID - 1672-7347(2022)06-0809-05 [pii]
LID - 10.11817/j.issn.1672-7347.2022.210696 [doi]
AB  - In this study, we reported a young male patient with acute chest pain who was 
      diagnosed as myocardial infarction. The regular medication was performed 
      following coronary intervention. Under such condition, this patient had 3 times 
      myocardial infarction within a half month. The laboratory results showed that 
      there might be a state of hypercoagulability. Aspirin combined with clopidogrel 
      and other treatment were administrated. Meanwhile, the examination demonstrated 
      that there was aspirin-resistant in the patient. The antiplatelet drug and 
      extended anticoagulation therapy were carried out. There was no further 
      myocardial infarction, and no coronary arteries stenosis was found in the 
      re-examination angiography. Aspirin resistance and hypercoagulability should be 
      considered when patients occurred the repeated myocardial infarction after 
      regular medication and coronary intervention. Replacement of the antiplatelet 
      treatment or combination with anticoagulant therapy is necessary in similar 
      patient to avoid the sever consequence.
FAU - Chen, Shunsong
AU  - Chen S
AD  - Department of Cardiology, Third Xiangya Hospital, Central South University, 
      Changsha 410013. 2289082221@qq.com.
FAU - Jiang, Weihong
AU  - Jiang W
AD  - Department of Cardiology, Third Xiangya Hospital, Central South University, 
      Changsha 410013.
FAU - Wang, Junwen
AU  - Wang J
AD  - Department of Cardiovascular Medicine Centre, Seventh Affiliated Hospital, Sun 
      Yat-Sen University, Shenzhen Guangdong 518107, China. wangjw226@mail.sysu.edu.cn.
LA  - eng
LA  - chi
PT  - Journal Article
TT  - 半月内反复心肌梗死青年患者1例.
PL  - China
TA  - Zhong Nan Da Xue Xue Bao Yi Xue Ban
JT  - Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. 
      Medical sciences
JID - 101230586
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Clopidogrel/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Male
MH  - *Myocardial Infarction/drug therapy
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Thrombophilia/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin resistance
OT  - recurrent myocardial infarction
OT  - young patient
EDAT- 2022/07/16 06:00
MHDA- 2022/07/19 06:00
CRDT- 2022/07/15 03:44
PHST- 2022/07/15 03:44 [entrez]
PHST- 2022/07/16 06:00 [pubmed]
PHST- 2022/07/19 06:00 [medline]
AID - 1672-7347(2022)06-0809-05 [pii]
AID - 10.11817/j.issn.1672-7347.2022.210696 [doi]
PST - ppublish
SO  - Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Jun 28;47(6):809-813. doi: 
      10.11817/j.issn.1672-7347.2022.210696.

PMID- 12043308
OWN - NLM
STAT- MEDLINE
DCOM- 20020717
LR  - 20131121
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 55
IP  - 1-2
DP  - 2002
TI  - [Course of pregnancy in a patient with systemic lupus erythematosus--case 
      report].
PG  - 116-9
AB  - Authors describe a successful pregnancy outcome after prednisone and aspirin 
      therapy in 19-year-old woman with systemic lupus erythematosus with the history 
      of recurrent urinary tract infections, pericarditis and encephalitis.
FAU - Jerzak, Małgorzata M
AU  - Jerzak MM
AD  - Instytutu Immunologii i Terapii Doświadczalnej Polskiej Akademii Nauk we 
      Wrocławiu. jerzak@immuno.iitd.pan.wroc.pl
FAU - Prusek, Wiesław
AU  - Prusek W
FAU - Podwysocka, Maria
AU  - Podwysocka M
FAU - Goluda, Marian
AU  - Goluda M
LA  - pol
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Przebieg ciazy u pacjentki z toczniem układowym--opis przypadku.
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Lupus Erythematosus, Systemic/*diagnosis/*drug therapy
MH  - Prednisone/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/*diagnosis/*drug therapy
MH  - Pregnancy Outcome
EDAT- 2002/06/05 10:00
MHDA- 2002/07/18 10:01
CRDT- 2002/06/05 10:00
PHST- 2002/06/05 10:00 [pubmed]
PHST- 2002/07/18 10:01 [medline]
PHST- 2002/06/05 10:00 [entrez]
PST - ppublish
SO  - Wiad Lek. 2002;55(1-2):116-9.

PMID- 16822451
OWN - NLM
STAT- MEDLINE
DCOM- 20060802
LR  - 20131121
IS  - 0094-3509 (Print)
IS  - 0094-3509 (Linking)
VI  - 55
IP  - 7
DP  - 2006 Jul
TI  - Clinical inquiries. What is the best management for patients who have a TIA while 
      on aspirin therapy?
PG  - 627-8
AB  - Alternative antiplatelet therapy for stroke prevention is indicated for patients 
      who experience transient ischemic attacks (TIAs) while on aspirin therapy 
      (strength of recommendation [SOR]: A, based on 1 meta-analysis and 1 randomized 
      controlled trial). The combination of aspirin and extended-release dipyridamole 
      reduces the risk of stroke following a TIA (SOR: A). Thieno-pyridines (eg, 
      clopidogrel and ticlopidine) are an alternative for patients at high risk for a 
      cardioembolic event. Ticlopidine reduces the risk of stroke following TIA, 
      specifically showing benefit for patients previously on aspirin (SOR: A). 
      Clopidogrel has not shown significant reduction in reoccurrence of stroke and has 
      not been studied for patients with a previous TIA. Aspirin and a thieno-pyridine 
      do not provide significant additional reduction in secondary strokes (SOR: A).
FAU - Ahmed, Nabila
AU  - Ahmed N
AD  - Ferris State University/Michigan State University, East Lansing, MI, USA.
FAU - Coffey, John B
AU  - Coffey JB
FAU - Oh, Robert
AU  - Oh R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Stroke/*prevention & control
RF  - 11
EDAT- 2006/07/11 09:00
MHDA- 2006/08/03 09:00
CRDT- 2006/07/11 09:00
PHST- 2006/07/11 09:00 [pubmed]
PHST- 2006/08/03 09:00 [medline]
PHST- 2006/07/11 09:00 [entrez]
AID - jfp_0706_5507h [pii]
PST - ppublish
SO  - J Fam Pract. 2006 Jul;55(7):627-8.

PMID- 322243
OWN - NLM
STAT- MEDLINE
DCOM- 19770520
LR  - 20191028
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - 16
IP  - 1
DP  - 1977 Feb
TI  - A double-blind trial of flurbiprofen and aspirin in soft-tissue trauma.
PG  - 58-61
AB  - A double-blind trial of flurbiprofen (150 mg daily) and aspirin (3.6 g daily) for 
      six days was carried out in 52 soft-tissue injuries in 28 professional 
      footballers. An analysis of daily pain scores in both injury categories (trauma 
      and sprains) showed that players taking flurbiprofen had significantly lower pain 
      scores from day 2 onwards compared to the aspirin group (P less than 0.01), the 
      effect being more marked in the trauma subgroup. Flurbiprofen was significantly 
      better than aspirin in reducing the time taken to achieve both training and match 
      fitness, and 65% of the players taking flurbiprofen were able to train within 
      three days of injury compared to 35% taking aspirin (P less than 0.05). The 
      possible effects of both anti-inflammatory agents on prostaglandin metabolism are 
      discussed, and their role in soft-tissue trauma outlined.
FAU - Muckle, D S
AU  - Muckle DS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Athletic Injuries/*drug therapy
MH  - Clinical Trials as Topic
MH  - Flurbiprofen/*therapeutic use
MH  - Humans
MH  - Leg Injuries/*drug therapy
MH  - Male
MH  - Muscles/injuries
MH  - Propionates/*therapeutic use
MH  - Sports Medicine
MH  - Sprains and Strains/drug therapy
EDAT- 1977/02/01 00:00
MHDA- 1977/02/01 00:01
CRDT- 1977/02/01 00:00
PHST- 1977/02/01 00:00 [pubmed]
PHST- 1977/02/01 00:01 [medline]
PHST- 1977/02/01 00:00 [entrez]
AID - 10.1093/rheumatology/16.1.58 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1977 Feb;16(1):58-61. doi: 10.1093/rheumatology/16.1.58.

PMID- 19193589
OWN - NLM
STAT- MEDLINE
DCOM- 20090707
LR  - 20191111
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 43
IP  - 2
DP  - 2009 Feb
TI  - Barriers to clopidogrel adherence following placement of drug-eluting stents.
PG  - 259-67
AB  - BACKGROUND: Nonadherence to clopidogrel after drug-eluting stent (DES) placement 
      is associated with in-stent thrombosis and adverse cardiac events. OBJECTIVE: To 
      identify the incidence of and barriers associated with nonadherence to 
      clopidogrel in patients receiving DES. METHODS: Patients who received a DES 
      between March 1, 2004, and August 31, 2005, from a single academic medical center 
      were eligible. Telephone interviews were conducted 6 or more months following 
      discharge. Nonadherence was defined as premature discontinuation of or less than 
      80% adherence to clopidogrel. Patients were asked to identify barriers to 
      adherence. Differences between adherent and nonadherent patients were analyzed 
      using chi(2) and t-test analysis. RESULTS: Of the 674 patients identified, 257 
      (38%) participated. The nonadherence rate was 20%. The majority (58%) of 
      nonadherent patients discontinued therapy prematurely. Patients identified the 
      main reason for discontinuation as medical barriers (18.56%), including perceived 
      adverse effects (9.28%). The incidence of rash was higher in patients who were 
      nonadherent (12% vs 4%; p = 0.049). Overall, 49% of patients recalled receiving 
      discharge counseling regarding adverse effects. A financial barrier was 
      identified by 22 (42%) patients in the nonadherent and 73 (36%) in the adherent 
      group, of whom 64% and 52%, respectively, reported having insurance coverage for 
      medications. Adherent patients reported higher copays ($29.69 vs $18.14; p = 
      0.01). CONCLUSIONS: Prospective studies should be conducted to aid in identifying 
      patients at risk for nonadherence and possible in-stent thrombosis in order to 
      identify interventions to improve adherence.
FAU - Pallares, Maria José
AU  - Pallares MJ
AD  - South Carolina College of Pharmacy, Medical University of South Carolina, 
      Charleston, SC, USA. mjpallares@gmail.com
FAU - Powers, Eric R
AU  - Powers ER
FAU - Zwerner, Peter L
AU  - Zwerner PL
FAU - Fowler, Andrew
AU  - Fowler A
FAU - Reeves, Rodney
AU  - Reeves R
FAU - Nappi, Jean M
AU  - Nappi JM
LA  - eng
PT  - Journal Article
DEP - 20090203
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Clopidogrel
MH  - Cohort Studies
MH  - *Drug-Eluting Stents/adverse effects
MH  - Exanthema/chemically induced
MH  - Female
MH  - Humans
MH  - Male
MH  - Medication Adherence/*psychology
MH  - Platelet Aggregation Inhibitors/economics/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/economics/therapeutic use
EDAT- 2009/02/06 09:00
MHDA- 2009/07/08 09:00
CRDT- 2009/02/06 09:00
PHST- 2009/02/06 09:00 [entrez]
PHST- 2009/02/06 09:00 [pubmed]
PHST- 2009/07/08 09:00 [medline]
AID - aph.1L286 [pii]
AID - 10.1345/aph.1l286 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2009 Feb;43(2):259-67. doi: 10.1345/aph.1l286. Epub 2009 Feb 3.

PMID- 11851941
OWN - NLM
STAT- MEDLINE
DCOM- 20020517
LR  - 20191105
IS  - 0958-7578 (Print)
IS  - 0958-7578 (Linking)
VI  - 11
IP  - 6
DP  - 2001 Dec
TI  - Measurement of blood volume after haemodilution with haemoglobin-based oxygen 
      carriers by a radiolabelled-albumin method.
PG  - 433-42
AB  - Recent studies have shown that the use of haemoglobin-based oxygen-carrying 
      solutions (HBOCs) for perioperative haemodilution could significantly reduce the 
      need for packed red blood cells in clinical practice. Though the effects of HBOCs 
      on plasma volume have been characterized in experimental models of volume 
      resuscitation from hypovolaemic shock, little is known about their action in 
      normovolaemic haemodilution conditions. We therefore applied a radiolabelled 
      serumalbumin method to determine blood volume after haemodilution with 
      crosslinked or conjugated haemoglobin, in comparison with a reference solution of 
      hydroxyethyl starch (HES). Three groups of New Zealand white rabbits were studied 
      (n = 7 each group) subjected to moderate exchange transfusion with low molecular 
      weight HES, bis(3,5-dibromosalicyl)fumarate crosslinked haemoglobin 
      (alphaalpha-Hb), or dextran-conjugated haemoglobin (Hb-Dex-BTC). HES induced no 
      changes in heart rate and blood pressure. The amplitude and duration of blood 
      pressure increase and bradycardia were similar in both haemoglobin groups. A 
      significant contraction of blood volume (12%) was observed 60 min after 
      haemodilution with alphaalpha-Hb, compared to HES and Hb-Dex-BTC. At the same 
      time point, a decrease in absolute haemoglobin (plasma haemoglobin x plasma 
      volume) was also noted. This study suggests that in haemodilution conditions, the 
      specific oncotic properties and circulating persistence of crosslinked and 
      conjugated haemoglobin solutions affect the pattern of blood volume distribution 
      differently.
FAU - Caron, A
AU  - Caron A
AD  - Department of Haematology and Physiology, University Henri Poincaré-Nancy 1, 5 
      rue Albert Lebrun, 54001 Nancy cedex, France. caron@pharma.u-nancy.fr
FAU - Mayer, J C
AU  - Mayer JC
FAU - Menu, P
AU  - Menu P
FAU - Alayash, A
AU  - Alayash A
FAU - Marie, P Y
AU  - Marie PY
FAU - Vigneron, C
AU  - Vigneron C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Transfus Med
JT  - Transfusion medicine (Oxford, England)
JID - 9301182
RN  - 0 (Blood Substitutes)
RN  - 0 (Dextrans)
RN  - 0 (Hemoglobins)
RN  - 0 (Radioactive Tracers)
RN  - 0 (Serum Albumin)
RN  - 0 (hemoglobin XL99alpha)
RN  - 0 (hemoglobin-dextran 10-benzene-tetracarboxylate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Gas Analysis
MH  - Blood Pressure/drug effects
MH  - Blood Substitutes/administration & dosage/chemistry/*pharmacology
MH  - *Blood Volume
MH  - Dextrans/pharmacology
MH  - Exchange Transfusion, Whole Blood/methods
MH  - Heart Rate/drug effects
MH  - Hemodilution/*methods
MH  - Hemoglobins/analysis/pharmacology
MH  - Rabbits
MH  - Radioactive Tracers
MH  - Serum Albumin
EDAT- 2002/02/20 10:00
MHDA- 2002/05/23 10:01
CRDT- 2002/02/20 10:00
PHST- 2002/02/20 10:00 [pubmed]
PHST- 2002/05/23 10:01 [medline]
PHST- 2002/02/20 10:00 [entrez]
AID - 337 [pii]
AID - 10.1046/j.1365-3148.2001.00337.x [doi]
PST - ppublish
SO  - Transfus Med. 2001 Dec;11(6):433-42. doi: 10.1046/j.1365-3148.2001.00337.x.

PMID- 9167842
OWN - NLM
STAT- MEDLINE
DCOM- 19970721
LR  - 20191102
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 25
IP  - 3
DP  - 1997 May
TI  - Effect of diaspirin crosslinked hemoglobin on systemic and regional blood 
      circulation in pregnant rats.
PG  - 275-88
AB  - Diaspirin crosslinked hemoglobin (DCLHb: Baxter Healthcare Corp., Round Lake, IL, 
      USA) is a biochemically stable hemoglobin based solution with excellent oxygen 
      carrying capacity. Studies have been conducted in male rats to determine the 
      effect of DCLHb on systemic and regional blood circulation. However, the 
      cardiovascular effect of DCLHb has not been studied in female rats. In the 
      present study the effect of DCLHb (400 mg/kg, i.v.) was observed on systemic 
      hemodynamic parameters and regional blood circulation in non-pregnant rats, and 
      in 9-day pregnant and 18-day pregnant rats. DCLHb increased mean arterial 
      pressure (MAP) and total peripheral resistance (TPR) and increased blood flow to 
      the heart, gastrointestinal tract (GIT), mesentery & pancreas, and skin in all 
      groups of rats. The basal blood flow to the ovaries was higher in 18-day pregnant 
      rats when compared to non-pregnant and 9-day pregnant rats. DCLHb further 
      increased blood flow to the ovaries of 18-day pregnant rats. It is concluded that 
      DCLHb increases blood flow to the heart, GIT and skin as a result of 
      redistribution of blood from the musculoskeletal system. Blood flow in female 
      reproductive organs is not altered by DCLHb in non-pregnant rats and during 
      mid-term pregnancy. However, in advanced stages of pregnancy DCLHb increases 
      blood flow to the ovaries.
FAU - Sen, A P
AU  - Sen AP
AD  - Department of Pharmaceutics, University of Illinois at Chicago 60612, USA.
FAU - Dong, Y
AU  - Dong Y
FAU - Gulati, A
AU  - Gulati A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Substitutes/*pharmacology
MH  - Cerebrovascular Circulation/drug effects
MH  - Coronary Circulation/drug effects
MH  - Digestive System/blood supply
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/*pharmacology
MH  - Liver/blood supply
MH  - Mesentery/blood supply
MH  - Musculoskeletal System/blood supply
MH  - Ovary/*blood supply
MH  - Pancreas/blood supply
MH  - Pregnancy
MH  - Rats
MH  - Regional Blood Flow/drug effects
MH  - Renal Circulation/drug effects
MH  - Skin/blood supply
MH  - Spleen/blood supply
MH  - Vascular Resistance/drug effects
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - 10.3109/10731199709118917 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1997 May;25(3):275-88. doi: 
      10.3109/10731199709118917.

PMID- 3053841
OWN - NLM
STAT- MEDLINE
DCOM- 19881219
LR  - 20190824
IS  - 0342-4642 (Print)
IS  - 0342-4642 (Linking)
VI  - 14
IP  - 6
DP  - 1988
TI  - The effect of nifedipine alone or combined with low dose acetylsalicyclic acid on 
      endotoxin-induced pulmonary hypertension in the piglet.
PG  - 595-601
AB  - Cardiovascular responses to the calcium antagonist nifedipine, alone and combined 
      with low dose acetylsalicyclic acid (ASA), were evaluated in a piglet model of 
      endotoxin-induced pulmonary hypertension. All animals were anesthetized, 
      paralyzed and mechanically ventilated. Cardiac output (CO), pulmonary artery 
      pressure (PAP), aortic blood pressure (SAP), pulmonary capillary wedge pressure 
      (PCWP), right atrial pressure (RAPM) and arterial blood gases were measured 
      before and after induction of pulmonary hypertension by E. coli endotoxin and 
      after treatment. Results of treated groups were compared to a control group of 
      piglets subjected to the same dose (0.15 micrograms/kg i.v.) of endotoxin. 
      Control animals responded to a bolus injection of endotoxin within 15 min with an 
      increase in mean PAP by 110%. Pulmonary vascular resistance (PVR) increased by 
      144%. Mean arterial pressure did not change significantly from baseline values. 
      In animals treated with a single dose of 1 mg/kg ASA prior to endotoxin, the 
      initial pulmonary response was not quantitatively different from control values, 
      whereas ASA 20 mg/kg abolished the pulmonary vascular reaction. The increase of 
      systemic vascular resistance (SVR) produced by endotoxin was aggravated by high 
      dose ASA. In piglets treated with nifedipine (4 micrograms/kg/min) over 30 min 
      after the application of endotoxin with and without additional infusion of 
      nifedipine 60 min prior to endotoxin the PVR could be attenuated. The combination 
      of nifedipine and low dose ASA showed synergistic effects compared to control. 
      The increase of mean PAP was significantly reduced, the PVR remained in baseline 
      range due to a marked elevation of cardiac output.
FAU - Schranz, D
AU  - Schranz D
AD  - Department of Pediatrics, Mainz, FRG.
FAU - Huth, R G
AU  - Huth RG
FAU - Stopfkuchen, H
AU  - Stopfkuchen H
FAU - Jüngst, B K
AU  - Jüngst BK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Intensive Care Med
JT  - Intensive care medicine
JID - 7704851
RN  - 0 (Drug Combinations)
RN  - 0 (Endotoxins)
RN  - 0 (Lipopolysaccharides)
RN  - 67924-63-4 (endotoxin, Escherichia coli)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Disease Models, Animal
MH  - Drug Combinations
MH  - Drug Evaluation, Preclinical
MH  - Drug Synergism
MH  - Endotoxins/administration & dosage/*adverse effects
MH  - *Escherichia coli
MH  - Female
MH  - Hemodynamics/*drug effects
MH  - Hypertension, Pulmonary/chemically induced/*prevention & control
MH  - Lipopolysaccharides/*adverse effects
MH  - Male
MH  - Nifedipine/administration & dosage/*pharmacology
MH  - Swine
MH  - Vascular Resistance/drug effects
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.1007/BF00256762 [doi]
PST - ppublish
SO  - Intensive Care Med. 1988;14(6):595-601. doi: 10.1007/BF00256762.

PMID- 6401254
OWN - NLM
STAT- MEDLINE
DCOM- 19830225
LR  - 20220408
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 84
IP  - 2
DP  - 1983 Feb
TI  - Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the 
      diuretic action of furosemide in cirrhosis with ascites.
PG  - 247-52
AB  - To investigate if lysine acetylsalicylate influences the hemodynamic and diuretic 
      responses to furosemide in cirrhosis, 21 nonazotemic patients with ascites were 
      studied. In 8 patients (group 1), the renal plasma flow and glomerular filtration 
      rate were serially measured before and during three 30-min periods after the i.v. 
      administration of lysine acetylsalicylate (450 mg). In 7 patients (group 2), 
      renal plasma flow, glomerular filtration rate, urine volume, and sodium excretion 
      were measured before and during three 20-min periods after the i.v. 
      administration of furosemide (40 mg). After a 45-min period in which urinary 
      losses were restored, a similar study was performed before and after a second 
      injection of furosemide (40 mg). Six patients (group 3) were studied with an 
      identical protocol as group 2, except that the second injection of furosemide was 
      preceded by the administration of lysine acetylsalicylate (450 mg). In 6 patients 
      of group 1, lysine acetylsalicylate caused a marked and reversible reduction of 
      renal plasma flow and glomerular filtration rate. In groups 2 and 3, the i.v. 
      injections of furosemide alone produced a significant increase in renal plasma 
      flow and glomerular filtration rate, and a marked diuresis and natriuresis. In 
      patients of group 3, pretreatment with lysine acetylsalicylate suppressed the 
      renal hemodynamic effect and markedly reduced the diuretic effect of the second 
      injection of furosemide. Lysine acetylsalicylate did not cause the appearance of 
      renal insufficiency in any of these patients. These results suggest that 
      prostaglandins are involved in the renal response to furosemide in cirrhosis with 
      ascites and that furosemide protects these patients from developing renal 
      insufficiency after acute administration of nonsteroidal antiinflammatory agents.
FAU - Planas, R
AU  - Planas R
FAU - Arroyo, V
AU  - Arroyo V
FAU - Rimola, A
AU  - Rimola A
FAU - Pérez-Ayuso, R M
AU  - Pérez-Ayuso RM
FAU - Rodés, J
AU  - Rodés J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Prostaglandins)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Diuresis/drug effects
MH  - Furosemide/*antagonists & inhibitors
MH  - Glomerular Filtration Rate/drug effects
MH  - Humans
MH  - Kidney/*drug effects
MH  - Liver Cirrhosis/*drug therapy
MH  - Liver Cirrhosis, Alcoholic/drug therapy
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Natriuresis/drug effects
MH  - Prostaglandins/physiology
MH  - Renal Circulation/drug effects
EDAT- 1983/02/01 00:00
MHDA- 1983/02/01 00:01
CRDT- 1983/02/01 00:00
PHST- 1983/02/01 00:00 [pubmed]
PHST- 1983/02/01 00:01 [medline]
PHST- 1983/02/01 00:00 [entrez]
AID - S0016508583000244 [pii]
PST - ppublish
SO  - Gastroenterology. 1983 Feb;84(2):247-52.

PMID- 2345249
OWN - NLM
STAT- MEDLINE
DCOM- 19900703
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 15
IP  - 7
DP  - 1990 Jun
TI  - Does antiplatelet therapy enhance myocardial salvage after coronary reperfusion?
PG  - 1662-6
AB  - The aim of this study was to test the hypothesis that either the cyclooxygenase 
      inhibitor aspirin or the thromboxane A2 receptor antagonist sulotroban exerts a 
      direct myocardial effect that enhances myocardial salvage afforded by 
      reperfusion. Accordingly, 21 anesthetized dogs underwent suture occlusion of the 
      left anterior descending coronary artery. At 2.5 h after occlusion, all dogs 
      received intravenous streptokinase (20,000 U/kg body weight over 30 min) and were 
      randomized to the following groups: group I (n = 7) received no additional 
      treatment, group II (n = 7) received aspirin (5 mg/kg intravenously) and group 
      III (n = 7) received sulotroban (10 mg/kg followed by 10 mg/kg per h 
      intravenously). At 3 h after occlusion, the dogs underwent coronary reperfusion 
      for the next 3 h. Myocardial infarct size as a percent of the hypoperfused zone 
      was similar among dogs in group I (42 +/- 8%), group II (41 +/- 10%) and group 
      III (45 +/- 11%). The incidence and the extent of myocardial hemorrhage were 
      similar in all three study groups. Infarct size as a percent of the hypoperfused 
      zone was significantly smaller in dogs without hemorrhage irrespective of 
      treatment (35 +/- 9% versus 63 +/- 5%, p less than 0.01).(ABSTRACT TRUNCATED AT 
      250 WORDS)
FAU - Shi, Y
AU  - Shi Y
AD  - Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, 
      Pennsylvania 19107.
FAU - Zalewski, A
AU  - Zalewski A
FAU - Walinsky, P
AU  - Walinsky P
FAU - Goldberg, S
AU  - Goldberg S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Sulfonamides)
RN  - 74574CO5A6 (sulotroban)
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/therapeutic use
MH  - Dogs
MH  - Fibrinolytic Agents/therapeutic use
MH  - Heart Diseases/chemically induced
MH  - Hemodynamics/drug effects
MH  - Hemorrhage/chemically induced
MH  - Myocardial Infarction/*pathology
MH  - *Myocardial Reperfusion
MH  - Myocardium/*pathology
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Streptokinase/adverse effects/therapeutic use
MH  - Sulfonamides/adverse effects/therapeutic use
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
AID - 0735-1097(90)92844-R [pii]
AID - 10.1016/0735-1097(90)92844-r [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1990 Jun;15(7):1662-6. doi: 10.1016/0735-1097(90)92844-r.

PMID- 12858504
OWN - NLM
STAT- MEDLINE
DCOM- 20041014
LR  - 20131121
IS  - 0001-5334 (Print)
IS  - 0001-5334 (Linking)
VI  - 36
IP  - 2
DP  - 2003 Apr
TI  - [Inhibition of vascular smooth muscle cell proliferation by non-steroidal 
      anti-inflammatory drugs].
PG  - 85-90
AB  - Abnormal vascular smooth muscle cell (VSMC) proliferation is known to play an 
      important role in the pathogenesis of atherosclerosis, restenosis and instent 
      stenosis. Recent studies suggest that salicylates, in addition to inhibiting 
      cyclooxygenase activity, exert an antiproliferative effect on VSMC growth both in 
      vitro and in vivo. However, whether all non-steroidal anti-inflammatory drugs 
      (NSAID) exert similar antiproliferative effects on VSMCs, and do so via a common 
      mechanism of action, remains unknown. In the present study, we demonstrated that 
      the NSAIDs, aspirin, ibuprofen and sulindac induced a dose-dependent inhibition 
      of proliferation in rat A10 VSMCs (IC50 = 1666 mumol/L, 937 mumol/L and 520 
      mumol/L, respectively). These drugs did not show significant cytotoxic effects as 
      determined by LDH release assay, even at the highest concentrations tested 
      (aspirin, 5000 mumol/L; ibuprofen, 2500 mumol/L; and sulindac, 1000 mumol/L). 
      Flow cytometric analyses showed that a 48 h exposure of A10 VSMCs to ibuprofen 
      (1000 mumol/L) and sulindac (750 mumol/L) led to a significant G1 arrest (from 
      68.7 +/- 2.0% of cells in G1 to 76.6 +/- 2.2% and 75.8 +/- 2.2%, respectively, p 
      < 0.05). In contrast, aspirin (2500 mumol/L) failed to induce a significant G1 
      arrest (68.1 +/- 5.2%). Clearer evidence of a G1 block was obtained by treatment 
      of cells with the mitotic inhibitor, nocodazole (40 ng/ml), for the final 24 h of 
      the experiment. Under these conditions, aspirin still failed to induce a G1 
      arrest (from 25.9 +/- 10.9% of cells in G1 to 19.6 +/- 2.3%) whereas ibuprofen 
      and sulindac led to a significant accumulation of cells in G1(51.8% +/- 17.2% and 
      54.1% +/- 10.6%, respectively, p < 0.05). These results indicate that ibuprofen 
      and sulindac inhibit VSMC proliferation by arresting the cell cycle in the G1 
      phase whereas the effect of aspirin appears to be independent of any special 
      phase of the cell cycle. Irrespective of mechanism, our results suggest that 
      NSAIDs might be of benefit to the treatment of vascular proliferative disorders.
FAU - Wang, Yue Qun
AU  - Wang YQ
AD  - College of Life Science, Hunan Normal University, Changsha 410081.
FAU - Brooks, Gavin
AU  - Brooks G
FAU - Harper, Jane
AU  - Harper J
FAU - Li, Yong Qing
AU  - Li YQ
FAU - Zhu, Chuan Bin
AU  - Zhu CB
FAU - Yuan, Wu Zhou
AU  - Yuan WZ
FAU - Wu, Xiu Shan
AU  - Wu XS
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Shi Yan Sheng Wu Xue Bao
JT  - Shi yan sheng wu xue bao
JID - 0413570
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 184SNS8VUH (Sulindac)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Cell Cycle/*drug effects
MH  - Cell Division/drug effects
MH  - Cells, Cultured
MH  - Dose-Response Relationship, Drug
MH  - Flow Cytometry
MH  - Ibuprofen/administration & dosage/pharmacology
MH  - Muscle, Smooth, Vascular/cytology/*drug effects
MH  - Rats
MH  - Sulindac/administration & dosage/pharmacology
EDAT- 2003/07/16 05:00
MHDA- 2004/10/16 09:00
CRDT- 2003/07/16 05:00
PHST- 2003/07/16 05:00 [pubmed]
PHST- 2004/10/16 09:00 [medline]
PHST- 2003/07/16 05:00 [entrez]
PST - ppublish
SO  - Shi Yan Sheng Wu Xue Bao. 2003 Apr;36(2):85-90.

PMID- 11010752
OWN - NLM
STAT- MEDLINE
DCOM- 20000922
LR  - 20131121
IS  - 1167-7422 (Print)
IS  - 1167-7422 (Linking)
VI  - 9
IP  - 47
DP  - 2000 Jun
TI  - Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: 
      primary prevention.
PG  - 89-90
AB  - (1) Aspirin reduces the risk of myocardial infarction in men over 40 with no 
      history of cardiovascular disease, and in hypertensive patients of both sexes 
      over that age. But it does not seem to reduce overall mortality, and its 
      risk-benefit ratio is not very favourable because of its gastrointestinal adverse 
      effects. (2) In patients with symptomatic lower-limb arterial disease, 
      ticlopidine and clopidogrel reduce the risk of coronary events.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Prescrire Int
JT  - Prescrire international
JID - 9439295
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - *Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Carotid Stenosis/drug therapy
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus/drug therapy
MH  - Digestive System/drug effects
MH  - Female
MH  - Humans
MH  - Hypertension/drug therapy
MH  - Leg/blood supply
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Infarction/mortality/prevention & control
MH  - Peripheral Vascular Diseases/drug therapy
MH  - *Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/therapeutic use
MH  - Risk Factors
MH  - *Stroke/mortality/prevention & control
MH  - Ticlopidine/antagonists & inhibitors/therapeutic use
EDAT- 2000/09/30 11:00
MHDA- 2000/09/30 11:01
CRDT- 2000/09/30 11:00
PHST- 2000/09/30 11:00 [pubmed]
PHST- 2000/09/30 11:01 [medline]
PHST- 2000/09/30 11:00 [entrez]
PST - ppublish
SO  - Prescrire Int. 2000 Jun;9(47):89-90.

PMID- 34384858
OWN - NLM
STAT- MEDLINE
DCOM- 20211130
LR  - 20220531
IS  - 1618-0402 (Electronic)
IS  - 0940-9602 (Linking)
VI  - 239
DP  - 2022 Jan
TI  - The effect of association of aspirin and omega 3 in rat temporomandibular joint 
      with induced arthritis.
PG  - 151812
LID - S0940-9602(21)00138-2 [pii]
LID - 10.1016/j.aanat.2021.151812 [doi]
AB  - This study aimed to evaluate the effects of omega-3 (ω3) polyunsaturated fatty 
      acids, in association with aspirin (AA), on the morphology of cytokine release in 
      the temporomandibular joint (TMJ) of rats induced with rheumatoid arthritis (IR) 
      by injecting 100 μL of complete Freund's adjuvant with bovine type II collagen at 
      the tail base. Thirty-two adult male rats were divided into treatment groups: 
      Sham, treated with 0.9% sodium chloride (NaCl) p.o.; IR-control, treated with 
      0.9% NaCl p.o.; IR-ω3 treated with ω3 PUFAS (85 mg/kg/day p.o.); and IR-ω3 + AA 
      treated with ω3 (85 mg/kg/day p.o.) + AA (20 mg/kg/day i.p.). After maintained 
      treatment for seven days, the animals were euthanized. Bilateral TMJs from each 
      rat were removed and one was subjected to histological immunoassays and 
      enzyme-linked immunosorbent assays to assess interleukin (IL)-1β, tumor necrosis 
      factor-α, and IL-10 levels. Data analysis was performed using the Kruskal-Wallis 
      and Dunn tests. In the IR-ω3 and IR-ω3 + AA groups, the TMJ was greater than in 
      the IR-control group (P < 0.0001). The addition of AA did not improve the effects 
      of ω3 (P = 0.0698). Similarly, the addition of AA conferred no additional effects 
      on the cytokine levels (P > 0.05); however, it increased the proteoglycan 
      density, compared with ω3 alone. We found that ω3 exhibited anti-inflammatory 
      activity in arthritic rats, and the addition of AA increased proteoglycan 
      density, but did not affect cytokine expression.
CI  - Copyright © 2021 Elsevier GmbH. All rights reserved.
FAU - Ceotto, Beatriz H
AU  - Ceotto BH
AD  - Department of Physiological Sciences, Piracicaba Dental School, University of 
      Campinas - UNICAMP - Piracicaba, São Paulo, Brazil. Electronic address: 
      bhceotto@hotmail.com.
FAU - Figueroba, Sidney R
AU  - Figueroba SR
AD  - Department of Physiological Sciences, Piracicaba Dental School, University of 
      Campinas - UNICAMP - Piracicaba, São Paulo, Brazil. Electronic address: 
      sfigueroba@uol.com.br.
FAU - Ferreira, Luiz Eduardo N
AU  - Ferreira LEN
AD  - Laboratory of Inflammation and Immunology, Guarulhos University, Guarulhos, São 
      Paulo, Brazil. Electronic address: luiz.enferreira@gmail.com.
FAU - Amorim, Klinger S
AU  - Amorim KS
AD  - Department of Physiological Sciences, Piracicaba Dental School, University of 
      Campinas - UNICAMP - Piracicaba, São Paulo, Brazil. Electronic address: 
      klinger.amorim@outlook.com.
FAU - Sánchez, Jonny B
AU  - Sánchez JB
AD  - Department of Physiological Sciences, Piracicaba Dental School, University of 
      Campinas - UNICAMP - Piracicaba, São Paulo, Brazil. Electronic address: 
      jonnyburga@gmail.com.
FAU - Gercina, Anne Caroline
AU  - Gercina AC
AD  - Department of Physiological Sciences, Piracicaba Dental School, University of 
      Campinas - UNICAMP - Piracicaba, São Paulo, Brazil. Electronic address: 
      annegerc@gmail.com.
FAU - Dos Santos, Victor Augusto B
AU  - Dos Santos VAB
AD  - Department of Physiological Sciences, Piracicaba Dental School, University of 
      Campinas - UNICAMP - Piracicaba, São Paulo, Brazil. Electronic address: 
      victorabs@outlook.com.br.
FAU - Groppo, Francisco C
AU  - Groppo FC
AD  - Department of Physiological Sciences, Piracicaba Dental School, University of 
      Campinas - UNICAMP - Piracicaba, São Paulo, Brazil. Electronic address: 
      fcgroppo1@fop.unicamp.br.
LA  - eng
PT  - Journal Article
DEP - 20210809
PL  - Germany
TA  - Ann Anat
JT  - Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische 
      Gesellschaft
JID - 100963897
RN  - 0 (Cytokines)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 9007-81-2 (Freund's Adjuvant)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Arthritis/chemically induced/drug therapy
MH  - *Aspirin/therapeutic use
MH  - Cattle
MH  - Cytokines
MH  - Fatty Acids, Omega-3/*therapeutic use
MH  - Freund's Adjuvant
MH  - Male
MH  - Rats
MH  - Temporomandibular Joint/physiopathology
OTO - NOTNLM
OT  - Aspirin
OT  - Cytokines
OT  - Eicosapentaenoic acid
OT  - Inflammation
OT  - Temporomandibular joint
EDAT- 2021/08/14 06:00
MHDA- 2021/12/01 06:00
CRDT- 2021/08/13 05:56
PHST- 2021/05/20 00:00 [received]
PHST- 2021/07/16 00:00 [revised]
PHST- 2021/07/21 00:00 [accepted]
PHST- 2021/08/14 06:00 [pubmed]
PHST- 2021/12/01 06:00 [medline]
PHST- 2021/08/13 05:56 [entrez]
AID - S0940-9602(21)00138-2 [pii]
AID - 10.1016/j.aanat.2021.151812 [doi]
PST - ppublish
SO  - Ann Anat. 2022 Jan;239:151812. doi: 10.1016/j.aanat.2021.151812. Epub 2021 Aug 9.

PMID- 1246039
OWN - NLM
STAT- MEDLINE
DCOM- 19760324
LR  - 20190709
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 19
IP  - 1
DP  - 1976 Jan
TI  - Synthesis and antiinflammatory properties of N-substituted 
      4,5-dioxopyrrolidine-3-carboxanilides.
PG  - 172-3
AB  - The synthesis and physical properties of a series of N-methyl- and 
      N-phenyl-4,5-dioxopyrrolidine-3-carboxanilides are described. Unlike previously 
      reported carboxanilides derived from 1,3(2H,4H)-dioxoisoquinoline and 
      2-oxobenzofuran, the currently described agents exist solely as the enol 
      tautomers and, as a result, do not display comparable acidic properties. None of 
      the newly reported compounds exhibited activity equal to that of aspirin in the 
      carrageenin-induced rat foot edema assay.
FAU - Kadin, S B
AU  - Kadin SB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Anilides)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Pyrrolidines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anilides/*chemical synthesis/therapeutic use
MH  - Animals
MH  - Anti-Inflammatory Agents/*chemical synthesis/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Edema/drug therapy
MH  - Pyrrolidines/chemical synthesis/therapeutic use
MH  - Rats
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1021/jm00223a033 [doi]
PST - ppublish
SO  - J Med Chem. 1976 Jan;19(1):172-3. doi: 10.1021/jm00223a033.

PMID- 16877945
OWN - NLM
STAT- MEDLINE
DCOM- 20070515
LR  - 20131121
IS  - 0263-6352 (Print)
IS  - 0263-6352 (Linking)
VI  - 24
IP  - 8
DP  - 2006 Aug
TI  - The effect of non-steroidal anti-inflammatory drugs and other commonly used 
      non-narcotic analgesics on blood pressure level in adults.
PG  - 1457-69
AB  - This review explores the blood pressure effects of three non-narcotic analgesics: 
      non-selective non-steroidal anti-inflammatory drugs (NSAID), paracetamol and 
      aspirin. The current evidence suggests that in normotensive, otherwise healthy 
      adults, short-term use (1-2 weeks) of NSAIDs is not associated with a significant 
      increase in blood pressure. Those with existing hypertension are more likely to 
      see a blood pressure elevation, although the magnitude of the effect is less 
      predictable and may vary with age, baseline blood pressure, type of NSAID and 
      concurrent antihypertensive therapy. The magnitude of the blood pressure increase 
      appears to be similar for both NSAIDs and paracetamol, while low-dose aspirin may 
      have more modest effects. In hypertensive adults who experience deterioration of 
      blood pressure control on NSAIDs, there is some, albeit suboptimal, evidence that 
      the blood pressure-raising effects of NSAIDs are less when used in conjunction 
      with dihydropyridine calcium-channel blockers than angiotensin-converting enzyme 
      inhibitors.
FAU - Wilson, Sarah L
AU  - Wilson SL
AD  - International Centre for Circulatory Health, National Heart and Lung Institute, 
      Imperial College London, St Mary's Campus, London, W2 1PG UK. 
      sarah.wilson@imperial.ac.uk
FAU - Poulter, Neil R
AU  - Poulter NR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antihypertensive Agents)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Hypertens. 2007 Jan;25(1):248; author reply 248-9. PMID: 17143199
MH  - Acetaminophen/adverse effects/*pharmacology
MH  - Adult
MH  - Analgesics, Non-Narcotic/adverse effects/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/adverse effects/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Hypertension/chemically induced/drug therapy/physiopathology
RF  - 32
EDAT- 2006/08/01 09:00
MHDA- 2007/05/16 09:00
CRDT- 2006/08/01 09:00
PHST- 2006/08/01 09:00 [pubmed]
PHST- 2007/05/16 09:00 [medline]
PHST- 2006/08/01 09:00 [entrez]
AID - 00004872-200608000-00002 [pii]
AID - 10.1097/01.hjh.0000239278.82196.a5 [doi]
PST - ppublish
SO  - J Hypertens. 2006 Aug;24(8):1457-69. doi: 10.1097/01.hjh.0000239278.82196.a5.

PMID- 3088757
OWN - NLM
STAT- MEDLINE
DCOM- 19860807
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 43
IP  - 1
DP  - 1986 Jul 1
TI  - Synergistic actions of paf-acether and sodium arachidonate in human platelet 
      aggregation. 2. Unexpected results after aspirin intake.
PG  - 113-20
AB  - The effect of sodium arachidonate and paf-acether on the activation of human 
      platelet rich plasma from volunteers 2.30 to 36 hours after 500 mg of aspirin 
      intake was studied. Concentrations of paf-acether which induce a reversible 
      aggregation in platelet rich plasma (PRP) (0.29-0.029 microM) and concentrations 
      of sodium arachidonate (AA) which don't produce aggregation (0.75-1mM) on the PRP 
      from these volunteers, induced full aggregation when added together. But no 
      cooperation activity was achieved in the 2.30 hours sample. Contrarily to the in 
      vitro studies performed in human normal PRP, ASA (200 micrograms/ml) or 
      indomethacin(12 microM) added to the PRP were unable to suppress the cooperative 
      aggregation effect; neither did apyrase (12U/ml), esculetin (10 microM) or 
      nordihydroguaiaretic acid (0.1 microM) have any action on the activated platelets 
      but the synergistic action is completely suppressed by BW 755C (0.1 mM). TXB2 
      formation is very low in all these activated samples and insufficient to cause 
      platelet aggregation. These results suggest 2 behaviors of platelets: synergistic 
      activity of paf-acether and exogenous AA in vitro on normal human PRP is mediated 
      mainly through active metabolites of AA formed via cyclooxygenase, as was 
      previously published. When cyclooxygenase is inhibited in vivo by administration 
      of 500 mg ASA, the cooperative effect of agonists is still present but the active 
      aggregating product(s) is probably, formed through a pathway different of that of 
      the cyclooxygenase or lypoxygenase.
FAU - Altman, R
AU  - Altman R
FAU - Scazziota, A
AU  - Scazziota A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Arachidonic Acids)
RN  - 0 (Catechols)
RN  - 0 (Platelet Activating Factor)
RN  - 0 (Pyrazoles)
RN  - 0 (Umbelliferones)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 66000-40-6 (4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine)
RN  - 7BO8G1BYQU (Masoprocol)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - EC 3.6.1.5 (Apyrase)
RN  - K72T3FS567 (Adenosine)
RN  - R16CO5Y76E (Aspirin)
RN  - SM2XD6V944 (esculetin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine
MH  - Adenosine/pharmacology
MH  - Administration, Oral
MH  - Adult
MH  - Apyrase/pharmacology
MH  - Arachidonic Acids/*pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Catechols/pharmacology
MH  - Drug Synergism
MH  - Epoprostenol/pharmacology
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Masoprocol
MH  - Platelet Activating Factor/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Pyrazoles/pharmacology
MH  - Thromboxane B2/metabolism
MH  - Time Factors
MH  - Umbelliferones/pharmacology
EDAT- 1986/07/01 00:00
MHDA- 1986/07/01 00:01
CRDT- 1986/07/01 00:00
PHST- 1986/07/01 00:00 [pubmed]
PHST- 1986/07/01 00:01 [medline]
PHST- 1986/07/01 00:00 [entrez]
AID - 10.1016/0049-3848(86)90049-6 [doi]
PST - ppublish
SO  - Thromb Res. 1986 Jul 1;43(1):113-20. doi: 10.1016/0049-3848(86)90049-6.

PMID- 33187021
OWN - NLM
STAT- MEDLINE
DCOM- 20211110
LR  - 20211110
IS  - 1600-0897 (Electronic)
IS  - 1046-7408 (Linking)
VI  - 85
IP  - 4
DP  - 2021 Apr
TI  - Inherited thrombophilia and anticoagulant therapy for women with reproductive 
      failure.
PG  - e13378
LID - 10.1111/aji.13378 [doi]
AB  - Reproductive failure (RF) is the inability to conceive or to carry a pregnancy to 
      term, and its prevalence is not negligible. Pregnancy is a prothrombotic 
      condition, which can be abnormally exaggerated in women with thrombophilia. 
      Antiphospholipid syndrome is a cause of RF and effectively managed with heparin 
      and aspirin. However, there are yet insufficient data in patients with RF and 
      inherited thrombophilia. This review focuses on the significance of inherited 
      thrombophilia and RF and the role of anticoagulants in pregnancy outcomes. A few 
      randomized case-control studies have investigated the effect of anticoagulation 
      in RF with thrombophilia, and the results are yet debatable. Some inherited 
      thrombophilia including mutations of factor V Leiden, prothrombin, and 
      methylenetetrahydrofolate reductase and protein S deficiency are associated with 
      RF and/or late pregnancy complications. There are several implications which 
      influence the diagnosis and treatment. First, there is a lack of studies 
      revealing appropriate thrombophilia markers and its cutoff values for RF 
      specifically. Second, some thrombophilia markers change with sex and age. Lastly, 
      the study designs of previous studies are heterogeneous in selecting the 
      thrombophilia markers and drugs. Further studies to find adequate thrombophilia 
      markers of RF are warranted and eventually elucidate the subgroups beneficial to 
      anticoagulation treatment.
CI  - © 2020 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd.
FAU - Han, Ae Ra
AU  - Han AR
AUID- ORCID: 0000-0002-5432-548X
AD  - Department of Obstetrics and Gynecology, Myuonggok Medical Research Center, 
      Konyang University College of Medicine, Daejeon, Korea.
FAU - Han, Jae Won
AU  - Han JW
AD  - Department of Obstetrics and Gynecology, Myuonggok Medical Research Center, 
      Konyang University College of Medicine, Daejeon, Korea.
FAU - Lee, Sung Ki
AU  - Lee SK
AUID- ORCID: 0000-0002-6941-192X
AD  - Department of Obstetrics and Gynecology, Myuonggok Medical Research Center, 
      Konyang University College of Medicine, Daejeon, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201125
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - Thrombophilia, hereditary
SB  - IM
MH  - Abortion, Habitual/*drug therapy
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Infertility, Female/*drug therapy
MH  - Pregnancy
MH  - Thrombophilia/*drug therapy
OTO - NOTNLM
OT  - aspirin
OT  - heparin
OT  - obstetric complication. anticoagulation
OT  - recurrent pregnancy loss
OT  - repeated implantation failure
OT  - reproductive failure
OT  - thrombophilia
EDAT- 2020/11/14 06:00
MHDA- 2021/11/11 06:00
CRDT- 2020/11/13 20:17
PHST- 2020/09/09 00:00 [revised]
PHST- 2020/05/27 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/11/11 06:00 [medline]
PHST- 2020/11/13 20:17 [entrez]
AID - 10.1111/aji.13378 [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 2021 Apr;85(4):e13378. doi: 10.1111/aji.13378. Epub 2020 Nov 
      25.

PMID- 20679133
OWN - NLM
STAT- MEDLINE
DCOM- 20101123
LR  - 20220311
IS  - 1521-0103 (Electronic)
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 335
IP  - 2
DP  - 2010 Nov
TI  - Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and 
      O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate 
      (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant 
      prodrugs.
PG  - 443-50
LID - 10.1124/jpet.110.171017 [doi]
AB  - Chronic inflammation is an underlying etiological factor in carcinogenesis; 
      nonsteroidal anti-inflammatory drugs (NSAIDs) and their chemically modified 
      NO-releasing prodrugs (NO-NSAIDs) are promising chemopreventive agents. The aim 
      of this study was to conduct a head-to-head comparison between two NO-ASAs 
      possessing different NO donor groups, an organic nitrate [3-nitrooxyphenyl 
      acetylsalicylate (NO-ASA; NCX-4016)] and an N-diazeniumdiolate [NONO-ASA, O(2)- 
      (acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA; 
      CVM-01)], as antiulcerogenic, analgesic, anti-inflammatory, and antipyretic 
      agents. All drugs were administered orally at equimolar doses. For 
      antiulcerogenic study, 6 h after administration, the number and size of 
      hemorrhagic lesions in stomachs from euthanized animals were counted. Tissue 
      samples were frozen for prostaglandin E(2) (PGE(2)), superoxide dismutase (SOD), 
      and malondialdehyde determination. For anti-inflammatory study, 1 h after drug 
      administration, the volume of carrageenan-induced rat paw edemas was measured for 
      6 h. For antipyretic study, 1 h after dosing, fever was induced by 
      intraperitoneal LPS, and body core temperatures measured for 5 h. For analgesic 
      study, time-dependent analgesic effect of prodrugs was evaluated by 
      carrageenan-induced hyperalgesia. Drugs were administered 30 min after 
      carrageenan. NO-ASA and NONO-ASA were equipotent as analgesic and 
      anti-inflammatory agents but were better than aspirin. Despite a drastic 
      reduction of PGE(2) in stomach tissue, both prodrugs were devoid of gastric side 
      effects. Lipid peroxidation induced by aspirin was higher than that observed by 
      prodrugs. SOD activity induced by both prodrugs was similar, but approximately 
      2-fold higher than that induced by aspirin. CVM-01 is as effective as NCX-4016 in 
      anti-inflammatory, analgesic, and antipyretic assays in vivo, and it showed an 
      equivalent safety profile in the stomach. These results underscore the use of 
      N-diazeniumdiolate moieties in drug design.
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
AD  - Department of Physiology and Pharmacology, City University of New York Medical 
      School, 138th St. and Convent Ave., New York, NY 10031, USA.
FAU - Velazquez, Carlos A
AU  - Velazquez CA
FAU - Pruski, April
AU  - Pruski A
FAU - Nia, Kamran V
AU  - Nia KV
FAU - Abdellatif, Khaled R
AU  - Abdellatif KR
FAU - Keefer, Larry K
AU  - Keefer LK
FAU - Kashfi, Khosrow
AU  - Kashfi K
LA  - eng
GR  - ZIA BC005673/ImNIH/Intramural NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100802
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Antipyretics)
RN  - 0 (Hydrazines)
RN  - 0 (O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate)
RN  - 0 (Prodrugs)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - EH04H13L6B (nitroaspirin)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - J Pharmacol Exp Ther. 2010 Dec;335(3):861
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse 
      effects/chemistry/*pharmacology/therapeutic use
MH  - Antioxidants/adverse effects/chemistry/*pharmacology/therapeutic use
MH  - Antipyretics/adverse effects/chemistry/pharmacology/therapeutic use
MH  - Aspirin/adverse effects/*analogs & derivatives/chemistry/pharmacology/therapeutic 
      use
MH  - Dinoprostone/metabolism
MH  - Disease Models, Animal
MH  - Edema/drug therapy
MH  - Fever/drug therapy
MH  - Gastric Mucosa/drug effects/enzymology/metabolism/pathology
MH  - Hydrazines/chemistry/*pharmacology/therapeutic use
MH  - Hyperalgesia/drug therapy
MH  - Lipid Peroxidation/drug effects
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Molecular Structure
MH  - Prodrugs/adverse effects/chemistry/*pharmacology/therapeutic use
MH  - Rats
MH  - Rats, Wistar
MH  - Stomach Ulcer/chemically induced/pathology
MH  - Superoxide Dismutase/metabolism
MH  - Tumor Necrosis Factor-alpha/blood
PMC - PMC2967407
EDAT- 2010/08/04 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/08/04 06:00
PHST- 2010/08/04 06:00 [entrez]
PHST- 2010/08/04 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - jpet.110.171017 [pii]
AID - 3631069 [pii]
AID - 10.1124/jpet.110.171017 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2010 Nov;335(2):443-50. doi: 10.1124/jpet.110.171017. Epub 
      2010 Aug 2.

PMID- 19797944
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20131121
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
VI  - 20
IP  - 3
DP  - 2013 May-Jun
TI  - Primary prevention of cardiovascular complications in type II diabetes patients 
      using aspirin: a complicated tale.
PG  - 275-8
LID - 10.1097/MJT.0b013e3181afbf17 [doi]
AB  - Diabetes is a disease that affects 23 million in the United States alone. Within 
      the past 20 years, there has been remarkable research performed concerning 
      primary prevention of cardiovascular events in type II diabetes patients. The 
      American Diabetes Association along with a government panel made recommendations 
      that diabetes patients at a high risk of cardiovascular events should be on a 
      low-dose aspirin regimen. However, more recent data show that aspirin has no 
      clinical benefit to the diabetic patient as compared with a control group. 
      Looking at research performed by groups in Japan, the United States, namely, the 
      Primary Prevention Project, and a group in Ireland, we learn that there is no 
      significant difference between diabetes patients who take aspirin and those who 
      do not with respect to cardiovascular events. These studies are criticized by 
      some newer research, and the prevailing thought about them call into question the 
      results they obtained.Furthermore, we learn that many type II diabetes patients 
      are not properly participating in an aspirin regimen or they are overusing 
      aspirin, and these variables appear to confound the situation. One study showed 
      that up to 50% of diabetes patients do not have their diabetes under control and 
      are therefore increasing their risk for a multitude of complications arising from 
      diabetes, including cardiovascular events.Finally, we learn of an upcoming 
      project studying aspirin from Bayer, Inc. Much of the information presented in 
      this article demonstrates the need for more and better research revolving around 
      primary prevention of cardiovascular events in type II diabetes patients using 
      aspirin.
FAU - Schmidt, Brian M
AU  - Schmidt BM
AD  - Department of Cardiology, Chicago Medical School, Chicago, IL, USA.
FAU - Arora, Rohit
AU  - Arora R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Drug Administration Schedule
MH  - Humans
MH  - Medication Adherence
MH  - Primary Prevention/*methods
MH  - Treatment Outcome
EDAT- 2009/10/03 06:00
MHDA- 2013/10/18 06:00
CRDT- 2009/10/03 06:00
PHST- 2009/10/03 06:00 [entrez]
PHST- 2009/10/03 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - 10.1097/MJT.0b013e3181afbf17 [doi]
PST - ppublish
SO  - Am J Ther. 2013 May-Jun;20(3):275-8. doi: 10.1097/MJT.0b013e3181afbf17.

PMID- 16905794
OWN - NLM
STAT- MEDLINE
DCOM- 20070110
LR  - 20131121
IS  - 0002-0729 (Print)
IS  - 0002-0729 (Linking)
VI  - 35
IP  - 5
DP  - 2006 Sep
TI  - Aspirin prophylaxis and the prevalence of anaemia.
PG  - 514-7
AB  - BACKGROUND: Anaemia and vascular disease are both common amongst the elderly and 
      frequently co-exist. Whilst a consensus exists concerning the benefits of 
      low-dose aspirin in reducing risk from atheromatous disease, nonetheless concerns 
      arise in view of its harmful effect on gastric mucosa and its influence upon 
      haemostasis, with the possibility of subsequent gastrointestinal bleeding. This 
      study examined the relationship between chronic low-dose aspirin therapy and the 
      presence of anaemia. SETTING: A cross-sectional study of a representative cohort 
      of 464 community-dwelling subjects aged 77 years. METHODS: Subjects underwent 
      comprehensive assessment of psychosocial, functional, medical and laboratory 
      variables. In accordance with the World Health Organization criteria, anaemia was 
      defined as less than 13 g/dl for men and 12 g/dl for women. RESULTS: Chronic 
      low-dose aspirin use was found amongst 29% of the 227 women and 38% of the 237 
      males (P = 0.026). Aspirin use was significantly associated with hypertension, 
      ischaemic heart disease and diabetes mellitus. Anaemia was 42% less common among 
      aspirin users, a statistically robust finding (OR 2.44, 95%CI 1.28-4.66) 
      according to logistic regression analysis which included the confounding 
      variables of gender, education, diabetes, hypertension, heart disease, peptic 
      diseases, antipeptic therapy and smoking. Similarly, no association was observed 
      between aspirin use and reduced serum iron or iron saturation, reduced mean 
      corpuscular haemoglobin or mean corpuscular volume. CONCLUSIONS: Chronic low-dose 
      aspirin use amongst an elderly cohort was associated with increased likelihood of 
      normal haemoglobin.
FAU - Hammerman-Rozenberg, Robert
AU  - Hammerman-Rozenberg R
AD  - Department of Geriatrics and Rehabilitation, Hadassah Hebrew University Medical 
      Center, Mount Scopus, Jerusalem, Israel.
FAU - Jacobs, Jeremy M
AU  - Jacobs JM
FAU - Azoulay, Daniel
AU  - Azoulay D
FAU - Stessman, Jochanan
AU  - Stessman J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Age Ageing
JT  - Age and ageing
JID - 0375655
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anemia/*epidemiology/etiology
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Cohort Studies
MH  - Comorbidity
MH  - Cross-Sectional Studies
MH  - Female
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Male
MH  - Prevalence
EDAT- 2006/08/15 09:00
MHDA- 2007/01/11 09:00
CRDT- 2006/08/15 09:00
PHST- 2006/08/15 09:00 [pubmed]
PHST- 2007/01/11 09:00 [medline]
PHST- 2006/08/15 09:00 [entrez]
AID - 35/5/514 [pii]
AID - 10.1093/ageing/afl066 [doi]
PST - ppublish
SO  - Age Ageing. 2006 Sep;35(5):514-7. doi: 10.1093/ageing/afl066.

PMID- 30571234
OWN - NLM
STAT- MEDLINE
DCOM- 20190508
LR  - 20190508
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
VI  - 72
IP  - 6
DP  - 2018 Dec
TI  - Preeclampsia Prevention Using Routine Versus Screening Test-Indicated Aspirin in 
      Low-Risk Women.
PG  - 1391-1396
LID - 10.1161/HYPERTENSIONAHA.118.11718 [doi]
AB  - The objective was to evaluate whether routine aspirin 75 mg is more 
      cost-effective than the Fetal Medicine Foundation screen-and-treat approach for 
      preeclampsia prevention in low-risk nulliparous women. A health economic decision 
      analytical model was devised to estimate the discounted net health and cost 
      outcomes of routine aspirin versus Fetal Medicine Foundation screening 
      test-indicated aspirin for a cohort of 100 000 low-risk nulliparous women. Both 
      strategies were compared with no intervention. A subanalysis also compared 
      disaggregated components of the algorithm. The analysis used data from hospital 
      administration, literature, and a randomized controlled trial. Sensitivity 
      analyses assessed the impact of aspirin adherence, test cost, and accuracy on 
      study results. Presumed rates of preeclampsia were 3.75% with no intervention 
      versus 0.45% with aspirin use. Results found that routine aspirin was the 
      preferred strategy, in terms of greater health gains and larger cost savings. It 
      provided 163 quality-adjusted life-years relative to no intervention, whereas the 
      screen-and-treat policy achieved 108 quality-adjusted life-years. Routine aspirin 
      would result in an estimated cost saving of €14.9 million annually relative to no 
      intervention, whereas screen-and-treat approach would result in a smaller cost 
      saving of €3.1 million. When the analysis was extended to consider alternative 
      screen-and-treat strategies, routine aspirin remained the optimally 
      cost-effective approach. In conclusion, routine aspirin use in low-risk 
      nulliparous women has a greater health gain and cost saving compared with both 
      the Fetal Medicine Foundation and other screen-and-treat approaches.
FAU - Mone, Fionnuala
AU  - Mone F
AD  - From the UCD Perinatal Research Centre, National Maternity Hospital, Obstetrics 
      and Gynaecology, School of Medicine, University College Dublin, Ireland (F.M., 
      C.M., P.M., F.M.M.).
FAU - O'Mahony, James F
AU  - O'Mahony JF
AD  - Centre for Health Policy and Management, School of Medicine, Trinity College 
      Dublin, Ireland (J.F.O., E.T., C.N.).
FAU - Tyrrell, Ella
AU  - Tyrrell E
AD  - Centre for Health Policy and Management, School of Medicine, Trinity College 
      Dublin, Ireland (J.F.O., E.T., C.N.).
FAU - Mulcahy, Cecilia
AU  - Mulcahy C
AD  - From the UCD Perinatal Research Centre, National Maternity Hospital, Obstetrics 
      and Gynaecology, School of Medicine, University College Dublin, Ireland (F.M., 
      C.M., P.M., F.M.M.).
FAU - McParland, Peter
AU  - McParland P
AD  - From the UCD Perinatal Research Centre, National Maternity Hospital, Obstetrics 
      and Gynaecology, School of Medicine, University College Dublin, Ireland (F.M., 
      C.M., P.M., F.M.M.).
FAU - Breathnach, Fionnuala
AU  - Breathnach F
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin (F.B., P.D., E.T., F.D.M.).
FAU - Morrison, John J
AU  - Morrison JJ
AD  - Department of Obstetrics and Gynaecology, National University of Ireland, Galway 
      (J.J.M.).
FAU - Higgins, John
AU  - Higgins J
AD  - Department of Obstetrics and Gynaecology, University College Cork, Ireland 
      (J.H.).
FAU - Daly, Sean
AU  - Daly S
AD  - Department of Obstetrics and Gynaecology, Coombe Women's and Infant's University 
      Hospital, Dublin, Ireland (S.D.).
FAU - Cotter, Amanda
AU  - Cotter A
AD  - Department of Obstetrics and Gynaecology, Graduate Entry Medical School, 
      University of Limerick, Ireland (A.C.).
FAU - Hunter, Alyson
AU  - Hunter A
AD  - Department of Fetal Medicine, Royal Jubilee Maternity Hospital, Belfast, United 
      Kingdom (A.H.).
FAU - Dicker, Patrick
AU  - Dicker P
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin (F.B., P.D., E.T., F.D.M.).
FAU - Tully, Elizabeth
AU  - Tully E
AD  - Centre for Health Policy and Management, School of Medicine, Trinity College 
      Dublin, Ireland (J.F.O., E.T., C.N.).
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin (F.B., P.D., E.T., F.D.M.).
FAU - Malone, Fergal D
AU  - Malone FD
AD  - Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, 
      Rotunda Hospital, Dublin (F.B., P.D., E.T., F.D.M.).
FAU - Normand, Charles
AU  - Normand C
AD  - Centre for Health Policy and Management, School of Medicine, Trinity College 
      Dublin, Ireland (J.F.O., E.T., C.N.).
AD  - Cicely Saunders Institute, King's College London, United Kingdom (C.N.).
FAU - McAuliffe, Fionnuala M
AU  - McAuliffe FM
AD  - From the UCD Perinatal Research Centre, National Maternity Hospital, Obstetrics 
      and Gynaecology, School of Medicine, University College Dublin, Ireland (F.M., 
      C.M., P.M., F.M.M.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hypertension
JT  - Hypertension (Dallas, Tex. : 1979)
JID - 7906255
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Humans
MH  - Mass Screening
MH  - Models, Theoretical
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/diagnosis/*prevention & control
MH  - Pregnancy
MH  - Prenatal Care
MH  - Quality-Adjusted Life Years
OTO - NOTNLM
OT  - aspirin
OT  - biomarkers
OT  - cost analysis
OT  - preeclampsia
OT  - pregnancy
OT  - prevention
EDAT- 2018/12/21 06:00
MHDA- 2019/05/09 06:00
CRDT- 2018/12/21 06:00
PHST- 2018/12/21 06:00 [entrez]
PHST- 2018/12/21 06:00 [pubmed]
PHST- 2019/05/09 06:00 [medline]
AID - 10.1161/HYPERTENSIONAHA.118.11718 [doi]
PST - ppublish
SO  - Hypertension. 2018 Dec;72(6):1391-1396. doi: 10.1161/HYPERTENSIONAHA.118.11718.

PMID- 34536296
OWN - NLM
STAT- MEDLINE
DCOM- 20220218
LR  - 20220218
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 150
IP  - 6
DP  - 2022 Mar 15
TI  - Low-dose aspirin use and mortality risk in patients with head and neck cancer: A 
      nationwide cohort study of 10 770 patients.
PG  - 969-975
LID - 10.1002/ijc.33814 [doi]
AB  - Several recent observational studies have linked low-dose aspirin use to improved 
      survival in patients with head and neck cancer. However, studies of patterns of 
      aspirin use and risk of cancer-specific mortality are lacking. This nationwide 
      cohort study included all patients in the Danish Cancer Registry with a primary 
      diagnosis of head and neck squamous cell cancer (HNSCC) during 2000 to 2016, aged 
      30 to 84 years, without prior cancer (except nonmelanoma skin cancer) and alive 
      1 year after diagnosis. Nationwide registries provided information on filled 
      prescriptions, mortality and potential confounding factors. For a subpopulation, 
      a clinical database provided additional information, including human 
      papillomavirus (HPV) tumor status. We used Cox proportional hazards regression 
      models to estimate adjusted hazard ratios (HRs) with 95% confidence intervals 
      (CIs) for the association between postdiagnostic low-dose aspirin use (≥1 
      prescription within first year after diagnosis) and risk of cancer-specific 
      mortality. We identified 10 770 patients with HNSCC during a median follow-up of 
      3.9 years. Of these, 1799 (16.7%) were low-dose aspirin users. Postdiagnostic use 
      of low-dose aspirin was associated with a HR of 0.97 (95% CI 0.82-1.15) for 
      cancer-specific mortality. Similar neutral associations were found according to 
      patterns of aspirin use. No apparent trends emerged according to age, sex, 
      topography or stage. A tendency towards a decreased cancer-specific mortality 
      risk with low-dose aspirin use was observed among HPV-positive patients; however, 
      the statistical precision was low. In conclusion, we did not observe an 
      association between postdiagnostic low-dose aspirin use and cancer-specific 
      mortality in a nationwide cohort of patients with HNSCC.
CI  - © 2021 UICC.
FAU - de la Cour, Cecilie D
AU  - de la Cour CD
AUID- ORCID: 0000-0002-4211-1134
AD  - Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 
      Copenhagen, Denmark.
FAU - von Buchwald, Christian
AU  - von Buchwald C
AD  - Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, 
      Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
FAU - Dehlendorff, Christian
AU  - Dehlendorff C
AUID- ORCID: 0000-0001-6161-4565
AD  - Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, 
      Denmark.
FAU - Garset-Zamani, Martin
AU  - Garset-Zamani M
AUID- ORCID: 0000-0003-3857-8003
AD  - Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, 
      Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
FAU - Grønhøj, Christian
AU  - Grønhøj C
AD  - Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, 
      Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
FAU - Carlander, Amanda-Louise F
AU  - Carlander AF
AD  - Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, 
      Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
FAU - Friis, Søren
AU  - Friis S
AD  - Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Society Research 
      Center, Copenhagen, Denmark.
FAU - Kjaer, Susanne K
AU  - Kjaer SK
AD  - Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 
      Copenhagen, Denmark.
AD  - Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, 
      Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210928
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Head and Neck Neoplasms/*mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Squamous Cell Carcinoma of Head and Neck/*mortality
OTO - NOTNLM
OT  - aspirin
OT  - head and neck neoplasms
OT  - human papillomavirus
OT  - pharmacoepidemiology
OT  - survival analysis
EDAT- 2021/09/19 06:00
MHDA- 2022/02/19 06:00
CRDT- 2021/09/18 17:05
PHST- 2021/09/03 00:00 [revised]
PHST- 2021/06/15 00:00 [received]
PHST- 2021/09/06 00:00 [accepted]
PHST- 2021/09/19 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2021/09/18 17:05 [entrez]
AID - 10.1002/ijc.33814 [doi]
PST - ppublish
SO  - Int J Cancer. 2022 Mar 15;150(6):969-975. doi: 10.1002/ijc.33814. Epub 2021 Sep 
      28.

PMID- 7127995
OWN - NLM
STAT- MEDLINE
DCOM- 19821218
LR  - 20190512
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 32
IP  - 5
DP  - 1982 Nov
TI  - How blind was the patient blind in AMIS?
PG  - 543-53
AB  - The Aspirin Myocardial Infarction Study (AMIS) was a double-blind 
      placebo-controlled trial to test the effect of aspirin on the survival of 4524 
      people who had experienced a prior heart attack. Shortly before their closeout 
      visits, 400 of the participants were randomly selected to be interviewed 
      concerning their perceptions of their treatment assignments; 380 were actually 
      interviewed. A bare majority (52)% correctly identified their study therapy, 28% 
      mistakenly named the alternative treatment, 13% declined to guess, and 7% 
      specified extraneous substances. According to the proposed formula for evaluating 
      the patient blind, only 24% of the sample made "informed" guesses regarding their 
      therapy, while the remainder guessed in an uninformed way or not at all. Those 
      who tested their capsules (usually be taste) showed proportionately more correct 
      responses than the nontesters. Correctness also varied with the reasons for the 
      subjects' guesses (e.g., side effects). Among the sample as a whole, most people 
      were only moderately or less than moderately certain their guess was correct. 
      Even among those who were in fact correct, only 18% were absolutely certain of 
      their choice.
FAU - Howard, J
AU  - Howard J
FAU - Whittemore, A S
AU  - Whittemore AS
FAU - Hoover, J J
AU  - Hoover JJ
FAU - Panos, M
AU  - Panos M
LA  - eng
GR  - NHLBI-79-311/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - *Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy
MH  - Perception
MH  - *Placebos
MH  - Random Allocation
MH  - *Research Design
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
AID - 10.1038/clpt.1982.201 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1982 Nov;32(5):543-53. doi: 10.1038/clpt.1982.201.

PMID- 4899996
OWN - NLM
STAT- MEDLINE
DCOM- 19691218
LR  - 20190511
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 37
IP  - 2
DP  - 1969 Oct
TI  - Sedative properties of simple analgesics.
PG  - 450-8
AB  - 1. An attempt has been made to assess under double blind conditions the sedative 
      action of phenacetin, paracetamol, and aspirin by testing their ability to 
      prolong sleep in the face of a rapidly filling bladder.2. The volume in the 
      bladder on awakening was independent of the rate of urine formation.3. Although 
      phenacetin prolonged sleep there was no corresponding increase in urine volume on 
      awakening. Apparently phenacetin sensitized the bladder to the distending volume 
      and reduced the rate of urine formation. It was unnecessary to postulate sedative 
      action to explain the results.4. Paracetamol had no effect on the mean sleep 
      interval or mean urine volume although the drug was not totally inactive since it 
      increased the variance of the results for sleep interval and urine volume.5. 
      Aspirin prolonged sleep interval, but this effect would be explained if it were 
      an antidiuretic because there was no increase in urine volume on awakening.6. 
      Apparently no sedative or hypnotic has been shown to increase the urine volume on 
      awakening under similar conditions.
FAU - Hunt, J N
AU  - Hunt JN
FAU - Lallemand, R C
AU  - Lallemand RC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Hypnotics and Sedatives)
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Clinical Trials as Topic
MH  - Diuresis/drug effects
MH  - Humans
MH  - *Hypnotics and Sedatives
MH  - Male
MH  - Phenacetin/*pharmacology
MH  - Placebos
MH  - Sleep/*drug effects
MH  - Urinary Bladder/anatomy & histology
MH  - Urine
PMC - PMC1703695
EDAT- 1969/10/01 00:00
MHDA- 1969/10/01 00:01
CRDT- 1969/10/01 00:00
PHST- 1969/10/01 00:00 [pubmed]
PHST- 1969/10/01 00:01 [medline]
PHST- 1969/10/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1969.tb10581.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1969 Oct;37(2):450-8. doi: 10.1111/j.1476-5381.1969.tb10581.x.

PMID- 36730057
OWN - NLM
STAT- MEDLINE
DCOM- 20230710
LR  - 20230718
IS  - 1536-3732 (Electronic)
IS  - 1049-2275 (Linking)
VI  - 34
IP  - 5
DP  - 2023 Jul-Aug 01
TI  - Evaluation of the Effects of Dual Antiplatelet Therapy on Guided Bone 
      Regeneration in Peri-Implant Bone Defect.
PG  - 1590-1594
LID - 10.1097/SCS.0000000000009137 [doi]
AB  - In this study, the authors aim to investigate the effect of dual antiplatelet 
      agents on peri-implant-guided bone regeneraation by studying a sample of rats 
      with titanium implants in their tibias. The rats were randomly divided into 5 
      groups: acetylsalicylic acid (ASA) (n=10), treated with 20 mg/kg of ASA; ASA+CLPD 
      (Clopidogrel): (n=10), treated with 20 mg/kg of ASA and 30 mg/kg of clopidogrel; 
      ASA+PRSG (Prasugrel): (n=10), treated with 20 mg/kg of ASA and 15 mg/kg of 
      prasugrel; ASA+TCGR (Ticagrelor): (n=10), treated with 20 mg/kg of ASA and 
      300 mg/kg of ticagrelor; and a control group (n=10) received no further treatment 
      after implant surgery. Bone defects created half of the implant length 
      circumferencial after implant insertion and defects filled with bone grafts. 
      After 8 weeks experimental period, the rats sacrified and implants with 
      surrounding bone tissues were collected to histologic analysis; bone filling 
      ratios of defects (%) and blood samples collected to biochemical analysis (urea, 
      creatinine, aspartate aminotransferase, alanine aminotransferase, phosphorus, 
      magnesium, alkaline phosphatase, calcium, and parathormone). A statistically 
      significant difference was not detected between the groups for all parameters ( P 
      >0.05). When the percentage of new bone formation was examined, it was found that 
      there was no statistically significant difference between the groups ( P >0.05). 
      Antiplatelet therapy may not adversely affect guided bone regeneration in 
      peri-implant bone defects.
CI  - Copyright © 2022 by Mutaz B. Habal, MD.
FAU - Kobat, Mehmet Ali
AU  - Kobat MA
AD  - Department of Cardiology, Faculty of Medicine, Firat University.
FAU - Dundar, Serkan
AU  - Dundar S
AD  - Department of Peridontology, Faculty of Dentistry, Firat University.
FAU - Bozoglan, Alihan
AU  - Bozoglan A
AD  - Department of Peridontology, Faculty of Dentistry, Firat University.
FAU - Gelen, Mehmet Ali
AU  - Gelen MA
AD  - Department of Cardiology, Faculty of Medicine, Firat University.
FAU - Artas, Gokhan
AU  - Artas G
AD  - Department of Medical Pathology, Faculty of Medicine, Firat Univeristy, Elazig, 
      Turkey.
FAU - Kirtay, Mustafa
AU  - Kirtay M
AD  - Private Practice, Oral and Maxillofacial Surgery, London, ON, Canada.
FAU - Tasdemir, İsmail
AU  - Tasdemir İ
AD  - Department of Periodontology, Faculty of Dentistry, Karamanoğlu Mehmet Bey 
      University, Karaman.
FAU - Karasu, Mehdi
AU  - Karasu M
AD  - Department of Cardiology, Divan Hospital, Malatya.
FAU - Habek, Osman
AU  - Habek O
AD  - Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Harran 
      University, Sanliurfa, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20221201
PL  - United States
TA  - J Craniofac Surg
JT  - The Journal of craniofacial surgery
JID - 9010410
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Dental Implants)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
MH  - Animals
MH  - Rats
MH  - *Platelet Aggregation Inhibitors/pharmacology
MH  - *Dental Implants
MH  - Osseointegration
MH  - Clopidogrel
MH  - Prasugrel Hydrochloride
MH  - Ticagrelor
MH  - Bone Regeneration
MH  - Aspirin/pharmacology
COIS- The authors report no conflicts of interest.
EDAT- 2023/02/03 06:00
MHDA- 2023/07/10 06:42
CRDT- 2023/02/02 13:16
PHST- 2022/01/16 00:00 [received]
PHST- 2022/09/14 00:00 [accepted]
PHST- 2023/07/10 06:42 [medline]
PHST- 2023/02/03 06:00 [pubmed]
PHST- 2023/02/02 13:16 [entrez]
AID - 00001665-202307000-00057 [pii]
AID - 10.1097/SCS.0000000000009137 [doi]
PST - ppublish
SO  - J Craniofac Surg. 2023 Jul-Aug 01;34(5):1590-1594. doi: 
      10.1097/SCS.0000000000009137. Epub 2022 Dec 1.

PMID- 8371066
OWN - NLM
STAT- MEDLINE
DCOM- 19931008
LR  - 20210217
IS  - 0022-2275 (Print)
IS  - 0022-2275 (Linking)
VI  - 34
IP  - 7
DP  - 1993 Jul
TI  - Induction of (omega-1)-oxidation of monocarboxylic acids by acetylsalicylic acid.
PG  - 1187-99
AB  - Monocarboxylic acids may be oxidized at the omega- and (omega-1)- positions to 
      form dicarboxylic acids (DCAs) and (omega-1)-hydroxy- or (omega-1)-oxoacids. The 
      significance of this pathway under normal conditions is unknown, but DCAs and 
      (omega-1)-hydroxyacids are prominent features of disease states. The stimulation 
      of this pathway has been linked to induction of fatty acid-binding protein and 
      peroxisomal proliferation. In this study, we examined the effect of 
      acetylsalicylic acid (ASA) on (omega-1)-oxidation. (Omega-1)-oxidation was 
      assessed in subcellular fractions of rat liver. Rats were fed a normal diet or an 
      ASA-supplemented diet. Products were identified by gas chromatography-mass 
      spectrometry (GC-MS) and by comparison with the properties of authentic synthetic 
      standards. Doses of ASA that produced relatively low serum concentrations (12-24 
      mg/dl) resulted in as much as a 20-fold increase in the capacity for 
      (omega-1)-oxidation of medium (C12-C15) and long chain (C16-C20) monocarboxylic 
      acids. Normal rat liver oxidizes monocarboxylic acids to (omega-1)-oxoacids, 
      while liver from ASA-treated rats converts these substrates to 
      (omega-1)-oxodicarboxylic acids and (omega-1)-oxoacids. The formation of oxoacids 
      and oxodicarboxylic acids may be due to different enzymes. The formation of 
      oxodicarboxylic acids appears to be more labile than the formation of oxoacids. 
      These two processes also are differentially induced by ASA and have different 
      substrate specificities. These results demonstrate that ASA is a potent stimulant 
      of (omega-1)-oxidation and induces the formation of products that can be 
      shortened in peroxisomes to key metabolic intermediates.
FAU - Kundu, R K
AU  - Kundu RK
AD  - Department of Pediatrics, Pritzker Medical School, University of Chicago, IL 
      60637.
FAU - Getz, G S
AU  - Getz GS
FAU - Tonsgard, J H
AU  - Tonsgard JH
LA  - eng
GR  - HD-04583/HD/NICHD NIH HHS/United States
GR  - NS2316/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Lipid Res
JT  - Journal of lipid research
JID - 0376606
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Keto Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Fatty Acids, Unsaturated/*metabolism
MH  - Keto Acids/metabolism
MH  - Liver/*drug effects/metabolism
MH  - Male
MH  - Oxidation-Reduction
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Subcellular Fractions/chemistry
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
AID - S0022-2275(20)37706-3 [pii]
PST - ppublish
SO  - J Lipid Res. 1993 Jul;34(7):1187-99.

PMID- 18997251
OWN - NLM
STAT- MEDLINE
DCOM- 20090421
LR  - 20131121
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 163
DP  - 2008 Oct
TI  - [Prevention of thrombolitic compications with atrial fibrillation].
PG  - 35-8
AB  - This study presents the modern principles of prevention and treatment of 
      thrombolitic complications in patients with atrial fibrillation. The adequate 
      tactics and algorithm of antithrombotic therapy in the case of variety versions 
      of this disease is considered in this study. It described the efficiency and 
      safety of oral anticoagulants (antagonist Vit K) varfarin with the purpose to 
      inform the practical doctors with principals of prevention and treatment of 
      hemorrhagic complications. This publication appears as a fragment from the series 
      of atrial fibrillation management and destinated for physicians and cardiologist.
FAU - Abuladze, G
AU  - Abuladze G
AD  - Iv. Javakhishvili Tbilisi State University.
FAU - Jinjolia, N
AU  - Jinjolia N
FAU - Narsia, E
AU  - Narsia E
FAU - Abashidze, R
AU  - Abashidze R
FAU - Kajaia, T
AU  - Kajaia T
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Humans
MH  - Thrombosis/*etiology/*prevention & control
EDAT- 2008/11/11 09:00
MHDA- 2009/04/22 09:00
CRDT- 2008/11/11 09:00
PHST- 2008/11/11 09:00 [pubmed]
PHST- 2009/04/22 09:00 [medline]
PHST- 2008/11/11 09:00 [entrez]
PST - ppublish
SO  - Georgian Med News. 2008 Oct;(163):35-8.

PMID- 1139734
OWN - NLM
STAT- MEDLINE
DCOM- 19751010
LR  - 20190823
IS  - 0009-2797 (Print)
IS  - 0009-2797 (Linking)
VI  - 10
IP  - 5
DP  - 1975 May
TI  - The action of arachidonic acid on the locomotive activity of mice.
PG  - 309-12
AB  - The intraperitoneal administration of methyl or sodium arachidonate (100 and 200 
      mg-kg causes, in mice, a significant decline in locomotive activity 30 min later, 
      and is able to oppose completely the antagonistic action of D-amphetamine (2.5 
      and 5 mg-kg). This effect seems to be related to increased synthesis of 
      prostaglandins, for it disappears partially after pretreatment with 
      acetylsalicylic acid, which alone has no effect on the spontaneous activity of 
      mice. Oleic acid, an unsaturated fatty acid not involved in prostaglandin 
      synthesis does not give significant results in the same conditions.
FAU - Laborit, H
AU  - Laborit H
FAU - Thuret, F
AU  - Thuret F
FAU - Laurent, J
AU  - Laurent J
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Chem Biol Interact
JT  - Chemico-biological interactions
JID - 0227276
RN  - 0 (Arachidonic Acids)
RN  - 0 (Oleic Acids)
RN  - CK833KGX7E (Amphetamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amphetamine/pharmacology
MH  - Animals
MH  - Arachidonic Acids/antagonists & inhibitors/*pharmacology
MH  - Aspirin/pharmacology
MH  - Male
MH  - Mice
MH  - Motor Activity/*drug effects
MH  - Oleic Acids/pharmacology
EDAT- 1975/05/01 00:00
MHDA- 1975/05/01 00:01
CRDT- 1975/05/01 00:00
PHST- 1975/05/01 00:00 [pubmed]
PHST- 1975/05/01 00:01 [medline]
PHST- 1975/05/01 00:00 [entrez]
AID - 0009-2797(75)90051-4 [pii]
AID - 10.1016/0009-2797(75)90051-4 [doi]
PST - ppublish
SO  - Chem Biol Interact. 1975 May;10(5):309-12. doi: 10.1016/0009-2797(75)90051-4.

PMID- 22687660
OWN - NLM
STAT- MEDLINE
DCOM- 20130729
LR  - 20211021
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 2011
DP  - 2011 Aug 4
TI  - Massive epistaxis in a patient with Eisenmenger syndrome: illustrating the 
      clot-versus-bleed conundrum.
LID - 10.1136/bcr.02.2011.3812 [doi]
LID - bcr0220113812
AB  - Eisenmenger syndrome (ES) causes polycythaemia and thrombocytopenia, thus 
      rendering patients at risk from both thrombosis and haemorrhage. The clinical 
      dilemma lies in how to treat one without precipitating the other. Our case 
      demonstrates this important clinical problem. A 35-year-old lady with ES taking 
      aspirin with clopidogrel for thrombo-prophylaxis presented with massive 
      epistaxis. Blood tests showed polycythaemia, thrombocytopenia and normal clotting 
      studies. A bone marrow biopsy ruled out leukaemia and normal imaging made 
      pulmonary haemorrhage unlikely. Drug induced platelet dysfunction on a background 
      of thrombocytopenia was the most likely cause of her epistaxis. Despite cessation 
      of her dual anti-platelet therapy and multiple nasal packing, heavy epistaxis 
      continued. She was given an infusion of platelets, and once her counts 
      normalised, she was re-started on anti-platelet therapy.
FAU - Liu, Alexander
AU  - Liu A
AD  - Acute Admissions Unit, Watford General Hospital, London, UK.
FAU - Saman, Harman
AU  - Saman H
FAU - Pusalkar, Pawan
AU  - Pusalkar P
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20110804
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Eisenmenger Complex/*complications
MH  - Epistaxis/*chemically induced
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Thrombocytopenia/*chemically induced
MH  - Thrombosis/etiology/prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
PMC - PMC4545113
COIS- Competing interests: None.
EDAT- 2011/01/01 00:00
MHDA- 2013/07/31 06:00
CRDT- 2012/06/13 06:00
PHST- 2012/06/13 06:00 [entrez]
PHST- 2011/01/01 00:00 [pubmed]
PHST- 2013/07/31 06:00 [medline]
AID - bcr.02.2011.3812 [pii]
AID - 10.1136/bcr.02.2011.3812 [doi]
PST - epublish
SO  - BMJ Case Rep. 2011 Aug 4;2011:bcr0220113812. doi: 10.1136/bcr.02.2011.3812.

PMID- 16469511
OWN - NLM
STAT- MEDLINE
DCOM- 20070920
LR  - 20131121
IS  - 1079-9796 (Print)
IS  - 1079-9796 (Linking)
VI  - 36
IP  - 2
DP  - 2006 Mar-Apr
TI  - Aspirin "resistance".
PG  - 171-6
AB  - A variable responsiveness to antiplatelet drugs is a clinical phenomenon that 
      does not principally differ from other drug treatments in other therapeutic 
      fields. The pharmacological part is to clarify whether a "true" resistance exists 
      in pharmacological terms, i.e., a reduced potency of the compound to work as 
      suggested and to find out the underlying cellular mechanism(s). Two principally 
      different methods of laboratory control for platelet sensitivity to aspirin (ASA) 
      are available: measurement of platelet function (ex vivo) or measurement of 
      inhibition of thromboxane formation. Both methods have limitations and did not 
      yet result in a generally accepted definition of a pharmacological ASA 
      "resistance". The new typological approach of Weber et al. [A.A. Weber, B. 
      Przytulski, A. Schanz, et al., Towards a definition of aspirin resistance: a 
      typological approach. Platelets 13 (2002) 37.] helps to identify different 
      subtypes of ASA resistance in pharmacological terms by combining in vitro 
      aggregometry with thromboxane measurement. Using this method, a "true" 
      pharmacological resistance, associated with a reduced antiplatelet response to 
      ASA and reduced inhibition of thromboxane formation, was found in patients 
      undergoing coronary artery bypass surgery. Platelets of these patients expressed 
      a hitherto unknown isoform of COX-2-COX-2a which might generate a different gene 
      product. In this context, it is interesting that CABG patients express 
      transiently an immunoreactive COX-2 protein with lower molecular weight. Studies 
      on the significance of this finding for ASA resistance are in progress.
FAU - Schrör, Karsten
AU  - Schrör K
AD  - Institut für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum 
      Düsseldorf, Heinrich-Heine-Universität, Universitätsstr. 1, Geb. 22.21, D-40225 
      Düsseldorf, Germany. kschroer@uni-duesseldorf.de
FAU - Weber, Artur-Aron
AU  - Weber AA
FAU - Hohlfeld, Thomas
AU  - Hohlfeld T
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060215
PL  - United States
TA  - Blood Cells Mol Dis
JT  - Blood cells, molecules & diseases
JID - 9509932
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cyclooxygenase 2/genetics/physiology
MH  - *Drug Resistance
MH  - Humans
MH  - Isoenzymes/physiology
MH  - Membrane Proteins/genetics/physiology
RF  - 440
EDAT- 2006/02/14 09:00
MHDA- 2007/09/21 09:00
CRDT- 2006/02/14 09:00
PHST- 2005/12/06 00:00 [received]
PHST- 2005/12/19 00:00 [accepted]
PHST- 2006/02/14 09:00 [pubmed]
PHST- 2007/09/21 09:00 [medline]
PHST- 2006/02/14 09:00 [entrez]
AID - S1079-9796(06)00019-2 [pii]
AID - 10.1016/j.bcmd.2005.12.017 [doi]
PST - ppublish
SO  - Blood Cells Mol Dis. 2006 Mar-Apr;36(2):171-6. doi: 10.1016/j.bcmd.2005.12.017. 
      Epub 2006 Feb 15.

PMID- 8804929
OWN - NLM
STAT- MEDLINE
DCOM- 19961204
LR  - 20190821
IS  - 0903-1936 (Print)
IS  - 0903-1936 (Linking)
VI  - 9
IP  - 6
DP  - 1996 Jun
TI  - Changes in neurokinin A airway responsiveness with inhaled 
      lysine-acetylsalicylate in asthma.
PG  - 1139-45
AB  - Endogenously released cyclooxygenase products modulate the bronchoconstrictor 
      response to various stimuli in asthma. Little is known of the change in airway 
      responsiveness to neurokinin A (NKA) after cyclooxygenase blockade. In this 
      randomized, double-blind, placebo-controlled study, we have investigated the 
      effect of the potent cyclooxygenase inhibitor, lysine acetylsalicylate (L-ASA) 
      administered by inhalation, on the bronchoconstrictor response both to neurokinin 
      A (NKA) and methacholine in nine asthmatic subjects. Subjects attended the 
      laboratory on four separate occasions to receive nebulized L-ASA (solution of 90 
      mg.mL-1) or matched placebo (glycine, solution of 30 mg.mL-1) 15 min prior to 
      bronchial challenge with NKA or methacholine, in a randomized, double-blind 
      order. Changes in airway calibre were followed as forced expiratory volume in one 
      second (FEV1) and agonist responsiveness, expressed as the provocative 
      concentration causing a 20% fall in FEV1 from baseline (PC20). L-ASA elicited a 
      significant fall in FEV1 from baseline. When compared with placebo, inhaled L-ASA 
      reduced the airway responsiveness to NKA in 8 of the 9 subjects studied, the 
      geometric mean (range) values for PC20 NKA increasing significantly from 153.2 
      (52.0-258.9) to 303.1 (83.4-668.5) micrograms.mL-1 after placebo and L-ASA, 
      respectively. However, no significant change in airway responsiveness to 
      methacholine was recorded after L-ASA, their geometric mean (range) PC20 values 
      being 1.60 (0.17-9.59) and 1.53 (0.09-14.01) mg.mL-1 after placebo and L-ASA, 
      respectively. The small decrease in airway responsiveness to neurokinin A after 
      administration of lysine acetylsalicylate by inhalation suggests that endogenous 
      prostaglandins may play a contributory protective role in the airway response to 
      neurokinin A in human asthma.
FAU - Crimi, N
AU  - Crimi N
AD  - Istituto Malattie Apparato Respiratorio, Università di Catania, Italy.
FAU - Polosa, R
AU  - Polosa R
FAU - Prosperini, G
AU  - Prosperini G
FAU - Magrì, S
AU  - Magrì S
FAU - Ciamarra, I
AU  - Ciamarra I
FAU - Mistretta, A
AU  - Mistretta A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0W5ETF9M2K (Methacholine Chloride)
RN  - 86933-74-6 (Neurokinin A)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Asthma/*drug therapy/physiopathology
MH  - Bronchial Provocation Tests
MH  - Constriction, Pathologic/physiopathology
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Methacholine Chloride/administration & dosage
MH  - Middle Aged
MH  - Neurokinin A/administration & dosage
MH  - Respiratory Function Tests
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
AID - 10.1183/09031936.96.09061139 [doi]
PST - ppublish
SO  - Eur Respir J. 1996 Jun;9(6):1139-45. doi: 10.1183/09031936.96.09061139.

PMID- 10423593
OWN - NLM
STAT- MEDLINE
DCOM- 20000713
LR  - 20191103
IS  - 1075-2765 (Print)
IS  - 1075-2765 (Linking)
VI  - 4
IP  - 2-3
DP  - 1997 Feb-Mar
TI  - Nonsteroidal anti-inflammatory drugs and aspirin: a comparison of the 
      antiplatelet effects.
PG  - 62-5
AB  - Antiplatelet effects of common analgesics were assessed in vitro. The Streck 
      Platelet Aggregation Test Kit (Omaha, NE) was used to measure percent platelet 
      aggregation in response to sodium arachidonate, collagen, adenosine diphosphate, 
      and ristocetin in patients on various analgesics. In comparison with the control 
      group, the response to arachidonate and collagen of ibuprofen (86% vs. 33% and 
      55% vs. 23%), naproxen (86% vs. 43% and 55% vs. 29%), indomethacin (86% vs. 26% 
      and 55% vs. 17%), and aspirin (86 vs. 21% and 55 vs. 23%) all demonstrated a 
      significant yet comparable reduction in platelet aggregation (p < 0.01). Because 
      of the comparable antiplatelet effects of aspirin and NSAIDs, the additional 
      benefits of daily aspirin in those patients on chronic and consistent NSAID 
      therapy must be reconsidered.
FAU - Cheng, J C
AU  - Cheng JC
AD  - Department of Medicine, North Chicago Veterans Affairs Medical Administration, IL 
      60064, USA.
FAU - Siegel, L B
AU  - Siegel LB
FAU - Katari, B
AU  - Katari B
FAU - Traynoff, S A
AU  - Traynoff SA
FAU - Ro, J O
AU  - Ro JO
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Count
MH  - Platelet Function Tests/instrumentation
EDAT- 1997/02/01 00:00
MHDA- 2000/07/15 11:00
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 2000/07/15 11:00 [medline]
PHST- 1997/02/01 00:00 [entrez]
AID - 10.1097/00045391-199702000-00002 [doi]
PST - ppublish
SO  - Am J Ther. 1997 Feb-Mar;4(2-3):62-5. doi: 10.1097/00045391-199702000-00002.

PMID- 483916
OWN - NLM
STAT- MEDLINE
DCOM- 19791128
LR  - 20131121
IS  - 0044-2542 (Print)
IS  - 0044-2542 (Linking)
VI  - 34
IP  - 10
DP  - 1979 May 15
TI  - [Inhibitors of platelet aggregation in the therapy of arteriosclerosis 
      obliterans].
PG  - 117-20
AB  - The central role of the thrombocytes in the initial atherogenesis and the 
      secondary formation of the thrombus on sclerotically changed walls of the vessels 
      is the basis of all experiments to perform a primary or secondary prevention of 
      the atherosclerosis with thrombocyte aggregation inhibitors. Of the numerous 
      thrombocyte-inhibiting substances acetyl salicylic acid, dipyridamol and 
      sulfinpyrazone proved most suitable for clinical purposes. Apparantly for 
      methodical reasons experiments of a primary prevention of the atherosclerosis 
      with aggregation inhibitors have hitherto not be performed. On the other hand, in 
      numerous quantitatively very different studies on patients with manifest 
      cerebral, coronary and peripheral arteriosclerosis the influencibility of the 
      course of the disease was tested by thrombocyte inhibitors. Since correct 
      prospective studies are connected with enormous organisational expenditure and 
      must extend for a longer period many extensive examinations have not yet 
      finished. In the present survey the hitherto existing reports from literature are 
      critically summarized, taking into particular consideration the per ipheral 
      angioorganopathies and first informations on an own study concerning the 
      prophylaxis of the diabetic angiopathy with Micristin are given. The present 
      state of knowledge allows the conclusion that the well founded theoretical 
      concept is apparantly confirmed by practice. However, the successes observed 
      could be statistically ascertained only in individual cases, so that at present a 
      final estimation of the prophylactic value of these preparations is not yet 
      possible.
FAU - Zabel Langhennig, R
AU  - Zabel Langhennig R
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Aggregationshemmer in der Therapie der Arteriosclerosis obliterans.
PL  - Germany
TA  - Z Gesamte Inn Med
JT  - Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete
JID - 21730470R
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Arteriosclerosis Obliterans/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Diabetic Angiopathies/drug therapy
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Sulfinpyrazone/therapeutic use
EDAT- 1979/05/15 00:00
MHDA- 1979/05/15 00:01
CRDT- 1979/05/15 00:00
PHST- 1979/05/15 00:00 [pubmed]
PHST- 1979/05/15 00:01 [medline]
PHST- 1979/05/15 00:00 [entrez]
PST - ppublish
SO  - Z Gesamte Inn Med. 1979 May 15;34(10):117-20.

PMID- 2575401
OWN - NLM
STAT- MEDLINE
DCOM- 19900306
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 28
IP  - 6
DP  - 1989 Dec
TI  - Benorylate hydrolysis by human plasma and human liver.
PG  - 703-8
AB  - 1. Benorylate (4-acetamido phenyl-O-acetylsalicylate) hydrolysis in vitro by 
      human plasma and by human liver microsomes and cytosol has been investigated. 2. 
      Benorylate was hydrolysed by a route involving initial hydrolysis of the acetyl 
      group to yield phenetsal followed by hydrolysis to paracetamol and salicylate. 
      Hydrolysis via acetylsalicylate was minor. 3. Benorylate was more actively 
      hydrolysed by liver cytosol than microsomes and about 10 times faster than 
      plasma. 4. Following a single oral dose benorylate (4 g) to volunteers only 
      salicylate and paracetamol were detected in the plasma. 5. The therapeutic 
      effects of benorylate appear to be mediated by salicylate and paracetamol.
FAU - Williams, F M
AU  - Williams FM
AD  - Wolfson Unit of Clinical Pharmacology, Department of Operative Dentistry, Medical 
      School, University of Newcastle upon Tyne.
FAU - Moore, U
AU  - Moore U
FAU - Seymour, R A
AU  - Seymour RA
FAU - Mutch, E M
AU  - Mutch EM
FAU - Nicholson, E
AU  - Nicholson E
FAU - Wright, P
AU  - Wright P
FAU - Wynne, H
AU  - Wynne H
FAU - Blain, P G
AU  - Blain PG
FAU - Rawlins, M D
AU  - Rawlins MD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Salicylates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - EC 3.1.- (Esterases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/blood
MH  - Aspirin/blood/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Cytosol/metabolism
MH  - Esterases/metabolism
MH  - Female
MH  - Humans
MH  - Hydrolysis
MH  - In Vitro Techniques
MH  - Liver/*metabolism
MH  - Male
MH  - Microsomes, Liver/metabolism
MH  - Salicylates/blood/*metabolism
PMC - PMC1380041
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1989.tb03563.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1989 Dec;28(6):703-8. doi: 
      10.1111/j.1365-2125.1989.tb03563.x.

PMID- 9455365
OWN - NLM
STAT- MEDLINE
DCOM- 19980305
LR  - 20131121
IS  - 0048-7848 (Print)
IS  - 0048-7848 (Linking)
VI  - 99
IP  - 3-4
DP  - 1995 Jul-Dec
TI  - [Do calcium antagonists potentiate analgesia?].
PG  - 187-91
AB  - Studying the analgesic action for some of the calcium antagonists (nifedipin and 
      verapamil) we found for the middle therapeutic doses analgesic effect of similar 
      intensity with the middle therapeutic doses for aspirin and paracetamol. While 
      associating these substances, we obtained an enhanced analgesic effect from 50% 
      for the substances when taken separately to 65-88% when associating calcium 
      antagonists with analgesic and antipyretics. This interaction on the analgesic 
      effect could be explained by the common intervention of the two groups of 
      substances on the physiological link between prostaglandins and calcium.
FAU - Hriscu, A
AU  - Hriscu A
AD  - Universitatea de Medicină şi Farmacie Gr. T. Popa, Iaşi.
LA  - rum
PT  - English Abstract
PT  - Journal Article
TT  - Antagoniştii calciului potenţează analgezia?
PL  - Romania
TA  - Rev Med Chir Soc Med Nat Iasi
JT  - Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi
JID - 0413735
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Calcium Channel Blockers)
RN  - 362O9ITL9D (Acetaminophen)
RN  - CJ0O37KU29 (Verapamil)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/pharmacology
MH  - Analgesics, Non-Narcotic/*pharmacology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Calcium Channel Blockers/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Mice
MH  - Nifedipine/pharmacology
MH  - Verapamil/pharmacology
EDAT- 1995/07/01 00:00
MHDA- 1998/02/10 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1998/02/10 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
PST - ppublish
SO  - Rev Med Chir Soc Med Nat Iasi. 1995 Jul-Dec;99(3-4):187-91.

PMID- 2666026
OWN - NLM
STAT- MEDLINE
DCOM- 19890829
LR  - 20191022
IS  - 0197-2456 (Print)
IS  - 0197-2456 (Linking)
VI  - 10
IP  - 2
DP  - 1989 Jun
TI  - Meta-analysis and evidence.
PG  - 188-204
AB  - Meta-analysis is the science of combining evidence from different studies, but 
      traditional statistical techniques contain neither a formal definition nor a 
      measure of evidence. It is argued in this paper that the log-likelihood ratio, as 
      a measure of the "weight of evidence," can be a very useful tool in the 
      meta-analysis. The mathematics and the philosophy behind the use of this index 
      are introduced. The construction and interpretation of "support curves" in fixed 
      and random-effects models are presented. The application of evidential techniques 
      is illustrated on six trials of aspirin therapy previously presented by Canner. 
      The possible dangers of focusing on statistical error rates instead of evidence 
      are discussed.
FAU - Goodman, S N
AU  - Goodman SN
AD  - Department of Oncology, Johns Hopkins University, Baltimore, Maryland.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Control Clin Trials
JT  - Controlled clinical trials
JID - 8006242
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Controlled Clin Trials 1989 Dec;10(4):435
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - *Data Interpretation, Statistical
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Models, Statistical
MH  - Myocardial Infarction/mortality
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
AID - 0197-2456(89)90030-5 [pii]
AID - 10.1016/0197-2456(89)90030-5 [doi]
PST - ppublish
SO  - Control Clin Trials. 1989 Jun;10(2):188-204. doi: 10.1016/0197-2456(89)90030-5.

PMID- 826460
OWN - NLM
STAT- MEDLINE
DCOM- 19770226
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 5
IP  - 3
DP  - 1976
TI  - Stimulation of human platelet aggregation by phospholipase-A and a saline 
      "extract" of a polyurethane.
PG  - 165-75
AB  - A saline extract of polyurethane (SPU) induces enzymatic conversion of 
      arachidonic acid (either exogenous or released through the action of exogenous 
      phospholipase-A) by activating a hitherto undiscovered labile enzyme, 
      synthetase-alpha which is not blocked by aspirin. Addition of SPU, plus 
      arachidonic acid or SPU plus phospholipase-A to platelet-rich plasma (PRP) 
      triggers a biphasic platelet aggregation. Incubation of SPU with PRP results in 
      activation and exhaustion of synthetase-alpha; this renders platelets refractory 
      to the various aggregating agents.
FAU - Iatridis, S G
AU  - Iatridis SG
FAU - Iatridis, P G
AU  - Iatridis PG
FAU - Tsiala-Paraschou, E
AU  - Tsiala-Paraschou E
FAU - Markidou, S G
AU  - Markidou SG
FAU - Ragatz, B H
AU  - Ragatz BH
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Polyurethanes)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EC 3.1.- (Phospholipases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Humans
MH  - Phospholipases/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Polyurethanes/*pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/biosynthesis
MH  - Stimulation, Chemical
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1159/000214132 [doi]
PST - ppublish
SO  - Haemostasis. 1976;5(3):165-75. doi: 10.1159/000214132.

PMID- 15753201
OWN - NLM
STAT- MEDLINE
DCOM- 20050425
LR  - 20181113
IS  - 0022-1007 (Print)
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Linking)
VI  - 201
IP  - 5
DP  - 2005 Mar 7
TI  - Controlling inflammation: a fat chance?
PG  - 671-4
AB  - The inflammatory response protects the body against infection and injury but can 
      itself become deregulated with deleterious consequences to the host. It is now 
      clear that several endogenous biochemical pathways activated during defense 
      reactions can counterregulate inflammation. New experimental evidence adds 
      resolvin E1 to this group of endogenous inhibitors and provides further rationale 
      for the beneficial effects of dietary supplementation with fish oils. It also 
      highlights an unexpected twist in the pharmacology of aspirin.
FAU - Flower, Roderick J
AU  - Flower RJ
AD  - The William Harvey Research Institute, London EC1M 6BQ, UK. r.j.flower@qmul.ac.uk
FAU - Perretti, Mauro
AU  - Perretti M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Dietary Fats)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/pharmacology
MH  - Dietary Fats/*pharmacology
MH  - Fatty Acids, Unsaturated/pharmacology
MH  - Humans
MH  - Inflammation/*diet therapy/*drug therapy/metabolism
MH  - Receptors, G-Protein-Coupled/metabolism
PMC - PMC2212824
EDAT- 2005/03/09 09:00
MHDA- 2005/04/26 09:00
CRDT- 2005/03/09 09:00
PHST- 2005/03/09 09:00 [pubmed]
PHST- 2005/04/26 09:00 [medline]
PHST- 2005/03/09 09:00 [entrez]
AID - jem.20050222 [pii]
AID - 20050222 [pii]
AID - 10.1084/jem.20050222 [doi]
PST - ppublish
SO  - J Exp Med. 2005 Mar 7;201(5):671-4. doi: 10.1084/jem.20050222.

PMID- 15485103
OWN - NLM
STAT- MEDLINE
DCOM- 20041231
LR  - 20170214
IS  - 0961-2033 (Print)
IS  - 0961-2033 (Linking)
VI  - 13
IP  - 9
DP  - 2004
TI  - The management of pregnant patients with antiphospholipid syndrome.
PG  - 683-7
AB  - Recurrent pregnancy loss is now considered a treatable clinical condition 
      associated with antiphospholipid antibodies. The management of pregnant patients 
      with antiphospholipid syndrome is mainly based on the use of 
      antiaggregant/anticoagulant agents (with aspirin and heparin) to prevent 
      thrombosis in the uteroplacental circulation. Interventions with these drug 
      therapies and monitored pregnancy have increased fetal survival.
FAU - Cervera, R
AU  - Cervera R
AD  - Department of Autoimmune Diseases, Hospital Clinic-Institut d'Investigacions 
      Biomèdiques August Pi i Sunyer, Barcelona, Catalonia, Spain. 
      rcervera@clinic.ub.es
FAU - Balasch, J
AU  - Balasch J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/etiology/*prevention & control
MH  - Anticoagulants/therapeutic use
MH  - Antiphospholipid Syndrome/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
RF  - 34
EDAT- 2004/10/16 09:00
MHDA- 2005/01/01 09:00
CRDT- 2004/10/16 09:00
PHST- 2004/10/16 09:00 [pubmed]
PHST- 2005/01/01 09:00 [medline]
PHST- 2004/10/16 09:00 [entrez]
AID - 10.1191/0961203304lu1092oa [doi]
PST - ppublish
SO  - Lupus. 2004;13(9):683-7. doi: 10.1191/0961203304lu1092oa.

PMID- 1798217
OWN - NLM
STAT- MEDLINE
DCOM- 19920413
LR  - 20191028
IS  - 0021-5120 (Print)
IS  - 0021-5120 (Linking)
VI  - 30
IP  - 6
DP  - 1991 Nov-Dec
TI  - Primary erythromelalgia: the role of skin sympathetic nerve activity.
PG  - 564-7
AB  - A 54-year-old man complained of burning pain, warm skin and erythema in his 
      extremities. A diagnosis of primary erythromelalgia was made. Microneurography 
      was used to clarify the role of skin sympathetic nerve activity in the 
      pathophysiology of primary erythromelalgia. The patient showed normal skin 
      sympathetic nerve activity but no vasoconstriction response. Aspirin activated 
      the skin sympathetic nerve activity and improved vasoconstriction producing 
      symptomatic relief. These results suggest that the lack of vasoconstriction 
      following vasoconstrictor activity of the skin sympathetic nerves results in 
      increased skin blood flow and burning pain.
FAU - Sugiyama, Y
AU  - Sugiyama Y
AD  - Department of Neurology, Nagoya University School of Medicine, Japan.
FAU - Hakusui, S
AU  - Hakusui S
FAU - Takahashi, A
AU  - Takahashi A
FAU - Iwase, S
AU  - Iwase S
FAU - Mano, T
AU  - Mano T
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - Jpn J Med
JT  - Japanese journal of medicine
JID - 0247713
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Electrophysiology
MH  - Erythromelalgia/drug therapy/*physiopathology
MH  - Humans
MH  - Male
MH  - Microcirculation/physiopathology
MH  - Middle Aged
MH  - Skin/blood supply/*innervation
MH  - Sympathetic Nervous System/*physiopathology
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
AID - 10.2169/internalmedicine1962.30.564 [doi]
PST - ppublish
SO  - Jpn J Med. 1991 Nov-Dec;30(6):564-7. doi: 10.2169/internalmedicine1962.30.564.

PMID- 10097241
OWN - NLM
STAT- MEDLINE
DCOM- 19990429
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 137
IP  - 4 Pt 2
DP  - 1999 Apr
TI  - Update on aspirin in the treatment and prevention of cardiovascular disease.
PG  - S9-S13
AB  - The effects of low-dose aspirin on cardiovascular disease have been tested in 
      randomized trials in 3 types of populations: (1) patients with a history of 
      cardiovascular disease; (2) patients with evolving acute myocardial infarction 
      (MI), and (3) apparently healthy subjects. In a very wide range of patients with 
      prior occlusive cardiovascular disease, aspirin reduces the risks of nonfatal MI, 
      nonfatal stroke, and vascular death. Initiating aspirin therapy within 24 hours 
      after the onset of symptoms of an acute MI also confers conclusive reductions in 
      the risk of nonfatal reinfarction, nonfatal stroke, and total cardiovascular 
      death. In primary prevention trials, aspirin has been shown to reduce the risk of 
      a first MI in men, but the data on stroke and total cardiovascular death are not 
      sufficient to allow firm conclusions to be drawn; randomized data from studies in 
      women are not yet available. The Women's Health Study, an ongoing large-scale 
      trial in female health care professionals, will provide the data necessary to 
      assess the balance of benefits and risks of aspirin in primary prevention. Until 
      then, the decision to use aspirin in primary prevention should be based on the 
      clinical judgment of the physician and considered as an adjunct in the management 
      of other cardiovascular disease risk factors.
FAU - Hennekens, C H
AU  - Hennekens CH
AD  - Division of Preventive Medicine, Department of Medicine, Brigham and Women's 
      Hospital, Harvard Medical School, Boston, MA 02215, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*drug therapy/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
RF  - 23
EDAT- 1999/03/31 00:00
MHDA- 1999/03/31 00:01
CRDT- 1999/03/31 00:00
PHST- 1999/03/31 00:00 [pubmed]
PHST- 1999/03/31 00:01 [medline]
PHST- 1999/03/31 00:00 [entrez]
AID - a97096 [pii]
AID - 10.1016/s0002-8703(99)70391-1 [doi]
PST - ppublish
SO  - Am Heart J. 1999 Apr;137(4 Pt 2):S9-S13. doi: 10.1016/s0002-8703(99)70391-1.

PMID- 421314
OWN - NLM
STAT- MEDLINE
DCOM- 19790524
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 59
IP  - 4
DP  - 1979 Apr
TI  - Aspirin-induced increase in collateral flow after acute coronary occlusion in 
      dogs.
PG  - 744-7
AB  - Aspirin (acetylsalicylic acid) has inhibitory effects on platelet function and 
      prostaglandin synthesis. Since alterations in either platelet function or 
      prostaglandin-mediated vascular responses could influence blood flow to ischemic 
      myocardium, we tested the effects of aspirin on coronary collateral flow after 
      acute occlusion of the left anterior descending coronary artery in dogs. Aspirin 
      dose (600 mg i.v.) consistently inhibited in vitro ADP-induced platelet 
      aggregation. In 13 open-chest dogs, regional myocardial blood flows (radioactive 
      microsphere technique) were determined at 5 minutes and 4 hours after occlusion). 
      In seven of these dogs, aspirin (600 mg i.v.) was administered 1 hour before 
      occlusion. In the aspirin-treated dogs, collateral flow increased significantly 
      (p less than 0.05), from 0.09 +/- 0.02 ml/min/g at 5 minutes to 0.15 and 0.02 
      ml/min/g 4 hours after occlusion. Collateral flow was not significantly altered 
      over 4 hours in control dogs. The aspirin-induced increase in collateral flow was 
      confined to epicardium (12 +/- 4% of normal zone flow at 5 minutes to 23 +/- 4% 
      at 4 hours after occlusion).
FAU - Capurro, N L
AU  - Capurro NL
FAU - Marr, K C
AU  - Marr KC
FAU - Aamodt, R
AU  - Aamodt R
FAU - Goldstein, R E
AU  - Goldstein RE
FAU - Epstein, S E
AU  - Epstein SE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adenosine Diphosphate/metabolism
MH  - Animals
MH  - Arterial Occlusive Diseases/*physiopathology
MH  - Aspirin/*pharmacology
MH  - Collateral Circulation/*drug effects
MH  - Coronary Vessels/*physiopathology
MH  - Dogs
MH  - Female
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Time Factors
EDAT- 1979/04/01 00:00
MHDA- 1979/04/01 00:01
CRDT- 1979/04/01 00:00
PHST- 1979/04/01 00:00 [pubmed]
PHST- 1979/04/01 00:01 [medline]
PHST- 1979/04/01 00:00 [entrez]
AID - 10.1161/01.cir.59.4.744 [doi]
PST - ppublish
SO  - Circulation. 1979 Apr;59(4):744-7. doi: 10.1161/01.cir.59.4.744.

PMID- 17086221
OWN - NLM
STAT- MEDLINE
DCOM- 20061127
LR  - 20181201
IS  - 0807-7096 (Electronic)
IS  - 0029-2001 (Linking)
VI  - 126
IP  - 21
DP  - 2006 Nov 2
TI  - [Antiplatelet therapy after aspirin-induced upper gastrointestinal bleeding].
PG  - 2802-4
AB  - It is common practice to replace aspirin with clopidogrel in patients with 
      gastrointestinal intolerance to aspirin. Recent studies suggest that a 
      combination of aspirin and a proton pump inhibitor is a better alternative for 
      these patients. The CAPRIE and CURE studies have not shown any clinically 
      relevant difference in effect between aspirin and clopidogrel. The incidence of 
      bleeding is also similar when aspirin is used in doses < 160 mg. A recent study 
      by Chan et al. concluded that a combination of aspirin and esomeprazole is 
      superior to clopidogrel in the prevention of recurrent gastrointestinal bleeding. 
      Using aspirin and a proton pump inhibitor is also the least expensive 
      alternative.
FAU - Johansen, Maren
AU  - Johansen M
AD  - RELIS Øst, Klinisk kjemisk avdeling, Laboratoriemedisinsk divisjon, Ullevål 
      universitetssykehus, 0407 Oslo. maren.johansen@relis.ulleval.no
LA  - nor
PT  - Journal Article
TT  - Platehemmerbehandling ved tidligere gastrointestinal blødning forårsaket av 
      acetylsalisylsyre.
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny 
      raekke
JID - 0413423
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - N3PA6559FT (Esomeprazole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Tidsskr Nor Laegeforen. 2007 Jan 4;127(1):64; author reply 64. PMID: 17205099
MH  - Anti-Ulcer Agents/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Drug Costs
MH  - Drug Therapy, Combination
MH  - Esomeprazole/administration & dosage/therapeutic use
MH  - Evidence-Based Medicine
MH  - Fibrinolytic Agents/administration & dosage/therapeutic use
MH  - Gastrointestinal Hemorrhage/chemically induced/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Risk Factors
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
EDAT- 2006/11/07 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/11/07 09:00
PHST- 2006/11/07 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/11/07 09:00 [entrez]
AID - 1447462 [pii]
PST - ppublish
SO  - Tidsskr Nor Laegeforen. 2006 Nov 2;126(21):2802-4.

PMID- 31801720
OWN - NLM
STAT- MEDLINE
DCOM- 20191209
LR  - 20211204
IS  - 1673-4254 (Print)
IS  - 2663-0842 (Electronic)
IS  - 1673-4254 (Linking)
VI  - 39
IP  - 10
DP  - 2019 Oct 30
TI  - [Bioinformatic analysis of direct protein targets of aspirin against human breast 
      cancer proliferation].
PG  - 1141-1148
LID - 10.12122/j.issn.1673-4254.2019.10.02 [doi]
AB  - OBJECTIVE: To explore the molecular mechanism underlying the inhibitory effects 
      of aspirin against human breast cancer cell proliferation through bioinformatics 
      analysis. METHODS: Drug Bank 5.1.3 was searched to identify direct protein 
      targets (DPTs) of aspirin, and the protein-protein interaction (PPI) network of 
      the DPTs was constructed online using STRING and the signaling pathways involved 
      were identified. The genetic alterations of 6 DPTs associated with human breast 
      cancer was analyzed and visualized by cBio Portal and OncoPrint, respectively. 
      The transcriptomic data of breast cancer and normal tissues were downloaded from 
      TCGA database, and the overexpressed genes were analyzed by DECenter. The 
      intersection between the genes associated with the DPTs obtained by STRING 
      analysis and the differentially over-expressed genes in TCGA was determined to 
      confirm the candidate DPTs as a potential target of aspirin, and GO functional 
      enrichment analysis was performed using Gene Ontology. The potential targets of 
      aspirin against the proliferation of human breast cancer cells were verified by 
      Western blotting. RESULTS: Eleven DPTs of aspirin were identified. KEGG pathway 
      enrichment indicated that 6 genes (EDNRA, IKBKB, NFKB2, NFKBIA, PTGS2 and TP53) 
      were associated with the occurrence and development of cancer. A total of 10 220 
      differentially expressed genes were identified from the TCGA database, and among 
      them 4 genes (CDC25C, TPX2, CDC20, PLK1) were found to be the potential targets 
      for aspirin. These genes were involved mostly in the regulation of cell cycle and 
      cell division. Western blotting showed that aspirin could down-regulate the 
      expression levels of several pivotal proteins that regulated cell cycle and cell 
      division, including CDC25C, TPX2, CDC20 and PLK1. CONCLUSIONS: CDC25C, TPX2, 
      CDC20 and PLK1 may be potential targets for aspirin to inhibit the proliferation 
      of human breast cancer cells, by affecting the progress of cell cycle and cell 
      division.
FAU - Zhu, Xingmei
AU  - Zhu X
AD  - Department of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang 
      712046, China.
AD  - Key Laboratory of Pharmacodynamics and Material Basis of Chinese Medicine of 
      Shaanxi Administration of Traditional Chinese Medicine, Xianyang 712046, China.
AD  - Shaanxi Key Laboratory of Traditional Medicine Foundation and New Drug Research, 
      Xianyang 712046, China.
FAU - Yang, Jiani
AU  - Yang J
AD  - Department of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang 
      712046, China.
AD  - Key Laboratory of Pharmacodynamics and Material Basis of Chinese Medicine of 
      Shaanxi Administration of Traditional Chinese Medicine, Xianyang 712046, China.
AD  - Shaanxi Key Laboratory of Traditional Medicine Foundation and New Drug Research, 
      Xianyang 712046, China.
FAU - Zhang, Enhu
AU  - Zhang E
AD  - Department of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang 
      712046, China.
AD  - Key Laboratory of Pharmacodynamics and Material Basis of Chinese Medicine of 
      Shaanxi Administration of Traditional Chinese Medicine, Xianyang 712046, China.
FAU - Qiao, Wei
AU  - Qiao W
AD  - Department of Gastroenterology, 521 Hospital of Norinco Group, Shaanxi, Xi'an, 
      710065, China.
FAU - Li, Xuejun
AU  - Li X
AD  - School of Basic Medicine, Peking University Health Science Center, Beijing, 
      100191, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Nan Fang Yi Ke Da Xue Xue Bao
JT  - Nan fang yi ke da xue xue bao = Journal of Southern Medical University
JID - 101266132
RN  - 0 (Cdc20 Proteins)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (TPX2 protein, human)
RN  - 156288-95-8 (CDC20 protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (polo-like kinase 1)
RN  - EC 3.1.3.48 (CDC25C protein, human)
RN  - EC 3.1.3.48 (cdc25 Phosphatases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Breast Neoplasms/*drug therapy
MH  - Cdc20 Proteins
MH  - Cell Cycle Proteins
MH  - Cell Proliferation
MH  - *Computational Biology
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Humans
MH  - Microtubule-Associated Proteins
MH  - Protein Serine-Threonine Kinases
MH  - Proto-Oncogene Proteins
MH  - cdc25 Phosphatases
PMC - PMC6867953
OTO - NOTNLM
OT  - aspirin
OT  - bioinformatics
OT  - cell cycle
OT  - cell division
OT  - human breast cancer
EDAT- 2019/12/06 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/12/06 06:00
PHST- 2019/12/06 06:00 [entrez]
PHST- 2019/12/06 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
AID - nfykdxxb-39-10-1141 [pii]
AID - 10.12122/j.issn.1673-4254.2019.10.02 [doi]
PST - ppublish
SO  - Nan Fang Yi Ke Da Xue Xue Bao. 2019 Oct 30;39(10):1141-1148. doi: 
      10.12122/j.issn.1673-4254.2019.10.02.

PMID- 3440392
OWN - NLM
STAT- MEDLINE
DCOM- 19880421
LR  - 20191022
IS  - 0197-2456 (Print)
IS  - 0197-2456 (Linking)
VI  - 8
IP  - 4 Suppl
DP  - 1987 Dec
TI  - Recruitment experience in the Aspirin Myocardial Infarction Study.
PG  - 74S-78S
AB  - The Aspirin Myocardial Infarction Study (AMIS) was a randomized double-masked 
      trial of the efficacy of aspirin in the secondary prevention of coronary heart 
      disease. Thirty clinics randomized 4524 post-myocardial infarction patients to 
      aspirin or placebo treatment. Recruitment was achieved in 14 months as planned, 
      but nearly half of the patients were not randomized until the last 5 months of 
      the recruitment period. Direct public appeal, self-referral, and review of 
      hospital records provided 75% of the participants. Physician referral accounted 
      for only 15%. The demographic characteristics of the sample revealed two thirds 
      to be 50 years of age or older, 90% to be male, and 90% to be white.
FAU - Schoenberger, J A
AU  - Schoenberger JA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Control Clin Trials
JT  - Controlled clinical trials
JID - 8006242
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic/*methods
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - *Patients
MH  - Random Allocation
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
AID - 0197-2456(87)90009-2 [pii]
AID - 10.1016/0197-2456(87)90009-2 [doi]
PST - ppublish
SO  - Control Clin Trials. 1987 Dec;8(4 Suppl):74S-78S. doi: 
      10.1016/0197-2456(87)90009-2.

PMID- 22654612
OWN - NLM
STAT- MEDLINE
DCOM- 20120927
LR  - 20220410
IS  - 1537-744X (Electronic)
IS  - 2356-6140 (Print)
IS  - 1537-744X (Linking)
VI  - 2012
DP  - 2012
TI  - Galectin-10 is released in the nasal lavage fluid of patients with 
      aspirin-sensitive respiratory disease.
PG  - 474020
LID - 10.1100/2012/474020 [doi]
LID - 474020
AB  - The aim of this work was to determine the presence of galectin-10 in nasal lavage 
      fluid (NLF) of patients with aspirin-sensitive respiratory disease (ASRD) before 
      and after challenge with L-ASA (aspirin) by ELISA. Fifteen ASRD patients, ten 
      aspirin-tolerant asthmatics (ATA), and fifteen healthy controls (HC) were 
      studied. The baseline presence of Galectin-10 in PBMC was determined using real 
      time PCR. Galectin-10 was evaluated in tissue of nasal polyps by western blot. 
      Our results showed a lower expression in PBMC of ASRD patients than in ATA and 
      healthy controls. However, a higher concentration of galectin-10 in NLF was found 
      in ASRD patients before and after L-ASA challenge; western blot confirmed a high 
      expression of galectin-10 in tissue from nasal polyps obtained from ASRD 
      patients. Our results suggest a probable role of galectin-10 in the inflammatory 
      response observed in ASRD patients; however, confirmatory studies are needed.
FAU - Negrete-Garcia, Ma Cristina
AU  - Negrete-Garcia MC
AD  - Department of Immunogenetics and Allergy, Instituto Nacional de Enfermedades 
      Respiratorias, Calzada Tlalpan 4502, 14080 Mexico, DF, Mexico. 
      crisdanmara@yahoo.com
FAU - Jiménez-Torres, Carla Yoneli
AU  - Jiménez-Torres CY
FAU - Alvarado-Vásquez, Noe
AU  - Alvarado-Vásquez N
FAU - Montes-Vizuet, A Rosalía
AU  - Montes-Vizuet AR
FAU - Velázquez-Rodriguez, J R
AU  - Velázquez-Rodriguez JR
FAU - Jimenez-Martinez, M Carmen
AU  - Jimenez-Martinez MC
FAU - Teran-Juárez, Luis Manuel
AU  - Teran-Juárez LM
LA  - eng
PT  - Journal Article
DEP - 20120430
PL  - United States
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
RN  - 0 (Galectins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Galectins/*metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Lavage Fluid/*chemistry
MH  - Respiratory Tract Diseases/*chemically induced/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Young Adult
PMC - PMC3361262
EDAT- 2012/06/02 06:00
MHDA- 2012/09/28 06:00
CRDT- 2012/06/02 06:00
PHST- 2011/10/31 00:00 [received]
PHST- 2012/01/22 00:00 [accepted]
PHST- 2012/06/02 06:00 [entrez]
PHST- 2012/06/02 06:00 [pubmed]
PHST- 2012/09/28 06:00 [medline]
AID - 10.1100/2012/474020 [doi]
PST - ppublish
SO  - ScientificWorldJournal. 2012;2012:474020. doi: 10.1100/2012/474020. Epub 2012 Apr 
      30.

PMID- 8773939
OWN - NLM
STAT- MEDLINE
DCOM- 19961112
LR  - 20190920
IS  - 0300-5577 (Print)
IS  - 0300-5577 (Linking)
VI  - 24
IP  - 2
DP  - 1996
TI  - Endothelial dysfunction in preeclampsia. Part II: Reducing the adverse 
      consequences of endothelial cell dysfunction in preeclampsia; therapeutic 
      perspectives.
PG  - 119-39
AB  - Next to low-dose Aspirin there appear to be several new and promising 
      pharmacologie approaches for reducing the adverse consequences of endothelial 
      cell dysfunction in preeclampsia. Among these are selective thromboxane-A2 
      synthetase and/or thromboxane-A2 receptor antagonists, stable prostacyclin 
      analogues, selective S(erotonin)2-receptor blockers, nitrovasodilators, 
      glycoprotein IIb/IIIa antagonists, hirudin, and ticlopidine. Early-onset 
      preeclampsia appears to be associated with certain disorders that are likely to 
      provoke an arterial thrombotic process by impairing the normal endothelial 
      cell-platelet interactions. Especially heterozygous hyperhomocysteinemia, protein 
      S deficiency and anticardiolipin antibodies appear to be fairly common. The 
      management of these 3 separate disease entities will be discussed.
FAU - Dekker, G A
AU  - Dekker GA
AD  - Department of Obstetrics and Gynecology, Free University Hospital, Amsterdam, The 
      Netherlands.
FAU - van Geijn, H P
AU  - van Geijn HP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Anticardiolipin/blood
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Endothelium, Vascular/*physiopathology
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - Homocysteine/blood
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Pre-Eclampsia/complications/*drug therapy/*physiopathology
MH  - Pregnancy
MH  - Protein S Deficiency/complications
RF  - 138
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1515/jpme.1996.24.2.119 [doi]
PST - ppublish
SO  - J Perinat Med. 1996;24(2):119-39. doi: 10.1515/jpme.1996.24.2.119.

PMID- 28185680
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20171031
IS  - 1768-3122 (Electronic)
IS  - 0248-8663 (Linking)
VI  - 38
IP  - 5
DP  - 2017 May
TI  - Recurrent pericarditis.
PG  - 307-311
LID - S0248-8663(16)31045-1 [pii]
LID - 10.1016/j.revmed.2016.12.006 [doi]
AB  - Recurrent pericarditis is the most troublesome complication of pericarditis 
      occurring in 15 to 30% of cases. The pathogenesis is often presumed to be 
      immune-mediated although a specific rheumatologic diagnosis is commonly difficult 
      to find. The clinical diagnosis is based on recurrent pericarditis chest pain and 
      additional objective evidence of disease activity (e.g. pericardial rub, ECG 
      changes, pericardial effusion, elevation of markers of inflammation, and/or 
      imaging evidence of pericardial inflammation by CT or cardiac MR). The mainstay 
      of medical therapy for recurrent pericarditis is aspirin or a non-steroidal 
      anti-inflammatory drug (NSAID) plus colchicine. Second-line therapy is considered 
      after failure of such treatments and it is generally based on low to moderate 
      doses of corticosteroids (e.g. prednisone 0.2 to 0.5 mg/kg/day or equivalent) 
      plus colchicine. More difficult cases are treated with combination of aspirin or 
      NSAID, colchicine and corticosteroids. Refractory cases are managed by 
      alternative medical options, including azathioprine, or intravenous human 
      immunoglobulins or biological agents (e.g. anakinra). When all medical therapies 
      fail, the last option may be surgical by pericardiectomy to be recommended in 
      well-experienced centres. Despite a significant impairment of the quality of 
      life, the most common forms of recurrent pericarditis (usually named as 
      "idiopathic recurrent pericarditis" since without a well-defined etiological 
      diagnosis) have good long-term outcomes with a negligible risk of developing 
      constriction and rarely cardiac tamponade during follow-up. The present article 
      reviews current knowledge on the definition, diagnosis, aetiology, therapy and 
      prognosis of recurrent pericarditis with a focus on the more recent available 
      literature.
CI  - Copyright © 2016 Société Nationale Française de Médecine Interne (SNFMI). 
      Published by Elsevier SAS. All rights reserved.
FAU - Imazio, M
AU  - Imazio M
AD  - University Cardiology, Department of Medical Sciences, AOU Città della Salute e 
      della Scienza di Torino, University of Torino, Torino, Italy. Electronic address: 
      massimo.imazio@yahoo.it.
FAU - Battaglia, A
AU  - Battaglia A
AD  - University Cardiology, Department of Medical Sciences, AOU Città della Salute e 
      della Scienza di Torino, University of Torino, Torino, Italy.
FAU - Gaido, L
AU  - Gaido L
AD  - University Cardiology, Department of Medical Sciences, AOU Città della Salute e 
      della Scienza di Torino, University of Torino, Torino, Italy.
FAU - Gaita, F
AU  - Gaita F
AD  - University Cardiology, Department of Medical Sciences, AOU Città della Salute e 
      della Scienza di Torino, University of Torino, Torino, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170206
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - *Pericarditis/diagnosis/epidemiology/etiology/therapy
MH  - Prognosis
MH  - Recurrence
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aetiology
OT  - Diagnosis
OT  - Pericarditis
OT  - Prognosis
OT  - Therapy
EDAT- 2017/02/12 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/02/11 06:00
PHST- 2016/10/20 00:00 [received]
PHST- 2016/12/15 00:00 [accepted]
PHST- 2017/02/12 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
PHST- 2017/02/11 06:00 [entrez]
AID - S0248-8663(16)31045-1 [pii]
AID - 10.1016/j.revmed.2016.12.006 [doi]
PST - ppublish
SO  - Rev Med Interne. 2017 May;38(5):307-311. doi: 10.1016/j.revmed.2016.12.006. Epub 
      2017 Feb 6.

PMID- 11958578
OWN - NLM
STAT- MEDLINE
DCOM- 20021122
LR  - 20170214
IS  - 0961-2033 (Print)
IS  - 0961-2033 (Linking)
VI  - 11
IP  - 2
DP  - 2002
TI  - Antiphospholipid antibodies do not a syndrome make.
PG  - 130-3
AB  - The association of antiphospholipid antibodies (aPLs) with a poor obstetric 
      history and/or thrombotic event is typical of the antiphospholipid syndrome 
      (APS). We report four cases of poor pregnancy outcome where a diagnostic label of 
      APS resulted in delayed recognition of other causes of pregnancy loss. Pregnancy 
      outcomes in these women were not improved with antithrombotic therapy alone. 
      Successful outcomes were achieved only when other causes of recurrent miscarriage 
      were considered and treated.
FAU - Stone, S
AU  - Stone S
AD  - Lupus Pregnancy Clinic, Guy's and St Thomas' Hospitals Trust, London, UK.
FAU - Langford, K
AU  - Langford K
FAU - Nelson-Piercy, C
AU  - Nelson-Piercy C
FAU - Khamashta, M A
AU  - Khamashta MA
FAU - Bewley, S
AU  - Bewley S
FAU - Hunt, B J
AU  - Hunt BJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Antibodies, Antiphospholipid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/drug therapy
MH  - Adult
MH  - Antibodies, Antiphospholipid/*analysis
MH  - Antiphospholipid Syndrome/*diagnosis/drug therapy
MH  - Aspirin/therapeutic use
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Outcome
EDAT- 2002/04/18 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/04/18 10:00
PHST- 2002/04/18 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/04/18 10:00 [entrez]
AID - 10.1191/0961203302lu157xx [doi]
PST - ppublish
SO  - Lupus. 2002;11(2):130-3. doi: 10.1191/0961203302lu157xx.

PMID- 23895811
OWN - NLM
STAT- MEDLINE
DCOM- 20131001
LR  - 20220316
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 166
IP  - 2
DP  - 2013 Aug
TI  - The combined use of aspirin, a statin, and blood pressure-lowering agents 
      (polypill components) and the risk of vascular morbidity and mortality in 
      patients with coronary artery disease.
PG  - 282-289.e1
LID - S0002-8703(13)00300-1 [pii]
LID - 10.1016/j.ahj.2013.04.011 [doi]
AB  - BACKGROUND AND AIMS: Patients with established coronary artery disease (CAD) are 
      likely to receive a combination of aspirin, a statin, and blood pressure 
      (BP)-lowering agents. Combining these pharmacologic agents into a cardiovascular 
      combination pill, such as a polypill, could be considered to reduce prescription 
      gaps and nonadherence in high-risk patients. We aimed to evaluate the effect of 
      the concomitant use of aspirin, a statin, and BP-lowering agent(s) in patients 
      with CAD on vascular morbidity and mortality in current clinical practice in an 
      observational study to provide insights in the combination pill concept related 
      to feasibility and applicability. METHODS: In total, 2,706 patients with CAD 
      enrolled in the Second Manifestations of ARTerial disease study were followed for 
      the occurrence of a subsequent vascular event (ie, myocardial infarction, 
      ischemic cerebrovascular accident, vascular death) and all-cause mortality. The 
      relationship between combination therapy and cardiovascular events and all-cause 
      mortality was assessed using Cox proportional hazards regression models to 
      calculate hazards ratios (HRs) with a 95% CI. Both covariate and propensity score 
      adjusting methods were used to reduce confounding by indication. RESULTS: A 
      combination of aspirin, a statin, and ≥1 BP-lowering agent(s) was used by 67% of 
      the patients. During a median of 5.0 years (interquartile range 2.4-10.2 years), 
      347 vascular events occurred and 162 patients died. Combination therapy with 
      aspirin, statin, and ≥1 BP-lowering agent was associated with a lower risk of 
      myocardial infarction (HR 0.68, 95% CI 0.49-0.96), ischemic cerebrovascular 
      accident (HR 0.37, 95% CI 0.16-0.84), composite vascular end point (HR 0.66, 95% 
      CI 0.49-0.88), vascular mortality (HR 0.53, 95% CI 0.33-0.85), and all-cause 
      mortality (HR 0.69, 95% CI 0.49-0.96) compared with the absence of combination 
      therapy, after adjusting for confounding covariates in a propensity score. The 
      use of 1 or only 2 components of combination therapy was associated with a higher 
      risk for cardiovascular events compared with the combined use of aspirin, a 
      statin, and ≥1 BP-lowering agent(s). CONCLUSION: Two-thirds of the patients with 
      CAD use a combination of aspirin, a statin, and ≥1 BP-lowering agent(s), 
      components of a cardiovascular fixed-dose combination pill. Combination therapy 
      with these agents is associated with a lower risk of vascular events and total 
      mortality. Although treatment effect in observational studies should be 
      interpreted with caution, the results of this study support supposed benefits 
      from combination therapy. However, the effect of fixed-dose combination pill on 
      clinical outcome needs to be demonstrated in randomized clinical trials.
CI  - Copyright © 2013 Mosby, Inc. All rights reserved.
FAU - Lafeber, Melvin
AU  - Lafeber M
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center 
      Utrecht, Utrecht, The Netherlands.
FAU - Spiering, Wilko
AU  - Spiering W
FAU - van der Graaf, Yolanda
AU  - van der Graaf Y
FAU - Nathoe, Hendrik
AU  - Nathoe H
FAU - Bots, Michiel L
AU  - Bots ML
FAU - Grobbee, Diederick E
AU  - Grobbee DE
FAU - Visseren, Frank L J
AU  - Visseren FL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130615
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Coronary Artery Disease/complications/*drug therapy
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse 
      effects
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk
EDAT- 2013/07/31 06:00
MHDA- 2013/10/18 06:00
CRDT- 2013/07/31 06:00
PHST- 2013/01/22 00:00 [received]
PHST- 2013/04/19 00:00 [accepted]
PHST- 2013/07/31 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - S0002-8703(13)00300-1 [pii]
AID - 10.1016/j.ahj.2013.04.011 [doi]
PST - ppublish
SO  - Am Heart J. 2013 Aug;166(2):282-289.e1. doi: 10.1016/j.ahj.2013.04.011. Epub 2013 
      Jun 15.

PMID- 26087271
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20150703
IS  - 1473-6500 (Electronic)
IS  - 0952-7907 (Linking)
VI  - 28
IP  - 4
DP  - 2015 Aug
TI  - New therapy in cardioprotection.
PG  - 417-23
LID - 10.1097/ACO.0000000000000211 [doi]
AB  - PURPOSE OF REVIEW: An increasing number of patients are presenting for major 
      surgery with cardiovascular comorbidities. Evidence of myocardial injury was 
      found in 8% of all noncardiac surgery patients older than 45 years and was 
      associated with adverse outcome. For this reason, there has been a lot of 
      interest in finding and evaluating effective cardioprotective interventions. 
      RECENT FINDINGS: Current evidence suggests that statins, volatile anesthetic 
      agents, and propofol are cardioprotective. Beta blockers reduce myocardial 
      injury, but the resultant hypotension may contribute to the increased all-cause 
      mortality and stroke risk seen. Likewise, alpha 2 agonists can be a cause of 
      cardiac injury if hypotension is not promptly managed. Continuation of aspirin 
      perioperatively can increase the risk of major bleeding with or without the 
      benefit of reduced myocardial risk. Contrary to the initial Evaluation of Nitrous 
      Oxide in the Gas Mixture for Anaesthesia study, nitrous oxide does not seem to 
      increase the risk of myocardial injury. SUMMARY: It is recommended that patients 
      already on statins or beta blockers should have them continued perioperatively. 
      If beta blockers are initiated, the dose should be titrated to heart rate and 
      blood pressure. The decision regarding continuation of aspirin should be on a 
      case-to-case basis based on patient and surgical risk factors.
FAU - Chow, Ka Ying
AU  - Chow KY
AD  - aQueen Mary Hospital, Hong Kong bHong Kong University, China.
FAU - Liu, Sophie E
AU  - Liu SE
FAU - Irwin, Michael G
AU  - Irwin MG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Anaesthesiol
JT  - Current opinion in anaesthesiology
JID - 8813436
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anesthetics, Inhalation)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Hypnotics and Sedatives)
RN  - R16CO5Y76E (Aspirin)
RN  - YI7VU623SF (Propofol)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Anesthetics, Inhalation
MH  - Aspirin/therapeutic use
MH  - Cardiotonic Agents/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/therapy
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Hypnotics and Sedatives
MH  - Ischemic Preconditioning
MH  - Propofol
EDAT- 2015/06/19 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/06/19 06:00
PHST- 2015/06/19 06:00 [entrez]
PHST- 2015/06/19 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - 10.1097/ACO.0000000000000211 [doi]
PST - ppublish
SO  - Curr Opin Anaesthesiol. 2015 Aug;28(4):417-23. doi: 10.1097/ACO.0000000000000211.

PMID- 20508286
OWN - NLM
STAT- MEDLINE
DCOM- 20100927
LR  - 20200106
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 62
IP  - 2
DP  - 2010 Mar-Apr
TI  - Effects of aspirin on the levels of hydrogen sulfide and sulfane sulfur in mouse 
      tissues.
PG  - 304-10
AB  - This study was designed to investigate the effect of aspirin (ASA) on anaerobic 
      cysteine metabolism, which yields sulfane sulfur-containing compounds and 
      hydrogen sulfide (H(2)S), in mouse liver and brain. In order to solve this 
      problem, we determined the levels of sulfane sulfur and H(2)S, and the activities 
      of cystathionase, the enzyme directly engaged in H(2)S synthesis, and rhodanese, 
      the enzyme that catalyzes sulfane sulfur transfer to different acceptors. 
      Moreover, we examined the effect of ASA on glial Gomori-positive cells (GGPC) in 
      the brain that contain sulfur-rich glial Gomori-positive material (GGPM). The 
      studies indicated an ASA-induced decrease in H(2)S levels in the brain and an 
      increase in the liver. ASA-treated animals had lower cerebral levels of 
      GGPM-containing GGPCs but the sulfane sulfur level was not affected. Conversely, 
      the sulfane sulfur content in the liver dropped. ASA did not change cystathionase 
      and rhodanese activity in either organ. The obtained results revealed that ASA 
      was able to influence anaerobic cysteine metabolism, leading to the formation of 
      sulfane sulfur and H(2)S in the mouse liver and brain, and to affect the numbers 
      of GGPM-containing GGPCs.
FAU - Bilska, Anna
AU  - Bilska A
AD  - Chair of Medical Biochemistry, Jagiellonian University, Collegium Medicum, 
      Kopernika, Kraków, Poland.
FAU - Iciek, Małgorzata
AU  - Iciek M
FAU - Kwiecień, Inga
AU  - Kwiecień I
FAU - Kaniecki, Karol
AU  - Kaniecki K
FAU - Paliborek, Magdalena
AU  - Paliborek M
FAU - Somogyi, Eugeniusz
AU  - Somogyi E
FAU - Piotrowska, Joanna
AU  - Piotrowska J
FAU - Wiliński, Bogdan
AU  - Wiliński B
FAU - Góralska, Marta
AU  - Góralska M
FAU - Srebro, Zbigniew
AU  - Srebro Z
FAU - Włodek, Lidia
AU  - Włodek L
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Sulfur Compounds)
RN  - K848JZ4886 (Cysteine)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Brain/drug effects/metabolism
MH  - Cysteine/*metabolism
MH  - Female
MH  - Hydrogen Sulfide/*analysis
MH  - Liver/drug effects/metabolism
MH  - Mice
MH  - Sulfur Compounds/*analysis
EDAT- 2010/05/29 06:00
MHDA- 2010/09/29 06:00
CRDT- 2010/05/29 06:00
PHST- 2009/04/28 00:00 [received]
PHST- 2009/11/14 00:00 [revised]
PHST- 2010/05/29 06:00 [entrez]
PHST- 2010/05/29 06:00 [pubmed]
PHST- 2010/09/29 06:00 [medline]
AID - S1734-1140(10)70270-X [pii]
AID - 10.1016/s1734-1140(10)70270-x [doi]
PST - ppublish
SO  - Pharmacol Rep. 2010 Mar-Apr;62(2):304-10. doi: 10.1016/s1734-1140(10)70270-x.

PMID- 18574266
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20211028
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 133
IP  - 6 Suppl
DP  - 2008 Jun
TI  - Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical 
      Practice Guidelines (8th Edition).
PG  - 199S-233S
LID - S0012-3692(08)60118-X [pii]
LID - 10.1378/chest.08-0672 [doi]
AB  - This article about currently available antiplatelet drugs is part of the 
      Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians 
      Evidence-Based Clinical Practice Guidelines (8th Edition). It describes the 
      mechanism of action, pharmacokinetics, and pharmacodynamics of aspirin, 
      reversible cyclooxygenase inhibitors, thienopyridines, and integrin alphaIIbbeta3 
      receptor antagonists. The relationships among dose, efficacy, and safety are 
      thoroughly discussed, with a mechanistic overview of randomized clinical trials. 
      The article does not provide specific management recommendations; however, it 
      does highlight important practical aspects related to antiplatelet therapy, 
      including the optimal dose of aspirin, the variable balance of benefits and 
      hazards in different clinical settings, and the issue of interindividual 
      variability in response to antiplatelet drugs.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - From the Catholic University School of Medicine, Rome, Italy. Electronic address: 
      carlo.patrono@rm.unicatt.it.
FAU - Baigent, Colin
AU  - Baigent C
AD  - Clinical Trial Service Unit, University of Oxford, Oxford, UK.
FAU - Hirsh, Jack
AU  - Hirsh J
AD  - Hamilton Civic Hospitals, Henderson Research Centre, Hamilton, ON, Canada.
FAU - Roth, Gerald
AU  - Roth G
AD  - Seattle VA Medical Center, Seattle, WA.
LA  - eng
GR  - MC_U137686849/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Practice Guideline
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacokinetics/pharmacology
MH  - Cyclooxygenase Inhibitors/pharmacokinetics/*pharmacology
MH  - *Evidence-Based Medicine
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/*pharmacology
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Pyridines/pharmacokinetics/*pharmacology
EDAT- 2008/07/24 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/07/24 09:00
PHST- 2008/07/24 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/24 09:00 [entrez]
AID - S0012-3692(08)60118-X [pii]
AID - 10.1378/chest.08-0672 [doi]
PST - ppublish
SO  - Chest. 2008 Jun;133(6 Suppl):199S-233S. doi: 10.1378/chest.08-0672.

PMID- 36912245
OWN - NLM
STAT- MEDLINE
DCOM- 20230320
LR  - 20230911
IS  - 1473-656X (Electronic)
IS  - 1040-872X (Linking)
VI  - 35
IP  - 2
DP  - 2023 Apr 1
TI  - Aspirin in pregnancy: a review of indications, timing, dosing and efficacy.
PG  - 94-100
LID - 10.1097/GCO.0000000000000846 [doi]
AB  - PURPOSE OF REVIEW: The aim of this study was to evaluate the recent literature 
      examining the utility of low-dose daily aspirin (LDA) in the prevention of 
      preeclampsia and other potential adverse perinatal sequelae. The evidence 
      supporting various aspirin doses and timing of initiation of treatment for this 
      purpose will be examined. The potential benefits of LDA therapy in pregnancy will 
      be discussed weighing against any potential associated harm. RECENT FINDINGS: 
      Findings from several recent meta-analyses of randomized controlled trials are 
      consistent with prior studies in showing a reduction in risk for preeclampsia 
      with LDA use in individuals at an increased risk for this complication. Some 
      studies suggest aspirin at a dose greater than the current recommended 81 mg is 
      associated with the highest reduction in preterm PE.Several studies have 
      demonstrated a reduction in risk for preterm birth, small for gestational age 
      (SGA) infant or intrauterine growth restriction (IUGR), and a reduction in the 
      risk of perinatal mortality associated with aspirin use. The findings of reduced 
      preterm birth (PTB) and IUGR were also demonstrated among low-risk 
      patients.Identifying patients at risk was re-evaluated, with resulting changes to 
      existing United States Preventive Services Task Force (USPSTF) guidelines. 
      SUMMARY: This review of recent evidence suggests a decreased rate of preeclampsia 
      at aspirin doses higher than the standardly used 81 mg when treatment is 
      initiated prior to 16 weeks of gestation. Although LDA use seems promising for 
      other outcomes such as preterm delivery and IUGR, further studies to strengthen 
      recommendations are warranted.
CI  - Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Joudi, Noor
AU  - Joudi N
AD  - Division of Maternal-Fetal Medicine and Obstetrics, Department of Obstetrics and 
      Gynecology, Stanford University Hospital, Stanford, California, USA.
FAU - Rode, Martha
AU  - Rode M
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230118
PL  - England
TA  - Curr Opin Obstet Gynecol
JT  - Current opinion in obstetrics & gynecology
JID - 9007264
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Infant, Newborn
MH  - Humans
MH  - Aspirin/therapeutic use
MH  - *Pre-Eclampsia/drug therapy/prevention & control
MH  - *Premature Birth/prevention & control
MH  - Fetal Growth Retardation/prevention & control
MH  - Infant, Small for Gestational Age
EDAT- 2023/03/14 06:00
MHDA- 2023/03/21 06:00
CRDT- 2023/03/13 06:43
PHST- 2023/03/14 06:00 [pubmed]
PHST- 2023/03/21 06:00 [medline]
PHST- 2023/03/13 06:43 [entrez]
AID - 00001703-202304000-00004 [pii]
AID - 10.1097/GCO.0000000000000846 [doi]
PST - ppublish
SO  - Curr Opin Obstet Gynecol. 2023 Apr 1;35(2):94-100. doi: 
      10.1097/GCO.0000000000000846. Epub 2023 Jan 18.

PMID- 19153328
OWN - NLM
STAT- MEDLINE
DCOM- 20090211
LR  - 20131121
IS  - 1538-3644 (Electronic)
IS  - 0004-0010 (Linking)
VI  - 144
IP  - 1
DP  - 2009 Jan
TI  - Antiplatelet agents in the perioperative period.
PG  - 69-76; discussion 76
LID - 10.1001/archsurg.144.1.69 [doi]
AB  - OBJECTIVE: To determine the use of the 3 major classes of antiplatelet drugs 
      (aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors), their 
      management in the perioperative period, and the risks associated with premature 
      withdrawal. DATA SOURCES: We reviewed the PubMed, EMBASE, and Cochrane databases 
      using the terms antiplatelet agents in the perioperative period, antiplatelet 
      agents and management of bleeding, drug-eluting stents and stent thrombosis, 
      substitutes for antiplatelet agents, and premature withdrawal of antiplatelet 
      agents. STUDY SELECTION: Randomized, double-blind, placebo-controlled trials; 
      prospective observational studies; review articles; clinical registry data; and 
      guidelines of professional bodies pertaining to antiplatelet agents were 
      included. DATA EXTRACTION AND SYNTHESIS: Two researchers independently read the 
      selected abstracts and selected the studies that matched the inclusion criteria. 
      Any discordance between the 2 researchers was resolved by discussion so that 99 
      articles were finally included. CONCLUSIONS: Aspirin use should not be stopped in 
      the perioperative period unless the risk of bleeding exceeds the thrombotic risk 
      from withholding the drug. With the exception of recent drug-eluting stent 
      implantation, clopidogrel bisulfate use should be stopped at least 5 days prior 
      to most elective surgery. Use of glycoprotein IIb/IIIa inhibitors must be 
      discontinued preoperatively for more than 12 hours to allow normal hemostasis. 
      Premature withdrawal of antiplatelet agents is associated with a 10% risk of all 
      vascular events. Following drug-eluting stent implantation, withdrawal is 
      associated with stent thrombosis and potentially fatal consequences. No 
      definitive guidelines exist to manage patients who are actively bleeding while 
      taking these drugs.
FAU - O'Riordan, James M
AU  - O'Riordan JM
AD  - Department of Surgery, Mater Misericordiae University Hospital, Dublin, Ireland.
FAU - Margey, Ronan J
AU  - Margey RJ
FAU - Blake, Gavin
AU  - Blake G
FAU - O'Connell, P Ronan
AU  - O'Connell PR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Arch Surg
JT  - Archives of surgery (Chicago, Ill. : 1960)
JID - 9716528
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Surg. 2009 Aug;144(8):787; author reply 787. PMID: 19687387
MH  - Algorithms
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Perioperative Care
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Pyridines/therapeutic use
MH  - Risk Factors
RF  - 99
EDAT- 2009/01/21 09:00
MHDA- 2009/02/12 09:00
CRDT- 2009/01/21 09:00
PHST- 2009/01/21 09:00 [entrez]
PHST- 2009/01/21 09:00 [pubmed]
PHST- 2009/02/12 09:00 [medline]
AID - 144/1/69 [pii]
AID - 10.1001/archsurg.144.1.69 [doi]
PST - ppublish
SO  - Arch Surg. 2009 Jan;144(1):69-76; discussion 76. doi: 10.1001/archsurg.144.1.69.

PMID- 27578463
OWN - NLM
STAT- MEDLINE
DCOM- 20180108
LR  - 20180205
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 118
DP  - 2016 Sep
TI  - Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease 
      phenotype: Topical NSAID and asthma control - A possible oversight link.
PG  - 1-3
LID - S0954-6111(16)30151-2 [pii]
LID - 10.1016/j.rmed.2016.07.004 [doi]
AB  - BACKGROUND: Patients with aspirin-exacerbated respiratory disease (AERD) also 
      recently known as nonsteroidal anti-inflammatory drug (NSAID) exacerbated 
      respiratory disease (NERD) must avoid aspirin and all other oral NSAIDs. The 
      effect of topical NSAID (tNSAID), especially salicylates which are commonly 
      present in topical medicated preparations, on asthma control of this phenotype is 
      studied. METHODS: The study inclusion criteria were adults with: 1) NSAID 
      hypersensitivity; 2) nasal polyposis/chronic rhinosinusitis; 3) not well-/poorly 
      controlled asthma and 4) exposure to tNSAID. Patients were given verbal and 
      written instructions to cease tNSAIDs exposure and asthma control was evaluated 
      during the 6 months prior and after intervention. RESULTS: There were eleven 
      patients (ten females) with a mean age of 56.5 (range 37-71) years. Prior known 
      oral NSAIDs hypersensitivity included aspirin (5), mefenamic acid (2), diclofenac 
      (2), Synflex (2) and ibuprofen (1). All, except 2, had arthropathies or spinal 
      disorders and were using tNSAID for a mean of 4.2 years. One, four and six 
      patients were using over-the-counter medicated oil containing salicylates, NSAID 
      gel/plasters and both respectively. All patients had cutaneous, with 4 having 
      concomitant inhalational exposure to these tNSAIDs. The mean duration of asthma 
      diagnosis and uncontrolled asthma were 25.2 and 4.5 years respectively. Except 
      for 2 patients, there was no change in asthma maintenance medications pre and 
      post-intervention. Asthma control significantly (p < 0.05) improved based on pre 
      and post-intervention ACT score, number of exacerbations, FEV1 were 14.9 and 
      22.1, 1.9 and 0.43, 1.28L and 1.67L respectively. CONCLUSIONS: It is paramount to 
      eliminate not only oral but topical NSAID exposure in NERD phenotype asthmatic 
      patients. When a long-standing asthma progressed to uncontrolled, a meticulous 
      evaluation of tNSAIDs exposure is warranted especially if the patient has 
      developed chronic pain.
CI  - Copyright © 2016 Elsevier Ltd. All rights reserved.
FAU - Tan, Jessica Han Ying
AU  - Tan JHY
AD  - Department of Respiratory & Critical Care Medicine, Singapore General Hospital, 
      Singapore.
FAU - Hsu, Anne Ann Ling
AU  - Hsu AAL
AD  - Department of Respiratory & Critical Care Medicine, Singapore General Hospital, 
      Singapore. Electronic address: anne.hsu.a.l@sgh.com.sg.
LA  - eng
PT  - Journal Article
DEP - 20160709
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Topical
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma, Aspirin-Induced/complications/*physiopathology
MH  - Disease Progression
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Hypersensitivity
MH  - Male
MH  - Middle Aged
MH  - *Phenotype
MH  - Respiration Disorders/*chemically induced
OTO - NOTNLM
OT  - Aspirin-exacerbated respiratory disease
OT  - Non-steroidal anti-inflammatory drug hypersensitivity
EDAT- 2016/09/01 06:00
MHDA- 2018/01/09 06:00
CRDT- 2016/09/01 06:00
PHST- 2016/02/16 00:00 [received]
PHST- 2016/06/22 00:00 [revised]
PHST- 2016/07/06 00:00 [accepted]
PHST- 2016/09/01 06:00 [entrez]
PHST- 2016/09/01 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
AID - S0954-6111(16)30151-2 [pii]
AID - 10.1016/j.rmed.2016.07.004 [doi]
PST - ppublish
SO  - Respir Med. 2016 Sep;118:1-3. doi: 10.1016/j.rmed.2016.07.004. Epub 2016 Jul 9.

PMID- 21538449
OWN - NLM
STAT- MEDLINE
DCOM- 20110823
LR  - 20220310
IS  - 1097-0258 (Electronic)
IS  - 0277-6715 (Linking)
VI  - 30
IP  - 11
DP  - 2011 May 20
TI  - Meta-analysis and sensitivity analysis for multi-arm trials with selection bias.
PG  - 1183-98
LID - 10.1002/sim.4143 [doi]
AB  - Multi-arm trials meta-analysis is a methodology used in combining evidence based 
      on a synthesis of different types of comparisons from all possible similar 
      studies and to draw inferences about the effectiveness of multiple 
      compared-treatments. Studies with statistically significant results are 
      potentially more likely to be submitted and selected than studies with 
      non-significant results; this leads to false-positive results. In meta-analysis, 
      combining only the identified selected studies uncritically may lead to an 
      incorrect, usually over-optimistic conclusion. This problem is known 
      asbiselection bias. In this paper, we first define a random-effect meta-analysis 
      model for multi-arm trials by allowing for heterogeneity among studies. This 
      general model is based on a normal approximation for empirical log-odds ratio. We 
      then address the problem of publication bias by using a sensitivity analysis and 
      by defining a selection model to the available data of a meta-analysis. This 
      method allows for different amounts of selection bias and helps to investigate 
      how sensitive the main interest parameter is when compared with the estimates of 
      the standard model. Throughout the paper, we use binary data from Antiplatelet 
      therapy in maintaining vascular patency of patients to illustrate the methods.
CI  - Copyright © 2011 John Wiley & Sons, Ltd.
FAU - Chootrakool, Hathaikan
AU  - Chootrakool H
AD  - Suan Dusit Rajabhat University, Thailand.
FAU - Shi, Jian Qing
AU  - Shi JQ
FAU - Yue, Rongxian
AU  - Yue R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110116
PL  - England
TA  - Stat Med
JT  - Statistics in medicine
JID - 8215016
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Blood Platelet Disorders/drug therapy
MH  - Clinical Trials as Topic/*methods
MH  - Dipyridamole/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - *Models, Statistical
MH  - *Selection Bias
EDAT- 2011/05/04 06:00
MHDA- 2011/08/24 06:00
CRDT- 2011/05/04 06:00
PHST- 2010/01/26 00:00 [received]
PHST- 2010/10/21 00:00 [accepted]
PHST- 2011/05/04 06:00 [entrez]
PHST- 2011/05/04 06:00 [pubmed]
PHST- 2011/08/24 06:00 [medline]
AID - 10.1002/sim.4143 [doi]
PST - ppublish
SO  - Stat Med. 2011 May 20;30(11):1183-98. doi: 10.1002/sim.4143. Epub 2011 Jan 16.

PMID- 1275070
OWN - NLM
STAT- MEDLINE
DCOM- 19760802
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 230
IP  - 5
DP  - 1976 May
TI  - Changes in body temperature produced by prostaglandins and pyrogens in the 
      chicken.
PG  - 1284-7
AB  - Bacterial pyrogen from S. abortus equi (SAE) was injected into the wing veins of 
      chickens. Following injection of 0.05-0.5 mug SAE, body temperatures did not 
      change significantly, whereas 2.0 or 10 mug of pyrogen caused falls in body 
      temperature of 0.56 +/- 0.10degrees C and 1.1 +/- 0.21degrees C (mean +/- SE, 
      n=5). The temperature falls were accompanied by a flushing of the comb and an 
      increase in respiratory rate and were not antagonized by 1.0 g of acetylsalicylic 
      acid (ASA) given orally. The injection of SAE (0.1 mug in 1 mul) into the 
      anterior hypothalamus produced fevers averaging 1.24 +/- 0.07 degrees C (n=9) 
      which were antagonized by oral ASA. Injections of SAE at other brainstem loci 
      produced no temperatur changes. Seven chickens were also injected with 0.1 mug 
      PGE in 1.0 mul into the anterior hypothalamus, and they developed fevers 
      averaging 0.90 +/- 0.16 degrees C. The results support the concept that 
      prostaglandins may be involved in fever in chickens but suggest that the action 
      of pyrogen injected intravenously may be different from that following its 
      injection directly into the hypothalamus.
FAU - Pittman, Q J
AU  - Pittman QJ
FAU - Veale, W L
AU  - Veale WL
FAU - Cockeram, A W
AU  - Cockeram AW
FAU - Cooper, K E
AU  - Cooper KE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Endotoxins)
RN  - 0 (Prostaglandins E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Behavior, Animal/drug effects
MH  - Body Temperature/*drug effects
MH  - Chickens
MH  - Dose-Response Relationship, Drug
MH  - Endotoxins/*pharmacology
MH  - Female
MH  - Prostaglandins E/*pharmacology
MH  - Respiration/drug effects
MH  - Salmonella
EDAT- 1976/05/01 00:00
MHDA- 1976/05/01 00:01
CRDT- 1976/05/01 00:00
PHST- 1976/05/01 00:00 [pubmed]
PHST- 1976/05/01 00:01 [medline]
PHST- 1976/05/01 00:00 [entrez]
AID - 10.1152/ajplegacy.1976.230.5.1284 [doi]
PST - ppublish
SO  - Am J Physiol. 1976 May;230(5):1284-7. doi: 10.1152/ajplegacy.1976.230.5.1284.

PMID- 25288823
OWN - NLM
STAT- MEDLINE
DCOM- 20150701
LR  - 20181202
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 49
IP  - 2
DP  - 2015 Feb
TI  - Evaluation of aspirin use in patients with diabetes receiving care in community 
      health.
PG  - 170-7
LID - 10.1177/1060028014554444 [doi]
AB  - BACKGROUND: The American Diabetes Association (ADA) recommends low-dose aspirin 
      therapy as a primary prevention strategy in patients with type 1 or type 2 
      diabetes mellitus (DM) at increased cardiovascular risk. However, not all 
      patients who are indicated are taking aspirin therapy, and it is not routinely 
      documented in the electronic health record (EHR). OBJECTIVE: To determine 
      frequencies of appropriate aspirin use and documentation in the EHR in adult 
      patients with DM. METHODS: Adult patients with DM were randomized and contacted 
      for participation in a telephonic survey between January and October 2013. 
      Patients who consented were administered a standardized oral telephone survey 
      regarding aspirin use. Patient demographics, current medications, allergies, past 
      medical history, and pertinent laboratory values were collected. Patients were 
      then stratified by the ADA-defined indication for aspirin. The primary outcomes 
      were rates of appropriate aspirin use and documentation of aspirin therapy in the 
      EHR. RESULTS: Investigators contacted 276 patients for inclusion. Of the 81 
      patients surveyed, 74% were indicated for aspirin therapy. Nearly all (92.3%) 
      patients reporting aspirin use were indicated for aspirin therapy compared with 
      only 57.1% of patients who did not report aspirin but were indicated (P = 
      0.0003). Alternatively, 96.7% of patients with aspirin use documented in their 
      EHR were indicated for aspirin therapy compared with only 60.8% of patients who 
      did not have aspirin use documented in the EHR but had an indication (P = 
      0.0002). Approximately 20% of the patients indicated for and reporting aspirin 
      use did not have aspirin documented in their EHR. CONCLUSIONS: Aspirin use in 
      patients with DM who are indicated for therapy is significantly underutilized and 
      underdocumented.
CI  - © The Author(s) 2014.
FAU - Fosmire Rundgren, Elaine W
AU  - Fosmire Rundgren EW
AD  - University of Rochester Medical Center Strong Memorial Hospital, Rochester, NY, 
      USA.
FAU - Anderson, Sarah L
AU  - Anderson SL
AD  - University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, 
      Aurora, CO, USA.
FAU - Marrs, Joel C
AU  - Marrs JC
AD  - University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, 
      Aurora, CO, USA joel.marrs@ucdenver.edu.
LA  - eng
PT  - Journal Article
DEP - 20141006
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Pharmacother. 2015 Jan;49(1):150-1. PMID: 25524930
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Data Collection
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Risk Factors
MH  - Young Adult
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular risk
OT  - community health
OT  - diabetes mellitus
EDAT- 2014/10/08 06:00
MHDA- 2015/07/02 06:00
CRDT- 2014/10/08 06:00
PHST- 2014/10/08 06:00 [entrez]
PHST- 2014/10/08 06:00 [pubmed]
PHST- 2015/07/02 06:00 [medline]
AID - 1060028014554444 [pii]
AID - 10.1177/1060028014554444 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2015 Feb;49(2):170-7. doi: 10.1177/1060028014554444. Epub 2014 
      Oct 6.

PMID- 11383324
OWN - NLM
STAT- MEDLINE
DCOM- 20020117
LR  - 20161124
IS  - 0939-4753 (Print)
IS  - 0939-4753 (Linking)
VI  - 11
IP  - 1
DP  - 2001 Feb
TI  - Antithrombotic drugs for older subjects. Guidelines formulated jointly by the 
      Italian Societies of Haemostasis and Thrombosis (SISET) and of Gerontology and 
      Geriatrics (SIGG).
PG  - 41-62
AB  - Older individuals contribute heavily to the percentage of deaths due to 
      myocardial infarction (MI) and stroke. The incidence of venous thromboembolism 
      (VTE) is highest in subjects > 65 years. Prospective intervention trials 
      involving groups of clinically comparable subjects > or = 60 allow the following 
      statements to be made with regard to the use of antithrombotic drugs in the 
      elderly. Antiplatelet agents. To prevent recurrence of ischaemic stroke and MI in 
      stable/unstable angina, MI, TIA/stroke or peripheral arterial disease, aspirin is 
      the drug of choice. Clopidogrel is more effective than aspirin in this respect. 
      Heparin. For the treatment of acute deep venous thrombosis (DVT) and pulmonary 
      embolism (PE), intravenous standard heparin or subcutaneous standard heparin are 
      effective (aPTT 1.5-2.0 times baseline values). As the risk of bleeding increases 
      with age, low-molecular-weight heparins (LMWH) are preferable in the elderly. For 
      the prophylaxis of VTE in general surgery in subjects at low-moderate risk, 
      low-dose heparin or low doses of LMWH are effective. In subjects at high risk, 
      adjusted-dose heparin plus physical devices or high-dose LMWH are recommended. 
      The combination of heparin and aspirin is the standard treatment for unstable 
      angina and non-Q wave MI. LMWH are as active as standard heparin in this 
      indication. Vitamin K antagonists. For the chronic treatment of VTE, warfarin is 
      also the treatment of choice (INR 2.0-3.0) in the elderly, though lower doses are 
      needed due to their hypersensitivity to oral anticoagulants. For the prevention 
      of thromboembolic stroke in patients > 75 with atrial fibrillation, warfarin is 
      the drug of choice. Patients aged 65-75 may receive warfarin or aspirin. 
      Thrombolytic agents. Thrombolytic agents are not recommended for treating DVT in 
      the elderly because of their limited risk/benefit ratio and should be confined to 
      massive PE. In the absence of contraindications, thrombolysis for MI may be 
      considered in the elderly.
FAU - Di Minno, G
AU  - Di Minno G
AD  - Cattedra di Gerontologia e Geriatria, Università degli Studi di Palermo, Clinica 
      Medica, Dipartimento di Medicina Clinica e Sperimentale, Policlinico Federico II, 
      Naples, Italy.
FAU - Tufano, A
AU  - Tufano A
FAU - Cerbone, A M
AU  - Cerbone AM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 12001-79-5 (Vitamin K)
RN  - 9005-49-6 (Heparin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aged
MH  - Angina, Unstable/drug therapy
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Practice Guidelines as Topic
MH  - Secondary Prevention
MH  - Thromboembolism/*drug therapy/prevention & control
MH  - Veins/drug effects
MH  - Vitamin K/antagonists & inhibitors
RF  - 144
EDAT- 2001/06/01 10:00
MHDA- 2002/01/23 10:01
CRDT- 2001/06/01 10:00
PHST- 2001/06/01 10:00 [pubmed]
PHST- 2002/01/23 10:01 [medline]
PHST- 2001/06/01 10:00 [entrez]
PST - ppublish
SO  - Nutr Metab Cardiovasc Dis. 2001 Feb;11(1):41-62.

PMID- 10468689
OWN - NLM
STAT- MEDLINE
DCOM- 19991007
LR  - 20190831
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 13
IP  - 8
DP  - 1999 Aug
TI  - Enteric coating of aspirin significantly decreases gastroduodenal mucosal 
      lesions.
PG  - 1109-14
AB  - BACKGROUND: Low-dose aspirin (acetylsalicylic acid, ASA) increases the risk of 
      developing peptic ulceration. AIM: To investigate the gastroduodenal mucosal 
      tolerability of enteric-coated ASA (EC-ASA) 100 mg/day compared to either placebo 
      (study 1) or plain ASA 100 mg/day (study 2) in healthy volunteers. METHODS: Study 
      1: In this double-blind study 18 volunteers received randomized dosing with 
      either EC-ASA 100 mg or placebo for 15 days. Study 2: 41 volunteers underwent 
      randomized 7-day dosing of either EC-ASA 100 mg or plain ASA 100 mg in this 
      double-blind, parallel-group, comparison study. In both studies acute 
      gastroduodenal mucosal lesions were assessed endoscopically before treatment, on 
      the morning of day 1 after the first dose (only in study 2), and on the morning 
      after the last dose of the test medication. RESULTS: Study 1 did not reveal any 
      significant differences between the lesion scores of EC-ASA and placebo. In 
      contrast, in study 2 significantly higher total gastroduodenal mucosal lesion 
      scores were observed on day 1 after the first dose and after 7 days of dosing 
      with plain ASA (mean sum of the lesion scores in the gastric fundus, body, antrum 
      and in the duodenal bulb: day 1: plain ASA 3.95+/-3.38 vs. EC-ASA 1.43+/-1.91, P 
      = 0.03; day 7: plain ASA 6.35+/-4.10 vs. EC-ASA 2.00+/-2.02, P = 0.0004). 
      Tolerance of the test drugs was good, and no other adverse events were observed. 
      CONCLUSIONS: Enteric-coated aspirin 100 mg/day causes significantly less 
      gastroduodenal damage over 7 days than the same dose of plain aspirin, when given 
      to healthy subjects. There was little gastric injury and no significant 
      differences between EC-ASA and placebo in this respect.
FAU - Dammann, H G
AU  - Dammann HG
AD  - Klinische Forschung Hamburg, Wissenschaftliches Institut, Hamburg, Germany. 
      HGDammann@compuserve.com
FAU - Burkhardt, F
AU  - Burkhardt F
FAU - Wolf, N
AU  - Wolf N
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Duodenal Diseases/*chemically induced/pathology
MH  - Female
MH  - Gastric Mucosa/pathology
MH  - Humans
MH  - Intestinal Mucosa/pathology
MH  - Male
MH  - Stomach Diseases/*chemically induced/pathology
MH  - Tablets, Enteric-Coated
EDAT- 1999/09/01 00:00
MHDA- 1999/09/01 00:01
CRDT- 1999/09/01 00:00
PHST- 1999/09/01 00:00 [pubmed]
PHST- 1999/09/01 00:01 [medline]
PHST- 1999/09/01 00:00 [entrez]
AID - apt588 [pii]
AID - 10.1046/j.1365-2036.1999.00588.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 1999 Aug;13(8):1109-14. doi: 
      10.1046/j.1365-2036.1999.00588.x.

PMID- 37352973
OWN - NLM
STAT- MEDLINE
DCOM- 20230717
LR  - 20230718
IS  - 2254-8874 (Electronic)
IS  - 2254-8874 (Linking)
VI  - 223
IP  - 7
DP  - 2023 Aug-Sep
TI  - Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in 
      cardiovascular secondary prevention in Spain.
PG  - 414-422
LID - S2254-8874(23)00077-2 [pii]
LID - 10.1016/j.rceng.2023.06.007 [doi]
AB  - INTRODUCTION AND OBJECTIVES: Despite advances in treatment, cardiovascular 
      disease is the second leading cause of death in Spain. The objective of this 
      study was to determine the cost-effectiveness of the CNIC-Polypill strategy 
      (acetylsalicylic acid 100 mg, atorvastatin 20/40 mg, ramipril 2.5/5/10 mg) 
      compared with the same separate monocomponents for the secondary prevention of 
      recurrent cardiovascular events in adults in Spain. MATERIALS AND METHODS: A 
      Markov cost-utility model was adapted considering 4 health states (stable, 
      subsequent major adverse cardiovascular event, subsequent ischemic stroke and 
      death) and the SMART risk equation over a lifetime horizon from the perspective 
      of the Spanish National Healthcare System. The CNIC-Polypill strategy was 
      compared with monocomponents in a hypothetical cohort of 1000 secondary 
      prevention patients. Effectiveness, epidemiological, cost and utilities data were 
      obtained from the NEPTUNO study, official databases and literature. Outcomes were 
      costs (in 2021 euros) per life-year (LY) and quality-adjusted LY (QALY) gained. A 
      3% discount rate was applied. Deterministic one-way and probabilistic sensitivity 
      analyses evaluated the robustness of the model. RESULTS: The CNIC-Polypill 
      strategy in secondary prevention results in more LY (13.22) and QALY (11.64) 
      gains at a lower cost than monocomponents. The CNIC-Polypill is dominant and 
      saves є280.68 per patient compared with monocomponents. The probabilistic 
      sensitivity analysis shows that 82.4% of the simulations are below the threshold 
      of є25,000 per QALY gained. CONCLUSIONS: The CNIC-Polypill strategy in secondary 
      cardiovascular prevention is cost-effective compared with the same separate 
      monocomponents, resulting in a cost-saving strategy to the Spanish National 
      Healthcare System.
CI  - Copyright © 2023 The Author(s). Published by Elsevier España, S.L.U. All rights 
      reserved.
FAU - González-Domínguez, A
AU  - González-Domínguez A
AD  - Fundación Weber, Madrid, Spain. Electronic address: 
      almudena.gonzalez@weber.org.es.
FAU - Durán, A
AU  - Durán A
AD  - Fundación Weber, Madrid, Spain.
FAU - Hidalgo-Vega, Á
AU  - Hidalgo-Vega Á
AD  - President Fundación Weber, Madrid, Spain; Professor at Universidad de Castilla-La 
      Mancha, Toledo, España.
FAU - Barrios, V
AU  - Barrios V
AD  - Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, Spain; 
      Servicio de Medicina, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20230621
PL  - Spain
TA  - Rev Clin Esp (Barc)
JT  - Revista clinica espanola
JID - 101632437
RN  - A0JWA85V8F (Atorvastatin)
RN  - R16CO5Y76E (Aspirin)
RN  - L35JN3I7SJ (Ramipril)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Cost-Benefit Analysis
MH  - Secondary Prevention/methods
MH  - Spain
MH  - Atorvastatin
MH  - *Aspirin/therapeutic use
MH  - Ramipril/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - Quality-Adjusted Life Years
OTO - NOTNLM
OT  - Cardiovascular diseases
OT  - Cost-effectiveness
OT  - Coste-efectividad
OT  - Enfermedades cardiovasculares
OT  - Polipíldora
OT  - Polypill
OT  - Prevención secundaria
OT  - Secondary prevention
EDAT- 2023/06/24 11:42
MHDA- 2023/07/17 06:42
CRDT- 2023/06/23 19:13
PHST- 2023/04/11 00:00 [received]
PHST- 2023/05/02 00:00 [accepted]
PHST- 2023/07/17 06:42 [medline]
PHST- 2023/06/24 11:42 [pubmed]
PHST- 2023/06/23 19:13 [entrez]
AID - S2254-8874(23)00077-2 [pii]
AID - 10.1016/j.rceng.2023.06.007 [doi]
PST - ppublish
SO  - Rev Clin Esp (Barc). 2023 Aug-Sep;223(7):414-422. doi: 
      10.1016/j.rceng.2023.06.007. Epub 2023 Jun 21.

PMID- 12477186
OWN - NLM
STAT- MEDLINE
DCOM- 20030515
LR  - 20190729
IS  - 1060-3271 (Print)
IS  - 1060-3271 (Linking)
VI  - 85
IP  - 6
DP  - 2002 Nov-Dec
TI  - Sequential determination of salicylic and acetylsalicylic acids by amperometric 
      multisite detection flow injection analysis.
PG  - 1253-9
AB  - An amperometric multisite detection flow injection analysis (FIA) system was 
      developed for sequential determination of 2 analytes with a single sample 
      injection and single detector. Tubular composite carbon electrodes with an inner 
      diameter similar to that of the FIA manifold tubing were constructed so that 
      measurements could be made without impairing the sample plug hydrodynamic 
      characteristics. The electrochemical behavior of the tubular voltammetric cell in 
      a low-dispersion FIA manifold and the behavior of the FIA system incorporating 
      this type of voltammetric cell intended for multisite detection were evaluated by 
      performing measurements with potassium hexacyanoferrate(II). Feasibility of the 
      approach was demonstrated in the sequential determination of salicylic and 
      acetylsalicylic acids in pharmaceutical products at a fixed potential of 0.98 V. 
      The system allows sequential determination of salicylic acid concentrations 
      ranging from 1.0 x 10(-5) to 5.0 x 10(-5) M and acetylsalicylic acid 
      concentrations between 1.0 x 10(-3) and 5.0 x 10(-3) M with good precision on 
      both detection sites and with relative standard deviations (RSDs) > or = 1.5% (n 
      = 10) and 2.1% (n = 10), respectively. A comparison of these results with those 
      of the U.S. Pharmacopeia procedure showed RSDs <5.0 and 1.0% for salicylic acid 
      and acetylsalicylic acid, respectively. The proposed method enables 15 
      determinations per hour, which corresponds to the analysis of approximately 8 
      samples per hour. The detection limits of the methodology were approximately 3.5 
      x 10(-6) and 1.1 x 10(-5) M, respectively, for the first and second monitoring 
      sites.
FAU - Catarino, Rita I L
AU  - Catarino RI
AD  - University of Porto, CEQUP/Department of Physical Chemistry, Faculty of Pharmacy, 
      Portugal.
FAU - Garcia, M Beatriz Q
AU  - Garcia MB
FAU - Lapa, Rui A S
AU  - Lapa RA
FAU - Lima, José L F C
AU  - Lima JL
FAU - Barrado, Enrique
AU  - Barrado E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J AOAC Int
JT  - Journal of AOAC International
JID - 9215446
RN  - 0 (Indicators and Reagents)
RN  - 0 (Solutions)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, Gas
MH  - Chromatography, Liquid
MH  - Colorimetry
MH  - Electrochemistry
MH  - Electrodes
MH  - Flow Injection Analysis
MH  - Fluorometry
MH  - Indicators and Reagents
MH  - Portugal
MH  - Salicylic Acid/*analysis
MH  - Solutions
MH  - Spectrophotometry, Infrared
MH  - Spectrum Analysis, Raman
EDAT- 2002/12/13 04:00
MHDA- 2003/05/16 05:00
CRDT- 2002/12/13 04:00
PHST- 2002/12/13 04:00 [pubmed]
PHST- 2003/05/16 05:00 [medline]
PHST- 2002/12/13 04:00 [entrez]
PST - ppublish
SO  - J AOAC Int. 2002 Nov-Dec;85(6):1253-9.

PMID- 3203166
OWN - NLM
STAT- MEDLINE
DCOM- 19890209
LR  - 20161123
IS  - 0100-879X (Print)
IS  - 0100-879X (Linking)
VI  - 21
IP  - 2
DP  - 1988
TI  - Inhibition of platelet aggregation by manoalide: preliminary results.
PG  - 337-40
AB  - Manoalide (MND), a sesterterpenoid first isolated from the marine sponge 
      Luffariela variabilis and later synthesized by Japanese chemists, exhibits 
      anti-inflammatory activity and directly inactivates bee and snake venom 
      phospholipase A2. We investigated the effects of MND on platelet aggregation 
      induced by PAF-acether, arachidonic acid (AA), ADP and thrombin. Rabbit platelet 
      aggregation was inhibited by MND in a dose-dependent manner. MND also inhibited 
      the aggregation induced by AA and ADP but not that induced by thrombin. Since 
      this marine natural product is also a potent inhibitor of lipoxygenase in human 
      polymorphonuclear neutrophils, MND appears to be a useful tool for determining 
      the role of phospholipase A2 in biological processes.
FAU - Freitas, J C
AU  - Freitas JC
AD  - Departmento de Fisiologia Geral, Universidade de São Paulo, Brasil.
FAU - Rodrigue, F
AU  - Rodrigue F
FAU - Lavaud, P
AU  - Lavaud P
FAU - Mencia-Huerta, J M
AU  - Mencia-Huerta JM
FAU - Braquet, P
AU  - Braquet P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Brazil
TA  - Braz J Med Biol Res
JT  - Brazilian journal of medical and biological research = Revista brasileira de 
      pesquisas medicas e biologicas
JID - 8112917
RN  - 0 (Platelet Activating Factor)
RN  - 0 (Terpenes)
RN  - E1DK0157K9 (manoalide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Platelet Activating Factor/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
MH  - Terpenes/administration & dosage/*pharmacology
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Braz J Med Biol Res. 1988;21(2):337-40.

PMID- 3774856
OWN - NLM
STAT- MEDLINE
DCOM- 19861208
LR  - 20181130
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 41
IP  - 7
DP  - 1986 Jul
TI  - [Tooth-socket dressing in the treatment of postextraction complications 
      (alveolitis sicca dolorosa). 1. The influence of glycerol and 
      polyoxyethyleneglycol 200 on the physicochemical properties of tablets with 
      acetylsalicylic acid and nipagine P].
PG  - 491-3
AB  - Using methylcellulose with an addition of glycerol or of polyoxyethylene glycol 
      200 tablets were made which produce after swelling a dressing designed for 
      treatment of Alveolitis sicca dolorosa. The pharmaceutical availability of 
      acetylsalicylic acid and of Nipagine P as well as the swelling degree increase on 
      a parallel line to increasing quantities of hydrophylizators in a tablet. However 
      the washing out time as well as that of half liberation remain in a reversed 
      proportionality to the content of glycerol and of polyoxyethylene glycol 200. The 
      dressings show non ideally plastic viscosity, they possess thixotropic properties 
      and are characterized by a high flow limit. Below the flow limit the dressing 
      possess in properties of on elastic body.
FAU - Kubis, A
AU  - Kubis A
FAU - Grabowska-Bochenek, J
AU  - Grabowska-Bochenek J
LA  - ger
PT  - Journal Article
TT  - Untersuchung von Zahnhöhleneinsätzen zur Behandlung der Postextraktionswunden 
      (Alveolitis sicca dolovosa). 1. Mitteilung: Einfluss von Glycerol und 
      Polyoxyethylenglycol 200 auf die physikochemischen Eigenschaften von Tabletten 
      mit Acetylsalicylsäure und Nipagin P.
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Parabens)
RN  - 0 (Tablets)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - PDC6A3C0OX (Glycerol)
RN  - R16CO5Y76E (Aspirin)
RN  - Z8IX2SC1OH (propylparaben)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Chemical Phenomena
MH  - Chemistry, Physical
MH  - Dry Socket/prevention & control
MH  - Glycerol
MH  - Humans
MH  - Parabens/*therapeutic use
MH  - Periodontal Dressings
MH  - Polyethylene Glycols
MH  - Tablets
MH  - Tooth Extraction/*adverse effects
EDAT- 1986/07/01 00:00
MHDA- 1986/07/01 00:01
CRDT- 1986/07/01 00:00
PHST- 1986/07/01 00:00 [pubmed]
PHST- 1986/07/01 00:01 [medline]
PHST- 1986/07/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1986 Jul;41(7):491-3.

PMID- 6854582
OWN - NLM
STAT- MEDLINE
DCOM- 19830708
LR  - 20190709
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 26
IP  - 6
DP  - 1983 Jun
TI  - 6-Aryl-4,5-dihydro-3(2H)-pyridazinones. A new class of compounds with platelet 
      aggregation inhibiting and hypotensive activities.
PG  - 800-7
AB  - This paper reports on the synthesis and pharmacological activity of 
      6-aryl-4,5-dihydro-3(2H)-pyridazinone derivatives. The compounds exhibit an 
      aggregation inhibiting action on human platelets in vitro and on rat platelets 
      under ex vivo conditions, as well as a hypotensive action on rats. The strongest 
      pharmacological effects were found with dihydropyridazinones, which have a 
      6-[p-[(chloroalkanoyl)amino]phenyl] substituent, together with a methyl group in 
      the 5-position. The antiaggregation activity of compounds of this type is in 
      vitro up to 16000 times and ex vivo up to 370 times greater than that of 
      acetylsalicylic acid; the hypotensive action is up to 40 times as great as that 
      of the comparative substance dihydralazine.
FAU - Thyes, M
AU  - Thyes M
FAU - Lehmann, H D
AU  - Lehmann HD
FAU - Gries, J
AU  - Gries J
FAU - König, H
AU  - König H
FAU - Kretzschmar, R
AU  - Kretzschmar R
FAU - Kunze, J
AU  - Kunze J
FAU - Lebkücher, R
AU  - Lebkücher R
FAU - Lenke, D
AU  - Lenke D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Pyridazines)
RN  - PCU411F5L6 (Dihydralazine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Pressure/*drug effects
MH  - Dihydralazine/pharmacology
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Pyridazines/chemical synthesis/*pharmacology
MH  - Rats
EDAT- 1983/06/01 00:00
MHDA- 1983/06/01 00:01
CRDT- 1983/06/01 00:00
PHST- 1983/06/01 00:00 [pubmed]
PHST- 1983/06/01 00:01 [medline]
PHST- 1983/06/01 00:00 [entrez]
AID - 10.1021/jm00360a004 [doi]
PST - ppublish
SO  - J Med Chem. 1983 Jun;26(6):800-7. doi: 10.1021/jm00360a004.

PMID- 25474553
OWN - NLM
STAT- MEDLINE
DCOM- 20160121
LR  - 20181113
IS  - 1476-5543 (Electronic)
IS  - 0743-8346 (Print)
IS  - 0743-8346 (Linking)
VI  - 35
IP  - 5
DP  - 2015 May
TI  - Early initiation of low-dose aspirin for reduction in preeclampsia risk in 
      high-risk women: a secondary analysis of the MFMU High-Risk Aspirin Study.
PG  - 328-31
LID - 10.1038/jp.2014.214 [doi]
AB  - OBJECTIVE: Early initiation of low-dose aspirin (LDA) may reduce preeclampsia 
      risk. We sought to determine whether LDA was beneficial when initiated <17w0d, 
      within a trial of high-risk women enrolled <26w0d. STUDY DESIGN: Secondary 
      analysis of the Maternal-Fetal Medicine Units High-Risk Aspirin study, including 
      women enrolled <17w0d, randomized to LDA (60 mg day(-1)) or placebo with chronic 
      hypertension (CHTN, n=186), diabetes (n=191) or prior preeclampsia (n=146). The 
      primary outcome was preeclampsia at any time in pregnancy, secondary outcomes 
      were early preeclampsia (<34w0d), late preeclampsia (⩾34w), small for gestational 
      age (SGA; neonatal birthweight <10th %) and composite (early preeclampsia or 
      SGA). Outcomes were compared by exact Χ(2)-tests. RESULTS: Baseline 
      characteristics were similar between treatment groups. Aspirin was associated 
      with a lower rate of late-onset preeclampsia ⩾34w (17.36% vs 24.42%, P=0.047), 
      with a 41% reduction in women with CHTN (18.28% vs 31.18%, P=0.041). There were 
      no other significant differences in the outcome. CONCLUSION: Aspirin initiated 
      <17w0d reduced the risk for late-onset preeclampsia by 29% supporting the 
      practice of early initiation of aspirin in high-risk women.
FAU - Moore, G S
AU  - Moore GS
AD  - University of Colorado Department of Obstetrics and Gynecology, Aurora, CO, USA.
FAU - Allshouse, A A
AU  - Allshouse AA
AD  - Colorado School of Public Health, Aurora, CO, USA.
FAU - Post, A L
AU  - Post AL
AD  - University of Colorado Department of Obstetrics and Gynecology, Aurora, CO, USA.
FAU - Galan, H L
AU  - Galan HL
AD  - University of Colorado Department of Obstetrics and Gynecology, Aurora, CO, USA.
FAU - Heyborne, K D
AU  - Heyborne KD
AD  - University of Colorado Department of Obstetrics and Gynecology, Aurora, CO, USA.
LA  - eng
GR  - U10 HD068282/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20141204
PL  - United States
TA  - J Perinatol
JT  - Journal of perinatology : official journal of the California Perinatal 
      Association
JID - 8501884
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Birth Weight
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Infant, Newborn
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Risk Factors
PMC - PMC4838902
MID - NIHMS777676
COIS- CONFLICT OF INTEREST The authors declare no conflict of interest.
EDAT- 2014/12/05 06:00
MHDA- 2016/01/23 06:00
CRDT- 2014/12/05 06:00
PHST- 2014/04/26 00:00 [received]
PHST- 2014/09/30 00:00 [revised]
PHST- 2014/10/01 00:00 [accepted]
PHST- 2014/12/05 06:00 [entrez]
PHST- 2014/12/05 06:00 [pubmed]
PHST- 2016/01/23 06:00 [medline]
AID - jp2014214 [pii]
AID - 10.1038/jp.2014.214 [doi]
PST - ppublish
SO  - J Perinatol. 2015 May;35(5):328-31. doi: 10.1038/jp.2014.214. Epub 2014 Dec 4.

PMID- 3837604
OWN - NLM
STAT- MEDLINE
DCOM- 19860922
LR  - 20151119
IS  - 0044-6033 (Print)
IS  - 0044-6033 (Linking)
VI  - 36
IP  - 5-6
DP  - 1985 Sep-Dec
TI  - The effect of prostaglandins E1, E2, F1 alpha and F2 alpha on pig erythrocytes 
      during haemolysis induced with aspirin and hypotonic NaCl solution.
PG  - 352-9
AB  - The effect of prostaglandins PGE1, PGE2, PGF1 alpha and PGF2 alpha was 
      investigated on the haemolysis of pig erythrocytes induced with aspirin and 
      hypotonic (0.119 M) NaCl solution. An inhibiting effect was observed of low 
      concentrations (2 X 10(-5) M, 2 X 10(-4) M and 2 X 10(-3) M) of aspirin on 
      haemolysis induced with hypotonic NaCl solution, while in a concentration of 2 X 
      10(-2) M aspirin itself caused haemolysis which amounted to 93% of the haemolysis 
      induced with 0.041 M NaCl solution. No differences were observed in the degree of 
      haemolysis inhibition in relation to the time of incubation of erythrocytes with 
      aspirin. Aspirin concentrations from 0.035 M to 0.280 M caused slight haemolysis 
      (9-15% of the haemolysis induced with water), the 0.560 M solution caused 
      haemolysis corresponding to 85% of the water-induced haemolysis. None of the 
      studied prostaglandins used in concentrations of 0.4 X 10(-3) M, 0.4 X 10(-4) M 
      and 0.4 X 10(-5) M had any significant effect on aspirin-induced haemolysis. PGE1 
      and PGE2 in concentrations of 0.4 X 10(-3) M, 0.4 X 10(-4) M and 0.4 X 10(-5) M 
      inhibited haemolysis induced with 0.119 M sodium chloride solution, and the 
      degree of haemolysis inhibition was from 8% to 35%. Prostaglandins PGF1 alpha and 
      PGF2 alpha in the same concentrations had no protective effect.
FAU - Ledwozyw, A
AU  - Ledwozyw A
FAU - Pruszkowska, R
AU  - Pruszkowska R
FAU - Trawińska, B
AU  - Trawińska B
FAU - Ruciński, T
AU  - Ruciński T
FAU - Kadiołka, A
AU  - Kadiołka A
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Acta Physiol Pol
JT  - Acta physiologica Polonica
JID - 2985166R
RN  - 0 (Hypotonic Solutions)
RN  - 0 (Prostaglandins)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Erythrocytes/*drug effects
MH  - *Hemolysis/drug effects
MH  - Hypotonic Solutions
MH  - Osmolar Concentration
MH  - Prostaglandins/*pharmacology
MH  - Sodium Chloride/*pharmacology
MH  - Swine/blood
EDAT- 1985/09/01 00:00
MHDA- 1985/09/01 00:01
CRDT- 1985/09/01 00:00
PHST- 1985/09/01 00:00 [pubmed]
PHST- 1985/09/01 00:01 [medline]
PHST- 1985/09/01 00:00 [entrez]
PST - ppublish
SO  - Acta Physiol Pol. 1985 Sep-Dec;36(5-6):352-9.

PMID- 32470453
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20200629
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 255
DP  - 2020 Aug 15
TI  - The impact of metformin and aspirin on T-cell mediated inflammation: A systematic 
      review of in vitro and in vivo findings.
PG  - 117854
LID - S0024-3205(20)30604-4 [pii]
LID - 10.1016/j.lfs.2020.117854 [doi]
AB  - Chronic inflammation and hyperglycaemia are well-established aspects in the 
      pathogenesis of type 2 diabetes mellitus (T2D), including the progression of its 
      associated complications such as cardiovascular diseases (CVDs). In fact, 
      emerging evidence shows that dysfunctional immune responses due to dysregulated 
      T-cell function aggravates CVD-related complications in T2D. However, there is a 
      lack of specific therapeutic interventions that protect patients with diabetes 
      who are at risk of heart failure. Metformin and aspirin are among the leading 
      therapies being used to protect or at the very least slow the progression of 
      CVD-related complications. The current review made use of major electronic 
      databases to identify and systematically synthesise emerging experimental data on 
      the impact of these pharmacological drugs on T-cell responses. The quality and 
      risk of bias of include evidence were independently assessed by two reviewers. 
      Overwhelming evidence showed that both metformin and aspirin can ameliorate 
      T-cell mediated inflammation by inducing regulatory T-cells (Tregs) polarisation, 
      inhibiting T-cell trafficking and activation as well as signal transducer and 
      activator of transcription (STAT)3 signalling. As a plausible mechanism to 
      mediate T-cell function, metformin showed enhanced potential to regulate 
      mechanistic targets of rapamycin (mTOR), STAT5 and 
      adenosine-monophosphate-activated protein kinase (AMPK) signalling pathways. 
      Whilst aspirin modulated nuclear factor kappa-light-chain-enhancer of activated 
      B-cells (NF-kB) and co-stimulatory signalling pathways and induced T-cell anergy. 
      Overall, synthesised data prompt further investigation into the combinational 
      effect of metformin and aspirin for the management of T2D-related cardiovascular 
      complications.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Nyambuya, Tawanda Maurice
AU  - Nyambuya TM
AD  - School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health 
      Sciences, University of KwaZulu-Natal, Durban, South Africa; Department of Health 
      Sciences, Faculty of Health and Applied Sciences, Namibia University of Science 
      and Technology, Windhoek, Namibia. Electronic address: mnyambuya@nust.na.
FAU - Dludla, Phiwayinkosi Vusi
AU  - Dludla PV
AD  - Biomedical Research and Innovation Platform, South African Medical Research 
      Council, Tygerberg, South Africa; Department of Life and Environmental Sciences, 
      Polytechnic University of Marche, Ancona, Italy. Electronic address: 
      pdludla@mrc.ac.za.
FAU - Mxinwa, Vuyolwethu
AU  - Mxinwa V
AD  - School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health 
      Sciences, University of KwaZulu-Natal, Durban, South Africa. Electronic address: 
      218081787@stu.ukzn.ac.za.
FAU - Mokgalaboni, Kabelo
AU  - Mokgalaboni K
AD  - School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health 
      Sciences, University of KwaZulu-Natal, Durban, South Africa. Electronic address: 
      218086707@stu.ukzn.ac.za.
FAU - Ngcobo, Siphamandla Raphael
AU  - Ngcobo SR
AD  - School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health 
      Sciences, University of KwaZulu-Natal, Durban, South Africa. Electronic address: 
      213514766@stu.ukzn.ac.za.
FAU - Tiano, Luca
AU  - Tiano L
AD  - Department of Life and Environmental Sciences, Polytechnic University of Marche, 
      Ancona, Italy. Electronic address: l.tiano@staff.univpm.it.
FAU - Nkambule, Bongani Brian
AU  - Nkambule BB
AD  - School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health 
      Sciences, University of KwaZulu-Natal, Durban, South Africa. Electronic address: 
      nkambuleb@ukzn.ac.za.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200526
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cardiovascular Diseases/prevention & control
MH  - Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/pharmacology
MH  - Inflammation/*drug therapy/pathology
MH  - Metformin/administration & dosage/*pharmacology
MH  - T-Lymphocytes/immunology
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular diseases
OT  - Inflammation
OT  - Metabolic diseases
OT  - Metformin
OT  - T-cells
OT  - Type 2 diabetes mellitus
COIS- Declaration of competing interest Authors declare that they have no conflict of 
      interest.
EDAT- 2020/05/30 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - S0024-3205(20)30604-4 [pii]
AID - 10.1016/j.lfs.2020.117854 [doi]
PST - ppublish
SO  - Life Sci. 2020 Aug 15;255:117854. doi: 10.1016/j.lfs.2020.117854. Epub 2020 May 
      26.

PMID- 18259082
OWN - NLM
STAT- MEDLINE
DCOM- 20080328
LR  - 20221207
IS  - 1423-0208 (Electronic)
IS  - 0251-5350 (Print)
IS  - 0251-5350 (Linking)
VI  - 30
IP  - 1
DP  - 2008
TI  - Anti-inflammatory agents and cognitive decline in a bi-racial population.
PG  - 45-50
LID - 10.1159/000115749 [doi]
AB  - In a prospective study among 4,409 subjects aged 65+ years, we assessed the 
      relation of nonsteroidal anti-inflammatory agents (NSAIDs) to cognition. The main 
      outcome was decline in global cognitive function, determined by average 
      performance across four cognitive tests, over up to four interviews. We found 
      similar rates of cognitive decline among recent users of aspirin and of other 
      NSAIDs (largely ibuprofen) compared to those who did not use these NSAIDs. For 
      lifetime duration of aspirin use, we failed to find an association with cognitive 
      decline. However, for other NSAIDs, increasing duration of lifetime use was 
      related to slower rates of cognitive decline, relative to no use of other NSAIDs 
      (5+ years vs. no use: mean difference = 0.12; p trend = 0.03). Overall, we found 
      no relation between regular aspirin use and cognitive decline, but long-term use 
      of ibuprofen may be related to decreased rates of cognitive decline in older 
      persons.
CI  - (c) 2008 S. Karger AG, Basel.
FAU - Grodstein, Francine
AU  - Grodstein F
AD  - Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, IL, 
      USA. fgrodstein@partners.org
FAU - Skarupski, Kimberly A
AU  - Skarupski KA
FAU - Bienias, Julia L
AU  - Bienias JL
FAU - Wilson, Robert S
AU  - Wilson RS
FAU - Bennett, David A
AU  - Bennett DA
FAU - Evans, Denis A
AU  - Evans DA
LA  - eng
GR  - R01 AG011101/AG/NIA NIH HHS/United States
GR  - AG11101/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20080207
PL  - Switzerland
TA  - Neuroepidemiology
JT  - Neuroepidemiology
JID - 8218700
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Black People/psychology/*statistics & numerical data
MH  - Chicago
MH  - Cognition/drug effects
MH  - Cognition Disorders/diagnosis/*epidemiology
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Neuropsychological Tests/statistics & numerical data
MH  - Prospective Studies
MH  - Risk Factors
MH  - White People/psychology/*statistics & numerical data
PMC - PMC2821440
EDAT- 2008/02/09 09:00
MHDA- 2008/03/29 09:00
CRDT- 2008/02/09 09:00
PHST- 2007/07/11 00:00 [received]
PHST- 2007/11/21 00:00 [accepted]
PHST- 2008/02/09 09:00 [pubmed]
PHST- 2008/03/29 09:00 [medline]
PHST- 2008/02/09 09:00 [entrez]
AID - 000115749 [pii]
AID - ned0030-0045 [pii]
AID - 10.1159/000115749 [doi]
PST - ppublish
SO  - Neuroepidemiology. 2008;30(1):45-50. doi: 10.1159/000115749. Epub 2008 Feb 7.

PMID- 1285871
OWN - NLM
STAT- MEDLINE
DCOM- 19930318
LR  - 20190918
IS  - 1046-7408 (Print)
IS  - 1046-7408 (Linking)
VI  - 28
IP  - 3-4
DP  - 1992 Oct-Dec
TI  - Umbilical and uterine artery flow velocity waveforms in pregnant women with 
      systemic lupus erythematosus treated with aspirin and glucocorticosteroids.
PG  - 168-71
AB  - Pregnancy in systemic lupus erythematosus (SLE) is at high risk to the mother and 
      fetus. Impaired utero-placental perfusion may increase fetal loss and 
      intrauterine growth retardation. We assessed the changes in impedance to blood 
      flow in the umbilical and uterine arteries in five patients with SLE treated with 
      low dose aspirin and corticosteroids, using Doppler ultrasound longitudinally 
      throughout pregnancy. Blood flow velocity waveforms of the umbilical and uterine 
      arteries were studied by transabdominal and transvaginal Doppler ultrasound, 
      respectively. Resistance index (RI) was measured every two to four weeks from 
      week 10 to term, and the values obtained were compared to those of normal 
      pregnancies. All five patients delivered uneventfully. One neonate was delivered 
      at 36 weeks (2550 g) and one neonate was growth retarded (1900 g at 38 weeks). 
      Three women delivered at 39 weeks (3585 g, 2850 g, and 2800 g). Most umbilical 
      artery RI values obtained throughout pregnancy were above the 95th percentile of 
      normal pregnancies. The highest values of RI of the umbilical artery were 
      assessed in the case of fetal growth retardation. However, most measurements of 
      RI of the uterine artery were under the 95th percentile of normal. The improved 
      pregnancy outcome in patients with SLE treated with aspirin and corticosteroids 
      seems to correlate with their normal uterine artery flow velocity wave forms.
FAU - Weiner, Z
AU  - Weiner Z
AD  - Department of Obstetrics and Gynecology, Rambam Medical Center, Haifa, Israel.
FAU - Lorber, M
AU  - Lorber M
FAU - Blumenfeld, Z
AU  - Blumenfeld Z
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 65VXC1MH0J (Fluocortolone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/epidemiology/etiology
MH  - Antibodies, Anticardiolipin/analysis
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Autoimmune Diseases/drug therapy/*physiopathology
MH  - *Blood Flow Velocity/drug effects
MH  - Female
MH  - Fluocortolone/pharmacology/*therapeutic use
MH  - Gestational Age
MH  - Humans
MH  - Lupus Erythematosus, Systemic/drug therapy/*physiopathology
MH  - Pregnancy
MH  - Pregnancy Complications/drug therapy/*physiopathology
MH  - Pregnancy Outcome
MH  - Regional Blood Flow/drug effects
MH  - *Ultrasonography, Prenatal
MH  - Umbilical Arteries/*physiology
MH  - Uterus/*blood supply
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 10.1111/j.1600-0897.1992.tb00783.x [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 1992 Oct-Dec;28(3-4):168-71. doi: 
      10.1111/j.1600-0897.1992.tb00783.x.

PMID- 35312251
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20220416
IS  - 1853-0605 (Electronic)
IS  - 0014-6722 (Print)
IS  - 0014-6722 (Linking)
VI  - 79
IP  - 1
DP  - 2022 Mar 7
TI  - [Use of aspirin 100 mg / day to prevent Preeclampsia, in high risk pregnancies, 
      in a cohort from Argentina].
PG  - 4-9
LID - 10.31053/1853.0605.v79.n1.32783 [doi]
AB  - OBJECTIVES: The objective of the present study was to analyse the use of 100 g 
      aspirin dose as prevention method for preeclampsia in high risk pregnant 
      patients. METHODS: A retrospective cohort study was performed in high risk 
      pregnant patients with a blood pressure protocol, and the use of 100 mg of 
      aspirin vs. its non-use was evaluated in the incidence of PREEC. Estimations 
      between the two groups were performed with and without variable adjustment by 
      means of binary logistic regression models. RESULTS: 633 high risk pregnant 
      patients were evaluated. The average age was 30±7 years old, and 25±8 weeks of 
      pregnancy. 281 women (44.3 %) within this group received aspirin. The total 
      prevalence of PREEC in our sample was 151 pregnant women (23.8 %). Pregnant 
      patients under the aspirin treatment developed less PREEC events (19.2% vs 27.5%, 
      p=0.019); with OR not adjusted 0.62 (IC95% 0.43-0.91 p= 0.017). The risk was 
      similar when it was adjusted by age, preeclampsia history, diabetes mellitus and 
      chronic high blood pressure. (OR adjusted 0.63 IC95% 0.43-0.92 p= 0.017). 
      CONCLUSIONS: The use of 100 mg of aspirin a day before the 20th week of pregnancy 
      in high risk pregnant patients decreased the risk of developing PREEC, regardless 
      the age and risk factors.
CI  - Universidad Nacional de Córdoba.
FAU - Espeche, Walter Gaston
AU  - Espeche WG
AD  - . wespeche@gmail.com.
FAU - Minetto, Julian
AU  - Minetto J
AD  - UNLP. jjminetto@hotmail.com.
FAU - Salazar, Martin Rogelio
AU  - Salazar MR
AD  - . salazarlandea@gmail.com.
LA  - spa
PT  - Journal Article
TT  - Utilización de aspirina 100 mg/día para prevenir Preeclampsia, en embarazos de 
      alto riego, en una cohorte de Argentina.
DEP - 20220307
PL  - Argentina
TA  - Rev Fac Cien Med Univ Nac Cordoba
JT  - Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)
JID - 8303003
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Argentina
MH  - *Aspirin/therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/drug therapy/epidemiology/prevention & control
MH  - Pregnancy
MH  - Pregnancy, High-Risk
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC9004295
OTO - NOTNLM
OT  - preeclampsia
OT  - eclampsia
OT  - pregnancy
OT  - aspirin
COIS- Conflicto de interés: Ninguno.
EDAT- 2022/03/22 06:00
MHDA- 2022/03/24 06:00
CRDT- 2022/03/21 12:47
PHST- 2021/04/21 00:00 [received]
PHST- 2021/08/08 00:00 [accepted]
PHST- 2022/03/21 12:47 [entrez]
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
AID - 32783 [pii]
AID - 10.31053/1853.0605.v79.n1.32783 [doi]
PST - epublish
SO  - Rev Fac Cien Med Univ Nac Cordoba. 2022 Mar 7;79(1):4-9. doi: 
      10.31053/1853.0605.v79.n1.32783.

PMID- 28661936
OWN - NLM
STAT- MEDLINE
DCOM- 20180321
LR  - 20181202
IS  - 1531-6963 (Electronic)
IS  - 1040-8711 (Linking)
VI  - 29
IP  - 5
DP  - 2017 Sep
TI  - Revisiting the role of steroids and aspirin in the management of acute Kawasaki 
      disease.
PG  - 547-552
LID - 10.1097/BOR.0000000000000425 [doi]
AB  - PURPOSE OF REVIEW: Kawasaki disease is an acute multisystem childhood vasculitis 
      with a predilection for the coronary arteries. The role of corticosteroids and 
      acetyl salicylic acid (ASA) in the treatment of acute Kawasaki disease are 
      matters of ongoing debate and changing attitudes from one extreme to the other. 
      Recent work has provided new evidence to guide our thinking about these two 
      therapeutic agents, which will be the focus of this review. RECENT FINDINGS: 
      Corticosteroids are effective and well tolerated in Kawasaki disease, both as 
      initial adjunctive treatment in those at high-risk for poor outcome, and as 
      rescue therapy after failed intravenous immunoglobulin (IVIG).Higher doses of ASA 
      (> 30 mg/kg/day) in the acute phase of Kawasaki disease, have no clear benefit 
      over antiplatelet doses in improving coronary outcome. SUMMARY: Corticosteroids 
      should be used in patients at high-risk for poor coronary outcome, and in 
      patients who fail IVIG. The absence of widely applicable and validated 
      risk-scoring systems in Kawasaki disease outside of Japan remains a limiting 
      factor to identify high-risk children. Current evidence does not demonstrate any 
      advantage of high-dose over low-dose ASA in the acute phase of Kawasaki disease, 
      in preventing coronary artery aneurysms.
FAU - Dhanrajani, Anita
AU  - Dhanrajani A
AD  - aHospital for Sick Children bHak-Ming and Deborah Chiu Chair in Paediatric 
      Translational Research, Professor of Paediatrics, Immunology and Medical Science, 
      University of Toronto, Senior Scientist and Rheumatologist, The Hospital for Sick 
      Children, Toronto, ON.
FAU - Yeung, Rae S M
AU  - Yeung RSM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Rheumatol
JT  - Current opinion in rheumatology
JID - 9000851
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Mucocutaneous Lymph Node Syndrome/*drug therapy
EDAT- 2017/07/01 06:00
MHDA- 2018/03/22 06:00
CRDT- 2017/06/30 06:00
PHST- 2017/07/01 06:00 [pubmed]
PHST- 2018/03/22 06:00 [medline]
PHST- 2017/06/30 06:00 [entrez]
AID - 10.1097/BOR.0000000000000425 [doi]
PST - ppublish
SO  - Curr Opin Rheumatol. 2017 Sep;29(5):547-552. doi: 10.1097/BOR.0000000000000425.

PMID- 8229486
OWN - NLM
STAT- MEDLINE
DCOM- 19931202
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 123
IP  - 5
DP  - 1993 Nov
TI  - Atrophie blanche with onset in childhood.
PG  - 753-5
AB  - Atrophie blanche (livedo vasculitis) is a superficial thrombotic condition 
      characterized by grouped and reticulated erythematous and purpuric macules, 
      painful ulcers, and atrophic scars, and is usually found in middle-aged women. We 
      describe an 8-year-old boy with atrophie blanche. Therapy with antiplatelet 
      medications seemed to alleviate pain and decrease the ulceration.
FAU - Suarez, S M
AU  - Suarez SM
AD  - Division of Dermatology, Children's Memorial Hospital, Northwestern University 
      Medical School, Chicago, Illinois 60614.
FAU - Paller, A S
AU  - Paller AS
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Dipyridamole/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Male
MH  - Skin Diseases, Vascular/*diagnosis/drug therapy/pathology
MH  - Vasculitis/*diagnosis/drug therapy/pathology
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
AID - S0022-3476(05)80854-6 [pii]
AID - 10.1016/s0022-3476(05)80854-6 [doi]
PST - ppublish
SO  - J Pediatr. 1993 Nov;123(5):753-5. doi: 10.1016/s0022-3476(05)80854-6.

PMID- 14980230
OWN - NLM
STAT- MEDLINE
DCOM- 20040309
LR  - 20191108
IS  - 1567-5688 (Print)
IS  - 1567-5688 (Linking)
VI  - 4
IP  - 5
DP  - 2003 Dec
TI  - Long-term statin safety and efficacy in secondary prevention: can combination 
      therapy improve outcomes?
PG  - 11-6
AB  - The use of statins has been associated with substantial reductions in vascular 
      morbidity and mortality. The Prospective Pravastatin Pooling Project (PPP) looked 
      at the long-term safety and efficacy of statins in secondary prevention, based on 
      pooled results from three key statin trials. PPP revealed a highly significant 
      relative risk reduction in total mortality, and demonstrated that pravastatin has 
      a similar incidence of muscle-related side effects as placebo. It has been 
      speculated that treatment with statins in combination with other cardiovascular 
      drugs may have a synergistic effect on reduction of cardiovascular complications. 
      However, for ethical reasons, evidence can only ever be sought from sub-group 
      analyses or meta-analyses of existing studies. Recent studies have focused on 
      statins plus acetyl- salicylic acid (ASA, aspirin). Evidence suggests that a 
      combination of statins with ASA provides a cardiovascular risk reduction that is 
      superior to the respective monotherapy. Thus, statins effectively reduce further 
      cardiovascular morbidity and mortality as well as total mortality in patients 
      with manifest coronary artery disease (CAD) or at high risk, also they act in 
      synergy with ASA and they are safe.
FAU - Wascher, Thomas C
AU  - Wascher TC
AD  - Diabetes and Metabolism Unit, Department of Internal Medicine, Karl-Franzens 
      University School of Medicine, Auenbruggerpl. 15, A-8036 Graz, Austria. 
      thomas.wascher@uni-graz.at
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Netherlands
TA  - Atheroscler Suppl
JT  - Atherosclerosis. Supplements
JID - 100973461
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage
MH  - Anticholesteremic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Artery Disease/*prevention & control
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
EDAT- 2004/02/26 05:00
MHDA- 2004/03/10 05:00
CRDT- 2004/02/26 05:00
PHST- 2004/02/26 05:00 [pubmed]
PHST- 2004/03/10 05:00 [medline]
PHST- 2004/02/26 05:00 [entrez]
AID - S1567-5688(03)90047-X [pii]
AID - 10.1016/s1567-5688(03)90002-x [doi]
PST - ppublish
SO  - Atheroscler Suppl. 2003 Dec;4(5):11-6. doi: 10.1016/s1567-5688(03)90002-x.

PMID- 12971030
OWN - NLM
STAT- MEDLINE
DCOM- 20031224
LR  - 20190827
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 43
IP  - 9
DP  - 2003 Sep
TI  - Relationship of arachidonic acid concentration to cyclooxygenase-dependent human 
      platelet aggregation.
PG  - 983-9
AB  - Inhibition of ex vivo arachidonic acid (AA)-induced aggregation is a biomarker 
      for the isotype selectivity of cyclooxygenase (COX) inhibitors since platelets 
      express COX-1 but not COX-2. At low concentrations, there is broad inter- and 
      intrasubject variability in AA-induced aggregation of platelets ex vivo. This 
      study defined a concentration that reliably induces aggregation without 
      overcoming inhibition by therapeutic aspirin therapy (ASA, 81-mg) treatment. 
      Logistic regression analysis of ex vivo aggregation, induced with increasing 
      concentrations of AA in platelet-rich plasma (PRP), estimated that platelets from 
      > or = 90% of subjects would aggregate at > or = 1.5 mM AA (95% confidence 
      interval [CI], 1.1, 2.1). A concentration of 1.6 mM AA failed to aggregate 
      platelets from 26 healthy volunteers, who had previously aggregated at this 
      concentration, following six daily oral doses of 81 mg of ASA. These data 
      demonstrate that 1.6 mM AA reproducibly induces platelet aggregation in PRP from 
      healthy volunteers without overcoming the antiplatelet effect of daily low-dose 
      aspirin therapy.
FAU - Burke, Joanne
AU  - Burke J
AD  - Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson 
      University, Philadelphia, Pennsylvania, USA.
FAU - Kraft, Walter K
AU  - Kraft WK
FAU - Greenberg, Howard E
AU  - Greenberg HE
FAU - Gleave, Melanie
AU  - Gleave M
FAU - Pitari, Giovanni M
AU  - Pitari GM
FAU - VanBuren, Sandi
AU  - VanBuren S
FAU - Wagner, John A
AU  - Wagner JA
FAU - Waldman, Scott A
AU  - Waldman SA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Arachidonic Acid/blood/*pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Cyclooxygenase Inhibitors/administration & dosage/pharmacology
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Prostaglandin-Endoperoxide Synthases/*blood
MH  - Reproducibility of Results
EDAT- 2003/09/16 05:00
MHDA- 2003/12/25 05:00
CRDT- 2003/09/16 05:00
PHST- 2003/09/16 05:00 [pubmed]
PHST- 2003/12/25 05:00 [medline]
PHST- 2003/09/16 05:00 [entrez]
AID - 10.1177/0091270003257216 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2003 Sep;43(9):983-9. doi: 10.1177/0091270003257216.

PMID- 11901464
OWN - NLM
STAT- MEDLINE
DCOM- 20020927
LR  - 20191105
IS  - 0218-8104 (Print)
IS  - 0218-8104 (Linking)
VI  - 6
IP  - 2
DP  - 2001 Dec
TI  - The effect of aspirin and prostaglandin E(1) on the patency of microvascular 
      anastomosis in the rats.
PG  - 177-85
AB  - The purpose of this study was to evaluate the effect of oral prostaglandin 
      E(1)(PGE(1)) on the patency of the microvascular anastomosis of the carotid 
      artery in rat. A total of 48 rats were used, and divided into three groups. The 
      first group (A) was used as a control with no medical agent being used after 
      anastomosis, the second group (B) was medicated with aspirin, and the third group 
      (C) was medicated with oral PGE(1). In each group, four rats were sacrificed 
      serially on every post-operative 3, 5, 10 and 15 days after arterial anastomosis. 
      Patency and histologic evaluations at the anastomotic site were observed. The 
      results revealed that the PGE(1) therapied group showed highest patency rate 
      (100%), lesser formation of mural thrombosis, and also minimal changes in the 
      intimal hyperplasia and medial fibrosis. From these findings, we could conclude 
      that PGE(1) has superior effect on maintaining the patency after microvascular 
      surgery.
FAU - Lee, K S
AU  - Lee KS
AD  - Department of Orthopaedic Surgery, Korea University Hospital, Seoul, Korea. 
      kuosam@chollian.net
FAU - Suh, J D
AU  - Suh JD
FAU - Han, S B
AU  - Han SB
FAU - Yoo, J C
AU  - Yoo JC
FAU - Lee, S J
AU  - Lee SJ
FAU - Cho, S J
AU  - Cho SJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Singapore
TA  - Hand Surg
JT  - Hand surgery : an international journal devoted to hand and upper limb surgery 
      and related research : journal of the Asia-Pacific Federation of Societies for 
      Surgery of the Hand
JID - 9602613
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - F5TD010360 (Alprostadil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Alprostadil/administration & dosage/*pharmacology/therapeutic use
MH  - Anastomosis, Surgical
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Carotid Arteries/*drug effects/pathology/*surgery
MH  - Carotid Artery Thrombosis/*prevention & control
MH  - Disease Models, Animal
MH  - Male
MH  - Microcirculation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/therapeutic 
      use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Vascular Patency/*drug effects
EDAT- 2002/03/20 10:00
MHDA- 2002/09/28 04:00
CRDT- 2002/03/20 10:00
PHST- 2002/03/20 10:00 [pubmed]
PHST- 2002/09/28 04:00 [medline]
PHST- 2002/03/20 10:00 [entrez]
AID - S0218810401000643 [pii]
AID - 10.1142/s0218810401000643 [doi]
PST - ppublish
SO  - Hand Surg. 2001 Dec;6(2):177-85. doi: 10.1142/s0218810401000643.

PMID- 9229576
OWN - NLM
STAT- MEDLINE
DCOM- 19970721
LR  - 20191102
IS  - 0889-8553 (Print)
IS  - 0889-8553 (Linking)
VI  - 25
IP  - 2
DP  - 1996 Jun
TI  - NSAID use and decreased risk of gastrointestinal cancers.
PG  - 333-48
AB  - The accumulating evidence suggests that aspirin or other NSAIDs may prevent or 
      inhibit the development of colon and perhaps other digestive tract cancers. 
      Although the clinical, experimental, and epidemiologic evidence is promising, the 
      hypothesis remains unproven except in the models of chemically induced colon 
      cancer in rodents and adenomatous polyps in patients with FAP. Clinicians should 
      await the results of randomized trials before using NSAIDs for cancer prevention 
      or treatment. Recommendations are as follows: 1. Experimental studies should 
      define the mechanism or mechanisms by which NSAIDs inhibit tumorigenesis in the 
      rodent model. 2. Experimental and clinical studies should define the optimal 
      drug, dosage, and treatment regimen. The new, selective COX-2 inhibitors should 
      be studied for efficacy and toxicity. 3. Epidemiologic studies should continue to 
      explore the issues of dosage, duration, drug, and toxicity. Because full-scale, 
      randomized trials are feasible only for studying intermediate end points such as 
      polyp recurrence or proliferative indices in high-risk populations, epidemiologic 
      studies have an ongoing role. 4. Carefully designed randomized, clinical trials, 
      now underway, are needed to test the efficacy of NSAIDs in inhibiting colorectal 
      polyps or cancer in humans. 5. Better criteria are needed as to who should take 
      aspirin and who should not.
FAU - Thun, M J
AU  - Thun MJ
AD  - Department of Epidemiology and Surveillance, American Cancer Society, Atlanta, 
      GA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Gastroenterol Clin North Am
JT  - Gastroenterology clinics of North America
JID - 8706257
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Colonic Neoplasms/chemically induced/metabolism/*prevention & control
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Prostaglandins/biosynthesis
MH  - Risk Factors
RF  - 71
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
AID - S0889-8553(05)70250-8 [pii]
AID - 10.1016/s0889-8553(05)70250-8 [doi]
PST - ppublish
SO  - Gastroenterol Clin North Am. 1996 Jun;25(2):333-48. doi: 
      10.1016/s0889-8553(05)70250-8.

PMID- 3322760
OWN - NLM
STAT- MEDLINE
DCOM- 19880311
LR  - 20190912
IS  - 0012-6578 (Print)
IS  - 0012-6578 (Linking)
VI  - 21
IP  - 12
DP  - 1987 Dec
TI  - Prevention of recurrent myocardial infarction and sudden death with aspirin 
      therapy.
PG  - 961-9
AB  - In October 1985, the Food and Drug Administration approved a new indication of 
      aspirin for the secondary prevention of recurrent myocardial infarction (MI) and 
      death in patients with MI or unstable angina. Clinical trials have demonstrated 
      the efficacy of this drug, especially when treatment is begun soon after the 
      initial event. The antiplatelet actions of aspirin seem to be the most plausible 
      explanation for its efficacy in reducing mortality and the rate of reinfarction. 
      A single daily 325-mg tablet is effective and produces side-effect incidences of 
      only zero to two percent above those produced by placebo. This article assesses 
      the current state of knowledge regarding the value of aspirin therapy in 
      survivors of acute MI and the implications for clinical practice.
FAU - Rumore, M M
AU  - Rumore MM
AD  - Professional Services Department, Sterling Drug Inc., New York, NY 10016.
FAU - Goldstein, G S
AU  - Goldstein GS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Drug Intell Clin Pharm
JT  - Drug intelligence & clinical pharmacy
JID - 0212457
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Death, Sudden/prevention & control
MH  - Humans
MH  - Myocardial Infarction/mortality/*prevention & control
MH  - Prognosis
MH  - Recurrence
RF  - 62
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
AID - 10.1177/106002808702101204 [doi]
PST - ppublish
SO  - Drug Intell Clin Pharm. 1987 Dec;21(12):961-9. doi: 10.1177/106002808702101204.

PMID- 34191011
OWN - NLM
STAT- MEDLINE
DCOM- 20220812
LR  - 20221104
IS  - 2055-6845 (Electronic)
VI  - 8
IP  - 5
DP  - 2022 Aug 11
TI  - Low-dose rivaroxaban plus aspirin in patients with polypharmacy and 
      multimorbidity: an analysis from the COMPASS trial.
PG  - 462-473
LID - 10.1093/ehjcvp/pvab050 [doi]
AB  - AIMS: To analyse whether the benefits and risks of rivaroxaban plus aspirin vary 
      in patients with comorbidities and receiving multiple drugs. In patients with 
      coronary or peripheral artery disease, adding low-dose rivaroxaban to aspirin 
      reduces cardiovascular events and mortality. Polypharmacy and multimorbidity are 
      frequent in such patients. METHODS AND RESULTS: We describe ischaemic events 
      (cardiovascular death, stroke, or myocardial infarction) and major bleeding in 
      participants from the randomized, double-blind COMPASS study by number of 
      cardiovascular medications and concomitant medical conditions. We compared event 
      rates and hazard ratios (HRs) for rivaroxaban plus aspirin vs. aspirin alone by 
      the number of medications and concomitant conditions, and tested for interaction 
      between polypharmacy or multimorbidity and the antithrombotic regimen. The risk 
      of ischaemic events was higher in patients with more concomitant drugs (HR 1.7, 
      95% confidence interval 1.5-2.1 for >4 vs. 0-2) and with more comorbidities (HR 
      2.3, 1.8-2.1 for >3 vs. 0-1). Multimorbidity, but not polypharmacy, was 
      associated with a higher risk of major bleeding. The relative efficacy, safety, 
      and net clinical benefit of rivaroxaban were not affected by the number of drugs 
      or comorbidities. Patients taking more concomitant medications derived the 
      largest absolute reduction in the net clinical outcome with added rivaroxaban 
      (1.1% vs. 0.4% reduction with >4 vs. 0-2 cardiovascular drugs, number needed to 
      treat 91 vs. 250). CONCLUSION: Adding low-dose rivaroxaban to aspirin resulted in 
      benefits irrespective of the number of concomitant drugs or comorbidities. 
      Multiple comorbidities and/or polypharmacy should not dissuade the addition of 
      rivaroxaban to aspirin in otherwise eligible patients.
CI  - © The Author(s) 2021. Published by Oxford University Press on behalf of the 
      European Society of Cardiology.
FAU - Vanassche, Thomas
AU  - Vanassche T
AUID- ORCID: 0000-0002-7404-8918
AD  - Department of Cardiovascular Sciences, University Hospitals Leuven, KU Leuven, 
      Herestraat 49, B-3000 Leuven, Belgium.
FAU - Verhamme, Peter
AU  - Verhamme P
AD  - Department of Cardiovascular Sciences, University Hospitals Leuven, KU Leuven, 
      Herestraat 49, B-3000 Leuven, Belgium.
FAU - Anand, Sonia S
AU  - Anand SS
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences, Hamilton, ON, Canada.
FAU - Shestakovska, Olga
AU  - Shestakovska O
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences, Hamilton, ON, Canada.
FAU - Leong, Darryl P
AU  - Leong DP
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences, Hamilton, ON, Canada.
FAU - Fox, Keith A A
AU  - Fox KAA
AD  - Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 
      Boston, MA, USA.
FAU - Avezum, Alvaro
AU  - Avezum A
AUID- ORCID: 0000-0002-3073-6890
AD  - International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
FAU - Alings, Marco
AU  - Alings M
AUID- ORCID: 0000-0003-2090-4683
AD  - Amphia Ziekenhuis and Werkgroep Cardiologische Centra Nederland, Utrecht, the 
      Netherlands.
FAU - Aboyans, Victor
AU  - Aboyans V
AD  - Department of Cardiology, Dupuytren University Hospital, and INSERM 1094 & IRD, 
      Limoges University, Limoges, France.
FAU - Maggioni, Aldo P
AU  - Maggioni AP
AD  - Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Florence, 
      Italy.
FAU - Widimsky, Petr
AU  - Widimsky P
AUID- ORCID: 0000-0001-5686-7752
AD  - Cardiocenter, University Hospital Kralovske Vinohrady and Third Faculty of 
      Medicine, Charles University, Prague, Czech Republic.
FAU - Muehlhofer, Eva
AU  - Muehlhofer E
AD  - Bayer AG, Wuppertal, Germany.
FAU - Berkowitz, Scott D
AU  - Berkowitz SD
AD  - Bayer U.S. LLC, Whippany, NJ, USA.
FAU - Yusuf, Salim
AU  - Yusuf S
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences, Hamilton, ON, Canada.
FAU - Connolly, Stuart J
AU  - Connolly SJ
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences, Hamilton, ON, Canada.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AUID- ORCID: 0000-0003-4126-1285
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences, Hamilton, ON, Canada.
FAU - Bosch, Jackie
AU  - Bosch J
AUID- ORCID: 0000-0001-6292-4207
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences, Hamilton, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J Cardiovasc Pharmacother
JT  - European heart journal. Cardiovascular pharmacotherapy
JID - 101669491
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - *Multimorbidity
MH  - *Rivaroxaban/adverse effects
OTO - NOTNLM
OT  - Chronic coronary syndrome
OT  - Multimorbidity
OT  - Polypharmacy
OT  - Prevention
OT  - Rivaroxaban
EDAT- 2021/07/01 06:00
MHDA- 2022/08/13 06:00
CRDT- 2021/06/30 12:26
PHST- 2021/05/17 00:00 [received]
PHST- 2021/06/09 00:00 [revised]
PHST- 2021/06/28 00:00 [accepted]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2022/08/13 06:00 [medline]
PHST- 2021/06/30 12:26 [entrez]
AID - 6311809 [pii]
AID - 10.1093/ehjcvp/pvab050 [doi]
PST - ppublish
SO  - Eur Heart J Cardiovasc Pharmacother. 2022 Aug 11;8(5):462-473. doi: 
      10.1093/ehjcvp/pvab050.

PMID- 6364447
OWN - NLM
STAT- MEDLINE
DCOM- 19840323
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 50
IP  - 4
DP  - 1983 Dec 30
TI  - Fibrinolytic activity and the effects of beta-pyridylcarbinol (Ronicol) in 
      patients with arteriosclerosis obliterans.
PG  - 797-9
AB  - Twenty-one patients with arteriosclerosis obliterans of lower extremities were 
      treated with beta-pyridylcarbinol (Ronicol) for five weeks. The long-term therapy 
      with beta-pyridylcarbinol did not influence platelet aggregability. Activation of 
      the fibrinolytic system was observed. This fibrinolytic effect of Ronicol was 
      abolished in patients treated with aspirin. In most cases a slight clinical 
      improvement was seen, manifested by elongation of pain-free walking distance and 
      increased blood flow in affected limbs. It is concluded that the therapeutic 
      effect of Ronicol in humans may be partly mediated by the release of endogenous 
      prostacyclin.
FAU - Grodzińska, L
AU  - Grodzińska L
FAU - Basista, M
AU  - Basista M
FAU - Kedzior, A
AU  - Kedzior A
FAU - Korbut, R
AU  - Korbut R
FAU - Kostka-Trabka, E
AU  - Kostka-Trabka E
FAU - Gryglewski, R
AU  - Gryglewski R
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis Obliterans/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Epoprostenol/metabolism
MH  - Fibrinolysis/drug effects
MH  - Humans
MH  - Leg/blood supply
MH  - Platelet Aggregation
MH  - Regional Blood Flow
MH  - Time Factors
EDAT- 1983/12/30 00:00
MHDA- 1983/12/30 00:01
CRDT- 1983/12/30 00:00
PHST- 1983/12/30 00:00 [pubmed]
PHST- 1983/12/30 00:01 [medline]
PHST- 1983/12/30 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1983 Dec 30;50(4):797-9.

PMID- 16308181
OWN - NLM
STAT- MEDLINE
DCOM- 20060329
LR  - 20140729
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 17
IP  - 1
DP  - 2006 Feb
TI  - A new definition of aspirin non-responsiveness by platelet function analyzer-100 
      and its predictors.
PG  - 7-13
AB  - BACKGROUND: Aspirin non-responsiveness has been described as having a normal 
      closure time (CT) by platelet function analyzer (PFA)-100 assay despite confirmed 
      treatment with aspirin. There is no standard definition of aspirin 
      non-responsiveness by PFA-100, with a variety of cut-off values having been used. 
      We proposed an alternative definition of aspirin non-responsiveness by PFA-100 
      assay. METHODS: One hundred eighty-four patients with diagnosis of stable 
      coronary artery disease or diabetes mellitus were included in the study. Blood 
      samples were drawn before and after the 7 days of aspirin therapy. An individual 
      was labelled as aspirin non-responder if his/her post-aspirin CT was not 2SD 
      above his/her baseline CT, where SD was calculated from the baseline CTs of the 
      study population. Aspirin non-responsiveness was also defined as having a normal 
      post-aspirin CT (< or =193 s) regardless of pre-aspirin CT. RESULTS: The baseline 
      CT ranged 82-187 s (mean 129.1 +/- 27.5, median 128 s) in the study population. 
      At the end of 1 week of aspirin administration, CT increased to a mean of 260.7 
      +/- 63.6 s (range 102-301). According to our definition, 28 (15.2%) of 184 
      patients were aspirin non-responders. Univariate analysis indicated that aspirin 
      non-responsiveness was closely associated with gender (P = 0.012) diabetes (P = 
      0.006), smoking (P = 0.0496) and hypertension (P = 0.021). Multivariate analysis 
      identified diabetes (P = 0.016) as the only significant independent predictor for 
      the presence of aspirin non-responsiveness. Thirty-four of 184 patients (18.5%) 
      classified as aspirin non-responders according to the second criteria. Seven 
      patients with prolongation of post-aspirin CT more than 2SD were classified as 
      aspirin non-responders by the second criteria. Only 1 patient without 
      prolongation of CT more than 2SD was classified as aspirin responsive by the 
      second criteria. CONCLUSION: Definition of aspirin non-responsiveness as 
      post-aspirin CTs < or =193 s might overestimate the prevalence of aspirin 
      non-responsiveness. Nevertheless, definition of aspirin non-responsiveness by 
      PFA-100 must be standardized and its utility as a predictor of cardiovascular 
      events needs to be further investigated.
FAU - Abaci, Adnan
AU  - Abaci A
AD  - Department of Cardiology, Gazi University School of Medicine, Ankara, Turkey. 
      abaci@gazi.edu.tr
FAU - Caliskan, Mustafa
AU  - Caliskan M
FAU - Bayram, Fahri
AU  - Bayram F
FAU - Yilmaz, Yucel
AU  - Yilmaz Y
FAU - Cetin, Mustafa
AU  - Cetin M
FAU - Unal, Ali
AU  - Unal A
FAU - Cetin, Servet
AU  - Cetin S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Artery Disease/blood/diagnosis/*drug therapy
MH  - Diabetes Mellitus/blood/diagnosis/*drug therapy
MH  - Diet
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Function Tests/instrumentation/*methods/statistics & numerical data
MH  - Predictive Value of Tests
MH  - Sensitivity and Specificity
EDAT- 2005/11/26 09:00
MHDA- 2006/03/30 09:00
CRDT- 2005/11/26 09:00
PHST- 2005/11/26 09:00 [pubmed]
PHST- 2006/03/30 09:00 [medline]
PHST- 2005/11/26 09:00 [entrez]
AID - L73180736236341K [pii]
AID - 10.1080/09537100500163358 [doi]
PST - ppublish
SO  - Platelets. 2006 Feb;17(1):7-13. doi: 10.1080/09537100500163358.

PMID- 6789586
OWN - NLM
STAT- MEDLINE
DCOM- 19810925
LR  - 20180216
IS  - 0001-5792 (Print)
IS  - 0001-5792 (Linking)
VI  - 65
IP  - 4
DP  - 1981
TI  - Effects of aspirin treatment upon fibrinolytic activity of peripheral blood 
      granulocytes.
PG  - 229-32
AB  - The effects of in vivo acetylsalicylic acid (ASA) treatment on the fibrinolytic 
      activity of peripheral blood granulocytes have been studied in a group of healthy 
      volunteers. Following a 4-day treatment with aspirin at a dose of 1 g/day, both 
      the plasminogen-dependent and the nonspecific fibrinolytic activity were 
      significantly decreased. On the contrary, no significant change in the 
      granulocyte fibrinolytic activity was found after treatment with 250 mg ASA/day. 
      It is suggested that the cellular release mechanism of such lytic enzymes rather 
      than their synthesis could have been affected by the drug.
FAU - Ghezzo, F
AU  - Ghezzo F
FAU - Trinchero, P
AU  - Trinchero P
FAU - Pegoraro, L
AU  - Pegoraro L
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - 9001-91-6 (Plasminogen)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrinolysis/*drug effects
MH  - Granulocytes/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptide Hydrolases/pharmacology
MH  - Plasminogen/metabolism
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1159/000207185 [doi]
PST - ppublish
SO  - Acta Haematol. 1981;65(4):229-32. doi: 10.1159/000207185.

PMID- 10726021
OWN - NLM
STAT- MEDLINE
DCOM- 20000407
LR  - 20191103
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 5
IP  - 4
DP  - 1999 Oct
TI  - Effects of ticlopidine or ticlopidine plus aspirin on platelet aggregation and 
      ATP release in normal volunteers: why aspirin improves ticlopidine antiplatelet 
      activity.
PG  - 243-6
AB  - Aspirin and ticlopidine are used to prevent arterial thrombosis. In some clinical 
      settings ticlopidine is administered with aspirin for improving antithrombotic 
      effect. We administered aspirin (100 mg/day), ticlopidine (500 mg/day), or 
      ticlopidine and aspirin for 7 days to healthy volunteers. Platelet aggregation 
      and ATP release induced by sodium arachidonate, ADP, or a combination of both 
      were measured. Sodium arachidonate (0.25 mmol/L), which produces no platelet 
      aggregation, combined with adenosine diphosphate (1 mumol/L), which produced a 
      reversible platelet aggregation of 20% after ticlopidine, resulted in a 
      synergistic platelet aggregation response in normal (74.6 +/- 9.2%) and in 
      ticlopidine platelet-rich plasma (59.1% +/- 14.9%, p < 0.0001). Synergism after 
      sodium arachidonate (0.75 mmol/L) plus adenosine diphosphate (4 mumol/L) fell 
      from 75.8% +/- 11.0% and 59.1% +/- 15.6% after ticlopidine or aspirin, 
      respectively, to 14.8% +/- 18.0% (p < 0.0001) after ticlopidine plus aspirin. 
      Aspirin and ticlopidine alone did not inhibit adenosine triphosphate release as 
      thoroughly as did aspirin plus ticlopidine. Aspirin or ticlopidine does not 
      adequately prevent platelet activity as ticlopidine plus aspirin do. Addition of 
      aspirin to treatment with ticlopidine improves their antiplatelet activity and 
      better results could be obtained in arterial thrombotic prevention strategies.
FAU - Altman, R
AU  - Altman R
AD  - Centro de Trombosis de Buenos Aires, Argentina.
FAU - Scazziota, A
AU  - Scazziota A
FAU - Rouvier, J
AU  - Rouvier J
FAU - Gonzalez, C
AU  - Gonzalez C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Triphosphate/*blood
MH  - Aspirin/*pharmacology
MH  - Drug Synergism
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Ticlopidine/*pharmacology
EDAT- 2000/03/22 00:00
MHDA- 2000/03/22 00:01
CRDT- 2000/03/22 00:00
PHST- 2000/03/22 00:00 [pubmed]
PHST- 2000/03/22 00:01 [medline]
PHST- 2000/03/22 00:00 [entrez]
AID - 10.1177/107602969900500407 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 1999 Oct;5(4):243-6. doi: 10.1177/107602969900500407.

PMID- 6691742
OWN - NLM
STAT- MEDLINE
DCOM- 19840223
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 37
IP  - 1
DP  - 1984 Jan
TI  - Prevention of thromboembolism using aspirin after mitral valve replacement with 
      porcine bioprosthesis.
PG  - 84-7
AB  - The thromboembolic rate of 768 patients who were treated only with aspirin after 
      mitral valve replacement or mitral plus aortic valve replacement with porcine 
      bioprostheses was evaluated. We analyzed the thromboembolic rate for the whole 
      series and for subgroups of patients categorized by atrial fibrillation, giant 
      left atrium, left atrial thrombosis, and dosage of aspirin (1 gm daily or 0.5 gm 
      every 48 hours). The total embolic rate was 1.4% (11/768). No patient in sinus 
      rhythm had an embolic event. The embolic rate for patients in atrial fibrillation 
      was 1.9% (11/583). There were no embolic events in 31 patients with a giant 
      atrium. An embolic event occurred in 1 of 42 patients with atrial thrombosis 
      (2.4%). Patients treated with 1 gm of aspirin daily had a 3% embolic rate (9/295) 
      while the incidence was 0.4% (2/473) in those treated with 0.5 gm every 48 hours 
      (p less than 0.01). Administration of aspirin after mitral valve replacement with 
      a bioprosthesis is a very effective treatment for prevention of thromboembolism. 
      In our experience, this treatment provides protection equal to or better than 
      that offered by oral anticoagulants for patients in atrial fibrillation as well 
      as for patients with a giant atrium or atrial thrombosis at operation. The dosage 
      and timing of aspirin administration may markedly affect the result of this type 
      of treatment. Oral anticoagulation with coumarin derivatives may not be 
      appropriate after mitral valve replacement with a bioprosthesis, and platelet 
      antiaggregates should be used for this purpose in the future.
FAU - Nuñez, L
AU  - Nuñez L
FAU - Gil Aguado, M
AU  - Gil Aguado M
FAU - Larrea, J L
AU  - Larrea JL
FAU - Celemín, D
AU  - Celemín D
FAU - Oliver, J
AU  - Oliver J
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Bioprosthesis/*adverse effects
MH  - Child
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Valve Prosthesis/*adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve/*surgery
MH  - Thromboembolism/*prevention & control
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - S0003-4975(10)60717-5 [pii]
AID - 10.1016/s0003-4975(10)60717-5 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1984 Jan;37(1):84-7. doi: 10.1016/s0003-4975(10)60717-5.

PMID- 36257283
OWN - NLM
STAT- MEDLINE
DCOM- 20221121
LR  - 20221121
IS  - 1768-3254 (Electronic)
IS  - 0223-5234 (Linking)
VI  - 244
DP  - 2022 Dec 15
TI  - Design, synthesis and anticancer evaluation of novel Se-NSAID hybrid molecules: 
      Identification of a Se-indomethacin analog as a potential therapeutic for breast 
      cancer.
PG  - 114839
LID - S0223-5234(22)00741-3 [pii]
LID - 10.1016/j.ejmech.2022.114839 [doi]
AB  - A total of twenty-five novel carboxylic acid, methylester, methylamide or cyano 
      nonsteroidal anti-inflammatory drug (NSAID) derivatives incorporating Se in the 
      chemical form of selenoester were reported. Twenty Se-NSAID analogs exhibited an 
      increase in cytotoxic potency compared with parent NSAID scaffolds (aspirin, 
      salicylic acid, naproxen, indomethacin and ketoprofen). Top five analogs were 
      selected to further study their cytotoxicity in a larger panel of cancer cells 
      and were also submitted to the DTP program of the NCI's panel of 60 cancer cell 
      lines. Compounds 4a and 4d stood out with IC(50) values below 10 μM in several 
      cancer cells along with a selectivity index higher than 5 in breast cancer cells. 
      Remarkably, analog 4d was found to inhibit cell growth notably in two breast 
      cancer cell lines by inducing apoptosis, and to be metabolized to release the 
      parent NSAID along with the Se fragment. Taken together, our results show that 
      Se-NSAID analog 4d could be a potential chemotherapeutic drug for breast cancer.
CI  - Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Ramos-Inza, Sandra
AU  - Ramos-Inza S
AD  - Department of Pharmaceutical Technology and Chemistry, University of Navarra, 
      Irunlarrea 1, E-31008, Pamplona, Spain; Instituto de Investigación Sanitaria de 
      Navarra (IdiSNA), Irunlarrea 3, E-31008, Pamplona, Spain.
FAU - Encío, Ignacio
AU  - Encío I
AD  - Instituto de Investigación Sanitaria de Navarra (IdiSNA), Irunlarrea 3, E-31008, 
      Pamplona, Spain; Department of Health Sciences, Public University of Navarra, 
      Avda. Barañain s/n, E-31008, Pamplona, Spain.
FAU - Raza, Asif
AU  - Raza A
AD  - Department of Pharmacology, Penn State Hershey Cancer Institute, CH72, Penn 
      State, USA.
FAU - Sharma, Arun K
AU  - Sharma AK
AD  - Department of Pharmacology, Penn State Hershey Cancer Institute, CH72, Penn 
      State, USA. Electronic address: asharma1@pennstatehealth.psu.edu.
FAU - Sanmartín, Carmen
AU  - Sanmartín C
AD  - Department of Pharmaceutical Technology and Chemistry, University of Navarra, 
      Irunlarrea 1, E-31008, Pamplona, Spain; Instituto de Investigación Sanitaria de 
      Navarra (IdiSNA), Irunlarrea 3, E-31008, Pamplona, Spain. Electronic address: 
      sanmartin@unav.es.
FAU - Plano, Daniel
AU  - Plano D
AD  - Department of Pharmaceutical Technology and Chemistry, University of Navarra, 
      Irunlarrea 1, E-31008, Pamplona, Spain; Instituto de Investigación Sanitaria de 
      Navarra (IdiSNA), Irunlarrea 3, E-31008, Pamplona, Spain. Electronic address: 
      dplano@unav.es.
LA  - eng
PT  - Journal Article
DEP - 20221013
PL  - France
TA  - Eur J Med Chem
JT  - European journal of medicinal chemistry
JID - 0420510
RN  - XXE1CET956 (Indomethacin)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Humans
MH  - Female
MH  - Indomethacin
MH  - *Breast Neoplasms/drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry
MH  - Naproxen/pharmacology
MH  - Aspirin/chemistry
MH  - *Antineoplastic Agents/chemistry
OTO - NOTNLM
OT  - Apoptosis
OT  - Cytotoxicity
OT  - NSAID
OT  - Selenium
OT  - Selenoester
COIS- Declaration of competing interest The authors declare the following financial 
      interests/personal relationships which may be considered as potential competing 
      interests: Daniel Plano reports financial support was provided by Plan de 
      Investigación de la Universidad de Navarra (PIUNA 2018-19). Arun K. Sharma 
      reports financial support was provided by Department of Pharmacology and Penn 
      State Cancer Institute of the Penn State College of Medicine.
EDAT- 2022/10/19 06:00
MHDA- 2022/11/22 06:00
CRDT- 2022/10/18 18:29
PHST- 2022/07/19 00:00 [received]
PHST- 2022/10/04 00:00 [revised]
PHST- 2022/10/07 00:00 [accepted]
PHST- 2022/10/19 06:00 [pubmed]
PHST- 2022/11/22 06:00 [medline]
PHST- 2022/10/18 18:29 [entrez]
AID - S0223-5234(22)00741-3 [pii]
AID - 10.1016/j.ejmech.2022.114839 [doi]
PST - ppublish
SO  - Eur J Med Chem. 2022 Dec 15;244:114839. doi: 10.1016/j.ejmech.2022.114839. Epub 
      2022 Oct 13.

PMID- 34254366
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20220202
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Linking)
VI  - 35
IP  - 10
DP  - 2021 Oct
TI  - Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in 
      heart transplantation.
PG  - e14424
LID - 10.1111/ctr.14424 [doi]
AB  - BACKGROUND: Early aspirin (ASA) use after orthotopic heart transplantation (OHT) 
      has been associated with lower rates of cardiac allograft vasculopathy (CAV). We 
      hypothesized that the inverse association between ASA use and CAV incidence may 
      be most pronounced in patients with allograft rejection. METHODS: Patients 
      receiving OHT at a single center 2004-2010 (n = 120) were categorized by early 
      ASA use post-transplant (ASA use for > 6 months in the first year) and the 
      presence of biopsy-defined acute cellular rejection (ACR) and/or 
      antibody-mediated rejection (AMR) during 5-year follow-up. Propensity scores for 
      ASA treatment were estimated using boosting models and applied by inverse 
      probability of treatment weighting. The association between ASA use and time to 
      moderate/severe CAV (ISHLT ≥ 2) was investigated. RESULTS: Among patients with 
      ACR or AMR, ASA therapy was associated with significantly lower rates of CAV≥ 2 
      (3.3 vs. 30.1%; P = .001; HR(adj) .07; 95% CI .01-.52), whereas ASA therapy was 
      not associated with lower rates of CAV in patients with no rejection (5.6 vs. 
      5.3%; P = .90; HR(adj) 1.26; 95% CI .08-20.30; p(interaction)  = .09). 
      CONCLUSIONS: Early ASA use after OHT was associated with lower rates of moderate 
      to severe CAV only in those patients with episodes of allograft rejection.
CI  - © 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Bergmark, Brian A
AU  - Bergmark BA
AUID- ORCID: 0000-0003-4360-7606
AD  - Thrombolysis in Myocardial Infarction (TIMI) Study Group, Boston, MA, USA.
AD  - Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
FAU - Zelniker, Thomas A
AU  - Zelniker TA
AD  - Division of Cardiology, Vienna General Hospital, Medical University of Vienna, 
      Vienna, Austria.
FAU - Kim, Miae
AU  - Kim M
AD  - Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
AD  - Center for Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA, USA.
FAU - Mehra, Mandeep R
AU  - Mehra MR
AD  - Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
AD  - Center for Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA, USA.
FAU - Stewart, Garrick C
AU  - Stewart GC
AD  - Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
AD  - Center for Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA, USA.
FAU - Page, Deborah S
AU  - Page DS
AD  - Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
AD  - Center for Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA, USA.
FAU - Woodcome, Erica L
AU  - Woodcome EL
AD  - Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
AD  - Center for Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA, USA.
FAU - Givertz, Michael M
AU  - Givertz MM
AD  - Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA, USA.
AD  - Center for Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20210719
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Allografts
MH  - *Aspirin/therapeutic use
MH  - Graft Rejection/drug therapy/etiology/prevention & control
MH  - *Heart Transplantation/adverse effects
MH  - Humans
MH  - Retrospective Studies
OTO - NOTNLM
OT  - coronary artery disease
OT  - heart (allograft) function/dysfunction
OT  - rejection: vascular
EDAT- 2021/07/14 06:00
MHDA- 2022/02/03 06:00
CRDT- 2021/07/13 06:44
PHST- 2021/07/01 00:00 [revised]
PHST- 2021/02/02 00:00 [received]
PHST- 2021/07/04 00:00 [accepted]
PHST- 2021/07/14 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
PHST- 2021/07/13 06:44 [entrez]
AID - 10.1111/ctr.14424 [doi]
PST - ppublish
SO  - Clin Transplant. 2021 Oct;35(10):e14424. doi: 10.1111/ctr.14424. Epub 2021 Jul 
      19.

PMID- 22635221
OWN - NLM
STAT- MEDLINE
DCOM- 20120924
LR  - 20131121
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Linking)
VI  - 21
IP  - 7
DP  - 2012 Jun
TI  - Primary antithrombotic prevention in carriers of antiphospholipid antibodies 
      without systemic autoimmune disorders.
PG  - 747-50
LID - 10.1177/0961203312437440 [doi]
AB  - Primary antithrombotic prevention with aspirin is not indicated in asymptomatic 
      patients with confirmed antiphospholipid (aPL) positivity without systemic 
      autoimmune disorders because: a) the estimated prevalence of thrombosis in 
      unselected cases is about 1% patient-years (range 0-2.8); b) this level of 
      thrombotic risk is equivalent to that of major bleeding associated with the use 
      of aspirin and therefore the expected benefit does not outweigh the risk; c) 
      these expectations have been confirmed by at least one randomized clinical trial, 
      although with methodological limits. The management of modifiable thrombotic risk 
      factors can be an alternative and safer strategy, considering that many vascular 
      events occur in the presence of concomitant non-aPL triggering conditions. 
      Whether primary prophylaxis with aspirin may be useful for some subsets of aPL 
      patients at particularly high thrombotic risk, such as those with overt systemic 
      autoimmune disorders or with special patterns of antibodies ('triple 
      positivity'), remains to be established.
FAU - Finazzi, G
AU  - Finazzi G
AD  - Division of Hematology, Ospedali Riuniti di Bergamo, Italy. 
      gfinazzi@ospedaliriuniti.bergamo.it
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Antiphospholipid
MH  - Antiphospholipid Syndrome/*complications
MH  - Aspirin/*therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Primary Prevention
MH  - Risk Factors
MH  - Thrombosis/immunology/*prevention & control
EDAT- 2012/05/29 06:00
MHDA- 2012/09/25 06:00
CRDT- 2012/05/29 06:00
PHST- 2012/05/29 06:00 [entrez]
PHST- 2012/05/29 06:00 [pubmed]
PHST- 2012/09/25 06:00 [medline]
AID - 21/7/747 [pii]
AID - 10.1177/0961203312437440 [doi]
PST - ppublish
SO  - Lupus. 2012 Jun;21(7):747-50. doi: 10.1177/0961203312437440.

PMID- 24291054
OWN - NLM
STAT- MEDLINE
DCOM- 20141215
LR  - 20181202
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 21
IP  - 5
DP  - 2014 Apr 15
TI  - Study of pharmacodynamic interaction of Phyllanthus emblica extract with 
      clopidogrel and ecosprin in patients with type II diabetes mellitus.
PG  - 579-85
LID - S0944-7113(13)00433-9 [pii]
LID - 10.1016/j.phymed.2013.10.024 [doi]
AB  - BACKGROUND: Diabetes mellitus is associated with oxidative stress which impairs 
      the platelet function. Phyllanthus emblica extract a rich source of vitamin C 
      plays an important role in scavenging free radicals. The effect of vitamin C on 
      platelet aggregation in healthy and coronary artery disease patients has been 
      demonstrated. The present study attempts to study the pharmacodynamic 
      interactions of P. emblica extract with clopidogrel and ecosprin. MATERIALS AND 
      METHODS: This was a randomized open label crossover study of 10 type II diabetic 
      patients. The dosage schedules were either single dose of 500 mg P. emblica 
      extract or 75 mg clopidogrel or 75 mg ecosprin or 500 mg P. emblica+75 mg 
      clopidogrel or 500 mg P. emblica+75 mg ecosprin. After single dose study and 
      washout period, patients received either 500 mg P. emblica extract twice daily or 
      75 mg clopidogrel or 75 mg ecosprin once daily or combinations for 10 days. 
      Platelet aggregation was measured at baseline and at 4h of treatment after single 
      and multiple dose study along with recording of bleeding and clotting time. 
      RESULTS: After single and multiple dose administration of the three treatments 
      and with combinations there was statistically significant decrease of platelet 
      aggregation compared to baseline. Further, the mean percent inhibition of 
      platelet aggregation was significant, when compared between single and multiple 
      doses of P. emblica. The bleeding and clotting time was prolonged with single and 
      multiple dose administration of all treatments compared to baseline. All 
      treatments were well tolerated. CONCLUSION: P. emblica extract demonstrated 
      significant antiplatelet activity with both single and multiple dose 
      administration.
CI  - Copyright © 2013 Elsevier GmbH. All rights reserved.
FAU - Fatima, Nishat
AU  - Fatima N
AD  - Department of Clinical Pharmacology & Therapeutics, Nizam's Institute of Medical 
      Sciences, Panjagutta, Hyderabad, India.
FAU - Pingali, Usharani
AU  - Pingali U
AD  - Department of Clinical Pharmacology & Therapeutics, Nizam's Institute of Medical 
      Sciences, Panjagutta, Hyderabad, India. Electronic address: 
      ushapingali@yahoo.com.
FAU - Muralidhar, N
AU  - Muralidhar N
AD  - Department of Clinical Pharmacology & Therapeutics, Nizam's Institute of Medical 
      Sciences, Panjagutta, Hyderabad, India.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20131128
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 0 (Plant Extracts)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Clopidogrel
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/complications
MH  - Diabetic Angiopathies/*prevention & control
MH  - Female
MH  - Herb-Drug Interactions
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Phyllanthus emblica
MH  - *Phytotherapy
MH  - Plant Extracts/pharmacology/therapeutic use
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Prospective Studies
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Clopidogrel
OT  - Ecosprin
OT  - Phyllanthus emblica
OT  - Platelet aggregation
EDAT- 2013/12/03 06:00
MHDA- 2014/12/17 06:00
CRDT- 2013/12/03 06:00
PHST- 2013/09/12 00:00 [received]
PHST- 2013/09/26 00:00 [revised]
PHST- 2013/10/17 00:00 [accepted]
PHST- 2013/12/03 06:00 [entrez]
PHST- 2013/12/03 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
AID - S0944-7113(13)00433-9 [pii]
AID - 10.1016/j.phymed.2013.10.024 [doi]
PST - ppublish
SO  - Phytomedicine. 2014 Apr 15;21(5):579-85. doi: 10.1016/j.phymed.2013.10.024. Epub 
      2013 Nov 28.

PMID- 20729752
OWN - NLM
STAT- MEDLINE
DCOM- 20110321
LR  - 20181201
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 56
IP  - 5
DP  - 2010 Nov
TI  - The influence of proton pump inhibitors on the antiplatelet potency of 
      clopidogrel evaluated by 5 different platelet function tests.
PG  - 532-9
LID - 10.1097/FJC.0b013e3181f68209 [doi]
AB  - Proton pump inhibitors (PPIs) are metabolized by the cytochrome P450 enzyme 
      system to a variable degree and may therefore interact with the metabolism of 
      clopidogrel to its active form. The conflicting data on this potential 
      interaction may be due to the use of different PPIs and platelet function tests 
      in recent studies. We therefore evaluated the influence of different PPIs on the 
      antiplatelet effect of clopidogrel by 5 platelet function tests in the same 
      population. Adenosine diphosphate (ADP)-inducible platelet reactivity was 
      assessed in 230 patients on dual antiplatelet therapy after angioplasty and 
      stenting for cardiovascular disease by the light transmission aggregometry, 
      VerifyNow P2Y12 assay, vasodilator-stimulated phosphoprotein phosphorylation 
      assay, multiple electrode aggregometry, and Impact-R. ADP-inducible platelet 
      reactivity showed no significant differences between patients without (n = 95, 
      41.3%) and with PPI therapy (n = 135, 58.7%) in each test system (all P > 0.05). 
      Furthermore, we observed no significant differences of ADP-inducible platelet 
      reactivity between patients without PPIs and patients with pantoprazole (n = 95, 
      70.4%), esomeprazole (n = 22, 16.3%), omeprazole (n = 9, 6.65%), or lansoprazole 
      (n = 9, 6.65%) (all P > 0.3). High on-treatment residual ADP-inducible platelet 
      reactivity occurred to a similar extent in patients without and with PPI therapy 
      in each assay (all P > 0.05). In conclusion, concomitant treatment with PPIs did 
      not attenuate the antiplatelet effect of clopidogrel in patients on dual 
      antiplatelet therapy irrespective of the type of PPI and the used test system.
FAU - Gremmel, Thomas
AU  - Gremmel T
AD  - Department of Internal Medicine II, Division of Angiology, Medical University of 
      Vienna, Vienna, Austria. thomas.gremmel@meduniwien.ac.at
FAU - Steiner, Sabine
AU  - Steiner S
FAU - Seidinger, Daniela
AU  - Seidinger D
FAU - Koppensteiner, Renate
AU  - Koppensteiner R
FAU - Panzer, Simon
AU  - Panzer S
FAU - Kopp, Christoph W
AU  - Kopp CW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/blood/therapy
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests/methods
MH  - Proton Pump Inhibitors/*pharmacology/therapeutic use
MH  - Stents
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2010/08/24 06:00
MHDA- 2011/03/22 06:00
CRDT- 2010/08/24 06:00
PHST- 2010/08/24 06:00 [entrez]
PHST- 2010/08/24 06:00 [pubmed]
PHST- 2011/03/22 06:00 [medline]
AID - 10.1097/FJC.0b013e3181f68209 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2010 Nov;56(5):532-9. doi: 10.1097/FJC.0b013e3181f68209.

PMID- 10569656
OWN - NLM
STAT- MEDLINE
DCOM- 19991130
LR  - 20220409
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 84
IP  - 9
DP  - 1999 Nov 1
TI  - Survey of C-reactive protein and cardiovascular risk factors in apparently 
      healthy men.
PG  - 1018-22
AB  - Several prospective studies have demonstrated a direct association between 
      C-reactive protein (CRP) levels and the risks of developing cardiovascular 
      disease. Few studies, however, have explored the interrelations between CRP 
      levels and other risk factors for cardiovascular disease. We evaluated the 
      relation of CRP with several cardiovascular risk factors in a cross-sectional 
      survey of 1,172 apparently healthy men. There were significant positive 
      associations between CRP levels and age, number of cigarettes smoked per day, 
      body mass index, systolic and diastolic blood pressure, total cholesterol, 
      triglycerides, lipoprotein(a), apolipoprotein B, tissue-type plasminogen 
      activator antigen, D-dimers, total homocysteine, and fibrinogen (all p values 
      <0.05). Significant inverse associations were observed for exercise frequency, 
      high-density lipoprotein cholesterol, and apolipoprotein A-I and A-II (all p 
      values <0.02). In multivariate analysis, age, smoking status, and serum levels of 
      tissue-type plasminogen activator antigen, fibrinogen, lipoprotein(a), and total 
      homocysteine were independent correlates of CRP levels. Finally, in an analysis 
      controlled either for all the independent correlates or for several usual risk 
      factors, we observed progressive increases in levels of CRP with increasing 
      prevalence of risk factors (p for trend <0.001 for independent correlates and 
      <0.01 for usual risk factors). In conclusion, in a large cohort of apparently 
      healthy men, CRP levels were associated with several cardiovascular risk factors. 
      These data are compatible with the hypothesis that CRP levels may be a marker for 
      preclinical cardiovascular disease.
FAU - Rohde, L E
AU  - Rohde LE
AD  - Brigham and Women's Hospital, The Department of Ambulatory Care and Prevention, 
      Harvard Medical School, Boston, Massachusetts 02115, USA.
FAU - Hennekens, C H
AU  - Hennekens CH
FAU - Ridker, P M
AU  - Ridker PM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Biomarkers)
RN  - 0 (Lipids)
RN  - 01YAE03M7J (beta Carotene)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects
MH  - Biomarkers/blood
MH  - C-Reactive Protein/*metabolism
MH  - Cardiovascular Diseases/*blood/diagnosis
MH  - Cohort Studies
MH  - Double-Blind Method
MH  - Humans
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Reference Values
MH  - Risk Factors
MH  - beta Carotene/administration & dosage
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
AID - S0002914999004919 [pii]
AID - 10.1016/s0002-9149(99)00491-9 [doi]
PST - ppublish
SO  - Am J Cardiol. 1999 Nov 1;84(9):1018-22. doi: 10.1016/s0002-9149(99)00491-9.

PMID- 26239882
OWN - NLM
STAT- MEDLINE
DCOM- 20161031
LR  - 20181202
IS  - 1879-3649 (Electronic)
IS  - 1537-1891 (Linking)
VI  - 77
DP  - 2016 Feb
TI  - Platelet reactivity in MitraClip patients.
PG  - 54-9
LID - S1537-1891(15)00175-5 [pii]
LID - 10.1016/j.vph.2015.07.015 [doi]
AB  - BACKGROUND: Common complications during MitraClip procedure are bleeding and 
      ischemic events. The right strategy of platelet inhibition is unknown and 
      challenging, as there are substantial interindividual response-variabilities to 
      antiplatelet drugs and additionally, many MitraClip patients are on permanent 
      oral anticoagulation because of atrial fibrillation. We aimed to investigate the 
      incidence of (i) high- and low on-treatment platelet reactivity (HTPR, LTPR) to 
      antiplatelet medication and (ii) clinical complications in MitraClip patients. 
      METHODS: In an observational single-center cohort study we investigated 73 
      patients who underwent MitraClip implantation. Clopidogrel effects were measured 
      using the vasodilator-stimulated protein phosphorylation (VASP) assay, aspirin 
      effects by light-transmission aggregometry (LTA). Clinical complications were 
      investigated during six-month follow-up. RESULTS: HTPR to clopidogrel was 
      observed in 44 patients, LTPR to clopidogrel in 6 patients. 16 patients had HTPR 
      to aspirin. Major complications occurred in 12 patients, overall bleeding 
      complications in 27 patients, overall ischemic events in two patients. The 
      incidence of HTPR/LTPR did not differ between patients with- vs. without clinical 
      complications. Bleeding complications were not more frequent in patients with 
      additional oral anticoagulation. CONCLUSIONS: In this study, the incidence of 
      HTPR to clopidogrel was very high (60% of patients). Despite these insufficient 
      clopidogrel antiplatelet effects, ischemic events were rare and bleeding 
      complications more frequent. Additionally, many patients undergoing MitraClip 
      procedure were on permanent oral anticoagulation because of atrial fibrillation. 
      The optimal antithrombotic regiment should be investigated in large scale 
      clinical trials under consideration of the high incidence of HTPR to clopidogrel 
      medication in MitraClip patients.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Polzin, Amin
AU  - Polzin A
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany. Electronic address: 
      Amin.polzin@med.uni-duesseldorf.de.
FAU - Afzal, Shazia
AU  - Afzal S
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Balzer, Jan
AU  - Balzer J
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Rassaf, Tienush
AU  - Rassaf T
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Kelm, Malte
AU  - Kelm M
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
FAU - Zeus, Tobias
AU  - Zeus T
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Düsseldorf, Düsseldorf, Germany.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150801
PL  - United States
TA  - Vascul Pharmacol
JT  - Vascular pharmacology
JID - 101130615
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Cohort Studies
MH  - Heart Valve Prosthesis Implantation/adverse effects/*methods
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Ischemia/chemically induced/epidemiology
MH  - Mitral Valve Insufficiency/blood/*therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Thrombosis/blood/prevention & control
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Clopidogrel
OT  - High on-treatment platelet reactivity
OT  - MitraClip
EDAT- 2015/08/05 06:00
MHDA- 2016/11/01 06:00
CRDT- 2015/08/05 06:00
PHST- 2015/05/05 00:00 [received]
PHST- 2015/06/21 00:00 [revised]
PHST- 2015/07/02 00:00 [accepted]
PHST- 2015/08/05 06:00 [entrez]
PHST- 2015/08/05 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - S1537-1891(15)00175-5 [pii]
AID - 10.1016/j.vph.2015.07.015 [doi]
PST - ppublish
SO  - Vascul Pharmacol. 2016 Feb;77:54-9. doi: 10.1016/j.vph.2015.07.015. Epub 2015 Aug 
      1.

PMID- 3198870
OWN - NLM
STAT- MEDLINE
DCOM- 19890117
LR  - 20190515
IS  - 0001-4966 (Print)
IS  - 0001-4966 (Linking)
VI  - 84
IP  - 4
DP  - 1988 Oct
TI  - Modification of spontaneous and evoked otoacoustic emissions and associated 
      psychoacoustic microstructure by aspirin consumption.
PG  - 1343-53
AB  - The discovery that aspirin consumption can abolish spontaneous otoacoustic 
      emissions [D. McFadden and H.S. Plattsmier, J. Acoust. Soc. Am. 76, 443-448 
      (1984)] provides a technique for further exploring the relation between 
      otoacoustic emissions (spontaneous and evoked) and psychoacoustic threshold 
      microstructure. Spontaneous emissions, delayed evoked emissions, synchronous 
      evoked emissions, and threshold microstructure in four subjects were monitored 
      before, during, and after consumption of 3.9 g of aspirin per day (three 325-mg 
      tablets every 6 h) for 3 or 4 days. The changes in spontaneous emissions are 
      consistent with the findings of McFadden and Plattsmier except that one 
      spontaneous emission appeared to plateau at a reduced level above the noise floor 
      during the last day and a half of the 3-day period of aspirin consumption. Evoked 
      emissions and threshold microstructure were also reduced by aspirin consumption 
      but persisted longer and recovered sooner. In most instances, the initial change 
      in threshold microstructure was a trend to increased sensitivity (reduced 
      thresholds), with a greater increase near threshold maxima than at threshold 
      minima. Further reduction in the levels of the evoked emissions was accompanied 
      by the eventual decrease in sensitivity (elevation of all thresholds).
FAU - Long, G R
AU  - Long GR
AD  - Department of Audiology and Speech Sciences, Purdue University, West Lafayette, 
      Indiana 47907.
FAU - Tubis, A
AU  - Tubis A
LA  - eng
GR  - NS 22095/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Acoust Soc Am
JT  - The Journal of the Acoustical Society of America
JID - 7503051
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Auditory Threshold/drug effects
MH  - Cochlea/*drug effects
MH  - Cochlear Microphonic Potentials/*drug effects
MH  - Evoked Potentials, Auditory/*drug effects
MH  - Female
MH  - Humans
MH  - Pitch Discrimination/drug effects
MH  - Psychoacoustics
EDAT- 1988/10/01 00:00
MHDA- 1988/10/01 00:01
CRDT- 1988/10/01 00:00
PHST- 1988/10/01 00:00 [pubmed]
PHST- 1988/10/01 00:01 [medline]
PHST- 1988/10/01 00:00 [entrez]
AID - 10.1121/1.396633 [doi]
PST - ppublish
SO  - J Acoust Soc Am. 1988 Oct;84(4):1343-53. doi: 10.1121/1.396633.

PMID- 22840198
OWN - NLM
STAT- MEDLINE
DCOM- 20121204
LR  - 20220409
IS  - 1049-023X (Print)
IS  - 1049-023X (Linking)
VI  - 27
IP  - 4
DP  - 2012 Aug
TI  - The use of the Revised Trauma Score as an entry criterion in traumatic 
      hemorrhagic shock studies: data from the DCLHb clinical trials.
PG  - 330-44
AB  - INTRODUCTION: The Revised Trauma Score (RTS) has been proposed as an entry 
      criterion to identify patients with mid-range survival probability for traumatic 
      hemorrhagic shock studies. HYPOTHESIS/PROBLEM: Determination of which of four RTS 
      strata (1-3.99, 2-4.99, 1-4.99, and 2-5.99) identifies patients with predicted 
      and actual mortality rates near 50% for use as an entry criterion in traumatic 
      hemorrhagic shock clinical trials. METHODS: Existing database analysis in which 
      demographic and injury severity data from two prior international Diaspirin 
      Cross-Linked Hemoglobin (DCLHb) clinical trials were used to identify an RTS 
      range that could be an optimal entry criterion in order to find the population of 
      trauma patients with mid-range predicted and actual mortality rates. RESULTS: Of 
      208 study patients, the mean age was 37 years, 65% sustained blunt trauma, 49% 
      received DCLHb, and 57% came from the European Union study arm. The mean values 
      were: ISS, 31 (SD = 18); RTS, 5.6 (SD = 1.8); and Glasgow Coma Scale (GCS), 10.4 
      (SD = 4.8). The mean TRISS-predicted mortality was 34% and the actual 28-day 
      mortality was 35%. The initially proposed 1-3.99 RTS range (n = 41) had the 
      highest predicted (79%) and actual (71%) mortality rates. The 2-5.99 RTS range (n 
      = 79) had a 62% predicted and 53% actual mortality, and included 76% blunt trauma 
      patients. Removal of GCS <5 patients from this RTS 2-5.99 subgroup caused a 48% 
      further reduction in eligible patients, leaving 41 patients (20% of 208 total 
      patients), 66% of whom sustained a blunt trauma injury. This subgroup had 54% 
      predicted and 49% actual mortality rates. Receiver operator curve (ROC) analysis 
      found the GCS to be as predictive of mortality as the RTS, both in the total 
      patient population and in the RTS 2-5.99 subgroup. CONCLUSION: The use of an RTS 
      2-5.99 inclusion criterion range identifies a traumatic hemorrhagic shock patient 
      subgroup with predicted and actual mortality that approach the desired 50% rate. 
      The exclusion of GCS <5 from this RTS 2-5.99 subgroup patients yields a smaller, 
      more uniform patient subgroup whose mortality is more likely related to 
      hemorrhagic shock than traumatic brain injury. Future studies should examine 
      whether the RTS or other physiologic criteria such as the GCS score are most 
      useful as traumatic hemorrhagic shock study entry criteria.
FAU - Sloan, Edward P
AU  - Sloan EP
AD  - Department of Emergency Medicine, University of Illinois at Chicago, Illinois 
      60612, USA. edsloan@uic.edu
FAU - Koenigsberg, Max
AU  - Koenigsberg M
FAU - Clark, James M
AU  - Clark JM
FAU - Desai, Amol
AU  - Desai A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120730
PL  - United States
TA  - Prehosp Disaster Med
JT  - Prehospital and disaster medicine
JID - 8918173
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
MH  - Adult
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Clinical Trials, Phase III as Topic
MH  - Female
MH  - Glasgow Coma Scale
MH  - Hemoglobins/*therapeutic use
MH  - Humans
MH  - Male
MH  - Multicenter Studies as Topic
MH  - Predictive Value of Tests
MH  - ROC Curve
MH  - Randomized Controlled Trials as Topic
MH  - Shock, Hemorrhagic/*drug therapy/*mortality
MH  - Shock, Traumatic/*drug therapy/*mortality
MH  - Survival Analysis
MH  - *Trauma Severity Indices
EDAT- 2012/07/31 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/07/31 06:00
PHST- 2012/07/31 06:00 [entrez]
PHST- 2012/07/31 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S1049023X12000970 [pii]
AID - 10.1017/S1049023X12000970 [doi]
PST - ppublish
SO  - Prehosp Disaster Med. 2012 Aug;27(4):330-44. doi: 10.1017/S1049023X12000970. Epub 
      2012 Jul 30.

PMID- 7045360
OWN - NLM
STAT- MEDLINE
DCOM- 19820814
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 9
IP  - 1
DP  - 1982 Jan-Feb
TI  - Aspirin and fenoprofen (Nalfon) in the treatment of juvenile rheumatoid arthritis 
      results of the double blind-trial. A segment II study.
PG  - 123-8
AB  - We compared efficacy and safety of aspirin (ASA) and fenoprofen in the treatment 
      of JRA. Ninety-nine children with JRA were given ASA or fenoprofen in a 12-wk, 
      multicentered, double-blind, parallel study. Initial fenoprofen dosage was 900 
      mg/m2/d increased to 1800 mg/m2/d (3200 mg/d-max). Initial ASA dosage was 1500 
      mg/m2/d increased to 3000 mg/m2/d (5450 mg/d-max). Adverse reactions forced 
      removal of 14% of ASA treated patients from the trial, whereas no fenoprofen 
      patient was removed for this reason. Forty of 50 ASA patients, and 47 of 49 
      fenoprofen patients completed at least 10 wk of therapy and analysis showed that 
      the 2 drugs were nearly identical in efficacy, but toxicity was considerably less 
      among fenoprofen treated patients.
FAU - Brewer, E J
AU  - Brewer EJ
FAU - Giannini, E H
AU  - Giannini EH
FAU - Baum, J
AU  - Baum J
FAU - Bernstein, B
AU  - Bernstein B
FAU - Fink, C W
AU  - Fink CW
FAU - Emery, H M
AU  - Emery HM
FAU - Schaller, J G
AU  - Schaller JG
LA  - eng
GR  - RR-00-350/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Fenoprofen/*therapeutic use
MH  - Humans
MH  - Male
MH  - Phenylpropionates/*therapeutic use
MH  - Random Allocation
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1982 Jan-Feb;9(1):123-8.

PMID- 11940487
OWN - NLM
STAT- MEDLINE
DCOM- 20020712
LR  - 20131121
IS  - 0390-6078 (Print)
IS  - 0390-6078 (Linking)
VI  - 87
IP  - 4
DP  - 2002 Apr
TI  - Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated 
      platelets.
PG  - 420-6
AB  - BACKGROUND AND OBJECTIVES: The combination of vitamin E with aspirin is becoming 
      an attractive therapeutic approach to prevent thrombotic vascular accidents. In 
      this study we investigated the capacity of vitamin E (50 and 100 M) to enhance 
      the antiplatelet effect of aspirin. DESIGN AND METHODS: The dose-response curves 
      of platelet aggregation, dense body secretion, phospholipase C activation and 
      calcium mobilization were measured in aspirin-treated platelets with and without 
      added vitamin E (50 and 100 M). The role of vitamin E in reducing platelet 
      adhesion to collagen was also studied. RESULTS: We demonstrated that, in 
      platelets incubated with 100 M vitamin E, collagen-concentration ( g/mL) able to 
      induce 50% of the maximal platelet aggregation and of the calcium mobilization 
      was higher than in controls (11.6 versus 3.8 and 21.3 versus 9.8, respectively). 
      Furthermore, 50 M vitamin E reduced platelet adhesion to collagen by about 80%. 
      INTERPRETATION AND CONCLUSIONS: These data demonstrate that vitamin E can 
      potentiate the antiplatelet activity of aspirin by inhibiting the early events of 
      platelet activation pathways induced by collagen. This finding provides a 
      rationale for combining aspirin and vitamin E to prevent thrombotic complications 
      in atherosclerotic patients.
FAU - Celestini, Andrea
AU  - Celestini A
AD  - Dept. of Experimental Medicine and Pathology, University La Sapienza, Rome, 
      Italy.
FAU - Pulcinelli, Fabio M
AU  - Pulcinelli FM
FAU - Pignatelli, Pasquale
AU  - Pignatelli P
FAU - Lenti, Luisa
AU  - Lenti L
FAU - Frati, Giacomo
AU  - Frati G
FAU - Gazzaniga, Pier Paolo
AU  - Gazzaniga PP
FAU - Violi, Francesco
AU  - Violi F
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 1406-18-4 (Vitamin E)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/cytology/drug effects
MH  - Collagen/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Vitamin E/*pharmacology
EDAT- 2002/04/10 10:00
MHDA- 2002/07/13 10:01
CRDT- 2002/04/10 10:00
PHST- 2002/04/10 10:00 [pubmed]
PHST- 2002/07/13 10:01 [medline]
PHST- 2002/04/10 10:00 [entrez]
PST - ppublish
SO  - Haematologica. 2002 Apr;87(4):420-6.

PMID- 21765446
OWN - NLM
STAT- MEDLINE
DCOM- 20120209
LR  - 20220316
IS  - 1745-7254 (Electronic)
IS  - 1671-4083 (Print)
IS  - 1671-4083 (Linking)
VI  - 32
IP  - 8
DP  - 2011 Aug
TI  - Combination of raloxifene, aspirin and estrogen as novel paradigm of hormone 
      replacement therapy in rabbit model of menopause.
PG  - 1031-7
LID - 10.1038/aps.2011.87 [doi]
AB  - AIM: To assess a novel hormone replacement therapy (HRT) paradigm using 
      raloxifene, aspirin combined with estrogen in rabbit model of menopause. METHODS: 
      Female New Zealand white rabbits were ovariectomized or sham-operated. The 
      ovariectomized rabbits were divided into 7 groups: estradiol valerate (E(2)), 
      raloxifene, aspirin, E(2) /raloxifene, E(2)/aspirin, E(2) /raloxifene/aspirin and 
      vehicle. Two weeks after the operation, the rabbits were administered the above 
      drugs for 12 weeks. Then, the mammary glands were examined histologically, uterus 
      was weighted, and blood sample was collected for analyzing the levels of 
      estrogen, serum lipids and monocyte chemoattractant protein (MCP)-1, and platelet 
      aggregation. The aortic tissue was examined morphometrically. RESULTS: Compared 
      with E(2) 0.1 mg·kg(-1)·d(-1) treatment alone, the pairing of raloxifene 10 
      mg·kg(-1)·d(-1) with E(2) significantly decreased the extent of mammary gland 
      branches and ducts (5.53%±1.23% vs 15.4%±2.17%, P<0.01), as well as the uterine 
      weight (2.16±0.35 g vs 4.91±0.75 g, P<0.01). However, E(2)/raloxifene or E(2) 
      alone treatment significantly stimulated platelet aggregation relative to vehicle 
      group. Addition of aspirin 5 mg·kg(-1)·d(-1) reduced platelet aggregation to 
      almost the same level as the vehicle group. E(2) treatment exerted a positive 
      effect on serum lipids and MCP-1, and a regression in aortic intimal plaque size 
      compared to the vehicle. Raloxifene reinforced the positive effects of E(2). 
      CONCLUSION: The combination of raloxifene, aspirin and E(2) exhibits positive 
      lipid, MCP-1 and atherosclerotic responses with minimal stimulation of breast and 
      uterine tissues as well as platelet aggregation in a rabbit model of the 
      menopause.
FAU - Yang, Fa-lin
AU  - Yang FL
AD  - Clinical Laboratory, Qilu Hospital, Shandong University, Ji-nan, China.
FAU - Hu, Ke-qing
AU  - Hu KQ
FAU - Wang, Xin
AU  - Wang X
FAU - Liu, Zi-mo
AU  - Liu ZM
FAU - Hu, Qin
AU  - Hu Q
FAU - Li, Ji-fu
AU  - Li JF
FAU - He, Hong
AU  - He H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110718
PL  - United States
TA  - Acta Pharmacol Sin
JT  - Acta pharmacologica Sinica
JID - 100956087
RN  - 0 (Estrogens)
RN  - 4F86W47BR6 (Raloxifene Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Drug Therapy, Combination/methods
MH  - Estrogens/blood/*pharmacology
MH  - Female
MH  - Hormone Replacement Therapy/methods
MH  - Menopause/*drug effects
MH  - Rabbits
MH  - Raloxifene Hydrochloride/*pharmacology
PMC - PMC4002536
EDAT- 2011/07/19 06:00
MHDA- 2012/02/10 06:00
CRDT- 2011/07/19 06:00
PHST- 2011/07/19 06:00 [entrez]
PHST- 2011/07/19 06:00 [pubmed]
PHST- 2012/02/10 06:00 [medline]
AID - aps201187 [pii]
AID - 10.1038/aps.2011.87 [doi]
PST - ppublish
SO  - Acta Pharmacol Sin. 2011 Aug;32(8):1031-7. doi: 10.1038/aps.2011.87. Epub 2011 
      Jul 18.

PMID- 2203556
OWN - NLM
STAT- MEDLINE
DCOM- 19901009
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 82
IP  - 3
DP  - 1990 Sep
TI  - Circadian variation of acute myocardial infarction and the effect of low-dose 
      aspirin in a randomized trial of physicians.
PG  - 897-902
AB  - Increased platelet aggregation in the morning and upon assuming an upright 
      posture may account at least in part for the observed circadian variation in 
      onset of acute myocardial infarction. The Physicians' Health Study, a randomized, 
      double-blind, placebo-controlled trial of alternate-day aspirin intake (325 mg) 
      among 22,071 US male physicians, afforded the opportunity to assess this 
      circadian pattern and examine whether it is altered by aspirin therapy. During a 
      5-year period of follow-up, 342 cases of nonfatal myocardial infarction were 
      confirmed, of which the time of onset was available in 211 (62%). The placebo 
      group showed a bimodal circadian variation in onset of myocardial infarction with 
      a primary peak between 4:00 AM and 10:00 AM (p less than 0.001). In the aspirin 
      group, however, this circadian variation was minimal (p = 0.16), due primarily to 
      a marked reduction in the morning peak of infarction. Specifically, aspirin was 
      associated with a 59.3% reduction in the incidence of infarction during the 
      morning waking hours, compared with a 34.1% reduction for the remaining hours of 
      the day. The greater reduction was observed during the 3-hour interval 
      immediately after awakening, a period with a risk of infarction twice that of any 
      other comparable time interval (p less than 0.001). Aspirin intake was associated 
      with a mean reduction in the incidence of infarction of 44.8% over the entire 
      24-hour cycle. These data support the hypothesis that increased platelet 
      aggregability in the morning and upon arising contributes to the occurrence of 
      myocardial infarction and that aspirin reduces the risk of infarction by 
      inhibiting platelet aggregation during these critical periods.
FAU - Ridker, P M
AU  - Ridker PM
AD  - Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, 
      Harvard Medical School, Boston, Mass 02146.
FAU - Manson, J E
AU  - Manson JE
FAU - Buring, J E
AU  - Buring JE
FAU - Muller, J E
AU  - Muller JE
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA-34944/CA/NCI NIH HHS/United States
GR  - HL-26490/HL/NHLBI NIH HHS/United States
GR  - HL-34595/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - *Circadian Rhythm
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*physiopathology/prevention & control
MH  - Randomized Controlled Trials as Topic
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
AID - 10.1161/01.cir.82.3.897 [doi]
PST - ppublish
SO  - Circulation. 1990 Sep;82(3):897-902. doi: 10.1161/01.cir.82.3.897.

PMID- 3795378
OWN - NLM
STAT- MEDLINE
DCOM- 19870218
LR  - 20131121
IS  - 0741-5214 (Print)
IS  - 0741-5214 (Linking)
VI  - 5
IP  - 1
DP  - 1987 Jan
TI  - Neointimal hyperplasia occurring after carotid endarterectomy in a canine model: 
      effect of endothelial cell seeding vs. perioperative aspirin.
PG  - 118-25
AB  - Neointimal hyperplasia of the arterial wall may occur after carotid 
      endarterectomy. This proliferative lesion is a pathologic response of the injured 
      arterial wall and may lead to progressive stenosis. We investigated the effect of 
      endothelial cell seeding (ECS) or antiplatelet therapy with aspirin (ASA) on 
      inhibition of this lesion in a canine model. Endarterectomies were performed in 
      160 carotid arteries; 46 endarterectomies were treated perioperatively with 
      aspirin (325 mg per day), 34 were seeded with a high density (3 X 10(6)) of 
      autogenous endothelial cells, and 80 were untreated control arteries. At selected 
      time intervals, the patent arteries were perfusion-fixed and the cross-sectional 
      area (measured in square millimeters) of neointimal hyperplasia was measured by 
      means of digital planimetry. At 6 weeks, patency of the endarterectomized carotid 
      artery was 88% in the ASA and ECS groups, in contrast to 35% in the control group 
      (p less than 0.01). The cross-sectional area of neointimal hyperplasia was not 
      significantly different in the ASA and the control groups at 6 weeks. However, 
      the ECS group showed a marked reduction in neointimal hyperplasia at 6 weeks (p 
      less than 0.01). This inhibition of neointimal hyperplasia after carotid 
      endarterectomy by ECS may reflect accelerated luminal healing or a direct 
      inhibition of smooth muscle cell proliferation in the injured arterial wall.
FAU - Bush, H L Jr
AU  - Bush HL Jr
FAU - Jakubowski, J A
AU  - Jakubowski JA
FAU - Sentissi, J M
AU  - Sentissi JM
FAU - Curl, G R
AU  - Curl GR
FAU - Hayes, J A
AU  - Hayes JA
FAU - Deykin, D
AU  - Deykin D
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Carotid Arteries/drug effects/*pathology
MH  - Dogs
MH  - Endarterectomy/*adverse effects
MH  - Hyperplasia/*etiology/prevention & control
MH  - Models, Cardiovascular
MH  - Platelet Aggregation/*drug effects
MH  - Premedication
MH  - Vascular Patency
EDAT- 1987/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - S0741521487000144 [pii]
PST - ppublish
SO  - J Vasc Surg. 1987 Jan;5(1):118-25.

PMID- 34364539
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20220802
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 148
IP  - 2
DP  - 2021 Aug
TI  - Innate immune cell dysregulation drives inflammation and disease in 
      aspirin-exacerbated respiratory disease.
PG  - 309-318
LID - S0091-6749(21)00973-8 [pii]
LID - 10.1016/j.jaci.2021.06.016 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is a complex inflammatory disorder 
      that is not generally viewed as a disease involving the adaptive immune system 
      but instead one largely driven by the innate immune system. This article focuses 
      on the cellular dysregulation involving 4 central cell types: eosinophils, 
      basophils, mast cells, and innate lymphoid type 2 cells. AERD can be envisioned 
      as involving a self-perpetuating vicious circle in which mediators produced by a 
      differentiated activated epithelial layer, such as IL-25, IL-33, and thymic 
      stromal lymphopoietin, engage and activate each of these innate immune cells. The 
      activation of these innate immune cells with their production of additional 
      cytokine/chemokine and lipid mediators leads to further recruitment and 
      activation of these innate immune cells. More importantly, numerous mediators 
      produced by these innate immune cells provoke the epithelium to induce further 
      inflammation. This self-perpetuating cycle of inflammation partially explains 
      both current interventions suggested to ameliorate AERD (eg, aspirin 
      desensitization, leukotriene modifiers, anti-IL-5/IL-5 receptor, anti-IL-4 
      receptor, and anti-IgE) and invites exploration of novel targets as specific 
      therapies for this condition (prostaglandin D(2) antagonists or cytokine 
      antagonists [IL-25, IL-33, thymic stromal lymphopoietin]). Several of these 
      interventions currently show promise in small retrospective analyses but now 
      require definite clinical trials.
CI  - Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Eid, Ryan
AU  - Eid R
AD  - Department of Medicine, University of Virginia Health System, Charlottesville, 
      Va.
FAU - Yan, Carol H
AU  - Yan CH
AD  - Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, 
      University of California, San Diego, San Diego, Calif.
FAU - Stevens, Whitney
AU  - Stevens W
AD  - Department of Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Ill; Department of Otolaryngology, Northwestern University Feinberg 
      School of Medicine, Chicago, Ill.
FAU - Doherty, Taylor A
AU  - Doherty TA
AD  - Department of Medicine, Division of Rheumatology, Allergy and Immunology, 
      University of California, San Diego, Calif; Veterans Affairs San Diego Health 
      Care System, La Jolla, Calif.
FAU - Borish, Larry
AU  - Borish L
AD  - Department of Medicine, University of Virginia Health System, Charlottesville, 
      Va; Department of Microbiology, University of Virginia Health System, 
      Charlottesville, Va. Electronic address: lb4m@virginia.edu.
LA  - eng
GR  - U01 AI123337/AI/NIAID NIH HHS/United States
GR  - U19 AI070535/AI/NIAID NIH HHS/United States
GR  - UG1 HL139126/HL/NHLBI NIH HHS/United States
GR  - I01 BX005073/BX/BLRD VA/United States
GR  - R21 AI151496/AI/NIAID NIH HHS/United States
GR  - K23 AI141694/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Cytokines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Asthma, Aspirin-Induced/*immunology/pathology/therapy
MH  - Cytokines/*immunology
MH  - Humans
MH  - Immunity, Innate/*drug effects
MH  - Inflammation/chemically induced/immunology/pathology/therapy
MH  - Leukocytes/*immunology/pathology
PMC - PMC8363117
MID - NIHMS1717985
OTO - NOTNLM
OT  - Aspirin-exacerbated respiratory disease
OT  - IgE
OT  - basophils
OT  - eosinophils
OT  - innate lymphoid cells
OT  - mast cells
OT  - type 2 inflammation
COIS- Conflict of Interest: None of the authors have any conflict of interest to report 
      relevant to the contents of this paper. WS has served on advisory boards for 
      GlaxoSmithKline, Bristol Myers Squibb, and GenenTech. LB has served on advisory 
      boards for GlaxoSmithKline and Regeneron.
EDAT- 2021/08/09 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/08/08 20:23
PHST- 2021/04/19 00:00 [received]
PHST- 2021/06/14 00:00 [revised]
PHST- 2021/06/17 00:00 [accepted]
PHST- 2021/08/08 20:23 [entrez]
PHST- 2021/08/09 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - S0091-6749(21)00973-8 [pii]
AID - 10.1016/j.jaci.2021.06.016 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2021 Aug;148(2):309-318. doi: 10.1016/j.jaci.2021.06.016.

PMID- 32641658
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 59
IP  - 21
DP  - 2020 Nov 1
TI  - Continued Aspirin Treatment May Be a Risk Factor of Delayed Bleeding after 
      Gastric Endoscopic Submucosal Dissection under Heparin Replacement: A 
      Retrospective Multicenter Study.
PG  - 2643-2651
LID - 10.2169/internalmedicine.4998-20 [doi]
AB  - Objective Gastric endoscopic submucosal dissection (ESD) under heparin 
      replacement (HR) of warfarin reportedly has a high risk of delayed bleeding 
      (24-57%). It is possible that the delayed bleeding risk may have changed over the 
      years. We evaluated the current risk of delayed bleeding after gastric ESD under 
      HR of anticoagulant agents. Methods We retrospectively reviewed the delayed 
      bleeding rate and analyzed the risk factors for delayed bleeding. Patients 
      Consecutive patients who underwent gastric ESD under HR of anticoagulant agents 
      from July 2015 to June 2017. Results A total of 32 patients with a solitary early 
      gastric cancer and taking anticoagulant agents were analyzed, including 24 
      patients on warfarin (the warfarin group) and 8 patients on direct oral 
      anticoagulants (the DOAC group). Three (9.4%) patients experienced delayed 
      bleeding: three (12.5%) patients in the warfarin group and no patients in the 
      DOAC group. Continued aspirin treatment was identified to be a risk factor of 
      delayed bleeding (p=0.01). Conclusion Careful management may be required for 
      patients undergoing gastric ESD under continued aspirin treatment in addition to 
      HR of anticoagulant agents; although the delayed bleeding risk after gastric ESD 
      under HR of anticoagulant agents might have decreased over the years.
FAU - Hamada, Kenta
AU  - Hamada K
AD  - Department of Gastroenterology and Hepatology, Okayama University Graduate School 
      of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
FAU - Kanzaki, Hiromitsu
AU  - Kanzaki H
AD  - Department of Gastroenterology and Hepatology, Okayama University Graduate School 
      of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
FAU - Inoue, Masafumi
AU  - Inoue M
AD  - Department of Gastroenterology, Japanese Red Cross Okayama Hospital, Japan.
FAU - Ishiyama, Shuhei
AU  - Ishiyama S
AD  - Department of Internal Medicine, Okayama Saiseikai General Hospital, Japan.
FAU - Yamauchi, Kenji
AU  - Yamauchi K
AD  - Department of Gastroenterology, Mitoyo General Hospital, Japan.
FAU - Miyahara, Koji
AU  - Miyahara K
AD  - Department of Internal Medicine, Hiroshima City Hospital, Japan.
FAU - Toyokawa, Tatsuya
AU  - Toyokawa T
AD  - Department of Gastroenterology, National Hospital Organization Fukuyama Medical 
      Center, Japan.
FAU - Tsuzuki, Takao
AU  - Tsuzuki T
AD  - Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, 
      Japan.
FAU - Miyaike, Jiro
AU  - Miyaike J
AD  - Department of Internal Medicine, Saiseikai Imabari Hospital, Japan.
FAU - Matsubara, Minoru
AU  - Matsubara M
AD  - Department of Internal Medicine, Sumitomo Besshi Hospital, Japan.
FAU - Takahashi, Sakuma
AU  - Takahashi S
AD  - Department of Gastroenterology, Kagawa Prefectural Central Hospital, Japan.
FAU - Nishimura, Mamoru
AU  - Nishimura M
AD  - Department of Internal Medicine, Okayama City Hospital, Japan.
FAU - Takenaka, Ryuta
AU  - Takenaka R
AD  - Department of Internal Medicine, Tsuyama Chuo Hospital, Japan.
FAU - Yunoki, Naoko
AU  - Yunoki N
AD  - Department of Internal Medicine, Akaiwa Medical Association Hospital, Japan.
FAU - Hori, Shinichiro
AU  - Hori S
AD  - Department of Endoscopy, National Hospital Organization Shikoku Cancer Center, 
      Japan.
FAU - Kobayashi, Sayo
AU  - Kobayashi S
AD  - Department of Internal Medicine, Fukuyama City Hospital, Japan.
FAU - Yamasaki, Yasushi
AU  - Yamasaki Y
AD  - Department of Gastroenterology and Hepatology, Okayama University Graduate School 
      of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
FAU - Kawahara, Yoshiro
AU  - Kawahara Y
AD  - Department of Endoscopy, Okayama University Hospital, Japan.
FAU - Ishikawa, Hideki
AU  - Ishikawa H
AD  - Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University 
      of Medicine, Japan.
FAU - Okada, Hiroyuki
AU  - Okada H
AD  - Department of Gastroenterology and Hepatology, Okayama University Graduate School 
      of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200707
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*adverse effects
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Endoscopic Mucosal Resection/*adverse effects
MH  - Female
MH  - Heparin/*adverse effects/therapeutic use
MH  - Humans
MH  - Japan
MH  - Male
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stomach Neoplasms/*surgery
MH  - Warfarin/*adverse effects/therapeutic use
PMC - PMC7691037
OTO - NOTNLM
OT  - anticoagulant agent
OT  - bleeding
OT  - endoscopic submucosal dissection
OT  - gastric cancer
OT  - heparin replacement
OT  - warfarin
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2020/07/10 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
PHST- 2020/07/10 06:00 [entrez]
AID - 10.2169/internalmedicine.4998-20 [doi]
PST - ppublish
SO  - Intern Med. 2020 Nov 1;59(21):2643-2651. doi: 10.2169/internalmedicine.4998-20. 
      Epub 2020 Jul 7.

PMID- 22031688
OWN - NLM
STAT- MEDLINE
DCOM- 20121211
LR  - 20131121
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 66
IP  - 5
DP  - 2011 Sep-Oct
TI  - [News on antithrombotic therapy and pregnancy].
PG  - 437-43
LID - 10.2515/therapie/2011061 [doi]
AB  - OBJECTIVES: State of the art of antithrombotics and their use recommendations 
      during pregnancy. METHODS: A review RESULTS: Aspirin and heparins remain the 
      safest molecules during pregnancy, and oral anticoagulants are still used for 
      mechanical valves. Heparinoids are the methods of choice in case of 
      heparin-induced thrombopenia but other molecules could find their place: 
      fondaparinux at first and possibly the direct thrombin inhibitors. Thrombolysis 
      may be used in case of life-threatening incident. At present, the new oral forms 
      can not be used during pregnancy CONCLUSIONS: During pregnancy, all 
      antithrombotics, except the oral forms, can be used, but the low molecular weight 
      heparins replacing the unfractionated ones in the treatment and prevention of 
      venous thromboembolism remain the treatment of choice.
CI  - © 2011 Société Française de Pharmacologie et de Thérapeutique.
FAU - Chauleur, Céline
AU  - Chauleur C
AD  - Département d'Obstétrique et Gynécologie, CHU Saint-Étienne Hôpital Nord, 
      Saint-Priest-en-Jarez, France. celine.chauleur@chu-st-etienne.fr
FAU - Gris, Jean-Christophe
AU  - Gris JC
FAU - Seffert, Pierre
AU  - Seffert P
FAU - Mismetti, Patrick
AU  - Mismetti P
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Mise au point sur les antithrombotiques et la grossesse.
DEP - 20111027
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Folic Acid Antagonists)
RN  - 12001-79-5 (Vitamin K)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.5 (Thrombin)
RN  - EC 3.4.21.6 (Factor Xa)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Factor Xa/adverse effects
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Folic Acid Antagonists/adverse effects
MH  - Heparin/administration & dosage/adverse effects/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/drug therapy
MH  - Pregnancy Trimester, Third/*physiology
MH  - Thrombin/antagonists & inhibitors
MH  - Thrombolytic Therapy
MH  - Venous Thromboembolism/drug therapy
MH  - Vitamin K/antagonists & inhibitors
EDAT- 2011/10/28 06:00
MHDA- 2012/12/12 06:00
CRDT- 2011/10/28 06:00
PHST- 2011/03/28 00:00 [received]
PHST- 2011/05/17 00:00 [accepted]
PHST- 2011/10/28 06:00 [entrez]
PHST- 2011/10/28 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
AID - th111986 [pii]
AID - 10.2515/therapie/2011061 [doi]
PST - ppublish
SO  - Therapie. 2011 Sep-Oct;66(5):437-43. doi: 10.2515/therapie/2011061. Epub 2011 Oct 
      27.

PMID- 26464196
OWN - NLM
STAT- MEDLINE
DCOM- 20160324
LR  - 20181113
IS  - 1460-2180 (Electronic)
IS  - 0143-3334 (Print)
IS  - 0143-3334 (Linking)
VI  - 36
IP  - 12
DP  - 2015 Dec
TI  - Modulation by aspirin and naproxen of nucleotide alterations and tumors in the 
      lung of mice exposed to environmental cigarette smoke since birth.
PG  - 1531-8
LID - 10.1093/carcin/bgv149 [doi]
AB  - Chemoprevention provides an important strategy for cancer control in passive 
      smokers. Due to the crucial role played by smoke-related chronic inflammation in 
      lung carcinogenesis, of special interest are extensively used pharmacological 
      agents, such as nonsteroidal anti-inflammatory drugs (NSAIDs). We evaluated the 
      ability of aspirin and naproxen, inhibitors of both cyclooxygenase-1 and 
      cyclooxygenase -2, to modulate environmental cigarette smoke (ECS)-induced lung 
      carcinogenesis in A/J mice of both genders. Based on a subchronic toxicity study 
      in 180 postweaning mice, we used 1600 mg/kg diet aspirin and 320 mg/kg diet 
      naproxen. In the tumor chemoprevention study, using 320 mice, exposure to ECS 
      started soon after birth and administration of NSAIDs started after weaning. At 
      10 weeks of life, the NSAIDs did not affect the presence of occult blood in 
      feces. As assessed in a subset of 40 mice, bulky DNA adducts and 
      8-hydroxy-2'-deoxyguanosine levels were considerably increased in ECS-exposed 
      mice and, irrespective of gender, both NSAIDs remarkably inhibited these 
      nucleotide alterations. After exposure for 4 months followed by 5 months in 
      filtered air, ECS induced a significant increase in the yield of surface lung 
      tumors, the 43.7% of which were adenomas and the 56.3% were adenocarcinomas. 
      Oct-4 (octamer-binding transcription factor 4), a marker of cell stemness, was 
      detected in some adenocarcinoma cells. The NAIDs attenuated the yield of lung 
      tumors, but prevention of ECS-induced lung adenomas was statistically significant 
      only in female mice treated with aspirin, which supports a role for estrogens in 
      ECS-related lung carcinogenesis and highlights the antiestrogenic properties of 
      NSAIDs.
CI  - © The Author 2015. Published by Oxford University Press. All rights reserved. For 
      Permissions, please email: journals.permissions@oup.com.
FAU - La Maestra, Sebastiano
AU  - La Maestra S
FAU - D'Agostini, Francesco
AU  - D'Agostini F
FAU - Izzotti, Alberto
AU  - Izzotti A
FAU - Micale, Rosanna T
AU  - Micale RT
FAU - Mastracci, Luca
AU  - Mastracci L
AD  - Department of Surgical and Diagnostic Sciences, University of Genoa, 16132 Genoa, 
      Italy.
FAU - Camoirano, Anna
AU  - Camoirano A
FAU - Balansky, Roumen
AU  - Balansky R
AD  - National Center of Oncology, Sofia 1756, Bulgaria.
FAU - Trosko, James E
AU  - Trosko JE
AD  - National Food Safety Toxicological Center, Department of Pediatrics and Human 
      Development, Michigan State University, East Lansing, MI 48824, USA.
FAU - Steele, Vernon E
AU  - Steele VE
AD  - National Cancer Institute, Division of Cancer Prevention, Chemopreventive Agent 
      Development Research Group, Bethesda, MD 20892, USA.
FAU - De Flora, Silvio
AU  - De Flora S
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20151013
PL  - England
TA  - Carcinogenesis
JT  - Carcinogenesis
JID - 8008055
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Octamer Transcription Factor-3)
RN  - 0 (Pou5f1 protein, mouse)
RN  - 0 (Tobacco Smoke Pollution)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticarcinogenic Agents/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - DNA Damage
MH  - Drug Evaluation, Preclinical
MH  - Female
MH  - Lung/metabolism/pathology
MH  - Lung Neoplasms/etiology/genetics/*prevention & control
MH  - Male
MH  - Mice
MH  - Naproxen/*pharmacology/toxicity
MH  - Octamer Transcription Factor-3/metabolism
MH  - Tobacco Smoke Pollution/*adverse effects
PMC - PMC4675832
EDAT- 2015/10/16 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/10/15 06:00
PHST- 2015/04/28 00:00 [received]
PHST- 2015/10/06 00:00 [accepted]
PHST- 2015/10/15 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/03/25 06:00 [medline]
AID - bgv149 [pii]
AID - 10.1093/carcin/bgv149 [doi]
PST - ppublish
SO  - Carcinogenesis. 2015 Dec;36(12):1531-8. doi: 10.1093/carcin/bgv149. Epub 2015 Oct 
      13.

PMID- 15726550
OWN - NLM
STAT- MEDLINE
DCOM- 20050721
LR  - 20151119
IS  - 1053-8569 (Print)
IS  - 1053-8569 (Linking)
VI  - 14
IP  - 4
DP  - 2005 Apr
TI  - A large simple clinical trial prototype for assessment of OTC drug effects using 
      patient-reported data.
PG  - 249-55
AB  - PURPOSE: Innovative methods are needed to assess risks related to treatment for 
      common medical conditions, where therapy is usually patient-directed or 
      over-the-counter (OTC), and where tolerability, i.e. patient experienced events, 
      may affect patterns of use. A large-scale, blinded, randomised trial was 
      conducted to compare the tolerability of paracetamol (acetaminophen), aspirin and 
      ibuprofen at OTC doses, with patient-reported adverse event (AE) data as the 
      primary outcome. METHODS: Patients with mild to moderate pain were randomised to 
      either: paracetamol up to 3 g/d, aspirin up to 3 g/d or ibuprofen up to 1200 mg/d 
      for 7 days. Patients recorded AE and severity in a diary as the primary data 
      source. After inclusion, contact with patients by general practitioner (GP) 
      investigators was by telephone after 24 hours and 7-9 days, and unscheduled 
      visits, when GPs recorded AE. The study outcome was the frequency of significant 
      adverse event (SGAE) (serious, severe, moderate or undefined intensity, or 
      resulting in withdrawal or an investigator visit). RESULTS: Of 8677 patients 
      included, 44 patients were non-evaluable, leaving 8633 evaluable patients; 1347 
      patients reported SGAE (paracetamol: 14.5%, aspirin: 18.7%, ibuprofen: 13.7%). 
      Completed diaries were returned by 98.5% of patients, and only 49 cases were lost 
      to follow-up (0.6%). Almost all patients were contacted by telephone, 99.3% at 
      the first call, and 98.5% at the second. Most SGAE were reported by patients; 
      only 27 patients (2%) had a SGAE reported only by the GP. The tolerability 
      rankings by treatment were consistent for all categories of SGAE: aspirin had the 
      highest incidence of SGAE, and ibuprofen and paracetamol, lower, comparable 
      incidences. CONCLUSIONS: A large, simple, randomised trial with patient-generated 
      data can provide a sensitive source of information on AE, particularly in 
      comparative safety assessments of OTC medications and other short-term therapies. 
      This suggests reconsideration of the view that investigators are the most valid 
      source for identifying and reporting AE.
FAU - Van Ganse, Eric
AU  - Van Ganse E
AD  - Pharmacoepidemiology Unit, EA 3091 CHU-Lyon, France. eric.van-ganse@chu-lyon.fr
FAU - Jones, Judith K
AU  - Jones JK
FAU - Moore, Nicholas
AU  - Moore N
FAU - Parc, Jean Marie Le
AU  - Parc JM
FAU - Wall, Richard
AU  - Wall R
FAU - Schneid, Helene
AU  - Schneid H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Analgesics)
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/adverse effects/pharmacology
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Analgesics/*adverse effects/pharmacology
MH  - Aspirin/adverse effects/pharmacology
MH  - Female
MH  - Humans
MH  - Ibuprofen/adverse effects/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Nonprescription Drugs/*adverse effects/pharmacology
MH  - Pain/*drug therapy
MH  - Patients
MH  - Randomized Controlled Trials as Topic
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2005/02/24 09:00
MHDA- 2005/07/22 09:00
CRDT- 2005/02/24 09:00
PHST- 2005/02/24 09:00 [pubmed]
PHST- 2005/07/22 09:00 [medline]
PHST- 2005/02/24 09:00 [entrez]
AID - 10.1002/pds.1083 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2005 Apr;14(4):249-55. doi: 10.1002/pds.1083.

PMID- 9101310
OWN - NLM
STAT- MEDLINE
DCOM- 19970617
LR  - 20191024
IS  - 0916-9636 (Print)
IS  - 0916-9636 (Linking)
VI  - 20
IP  - 1
DP  - 1997 Mar
TI  - Role of nitric oxide in desmopressin-induced vasodilation of microperfused rabbit 
      afferent arterioles.
PG  - 29-34
AB  - We have previously reported that desmopressin (dDAVP) increased the lumen 
      diameter of norepinephrine (NE)-constricted isolated microperfused rabbit 
      afferent arterioles. In this study, we examined the role of nitric oxide in 
      dDAVP-induced vasodilation of afferent arterioles. We microdissected a 
      superficial afferent arteriole from the kidney of a New Zealand white rabbit. 
      Each afferent arteriole was cannulated with a pipette system and microperfused in 
      vitro at 60 mmHg. dDAVP increased the lumen diameter of NE-preconstricted rabbit 
      afferent arterioles dose-dependently. dDAVP-induced vasodilation was abolished by 
      pretreatment with NG-nitro-L-arginine (L-NNA, 10(-4)M) (L-NNA + NE, 6.7 +/- 1.1 
      microns; L-NNA + NE + dDAVP, 7.3 +/- 1.4 microns, n = 8). dDAVP increased the 
      lumen diameter of NE-preconstricted afferent arterioles pretreated with L-NNA and 
      L-arginine (10(-2)M) (L-NNA + L-arginine + NE, 6.1 +/- 1.1 microns; L-NNA + 
      L-arginine + NE + dDAVP, 8.7 +/- 0.9 microns*; *p < 0.05, n = 6). 
      Aspirin-DL-lysine (10(-4)M) did not influence dDAVP-induced afferent arteriolar 
      vasodilation (aspirin + NE, 6.4 +/- 0.8 microns; aspirin + NE + dDAVP, 9.6 +/- 
      1.3 microns *; *p < 0.05, n = 5). These results suggest that nitric oxide may be 
      responsible for dDAVP-induced afferent arteriolar vasodilation.
FAU - Kiyomoto, K
AU  - Kiyomoto K
AD  - Department of Pharmacology, Kagawa Medical School, Japan.
FAU - Tamaki, T
AU  - Tamaki T
FAU - Tomohiro, A
AU  - Tomohiro A
FAU - Nishiyama, A
AU  - Nishiyama A
FAU - Aki, Y
AU  - Aki Y
FAU - Kimura, S
AU  - Kimura S
FAU - Abe, Y
AU  - Abe Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hypertens Res
JT  - Hypertension research : official journal of the Japanese Society of Hypertension
JID - 9307690
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vasoconstrictor Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
RN  - X4W3ENH1CV (Norepinephrine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Arterioles/drug effects
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Deamino Arginine Vasopressin/*pharmacology
MH  - Enzyme Inhibitors/pharmacology
MH  - Hypoglycemic Agents/*pharmacology
MH  - In Vitro Techniques
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - NG-Nitroarginine Methyl Ester/pharmacology
MH  - Nitric Oxide/*physiology
MH  - Nitric Oxide Synthase/antagonists & inhibitors
MH  - Norepinephrine/pharmacology
MH  - Perfusion
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Rabbits
MH  - Vascular Resistance/drug effects
MH  - Vasoconstrictor Agents/pharmacology
MH  - Vasodilation/*drug effects
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
AID - 10.1291/hypres.20.29 [doi]
PST - ppublish
SO  - Hypertens Res. 1997 Mar;20(1):29-34. doi: 10.1291/hypres.20.29.

PMID- 32918079
OWN - NLM
STAT- MEDLINE
DCOM- 20210915
LR  - 20211117
IS  - 1758-535X (Electronic)
IS  - 1079-5006 (Print)
IS  - 1079-5006 (Linking)
VI  - 76
IP  - 6
DP  - 2021 May 22
TI  - Association Between Long-Term Aspirin Use and Frailty in Men: The Physicians' 
      Health Study.
PG  - 1077-1083
LID - 10.1093/gerona/glaa233 [doi]
AB  - BACKGROUND: Chronic inflammation may lead to frailty, however the potential for 
      anti-inflammatory medications such as aspirin to prevent frailty is unknown. We 
      sought to examine the association between long-term aspirin use and prevalent 
      frailty. METHODS: We included 12 101 men ≥60 years who participated in the 
      Physicians' Health Study I, a completed aspirin randomized controlled trial 
      (1982-1989). Annual questionnaires collected self-reported data on daily aspirin 
      use, lifestyle, and clinical variables. Average aspirin use was summed into 2 
      categories: ≤60 days/year and >60 days/year. Frailty was assessed using a 33-item 
      index 11 years after trial completion. A score of ≥0.21 was considered frail. 
      Propensity score inverse probability of treatment weighting was used for 
      statistical control of confounding. Logistic regression models estimated odds of 
      frailty as a function of categories of average aspirin use. RESULTS: Mean age was 
      70.5 years (range 60-101). Following an average of 11 ± 0.6 years of follow-up, 
      aspirin use was reported as ≤60 days/year for 15%; 2413 participants (20%) were 
      frail. Frequency of aspirin use was associated with smoking, alcohol consumption, 
      hypertension, and cardiovascular disease, but negatively associated with bleeding 
      and Coumadin use. The odds ratio (95% confidence intervals) for frailty was 0.85 
      (0.76-0.96) for average aspirin use >60 days/year versus aspirin use ≤60 
      days/year. Results were similar using an alternate definition of frailty. 
      CONCLUSIONS: Long-term regular aspirin use is inversely associated with frailty 
      among older men, even after consideration of multimorbidity and health behaviors. 
      Work is needed to understand the role of medications with anti-inflammatory 
      properties on aging.
CI  - Published by Oxford University Press on behalf of The Gerontological Society of 
      America 2020.
FAU - Orkaby, Ariela R
AU  - Orkaby AR
AUID- ORCID: 0000-0002-4297-6306
AD  - New England GRECC (Geriatric Research, Education, and Clinical Center), VA Boston 
      Healthcare System, Massachusetts.
AD  - Division of Aging, Brigham & Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts.
FAU - Yang, Laiji
AU  - Yang L
AD  - Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, 
      Massachusetts.
FAU - Dufour, Alyssa B
AU  - Dufour AB
AD  - Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, 
      Massachusetts.
FAU - Travison, Thomas G
AU  - Travison TG
AUID- ORCID: 0000-0002-1030-7175
AD  - Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, 
      Massachusetts.
FAU - Sesso, Howard D
AU  - Sesso HD
AD  - Division of Aging, Brigham & Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts.
AD  - Division of Preventive Medicine, Brigham & Women's Hospital, Harvard Medical 
      School, Boston, Massachusetts.
FAU - Driver, Jane A
AU  - Driver JA
AD  - New England GRECC (Geriatric Research, Education, and Clinical Center), VA Boston 
      Healthcare System, Massachusetts.
AD  - Division of Aging, Brigham & Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts.
FAU - Djousse, Luc
AU  - Djousse L
AD  - Division of Aging, Brigham & Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts.
AD  - MAVERIC (Massachusetts Veterans Epidemiology Research and Information Center), VA 
      Boston Healthcare System, Massachusetts.
FAU - Gaziano, J Michael
AU  - Gaziano JM
AD  - Division of Aging, Brigham & Women's Hospital, Harvard Medical School, Boston, 
      Massachusetts.
AD  - MAVERIC (Massachusetts Veterans Epidemiology Research and Information Center), VA 
      Boston Healthcare System, Massachusetts.
LA  - eng
GR  - P30 AG031679/AG/NIA NIH HHS/United States
GR  - IK2 CX001800/CX/CSRD VA/United States
GR  - R03 AG060169/AG/NIA NIH HHS/United States
GR  - R01 CA040360/CA/NCI NIH HHS/United States
GR  - R01 CA097193/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Gerontol A Biol Sci Med Sci
JT  - The journals of gerontology. Series A, Biological sciences and medical sciences
JID - 9502837
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Frailty/etiology/*prevention & control
MH  - Humans
MH  - Inflammation/complications/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Surveys and Questionnaires
MH  - Time Factors
PMC - PMC8140052
OTO - NOTNLM
OT  - Aspirin
OT  - Frailty
OT  - Geroscience
OT  - Pharmacoepidemiology
OT  - Prevention
EDAT- 2020/09/13 06:00
MHDA- 2021/09/16 06:00
CRDT- 2020/09/12 05:33
PHST- 2020/01/21 00:00 [received]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2021/09/16 06:00 [medline]
PHST- 2020/09/12 05:33 [entrez]
AID - 5904446 [pii]
AID - glaa233 [pii]
AID - 10.1093/gerona/glaa233 [doi]
PST - ppublish
SO  - J Gerontol A Biol Sci Med Sci. 2021 May 22;76(6):1077-1083. doi: 
      10.1093/gerona/glaa233.

PMID- 7564340
OWN - NLM
STAT- MEDLINE
DCOM- 19951107
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 25
IP  - 6
DP  - 1995 Jun
TI  - Inhibition of restenosis by beraprost sodium (a prostaglandin I2 analogue) in the 
      atherosclerotic rabbit artery after angioplasty.
PG  - 947-52
AB  - We examined the effect of beraprost sodium (BPS), a stable prostaglandin I2 
      (PGI2) analogue, on restenosis after balloon angioplasty in the atherosclerotic 
      artery in rabbits. Regional atherosclerosis was induced in the femoral artery of 
      New Zealand white rabbits by balloon deendothelialization and 2% cholesterol 
      diet. After establishment of atheroma in the femoral artery, angioplasty was 
      performed. In all, 65 rabbits were assigned to the following six subcutaneous 
      drug treatment groups: control group (n = 13, saline 0.25 ml/kg); BPS low-dose 
      group (n = 11, BPS 50 micrograms/kg twice daily); BPS high-dose group (n = 12, 
      BPS 100 micrograms/kg twice daily); 2-day BPS high-dose group (n = 11, BPS 100 
      micrograms/kg twice daily for 2 days after angioplasty); aspirin (ASA) group (n = 
      10, ASA 30 mg once daily); and BPS+ASA group (n = 8, BPS 50 micrograms/kg twice 
      daily plus ASA 30 mg once daily). Administration of each drug was started 30 min 
      before balloon angioplasty and was continued until 4 weeks thereafter, except in 
      the 2-day BPS high-dose group. Re-examination 4 weeks after the angioplasty 
      showed significant (p < 0.05) preservation of the luminal diameter in the BPS 
      high-dose and 2-day BPS high-dose groups (1.30 +/- 0.15 and 1.25 +/- 0.09 mm, 
      respectively) as compared with that in the control group (0.83 +/- 0.10 mm); 
      however, the luminal diameter in the BPS low-dose, ASA, and BPS+ASA groups (0.94 
      +/- 0.18, 1.06 +/- 0.11, and 1.05 +/- 0.15 mm, respectively) was not 
      significantly different from that in the control group.
FAU - Isogaya, M
AU  - Isogaya M
AD  - Basic Research Laboratories Laboratory Pharmacology, Toray Industries, Kamakura, 
      Japan.
FAU - Yamada, N
AU  - Yamada N
FAU - Koike, H
AU  - Koike H
FAU - Ueno, Y
AU  - Ueno Y
FAU - Kumagai, H
AU  - Kumagai H
FAU - Ochi, Y
AU  - Ochi Y
FAU - Okazaki, S
AU  - Okazaki S
FAU - Nishio, S
AU  - Nishio S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Cholesterol, Dietary)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 35E3NJJ4O6 (beraprost)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Angioplasty, Balloon
MH  - Animals
MH  - Arteriosclerosis/chemically induced/*prevention & control/therapy
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Cholesterol, Dietary/administration & dosage
MH  - Disease Models, Animal
MH  - Drug Synergism
MH  - Epoprostenol/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
MH  - Femoral Artery/drug effects/pathology
MH  - Iliac Artery/drug effects/pathology
MH  - Injections, Subcutaneous
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Rabbits
MH  - Random Allocation
MH  - Recurrence
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
AID - 10.1097/00005344-199506000-00013 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1995 Jun;25(6):947-52. doi: 
      10.1097/00005344-199506000-00013.

PMID- 1496272
OWN - NLM
STAT- MEDLINE
DCOM- 19920908
LR  - 20131121
IS  - 0035-2659 (Print)
IS  - 0035-2659 (Linking)
VI  - 59
IP  - 4
DP  - 1992 Apr
TI  - [Erythromelalgia in adults. Apropos of 16 cases].
PG  - 258-63
AB  - The authors report sixteen consecutive cases of erythromelalgia, an infrequent 
      disease in which local heat, redness, and pain develop in the hands and/or feet 
      in recurrent attacks. The disease was essential in nine patients; in the 
      remaining seven, the cause was a myeloproliferative syndrome (polycythemia vera 
      in 3 cases and thrombocythemia in 1 case) or a drug (bromocriptine, nicardipine, 
      and nifedipine, one case each). Acetylsalicylic acid was effective in only six of 
      the nine essential cases. Intravascular platelet activation and aggregation with 
      plugging of the arterioles has been suggested as the mechanism of erythromelalgia 
      in patients with myeloproliferative disorders. Other, as yet unelucidated 
      pathophysiologic events underlie the juvenile-onset forms, which usually fail to 
      respond to acetylsalicylic acid.
FAU - Levesque, H
AU  - Levesque H
AD  - Service de Médecine Interne, Diabétologie, Angéiologie, CHU Rouen-Boisguillaume.
FAU - Cailleux, N
AU  - Cailleux N
FAU - Courtois, H
AU  - Courtois H
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Les érythromélalgies de l'adulte. A propos de 16 observations.
PL  - France
TA  - Rev Rhum Mal Osteoartic
JT  - Revue du rhumatisme et des maladies osteo-articulaires
JID - 0407211
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Erythromelalgia/complications/*diagnosis/drug therapy/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myeloproliferative Disorders/complications
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
PST - ppublish
SO  - Rev Rhum Mal Osteoartic. 1992 Apr;59(4):258-63.

PMID- 485729
OWN - NLM
STAT- MEDLINE
DCOM- 19791121
LR  - 20131121
IS  - 0003-9780 (Print)
IS  - 0003-9780 (Linking)
VI  - 239
IP  - 2
DP  - 1979 Jun
TI  - The role of endogenous prostaglandins in the renal vascular response to 
      clonidine.
PG  - 319-25
AB  - The effect of clonidine has been studied in the isolated perfused rabbit kidney. 
      The drug produced a dose-dependent increase in perfusion pressure and in urine 
      flow both of which could be blocked by phentolamine. Addition of acetylsalicylic 
      acid to the medium caused an increase in perfusion pressure and a decrease in 
      urine volume induced by clonidine. Further addition of prostaglandin E2 to the 
      medium prevented the changes induced by acetylsalicylic acid. These results were 
      taken as evidence that clonidine can increase the biosynthesis of prostaglandins 
      which could act as a modulator system for the effects of the drug in the kidney.
FAU - Ercan, Z S
AU  - Ercan ZS
FAU - Bor, N M
AU  - Bor NM
FAU - Türker, R K
AU  - Türker RK
LA  - eng
PT  - Journal Article
PL  - Belgium
TA  - Arch Int Pharmacodyn Ther
JT  - Archives internationales de pharmacodynamie et de therapie
JID - 0405353
RN  - 0 (Prostaglandins)
RN  - MN3L5RMN02 (Clonidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Pressure/drug effects
MH  - Clonidine/*pharmacology
MH  - Drug Synergism
MH  - Female
MH  - Kidney/*blood supply
MH  - Male
MH  - Perfusion
MH  - Prostaglandins/*physiology
MH  - Rabbits
MH  - Regional Blood Flow/drug effects
EDAT- 1979/06/01 00:00
MHDA- 1979/06/01 00:01
CRDT- 1979/06/01 00:00
PHST- 1979/06/01 00:00 [pubmed]
PHST- 1979/06/01 00:01 [medline]
PHST- 1979/06/01 00:00 [entrez]
PST - ppublish
SO  - Arch Int Pharmacodyn Ther. 1979 Jun;239(2):319-25.

PMID- 24898335
OWN - NLM
STAT- MEDLINE
DCOM- 20150302
LR  - 20181202
IS  - 1878-5034 (Electronic)
IS  - 0006-355X (Linking)
VI  - 51
IP  - 2-3
DP  - 2014
TI  - Gender differences in hemorheological parameters and in in vitro platelet 
      aggregation in acetylsalicylic acid and clopidogrel treated vascular patients.
PG  - 197-206
LID - 10.3233/BIR-140661 [doi]
AB  - BACKGROUND: Sex-specific response to antiplatelet medications have been reported 
      in several previous studies. OBJECTIVE: We investigated a possible connection 
      between gender differences in hemorheological parameters and in vitro platelet 
      aggregation in vascular patients treated with widely used antiplatelet agents. 
      METHODS: In vitro platelet aggregation was assessed in 2687 patients treated with 
      100 mg acetylsalicylic acid (ASA), 1047 patients treated with 75 mg clopidogrel 
      and 311 patients on dual antiplatelet therapy (100 mg aspirin and 75 mg 
      clopidogrel) according to the method of Born. In subgroups of patients fibrinogen 
      concentration, whole blood and plasma viscosity, red blood cell aggregation and 
      hematocrit were simultaneously measured. The subjects were divided into groups 
      according to their gender. RESULTS: ADP induced platelet aggregation was 
      significantly higher in women in the case of ASA treatment (p<0.001). No gender 
      differences could be observed in platelet function in patients treated with 
      clopidogrel or on dual antiplatelet therapy. Hematocrit and whole blood viscosity 
      were significantly higher in men in all groups (p<0.001), while no significant 
      gender differences were observed in red blood cell aggregation indices in either 
      group. Fibrinogen concentration was significantly higher in women than in men 
      among patients treated with 100 mg ASA (p<0.05), but not in the other groups. 
      CONCLUSIONS: Significantly higher fibrinogen concentration found in aspirin 
      treated women than men may play a role in higher ADP induced platelet 
      aggregation. Gender differences in response to monotherapy suggest that benefits 
      from combination therapy may be greater in females. The clinical relevance of 
      higher ADP induced platelet aggregation in women treated with ASA needs further 
      investigation.
FAU - Koltai, Katalin
AU  - Koltai K
AD  - 1st Department of Medicine, School of Medicine, University of Pécs, Pécs, 
      Hungary.
FAU - Papp, Judit
AU  - Papp J
AD  - 1st Department of Medicine, School of Medicine, University of Pécs, Pécs, 
      Hungary.
FAU - Kenyeres, Peter
AU  - Kenyeres P
AD  - 1st Department of Medicine, School of Medicine, University of Pécs, Pécs, 
      Hungary.
FAU - Feher, Gergely
AU  - Feher G
AD  - 1st Department of Medicine, School of Medicine, University of Pécs, Pécs, Hungary 
      Department of Neurology, School of Medicine, University of Pécs, Pécs, Hungary.
FAU - Tibold, Antal
AU  - Tibold A
AD  - Department of Public Health, School of Medicine, University of Pécs, Pécs, 
      Hungary.
FAU - Alexy, Tamas
AU  - Alexy T
AD  - 1st Department of Medicine, School of Medicine, University of Pécs, Pécs, Hungary 
      Division of Cardiology, Emory University, Atlanta, GA, USA.
FAU - Marton, Zsolt
AU  - Marton Z
AD  - 1st Department of Medicine, School of Medicine, University of Pécs, Pécs, 
      Hungary.
FAU - Kesmarky, Gabor
AU  - Kesmarky G
AD  - 1st Department of Medicine, School of Medicine, University of Pécs, Pécs, 
      Hungary.
FAU - Toth, Kalman
AU  - Toth K
AD  - 1st Department of Medicine, School of Medicine, University of Pécs, Pécs, 
      Hungary.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Biorheology
JT  - Biorheology
JID - 0372526
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9001-32-5 (Fibrinogen)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Erythrocyte Aggregation
MH  - Female
MH  - Fibrinogen/*metabolism
MH  - Hematocrit
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/physiology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - *Rheology
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - erythrocyte aggregation
OT  - fibrinogen
OT  - optical aggregometry
OT  - thienopyridines
OT  - viscosity
EDAT- 2014/06/06 06:00
MHDA- 2015/03/03 06:00
CRDT- 2014/06/06 06:00
PHST- 2014/06/06 06:00 [entrez]
PHST- 2014/06/06 06:00 [pubmed]
PHST- 2015/03/03 06:00 [medline]
AID - 1W7P357460681255 [pii]
AID - 10.3233/BIR-140661 [doi]
PST - ppublish
SO  - Biorheology. 2014;51(2-3):197-206. doi: 10.3233/BIR-140661.

PMID- 35954272
OWN - NLM
STAT- MEDLINE
DCOM- 20220815
LR  - 20221106
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 11
IP  - 15
DP  - 2022 Aug 5
TI  - Non-Coding RNAs and Prediction of Preeclampsia in the First Trimester of 
      Pregnancy.
LID - 10.3390/cells11152428 [doi]
LID - 2428
AB  - Preeclampsia (PE) is a major cause of maternal and perinatal morbidity and 
      mortality. The only fundamental treatment for PE is the termination of pregnancy. 
      Therefore, not only severe maternal complications but also perinatal 
      complications due to immaturity of the infant associated with early delivery are 
      serious issues. The treatment and prevention of preterm onset preeclampsia (POPE) 
      are challenging. In 2017, the ASPRE trial showed that a low oral dose of aspirin 
      administered to POPE high-risk women in early pregnancy reduced POPE by 62%. A 
      prediction algorithm at 11-13 weeks of gestation identifies POPE with 75% 
      sensitivity when the false positive rate is set at 10%. New biomarkers to 
      increase the accuracy of the prediction model for POPE high-risk women in early 
      pregnancy are needed. In this review, we focused on non-coding RNAs (ncRNAs) as 
      potential biomarkers for the prediction of POPE. Highly expressed ncRNAs in the 
      placenta in early pregnancy may play crucial roles in placentation. Furthermore, 
      placenta-specific ncRNAs have been detected in maternal blood. In this review, we 
      summarized ncRNAs that were highly expressed in the primary human placenta in 
      early pregnancy. We also presented highly expressed ncRNAs in the placenta that 
      were associated with or predictive of the development of PE in an expression 
      analysis of maternal blood during the first trimester of pregnancy. These 
      previous studies showed that the chromosome 19 microRNA (miRNA) -derived miRNAs 
      (e.g., miR-517-5p, miR-518b, and miR-520h), the hypoxia-inducible miRNA 
      (miR-210), and long non-coding RNA H19, were not only highly expressed in the 
      early placenta but were also significantly up-regulated in the blood at early 
      gestation in pregnant women who later developed PE. These maternal circulating 
      ncRNAs in early pregnancy are expected to be possible biomarkers for POPE.
FAU - Ogoyama, Manabu
AU  - Ogoyama M
AUID- ORCID: 0000-0001-9410-1782
AD  - Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 
      Yakushiji, Shimotsuke 329-0498, Japan.
FAU - Takahashi, Hironori
AU  - Takahashi H
AUID- ORCID: 0000-0003-1652-9438
AD  - Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 
      Yakushiji, Shimotsuke 329-0498, Japan.
FAU - Suzuki, Hirotada
AU  - Suzuki H
AD  - Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 
      Yakushiji, Shimotsuke 329-0498, Japan.
FAU - Ohkuchi, Akihide
AU  - Ohkuchi A
AUID- ORCID: 0000-0002-8861-1572
AD  - Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 
      Yakushiji, Shimotsuke 329-0498, Japan.
FAU - Fujiwara, Hiroyuki
AU  - Fujiwara H
AD  - Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 
      Yakushiji, Shimotsuke 329-0498, Japan.
FAU - Takizawa, Toshihiro
AU  - Takizawa T
AD  - Department of Molecular Medicine and Anatomy, Nippon Medical School, 1-1-5 
      Sendagi, Tokyo 113-8602, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220805
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (Biomarkers)
RN  - 0 (MicroRNAs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Biomarkers
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - *MicroRNAs/metabolism
MH  - *Pre-Eclampsia/diagnosis/genetics
MH  - Pregnancy
MH  - Pregnancy Trimester, First
PMC - PMC9368389
OTO - NOTNLM
OT  - first trimester
OT  - non-coding RNA
OT  - placentation
OT  - prediction
OT  - preeclampsia
COIS- The authors declare no conflict of interest.
EDAT- 2022/08/13 06:00
MHDA- 2022/08/16 06:00
CRDT- 2022/08/12 01:04
PHST- 2022/07/18 00:00 [received]
PHST- 2022/08/02 00:00 [revised]
PHST- 2022/08/03 00:00 [accepted]
PHST- 2022/08/12 01:04 [entrez]
PHST- 2022/08/13 06:00 [pubmed]
PHST- 2022/08/16 06:00 [medline]
AID - cells11152428 [pii]
AID - cells-11-02428 [pii]
AID - 10.3390/cells11152428 [doi]
PST - epublish
SO  - Cells. 2022 Aug 5;11(15):2428. doi: 10.3390/cells11152428.

PMID- 21351304
OWN - NLM
STAT- MEDLINE
DCOM- 20110624
LR  - 20230120
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 20
IP  - 3
DP  - 2011 Mar
TI  - Validation of the National Health Insurance Research Database with ischemic 
      stroke cases in Taiwan.
PG  - 236-42
LID - 10.1002/pds.2087 [doi]
AB  - OBJECTIVE: The National Health Insurance Research Database (NHIRD) is commonly 
      used for pharmacoepidemiological research in Taiwan. This study evaluated the 
      validity of the database for patients with a principal diagnosis of ischemic 
      stroke. STUDY DESIGN AND METHODS: This cross-sectional study compares records in 
      the NHIRD with those in one medical center. Patients hospitalized for ischemic 
      stroke in 1999 were identified from both databases. The discharge notes, 
      laboratory data, and medication orders during admission and the first discharge 
      visit were reviewed to validate ischemic stroke diagnoses and aspirin prescribing 
      in the NHIRD. Agreement between the two databases in comorbidities of ischemic 
      stroke diagnosis was evaluated using ICD-9 codes. RESULTS: Three hundred and 
      seventy two cases were identified from the NHIRD; among them, 364 cases (97.85%) 
      were confirmed as ischemic stroke by radiology examination and clinical 
      presentation. Among these confirmed cases, 344 (94.51%) were assigned 'ischemic 
      stroke' as the principal diagnosis in the NHIRD. The overall agreement of 
      comorbid diagnoses between the databases was 48.39%. The PPV for selected 
      conditions also varied widely, from 0.50 for fracture to 1.00 for colon cancer. 
      The accuracy of recorded aspirin prescriptions was higher in first post-discharge 
      visits (PPV = 0.94) than during hospitalization (PPV = 0.88). CONCLUSION: The 
      accuracy of the NHIRD in recording ischemic stroke diagnoses and aspirin 
      prescriptions was high, and the NHIRD appears to be a valid resource for 
      population research in ischemic stroke.
CI  - Copyright © 2010 John Wiley & Sons, Ltd.
FAU - Cheng, Ching-Lan
AU  - Cheng CL
AD  - Institute of Biopharmaceutical Science, College of Medicine, National Cheng Kung 
      University, Tainan, Taiwan.
FAU - Kao, Yea-Huei Yang
AU  - Kao YH
FAU - Lin, Swu-Jane
AU  - Lin SJ
FAU - Lee, Cheng-Han
AU  - Lee CH
FAU - Lai, Ming Liang
AU  - Lai ML
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101229
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Brain Ischemia/*complications
MH  - Cross-Sectional Studies
MH  - Databases, Factual/*standards
MH  - Drug Prescriptions/statistics & numerical data
MH  - Humans
MH  - Insurance Claim Review/*statistics & numerical data
MH  - National Health Programs/*standards
MH  - Pharmacoepidemiology/methods
MH  - Practice Patterns, Physicians'/statistics & numerical data
MH  - Reproducibility of Results
MH  - Stroke/diagnosis/drug therapy/*epidemiology/etiology
MH  - Taiwan
EDAT- 2011/02/26 06:00
MHDA- 2011/06/28 06:00
CRDT- 2011/02/26 06:00
PHST- 2010/05/03 00:00 [received]
PHST- 2010/10/24 00:00 [revised]
PHST- 2010/11/16 00:00 [accepted]
PHST- 2011/02/26 06:00 [entrez]
PHST- 2011/02/26 06:00 [pubmed]
PHST- 2011/06/28 06:00 [medline]
AID - 10.1002/pds.2087 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):236-42. doi: 10.1002/pds.2087. Epub 
      2010 Dec 29.

PMID- 11259566
OWN - NLM
STAT- MEDLINE
DCOM- 20010503
LR  - 20171116
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 297
IP  - 1
DP  - 2001 Apr
TI  - The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by 
      myocardial ischemia-reperfusion in the anesthetized rat.
PG  - 380-7
AB  - NCX 4016, a nitro-ester of aspirin endowed with antithrombotic activity, appears 
      to have clinical potential in treating cardiac complications related to coronary 
      insufficiency. This compound has been shown to improve postischemic ventricular 
      dysfunction and to reduce myocardial infarct size in the rabbit. The 
      cardioprotection conferred by NCX 4016 (10, 30, and 100 mg/kg) and aspirin (ASA, 
      54 mg/kg) was evaluated in anesthetized rats subjected to 30 min of myocardial 
      ischemia followed by 120 min of reperfusion (MI/R). Drugs were given orally for 5 
      consecutive days. NCX 4016 displayed remarkable cardioprotection in rats 
      subjected to MI/R as was evident in the reduction of ventricular premature beats 
      and in the incidence of ventricular tachycardia and fibrillation; they were 
      reduced dose dependently and correlated with survival of all rats treated with 
      the higher dose of NCX 4016. In these animals, infarct size was restricted 
      proportionally to the dose of NCX 4016 associated with diminution of both plasma 
      creatine phosphokinase and cardiac myeloperoxidase activities. ASA showed only a 
      minor degree of protection against MI/R damage. Rats treated with 
      N(G)-nitro-L-arginine methyl ester (L-NAME, 10 mg/kg) demonstrated aggravated 
      myocardial damage in terms of arrhythmias, mortality, and infarct size. 
      Supplementation of nitric oxide (NO) with NCX 4016 (100 mg/kg) greatly reduced 
      the worsening effect caused by L-NAME. The beneficial effects of NCX 4016 appear 
      to derive in large part from the NO moiety, which modulates a number of cellular 
      events leading to inflammation, obstruction of the coronary microcirculation, 
      arrhythmias, and myocardial necrosis.
FAU - Rossoni, G
AU  - Rossoni G
AD  - Department of Pharmacological Sciences, Chemotherapy and Medical Toxicology, 
      University of Milan, Via Vanelli 32, 20129 Milan, Italy. 
      guiseppe.rossoni@unimi.it
FAU - Manfredi, B
AU  - Manfredi B
FAU - Colonna, V D
AU  - Colonna VD
FAU - Bernareggi, M
AU  - Bernareggi M
FAU - Berti, F
AU  - Berti F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EC 2.7.3.2 (Creatine Kinase)
RN  - EH04H13L6B (nitroaspirin)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Animals
MH  - Arrhythmias, Cardiac/prevention & control
MH  - Aspirin/analogs & derivatives/*therapeutic use
MH  - Creatine Kinase/blood
MH  - Cyclic GMP/blood
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Hemodynamics/drug effects
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Myocardial Ischemia/*drug therapy
MH  - Myocardial Reperfusion
MH  - NG-Nitroarginine Methyl Ester/pharmacology
MH  - Peroxidase/blood
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Rats
MH  - Rats, Wistar
EDAT- 2001/03/22 10:00
MHDA- 2001/05/05 10:01
CRDT- 2001/03/22 10:00
PHST- 2001/03/22 10:00 [pubmed]
PHST- 2001/05/05 10:01 [medline]
PHST- 2001/03/22 10:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2001 Apr;297(1):380-7.

PMID- 11251355
OWN - NLM
STAT- MEDLINE
DCOM- 20010705
LR  - 20171116
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 30 Suppl 2
DP  - 2000
TI  - Low-molecular-weight heparin and other antithrombotic agents in the setting of a 
      primarily medical treatment of unstable coronary artery disease.
PG  - 122-7; discussion 106-7
AB  - Antithrombotic treatment of acute coronary syndromes (ACS) comprises aspirin and 
      (low-molecular-weight) heparin. Adjunctive treatment with intravenous 
      glycoprotein IIb/IIIa receptor antagonists may be used in high-risk individuals, 
      especially when they undergo percutaneous coronary interventions. Results from 
      large-scale trials studying the efficacy and safety of oral glycoprotein IIb/IIIa 
      blockers in patients with ACS have been disappointing. Thrombolytic therapy is 
      not indicated in ACS.
CI  - Copyright 2001 S. Karger AG, Basel
FAU - Verheugt, F W
AU  - Verheugt FW
AD  - Heartcenter, University Medical Center St. Radboud, Nijmegen, The Netherlands. 
      f.verheugt@cardio.azn.nl
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Administration, Oral
MH  - Angina, Unstable/drug therapy
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Contraindications
MH  - Coronary Disease/*drug therapy
MH  - Drug Therapy, Combination
MH  - Heparin/administration & dosage/adverse effects/therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Randomized Controlled Trials as Topic
MH  - Thrombolytic Therapy
RF  - 27
EDAT- 2001/03/17 10:00
MHDA- 2001/07/06 10:01
CRDT- 2001/03/17 10:00
PHST- 2001/03/17 10:00 [pubmed]
PHST- 2001/07/06 10:01 [medline]
PHST- 2001/03/17 10:00 [entrez]
AID - 54177 [pii]
AID - 10.1159/000054177 [doi]
PST - ppublish
SO  - Haemostasis. 2000;30 Suppl 2:122-7; discussion 106-7. doi: 10.1159/000054177.

PMID- 8198239
OWN - NLM
STAT- MEDLINE
DCOM- 19940630
LR  - 20190821
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 49
IP  - 1
DP  - 1994 Jan
TI  - Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocation 
      in aspirin-sensitive subjects.
PG  - 43-9
AB  - The ability of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) to 
      inhibit the cyclo-oxygenase which catalyzes formation of prostaglandins appears 
      to be central to the mechanisms involved in aspirin sensitivity. We have 
      investigated whether the plasma levels of acetylsalicylic acid (ASA) and its main 
      metabolite salicylic acid (SA) at the time of intolerance reactions correspond 
      with the concentrations required for enzyme inhibition in vitro. Twelve 
      aspirin-sensitive and 15 aspirin-tolerant subjects were followed during 
      provocation with aspirin. ASA and SA concentrations in plasma were determined by 
      HPLC. After oral provocation (up to 460 mg cumulative dose), the levels of ASA 
      and SA in plasma were equivalent in aspirin-sensitive and aspirin-tolerant 
      subjects. For the aspirin-sensitive subjects, at the time of adverse reaction, 
      the concentration range was 2.9-33.3 microM for ASA and 18.1-245 microM for SA. 
      Oral provocation with sodium salicylate yielding 10-fold higher SA levels did not 
      elicit intolerance reactions. Statistically significantly lower levels of ASA and 
      SA (P < or = 0.01) evoked airway obstruction, as compared with merely 
      extrapulmonary symptoms. Bronchial absorption of aspirin was found after 
      inhalation of lysine-aspirin and was comparable in asthmatic and nonasthmatic 
      subjects. In three aspirin-sensitive subjects who developed airway obstruction, 
      the plasma levels for ASA and SA were 0.9-2.6 microM and 0.0-6.7 microM, 
      respectively. In conclusion, the plasma levels of ASA reached at the time of a 
      positive reaction are of the magnitude known to inhibit cyclo-oxygenases. Neither 
      differences in bioavailability of ASA nor the formation of SA seems to contribute 
      to the aspirin-elicited reactions.
FAU - Dahlén, B
AU  - Dahlén B
AD  - Department of Thoracic Medicine, Karolinska Hospital, Stockholm, Sweden.
FAU - Boréus, L O
AU  - Boréus LO
FAU - Anderson, P
AU  - Anderson P
FAU - Andersson, R
AU  - Andersson R
FAU - Zetterström, O
AU  - Zetterström O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Free Radical Scavengers)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Airway Obstruction/blood/chemically induced/*immunology/physiopathology
MH  - Aspirin/*adverse effects/*blood/immunology
MH  - Asthma/blood/*immunology/physiopathology
MH  - *Bronchial Provocation Tests
MH  - Female
MH  - Forced Expiratory Volume
MH  - Free Radical Scavengers
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/*blood
MH  - Salicylic Acid
MH  - Sodium Salicylate/administration & dosage/immunology
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1994.tb00772.x [doi]
PST - ppublish
SO  - Allergy. 1994 Jan;49(1):43-9. doi: 10.1111/j.1398-9995.1994.tb00772.x.

PMID- 7229932
OWN - NLM
STAT- MEDLINE
DCOM- 19810720
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 1
DP  - 1981 Jan
TI  - Determination of drug stability in aspirin tablet formulations by high-pressure 
      liquid chromatography.
PG  - 64-7
AB  - Salicylic acid and aspirin were resolved from the other salicylates in thermally 
      degraded multicomponent tablets and determined quantitatively. The analytical 
      method involved wetting the powdered tablet with acetic acid and diluting with 
      chloroform to extract the drug components. Automated high-pressure liquid 
      chromatographic analyses of filtered extracts were performed on a silica column 
      with a mobile phase of acetic acid in heptane. The method was capable of 
      resolving the major thermally induced transformation products in tablet 
      formulations. It was sensitive to approximately 0.1 mg of salicylic acid/tablet. 
      Good agreement with the compendial method for free salicylic acid was obtained.
FAU - Taguchi, V Y
AU  - Taguchi VY
FAU - Cotton, M L
AU  - Cotton ML
FAU - Yates, C H
AU  - Yates CH
FAU - Millar, J F
AU  - Millar JF
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - Chemistry, Pharmaceutical
MH  - Chromatography, High Pressure Liquid
MH  - Drug Stability
MH  - Salicylates
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - S0022-3549(15)43556-7 [pii]
AID - 10.1002/jps.2600700112 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Jan;70(1):64-7. doi: 10.1002/jps.2600700112.

PMID- 20338720
OWN - NLM
STAT- MEDLINE
DCOM- 20100721
LR  - 20131121
IS  - 1769-6623 (Electronic)
IS  - 0750-7658 (Linking)
VI  - 29
IP  - 3
DP  - 2010 Mar
TI  - [Prevention of preeclampsia].
PG  - e31-5
LID - 10.1016/j.annfar.2010.02.014 [doi]
AB  - Aspirin has shown efficacy in preventing PE with a 10 % incidence reduction. The 
      treatment must be started between the 12(th) and 14(th) week of amenorrhea with a 
      dose of 75 to 160 mg once daily. This treatment is all the more effective as it 
      is given to a high risk population. The supplementation with 1,5 g of calcium per 
      day appears effective as well in the prevention of PE, especially in the 
      malnourished and young patents. Insufficient data is currently available to 
      recommend antioxidant supplementation. Low molecular weight heparin is 
      potentially beneficial in the prevention of PE, however its efficacy remains to 
      be demonstrated and indications determined. Nitric oxide (NO) or NO releasers are 
      not effective and can cause headaches. Diuretics reduce the birth weight without 
      improving the incidence of PE.
CI  - Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
FAU - Deruelle, P
AU  - Deruelle P
AD  - Pôle d'obstétrique, hôpital Jeanne-de-Flandre, CHRU de Lille, 59037 Lille cedex, 
      France. deruelle@chru-lille.fr
FAU - Girard, J-M
AU  - Girard JM
FAU - Coutty, N
AU  - Coutty N
FAU - Subtil, D
AU  - Subtil D
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Prévention de la prééclampsie.
DEP - 20100324
PL  - France
TA  - Ann Fr Anesth Reanim
JT  - Annales francaises d'anesthesie et de reanimation
JID - 8213275
RN  - 0 (Anticoagulants)
RN  - 0 (Antioxidants)
RN  - 0 (Calcium Compounds)
RN  - 0 (Diuretics)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticoagulants/therapeutic use
MH  - Antioxidants/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Calcium Compounds/therapeutic use
MH  - Diuretics/adverse effects/therapeutic use
MH  - Female
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Male
MH  - Malnutrition/complications
MH  - Nitric Oxide Donors/adverse effects/therapeutic use
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Risk
MH  - Young Adult
RF  - 52
EDAT- 2010/03/27 06:00
MHDA- 2010/07/22 06:00
CRDT- 2010/03/27 06:00
PHST- 2010/03/27 06:00 [entrez]
PHST- 2010/03/27 06:00 [pubmed]
PHST- 2010/07/22 06:00 [medline]
AID - S0750-7658(10)00064-X [pii]
AID - 10.1016/j.annfar.2010.02.014 [doi]
PST - ppublish
SO  - Ann Fr Anesth Reanim. 2010 Mar;29(3):e31-5. doi: 10.1016/j.annfar.2010.02.014. 
      Epub 2010 Mar 24.

PMID- 17440162
OWN - NLM
STAT- MEDLINE
DCOM- 20070430
LR  - 20220311
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Linking)
VI  - 99
IP  - 8
DP  - 2007 Apr 18
TI  - A large cohort study of long-term daily use of adult-strength aspirin and cancer 
      incidence.
PG  - 608-15
AB  - BACKGROUND: Epidemiologic evidence indicates that aspirin use is associated with 
      reduced risks of colon cancer and possibly several other cancers, including 
      prostate and breast cancers. Recent results from the Women's Health Study 
      randomized trial indicate that long-term use of low-dose aspirin (100 mg every 
      other day) does not substantially reduce cancer risk. However, the potential 
      effect of long-term daily use of higher doses of aspirin on cancer incidence 
      remains uncertain. METHODS: We examined associations between long-term daily use 
      of adult-strength aspirin (> or = 325 mg/day) and both overall cancer incidence 
      and incidence of 10 types of cancer among 69,810 men and 76,303 women 
      participating in the Cancer Prevention Study II Nutrition Cohort, a relatively 
      elderly population. Aspirin use was reported at enrollment in 1992-1993 and 
      updated in 1997, 1999, and 2001. Multivariable Cox proportional hazards 
      regression was used to calculate rate ratios (RRs). RESULTS: During follow-up 
      through June 2003, 10,931 men and 7196 women were diagnosed with cancer. 
      Long-term (> or = 5 years) daily use of adult-strength aspirin, compared with no 
      use, was associated with lower overall cancer incidence in men 
      (multivariable-adjusted RR = 0.84, 95% confidence interval [CI] = 0.76 to 0.93) 
      and non-statistically significantly lower overall cancer incidence in women 
      (multivariable-adjusted RR = 0.86, 95% CI = 0.73 to 1.03). Overall cancer 
      incidence per 100,000 person-years (standardized to the age distributions of men 
      and women in the study) with long-term daily aspirin use and no aspirin use was 
      1858 and 2163, respectively, among men and 1083 and 1169, respectively, among 
      women. Long-term daily aspirin use was associated with lower incidence of 
      colorectal cancer (RR = 0.68, 95% CI = 0.52 to 0.90 among men and women combined) 
      and prostate cancer (RR = 0.81, 95% CI = 0.70 to 0.94) and a non-statistically 
      significant lower risk of female breast cancer (RR = 0.83, 95% CI = 0.63 to 
      1.10). CONCLUSIONS: Long-term daily use of adult-strength aspirin may be 
      associated with modestly reduced overall cancer incidence in populations among 
      whom colorectal, prostate, and breast cancers are common.
FAU - Jacobs, Eric J
AU  - Jacobs EJ
AD  - Department of Epidemiology and Surveillance Research, American Cancer Society, 
      National Home Office, 1599 Clifton Rd NE, Atlanta, GA 30329, USA. 
      eric.jacobs@cancer.org
FAU - Thun, Michael J
AU  - Thun MJ
FAU - Bain, Elizabeth B
AU  - Bain EB
FAU - Rodriguez, Carmen
AU  - Rodriguez C
FAU - Henley, S Jane
AU  - Henley SJ
FAU - Calle, Eugenia E
AU  - Calle EE
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Natl Cancer Inst. 2007 Apr 18;99(8):582-3. PMID: 17440153
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Neoplasms/*epidemiology
MH  - Retrospective Studies
MH  - Time Factors
MH  - United States/epidemiology
EDAT- 2007/04/19 09:00
MHDA- 2007/05/01 09:00
CRDT- 2007/04/19 09:00
PHST- 2007/04/19 09:00 [pubmed]
PHST- 2007/05/01 09:00 [medline]
PHST- 2007/04/19 09:00 [entrez]
AID - 99/8/608 [pii]
AID - 10.1093/jnci/djk132 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2007 Apr 18;99(8):608-15. doi: 10.1093/jnci/djk132.

PMID- 17441704
OWN - NLM
STAT- MEDLINE
DCOM- 20070706
LR  - 20131121
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 50
IP  - 10
DP  - 2007 May 17
TI  - Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric 
      oxide-donating aspirin involves a quinone methide but not nitric oxide nor 
      aspirin.
PG  - 2424-31
AB  - Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and 
      biologists alike. It consists of ASA and a -ONO2 group connected through a spacer 
      and is in preclinical development as an antitumor drug. We report that, contrary 
      to current beliefs, neither ASA nor NO contributes to this antitumor effect. 
      Rather, an unsubstituted QM was identified as the sole cytotoxic agent. QM forms 
      from 1 after carboxylic ester hydrolysis and, in accordance with the HSAB theory, 
      selectively reacts with cellular GSH, which in turn triggers cell death. 
      Remarkably, a derivative lacking ASA and the -ONO2 group is 10 times more 
      effective than 1. Thus, our data provide a conclusive molecular mechanism for the 
      antitumor activity of 1. Equally importantly, we show for the first time that a 
      "presumed invisible" linker in a hybrid drug is not so invisible after all and is 
      in fact solely responsible for the biological effect.
FAU - Hulsman, Niels
AU  - Hulsman N
AD  - Laboratory for Experimental Oncology and Radiobiology, Academic Medical Center, 
      University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
FAU - Medema, Jan Paul
AU  - Medema JP
FAU - Bos, Carina
AU  - Bos C
FAU - Jongejan, Aldo
AU  - Jongejan A
FAU - Leurs, Rob
AU  - Leurs R
FAU - Smit, Martine J
AU  - Smit MJ
FAU - de Esch, Iwan J P
AU  - de Esch IJ
FAU - Richel, Dick
AU  - Richel D
FAU - Wijtmans, Maikel
AU  - Wijtmans M
LA  - eng
PT  - Journal Article
DEP - 20070419
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indolequinones)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - 138230-21-4 (quinone methide)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/chemical synthesis/chemistry/*pharmacology
MH  - Apoptosis
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cell Line, Tumor
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Indolequinones/chemical synthesis/chemistry/*pharmacology
MH  - Magnetic Resonance Spectroscopy
MH  - Nitric Oxide/*analogs & derivatives/chemical synthesis/chemistry/*pharmacology
MH  - Nitric Oxide Donors/chemical synthesis/chemistry/*pharmacology
MH  - Structure-Activity Relationship
EDAT- 2007/04/20 09:00
MHDA- 2007/07/07 09:00
CRDT- 2007/04/20 09:00
PHST- 2007/04/20 09:00 [pubmed]
PHST- 2007/07/07 09:00 [medline]
PHST- 2007/04/20 09:00 [entrez]
AID - 10.1021/jm061371e [doi]
PST - ppublish
SO  - J Med Chem. 2007 May 17;50(10):2424-31. doi: 10.1021/jm061371e. Epub 2007 Apr 19.

PMID- 12723895
OWN - NLM
STAT- MEDLINE
DCOM- 20040219
LR  - 20170214
IS  - 0960-3271 (Print)
IS  - 0960-3271 (Linking)
VI  - 22
IP  - 3
DP  - 2003 Mar
TI  - Potential adverse interaction between aspirin and lisinopril in hypertensive 
      rats.
PG  - 143-7
AB  - The potential clinical effect of aspirin (ASA) in patients treated with 
      angiotensin converting enzyme (ACE) inhibitors is debatable. Several studies have 
      suggested that ASA attenuates the beneficial effects of ACE inhibitors in 
      hypertension, congestive heart failure (CHF) or coronary artery disease (CAD) and 
      have questioned the safety of using ASA concomitantly with these agents. The 
      present study aims to investigate the possible interaction between ASA and ACE 
      inhibitor in hypertensive rats. Hypertension was induced in adult male Wistar 
      rats using Methylprednisolone (MP) 20 mg/kg per week s.c. for 2 weeks. The 
      systolic blood pressure (SBP) was measured by noninvasive BP technique. The 
      effect of Lisinopril (LS) 15 mg/kg per day and that of combination of LS and ASA; 
      100 and 25 mg/kg per day p.o. was studied on hypertension induced by 
      glucocorticoid. Concurrent ASA treatment with LS did not hinder the hypotensive 
      effect of LS at either dose. However ASA 100 mg/kg per day caused mortality in 
      animals and produced massive cardiac necrosis and renal damage as evident from 
      histopathology. Treatment with ASA 25 mg/kg per day caused lower mortality with 
      variable effects on cardiac and renal tissues. These results indicate that ASA 
      attenuates the beneficial effects of ACE inhibitor on survival in hypertensive 
      rats and this effect was more pronounced at higher dose of ASA.
FAU - Dubey, K
AU  - Dubey K
AD  - Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, Hamdard Nagar, 
      New Delhi 110 062, India. kdb104@rediffmail.com
FAU - Balani, D K
AU  - Balani DK
FAU - Pillai, K K
AU  - Pillai KK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Hum Exp Toxicol
JT  - Human & experimental toxicology
JID - 9004560
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - E7199S1YWR (Lisinopril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*pharmacology
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Body Weight/drug effects
MH  - Drug Antagonism
MH  - Hemodynamics/drug effects
MH  - Hypertension/*drug therapy/mortality/pathology
MH  - Kidney/pathology
MH  - Lisinopril/*pharmacology
MH  - Male
MH  - Myocardium/pathology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Survival Rate
EDAT- 2003/05/02 05:00
MHDA- 2004/02/20 05:00
CRDT- 2003/05/02 05:00
PHST- 2003/05/02 05:00 [pubmed]
PHST- 2004/02/20 05:00 [medline]
PHST- 2003/05/02 05:00 [entrez]
AID - 10.1191/0960327103ht331oa [doi]
PST - ppublish
SO  - Hum Exp Toxicol. 2003 Mar;22(3):143-7. doi: 10.1191/0960327103ht331oa.

PMID- 711034
OWN - NLM
STAT- MEDLINE
DCOM- 19790124
LR  - 20190827
IS  - 0015-5691 (Print)
IS  - 0015-5691 (Linking)
VI  - 74
IP  - 6
DP  - 1978 Sep
TI  - [Irritative activity of antiinflammatory agents, betamethasone 17-valerate, 
      beclomethasone 17, 21-dipropionate, betamethasone 17, 21-dipropionate, or 
      indomethacin on the gastrointestinal tract in rats and dogs (author's transl)].
PG  - 773-81
AB  - Irritative effects of three steroidal anti-inflammatory drugs on the 
      gastrointestinal tract of rats and dogs were determined. With either single or 
      repeated subcutaneous administration these drugs dose dependently irritated the 
      gastric mucosa of both species. The intestinal mucosa was less affected. 
      Concomitant oral administration of aspirin or subcutaneous administration of 
      indomethacin revealed an aggravation of aspirin-induced gastric ulcers by 
      betamethasone valerate and inhibition of indomethacin-induced intestinal ulcers 
      by beta-methasone dipropionate. These two steroidal drugs had no noxious effect 
      on healing of chronic gastric ulcers induced in rats and dogs. Betamethasone 
      valerate, however, delayed the healing of gastric ulcer in rats. Indomethacin, a 
      non-steroidal anti-inflammatory drug, also induced serious damage to the gastric 
      and intestinal mucosa both of rats and dogs. Indomethacin ingestion delayed the 
      healing of chronic gastric ulcer in rats but not in dogs. Since both steroidal 
      and non-steroidal drugs induce damage to the gastrointestinal tract, a careful 
      monitoring of the patients' complaints should be carried out when these compounds 
      are used as a systemic treatment. Steroidal drugs used in this study, however, 
      appear to be highly safe from the point of dose inasmuch as they are used as a 
      topical treatment.
FAU - Okabe, S
AU  - Okabe S
FAU - Tabata, K
AU  - Tabata K
FAU - Ishihara, Y
AU  - Ishihara Y
FAU - Kunimi, H
AU  - Kunimi H
FAU - Izumi, K
AU  - Izumi K
FAU - Uchida, N
AU  - Uchida N
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Yakurigaku Zasshi
JT  - Nihon yakurigaku zasshi. Folia pharmacologica Japonica
JID - 0420550
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Irritants)
RN  - 9842X06Q6M (Betamethasone)
RN  - 9IFA5XM7R2 (Betamethasone Valerate)
RN  - KGZ1SLC28Z (Beclomethasone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Beclomethasone/*adverse effects
MH  - Betamethasone/*adverse effects
MH  - Betamethasone Valerate/adverse effects
MH  - Chronic Disease
MH  - Digestive System/*drug effects
MH  - Dogs
MH  - Indomethacin/*adverse effects
MH  - *Irritants
MH  - Male
MH  - Rats
MH  - Stomach Ulcer/chemically induced
EDAT- 1978/09/01 00:00
MHDA- 1978/09/01 00:01
CRDT- 1978/09/01 00:00
PHST- 1978/09/01 00:00 [pubmed]
PHST- 1978/09/01 00:01 [medline]
PHST- 1978/09/01 00:00 [entrez]
AID - 10.1254/fpj.74.773 [doi]
PST - ppublish
SO  - Nihon Yakurigaku Zasshi. 1978 Sep;74(6):773-81. doi: 10.1254/fpj.74.773.

PMID- 35271236
OWN - NLM
STAT- MEDLINE
DCOM- 20220314
LR  - 20220314
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 122
IP  - 2
DP  - 2022
TI  - [Modern strategies of antithrombotic therapy in patients with multifocal 
      atherosclerosis].
PG  - 49-55
LID - 10.17116/jnevro202212202149 [doi]
AB  - The manuscript is devoted to the problem of selection of antithrombotic therapy 
      in the management of patients with multifocal atherosclerosis. The leading role 
      of cerebrovascular pathology in the structure of mortality and causes of 
      disability is noted. The questions of etiology and pathogenesis of acute 
      cerebrovascular accident are considered. The pathogenetic subtypes of ischemic 
      stroke and the criteria for their diagnosis were analyzed. The important role of 
      antithrombotic therapy in the prevention of noncardioembolic stroke is presented. 
      Considering the evidence-based medicine data based on the analysis of randomized 
      trials results, modern strategies of antithrombotic therapy were demonstrated. A 
      comparative analysis of the clinical trials results was carried out. New ideas 
      about the benefits of combination therapy with acetylsalicylic acid at a dose of 
      100 mg/day and with rivaroxaban 2.5 mg twice daily, established in the COMPASS 
      study, are presented.
FAU - Kucherenko, S S
AU  - Kucherenko SS
AUID- ORCID: 0000-0001-8258-094X
AD  - Sokolov North-Western District Scientific and Clinical Center, St. Petersburg, 
      Russia.
AD  - Almazov National Medical Research Center, St. Petersburg, Russia.
FAU - Alekseeva, T M
AU  - Alekseeva TM
AUID- ORCID: 0000-0002-4441-1165
AD  - Almazov National Medical Research Center, St. Petersburg, Russia.
LA  - rus
PT  - Journal Article
TT  - Sovremennye strategii antitromboticheskoi terapii pri mul'tifokal'nom 
      ateroskleroze.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Atherosclerosis/complications/drug therapy
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - *Stroke/drug therapy
OTO - NOTNLM
OT  - antithrombotic therapy
OT  - multifocal atherosclerosis
OT  - prevention of noncardioembolic ischemic stroke
EDAT- 2022/03/11 06:00
MHDA- 2022/03/15 06:00
CRDT- 2022/03/10 16:57
PHST- 2022/03/10 16:57 [entrez]
PHST- 2022/03/11 06:00 [pubmed]
PHST- 2022/03/15 06:00 [medline]
AID - 10.17116/jnevro202212202149 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(2):49-55. doi: 
      10.17116/jnevro202212202149.

PMID- 3701609
OWN - NLM
STAT- MEDLINE
DCOM- 19860613
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 75
IP  - 3
DP  - 1986 Mar
TI  - Comparison of gastrointestinal pH in dogs and humans: implications on the use of 
      the beagle dog as a model for oral absorption in humans.
PG  - 271-4
AB  - Gastrointestinal pH as a function of time was recorded for 4 beagle dogs and 10 
      human subjects using radiotelemetric pH measuring equipment. Results indicated 
      that in the quiescent phase, gastric pH in the dogs (mean = 1.8 +/- 0.07 SEM) was 
      significantly (p less than 0.05) higher than in humans (1.1 +/- 0.15). No 
      significant difference in the time for the pH monitoring device to empty from the 
      stomach was noted for the two species (99.8 +/- 27.2 min for dogs, 59.7 +/- 14.8 
      min for humans, p greater than 0.05). The fasting intestinal pH in dogs was 
      consistently higher than in humans, with an average canine intestinal pH of 7.3 
      +/- 0.09 versus 6.0 +/- 0.14 for humans. The implication of these observations 
      for extrapolation of drug absorption data from dogs to humans are discussed.
FAU - Lui, C Y
AU  - Lui CY
FAU - Amidon, G L
AU  - Amidon GL
FAU - Berardi, R R
AU  - Berardi RR
FAU - Fleisher, D
AU  - Fleisher D
FAU - Youngberg, C
AU  - Youngberg C
FAU - Dressman, J B
AU  - Dressman JB
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Capsules)
RN  - 0 (Pharmaceutical Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - J Pharm Sci 1986 Dec;75(12):1207
MH  - Animals
MH  - Aspirin/metabolism
MH  - Capsules
MH  - Digestive System/*metabolism
MH  - Dogs
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - *Intestinal Absorption
MH  - Male
MH  - Models, Biological
MH  - Permeability
MH  - Pharmaceutical Preparations/*metabolism
MH  - Rats
MH  - Species Specificity
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
AID - S0022-3549(15)47055-8 [pii]
AID - 10.1002/jps.2600750313 [doi]
PST - ppublish
SO  - J Pharm Sci. 1986 Mar;75(3):271-4. doi: 10.1002/jps.2600750313.

PMID- 1201124
OWN - NLM
STAT- MEDLINE
DCOM- 19760226
LR  - 20190717
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 18
IP  - 6 Suppl
DP  - 1975 Nov-Dec
TI  - Postsecretory reabsorption of urate in man.
PG  - 805-9
AB  - These results are consistent with a model for renal tubular transport of urate in 
      which there is reabsorption of both filtered and secreted urate. Urate secretion 
      greatly exceeds total urate excretion, and most secreted urate is reabsorbed. At 
      least a portion of urate reabsorption occurs at a site distal to or coextensive 
      with the urate secretory site. There appear to be at least two distinct 
      reabsorptive mechanisms for urate. The results of the flow rate and vasopressin 
      studies are consistent with the hypothesis that urate reabsorption occurs in both 
      the distal and the proximal tubule in man. The distal reabsorptive site appears 
      to be quite small. It may be passive since it does not appear to be inhibited by 
      uricosuric drugs. This reabsorptive site may account for less than 15% of total 
      urate reabsorption. Both volume expansion and probenecid may inhibit urate 
      absorption only in the proximal tubule. Thus reabsorption in the proximal tubule 
      coud account for more than 90% of total urate reabsorption. Reabsorption at the 
      postulated collecting duct reabsorptive site appears to be too small in magnitude 
      to account for all reabsorptions of secreted urate. This could be explained if 
      the reabsorptive site in the proximal tubule is coextensive with or distal to the 
      secretory site. Alternatively, there might be two reabsorptive sites in the 
      proximal tubule: a presecretory site accounting for the reabsorption of most 
      filtered urate, and a site either coextensive or distal to the secretory site 
      accounting for a major component of reabsorption of secreted urate. Finally urate 
      reabsorption would also take place in the collecting duct, perhaps at a passive, 
      flow-dependent site.
FAU - Diamond, H S
AU  - Diamond HS
FAU - Meisel, A D
AU  - Meisel AD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 268B43MJ25 (Uric Acid)
RN  - 2KNI5N06TI (Pyrazinamide)
RN  - PO572Z7917 (Probenecid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Humans
MH  - Kidney Tubules/drug effects/*metabolism
MH  - Probenecid/pharmacology
MH  - Pyrazinamide/pharmacology
MH  - Uric Acid/*metabolism
EDAT- 1975/11/01 00:00
MHDA- 1975/11/01 00:01
CRDT- 1975/11/01 00:00
PHST- 1975/11/01 00:00 [pubmed]
PHST- 1975/11/01 00:01 [medline]
PHST- 1975/11/01 00:00 [entrez]
AID - 10.1002/art.1780180725 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1975 Nov-Dec;18(6 Suppl):805-9. doi: 10.1002/art.1780180725.

PMID- 8697924
OWN - NLM
STAT- MEDLINE
DCOM- 19960905
LR  - 20140226
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 34
IP  - 9
DP  - 1995 Sep
TI  - [Effects of low dose aspirin on platelet function and prostaglandins metabolism 
      in systemic and coronary circulation in patients with ischemia heart disease].
PG  - 595-8
AB  - Eleven patients with ischemia heart disease (IHD) were treated with low dose 
      aspirin (ASA, 50mg/day) for more than two weeks (ASA group). 29 cases with IHD 
      not taking ASA served as patient control (NASA group) and 13 cases without IHD 
      not taking ASA as normal control. Blood samples for measurement of plasma (serum) 
      TXB2 and 6-keto-PGF1 alpha were simultaneously taken from aortic root (AO) and 
      coronary sinus (CS). The results showed: ASA group had lower plasma TXB2 level in 
      AO blood than NASA group (P < 0.05), but there was no significant difference in 
      plasma 6-keto-PGF1 alpha level between the two groups. Both of plasma and serum 
      TXB2/6-keto-PGF1 alpha ratios in AO blood in ASA group were significantly lower 
      than those in NASA group (P < 0.05 and P < 0.0005 respectively). Plasma TXB2 
      CS/AO ratio and 6-keto-PGF1 alpha CS/AO ratio in ASA group were significantly 
      lower than those in NASA group (P < 0.05), but not different from those in 
      control group. Both ASA and NASA groups had lower serum TXB2 CS/AO ratios than 
      control group (P < 0.05). The results suggest that low dose aspirin inhibits 
      selectively TXA2 synthesis in systemic circulation and inhibits synthesis and/or 
      release of TXA2 and PGI2 equally (no selectivity) in coronary circulation, but 
      could not completely inhibit intracoronary platelet activation.
FAU - Liu, H
AU  - Liu H
AD  - Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing.
FAU - Chen, Z
AU  - Chen Z
FAU - Gao, R
AU  - Gao R
LA  - chi
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Coronary Circulation/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/blood/*drug therapy/physiopathology
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Thromboxane B2/blood
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 1995 Sep;34(9):595-8.

PMID- 21946421
OWN - NLM
STAT- MEDLINE
DCOM- 20120503
LR  - 20131121
IS  - 1932-751X (Electronic)
IS  - 1932-7501 (Linking)
VI  - 32
IP  - 1
DP  - 2012 Jan-Feb
TI  - Aspirin for primary prevention of myocardial infarction: what is the evidence?
PG  - 1-8
LID - 10.1097/HCR.0b013e31822f1aa7 [doi]
AB  - BACKGROUND: Aspirin has been advocated as a primary prevention measure for 
      myocardial infarction (MI) for more than 2 decades. While several meta-analyses 
      have supported this view, others have differed. All these analyses have focused 
      on data from 6 major clinical trials. METHODS: We have provided a detailed 
      analysis of the methods used in the individual trials (n = 6) included in the 
      published meta-analyses. RESULTS: The major limitations of the meta-analyses 
      relate to inclusion of heterogeneous trials characterized by widely differing 
      study cohorts, absence of true control groups, lack of identification of silent 
      MIs, failure to specify type of stroke, and inadequate information on management 
      of conventional cardiac risk factors such as hypertension and hyperlipidemia. 
      These issues preclude meaningful conclusions on the effects of aspirin in primary 
      prevention of MI. CONCLUSIONS: This analysis does not support a general 
      recommendation for the use of aspirin for primary prevention of MI and also 
      suggests that effective management of risk factors in accordance with current 
      guidelines may attenuate any potential benefit from aspirin with respect to MI. 
      However, there may be a modest benefit in postmenopausal women with respect to 
      stroke.
FAU - Kappagoda, Tissa
AU  - Kappagoda T
AD  - Division of Cardiovascular Medicine, Department of Internal Medicine, University 
      of California, Davis, California, USA. ctkappagoda@ucdavis.edu
FAU - Amsterdam, Ezra
AU  - Amsterdam E
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - J Cardiopulm Rehabil Prev
JT  - Journal of cardiopulmonary rehabilitation and prevention
JID - 101291247
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention/*methods
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
EDAT- 2011/09/29 06:00
MHDA- 2012/05/04 06:00
CRDT- 2011/09/28 06:00
PHST- 2011/09/28 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2012/05/04 06:00 [medline]
AID - 10.1097/HCR.0b013e31822f1aa7 [doi]
PST - ppublish
SO  - J Cardiopulm Rehabil Prev. 2012 Jan-Feb;32(1):1-8. doi: 
      10.1097/HCR.0b013e31822f1aa7.

PMID- 9558275
OWN - NLM
STAT- MEDLINE
DCOM- 19980522
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 114
IP  - 5
DP  - 1998 May
TI  - Intractable upper gastrointestinal ulceration due to aspirin in patients who have 
      undergone surgery for peptic ulcer.
PG  - 883-92
AB  - BACKGROUND & AIMS: Postsurgical ulcer recurrence is a challenging problem. The 
      aim of this study was to define the role of aspirin in postsurgical ulcers. 
      METHODS: We studied 30 patients with postsurgical ulcer and aspirin abuse. 
      Preoperatively 13 had stenosis, 7 bleeding, and 7 perforation or penetration; 18 
      had undergone vagotomy and 11 gastrectomy. RESULTS: Of 30 patients, 15 admitted 
      long-term aspirin use (1-4 g/day), whereas 15 denied use but had positive 
      salicylate blood levels (15.1 +/- 2.25 mg/100 mL; >1 mmol/L). Gastrin or gastric 
      secretion was normal in the 24 patients tested. On follow-up, 3 (10%) healed 
      after surgery (all stopped taking aspirin), whereas 27 continued and had new 
      ulcers; 12 (44%) developed stenosis, and 6 (23%) developed bleeding. A second 
      operation was required in 16 patients who had continued aspirin abuse, which was 
      surreptitious in 10 (63%). Thirteen of these 16 had recurrent ulceration (7 [43%] 
      with stenosis and 1 with bleeding); 1 died and 2 stopped taking aspirin and 
      healed. A third operation was required in 8 patients. All had continued aspirin 
      abuse (75% surreptitiously), and all again had relapses (3 with stenosis); 1 
      underwent an unsuccessful fourth operation, and 3 died. CONCLUSIONS: With 
      continued aspirin abuse, recurrent ulceration is the rule, and complications, 
      especially stenosis, are common. Surreptitious aspirin abuse, if discovered, is a 
      clear contraindication to elective ulcer surgery, because aspirin-abuse 
      ulceration is incurable by gastric surgery.
FAU - Hirschowitz, B I
AU  - Hirschowitz BI
AD  - Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, 
      Birmingham, Alabama 35294-0007, USA.
FAU - Lanas, A
AU  - Lanas A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Humans
MH  - Intestinal Diseases/*chemically induced
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*surgery
MH  - *Postoperative Complications
MH  - Recurrence
MH  - Reoperation
MH  - Stomach Diseases/*chemically induced
MH  - Treatment Outcome
MH  - Ulcer/*chemically induced
EDAT- 1998/05/30 00:00
MHDA- 1998/05/30 00:01
CRDT- 1998/05/30 00:00
PHST- 1998/05/30 00:00 [pubmed]
PHST- 1998/05/30 00:01 [medline]
PHST- 1998/05/30 00:00 [entrez]
AID - S0016508598004247 [pii]
AID - 10.1016/s0016-5085(98)70307-5 [doi]
PST - ppublish
SO  - Gastroenterology. 1998 May;114(5):883-92. doi: 10.1016/s0016-5085(98)70307-5.

PMID- 21673005
OWN - NLM
STAT- MEDLINE
DCOM- 20111123
LR  - 20211020
IS  - 1468-2982 (Electronic)
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 31
IP  - 10
DP  - 2011 Jul
TI  - Migraine and cardiovascular disease in women and the role of aspirin: subgroup 
      analyses in the Women's Health Study.
PG  - 1106-15
LID - 10.1177/0333102411412628 [doi]
AB  - BACKGROUND: Migraine with aura (MA) has been associated with increased risk of 
      cardiovascular disease (CVD). The role of aspirin on this association remains 
      unclear. METHODS: Post-hoc subgroup analyses of the Women's Health Study, a 
      randomized trial testing 100 mg aspirin on alternate days in primary prevention 
      of CVD among 39,876 women aged ≥ 45. RESULTS: During 10 years, 998 major CVD 
      events were confirmed in 39,757 women with complete migraine information. Aspirin 
      reduced risk of ischaemic stroke (relative risk, RR, 0.76, 95% CI 0.63-0.93) but 
      not other CVD. Migraine or MA did not modify the effect of aspirin on CVD except 
      for myocardial infarction (MI) (p for interaction = 0.01). Women with MA on 
      aspirin had increased risk of MI (RR 3.72, 95% CI 1.39-9.95). Further exploratory 
      analyses indicate that this increased risk is only apparent among women with MA 
      on aspirin who ever smoked or had history of hypertension (p for 
      interaction<0.01). CONCLUSIONS: In post-hoc subgroup analyses, aspirin had 
      similar protective effects on ischaemic stroke for women with or without 
      migraine. By contrast, our data suggest that women with MA on aspirin had 
      increased risk of MI. The small number of outcome events in subgroups, the 
      exploratory nature of our analyses, and lack of plausible mechanisms raise the 
      possibility of a chance finding, which must caution the interpretation.
FAU - Kurth, Tobias
AU  - Kurth T
AD  - Brigham and Women's Hospital, USA. tkurth@rics.bwh.harvard.edu
FAU - Diener, Hans-Christoph
AU  - Diener HC
FAU - Buring, Julie E
AU  - Buring JE
LA  - eng
SI  - ClinicalTrials.gov/NCT00000479
GR  - R01 CA047988/CA/NCI NIH HHS/United States
GR  - R01 CA047988-21/CA/NCI NIH HHS/United States
GR  - R01 HL043851/HL/NHLBI NIH HHS/United States
GR  - R01 HL043851-10/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20110614
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*complications/*prevention & control
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Migraine with Aura/*complications
MH  - Primary Prevention/methods
MH  - Risk Factors
PMC - PMC3143294
MID - NIHMS299548
EDAT- 2011/06/16 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/06/16 06:00
PHST- 2011/06/16 06:00 [entrez]
PHST- 2011/06/16 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 0333102411412628 [pii]
AID - 10.1177/0333102411412628 [doi]
PST - ppublish
SO  - Cephalalgia. 2011 Jul;31(10):1106-15. doi: 10.1177/0333102411412628. Epub 2011 
      Jun 14.

PMID- 33023261
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 56
IP  - 10
DP  - 2020 Oct 2
TI  - Ticagrelor as an Alternative Antiplatelet Therapy in Cardiac Patients 
      Non-Sensitive to Aspirin.
LID - 10.3390/medicina56100519 [doi]
LID - 519
AB  - Background and Objectives: Aspirin (acetylsalicylic acid-ASA) is a first-line 
      antiplatelet therapy provided to patients with coronary artery disease (CAD). 
      However, it has been demonstrated that 20-30% of these patients are non-sensitive 
      to their ASA therapy. ASA non-sensitivity is a phenomenon where low-dose ASA 
      (81-325 mg) does not completely inhibit arachidonic-acid-induced platelet 
      aggregation, putting patients at risk of adverse cardio-thrombotic events. 
      Ticagrelor is a P2Y12 receptor inhibitor and alternative antiplatelet that has 
      been approved to reduce the risk of stroke, myocardial infarction, and overall 
      cardiovascular-related death. In this study, we aimed to identify ASA 
      non-sensitive patients and evaluate if they would be sensitive to ticagrelor. 
      Materials and Methods: For this pilot study, thirty-eight patients with CAD 
      taking 81 mg ASA were recruited. Blood samples were collected from each patient 
      and platelet rich plasma (PRP) from each sample was isolated. Light-transmission 
      aggregometry (LTA) was used to determine baseline ASA sensitivity in each patient 
      using 0.5 mg/mL arachidonic acid as a platelet agonist. Patients with ≥20% 
      maximal platelet aggregation after activation were considered ASA non-sensitive. 
      Fresh PRP samples from all patients were then spiked with a clinical dosage of 
      ticagrelor (3 μM-approximately equivalent to a loading dose of 180 mg 
      ticagrelor). Sensitivity was determined using LTA and 5 μM ADP as a platelet 
      agonist. Patients with ≥46% maximal platelet aggregation were considered 
      ticagrelor non-sensitive. Results: Of the 38 CAD patients taking 81 mg ASA, 32% 
      (12/38) were non-sensitive to their 81 mg ASA therapy. All 38 of the recruited 
      patients (100%) were sensitive to ticagrelor ex vivo. In conclusion, we were able 
      to identify ASA non-sensitivity using LTA and determine that ASA non-sensitive 
      patients were sensitive to ticagrelor. Conclusions: Our results suggest that 
      ticagrelor is a promising alternative therapy for patients who are non-sensitive 
      to ASA.
FAU - Khan, Hamzah
AU  - Khan H
AD  - Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON M5B 1W8, 
      Canada.
FAU - Gallant, Reid
AU  - Gallant R
AD  - Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute 
      of St. Michael's Hospital, Toronto, ON M5B 1W8, Canada.
FAU - Jain, Shubha
AU  - Jain S
AD  - Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON M5B 1W8, 
      Canada.
FAU - Al-Omran, Mohammed
AU  - Al-Omran M
AD  - Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON M5B 1W8, 
      Canada.
AD  - Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute 
      of St. Michael's Hospital, Toronto, ON M5B 1W8, Canada.
AD  - Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada.
FAU - De Mestral, Charles
AU  - De Mestral C
AD  - Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON M5B 1W8, 
      Canada.
AD  - Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute 
      of St. Michael's Hospital, Toronto, ON M5B 1W8, Canada.
AD  - Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada.
FAU - Greco, Elisa
AU  - Greco E
AD  - Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON M5B 1W8, 
      Canada.
AD  - Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada.
FAU - Wheatcroft, Mark
AU  - Wheatcroft M
AD  - Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON M5B 1W8, 
      Canada.
AD  - Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada.
FAU - Alazonni, Ashraf
AU  - Alazonni A
AD  - Division of Cardiology, Scarborough Health Network, Toronto, ON M1P 2T7, Canada.
FAU - Abdin, Rawand
AU  - Abdin R
AD  - Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada.
FAU - Rand, Margaret L
AU  - Rand ML
AD  - Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, 
      ON M5S 1A8, Canada.
AD  - Departments of Biochemistry and Pediatrics, University of Toronto, Toronto, ON 
      M5G 1X8, Canada.
AD  - Translational Medicine, Research Institute, Division of Haematology/Oncology, The 
      Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
FAU - Ni, Heyu
AU  - Ni H
AD  - Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute 
      of St. Michael's Hospital, Toronto, ON M5B 1W8, Canada.
AD  - Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, 
      ON M5S 1A8, Canada.
FAU - Qadura, Mohammad
AU  - Qadura M
AD  - Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON M5B 1W8, 
      Canada.
AD  - Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute 
      of St. Michael's Hospital, Toronto, ON M5B 1W8, Canada.
AD  - Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada.
LA  - eng
GR  - NA/Innovation Fund of the Alternative Funding Plan for the Academic Health 
      Sciences Centres of Ontario/
PT  - Journal Article
DEP - 20201002
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Humans
MH  - Pilot Projects
MH  - Platelet Aggregation
MH  - *Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Ticagrelor/pharmacology/therapeutic use
PMC - PMC7600331
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - aspirin
OT  - atherosclerosis
OT  - light-transmission aggregometry
OT  - non-sensitivity
OT  - personalized medicine
OT  - resistance
OT  - ticagrelor
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2020/10/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/07 01:02
PHST- 2020/08/26 00:00 [received]
PHST- 2020/09/22 00:00 [revised]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2020/10/07 01:02 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - medicina56100519 [pii]
AID - medicina-56-00519 [pii]
AID - 10.3390/medicina56100519 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2020 Oct 2;56(10):519. doi: 10.3390/medicina56100519.

PMID- 9387203
OWN - NLM
STAT- MEDLINE
DCOM- 19980120
LR  - 20131121
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 23
IP  - 5
DP  - 1997
TI  - Erythromelalgia and vascular complications in polycythemia vera.
PG  - 441-54
AB  - The vascular complications in patients with polycythemia vera are microvascular 
      circulatory disturbances typical of thrombocythemia including erythromelalgia, 
      peripheral ischemia, atypical cerebral ischemic attacks, and major arterial and 
      venous thrombotic events. These are positively related to hematocrits due to the 
      increased red cell mass and its concomitant increased whole blood viscosity. 
      Phlebotomy does not prevent the aspirin-responsive microcirculatory circulation 
      disturbances in polycythemia vera because thrombocythemia (platelet count > 400 x 
      10(9)/L) persists. The risk of major vascular ischemic episodes in poorly 
      controlled polycythemia vera at hematocrits between 0.45 and 0.50 is rather high. 
      The risk of vascular complications in polycythemia vera is best controlled by 
      maintaining the hematocrit at less than 0.45 and the platelet count below 400 x 
      10(9)/L. The microvascular syndrome associated with thrombocythemia in early 
      stage polycythemia vera in remission by phlebotomy is easily and best controlled 
      by low-dose aspirin (50 to 100 mg) or by selective reduction of platelet count to 
      normal with low-dose myelosuppressive agents. The potential leukemogenic 
      myelosuppressive agents busulfan and hydroxyurea and the nonleukemogenic cytosine 
      interferon-alpha have proven to be effective in the control of the proliferative 
      phase of polycythemia vera. However, data on the natural history of polycythemia 
      vera and the best treatment modality of the various stages of myeloproliferative 
      disease are still lacking.
FAU - Michiels, J J
AU  - Michiels JJ
AD  - Department of Clinical Hematology, Academic Medical Center, Amsterdam, The 
      Netherlands.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Erythromelalgia/*complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Polycythemia Vera/*complications
MH  - Vascular Diseases/*complications/drug therapy/prevention & control
RF  - 72
EDAT- 1997/01/01 00:00
MHDA- 1997/12/05 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/12/05 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1055/s-2007-996121 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 1997;23(5):441-54. doi: 10.1055/s-2007-996121.

PMID- 20303949
OWN - NLM
STAT- MEDLINE
DCOM- 20100817
LR  - 20131121
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 635
IP  - 1-3
DP  - 2010 Jun 10
TI  - Oral administration of ethanol with aspirin increases the concentration of 
      salicylic acid in plasma and organs, especially the brain, in mice.
PG  - 184-7
LID - 10.1016/j.ejphar.2010.02.046 [doi]
AB  - Aspirin (acetylsalicylic acid) has been widely used as an over-the-counter drug 
      to relieve pain throughout the world. In suicide attempts, aspirin is one of the 
      most common drugs taken in large quantities. The concentration of salicylic acid 
      shows a low-level distribution in the mouse brain, a site that may be critical 
      regarding the expression of symptoms (e.g. hyperpnea, coma, convulsion and 
      tremor) during acute aspirin toxicity. Therefore, it was suggested that 
      sensitivity to salicylic acid concerning acute toxicity was higher in the brain 
      than in other organs. Moreover, it is thought that it is common for aspirin and 
      ethanol to be ingested at the same time. Therefore, the present study was 
      designed to investigate the influence of ethanol on the distribution of salicylic 
      acid, which is a primary metabolite of aspirin, and its related metabolite, 
      salicyluric acid. The oral co-administration of aspirin (0.5g/kg) and ethanol 
      (2.5g/kg; 10ml/kg of 25% (w/v)) enhanced the concentrations of salicylic acid in 
      the plasma and organs, especially in the brain, compared with the aspirin 
      alone-treated group. On the other hand, ethanol did not influence the 
      concentrations of salicyluric acid in the plasma and kidney compared with the 
      aspirin alone-treated group. These results suggest that ethanol enhances aspirin 
      absorption from the gastrointestinal tract but has no influence on its 
      metabolism. Thus, it is dangerous to ingest the alcohol and aspirin at the same 
      time, as this may exacerbate the acute toxicity of aspirin.
FAU - Kato, Hideaki
AU  - Kato H
AD  - Department of Forensic Medicine, Graduate School of Medical Science, Kyoto 
      Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan.
FAU - Yoshimoto, Kanji
AU  - Yoshimoto K
FAU - Kobayashi, Masaki
AU  - Kobayashi M
FAU - Sakabe, Masaaki
AU  - Sakabe M
FAU - Funaki, Hironao
AU  - Funaki H
FAU - Ikegaya, Hiroshi
AU  - Ikegaya H
LA  - eng
PT  - Journal Article
DEP - 20100319
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 3K9958V90M (Ethanol)
RN  - 487-54-7 (salicylurate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage/metabolism/pharmacokinetics
MH  - Brain/*drug effects/*metabolism
MH  - Ethanol/*administration & dosage/*pharmacology
MH  - Hippurates/blood/metabolism/pharmacokinetics
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Salicylates/*blood/metabolism/*pharmacokinetics
MH  - Tissue Distribution/drug effects
EDAT- 2010/03/23 06:00
MHDA- 2010/08/18 06:00
CRDT- 2010/03/23 06:00
PHST- 2009/08/21 00:00 [received]
PHST- 2010/02/02 00:00 [revised]
PHST- 2010/02/24 00:00 [accepted]
PHST- 2010/03/23 06:00 [entrez]
PHST- 2010/03/23 06:00 [pubmed]
PHST- 2010/08/18 06:00 [medline]
AID - S0014-2999(10)00190-1 [pii]
AID - 10.1016/j.ejphar.2010.02.046 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2010 Jun 10;635(1-3):184-7. doi: 10.1016/j.ejphar.2010.02.046. 
      Epub 2010 Mar 19.

PMID- 37126817
OWN - NLM
STAT- MEDLINE
DCOM- 20230517
LR  - 20230525
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 176
IP  - 5
DP  - 2023 May
TI  - In limb or pelvic fracture, aspirin was noninferior to enoxaparin for reducing 
      all-cause death.
PG  - JC56
LID - 10.7326/J23-0024 [doi]
AB  - Major Extremity Trauma Research Consortium (METRC); O'Toole RV, Stein DM, O'Hara 
      NN, et al. Aspirin or low-molecular-weight heparin for thromboprophylaxis after a 
      fracture. N Engl J Med. 2023;388:203-213. 36652352.
FAU - Griffin, Michael
AU  - Griffin M
AD  - Liverpool Centre for Cardiovascular Science, University of Liverpool and 
      Liverpool Heart & Chest Hospital, Liverpool, England, UK (M.G., G.Y.L.).
FAU - Lip, Gregory Y H
AU  - Lip GYH
AD  - Liverpool Centre for Cardiovascular Science, University of Liverpool and 
      Liverpool Heart & Chest Hospital, Liverpool, England, UK (M.G., G.Y.L.).
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20230502
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Enoxaparin)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anticoagulants)
SB  - IM
CON - N Engl J Med. 2023 Jan 19;388(3):203-213. PMID: 36652352
MH  - Humans
MH  - Enoxaparin/adverse effects
MH  - Aspirin/therapeutic use
MH  - Anticoagulants/adverse effects
MH  - *Venous Thromboembolism/drug therapy/prevention & control
MH  - *Fractures, Bone/prevention & control
MH  - Extremities
COIS- Disclosures: The commentators have reported no disclosures of interest. Forms can 
      be viewed at 
      www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J23-0024.
EDAT- 2023/05/01 18:42
MHDA- 2023/05/17 06:42
CRDT- 2023/05/01 17:04
PHST- 2023/05/17 06:42 [medline]
PHST- 2023/05/01 18:42 [pubmed]
PHST- 2023/05/01 17:04 [entrez]
AID - 10.7326/J23-0024 [doi]
PST - ppublish
SO  - Ann Intern Med. 2023 May;176(5):JC56. doi: 10.7326/J23-0024. Epub 2023 May 2.

PMID- 34478054
OWN - NLM
STAT- MEDLINE
DCOM- 20211126
LR  - 20211126
IS  - 1558-822X (Electronic)
IS  - 1558-8211 (Linking)
VI  - 16
IP  - 5
DP  - 2021 Oct
TI  - Management Issues and Controversies in Low-Risk Patients with Essential 
      Thrombocythemia and Polycythemia Vera.
PG  - 473-482
LID - 10.1007/s11899-021-00649-x [doi]
AB  - PURPOSE OF REVIEW: Essential thrombocythemia (ET) and polycythemia vera (PV) are 
      the most common myeloproliferative neoplasms (MPNs). Treatment of ET and PV is 
      based on the risk for subsequent thrombosis. High-risk patients, defined as older 
      than 60, JAK2 V617F-positive patients, or patients with a history of prior 
      thrombosis, merit cytoreduction to control blood counts, whereas a watchful 
      waiting paradigm is utilized in low-risk patients. However, low-risk patients 
      have a host of other specific management issues that arise during their disease 
      course. This review will discuss the most common management issues specific to 
      the care of low-risk patients, including anti-platelet therapy dosing, pregnancy, 
      and indications for early cytoreduction. RECENT FINDINGS: Although low-dose 
      aspirin is well established in PV, its indications and dosing regimens are less 
      clear in ET. Recent evidence has supported twice daily low-dose aspirin in ET and 
      observation alone in very low-risk ET patients. Pregnancy is not contraindicated 
      in MPNs, and we recommend aspirin throughout pregnancy with consideration for 
      prophylactic postpartum anticoagulation. High phlebotomy needs, symptom burden, 
      and extreme thrombocytosis are common reasons for initiation of cytoreduction in 
      low-risk patients, although we typically do not start cytoreduction for an 
      isolated high platelet count alone. Recent data has also demonstrated a potential 
      disease-modifying effect of interferons in MPNs, with some experts now advocating 
      the early use of interferon in low-risk patients, although more mature data is 
      needed before practice guidelines change. We evaluate the literature to inform 
      clinical decision-making regarding these controversies, including most recent 
      data that has challenged the "watchful waiting" paradigm. Our discussion provides 
      guidance on common clinical scenarios seen in low-risk ET and PV patients, who 
      face a myriad of complex management decisions in their care.
CI  - © 2021. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - How, Joan
AU  - How J
AD  - Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical 
      School, Zero Emerson, Office 138, Boston, MA, 02114, USA.
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital, 
      Harvard Medical School, Boston, MA, 02115, USA.
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical 
      School, Boston, MA, 02115, USA.
FAU - Hobbs, Gabriela
AU  - Hobbs G
AD  - Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical 
      School, Zero Emerson, Office 138, Boston, MA, 02114, USA. ghobbs@partners.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210903
PL  - United States
TA  - Curr Hematol Malig Rep
JT  - Current hematologic malignancy reports
JID - 101262565
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Disease Management
MH  - Female
MH  - Humans
MH  - Phlebotomy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Polycythemia Vera/*therapy
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/therapy
MH  - Thrombocythemia, Essential/*therapy
OTO - NOTNLM
OT  - Essential thrombocythemia
OT  - Low-risk
OT  - Myeloproliferative neoplasm
OT  - Polycythemia vera
EDAT- 2021/09/04 06:00
MHDA- 2021/11/27 06:00
CRDT- 2021/09/03 12:32
PHST- 2021/06/02 00:00 [accepted]
PHST- 2021/09/04 06:00 [pubmed]
PHST- 2021/11/27 06:00 [medline]
PHST- 2021/09/03 12:32 [entrez]
AID - 10.1007/s11899-021-00649-x [pii]
AID - 10.1007/s11899-021-00649-x [doi]
PST - ppublish
SO  - Curr Hematol Malig Rep. 2021 Oct;16(5):473-482. doi: 10.1007/s11899-021-00649-x. 
      Epub 2021 Sep 3.

PMID- 28634365
OWN - NLM
STAT- MEDLINE
DCOM- 20181231
LR  - 20181231
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 7
IP  - 1
DP  - 2017 Jun 20
TI  - Different levels of blood pressure, different benefit from dual antiplatelet 
      therapy in minor stroke or TIA patients.
PG  - 3884
LID - 10.1038/s41598-017-04169-8 [doi]
LID - 3884
AB  - The study aimed to evaluate whether the benefits of dual antiplatelet therapy 
      would be influenced by blood pressure (BP) levels, among acute minor stroke or 
      transient ischemic attack (TIA). In CHANCE (Clopidogrel in High-Risk Patients 
      with Acute Nondisabling cerebrovascular Events) trail, Patients were stratified 
      by systolic BP (SBP) and diastolic BP (DBP) level measured on admission, 
      respectively, using the supine position BP within 24 hours after symptoms onset. 
      The primary efficacy outcome was stroke recurrence, bleeding was the safety 
      outcome. Patients with SBP ≥ 140 mmHg, dual antiplatelet treatment could reduce 
      the risk of stroke recurrence significantly (HR 0.654, 95% CI 0.529-0.793, 
      p < 0.001) than mono antiplatelet therapy. And patients with DBP ≥ 90 mmHg, 
      clopidogrel-aspirin significantly reduced the risk of recurrent stroke (HR 0.588, 
      95% CI 0.463-0.746, p < 0.001), compared with aspirin alone. However, in patients 
      with SBP < 140 mmHg or DBP < 90 mmHg, no significant difference was observed 
      between clopidogrel plus aspirin and aspirin alone. there was no difference in 
      bleeding episodes by treatment assignment across categories of SBP or DBP. 
      Patients with SBP ≥ 140 mmHg or DBP ≥ 90 mmHg after minor stroke or TIA got more 
      benefits from dual antiplatelet therapy. Bleeding risk from dual antiplatelet 
      treatment did not increase among patients with higher BP level on admission.
FAU - Xu, Jie
AU  - Xu J
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Tao, Yongli
AU  - Tao Y
AD  - Department of Neurology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, Henan, China.
FAU - Li, Hao
AU  - Li H
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Gu, Hongqiu
AU  - Gu H
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Xie, Xuewei
AU  - Xie X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Meng, Xia
AU  - Meng X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China.
FAU - Xu, Yuming
AU  - Xu Y
AD  - Department of Neurology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, Henan, China.
FAU - Wang, Yilong
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China. yilong528@aliyun.com.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China. yilong528@aliyun.com.
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China. yongjunwang111@aliyun.com.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      China. yongjunwang111@aliyun.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170620
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Clopidogrel/administration & dosage/adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*blood/diagnosis/*physiopathology
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Proportional Hazards Models
MH  - Stroke/diagnosis/*etiology/*physiopathology
MH  - Treatment Outcome
PMC - PMC5478626
COIS- The authors declare that they have no competing interests.
EDAT- 2017/06/22 06:00
MHDA- 2019/01/01 06:00
CRDT- 2017/06/22 06:00
PHST- 2016/11/25 00:00 [received]
PHST- 2017/05/11 00:00 [accepted]
PHST- 2017/06/22 06:00 [entrez]
PHST- 2017/06/22 06:00 [pubmed]
PHST- 2019/01/01 06:00 [medline]
AID - 10.1038/s41598-017-04169-8 [pii]
AID - 4169 [pii]
AID - 10.1038/s41598-017-04169-8 [doi]
PST - epublish
SO  - Sci Rep. 2017 Jun 20;7(1):3884. doi: 10.1038/s41598-017-04169-8.

PMID- 8210928
OWN - NLM
STAT- MEDLINE
DCOM- 19931101
LR  - 20131121
VI  - 40
IP  - 3
DP  - 1993 May-Jun
TI  - [Asthma induced by aspirin and arachidonic acid metabolites. I. In search of 
      answers to an enigma (first part)].
PG  - 54-9
AB  - Acetylsalicylic acid, one of the most commonly used drugs and high on the list of 
      causes of drug reactions. Since early publication on 1902 by Hirschberg, a great 
      deal of information has emerged on aspirin sensitivity, including data on 
      epidemiology, further characterization of the two major subtypes of sensitivity 
      (bronchospastic and urticarial types), hereditary aspects, cross-reactions to 
      other nonsteroidal antiinflammatory drugs, and methods of desensitization. 
      Although the pathogenesis of aspirin-sensitive asthma remains unknown, several 
      theories has been proposed to explain the disease enigma.
FAU - Salazar Villa, R M
AU  - Salazar Villa RM
AD  - Div. Allergy & Immunology, Scripps Clinic & Research Foundation, La Jolla, CA.
FAU - Zambrano Villa, S
AU  - Zambrano Villa S
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Asma inducida por aspirina y metabolitos del ácido araquidónico. I. En busca de 
      respuestas a un enigma (primera parte).
PL  - Mexico
TA  - Rev Alerg
JT  - Revista alergia : organo oficial de la Sociedad Mexicana de Alergia e Inmunlogia
JID - 9317222
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid/*adverse effects/*metabolism
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced
MH  - Humans
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
PST - ppublish
SO  - Rev Alerg. 1993 May-Jun;40(3):54-9.

PMID- 26815583
OWN - NLM
STAT- MEDLINE
DCOM- 20181106
LR  - 20181106
IS  - 1603-6824 (Electronic)
IS  - 0041-5782 (Linking)
VI  - 178
IP  - 3
DP  - 2016 Jan 18
TI  - [Antiphospholipid syndrome and pregnancy].
PG  - V09150730
LID - V09150730 [pii]
AB  - Antiphospholipid syndrome (APS) is the association of antiphospholipid antibodies 
      with thromboses and/or obstetric morbidity. Obstetric morbidity includes 
      recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, 
      premature birth and fetal growth restriction. Although current treatment regimens 
      including aspirin and low-molecular weight heparin have improved pregnancy 
      outcomes, 30% of affected women have pregnancy complica-tions. Women with APS are 
      therefore high-risk pregnancies who should be monitored in specialist centres 
      according to international standards.
FAU - Schreiber, Karen
AU  - Schreiber K
FAU - Lykke, Jacob Alexander
AU  - Lykke JA
FAU - Langhoff-Roos, Jens
AU  - Langhoff-Roos J
FAU - Nielsen, Henriette Svarre
AU  - Nielsen HS
FAU - Jacobsen, Søren
AU  - Jacobsen S
AD  - sj@dadlnet.dk.
LA  - dan
PT  - Journal Article
PT  - Review
TT  - Antifosfolipidsyndrom og graviditet.
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - 0 (Anticoagulants)
RN  - 0 (Antimalarials)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Antimalarials/therapeutic use
MH  - Antiphospholipid Syndrome/classification/*complications/drug therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*etiology
MH  - Pregnancy, High-Risk
EDAT- 2016/01/28 06:00
MHDA- 2018/11/07 06:00
CRDT- 2016/01/28 06:00
PHST- 2016/01/28 06:00 [entrez]
PHST- 2016/01/28 06:00 [pubmed]
PHST- 2018/11/07 06:00 [medline]
AID - V09150730 [pii]
PST - ppublish
SO  - Ugeskr Laeger. 2016 Jan 18;178(3):V09150730.

PMID- 2706976
OWN - NLM
STAT- MEDLINE
DCOM- 19890605
LR  - 20131121
IS  - 0010-6178 (Print)
IS  - 0010-6178 (Linking)
VI  - 53
IP  - 1
DP  - 1989 Jan
TI  - Reye's syndrome in an adult.
PG  - 3-5
AB  - There have been over 3,500 cases of Reye's syndrome reported to the CDC since 
      1973. The temporal use of aspirin with a prodromal viral illness has been 
      statistically associated with the etiology of the syndrome. Reye's syndrome 
      presents as an acute progressive encephalopathy with varying levels of coma and 
      normal cerebrospinal fluid (CSF). Hepatic transaminases are elevated, and the 
      serum aspartate aminotransaminase (AST) is usually elevated three to 30 times 
      normal. Histological changes on liver biopsy are characterized by microvesicular 
      intrahepatocyte lipid deposition, which is rarely found in other diseases. The 
      syndrome has rarely been reported to occur in adults over 18 years old. We report 
      the 25th case of Reye's syndrome occurring in an adult, which initially presented 
      as acetominophen toxicity but was shown to be Reye's syndrome on histological 
      examination of the liver.
FAU - Eagel, B A
AU  - Eagel BA
FAU - Vinoski, B
AU  - Vinoski B
FAU - Krugman, D
AU  - Krugman D
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Conn Med
JT  - Connecticut medicine
JID - 0372745
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aspirin/*poisoning
MH  - Diagnosis, Differential
MH  - Humans
MH  - Liver/pathology
MH  - Male
MH  - Reye Syndrome/*pathology
MH  - Suicide
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Conn Med. 1989 Jan;53(1):3-5.

PMID- 32865376
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20210401
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 383
IP  - 15
DP  - 2020 Oct 8
TI  - Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve 
      Implantation.
PG  - 1447-1457
LID - 10.1056/NEJMoa2017815 [doi]
AB  - BACKGROUND: The effect of single as compared with dual antiplatelet treatment on 
      bleeding and thromboembolic events after transcatheter aortic-valve implantation 
      (TAVI) in patients who do not have an indication for long-term anticoagulation 
      has not been well studied. METHODS: In a randomized, controlled trial, we 
      assigned a subgroup of patients who were undergoing TAVI and did not have an 
      indication for long-term anticoagulation, in a 1:1 ratio, to receive aspirin 
      alone or aspirin plus clopidogrel for 3 months. The two primary outcomes were all 
      bleeding (including minor, major, and life-threatening or disabling bleeding) and 
      non-procedure-related bleeding over a period of 12 months. Most bleeding at the 
      TAVI puncture site was counted as non-procedure-related. The two secondary 
      outcomes were a composite of death from cardiovascular causes, 
      non-procedure-related bleeding, stroke, or myocardial infarction (secondary 
      composite 1) and a composite of death from cardiovascular causes, ischemic 
      stroke, or myocardial infarction (secondary composite 2) at 1 year, with both 
      outcomes tested sequentially for noninferiority (noninferiority margin, 7.5 
      percentage points) and superiority. RESULTS: A total of 331 patients were 
      assigned to receive aspirin alone and 334 were assigned to receive aspirin plus 
      clopidogrel. A bleeding event occurred in 50 patients (15.1%) receiving aspirin 
      alone and in 89 (26.6%) receiving aspirin plus clopidogrel (risk ratio, 0.57; 95% 
      confidence interval [CI], 0.42 to 0.77; P = 0.001). Non-procedure-related 
      bleeding occurred in 50 patients (15.1%) and 83 patients (24.9%), respectively 
      (risk ratio, 0.61; 95% CI, 0.44 to 0.83; P = 0.005). A secondary composite 1 
      event occurred in 76 patients (23.0%) receiving aspirin alone and in 104 (31.1%) 
      receiving aspirin plus clopidogrel (difference, -8.2 percentage points; 95% CI 
      for noninferiority, -14.9 to -1.5; P<0.001; risk ratio, 0.74; 95% CI for 
      superiority, 0.57 to 0.95; P = 0.04). A secondary composite 2 event occurred in 
      32 patients (9.7%) and 33 patients (9.9%), respectively (difference, -0.2 
      percentage points; 95% CI for noninferiority, -4.7 to 4.3; P = 0.004; risk ratio, 
      0.98; 95% CI for superiority, 0.62 to 1.55; P = 0.93). A total of 44 patients 
      (13.3%) and 32 (9.6%), respectively, received oral anticoagulation during the 
      trial. CONCLUSIONS: Among patients undergoing TAVI who did not have an indication 
      for oral anticoagulation, the incidence of bleeding and the composite of bleeding 
      or thromboembolic events at 1 year were significantly less frequent with aspirin 
      than with aspirin plus clopidogrel administered for 3 months. (Funded by the 
      Netherlands Organization for Health Research and Development; POPular TAVI EU 
      Clinical Trials Register number, 2013-003125-28; ClinicalTrials.gov number, 
      NCT02247128.).
CI  - Copyright © 2020 Massachusetts Medical Society.
FAU - Brouwer, Jorn
AU  - Brouwer J
AUID- ORCID: 0000-0002-7815-1031
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Nijenhuis, Vincent J
AU  - Nijenhuis VJ
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Delewi, Ronak
AU  - Delewi R
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Hermanides, Renicus S
AU  - Hermanides RS
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Holvoet, Wouter
AU  - Holvoet W
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Dubois, Christophe L F
AU  - Dubois CLF
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Frambach, Peter
AU  - Frambach P
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - De Bruyne, Bernard
AU  - De Bruyne B
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - van Houwelingen, Gert K
AU  - van Houwelingen GK
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Van Der Heyden, Jan A S
AU  - Van Der Heyden JAS
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Toušek, Petr
AU  - Toušek P
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - van der Kley, Frank
AU  - van der Kley F
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Buysschaert, Ian
AU  - Buysschaert I
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Schotborgh, Carl E
AU  - Schotborgh CE
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Ferdinande, Bert
AU  - Ferdinande B
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - van der Harst, Pim
AU  - van der Harst P
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Roosen, John
AU  - Roosen J
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Peper, Joyce
AU  - Peper J
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Thielen, Frederick W F
AU  - Thielen FWF
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Veenstra, Leo
AU  - Veenstra L
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Chan Pin Yin, Dean R P P
AU  - Chan Pin Yin DRPP
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Swaans, Martin J
AU  - Swaans MJ
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Rensing, Benno J W M
AU  - Rensing BJWM
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - van 't Hof, Arnoud W J
AU  - van 't Hof AWJ
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Timmers, Leo
AU  - Timmers L
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Kelder, Johannes C
AU  - Kelder JC
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Stella, Pieter R
AU  - Stella PR
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Baan, Jan
AU  - Baan J
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
FAU - Ten Berg, Jurriën M
AU  - Ten Berg JM
AD  - From the Department of Cardiology, St. Antonius Hospital, Nieuwegein (J. Brouwer, 
      V.J.N., J.P., D.R.P.P.C.P.Y., M.J.S., B.J.W.M.R., L.T., J.C.K., J.M.B.), the 
      Department of Cardiology, Amsterdam University Medical Center, Amsterdam (R.D., 
      J. Baan), the Department of Cardiology, Isala Hospital, Zwolle (R.S.H.), the 
      Department of Cardiology, Maastricht University Medical Center (W.H., L.V., 
      A.W.J.H.) and the Cardiovascular Research Institute Maastricht (A.W.J.H., 
      J.M.B.), Maastricht, the Department of Cardiology, Medisch Spectrum Twente, 
      Enschede (G.K.H.), the Department of Cardiology, Leiden University Medical 
      Center, Leiden (F.K.), the Department of Cardiology, Haga Hospital, The Hague 
      (C.E.S.), the Department of Cardiology, University Medical Center Groningen, 
      Groningen (P.H.), Erasmus School of Health Policy and Management, Erasmus 
      University, Rotterdam (F.W.F.T.), the Department of Cardiology, Zuyderland 
      Medical Center, Heerlen (A.W.J.H.), and the Department of Cardiology, Division of 
      Heart and Lungs, University Medical Center Utrecht, Utrecht University, Utrecht 
      (P.R.S.) - all in the Netherlands; the Department of Cardiology, University 
      Hospital Leuven, Leuven (C.L.F.D.), Cardiovascular Center Aalst, Onze Lieve 
      Vrouwe Clinic (B.D.B.), and the Department of Cardiology, Algemeen Stedelijk 
      Hospital Aalst (I.B.), Aalst, the Department of Cardiology, Sint-Jan Hospital, 
      Brugge (J.A.S.V.D.H.), the Department of Cardiology, Hospital Oost-Limburg, Genk 
      (B.F.), and the Department of Cardiology, Imelda Hospital, Bonheiden (J.R.) - all 
      in Belgium; the Department of Cardiology, Institut National de Chirurgie 
      Cardiaque et de Cardiologie Interventionnelle, Luxembourg, Luxembourg (P.F.); and 
      the Department of Cardiology, University Hospital Královské Vinohrady and Third 
      Medical Faculty, Charles University, Prague, Czech Republic (P.T.).
LA  - eng
SI  - EudraCT/2013-003125-28
SI  - ClinicalTrials.gov/NCT02247128
PT  - Equivalence Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200830
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Nat Rev Cardiol. 2020 Nov;17(11):679. PMID: 32913309
CIN - Eur Heart J. 2020 Dec 1;41(45):4301-4302. PMID: 33099597
CIN - N Engl J Med. 2021 Jan 7;384(1):89-90. PMID: 33406345
CIN - N Engl J Med. 2021 Jan 7;384(1):90. PMID: 33406346
CIN - N Engl J Med. 2021 Jan 7;384(1):90. PMID: 33406347
CIN - Ann Intern Med. 2021 Feb;174(2):JC21. PMID: 33524286
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/mortality
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Postoperative Period
MH  - Thrombosis/epidemiology/*prevention & control
MH  - *Transcatheter Aortic Valve Replacement
EDAT- 2020/09/01 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
PHST- 2020/09/01 06:00 [entrez]
AID - 10.1056/NEJMoa2017815 [doi]
PST - ppublish
SO  - N Engl J Med. 2020 Oct 8;383(15):1447-1457. doi: 10.1056/NEJMoa2017815. Epub 2020 
      Aug 30.

PMID- 25374889
OWN - NLM
STAT- MEDLINE
DCOM- 20150702
LR  - 20220408
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2014
DP  - 2014
TI  - The prognostic impact of high on-treatment platelet reactivity with aspirin or 
      ADP receptor antagonists: systematic review and meta-analysis.
PG  - 610296
LID - 10.1155/2014/610296 [doi]
LID - 610296
AB  - OBJECTIVE: Negative results of recent randomized clinical trials testing the 
      hypothesis of target therapy for patients with high on-treatment platelet 
      reactivity (HOPR) have questioned its independent impact on clinical outcomes. 26 
      studies with 28.178 patients were included, with a median age of 66.8 (64-68) and 
      22.7% (22.4-27.8), of female gender. After a median follow-up of 1 year (0.1-1), 
      cardiac adverse events occurred in 8.3% (3-11; all results are reported as median 
      and interquartile range) of patients. Pooling all studies together, on-treatment 
      platelet reactivity significantly increased the risk of adverse events (OR 1.33 
      [1.09, 1.64], I(2) = 0%). However, a sensitivity analysis showed that HOPR did 
      not increase the risk of adverse events for patients with ACS, AMI, or stable 
      angina as well as patients resistant to aspirin, ADP antagonists, or both. For 
      all studies, publication bias was formally evident; after adjusting for this, 
      HOPR did not significantly increase adverse cardiac events (OR 1.1 : 0.89-1.22, 
      I(2) 0%). CONCLUSIONS: After adjusting for clinical confounders (like risk 
      factors and clinical presentation) and for relevant publication bias, HOPR was 
      not an independent prognostic indicator in unselected patients with both stable 
      and unstable coronary disease for an adverse cardiac event. The clinical 
      importance of HOPR for high-risk populations remains to be assessed.
FAU - D'Ascenzo, Fabrizio
AU  - D'Ascenzo F
AD  - Department of Internal Medicine, Division of Cardiology, Città Della Salute e 
      Della Scienza, Turin, Italy.
FAU - Barbero, Umberto
AU  - Barbero U
AD  - Department of Internal Medicine, Division of Cardiology, Città Della Salute e 
      Della Scienza, Turin, Italy.
FAU - Bisi, Marta
AU  - Bisi M
AD  - Department of Internal Medicine, Division of Cardiology, Città Della Salute e 
      Della Scienza, Turin, Italy.
FAU - Moretti, Claudio
AU  - Moretti C
AD  - Department of Internal Medicine, Division of Cardiology, Città Della Salute e 
      Della Scienza, Turin, Italy.
FAU - Omedè, Pierluigi
AU  - Omedè P
AD  - Department of Internal Medicine, Division of Cardiology, Città Della Salute e 
      Della Scienza, Turin, Italy.
FAU - Cerrato, Enrico
AU  - Cerrato E
AD  - Department of Internal Medicine, Division of Cardiology, Città Della Salute e 
      Della Scienza, Turin, Italy.
FAU - Quadri, Giorgio
AU  - Quadri G
AD  - Department of Internal Medicine, Division of Cardiology, Città Della Salute e 
      Della Scienza, Turin, Italy.
FAU - Conrotto, Federico
AU  - Conrotto F
AUID- ORCID: 0000-0002-5402-6826
AD  - Department of Internal Medicine, Division of Cardiology, Città Della Salute e 
      Della Scienza, Turin, Italy.
FAU - Zoccai, Giuseppe Biondi
AU  - Zoccai GB
AD  - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University 
      of Rome, Latina, Italy.
FAU - DiNicolantonio, James J
AU  - DiNicolantonio JJ
AD  - Mid America Heart Institute at Saint Luke's Hospital, Kansas City, MO, USA.
FAU - Gasparini, Mauro
AU  - Gasparini M
AD  - Politecnico of Turin, Turin, Italy.
FAU - Bangalore, Sripal
AU  - Bangalore S
AD  - New York University School of Medicine, New York, NY, USA.
FAU - Gaita, Fiorenzo
AU  - Gaita F
AD  - Department of Internal Medicine, Division of Cardiology, Città Della Salute e 
      Della Scienza, Turin, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20141013
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Prognosis
MH  - Purinergic P2Y Receptor Antagonists/*pharmacology
MH  - Treatment Outcome
PMC - PMC4211328
EDAT- 2014/11/07 06:00
MHDA- 2015/07/03 06:00
CRDT- 2014/11/07 06:00
PHST- 2014/02/15 00:00 [received]
PHST- 2014/06/26 00:00 [revised]
PHST- 2014/06/26 00:00 [accepted]
PHST- 2014/11/07 06:00 [entrez]
PHST- 2014/11/07 06:00 [pubmed]
PHST- 2015/07/03 06:00 [medline]
AID - 10.1155/2014/610296 [doi]
PST - ppublish
SO  - Biomed Res Int. 2014;2014:610296. doi: 10.1155/2014/610296. Epub 2014 Oct 13.

PMID- 7922363
OWN - NLM
STAT- MEDLINE
DCOM- 19941118
LR  - 20190728
IS  - 0960-9822 (Print)
IS  - 0960-9822 (Linking)
VI  - 4
IP  - 5
DP  - 1994 May 1
TI  - Prostaglandin synthase. At the heart of the matter.
PG  - 452-4
AB  - The structure of prostaglandin synthase, the target of aspirin therapy in 
      cardiovascular disease, reveals a remarkable integration of the enzyme's 
      catalytic and membrane-binding properties.
FAU - Blake, C
AU  - Blake C
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Biol
JT  - Current biology : CB
JID - 9107782
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Binding Sites
MH  - Cardiovascular Diseases/drug therapy/enzymology
MH  - Cell Membrane/enzymology
MH  - Humans
MH  - Models, Molecular
MH  - Molecular Structure
MH  - Prostaglandin-Endoperoxide Synthases/*chemistry/drug effects/metabolism
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
AID - S0960-9822(00)00101-9 [pii]
AID - 10.1016/s0960-9822(00)00101-9 [doi]
PST - ppublish
SO  - Curr Biol. 1994 May 1;4(5):452-4. doi: 10.1016/s0960-9822(00)00101-9.

PMID- 16732698
OWN - NLM
STAT- MEDLINE
DCOM- 20071026
LR  - 20190917
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 7
IP  - 9
DP  - 2006 Jun
TI  - Clopidogrel in the treatment of ischaemic heart disease.
PG  - 1109-20
AB  - Clopidogrel is an effective antiplatelet agent that has undergone rigorous 
      assessment in the setting of ischaemic heart disease over the last decade. There 
      is extensive evidence for the use of this drug in patients undergoing 
      percutaneous coronary intervention, in those with stable ischaemic heart disease 
      and also in those with acute coronary syndromes. This article examines the use of 
      clopidogrel in patients with ischaemic heart disease.
FAU - Walsh, Simon J
AU  - Walsh SJ
AD  - Regional Medical Cardiology Centre, Royal Victoria Hospital, Grosvenor Road, 
      Belfast, BT12 6BA, Northern Ireland.
FAU - McClelland, Anthony J
AU  - McClelland AJ
FAU - Adgey, Jennifer A
AU  - Adgey JA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*drug therapy/therapy
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
RF  - 68
EDAT- 2006/05/31 09:00
MHDA- 2007/10/30 09:00
CRDT- 2006/05/31 09:00
PHST- 2006/05/31 09:00 [pubmed]
PHST- 2007/10/30 09:00 [medline]
PHST- 2006/05/31 09:00 [entrez]
AID - 10.1517/14656566.7.9.1109 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2006 Jun;7(9):1109-20. doi: 10.1517/14656566.7.9.1109.

PMID- 16114291
OWN - NLM
STAT- MEDLINE
DCOM- 20050922
LR  - 20131121
IS  - 0028-2162 (Print)
IS  - 0028-2162 (Linking)
VI  - 149
IP  - 31
DP  - 2005 Jul 30
TI  - [The polypill: not an effective strategy for reduction of cardiovascular 
      disease].
PG  - 1741
AB  - The implementation of the intriguing concept of the polypill to prevent 
      cardiovascular events remains doubtful due to a lack of evidence, expected 
      adherence problems, the inevitable overtreatment and undertreatment of 
      individuals, and potential side effects. Lifestyle changes and individual 
      interventions are more preferable strategies.
FAU - Westerweel, P E
AU  - Westerweel PE
AD  - Universitair Medisch Centrum Utrecht, afd. Vasculaire Geneeskunde, Heidelberglaan 
      100, 3584 CX Utrecht.
FAU - van Wijk, J P H
AU  - van Wijk JP
FAU - Verhaar, M C
AU  - Verhaar MC
LA  - dut
PT  - Comment
PT  - English Abstract
PT  - Journal Article
TT  - De 'polypil': geen effectieve strategie tegen hart- en vaatziekten.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 935E97BOY8 (Folic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Ned Tijdschr Geneeskd. 2005 Jul 30;149(31):1740. PMID: 16114290
MH  - Antihypertensive Agents/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Drug Combinations
MH  - Evidence-Based Medicine
MH  - Female
MH  - Folic Acid/*administration & dosage
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Primary Prevention
EDAT- 2005/08/24 09:00
MHDA- 2005/09/24 09:00
CRDT- 2005/08/24 09:00
PHST- 2005/08/24 09:00 [pubmed]
PHST- 2005/09/24 09:00 [medline]
PHST- 2005/08/24 09:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2005 Jul 30;149(31):1741.

PMID- 1339575
OWN - NLM
STAT- MEDLINE
DCOM- 19931119
LR  - 20181217
IS  - 1230-5359 (Print)
IS  - 1230-5359 (Linking)
VI  - 32
IP  - 3-4
DP  - 1992
TI  - Effects of acetylsalicylic acid, chlormethine and glucose on cow's mammary gland.
PG  - 55-64
AB  - It was found that 100 ml of 5% glucose solution, 200 ml of acetylsalicyclic acid 
      or 200 ml of chlormethine introduced into udder quarter caused a temporary 
      irritation of mammary gland in healthy cows after a single intramammary 
      inlocation. The changes in milk manifested by an increase of somatic cells 
      number, serum albumins level and LDH activity, and decreased lactose content 
      disappeared after 48-60 hours.
FAU - Malinowski, E
AU  - Malinowski E
AD  - Department of Physiopathology of Reproduction and Mammary Gland, National 
      Veterinary Research Institute, Poland.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Arch Vet Pol
JT  - Archivum veterinarium Polonicum
JID - 9313674
RN  - 0 (Serum Albumin)
RN  - 50D9XSG0VR (Mechlorethamine)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - IY9XDZ35W2 (Glucose)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cattle
MH  - Female
MH  - Glucose/administration & dosage/*pharmacology
MH  - Infusions, Parenteral
MH  - L-Lactate Dehydrogenase/metabolism
MH  - Lactation
MH  - Lactose/metabolism
MH  - Mammary Glands, Animal/cytology/drug effects/*physiology
MH  - Mechlorethamine/administration & dosage/*pharmacology
MH  - Milk/drug effects/*metabolism
MH  - Serum Albumin/metabolism
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Arch Vet Pol. 1992;32(3-4):55-64.

PMID- 3603404
OWN - NLM
STAT- MEDLINE
DCOM- 19870724
LR  - 20220408
IS  - 0040-3709 (Print)
IS  - 0040-3709 (Linking)
VI  - 35
IP  - 2
DP  - 1987 Apr
TI  - Aspirin and acetaminophen use by pregnant women and subsequent child IQ and 
      attention decrements.
PG  - 211-9
AB  - In a longitudinal prospective study of 1,529 women pregnant in 1974-1975, aspirin 
      and acetaminophen were the two medications most frequently taken during the first 
      half of pregnancy (46 and 41%, respectively). In a selected cohort of 421 
      offspring of these women, examined at 4 years of age, maternal aspirin use during 
      the first half of pregnancy was significantly related to IQ and attention 
      decrements in the exposed children. Multiple regression analyses were used to 
      statistically adjust for a variety of potentially confounding factors including 
      demographic characteristics, child characteristics, other exposures, and 
      lifestyle/environmental variables. Continuous dose-response and step-function 
      parameterizations of aspirin exposure were both statistically significant and not 
      clearly distinguishable from each other. The estimated aspirin effect is 
      significantly greater for girls than boys. Aspirin effects on offspring function 
      were found in the absence of effects on physical size both at birth and at 4 
      years. Maternal acetaminophen use was not significantly related to child IQ or 
      attention. As this exploratory research originated from observations of a data 
      set gathered for other purposes, it would be desirable to have these findings 
      replicated in other studies. Further follow-up of the children at a later age is 
      planned.
FAU - Streissguth, A P
AU  - Streissguth AP
FAU - Treder, R P
AU  - Treder RP
FAU - Barr, H M
AU  - Barr HM
FAU - Shepard, T H
AU  - Shepard TH
FAU - Bleyer, W A
AU  - Bleyer WA
FAU - Sampson, P D
AU  - Sampson PD
FAU - Martin, D C
AU  - Martin DC
LA  - eng
GR  - AA01455-01-11/AA/NIAAA NIH HHS/United States
GR  - MCJ-530481-01-1/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Teratology
JT  - Teratology
JID - 0153257
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Attention/*drug effects
MH  - Behavior/drug effects
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - *Intelligence
MH  - Maternal-Fetal Exchange
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious
MH  - Socioeconomic Factors
EDAT- 1987/04/01 00:00
MHDA- 1987/04/01 00:01
CRDT- 1987/04/01 00:00
PHST- 1987/04/01 00:00 [pubmed]
PHST- 1987/04/01 00:01 [medline]
PHST- 1987/04/01 00:00 [entrez]
AID - 10.1002/tera.1420350207 [doi]
PST - ppublish
SO  - Teratology. 1987 Apr;35(2):211-9. doi: 10.1002/tera.1420350207.

PMID- 3826831
OWN - NLM
STAT- MEDLINE
DCOM- 19870415
LR  - 20131121
IS  - 0002-9645 (Print)
IS  - 0002-9645 (Linking)
VI  - 48
IP  - 1
DP  - 1987 Jan
TI  - Effect of aspirin on ex vivo generation of thromboxane in healthy horses.
PG  - 13-6
AB  - Different dosages of aspirin were administered (by nasogastric tube) to 3 groups 
      of 5 healthy adult horses to determine the minimal effective dosage needed to 
      decrease serum thromboxane B2 (TxB2) concentrations and to determine the duration 
      of this decrease. When compared with their base-line serum TxB2 concentrations, 
      horses in group 1 (given 5 mg/kg) had a 71% decrease in TxB2 concentrations at 24 
      hours after aspirin was given and a 86% decrease at 48 hours; serum TxB2 
      concentrations were back to base-line values by 120 hours. Horses in group 2 
      (given 10 mg/kg) had a 60% decrease in TxB2 concentrations at 24 hours after 
      aspirin was given, an 84% decrease at 48 hours, a 48% decrease at 96 hours, and 
      an 18% decrease at 6 days. Horses in group 3 (given 20 mg/kg) had a 68% decrease 
      in TxB2 concentrations at 24 hours, a 93% decrease at 72 hours, an 87% decrease 
      at 96 hours, and a 70% decrease at 6 days after aspirin treatment was given. All 
      groups had a statistically significant decrease in TxB2 concentrations (P less 
      than 0.05) by 12 hours after aspirin was given, which persisted 96 hours for 
      group 1 and throughout the study for groups 2 and 3. The maximal TxB2 decrease 
      was similar among the 3 groups (90% decrease from base line), and there were no 
      significant differences among the TxB2 concentrations between 24 and 72 hours 
      after treatment was given.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Baxter, G M
AU  - Baxter GM
FAU - Moore, J N
AU  - Moore JN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Horses/*metabolism
MH  - Thromboxane B2/*biosynthesis/blood
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Am J Vet Res. 1987 Jan;48(1):13-6.

PMID- 16008176
OWN - NLM
STAT- MEDLINE
DCOM- 20050729
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 97
IP  - 10
DP  - 2004 Oct
TI  - [Patent foramen ovale and stroke].
PG  - 987-93
AB  - About a quarter of the adult population is known to have a patent foramen ovale, 
      rarely accompanied by the presence of an interatrial septal aneurysm. A patent 
      foramen ovale is found in more than 40% of patients younger than 60 years who had 
      a cryptogenic ischemic stroke. Clinical and echocardiographic parameters allow 
      the identification of patients at high risk of recurrence after a first 
      cryptogenic stroke even if treated with Aspirin. A multidisciplinary approach 
      allow the selected patients to benefit of a correction of their cardiac anomaly 
      with promising long term results.
FAU - Meier, J M
AU  - Meier JM
AD  - Service de cardiologie, Centre hospitalier universitaire vaudois, Lausanne, 
      Suisse. Jean-Marc.Meier@chuv.hospvd.ch
FAU - Delabays, A
AU  - Delabays A
FAU - Girod, G
AU  - Girod G
FAU - Eeckhout, E
AU  - Eeckhout E
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Foramen ovale perméable et accident vasculaire cérébral.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Aspirin/therapeutic use
MH  - Heart Septal Defects, Atrial/*complications
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Recurrence
MH  - Risk Factors
MH  - Stroke/*etiology
RF  - 28
EDAT- 2005/07/13 09:00
MHDA- 2005/07/30 09:00
CRDT- 2005/07/13 09:00
PHST- 2005/07/13 09:00 [pubmed]
PHST- 2005/07/30 09:00 [medline]
PHST- 2005/07/13 09:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 2004 Oct;97(10):987-93.

PMID- 26057492
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181113
IS  - 2385-2070 (Electronic)
IS  - 1723-2007 (Print)
IS  - 1723-2007 (Linking)
VI  - 14
IP  - 2
DP  - 2016 Mar
TI  - Use of a haemostatic matrix (Floseal®) does not reduce blood loss in minimally 
      invasive total knee arthroplasty performed under continued aspirin.
PG  - 134-9
LID - 10.2450/2015.0023-15 [doi]
AB  - BACKGROUND: Aspirin is being used for primary and secondary cardiovascular 
      prevention. It has been proposed that aspirin should be discontinued 5 to 7 days 
      before surgery. However, discontinuation might increase the risk of cardiac and 
      thrombo-embolic co-morbidity. Aspirin also increases the risk of bleeding during 
      and after total knee arthroplasty. This study evaluated if the intra-articular 
      use of a haemostatic matrix (Floseal®) might decrease blood loss in total knee 
      arthroplasty performed under continued aspirin use. MATERIALS AND METHODS: We 
      retrospectively compared matched pairs in two groups (80 patients in each group). 
      Patients in both groups were taking aspirin: one group was managed with 
      conventional haemostasis (with bovie electrocoagulation), while the other group 
      was treated with an intra-articular haemostatic matrix as an adjunct to 
      electrocoagulation. The outcomes compared were haemoglobin and haematocrit levels 
      at days 2 and 4 after surgery as surrogates for blood loss, transfusion rate, 
      surgical time, and length of stay in the hospital. RESULTS: No differences were 
      observed between the two groups for haemoglobin and haematocrit levels on days 2 
      and 4. There were no differences in transfusion rate, surgical time or length of 
      stay in hospital between the two groups. DISCUSSION: The present study shows that 
      the use of Floseal® has no effect on reducing either visible or hidden blood loss 
      after total knee arthroplasty with peri-operative continuation of aspirin use, as 
      assessed by a drop in haemoglobin or haematocrit.
FAU - Schwab, Pierre-Emmanuel
AU  - Schwab PE
AD  - Department of Orthopaedic Surgery, University Hospital Saint Luc-UCL, Brussels, 
      Belgium.
FAU - Thienpont, Emmanuel
AU  - Thienpont E
AD  - Department of Orthopaedic Surgery, University Hospital Saint Luc-UCL, Brussels, 
      Belgium.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150529
PL  - Italy
TA  - Blood Transfus
JT  - Blood transfusion = Trasfusione del sangue
JID - 101237479
RN  - 0 (FloSeal Matrix)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/*administration & dosage
MH  - Blood Loss, Surgical/*prevention & control
MH  - Female
MH  - Gelatin Sponge, Absorbable/*administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Minimally Invasive Surgical Procedures
MH  - Retrospective Studies
PMC - PMC4781780
EDAT- 2015/06/10 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/06/10 06:00
PHST- 2015/02/22 00:00 [received]
PHST- 2015/03/24 00:00 [accepted]
PHST- 2015/06/10 06:00 [entrez]
PHST- 2015/06/10 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 2015.0023-15 [pii]
AID - blt-16-134 [pii]
AID - 10.2450/2015.0023-15 [doi]
PST - ppublish
SO  - Blood Transfus. 2016 Mar;14(2):134-9. doi: 10.2450/2015.0023-15. Epub 2015 May 
      29.

PMID- 363751
OWN - NLM
STAT- MEDLINE
DCOM- 19790223
LR  - 20190823
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 18
IP  - 11-12
DP  - 1978 Nov-Dec
TI  - A comparative analgesic study of propoxyphene, fenoprofen, the combination of 
      propoxyphene and fenoprofen, aspirin, and placebo.
PG  - 556-63
AB  - Groups of 27 inpatients with moderate or severe postoperative, fracture, or 
      somatic pain were given single oral doses of propoxyphene napsylate (P), 
      fenoprofen calcium (F), combinations of P and F, aspirin, or placebo. The 
      increasing rank order for effectiveness, with doses in milligrams, was placebo, 
      P50, aspirin 650, F600, F50, P50 + F50, F200, P50 + F600, P50 + F200, P200 + F50, 
      P200, P200 + F200, and P200 + F600. The overall analgesic response to 
      propoxyphene in this dose range (50 to 200 mg) increased linearly with increasing 
      doses. The fenoprofen response also increased in proportion to the dose up to 200 
      mg; the overall response to 600 mg was not significantly different from that to 
      200 mg. Propoxyphene napsylate and fenoprofen calcium had additive analgesic 
      effects. There were no drug-related adverse reports.
FAU - Sunshine, A
AU  - Sunshine A
FAU - Slafta, J
AU  - Slafta J
FAU - Gruber, C Jr
AU  - Gruber C Jr
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Phenylpropionates)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
RN  - S2F83W92TK (Dextropropoxyphene)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dextropropoxyphene/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fenoprofen/*therapeutic use
MH  - Humans
MH  - Male
MH  - Pain/*drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - Placebos
MH  - Time Factors
EDAT- 1978/11/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1978.tb01585.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1978 Nov-Dec;18(11-12):556-63. doi: 
      10.1002/j.1552-4604.1978.tb01585.x.

PMID- 1285048
OWN - NLM
STAT- MEDLINE
DCOM- 19931109
LR  - 20161123
IS  - 0094-1298 (Print)
IS  - 0094-1298 (Linking)
VI  - 19
IP  - 4
DP  - 1992 Oct
TI  - Thrombosis and antithrombotic therapy in microvascular surgery.
PG  - 799-807
AB  - Thrombosis in microsurgery can either totally or partially reduce the perfusion 
      to the free tissue transfer. Total occlusion normally occurs at or near the 
      microvascular anastomosis, while microscopic vasospasm in the distal 
      microcirculation can account for malperfusion and wound healing problems. The 
      mechanisms of the anastomotic and microcirculatory responses to thrombosis are 
      discussed. Drug therapy for each risk zone is identified, and a rationale for 
      therapy is given.
FAU - Johnson, P C
AU  - Johnson PC
AD  - Division of Plastic and Reconstructive Surgery, University of Pittsburgh School 
      of Medicine, Pennsylvania.
FAU - Barker, J H
AU  - Barker JH
LA  - eng
GR  - R29 HL45891-01A1/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Clin Plast Surg
JT  - Clinics in plastic surgery
JID - 0424767
RN  - 0 (Dextrans)
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Dextrans/therapeutic use
MH  - Fibrinolytic Agents/therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - *Microsurgery
MH  - Postoperative Complications
MH  - *Surgical Flaps
MH  - Thrombosis/*etiology/*prevention & control
RF  - 44
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
PST - ppublish
SO  - Clin Plast Surg. 1992 Oct;19(4):799-807.

PMID- 6419710
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20191023
IS  - 0344-8444 (Print)
IS  - 0344-8444 (Linking)
VI  - 102
IP  - 2
DP  - 1983
TI  - The effect of prophylaxis for thrombosis on heterotopic ossification following 
      total hip joint replacement.
PG  - 114-7
AB  - The effect of prophylaxis for thrombosis on heterotopic ossification was 
      investigated using 216 total hip joint endoprostheses implanted between 1976 and 
      1978. During this period a random comparative study of low dose heparin and 
      oxyphenbutazone/acetylsalycilic acid was carried out. The rate of ossification in 
      the 216 hip joints was 17.6%, and was about average for the values specified in 
      literature on this subject. Heterotopic ossification occurred in 30.1% of the 103 
      hip joints treated with heparin, whilst the rate of ossification in the 113 hip 
      joints treated with oxyphenbutazone/acetylsalycilic acid was only 6.2%. This 
      represents a statistically significant difference in disfavour of prophylaxis 
      with heparin.
FAU - Eyb, R
AU  - Eyb R
FAU - Knahr, K
AU  - Knahr K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Arch Orthop Trauma Surg (1978)
JT  - Archives of orthopaedic and traumatic surgery. Archiv fur orthopadische und 
      Unfall-Chirurgie
JID - 7803037
RN  - 9005-49-6 (Heparin)
RN  - H806S4B3NS (Oxyphenbutazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Heparin/*pharmacology
MH  - Hip Prosthesis/*adverse effects
MH  - Humans
MH  - Ossification, Heterotopic/*epidemiology/etiology
MH  - Oxyphenbutazone/*pharmacology
MH  - Thrombosis/*prevention & control
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1007/BF02498727 [doi]
PST - ppublish
SO  - Arch Orthop Trauma Surg (1978). 1983;102(2):114-7. doi: 10.1007/BF02498727.

PMID- 29938524
OWN - NLM
STAT- MEDLINE
DCOM- 20190325
LR  - 20190325
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 14
IP  - 4
DP  - 2018 Jul
TI  - Prescribing patterns of oral antiplatelets in Wales: evolving trends from 2005 to 
      2016.
PG  - 277-282
LID - 10.2217/fca-2018-0003 [doi]
AB  - AIM: Antiplatelets have been used for decades to prevent atherothrombotic 
      disease, but there is limited 'real-life' prescribing data. We hereby report the 
      prescribing patterns for oral antiplatelets in Wales, UK. METHODS/RESULTS: 
      Retrospective analysis of anonymized data in Wales from 2005 to 2016 revealed 
      differences in prescribing patterns of oral antiplatelets. Aspirin and 
      dipyridamole use declined with a corresponding increase in clopidogrel 
      prescription. Costs declined with a sharp decrease coinciding with clopidogrel 
      coming off patent. Prasugrel and ticagrelor have shown significant cost 
      contribution (29% of total) despite only forming 1% of total items prescribed in 
      2016. CONCLUSION: This first-look analysis of real-life antiplatelet data 
      demonstrates a decrease in the overall prescribing costs with varying patterns. 
      This may aid policy-makers in reviewing funding strategies.
FAU - Protty, Majd B
AU  - Protty MB
AD  - Sir Geraint Evans Cardiovascular Research Building, Cardiff University, Heath 
      Park, Cardiff, Wales, UK.
FAU - Wilkins, Simon J
AU  - Wilkins SJ
AD  - Sir Geraint Evans Cardiovascular Research Building, Cardiff University, Heath 
      Park, Cardiff, Wales, UK.
AD  - Welsh Medicines Resource Centre, University Hospital Llandough, Cardiff, Wales, 
      UK.
FAU - Hoskins, Hannah C
AU  - Hoskins HC
AD  - Department of Cardiology, University Hospital of Wales, Heath Park, Cardiff, 
      Wales, UK.
FAU - Dawood, Ban B
AU  - Dawood BB
AD  - Acute Medicine Department, Solihull Hospital, Lode Lane, Solihull, UK.
FAU - Hayes, Jamie
AU  - Hayes J
AD  - Welsh Medicines Resource Centre, University Hospital Llandough, Cardiff, Wales, 
      UK.
LA  - eng
PT  - Journal Article
DEP - 20180625
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/economics/therapeutic use
MH  - Clopidogrel/economics/therapeutic use
MH  - Dipyridamole/economics/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/economics/*therapeutic use
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Prasugrel Hydrochloride/economics/therapeutic use
MH  - Retrospective Studies
MH  - Ticagrelor/economics/therapeutic use
MH  - Wales
OTO - NOTNLM
OT  - antiplatelets
OT  - atherothrombosis
OT  - clopidogrel
OT  - prasugrel
OT  - ticagrelor
EDAT- 2018/06/26 06:00
MHDA- 2019/03/26 06:00
CRDT- 2018/06/26 06:00
PHST- 2018/06/26 06:00 [pubmed]
PHST- 2019/03/26 06:00 [medline]
PHST- 2018/06/26 06:00 [entrez]
AID - 10.2217/fca-2018-0003 [doi]
PST - ppublish
SO  - Future Cardiol. 2018 Jul;14(4):277-282. doi: 10.2217/fca-2018-0003. Epub 2018 Jun 
      25.

PMID- 25406671
OWN - NLM
STAT- MEDLINE
DCOM- 20150703
LR  - 20181202
IS  - 1129-2377 (Electronic)
IS  - 1129-2369 (Print)
IS  - 1129-2369 (Linking)
VI  - 15
IP  - 1
DP  - 2014 Nov 19
TI  - Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine 
      compared with acetaminophen alone in episodic tension-type headache: 
      meta-analysis of four randomized, double-blind, placebo-controlled, crossover 
      studies.
PG  - 76
LID - 10.1186/1129-2377-15-76 [doi]
AB  - BACKGROUND: Most patients with episodic tension-type headache treat headache 
      episodes with over-the-counter medication. Combination analgesics containing 
      caffeine may be more effective and as well tolerated as monotherapy. The aim of 
      this study was to evaluate the efficacy of the combination of acetylsalicylic 
      acid, acetaminophen (paracetamol) and caffeine in episodic tension-type headache 
      using recently recommended endpoints. METHODS: Four randomized, controlled trials 
      of identical design in 1,900 patients with episodic tension-type headache 
      comparing acetylsalicylic acid, acetaminophen and caffeine vs. acetaminophen or 
      placebo were pooled. Analysis populations were 'all headache episodes' and those 
      with 'severe pain at baseline'. Post-hoc defined primary endpoint: headache 
      episodes pain-free at 2 h. Secondary endpoints: headache episodes pain-free at 
      1 h, headache response at 2 h (mild or no pain), degree of interference with 
      daily activities. RESULTS: 6,861 headache episodes were treated, including 2,215 
      severe headache episodes. The proportion of headache episodes pain-free at 2 h 
      was significantly higher with the triple combination (28.5%) vs. acetaminophen 
      (21.0%) and placebo (18.0%) (p < 0.0001), and similarly for those severe at 
      baseline (20.2% vs. 12.1% and 10.8%; p ≤ 0.0003). A similar pattern of 
      superiority was observed for secondary endpoints. The triple combination was 
      generally well tolerated. CONCLUSIONS: The combination of acetylsalicylic acid, 
      acetaminophen and caffeine is effective and well tolerated in episodic 
      tension-type headache, and significantly superior to acetaminophen with regard to 
      being pain-free at 2 h, headache response at 2 h and ability to return to daily 
      activities, even in those with pain rated severe at baseline.
FAU - Diener, Hans-Christoph
AU  - Diener HC
AD  - Department of Neurology, University Hospital Essen, University Duisburg-Essen, 
      Hufelandstr, 55, 45122 Essen, Germany. hans.diener@uk-essen.de.
FAU - Gold, Morris
AU  - Gold M
FAU - Hagen, Martina
AU  - Hagen M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20141119
PL  - England
TA  - J Headache Pain
JT  - The journal of headache and pain
JID - 100940562
RN  - 0 (Analgesics)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/*therapeutic use
MH  - Analgesics/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Caffeine/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Pain Measurement
MH  - Tension-Type Headache/*drug therapy
MH  - Treatment Outcome
PMC - PMC4256978
EDAT- 2014/11/20 06:00
MHDA- 2015/07/04 06:00
CRDT- 2014/11/20 06:00
PHST- 2014/09/04 00:00 [received]
PHST- 2014/11/03 00:00 [accepted]
PHST- 2014/11/20 06:00 [entrez]
PHST- 2014/11/20 06:00 [pubmed]
PHST- 2015/07/04 06:00 [medline]
AID - 1129-2377-15-76 [pii]
AID - 10.1186/1129-2377-15-76 [doi]
PST - epublish
SO  - J Headache Pain. 2014 Nov 19;15(1):76. doi: 10.1186/1129-2377-15-76.

PMID- 9746481
OWN - NLM
STAT- MEDLINE
DCOM- 19981119
LR  - 20190305
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 275
IP  - 4
DP  - 1998 Oct
TI  - Effect of cross-linked hemoglobin transfusion on endothelial-dependent dilation 
      in cat pial arterioles.
PG  - H1313-21
LID - 10.1152/ajpheart.1998.275.4.H1313 [doi]
AB  - We determined whether addition of hemoglobin to the plasma would inhibit 
      endothelial-dependent dilation in brain where tight endothelial junctions limit 
      hemoglobin extravasation. Pial arteriolar diameter was measured by intravital 
      microscopy through closed cranial windows in anesthetized cats either without 
      transfusion (hematocrit = 32%) or after exchange transfusion with an albumin or 
      sebacyl-cross-linked human hemoglobin solution (hematocrit = 18%). Dilation of 
      small, medium, and large arterioles to acetylcholine and ADP was not 
      significantly altered by hemoglobin transfusion. The dilatory responses were 
      inhibited by the nitric oxide synthase inhibitor NG-nitro-L-arginine, although 
      significant dilation to 30 microM acetylcholine persisted in small arterioles in 
      the control and albumin-transfused group but not in the hemoglobin-transfused 
      group. The dilatory response to the nitric oxide donor 3-morpholinosydnonimine 
      was unaffected by albumin or hemoglobin transfusion, but the response to 
      nitroprusside was reduced by one-third after hemoglobin transfusion. When 
      cross-linked hemoglobin was superfused through the cranial window, the 
      acetylcholine response became inhibited at a hemoglobin concentration of 0.1 
      microM and was completely blocked at 10 microM. Because this concentration is 
      substantially less than the 500 microM hemoglobin concentration in plasma after 
      transfusion when there was no inhibition of the acetylcholine response, 
      hemoglobin permeation of the blood-brain barrier was considered negligible. We 
      conclude that exchange of red cell-based hemoglobin with plasma-based hemoglobin 
      does not produce a more effective sink for endothelial-derived nitric oxide 
      evoked by agonist receptor-mediated activation. Furthermore, decreased hematocrit 
      does not affect agonist-evoked endothelial-dependent dilation.
FAU - Asano, Y
AU  - Asano Y
AD  - Department of Anesthesiology/Critical Care Medicine, The Johns Hopkins University 
      School of Medicine, Baltimore, MD 21287, USA.
FAU - Koehler, R C
AU  - Koehler RC
FAU - Ulatowski, J A
AU  - Ulatowski JA
FAU - Traystman, R J
AU  - Traystman RJ
FAU - Bucci, E
AU  - Bucci E
LA  - eng
GR  - HL-48517/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Decanoic Acids)
RN  - 0 (Hemoglobins)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Salicylates)
RN  - 0 (Serum Albumin)
RN  - 0 (bis(3,5-dibromosalicyl)sebacate-crosslinked hemoglobin)
RN  - 2149-70-4 (Nitroarginine)
RN  - 5O5U71P6VQ (linsidomine)
RN  - 74134-05-7 (bis(3,5-dibromosalicyl)sebacate)
RN  - D46583G77X (Molsidomine)
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylcholine/pharmacology
MH  - Animals
MH  - Arterioles/*physiology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cats
MH  - Cross-Linking Reagents
MH  - Decanoic Acids
MH  - Endothelium, Vascular/*physiology
MH  - Hemoglobins/*pharmacology
MH  - Humans
MH  - Male
MH  - Molsidomine/analogs & derivatives/pharmacology
MH  - Nitric Oxide Donors/pharmacology
MH  - Nitroarginine/pharmacology
MH  - Perfusion
MH  - Pia Mater/*blood supply
MH  - Salicylates
MH  - Serum Albumin/pharmacology
MH  - Vasodilation/drug effects/*physiology
EDAT- 1998/09/24 00:00
MHDA- 1998/09/24 00:01
CRDT- 1998/09/24 00:00
PHST- 1998/09/24 00:00 [pubmed]
PHST- 1998/09/24 00:01 [medline]
PHST- 1998/09/24 00:00 [entrez]
AID - 10.1152/ajpheart.1998.275.4.H1313 [doi]
PST - ppublish
SO  - Am J Physiol. 1998 Oct;275(4):H1313-21. doi: 10.1152/ajpheart.1998.275.4.H1313.

PMID- 10754379
OWN - NLM
STAT- MEDLINE
DCOM- 20000713
LR  - 20181130
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 29
IP  - 5
DP  - 1999
TI  - Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on 
      primary hemostasis using a quantitative bleeding time test apparatus.
PG  - 269-76
AB  - We examined and compared the effects of aspirin (ASA), ticlopidine (TP) and 
      cilostazol (CS) on bleeding time (BT) in 10 healthy adult male subjects using a 
      newly developed quantitative bleeding time (QBT) test apparatus capable of 
      simultaneously measuring total blood loss (Tv), maximum bleeding rate (Rmax), and 
      bleeding pattern in addition to BT. All 3 drugs inhibited platelet aggregation 
      response to ADP, collagen, epinephrine and arachidonic acid (p < 0.05), but not 
      to ristocetin. Following oral administration of ASA (330 mg/day) or TP (300 
      mg/day) for 3 days, BT was significantly prolonged (mean BT increased from 359.3 
      to 646.0 s, p < 0.001, and from 323.3 to 528. 7 s, p < 0.01, respectively) and Tv 
      was significantly increased (from 14.5 to 30.2 microl, p < 0.05, and from 12.5 to 
      19.2 microl, p < 0.01, respectively). Aspirin also increased Rmax (from 0.118 to 
      0. 159 microl/s, p < 0.05). The prolonged bleeding patterns after administration 
      of ASA and TP were both type III, which has been reported to be less likely to 
      lead to bleeding accidents. In contrast, none of these QBT parameters were 
      altered by CS administration.
CI  - Copyright 2000 S. Karger AG, Basel
FAU - Tamai, Y
AU  - Tamai Y
AD  - First Department of Internal Medicine, Hirosaki University School of Medicine, 
      Hirosaki, Japan. ytamai@cc.hirosaki-u.ac.jp
FAU - Takami, H
AU  - Takami H
FAU - Nakahata, R
AU  - Nakahata R
FAU - Ono, F
AU  - Ono F
FAU - Munakata, A
AU  - Munakata A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*pharmacology
MH  - Bleeding Time/methods
MH  - Cilostazol
MH  - Fibrinolytic Agents/adverse effects/pharmacology
MH  - Gastrointestinal Diseases/etiology
MH  - Headache/etiology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology
MH  - Tetrazoles/adverse effects/*pharmacology
MH  - Ticlopidine/adverse effects/*pharmacology
EDAT- 2000/04/08 09:00
MHDA- 2000/07/15 11:00
CRDT- 2000/04/08 09:00
PHST- 2000/04/08 09:00 [pubmed]
PHST- 2000/07/15 11:00 [medline]
PHST- 2000/04/08 09:00 [entrez]
AID - 22512 [pii]
AID - 10.1159/000022512 [doi]
PST - ppublish
SO  - Haemostasis. 1999;29(5):269-76. doi: 10.1159/000022512.

PMID- 17230036
OWN - NLM
STAT- MEDLINE
DCOM- 20070319
LR  - 20131121
IS  - 1424-8832 (Print)
IS  - 1424-8832 (Linking)
VI  - 35
IP  - 5
DP  - 2006
TI  - Modifications produced by indomethacin and L-NAME in the effect of ultralow-dose 
      aspirin on platelet activity in portal hypertension.
PG  - 357-63
AB  - In our previous study, we demonstrated the effect of ultralow-dose aspirin (ULDA) 
      on platelet activity and bleeding in rats with portal hypertension (PHT) produced 
      by portal vein ligation (PVL). This paper reports modifications in this effect 
      caused by blocking NO production by nitro arginine methyl ester (NAME) and 
      cyclooxygenase (COX) activity with indomethacin. PVL rats and sham-operated 
      controls were treated with placebo, indomethacin or NAME and 30 min thereafter 
      with placebo or ULDA treatment. Platelet activity was studied by a model of in 
      vivo laser-induced thrombus production in the mesenteric circulation, induced 
      hemorrhage time (IHT) and platelet aggregation ex vivo induced by adenosine 
      diphosphate in an aggregometer. The PVL group receiving placebo showed a 
      decreased platelet activity with prolonged IHT, an effect that was reversed by 
      ULDA. Indomethacin induced a decreased platelet activity in the control rats and 
      a prolonged IHT. In PHT with ULDA, in vivo platelet activity was enhanced but the 
      normalization of IHT observed in rats without indomethacin was blunted. The 
      addition of NAME normalized the diminished in vivo platelet aggregation and 
      increased the IHT observed in PVL animals. These changes decreased the effect of 
      ULDA in both sham-operated and PVL animals. The effect of indomethacin was more 
      clearly modified by ULDA than the effect of NAME, thus suggesting that 
      modifications in the COX pathway might alter the effect of ULDA. The simultaneous 
      administration of indomethacin and ULDA could inhibit its beneficial effect on 
      bleeding in rats with PHT.
CI  - Copyright 2006 S. Karger AG, Basel.
FAU - Eizayaga, Francisco X
AU  - Eizayaga FX
AD  - Facultad de Medicina, Universidad Maimónides, Buenos Aires, Argentina.
FAU - Aguejouf, Omar
AU  - Aguejouf O
FAU - Desplat, Vanessa
AU  - Desplat V
FAU - Belon, Philippe
AU  - Belon P
FAU - Doutremepuich, Christian
AU  - Doutremepuich C
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pathophysiol Haemost Thromb
JT  - Pathophysiology of haemostasis and thrombosis
JID - 101142710
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Coagulation Tests
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Disease Models, Animal
MH  - Drug Interactions
MH  - Hypertension, Portal/*drug therapy
MH  - Indomethacin/administration & dosage/*pharmacology
MH  - Male
MH  - NG-Nitroarginine Methyl Ester/administration & dosage/*pharmacology
MH  - Nitric Oxide/antagonists & inhibitors/biosynthesis
MH  - Platelet Activation/*drug effects
MH  - Platelet Function Tests
MH  - Rats
MH  - Rats, Wistar
MH  - Splanchnic Circulation
MH  - Thrombosis
EDAT- 2007/01/19 09:00
MHDA- 2007/03/21 09:00
CRDT- 2007/01/19 09:00
PHST- 2005/11/11 00:00 [received]
PHST- 2006/03/27 00:00 [accepted]
PHST- 2007/01/19 09:00 [pubmed]
PHST- 2007/03/21 09:00 [medline]
PHST- 2007/01/19 09:00 [entrez]
AID - 000097689 [pii]
AID - 10.1159/000097689 [doi]
PST - ppublish
SO  - Pathophysiol Haemost Thromb. 2006;35(5):357-63. doi: 10.1159/000097689.

PMID- 28128037
OWN - NLM
STAT- MEDLINE
DCOM- 20180112
LR  - 20180112
IS  - 1708-8283 (Electronic)
IS  - 0883-0738 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Apr
TI  - Secondary Prevention of Childhood Arterial Ischemic Stroke.
PG  - 488-493
LID - 10.1177/0883073816686911 [doi]
AB  - This study aimed to know how frontline physicians in France, Belgium, and 
      Switzerland implement guidelines regarding the secondary prevention of childhood 
      arterial ischemic stroke and to introduce physicians' point of view on a clinical 
      trial assessing the efficacy of aspirin as a preventive strategy. The authors 
      conducted an online survey directed at specialists throughout dedicated networks 
      and used a mixed method for data analysis. Overall, 63 physicians responded, and 
      88% prescribe aspirin when sickle cell disease, cardio-embolic stroke, and 
      dissection of cervical arteries are excluded. Prescribing habits vary among 
      respondents with respect to their specialty. A majority would choose placebo or a 
      treatment given to historical controls to compare with an aspirin arm in a trial. 
      In studied countries, there seems to be good adherence to guidelines regarding 
      the secondary prevention of childhood stroke. A trial assessing the efficacy of 
      aspirin could be well accepted if several factors regarding study design were 
      taken into account.
FAU - Darteyre, Stéphane
AU  - Darteyre S
AD  - 1 INSERM, UMR 1059, SAINBIOSE, Dysfonction Vasculaire et Hémostase, Université 
      Jean Monnet, Saint-Étienne, France.
FAU - Renaud, Cyrille
AU  - Renaud C
AD  - 2 CHU Saint-Étienne, French Center for Pediatric stroke and Pediatric 
      Rehabilitation Unit, Saint-Étienne, France.
FAU - Fluss, Joel
AU  - Fluss J
AD  - 3 Pediatric Neurology Unit, Children's Hospital, Geneva, Switzerland.
FAU - Laporte, Silvy
AU  - Laporte S
AD  - 1 INSERM, UMR 1059, SAINBIOSE, Dysfonction Vasculaire et Hémostase, Université 
      Jean Monnet, Saint-Étienne, France.
AD  - 4 CHU Saint-Étienne, Unité de Recherche Clinique, Innovation, Pharmacologie, 
      Hôpital Nord, Saint-Étienne France.
FAU - Bertoletti, Laurent
AU  - Bertoletti L
AD  - 1 INSERM, UMR 1059, SAINBIOSE, Dysfonction Vasculaire et Hémostase, Université 
      Jean Monnet, Saint-Étienne, France.
AD  - 5 INSERM, CIC1408, Saint-Étienne, France.
AD  - 6 CHU Saint-Étienne, Service de Médecine Vasculaire et Thérapeutique, Hôpital 
      Nord, Saint-Étienne, France.
FAU - Chabrier, Stéphane
AU  - Chabrier S
AD  - 1 INSERM, UMR 1059, SAINBIOSE, Dysfonction Vasculaire et Hémostase, Université 
      Jean Monnet, Saint-Étienne, France.
AD  - 2 CHU Saint-Étienne, French Center for Pediatric stroke and Pediatric 
      Rehabilitation Unit, Saint-Étienne, France.
AD  - 5 INSERM, CIC1408, Saint-Étienne, France.
LA  - eng
PT  - Journal Article
DEP - 20170127
PL  - United States
TA  - J Child Neurol
JT  - Journal of child neurology
JID - 8606714
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Belgium
MH  - Brain Ischemia/*prevention & control
MH  - Child
MH  - France
MH  - Guideline Adherence
MH  - Health Care Surveys
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - *Practice Patterns, Physicians'
MH  - Secondary Prevention
MH  - Stroke/*prevention & control
MH  - Switzerland
OTO - NOTNLM
OT  - children
OT  - clinical trial
OT  - community survey
OT  - secondary prevention
OT  - stroke
EDAT- 2017/01/28 06:00
MHDA- 2018/01/13 06:00
CRDT- 2017/01/28 06:00
PHST- 2017/01/28 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
PHST- 2017/01/28 06:00 [entrez]
AID - 10.1177/0883073816686911 [doi]
PST - ppublish
SO  - J Child Neurol. 2017 Apr;32(5):488-493. doi: 10.1177/0883073816686911. Epub 2017 
      Jan 27.

PMID- 25252119
OWN - NLM
STAT- MEDLINE
DCOM- 20150921
LR  - 20150224
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 30
IP  - 3
DP  - 2015 Mar
TI  - Effect of low-dose proton pump inhibitor on preventing upper gastrointestinal 
      bleeding in chronic kidney disease patients receiving aspirin.
PG  - 478-84
LID - 10.1111/jgh.12780 [doi]
AB  - BACKGROUND AND AIM: Upper gastrointestinal bleeding (UGIB) leads to significant 
      morbidity and mortality in chronic kidney disease (CKD) patients. This study 
      determined the efficacy of using a low-dose proton pump inhibitor (PPI) to reduce 
      the risk of non-variceal UGIB in CKD patients receiving aspirin. METHODS: We 
      retrospectively reviewed the medical records of 500 CKD patients who received 
      aspirin between January 2008 and March 2013. Cumulative incidence analysis using 
      the Kaplan-Meier method was performed to analyze the rate of non-variceal UGIB 
      and association with the administration of low-dose PPI. RESULTS: Of the 500 
      patients, 191 received low-dose PPI. Over the follow-up period, which lasted 1067 
      person-years, three patients in the low-dose PPI group (8.9 per 1000 
      person-years) and 19 patients in the non-PPI group (25.9 per 1000 person-years) 
      developed non-variceal UGIB, respectively (P = 0.113). Low-dose PPI use did not 
      decrease the risk of UGIB in CKD patients, including patients who did not receive 
      dialysis (P = 0.127). However, according to the subgroup analysis of 230 patients 
      who received dialysis, the low-dose PPI group (14.4 per 1000 person-years) 
      demonstrated significantly reduced incidence and risk of non-variceal UGIB in 
      comparison with the non-PPI group (53.8 per 1000 person-years) (P = 0.032). 
      CONCLUSION: Prophylactic low-dose PPI can reduce the risk of non-variceal UGIB in 
      dialysis patients receiving aspirin.
CI  - © 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing 
      Asia Pty Ltd.
FAU - Lim, Hyun
AU  - Lim H
AD  - Department of Internal Medicine, Hallym University College of Medicine, Anyang, 
      South Korea.
FAU - Kim, Jong Hyeok
AU  - Kim JH
FAU - Baik, Gwang Ho
AU  - Baik GH
FAU - Park, Ji Won
AU  - Park JW
FAU - Kang, Ho Suk
AU  - Kang HS
FAU - Moon, Sung Hoon
AU  - Moon SH
FAU - Park, Choong Kee
AU  - Park CK
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Dialysis
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Hemorrhage/*chemically 
      induced/epidemiology/mortality/*prevention & control
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Renal Insufficiency, Chronic/*therapy
MH  - Retrospective Studies
MH  - Risk
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - prophylaxis
OT  - proton pump inhibitors
OT  - upper gastrointestinal bleeding
EDAT- 2014/09/25 06:00
MHDA- 2015/09/22 06:00
CRDT- 2014/09/25 06:00
PHST- 2014/09/15 00:00 [accepted]
PHST- 2014/09/25 06:00 [entrez]
PHST- 2014/09/25 06:00 [pubmed]
PHST- 2015/09/22 06:00 [medline]
AID - 10.1111/jgh.12780 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2015 Mar;30(3):478-84. doi: 10.1111/jgh.12780.

PMID- 7021072
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20190909
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 7
IP  - 7
DP  - 1981
TI  - A single-dose analgesic study of naproxen sodium and soluble aspirin in patients 
      with rheumatoid arthritis.
PG  - 471-4
AB  - Nineteen patients with moderate or severe pain due to rheumatoid arthritis were 
      entered into a double-blind, crossover comparison of single doses of 550 mg 
      naproxen sodium and 900 mg soluble aspirin. Pain relief, measured on a visual 
      analogue scale, showed a rapid onset of action of both drugs. Pain relief reached 
      50% of its maximum within 1 hour on both drugs. There were no significant 
      differences in the pain relief/time curves. Five patients found no relief of pain 
      with either drug but of the remaining 14 patients 10 reported an onset of action 
      of both drugs within half an hour. Nine patient on naproxen sodium and 7 on 
      soluble aspirin rated pain relief as good or very good. At the end of the study, 
      7 patients preferred soluble aspirin, 4 preferred naproxen sodium and the 
      remainder gave no preference. There were no side-effects on eigher drug.
FAU - Huskisson, E C
AU  - Huskisson EC
FAU - Engler, C
AU  - Engler C
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naproxen/*therapeutic use
MH  - Random Allocation
MH  - Time Factors
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1185/03007998109114286 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1981;7(7):471-4. doi: 10.1185/03007998109114286.

PMID- 37282368
OWN - NLM
STAT- MEDLINE
DCOM- 20230608
LR  - 20230608
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Linking)
VI  - 29
DP  - 2023 Jun 7
TI  - Exploring the Association between Low-dose Aspirin Intake and Hyperuricemia in 
      Individuals over 40: A Cross-Sectional Study using NHANES Data (2011-2018).
PG  - e939546
LID - 10.12659/MSM.939546 [doi]
AB  - BACKGROUND Long-term aspirin treatment was recommended for secondary prevention 
      of cardiovascular and cerebrovascular disease. However, some studies reveal 
      low-dose aspirin (LDA) can raise serum uric acid (SUA) levels. Thus, the purpose 
      of this study was to analyze whether LDA intake is associated with hyperuricemia. 
      MATERIAL AND METHODS Data was collected from the National Health and Nutrition 
      Examination Survey (NHANES) between 2011 and 2018. All participants over 40 years 
      old and who selected "preventive aspirin use" were included in the study. 
      Logistic regression analyses were used to evaluate the relationship between LDA 
      intake and hyperuricemia. The stratified analysis was based on race and estimated 
      glomerular filtration rate (eGFR). RESULTS A total of 3540 participants were 
      included in the study. Of them, 805 (22.7%) took LDA, and 190 (31.6%) had 
      hyperuricemia. There was no significant association between hyperuricemia and LDA 
      intake (OR=1.22, 95% CI: 0.97-1.54) after adjusting for confounding factors. 
      However, further subgroup analysis by age showed a significant association 
      between LDA intake and hyperuricemia (OR=3.44, 95% CI: 1.88-6.27) among those 40 
      to 50 years of age. After adjusting for confounding factors, the relationship was 
      still significant (OR=2.28, 95% CI: 1.10-4.73); we also found that race (Hispanic 
      American, OR=1.84, 95% CI: 1.11-3.06) and eGFR under 60 mL/min/1.73 m² (OR=1.94, 
      95% CI: 1.04-3.62) may play important roles in the development of hyperuricemia. 
      CONCLUSIONS LDA does not increase the hyperuricemia risk in people over 40 years. 
      However, those aged between 40 and 50 years, Hispanic American, and with impaired 
      renal function should have careful evaluation during LDA treatment.
FAU - Zhu, Bin
AU  - Zhu B
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (mainland).
FAU - Cao, MingNan
AU  - Cao M
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (mainland).
FAU - Wu, Qiao
AU  - Wu Q
AD  - Infectious Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, 
      China (mainland).
FAU - Liu, Kejia
AU  - Liu K
AD  - DHC Mediway Technology Co Ltd., Beijing, China (mainland).
FAU - Guo, Wei
AU  - Guo W
AD  - Department of Emergency, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (mainland).
FAU - Zhao, Zhigang
AU  - Zhao Z
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20230607
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 268B43MJ25 (Uric Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Adult
MH  - Middle Aged
MH  - Child, Preschool
MH  - *Hyperuricemia/chemically induced
MH  - Nutrition Surveys
MH  - Cross-Sectional Studies
MH  - Uric Acid
MH  - Risk Factors
MH  - Aspirin/adverse effects
EDAT- 2023/06/07 06:42
MHDA- 2023/06/08 06:42
CRDT- 2023/06/07 02:15
PHST- 2023/06/08 06:42 [medline]
PHST- 2023/06/07 06:42 [pubmed]
PHST- 2023/06/07 02:15 [entrez]
AID - 939546 [pii]
AID - 10.12659/MSM.939546 [doi]
PST - epublish
SO  - Med Sci Monit. 2023 Jun 7;29:e939546. doi: 10.12659/MSM.939546.

PMID- 770552
OWN - NLM
STAT- MEDLINE
DCOM- 19760706
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 57
IP  - 5
DP  - 1976 May
TI  - Refractory period to aspirin in a patient with aspirin-induced asthma.
PG  - 440-8
AB  - Oral aspirin challenge was used to detect unrecognized aspirin intolerance in a 
      select group of 50 asthmatic patients who denied aspirin intolerance. A 
      double-blind protocol was used to further study those patients who reacted to 
      initial graded aspirin challenge. In one patient the use of a double-blind 
      protocol led to the serendipitous discovery of a 72-hr refractory period to the 
      adverse effects of aspirin, after initial ingestion of aspirin resulted in 
      respiratory and systemic symptoms.
FAU - Zeiss, C R
AU  - Zeiss CR
FAU - Lockey, R F
AU  - Lockey RF
LA  - eng
PT  - Case Reports
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced/diagnosis
MH  - Clinical Trials as Topic
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Time Factors
EDAT- 1976/05/01 00:00
MHDA- 1976/05/01 00:01
CRDT- 1976/05/01 00:00
PHST- 1976/05/01 00:00 [pubmed]
PHST- 1976/05/01 00:01 [medline]
PHST- 1976/05/01 00:00 [entrez]
AID - 0091-6749(76)90059-2 [pii]
AID - 10.1016/0091-6749(76)90059-2 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1976 May;57(5):440-8. doi: 10.1016/0091-6749(76)90059-2.

PMID- 35408523
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220531
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 27
IP  - 7
DP  - 2022 Mar 25
TI  - Prediction of Low-Dose Aspirin-Induced Gastric Toxicity Using Nuclear Magnetic 
      Resonance Spectroscopy-Based Pharmacometabolomics in Rats.
LID - 10.3390/molecules27072126 [doi]
LID - 2126
AB  - BACKGROUND: Low-dose aspirin (LDA) is the backbone for secondary prevention of 
      coronary artery disease, although limited by gastric toxicity. This study aimed 
      to identify novel metabolites that could predict LDA-induced gastric toxicity 
      using pharmacometabolomics. METHODS: Pre-dosed urine samples were collected from 
      male Sprague-Dawley rats. The rats were treated with either LDA (10 mg/kg) or 1% 
      methylcellulose (10 mL/kg) per oral for 28 days. The rats' stomachs were examined 
      for gastric toxicity using a stereomicroscope. The urine samples were analyzed 
      using a proton nuclear magnetic resonance spectroscopy. Metabolites were 
      systematically identified by exploring established databases and multivariate 
      analyses to determine the spectral pattern of metabolites related to LDA-induced 
      gastric toxicity. RESULTS: Treatment with LDA resulted in gastric toxicity in 
      20/32 rats (62.5%). The orthogonal projections to latent structures discriminant 
      analysis (OPLS-DA) model displayed a goodness-of-fit (R(2)Y) value of 0.947, 
      suggesting near-perfect reproducibility and a goodness-of-prediction (Q(2)Y) of 
      -0.185 with perfect sensitivity, specificity and accuracy (100%). Furthermore, 
      the area under the receiver operating characteristic (AUROC) displayed was 1. The 
      final OPLS-DA model had an R(2)Y value of 0.726 and Q(2)Y of 0.142 with 
      sensitivity (100%), specificity (95.0%) and accuracy (96.9%). Citrate, hippurate, 
      methylamine, trimethylamine N-oxide and alpha-keto-glutarate were identified as 
      the possible metabolites implicated in the LDA-induced gastric toxicity. 
      CONCLUSION: The study identified metabolic signatures that correlated with the 
      development of a low-dose Aspirin-induced gastric toxicity in rats. This 
      pharmacometabolomic approach could further be validated to predict LDA-induced 
      gastric toxicity in patients with coronary artery disease.
FAU - Sha'aban, Abubakar
AU  - Sha'aban A
AUID- ORCID: 0000-0002-5491-9851
AD  - School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, 
      Malaysia.
AD  - Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical 
      Sciences, Ahmadu Bello University, Zaria 810107, Nigeria.
FAU - Zainal, Hadzliana
AU  - Zainal H
AD  - School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, 
      Malaysia.
FAU - Khalil, Nor Azlina
AU  - Khalil NA
AD  - Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang 13200, 
      Malaysia.
FAU - Abd Aziz, Fatimatuzzahra'
AU  - Abd Aziz F
AUID- ORCID: 0000-0002-8123-126X
AD  - School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, 
      Malaysia.
FAU - Ch'ng, Ewe Seng
AU  - Ch'ng ES
AUID- ORCID: 0000-0001-8831-8678
AD  - Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang 13200, 
      Malaysia.
AD  - School of Medical and Life Sciences, Sunway University, Bandar Sunway 47500, 
      Malaysia.
FAU - Teh, Chin-Hoe
AU  - Teh CH
AUID- ORCID: 0000-0002-1511-9130
AD  - Bruker (Malaysia) Sdn Bhd, Bayan Lepas 11900, Malaysia.
FAU - Mohammed, Mustapha
AU  - Mohammed M
AUID- ORCID: 0000-0002-5021-1610
AD  - School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, 
      Malaysia.
AD  - Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical 
      Sciences, Ahmadu Bello University, Zaria 810107, Nigeria.
FAU - Ibrahim, Baharudin
AU  - Ibrahim B
AD  - School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, 
      Malaysia.
AD  - Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur 50603, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20220325
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects
MH  - *Coronary Artery Disease
MH  - Humans
MH  - Magnetic Resonance Spectroscopy/methods
MH  - Male
MH  - *Metabolomics/methods
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reproducibility of Results
MH  - Stomach
PMC - PMC9000689
OTO - NOTNLM
OT  - aspirin
OT  - gastric toxicity
OT  - multivariate analysis
OT  - nuclear magnetic resonance
OT  - pharmacometabolomic
OT  - spectroscopy
COIS- The authors declare no conflict of interest.
EDAT- 2022/04/13 06:00
MHDA- 2022/04/14 06:00
CRDT- 2022/04/12 01:10
PHST- 2022/01/27 00:00 [received]
PHST- 2022/03/21 00:00 [revised]
PHST- 2022/03/22 00:00 [accepted]
PHST- 2022/04/12 01:10 [entrez]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
AID - molecules27072126 [pii]
AID - molecules-27-02126 [pii]
AID - 10.3390/molecules27072126 [doi]
PST - epublish
SO  - Molecules. 2022 Mar 25;27(7):2126. doi: 10.3390/molecules27072126.

PMID- 25812803
OWN - NLM
STAT- MEDLINE
DCOM- 20160129
LR  - 20150602
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 15
IP  - 3
DP  - 2015 Jun
TI  - Statins and aspirin: do they really work in women?
PG  - 151-62
LID - 10.1007/s40256-015-0111-x [doi]
AB  - Cardiovascular disease continues to be the most common cause of mortality in 
      women in the USA. As a result, greater emphasis has been placed on preventive 
      measures. Studies examining the role of aspirin and HMG-CoA reductase inhibitors 
      (statins) have shown important clinical differences in men versus women in the 
      preventive realm. This has led to inconsistent recommendations by guideline 
      committees and clinicians alike. This review presents a summary of the past and 
      current guidelines. In addition, important clinical trials influencing current 
      era practice are also discussed. Both strengths and limitations of these studies 
      are described in detail, along with recommendations regarding future directions 
      and the scope of aspirin and statin use for primary and secondary prevention of 
      cardiovascular disease.
FAU - Desai, Hemal
AU  - Desai H
AD  - Baptist Health Lexington, Division of Cardiovascular Medicine, 1740 Nicholasville 
      Road, Lexington, KY, 40503, USA.
FAU - Hollingsworth, Paula W
AU  - Hollingsworth PW
FAU - Chugh, Atul R
AU  - Chugh AR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Male
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Primary Prevention/methods
MH  - Secondary Prevention/methods
MH  - Sex Factors
EDAT- 2015/03/31 06:00
MHDA- 2016/01/30 06:00
CRDT- 2015/03/28 06:00
PHST- 2015/03/28 06:00 [entrez]
PHST- 2015/03/31 06:00 [pubmed]
PHST- 2016/01/30 06:00 [medline]
AID - 10.1007/s40256-015-0111-x [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2015 Jun;15(3):151-62. doi: 10.1007/s40256-015-0111-x.

PMID- 20228719
OWN - NLM
STAT- MEDLINE
DCOM- 20100609
LR  - 20220408
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 101
IP  - 1
DP  - 2010 Feb
TI  - Aspirin and clopidogrel resistance: should we worry about?
PG  - 35-47
AB  - Antiplatelet therapy is a cornerstone of coronary artery disease treatment and 
      prevention. Aspirin and clopidogrel has emerged as the gold standard combination 
      for patients receiving coronary stent and/or suffering from acute coronary 
      syndrome. Despite their efficacy, recurrent events still occur and resistance to 
      antiplatelet drugs might be one of the responsible factors. Aspirin and 
      clopidogrel resistance are emerging entities primarily defined in biological 
      studies by inability of the drug to achieve expected antiplatelet effect based on 
      platelet function tests. Mechanisms of this variability of response remain 
      complex and partially unknown. Moreover, clinical papers linked this biological 
      entity with worse clinical outcomes, and therefore, tailored therapy based on 
      platelet tests has been proposed. Mean while, new antiplatelet drugs will soon 
      change the field while achieving homogeneous degree of platelet inhibition. The 
      present review aims to summarize biological and clinical data about resistance to 
      antiplatelet therapy, and try to estimate how much this might change our 
      prescription in daily clinical practice.
FAU - Cuisset, T
AU  - Cuisset T
AD  - Department of Cardiology, University Hospital of Marseille, Marseille, France. 
      thomascuisset@voila.fr
FAU - Cayla, G
AU  - Cayla G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - Drug Resistance/*physiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thromboembolism/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
RF  - 78
EDAT- 2010/03/17 06:00
MHDA- 2010/06/10 06:00
CRDT- 2010/03/16 06:00
PHST- 2010/03/16 06:00 [entrez]
PHST- 2010/03/17 06:00 [pubmed]
PHST- 2010/06/10 06:00 [medline]
AID - R10103033 [pii]
PST - ppublish
SO  - Minerva Med. 2010 Feb;101(1):35-47.

PMID- 19788357
OWN - NLM
STAT- MEDLINE
DCOM- 20091224
LR  - 20131121
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
VI  - 49
IP  - 9
DP  - 2009 Nov 1
TI  - Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, 
      and historic evidence.
PG  - 1405-10
LID - 10.1086/606060 [doi]
AB  - The high case-fatality rate--especially among young adults--during the 1918-1919 
      influenza pandemic is incompletely understood. Although late deaths showed 
      bacterial pneumonia, early deaths exhibited extremely "wet," sometimes 
      hemorrhagic lungs. The hypothesis presented herein is that aspirin contributed to 
      the incidence and severity of viral pathology, bacterial infection, and death, 
      because physicians of the day were unaware that the regimens (8.0-31.2 g per day) 
      produce levels associated with hyperventilation and pulmonary edema in 33% and 3% 
      of recipients, respectively. Recently, pulmonary edema was found at autopsy in 
      46% of 26 salicylate-intoxicated adults. Experimentally, salicylates increase 
      lung fluid and protein levels and impair mucociliary clearance. In 1918, the US 
      Surgeon General, the US Navy, and the Journal of the American Medical Association 
      recommended use of aspirin just before the October death spike. If these 
      recommendations were followed, and if pulmonary edema occurred in 3% of persons, 
      a significant proportion of the deaths may be attributable to aspirin.
FAU - Starko, Karen M
AU  - Starko KM
AD  - karenstarko@gmail.com
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Clin Infect Dis. 2010 Apr 15;50(8):1203; author reply 1203. PMID: 20233050
MH  - Aspirin/*adverse effects
MH  - Disease Outbreaks/history
MH  - History, 20th Century
MH  - Humans
MH  - Influenza, Human/*etiology/history/*mortality
MH  - United States
EDAT- 2009/10/01 06:00
MHDA- 2009/12/25 06:00
CRDT- 2009/10/01 06:00
PHST- 2009/10/01 06:00 [entrez]
PHST- 2009/10/01 06:00 [pubmed]
PHST- 2009/12/25 06:00 [medline]
AID - 10.1086/606060 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2009 Nov 1;49(9):1405-10. doi: 10.1086/606060.

PMID- 6878734
OWN - NLM
STAT- MEDLINE
DCOM- 19830920
LR  - 20190825
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 25
IP  - 4
DP  - 1983 Apr
TI  - Effects of aspirin and indomethacin on cerebral circulation in the conscious rat: 
      evidence for a physiological role of endogenous prostaglandins.
PG  - 549-56
AB  - The purpose of this work was to evaluate the effects of equipotent doses of two 
      different inhibitors of cyclo-oxygenase, indomethacin and aspirin, on cerebral 
      blood flow and cerebral vascular resistances in the conscious undisturbed rat, 
      using the reference sample radioactive microsphere method. We found that both, 
      aspirin (50 mg/kg) and indomethacin (5 mg/kg) at 3, 15 and 60 min after their 
      intravenous administration, increased cerebral vascular resistances and decreased 
      cerebral blood flow to a similar extent. Both drugs completely abolished the 
      hypotensive effect of 5 mg/kg i.v. arachidonic acid and they did not change 
      arterial PO2, PCO2 or pH values. We conclude that the pharmacological inhibition 
      of cyclooxygenase in the conscious undisturbed rat leads to a cerebral 
      vasoconstriction and consequently to a decrease in cerebral blood flow. Our 
      results evidence that prostaglandins are a physiological factor that actively 
      contributes to the maintenance of cerebral circulation.
FAU - Quintana, A
AU  - Quintana A
FAU - Raczka, E
AU  - Raczka E
FAU - Giralt, M T
AU  - Giralt MT
FAU - Quintana, M A
AU  - Quintana MA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Brain/blood supply
MH  - Cerebrovascular Circulation/*drug effects
MH  - Consciousness/physiology
MH  - Indomethacin/*pharmacology
MH  - Kinetics
MH  - Male
MH  - Prostaglandins/*physiology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Vascular Resistance/drug effects
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 0090-6980(83)90027-8 [pii]
AID - 10.1016/0090-6980(83)90027-8 [doi]
PST - ppublish
SO  - Prostaglandins. 1983 Apr;25(4):549-56. doi: 10.1016/0090-6980(83)90027-8.

PMID- 22490629
OWN - NLM
STAT- MEDLINE
DCOM- 20130610
LR  - 20181201
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 40
IP  - 1
DP  - 2012 Jan
TI  - [Effects of intensive antiplatelet therapy for patients with high on-treatment 
      platelet reactivity after coronary stent implantation].
PG  - 25-9
AB  - OBJECTIVE: To explore the effects of intensive antiplatelet therapy for patients 
      with high on-treatment platelet reactivity (HPR) after coronary stent 
      implantation. METHODS: Between March 2009 and February 2011, a total of 3316 
      consecutive acute coronary syndrome patients undergoing drug-eluting stent 
      implanting from 3 hospitals were enrolled. Among them, 840 patients (25.3%) were 
      identified as HPR (defined as 20 µmol/L adenosine diphosphate induced platelet 
      aggregation of ≥ 55% at 24 hours after administration of 300 mg clopidogrel 
      loading dose and 300 mg aspirin). The HPR patients were randomly assigned to 
      receive standard (aspirin 300 mg/d and clopidogrel 75 mg/d, n = 280) or 
      intensified (n = 560) antiplatelet therapy by the ratio of 1:2. Patients in the 
      intensive group were initially treated with a double maintenance dose of 
      clopidogrel (150 mg/d) and aspirin (300 mg/d). After 3 days, patients with 
      unsolved HPR received additional cilostazol treatment (50 - 100 mg, bid). The 
      reversion rate of HPR and clinical events were observed. RESULTS: In the 
      intensive group, HPR reversed in 304 out of 560 patients (54.3%) at 3 days post 
      therapy and the remaining 256 patients with HPR were treated with additional 
      cilostazol regimen for another 3 days and the total reversion rate of HPR was 
      81.1% (454/560). The reversion rate of HPR at 30 days in the intensified group 
      was significantly higher than that of the standard group (69.9% vs. 55.7%, P = 
      0.000). At 30 days after percutaneous coronary intervention, 1 patient suffered 
      from subacute stent thrombosis (0.2%) in intensified group and no stent 
      thrombosis was observed in standard group (P = 1.000). There were no death, major 
      or minor bleeding in both two groups. Minimal bleeding was also similar in the 
      two groups (intensive: 4.28% vs. standard: 2.14%, P = 0.166). CONCLUSIONS: The 
      intensified antiplatelet therapy regimens could significantly increase the 
      reversion rate of HPR in acute coronary syndrome patients undergoing coronary 
      stenting without increasing the risk of bleeding. The clinic impact of this 
      strategy needs to be elucidated by long term follow-up outcome studies.
FAU - Guan, Shao-yi
AU  - Guan SY
AD  - General Hospital of Shenyang Military Region, Shenyang, China.
FAU - Han, Ya-ling
AU  - Han YL
FAU - Li, Yi
AU  - Li Y
FAU - Guo, Liang
AU  - Guo L
FAU - Yang, Bai-song
AU  - Yang BS
FAU - Wang, Shou-li
AU  - Wang SL
FAU - Jing, Quan-min
AU  - Jing QM
FAU - Wang, Xiao-zeng
AU  - Wang XZ
FAU - Ma, Ying-yan
AU  - Ma YY
FAU - Liu, Xiao-dong
AU  - Liu XD
LA  - chi
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - A74586SNO7 (Clopidogrel)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cilostazol
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Drug-Eluting Stents
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Tetrazoles/administration & dosage/therapeutic use
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
EDAT- 2012/04/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2012/04/12 06:00
PHST- 2012/04/12 06:00 [entrez]
PHST- 2012/04/12 06:00 [pubmed]
PHST- 2013/06/12 06:00 [medline]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2012 Jan;40(1):25-9.

PMID- 15630484
OWN - NLM
STAT- MEDLINE
DCOM- 20050705
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 93
IP  - 1
DP  - 2005 Jan
TI  - Prevention of cardiovascular disease in type-2 diabetes: how to improve the 
      clinical efficacy of aspirin.
PG  - 8-16
AB  - Atherosclerotic cardiovascular disease and its thrombotic complications are the 
      principal causes of morbidity and mortality in patients with type-2 diabetes. 
      Aspirin reduces the risk of thrombotic events in a broad range of patients with 
      vascular disease and, in selected individuals, is beneficial for primary 
      prevention. Although recommended by existing guidelines, in secondary and in 
      primary prevention trials the clinical efficacy of low-dose aspirin in patients 
      with diabetes appears to be substantially lower than in individuals without 
      diabetes. In this review, we discuss possible mechanisms that may contribute to 
      reduce the antithrombotic activity of aspirin in diabetes. We also discuss 
      adjuvant therapies used in diabetic patients that may potentially improve the 
      antithrombotic efficacy of aspirin.
FAU - Evangelista, Virgilio
AU  - Evangelista V
AD  - Laboratory of Vascular Biology and Pharmacology, Consorzio Mario Negri Sud, Via 
      Nazionale, 66030 S. Maria Imbaro, Chieti, Italy. evangelista@negrisud.it
FAU - Totani, Licia
AU  - Totani L
FAU - Rotondo, Serenella
AU  - Rotondo S
FAU - Lorenzet, Roberto
AU  - Lorenzet R
FAU - Tognoni, Gianni
AU  - Tognoni G
FAU - De Berardis, Giorgia
AU  - De Berardis G
FAU - Nicolucci, Antonio
AU  - Nicolucci A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Thiazolidinediones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/etiology/*prevention & control
MH  - Diabetes Complications/prevention & control
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Drug Resistance
MH  - Humans
MH  - Inflammation/drug therapy
MH  - Thiazolidinediones/therapeutic use
RF  - 133
EDAT- 2005/01/05 09:00
MHDA- 2005/07/06 09:00
CRDT- 2005/01/05 09:00
PHST- 2005/01/05 09:00 [pubmed]
PHST- 2005/07/06 09:00 [medline]
PHST- 2005/01/05 09:00 [entrez]
AID - 05010008 [pii]
AID - 10.1160/TH04-07-0453 [doi]
PST - ppublish
SO  - Thromb Haemost. 2005 Jan;93(1):8-16. doi: 10.1160/TH04-07-0453.

PMID- 8303730
OWN - NLM
STAT- MEDLINE
DCOM- 19940308
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 25
IP  - 2
DP  - 1994 Feb
TI  - Failure of aspirin treatment after stroke.
PG  - 275-7
AB  - BACKGROUND AND PURPOSE: Despite its low efficacy, aspirin is the most widely used 
      drug for secondary stroke prevention. The reasons why stroke recurs while 
      patients are on aspirin are unknown. We have analyzed a series of patients who 
      had recurrent strokes while on aspirin. METHODS: Out of 2231 consecutive patients 
      who were admitted to the Tel Aviv Medical Center from May 1988 through December 
      1992 with the diagnosis of ischemic stroke, 129 admissions were due to recurrent 
      ischemic strokes while the patients were already on aspirin, and these were 
      defined as aspirin failures. The clinical characteristics of those patients in 
      whom aspirin treatment failed were compared with three control groups, each 
      comprising 129 patients who had had only a single ischemic stroke and were then 
      taking aspirin. One control group was matched for aspirin dose and date of first 
      stroke; another control group was matched for age, sex, and date of first stroke; 
      and a third control group was matched for age, sex, date of first stroke, and 
      aspirin dose. Statistical analysis was carried out by two-tailed Student's t test 
      and chi 2 test. RESULTS: The average period until stroke was longer for patients 
      on higher aspirin doses. Patients matched for aspirin dose and date of first 
      stroke did not differ significantly in age (72.4 years in aspirin failures versus 
      74.2 years in the first control group) and sex (89 versus 94 men, respectively). 
      Matching for age, sex, and date of first stroke but not for aspirin dose 
      demonstrated a trend toward high frequency of aspirin failure in patients taking 
      lower doses of aspirin (chi 2 test for trend = 3.5; P = .06). Comparison of 
      aspirin-failure patients with a control group matched for age, sex, date of first 
      ischemic stroke, and aspirin dose demonstrated that these patients more commonly 
      had statistically significant hyperlipidemia (odds ratio, 2.6; 95% confidence 
      interval, 1.0 to 6.8; P = .04) and ischemic heart disease (odds ratio, 2.3; 95% 
      confidence interval, 1.3 to 3.9; P = .002). CONCLUSIONS: We conclude that age and 
      sex do not influence the efficacy of aspirin. Lower aspirin dose in patients with 
      stroke recurrence suggests that aspirin doses of 500 mg daily or more should be 
      used in secondary stroke prevention. Hyperlipidemia and ischemic heart disease 
      are risk factors for stroke recurrence despite aspirin treatment, which requires 
      further clinical and laboratory evaluation.
FAU - Bornstein, N M
AU  - Bornstein NM
AD  - Department of Neurology, Tel Aviv Medical Center, Israel.
FAU - Karepov, V G
AU  - Karepov VG
FAU - Aronovich, B D
AU  - Aronovich BD
FAU - Gorbulev, A Y
AU  - Gorbulev AY
FAU - Treves, T A
AU  - Treves TA
FAU - Korczyn, A D
AU  - Korczyn AD
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 1994 Jul;25(7):1525-6. PMID: 8023375
CIN - Stroke. 1994 Aug;25(8):1701-2. PMID: 8042226
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Cerebrovascular Disorders/*drug therapy/epidemiology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Risk Factors
MH  - Treatment Failure
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
AID - 10.1161/01.str.25.2.275 [doi]
PST - ppublish
SO  - Stroke. 1994 Feb;25(2):275-7. doi: 10.1161/01.str.25.2.275.

PMID- 3374771
OWN - NLM
STAT- MEDLINE
DCOM- 19880712
LR  - 20190726
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 27
IP  - 3
DP  - 1988 Mar
TI  - Effect of aspirin on haloperidol-induced cataleptic behavior in mice.
PG  - 327-9
AB  - Haloperidol given intraperitoneally dose-dependently elicited cataleptic 
      behavior, evaluated by high bar and four-cork tests, in mice. The 
      haloperidol-induced cataleptic behavior was reduced dose-dependently after oral 
      treatment with aspirin, a cyclooxygenase inhibitor. The intra-cerebroventricular 
      administration of prostaglandin F2a produced cataleptic behavior of long duration 
      determined by the high bar test. It is suggested that prostaglandins may 
      participate in the induction of cataleptic behavior in part.
FAU - Ono, N
AU  - Ono N
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Fukuoka 
      University, Japan.
FAU - Saito, R
AU  - Saito R
FAU - Abiru, T
AU  - Abiru T
FAU - Matsushita, Y
AU  - Matsushita Y
FAU - Kamiya, H
AU  - Kamiya H
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Prostaglandins)
RN  - J6292F8L3D (Haloperidol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Catalepsy/*chemically induced/prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Haloperidol/*toxicity
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Prostaglandins/physiology
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
AID - 10.1016/0028-3908(88)90051-2 [doi]
PST - ppublish
SO  - Neuropharmacology. 1988 Mar;27(3):327-9. doi: 10.1016/0028-3908(88)90051-2.

PMID- 10528350
OWN - NLM
STAT- MEDLINE
DCOM- 19991124
LR  - 20131121
IS  - 0035-3787 (Print)
IS  - 0035-3787 (Linking)
VI  - 155
IP  - 9
DP  - 1999
TI  - [Prevention of cerebral ischemia: anti-platelet agents].
PG  - 688-93
AB  - Besides the optimal management of risk factors for stroke and carotid surgery, 
      antiplatelet agents are the cornerstone for prevention of cerebral ischaemia. The 
      aim of this overview is to determine their role in the prevention of cerebral 
      ischaemia, from available literature. In primary prevention, the benefit of 
      aspirin has been established only for patients with non-valvular atrial 
      fibrillation and a low risk of cardioembolism, or as an alternative choice of 
      warfarin, and in subjects at high risk of atherosclerosis. In secondary 
      prevention, antiplatelet agents are effective to reduce the risk in patients with 
      ischaemic stroke due to atherosclerosis: aspirin (50 to 1300 mg), ticlopidine 
      (500 mg), clopidogrel (75 mg) and dipyridamole (400 mg) are effective, but the 
      higher levels of risk reduction are obtained with clopidogrel, ticlopidine and 
      the association aspirin--dipyridamole. Aspirin is recommended in most other 
      causes of cerebral ischaemia, except in high risk cardiopathies when 
      anticoagulation is possible. Other domains should still be explored: are 
      antiplatelet agents also effective to reduce the risk of cerebral ischaemia in 
      patients with other causes, especially lipohyalinosis of the deep perforators 
      leading to lacunar infarcts? In daily practice, does prescription follow 
      recommendations? Will it be possible to reproduce the results of the European 
      Stroke Prevention Study (ESPS)2? Are antiplatelet agents other than aspirin 
      effective in non-valvular atrial fibrillation? Are other associations of 
      antiplatelet agents more effective than these agents alone? Finally, what will be 
      the role of new antiplatelet agents in the future?
FAU - Leys, D
AU  - Leys D
AD  - Service de neurologie et pathologie neurovasculaire, Centre Hospitalier et 
      Universitaire de Lille. dleys@chru-lille.fr
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Prévention de l'ischémie cérébrale: les agents antiplaquettaires.
PL  - France
TA  - Rev Neurol (Paris)
JT  - Revue neurologique
JID - 2984779R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis/complications
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/complications
MH  - Brain Ischemia/*prevention & control
MH  - Humans
MH  - Intracranial Embolism/complications
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 39
EDAT- 1999/10/21 00:00
MHDA- 1999/10/21 00:01
CRDT- 1999/10/21 00:00
PHST- 1999/10/21 00:00 [pubmed]
PHST- 1999/10/21 00:01 [medline]
PHST- 1999/10/21 00:00 [entrez]
AID - MDOI-RN-09-1999-155-9-0035-3787-101019-ART12 [pii]
PST - ppublish
SO  - Rev Neurol (Paris). 1999;155(9):688-93.

PMID- 34329734
OWN - NLM
STAT- MEDLINE
DCOM- 20220204
LR  - 20221003
IS  - 1872-9754 (Electronic)
IS  - 0197-0186 (Print)
IS  - 0197-0186 (Linking)
VI  - 149
DP  - 2021 Oct
TI  - Identification of a potent Nrf2 displacement activator among aspirin-containing 
      prodrugs.
PG  - 105148
LID - S0197-0186(21)00194-7 [pii]
LID - 10.1016/j.neuint.2021.105148 [doi]
AB  - Aspirin is a desired leaving group in prodrugs aimed at treatment of 
      neurodegeneration and other conditions. A library of aspirin derivatives of 
      various scaffolds potentially activating Nrf2 has been tested in Neh2-luc 
      reporter assay which screens for direct Nrf2 protein stabilizers working via 
      disruption of Nrf2-Keap1 interaction. Most aspirin prodrugs had a pro-alkylating 
      or pro-oxidant motif in the structure and, therefore, were toxic at high 
      concentrations. However, among the active compounds, we identified a molecule 
      resembling a well-known Nrf2 displacement activator, 
      bis-1,4-(4-methoxybenzenesulfonamidyl) naphthalene (NMBSA). The direct comparison 
      of the newly identified compound with NMBSA and its improved analog in the 
      reporter assay showed no quenching with N-acetyl cysteine, thus pointing to Nrf2 
      stabilization mechanism without cysteine alkylation. The potency of the newly 
      identified compound in the reporter assay was much stronger than NMBSA, despite 
      its inhibitory action in the commercial fluorescence polarization assay was 
      observed only in the millimolar range. Molecular docking predicted that 
      mono-deacetylation of the novel prodrug should generate a potent displacement 
      activator. The time-course of reporter activation with the novel prodrug had a 
      pronounced lag-period pointing to a plausible intracellular transformation 
      leading to an active product. Treatment of the novel prodrug with blood plasma or 
      cell lysate demonstrated stepwise deacetylation as judge by liquid 
      chromatography-mass spectrometry (LC-MS). Hence, the esterase-catalyzed 
      hydrolysis of the prodrug liberates only acetyl groups from aspirin moiety and 
      generates a potent Nrf2 activator. The discovered mechanism of prodrug activation 
      makes the newly identified compound a promising lead for future optimization 
      studies.
CI  - Copyright © 2021 Elsevier Ltd. All rights reserved.
FAU - Gaisina, Irina N
AU  - Gaisina IN
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, University of 
      Illinois, Chicago, IL, USA. Electronic address: igaysina@uic.edu.
FAU - Hushpulian, Dmitry M
AU  - Hushpulian DM
AD  - Faculty of Biology and Biotechnology, National Research University Higher School 
      of Economics, Moscow, Russia.
FAU - Gaisin, Arsen M
AU  - Gaisin AM
AD  - Integrated Molecular Structure Education and Research Center, Northwestern 
      University, Evanston, IL, USA.
FAU - Kazakov, Eliot H
AU  - Kazakov EH
AD  - Fordham University, Bronx, NY, USA.
FAU - Ammal Kaidery, Navneet
AU  - Ammal Kaidery N
AD  - Darby Children's Research Institute, Medical University of South Carolina, 
      Charleston, SC, USA; Department of Pediatrics, Medical University of South 
      Carolina, Charleston, SC, USA.
FAU - Ahuja, Manuj
AU  - Ahuja M
AD  - Darby Children's Research Institute, Medical University of South Carolina, 
      Charleston, SC, USA; Department of Pediatrics, Medical University of South 
      Carolina, Charleston, SC, USA; Department of Pharmaceutical Sciences, University 
      of Buffalo, Buffalo, NY, USA.
FAU - Poloznikov, Andrey A
AU  - Poloznikov AA
AD  - Faculty of Biology and Biotechnology, National Research University Higher School 
      of Economics, Moscow, Russia.
FAU - Gazaryan, Irina G
AU  - Gazaryan IG
AD  - Faculty of Biology and Biotechnology, National Research University Higher School 
      of Economics, Moscow, Russia; Department of Chemical Enzymology, M.V.Lomonosov 
      Moscow State University, Moscow, Russia; Department of Chemistry and Physical 
      Sciences, Pace University, Pleasantville, NY, USA.
FAU - Thatcher, Gregory R J
AU  - Thatcher GRJ
AD  - Department of Pharmacology & Toxicology, College of Pharmacy, University of 
      Arizona, Tucson, AZ, USA.
FAU - Thomas, Bobby
AU  - Thomas B
AD  - Darby Children's Research Institute, Medical University of South Carolina, 
      Charleston, SC, USA; Department of Pediatrics, Medical University of South 
      Carolina, Charleston, SC, USA; Department of Neuroscience, Medical University of 
      South Carolina, Charleston, SC, USA; Department of Drug Discovery, Medical 
      University of South Carolina, Charleston, SC, USA. Electronic address: 
      thomasbo@musc.edu.
LA  - eng
GR  - R01 NS101967/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210727
PL  - England
TA  - Neurochem Int
JT  - Neurochemistry international
JID - 8006959
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - 0 (Prodrugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cell Line, Tumor
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - NF-E2-Related Factor 2/agonists/*metabolism
MH  - Prodrugs/*pharmacology
MH  - Protein Structure, Tertiary
PMC - PMC8387448
MID - NIHMS1730834
OTO - NOTNLM
OT  - Antioxidant program
OT  - Keap1
OT  - Luciferase fusion reporter assay
OT  - Mass-spectroscopy
OT  - Nrf2
OT  - Prodrug activation
COIS- Declaration of competing interests None
EDAT- 2021/07/31 06:00
MHDA- 2022/02/05 06:00
CRDT- 2021/07/30 20:12
PHST- 2021/07/06 00:00 [received]
PHST- 2021/07/21 00:00 [revised]
PHST- 2021/07/26 00:00 [accepted]
PHST- 2021/07/31 06:00 [pubmed]
PHST- 2022/02/05 06:00 [medline]
PHST- 2021/07/30 20:12 [entrez]
AID - S0197-0186(21)00194-7 [pii]
AID - 10.1016/j.neuint.2021.105148 [doi]
PST - ppublish
SO  - Neurochem Int. 2021 Oct;149:105148. doi: 10.1016/j.neuint.2021.105148. Epub 2021 
      Jul 27.

PMID- 7516881
OWN - NLM
STAT- MEDLINE
DCOM- 19940722
LR  - 20190825
IS  - 0014-2972 (Print)
IS  - 0014-2972 (Linking)
VI  - 24 Suppl 1
DP  - 1994 Feb
TI  - Antiplatelet drugs.
PG  - 46-9
AB  - The evidence in support of the safety and efficacy of aspirin in the secondary 
      prevention of platelet dependent vascular occlusion is compelling. The utility of 
      this drug has stalled the development of potential competitors, such as 
      thromboxane antagonists. The emergence of glycoprotein IIb/IIIa antagonists as 
      the most promising competitors for aspirin has focused attention on the 
      possibility of delivering these drugs at an effective dose safely.
FAU - Fitzgerald, G A
AU  - Fitzgerald GA
AD  - Department of Medicine and Experimental Therapeutics, University College, Dublin, 
      Ireland.
FAU - Meagher, E A
AU  - Meagher EA
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Integrins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 64ALC7F90C (Dipyridamole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arterial Occlusive Diseases/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Integrins/*antagonists & inhibitors
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex
MH  - Ticlopidine/therapeutic use
RF  - 43
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
AID - 10.1111/j.1365-2362.1994.tb02427.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 1994 Feb;24 Suppl 1:46-9. doi: 
      10.1111/j.1365-2362.1994.tb02427.x.

PMID- 2221486
OWN - NLM
STAT- MEDLINE
DCOM- 19901109
LR  - 20131121
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 65
IP  - 4
DP  - 1990 Oct
TI  - Oral gold therapy in steroid-dependent asthma, nasal polyposis, and aspirin 
      hypersensitivity.
PG  - 288-90
AB  - Eight patients are described who fulfill the criteria for the triad of asthma, 
      nasal polyposis, and aspirin hypersensitivity who have been treated with oral 
      chrysotherapy from 7 to 17 months. Patient diary and symptom scores reflect an 
      overall improvement in global symptoms. Monthly pulmonary assessment (spirometry) 
      does not indicate a significant change (improvement or deterioration) but average 
      daily oral prednisone requirements have decreased. One of eight patients 
      experienced a minor side effect of treatment but did not require discontinuation 
      of therapy. Oral gold therapy may prove to be an alternative therapy in a select 
      population of patients and permit a reduction or discontinuation of oral 
      corticosteroid therapy.
FAU - McNeil, D L
AU  - McNeil DL
AD  - Division of Immunology, Ohio State University, Columbus.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - 0 (Adrenal Cortex Hormones)
RN  - 3H04W2810V (Auranofin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/*pharmacology
MH  - Aspirin/*adverse effects
MH  - Asthma/*drug therapy
MH  - Auranofin/*therapeutic use
MH  - Drug Hypersensitivity/etiology
MH  - Humans
MH  - Nasal Polyps
MH  - Prospective Studies
EDAT- 1990/10/01 00:00
MHDA- 1990/10/01 00:01
CRDT- 1990/10/01 00:00
PHST- 1990/10/01 00:00 [pubmed]
PHST- 1990/10/01 00:01 [medline]
PHST- 1990/10/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1990 Oct;65(4):288-90.

PMID- 370158
OWN - NLM
STAT- MEDLINE
DCOM- 19790516
LR  - 20190823
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 19
IP  - 2-3
DP  - 1979 Feb-Mar
TI  - Replicate studies comparing the relative efficacies of aspirin and indoprofen in 
      oral surgery outpatients.
PG  - 151-9
AB  - The results from the present studies confirm that indoprofen is an orally 
      effective analgesic drug. Both the 100- and 200-mg dosages of indoprofen 
      demonstrated superior analgesic activity when compared to 600 mg aspirin.
FAU - Cooper, S A
AU  - Cooper SA
FAU - Breen, J F
AU  - Breen JF
FAU - Giuliani, R L
AU  - Giuliani RL
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Phenylpropionates)
RN  - 0 (Placebos)
RN  - CPE46ZU14N (Indoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Indoprofen/*therapeutic use
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - Placebos
MH  - Time Factors
MH  - Tooth Extraction/adverse effects
EDAT- 1979/02/01 00:00
MHDA- 1979/02/01 00:01
CRDT- 1979/02/01 00:00
PHST- 1979/02/01 00:00 [pubmed]
PHST- 1979/02/01 00:01 [medline]
PHST- 1979/02/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1979.tb02473.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1979 Feb-Mar;19(2-3):151-9. doi: 
      10.1002/j.1552-4604.1979.tb02473.x.

PMID- 14967066
OWN - NLM
STAT- MEDLINE
DCOM- 20040423
LR  - 20181025
IS  - 1175-3277 (Print)
IS  - 1175-3277 (Linking)
VI  - 4
IP  - 1
DP  - 2004
TI  - Failure of aspirin to prevent atherothrombosis: potential mechanisms and 
      implications for clinical practice.
PG  - 57-67
AB  - Aspirin (acetylsalicylic acid) reduces the odds of serious atherothrombotic 
      vascular events and death in a broad category of high risk patients by about 
      one-quarter. The mechanism is believed to be inhibition of thromboxane 
      biosynthesis by inactivation of platelet cyclo-oxygenase-1 enzyme. However, 
      aspirin is not that effective; it still fails to prevent the majority of serious 
      vascular events. Mechanisms that may account for the failure of aspirin to 
      prevent vascular events include non-atherothrombotic causes of vascular disease, 
      non-adherence to aspirin therapy, an inadequate dosage, alternative "upstream" 
      pathways of platelet activation (e.g. via stimulation of the ADP, collagen or 
      thrombin receptors on platelets), aspirin-insensitive thromboxane biosynthesis 
      (e.g. via monocyte cyclo-oxygenase-2), or drugs that interfere with the 
      antiplatelet effects of aspirin. Genetic or acquired factors may further modify 
      the inhibitory effects of aspirin on platelets (e.g. polymorphisms involving 
      platelet-associated proteins, increased platelet turnover states). Identification 
      and treatment of the potential causes of aspirin failure could prevent at least 
      another 20% of serious vascular events (i.e. over and above those that are 
      currently prevented by aspirin). There is currently no role for routine 
      laboratory testing to measure the antiplatelet effects of aspirin. Clinicians 
      should ensure that patients at high risk of atherothrombosis (>3% risk over 5 
      years) are compliant with aspirin therapy and are taking the correct dosage 
      (75-150 mg/day). Patients who cannot tolerate aspirin, are allergic to aspirin, 
      or have experienced recurrent serious atherothrombotic events whilst taking 
      aspirin, should be treated with clopidogrel, and patients with acute coronary 
      syndromes benefit from the combination of clopidogrel plus aspirin. Future 
      research is required to standardize and validate laboratory testing of the 
      antiplatelet effects of aspirin and to identify treatments that can both improve 
      these laboratory measures and reduce the risk of future atherothrombotic events.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AD  - Department of Haematology, Royal Perth Hospital, Box x2213 GPO, Perth, WA 6001, 
      Australia. john.eikelboom@health.wa.gov.au
FAU - Hankey, Graeme J
AU  - Hankey GJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Coronary Artery Disease/blood/*drug therapy/epidemiology
MH  - Coronary Thrombosis/blood/*drug therapy/epidemiology
MH  - Fibrinolytic Agents/pharmacology/*therapeutic use
MH  - Humans
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Risk Factors
MH  - Treatment Failure
RF  - 119
EDAT- 2004/02/18 05:00
MHDA- 2004/04/24 05:00
CRDT- 2004/02/18 05:00
PHST- 2004/02/18 05:00 [pubmed]
PHST- 2004/04/24 05:00 [medline]
PHST- 2004/02/18 05:00 [entrez]
AID - 416 [pii]
AID - 10.2165/00129784-200404010-00006 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2004;4(1):57-67. doi: 10.2165/00129784-200404010-00006.

PMID- 19466986
OWN - NLM
STAT- MEDLINE
DCOM- 20100416
LR  - 20211020
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 157
IP  - 6
DP  - 2009 Jul
TI  - The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers.
PG  - 931-4
LID - 10.1111/j.1476-5381.2009.00243.x [doi]
AB  - BACKGROUND AND PURPOSE: Aspirin reduces the risk of myocardial infarction and 
      stroke by inhibiting thromboxane production in platelets. This inhibition can be 
      competitively antagonized by some non-steroidal anti-inflammatory drugs (NSAIDs). 
      EXPERIMENTAL APPROACH: By measuring thromboxane B(2) production in healthy 
      volunteers, we investigated whether ibuprofen (800 mg three times daily for 7 
      days) or diclofenac (50 mg three times daily for 7 days) taken concurrently with 
      aspirin 80 mg (once daily for 7 days) influenced the inhibitory effect of 
      aspirin. The effects were compared with aspirin 30 mg (once daily for 7 days), 
      which is the lowest dose of aspirin with a proven thromboprophylactic effect. KEY 
      RESULTS: The median percentage inhibition of thromboxane B(2) levels by 30 mg or 
      80 mg aspirin was 90.3% (range 83.1-96.0%) and 98.0% (range 96.8-99.2%) 
      respectively. The inhibition by concurrent administration of slow release 
      diclofenac and 80 mg aspirin was 98.1% (range 97.2-98.9%), indicating no 
      interference between aspirin and diclofenac. The inhibition decreased 
      significantly by concurrent administration of immediate release ibuprofen and 80 
      mg aspirin (86.6%; range 77.6-95.1%) to a level less than 30 mg aspirin. 
      CONCLUSIONS AND IMPLICATIONS: As alternatives are easily available, NSAIDs such 
      as diclofenac should be preferred to ibuprofen for combined use with aspirin.
FAU - Schuijt, M P
AU  - Schuijt MP
AD  - Clinical Chemistry, Canisius Wilhemina Hospital, Nijmegen 6532 SZ, The 
      Netherlands.
FAU - Huntjens-Fleuren, H W H A
AU  - Huntjens-Fleuren HW
FAU - de Metz, M
AU  - de Metz M
FAU - Vollaard, E J
AU  - Vollaard EJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20090519
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*blood/pharmacokinetics
MH  - Aspirin/antagonists & inhibitors/*blood/pharmacokinetics
MH  - Cross-Over Studies
MH  - Delayed-Action Preparations
MH  - Diclofenac/blood/pharmacokinetics
MH  - Drug Interactions/physiology
MH  - Female
MH  - Humans
MH  - Ibuprofen/*blood/pharmacokinetics
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects/physiology
MH  - Risk Factors
MH  - Thromboxane B2/antagonists & inhibitors/blood
PMC - PMC2737651
EDAT- 2009/05/27 09:00
MHDA- 2010/04/17 06:00
CRDT- 2009/05/27 09:00
PHST- 2009/05/27 09:00 [entrez]
PHST- 2009/05/27 09:00 [pubmed]
PHST- 2010/04/17 06:00 [medline]
AID - BPH243 [pii]
AID - 10.1111/j.1476-5381.2009.00243.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 2009 Jul;157(6):931-4. doi: 10.1111/j.1476-5381.2009.00243.x. 
      Epub 2009 May 19.

PMID- 11929345
OWN - NLM
STAT- MEDLINE
DCOM- 20020624
LR  - 20181113
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 20
IP  - 3
DP  - 2002
TI  - Optimising drug utilisation in long term care.
PG  - 143-52
AB  - Providing quality long term care for the elderly while containing costs is 
      presenting major challenges for governments and policy makers. Although 
      international variability exists with respect to the number of medications and 
      other factors influencing suboptimal pharmacotherapy, suboptimal pharmacotherapy 
      among elderly persons is common. This international problem requires a creative 
      and multifaceted approach to improve and rationalise prescribing. We outline the 
      non-regulatory efforts and regulatory means to approaching this problem. The 
      recent introduction of a prospective payment system for long-term care in the US 
      has underscored the importance of a regulatory approach to counter-balance the 
      cost containment efforts which bundle the cost of medications into a 
      prospectively set per diem rate. An examination of how US regulatory bodies are 
      considering improving prescribing is provided. Considering the case of coronary 
      heart disease, we provide data regarding the performance of a quality indicator 
      aimed at stimulating quality prescribing for this medical condition. Although the 
      use of regulatory approaches can improve prescribing, it is also recognised that 
      a more holistic approach involving multidisciplinary teams and greater focus on 
      the patient is the ultimate aspiration. This is particularly the case with the 
      elderly in whom appropriate drug therapy can have a major impact on outcomes. A 
      major cultural shift in the way society views and treats the elderly may be 
      required in order to produce dramatic improvements in long term care for older 
      people.
FAU - Lapane, Kate L
AU  - Lapane KL
AD  - Department of Community Health, Brown Medical School, Brown University, 
      Providence, Rhode Island 02912, USA. Kate_Lapane@brown.edu
FAU - Hughes, Carmel M
AU  - Hughes CM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/therapeutic use
MH  - Coronary Disease/prevention & control
MH  - Drug Prescriptions
MH  - Drug Utilization/*economics
MH  - Humans
MH  - Long-Term Care/*economics
MH  - Platelet Aggregation Inhibitors/therapeutic use
EDAT- 2002/04/04 10:00
MHDA- 2002/06/25 10:01
CRDT- 2002/04/04 10:00
PHST- 2002/04/04 10:00 [pubmed]
PHST- 2002/06/25 10:01 [medline]
PHST- 2002/04/04 10:00 [entrez]
AID - 200301 [pii]
AID - 10.2165/00019053-200220030-00001 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2002;20(3):143-52. doi: 10.2165/00019053-200220030-00001.

PMID- 1595104
OWN - NLM
STAT- MEDLINE
DCOM- 19920630
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 23
IP  - 6
DP  - 1992 Jun
TI  - European stroke prevention study: effectiveness of antiplatelet therapy in 
      diabetic patients in secondary prevention of stroke.
PG  - 851-4
AB  - BACKGROUND AND PURPOSE: The European Stroke Prevention Study was a multicenter 
      trial comparing the effect of a combination of 75 mg dipyridamole and 330 mg 
      acetylsalicylic acid three times a day with the effect of a placebo in the 
      prevention of stroke or death in 1,861 patients after one or more episodes of 
      recent transient ischemic attack or cerebral infarction. METHODS: The present 
      study represents a secondary analysis of the efficacy of study medication in 
      diabetic (n = 216) and nondiabetic (n = 1,645) patients. RESULTS: The risk of end 
      point events was greater in diabetic than in nondiabetic subjects. Total end 
      point reduction in individuals receiving the combination of dipyridamole and 
      acetylsalicylic acid was 39% in nondiabetic subjects and 23% in diabetic subjects 
      in the explanatory analysis, and the reduction in the risk of stroke was 48% and 
      32%, respectively. However, a statistically significant reduction of risk was 
      obtained only in nondiabetic subjects. CONCLUSIONS: The combination of 
      dipyridamole and acetylsalicylic acid appeared to be more effective in 
      nondiabetic subjects than in diabetic subjects in the prevention of death and 
      stroke although the low number of diabetic patients may at least in part explain 
      this result.
FAU - Sivenius, J
AU  - Sivenius J
AD  - Department of Neurology, University of Kuopio, Finland.
FAU - Laakso, M
AU  - Laakso M
FAU - Riekkinen, P Sr
AU  - Riekkinen P Sr
FAU - Smets, P
AU  - Smets P
FAU - Lowenthal, A
AU  - Lowenthal A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 1993 May;24(5):760. PMID: 8488534
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Diabetes Complications
MH  - Diabetes Mellitus/*drug therapy
MH  - Dipyridamole/*therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 1992/06/11 19:15
MHDA- 2001/03/28 10:01
CRDT- 1992/06/11 19:15
PHST- 1992/06/11 19:15 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1992/06/11 19:15 [entrez]
AID - 10.1161/01.str.23.6.851 [doi]
PST - ppublish
SO  - Stroke. 1992 Jun;23(6):851-4. doi: 10.1161/01.str.23.6.851.

PMID- 35732453
OWN - NLM
STAT- MEDLINE
DCOM- 20230117
LR  - 20230215
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 62
IP  - 2
DP  - 2023 Jan 15
TI  - Small Intestinal Perforation Caused by Enteric-coated Low-dose Aspirin.
PG  - 233-235
LID - 10.2169/internalmedicine.9681-22 [doi]
AB  - A 77-year-old man presented with abdominal pain for 1 week. He was taking 
      enteric-coated low-dose aspirin (LDA) to prevent secondary cardiovascular events 
      and a proton pump inhibitor (PPI). Computed tomography indicated a small 
      intestinal perforation; thus, small intestine resection was performed. Two months 
      after surgery, he experienced a recurrence of the perforation. Since his repeated 
      perforation was suspected to be due to LDA, LDA was discontinued. He has 
      experienced no further recurrence since then. This is the first case of small 
      intestinal perforation caused by enteric-coated LDA. Enteric-coated LDA may cause 
      small intestinal perforation in patients with severe atherosclerosis under PPI 
      administration.
FAU - Matsubara, Shohei
AU  - Matsubara S
AD  - Department of Internal Medicine, Oida Hospital, Japan.
FAU - Sada, Ken-Ei
AU  - Sada KE
AD  - Department of Clinical Epidemiology, Kochi Medical School, Kochi University, 
      Japan.
FAU - Sawada, Haruo
AU  - Sawada H
AD  - Department of Internal Medicine, Oida Hospital, Japan.
FAU - Oida, Jiro
AU  - Oida J
AD  - Department of Surgery, Oida Hospital, Japan.
FAU - Tanaka, Kimiaki
AU  - Tanaka K
AD  - Department of Surgery, Oida Hospital, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220621
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Male
MH  - Humans
MH  - Aged
MH  - *Intestinal Perforation/chemically induced/diagnostic imaging/surgery
MH  - Aspirin/adverse effects
MH  - Proton Pump Inhibitors/adverse effects
MH  - Abdominal Pain
PMC - PMC9908378
OTO - NOTNLM
OT  - aspirin
OT  - atherosclerosis
OT  - case report
OT  - proton pump inhibitor
OT  - small intestinal perforation
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2022/06/23 06:00
MHDA- 2023/01/18 06:00
CRDT- 2022/06/22 21:13
PHST- 2022/06/23 06:00 [pubmed]
PHST- 2023/01/18 06:00 [medline]
PHST- 2022/06/22 21:13 [entrez]
AID - 10.2169/internalmedicine.9681-22 [doi]
PST - ppublish
SO  - Intern Med. 2023 Jan 15;62(2):233-235. doi: 10.2169/internalmedicine.9681-22. 
      Epub 2022 Jun 21.

PMID- 15230045
OWN - NLM
STAT- MEDLINE
DCOM- 20041019
LR  - 20131121
IS  - 0023-2149 (Print)
IS  - 0023-2149 (Linking)
VI  - 82
IP  - 5
DP  - 2004
TI  - [Anti-ischemic effects of trimetazidine in patients with post-infarction heart 
      failure].
PG  - 57-62
AB  - The antiishemic efficiency of course monotherapy with trimethazidine and its 
      impact on myocardial perfusion were studied in patients with postinfarct 
      dysfunction of the left ventricle (LV), which was associated with moderate heart 
      failure (HF). This prospective controlled clinical study included 47 patients who 
      had experienced myocardial infarction. The patients had also angina pectoris on 
      exertion and NYHA Functional Classes (FC) II-III HF. The patients were randomized 
      into 2 groups: Group 1 comprised patients with more than 50-W exercise tolerance 
      (ET), FC II angina, and FC II HF; Group 2 consisted of those with 50-W or less 
      ET, FC II-III angina, and FC II-III HF. Four-week course therapy with 
      trimethazidine in a dose of 60 mg/day was found to exert a pronounced 
      antiischemic effect in patients with reversible LV ischemia associated with HF. 
      The tolerance of the drug during its 4-week course therapy was good and the drug 
      caused no adverse reactions.
FAU - Tepliakov, A T
AU  - Tepliakov AT
FAU - Sankevich, qT V
AU  - Sankevich qV
FAU - Stepacheva, T A
AU  - Stepacheva TA
FAU - Garganeeva, A A
AU  - Garganeeva AA
FAU - Filippov, E A
AU  - Filippov EA
FAU - Pushnikova, E Iu
AU  - Pushnikova EIu
FAU - Kaliuzhin, V V
AU  - Kaliuzhin VV
FAU - Efimova, I Iu
AU  - Efimova I
FAU - Zavadovskiĭ, K V
AU  - Zavadovskiĭ KV
LA  - rus
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Anti-ishemicheskaia éffektivnost' trimetazidina u bol'nykh s postinfarktnoĭ 
      serdechnoĭ nedostatochnost'iu.
PL  - Russia (Federation)
TA  - Klin Med (Mosk)
JT  - Klinicheskaia meditsina
JID - 2985204R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Vasodilator Agents)
RN  - N9A0A0R9S8 (Trimetazidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Infarction
MH  - Trimetazidine/*therapeutic use
MH  - Vasodilator Agents/*therapeutic use
EDAT- 2004/07/03 05:00
MHDA- 2004/10/20 09:00
CRDT- 2004/07/03 05:00
PHST- 2004/07/03 05:00 [pubmed]
PHST- 2004/10/20 09:00 [medline]
PHST- 2004/07/03 05:00 [entrez]
PST - ppublish
SO  - Klin Med (Mosk). 2004;82(5):57-62.

PMID- 33159252
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20230415
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 51
IP  - 2
DP  - 2021 Feb
TI  - Platelet reactivity in response to aspirin and ticagrelor in African-Americans 
      and European-Americans.
PG  - 249-259
LID - 10.1007/s11239-020-02327-w [doi]
AB  - Platelet gene polymorphisms are associated with variable on-treatment platelet 
      reactivity and vary by race. Whether differences in platelet reactivity and 
      aspirin or ticagrelor exist between African-American and European-Americans 
      remains poorly understood. Biological samples from three prior prospective 
      antiplatelet challenge studies at the Duke Clinical Research Unit were used to 
      compare platelet reactivity between African-American and European-American 
      subjects. Platelet reactivity at baseline, on-aspirin, on-ticagrelor, and the 
      treatment effect of aspirin or ticagrelor were compared between groups using an 
      adjusted mixed effects model. Compared with European-Americans (n = 282; 50% 
      female; mean ± standard deviation age, 50 ± 16), African-Americans (n = 209; 67% 
      female; age 48 ± 12) had lower baseline platelet reactivity with platelet 
      function analyzer-100 (PFA-100) (p < 0.01) and with light transmission 
      aggregometry (LTA) in response to arachidonic acid (AA), adenosine diphosphate 
      (ADP), and epinephrine agonists (p < 0.05). African-Americans had lower platelet 
      reactivity on aspirin in response to ADP, epinephrine, and collagen (p < 0.05) 
      and on ticagrelor in response to AA, ADP, and collagen (p < 0.05). The treatment 
      effect of aspirin was greater in European-Americans with an AA agonist 
      (p = 0.002). Between-race differences with in vitro aspirin mirrored those seen 
      in vivo. The treatment effect of ticagrelor was greater in European-Americans in 
      response to ADP (p < 0.05) but with collagen, the treatment effect was greater 
      for African-Americans (p < 0.05). Platelet reactivity was overall lower in 
      African-Americans off-treatment, on aspirin, and on ticagrelor. 
      European-Americans experienced greater platelet suppression on aspirin and on 
      ticagrelor. The aspirin response difference in vivo and in vitro suggests a 
      mechanism intrinsic to the platelet. Whether the absolute level of platelet 
      reactivity or the degree of platelet suppression after treatment is more 
      important for clinical outcomes is uncertain.
FAU - Infeld, Margaret
AU  - Infeld M
AUID- ORCID: 0000-0002-1923-6166
AD  - Division of Cardiology, Department of Medicine, Larner College of Medicine, 
      University of Vermont, Burlington, VT, USA.
FAU - Friede, Kevin A
AU  - Friede KA
AD  - Division of Cardiology, Department of Medicine, Duke University, Durham, NC, USA.
FAU - San, Tan Ru
AU  - San TR
AD  - Department of Cardiology, National Heart Centre, Singapore, Singapore.
FAU - Knickerbocker, Holly J
AU  - Knickerbocker HJ
AD  - Center for Applied Genomics & Precision Medicine, Duke University, 2187 CIEMAS, 
      Campus Box 3382, Durham, NC, 27708, USA.
FAU - Ginsburg, Geoffrey S
AU  - Ginsburg GS
AD  - Center for Applied Genomics & Precision Medicine, Duke University, 2187 CIEMAS, 
      Campus Box 3382, Durham, NC, 27708, USA.
AD  - Division of Cardiology, Department of Medicine, Duke University, Durham, NC, USA.
FAU - Ortel, Thomas L
AU  - Ortel TL
AD  - Division of Hematology, Duke University, Durham, NC, USA.
FAU - Voora, Deepak
AU  - Voora D
AD  - Center for Applied Genomics & Precision Medicine, Duke University, 2187 CIEMAS, 
      Campus Box 3382, Durham, NC, 27708, USA. deepak.voora@duke.edu.
AD  - Division of Cardiology, Department of Medicine, Duke University, Durham, NC, USA. 
      deepak.voora@duke.edu.
LA  - eng
GR  - 2012/0003R/Duke-National University Singapore/
GR  - 5RC1GM091083/National Institutes of General Medical Sciences/
GR  - R01 HL118049/HL/NHLBI NIH HHS/United States
GR  - U01 DD000014/DD/NCBDD CDC HHS/United States
GR  - 5U01DD000014/CC/CDC HHS/United States
GR  - RC1 GM091083/GM/NIGMS NIH HHS/United States
GR  - UL1 RR024128/RR/NCRR NIH HHS/United States
GR  - R01HL118049/Foundation for the National Institutes of Health/
GR  - 5UL1RR024128/RR/NCRR NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
DEP - 20201106
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Black or African American
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Ticagrelor/*pharmacology
MH  - White People
PMC - PMC7889728
MID - NIHMS1644827
OTO - NOTNLM
OT  - African-American
OT  - Aspirin
OT  - European-American
OT  - Light transmission aggregometry
OT  - Platelet reactivity
OT  - Ticagrelor
EDAT- 2020/11/08 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/11/07 05:34
PHST- 2020/10/30 00:00 [accepted]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/11/07 05:34 [entrez]
AID - 10.1007/s11239-020-02327-w [pii]
AID - 10.1007/s11239-020-02327-w [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2021 Feb;51(2):249-259. doi: 10.1007/s11239-020-02327-w. 
      Epub 2020 Nov 6.

PMID- 34648924
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20220202
IS  - 1532-8406 (Electronic)
IS  - 0883-5403 (Linking)
VI  - 37
IP  - 2
DP  - 2022 Feb
TI  - Aspirin Thromboprophylaxis Is Associated With Less Major Bleeding Events 
      Following Total Joint Arthroplasty.
PG  - 379-384.e2
LID - S0883-5403(21)00768-3 [pii]
LID - 10.1016/j.arth.2021.10.001 [doi]
AB  - BACKGROUND: There is ongoing debate on what is optimal prophylactic agent to 
      reduce venous thromboembolism (VTE) following total joint arthroplasty (TJA). 
      Although many studies assess the efficacy of these agents in VTE prevention, no 
      attention is given to their adverse effect on major bleeding events (MBEs). This 
      study compared the incidence of MBE in patients receiving aspirin as VTE 
      prophylaxis vs other chemoprophylaxis. METHODS: A single-institution, 
      retrospective study of 35,860 patients undergoing TJA between 2009 and 2020 was 
      conducted. Demographic variables, co-morbidities, type of chemoprophylaxis, and 
      intraoperative factors were collected. MBE was defined using the 2010 criteria 
      for major bleeding in surgical patients presented by the Scientific and 
      Standardization Committee of the International Society on Thrombosis and 
      Haemostasis. To enhance capture rate, comprehensive queries utilizing MBE 
      keywords were conducted in clinical notes, physician dictations, and phone call 
      logs. Univariate followed by multivariate regression was performed as well as 
      propensity score matched analysis. RESULTS: Overall, 270 patients (0.75%) in this 
      cohort developed MBE. The MBE rate was 0.5% in the aspirin group and 1.2% in the 
      non-aspirin group. After adjusting for confounders, multiple logistic regression 
      and propensity score matched analysis revealed almost 2 times lower odds of MBE 
      in patients who received aspirin. Variables independently associated with 
      increased MBE risk included increasing age, body mass index, American Society of 
      Anesthesiologists score, revision surgery, peptic ulcer disease, coagulopathy, 
      intraoperative blood transfusion, and active smoking. CONCLUSION: Administration 
      of aspirin for VTE prophylaxis, compared to other chemoprophylaxis agents may 
      have an association with lower risk of major bleeding following TJA. Future 
      randomized controlled trials should examine these findings.
CI  - Copyright © 2021. Published by Elsevier Inc.
FAU - Shohat, Noam
AU  - Shohat N
AD  - Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA; 
      Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
FAU - Ludwick, Leanne
AU  - Ludwick L
AD  - Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA.
FAU - Goh, Graham S
AU  - Goh GS
AD  - Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA.
FAU - Streicher, Sydney
AU  - Streicher S
AD  - Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA.
FAU - Chisari, Emanuele
AU  - Chisari E
AD  - Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA.
FAU - Parvizi, Javad
AU  - Parvizi J
AD  - Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA.
LA  - eng
PT  - Journal Article
DEP - 20211012
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants
MH  - Arthroplasty
MH  - *Arthroplasty, Replacement, Hip
MH  - Aspirin/adverse effects
MH  - Hemorrhage
MH  - Humans
MH  - Retrospective Studies
MH  - *Venous Thromboembolism/epidemiology/etiology/prevention & control
OTO - NOTNLM
OT  - aspirin
OT  - major bleeding event
OT  - risk factors
OT  - total joint arthroplasty
OT  - venous thromboembolism
EDAT- 2021/10/15 06:00
MHDA- 2022/01/28 06:00
CRDT- 2021/10/14 20:13
PHST- 2021/07/15 00:00 [received]
PHST- 2021/09/27 00:00 [revised]
PHST- 2021/10/04 00:00 [accepted]
PHST- 2021/10/15 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
PHST- 2021/10/14 20:13 [entrez]
AID - S0883-5403(21)00768-3 [pii]
AID - 10.1016/j.arth.2021.10.001 [doi]
PST - ppublish
SO  - J Arthroplasty. 2022 Feb;37(2):379-384.e2. doi: 10.1016/j.arth.2021.10.001. Epub 
      2021 Oct 12.

PMID- 23898692
OWN - NLM
STAT- MEDLINE
DCOM- 20151006
LR  - 20181202
IS  - 0024-3477 (Print)
IS  - 0024-3477 (Linking)
VI  - 135
IP  - 5-6
DP  - 2013 May-Jun
TI  - [Anticoagulant therapy in patients with permanent atrial fibrillation - evidence 
      based medicine and clinical practice].
PG  - 129-34
AB  - Objective of study was to assess the concordance of the tromboprophylactic 
      treatment in patients with permanent atrial fibrillation (pAF) with guidelines of 
      the European Society of Cardiology. Prospective cross-sectional study 
      consecutivelly included 674 patients (400 S59%C male) discharged from cardiology 
      department with the diagnosis pAF. The thromboembolic risk (TE) has been 
      established according to CHA2DS2-VASc score, whereas the bleeding risk has been 
      assessed according to HAS-BLED score. 578 (86%) belonged to the group of high, 57 
      (8%) to the group of moderate, and 39 (6%) patients to the group of low TE risk. 
      601 (89%) patients received thromboprophylaxis: 310 (46%) warfarin, 258 (38%) 
      acetylsalicylic acid, and 33 (5%) patients clopidogrel. Warfarin has been 
      prescribed to 47% of patients with high, 49% of patients with moderate and to 26% 
      of patients with low TE risk (P=0.03). Acetylsalicylic acid (ASA) has equally 
      been prescribed to patients of all TE risk groups: low, moderate and high (39% 
      vs. 39% vs.38%/o; P=0.998). ASA (P<0.001) and warfarin (P=0.007) have been used 
      more frequently in the group of patients with high bleeding risk, in which the 
      same incidence of warfarin and ASA administration has been registered (53% vs. 
      47%; P=0.416). Age > or =75 has been an independent predictor of 
      non-administration (OR 1.7; 95% CI 1.2-2.4; P=0.003), whereas the history of 
      stroke was for warfarin administration (OR 0.47; 95% CI 0.29-0.76; P-0.002). In 
      prescribing thromboprophylaxis to patients with pAF, cardiologists do not observe 
      the recommended clinical guidelines. Despite nonexistence of contraindications, a 
      significant number of patients with high TE risk has not been administered 
      warfarin. At the same time, warfarin has been administered to the patients with 
      low TE risk, exposing them unnecessarily to the undesired effect of anticoagulant 
      treatment.
FAU - Bozić, Ivona
AU  - Bozić I
AD  - Klinicki bolnicki centar Split
FAU - Capkun, Vesna
AU  - Capkun V
FAU - Bozić, Dorotea
AU  - Bozić D
FAU - Karabuva, Svjetlana
AU  - Karabuva S
FAU - Caljkusić, Kresimir
AU  - Caljkusić K
FAU - Trgo, Gorana
AU  - Trgo G
FAU - Carević, Vedran
AU  - Carević V
FAU - Fabijanić, Damir
AU  - Fabijanić D
LA  - hrv
PT  - Journal Article
TT  - Antikoagulantno lijecenje u bolesnika s trajnom fibrilacijom atrija - medicina 
      utemeljena na dokazima i klinicka praksa.
PL  - Croatia
TA  - Lijec Vjesn
JT  - Lijecnicki vjesnik
JID - 0074253
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Cross-Sectional Studies
MH  - Evidence-Based Medicine
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Risk Factors
MH  - Stroke/chemically induced
MH  - Thromboembolism/*prevention & control
MH  - Warfarin/adverse effects/therapeutic use
EDAT- 2013/08/01 06:00
MHDA- 2015/10/07 06:00
CRDT- 2013/08/01 06:00
PHST- 2013/08/01 06:00 [entrez]
PHST- 2013/08/01 06:00 [pubmed]
PHST- 2015/10/07 06:00 [medline]
PST - ppublish
SO  - Lijec Vjesn. 2013 May-Jun;135(5-6):129-34.

PMID- 16181986
OWN - NLM
STAT- MEDLINE
DCOM- 20051228
LR  - 20131121
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 116
IP  - 6
DP  - 2005
TI  - Marked increase of fibrin gel permeability with very low dose ASA treatment.
PG  - 509-17
AB  - INTRODUCTION: Previous data from our group show that acetylsalicylic acid (ASA), 
      especially at low dose, alters the network structure of fibrin, rendering it more 
      porous. The present study was performed to extend the dose-response curve for 
      effects of ASA on fibrinogen clotting properties and to examine the variability 
      of these effects during a 24-h dose interval. MATERIAL AND METHODS: Fifteen 
      healthy volunteers received ASA 37.5 mg daily (low dose) for 10 days and, after 
      an interval of 2 weeks, 320 mg daily (medium dose) for 7 days, followed by a 
      single bolus dose of 640 mg (high dose). The plasma fibrinogen concentrations 
      were determined and the permeability of fibrin gels (Ks) was assayed with a 
      recently modified flow measurement technique. Three-dimensional (3D) structure of 
      the fibrin network was studied by confocal microscopy. RESULTS: ASA therapy did 
      not influence fibrinogen concentrations. Compared to baseline, Ks levels were 
      increased by 21% and 31% in samples during medium and high dose ASA treatment 
      (p<0.01) and, even more markedly, by 44% (p<0.0001) with very low dose ASA 
      treatment (p<0.01, compared to the higher doses). The effects of ASA on fibrin 
      gel permeability were stable over a 24-h dose interval. During ASA treatment, 
      thicker fibrin fibers and larger network pores with irregular structure were 
      observed by confocal microscopy. CONCLUSIONS: Acetylation of lysine residues in 
      the fibrinogen molecule may explain the alterations in its clotting property, 
      resulting in altered fibrin gel permeability. The mechanism(s) behind the greater 
      increase in fibrin gel permeability and alterations in 3D structure of the fibrin 
      network observed, and why this phenomenon is more pronounced at low compared to 
      intermediate or high ASA doses, deserve further investigations.
FAU - Antovic, Aleksandra
AU  - Antovic A
AD  - Dept. of Surgical Sciences, Coagulation Research Division, Karolinska University 
      Hospital, Sweden. saskaant@yahoo.com
FAU - Perneby, Christina
AU  - Perneby C
FAU - Ekman, Gunilla Jacobsson
AU  - Ekman GJ
FAU - Wallen, Håkan N
AU  - Wallen HN
FAU - Hjemdahl, Paul
AU  - Hjemdahl P
FAU - Blombäck, Margareta
AU  - Blombäck M
FAU - He, Shu
AU  - He S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Gels)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9001-31-4 (Fibrin)
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Coagulation Tests
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Fibrin/drug effects/*metabolism
MH  - Fibrinogen/analysis/metabolism
MH  - Fibrinolytic Agents/*administration & dosage/pharmacology
MH  - Gels
MH  - Humans
MH  - Imaging, Three-Dimensional
MH  - Male
MH  - Microscopy, Confocal
MH  - Permeability/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Porosity
MH  - Time Factors
EDAT- 2005/09/27 09:00
MHDA- 2005/12/29 09:00
CRDT- 2005/09/27 09:00
PHST- 2004/10/11 00:00 [received]
PHST- 2005/02/01 00:00 [revised]
PHST- 2005/02/09 00:00 [accepted]
PHST- 2005/09/27 09:00 [pubmed]
PHST- 2005/12/29 09:00 [medline]
PHST- 2005/09/27 09:00 [entrez]
AID - S0049-3848(05)00073-3 [pii]
AID - 10.1016/j.thromres.2005.02.007 [doi]
PST - ppublish
SO  - Thromb Res. 2005;116(6):509-17. doi: 10.1016/j.thromres.2005.02.007.

PMID- 14513200
OWN - NLM
STAT- MEDLINE
DCOM- 20040204
LR  - 20160512
IS  - 1618-2642 (Print)
IS  - 1618-2642 (Linking)
VI  - 377
IP  - 5
DP  - 2003 Nov
TI  - Non-particulate (continuous bed or monolithic) restricted-access reversed-phase 
      media for sample clean-up and separation by capillary-format liquid 
      chromatography.
PG  - 902-8
AB  - Restricted-access reversed-phase non-particulate (continuous bed or monolithic) 
      stationary phases of different hydrophobicity synthesized in 100 microm i.d. 
      fused silica capillaries have been evaluated. A specific property of 
      restricted-access media (RAM) is that they interact with small analytes and 
      exclude big molecules, e.g. proteins, from access to the active sites and 
      adsorption on the surface. This dual property facilitates direct injection of 
      biological fluids for drug or drug-metabolite analysis. Different RAM and 
      RAM-precursor capillary columns were tested to assess the influence of 
      chromatographic bed morphology on loadability. Inverse size-exclusion 
      chromatography was used for investigation of pore structural properties of the 
      capillary-format continuous beds. The data obtained were used to discuss the 
      mechanism of separation of the biological samples using capillary columns and to 
      propose a model for the topochemical architecture of the RAM investigated. 
      Different morphology of the non-particulate reversed-phase precursors resulted in 
      two types of RAM material shielded with hydrophilic polymer, classified as 
      homogeneous or heterogeneous topochemistry stationary phases. Capillary columns 
      were applied for chromatography of biological fluids. High resolution was 
      obtained, without the need for column switching, when capillary columns operated 
      in gradient conditions. Extensive evaluation of the chromatographic properties 
      (hydrophobicity, efficiency, separation impedance, and loadability) of the 
      non-particulate reversed-phase materials was performed before and after shielding 
      with hydrophilic polymer to generate restricted-access properties. Minor changes 
      of hydrophobicity, efficiency, or separation impedance were observed after the 
      shielding.
FAU - Jarmalaviciene, Reda
AU  - Jarmalaviciene R
AD  - Vytautas Magnus University, Vileikos str. 8, 3035, Kaunas, Lithuania.
FAU - Kornysova, Olga
AU  - Kornysova O
FAU - Westerlund, Douglas
AU  - Westerlund D
FAU - Maruska, Audrius
AU  - Maruska A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20030926
PL  - Germany
TA  - Anal Bioanal Chem
JT  - Analytical and bioanalytical chemistry
JID - 101134327
RN  - 0 (Benzoates)
RN  - 0 (Organic Chemicals)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/chemistry/isolation & purification
MH  - Animals
MH  - Aspirin/chemistry/isolation & purification
MH  - Benzoates/chemistry/isolation & purification
MH  - Caffeine/chemistry/isolation & purification
MH  - Cattle
MH  - Chromatography, High Pressure Liquid/instrumentation/*methods
MH  - Electrophoresis, Capillary/instrumentation/*methods
MH  - Flow Injection Analysis/methods
MH  - Organic Chemicals/chemistry/*isolation & purification
MH  - Silicon Dioxide/chemistry
MH  - Time Factors
EDAT- 2003/09/27 05:00
MHDA- 2004/02/05 05:00
CRDT- 2003/09/27 05:00
PHST- 2003/04/29 00:00 [received]
PHST- 2003/08/19 00:00 [revised]
PHST- 2003/08/25 00:00 [accepted]
PHST- 2003/09/27 05:00 [pubmed]
PHST- 2004/02/05 05:00 [medline]
PHST- 2003/09/27 05:00 [entrez]
AID - 10.1007/s00216-003-2244-z [doi]
PST - ppublish
SO  - Anal Bioanal Chem. 2003 Nov;377(5):902-8. doi: 10.1007/s00216-003-2244-z. Epub 
      2003 Sep 26.

PMID- 30706438
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20210109
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 176
IP  - 7
DP  - 2019 Apr
TI  - Aspirin eugenol ester attenuates oxidative injury of vascular endothelial cells 
      by regulating NOS and Nrf2 signalling pathways.
PG  - 906-918
LID - 10.1111/bph.14592 [doi]
AB  - BACKGROUND AND PURPOSE: Aspirin eugenol ester (AEE) is a new drug compound 
      synthesized by combining aspirin with eugenol. It was reported to possess 
      anti-thrombotic, anti-atherosclerotic, and anti-oxidative effects. However, its 
      molecular mechanism against oxidative injury is unclear. This study investigated 
      how AEE affected the oxidative injury of vascular endothelial cells in vivo and 
      in vitro. EXPERIMENTAL APPROACH: A hamster model of atherosclerosis induced by a 
      high fat diet (HFD) and an in vitro model of oxidative stress, H(2) O(2) -induced 
      apoptosis of HUVECs, were used to investigate the anti-oxidative effects of AEE. 
      KEY RESULTS: AEE significantly reduced the stimulatory effect of HFD on 
      malondialdehyde, the inhibitory effect of HFD on SOD activity and GSH/GSSG ratio, 
      and the overexpression of inducible NOS (iNOS) in the aorta. In vitro, incubation 
      of HUVECs with H(2) O(2) led their apoptosis, dysfunctions of the NO systems 
      (including increased iNOS activity, decreased endothelial NOS activity, and 
      increased production of NO), an imbalance in calcium homeostasis and energy 
      metabolism with an increase in intracellular free calcium and decrease in ATP, 
      and a down-regulation of Nrf2. In contrast, in the HUVECs pretreated with 1 μM 
      AEE for 24 hr, the above adverse effects induced by H(2) O(2) were significantly 
      ameliorated. Moreover, the decrease in NO production and activity of iNOS induced 
      by AEE was significantly attenuated in Nrf2-inhibited HUVECs. CONCLUSION AND 
      IMPLICATION: AEE protects vascular endothelial cells from oxidative injury by 
      regulating NOS and Nrf2 signalling pathways. This suggests that AEE is a novel 
      potential agent for the prevention of atherosclerosis.
CI  - © 2019 The British Pharmacological Society.
FAU - Huang, Mei-Zhou
AU  - Huang MZ
AUID- ORCID: 0000-0003-2538-0217
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Yang, Ya-Jun
AU  - Yang YJ
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Liu, Xi-Wang
AU  - Liu XW
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Qin, Zhe
AU  - Qin Z
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
FAU - Li, Jian-Yong
AU  - Li JY
AUID- ORCID: 0000-0003-3317-0666
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190306
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (aspirin eugenol ester)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 3T8H1794QW (Eugenol)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Atherosclerosis/*metabolism/prevention & control
MH  - Cells, Cultured
MH  - Cricetinae
MH  - Diet, High-Fat
MH  - Eugenol/*analogs & derivatives/pharmacology
MH  - Human Umbilical Vein Endothelial Cells/*drug effects/metabolism
MH  - Humans
MH  - NF-E2-Related Factor 2/genetics/*metabolism
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Synthase/*metabolism
MH  - Oxidative Stress/*drug effects
PMC - PMC6433644
COIS- The study was supported by the grants from National Natural Science Foundation of 
      China. The authors declare no conflicts of interest.
EDAT- 2019/02/02 06:00
MHDA- 2020/04/25 06:00
CRDT- 2019/02/02 06:00
PHST- 2018/11/16 00:00 [received]
PHST- 2019/01/03 00:00 [accepted]
PHST- 2019/02/02 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
PHST- 2019/02/02 06:00 [entrez]
AID - BPH14592 [pii]
AID - 10.1111/bph.14592 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2019 Apr;176(7):906-918. doi: 10.1111/bph.14592. Epub 2019 Mar 6.

PMID- 26414108
OWN - NLM
STAT- MEDLINE
DCOM- 20161014
LR  - 20181202
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 43
IP  - 1
DP  - 2016 Jan
TI  - Low-dose adjunctive cilostazol in patients with complex lesions undergoing 
      percutaneous coronary intervention.
PG  - 29-33
LID - 10.1111/1440-1681.12495 [doi]
AB  - Patients with complex coronary lesions undergoing percutaneous coronary 
      intervention (PCI) have more major adverse cardiac events (MACE) than do those 
      with simpler cases. Therefore, intensive antiplatelet therapy might be needed in 
      these patients. A total of 127 patients with complex lesions undergoing PCI in 
      the Second Hospital of Tianjin Medical University from October 2012 to April 2014 
      were randomized to receive either dual (aspirin plus clopidogrel, DAPT, n = 66), 
      or triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol; TAPT, 
      n = 61). Patients in the TAPT group received low-dose cilostazol (100 mg loading, 
      followed with 50 mg twice per day) for 3-6 months. The primary endpoint was 
      composite MACE. The complex coronary target lesions were defined as at least one 
      of the following: left main disease; severe 3-vessel disease; chronic total 
      occlusion lesions; true bifurcation lesion; ostial lesions; severe calcified 
      lesions; and highly thrombotic lesions. The two groups had similar baseline 
      clinical and angiographic characteristics. One-year clinical outcomes showed that 
      the TAPT group had significantly lower incidences of myocardial infarction (1.6% 
      vs 13.6%, P = 0.018) and MACE (1.6% vs 16.7%, P = 0.004) than DAPT group. The 
      DAPT group had two cases of stent thrombosis, while the TAPT group did not. 
      Furthermore, adjunctive low-dose cilostazol didn't significantly increase the 
      incidence of bleeding events (26.2% vs 19.7%, P = 0.381) regardless of major 
      (4.9% vs 4.5%, P = 0.921) or minor (21.3% vs 15.2%, P = 0.368) bleeding events. 
      In conclusion, low-dose adjunctive cilostazol seems superior to dual antiplatelet 
      therapy in reducing recurrent ischemic events in patients with complex coronary 
      lesions and the two test groups have a similar incidence of bleeding events.
CI  - © 2015 Wiley Publishing Asia Pty Ltd.
FAU - Zheng, Xin-Tian
AU  - Zheng XT
AD  - Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, 
      Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Chen, Kang-Yin
AU  - Chen KY
AD  - Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, 
      Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Liu, Tong
AU  - Liu T
AD  - Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, 
      Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Xu, Ling-Xia
AU  - Xu LX
AD  - Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, 
      Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Che, Jing-Jin
AU  - Che JJ
AD  - Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, 
      Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Rha, Seung-Woon
AU  - Rha SW
AD  - Cardiovascular Centre, Korea University Guro Hospital, Seoul, Korea.
FAU - Li, Guang-Ping
AU  - Li GP
AD  - Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, 
      Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of 
      Tianjin Medical University, Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - A74586SNO7 (Clopidogrel)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cilostazol
MH  - Clopidogrel
MH  - Coronary Disease/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*adverse effects/*pharmacology/therapeutic use
MH  - *Safety
MH  - Tetrazoles/*adverse effects/*pharmacology/therapeutic use
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - cilostazol
OT  - complex coronary lesions
OT  - dual antiplatelet therapy
OT  - percutaneous coronary intervention
OT  - triple antiplatelet therapy
EDAT- 2015/09/29 06:00
MHDA- 2016/10/16 06:00
CRDT- 2015/09/29 06:00
PHST- 2015/06/22 00:00 [received]
PHST- 2015/09/13 00:00 [revised]
PHST- 2015/09/22 00:00 [accepted]
PHST- 2015/09/29 06:00 [entrez]
PHST- 2015/09/29 06:00 [pubmed]
PHST- 2016/10/16 06:00 [medline]
AID - 10.1111/1440-1681.12495 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2016 Jan;43(1):29-33. doi: 10.1111/1440-1681.12495.

PMID- 3137190
OWN - NLM
STAT- MEDLINE
DCOM- 19881011
LR  - 20131121
IS  - 0017-6192 (Print)
IS  - 0017-6192 (Linking)
VI  - 36
IP  - 6
DP  - 1988 Jun
TI  - [Treatment of acute inner ear diseases (sudden deafness and vestibular disorder) 
      with meclofenoxate and acetylsalicylic acid].
PG  - 226-9
AB  - Sixty patients suffering from an acute inner ear disease were treated by a 
      combination of acetylsalicylic acid (Micristin), an inhibitor of platelet 
      aggregation, and meclofenoxate (Cerutil), a nootropic drug. The success rate in 
      26 patients with acute isolated unilateral vestibular disorder was 73% (69% with 
      complete recovery), and 83% (57% complete remission) in 34 patients with sudden 
      deafness, with an average hearing improvement of 22.4 dB. The success rate of 
      this therapy was similar to that achieved by the usual therapy or no treatment in 
      subjects with sudden deafness and vestibular disorder which we reported in 1984.
FAU - Weinaug, P
AU  - Weinaug P
AD  - HNO-Abteilung, Kreisgesundheitseinrichtung Hildburghausen.
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Zur Therapie akuter Innenohrerkrankungen (Hörsturz und Vestibularisausfall) mit 
      Meklofenoxat und Azetylsalizylsäure.
PL  - Germany
TA  - HNO
JT  - HNO
JID - 2985099R
RN  - 0 (Glycolates)
RN  - C76QQ2I0RG (Meclofenoxate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/*therapeutic use
MH  - Glycolates/*therapeutic use
MH  - Hearing Loss, Sudden/*drug therapy
MH  - Humans
MH  - Labyrinth Diseases/*drug therapy
MH  - Meclofenoxate/*therapeutic use
MH  - Middle Aged
EDAT- 1988/06/01 00:00
MHDA- 1988/06/01 00:01
CRDT- 1988/06/01 00:00
PHST- 1988/06/01 00:00 [pubmed]
PHST- 1988/06/01 00:01 [medline]
PHST- 1988/06/01 00:00 [entrez]
PST - ppublish
SO  - HNO. 1988 Jun;36(6):226-9.

PMID- 6780841
OWN - NLM
STAT- MEDLINE
DCOM- 19810413
LR  - 20131121
IS  - 0341-3098 (Print)
IS  - 0341-3098 (Linking)
VI  - 122
IP  - 43
DP  - 1980 Oct 24
TI  - [Prophylaxis of thromboembolism in abdominal surgery. Comparison of low dose 
      heparin, acetylsalicylic acid and their combination (author's transl)].
PG  - 1495-8
AB  - The aim of the study was to compare the effect of three possibilities of 
      prophylaxis of thromboembolism: low dose heparin, acetylsalicylic acid (ASA) and 
      a combination of the two. The evaluation of the clinical observations showed no 
      significant differences between the three prophylaxis groups. The iodine 
      fibrinogen test showed no different reaction with regard to the leg, a 
      superiority of ASA in the thigh was suggested, at least in our random samples. 
      Whether this observation is the reason why the frequency of fatal pulmonary 
      emboli can be reduced by ASA is discussed. The complete calculation points to a 
      superiority for ASA here. The size of the selected samples is, however, too small 
      for more definite statements.
FAU - Zekert, F
AU  - Zekert F
FAU - Hofbauer, F
AU  - Hofbauer F
FAU - Mühlbacher, F
AU  - Mühlbacher F
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Thromboembolie-Prophylaxe in der Abdominalchirurgie. Vergleich von niedrig 
      dosiertem Heparin, Azetylsalizylsäure und deren Kombination.
PL  - Germany
TA  - MMW Munch Med Wochenschr
JT  - MMW, Munchener medizinische Wochenschrift
JID - 7801805
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdomen/surgery
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
MH  - Thromboembolism/*prevention & control
EDAT- 1980/10/24 00:00
MHDA- 1980/10/24 00:01
CRDT- 1980/10/24 00:00
PHST- 1980/10/24 00:00 [pubmed]
PHST- 1980/10/24 00:01 [medline]
PHST- 1980/10/24 00:00 [entrez]
PST - ppublish
SO  - MMW Munch Med Wochenschr. 1980 Oct 24;122(43):1495-8.

PMID- 718423
OWN - NLM
STAT- MEDLINE
DCOM- 19790124
LR  - 20190902
IS  - 0340-5761 (Print)
IS  - 0340-5761 (Linking)
VI  - 41
IP  - 1
DP  - 1978 Oct 13
TI  - Distention ulcer as a model for testing of drugs for ulcerogenic side effects.
PG  - 99-105
AB  - A modification of the distention ulcer was studied in albino rats and a new 
      possibility of testing ulcerogenic side effects of drugs was described. The 
      distention alone was not sufficient to produce lesions. The severity of ulcer 
      lesions was highly dependent on the volume of the acid solution. Large volumes of 
      0.1 N HC1 evoked severe ulcers within 1 h. Small amounts of weak acid solution 
      did not cause any ulceration. Anti-inflammatory drugs administered in therapeutic 
      doses, which did not yet produce any ulcers in animals, increased the sensitivity 
      of the gastric mucosa against the aggresive factor, the acid. In animals 
      pretreated by anti-inflammatory drugs in toxic doses an earlier development of 
      ulceration was observed by distention with acid. Stress also accelerated and 
      aggravated the formation of distention ulcers.
FAU - Szelenyi, I
AU  - Szelenyi I
FAU - Thiemer, K
AU  - Thiemer K
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arch Toxicol
JT  - Archives of toxicology
JID - 0417615
RN  - QTT17582CB (Hydrochloric Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - *Disease Models, Animal
MH  - Hydrochloric Acid/pharmacology
MH  - Indomethacin/pharmacology
MH  - Male
MH  - Rats
MH  - Stomach/physiopathology
MH  - Stomach Ulcer/*chemically induced
MH  - Stress, Physiological/physiopathology
MH  - Time Factors
EDAT- 1978/10/13 00:00
MHDA- 1978/10/13 00:01
CRDT- 1978/10/13 00:00
PHST- 1978/10/13 00:00 [pubmed]
PHST- 1978/10/13 00:01 [medline]
PHST- 1978/10/13 00:00 [entrez]
AID - 10.1007/BF00351774 [doi]
PST - ppublish
SO  - Arch Toxicol. 1978 Oct 13;41(1):99-105. doi: 10.1007/BF00351774.

PMID- 11307125
OWN - NLM
STAT- MEDLINE
DCOM- 20010830
LR  - 20220330
IS  - 0883-5403 (Print)
IS  - 0883-5403 (Linking)
VI  - 16
IP  - 3
DP  - 2001 Apr
TI  - A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
PG  - 293-300
AB  - Deep venous thrombosis (DVT) is common in total knee arthroplasty (TKA). Because 
      of the rarity of the most serious outcomes, most randomized controlled trials 
      lack the power to analyze these outcomes. A meta-analysis was performed for 
      agents used in DVT prophylaxis in TKA employing a Medline literature search. 
      Study inclusion criteria were randomized controlled trials comparing prophylactic 
      agents in elective TKA with mandatory screening for DVT by venography. Fourteen 
      studies (3,482 patients) met inclusion criteria. For total DVT, all agents except 
      dextran and aspirin protected significantly better than placebo (P < .0001). For 
      proximal DVT rates, low-molecular-weight heparin was significantly better than 
      warfarin (P = .0002). There was a trend that aspirin was better than warfarin (P 
      = .0106). No significant difference was found for symptomatic pulmonary embolism, 
      fatal pulmonary embolism, major hemorrhage, or total mortality.
FAU - Brookenthal, K R
AU  - Brookenthal KR
AD  - Department of Orthopaedic Surgery, Hospital of the University of Pennsylvania, 
      Philadelphia, Pennsylvania 19104, USA. keithbrookenthal@yahoo.com
FAU - Freedman, K B
AU  - Freedman KB
FAU - Lotke, P A
AU  - Lotke PA
FAU - Fitzgerald, R H
AU  - Fitzgerald RH
FAU - Lonner, J H
AU  - Lonner JH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Male
MH  - Postoperative Complications/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Venous Thrombosis/*prevention & control
MH  - Warfarin/therapeutic use
EDAT- 2001/04/18 10:00
MHDA- 2001/08/31 10:01
CRDT- 2001/04/18 10:00
PHST- 2001/04/18 10:00 [pubmed]
PHST- 2001/08/31 10:01 [medline]
PHST- 2001/04/18 10:00 [entrez]
AID - S0883-5403(01)55811-8 [pii]
AID - 10.1054/arth.2001.21499 [doi]
PST - ppublish
SO  - J Arthroplasty. 2001 Apr;16(3):293-300. doi: 10.1054/arth.2001.21499.

PMID- 11293143
OWN - NLM
STAT- MEDLINE
DCOM- 20010628
LR  - 20131121
IS  - 0391-5387 (Print)
IS  - 0391-5387 (Linking)
VI  - 21
IP  - 6
DP  - 1999 Nov-Dec
TI  - [Follow-up of children in obstetrical clinical trials: research experience in 
      Italy].
PG  - 243-8
AB  - The effectiveness of treatments for the mother exposed to adverse events in 
      pregnancy is not always interpreted in the light of possible effects on the 
      child. The follow-up of infants is an important component of obstetric and 
      perinatal audit not only in randomised clinical trials but as part of routine 
      health care. The results of the 18 month's follow-up of children born from women 
      recruited in the Italian Study of Aspirin in Pregnancy and in the Italian Trial 
      on Nifedipine in Pregnancy are discussed. No significant differences emerged 
      between treatment and no-treatment groups with respect to indicators of 
      development and health status. Malformations, diseases, and other health problems 
      showed no specific patterns and were much the same in the groups. Our findings 
      suggest that the use of low-dose aspirin and calcium channel blocker nifedipine 
      in pregnancy is safe with respect to the risks of malformation and of major 
      impairment in development at 18 months of age.
FAU - Bortolus, R
AU  - Bortolus R
AD  - Istituto di Ricerche Farmacologiche Mario Negri di Milano, Italia.
FAU - Parazzini, F
AU  - Parazzini F
FAU - Zanardo, V
AU  - Zanardo V
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Il follow-up dei bambini nei trial clinici ostetrici: esperienze di ricerca in 
      Italia.
PL  - Italy
TA  - Pediatr Med Chir
JT  - La Pediatria medica e chirurgica : Medical and surgical pediatrics
JID - 8100625
RN  - 0 (Calcium Channel Blockers)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Calcium Channel Blockers/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant
MH  - Italy
MH  - Nifedipine/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - *Prenatal Exposure Delayed Effects
MH  - *Randomized Controlled Trials as Topic
EDAT- 2001/04/11 10:00
MHDA- 2001/06/29 10:01
CRDT- 2001/04/11 10:00
PHST- 2001/04/11 10:00 [pubmed]
PHST- 2001/06/29 10:01 [medline]
PHST- 2001/04/11 10:00 [entrez]
PST - ppublish
SO  - Pediatr Med Chir. 1999 Nov-Dec;21(6):243-8.

PMID- 7245121
OWN - NLM
STAT- MEDLINE
DCOM- 19810810
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 45
IP  - 1
DP  - 1981 Feb 23
TI  - A native whole blood assay for blood-materials interaction.
PG  - 12-7
AB  - A convenient, accurate, and reproducible method was developed and characterized 
      to test the effects of particulate solids and soluble agents on native whole 
      blood. The effects of citrate anticoagulation and of variation in flow and column 
      parameters were characterized by ancillary experiments. The study utilized a 
      relatively homogeneous strain of large rabbits that had received intravenous 
      [C14]-serotonin as a platelet radiolabel. The assay induced a 4 min contact time 
      of either the test sample or saline control with freshly drawn arterial blood and 
      was followed by a series of hemostatic measurements, both before and after 
      passage of the blood through a standard 1 g glass bead column. Changes induced by 
      soluble (ADP, ellagic acid, aspirin) and particulate (collagen) agents in the 
      reactivity of this blood to the subsequent challenge of a large area of reactive 
      surface revealed reproducible quantitative effects on platelets and clotting. 
      Generally comparable results were obtained with native whole human blood when the 
      glass bead surface was adjusted (2 g) for the species difference in coagulability 
      and platelet reactivity.
FAU - Dodds, W J
AU  - Dodds WJ
FAU - DiNovo, J M
AU  - DiNovo JM
FAU - Bergeron, J A
AU  - Bergeron JA
LA  - eng
GR  - HL24017/HL/NHLBI NIH HHS/United States
GR  - HV42981/HV/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Citrates)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - OGG85SX4E4 (Imipramine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Coagulation/*drug effects
MH  - *Blood Physiological Phenomena
MH  - Blood Platelets/*drug effects
MH  - Citrates/pharmacology
MH  - Collagen/pharmacology
MH  - Imipramine/pharmacology
MH  - *Methods
MH  - Rabbits
MH  - *Science
EDAT- 1981/02/23 00:00
MHDA- 1981/02/23 00:01
CRDT- 1981/02/23 00:00
PHST- 1981/02/23 00:00 [pubmed]
PHST- 1981/02/23 00:01 [medline]
PHST- 1981/02/23 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1981 Feb 23;45(1):12-7.

PMID- 22906907
OWN - NLM
STAT- MEDLINE
DCOM- 20121106
LR  - 20181201
IS  - 0065-2326 (Print)
IS  - 0065-2326 (Linking)
VI  - 47
DP  - 2012
TI  - Stents and antiplatelet therapy.
PG  - 114-24
LID - 10.1159/000338054 [doi]
AB  - Coronary stents are used during the majority of percutaneous coronary 
      interventions. When compared to medical therapy, they have been shown to decrease 
      mortality for patients with acute coronary syndromes, and to improve symptom 
      control in patients with stable angina. Their use, however, may be complicated by 
      stent thrombosis (ST), a potentially fatal event. Early ST, which occurs during 
      the first month following device implantation, is usually linked to procedural 
      factors, with similar frequencies for bare metal stents and drug-eluting stents 
      (DES). Late and very late (between 1 month and 1 year, respectively, and >1 year 
      after the procedure) ST, which appear to be more frequent with DES, are due to 
      factors such as incomplete stent apposition, delayed or dysfunctional 
      endothelialization, and chronic inflammation. Furthermore, discontinuation of 
      antiplatelet therapy (which includes the association of aspirin and 
      thienopyridines) or resistance to these molecules may also lead to ST. New stent 
      designs as well as the use of more potent antiplatelet therapies should 
      contribute to reducing the incidence of ST in the future.
CI  - Copyright © 2012 S. Karger AG, Basel.
FAU - Fassa, Amir-Ali
AU  - Fassa AA
AD  - Cardiology Department, Bichat Hospital, AP-HP, Paris, France.
FAU - Urban, Philip
AU  - Urban P
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120809
PL  - Switzerland
TA  - Adv Cardiol
JT  - Advances in cardiology
JID - 0270063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thienopyridines)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy/*therapy
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Drug-Eluting Stents
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Prosthesis Design
MH  - Risk Factors
MH  - *Stents/adverse effects
MH  - Thienopyridines/therapeutic use
MH  - Thrombosis/epidemiology/*etiology/physiopathology
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
EDAT- 2012/08/22 06:00
MHDA- 2012/11/07 06:00
CRDT- 2012/08/22 06:00
PHST- 2012/08/22 06:00 [entrez]
PHST- 2012/08/22 06:00 [pubmed]
PHST- 2012/11/07 06:00 [medline]
AID - 000338054 [pii]
AID - 10.1159/000338054 [doi]
PST - ppublish
SO  - Adv Cardiol. 2012;47:114-24. doi: 10.1159/000338054. Epub 2012 Aug 9.

PMID- 7972781
OWN - NLM
STAT- MEDLINE
DCOM- 19941128
LR  - 20161123
IS  - 0033-8419 (Print)
IS  - 0033-8419 (Linking)
VI  - 193
IP  - 2
DP  - 1994 Nov
TI  - Low-dose aspirin combined with dipyridamole versus anticoagulants after 
      femoropopliteal percutaneous transluminal angioplasty.
PG  - 567-71
AB  - PURPOSE: To investigate whether anticoagulation or platelet inhibition treatment 
      provides better prevention of reobstruction after percutaneous transluminal 
      angioplasty (PTA). MATERIALS AND METHODS: In a controlled study, 160 patients 
      received either oral anticoagulants or a combination of low-dose acetylsalicylic 
      acid (25 mg) and dipyridamole (200 mg) (ASAD) twice daily for 1 year after 
      successful femoropopliteal PTA. Compliance was comparable. The patients in the 
      two groups had similar clinical and angiographic characteristics. Patency was 
      assessed with noninvasive methods 1 day and then 3, 6, and 12 months after PTA 
      and was confirmed at angiography at the end of the study in 112 patients. 
      RESULTS: Patency in patients who received anticoagulants was 53% and was not 
      statistically significantly different from 69% in patients who received ASAD (P = 
      .18). With anticoagulants, there were four bleeding complications (one was 
      fatal); with ASAD, only five minor complications occurred. CONCLUSION: ASAD is at 
      least as effective as anticoagulants for secondary prevention of obstruction 
      after PTA but has less severe side effects.
FAU - Do, D D
AU  - Do DD
AD  - Department of Medicine, University Hospital, Bern, Switzerland.
FAU - Mahler, F
AU  - Mahler F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Radiology
JT  - Radiology
JID - 0401260
RN  - 64ALC7F90C (Dipyridamole)
RN  - Q08SIO485D (Phenprocoumon)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - *Angioplasty, Balloon
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dipyridamole/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - *Femoral Artery/diagnostic imaging
MH  - Humans
MH  - Life Tables
MH  - Male
MH  - Phenprocoumon/*administration & dosage/adverse effects
MH  - *Popliteal Artery/diagnostic imaging
MH  - Prospective Studies
MH  - Radiography
MH  - Vascular Patency
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
AID - 10.1148/radiology.193.2.7972781 [doi]
PST - ppublish
SO  - Radiology. 1994 Nov;193(2):567-71. doi: 10.1148/radiology.193.2.7972781.

PMID- 17378868
OWN - NLM
STAT- MEDLINE
DCOM- 20070529
LR  - 20131121
IS  - 1356-1294 (Print)
IS  - 1356-1294 (Linking)
VI  - 13
IP  - 2
DP  - 2007 Apr
TI  - Evaluation of the uses of aspirin, statins and ACEIs/ARBs in a diabetes 
      outpatient population in southern Thailand.
PG  - 221-6
AB  - OBJECTIVE: To evaluate the uses of aspirin, statins and angiotensin converting 
      enzymes inhibitors/angiotensin receptor blockers (ACEIs/ARBs) in a diabetes 
      population in southern Thailand. METHODS: A review of outpatient medical records 
      at the diabetic clinics of the regional hospital (n=304) and a community hospital 
      (n=313), and a review of pharmacy computerized diabetes prescribing data (n=398) 
      of the teaching hospital. All were in the province of Songkhla, southern 
      Thailand. RESULTS: A total of 1015 diabetes patients, mean age (SD) 60.1 (12.1) 
      years, were identified, with type 2 diabetes being most prevalent (93%). Females 
      constituted 69%. Hypertension was a co-morbidity in almost half. Mean time (SD) 
      since diagnosis was 5.8 (4.7) years. Where lipid profiles were available, less 
      than one-third achieved the target LDL-C of <2.6 mmol L(-1). Almost all patients 
      (96%) were candidates for treatment with a statin according to the American 
      Diabetes Association (ADA) recommendation, whereas only 6.6 and 38.5% were 
      actually taking one in the regional and the teaching hospital, respectively. Over 
      90% should have been taking primary prophylactic aspirin, whereas only 5.7-29% 
      were actually prescribed one. A few had existing cardiovascular/cerebrovascular 
      disease, and all were taking aspirin. There was no documented proteinuria status; 
      however, 30-50% were on a ACEI/ARB, most likely as part of an antihypertensive 
      regimen. CONCLUSIONS: Aspirin as a primary prophylaxis of cardiovascular disease 
      in diabetes is remarkably underused. Screening for albuminuria was apparently 
      lacking. Statin therapy also presented a major deficiency. ACEI/ARB was probably 
      prescribed for hypertension rather than in relation to proteinuria.
FAU - Pongwecharak, J
AU  - Pongwecharak J
AD  - Department of Clinical Pharmacy, Faculty of Pharmaceutical Science, Prince of 
      Songkla University, Hatyai, Songkla, Thailand. pjurapor@pharmacy.psu.ac.th
FAU - Maila-ead, C
AU  - Maila-ead C
FAU - Sakulthap, J
AU  - Sakulthap J
FAU - Sripanitkulchai, N
AU  - Sripanitkulchai N
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Eval Clin Pract
JT  - Journal of evaluation in clinical practice
JID - 9609066
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus
MH  - Drug Prescriptions
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Male
MH  - Medical Audit
MH  - Middle Aged
MH  - *Outpatients
MH  - Thailand
EDAT- 2007/03/24 09:00
MHDA- 2007/05/30 09:00
CRDT- 2007/03/24 09:00
PHST- 2007/03/24 09:00 [pubmed]
PHST- 2007/05/30 09:00 [medline]
PHST- 2007/03/24 09:00 [entrez]
AID - JEP680 [pii]
AID - 10.1111/j.1365-2753.2006.00680.x [doi]
PST - ppublish
SO  - J Eval Clin Pract. 2007 Apr;13(2):221-6. doi: 10.1111/j.1365-2753.2006.00680.x.

PMID- 19169991
OWN - NLM
STAT- MEDLINE
DCOM- 20090320
LR  - 20131121
IS  - 0171-6425 (Print)
IS  - 0171-6425 (Linking)
VI  - 57
IP  - 1
DP  - 2009 Feb
TI  - Preoperative platelet inhibition with ASA does not influence postoperative blood 
      loss following coronary artery bypass grafting.
PG  - 18-21
LID - 10.1055/s-2008-1038791 [doi]
AB  - INTRODUCTION: Platelet inhibition is thought to increase perioperative blood loss 
      in patients with planned coronary artery bypass grafting (CABG). This 
      retrospective study reviews the results of over 10 000 patients with CABG, 
      comparing continued platelet inhibition with preoperative disruption of this 
      therapy. PATIENTS AND METHODS: From 1995 to 2007, 12 023 patients underwent 
      isolated CABG and were included in this study. The data were evaluated with 
      regard to preoperative aspirin therapy, EuroScore relevant risk factors, and the 
      operative results. Parameters of the operative outcome were in-hospital 
      mortality, perioperative infarctions, reexploration rate, strokes, pericardial 
      tamponade, blood transfusions, and perioperative drainage loss. RESULTS: The 
      patients were divided into two groups: group A (continuous aspirin therapy till 
      surgery [n = 2519]), and group B (patients with preoperative interruption of 
      their aspirin therapy for at least five days [n = 9504]). There was no difference 
      between the groups with regard to age, EuroScore (4.3 +/- 2.8 vs. 4.2 +/- 2.9), 
      emergency cases (8.8 % vs. 8.7 %), left main stenoses (17.9 % vs. 17.6 %), 
      duration of surgery (198 +/- 53 vs. 198 +/- 52 min.) and sex distribution. The 
      postoperative drainage loss did not differ between groups A and B (834 +/- 781 ml 
      vs. 902 +/- 811 ml), nor did the number of postoperatively administered red cell 
      packages (0.88 +/- 2.7 vs. 1.01 +/- 2.9). When analyzing the three subgroups 
      "on-pump primary CABG", "OPCAB procedures", and "redo CABG", again no difference 
      was found in the main outcome parameters. Only the redo CABG of group B had a 
      higher reexploration rate compared to group A (5 % vs. 3.3 %, P < 0.05). 
      CONCLUSION: Preoperative aspirin therapy does not seem to influence the operative 
      outcome of isolated CABG. Therefore, the often given recommendation to stop this 
      therapy prior to elective CABG procedures should be abandoned.
FAU - Gulbins, H
AU  - Gulbins H
AD  - Department of Cardiovascular Surgery, University Heart Center at University 
      Hospital Eppendorf, Hamburg, Germany. helmutgulbins@aol.com
FAU - Malkoc, A
AU  - Malkoc A
FAU - Ennker, I C
AU  - Ennker IC
FAU - Ennker, J
AU  - Ennker J
LA  - eng
PT  - Journal Article
DEP - 20090123
PL  - Germany
TA  - Thorac Cardiovasc Surg
JT  - The Thoracic and cardiovascular surgeon
JID - 7903387
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Coronary Artery Bypass/*adverse effects
MH  - Coronary Artery Bypass, Off-Pump/adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Hemorrhage/etiology/*prevention & control
MH  - Practice Guidelines as Topic
MH  - Preoperative Care
MH  - Reoperation
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2009/01/27 09:00
MHDA- 2009/03/21 09:00
CRDT- 2009/01/27 09:00
PHST- 2009/01/27 09:00 [entrez]
PHST- 2009/01/27 09:00 [pubmed]
PHST- 2009/03/21 09:00 [medline]
AID - 10.1055/s-2008-1038791 [doi]
PST - ppublish
SO  - Thorac Cardiovasc Surg. 2009 Feb;57(1):18-21. doi: 10.1055/s-2008-1038791. Epub 
      2009 Jan 23.

PMID- 25164005
OWN - NLM
STAT- MEDLINE
DCOM- 20150522
LR  - 20211021
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
VI  - 34
IP  - 10
DP  - 2014 Oct
TI  - Cost effectiveness of apixaban versus aspirin for stroke prevention in patients 
      with non-valvular atrial fibrillation in Belgium.
PG  - 709-21
LID - 10.1007/s40261-014-0224-z [doi]
AB  - BACKGROUND AND OBJECTIVE: Evidence indicates that vitamin K antagonists (VKAs) 
      and oral anticoagulant therapy are under-utilised for stroke prevention in 
      patients with non-valvular atrial fibrillation (AF), and patients who decline or 
      cannot tolerate such treatment are often prescribed aspirin instead. Apixaban has 
      been shown in the AVERROES trial to be superior to aspirin in preventing stroke 
      and systemic embolism without significantly increasing the risk of major bleeding 
      among patients with AF who are unsuitable for VKA therapy. This study estimates 
      the economic implications and potential cost effectiveness of apixaban compared 
      with aspirin in such individuals from the perspective of healthcare payers in 
      Belgium. METHODS: A Markov model was developed to evaluate the clinical and 
      economic impact of apixaban compared with aspirin in patients unsuitable for VKA 
      therapy. The clinical events modelled include ischaemic and haemorrhagic stroke, 
      systemic embolism, intracranial haemorrhage, other major bleeding, clinically 
      relevant non-major bleeding, myocardial infarction, cardiovascular 
      hospitalisation and treatment discontinuations obtained from AVERROES. Outcomes 
      included life-years and quality-adjusted life-years (QALYs) gained, costs and 
      incremental cost-effectiveness ratios (ICERs) over a lifetime. RESULTS: Apixaban 
      was projected to increase life expectancy and QALYs compared with aspirin, with 
      an associated increase in drug acquisition costs. The estimated ICER was 
      <euro>7,334 per QALY gained with apixaban compared with aspirin. CONCLUSIONS: 
      Apixaban is a cost-effective alternative to aspirin for patients with AF in 
      Belgium who decline or cannot tolerate VKA treatment.
FAU - Kongnakorn, Thitima
AU  - Kongnakorn T
AD  - Evidera, Bangkok, Thailand, Thitima.Kongnakorn@evidera.com.
FAU - Lanitis, Tereza
AU  - Lanitis T
FAU - Lieven, Annemans
AU  - Lieven A
FAU - Thijs, Vincent
AU  - Thijs V
FAU - Marbaix, Sophie
AU  - Marbaix S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Clin Drug Investig. 2014 Oct;34(10):753. Annemans, Lievens [corrected to Lieven, 
      Annemans]
MH  - Aged
MH  - Aspirin/adverse effects/economics/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy/economics
MH  - Belgium
MH  - Cost-Benefit Analysis
MH  - Factor Xa Inhibitors/adverse effects/economics/therapeutic use
MH  - Female
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Platelet Aggregation Inhibitors/adverse effects/economics/therapeutic use
MH  - Pyrazoles/adverse effects/economics/*therapeutic use
MH  - Pyridones/adverse effects/economics/*therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Stroke/economics/*prevention & control
EDAT- 2014/08/29 06:00
MHDA- 2015/05/23 06:00
CRDT- 2014/08/29 06:00
PHST- 2014/08/29 06:00 [entrez]
PHST- 2014/08/29 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - 10.1007/s40261-014-0224-z [doi]
PST - ppublish
SO  - Clin Drug Investig. 2014 Oct;34(10):709-21. doi: 10.1007/s40261-014-0224-z.

PMID- 504968
OWN - NLM
STAT- MEDLINE
DCOM- 19800128
LR  - 20131121
IS  - 0036-553X (Print)
IS  - 0036-553X (Linking)
VI  - 23
IP  - 3
DP  - 1979 Sep
TI  - Platelet heterogeneity. Relationship between buoyant density, size, lipid 
      peroxidation and platelet age.
PG  - 204-10
AB  - Human platelets were separated into 2 density populations by repeated 
      centrifugations of platelet-rich plasma at increasing gravitational force. The 
      heaviest platelet fraction was rich in larger platelets. The lightest platelet 
      fraction was rich in smaller platelets. In both fractions and in the platelet 
      button, lipid peroxidation (malonaldehyde-MDA-production after addition of 
      thrombin) was measured at basal condition, on the 1st, 3rd, 5th, 7th and 9th day 
      after aspirin ingestion. At basal conditions and after ingestion of aspirin, MDA 
      production was higher in the heavy-large platelets than in light-small ones, but 
      a parallel increase of MDA production was observed in the light and in the heavy 
      population and in the platelet button. The data are not compatible with the 
      hypothesis that platelet density and size are age-related. Aspirin inhibits 
      platelet lipid peroxidation by permanently acetylating their cyclooxygenase and 
      if the heaviest platelets were the young ones, lipid peroxidation should reappear 
      sooner in them.
FAU - Leone, G
AU  - Leone G
FAU - Agostini, A
AU  - Agostini A
FAU - DeCrescenzo, A
AU  - DeCrescenzo A
FAU - Bizzi, B
AU  - Bizzi B
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Scand J Haematol
JT  - Scandinavian journal of haematology
JID - 0404507
RN  - 0 (Lipid Peroxides)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*physiology
MH  - Cell Separation
MH  - Cell Survival
MH  - Humans
MH  - Lipid Peroxides/metabolism
MH  - Malondialdehyde/biosynthesis
MH  - Thrombin/pharmacology
EDAT- 1979/09/01 00:00
MHDA- 1979/09/01 00:01
CRDT- 1979/09/01 00:00
PHST- 1979/09/01 00:00 [pubmed]
PHST- 1979/09/01 00:01 [medline]
PHST- 1979/09/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Haematol. 1979 Sep;23(3):204-10.

PMID- 28957935
OWN - NLM
STAT- MEDLINE
DCOM- 20171013
LR  - 20171013
IS  - 1538-7488 (Electronic)
IS  - 0002-936X (Linking)
VI  - 117
IP  - 10
DP  - 2017 Oct
TI  - Aspirin Lowers the Risk of Preeclampsia.
PG  - 62
LID - 10.1097/01.NAJ.0000525880.12596.d7 [doi]
AB  - According to this study.
FAU - Rosenberg, Karen
AU  - Rosenberg K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Nurs
JT  - The American journal of nursing
JID - 0372646
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
EDAT- 2017/09/29 06:00
MHDA- 2017/10/14 06:00
CRDT- 2017/09/29 06:00
PHST- 2017/09/29 06:00 [entrez]
PHST- 2017/09/29 06:00 [pubmed]
PHST- 2017/10/14 06:00 [medline]
AID - 00000446-201710000-00032 [pii]
AID - 10.1097/01.NAJ.0000525880.12596.d7 [doi]
PST - ppublish
SO  - Am J Nurs. 2017 Oct;117(10):62. doi: 10.1097/01.NAJ.0000525880.12596.d7.

PMID- 7141304
OWN - NLM
STAT- MEDLINE
DCOM- 19830119
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 12
IP  - 3
DP  - 1982
TI  - Platelet adherence to collagen. The influence of acetylsalicylic acid.
PG  - 262-7
AB  - Under conditions of low shear and in the absence of laminar flow the addition of 
      acetylsalicylic acid (ASA), but not of sodium salicylate, to human platelet-rich 
      plasma (PRP) in vitro significantly inhibited platelet adherence to collagen (p 
      less than 0.001). Inhibition was of similar degree (17%) at ASA concentrations of 
      10 and 1,000 microM, but was less (10% inhibition) in PRP with erythrocytes added 
      to 40% hematocrit. The ingestion of 600 mg ASA had negligible effect on platelet 
      adherence in whole blood or in PRP. There was no correlation between the effects 
      of ASA on adherence and on platelet aggregation in vitro or ex vivo. It is 
      concluded that the effect of ASA on platelet adherence is unlikely to be 
      important in vivo, except perhaps in vascular sites where flow is non-laminar and 
      where shear rates and/or the physical forces on platelets are low.
FAU - Mant, M J
AU  - Mant MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Collagen/*metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Sodium Salicylate/pharmacology
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1159/000214681 [doi]
PST - ppublish
SO  - Haemostasis. 1982;12(3):262-7. doi: 10.1159/000214681.

PMID- 8169801
OWN - NLM
STAT- MEDLINE
DCOM- 19940601
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 83
IP  - 2
DP  - 1994 Feb
TI  - A novel skeletal drug-delivery system using self-setting calcium phosphate 
      cement. 4. Effects of the mixing solution volume on the drug-release rate of 
      heterogeneous aspirin-loaded cement.
PG  - 259-63
AB  - The effect of the mixing solution volume was investigated on the in vitro 
      drug-release rate of a novel drug-delivery device based on a self-setting 
      bioactive calcium phosphate cement containing aspirin as a model drug. Equimolar 
      mixtures of metastable calcium phosphate powders containing various proportions 
      (3-40 w/w %) of seed hydroxyapatite crystals transformed into hydroxyapatite 
      after being mixed with dilute phosphoric acid. The drug release from cement 
      pellets in vitro into a 0.1 mol/L phosphate buffer at pH 7.40 and 37 degrees C by 
      the rotating disk method continued for more than 1 week. The drug-release rate 
      from the cement increased with increasing volumes of mixing solution. The 
      relationship between the liquid/powder ratio and the porosity of the cement was a 
      straight line, indicating that the cement porosity depended on the amount of the 
      mixing solution, but was independent of the amount of seed crystals. Drug release 
      from the cement followed the modified Fick's law, with the rate increasing with 
      the amount of mixing solution, since the porosity depended on the amount. The 
      tortuosity of the cements was estimated from the modified Fick's equation, and 
      the relationships between the drug release rate and the tortuosity of the pore in 
      the drug-loaded cement in the plots were nonlinear. The results suggested that 
      the drug-release rates from the cement were controlled by the drug diffusion in 
      the pores.
FAU - Otsuka, M
AU  - Otsuka M
AD  - Kobe Pharmaceutical University, Kyoritsu, Japan.
FAU - Matsuda, Y
AU  - Matsuda Y
FAU - Suwa, Y
AU  - Suwa Y
FAU - Fox, J L
AU  - Fox JL
FAU - Higuchi, W I
AU  - Higuchi WI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Bone Cements)
RN  - 0 (Calcium Phosphates)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Hydroxyapatites)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - *Bone Cements
MH  - Bone and Bones/*metabolism
MH  - Calcium Phosphates/*administration & dosage/chemistry/pharmacokinetics
MH  - Chemistry, Pharmaceutical
MH  - Delayed-Action Preparations
MH  - *Drug Delivery Systems
MH  - Fourier Analysis
MH  - Hardness
MH  - Hydroxyapatites/chemistry
MH  - Porosity
MH  - Spectrophotometry, Infrared
MH  - Spectrophotometry, Ultraviolet
MH  - X-Ray Diffraction
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
AID - S0022-3549(15)49373-6 [pii]
AID - 10.1002/jps.2600830230 [doi]
PST - ppublish
SO  - J Pharm Sci. 1994 Feb;83(2):259-63. doi: 10.1002/jps.2600830230.

PMID- 12390063
OWN - NLM
STAT- MEDLINE
DCOM- 20021122
LR  - 20190813
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 162
IP  - 19
DP  - 2002 Oct 28
TI  - Frequency of analgesic use and risk of hypertension in younger women.
PG  - 2204-8
AB  - BACKGROUND: In addition to their antipyretic, anti-inflammatory, and 
      pain-relieving effects, analgesics may interfere with blood pressure regulation. 
      However, little prospective information is available on the association between 
      analgesic use and the risk of hypertension. METHODS: We performed a prospective 
      study of 80 020 women aged 31 to 50 years who participated in the Nurses' Health 
      Study II and had no previous history of hypertension. Frequency of use (in days 
      per month) of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and 
      acetaminophen was collected by mailed questionnaire in 1995. Incident cases of 
      physician-diagnosed hypertension were identified by self-report on the 1997 
      biennial questionnaire. RESULTS: During 164 090 person-years of follow-up, 1650 
      incident cases of hypertension were identified. At least 1 d/mo, 51.2% of the 
      cohort used aspirin, 76.7% used NSAIDs, and 72.5% used acetaminophen. After 
      adjusting for age, all 3 classes of analgesics were associated with an increased 
      risk of incident hypertension (P<.001 for trend). After further adjustment for 
      all 3 analgesics and other potential risk factors, only NSAIDs and acetaminophen 
      (P<.001 for trend for both) were significantly associated with risk of 
      hypertension. Compared with nonusers, the relative risk of hypertension for women 
      taking NSAIDs 22 d/mo or more was 1.86 (95% confidence interval, 1.51-2.28) and 
      for those taking acetaminophen 22 d/mo or more was 2.00 (95% confidence interval, 
      1.52-2.62). CONCLUSIONS: Use of NSAIDs and use of acetaminophen were 
      significantly associated with increased risk of hypertension, but aspirin use was 
      not. A substantial proportion of hypertension in the United States, and the 
      associated morbidity and mortality, may be due to the use of these medications.
FAU - Curhan, Gary C
AU  - Curhan GC
AD  - Channing Laboratory, Brigham and Women's Hospital, 181 Longwood Ave, Boston, MA 
      02115, USA. Gary.Curhan@channing.harvard.edu
FAU - Willett, Walter C
AU  - Willett WC
FAU - Rosner, Bernard
AU  - Rosner B
FAU - Stampfer, Meir J
AU  - Stampfer MJ
LA  - eng
GR  - CA50385/CA/NCI NIH HHS/United States
GR  - CA87969/CA/NCI NIH HHS/United States
GR  - DK52866/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Intern Med. 2003 May 12;163(9):1113-4; author reply 1115-6. PMID: 12742815
CIN - Arch Intern Med. 2003 May 12;163(9):1114-5; author reply 1115-6. PMID: 12742816
CIN - Arch Intern Med. 2003 May 12;163(9):1114; author reply 1115-6. PMID: 12742817
CIN - Arch Intern Med. 2003 May 12;163(9):1115; author reply 1115-6. PMID: 12742818
MH  - Acetaminophen/adverse effects/therapeutic use
MH  - Adult
MH  - Analgesics/*adverse effects/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Hypertension/*chemically induced
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Surveys and Questionnaires
EDAT- 2002/10/24 04:00
MHDA- 2002/11/26 04:00
CRDT- 2002/10/24 04:00
PHST- 2002/10/24 04:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/10/24 04:00 [entrez]
AID - ioi10795 [pii]
AID - 10.1001/archinte.162.19.2204 [doi]
PST - ppublish
SO  - Arch Intern Med. 2002 Oct 28;162(19):2204-8. doi: 10.1001/archinte.162.19.2204.

PMID- 6394131
OWN - NLM
STAT- MEDLINE
DCOM- 19850321
LR  - 20131121
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 7
IP  - 1
DP  - 1984
TI  - A controlled comparative evaluation of acetaminophen and aspirin in the treatment 
      of postoperative pain.
PG  - 89-97
AB  - The analgesic effects of acetaminophen (1 gm), aspirin (650 mg), and placebo were 
      evaluated in a double-blind, randomized parallel study. The subjects were 162 
      outpatients who had experienced moderate or severe pain as a result of dental 
      surgery involving bone removal. Patients evaluated the intensity of their pain 
      and the extent of their relief from pain at 30 minutes, at one hour, and at each 
      subsequent hour for six hours after the administration of the study medication. 
      During the six-hour period, 135 of the 162 patients were remedicated. At the end 
      of the six-hour period each patient assessed overall treatment. Two measures of 
      analgesia were derived from patients' evaluations of the intensity of pain, and 
      three other measures were derived from evaluations of relief from pain. On all 
      six measures used, the groups receiving acetaminophen and aspirin reported 
      analgesic effects significantly superior (P less than 0.05) to those of placebo. 
      Acetaminophen was significantly better than aspirin with respect to the maximum 
      difference in the intensity of pain (P less than 0.05) and the maximum pain 
      relief achieved (P less than 0.03) and according to the global evaluation (P less 
      than 0.02). These differences were most striking in patients with severe initial 
      pain.
FAU - Mehlisch, D R
AU  - Mehlisch DR
FAU - Frakes, L A
AU  - Frakes LA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Random Allocation
MH  - Tooth Extraction
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1984;7(1):89-97.

PMID- 26385700
OWN - NLM
STAT- MEDLINE
DCOM- 20160627
LR  - 20150919
IS  - 1472-0213 (Electronic)
IS  - 1472-0205 (Linking)
VI  - 32
IP  - 10
DP  - 2015 Oct
TI  - Towards evidence-based emergency medicine: best BETs from the Manchester Royal 
      Infirmary. BET 1: Which form of aspirin is the fastest to inhibit platelet 
      aggregation in emergency department patients with non-ST segment elevation 
      myocardial infarction?
PG  - 823-6
LID - 10.1136/emermed-2015-205240.1 [doi]
AB  - A short cut review was carried out to establish whether, in patients with 
      suspected acute coronary syndromes presenting to the emergency department, what 
      form of aspirin has the most rapid onset of action. Papers comparing the speed of 
      onset of chewable aspirin, or soluble aspirin or solid aspirin were included. 
      This summarises all three parts of a combined best evidence topic report (BET). 
      The clinical bottom line is that chewable aspirin may be faster than soluble 
      aspirin at decreasing the amount of time to achieve platelet inhibition in a 
      patient. Soluble aspirin is faster than whole solid aspirin, which is faster than 
      enteric-coated aspirin.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Morris, Niall
AU  - Morris N
AD  - University of Manchester, Manchester.
FAU - Rigg, Kaitlynn
AU  - Rigg K
AD  - McMaster University, Canada.
FAU - Hogg, Kerstin
AU  - Hogg K
AD  - McMaster University, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Emerg Med J
JT  - Emergency medicine journal : EMJ
JID - 100963089
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/*administration & dosage
MH  - *Emergency Service, Hospital
MH  - Evidence-Based Emergency Medicine
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage
EDAT- 2015/09/20 06:00
MHDA- 2016/06/28 06:00
CRDT- 2015/09/20 06:00
PHST- 2015/09/20 06:00 [entrez]
PHST- 2015/09/20 06:00 [pubmed]
PHST- 2016/06/28 06:00 [medline]
AID - emermed-2015-205240.1 [pii]
AID - 10.1136/emermed-2015-205240.1 [doi]
PST - ppublish
SO  - Emerg Med J. 2015 Oct;32(10):823-6. doi: 10.1136/emermed-2015-205240.1.

PMID- 31248548
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20200518
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 73
IP  - 25
DP  - 2019 Jul 2
TI  - Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the 
      COMPASS Trial.
PG  - 3271-3280
LID - S0735-1097(19)34924-1 [pii]
LID - 10.1016/j.jacc.2019.02.079 [doi]
AB  - BACKGROUND: The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation 
      Strategies) trial showed that the combination of low-dose rivaroxaban and aspirin 
      reduced major vascular events in patients with stable vascular disease. 
      OBJECTIVES: The purpose of this study was to identify subsets of patients at 
      higher risk of recurrent vascular events, which may help focus the use of 
      rivaroxaban and aspirin therapy. METHODS: COMPASS patients with vascular disease 
      were risk stratified using 2 methods: the REACH (REduction of Atherothrombosis 
      for Continued Health) atherothrombosis risk score and CART (Classification and 
      Regression Tree) analysis. The absolute risk differences for rivaroxaban with 
      aspirin were compared to aspirin alone over 30 months for the composite of 
      cardiovascular death, myocardial infarction, stroke, acute limb ischemia, or 
      vascular amputation; for severe bleeding; and for the net clinical benefit. 
      RESULTS: High-risk patients using the REACH score were those with 2 or more 
      vascular beds affected, history of heart failure (HF), or renal insufficiency, 
      and by CART analysis were those with ≥2 vascular beds affected, history of HF, or 
      diabetes. Rivaroxaban and aspirin combination reduced the serious vascular event 
      incidence by 25% (4.48% vs. 5.95%, hazard ratio: 0.75; 95% confidence interval: 
      0.66 to 0.85), equivalent to 23 events prevented per 1,000 patients treated for 
      30 months, at the cost of a nonsignificant 34% increase in severe bleeding (1.34; 
      95% confidence interval: 0.95 to 1.88), or 2 events caused per 1,000 patients 
      treated. Among patients with ≥1 high-risk feature identified from the CART 
      analysis, rivaroxaban and aspirin prevented 33 serious vascular events, whereas 
      in lower-risk patients, rivaroxaban and aspirin treatment led to the avoidance of 
      10 events per 1,000 patients treated for 30 months. CONCLUSIONS: In patients with 
      vascular disease, further risk stratification can identify higher-risk patients 
      (≥2 vascular beds affected, HF, renal insufficiency, or diabetes). The net 
      clinical benefit remains favorable for most patients treated with rivaroxaban and 
      aspirin compared with aspirin.
CI  - Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Anand, Sonia S
AU  - Anand SS
AD  - Department of Medicine, Population Health Research Institute, McMaster 
      University, Hamilton Health Sciences, Hamilton, Ontario, Canada. Electronic 
      address: anands@mcmaster.ca.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AD  - Department of Medicine, Population Health Research Institute, McMaster 
      University, Hamilton Health Sciences, Hamilton, Ontario, Canada.
FAU - Dyal, Leanne
AU  - Dyal L
AD  - Department of Statistics, Population Health Research Institute, McMaster 
      University, Hamilton Health Sciences, Hamilton, Ontario, Canada.
FAU - Bosch, Jackie
AU  - Bosch J
AD  - School of Rehabilitative Science, Population Health Research Institute, McMaster 
      University, Hamilton Health Sciences, Hamilton, Ontario, Canada.
FAU - Neumann, Christoph
AU  - Neumann C
AD  - Bayer AG, Wuppertal, Germany.
FAU - Widimsky, Petr
AU  - Widimsky P
AD  - Department of Cardiology, University Hospital Kralovske Vinohrady and Third 
      Faculty of Medicine, Charles University, Prague, Czech Republic.
FAU - Avezum, Alvaro A
AU  - Avezum AA
AD  - Research Division, Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
FAU - Probstfield, Jeffrey
AU  - Probstfield J
AD  - Department of Medicine and Cardiology, University of Washington, Seattle, 
      Washington.
FAU - Cook Bruns, Nancy
AU  - Cook Bruns N
AD  - Bayer AG, Wuppertal, Germany.
FAU - Fox, Keith A A
AU  - Fox KAA
AD  - Center for Cardiovascular Science, University of Edinburgh, Edinburgh, United 
      Kingdom.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart and Vascular Centre, Harvard Medical School, 
      Boston, Massachusetts.
FAU - Connolly, Stuart J
AU  - Connolly SJ
AD  - Department of Medicine, Population Health Research Institute, McMaster 
      University, Hamilton Health Sciences, Hamilton, Ontario, Canada.
FAU - Yusuf, Salim
AU  - Yusuf S
AD  - Department of Medicine, Population Health Research Institute, McMaster 
      University, Hamilton Health Sciences, Hamilton, Ontario, Canada.
CN  - COMPASS Trial Investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2019 Jul 2;73(25):3292-3294. PMID: 31248550
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Drug Therapy, Combination
MH  - Factor Xa Inhibitors/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Rivaroxaban/*therapeutic use
OTO - NOTNLM
OT  - net-clinical benefit
OT  - risk stratification
OT  - rivaroxaban
OT  - vascular disease
EDAT- 2019/06/30 06:00
MHDA- 2020/05/19 06:00
CRDT- 2019/06/29 06:00
PHST- 2018/12/07 00:00 [received]
PHST- 2019/02/19 00:00 [revised]
PHST- 2019/02/26 00:00 [accepted]
PHST- 2019/06/29 06:00 [entrez]
PHST- 2019/06/30 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
AID - S0735-1097(19)34924-1 [pii]
AID - 10.1016/j.jacc.2019.02.079 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2019 Jul 2;73(25):3271-3280. doi: 10.1016/j.jacc.2019.02.079.

PMID- 678089
OWN - NLM
STAT- MEDLINE
DCOM- 19780929
LR  - 20190704
IS  - 0004-0010 (Print)
IS  - 0004-0010 (Linking)
VI  - 113
IP  - 7
DP  - 1978 Jul
TI  - Thromboembolic risk of postsplenectomy thrombocytosis.
PG  - 808-9
AB  - Although thrombocytosis is a very common finding after splenectomy, the 
      thromboembolic risk of postsplenectomy thrombocytosis has not been clarified. To 
      our knowledge, this retrospective study of 318 patients without 
      myeloproliferative disorders who underwent splenectomy is the largest of its 
      type. Thrombocytosis developed in 75% of the patients. No substantial increase in 
      the incidence of thromboembolism was detected in patients with thrombocytosis.
FAU - Boxer, M A
AU  - Boxer MA
FAU - Braun, J
AU  - Braun J
FAU - Ellman, L
AU  - Ellman L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Surg
JT  - Archives of surgery (Chicago, Ill. : 1960)
JID - 9716528
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - *Postoperative Complications
MH  - Retrospective Studies
MH  - Risk
MH  - *Splenectomy
MH  - Thrombocytosis/complications/*etiology
MH  - Thromboembolism/*etiology/prevention & control
EDAT- 1978/07/01 00:00
MHDA- 1978/07/01 00:01
CRDT- 1978/07/01 00:00
PHST- 1978/07/01 00:00 [pubmed]
PHST- 1978/07/01 00:01 [medline]
PHST- 1978/07/01 00:00 [entrez]
AID - 10.1001/archsurg.1978.01370190030004 [doi]
PST - ppublish
SO  - Arch Surg. 1978 Jul;113(7):808-9. doi: 10.1001/archsurg.1978.01370190030004.

PMID- 9278200
OWN - NLM
STAT- MEDLINE
DCOM- 19971001
LR  - 20190512
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 44
IP  - 2
DP  - 1997 Aug
TI  - A comparison of the effects of aspirin on bleeding time measured using the 
      Simplate method and closure time measured using the PFA-100, in healthy 
      volunteers.
PG  - 151-5
AB  - AIMS: The aim of this study was to compare the effects of aspirin on platelet 
      function as measured by the 'classical' template bleeding time with a new ex vivo 
      method measuring closure times using the PFA-100 machine. Platelet aggregation in 
      response to arachidonic acid was also measured ex vivo. METHODS: The trial was a 
      randomized, double-blind, placebo-controlled crossover design, with each 
      volunteer taking 750 mg aspirin (BP) or placebo, three times a day for 5 days, 
      with an 18 day wash-out period between treatments. Bleeding times and closure 
      times were measured before the first dose on the first day and 0.5 h after the 
      last dose on the fifth day of each treatment period. They were also measured 2 
      weeks after the last day of the trial. RESULTS: Baseline bleeding times 
      (pre-placebo) were 415 s using the Simplate, whilst baseline closure times were 
      115 s using the PFA-100. Aspirin treatment caused an increase of both the 
      template bleeding time (61%) and the closure time of the PFA-100 (79%) when 
      compared with the effects of placebo. The platelet aggregatory response to 
      arachidonic acid was completely inhibited following aspirin treatment and was 
      unaffected following placebo. Two weeks after the end of the trial, all values 
      had returned to pre-treatment levels. The template bleeding time was unaltered in 
      1 of the 12 volunteers during aspirin treatment and was significantly prolonged 
      in 3 of the 12 volunteers during placebo treatment. The PFA-100 closure time was 
      unaltered in 1 of the 12 volunteers during aspirin treatment and was prolonged in 
      1 subject during placebo treatment. CONCLUSIONS: The change in closure time using 
      the PFA-100 is as sensitive and reproducible to the effects of aspirin on 
      platelet function as is the template bleeding time test. However, the PFA-100 
      produced less variable effects with fewer false positive results.
FAU - Marshall, P W
AU  - Marshall PW
AD  - Clinical Pharmacology Unit, Zeneca Pharmaceuticals, Alderley Park, Macclesfield, 
      UK.
FAU - Williams, A J
AU  - Williams AJ
FAU - Dixon, R M
AU  - Dixon RM
FAU - Growcott, J W
AU  - Growcott JW
FAU - Warburton, S
AU  - Warburton S
FAU - Armstrong, J
AU  - Armstrong J
FAU - Moores, J
AU  - Moores J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arachidonic Acid/antagonists & inhibitors
MH  - Aspirin/*pharmacology
MH  - *Bleeding Time
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Reference Values
PMC - PMC2042813
EDAT- 1997/08/01 00:00
MHDA- 1997/08/01 00:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 1997/08/01 00:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
AID - 10.1046/j.1365-2125.1997.00639.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1997 Aug;44(2):151-5. doi: 10.1046/j.1365-2125.1997.00639.x.

PMID- 35999660
OWN - NLM
STAT- MEDLINE
DCOM- 20230126
LR  - 20230221
IS  - 2163-0763 (Electronic)
IS  - 2163-0755 (Linking)
VI  - 94
IP  - 2
DP  - 2023 Feb 1
TI  - The impact of low-dose aspirin in the Brain Injury Guidelines on outcomes in 
      traumatic brain injury: A retrospective cohort study.
PG  - 320-327
LID - 10.1097/TA.0000000000003772 [doi]
AB  - BACKGROUND: Current Brain Injury Guidelines (BIG) characterize patients with 
      intracranial hemorrhage taking antiplatelet or anticoagulant agents as BIG 3 (the 
      most severe category) regardless of trauma severity. This study assessed the risk 
      of in-hospital mortality or need for neurosurgery in patients taking low-dose 
      aspirin who otherwise would be classified as BIG 1. METHODS: This was a 
      retrospective study at an academic level 1 trauma center. Patients were included 
      if they were admitted with traumatic intracerebral hemorrhage and were evaluated 
      by the BIG criteria. Exclusion criteria included indeterminate BIG status or 
      patients with missing primary outcomes documentation. Patients were categorized 
      as BIG 1, BIG 2, BIG 3, or BIG 1 on aspirin (patients with BIG 1 features taking 
      low-dose aspirin). The primary endpoint was a composite of neurosurgical 
      intervention and all-cause in-hospital mortality. Key secondary endpoints include 
      rate of intracranial hemorrhage progression, and intensive care unit- and 
      hospital-free days. RESULTS: A total of 1,520 patients met the inclusion 
      criteria. Median initial Glasgow Coma Scale was 14 (interquartile range [IQR], 
      12-15), Injury Severity Scale score was 17 (IQR, 10-25), and Abbreviated Injury 
      Scale subscore head and neck (AIS Head ) was 3 (IQR, 3-4). The rate of the 
      primary outcome for BIG 1, BIG 1 on aspirin, BIG 2, and BIG 3 was 1%, 2.2%, 1%, 
      and 27%, respectively; the difference between BIG 1 on aspirin and BIG 3 was 
      significant ( p < 0.001). CONCLUSION: Patients taking low-dose aspirin with 
      otherwise BIG 1-grade injuries experienced mortality and required neurosurgery 
      significantly less often than other patients categorized as BIG 3. Inclusion of 
      low-dose aspirin in the BIG criteria should be reevaluated. LEVEL OF EVIDENCE: 
      Therapeutic/Care Management; Level IV.
CI  - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Webb, Andrew J
AU  - Webb AJ
AD  - From the Department of Pharmacy (A.J.W., H.J.O., C.A.B.), Oregon Health and 
      Science University, Portland, Oregon; Department of Pharmacy (A.J.W.), 
      Massachusetts General Hospital, Boston, Massachusetts; Department of Pharmacy 
      (A.J.P.), University Hospital, Newark, New Jersey; Department of Surgery (C.K., 
      E.G., M.S.), Oregon Health and Science University; and Department of Neurosurgery 
      (D.N.M.), Oregon Health and Science University, Portland, Oregon.
FAU - Oetken, Heath J
AU  - Oetken HJ
FAU - Plott, A Joseph
AU  - Plott AJ
FAU - Knapp, Christopher
AU  - Knapp C
FAU - Munger, Daniel N
AU  - Munger DN
FAU - Gibson, Erica
AU  - Gibson E
FAU - Schreiber, Martin
AU  - Schreiber M
FAU - Barton, Cassie A
AU  - Barton CA
LA  - eng
PT  - Journal Article
DEP - 20220824
PL  - United States
TA  - J Trauma Acute Care Surg
JT  - The journal of trauma and acute care surgery
JID - 101570622
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Retrospective Studies
MH  - Aspirin/therapeutic use
MH  - *Brain Injuries, Traumatic/complications/drug therapy
MH  - *Brain Injuries
MH  - Intracranial Hemorrhages
MH  - Glasgow Coma Scale
EDAT- 2022/08/25 06:00
MHDA- 2023/01/27 06:00
CRDT- 2022/08/24 00:03
PHST- 2022/08/25 06:00 [pubmed]
PHST- 2023/01/27 06:00 [medline]
PHST- 2022/08/24 00:03 [entrez]
AID - 01586154-202302000-00019 [pii]
AID - 10.1097/TA.0000000000003772 [doi]
PST - ppublish
SO  - J Trauma Acute Care Surg. 2023 Feb 1;94(2):320-327. doi: 
      10.1097/TA.0000000000003772. Epub 2022 Aug 24.

PMID- 8428068
OWN - NLM
STAT- MEDLINE
DCOM- 19930310
LR  - 20131121
IS  - 0951-7383 (Print)
IS  - 0951-7383 (Linking)
VI  - 6
IP  - 1
DP  - 1993 Feb
TI  - Strategies for preventing stroke.
PG  - 60-5
AB  - The limited effectiveness of any therapy for acute stroke dictates that emphasis 
      be placed on strategies for preventing stroke. The identification and management 
      of risk factors is paramount. Modifiable risk factors include hypertension, 
      smoking, hyperlipidemia, and diabetes. Patients with transient ischemic attacks 
      or stroke are at risk for recurrent stroke and should be considered for 
      antithrombotic therapy and carotid endarterectomy. Patients with nonvalvular 
      atrial fibrillation should also be treated with antithrombotic therapy. The 
      proper management of other cardiac, malignant, and hematologic disorders is 
      important in preventing stroke in these high-risk patients.
FAU - Kanter, M C
AU  - Kanter MC
AD  - Department of Medicine (Neurology), University of Texas Health Science Center, 
      San Antonio 78284-7883.
FAU - Sherman, D G
AU  - Sherman DG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Neurol Neurosurg
JT  - Current opinion in neurology and neurosurgery
JID - 8809879
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Pressure
MH  - Cerebrovascular Disorders/*drug therapy/etiology/surgery
MH  - Endarterectomy, Carotid
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/blood/complications
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/*therapeutic use
RF  - 37
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
PST - ppublish
SO  - Curr Opin Neurol Neurosurg. 1993 Feb;6(1):60-5.

PMID- 23761511
OWN - NLM
STAT- MEDLINE
DCOM- 20140916
LR  - 20211021
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 2013
DP  - 2013 Jun 10
TI  - Altered mental status and complete heart block: an unusual presentation of 
      aspirin toxicity.
LID - 10.1136/bcr-2013-010083 [doi]
LID - bcr2013010083
AB  - Aspirin is one of the most commonly used medications. We report a patient who 
      presented with severe weakness, altered mental status and complete heart block 
      requiring temporary pacing. Despite the patient's family denying that the patient 
      used aspirin, an arterial blood gas that revealed a respiratory alkalosis and 
      metabolic acidosis suggested the diagnosis of salicylate toxicity. The salicylate 
      level was extremely elevated and the patient was successfully treated with 
      haemodialysis. Our case illustrates that salicylate toxicity should be considered 
      in a patient with a combined metabolic acidosis and respiratory alkalosis. A 
      prompt salicylate level should be obtained. This is also the first case of 
      salicylate toxicity causing complete heart block in an adult. The heart block 
      resolved with treatment of the salicylate toxicity.
FAU - Aggarwal, Nidhi
AU  - Aggarwal N
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, 
      Maimonides Medical Center, Brooklyn, New York, USA.
FAU - Kupfer, Yizhak
AU  - Kupfer Y
FAU - Chawla, Kabu
AU  - Chawla K
FAU - Tessler, Sidney
AU  - Tessler S
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20130610
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acidosis/chemically induced
MH  - Aged
MH  - Aspirin/*toxicity
MH  - Female
MH  - Heart Block/*chemically induced/surgery
MH  - Humans
MH  - Mental Disorders/*chemically induced
MH  - Pacemaker, Artificial
PMC - PMC3703023
EDAT- 2013/06/14 06:00
MHDA- 2014/09/17 06:00
CRDT- 2013/06/14 06:00
PHST- 2013/06/14 06:00 [entrez]
PHST- 2013/06/14 06:00 [pubmed]
PHST- 2014/09/17 06:00 [medline]
AID - bcr-2013-010083 [pii]
AID - 10.1136/bcr-2013-010083 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Jun 10;2013:bcr2013010083. doi: 10.1136/bcr-2013-010083.

PMID- 32967430
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20220531
IS  - 1945-8932 (Electronic)
IS  - 1945-8932 (Linking)
VI  - 35
IP  - 3
DP  - 2021 May
TI  - Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in 
      Aspirin Exacerbated Respiratory Disease.
PG  - 399-407
LID - 10.1177/1945892420961969 [doi]
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) affects 7% of 
      asthmatics. Usual therapies are inadequate for asthma and/or nasal polyposis, 
      leading to decreased quality of life. OBJECTIVE: Our objective was to evaluate 
      the efficacy of dupilumab in AERD patients with uncontrolled, chronic 
      rhinosinusitis with nasal polyposis (CRSwNP). METHODS: Patients 18 years and 
      older with a physician diagnosis of AERD and sino-nasal outcome test 22 (SNOT 22) 
      score ≥19 despite standard medical therapy were eligible for the study. Patients 
      received one month of placebo dosing, followed by 6 months of dupilumab. Patients 
      were blinded to the order of therapy. Wilcoxon-paired rank sum test was used to 
      compare study outcomes at baseline and the completion of the study. RESULTS: Ten 
      patients completed the study. The median baseline SNOT 22 score improved from 46 
      [IQR: 34 to 64.8] to 9.5 [IQR: 2.5 to 19] after 6 months of therapy (p = 0.0050). 
      The median baseline Lund MacKay score improved from 21.5 [IQR: 17 to 23.3] to 4 
      [IQR: 1.2 to 6] after 6 months of therapy (p = 0.0050). There was also 
      improvement in the following secondary outcomes: asthma control test (ACT), mini 
      asthma quality of life questionnaire (AQLQ), and University of Pennsylvania Smell 
      Identification test (UPSIT). Exhaled nitric oxide (FeNO), total serum IgE, 
      24-hour urinary leukotriene E(4), and serum thymus and activation regulated 
      cytokine (TARC) also decreased. There were no significant study-related adverse 
      events. CONCLUSION: Dupilumab was highly effective as add-on therapy for CRSwNP 
      in AERD, improving patient-reported outcomes, sinus opacification, and markers of 
      T2 inflammation.
FAU - Mustafa, S Shahzad
AU  - Mustafa SS
AUID- ORCID: 0000-0001-9691-7590
AD  - Division of Allergy, Immunology, Rheumatology, Rochester Regional Health, 
      Rochester, New York.
AD  - Division of Allergy, Immunology, Rheumatology, University of Rochester, 
      Rochester, New York.
FAU - Vadamalai, Karthik
AU  - Vadamalai K
AD  - Division of Critical Care, Mercy Hospital, Springfield, Missouri.
FAU - Scott, Bryan
AU  - Scott B
AD  - Division of Allergy, Immunology, Rheumatology, Rochester Regional Health, 
      Rochester, New York.
FAU - Ramsey, Allison
AU  - Ramsey A
AD  - Division of Allergy, Immunology, Rheumatology, Rochester Regional Health, 
      Rochester, New York.
AD  - Division of Allergy, Immunology, Rheumatology, University of Rochester, 
      Rochester, New York.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200923
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 420K487FSG (dupilumab)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Aspirin/adverse effects
MH  - Chronic Disease
MH  - Humans
MH  - *Nasal Polyps/drug therapy
MH  - Quality of Life
MH  - *Rhinitis/drug therapy
OTO - NOTNLM
OT  - Samter’s triad
OT  - aspirin exacerbated respiratory disease
OT  - chronic sinusitis with nasal polyposis
OT  - dupilumab
OT  - nasal polyposis
EDAT- 2020/09/25 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/24 05:23
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/09/24 05:23 [entrez]
AID - 10.1177/1945892420961969 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2021 May;35(3):399-407. doi: 10.1177/1945892420961969. Epub 
      2020 Sep 23.

PMID- 34076601
OWN - NLM
STAT- MEDLINE
DCOM- 20211224
LR  - 20211224
IS  - 1558-2035 (Electronic)
IS  - 1558-2027 (Linking)
VI  - 22
IP  - 7
DP  - 2021 Jul 1
TI  - Oral aspirin or low dose of intravenous lysine acetylsalicylate in ST-elevation 
      myocardial infarction undergoing primary percutaneous coronary intervention.
PG  - 539-545
LID - 10.2459/JCM.0000000000001174 [doi]
AB  - AIM: To compare the pharmacodynamic effect of an oral loading dose of 'noncoated' 
      ASA 300 mg vs. an intravenous bolus injection of lysine acetylsalicylate 150 mg 
      in patients with STEMI undergoing pPCI. METHODS: This was a prospective 
      single-center, open label, pharmacodynamic study, including nonconsecutive 
      patients presenting at our catheterization laboratory with STEMI undergoing pPCI 
      and not receiving ASA within the previous 7 days. Pharmacodynamic analyses were 
      performed at five time points: baseline, and 1, 2, 4 and 12 h after the loading 
      dose, and measured as ASA reaction units (ARU) by the Verify Now System. An ARU 
      more than 550 was considered as nonresponsiveness to study drugs. The primary end 
      point was the different rate of patients with ARU more than 550 at 2 h after the 
      loading dose of oral vs. intravenous ASA. Secondary end points included the 
      comparison of ARU more than 550 at the other time points and the comparison of 
      continuous ARU at each time point. RESULTS: The study was planned with a sample 
      size of 68 patients, but it was prematurely stopped due to slow enrollment after 
      the inclusion of 23 patients, 12 randomized to oral ASA and 11 to intravenous 
      lysine acetylsalicylate. At 2 h the rate of patients with ARU more than 550 was 
      numerically but not significantly higher in patients receiving oral ASA as 
      compared with intravenous lysine acetylsalicylate (33 vs. 14.2%; Δ -0.19, 95% 
      confidence interval -0.59-0.21, P = 0.58). The difference over time was NS 
      (P = 0.98), though the prevalence of ARU more than 550 was higher at the other 
      time points. Both routes of administration reduced ARU values over time, though 
      with no overall significant difference between profiles (P overall = 0.48). 
      CONCLUSION: In patients with STEMI undergoing pPCI the rate of nonresponsiveness 
      to ASA was not different comparing an oral 'noncoated' loading dose of ASA with 
      an intravenous bolus injection of lysine acetylsalicylate. However, as patient 
      enrollment was prematurely terminated, this study is underpowered to draw a 
      definite conclusion.
CI  - Copyright © 2021 Italian Federation of Cardiology - I.F.C. All rights reserved.
FAU - Ferlini, Marco
AU  - Ferlini M
AD  - Division of Cardiology.
FAU - Leonardi, Sergio
AU  - Leonardi S
AD  - Coronary Care Unit, Fondazione IRCCS Policlinico San Matteo.
AD  - Department of Molecular Medicine, University of Pavia.
FAU - Mandurino Mirizzi, Alessandro
AU  - Mandurino Mirizzi A
AD  - Division of Cardiology.
FAU - Montalto, Claudio
AU  - Montalto C
AD  - Division of Cardiology.
AD  - Department of Molecular Medicine, University of Pavia.
FAU - Crimi, Gabriele
AU  - Crimi G
AD  - Division of Cardiology.
FAU - Repetto, Alessandra
AU  - Repetto A
AD  - Division of Cardiology.
FAU - Marinoni, Barbara
AU  - Marinoni B
AD  - Division of Cardiology.
FAU - Somaschini, Alberto
AU  - Somaschini A
AD  - Division of Cardiology.
AD  - Department of Molecular Medicine, University of Pavia.
FAU - Ferrario, Maurizio
AU  - Ferrario M
AD  - Division of Cardiology.
FAU - Klersy, Catherine
AU  - Klersy C
AD  - Clinical Epidemiology & Biometry Unit, Fondazione IRCCS Policlinico San Matteo, 
      Pavia, Italy.
FAU - Oltrona Visconti, Luigi
AU  - Oltrona Visconti L
AD  - Division of Cardiology.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Med (Hagerstown)
JT  - Journal of cardiovascular medicine (Hagerstown, Md.)
JID - 101259752
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacokinetics
MH  - Coronary Care Units/methods/statistics & numerical data
MH  - Drug Monitoring/*methods
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Lysine/administration & dosage/*analogs & derivatives/pharmacokinetics
MH  - Male
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacokinetics
MH  - Preoperative Care/methods
MH  - Prospective Studies
MH  - ST Elevation Myocardial Infarction/diagnosis/*drug therapy/surgery
EDAT- 2021/06/03 06:00
MHDA- 2021/12/25 06:00
CRDT- 2021/06/02 12:18
PHST- 2021/06/02 12:18 [entrez]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/12/25 06:00 [medline]
AID - 01244665-202107000-00003 [pii]
AID - 10.2459/JCM.0000000000001174 [doi]
PST - ppublish
SO  - J Cardiovasc Med (Hagerstown). 2021 Jul 1;22(7):539-545. doi: 
      10.2459/JCM.0000000000001174.

PMID- 8927904
OWN - NLM
STAT- MEDLINE
DCOM- 19961114
LR  - 20131121
IS  - 1661-8157 (Print)
IS  - 1661-8157 (Linking)
VI  - 85
IP  - 39
DP  - 1996 Sep 24
TI  - [Secondary prevention of arteriosclerosis].
PG  - 1201-5
AB  - Secondary prevention of arteriosclerosis tries to inhibit progression of the 
      atherosclerotic process. Therapeutic measures focus on modification of 
      cardiovascular risk factors and antithrombotic treatment. Hypercholesterolemia is 
      the main risk factor for coronary artery disease. The risk of a coronary event is 
      correlated to the plasma cholesterol level. Lowering plasma cholesterol results 
      in reduction of vascular morbidity and mortality. Cigarette smoking is the 
      predominant risk factor for peripheral arterial occlusive disease (PAOD). Smoking 
      cessation reduces progression of PAOD and lowers cardiovascular morbidity and 
      mortality. The preventive effect of antihypertensive therapy in hypertensive 
      patients is most pronounced for cerebrovascular events. Antihypertensive measures 
      improve prognosis after stroke and myocardial infarction. The increased 
      cardiovascular risk in diabetics is in part explained by hyperglycemia and 
      hyperinsulinemia, but also depends on coexisting dyslipidemia and hypertension. 
      Intensive treatment of elevated blood glucose levels, dyslipidemia and 
      hypertension are important preventive measures. Aspirin is highly effective in 
      secondary prevention of vascular events. For the coronary arteries, low-dose 
      aspirin is well established. Whether low-dose aspirin is equally effective for 
      reducing progression of arteriosclerosis in the cerebrovascular and in the 
      peripheral vessels is questionable. Ticlopidine serves as an alternative to 
      aspirin; however, neutropenia may occur, which requires supervision of the 
      patient.
FAU - Hoffmann, U
AU  - Hoffmann U
AD  - Abteilung Angiologie, Department für Innere Medizin, Universitätsspital Zürich.
FAU - Leu, A J
AU  - Leu AJ
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Sekundärprävention der Arteriosklerose.
PL  - Switzerland
TA  - Praxis (Bern 1994)
JT  - Praxis
JID - 101468093
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticholesteremic Agents/therapeutic use
MH  - Antihypertensive Agents/therapeutic use
MH  - Arteriosclerosis/etiology/*prevention & control
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Factors
MH  - Smoking Cessation
RF  - 20
EDAT- 1996/09/24 00:00
MHDA- 1996/09/24 00:01
CRDT- 1996/09/24 00:00
PHST- 1996/09/24 00:00 [pubmed]
PHST- 1996/09/24 00:01 [medline]
PHST- 1996/09/24 00:00 [entrez]
PST - ppublish
SO  - Praxis (Bern 1994). 1996 Sep 24;85(39):1201-5.

PMID- 1434877
OWN - NLM
STAT- MEDLINE
DCOM- 19921211
LR  - 20190516
IS  - 0025-6196 (Print)
IS  - 0025-6196 (Linking)
VI  - 67
IP  - 6
DP  - 1992 Jun
TI  - Results of a randomized controlled trial of carotid endarterectomy for 
      asymptomatic carotid stenosis. Mayo Asymptomatic Carotid Endarterectomy Study 
      Group.
PG  - 513-8
AB  - We undertook a randomized controlled trial designed to compare the effects of 
      carotid endarterectomy with medical treatment using low-dose aspirin in patients 
      with asymptomatic carotid stenosis. During 30 months of recruitment, 71 
      randomized and 87 eligible nonrandomized patients participated in a follow-up 
      protocol. The total ipsilateral perioperative stroke and death rate was 0% among 
      randomized patients and 3% among nonrandomized patients, and the major stroke and 
      death rate was 0% for both groups. Too few cerebral ischemic events occurred to 
      judge the comparative effectiveness of carotid endarterectomy versus low-dose 
      aspirin for asymptomatic carotid stenosis. The trial was terminated early because 
      of a significantly higher number of myocardial infarctions and transient cerebral 
      ischemic events in the surgical group than in the medical group. Most of the 
      events were not temporally related to the surgical procedure, but there was 
      evidence that these events could have related to the absence of aspirin use in 
      the surgical group. These observations reinforce the appropriateness of the use 
      of aspirin throughout the perioperative period and beyond (unless 
      contraindications exist) in patients with asymptomatic carotid stenosis who 
      undergo carotid endarterectomy.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Mayo Clin Proc. 1992 Jun;67(6):597-600. PMID: 1434888
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Carotid Stenosis/*surgery
MH  - Cerebrovascular Disorders/*prevention & control
MH  - *Endarterectomy, Carotid/mortality
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications
EDAT- 1992/06/01 00:00
MHDA- 1992/06/01 00:01
CRDT- 1992/06/01 00:00
PHST- 1992/06/01 00:00 [pubmed]
PHST- 1992/06/01 00:01 [medline]
PHST- 1992/06/01 00:00 [entrez]
AID - S0025-6196(12)60456-X [pii]
AID - 10.1016/s0025-6196(12)60456-x [doi]
PST - ppublish
SO  - Mayo Clin Proc. 1992 Jun;67(6):513-8. doi: 10.1016/s0025-6196(12)60456-x.

PMID- 18332613
OWN - NLM
STAT- MEDLINE
DCOM- 20080522
LR  - 20131121
IS  - 1424-8840 (Electronic)
IS  - 1424-8832 (Linking)
VI  - 36
IP  - 1
DP  - 2007
TI  - Reverse effect of aspirin: is the prothrombotic effect after aspirin 
      discontinuation mediated by cyclooxygenase 2 inhibition?
PG  - 40-4
LID - 10.1159/000112638 [doi]
AB  - BACKGROUND: While aspirin is the drug most often used to prevent cardiovascular 
      complications, its discontinuation induces an increased risk of acute coronary 
      syndrome and ischemic stroke in some patients. OBJECTIVES: We hypothesized that 
      infinitesimal concentrations of aspirin could persist in plasma after its 
      discontinuation, thereby inducing a prothrombotic effect that could be due to a 
      modification in the mechanism of action of aspirin via the cyclooxygenase 1 
      (COX-1) and COX-2 pathways. METHODS AND RESULTS: We studied the effects of 
      ultra-low-dose aspirin (ULDA) as well as those of sc-560 and ns-398, specific 
      COX-1 and COX-2 inhibitors, on induced hemorrhagic time and in a model of 
      laser-induced thrombosis in rats. In the laser-induced thrombosis model, ULDA 
      treatment increased the number of emboli and the duration of embolization, 
      thereby confirming its prothrombotic effect described in previous publications. 
      This effect was also observed in rats pretreated with sc-560 but not in those 
      pretreated with ns-398. CONCLUSIONS: We demonstrated that ULDA induced a 
      prothrombotic effect in the rats studied. This strongly suggests that a very 
      small amount of aspirin could remain in the patient's blood after aspirin 
      therapy, leading to cardiovascular complications. This effect may be mediated by 
      the COX-2 pathway.
CI  - Copyright 2008 S. Karger AG, Basel.
FAU - Doutremepuich, Christian
AU  - Doutremepuich C
AD  - Laboratoire d'Hématologie, UFR des Sciences Pharmaceutiques, Université Victor 
      Segalen Bordeaux 2, Bordeaux, France. Christian.Doutremepuich@heph.u-bordeaux2.fr
FAU - Aguejouf, Omar
AU  - Aguejouf O
FAU - Eizayaga, Francisco X
AU  - Eizayaga FX
FAU - Desplat, Vanessa
AU  - Desplat V
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20080306
PL  - Switzerland
TA  - Pathophysiol Haemost Thromb
JT  - Pathophysiology of haemostasis and thrombosis
JID - 101142710
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Membrane Proteins)
RN  - 0 (Nitrobenzenes)
RN  - 0 (Pyrazoles)
RN  - 0 (SC 560)
RN  - 0 (Sulfonamides)
RN  - 123653-11-2 (N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (Ptgs1 protein, rat)
RN  - EC 1.14.99.1 (Ptgs2 protein, rat)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/blood/pharmacokinetics/*toxicity
MH  - Bleeding Time
MH  - Cyclooxygenase 1/physiology
MH  - Cyclooxygenase 2/*physiology
MH  - Cyclooxygenase 2 Inhibitors/administration & 
      dosage/blood/pharmacokinetics/*toxicity
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Lasers/adverse effects
MH  - Male
MH  - Membrane Proteins/physiology
MH  - Metabolic Clearance Rate
MH  - Nitrobenzenes/pharmacology
MH  - Pyrazoles/pharmacology
MH  - Random Allocation
MH  - Rats
MH  - Rats, Wistar
MH  - Substance Withdrawal Syndrome/*enzymology/etiology
MH  - Sulfonamides/pharmacology
MH  - Thrombophilia/chemically induced/*enzymology
MH  - Thrombosis/enzymology/etiology
EDAT- 2008/03/12 09:00
MHDA- 2008/05/23 09:00
CRDT- 2008/03/12 09:00
PHST- 2007/06/26 00:00 [received]
PHST- 2007/11/26 00:00 [accepted]
PHST- 2008/03/12 09:00 [pubmed]
PHST- 2008/05/23 09:00 [medline]
PHST- 2008/03/12 09:00 [entrez]
AID - 000112638 [pii]
AID - 10.1159/000112638 [doi]
PST - ppublish
SO  - Pathophysiol Haemost Thromb. 2007;36(1):40-4. doi: 10.1159/000112638. Epub 2008 
      Mar 6.

PMID- 8758317
OWN - NLM
STAT- MEDLINE
DCOM- 19961016
LR  - 20131121
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 109
IP  - 3
DP  - 1996 Mar
TI  - A prospective randomized placebo-controlled trial of low-dose aspirin for 
      prevention of intra-uterine growth retardation.
PG  - 238-42
AB  - OBJECTIVE: To evaluate the effects of low-dose aspirin on placental circulation 
      and on the prevention of intrauterine growth retardation (IUGR). MATERIAL AND 
      METHODS: We conducted a prospective randomized, double blind, controlled clinical 
      trial in 84 pregnant women (mainly nulliparous women) at high risk of IUGR. From 
      the 28th-30th week of gestation onward, low dose aspirin (75 mg daily, study 
      group, n = 40) or placebo (control group, n = 44) was given consecutively for 6 
      to 8 weeks. Pulse-wave umbilical artery Doppler velocimetry was measured before 
      and after drug use. RESULTS: The mean value of systolic/diastolic ratio of 
      umbilical artery flow velocity waveforms in the study group was significantly 
      lower than that in the control group after drug use, but there was no difference 
      between the two groups before drug use. The incidences of IRGR and preeclampsia 
      in the study group (7.5% and 10.0% respectively) were significantly lower than 
      those in the control group (27.3% of both). No adverse effects of low dose 
      aspirin on both mother and fetus were observed. CONCLUSIONS: Low dose aspirin 
      administration (75 mg daily) beginning at the early stage of third trimester may 
      improve the fetoplacental circulation, and thus prevent IUGR and/or preeclampsia 
      effectively.
FAU - Wang, Z
AU  - Wang Z
AD  - Department of Obstetrics and Gynecology, Xiehe Hospital, Tongji Medical 
      University, Wuhan.
FAU - Li, W
AU  - Li W
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Double-Blind Method
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Humans
MH  - Placenta/*blood supply
MH  - Pregnancy
MH  - Prospective Studies
MH  - Regional Blood Flow
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
PST - ppublish
SO  - Chin Med J (Engl). 1996 Mar;109(3):238-42.

PMID- 29466159
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20180510
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 8
DP  - 2018 Feb 22
TI  - Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
PG  - 699-707
LID - 10.1056/NEJMoa1712746 [doi]
AB  - BACKGROUND: Clinical trials and meta-analyses have suggested that aspirin may be 
      effective for the prevention of venous thromboembolism (proximal deep-vein 
      thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but 
      comparisons with direct oral anticoagulants are lacking for prophylaxis beyond 
      hospital discharge. METHODS: We performed a multicenter, double-blind, 
      randomized, controlled trial involving patients who were undergoing total hip or 
      knee arthroplasty. All the patients received once-daily oral rivaroxaban (10 mg) 
      until postoperative day 5 and then were randomly assigned to continue rivaroxaban 
      or switch to aspirin (81 mg daily) for an additional 9 days after total knee 
      arthroplasty or for 30 days after total hip arthroplasty. Patients were followed 
      for 90 days for symptomatic venous thromboembolism (the primary effectiveness 
      outcome) and bleeding complications, including major or clinically relevant 
      nonmajor bleeding (the primary safety outcome). RESULTS: A total of 3424 patients 
      (1804 undergoing total hip arthroplasty and 1620 undergoing total knee 
      arthroplasty) were enrolled in the trial. Venous thromboembolism occurred in 11 
      of 1707 patients (0.64%) in the aspirin group and in 12 of 1717 patients (0.70%) 
      in the rivaroxaban group (difference, 0.06 percentage points; 95% confidence 
      interval [CI], -0.55 to 0.66; P<0.001 for noninferiority and P=0.84 for 
      superiority). Major bleeding complications occurred in 8 patients (0.47%) in the 
      aspirin group and in 5 (0.29%) in the rivaroxaban group (difference, 0.18 
      percentage points; 95% CI, -0.65 to 0.29; P=0.42). Clinically important bleeding 
      occurred in 22 patients (1.29%) in the aspirin group and in 17 (0.99%) in the 
      rivaroxaban group (difference, 0.30 percentage points; 95% CI, -1.07 to 0.47; 
      P=0.43). CONCLUSIONS: Among patients who received 5 days of rivaroxaban 
      prophylaxis after total hip or total knee arthroplasty, extended prophylaxis with 
      aspirin was not significantly different from rivaroxaban in the prevention of 
      symptomatic venous thromboembolism. (Funded by the Canadian Institutes of Health 
      Research; ClinicalTrials.gov number, NCT01720108 .).
FAU - Anderson, David R
AU  - Anderson DR
AUID- ORCID: 0000-0003-0845-1722
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Dunbar, Michael
AU  - Dunbar M
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Murnaghan, John
AU  - Murnaghan J
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Kahn, Susan R
AU  - Kahn SR
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Gross, Peter
AU  - Gross P
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Forsythe, Michael
AU  - Forsythe M
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Pelet, Stephane
AU  - Pelet S
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Fisher, William
AU  - Fisher W
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Belzile, Etienne
AU  - Belzile E
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Dolan, Sean
AU  - Dolan S
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Crowther, Mark
AU  - Crowther M
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Bohm, Eric
AU  - Bohm E
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - MacDonald, Steven J
AU  - MacDonald SJ
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Gofton, Wade
AU  - Gofton W
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Kim, Paul
AU  - Kim P
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Zukor, David
AU  - Zukor D
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Pleasance, Susan
AU  - Pleasance S
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Andreou, Pantelis
AU  - Andreou P
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Doucette, Steve
AU  - Doucette S
AUID- ORCID: 0000-0002-0226-0143
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Theriault, Chris
AU  - Theriault C
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Abianui, Abongnwen
AU  - Abianui A
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Carrier, Marc
AU  - Carrier M
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Kovacs, Michael J
AU  - Kovacs MJ
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Rodger, Marc A
AU  - Rodger MA
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Coyle, Doug
AU  - Coyle D
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Wells, Philip S
AU  - Wells PS
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
FAU - Vendittoli, Pascal-Andre
AU  - Vendittoli PA
AD  - From the Departments of Medicine (D.R.A.), Surgery (M.D.), and Community Health 
      and Epidemiology (P.A.), Dalhousie University, and the Nova Scotia Health 
      Authority (S. Pleasance, S. Doucette, C.T., A.A.), Halifax, the Department of 
      Surgery, University of Toronto, Toronto (J.M.), the Departments of Medicine 
      (S.R.K.) and Surgery (W.F., D.Z.), McGill University, and the Department of 
      Surgery, University of Montreal (P.-A.V.), Montreal, the Department of Medicine, 
      McMaster University, Hamilton, ON (P.G., M. Crowther), the Department of Surgery, 
      Dalhousie University, Moncton, NB (M.F.), the Department of Surgery, Laval 
      University, Quebec, QC (S. Pelet, E. Belzile), the Department of Medicine, 
      Dalhousie University, Saint John, NB (S. Dolan), the Department of Surgery, 
      University of Manitoba, Winnipeg (E. Bohm), the Departments of Surgery (S.J.M.) 
      and Medicine (M.J.K.), University of Western Ontario, London, and the Department 
      of Surgery (W.G., P.K.), Division of Hematology, Department of Medicine (M. 
      Carrier, M.A.R., P.S.W.), and School of Epidemiology and Public Health (D.C.), 
      University of Ottawa, Ottawa - all in Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT01720108
SI  - ClinicalTrials.gov/NCT01720108
PT  - Equivalence Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. ;378(19):1848. PMID: 29745631
CIN - Z Orthop Unfall. 2019 Feb;157(1):16. PMID: 30786298
CIN - Am J Phys Med Rehabil. 2019 May;98(5):e40-e42. PMID: 30998542
MH  - Aged
MH  - *Arthroplasty, Replacement, Hip
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Factor Xa Inhibitors/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Risk Factors
MH  - Rivaroxaban/adverse effects/*therapeutic use
MH  - Venous Thromboembolism/*prevention & control
EDAT- 2018/02/22 06:00
MHDA- 2018/02/27 06:00
CRDT- 2018/02/22 06:00
PHST- 2018/02/22 06:00 [entrez]
PHST- 2018/02/22 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
AID - 10.1056/NEJMoa1712746 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Feb 22;378(8):699-707. doi: 10.1056/NEJMoa1712746.

PMID- 21784392
OWN - NLM
STAT- MEDLINE
DCOM- 20111108
LR  - 20220408
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 108
IP  - 7
DP  - 2011 Oct 1
TI  - Safety of dental extractions during uninterrupted single or dual antiplatelet 
      treatment.
PG  - 964-7
LID - 10.1016/j.amjcard.2011.05.029 [doi]
AB  - Optimal dental management in patients on long-term antiplatelet treatment is not 
      clearly defined. Antiplatelet discontinuation increases the risk of thrombotic 
      complications, whereas uninterrupted antiplatelet therapy, which is the currently 
      recommended approach, is assumed to increase the bleeding hazard after dental 
      procedures. We sought to prospectively compare the risk of immediate and late 
      postextraction bleeding in patients receiving uninterrupted single or dual 
      antiplatelet therapy. We recruited 643 consecutive patients referred for dental 
      extractions. In total 111 (17.3%) were on clinically indicated antiplatelet 
      therapy: aspirin (n = 42), clopidogrel (n = 36), and aspirin and clopidogrel (n = 
      33). Controls (n = 532, 82.7%) were not on antiplatelet treatment. Immediate and 
      late bleeding complications were recorded. Compared to controls the risk of 
      prolonged immediate bleeding was higher in patients on dual antiplatelet therapy 
      (relative risk [RR] 177.3, 95% confidence interval [CI] 43.5 to 722, p <0.001) 
      but not in patients on aspirin alone (RR = 6.3, 95% CI 0.6 to 68.4, p = 0.2) or 
      clopidogrel alone (RR = 7.4, 95% CI 0.7 to 79.5, p = 0.18); however, all 
      immediate bleeding complications in all treatment groups were successfully 
      managed with local hemostatic measures. No patient developed any late hemorrhage. 
      In conclusion, dental extractions may be safely performed in patients receiving 
      single or dual antiplatelet therapy when appropriate local hemostatic measures 
      are taken, thus averting thrombotic risk of temporary antiplatelet 
      discontinuation.
CI  - Copyright © 2011 Elsevier Inc. All rights reserved.
FAU - Lillis, Theodoros
AU  - Lillis T
AD  - Department of Dentoalveolar Surgery, Implant Surgery and Radiology, Aristotle 
      University Dental School, Thessaloniki, Greece.
FAU - Ziakas, Antonios
AU  - Ziakas A
FAU - Koskinas, Konstantinos
AU  - Koskinas K
FAU - Tsirlis, Anastasios
AU  - Tsirlis A
FAU - Giannoglou, George
AU  - Giannoglou G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110723
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Hemostatics)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Greece/epidemiology
MH  - Hemostatics/administration & dosage
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Postoperative Hemorrhage/chemically induced/*epidemiology/prevention & control
MH  - Retrospective Studies
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Time Factors
MH  - Tooth Extraction/*methods
EDAT- 2011/07/26 06:00
MHDA- 2011/11/09 06:00
CRDT- 2011/07/26 06:00
PHST- 2011/01/23 00:00 [received]
PHST- 2011/05/09 00:00 [revised]
PHST- 2011/05/09 00:00 [accepted]
PHST- 2011/07/26 06:00 [entrez]
PHST- 2011/07/26 06:00 [pubmed]
PHST- 2011/11/09 06:00 [medline]
AID - S0002-9149(11)01915-1 [pii]
AID - 10.1016/j.amjcard.2011.05.029 [doi]
PST - ppublish
SO  - Am J Cardiol. 2011 Oct 1;108(7):964-7. doi: 10.1016/j.amjcard.2011.05.029. Epub 
      2011 Jul 23.

PMID- 22257511
OWN - NLM
STAT- MEDLINE
DCOM- 20120227
LR  - 20131121
IS  - 0030-6002 (Print)
IS  - 0030-6002 (Linking)
VI  - 153
IP  - 4
DP  - 2012 Jan 29
TI  - [The possible options for the prevention of preeclampsia].
PG  - 144-51
LID - 10.1556/OH.2012.29267 [doi]
AB  - This review summarizes the possible options for the prevention of preeclampsia 
      based on important factors of patomechanism. The effects of antioxidants have 
      been described in numerous clinical researches based on the oxidative hypothesis. 
      Another important factor is the change of nitric oxide activity. Nitric oxide 
      donors are able to compensate the symptoms of preeclampsia. The inverse 
      relationship between the calcium intake and gestational hypertension has been 
      known for a long time. The calcium supplementation seems to be a good opportunity 
      to prevent preeclampsia. With low molecular weight heparins we can intervene in 
      the patomechanisms of preeclampsia by antithrombocyte effects, vasoactive 
      properties and impact on throphoblast cell morphology and differentiation. 
      Thrombocyte aggregation inhibitors were examined in number of studies because 
      they reduced thromboxane mediated vasoconstriction and inhibited placental 
      thrombosis. Several studies verify whether prophylaxis with low molecular weight 
      heparins and low dose aspirin could improve pregnancy outcome in preeclampsia.
FAU - Fodor, Andrea
AU  - Fodor A
AD  - Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Aneszteziológiai és 
      Intenzív Terápiás Tanszék Debrecen Nagyerdei krt. dofadr@freemail.hu
FAU - Gyorffy, András
AU  - Gyorffy A
FAU - Váradi, Magdolna
AU  - Váradi M
FAU - Fülesdi, Béla
AU  - Fülesdi B
FAU - Major, Tamás
AU  - Major T
LA  - hun
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - A praeeclampsia megelőzésének lehetőségei.
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
RN  - 0 (Anticoagulants)
RN  - 0 (Antioxidants)
RN  - 0 (Calcium Compounds)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Antioxidants/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Calcium/metabolism
MH  - Calcium Compounds/*administration & dosage
MH  - Dietary Supplements
MH  - Female
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Nitric Oxide/metabolism
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pre-Eclampsia/drug therapy/metabolism/physiopathology/*prevention & control
MH  - Pregnancy
EDAT- 2012/01/20 06:00
MHDA- 2012/03/01 06:00
CRDT- 2012/01/20 06:00
PHST- 2012/01/20 06:00 [entrez]
PHST- 2012/01/20 06:00 [pubmed]
PHST- 2012/03/01 06:00 [medline]
AID - G058608444030111 [pii]
AID - 10.1556/OH.2012.29267 [doi]
PST - ppublish
SO  - Orv Hetil. 2012 Jan 29;153(4):144-51. doi: 10.1556/OH.2012.29267.

PMID- 20727671
OWN - NLM
STAT- MEDLINE
DCOM- 20110208
LR  - 20131121
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 112
IP  - 9
DP  - 2010 Nov
TI  - Surgery for carpal tunnel syndrome under antiplatelet therapy.
PG  - 791-3
LID - 10.1016/j.clineuro.2010.07.002 [doi]
AB  - OBJECTIVE: Antiplatelet therapy is often instituted after cardiovascular or 
      neurological ischemic events. In general, discontinuation of the antiplatelet 
      medication for several days is warranted previous to surgery. However, 
      discontinuation can lead to ischemic events. For some forms of surgery, the risks 
      of an ischemic event, and especially, its consequences do not outweigh the 
      benefit of discontinuation of the antiplatelet therapy. Retrospective analysis 
      was done of a cohort of patients treated for carpal tunnel syndrome with special 
      emphasis on postoperative hemorrhage in combination with antiplatelet medication. 
      METHODS: Retrospective analysis of cohort consisting of 362 consecutive patients 
      treated for carpal tunnel syndrome in the Neurosurgical Centre, Nijmegen was 
      done. RESULTS: In 362 patients 423 operations on carpal tunnel release were done. 
      Thirty-one patients were on antiplatelet therapy, of which 6 did not discontinue 
      the medication before surgery. The remaining patients stopped at least seven days 
      before surgery. A postoperative hemorrhage did not occur in any of the 423 
      operations. CONCLUSION: There seems no reasonable evidence that discontinuation 
      of aspirin for carpal tunnel syndrome is justified. Bleeding complications are 
      considered rare, moreover the impact of an ischemic cardiovascular or a cerebral 
      event would be far more severe than that of postoperative hemorrhage in the 
      wrist.
CI  - Copyright © 2010 Elsevier B.V. All rights reserved.
FAU - Boogaarts, Hieronymus D
AU  - Boogaarts HD
AD  - Department of Neurosurgery, Radboud University Nijmegen Medical Centre, Reinier 
      Postlaan 4, 6500 HB Nijmegen, The Netherlands. H.Boogaarts@nch.umcn.nl
FAU - Verbeek, André L M
AU  - Verbeek AL
FAU - Bartels, Ronald H M A
AU  - Bartels RH
LA  - eng
PT  - Journal Article
DEP - 20100819
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anesthesia, Local
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Carpal Tunnel Syndrome/*complications/*surgery
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Perioperative Care
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Postoperative Hemorrhage/*chemically induced/*epidemiology
MH  - Retrospective Studies
MH  - Risk
EDAT- 2010/08/24 06:00
MHDA- 2011/02/09 06:00
CRDT- 2010/08/24 06:00
PHST- 2009/08/27 00:00 [received]
PHST- 2010/05/18 00:00 [revised]
PHST- 2010/07/04 00:00 [accepted]
PHST- 2010/08/24 06:00 [entrez]
PHST- 2010/08/24 06:00 [pubmed]
PHST- 2011/02/09 06:00 [medline]
AID - S0303-8467(10)00199-X [pii]
AID - 10.1016/j.clineuro.2010.07.002 [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 2010 Nov;112(9):791-3. doi: 
      10.1016/j.clineuro.2010.07.002. Epub 2010 Aug 19.

PMID- 21388846
OWN - NLM
STAT- MEDLINE
DCOM- 20120608
LR  - 20131121
IS  - 1532-2149 (Electronic)
IS  - 1090-3801 (Linking)
VI  - 15
IP  - 8
DP  - 2011 Sep
TI  - Pharmacological action of choline and aspirin coadministration on acute 
      inflammatory pain.
PG  - 858-65
LID - 10.1016/j.ejpain.2011.02.001 [doi]
AB  - Non-steroidal anti-inflammatory drugs (NSAIDs) are effective for relieving pain 
      but undesirable side effects limit their clinical usefulness. Choline is a α7 
      nicotinic receptor agonist that has antinociceptive effects in a variety of pain 
      models. Drug combination is a strategy in the management of pain to reduce side 
      effects. The aim of the study was to evaluate the nature of the interaction 
      between choline and aspirin in two distinct inflammatory pain models. The 
      analgesic mechanism of choline was also investigated. In the writhing test, 
      intravenous administration of choline or aspirin showed dose-dependent 
      antinociceptive activity, and isobolographic analysis revealed a synergistic 
      nature of the interaction between choline and aspirin. More importantly, 
      coadministration choline with aspirin could significantly shorten the 
      antinociceptive latency of aspirin and prolong the antinociceptive duration of 
      aspirin in the writhing test. In the carrageenan test, single administration of 
      choline or aspirin significantly attenuated carrageenan-induced thermal 
      hyperalgesia in a dose-dependent relationship. Coadministration of non-analgesic 
      doses of aspirin with choline significantly suppressed the thermal hyperalgesia, 
      with a longer duration efficacy. Furthermore, we found that α7 nicotinic, 
      muscarinic, and opioid-receptors are involved in the antinociceptive effect of 
      choline in the writhing test and the antinociceptive effect produced by 
      systemically administered choline may be via a peripheral mechanism. In 
      conclusion, coadministration of choline and aspirin holds promise for development 
      as a safe analgesic drug combination for inflammatory pain, with a higher potency 
      and longer duration than either aspirin or choline alone.
CI  - Copyright © 2011 European Federation of International Association for the Study 
      of Pain Chapters. Published by Elsevier Ltd. All rights reserved.
FAU - Yong-Ping, Shi
AU  - Yong-Ping S
AD  - Thadweik Academy of Medicine, Beijing 100039, China.
FAU - Jin-Da, Wang
AU  - Jin-Da W
FAU - Ru-Huan, Wang
AU  - Ru-Huan W
FAU - Xiang-Di, Zhao
AU  - Xiang-Di Z
FAU - Hai-Tao, Yu
AU  - Hai-Tao Y
FAU - Hai, Wang
AU  - Hai W
LA  - eng
PT  - Journal Article
DEP - 20110308
PL  - England
TA  - Eur J Pain
JT  - European journal of pain (London, England)
JID - 9801774
RN  - 0 (Analgesics)
RN  - 0 (Drug Combinations)
RN  - 0 (Nicotinic Agonists)
RN  - N91BDP6H0X (Choline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Analgesics/pharmacology/therapeutic use
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Choline/*pharmacology/therapeutic use
MH  - Disease Models, Animal
MH  - Drug Combinations
MH  - Female
MH  - Inflammation/chemically induced/drug therapy/physiopathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Nicotinic Agonists/pharmacology/therapeutic use
MH  - Pain/chemically induced/*drug therapy/physiopathology
EDAT- 2011/03/11 06:00
MHDA- 2012/06/09 06:00
CRDT- 2011/03/11 06:00
PHST- 2010/07/29 00:00 [received]
PHST- 2011/01/13 00:00 [revised]
PHST- 2011/02/02 00:00 [accepted]
PHST- 2011/03/11 06:00 [entrez]
PHST- 2011/03/11 06:00 [pubmed]
PHST- 2012/06/09 06:00 [medline]
AID - S1090-3801(11)00034-6 [pii]
AID - 10.1016/j.ejpain.2011.02.001 [doi]
PST - ppublish
SO  - Eur J Pain. 2011 Sep;15(8):858-65. doi: 10.1016/j.ejpain.2011.02.001. Epub 2011 
      Mar 8.

PMID- 523785
OWN - NLM
STAT- MEDLINE
DCOM- 19800327
LR  - 20131121
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 26
IP  - 3
DP  - 1979 Dec
TI  - Dipyridamole levels in plasma of man and other species.
PG  - 495-508
AB  - Measurements were made of the concentration of dipyridamole in the plasma of man, 
      dogs, pigs, and pigeons at different times after oral administration of the drug. 
      In dogs and in man, there was considerable variation in the plasma levels of the 
      drug in different subjects. Pigs and pigeons always had much lower levels of the 
      drug in plasma than did men and dogs given comparable doses. After intravenous 
      injection of dipyridamole to pigs, a large proportion of the drug appeared to 
      leave the plasma almost immediately; subsequently, the half-life of the drug 
      remaining in the plasma was quite similar to that previously reported in man. The 
      administration of aspirin with dipyridamole sometimes resulted in higher blood 
      levels of the drug in dogs, man, and pigs, but the effects were small. The wide 
      variations in plasma drug levels observed indicate that in future human or 
      experimental trials designed to evaluate the antithrombotic effect of 
      dipyridamole, plasma levels of the drug should be routinely monitored.
FAU - Tyce, G M
AU  - Tyce GM
FAU - Fuster, V
AU  - Fuster V
FAU - Owen, C A Jr
AU  - Owen CA Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Columbidae
MH  - Dipyridamole/administration & dosage/*blood
MH  - Dogs
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Species Specificity
MH  - Swine
MH  - Time Factors
EDAT- 1979/12/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1979/12/01 00:00
PHST- 1979/12/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1979/12/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1979 Dec;26(3):495-508.

PMID- 24854040
OWN - NLM
STAT- MEDLINE
DCOM- 20160229
LR  - 20191112
IS  - 1876-1038 (Electronic)
IS  - 1574-8871 (Linking)
VI  - 9
IP  - 2
DP  - 2014
TI  - Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in 
      Oncology: Review of the Literature.
PG  - 102-14
AB  - In recent years an increasing attention is focused on the potential effects of 
      drugs on cancer incidence and/or cancer survival. Many medications of common use, 
      developed for a variety of medical non-cancer situations, have been found to have 
      potential anti- cancer effects. In this article, we performed an overview of the 
      literature evidence for several commonly used non-cancer medications, such as 
      aspirin, beta-blockers, metformin and other anti- diabetics, cardiac glycosides, 
      anticoagulant heparin, statins, psychotropic drugs, vitamins, calcium and 
      estrogens which have been shown to have anticancer effects, in observational and 
      experimental studies. A huge amount of data supports the idea that a few of these 
      commonly used medicines could decrease cancer death-rate, particularly aspirin, 
      statins and metformin, crosswise different types of cancer. To date, no mature 
      data are available from randomized and prospective trials; perhaps, the results 
      of some studies underway will allow us to answer some questions on the possible 
      use of these drugs in our clinical practice in primary and secondary prevention, 
      or even in adjuvant setting.
FAU - Prochilo, Tiziana
AU  - Prochilo T
FAU - Di Biasi, Brunella
AU  - Di Biasi B
FAU - Aroldi, Francesca
AU  - Aroldi F
FAU - Bertocchi, Paola
AU  - Bertocchi P
FAU - Sabatini, Tony
AU  - Sabatini T
FAU - Meriggi, Fausto
AU  - Meriggi F
FAU - Zaniboni, Alberto
AU  - Zaniboni A
AD  - UO di Oncologia, Fondazione Poliambulanza Via Bissolati 57, 25124, Brescia, 
      Italy. zanib@numerica.it.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Rev Recent Clin Trials
JT  - Reviews on recent clinical trials
JID - 101270873
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Glycosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Psychotropic Drugs)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Glycosides/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Metformin/therapeutic use
MH  - Neoplasms/*drug therapy
MH  - Psychotropic Drugs/therapeutic use
EDAT- 2014/05/24 06:00
MHDA- 2016/03/02 06:00
CRDT- 2014/05/24 06:00
PHST- 2014/01/31 00:00 [received]
PHST- 2014/04/11 00:00 [revised]
PHST- 2014/05/10 00:00 [accepted]
PHST- 2014/05/24 06:00 [entrez]
PHST- 2014/05/24 06:00 [pubmed]
PHST- 2016/03/02 06:00 [medline]
AID - RRCT-EPUB-60637 [pii]
AID - 10.2174/1574887109666140522120931 [doi]
PST - ppublish
SO  - Rev Recent Clin Trials. 2014;9(2):102-14. doi: 10.2174/1574887109666140522120931.

PMID- 17094014
OWN - NLM
STAT- MEDLINE
DCOM- 20070907
LR  - 20131121
IS  - 0003-6072 (Print)
IS  - 0003-6072 (Linking)
VI  - 91
IP  - 4
DP  - 2007 May
TI  - Acetylsalicylic acid as antifungal in Eremothecium and other yeasts.
PG  - 393-405
AB  - Interesting distribution patterns of acetylsalicylic acid (ASA, aspirin) 
      sensitive 3-hydroxy (OH) oxylipins were previously reported in some 
      representatives of the yeast genus Eremothecium--an important group of plant 
      pathogens. Using immunofluorescence microscopy and 3-OH oxylipin specific 
      antibodies in this study, we were able to map the presence of these compounds 
      also in other Eremothecium species. In Eremothecium cymbalariae, these oxylipins 
      were found to cover mostly the spiky tips of narrowly triangular ascospores while 
      in Eremothecium gossypii, oxylipins covered the whole spindle-shaped ascospore 
      with terminal appendages. The presence of these oxylipins was confirmed by 
      chemical analysis. When ASA, a 3-OH oxylipin inhibitor, was added to these yeasts 
      in increasing concentrations, the sexual stage was found to be the most 
      sensitive. Our results suggest that 3-OH oxylipins, produced by mitochondria 
      through incomplete beta-oxidation, are associated with the development of the 
      sexual stages in both yeasts. Strikingly, preliminary studies on yeast growth 
      suggest that yeasts, characterized by mainly an aerobic respiration rather than a 
      fermentative pathway, are more sensitive to ASA than yeasts characterized by both 
      pathways. These data further support the role of mitochondria in sexual as well 
      as asexual reproduction of yeasts and its role to serve as a target for ASA 
      antifungal action.
FAU - Leeuw, N J
AU  - Leeuw NJ
AD  - Industrial Biotechnology, Department of Microbial, Biochemical and Food 
      Biotechnology, UNESCO MIRCEN, University of the Free State, P.O. Box 339, 
      Bloemfontein, South Africa.
FAU - Swart, C W
AU  - Swart CW
FAU - Ncango, D M
AU  - Ncango DM
FAU - Pohl, C H
AU  - Pohl CH
FAU - Sebolai, O M
AU  - Sebolai OM
FAU - Strauss, C J
AU  - Strauss CJ
FAU - Botes, P J
AU  - Botes PJ
FAU - van Wyk, P W J
AU  - van Wyk PW
FAU - Nigam, S
AU  - Nigam S
FAU - Kock, J L F
AU  - Kock JL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061109
PL  - Netherlands
TA  - Antonie Van Leeuwenhoek
JT  - Antonie van Leeuwenhoek
JID - 0372625
RN  - 0 (Fungicides, Industrial)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Fungicides, Industrial/*pharmacology
MH  - Gas Chromatography-Mass Spectrometry
MH  - Microscopy, Electron, Scanning
MH  - Microscopy, Fluorescence
MH  - Mitochondria/metabolism
MH  - Saccharomycetales/*drug effects/metabolism/ultrastructure
EDAT- 2006/11/10 09:00
MHDA- 2007/09/08 09:00
CRDT- 2006/11/10 09:00
PHST- 2006/06/27 00:00 [received]
PHST- 2006/10/09 00:00 [accepted]
PHST- 2006/11/10 09:00 [pubmed]
PHST- 2007/09/08 09:00 [medline]
PHST- 2006/11/10 09:00 [entrez]
AID - 10.1007/s10482-006-9124-4 [doi]
PST - ppublish
SO  - Antonie Van Leeuwenhoek. 2007 May;91(4):393-405. doi: 10.1007/s10482-006-9124-4. 
      Epub 2006 Nov 9.

PMID- 17287637
OWN - NLM
STAT- MEDLINE
DCOM- 20070516
LR  - 20220311
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 18
IP  - 2
DP  - 2007 Mar
TI  - Clinical relevance of aspirin resistance in patients with stable coronary artery 
      disease: a prospective follow-up study (PROSPECTAR).
PG  - 187-92
AB  - Aspirin resistance may increase the risk of major adverse cardiac events (MACE) 
      more than threefold in patients with stable coronary artery disease (CAD). This 
      study aimed to determine the prevalence of aspirin resistance in patients with 
      stable CAD, the role of aspirin resistance on outcome in the follow-up, and the 
      effect of clopidogrel therapy in MACE prevention in aspirin-resistant 
      individuals. We detected the prevalence of aspirin resistance in 234 patients 
      with stable CAD. Platelet function was determined by PFA-100 with collagen and/or 
      epinephrine and collagen and/or ADP cartridges. The mean follow-up time was 20.6 
      +/- 6.9 months. The primary endpoints of the study were occurrence of myocardial 
      infarction, unstable angina, stroke and cardiac death. Of patients, 22.2% (n = 
      52) were aspirin resistant by PFA-100. During follow-up, MACE occurred in eight 
      patients (15.4%) with aspirin resistance and in 20 patients (11.0%) with 
      aspirin-sensitive platelet aggregation (P = 0.269). MACE increased in 
      aspirin-resistant patients after termination of clopidogrel therapy. Eleven 
      patients experienced MACE after cessation of clopidogrel therapy (P < 0.001). The 
      MACE risk in patients with stable CAD having detected aspirin resistance was 
      similar compared with patients having aspirin-sensitive platelet aggregation by 
      PFA-100. The MACE prevalence increased during follow-up, however, just after 
      cessation of clopidogrel therapy.
FAU - Pamukcu, Burak
AU  - Pamukcu B
AD  - Istanbul Faculty of Medicine, Department of Cardiology, Istanbul University, 
      Istanbul, Turkey. bpamukcu@istanbul.edu.tr
FAU - Oflaz, Huseyin
AU  - Oflaz H
FAU - Onur, Imran
AU  - Onur I
FAU - Oncul, Aytac
AU  - Oncul A
FAU - Ozcan, Mustafa
AU  - Ozcan M
FAU - Umman, Berrin
AU  - Umman B
FAU - Mercanoglu, Fehmi
AU  - Mercanoglu F
FAU - Meric, Mehmet
AU  - Meric M
FAU - Nisanci, Yilmaz
AU  - Nisanci Y
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Coronary Artery Disease/*complications/*drug therapy/epidemiology/mortality
MH  - Death
MH  - *Drug Resistance
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests
MH  - Prevalence
MH  - Stroke
MH  - Survival Analysis
MH  - Ticlopidine/analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2007/02/09 09:00
MHDA- 2007/05/17 09:00
CRDT- 2007/02/09 09:00
PHST- 2007/02/09 09:00 [pubmed]
PHST- 2007/05/17 09:00 [medline]
PHST- 2007/02/09 09:00 [entrez]
AID - 00001721-200703000-00015 [pii]
AID - 10.1097/MBC.0b013e328040c115 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2007 Mar;18(2):187-92. doi: 
      10.1097/MBC.0b013e328040c115.

PMID- 20808298
OWN - NLM
STAT- MEDLINE
DCOM- 20110119
LR  - 20211020
IS  - 1572-0241 (Electronic)
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 105
IP  - 12
DP  - 2010 Dec
TI  - Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, 
      Lung, Colorectal, And Ovarian Cancer Screening Trial.
PG  - 2646-55
LID - 10.1038/ajg.2010.349 [doi]
AB  - OBJECTIVES: Non-steroidal anti-inflammatory drugs (NSAIDs) have been documented 
      in animal and human studies to reduce risk for colorectal cancer and adenomatous 
      polyps, but risk modification for subgroups of the population and effects on 
      hyperplastic polyps have been less studied. METHODS: Data on recent use of two 
      frequently ingested NSAIDs, aspirin and ibuprofen, were collected at baseline 
      from participants aged 55-74 years in the 10 centers of the Prostate, Lung, 
      Colorectal, and Ovarian Cancer Screening Trial (PLCO). Participants randomized to 
      the intervention arm of the trial received a flexible sigmoidoscopy during a 
      baseline examination. Follow-up of detected polyps was accomplished outside the 
      Trial setting and relevant records were sought and abstracted. Cases (n=4,017) 
      included subjects with a biopsy-proven polyp in the left side of the colon 
      (descending colon, sigmoid, and rectum) detected as a consequence of PLCO 
      screening; controls (n=38,396) were subjects with no left-sided colon polyp. 
      RESULTS: Regular use of aspirin (≥ 4 times/month) in the past year was inversely 
      associated with hyperplastic polyps (odds ratios (OR)=0.8, 95% confidence 
      interval (CI)=0.7-0.9), adenomatous polyps (OR=0.8, 95% CI=0.8-0.9), and advanced 
      adenomas (OR=0.8, 95% CI=0.7-0.9). As frequency of aspirin use increased, the 
      prevalence of polyps decreased significantly for each histological classification 
      (P for trend ≤ 0.0004). Similar patterns were found for adenomas and ibuprofen. 
      Overall protection was consistent in both the descending colon or sigmoid and the 
      rectum, but more evident in males. In males, the OR for heavy use of combined 
      aspirin and ibuprofen (≥ 2 times/day) was 0.6 (95% CI=0.5-0.8), as opposed to 0.9 
      (95% CI=0.8-1.1) in females. The protective effects of NSAIDs for females were 
      apparent only among those with body mass index (BMI) <25 (OR=0.8, 95% CI=0.7-1.0 
      for regular use of NSAIDs; P interaction=0.04). We also found a slightly stronger 
      protection of NSAIDs in the 70-74 years age group compared with those aged 55-69 
      years. CONCLUSIONS: This study of a large general risk population supports 
      previous work that recent use of aspirin and ibuprofen is associated with a 
      decreased risk of colorectal adenomas and demonstrates that this protective 
      effect may be stronger in certain population subgroups and is also evident for 
      aspirin and hyperplastic polyps.
FAU - Johnson, Christine Cole
AU  - Johnson CC
AD  - Department of Biostatistics and Research Epidemiology, Josephine Ford Cancer 
      Center, Henry Ford Hospital, Detroit, Michigan 48202, USA. cjohnso1@hfhs.org
FAU - Hayes, Richard B
AU  - Hayes RB
FAU - Schoen, Robert E
AU  - Schoen RE
FAU - Gunter, Marc J
AU  - Gunter MJ
FAU - Huang, Wen-Yi
AU  - Huang WY
CN  - PLCO Trial Team
LA  - eng
GR  - N01 CN25522/CN/NCI NIH HHS/United States
GR  - ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
DEP - 20100831
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Biopsy
MH  - Colonic Polyps/epidemiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Ibuprofen/administration & dosage/*therapeutic use
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Sex Factors
MH  - Sigmoidoscopy
MH  - United States/epidemiology
PMC - PMC5557093
MID - NIHMS892014
EDAT- 2010/09/03 06:00
MHDA- 2011/01/20 06:00
CRDT- 2010/09/03 06:00
PHST- 2010/09/03 06:00 [entrez]
PHST- 2010/09/03 06:00 [pubmed]
PHST- 2011/01/20 06:00 [medline]
AID - ajg2010349 [pii]
AID - 10.1038/ajg.2010.349 [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2010 Dec;105(12):2646-55. doi: 10.1038/ajg.2010.349. Epub 
      2010 Aug 31.

PMID- 7736746
OWN - NLM
STAT- MEDLINE
DCOM- 19950607
LR  - 20190706
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 23
IP  - 5
DP  - 1995 May
TI  - Yohimbine modulates diaspirin crosslinked hemoglobin-induced systemic 
      hemodynamics and regional circulatory effects.
PG  - 874-84
AB  - OBJECTIVE: Diaspirin crosslinked hemoglobin, a hemoglobin-based blood substitute, 
      is proposed to be an effective resuscitative solution. It produces an immediate, 
      but limited increase in blood pressure when administered to conscious or 
      anesthetized rats. This vasoactivity is associated with an increase in blood flow 
      to several major organs. It has been shown that alpha-adrenergic receptors in the 
      peripheral vascular system are sensitized by diaspirin crosslinked hemoglobin in 
      rats. The present study was conducted to determine the effect of yohimbine, an 
      alpha 2-adrenergic receptor antagonist on systemic hemodynamics and regional 
      circulatory effects of diaspirin crosslinked hemoglobin. DESIGN: Prospective, 
      randomized comparison of cardiovascular effects of diaspirin crosslinked 
      hemoglobin in control and yohimbine-pretreated rats. SETTING: Laboratory of 
      experimental medicine. SUBJECTS: Male Sprague-Dawley rats weighing 300 to 350 g. 
      INTERVENTIONS: Modified, highly purified, and heat-pasteurized hemoglobin 
      (diaspirin crosslinked hemoglobin) in control and yohimbine-treated (2 mg/kg 
      i.v.) rats. MEASUREMENTS AND MAIN RESULTS: The systemic hemodynamics and regional 
      circulation were measured using a radioactive microsphere technique. Diaspirin 
      crosslinked hemoglobin (400 mg/kg i.v.) produced an increase in blood pressure 
      and total peripheral resistance, while heart rate, cardiac output, and stroke 
      volume were not significantly altered in control rats. In yohimbine-pretreated (2 
      mg/kg i.v.) animals, diaspirin crosslinked hemoglobin did not produce any change 
      in heart rate, stroke volume, cardiac output, and total peripheral resistance, 
      but a slight increase in blood pressure was observed compared with baseline 
      values obtained after the administration of yohimbine. The increase in blood 
      pressure induced by diaspirin crosslinked hemoglobin was significantly blocked by 
      pretreatment with yohimbine. Yohimbine (2 mg/kg i.v.) per se decreased blood 
      pressure, while other systemic hemodynamic parameters were not affected. 
      Diaspirin crosslinked hemoglobin increased blood flow to the heart, 
      gastrointestinal tract (stomach, small intestine, cecum, and large intestine), 
      portal (spleen, mesentery, and pancreas) and skin, while blood flow to the brain 
      (cerebral hemispheres, diencephalon, cerebellum, and brain stem), liver, kidneys, 
      and musculoskeletal system was not affected in control rats. In 
      yohimbine-pretreated animals, diaspirin crosslinked hemoglobin produced an 
      increase in blood flow to the heart, brain (cerebellum and brain stem), liver, 
      small intestine, cecum, spleen, mesentery and pancreas, kidneys, skin and 
      musculoskeletal system, while blood flow to the stomach and large intestine was 
      not affected. Yohimbine pretreatment significantly attenuated the diaspirin 
      crosslinked hemoglobin-induced increase in blood flow to the large intestine, 
      mesentery, and pancreas. CONCLUSIONS: The cardiovascular actions of diaspirin 
      crosslinked hemoglobin are partially mediated through alpha 2-adrenergic 
      receptors. Adrenergic receptor antagonists may be useful in attenuating the 
      pressor effect of diaspirin crosslinked hemoglobin while maintaining the regional 
      perfusion.
FAU - Sharma, A C
AU  - Sharma AC
AD  - Department of Pharmaceutics and Pharmacodynamics, University of Illinois at 
      Chicago, USA.
FAU - Gulati, A
AU  - Gulati A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Hemoglobins)
RN  - 0 (Receptors, Adrenergic, alpha-2)
RN  - 2Y49VWD90Q (Yohimbine)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Crit Care Med. 1995 May;23(5):801-4. PMID: 7736735
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cerebrovascular Circulation/drug effects
MH  - Coronary Circulation/drug effects
MH  - Digestive System/blood supply/drug effects
MH  - Drug Interactions
MH  - Hemodynamics/*drug effects
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Microspheres
MH  - Musculoskeletal System/blood supply/drug effects
MH  - Portal System/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Adrenergic, alpha-2/drug effects/physiology
MH  - Regional Blood Flow/drug effects
MH  - Renal Circulation/drug effects
MH  - Time Factors
MH  - Yohimbine/*pharmacology
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
AID - 10.1097/00003246-199505000-00016 [doi]
PST - ppublish
SO  - Crit Care Med. 1995 May;23(5):874-84. doi: 10.1097/00003246-199505000-00016.

PMID- 31416506
OWN - NLM
STAT- MEDLINE
DCOM- 20190826
LR  - 20200808
IS  - 1008-8830 (Print)
IS  - 1008-8830 (Linking)
VI  - 21
IP  - 8
DP  - 2019 Aug
TI  - [Clinical effect and safety of clopidogrel combined with aspirin in 
      antithrombotic therapy for children with Kawasaki disease complicated by 
      small/medium-sized coronary artery aneurysms].
PG  - 801-805
AB  - OBJECTIVE: To study the clinical effect and safety of clopidogrel combined with 
      aspirin in antithrombotic therapy for children with Kawasaki disease (KD) 
      complicated by coronary artery aneurysm (CAA). METHODS: A total of 77 KD children 
      who were diagnosed with multiple small/medium-sized CAAs by echocardiography 
      between January 2013 and June 2018 were enrolled. They were randomly divided into 
      observation group with 38 children (treated with clopidogrel and aspirin) and 
      control group with 39 children (treated with low-molecular-weight heparin and 
      aspirin). All children were followed up regularly, and the first 3 months of the 
      course of the disease was the observation period. The children were observed in 
      terms of the change of the coronary artery and the incidence of complications. 
      RESULTS: At month 3 of follow-up, among the children in the observation group, 6 
      had normal coronary artery, 11 had coronary artery retraction, 19 had stable 
      coronary artery, and 2 progressed to giant coronary aneurysm; among the children 
      in the control group, 7 had normal coronary artery, 12 had coronary artery 
      retraction, 19 had stable coronary artery, and 1 progressed to giant coronary 
      aneurysm; there was no significant difference in the change of the coronary 
      artery between the two groups (P>0.05). There were 2 cases of epistaxis and 6 
      cases of skin ecchymosis in the observation group, and 1 case of epistaxis and 7 
      cases of petechiae and ecchymosis at the injection site in the control group, and 
      no other serious bleeding events were observed in either group. CONCLUSIONS: 
      Clopidogrel combined with low-dose aspirin is safe and effective in 
      antithrombotic therapy for children with KD complicated by CAA.
FAU - Liu, Yi-Ling
AU  - Liu YL
AD  - Department of Pediatric Cardiology, Chengdu Women's & Children's Central 
      Hospital, Chengdu 610091, China. wxm6910@163.com.
FAU - Wang, Xian-Min
AU  - Wang XM
FAU - Chen, Ting-Ting
AU  - Chen TT
FAU - Shi, Kun
AU  - Shi K
FAU - Lu, Ya-Heng
AU  - Lu YH
FAU - Guo, Yong-Hong
AU  - Guo YH
FAU - Li, Yan
AU  - Li Y
LA  - chi
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhongguo Dang Dai Er Ke Za Zhi
JT  - Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
JID - 100909956
RN  - 0 (Fibrinolytic Agents)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Clopidogrel
MH  - *Coronary Aneurysm/drug therapy/etiology
MH  - Coronary Vessels
MH  - Fibrinolytic Agents
MH  - Humans
MH  - *Mucocutaneous Lymph Node Syndrome/complications
PMC - PMC7389908
EDAT- 2019/08/17 06:00
MHDA- 2019/08/27 06:00
CRDT- 2019/08/17 06:00
PHST- 2019/08/17 06:00 [entrez]
PHST- 2019/08/17 06:00 [pubmed]
PHST- 2019/08/27 06:00 [medline]
AID - 10.7499/j.issn.1008-8830.2019.08.012 [pii]
AID - zgddekzz-21-8-801 [pii]
AID - 10.7499/j.issn.1008-8830.2019.08.012 [doi]
PST - ppublish
SO  - Zhongguo Dang Dai Er Ke Za Zhi. 2019 Aug;21(8):801-805. doi: 
      10.7499/j.issn.1008-8830.2019.08.012.

PMID- 1818783
OWN - NLM
STAT- MEDLINE
DCOM- 19920721
LR  - 20191022
IS  - 0742-0528 (Print)
IS  - 0742-0528 (Linking)
VI  - 8
IP  - 5
DP  - 1991
TI  - Aspirin, platelet aggregation, and the circadian variation of acute thrombotic 
      events.
PG  - 327-35
AB  - The onset of several acute cardiovascular diseases occurs in a circadian pattern, 
      with a peak incidence in the hours soon after awakening. This finding, coupled 
      with laboratory data that confirm a surge in platelet activation during the early 
      morning hours, suggests that acute changes in platelet aggregability may be an 
      important trigger of thrombosis. Therefore, the efficacy of antiplatelet agents, 
      such as aspirin, in reducing risks of vascular occlusion may result, at least in 
      part, from a blunting of these short-term changes in platelet aggregability. In 
      this review, clinical and laboratory evidence describing these cyclical changes 
      is discussed, as is current evidence of the effects of aspirin on platelet 
      function and the circadian variation of acute thrombosis.
FAU - Ridker, P M
AU  - Ridker PM
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 
      02146.
FAU - Willich, S N
AU  - Willich SN
FAU - Muller, J E
AU  - Muller JE
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Chronobiol Int
JT  - Chronobiology international
JID - 8501362
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Cardiovascular Diseases/blood/etiology
MH  - Circadian Rhythm/*physiology
MH  - Humans
MH  - Platelet Aggregation/drug effects/physiology
MH  - Thrombosis/blood/*etiology/prevention & control
RF  - 33
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.3109/07420529109059169 [doi]
PST - ppublish
SO  - Chronobiol Int. 1991;8(5):327-35. doi: 10.3109/07420529109059169.

PMID- 25879618
OWN - NLM
STAT- MEDLINE
DCOM- 20160630
LR  - 20150911
IS  - 1525-1470 (Electronic)
IS  - 0736-8046 (Linking)
VI  - 32
IP  - 5
DP  - 2015 Sep-Oct
TI  - Children with Warts: A Retrospective Study in an Outpatient Setting.
PG  - 679-83
LID - 10.1111/pde.12584 [doi]
AB  - BACKGROUND: The purpose is to investigate the demographics and course of common 
      warts in children in an outpatient setting. METHODS: A retrospective medical 
      chart review and telephone survey study were completed on an outpatient cohort of 
      children (0-17 yrs) with a clinical diagnosis of warts at a single-center, 
      university-based pediatric dermatology practice. The main outcome measures 
      included management, time to resolution, and associated factors of warts in 
      children. RESULTS: Of the 254 patients we contacted, 214 agreed to participate in 
      the survey. The most commonly involved sites were the hands and the head and neck 
      area. Most children received some form of therapy, but it is unclear that any 
      form of treatment altered the course. However, children with a medical history of 
      childhood infections or more than one anatomic site had significantly greater 
      risk of having a longer time to resolution. CONCLUSION: Warts resolved in 65% of 
      children by 2 years and in 80% within 4 years, regardless of treatment. With the 
      exception of a history of childhood infections and having more than one anatomic 
      site, time to resolution was not altered by wart or patient characteristics. Thus 
      counseling without aggressive destructive treatment is a reasonable approach to 
      managing warts in most children. Our findings will provide guidance in the 
      process of shared decision making with parents and children.
CI  - © 2015 Wiley Periodicals, Inc.
FAU - Kuwabara, Anne M
AU  - Kuwabara AM
AD  - Division of Pediatric Dermatology, Departments of Pediatrics and Dermatology, 
      School of Medicine, Johns Hopkins University, Baltimore, Maryland.
FAU - Rainer, Barbara M
AU  - Rainer BM
AD  - Division of Pediatric Dermatology, Departments of Pediatrics and Dermatology, 
      School of Medicine, Johns Hopkins University, Baltimore, Maryland.
FAU - Basdag, Hatice
AU  - Basdag H
AD  - Division of Pediatric Dermatology, Departments of Pediatrics and Dermatology, 
      School of Medicine, Johns Hopkins University, Baltimore, Maryland.
FAU - Cohen, Bernard A
AU  - Cohen BA
AD  - Division of Pediatric Dermatology, Departments of Pediatrics and Dermatology, 
      School of Medicine, Johns Hopkins University, Baltimore, Maryland.
LA  - eng
PT  - Journal Article
DEP - 20150415
PL  - United States
TA  - Pediatr Dermatol
JT  - Pediatric dermatology
JID - 8406799
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - *Cryotherapy
MH  - Female
MH  - Humans
MH  - Male
MH  - *Occlusive Dressings
MH  - Outpatients
MH  - Prognosis
MH  - Retrospective Studies
MH  - Surveys and Questionnaires
MH  - Warts/*therapy
EDAT- 2015/04/17 06:00
MHDA- 2016/07/01 06:00
CRDT- 2015/04/17 06:00
PHST- 2015/04/17 06:00 [entrez]
PHST- 2015/04/17 06:00 [pubmed]
PHST- 2016/07/01 06:00 [medline]
AID - 10.1111/pde.12584 [doi]
PST - ppublish
SO  - Pediatr Dermatol. 2015 Sep-Oct;32(5):679-83. doi: 10.1111/pde.12584. Epub 2015 
      Apr 15.

PMID- 5077174
OWN - NLM
STAT- MEDLINE
DCOM- 19721204
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 13
IP  - 8
DP  - 1972 Aug
TI  - Aspirin ingestion and perforated peptic ulcer.
PG  - 631-3
AB  - The results of a prospective inquiry into the aspirin taking habits of a 
      consecutive series of 118 patients admitted to a large general hospital with 
      acute perforation of peptic ulcer are presented. The series shows considerable 
      increase in the proportion of females to males and of ulcers of the stomach 
      compared to pyloro-duodenal perforations in contrast to British experience. 
      Forty-five per cent of males and 75% of females were accustomed to taking at 
      least two doses of an aspirin preparation weekly and most of the women took at 
      least two doses daily. There was a highly significant association of heavy 
      aspirin intake with ulcers of the stomach. The data support the theory that 
      aspirin abuse is a cause of chronic gastric ulcer. It also supports the 
      hypothesis that aspirin is the environmental factor responsible for the epidemic 
      of gastric ulcers in middle-aged women in eastern Australia.
FAU - Duggan, J M
AU  - Duggan JM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Duodenal Ulcer/chemically induced
MH  - Female
MH  - Humans
MH  - Male
MH  - Peptic Ulcer Perforation/*chemically induced
MH  - Sex Factors
MH  - Stomach Ulcer/chemically induced
MH  - Substance-Related Disorders
PMC - PMC1412269
EDAT- 1972/08/01 00:00
MHDA- 1972/08/01 00:01
CRDT- 1972/08/01 00:00
PHST- 1972/08/01 00:00 [pubmed]
PHST- 1972/08/01 00:01 [medline]
PHST- 1972/08/01 00:00 [entrez]
AID - 10.1136/gut.13.8.631 [doi]
PST - ppublish
SO  - Gut. 1972 Aug;13(8):631-3. doi: 10.1136/gut.13.8.631.

PMID- 21223254
OWN - NLM
STAT- MEDLINE
DCOM- 20110512
LR  - 20131121
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 152
IP  - 5
DP  - 2011 Mar
TI  - Enhanced ex vivo inhibition of platelet function following addition of 
      dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: 
      first results from the TRinity AntiPlatelet responsiveness (TrAP) study.
PG  - 640-7
LID - 10.1111/j.1365-2141.2010.08539.x [doi]
AB  - Ex vivo dipyridamole 'non-responsiveness' has not been extensively studied in 
      ischaemic cerebrovascular disease. Platelet surface marker expression, 
      leucocyte-platelet complex formation and inhibition of platelet function at high 
      shear stress as detected by the PFA-100® Collagen-Adenosine-diphosphate (C-ADP) 
      and Collagen-Epinephrine cartridges was assessed in 52 patients within 4 weeks of 
      transient ischaemic attack (TIA) or ischaemic stroke on aspirin, and then 14 d 
      (14 d) and >90 d (90 d) after adding dipyridamole. A novel definition of 
      'Dipyridamole non-responsiveness' was used. The median C-ADP closure time 
      increased following addition of dipyridamole, remained elevated at 90 d (P ≤ 
      0·03), and was unaffected by aspirin dose. 59% at 14 d and 56% at 90 d were 
      'dipyridamole non-responders' on the PFA-100. The proportion of non-responders at 
      14 and 90 d was similar (P= 0·9). Compared with baseline (4·6%), median 
      monocyte-platelet complexes increased at 14 d (5·0%, P= 0·03) and 90 d (4·9%, P= 
      0·04). Low C-ADP closure times were associated with increased monocyte-platelet 
      complexes at 14 d (r= -0·32, P= 0·02) and 90 d (r= -0·33, P = 0·02). 
      Monocyte-platelet complexes increased in the subgroup of dipyridamole 
      non-responders on the PFA-100 (P≤ 0·045), but not in responders (P ≥ 0·5), at 14 
      and 90 d versus baseline. Additional inhibition of platelet function has been 
      detected with the PFA-100 when dipyridamole is added to aspirin. Elevated 
      monocyte-platelet complexes may contribute to ex vivo dipyridamole 
      non-responsiveness.
CI  - © 2011 Blackwell Publishing Ltd.
FAU - Tobin, William Oliver
AU  - Tobin WO
AD  - Department of Neurology, The Adelaide and Meath Hospital/National Children's 
      Hospital, Tallaght, Dublin, UK.
FAU - Kinsella, Justin A
AU  - Kinsella JA
FAU - Collins, Daniel Ronan
AU  - Collins DR
FAU - Coughlan, Tara
AU  - Coughlan T
FAU - O'Neill, Desmond
AU  - O'Neill D
FAU - Egan, Bridget
AU  - Egan B
FAU - Tierney, Sean
AU  - Tierney S
FAU - Feeley, Thomas Martin
AU  - Feeley TM
FAU - Murphy, Raymond P
AU  - Murphy RP
FAU - McCabe, Dominick J H
AU  - McCabe DJ
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20110112
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/physiology
MH  - Blood Specimen Collection/methods
MH  - Dipyridamole/*pharmacology/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*blood/drug therapy
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Stroke/*blood/drug therapy
EDAT- 2011/01/13 06:00
MHDA- 2011/05/13 06:00
CRDT- 2011/01/13 06:00
PHST- 2011/01/13 06:00 [entrez]
PHST- 2011/01/13 06:00 [pubmed]
PHST- 2011/05/13 06:00 [medline]
AID - 10.1111/j.1365-2141.2010.08539.x [doi]
PST - ppublish
SO  - Br J Haematol. 2011 Mar;152(5):640-7. doi: 10.1111/j.1365-2141.2010.08539.x. Epub 
      2011 Jan 12.

PMID- 15977911
OWN - NLM
STAT- MEDLINE
DCOM- 20050720
LR  - 20190917
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 25
IP  - 4
DP  - 2005 Apr
TI  - Current use of nonsteroidal antiinflammatory drugs and the risk of acute 
      myocardial infarction.
PG  - 503-10
AB  - STUDY OBJECTIVE: To evaluate the risk of acute myocardial infarction during 
      current exposure to nonsteroidal antiinflammatory drugs (NSAIDs). DESIGN: 
      Retrospective case-control analysis. SETTING: General practice offices. SUBJECTS: 
      A total of 8688 case patients, aged 89 years or younger, with a first-time acute 
      myocardial infarction and 33,923 control subjects matched on age, sex, calendar 
      time, and general practice attended. INTERVENTION: The United Kingdom General 
      Practice Research Database was searched for potential cases of first-time acute 
      myocardial infarction between January 1995 and April 2001. Control subjects 
      without acute myocardial infarction were identified at random. MEASUREMENTS AND 
      MAIN RESULTS: Exposure to NSAIDs was assessed, and 650 case patients and 2339 
      control subjects were found to be currently taking NSAIDs. After adjusting for 
      various risk factors for acute myocardial infarction (e.g., hypertension, 
      hyperlipidemia, diabetes mellitus, ischemic heart disease, body mass index, 
      smoking), the relative risk (expressed as odds ratio [OR]) of acute myocardial 
      infarction was 1.07 (95% confidence interval [CI] 0.96-1.19) for subjects with 
      current NSAID exposure compared with those not taking NSAIDs. The adjusted OR for 
      current diclofenac use was 1.23 (95% CI 1.00-1.51), for current ibuprofen use 
      1.16 (95% CI 0.92-1.46), and for current naproxen use 0.96 (95% CI 0.66-1.38) 
      compared with those not taking NSAIDs. Current aspirin use combined with current 
      NSAID use was associated with a statistically significant risk reduction 
      (adjusted OR 0.74, 95% CI 0.57-0.97), compared with nonuse of NSAIDs and aspirin. 
      Current use of aspirin together with current use of ibuprofen yielded an adjusted 
      OR of 0.69 (95% CI 0.42-1.15). CONCLUSIONS: Our results provide additional 
      evidence that the risk of first-time acute myocardial infarction during current 
      use of NSAIDs is not materially altered. We found no evidence for a reduced 
      cardioprotective effect of aspirin with concomitant NSAID use.
FAU - Fischer, Lorenz M
AU  - Fischer LM
AD  - Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and 
      Toxicology, University Hospital, Basel, Switzerland.
FAU - Schlienger, Raymond G
AU  - Schlienger RG
FAU - Matter, Christian M
AU  - Matter CM
FAU - Jick, Hershel
AU  - Jick H
FAU - Meier, Christoph R
AU  - Meier CR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Case-Control Studies
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*chemically induced/*prevention & control
MH  - Retrospective Studies
MH  - Risk
EDAT- 2005/06/28 09:00
MHDA- 2005/07/21 09:00
CRDT- 2005/06/28 09:00
PHST- 2005/06/28 09:00 [pubmed]
PHST- 2005/07/21 09:00 [medline]
PHST- 2005/06/28 09:00 [entrez]
AID - 10.1592/phco.25.4.503.61021 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2005 Apr;25(4):503-10. doi: 10.1592/phco.25.4.503.61021.

PMID- 29249187
OWN - NLM
STAT- MEDLINE
DCOM- 20190109
LR  - 20190314
IS  - 1747-6356 (Electronic)
IS  - 1747-6348 (Linking)
VI  - 12
IP  - 2
DP  - 2018 Feb
TI  - An update on the management of aspirin-exacerbated respiratory disease.
PG  - 137-143
LID - 10.1080/17476348.2018.1417843 [doi]
AB  - Clinical features of aspirin-exacerbated respiratory disease (AERD) consist of 
      moderate to severe asthma associated with chronic rhinosinusitis (CRS), which are 
      derived from overproduction of cysteinyl leukotrienes along with chronic type 2 
      mediated inflammation in the upper and lower airway mucosa. Area covered: This 
      review provides recent up-to-date information regarding phenotypes of AERD and 
      encompasses comprehensive diagnostic methods and treatment options. To confirm 
      the diagnosis of AERD, provocation testing via nasal, inhalation or the oral 
      route of aspirin remains the gold standard; in vitro diagnostic methods are still 
      not available. Essential management is to avoid cross-reacting cyclooxygenase 1 
      (COX-1) inhibitors along with use of highly selective COX-2 inhibitors and to 
      maintain pharmacologic treatment depending on the severity of asthma and chronic 
      rhinosinusitis. Recent biologics, including anti-IgE and anti-IL5 antibodies, are 
      required in severe AERD patients with CRS. Aspirin desensitization can be 
      recommended when indicated. Expert commentary: AERD is a heterogeneous disease in 
      terms of severity and associated allergic disease. When performing diagnosis and 
      treatment for AERD, such disease characteristics need to be kept in mind.
FAU - Lee, Ji-Ho
AU  - Lee JH
AD  - a Department of Allergy and Clinical Immunology , Ajou University School of 
      Medicine , Suwon , South Korea.
FAU - Jung, Chang-Gyu
AU  - Jung CG
AD  - b Division of Allergy and Clinical Immunology, Department of Internal Medicine , 
      Keimyung University, Dongsan Medical Center , Daegu , South Korea.
FAU - Park, Hae-Sim
AU  - Park HS
AD  - a Department of Allergy and Clinical Immunology , Ajou University School of 
      Medicine , Suwon , South Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20171218
PL  - England
TA  - Expert Rev Respir Med
JT  - Expert review of respiratory medicine
JID - 101278196
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/*adverse effects
MH  - Desensitization, Immunologic/*methods
MH  - *Disease Management
MH  - Humans
MH  - Respiratory Tract Diseases/chemically induced/*therapy
OTO - NOTNLM
OT  - Aspirin-exacerbated respiratory disease
OT  - leukotriene
OT  - management
OT  - provocation test
OT  - severe asthma
EDAT- 2017/12/19 06:00
MHDA- 2019/01/10 06:00
CRDT- 2017/12/19 06:00
PHST- 2017/12/19 06:00 [pubmed]
PHST- 2019/01/10 06:00 [medline]
PHST- 2017/12/19 06:00 [entrez]
AID - 10.1080/17476348.2018.1417843 [doi]
PST - ppublish
SO  - Expert Rev Respir Med. 2018 Feb;12(2):137-143. doi: 
      10.1080/17476348.2018.1417843. Epub 2017 Dec 18.

PMID- 23212718
OWN - NLM
STAT- MEDLINE
DCOM- 20130409
LR  - 20211021
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 127
IP  - 3
DP  - 2013 Jan 22
TI  - Drug resistance and pseudoresistance: an unintended consequence of enteric 
      coating aspirin.
PG  - 377-85
LID - 10.1161/CIRCULATIONAHA.112.117283 [doi]
AB  - BACKGROUND: Low dose aspirin reduces the secondary incidence of myocardial 
      infarction and stroke. Drug resistance to aspirin might result in treatment 
      failure. Despite this concern, no clear definition of aspirin resistance has 
      emerged, and estimates of its incidence have varied remarkably. We aimed to 
      determine the commonality of a mechanistically consistent, stable, and specific 
      phenotype of true pharmacological resistance to aspirin-such as might be 
      explained by genetic causes. METHODS AND RESULTS: Healthy volunteers (n=400) were 
      screened for their response to a single oral dose of 325-mg immediate release or 
      enteric coated aspirin. Response parameters reflected the activity of the 
      molecular target of aspirin, cyclooxygenase-1. Individuals who appeared aspirin 
      resistant on 1 occasion underwent repeat testing, and if still resistant were 
      exposed to low-dose enteric coated aspirin (81 mg) and clopidogrel (75 mg) for 1 
      week each. Variable absorption caused a high frequency of apparent resistance to 
      a single dose of 325-mg enteric coated aspirin (up to 49%) but not to immediate 
      release aspirin (0%). All individuals responded to aspirin on repeated exposure, 
      extension of the postdosing interval, or addition of aspirin to their platelets 
      ex vivo. CONCLUSIONS: Pharmacological resistance to aspirin is rare; this study 
      failed to identify a single case of true drug resistance. Pseudoresistance, 
      reflecting delayed and reduced drug absorption, complicates enteric coated but 
      not immediate release aspirin administration. CLINICAL TRIAL REGISTRATION: URL: 
      http://www.clinicaltrials.gov. Unique identifier: NCT00948987.
FAU - Grosser, Tilo
AU  - Grosser T
AD  - Institute for Translational Medicine and Therapeutics, Perelman School of 
      Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Fries, Susanne
AU  - Fries S
FAU - Lawson, John A
AU  - Lawson JA
FAU - Kapoor, Shiv C
AU  - Kapoor SC
FAU - Grant, Gregory R
AU  - Grant GR
FAU - FitzGerald, Garret A
AU  - FitzGerald GA
LA  - eng
SI  - ClinicalTrials.gov/NCT00948987
GR  - P50 HL054500/HL/NHLBI NIH HHS/United States
GR  - UL1 RR024134/RR/NCRR NIH HHS/United States
GR  - HL 54500/HL/NHLBI NIH HHS/United States
GR  - UL1-RR-024134/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20121204
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 2013 Sep 17;128(12):e189. PMID: 24043151
CIN - Circulation. 2013 Sep 17;128(12):e190. PMID: 24043152
CIN - Circulation. 2013 Sep 17;128(12):e191. PMID: 24043153
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Cross-Over Studies
MH  - Cyclooxygenase 1/*drug effects
MH  - Cyclooxygenase Inhibitors/administration & dosage/*pharmacology/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/therapeutic 
      use
MH  - Stroke/prevention & control
MH  - Tablets, Enteric-Coated
MH  - Ticlopidine/administration & dosage/analogs & derivatives/pharmacology
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC3552520
MID - NIHMS431944
EDAT- 2012/12/06 06:00
MHDA- 2013/04/10 06:00
CRDT- 2012/12/06 06:00
PHST- 2012/12/06 06:00 [entrez]
PHST- 2012/12/06 06:00 [pubmed]
PHST- 2013/04/10 06:00 [medline]
AID - CIRCULATIONAHA.112.117283 [pii]
AID - 10.1161/CIRCULATIONAHA.112.117283 [doi]
PST - ppublish
SO  - Circulation. 2013 Jan 22;127(3):377-85. doi: 10.1161/CIRCULATIONAHA.112.117283. 
      Epub 2012 Dec 4.

PMID- 6408333
OWN - NLM
STAT- MEDLINE
DCOM- 19830826
LR  - 20190814
IS  - 0024-4201 (Print)
IS  - 0024-4201 (Linking)
VI  - 18
IP  - 4
DP  - 1983 Apr
TI  - Potentiating effect of 5,8,11-eicosatrienoic acid on human platelet aggregation.
PG  - 291-4
AB  - 5,8,11-Eicosatrienoic acid (20:3 omega 9), a fatty acid increased in the platelet 
      phospholipids of man and animals fed saturated fats, was either added to human 
      platelets simultaneously with the aggregating agents, or incorporated into the 
      platelet phospholipids by preincubation. 20:3 omega 9 markedly increased the 
      response of platelets to all aggregating agents tested when added simultaneously 
      with the agent, but solely to thrombin and ionophore, after incorporation into 
      the platelet phospholipids. The potentiating effects of 20:3 omega 9 on thrombin 
      aggregation do not appear to be related to prostaglandin formation, but rather to 
      the production of a monohydroxy derivative through the lipoxygenase pathway.
FAU - Lagarde, M
AU  - Lagarde M
FAU - Burtin, M
AU  - Burtin M
FAU - Sprecher, H
AU  - Sprecher H
FAU - Dechavanne, M
AU  - Dechavanne M
FAU - Renaud, S
AU  - Renaud S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Lipids
JT  - Lipids
JID - 0060450
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 37H9VM9WZL (Calcimycin)
RN  - 3K9958V90M (Ethanol)
RN  - EC 3.4.21.5 (Thrombin)
RN  - FC398RK06S (8,11,14-Eicosatrienoic Acid)
RN  - JQS194YH3X (mead acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 8,11,14-Eicosatrienoic Acid/*pharmacology
MH  - Aspirin/pharmacology
MH  - Calcimycin/pharmacology
MH  - Drug Synergism
MH  - Ethanol/pharmacology
MH  - Fatty Acids, Unsaturated/*pharmacology
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Thrombin/pharmacology
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 10.1007/BF02534704 [doi]
PST - ppublish
SO  - Lipids. 1983 Apr;18(4):291-4. doi: 10.1007/BF02534704.

PMID- 7305554
OWN - NLM
STAT- MEDLINE
DCOM- 19820120
LR  - 20161123
IS  - 0003-9780 (Print)
IS  - 0003-9780 (Linking)
VI  - 252
IP  - 1
DP  - 1981 Jul
TI  - A study on constrictor response of dog coronary arteries to acetylsalicylic acid.
PG  - 86-96
AB  - The present study was designed to investigate the effects of acetylsalicylic acid 
      at a high dose on dog coronary arteries. In the isolated and perfused dog hearts, 
      an intracoronary injection of acetylsalicylic acid (10 mg) decreased coronary 
      blood flow concomitant with diminution of myocardial contractile force, but did 
      not change heart rate. In the isolated dog coronary arterial strips, 
      acetylsalicylic acid (10-4 M) produced the contractions of them, which were 
      significantly inhibited by calcium-free solution, diltiazem, nifedipine, 
      phospholipase A2, arachidonate and prostaglandin E1. The results indicate that 
      acetylsalicylic acid at a high dose produces coronary arterial contracture 
      probably through inhibition of intravascular synthesis of vasodilating 
      prostaglandins.
FAU - Sakanashi, M
AU  - Sakanashi M
FAU - Araki, H
AU  - Araki H
FAU - Furukawa, T
AU  - Furukawa T
FAU - Rokutanda, M
AU  - Rokutanda M
FAU - Yonemura, K
AU  - Yonemura K
LA  - eng
PT  - Journal Article
PL  - Belgium
TA  - Arch Int Pharmacodyn Ther
JT  - Archives internationales de pharmacodynamie et de therapie
JID - 0405353
RN  - 0 (Vasoconstrictor Agents)
RN  - EC 3.1.1.32 (Phospholipases A)
RN  - EC 3.1.1.4 (Phospholipases A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Coronary Vessels/*drug effects
MH  - Dogs
MH  - Female
MH  - Heart Rate/drug effects
MH  - In Vitro Techniques
MH  - Male
MH  - Myocardial Contraction/drug effects
MH  - Phospholipases A/pharmacology
MH  - Phospholipases A2
MH  - *Vasoconstrictor Agents
EDAT- 1981/07/01 00:00
MHDA- 1981/07/01 00:01
CRDT- 1981/07/01 00:00
PHST- 1981/07/01 00:00 [pubmed]
PHST- 1981/07/01 00:01 [medline]
PHST- 1981/07/01 00:00 [entrez]
PST - ppublish
SO  - Arch Int Pharmacodyn Ther. 1981 Jul;252(1):86-96.

PMID- 314697
OWN - NLM
STAT- MEDLINE
DCOM- 19791121
LR  - 20190515
IS  - 0300-9734 (Print)
IS  - 0300-9734 (Linking)
VI  - 84
IP  - 2
DP  - 1979
TI  - Kinetics of acetylsalicylate and D-lactate transport across isolated frog gastric 
      mucosa.
PG  - 137-44
AB  - Luminal to submucosal migration of 14C-acetylsalicylate and D-lactate and some 
      electrical properties were studied in isolated frog gastric mucosae. With both 
      compounds, the unionized acids permeated much more rapidly than the ionized 
      conjugate bases. The permeability coefficient for unionized acetylsalicylic acid 
      increased from 0.27 to 0.43 mumoles, h-1, cm-2, mM-1 when its luminal 
      concentration was increased above 3 mM. Simultaneously there was an increase in 
      mucosal ion conductance. Acetylsalicylic acid has been shown previously to 
      increase gastric mucosal permeation of ions and uncharged larger molecules. The 
      present results indicate that above a threshold concentration the unionized form 
      also enhances absorption of this drug per se. Unionized D-lactic acid had no 
      effect of mucosal ion conductance and the permeability coefficient (0.07 mumoles, 
      h-1, cm-2, mM-1) was independent of its luminal concentration.
FAU - Flemström, G
AU  - Flemström G
LA  - eng
PT  - Journal Article
PL  - Sweden
TA  - Ups J Med Sci
JT  - Upsala journal of medical sciences
JID - 0332203
RN  - 0 (Lactates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anura
MH  - Aspirin/*metabolism
MH  - Biological Transport
MH  - Cell Membrane Permeability
MH  - Gastric Mucosa/*metabolism/physiology
MH  - Kinetics
MH  - Lactates/*metabolism
MH  - Rana temporaria
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.3109/03009737909179149 [doi]
PST - ppublish
SO  - Ups J Med Sci. 1979;84(2):137-44. doi: 10.3109/03009737909179149.

PMID- 37065507
OWN - NLM
STAT- MEDLINE
DCOM- 20230419
LR  - 20230421
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 12
DP  - 2023
TI  - Neurological involvement, immune response, and biomarkers in Kawasaki disease 
      along with its pathogenesis, therapeutic and diagnostic updates.
PG  - 235
LID - 10.12688/f1000research.130169.2 [doi]
LID - 235
AB  - Kawasaki disease is an acute, febrile disease that is not typically fatal if 
      treated and affects infants and children more commonly. More than 80% of the 
      afflicted patients are under the age of four. This disease most commonly affects 
      coronary arteries. In a minority of cases, Aneurysms can burst or produce 
      thrombosis, and they can cause infarction. The distinctive redness in the palms 
      and soles of the feet might result from a delayed-type hypersensitivity reaction 
      to a cross-reactive or recently discovered antigen (s). Autoantibodies against 
      epithelial cells and smooth muscle cells are produced as a result of subsequent 
      macromolecule synthesis and polyclonal white blood cell activation, which 
      intensifies the redness. Kawasaki disease's clinical manifestations range from 
      oral skin disease to the blistering of the mucosa, symptoms involving the hands 
      and the feet, skin disease of the palms and soles, a desquamative rash, and 
      cervical lymphatic tissue enlargement (so it is also referred to as tissue layer 
      lymphatic tissue syndrome). Most untreated patients develop some vessel sequelae, 
      from well-organized coronary inflammation to severe arterial blood vessel 
      dilatation to giant artery aneurysms with rupture or occlusion, infarction, and 
      thrombosis. With human gamma globulin administration, reasonable standards of 
      medical care, and the use of analgesics, the speed of symptomatic progression and 
      inflammatory artery changes are reduced. In this review, we have covered the 
      immunology of Kawasaki disease, its biomarkers, and the neurological 
      manifestations of this multisystem illness. We have also included a discussion on 
      its pathogenesis, diagnosis, and treatment.
CI  - Copyright: © 2023 Amir O et al.
FAU - Amir, Omniat
AU  - Amir O
AUID- ORCID: 0000-0002-5021-263X
AD  - Medicine, Almanhal academy, Khartoum, Sudan.
FAU - Prajjwal, Priyadarshi
AU  - Prajjwal P
AUID- ORCID: 0000-0001-7894-1829
AD  - Neurology, Bharati Vidyapeeth University Medical College and Hospital, Pune, 
      India.
FAU - Inban, Pugazhendi
AU  - Inban P
AD  - Medicine, Government Medical College Omandurar, Chennai, India.
FAU - Gadam, Srikanth
AU  - Gadam S
AUID- ORCID: 0000-0003-1800-1207
AD  - Postdoctoral Research Fellow, Mayo Clinic, USA, USA.
FAU - Aleti, Soumya
AU  - Aleti S
AD  - Internal Medicine, Berkshire Medical Center, Pittsfield, Massachusetts, USA.
FAU - Sunasra, Rayyan Rafik
AU  - Sunasra RR
AD  - Medicine, Hinduhriday Samrat Balasaheb Thackeray Medical College, Mumbai, India.
FAU - Gupta, Karan
AU  - Gupta K
AD  - Orthopedics, Government medical college, Patiala, India.
FAU - Elhag, Mustafa
AU  - Elhag M
AD  - Medicine, Almanhal academy, Khartoum, Sudan.
FAU - Mahmoud, Mohammed
AU  - Mahmoud M
AD  - Medicine, Almanhal academy, Khartoum, Sudan.
FAU - Alsir, Omklthoum
AU  - Alsir O
AD  - Medicine, Almanhal academy, Khartoum, Sudan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230302
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Infant
MH  - Child
MH  - Humans
MH  - *Mucocutaneous Lymph Node Syndrome/therapy/drug therapy
MH  - Aspirin/therapeutic use
MH  - Biomarkers
MH  - Coronary Vessels
MH  - Acute Disease
MH  - Immunity
PMC - PMC10102713
OTO - NOTNLM
OT  - Inflammation
OT  - Kawasaki
OT  - Rash
OT  - Strawberry Tongue
COIS- No competing interests were disclosed.
EDAT- 2023/04/19 06:00
MHDA- 2023/04/19 06:41
CRDT- 2023/04/18 01:43
PHST- 2023/03/20 00:00 [accepted]
PHST- 2023/04/19 06:41 [medline]
PHST- 2023/04/18 01:43 [entrez]
PHST- 2023/04/19 06:00 [pubmed]
AID - 10.12688/f1000research.130169.2 [doi]
PST - epublish
SO  - F1000Res. 2023 Mar 2;12:235. doi: 10.12688/f1000research.130169.2. eCollection 
      2023.

PMID- 11795179
OWN - NLM
STAT- MEDLINE
DCOM- 20020207
LR  - 20141120
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 47
IP  - 11
DP  - 2001 Nov
TI  - [Initial experience with use of cationic propyl gallate as an inducer of 
      thrombocyte aggregation in evaluation of anti-aggregation therapy].
PG  - 747-52
AB  - INTRODUCTION AND OBJECTIVE: Acetylsalicylic acid (ASA) is one of the basic 
      preparations which are used in the treatment of cardiovascular diseases. ASA 
      administration leads to irreversible restriction of platelet aggregation. The 
      objective of our work was to test possibilities of monitoring the effectiveness 
      of ASA therapy by measuring the platelet aggregability in vitro after induction 
      with cationic propyl gallate (CPG) which is considered a very potent aggregation 
      inductor. METHOD: We examined a group of 27 healthy volunteers divided into two 
      sub-groups (n = 19, n = 8). In the first sub-group the platelet aggregation was 
      examined before and after 24 hours following ingestion of 400 mg ASA after 
      induction with ADP, collagen, adrenaline and CPG. In the second sub-group the 
      platelet aggregation was examined before and after three-day administration of 
      ASA--100 mg/day. RESULTS AND CONCLUSION: In a group of 27 volunteers we assessed 
      normal values of aggregation after different inductors. A low stability of the 
      methods used was proved (low stability or insignificant correlation of results of 
      the same method before and after ASA ingestion. The most useful parameter by 
      means of which it was possible to monitor the effectiveness of administration of 
      400 or 100 mg ASA was the C/G slope (paired t-test, p < 0.0000002, and p < 0.001 
      resp.). In parameter CPG slope we were able to assess in both groups the cut-off 
      value (< 53%/min.) by means of which it is possible to discriminate probands 
      according to ASA therapy (contrary to the other commonly used inductors). From 
      the results ensues that when assessing the thrombocyte aggregation after CPG 
      induction we find a significantly lower percentage of so-called ASA 
      non-respondents than after other inductors. We consider the use of assessment of 
      thrombocyte aggregation after CPG induction when monitoring antiaggregation 
      therapy a very promising procedure.
FAU - Petrzelová, A
AU  - Petrzelová A
AD  - Oddĕlení laboratorní medicíny Nemocnice Sternberk.
FAU - Stejskal, D
AU  - Stejskal D
FAU - Prosková, J
AU  - Prosková J
FAU - Oral, I
AU  - Oral I
FAU - Dostálová, S
AU  - Dostálová S
FAU - Lacnák, B
AU  - Lacnák B
FAU - Sebecková, I
AU  - Sebecková I
FAU - Horalík, D
AU  - Horalík D
FAU - Zapletalová, J
AU  - Zapletalová J
FAU - Bartek, J
AU  - Bartek J
FAU - Vecerová, H
AU  - Vecerová H
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - První zkusenosti s vyuzitím kationického propylgallátu jako induktoru agregace 
      trombocytů v hodnocení úcinnosti antiagregacní terapie.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - 0 (Cations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 8D4SNN7V92 (Propyl Gallate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cations
MH  - Drug Monitoring
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Propyl Gallate/*pharmacology
EDAT- 2002/01/25 10:00
MHDA- 2002/02/08 10:01
CRDT- 2002/01/25 10:00
PHST- 2002/01/25 10:00 [pubmed]
PHST- 2002/02/08 10:01 [medline]
PHST- 2002/01/25 10:00 [entrez]
PST - ppublish
SO  - Vnitr Lek. 2001 Nov;47(11):747-52.

PMID- 22398636
OWN - NLM
STAT- MEDLINE
DCOM- 20130212
LR  - 20220801
IS  - 1432-1971 (Electronic)
IS  - 0172-0643 (Linking)
VI  - 33
IP  - 7
DP  - 2012 Oct
TI  - An unusual case of incomplete Kawasaki disease in an adolescent returning from 
      holiday in Montana.
PG  - 1196-9
LID - 10.1007/s00246-012-0246-3 [doi]
AB  - Here we present an unusual case of incomplete Kawasaki disease in a 15-year-old 
      boy returning from a holiday with his family in Montana. His symptoms were 
      initial diarrhoea and lethargy, with fever, rash, conjunctivitis, and arthralgia 
      developing during the course of his illness. His condition worsened while he was 
      at his local hospital, and he was transferred to the regional tertiary paediatric 
      hospital. An initial echocardiogram was normal; however, repeat echocardiogram 
      showed dilated coronary arteries with subsequent development of peeling of the 
      skin on the hands and feet. The patient was started on intravenous immunoglobulin 
      and high-dose aspirin and improved clinically. He was discharged home and remains 
      under follow-up by the infectious diseases and cardiology teams.
FAU - Hyams, Catherine
AU  - Hyams C
AD  - Department of Paediatrics, Chase Farm Hospital, Barnet and Chase Farm Hospitals 
      NHS Trust, London, England.
FAU - Day, Thomas G
AU  - Day TG
FAU - Ramroop, Shiva
AU  - Ramroop S
FAU - Paget, Stephanie
AU  - Paget S
FAU - Howard, Sasha
AU  - Howard S
FAU - McMillan, Merlin
AU  - McMillan M
FAU - Vora, Surabhi
AU  - Vora S
FAU - de Keyser, Paul
AU  - de Keyser P
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20120308
PL  - United States
TA  - Pediatr Cardiol
JT  - Pediatric cardiology
JID - 8003849
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/therapeutic use
MH  - Diagnosis, Differential
MH  - Echocardiography
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/drug therapy
EDAT- 2012/03/09 06:00
MHDA- 2013/02/13 06:00
CRDT- 2012/03/09 06:00
PHST- 2011/12/22 00:00 [received]
PHST- 2012/02/07 00:00 [accepted]
PHST- 2012/03/09 06:00 [entrez]
PHST- 2012/03/09 06:00 [pubmed]
PHST- 2013/02/13 06:00 [medline]
AID - 10.1007/s00246-012-0246-3 [doi]
PST - ppublish
SO  - Pediatr Cardiol. 2012 Oct;33(7):1196-9. doi: 10.1007/s00246-012-0246-3. Epub 2012 
      Mar 8.

PMID- 15982864
OWN - NLM
STAT- MEDLINE
DCOM- 20060120
LR  - 20131121
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 73
IP  - 3-4
DP  - 2005 Sep-Oct
TI  - Angiogenesis and lipoxins.
PG  - 271-5
AB  - Angiogenesis, the growth of new capillaries from pre-existing ones, occurs 
      through dynamic functions of the endothelial cells (EC), including migration, 
      proliferation and maturation, which are essential to achieve an organized 
      formation of the vessel sprout. Aspirin-triggered lipoxins (ATL), the 15R 
      enantiomeric counterparts of native lipoxins, are endogenous lipid mediators 
      generated within the vascular lumen during multicellular responses, which display 
      potent and well-described immunomodulatory actions. Here we present some of the 
      findings regarding the inhibition of EC responses in vitro and in vivo by these 
      novel compounds and the modulation of fundamental steps of the angiogenic 
      process, identifying previously unappreciated vascular actions of locally 
      generated ATL and their longer acting synthetic analogs.
FAU - Fierro, Iolanda M
AU  - Fierro IM
AD  - Departamento de Farmacologia e Psicobiologia, Instituto de Biologia Roberto 
      Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil 
      20551-030. iolanda@uerj.br
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Eicosanoids)
RN  - 0 (Lipoxins)
RN  - 0 (Receptors, Lipoxin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/pharmacology
MH  - Eicosanoids/*physiology
MH  - Endothelium, Vascular/*physiology
MH  - Humans
MH  - Lipoxins/*physiology
MH  - Neovascularization, Physiologic/drug effects/*physiology
MH  - Receptors, Lipoxin
RF  - 50
EDAT- 2005/06/29 09:00
MHDA- 2006/01/21 09:00
CRDT- 2005/06/29 09:00
PHST- 2005/06/29 09:00 [pubmed]
PHST- 2006/01/21 09:00 [medline]
PHST- 2005/06/29 09:00 [entrez]
AID - S0952-3278(05)00094-3 [pii]
AID - 10.1016/j.plefa.2005.05.016 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):271-5. doi: 
      10.1016/j.plefa.2005.05.016.

PMID- 11197445
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20220408
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 357
IP  - 9250
DP  - 2001 Jan 13
TI  - Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised 
      trial in general practice. Collaborative Group of the Primary Prevention Project.
PG  - 89-95
AB  - BACKGROUND: In addition to the treatment of specific cardiovascular risk factors, 
      intervention which interferes with the general mechanisms of atherosclerosis 
      could further reduce the incidence of cardiovascular events. We aimed to 
      investigate in general practice the efficacy of antiplatelets and antioxidants in 
      primary prevention of cardiovascular events in people with one or more major 
      cardiovascular risk factors. METHODS: We did a randomised controlled open 2x2 
      factorial trial to investigate low-dose aspirin (100 mg/day) and vitamin E (300 
      mg/day) in the prevention of cardiovascular events, in people with one or more of 
      the following: hypertension, hypercholesterolaemia, diabetes, obesity, family 
      history of premature myocardial infarction, or individuals who were elderly. 
      FINDINGS: 4495 people (2583 female, mean age 64.4 years) were included in the 
      trial. After a mean follow-up of 3.6 years the trial was prematurely stopped on 
      ethical grounds when newly available evidence from other trials on the benefit of 
      aspirin in primary prevention was strictly consistent with the results of the 
      second planned interim analysis. Aspirin lowered the frequency of all the 
      endpoints, being significant for cardiovascular death (from 1.4 to 0.8%; relative 
      risk 0.56 [95% CI 0.31-0.99]) and total cardiovascular events (from 8.2 to 6.3%; 
      0.77 [0.62-0.95]). Severe bleedings were more frequent in the aspirin group than 
      the no-aspirin group (1.1% vs 0.3%; p<0.0008). Vitamin E showed no effect on any 
      prespecified endpoint. Analyses were by intention-to-treat. INTERPRETATION: In 
      women and men at risk of having a cardiovascular event because of the presence of 
      at least one major risk factor, low-dose aspirin given in addition to treatment 
      of specific risk factors contributes an additional preventive effect, with an 
      acceptable safety profile. The results on vitamin E's cardiovascular primary 
      preventive efficacy are not conclusive per se, although our results are 
      consistent with the negative results of other large published trials on secondary 
      prevention.
FAU - de Gaetano, G
AU  - de Gaetano G
CN  - Collaborative Group of the Primary Prevention Project
LA  - eng
PT  - Clinical Trial
PT  - Comment
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Fibrinolytic Agents)
RN  - 1406-18-4 (Vitamin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 2001 Jul-Aug;135(1):8
EIN - Lancet 2001 Apr 7;357(9262):1134
CON - Lancet. 2001 Jan 13;357(9250):101-5. PMID: 11197396
CIN - Lancet. 2001 Jan 13;357(9250):84-5. PMID: 11197440
CIN - Lancet. 2001 May 26;357(9269):1704; author reply 1706. PMID: 11428361
CIN - Lancet. 2001 May 26;357(9269):1704; author reply 1706. PMID: 11428362
CIN - Lancet. 2001 May 26;357(9269):1705-6. PMID: 11428363
CIN - Lancet. 2001 May 26;357(9269):1705-6. PMID: 11548768
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*prevention & control
MH  - Family Practice
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Vitamin E/*therapeutic use
EDAT- 2001/02/24 12:00
MHDA- 2001/04/03 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/04/03 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
AID - S014067360003539X [pii]
AID - 10.1016/s0140-6736(00)03539-x [doi]
PST - ppublish
SO  - Lancet. 2001 Jan 13;357(9250):89-95. doi: 10.1016/s0140-6736(00)03539-x.

PMID- 6698383
OWN - NLM
STAT- MEDLINE
DCOM- 19840406
LR  - 20190825
IS  - 0306-3623 (Print)
IS  - 0306-3623 (Linking)
VI  - 15
IP  - 1
DP  - 1984
TI  - Colonic absorption of acetylsalicylic acid in the rat.
PG  - 55-8
AB  - Aspirin is absorbed in the colon by passive diffusion to a significant degree in 
      spite of the alkaline pH of the colonic lumen. Aspirin absorption by the colon is 
      enhanced by increasing the hydrogen ion concentration. Butyric acid, by markedly 
      reducing the absorption rate of aspirin, may be partially responsible for the 
      unpredictable absorption of rectally administered aspirin. The addition of 
      glycerol to aspirin preparations does not hinder the absorption of aspirin by the 
      colon.
FAU - Meshkinpour, H
AU  - Meshkinpour H
FAU - Hollander, D
AU  - Hollander D
FAU - Harmon, D
AU  - Harmon D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gen Pharmacol
JT  - General pharmacology
JID - 7602417
RN  - 0 (Fatty Acids)
RN  - PDC6A3C0OX (Glycerol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*metabolism
MH  - Biological Transport
MH  - Colon/*metabolism
MH  - Fatty Acids/pharmacology
MH  - Glycerol/pharmacology
MH  - Hydrogen-Ion Concentration
MH  - Intestinal Absorption/drug effects
MH  - Kinetics
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 0306-3623(84)90081-8 [pii]
AID - 10.1016/0306-3623(84)90081-8 [doi]
PST - ppublish
SO  - Gen Pharmacol. 1984;15(1):55-8. doi: 10.1016/0306-3623(84)90081-8.

PMID- 11194887
OWN - NLM
STAT- MEDLINE
DCOM- 20010315
LR  - 20131121
IS  - 0044-2771 (Print)
IS  - 0044-2771 (Linking)
VI  - 38
IP  - 12
DP  - 2000 Dec
TI  - [Aminosalicylates and aspirin for colonic cancer: from anti-inflammatory to 
      antineoplastic drugs?].
PG  - 963-70
AB  - The aim of this article is to review potential antineoplastic properties of 
      anti-inflammatory compounds commonly used in various inflammatory diseases such 
      as aminosalicylates, aspirin and other nonsteroidal drugs. Starting from 
      experimental and epidemiologic evidence showing prophylaxis and/or tumor 
      regression/suppression, specific antineoplastic actions especially the inhibition 
      of cyclooxygenase-(COX)dependent and COX-independent steps including the role of 
      transcription factor (NFkappaB) in the cell cycle regulation are reviewed. In 
      addition other mechanisms by which these drugs may exert antitumor effects, also 
      may be important such as induction of apoptosis of cancer cells and/or inhibition 
      of potentially carcinogenic oxidative DNA damage. Based on this knowledge 
      potential clinical implications are discussed.
FAU - Allgayer, H
AU  - Allgayer H
AD  - Abteilung Krebsnachsorge, Rehaklinik Ob der Tauber der LVA Württemberg, 
      Akademisches Lehrkrankenhaus, Universität Heidelberg.
FAU - Tillmann, T
AU  - Tillmann T
FAU - Hombach, A
AU  - Hombach A
FAU - Kruis, W
AU  - Kruis W
FAU - Pohl, C
AU  - Pohl C
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Aminosalizylate und Aspirin bei Kolonkarzinomen: vom Entzündungshemmer zum 
      Tumorprophylaktikum?
PL  - Germany
TA  - Z Gastroenterol
JT  - Zeitschrift fur Gastroenterologie
JID - 0033370
RN  - 0 (Antineoplastic Agents)
RN  - 4Q81I59GXC (Mesalamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/*therapeutic use
MH  - Colonic Neoplasms/*drug therapy
MH  - DNA Damage
MH  - Humans
MH  - Mesalamine/*therapeutic use
MH  - Treatment Outcome
EDAT- 2001/02/24 12:00
MHDA- 2001/03/17 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/03/17 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
AID - 10.1055/s-2000-10027 [doi]
PST - ppublish
SO  - Z Gastroenterol. 2000 Dec;38(12):963-70. doi: 10.1055/s-2000-10027.

PMID- 606701
OWN - NLM
STAT- MEDLINE
DCOM- 19780426
LR  - 20171213
IS  - 0161-7567 (Print)
IS  - 0161-7567 (Linking)
VI  - 43
IP  - 6
DP  - 1977 Dec
TI  - Ventilatory responses to hypercapnia and hypoxia during continuous aspirin 
      ingestion.
PG  - 971-6
AB  - Hypercapnic and hypoxic ventilatory responses were serially measured in nine 
      normal subjects given 3.9 g aspirin (ASA) per day for 9 days. Minute ventilation 
      (VE), end-tidal carbon dioxide tension (PETCO2), venous bicarbonate concentration 
      [HCO3-], oxygen consumption (VO2), hypercapnic ventilatory response 
      (deltaVE/deltaPCO2), and isocapnic hypoxic ventilatory response (A) were 
      determined before, 2 h after the first dose, and at 72-h intervals during the 
      next 14 days. Serum salicylate levels averaged 18.6 +/- 2.0 mg/dl. VE increased 
      (P less than 0.05, PETCO2 decreased (P less than 0.05), and [HCO3-] did not 
      change significantly during drug ingestion. deltaVE/deltaPCO2 increased gradually 
      to a value 37% greater than control by day 3 and remained constant (P less 0.01). 
      A increased by 251% and VO2 by 18% within 2 h and remained constant for the 
      remainder of the ASA period (P less than 0.01). All values returned to base line 
      within 24 h following cessation of ASA. We conclude that during continuous ASA 
      ingestion there is a gradual increase of hypercapnic ventilatory response. This 
      may reflect slow entrance of ASA into the central nervous system. In contrast, 
      there is a rapid rise in hypoxic ventilatory response which may be mechanically 
      linked to changes in metabolic rate.
FAU - Riley, D J
AU  - Riley DJ
FAU - Legawiec, B A
AU  - Legawiec BA
FAU - Santiago, T V
AU  - Santiago TV
FAU - Edelman, N H
AU  - Edelman NH
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Appl Physiol Respir Environ Exerc Physiol
JT  - Journal of applied physiology: respiratory, environmental and exercise physiology
JID - 7801242
RN  - 0 (Bicarbonates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Bicarbonates/blood
MH  - Female
MH  - Humans
MH  - Hypercapnia/*physiopathology
MH  - Hypoxia/*physiopathology
MH  - Male
MH  - Oxygen Consumption
MH  - Respiration/*drug effects
MH  - Time Factors
OID - NASA: 78109119
EDAT- 1977/12/01 00:00
MHDA- 1977/12/01 00:01
CRDT- 1977/12/01 00:00
PHST- 1977/12/01 00:00 [pubmed]
PHST- 1977/12/01 00:01 [medline]
PHST- 1977/12/01 00:00 [entrez]
AID - 10.1152/jappl.1977.43.6.971 [doi]
PST - ppublish
SO  - J Appl Physiol Respir Environ Exerc Physiol. 1977 Dec;43(6):971-6. doi: 
      10.1152/jappl.1977.43.6.971.

PMID- 1764882
OWN - NLM
STAT- MEDLINE
DCOM- 19920220
LR  - 20180605
IS  - 0095-5108 (Print)
IS  - 0095-5108 (Linking)
VI  - 18
IP  - 4
DP  - 1991 Dec
TI  - Prevention of preeclampsia.
PG  - 779-92
AB  - Preeclampsia is a disease unique to pregnancy. Treatment for the disease has 
      remained suboptimal because of the unknown etiology of the disease. Preventive 
      strategies have been suggested and have provided new ways to approach the patient 
      at risk for developing preeclampsia.
FAU - Repke, J T
AU  - Repke JT
AD  - Johns Hopkins University School of Medicine, Baltimore, Maryland.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Perinatol
JT  - Clinics in perinatology
JID - 7501306
RN  - 0 (Calcium, Dietary)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Calcium, Dietary/therapeutic use
MH  - Female
MH  - Hemodynamics
MH  - Humans
MH  - Nutritional Physiological Phenomena
MH  - Pre-Eclampsia/physiopathology/*prevention & control/therapy
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Primary Prevention/methods
RF  - 57
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
AID - S0095-5108(18)30495-0 [pii]
PST - ppublish
SO  - Clin Perinatol. 1991 Dec;18(4):779-92.

PMID- 11565646
OWN - NLM
STAT- MEDLINE
DCOM- 20011004
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 72
IP  - 3
DP  - 2001 Sep
TI  - Warfarin therapy does not increase bleeding in patients undergoing heart 
      transplantation.
PG  - 714-8
AB  - BACKGROUND: Historically, warfarin has been discontinued or rapidly reversed with 
      fresh frozen plasma in patients awaiting heart transplantation because of 
      concerns regarding excessive bleeding. Because preoperative warfarin may have 
      effects on bleeding after cardiac operations, we reviewed our experience to 
      determine the risks in patients undergoing heart transplantation while maintained 
      on warfarin. METHODS: The records of consecutive adult patients undergoing heart 
      transplantation from January 1996 to December 1998 were reviewed. Preoperative 
      and 24-hour postoperative data were obtained, including patient demographics; 
      hematologic laboratory values; medication use; repeat or primary sternotomy data; 
      allogeneic blood product administration; and chest tube drainage. Multivariate 
      linear and logistic regression analyses were performed using these variables to 
      determine risk factors for bleeding after heart transplantation. RESULTS: Ninety 
      adult patients, mean age 50 years, underwent orthotopic heart transplantation 
      during the 36-month period. No relationships existed between preoperative 
      international normalized ratio (INR, mean = 1.83 +/- 0.1, p = 0.84) or 
      postoperative INR (mean = 2.2 +/- 0.9, p = 0.63) and chest tube drainage (mean = 
      721 +/- 63 mL). Relationships were observed between total blood product 
      administration and preoperative INR (partial r = 0.30, p = 0.01) and 
      postoperative INR (partial r = -0.37, p = 0.002); however, preoperative INR did 
      not correlate (p = 0.29) when perioperative use of fresh frozen plasma was 
      factored as a covariate. Inverse relationships were evident between postoperative 
      INR and total blood product exposures, as well as transfusions of platelets 
      (partial r = -0.26, p = 0.03), fresh frozen plasma (partial r = -0.28, p = 0.02), 
      and red cells (partial r = -0.25, p = 0.04). CONCLUSIONS: Although we noted no 
      correlations between INR and chest tube output, inverse relationships were 
      observed with transfusion requirements in the first 24 hours after 
      transplantation. Preoperative warfarin may be safely continued in patients 
      awaiting heart transplantation.
FAU - Morris, C D
AU  - Morris CD
AD  - Joseph B. Whitehead Department of Surgery, Emory University School of Medicine, 
      Atlanta, Georgia, USA.
FAU - Vega, J D
AU  - Vega JD
FAU - Levy, J H
AU  - Levy JH
FAU - Buist, N N
AU  - Buist NN
FAU - Smith, A L
AU  - Smith AL
FAU - Despotis, G J
AU  - Despotis GJ
FAU - Kanter, K R
AU  - Kanter KR
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Transfusion
MH  - Chest Tubes
MH  - *Heart Transplantation
MH  - Humans
MH  - International Normalized Ratio
MH  - Logistic Models
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Platelet Count
MH  - Postoperative Care
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Preoperative Care
MH  - ROC Curve
MH  - Risk Factors
MH  - Warfarin/administration & dosage/*adverse effects
EDAT- 2001/09/22 10:00
MHDA- 2001/10/05 10:01
CRDT- 2001/09/22 10:00
PHST- 2001/09/22 10:00 [pubmed]
PHST- 2001/10/05 10:01 [medline]
PHST- 2001/09/22 10:00 [entrez]
AID - S0003-4975(01)02828-4 [pii]
AID - 10.1016/s0003-4975(01)02828-4 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 2001 Sep;72(3):714-8. doi: 10.1016/s0003-4975(01)02828-4.

PMID- 2518282
OWN - NLM
STAT- MEDLINE
DCOM- 19901005
LR  - 20191029
IS  - 0921-299X (Print)
IS  - 0921-299X (Linking)
VI  - 1
IP  - 4
DP  - 1989
TI  - Protection against pulmonary oxygen toxicity by interleukin-1 and tumor necrosis 
      factor: role of antioxidant enzymes and effect of cyclooxygenase inhibitors.
PG  - 361-7
AB  - Rats injected with interleukin-1 (10 micrograms) and tumor necrosis factor (10 
      micrograms) and then exposed continuously to hyperoxia (greater than 99% O2, 1 
      atm) survived longer, had increased lung reduced/oxidized glutathione ratios, 
      smaller pleural effusions, less pulmonary hypertension and improved arterial 
      blood gases. The percentage of animals surviving for 72 hours in hyperoxia 
      increased from 8% to 94%. Although relatively small increases in glutathione 
      redox cycle enzymes occurred four and sixteen hours following cytokine injection, 
      dramatic increases in all major antioxidant enzymes including superoxide 
      dismutase, glucose-6-phosphate dehydrogenase, glutathione reductase, glutathione 
      peroxidase, and catalase had occurred following 72 hours of exposure to 
      hyperoxia. The protective effect of IL-1 + TNF against lethal pulmonary O2 
      toxicity could be partially inhibited by pre-injection of lysine acetylsalicylate 
      or, less effectively, of ibuprofen. Recent studies have suggested that both IL-1 
      and TNF can induce manganese (mitochondrial) superoxide dismutase mRNA and 
      protein synthesis in a variety of cell types. Preliminary studies suggest that 
      IL-1 alone, in ample dosage, can provide protection against lethal pulmonary O2 
      toxicity. Future studies should be directed toward identification of acute phase 
      changes in lung antioxidant enzymes, surfactant proteins and/or lipid components, 
      enzymes needed for synthesis of surfactant phospholipids, and/or other protective 
      proteins. Additional work also needs to be done in identifying the lung cell 
      types in which early enzyme induction occurs. These studies should provide a 
      better understanding of mechanisms whereby protection against pulmonary O2 
      toxicity can occur. An understanding of the molecular mechanisms inducing 
      protective proteins should lead to more precise pharmacologic control of these 
      processes.
FAU - White, C W
AU  - White CW
AD  - Department of Pediatrics, Webb-Waring Lung Institute, Children's Hospital, 
      Denver, CO.
FAU - Ghezzi, P
AU  - Ghezzi P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Biotherapy
JT  - Biotherapy (Dordrecht, Netherlands)
JID - 8903031
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Enzymes)
RN  - 0 (Interleukin-1)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Antioxidants
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cyclooxygenase Inhibitors
MH  - Drug Therapy, Combination
MH  - Enzymes/physiology
MH  - Ibuprofen/pharmacology
MH  - Interleukin-1/*therapeutic use
MH  - Lung Diseases/chemically induced/*prevention & control
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Oxygen/*toxicity
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Tumor Necrosis Factor-alpha/*therapeutic use
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1007/BF02171012 [doi]
PST - ppublish
SO  - Biotherapy. 1989;1(4):361-7. doi: 10.1007/BF02171012.

PMID- 176688
OWN - NLM
STAT- MEDLINE
DCOM- 19760602
LR  - 20190823
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 11
IP  - 1
DP  - 1976 Jan
TI  - Aspirin as a quantitative acetylating reagent for the fatty acid oxygenase that 
      forms prostaglandins.
PG  - 23-30
AB  - A selective acetylation of the prostaglandin-forming fatty acid oxygenase (part 
      of the prostaglandin "synthetase" system) occurs with 100 muM concentrations of 
      aspirin (acetylsalicylic acid). The amount of acetylation, measured by counting 
      the [3H]acetyl-protein formed, was proportional to the amount of active, 
      functional oxygenase in a sample. When samples were aged to allow spontaneous 
      inactivation of the oxygenase, the amount of acetylation was proportional to the 
      remaining measurable activity rather than the initial amount of oxygenase protein 
      in the sample. Diethyl dithiocarbamate inhibited the oxygenase activity, but did 
      not interfere with the subsequent acetylation by aspirin. Indomethacin, on the 
      other hand, appeared to inactivate the oxygenase in a manner that interfered only 
      partially with the action of aspirin as an acetylating reagent. The amount of 
      acetylation appeared to be dependent upon the amount of native, undenatured 
      enzyme. The results suggest that the acetylation may be dependent upon an 
      essential functional group or conformation of groups in the catalytic peptide 
      chain(s) that can be destroyed during spontaneous inactivation of the oxygenase, 
      and altered by indomethacin.
FAU - Rome, L H
AU  - Rome LH
FAU - Lands, W E
AU  - Lands WE
FAU - Roth, G J
AU  - Roth GJ
FAU - Majerus, P W
AU  - Majerus PW
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Prostaglandins)
RN  - 99Z2744345 (Ditiocarb)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/*metabolism
MH  - Ditiocarb/pharmacology
MH  - Enzyme Activation/drug effects
MH  - Indomethacin/pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - Prostaglandins/*biosynthesis
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 0090-6980(76)90169-6 [pii]
AID - 10.1016/0090-6980(76)90169-6 [doi]
PST - ppublish
SO  - Prostaglandins. 1976 Jan;11(1):23-30. doi: 10.1016/0090-6980(76)90169-6.

PMID- 4531009
OWN - NLM
STAT- MEDLINE
DCOM- 19750310
LR  - 20190501
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 71
IP  - 12
DP  - 1974 Dec
TI  - Sites of acetylation of sickle cell hemoglobin by aspirin.
PG  - 4693-7
AB  - Aspirin acetylates a variety of sites on both the alpha and beta chains of 
      hemoglobin S. Nevertheless, the vast majority of acetyl groups become attached to 
      three loci: betaLys 59, betaLys 144, and alphaLys 90. These observations reveal 
      some molecular details of this transacylation reaction and suggest interesting 
      possibilities for its extension to other acylsalicylates with a variety of 
      different structures.
FAU - Shamsuddin, M
AU  - Shamsuddin M
FAU - Mason, R G
AU  - Mason RG
FAU - Ritchey, J M
AU  - Ritchey JM
FAU - Honig, G R
AU  - Honig GR
FAU - Klotz, I M
AU  - Klotz IM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Carbon Radioisotopes)
RN  - 0 (Hemoglobin, Sickle)
RN  - 0 (Hemoglobins, Abnormal)
RN  - 0 (Peptides)
RN  - EC 3.4.21.4 (Trypsin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*metabolism
MH  - Binding Sites
MH  - Carbon Radioisotopes
MH  - Chromatography, Ion Exchange
MH  - Hemoglobin, Sickle/*metabolism
MH  - Hemoglobins, Abnormal/*metabolism
MH  - Hydrolysis
MH  - Models, Structural
MH  - Peptides/metabolism
MH  - Protein Conformation
MH  - Trypsin
PMC - PMC433962
EDAT- 1974/12/01 00:00
MHDA- 1974/12/01 00:01
CRDT- 1974/12/01 00:00
PHST- 1974/12/01 00:00 [pubmed]
PHST- 1974/12/01 00:01 [medline]
PHST- 1974/12/01 00:00 [entrez]
AID - 10.1073/pnas.71.12.4693 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1974 Dec;71(12):4693-7. doi: 10.1073/pnas.71.12.4693.

PMID- 15613205
OWN - NLM
STAT- MEDLINE
DCOM- 20080825
LR  - 20161124
IS  - 1526-4610 (Electronic)
IS  - 0017-8748 (Linking)
VI  - 39
IP  - 2
DP  - 1999 Feb
TI  - Safety and efficacy of combined lysine acetylsalicylate and metoclopramide: 
      repeated intakes in migraine attacks.
PG  - 125-31
AB  - The efficacy of the combination of lysine acetylsalicylate and metoclopramide in 
      the treatment of migraine attacks has been established previously. The value of 
      repeated doses of such a combination has been reported in a recent study. The 
      purposes of this open-label study performed by general practitioners on a very 
      large sample of migraine sufferers were to confirm that repeated doses of the 
      combined treatment are efficient and well-tolerated, and to assess the efficacy 
      of treatment according to the initial headache intensity. Three thousand seven 
      hundred twenty-seven general practitioners entered 7259 migraine sufferers. 
      Patients had to use a first dose, the efficacy of which was assessed 2 hours 
      later. In the case of failure, they were then able to take a second dose and 
      possibly a third dose, 2 hours after the second, in the case of persistent 
      failure. Twelve thousand five hundred sixty-two migraine attacks were analyzed. 
      Tolerance, as assessed by the patients, was considered as good in more than 85% 
      of attacks, whatever the number of doses utilized. Five hundred thirty-five 
      adverse effects were reported after the use of 22,697 sachets. Of 12,515 attacks 
      documented for efficacy, patients considered the treatment as good or excellent 
      in 80% of attacks treated with one dose, 55% of those treated with two doses, and 
      27% of those treated with three doses. Relief of headache (reduction of its 
      severity from grade 3 or 2 to 1 or 0) was observed in 51% of episodes after the 
      first sachet, 51% of episodes treated with a second sachet, and 56% of episodes 
      treated with a third sachet. The first dose of treatment was found to be more 
      effective when the initial severity of the headache was moderate (improvement in 
      66% of attacks) than when it was severe (improvement in 30% of attacks). Efficacy 
      appeared to increase according to the number of doses when headache was initially 
      severe. This trial confirms that repeated doses of this combination is 
      well-tolerated and effective. Our results show that repeated doses are 
      particularly useful for severe attacks.
FAU - Pradalier, A
AU  - Pradalier A
AD  - Department of Internal Medicine 4, Centre Migraines et Céphalées, Hôpital Louis 
      Mourier, Colombes, France.
FAU - Chabriat, H
AU  - Chabriat H
FAU - Danchot, J
AU  - Danchot J
FAU - Baudesson, G
AU  - Baudesson G
FAU - Joire, J E
AU  - Joire JE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - 0 (Analgesics)
RN  - 0 (Antiemetics)
RN  - K3Z4F929H6 (Lysine)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Antiemetics/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*analogs & derivatives/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Drug Tolerance
MH  - Female
MH  - France
MH  - Humans
MH  - Lysine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Metoclopramide/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2004/12/23 09:00
MHDA- 2008/08/30 09:00
CRDT- 2004/12/23 09:00
PHST- 2004/12/23 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2004/12/23 09:00 [entrez]
AID - HEDhed3902125 [pii]
AID - 10.1046/j.1526-4610.1999.3902125.x [doi]
PST - ppublish
SO  - Headache. 1999 Feb;39(2):125-31. doi: 10.1046/j.1526-4610.1999.3902125.x.

PMID- 505502
OWN - NLM
STAT- MEDLINE
DCOM- 19800119
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 10
IP  - 5
DP  - 1979 Sep-Oct
TI  - Cerebral arteritis in scleroderma.
PG  - 595-7
AB  - Central nervous system (CNS) involvement is rare in scleroderma unless there are 
      concomitant abnormalities in renal or lung function or malignant hypertension. A 
      43-year-old woman with typical scleroderma developed subacute encephalopathy 
      despite absence of the above abnormalities. Cerebral angiography demonstrated a 
      focal arteritis. The patient improved while being given corticosteroids. We 
      believe this case indicates that cerebral arteritis can occur in scleroderma.
FAU - Estey, E
AU  - Estey E
FAU - Lieberman, A
AU  - Lieberman A
FAU - Pinto, R
AU  - Pinto R
FAU - Meltzer, M
AU  - Meltzer M
FAU - Ransohoff, J
AU  - Ransohoff J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Adult
MH  - Arteritis/diagnostic imaging/drug therapy/*etiology
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cerebral Angiography
MH  - Cerebral Arterial Diseases/diagnostic imaging/drug therapy/*etiology
MH  - Female
MH  - Humans
MH  - Methylprednisolone/administration & dosage/therapeutic use
MH  - Scleroderma, Systemic/*complications/diagnostic imaging/drug therapy
EDAT- 1979/09/01 00:00
MHDA- 1979/09/01 00:01
CRDT- 1979/09/01 00:00
PHST- 1979/09/01 00:00 [pubmed]
PHST- 1979/09/01 00:01 [medline]
PHST- 1979/09/01 00:00 [entrez]
AID - 10.1161/01.str.10.5.595 [doi]
PST - ppublish
SO  - Stroke. 1979 Sep-Oct;10(5):595-7. doi: 10.1161/01.str.10.5.595.

PMID- 7011226
OWN - NLM
STAT- MEDLINE
DCOM- 19810513
LR  - 20220330
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 31
IP  - 3
DP  - 1981 Mar
TI  - Influence of aspirin and dipyridamole on patency of coronary artery bypass 
      grafts.
PG  - 204-10
AB  - A prospective randomized trial was performed to determine if the administration 
      of inhibitors of platelet function would improve the patency of coronary artery 
      bypass grafts. Patients were operated on for intractable angina with 
      angiographically demonstrable lesions. The left internal mammary artery (IMA) was 
      used for bypass of lesions of the left anterior descending coronary artery (LAD). 
      Saphenous vein grafts were used for the LAD if the IMA was inadequate and for all 
      other vessels. Treated patients received 1,300 mg of aspirin and 100 mg of 
      dipyridamole (Persantine) orally each day. Control patients received neither 
      drug. Patients returned 3 to 6 months after operation for repeat angiography. 
      Results were analyzed by chi-square. One hundred seventy-four patients entered 
      the study from June, 1973, through December, 1975, and 113 were analyzed. In the 
      control group, 66 patients had 27 IMA-LAD grafts and 93 saphenous vein grafts. In 
      the treatment group, 47 patients underwent 18 IMA-LAD grafts and 75 saphenous 
      vein grafts. Ninety-eight of the 120 grafts (82%) were patent in the control 
      group, and 87 of 93 grafts (94%) were patent in the treatment group (x2 = 6.34, p 
      less than 0.02). Of the 45 IMA-LAD grafts in both groups, only 1 was occluded, a 
      patency of 98%. In the control group, 72 of 93 saphenous vein grafts (77%) were 
      patent. In the treatment group, 69 of 75 (92%) were patent (x2 = 6.54, p less 
      than 0.02). The results of the study show a 15% difference between the two groups 
      in the early patency of saphenous vein grafts. We continue to use aspirin and 
      dipyridamole to improve the patency of saphenous vein bypass grafts.
FAU - Mayer, J E Jr
AU  - Mayer JE Jr
FAU - Lindsay, W G
AU  - Lindsay WG
FAU - Castaneda, W
AU  - Castaneda W
FAU - Nicoloff, D M
AU  - Nicoloff DM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/prevention & control
MH  - Prospective Studies
MH  - Random Allocation
MH  - Thrombosis/prevention & control
EDAT- 1981/03/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
AID - S0003-4975(10)60927-7 [pii]
AID - 10.1016/s0003-4975(10)60927-7 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1981 Mar;31(3):204-10. doi: 10.1016/s0003-4975(10)60927-7.

PMID- 23441445
OWN - NLM
STAT- MEDLINE
DCOM- 20130314
LR  - 20131121
IS  - 1764-1489 (Print)
IS  - 1764-1489 (Linking)
VI  - 44
IP  - 6
DP  - 2012 Dec
TI  - Aspirin desensitization in a woman with inherited thrombophilia and recurrent 
      miscarriage.
PG  - 256-7
AB  - Women with inherited thrombophilia and recurrent miscarriage might benefit from 
      preconceptional antiagreggation with low-dose acetylsalicylic acid (ASA), but 
      concerns about severe adverse reactions may prevent physicians from performing 
      this treatment in patients with ASA hypersensitivity. We report the first known 
      case of ASA desensitization in a 41-year-old woman with inherited thrombophilia, 
      who had homozygosity (4G/4G polymorphism) of the plasminogen activator 
      inhibitor-1 (PAI-1) gene and first trimester recurrent miscarriage, and had 
      previously presented with anaphylaxis to ASA. Desensitization was completed 
      despite one self-limited adverse reaction, and the patient has maintained a daily 
      ASA intake of 100 mg with good tolerance.
FAU - Santos, N
AU  - Santos N
AD  - Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal.
FAU - Gaspar, A
AU  - Gaspar A
FAU - Livramento, S
AU  - Livramento S
FAU - Sampaio, G
AU  - Sampaio G
FAU - Morais-Almeida, M
AU  - Morais-Almeida M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Italy
TA  - Eur Ann Allergy Clin Immunol
JT  - European annals of allergy and clinical immunology
JID - 101466614
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (SERPINE1 protein, human)
RN  - R16CO5Y76E (Aspirin)
RN  - Thrombophilia, hereditary
SB  - IM
MH  - Abortion, Habitual/blood/genetics/*prevention & control
MH  - Administration, Oral
MH  - Adult
MH  - Anaphylaxis/diagnosis/immunology/*therapy
MH  - Aspirin/administration & dosage/adverse effects/*immunology
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/diagnosis/immunology/*therapy
MH  - Female
MH  - Homozygote
MH  - Humans
MH  - Plasminogen Activator Inhibitor 1/genetics
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*immunology
MH  - Polymorphism, Genetic
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Thrombophilia/blood/*drug therapy/genetics
MH  - Treatment Outcome
EDAT- 2013/02/28 06:00
MHDA- 2013/03/15 06:00
CRDT- 2013/02/28 06:00
PHST- 2013/02/28 06:00 [entrez]
PHST- 2013/02/28 06:00 [pubmed]
PHST- 2013/03/15 06:00 [medline]
PST - ppublish
SO  - Eur Ann Allergy Clin Immunol. 2012 Dec;44(6):256-7.

PMID- 2034931
OWN - NLM
STAT- MEDLINE
DCOM- 19910627
LR  - 20131121
IS  - 1013-2058 (Print)
IS  - 1013-2058 (Linking)
VI  - 80
IP  - 14
DP  - 1991 Apr 2
TI  - [Perennial rhinopathy. A brief synopsis].
PG  - 353-6
AB  - Among the perennial rhinitides three forms should be distinguished because of 
      therapeutic and prophylactic consequences: allergic, nonallergic eosinophilic 
      (NARES syndrome) and nonallergic non-eosinophilic (vasomotor) rhinitis. Their 
      distinction is based on history as well as on clinical criteria and allergy 
      tests, necessitating an optimal collaboration between the general practitioner, 
      the otorhinolaryngologist and the clinical immunologist. The therapeutic approach 
      to the three forms is outlined.
FAU - Wüthrich, B
AU  - Wüthrich B
AD  - Allergiestation der Dermatologischen Klinik, Universitätsspital, Zürich.
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Die perenniale Rhinopathie. Eine kurze Synopsis.
PL  - Switzerland
TA  - Schweiz Rundsch Med Prax
JT  - Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis
JID - 8403202
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Diagnosis, Differential
MH  - Drug Hypersensitivity/diagnosis
MH  - Humans
MH  - Nasal Polyps/diagnosis
MH  - Rhinitis, Allergic, Perennial/*diagnosis/therapy
RF  - 31
EDAT- 1991/04/02 00:00
MHDA- 1991/04/02 00:01
CRDT- 1991/04/02 00:00
PHST- 1991/04/02 00:00 [pubmed]
PHST- 1991/04/02 00:01 [medline]
PHST- 1991/04/02 00:00 [entrez]
PST - ppublish
SO  - Schweiz Rundsch Med Prax. 1991 Apr 2;80(14):353-6.

PMID- 2395799
OWN - NLM
STAT- MEDLINE
DCOM- 19901009
LR  - 20190818
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 7
IP  - 7
DP  - 1990 Jul
TI  - Sulfate homeostasis. II. Influence of chronic aspirin administration on inorganic 
      sulfate in humans.
PG  - 719-22
AB  - The purpose of the present investigation was to determine the effect of chronic 
      aspirin administration on the serum concentration and renal clearance of 
      inorganic sulfate in healthy volunteers. In a randomized crossover study, eight 
      male subjects received either no treatment or 975 mg of enteric-coated aspirin 
      three times daily for 8 days. Blood and urine samples were collected on the 
      eighth day over a 7-hr period. Midpoint salicylic acid concentrations in serum 
      varied between 55 and 182 micrograms/ml (mean concentration of 109 
      micrograms/ml). Serum inorganic sulfate concentrations demonstrated a small but 
      significant decrease on the eighth day of aspirin administration but there was no 
      apparent change in the renal clearance of sulfate. There were significant 
      correlations between the renal clearances, urinary excretion rates, and serum 
      concentrations of creatinine and sulfate, reflecting the dependence of sulfate 
      homeostasis on renal function. The serum concentration and renal clearance of 
      creatinine, sodium, potassium, calcium, magnesium, and phosphorus were unaffected 
      by aspirin treatment.
FAU - Morris, M E
AU  - Morris ME
AD  - Department of Pharmaceutics, State University of New York, Buffalo, Amherst 
      14260.
FAU - Benincosa, L J
AU  - Benincosa LJ
LA  - eng
GR  - GM07145/GM/NIGMS NIH HHS/United States
GR  - GM40551/GM/NIGMS NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Electrolytes)
RN  - 0 (Sulfates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Chromatography, High Pressure Liquid
MH  - Creatinine/urine
MH  - Electrolytes/blood
MH  - Homeostasis
MH  - Humans
MH  - Male
MH  - Spectrophotometry, Ultraviolet
MH  - Sulfates/*metabolism
MH  - Tablets, Enteric-Coated
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
AID - 10.1023/a:1015811504674 [doi]
PST - ppublish
SO  - Pharm Res. 1990 Jul;7(7):719-22. doi: 10.1023/a:1015811504674.

PMID- 3606466
OWN - NLM
STAT- MEDLINE
DCOM- 19870824
LR  - 20191029
IS  - 0276-5047 (Print)
IS  - 0276-5047 (Linking)
VI  - 7
IP  - 4
DP  - 1987 Jul-Aug
TI  - Aspirin treatment reduces platelet resistance to deformation.
PG  - 385-8
AB  - The present investigation has evaluated the influence of aspirin, its 
      constituents, and other nonsteroidal anti-inflammatory agents on the resistance 
      of human platelets to aspiration into micropipettes. Aspirin increased the length 
      of platelet extensions into the micropipette over the entire negative tension 
      range of 0.04 to 0.40 dynes/cm after exposure to the drug in vitro or after 
      ingestion of the agent. Other cyclooxygenase inhibitors, ibuprofen and 
      indomethacin, did not increase platelet deformability. The influence of aspirin 
      was mimicked to some degree by high concentrations of salicylic acid, but 
      acetylation of platelets with acetic anhydride had little influence on platelet 
      deformability. Incubation of platelets with both salicylic acid and acetic 
      anhydride had no more effect than salicylic acid alone. Benzoic acid, chemically 
      similar to salicylic acid, had a minimal effect. The studies demonstrate that 
      aspirin makes platelets more deformable, while components of the drug or other 
      nonsteroidal antiinflammatory agents and cyclooxygenase inhibitors do not have 
      the same influence on resistance to deformation.
FAU - Burris, S M
AU  - Burris SM
FAU - Smith, C M 2nd
AU  - Smith CM 2nd
FAU - Rao, G H
AU  - Rao GH
FAU - White, J G
AU  - White JG
LA  - eng
GR  - CA-21737/CA/NCI NIH HHS/United States
GR  - HL-11880/HL/NHLBI NIH HHS/United States
GR  - HL-27355/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arteriosclerosis
JT  - Arteriosclerosis (Dallas, Tex.)
JID - 8401388
RN  - 0 (Acetic Anhydrides)
RN  - 0 (Salicylates)
RN  - 2E48G1QI9Q (acetic anhydride)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetic Anhydrides/pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Humans
MH  - Ibuprofen/pharmacology
MH  - Indomethacin/pharmacology
MH  - Salicylates/pharmacology
MH  - Salicylic Acid
EDAT- 1987/07/01 00:00
MHDA- 1987/07/01 00:01
CRDT- 1987/07/01 00:00
PHST- 1987/07/01 00:00 [pubmed]
PHST- 1987/07/01 00:01 [medline]
PHST- 1987/07/01 00:00 [entrez]
AID - 10.1161/01.atv.7.4.385 [doi]
PST - ppublish
SO  - Arteriosclerosis. 1987 Jul-Aug;7(4):385-8. doi: 10.1161/01.atv.7.4.385.

PMID- 1814734
OWN - NLM
STAT- MEDLINE
DCOM- 19920623
LR  - 20181130
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 16
IP  - 3
DP  - 1991 Jul-Sep
TI  - The effect of aluminium chloride upon the transition of drugs through the 
      blood-brain barrier into the central nervous system.
PG  - 171-5
AB  - In order to determine the effect of Al3+ upon the transition of drugs through the 
      blood-brain barrier into the central nervous system we examined its effect upon a 
      drug that dissociates as a cation (quinidine) and drugs that dissociate as anions 
      (acetylsalicylic acid and pentobarbital). The entry and exit of quinidine into 
      and out of the brain in mice pre-treated with AlCl3 was inhibited. Al3+ did not 
      compete with acetylsalicylic acid for the penetration through the blood-brain 
      barrier but did slow down its elimination from the brain. Brain kinetics of the 
      examined drugs showed good correlation with their central pharmacodynamic 
      effects.
FAU - Jakovljević, V
AU  - Jakovljević V
AD  - Department of Pharmacology and Toxicology, Medical Faculty, University of Novi 
      Sad, Yugoslavia.
FAU - Banić, B
AU  - Banić B
FAU - Radunović, A
AU  - Radunović A
LA  - eng
PT  - Journal Article
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (Aluminum Compounds)
RN  - 0 (Chlorides)
RN  - 3CYT62D3GA (Aluminum Chloride)
RN  - CPD4NFA903 (Aluminum)
RN  - I4744080IR (Pentobarbital)
RN  - ITX08688JL (Quinidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aluminum/*pharmacology
MH  - Aluminum Chloride
MH  - *Aluminum Compounds
MH  - Animals
MH  - Aspirin/*pharmacokinetics/pharmacology
MH  - Blood-Brain Barrier/*drug effects/physiology
MH  - Brain/*metabolism
MH  - Chlorides/*pharmacology
MH  - Female
MH  - Male
MH  - Mice
MH  - Muscle Relaxation/drug effects
MH  - Pentobarbital/pharmacokinetics/pharmacology
MH  - Quinidine/*pharmacokinetics/pharmacology
MH  - Sleep/drug effects
EDAT- 1991/07/01 00:00
MHDA- 2000/06/01 00:00
CRDT- 1991/07/01 00:00
PHST- 1991/07/01 00:00 [pubmed]
PHST- 2000/06/01 00:00 [medline]
PHST- 1991/07/01 00:00 [entrez]
AID - 10.1007/BF03189955 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 1991 Jul-Sep;16(3):171-5. doi: 
      10.1007/BF03189955.

PMID- 2591706
OWN - NLM
STAT- MEDLINE
DCOM- 19900125
LR  - 20190824
IS  - 0306-3623 (Print)
IS  - 0306-3623 (Linking)
VI  - 20
IP  - 6
DP  - 1989
TI  - Lymphatic transport of salicylates in dogs.
PG  - 779-83
AB  - 1. Pharmacokinetic parameters were determined for acetylsalicylic acid (ASA) and 
      salicylic acid (SA) in plasma and lymph following the intravenous or oral 
      administration of a water-soluble preparation of lysine-acetylsalicylic acid to 
      dogs. 2. By both routes of administration, ASA but not SA, tended to be deposited 
      in lymph, as indicated by the ratio between the area under the concentration-time 
      curve constructed for the parent compound and its metabolite in lymph and plasma. 
      3. A reduced conversion of ASA to SA by esterases in lymph, and lymphatic 
      absorption of ASA following the oral administration might be factors responsible 
      for the accumulation of the compound in the lymphatic system. 4. It is suggested 
      that the lymphatic system might serve as a temporary reservoir compartment for 
      ASA.
FAU - Sudo, L S
AU  - Sudo LS
AD  - Department of Pharmacology, University of São Paulo, Brazil.
FAU - Almeida, M G
AU  - Almeida MG
FAU - Yasaka, W
AU  - Yasaka W
FAU - Garcia-Leme, J
AU  - Garcia-Leme J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gen Pharmacol
JT  - General pharmacology
JID - 7602417
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacokinetics
MH  - Dogs
MH  - Injections, Intravenous
MH  - Lymph/metabolism
MH  - Lymphatic System/*metabolism
MH  - Salicylates/administration & dosage/blood/*pharmacokinetics
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 0306-3623(89)90329-7 [pii]
AID - 10.1016/0306-3623(89)90329-7 [doi]
PST - ppublish
SO  - Gen Pharmacol. 1989;20(6):779-83. doi: 10.1016/0306-3623(89)90329-7.

PMID- 33920569
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210518
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 57
IP  - 4
DP  - 2021 Apr 17
TI  - Aspirin Desensitization: Implications for Acetylsalicylic Acid-Sensitive Pregnant 
      Women.
LID - 10.3390/medicina57040390 [doi]
LID - 390
AB  - Low-dose acetylsalicylic acid (ASA) is widely used during pregnancy to prevent 
      obstetric complications of placental dysfunction, such as preeclampsia, 
      stillbirth and fetal growth restriction, and obstetric complications in pregnant 
      women with antiphospholipid syndrome. ASA-sensitive pregnant women cannot benefit 
      from the effects of ASA due to the possibility of severe or potentially 
      life-threatening hypersensitivity reactions to ASA. ASA desensitization is a 
      valuable and safe therapeutic option for these women, allowing them to start 
      daily prophylaxis with ASA and prevent pregnancy complications. The authors 
      discuss the recent advances in obstetric conditions preventable by ASA and the 
      management of ASA hypersensitivity in pregnancy, including ASA desensitization. 
      To encourage the implementation of ASA desensitization protocols in ASA-sensitive 
      pregnant women, they also propose a practical approach for use in daily clinical 
      practice.
FAU - Benito-Garcia, Filipe
AU  - Benito-Garcia F
AD  - Immunoallergy Department, CUF Descobertas Hospital, 1998-018 Lisbon, Portugal.
FAU - Pires, Inês
AU  - Pires I
AUID- ORCID: 0000-0002-6150-5323
AD  - São Bernardo Hospital, Centro Hospitalar de Setúbal, 2910-549 Setúbal, Portugal.
FAU - Lima, Jorge
AU  - Lima J
AUID- ORCID: 0000-0002-0831-2741
AD  - Department of Obstetrics and Gynecology, CUF Descobertas Hospital, 1998-018 
      Lisbon, Portugal.
AD  - Comprehensive Health Research Centre (CHRC), CEDOC, NOVA Medical School, 
      Universidade Nova de Lisboa, 1169-056 Lisbon, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20210417
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Antiphospholipid Syndrome/complications/drug therapy
MH  - Aspirin/adverse effects
MH  - Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/drug therapy/prevention & control
MH  - Pregnancy
MH  - Pregnant Women
PMC - PMC8073510
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirin desensitization
OT  - antiphospholipid syndrome
OT  - fetal growth restriction
OT  - preeclampsia
OT  - pregnancy
COIS- The authors declare no conflict of interest. Abbreviations: APL (antiphospholipid 
      antibody); APLS (antiphospholipid syndrome); ASA (acetylsalicylic acid); COX 
      (cyclooxygenase); DRESS (drug reaction with eosinophilia and systemic symptoms); 
      FGR (fetal growth restriction); NECD(NSAID-exacerbated cutaneous disease); NERD 
      (NSAID-exacerbated respiratory disease); NIUA (NSAID-induced 
      urticaria/angioedema); NSAID (nonsteroidal anti-inflammatory drug); OPT (oral 
      provocation test); PE (preeclampsia); PGE(2), (prostaglandin E(2))(;) PGI(2) 
      (prostacyclin); PIGF (placental growth factor); sFlt-1 (soluble fmc-like tyrosine 
      kinase); SNIDR (single-NSAID-induced delayed reactions); SNIUAA 
      (single-NSAID-induced urticaria/angioedema or anaphylaxis); TXA(2) (thromboxane 
      A(2)) VEGF (vascular endothelial growth factor).
EDAT- 2021/05/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/04/30 01:16
PHST- 2021/03/14 00:00 [received]
PHST- 2021/04/14 00:00 [revised]
PHST- 2021/04/15 00:00 [accepted]
PHST- 2021/04/30 01:16 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - medicina57040390 [pii]
AID - medicina-57-00390 [pii]
AID - 10.3390/medicina57040390 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2021 Apr 17;57(4):390. doi: 10.3390/medicina57040390.

PMID- 8388581
OWN - NLM
STAT- MEDLINE
DCOM- 19930621
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 69
IP  - 4
DP  - 1993 Apr 1
TI  - Microbubble-induced phospholipase C activation does not correlate with platelet 
      aggregation.
PG  - 394-6
AB  - The effect of nitrogen-(N2-)microbubbles on platelets resembles that of common 
      platelet agonists with respect to aggregation and secretion, but is considerably 
      slower and is poorly inhibited by aspirin. This paper reports the effect of 
      microbubbles on platelet phospholipase C activity in gelfiltered human platelets 
      prelabelled with [32P]Pi ([32P]-GFP). The experiments were run in the presence of 
      an ADP scavenging system in order to rule out effects of ADP. Stimulation of 
      [32P]-GFP for 30 min with microbubbles caused a significant reduction in single 
      platelets (p < 0.0004) and a significant increase in 32P-activity in the 
      phosphatidic acid (PA) fraction (p < 0.02). Epinephrine potentiated the 
      microbubble-induced reduction in single platelets (p < 0.05), but did not enhance 
      the amount of 32P in the platelet [32P]PA fraction. The 32P-radioactivity in the 
      PI-fraction increased with time to a similar extent when [32P]-GFP was stirred 
      for 30 min in absence of microbubbles as it did after 30 min of agonist exposure. 
      There were no significant changes in the [32P]PIP and [32P]PIP2 fractions. 
      Aspirin abolished the microbubble-induced increase in 32P-activity in the PA 
      fraction, but had no significant effect on the reduction in single platelets. 
      Aspirin had a small but significant, reducing effect on platelet aggregation 
      induced by a combination of epinephrine and microbubbles (p < 0.05). With 
      epinephrine, however, aspirin did not completely abolish the increase in 
      [32P]-PA. It is concluded that microbubbles alone cause platelets to aggregate by 
      a novel mechanism that operates independent of cyclooxygenase-dependent 
      arachidonic acid metabolites and phospholipase C activation.
FAU - Malmgren, R
AU  - Malmgren R
AD  - Department of Experimental Surgery, Karolinska Institute, Stockholm, Sweden.
FAU - Thorsen, T
AU  - Thorsen T
FAU - Nordvik, A
AU  - Nordvik A
FAU - Holmsen, H
AU  - Holmsen H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Gases)
RN  - 0 (Phosphatidylinositol 4,5-Diphosphate)
RN  - 0 (Phosphatidylinositols)
RN  - EC 3.1.4.- (Type C Phospholipases)
RN  - N762921K75 (Nitrogen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Enzyme Activation
MH  - Epinephrine/pharmacology
MH  - *Gases
MH  - Humans
MH  - *Nitrogen
MH  - Phosphatidylinositol 4,5-Diphosphate
MH  - Phosphatidylinositols/analysis
MH  - *Platelet Aggregation
MH  - Type C Phospholipases/*metabolism
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1993 Apr 1;69(4):394-6.

PMID- 36191535
OWN - NLM
STAT- MEDLINE
DCOM- 20221019
LR  - 20221202
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 219
DP  - 2022 Nov
TI  - Oral anticoagulant management of patients with mechanical heart valves at the 
      Salam Centre of Khartoum: Observations on quality of anticoagulation and 
      thrombotic risk.
PG  - 155-161
LID - S0049-3848(22)00400-5 [pii]
LID - 10.1016/j.thromres.2022.09.018 [doi]
AB  - INTRODUCTION: Rheumatic heart disease with mechanical heart valve (MHV) 
      replacement is common in Africa. However, MHV requires long-life anticoagulation 
      and managing this can be challenging. METHODS AND RESULTS: We report data of a 
      prospective observational study conducted between August 2018 and September 2019 
      in MHV patients in the Salam Centre for Cardiac Surgery built in Khartoum, by 
      Emergency, an Italian Non-Governmental Organization, to evaluate the quality of 
      anticoagulation control and the risk of thrombotic complications. RESULTS: We 
      studied 3647 patients (median age 25.1 years; 53.9 % female). Median Time in 
      Therapeutic Range (TTR) was 53 % (interquartile range 37 % to 67 %) and 70 
      thrombotic events (rate 1.8 × 100 pt-years [95 % CI 1.38-2.23]) were recorded. 
      Among patients in the first quartile of TTR (≤37 %), we recorded 34/70 (48.6 %) 
      of all thrombotic events (rate 3.7 × 100 pt-years [95 % CI 2.5-5.1]), with a high 
      mortality rate (2.2 × 100 pt-years [95 % CI 1.3-3.3]). In patients with 
      guideline-recommended TTR (≥65 %) the event rate was 0.8 × 100 pt-years for 
      thrombotic events [95 % CI 0.3-1.5] and 0.4 × 100 pt-years for mortality [95 % CI 
      0.1-0.9]. Multivariable analysis showed that having a TTR in the lowest quartile 
      (≤37 %) and being noncompliant are significantly associated with increased 
      thrombotic risk. Aspirin use or different valve type did not influence the 
      thrombotic risk. Almost 40 % of all thromboembolic complications could have been 
      potentially prevented by further improving VKA management to obtain a TTR > 37 %. 
      CONCLUSION: The thrombotic risk of MHV patients on VKAs living in a low-income 
      country like Sudan is associated with low quality of anticoagulation control. 
      Efforts should be made to decrease the number of non-compliant patients and to 
      reach a guideline-recommended TTR of ≥65 %.
CI  - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Erba, Nicoletta
AU  - Erba N
AD  - Medical Division, Emergency, ONG Onlus, Milan, Italy.
FAU - Tosetto, Alberto
AU  - Tosetto A
AD  - Hematology Department, San Bortolo Hospital, Vicenza, Italy.
FAU - Langer, Martin
AU  - Langer M
AD  - Medical Division, Emergency, ONG Onlus, Milan, Italy.
FAU - Abdallah, Suha Abdelwahab
AU  - Abdallah SA
AD  - Medical Division, Emergency, ONG Onlus, Milan, Italy.
FAU - Giovanella, Elena
AU  - Giovanella E
AD  - Medical Division, Emergency, ONG Onlus, Milan, Italy.
FAU - Lentini, Salvatore
AU  - Lentini S
AD  - Medical Division, Emergency, ONG Onlus, Milan, Italy.
FAU - Masini, Franco
AU  - Masini F
AD  - Medical Division, Emergency, ONG Onlus, Milan, Italy.
FAU - Mocini, Alessandro
AU  - Mocini A
AD  - Medical Division, Emergency, ONG Onlus, Milan, Italy.
FAU - Portella, Gennarina
AU  - Portella G
AD  - Medical Division, Emergency, ONG Onlus, Milan, Italy.
FAU - Salvati, Alessandro Cristian
AU  - Salvati AC
AD  - Medical Division, Emergency, ONG Onlus, Milan, Italy.
FAU - Squizzato, Alessandro
AU  - Squizzato A
AD  - Research Center on Thromboembolic Disorders and Antithrombotic Therapies, ASST 
      Lariana, University of Insubria, Como, Italy.
FAU - Testa, Sophie
AU  - Testa S
AD  - Hemostasis and Thrombosis Center, Laboratory Medicine Department, ASST Cremona, 
      Cremona, Italy.
FAU - Lip, Gregory Y H
AU  - Lip GYH
AD  - Liverpool Centre for Cardiovascular Science, University of Liverpool and 
      Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Department of 
      Clinical Medicine, Aalborg University, Aalborg, Denmark.
FAU - Poli, Daniela
AU  - Poli D
AD  - Thrombosis Centre, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 
      Electronic address: polida@aou-careggi.toscana.it.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220921
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Anticoagulants/adverse effects
MH  - Aspirin/pharmacology
MH  - Blood Coagulation
MH  - Female
MH  - Heart Valves
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - *Thrombosis/chemically induced/etiology
OTO - NOTNLM
OT  - Africa
OT  - Mechanical heart valves
OT  - Oral anticoagulants
OT  - Thrombotic risk
OT  - Warfarin
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/10/04 06:00
MHDA- 2022/10/20 06:00
CRDT- 2022/10/03 18:28
PHST- 2022/07/11 00:00 [received]
PHST- 2022/09/14 00:00 [revised]
PHST- 2022/09/19 00:00 [accepted]
PHST- 2022/10/04 06:00 [pubmed]
PHST- 2022/10/20 06:00 [medline]
PHST- 2022/10/03 18:28 [entrez]
AID - S0049-3848(22)00400-5 [pii]
AID - 10.1016/j.thromres.2022.09.018 [doi]
PST - ppublish
SO  - Thromb Res. 2022 Nov;219:155-161. doi: 10.1016/j.thromres.2022.09.018. Epub 2022 
      Sep 21.

PMID- 20728206
OWN - NLM
STAT- MEDLINE
DCOM- 20101112
LR  - 20151119
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 126
IP  - 4
DP  - 2010 Oct
TI  - The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated 
      respiratory diseases.
PG  - 738-44
LID - 10.1016/j.jaci.2010.06.036 [doi]
AB  - BACKGROUND: Patients with aspirin-exacerbated respiratory disease have been shown 
      to benefit clinically from aspirin desensitization followed by chronic high-dose 
      aspirin therapy. However, the mechanism of this phenomenon is still unclear. 
      OBJECTIVE: The aim of this study was to characterize the airway inflammatory 
      response to aspirin desensitization and after treatment with high-dose aspirin 
      for 6 months. METHODS: Twenty-one adult patients with asthma, chronic polypoid 
      sinusitis, and a convincing history of acute respiratory reaction to the 
      ingestion of aspirin or nonsteroidal anti-inflammatory drugs were selected. These 
      patients underwent an oral desensitization to aspirin over a 2-day period, 
      followed by daily ingestion of aspirin 650 mg twice daily. Induced sputum samples 
      and exhaled nitric oxide measurements were taken before the procedure, during the 
      second day of the procedure, and after 6 months of treatment. RESULTS: There was 
      a significant elevation in both the exhaled nitric oxide level (P = .03) and 
      sputum tryptase level (P = .05) during the desensitization process. After 6 
      months of aspirin treatment, sputum IL-4 (P = .0007) and matrix metalloproteinase 
      9 (MMP-9; P = .05) decreased significantly compared with baseline. 
      Predesensitization to postdesensitization changes in MMP-9 and tissue inhibitors 
      of metalloproteinases 1 were highly correlated (r = 0.79; P = .0003). Immediately 
      after the desensitization, MMP-9 and tryptase were correlated (r = 0.82; P = 
      .001), whereas IL-4 was inversely related with FMS-like tyrosine kinase 3 ligand 
      (FLT3-L) (r = -0.79; P = .0008). There was a significant decrease in the average 
      symptom score at 6 months. CONCLUSION: Consistent with previous reports, acute 
      aspirin desensitization in patients with aspirin-exacerbated respiratory disease 
      involves mast cell degranulation. In contrast, long-term treatment with aspirin 
      involves suppression of IL-4 as well as downregulation of proinflammatory MMP-9 
      while T(H)1 marker FLT3-L increases.
CI  - Copyright © 2010 American Academy of Allergy, Asthma & Immunology. Published by 
      Mosby, Inc. All rights reserved.
FAU - Katial, Rohit K
AU  - Katial RK
AD  - Division of Allergy and Immunology, National Jewish Health, Denver, CO 80206, 
      USA. katialr@njhealth.org
FAU - Strand, Matthew
AU  - Strand M
FAU - Prasertsuntarasai, Theerapol
AU  - Prasertsuntarasai T
FAU - Leung, Roxanne
AU  - Leung R
FAU - Zheng, Weihong
AU  - Zheng W
FAU - Alam, Rafeul
AU  - Alam R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20100821
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Membrane Proteins)
RN  - 0 (flt3 ligand protein)
RN  - 207137-56-2 (Interleukin-4)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Allergy Clin Immunol. 2010 Oct;126(4):745-6. PMID: 20920763
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Asthma/complications/drug therapy
MH  - Biomarkers/*analysis
MH  - Chronic Disease
MH  - Desensitization, Immunologic/*methods
MH  - Female
MH  - Humans
MH  - Inflammation/drug therapy/immunology
MH  - Interleukin-4/analysis
MH  - Male
MH  - Matrix Metalloproteinase 9/analysis
MH  - Membrane Proteins/analysis
MH  - Middle Aged
MH  - Respiratory Tract Diseases/chemically induced/complications/*drug therapy
MH  - Sinusitis/complications/drug therapy
MH  - Sputum/*chemistry/immunology
MH  - Treatment Outcome
EDAT- 2010/08/24 06:00
MHDA- 2010/11/13 06:00
CRDT- 2010/08/24 06:00
PHST- 2010/04/16 00:00 [received]
PHST- 2010/05/28 00:00 [revised]
PHST- 2010/06/29 00:00 [accepted]
PHST- 2010/08/24 06:00 [entrez]
PHST- 2010/08/24 06:00 [pubmed]
PHST- 2010/11/13 06:00 [medline]
AID - S0091-6749(10)01038-9 [pii]
AID - 10.1016/j.jaci.2010.06.036 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2010 Oct;126(4):738-44. doi: 10.1016/j.jaci.2010.06.036. 
      Epub 2010 Aug 21.

PMID- 2515856
OWN - NLM
STAT- MEDLINE
DCOM- 19900307
LR  - 20141120
IS  - 0232-766X (Print)
IS  - 0232-766X (Linking)
VI  - 48
IP  - 9
DP  - 1989
TI  - Spontaneous atherosclerotic lesions and prostacyclin formation in rabbits: 
      effects of combined dipyridamole and aspirin.
PG  - 721-5
AB  - The influence of dipyridamole and lysine acetylsalicylate on the incidence of 
      atherosclerotic lesions and on arterial prostacyclin formation was studied in 
      rabbits. Male New Zealand rabbits received i.m. for 16 months dipyridamole (12.5 
      mg/kg/day) and lysine acetylsalicylate (0.5 mg/kg/day). The incidence of 
      spontaneous atherosclerotic lesions in the aorta was reduced by 16.4% with 
      respect to untreated animals. Administration of the drugs significantly increased 
      prostacyclin formation with respect to the untreated rabbits both in animals 
      developing (1124 +/- 197 pg/mg/3 min vs 316 +/- 49 pg/mg/3 min) or not developing 
      lesions (499 +/- 40 pg/mg/3 min vs 246 +/- 19 pg/mg/3 min). The observed increase 
      in prostacyclin formation could account for the lowered incidence of 
      atherosclerotic lesions in rabbits receiving the combination of dipyridamole and 
      lysine acetylsalicylate.
FAU - Lasierra, J
AU  - Lasierra J
AD  - Services of Hematology and Pathologic Anatomy, San Millán Hospital, Logroño, 
      Spain.
FAU - Gonzalez, J
AU  - Gonzalez J
FAU - Aza, M J
AU  - Aza MJ
FAU - Melon, J
AU  - Melon J
FAU - Vazquez, E
AU  - Vazquez E
FAU - Collado, P S
AU  - Collado PS
FAU - Castellarnau, C
AU  - Castellarnau C
FAU - Rutllant, M
AU  - Rutllant M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Biomed Biochim Acta
JT  - Biomedica biochimica acta
JID - 8304435
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 64ALC7F90C (Dipyridamole)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/*biosynthesis
MH  - Animals
MH  - Aorta/pathology
MH  - Arteries/drug effects/metabolism/pathology
MH  - Arteriosclerosis/pathology/*prevention & control
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Epoprostenol/*biosynthesis
MH  - In Vitro Techniques
MH  - Male
MH  - Muscle, Smooth, Vascular/*metabolism
MH  - Rabbits
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Biomed Biochim Acta. 1989;48(9):721-5.

PMID- 7138304
OWN - NLM
STAT- MEDLINE
DCOM- 19821216
LR  - 20190704
IS  - 0004-0010 (Print)
IS  - 0004-0010 (Linking)
VI  - 117
IP  - 11
DP  - 1982 Nov
TI  - Aspirin and dipyridamole inhibit endothelial healing.
PG  - 1459-64
AB  - Aspirin and dipyridamole have been used to treat the thromboembolic complications 
      of atherosclerosis. We studied the effects of these drugs on the rate of 
      endothelial healing after a standard de-endothelializing injury of the thoracic 
      aorta. Twenty-five rabbits received 13.5 mg/kg/day of aspirin and 15 mg/kg/day of 
      dipyridamole one week before injury and for the period of endothelial regrowth. 
      There were 25 control animals. Mean serum aspirin salicylate levels were 12 
      micrograms/dL at the time of injury and 15 micrograms/dL at death. Areas of 
      endothelial regrowth were measured by Evans blue dye at 1, 4, 7 and 14 days after 
      injury. The percentage of endothelial regrowth was measured by computer-assisted 
      morphometry. Antiplatelet treatment retarded endothelial regrowth by 66% at four 
      days, 22% at seven days, and 28% at 14 days. Antiplatelet drugs must be used 
      cautiously, as re-endothelialization of injured arteries is retarded.
FAU - Bomberger, R A
AU  - Bomberger RA
FAU - DePalma, R G
AU  - DePalma RG
FAU - Ambrose, T A
AU  - Ambrose TA
FAU - Manalo, P
AU  - Manalo P
LA  - eng
GR  - R0I HL26338/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Surg
JT  - Archives of surgery (Chicago, Ill. : 1960)
JID - 9716528
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta, Thoracic/drug effects/*pathology/physiopathology
MH  - Aspirin/*pharmacology
MH  - Dipyridamole/*pharmacology
MH  - Endothelium/drug effects/pathology/physiopathology
MH  - Male
MH  - Rabbits
MH  - Regeneration/drug effects
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
AID - 10.1001/archsurg.1982.01380350057008 [doi]
PST - ppublish
SO  - Arch Surg. 1982 Nov;117(11):1459-64. doi: 10.1001/archsurg.1982.01380350057008.

PMID- 10436127
OWN - NLM
STAT- MEDLINE
DCOM- 19990830
LR  - 20220317
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 30
IP  - 8
DP  - 1999 Aug
TI  - Therapeutic benefit. Aspirin revisited in light of the introduction of 
      clopidogrel.
PG  - 1716-21
AB  - BACKGROUND: Antiplatelet agents are widely recognized for their efficacy in 
      reducing the occurrence of vascular events in patients with atherothrombotic 
      disease. Aspirin is currently considered to be the "reference standard" 
      antiplatelet agent and is recommended by the American Heart Association for use 
      in patients with a wide range of manifestations of cardiovascular disease on the 
      basis of its high benefit-to-risk and benefit-to-cost ratios. Recently, 
      clopidogrel (Plavix, Bristol-Myers Squibb Co), another antiplatelet agent, was 
      approved by the Food and Drug Administration for many of the same indications as 
      aspirin. SUMMARY OF REVIEW: Because physicians will be faced with deciding 
      whether to switch from the well-established practice of recommending aspirin for 
      use in patients with atherothrombotic disease, both aspirin and clopidogrel are 
      compared with respect to the primary factors that influence such decisions (ie, 
      their relative efficacy, safety, cost, and convenience of use). CONCLUSIONS: 
      Based on the available evidence, aspirin is preferred for the majority of stroke 
      or myocardial infarction patients at risk of recurrent atherothrombotic events. 
      Clopidogrel may, however, provide valuable therapeutic benefit over aspirin in 
      patients with peripheral arterial disease and in stroke or myocardial infarction 
      patients for whom aspirin treatment is contraindicated or for whom aspirin fails 
      to achieve the desired therapeutic effect.
FAU - Gorelick, P B
AU  - Gorelick PB
AD  - Center for Stroke Research, Chicago, Ill, USA.
FAU - Born, G V
AU  - Born GV
FAU - D'Agostino, R B
AU  - D'Agostino RB
FAU - Hanley, D F Jr
AU  - Hanley DF Jr
FAU - Moye, L
AU  - Moye L
FAU - Pepine, C J
AU  - Pepine CJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clopidogrel
MH  - *Decision Making
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Secondary Prevention
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
RF  - 47
EDAT- 1999/08/06 10:00
MHDA- 2001/03/28 10:01
CRDT- 1999/08/06 10:00
PHST- 1999/08/06 10:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1999/08/06 10:00 [entrez]
AID - 10.1161/01.str.30.8.1716 [doi]
PST - ppublish
SO  - Stroke. 1999 Aug;30(8):1716-21. doi: 10.1161/01.str.30.8.1716.

PMID- 26448336
OWN - NLM
STAT- MEDLINE
DCOM- 20160919
LR  - 20151106
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
VI  - 22
IP  - 6
DP  - 2015 Nov-Dec
TI  - Pharmacist's evolving role in the nonopioid, over-the-counter, analgesic 
      selection process.
PG  - 423-30
LID - 10.1097/MJT.0000000000000341 [doi]
AB  - The pharmacist provides an integral role in pain management and treatment by 
      focusing on the selection and evaluation of analgesic agents in a process that is 
      patient specific, patient focused, and patient centered in a personalized care 
      plan. Counseling patients (and the families of patients) who are using 
      acetaminophen, aspirin, and/or nonsteroidal anti-inflammatory drugs for acute 
      musculoskeletal pain and inflammation regarding the appropriate use of these 
      agents is a key component of the pharmacist's overall pharmacotherapeutic role. 
      This article reviews the importance of explaining the therapeutic and 
      nontherapeutic effects of these agents, cautions, contraindications, dosing 
      parameters, and the avoidance of acetaminophen/aspirin and multiple nonsteroidal 
      anti-inflammatory drug use to patients and prescribers. The article also 
      discusses the need to evaluate the cytochrome P450 system and the patient's 
      pharmacotherapy and comorbid disease history to identify potential drug-mediated 
      interactions. Evaluation of patients for comorbidities, allergies, and 
      gastrointestinal, renal, hepatic, hematologic, and cardiovascular risks is also 
      addressed, as are essential laboratory tests and the special needs of elderly 
      patients.
FAU - Barkin, Robert L
AU  - Barkin RL
AD  - Departments of Anesthesiology, Pharmacology, and Family Medicine, Rush Medical 
      College, Rush University Medical Center, Chicago, IL; and Pain Centers of North 
      Shore University Health System, Department of Anesthesiology, Skokie Hospital, 
      Skokie, IL; and Evanston Hospital, Evanston, IL.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Analgesics/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Counseling
MH  - Humans
MH  - Nonprescription Drugs/*therapeutic use
MH  - *Pharmacists
MH  - *Professional Role
MH  - Referral and Consultation
EDAT- 2015/10/09 06:00
MHDA- 2016/09/20 06:00
CRDT- 2015/10/09 06:00
PHST- 2015/10/09 06:00 [entrez]
PHST- 2015/10/09 06:00 [pubmed]
PHST- 2016/09/20 06:00 [medline]
AID - 10.1097/MJT.0000000000000341 [doi]
PST - ppublish
SO  - Am J Ther. 2015 Nov-Dec;22(6):423-30. doi: 10.1097/MJT.0000000000000341.

PMID- 29024912
OWN - NLM
STAT- MEDLINE
DCOM- 20180618
LR  - 20180618
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 219
DP  - 2017 Dec
TI  - How important is aspirin adherence when evaluating effectiveness of low-dose 
      aspirin?
PG  - 1-9
LID - S0301-2115(17)30464-5 [pii]
LID - 10.1016/j.ejogrb.2017.10.004 [doi]
AB  - Low-dose aspirin (LDA) is advocated for women at high-risk of pre-eclampsia, 
      providing a modest, 10%, reduction in risk. Cardiology meta-analyses demonstrate 
      18% reduction in serious vascular events with LDA. Non-responsiveness to aspirin 
      (sometimes termed aspirin resistance) and variable clinical effectiveness are 
      often attributed to suboptimal adherence. The aim of this review was to identify 
      the scope of adherence assessments in RCTs evaluating aspirin effectiveness in 
      cardiology and obstetrics and discuss the quality of information provided by 
      current methods. We searched MEDLINE, EMBASE and the Cochrane Library, limited to 
      humans and English language, for RCTs evaluating aspirin in cardiology; 
      14/03/13-13/03/16 and pregnancy 1957-13/03/16. Search terms; 'aspirin', 
      'acetylsalicylic acid' appearing adjacent to 'myocardial infarction' or 
      'pregnancy', 'pregnant', 'obstetric' were used. 38% (25/68) of obstetric and 32% 
      (20/62) of cardiology RCTs assessed aspirin adherence and 24% (6/25) and 29% 
      (6/21) of obstetric and cardiology RCTs, respectively, defined acceptable 
      adherence. Semi-quantitative methods (pill counts, medication weighing) prevailed 
      in obstetric RCTs (93%), qualitative methods (interviews, questionnaires) were 
      more frequent in obstetrics (67%). Two obstetric RCTs quantified serum 
      thromboxane B(2) and salicylic acid, but no quantitative methods were used in 
      cardiology Aspirin has proven efficacy, but suboptimal adherence is widespread 
      and difficult to accurately quantify. Little is currently known about aspirin 
      adherence in pregnancy. RCTs evaluating aspirin effectiveness show over-reliance 
      on qualitative adherence assessments vulnerable to inherent inaccuracies. 
      Reliable adherence data is important to assess and optimise the clinical 
      effectiveness of LDA. We propose that adherence should be formally assessed in 
      future trials and that development of quantitative assessments may prove valuable 
      for trial protocols.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - Navaratnam, Kate
AU  - Navaratnam K
AD  - Centre for Women's Health Research, Institute of Translational Medicine, 
      University of Liverpool, Crown Street, Liverpool, L8 7SS, UK. Electronic address: 
      Kate.Navaratnam@liverpool.ac.uk.
FAU - Alfirevic, Zarko
AU  - Alfirevic Z
AD  - Centre for Women's Health Research, Institute of Translational Medicine, 
      University of Liverpool, Crown Street, Liverpool, L8 7SS, UK.
FAU - Pirmohamed, Munir
AU  - Pirmohamed M
AD  - The Wolfson Centre for Personalised Medicine, Institute of Translational 
      Medicine, University of Liverpool, Brownlow Street, Liverpool, L69 3GL, UK.
FAU - Alfirevic, Ana
AU  - Alfirevic A
AD  - The Wolfson Centre for Personalised Medicine, Institute of Translational 
      Medicine, University of Liverpool, Brownlow Street, Liverpool, L69 3GL, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171003
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Cardiology/*statistics & numerical data
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Humans
MH  - *Medication Adherence
MH  - Obstetrics/*statistics & numerical data
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - Aspirin adherence
OT  - Aspirin effectiveness
OT  - Aspirin non-responsiveness
OT  - Obstetrics
OT  - Pregnancy
EDAT- 2017/10/13 06:00
MHDA- 2018/06/19 06:00
CRDT- 2017/10/13 06:00
PHST- 2017/07/13 00:00 [received]
PHST- 2017/09/28 00:00 [revised]
PHST- 2017/10/02 00:00 [accepted]
PHST- 2017/10/13 06:00 [pubmed]
PHST- 2018/06/19 06:00 [medline]
PHST- 2017/10/13 06:00 [entrez]
AID - S0301-2115(17)30464-5 [pii]
AID - 10.1016/j.ejogrb.2017.10.004 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2017 Dec;219:1-9. doi: 
      10.1016/j.ejogrb.2017.10.004. Epub 2017 Oct 3.

PMID- 36169125
OWN - NLM
STAT- MEDLINE
DCOM- 20220929
LR  - 20221011
IS  - 1972-6481 (Electronic)
IS  - 1827-6806 (Linking)
VI  - 23
IP  - 10
DP  - 2022 Oct
TI  - [Aspirin in primary cardiovascular prevention - a 2022 update].
PG  - 746-760
LID - 10.1714/3881.38640 [doi]
AB  - In the context of secondary prevention, the efficacy of aspirin in reducing 
      cardiovascular events is widely acknowledged. However, its use for primary 
      prevention is still debated because of uncertain data regarding the risk-benefit 
      ratio. Despite the reduction in atherothrombotic events, almost all randomized 
      clinical trials and meta-analyses have failed to demonstrate a net clinical 
      benefit, as cardiovascular outcome improvement was counterbalanced by increased 
      bleeding. We have, however, to acknowledge that, within the population eligible 
      for primary prevention, cardiovascular risk distribution is extremely 
      heterogeneous. Using data obtained from the most recent trials, we performed a 
      meta-regression of benefits and risks associated with aspirin related to 10-year 
      risk of major adverse cardiovascular events (MACEs). We are thus proposing a 
      tailored approach to find the proper patient category to treat with aspirin in 
      primary prevention. In patients <70 years old with an optimal control of 
      cardiovascular risk factors, physicians should carefully evaluate individual MACE 
      risk and make a therapeutic decision accordingly, also considering bleeding risk 
      and patient preference. The results of net clinical benefit analysis of aspirin 
      therapy suggest that patients with intermediate-high cardiovascular risk (10-year 
      MACE risk >10%) without a prohibitive bleeding risk may represent the target 
      population, since in these patients the reduction in atherothrombotic events 
      overcomes the induced excess of bleeding. Antiplatelet therapy benefits also 
      appear to be amplified by the simultaneous administration of gastroprotective 
      agents and treatment of other cardiovascular risk factors, such as dyslipidemia 
      and hypertension.
FAU - Michelotti, Erica
AU  - Michelotti E
AD  - Cardiologia Universitaria, Dipartimento Cardio-Toraco-Vascolare, Azienda 
      Ospedaliero-Universitaria Pisana, Pisa.
FAU - Negro, Francesco
AU  - Negro F
AD  - Cardiologia Universitaria, Dipartimento Cardio-Toraco-Vascolare, Azienda 
      Ospedaliero-Universitaria Pisana, Pisa.
FAU - Morganti, Riccardo
AU  - Morganti R
AD  - Sezione Operativa Dipartimentale di Supporto Statistico, Azienda 
      Ospedaliero-Universitaria Pisana, Pisa.
FAU - De Caterina, Raffaele
AU  - De Caterina R
AD  - Cardiologia Universitaria, Dipartimento Cardio-Toraco-Vascolare, Azienda 
      Ospedaliero-Universitaria Pisana, Pisa.
LA  - ita
PT  - Journal Article
PT  - Meta-Analysis
TT  - L’aspirina in prevenzione cardiovascolare primaria – un aggiornamento al 2022.
PL  - Italy
TA  - G Ital Cardiol (Rome)
JT  - Giornale italiano di cardiologia (2006)
JID - 101263411
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Aspirin/adverse effects
MH  - *Cardiovascular Diseases/chemically induced/prevention & control
MH  - Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors
MH  - Primary Prevention/methods
MH  - Risk Assessment
EDAT- 2022/09/29 06:00
MHDA- 2022/09/30 06:00
CRDT- 2022/09/28 06:53
PHST- 2022/09/28 06:53 [entrez]
PHST- 2022/09/29 06:00 [pubmed]
PHST- 2022/09/30 06:00 [medline]
AID - 10.1714/3881.38640 [doi]
PST - ppublish
SO  - G Ital Cardiol (Rome). 2022 Oct;23(10):746-760. doi: 10.1714/3881.38640.

PMID- 9822061
OWN - NLM
STAT- MEDLINE
DCOM- 19981208
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 114
IP  - 5 Suppl
DP  - 1998 Nov
TI  - Use of antithrombotic agents during pregnancy.
PG  - 524S-530S
AB  - Anticoagulant therapy is indicated during pregnancy for the prevention and 
      treatment of VTE, for the prevention and treatment of systemic embolism in 
      patients with mechanical heart valves, and, in combination with aspirin, for the 
      prevention of pregnancy loss in women with APLA and previous pregnancy losses. 
      Several questions concerning anticoagulant therapy remain unanswered. Oral 
      anticoagulants are fetopathic, but the true risks of the warfarin embryopathy and 
      CNS abnormalities are unknown. There is some evidence that warfarin embryopathy 
      occurs only when oral anticoagulants are administered between the 6th and the 
      12th weeks of gestation and that oral anticoagulants may not be fetopathic when 
      administered in the first 6 weeks of gestation. Oral anticoagulant therapy should 
      be avoided in the weeks before delivery because of the risk of serious perinatal 
      bleeding caused by the trauma of delivery to the anticoagulated fetus. The safety 
      of aspirin during the first trimester of pregnancy is still a subject of debate. 
      There is a concern about the efficacy of unfractionated heparin in the prevention 
      of arterial embolism in pregnant women with mechanical heart valves. Finally, the 
      role of LMWH and heparinoids and appropriate dosing have still to be determined. 
      Because it is safe for the fetus, heparin is the anticoagulant of choice during 
      pregnancy for situations in which its efficacy is established. The evidence for 
      the efficacy of heparin for the prevention and treatment of VTE disorders during 
      pregnancy is based on level IV studies. There is some doubt that heparin is 
      effective for the prevention of systemic embolism in patients with mechanical 
      heart valves. Low doses of heparin or poorly controlled heparin therapy are not 
      effective in preventing systemic embolism in patients with mechanical heart 
      valves.
FAU - Ginsberg, J S
AU  - Ginsberg JS
AD  - McMaster University Medical Centre, Hamilton, ON, Canada.
FAU - Hirsh, J
AU  - Hirsh J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Antibodies, Antiphospholipid/analysis
MH  - Aspirin/adverse effects/therapeutic use
MH  - Female
MH  - Fetus/drug effects
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heart Valve Prosthesis Implantation/adverse effects
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*drug therapy/*prevention & control
MH  - Thromboembolism/drug therapy/etiology/prevention & control
MH  - Warfarin/adverse effects/therapeutic use
RF  - 57
EDAT- 1998/11/20 00:00
MHDA- 1998/11/20 00:01
CRDT- 1998/11/20 00:00
PHST- 1998/11/20 00:00 [pubmed]
PHST- 1998/11/20 00:01 [medline]
PHST- 1998/11/20 00:00 [entrez]
AID - S0012-3692(16)32959-2 [pii]
AID - 10.1378/chest.114.5_supplement.524s [doi]
PST - ppublish
SO  - Chest. 1998 Nov;114(5 Suppl):524S-530S. doi: 10.1378/chest.114.5_supplement.524s.

PMID- 30359352
OWN - NLM
STAT- MEDLINE
DCOM- 20190624
LR  - 20190624
IS  - 1175-8716 (Electronic)
IS  - 0028-8446 (Linking)
VI  - 131
IP  - 1484
DP  - 2018 Oct 26
TI  - Are the benefits of aspirin likely to exceed the risk of major bleeds among 
      people in whom aspirin is recommended for the primary prevention of 
      cardiovascular disease?
PG  - 19-25
AB  - AIM: The 2018 New Zealand Consensus Statement on cardiovascular disease (CVD) 
      risk assessment and management recommends the use of aspirin in people aged less 
      than 70 years with a five-year CVD risk >15% but without prior CVD. We determined 
      whether the estimated number of CVD events avoided by taking aspirin is likely to 
      exceed the number of additional major bleeds caused by aspirin in this patient 
      population. METHOD: Major bleeding rates were obtained from the PREDICT primary 
      care study, a large New Zealand cohort of people eligible for CVD risk 
      assessment, after excluding those with no other indications for (eg, established 
      CVD) or contraindications/cautions (eg, prior major bleed) to aspirin use. We 
      modelled the benefits (CVD events avoided) and harms (additional major bleeds) of 
      aspirin for primary prevention of CVD over five years using hypothetical 
      populations aged 40 to 79 years, stratified by sex, age-group and estimated 
      five-year CVD risk. Two clinical scenarios were modelled, according to whether or 
      not optimisation of lipid- and blood pressure-lowering therapy was required prior 
      to aspirin initiation. RESULTS: In both clinical scenarios the number of CVD 
      events prevented by aspirin over five years was estimated to be, on average, more 
      than the number of bleeds caused by aspirin among people aged less than 70 years 
      with estimated five-year CVD risk of >15%. However, the magnitude of the net 
      benefit of aspirin was modest among people aged 60-69 years, particularly if 
      lipid- and blood pressure-lowering therapy had not already been optimised. 
      CONCLUSION: The benefits of aspirin are likely to exceed the risk of major bleeds 
      among people in whom aspirin is recommended for the primary prevention of CVD. A 
      more cautious approach to the use of aspirin is appropriate for people aged 60-69 
      years who are likely to have a smaller net benefit from aspirin, particularly 
      those in whom lipid- and blood pressure-lowering therapy has not already been 
      optimised or who have other bleeding risk factors, such as diabetes or smoking. 
      More specific recommendations will be possible when bleeding risk equations are 
      developed to complement the recently developed New Zealand CVD risk equations.
FAU - Selak, Vanessa
AU  - Selak V
AD  - Senior Lecturer, Epidemiology & Biostatistics, University of Auckland, Auckland.
FAU - Jackson, Rod
AU  - Jackson R
AD  - Professor, Epidemiology & Biostatistics, University of Auckland, Auckland.
FAU - Poppe, Katrina
AU  - Poppe K
AD  - Senior Research Fellow, Epidemiology & Biostatistics, University of Auckland, 
      Auckland.
FAU - Kerr, Andrew
AU  - Kerr A
AD  - Associate Professor, Epidemiology & Biostatistics, University of Auckland, 
      Auckland; Cardiologist, Middlemore Hospital, Auckland.
FAU - Wells, Sue
AU  - Wells S
AD  - Associate Professor, Epidemiology & Biostatistics, University of Auckland, 
      Auckland.
LA  - eng
PT  - Journal Article
DEP - 20181026
PL  - New Zealand
TA  - N Z Med J
JT  - The New Zealand medical journal
JID - 0401067
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Hypolipidemic Agents/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - New Zealand
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Primary Prevention
MH  - Risk Assessment
COIS- This research was funded by a project grant (15/165) from the Health Research 
      Council of New Zealand (HRC). RJ, KP, AK and SW are receiving funding from the 
      HRC for a programme and project grants for CVD research. KP is the recipient of a 
      National Heart Foundation of New Zealand Hynds Senior Fellowship. SW is the 
      recipient of a Fellowship in Health Innovation and Quality Improvement, funded by 
      the Stevenson Foundation. SW and KP have received funding from the Heart 
      Foundation of New Zealand (project grant for quality improvement and structural 
      heart disease, respectively) and SW from Roche Diagnostics Ltd (project grant for 
      point of care testing trial).
EDAT- 2018/10/26 06:00
MHDA- 2019/06/25 06:00
CRDT- 2018/10/26 06:00
PHST- 2018/10/26 06:00 [entrez]
PHST- 2018/10/26 06:00 [pubmed]
PHST- 2019/06/25 06:00 [medline]
PST - epublish
SO  - N Z Med J. 2018 Oct 26;131(1484):19-25.

PMID- 25860557
OWN - NLM
STAT- MEDLINE
DCOM- 20160226
LR  - 20221207
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 29
IP  - 2
DP  - 2015 Apr
TI  - Correlation Between SNPs in Candidate Genes and VerifyNow-Detected Platelet 
      Responsiveness to Aspirin and Clopidogrel Treatment.
PG  - 137-46
LID - 10.1007/s10557-015-6585-6 [doi]
AB  - PURPOSE: Patients with high on-treatment platelet reactivity (HPR) against 
      aspirin or clopidogrel are at increased risk for adverse cardiovascular events. 
      In this study, we explored the predictive value of common SNPs for the 
      on-treatment platelet reactivity (OPR) against aspirin and clopidogrel assessed 
      by VerifyNow assays. METHODS: This study recruited 286 Han Chinese individuals 
      undergoing antiplatelet treatment, including 159 cases with aspirin only (100 
      mg/day) and 127 cases with dual therapy (aspirin 100 mg/day plus clopidogrel 75 
      mg/day) for at least 2 weeks. The OPR against aspirin and clopidogrel were 
      assessed by VerifyNow Aspirin (ARU) and P2Y12 assays (PRU), respectively. 
      Genotyping for the selected 25 SNPs within 11 genes and 2 GWAS loci was carried 
      out by ABI multiplex SNaPshot method. RESULTS: The results indicated that 
      rs4244285 (CYP2C19) and rs342293 (7q22.3) were significantly associated with PRU 
      value (both P < 0.01). As for the OPR to aspirin, a weak statistical significance 
      was observed in rs5445 (GNB3) (P = 0.049) and rs5758 (TBXA2R) (P = 0.045). After 
      adjusting for the covariates including gender, age and smoking, carriers of 
      allele A of rs4244285 remained as a strong predictor for HPR against clopidogrel. 
      CONCLUSION: The current study suggests that common SNPs may predict OPR against 
      clopidogrel as assessed by VerifyNow P2Y12, but are less likely to respond 
      against aspirin as assessed by VerifyNow Aspirin.
FAU - Cui, Hanbin
AU  - Cui H
AD  - Cardiology Center, Ningbo First Hospital, Ningbo University, Ningbo, 315010, 
      People's Republic of China, hanbincui@hotmail.com.
FAU - Lin, Shaoyi
AU  - Lin S
FAU - Chen, Xiaomin
AU  - Chen X
FAU - Gao, Wenhui
AU  - Gao W
FAU - Li, Xiaojing
AU  - Li X
FAU - Zhou, Honglin
AU  - Zhou H
FAU - Du, Weiping
AU  - Du W
FAU - Wang, Shenghuang
AU  - Wang S
FAU - Zhao, Ruochi
AU  - Zhao R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Asian People/genetics
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Clopidogrel
MH  - Cytochrome P-450 CYP2C19/*genetics
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects/*genetics
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - *Polymorphism, Single Nucleotide
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
EDAT- 2015/04/11 06:00
MHDA- 2016/02/27 06:00
CRDT- 2015/04/11 06:00
PHST- 2015/04/11 06:00 [entrez]
PHST- 2015/04/11 06:00 [pubmed]
PHST- 2016/02/27 06:00 [medline]
AID - 10.1007/s10557-015-6585-6 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2015 Apr;29(2):137-46. doi: 10.1007/s10557-015-6585-6.

PMID- 25281703
OWN - NLM
STAT- MEDLINE
DCOM- 20150219
LR  - 20220318
IS  - 1530-8561 (Electronic)
IS  - 0009-9147 (Linking)
VI  - 60
IP  - 12
DP  - 2014 Dec
TI  - Precision and reliability of 5 platelet function tests in healthy volunteers and 
      donors on daily antiplatelet agent therapy.
PG  - 1524-31
LID - 10.1373/clinchem.2014.226332 [doi]
AB  - BACKGROUND: Anticoagulation protocols used during mechanical circulatory support 
      call for titration of antiplatelet agents. We compared the precision and 
      reliability of 5 platelet function tests in healthy volunteers and donors on 
      daily antiplatelet therapy to distinguish their efficacy for titrating 
      antiplatelet therapy. METHODS: We assessed arachidonic acid-induced platelet 
      function by light transmission aggregometry (LTA), Multiplate impedance 
      aggregometry, VerifyNow, and platelet mapping by thromboelastography (TEG PM). We 
      assessed ADP-induced platelet function by the same methods and flow cytometry. 
      Forty healthy volunteers and 10-13 volunteers on daily aspirin and/or clopidogrel 
      therapy were evaluated. We compared tests for intraassay precision, interassay 
      precision (samples from 2 separate blood draws), and reliability coefficient. 
      RESULTS: For arachidonic acid-induced platelet aggregation in healthy volunteers, 
      intra- and interassay CVs were ≤ 10% for all methods. Intra- and interassay 
      precision among donors on daily aspirin was ≤ 30% for all methods except LTA (38% 
      interassay CV) and TEG PM (95% intraassay and 104% interassay CV). For 
      ADP-induced platelet function, intra- and interassay precision was ≤ 10% and ≤ 
      30% for all methods. Only Multiplate demonstrated moderate or greater (R > 0.40) 
      reliability coefficients for arachidonic acid-induced platelet function among all 
      subjects. All methods of ADP-induced platelet function, except TEG PM, 
      demonstrated substantial or greater (R > 0.60) reliability among all subjects. 
      CONCLUSIONS: TEG PM is least suited to monitor effects of antiplatelet agents. 
      Multiplate impedance aggregometry was the only method to demonstrate an 
      acceptable reliability coefficient among healthy volunteers and donors on both 
      aspirin and clopidogrel therapy.
CI  - © 2014 American Association for Clinical Chemistry.
FAU - Karon, Brad S
AU  - Karon BS
AD  - Department of Laboratory Medicine and Pathology and karon.bradley@mayo.edu.
FAU - Tolan, Nicole V
AU  - Tolan NV
AD  - Current address: Department of Pathology, Beth Israel Deaconess Medical Center 
      and Harvard Medical School, Boston, MA.
FAU - Koch, Christopher D
AU  - Koch CD
AD  - Department of Laboratory Medicine and Pathology and.
FAU - Wockenfus, Amy M
AU  - Wockenfus AM
AD  - Department of Laboratory Medicine and Pathology and.
FAU - Miller, Randall S
AU  - Miller RS
AD  - Department of Laboratory Medicine and Pathology and.
FAU - Lingineni, Ravi K
AU  - Lingineni RK
AD  - Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN;
FAU - Pruthi, Rajiv K
AU  - Pruthi RK
AD  - Department of Laboratory Medicine and Pathology and.
FAU - Chen, Dong
AU  - Chen D
AD  - Department of Laboratory Medicine and Pathology and.
FAU - Jaffe, Allan S
AU  - Jaffe AS
AD  - Department of Laboratory Medicine and Pathology and.
LA  - eng
PT  - Journal Article
DEP - 20141003
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Clin Chem. 2014 Dec;60(12):1469-70. PMID: 25332313
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Function Tests/*standards
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
EDAT- 2014/10/05 06:00
MHDA- 2015/02/20 06:00
CRDT- 2014/10/05 06:00
PHST- 2014/10/05 06:00 [entrez]
PHST- 2014/10/05 06:00 [pubmed]
PHST- 2015/02/20 06:00 [medline]
AID - clinchem.2014.226332 [pii]
AID - 10.1373/clinchem.2014.226332 [doi]
PST - ppublish
SO  - Clin Chem. 2014 Dec;60(12):1524-31. doi: 10.1373/clinchem.2014.226332. Epub 2014 
      Oct 3.

PMID- 12542814
OWN - NLM
STAT- MEDLINE
DCOM- 20030523
LR  - 20190910
IS  - 1034-4810 (Print)
IS  - 1034-4810 (Linking)
VI  - 39
IP  - 1
DP  - 2003 Jan-Feb
TI  - School-aged children with Kawasaki disease: high incidence of cervical 
      lymphadenopathy and coronary artery involvement.
PG  - 55-7
AB  - OBJECTIVE: We describe 10 school-aged children with Kawasaki disease (KD) with a 
      high incidence of cervical lymphadenopathy and coronary abnormality. METHODS: 
      Based on a database of 1002 children with KD in Chang Gung Children's Hospital 
      from January 1983 to March 2001, 10 (1%) school-aged patients (five boys, five 
      girls) who met the diagnostic criteria of KD were included for analysis. RESULTS: 
      Cervical lymphadenopathy was noted in all (100%) of these patients. Unilateral 
      neck mass mimicking acute suppurative infections not responding to antibiotic 
      therapy was the initial presentation in nine (90%) of the 10 patients. The mean 
      interval between disease onset and diagnosis was 9.9 +/- 3.3 days (range, 6-15 
      days). Seven (70%) of these patients responded to one course of high-dose 
      intravenous immunoglobulin (IVIG) therapy (2 g/kg) and oral aspirin (80-100 mg/kg 
      per day), two (20%) required a second course of IVIG, and one (10%) responded to 
      high-dose aspirin treatment only. Coronary artery abnormality (dilatation or 
      aneurysm) was documented by echocardiography in seven (70%) patients (four boys, 
      three girls). In six patients, the coronary artery abnormalities resolved in 1 
      year, while one patient had persistent right coronary artery aneurysm, which 
      necessitated continued anticoagulant and low-dose aspirin therapy. CONCLUSION: 
      The incidence of school-aged children among patients with KD is about 1% in our 
      hospital. These patients are notable for the high incidence of initial 
      manifestations of unilateral neck mass and coronary artery involvement. This 
      disease should be listed as the differential diagnosis in school-aged children 
      presenting with fever and neck mass that do not respond to antibiotic therapy.
FAU - Fan, P C
AU  - Fan PC
AD  - Department of Paediatrics (Taoyuan), Chang Gung Children's Hospital, Taiwan, ROC.
FAU - Chiu, C H
AU  - Chiu CH
FAU - Yen, M H
AU  - Yen MH
FAU - Huang, Y C
AU  - Huang YC
FAU - Li, C C
AU  - Li CC
FAU - Lin, T Y
AU  - Lin TY
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Child
MH  - Coronary Vessel Anomalies/drug therapy/*epidemiology
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Incidence
MH  - Lymphatic Diseases/drug therapy/*epidemiology
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/drug therapy/*epidemiology/physiopathology
MH  - Neck/pathology
MH  - Taiwan/epidemiology
EDAT- 2003/01/25 04:00
MHDA- 2003/05/24 05:00
CRDT- 2003/01/25 04:00
PHST- 2003/01/25 04:00 [pubmed]
PHST- 2003/05/24 05:00 [medline]
PHST- 2003/01/25 04:00 [entrez]
AID - 085 [pii]
AID - 10.1046/j.1440-1754.2003.00085.x [doi]
PST - ppublish
SO  - J Paediatr Child Health. 2003 Jan-Feb;39(1):55-7. doi: 
      10.1046/j.1440-1754.2003.00085.x.

PMID- 18193919
OWN - NLM
STAT- MEDLINE
DCOM- 20080505
LR  - 20181113
IS  - 0312-5963 (Print)
IS  - 0312-5963 (Linking)
VI  - 47
IP  - 2
DP  - 2008
TI  - Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition 
      of platelet aggregation in healthy subjects.
PG  - 129-37
AB  - OBJECTIVE: The objective of this study was to develop a mechanism-based 
      pharmacodynamic model that characterizes the antiplatelet effects of aspirin 
      (acetylsalicylic acid) and ibuprofen alone and in combination. METHODS: Ten 
      healthy volunteers were enrolled in a single-blinded, randomized, three-way 
      crossover study. Treatments consisted of single doses of oral aspirin (325 mg) 
      and ibuprofen (400 mg) and concomitant administration of aspirin (325 mg) and 
      ibuprofen (400 mg). Ex vivo whole blood platelet aggregation induced by collagen 
      (1 microg/mL) or arachidonic acid (0.5 mmol/L) was measured by impedance 
      aggregometry. Model development and population parameter estimation were 
      performed using nonlinear mixed-effects modelling implemented in NONMEM. RESULTS: 
      Relatively complete inhibition of platelet aggregation was achieved following 
      aspirin treatment (approximately 77% inhibition within 2 hours), and return to 
      baseline values occurred within 72-96 hours after dosing. In contrast, treatment 
      with ibuprofen alone or in combination with aspirin produced transient inhibition 
      of platelet aggregation, with complete recovery observed in 6-8 hours. The final 
      pharmacodynamic model was based on the turnover of cyclo-oxygenase-1 (COX-1) 
      enzyme, and incorporated irreversible inhibition by aspirin and reversible 
      binding and antiplatelet effects of ibuprofen. The temporal response profiles 
      from all three study arms were well described by the final model, and the 
      parameters were estimated with good precision. The apparent turnover rate 
      constant for COX-1 (kout) and the irreversible inhibition rate constant for 
      aspirin (K) were estimated to be 0.0209 h(-1) and 0.152 (mg/L)(-1).h(-1), with 
      interindividual variability of 30.6% and 26.2%, respectively. Simulations were 
      used to evaluate the influence of clinically relevant ibuprofen regimens on the 
      antiplatelet effect of aspirin, confirming clinical reports that the antiplatelet 
      effect of aspirin would be blocked when multiple daily doses of ibuprofen are 
      given, even if taken after aspirin administration. CONCLUSIONS: A mechanism-based 
      pharmacodynamic model has been developed that characterizes the antiplatelet 
      effects of aspirin and ibuprofen, alone and concomitantly, and predicts a 
      significant inhibition of aspirin antiplatelet effects in the presence of a 
      typical ibuprofen dosing regimen.
FAU - Hong, Ying
AU  - Hong Y
AD  - Department of Pharmaceutical Sciences, University at Buffalo, State University of 
      New York, Buffalo, New York 14260, USA.
FAU - Gengo, Fran M
AU  - Gengo FM
FAU - Rainka, Michelle M
AU  - Rainka MM
FAU - Bates, Vernice E
AU  - Bates VE
FAU - Mager, Donald E
AU  - Mager DE
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Clin Pharmacokinet
JT  - Clinical pharmacokinetics
JID - 7606849
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/blood/pharmacokinetics/*pharmacology
MH  - Collagen/pharmacology
MH  - Cross-Over Studies
MH  - Cyclooxygenase Inhibitors/administration & dosage/pharmacokinetics/pharmacology
MH  - Half-Life
MH  - Humans
MH  - Ibuprofen/blood/pharmacokinetics/*pharmacology
MH  - Middle Aged
MH  - Models, Biological
MH  - Monte Carlo Method
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & 
      dosage/pharmacokinetics/pharmacology
MH  - Single-Blind Method
MH  - Time Factors
EDAT- 2008/01/16 09:00
MHDA- 2008/05/06 09:00
CRDT- 2008/01/16 09:00
PHST- 2008/01/16 09:00 [pubmed]
PHST- 2008/05/06 09:00 [medline]
PHST- 2008/01/16 09:00 [entrez]
AID - 4726 [pii]
AID - 10.2165/00003088-200847020-00006 [doi]
PST - ppublish
SO  - Clin Pharmacokinet. 2008;47(2):129-37. doi: 10.2165/00003088-200847020-00006.

PMID- 26319435
OWN - NLM
STAT- MEDLINE
DCOM- 20160902
LR  - 20190309
IS  - 2213-2317 (Electronic)
IS  - 2213-2317 (Linking)
VI  - 6
DP  - 2015 Dec
TI  - Positional isomerism markedly affects the growth inhibition of colon cancer cells 
      by NOSH-aspirin: COX inhibition and modeling.
PG  - 318-325
LID - S2213-2317(15)00104-4 [pii]
LID - 10.1016/j.redox.2015.08.014 [doi]
AB  - We recently reported the synthesis of NOSH-aspirin, a novel hybrid that releases 
      both nitric oxide (NO) and hydrogen sulfide (H2S). In NOSH-aspirin, the two 
      moieties that release NO and H2S are covalently linked at the 1, 2 positions of 
      acetyl salicylic acid, i.e. ortho-NOSH-aspirin (o-NOSH-aspirin). In the present 
      study, we compared the effects of the positional isomers of NOSH-ASA 
      (o-NOSH-aspirin, m-NOSH-aspirin and p-NOSH-aspirin) to that of aspirin on growth 
      of HT-29 and HCT 15 colon cancer cells, belonging to the same histological 
      subtype, but with different expression of cyclooxygenase (COX) enzymes; HT-29 
      express both COX-1 and COX-2, whereas HCT 15 is COX-null. We also analyzed the 
      effect of these compounds on proliferation and apoptosis in HT-29 cells. Since 
      the parent compound aspirin, inhibits both COX-1 and COX-2, we also evaluated the 
      effects of these compounds on COX-1 and COX-2 enzyme activities and also 
      performed modeling of the interactions between the positional isomers of 
      NOSH-aspirin and COX-1 and COX-2 enzymes. We observed that the three positional 
      isomers of NOSH aspirin inhibited the growth of both colon cancer cell lines with 
      IC50s in the nano-molar range. In particular in HT-29 cells the IC50s for growth 
      inhibition were: o-NOSH-ASA, 0.04±0.011 µM; m-NOSH-ASA, 0.24±0.11 µM; p-NOSH-ASA, 
      0.46±0.17 µM; and in HCT 15 cells the IC50s for o-NOSH-ASA, m-NOSH-ASA, and 
      p-NOSH-ASA were 0.062 ±0.006 µM, 0.092±0.004 µM, and 0.37±0.04 µM, respectively. 
      The IC50 for aspirin in both cell lines was >5mM at 24h. The reduction of cell 
      growth appeared to be mediated through inhibition of proliferation, and induction 
      of apoptosis. All 3 positional isomers of NOSH-aspirin preferentially inhibited 
      COX-1 over COX-2. These results suggest that the three positional isomers of 
      NOSH-aspirin have the same biological actions, but that o-NOSH-ASA displayed the 
      strongest anti-neoplastic potential.
CI  - Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Vannini, Federica
AU  - Vannini F
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, NY 
      10031, United States.
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, NY 
      10031, United States.
FAU - Kodela, Ravinder
AU  - Kodela R
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, NY 
      10031, United States.
FAU - Rao, Praveen P N
AU  - Rao PPN
AD  - School of Pharmacy Health Science Campus, University of Waterloo, Waterloo, 
      Ontario, Canada N2L 3G1.
FAU - Kashfi, Khosrow
AU  - Kashfi K
AD  - Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, NY 
      10031, United States; Avicenna Pharmaceuticals Inc., New York, NY 10019, United 
      States. Electronic address: kashfi@med.cuny.edu.
LA  - eng
GR  - R24DA018055/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150820
PL  - Netherlands
TA  - Redox Biol
JT  - Redox biology
JID - 101605639
RN  - 0 (4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoate)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Disulfides)
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/chemical synthesis/*chemistry/pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*analogs & derivatives/chemical synthesis/chemistry/pharmacology
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cyclooxygenase 1/*chemistry/genetics/metabolism
MH  - Cyclooxygenase 2/*chemistry/genetics/metabolism
MH  - Cyclooxygenase Inhibitors/chemical synthesis/*chemistry/pharmacology
MH  - Disulfides/chemical synthesis/*chemistry/pharmacology
MH  - Gene Expression
MH  - HT29 Cells
MH  - Humans
MH  - Hydrogen Sulfide/chemistry/metabolism
MH  - Inhibitory Concentration 50
MH  - Molecular Docking Simulation
MH  - Nitrates/chemical synthesis/*chemistry/pharmacology
MH  - Nitric Oxide/chemistry/metabolism
MH  - Nitric Oxide Donors/chemical synthesis/*chemistry/pharmacology
MH  - Sheep
MH  - Stereoisomerism
MH  - Structure-Activity Relationship
PMC - PMC4556775
OTO - NOTNLM
OT  - Aspirin
OT  - Colon cancer
OT  - Cyclooxygenase
OT  - Hydrogen sulfide
OT  - Molecular docking
OT  - NSAIDs
OT  - Nitric oxide
EDAT- 2015/09/01 06:00
MHDA- 2016/09/03 06:00
CRDT- 2015/08/31 06:00
PHST- 2015/06/28 00:00 [received]
PHST- 2015/08/14 00:00 [revised]
PHST- 2015/08/17 00:00 [accepted]
PHST- 2015/08/31 06:00 [entrez]
PHST- 2015/09/01 06:00 [pubmed]
PHST- 2016/09/03 06:00 [medline]
AID - S2213-2317(15)00104-4 [pii]
AID - 10.1016/j.redox.2015.08.014 [doi]
PST - ppublish
SO  - Redox Biol. 2015 Dec;6:318-325. doi: 10.1016/j.redox.2015.08.014. Epub 2015 Aug 
      20.

PMID- 24285345
OWN - NLM
STAT- MEDLINE
DCOM- 20140602
LR  - 20160303
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 135
IP  - 1
DP  - 2014 Jul 1
TI  - Incident cancer risk after the start of aspirin use: results from a Dutch 
      population-based cohort study of low dose aspirin users.
PG  - 157-65
LID - 10.1002/ijc.28634 [doi]
AB  - Observational and intervention studies suggest that low dose aspirin use may 
      prevent cancer. The objective of this study was to investigate the protective 
      effect of long term low dose aspirin use (≤100 mg daily) on cancer in general and 
      site-specific cancer among low dose aspirin users in the Dutch general 
      population. We conducted a population-based cohort study with detailed 
      information on aspirin exposure and cancer incidence. Only incident (new) low 
      dose aspirin users, who were included in the linkage between PHARMO and the 
      Eindhoven Cancer Registry (1998-2010) and free of cancer before the start of 
      follow up were included. A Cox proportional hazard model with cumulative aspirin 
      use as a time-varying determinant was used to obtain hazard ratios (HR). Duration 
      of aspirin use amongst 109,276 incident low dose aspirin users was not associated 
      with a decreased risk of any of the site-specific cancers or cancer in general 
      (adjusted HR per year of aspirin use for all cancers: 1.02, 95% confidence 
      interval [CI] 1.00-1.04, HR of >6 years aspirin use compared to <2 years: 1.17, 
      95% CI 1.02-1.34). After adjusting for current and past aspirin use, 2-6 years of 
      low dose aspirin use was associated with a reduced colorectal cancer risk 
      compared to <2 years of aspirin use (adjusted HR 0.75, 95% CI 0.59-0.96). 
      However, a clear dose-response relationship was not observed (adjusted HR >6 
      years aspirin use 0.95, 95% CI 0.60-1.49). Our results do not support the primary 
      prevention of cancer among long term aspirin users.
CI  - © 2013 UICC.
FAU - Hollestein, Loes M
AU  - Hollestein LM
AD  - Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The 
      Netherlands.
FAU - van Herk-Sukel, Myrthe P P
AU  - van Herk-Sukel MP
FAU - Ruiter, Rikje
AU  - Ruiter R
FAU - de Vries, Esther
AU  - de Vries E
FAU - Mathijssen, Ron H J
AU  - Mathijssen RH
FAU - Wiemer, Erik A C
AU  - Wiemer EA
FAU - Stijnen, Theo
AU  - Stijnen T
FAU - Coebergh, Jan-Willem W
AU  - Coebergh JW
FAU - Lemmens, Valery E P P
AU  - Lemmens VE
FAU - Herings, Ron M C
AU  - Herings RM
FAU - Stricker, Bruno H C
AU  - Stricker BH
FAU - Nijsten, Tamar
AU  - Nijsten T
LA  - eng
PT  - Journal Article
DEP - 20131209
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*drug therapy/epidemiology/pathology
MH  - Proportional Hazards Models
MH  - Risk Factors
OTO - NOTNLM
OT  - aspirin
OT  - cancer
OT  - chemoprevention
OT  - epidemiology
OT  - population-based
EDAT- 2013/11/29 06:00
MHDA- 2014/06/03 06:00
CRDT- 2013/11/29 06:00
PHST- 2013/08/15 00:00 [received]
PHST- 2013/10/31 00:00 [revised]
PHST- 2013/11/04 00:00 [accepted]
PHST- 2013/11/29 06:00 [entrez]
PHST- 2013/11/29 06:00 [pubmed]
PHST- 2014/06/03 06:00 [medline]
AID - 10.1002/ijc.28634 [doi]
PST - ppublish
SO  - Int J Cancer. 2014 Jul 1;135(1):157-65. doi: 10.1002/ijc.28634. Epub 2013 Dec 9.

PMID- 373084
OWN - NLM
STAT- MEDLINE
DCOM- 19790626
LR  - 20131121
IS  - 0301-3847 (Print)
IS  - 0301-3847 (Linking)
IP  - 24
DP  - 1979
TI  - A comparative, double-blind study on tolfenamic acid in the treatment of 
      rheumatoid arthritis.
PG  - 13-6
AB  - Sixty patients with diagnosed rheumatoid arthritis were treated at random with 
      tolfenamic acid, a new nonsteroid anti-inflammatory analgesic, in a daily dose of 
      600 mg, or with phenylbutazone 300 mg or acetylsalicylic acid 1,500 mg daily. 
      Both the patients and the physician found that tolfenamic acid had a clearly 
      better effect than phenylbutazone or the low-dose acetylsalicylic acid used as a 
      control. Tolfenamic acid and acetylsalicylic acid were well tolerated. Serious 
      side-effects (leukopenia and thrombocytopenia in one case, hematemesis and melena 
      in another) only occurred in those patients who received phenylbutazone.
FAU - Rejholec, V
AU  - Rejholec V
FAU - Vapaatalo, H
AU  - Vapaatalo H
FAU - Tokola, O
AU  - Tokola O
FAU - Gothoni, G
AU  - Gothoni G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Norway
TA  - Scand J Rheumatol Suppl
JT  - Scandinavian journal of rheumatology. Supplement
JID - 0400360
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (ortho-Aminobenzoates)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenylbutazone/administration & dosage/adverse effects/therapeutic use
MH  - ortho-Aminobenzoates/administration & dosage/adverse effects/*therapeutic use
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Rheumatol Suppl. 1979;(24):13-6.

PMID- 35198081
OWN - NLM
STAT- MEDLINE
DCOM- 20220421
LR  - 20230110
IS  - 1838-7640 (Electronic)
IS  - 1838-7640 (Linking)
VI  - 12
IP  - 4
DP  - 2022
TI  - Unlabeled aspirin as an activatable theranostic MRI agent for breast cancer.
PG  - 1937-1951
LID - 10.7150/thno.53147 [doi]
AB  - Rationale: Chemical exchange saturation transfer (CEST) magnetic resonance 
      imaging (MRI) is emerging as an alternative to gadolinium-based contrast MRI. We 
      have evaluated the possibility of CEST MRI of orthotopic breast tumor xenografts 
      with unlabeled aspirin's conversion to salicylic acid (SA) through various 
      enzymatic activities, most notably inhibition of cyclooxygenase (COX)-1/-2 
      enzymes. Methods: We measured the COX-1/-2 expression in four breast cancer cell 
      lines by Western Blot analysis and selected the highest and lowest expressing 
      cell lines. We then performed CEST MRI following aspirin treatment to detect SA 
      levels and ELISA to measure levels of downstream prostaglandin E2 (PGE2). We also 
      injected aspirin into the tail vein of mice growing orthotopic tumor xenografts 
      which expressed high and low COX-1/-2 and acquired SA CEST MR images of these 
      tumor xenografts for up to 70 minutes. Tumors were then harvested to perform 
      Western Blot and ELISA experiments to measure COX-1/-2 expression and PGE2 
      levels, respectively. Results: Western Blots determined that SUM159 cells 
      contained significantly higher COX-1/-2 expression levels than MDA-MB-231 cells, 
      in line with higher levels of downstream PGE2. SA CEST MRI yielded similar 
      contrast at approximately 3% for both cell lines, independent of COX-1/-2 
      expression level. PGE2 levels decreased by about 50% following aspirin treatment. 
      Results from our mouse study aligned with cultured cells, the overall SA CEST MRI 
      contrast in both MDA-MB-231 and SUM159 tumor xenograft models was 5~8% at one 
      hour post injection. PGE2 levels were ten times higher in SUM159 than MDA-MB-231 
      and decreased by 50%. The CEST contrast directly depended on the injected dose, 
      with ~6%, ~3% and ~1.5% contrast observed following injection of 100 µL of 300 
      mM, 200 mM and 150 mM aspirin, respectively. Conclusions: Our data demonstrate 
      the feasibility of using aspirin as a noninvasive activatable CEST MRI contrast 
      agent for breast tumor detection.
CI  - © The author(s).
FAU - Pavuluri, KowsalyaDevi
AU  - Pavuluri K
AD  - Division of MR Research, The Russell H. Morgan Department of Radiology and 
      Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, 
      MD.
FAU - Yang, Ethan
AU  - Yang E
AD  - Division of Cancer Imaging Research, The Russell H. Morgan Department of 
      Radiology and Radiological Science; The Johns Hopkins University School of 
      Medicine, Baltimore, MD.
FAU - Ayyappan, Vinay
AU  - Ayyappan V
AD  - Division of Cancer Imaging Research, The Russell H. Morgan Department of 
      Radiology and Radiological Science; The Johns Hopkins University School of 
      Medicine, Baltimore, MD.
FAU - Sonkar, Kanchan
AU  - Sonkar K
AD  - Division of Cancer Imaging Research, The Russell H. Morgan Department of 
      Radiology and Radiological Science; The Johns Hopkins University School of 
      Medicine, Baltimore, MD.
FAU - Tan, Zheqiong
AU  - Tan Z
AD  - Division of Cancer Imaging Research, The Russell H. Morgan Department of 
      Radiology and Radiological Science; The Johns Hopkins University School of 
      Medicine, Baltimore, MD.
AD  - Department of Medical Laboratory, The Central Hospital of Wuhan, Tongji Medical 
      College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
FAU - Tressler, Caitlin M
AU  - Tressler CM
AD  - Division of Cancer Imaging Research, The Russell H. Morgan Department of 
      Radiology and Radiological Science; The Johns Hopkins University School of 
      Medicine, Baltimore, MD.
FAU - Bo, Shaowei
AU  - Bo S
AD  - Division of MR Research, The Russell H. Morgan Department of Radiology and 
      Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, 
      MD.
FAU - Bibic, Adnan
AU  - Bibic A
AD  - F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger 
      Institute, Baltimore, MD.
FAU - Glunde, Kristine
AU  - Glunde K
AD  - Division of Cancer Imaging Research, The Russell H. Morgan Department of 
      Radiology and Radiological Science; The Johns Hopkins University School of 
      Medicine, Baltimore, MD.
AD  - The Department of Biological Chemistry, The Johns Hopkins University School of 
      Medicine, Baltimore, MD.
AD  - Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of 
      Medicine, Baltimore, MD.
FAU - McMahon, Michael T
AU  - McMahon MT
AD  - Division of MR Research, The Russell H. Morgan Department of Radiology and 
      Radiological Science; The Johns Hopkins University School of Medicine, Baltimore, 
      MD.
AD  - F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger 
      Institute, Baltimore, MD.
LA  - eng
GR  - R01 CA213428/CA/NCI NIH HHS/United States
GR  - R01 CA213492/CA/NCI NIH HHS/United States
GR  - R01 CA264901/CA/NCI NIH HHS/United States
GR  - P41 EB024495/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20220124
PL  - Australia
TA  - Theranostics
JT  - Theranostics
JID - 101552395
RN  - 0 (Contrast Media)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin
MH  - *Breast Neoplasms/diagnostic imaging/drug therapy
MH  - Contrast Media
MH  - Dinoprostone
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging/methods
MH  - Mice
MH  - Theranostic Nanomedicine
PMC - PMC8825591
OTO - NOTNLM
OT  - CEST
OT  - MRI
OT  - aspirin
OT  - breast cancer
OT  - gadolinium
OT  - salicylic acid
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2022/02/25 06:00
MHDA- 2022/04/22 06:00
CRDT- 2022/02/24 05:42
PHST- 2020/09/11 00:00 [received]
PHST- 2021/11/17 00:00 [accepted]
PHST- 2022/02/24 05:42 [entrez]
PHST- 2022/02/25 06:00 [pubmed]
PHST- 2022/04/22 06:00 [medline]
AID - thnov12p1937 [pii]
AID - 10.7150/thno.53147 [doi]
PST - epublish
SO  - Theranostics. 2022 Jan 24;12(4):1937-1951. doi: 10.7150/thno.53147. eCollection 
      2022.

PMID- 32615977
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 2662-7671 (Electronic)
IS  - 2662-7671 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 2
TI  - Synergistic platelet inhibition between Omega-3 and acetylsalicylic acid dose 
      titration; an observational study.
PG  - 204
LID - 10.1186/s12906-020-02990-9 [doi]
LID - 204
AB  - BACKGROUND: Omega-3 and acetylsalicylic acid (ASA) are two widely used 
      "over-the-counter" drugs. Previous research has shown multiple electrode 
      aggregometry (MEA) can detect ASA and varying Omega-3 platelet inhibiting 
      effects. Synergistic platelet inhibiting effects of ASA and Omega-3 have been 
      found using other methods than MEA. The aim of this study was to investigate the 
      antiplatelet effects of Omega-3, and ASA synergism with MEA. METHODS: Ten healthy 
      male volunteers ingested Omega-3 (1260 mg/day) for 5 days. MEA was used to 
      analyse platelet function before and after Omega-3 intake. Aggregation was 
      initiated using three different agonists and measured as area under the curve 
      (AUC): adenosine diphosphate (ADP), thrombin receptor activating peptide (TRAP) 
      and arachidonic acid (ASPI). Two concentrations of ASA were dose titrated ex vivo 
      to 2 out of 3 ASPI test cells in order to measure synergism between Omega-3 and 
      ASA. RESULTS: Following 5 days Omega-3 intake, ADP, TRAP and ASPI AUC did not 
      change significantly. In vitro ASA before Omega-3 intake, reduced ASPI AUC 
      < 30 U, indicating a strong platelet inhibiting effect. Below this AUC level, the 
      5 days Omega-3 intake increased ASPI-AUC with the ex vivo added low dose ASA 
      (P = 0.02) and high dose ASA (P = 0.04). CONCLUSIONS: No synergism between ASA 
      and Omega-3 was found using the MEA ASPI test. The surprising increase in 
      ASPI-AUC following Omega-3 intake and ex vivo ASA suggest that there are 
      methodological issuses with the MEA ASPI test. TRIAL REGISTRATION: Trial 
      registration ISRCTN78027929 . Registered 19 May 2015.
FAU - Bagger, Harald
AU  - Bagger H
AD  - Institution of Clinical Science, Medical Faculty, Lund University, S-22185, Lund, 
      Sweden.
FAU - Hansson, Mattias
AU  - Hansson M
AD  - Institution of Clinical Science, Medical Faculty, Lund University, S-22185, Lund, 
      Sweden.
FAU - Kander, Thomas
AU  - Kander T
AD  - Institution of Clinical Science, Medical Faculty, Lund University, S-22185, Lund, 
      Sweden.
AD  - Department of Anaesthesiology and Intensive Care, Skane University Hospital, 
      S-22185, Lund, Sweden.
FAU - Schött, Ulf
AU  - Schött U
AUID- ORCID: 0000-0002-4190-5856
AD  - Institution of Clinical Science, Medical Faculty, Lund University, S-22185, Lund, 
      Sweden. ulf.schott@skane.se.
AD  - Department of Anaesthesiology and Intensive Care, Skane University Hospital, 
      S-22185, Lund, Sweden. ulf.schott@skane.se.
LA  - eng
GR  - ISEX-ALF for T5 students/Medicinska Fakulteten, Lunds Universitet/
PT  - Journal Article
PT  - Observational Study
DEP - 20200702
PL  - England
TA  - BMC Complement Med Ther
JT  - BMC complementary medicine and therapies
JID - 101761232
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Peptide Fragments)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 145229-76-1 (thrombin receptor peptide SFLLRNP)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/metabolism
MH  - Adult
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Fatty Acids, Omega-3/administration & dosage/*pharmacology
MH  - Humans
MH  - Male
MH  - Peptide Fragments/metabolism
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Young Adult
PMC - PMC7331184
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Coagulation
OT  - Omega-3
COIS- All authors declare that they have no competing interests.
EDAT- 2020/07/04 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/02/14 00:00 [received]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1186/s12906-020-02990-9 [pii]
AID - 2990 [pii]
AID - 10.1186/s12906-020-02990-9 [doi]
PST - epublish
SO  - BMC Complement Med Ther. 2020 Jul 2;20(1):204. doi: 10.1186/s12906-020-02990-9.

PMID- 26707505
OWN - NLM
STAT- MEDLINE
DCOM- 20170208
LR  - 20170208
IS  - 1467-1107 (Electronic)
IS  - 1047-9511 (Linking)
VI  - 26
IP  - 5
DP  - 2016 Jun
TI  - Kawasaki disease in a healthcare provider: an adult case in a paediatric 
      resident.
PG  - 976-8
LID - 10.1017/S1047951115002644 [doi]
AB  - Kawasaki disease is a small-to-medium-vessel vasculitis of unknown origin that 
      predominantly affects children, although the disease can occur in adults. We 
      report the case of a 26-year-old paediatric resident with fever, exanthema, 
      ocular changes, arthralgia, and desquamation of palms and soles. Diagnosis was 
      established after the fever resolved, and no treatment with intravenous 
      gammaglobulin was administered. His echocardiogram showed normal coronary 
      arteries. Acute Kawasaki disease in adults is a rare and under-recognised 
      condition. It is important to consider the disease in patients with prolonged 
      fever associated with unusual clinical features.
FAU - Garrido-García, Luis M
AU  - Garrido-García LM
AD  - 1Cardiology Service,Instituto Nacional de Pediatría,México City,Mexico.
FAU - López-Amézquita, Martín
AU  - López-Amézquita M
AD  - 1Cardiology Service,Instituto Nacional de Pediatría,México City,Mexico.
FAU - Villaverde-Rosas, Rodrigo
AU  - Villaverde-Rosas R
AD  - 2Allergy and Immunology Service,Instituto Nacional de Pediatría,México 
      City,Mexico.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20151228
PL  - England
TA  - Cardiol Young
JT  - Cardiology in the young
JID - 9200019
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Echocardiography
MH  - Fever/etiology
MH  - Humans
MH  - Male
MH  - Mexico
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/*drug therapy
MH  - Physicians
OTO - NOTNLM
OT  - Kawasaki disease
OT  - adults
OT  - vasculitis
EDAT- 2015/12/29 06:00
MHDA- 2017/02/09 06:00
CRDT- 2015/12/29 06:00
PHST- 2015/12/29 06:00 [entrez]
PHST- 2015/12/29 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
AID - S1047951115002644 [pii]
AID - 10.1017/S1047951115002644 [doi]
PST - ppublish
SO  - Cardiol Young. 2016 Jun;26(5):976-8. doi: 10.1017/S1047951115002644. Epub 2015 
      Dec 28.

PMID- 3798029
OWN - NLM
STAT- MEDLINE
DCOM- 19870129
LR  - 20191030
IS  - 0036-5556 (Print)
IS  - 0036-5556 (Linking)
VI  - 20
IP  - 2
DP  - 1986
TI  - Effects of acetylsalicylic acid and naproxen on the mechanical and biochemical 
      properties of intact skin in rats.
PG  - 161-3
AB  - Acetylsalicylic acid, ASA (150 mg/kg/12 h), and naproxen (20 mg/kg/12 h) were 
      administered to young male rats for 9 and 18 days. The doses were set to provide 
      serum concentrations comparable with anti-inflammatory steady state levels in 
      humans. Mechanical tests were performed on skin from the back of the rats. The 
      drugs did not affect the tensile strength of intact skin, nor were differences 
      found in the dry weight or content and concentration of collagen in the skin. 
      However, the rate of collagen synthesis decreased significantly during the study 
      in the ASA treated rats. The naproxen, on the other hand, had no effect. The 
      results may be interpreted as the ASA having an inhibitory effect both on the 
      synthesis and degradation of collagen in skin.
FAU - Solheim, L F
AU  - Solheim LF
FAU - Rönningen, H
AU  - Rönningen H
FAU - Barth, E
AU  - Barth E
FAU - Langeland, N
AU  - Langeland N
LA  - eng
PT  - Journal Article
PL  - Sweden
TA  - Scand J Plast Reconstr Surg
JT  - Scandinavian journal of plastic and reconstructive surgery
JID - 0121375
RN  - 57Y76R9ATQ (Naproxen)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Biomechanical Phenomena
MH  - Collagen/biosynthesis
MH  - Male
MH  - Naproxen/*pharmacology
MH  - Rats
MH  - Skin/*drug effects/metabolism
MH  - Skin Physiological Phenomena
MH  - Tensile Strength
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.3109/02844318609006314 [doi]
PST - ppublish
SO  - Scand J Plast Reconstr Surg. 1986;20(2):161-3. doi: 10.3109/02844318609006314.

PMID- 23532686
OWN - NLM
STAT- MEDLINE
DCOM- 20131030
LR  - 20151119
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 13
IP  - 2
DP  - 2013 Apr
TI  - Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin 
      (acetylsalicylic acid) plus extended-release dipyridamole are not altered by 
      coadministration with the potent CYP2C19 inhibitor omeprazole.
PG  - 113-20
LID - 10.1007/s40256-013-0018-3 [doi]
AB  - BACKGROUND: The fixed-dose combination of aspirin (acetylsalicylic acid) 25 mg 
      plus extended-release dipyridamole 200 mg (ASA+ER-DP) is used for long-term 
      secondary stroke prevention in patients who have experienced non-cardioembolic 
      stroke or transient ischemic attack. Although the theoretical risk is low that 
      the antiplatelet activity of ASA+ER-DP will be affected by concomitant use of a 
      proton pump inhibitor (PPI), no formal drug-drug interaction studies have been 
      conducted. OBJECTIVE: This study aimed to determine whether the PPI omeprazole 
      influences the pharmacokinetic (PK) and pharmacodynamic (PD) behavior of 
      ASA+ER-DP. STUDY DESIGN AND SETTING: This was a randomized, open-label, 
      multiple-dose, crossover, drug-drug interaction study carried out in a clinical 
      trial unit. PARTICIPANTS: Sixty healthy male and female volunteers aged 18-50 
      years were included in the study. INTERVENTION: Participants were randomized to 
      one of two treatment sequences (ABCD or CDAB), each comprising four 7-day 
      treatments with a washout of ≥14 days between the second and third treatments. 
      Treatment A=ASA+ER-DP 25 mg/200 mg (Aggrenox®) twice daily (BID) alone; 
      B=ASA+ER-DP 25 mg/200 mg BID+omeprazole (Prilosec®) 80 mg once daily (QD) 
      following ASA+ER-DP alone for 7 days; C=omeprazole 80 mg QD alone; D=omeprazole 
      80 mg QD+ASA+ER-DP 25 mg/200 mg BID following omeprazole alone for 7 days. MAIN 
      OUTCOME MEASURES: The main outcome measures were systemic PK exposure to ER-DP 
      and ASA inhibition of arachidonic acid-induced platelet aggregation. RESULTS: 
      Systemic exposure to ER-DP was similar with and without omeprazole, based on 
      steady-state area under the concentration-time curve (AUC) from 0 to 12 h 
      (AUC0-12,ss, ng·h/mL) and maximum plasma concentration (Cmax,ss, ng/mL). For the 
      treatment comparison D versus A, the percent mean ratios were 96.38 (90% 
      confidence interval [CI] 90.96-102.13) for AUC0-12,ss and 92.03 (86.95-97.40) for 
      Cmax,ss. The ER-DP concentration versus time profiles were nearly superimposable. 
      There was no effect on the PDs of the ASA component: the extent of ASA inhibition 
      of arachidonic acid-induced platelet aggregation was almost identical with and 
      without omeprazole, with a percent mean ratio for treatment D versus A = 99.02 
      (90 % CI 98.32-99.72) at 4 h after last dose. All treatments were well tolerated. 
      CONCLUSION: The PK and PD behavior of ASA + ER-DP was not altered by concurrent 
      administration of omeprazole.
FAU - Offman, Elliot
AU  - Offman E
AD  - Clinical Pharmacology Sciences, Celerion, 100 Boulevard Alexis-Nihon, Bureau 
      (Suite) 360, Montreal, QC, H4M 2N8, Canada. elliot.offman@celerion.com
FAU - Schobelock, Michael J
AU  - Schobelock MJ
FAU - Brickl, Rolf
AU  - Brickl R
FAU - VanderMaelen, Cam P
AU  - VanderMaelen CP
FAU - Ehrlich, Jerome
AU  - Ehrlich J
FAU - Eisert, Wolfgang
AU  - Eisert W
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*pharmacokinetics
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Cross-Over Studies
MH  - Dipyridamole/administration & dosage/adverse effects/*pharmacokinetics
MH  - Drug Combinations
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/administration & dosage/adverse effects/*pharmacokinetics
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*pharmacokinetics
MH  - Proton Pump Inhibitors/administration & dosage/adverse effects/*pharmacokinetics
MH  - Young Adult
EDAT- 2013/03/28 06:00
MHDA- 2013/10/31 06:00
CRDT- 2013/03/28 06:00
PHST- 2013/03/28 06:00 [entrez]
PHST- 2013/03/28 06:00 [pubmed]
PHST- 2013/10/31 06:00 [medline]
AID - 10.1007/s40256-013-0018-3 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2013 Apr;13(2):113-20. doi: 10.1007/s40256-013-0018-3.

PMID- 32914651
OWN - NLM
STAT- MEDLINE
DCOM- 20220110
LR  - 20220110
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 26
IP  - 2
DP  - 2021 Mar
TI  - Recommendation of Aspirin-Guide App and Physicians Clinical Decision of Aspirin 
      Use to Prevent CVD Among Diabetic Patients, Is there any Differences?
PG  - 158-164
LID - 10.1177/1074248420958976 [doi]
AB  - OBJECTIVE: This study aims to identify the prevalence of aspirin use among type 2 
      diabetic (T2DM) patients and assess the concordance in aspirin use among these 
      patients as prescribed by physicians and as recommended by the Aspirin-Guide app. 
      METHODS: A total of 301 T2DM patients from King Khalid University Hospital in 
      Riyadh, Saudi Arabia participated in this cross-sectional study. Patient's 
      electronic medical records through eSihi system were reviewed and all data 
      included in the free online and mobile app called Aspirin-Guide were collected in 
      a specially designed data checklist. RESULT: The prevalence of aspirin use was 
      more common in patients who were in the age group of 51 to 59 and male 
      participants' with T2DM. Males were nearly twice more likely to use aspirin 
      compared to females (P = 0.001). Based on recommendations from the Aspirin-Guide 
      app, 26% of the patients who were on aspirin (N = 51) were not eligible for 
      aspirin therapy, while 37.7% (N = 40) of the patients eligible for aspirin 
      therapy had not been put on aspirin by their physicians (P = 0.039). Male sex (P 
      = 0.003), use of statins (P = 0.001), and being advised to use aspirin (P = 
      0.041), were significantly associated with aspirin use in T2DM patients. 
      CONCLUSION: There was a significant difference in the proportion of patients 
      currently on aspirin as prescribed by their physicians and those eligible for 
      aspirin therapy as per the Aspirin-Guide app. The use of an app to uniformized 
      aspirin use among eligible patients should be based on up-to-date guidelines and 
      account for patient acceptability and willingness to commence treatment.
FAU - Batais, Mohammed Ali
AU  - Batais MA
AD  - 191082College of Medicine, King Saud University, Riyadh, Saudi Arabia.
FAU - Almutairi, Khalid M
AU  - Almutairi KM
AD  - Department of Community Health Science, 191082College of Applied Medical Science, 
      King Saud University, Riyadh, Saudi Arabia.
FAU - Almigbal, Turky H
AU  - Almigbal TH
AD  - 191082College of Medicine, King Saud University, Riyadh, Saudi Arabia.
FAU - Alodhayani, Abdulaziz
AU  - Alodhayani A
AD  - 191082College of Medicine, King Saud University, Riyadh, Saudi Arabia.
FAU - Alonazi, Wadi B
AU  - Alonazi WB
AD  - College of Business Administration, 191082King Saud University, Riyadh, Saudi 
      Arabia.
FAU - Vinluan, Jason M
AU  - Vinluan JM
AUID- ORCID: 0000-0001-8670-3580
AD  - Department of Community Health Science, 191082College of Applied Medical Science, 
      King Saud University, Riyadh, Saudi Arabia.
FAU - Asnar, Joram B
AU  - Asnar JB
AD  - Department of Community Health Science, 191082College of Applied Medical Science, 
      King Saud University, Riyadh, Saudi Arabia.
FAU - Salem, Rahaf ElHussein
AU  - Salem RE
AD  - 191082College of Medicine, King Saud University, Riyadh, Saudi Arabia.
FAU - Aljubab, Reem Abdulwahab
AU  - Aljubab RA
AD  - 191082College of Medicine, King Saud University, Riyadh, Saudi Arabia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200911
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Decision-Making
MH  - Cross-Sectional Studies
MH  - Diabetes Complications
MH  - Diabetes Mellitus, Type 2
MH  - Drug Utilization/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Medication Adherence/*statistics & numerical data
MH  - Middle Aged
MH  - Mobile Applications
MH  - Physicians
MH  - Saudi Arabia
OTO - NOTNLM
OT  - aspirin-guide app
OT  - cardiovascular disease
OT  - low dose aspirin therapy
OT  - type 2 diabetes mellitus
EDAT- 2020/09/12 06:00
MHDA- 2022/01/11 06:00
CRDT- 2020/09/11 08:38
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2022/01/11 06:00 [medline]
PHST- 2020/09/11 08:38 [entrez]
AID - 10.1177/1074248420958976 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2021 Mar;26(2):158-164. doi: 
      10.1177/1074248420958976. Epub 2020 Sep 11.

PMID- 23612
OWN - NLM
STAT- MEDLINE
DCOM- 19780329
LR  - 20131121
IS  - 0049-8254 (Print)
IS  - 0049-8254 (Linking)
VI  - 7
IP  - 9
DP  - 1977 Sep
TI  - Comparative metabolism of benorylate and an equivalent mixture of aspirin and 
      paracetamol in neonate and adult rabbits.
PG  - 561-71
AB  - 1. Benorylate was well absorbed in rabbits, but more slowly than an equimolar 
      mixture of aspirin and paracetamol. 2. Benorylate was extensively hydrolysed and 
      converted to the typical metabolites of aspirin and paracetamol by both neonate 
      and mature rabbits. 3. Absorption of either aspirin-paracetamol or benorylate was 
      slower in neonate rabbits than in adult rabbits. 4. The excretion rate in adult 
      rabbits was faster, for both aspirin and paracetamol metabolites, than in neonate 
      rabbits.
FAU - Davison, C
AU  - Davison C
FAU - Dorrbecker, B R
AU  - Dorrbecker BR
FAU - Edelson, J
AU  - Edelson J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Xenobiotica
JT  - Xenobiotica; the fate of foreign compounds in biological systems
JID - 1306665
RN  - 0 (Glucuronates)
RN  - 0 (Salicylates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*metabolism
MH  - Animals
MH  - Animals, Newborn
MH  - Aspirin/*metabolism
MH  - Female
MH  - Glucuronates/metabolism
MH  - Male
MH  - Rabbits
MH  - Salicylates/*metabolism
EDAT- 1977/09/01 00:00
MHDA- 1977/09/01 00:01
CRDT- 1977/09/01 00:00
PHST- 1977/09/01 00:00 [pubmed]
PHST- 1977/09/01 00:01 [medline]
PHST- 1977/09/01 00:00 [entrez]
AID - 10.3109/00498257709038691 [doi]
PST - ppublish
SO  - Xenobiotica. 1977 Sep;7(9):561-71. doi: 10.3109/00498257709038691.

PMID- 29141364
OWN - NLM
STAT- MEDLINE
DCOM- 20180629
LR  - 20181202
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 97
IP  - 41
DP  - 2017 Nov 7
TI  - [Effects of combination therapy with aspirin, prednisone, and Elevit in patients 
      with unexplained recurrent early pregnancy loss].
PG  - 3250-3254
LID - 10.3760/cma.j.issn.0376-2491.2017.41.011 [doi]
AB  - Objective: To investigate the effect of triple therapy with aspirin, prednisone 
      and Elevit in patients with unexplained recurrent early pregnancy loss. Methods: 
      From January 1, 2013 to December 31, 2016, a total of 353 women of childbearing 
      age were enrolled in Peking Union Medical College Hospital, including blood, 
      urine and vaginal swabs. One hundred and fifty-five patients were observed normal 
      results of blood test, urine test and vaginal swabs. According to the treatment 
      regimen, 155 patients were divided into two groups, 89 patients (57.42%) treated 
      with (aspirin, prednisone, and Elevit) as experimental group, and the other 66 
      cases (42.58%) taking folic acid as control group. The fetal bud, fetal heart and 
      neck hyaline layer thickness were examined by ultrasonography at 12 weeks. 
      Visible fetal bud, fetal heart, and nuchal translucency thickness <0.3 cm were 
      used as indicators of successful treatment. t test and χ(2) test were used to 
      analyze and compare the statistical significance of the differences between the 
      two groups of patients, and the Logistic method was used to analyze the data and 
      observe the effect of medication. Results: There were 67 patients successfully 
      treated in the experimental group, the successful rate was 83.75% (67/80), and 33 
      patients in the control group were successfully treated, the successful rate was 
      54.10% (33/61). There were significant statistical differences in two groups 
      (P<0.05). Conclusion: The effect of triple therapy with aspirin, prednisone and 
      Elevit in patients with unexplained recurrent early pregnancy loss is 
      significant.
FAU - Ou, H
AU  - Ou H
AD  - Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union 
      Medical College Hospital, Beijing 100730, China.
FAU - Yu, Q
AU  - Yu Q
LA  - chi
PT  - Clinical Trial
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Glucocorticoids)
RN  - 0 (Vitamins)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Abortion, Habitual/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Embryo Loss
MH  - Female
MH  - Glucocorticoids/*therapeutic use
MH  - Humans
MH  - Prednisone/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Vitamins/*therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Early recurrent spontaneous abortion
OT  - Elevit
OT  - Prednisone
EDAT- 2017/11/17 06:00
MHDA- 2018/06/30 06:00
CRDT- 2017/11/17 06:00
PHST- 2017/11/17 06:00 [entrez]
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2018/06/30 06:00 [medline]
AID - 10.3760/cma.j.issn.0376-2491.2017.41.011 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2017 Nov 7;97(41):3250-3254. doi: 
      10.3760/cma.j.issn.0376-2491.2017.41.011.

PMID- 23059927
OWN - NLM
STAT- MEDLINE
DCOM- 20130708
LR  - 20181202
IS  - 1476-5446 (Electronic)
IS  - 1462-0049 (Linking)
VI  - 13
IP  - 3
DP  - 2012
TI  - Should acetylsalicylic acid (ASA) therapy for prevention of thromboembolic events 
      be stopped prior to surgical extractions?
PG  - 89-90
LID - 10.1038/sj.ebd.6400881 [doi]
AB  - DESIGN: Randomised controlled trial. INTERVENTION: Patients with coronary artery 
      disease who were receiving 100 mg/day of ASA for the prevention of thromboembolic 
      events, and requiring at least one molar tooth extracted were randomised to 
      either having their ASA therapy suspended for seven days before tooth extraction 
      and restarted the day following the surgical procedure or not having their ASA 
      therapy suspended at any point before or after the procedure. A single dentist 
      who was unaware of the patients' ASA therapy status performed all the 
      extractions. OUTCOME MEASURE: Outcomes were a platelet aggregation test carried 
      out on the day of the operation and the amount of bleeding measured during the 
      intra-operative period. RESULTS: Bleeding was controlled with local haemostatic 
      methods and there were no reported episodes of haemorrhaging during the intra- 
      and post-operative periods. The mean (±SD) volume of bleeding was 12.10 ±9.37 mL 
      for patients who underwent ASA therapy suspension and 16.38±13.54 mL for those 
      patients whose treatments were unaltered (P= .151). The platelet reactivity index 
      values exhibited statistically significant differences between the two 
      investigated groups (P= .004). The platelet reactivity index values for the group 
      with ASA therapy suspended was 242.58 ± 71.26 compared with 192.09 ± 60.54 in the 
      group that continued with ASA. CONCLUSIONS: There was no difference in the amount 
      of bleeding that occurred during tooth extraction between patients who continued 
      ASA therapy and patients who suspended their ASA therapy. The platelet reactivity 
      test demonstrated a reduction in platelet aggregation in the ASA therapy group, 
      but this was without clinical consequence.
FAU - Dodson, Tom
AU  - Dodson T
AD  - Department of Oral and Maxillofacial Surgery, Harvard School of Dental Medicine, 
      Boston, MA, USA.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - England
TA  - Evid Based Dent
JT  - Evidence-based dentistry
JID - 100883603
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - J Oral Maxillofac Surg. 2011 Dec;69(12):2949-55. PMID: 21802823
MH  - Aspirin/*administration & dosage
MH  - *Blood Loss, Surgical
MH  - Coronary Disease/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - *Tooth Extraction
EDAT- 2012/10/13 06:00
MHDA- 2013/07/09 06:00
CRDT- 2012/10/13 06:00
PHST- 2012/10/13 06:00 [entrez]
PHST- 2012/10/13 06:00 [pubmed]
PHST- 2013/07/09 06:00 [medline]
AID - 6400881 [pii]
AID - 10.1038/sj.ebd.6400881 [doi]
PST - ppublish
SO  - Evid Based Dent. 2012;13(3):89-90. doi: 10.1038/sj.ebd.6400881.

PMID- 15225580
OWN - NLM
STAT- MEDLINE
DCOM- 20040812
LR  - 20131121
IS  - 0027-5107 (Print)
IS  - 0027-5107 (Linking)
VI  - 551
IP  - 1-2
DP  - 2004 Jul 13
TI  - The biological revolution - towards a mechanistic understanding of the impact of 
      diet on cancer risk.
PG  - 43-9
AB  - There is strong epidemiological evidence to show that differences in diet explain 
      a significant proportion of the variation in cancer incidence worldwide. However, 
      because of the complex nature of eating behaviour and the chemical heterogeneity 
      of foods, it remains very difficult to ascertain which aspects of diet, in what 
      quantities and over what time-frames are responsible for modifying risk. In 
      addition, there are few dietary intervention studies demonstrating reduction in 
      cancer risk. Much faster progress has been made in understanding the biological 
      basis of cancer. It is now clear that damage to the genome resulting in aberrant 
      expression of genes (principally suppression of tumour suppressor genes (TSGs) 
      and inappropriate expression of oncogenes) is fundamental to tumorigenesis. It is 
      also becoming clear that much of the inter-individual variation in cancer 
      experience is due to differences in the amount of damage experienced and/or the 
      capacity to repair that damage. Both of these processes are influenced strongly 
      by dietary factors and by genetic predisposition (polymorphisms in the requisite 
      genes). It is possible that understanding diet:gene interactions in DNA damage 
      and in repair will not only explain much of the inter-individual variation in 
      risk but also offer opportunities to design better dietary intervention studies 
      aimed at chemoprevention. The Human Genome maps and the SNPs databases, together 
      with the rapid development of tools suitable for investigating genetic and 
      epigenetic changes in small tissue biopsies provide the means to begin to test 
      hypotheses about the mechanisms by which diet influences cancer risk directly in 
      human subjects. This is likely to form a significant component of the emerging 
      science of nutrigenomics.
FAU - Mathers, John C
AU  - Mathers JC
AD  - Human Nutrition Research Centre, School of Clinical Medical Sciences, University 
      of Newcastle, Newcastle upon Tyne NE1 7RU, UK. john.mathers@ncl.ac.uk
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Mutat Res
JT  - Mutation research
JID - 0400763
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticarcinogenic Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Chemoprevention
MH  - DNA Repair/genetics
MH  - *Diet
MH  - Humans
MH  - Neoplasms/*etiology/genetics
MH  - Polymorphism, Single Nucleotide
MH  - Risk
RF  - 51
EDAT- 2004/07/01 05:00
MHDA- 2004/08/13 05:00
CRDT- 2004/07/01 05:00
PHST- 2003/10/21 00:00 [received]
PHST- 2004/01/26 00:00 [revised]
PHST- 2004/01/26 00:00 [accepted]
PHST- 2004/07/01 05:00 [pubmed]
PHST- 2004/08/13 05:00 [medline]
PHST- 2004/07/01 05:00 [entrez]
AID - S002751070400140X [pii]
AID - 10.1016/j.mrfmmm.2004.01.011 [doi]
PST - ppublish
SO  - Mutat Res. 2004 Jul 13;551(1-2):43-9. doi: 10.1016/j.mrfmmm.2004.01.011.

PMID- 6487496
OWN - NLM
STAT- MEDLINE
DCOM- 19841220
LR  - 20190511
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 18
IP  - 4
DP  - 1984 Oct
TI  - Interaction of isoxicam with acetylsalicylic acid.
PG  - 567-71
AB  - Ten healthy male volunteers were given 200 mg p.o. of isoxicam after an overnight 
      fast and the plasma concentrations over time followed for 96 h by h.p.l.c. Five 
      days later enteric coated acetylsalicylic acid (ASA) 650 mg four times daily was 
      started and continued for 10 days producing steady state trough plasma salicylate 
      of 83 mg/l (range 21-133). A second 200 mg isoxicam dose was given 5 days after 
      starting ASA and the plasma concentration time-curve again followed. After ASA, 
      there was no change in lag time (0.54 vs 0.51 h), time to peak concentration (10 
      vs 10 h), or disappearance t1/2 (28.7 vs 31.0 h) however the peak isoxicam 
      concentration and AUC were reduced 18 and 22% respectively (P less than 0.01). 
      Plasma protein binding of isoxicam studied by equilibrium dialysis was 96 +/- 1% 
      in the absence and 86 +/- 5% in the presence of ASA. The reduction in binding was 
      unrelated to plasma SA concentrations achieved or observed reductions in AUC for 
      plasma isoxicam. ASA decreased plasma isoxicam binding, peak plasma isoxicam 
      concentrations and AUC without altering the apparent disappearance half-life of 
      total plasma isoxicam after a single oral dose.
FAU - Esquivel, M
AU  - Esquivel M
FAU - Cussenot, F
AU  - Cussenot F
FAU - Ogilvie, R I
AU  - Ogilvie RI
FAU - East, D S
AU  - East DS
FAU - Shaw, D H Jr
AU  - Shaw DH Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Blood Proteins)
RN  - 0 (Thiazines)
RN  - 13T4O6VMAM (Piroxicam)
RN  - 8XU734C4NG (isoxicam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/*metabolism
MH  - Aspirin/*pharmacology
MH  - Blood Proteins/metabolism
MH  - Drug Interactions
MH  - Humans
MH  - Male
MH  - *Piroxicam/*analogs & derivatives
MH  - Protein Binding
MH  - Thiazines/*metabolism
PMC - PMC1463616
EDAT- 1984/10/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1984/10/01 00:00
PHST- 1984/10/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1984/10/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1984.tb02505.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1984 Oct;18(4):567-71. doi: 
      10.1111/j.1365-2125.1984.tb02505.x.

PMID- 16019910
OWN - NLM
STAT- MEDLINE
DCOM- 20051114
LR  - 20191109
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 22
IP  - 3
DP  - 2005 May
TI  - Investigation of the release of aspirin from spray-congealed micro-pellets.
PG  - 245-51
AB  - The release behaviour of aspirin from spray-congealed hydrogenated soybean oil 
      micro-pellets of different sizes was studied. The purpose of this study was to 
      investigate the effect of particle size of micro-pellets on the drug release 
      profile and mechanism. Micro-pellets produced were sieved into several fractions 
      and their drug content and dissolution profiles in two media were determined. The 
      dissolution mechanism was studied by fitting the data to release kinetic models. 
      Micro-pellets with high encapsulation efficiency were successfully produced. The 
      micro-pellets were able to sustain the release of aspirin in pH 1.2 and pH 6.8 
      dissolution media. As particle size of micro-pellets increased, the drug release 
      rate decreased. The drug release mechanism was affected by the size of 
      micro-pellets. Micro-pellets in the range of 90-250 microm tended to follow the 
      first order or Higuchi model. However, micro-pellets in the range of 250-355 
      microm were found to follow zero-order release model. This result showed that 
      drug release could be modified by controlling the size of micro-pellets and that 
      controlled release of drug might be achieved by using larger size micro-pellets.
FAU - Guo, Q Y
AU  - Guo QY
AD  - National University of Singapore, Singapore.
FAU - Chan, L W
AU  - Chan LW
FAU - Heng, P W S
AU  - Heng PW
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Capsules)
RN  - 0 (Delayed-Action Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics
MH  - Aspirin/*pharmacokinetics
MH  - Capsules
MH  - Delayed-Action Preparations
MH  - Drug Compounding/methods
MH  - Hydrogen-Ion Concentration
MH  - Models, Theoretical
MH  - Particle Size
EDAT- 2005/07/16 09:00
MHDA- 2005/11/15 09:00
CRDT- 2005/07/16 09:00
PHST- 2005/07/16 09:00 [pubmed]
PHST- 2005/11/15 09:00 [medline]
PHST- 2005/07/16 09:00 [entrez]
AID - WT0J7387184T75N8 [pii]
AID - 10.1080/02652040500100345 [doi]
PST - ppublish
SO  - J Microencapsul. 2005 May;22(3):245-51. doi: 10.1080/02652040500100345.

PMID- 35906782
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20221017
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 199
IP  - 1
DP  - 2022 Oct
TI  - Validation of thrombotic risk factors in 1381 patients with essential 
      thrombocythaemia: A multicentre retrospective real-life study.
PG  - 86-94
LID - 10.1111/bjh.18387 [doi]
AB  - Thrombosis and haemorrhage are frequent in patients with essential 
      thrombocythaemia (ET). The 2016 revised International Prognostic Score for 
      Thrombosis in Essential Thrombocythaemia-thrombosis (r-IPSET-t) score stratifies 
      patients into very-low- (VLR), low- (LR), intermediate- (IR) and high-risk (HR) 
      groups. We validated the r-IPSET-t in the biggest population of patients with ET 
      (n = 1381) to date and found it to be a better fit than the earlier IPSET-t 
      score. With an average follow-up of 87.7 months, there were 0.578 thrombotic 
      events/person-year and 0.286 bleeding events/person-year after diagnosis. The 
      10-year thrombosis-free survival was 88% and 99% for the r-IPSET-t LR and VLR 
      groups (p < 0.001). Cytoreduction was a thrombotic risk factor in younger 
      patients (aged <60 years, hazard ratio 9.49, p = 0.026; aged ≥60 years, hazard 
      ratio 1.04, p = 0.93). In multivariable Cox regression analysis, anti-aggregation 
      after diagnosis was protective for thrombosis (hazard ratio 0.31, p = 0.005) but 
      a risk factor for major bleeding (hazard ratio 10.56, p = 0.021). Of the IPSET-t 
      HR and LR groups, 132/780 and 249/301 were re-classified as LR and VLR 
      respectively (p < 0.001). The European LeukemiaNET (ELN) does not recommend 
      aspirin for VLR patients but in this real-life analysis 83.1% of VLR patients 
      received it. Our results validate the r-IPSET-t score as more predictive for 
      thrombosis than the ELN-recommended IPSET-t and raise concerns about unnecessary 
      cytoreductive and anti-aggregative therapy.
CI  - © 2022 British Society for Haematology and John Wiley & Sons Ltd.
FAU - Stuckey, Ruth
AU  - Stuckey R
AUID- ORCID: 0000-0001-6955-2290
AD  - Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las 
      Palmas, Spain.
FAU - Ianotto, Jean-Christophe
AU  - Ianotto JC
AD  - Service d'Hématologie Clinique, Institut de Cancéro-Hématologie, Centre 
      Hospitalier Régional et Universitaire de Brest, Brest, France.
FAU - Santoro, Marco
AU  - Santoro M
AD  - Hematology Unit, Department of Health Promotion, Mother and Child Care, Internal 
      Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 
      Italy.
FAU - Czyż, Anna
AU  - Czyż A
AUID- ORCID: 0000-0001-6641-0182
AD  - Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Perez Encinas, Manuel M
AU  - Perez Encinas MM
AD  - Hematology Department, Hospital Clínico Universitario de Santiago de Compostela, 
      Santiago de Compostela, Spain.
FAU - Gómez-Casares, María Teresa
AU  - Gómez-Casares MT
AD  - Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las 
      Palmas, Spain.
FAU - Noya Pereira, Maria Soledad
AU  - Noya Pereira MS
AD  - Hematology Department, Hospital Clínico Universitario de A Coruña, A Coruña, 
      Spain.
FAU - de Nałęcz, Anna Kulikowska
AU  - de Nałęcz AK
AD  - Department of Hematology, Oncology and Internal Medicine, Szpital Wojewódzki, 
      Opole, Poland.
FAU - Gołos, Aleksandra
AU  - Gołos A
AD  - Department of Hematology, Institute of Hematology, Warsaw, Poland.
FAU - Lewandowski, Krzysztof
AU  - Lewandowski K
AD  - Department of Hematology and Bone Marrow Transplantation, Poznan University of 
      Medical Sciences, Poznan, Poland.
FAU - Szukalski, Łukasz
AU  - Szukalski Ł
AD  - Department of Haematology CM UMK in Bydgoszcz, Nicolaus Copernicus University in 
      Toruń, Toruń, Poland.
FAU - González-Martín, Jesús M
AU  - González-Martín JM
AD  - Investigation Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las 
      Palmas, Spain.
FAU - Wróbel, Tomasz
AU  - Wróbel T
AD  - Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Sobas, Marta Anna
AU  - Sobas MA
AUID- ORCID: 0000-0003-0781-8668
AD  - Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical 
      University, Wroclaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20220729
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Thrombocythemia, Essential/diagnosis
MH  - *Thrombosis/diagnosis/epidemiology/etiology
OTO - NOTNLM
OT  - aspirin
OT  - cytoreduction
OT  - myeloproliferative neoplasm
OT  - prognosis
OT  - vascular events
EDAT- 2022/07/31 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/07/30 02:22
PHST- 2022/07/07 00:00 [revised]
PHST- 2022/02/22 00:00 [received]
PHST- 2022/07/17 00:00 [accepted]
PHST- 2022/07/31 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/07/30 02:22 [entrez]
AID - 10.1111/bjh.18387 [doi]
PST - ppublish
SO  - Br J Haematol. 2022 Oct;199(1):86-94. doi: 10.1111/bjh.18387. Epub 2022 Jul 29.

PMID- 23650199
OWN - NLM
STAT- MEDLINE
DCOM- 20131227
LR  - 20181202
IS  - 1024-2708 (Print)
IS  - 1024-2708 (Linking)
VI  - 19
IP  - 3
DP  - 2013 Jun
TI  - Aspirin desensitisation for Chinese patients with coronary artery disease.
PG  - 207-13
LID - 10.12809/hkmj133914 [doi]
AB  - OBJECTIVE. To assess the efficacy and safety of aspirin desensitisation in 
      Chinese patients with coronary artery disease. DESIGN. Case series. SETTING. A 
      regional hospital in Hong Kong. PATIENTS. Chinese patients with coronary artery 
      disease and a history of a hypersensitivity reaction to aspirin or non-steroidal 
      anti-inflammatory drug, who underwent aspirin desensitisation between February 
      2008 and July 2012. RESULTS. There were 24 Chinese patients with coronary artery 
      disease who were admitted to our unit for aspirin desensitisation during this 
      period. The majority (79%) were clinical admissions for desensitisation; eight 
      (33%) of them developed a hypersensitivity reaction during desensitisation. Half 
      of the latter had only limited cutaneous reactions and were able to complete the 
      desensitisation protocol and developed aspirin tolerance. Overall, 20 (83%) of 
      the patients were successfully desensitised at the initial attempt. No serious 
      adverse reactions occurred in the cohort. Twelve of the patients had significant 
      coronary artery disease revealed by coronary angiography and received a 
      percutaneous coronary intervention, nine of whom received drug-eluting stents 
      while three received bare metal stents due to financial constraints. All 11 
      successfully desensitised patients received aspirin and clopidogrel as double 
      antiplatelet therapy after percutaneous coronary intervention. The remaining 
      patient had a bare metal stent implant due to failed aspirin desensitisation. 
      CONCLUSION. Given the potentially different genetic basis of aspirin 
      hypersensitivity in different ethnicities, recourse to desensitisation in the 
      Chinese population has not previously been addressed. This study demonstrated 
      that aspirin desensitisation using a rapid protocol can be performed effectively 
      and safely in Chinese patients. Our results were comparable to those in other 
      reported studies involving other ethnicities. Successful aspirin desensitisation 
      permits patients to pursue long-term double antiplatelet therapy that includes 
      aspirin after percutaneous coronary intervention, and thus allows the use of 
      drug-eluting stents as a feasible option.
FAU - Lee, Joe K T
AU  - Lee JK
AD  - Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong 
      Kong.
FAU - Tsui, K L
AU  - Tsui KL
FAU - Cheung, C Y
AU  - Cheung CY
FAU - Chau, C H
AU  - Chau CH
FAU - Chan, H L
AU  - Chan HL
FAU - Wu, K L
AU  - Wu KL
FAU - Cheung, Gary S H
AU  - Cheung GS
FAU - Choi, M C
AU  - Choi MC
FAU - Chan, K K
AU  - Chan KK
FAU - Li, S K
AU  - Li SK
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - China
TA  - Hong Kong Med J
JT  - Hong Kong medical journal = Xianggang yi xue za zhi
JID - 9512509
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects/immunology
MH  - Clopidogrel
MH  - Coronary Angiography
MH  - Coronary Artery Disease/drug therapy
MH  - Desensitization, Immunologic/adverse effects/*methods
MH  - Drug Hypersensitivity/*therapy
MH  - Drug-Eluting Stents
MH  - Female
MH  - Hong Kong
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/immunology
MH  - Retrospective Studies
MH  - Stents
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
MH  - Time Factors
OTO - NOTNLM
OT  - Anti-inflammatory agents, non-steroidal
OT  - Aspirin
OT  - Coronary artery disease
OT  - Desensitization, immunologic
EDAT- 2013/05/08 06:00
MHDA- 2013/12/29 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/05/08 06:00 [entrez]
PHST- 2013/05/08 06:00 [pubmed]
PHST- 2013/12/29 06:00 [medline]
AID - 10.12809/hkmj133914 [doi]
PST - ppublish
SO  - Hong Kong Med J. 2013 Jun;19(3):207-13. doi: 10.12809/hkmj133914. Epub 2013 May 
      6.

PMID- 1427126
OWN - NLM
STAT- MEDLINE
DCOM- 19921201
LR  - 20180216
IS  - 0304-324X (Print)
IS  - 0304-324X (Linking)
VI  - 38
IP  - 5
DP  - 1992
TI  - Lack of association of nonsteroidal anti-inflammatory drug use and cognitive 
      decline in the elderly.
PG  - 275-9
AB  - Folstein Mini-Mental State Examination (MMSE) scores obtained in an ambulatory 
      elderly population were used to examine the effect of nonsteroidal 
      anti-inflammatory drug (NSAID) use on cognitive performance. There were 1,310 
      participants who met the inclusion criteria for the study, of whom 873 (66.6%) 
      were women and 437 (33.3%) were men. There were no differences in mean MMSE 
      scores or in the five dimensions of cognitive function measured by the MMSE for 
      subjects reporting NSAIDs or aspirin use.
FAU - May, F E
AU  - May FE
AD  - Department of Pharmacy Practice, College of Pharmacy, University of Florida, 
      Gainesville.
FAU - Moore, M T
AU  - Moore MT
FAU - Stewart, R B
AU  - Stewart RB
FAU - Hale, W E
AU  - Hale WE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Gerontology
JT  - Gerontology
JID - 7601655
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/adverse effects
MH  - Cognition Disorders/*chemically induced
MH  - Female
MH  - Humans
MH  - Male
MH  - Psychological Tests
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1159/000213340 [doi]
PST - ppublish
SO  - Gerontology. 1992;38(5):275-9. doi: 10.1159/000213340.

PMID- 1704148
OWN - NLM
STAT- MEDLINE
DCOM- 19910313
LR  - 20131121
IS  - 0035-2640 (Print)
IS  - 0035-2640 (Linking)
VI  - 40
IP  - 28
DP  - 1990 Dec 1
TI  - [Kawasaki disease].
PG  - 2604-8
AB  - First described in Japan in 1967, Kawasaki disease is now observed in all 
      countries. Despite extensive research, the aetiology of this infectious disease 
      which affects mainly infants and young children remains mysterious. The six main 
      clinical presentations of Kawasaki disease are: prolonged fever, conjunctivitis, 
      lesions of the oral and pharyngeal mucosa, inflammatory reddening and swelling of 
      the hands and feet, skin rash and cervical lymph node enlargement. Laboratory 
      data show an inflammatory syndrome and thrombocytosis. The disease usually 
      resolves within a few weeks. The major risk is cardiovascular involvement with 
      pericarditis, myocarditis and, chiefly, coronary artery aneurysms which usually 
      regress but are the main cause of mortality (1 to 2 p. 100 of the cases). 
      Treatment consists of gammaglobulins and aspirin in high doses; when administered 
      at an early stage, it prevents the formation of coronary aneurysms.
FAU - Floret, D
AU  - Floret D
AD  - Unité de réanimation pédiatrique, hôpital Edouard-Herriot, Lyon, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - La maladie de Kawasaki.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
RN  - 0 (gamma-Globulins)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Humans
MH  - *Mucocutaneous Lymph Node Syndrome/diagnosis/drug therapy/etiology
MH  - gamma-Globulins/therapeutic use
RF  - 20
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
PST - ppublish
SO  - Rev Prat. 1990 Dec 1;40(28):2604-8.

PMID- 4011513
OWN - NLM
STAT- MEDLINE
DCOM- 19850820
LR  - 20201209
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 78
IP  - 1
DP  - 1985 Jul
TI  - Adult respiratory distress syndrome induced by salicylate toxicity.
PG  - 117-9, 123
AB  - Noncardiogenic pulmonary edema induced by salicylate toxicity is becoming a 
      well-recognized entity. However, the diagnosis can be easily missed early in the 
      disease course. We report here adult respiratory distress syndrome (ARDS) in a 
      54-year-old man found to have salicylate toxicity one day after admission to the 
      alcohol detoxification service at a community hospital. He had been taking one 
      enteric-coated aspirin tablet twice a day for more than one year. He also had a 
      40 pack-year history of cigarette smoking. The list in any standard medical text 
      of factors triggering ARDS is quite lengthy. Over the past few years, salicylate 
      toxicity has been added to this list. As the case reported here illustrates, it 
      is most important that salicylate toxicity be considered in the differential 
      diagnosis for any patient with acute onset of pulmonary edema and normal cardiac 
      function.
FAU - Niehoff, J M
AU  - Niehoff JM
FAU - Baltatzis, P A
AU  - Baltatzis PA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiratory Distress Syndrome/*chemically induced
MH  - Salicylates/*adverse effects
EDAT- 1985/07/01 00:00
MHDA- 1985/07/01 00:01
CRDT- 1985/07/01 00:00
PHST- 1985/07/01 00:00 [pubmed]
PHST- 1985/07/01 00:01 [medline]
PHST- 1985/07/01 00:00 [entrez]
AID - 10.1080/00325481.1985.11699058 [doi]
PST - ppublish
SO  - Postgrad Med. 1985 Jul;78(1):117-9, 123. doi: 10.1080/00325481.1985.11699058.

PMID- 23773710
OWN - NLM
STAT- MEDLINE
DCOM- 20140318
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 11
IP  - 8
DP  - 2013 Aug
TI  - A guide to GRADE guidelines for the readers of JTH.
PG  - 1603-8
LID - 10.1111/jth.12320 [doi]
AB  - More than 70 organizations worldwide have adopted the GRADE methodology for 
      guideline development. The ninth iteration of the American Collage of Chest 
      Physicians guidelines (AT9) adopted structural and policy changes that resulted 
      in a greater adherence to GRADE guidance than previous iterations. The most 
      important of these changes include minimizing the impact of financial and 
      intellectual conflict of interest, increasing the rigor of evidence evaluation, 
      acknowledging uncertainty in estimates of typical values and preferences, and 
      awareness of the large variability in values and preferences. One of the 
      consequences of the greater adherence to GRADE methodology is an increase in weak 
      vs. strong recommendations in AT9. The result of the GRADE process highlights the 
      desirability of higher-quality evidence both regarding the outcomes of 
      alternative management strategies and regarding the distribution of values and 
      preferences in patients considering those alternatives. It also encourages shared 
      decision making in encounters between physicians and patients. Although some 
      physicians might find the uncertainty underlying medical practice discouraging or 
      unsettling, relative to denying or obscuring the uncertainty, acknowledging and 
      addressing the uncertainty will lead to more credible, realistic, and useful 
      recommendations.
CI  - © 2013 International Society on Thrombosis and Haemostasis.
FAU - Guyatt, G
AU  - Guyatt G
AD  - Department of Clinical Epidemiology and Biostatistics, McMaster University, 
      Hamilton, ON, Canada.
FAU - Eikelboom, J W
AU  - Eikelboom JW
FAU - Akl, E A
AU  - Akl EA
FAU - Crowther, M
AU  - Crowther M
FAU - Gutterman, D
AU  - Gutterman D
FAU - Kahn, S R
AU  - Kahn SR
FAU - Schunemann, H
AU  - Schunemann H
FAU - Hirsh, J
AU  - Hirsh J
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Decision Making
MH  - Evidence-Based Medicine/methods
MH  - Fibrinolytic Agents/therapeutic use
MH  - Guideline Adherence
MH  - Hematology/*standards
MH  - Humans
MH  - International Cooperation
MH  - *Practice Guidelines as Topic
MH  - Review Literature as Topic
MH  - Societies, Medical
MH  - Treatment Outcome
MH  - United States
OTO - NOTNLM
OT  - antithrombotic agents
OT  - aspirin
OT  - conflict of interest
OT  - evidence-based medicine
OT  - guidelines
EDAT- 2013/06/19 06:00
MHDA- 2014/03/19 06:00
CRDT- 2013/06/19 06:00
PHST- 2013/04/14 00:00 [received]
PHST- 2013/06/19 06:00 [entrez]
PHST- 2013/06/19 06:00 [pubmed]
PHST- 2014/03/19 06:00 [medline]
AID - S1538-7836(22)13650-0 [pii]
AID - 10.1111/jth.12320 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2013 Aug;11(8):1603-8. doi: 10.1111/jth.12320.

PMID- 8795667
OWN - NLM
STAT- MEDLINE
DCOM- 19961010
LR  - 20190503
IS  - 0040-6376 (Print)
IS  - 1468-3296 (Electronic)
IS  - 0040-6376 (Linking)
VI  - 51
IP  - 8
DP  - 1996 Aug
TI  - Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway 
      response to sodium metabisulphite and adenosine 5'-monophosphate challenge in 
      asthma.
PG  - 799-804
AB  - BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are used to assess the 
      role of prostaglandins in asthma but their effects on bronchoconstrictor 
      challenges have been inconsistent. The effects of three nebulised nonsteroidal 
      anti-inflammatory drugs on the airway response to inhaled sodium metabisulphite 
      (MBS) and adenosine 5'-monophosphate (AMP) were compared in the same asthmatic 
      subjects to see whether contractile prostaglandins were involved in MBS or AMP 
      induced bronchoconstriction. A possible protective effect of the osmolarity or pH 
      of the inhaled solutions was also assessed. METHODS: Two double blind placebo 
      controlled studies were carried out. In study 1, 15 non-aspirin sensitive 
      patients with mild asthma attended on four occasions and inhaled 5 ml of lysine 
      aspirin (L-aspirin) 900 mg, indomethacin 50 mg, sodium salicylate 800 mg, or 
      saline 20 minutes before an inhaled MBS challenge. On four further occasions 14 
      of the patients inhaled the same solutions followed by an inhaled AMP challenge. 
      In study 2, 10 of the patients attended on four additional occasions and inhaled 
      5 ml of 0.9%, 3%, 10%, or 9.5% saline with indomethacin 50 mg 20 minutes before 
      an inhaled MBS challenge. RESULTS: In study 1 inhaled lysine aspirin had a 
      similar effect on MBS and AMP induced bronchoconstriction, increasing the 
      provocative dose causing a 20% fall in FEV1 (PD20) by 1.29 (95% CI 0.54 to 2.03) 
      and 1.23 (95% CI 0.53 to 1.93) doubling doses, respectively. Indomethacin 
      increased the MBS PD20 and AMP PD20 by 0.64 (95% CI -0.1 to 1.38) and 0.99 (95% 
      CI 0.29 to 1.69) doubling doses, respectively. Sodium salicylate had no 
      significant effect on either challenge. The two solutions causing most inhibition 
      were the most acidic and the most alkaline. In study 2 inhaled 9.5% saline with 
      indomethacin (osmolarity 3005 mOsm/kg) increased the MBS PD20 by 1.1 doubling 
      doses (95% CI 0.2 to 2.0) compared with only 0.09 (95% CI -0.83 to 1.0) and 0.04 
      (95% CI -0.88 to 0.95) doubling doses with 3% saline (918 mOsm/kg) and 10% saline 
      (2994 mOsm/ kg), respectively. CONCLUSIONS: Inhaled L-aspirin and indomethacin 
      have broadly similar protective effects against MBS and AMP induced 
      bronchoconstriction in the doses given, although the effect of indomethacin on 
      MBS was not quite statistically significant. The osmolarity and pH of the 
      solutions did not appear to be important determinants of the response. The effect 
      of L-aspirin and indomethacin is likely to be the result of cyclooxygenase 
      inhibition reducing the production of contractile prostaglandins during MBS and 
      AMP challenge.
FAU - Wang, M
AU  - Wang M
AD  - Respiratory Medicine Unit, City Hospital, Nottingham, UK.
FAU - Wisniewski, A
AU  - Wisniewski A
FAU - Pavord, I
AU  - Pavord I
FAU - Knox, A
AU  - Knox A
FAU - Tattersfield, A
AU  - Tattersfield A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Thorax
JT  - Thorax
JID - 0417353
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Bronchoconstrictor Agents)
RN  - 0 (Sulfites)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - 4VON5FNS3C (sodium metabisulfite)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adenosine Monophosphate
MH  - Administration, Inhalation
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/analogs & derivatives/pharmacology
MH  - Asthma/*drug therapy/physiopathology
MH  - Bronchial Hyperreactivity/*prevention & control
MH  - Bronchial Provocation Tests
MH  - *Bronchoconstrictor Agents
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Indomethacin/administration & dosage/pharmacology
MH  - Lung/*physiopathology
MH  - Lysine/administration & dosage/analogs & derivatives/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Osmolar Concentration
MH  - Sodium Salicylate/administration & dosage/pharmacology
MH  - Sulfites
PMC - PMC472543
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - 10.1136/thx.51.8.799 [doi]
PST - ppublish
SO  - Thorax. 1996 Aug;51(8):799-804. doi: 10.1136/thx.51.8.799.

PMID- 18699939
OWN - NLM
STAT- MEDLINE
DCOM- 20090116
LR  - 20140730
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 63
IP  - 9
DP  - 2008 Sep
TI  - Long-term treatment with aspirin desensitization: a prospective clinical trial 
      comparing 100 and 300 mg aspirin daily.
PG  - 1228-34
LID - 10.1111/j.1398-9995.2008.01658.x [doi]
AB  - BACKGROUND: The daily dose of aspirin in desensitization in aspirin-sensitive 
      asthmatics with nasal polyps is still a matter of debate. AIMS OF THE STUDY: To 
      compare two doses of aspirin during the first year of desensitization and to 
      evaluate long-term effects on nasal/pulmonary symptoms. METHODS: Patients with 
      positive aspirin provocation test were treated with either 100 or 300 mg aspirin 
      daily. RESULTS: In all patients taking 100 mg aspirin (n = 7) recurrent nasal 
      polyps were observed. No patient experienced reduction of asthma medication or 
      improvement of pulmonary function. In the 300 mg group no recurrent nasal polyps 
      were seen. Asthma medication could be reduced in three patients, pulmonary 
      function was improved in five patients. Thirty-nine consecutively desensitized 
      patients, taking 300 mg aspirin, showed significant improvement of olfaction and 
      polyp-free nasal passages during the first year of therapy. After a median 
      follow-up of 27 months no sinus revision surgery was necessary. CONCLUSIONS: 
      Aspirin desensitization followed by 300 mg aspirin daily is efficacious and 
      results in polyp-free nasal airways, improvement of sense of smell, and reduction 
      of the need for sinus revision surgery for recurrent nasal polyps. Aspirin in a 
      dose of 100 mg daily is not sufficient to effectively reduce nasal and bronchial 
      or pulmonary symptoms and to prevent recurrent nasal polyps by at least the first 
      12 months of treatment.
FAU - Rozsasi, A
AU  - Rozsasi A
AD  - Department of Otorhinolaryngology, University of Ulm, Ulm, Germany.
FAU - Polzehl, D
AU  - Polzehl D
FAU - Deutschle, T
AU  - Deutschle T
FAU - Smith, E
AU  - Smith E
FAU - Wiesmiller, K
AU  - Wiesmiller K
FAU - Riechelmann, H
AU  - Riechelmann H
FAU - Keck, T
AU  - Keck T
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Asthma/chemically induced/immunology/*therapy
MH  - *Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/*therapy
MH  - Recurrence
MH  - Respiratory Function Tests
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2008/08/14 09:00
MHDA- 2009/01/17 09:00
CRDT- 2008/08/14 09:00
PHST- 2008/08/14 09:00 [pubmed]
PHST- 2009/01/17 09:00 [medline]
PHST- 2008/08/14 09:00 [entrez]
AID - ALL1658 [pii]
AID - 10.1111/j.1398-9995.2008.01658.x [doi]
PST - ppublish
SO  - Allergy. 2008 Sep;63(9):1228-34. doi: 10.1111/j.1398-9995.2008.01658.x.

PMID- 10598366
OWN - NLM
STAT- MEDLINE
DCOM- 20000114
LR  - 20190905
IS  - 0891-1150 (Print)
IS  - 0891-1150 (Linking)
VI  - 66
IP  - 10
DP  - 1999 Nov-Dec
TI  - Aspirin, ticlopidine, and clopidogrel in acute coronary syndromes: underused 
      treatments could save thousands of lives.
PG  - 615-8, 621-4, 627-8
AB  - Aspirin is the cornerstone of therapy for unstable angina and acute myocardial 
      infarction and the foundation on which other therapies are added, both in the 
      short term and the long term. Yet, despite clear data, aspirin is woefully 
      underused or is often used late. Prompt administration of aspirin could save 
      thousands of lives each year. Ticlopidine and clopidogrel have a synergistic 
      effect when used with aspirin, and can also have a role in treating patients who 
      are aspirin-resistant or have diffuse atherosclerosis.
FAU - Tan, W A
AU  - Tan WA
AD  - Section of Interventional Radiology, Pittsburgh Vascular Institute, University of 
      Pittsburgh Medical Center-Shadyside, USA.
FAU - Moliterno, D J
AU  - Moliterno DJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cleve Clin J Med
JT  - Cleveland Clinic journal of medicine
JID - 8703441
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/prevention & control
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Coronary Disease/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & 
      derivatives/*therapeutic use
RF  - 68
EDAT- 1999/12/22 00:00
MHDA- 1999/12/22 00:01
CRDT- 1999/12/22 00:00
PHST- 1999/12/22 00:00 [pubmed]
PHST- 1999/12/22 00:01 [medline]
PHST- 1999/12/22 00:00 [entrez]
AID - 10.3949/ccjm.66.10.615 [doi]
PST - ppublish
SO  - Cleve Clin J Med. 1999 Nov-Dec;66(10):615-8, 621-4, 627-8. doi: 
      10.3949/ccjm.66.10.615.

PMID- 6814274
OWN - NLM
STAT- MEDLINE
DCOM- 19821216
LR  - 20190627
IS  - 0002-9610 (Print)
IS  - 0002-9610 (Linking)
VI  - 144
IP  - 5
DP  - 1982 Nov
TI  - Inhibition of gastric mucosal carbonic anhydrase by taurocholic acid and other 
      ulcerogenic agents.
PG  - 554-7
AB  - Carbonic anhydrase, an enzyme catalyzing hydration of CO2 and vice versa, is 
      exceptionally abundant in the gastric mucosa, including the surface epithelial 
      cells where it seems to have a protective function. The present study evaluated 
      various ulcerogenic agents in terms of their ability to influence the activity of 
      carbonic anhydrase in the gastric mucosa. Taurocholic acid, acetylsalicylic acid, 
      and ethanol all significantly inhibited carbonic anhydrase derived from gastric 
      mucosa of the rat in in vitro conditions, and this inhibition occurred in 
      concentrations that are likely to be present within the stomach. In contrast, 
      lysolecithin and urea had no effect on carbonic anhydrase activity. In in vivo 
      situations, intragastric taurocholic acid (20 mM) likewise significantly 
      inhibited the activity of carbonic anhydrase in the gastric mucosa. The 
      inhibition was stronger in the presence of luminal acid (hydrochloric acid, 100 
      mM) than in the absence of it. In contrast, intragastric acetylsalicylic acid (20 
      mM) or ethanol (20 percent vol/vol) had no effect. Yet, intravenous 
      acetylsalicylic acid (20 mg/kg body weight) did have a slight but significant 
      inhibitory action. The results indicate that taurocholic acid is able to inhibit 
      gastric mucosal carbonic anhydrase, a feature which may contribute to its 
      ulcerogenic action. Even though acetylsalicylic acid and ethanol likewise inhibit 
      gastric carbonic anhydrase in vitro conditions, their action in in vivo 
      situations remains questionable.
FAU - Kivilaakso, E
AU  - Kivilaakso E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Surg
JT  - American journal of surgery
JID - 0370473
RN  - 0 (Carbonic Anhydrase Inhibitors)
RN  - 5E090O0G3Z (Taurocholic Acid)
RN  - EC 4.2.1.1 (Carbonic Anhydrases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - *Carbonic Anhydrase Inhibitors
MH  - Carbonic Anhydrases
MH  - Gastric Mucosa/*drug effects
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Taurocholic Acid/pharmacology
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
AID - 0002-9610(82)90579-7 [pii]
AID - 10.1016/0002-9610(82)90579-7 [doi]
PST - ppublish
SO  - Am J Surg. 1982 Nov;144(5):554-7. doi: 10.1016/0002-9610(82)90579-7.

PMID- 10796063
OWN - NLM
STAT- MEDLINE
DCOM- 20000628
LR  - 20191025
IS  - 0767-3981 (Print)
IS  - 0767-3981 (Linking)
VI  - 14
IP  - 2
DP  - 2000 Mar-Apr
TI  - Gastroduodenal tolerability of medium dose enteric-coated aspirin: a placebo 
      controlled endoscopic study of a new enteric-coated formulation versus regular 
      formulation in healthy volunteers.
PG  - 155-7
AB  - We compared, in a cross-over study, the toxicity of 300 mg enteric-coated aspirin 
      with regular aspirin used for the prevention of cardiovascular events. In terms 
      of endoscopic haemorrhagic lesions, enteric-coated aspirin is less gastrotoxic 
      than regular aspirin.
FAU - Blondon, H
AU  - Blondon H
AD  - Unité de recherches thérapeutiques, hôpital Lariboisière, Paris, France.
FAU - Barbier, J P
AU  - Barbier JP
FAU - Mahé, I
AU  - Mahé I
FAU - Deverly, A
AU  - Deverly A
FAU - Kolsky, H
AU  - Kolsky H
FAU - Bergmann, J F
AU  - Bergmann JF
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdominal Pain/chemically induced
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Duodenum/*drug effects/pathology
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Gastric Mucosa/drug effects/pathology
MH  - Humans
MH  - Male
MH  - Severity of Illness Index
MH  - Stomach/*drug effects/pathology
MH  - Tablets, Enteric-Coated
EDAT- 2000/05/05 09:00
MHDA- 2000/07/06 11:00
CRDT- 2000/05/05 09:00
PHST- 2000/05/05 09:00 [pubmed]
PHST- 2000/07/06 11:00 [medline]
PHST- 2000/05/05 09:00 [entrez]
AID - S0767398100001316 [pii]
AID - 10.1111/j.1472-8206.2000.tb00404.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2000 Mar-Apr;14(2):155-7. doi: 
      10.1111/j.1472-8206.2000.tb00404.x.

PMID- 26520197
OWN - NLM
STAT- MEDLINE
DCOM- 20170724
LR  - 20170724
IS  - 0210-5705 (Print)
IS  - 0210-5705 (Linking)
VI  - 38 Suppl 1
DP  - 2015 Sep
TI  - [Gastrointestinal bleeding].
PG  - 56-63
LID - S0210-5705(15)30020-0 [pii]
LID - 10.1016/S0210-5705(15)30020-0 [doi]
AB  - In the Digestive Disease Week in 2015 there have been some new contributions in 
      the field of gastrointestinal bleeding that deserve to be highlighted. Treatment 
      of celecoxib with a proton pump inhibitor is safer than treatment with 
      nonselective NSAID and a proton pump inhibitor in high risk gastrointestinal and 
      cardiovascular patients who mostly also take acetylsalicylic acid. Several 
      studies confirm the need to restart the antiplatelet or anticoagulant therapy at 
      an early stage after a gastrointestinal hemorrhage. The need for urgent endoscopy 
      before 6-12 h after the onset of upper gastrointestinal bleeding episode may be 
      beneficial in patients with hemodynamic instability and high risk for 
      comorbidity. It is confirmed that in Western but not in Japanese populations, 
      gastrointestinal bleeding episodes admitted to hospital during weekend days are 
      associated with a worse prognosis associated with delays in the clinical 
      management of the events. The strategy of a restrictive policy on blood 
      transfusions during an upper GI bleeding event has been challenged. Several 
      studies have shown the benefit of identifying the bleeding vessel in non varicose 
      underlying gastric lesions by Doppler ultrasound which allows direct endoscopic 
      therapy in the patient with upper GI bleeding. Finally, it has been reported that 
      lower gastrointestinal bleeding diverticula band ligation or hemoclipping are 
      both safe and have the same long-term outcomes.
CI  - Copyright © 2015 Elsevier España, S.L.U. All rights reserved.
FAU - Lanas, Ángel
AU  - Lanas Á
AD  - Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, 
      Universidad de Zaragoza, IIS Aragón, CIBERehd, Zaragoza, España. Electronic 
      address: alanas@unizar.es.
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Hemorragia gastrointestinal.
PL  - Spain
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anemia/etiology/therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Transfusion
MH  - Celecoxib/therapeutic use
MH  - Drug Therapy, Combination
MH  - Endoscopy, Gastrointestinal
MH  - *Gastrointestinal Hemorrhage/etiology/therapy
MH  - Hemorrhagic Disorders/chemically induced
MH  - Hemostatic Techniques
MH  - Humans
MH  - Ligation
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Thrombophilia/drug therapy
OTO - NOTNLM
OT  - Anticoagulantes
OT  - Anticoagulants
OT  - Antiinflamatorios no esteroideos
OT  - Aspirin
OT  - Doppler
OT  - Gastrointestinal bleeding
OT  - Hemorragia gastrointestinal
OT  - Nonsteroidal antinflammatory drugs
OT  - Tratamiento endoscópico
OT  - Ácido acetilsalicílico
OT  - Úlcera péptica
EDAT- 2015/11/02 06:00
MHDA- 2017/07/25 06:00
CRDT- 2015/11/02 06:00
PHST- 2015/11/02 06:00 [entrez]
PHST- 2015/11/02 06:00 [pubmed]
PHST- 2017/07/25 06:00 [medline]
AID - S0210-5705(15)30020-0 [pii]
AID - 10.1016/S0210-5705(15)30020-0 [doi]
PST - ppublish
SO  - Gastroenterol Hepatol. 2015 Sep;38 Suppl 1:56-63. doi: 
      10.1016/S0210-5705(15)30020-0.

PMID- 12510862
OWN - NLM
STAT- MEDLINE
DCOM- 20030604
LR  - 20220330
IS  - 0867-5910 (Print)
IS  - 0867-5910 (Linking)
VI  - 53
IP  - 4 Pt 2
DP  - 2002 Dec
TI  - The role of reactive oxygen species in action of nitric oxide-donors on 
      stress-induced gastric mucosal lesions.
PG  - 761-73
AB  - The experimental model of acute gastritis such as water immersion restraint (WRS) 
      stress-induced gastric injury is useful tool in examination of pathomechanism of 
      acute gastritis. Nitric oxide (NO) plays an important role in the maintenance of 
      gastric barrier, however, the interaction between reactive oxygen species (ROS) 
      and NO on gastric mucosal integrity has been little studied. The purpose of our 
      present study was to explain the participation of ROS in healing of WRS-induced 
      gastric lesions accelerated by NO. Experiments were carrying out on 120 male 
      Wistar rats. To assess gastric blood flow (GBF) laser Doppler flowmeter was used 
      and the number of gastric lesions was counted in each stomach. The colorimetric 
      assays were used to determine gastric tissue level of malondialdehyde (MDA) and 
      4-hydroxynonenal (4-HNE), the products of lipid peroxidation by ROS, as well as 
      superoxide dismutase (SOD) activity, the enzyme scavanger of ROS. We demonstrated 
      that 3.5 h of WRS resulted in appearance of acute gastric lesions accompanied by 
      a significant decrease of GBF. Biological effects of ROS were estimated by 
      measuring tissue levels of MDA and 4-HNE, as well as the SOD activity. It was 
      demonstrated that 3.5 h of WRS led to significant increase of mucosal levels of 
      MDA and 4-HNE, and it was accompanied by a decrease of SOD activity. Pretreatment 
      with NO-donors (SIN-1, SNAP, nitroglycerin, NO-ASA) resulted in reduction in 
      gastric lesion number, increment of GBF, decrease of MDA and 4-HNE tissue level 
      and increase of SOD activity. Suppression of ROS plays an important role in the 
      action of NO-donors on healing of acute gastric lesions induced by 3.5 h of WRS. 
      NO-donors caused an attenuation of lipid peroxidation as documented by a decrease 
      of MDA and 4-HNE levels and enhancement of antioxidative properties as evidenced 
      by an increase of SOD activity.
FAU - Kwiecień, S
AU  - Kwiecień S
AD  - Department of Physiology, Jagiellonian University School of Medicine, Cracow, 
      Poland.
FAU - Brzozowski, T
AU  - Brzozowski T
FAU - Konturek, P Ch
AU  - Konturek PCh
FAU - Konturek, S J
AU  - Konturek SJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Poland
TA  - J Physiol Pharmacol
JT  - Journal of physiology and pharmacology : an official journal of the Polish 
      Physiological Society
JID - 9114501
RN  - 0 (Aldehydes)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 5O5U71P6VQ (linsidomine)
RN  - 79032-48-7 (S-Nitroso-N-Acetylpenicillamine)
RN  - D46583G77X (Molsidomine)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - K1CVM13F96 (4-hydroxy-2-nonenal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aldehydes/analysis/*metabolism
MH  - Animals
MH  - Aspirin/*analogs & derivatives/metabolism/therapeutic use
MH  - Gastric Mucosa/blood supply/metabolism
MH  - Lipid Peroxidation/physiology
MH  - Male
MH  - Malondialdehyde/analysis/*metabolism
MH  - Molsidomine/*analogs & derivatives/metabolism
MH  - Nitric Oxide Donors/*metabolism
MH  - Nitroglycerin/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Reactive Oxygen Species/metabolism
MH  - Regional Blood Flow
MH  - S-Nitroso-N-Acetylpenicillamine/metabolism
MH  - Statistics, Nonparametric
MH  - Stomach Ulcer/*metabolism/prevention & control
MH  - Stress, Psychological/complications
MH  - Superoxide Dismutase/*metabolism
EDAT- 2003/01/04 04:00
MHDA- 2003/06/05 05:00
CRDT- 2003/01/04 04:00
PHST- 2003/01/04 04:00 [pubmed]
PHST- 2003/06/05 05:00 [medline]
PHST- 2003/01/04 04:00 [entrez]
PST - ppublish
SO  - J Physiol Pharmacol. 2002 Dec;53(4 Pt 2):761-73.

PMID- 3257376
OWN - NLM
STAT- MEDLINE
DCOM- 19880212
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 45
IP  - 1
DP  - 1988 Jan
TI  - Preoperative aspirin ingestion increases operative blood loss after coronary 
      artery bypass grafting.
PG  - 71-4
AB  - Thirty-four patients were entered into a non-blinded, randomized study to test 
      the effect of preoperative aspirin ingestion on postoperative blood loss and 
      transfusion requirements after coronary artery bypass grafting. Sixteen patients 
      in the aspirin-treated group had significantly increased chest-tube blood loss 12 
      hours after operation (1,513 +/- 978 versus 916 +/- 482 ml; p = 0.038). In 
      addition, aspirin users had significantly increased requirements for 
      postoperative packed red blood cells (4.4 +/- 3.5 versus 1.8 +/- 1.3 units; p = 
      0.014), platelets (1.3 +/- 1.3 versus 0.2 +/- 0.4 six-donor units, p = 0.0049), 
      and fresh-frozen plasma (3.6 +/- 5.0 versus 0.78 +/- 1.6 units; p = 0.042) 
      transfusions. The only patients requiring reoperation for bleeding were in the 
      aspirin-treated group (2 patients). Six patients were not entered into the 
      randomized part of the study because of excessively prolonged post-aspirin 
      bleeding times (greater than 10 minutes). This finding suggests that a subset of 
      patients are particularly sensitive to aspirin and have significantly prolonged 
      bleeding times after aspirin ingestion. We conclude that aspirin ingestion 
      increases postoperative blood loss and transfusion requirements, and we recommend 
      discontinuation of aspirin therapy before cardiac procedures.
FAU - Ferraris, V A
AU  - Ferraris VA
AD  - Department of Surgery, Letterman Army Medical Center, Presidio of San Francisco, 
      CA 94129-6700.
FAU - Ferraris, S P
AU  - Ferraris SP
FAU - Lough, F C
AU  - Lough FC
FAU - Berry, W R
AU  - Berry WR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Blood Transfusion
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Hemorrhage/*chemically induced/therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications
MH  - *Premedication
MH  - Prospective Studies
MH  - Random Allocation
MH  - Risk Factors
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - S0003-4975(10)62401-0 [pii]
AID - 10.1016/s0003-4975(10)62401-0 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1988 Jan;45(1):71-4. doi: 10.1016/s0003-4975(10)62401-0.

PMID- 8333454
OWN - NLM
STAT- MEDLINE
DCOM- 19930819
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 169
IP  - 1
DP  - 1993 Jul
TI  - Hepatic infarction during pregnancy complicated by antiphospholipid syndrome.
PG  - 199-202
AB  - A 33-year-old woman, gravida 4, was seen at 9 weeks' gestation. The patient had 
      experienced hepatic infarction during her first pregnancy and had repeated 
      hepatic infarction during her third pregnancy. A diagnosis of antiphospholipid 
      syndrome was made. The patient was maintained on a regimen of prednisolone and 
      aspirin and was delivered of a viable infant.
FAU - Kinoshita, K
AU  - Kinoshita K
AD  - Department of Obstetrics and Gynecology, Health Insurance Hitoyoshi General 
      Hospital, Kumamoto, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antiphospholipid Syndrome/*complications/diagnosis/drug therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Fetal Death/etiology
MH  - Humans
MH  - Infarction/*etiology
MH  - Liver/*blood supply
MH  - Prednisolone/therapeutic use
MH  - Pregnancy
MH  - *Pregnancy Complications
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
AID - 0002-9378(93)90164-E [pii]
AID - 10.1016/0002-9378(93)90164-e [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1993 Jul;169(1):199-202. doi: 10.1016/0002-9378(93)90164-e.

PMID- 18492771
OWN - NLM
STAT- MEDLINE
DCOM- 20080828
LR  - 20171116
IS  - 0193-1849 (Print)
IS  - 0193-1849 (Linking)
VI  - 295
IP  - 1
DP  - 2008 Jul
TI  - The nitric oxide-donating derivative of acetylsalicylic acid, NCX 4016, 
      stimulates glucose transport and glucose transporters translocation in 3T3-L1 
      adipocytes.
PG  - E162-9
LID - 10.1152/ajpendo.00622.2007 [doi]
AB  - NCX 4016 is a nitric oxide (NO)-donating derivative of acetylsalicylic acid. NO 
      and salicylate, in vivo metabolites of NCX 4016, were shown to be potential 
      actors in controlling glucose homeostasis. In this study, we evaluated the action 
      of NCX 4016 on the capacity of 3T3-L1 adipocytes to transport glucose in basal 
      and insulin-stimulated conditions. NCX 4016 induced a twofold increase in glucose 
      uptake in parallel with the translocation of the glucose transporters GLUT1 and 
      GLUT4 to the plasma membrane, leaving unaffected their total expression levels. 
      Importantly, NCX 4016 further increased glucose transport induced by a 
      physiological concentration of insulin. The stimulatory effect of NCX 4016 on 
      glucose uptake appears to be mediated by its NO moiety. Indeed, it is inhibited 
      by a NO scavenger and treatment with acetylsalicylic or salicylic acid had no 
      effect. Although NO is involved in the action of NCX 4016, it did not mainly 
      depend on the soluble cGMP cyclase/protein kinase G pathway. Furthermore, NCX 
      4016-stimulated glucose transport did not involve the insulin-signaling cascade 
      required to stimulate glucose transport. NCX 4016 induces a small activation of 
      the mitogen-activated protein kinases p38 and c-Jun NH(2)-terminal kinase and no 
      activation of other stress-activated signaling molecules, including extracellular 
      signal-regulated kinase, inhibitory factor kappaB, or AMP-activated kinases. 
      Interestingly, NCX 4016 modified the content of S-nitrosylated proteins in 
      adipocytes. Taken together, our results indicate that NCX 4016 induced glucose 
      transport in adipocytes through a novel mechanism possibly involving 
      S-nitrosylation. NCX 4016 thus possesses interesting characteristics to be 
      considered as a candidate molecule for the treatment of patients suffering from 
      metabolic syndrome and type 2 diabetes.
FAU - Kaddai, V
AU  - Kaddai V
AD  - Institut National de la Santé et de la Recherche Médicale Unité 895, Cellular and 
      Molecular Physiopathology of Obesity and Diabetes, Faculté de Médecine, 
      University of Nice/Sophia-Antipolis, Nice, France.
FAU - Gonzalez, T
AU  - Gonzalez T
FAU - Bolla, M
AU  - Bolla M
FAU - Le Marchand-Brustel, Y
AU  - Le Marchand-Brustel Y
FAU - Cormont, M
AU  - Cormont M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080520
PL  - United States
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
RN  - 0 (Glucose Transporter Type 1)
RN  - 0 (Glucose Transporter Type 4)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Slc2a1 protein, mouse)
RN  - 0 (Slc2a4 protein, mouse)
RN  - 169D1260KM (Nitroprusside)
RN  - 9G2MP84A8W (Deoxyglucose)
RN  - EH04H13L6B (nitroaspirin)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 3T3-L1 Cells
MH  - Adipocytes/*drug effects/metabolism
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Biological Transport/drug effects
MH  - Blotting, Western
MH  - Cell Membrane/drug effects/metabolism
MH  - Deoxyglucose/metabolism
MH  - Glucose/*metabolism
MH  - Glucose Transporter Type 1/*metabolism
MH  - Glucose Transporter Type 4/*metabolism
MH  - Immunohistochemistry
MH  - Mice
MH  - Microscopy, Fluorescence
MH  - Nitric Oxide Donors/*pharmacology
MH  - Nitroprusside/pharmacology
MH  - Stimulation, Chemical
EDAT- 2008/05/22 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/05/22 09:00
PHST- 2008/05/22 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/05/22 09:00 [entrez]
AID - 00622.2007 [pii]
AID - 10.1152/ajpendo.00622.2007 [doi]
PST - ppublish
SO  - Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E162-9. doi: 
      10.1152/ajpendo.00622.2007. Epub 2008 May 20.

PMID- 3129687
OWN - NLM
STAT- MEDLINE
DCOM- 19880602
LR  - 20210112
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 32
IP  - 3
DP  - 1988 Mar
TI  - Depression by morphine and the non-opioid analgesic agents, metamizol (dipyrone), 
      lysine acetylsalicylate, and paracetamol, of activity in rat thalamus neurones 
      evoked by electrical stimulation of nociceptive afferents.
PG  - 313-326
LID - 10.1016/0304-3959(88)90043-7 [doi]
AB  - Pyrazolone and salicylic acid derivatives and the aniline derivative, 
      paracetamol, are often classified as peripherally acting analgesic agents, while 
      morphine is a centrally acting analgesic agent. Since indications exist that the 
      non-opioid analgesic agents can also produce central effects, experiments were 
      carried out on rats under urethane anaesthesia in which activity was recorded 
      from single neurones in the dorsomedial part of the ventral nucleus (VDM) of the 
      thalamus that was elicited by supramaximal electrical stimulation of nociceptive 
      afferents in the sural nerve. In addition, activity was recorded in ascending 
      axons of the spinal cord which was evoked by electrical stimulation of 
      nociceptive afferents in the sural nerve. The substances studied were morphine, 
      the pyrazolone derivatives, metamizol (dipyrone) and aminophenazone 
      ('Pyramidon'), lysine acetylsalicylate, and paracetamol. All drugs were found to 
      depress dose-dependently evoked activity in VDM neurones after intravenous (i.v.) 
      injection. The ED50 of morphine in depressing evoked activity in VDM neurones is 
      0.05 mg/kg. Morphine also dose-dependently reduced activity in ascending axons of 
      the spinal cord, the ED50 being 1.7 mg/kg. The ED50 of metamizol in depressing 
      evoked activity in VDM neurones is 120 mg/kg, and that of aminophenazone is 22.7 
      mg/kg. The 2 ED50 values differ significantly. It has been found previously that 
      metamizol increased nociceptive activity in some ascending axons and 
      aminophenazone increased this activity in all ascending axons tested. The ED50 of 
      lysine acetylsalicylate in depressing evoked activity in VDM neurones is 74 
      mg/kg. The drug did not reduce nociceptive activity in ascending axons of the 
      spinal cord. The ED50 of paracetamol in depressing evoked activity in VDM 
      neurones is 19.0 mg/kg. Paracetamol did not depress nociceptive activity in 
      ascending axons of the spinal cord at a dose as high as 150 mg/kg administered by 
      intraperitoneal injection. Naloxone (0.2 mg/kg i.v.) abolished the depressant 
      effects of morphine but failed to reduce those of the non-opioid analgesic agents 
      even at a high dose (1 mg/kg i.v.). Unlike morphine, the non-opioid analgesic 
      agents did not completely block evoked activity in VDM neurones but only 
      partially blocked their activation. The results suggest that the non-opioid 
      analgesic agents tested can produce a central analgesic effect which, however, is 
      weaker than that of morphine.
FAU - Carlsson, Karl-Heinz
AU  - Carlsson KH
AD  - Institut für Pharmakologie und Toxikologie, Universität des Saarlandes, D-6650 
      Homburg/SaarF.R.G.
FAU - Monzel, Wolfgang
AU  - Monzel W
FAU - Jurna, Ilmar
AU  - Jurna I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - 0 (Analgesics)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 6429L0L52Y (Dipyrone)
RN  - 76I7G6D29C (Morphine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acetaminophen/pharmacology
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Dipyrone/pharmacology
MH  - Electric Stimulation
MH  - Female
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Morphine/*pharmacology
MH  - Neurons/drug effects/physiology
MH  - Nociceptors/*drug effects/physiology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Thalamus/*drug effects/physiology
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
AID - 00006396-198803000-00008 [pii]
AID - 10.1016/0304-3959(88)90043-7 [doi]
PST - ppublish
SO  - Pain. 1988 Mar;32(3):313-326. doi: 10.1016/0304-3959(88)90043-7.

PMID- 11234463
OWN - NLM
STAT- MEDLINE
DCOM- 20010412
LR  - 20131121
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 55
IP  - 6
DP  - 2000 Nov-Dec
TI  - [Study of combined anticoagulant (fluindione)-aspirin therapy in patients with 
      atrial fibrillation at high risk for thromboembolic complications. A randomized 
      trial (FFAACS)].
PG  - 681-9
AB  - BACKGROUND: A combination of low-dose aspirin (A) and anticoagulation (AC) may 
      provide better protection against thromboembolic events compared with AC alone in 
      high-risk patients with atrial fibrillation (AF). METHODS: We performed a 
      multicentric placebo-controlled double blind-trial to test the preventive 
      efficacy against thromboembolic events of the addition of aspirin (A) (100 mg) or 
      placebo (P) to anticoagulant treatment in patients with high-risk atrial 
      fibrillation. A total of 157 patients were included, with atrial fibrillation and 
      previous thromboembolic event or older than 65 years with either a history of 
      hypertension, a recent episode of heart failure or a left ventricular 
      dysfunction. All patients received fluindione (F) and P or F and A, with an INR 
      target between 2 and 2.6. The primary endpoint was a combined endpoint of stroke 
      (ischaemic or haemorrhagic), myocardial infarction, systemic arterial emboli or 
      vascular death. RESULTS: The study had to be stopped prematurely owing to a too 
      low recruitment rate. During follow-up (0.84 years) 3 non-fatal thromboembolic 
      events were recorded (1P, 2A) and 6 patients died (3P, 3A), none of them from a 
      thromboembolic complication. However, 3 deaths were secondary to severe 
      haemorrhagic complications (1P, 2A). Non-fatal haemorrhagic complications 
      occurred more often in group A (n = 10, 13.1 pour cent) compared with group P (n 
      = 1, 1.2 pour cent), p = 0.003. CONCLUSION: The FFAACS study was not able to show 
      any therapeutic benefit from the addition of aspirin to anticoagulant in patients 
      with high-risk AF. Such a combination increased the incidence rate of bleeding 
      complications, which therefore greatly reduces its potential overall benefit.
FAU - Lechat, P
AU  - Lechat P
AD  - Service de Pharmacologie, Hôpital Pitié Salpêtrière, 47 Bd de l'Hôpital 75013 
      Paris, France.
FAU - Lardoux, H
AU  - Lardoux H
FAU - Mallet, A
AU  - Mallet A
FAU - Sanchez, P
AU  - Sanchez P
FAU - Derumeaux, G
AU  - Derumeaux G
FAU - Lecompte, T
AU  - Lecompte T
FAU - Maillard, L
AU  - Maillard L
FAU - Mas, J L
AU  - Mas JL
FAU - Mentré, F
AU  - Mentré F
FAU - Pousset, F
AU  - Pousset F
FAU - Lacomblez, L
AU  - Lacomblez L
FAU - Pisica, G
AU  - Pisica G
FAU - Solbes-Latourette, S
AU  - Solbes-Latourette S
FAU - Raynaud, P
AU  - Raynaud P
FAU - Chaumet-Riffaud, P
AU  - Chaumet-Riffaud P
CN  - Investigateurs de FFAACS
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
TT  - Etude de l'association anticoagulant (fluindione)-aspirine, chez les patients en 
      fibrillation auriculaire à haut risque de complications thrombo-emboliques. Une 
      étude randomisée (FFAACS).
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Anticoagulants)
RN  - 5M7Y6274ZE (Phenindione)
RN  - EQ35YMS20Q (fluindione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Patient Selection
MH  - Phenindione/*analogs & derivatives/*therapeutic use
MH  - Recurrence
MH  - Risk Factors
MH  - Thromboembolism/epidemiology/etiology/*prevention & control
EDAT- 2001/03/10 10:00
MHDA- 2001/04/17 10:01
CRDT- 2001/03/10 10:00
PHST- 2001/03/10 10:00 [pubmed]
PHST- 2001/04/17 10:01 [medline]
PHST- 2001/03/10 10:00 [entrez]
PST - ppublish
SO  - Therapie. 2000 Nov-Dec;55(6):681-9.

PMID- 1558300
OWN - NLM
STAT- MEDLINE
DCOM- 19920504
LR  - 20190824
IS  - 0145-6008 (Print)
IS  - 0145-6008 (Linking)
VI  - 16
IP  - 1
DP  - 1992 Feb
TI  - Effects of indomethacin, aspirin, and acetaminophen on ethanol diuresis in rats.
PG  - 38-40
AB  - A number of studies have indicated that prostaglandin synthetase inhibitors 
      (PGSI) can antagonize several effects of ethanol. This study examines the 
      influence of intraperitoneal pretreatment with the PGSI indomethacin (5.0 or 10.0 
      mg/kg), aspirin (15.0 or 30.0 mg/kg) and acetaminophen (15.0 or 30.0 mg/kg) on 
      the diuretic effect produced by orally administered ethanol (4.0 g/kg) in female 
      rats. Pretreatments with indomethacin and aspirin led to an antagonism of 
      ethanol's diuretic effect. Nevertheless, acetaminophen failed to antagonize this 
      effect. These results are in agreement with data from the literature on PGSI 
      versus ethanol and suggest possible involvement of prostaglandins in the diuretic 
      effect of ethanol.
FAU - Morato, G S
AU  - Morato GS
AD  - Department of Pharmacology, Universidade Federal de Santa Catarina, 
      Florianópolis, Brazil.
FAU - Lemos, T
AU  - Lemos T
FAU - Morato, E F
AU  - Morato EF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Alcohol Clin Exp Res
JT  - Alcoholism, clinical and experimental research
JID - 7707242
RN  - 0 (Prostaglandins)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Alcohol Drinking/*physiopathology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Diuresis/*drug effects/physiology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Indomethacin/*pharmacology
MH  - Prostaglandins/*physiology
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
AID - 10.1111/j.1530-0277.1992.tb00632.x [doi]
PST - ppublish
SO  - Alcohol Clin Exp Res. 1992 Feb;16(1):38-40. doi: 
      10.1111/j.1530-0277.1992.tb00632.x.

PMID- 20388864
OWN - NLM
STAT- MEDLINE
DCOM- 20100716
LR  - 20131121
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 44
IP  - 5
DP  - 2010 May
TI  - Aspirin dosing for the prevention and treatment of ischemic stroke: an 
      indication-specific review of the literature.
PG  - 851-62
LID - 10.1345/aph.1M346 [doi]
AB  - OBJECTIVE: To evaluate the efficacy of aspirin for the treatment and prevention 
      of ischemic stroke and identify the minimum dose proven to be effective for each 
      indication. DATA SOURCES: PubMed and MEDLINE searches (up to January 2010) were 
      performed to identify primary literature, using search terms including aspirin, 
      stroke prevention, acute ischemic stroke, acetylsalicylic acid, atrial 
      fibrillation, myocardial infarction, and carotid endarterectomy. Additionally, 
      reference citations from publications identified were reviewed. STUDY SELECTION 
      AND DATA EXTRACTION: Articles published in English were evaluated and relevant 
      primary literature evaluating the efficacy of aspirin in the prevention of stroke 
      was included in this review. DATA SYNTHESIS: Antiplatelet therapy is the 
      benchmark for the prevention of ischemic stroke. Aspirin has been proven to 
      prevent ischemic stroke in a variety of settings. Despite the frequency at which 
      aspirin continues to be prescribed in patients at risk of ischemic stroke, there 
      remains confusion in clinical practice as to what minimum dose is required in 
      various at-risk patients. A thorough review of the primary literature suggests 
      that low-dose (50-81 mg daily) aspirin is insufficient for some indications. 
      Acute ischemic stroke treatment requires 160-325 mg, while atrial fibrillation 
      and carotid arterial disease require daily doses of 325 and 81-325 mg, 
      respectively. CONCLUSIONS: Available evidence suggests that aspirin dosing must 
      be individualized according to indication. Recommendations provided by national 
      guidelines at times recommend lower doses of aspirin than have been proven 
      effective. Higher doses are indicated for stroke prevention in atrial 
      fibrillation (325 mg) and acute ischemic stroke patients (160-325 mg). Aspirin 
      has not yet been proven effective for primary prevention of strokes in men, and a 
      minimum dose for these patients cannot be determined from the available data.
FAU - Ansara, Alexander J
AU  - Ansara AJ
AD  - Department of Pharmacy, Methodist Hospital (Clarian Health), Indianapolis, IN 
      46202, USA. aansara@clarian.org
FAU - Nisly, Sarah A
AU  - Nisly SA
FAU - Arif, Sally A
AU  - Arif SA
FAU - Koehler, Julia M
AU  - Koehler JM
FAU - Nordmeyer, Sarah T
AU  - Nordmeyer ST
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100413
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/pharmacology/*therapeutic use
MH  - Atherosclerosis/blood/*drug therapy/enzymology
MH  - Carotid Artery Diseases/blood/drug therapy/enzymology/surgery
MH  - Dose-Response Relationship, Drug
MH  - Endothelium, Vascular/drug effects/enzymology
MH  - Humans
MH  - Ischemia/blood/*drug therapy/enzymology
MH  - Myocardial Infarction/blood/drug therapy/enzymology
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/pharmacology/*therapeutic use
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Stroke/enzymology/etiology/*prevention & control
MH  - Thromboxane A2/metabolism
RF  - 68
EDAT- 2010/04/15 06:00
MHDA- 2010/07/17 06:00
CRDT- 2010/04/15 06:00
PHST- 2010/04/15 06:00 [entrez]
PHST- 2010/04/15 06:00 [pubmed]
PHST- 2010/07/17 06:00 [medline]
AID - aph.1M346 [pii]
AID - 10.1345/aph.1M346 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2010 May;44(5):851-62. doi: 10.1345/aph.1M346. Epub 2010 Apr 
      13.

PMID- 22866967
OWN - NLM
STAT- MEDLINE
DCOM- 20130607
LR  - 20220316
IS  - 1557-7716 (Electronic)
IS  - 1523-0864 (Linking)
VI  - 18
IP  - 5
DP  - 2013 Feb 10
TI  - Aspirin inhibits oxidant stress, reduces age-associated functional declines, and 
      extends lifespan of Caenorhabditis elegans.
PG  - 481-90
LID - 10.1089/ars.2011.4151 [doi]
AB  - AIMS: Oxidative stress and inflammation are leading risk factors for 
      age-associated functional declines. We assessed aspirin effects on endogenous 
      oxidative-stress levels, lifespan, and age-related functional declines, in the 
      nematode Caenorhabditis elegans. RESULTS: Both aspirin and its salicylate moiety, 
      at nontoxic concentrations (0.5-1 mM), attenuated endogenous levels of reactive 
      oxygen species (p<0.001), and upregulated antioxidant genes encoding superoxide 
      dismutases (especially sod-3, p<0.001), catalases (especially ctl-2, p<0.0001), 
      and two glutathione-S-transferases (gst-4 and gst-10; each p<0.005). Aspirin, and 
      to a lesser degree salicylate, improved survival of hydrogen peroxide, and in the 
      absence of exogenous stress aspirin extended lifespan by 21%-23% (each p<10(-9)), 
      while salicylate added 14% (p<10(-6)). Aspirin and salicylate delayed 
      age-dependent declines in motility and pharyngeal pumping (each p<0.005), and 
      decreased intracellular protein aggregation (p<0.0001)-all established markers of 
      physiological aging-consistent with slowing of the aging process. Aspirin fails 
      to improve stress resistance or lifespan in nematodes lacking DAF-16, implying 
      that it acts through this FOXO transcription factor. INNOVATION: Studies in mice 
      and humans suggest that aspirin may protect against multiple age-associated 
      diseases by reducing all-cause mortality. We now demonstrate that aspirin 
      markedly slows many measures of aging in the nematode. CONCLUSIONS: Aspirin 
      treatment is associated with diminished endogenous oxidant stress and enhanced 
      resistance to exogenous peroxide, both likely mediated by activation of 
      antioxidant defenses. Our evidence indicates that aspirin attenuates insulin-like 
      signaling, thus protecting against oxidative stress, postponing age-associated 
      functional declines and extending C. elegans lifespan under benign conditions.
FAU - Ayyadevara, Srinivas
AU  - Ayyadevara S
AD  - Central Arkansas Veterans Healthcare System, Little Rock, Arkansas 72205, USA. 
      AyyadevaraSrinivas@uams.edu
FAU - Bharill, Puneet
AU  - Bharill P
FAU - Dandapat, Abhijit
AU  - Dandapat A
FAU - Hu, Changping
AU  - Hu C
FAU - Khaidakov, Magomed
AU  - Khaidakov M
FAU - Mitra, Sona
AU  - Mitra S
FAU - Shmookler Reis, Robert J
AU  - Shmookler Reis RJ
FAU - Mehta, Jawahar L
AU  - Mehta JL
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20120907
PL  - United States
TA  - Antioxid Redox Signal
JT  - Antioxidants & redox signaling
JID - 100888899
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aging/*physiology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Caenorhabditis elegans/*drug effects/metabolism/physiology
MH  - Life Expectancy
MH  - Locomotion
MH  - Microscopy, Fluorescence
MH  - Oxidative Stress/*drug effects
EDAT- 2012/08/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2012/08/08 06:00
PHST- 2012/08/08 06:00 [entrez]
PHST- 2012/08/08 06:00 [pubmed]
PHST- 2013/06/08 06:00 [medline]
AID - 10.1089/ars.2011.4151 [doi]
PST - ppublish
SO  - Antioxid Redox Signal. 2013 Feb 10;18(5):481-90. doi: 10.1089/ars.2011.4151. Epub 
      2012 Sep 7.

PMID- 17111262
OWN - NLM
STAT- MEDLINE
DCOM- 20070227
LR  - 20131121
IS  - 0957-5243 (Print)
IS  - 0957-5243 (Linking)
VI  - 17
IP  - 10
DP  - 2006 Dec
TI  - Aspirin may be more effective in preventing colorectal adenomas in patients with 
      higher BMI (United States).
PG  - 1299-304
AB  - Obesity is a risk factor for colon cancer, possibly due to elevated levels of 
      circulating cytokines derived from adipose tissue. Aspirin, which may affect the 
      levels of these cytokines, has been shown in randomized controlled trials to 
      decrease the risk of colorectal adenomas. We hypothesized that the 
      chemopreventive effect of aspirin might be greater in individuals with higher 
      body mass index (BMI). Data were available from the Aspirin/Folate Polyp 
      Prevention Study, a randomized controlled trial of aspirin and folic acid to 
      prevent recurrent colorectal adenomas. Obesity was defined as BMI > or = 30 
      (kg/m2), overweight as BMI of 25-29 (kg/m2) and normal weight as BMI <25 (kg/m2). 
      For the analysis of the effect of aspirin on the recurrence of colorectal adenoma 
      by BMI, we computed risk ratios for aspirin versus placebo within the three BMI 
      strata using a modified Poisson model. Overall the risk reduction of adenomas 
      with a daily dose of 325 mg aspirin was greater among subjects with higher BMI. 
      Among obese subjects the risk ratio (RR) for advanced adenomas compared with 
      placebo was 0.44 (95% CI 0.17-1.10), versus RR = 1.23 (95% CI 0.55-2.77) among 
      those with normal weight. However, 81 mg aspirin daily did not interact with BMI 
      to modify the risk of adenomas in such a fashion. The more pronounced effect of 
      325 mg aspirin in individuals with higher BMI suggests a possible protective role 
      of anti-inflammatory aspirin against increased adipose-driven cytokines among 
      obese subjects.
FAU - Kim, Sangmi
AU  - Kim S
AD  - Department of Epidemiology, School of Public Health, University of North 
      Carolina, Chapel Hill, NC 27599-7555, USA.
FAU - Baron, John A
AU  - Baron JA
FAU - Mott, Leila A
AU  - Mott LA
FAU - Burke, Carol A
AU  - Burke CA
FAU - Church, Timothy R
AU  - Church TR
FAU - McKeown-Eyssen, Gail E
AU  - McKeown-Eyssen GE
FAU - Cole, Bernard F
AU  - Cole BF
FAU - Haile, Robert W
AU  - Haile RW
FAU - Sandler, Robert S
AU  - Sandler RS
LA  - eng
GR  - P30 DK34987/DK/NIDDK NIH HHS/United States
GR  - R01 CA59005/CA/NCI NIH HHS/United States
GR  - RR000046/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenomatous Polyps/*prevention & control
MH  - Aspirin/*pharmacology
MH  - *Body Mass Index
MH  - Colorectal Neoplasms/*prevention & control
MH  - Confidence Intervals
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Recurrence
MH  - United States
EDAT- 2006/11/18 09:00
MHDA- 2007/02/28 09:00
CRDT- 2006/11/18 09:00
PHST- 2006/05/17 00:00 [received]
PHST- 2006/08/17 00:00 [accepted]
PHST- 2006/11/18 09:00 [pubmed]
PHST- 2007/02/28 09:00 [medline]
PHST- 2006/11/18 09:00 [entrez]
AID - 10.1007/s10552-006-0075-x [doi]
PST - ppublish
SO  - Cancer Causes Control. 2006 Dec;17(10):1299-304. doi: 10.1007/s10552-006-0075-x.

PMID- 22724410
OWN - NLM
STAT- MEDLINE
DCOM- 20130425
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 18
IP  - 33
DP  - 2012
TI  - Clinical use of aspirin in ischemic heart disease: past, present and future.
PG  - 5215-23
AB  - Aspirin is an antiplatelet drug, inhibiting the cyclooxygenase activity of 
      platelet prostaglandin H synthase-1 and almost complete suppressing platelet 
      capacity to generate the prothrombotic and proatherogenic thromboxane A2. 
      Antiplatelet therapy with aspirin reduces the risk of serious vascular events by 
      about a quarter in patients who are at high risk because they already have 
      occlusive vascular disease. However, the inhibition of thromboxane-dependent 
      platelet function by aspirin is effective for the prevention of thrombosis, but 
      is also associated with excess bleeding, although the absolute increase in major 
      gastrointestinal or other major extracranial bleeds is an order of magnitude 
      smaller. For secondary prevention of vascular events, the benefits of aspirin 
      therapy substantially exceed the risks. Therefore, aspirin is a cornerstone of 
      antithrombotic therapy in acute coronary syndromes, in chronic ischemic heart 
      disease and in percutaneous coronary intervention. On the other hand, the role of 
      aspirin in primary prevention remains uncertain and it is still debated, because 
      the absolute risk of vascular complications is the major determinant of the 
      absolute benefit of antiplatelet prophylaxis and the reduction in vascular events 
      needs to be weighed against any increase in major bleeds. Future data from 
      ongoing studies will help us to identify people at high vascular risk who take 
      advantage from aspirin therapy for primary prevention or will indicate if 
      specific category of high risk patients, like patients with diabetes, could be 
      better protected from an increase in the frequency of aspirin administration.
FAU - De Caterina, Raffaele
AU  - De Caterina R
AD  - Institute of Cardiology, "G. d'Annunzio" University - Chieti, C/o Ospedale SS. 
      Annunziata, Via dei Vestini, 66013 Chieti, Italy. rdecater@unich.it
FAU - Renda, Giulia
AU  - Renda G
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/history/*therapeutic use
MH  - Blood Platelets/*drug effects/metabolism
MH  - Cyclooxygenase 1/blood
MH  - Cyclooxygenase Inhibitors/adverse effects/history/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Myocardial Ischemia/blood/*drug therapy
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/adverse effects/history/*therapeutic use
MH  - *Primary Prevention/history/trends
MH  - Risk Factors
MH  - *Secondary Prevention/history/trends
MH  - Thromboxane A2/blood
MH  - Treatment Outcome
EDAT- 2012/06/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2012/06/26 06:00
PHST- 2012/04/16 00:00 [received]
PHST- 2012/04/26 00:00 [accepted]
PHST- 2012/06/26 06:00 [entrez]
PHST- 2012/06/26 06:00 [pubmed]
PHST- 2013/04/26 06:00 [medline]
AID - CPD-EPUB-20120619-3 [pii]
AID - 10.2174/138161212803251943 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2012;18(33):5215-23. doi: 10.2174/138161212803251943.

PMID- 3665179
OWN - NLM
STAT- MEDLINE
DCOM- 19871201
LR  - 20131121
IS  - 0196-6383 (Print)
IS  - 0196-6383 (Linking)
VI  - 23
DP  - 1987
TI  - The basis for aspirin dosage in stroke prevention.
PG  - 47-54
AB  - Many strokes are thought to develop as a consequence of platelet aggregation on 
      areas of arterial endothelial damage, with subsequent embolism or thrombus 
      formation. Aspirin prevents platelet adhesion and aggregation by inhibiting the 
      formation of thromboxane A2 by platelets. This suggests that aspirin could be 
      used to prevent stroke. However aspirin also inhibits endothelial formation of 
      the anti-aggregatory substance prostacyclin, though probably only in a slightly 
      higher dose than that just capable of inhibiting platelet aggregation. 
      Consequently, too high an aspirin dose may defeat its purpose. The effect of 
      aspirin on platelets lasts for as long as they survive, whereas the effects of 
      aspirin on endothelium are shorter. Theoretical considerations suggest that 
      aspirin, given in brief pulses just to reach platelet inhibitory concentrations 
      in plasma, and administered at the maximum interval that will maintain inhibition 
      of platelet aggregation, should offer the most favourable balance between altered 
      platelet and altered endothelial function from the viewpoint of stroke 
      prevention. Data are presented showing that rapid rather than slow or delayed 
      release aspirin preparations are necessary to achieve suitable plasma aspirin 
      concentration-time profiles in humans, and that a peak plasma aspirin 
      concentration of around 1.2 mg/L is necessary in vivo to inhibit aggregability of 
      previously untreated platelets.
FAU - Brandon, R A
AU  - Brandon RA
AD  - Department of Medicine, University of Queensland, Brisbane.
FAU - Eadie, M J
AU  - Eadie MJ
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Clin Exp Neurol
JT  - Clinical and experimental neurology
JID - 7909724
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Endothelium, Vascular/drug effects
MH  - Humans
MH  - Intracranial Embolism and Thrombosis/prevention & control
MH  - Ischemic Attack, Transient/prevention & control
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Neurol. 1987;23:47-54.

PMID- 1918515
OWN - NLM
STAT- MEDLINE
DCOM- 19911028
LR  - 20191028
IS  - 0140-1971 (Print)
IS  - 0140-1971 (Linking)
VI  - 14
IP  - 2
DP  - 1991 Jun
TI  - The challenge of deliberate self-harm by young adolescents.
PG  - 135-48
AB  - This paper describes a model of crisis intervention to families of adolescents 
      below the age of 16 who deliberately harm themselves and summarizes the premises 
      which guide our practice. The adolescent's "overdose" is understood as an attempt 
      to resolve relationship conflicts and so the initial interview aims to explore 
      the predicament for the adolescent and the family and decide what further help 
      may be required. Verbatim extracts from one session illustrate this process.
FAU - Reder, P
AU  - Reder P
AD  - Department of Child and Family Psychiatry, Charing Cross Hospital, London, U.K.
FAU - Lucey, C
AU  - Lucey C
FAU - Fredman, G
AU  - Fredman G
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - J Adolesc
JT  - Journal of adolescence
JID - 7808986
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/poisoning
MH  - Drug Overdose
MH  - Family
MH  - Female
MH  - Humans
MH  - Interview, Psychological
MH  - Patient Discharge
MH  - Psychotherapy/*methods
MH  - Suicide, Attempted/*psychology
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
AID - 0140-1971(91)90026-N [pii]
AID - 10.1016/0140-1971(91)90026-n [doi]
PST - ppublish
SO  - J Adolesc. 1991 Jun;14(2):135-48. doi: 10.1016/0140-1971(91)90026-n.

PMID- 2180779
OWN - NLM
STAT- MEDLINE
DCOM- 19900501
LR  - 20191022
IS  - 0364-2356 (Print)
IS  - 0364-2356 (Linking)
VI  - 15
IP  - 2
DP  - 1990 Spring
TI  - Rectal stenosis following the use of suppositories containing paracetamol and 
      acetylsalicylic acid.
PG  - 171-3
AB  - The authors report the case of a 74-year-old woman presenting a rectal stenosis 
      that arose after the prolonged use of suppositories containing an association of 
      paracetamol and acetylsalicylic acid (Perdolan). On the basis of a review of the 
      literature, the clinical, histological, and radiological features are discussed.
FAU - Baekelandt, M
AU  - Baekelandt M
AD  - Department of Radiology, O.L. Vrouwziekenhuis Aalst, Belgium.
FAU - Vansteenberge, R
AU  - Vansteenberge R
FAU - Van der Spek, P
AU  - Van der Spek P
FAU - D'Haenens, P
AU  - D'Haenens P
FAU - Rollier, A
AU  - Rollier A
FAU - Stockx, L
AU  - Stockx L
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Gastrointest Radiol
JT  - Gastrointestinal radiology
JID - 7611134
RN  - 0 (Suppositories)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*adverse effects
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Humans
MH  - Intestinal Obstruction/*chemically induced
MH  - Rectal Diseases/*chemically induced
MH  - Suppositories
RF  - 12
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1007/BF01888766 [doi]
PST - ppublish
SO  - Gastrointest Radiol. 1990 Spring;15(2):171-3. doi: 10.1007/BF01888766.

PMID- 952105
OWN - NLM
STAT- MEDLINE
DCOM- 19761002
LR  - 20161123
IS  - 0044-409X (Print)
IS  - 0044-409X (Linking)
VI  - 101
IP  - 10
DP  - 1976
TI  - [Postoperative prophylaxis of thromboembolism. Present position.(author's 
      transl)].
PG  - 577-85
AB  - Only anti-coagulators and aggregation-stoppers may be said to be the medicamental 
      prophylaxis of thromboembolism. The Cumarin-Indandion group is burdened with 
      continuous laboratory controls. Contraindications excluding a general prophylaxis 
      for this group as well as for Heparin and ASS exist. Infukoll, which is virtually 
      always applicable, has the disadvantage that it has to be infused. Heparin- and 
      Dextranspreparations however can already be used preoperatively, which means that 
      a further decline of the coagulation complications can be expected.
FAU - Flemming, F
AU  - Flemming F
FAU - Thomas, E
AU  - Thomas E
FAU - Widera, R
AU  - Widera R
LA  - ger
PT  - Case Reports
PT  - Journal Article
TT  - Derzeitiger Stand der postoperativen Thromboembolieprophylaxe.
PL  - Germany
TA  - Zentralbl Chir
JT  - Zentralblatt fur Chirurgie
JID - 0413645
RN  - 0 (Coumarins)
RN  - 0 (Dextrans)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Coumarins/therapeutic use
MH  - Dextrans/therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
MH  - Preoperative Care
MH  - Thromboembolism/*prevention & control
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Zentralbl Chir. 1976;101(10):577-85.

PMID- 9193008
OWN - NLM
STAT- MEDLINE
DCOM- 19970710
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 79
IP  - 2
DP  - 1997 Jan 15
TI  - Interaction between enalapril and aspirin on mortality after acute myocardial 
      infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril 
      Survival Study II (CONSENSUS II).
PG  - 115-9
AB  - The use of angiotensin-converting enzyme (ACE) inhibitors early after an acute 
      myocardial infarction to reduce mortality has been studied in several trials with 
      inconsistent results. Aspirin (ASA) has become a well-documented therapeutic 
      adjunct in patients with coronary heart disease. Attention has recently been 
      focused on a possible interaction between ASA and ACE inhibitors. We therefore 
      reanalyzed data from the Cooperative New Scandinavian Enalapril Survival Study II 
      (CONSENSUS II) to find any evidence of differential effects of the ACE inhibitor 
      enalapril in subgroups defined by use of ASA at baseline. Logistic regression 
      tested the multiplicative interaction. We used Rothman synergy index S, which 
      would be equal to unity under additivity, and less than unity when suggesting 
      antagonism, to examine the postulated interaction with departure from an additive 
      model. Logistic regression showed that the enalapril-ASA interaction term was a 
      significant predictor of mortality at the end of the study (p = 0.047), and was a 
      borderline significant predictor of mortality 30 days after randomization (p = 
      0.085). The Rothman synergy index S was 0.66 (95% confidence interval 0.46 to 
      0.94) for mortality at the end of the study, and 0.68 ( 0.44 to 1.04) for 30-day 
      mortality, indicating antagonism between enalapril and ASA with departure from an 
      additive model. Thus, we found evidence of enalapril-ASA interaction. The effect 
      of enalapril was less favorable among patients taking ASA than among patients not 
      taking ASA at baseline.
FAU - Nguyen, K N
AU  - Nguyen KN
AD  - Department of Pharmacotherapeutics, University of Oslo, Norway.
FAU - Aursnes, I
AU  - Aursnes I
FAU - Kjekshus, J
AU  - Kjekshus J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Placebos)
RN  - 69PN84IO1A (Enalapril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Cardiol. 1997 Oct 15;80(8):1122. PMID: 9352997
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/antagonists & 
      inhibitors/*therapeutic use
MH  - Aspirin/administration & dosage/antagonists & inhibitors/*therapeutic use
MH  - Cause of Death
MH  - Confidence Intervals
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Enalapril/administration & dosage/antagonists & inhibitors/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Forecasting
MH  - Heart Failure/physiopathology
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Myocardial Infarction/*drug therapy
MH  - Placebos
MH  - Recurrence
MH  - Retrospective Studies
MH  - Scandinavian and Nordic Countries
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 1997/01/15 00:00
MHDA- 1997/01/15 00:01
CRDT- 1997/01/15 00:00
PHST- 1997/01/15 00:00 [pubmed]
PHST- 1997/01/15 00:01 [medline]
PHST- 1997/01/15 00:00 [entrez]
AID - S0002914996006960 [pii]
AID - 10.1016/s0002-9149(96)00696-0 [doi]
PST - ppublish
SO  - Am J Cardiol. 1997 Jan 15;79(2):115-9. doi: 10.1016/s0002-9149(96)00696-0.

PMID- 8339418
OWN - NLM
STAT- MEDLINE
DCOM- 19930902
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 88
IP  - 2
DP  - 1993 Aug
TI  - Transdermal modification of platelet function. A dermal aspirin preparation 
      selectively inhibits platelet cyclooxygenase and preserves prostacyclin 
      biosynthesis.
PG  - 556-61
AB  - BACKGROUND: Even low doses of oral aspirin inhibit prostacyclin (prostaglandin 
      [PG] I2) formation and cause gastrointestinal toxicity. We examined the skin as a 
      novel route for continuous low-dose aspirin administration and selective 
      inhibition of platelet cyclooxygenase in humans. METHODS AND RESULTS: Aspirin 250 
      or 750 mg/d for 10 days induced a dose-dependent inhibition of serum thromboxane 
      (TX) B2. At the highest dose, five of six subjects responded, with a mean 
      reduction in serum TXB2 of 95 +/- 3% (P = .003). Urinary 2,3-dinor TXB2, an index 
      of in vivo TXA2 formation, decreased by 68 +/- 7% and recovered slowly, 
      consistent with inhibition of platelet cyclooxygenase in vivo. In contrast, PGI2 
      biosynthesis, determined as excretion of 2,3-dinor-6-keto PGF1 alpha, was 81 +/- 
      5% of baseline at 10 days. Intravenous bradykinin increased PGI2 biosynthesis 5.1 
      +/- 1.6-fold (n = 4) before aspirin treatment. Oral aspirin 75 mg/d for 14 days 
      abolished bradykinin-induced PGI2 formation, whereas dermal aspirin 750 mg/d had 
      no effect despite similar inhibition of TXA2 biosynthesis. In five subjects, 
      plasma aspirin and salicylate were determined after a single application of 750 
      mg. Aspirin was absorbed slowly, with peak levels of 0.24 +/- 0.11 micrograms/mL 
      at 3 hours. Salicylate levels peaked at 6 to 12 hours, with plasma levels of 0.79 
      +/- 0.14 micrograms/mL. CONCLUSIONS: Thus, it is possible to achieve selective 
      inhibition of platelet cyclooxygenase by aspirin applied to the skin. This 
      approach may be applicable to other antiplatelet agents and be useful in patients 
      at risk for gastrointestinal bleeding or toxicity.
FAU - Keimowitz, R M
AU  - Keimowitz RM
AD  - Hematology Section, Gundersen Clinic, La Crosse, Wis.
FAU - Pulvermacher, G
AU  - Pulvermacher G
FAU - Mayo, G
AU  - Mayo G
FAU - Fitzgerald, D J
AU  - Fitzgerald DJ
LA  - eng
GR  - HL-40056/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Salicylates)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 63250-09-9 (2,3-dinor-thromboxane B2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Administration, Cutaneous
MH  - Adult
MH  - Aspirin/*administration & dosage/blood/pharmacology
MH  - Blood Platelets/*drug effects/*metabolism
MH  - Bradykinin/pharmacology
MH  - Cyclooxygenase Inhibitors/*administration & dosage/pharmacology
MH  - Epoprostenol/*biosynthesis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Thromboxane B2/analogs & derivatives/blood/urine
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
AID - 10.1161/01.cir.88.2.556 [doi]
PST - ppublish
SO  - Circulation. 1993 Aug;88(2):556-61. doi: 10.1161/01.cir.88.2.556.

PMID- 1174333
OWN - NLM
STAT- MEDLINE
DCOM- 19751125
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 25
IP  - 6
DP  - 1975 Jun
TI  - [Quantitative determination of the main metabolites of acetylsalicylic acid. 1. A 
      method for the quantitative determination of salicylic acid and its metabolites. 
      Studies in healthy individuals].
PG  - 941-4
AB  - For special purposes a combination of methods is described which allows to 
      determine salicylic acid (including acetylsalicylic acid) and its main 
      metabolites in blood plasma and urine separately and quantitatively. Salicylic 
      acid (SA) and salicyluric acid (SU) are extracted from the acidified fluid with 
      ether and afterwards reextracted in an aqueous phase. By fluorometry at different 
      wavelengths, it is possible to differentiate between SA and SU. The conjugates of 
      SA and SU are hydrolyzed with sulfuric acid and then extracted in the form of SA 
      and SU. The four analyses (SA, SU and their conjugates) are of satisfying 
      accuracy and sensitivity. To test the validity of the method in vivo, the 
      concentrations of SA and its conjugates were determined in the plasma and urines 
      of healthy volunteers. By a simplified, but nevertheless accurate, modification 
      of the described method total salicylate in the urine can be determined.
FAU - Pütter, J
AU  - Pütter J
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Quantitative Bestimmung der Hauptmetaboliten der Acetylsalizylsäure. 1. Eine 
      Methode zur quantatativen Bestimmung der Salizylsäure und ihrer Metaboliten; 
      Untersuchungen bei Gesunden.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Gentisates)
RN  - 0 (Glucuronates)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/analysis/*metabolism
MH  - Gentisates/analysis
MH  - Glucuronates/analysis
MH  - Humans
MH  - Hydrolysis
MH  - Kidney Failure, Chronic/blood
MH  - Methods
MH  - Salicylates/*analysis/metabolism/urine
MH  - Spectrometry, Fluorescence
EDAT- 1975/06/01 00:00
MHDA- 1975/06/01 00:01
CRDT- 1975/06/01 00:00
PHST- 1975/06/01 00:00 [pubmed]
PHST- 1975/06/01 00:01 [medline]
PHST- 1975/06/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1975 Jun;25(6):941-4.

PMID- 33739074
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1827-1839 (Electronic)
IS  - 0392-9590 (Linking)
VI  - 40
IP  - 3
DP  - 2021 Jun
TI  - Do we have a unified consensus on antithrombotic management of PAD?
PG  - 229-239
LID - 10.23736/S0392-9590.21.04597-1 [doi]
AB  - Peripheral artery disease (PAD) is one of the most frequent manifestations of 
      atherosclerosis with high rates of morbidity and mortality. Platelets and 
      coagulation are involved in the progression of atherosclerosis and thromboembolic 
      complications. PAD patients have increased prothrombotic potential, which 
      includes platelet hyperaggregability and increased pro-coagulant state. 
      Therefore, antithrombotic treatment is of utmost importance for the prevention of 
      cardiovascular events in this group of patients. Aspirin is the basic 
      antiplatelet drug, but with limited efficacy in PAD. In contrast to coronary 
      artery disease, its effect on the prevention of cardiovascular events in PAD has 
      been limited proven. Particularly in asymptomatic PAD, there is no evidence for 
      risk reduction with aspirin. Clopidogrel and ticagrelor are more effective than 
      aspirin. Clopidogrel is thus an effective alternative to aspirin for prevention 
      of cardiovascular events in symptomatic PAD. In patients who are non-responders 
      to clopidogrel, ticagrelor is indicated. Dual antiplatelet treatment (DAPT) with 
      aspirin and ticagrelor in patients with coronary artery disease and concomitant 
      PAD significantly decreased the rate of major adverse cardiovascular events, 
      including adverse limb events. However, in the CHARISMA Trial, aspirin and 
      clopidogrel were not more effective than aspirin alone and increased bleeding 
      complications. Therefore, DAPT seems effective only in PAD accompanied by 
      coronary artery disease. Anticoagulant treatment for symptomatic PAD with vitamin 
      K antagonists alone or in combination with aspirin is not more effective than 
      single antiplatelet treatment but increases the rate of major bleeding. Low dose 
      rivaroxaban combined with aspirin in PAD patients significantly reduces 
      cardiovascular events, including limb-threatening ischemia and limb amputations. 
      Anticoagulation and antiplatelet treatment after percutaneous or surgical 
      revascularization of PAD improve the patency of treated vessels. Aspirin with or 
      without dipyridamole improved patency of infra-inguinal by-pass grafts at one 
      year. The combination of clopidogrel with aspirin was more effective than aspirin 
      alone in the prevention of prosthetic graft occlusions in patients undergoing 
      below-knee by-pass-grafting. Oral vitamin K antagonists were not more effective 
      than aspirin in the prevention of infra-inguinal by-pass occlusion. The 
      combination of low dose rivaroxaban and aspirin was effective in preventing major 
      adverse cardiovascular events and adverse limb events after infrainguinal 
      endovascular or surgical revascularization in patients with intermittent 
      claudication. However, the data on antithrombotic treatment after 
      revascularization for limb-threatening ischemia is scanty and inconclusive. In 
      conclusion: Antithrombotic treatment of PAD is a cornerstone for the management 
      of these patients. Antiplatelet drugs prevent the initiation and progression of 
      atherosclerosis and are effective also in the prevention of thromboembolic 
      events. Simultaneous use of antiplatelet and anticoagulation drugs is accompanied 
      by an increased risk of bleeding. However, combined treatment with aspirin and 
      low-dose rivaroxaban is more effective than single antithrombotic treatment and 
      safer than full-dose combined treatment.
FAU - Poredos, Pavel
AU  - Poredos P
AD  - Department of Vascular Disease, University Medical Center Ljubljana, Ljubljana, 
      Slovenia.
FAU - Antignani, Pier L
AU  - Antignani PL
AD  - Vascular Center, Nuova Villa Claudia, Rome, Italy - antignanipl@gmail.com.
FAU - Blinc, Ales
AU  - Blinc A
AD  - Department of Vascular Disease, University Medical Center Ljubljana, Ljubljana, 
      Slovenia.
FAU - Fras, Zlatko
AU  - Fras Z
AD  - Department of Vascular Disease, University Medical Center Ljubljana, Ljubljana, 
      Slovenia.
FAU - Jezovnik, Mateja K
AU  - Jezovnik MK
AD  - Department of Advanced Cardiopulmonary Therapies and Transplantation, Health 
      Science Center, University of Texas, Houston, TX, USA.
FAU - Fareed, Jawed
AU  - Fareed J
AD  - Loyola University Medical Center, Maywood, IL, USA.
FAU - Mansilha, Armando
AU  - Mansilha A
AD  - Department of Angiology and Vascular Surgery, Hospital CUF Porto, Porto, 
      Portugal.
LA  - eng
PT  - Journal Article
DEP - 20210319
PL  - Italy
TA  - Int Angiol
JT  - International angiology : a journal of the International Union of Angiology
JID - 8402693
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Consensus
MH  - *Fibrinolytic Agents/adverse effects
MH  - Humans
MH  - *Peripheral Arterial Disease/drug therapy
MH  - Platelet Aggregation Inhibitors/adverse effects
EDAT- 2021/03/20 06:00
MHDA- 2021/09/18 06:00
CRDT- 2021/03/19 10:16
PHST- 2021/03/20 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2021/03/19 10:16 [entrez]
AID - S0392-9590.21.04597-1 [pii]
AID - 10.23736/S0392-9590.21.04597-1 [doi]
PST - ppublish
SO  - Int Angiol. 2021 Jun;40(3):229-239. doi: 10.23736/S0392-9590.21.04597-1. Epub 
      2021 Mar 19.

PMID- 23677911
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20150403
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 20
IP  - 6
DP  - 2014 Sep
TI  - Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 
      in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of 
      Healthy Individuals.
PG  - 629-36
LID - 10.1177/1076029613488934 [doi]
AB  - It is implicated that diabetic patients are more resistant to aspirin therapy 
      than patients with other diseases or healthy individuals. We evaluated the 
      inhibitory effects of aspirin on aggregation and the cyclooxygenase activity of 
      platelets of 10 patients with severe type-2 diabetes mellitis (DM) and compared 
      the results with those of healthy individuals. Although platelet aggregation had 
      a tendency to be more resistant to aspirin with the DM group, there was no 
      significant difference in half maximal inhibitory concentration 50 values of 
      aspirin on the cyclooxygenase activity between the patients with DM and healthy 
      individuals. Thus, the residual platelet aggregability uninhibited by aspirin 
      appears to be independent of the cyclooxygenase activity. Since adenosine 
      diphosphate (ADP) receptor blocking almost completely inhibited the residual 
      platelet aggregability, it is suggested that hyperreactivity to ADP is more 
      prevalent in patients with DM.
CI  - © The Author(s) 2013.
FAU - Kimura, Yukio
AU  - Kimura Y
AD  - Department of Laboratory Medicine, School of Medicine, University of Yamanashi, 
      Chuo, Yamanashi, Japan.
FAU - Takano, Katsuhiro
AU  - Takano K
AD  - Department of Laboratory Medicine, School of Medicine, University of Yamanashi, 
      Chuo, Yamanashi, Japan.
FAU - Satoh, Kaneo
AU  - Satoh K
AD  - Department of Laboratory Medicine, School of Medicine, University of Yamanashi, 
      Chuo, Yamanashi, Japan.
FAU - Aida, Kaoru
AU  - Aida K
AD  - 3rd Department of Internal Medicine, School of Medicine, University of Yamanashi, 
      Chuo, Yamanashi, Japan.
FAU - Kobayashi, Tetsuro
AU  - Kobayashi T
AD  - 3rd Department of Internal Medicine, School of Medicine, University of Yamanashi, 
      Chuo, Yamanashi, Japan.
FAU - Ozaki, Yukio
AU  - Ozaki Y
AD  - Department of Laboratory Medicine, School of Medicine, University of Yamanashi, 
      Chuo, Yamanashi, Japan yozaki@yamanashi.ac.jp.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20130514
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - Blood Platelets/*enzymology
MH  - Cyclooxygenase 1/*blood
MH  - Cyclooxygenase Inhibitors/*administration & dosage/pharmacokinetics
MH  - Diabetes Mellitus, Type 2/*enzymology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
OTO - NOTNLM
OT  - anti-platelet agents
OT  - aspirin
OT  - cyclooxygenase
OT  - diabetes mellitus
EDAT- 2013/05/17 06:00
MHDA- 2015/10/16 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/05/17 06:00 [entrez]
PHST- 2013/05/17 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - 1076029613488934 [pii]
AID - 10.1177/1076029613488934 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2014 Sep;20(6):629-36. doi: 10.1177/1076029613488934. 
      Epub 2013 May 14.

PMID- 24781035
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20151119
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 20
IP  - 6
DP  - 2014 Sep
TI  - The efficacy of sulodexide in the prevention of postthrombotic syndrome.
PG  - 594-9
LID - 10.1177/1076029614533143 [doi]
AB  - AIM: The aim of this open, observational registry was to evaluate the effects of 
      antithrombotic treatment on the development of postthrombotic syndrome (PTS): the 
      effects of "standard management" (SM; according to International Union of 
      Angiology guidelines) were compared to SM in association with sulodexide or 
      aspirin. METHODS: Postthrombotic syndrome occurrence was observed in 3 
      nonparallel groups after deep venous thrombosis (DVT); the registry started after 
      the end of the anticoagulation period. The target was to observe the occurrence 
      of PTS in 5 years. Three possible options were suggested to the patients, and the 
      patients and their caregivers defined the type of management. A group of 167 
      patients was involved in the SM with reevaluation every 6 months; the sulodexide 
      group included 124 patients and the aspirin group included 48 patients. RESULTS: 
      The 3 groups were clinically similar and comparable for age and sex distribution. 
      Of the 167 patients in the SM group, 154 patients completed 60 months of 
      follow-up. The percentage of patients with PTS in the SM group ranged from 14.9% 
      (1 year after the end of anticoagulation) to 19.5% (60 months). In the 
      nonparallel group using sulodexide (124 comparable patients at inclusion; 115 at 
      60 months), the percentage of PTS was variable from 8.8% (1 year after 
      anticoagulants) to 12.17% at 60 months. These percentages are significantly lower 
      than those observed with SM. In the nonparallel aspirin group (48 patients at 
      inclusion and 34 at 54 months), there was a PTS incidence of 23.5% at 54 months 
      (vs 12.17% in the sulodexide group and 18.23% in the SM group). The incidence of 
      PTS was significantly higher in comparison with the other 2 groups. The incidence 
      of PTS was lower in the sulodexide group in comparison with the 2 other groups. 
      CONCLUSIONS: Sulodexide administration after DVT appears to be effective in 
      preventing PTS in association with recommended management and a number of 
      recurrent DVTs. Modalities of treatment, dosages, and timing of administration 
      should be explored in more comprehensive and complete studies.
CI  - © The Author(s) 2014.
FAU - Luzzi, Roberta
AU  - Luzzi R
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Belcaro, Gianni
AU  - Belcaro G
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy cardres@abol.it.
FAU - Dugall, Mark
AU  - Dugall M
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Hu, Shu
AU  - Hu S
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Arpaia, Guido
AU  - Arpaia G
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Ledda, Andrea
AU  - Ledda A
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Ippolito, Edmondo
AU  - Ippolito E
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Corsi, Marcello
AU  - Corsi M
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Ricci, Andrea
AU  - Ricci A
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Cotellese, Roberto
AU  - Cotellese R
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Agus, Giovanni
AU  - Agus G
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Errichi, Bruno M
AU  - Errichi BM
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Cornelli, Umberto
AU  - Cornelli U
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Cesarone, M Rosaria
AU  - Cesarone MR
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
FAU - Hosoi, Morio
AU  - Hosoi M
AD  - Department of Biomed Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara 
      University, Chieti and Pescara, Italy.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20140429
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Glycosaminoglycans)
RN  - 75HGV0062C (glucuronyl glucosamine glycan sulfate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/adverse effects
MH  - Glycosaminoglycans/*administration & dosage/adverse effects
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Postthrombotic Syndrome/epidemiology/*prevention & control
MH  - Time Factors
OTO - NOTNLM
OT  - DVT
OT  - postthrombotic syndrome
OT  - sulodexide
OT  - thrombosis
OT  - veins
OT  - venous ulcers
EDAT- 2014/05/02 06:00
MHDA- 2015/10/16 06:00
CRDT- 2014/05/01 06:00
PHST- 2014/05/01 06:00 [entrez]
PHST- 2014/05/02 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - 1076029614533143 [pii]
AID - 10.1177/1076029614533143 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2014 Sep;20(6):594-9. doi: 10.1177/1076029614533143. 
      Epub 2014 Apr 29.

PMID- 33461308
OWN - NLM
STAT- MEDLINE
DCOM- 20211223
LR  - 20211223
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 143
IP  - 12
DP  - 2021 Mar 23
TI  - Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney 
      Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or 
      Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
PG  - 1215-1223
LID - 10.1161/CIRCULATIONAHA.120.051020 [doi]
AB  - BACKGROUND: In the AUGUSTUS trial (An Open-Label, 2×2 Factorial, Randomized 
      Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K 
      Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial 
      Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), 
      apixaban resulted in less bleeding and fewer hospitalizations than vitamin K 
      antagonists, and aspirin caused more bleeding than placebo in patients with 
      atrial fibrillation and acute coronary syndrome or percutaneous coronary 
      intervention treated with a P2Y(12) inhibitor. We evaluated the risk-benefit 
      balance of antithrombotic therapy according to kidney function. METHODS: In 4456 
      patients, the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula 
      was used to calculate baseline estimated glomerular filtration rate (eGFR). The 
      effect of apixaban versus vitamin K antagonists and aspirin versus placebo was 
      assessed across kidney function categories by using Cox models. The primary 
      outcome was International Society on Thrombosis and Haemostasis major or 
      clinically relevant nonmajor bleeding. Secondary outcomes included death or 
      hospitalization and ischemic events (death, stroke, myocardial infarction, stent 
      thrombosis [definite or probable], or urgent revascularization). Creatinine 
      clearance <30 mL/min was an exclusion criterion in the AUGUSTUS trial. RESULTS: 
      Overall, 30%, 52%, and 19% had an eGFR of >80, >50 to 80, and 30 to 50 
      mL·min(-1)·1.73 m(-2), respectively. At the 6-month follow-up, a total of 543 
      primary outcomes of bleeding, 1125 death or hospitalizations, and 282 ischemic 
      events occurred. Compared with vitamin K antagonists, patients assigned apixaban 
      had lower rates for all 3 outcomes across most eGFR categories without 
      significant interaction. The absolute risk reduction with apixaban was most 
      pronounced in those with an eGFR of 30 to 50 mL·min(-1)·1.73 m(-2) for bleeding 
      events with rates of 13.1% versus 21.3% (hazard ratio, 0.59; 95% CI, 0.41-0.84). 
      Patients assigned aspirin had a higher risk of bleeding in all eGFR categories 
      with an even greater increase among those with eGFR >80 mL·min(-1)·1.73 m(-2): 
      16.6% versus 5.6% (hazard ratio, 3.22; 95% CI, 2.19-4.74; P for 
      interaction=0.007). The risk of death or hospitalization and ischemic events were 
      comparable to aspirin and placebo across eGFR categories with hazard ratios 
      ranging from 0.97 (95% CI, 0.76-1.23) to 1.28 (95% CI, 1.02-1.59) and from 0.75 
      (95% CI, 0.48-1.17) to 1.34 (95% CI, 0.81-2.22), respectively. CONCLUSIONS: The 
      safety and efficacy of apixaban was consistent irrespective of kidney function, 
      compared with warfarin, and in accordance with the overall trial results. The 
      risk of bleeding with aspirin was consistently higher across all kidney function 
      categories. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: 
      NCT02415400.
FAU - Hijazi, Ziad
AU  - Hijazi Z
AD  - Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, 
      Uppsala University, Sweden (Z.H.).
FAU - Alexander, John H
AU  - Alexander JH
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 
      (J.H.A., Z.L., D.M.W., C.B.G., R.D.L.).
FAU - Li, Zhuokai
AU  - Li Z
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 
      (J.H.A., Z.L., D.M.W., C.B.G., R.D.L.).
FAU - Wojdyla, Daniel M
AU  - Wojdyla DM
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 
      (J.H.A., Z.L., D.M.W., C.B.G., R.D.L.).
FAU - Mehran, Roxana
AU  - Mehran R
AD  - Zena and Michael A. Weiner Cardiovascular Institute, Icahn School of Medicine at 
      Mount Sinai, and Cardiovascular Research Foundation, New York, NY (R.M.).
FAU - Granger, Christopher B
AU  - Granger CB
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 
      (J.H.A., Z.L., D.M.W., C.B.G., R.D.L.).
FAU - Parkhomenko, Alexander
AU  - Parkhomenko A
AD  - NSC Institute of Cardiology, Kyiv, Ukraine (A.P.).
FAU - Bahit, M Cecilia
AU  - Bahit MC
AD  - Instituto de Neurología Cognitiva (INECO) Neurociencias Oroño, Fundación INECO, 
      Rosario, Argentina (M.C.B.).
FAU - Windecker, Stephan
AU  - Windecker S
AD  - Bern University Hospital, Inselspital, University of Bern, Switzerland (S.W.).
FAU - Aronson, Ronald
AU  - Aronson R
AD  - Bristol-Myers Squibb, Lawrenceville, NJ (R.A.).
FAU - Berwanger, Otavio
AU  - Berwanger O
AD  - Hospital Israelita Albert Einstein, São Paulo, Brazil (O.B.).
FAU - Halvorsen, Sigrun
AU  - Halvorsen S
AD  - Oslo University Hospital Ulleval, Norway (S.H.).
FAU - de Waha-Thiele, Suzanne
AU  - de Waha-Thiele S
AD  - University Heart Centre Lübeck, University Hospital Schleswig-Holstein, Germany 
      (S.dW.-T.).
AD  - German Center for Cardiovascular Research (DZHK), Lübeck (S.dW.-T.).
FAU - Sinnaeve, Peter
AU  - Sinnaeve P
AD  - University Hospitals Leuven, University of Leuven, Belgium (P.S.).
FAU - Darius, Harald
AU  - Darius H
AD  - Vivantes Neukoelln Medical Center, Berlin, Germany (H.D.).
FAU - Storey, Robert F
AU  - Storey RF
AD  - Department of Infection, Immunity, and Cardiovascular Disease, University of 
      Sheffield, United Kingdom (R.F.S.).
FAU - Lopes, Renato D
AU  - Lopes RD
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 
      (J.H.A., Z.L., D.M.W., C.B.G., R.D.L.).
LA  - eng
SI  - ClinicalTrials.gov/NCT02415400
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210119
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 12001-79-5 (Vitamin K)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Factor Xa Inhibitors/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Kidney/*pathology
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*methods
MH  - Pyrazoles/pharmacology/*therapeutic use
MH  - Pyridones/pharmacology/*therapeutic use
MH  - Vitamin K/*antagonists & inhibitors
OTO - NOTNLM
OT  - acute coronary syndrome
OT  - anticoagulant
OT  - atrial fibrillation
OT  - fibrinolytic agents
OT  - kidney function tests
EDAT- 2021/01/20 06:00
MHDA- 2021/12/24 06:00
CRDT- 2021/01/19 05:35
PHST- 2021/01/20 06:00 [pubmed]
PHST- 2021/12/24 06:00 [medline]
PHST- 2021/01/19 05:35 [entrez]
AID - 10.1161/CIRCULATIONAHA.120.051020 [doi]
PST - ppublish
SO  - Circulation. 2021 Mar 23;143(12):1215-1223. doi: 
      10.1161/CIRCULATIONAHA.120.051020. Epub 2021 Jan 19.

PMID- 11421882
OWN - NLM
STAT- MEDLINE
DCOM- 20010809
LR  - 20190901
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 15
IP  - 7
DP  - 2001 Jul
TI  - Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in 
      patients using aspirin to prevent ischaemic heart disease.
PG  - 1055-9
AB  - BACKGROUND: Aspirin use in the secondary prevention of ischaemic heart disease 
      may provoke gastrointestinal discomfort. OBJECTIVE: To register gastrointestinal 
      symptoms and complications in patients with cardiovascular disease using aspirin 
      and to relate these symptoms to infection with H. pylori. METHODS: Blood samples 
      were obtained from 398 consecutive patients in the Coronary-Care Unit, University 
      Hospital Nijmegen and analysed for serum antibody levels to H. pylori infection. 
      Questionnaires were sent 2 weeks after discharge to assess gastrointestinal 
      symptoms. RESULTS: Questionnaires were returned by 314 patients (79%). A total of 
      183 out of 314 patients (46%) reported gastrointestinal symptoms. Of 238 patients 
      using 80-100 mg aspirin daily, 145 (61%) recorded gastrointestinal symptoms. 
      Besides aspirin, the use of calcium antagonists was correlated with 
      gastrointestinal symptoms. Of the 128 patients using calcium antagonists, 84 
      (66%) reported gastrointestinal symptoms. The prevalence of gastrointestinal 
      symptoms in H. pylori-positive and -negative patients using aspirin was 48% and 
      52%, respectively. CONCLUSIONS: Two weeks after discharge almost 50% of the 
      patients with cardiovascular disease experienced gastrointestinal symptoms, 
      especially patients using aspirin or calcium antagonists. Patients seropositive 
      for H. pylori and using aspirin or calcium antagonists did not have more 
      gastrointestinal discomfort compared to non-infected patients.
FAU - Laheij, R J
AU  - Laheij RJ
AD  - Department of Gastroenterology, University Hospital Nijmegen, the Netherlands. 
      r.laheij@gastro.azn.nl
FAU - Jansen, J B
AU  - Jansen JB
FAU - Verbeek, A L
AU  - Verbeek AL
FAU - Verheugt, F W
AU  - Verheugt FW
LA  - eng
PT  - Journal Article
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Calcium Channel Blockers/adverse effects/therapeutic use
MH  - Deglutition Disorders/etiology
MH  - Dyspepsia/etiology
MH  - Fibrinolytic Agents/*adverse effects/therapeutic use
MH  - Flatulence/etiology
MH  - Gastroesophageal Reflux/etiology
MH  - Health Surveys
MH  - Helicobacter Infections/*complications
MH  - Helicobacter pylori/pathogenicity
MH  - Myocardial Ischemia/*prevention & control
MH  - Nausea/etiology
MH  - Pain/etiology
MH  - Risk Factors
EDAT- 2001/06/26 10:00
MHDA- 2001/08/10 10:01
CRDT- 2001/06/26 10:00
PHST- 2001/06/26 10:00 [pubmed]
PHST- 2001/08/10 10:01 [medline]
PHST- 2001/06/26 10:00 [entrez]
AID - apt1016 [pii]
AID - 10.1046/j.1365-2036.2001.01016.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2001 Jul;15(7):1055-9. doi: 
      10.1046/j.1365-2036.2001.01016.x.

PMID- 6331883
OWN - NLM
STAT- MEDLINE
DCOM- 19841016
LR  - 20161123
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 6
IP  - 4
DP  - 1984
TI  - Comparative effects of aspirin and enteric-coated aspirin on loss of chromium 
      51-labeled erythrocytes from the gastrointestinal tract.
PG  - 461-6
AB  - Sodium chromate Cr 51 was used to label red blood cells of 19 healthy male 
      volunteers, whose stools were collected for four days before and four days during 
      oral administration of either uncoated (N = 9) or enteric-coated (N = 10) 
      aspirin. Each subject received 2.925 gm/day of aspirin, in three equal doses 
      separated by eight-hour intervals, for a total of seven days. During drug use, 
      stools were collected on days 4 through 7. Fecal blood content, estimated by 
      measuring radioactivity in the stools, was significantly higher (P less than 
      0.001) during use of either type of aspirin than at baseline, but losses measured 
      during use of the coated aspirin (mean, 1.54 ml/day) were significantly lower (P 
      less than 0.001) than those measured during use of the uncoated aspirin (mean, 
      4.33 ml/day). The two types of aspirin produced equivalent serum concentrations 
      of salicylates. We conclude that enteric-coated aspirin reduces gastrointestinal 
      blood loss.
FAU - Robbins, D C
AU  - Robbins DC
FAU - Schwartz, R S
AU  - Schwartz RS
FAU - Kutny, K
AU  - Kutny K
FAU - Vallejo, G
AU  - Vallejo G
FAU - Horton, E S
AU  - Horton ES
FAU - Cotter, J M
AU  - Cotter JM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Chromium Radioisotopes
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Hemorrhage/*chemically induced/diagnostic imaging
MH  - Hematocrit
MH  - Humans
MH  - Male
MH  - Radionuclide Imaging
MH  - Tablets, Enteric-Coated
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1984;6(4):461-6.

PMID- 6989410
OWN - NLM
STAT- MEDLINE
DCOM- 19800712
LR  - 20131121
IS  - 0006-341X (Print)
IS  - 0006-341X (Linking)
VI  - 36
IP  - 1
DP  - 1980 Mar
TI  - A stochastic model for the occurrence of transient ischemic attacks.
PG  - 91-103
AB  - This paper presents the development, application and evaluation of a stochastic 
      model of the frequency of occurrence of transient ischemic attacks (TIAs). TIAs 
      occur during periods of abnormal arterial activity. The TIAs which occur during a 
      single period of abnormal activity are called a cluster of TIAs. Thus, the number 
      of TIAs occurring in a time interval is determined by the number of clusters of 
      TIAs occurring and the number of TIAs per cluster. The distribution of the number 
      of clusters, which is a modification of the Poisson distribution, is obtained 
      through the use of infinitesimal probabilities and the method of generating 
      function. The number of TIAs per cluster follows the logarithmic series 
      distribution. The distribution of the number of TIAs is then a modification of 
      the negative binomial distribution, which allows for censoring of the data that 
      may be related to the occurrence of the clusters of TIAs. Estimates for the 
      parameters, based on observed frequencies, are obtained, which allow the model to 
      be applied to data from the Aspirin in Transient Ischemic Attacks Study.
FAU - Dunn, J K
AU  - Dunn JK
FAU - Hardy, R J
AU  - Hardy RJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biometrics
JT  - Biometrics
JID - 0370625
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - Clinical Trials as Topic
MH  - Humans
MH  - *Ischemic Attack, Transient/prevention & control
MH  - *Models, Cardiovascular
MH  - Placebos
MH  - *Probability
MH  - *Stochastic Processes
EDAT- 1980/03/01 00:00
MHDA- 1980/03/01 00:01
CRDT- 1980/03/01 00:00
PHST- 1980/03/01 00:00 [pubmed]
PHST- 1980/03/01 00:01 [medline]
PHST- 1980/03/01 00:00 [entrez]
PST - ppublish
SO  - Biometrics. 1980 Mar;36(1):91-103.

PMID- 31444100
OWN - NLM
STAT- MEDLINE
DCOM- 20201020
LR  - 20201020
IS  - 1873-2615 (Electronic)
IS  - 1050-1738 (Linking)
VI  - 30
IP  - 5
DP  - 2020 Jul
TI  - Modulation of microRNAs by aspirin in cardiovascular disease.
PG  - 249-254
LID - S1050-1738(19)30114-8 [pii]
LID - 10.1016/j.tcm.2019.08.005 [doi]
AB  - Aspirin is among the most widely prescribed drugs in cardiovascular and 
      cerebrovascular diseases for both primary and secondary prevention. The major 
      mechanisms underlying its benefits are the inhibitory effects on platelet 
      activation and prostanoid biosynthesis induced by COX-1 and COX-2 inactivation. 
      MicroRNAs (miRNAs) are newly proposed mediators of the effects of aspirin. In 
      this review, we summarize the evidence on the links between miRNAs and aspirin 
      use in relation to cardiovascular diseases. In addition, we discuss the studies 
      suggesting a possible role for miRNAs as biomarkers of aspirin resistance, a 
      condition during which atherothrombotic events occur despite aspirin use, and 
      which affects a considerable proportion of patients with cardiovascular disease.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Paseban, Maryam
AU  - Paseban M
AD  - Department of Physiology, Faculty of Medicine, Mashhad University of Medical 
      Sciences, Mashhad, Iran.
FAU - Marjaneh, Reyhaneh Moradi
AU  - Marjaneh RM
AD  - Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.
FAU - Banach, Maciej
AU  - Banach M
AD  - Department of Hypertension, WAM University Hospital in Lodz, Medical University 
      of Lodz, Lodz, Poland; Polish Mother's Memorial Hospital Research Institute 
      (PMMHRI), Lodz, Poland.
FAU - Riahi, Maryam Matbou
AU  - Riahi MM
AD  - Heart Failure Research Center, Cardiovascular Research Institute, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Bo, Simona
AU  - Bo S
AD  - Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, 
      University of Turin, Torino, Italy.
FAU - Sahebkar, Amirhossein
AU  - Sahebkar A
AD  - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad, Iran; Neurogenic Inflammation Research 
      Center, Mashhad University of Medical Sciences, Mashhad, Iran; School of 
      Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic 
      address: sahebkara@mums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190814
PL  - United States
TA  - Trends Cardiovasc Med
JT  - Trends in cardiovascular medicine
JID - 9108337
RN  - 0 (Lipoxins)
RN  - 0 (MicroRNAs)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Trends Cardiovasc Med. 2020 Jul;30(5):255-256. PMID: 31547951
MH  - Animals
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Platelets/*drug effects/metabolism
MH  - Cardiovascular Diseases/*drug therapy/genetics/metabolism
MH  - Docosahexaenoic Acids/metabolism
MH  - Drug Resistance
MH  - Eicosapentaenoic Acid/metabolism
MH  - Endothelial Cells/drug effects/metabolism
MH  - Humans
MH  - Lipoxins/metabolism
MH  - MicroRNAs/genetics/*metabolism
MH  - Myocytes, Smooth Muscle/drug effects/metabolism
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirin resistance
OT  - Cardiovascular disease
OT  - MicroRNA
OT  - Thrombosis
EDAT- 2019/08/25 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/08/25 06:00
PHST- 2019/04/08 00:00 [received]
PHST- 2019/07/12 00:00 [revised]
PHST- 2019/08/06 00:00 [accepted]
PHST- 2019/08/25 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/08/25 06:00 [entrez]
AID - S1050-1738(19)30114-8 [pii]
AID - 10.1016/j.tcm.2019.08.005 [doi]
PST - ppublish
SO  - Trends Cardiovasc Med. 2020 Jul;30(5):249-254. doi: 10.1016/j.tcm.2019.08.005. 
      Epub 2019 Aug 14.

PMID- 24127927
OWN - NLM
STAT- MEDLINE
DCOM- 20140507
LR  - 20211021
IS  - 1752-8062 (Electronic)
IS  - 1752-8054 (Print)
IS  - 1752-8054 (Linking)
VI  - 6
IP  - 5
DP  - 2013 Oct
TI  - Initiation of aspirin therapy modulates angiogenic protein levels in women with 
      breast cancer receiving tamoxifen therapy.
PG  - 386-90
LID - 10.1111/cts.12070 [doi]
AB  - Aspirin has a range of antineoplastic properties linked to inhibition of 
      cyclooxygenase enzymes in tumor cells, platelet inhibition and to inhibition of 
      angiogenesis. We undertook a prospective study to determine the influence of a 
      45-day course of aspirin therapy on circulating and intraplatelet levels of 
      selected proangiogenic (vascular endothelial growth factor [VEGF]) and 
      antiangiogenic (thrombospondin-1 [TSP-1]) proteins, and platelet protein release 
      in women diagnosed with breast cancer who were receiving tamoxifen therapy. 
      Initiation of aspirin therapy increases serum and intraplatelet levels of TSP-1 
      without a corresponding increase in VEGF levels. Following aspirin therapy, VEGF 
      levels decreased (relative to pretreatment levels) while TSP-1 returned to 
      pretreatment levels. Plasma TSP-1 and VEGF levels did not change on aspirin 
      therapy. Aspirin use also decreased thrombin receptor mediated release of TSP-1 
      and VEGF from platelets. The selective impact on platelet angiogenic protein 
      content and release supports one mechanism by which aspirin can modify the 
      angiogenic balance in women receiving tamoxifen therapy. Aspirin therapy appears 
      to favor an overall antiangiogenic balance in women with breast cancer who are 
      receiving tamoxifen therapy.
CI  - © 2013 Wiley Periodicals, Inc.
FAU - Holmes, Chris E
AU  - Holmes CE
AD  - Department of Medicine, University of Vermont, Burlington, Vermont, USA.
FAU - Jasielec, Jagoda
AU  - Jasielec J
FAU - Levis, Jamie E
AU  - Levis JE
FAU - Skelly, Joan
AU  - Skelly J
FAU - Muss, Hyman B
AU  - Muss HB
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130515
PL  - United States
TA  - Clin Transl Sci
JT  - Clinical and translational science
JID - 101474067
RN  - 0 (Angiogenic Proteins)
RN  - 0 (Receptors, Thrombin)
RN  - 0 (Thrombospondin 1)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenic Proteins/*blood
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/metabolism
MH  - Breast Neoplasms/*blood/*drug therapy
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Platelet Activation/drug effects
MH  - Receptors, Thrombin/metabolism
MH  - Tamoxifen/pharmacology/*therapeutic use
MH  - Thrombospondin 1/blood
MH  - Vascular Endothelial Growth Factor A/blood
PMC - PMC5350889
OTO - NOTNLM
OT  - TSP-1 tamoxifen
OT  - VEGF
OT  - breast cancer
OT  - platelet activation
EDAT- 2013/10/17 06:00
MHDA- 2014/05/08 06:00
CRDT- 2013/10/17 06:00
PHST- 2013/10/17 06:00 [entrez]
PHST- 2013/10/17 06:00 [pubmed]
PHST- 2014/05/08 06:00 [medline]
AID - CTS12070 [pii]
AID - 10.1111/cts.12070 [doi]
PST - ppublish
SO  - Clin Transl Sci. 2013 Oct;6(5):386-90. doi: 10.1111/cts.12070. Epub 2013 May 15.

PMID- 17635378
OWN - NLM
STAT- MEDLINE
DCOM- 20071214
LR  - 20131121
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 26
IP  - 3
DP  - 2007 Aug 1
TI  - Aspirin chemoprevention in patients with increased risk for colorectal cancer: a 
      cost-effectiveness analysis.
PG  - 431-41
AB  - BACKGROUND: Aspirin chemoprevention combined with colonoscopy screening is not 
      cost-effective for the general population. However, the cost-effectiveness of 
      aspirin in individuals with prior adenoma resection has not been evaluated. AIM: 
      To evaluate the cost-effectiveness of aspirin chemoprevention alone and in 
      combination with colonoscopy surveillance in patients with prior adenoma 
      resection. METHODS: A model of the natural history of individuals with a history 
      of endoscopic polypectomy was constructed. Four strategies were compared: (i) no 
      intervention, (ii) routine colonoscopy surveillance, (iii) aspirin 
      chemoprevention alone, and (iv) aspirin therapy combined with colonoscopy. 
      RESULTS: Compared with no intervention, all other strategies were more costly but 
      were associated with gains in years of life saved. Aspirin chemoprevention alone 
      was associated with a gain of 0.0092 years, whereas routine colonoscopic 
      surveillance and combination strategy were associated with further gains in years 
      of life saved (0.0124 and 0.0138 years, respectively). Compared with no 
      intervention, the incremental cost-effectiveness ratio of routine colonoscopy 
      surveillance was $78,226 per year of life saved, and the incremental 
      cost-effectiveness ratio of combination aspirin and colonoscopy was $60,942 per 
      year of life saved. CONCLUSION: Aspirin chemoprevention combined with 
      colonoscopic surveillance in post-polypectomy patients may be considered a 
      cost-effective strategy.
FAU - DuPont, A W
AU  - DuPont AW
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, University 
      of Texas Medical Branch, Galveston, TX 77555-0764, USA. awdupont@utmb.edu
FAU - Arguedas, M R
AU  - Arguedas MR
FAU - Wilcox, C M
AU  - Wilcox CM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Aliment Pharmacol Ther. 2007 Nov 15;26(10):1455-6. PMID: 17868432
MH  - Adenoma/surgery
MH  - Anti-Inflammatory Agents, Non-Steroidal/economics/*therapeutic use
MH  - Aspirin/economics/*therapeutic use
MH  - Cohort Studies
MH  - Colonoscopy
MH  - Colorectal Neoplasms/*drug therapy/mortality/prevention & control
MH  - *Cost-Benefit Analysis/economics
MH  - Humans
MH  - Markov Chains
MH  - Risk Factors
MH  - Treatment Outcome
RF  - 71
EDAT- 2007/07/20 09:00
MHDA- 2007/12/15 09:00
CRDT- 2007/07/20 09:00
PHST- 2007/07/20 09:00 [pubmed]
PHST- 2007/12/15 09:00 [medline]
PHST- 2007/07/20 09:00 [entrez]
AID - APT3380 [pii]
AID - 10.1111/j.1365-2036.2007.03380.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2007 Aug 1;26(3):431-41. doi: 
      10.1111/j.1365-2036.2007.03380.x.

PMID- 6414841
OWN - NLM
STAT- MEDLINE
DCOM- 19831217
LR  - 20131121
IS  - 0014-8318 (Print)
IS  - 0014-8318 (Linking)
VI  - 46
IP  - 5
DP  - 1983 Sep-Oct
TI  - [Mechanisms of interaction of acetylsalicylic acid and indomethacin with 
      endoperoxide prostaglandin synthetase].
PG  - 44-8
AB  - A study was made of the character and kinetics of interaction of acetylsalicylic 
      acid and indomethacin with endoperoxide prostaglandin synthetase (PGH-synthetase) 
      of sheep vesicular glands and human platelets. Enzymatic activity of 
      PGH-synthetase was determined polarographically with the aid of Clark's 
      electrodes. Acetylsalicylic acid was found to inhibit PGH-synthetase of sheep 
      vesicular glands and human platelets at concentrations of the order of 1 x 10(-6) 
      and 1 x 10(-4) M, whereas indomethacin at concentrations of 1 x 10(-6) and 1 x 
      10(-7) M, respectively. Acetylsalicylic acid inhibited PGH-synthetase from sheep 
      vesicular glands and that from human platelets at an equal rate. Indomethacin 
      inhibited the enzyme from sheep vesicular glands to a higher degree. Indomethacin 
      reversibly interacted with PGH-synthetase. Meanwhile acetylsalicylic acid 
      inhibited this enzyme irreversibly.
FAU - Muratov, V K
AU  - Muratov VK
FAU - Igumnova, N D
AU  - Igumnova ND
FAU - Basevich, V V
AU  - Basevich VV
FAU - Churiukanov, V V
AU  - Churiukanov VV
FAU - Mevkh, A T
AU  - Mevkh AT
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - O mekhanizmakh vzaimodeĭstviia atsetilsalitsilovoĭ kisloty i indometatsina s 
      éndoperoksidprostaglandinsintetazoĭ.
PL  - Russia (Federation)
TA  - Farmakol Toksikol
JT  - Farmakologiia i toksikologiia
JID - 16920420R
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/enzymology
MH  - *Cyclooxygenase Inhibitors
MH  - Humans
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Seminal Vesicles/enzymology
MH  - Sheep
EDAT- 1983/09/01 00:00
MHDA- 1983/09/01 00:01
CRDT- 1983/09/01 00:00
PHST- 1983/09/01 00:00 [pubmed]
PHST- 1983/09/01 00:01 [medline]
PHST- 1983/09/01 00:00 [entrez]
PST - ppublish
SO  - Farmakol Toksikol. 1983 Sep-Oct;46(5):44-8.

PMID- 15216946
OWN - NLM
STAT- MEDLINE
DCOM- 20040729
LR  - 20131121
IS  - 1120-009X (Print)
IS  - 1120-009X (Linking)
VI  - 16
IP  - 2
DP  - 2004 Apr
TI  - Influence of acetylsalicylic acid (aspirin) on biofilm production by Candida 
      species.
PG  - 134-8
AB  - Candida spp. are important causative agents of infections associated with biofilm 
      formation. Management of biofilm-related infections is extremely difficult and 
      therefore new therapeutic solutions are needed. This study for the first time 
      explored the possible effect of aspirin on Candida spp. Biofilm-producing 
      capacity. Two strains of C. guilliermondii, and one strain per species of C. 
      kefyr, C. glabrata, C. albicans, and C. parapsilosis were included in the study. 
      The antifungal property of aspirin was tested by the broth microdilution method, 
      while effect of aspirin on biofilm formation was determined by the 
      microtiter-plate test. The minimal inhibitory concentrations of aspirin obtained 
      ranged from 2.17 to 8.67 mM and minimal fungicidal concentrations were from 4.33 
      to 8.67 mM. The concentrations of aspirin which induced statistically significant 
      decrease in biofilm formation ranged from 0.43 mM to 1.73 mM of aspirin, 
      depending on the tested yeast strain. Therefore, the significant effects of 
      aspirin on growth and biofilm formation of Candida spp. were achieved only with 
      suprapharmacological concentrations of the drug. The influence of the inoculum 
      size on the effect of aspirin on biofilm formation was determined for C. albicans 
      only and a significant decrease was observed also at suprapharmacological 
      concentrations of aspirin, irrespective of the inoculum size. The results 
      obtained in the present study show aspirin to be a drug with the potential to 
      affect and suppress biofilm formation by Candida spp., and provide support for 
      further investigation.
FAU - Stepanović, S
AU  - Stepanović S
AD  - Department of Bacteriology, Institute of Microbiology and Immunology, School of 
      Medicine, University of Belgrade, Dr. Subotića 1, 11000 Belgrade, Serbia. 
      stepan@afrodita.rcub.bg.ac.yu
FAU - Vuković, D
AU  - Vuković D
FAU - Jesić, M
AU  - Jesić M
FAU - Ranin, L
AU  - Ranin L
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Biofilms/*drug effects/growth & development
MH  - Candida/classification/*drug effects/physiology
MH  - Humans
MH  - Microbial Sensitivity Tests
EDAT- 2004/06/26 05:00
MHDA- 2004/07/30 05:00
CRDT- 2004/06/26 05:00
PHST- 2004/06/26 05:00 [pubmed]
PHST- 2004/07/30 05:00 [medline]
PHST- 2004/06/26 05:00 [entrez]
AID - 10.1179/joc.2004.16.2.134 [doi]
PST - ppublish
SO  - J Chemother. 2004 Apr;16(2):134-8. doi: 10.1179/joc.2004.16.2.134.

PMID- 16861926
OWN - NLM
STAT- MEDLINE
DCOM- 20070103
LR  - 20220225
IS  - 1551-4005 (Electronic)
IS  - 1551-4005 (Linking)
VI  - 5
IP  - 15
DP  - 2006 Aug
TI  - Nitrogen oxide-releasing aspirin induces histone H2AX phosphorylation, ATM 
      activation and apoptosis preferentially in S-phase cells: involvement of reactive 
      oxygen species.
PG  - 1669-74
AB  - Nitric oxide-releasing acetylsalicylic acid (NO-ASA; NO-aspirin) developed as an 
      anti-inflammatory agent that was expected to avoid some of the adverse effects of 
      aspirin (ASA), was recently shown to be cytotoxic to cells of different tumor 
      lines. The cytotoxic properties and potency of NO-ASA are different than those of 
      ASA which implies that the intracellular targets for NO-ASA and ASA, and their 
      mechanism of action, are different. The aim of the present study was to reveal 
      whether the cytotoxicity induced by NO-ASA is mediated by damage to DNA. We 
      observed that even brief (1 h) treatment of human B-lymphoblastoid TK6 cells with 
      >or=5 microM NO-ASA led to DNA damage revealed by the alkaline and neutral comet 
      assays, histone H2AX phosphorylation on Ser 139, and ATM phosphorylation on Ser 
      1981, a marker of activation of this kinase. The induction of H2AX 
      phosphorylation was preferential to S-phase cells. Exposure to >or=5 microM 
      NO-ASA for over 3 h led to apoptosis, also preferentially of S-phase cells. 
      Apoptosis was atypical; while chromatin was highly condensed there was no 
      evidence of nuclear fragmentation nor were the cells positive in the TUNEL assay 
      though they did express activated caspase-3. The induction of phosphorylation of 
      H2AX on Ser 139 by NO-ASA was markedly attenuated in the presence of 
      N-acetyl-L-cysteine, a scavenger of reactive oxygen species (ROS). The data imply 
      that the NO-ASA induces DNA damage through oxidative stress; the 
      oxidation-generated lesions provide a signal for induction of H2AX 
      phosphorylation during DNA replication, perhaps when the progressing replication 
      forks collide with the primary lesions converting them to DNA double-strand 
      breaks. Because neither induction of H2AX phosphorylation nor apoptosis were 
      observed at equimolar concentrations of ASA, the NO moiety attached to ASA 
      appeared to mediate these effects.
FAU - Tanaka, Toshiki
AU  - Tanaka T
AD  - Brander Cancer Research Institute and Department of Pathology, New York Medical 
      College, Valhalla, New York, USA.
FAU - Kurose, Akira
AU  - Kurose A
FAU - Halicka, H Dorota
AU  - Halicka HD
FAU - Huang, Xuan
AU  - Huang X
FAU - Traganos, Frank
AU  - Traganos F
FAU - Darzynkiewicz, Zbigniew
AU  - Darzynkiewicz Z
LA  - eng
GR  - R01 CA028704/CA/NCI NIH HHS/United States
GR  - R01 CA028704-27/CA/NCI NIH HHS/United States
GR  - R01CA28704/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20060801
PL  - United States
TA  - Cell Cycle
JT  - Cell cycle (Georgetown, Tex.)
JID - 101137841
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (H2AX protein, human)
RN  - 0 (Histones)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 17885-08-4 (Phosphoserine)
RN  - EC 2.7.11.1 (ATM protein, human)
RN  - EC 2.7.11.1 (Ataxia Telangiectasia Mutated Proteins)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Ataxia Telangiectasia Mutated Proteins
MH  - Cell Cycle Proteins/*metabolism
MH  - Cell Nucleus/drug effects
MH  - Comet Assay
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - DNA-Binding Proteins/*metabolism
MH  - Histones/*metabolism
MH  - Humans
MH  - Phosphorylation/drug effects
MH  - Phosphoserine/metabolism
MH  - Protein Serine-Threonine Kinases/*metabolism
MH  - Reactive Oxygen Species/*metabolism
MH  - S Phase/*drug effects
MH  - Tumor Cells, Cultured
MH  - Tumor Suppressor Proteins/*metabolism
EDAT- 2006/07/25 09:00
MHDA- 2007/01/04 09:00
CRDT- 2006/07/25 09:00
PHST- 2006/07/25 09:00 [pubmed]
PHST- 2007/01/04 09:00 [medline]
PHST- 2006/07/25 09:00 [entrez]
AID - 3100 [pii]
AID - 10.4161/cc.5.15.3100 [doi]
PST - ppublish
SO  - Cell Cycle. 2006 Aug;5(15):1669-74. doi: 10.4161/cc.5.15.3100. Epub 2006 Aug 1.

PMID- 9778323
OWN - NLM
STAT- MEDLINE
DCOM- 19981105
LR  - 20201216
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 98
IP  - 16
DP  - 1998 Oct 20
TI  - Randomized multicenter comparison of conventional anticoagulation versus 
      antiplatelet therapy in unplanned and elective coronary stenting. The full 
      anticoagulation versus aspirin and ticlopidine (fantastic) study.
PG  - 1597-603
AB  - BACKGROUND: Dual therapy with ticlopidine and aspirin has been shown to be as 
      effective as or more effective than conventional anticoagulation in patients with 
      an optimal result after implantation of intracoronary metallic stents. However, 
      the safety and efficacy of antiplatelet therapy alone in an unselected population 
      has not been evaluated. METHODS: Patients were randomized to conventional 
      anticoagulation or to treatment with antiplatelet therapy alone. Indications for 
      stenting were classified as elective (decided before the procedure) or unplanned 
      (to salvage failed angioplasty or to optimize the results of balloon 
      angioplasty). After stenting, patients received aspirin and either ticlopidine or 
      conventional anticoagulation (heparin or oral anticoagulant). The primary end 
      point was the occurrence of bleeding or peripheral vascular complications; 
      secondary end points were cardiac events (death, infarction, or stent occlusion) 
      and duration of hospitalization. RESULTS: In 13 centers, 236 patients were 
      randomized to anticoagulation and 249 to antiplatelet therapy. Stenting was 
      elective in 58% of patients and unplanned in 42%. Stent implantation was 
      successfully achieved in 99% of patients. A primary end point occurred in 33 
      patients (13.5%) in the antiplatelet group and 48 patients (21%) in the 
      anticoagulation group (odds ratio=0.6 [95% CI 0.36 to 0.98], P=0.03). Major 
      cardiac-related events in electively stented patients were less common (odds 
      ratio=0.23 [95% CI 0.05 to 0.91], P=0.01) in the antiplatelet group (3 of 123, 
      2.4%) than the anticoagulation group (11 of 111, 9.9%). Hospital stay was 
      significantly shorter in the antiplatelet group (4.3+/-3.6 versus 6. 4+/-3.7 
      days, P=0.0001). CONCLUSIONS: Antiplatelet therapy after coronary stenting 
      significantly reduced rates of bleeding and subacute stent occlusion compared 
      with conventional anticoagulation.
FAU - Bertrand, M E
AU  - Bertrand ME
AD  - Dept de Cardiologie B, Hôpital Cardiologique, 59037 Lille, France. 
      bertrandme@aol.com
FAU - Legrand, V
AU  - Legrand V
FAU - Boland, J
AU  - Boland J
FAU - Fleck, E
AU  - Fleck E
FAU - Bonnier, J
AU  - Bonnier J
FAU - Emmanuelson, H
AU  - Emmanuelson H
FAU - Vrolix, M
AU  - Vrolix M
FAU - Missault, L
AU  - Missault L
FAU - Chierchia, S
AU  - Chierchia S
FAU - Casaccia, M
AU  - Casaccia M
FAU - Niccoli, L
AU  - Niccoli L
FAU - Oto, A
AU  - Oto A
FAU - White, C
AU  - White C
FAU - Webb-Peploe, M
AU  - Webb-Peploe M
FAU - Van Belle, E
AU  - Van Belle E
FAU - McFadden, E P
AU  - McFadden EP
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Arterial Occlusive Diseases/prevention & control
MH  - Aspirin/adverse effects/therapeutic use
MH  - Coronary Disease/complications/*therapy
MH  - Drug Therapy, Combination
MH  - *Elective Surgical Procedures
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/prevention & control
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - *Stents
MH  - Ticlopidine/adverse effects/therapeutic use
MH  - Treatment Outcome
EDAT- 1998/10/20 00:00
MHDA- 1998/10/20 00:01
CRDT- 1998/10/20 00:00
PHST- 1998/10/20 00:00 [pubmed]
PHST- 1998/10/20 00:01 [medline]
PHST- 1998/10/20 00:00 [entrez]
AID - 10.1161/01.cir.98.16.1597 [doi]
PST - ppublish
SO  - Circulation. 1998 Oct 20;98(16):1597-603. doi: 10.1161/01.cir.98.16.1597.

PMID- 6663486
OWN - NLM
STAT- MEDLINE
DCOM- 19840316
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 72
IP  - 12
DP  - 1983 Dec
TI  - Comparison of aspirin and copper aspirinate with respect to gastric mucosal 
      damage in the rat.
PG  - 1457-61
AB  - The copper salt of aspirin has been compared with aspirin in terms of damage to 
      mucosal tissue. Using a protein-bound dye to highlight erosions, it has been 
      found that copper aspirinate is at least as damaging as aspirin itself. This 
      finding is not in agreement with previously published claims. Copper aspirinate 
      produced more widespread superficial erosions and slightly less deep erosions 
      than aspirin alone. Mixtures of the copper(II) ion and aspirin produced results 
      similar to copper aspirinate, suggesting that the hydrolysis products of copper 
      aspirinate, copper(II) ion and aspirin, together may be especially damaging to 
      the mucosa. Copper alone was not damaging, but aspirin alone yielded intermediate 
      results. Short incubation times produced only erosions (no ulcers), which were 
      clearly differentiated into two classes by depth of color. Histological 
      examination verified this classification into superficial and deep erosions.
FAU - Alich, A A
AU  - Alich AA
FAU - Welsh, V J
AU  - Welsh VJ
FAU - Wittmers, L E Jr
AU  - Wittmers LE Jr
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Buffers)
RN  - 789U1901C5 (Copper)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Buffers
MH  - Copper/toxicity
MH  - Gastric Mucosa/*drug effects
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach Ulcer/*chemically induced
EDAT- 1983/12/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1983/12/01 00:00
PHST- 1983/12/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1983/12/01 00:00 [entrez]
AID - S0022-3549(15)44905-6 [pii]
AID - 10.1002/jps.2600721222 [doi]
PST - ppublish
SO  - J Pharm Sci. 1983 Dec;72(12):1457-61. doi: 10.1002/jps.2600721222.

PMID- 17008926
OWN - NLM
STAT- MEDLINE
DCOM- 20061019
LR  - 20171116
IS  - 1743-4386 (Electronic)
IS  - 1743-4378 (Linking)
VI  - 3
IP  - 10
DP  - 2006 Oct
TI  - Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal 
      and cardiovascular risks.
PG  - 563-73
AB  - Ulcer complications associated with the use of NSAIDs, in high-risk patients, are 
      often caused by a failure to identify patients' risk factors, concomitant use of 
      aspirin or multiple NSAIDs, and underutilization of gastroprotective agents. 
      Current data suggest that cyclo-oxygenase 2 (COX2) inhibitors and some 
      nonselective NSAIDs increase the risk of myocardial infarction. Physicians must, 
      therefore, take into account both the gastrointestinal and the cardiovascular 
      risks of individual patients when prescribing NSAIDs. In patients with a low 
      cardiovascular risk, NSAIDs can be prescribed according to the level of 
      gastrointestinal risk. Patients with a moderate gastrointestinal risk (one or two 
      risk factors) should receive a COX2 inhibitor or an NSAID plus a PPI or 
      misoprostol. Patients with more than two gastrointestinal risk factors or prior 
      ulcer complications require the combination of a COX2 inhibitor and a PPI. 
      Patients with a high cardiovascular risk (e.g. coronary heart disease or an 
      estimated 10-year cardiovascular risk greater than 10%) should receive 
      prophylactic aspirin and combination therapy with a PPI or misoprostol 
      irrespective of the presence of gastrointestinal risk factors. Naproxen is the 
      preferred NSAID because it is not associated with excess cardiovascular risk. 
      Patients with a high cardiovascular risk and a very high gastrointestinal risk 
      should avoid using NSAIDs or COX2 inhibitors.
FAU - Chan, Francis K L
AU  - Chan FK
AD  - Department of Medicine & Therapeutics, The Chinese University of Hong Kong, 
      Prince of Wales Hospital, Shatin, Hong Kong. fklchan@cuhk.edu.hk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Nat Clin Pract Gastroenterol Hepatol
JT  - Nature clinical practice. Gastroenterology & hepatology
JID - 101226510
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/chemically induced/*etiology
MH  - Contraindications
MH  - Cyclooxygenase 2 Inhibitors/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Diseases/chemically induced/*etiology
MH  - Humans
MH  - Risk Assessment
MH  - Risk Factors
MH  - Ulcer/chemically induced
RF  - 71
EDAT- 2006/09/30 09:00
MHDA- 2006/10/20 09:00
CRDT- 2006/09/30 09:00
PHST- 2006/01/04 00:00 [received]
PHST- 2006/07/25 00:00 [accepted]
PHST- 2006/09/30 09:00 [pubmed]
PHST- 2006/10/20 09:00 [medline]
PHST- 2006/09/30 09:00 [entrez]
AID - ncpgasthep0610 [pii]
AID - 10.1038/ncpgasthep0610 [doi]
PST - ppublish
SO  - Nat Clin Pract Gastroenterol Hepatol. 2006 Oct;3(10):563-73. doi: 
      10.1038/ncpgasthep0610.

PMID- 8937281
OWN - NLM
STAT- MEDLINE
DCOM- 19961220
LR  - 20150616
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 348
IP  - 9039
DP  - 1996 Nov 23
TI  - Risk of aspirin-associated major upper-gastrointestinal bleeding with 
      enteric-coated or buffered product.
PG  - 1413-6
AB  - BACKGROUND: Aspirin products are known to cause irritation and injury to the 
      gastric mucosa. The belief that enteric-coated and buffered varieties are less 
      likely to occasion major upper-gastrointestinal bleeding (UGIB) than plain 
      aspirin was tested in data from a multicentre case-control study. METHODS: 550 
      incident cases of UGIB admitted to hospital with melaena or haematemesis and 
      confirmed by endoscopy, and 1202 controls identified from population census 
      lists, were interviewed about use of aspirin and other non-steroidal 
      anti-inflammatory drugs (NSAIDs) during the 7 days before the onset of bleeding 
      (cases) or interview (controls). Relative risks of UGIB for each type of aspirin 
      used regularly (at least every other day) were calculated overall, and according 
      to dose, by multiple logistic regression, with control for age, sex, marital 
      status, date, education, cigarette smoking, alcohol use, and use of NSAIDs. 
      FINDINGS: The relative risks of UGIB for plain, enteric-coated, and buffered 
      aspirin at average daily doses of 325 mg or less were 2.6, 2.7, and 3.1, 
      respectively. At doses greater than 325 mg, the relative risk was 5.8 for plain 
      and 7.0 for buffered aspirin; there were insufficient data to evaluate 
      enteric-coated aspirin at this dose level. There were no important differences in 
      risk attributable to the three aspirin forms according to bleeding site (gastric 
      vs duodenal), or when users of NSAIDs were excluded. INTERPRETATION: Use of low 
      doses of enteric-coated or buffered aspirin carries a three-fold increase in the 
      risk of major UGIB. The assumption that these formulations are less harmful than 
      plain aspirin may be mistaken.
FAU - Kelly, J P
AU  - Kelly JP
AD  - Slone Epidemiology Unit, School of Public Health, Boston University School of 
      Medicine, Brookline, Massachusetts 02146, USA.
FAU - Kaufman, D W
AU  - Kaufman DW
FAU - Jurgelon, J M
AU  - Jurgelon JM
FAU - Sheehan, J
AU  - Sheehan J
FAU - Koff, R S
AU  - Koff RS
FAU - Shapiro, S
AU  - Shapiro S
LA  - eng
GR  - 2 R01 DK36997-0502/DK/NIDDK NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Buffers)
RN  - 0 (Tablets)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 1996 Nov 23;348(9039):1394-5. PMID: 8937273
CIN - Lancet. 1997 Feb 8;349(9049):430-1. PMID: 9033489
CIN - Lancet. 1997 Feb 8;349(9049):431. PMID: 9033490
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Buffers
MH  - Case-Control Studies
MH  - Endoscopy, Gastrointestinal
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Hematemesis/chemically induced
MH  - Humans
MH  - Melena/chemically induced
MH  - Middle Aged
MH  - Risk
MH  - Tablets
MH  - Tablets, Enteric-Coated
EDAT- 1996/11/23 00:00
MHDA- 1996/11/23 00:01
CRDT- 1996/11/23 00:00
PHST- 1996/11/23 00:00 [pubmed]
PHST- 1996/11/23 00:01 [medline]
PHST- 1996/11/23 00:00 [entrez]
AID - S0140-6736(96)01254-8 [pii]
AID - 10.1016/S0140-6736(96)01254-8 [doi]
PST - ppublish
SO  - Lancet. 1996 Nov 23;348(9039):1413-6. doi: 10.1016/S0140-6736(96)01254-8.

PMID- 27871515
OWN - NLM
STAT- MEDLINE
DCOM- 20170914
LR  - 20220321
IS  - 1873-4529 (Electronic)
IS  - 0952-8180 (Print)
IS  - 0952-8180 (Linking)
VI  - 35
DP  - 2016 Dec
TI  - Perioperative antiplatelet therapy and cardiovascular outcomes in patients 
      undergoing joint and spine surgery.
PG  - 163-169
LID - S0952-8180(16)30423-8 [pii]
LID - 10.1016/j.jclinane.2016.07.028 [doi]
AB  - STUDY OBJECTIVE: Perioperative thrombotic complications after orthopedic surgery 
      are associated with significant morbidity and mortality. The use of aspirin to 
      reduce perioperative cardiovascular complications in certain high-risk cohorts 
      remains controversial. Few studies have addressed aspirin use, bleeding, and 
      cardiovascular outcomes among high-risk patients undergoing joint and spine 
      surgery. DESIGN/SETTING/PATIENTS: We performed a retrospective comparison of 
      adults undergoing knee, hip, or spine surgery at a tertiary care center during 2 
      periods between November 2008 and December 2009 (reference period) and between 
      April 2013 and December 2013 (contemporary period). MEASUREMENTS: Patient 
      demographics, comorbidities, management, and outcomes were ascertained using 
      hospital datasets. MAIN RESULTS: A total of 5690 participants underwent 3075 
      joint and spine surgeries in the reference period and 2791 surgeries in the 
      contemporary period. Mean age was 61±13 years, and 59% were female. In the 
      overall population, incidence of myocardial injury (3.1% vs 5.8%, P<.0001), 
      hemorrhage (0.2% vs 0.8%, P=.0009), and red blood cell transfusion (17.2% vs 
      24.8%, P<.001) were lower in the contemporary period. Among 614 participants with 
      a preoperative diagnosis of coronary artery disease (CAD), in-hospital aspirin 
      use was significantly higher in the contemporary period (66% vs 30.7%, P<.0001); 
      numerically, fewer participants developed myocardial injury (13.5% vs 19.3%, 
      P=.05), had hemorrhage (0.3% vs 2.1%, P=.0009), and had red blood cell 
      transfusion (37.2% vs 44.2%, P<.001) in the contemporary vs reference period. 
      CONCLUSIONS: In a large tertiary care center, the incidence of perioperative 
      bleeding and cardiovascular events decreased over time. In participants with CAD, 
      perioperative aspirin use increased and appears to be safe.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Smilowitz, Nathaniel R
AU  - Smilowitz NR
AD  - Department of Medicine, Division of Cardiology, New York University School of 
      Medicine, New York, New York, USA.
FAU - Oberweis, Brandon S
AU  - Oberweis BS
AD  - Department of Medicine, Division of Cardiology, Columbia University Medical 
      Center, New York, New York, USA.
FAU - Nukala, Swetha
AU  - Nukala S
AD  - Department of Clinical Quality and Clinical Effectiveness, New York University 
      School of Medicine, New York, New York, USA.
FAU - Rosenberg, Andrew
AU  - Rosenberg A
AD  - Department of Anesthesiology, New York University School of Medicine, New York, 
      New York, USA.
FAU - Stuchin, Steven
AU  - Stuchin S
AD  - Department of Orthopedic Surgery, New York University School of Medicine, New 
      York, New York, USA.
FAU - Iorio, Richard
AU  - Iorio R
AD  - Department of Orthopedic Surgery, New York University School of Medicine, New 
      York, New York, USA.
FAU - Errico, Thomas
AU  - Errico T
AD  - Department of Orthopedic Surgery, New York University School of Medicine, New 
      York, New York, USA.
FAU - Radford, Martha J
AU  - Radford MJ
AD  - Department of Medicine, Division of Cardiology, New York University School of 
      Medicine, New York, New York, USA; Department of Population Health, New York 
      University School of Medicine, New York, New York, USA.
FAU - Berger, Jeffrey S
AU  - Berger JS
AD  - Department of Medicine, Division of Cardiology, New York University School of 
      Medicine, New York, New York, USA; Department of Surgery, Division of Vascular 
      Surgery, New York University School of Medicine, New York, New York, USA. 
      Electronic address: jeffrey.berger@nyumc.org.
LA  - eng
GR  - R01 HL114978/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
DEP - 20160819
PL  - United States
TA  - J Clin Anesth
JT  - Journal of clinical anesthesia
JID - 8812166
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Loss, Surgical/mortality/statistics & numerical data
MH  - Coronary Artery Disease/complications/*drug therapy/mortality
MH  - Erythrocyte Transfusion/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Orthopedic Procedures/*adverse effects/mortality
MH  - Perioperative Care/*methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Postoperative Hemorrhage/chemically induced/epidemiology/mortality
MH  - Retrospective Studies
MH  - Tertiary Care Centers
MH  - Thrombosis/etiology/*prevention & control
MH  - Treatment Outcome
PMC - PMC5563846
MID - NIHMS893802
OTO - NOTNLM
OT  - Antiplatelet
OT  - Aspirin
OT  - Bleeding
OT  - Cardiovascular
OT  - Coronary artery disease
OT  - Myocardial infarction
OT  - Myocardial injury
OT  - Orthopedic surgery
OT  - Perioperative
OT  - Transfusion
COIS- Disclosures: The authors report no relevant disclosures or conflicts of interest.
EDAT- 2016/11/23 06:00
MHDA- 2017/09/15 06:00
CRDT- 2016/11/23 06:00
PHST- 2015/07/08 00:00 [received]
PHST- 2016/05/13 00:00 [revised]
PHST- 2016/07/11 00:00 [accepted]
PHST- 2016/11/23 06:00 [entrez]
PHST- 2016/11/23 06:00 [pubmed]
PHST- 2017/09/15 06:00 [medline]
AID - S0952-8180(16)30423-8 [pii]
AID - 10.1016/j.jclinane.2016.07.028 [doi]
PST - ppublish
SO  - J Clin Anesth. 2016 Dec;35:163-169. doi: 10.1016/j.jclinane.2016.07.028. Epub 
      2016 Aug 19.

PMID- 25295680
OWN - NLM
STAT- MEDLINE
DCOM- 20160919
LR  - 20211021
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Print)
IS  - 1088-0224 (Linking)
VI  - 20
IP  - 8
DP  - 2014 Aug
TI  - Contemporary use of dual antiplatelet therapy for preventing cardiovascular 
      events.
PG  - 659-65
AB  - OBJECTIVES: CHARISMA was a landmark randomized clinical trial that failed to 
      demonstrate a benefit of dual antiplatelet therapy (DAPT) over aspirin alone for 
      preventing cardiovascular events. However, subgroup analyses of the trial found 
      fewer major adverse cardiovascular events (MACEs) for patients with established 
      cardiovascular disease but more MACEs for patients with multiple risk factors 
      without established cardiovascular disease. Our objective was to examine DAPT use 
      in contemporary clinical practice after publication of CHARISMA results. STUDY 
      DESIGN: Retrospective analysis of a large clinical registry of outpatient 
      cardiovascular visits to over 1000 physicians that collected data on patient 
      clinical history, symptoms, vital signs, and medications. METHODS: Clinical 
      characteristics and prescription rates of aspirin and clopidogrel were compared 
      for patients with established cardiovascular disease and for patients with only 
      multiple cardiovascular risk factors. Prescription of DAPT by calendar quarter 
      was evaluated from 2008 to 2011 using multivariable Poisson regression models. 
      RESULTS: Of 167,839 patients with established cardiovascular disease, 20.5% were 
      prescribed both aspirin and clopidogrel. Of 20,478 patients with multiple risk 
      factors but no known cardiovascular disease, 3.5% were prescribed both aspirin 
      and clopidogrel. Across 14 calendar quarters, prescription rates of DAPT did not 
      change significantly for patients with established CVD but decreased for patients 
      with multiple risk factors with an incidence rate ratio of 0.77. CONCLUSIONS: Use 
      of DAPT is modest in patients with established cardiovascular disease, for whom 
      the CHARISMA trial suggested decreased MACEs, and prescription rates have 
      remained stable over time. Use of DAPT in patients with multiple risk factors 
      only, for whom CHARISMA suggested that DAPT may lead to increased MACE, was low 
      and decreased over time.
FAU - Goldsweig, Andrew M
AU  - Goldsweig AM
FAU - Reid, Kimberly J
AU  - Reid KJ
FAU - Gosch, Kensey
AU  - Gosch K
FAU - Tang, Fengming
AU  - Tang F
FAU - Fang, Margaret C
AU  - Fang MC
FAU - Maddox, Thomas M
AU  - Maddox TM
FAU - Chan, Paul S
AU  - Chan PS
FAU - Cohen, David J
AU  - Cohen DJ
FAU - Chen, Jersey
AU  - Chen J
AD  - Kaiser Permanente, Mid-Atlantic Permanente Research Institute, 2101 East 
      Jefferson St, 3 West, Rockville, MD 20852. E-mail: jersey.chen@kp.org.
LA  - eng
GR  - K08 HS018781/HS/AHRQ HHS/United States
GR  - K23 HL102224/HL/NHLBI NIH HHS/United States
GR  - K23HL102224/HL/NHLBI NIH HHS/United States
GR  - 1K08HS018781-01/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Secondary Prevention/methods/statistics & numerical data
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
PMC - PMC4539274
MID - NIHMS715008
EDAT- 2014/10/09 06:00
MHDA- 2016/09/20 06:00
CRDT- 2014/10/09 06:00
PHST- 2014/10/09 06:00 [entrez]
PHST- 2014/10/09 06:00 [pubmed]
PHST- 2016/09/20 06:00 [medline]
AID - 85643 [pii]
PST - ppublish
SO  - Am J Manag Care. 2014 Aug;20(8):659-65.

PMID- 18091399
OWN - NLM
STAT- MEDLINE
DCOM- 20080124
LR  - 20131121
IS  - 1538-4683 (Electronic)
IS  - 1061-5377 (Linking)
VI  - 16
IP  - 1
DP  - 2008 Jan-Feb
TI  - Platelet inhibitors: what are the data in women?
PG  - 23-9
AB  - Cardiovascular disease is the leading cause of disability and mortality among 
      women in the United States. However, relative to their representation among the 
      overall population of patients presenting with acute coronary syndromes, women 
      have been underrepresented in clinical trials of treatment strategies for acute 
      coronary syndromes. In general, subgroup analyses and meta-analyses of the data 
      from the major treatment trials have demonstrated similar treatment effects among 
      women and men, but questions recently have been raised regarding the role and 
      effect of antiplatelet therapy in the treatment of women. This article will 
      review the use of antiplatelet therapy in women from the perspective of both 
      primary and secondary prevention using as a focus for discussion recent 
      randomized clinical trial data and registry observations of the potential 
      benefits and risks of antiplatelet therapy in women.
FAU - Tempelhof, Michael W
AU  - Tempelhof MW
AD  - Division of Cardiovascular Medicine, Department of Medicine, Duke University 
      Medical Center, Durham, North Carolina 27715-7969, USA.
FAU - Newby, L Kristin
AU  - Newby LK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiol Rev
JT  - Cardiology in review
JID - 9304686
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Registries
MH  - Risk Assessment
MH  - Risk Factors
RF  - 41
EDAT- 2007/12/20 09:00
MHDA- 2008/01/25 09:00
CRDT- 2007/12/20 09:00
PHST- 2007/12/20 09:00 [pubmed]
PHST- 2008/01/25 09:00 [medline]
PHST- 2007/12/20 09:00 [entrez]
AID - 00045415-200801000-00004 [pii]
AID - 10.1097/CRD.0b013e31815a7e30 [doi]
PST - ppublish
SO  - Cardiol Rev. 2008 Jan-Feb;16(1):23-9. doi: 10.1097/CRD.0b013e31815a7e30.

PMID- 19843493
OWN - NLM
STAT- MEDLINE
DCOM- 20100118
LR  - 20181201
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 31
IP  - 9
DP  - 2009 Sep
TI  - A comparison of aspirin and clopidogrel with or without proton pump inhibitors 
      for the secondary prevention of cardiovascular events in patients at high risk 
      for gastrointestinal bleeding.
PG  - 2038-47
LID - 10.1016/j.clinthera.2009.09.005 [doi]
AB  - OBJECTIVE: This study was conducted to compare the risk of recurrent 
      hospitalization for major gastrointestinal (GI) complications (peptic ulcer, 
      bleeding, and perforation) in patients at high GI risk who require ongoing 
      antiplatelet therapy (aspirin [acetylsalicylic acid] or clopidogrel) with or 
      without proton pump inhibitors (PPIs). METHODS: This population-based, 
      retrospective cohort study employed data from the Taiwanese National Health 
      Insurance database (January 2001 through December 2006) for patients who had a 
      history of hospitalization for GI complications before the initiation of 
      antiplatelet therapy with aspirin or clopidogrel. Recurrent hospitalizations for 
      major GI complications were analyzed using a Cox proportional hazards model, with 
      adjustment for age, sex, ulcer-related medical history, ulcer-related risk 
      factors, and use of ulcer-related medications during follow-up. The propensity 
      score method was applied to adjust for selection bias. RESULTS: The analysis 
      included data from 14,627 patients (12,001 receiving aspirin, 2626 receiving 
      clopidogrel). The incidence of recurrent hospitalization for major GI 
      complications was 0.125 per person-year in aspirin users, 0.103 per person-year 
      in users of aspirin plus a PPI, 0.128 per person-year in clopidogrel users, and 
      0.152 per person-year in users of clopidogrel plus a PPI. Among aspirin users, 
      those taking PPIs had a significantly lower adjusted risk of hospitalization for 
      major GI complications than did non-PPI users (hazard ratio [HR] = 0.76; 95% CI, 
      0.64-0.91). Use of a PPI was not associated with a significant risk reduction 
      among clopidogrel users (HR = 1.08; 95% CI, 0.89-1.33). An adjusted survival 
      curve for the risk of recurrent hospitalization for major GI complications 
      indicated that the risk increased numerically faster in clopidogrel users 
      compared with those using aspirin plus a PPI, although the mean drug cost per 
      person-year was 5.08 times higher in clopidogrel users than in users of aspirin 
      plus a PPI. CONCLUSIONS: In this analysis in patients at high GI risk who were 
      receiving antiplatelet therapy for the secondary prevention of cardiovascular 
      events, aspirin plus a PPI was associated with a reduced risk of recurrent 
      hospitalization for major GI complications. This was not the case for clopidogrel 
      plus a PPI.
FAU - Hsiao, Fei-Yuan
AU  - Hsiao FY
AD  - Pharmaceutical Health Services Research Department, University of Maryland School 
      of Pharmacy, Baltimore, Maryland, USA.
FAU - Tsai, Yi-Wen
AU  - Tsai YW
FAU - Huang, Weng-Foung
AU  - Huang WF
FAU - Wen, Yu-Wen
AU  - Wen YW
FAU - Chen, Pei-Fen
AU  - Chen PF
FAU - Chang, Po-Yin
AU  - Chang PY
FAU - Kuo, Ken N
AU  - Kuo KN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/economics/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Clopidogrel
MH  - Databases, Factual
MH  - Drug Costs
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Hemorrhage/*chemically induced/prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Readmission/statistics & numerical data
MH  - Peptic Ulcer/chemically induced/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/economics/therapeutic use
MH  - Proportional Hazards Models
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Secondary Prevention/methods
MH  - Taiwan
MH  - Ticlopidine/adverse effects/*analogs & derivatives/economics/therapeutic use
EDAT- 2009/10/22 06:00
MHDA- 2010/01/19 06:00
CRDT- 2009/10/22 06:00
PHST- 2009/07/09 00:00 [accepted]
PHST- 2009/10/22 06:00 [entrez]
PHST- 2009/10/22 06:00 [pubmed]
PHST- 2010/01/19 06:00 [medline]
AID - S0149-2918(09)00334-8 [pii]
AID - 10.1016/j.clinthera.2009.09.005 [doi]
PST - ppublish
SO  - Clin Ther. 2009 Sep;31(9):2038-47. doi: 10.1016/j.clinthera.2009.09.005.

PMID- 26370865
OWN - NLM
STAT- MEDLINE
DCOM- 20160310
LR  - 20181202
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 54
IP  - 18
DP  - 2015
TI  - Aspirin and Eicosapentaenoic Acid May Arrest Progressive IgA Nephropathy: A 
      Potential Alternative to Immunosuppression.
PG  - 2377-82
LID - 10.2169/internalmedicine.54.4623 [doi]
AB  - Immunoglobulin (Ig) A nephropathy is a prevalent form of primary 
      glomerulonephritis, which leads to end-stage renal failure in a significant 
      proportion of patients. Immunotherapy, including steroid use, is widely used to 
      induce disease remission; however, it can cause serious side effects. We herein 
      report 3 cases of progressive IgA nephropathy and their successful treatment with 
      a combination of aspirin and eicosapentaenoic acid (EPA) without the use of 
      steroids. The precise mechanism responsible for the combination therapy is still 
      unknown; however, aspirin may potentiate the production of anti-inflammatory 
      lipid mediators derived from EPA. Further clinical trials are required to 
      substantiate this treatment regimen.
FAU - Hirahashi, Junichi
AU  - Hirahashi J
AD  - Department of Nephrology and Endocrinology, Graduate School of Medicine, The 
      University of Tokyo, Japan.
FAU - Hanafusa, Norio
AU  - Hanafusa N
FAU - Wada, Takehiko
AU  - Wada T
FAU - Arita, Makoto
AU  - Arita M
FAU - Hishikawa, Keiichi
AU  - Hishikawa K
FAU - Hayashi, Matsuhiko
AU  - Hayashi M
FAU - Nangaku, Masaomi
AU  - Nangaku M
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20150915
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Eicosapentaenoic Acid/*therapeutic use
MH  - Female
MH  - Glomerulonephritis, IGA/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Young Adult
EDAT- 2015/09/16 06:00
MHDA- 2016/03/11 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/03/11 06:00 [medline]
AID - 10.2169/internalmedicine.54.4623 [doi]
PST - ppublish
SO  - Intern Med. 2015;54(18):2377-82. doi: 10.2169/internalmedicine.54.4623. Epub 2015 
      Sep 15.

PMID- 4004834
OWN - NLM
STAT- MEDLINE
DCOM- 19850708
LR  - 20131121
IS  - 0232-766X (Print)
IS  - 0232-766X (Linking)
VI  - 44
IP  - 2
DP  - 1985
TI  - [The effect of acetylsalicylic acid on the transmural potential difference of 
      gastric mucosa of infants, adolescents and adults].
PG  - 283-8
AB  - The transmural electric potential difference (PD) of the gastric mucosa was 
      investigated in children, teen-agers, and adults. Acetylsalicylic acid, a well 
      known barrier breaker, causes in adults a characteristic decrease of the gastric 
      PD. This effect in teen-agers is considerably weaker than in adults, while in 
      children there is no significant decrease of the potential difference after local 
      acetylsalicylic acid application.
FAU - König, A
AU  - König A
FAU - Nikolaides, N
AU  - Nikolaides N
FAU - Ballke, E H
AU  - Ballke EH
FAU - Griefahn, B
AU  - Griefahn B
FAU - Jährig, K
AU  - Jährig K
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Einfluss von Azetylsalizylsäure auf die transmurale Potentialdifferenz der 
      Magenschleimhaut bei Kindern, Jugendlichen und Erwachsenen.
PL  - Germany
TA  - Biomed Biochim Acta
JT  - Biomedica biochimica acta
JID - 8304435
RN  - 0 (Electrolytes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aspirin/*pharmacology
MH  - Child
MH  - Child, Preschool
MH  - Electrolytes/metabolism
MH  - Gastric Mucosa/*drug effects/physiology
MH  - Humans
MH  - Membrane Potentials/drug effects
MH  - Time Factors
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Biomed Biochim Acta. 1985;44(2):283-8.

PMID- 36121499
OWN - NLM
STAT- MEDLINE
DCOM- 20221011
LR  - 20221207
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 78
IP  - 11
DP  - 2022 Nov
TI  - The impact of enteric coating of aspirin on aspirin responsiveness in patients 
      with suspected or newly diagnosed ischemic stroke: prospective cohort study: 
      results from the (ECASIS) study.
PG  - 1801-1811
LID - 10.1007/s00228-022-03391-2 [doi]
AB  - BACKGROUND AND PURPOSE: Uncertainty remains regarding the impact of 
      enteric-coated aspirin (EC-ASA) on secondary prevention of ischemic stroke 
      compared to plain aspirin (P-ASA). Hence, this study was designed to investigate 
      the effect of EC formulation on ASA response via evaluating thromboxane B2 (TXB2) 
      levels in patients with suspected or newly diagnosed stroke. METHODS: A 
      prospective cohort study on suspected or newly diagnosed ischemic stroke patients 
      who are aspirin-naive was conducted. Patients were received either EC aspirin or 
      plain aspirin for at least 3 days. The primary outcome was the proportion of 
      aspirin non-responsiveness between two groups (level of residual serum TXB2 
      associated with elevated thrombotic risk (< 99.0% inhibition or TXB2 > 3.1 ng/ml) 
      within 72 h after three daily aspirin doses, while secondary outcomes were the 
      incidence of early gastrointestinal tract (GIT) bleeding with the various aspirin 
      preparations. (Trial registration: Clinicaltrials.gov NCT04330872 registered on 
      02 April 2020). RESULTS: Of 42 patients, ischemic strokes were confirmed in both 
      P-ASA (81%) and EC-ASA (67%) arms. ASA non-responsiveness showed no significant 
      difference between the two formulations (P-ASA vs. EC-ASA; 28.6% vs 23.8%; 
      P = 0.726). Univariate and multivariate logistic regression analysis showed that 
      patients treated with EC-ASA were more likely to have a lower rate of 
      non-responders compared to P-ASA (unadjusted OR 0.78; 95% CI 0.20, 3.11); with 
      the risk highest in type 2 diabetic patients with HBA1c > 6.5% (adjusted OR 6; 
      95% CI 1.02, 35.27; P = 0.047). No incidence of GIT bleeding observed throughout 
      the study. CONCLUSION: A significant proportion of ASA non-responsiveness was 
      recorded regardless of ASA formulation administered. The increased risk of ASA 
      non-responsiveness in diabetic patients needs further exploration by larger 
      prospective studies.
CI  - © 2022. The Author(s).
FAU - Elshafei, Mohamed Nabil
AU  - Elshafei MN
AUID- ORCID: 0000-0002-3229-6825
AD  - Clinical Pharmacy Department, Hamad General Hospital, Hamad Medical Corporation, 
      P.O. 3050, Doha, Qatar. mohnabil2010@yahoo.com.
FAU - Imam, Yahia
AU  - Imam Y
AD  - Neurology Department, Hamad General Hospital, Hamad Medical Corporation, Doha, 
      Qatar.
AD  - Weill Cornell Medicine-Qatar, Doha, Qatar.
FAU - Alsaud, Arwa Ebrahim
AU  - Alsaud AE
AD  - Internal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, 
      Doha, Qatar.
FAU - Chandra, Prem
AU  - Chandra P
AD  - Biostatstics Section, Medical Research Center, Hamad Medical Corporation, Doha, 
      Qatar.
FAU - Parray, Aijaz
AU  - Parray A
AD  - The Neuroscience Institute, Academic Health Systems, Hamad Medical Corporation, 
      Doha, Qatar.
FAU - Abdelmoneim, Mohamed S
AU  - Abdelmoneim MS
AD  - Neurology Department, Hamad General Hospital, Hamad Medical Corporation, Doha, 
      Qatar.
AD  - The Neuroscience Institute, Academic Health Systems, Hamad Medical Corporation, 
      Doha, Qatar.
FAU - Obeidat, Khaldun
AU  - Obeidat K
AD  - Internal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, 
      Doha, Qatar.
FAU - Saeid, Razan
AU  - Saeid R
AD  - Internal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, 
      Doha, Qatar.
FAU - Ali, Mohammad
AU  - Ali M
AD  - Internal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, 
      Doha, Qatar.
FAU - Ayadathil, Raheem
AU  - Ayadathil R
AD  - The Neuroscience Institute, Academic Health Systems, Hamad Medical Corporation, 
      Doha, Qatar.
FAU - Mohamed, Mouhand F H
AU  - Mohamed MFH
AD  - Internal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, 
      Doha, Qatar.
FAU - Abdallah, Ibtihal M
AU  - Abdallah IM
AD  - Clinical Pharmacy Department, Hamad General Hospital, Hamad Medical Corporation, 
      P.O. 3050, Doha, Qatar.
FAU - Mohammed, Shaban
AU  - Mohammed S
AD  - Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
FAU - Akhtar, Naveed
AU  - Akhtar N
AD  - Neurology Department, Hamad General Hospital, Hamad Medical Corporation, Doha, 
      Qatar.
AD  - Weill Cornell Medicine-Qatar, Doha, Qatar.
FAU - Danjuma, Mohammed Ibn-Masoud
AU  - Danjuma MI
AD  - Internal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, 
      Doha, Qatar.
AD  - College of Medicine, Qatar University, Doha, Qatar.
LA  - eng
SI  - ClinicalTrials.gov/NCT04330872
PT  - Journal Article
DEP - 20220919
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Glycated Hemoglobin
MH  - Humans
MH  - *Ischemic Stroke
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Prospective Studies
MH  - Thromboxane B2
PMC - PMC9546947
OTO - NOTNLM
OT  - Aspirin response
OT  - Enteric-coated aspirin
OT  - Plain aspirin
OT  - Stroke
OT  - Thromboxane B2
COIS- The authors declare no competing interests.
EDAT- 2022/09/20 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/09/19 11:14
PHST- 2021/12/13 00:00 [received]
PHST- 2022/08/22 00:00 [accepted]
PHST- 2022/09/20 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/09/19 11:14 [entrez]
AID - 10.1007/s00228-022-03391-2 [pii]
AID - 3391 [pii]
AID - 10.1007/s00228-022-03391-2 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2022 Nov;78(11):1801-1811. doi: 10.1007/s00228-022-03391-2. 
      Epub 2022 Sep 19.

PMID- 3873326
OWN - NLM
STAT- MEDLINE
DCOM- 19850712
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 30
IP  - 6
DP  - 1985 Jun
TI  - Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level 
      dosing of enteric-coated aspirin granules two and four times a day.
PG  - 509-12
AB  - When administered on a chronic high-dosage regimen, enteric-coated aspirin 
      granules produced significantly less gastric damage than plain aspirin or 
      aspirin-antacid combinations. Clinically meaningful damage occurred in all 
      subjects receiving plain aspirin, 93% of those receiving aspirin-antacid 
      combination and only 27% and 20% of those receiving enteric-coated aspirin 
      granules qid and bid, respectively. All three aspirin formulations were taken as 
      1 g qid (4 g/day) and an additional group received enteric granules administered 
      as 2 g bid (4 g/day). Gastric damage was assessed by means of endoscopy carried 
      out after seven days of treatment. Enteric granules are equally safe when 
      administered on a bid or qid regimen (at same total daily dosage) and, in a bid 
      regimen, should provide a compliance advantage for patients on high-dose therapy 
      for diseases such as rheumatoid arthritis.
FAU - Lanza, F L
AU  - Lanza FL
FAU - Rack, M F
AU  - Rack MF
FAU - Wagner, G S
AU  - Wagner GS
FAU - Balm, T K
AU  - Balm TK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Duodenum/pathology
MH  - Female
MH  - Gastric Mucosa/drug effects/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced/pathology/*prevention & control
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
MH  - Stomach/pathology
MH  - Stomach Ulcer/chemically induced/pathology/*prevention & control
MH  - Tablets, Enteric-Coated
EDAT- 1985/06/01 00:00
MHDA- 1985/06/01 00:01
CRDT- 1985/06/01 00:00
PHST- 1985/06/01 00:00 [pubmed]
PHST- 1985/06/01 00:01 [medline]
PHST- 1985/06/01 00:00 [entrez]
AID - 10.1007/BF01320255 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1985 Jun;30(6):509-12. doi: 10.1007/BF01320255.

PMID- 9765661
OWN - NLM
STAT- MEDLINE
DCOM- 19981109
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 27 Suppl 2
DP  - 1998 Jun
TI  - [Management of a suspicion of heparin-induced thrombopenia].
PG  - 18-21
AB  - A COMPLEX SITUATION: During the acute phase of heparin-induced thrombocytopenia, 
      the question must be raised as to whether an antithrombotic therapy is to be 
      continued using a compound other than heparin. Later the risk of reintroducing 
      heparin again can be discussed. THERAPEUTIC PROPOSITIONS: Excepting vena cava 
      interruption, surgical revascularization and thrombolysis, possible therapeutic 
      propositions can be divided into two categories; anticoagulants and related 
      compounds (hirudin); and oral anticoagulants (anti-vitamin K) and antiplatelet 
      agents (aspirin for example). Low molecular-weight heparin cannot be recommended 
      in 1998 in patients with heparin-induced thrombocytopenia due to standard 
      heparin. IN PRACTICE: Unfractionated heparin or low-molecular weight heparin must 
      be stopped immediately. The hematology laboratory should be consulted. It must be 
      remembered that prevention, based on a careful assessment of the benefit/risk 
      ratio when initiating heparin therapy, is essential.
FAU - Samama, C M
AU  - Samama CM
AD  - Département d'Anesthésie-Réanimation, Groupe Hospitalier Pitié-Salpêtrière, 
      Paris. cmSamama.pitie@invivo.edu
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Conduite è tenir devant une suspicion de thrombopénie induite par héparine.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*adverse effects
MH  - Aspirin/therapeutic use
MH  - Heparin/*adverse effects
MH  - *Hirudin Therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Factors
MH  - Thrombocytopenia/*chemically induced/*therapy
RF  - 10
EDAT- 1998/10/10 00:00
MHDA- 1998/10/10 00:01
CRDT- 1998/10/10 00:00
PHST- 1998/10/10 00:00 [pubmed]
PHST- 1998/10/10 00:01 [medline]
PHST- 1998/10/10 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1998 Jun;27 Suppl 2:18-21.

PMID- 4089814
OWN - NLM
STAT- MEDLINE
DCOM- 19860317
LR  - 20141120
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 54
IP  - 4
DP  - 1985 Dec 17
TI  - Early platelet-collagen interactions in whole blood and their modifications by 
      aspirin and dipyridamole evaluated by a new method (BASIC wave).
PG  - 799-803
AB  - It is shown that the supernatant of unstirred whole blood at 37 degrees C, 
      stimulated by 1 microgram/ml of collagen for 10 sec, produces a rapid generation 
      of pro and antiaggregatory compounds with a final proaggregatory activity which 
      can be detected for more than 60 min on a platelet rich plasma (PRP) by 
      turbidometric aggregometry. A reversible aggregation wave that we have called 
      BASIC wave (for Blood Aggregation Stimulatory and Inhibitory Compounds) is 
      recorded. The collagen stimulation of unstirred PRP produces a similar but 
      smaller BASIC wave. BASIC's intensity increases if erythrocytes are added to PRP 
      but decreases if white blood cells are added instead. Aspirin abolishes "ex vivo" 
      the ability of whole blood and PRP to generate BASIC waves and dipyridamole "in 
      vitro" significantly reduces BASIC's intensity in whole blood in every tested 
      sample, but shows little effect in PRP.
FAU - Pérez-Requejo, J L
AU  - Pérez-Requejo JL
FAU - Aznar, J
AU  - Aznar J
FAU - Santos, M T
AU  - Santos MT
FAU - Vallés, J
AU  - Vallés J
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Collagen/*pharmacology
MH  - Dipyridamole/*pharmacology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1985/12/17 00:00
MHDA- 1985/12/17 00:01
CRDT- 1985/12/17 00:00
PHST- 1985/12/17 00:00 [pubmed]
PHST- 1985/12/17 00:01 [medline]
PHST- 1985/12/17 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1985 Dec 17;54(4):799-803.

PMID- 6804241
OWN - NLM
STAT- MEDLINE
DCOM- 19820708
LR  - 20190825
IS  - 0302-2838 (Print)
IS  - 0302-2838 (Linking)
VI  - 8
IP  - 3
DP  - 1982
TI  - Influence of indomethacin and aspirin on the vesicosphincteric dynamics of 
      prostatectomized patients.
PG  - 163-72
AB  - The urodynamic and clinical effects of two known prostaglandin synthetase 
      inhibitors--indomethacin and aspirin--were analysed using 59 prostatectomized 
      patients as experimental subjects. We obtained clinical and urodynamic results 
      within each group by comparing the situation before and after medication. A 
      placebo group of 12 patients was used to get an idea of the natural evolution of 
      the situation. A urodynamic workup was done 1 h and 30 min after the 
      administration of the drugs and placebo and the clinical results were analysed on 
      the 8th day of treatment, at which time a few patients were again studied 
      urodynamically. The clinical results were again evaluated a short time after the 
      treatment had been terminated. Marked clinical and urodynamic changes showed that 
      bladder and urethral structures had been affected. Urodynamic modifications, were 
      statistically analysed. We concluded that changes noted were at least partially 
      due to prostaglandin synthesis inhibition and the resulting inhibition of 
      prostaglandin action.
FAU - Matos-Ferreira, A
AU  - Matos-Ferreira A
FAU - Reis-Santos, J M
AU  - Reis-Santos JM
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Eur Urol
JT  - European urology
JID - 7512719
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandin Antagonists)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - *Cyclooxygenase Inhibitors
MH  - Humans
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Prostaglandin Antagonists/metabolism
MH  - Prostaglandin-Endoperoxide Synthases/pharmacology
MH  - *Prostatectomy
MH  - Urethra/*drug effects
MH  - Urinary Bladder/*drug effects
MH  - Urodynamics/drug effects
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1159/000473506 [doi]
PST - ppublish
SO  - Eur Urol. 1982;8(3):163-72. doi: 10.1159/000473506.

PMID- 30358301
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 0021-4892 (Print)
IS  - 0021-4892 (Linking)
VI  - 65
IP  - 7
DP  - 2016 Aug
TI  - [Side Effects of Acetaminophen and their Management].
PG  - 701-708
AB  - Acetaminophen, a para-aminohenol derivative, was first clinically used in 1893. 
      In 1980 s, the relevance of aspirin for Reye's syndrome became a problem, then 
      acetaminophen came into use for various kinds of cases such as children, pregnant 
      women and the elderly for pain management or alleviation of fever. However, 
      because acetaminophen has a very weak COX-1 and COX-2 inhibitory effect it has 
      weak or no anti-inflam- matory effect Therefore physicians do not wish to use 
      acetaminophen for management of pain in which in- flammation is thought to be the 
      main mechanism. But recently acetaminophen has become reevaluated as an 
      indication for patients with chronic pain. In 2011, the maximum daily dose of 
      acetaminophen in Japan was increased from 1,500 ng - day-- to 4,000 mg - day-1 
      (international dosage). As acetaminophen has few side effects of gastrointestinal 
      and renal systems, its use is recommended for the control of long term pain man- 
      agement The side effects of acetaminophen and their management are discussed.
FAU - Saeki, Shigeru
AU  - Saeki S
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Masui
JT  - Masui. The Japanese journal of anesthesiology
JID - 0413707
RN  - 362O9ITL9D (Acetaminophen)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*adverse effects
MH  - Aspirin/administration & dosage
MH  - Chronic Pain/drug therapy
MH  - Cyclooxygenase 1
MH  - Fever
MH  - Humans
MH  - Pain Management
MH  - Reye Syndrome
EDAT- 2016/08/01 00:00
MHDA- 2016/08/01 00:01
CRDT- 2018/10/26 06:00
PHST- 2018/10/26 06:00 [entrez]
PHST- 2016/08/01 00:00 [pubmed]
PHST- 2016/08/01 00:01 [medline]
PST - ppublish
SO  - Masui. 2016 Aug;65(7):701-708.

PMID- 18605070
OWN - NLM
STAT- MEDLINE
DCOM- 20081017
LR  - 20131121
IS  - 0870-2551 (Print)
IS  - 0870-2551 (Linking)
VI  - 27
IP  - 4
DP  - 2008 Apr
TI  - Antiplatelet therapy and cardiovascular primary prevention: influence of gender, 
      age and other risk factors.
PG  - 513-27
AB  - Intervention for cardiovascular primary prevention has shown promising results in 
      several trials. Studies performed up to 2002 showed a significant effect of 
      aspirin in primary prevention of ischemic heart disease, with a significant 
      reduction in non-fatal acute myocardial infarction, especially in men. Since 
      then, new evidence has demonstrated the potential effect of antiplatelet therapy 
      in cardiovascular primary prevention, particularly in less represented subgroups. 
      In this article, we review the main studies on antiplatelet therapy and 
      cardiovascular primary prevention, highlighting the results for these subgroups 
      in terms of gender, age and presence of diabetes, chronic renal failure or atrial 
      fibrillation, and then propose some clinical guidelines.
FAU - Sousa, Catarina S
AU  - Sousa CS
AD  - Serviço de Cardiologia 2, Hospital Pulido Valente, EPE, Lisboa, Portugal. 
      sousa.cat@gmail.com
FAU - Fonseca, Teresa
AU  - Fonseca T
FAU - Clara, J Gorjão
AU  - Clara JG
LA  - eng
LA  - por
PT  - Journal Article
PT  - Review
PL  - Portugal
TA  - Rev Port Cardiol
JT  - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de 
      Cardiologia = Portuguese journal of cardiology : an official journal of the 
      Portuguese Society of Cardiology
JID - 8710716
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Risk Factors
MH  - Sex Factors
RF  - 34
EDAT- 2008/07/09 09:00
MHDA- 2008/10/18 09:00
CRDT- 2008/07/09 09:00
PHST- 2008/07/09 09:00 [pubmed]
PHST- 2008/10/18 09:00 [medline]
PHST- 2008/07/09 09:00 [entrez]
PST - ppublish
SO  - Rev Port Cardiol. 2008 Apr;27(4):513-27.

PMID- 708486
OWN - NLM
STAT- MEDLINE
DCOM- 19781220
LR  - 20190718
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 30
IP  - 4
DP  - 1978 Aug
TI  - Fatty acids and the initial events of endothelial damage seen by scanning and 
      transmission electron microscopy.
PG  - 273-84
AB  - A method was developed for observing changes in the endothelial cells in rabbit 
      ear veins in vivo by scanning electron microscopy. Injection of fatty acids into 
      the ear vein caused damage to the endothelium. The first signs of damage seen 
      were marked bulges in the nuclei and loss of the rhomboidal shape of the 
      endothelial cells. More severe damage included loss of nuclei, leaving holes in 
      the cytoplasm. Some parts of the damaged endothelium showed complete separation 
      of cells from each other and exposure of sub-endothelial tissue to which 
      platelets with pseudopodia were adhering. Damage to the endothelium was produced 
      by arachidonic, linoleic, gamma-linolenic, 8,11,14-eicosatrienoic, 
      5,8,11,14,-eicosatetraenoic or 15-hydroperoxy-5,8,11,13-eicosatetraenoic acids. 
      The effect of arachidonic acid was not prevented by pre-treating the animals with 
      aspirin. It appears that damage produced by the fatty acids is non-specific.
FAU - Sedar, A W
AU  - Sedar AW
FAU - Silver, M J
AU  - Silver MJ
FAU - Kocsis, J J
AU  - Kocsis JJ
FAU - Smith, J B
AU  - Smith JB
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Arachidonic Acids)
RN  - 0 (Fatty Acids)
RN  - 0 (Linolenic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/pharmacology
MH  - Ear/*ultrastructure
MH  - Endothelium/injuries/ultrastructure
MH  - Fatty Acids/*pharmacology
MH  - Linolenic Acids/pharmacology
MH  - Rabbits
MH  - Veins/ultrastructure
EDAT- 1978/08/01 00:00
MHDA- 1978/08/01 00:01
CRDT- 1978/08/01 00:00
PHST- 1978/08/01 00:00 [pubmed]
PHST- 1978/08/01 00:01 [medline]
PHST- 1978/08/01 00:00 [entrez]
AID - 0021-9150(78)90120-X [pii]
AID - 10.1016/0021-9150(78)90120-x [doi]
PST - ppublish
SO  - Atherosclerosis. 1978 Aug;30(4):273-84. doi: 10.1016/0021-9150(78)90120-x.

PMID- 12942390
OWN - NLM
STAT- MEDLINE
DCOM- 20030910
LR  - 20131121
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
VI  - 37 Suppl 2
DP  - 2003
TI  - Alternative treatment modalities in human immunodeficiency virus/acquired immune 
      deficiency syndrome.
PG  - S150-3
AB  - Historically, individuals infected with human immunodeficiency virus or those 
      with acquired immune deficiency syndrome have used alternative treatment 
      modalities for the management of their diseases. Using alternative medicine was 
      often their only option, especially when no effective pharmaceutical regimens 
      were available. Even with the advent of highly active antiretroviral therapy, the 
      use of alternative therapies continues, paralleling the huge increase of its use 
      in the general population.
FAU - Ernst, Jerome
AU  - Ernst J
AD  - AIDS Community Research Initiative of America, New York, New York 10010, USA. 
      jerrye@aol.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 7LP2MPO46S (S-Adenosylmethionine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Topical
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - *Complementary Therapies
MH  - Depressive Disorder, Major/drug therapy/etiology
MH  - HIV Infections/complications/*therapy
MH  - Humans
MH  - Peripheral Nervous System Diseases/etiology/therapy
MH  - S-Adenosylmethionine/therapeutic use
RF  - 10
EDAT- 2003/08/28 05:00
MHDA- 2003/09/11 05:00
CRDT- 2003/08/28 05:00
PHST- 2003/08/28 05:00 [pubmed]
PHST- 2003/09/11 05:00 [medline]
PHST- 2003/08/28 05:00 [entrez]
AID - CID30541 [pii]
AID - 10.1086/375881 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2003;37 Suppl 2:S150-3. doi: 10.1086/375881.

PMID- 1977396
OWN - NLM
STAT- MEDLINE
DCOM- 19901102
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 40
IP  - 7
DP  - 1990 Jul
TI  - High-pressure liquid chromatographic evaluation of cyclic 
      paracetamol-acetylsalicylate and its active metabolites with results of a 
      comparative pharmacokinetic investigation in the rat.
PG  - 813-7
AB  - Like benorilate, its correlated open ester, MR 897, a cyclic ester between 
      acetylsalicylic acid and paracetamol, gives rise to acetylsalicylic acid, 
      salicylic acid and paracetamol by enzymatic hydrolysis. An analytical method was 
      developed, which detects parent drugs and active metabolites, in order to compare 
      the pharmacokinetic and metabolic behaviour of the two products. The method was 
      specifically validated for quantitative analysis of salicylic acid and 
      paracetamol, which are the main systemic metabolites of both MR 897 and 
      benorilate. Extraction from plasma or tissue homogenate was carried out in two 
      steps with diethyl ether and acetate. Recovery of the analytical substances 
      ranged from 82.7% for paracetamol to 98.5% for salicylic acid. The results of a 
      comparative pharmacokinetic investigation of MR 897 and benorilate in the rat 
      confirm higher bioavailability and a more favourable plasma level profile with MR 
      897.
FAU - Marzo, A
AU  - Marzo A
AD  - B.T.B. Industria Chimica S.p.A., Laboratory of Drug Metabolism and 
      Pharmacokinetics, Tribiano, Italy.
FAU - Quadro, G
AU  - Quadro G
FAU - Treffner, E
AU  - Treffner E
FAU - Ripamonti, M
AU  - Ripamonti M
FAU - Meroni, G
AU  - Meroni G
FAU - Lucarelli, C
AU  - Lucarelli C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Acetanilides)
RN  - 0 (Salicylates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 87549-36-8 (MR 897)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis/pharmacokinetics
MH  - *Acetanilides
MH  - Animals
MH  - Aspirin/*analysis/pharmacokinetics
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Reference Standards
MH  - *Salicylates/*analogs & derivatives/analysis/pharmacokinetics
MH  - Spectrophotometry, Ultraviolet
MH  - Tissue Distribution
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1990 Jul;40(7):813-7.

PMID- 24972844
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20140726
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 134
IP  - 2
DP  - 2014 Aug
TI  - Low-molecular -weight heparin in pregnancies after ART -a retrospective study-.
PG  - 336-9
LID - S0049-3848(14)00329-6 [pii]
LID - 10.1016/j.thromres.2014.06.004 [doi]
AB  - INTRODUCTION: The utility of an antithrombotic prophylaxis in Assisted 
      Reproductive Technologies (ART) is highly debated. It has been hypothesised that 
      specific effects of heparin on the coagulation system during implantation can 
      improve the number of clinical pregnancies and live births. MATERIALS AND 
      METHODS: We studied a cohort of 327 women undergone at least 1 ART cycle before 
      thrombophilia testing. Overall, a number of 751cycles was analysed. 
      Low-Molecular-Weight Heparin (LMWH) and/or low-dose aspirin (ASA) were prescribed 
      in 132 (17.6%) cycles. Furthermore, all the women underwent thrombophilia 
      screening. RESULTS: The univariate analysis showed that LMWH with/without ASA was 
      significantly associated with both the outcomes clinical pregnancy and live 
      birth, while the use of ASA was not associated with live birth. The logistic 
      regression showed that the use of LMWH was significantly associated with both the 
      outcomes, clinical pregnancy (OR: 6.0, 95%CI: 2.8-15.6) and live birth (OR: 10.7, 
      95%CI: 3.2-36.1). The type of ART procedure significantly influenced the 
      likelihood of achieving clinical pregnancy. CONCLUSIONS: Present findings suggest 
      that LMWH alone or combined with ASA could have a role in fostering the 
      implantation of embryos and improving the number of live births after ART.
CI  - Copyright © 2014 Elsevier Ltd. All rights reserved.
FAU - Grandone, E
AU  - Grandone E
AD  - Atherosclerosis and Thrombosis Unit, I.R.C.C.S. "Casa Sollievo della Sofferenza", 
      S. Giovanni Rotondo, Foggia, Italy. Electronic address: 
      e.grandone@operapadrepio.it.
FAU - Villani, M
AU  - Villani M
AD  - Atherosclerosis and Thrombosis Unit, I.R.C.C.S. "Casa Sollievo della Sofferenza", 
      S. Giovanni Rotondo, Foggia, Italy.
FAU - Dentali, F
AU  - Dentali F
AD  - Department of Clinical Medicine, Insubria University, Varese, Italy.
FAU - Tiscia, G L
AU  - Tiscia GL
AD  - Atherosclerosis and Thrombosis Unit, I.R.C.C.S. "Casa Sollievo della Sofferenza", 
      S. Giovanni Rotondo, Foggia, Italy.
FAU - Colaizzo, D
AU  - Colaizzo D
AD  - Atherosclerosis and Thrombosis Unit, I.R.C.C.S. "Casa Sollievo della Sofferenza", 
      S. Giovanni Rotondo, Foggia, Italy.
FAU - Cappucci, F
AU  - Cappucci F
AD  - Atherosclerosis and Thrombosis Unit, I.R.C.C.S. "Casa Sollievo della Sofferenza", 
      S. Giovanni Rotondo, Foggia, Italy.
FAU - Fischetti, L
AU  - Fischetti L
AD  - Atherosclerosis and Thrombosis Unit, I.R.C.C.S. "Casa Sollievo della Sofferenza", 
      S. Giovanni Rotondo, Foggia, Italy.
FAU - Ageno, W
AU  - Ageno W
AD  - Department of Clinical Medicine, Insubria University, Varese, Italy.
FAU - Margaglione, M
AU  - Margaglione M
AD  - Medical Genetics, University of Foggia, Foggia, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140611
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Embryo Implantation
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Live Birth
MH  - Middle Aged
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - *Reproductive Techniques, Assisted
MH  - Retrospective Studies
MH  - Thrombophilia/diagnosis
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Assisted Reproductive Technologies
OT  - Low-molecular- weight heparins
EDAT- 2014/06/29 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/06/29 06:00
PHST- 2014/04/09 00:00 [received]
PHST- 2014/05/25 00:00 [revised]
PHST- 2014/06/03 00:00 [accepted]
PHST- 2014/06/29 06:00 [entrez]
PHST- 2014/06/29 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - S0049-3848(14)00329-6 [pii]
AID - 10.1016/j.thromres.2014.06.004 [doi]
PST - ppublish
SO  - Thromb Res. 2014 Aug;134(2):336-9. doi: 10.1016/j.thromres.2014.06.004. Epub 2014 
      Jun 11.

PMID- 25776469
OWN - NLM
STAT- MEDLINE
DCOM- 20160125
LR  - 20150429
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 135
IP  - 5
DP  - 2015 May
TI  - Aspirin resistance in children and young adults with splenectomized thalassemia 
      diseases.
PG  - 916-22
LID - S0049-3848(15)00109-7 [pii]
LID - 10.1016/j.thromres.2015.03.003 [doi]
AB  - Aspirin is now recommended for splenectomized thalassemia patients with high 
      platelet counts. However, aspirin resistance defined by arachinodic acid (ACA) 
      induced platelet aggregation ≥20%, has never been reported in this group of 
      patients. In this study, twenty-four splenectomized thalassemia patients 
      (15.7±4.1years), with platelet counts ≥800x10(9)/L, and 21 non-splenectomized 
      severe thalassemia patients (14.3±3.2years), were enrolled. After taking aspirin 
      (2mg/kg/day), seven patients (29.2%) displayed aspirin resistance. Serum 
      thromboxane B2 (TXB2) levels in the aspirin responsive group decreased 
      significantly [52.6(8.8-174.6) vs 4.0(1.6-7.3) mcg/mL, p<0.001], while no change 
      was demonstrated in the aspirin resistant group. Having increased aspirin to 
      4mg/kg/day, three of the seven aspirin resistant patients responded, while one 
      developed upper GI bleeding from esophageal varices and was withdrawn from the 
      study. For the three remaining patients, their doses were increased to the 
      maximum of 300mg/day, and two of the three responded. Thrombin antithrombin 
      complex and D-dimer levels were significantly decreased after taking aspirin 
      (2mg/kg/day), although D-dimer level was still significantly higher than that in 
      non-splenectomized group. Therefore, aspirin dosage can be adjusted individually 
      to reach maximum effect of platelet inhibition. In addition, aspirin can reduce 
      the levels of coagulation markers.
CI  - Copyright © 2015 Elsevier Ltd. All rights reserved.
FAU - Sirachainan, Nongnuch
AU  - Sirachainan N
AD  - Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand. Electronic address: nongnuch.sir@mahidol.ac.th.
FAU - Wijarn, Piyathida
AU  - Wijarn P
AD  - Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Chuansumrit, Ampaiwan
AU  - Chuansumrit A
AD  - Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Kadegasem, Praguywan
AU  - Kadegasem P
AD  - Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Wongwerawattanakoon, Pakawan
AU  - Wongwerawattanakoon P
AD  - Department of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Soisamrong, Anucha
AU  - Soisamrong A
AD  - Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150307
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (fibrin fragment D)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Child
MH  - Child, Preschool
MH  - Drug Resistance
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/analysis
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Count
MH  - Platelet Function Tests
MH  - *Splenectomy
MH  - Thalassemia/blood/*complications
MH  - Thromboembolism/blood/*etiology/*prevention & control
MH  - Thromboxane B2/blood
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Resistance
OT  - Splenectomy
OT  - Thalassemia
OT  - Thromboembolism
EDAT- 2015/03/18 06:00
MHDA- 2016/01/26 06:00
CRDT- 2015/03/18 06:00
PHST- 2014/10/24 00:00 [received]
PHST- 2015/01/15 00:00 [revised]
PHST- 2015/03/03 00:00 [accepted]
PHST- 2015/03/18 06:00 [entrez]
PHST- 2015/03/18 06:00 [pubmed]
PHST- 2016/01/26 06:00 [medline]
AID - S0049-3848(15)00109-7 [pii]
AID - 10.1016/j.thromres.2015.03.003 [doi]
PST - ppublish
SO  - Thromb Res. 2015 May;135(5):916-22. doi: 10.1016/j.thromres.2015.03.003. Epub 
      2015 Mar 7.

PMID- 28703305
OWN - NLM
STAT- MEDLINE
DCOM- 20180514
LR  - 20180514
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 69
IP  - 10
DP  - 2017 Oct
TI  - Use of multicriteria decision analysis for assessing the benefit and risk of 
      over-the-counter analgesics.
PG  - 1364-1373
LID - 10.1111/jphp.12770 [doi]
AB  - OBJECTIVES: To test the ability of a multicriteria decision analysis (MCDA) model 
      to incorporate disparate data sources of varying quality along with clinical 
      judgement in a benefit-risk assessment of six well-known pain-relief drugs. 
      METHODS: Six over-the-counter (OTC) analgesics were evaluated against three 
      favourable effects and eight unfavourable effects by seven experts who specialise 
      in the relief of pain, two in a 2-day facilitated workshop whose input data and 
      judgements were later peer-reviewed by five additional experts. KEY FINDINGS: 
      Ibuprofen salts and solubilised emerged with the best benefit-risk profile, 
      followed by naproxen, ibuprofen acid, diclofenac, paracetamol and aspirin. 
      CONCLUSIONS: Multicriteria decision analysis enabled participants to evaluate the 
      OTC analgesics against a range of favourable and unfavourable effects in a group 
      setting that enabled all issues to be openly aired and debated. The model was 
      easily communicated and understood by the peer reviewers, so the model should be 
      comprehensible to physicians, pharmacists and other health professionals.
CI  - © 2017 Royal Pharmaceutical Society.
FAU - Moore, Andrew
AU  - Moore A
AD  - Pain Research, Nuffield Division of Anaesthetics, University of Oxford, Oxford, 
      UK.
FAU - Crossley, Anne
AU  - Crossley A
AUID- ORCID: 0000-0002-5577-9029
AD  - Reckitt Benckiser Consumer Health, Slough, UK.
FAU - Ng, Bernard
AU  - Ng B
AD  - Reckitt Benckiser Consumer Health, Slough, UK.
FAU - Phillips, Lawrence
AU  - Phillips L
AD  - Department of Management, London School of Economics and Political Science, 
      London, UK.
FAU - Sancak, Özgür
AU  - Sancak Ö
AD  - Reckitt Benckiser Consumer Health, Slough, UK.
FAU - Rainsford, K D
AU  - Rainsford KD
AD  - Biomedical Research Centre, Sheffield Hallam University, Sheffield, UK.
LA  - eng
PT  - Journal Article
DEP - 20170713
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Analgesics)
RN  - 0 (Nonprescription Drugs)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - *Decision Support Techniques
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Ibuprofen/adverse effects/therapeutic use
MH  - Naproxen/adverse effects/therapeutic use
MH  - Nonprescription Drugs/adverse effects/*therapeutic use
MH  - Pain/drug therapy
MH  - Risk Assessment
OTO - NOTNLM
OT  - decision conferencing
OT  - group judgements
OT  - multicriteria decision analysis
OT  - over-the-counter analgesics
OT  - pain relief
EDAT- 2017/07/14 06:00
MHDA- 2018/05/15 06:00
CRDT- 2017/07/14 06:00
PHST- 2017/01/30 00:00 [received]
PHST- 2017/05/13 00:00 [accepted]
PHST- 2017/07/14 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
PHST- 2017/07/14 06:00 [entrez]
AID - 10.1111/jphp.12770 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2017 Oct;69(10):1364-1373. doi: 10.1111/jphp.12770. Epub 2017 
      Jul 13.

PMID- 7846945
OWN - NLM
STAT- MEDLINE
DCOM- 19950309
LR  - 20131121
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 83 Suppl 5
DP  - 1994
TI  - [Prevention of embolisms in atrial fibrillation: anticoagulation and antiplatelet 
      therapy].
PG  - 49-58
AB  - Over the past five years, the results of six prospective randomized trials have 
      set new standards in the primary and secondary prevention of thromboembolism in 
      "nonvalvular" ("nonrheumatic") atrial fibrillation. On the one hand, they have 
      confirmed the increased risk of stroke in these patients amounting to about 5% 
      per year and an annual recurrence rate after a recent transient ischaemic attack 
      or minor stroke of 12%. On the other hand, the results of these trials have 
      unanimously demonstrated a > or = 60% risk reduction with oral anticoagulation at 
      an acceptable risk of major bleeding complications. A reduced intensity of 
      anticoagulant therapy with a target INR of 2.0-3.0 is effective in most of these 
      patients. Both clinical and echocardiographic features allow the identification 
      of subgroups at low or high risk of thromboembolic complications and provide the 
      basis for the individual benefit-to-risk assessment of anticoagulant therapy. 
      Aspirin is currently recommended as a second choice therapy for patients who are 
      poor candidates for oral anticoagulants or who are considered to be at low risk 
      for thromboembolism.
FAU - Kienast, J
AU  - Kienast J
AD  - Med. Klinik und Poliklinik, Univ. Münster.
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Embolieprophylaxe bei Vorhofflimmern: Antikoagulation und antithrombozytäre 
      Therapie.
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Humans
MH  - Intracranial Embolism and Thrombosis/etiology/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
RF  - 82
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Kardiol. 1994;83 Suppl 5:49-58.

PMID- 556564
OWN - NLM
STAT- MEDLINE
DCOM- 19770902
LR  - 20191028
IS  - 0304-1328 (Print)
IS  - 0304-1328 (Linking)
VI  - 85
IP  - 3
DP  - 1977 Jun
TI  - Interactions of immune complexes and platelets in rabbits immunized with 
      hapten-carrier conjugates.
PG  - 207-14
AB  - The thrombopenic effects of immune complexes were studied in 32 rabbits, 
      immunized actively with aspirin. The test animals were exposed to hapten-protein 
      conjugates with a hapten density ranging from 0.6 to 38, and to pure hapten. The 
      resulting thrombopenia and leucopenia correlated closely with the presence of 
      immune complexes in the serum as detected by the platelet aggregation 
      sedimentation pattern test (P1.A.). This platelet-aggregation activity sedimented 
      mainly in the 19S fraction. The effects induced by polyvalent antigens where 
      dose-dependent and could be modified by a prior injection of aspirin. Expectedly, 
      monovalent antigens were only marginally effective.
FAU - Kekomäki, R
AU  - Kekomäki R
FAU - Kauppinen, H L
AU  - Kauppinen HL
FAU - Penttinen, K
AU  - Penttinen K
FAU - Myllylä, G
AU  - Myllylä G
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Acta Pathol Microbiol Scand C
JT  - Acta pathologica et microbiologica Scandinavica. Section C, Immunology
JID - 7508469
RN  - 0 (Antigen-Antibody Complex)
RN  - 0 (Antigens)
RN  - 0 (Haptens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antibody Formation
MH  - *Antigen-Antibody Complex
MH  - Antigens
MH  - Aspirin/immunology
MH  - Blood Platelets/*immunology
MH  - Dose-Response Relationship, Immunologic
MH  - Haptens
MH  - Leukopenia/etiology
MH  - Platelet Aggregation
MH  - Rabbits
MH  - Thrombocytopenia/etiology
EDAT- 1977/06/01 00:00
MHDA- 1977/06/01 00:01
CRDT- 1977/06/01 00:00
PHST- 1977/06/01 00:00 [pubmed]
PHST- 1977/06/01 00:01 [medline]
PHST- 1977/06/01 00:00 [entrez]
AID - 10.1111/j.1699-0463.1977.tb03632.x [doi]
PST - ppublish
SO  - Acta Pathol Microbiol Scand C. 1977 Jun;85(3):207-14. doi: 
      10.1111/j.1699-0463.1977.tb03632.x.

PMID- 7053442
OWN - NLM
STAT- MEDLINE
DCOM- 19820222
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 247
IP  - 1
DP  - 1982 Jan 1
TI  - Aspirin and analgesic nephropathy.
PG  - 55-7
AB  - To assess the effects of long-term aspirin ingestion on renal function, we 
      studied all of the patients at the Massachusetts General Hospital Arthritis 
      Clinic who had been taking aspirin continuously for ten or more years. Aspirin 
      ingestion was documented by multiple, random, unannounced blood salicylate 
      levels. Most of these 46 patients had seropositive rheumatoid arthritis. All 
      creatinine and BUN levels were normal. Maximum recorded specific gravities were 
      greater than 1.019 in 43 of 46 patients. These data suggest that long-term 
      salicylate ingestion does not cause renal damage.
FAU - Emkey, R D
AU  - Emkey RD
FAU - Mills, J A
AU  - Mills JA
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Salicylates)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Creatinine/blood
MH  - Female
MH  - History, 17th Century
MH  - Humans
MH  - Kidney/*drug effects
MH  - Kidney Diseases/*chemically induced
MH  - Male
MH  - Nephritis, Interstitial/chemically induced
MH  - Proteinuria/chemically induced
MH  - Random Allocation
MH  - Salicylates/blood
MH  - Time Factors
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1982 Jan 1;247(1):55-7.

PMID- 8560051
OWN - NLM
STAT- MEDLINE
DCOM- 19960227
LR  - 20161123
IS  - 0034-9356 (Print)
IS  - 0034-9356 (Linking)
VI  - 42
IP  - 8
DP  - 1995 Oct
TI  - [Postoperative analgesia in herniated disk surgery. Comparative study of 
      diclofenac , lysine acetylsalicylate, and ketorolac].
PG  - 316-9
AB  - INTRODUCTION: Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in 
      treating musculoskeletal pain and are theoretically ideal for treating 
      postoperative pain of the lumbar column. OBJECTIVES: To compare the analgesic 
      efficacy and side effects of treatment with 3 NSAIDs (lysine acetylsalicylate, 
      ketorolac and diclofenac) in the treatment of pain after surgery for lumbar disc 
      hernia. PATIENTS AND METHODS: We enrolled 75 ASA I-II patients undergoing 
      discectomy because of lumbar disc hernia; balanced general anesthesia was used in 
      all cases. The patients were randomly distributed in 3 groups based on type of 
      analgesia given in the immediate postoperative period. Group A received lysine 
      acetylsalicylate (1800 mg), group B received ketorolac (30 mg) and group C 
      received diclofenac (75 mg). The analgesics were diluted in 100 mg of saline 
      solution and administered through a peripheral vein over 10 min. We evaluated the 
      analgesia attained on a visual analog scale (VAS) and the physiological response 
      to pain was assessed by monitoring changes in arterial pressure, heart rate and 
      breathing frequency. If analgesia was insufficient 30 min after administration of 
      the drug, 200 mg of lysine cloximate was given as a top-up. The side effects of 
      each drug were also recorded. RESULTS: VAS evaluation showed significant 
      reductions in pain 60 min after administration in groups A and B and after 120 
      min in group C. Nine patients in each group required lysine cloximate. There were 
      no significant differences in physiological response among the 3 groups. No 
      patient suffered major side effects. Mild side effects were reported most often 
      in group B. CONCLUSIONS: The NSAIDs studied were inadequately for treating pain 
      after surgery for lumbar disc hernia. Ketorolac was no better than the other 
      analgesics studied but was associated with a higher number of mild side effects.
FAU - Izquierdo, E
AU  - Izquierdo E
AD  - Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Clínic 
      i Provincial, Barcelona.
FAU - Fábregas, N
AU  - Fábregas N
FAU - Valero, R
AU  - Valero R
FAU - Salvador, L
AU  - Salvador L
FAU - Soley, R
AU  - Soley R
FAU - Nalda, M A
AU  - Nalda MA
LA  - spa
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Analgesia postoperatoria en la cirugía de hernia discal. Estudio comparativo de 
      diclofenaco, acetilsalicilato de lisina y ketorolaco.
PL  - Spain
TA  - Rev Esp Anestesiol Reanim
JT  - Revista espanola de anestesiologia y reanimacion
JID - 0134516
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 144O8QL0L1 (Diclofenac)
RN  - D8K2JPN18B (Tolmetin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - YZI5105V0L (Ketorolac)
SB  - IM
MH  - Adult
MH  - Analgesics/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Diclofenac/*therapeutic use
MH  - *Diskectomy
MH  - Female
MH  - Humans
MH  - Intervertebral Disc Displacement/surgery
MH  - Ketorolac
MH  - Lumbar Vertebrae/surgery
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Tolmetin/*analogs & derivatives/therapeutic use
MH  - Treatment Failure
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
PST - ppublish
SO  - Rev Esp Anestesiol Reanim. 1995 Oct;42(8):316-9.

PMID- 8447967
OWN - NLM
STAT- MEDLINE
DCOM- 19930415
LR  - 20190914
IS  - 0741-8329 (Print)
IS  - 0741-8329 (Linking)
VI  - 10
IP  - 1
DP  - 1993 Jan-Feb
TI  - The behavioral teratogenicity of alcohol is not affected by pretreatment with 
      aspirin.
PG  - 51-7
AB  - Prenatal alcohol exposure is associated with a variety of developmental 
      abnormalities, including neuroanatomical, physical, and behavioral features. 
      Several mechanisms for alcohol's teratogenic effects have been proposed. This 
      study addresses the role of prostaglandins in the abnormal development that often 
      occurs after maternal alcohol consumption. On gestation days 8 to 18, pregnant 
      Sprague-Dawley rats were prenatally treated with 6 g/kg alcohol following 
      pretreatment with 150 mg/kg aspirin. Behavioral testing of offspring included 
      measures of open-field activity, exploratory behavior, passive avoidance, active 
      avoidance, and acoustic startle response. In most cases, pretreatment with 
      aspirin did not affect performance in alcohol-exposed or control rats.
FAU - Mattson, S N
AU  - Mattson SN
AD  - SDSU/UCSD Joint Doctoral Program in Clinical Psychology, Department of 
      Psychology, San Diego, CA 92120.
FAU - Carlos, R
AU  - Carlos R
FAU - Riley, E P
AU  - Riley EP
LA  - eng
GR  - AA03249/AA/NIAAA NIH HHS/United States
GR  - AA06902/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Alcohol
JT  - Alcohol (Fayetteville, N.Y.)
JID - 8502311
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Avoidance Learning/drug effects
MH  - Behavior, Animal/*drug effects
MH  - Ethanol/*toxicity
MH  - Exploratory Behavior/drug effects
MH  - Female
MH  - Fetus/*drug effects
MH  - Motor Activity/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reflex, Startle
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 0741-8329(93)90053-Q [pii]
AID - 10.1016/0741-8329(93)90053-q [doi]
PST - ppublish
SO  - Alcohol. 1993 Jan-Feb;10(1):51-7. doi: 10.1016/0741-8329(93)90053-q.

PMID- 31237644
OWN - NLM
STAT- MEDLINE
DCOM- 20190710
LR  - 20200225
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 321
IP  - 24
DP  - 2019 Jun 25
TI  - Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month 
      Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients 
      Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
PG  - 2414-2427
LID - 10.1001/jama.2019.8145 [doi]
AB  - IMPORTANCE: Very short mandatory dual antiplatelet therapy (DAPT) after 
      percutaneous coronary intervention (PCI) with a drug-eluting stent may be an 
      attractive option. OBJECTIVE: To test the hypothesis of noninferiority of 1 month 
      of DAPT compared with standard 12 months of DAPT for a composite end point of 
      cardiovascular and bleeding events. DESIGN, SETTING, AND PARTICIPANTS: 
      Multicenter, open-label, randomized clinical trial enrolling 3045 patients who 
      underwent PCI at 90 hospitals in Japan from December 2015 through December 2017. 
      Final 1-year clinical follow-up was completed in January 2019. INTERVENTIONS: 
      Patients were randomized either to 1 month of DAPT followed by clopidogrel 
      monotherapy (n=1523) or to 12 months of DAPT with aspirin and clopidogrel 
      (n=1522). MAIN OUTCOMES AND MEASURES: The primary end point was a composite of 
      cardiovascular death, myocardial infarction (MI), ischemic or hemorrhagic stroke, 
      definite stent thrombosis, or major or minor bleeding at 12 months, with a 
      relative noninferiority margin of 50%. The major secondary cardiovascular end 
      point was a composite of cardiovascular death, MI, ischemic or hemorrhagic 
      stroke, or definite stent thrombosis and the major secondary bleeding end point 
      was major or minor bleeding. RESULTS: Among 3045 patients randomized, 36 withdrew 
      consent; of 3009 remaining, 2974 (99%) completed the trial. One-month DAPT was 
      both noninferior and superior to 12-month DAPT for the primary end point, 
      occurring in 2.36% with 1-month DAPT and 3.70% with 12-month DAPT (absolute 
      difference, -1.34% [95% CI, -2.57% to -0.11%]; hazard ratio [HR], 0.64 [95% CI, 
      0.42-0.98]), meeting criteria for noninferiority (P < .001) and for superiority 
      (P = .04). The major secondary cardiovascular end point occurred in 1.96% with 
      1-month DAPT and 2.51% with 12-month DAPT (absolute difference, -0.55% [95% CI, 
      -1.62% to 0.52%]; HR, 0.79 [95% CI, 0.49-1.29]), meeting criteria for 
      noninferiority (P = .005) but not for superiority (P = .34). The major secondary 
      bleeding end point occurred in 0.41% with 1-month DAPT and 1.54% with 12-month 
      DAPT (absolute difference, -1.13% [95% CI, -1.84% to -0.42%]; HR, 0.26 [95% CI, 
      0.11-0.64]; P = .004 for superiority). CONCLUSIONS AND RELEVANCE: Among patients 
      undergoing PCI, 1 month of DAPT followed by clopidogrel monotherapy, compared 
      with 12 months of DAPT with aspirin and clopidogrel, resulted in a significantly 
      lower rate of a composite of cardiovascular and bleeding events, meeting criteria 
      for both noninferiority and superiority. These findings suggest that a shorter 
      duration of DAPT may provide benefit, although given study limitations, 
      additional research is needed in other populations. TRIAL REGISTRATION: 
      ClinicalTrials.gov Identifier: NCT02619760.
FAU - Watanabe, Hirotoshi
AU  - Watanabe H
AD  - Department of Cardiovascular Medicine, Kyoto University Graduate School of 
      Medicine, Kyoto, Japan.
FAU - Domei, Takenori
AU  - Domei T
AD  - Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan.
FAU - Morimoto, Takeshi
AU  - Morimoto T
AD  - Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, 
      Japan.
FAU - Natsuaki, Masahiro
AU  - Natsuaki M
AD  - Department of Cardiovascular Medicine, Saga University, Saga, Japan.
FAU - Shiomi, Hiroki
AU  - Shiomi H
AD  - Department of Cardiovascular Medicine, Kyoto University Graduate School of 
      Medicine, Kyoto, Japan.
FAU - Toyota, Toshiaki
AU  - Toyota T
AD  - Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, 
      Kobe, Japan.
FAU - Ohya, Masanobu
AU  - Ohya M
AD  - Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
FAU - Suwa, Satoru
AU  - Suwa S
AD  - Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni, 
      Japan.
FAU - Takagi, Kensuke
AU  - Takagi K
AD  - Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.
FAU - Nanasato, Mamoru
AU  - Nanasato M
AD  - Department of Cardiology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, 
      Japan.
FAU - Hata, Yoshiki
AU  - Hata Y
AD  - Department of Cardiology, Minamino Cardiovascular Hospital, Hachioji, Japan.
FAU - Yagi, Masahiro
AU  - Yagi M
AD  - Department of Cardiology, Sendai Cardiovascular Center, Sendai, Japan.
FAU - Suematsu, Nobuhiro
AU  - Suematsu N
AD  - Department of Cardiology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
FAU - Yokomatsu, Takafumi
AU  - Yokomatsu T
AD  - Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.
FAU - Takamisawa, Itaru
AU  - Takamisawa I
AD  - Department of Cardiology, Sakakibara Heart Institute, Fuchu, Japan.
FAU - Doi, Masayuki
AU  - Doi M
AD  - Department of Cardiology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
FAU - Noda, Toshiyuki
AU  - Noda T
AD  - Department of Cardiology, Gifu Prefectural General Medical Center, Gifu, Japan.
FAU - Okayama, Hideki
AU  - Okayama H
AD  - Department of Cardiology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
FAU - Seino, Yoshitane
AU  - Seino Y
AD  - Department of Cardiology, Hoshi General Hospital, Koriyama, Japan.
FAU - Tada, Tomohisa
AU  - Tada T
AD  - Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan.
FAU - Sakamoto, Hiroki
AU  - Sakamoto H
AD  - Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan.
FAU - Hibi, Kiyoshi
AU  - Hibi K
AD  - Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.
FAU - Abe, Mitsuru
AU  - Abe M
AD  - Department of Cardiology, National Hospital Organization Kyoto Medical Center, 
      Kyoto, Japan.
FAU - Kawai, Kazuya
AU  - Kawai K
AD  - Department of Cardiology, Chikamori Hospital, Kochi, Japan.
FAU - Nakao, Koichi
AU  - Nakao K
AD  - Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, 
      Kumamoto, Japan.
FAU - Ando, Kenji
AU  - Ando K
AD  - Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan.
FAU - Tanabe, Kengo
AU  - Tanabe K
AD  - Department of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
FAU - Ikari, Yuji
AU  - Ikari Y
AD  - Department of Cardiology, Tokai University Hospital, Isehara, Japan.
FAU - Hanaoka, Keiichi Igarashi
AU  - Hanaoka KI
AD  - Hanaoka Seishu Memorial Cardiovascular Clinic, Sapporo, Japan.
FAU - Morino, Yoshihiro
AU  - Morino Y
AD  - Department of Cardiology, Iwate Medical University Hospital, Morioka, Japan.
FAU - Kozuma, Ken
AU  - Kozuma K
AD  - Department of Cardiology, Teikyo University Hospital, Tokyo, Japan.
FAU - Kadota, Kazushige
AU  - Kadota K
AD  - Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
FAU - Furukawa, Yutaka
AU  - Furukawa Y
AD  - Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, 
      Kobe, Japan.
FAU - Nakagawa, Yoshihisa
AU  - Nakagawa Y
AD  - Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, 
      Japan.
FAU - Kimura, Takeshi
AU  - Kimura T
AD  - Department of Cardiovascular Medicine, Kyoto University Graduate School of 
      Medicine, Kyoto, Japan.
CN  - STOPDAPT-2 Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT02619760
PT  - Comparative Study
PT  - Equivalence Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2019 Jun 25;321(24):2409-2411. PMID: 31237621
CIN - J Urol. 2019 Nov;202(5):859-860. PMID: 31403922
CIN - JAMA. 2019 Nov 5;322(17):1715. PMID: 31688878
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prasugrel Hydrochloride/adverse effects/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
PMC - PMC6593641
COIS- Conflict of Interest Disclosures: Dr Watanabe reported receipt of personal fees 
      from Abbott Vascular Japan and Daiichi Sankyo. Dr Yagi reported receipt of 
      personal fees from Otsuka Pharmaceutical, Daiichi Sankyo, and Kowa 
      Pharmaceuticals. Dr Hibi reported receipt of personal fees from Abbott Vascular. 
      Dr Nakao reported receipt of personal fees from Sanofi, Bayer, Daiichi-Sankyo, 
      and Boehringer Ingelheim. Dr Tanabe reported receipt of personal fees from Abbott 
      Vascular, AstraZeneca, Sanofi, Daiichi Sankyo, Terumo, Boston Scientific, Japan 
      Lifeline, Bayer, and Medtronic and advisory board membership for Abbott Vascular 
      and Terumo Japan. Dr Morino reported receipt of personal fees from Abbott 
      Vascular and advisory board membership for Abbott Vascular and Terumo Japan. Dr 
      Kozuma reported receipt of grants and personal fees from Abbott Vascular and 
      advisory board membership for Abbott Vascular and Terumo Japan. Dr Furukawa 
      reported receipt of personal fees from Daiichi Sankyo, Bayer, and Sanofi. Dr 
      Nakagawa reported advisory board membership for Abbott Vascular. Dr Kimura 
      reported receipt of personal fees from Abbott Vascular and grants from Abbott 
      Vascular and Boston Scientific and advisory board membership for Abbott Vascular 
      and Terumo Japan. No other disclosures were reported.
EDAT- 2019/06/27 06:00
MHDA- 2019/07/11 06:00
CRDT- 2019/06/26 06:00
PHST- 2019/06/26 06:00 [entrez]
PHST- 2019/06/27 06:00 [pubmed]
PHST- 2019/07/11 06:00 [medline]
AID - 2736563 [pii]
AID - joi190060 [pii]
AID - 10.1001/jama.2019.8145 [doi]
PST - ppublish
SO  - JAMA. 2019 Jun 25;321(24):2414-2427. doi: 10.1001/jama.2019.8145.

PMID- 25657084
OWN - NLM
STAT- MEDLINE
DCOM- 20160601
LR  - 20181113
IS  - 1745-7262 (Electronic)
IS  - 1008-682X (Print)
IS  - 1008-682X (Linking)
VI  - 17
IP  - 5
DP  - 2015 Sep-Oct
TI  - Heart healthy equals prostate healthy and statins, aspirin, and/or metformin 
      (S.A.M.) are the ideal recommendations for prostate cancer prevention.
PG  - 783-91
LID - 10.4103/1008-682X.148070 [doi]
AB  - Cardiovascular disease (CVD) has been the number one cause of death in the U.S. 
      for 114 of the last 115 years. Lifestyle factors that promote CVD also appear to 
      increase prostate cancer risk and those that reduce CVD risk also appear to 
      reduce the risk of prostate cancer. The largest randomized trials utilizing 
      dietary supplements or pharmacologic agents for prostate cancer prevention 
      (Selenium and Vitamin E Cancer Prevention Trial [SELECT]) have also shed light on 
      the problems and future solutions in this area. Dietary supplements that have not 
      been found to be CVD protective, such as selenium and Vitamin E have not been 
      found to be prostate protective. In addition, over exposure to specific 
      anti-oxidants in nutritionally replete populations may be encouraging cancer 
      growth. Future trials of dietary supplements to prevent prostate cancer could be 
      problematic because by the time a definitive trial is initiated the participants 
      will no longer be "deficient" in the nutrient being tested, which arguably 
      occurred in the SELECT trial. It is also interesting that statins, aspirin, 
      and/or metformin (S.A.M.) are 3 generic, low-cost, heart healthy agents derived 
      from natural sources with separate mechanism of actions, which all appear to have 
      the best benefit to risk ratio compared to any other agent available for prostate 
      cancer prevention, especially aggressive disease, or as an ancillary agent (s) to 
      conventional cancer treatment. It is time to focus on the forest over the trees 
      and recommend proven CVD protective measures for men concerned about their risk 
      of prostate cancer.
FAU - Moyad, Mark A
AU  - Moyad MA
AD  - Department of Urology, University of Michigan Medical Center, Ann Arbor, 
      Michigan, USA.
FAU - Vogelzang, Nicholas J
AU  - Vogelzang NJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Asian J Androl
JT  - Asian journal of andrology
JID - 100942132
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prostatic Neoplasms/*prevention & control
MH  - United States
PMC - PMC4577591
EDAT- 2015/02/07 06:00
MHDA- 2016/06/02 06:00
CRDT- 2015/02/07 06:00
PHST- 2015/02/07 06:00 [entrez]
PHST- 2015/02/07 06:00 [pubmed]
PHST- 2016/06/02 06:00 [medline]
AID - 148070 [pii]
AID - AJA-17-783 [pii]
AID - 10.4103/1008-682X.148070 [doi]
PST - ppublish
SO  - Asian J Androl. 2015 Sep-Oct;17(5):783-91. doi: 10.4103/1008-682X.148070.

PMID- 14722396
OWN - NLM
STAT- MEDLINE
DCOM- 20040219
LR  - 20190717
IS  - 0002-9629 (Print)
IS  - 0002-9629 (Linking)
VI  - 327
IP  - 1
DP  - 2004 Jan
TI  - Sudden painless unilateral vision loss caused by branch retinal artery occlusion: 
      implications for the primary care physician.
PG  - 44-6
AB  - We report a case of sudden onset visual loss caused by branch retinal artery 
      occlusion. Systematic search for the cause of branch retinal artery occlusion 
      revealed Factor V Leiden mutation and antiphospholipid antibody syndrome as the 
      cause. Implications for diagnosis and management are discussed.
FAU - Kondamudi, Vasantha
AU  - Kondamudi V
AD  - Department of Family Practice, The Brooklyn Hospital Center, NY 11201, USA. 
      nkondamudi@pol.net
FAU - Reddy, Rekha
AU  - Reddy R
FAU - Kondamudi, Noah
AU  - Kondamudi N
FAU - Harvey, Raymond
AU  - Harvey R
FAU - Delarosa, Maritza
AU  - Delarosa M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (factor V Leiden)
RN  - 9001-24-5 (Factor V)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blindness/drug therapy/*etiology
MH  - Eye/*blood supply/drug effects
MH  - Factor V/genetics
MH  - Heparin/administration & dosage/therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - *Physicians, Family
MH  - Practice Guidelines as Topic
MH  - Referral and Consultation
MH  - Retinal Artery Occlusion/*complications/drug therapy/genetics
MH  - Treatment Outcome
EDAT- 2004/01/15 05:00
MHDA- 2004/02/20 05:00
CRDT- 2004/01/15 05:00
PHST- 2004/01/15 05:00 [pubmed]
PHST- 2004/02/20 05:00 [medline]
PHST- 2004/01/15 05:00 [entrez]
AID - S0002-9629(15)34149-5 [pii]
AID - 10.1097/00000441-200401000-00009 [doi]
PST - ppublish
SO  - Am J Med Sci. 2004 Jan;327(1):44-6. doi: 10.1097/00000441-200401000-00009.

PMID- 8952863
OWN - NLM
STAT- MEDLINE
DCOM- 19970109
LR  - 20131121
IS  - 0753-3322 (Print)
IS  - 0753-3322 (Linking)
VI  - 50
IP  - 6-7
DP  - 1996
TI  - Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction.
PG  - 243-53
AB  - For the treatment of acute myocardial infarction, heparin has been a topic of 
      continuing debate for the past four decades. After review of the available data, 
      the American College of Cardiology/American Heart Association Guidelines for the 
      Early Management of Patients with Acute Myocardial Infarction, published in 1990, 
      recommended intravenous heparin administration together or immediately after 
      thrombolytic therapy to maintain the activated partial thromboplastin time 
      approximately 1.5 to 2.0 times the control value for 24 to 72 hours. Over the 
      past five years, with the proven benefits or thrombolytic therapy and 
      antiplatelet therapy, investigators have been in search of the ideal thrombolytic 
      agent as well as the best adjunctive antithrombotic strategy. We review a number 
      of angiographic patency trials as well as the major thrombolytic mortality 
      reduction trials in which adjunctive heparin therapy was directly assessed. These 
      trials established the need for intravenous heparin administration with tissue 
      plasminogen activator, but, on the other hand, do not substantiate the need for 
      either subcutaneous or intravenous heparin use with streptokinase. New data from 
      a large scale trial emphasizes the importance of maintaining the aPTT in the 
      55-70 second range to prevent bleeding complications and optimize clinical 
      outcomes.
FAU - Metz, B K
AU  - Metz BK
AD  - Department of Cardiology, Joseph J Jacobs Center for Thrombosis and Vascular 
      Biology, Cleveland Clinic Foundation, OH 44195, USA.
FAU - Topol, E J
AU  - Topol EJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Review
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Thrombolytic Therapy
RF  - 33
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 0753-3322(96)84821-9 [pii]
AID - 10.1016/0753-3322(96)84821-9 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 1996;50(6-7):243-53. doi: 10.1016/0753-3322(96)84821-9.

PMID- 22867637
OWN - NLM
STAT- MEDLINE
DCOM- 20130129
LR  - 20161125
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 143
IP  - 2
DP  - 2012 Sep 28
TI  - Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with 
      warfarin and aspirin.
PG  - 648-55
LID - 10.1016/j.jep.2012.07.029 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Danshen-Gegen (DG) product has clinically been 
      proven to be an effective agent for heart-tonic efficacy by our previous 
      research. In the mean time, herb-drug interactions between DG product and its 
      commonly co-administered drugs, such as aspirin or warfarin need to be explored 
      to ensure its safe clinical usage. AIM OF THE STUDY: Current study aims to 
      investigate whether DG extract interacts with warfarin or aspirin when 
      administered concomitantly to ensure the safety and efficacy of their usage. 
      MATERIAL AND METHODS: Five groups of SD rats (n=6/group) received DG alone (0.15 
      g/kg, human relevant dose), warfarin alone (0.2 mg/kg), warfarin (0.2 mg/kg) in 
      combination with DG (0.15 g/kg), aspirin alone (10.3 mg/kg), or aspirin (10.3 
      mg/kg) in combination with DG (0.15 g/kg), respectively. DG product was given 
      twice daily for 5 day. Warfain or aspirin were given once daily for 5 day. DG 
      morning doses were given 2 h post that of warfarin/aspirin. Following first 
      dosing on day 5, plasma samples were collected at different time points. For the 
      pharmacodynamic measurement, whole blood was collected at 30 min after DG dosing 
      or at 2.5 h after warfarin/aspirin dosing, and the prothrombin time assay was 
      conducted. RESULTS: Co-administration of DG with warfarin could significantly 
      decrease the C(max), AUC and the prothrombin time of warfarin (p<0.05). In the 
      mean time, the C(max) and AUC of danshensu, the active bioavailable component of 
      DG were significantly increased (p<0.01) in presence of warfarin. 
      Co-administration of DG with aspirin could significantly increase the C(max) and 
      AUC of both aspirin (p<0.01) and its metabolite salicylic acid (p<0.01) and 
      significantly decrease the prothrombin time of aspirin (p<0.05). However, the 
      pharmacokinetics parameters of danshensu were not significantly affected by 
      aspirin. CONCLUSION: Our animal study indicated that co-administration of DG with 
      warfarin/aspirin can cause significant pharmacokinetic and pharmacodynamic 
      herb-drug interactions in rat.
CI  - Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
FAU - Zhou, Limin
AU  - Zhou L
AD  - School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 
      Shatin, New Territories, Hong Kong Special Administrative Region.
FAU - Wang, Shu
AU  - Wang S
FAU - Zhang, Zhen
AU  - Zhang Z
FAU - Lau, Bik San
AU  - Lau BS
FAU - Fung, Kwok Pui
AU  - Fung KP
FAU - Leung, Ping Chung
AU  - Leung PC
FAU - Zuo, Zhong
AU  - Zuo Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120731
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Anticoagulants)
RN  - 0 (Danshen-Gegen)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Lactates)
RN  - 4GF33A5PAJ (3,4-dihydroxyphenyllactic acid)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/*administration & dosage/blood/pharmacokinetics
MH  - Area Under Curve
MH  - Aspirin/*administration & dosage/blood/pharmacokinetics
MH  - Drugs, Chinese Herbal/*administration & dosage/pharmacokinetics
MH  - *Herb-Drug Interactions
MH  - Lactates/blood
MH  - Male
MH  - Prothrombin Time
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Salicylic Acid/blood
MH  - Warfarin/*administration & dosage/blood/pharmacokinetics
EDAT- 2012/08/08 06:00
MHDA- 2013/01/30 06:00
CRDT- 2012/08/08 06:00
PHST- 2012/04/25 00:00 [received]
PHST- 2012/07/16 00:00 [revised]
PHST- 2012/07/23 00:00 [accepted]
PHST- 2012/08/08 06:00 [entrez]
PHST- 2012/08/08 06:00 [pubmed]
PHST- 2013/01/30 06:00 [medline]
AID - S0378-8741(12)00498-9 [pii]
AID - 10.1016/j.jep.2012.07.029 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2012 Sep 28;143(2):648-55. doi: 10.1016/j.jep.2012.07.029. Epub 
      2012 Jul 31.

PMID- 25122202
OWN - NLM
STAT- MEDLINE
DCOM- 20141031
LR  - 20211021
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 83
IP  - 11
DP  - 2014 Sep 9
TI  - Aspirin for secondary prevention after stroke of unknown etiology in 
      resource-limited settings.
PG  - 1004-11
LID - 10.1212/WNL.0000000000000779 [doi]
AB  - OBJECTIVE: To analyze the potential impact of aspirin therapy for long-term 
      secondary prevention after stroke of undetermined etiology in resource-limited 
      settings without access to neuroimaging to distinguish ischemic stroke from 
      intracerebral hemorrhage (ICH). METHODS: We conducted a decision analysis using a 
      Markov state transition model. Sensitivity analyses were performed across the 
      worldwide reported range of the proportion of strokes due to ICH and the 95% 
      confidence intervals (CIs) of aspirin-associated relative risks in patients with 
      ICH. RESULTS: For patients with stroke of undetermined etiology, long-term 
      aspirin was the preferred treatment strategy across the worldwide reported range 
      of the proportion of strokes due to ICH. At 34% of strokes due to ICH (the 
      highest proportion reported in a large epidemiologic study), the benefit of 
      aspirin remained beyond the upper bounds of the 95% CIs of aspirin-associated 
      post-ICH relative risks most concerning to clinicians (ICH recurrence risk and 
      mortality risk if ICH recurs on aspirin). Based on the estimated 11,590,204 
      strokes in low- and middle-income countries in 2010, our model predicts that 
      aspirin therapy for secondary stroke prevention in all patients with stroke in 
      these countries could lead to an estimated yearly decrease of 84,492 recurrent 
      strokes and 4,056 stroke-related mortalities. CONCLUSIONS: The concern that the 
      risks of aspirin in patients with stroke of unknown etiology could outweigh the 
      benefits is not supported by our model, which predicts that aspirin for secondary 
      prevention in patients with stroke of undetermined etiology in resource-limited 
      settings could lead to decreased stroke-related mortality and stroke recurrence.
CI  - © 2014 American Academy of Neurology.
FAU - Berkowitz, Aaron L
AU  - Berkowitz AL
AD  - From the Department of Neurology (A.L.B., S.H.C.), Brigham and Women's Hospital, 
      Harvard Medical School; and Department of Neurology (M.B.W., M.T.B.), 
      Massachusetts General Hospital, Harvard Medical School, Boston. 
      aberkowitz3@partners.org.
FAU - Westover, M Brandon
AU  - Westover MB
AD  - From the Department of Neurology (A.L.B., S.H.C.), Brigham and Women's Hospital, 
      Harvard Medical School; and Department of Neurology (M.B.W., M.T.B.), 
      Massachusetts General Hospital, Harvard Medical School, Boston.
FAU - Bianchi, Matt T
AU  - Bianchi MT
AD  - From the Department of Neurology (A.L.B., S.H.C.), Brigham and Women's Hospital, 
      Harvard Medical School; and Department of Neurology (M.B.W., M.T.B.), 
      Massachusetts General Hospital, Harvard Medical School, Boston.
FAU - Chou, Sherry H-Y
AU  - Chou SH
AD  - From the Department of Neurology (A.L.B., S.H.C.), Brigham and Women's Hospital, 
      Harvard Medical School; and Department of Neurology (M.B.W., M.T.B.), 
      Massachusetts General Hospital, Harvard Medical School, Boston.
LA  - eng
GR  - K23 NS073806/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20140813
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/economics/*therapeutic use
MH  - Brain Ischemia/economics/mortality/prevention & control
MH  - Cerebral Hemorrhage/economics/mortality/prevention & control
MH  - Cost-Benefit Analysis
MH  - Decision Trees
MH  - Humans
MH  - Internationality
MH  - Markov Chains
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/economics/*therapeutic use
MH  - Poverty Areas
MH  - Risk Factors
MH  - Secondary Prevention/*economics
MH  - Sensitivity and Specificity
MH  - Stroke/*economics/mortality/*prevention & control
MH  - Time Factors
MH  - Young Adult
PMC - PMC4162302
EDAT- 2014/08/15 06:00
MHDA- 2014/11/02 06:00
CRDT- 2014/08/15 06:00
PHST- 2014/08/15 06:00 [entrez]
PHST- 2014/08/15 06:00 [pubmed]
PHST- 2014/11/02 06:00 [medline]
AID - WNL.0000000000000779 [pii]
AID - NEUROLOGY2014583682 [pii]
AID - 10.1212/WNL.0000000000000779 [doi]
PST - ppublish
SO  - Neurology. 2014 Sep 9;83(11):1004-11. doi: 10.1212/WNL.0000000000000779. Epub 
      2014 Aug 13.

PMID- 11025787
OWN - NLM
STAT- MEDLINE
DCOM- 20001019
LR  - 20190813
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 160
IP  - 18
DP  - 2000 Oct 9
TI  - Cost-effectiveness of new antiplatelet regimens used as secondary prevention of 
      stroke or transient ischemic attack.
PG  - 2773-8
AB  - BACKGROUND: Compared with aspirin alone, use of the new antiplatelet regimens, 
      including aspirin combined with dipyridamole and clopidogrel bisulfate, has been 
      found to further reduce the risk of stroke and other vascular events in patients 
      who have experienced stroke or transient ischemic attack. However, their 
      cost-effectiveness ratios relative to aspirin alone have not been estimated. 
      METHODS: We developed a Markov model to measure the clinical benefits and the 
      economic consequences of the following strategies to treat high-risk patients 
      aged 65 years or older: (1) aspirin, 325 mg/d; (2) aspirin, 50 mg/d, and 
      dipyridamole, 400 mg/d; and (3) clopidogrel bisulfate, 75 mg/d. Input data were 
      obtained by literature review. Outcomes were expressed as US dollars per 
      quality-adjusted life-year (QALY). RESULTS: The use of aspirin combined with 
      dipyridamole was more effective and less costly compared with the use of aspirin 
      alone, providing a gain of 0.3 QALY for a 65-year-old patient. This regimen 
      remained cost-effective despite wide sensitivity analyses. Clopidogrel was more 
      effective and more costly compared with aspirin alone, yielding a gain of 0.2 
      QALY with a marginal cost-effectiveness ratio of $26,580 per each additional QALY 
      (patient aged 65 years). Sensitivity analyses demonstrated that the efficacy of 
      clopidogrel and its cost were key factors in determining its cost-effectiveness 
      ratio compared with aspirin, which exceeded $50,000 when its efficacy decreased 
      by half or its cost doubled. CONCLUSION: To prevent stroke in high-risk patients, 
      dipyridamole combined with aspirin was more effective and less costly than 
      aspirin alone, and clopidogrel was cost-effective compared with current standards 
      of medical practice, except in extreme scenarios.
FAU - Sarasin, F P
AU  - Sarasin FP
AD  - Department of Internal Medicine, Hôpital Cantonal, 24 rue Micheli du Crest, 1211 
      Geneva 14, Switzerland. francois.sarasin@hcuge.ch
FAU - Gaspoz, J M
AU  - Gaspoz JM
FAU - Bounameaux, H
AU  - Bounameaux H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Intern Med. 2001 May 14;161(9):1236. PMID: 11343452
CIN - Arch Intern Med. 2001 May 14;161(9):1236. PMID: 11343453
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/economics
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Decision Trees
MH  - Dipyridamole/administration & dosage/adverse effects/economics
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ischemic Attack, Transient/*economics/prevention & control
MH  - Markov Chains
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*economics
MH  - Quality-Adjusted Life Years
MH  - Recurrence
MH  - Stroke/*economics/prevention & control
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & 
      derivatives/economics
EDAT- 2000/10/12 11:00
MHDA- 2000/10/21 11:01
CRDT- 2000/10/12 11:00
PHST- 2000/10/12 11:00 [pubmed]
PHST- 2000/10/21 11:01 [medline]
PHST- 2000/10/12 11:00 [entrez]
AID - ioi90839 [pii]
AID - 10.1001/archinte.160.18.2773 [doi]
PST - ppublish
SO  - Arch Intern Med. 2000 Oct 9;160(18):2773-8. doi: 10.1001/archinte.160.18.2773.

PMID- 10393393
OWN - NLM
STAT- MEDLINE
DCOM- 20000104
LR  - 20171101
IS  - 0008-6312 (Print)
IS  - 0008-6312 (Linking)
VI  - 91
IP  - 1
DP  - 1999
TI  - Aspirin sensitivity: the role for aspirin challenge and desensitization in 
      postmyocardial infarction patients.
PG  - 8-13
AB  - Aspirin is one of the world's most commonly used medications and its use benefits 
      many diverse conditions. Adverse reactions, however, are relatively common as 
      well. Hypersensitivity to aspirin can be manifested as acute asthma, urticaria 
      and/or angioedema, or a systemic anaphylactoid reaction. We report 3 cases in 
      whom aspirin was indicated for secondary prophylaxis of myocardial infarction but 
      in whom a remote history of an untoward reaction to it prevented its initial use. 
      These patients all underwent further evaluation of their pulmonary and allergic 
      history and all 3 were challenged with aspirin. Two patients were found not to be 
      sensitive and started on aspirin, the other had a classic asthmatic reaction to 
      the drug and was successfully desensitized to aspirin allowing for its use.
FAU - Schaefer, O P
AU  - Schaefer OP
AD  - Division of Pulmonary, Allergy and Critical Care Medicine, University of 
      Massachusetts Medical School, Worcester, Mass., USA. 
      oren.schaefer@banyan.ummed.edu
FAU - Gore, J M
AU  - Gore JM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/chemically induced/diagnosis/immunology
MH  - *Desensitization, Immunologic
MH  - Diagnosis, Differential
MH  - Dose-Response Relationship, Drug
MH  - Drug Eruptions/diagnosis/immunology/therapy
MH  - Drug Hypersensitivity/diagnosis/immunology/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Treatment Outcome
EDAT- 1999/07/07 00:00
MHDA- 1999/07/07 00:01
CRDT- 1999/07/07 00:00
PHST- 1999/07/07 00:00 [pubmed]
PHST- 1999/07/07 00:01 [medline]
PHST- 1999/07/07 00:00 [entrez]
AID - 6871 [pii]
AID - 10.1159/000006871 [doi]
PST - ppublish
SO  - Cardiology. 1999;91(1):8-13. doi: 10.1159/000006871.

PMID- 1124537
OWN - NLM
STAT- MEDLINE
DCOM- 19750627
LR  - 20190818
IS  - 0300-483X (Print)
IS  - 0300-483X (Linking)
VI  - 3
IP  - 2
DP  - 1975
TI  - Effects of prenatal administration of acetylsalicylic acid in rats.
PG  - 207-11
AB  - Acetylsalicylic acid (ASA) administration (200 mg/kg/day) during the last six 
      days of pregnancy in the rat has been observed to result in: (a) a prolongation 
      of the duration of pregnancy; (b) a prolongation of the parturition time; (c) the 
      appearance, in some individuals, of dystocia with possible secondary death of 
      foetuses in utero.
FAU - Tuchmann-Duplessis, H
AU  - Tuchmann-Duplessis H
FAU - Hiss, D
AU  - Hiss D
FAU - Mottot, G
AU  - Mottot G
FAU - Rosner, I
AU  - Rosner I
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Toxicology
JT  - Toxicology
JID - 0361055
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Aspirin/*pharmacology
MH  - Behavior, Animal/drug effects
MH  - Body Weight/drug effects
MH  - Female
MH  - Fetal Death
MH  - Pregnancy
MH  - Prenatal Care
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Time Factors
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 0300-483X(75)90085-2 [pii]
AID - 10.1016/0300-483x(75)90085-2 [doi]
PST - ppublish
SO  - Toxicology. 1975;3(2):207-11. doi: 10.1016/0300-483x(75)90085-2.

PMID- 18160579
OWN - NLM
STAT- MEDLINE
DCOM- 20091001
LR  - 20181201
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 15
IP  - 4
DP  - 2009 Jul-Aug
TI  - Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential 
      thrombocythemia.
PG  - 465-6
AB  - Essential thrombocythemia is a clonal myeloproliferative disorder that causes 
      thrombocytosis. Essential thrombocythemia is characterized by increased incidence 
      of thrombosis with arterial event more than venous events and hemorrhagic 
      complications. Acetylsalicylic acid enhances both minor and major bleedings. The 
      authors describe pericardial hemorrhage, which is related to the use of low-dose 
      acetylsalicylic acid in a patient with essential thrombocythemia. The patient was 
      successfully managed with clopidogrel therapy during the 16 months follow-up 
      without recurrent thrombotic or hemorrhagic events.
FAU - Kayrak, Mehmet
AU  - Kayrak M
AD  - Department of Cardiology, Selcuk University Meram Faculty of Medicine, Konya, 
      Turkey.
FAU - Acar, Kadir
AU  - Acar K
FAU - Yazici, Mehmet
AU  - Yazici M
FAU - Kaya, Coskun
AU  - Kaya C
FAU - Ayhan, S Selim
AU  - Ayhan SS
FAU - Gok, Hasan
AU  - Gok H
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20071226
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clopidogrel
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pericardial Effusion/*chemically induced
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Thrombocythemia, Essential/*drug therapy
MH  - Thrombosis/prevention & control
MH  - Ticlopidine/administration & dosage/analogs & derivatives
EDAT- 2007/12/28 09:00
MHDA- 2009/10/02 06:00
CRDT- 2007/12/28 09:00
PHST- 2007/12/28 09:00 [pubmed]
PHST- 2009/10/02 06:00 [medline]
PHST- 2007/12/28 09:00 [entrez]
AID - 1076029607308874 [pii]
AID - 10.1177/1076029607308874 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2009 Jul-Aug;15(4):465-6. doi: 10.1177/1076029607308874. 
      Epub 2007 Dec 26.

PMID- 16670811
OWN - NLM
STAT- MEDLINE
DCOM- 20070314
LR  - 20211020
IS  - 0340-1855 (Print)
IS  - 0340-1855 (Linking)
VI  - 65
IP  - 3
DP  - 2006 May
TI  - [Systematic lupus erythematosus and antiphospholipid syndrome during pregnancy].
PG  - 192-4, 196-9
AB  - Women with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) 
      are subject to several complications during pregnancy, including reactivation of 
      SLE, thrombosis, miscarriage, neonatal lupus, pregnancy-induced hypertension, 
      pulmonary hypertension and drug toxicity. Correct management of these patients 
      requires combined medical-obstetric care, close surveillance of baby's growth and 
      well-being, control of SLE activity and correct thromboprophylaxis. With good 
      care, most pregnancies in women with SLE and APS end successfully.
FAU - Ruiz-Irastorza, G
AU  - Ruiz-Irastorza G
AD  - Service and Department of Internal Medicine, Hospital de Cruces, University of 
      the Basque Country, Bizkaia.
FAU - Khamashta, M A
AU  - Khamashta MA
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Systemischer Lupus erythematodes und Antiphospholipidsyndrome in der 
      Schwangerschaft.
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Anticoagulants)
RN  - 0 (Immunosuppressive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/adverse effects
MH  - Antiphospholipid Syndrome/*diagnosis/drug therapy/immunology
MH  - Aspirin/adverse effects/therapeutic use
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/therapeutic use
MH  - Infant, Newborn
MH  - Lupus Erythematosus, Systemic/*diagnosis/drug therapy/immunology
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Risk Factors
MH  - Thrombophilia/diagnosis/drug therapy/immunology
RF  - 45
EDAT- 2006/05/04 09:00
MHDA- 2007/03/16 09:00
CRDT- 2006/05/04 09:00
PHST- 2006/05/04 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2006/05/04 09:00 [entrez]
AID - 10.1007/s00393-006-0058-z [doi]
PST - ppublish
SO  - Z Rheumatol. 2006 May;65(3):192-4, 196-9. doi: 10.1007/s00393-006-0058-z.

PMID- 581112
OWN - NLM
STAT- MEDLINE
DCOM- 19781018
LR  - 20191210
IS  - 0001-5598 (Print)
IS  - 0001-5598 (Linking)
VI  - 88
IP  - 4
DP  - 1978 Aug
TI  - Short-term effect of acetylsalicylic acid analogue on pituitary-thyroid axis and 
      plasma cortisol level in healthy human volunteers.
PG  - 698-702
AB  - The effect of acetylsalicylic acid analogue (aloxiprinum; Superpyrin Spofa) 
      administered perorally in a daily dose of 1 g per 10 kg body weight on serum 
      levels of free thyroxine (FT4), total thyroxine (T4), triiodothyronine (T3), 
      cortisol (F) and thyrotrophin (TSH) was studied in healthy human volunteers. In a 
      first experiment the drug was administered for 3 days to 7 subjects, the total 
      daily dose being divided into 4-5 aliquots, while the same total dose was 
      administered within 4 h to another 8 subjects in a second experiment. In both 
      experiments a highly significant increase of FT4 was found during the period of 
      treatment, while the levels of other hormones i.e. (T3, T4, F and TSH) were 
      decreased, in most cases significantly. After the withdrawal of the drug there 
      was not only a return of all levels to the initial value, but in most cases an 
      "overshoot" above this value was detected.
FAU - Langer, P
AU  - Langer P
FAU - Földes, O
AU  - Földes O
FAU - Michajlovskij, N
AU  - Michajlovskij N
FAU - Jezová, D
AU  - Jezová D
FAU - Klimes, I
AU  - Klimes I
FAU - Michalko, J
AU  - Michalko J
FAU - Závada, M
AU  - Závada M
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Acta Endocrinol (Copenh)
JT  - Acta endocrinologica
JID - 0370312
RN  - 06LU7C9H1V (Triiodothyronine)
RN  - 6QT214X4XU (aloxiprin)
RN  - 9002-71-5 (Thyrotropin)
RN  - Q51BO43MG4 (Thyroxine)
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adult
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Humans
MH  - Hydrocortisone/*blood
MH  - Male
MH  - Pituitary Gland/*drug effects
MH  - Thyroid Gland/*drug effects
MH  - Thyrotropin/blood
MH  - Thyroxine/blood
MH  - Time Factors
MH  - Triiodothyronine/blood
EDAT- 1978/08/01 00:00
MHDA- 1978/08/01 00:01
CRDT- 1978/08/01 00:00
PHST- 1978/08/01 00:00 [pubmed]
PHST- 1978/08/01 00:01 [medline]
PHST- 1978/08/01 00:00 [entrez]
AID - 10.1530/acta.0.0880698 [doi]
PST - ppublish
SO  - Acta Endocrinol (Copenh). 1978 Aug;88(4):698-702. doi: 10.1530/acta.0.0880698.

PMID- 26511379
OWN - NLM
STAT- MEDLINE
DCOM- 20160913
LR  - 20161126
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 768
DP  - 2015 Dec 5
TI  - NCX 4040, a nitric oxide-donating aspirin derivative, inhibits Prevotella 
      intermedia lipopolysaccharide-induced production of proinflammatory mediators in 
      murine macrophages.
PG  - 87-95
LID - S0014-2999(15)30313-7 [pii]
LID - 10.1016/j.ejphar.2015.10.032 [doi]
AB  - In this study, the effects and underlying mechanisms of NCX 4040, a nitric oxide 
      (NO)-donating aspirin derivative, on the production of proinflammatory mediators 
      were examined using murine macrophages exposed to lipopolysaccharide (LPS) from 
      Prevotella intermedia, a pathogen implicated in the etiology of periodontal 
      disease. NCX 4040 significantly reduced P. intermedia LPS-induced production of 
      inducible NO synthase (iNOS)-derived NO, IL-1β and IL-6 as well as their mRNA 
      expression in RAW264.7 cells. Notably, NCX 4040 was much more effective than the 
      parental compound aspirin in reducing LPS-induced production of inflammatory 
      mediators. NCX 4040 induced the expression of heme oxygenase-1 (HO-1) in cells 
      treated with P. intermedia LPS, and the suppressive effect of NCX 4040 on 
      LPS-induced NO production was significantly reversed by SnPP, a competitive HO-1 
      inhibitor. NCX 4040 did not influence LPS-induced phosphorylation of JNK and p38. 
      IκB-α degradation as well as nuclear translocation and DNA-binding activities of 
      NF-κB p65 and p50 subunits induced by P. intermedia LPS were significantly 
      reduced by NCX 4040. Besides, LPS-induced phosphorylation of STAT1 and STAT3 was 
      significantly down-regulated by NCX 4040. Further, NCX 4040 elevated the SOCS1 
      mRNA in cells stimulated with LPS. This study indicates that NCX 4040 inhibits P. 
      intermedia LPS-induced production of NO, IL-1β and IL-6 in murine macrophages 
      through anti-inflammatory HO-1 induction and suppression of NF-κB, STAT1 and 
      STAT3 activation, which is associated with the activation of SOCS1 signaling. NCX 
      4040 could potentially be a promising tool in the treatment of periodontal 
      disease, although further studies are required to verify this.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Choi, Eun-Young
AU  - Choi EY
AD  - Department of Biological Science, College of Medical and Life Sciences, Silla 
      University, Busan, Korea.
FAU - Choe, So-Hui
AU  - Choe SH
AD  - Department of Biological Science, College of Medical and Life Sciences, Silla 
      University, Busan, Korea.
FAU - Hyeon, Jin-Yi
AU  - Hyeon JY
AD  - Department of Biological Science, College of Medical and Life Sciences, Silla 
      University, Busan, Korea.
FAU - Park, Hae Ryoun
AU  - Park HR
AD  - Department of Oral Pathology, School of Dentistry, Pusan National University, 
      Yangsan, Gyeongsangnam-do, Korea; Institute of Translational Dental Sciences, 
      Pusan National University, Yangsan, Gyeongsangnam-do, Korea.
FAU - Choi, Jeom-Il
AU  - Choi JI
AD  - Department of Periodontology, School of Dentistry, Pusan National University, 
      Yangsan, Gyeongsangnam-do, Korea; Dental Research Institute, Pusan National 
      University Dental Hospital, Yangsan, Gyeongsangnam-do, Korea.
FAU - Choi, In Soon
AU  - Choi IS
AD  - Department of Biological Science, College of Medical and Life Sciences, Silla 
      University, Busan, Korea.
FAU - Kim, Sung-Jo
AU  - Kim SJ
AD  - Department of Periodontology, School of Dentistry, Pusan National University, 
      Yangsan, Gyeongsangnam-do, Korea; Dental Research Institute, Pusan National 
      University Dental Hospital, Yangsan, Gyeongsangnam-do, Korea; Institute of 
      Translational Dental Sciences, Pusan National University, Yangsan, 
      Gyeongsangnam-do, Korea. Electronic address: sungjokim@pusan.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151025
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Inflammation Mediators)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Membrane Proteins)
RN  - 0 (NCX 4040)
RN  - 0 (NF-kappa B)
RN  - 0 (Nitro Compounds)
RN  - 0 (STAT1 Transcription Factor)
RN  - 0 (STAT3 Transcription Factor)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - EC 1.14.14.18 (Hmox1 protein, mouse)
RN  - EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/metabolism/pharmacology
MH  - Enzyme Induction/drug effects
MH  - Heme Oxygenase-1/biosynthesis
MH  - Inflammation Mediators/*metabolism
MH  - JNK Mitogen-Activated Protein Kinases/metabolism
MH  - Lipopolysaccharides/*pharmacology
MH  - Macrophages/*drug effects/*metabolism
MH  - Membrane Proteins/biosynthesis
MH  - Mice
MH  - NF-kappa B/metabolism
MH  - Nitric Oxide/*biosynthesis
MH  - Nitro Compounds/metabolism/*pharmacology
MH  - Phosphorylation/drug effects
MH  - Prevotella intermedia/*chemistry
MH  - RAW 264.7 Cells
MH  - STAT1 Transcription Factor/metabolism
MH  - STAT3 Transcription Factor/metabolism
MH  - p38 Mitogen-Activated Protein Kinases/metabolism
OTO - NOTNLM
OT  - HO-1
OT  - Lipopolysaccharide
OT  - NCX 4040
OT  - NF-κB
OT  - Proinflammatory mediators
OT  - SOCS1
OT  - STAT
EDAT- 2015/10/30 06:00
MHDA- 2016/09/14 06:00
CRDT- 2015/10/30 06:00
PHST- 2015/07/25 00:00 [received]
PHST- 2015/09/15 00:00 [revised]
PHST- 2015/10/19 00:00 [accepted]
PHST- 2015/10/30 06:00 [entrez]
PHST- 2015/10/30 06:00 [pubmed]
PHST- 2016/09/14 06:00 [medline]
AID - S0014-2999(15)30313-7 [pii]
AID - 10.1016/j.ejphar.2015.10.032 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2015 Dec 5;768:87-95. doi: 10.1016/j.ejphar.2015.10.032. Epub 
      2015 Oct 25.

PMID- 22874127
OWN - NLM
STAT- MEDLINE
DCOM- 20130516
LR  - 20131121
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 27
IP  - 5
DP  - 2012 Sep
TI  - The aspirin controversy in primary prevention.
PG  - 499-507
LID - 10.1097/HCO.0b013e328356ae95 [doi]
AB  - PURPOSE OF REVIEW: Apparently conflicting meta-analysis results have led to 
      renewed debate about the role of aspirin for the primary prevention of 
      cardiovascular disease. We review the results of meta-analyses comparing aspirin 
      with placebo or no aspirin for the primary prevention of cardiovascular disease 
      and critically evaluate whether aspirin provides a net benefit. RECENT FINDINGS: 
      The results of four independently conducted meta-analyses between 2009 and 2012 
      involving between 95 000 and 102 621 individuals at low risk of cardiovascular 
      disease are consistent with the results of the 2002 Antithrombotic Trialists' 
      Collaboration meta-analysis, which found that aspirin reduces cardiovascular 
      events primarily by reducing nonfatal myocardial infarction (MI). There is no 
      convincing evidence that aspirin reduces cardiovascular mortality, but estimates 
      from all of the meta-analyses suggest a modest reduction in all-cause mortality. 
      Aspirin reduces ischaemic stroke but increases haemorrhagic stroke and major 
      bleeding. SUMMARY: The meta-analysis results consistently indicate that, in 
      individuals at low risk for cardiovascular disease, aspirin reduces the risk of 
      MI at the cost of an increase in major bleeding and produces a modest nominally 
      significant reduction in total mortality. These results suggest that 
      recommendations for primary prevention with aspirin should be individualized, 
      taking into account the balance between benefits and risks and individual values 
      and preferences.
FAU - Raju, Nina C
AU  - Raju NC
AD  - Haematology Unit, Pathology Queensland and Internal Medicine Unit, The Prince 
      Charles Hospital, Brisbane, Australia. Nina_Raju@health.qld.gov.au
FAU - Eikelboom, John W
AU  - Eikelboom JW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Risk Assessment
EDAT- 2012/08/10 06:00
MHDA- 2013/05/17 06:00
CRDT- 2012/08/10 06:00
PHST- 2012/08/10 06:00 [entrez]
PHST- 2012/08/10 06:00 [pubmed]
PHST- 2013/05/17 06:00 [medline]
AID - 00001573-201209000-00007 [pii]
AID - 10.1097/HCO.0b013e328356ae95 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2012 Sep;27(5):499-507. doi: 10.1097/HCO.0b013e328356ae95.

PMID- 19443791
OWN - NLM
STAT- MEDLINE
DCOM- 20090727
LR  - 20161122
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 40
IP  - 7
DP  - 2009 Jul
TI  - Reduced platelet activity is associated with early clot growth and worse 3-month 
      outcome after intracerebral hemorrhage.
PG  - 2398-401
LID - 10.1161/STROKEAHA.109.550939 [doi]
AB  - BACKGROUND AND PURPOSE: Antiplatelet medication use and reduced platelet activity 
      may be associated with mortality after intracerebral hemorrhage (ICH). We tested 
      the hypothesis that reduced platelet activity is associated with early ICH clot 
      growth and worse outcomes. METHODS: We prospectively identified patients with 
      spontaneous ICH, measured platelet activity (VerifyNow-ASA, Accumetrics) on 
      admission, and recorded antiplatelet medication use. ICH volume was calculated 
      using computerized volumetric analysis. Data were analyzed with nonparametric 
      statistics and repeated measures ANOVA as appropriate. Patients were 
      prospectively followed for functional outcomes. Data are presented as mean+/-SD 
      or median [Q1 to Q3]. RESULTS: Reduced platelet activity (<or=550 aspirin 
      reaction units [ARU]) was associated with increased ICH volume growth (P<0.05) 
      for patients with the diagnostic CT within 12 hours. In the subset of patients 
      not known to take aspirin, 24% had reduced platelet activity. Sixteen (24%) 
      patients received a platelet transfusion 21.2+/-11.4 hours after symptom onset 
      with an increase in platelet activity (448 [414-479] to 586 [530-639] ARU, 
      P=0.001), but without impact on outcomes. Reduced platelet activity was 
      associated with worse modified Rankin Scores at 3 months (P=0.02). CONCLUSIONS: 
      Reduced platelet activity was associated with early ICH volume growth and worse 
      functional outcome. Because platelet activity can be increased with platelet 
      transfusion, increasing platelet activity is a potential method to reduce ICH 
      volume growth and improve functional outcomes.
FAU - Naidech, Andrew M
AU  - Naidech AM
AD  - Department of Neurology, Northwestern University, Chicago, IL 60611, USA. 
      a-naidech@northwestern.edu
FAU - Jovanovic, Borko
AU  - Jovanovic B
FAU - Liebling, Storm
AU  - Liebling S
FAU - Garg, Rajeev K
AU  - Garg RK
FAU - Bassin, Sarice L
AU  - Bassin SL
FAU - Bendok, Bernard R
AU  - Bendok BR
FAU - Bernstein, Richard A
AU  - Bernstein RA
FAU - Alberts, Mark J
AU  - Alberts MJ
FAU - Batjer, H Hunt
AU  - Batjer HH
LA  - eng
PT  - Journal Article
DEP - 20090514
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 2009 Nov;40(11):e645; author reply e646. PMID: 19797180
MH  - Aged
MH  - Aspirin/adverse effects/pharmacology
MH  - Blood Coagulation/drug effects/*physiology
MH  - Blood Platelets/drug effects/*physiology
MH  - Cerebral Hemorrhage/*blood/*diagnosis/therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology
MH  - Platelet Transfusion
MH  - Prognosis
MH  - Prospective Studies
EDAT- 2009/05/16 09:00
MHDA- 2009/07/28 09:00
CRDT- 2009/05/16 09:00
PHST- 2009/05/16 09:00 [entrez]
PHST- 2009/05/16 09:00 [pubmed]
PHST- 2009/07/28 09:00 [medline]
AID - STROKEAHA.109.550939 [pii]
AID - 10.1161/STROKEAHA.109.550939 [doi]
PST - ppublish
SO  - Stroke. 2009 Jul;40(7):2398-401. doi: 10.1161/STROKEAHA.109.550939. Epub 2009 May 
      14.

PMID- 28811088
OWN - NLM
STAT- MEDLINE
DCOM- 20180514
LR  - 20221207
IS  - 1544-3450 (Electronic)
IS  - 1086-5802 (Linking)
VI  - 57
IP  - 5
DP  - 2017 Sep-Oct
TI  - Primary prevention aspirin use in high-risk patients: A pharmacist intervention 
      and comparison of risk stratification tools.
PG  - 585-590
LID - S1544-3191(17)30785-9 [pii]
LID - 10.1016/j.japh.2017.07.003 [doi]
AB  - OBJECTIVES: The objectives of this project are 1) to describe aspirin use for 
      primary prevention in an underserved, minority population; 2) to determine the 
      impact of a pharmacist-led intervention on the prevalence of aspirin use for 
      primary prevention; and 3) to compare aspirin indications based on Framingham 
      Risk Score (FRS) and atherosclerotic cardiovascular disease (ASCVD) risk score. 
      METHODS: Men and women age 45-79 and 55-79 years, respectively, without ASCVD 
      were screened for aspirin use. An FRS of 10% or greater and low risk for a 
      serious bleed were considered indications for primary prevention aspirin on the 
      basis of guideline-directed medical therapy recommendations. When treatment with 
      aspirin was indicated, providers were notified with patient-specific messages. 
      Patients' FRS and ASCVD risk score distributions were plotted and compared. 
      Primary prevention aspirin indications were identified using both risk 
      stratification tools. RESULTS: One hundred sixteen patients were evaluated for 
      aspirin use in a predominantly black (80%), middle-aged (mean age, 58 years), and 
      indigent population. Thirty-one patients (27%) had an FRS of 10% or greater and 
      low risk for bleeding, and 10 patients (9%) were taking aspirin at baseline. 
      Providers approved recommendations to start administering aspirin in 19 of 31 
      patients (61%), which significantly increased the overall proportion receiving 
      aspirin compared to baseline (9%-25%; P < 0.01). Patients were more than twice as 
      likely to meet the minimum risk score threshold (≥10%) for a primary prevention 
      aspirin indication using ASCVD risk scores versus FRS (70% vs. 30%; P < 0.01). 
      CONCLUSIONS: Baseline utilization of primary prevention aspirin was low in an 
      indigent, minority population. A provider-focused pharmacist intervention 
      improved the prevalence of aspirin use for primary prevention, while minimizing 
      risk for serious bleeding events. Among our cohort, more patients had indications 
      for primary prevention aspirin using ASCVD risk scores versus FRS.
CI  - Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. 
      All rights reserved.
FAU - Coon, Scott A
AU  - Coon SA
FAU - Brooks, Amie D
AU  - Brooks AD
FAU - Wolff, Stephen E
AU  - Wolff SE
LA  - eng
PT  - Journal Article
DEP - 20170812
PL  - United States
TA  - J Am Pharm Assoc (2003)
JT  - Journal of the American Pharmacists Association : JAPhA
JID - 101176252
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Black or African American/*statistics & numerical data
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pharmacists
MH  - Primary Prevention/methods/*statistics & numerical data
MH  - Professional Role
MH  - Risk Factors
MH  - Vulnerable Populations/*statistics & numerical data
EDAT- 2017/08/16 06:00
MHDA- 2018/05/15 06:00
CRDT- 2017/08/17 06:00
PHST- 2016/11/22 00:00 [received]
PHST- 2017/05/28 00:00 [revised]
PHST- 2017/07/07 00:00 [accepted]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
PHST- 2017/08/17 06:00 [entrez]
AID - S1544-3191(17)30785-9 [pii]
AID - 10.1016/j.japh.2017.07.003 [doi]
PST - ppublish
SO  - J Am Pharm Assoc (2003). 2017 Sep-Oct;57(5):585-590. doi: 
      10.1016/j.japh.2017.07.003. Epub 2017 Aug 12.

PMID- 9262254
OWN - NLM
STAT- MEDLINE
DCOM- 19970828
LR  - 20190512
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 89
IP  - 15
DP  - 1997 Aug 6
TI  - Suppression of human colorectal mucosal prostaglandins: determining the lowest 
      effective aspirin dose.
PG  - 1152-60
AB  - BACKGROUND: A variety of studies have supported the finding that regular intake 
      of aspirin (acetylsalicylic acid) or nonsteroidal anti-inflammatory agents can 
      affect colorectal cancer carcinogenesis. These agents inhibit the synthesis of 
      prostaglandins. High levels of prostaglandins are observed in colon cancer 
      tissues. PURPOSE: Experiments were planned to determine the lowest dose of 
      aspirin that can markedly suppress the levels of mucosal prostaglandins E2 and 
      F(2alpha) in colorectal mucosa and to determine whether a relationship exists 
      between these levels and plasma levels of both acetylsalicylic acid and its 
      metabolite, salicylic acid. METHODS: Healthy men and women aged 18 years or older 
      participated in the study. The participants took a single, daily dose of aspirin 
      (40.5, 81, 162, 324, or 648 mg) or a placebo for 14 days. Colorectal biopsy 
      specimens were taken at baseline, 24 hours after the first dose of aspirin, and 
      24-30 hours and 72-78 hours after the last, i.e., fourteenth, daily dose of 
      aspirin. The biopsy specimens were assayed for prostaglandins E2 and F(2alpha) by 
      use of a competitive enzyme immunoassay. Plasma concentrations of acetylsalicylic 
      acid and salicylic acid were determined by use of high-performance liquid 
      chromatography. All P values are two-sided. RESULTS: A total of 65 subjects (10 
      receiving placebo, groups of 10 each receiving 40.5, 81, 162, or 324 mg of 
      aspirin, and a group of 15 receiving 648 mg of aspirin) completed the protocol. 
      One subject reported unacceptable drug-induced toxic effects and did not complete 
      the protocol; other subjects reported acceptable side effects. The lowest dose to 
      significantly suppress colorectal mucosal prostaglandin E2 concentrations from 
      baseline at 24 hours after the first dose (by 22.6%; P = .002) and at 24-30 hours 
      after the last dose (by 14.2%; P = .021) was 162 mg. At 72-78 hours after the 
      last dose, there was significant suppression for subjects receiving 81 mg (by 
      23.7%; P = .008). The lowest dose to significantly suppress colorectal mucosal 
      prostaglandin F(2alpha) concentrations from baseline at 24 hours after the first 
      dose (by 18.3%; P = .032) was 324 mg. The lowest dose causing a marked reduction 
      in the level of prostaglandin F(2alpha) at 24-30 hours (by 15.1%; P = .003) and 
      72-78 hours (by 23.0%; P = .0002) after the last dose was 40.5 mg. No detectable 
      amounts of acetylsalicylic acid or salicylic acid were present in the plasma at 
      any of the biopsy time points. CONCLUSIONS: The lowest doses of aspirin taken 
      daily for 14 days to significantly suppress concentrations of colorectal mucosal 
      prostaglandins E2 and F(2alpha) were 81 and 40.5 mg, respectively. The 
      suppression occurred without detectable amounts of aspirin or salicylic acid in 
      the plasma at the time points studied. On the basis of these observations, we 
      recommend a single, daily dose of 81 mg of aspirin in future studies of this drug 
      as a chemopreventive agent for colorectal cancer.
FAU - Ruffin, M T 4th
AU  - Ruffin MT 4th
AD  - Department of Family Practice, University of Michigan Medical School, Department 
      of Veterans Affairs (VA) Medical Center, Ann Arbor, USA.
FAU - Krishnan, K
AU  - Krishnan K
FAU - Rock, C L
AU  - Rock CL
FAU - Normolle, D
AU  - Normolle D
FAU - Vaerten, M A
AU  - Vaerten MA
FAU - Peters-Golden, M
AU  - Peters-Golden M
FAU - Crowell, J
AU  - Crowell J
FAU - Kelloff, G
AU  - Kelloff G
FAU - Boland, C R
AU  - Boland CR
FAU - Brenner, D E
AU  - Brenner DE
LA  - eng
GR  - CN25429/CN/NCI NIH HHS/United States
GR  - MO1-RR00042/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandins)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & 
      dosage/blood/*pharmacokinetics
MH  - Aspirin/*administration & dosage/blood/*pharmacokinetics
MH  - *Colon
MH  - Colorectal Neoplasms/metabolism/*prevention & control
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Intestinal Mucosa/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Prostaglandins/metabolism
MH  - *Rectum
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Time Factors
EDAT- 1997/08/06 00:00
MHDA- 2001/03/28 10:01
CRDT- 1997/08/06 00:00
PHST- 1997/08/06 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1997/08/06 00:00 [entrez]
AID - 10.1093/jnci/89.15.1152 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 1997 Aug 6;89(15):1152-60. doi: 10.1093/jnci/89.15.1152.

PMID- 31805980
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 19
IP  - 1
DP  - 2019 Dec 5
TI  - Could aspirin be a lifesaver for prostate cancer patients in prostate 
      cancer-specific mortality?: an update systematic review and meta-analysis.
PG  - 1186
LID - 10.1186/s12885-019-6415-5 [doi]
LID - 1186
AB  - BACKGROUND: Currently, clinical studies on the prognosis of prostate cancer (PC) 
      taking aspirin were developing, but the precise mechanism of aspirin on tumor 
      cells was still unclear. In addition, the conclusion that aspirin can improve the 
      prognosis of PC patients continues to be controversial. Therefore, we collected 
      comprehensive literatures and performed our study to explore the prognostic 
      effect of aspirin on PC. METHODS: A comprehensive literature search was performed 
      in April 2019 based on PUBMED. EMBASE. Hazard Ratio (HR) as well as its 95% 
      confidence interval (CIs) for prostate cancer specific mortality (PCSM) was 
      extracted from eligible studies. RESULT: A total of 10 eligible articles were 
      used in our study. The pooled results showed that PC patients who used aspirin or 
      taking aspirin did not have lower PCSM than those who had not used (HR =0.89, 95% 
      CI: 0.73-1.08, P>0.05). In subgroup analysis, we found that taking aspirin before 
      diagnosis of prostate cancer and taking aspirin after diagnosis of prostate 
      cancer did not have significant association with PCSM. (pre-diagnostic use, 
      HR = 0.88, 95% CI: 0.72-1.06; post-diagnosis use, HR = 0.88, 95% CI: 0.67-1.17). 
      In addition, we found no significant association between aspirin use or its 
      duration and the risk of PCSM. Another important result demonstrated that aspirin 
      use was not associated with risk of PSCM in either high risk (T ≥ 3 and/or 
      Gleason score ≥ 8) or low risk PC patients(low-risk PC, HR = 1.05, 95% CI: 
      0.81-1.35; high-risk PC, HR = 0.97, 95% CI: 0.75-1.24). CONCLUSION: Our results 
      demonstrated that there was no significant association between aspirin use and 
      the risk of PCSM. At the same time, the dosage and duration of aspirin use had no 
      statistical influence on the risk of PCSM in high/low risk PC. Further studies 
      are needed to confirm the findings.
FAU - Zhou, Jiatong
AU  - Zhou J
AD  - Department of Urology, The Second Hospital of Tianjin Medical University, No. 23, 
      Pingjiang Road, Hexi District, Tianjin, 300211, China.
FAU - Xia, Shuai
AU  - Xia S
AD  - Department of Urology, The Second Hospital of Tianjin Medical University, No. 23, 
      Pingjiang Road, Hexi District, Tianjin, 300211, China.
FAU - Li, Tao
AU  - Li T
AD  - Department of Urology, The Second Hospital of Tianjin Medical University, No. 23, 
      Pingjiang Road, Hexi District, Tianjin, 300211, China.
FAU - Liu, Ranlu
AU  - Liu R
AD  - Department of Urology, The Second Hospital of Tianjin Medical University, No. 23, 
      Pingjiang Road, Hexi District, Tianjin, 300211, China. 16622080858@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20191205
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Case-Control Studies
MH  - Humans
MH  - Male
MH  - Mortality
MH  - Neoplasm Grading
MH  - Prognosis
MH  - Prostate-Specific Antigen
MH  - Prostatic Neoplasms/*mortality
PMC - PMC6894469
OTO - NOTNLM
OT  - Aspirin
OT  - Meta-analysis
OT  - Prognosis
OT  - Prostate cancer
COIS- The authors declare that they have no conflict of interests.
EDAT- 2019/12/07 06:00
MHDA- 2020/04/03 06:00
CRDT- 2019/12/07 06:00
PHST- 2019/05/20 00:00 [received]
PHST- 2019/11/29 00:00 [accepted]
PHST- 2019/12/07 06:00 [entrez]
PHST- 2019/12/07 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
AID - 10.1186/s12885-019-6415-5 [pii]
AID - 6415 [pii]
AID - 10.1186/s12885-019-6415-5 [doi]
PST - epublish
SO  - BMC Cancer. 2019 Dec 5;19(1):1186. doi: 10.1186/s12885-019-6415-5.

PMID- 25345590
OWN - NLM
STAT- MEDLINE
DCOM- 20150303
LR  - 20161125
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 90
IP  - 1
DP  - 2015 Jan
TI  - Occurrence of the JAK2 V617F mutation in patients with peripheral arterial 
      disease.
PG  - E17-21
LID - 10.1002/ajh.23874 [doi]
AB  - The acquired JAK2 V617F mutation is common in patients with myeloproliferative 
      neoplasms. We previously showed that JAK2 V617F is also found in coronary 
      patients, most of them affected by coronary atherosclerosis. Peripheral arterial 
      disease (PAD) is another important manifestation of atherosclerosis. However, 
      prevalence of the JAK2 V617F mutation and its effect on clinical or hematologic 
      characteristics is unknown in PAD patients. In the present study we determined 
      the prevalence of JAK2 V617F in a cohort of 287 patients with sonographically 
      proven PAD and compared mutation frequency with mutational status of 997 healthy 
      people from the KORA F4 study. JAK2 V617F screening and quantification of allele 
      burden in both cohorts was performed with same allele-specific quantitative 
      real-time PCR method. From a total of 287 PAD patients, 9 individuals were tested 
      positive for the JAK2 V617F mutation. One patient showed elevated hemoglobin 
      values, indicating polycythemia vera. Observed JAK2 V617F frequency (3.1%) in PAD 
      patients showed a 5-fold, highly significant increase compared with healthy 
      people (P < 0.001). Furthermore, occurrence of the mutation in PAD patients was 
      significantly decreased in patients using aspirin (P = 0.003). We conclude that 
      the prevalence of JAK2 V617F mutation is significantly increased in PAD patients 
      compared to the general population. Future studies are warranted to confirm our 
      observations and to define the underlying mechanisms behind our findings.
CI  - © 2014 Wiley Periodicals, Inc.
FAU - Muendlein, Axel
AU  - Muendlein A
AD  - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, 
      Austria.
FAU - Kinz, Elena
AU  - Kinz E
FAU - Gasser, Klaus
AU  - Gasser K
FAU - Leiherer, Andreas
AU  - Leiherer A
FAU - Rein, Philipp
AU  - Rein P
FAU - Saely, Christoph H
AU  - Saely CH
FAU - Grallert, Harald
AU  - Grallert H
FAU - Peters, Annette
AU  - Peters A
FAU - Fraunberger, Peter
AU  - Fraunberger P
FAU - Drexel, Heinz
AU  - Drexel H
FAU - Lang, Alois H
AU  - Lang AH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141120
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - EC 2.7.10.2 (JAK2 protein, human)
RN  - EC 2.7.10.2 (Janus Kinase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Female
MH  - Genotyping Techniques
MH  - Humans
MH  - Janus Kinase 2/*genetics
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Mutation
MH  - Peripheral Arterial Disease/diagnostic imaging/enzymology/epidemiology/*genetics
MH  - Regression Analysis
MH  - Ultrasonography
EDAT- 2014/10/28 06:00
MHDA- 2015/03/04 06:00
CRDT- 2014/10/28 06:00
PHST- 2014/10/20 00:00 [received]
PHST- 2014/10/21 00:00 [accepted]
PHST- 2014/10/28 06:00 [entrez]
PHST- 2014/10/28 06:00 [pubmed]
PHST- 2015/03/04 06:00 [medline]
AID - 10.1002/ajh.23874 [doi]
PST - ppublish
SO  - Am J Hematol. 2015 Jan;90(1):E17-21. doi: 10.1002/ajh.23874. Epub 2014 Nov 20.

PMID- 24802171
OWN - NLM
STAT- MEDLINE
DCOM- 20150526
LR  - 20141203
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 64
IP  - 5
DP  - 2014 Nov
TI  - Cardiovascular and bleeding risk of non-cardiac surgery in patients on 
      antiplatelet therapy.
PG  - 334-8
LID - S0914-5087(14)00091-4 [pii]
LID - 10.1016/j.jjcc.2014.02.027 [doi]
AB  - BACKGROUND: The perioperative risk of non-cardiac surgery (NCS) in the patients 
      on antiplatelet therapy after percutaneous coronary intervention (PCI) remains 
      unclear. METHODS: This study was a retrospective and single center study. Between 
      January 2008 and December 2011, 198 patients who had already received PCI 
      underwent NCS in our hospital. Among them, 63 patients underwent surgery on dual 
      antiplatelet therapy (DAPT group) and 88 patients on single antiplatelet therapy 
      (SAPT group). We compared bleeding events and cardiovascular events during 
      perioperative period between the two groups. RESULTS: There was no stent 
      thrombosis in either group. The bleeding events in the DAPT group were 
      significantly higher than that in the SAPT group (9.5% vs 2.3%, p=0.049). There 
      was no difference in events between with or without heparin-bridge in the SAPT 
      group. CONCLUSIONS: The frequency of bleeding events was higher in the DAPT 
      group. Both bleeding and cardiovascular events with aspirin alone were low in our 
      study. It may be safe to undergo NCS with SAPT after PCI.
CI  - Copyright © 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Yamamoto, Kei
AU  - Yamamoto K
AD  - Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical 
      University, Saitama, Japan.
FAU - Wada, Hiroshi
AU  - Wada H
AD  - Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical 
      University, Saitama, Japan.
FAU - Sakakura, Kenichi
AU  - Sakakura K
AD  - Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical 
      University, Saitama, Japan.
FAU - Ikeda, Nahoko
AU  - Ikeda N
AD  - Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical 
      University, Saitama, Japan.
FAU - Yamada, Yoko
AU  - Yamada Y
AD  - Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical 
      University, Saitama, Japan.
FAU - Katayama, Takuji
AU  - Katayama T
AD  - Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical 
      University, Saitama, Japan.
FAU - Sugawara, Yoshitaka
AU  - Sugawara Y
AD  - Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical 
      University, Saitama, Japan.
FAU - Mitsuhashi, Takeshi
AU  - Mitsuhashi T
AD  - Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical 
      University, Saitama, Japan.
FAU - Ako, Junya
AU  - Ako J
AD  - Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical 
      University, Saitama, Japan.
FAU - Momomura, Shin-ichi
AU  - Momomura S
AD  - Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical 
      University, Saitama, Japan. Electronic address: momoshin@omiya.jichi.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20140505
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Membrane Proteins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (TMEM158 protein, human)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*chemically induced/epidemiology
MH  - Female
MH  - Hemorrhage/*chemically induced/epidemiology
MH  - Heparin/administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Membrane Proteins
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention
MH  - Perioperative Care/*adverse effects
MH  - Perioperative Period
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Retrospective Studies
MH  - Stents/*adverse effects
MH  - Time Factors
MH  - Tumor Suppressor Proteins
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - Bleeding
OT  - Heparin-bridge
OT  - Non cardiac surgery
OT  - Stent thrombosis
EDAT- 2014/05/08 06:00
MHDA- 2015/05/27 06:00
CRDT- 2014/05/08 06:00
PHST- 2013/09/30 00:00 [received]
PHST- 2014/01/17 00:00 [revised]
PHST- 2014/02/04 00:00 [accepted]
PHST- 2014/05/08 06:00 [entrez]
PHST- 2014/05/08 06:00 [pubmed]
PHST- 2015/05/27 06:00 [medline]
AID - S0914-5087(14)00091-4 [pii]
AID - 10.1016/j.jjcc.2014.02.027 [doi]
PST - ppublish
SO  - J Cardiol. 2014 Nov;64(5):334-8. doi: 10.1016/j.jjcc.2014.02.027. Epub 2014 May 
      5.

PMID- 25363997
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181202
IS  - 1557-2501 (Electronic)
IS  - 1042-3931 (Linking)
VI  - 26
IP  - 11
DP  - 2014 Nov
TI  - Outcome of patients on oral anticoagulation undergoing coronary artery stenting: 
      data from discharge to 12 months in the Warfarin and Coronary Stenting 
      (WAR-STENT) Registry.
PG  - 563-9
AB  - OBJECTIVES: To obtain further, and more focused, information on the efficacy and 
      safety of the antithrombotic regimens, including triple therapy (TT) of warfarin, 
      aspirin, and clopidogrel; dual therapy (DT) of warfarin and single antiplatelet 
      agent (aspirin or clopidogrel); and dual-antiplatelet therapy (DAPT) of aspirin 
      and clopidogrel, prescribed to patients on oral anticoagulation (OAC) undergoing 
      percutaneous coronary intervention with stent (PCI-S). BACKGROUND: The true 
      efficacy and safety of TT, DT, and DAPT in OAC patients undergoing PCI-S is 
      largely undefined. METHODS: We analyzed the database of the prospective, 
      multicenter WARfarin and coronary STENTing (WAR-STENT) registry 
      (ClinicalTrials.gov identifier NCT00722319), only including the post-discharge 
      period. RESULTS: Of the 401 patients discharged alive from index hospitalization, 
      339 (85%), 20 (5%), and 42 (10%) were prescribed TT, DT, and DAPT, respectively. 
      Throughout a mean follow-up of 368.3 ± 22.8 days, major adverse cardiovascular 
      events (MACE) (including cardiovascular death, myocardial infarction, repeat 
      revascularization, stent thrombosis, and thromboembolism), total bleeding, major 
      bleeding, and combination of MACE plus total bleeding were comparable across the 
      three treatment groups. The absolute rate of major bleeding with TT was 4%. The 
      antithrombotic treatment actually ongoing at major bleeding was TT in 44%, DT in 
      50%, and DAPT in 6% of cases. CONCLUSION: In the real-world population of OAC 
      patients undergoing PCI-S in the WAR-STENT registry, the three antithrombotic 
      regimens of TT, DT, and DAPT showed comparable efficacy and safety. Due to 
      several limitations, our data cannot be considered conclusive in confuting the 
      current recommendations to prescribe TT. Further properly designed and sized 
      studies are warranted.
FAU - Rubboli, Andrea
AU  - Rubboli A
AD  - Division of Cardiology, Laboratory of Interventional Cardiology, Ospedale 
      Maggiore, Largo Nigrisoli 2, 40133 Bologna, Italy. andrearubboli@libero.it.
FAU - Saia, Francesco
AU  - Saia F
FAU - Sciahbasi, Alessandro
AU  - Sciahbasi A
FAU - Bacchi-Reggiani, Maria Letizia
AU  - Bacchi-Reggiani ML
FAU - Steffanon, Luigi
AU  - Steffanon L
FAU - Briguori, Carlo
AU  - Briguori C
FAU - Calabrò, Paolo
AU  - Calabrò P
FAU - Palmieri, Cataldo
AU  - Palmieri C
FAU - Rizzi, Andrea
AU  - Rizzi A
FAU - Imperadore, Ferdinando
AU  - Imperadore F
FAU - Sangiorgi, Giuseppe M
AU  - Sangiorgi GM
FAU - Valgimigli, Marco
AU  - Valgimigli M
FAU - Carosio, Giuseppe
AU  - Carosio G
FAU - Steffenino, Giuseppe
AU  - Steffenino G
FAU - Galvani, Marcello
AU  - Galvani M
FAU - Di Pasquale, Giuseppe
AU  - Di Pasquale G
FAU - La Vecchia, Luigi
AU  - La Vecchia L
FAU - Maggioni, Aldo P
AU  - Maggioni AP
FAU - Bolognese, Leonardo
AU  - Bolognese L
CN  - WARfarin and Coronary STENTing (WAR-STENT) Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT00722319
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Invasive Cardiol
JT  - The Journal of invasive cardiology
JID - 8917477
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Databases, Bibliographic
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Prospective Studies
MH  - Registries
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
MH  - Warfarin/*adverse effects/*therapeutic use
FIR - Rubboli, Andrea
IR  - Rubboli A
FIR - Di Pasquale, Giuseppe
IR  - Di Pasquale G
FIR - Steffenino, Giuseppe
IR  - Steffenino G
FIR - Mistrorigo, Stefano
IR  - Mistrorigo S
FIR - La Vecchia, Luigi
IR  - La Vecchia L
FIR - D'Andrea, Davide
IR  - D'Andrea D
FIR - Grasso, Salvatore
IR  - Grasso S
FIR - Maggiolini, Stefano
IR  - Maggiolini S
FIR - Sciahbasi, Alessandro
IR  - Sciahbasi A
FIR - Lioy, Ernesto
IR  - Lioy E
FIR - Caiazzo, Gianluca
IR  - Caiazzo G
FIR - Briguori, Carlo
IR  - Briguori C
FIR - Franco, Nicoletta
IR  - Franco N
FIR - Piovaccari, Giancarlo
IR  - Piovaccari G
FIR - Basile, Eloisa
IR  - Basile E
FIR - Leone, Antonio M
IR  - Leone AM
FIR - Nicolino, Annamaria
IR  - Nicolino A
FIR - Moshiri, Sharham
IR  - Moshiri S
FIR - Mameli, Stefano
IR  - Mameli S
FIR - Steffanon, Luigi
IR  - Steffanon L
FIR - Benassi, Alberto
IR  - Benassi A
FIR - Cannarozzo, Pierpaolo
IR  - Cannarozzo P
FIR - Carosio, Giuseppe
IR  - Carosio G
FIR - Pasqualini, Paola
IR  - Pasqualini P
FIR - Severi, Silva
IR  - Severi S
FIR - Ducci, Kenneth
IR  - Ducci K
FIR - Bolognese, Leonardo
IR  - Bolognese L
FIR - Capecchi, Alessandro
IR  - Capecchi A
FIR - Pancaldi, Leonardo G
IR  - Pancaldi LG
FIR - Vignali, Luigi
IR  - Vignali L
FIR - Ardissino, Diego
IR  - Ardissino D
FIR - Saia, Francesco
IR  - Saia F
FIR - Bordoni, Barbara
IR  - Bordoni B
FIR - Marzocchi, Antonio
IR  - Marzocchi A
FIR - Varani, Elisabetta
IR  - Varani E
FIR - Margheri, Massimo
IR  - Margheri M
FIR - Piccalò, Giacomo
IR  - Piccalò G
FIR - Mafrici, Antonio
IR  - Mafrici A
FIR - Calabrò, Paolo
IR  - Calabrò P
FIR - Sordelli, Chiara
IR  - Sordelli C
FIR - Boarin, Simona
IR  - Boarin S
FIR - Galvani, Marcello
IR  - Galvani M
FIR - Catanzariti, Pasquale
IR  - Catanzariti P
FIR - Tartagni, Flavio
IR  - Tartagni F
FIR - Santi, Michela
IR  - Santi M
FIR - Casa, Stefano Della
IR  - Casa SD
FIR - Palmieri, Cataldo
IR  - Palmieri C
FIR - Bovenzi, Francesco
IR  - Bovenzi F
FIR - Rizzi, Andrea
IR  - Rizzi A
FIR - Cuccia, Claudio
IR  - Cuccia C
FIR - Imperadore, Ferdinando
IR  - Imperadore F
FIR - Monti, Monia
IR  - Monti M
FIR - Valgimigli, Marco
IR  - Valgimigli M
FIR - Magnavacchi, Paolo
IR  - Magnavacchi P
FIR - Dallago, Michele
IR  - Dallago M
FIR - Bonmassari, Roberto
IR  - Bonmassari R
FIR - Sbarzaglia, Paolo
IR  - Sbarzaglia P
FIR - Cavallini, Claudio
IR  - Cavallini C
FIR - Russolillo, Enrico
IR  - Russolillo E
FIR - Lambertini, Simona
IR  - Lambertini S
FIR - Sangiorgi, Giuseppe M
IR  - Sangiorgi GM
FIR - Rubartelli, Paolo
IR  - Rubartelli P
EDAT- 2014/11/05 06:00
MHDA- 2016/12/15 06:00
CRDT- 2014/11/04 06:00
PHST- 2014/11/04 06:00 [entrez]
PHST- 2014/11/05 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
PST - ppublish
SO  - J Invasive Cardiol. 2014 Nov;26(11):563-9.

PMID- 17221106
OWN - NLM
STAT- MEDLINE
DCOM- 20080221
LR  - 20190917
IS  - 0004-2730 (Print)
IS  - 0004-2730 (Linking)
VI  - 50
IP  - 6
DP  - 2006 Dec
TI  - Aspirin therapy is still underutilized among patients with type 2 diabetes.
PG  - 1014-9
AB  - The daily use of aspirin in patients with type 2 diabetes mellitus (DM2) reduces 
      significantly cardiovascular events (CVE). In the absence of contraindications, 
      American Diabetes Association (ADA) recommends the use of aspirin to all DM2 
      patients older than 40 years of age. To evaluate aspirin use among 636 out 
      patients with DM2 who participate in a regional multicenter study in Southern 
      Brazil, a standard questionnaire was used. Patients also underwent a physical 
      examination and laboratorial tests. All patients were older than 40 years (mean 
      58 +/- 11 years old; 42% male) and by ADA guidelines most of them should be using 
      aspirin. However, only 177 (27.5%) were on this medication. The use of aspirin 
      was higher when any CVE were present. However, the percentage of users was still 
      below the expected, not even reaching 50%. In conclusion, even though the use of 
      aspirin is greater in patients with CVE, and its benefits are well documented, it 
      is still underutilized. Strategies to enhance the use of aspirin should be 
      developed to reduce the morbidity and mortality from cardiovascular diseases in 
      patients with DM2.
FAU - Leitão, Cristiane B
AU  - Leitão CB
AD  - Endocrinology Division, Hospital de Clinicas de Porto Alegre.
FAU - Krahe, Ana L
AU  - Krahe AL
FAU - Nabinger, Gustavo B
AU  - Nabinger GB
FAU - Picon, Paula X
AU  - Picon PX
FAU - Pecis, Miriam
AU  - Pecis M
FAU - Zaslavsky, Lérida M
AU  - Zaslavsky LM
FAU - Gross, Jorge L
AU  - Gross JL
FAU - Canani, Luis H
AU  - Canani LH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Brazil
TA  - Arq Bras Endocrinol Metabol
JT  - Arquivos brasileiros de endocrinologia e metabologia
JID - 0403437
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/*therapeutic use
MH  - Brazil
MH  - Cardiovascular Diseases/*prevention & control
MH  - Contraindications
MH  - Diabetes Mellitus, Type 2/diagnosis/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Societies, Medical
MH  - Surveys and Questionnaires
MH  - United States
EDAT- 2007/01/16 09:00
MHDA- 2008/02/22 09:00
CRDT- 2007/01/16 09:00
PHST- 2005/10/06 00:00 [received]
PHST- 2006/07/10 00:00 [accepted]
PHST- 2007/01/16 09:00 [pubmed]
PHST- 2008/02/22 09:00 [medline]
PHST- 2007/01/16 09:00 [entrez]
AID - S0004-27302006000600006 [pii]
AID - 10.1590/s0004-27302006000600006 [doi]
PST - ppublish
SO  - Arq Bras Endocrinol Metabol. 2006 Dec;50(6):1014-9. doi: 
      10.1590/s0004-27302006000600006.

PMID- 1531663
OWN - NLM
STAT- MEDLINE
DCOM- 19920331
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 19
IP  - 3
DP  - 1992 Mar 1
TI  - Effects of aspirin on coronary reocclusion and recurrent ischemia after 
      thrombolysis: a meta-analysis.
PG  - 671-7
AB  - Reocclusion of infarct-related coronary arteries within 2 weeks of thrombolytic 
      therapy varies from 5% to 45% and neither clinical nor angiographic variables 
      have been proved to be predictive of reocclusion. The goal of the present study 
      was to evaluate whether aspirin could prevent coronary reocclusion and recurrent 
      ischemia after thrombolysis. For this purpose, a meta-analysis including 32 
      studies was performed. Although the studies showed very similar demographic data, 
      the reocclusion rate assessed by angiography in 419 patients treated with aspirin 
      was 11% compared with 25% in 513 patients without aspirin therapy (p less than 
      0.001). Recurrent ischemic events were present in 25% of 2,977 patients treated 
      with aspirin and 41% of 721 patients treated without aspirin (p less than 0.001). 
      The effect of aspirin was similar in trials with either streptokinase or 
      recombinant tissue-type plasminogen activator (rt-PA). Thus, aspirin in the 
      presence of heparin might prevent coronary reocclusion after thrombolysis.
FAU - Roux, S
AU  - Roux S
AD  - Pharmaceutical Research Department, F. Hoffmann-La Roche, Ltd., Basel, 
      Switzerland.
FAU - Christeller, S
AU  - Christeller S
FAU - Lüdin, E
AU  - Lüdin E
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - EC 3.4.- (Streptokinase)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 1992 Dec;20(7):1679. PMID: 1452944
CIN - J Am Coll Cardiol. 1992 Mar 1;19(3):678-80. PMID: 1538027
MH  - Angina Pectoris/epidemiology/prevention & control
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Coronary Thrombosis/complications/epidemiology/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/etiology
MH  - Recurrence
MH  - Streptokinase/therapeutic use
MH  - *Thrombolytic Therapy
MH  - Tissue Plasminogen Activator/therapeutic use
MH  - Treatment Outcome
MH  - Vascular Patency/drug effects
EDAT- 1992/03/01 00:00
MHDA- 1992/03/01 00:01
CRDT- 1992/03/01 00:00
PHST- 1992/03/01 00:00 [pubmed]
PHST- 1992/03/01 00:01 [medline]
PHST- 1992/03/01 00:00 [entrez]
AID - S0735-1097(10)80290-6 [pii]
AID - 10.1016/s0735-1097(10)80290-6 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1992 Mar 1;19(3):671-7. doi: 10.1016/s0735-1097(10)80290-6.

PMID- 7739307
OWN - NLM
STAT- MEDLINE
DCOM- 19950607
LR  - 20220318
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 345
IP  - 8959
DP  - 1995 May 13
TI  - Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin 
      in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) 
      Refrattorie Group.
PG  - 1201-4
AB  - Intravenous heparin has been used in the control of myocardial ischaemia in 
      patients with unstable angina. We set out to assess the efficacy of subcutaneous 
      heparin in reducing myocardial ischaemia in patients with unstable angina. 343 of 
      399 patients with unstable angina were monitored for 24 h and 108 were refractory 
      to conventional antianginal treatment and were entered into a randomised 
      multicentre trial. 37 patients were assigned to heparin infusion (partial 
      thromboplastin time 1.5-2 times baseline), 35 to subcutaneous heparin (adjusted 
      dose with partial thromboplastin time 1.5-2 times baseline), and 36 to aspirin 
      (325 mg daily). All had additional conventional antianginal therapy. After the 
      run-in patients were monitored for 3 days. The primary endpoint was reduced 
      myocardial ischaemia assessed by the number of anginal attacks, silent ischaemic 
      episodes, and duration of ischaemia per day. At 1 week and 1 month we accounted 
      for anginal attacks and other clinical events (myocardial infarction, 
      revascularisation procedures, and death). Aspirin did not significantly affect 
      the incidence of myocardial ischaemia. On the first 3 days, infused and 
      subcutaneous heparin significantly decreased the frequency of angina (on average 
      by 91% and 86%, respectively), episodes of silent ischaemia (by 56% and 46%), and 
      the overall duration of ischaemia (66% and 61%) versus run-in day and aspirin (p 
      < 0.001 for all variables). The favourable effects of heparin therapy remained 
      evident during follow-up. Only minor bleeding complications occurred. 
      Subcutaneous heparin is effective in the control of myocardial ischaemia in 
      patients with unstable angina.
FAU - Neri Serneri, G G
AU  - Neri Serneri GG
AD  - Clinica Medica and Cardiologia, University of Florence, Italy.
FAU - Modesti, P A
AU  - Modesti PA
FAU - Gensini, G F
AU  - Gensini GF
FAU - Branzi, A
AU  - Branzi A
FAU - Melandri, G
AU  - Melandri G
FAU - Poggesi, L
AU  - Poggesi L
FAU - Rostagno, C
AU  - Rostagno C
FAU - Tamburini, C
AU  - Tamburini C
FAU - Carnovali, M
AU  - Carnovali M
FAU - Magnani, B
AU  - Magnani B
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Lancet 1995 Jul 8;346(8967):130
CIN - Lancet. 1995 Jul 22;346(8969):248; author reply 249. PMID: 7616817
CIN - Lancet. 1995 Jul 22;346(8969):248; author reply 249. PMID: 7616818
MH  - Angina, Unstable/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Infusions, Intravenous
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/drug therapy
MH  - Treatment Outcome
EDAT- 1995/05/13 00:00
MHDA- 1995/05/13 00:01
CRDT- 1995/05/13 00:00
PHST- 1995/05/13 00:00 [pubmed]
PHST- 1995/05/13 00:01 [medline]
PHST- 1995/05/13 00:00 [entrez]
AID - S0140-6736(95)91990-2 [pii]
AID - 10.1016/s0140-6736(95)91990-2 [doi]
PST - ppublish
SO  - Lancet. 1995 May 13;345(8959):1201-4. doi: 10.1016/s0140-6736(95)91990-2.

PMID- 6123327
OWN - NLM
STAT- MEDLINE
DCOM- 19820708
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 31
IP  - 6
DP  - 1982 Mar 15
TI  - Selective actions of aspirin- and sulphasalazine-like drugs against prostaglandin 
      synthesis and breakdown.
PG  - 969-71
AB  - Groups of ten aspirin- and five sulphasalazine-like drugs were tested as 
      inhibitors of prostaglandin synthesis (rabbit renal medulla 14,000 g 
      supernatants) and prostaglandin breakdown (rabbit colon 100,000 g supernatants). 
      The aspirin-like drugs exhibited selectivity against synthesis but all also 
      inhibited breakdown at higher doses. The sulphasalazine-like drugs (including 
      diphloretin phosphate and carbenoxolone) exhibited selectivity against breakdown 
      and some, but not all, inhibited synthesis at higher doses. It is proposed that 
      there are accordingly two pharmacologically distinct groups of drugs, and that 
      they can be characterised by the ratios of ID50S against breakdown and synthesis 
      (M/S ratio).
FAU - Moore, P K
AU  - Moore PK
FAU - Hoult, J R
AU  - Hoult JR
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Prostaglandin Antagonists)
RN  - 0 (Prostaglandins)
RN  - 39201-04-2 (diphloretin phosphate)
RN  - 3XC8GUZ6CB (Sulfasalazine)
RN  - 9014-72-6 (Polyphloretin Phosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Male
MH  - Polyphloretin Phosphate/pharmacology
MH  - Prostaglandin Antagonists/*pharmacology
MH  - Prostaglandins/*metabolism
MH  - Rabbits
MH  - Sulfasalazine/*pharmacology
EDAT- 1982/03/15 00:00
MHDA- 1982/03/15 00:01
CRDT- 1982/03/15 00:00
PHST- 1982/03/15 00:00 [pubmed]
PHST- 1982/03/15 00:01 [medline]
PHST- 1982/03/15 00:00 [entrez]
AID - 0006-2952(82)90329-X [pii]
AID - 10.1016/0006-2952(82)90329-x [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1982 Mar 15;31(6):969-71. doi: 10.1016/0006-2952(82)90329-x.

PMID- 7409302
OWN - NLM
STAT- MEDLINE
DCOM- 19801124
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 8
IP  - 4
DP  - 1980
TI  - Effect of ibuprofen or aspirin on probenecid-induced uricosuria.
PG  - 283-5
AB  - We dosed eight normal volunteers with single doses of probenecid alone and with 
      aspirin or ibuprofen. Urinary urate clearance was increased by probenecid. This 
      increase was partially inhibited by aspirin but not by ibuprofen.
FAU - Brooks, C D
AU  - Brooks CD
FAU - Ulrich, J E
AU  - Ulrich JE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 268B43MJ25 (Uric Acid)
RN  - AYI8EX34EU (Creatinine)
RN  - PO572Z7917 (Probenecid)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Creatinine/urine
MH  - Female
MH  - Humans
MH  - Ibuprofen/*pharmacology
MH  - Male
MH  - Pilot Projects
MH  - *Probenecid
MH  - Uric Acid/*urine
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1177/030006058000800407 [doi]
PST - ppublish
SO  - J Int Med Res. 1980;8(4):283-5. doi: 10.1177/030006058000800407.

PMID- 6856771
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20131121
IS  - 0033-7587 (Print)
IS  - 0033-7587 (Linking)
VI  - 94
IP  - 1
DP  - 1983 Apr
TI  - The effect of X rays, DTPA, and aspirin on the absorption of plutonium from the 
      gastrointestinal tract of rats.
PG  - 89-96
AB  - To measure the effect of radiation on plutonium transport, rats that were exposed 
      to 250-kVp X rays were given 238Pu 3 days afterwards by either gavage or 
      injection into a ligated segment of the duodenum. In a second group of 
      experiments, rats were either injected intraduodenally with 238Pu-DTPA or 
      administered the chelate intravenously and the 238Pu by gavage. In a third 
      experiment, rats that had been gavaged with 200 or 400 mg/kg/day of aspirin for 2 
      days were injected intragastrically with 238Pu nitrate. Results of the first 
      experiment showed a dose-dependent increase in 238Pu absorption between 800 and 
      1500 rad of lower-body X irradiation. Intravenous or intraduodenal injections of 
      DTPA caused a marked increase in 238Pu absorption but resulted in decreased 
      plutonium deposition in the skeleton and liver. Retention of 238Pu in the 
      skeleton of rats given aspirin was double that of controls, but the effect on 
      plutonium absorption was less marked than that of DTPA.
FAU - Sullivan, M F
AU  - Sullivan MF
FAU - Gorham, L S
AU  - Gorham LS
FAU - Miller, B M
AU  - Miller BM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Radiat Res
JT  - Radiation research
JID - 0401245
RN  - 53023GN24M (Plutonium)
RN  - 7A314HQM0I (Pentetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Biological Transport
MH  - Digestive System/*metabolism
MH  - Female
MH  - Intestinal Absorption
MH  - Pentetic Acid/*pharmacology
MH  - Plutonium/*metabolism
MH  - *Radiation, Ionizing
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Therapeutic Irrigation
MH  - *X-Rays
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
PST - ppublish
SO  - Radiat Res. 1983 Apr;94(1):89-96.

PMID- 136263
OWN - NLM
STAT- MEDLINE
DCOM- 19770129
LR  - 20190509
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 2
IP  - 3
DP  - 1975 Jun
TI  - Kinetics of salicylate metabolism.
PG  - 233-8
AB  - 1 Nine patients with rheumatoid arthritis or non-inflammatory backache were given 
      soluble aspirin (65 mg/kg body weight) daily. There was no significant difference 
      between the plasma salicylate of those with rheumatoid arthritis and those with 
      backache. 2 Two patients had plasma salicylate values that differed significantly 
      from the remainder but neither these results nor the marginal differences between 
      plasma salicylate levels of the others could be explained by individual 
      variations in the capacity for excreting salicyluric acid or salicyl phenolic 
      glucuronide. 3 Increasing the dose of aspirin in four patients demonstrated the 
      reduced proportions of salicyluric acid and salicyl phenolic glucuronide excreted 
      at high doses and the increased importance of unchanged salicylic acid as an 
      excretory pathway. These findings are consistent with a limiting capacity for 
      salicyluric acid and salicyl phenolic glucuronide synthesis and excretion. 4 The 
      findings in one patient suggested that inter-subject variations in the capacity 
      for producing salicyl phenolic glucuronide and salicyluric acid may have an 
      effect on plasma salicylate levels at high doses of aspirin.
FAU - Gibson, T
AU  - Gibson T
FAU - Zaphiropoulos, G
AU  - Zaphiropoulos G
FAU - Grove, J
AU  - Grove J
FAU - Widdop, B
AU  - Widdop B
FAU - Berry, D
AU  - Berry D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/metabolism
MH  - Aspirin/metabolism
MH  - Back Pain/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/*metabolism
PMC - PMC1402571
EDAT- 1975/06/01 00:00
MHDA- 1975/06/01 00:01
CRDT- 1975/06/01 00:00
PHST- 1975/06/01 00:00 [pubmed]
PHST- 1975/06/01 00:01 [medline]
PHST- 1975/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1975.tb01581.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1975 Jun;2(3):233-8. doi: 
      10.1111/j.1365-2125.1975.tb01581.x.

PMID- 33632886
OWN - NLM
STAT- MEDLINE
DCOM- 20211019
LR  - 20220531
IS  - 1759-8486 (Electronic)
IS  - 1759-8478 (Print)
IS  - 1759-8478 (Linking)
VI  - 13
IP  - 11
DP  - 2021 Nov
TI  - Reduction of thromboembolic complications during the endovascular treatment of 
      unruptured aneurysms by employing a tailored dual antiplatelet regimen using 
      aspirin and prasugrel.
PG  - 1044-1048
LID - 10.1136/neurintsurg-2020-016994 [doi]
AB  - BACKGROUND: Thromboembolic complications (TECs) are frequent during the 
      endovascular treatment of unruptured aneurysms. To prevent TECs, dual 
      antiplatelet therapy using aspirin and clopidogrel is recommended for the 
      perioperative period. In patients with a poor response, clopidogrel is a risk 
      factor for TECs. To prevent TECs, our study assessed the stratified use of 
      prasugrel. METHODS: Patients who underwent endovascular therapy for unruptured 
      cerebral aneurysms from April 2017 to August 2019 were enrolled in this clinical 
      study and given premedication with aspirin and clopidogrel for 2 weeks prior to 
      the procedure. P2Y12 reaction units (PRU) were measured using the VerifyNow assay 
      on the day before the procedure (tailored group). In subgroups with PRU <240, the 
      clopidogrel dose was maintained (CPG subgroup). In subgroups with PRU ≥240, 
      clopidogrel was changed to prasugrel (PSG subgroup). We compared the occurrence 
      of TECs with retrospective consecutive cases from January 2015 to March 2017 
      without PRU assessments (non-tailored group). The frequency of TECs within 30 
      days was assessed as the primary endpoint. RESULTS: The tailored and non-tailored 
      groups comprised 167 and 50 patients, respectively. TECs occurred in 11 (6.6%) 
      and 8 (16%) patients in the tailored and non-tailored groups (P=0.048), 
      respectively. The HR for TECs was significantly reduced in the tailored group (HR 
      0.3, 95% CI 0.11 to 0.81); P=0.017) compared with the non-tailored group. 
      CONCLUSION: The results suggest that tailored dual antiplatelet therapy 
      medication with PRU significantly reduces the frequency of TECs without 
      increasing hemorrhagic complications.
CI  - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Higashiguchi, Saeko
AU  - Higashiguchi S
AUID- ORCID: 0000-0001-8887-0681
AD  - Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
FAU - Sadato, Akiyo
AU  - Sadato A
AD  - Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan 
      asadato@fujita-hu.ac.jp.
FAU - Nakahara, Ichiro
AU  - Nakahara I
AD  - Department of Comprehensive Strokology, Fujita Health University, Toyoake, Aichi, 
      Japan.
FAU - Matsumoto, Shoji
AU  - Matsumoto S
AD  - Department of Comprehensive Strokology, Fujita Health University, Toyoake, Aichi, 
      Japan.
FAU - Hayakawa, Motoharu
AU  - Hayakawa M
AD  - Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
FAU - Adachi, Kazuhide
AU  - Adachi K
AD  - Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
FAU - Hasebe, Akiko
AU  - Hasebe A
AD  - Department of Comprehensive Strokology, Fujita Health University, Toyoake, Aichi, 
      Japan.
FAU - Suyama, Yoshio
AU  - Suyama Y
AD  - Department of Comprehensive Strokology, Fujita Health University, Toyoake, Aichi, 
      Japan.
FAU - Omi, Tatsuo
AU  - Omi T
AD  - Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
FAU - Yamashiro, Kei
AU  - Yamashiro K
AUID- ORCID: 0000-0002-6871-0792
AD  - Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
FAU - Wakako, Akira
AU  - Wakako A
AD  - Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
FAU - Ishihara, Takuma
AU  - Ishihara T
AD  - Innovative and Clinical Research Promotion Center, Gifu University Hospital, 
      Gifu, Gifu, Japan.
FAU - Kawazoe, Yushi
AU  - Kawazoe Y
AD  - Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
FAU - Kumai, Tadashi
AU  - Kumai T
AD  - Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
FAU - Tanabe, Jun
AU  - Tanabe J
AUID- ORCID: 0000-0002-5015-8573
AD  - Department of Comprehensive Strokology, Fujita Health University, Toyoake, Aichi, 
      Japan.
FAU - Suyama, Kenichiro
AU  - Suyama K
AD  - Department of Comprehensive Strokology, Fujita Health University, Toyoake, Aichi, 
      Japan.
FAU - Watanabe, Sadayoshi
AU  - Watanabe S
AUID- ORCID: 0000-0001-5763-5849
AD  - Department of Comprehensive Strokology, Fujita Health University, Toyoake, Aichi, 
      Japan.
FAU - Suzuki, Takeya
AU  - Suzuki T
AD  - Department of Comprehensive Strokology, Fujita Health University, Toyoake, Aichi, 
      Japan.
FAU - Hirose, Yuichi
AU  - Hirose Y
AD  - Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210225
PL  - England
TA  - J Neurointerv Surg
JT  - Journal of neurointerventional surgery
JID - 101517079
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/therapeutic use
MH  - Humans
MH  - *Intracranial Aneurysm/drug therapy/surgery
MH  - Platelet Aggregation Inhibitors
MH  - Prasugrel Hydrochloride/therapeutic use
MH  - Retrospective Studies
PMC - PMC8526880
OTO - NOTNLM
OT  - aneurysm
OT  - catheter
OT  - embolic
OT  - hemorrhage
OT  - intervention
COIS- Competing interests: None declared.
EDAT- 2021/02/27 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/02/26 05:54
PHST- 2020/10/17 00:00 [received]
PHST- 2021/01/05 00:00 [revised]
PHST- 2021/01/09 00:00 [accepted]
PHST- 2021/02/27 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/02/26 05:54 [entrez]
AID - neurintsurg-2020-016994 [pii]
AID - 10.1136/neurintsurg-2020-016994 [doi]
PST - ppublish
SO  - J Neurointerv Surg. 2021 Nov;13(11):1044-1048. doi: 
      10.1136/neurintsurg-2020-016994. Epub 2021 Feb 25.

PMID- 7115637
OWN - NLM
STAT- MEDLINE
DCOM- 19821203
LR  - 20190719
IS  - 0306-5456 (Print)
IS  - 0306-5456 (Linking)
VI  - 89
IP  - 9
DP  - 1982 Sep
TI  - Aggregation of human platelets by amniotic fluid.
PG  - 733-7
AB  - Twenty-four amniotic fluid samples were examined for their effects on human 
      platelets. All samples caused irreversible platelet aggregation. The active 
      material precipitated with high-speed ultracentrifugation and was completely 
      inhibited by prior incubation with purified collagenase. The presence of free 
      collagen in amniotic fluid was further confirmed by polyacrylamide-gel 
      electrophoresis and hydroxyproline assays. Beside platelet-aggregating activity, 
      amniotic fluid samples were also shown to significantly shorten the 
      recalcification time of normal plasma. This procoagulant activity appears to be 
      related to the presence of thromboplastin, collagen and other as yet unidentified 
      procoagulant material in amniotic fluid. The presence of activators of platelets 
      and clotting factors in amniotic fluid would account for the strong 
      clot-promoting activity of this fluid. These studies suggest that the ideal 
      management of the coagulopathy of pregnancy should include a combination of 
      anticoagulant and antiplatelet drugs.
FAU - Salem, H H
AU  - Salem HH
FAU - Walters, W A
AU  - Walters WA
FAU - Perkin, J L
AU  - Perkin JL
FAU - Handley, C J
AU  - Handley CJ
FAU - Firkin, B G
AU  - Firkin BG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Obstet Gynaecol
JT  - British journal of obstetrics and gynaecology
JID - 7503752
RN  - 0 (Blood Coagulation Factors)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amniotic Fluid/analysis/*physiology
MH  - Aspirin/pharmacology
MH  - Blood Coagulation Factors
MH  - Collagen/analysis/physiology
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Humans
MH  - *Platelet Aggregation/drug effects
EDAT- 1982/09/01 00:00
MHDA- 1982/09/01 00:01
CRDT- 1982/09/01 00:00
PHST- 1982/09/01 00:00 [pubmed]
PHST- 1982/09/01 00:01 [medline]
PHST- 1982/09/01 00:00 [entrez]
AID - 10.1111/j.1471-0528.1982.tb05100.x [doi]
PST - ppublish
SO  - Br J Obstet Gynaecol. 1982 Sep;89(9):733-7. doi: 
      10.1111/j.1471-0528.1982.tb05100.x.

PMID- 18597839
OWN - NLM
STAT- MEDLINE
DCOM- 20081028
LR  - 20221207
IS  - 1096-0260 (Electronic)
IS  - 0091-7435 (Print)
IS  - 0091-7435 (Linking)
VI  - 47
IP  - 2
DP  - 2008 Aug
TI  - Does differential prophylactic aspirin use contribute to racial and geographic 
      disparities in stroke and coronary heart disease (CHD)?
PG  - 161-6
LID - 10.1016/j.ypmed.2008.05.009 [doi]
AB  - CONTEXT: Aspirin use may reduce the risk of stroke and coronary heart disease. 
      Differential use for vascular prophylaxis may contribute to racial and geographic 
      disparities in stroke and coronary heart disease morbidity or mortality. 
      OBJECTIVE: To assess the prevalence and predictors of aspirin use for primary 
      prophylaxis of stroke in the general population free of clinically diagnosed 
      stroke or coronary heart disease. DESIGN AND SETTING: Cross-sectional analysis of 
      16,908 participants (age 45 or greater), from a population-based national cohort 
      study (REasons for Geographic And Racial Differences in Stroke) enrolled from 
      February 2003-August 2006 with oversampling from the southeastern Stroke Belt and 
      African Americans. Individuals with a prior stroke or coronary heart disease, or 
      regular use of aspirin for pain relief were excluded from analyses. MAIN OUTCOME 
      MEASURES: Aspirin use and reasons for use were assessed using a computer-assisted 
      telephone interview. RESULTS: Prophylactic aspirin use was substantially higher 
      among whites (34.7%) than African Americans (27.2%; p<0.0001). There was a higher 
      prevalence of aspirin use for prophylaxis in the Stroke Belt (32.1%) than in the 
      rest of the nation (30.8%; p=0.07). After adjustment for measures of 
      socio-economic status, the odds ratio of aspirin use in the rest of the nation 
      compared to Stroke Belt was 0.90 (95% CI 0.84-0.97). There was a higher 
      likelihood of prophylactic aspirin use among participants who were white, male, 
      older, past cigarette smokers, or of higher socio-economic status (higher income 
      or education). CONCLUSIONS: In this study, aspirin use to prevent stroke and 
      coronary heart disease was higher among whites than African Americans, raising 
      the possibility that differential aspirin use could contribute to the racial 
      disparities in vascular disease mortality. Counter to our hypothesis, aspirin use 
      was more common in the Stroke Belt than the rest of the country, so differential 
      aspirin use in the Stroke Belt is unlikely to contribute to geographic 
      disparities in stroke.
FAU - Glasser, Stephen P
AU  - Glasser SP
AD  - Preventive Medicine and Epidemiology, University of Alabama at Birmingham, 
      Birmingham, Alabama 35205, USA. sglasser@uab.edu
FAU - Cushman, Mary
AU  - Cushman M
FAU - Prineas, Ronald
AU  - Prineas R
FAU - Kleindorfer, Dawn
AU  - Kleindorfer D
FAU - Prince, Valerie
AU  - Prince V
FAU - You, Zhiying
AU  - You Z
FAU - Howard, Virginia J
AU  - Howard VJ
FAU - Howard, George
AU  - Howard G
LA  - eng
GR  - R01 HL080477/HL/NHLBI NIH HHS/United States
GR  - U01 NS041588/NS/NINDS NIH HHS/United States
GR  - U01 NS041588-06/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20080527
PL  - United States
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Black or African American
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Disease/ethnology/mortality/*prevention & control
MH  - Cross-Sectional Studies
MH  - *Geography
MH  - *Health Status Disparities
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Stroke/ethnology/mortality/*prevention & control
MH  - United States/epidemiology
MH  - *White People
PMC - PMC2556126
MID - NIHMS66053
EDAT- 2008/07/04 09:00
MHDA- 2008/10/29 09:00
CRDT- 2008/07/04 09:00
PHST- 2008/01/06 00:00 [received]
PHST- 2008/04/29 00:00 [revised]
PHST- 2008/05/19 00:00 [accepted]
PHST- 2008/07/04 09:00 [pubmed]
PHST- 2008/10/29 09:00 [medline]
PHST- 2008/07/04 09:00 [entrez]
AID - S0091-7435(08)00269-7 [pii]
AID - 10.1016/j.ypmed.2008.05.009 [doi]
PST - ppublish
SO  - Prev Med. 2008 Aug;47(2):161-6. doi: 10.1016/j.ypmed.2008.05.009. Epub 2008 May 
      27.

PMID- 2956834
OWN - NLM
STAT- MEDLINE
DCOM- 19870909
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 60
IP  - 3
DP  - 1987 Jul 31
TI  - Restenosis after arterial angioplasty: a hemorrheologic response to injury.
PG  - 10B-16B
AB  - Restenosis after arterial angioplasty appears to be a response to deep arterial 
      injury, which is much more thrombogenic than superficial injury (endothelial 
      denudation). Deep arterial injury exposes collagen, elastin and smooth muscle 
      cells to circulating blood, releases tissue thromboplastin and causes immediate 
      platelet-thrombus deposition as a result of activation of platelets and the 
      clotting system, both of which mutually facilitate activation of the other. 
      Regrowth of endothelium also is protective against platelet deposition. Platelet 
      adherence to collagen, and thus to the arterial wall that is deeply injured, 
      increases with shear rate (related inversely to the fourth power of luminal 
      cross-sectional area and directly to blood flow); thus, the effect of shear rate 
      increases the importance of adequate dilatation at the time of the procedure. 
      Therapy that will reduce acute platelet-thrombus deposition appears to be an 
      important factor for reduction of restenosis. Vasoconstriction occurs 
      experimentally after arterial angioplasty in arterial segments proximal and 
      distal to the dilated segment where there has been no necrosis of smooth muscle 
      cells. The vasoconstriction is directly related to the severity of platelet 
      deposition, can be reduced by reducing platelet deposition with low dose aspirin 
      (1 mg/kg daily) and is probably mediated by vasoconstrictor substances from 
      platelets (thromboxane A2, serotonin and other substances). Platelet-membrane 
      receptor inhibitors to these substances reduce the vasoconstriction but do not 
      reduce platelet deposition. Therapeutic intervention should probably involve both 
      anticoagulation and platelet inhibition. Platelet-membrane receptor inhibition to 
      the fibrinogen receptor, factor VIII-von Willebrand factor or both may be 
      necessary acutely to sufficiently reduce acute platelet-thrombus deposition.
FAU - Chesebro, J H
AU  - Chesebro JH
FAU - Lam, J Y
AU  - Lam JY
FAU - Badimon, L
AU  - Badimon L
FAU - Fuster, V
AU  - Fuster V
LA  - eng
GR  - CRC-RR585/RR/NCRR NIH HHS/United States
GR  - HL 17430/HL/NHLBI NIH HHS/United States
GR  - HL 31025/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon
MH  - Animals
MH  - Arterial Occlusive Diseases/pathology/*therapy
MH  - Arteries/*injuries
MH  - Aspirin/therapeutic use
MH  - Microscopy, Electron, Scanning
MH  - Platelet Adhesiveness
MH  - Platelet Aggregation
MH  - Recurrence
MH  - Rheology
MH  - Swine
MH  - Thrombosis/etiology
MH  - Vasoconstriction
EDAT- 1987/07/31 00:00
MHDA- 1987/07/31 00:01
CRDT- 1987/07/31 00:00
PHST- 1987/07/31 00:00 [pubmed]
PHST- 1987/07/31 00:01 [medline]
PHST- 1987/07/31 00:00 [entrez]
AID - 0002-9149(87)90477-2 [pii]
AID - 10.1016/0002-9149(87)90477-2 [doi]
PST - ppublish
SO  - Am J Cardiol. 1987 Jul 31;60(3):10B-16B. doi: 10.1016/0002-9149(87)90477-2.

PMID- 23831164
OWN - NLM
STAT- MEDLINE
DCOM- 20131203
LR  - 20161125
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 112
IP  - 8
DP  - 2013 Oct 15
TI  - Effect of baseline gastrointestinal risk and use of proton pump inhibitors on 
      frequency of discontinuation of aspirin for secondary cardiovascular prevention 
      in United kingdom primary care.
PG  - 1075-82
LID - S0002-9149(13)01276-9 [pii]
LID - 10.1016/j.amjcard.2013.05.051 [doi]
AB  - For patients at high cardiovascular and high gastrointestinal (GI) risk, 
      coprescription of a proton pump inhibitor (PPI) with low-dose aspirin is 
      recommended. We aimed to quantify the extent to which low-dose aspirin 
      discontinuation in patients at high cardiovascular risk is affected by PPI use 
      and baseline GI risk. Patients aged 50 to 84 years who had evidence of ischemic 
      heart disease or cardiovascular disease and who were new users of low-dose 
      aspirin in 2000 to 2007 were identified using The Health Improvement Network (n = 
      35,604). Aspirin discontinuation was defined as a period of at least 90 days 
      after completion of the last prescribed course during which no repeat 
      prescription was issued. The incidence of low-dose aspirin discontinuation was 
      26.8 per 100 person-years (95% confidence interval [CI] 26.2 to 27.4). The age-, 
      gender-, and indication-adjusted risk of aspirin discontinuation was 15% less 
      among continuous PPI users than among PPI nonusers (hazard ratio [HR] 0.85, 95% 
      CI 0.78 to 0.92); after further adjusting for number of coprescribed medications, 
      the HR was 0.95 (95% CI 0.87 to 1.03). Continuous PPI use was associated with a 
      reduced risk of aspirin discontinuation among patients at high GI risk (HR 0.83; 
      95% CI 0.74 to 0.93) but not among those at low GI risk (HR 1.08; 95% CI 0.96 to 
      1.21). In conclusion, among patients at high GI risk, concomitant users of 
      aspirin and PPI showed a greater aspirin adherence than aspirin users not on PPI. 
      Further studies need to confirm factors with the potential to increase adherence 
      to long-term aspirin.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Martín Merino, Elisa
AU  - Martín Merino E
AD  - Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.
FAU - Johansson, Saga
AU  - Johansson S
FAU - Nagy, Péter
AU  - Nagy P
FAU - García Rodríguez, Luis A
AU  - García Rodríguez LA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130704
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Diseases/chemically induced/drug therapy/*epidemiology
MH  - Gastrointestinal Tract/*drug effects
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Primary Health Care/*methods
MH  - Prognosis
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Secondary Prevention/*methods
MH  - Time Factors
MH  - United Kingdom/epidemiology
EDAT- 2013/07/09 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/07/09 06:00
PHST- 2013/04/05 00:00 [received]
PHST- 2013/05/29 00:00 [revised]
PHST- 2013/05/29 00:00 [accepted]
PHST- 2013/07/09 06:00 [entrez]
PHST- 2013/07/09 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - S0002-9149(13)01276-9 [pii]
AID - 10.1016/j.amjcard.2013.05.051 [doi]
PST - ppublish
SO  - Am J Cardiol. 2013 Oct 15;112(8):1075-82. doi: 10.1016/j.amjcard.2013.05.051. 
      Epub 2013 Jul 4.

PMID- 17884201
OWN - NLM
STAT- MEDLINE
DCOM- 20090827
LR  - 20161124
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 131
IP  - 1
DP  - 2008 Dec 17
TI  - Very late multivessel thrombosis of bare metal stents with concomitant patent 
      drug-eluting stents after withdrawal of aspirin.
PG  - e7-9
AB  - Very late stent thrombosis occurs in both drug eluting stent and bare metal 
      stent. Withdrawal of antiplatelet therapy appears to be a potent correlate of 
      late stent thrombosis that leads in majority of cases to acute myocardial 
      infarction or death. A case is reported of very late bare metal stents thrombosis 
      (33 months) in two different vessels after aspirin discontinuation because of a 
      prostatectomy in patient treated simultaneously with bare metal stents and 
      paclitaxel eluting stents, found patent. In conclusion, this case raise the 
      question on the possible need to continue the antiplatelet therapy performing 
      invasive or surgical procedures also in all patients treated with long-standing 
      coronary bare metal stent.
FAU - Rossi, Marco L
AU  - Rossi ML
FAU - Zavalloni, Dennis
AU  - Zavalloni D
FAU - Gasparini, Gabriele L
AU  - Gasparini GL
FAU - Presbitero, Patrizia
AU  - Presbitero P
LA  - eng
PT  - Case Reports
PT  - Letter
DEP - 20070919
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - *Drug-Eluting Stents/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Radiography
MH  - Stents/adverse effects
MH  - Substance Withdrawal Syndrome/*diagnostic imaging
MH  - Thrombosis/*diagnostic imaging
MH  - Time Factors
EDAT- 2007/09/22 09:00
MHDA- 2009/08/28 09:00
CRDT- 2007/09/22 09:00
PHST- 2007/04/23 00:00 [received]
PHST- 2007/06/30 00:00 [accepted]
PHST- 2007/09/22 09:00 [pubmed]
PHST- 2009/08/28 09:00 [medline]
PHST- 2007/09/22 09:00 [entrez]
AID - S0167-5273(07)01483-0 [pii]
AID - 10.1016/j.ijcard.2007.06.144 [doi]
PST - ppublish
SO  - Int J Cardiol. 2008 Dec 17;131(1):e7-9. doi: 10.1016/j.ijcard.2007.06.144. Epub 
      2007 Sep 19.

PMID- 24133627
OWN - NLM
STAT- MEDLINE
DCOM- 20140519
LR  - 20220321
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Print)
IS  - 2045-7634 (Linking)
VI  - 2
IP  - 1
DP  - 2013 Feb
TI  - Preventive effects of low-dose aspirin on colorectal adenoma growth in patients 
      with familial adenomatous polyposis: double-blind, randomized clinical trial.
PG  - 50-6
LID - 10.1002/cam4.46 [doi]
AB  - There are several reports of clinical trials of aspirin in sporadic colon cancer. 
      However, only one double-blind trial of aspirin in patients with familial 
      adenomatous polyposis (FAP) has been reported to date. This double-blind, 
      randomized, placebo-controlled clinical trial was therefore performed to evaluate 
      the influence of low-dose aspirin enteric-coated tablets (100 mg/day for 6-10 
      months) in 34 subjects with FAP (17 each in the aspirin and placebo groups). The 
      increase in mean diameter of colorectal polyps tended to be greater in the 
      placebo group compared with the aspirin group, which showed a response ratio, 
      that is, aspirin response rate (number of subjects with reduced 
      polyps/total)/placebo response rate (number of subjects with reduced 
      polyps/total), of 2.33 (95% confidence interval: 0.72-7.55). Subgroup analysis 
      revealed that the number of subjects with a mean baseline polyp diameter of ≤2 
      mm, and the diameter and number of polyps after intervention showed a significant 
      reduction in the aspirin group. Adverse effects of aspirin, such as anastomotic 
      ulcer, aphtha in the large intestine, and progression of anemia, occurred in 
      three subjects. Moreover, none of the subjects developed colorectal cancer. The 
      results thus indicated a potential for aspirin to reduce colorectal adenoma 
      development in patients with FAP, but careful follow-up is needed to avoid or 
      rapidly counter severe adverse effects.
FAU - Ishikawa, Hideki
AU  - Ishikawa H
AD  - Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical 
      Science, Kyoto Prefectural University of Medicine Kyoto, Japan.
FAU - Wakabayashi, Keiji
AU  - Wakabayashi K
FAU - Suzuki, Sadao
AU  - Suzuki S
FAU - Mutoh, Michihiro
AU  - Mutoh M
FAU - Hirata, Keiji
AU  - Hirata K
FAU - Nakamura, Tomiyo
AU  - Nakamura T
FAU - Takeyama, Ikuko
AU  - Takeyama I
FAU - Kawano, Atsuko
AU  - Kawano A
FAU - Gondo, Nobuhisa
AU  - Gondo N
FAU - Abe, Takashi
AU  - Abe T
FAU - Tokudome, Shinkan
AU  - Tokudome S
FAU - Goto, Chiho
AU  - Goto C
FAU - Matsuura, Nariaki
AU  - Matsuura N
FAU - Sakai, Toshiyuki
AU  - Sakai T
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130203
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/*prevention & control
MH  - Adenomatous Polyposis Coli/*drug therapy/pathology
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Anticarcinogenic Agents/administration & dosage/adverse effects/therapeutic use
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Colonoscopy
MH  - Colorectal Neoplasms/*prevention & control
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Selection
MH  - Tablets, Enteric-Coated
MH  - Treatment Outcome
PMC - PMC3797560
OTO - NOTNLM
OT  - Adenoma
OT  - FAP
OT  - chemoprevention
OT  - colorectum
OT  - low-dose aspirin
EDAT- 2013/10/18 06:00
MHDA- 2014/05/20 06:00
CRDT- 2013/10/18 06:00
PHST- 2012/03/30 00:00 [received]
PHST- 2012/10/19 00:00 [revised]
PHST- 2012/10/22 00:00 [accepted]
PHST- 2013/10/18 06:00 [entrez]
PHST- 2013/10/18 06:00 [pubmed]
PHST- 2014/05/20 06:00 [medline]
AID - 10.1002/cam4.46 [doi]
PST - ppublish
SO  - Cancer Med. 2013 Feb;2(1):50-6. doi: 10.1002/cam4.46. Epub 2013 Feb 3.

PMID- 17437728
OWN - NLM
STAT- MEDLINE
DCOM- 20070605
LR  - 20181201
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 99
IP  - 8
DP  - 2007 Apr 15
TI  - Comparison of two antiplatelet regimens (aspirin alone versus aspirin + 
      ticlopidine or clopidogrel) after intracoronary implantation of a 
      carbofilm-coated stent.
PG  - 1062-6
AB  - Stent thrombosis (ST) is an infrequent (0.5% to 1.5%) complication of 
      intracoronary stenting, with severe clinical consequences. This multicenter, 
      randomized study evaluated the clinical outcome in 479 patients (598 lesions 
      treated) who underwent elective coronary stenting with a Carbofilm-coated stent 
      (CarboStent) who met prespecified eligibility criteria and were randomly assigned 
      to receive aspirin alone (n = 235) or aspirin plus a thienopyridine antiplatelet 
      regimen (n = 244). Clinical, angiographic, and procedural characteristics were 
      similar between groups. The primary end point was the incidence of 30-day ST; 
      secondary end points included major vascular or bleeding complications within 30 
      days and death, acute myocardial infarction, and target vessel revascularization 
      at 6 months. ST occurred in 4 patients (1.4%) in the aspirin-only group and in 1 
      patient (0.3%) in the aspirin-plus-thienopyridine group (relative risk 0.23, 95% 
      confidence interval 0.03 to 2.08, p = NS). After careful review of cases, 89 
      patients (19%) with protocol deviations were identified. When they were excluded 
      from the analysis, no ST was observed in either group. Secondary end points were 
      reached by 4% of the aspirin-alone group and 8% of the 
      aspirin-plus-thienopyridine group (relative risk 2.35, 95% confidence interval 
      0.94 to 5.85, p = NS). In conclusion, after optimal intracoronary implantation of 
      the CarboStent, antiplatelet therapy with aspirin alone was safe and provided 
      efficacy comparable to aspirin plus a thienopyridine in the prevention of ST.
FAU - Bartorelli, Antonio Luca
AU  - Bartorelli AL
AD  - Institute of Cardiology, University of Milan, Centro Cardiologico Monzino, IRCCS, 
      Milan, Italy. antonio.bartorelli@ccfm.it
FAU - Tamburino, Corrado
AU  - Tamburino C
FAU - Trabattoni, Daniela
AU  - Trabattoni D
FAU - Galassi, Alfredo
AU  - Galassi A
FAU - Serdoz, Roberto
AU  - Serdoz R
FAU - Sheiban, Imad
AU  - Sheiban I
FAU - Piovaccari, Giancarlo
AU  - Piovaccari G
FAU - Zimarino, Marco
AU  - Zimarino M
FAU - Benassi, Alberto
AU  - Benassi A
FAU - Di Mario, Carlo
AU  - Di Mario C
FAU - Sangiorgio, Pietro
AU  - Sangiorgio P
FAU - Chierchia, Sergio
AU  - Chierchia S
FAU - Reimers, Bernhard
AU  - Reimers B
CN  - Sorin Group
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20070305
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Coated Materials, Biocompatible)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 7440-44-0 (Carbon)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Carbon
MH  - Cause of Death
MH  - Clopidogrel
MH  - *Coated Materials, Biocompatible
MH  - Coronary Disease/*surgery
MH  - Coronary Restenosis/etiology
MH  - Coronary Thrombosis/etiology
MH  - Drug Combinations
MH  - Equipment Design
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/etiology
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Hemorrhage/etiology
MH  - Prospective Studies
MH  - Reoperation
MH  - *Stents
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/*therapeutic use
MH  - Treatment Outcome
EDAT- 2007/04/18 09:00
MHDA- 2007/06/06 09:00
CRDT- 2007/04/18 09:00
PHST- 2006/08/01 00:00 [received]
PHST- 2006/11/28 00:00 [revised]
PHST- 2006/11/28 00:00 [accepted]
PHST- 2007/04/18 09:00 [pubmed]
PHST- 2007/06/06 09:00 [medline]
PHST- 2007/04/18 09:00 [entrez]
AID - S0002-9149(07)00077-X [pii]
AID - 10.1016/j.amjcard.2006.11.067 [doi]
PST - ppublish
SO  - Am J Cardiol. 2007 Apr 15;99(8):1062-6. doi: 10.1016/j.amjcard.2006.11.067. Epub 
      2007 Mar 5.

PMID- 21346557
OWN - NLM
STAT- MEDLINE
DCOM- 20110725
LR  - 20131121
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 22
IP  - 3
DP  - 2011 Apr
TI  - Some considerations about the hypercoagulable states and their treatments.
PG  - 155-9
LID - 10.1097/MBC.0b013e3283436401 [doi]
AB  - Inherited and acquired tendency to the formation of clots represents an important 
      cause of morbidity and mortality for ischemic events in young people (aged 
      between 40 and 50 years) that is more and more frequently identified. The 
      haemostasis' disorders may happen on the venous or arterial side. Arterial 
      thrombus is a 'white' thrombus, also called temporary thrombus. It consists of 
      aggregate platelets only. On the contrary, venous thrombus is 'red' or permanent 
      thrombus composed of platelets, red cells and fibrin. The first is the result of 
      platelets' adhesion or aggregation. Instead, the permanent thrombus derives from 
      the coagulant factors successively acting on 'white' thrombus. The different 
      pathogenesis justifies both the distinction between 'hypercoagulability' and 
      'thrombophilia' and the different treatments employed. Antiphospholipid antibody 
      syndrome, polycythemia vera, atrial fibrillation-acquired hyperhomocysteinemia, 
      diabetes mellitus and myeloproliferative disease are the most frequent causes of 
      acquired hypercoagulable state, prevalently responsible for deep venous 
      thrombosis. Among the inherited forms, congenital hyperhomocysteinemia, factor V 
      Leiden mutation, proteins C and S deficiency and antithrombin mutation are 
      included. These may induce both venous and arterial acute events. 
      Hyperhomocysteinemia can be congenital and acquired and is more correctly named 
      as 'thrombophilia' rather than 'hypercoagulability'. That happens because it 
      involves the platelets' aggregation rather than the coagulant cascade. The 
      optimal treatment of thrombophilias consists of oral (warfarin) or injectable 
      (heparins) anticoagulants. Direct thrombin inhibitors, platelet glycoprotein 
      IIb/IIIa antagonists, and tissue factor inhibitors also appear to be some 
      attractive approaches. For acquired forms, treatments of their aetiologies must 
      also be carried out. For acquired hyperhomocysteinemia, both antiplatelets' 
      therapy (aspirin + clopidogrel) and new direct thrombin inhibitors (as 
      dabigatran) could be considered. Finally, as secondary prevention of an arterial 
      acute event (stroke, IMA or peripheral ischemia) due to hyperhomocysteinemia, 
      lifetime dual antiplatelets' therapy should be used.
FAU - Cacciapuoti, Federico
AU  - Cacciapuoti F
LA  - eng
PT  - Editorial
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - Thrombophilia, hereditary
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thrombophilia/*drug therapy/genetics/metabolism
MH  - Warfarin/therapeutic use
EDAT- 2011/02/25 06:00
MHDA- 2011/07/26 06:00
CRDT- 2011/02/25 06:00
PHST- 2011/02/25 06:00 [entrez]
PHST- 2011/02/25 06:00 [pubmed]
PHST- 2011/07/26 06:00 [medline]
AID - 10.1097/MBC.0b013e3283436401 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2011 Apr;22(3):155-9. doi: 
      10.1097/MBC.0b013e3283436401.

PMID- 30989683
OWN - NLM
STAT- MEDLINE
DCOM- 20200129
LR  - 20200129
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 44
IP  - 5
DP  - 2019 Oct
TI  - Aspirin resistance mediated by oxidative stress-induced 8-Isoprostaglandin F2.
PG  - 823-828
LID - 10.1111/jcpt.12838 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Aspirin resistance refers to a patient's poor 
      response to aspirin. There are many factors that can contribute to aspirin 
      resistance, including single-nucleotide polymorphisms, medication compliance, 
      drug-drug interactions and inflammation. COMMENT: Recently, oxidative 
      stress-induced 8-isoprostaglandin F2α has attracted considerable attention 
      because it is considered as a mechanism of aspirin resistance in many diseases, 
      including coronary artery disease, neurology system disease, metabolic syndrome, 
      cancer, chronic obstructive pulmonary disease and chronic kidney disease. In 
      these diseases, increased oxidative stress may promote platelet activation and 
      reduce the efficacy of aspirin by producing excessive amounts of 
      8-isoprostaglandin F2α. WHAT IS NEW AND CONCLUSION: Given the wide clinical use 
      of aspirin, it is essential to understand why some patients do not response to 
      it. This article reviews current research on aspirin resistance mediated by 
      oxidative stress-induced 8-isoprostaglandin F2α.
CI  - © 2019 John Wiley & Sons Ltd.
FAU - Guo, Juan
AU  - Guo J
AUID- ORCID: 0000-0002-9665-3449
AD  - Department of Neurology, Shengjing Hospital, China Medical University, Shenyang, 
      China.
FAU - Wang, Jue
AU  - Wang J
AD  - Department of Neurology, Shengjing Hospital, China Medical University, Shenyang, 
      China.
FAU - Feng, Juan
AU  - Feng J
AUID- ORCID: 0000-0002-1815-7036
AD  - Department of Neurology, Shengjing Hospital, China Medical University, Shenyang, 
      China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190415
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 27415-26-5 (8-epi-prostaglandin F2alpha)
RN  - B7IN85G1HY (Dinoprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Dinoprost/adverse effects/*analogs & derivatives
MH  - Drug Resistance/*drug effects/physiology
MH  - Humans
MH  - Oxidative Stress/*physiology
OTO - NOTNLM
OT  - 8-isoprostaglandin F2α
OT  - aspirin resistance
OT  - cardiovascular and cerebrovascular disease
OT  - oxidative stress
OT  - platelet activation
OT  - thromboxane A2
EDAT- 2019/04/17 06:00
MHDA- 2020/01/30 06:00
CRDT- 2019/04/17 06:00
PHST- 2018/11/22 00:00 [received]
PHST- 2019/03/07 00:00 [revised]
PHST- 2019/03/11 00:00 [accepted]
PHST- 2019/04/17 06:00 [pubmed]
PHST- 2020/01/30 06:00 [medline]
PHST- 2019/04/17 06:00 [entrez]
AID - 10.1111/jcpt.12838 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2019 Oct;44(5):823-828. doi: 10.1111/jcpt.12838. Epub 2019 Apr 
      15.

PMID- 4017642
OWN - NLM
STAT- MEDLINE
DCOM- 19850925
LR  - 20190829
IS  - 0271-3683 (Print)
IS  - 0271-3683 (Linking)
VI  - 4
IP  - 5
DP  - 1985 May
TI  - Alterations in ocular and optic nerve blood flow during intraocular surgery in 
      aspirin pretreated rabbits.
PG  - 563-8
AB  - The effect of intraocular surgery on ocular and optic nerve blood flow was 
      determined in rabbits either untreated or pretreated with aspirin. Surgery was 
      either extracapsular lens extraction through a 100 degrees corneal incision or a 
      sham-operation in which a 45 degrees corneal incision was performed and the lens 
      left in place. In both cases, the incisions were not sutured and the intraocular 
      pressure remained zero for one hour. A (85Sr) radioactive microsphere technique 
      was used to measure blood flow in the iris, scraped ciliary processes, retina, 
      choroid, and optic nerve. In rabbits not receiving aspirin pretreatment, blood 
      flow was statistically increased in all portions of the eye, except the retina 
      and optic nerve, studied for sham-operated eyes, and in the iris and optic nerve 
      in the lens extraction group. In rabbits pretreated with aspirin, blood flow 
      remained at normal levels. These results are consistent with the hypothesis that 
      prostaglandins released during ocular surgery cause increased ocular tissue blood 
      flow.
FAU - Jay, W M
AU  - Jay WM
FAU - Aziz, M Z
AU  - Aziz MZ
FAU - Green, K
AU  - Green K
LA  - eng
GR  - EY04559/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Curr Eye Res
JT  - Current eye research
JID - 8104312
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Choroid/blood supply
MH  - Ciliary Body/blood supply
MH  - Eye/blood supply
MH  - Lens, Crystalline/*surgery
MH  - Optic Nerve/*blood supply
MH  - *Premedication
MH  - Rabbits
MH  - Regional Blood Flow/drug effects
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
AID - 10.3109/02713688508999987 [doi]
PST - ppublish
SO  - Curr Eye Res. 1985 May;4(5):563-8. doi: 10.3109/02713688508999987.

PMID- 10194170
OWN - NLM
STAT- MEDLINE
DCOM- 19990517
LR  - 20161124
IS  - 1073-449X (Print)
IS  - 1073-449X (Linking)
VI  - 159
IP  - 4 Pt 1
DP  - 1999 Apr
TI  - Different effects of inhaled aspirinlike drugs on allergen-induced early and late 
      asthmatic responses.
PG  - 1228-33
AB  - Little is known about the anti-asthmatic effects of powerful anti-inflammatory 
      agents such as aspirin-like drugs. We compared the effects of two aspirin-like 
      drugs with different pharmacologic activities, sodium salicylate (SSA) and 
      indomethacin, with the effect of lysine acetylsalicylate (LASA), inhaled 30 min 
      before challenge, on the early and the late asthmatic response induced by a 
      single dose of allergen causing a 25% decrease in FEV1 in a preliminary 
      challenge. Inhaled SSA partially prevented both the early and late response, 
      providing a protection with respect to placebo of 22 +/- 6% in the early phase 
      and 23 +/- 9% in the late phase of the response. These values were lower (but not 
      significantly) than those of LASA (41 +/- 9% and 39 +/- 11%, respectively). In a 
      second group of patients, indomethacin failed to affect the early response, while 
      LASA provided a protection of 31 +/- 7%. However, these two drugs were equally 
      effective in reducing the late response (44 +/- 18% and 39 +/- 17% protection for 
      LASA and indomethacin, respectively). In subjects with an early response, despite 
      being ineffective in preventing allergen-induced bronchoconstriction, 
      indomethacin blocked the allergen-induced increase in bronchial 
      hyperresponsiveness measured 2 h after challenge. We conclude that inhaled 
      salicylates, but not indomethacin, exert a protective activity against the early 
      allergic response. This difference is not explained by the different pattern of 
      cyclooxygenase inhibitory activity of these drugs.
FAU - Sestini, P
AU  - Sestini P
AD  - Institute of Respiratory Diseases, University of Siena; Division of Pneumology, 
      Hospital of Garbagnate; Institute of Cardiovascular and Respiratory Diseases, 
      Ospedale S. Raffaele, Milan, Italy. sestini@unisi.it
FAU - Refini, R M
AU  - Refini RM
FAU - Pieroni, M G
AU  - Pieroni MG
FAU - Vaghi, A
AU  - Vaghi A
FAU - Robuschi, M
AU  - Robuschi M
FAU - Bianco, S
AU  - Bianco S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (Allergens)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Adult
MH  - Allergens
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/*analogs & derivatives/pharmacology
MH  - Asthma/immunology/*physiopathology
MH  - Bronchial Hyperreactivity/*physiopathology
MH  - Bronchial Provocation Tests
MH  - Double-Blind Method
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Indomethacin/*administration & dosage/pharmacology
MH  - Lysine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Male
MH  - Sodium Salicylate/*administration & dosage/pharmacology
EDAT- 1999/04/08 00:00
MHDA- 1999/04/08 00:01
CRDT- 1999/04/08 00:00
PHST- 1999/04/08 00:00 [pubmed]
PHST- 1999/04/08 00:01 [medline]
PHST- 1999/04/08 00:00 [entrez]
AID - 10.1164/ajrccm.159.4.9709045 [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1228-33. doi: 
      10.1164/ajrccm.159.4.9709045.

PMID- 22722313
OWN - NLM
STAT- MEDLINE
DCOM- 20120907
LR  - 20211021
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 107
IP  - 1
DP  - 2012 Jun 26
TI  - Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: 
      a PLCO study.
PG  - 207-14
LID - 10.1038/bjc.2012.227 [doi]
AB  - BACKGROUND: Although most epidemiological studies suggest that non-steroidal 
      anti-inflammatory drug use is inversely associated with prostate cancer risk, the 
      magnitude and specificity of this association remain unclear. METHODS: We 
      examined self-reported aspirin and ibuprofen use in relation to prostate cancer 
      risk among 29 450 men ages 55-74 who were initially screened for prostate cancer 
      from 1993 to 2001 in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening 
      Trial. Men were followed from their first screening exam until 31 December 2009, 
      during which 3575 cases of prostate cancer were identified. RESULTS: After 
      adjusting for potential confounders, the hazard ratios (HRs) of prostate cancer 
      associated with <1 and ≥ 1 pill of aspirin daily were 0.98 (95% confidence 
      interval (CI), 0.90-1.07) and 0.92 (95% CI: 0.85-0.99), respectively, compared 
      with never use (P for trend 0.04). The effect of taking at least one aspirin 
      daily was more pronounced when restricting the analyses to men older than age 65 
      or men who had a history of cardiovascular-related diseases or arthritis (HR (95% 
      CI); 0.87 (0.78-0.97), 0.89 (0.80-0.99), and 0.88 (0.78-1.00), respectively). The 
      data did not support an association between ibuprofen use and prostate cancer 
      risk. CONCLUSION: Daily aspirin use, but not ibuprofen use, was associated with 
      lower risk of prostate cancer risk.
FAU - Shebl, F M
AU  - Shebl FM
AD  - Department of Human Health and Services, Division of Cancer Epidemiology and 
      Genetics, National Cancer Institute, NIH, Rockville, MD, USA. 
      fatma.shebl@yale.edu
FAU - Sakoda, L C
AU  - Sakoda LC
FAU - Black, A
AU  - Black A
FAU - Koshiol, J
AU  - Koshiol J
FAU - Andriole, G L
AU  - Andriole GL
FAU - Grubb, R
AU  - Grubb R
FAU - Church, T R
AU  - Church TR
FAU - Chia, D
AU  - Chia D
FAU - Zhou, C
AU  - Zhou C
FAU - Chu, L W
AU  - Chu LW
FAU - Huang, W-Y
AU  - Huang WY
FAU - Peters, U
AU  - Peters U
FAU - Kirsh, V A
AU  - Kirsh VA
FAU - Chatterjee, N
AU  - Chatterjee N
FAU - Leitzmann, M F
AU  - Leitzmann MF
FAU - Hayes, R B
AU  - Hayes RB
FAU - Hsing, A W
AU  - Hsing AW
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20120621
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Ibuprofen/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/*prevention & control
MH  - Risk
MH  - Risk Reduction Behavior
PMC - PMC3389420
EDAT- 2012/06/23 06:00
MHDA- 2012/09/08 06:00
CRDT- 2012/06/23 06:00
PHST- 2012/06/23 06:00 [entrez]
PHST- 2012/06/23 06:00 [pubmed]
PHST- 2012/09/08 06:00 [medline]
AID - bjc2012227 [pii]
AID - 10.1038/bjc.2012.227 [doi]
PST - ppublish
SO  - Br J Cancer. 2012 Jun 26;107(1):207-14. doi: 10.1038/bjc.2012.227. Epub 2012 Jun 
      21.

PMID- 2384364
OWN - NLM
STAT- MEDLINE
DCOM- 19900918
LR  - 20190510
IS  - 0021-8812 (Print)
IS  - 0021-8812 (Linking)
VI  - 68
IP  - 6
DP  - 1990 Jun
TI  - Effects of feeding aspirin and soybean oil to weanling pigs.
PG  - 1639-47
AB  - Three trials were conducted with 216 Yorkshire x Duroc x Hampshire crossbred pigs 
      (equal males and females) weaned at 3 to 4 wk of age (avg 7.4 kg initially) to 
      determine the effectiveness of aspirin in an 18% CP corn-soybean meal starter 
      diet (with and without soybean oil in Trial III) for improving postweaning 
      performance and reducing scours. When aspirin levels common to all trials (0, 250 
      ppm) or common to Trials II and III (0, 125 and 250 ppm) were compared, 
      improvements in ADG (P less than .10) and daily feed intake (P less than .05) 
      were observed with no effect on efficiency of feed utilization. There was a 
      quadratic effect of aspirin (P less than .10) in Trials II and III, the trend 
      suggesting that the response to 125 ppm was as effective as the response to 250 
      ppm aspirin. The addition of soybean oil in Trial III did not enhance the 
      response. In all trials, scouring was reduced (P less than .05) when pigs were 
      fed 125 or 250 ppm aspirin; the improvement was greatest for 125 ppm aspirin 
      after 5 d on test. Pooled data suggested no effect (P greater than .10) of 
      aspirin on hemoglobin concentrations and blood clotting times; slightly higher (P 
      less than .10) hematocrit values and DM content of colon digesta occurred in pigs 
      fed 125 ppm aspirin vs controls.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Xu, Z R
AU  - Xu ZR
AD  - Dept. of Anim. Sci., Virginia Polytechnic Institute and State University, 
      Blacksburg.
FAU - Kornegay, E T
AU  - Kornegay ET
FAU - Sweet, L A
AU  - Sweet LA
FAU - Lindemann, M D
AU  - Lindemann MD
FAU - Veit, H P
AU  - Veit HP
FAU - Watkins, B A
AU  - Watkins BA
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Anim Sci
JT  - Journal of animal science
JID - 8003002
RN  - 0 (Fatty Acids)
RN  - 0 (Plant Oils)
RN  - 8001-22-7 (Soybean Oil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animal Feed/analysis
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Diarrhea/prevention & control/*veterinary
MH  - Fatty Acids/analysis/blood
MH  - Female
MH  - Immunity/drug effects
MH  - Least-Squares Analysis
MH  - Liver/analysis
MH  - Male
MH  - Plant Oils/*administration & dosage
MH  - Soybean Oil/*administration & dosage/pharmacology
MH  - Swine
MH  - Swine Diseases/*prevention & control
MH  - Weaning
MH  - Weight Gain/drug effects
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
AID - 10.2527/1990.6861639x [doi]
PST - ppublish
SO  - J Anim Sci. 1990 Jun;68(6):1639-47. doi: 10.2527/1990.6861639x.

PMID- 28888067
OWN - NLM
STAT- MEDLINE
DCOM- 20190828
LR  - 20200930
IS  - 1552-4981 (Electronic)
IS  - 1552-4973 (Linking)
VI  - 106
IP  - 5
DP  - 2018 Jul
TI  - Injectable thermosensitive alginate/β-tricalcium phosphate/aspirin hydrogels for 
      bone augmentation.
PG  - 1739-1751
LID - 10.1002/jbm.b.33982 [doi]
AB  - In this study, an injectable and thermo-sensitive alginate/β-tricalcium phosphate 
      hydrogel (TSAH/β-TCP) was prepared for aspirin release to a bone defect. Aspirin 
      was dissolved into a mixture of poly(N-isopropylacrylamide) (PNIPAAm), an 
      aminated alginate-g-PNIPAAm co-polymer, and β-TCP powders. Scanning electron 
      microscopy showed that TSAH/β-TCP had an interconnected porous microstructure 
      with a porosity of 86.78%. The cross-linked hydrogel released approximately 40% 
      of the aspirin in the first 3 days and then slowly released the remainder. At a 
      low concentration (≤100 μg/mL), aspirin did not promote cell proliferation, but 
      enhanced the alkaline phosphatase activity, and osteocalcin (OCN) and collagen I 
      expression of human bone marrow-derived mesenchymal stem cells. The 
      TSAH/β-TCP/aspirin hydrogel was injected into the periosteum of the rat cranial 
      bone, and its in vivo bone-forming ability was evaluated at 12 weeks. A bone 
      morphogenetic protein 2 (BMP-2)-loaded TSAH/β-TCP hydrogel was injected as a 
      control. Micro-computed tomography showed that the percentage of mineralized 
      tissue in the TSAH/β-TCP/BMP-2 and TSAH/β-TCP/aspirin groups were similar and 
      significantly higher than that in the TSAH/β-TCP group. Immunohistochemical 
      staining showed considerable expression of OCN, especially in the 
      TSAH/β-TCP/BMP-2 and TSAH/β-TCP/aspirin groups. These results suggest that the 
      injectable TSAH/β-TCP/aspirin hydrogel has great potential for bone regeneration. 
      © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 
      1739-1751, 2018.
CI  - © 2017 Wiley Periodicals, Inc.
FAU - Fang, Xiaoqian
AU  - Fang X
AD  - Department of Prosthodontics School and Hospital of Stomatology Peking 
      University, Beijing 100081, China.
AD  - Fifth Clinical Division School and Hospital of Stomatology Peking University, 
      Beijing 100020, China.
FAU - Lei, Lei
AU  - Lei L
AD  - Department of Prosthodontics School and Hospital of Stomatology Peking 
      University, Beijing 100081, China.
FAU - Jiang, Ting
AU  - Jiang T
AD  - Department of Prosthodontics School and Hospital of Stomatology Peking 
      University, Beijing 100081, China.
AD  - National Engineering Laboratory for Digital and Material Technology of 
      Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing 100081, 
      China.
FAU - Chen, Ying
AU  - Chen Y
AD  - Department of Prosthodontics School and Hospital of Stomatology Peking 
      University, Beijing 100081, China.
FAU - Kang, Yunqing
AU  - Kang Y
AD  - Department of Ocean and Mechanical Engineering, Florida Atlantic University, Boca 
      Raton, Florida 33431.
AD  - Department of Biomedical Science, Florida Atlantic University, Boca Raton, 
      Florida 33431.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170909
PL  - United States
TA  - J Biomed Mater Res B Appl Biomater
JT  - Journal of biomedical materials research. Part B, Applied biomaterials
JID - 101234238
RN  - 0 (Acrylic Resins)
RN  - 0 (Alginates)
RN  - 0 (BMP2 protein, human)
RN  - 0 (Bone Morphogenetic Protein 2)
RN  - 0 (Calcium Phosphates)
RN  - 0 (Hydrogels)
RN  - 0 (beta-tricalcium phosphate)
RN  - 25189-55-3 (poly-N-isopropylacrylamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acrylic Resins/chemistry/pharmacokinetics
MH  - *Alginates/chemistry/pharmacokinetics/pharmacology
MH  - Animals
MH  - *Aspirin/chemistry/pharmacokinetics/pharmacology
MH  - Bone Morphogenetic Protein 2/chemistry/pharmacokinetics/pharmacology
MH  - Bone Regeneration/*drug effects
MH  - *Calcium Phosphates/chemistry/pharmacokinetics/pharmacology
MH  - Humans
MH  - Hydrogels/chemistry/pharmacokinetics/pharmacology
MH  - Male
MH  - Mesenchymal Stem Cells/metabolism/pathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - *Skull/injuries/metabolism/pathology
MH  - X-Ray Microtomography
OTO - NOTNLM
OT  - aspirin
OT  - bone regeneration
OT  - injectable hydrogel
OT  - β-TCP
EDAT- 2017/09/10 06:00
MHDA- 2019/08/29 06:00
CRDT- 2017/09/10 06:00
PHST- 2017/02/24 00:00 [received]
PHST- 2017/08/17 00:00 [revised]
PHST- 2017/08/22 00:00 [accepted]
PHST- 2017/09/10 06:00 [pubmed]
PHST- 2019/08/29 06:00 [medline]
PHST- 2017/09/10 06:00 [entrez]
AID - 10.1002/jbm.b.33982 [doi]
PST - ppublish
SO  - J Biomed Mater Res B Appl Biomater. 2018 Jul;106(5):1739-1751. doi: 
      10.1002/jbm.b.33982. Epub 2017 Sep 9.

PMID- 12780835
OWN - NLM
STAT- MEDLINE
DCOM- 20030710
LR  - 20220409
IS  - 1464-4096 (Print)
IS  - 1464-4096 (Linking)
VI  - 91
IP  - 9
DP  - 2003 Jun
TI  - Morbidity of transrectal ultrasonography-guided prostate biopsies in patients 
      after the continued use of low-dose aspirin.
PG  - 798-800
AB  - OBJECTIVE: To determine whether low-dose aspirin increases morbidity after 
      transrectal ultrasonography-guided sextant prostate biopsy. PATIENTS AND METHODS: 
      In a single-centre prospective cohort study of 200 patients who underwent sextant 
      prostate biopsies, those routinely taking low-dose aspirin were encouraged to 
      continue to do so before and after biopsy. The morbidity in each case was 
      assessed using a standardized questionnaire that patients completed in the 7 days 
      after biopsy. The presence of haematuria, rectal bleeding and haematospermia were 
      recorded. The questionnaire also directed the patient to record fevers, use of 
      analgesia and any further treatment received. RESULTS: In all, 36 patients took 
      aspirin whilst the other 141 did not. There were no major complications in either 
      group. Of the patients on aspirin, 20 (56%) had haematuria, compared with 83 
      (59%) of those not taking aspirin (difference 3%, 95% confidence interval, CI, 
      -15 to 21). Overall bleeding (haematuria, rectal bleeding and haematospermia) 
      occurred in 22 patients (61%) of the aspirin group and 105 (74%) of the other 
      group (difference 13%, 95% CI -4 to 31). Comparisons of other morbidities between 
      the groups are also discussed. CONCLUSIONS: There was no statistically 
      significant difference in the incidence of haematuria or overall bleeding after 
      biopsy between the groups. There is no evidence that aspirin needs to be 
      discontinued before sextant prostate biopsy.
FAU - Maan, Z
AU  - Maan Z
AD  - Department of Urology, St. George's Hospital, London, UK. zafski@hotmail.com
FAU - Cutting, C W
AU  - Cutting CW
FAU - Patel, U
AU  - Patel U
FAU - Kerry, S
AU  - Kerry S
FAU - Pietrzak, P
AU  - Pietrzak P
FAU - Perry, M J A
AU  - Perry MJ
FAU - Kirby, R S
AU  - Kirby RS
LA  - eng
PT  - Journal Article
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Biopsy, Needle/methods
MH  - Blood
MH  - Cohort Studies
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Hematuria/chemically induced
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Postoperative Hemorrhage/etiology
MH  - Prospective Studies
MH  - Prostatic Neoplasms/*diagnostic imaging
MH  - Rectal Diseases/chemically induced
MH  - Risk Factors
MH  - Semen
MH  - Ultrasonography, Interventional
EDAT- 2003/06/05 05:00
MHDA- 2003/07/11 05:00
CRDT- 2003/06/05 05:00
PHST- 2003/06/05 05:00 [pubmed]
PHST- 2003/07/11 05:00 [medline]
PHST- 2003/06/05 05:00 [entrez]
AID - 4238 [pii]
AID - 10.1046/j.1464-410x.2003.04238.x [doi]
PST - ppublish
SO  - BJU Int. 2003 Jun;91(9):798-800. doi: 10.1046/j.1464-410x.2003.04238.x.

PMID- 32543684
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20201220
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 323
IP  - 23
DP  - 2020 Jun 16
TI  - Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and 
      Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO 
      Randomized Clinical Trial.
PG  - 2407-2416
LID - 10.1001/jama.2020.7580 [doi]
AB  - IMPORTANCE: Discontinuing aspirin after short-term dual antiplatelet therapy 
      (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of 
      ticagrelor monotherapy has not been exclusively evaluated in patients with acute 
      coronary syndromes (ACS). OBJECTIVE: To determine whether switching to ticagrelor 
      monotherapy after 3 months of DAPT reduces net adverse clinical events compared 
      with ticagrelor-based 12-month DAPT in patients with ACS treated with 
      drug-eluting stents. DESIGN, SETTING, AND PARTICIPANTS: A randomized multicenter 
      trial was conducted in 3056 patients with ACS treated with drug-eluting stents 
      between August 2015 and October 2018 at 38 centers in South Korea. Follow-up was 
      completed in October 2019. INTERVENTIONS: Patients were randomized to receive 
      ticagrelor monotherapy (90 mg twice daily) after 3-month DAPT (n = 1527) or 
      ticagrelor-based 12-month DAPT (n = 1529). MAIN OUTCOMES AND MEASURES: The 
      primary outcome was a 1-year net adverse clinical event, defined as a composite 
      of major bleeding and adverse cardiac and cerebrovascular events (death, 
      myocardial infarction, stent thrombosis, stroke, or target-vessel 
      revascularization). Prespecified secondary outcomes included major bleeding and 
      major adverse cardiac and cerebrovascular events. RESULTS: Among 3056 patients 
      who were randomized (mean age, 61 years; 628 women [20%]; 36% ST-elevation 
      myocardial infarction), 2978 patients (97.4%) completed the trial. The primary 
      outcome occurred in 59 patients (3.9%) receiving ticagrelor monotherapy after 
      3-month DAPT and in 89 patients (5.9%) receiving ticagrelor-based 12-month DAPT 
      (absolute difference, -1.98% [95% CI, -3.50% to -0.45%]; hazard ratio [HR], 0.66 
      [95% CI, 0.48 to 0.92]; P = .01). Of 10 prespecified secondary outcomes, 8 showed 
      no significant difference. Major bleeding occurred in 1.7% of patients with 
      ticagrelor monotherapy after 3-month DAPT and in 3.0% of patients with 
      ticagrelor-based 12-month DAPT (HR, 0.56 [95% CI, 0.34 to 0.91]; P = .02). The 
      incidence of major adverse cardiac and cerebrovascular events was not 
      significantly different between the ticagrelor monotherapy after 3-month DAPT 
      group (2.3%) vs the ticagrelor-based 12-month DAPT group (3.4%) (HR, 0.69 [95% 
      CI, 0.45 to 1.06]; P = .09). CONCLUSIONS AND RELEVANCE: Among patients with acute 
      coronary syndromes treated with drug-eluting stents, ticagrelor monotherapy after 
      3 months of dual antiplatelet therapy, compared with ticagrelor-based 12-month 
      dual antiplatelet therapy, resulted in a modest but statistically significant 
      reduction in a composite outcome of major bleeding and cardiovascular events at 1 
      year. The study population and lower than expected event rates should be 
      considered in interpreting the trial. TRIAL REGISTRATION: ClinicalTrials.gov 
      Identifier: NCT02494895.
FAU - Kim, Byeong-Keuk
AU  - Kim BK
AD  - Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, 
      South Korea.
FAU - Hong, Sung-Jin
AU  - Hong SJ
AD  - Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, 
      South Korea.
FAU - Cho, Yun-Hyeong
AU  - Cho YH
AD  - Myongji Hospital, Hanyang University College of Medicine, Goyang, South Korea.
FAU - Yun, Kyeong Ho
AU  - Yun KH
AD  - Wonkwang University Hospital, Iksan, South Korea.
FAU - Kim, Yong Hoon
AU  - Kim YH
AD  - Kangwon National University School of Medicine, Chuncheon, South Korea.
FAU - Suh, Yongsung
AU  - Suh Y
AD  - Myongji Hospital, Hanyang University College of Medicine, Goyang, South Korea.
FAU - Cho, Jae Young
AU  - Cho JY
AD  - Wonkwang University Hospital, Iksan, South Korea.
FAU - Her, Ae-Young
AU  - Her AY
AD  - Kangwon National University School of Medicine, Chuncheon, South Korea.
FAU - Cho, Sungsoo
AU  - Cho S
AD  - Dankook University Hospital, Dankook University College of Medicine, Cheonan, 
      South Korea.
FAU - Jeon, Dong Woon
AU  - Jeon DW
AD  - National Health Insurance Service Ilsan Hospital, Goyang-City, South Korea.
FAU - Yoo, Sang-Yong
AU  - Yoo SY
AD  - Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, 
      South Korea.
FAU - Cho, Deok-Kyu
AU  - Cho DK
AD  - Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, South 
      Korea.
FAU - Hong, Bum-Kee
AU  - Hong BK
AD  - Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South 
      Korea.
FAU - Kwon, Hyuckmoon
AU  - Kwon H
AD  - Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South 
      Korea.
FAU - Ahn, Chul-Min
AU  - Ahn CM
AD  - Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, 
      South Korea.
FAU - Shin, Dong-Ho
AU  - Shin DH
AD  - Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, 
      South Korea.
FAU - Nam, Chung-Mo
AU  - Nam CM
AD  - Department of Preventive Medicine and Biostatistics, Yonsei University College of 
      Medicine, Seoul, South Korea.
FAU - Kim, Jung-Sun
AU  - Kim JS
AD  - Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, 
      South Korea.
FAU - Ko, Young-Guk
AU  - Ko YG
AD  - Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, 
      South Korea.
FAU - Choi, Donghoon
AU  - Choi D
AD  - Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, 
      South Korea.
FAU - Hong, Myeong-Ki
AU  - Hong MK
AD  - Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, 
      South Korea.
FAU - Jang, Yangsoo
AU  - Jang Y
AD  - Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, 
      South Korea.
CN  - TICO Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT02494895
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
CIN - Ann Intern Med. 2020 Oct 20;173(8):JC43. PMID: 33075261
MH  - Acute Coronary Syndrome/*drug therapy/therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Drug Therapy, Combination
MH  - Drug-Eluting Stents
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Sirolimus/administration & dosage
MH  - Ticlopidine/adverse effects/*therapeutic use
PMC - PMC7298605
COIS- Conflict of Interest Disclosures: None reported.
EDAT- 2020/06/17 06:00
MHDA- 2020/07/02 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
AID - 2767161 [pii]
AID - joi200048 [pii]
AID - 10.1001/jama.2020.7580 [doi]
PST - ppublish
SO  - JAMA. 2020 Jun 16;323(23):2407-2416. doi: 10.1001/jama.2020.7580.

PMID- 28071789
OWN - NLM
STAT- MEDLINE
DCOM- 20180628
LR  - 20220318
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 174
IP  - 22
DP  - 2017 Nov
TI  - Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in 
      apolipoprotein E(-/-) mice.
PG  - 4043-4054
LID - 10.1111/bph.13707 [doi]
AB  - BACKGROUND AND PURPOSE: Atherosclerosis is characterized by a chronic 
      non-resolving inflammation in the arterial wall. Aspirin-triggered lipoxin A4 
      (ATL) is a potent anti-inflammatory mediator, involved in the resolution of 
      inflammation. However, the therapeutic potential of immune targeting by means of 
      ATL in atherosclerosis has not previously been explored. The aim of the present 
      study was to determine the effects of ATL and its receptor Fpr2 on 
      atherosclerosis development and progression in apolipoprotein E deficient 
      (ApoE(-/-) ) mice. EXPERIMENTAL APPROACH: ApoE(-/-)  × Fpr2(+/+) and ApoE(-/-) 
       × Fpr2(-/-) mice were generated. Four-week-old mice fed a high-fat diet for 
      4 weeks and 16-week-old mice fed chow diet received osmotic pumps containing 
      either vehicle or ATL for 4 weeks. Atherosclerotic lesion size and cellular 
      composition were measured in the aortic root and thoracic aorta. Lipid levels and 
      leukocyte counts were measured in blood and mRNA was isolated from abdominal 
      aorta and spleen. KEY RESULTS: ATL blocked atherosclerosis progression in the 
      aortic root and thoracic aorta of ApoE(-/-) mice. In addition, ATL reduced 
      macrophage infiltration and apoptotic cells in atherosclerotic lesions. The mRNA 
      levels of several cytokines and chemokines in the spleen and aorta were reduced 
      by ATL, whereas circulating leukocyte levels were unchanged. The ATL-induced 
      athero-protection was absent in ApoE(-/-) mice lacking the Fpr2 receptor. 
      CONCLUSION AND IMPLICATIONS: ATL blocked atherosclerosis progression by means of 
      an Fpr2-mediated reduced local and systemic inflammation. These results suggest 
      this anti-inflammatory and pro-resolving agent has therapeutic potential for the 
      treatment of atherosclerosis. LINKED ARTICLES: This article is part of a themed 
      section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view 
      the other articles in this section visit 
      http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and 
      http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.
CI  - © 2017 The British Pharmacological Society.
FAU - Petri, Marcelo H
AU  - Petri MH
AD  - Experimental Cardiovascular Research Group, Cardiovascular Medicine Unit, Center 
      for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Laguna-Fernandez, Andrés
AU  - Laguna-Fernandez A
AD  - Experimental Cardiovascular Research Group, Cardiovascular Medicine Unit, Center 
      for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Arnardottir, Hildur
AU  - Arnardottir H
AD  - Experimental Cardiovascular Research Group, Cardiovascular Medicine Unit, Center 
      for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Wheelock, Craig E
AU  - Wheelock CE
AD  - Department of Medical Biochemistry and Biophysics, Karlinska Institutet, 
      Stockholm, Sweden.
FAU - Perretti, Mauro
AU  - Perretti M
AD  - William Harvey Research Institute, Barts and The London School of Medicine, Queen 
      Mary University of London, London, UK.
FAU - Hansson, Göran K
AU  - Hansson GK
AD  - Experimental Cardiovascular Research Group, Cardiovascular Medicine Unit, Center 
      for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Bäck, Magnus
AU  - Bäck M
AD  - Experimental Cardiovascular Research Group, Cardiovascular Medicine Unit, Center 
      for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, 
      Sweden.
AD  - Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20170214
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Apolipoproteins E)
RN  - 0 (Cytokines)
RN  - 0 (Lipoxins)
RN  - 0 (Receptors, Formyl Peptide)
RN  - 0 (formyl peptide receptor 2, mouse)
RN  - 0 (lipoxin A4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta/drug effects/metabolism/pathology
MH  - Apolipoproteins E/*genetics
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Atherosclerosis/*drug therapy/genetics/metabolism/pathology
MH  - Cytokines/genetics
MH  - Female
MH  - Lipoxins/pharmacology/*therapeutic use
MH  - Mice, Knockout
MH  - Receptors, Formyl Peptide/*genetics
PMC - PMC5659998
EDAT- 2017/01/11 06:00
MHDA- 2018/06/29 06:00
CRDT- 2017/01/11 06:00
PHST- 2016/06/17 00:00 [received]
PHST- 2016/12/18 00:00 [revised]
PHST- 2016/12/29 00:00 [accepted]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2018/06/29 06:00 [medline]
PHST- 2017/01/11 06:00 [entrez]
AID - BPH13707 [pii]
AID - 10.1111/bph.13707 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2017 Nov;174(22):4043-4054. doi: 10.1111/bph.13707. Epub 2017 Feb 
      14.

PMID- 16258799
OWN - NLM
STAT- MEDLINE
DCOM- 20060228
LR  - 20181113
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 94 Suppl 3
DP  - 2005
TI  - [Primary prevention of coronary heart disease? What is cost effective in the 
      clinical practice?].
PG  - III/92-9
AB  - In the primary prevention of coronary heart disease (CHD), the effect of aspirin 
      and statins is well documented in several controlled randomized trials. For 
      aspirin the results can be transferred into clinical practice due to its low 
      price; for the more expensive statins, however, serious economic problems exist. 
      In contrast to secondary prevention these drugs do not reach cost-efficiency in 
      primary prevention; due to their high prices for the criteria of the randomized 
      controlled studies values >60 000 or >100 000 [US dollars/YLS] are gained. Data 
      from England and Scotland indicate that according to the inclusion criteria of 
      the WOSCOPS- and AFCAPS/TexCAPS studies almost 20 and 60%, respectively, of the 
      adult population had to be treated with a statin. Results of newer studies may 
      even increase these numbers. These costs cannot be covered by any health care 
      system. Primary prevention of CHD with statins reveals paradigmatically that for 
      financial reasons evidence-based medicine can no longer be transferred into 
      clinical practice. The limited resources of all health care systems make 
      rationing with treatment allocation only to the high risk groups necessary. The 
      American, European and German guidelines propose a > or =2% annual risk of CHD as 
      the limit, for financial reasons the Britisch recommendations favor a limit of 
      3%; in order to save >50% of the costs. Despite the financial restraints of the 
      German health care system, the limit of > or =2% annual risk of CHD as proposed 
      by the German Cardiac Society may be realistic when the different preventive 
      measures are applied following a step-by-step plan based on the costs. According 
      to the Procam algorithms, persons without diabetes mellitus or familiar 
      disposition, who in case of nicotine abuse have given up smoking and if 
      hypertensive have blood pressure values within the therapeutic range, statins are 
      only to be given under the following conditions: LDL-cholesterol > or =175 or > 
      or =190 mg/dl, for a HDL-cholesterol < or =35 or < or =45 mg/dl, or triglyceride 
      levels > or =200 or > or =175 mg/dl, respectively. Diabetics without CHD have the 
      same risk as non-diabetics with CHD. Therefore, in diabetics the same measures 
      should be taken for primary prevention as in non-diabetics for secondary 
      prevention. Evaluation of cost-efficiency indicates that intensive blood sugar 
      control as well as intensive antihypertensive treatment and application of 
      statins are all cost-effective in primary prevention of diabetics.
FAU - Kübler, W
AU  - Kübler W
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Primärprävention der koronaren Herzerkrankung: Was ist in der Praxis bezahlbar?
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*economics/*therapeutic use
MH  - Coronary Artery Disease/*economics/epidemiology/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*economics/*therapeutic use
MH  - Internationality
MH  - Practice Guidelines as Topic
MH  - Practice Patterns, Physicians'/economics
MH  - Primary Prevention/economics/methods
MH  - Risk Assessment/*methods
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2005/11/01 09:00
MHDA- 2006/03/01 09:00
CRDT- 2005/11/01 09:00
PHST- 2005/11/01 09:00 [pubmed]
PHST- 2006/03/01 09:00 [medline]
PHST- 2005/11/01 09:00 [entrez]
AID - 10.1007/s00392-005-1313-z [doi]
PST - ppublish
SO  - Z Kardiol. 2005;94 Suppl 3:III/92-9. doi: 10.1007/s00392-005-1313-z.

PMID- 1960551
OWN - NLM
STAT- MEDLINE
DCOM- 19920109
LR  - 20181130
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 9
IP  - 12
DP  - 1991 Dec
TI  - A randomized prospective assessment of recombinant leukocyte A human interferon 
      with or without aspirin in advanced renal adenocarcinoma.
PG  - 2104-9
AB  - We performed a prospective, controlled trial of recombinant leukocyte A 
      interferon (IFN-alpha 2A) with or without aspirin (ASA) in 176 patients with 
      assessable advanced renal cell cancer in light of a 34% response rate (10 of 29 
      patients) from the two-agent regimen in an earlier nonrandomized trial. This 
      encouraging result was substantially higher than the 15% response rate typically 
      achieved with IFN therapy alone. Eighty-seven patients received IFN-alpha 2A 20 x 
      10(6) U/m2 intramuscularly three times a week, and 89 received the same IFN 
      therapy with ASA 600 mg orally four times each day. Each group was balanced as to 
      relevant prognostic discriminants. Response rates were 8% for the group receiving 
      ASA in addition to IFN, and 13% for the group receiving IFN alone (P = .30). The 
      median times to progression were 1.9 months for the group receiving IFN with ASA 
      and 2.7 months for the group receiving IFN alone (log-rank P = .36). The median 
      survival durations were 8.8 months for the IFN and ASA group and 8.0 months for 
      the IFN-only group (log-rank P = .60). These figures are also inferior to those 
      typically reported from other studies. Our findings reemphasize the crucial role 
      of randomized trials, admittedly cumbersome and time-consuming, to determine 
      accurately the value of apparently promising therapies. Although some patients 
      may derive benefit from IFN therapy, our findings raise disturbing questions 
      regarding the potential IFN-alpha 2A according to the dose and schedule used in 
      this trial to have any substantive impact on the ultimate outcome of disseminated 
      renal cell cancer.
FAU - Creagan, E T
AU  - Creagan ET
AD  - Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905.
FAU - Twito, D I
AU  - Twito DI
FAU - Johansson, S L
AU  - Johansson SL
FAU - Schaid, D J
AU  - Schaid DJ
FAU - Johnson, P S
AU  - Johnson PS
FAU - Flaum, M A
AU  - Flaum MA
FAU - Buroker, T R
AU  - Buroker TR
FAU - Geeraerts, L H
AU  - Geeraerts LH
FAU - Veeder, M H
AU  - Veeder MH
FAU - Gesme, D H Jr
AU  - Gesme DH Jr
AU  - et al.
LA  - eng
GR  - CA-15083/CA/NCI NIH HHS/United States
GR  - CA-25224/CA/NCI NIH HHS/United States
GR  - CA-35269/CA/NCI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/adverse effects/antagonists & inhibitors/*therapeutic use
MH  - Kidney Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Recombinant Proteins
MH  - Survival Analysis
EDAT- 1991/12/11 19:15
MHDA- 2001/03/28 10:01
CRDT- 1991/12/11 19:15
PHST- 1991/12/11 19:15 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1991/12/11 19:15 [entrez]
AID - 10.1200/JCO.1991.9.12.2104 [doi]
PST - ppublish
SO  - J Clin Oncol. 1991 Dec;9(12):2104-9. doi: 10.1200/JCO.1991.9.12.2104.

PMID- 18388038
OWN - NLM
STAT- MEDLINE
DCOM- 20080703
LR  - 20131121
IS  - 1940-1574 (Electronic)
IS  - 0003-3197 (Linking)
VI  - 59
IP  - 3
DP  - 2008 Jun-Jul
TI  - Effects of policosanol (10 mg/d) versus aspirin (100 mg/d) in patients with 
      intermittent claudication: a 10-week, randomized, comparative study.
PG  - 269-77
LID - 10.1177/0003319707306963 [doi]
AB  - Antiplatelet therapy, including aspirin, is recommended to lower the vascular 
      risk in patients with intermittent claudication. Policosanol has increased 
      walking distances in these patients, probably because of its antiplatelet 
      effects, but the effect of shorter treatment has not been studied. This 
      double-blind study compared the effects of policosanol 10 mg/d and aspirin 100 
      mg/d for 10 weeks on walking distances in claudicants. Thirty-nine patients were 
      randomized to policosanol or aspirin. Walking distances on a treadmill were 
      assessed before and after treatment. Policosanol significantly increased the 
      initial and absolute claudication distances, while aspirin changed neither 
      variable. Policosanol, not aspirin, significantly lowered serum low-density 
      lipoprotein-cholesterol and total cholesterol while raising high-density 
      lipoprotein-cholesterol. In conclusion, treatments of policosanol, not aspirin, 
      for 10 weeks significantly increased walking distances, but modestly, in contrast 
      with previous results. Therefore, the duration of treatments at the doses tested 
      was too short for meaningful effects on the treadmill test.
FAU - Illnait, José
AU  - Illnait J
AD  - Medical Surgical Research Centre, Havana City, Cuba. clinica@enet.cu
FAU - Castaño, Gladys
AU  - Castaño G
FAU - Alvarez, Ernesto
AU  - Alvarez E
FAU - Fernández, Lilia
AU  - Fernández L
FAU - Mas, Rosa
AU  - Mas R
FAU - Mendoza, Sarahí
AU  - Mendoza S
FAU - Gamez, Rafael
AU  - Gamez R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080402
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Fatty Alcohols)
RN  - 0 (Lipids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 142583-61-7 (policosanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Exercise Test
MH  - Fatty Alcohols/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Intermittent Claudication/blood/*drug therapy/physiopathology
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Recovery of Function
MH  - Treatment Outcome
MH  - Walking
EDAT- 2008/04/05 09:00
MHDA- 2008/07/04 09:00
CRDT- 2008/04/05 09:00
PHST- 2008/04/05 09:00 [pubmed]
PHST- 2008/07/04 09:00 [medline]
PHST- 2008/04/05 09:00 [entrez]
AID - 0003319707306963 [pii]
AID - 10.1177/0003319707306963 [doi]
PST - ppublish
SO  - Angiology. 2008 Jun-Jul;59(3):269-77. doi: 10.1177/0003319707306963. Epub 2008 
      Apr 2.

PMID- 34309219
OWN - NLM
STAT- MEDLINE
DCOM- 20220106
LR  - 20220106
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 11
IP  - 12
DP  - 2021 Dec
TI  - Cost-effectiveness analysis comparing dupilumab and aspirin desensitization 
      therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated 
      respiratory disease.
PG  - 1626-1636
LID - 10.1002/alr.22865 [doi]
AB  - BACKGROUND: Chronic rhinosinusitis with nasal polyposis (CRSwNP) in the setting 
      of aspirin-exacerbated respiratory disease (AERD) is a disease that is difficult 
      to treat and prone to recurrence. Dupilumab is a promising treatment for these 
      patients, but its cost-effectiveness has not yet been compared with aspirin 
      (acetylsalicyclic acid, or ASA) desensitization, a known and effective treatment. 
      We aimed to compare the cost-effectiveness of ASA desensitization with dupilumab 
      therapy for the treatment of CRSwNP in AERD. METHODS: Analyses of 
      cost-effectiveness, as measured in quality-adjusted life years (QALYs), and 
      cost-utility, as measured in number of required revision endoscopic sinus 
      surgeries (ESSs), were conducted. RESULTS: ASA desensitization after ESS was 
      cost-effective and dominated appropriate medical management. Adding salvage 
      dupilumab was also cost-effective (incremental cost-effectiveness ratio [ICER] 
      $135,517.33), and upfront dupilumab therapy was not cost-effective in any 
      scenario (ICER $273,181.32). The cost-utility analysis demonstrated that, over a 
      10-year period per patient, appropriate medical management after ESS cost 
      $54,125.31 and resulted in 2.25 revision ESSs, ASA desensitization after ESS cost 
      $53,775.15 and resulted in 2.02 revision ESSs, ASA desensitization with salvage 
      dupilumab cost $121,176.25 and resulted in 1.68 revision ESSs, and upfront 
      dupilumab cost $185,950.34 and resulted in 1.51 revision ESSs. CONCLUSION: 
      Dupilumab for the treatment of severe CRSwNP was found to be cost-effective as 
      salvage therapy under the willingness-to-pay threshold of $150,000. Further 
      analysis highlighted that the cost-effectiveness of dupilumab was most sensitive 
      to drug price and expected gains in quality of life. This suggests that 
      additional investigation into improving patient population selection and 
      tailoring treatment algorithms may improve the cost-effectiveness of dupilumab in 
      specific scenarios.
CI  - © 2021 ARS-AAOA, LLC.
FAU - Yong, Michael
AU  - Yong M
AUID- ORCID: 0000-0002-7774-5786
AD  - Faculty of Medicine, Division of Otolaryngology-Head and Neck Surgery, University 
      of British Columbia, Vancouver, BC, Canada.
FAU - Wu, Yu Qi
AU  - Wu YQ
AD  - Faculty of Medicine, Division of Otolaryngology-Head and Neck Surgery, University 
      of British Columbia, Vancouver, BC, Canada.
FAU - Howlett, Joel
AU  - Howlett J
AD  - Faculty of Medicine, Division of Otolaryngology-Head and Neck Surgery, University 
      of British Columbia, Vancouver, BC, Canada.
FAU - Ballreich, Jeromie
AU  - Ballreich J
AD  - Department of Health Policy and Management, Johns Hopkins Bloomberg School of 
      Public Health, Baltimore, MD.
FAU - Walgama, Evan
AU  - Walgama E
AD  - Division of Head & Neck Surgery, MD Anderson Cancer Center, Houston, TX.
FAU - Thamboo, Andrew
AU  - Thamboo A
AD  - Faculty of Medicine, Division of Otolaryngology-Head and Neck Surgery, University 
      of British Columbia, Vancouver, BC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20210726
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 420K487FSG (dupilumab)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Aspirin/adverse effects
MH  - Chronic Disease
MH  - Cost-Benefit Analysis
MH  - Desensitization, Immunologic
MH  - Humans
MH  - *Nasal Polyps/drug therapy
MH  - Quality of Life
MH  - *Rhinitis/drug therapy
OTO - NOTNLM
OT  - aspirin desensitization
OT  - aspirin-exacerbated respiratory disease
OT  - biologic
OT  - chronic rhinosinusitis
OT  - chronic rhinosinusitis with nasal polyposis
OT  - cost-effectiveness analysis
OT  - cost-utility analysis
OT  - dupilumab
EDAT- 2021/07/27 06:00
MHDA- 2022/01/07 06:00
CRDT- 2021/07/26 09:12
PHST- 2021/06/25 00:00 [revised]
PHST- 2021/05/11 00:00 [received]
PHST- 2021/06/25 00:00 [accepted]
PHST- 2021/07/27 06:00 [pubmed]
PHST- 2022/01/07 06:00 [medline]
PHST- 2021/07/26 09:12 [entrez]
AID - 10.1002/alr.22865 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2021 Dec;11(12):1626-1636. doi: 10.1002/alr.22865. Epub 
      2021 Jul 26.

PMID- 6609524
OWN - NLM
STAT- MEDLINE
DCOM- 19840618
LR  - 20131121
IS  - 0302-2994 (Print)
IS  - 0302-2994 (Linking)
VI  - 523
DP  - 1983
TI  - Vibratory stimulation for the alleviation of chronic pain.
PG  - 1-51
AB  - The pain relieving effect of vibratory stimulation was studied in 731 patients 
      suffering from acute pain (135 patients) or chronic pain (596 patients). Most of 
      the patients had previously undergone treatments of various kinds without 
      sufficient pain relief. The effect of vibratory stimulation was assessed before, 
      during and after stimulation using different rating scales. About 70% of the 
      patients reported reduction of pain during vibratory stimulation. In many 
      patients there was a clear relation between the degree of reduction of pain and 
      the intensity of pain before the beginning of stimulation. In general, relief of 
      pain by more than 50% during stimulation was obtained in the patients who 
      reported light, light to moderate, or moderate pain. The patients with moderate 
      to severe, or severe pain before stimulation generally reported a reduction of 
      pain of 50% or less. The best pain reducing site was found to be either the area 
      of pain or close to it, the antagonistic muscle or a trigger point near the 
      painful area. In most patients suffering from musculoskeletal pain the best pain 
      reducing effect was obtained when the vibratory stimulation was applied with 
      moderate pressure (at which contact was achieved with underlying bone) at a 
      frequency of 50-150 Hz. To obtain a maximal duration of pain relief the 
      stimulation had to be applied for 30-45 minutes. Many of the patients experienced 
      pain relief lasting for more than 3 hours. It may be noticed that in many 
      patients the pain relief lasted for 12 hours or more. There was a good 
      correlation between the degree of pain relief and its duration. In the patients 
      who experienced a pain reduction of 50% or less the pain relief generally lasted 
      for less than 6 hours while in the patients who experienced pain relief of more 
      than 50% it lasted for more than 6 hours. In comparison with high or low 
      frequency TENS, vibratory stimulation was found to be as effective and in some 
      patients even more effective in reducing chronic musculoskeletal or orofacial 
      pain. The effect of 20 Hz, 100 Hz and 200 Hz vibratory stimulation, high 
      frequency TENS, low frequency TENS and "placebo" vibratory stimulation was 
      examined in various chronic musculoskeletal pain syndromes. 82% of the patients 
      experienced a relief of pain with any of the above mentioned methods; 47% of the 
      patients experienced a reduction of pain with vibratory stimulation or TENS 
      stimulation.(ABSTRACT TRUNCATED AT 400 WORDS)
FAU - Lundeberg, T C
AU  - Lundeberg TC
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Acta Physiol Scand Suppl
JT  - Acta physiologica Scandinavica. Supplementum
JID - 0376307
RN  - 36B82AMQ7N (Naloxone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Chronic Disease
MH  - Cryotherapy
MH  - Electric Stimulation Therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naloxone/therapeutic use
MH  - *Pain Management
MH  - Time Factors
MH  - *Vibration
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Physiol Scand Suppl. 1983;523:1-51.

PMID- 8719352
OWN - NLM
STAT- MEDLINE
DCOM- 19960926
LR  - 20190905
IS  - 0036-5599 (Print)
IS  - 0036-5599 (Linking)
VI  - 29
IP  - 4
DP  - 1995 Dec
TI  - Aspirin, a silent risk factor in urology.
PG  - 369-74
AB  - Aspirin is a widely used drug for its analgetic, antiinflamatory and antipyretic 
      effects as well as for prophylactic effect in cardiovascular diseases. However, 
      an increased number of operative hemorrhagic complications in patients on daily 
      aspirin have been reported, an adverse effect highly relevant in urology. In this 
      review the normal hemostatic mechanism and the chief pharmacological effect of 
      aspirin on hemostasis is described. The literature is reviewed for hemorrhagic 
      complications to aspirin in urology. Few reports indicate that aspirin increases 
      bleeding and need for transfusion following prostatectomy, but no 
      placebo-controlled clinical trials with large patient groups have been carried 
      out. Following prostate biopsy and extracorporeal shock wave lithotripsy 
      aspirin-induced hemorrhagic complications have been reported. Cessation of 
      aspirin ingestion one week prior to invasive urologic procedures and correction 
      of bleeding complications with desmopressin, platelet concentration or fresh 
      whole blood is described.
FAU - Zhu, J P
AU  - Zhu JP
AD  - Department of Surgery A, Hillerød Hospital, Denmark.
FAU - Davidsen, M B
AU  - Davidsen MB
FAU - Meyhoff, H H
AU  - Meyhoff HH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Scand J Urol Nephrol
JT  - Scandinavian journal of urology and nephrology
JID - 0114501
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Scand J Urol Nephrol. 1997 Aug;31(4):381. PMID: 9290170
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Lithotripsy
MH  - Male
MH  - Postoperative Hemorrhage/blood/*chemically induced
MH  - Prostate/pathology
MH  - Prostatectomy
MH  - Risk Factors
MH  - Urologic Diseases/blood/*surgery
RF  - 64
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
AID - 10.3109/00365599509180016 [doi]
PST - ppublish
SO  - Scand J Urol Nephrol. 1995 Dec;29(4):369-74. doi: 10.3109/00365599509180016.

PMID- 3113798
OWN - NLM
STAT- MEDLINE
DCOM- 19871020
LR  - 20131121
IS  - 0147-958X (Print)
IS  - 0147-958X (Linking)
VI  - 10
IP  - 3
DP  - 1987 May
TI  - Misoprostol attenuates aspirin-induced changes in potential difference and 
      associated damage in canine gastric mucosa.
PG  - 145-51
AB  - Aspirin induces ulceration, cellular exfoliation, and blood loss associated with 
      decreases in gastric mucosal potential difference (PD). Certain prostaglandins 
      prevent the development of experimental gastric and duodenal ulcers and modify 
      indices related to ulceration. Misoprostol, a synthetic PGE1 derivative with 
      gastric antisecretory and mucosal protective activities, was examined at gastric 
      antisecretory doses in dogs with Heidenhain pouches, to determine its effect on 
      aspirin-associated changes in PD, K+ efflux, blood loss, and cell shedding, as 
      measured by DNA release. These parameters were examined before, during, and up to 
      4 hours after exposure of the pouches to aspirin. Disruption of the gastric 
      mucosal barrier (GMB) by aspirin was associated with a fall in PD and losses of 
      K+, DNA, and blood into the pouches. Misoprostol inhibited the fall in PD and 
      prevented blood loss over the entire period examined. Cell loss was inhibited 
      only during the recovery period immediately following aspirin. The effect of 
      misoprostol on GMB is consistent with studies in which prostaglandins preserve 
      the GMB and prevent necrotic ulcerations while allowing superficial cell damage.
FAU - Gullikson, G W
AU  - Gullikson GW
FAU - Anglin, C P
AU  - Anglin CP
FAU - Kessler, L K
AU  - Kessler LK
FAU - Smeach, S
AU  - Smeach S
FAU - Bauer, R F
AU  - Bauer RF
FAU - Dajani, E Z
AU  - Dajani EZ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Canada
TA  - Clin Invest Med
JT  - Clinical and investigative medicine. Medecine clinique et experimentale
JID - 7804071
RN  - 0 (Anti-Ulcer Agents)
RN  - 0E43V0BB57 (Misoprostol)
RN  - 9007-49-2 (DNA)
RN  - F5TD010360 (Alprostadil)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Alprostadil/*analogs & derivatives/pharmacology
MH  - Animals
MH  - Anti-Ulcer Agents/*pharmacology
MH  - Aspirin/antagonists & inhibitors/*pharmacology
MH  - DNA/metabolism
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Epithelium/pathology
MH  - Female
MH  - Gastric Mucosa/cytology/*drug effects/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Membrane Potentials/*drug effects
MH  - Misoprostol
MH  - Potassium/metabolism
MH  - Stomach Ulcer/chemically induced
EDAT- 1987/05/01 00:00
MHDA- 1987/05/01 00:01
CRDT- 1987/05/01 00:00
PHST- 1987/05/01 00:00 [pubmed]
PHST- 1987/05/01 00:01 [medline]
PHST- 1987/05/01 00:00 [entrez]
PST - ppublish
SO  - Clin Invest Med. 1987 May;10(3):145-51.

PMID- 26640116
OWN - NLM
STAT- MEDLINE
DCOM- 20161019
LR  - 20161230
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 46
IP  - 2
DP  - 2016 Feb
TI  - A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
PG  - 130-40
LID - 10.1111/eci.12575 [doi]
AB  - BACKGROUND: The long-term risk-benefit effect of occasional and regular use of 
      low-dose aspirin (≤ 100 mg per day) in primary prevention of vascular diseases 
      and cancers was calculated. METHODS: One representative database of 1 000 000 
      participants from Taiwan's National Health Insurance scheme in 1997-2000 was 
      used. The potential study subjects were those aged 30-95 years, were found not to 
      have been prescribed aspirin before 1 January 2000, but to have first been 
      prescribed low-dose aspirin (≤ 100 mg per day) after that date and were followed 
      up to 31 December 2009. Participants prescribed low-dose aspirin < 20% during the 
      study period were considered occasional users and those prescribed ≥ 80% regular 
      users. After the propensity score matching, rate differences of haemorrhage, 
      ischaemia and cancer between these users were calculated their net clinical risk. 
      RESULTS: A total of 1720 pairs were analysed. During the study period, 
      haemorrhage and ischaemia occurred in 25 (1·45%) and 67 participants (3·90%) in 
      occasional users and 69 (4·01%) and 100 participants (5·81%) in regular users, 
      whereas cancer occurred in 32 participants (1·86%) in occasional users and 26 
      participants (1·51%) in regular users. The crude and adjusted net clinical risks 
      of low-dose aspirin use between the two frequency of users (≥ 80% vs. < 20%) were 
      4·12% (95% CI = 2·19%, 6·07%; P < 0·001) and 3·93% (95% CI = 2·01%, 5·84%; P < 
      0·001). CONCLUSIONS: A long-term regular use of low-dose aspirin might not be 
      better than occasional use in the primary prevention against major vascular 
      diseases and cancer.
CI  - © 2015 Stichting European Society for Clinical Investigation Journal Foundation.
FAU - Wu, I-Chen
AU  - Wu IC
AD  - Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical 
      University Hospital, Kaohsiung, Taiwan.
AD  - Faculty of Medicine, Department of Medicine, College of Medicine, Kaohsiung 
      Medical University, Kaohsiung, Taiwan.
FAU - Hsieh, Hui-Min
AU  - Hsieh HM
AD  - Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan.
FAU - Yu, Fang-Jung
AU  - Yu FJ
AD  - Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical 
      University Hospital, Kaohsiung, Taiwan.
AD  - Faculty of Medicine, Department of Medicine, College of Medicine, Kaohsiung 
      Medical University, Kaohsiung, Taiwan.
FAU - Wu, Meng-Chieh
AU  - Wu MC
AD  - Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical 
      University Hospital, Kaohsiung, Taiwan.
FAU - Wu, Tzung-Shiun
AU  - Wu TS
AD  - Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical 
      University Hospital, Kaohsiung, Taiwan.
FAU - Wu, Ming-Tsang
AU  - Wu MT
AD  - Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan.
AD  - Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung, 
      Taiwan.
AD  - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160104
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Databases, Factual
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/epidemiology
MH  - Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Intracranial Hemorrhages/chemically induced/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology/prevention & control
MH  - Neoplasms/epidemiology/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Primary Prevention
MH  - Risk Assessment
MH  - Stroke/epidemiology/prevention & control
MH  - Taiwan/epidemiology
OTO - NOTNLM
OT  - cancer
OT  - haemorrhage
OT  - low-dose aspirin
OT  - primary prevention
OT  - risk-benefit analysis
OT  - vascular disease
EDAT- 2015/12/08 06:00
MHDA- 2016/11/12 06:00
CRDT- 2015/12/08 06:00
PHST- 2015/08/03 00:00 [received]
PHST- 2015/11/25 00:00 [accepted]
PHST- 2015/12/08 06:00 [entrez]
PHST- 2015/12/08 06:00 [pubmed]
PHST- 2016/11/12 06:00 [medline]
AID - 10.1111/eci.12575 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2016 Feb;46(2):130-40. doi: 10.1111/eci.12575. Epub 2016 Jan 
      4.

PMID- 239345
OWN - NLM
STAT- MEDLINE
DCOM- 19751028
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 293
IP  - 7
DP  - 1975 Aug 14
TI  - Decreased serum salicylate concentrations in children with rheumatic fever 
      treated with antacid.
PG  - 323-5
AB  - To determine if the common practice of giving antacids to patients on salicylate 
      therapy has an effect on serum salicylate concentrations, we gave a widely used 
      antacid, aluminum and magnesium hydroxide, and aspirin concomitantly to three 
      children with rheumatic fever. Urinary pH increased appreciably, and serum 
      salicylate concentrations decreased by 30 to 70 per cent. In five healthy adult 
      volunteers concomitant administration of antacid had no effect on the 
      bioavailability of aspirin. Pharmacokinetic analysis revealed that the 
      antacid-induced decrease of serum salicylate concentrations was due to increased 
      renal clearance of salicylate caused by the rise in urinalry pH.
FAU - Levy, G
AU  - Levy G
FAU - Lampman, T
AU  - Lampman T
FAU - Kamath, B L
AU  - Kamath BL
FAU - Garrettson, L K
AU  - Garrettson LK
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antacids)
RN  - 0 (Hydroxides)
RN  - 0 (Salicylates)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - I38ZP9992A (Magnesium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aluminum Hydroxide/administration & dosage/adverse effects
MH  - Antacids/*adverse effects
MH  - Aspirin/administration & dosage/metabolism/therapeutic use
MH  - Biological Availability
MH  - Child
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Hydroxides/administration & dosage/adverse effects
MH  - Kidney/physiology
MH  - Magnesium/administration & dosage/adverse effects
MH  - Male
MH  - Rheumatic Fever/*blood/drug therapy/urine
MH  - Salicylates/*blood
EDAT- 1975/08/14 00:00
MHDA- 1975/08/14 00:01
CRDT- 1975/08/14 00:00
PHST- 1975/08/14 00:00 [pubmed]
PHST- 1975/08/14 00:01 [medline]
PHST- 1975/08/14 00:00 [entrez]
AID - 10.1056/NEJM197508142930703 [doi]
PST - ppublish
SO  - N Engl J Med. 1975 Aug 14;293(7):323-5. doi: 10.1056/NEJM197508142930703.

PMID- 23871093
OWN - NLM
STAT- MEDLINE
DCOM- 20140313
LR  - 20130813
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 332
IP  - 1-2
DP  - 2013 Sep 15
TI  - The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary 
      prevention following TIA or stroke: a meta-analysis of randomized controlled 
      trials.
PG  - 92-6
LID - S0022-510X(13)00302-X [pii]
LID - 10.1016/j.jns.2013.06.025 [doi]
AB  - OBJECTIVE: Stroke is becoming a common disease worldwide, and has an increased 
      rate of recurrence yearly after a transient ischemic attack (TIA) or stroke. 
      Aspirin, dipyridamole, clopidogrel and aspirin plus dipyridamole combination 
      therapy have been recommended for the secondary prevention of stroke in 
      Americans. DESIGN: We performed meta-analyses to assess the effectiveness and 
      safety of combination therapy with aspirin and dipyridamole (A+D) versus aspirin 
      (A) alone in secondary prevention after transient ischemic attack (TIA) or stroke 
      of presumed arterial origin within one week and six months. DATA SOURCES: 
      Medline, Embase, and the Cochrane Library. SELECTION OF STUDIES: Eligible studies 
      were completed randomized controlled trials investigating the effect of aspirin 
      plus dipyridamole versus aspirin in patients with previous TIA or stroke. 
      RESULTS: Five trials involving the use of aspirin and dipyridamole were included, 
      4318 allocated to A+D and 4304 to A alone. Meta-analysis of trials showed a 
      significant protective effect of reducing or preventing recurrence of stroke 
      (P=0.01), and ischemic event (P=0.003). The statistics showed no significant 
      difference in vascular event, death from all cause and myocardial infarction 
      (P>0.05). There were similarities with all bleeding events, major bleeding and 
      intracranial hemorrhage was significant (P>0.05) between two groups. CONCLUSIONS: 
      Aspirin plus dipyridamole combination therapy was beneficial in reducing the 
      recurrence of stroke, and did not increase the bleeding event. Hence, aspirin 
      plus dipyridamole combination therapy is effective and safe for the secondary 
      prevention of stroke.
CI  - © 2013 Elsevier B.V. All rights reserved.
FAU - Li, Xia
AU  - Li X
AD  - Department of Intensive Care Units, Gongren Hospital of Liuzhou, Guangxi, China.
FAU - Zhou, Guoyu
AU  - Zhou G
FAU - Zhou, Xueying
AU  - Zhou X
FAU - Zhou, Shengnian
AU  - Zhou S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20130717
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Fibrinolytic Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Neurol Sci. 2014 Jan 15;336(1-2):290. PMID: 24139840
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - *Randomized Controlled Trials as Topic
MH  - Stroke/*drug therapy
OTO - NOTNLM
OT  - Antiplatelet
OT  - Aspirin
OT  - Combination therapy
OT  - Dipyridamole
OT  - Meta analysis
OT  - Stroke prevention
EDAT- 2013/07/23 06:00
MHDA- 2014/03/14 06:00
CRDT- 2013/07/23 06:00
PHST- 2012/12/12 00:00 [received]
PHST- 2013/01/04 00:00 [revised]
PHST- 2013/06/21 00:00 [accepted]
PHST- 2013/07/23 06:00 [entrez]
PHST- 2013/07/23 06:00 [pubmed]
PHST- 2014/03/14 06:00 [medline]
AID - S0022-510X(13)00302-X [pii]
AID - 10.1016/j.jns.2013.06.025 [doi]
PST - ppublish
SO  - J Neurol Sci. 2013 Sep 15;332(1-2):92-6. doi: 10.1016/j.jns.2013.06.025. Epub 
      2013 Jul 17.

PMID- 32513597
OWN - NLM
STAT- MEDLINE
DCOM- 20210615
LR  - 20211002
IS  - 1878-0946 (Electronic)
IS  - 1744-165X (Print)
IS  - 1744-165X (Linking)
VI  - 25
IP  - 5
DP  - 2020 Oct
TI  - Prevention of preeclampsia.
PG  - 101123
LID - S1744-165X(20)30048-2 [pii]
LID - 10.1016/j.siny.2020.101123 [doi]
AB  - Preeclampsia is an obstetric disorder that affects 3-8% of pregnant women and 
      remains a leading cause of short- and long-term neonatal and maternal morbidity 
      and mortality. Professional societies recommend the use of low dose aspirin to 
      prevent preeclampsia in high-risk women. However, interest in prevention of this 
      disease and better understanding of its pathophysiology have led to growing 
      research on other agents. This review focuses on the main therapeutic agents 
      evaluated or in use for preeclampsia prevention.
CI  - © 2020 Elsevier Ltd. All rights reserved.
FAU - Ma'ayeh, Marwan
AU  - Ma'ayeh M
AD  - Department of Obstetrics & Gynecology, The Ohio State University College of 
      Medicine, 395 W 12th Ave, 5th Floor, Columbus, OH, USA. Electronic address: 
      maay01@osumc.edu.
FAU - Costantine, Maged M
AU  - Costantine MM
AD  - Department of Obstetrics & Gynecology, The Ohio State University College of 
      Medicine, 395 W 12th Ave, 5th Floor, Columbus, OH, USA.
LA  - eng
GR  - UG1 HD027915/HD/NICHD NIH HHS/United States
GR  - UH3 HL140131/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200602
PL  - Netherlands
TA  - Semin Fetal Neonatal Med
JT  - Seminars in fetal & neonatal medicine
JID - 101240003
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Hypertension/drug therapy/prevention & control
MH  - Pre-Eclampsia/*drug therapy/physiopathology/*prevention & control
MH  - Pregnancy
PMC - PMC8236336
MID - NIHMS1717580
OTO - NOTNLM
OT  - Aspirin
OT  - Esomeprazole
OT  - Metformin
OT  - Preeclampsia
OT  - Pregnancy
OT  - Statin
EDAT- 2020/06/10 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - S1744-165X(20)30048-2 [pii]
AID - 10.1016/j.siny.2020.101123 [doi]
PST - ppublish
SO  - Semin Fetal Neonatal Med. 2020 Oct;25(5):101123. doi: 10.1016/j.siny.2020.101123. 
      Epub 2020 Jun 2.

PMID- 6606362
OWN - NLM
STAT- MEDLINE
DCOM- 19840126
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 75
IP  - 5A
DP  - 1983 Nov 14
TI  - Pharmacokinetic considerations of common analgesics and antipyretics.
PG  - 30-7
AB  - Knowledge of pharmacokinetics (action of organisms on drugs) and pharmacodynamics 
      (drug action on living organisms) allows for the proper assessment of the most 
      suitable dose, dosing intervals, route of administration, as well as dose 
      adjustment when clinically indicated. The basic physical scientific principles of 
      the movement of drug particles across biologic barriers, their subsequent 
      conversion to other chemical forms, and their elimination are reviewed in general 
      terms. The specific metabolic pathways for aspirin and paracetamol 
      (acetaminophen) are then discussed in more detail. Elimination of salicylate 
      involves two saturable (nonlinear) major pathways and three apparently 
      first-order (linear) minor pathways; these mixed order kinetics lead to somewhat 
      complex mathematics affecting elimination half-life which, in turn, can have 
      implications for anticipating side effects and toxicity. The kinetics of 
      acetaminophen also involve various pathways, but studies have shown a good 
      correlation between the expected and the observed elimination half-life of this 
      drug. Comparison is made between the in vivo handling of the two analgesics, but 
      it is stressed that these data apply only to healthy adults under normal 
      conditions and cannot be extrapolated to patients with underlying disease 
      processes.
FAU - Hartwig-Otto, H
AU  - Hartwig-Otto H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/metabolism
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism
MH  - Aspirin/metabolism
MH  - Biotransformation
MH  - Half-Life
MH  - Humans
MH  - Kinetics
MH  - Models, Biological
EDAT- 1983/11/14 00:00
MHDA- 1983/11/14 00:01
CRDT- 1983/11/14 00:00
PHST- 1983/11/14 00:00 [pubmed]
PHST- 1983/11/14 00:01 [medline]
PHST- 1983/11/14 00:00 [entrez]
AID - 0002-9343(83)90230-9 [pii]
AID - 10.1016/0002-9343(83)90230-9 [doi]
PST - ppublish
SO  - Am J Med. 1983 Nov 14;75(5A):30-7. doi: 10.1016/0002-9343(83)90230-9.

PMID- 8357092
OWN - NLM
STAT- MEDLINE
DCOM- 19930921
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 44
IP  - 9
DP  - 1993 Sep
TI  - Clinical and angiographic determinants of initial percutaneous transluminal 
      coronary angioplasty success.
PG  - 677-82
AB  - Clinical and anatomic determinants of primary success of percutaneous 
      transluminal coronary angioplasty were retrospectively evaluated in 299 patients. 
      Successful angioplasty (residual stenosis < 50%) was achieved in 350 (94%) of 373 
      lesions. The success rate in patients chronically treated with aspirin was higher 
      than that of patients not treated with aspirin (95% versus 86%, P < 0.03). An 
      additional finding was that the success rate in patients referred for coronary 
      angioplasty because of acute myocardial infarction or postinfarction angina was 
      lower than that of those without these characteristics (89% versus 96%, P < 
      0.01). No other clinical features studied influenced the outcome of coronary 
      angioplasty. The angiographic characteristics of the lesions did not differ 
      between patients with successful or failed angioplasty except for the degree of 
      stenosis prior to the procedure, being lower in patients with successful 
      procedure (92.4 +/- 7.6% versus 97.3 +/- 3.1%), P < 0.002). Thus coronary 
      angioplasty can be performed with a high rate of success. Long-term pretreatment 
      with aspirin may have a beneficial effect.
FAU - Ilia, R
AU  - Ilia R
AD  - Department of Internal Medicine, Yale University School of Medicine, New Haven, 
      Connecticut.
FAU - Kolanski, D
AU  - Kolanski D
FAU - Setaro, J
AU  - Setaro J
FAU - Brennan, J
AU  - Brennan J
FAU - Cabin, H
AU  - Cabin H
FAU - Cleman, M
AU  - Cleman M
FAU - Remetz, M
AU  - Remetz M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/therapy
MH  - Angiography
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/therapeutic use
MH  - Coronary Artery Bypass
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/therapy
MH  - Retrospective Studies
EDAT- 1993/09/01 00:00
MHDA- 1993/09/01 00:01
CRDT- 1993/09/01 00:00
PHST- 1993/09/01 00:00 [pubmed]
PHST- 1993/09/01 00:01 [medline]
PHST- 1993/09/01 00:00 [entrez]
AID - 10.1177/000331979304400901 [doi]
PST - ppublish
SO  - Angiology. 1993 Sep;44(9):677-82. doi: 10.1177/000331979304400901.

PMID- 26073347
OWN - NLM
STAT- MEDLINE
DCOM- 20160427
LR  - 20220317
IS  - 1532-8406 (Electronic)
IS  - 0883-5403 (Linking)
VI  - 30
IP  - 9 Suppl
DP  - 2015 Sep
TI  - Direct Costs of Aspirin versus Warfarin for Venous Thromboembolism Prophylaxis 
      after Total Knee or Hip Arthroplasty.
PG  - 36-8
LID - S0883-5403(15)00477-5 [pii]
LID - 10.1016/j.arth.2015.04.048 [doi]
AB  - Interest in aspirin as an alternative strategy for venous thromboembolism 
      prophylaxis after arthroplasty has grown, as studies have suggested improved 
      clinical efficacy and lower complication rates with aspirin compared to warfarin. 
      The goal of this study was to compare the direct costs of an episode of 
      arthroplasty care, when using aspirin instead of warfarin. The charts of patients 
      who either received aspirin or warfarin after arthroplasty from January 2008 to 
      March 2010 were retrospectively reviewed. Charges were recorded for their index 
      admission, and for subsequent admissions related to either VTE or complications 
      of prophylaxis. Multivariate analysis revealed that aspirin was an independent 
      predictor of decreased cost of index hospitalization, and total episode of care 
      charges, achieved largely through a shorter length of hospitalization.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Gutowski, Christina J
AU  - Gutowski CJ
AD  - Department of Orthopaedic Surgery, Thomas Jefferson University Hospital, 
      Philadelphia, Pennsylvania.
FAU - Zmistowski, Benjamin M
AU  - Zmistowski BM
AD  - Department of Orthopaedic Surgery, Thomas Jefferson University Hospital, 
      Philadelphia, Pennsylvania.
FAU - Lonner, Jess H
AU  - Lonner JH
AD  - Rothman Institute for Orthopaedics, Sewell, New Jersey.
FAU - Purtill, James J
AU  - Purtill JJ
AD  - Rothman Institute for Orthopaedics, Philadelphia, Pennsylvania.
FAU - Parvizi, Javad
AU  - Parvizi J
AD  - Rothman Institute for Orthopaedics, Philadelphia, Pennsylvania.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20150603
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/therapeutic use
MH  - Arthroplasty, Replacement, Hip/*economics
MH  - Arthroplasty, Replacement, Knee/*economics
MH  - Aspirin/*economics/therapeutic use
MH  - Female
MH  - Health Care Costs
MH  - Humans
MH  - Length of Stay/economics
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Patient Admission
MH  - Patient Satisfaction
MH  - Postoperative Period
MH  - Retrospective Studies
MH  - Venous Thromboembolism/*drug therapy/etiology/*prevention & control
MH  - Warfarin/*economics/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - aspirin
OT  - cost analysis
OT  - total joint arthroplasty
OT  - venous thromboembolism prophylaxis
OT  - warfarin
EDAT- 2015/06/16 06:00
MHDA- 2016/04/28 06:00
CRDT- 2015/06/16 06:00
PHST- 2014/08/02 00:00 [received]
PHST- 2015/04/08 00:00 [revised]
PHST- 2015/04/13 00:00 [accepted]
PHST- 2015/06/16 06:00 [entrez]
PHST- 2015/06/16 06:00 [pubmed]
PHST- 2016/04/28 06:00 [medline]
AID - S0883-5403(15)00477-5 [pii]
AID - 10.1016/j.arth.2015.04.048 [doi]
PST - ppublish
SO  - J Arthroplasty. 2015 Sep;30(9 Suppl):36-8. doi: 10.1016/j.arth.2015.04.048. Epub 
      2015 Jun 3.

PMID- 327730
OWN - NLM
STAT- MEDLINE
DCOM- 19770812
LR  - 20161123
IS  - 0044-409X (Print)
IS  - 0044-409X (Linking)
VI  - 102
IP  - 8
DP  - 1977
TI  - [Possibilities of drug-induced prevention of thrombosis with special reference to 
      pre-, per- and postoperative time of treatment].
PG  - 449-58
AB  - According to the postoperative prophylaxis of thromboembolia a review of actual 
      publications is given. The therapeutical problems of Coumarin, Dextran, 
      Acetylsalicylic acid and low dosis Heparin were discussed. A final answer to the 
      various questions can not be given. Concerning the prophylaxis low dosis Heparin 
      seems to become the anticoagulant of choice.
FAU - Fisher, M
AU  - Fisher M
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Möglichkeiten der medikamentösen Thromboseprophylaxe unter besonderer 
      Berücksichtigung der prä-, per- und postoperativen Behandlungszeit.
PL  - Germany
TA  - Zentralbl Chir
JT  - Zentralblatt fur Chirurgie
JID - 0413645
RN  - 0 (Coumarins)
RN  - 0 (Dextrans)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Coumarins/therapeutic use
MH  - Dextrans/therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Phlebography
MH  - Postoperative Complications/prevention & control
MH  - Thromboembolism/diagnostic imaging/*prevention & control
MH  - Time Factors
RF  - 40
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Zentralbl Chir. 1977;102(8):449-58.

PMID- 27888917
OWN - NLM
STAT- MEDLINE
DCOM- 20170327
LR  - 20170327
IS  - 1557-8259 (Electronic)
IS  - 0030-6665 (Linking)
VI  - 50
IP  - 1
DP  - 2017 Feb
TI  - Aspirin-Exacerbated Respiratory Disease.
PG  - 83-94
LID - S0030-6665(16)30165-7 [pii]
LID - 10.1016/j.otc.2016.08.007 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is characterized by the triad of 
      asthma, sinonasal polyposis, and aspirin intolerance. The hallmark of the disease 
      is baseline overproduction of cysteinyl leukotrienes via the 5-lipoxygenase 
      pathway, exacerbated by ingestion of aspirin. Patients with AERD have high rates 
      of recidivistic polyposis following sinus surgery, although the improvement in 
      quality of life following surgery is similar to aspirin-tolerant patients. The 
      diagnosis is secured by a positive aspirin provocation test, usually administered 
      by a medical allergist. Aspirin therapy is a unique treatment consideration for 
      patients with AERD.
CI  - Copyright Â© 2016 Elsevier Inc. All rights reserved.
FAU - Walgama, Evan S
AU  - Walgama ES
AD  - Department of Otolaryngology/Head and Neck Surgery, Stanford School of Medicine, 
      Stanford Sinus Center, 801 Welch Road, Palo Alto, CA 94304, USA.
FAU - Hwang, Peter H
AU  - Hwang PH
AD  - Department of Otolaryngology/Head and Neck Surgery, Stanford School of Medicine, 
      Stanford Sinus Center, 801 Welch Road, Palo Alto, CA 94304, USA. Electronic 
      address: hwangph@stanford.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Otolaryngol Clin North Am
JT  - Otolaryngologic clinics of North America
JID - 0144042
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Leukotrienes)
RN  - EC 1.13.11.34 (Arachidonate 5-Lipoxygenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology
MH  - Arachidonate 5-Lipoxygenase/metabolism
MH  - *Aspirin/adverse effects/pharmacology
MH  - *Asthma, Aspirin-Induced/diagnosis/metabolism/therapy
MH  - Disease Management
MH  - Humans
MH  - Leukotrienes/metabolism
MH  - *Nasal Polyps/etiology/metabolism/therapy
OTO - NOTNLM
OT  - Aspirin-exacerbated respiratory disease
OT  - Chronic rhinosinusitis
OT  - Nasal polyposis
OT  - Sinus surgery
EDAT- 2016/11/28 06:00
MHDA- 2017/03/28 06:00
CRDT- 2016/11/28 06:00
PHST- 2016/11/28 06:00 [entrez]
PHST- 2016/11/28 06:00 [pubmed]
PHST- 2017/03/28 06:00 [medline]
AID - S0030-6665(16)30165-7 [pii]
AID - 10.1016/j.otc.2016.08.007 [doi]
PST - ppublish
SO  - Otolaryngol Clin North Am. 2017 Feb;50(1):83-94. doi: 10.1016/j.otc.2016.08.007.

PMID- 17691998
OWN - NLM
STAT- MEDLINE
DCOM- 20070830
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 13
IP  - 22
DP  - 2007
TI  - How to advise aspirin use in patients who need NSAIDs.
PG  - 2248-60
AB  - NSAIDs are widely used all over the world. NSAID use is rising due to increasing 
      availability without a prescription, use of aspirin for prevention of thrombotic 
      disorders and the ageing population. Aspirin is used as an analgesic drug in many 
      countries, but the main current indication is low-dose aspirin for the prevention 
      of cardiovascular events. However, NSAIDs and aspirin use account for 
      approximately 20-25% of all reported drug adverse events. Most of those are 
      gastrointestinal including dyspepsia, hemorrhage, perforation and even death. The 
      COX-2- selective inhibitors (coxibs) have demonstrated equivalent efficacy to 
      nonspecific NSAIDs in the management of arthritis and pain but have less 
      gastrointestinal adverse events, although coxibs and probably all NSAIDs, 
      significantly increase risk of serious thromboembolic events. Concomitant use of 
      low-dose aspirin is present in more than 20% of all patients taking either NSAIDs 
      or coxibs, thus increasing the risk of gastrointestinal side effects. 
      Furthermore, at present, it is not known whether aspirin decreases the 
      cardiovascular risks of COX-2 inhibitors or NSAIDs. Appropriate strategies for 
      gastrointestinal risk reduction with NSAIDs and aspirin must consider the overall 
      health status of our patients including the presence of cardiovascular and 
      gastrointestinal risk factors. Use of the lowest possible dose of these drugs, 
      gastroprotectants, especially proton pump inhibitors and Helicobacter pylori 
      eradication will reduce the risk of gastrointestinal side effects in patients 
      taking low-dose aspirin and NSAIDs or coxibs.
FAU - Sopena, F
AU  - Sopena F
AD  - Department of Gastroenterology University Hospital Lozano Blesa Zaragoza, Spain.
FAU - Lanas, A
AU  - Lanas A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/chemically induced/*prevention & control
MH  - Cyclooxygenase 2 Inhibitors/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Pain/*drug therapy
MH  - Risk Assessment
MH  - Risk Factors
RF  - 100
EDAT- 2007/08/21 09:00
MHDA- 2007/08/31 09:00
CRDT- 2007/08/21 09:00
PHST- 2007/08/21 09:00 [pubmed]
PHST- 2007/08/31 09:00 [medline]
PHST- 2007/08/21 09:00 [entrez]
AID - 10.2174/138161207781368837 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2007;13(22):2248-60. doi: 10.2174/138161207781368837.

PMID- 31994783
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20210611
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 27
IP  - 5
DP  - 2020 May
TI  - Risk factors associated with progressive lacunar strokes and benefit from dual 
      antiplatelet therapy.
PG  - 817-824
LID - 10.1111/ene.14159 [doi]
AB  - BACKGROUND AND PURPOSE: Early neurological deterioration (END) occurs in 20%-30% 
      of patients with lacunar stroke and challenges their clinical management. This 
      retrospective cohort study analyzed clinical and neuroimaging risk factors 
      predicting the occurrence of END, the functional outcome after END and potential 
      benefit from dual antiplatelet therapy (DAPT) in patients with lacunar strokes. 
      METHODS: Factors associated with END and benefit from DAPT were retrospectively 
      analyzed in 308 patients with lacunar stroke symptoms and detected lacunar 
      infarction by magnetic resonance imaging. END was defined by deterioration of ≥3 
      total National Institutes of Health Stroke Scale (NIHSS) points, ≥2 NIHSS points 
      for limb paresis or documented deterioration within 5 days after admission. 
      Patients were treated with DAPT according to in-house standards. The primary 
      efficacy end-point for functional outcome was fulfilled if NIHSS at discharge 
      improved after END at least to the score at admission. RESULTS: Male gender [odds 
      ratio (OR) 2.08; 95% confidence interval (CI) 1.09-4.00], higher age (OR = 1.65 
      per 10 years; 95% CI 1.18-2.31), motor paresis (OR = 18.89, 95% CI 4.66-76.57) 
      and infarction of the internal capsule or basal ganglia (OR = 3.58, 95% CI 
      1.26-10.14) were associated with an increased risk for END. A larger diameter of 
      infarction (OR = 0.85, 95% CI 0.76-0.95), more microangiopathic lesions 
      (OR = 0.75, 95% CI 0.57-0.99) and pontine localization (OR = 0.29, 95% CI 
      0.12-0.65) were factors associated with unfavorable functional outcome after END 
      occurred. Localization in the internal capsule or basal ganglia was identified as 
      a significant predictive factor for a benefit from DAPT after END. CONCLUSIONS: 
      Identified clinical and neuroimaging factors predicting END occurrence, 
      functional outcome after END and potential benefit from DAPT might improve the 
      clinical management of patients with lacunar strokes.
CI  - © 2020 The Authors. European Journal of Neurology published by John Wiley & Sons 
      Ltd on behalf of European Academy of Neurology.
FAU - Berberich, A
AU  - Berberich A
AUID- ORCID: 0000-0002-6991-1334
AD  - Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
FAU - Schneider, C
AU  - Schneider C
AD  - Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
FAU - Herweh, C
AU  - Herweh C
AD  - Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, 
      Germany.
FAU - Hielscher, T
AU  - Hielscher T
AD  - Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
FAU - Reiff, T
AU  - Reiff T
AD  - Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
FAU - Bendszus, M
AU  - Bendszus M
AD  - Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, 
      Germany.
FAU - Gumbinger, C
AU  - Gumbinger C
AD  - Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
FAU - Ringleb, P
AU  - Ringleb P
AD  - Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200218
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*therapeutic use
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stroke, Lacunar/diagnostic imaging/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - dual antiplatelet therapy
OT  - lacunar stroke
OT  - risk factors
EDAT- 2020/01/30 06:00
MHDA- 2021/06/12 06:00
CRDT- 2020/01/30 06:00
PHST- 2019/09/26 00:00 [received]
PHST- 2020/01/22 00:00 [accepted]
PHST- 2020/01/30 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
PHST- 2020/01/30 06:00 [entrez]
AID - 10.1111/ene.14159 [doi]
PST - ppublish
SO  - Eur J Neurol. 2020 May;27(5):817-824. doi: 10.1111/ene.14159. Epub 2020 Feb 18.

PMID- 25493120
OWN - NLM
STAT- MEDLINE
DCOM- 20150914
LR  - 20220321
IS  - 1936-9018 (Electronic)
IS  - 1936-900X (Print)
IS  - 1936-900X (Linking)
VI  - 15
IP  - 7
DP  - 2014 Nov
TI  - Shock index and prediction of traumatic hemorrhagic shock 28-day mortality: data 
      from the DCLHb resuscitation clinical trials.
PG  - 795-802
LID - 10.5811/westjem.2014.7.21304 [doi]
AB  - INTRODUCTION: To assess the ability of the shock index (SI) to predict 28-day 
      mortality in traumatic hemorrhagic shock patients treated in the diaspirin 
      cross-linked hemoglobin (DCLHb) resuscitation clinical trials. METHODS: We used 
      data from two parallel DCLHb traumatic hemorrhagic shock efficacy trials, one in 
      U.S. emergency departments, and one in the European Union prehospital setting to 
      assess the relationship between SI values and 28-day mortality. RESULTS: In the 
      219 patients, the mean age was 37 years, 64% sustained a blunt injury, 48% 
      received DCLHb, 36% died, and 88% had an SI≥1.0 at study entry. The percentage of 
      patients with an SI≥1.0 dropped by 57% (88 to 38%) from the time of study entry 
      to 120 minutes after study resuscitation (p<0.001). Patients with a SI≥1.0, 1.4, 
      and 1.8 at any time point were 2.3, 2.7, and 3.1 times, respectively, more likely 
      to die by 28 days than were patients with SI values below these cutoffs 
      (p<0.001). Similarly, after 120 minutes of resuscitation, patients with a SI≥1.0 
      were 3.9× times more likely to die by 28 days (40 vs. 15%, p<0.001). Although the 
      distribution of SI values differed based on treatment group, the receiver 
      operator characeristics data showed no difference in SI predictive ability for 
      28-day mortality in patients treated with DCLHb. CONCLUSION: In these traumatic 
      hemorrhagic shock patients, the shock index correlates with 28-day mortality, 
      with higher SI values indicating greater mortality risk. Although DCLHb treatment 
      did alter the distribution of SI values, it did not influence the ability of the 
      SI to predict 28-day mortality.
FAU - Sloan, Edward P
AU  - Sloan EP
AD  - University of Illinois at Chicago, Department of Emergency Medicine, Chicago, 
      Illinois.
FAU - Koenigsberg, Max
AU  - Koenigsberg M
AD  - Advocate Illinois Masonic Medical Center, Department of Emergency Medicine, 
      Chicago, Illinois.
FAU - Clark, James M
AU  - Clark JM
AD  - Rush Medical College, Rush University Medical Center, Chicago, Illinois.
FAU - Weir, William B
AU  - Weir WB
AD  - University of Illinois College of Medicine at Urbana-Champaign, Carle Physician 
      Group, Department of Emergency Medicine, Illinois.
FAU - Philbin, Nora
AU  - Philbin N
AD  - Unity Point Methodist, Department of Pediatrics, Peoria, Illinois.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140925
PL  - United States
TA  - West J Emerg Med
JT  - The western journal of emergency medicine
JID - 101476450
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Blood Substitutes/*therapeutic use
MH  - *Emergency Medical Services
MH  - Europe/epidemiology
MH  - Female
MH  - Fluid Therapy
MH  - Hemoglobins/*therapeutic use
MH  - Humans
MH  - Male
MH  - Predictive Value of Tests
MH  - *Resuscitation/methods/mortality
MH  - Shock, Hemorrhagic/etiology/mortality/prevention & control/*therapy
MH  - Survival Analysis
MH  - Time Factors
MH  - Treatment Outcome
MH  - United States/epidemiology
MH  - Wounds and Injuries/complications/mortality/physiopathology/*therapy
PMC - PMC4251221
EDAT- 2014/12/11 06:00
MHDA- 2015/09/15 06:00
CRDT- 2014/12/11 06:00
PHST- 2014/01/25 00:00 [received]
PHST- 2014/06/19 00:00 [revised]
PHST- 2014/07/31 00:00 [accepted]
PHST- 2014/12/11 06:00 [entrez]
PHST- 2014/12/11 06:00 [pubmed]
PHST- 2015/09/15 06:00 [medline]
AID - wjem-15-795 [pii]
AID - 10.5811/westjem.2014.7.21304 [doi]
PST - ppublish
SO  - West J Emerg Med. 2014 Nov;15(7):795-802. doi: 10.5811/westjem.2014.7.21304. Epub 
      2014 Sep 25.

PMID- 12804454
OWN - NLM
STAT- MEDLINE
DCOM- 20030728
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 2
DP  - 2003
TI  - Anti-inflammatory treatment for carditis in acute rheumatic fever.
PG  - CD003176
AB  - BACKGROUND: Rheumatic heart disease remains the most important cause of acquired 
      heart disease in developing countries. Although the prevention of rheumatic fever 
      and the management of recurrences is well established the optimal management of 
      active rheumatic carditis is still unclear. OBJECTIVES: To assess the effects of 
      anti-inflammatory agents such as aspirin, corticosteroids and immunoglobulin for 
      preventing or reducing further heart valve damage in patients with acute 
      rheumatic fever. SEARCH STRATEGY: We searched the Cochrane Controlled Trials 
      Register (Issue 4, 2000), MEDLINE (1966 to April 2002), EMBASE (1998 to November 
      2002), LILACS (1998 to November 2002), Index Medicus (1950 to December 2000) and 
      references lists of identified studies. SELECTION CRITERIA: Randomised controlled 
      trials comparing anti-inflammatory agents (e.g. aspirin, steroids, 
      immunoglobulins) with placebo or controls, or comparing any of the 
      anti-inflammatory agents with one another, in patients with acute rheumatic fever 
      diagnosed according to the Jones, or modified Jones criteria. The presence of 
      cardiac disease one year after treatment was the major outcome criteria selected. 
      DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and 
      assessed trial quality. MAIN RESULTS: Eight randomised controlled trials 
      involving 996 people were included. Several steroidal agents viz. ACTH, 
      cortisone, hydrocortisone, dexamethasone and prednisone, and intravenous 
      immunoglobulin were compared to aspirin, placebo or no treatment in the various 
      studies. Six of the trials were conducted between 1950 and 1965, whilst the 
      remaining two were done in the last 10 years. Overall there was no significant 
      difference in the risk of cardiac disease at one year between the 
      corticosteroid-treated and aspirin-treated groups (relative risk 0.87, 95% 
      confidence interval 0.66 to 1.15). Similarly use of prednisone (relative risk 
      1.78, 95% confidence interval 0.98 to 3.34) or intravenous immunoglobulins 
      (relative risk 0.87, 95%confidence interval 0.55 to 1.39) when compared to 
      placebo did not reduce the risk of developing heart valve lesions at one year. 
      REVIEWER'S CONCLUSIONS: There is no benefit in using corticosteroids or 
      intravenous immunoglobulins to reduce the risk of heart valve lesions in patients 
      with acute rheumatic fever. The antiquity of most of the trials restricted 
      adequate statistical analysis of the data and acceptable assessment of clinical 
      outcomes by current standards. New randomised controlled trials in patients with 
      acute rheumatic fever to assess the effects of corticosteroids such as oral 
      prednisone and intravenous methylprednisone, and other new anti-inflammatory 
      agents are warranted. Advances in echocardiography will allow for more objective 
      and precise assessment of cardiac outcomes.
FAU - Cilliers, A M
AU  - Cilliers AM
AD  - Division of Paediatric Cardiology, Chris Hani Baragwanath Hospital, P.O. Box 
      2588, Northcliff, Johannesburg, South Africa. amcilliers@icon.co.za
FAU - Manyemba, J
AU  - Manyemba J
FAU - Saloojee, H
AU  - Saloojee H
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Steroids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UIN - Cochrane Database Syst Rev. 2012;6:CD003176. PMID: 22696333
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Myocarditis/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Rheumatic Heart Disease/*drug therapy
MH  - Steroids
RF  - 62
EDAT- 2003/06/14 05:00
MHDA- 2003/07/29 05:00
CRDT- 2003/06/14 05:00
PHST- 2003/06/14 05:00 [pubmed]
PHST- 2003/07/29 05:00 [medline]
PHST- 2003/06/14 05:00 [entrez]
AID - 10.1002/14651858.CD003176 [doi]
PST - ppublish
SO  - Cochrane Database Syst Rev. 2003;(2):CD003176. doi: 10.1002/14651858.CD003176.

PMID- 15199473
OWN - NLM
STAT- MEDLINE
DCOM- 20040722
LR  - 20131121
IS  - 1528-9648 (Print)
IS  - 1528-9648 (Linking)
VI  - 3
IP  - 2
DP  - 2003 May
TI  - Aspirin and other cyclooxygenase inhibitors: new therapeutic insights.
PG  - 107-12
AB  - Aspirin acetylates serine-530 of cyclooxygenase-1 (COX-1), thereby blocking 
      thromboxane A (2) synthesis in platelets and reducing platelet aggregation. This 
      mechanism of action accounts for the effect of aspirin on prevention of coronary 
      artery and cerebrovascular thrombosis. Aspirin is less effective in inhibiting 
      COX-2 activity, whereas celecoxib and rofecoxib selectively inhibit COX-2 
      activity as they contain a side chain to anchor to the side pocket of COX-2 
      substrate channel. Aspirin and salicylate at therapeutic concentrations inhibit 
      COX-2 protein expression through interference with binding of CCAAT/enhancer 
      binding protein beta (C/EBPbeta) to its cognate site on COX-2 promoter/enhancer. 
      Expression of other genes, such as inducible nitric oxide synthase and 
      interleukin-4, may be inhibited by aspirin and salicylate by a C/EBP-dependent 
      mechanism. Aspirin at suprapharmacological concentrations inhibits 
      NF-kappaB-mediated gene transcription and protects tissue from injury. These 
      recent studies provide new insight into the pharmacological actions of aspirin 
      and salicylate preparations and implicate C/EBPbeta as a potential target for 
      therapy of inflammation and tissue injury.
FAU - Wu, Kenneth K
AU  - Wu KK
AD  - Vascular Biology Research Center and Division of Hematology, The University of 
      Texas-Houston Health Science Center, Houston, TX 77030-1503, USA. 
      kenneth.k.wu@uth.tmc.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Vasc Med
JT  - Seminars in vascular medicine
JID - 100940307
RN  - 0 (CCAAT-Enhancer-Binding Protein-beta)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - 0 (NF-kappa B)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*pharmacology/therapeutic use
MH  - CCAAT-Enhancer-Binding Protein-beta/metabolism
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/adverse effects/*pharmacology
MH  - Enzyme Induction/drug effects
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Isoenzymes/biosynthesis/genetics/metabolism
MH  - Membrane Proteins
MH  - NF-kappa B/genetics
MH  - Phosphorylation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/biosynthesis/genetics/metabolism
MH  - Protein Binding/drug effects
MH  - Sodium Salicylate/pharmacology/therapeutic use
MH  - Transcriptional Activation/drug effects
RF  - 34
EDAT- 2004/06/17 05:00
MHDA- 2004/07/23 05:00
CRDT- 2004/06/17 05:00
PHST- 2004/06/17 05:00 [pubmed]
PHST- 2004/07/23 05:00 [medline]
PHST- 2004/06/17 05:00 [entrez]
AID - 10.1055/s-2003-40668 [doi]
PST - ppublish
SO  - Semin Vasc Med. 2003 May;3(2):107-12. doi: 10.1055/s-2003-40668.

PMID- 31222516
OWN - NLM
STAT- MEDLINE
DCOM- 20200522
LR  - 20200522
IS  - 0942-0940 (Electronic)
IS  - 0001-6268 (Linking)
VI  - 161
IP  - 8
DP  - 2019 Aug
TI  - The importance of aspirin, catheterization accuracy, and catheter design in 
      external ventricular drainage-related hemorrhage: a multicenter study of 1002 
      procedures.
PG  - 1623-1632
LID - 10.1007/s00701-019-03978-2 [doi]
AB  - BACKGROUND: External ventricular drainage (EVD) is the commonest neurosurgical 
      procedure performed in daily neurosurgical practice, but relatively few studies 
      have investigated the incidence and risk factors of its related hemorrhagic 
      complications. METHODS: This was a multicenter retrospective review of 
      consecutive EVD procedures. Patients 18 years or older who underwent EVD and had 
      a routine postoperative computed tomography (CT) scan performed within 24 hours 
      were included. EVD-related hemorrhage was defined as new intracranial hemorrhage 
      immediately adjacent or within the ventricular catheter trajectory. The volume of 
      hemorrhage and the position of the catheter tip were assessed. A review of 
      patient-, disease-, and surgery-related factors including the ventricular 
      catheter design utilized was conducted. The Bonferroni correction was applied to 
      the alpha level of significance (0.05) for multivariable analysis. RESULTS: Nine 
      hundred sixty-two patients underwent 1002 EVD performed by neurosurgeons in the 
      operating theater. Sixteen percent (154) of patients were on aspirin before the 
      procedure. Thirty-four percent (333) of patients had intracerebral hemorrhage, 
      25% (251) had aneurysmal subarachnoid hemorrhage and 16% (158) had traumatic 
      brain injury. The mean duration from EVD to the first postoperative CT scan was 
      20 ± 4 h. EVD-related hematomas were detected after 81 procedures with a 
      per-catheter risk of 8.1%. Mean hematoma volume was 1.2 ± 3.3 ml. Most were less 
      than 1 ml (grade I, 79%, 64), 1 to 15 ml (grade II) in 20% (16) and a single clot 
      larger than 15 ml (grade III, 1%) were detected. Clinically significant 
      hemorrhage that resulted in catheter occlusion occurred in 1.7% (17) of 
      procedures. Most catheters (62%, 625) were optimally placed, i.e., its tip being 
      within the ipsilateral frontal horn or third ventricle. Three 
      non-antibiotic-impregnated ventricular catheter designs were used with 55% (550) 
      being the 2.2-mm Integra™ catheter, 14% (137) being the 2.8-mm Medtronic™ 
      catheter, and 31% (315) being the 3.1-mm Codman™ catheter. Independent 
      significant predictors for EVD-related hemorrhage were the preoperative 
      prescription of aspirin (adjusted OR 1.94; 95% CI 1.10-3.44), catheter 
      malposition (aOR 1.99; 95% CI 1.22-3.23), and use of the 2.8-mm Medtronic™ 
      catheter (aOR 4.22; 95% CI 2.39-7.41). CONCLUSIONS: The per-catheter risk of 
      hemorrhage was 8.1%, but the incidence of symptomatic hemorrhage was low. The 
      only patient risk factor was aspirin intake. This is the first study to evaluate 
      and establish an association between catheter malposition and catheter design 
      with EVD-related hemorrhage.
FAU - Woo, Peter Y M
AU  - Woo PYM
AUID- ORCID: 0000-0002-7345-7904
AD  - Department of Neurosurgery, Kwong Wah Hospital, Hong Kong, China. 
      wym307@ha.org.hk.
FAU - Ng, Ben C F
AU  - Ng BCF
AD  - Department of Neurosurgery, Queen Elizabeth Hospital, Hong Kong, China.
FAU - Xiao, Jacob X
AU  - Xiao JX
AD  - Department of Neurosurgery, Kwong Wah Hospital, Hong Kong, China.
FAU - Wong, Daniel
AU  - Wong D
AD  - Department of Neurosurgery, Kwong Wah Hospital, Hong Kong, China.
FAU - Seto, Andrew
AU  - Seto A
AD  - Department of Neurosurgery, Kwong Wah Hospital, Hong Kong, China.
FAU - Lam, Sandy
AU  - Lam S
AD  - Department of Neurosurgery, Kwong Wah Hospital, Hong Kong, China.
FAU - Yim, Carmen
AU  - Yim C
AD  - Department of Neurosurgery, Kwong Wah Hospital, Hong Kong, China.
FAU - Lo, Hong-Yip
AU  - Lo HY
AD  - Department of Neurosurgery, Kwong Wah Hospital, Hong Kong, China.
FAU - Po, Yin-Chung
AU  - Po YC
AD  - Department of Neurosurgery, Princess Margaret Hospital, Hong Kong, China.
FAU - Wong, Larry Y W
AU  - Wong LYW
AD  - Department of Neurosurgery, Queen Elizabeth Hospital, Hong Kong, China.
FAU - Lee, Michael W Y
AU  - Lee MWY
AD  - Department of Neurosurgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong, 
      China.
FAU - Yam, Kwong-Yui
AU  - Yam KY
AD  - Department of Neurosurgery, Tuen Mun Hospital, Hong Kong, China.
FAU - Pu, Jenny K S
AU  - Pu JKS
AD  - Division of Neurosurgery, Department of Surgery, Queen Mary Hospital, Hong Kong, 
      China.
FAU - Chan, Kwong-Yau
AU  - Chan KY
AD  - Department of Neurosurgery, Kwong Wah Hospital, Hong Kong, China.
FAU - Poon, Wai-Sang
AU  - Poon WS
AD  - Division of Neurosurgery, Department of Surgery, Prince of Wales Hospital, Hong 
      Kong, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20190620
PL  - Austria
TA  - Acta Neurochir (Wien)
JT  - Acta neurochirurgica
JID - 0151000
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Catheterization/adverse effects/instrumentation/*methods
MH  - Catheters/*adverse effects/standards
MH  - Drainage/adverse effects/instrumentation/*methods
MH  - Female
MH  - Humans
MH  - Intracranial Hemorrhages/epidemiology/*etiology
MH  - Male
MH  - Middle Aged
MH  - Neurosurgical Procedures/adverse effects/instrumentation/*methods
MH  - Postoperative Complications/epidemiology/*etiology
MH  - Third Ventricle/surgery
OTO - NOTNLM
OT  - External ventricular drainage
OT  - Hemorrhage
OT  - Tract hematoma
OT  - Ventricular catheter
EDAT- 2019/06/22 06:00
MHDA- 2020/05/23 06:00
CRDT- 2019/06/22 06:00
PHST- 2019/03/20 00:00 [received]
PHST- 2019/06/05 00:00 [accepted]
PHST- 2019/06/22 06:00 [pubmed]
PHST- 2020/05/23 06:00 [medline]
PHST- 2019/06/22 06:00 [entrez]
AID - 10.1007/s00701-019-03978-2 [pii]
AID - 10.1007/s00701-019-03978-2 [doi]
PST - ppublish
SO  - Acta Neurochir (Wien). 2019 Aug;161(8):1623-1632. doi: 
      10.1007/s00701-019-03978-2. Epub 2019 Jun 20.

PMID- 33706988
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 144 Suppl 1
DP  - 2021 Apr 1
TI  - Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial 
      Fibrillation.
PG  - S32-S39
LID - S0002-9149(20)31344-8 [pii]
LID - 10.1016/j.amjcard.2020.12.017 [doi]
AB  - In patients with atrial fibrillation who undergo percutaneous coronary 
      intervention (PCI), both anticoagulation and dual antiplatelet therapy (aspirin 
      plus a P2Y(12) inhibitor) are indicated. However, this "triple" antithrombotic 
      therapy is associated with high rates of bleeding. Finding the right balance of 
      reducing ischemic risk and protecting coronary stents from restenosis while not 
      increasing bleeding risk is difficult. In the past 5 years, 6 randomized clinical 
      trials have shown the benefit of dropping aspirin from the triple therapy regimen 
      to create "dual" therapy (oral anticoagulants and P2Y(12) inhibitors alone) with 
      reductions in bleeding without a significant increase in ischemic events. Because 
      of small trends toward higher risk of stent thrombosis, especially in higher risk 
      patients with acute coronary syndromes, current recommendations call for dual 
      therapy as the "default" regimen, but that risk stratification be used to help 
      inform the decision on potentially using a brief period of triple therapy in 
      selected high ischemic risk patients. For long-term therapy (after one year 
      post-PCI), recent studies have found oral anticoagulation alone without any 
      antiplatelet therapy has a favorable benefit risk ratio. Thus, while dropping 
      aspirin at varying times post-PCI has become an attractive strategy in many 
      patient groups, careful patient selection and individualized assessment of the 
      risk:benefit balance is warranted.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Cannon, Christopher P
AU  - Cannon CP
AD  - Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, Massachusetts. Electronic address: cpcannon@bwh.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Atrial Fibrillation/*drug therapy
MH  - Drug Administration Schedule
MH  - *Dual Anti-Platelet Therapy
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Stents
COIS- Declaration of Competing Interest The authors declare the following financial 
      interests/personal relationships which may be considered as potential competing 
      interests: Christopher Cannon reports financial support was provided by Academic 
      CME. Christopher Cannon reports a relationship with Amgen, Boehringer-Ingelheim 
      (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck, Novo Nordisk, 
      Pfizer that includes: funding grants. Christopher Cannon reports a relationship 
      with Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, 
      Corvidia, Eli Lilly, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, 
      Rhoshan, Sanofi that includes: consulting or advisory. This author has no patents 
      to disclose. The corresponding author reports no additional activities to 
      disclose.
EDAT- 2021/03/13 06:00
MHDA- 2021/04/10 06:00
CRDT- 2021/03/12 06:01
PHST- 2020/11/21 00:00 [received]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2021/03/12 06:01 [entrez]
PHST- 2021/03/13 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - S0002-9149(20)31344-8 [pii]
AID - 10.1016/j.amjcard.2020.12.017 [doi]
PST - ppublish
SO  - Am J Cardiol. 2021 Apr 1;144 Suppl 1:S32-S39. doi: 10.1016/j.amjcard.2020.12.017.

PMID- 9613967
OWN - NLM
STAT- MEDLINE
DCOM- 19980721
LR  - 20190831
IS  - 1387-2273 (Print)
IS  - 1387-2273 (Linking)
VI  - 707
IP  - 1-2
DP  - 1998 Apr 10
TI  - Determination of aspirin and salicylic acid in transdermal perfusates.
PG  - 322-7
AB  - A high-performance liquid chromatographic (HPLC) method has been developed for 
      the simultaneous determination of aspirin and salicylic acid in transdermal 
      perfusates. The compounds were separated on a C8 Nucleosil column (5 microm, 
      250x4.6 mm) using a mobile phase containing a mixture of 
      water-acetonitrile-orthophosphoric acid (650:350:2, v/v/v) and a flow-rate of 1 
      ml/min. The transdermal samples were in phosphate-buffered saline (PBS) and could 
      be injected directly onto the HPLC system. The method was reproducible with 
      inter-day R.S.D. values of no greater than 3.46 and 2.60% for aspirin and 
      salicylic acid, respectively. The method was linear over the concentration range 
      0.2-5.0 microg/ml and had a limit of detection of 0.05 microg/ml for both 
      compounds. For certain samples, it was necessary to ensure that no transmembrane 
      leakage of the aspirin prodrugs had occurred. In these cases, a gradient was 
      introduced by increasing the acetonitrile content of the mobile phase after the 
      salicylic acid had eluted. The method has been applied to the determination of 
      aspirin and salicylic acid in PBS following in vitro application of the compounds 
      to mouse skin samples.
FAU - McMahon, G P
AU  - McMahon GP
AD  - Department of Chemistry, The Royal College of Surgeons in Ireland, St. Stephen's 
      Green, Dublin.
FAU - O'Connor, S J
AU  - O'Connor SJ
FAU - Fitzgerald, D J
AU  - Fitzgerald DJ
FAU - le Roy, S
AU  - le Roy S
FAU - Kelly, M T
AU  - Kelly MT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Chromatogr B Biomed Sci Appl
JT  - Journal of chromatography. B, Biomedical sciences and applications
JID - 9714109
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis
MH  - Aspirin/*analysis
MH  - Calibration
MH  - Chromatography, High Pressure Liquid
MH  - Indicators and Reagents
MH  - Mice
MH  - Reference Standards
MH  - Reproducibility of Results
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Skin/*chemistry
EDAT- 1998/06/05 00:00
MHDA- 1998/06/05 00:01
CRDT- 1998/06/05 00:00
PHST- 1998/06/05 00:00 [pubmed]
PHST- 1998/06/05 00:01 [medline]
PHST- 1998/06/05 00:00 [entrez]
AID - 10.1016/s0378-4347(97)00580-x [doi]
PST - ppublish
SO  - J Chromatogr B Biomed Sci Appl. 1998 Apr 10;707(1-2):322-7. doi: 
      10.1016/s0378-4347(97)00580-x.

PMID- 3247841
OWN - NLM
STAT- MEDLINE
DCOM- 19890619
LR  - 20190815
IS  - 0001-6349 (Print)
IS  - 0001-6349 (Linking)
VI  - 67
IP  - 7
DP  - 1988
TI  - Treatment of habitual abortions associated with autoimmune abnormalities. A 
      report of two cases.
PG  - 663-4
AB  - In a study of the etiology of idiopathic habitual abortion, we have found 2 
      patients with a history of 5 and 4 spontaneous abortions respectively, possibly 
      caused by autoimmune abnormalities. In the plasma of one of the patients we had 
      found the presence of lupus anticoagulans and other lupus antibodies, whereas the 
      other suffered from a latent autoimmune hepatitis. We describe the successful 
      treatment of the 2 womens' subsequent pregnancies with subcutaneous heparin 
      supplemented with acetylsalicylic acid.
FAU - Christiansen, O B
AU  - Christiansen OB
AD  - Department of Clinical Immunology, Aalborg Hospital, Denmark.
FAU - Andersen, E S
AU  - Andersen ES
FAU - Lauritsen, J G
AU  - Lauritsen JG
FAU - Grunnet, N
AU  - Grunnet N
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Acta Obstet Gynecol Scand
JT  - Acta obstetricia et gynecologica Scandinavica
JID - 0370343
RN  - 0 (Autoantibodies)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*immunology
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Autoantibodies/analysis
MH  - Autoimmune Diseases/*complications/drug therapy/immunology
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Pregnancy
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.3109/00016348809004284 [doi]
PST - ppublish
SO  - Acta Obstet Gynecol Scand. 1988;67(7):663-4. doi: 10.3109/00016348809004284.

PMID- 6090029
OWN - NLM
STAT- MEDLINE
DCOM- 19841114
LR  - 20190913
IS  - 0309-1651 (Print)
IS  - 0309-1651 (Linking)
VI  - 8
IP  - 8
DP  - 1984 Aug
TI  - Platelet-facilitated adhesion of SV40-3T3 cells to collagen.
PG  - 659-63
AB  - The adhesion of SV40-3T3 cells to collagen has been used as a model to 
      investigate factors which may influence the arrest and attachment of metastatic 
      cells in the blood circulation. Adhesion of the transformed cells to collagen 
      films was stimulated by pretreatment of the substrate with human plasma, a source 
      of the cell attachment factor fibronectin, and equally effectively by platelets 
      previously sedimented on to the collagen substrate. Platelet-facilitated adhesion 
      of the transformed cells was related to the number of platelets deposited but 
      there was no requirement for plasma components or for the release of platelet 
      constituents.
FAU - Evans, P M
AU  - Evans PM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cell Biol Int Rep
JT  - Cell biology international reports
JID - 7708050
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*cytology
MH  - Cell Adhesion
MH  - *Cell Transformation, Viral
MH  - Collagen/*metabolism
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Mice
MH  - Simian virus 40
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 10.1016/0309-1651(84)90046-8 [doi]
PST - ppublish
SO  - Cell Biol Int Rep. 1984 Aug;8(8):659-63. doi: 10.1016/0309-1651(84)90046-8.

PMID- 7278083
OWN - NLM
STAT- MEDLINE
DCOM- 19811124
LR  - 20190711
IS  - 0023-2173 (Print)
IS  - 0023-2173 (Linking)
VI  - 59
IP  - 16
DP  - 1981 Aug 17
TI  - Effect of low dose of cimetidine on gastric potentials difference and 
      acetylsalicylic acid-induced change.
PG  - 911-2
AB  - Cimetidine in a low dose of 10 mg given intravenously increases significantly the 
      gastric potential difference (GPD) without any inhibitory effect on gastric acid 
      secretion. The increase of GPD after 200 mg cimetidine is higher than after 10 
      mg. While the high dose of cimetidine prevents the acetylsalicylic acid 
      (ASA)-induced GPD drop, cimetidine in a dose of 10 mg is not able to protect this 
      change. Nevertheless the low dose of cimetidine may have a clinical significance 
      and should be evaluated by clinical studies.
FAU - Massarrat, S
AU  - Massarrat S
FAU - Herbert, V
AU  - Herbert V
FAU - Veith, R
AU  - Veith R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Klin Wochenschr
JT  - Klinische Wochenschrift
JID - 2985205R
RN  - 0 (Guanidines)
RN  - 80061L1WGD (Cimetidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Cimetidine/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/*drug effects
MH  - Guanidines/*pharmacology
MH  - Humans
MH  - Membrane Potentials/drug effects
EDAT- 1981/08/17 00:00
MHDA- 1981/08/17 00:01
CRDT- 1981/08/17 00:00
PHST- 1981/08/17 00:00 [pubmed]
PHST- 1981/08/17 00:01 [medline]
PHST- 1981/08/17 00:00 [entrez]
AID - 10.1007/BF01721926 [doi]
PST - ppublish
SO  - Klin Wochenschr. 1981 Aug 17;59(16):911-2. doi: 10.1007/BF01721926.

PMID- 7211265
OWN - NLM
STAT- MEDLINE
DCOM- 19810513
LR  - 20190821
IS  - 0001-639X (Print)
IS  - 0001-639X (Linking)
VI  - 58
IP  - 5
DP  - 1980 Oct
TI  - Influence of tranexamic acid and acetylsalicylic acid on the thickness of the 
      normal cornea.
PG  - 767-72
AB  - In a masked cross-over study ten normal subjects were treated with tranexamic 
      acid and acetylsalicylic acid one g three times daily for seven days. The central 
      corneal thickness. was found to increase in response to acetylsalicylic acid and 
      to decrease in response to tranexamic acid. This finding provides evidence for 
      the involvement of the fibrinolytic system in the regulation of the normal 
      corneal thickness. The endothelial morphology, as seen with the specular 
      microscope, was unchanged during treatment with either drug.
FAU - Olsen, T
AU  - Olsen T
FAU - Ehlers, N
AU  - Ehlers N
FAU - Bramsen, T
AU  - Bramsen T
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Acta Ophthalmol (Copenh)
JT  - Acta ophthalmologica
JID - 0370347
RN  - 0 (Cyclohexanecarboxylic Acids)
RN  - 6T84R30KC1 (Tranexamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Cornea/anatomy & histology/cytology/*drug effects
MH  - Cyclohexanecarboxylic Acids/*pharmacology
MH  - Endothelium/cytology/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Tranexamic Acid/*pharmacology
EDAT- 1980/10/01 00:00
MHDA- 1980/10/01 00:01
CRDT- 1980/10/01 00:00
PHST- 1980/10/01 00:00 [pubmed]
PHST- 1980/10/01 00:01 [medline]
PHST- 1980/10/01 00:00 [entrez]
AID - 10.1111/j.1755-3768.1980.tb06690.x [doi]
PST - ppublish
SO  - Acta Ophthalmol (Copenh). 1980 Oct;58(5):767-72. doi: 
      10.1111/j.1755-3768.1980.tb06690.x.

PMID- 32456353
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 10
DP  - 2020 May 24
TI  - Preventive Effects of Neuroprotective Agents in a Neonatal Rat of Photothrombotic 
      Stroke Model.
LID - 10.3390/ijms21103703 [doi]
LID - 3703
AB  - Neonatal ischemic stroke has a higher incidence than childhood stroke. Seizures 
      are the first sign for the need for clinical assessment in neonates, but many 
      questions remain regarding treatments and follow-up modalities. In the absence of 
      a known pathophysiological mechanism, only supportive care is currently provided. 
      Stroke-induced microglia activation and neuroinflammation are believed to play a 
      central role in the pathological progression of neonatal ischemic stroke. We 
      induced a photothrombotic infarction with Rose Bengal in neonatal rats to 
      investigate the effects of pre- and post-treatment with Aspirin (ASA), 
      Clopidogrel (Clop), and Coenzyme Q10 (CoQ10), which are known for their 
      neuroprotective effects in adult stroke. Pre-stroke medication ameliorates 
      cerebral ischemic injury and reduces infarct volume by reducing microglia 
      activation, cellular reactive oxygen species (ROS) production, and cytokine 
      release. Post-stroke administration of ASA, Clop, and CoQ10 increased motor 
      function and reduced the volume of infarction, and the statistical evidence was 
      stronger than that seen in the pre-stroke treatment. In this study, we 
      demonstrated that ASA, Clop, and CoQ10 treatment before and after the stroke 
      reduced the scope of stroke lesions and increased behavioral activity. It 
      suggests that ASA, Clop, and CoQ10 medication could significantly have 
      neuroprotective effects in the neonates who have suffered strokes.
FAU - Yi, Yoon Young
AU  - Yi YY
AD  - Department of Pediatrics, Hallym University and Kangdong Sacred Heart Hospital, 
      Seoul 05355, Korea.
FAU - Shin, Hyo Jung
AU  - Shin HJ
AUID- ORCID: 0000-0002-3530-101X
AD  - Department of Medical Science, Chungnam National University, Daejeon 35015, 
      Korea.
AD  - Department of Anatomy and Cell Biology, Chungnam National University, Daejeon 
      35015, Korea.
AD  - Brain Research Institute, Chungnam National University, Daejeon 35015, Korea.
FAU - Choi, Seung Gyu
AU  - Choi SG
AD  - Department of Medical Science, Chungnam National University, Daejeon 35015, 
      Korea.
AD  - Department of Anatomy and Cell Biology, Chungnam National University, Daejeon 
      35015, Korea.
FAU - Kang, Joon Won
AU  - Kang JW
AUID- ORCID: 0000-0001-5756-3814
AD  - Department of Medical Science, Chungnam National University, Daejeon 35015, 
      Korea.
AD  - Department of Pediatrics, Chungnam National University Hospital, Daejeon 35015, 
      Korea.
FAU - Song, Hee-Jung
AU  - Song HJ
AD  - Department of Medical Science, Chungnam National University, Daejeon 35015, 
      Korea.
AD  - Department of Neurology, Chungnam National University and Sejong Hospital, Sejong 
      30099, Korea.
FAU - Kim, Sung Koo
AU  - Kim SK
AD  - Department of Pediatrics, Hallym University and Dongtan Sacred Heart Hospital, 
      Hwasung Gyunggi-do 18450, Korea.
FAU - Kim, Dong Woon
AU  - Kim DW
AUID- ORCID: 0000-0001-7691-1394
AD  - Department of Medical Science, Chungnam National University, Daejeon 35015, 
      Korea.
AD  - Department of Anatomy and Cell Biology, Chungnam National University, Daejeon 
      35015, Korea.
AD  - Brain Research Institute, Chungnam National University, Daejeon 35015, Korea.
LA  - eng
GR  - 2020R1C1C1007488, 2019R1A2C2004884, 2018R1D1A1B07045664, 
      2015R1C1A1A01052351/National Research Foundation of Korea/
PT  - Journal Article
DEP - 20200524
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Neuroprotective Agents)
RN  - 1339-63-5 (Ubiquinone)
RN  - 1ZPG1ELY14 (Rose Bengal)
RN  - A74586SNO7 (Clopidogrel)
RN  - EJ27X76M46 (coenzyme Q10)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Brain Ischemia
MH  - Clopidogrel/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - *Inflammation
MH  - Neuroprotective Agents/pharmacology/therapeutic use
MH  - Rats
MH  - Rose Bengal/toxicity
MH  - Stroke/chemically induced/*prevention & control
MH  - Ubiquinone/*analogs & derivatives/pharmacology/therapeutic use
PMC - PMC7279317
OTO - NOTNLM
OT  - Aspirin
OT  - Coenzyme Q10
OT  - clopidogrel
OT  - neonatal period
OT  - neuroprotection
OT  - photothrombotic stroke
COIS- The authors declare no conflict of interest.
EDAT- 2020/05/28 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/05/20 00:00 [revised]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - ijms21103703 [pii]
AID - ijms-21-03703 [pii]
AID - 10.3390/ijms21103703 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 May 24;21(10):3703. doi: 10.3390/ijms21103703.

PMID- 23792451
OWN - NLM
STAT- MEDLINE
DCOM- 20140722
LR  - 20220408
IS  - 1476-5594 (Electronic)
IS  - 0950-9232 (Print)
IS  - 0950-9232 (Linking)
VI  - 33
IP  - 23
DP  - 2014 Jun 5
TI  - Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: 
      power and promise of molecular pathological epidemiology.
PG  - 2949-55
LID - 10.1038/onc.2013.244 [doi]
AB  - Regular use of aspirin reduces incidence and mortality of various cancers, 
      including colorectal cancer. Anticancer effect of aspirin represents one of the 
      'Provocative Questions' in cancer research. Experimental and clinical studies 
      support a carcinogenic role for PTGS2 (cyclooxygenase-2), which is an important 
      enzymatic mediator of inflammation, and a target of aspirin. Recent 'molecular 
      pathological epidemiology' (MPE) research has shown that aspirin use is 
      associated with better prognosis and clinical outcome in PIK3CA-mutated 
      colorectal carcinoma, suggesting somatic PIK3CA mutation as a molecular biomarker 
      that predicts response to aspirin therapy. The PI3K 
      (phosphatidylinositol-4,5-bisphosphonate 3-kinase) enzyme has a pivotal role in 
      the PI3K-AKT signaling pathway. Activating PIK3CA oncogene mutations are observed 
      in various malignancies including breast cancer, ovarian cancer, brain tumor, 
      hepatocellular carcinoma, lung cancer and colon cancer. The prevalence of PIK3CA 
      mutations increases continuously from rectal to cecal cancers, supporting the 
      'colorectal continuum' paradigm, and an important interplay of gut microbiota and 
      host immune/inflammatory reaction. MPE represents an interdisciplinary 
      integrative science, conceptually defined as 'epidemiology of molecular 
      heterogeneity of disease'. As exposome and interactome vary from person to person 
      and influence disease process, each disease process is unique (the unique disease 
      principle). Therefore, MPE concept and paradigm can extend to non-neoplastic 
      diseases including diabetes mellitus, cardiovascular diseases, metabolic 
      diseases, and so on. MPE research opportunities are currently limited by paucity 
      of tumor molecular data in the existing large-scale population-based studies. 
      However, genomic, epigenomic and molecular pathology testings (for example, 
      analyses for microsatellite instability, MLH1 promoter CpG island methylation, 
      and KRAS and BRAF mutations in colorectal tumors) are becoming routine clinical 
      practices. In order for integrative molecular and population science to be 
      routine practice, we must first reform education curricula by integrating both 
      population and molecular biological sciences. As consequences, next-generation 
      hybrid molecular biological and population scientists can advance science, moving 
      closer to personalized precision medicine and health care.
FAU - Ogino, S
AU  - Ogino S
AD  - 1] Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, MA, USA [2] Department of Medical Oncology, Dana-Farber Cancer Institute, 
      Boston, MA, USA [3] Department of Epidemiology, Harvard School of Public Health, 
      Boston, MA, USA.
FAU - Lochhead, P
AU  - Lochhead P
AD  - Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
FAU - Giovannucci, E
AU  - Giovannucci E
AD  - 1] Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA 
      [2] Department of Nutrition, Harvard School of Public Health, Boston, MA, USA [3] 
      Channing Division of Network Medicine, Department of Medicine, Brigham and 
      Women's Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Meyerhardt, J A
AU  - Meyerhardt JA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Fuchs, C S
AU  - Fuchs CS
AD  - 1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 
      [2] Channing Division of Network Medicine, Department of Medicine, Brigham and 
      Women's Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Chan, A T
AU  - Chan AT
AD  - 1] Channing Division of Network Medicine, Department of Medicine, Brigham and 
      Women's Hospital, Harvard Medical School, Boston, MA, USA [2] Division of 
      Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
LA  - eng
GR  - P01 CA087969/CA/NCI NIH HHS/United States
GR  - R01 CA151993/CA/NCI NIH HHS/United States
GR  - K24 DK098311/DK/NIDDK NIH HHS/United States
GR  - P01 CA87969/CA/NCI NIH HHS/United States
GR  - R01 CA169141/CA/NCI NIH HHS/United States
GR  - UM1 CA167552/CA/NCI NIH HHS/United States
GR  - P50 CA127003/CA/NCI NIH HHS/United States
GR  - CAF/10/15/CSO_/Chief Scientist Office/United Kingdom
GR  - R01 CA124908/CA/NCI NIH HHS/United States
GR  - R01 CA137178/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20130624
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Biomarkers, Tumor/*genetics/metabolism
MH  - Class I Phosphatidylinositol 3-Kinases
MH  - Colorectal Neoplasms/drug therapy/*genetics
MH  - Gene Expression Regulation
MH  - Humans
MH  - Molecular Epidemiology/*methods
MH  - Mutation
MH  - Phosphatidylinositol 3-Kinases/*genetics
MH  - Prognosis
MH  - Signal Transduction/drug effects
MH  - Translational Research, Biomedical
PMC - PMC3818472
MID - NIHMS499165
EDAT- 2013/06/25 06:00
MHDA- 2014/07/23 06:00
CRDT- 2013/06/25 06:00
PHST- 2013/02/21 00:00 [received]
PHST- 2013/04/26 00:00 [revised]
PHST- 2013/04/27 00:00 [accepted]
PHST- 2013/06/25 06:00 [entrez]
PHST- 2013/06/25 06:00 [pubmed]
PHST- 2014/07/23 06:00 [medline]
AID - onc2013244 [pii]
AID - 10.1038/onc.2013.244 [doi]
PST - ppublish
SO  - Oncogene. 2014 Jun 5;33(23):2949-55. doi: 10.1038/onc.2013.244. Epub 2013 Jun 24.

PMID- 30082425
OWN - NLM
STAT- MEDLINE
DCOM- 20191125
LR  - 20191125
IS  - 1470-2738 (Electronic)
IS  - 0143-005X (Print)
IS  - 0143-005X (Linking)
VI  - 72
IP  - 11
DP  - 2018 Nov
TI  - Use of online promotion to encourage patient awareness of aspirin use to prevent 
      heart attack and stroke.
PG  - 1059-1063
LID - 10.1136/jech-2018-210676 [doi]
AB  - BACKGROUND: Literature on health promotion evaluation and public understanding of 
      health suggests the importance of investigating behaviour over time in 
      conjunction with information environment trends as a way of understanding 
      programme impact. We analysed population response to online promotion of an 
      educational tool built by the Ask About Aspirin campaign in the USA to inform 
      people about aspirin as a preventive aid. METHODS: We collected 156 weeks of time 
      series data on audience behaviour, namely use of a self-assessment tool. We then 
      used the Autoregressive Integrated Moving Average (ARIMA) modelling to predict 
      that outcome as a function of paid search engine advertising, paid social media 
      promotion and general search interest in aspirin. RESULTS: Through ARIMA 
      modelling of tool engagement data adjusted for outcome series autocorrelation, we 
      found a significant effect of online promotional effort on audience behaviour. 
      Total paid search advertising positively predicted weekly total of individuals 
      who started using the self-assessment tool, coefficient=0.023, t=3.28, p=0.001. 
      This effect did not appear to be an artefact of broader secular trends, as Google 
      search data on the topic of aspirin use did not add explanatory power in the 
      final model nor did controlling for general search interest eliminate the 
      significant coefficient for paid search promotion. CONCLUSION: Results hold 
      implications both for educational tool development and for understanding health 
      promotion campaign effects. We witnessed substantial but ephemeral effects on 
      tool use as a function of paid search efforts, suggesting prioritisation of 
      efforts to affect search engine results as a dissemination tactic.
CI  - © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Southwell, Brian G
AU  - Southwell BG
AUID- ORCID: 0000-0001-5091-8782
AD  - Science in the Public Sphere Program, RTI International, Research Triangle Park, 
      North Carolina, USA.
FAU - Eder, Milton
AU  - Eder M
AD  - School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
FAU - Finnegan, John
AU  - Finnegan J
AD  - School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
FAU - Hirsch, Alan T
AU  - Hirsch AT
AD  - School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
FAU - Luepker, Russell V
AU  - Luepker RV
AD  - School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
FAU - Duval, Sue
AU  - Duval S
AD  - School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
FAU - Russell, Carol
AU  - Russell C
AD  - Russell Herder, Minneapolis, Minnesota, USA.
FAU - O'Byrne, Sam
AU  - O'Byrne S
AD  - Russell Herder, Minneapolis, Minnesota, USA.
LA  - eng
GR  - R01 HL126041/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20180806
PL  - England
TA  - J Epidemiol Community Health
JT  - Journal of epidemiology and community health
JID - 7909766
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Promotion/*methods
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Search Engine
MH  - Self-Assessment
MH  - *Social Media
MH  - Stroke/*prevention & control
PMC - PMC6226241
MID - NIHMS990493
OTO - NOTNLM
OT  - cardiovascular disease
OT  - health promotion
OT  - social science
OT  - time-series
COIS- Competing interests: None declared.
EDAT- 2018/08/08 06:00
MHDA- 2019/11/26 06:00
CRDT- 2018/08/08 06:00
PHST- 2018/02/27 00:00 [received]
PHST- 2018/06/07 00:00 [revised]
PHST- 2018/07/19 00:00 [accepted]
PHST- 2018/08/08 06:00 [pubmed]
PHST- 2019/11/26 06:00 [medline]
PHST- 2018/08/08 06:00 [entrez]
AID - jech-2018-210676 [pii]
AID - 10.1136/jech-2018-210676 [doi]
PST - ppublish
SO  - J Epidemiol Community Health. 2018 Nov;72(11):1059-1063. doi: 
      10.1136/jech-2018-210676. Epub 2018 Aug 6.

PMID- 36209937
OWN - NLM
STAT- MEDLINE
DCOM- 20230404
LR  - 20230407
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 228
IP  - 4
DP  - 2023 Apr
TI  - Low-dose aspirin for the prevention of superimposed preeclampsia in women with 
      chronic hypertension: a systematic review and meta-analysis.
PG  - 395-408
LID - S0002-9378(22)00803-1 [pii]
LID - 10.1016/j.ajog.2022.09.046 [doi]
AB  - OBJECTIVE: This systematic review and meta-analysis investigated whether the use 
      of low-dose aspirin during pregnancy by women with chronic hypertension reduces 
      the odds of superimposed preeclampsia and poor perinatal outcomes. DATA SOURCES: 
      In September 2021, the following sources were searched: Embase, MEDLINE, Cochrane 
      Central Register of Controlled Trials, ClinicalTrials.gov, the World Health 
      Organization International Clinical Trials Registry Platform, and EU Clinical 
      Trials Register. Only human studies were included, with no time or language 
      restrictions. STUDY ELIGIBILITY CRITERIA: Cohort, case-control, and randomized 
      controlled studies reporting women with chronic hypertension pregnant with a 
      singleton were included. Eligible studies compared low-dose aspirin use during 
      pregnancy with a control arm. METHODS: Risk of bias was assessed using the RoB 2 
      and ROBINS-I tools. A meta-analysis was performed using a random-effects model, 
      estimating odds ratios and 95% confidence and prediction intervals, and the 
      quality of data was assessed with the GRADE approach. Heterogeneity was 
      investigated in regard to study methodology, timing of commencement of aspirin, 
      and the outcome of preterm preeclampsia. RESULTS: Nine studies (3 retrospective 
      cohort studies and 6 randomized trials) including 2150 women with chronic 
      hypertension were included. Low-dose aspirin prophylaxis did not significantly 
      reduce the odds of superimposed preeclampsia in the randomized controlled trials 
      (odds ratio, 0.83; 95% confidence interval, 0.55-1.25; prediction interval, 
      0.27-2.56; low-quality evidence) or observational studies (odds ratio, 1.21; 95% 
      confidence interval, 0.78-1.87; prediction interval, 0.07-20.80; very low-quality 
      evidence). Low-dose aspirin also did not reduce the odds of preterm preeclampsia 
      (odds ratio, 1.17; 95% confidence interval, 0.74-1.86), and early aspirin 
      initiation had no significant impact. There was no significant effect on 
      small-for-gestational-age neonates or perinatal mortality; however, there was a 
      significant reduction in preterm birth (odds ratio, 0.63; 95% confidence 
      interval, 0.45-0.89; moderate-quality evidence). The quality of the evidence is 
      limited by heterogeneity and risk of bias. CONCLUSION: This meta-analysis was 
      unable to demonstrate a significant change in the odds of superimposed 
      preeclampsia, small-for-gestational-age infants, or perinatal mortality with the 
      use of low-dose aspirin in women with chronic hypertension. However, significant 
      reduction in preterm birth justifies the continued use of aspirin prophylaxis. 
      This work was prospectively registered on the International Prospective Register 
      of Systematic Reviews (registration number CRD42021285921).
CI  - Copyright © 2022 Elsevier Inc. All rights reserved.
FAU - Richards, Eleanor M F
AU  - Richards EMF
AD  - Department of Obstetrics and Gynaecology, Cambridge University Hospitals NHS 
      Foundation Trust, Cambridge, United Kingdom. Electronic address: 
      eleanor.richards7@nhs.net.
FAU - Giorgione, Veronica
AU  - Giorgione V
AD  - Molecular and Clinical Sciences Research Institute, St. George's University of 
      London, London, United Kingdom; Fetal Medicine Unit, Department of Obstetrics and 
      Gynaecology, St. George's University Hospitals NHS Foundation Trust, London, 
      United Kingdom.
FAU - Stevens, Oliver
AU  - Stevens O
AD  - MRC Centre for Global Infectious Disease Analysis, School of Public Health, 
      Imperial College London, London, United Kingdom.
FAU - Thilaganathan, Basky
AU  - Thilaganathan B
AD  - Molecular and Clinical Sciences Research Institute, St. George's University of 
      London, London, United Kingdom; Fetal Medicine Unit, Department of Obstetrics and 
      Gynaecology, St. George's University Hospitals NHS Foundation Trust, London, 
      United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20221007
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Obstet Gynecol. 2023 Apr;228(4):488-489. PMID: 36574874
CIN - Am J Obstet Gynecol. 2023 Apr;228(4):487-488. PMID: 36581109
MH  - Pregnancy
MH  - Infant, Newborn
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/prevention & control/drug therapy
MH  - *Premature Birth/prevention & control
MH  - Retrospective Studies
MH  - Aspirin/therapeutic use
MH  - *Perinatal Death
MH  - *Hypertension/drug therapy
OTO - NOTNLM
OT  - antiplatelet
OT  - aspirin
OT  - chronic hypertension
OT  - essential hypertension
OT  - perinatal morbidity
OT  - preeclampsia
OT  - pregnancy
OT  - preterm birth
OT  - small for gestational age
EDAT- 2022/10/10 06:00
MHDA- 2023/04/04 06:42
CRDT- 2022/10/09 19:24
PHST- 2022/08/05 00:00 [received]
PHST- 2022/09/26 00:00 [revised]
PHST- 2022/09/26 00:00 [accepted]
PHST- 2023/04/04 06:42 [medline]
PHST- 2022/10/10 06:00 [pubmed]
PHST- 2022/10/09 19:24 [entrez]
AID - S0002-9378(22)00803-1 [pii]
AID - 10.1016/j.ajog.2022.09.046 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2023 Apr;228(4):395-408. doi: 10.1016/j.ajog.2022.09.046. 
      Epub 2022 Oct 7.

PMID- 7850577
OWN - NLM
STAT- MEDLINE
DCOM- 19950316
LR  - 20181130
IS  - 1073-2322 (Print)
IS  - 1073-2322 (Linking)
VI  - 3
IP  - 1
DP  - 1995 Jan
TI  - Calcitonin gene-related peptide release in endotoxicosis may be mediated by 
      prostaglandins.
PG  - 34-9
AB  - Three cyclo-oxygenase inhibitors (ibuprofen, indomethacin, and high dose aspirin) 
      and two inhibitors of thromboxane biosynthesis (imidazole and low dose aspirin) 
      were used to evaluate the role of prostaglandins and thromboxane in the release 
      of calcitonin gene-related peptide (CGRP) during endotoxicosis. Endotoxin 
      (lipopolysaccharide B from Salmonella Enteritidis, 5 mg/kg, intravenously) was 
      administered to rats lightly anesthetized with ether during injection. After 3 h, 
      endotoxin significantly elevated plasma CGRP levels by 3-fold. Ibuprofen (50 
      mg/kg, subcutaneously), indomethacin (10 mg/kg, subcutaneously) and high dose 
      aspirin (100 mg/kg, intraperitoneally (i.p.)), but not imidazole (30 mg/kg, i.p.) 
      or low dose aspirin (15 mg/kg, i.p.), significantly blocked endotoxin-induced 
      CGRP elevations, suggesting that a prostaglandin, but not thromboxane, served as 
      a mediator of CGRP release during endotoxicosis. Because endotoxin-induced 
      production of prostaglandins is greatly diminished in endotoxin-tolerant rats 
      (following multiple exposures to low dose endotoxin), we tested whether 
      endotoxin-induced CGRP release also becomes diminished in tolerant rats. 
      Accumulation of plasma CGRP was greatly diminished in endotoxin-tolerant rats 
      exposed to endotoxin (5 mg/kg, intravenously), consistent with a mediator role 
      for prostaglandins in the CGRP release during endotoxicosis.
FAU - Wang, X
AU  - Wang X
AD  - Institute of Vascular Medicine, Third Clinical College Beijing Medical 
      University, People's Republic of China.
FAU - Han, C
AU  - Han C
FAU - Jones, S B
AU  - Jones SB
FAU - Yang, L
AU  - Yang L
FAU - Fiscus, R R
AU  - Fiscus RR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Shock
JT  - Shock (Augusta, Ga.)
JID - 9421564
RN  - 0 (Blood Glucose)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Imidazoles)
RN  - 0 (Lactates)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Prostaglandins)
RN  - 0 (Thromboxanes)
RN  - 0 (lipopolysaccharide B)
RN  - 7GBN705NH1 (imidazole)
RN  - JHB2QIZ69Z (Calcitonin Gene-Related Peptide)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Blood Glucose/analysis
MH  - Blood Pressure/drug effects
MH  - Calcitonin Gene-Related Peptide/*metabolism/physiology
MH  - Cyclooxygenase Inhibitors/*pharmacology/therapeutic use
MH  - Drug Tolerance
MH  - Ibuprofen/pharmacology/therapeutic use
MH  - Imidazoles/*pharmacology/therapeutic use
MH  - Indomethacin/pharmacology/therapeutic use
MH  - Lactates/blood
MH  - Lipopolysaccharides/toxicity
MH  - Male
MH  - Prostaglandins/*physiology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Rats, Wistar
MH  - Shock, Septic/blood/drug therapy/*physiopathology
MH  - Thromboxanes/biosynthesis/physiology
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Shock. 1995 Jan;3(1):34-9.

PMID- 6238561
OWN - NLM
STAT- MEDLINE
DCOM- 19841130
LR  - 20131121
IS  - 0003-0805 (Print)
IS  - 0003-0805 (Linking)
VI  - 130
IP  - 5
DP  - 1984 Nov
TI  - Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia.
PG  - 857-62
AB  - Normal CD-1 mice were inoculated intratracheally with Streptococcus pneumoniae 
      and treated with aspirin in order to assess the effects of that drug on pulmonary 
      antibacterial mechanisms. Animals pretreated for 72 h with aspirin prior to 
      bacterial challenge and animals given aspirin immediately after infection 
      experienced worse survival rates than did control mice (p less than 0.01 and p 
      less than 0.05, respectively). When challenged with a sublethal inoculum, 
      pretreated and immediately treated animals demonstrated significant impairments 
      in their ability to clear viable pneumococci from the lungs; the inefficient 
      pulmonary clearance was associated with a marked attenuation in the ability of 
      aspirin-treated mice to recruit granulocytes and macrophages into the 
      bronchoalveolar spaces. Survival in mice administered aspirin 6 h after 
      pneumococcal challenge was not adversely affected; however, the pulmonary 
      clearance and cellular response were significantly impaired. We conclude that 
      aspirin can disrupt host defense against pneumococci by blunting the normal 
      pulmonary inflammatory reaction to organisms deposited into the lower respiratory 
      tract.
FAU - Esposito, A L
AU  - Esposito AL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Rev Respir Dis
JT  - The American review of respiratory disease
JID - 0370523
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects/metabolism
MH  - Female
MH  - Granulocytes/immunology
MH  - Kinetics
MH  - Lung/*drug effects/immunology
MH  - Macrophages/immunology
MH  - Mice
MH  - Neutrophils/immunology
MH  - Phagocytosis/drug effects
MH  - Pneumonia, Pneumococcal/*immunology/mortality
MH  - Specific Pathogen-Free Organisms
EDAT- 1984/11/01 00:00
MHDA- 1984/11/01 00:01
CRDT- 1984/11/01 00:00
PHST- 1984/11/01 00:00 [pubmed]
PHST- 1984/11/01 00:01 [medline]
PHST- 1984/11/01 00:00 [entrez]
AID - 10.1164/arrd.1984.130.5.857 [doi]
PST - ppublish
SO  - Am Rev Respir Dis. 1984 Nov;130(5):857-62. doi: 10.1164/arrd.1984.130.5.857.

PMID- 12397524
OWN - NLM
STAT- MEDLINE
DCOM- 20030303
LR  - 20131121
IS  - 0935-8943 (Print)
IS  - 0935-8943 (Linking)
VI  - 81
IP  - 10
DP  - 2002 Oct
TI  - [Aspirin sensitivity: long term follow-up after up to 3 years of adaptive 
      desensitization using a maintenance dose of 100 mg of aspirin a day].
PG  - 732-8
AB  - BACKGROUND: The full clinical picture of aspirin intolerance, Sampter's triad, is 
      associated with nasal polyposis, clinical sensitivity to most non steroidal 
      antiinflammatory drugs (NSAID) and intrinsic bronchial asthma. But the triad can 
      be incomplete and nasal polyposis can be the first clinical symptom of aspirin 
      sensitivity. Although the exact mechanisms of aspirin intolerance as well as 
      those of desensitization remain obscure, an in vitro assay on eicosanoid 
      metabolism has been proven to be helpful in diagnosis and treatment as it 
      correlates well to the individual severity of clinical symptoms. METHODS: For 
      this investigation 30 patients, who were undergoing adaptive desensitization for 
      aspirin intolerance, were followed-up between 1 and 3 years. They received a 
      maintenance dose of oral aspirin of only 100 mg a day after an initial 
      application of higher doses. Their clinical course as well as their in vitro 
      parameters of eicosanoid release were monitored throughout the individual 
      observation period. RESULTS: Desensitization was successful in 25 of the 30 
      patients regarding the recurrence rate of nasal polyps, severity of bronchial 
      asthma and sense of smell. There was a clear positive correlation between 
      clinical and in vitro parameters. Discontinuing of aspirin therapy lead to 
      worsening of clinical symptoms, regardless of the prior duration of treatment. 
      CONCLUSIONS: This article reviews the role of the in vitro assay and presents a 
      desensitization protocol that can be maintained as a long term treatment without 
      adverse side effects. Results suggest that the recurrence rate of nasal polyps 
      after surgical therapy can be reduced using this protocol, however, only long 
      term treatment can secure a beneficial outcome over time.
FAU - Gosepath, J
AU  - Gosepath J
AD  - Universitäts-HNO-Klinik Mainz, Germany. gosepath@hno.klinik.uni-mainz.de
FAU - Schäfer, D
AU  - Schäfer D
FAU - Mann, W J
AU  - Mann WJ
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Analgetika-Intoleranz: Langzeitergebnisse bis zu 3 Jahren bei adaptiver 
      Desaktivierung mit einer täglichen Erhaltungsdosis von 100 mg Aspirin.
PL  - Germany
TA  - Laryngorhinootologie
JT  - Laryngo- rhino- otologie
JID - 8912371
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/chemically induced/therapy
MH  - Desensitization, Immunologic/*methods
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Hypersensitivity/*therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Long-Term Care
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/chemically induced/therapy
EDAT- 2002/10/25 04:00
MHDA- 2003/03/04 04:00
CRDT- 2002/10/25 04:00
PHST- 2002/10/25 04:00 [pubmed]
PHST- 2003/03/04 04:00 [medline]
PHST- 2002/10/25 04:00 [entrez]
AID - 10.1055/s-2002-35002 [doi]
PST - ppublish
SO  - Laryngorhinootologie. 2002 Oct;81(10):732-8. doi: 10.1055/s-2002-35002.

PMID- 2486939
OWN - NLM
STAT- MEDLINE
DCOM- 19910304
LR  - 20131121
IS  - 1042-6922 (Print)
IS  - 1042-6922 (Linking)
VI  - 6
IP  - 3
DP  - 1989
TI  - Time-course of aspirin and salicylate in ocular tissues of rabbits.
PG  - 465-75
AB  - The time courses of aspirin and salicylate in plasma and ocular tissues of 
      rabbits were investigated after the i.v. administration of aspirin. Unhydrolyzed 
      aspirin rapidly disappears from plasma and many ocular compartments but persists 
      up to 4 hours in aqueous and vitreous humours. Salicylate decreases in plasma 
      follow an exponential kinetics; in aqueous humour and in vascularized tissues the 
      behaviour is similar but with a half-life longer than in plasma. In the cornea, 
      lens and vitreous humour, the concentration of salicylate reaches a peak between 
      2 and 4 hours, then it decreases very slowly. Our results show that aspirin is 
      protected from the hydrolytic action of plasmatic esterases in aqueous and 
      vitreous humours but is rapidly hydrolyzed in the cornea and lens by local 
      esterases present in these tissues. It is possible that both aspirin and 
      salicylate leave the eye by means of an active transport. Our results also 
      indicate that salicylate can accumulate in the cornea, lens and retina when 
      aspirin is administered repeatedly.
FAU - Valeri, P
AU  - Valeri P
AD  - Institute of Pharmacology and Pharmacognosy, University of Rome La Sapienza, 
      Italy.
FAU - Romanelli, L
AU  - Romanelli L
FAU - Martinelli, B
AU  - Martinelli B
FAU - Guglielmotti, A
AU  - Guglielmotti A
FAU - Catanese, B
AU  - Catanese B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Lens Eye Toxic Res
JT  - Lens and eye toxicity research
JID - 8916639
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aqueous Humor/metabolism
MH  - Aspirin/administration & dosage/*pharmacokinetics
MH  - Ciliary Body/metabolism
MH  - Cornea/metabolism
MH  - Eye/*metabolism
MH  - Half-Life
MH  - Injections, Intravenous
MH  - Iris/metabolism
MH  - Lens, Crystalline/metabolism
MH  - Male
MH  - Rabbits
MH  - Retina/metabolism
MH  - Salicylates/*pharmacokinetics
MH  - Salicylic Acid
MH  - Tissue Distribution
MH  - Vitreous Body/metabolism
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Lens Eye Toxic Res. 1989;6(3):465-75.

PMID- 9044241
OWN - NLM
STAT- MEDLINE
DCOM- 19970617
LR  - 20131121
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 18
IP  - 8
DP  - 1996 Oct
TI  - A highly sensitive HPLC method for the simultaneous determination of 
      acetylsalicylic, salicylic and salicyluric acids in biologic fluids: 
      pharmacokinetic, metabolic and monitoring implications.
PG  - 527-32
AB  - A number of methods have been developed for the determination of acetylsalicylic 
      acid (ASA, aspirin). However, they are not sensitive enough for the simultaneous 
      determination of ASA and its major metabolites salicylic (SA) and salicyluric 
      (SUA) acids at the low dosage schedules (30-100 mg ASA/d). The HPLC method with 
      UV detection described here fulfills these requirements. The calibration curves 
      were linear at the range 0.18-10 mumol/l. Coefficients of variation were 3.9% for 
      SUA, 7.89% for ASA and 5.88% for SA. The recovery of ASA, SA and SUA was between 
      90-105%. ASA administered in doses of 30-400 mg was rapidly absorbed from 
      gastrointestinal tract and deacetylated, forming the dominant plasma metabolite 
      SA. SA was eliminated to about 60% by conjugation with glycine and therefore SUA 
      was a dominant metabolite in urine. ASA was never found in urine at the low-dose 
      ASA treatment. For this reason, SUA, but not ASA, can be determined in urine and 
      may be used for monitoring patient compliance.
FAU - Krivosíková, Z
AU  - Krivosíková Z
AD  - Institute of Preventive and Clinical Medicine, Bratislava, Slovakia.
FAU - Spustová, V
AU  - Spustová V
FAU - Dzúrik, R
AU  - Dzúrik R
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis/blood/pharmacokinetics/urine
MH  - Aspirin/*analysis/blood/pharmacokinetics/urine
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Female
MH  - Hippurates/*analysis/blood/urine
MH  - Humans
MH  - Male
MH  - Salicylates/*analysis/blood/urine
MH  - Salicylic Acid
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 1996 Oct;18(8):527-32.

PMID- 24751345
OWN - NLM
STAT- MEDLINE
DCOM- 20150110
LR  - 20191210
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 469
IP  - 1
DP  - 2014 Jul 20
TI  - Optical microscopy as a comparative analytical technique for single-particle 
      dissolution studies.
PG  - 10-6
LID - S0378-5173(14)00264-6 [pii]
LID - 10.1016/j.ijpharm.2014.04.036 [doi]
AB  - Novel, simple and cost effective methods are needed to replace advanced chemical 
      analytical techniques, in small-scale dissolution studies. Optical microscopy of 
      individual particles could provide such a method. The aim of the present work was 
      to investigate and verify the applicability of optical microscopy as an 
      analytical technique for drug dissolution studies. The evaluation was performed 
      by comparing image and chemical analysis data of individual dissolving particles. 
      It was shown that the data obtained by image analysis and UV-spectrophotometry 
      produced practically identical dissolution curves, with average similarity and 
      difference factors above 82 and below 4, respectively. The relative standard 
      deviation for image analysis data, of the studied particle size range, varied 
      between 1.9% and 3.8%. Consequently, it is proposed that image analysis can be 
      used, on its own, as a viable analytical technique in single-particle dissolution 
      studies. The possibility for significant reductions in sample preparation, 
      operational cost, time and substance consumption gives optical detection a clear 
      advantage over chemical analytical methods. Thus, image analysis could be an 
      ideal and universal analytical technique for rapid small-scale dissolution 
      studies.
CI  - Copyright © 2014 Elsevier B.V. All rights reserved.
FAU - Svanbäck, Sami
AU  - Svanbäck S
AD  - Division of Pharmaceutical Technology, University of Helsinki, P.O. Box 56, 
      Helsinki FI-00014, Finland. Electronic address: sami.svanback@helsinki.fi.
FAU - Ehlers, Henrik
AU  - Ehlers H
AD  - Division of Pharmaceutical Technology, University of Helsinki, P.O. Box 56, 
      Helsinki FI-00014, Finland.
FAU - Yliruusi, Jouko
AU  - Yliruusi J
AD  - Division of Pharmaceutical Technology, University of Helsinki, P.O. Box 56, 
      Helsinki FI-00014, Finland.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Validation Study
DEP - 20140419
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Powders)
RN  - 362O9ITL9D (Acetaminophen)
RN  - C137DTR5RG (Theophylline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*chemistry
MH  - Aspirin/*chemistry
MH  - Kinetics
MH  - *Microscopy
MH  - Particle Size
MH  - Powders
MH  - Reproducibility of Results
MH  - Solubility
MH  - Spectrophotometry, Ultraviolet
MH  - Technology, Pharmaceutical/*methods
MH  - Theophylline/*chemistry
OTO - NOTNLM
OT  - Acetylsalicylic acid (PubChem CID:2244)
OT  - Dissolution
OT  - Image analysis
OT  - Microscopy
OT  - Paracetamol (PubChem CID:1983)
OT  - Quantitative analysis
OT  - Single-particle
OT  - Small-scale
OT  - Theophylline (PubChem CID:2153)
EDAT- 2014/04/23 06:00
MHDA- 2015/01/13 06:00
CRDT- 2014/04/23 06:00
PHST- 2013/12/24 00:00 [received]
PHST- 2014/04/08 00:00 [revised]
PHST- 2014/04/12 00:00 [accepted]
PHST- 2014/04/23 06:00 [entrez]
PHST- 2014/04/23 06:00 [pubmed]
PHST- 2015/01/13 06:00 [medline]
AID - S0378-5173(14)00264-6 [pii]
AID - 10.1016/j.ijpharm.2014.04.036 [doi]
PST - ppublish
SO  - Int J Pharm. 2014 Jul 20;469(1):10-6. doi: 10.1016/j.ijpharm.2014.04.036. Epub 
      2014 Apr 19.

PMID- 2951565
OWN - NLM
STAT- MEDLINE
DCOM- 19870429
LR  - 20131121
IS  - 0261-989X (Print)
IS  - 0261-989X (Linking)
VI  - 4
IP  - 4
DP  - 1986 Oct-Dec
TI  - Effects of different doses of acetylsalicylic acid on platelet aggregation: an 
      experimental study of prosthetic materials in dogs.
PG  - 325-34
AB  - Laminar flow is the condition best suited to the study of platelet thrombi. This 
      type of thrombus is predominant in arteries, in the tubes of cannulas used in 
      artificial circulatory systems, in cardiac valve prostheses and in prosthetic 
      arterial implants. Antiplatelet drugs could, in these cases, reduce the extent of 
      thrombus formation. At present the optimal dose of acetylsalicylic acid (ASA) to 
      achieve the best antithrombotic effect is unknown; some papers show that high 
      doses augment experimental thrombosis. By means of autologous platelets labelled 
      with 111In-oxine, we have quantified the accumulation on different materials used 
      in cardiovascular surgery (woven, knitted and double velour Dacron, Avcothane 51 
      elastomere and smooth surface and rough surface pericardium). Samples of these 
      fabrics were placed in a laminar flow chamber connected between the right atrium 
      and femoral artery of the experimental animals (dogs). The animals were divided 
      into four groups of eight dogs: Group I: no treatment Group II: animals treated 
      one week earlier with ASA (1 mg/kg/day) Group III: as in Group II, but at a dose 
      of 5 mg/kg/day Group IV: as in Group II, but at a dose of 20 mg/kg/day. The 
      materials upon which the least amount of platelets were accumulated were the 
      smooth, epicardial surface of pericardium (SP) and Avcothane (AV). The least 
      deposition was produced in Group III, with the exception of SP. In the case of 
      this material, there was no difference between Groups I and III. In Group IV, the 
      deposit was greater with respect to the untreated group (Group I), except in the 
      case of AV, in which there was no difference between Groups I and IV.
FAU - Escudero, C
AU  - Escudero C
FAU - Alvarez, L
AU  - Alvarez L
FAU - Rodríguez, V
AU  - Rodríguez V
FAU - Ortiz, J
AU  - Ortiz J
FAU - Castillo-Olivares, J L
AU  - Castillo-Olivares JL
LA  - eng
PT  - Journal Article
PL  - England
TA  - Life Support Syst
JT  - Life support systems : the journal of the European Society for Artificial Organs
JID - 8219681
RN  - 0 (Polyethylene Terephthalates)
RN  - 0 (Polyurethanes)
RN  - 0 (Silicone Elastomers)
RN  - 37226-50-9 (Avcothane)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage
MH  - Dogs
MH  - Pericardium
MH  - Platelet Aggregation/*drug effects
MH  - *Polyethylene Terephthalates
MH  - *Polyurethanes
MH  - *Prostheses and Implants
MH  - *Silicone Elastomers
EDAT- 1986/10/01 00:00
MHDA- 1986/10/01 00:01
CRDT- 1986/10/01 00:00
PHST- 1986/10/01 00:00 [pubmed]
PHST- 1986/10/01 00:01 [medline]
PHST- 1986/10/01 00:00 [entrez]
PST - ppublish
SO  - Life Support Syst. 1986 Oct-Dec;4(4):325-34.

PMID- 21636287
OWN - NLM
STAT- MEDLINE
DCOM- 20120501
LR  - 20211020
IS  - 1873-734X (Electronic)
IS  - 1010-7940 (Print)
IS  - 1010-7940 (Linking)
VI  - 41
IP  - 1
DP  - 2012 Jan
TI  - Aspirin resistance in off-pump coronary artery bypass grafting.
PG  - 108-12
LID - 10.1016/j.ejcts.2011.04.021 [doi]
AB  - OBJECTIVE: Anti-platelet therapy with aspirin is the cornerstone of treatment 
      after coronary artery bypass grafting (CABG). Aspirin resistance describes the 
      clinical observation of the inability of aspirin to prevent thrombotic 
      complications or the laboratory phenomenon of absence of the effect of aspirin on 
      platelet inhibition tests. Off-pump CABG (OPCAB) is associated with reduced 
      platelet activation and turnover compared to on-pump surgery which may indicate 
      that aspirin is more effective after OPCAB. Our aim was to evaluate the efficacy 
      of aspirin and incidence of aspirin resistance in patients undergoing OPCAB. 
      METHODS: A total of 331 patients was recruited, of which 111 underwent primary 
      OPCAB (group A) and 220 controls with ischaemic heart disease received medical 
      therapy. Arachidonic acid-induced platelet aggregation and urinary 11-dehydro 
      thromboxane B2 (11-dehydroTxB2) were measured at baseline and following aspirin 
      administration on days 1, 4 and 10. A 6-month follow-up was completed in patients 
      who developed aspirin resistance. RESULTS: On the first postoperative day, 78 
      patients (70.3%) were aspirin sensitive (AS) and 33 (29.7%) were aspirin 
      resistant (AR). Of the latter, 18 (16.2%) and five (4.5%) patients remained 
      resistant on days 4 and 10, respectively. AR patients had significantly greater 
      platelet aggregation and urinary 11-dehydroTxB2 levels at all time points than 
      those in the AS group. All patients in the AR group were AS by 6 months. All 
      controls were sensitive to aspirin with similar platelet aggregation and 
      11-dehydroTxB2 to those in the AS group. CONCLUSIONS: Aspirin resistance is a 
      transient phenomenon during the early postoperative period in approximately 30% 
      of patients undergoing OPCAB.
FAU - Wang, Zanxin
AU  - Wang Z
AD  - Department of Cardiovascular Surgery, Tianjin Medical University General 
      Hospital, Tianjin, PR China.
FAU - Gao, Fei
AU  - Gao F
FAU - Men, Jianlong
AU  - Men J
FAU - Ren, Jing
AU  - Ren J
FAU - Modi, Paul
AU  - Modi P
FAU - Wei, Minxin
AU  - Wei M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European 
      Association for Cardio-thoracic Surgery
JID - 8804069
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur J Cardiothorac Surg. 2012 Oct;42(4):760-1; author reply 761. PMID: 22551968
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biomarkers/urine
MH  - Case-Control Studies
MH  - *Coronary Artery Bypass, Off-Pump/adverse effects
MH  - Drug Administration Schedule
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Count
MH  - Postoperative Care/methods
MH  - Postoperative Period
MH  - Thrombosis/etiology/prevention & control
MH  - Thromboxane B2/analogs & derivatives/urine
PMC - PMC3241077
EDAT- 2011/06/04 06:00
MHDA- 2012/05/02 06:00
CRDT- 2011/06/04 06:00
PHST- 2011/06/04 06:00 [entrez]
PHST- 2011/06/04 06:00 [pubmed]
PHST- 2012/05/02 06:00 [medline]
AID - j.ejcts.2011.04.021 [pii]
AID - 10.1016/j.ejcts.2011.04.021 [doi]
PST - ppublish
SO  - Eur J Cardiothorac Surg. 2012 Jan;41(1):108-12. doi: 10.1016/j.ejcts.2011.04.021.

PMID- 25322834
OWN - NLM
STAT- MEDLINE
DCOM- 20160601
LR  - 20230120
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 13
IP  - 5
DP  - 2015
TI  - Relation between the Change in Mean Platelet Volume and Clopidogrel Resistance in 
      Patients Undergoing Percutaneous Coronary Intervention.
PG  - 687-93
AB  - We aimed to determine the association between the change in mean platelet volume 
      (MPV) over time and aspirin/ clopidogrel resistance in patients undergoing 
      percutaneous coronary intervention (PCI). The MPV and platelet function were 
      analysed in 302 patients who underwent PCI. MPV changes were associated with 
      increased aspirin reaction units (ARU, r = 0.114; P = 0.047), increased P2Y12 
      reaction units (PRU, r = 0.193; P = 0.001), and decreased P2Y12% inhibition (PI%, 
      r = - 0.273; P < 0.001). The group with increasing MPV values showed 
      significantly higher PRU values and lower PI% compared with the group with 
      decreasing MPV values (222.5 ± 73.9 vs. 195.6 ± 63.7 PRU, P = 0.001; 24.1 ± 21.0 
      vs. 32.8 ± 18.5 PI%, P < 0.001, respectively). The clopidogrel resistant group 
      (≥235 PRU or ≤15% of PI%) showed a significantly higher positive change in MPV 
      (ΔMPV) values than the clopidogrel responder group (0.53 ± 0.78 vs. 0.13 ± 0.69 
      fL, P < 0.001). When the ΔMPV cut-off level was set at 0.20 fL using the receiver 
      operating characteristic curve, the sensitivity and specificity for 
      differentiating between the clopidogrel resistant and responder groups were 72.6% 
      and 59.3%, respectively. After adjusting for traditional risk factors, the odds 
      ratio in the clopidogrel resistant group with ΔMPV ≥0.2 fL was 4.10 (95% 
      confidence interval; 1.84-9.17). In conclusion, ΔMPV was associated with PRU and 
      PI%; a positive ΔMPV was an independent predictive marker for clopidogrel 
      resistance after PCI.
FAU - Koh, Young-Youp
AU  - Koh YY
FAU - Kim, Hyung Ho
AU  - Kim HH
FAU - Choi, Dong-Hyun
AU  - Choi DH
AD  - College of Medicine, Chosun University, 375 Seo-suk dong, Dong-Gu, Gwangju 
      501-759, Republic of Korea. dhchoi@chosun.ac.kr.
FAU - Lee, Young-Min
AU  - Lee YM
FAU - Ki, Young-Jae
AU  - Ki YJ
FAU - Kang, Seong-Ho
AU  - Kang SH
FAU - Park, Geon
AU  - Park G
FAU - Chung, Joong-Wha
AU  - Chung JW
FAU - Chang, Kyong-Sig
AU  - Chang KS
FAU - Hong, Soon-Pyo
AU  - Hong SP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Mean Platelet Volume
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Platelet Function Tests
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Treatment Outcome
EDAT- 2014/10/18 06:00
MHDA- 2016/06/02 06:00
CRDT- 2014/10/18 06:00
PHST- 2015/06/23 00:00 [received]
PHST- 2015/08/10 00:00 [revised]
PHST- 2015/09/15 00:00 [accepted]
PHST- 2014/10/18 06:00 [entrez]
PHST- 2014/10/18 06:00 [pubmed]
PHST- 2016/06/02 06:00 [medline]
AID - CVP-EPUB-62902 [pii]
AID - 10.2174/1570161112666141017121118 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2015;13(5):687-93. doi: 10.2174/1570161112666141017121118.

PMID- 10746868
OWN - NLM
STAT- MEDLINE
DCOM- 20000428
LR  - 20190915
IS  - 0148-5016 (Print)
IS  - 0148-5016 (Linking)
VI  - 44
IP  - 2
DP  - 2000 Mar-Apr
TI  - Functional activity of mouse sperm was not affected by low doses of aspirin-like 
      drugs.
PG  - 117-28
AB  - To investigate some possible effects of low doses of nonsteroidal 
      anti-inflammatory drugs upon functional activity of mouse sperm, the authors 
      injected lysine acetyl salicylate (im 14.3 mg/kg day(-1), ibuprofen (ip 5.6 mg/kg 
      day(-1)), or piroxicam (ip 0.28 mg/kg day(-1) to pregnant females (the male 
      cohort was sacrificed at adulthood) (A) or to adult males during 35 (B) or 60 (C) 
      days. Parameters measured were motility, viability, acrosomal integrity, 
      responses to hypoosmotic shock, in vitro fertilization index, and testosterone 
      plasma levels. Salicylate evoked a slight reduction in the percentage of swollen 
      gametes in A, and ibuprofen diminished testosterone plasma levels in B. The other 
      parameters remained unchanged in all groups. Results are well supported by the 
      low doses assayed, which are equivalent to the content of one tablet commercially 
      available for each compound.
FAU - Stutz, G
AU  - Stutz G
AD  - Instituto de Fisiologia, Facultad de Ciencias Médicas, Universidad Nacional de 
      Córdoba, Argentina.
FAU - Martini, A C
AU  - Martini AC
FAU - Ruiz, R D
AU  - Ruiz RD
FAU - Fiol De Cuneo, M
AU  - Fiol De Cuneo M
FAU - Munoz, L
AU  - Munoz L
FAU - Lacuara, J L
AU  - Lacuara JL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Arch Androl
JT  - Archives of andrology
JID - 7806755
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Epididymis/cytology/embryology
MH  - Female
MH  - Fertility/drug effects
MH  - Male
MH  - Mice
MH  - Spermatozoa/*drug effects
EDAT- 2000/04/04 09:00
MHDA- 2000/05/08 09:00
CRDT- 2000/04/04 09:00
PHST- 2000/04/04 09:00 [pubmed]
PHST- 2000/05/08 09:00 [medline]
PHST- 2000/04/04 09:00 [entrez]
AID - 10.1080/014850100262281 [doi]
PST - ppublish
SO  - Arch Androl. 2000 Mar-Apr;44(2):117-28. doi: 10.1080/014850100262281.

PMID- 9825951
OWN - NLM
STAT- MEDLINE
DCOM- 19990204
LR  - 20220408
IS  - 0114-5916 (Print)
IS  - 0114-5916 (Linking)
VI  - 19
IP  - 5
DP  - 1998 Nov
TI  - Migraine in pregnancy: what are the safest treatment options?
PG  - 383-8
AB  - The occurrence of migraine in women is influenced by hormonal changes throughout 
      the lifecycle. A beneficial effect of pregnancy on migraine, mainly during the 
      last 2 trimesters, has been observed in 55 to 90% of women who are pregnant, 
      irrespective of the type of migraine. A higher percentage of women with menstrual 
      migraine find that their condition improves when they are pregnant. However, in 
      rare cases migraine may appear for the first time during pregnancy. The positive 
      effects of pregnancy on migraine and the possible worsening post partum are 
      probably related to the uniformly high and stable estrogen levels during 
      pregnancy and the rapid fall-off thereafter. Nondrug therapies (relaxation, 
      sleep, massage, ice packs, biofeedback) should be tried first to treat migraine 
      in women who are pregnant. For treatment of acute migraine attacks 1000 mg of 
      paracetamol (acetaminophen) preferably as a suppository is considered the first 
      choice drug treatment. The risks associated with use of aspirin (acetylsalicylic 
      acid) and ibuprofen are considered to be small when the agents are taken 
      episodically and if they are avoided during the last trimester of pregnancy. The 
      'triptans' (sumatriptan, zolmitriptan, naratriptan), dihydroergotamine and 
      ergotamine tartrate are contraindicated in women who are pregnant. 
      Prochlorperazine for treatment of nausea is unlikely to be harmful during 
      pregnancy. Metoclopramide is probably acceptable to use during the second and 
      third trimester. Prophylactic treatment is rarely indicated and the only agents 
      that can be given during pregnancy are the beta-blockers metoprolol and 
      propranolol.
FAU - Pfaffenrath, V
AU  - Pfaffenrath V
AD  - vpfa@aol.com
FAU - Rehm, M
AU  - Rehm M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Analgesics, Non-Narcotic/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Migraine Disorders/complications/*drug therapy
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
RF  - 52
EDAT- 1998/11/24 00:00
MHDA- 1998/11/24 00:01
CRDT- 1998/11/24 00:00
PHST- 1998/11/24 00:00 [pubmed]
PHST- 1998/11/24 00:01 [medline]
PHST- 1998/11/24 00:00 [entrez]
AID - 10.2165/00002018-199819050-00005 [doi]
PST - ppublish
SO  - Drug Saf. 1998 Nov;19(5):383-8. doi: 10.2165/00002018-199819050-00005.

PMID- 9092536
OWN - NLM
STAT- MEDLINE
DCOM- 19970515
LR  - 20210209
IS  - 0021-9258 (Print)
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
VI  - 272
IP  - 15
DP  - 1997 Apr 11
TI  - Inhibition of activator protein 1 activity and neoplastic transformation by 
      aspirin.
PG  - 9962-70
AB  - Aspirin, along with its analgesic-antipyretic uses, is now also being considered 
      for prevention of cardiovascular disease, cancer, and treatment of human 
      immunodeficiency virus infection. Although many of aspirin's pharmacological 
      actions are related to its ability to inhibit prostaglandin biosynthesis, some of 
      its beneficial therapeutic effects are not completely understood. Transcription 
      factor activator protein 1 (AP-1) is critical for the induction of neoplastic 
      transformation and induction of multiple genes involved in inflammation and 
      infection. We have used the JB6 mouse epidermal cell lines, a system that has 
      been used extensively as an in vitro model for the study of tumor promotion and 
      anti-tumor promotion, to study the anti-carcinogenesis effect of aspirin at the 
      molecular level. Aspirin and aspirin-like salicylates inhibited the activation of 
      AP-1 in the same dose range as seen for the inhibition of tumor promoter-induced 
      transformation. The inhibition of AP-1 and tumor promoter-induced transformation 
      in JB6 cells occurs through a prostaglandin independent- and an Erk1- or 
      Erk2-independent pathway. The mechanism of AP-1 and transformation inhibition in 
      this cell culture model may involve the elevation of H+ concentration. The 
      inhibition effects on the activation of AP-1 activity by aspirin and aspirin-like 
      salicylates may further explain the anti-carcinogenesis mechanism of action of 
      these drugs.
FAU - Dong, Z
AU  - Dong Z
AD  - The Hormel Institute, University of Minnesota, Austin, Minnesota 55912, 
      USA.zgdong@wolf.co.net
FAU - Huang, C
AU  - Huang C
FAU - Brown, R E
AU  - Brown RE
FAU - Ma, W Y
AU  - Ma WY
LA  - eng
GR  - R01 GM045928/GM/NIGMS NIH HHS/United States
GR  - GM45928/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Carcinogens)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Transcription Factor AP-1)
RN  - 731DCA35BT (Diethylstilbestrol)
RN  - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinases)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Antineoplastic Agents, Hormonal/pharmacology
MH  - Aspirin/*pharmacology
MH  - Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors
MH  - Carcinogens/pharmacology
MH  - Cell Adhesion
MH  - Cell Transformation, Neoplastic/*drug effects
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Diethylstilbestrol/pharmacology
MH  - Genes, jun
MH  - Genes, ras
MH  - Hydrogen-Ion Concentration
MH  - Indomethacin/pharmacology
MH  - Mice
MH  - Mitogen-Activated Protein Kinase 1
MH  - Mitogen-Activated Protein Kinase 3
MH  - *Mitogen-Activated Protein Kinases
MH  - Phosphorylation
MH  - Sodium Salicylate/pharmacology
MH  - Tetradecanoylphorbol Acetate/pharmacology
MH  - Transcription Factor AP-1/*antagonists & inhibitors
MH  - Tumor Cells, Cultured
PMC - PMC4003901
MID - NIHMS475764
EDAT- 1997/04/11 00:00
MHDA- 1997/04/11 00:01
CRDT- 1997/04/11 00:00
PHST- 1997/04/11 00:00 [pubmed]
PHST- 1997/04/11 00:01 [medline]
PHST- 1997/04/11 00:00 [entrez]
AID - S0021-9258(18)40840-X [pii]
AID - 10.1074/jbc.272.15.9962 [doi]
PST - ppublish
SO  - J Biol Chem. 1997 Apr 11;272(15):9962-70. doi: 10.1074/jbc.272.15.9962.

PMID- 8410869
OWN - NLM
STAT- MEDLINE
DCOM- 19931123
LR  - 20131121
IS  - 0024-7758 (Print)
IS  - 0024-7758 (Linking)
VI  - 38
IP  - 8
DP  - 1993 Aug
TI  - Successful pregnancy outcome with combination therapy in women with the 
      antiphospholipid antibody syndrome.
PG  - 625-9
AB  - Four women with the antiphospholipid syndrome associated with lupus anticoagulant 
      and a poor obstetric history were treated with a combination of 
      glucocorticosteroids, anticoagulants and platelet inhibitor therapy. All patients 
      had at least one previous miscarriage while receiving prednisone and low-dose 
      aspirin. The treatment regimen included: aspirin, dipyridamole, prednisone, and 
      warfarin or heparin. This treatment resulted in a successful pregnancy outcome in 
      all cases, without preeclampsia or recurrence of thrombosis. One patient 
      developed a vertebral compression fracture while receiving heparin and 
      prednisone. Two pregnancies required cesarean delivery for fetal distress at 32 
      and 34 weeks. All four infant birth weights were appropriate for the gestational 
      age. This regimen may be a therapeutic option for patients with the 
      antiphospholipid antibody syndrome, especially if they have failed other commonly 
      used treatments.
FAU - Menashe, Y
AU  - Menashe Y
AD  - Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel 
      Hashomer, Israel.
FAU - Ben-Baruch, G
AU  - Ben-Baruch G
FAU - Greenspoon, J S
AU  - Greenspoon JS
FAU - Carp, H J
AU  - Carp HJ
FAU - Rosen, D J
AU  - Rosen DJ
FAU - Mashiach, S
AU  - Mashiach S
FAU - Many, A
AU  - Many A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Reprod Med
JT  - The Journal of reproductive medicine
JID - 0173343
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Antiphospholipid Syndrome/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Prednisone/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Pregnancy Outcome
MH  - Warfarin/therapeutic use
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
PST - ppublish
SO  - J Reprod Med. 1993 Aug;38(8):625-9.

PMID- 19450314
OWN - NLM
STAT- MEDLINE
DCOM- 20160422
LR  - 20211020
IS  - 1752-8526 (Electronic)
IS  - 1462-3846 (Linking)
VI  - 2008
DP  - 2008 Apr 14
TI  - Recurrent miscarriage.
LID - 1409 [pii]
AB  - INTRODUCTION: Recurrent miscarriage is the spontaneous loss of three or more 
      consecutive pregnancies with the same biological father in the first trimester, 
      and affects 1-2% of women, half of whom have no identifiable cause. Overall, 75% 
      of affected women will have a successful subsequent pregnancy, but this rate 
      falls for older mothers and with increasing number of miscarriages. 
      Antiphospholipid syndrome, with anticardiolipin or lupus anticoagulant 
      antibodies, is present in 15% of women with recurrent first and second trimester 
      miscarriage. METHODS AND OUTCOMES: We conducted a systematic review and aimed to 
      answer the following clinical questions: What are the effects of treatments for 
      unexplained recurrent miscarriage? What are the effects of treatments for 
      recurrent miscarriage caused by antiphospholipid syndrome? We searched: Medline, 
      Embase, The Cochrane Library and other important databases up to April 2007 
      (Clinical Evidence reviews are updated periodically, please check our website for 
      the most up-to-date version of this review). We included harms alerts from 
      relevant organisations such as the US Food and Drug Administration (FDA) and the 
      UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 
      14 systematic reviews, RCTs, or observational studies that met our inclusion 
      criteria. We performed a GRADE evaluation of the quality of evidence for 
      interventions. CONCLUSIONS: In this systematic review we present information 
      relating to the effectiveness and safety of the following interventions: aspirin 
      (low dose), bed rest, corticosteroids, early scanning in subsequent pregnancies, 
      heparin plus low-dose aspirin, human chorionic gonadotrophin, intravenous 
      immunoglobulin treatment, lifestyle adaptation, oestrogen, paternal white cell 
      immunisation, progesterone, trophoblastic membrane infusion, and vitamin 
      supplementation.
FAU - Duckitt, Kirsten
AU  - Duckitt K
AD  - John Radcliffe Hospital, Oxford, UK.
FAU - Qureshi, Aysha
AU  - Qureshi A
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20080414
PL  - England
TA  - BMJ Clin Evid
JT  - BMJ clinical evidence
JID - 101294314
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abortion, Habitual/drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Antiphospholipid Syndrome/drug therapy
MH  - Aspirin/administration & dosage
MH  - *Heparin/administration & dosage
MH  - Humans
PMC - PMC2907979
EDAT- 2008/01/01 00:00
MHDA- 2016/04/23 06:00
CRDT- 2009/05/20 09:00
PHST- 2009/05/20 09:00 [entrez]
PHST- 2008/01/01 00:00 [pubmed]
PHST- 2016/04/23 06:00 [medline]
AID - 1409 [pii]
PST - epublish
SO  - BMJ Clin Evid. 2008 Apr 14;2008:1409.

PMID- 28499532
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20171226
IS  - 1558-0474 (Electronic)
IS  - 0889-8545 (Linking)
VI  - 44
IP  - 2
DP  - 2017 Jun
TI  - Updates on the Recognition, Prevention and Management of Hypertension in 
      Pregnancy.
PG  - 219-230
LID - S0889-8545(17)30034-7 [pii]
LID - 10.1016/j.ogc.2017.02.007 [doi]
AB  - Systematic reviews with meta-analysis represent the highest level of evidence 
      used to guide clinical practice. The defining criteria used to diagnose 
      preeclampsia have evolved, and will likely continue to evolve. Proteinuria is 
      sufficient but not necessary when defining preeclampsia. Hypertension without 
      proteinuria but with severe features is diagnostic. The methods used to measure 
      urinary protein have changed. The gold standard remains the 24-hour urine test. 
      The efficacy of low-dose aspirin in preventing preeclampsia is a function of 
      baseline risk. Data suggest that treating mild to moderate blood pressure has 
      clear maternal benefits with little fetal or neonatal risk.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Jackson, Jessica R
AU  - Jackson JR
AD  - Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of 
      Florida College of Medicine, PO Box 100294, Gainesville, FL 32610-0294, USA.
FAU - Gregg, Anthony R
AU  - Gregg AR
AD  - Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of 
      Florida Health System, University of Florida College of Medicine, PO Box 100294, 
      Gainesville, FL 32610-0294, USA. Electronic address: greggar@ufl.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Obstet Gynecol Clin North Am
JT  - Obstetrics and gynecology clinics of North America
JID - 8709551
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/*diagnosis/prevention & control/*therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*diagnosis/*therapy
OTO - NOTNLM
OT  - Aspirin
OT  - Criteria
OT  - Hypertension
OT  - Pregnancy
OT  - Proteinuria
OT  - Treatment
EDAT- 2017/05/14 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/05/14 06:00
PHST- 2017/05/14 06:00 [entrez]
PHST- 2017/05/14 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - S0889-8545(17)30034-7 [pii]
AID - 10.1016/j.ogc.2017.02.007 [doi]
PST - ppublish
SO  - Obstet Gynecol Clin North Am. 2017 Jun;44(2):219-230. doi: 
      10.1016/j.ogc.2017.02.007.

PMID- 31513909
OWN - NLM
STAT- MEDLINE
DCOM- 20200309
LR  - 20210124
IS  - 1534-4436 (Electronic)
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 123
IP  - 5
DP  - 2019 Nov
TI  - Suppression of aspirin-mediated eosinophil activation by prostaglandin E(2): 
      Relevance to aspirin and nonsteroidal anti-inflammatory drug hypersensitivity.
PG  - 503-506
LID - S1081-1206(19)31058-0 [pii]
LID - 10.1016/j.anai.2019.09.003 [doi]
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is characterized by 
      severe, sometimes life-threatening reactions to nonsteroidal anti-inflammatory 
      drugs (NSAIDs). Mechanisms driving the disease include overproduction of 
      leukotrienes and loss of anti-inflammatory prostaglandin E(2) (PGE(2)) 
      production. Many cell types contribute to the disease; however, eosinophils are 
      markedly elevated and are important drivers of pathologic findings. OBJECTIVE: To 
      investigate the capacity of aspirin and NSAIDs to drive eosinophil activation and 
      the ability of PGE(2) to inhibit this activation. METHODS: Eosinophils were 
      purified from blood of healthy individuals without AERD and stimulated with 
      lysine aspirin, ketorolac, or sodium salicylate. The role of PGE(2) in altering 
      activation was determined by incubating eosinophils with increasing doses of 
      PGE(2) before lysine aspirin stimulation. Specific PGE(2) receptor use was 
      determined by incubating eosinophils with receptor agonists and antagonists 
      before aspirin stimulation. Cysteinyl leukotrienes (CysLTs), leukotriene B(4) 
      (LTB(4)), and eosinophil-derived neurotoxin (EDN) were quantified by 
      enzyme-linked immunosorbent assay. RESULTS: Stimulation of eosinophils with 
      lysine aspirin, ketorolac, or sodium salicylate resulted in secretion of CysLTs 
      and LTB(4) in the absence of EDN release. Low doses of PGE(2) inhibited LTB(4) 
      and CysLT release, an effect lost at higher PGE(2) concentrations. Use of 
      butaprost, an EP(2) receptor agonist, suppressed lysine aspirin stimulation. This 
      mechanism was supported by blocking activity of the EP(1) and EP(3) receptors. 
      CONCLUSION: Eosinophils can be directly activated by NSAIDs via 
      cyclooxygenase-independent pathways to produce CysLTs and LTB(4). This effect can 
      be inhibited by PGE(2) acting through the EP(2) receptor. The recognized loss of 
      EP(2) receptor expression combined with low PGE(2) levels explains in part the 
      sensitivity to NSAIDs.
CI  - Copyright © 2019 American College of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Pal, Kavita
AU  - Pal K
AD  - Departments of Medicine, University of Virginia Health System, Charlottesville, 
      Virginia.
FAU - Ramsden, Madison
AU  - Ramsden M
AD  - Departments of Medicine, University of Virginia Health System, Charlottesville, 
      Virginia.
FAU - Shim, Yun M
AU  - Shim YM
AD  - Departments of Medicine, University of Virginia Health System, Charlottesville, 
      Virginia.
FAU - Borish, Larry
AU  - Borish L
AD  - Departments of Medicine, University of Virginia Health System, Charlottesville, 
      Virginia; Department of Microbiology, University of Virginia Health System, 
      Charlottesville, Virginia. Electronic address: lb4m@virginia.edu.
FAU - Payne, Spencer C
AU  - Payne SC
AD  - Department of Otolaryngology, University of Virginia Health System, 
      Charlottesville, Virginia.
FAU - Steinke, John W
AU  - Steinke JW
AD  - Departments of Medicine, University of Virginia Health System, Charlottesville, 
      Virginia.
LA  - eng
GR  - R01 HL132177/HL/NHLBI NIH HHS/United States
GR  - U01 AI123337/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20190909
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Leukotrienes)
RN  - 0 (cysteinyl-leukotriene)
RN  - 1HGW4DR56D (Leukotriene B4)
RN  - K3Z4F929H6 (Lysine)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - K848JZ4886 (Cysteine)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - YZI5105V0L (Ketorolac)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology
MH  - Aspirin/adverse effects/*analogs & derivatives/pharmacology
MH  - Cells, Cultured
MH  - Cysteine/metabolism
MH  - Dinoprostone/*pharmacology
MH  - Drug Hypersensitivity
MH  - Eosinophils/*drug effects/metabolism
MH  - Humans
MH  - Ketorolac/adverse effects/*pharmacology
MH  - Leukotriene B4/metabolism
MH  - Leukotrienes/metabolism
MH  - Lysine/adverse effects/*analogs & derivatives/pharmacology
MH  - Sodium Salicylate/adverse effects/*pharmacology
PMC - PMC6825585
MID - NIHMS1539433
EDAT- 2019/09/13 06:00
MHDA- 2020/03/10 06:00
CRDT- 2019/09/13 06:00
PHST- 2019/01/04 00:00 [received]
PHST- 2019/08/21 00:00 [revised]
PHST- 2019/09/03 00:00 [accepted]
PHST- 2019/09/13 06:00 [pubmed]
PHST- 2020/03/10 06:00 [medline]
PHST- 2019/09/13 06:00 [entrez]
AID - S1081-1206(19)31058-0 [pii]
AID - 10.1016/j.anai.2019.09.003 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2019 Nov;123(5):503-506. doi: 
      10.1016/j.anai.2019.09.003. Epub 2019 Sep 9.

PMID- 20962655
OWN - NLM
STAT- MEDLINE
DCOM- 20110316
LR  - 20220409
IS  - 1365-2346 (Electronic)
IS  - 0265-0215 (Linking)
VI  - 28
IP  - 1
DP  - 2011 Jan
TI  - Tranexamic acid partially improves platelet function in patients treated with 
      dual antiplatelet therapy.
PG  - 57-62
LID - 10.1097/EJA.0b013e32834050ab [doi]
AB  - BACKGROUND: Although the impact of tranexamic acid on platelet function remains 
      controversial, tranexamic acid is part of clinical algorithms for the management 
      of platelet dysfunction. The goal of our prospective, observational study was to 
      examine the effects of tranexamic acid on platelet function in patients treated 
      with dual antiplatelet therapy compared to those who ceased antiplatelet therapy 
      for at least 7 days. METHODS: Forty patients scheduled for cardiac surgery were 
      enrolled in this study. Group 1 consisted of 20 patients who ceased antiplatelet 
      therapy with aspirin and clopidogrel at least 7 days before surgery. Group 2 
      consisted of 20 patients who were treated with aspirin and clopidogrel until the 
      day before surgery. Using the Multiplate device (Dynabyte, Munich, Germany), 
      multiple electrode aggregometry (MEA) was performed following platelet 
      stimulation with thrombin receptor activating peptide-6 (TRAP-6), arachidonic 
      acid or ADP on blood collected 20 min before and after application of 2 g 
      tranexamic acid. RESULTS: Compared with group 1, platelet aggregation was 
      statistically significantly reduced in ASPItest and ADPtest in group 2, whereas 
      there were no significant differences in the TRAPtest. In group 1, platelet 
      aggregation did not differ significantly before and after tranexamic acid 
      treatment. In contrast, in group 2, we observed a significant increase in 
      arachidonic acid-induced [295 (280/470) arbitrary aggregation units × min 
      [AU*min; median (25th/75th percentile) vs. 214 (83/409) AU*min, P = 0.01] and 
      ADP-induced platelet aggregation [560 AU*min (400/760 AU*min) vs. 470 AU*min 
      (282/550 AU*min), P = 0.013], whereas platelet aggregation following stimulation 
      with TRAP-6 did not change significantly [980 (877/1009) AU*min, median 
      (25th/75th percentile) after tranexamic acid vs. 867 (835/961) AU*min before 
      tranexamic acid, P = 0.464]. CONCLUSION: The results of this study indicate that 
      tranexamic acid potentially corrects defects in arachidonic acid-induced and 
      ADP-induced platelet aggregation imposed by dual antiplatelet therapy. However, 
      platelet aggregation in response to arachidonic acid or ADP in the blood of 
      patients who have not received aspirin and clopidogrel is unaffected by 
      tranexamic acid. These results support the use of tranexamic acid to partially 
      reverse platelet aggregation dysfunction due to antiplatelet therapy.
FAU - Weber, Christian F
AU  - Weber CF
AD  - Clinic for Anaesthesiology, Intensive Care Medicine and Pain Therapy, J.-W. 
      Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.
FAU - Görlinger, Klaus
AU  - Görlinger K
FAU - Byhahn, Christian
AU  - Byhahn C
FAU - Moritz, Anton
AU  - Moritz A
FAU - Hanke, Alexander A
AU  - Hanke AA
FAU - Zacharowski, Kai
AU  - Zacharowski K
FAU - Meininger, Dirk
AU  - Meininger D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Eur J Anaesthesiol
JT  - European journal of anaesthesiology
JID - 8411711
RN  - 0 (Antifibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 6T84R30KC1 (Tranexamic Acid)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Antifibrinolytic Agents/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Clopidogrel
MH  - Coronary Artery Bypass/methods
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Tranexamic Acid/*pharmacology
EDAT- 2010/10/22 06:00
MHDA- 2011/03/17 06:00
CRDT- 2010/10/22 06:00
PHST- 2010/10/22 06:00 [entrez]
PHST- 2010/10/22 06:00 [pubmed]
PHST- 2011/03/17 06:00 [medline]
AID - 10.1097/EJA.0b013e32834050ab [doi]
PST - ppublish
SO  - Eur J Anaesthesiol. 2011 Jan;28(1):57-62. doi: 10.1097/EJA.0b013e32834050ab.

PMID- 15276512
OWN - NLM
STAT- MEDLINE
DCOM- 20050524
LR  - 20131121
IS  - 1552-6259 (Electronic)
IS  - 0003-4975 (Linking)
VI  - 78
IP  - 2
DP  - 2004 Aug
TI  - Reexploration for bleeding after coronary artery bypass surgery: risk factors, 
      outcomes, and the effect of time delay.
PG  - 527-34; discussion 534
AB  - BACKGROUND: We aimed to identify risk factors for reexploration for bleeding 
      after surgical revascularization in our practice. We also looked at the impact of 
      resternotomy and the effect of time delay on mortality and other in-hospital 
      outcomes. METHODS: In all, 2,898 consecutive patients undergoing coronary artery 
      bypass grafting between April 1999 and March 2002 were retrospectively analyzed 
      from our cardiac surgery registry. Multivariate logistic regression analysis was 
      used to identify risk factors for reexploration for bleeding. To assess the 
      effect of preoperative aspirin and heparin, reexploration patients were 
      propensity matched with unique patients not requiring reexploration. We carried 
      out a casenote review to ascertain the timing and causes for bleeding in patients 
      undergoing resternotomy. RESULTS: Eighty-nine patients (3.1%) underwent 
      reexploration for bleeding. Multivariate analysis revealed smaller body mass 
      index (p = 0.003), nonelective surgery (p = 0.022), 5 or more distal anastomoses 
      (p = 0.035), and increased age (p = 0.041) to have increased risks. 
      Propensity-matched analysis showed that preoperative use of aspirin (p = 0.004) 
      and heparin (p = 0.001) were associated with increased risk in the on-pump 
      coronary surgery group only. Patients requiring resternotomy had a significantly 
      greater need for inotropic agents (p < 0.001), and longer intensive care unit 
      stay (p < 0.001) and postoperative stay (p < 0.001) than their propensity-matched 
      controls. However, there was no significant difference in the mortality rate. 
      Adverse outcomes were significantly higher when patients waited more than 12 
      hours after return to the intensive care unit for resternotomy. CONCLUSIONS: Risk 
      factors for reexploration for bleeding after coronary artery bypass grafting 
      include older age, smaller body mass index, nonelective cases, and 5 or more 
      distal anastomoses. Preoperative aspirin and heparin were risk factors for the 
      on-pump coronary artery surgery group. Patients needing reexploration are at 
      higher risk of complications if the time to reexploration is prolonged. Policies 
      that promote early return to the operating theater for reexploration should be 
      encouraged.
FAU - Karthik, Shishir
AU  - Karthik S
AD  - Department of Cardiothoracic Surgery, The Cardiothoracic Centre-Liverpool, 
      Liverpool, United Kingdom. suchkats@yahoo.com
FAU - Grayson, Antony D
AU  - Grayson AD
FAU - McCarron, Emer E
AU  - McCarron EE
FAU - Pullan, D Mark
AU  - Pullan DM
FAU - Desmond, Michael J
AU  - Desmond MJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 0 (Anticoagulants)
RN  - 0 (Cardiotonic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Body Mass Index
MH  - Cardiotonic Agents/therapeutic use
MH  - *Coronary Artery Bypass/statistics & numerical data
MH  - Female
MH  - Heparin/adverse effects/therapeutic use
MH  - Hospital Mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteotomy/statistics & numerical data
MH  - Postoperative Hemorrhage/chemically induced/*surgery
MH  - Reoperation/statistics & numerical data
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sternum/surgery
MH  - Treatment Outcome
RF  - 18
EDAT- 2004/07/28 05:00
MHDA- 2005/05/25 09:00
CRDT- 2004/07/28 05:00
PHST- 2004/02/20 00:00 [accepted]
PHST- 2004/07/28 05:00 [pubmed]
PHST- 2005/05/25 09:00 [medline]
PHST- 2004/07/28 05:00 [entrez]
AID - S000349750400493X [pii]
AID - 10.1016/j.athoracsur.2004.02.088 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 2004 Aug;78(2):527-34; discussion 534. doi: 
      10.1016/j.athoracsur.2004.02.088.

PMID- 663281
OWN - NLM
STAT- MEDLINE
DCOM- 19780814
LR  - 20190823
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 15
IP  - 3
DP  - 1978 Mar
TI  - Release of prostaglandin-like substance from inflamed synovial tissue of rat.
PG  - 447-55
AB  - Influence of inflammation on the release of prostaglandin-like substance (PG) 
      from synovial tissue of rat was studied. 1) In carrageenin inflammation, PG 
      release was proportional to the increase in synovial tissue weight. 2) PG release 
      was only increased in the later phase of dextran inflammation. 3) Aspirin 
      suppressed PG release from both non-inflamed and inflamed synovial tissues, but 
      hydrocortisone suppressed that only in inflamed tissue.
FAU - Arai, Y
AU  - Arai Y
FAU - Aizawa, Y
AU  - Aizawa Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Dextrans)
RN  - 0 (Prostaglandins)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Carrageenan
MH  - Dextrans
MH  - Hydrocortisone/pharmacology
MH  - Male
MH  - Prostaglandins/*metabolism
MH  - Rats
MH  - Secretory Rate/drug effects
MH  - Synovitis/chemically induced/*metabolism
EDAT- 1978/03/01 00:00
MHDA- 1978/03/01 00:01
CRDT- 1978/03/01 00:00
PHST- 1978/03/01 00:00 [pubmed]
PHST- 1978/03/01 00:01 [medline]
PHST- 1978/03/01 00:00 [entrez]
AID - 0090-6980(78)90128-4 [pii]
AID - 10.1016/0090-6980(78)90128-4 [doi]
PST - ppublish
SO  - Prostaglandins. 1978 Mar;15(3):447-55. doi: 10.1016/0090-6980(78)90128-4.

PMID- 36153214
OWN - NLM
STAT- MEDLINE
DCOM- 20221108
LR  - 20221108
IS  - 1579-2129 (Electronic)
IS  - 0300-2896 (Print)
IS  - 0300-2896 (Linking)
VI  - 58
IP  - 11
DP  - 2022 Nov
TI  - Pre-hospital Aspirin Use and Patient Outcomes in COVID-19: Results from the 
      International Viral Infection and Respiratory Illness Universal Study (VIRUS).
PG  - 746-753
LID - S0300-2896(22)00510-5 [pii]
LID - 10.1016/j.arbres.2022.07.017 [doi]
AB  - INTRODUCTION: The goal of this investigation is to assess the association between 
      prehospital use of aspirin (ASA) and patient-centered outcomes in a large global 
      cohort of hospitalized COVID-19 patients. METHODS: This study utilizes data from 
      the Society of Critical Care Medicine Discovery Viral Infection and Respiratory 
      Illness Universal Study (VIRUS) Registry. Adult patients hospitalized from 
      February 15th, 2020, to September 30th, 2021, were included. Multivariable 
      regression analyses were utilized to assess the association between pre-hospital 
      use of ASA and the primary outcome of overall hospital mortality. RESULTS: 21,579 
      patients were included from 185 hospitals (predominantly US-based, 71.3%), with 
      4691 (21.7%) receiving pre-hospital ASA. Patients receiving ASA, compared to 
      those without pre-admission ASA use, were generally older (median 70 vs. 59 
      years), more likely to be male (58.7 vs. 56.0%), caucasian (57.4 vs. 51.6%), and 
      more commonly had higher rates of medical comorbidities. In multivariable 
      analyses, patients receiving pre-hospital ASA had lower mortality (HR: 0.89, 95% 
      CI 0.82-0.97, p=0.01) and reduced hazard for progression to severe disease or 
      death (HR: 0.91, 95% CI 0.84-0.99, p=0.02) and more hospital free days (1.00 
      days, 95% CI 0.66-1.35, p=0.01) compared to those without pre-hospital ASA use. 
      The overall direction and significance of the results remained the same in 
      sensitivity analysis, after adjusting the multivariable model for time since 
      pandemic. CONCLUSIONS: In this large international cohort, pre-hospital use of 
      ASA was associated with a lower hazard for death in hospitalized patients with 
      COVID-19. Randomized controlled trials may be warranted to assess the utility of 
      pre-hospital use of ASA.
CI  - Copyright © 2022 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.
FAU - Lal, Amos
AU  - Lal A
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo 
      Clinic, Rochester, MN, USA. Electronic address: Lal.Amos@mayo.edu.
FAU - Garces, Juan Pablo Domecq
AU  - Garces JPD
AD  - Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo 
      Clinic, Rochester, MN, USA; Division of Critical Care Medicine, Department of 
      Internal Medicine, Mayo Clinic Health System, Mankato, MN, USA.
FAU - Bansal, Vikas
AU  - Bansal V
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo 
      Clinic, Rochester, MN, USA.
FAU - Tekin, Aysun
AU  - Tekin A
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo 
      Clinic, Rochester, MN, USA.
FAU - Zec, Simon
AU  - Zec S
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo 
      Clinic, Rochester, MN, USA.
FAU - Khanna, Ashish K
AU  - Khanna AK
AD  - Section on Critical Care Medicine, Department of Anesthesiology, Wake Forest 
      University School of Medicine, Atrium Health Wake Forest Baptist Medical Center, 
      Winston-Salem, NC, USA; Outcomes Research Consortium, Cleveland, OH, USA.
FAU - Warner, Matthew A
AU  - Warner MA
AD  - Division of Critical Care Medicine, Department of Anesthesiology and 
      Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Christie, Amy B
AU  - Christie AB
AD  - Atrium Health Navicent, Macon, GA, USA.
FAU - Cartin-Ceba, Rodrigo
AU  - Cartin-Ceba R
AD  - Department of Critical Care Medicine, Mayo Clinic, AZ, USA.
FAU - Banner-Goodspeed, Valerie M
AU  - Banner-Goodspeed VM
AD  - Beth Israel Deaconess Medical Center, Boston, MA, USA.
FAU - Armaignac, Donna Lee
AU  - Armaignac DL
AD  - Center for Advanced Analytics, Baptist Health South Florida, USA.
FAU - Cheruku, Sreekanth R
AU  - Cheruku SR
AD  - Department of Anesthesiology and Pain Management, UT Southwestern Medical Center, 
      USA.
FAU - Raju, Umamaheswara
AU  - Raju U
AD  - Gandhi Medical College and Hospital, Hyderabad, India.
FAU - Tarabichi, Yasir
AU  - Tarabichi Y
AD  - MetroHealth Medical Center, USA.
FAU - Denson, Joshua L
AU  - Denson JL
AD  - Section of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane 
      School of Medicine, New Orleans, USA.
FAU - Kumar, Vishakha
AU  - Kumar V
AD  - Society of Critical Care Medicine, Mount Prospect, IL, USA.
FAU - Walkey, Allan
AU  - Walkey A
AD  - Pulmonary Center, Division of Pulmonary, Allergy, Critical Care and Sleep 
      Medicine, Department of Medicine, Evans Center of Implementation and Improvement 
      Sciences, Boston University School of Medicine, Boston, MA, USA.
FAU - Boman, Karen
AU  - Boman K
AD  - Society of Critical Care Medicine, Mount Prospect, IL, USA.
FAU - Deo, Neha
AU  - Deo N
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo 
      Clinic, Rochester, MN, USA.
FAU - Kashyap, Rahul
AU  - Kashyap R
AD  - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, 
      MN, USA.
FAU - Gajic, Ognjen
AU  - Gajic O
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo 
      Clinic, Rochester, MN, USA.
CN  - from the Society of Critical Care Medicine Discovery Viral Infection, Respiratory 
      Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group
LA  - eng
LA  - spa
PT  - Journal Article
DEP - 20220908
PL  - Spain
TA  - Arch Bronconeumol
JT  - Archivos de bronconeumologia
JID - 0354720
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Male
MH  - Female
MH  - *COVID-19/epidemiology
MH  - Aspirin/therapeutic use
MH  - SARS-CoV-2
MH  - Pandemics
MH  - *Virus Diseases
MH  - Hospitalization
MH  - Hospital Mortality
PMC - PMC9451929
OTO - NOTNLM
OT  - Aspirin
OT  - COVID-19
OT  - Length of stay
OT  - Mechanical ventilation
OT  - Mortality
EDAT- 2022/09/25 06:00
MHDA- 2022/11/09 06:00
CRDT- 2022/09/24 22:05
PHST- 2022/06/22 00:00 [received]
PHST- 2022/07/26 00:00 [revised]
PHST- 2022/07/26 00:00 [accepted]
PHST- 2022/09/25 06:00 [pubmed]
PHST- 2022/11/09 06:00 [medline]
PHST- 2022/09/24 22:05 [entrez]
AID - S0300-2896(22)00510-5 [pii]
AID - 10.1016/j.arbres.2022.07.017 [doi]
PST - ppublish
SO  - Arch Bronconeumol. 2022 Nov;58(11):746-753. doi: 10.1016/j.arbres.2022.07.017. 
      Epub 2022 Sep 8.

PMID- 24120718
OWN - NLM
STAT- MEDLINE
DCOM- 20140325
LR  - 20181202
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 51
IP  - 12
DP  - 2013 Dec
TI  - No clinically relevant interaction between sugammadex and aspirin on platelet 
      aggregation and coagulation parameters.
PG  - 976-85
LID - 10.5414/CP201970 [doi]
AB  - OBJECTIVES: This study evaluated interaction potential between sugammadex and 
      aspirin on platelet aggregation. METHODS: This was a randomized, double-blind, 
      placebo-controlled, four-period crossover study in 26 healthy adult males. 
      Treatments were i.v. placebo, i.v. sugammadex 4 mg/kg, and i.v. 
      placebo/sugammadex with oncedaily oral aspirin 75 mg. Primary objective was to 
      assess interaction between sugammadex and aspirin on platelet aggregation using 
      collagen-induced whole-blood aggregometry. Effects on activated partial 
      thromboplastin time (APTT) and cutaneous bleeding time were also evaluated. 
      Platelet aggregation and APTT were evaluated by geometric mean ratios, using 
      area-under-effect curves 3 - 30 minutes after sugammadex/placebo dosing. Bleeding 
      time ratio was evaluated at 5 minutes post-dosing. Non-inferiority margins were 
      pre-specified via literature review. Type I error was controlled using a 
      hierarchical strategy. RESULTS: Ratio for platelet aggregation for aspirin with 
      sugammadex vs. aspirin alone was 1.01, with lower limit of two-sided 90% CI of 
      0.91(above non-inferiority margin of 0.75). Ratio for statistical interaction 
      between sugammadex and aspirin on APTT was 1.01, with upper 90% CI of 1.04 (below 
      non-inferiority margin of 1.50), and for sugammadex vs. placebo alone was 1.06, 
      with an upper 90% CI of 1.07 (below non-inferiority margin of 1.50). Ratio for 
      bleeding time for aspirin with sugammadex vs. aspirin plus placebo was 1.20, with 
      upper 90% CI of 1.45 (below non-inferiority margin of 1.50). Sugammadex was 
      generally well tolerated. CONCLUSION: There was no clinically relevant reduction 
      in platelet aggregation with addition of sugammadex 4 mg/kg to aspirin. 
      Pre-determined non-inferiority margins were not exceeded for bleeding time and 
      APTT.
FAU - de Kam, Pieter-Jan
AU  - de Kam PJ
FAU - El Galta, Rachid
AU  - El Galta R
FAU - Kruithof, Annelieke C
AU  - Kruithof AC
FAU - Fennema, Hein
AU  - Fennema H
FAU - van Lierop, Marie-José
AU  - van Lierop MJ
FAU - Mihara, Katsuhiro
AU  - Mihara K
FAU - Burggraaf, Jacobus
AU  - Burggraaf J
FAU - Moerland, Matthijs
AU  - Moerland M
FAU - Peeters, Pierre
AU  - Peeters P
FAU - Troyer, Matthew D
AU  - Troyer MD
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (gamma-Cyclodextrins)
RN  - 361LPM2T56 (Sugammadex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Platelet Aggregation/*drug effects
MH  - Sugammadex
MH  - gamma-Cyclodextrins/*pharmacology
EDAT- 2013/10/15 06:00
MHDA- 2014/03/26 06:00
CRDT- 2013/10/15 06:00
PHST- 2013/11/26 00:00 [accepted]
PHST- 2013/10/15 06:00 [entrez]
PHST- 2013/10/15 06:00 [pubmed]
PHST- 2014/03/26 06:00 [medline]
AID - 10960 [pii]
AID - 10.5414/CP201970 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2013 Dec;51(12):976-85. doi: 10.5414/CP201970.

PMID- 15712641
OWN - NLM
STAT- MEDLINE
DCOM- 20050308
LR  - 20220330
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 50
IP  - 1
DP  - 2005 Jan
TI  - Endoscopy in asymptomatic minidose aspirin consumers.
PG  - 78-80
AB  - Aspirin is widely used for its antiplatelet activity, but it harbors a risk of 
      severe adverse gastrointestinal effects, such as bleeding and perforation, 
      especially in elderly people. Our aim to assess the prevalence of upper 
      gastrointestinal lesions and the effect of aspirin on the gastrointestinal mucosa 
      in asymptomatic subjects taking minidose aspirin (100 to 325 mg per day) for more 
      than 3 months. A prospective, open design was used. Patients attending the 
      ophthalmology and cardiology outpatient clinics who had a medical history of more 
      than 3 months of regular aspirin consumption were referred for 
      esophagogastroduodenoscopy (EGD). Of the 90 patients referred for EGD, 44 were 
      symptomatic (epigastric pain or dyspepsia) and were excluded from the study. The 
      46 asymptomatic patients included 22 men and 24 women of mean age 70 +/- 10 years 
      (range, 36 to 87 years); 32% were current or former smokers. Mean daily aspirin 
      dose was 129.34 +/- 76.61 mg. Only 24% were taking a gastroprotective agent. EGD 
      revealed ulcer or erosions in 47.83% of the patients: erosive gastroduodenitis in 
      13 patients, gastric ulcer in 14, duodenal ulcer in 2, and gastric and duodenal 
      ulcers in 2. Urease test for Helicobacter pylori infection was positive in 26%. 
      Univariate and multivariate analysis revealed no factor other than aspirin 
      predictive of a positive endoscopy. Minidose aspirin treatment is associated with 
      a high prevalence of ulcerations of the stomach and duodenum.
FAU - Niv, Yaron
AU  - Niv Y
AD  - Department of Gastroenterology, Rabin Medical Center, Beilinson Campus, Petah 
      Tiqva, Israel. yniv@clalit.org.il
FAU - Battler, Alex
AU  - Battler A
FAU - Abuksis, Galia
AU  - Abuksis G
FAU - Gal, Eyal
AU  - Gal E
FAU - Sapoznikov, Boris
AU  - Sapoznikov B
FAU - Vilkin, Alex
AU  - Vilkin A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse 
      effects/therapeutic use
MH  - Aspirin/*administration & dosage/*adverse effects/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Duodenal Ulcer/chemically induced/epidemiology/pathology
MH  - *Endoscopy, Digestive System
MH  - Female
MH  - Gastric Mucosa/drug effects/pathology
MH  - Gastrointestinal Tract/*drug effects/pathology
MH  - Humans
MH  - Intestinal Mucosa/drug effects/pathology
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Prospective Studies
MH  - Stomach Ulcer/chemically induced/epidemiology/pathology
MH  - Vascular Diseases/*prevention & control
EDAT- 2005/02/17 09:00
MHDA- 2005/03/09 09:00
CRDT- 2005/02/17 09:00
PHST- 2005/02/17 09:00 [pubmed]
PHST- 2005/03/09 09:00 [medline]
PHST- 2005/02/17 09:00 [entrez]
AID - 10.1007/s10620-005-1281-1 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2005 Jan;50(1):78-80. doi: 10.1007/s10620-005-1281-1.

PMID- 7438358
OWN - NLM
STAT- MEDLINE
DCOM- 19810219
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 62
IP  - 6
DP  - 1980 Dec
TI  - Relative effects of aspirin on platelet aggregation and prostaglandin-mediated 
      coronary vasodilatation in the dog.
PG  - 1221-7
AB  - Aspirin, as an inhibitor of platelet aggregation, may be of benefit in ischemic 
      heart disease. However, aspirin blocks not only platelet aggregation but also 
      synthesis of prostacyclin, a vasodilator and platelet deaggregator. The relative 
      sensitivity of prostaglandin-mediated coronary vasodilatation and platelet 
      aggregation to inhibition by aspirin remains uncertain. We therefore investigated 
      the relative dose-response relationship of aspirin on arachidonic acid-induced 
      increments in coronary blood flow and on ADP-induced aggregation of platelets. In 
      11 open-chest dogs, intracoronary arachidonic acid, 0.1-3.0 mg, produced 
      dose-related increases in coronary blood flow that were inhibited progressively 
      by i.v. aspirin over the dose range 0.3-3.0 mg/kg. Aspirin at 3 mg/kg almost 
      completely obliterated the response to 3 mg of arachidonic acid. Similarly, 
      aspirin doses of 0.3-3.0 mg/kg progressively raised the minimal concentration of 
      ADP necessary for platelet aggregation. The threshold concentration of ADP that 
      produced aggregation of platelets from 10 control dogs ranged from 2.3 x 10(-6) M 
      to 1.2 x 10(-5) M. Aspirin at 3 mg/kg completely inhibited aggregation of 
      platelets from 11 of 12 dogs, even with ADP at 2.3 x 10(-4) M concentration, the 
      maximum tested. Aspirin at 0.1 mg/kg failed to inhibit either ADP-induced 
      platelet aggregation or arachidonic acid-induced increments in coronary blood 
      flow. Thus, the two test systems showed similar sensitivity to inhibition by 
      aspirin with respect to threshold dose and maximal effect. These results show 
      that very low doses of aspirin inhibit arachidonic acid-induced coronary 
      vasodilatation and that aspirin at low doses does not appear to selectively 
      inhibit platelet activity relative to coronary vasodilatation.
FAU - Capurro, N L
AU  - Capurro NL
FAU - Lipson, L C
AU  - Lipson LC
FAU - Bonow, R O
AU  - Bonow RO
FAU - Goldstein, R E
AU  - Goldstein RE
FAU - Shulman, N R
AU  - Shulman NR
FAU - Epstein, S E
AU  - Epstein SE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Arachidonic Acids)
RN  - 0 (Prostaglandins)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Animals
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/*pharmacology
MH  - Coronary Circulation/drug effects
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Prostaglandins/*pharmacology
MH  - Vasodilation/*drug effects
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
AID - 10.1161/01.cir.62.6.1221 [doi]
PST - ppublish
SO  - Circulation. 1980 Dec;62(6):1221-7. doi: 10.1161/01.cir.62.6.1221.

PMID- 15272097
OWN - NLM
STAT- MEDLINE
DCOM- 20041207
LR  - 20131121
IS  - 1534-7796 (Electronic)
IS  - 0033-3174 (Linking)
VI  - 66
IP  - 4
DP  - 2004 Jul-Aug
TI  - Posttraumatic stress, nonadherence, and adverse outcome in survivors of a 
      myocardial infarction.
PG  - 521-6
AB  - OBJECTIVE: Posttraumatic stress disorder (PTSD) symptoms have been reported in 
      patients with coronary vascular disease, after the trauma of a myocardial 
      infarction (MI). The effect of these symptoms on post-MI disease control has not 
      been elucidated. We conducted a study that sought to determine whether PTSD 
      symptoms post-MI are associated with increased likelihood of cardiovascular 
      readmission and with nonadherence to treatment recommendations. METHODS: Patients 
      were recruited during a visit in a cardiology clinic 6 months post-MI and were 
      followed for 1 year. Adherence to aspirin was measured by platelet thromboxane 
      production (an indication of aspirin's effect). Medical outcome was measured as 
      rate of admission due to cardiovascular causes during the follow-up period. 
      Self-report measures of PTSD (Impact of Event Scale), Depression, and Global 
      Distress (SCL-90-R) were administered at enrollment. RESULTS: Seventy-three 
      patients were studied. Above-threshold PTSD symptom scores at enrollment, but not 
      depression or global distress scores, were significant predictors of nonadherence 
      to aspirin and of an increased likelihood of cardiovascular readmission over the 
      course of the following year. CONCLUSIONS: PTSD symptoms predicted poor disease 
      control in this cohort of MI survivors. The data suggest that screening MI 
      survivors for symptoms of PTSD may be beneficial if this high-risk population is 
      to be targeted for interventions.
FAU - Shemesh, Eyal
AU  - Shemesh E
AD  - Department of Psychiatry, Mount Sinai Medical Center, Box 1230, 1 Gustave L. Levy 
      Place, New York, NY 10029, USA. eyal.shemesh@mssm.edu
FAU - Yehuda, Rachel
AU  - Yehuda R
FAU - Milo, Olga
AU  - Milo O
FAU - Dinur, Irit
AU  - Dinur I
FAU - Rudnick, Abraham
AU  - Rudnick A
FAU - Vered, Zvi
AU  - Vered Z
FAU - Cotter, Gad
AU  - Cotter G
LA  - eng
GR  - MH63755/MH/NIMH NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Psychosom Med
JT  - Psychosomatic medicine
JID - 0376505
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Israel/epidemiology
MH  - Life Change Events
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/complications/diagnosis/*drug therapy
MH  - Personality Inventory
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prognosis
MH  - Psychiatric Status Rating Scales
MH  - Severity of Illness Index
MH  - Stress Disorders, Post-Traumatic/diagnosis/*epidemiology/etiology
MH  - Survival Analysis
MH  - Survivors/psychology/*statistics & numerical data
MH  - Thromboxanes/blood
MH  - Treatment Outcome
MH  - *Treatment Refusal
EDAT- 2004/07/24 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/07/24 05:00
PHST- 2004/07/24 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/07/24 05:00 [entrez]
AID - 66/4/521 [pii]
AID - 10.1097/01.psy.0000126199.05189.86 [doi]
PST - ppublish
SO  - Psychosom Med. 2004 Jul-Aug;66(4):521-6. doi: 10.1097/01.psy.0000126199.05189.86.

PMID- 35988056
OWN - NLM
STAT- MEDLINE
DCOM- 20230202
LR  - 20230208
IS  - 2831-090X (Electronic)
IS  - 2831-0896 (Print)
IS  - 2831-0896 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Feb 1
TI  - Impact of subchorionic hematoma on pregnancy outcomes in women with recurrent 
      pregnancy loss.
PG  - 170-175
LID - 10.17305/bjbms.2022.7705 [doi]
AB  - We conducted a retrospective cohort study with the aim of investigating the 
      relationship between subchorionic hematoma (SCH) and pregnancy outcomes in women 
      with recurrent pregnancy loss (RPL). We reviewed all RPL patients who came to the 
      Fourth Hospital of Shijiazhuang from January 2019 to June 2021. Two groups were 
      divided according to the presence or absence of SCH. Live birth rate was 
      considered as the primary outcome. Secondary outcomes included adverse pregnancy 
      outcomes and complications. Univariable and multivariable analyses were 
      conducted. Of 274 RPL women included in the final analysis, 49 (17.9%) had SCH. 
      The occurrence of thrombophilia was significantly higher in SCH group than that 
      in non-SCH group (38.8% vs 24.4%, P=0.041). There were no significant differences 
      between the two groups in live birth rate, adverse pregnancy outcomes and 
      pregnancy complications. Among women with SCH, live birth rate or SCH duration 
      was not associated with continued use of low-dose aspirin (LDA) after the 
      diagnosis of SCH. Our findings suggest that SCH does not reduce live birth rate 
      in RPL women or increase the risk of adverse pregnancy outcomes or pregnancy 
      complications. Continued use of LDA after the detection of a hematoma is unlikely 
      to affect SCH duration or the live birth rate.
FAU - Fu, Zijie
AU  - Fu Z
AD  - Department of Gynecology, The First Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Ding, Xuelei
AU  - Ding X
AD  - Department of Gynecological Endocrinology, The Fourth Hospital of Shijiazhuang 
      (Obstetrics and Gynecology Hospital Affiliated to Hebei Medical University), 
      Shijiazhuang, China.
FAU - Wei, Dawei
AU  - Wei D
AD  - Department of Neonatology, The Fourth Hospital of Shijiazhuang (Obstetrics and 
      Gynecology Hospital Affiliated to Hebei Medical University), Shijiazhuang, China.
FAU - Li, Jun
AU  - Li J
AD  - Department of Reproductive Medicine, Reproductive Medical Center, The First 
      Hospital of Hebei Medical University, Shijiazhuang, China.
FAU - Cang, Rong
AU  - Cang R
AD  - Department of Gynecological Endocrinology, The Fourth Hospital of Shijiazhuang 
      (Obstetrics and Gynecology Hospital Affiliated to Hebei Medical University), 
      Shijiazhuang, China.
FAU - Li, Xiaodong
AU  - Li X
AD  - Department of Gynecology, The First Hospital of Hebei Medical University, 
      Shijiazhuang, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230201
PL  - Bosnia and Herzegovina
TA  - Biomol Biomed
JT  - Biomolecules & biomedicine
JID - 9918522188506676
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Humans
MH  - Female
MH  - Pregnancy Outcome/epidemiology
MH  - Retrospective Studies
MH  - *Pregnancy Complications
MH  - *Abortion, Habitual/epidemiology
MH  - Aspirin/therapeutic use
MH  - Hematoma/complications
PMC - PMC9901910
EDAT- 2022/08/22 06:00
MHDA- 2023/02/03 06:00
CRDT- 2022/08/21 10:01
PHST- 2022/06/15 00:00 [received]
PHST- 2022/08/09 00:00 [accepted]
PHST- 2022/08/22 06:00 [pubmed]
PHST- 2023/02/03 06:00 [medline]
PHST- 2022/08/21 10:01 [entrez]
AID - BJBMS-22-326 [pii]
AID - 10.17305/bjbms.2022.7705 [doi]
PST - epublish
SO  - Biomol Biomed. 2023 Feb 1;23(1):170-175. doi: 10.17305/bjbms.2022.7705.

PMID- 6383336
OWN - NLM
STAT- MEDLINE
DCOM- 19841018
LR  - 20190904
IS  - 0300-8428 (Print)
IS  - 0300-8428 (Linking)
VI  - 79
IP  - 3
DP  - 1984 May-Jun
TI  - Separate and combined use of verapamil, aspirin and captopril in experimental 
      chronic pulmonary hypertension.
PG  - 375-8
AB  - In Wistar rats, rendered pulmonary hypertensive by chronic confinement in 
      normobaric "hypoxic cages", impairment of transmembrane transport of calcium by 
      Verapamil and blockage of the action of Angiotensin I converting enzyme by 
      Captopril when applied simultaneously did not show an additive effect in reducing 
      the rise of pulmonary artery pressure and decreasing the augmentation of right 
      ventricular mass. Similarly, the action of Verapamil together with decrease of 
      prostaglandin synthetase activity by Aspirin showed no additive effect. Although 
      in this way the results of the present study failed to give substantial support 
      to the idea of the existence of several mediators of hypoxic pulmonary 
      vasoconstriction, they by no means deny this possibility.
FAU - Kentera, D
AU  - Kentera D
FAU - Susić, D
AU  - Susić D
FAU - Zdravković, M
AU  - Zdravković M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Basic Res Cardiol
JT  - Basic research in cardiology
JID - 0360342
RN  - 9DLQ4CIU6V (Proline)
RN  - 9G64RSX1XD (Captopril)
RN  - CJ0O37KU29 (Verapamil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Captopril/*therapeutic use
MH  - Cardiac Volume/drug effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hypertension, Pulmonary/*drug therapy
MH  - Proline/*analogs & derivatives
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Verapamil/*therapeutic use
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
AID - 10.1007/BF01908038 [doi]
PST - ppublish
SO  - Basic Res Cardiol. 1984 May-Jun;79(3):375-8. doi: 10.1007/BF01908038.

PMID- 11152927
OWN - NLM
STAT- MEDLINE
DCOM- 20010419
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 100
IP  - 6
DP  - 2000 Dec 15
TI  - Abciximab treatment in vitro after aspirin treatment in vivo has additive effects 
      on platelet aggregation, ATP release, and P-selectin expression.
PG  - 479-88
AB  - To prevent arterial thrombosis, abciximab is administered together with aspirin. 
      However, whether or not there are benefits to combine abciximab with aspirin is 
      not yet well defined. Healthy volunteers were studied for the effect of aspirin + 
      abciximab using sodium arachidonate and adenosine diphosphate (ADP) alone or in 
      combination to induce platelet activation/aggregation. Abciximab produced 
      complete inhibition of platelet aggregation induced with ADP but only 40% 
      inhibition of aggregation induced by 0.75-mmol/l sodium arachidonate. Abciximab 
      added in vitro to platelet-rich plasma (PRP) from platelets from aspirin-treated 
      donors produced an almost complete inhibition of platelet aggregation. Aspirin, 
      and abciximab alone, did not inhibit adenosine triphosphate (ATP) release as 
      thoroughly as aspirin + abciximab did. Abciximab (3-5 microg/ml) produced 
      inhibition of P-selectin expression induced with 5 (from 46.2 +/- 6.0% to 27.4 
      +/- 7.0%, P=0.002) and 20-micromol/l ADP (from 53.1 +/- 8.1% to 35.1 +/- 11.0%, 
      P=0.019), but no effect was observed when 0.75-mmol/l sodium arachidonate was 
      used (P=0.721). Aspirin diminished P-selectin expression in sodium 
      arachidonate-stimulated platelets (from 77.7 +/- 11.8% to 40.2 +/- 3.6%, 
      P<0.0001) in non-aspirinated and platelets from aspirin-treated donors, 
      respectively. Abciximab (3, 4, and 5 microg/ml) added to platelets from 
      aspirin-treated donors decreased P-selectin expression in platelets stimulated 
      with sodium arachidonate from 40.2 +/- 8.6% to 25.6 +/- 11.5% (P=0.027), to 20.5 
      +/- 3.5% (P<0.0001), and to 22.5 +/- 1.8% (P<0.0001). We concluded that the 
      antiplatelet effect of abciximab is greatly increased by aspirin.
FAU - Scazziota, A
AU  - Scazziota A
AD  - Centro de Trombosis de Buenos Aires, Viamonte 2008, 1056, Buenos Aires, 
      Argentina.
FAU - Altman, R
AU  - Altman R
FAU - Rouvier, J
AU  - Rouvier J
FAU - Gonzalez, C
AU  - Gonzalez C
FAU - Ahmed, Z
AU  - Ahmed Z
FAU - Jeske, W P
AU  - Jeske WP
FAU - Walenga, J M
AU  - Walenga JM
FAU - Fareed, J
AU  - Fareed J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - R16CO5Y76E (Aspirin)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - Adenosine Diphosphate/pharmacology
MH  - Adenosine Triphosphate/biosynthesis
MH  - Adult
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/drug effects/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunoglobulin Fab Fragments/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - P-Selectin/biosynthesis
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
EDAT- 2001/01/12 11:00
MHDA- 2001/04/21 10:01
CRDT- 2001/01/12 11:00
PHST- 2001/01/12 11:00 [pubmed]
PHST- 2001/04/21 10:01 [medline]
PHST- 2001/01/12 11:00 [entrez]
AID - S0049-3848(00)00361-3 [pii]
AID - 10.1016/s0049-3848(00)00361-3 [doi]
PST - ppublish
SO  - Thromb Res. 2000 Dec 15;100(6):479-88. doi: 10.1016/s0049-3848(00)00361-3.

PMID- 34619509
OWN - NLM
STAT- MEDLINE
DCOM- 20211123
LR  - 20211123
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 266
DP  - 2022 Feb 5
TI  - Earth friendly spectrophotometric methods based on different manipulation 
      approaches for simultaneous determination of aspirin and omeprazole in binary 
      mixture and pharmaceutical dosage form: Comparative statistical study.
PG  - 120436
LID - S1386-1425(21)01013-1 [pii]
LID - 10.1016/j.saa.2021.120436 [doi]
AB  - Aspirin and omeprazole combining has proven their effectiveness clinically in the 
      treatment and prevention of cardiovascular diseases in patient with gastric 
      diseases and gastric ulcers. Simultaneous determination of omeprazole and aspirin 
      in their combination is a challenge due to the overlapping spectra of these 
      drugs. Six smart and different spectrophotometric methods were developed for the 
      analysis of omeprazole and aspirin in binary mixture and pharmaceutical dosage 
      form. These smart methods characterized by simplicity and accuracy. The first two 
      methods based on minimal mathematical data processing based on the zero order 
      absorption spectra were; dual wavelength and advanced absorbance subtraction 
      methods. The third method is first and second derivative spectrophotometric 
      method that based on derivative spectra. The last three methods based on ratio 
      spectra manipulation are named; ratio difference, mean centering and derivative 
      ratio spectrophotometric methods. The linearity range of omeprazole was 
      2-20 μg/mL for dual wavelength method and 2-30 μg/mL for the other ones, while 
      aspirin showed a good linearity over a range of 2.5-30 μg/mL for all methods. The 
      correlation coefficients were greater than 0.999. The results of the developed 
      methods are statistically compared with each other and with the results of the 
      reported HPLC method showing no significant difference. The greenness of the 
      developed methods was assessed using eco-scale scoring method revealing excellent 
      greenness of the applied methods. This spectrophotometric methods is more 
      sensitive and greener with comparing by the reported one so, these developed 
      methods are considered eco-friendly to the environment.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Elmasry, Manal S
AU  - Elmasry MS
AD  - Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 
      44519, Egypt.
FAU - Hassan, Wafaa S
AU  - Hassan WS
AD  - Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 
      44519, Egypt.
FAU - El-Mammli, Magda Y
AU  - El-Mammli MY
AD  - Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 
      44519, Egypt.
FAU - Badrawy, Mohamed
AU  - Badrawy M
AD  - Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian 
      University, Badr 11829, Egypt. Electronic address: mohamed-badrawy@eru.edu.eg.
LA  - eng
PT  - Journal Article
DEP - 20210927
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 0 (Pharmaceutical Preparations)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - Humans
MH  - *Omeprazole
MH  - *Pharmaceutical Preparations
MH  - Spectrophotometry
OTO - NOTNLM
OT  - Advanced absorbance subtraction
OT  - Aspirin
OT  - Derivative
OT  - Dual wavelength
OT  - Mean centering
OT  - Omeprazole
OT  - Ratio Derivative
OT  - Ratio Difference
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/10/08 06:00
MHDA- 2021/11/24 06:00
CRDT- 2021/10/07 20:25
PHST- 2021/06/14 00:00 [received]
PHST- 2021/08/17 00:00 [revised]
PHST- 2021/09/22 00:00 [accepted]
PHST- 2021/10/08 06:00 [pubmed]
PHST- 2021/11/24 06:00 [medline]
PHST- 2021/10/07 20:25 [entrez]
AID - S1386-1425(21)01013-1 [pii]
AID - 10.1016/j.saa.2021.120436 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2022 Feb 5;266:120436. doi: 
      10.1016/j.saa.2021.120436. Epub 2021 Sep 27.

PMID- 14972745
OWN - NLM
STAT- MEDLINE
DCOM- 20040409
LR  - 20191108
IS  - 1381-3455 (Print)
IS  - 1381-3455 (Linking)
VI  - 111
IP  - 3
DP  - 2003 Jul
TI  - Dietary L-arginine restores aspirin-induced endothelial dysfunction in rat aorta.
PG  - 232-8
AB  - L-Arginine induced elevation of the vascular prostanoid led us to think that the 
      risk of coronary spasm may increase in L-arginine consumers when they are 
      subjected to cyclooxygenase inhibitors and this limits the therapeutic value of 
      aspirin. So the aim was to investigate the interaction of aspirin and dietary 
      L-arginine in male rats. Animals were divided into four groups and fed with 
      normal food. The first group received tap water while the second, third and 
      fourth groups were subjected daily to aspirin (8.6 mg/kg), L-arginine (143 mg/kg) 
      and aspirin + L-arginine combination in their drinking water respectively for 7 
      days. Vasomotor responses were recorded in the aortic rings suspended for 
      isometric-force recordings. Aspirin treatment significantly reduced the dilation 
      to acetylcholine and sodium nitroprusside. Attenuated phenylephrine contractility 
      was associated with normal acetylcholine response in L-arginine group. Addition 
      of L-arginine to aspirin treatment completely prevented aspirin-induced 
      endothelial dysfunction but defective response to sodium nitroprusside persisted. 
      Dietary L-arginine without affecting maximal dilation to acetylcholine 
      significantly increased the share of dilator prostanoid which appears to resist 
      aspirin. These results demonstrated that dietary L-arginine increases dilator 
      prostaoid in rat aortic rings. Contrary to our expectation, co-administered 
      L-arginine protected aspirin induced endothelial dysfunction and ruled out the 
      limitation of aspirin use in L-arginine consumers.
FAU - Bilgen, I
AU  - Bilgen I
AD  - Department of Physiology, Akdeniz University Medical Faculty, Antalya, Turkey.
FAU - Oner, G
AU  - Oner G
FAU - Eren, E
AU  - Eren E
LA  - eng
PT  - Journal Article
PL  - England
TA  - Arch Physiol Biochem
JT  - Archives of physiology and biochemistry
JID - 9510153
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Prostaglandins)
RN  - 0 (Vasoconstrictor Agents)
RN  - 0 (Vasodilator Agents)
RN  - 169D1260KM (Nitroprusside)
RN  - 1WS297W6MV (Phenylephrine)
RN  - 94ZLA3W45F (Arginine)
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylcholine/pharmacology
MH  - Animal Feed
MH  - Animals
MH  - Aorta, Thoracic/drug effects/metabolism/physiopathology
MH  - Arginine/*pharmacology
MH  - Aspirin/pharmacology/*toxicity
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Endothelium, Vascular/*drug effects/metabolism/physiopathology
MH  - Male
MH  - Nitric Oxide Donors/pharmacology
MH  - Nitroprusside/pharmacology
MH  - Phenylephrine/pharmacology
MH  - Prostaglandins/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Vasoconstrictor Agents/pharmacology
MH  - Vasodilator Agents/pharmacology
EDAT- 2004/02/20 05:00
MHDA- 2004/04/10 05:00
CRDT- 2004/02/20 05:00
PHST- 2004/02/20 05:00 [pubmed]
PHST- 2004/04/10 05:00 [medline]
PHST- 2004/02/20 05:00 [entrez]
AID - 10.1076/apab.111.3.232.23454 [doi]
PST - ppublish
SO  - Arch Physiol Biochem. 2003 Jul;111(3):232-8. doi: 10.1076/apab.111.3.232.23454.

PMID- 25869458
OWN - NLM
STAT- MEDLINE
DCOM- 20160211
LR  - 20191210
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 74
DP  - 2015 Jul 10
TI  - Semi-physiologic model validation and bioequivalence trials simulation to select 
      the best analyte for acetylsalicylic acid.
PG  - 86-94
LID - S0928-0987(15)00145-1 [pii]
LID - 10.1016/j.ejps.2015.04.002 [doi]
AB  - The objective of this paper is to apply a previously developed semi-physiologic 
      pharmacokinetic model implemented in NONMEM to simulate bioequivalence trials 
      (BE) of acetyl salicylic acid (ASA) in order to validate the model performance 
      against ASA human experimental data. ASA is a drug with first-pass hepatic and 
      intestinal metabolism following Michaelis-Menten kinetics that leads to the 
      formation of two main metabolites in two generations (first and second generation 
      metabolites). The first aim was to adapt the semi-physiological model for ASA in 
      NOMMEN using ASA pharmacokinetic parameters from literature, showing its 
      sequential metabolism. The second aim was to validate this model by comparing the 
      results obtained in NONMEM simulations with published experimental data at a dose 
      of 1000 mg. The validated model was used to simulate bioequivalence trials at 3 
      dose schemes (100, 1000 and 3000 mg) and with 6 test formulations with decreasing 
      in vivo dissolution rate constants versus the reference formulation (kD 8-0.25 h 
      (-1)). Finally, the third aim was to determine which analyte (parent drug, first 
      generation or second generation metabolite) was more sensitive to changes in 
      formulation performance. The validation results showed that the 
      concentration-time curves obtained with the simulations reproduced closely the 
      published experimental data, confirming model performance. The parent drug (ASA) 
      was the analyte that showed to be more sensitive to the decrease in 
      pharmaceutical quality, with the highest decrease in Cmax and AUC ratio between 
      test and reference formulations.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Cuesta-Gragera, Ana
AU  - Cuesta-Gragera A
AD  - Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, 
      University of Valencia, Av. Vicente Andrés Estellés s/n, 46100 Burjassot, 
      Valencia, Spain.
FAU - Navarro-Fontestad, Carmen
AU  - Navarro-Fontestad C
AD  - Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, 
      University of Valencia, Av. Vicente Andrés Estellés s/n, 46100 Burjassot, 
      Valencia, Spain.
FAU - Mangas-Sanjuan, Victor
AU  - Mangas-Sanjuan V
AD  - Department of Engineering, Pharmacy Section, Miguel Hernández University, 
      Carretera Alicante Valencia km 87, 03550 San Juan de Alicante, Alicante, Spain.
FAU - González-Álvarez, Isabel
AU  - González-Álvarez I
AD  - Department of Engineering, Pharmacy Section, Miguel Hernández University, 
      Carretera Alicante Valencia km 87, 03550 San Juan de Alicante, Alicante, Spain.
FAU - García-Arieta, Alfredo
AU  - García-Arieta A
AD  - Pharmacokinetics Service, Division of Pharmacology and Clinical Evaluation, 
      Department of Human Use Medicines, Spanish Agency for Medicines and Health Care 
      Products (AEMPS), Campezo 1, 28022 Madrid, Spain.
FAU - Trocóniz, Iñaki F
AU  - Trocóniz IF
AD  - Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, 
      University of Navarra, Irunlarrea 1, 31008 Pamplona, Navarra, Spain.
FAU - Casabó, Vicente G
AU  - Casabó VG
AD  - Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, 
      University of Valencia, Av. Vicente Andrés Estellés s/n, 46100 Burjassot, 
      Valencia, Spain.
FAU - Bermejo, Marival
AU  - Bermejo M
AD  - Department of Engineering, Pharmacy Section, Miguel Hernández University, 
      Carretera Alicante Valencia km 87, 03550 San Juan de Alicante, Alicante, Spain. 
      Electronic address: mbermejo@goumh.umh.es.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20150411
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers, Pharmacological)
RN  - 0 (Hippurates)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/blood/chemistry/*pharmacokinetics
MH  - Aspirin/administration & dosage/blood/chemistry/*pharmacokinetics
MH  - Biomarkers, Pharmacological/blood
MH  - Biotransformation
MH  - Chemistry, Pharmaceutical
MH  - Computer Simulation
MH  - Dose-Response Relationship, Drug
MH  - Drug Liberation
MH  - Hippurates/blood/metabolism
MH  - Humans
MH  - *Models, Biological
MH  - Pharmacology, Clinical/*methods
MH  - Salicylic Acid/blood/metabolism
MH  - Software
MH  - Therapeutic Equivalency
MH  - Tissue Distribution
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Analyte
OT  - Bioequivalence
OT  - First-pass metabolism
OT  - Simulation
EDAT- 2015/04/15 06:00
MHDA- 2016/02/13 06:00
CRDT- 2015/04/15 06:00
PHST- 2015/02/21 00:00 [received]
PHST- 2015/04/05 00:00 [accepted]
PHST- 2015/04/15 06:00 [entrez]
PHST- 2015/04/15 06:00 [pubmed]
PHST- 2016/02/13 06:00 [medline]
AID - S0928-0987(15)00145-1 [pii]
AID - 10.1016/j.ejps.2015.04.002 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2015 Jul 10;74:86-94. doi: 10.1016/j.ejps.2015.04.002. Epub 2015 
      Apr 11.

PMID- 31243390
OWN - NLM
STAT- MEDLINE
DCOM- 20200116
LR  - 20220420
IS  - 1759-5010 (Electronic)
IS  - 1759-5002 (Linking)
VI  - 16
IP  - 11
DP  - 2019 Nov
TI  - Role of aspirin in primary prevention of cardiovascular disease.
PG  - 675-686
LID - 10.1038/s41569-019-0225-y [doi]
AB  - The benefits of aspirin therapy for the secondary prevention of cardiovascular 
      disease clearly outweigh the risks of bleeding, and low-dose aspirin is uniformly 
      recommended in this setting. However, no clear consensus exists about whether, 
      and if so in whom, aspirin therapy is appropriate for the primary prevention of 
      cardiovascular disease. Three trials of low-dose aspirin versus placebo in three 
      populations at increased risk of myocardial infarction or ischaemic stroke in the 
      absence of established cardiovascular disease were reported in 2018. The ASPREE 
      trial in elderly people was terminated early for futility because aspirin had no 
      effect on disability-free survival but significantly increased the risk of major 
      haemorrhage and, unexpectedly, all-cause mortality. In the ASCEND trial in 
      patients with diabetes mellitus and no evidence of vascular disease, aspirin 
      significantly reduced serious vascular events but increased major bleeding. In 
      the ARRIVE trial in people with multiple risk factors for cardiovascular disease, 
      aspirin had no effect on major cardiovascular events but increased 
      gastrointestinal bleeding. The aim of this Review is to place these new results 
      in the context of previous evidence on aspirin for the primary prevention of 
      cardiovascular disease and to appraise whether the new evidence is likely to 
      enable the more targeted use of aspirin in particular individuals for whom the 
      net benefit is both clinically worthwhile and statistically definite.
FAU - Patrono, Carlo
AU  - Patrono C
AUID- ORCID: 0000-0002-6447-2424
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. 
      carlo.patrono@unicatt.it.
FAU - Baigent, Colin
AU  - Baigent C
AD  - Medical Research Council Population Health Research Unit, and Clinical Trial 
      Service Unit and Epidemiological Studies Unit, Nuffield Department of Population 
      Health, University of Oxford, Oxford, UK.
LA  - eng
GR  - CH/1996001/9454/BHF_/British Heart Foundation/United Kingdom
GR  - MC_U137686849/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_00017/4/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_12026/6/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20190626
PL  - England
TA  - Nat Rev Cardiol
JT  - Nature reviews. Cardiology
JID - 101500075
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Brain Ischemia/complications/prevention & control
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Complications/complications
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - *Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Stroke/etiology/prevention & control
EDAT- 2019/06/28 06:00
MHDA- 2020/01/17 06:00
CRDT- 2019/06/28 06:00
PHST- 2019/05/16 00:00 [accepted]
PHST- 2019/06/28 06:00 [pubmed]
PHST- 2020/01/17 06:00 [medline]
PHST- 2019/06/28 06:00 [entrez]
AID - 10.1038/s41569-019-0225-y [pii]
AID - 10.1038/s41569-019-0225-y [doi]
PST - ppublish
SO  - Nat Rev Cardiol. 2019 Nov;16(11):675-686. doi: 10.1038/s41569-019-0225-y. Epub 
      2019 Jun 26.

PMID- 10505289
OWN - NLM
STAT- MEDLINE
DCOM- 19991119
LR  - 20191103
IS  - 0340-9937 (Print)
IS  - 0340-9937 (Linking)
VI  - 24
IP  - 5
DP  - 1999 Aug
TI  - [Drug therapy for prognostic improvement after acute myocardial infarct].
PG  - 389-97
AB  - This review article summarizes the long-term standard therapy for patients with 
      myocardial infarction. The chronic therapy is able to significantly improve 
      quality of life and survival of affected patients. Previous studies showed that 
      in most western countries, the established standard therapy is not given to all 
      patients who would benefit from chronic treatment. The essential parts of today's 
      myocardial infarction treatment consists of effective beta-blockade, inhibition 
      of the angiotensin-conversion enzyme, inhibition of platelet aggregation and 
      lipid lowering agents. This article reviews the clinical benefits which may be 
      expected from each of these therapeutic approaches. Newer, but not yet proven 
      strategies, like blockade of the angiotensin receptor subtype 1 and treatment 
      with antioxidative agents will be discussed.
FAU - Willenbrock, R
AU  - Willenbrock R
AD  - Franz-Volhard-Klinik am Max-Delbrück-Centrum für Molekulare Medizin, 
      Universitätsklinik Charité, Humboldt-Universität Berlin. 
      willenbrock@fvk-berlin.de
FAU - Monti, J
AU  - Monti J
FAU - Dietz, R
AU  - Dietz R
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Medikamentöse Therapie zur Prognoseverbesserung nach akutem Myokardinfarkt.
PL  - Germany
TA  - Herz
JT  - Herz
JID - 7801231
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/adverse effects/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy/mortality
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
MH  - Survival Rate
RF  - 47
EDAT- 1999/10/03 00:00
MHDA- 1999/10/03 00:01
CRDT- 1999/10/03 00:00
PHST- 1999/10/03 00:00 [pubmed]
PHST- 1999/10/03 00:01 [medline]
PHST- 1999/10/03 00:00 [entrez]
AID - 10.1007/BF03043930 [doi]
PST - ppublish
SO  - Herz. 1999 Aug;24(5):389-97. doi: 10.1007/BF03043930.

PMID- 2373002
OWN - NLM
STAT- MEDLINE
DCOM- 19900829
LR  - 20131121
IS  - 0098-8243 (Print)
IS  - 0098-8243 (Linking)
VI  - 16
IP  - 6
DP  - 1990 Jun
TI  - Thromboembolic disease during pregnancy: problems with anticoagulant therapy.
PG  - 31-5
AB  - Thromboembolic complications of pregnancy and the puerperium deserve renewed 
      attention not only because they are the most frequent nonobstetrical 
      complications encountered in these circumstances, but also because of current 
      litigious attitudes, the greater survival of women with prosthetic heart valves, 
      and the inadequacy of current treatment regimens that put the physician, as well 
      as the patient, in special peril. New techniques are available to the clinical 
      laboratory for studying the coagulation and hypocoagulant proteins, coagulation 
      inhibitors, and the fibrinolytic system. They provide fresh insight into this 
      perplexing medical problem. Attention to the details of current investigations, 
      efforts to control the risk factors, and the perspicacious use and suitable 
      monitoring of pharmacological agents can be expected to reduce the risks for both 
      the pregnant patient and her attending physicians.
FAU - Wehrmacher, W H
AU  - Wehrmacher WH
AD  - Department of Pathology, Loyola University Stritch School of Medicine, Maywood, 
      IL.
FAU - Messmore, H L
AU  - Messmore HL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Compr Ther
JT  - Comprehensive therapy
JID - 7605837
RN  - 0 (Anticoagulants)
RN  - 0 (Blood Coagulation Factors)
RN  - 0 (Protein C)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Coagulation Factors/analysis
MH  - Female
MH  - Fibrinolysis
MH  - Heart Valve Prosthesis
MH  - Heparin/adverse effects/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/blood/*drug therapy/prevention & control
MH  - Protein C/analysis
MH  - Thromboembolism/blood/*drug therapy/prevention & control
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
PST - ppublish
SO  - Compr Ther. 1990 Jun;16(6):31-5.

PMID- 375153
OWN - NLM
STAT- MEDLINE
DCOM- 19790728
LR  - 20190712
IS  - 0030-4220 (Print)
IS  - 0030-4220 (Linking)
VI  - 47
IP  - 6
DP  - 1979 Jun
TI  - Evaluation of sedative/analgesic combination for postoperative pain.
PG  - 513-4
AB  - Current pain concepts suggest a dual role in pain perception. Both motivational, 
      effective, and somatosensory components are noted. Pain affects the patient's 
      psyche and, conversely, the patient's state of mind modifies pain perception. 
      Consequently, it might be expected that a sedative/analgesic combination might be 
      more effective than either the sedative or the analgesic alone in controlling 
      pain. A clinical study was carried out to compare a promethazine-A.P.C. 
      combination with promethazine and A.P.C. alone. One hundred forty-nine patients 
      undergoing third molar removal were studied, with each patient serving as his own 
      control. The results indicated a significant difference between the 
      promethazine-A.P.C. combination and prometazine alone or Phenergan alone. No 
      significant difference was noted between the promethazine-A.P.C. combination and 
      A.P.C. alone.
FAU - Upton, L G
AU  - Upton LG
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Oral Surg Oral Med Oral Pathol
JT  - Oral surgery, oral medicine, and oral pathology
JID - 0376406
RN  - 0 (Drug Combinations)
RN  - 0 (Placebos)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - FF28EJQ494 (Promethazine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anxiety/prevention & control
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Caffeine/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Drug Evaluation
MH  - Humans
MH  - Pain, Postoperative/*drug therapy
MH  - Phenacetin/administration & dosage/*therapeutic use
MH  - Placebos
MH  - Promethazine/administration & dosage/*therapeutic use
MH  - Tooth Extraction
EDAT- 1979/06/01 00:00
MHDA- 1979/06/01 00:01
CRDT- 1979/06/01 00:00
PHST- 1979/06/01 00:00 [pubmed]
PHST- 1979/06/01 00:01 [medline]
PHST- 1979/06/01 00:00 [entrez]
AID - 10.1016/0030-4220(79)90272-x [doi]
PST - ppublish
SO  - Oral Surg Oral Med Oral Pathol. 1979 Jun;47(6):513-4. doi: 
      10.1016/0030-4220(79)90272-x.

PMID- 359253
OWN - NLM
STAT- MEDLINE
DCOM- 19781220
LR  - 20190907
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 5
IP  - 7
DP  - 1978
TI  - Relationship of plasma salicylate levels to pain relief with two different 
      salicylates.
PG  - 572-9
AB  - In a preliminary open study of salsalate (3 g daily for 4 weeks) in 61 patients 
      with rheumatoid arthritis or osteoarthrosis, it was found that although the drug 
      produced satisfactory analgesia in 64% of patients, the incidence of side-effects 
      was high (57% of patients): most were symptoms of salicylism and probably related 
      to the high plasma salicylate levels achieved. In a second open study, 20 
      patients with osteoarthrosis were treated for 4 weeks with 250 mg diflunisal 
      twice daily and then crossed over to salsalate (3 g daily) for a further 2 weeks. 
      The results of subjective assessments of pain relief showed that both drugs 
      produced satisfactory analgesia, and neither was associated with a significant 
      level of gastro-intestinal bleeding. During the diflunisal treatment period there 
      were no reports of salicylism, and plasma salicylate levels were very much lower 
      than those measured after salsalate. The pain relieving effects of both drugs, 
      assessed from patient preference for one or the other treatment, were unrelated 
      to the plasma salicylate levels and it is suggested that plasma levels may have 
      more relationship to the incidence of side-effects than with therapeutic effects.
FAU - Hicklin, J A
AU  - Hicklin JA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Analgesics)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Biphenyl Compounds/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Occult Blood
MH  - Osteoarthritis/drug therapy
MH  - Pain/*drug therapy
MH  - Salicylates/*blood
MH  - Time Factors
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1185/03007997809109004 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1978;5(7):572-9. doi: 10.1185/03007997809109004.

PMID- 30276549
OWN - NLM
STAT- MEDLINE
DCOM- 20191105
LR  - 20191105
IS  - 1432-1440 (Electronic)
IS  - 0946-2716 (Linking)
VI  - 96
IP  - 11
DP  - 2018 Nov
TI  - Low-dose aspirin treatment enhances the adhesion of preeclamptic decidual 
      mesenchymal stem/stromal cells and reduces their production of pro-inflammatory 
      cytokines.
PG  - 1215-1225
LID - 10.1007/s00109-018-1695-9 [doi]
AB  - Preeclampsia (PE) is a hypertensive disorder of human pregnancy. Low-dose aspirin 
      (acetylsalicylic acid) (60-150 mg/day) is used to prevent PE when taken early in 
      pregnancy. The effect of aspirin on term PE remains uncertain. Abnormal 
      placentation is a hallmark of PE and leads to increased placental oxidative 
      stress, which triggers the release of anti-angiogenic factors that cause local 
      damage to the decidual vasculature. The damage subsequently spreads systemically 
      and culminates in maternal clinical symptoms. Decidua basalis mesenchymal 
      stem/stromal cells (DMSCs) reside in a vascular microenvironment. In PE, DMSCs 
      are exposed to abnormally high levels of oxidative stress and circulating 
      inflammatory factors from the maternal blood. We previously showed that 
      colony-forming unit ability and resistance to oxidative stress in DMSCs are 
      reduced in MSCs derived from term PE pregnancies (PE-DMSCs). The action, if any, 
      of aspirin on term PE-DMSCs has not been reported. In this study, aspirin 
      (5 μg/mL) was found to significantly increase PE-DMSC adhesion compared to 
      untreated PE-DMSCs and gestation-matched control DMSCs (p value < 0.001) but had 
      no effect on PE-DMSC proliferation. ELISA analysis showed that aspirin 
      significantly decreased the production of inflammatory cytokines IFN-γ (p 
      value < 0.05) and IL-8 (p value < 0.001) in PE-DMSCs. In addition, aspirin 
      treatment increased the antioxidant capacity of PE-DMSCs compared with the 
      untreated group (p value < 0.05). This study is the first to reveal a novel, 
      beneficial action of aspirin on PE-DMSCs from term PE pregnancies by improving 
      their adhesion, suppressing their production of pro-inflammatory cytokines 
      production, and increasing their antioxidant capacity. KEY MESSAGES: Preeclampsia 
      (PE) is a serious hypertensive disorder of pregnancy. The risk of PE is reduced 
      by aspirin but the mechanism is poorly understood. Decidua basalis mesenchymal 
      stem/stromal cells (DMSCs) are abnormal in PE. Aspirin treatment improves 
      multiple functions of PE-DMSCs. Improved DMSC function may contribute to the 
      beneficial effect of aspirin.
FAU - Khanabdali, Ramin
AU  - Khanabdali R
AD  - Department of Maternal-Fetal Medicine Pregnancy Research Centre, The Royal 
      Women's Hospital, Parkville, Victoria, Australia.
AD  - Department of Obstetrics and Gynaecology, Melbourne Medical School, The 
      University of Melbourne, Parkville, Victoria, Australia.
FAU - Shakouri-Motlagh, Aida
AU  - Shakouri-Motlagh A
AD  - Department of Maternal-Fetal Medicine Pregnancy Research Centre, The Royal 
      Women's Hospital, Parkville, Victoria, Australia.
FAU - Wilkinson, Sarah
AU  - Wilkinson S
AD  - Department of Obstetrics and Gynaecology, Melbourne Medical School, The 
      University of Melbourne, Parkville, Victoria, Australia.
FAU - Murthi, Padma
AU  - Murthi P
AD  - Department of Medicine, School of Clinical Sciences, Monash University, Clayton, 
      Victoria, Australia.
AD  - The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, 
      Australia.
FAU - Georgiou, Harry M
AU  - Georgiou HM
AD  - Department of Obstetrics and Gynaecology, Melbourne Medical School, The 
      University of Melbourne, Parkville, Victoria, Australia.
FAU - Brennecke, Shaun P
AU  - Brennecke SP
AD  - Department of Maternal-Fetal Medicine Pregnancy Research Centre, The Royal 
      Women's Hospital, Parkville, Victoria, Australia.
AD  - Department of Obstetrics and Gynaecology, Melbourne Medical School, The 
      University of Melbourne, Parkville, Victoria, Australia.
FAU - Kalionis, Bill
AU  - Kalionis B
AUID- ORCID: 0000-0002-0132-9858
AD  - Department of Maternal-Fetal Medicine Pregnancy Research Centre, The Royal 
      Women's Hospital, Parkville, Victoria, Australia. bill.kalionis@thewomens.org.au.
AD  - Department of Obstetrics and Gynaecology, Melbourne Medical School, The 
      University of Melbourne, Parkville, Victoria, Australia. 
      bill.kalionis@thewomens.org.au.
LA  - eng
PT  - Journal Article
DEP - 20181001
PL  - Germany
TA  - J Mol Med (Berl)
JT  - Journal of molecular medicine (Berlin, Germany)
JID - 9504370
RN  - 0 (Cytokines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Cell Adhesion/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cytokines/*physiology
MH  - Decidua/cytology
MH  - Female
MH  - Humans
MH  - Male
MH  - Mesenchymal Stem Cells/*drug effects/physiology
MH  - Pre-Eclampsia
MH  - Pregnancy
OTO - NOTNLM
OT  - Aspirin
OT  - Decidua
OT  - Mesenchymal stem/stromal cells
OT  - Preeclampsia
EDAT- 2018/10/03 06:00
MHDA- 2019/11/07 06:00
CRDT- 2018/10/03 06:00
PHST- 2018/01/24 00:00 [received]
PHST- 2018/09/17 00:00 [accepted]
PHST- 2018/09/07 00:00 [revised]
PHST- 2018/10/03 06:00 [pubmed]
PHST- 2019/11/07 06:00 [medline]
PHST- 2018/10/03 06:00 [entrez]
AID - 10.1007/s00109-018-1695-9 [pii]
AID - 10.1007/s00109-018-1695-9 [doi]
PST - ppublish
SO  - J Mol Med (Berl). 2018 Nov;96(11):1215-1225. doi: 10.1007/s00109-018-1695-9. Epub 
      2018 Oct 1.

PMID- 4499917
OWN - NLM
STAT- MEDLINE
DCOM- 19781122
LR  - 20161123
IS  - 0010-8650 (Print)
IS  - 0010-8650 (Linking)
VI  - 20
IP  - 2
DP  - 1972
TI  - Antithrombotic drugs and experimental thrombosis.
PG  - 135-41
AB  - A series of standardized thrombosis models in rats has been used to survey some 
      most important groups of antithrombotics. Most results confirmed the previous 
      clinical and experimental experience but some of them bring new evidence. Very 
      effective from this aspect appear to be dipyridamole, low-molecular weight 
      dextran and flavonoids. Particularly favourable was the effect of the combination 
      of flavonoids and acetylsalicylic acid which eliminates some untoward effects of 
      the latter drug.
FAU - Hladovec, J
AU  - Hladovec J
LA  - eng
PT  - Journal Article
PL  - Czech Republic
TA  - Cor Vasa
JT  - Cor et vasa
JID - 0372614
RN  - 0 (Dextrans)
RN  - 0 (Drug Combinations)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Flavonoids)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Dextrans/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Disease Models, Animal
MH  - Drug Combinations
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Flavonoids/therapeutic use
MH  - Molecular Weight
MH  - Rats
MH  - Thrombosis/*drug therapy
EDAT- 1972/01/01 00:00
MHDA- 1972/01/01 00:01
CRDT- 1972/01/01 00:00
PHST- 1972/01/01 00:00 [pubmed]
PHST- 1972/01/01 00:01 [medline]
PHST- 1972/01/01 00:00 [entrez]
PST - ppublish
SO  - Cor Vasa. 1972;20(2):135-41.

PMID- 11820060
OWN - NLM
STAT- MEDLINE
DCOM- 20020222
LR  - 20131121
IS  - 0028-2162 (Print)
IS  - 0028-2162 (Linking)
VI  - 146
IP  - 2
DP  - 2002 Jan 12
TI  - [Acetylsalicylic acid in primary prevention of cardiovascular events; literature 
      study].
PG  - 68-72
AB  - OBJECTIVE: To evaluate literature data on the use of acetylsalicylic acid (ASA) 
      as a primary prevention measure for cardiovascular events. DESIGN: Literature 
      search. METHOD: Using Medline, all randomised placebo-controlled trials of ASA 
      published between 1985 and 1 May 2001, and which used cardiovascular morbidity 
      and death as outcome measures were identified (search query: 'aspirin' and 
      'primary prevention'). Using the raw data presented in the source publication on 
      death, fatal and non-fatal myocardial infarctions and cerebrovascular accidents 
      (CVAs), all relative and absolute risk reductions were recalculated with 
      confidence intervals. RESULTS: In healthy middle-aged men, men with an increased 
      cardiovascular risk profile and persons with diabetes mellitus or hypertension, 
      the use of ASA reduces the incidence of myocardial infarction and has a neutral 
      effect on cerebrovascular events. The protective effect of ASA seemed most marked 
      in those persons with an increased risk of manifest atherosclerotic vascular 
      disease. CONCLUSION: Notwithstanding these findings, for each patient it remains 
      essential to weigh up the cardiovascular risk profile against the small increased 
      risk of complications when prescribing ASA.
FAU - Bredie, S J H
AU  - Bredie SJ
AD  - Afd. Algemeen Interne Geneeskunde, Universitair Medisch Centrum St Radboud, 
      Postbus 9101, 6500 HB Nijmegen. s.bredie@aig.azn.nl
FAU - Wollersheim, H C H
AU  - Wollersheim HC
FAU - Verheugt, F W A
AU  - Verheugt FW
FAU - Thien, Th
AU  - Thien T
LA  - dut
PT  - English Abstract
PT  - Journal Article
PT  - Meta-Analysis
TT  - Acetylsalicylzuur bij de primaire preventie van cardiovasculaire aandoeningen; 
      literatuurstudie.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Arteriosclerosis/drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Diabetes Mellitus/drug therapy
MH  - Humans
MH  - Hyperlipidemias/drug therapy
MH  - Hypertension/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Netherlands/epidemiology
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Risk
MH  - Stroke/*prevention & control
EDAT- 2002/02/01 10:00
MHDA- 2002/02/23 10:01
CRDT- 2002/02/01 10:00
PHST- 2002/02/01 10:00 [pubmed]
PHST- 2002/02/23 10:01 [medline]
PHST- 2002/02/01 10:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2002 Jan 12;146(2):68-72.

PMID- 10389531
OWN - NLM
STAT- MEDLINE
DCOM- 19990727
LR  - 20131121
IS  - 0028-2162 (Print)
IS  - 0028-2162 (Linking)
VI  - 143
IP  - 23
DP  - 1999 Jun 5
TI  - [Lowering of diastolic blood pressure < or = 90 mmHg should not be attempted, 
      except in type 2 diabetics; the 'Hypertension optimal treatment' (HOT) trial].
PG  - 1188-91
AB  - Recently the 'Hypertension optimal treatment' (HOT) study was reported. In this 
      study 18,790 patients with diastolic blood pressure between 100 and 115 mmHg were 
      randomly assigned target pressures of < or = 90, < or = 85 and < or = 80 mmHg 
      respectively, and treated with a felodipine-based antihypertensive regimen. In 
      all three groups an impressive fall in both diastolic and systolic blood 
      pressures, and as a consequence very few major cardiovascular events (the primary 
      endpoint of the study) were observed, but there was no difference in endpoint 
      scores among the three groups. Type 2 diabetic patients fared substantially 
      better than non-diabetic patients and they are likely to profit if their 
      diastolic pressure is decreased below 80 mmHg. In the remaining patients rigorous 
      maintenance of present-day standards (diastolic pressure < or = 90 mmHg) is 
      advised. The addition of 75 mg aspirin 1 dd resulted in a modest but significant 
      reduction of major cardiovascular events, but at the cost of increased 
      gastrointestinal bleedings.
FAU - Wesseling, H
AU  - Wesseling H
AD  - Klinisch farmacoloog, Paterswolde.
LA  - dut
PT  - Clinical Trial
PT  - Comment
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Niet streven naar diastolische bloeddruk < or = 90 mmHg, behalve bij 
      type-2-diabetici; het 'Hypertension optimal treatment' (HOT)-onderzoek.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Calcium Channel Blockers)
RN  - OL961R6O2C (Felodipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Ned Tijdschr Geneeskd. 1999 Jun 5;143(23):1197-201. PMID: 10389533
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Pressure/*drug effects/physiology
MH  - Calcium Channel Blockers/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diastole
MH  - Felodipine/pharmacology/*therapeutic use
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Hypertension/*drug therapy/etiology
MH  - Male
MH  - Middle Aged
MH  - Netherlands/epidemiology
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 1999/07/02 00:00
MHDA- 1999/07/02 00:01
CRDT- 1999/07/02 00:00
PHST- 1999/07/02 00:00 [pubmed]
PHST- 1999/07/02 00:01 [medline]
PHST- 1999/07/02 00:00 [entrez]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 1999 Jun 5;143(23):1188-91.

PMID- 8417546
OWN - NLM
STAT- MEDLINE
DCOM- 19930126
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 125
IP  - 1
DP  - 1993 Jan
TI  - Aspirin inhibits platelet activity but does not attenuate experimental 
      atherosclerosis.
PG  - 79-86
AB  - We evaluated the antiatherosclerotic potential of aspirin, a platelet inhibitor, 
      in lipid-fed rabbits (0.3% cholesterol diet). Seventy-five male New Zealand white 
      rabbits were divided into treated or control groups. The treated groups were 
      given aspirin by daily gavage for 12 weeks (1 mg/kg, 10 mg/kg, 30 mg/kg, and 60 
      mg/kg) and 10 rabbits served as controls. Increased bleeding time was observed in 
      the aspirin-treated groups (average, 58 +/- 10 seconds to 75 +/- 17 seconds; p < 
      0.001). Only high-dose aspirin (60 mg/kg/day) significantly inhibited platelet 
      aggregation (1.04 +/- 0.15 vs 0.67 +/- 0.14; p < 0.05). Seventeen additional 
      rabbits had aortic endothelial injury produced by a balloon catheter. Eight of 
      them were given aspirin (40 mg/kg/day), and the other nine served as controls. 
      The average percent of surface lesions and lesion thickness of the aorta and 
      pulmonary artery were not significantly reduced by aspirin. These results show 
      that at doses that cause antiplatelet effects, aspirin does not attenuate 
      atherosclerosis.
FAU - Sun, Y P
AU  - Sun YP
AD  - Department of Medicine, University of California, San Francisco 94143-0124.
FAU - Zhu, B Q
AU  - Zhu BQ
FAU - Sievers, R E
AU  - Sievers RE
FAU - Isenberg, W M
AU  - Isenberg WM
FAU - Parmley, W W
AU  - Parmley WW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Cholesterol, Dietary)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Angioplasty, Balloon
MH  - Animals
MH  - Aorta/injuries/pathology
MH  - Arteriosclerosis/blood/*drug therapy/epidemiology/pathology
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Bleeding Time
MH  - Cholesterol/blood
MH  - Cholesterol, Dietary/administration & dosage
MH  - Depression, Chemical
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
MH  - Random Allocation
MH  - Weight Gain/drug effects
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 0002-8703(93)90059-I [pii]
AID - 10.1016/0002-8703(93)90059-i [doi]
PST - ppublish
SO  - Am Heart J. 1993 Jan;125(1):79-86. doi: 10.1016/0002-8703(93)90059-i.

PMID- 667721
OWN - NLM
STAT- MEDLINE
DCOM- 19780915
LR  - 20190720
IS  - 0008-4212 (Print)
IS  - 0008-4212 (Linking)
VI  - 56
IP  - 3
DP  - 1978 Jun
TI  - Transmucosal potential-difference profile in rat upper gastrointestinal tract. A 
      simple model for testing gastric effects of pharmacologic agents.
PG  - 471-3
AB  - Transmucosal potential difference in the rat upper gastrointestinal tract is 
      described by a simple in vivo technique. Values for potential difference between 
      blood (reference) and lumen (in millivolts) were the following: esophagus, -13.7 
      +/- 1.6 (mean +/- SE); forestomach (rumen), -39.2 +/- 0.8; stomach fundus, -39.1 
      +/- 0.4; pylorus -26.6 +/- 0.6; and duodenum, -9.2 +/- 0.4. These values 
      (excluding rumen) are strikingly similar to those obtained in man. Aspirin, 
      taurocholic acid, and alcohol all produced falls in gastric potential difference 
      very similar to those found in man. The rat appears to be a promising and 
      convenient model for screening gastric effects of certain pharmacological agents 
      before use in man.
FAU - Tarnawski, A
AU  - Tarnawski A
FAU - Ivey, K J
AU  - Ivey KJ
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 3K9958V90M (Ethanol)
RN  - 5E090O0G3Z (Taurocholic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Digestive System/*drug effects
MH  - Ethanol/pharmacology
MH  - Gastric Mucosa/*drug effects
MH  - Male
MH  - Membrane Potentials/drug effects
MH  - Mucous Membrane/drug effects
MH  - Rats
MH  - Taurocholic Acid/pharmacology
EDAT- 1978/06/01 00:00
MHDA- 1978/06/01 00:01
CRDT- 1978/06/01 00:00
PHST- 1978/06/01 00:00 [pubmed]
PHST- 1978/06/01 00:01 [medline]
PHST- 1978/06/01 00:00 [entrez]
AID - 10.1139/y78-070 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 1978 Jun;56(3):471-3. doi: 10.1139/y78-070.

PMID- 18195669
OWN - NLM
STAT- MEDLINE
DCOM- 20080219
LR  - 20181201
IS  - 1545-2913 (Print)
IS  - 1545-2913 (Linking)
VI  - 4
IP  - 4
DP  - 2007 Fall
TI  - Antiplatelet agents and randomized trials.
PG  - 177-83
AB  - Patients who have transient ischemic attack (TIA) or ischemic stroke are at a 
      high risk of having a first or recurrent stroke. The annual risk is between 5% 
      and 15%; the risk is highest in the first 48 hours following a TIA and highest in 
      the first 7 days following an ischemic stroke. Secondary prevention includes 
      antithrombotic therapy, treatment of risk factors, and interventional treatment 
      of carotid stenosis. Antithrombotic options can include antiplatelet drugs such 
      as aspirin, aspirin plus extended-release dipyridamole (ER-DP), clopidogrel, or 
      clopidogrel plus aspirin. Oral anticoagulation is used in patients with a cardiac 
      source of embolism such as atrial fibrillation. Aspirin monotherapy offers a 
      modest risk reduction for recurrent stroke and for the combined endpoint of 
      nonfatal stroke, myocardial infarction (MI), and vascular death. The combination 
      of ER-DP and aspirin was shown to be superior to aspirin monotherapy in several 
      trials. Clopidogrel is superior to aspirin in high-risk patients suffering from 
      stroke, MI, or peripheral arterial disease. The combination of clopidogrel plus 
      aspirin is not superior to aspirin or clopidogrel monotherapy and carries a 
      significantly higher bleeding risk. The combination might offer benefit in 
      short-term secondary prevention after TIA or stroke. Another ongoing trial is 
      currently investigating the possible benefit and side effects of aspirin plus 
      ER-DP versus clopidogrel in secondary stroke prevention.
FAU - Diener, Hans-Christoph
AU  - Diener HC
AD  - Department of Neurology, University Dusiburg-Essen, Essen, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Rev Neurol Dis
JT  - Reviews in neurological diseases
JID - 101223246
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Dipyridamole/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ischemic Attack, Transient/complications
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Secondary Prevention
MH  - Stroke/etiology/*prevention & control
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
RF  - 42
EDAT- 2008/01/16 09:00
MHDA- 2008/02/20 09:00
CRDT- 2008/01/16 09:00
PHST- 2008/01/16 09:00 [pubmed]
PHST- 2008/02/20 09:00 [medline]
PHST- 2008/01/16 09:00 [entrez]
PST - ppublish
SO  - Rev Neurol Dis. 2007 Fall;4(4):177-83.

PMID- 5259760
OWN - NLM
STAT- MEDLINE
DCOM- 19691216
LR  - 20190501
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 63
IP  - 3
DP  - 1969 Jul
TI  - Central nervous system activity associated with the pain evoked by bradykinin and 
      its alteration by morphine and aspirin.
PG  - 705-12
AB  - Synthetic bradykinin, a nonapeptide formed from alpha-2 globulin in plasma, 
      injected intra-arterially or intraperitoneally in cats in doses of 10-50 mug, 
      evoked activity in the central nervous system in pathways associated with the 
      signaling of pain. Similar injections of bradykinin in intact normal cats and 
      dogs evoked manifestations of pain, and in conscious humans elicited verbal 
      reports of pain perceived in the area of injection. Single unit activity was 
      recorded in the medial reticular formation of the brainstem, in the medial 
      thalamus and, more laterally, among the posterior group nuclei and the 
      suprageniculate nucleus. Bradykinin did not evoke any cortical or subcortical 
      slow potentials such as those evoked by electrical stimulation of the foot pads. 
      When bradykinin was given together with the electrical stimulus, the responses 
      evoked by the latter were blocked. Morphines uppressed bradykinin-evoked 
      activity. Aspirin caused marked fluctuations in activity, unrelated to the 
      bradykinin injection; the bradykinin block of evoked potentials could no longer 
      be observed after aspirin dosage. The results are discussed in terms of the 
      peripheral and central sites of analgesic action and the likelihood of the 
      existence of chemosensitive pain receptors.
FAU - Lim, R K
AU  - Lim RK
FAU - Krauthamer, G
AU  - Krauthamer G
FAU - Guzman, F
AU  - Guzman F
FAU - Fulp, R R
AU  - Fulp RR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 76I7G6D29C (Morphine)
RN  - R16CO5Y76E (Aspirin)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bradykinin/*pharmacology
MH  - Cats
MH  - Central Nervous System/*drug effects
MH  - Dogs
MH  - Evoked Potentials
MH  - Injections, Intra-Arterial
MH  - Injections, Intraperitoneal
MH  - Morphine/*pharmacology
MH  - Pain
PMC - PMC223509
EDAT- 1969/07/01 00:00
MHDA- 1969/07/01 00:01
CRDT- 1969/07/01 00:00
PHST- 1969/07/01 00:00 [pubmed]
PHST- 1969/07/01 00:01 [medline]
PHST- 1969/07/01 00:00 [entrez]
AID - 10.1073/pnas.63.3.705 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1969 Jul;63(3):705-12. doi: 10.1073/pnas.63.3.705.

PMID- 35124321
OWN - NLM
STAT- MEDLINE
DCOM- 20220324
LR  - 20220531
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
VI  - 31
IP  - 4
DP  - 2022 Apr
TI  - Functional Abilities of an International Post-Stroke Population: Standard 
      Assessment of Global Everyday Activities (SAGEA) Scale.
PG  - 106329
LID - S1052-3057(22)00026-X [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2022.106329 [doi]
AB  - BACKGROUND AND OBJECTIVES: Function is an important outcome after stroke; 
      traditional assessments may not capture functional deficits important to 
      patients. We examined the validity of the Standard Assessment of Global Everyday 
      Activities (SAGEA), a patient-reported outcome that assesses activities important 
      to patients and for use in international clinical trials. METHODS: The 
      NAVIGATE-ESUS trial evaluated rivaroxaban compared to aspirin in preventing 
      recurrent stroke in 7213 participants. The Modified Rankin Scale (mRS), the 
      National Institutes of Health Stroke Scale (NIHSS), and the SAGEA were collected 
      at entry. Chi square tests were used to compare proportions and Spearman rank 
      correlations were used to compare between measures. SAGEA was compared to the 
      Modified Frailty Index (MFI) and the occurrence of infarct to examine criterion 
      validity RESULTS: Participants were 67 years, 2/3 were male, and at baseline 30% 
      had no disability and 58% had slight disability according to mRS scores. SAGEA 
      was weakly correlated with the mRS (r=0.37), the NIHSS (r=0.29) and the MFI 
      (r=0.30). Of the 2154 with an mRS score of 0, 61% reported difficulty on the 
      SAGEA. The largest discrepancies between SAGEA and other measures were because of 
      cognitive functional deficits detected by the SAGEA that were not identified on 
      other assessments. A larger number of MRI identified infarcts (acute and covert) 
      were associated with a higher SAGEA score (p=0.007). CONCLUSIONS: The SAGEA is a 
      simple, globally applicable measure of cognitive and functional abilities that 
      identifies issues that other commonly used assessments of disability and function 
      do not capture.
CI  - Copyright © 2022. Published by Elsevier Inc.
FAU - Bosch, Jackie
AU  - Bosch J
AD  - Department of Rehabilitation Sciences, McMaster University, Hamilton, Ontario, 
      Canada; Population Health Research Institute, McMaster University, Hamilton 
      Health Sciences, Hamilton, Ontario, Canada. Electronic address: 
      boschj@mcmaster.ca.
FAU - Pearce, Lesly A
AU  - Pearce LA
AD  - Biostatistics Consultant, St. Catharines, Ontario, Canada.
FAU - Sharma, Mike
AU  - Sharma M
AD  - Department of Medicine (Neurology), McMaster University, Population Health 
      Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.
FAU - Mikulík, Robert
AU  - Mikulík R
AD  - International Clinical Research Centre and Department of Neurology, St. Anne's 
      University Hospital and Medical Facility of Masaryk University, Brno, Czech 
      Republic.
FAU - Whiteley, William N
AU  - Whiteley WN
AD  - Center for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United 
      Kingdom.
FAU - Canavan, Michelle
AU  - Canavan M
AD  - National University Ireland - Galway, Galway, Ireland.
FAU - Hart, Robert G
AU  - Hart RG
AD  - Population Health Research Institute, McMaster University, Hamilton Health 
      Sciences, Hamilton, Ontario, Canada.
FAU - O'Donnell, Martin J
AU  - O'Donnell MJ
AD  - Population Health Research Institute, McMaster University, Hamilton Health 
      Sciences, Hamilton, Ontario, Canada; HRB-Clinical Research Facility, National 
      University Ireland - Galway, Galway, Ireland.
LA  - eng
GR  - SCAF/17/01/CSO_/Chief Scientist Office/United Kingdom
PT  - Clinical Trial
PT  - Journal Article
DEP - 20220203
PL  - United States
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National 
      Stroke Association
JID - 9111633
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Activities of Daily Living
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Rivaroxaban/therapeutic use
MH  - *Stroke/drug therapy/therapy
OTO - NOTNLM
OT  - Clinical trial
OT  - ESUS
OT  - Embolic strokes of undetermined source
OT  - Functional scale
COIS- Declaration of Competing Interest J.B. received fees for an Advisory Board and as 
      an Adjudication Committee Member from Bayer, outside the submitted work. M.S. 
      reports personal fees from BMS and Daichii Sankyo, outside the submitted work. 
      M.C. received a travel grant from Boehringer Ingelheim and Bayer for conference 
      attendance. W.W. is supported by a Scottish Senior Clinical Fellowship [CSO 
      SCAF/17/01] and received grants from the Alzheimer's Society [UK], Chief 
      Scientist's Office, UK MRC, and the UK Stroke Association. S.Y. is supported by 
      the Heart & Stroke Foundation/Marion W. Burke Chair in Cardiovascular Disease and 
      has received research grants, honoraria and travel expenses for lectures from 
      Bayer, Boehringer Ingelheim, Bristol-Myers Squibb AstraZeneca and Sanofi, outside 
      the submitted work. R.H. reports grants and personal fees from Bayer AG, outside 
      the submitted work.
EDAT- 2022/02/07 06:00
MHDA- 2022/03/25 06:00
CRDT- 2022/02/06 20:32
PHST- 2021/11/18 00:00 [received]
PHST- 2022/01/01 00:00 [revised]
PHST- 2022/01/15 00:00 [accepted]
PHST- 2022/02/07 06:00 [pubmed]
PHST- 2022/03/25 06:00 [medline]
PHST- 2022/02/06 20:32 [entrez]
AID - S1052-3057(22)00026-X [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2022.106329 [doi]
PST - ppublish
SO  - J Stroke Cerebrovasc Dis. 2022 Apr;31(4):106329. doi: 
      10.1016/j.jstrokecerebrovasdis.2022.106329. Epub 2022 Feb 3.

PMID- 12660666
OWN - NLM
STAT- MEDLINE
DCOM- 20030619
LR  - 20151119
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 145
IP  - 3
DP  - 2003 Mar
TI  - Drug prescriptions after acute myocardial infarction: dosage, compliance, and 
      persistence.
PG  - 438-44
AB  - BACKGROUND: Although it has been well documented that aspirin, beta-blockers, 
      angiotensin-converting enzyme (ACE) inhibitors, and lipid-lowering drugs are 
      under-prescribed for patients with acute myocardial infarction (Am Heart J 
      2003;145:438-44.), few studies have examined dosage and long-term compliance and 
      persistence patterns for the use of these drugs after AMI. METHODS: Using Quebec 
      administrative data on all elderly (aged > or =65 years) survivors of hospital 
      admissions for AMI between 1996 and 1998 (n = 14,057), we studied the discharge 
      prescriptions, dosages, patient compliance, and persistence during this period 
      for aspirin, beta-blockers, ACE inhibitors, and lipid-lowering drugs. RESULTS: 
      Rates of discharge medications were suboptimal (aspirin 65%, beta-blockers 54%, 
      ACE inhibitors 45%, lipid-lowering drugs 21%). Most patients with prescriptions 
      for aspirin and ACE inhibitors were prescribed dosages equivalent to those 
      administered in clinical trials (99% and 88%, respectively). In contrast, only 
      20% of patients with beta-blocker prescriptions and 48% of patients with 
      lipid-lowering drug prescriptions were prescribed clinical trial doses. For 
      patients with discharge prescriptions, 1-year compliance rates were high (aspirin 
      74%, beta-blockers 74%, ACE inhibitors 70%, lipid-lowering drugs 84%), as were 
      the 1-year persistence rates (aspirin 71%, beta-blockers 72%, ACE inhibitors 69%, 
      lipid-lowering drugs 80%). CONCLUSION: Although cardiac drugs are 
      under-prescribed to patients with AMI, once prescribed, patients are likely to 
      adhere to these prescriptions, with high rates of compliance and persistence.
FAU - Simpson, Ewurabena
AU  - Simpson E
AD  - Division of Clinical Epidemiology, Montreal General Hospital, Montreal, Quebec, 
      Canada.
FAU - Beck, Christine
AU  - Beck C
FAU - Richard, Hugues
AU  - Richard H
FAU - Eisenberg, Mark J
AU  - Eisenberg MJ
FAU - Pilote, Louise
AU  - Pilote L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Hypolipidemic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adrenergic beta-Antagonists/administration & dosage/*therapeutic use
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic/statistics & numerical data
MH  - Databases as Topic
MH  - Drug Administration Schedule
MH  - Female
MH  - Guideline Adherence
MH  - Hospital Records
MH  - Humans
MH  - Hypolipidemic Agents/administration & dosage/*therapeutic use
MH  - Male
MH  - Myocardial Infarction/*drug therapy
MH  - Patient Compliance
MH  - Patient Discharge
MH  - Practice Patterns, Physicians'
MH  - Quebec
EDAT- 2003/03/28 05:00
MHDA- 2003/06/20 05:00
CRDT- 2003/03/28 05:00
PHST- 2003/03/28 05:00 [pubmed]
PHST- 2003/06/20 05:00 [medline]
PHST- 2003/03/28 05:00 [entrez]
AID - S0002870302948337 [pii]
AID - 10.1067/mhj.2003.143 [doi]
PST - ppublish
SO  - Am Heart J. 2003 Mar;145(3):438-44. doi: 10.1067/mhj.2003.143.

PMID- 6304282
OWN - NLM
STAT- MEDLINE
DCOM- 19830708
LR  - 20190913
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 6
IP  - 1
DP  - 1983 Jan
TI  - Studies on aspirin derivatives with very little side effect. IV. Inhibitory 
      effect of aspirin-isopropylantipyrine (AIA) on several experimental thromboses.
PG  - 9-17
AB  - The effect of a new aspirin derivative, aspirin-isopropylantipyrine (AIA), with 
      potent platelet anti-aggregant activity, on several experimental thromboses was 
      evaluated and compared with that of aspirin. AIA (50 mg/kg, s.c.) as well as 
      aspirin (50 mg/kg, s.c.) significantly inhibited thrombus formation in 
      extracorporeal shunt model of rats. AIA (50 mg/kg, s.c.) significantly shortened 
      the duration of apnea and respiratory distress induced by a rapid injection of 
      adenosine 5'-diphosphate in rats, while aspirin (50 mg/kg, s.c.) did not. 
      Inhibitory effect of AIA (50 mg/kg, s.c.) on arachidonic acid-induced mortality 
      in mice was less than that of aspirin (50 mg/kg, s.c.). AIA and aspirin (10 
      mg/kg/d X 10, s.c.) had no effect on laurate-induced arterial occlusive disease 
      in rats. AIA (200 microM) showed weak and reversible inhibition of prostaglandin 
      I2 generation in isolated rat aorta strip, while aspirin (200 microM) showed 
      irreversible inhibition. AIA (50 and 200 microM inhibited Ca2+-, K+- or 
      norepinephrine-induced contraction on isolated rat aorta strip. AIA (200 microM) 
      had no effect on malondialdehyde formation, cyclic AMP level and adenylate 
      cyclase activity in rat platelets. AIA (100 microM) inhibited arachidonic 
      acid-induced contraction on rat fundus strip by about 50%, while aspirin (100 
      microM) did not. These results strongly suggest that anti-thrombotic activity of 
      AIA was originated at least from its anti-aggregant effect on platelets, 
      differing from aspirin.
FAU - Aonuma, S
AU  - Aonuma S
FAU - Kohama, Y
AU  - Kohama Y
FAU - Fujimoto, S
AU  - Fujimoto S
FAU - Nomura, M
AU  - Nomura M
FAU - Yamahata, E
AU  - Yamahata E
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Arachidonic Acids)
RN  - 0 (N-3'a-propylphenazonyl-2-acetoxybenzamide)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - E0399OZS9N (Cyclic AMP)
RN  - EC 4.6.1.1 (Adenylyl Cyclases)
RN  - R16CO5Y76E (Aspirin)
RN  - T3CHA1B51H (Antipyrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adenylyl Cyclases/metabolism
MH  - Animals
MH  - Antipyrine/*analogs & derivatives/pharmacology
MH  - Arachidonic Acid
MH  - Arachidonic Acids
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cyclic AMP/blood
MH  - Epoprostenol/biosynthesis
MH  - Malondialdehyde/pharmacology
MH  - Muscle Contraction/drug effects
MH  - Rats
MH  - Thrombosis/blood/chemically induced/*prevention & control
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1248/bpb1978.6.9 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1983 Jan;6(1):9-17. doi: 10.1248/bpb1978.6.9.

PMID- 27817899
OWN - NLM
STAT- MEDLINE
DCOM- 20170217
LR  - 20181202
IS  - 1879-1298 (Electronic)
IS  - 0045-6535 (Linking)
VI  - 168
DP  - 2017 Feb
TI  - Determination and characterization of pharmaceuticals in sludge from municipal 
      and livestock wastewater treatment plants.
PG  - 1211-1221
LID - S0045-6535(16)31461-8 [pii]
LID - 10.1016/j.chemosphere.2016.10.077 [doi]
AB  - This study investigated 24 pharmaceuticals compounds belonging to the classes of 
      analgesics, stimulants, anti-seizures, non-steroidal anti-inflammatory drugs 
      (NSAIDs), and antibiotics in the sludge of 12 municipal sewage treatment plants 
      (S-sludge) and 4 livestock wastewater treatment plants (L-sludge) located across 
      Korea. Over 70% of the target compounds were detected in at least one sample of 
      S-sludge and L-sludge. The total concentration of the target pharmaceutical 
      compounds detected in S-sludge was 2.622-422.8 mg kg(-1)and the most dominant 
      compound was acetylsalicylic acid (ASA: 0.374-367.0 mg kg(-1)) whereas in 
      L-sludge, the total concentration was 43.87-156.8 mg kg(-1)and the most abundant 
      compound was oxytetracycline (OTC: 34.54-86.39 mg kg(-1)). Cluster analysis 
      revealed two distinct groups: group A, which were S-sludge samples including ASA, 
      carbamazepine (CBM), and others, and group B were L-sludge samples, dominated by 
      antibiotics (CTC, OTC, LIN). The total daily load amount of the target 
      pharmaceuticals in S-sludge was 0.010-268.9 kg day(-1) while the L-sludge was 
      0.021-0.529 kg day(-1). The estimated amounts of the target pharmaceutical 
      discharged from S-sludge and L-sludge into the Korean environment were 
      150.2 ± 47.94 ton yr(-1) and 15.05 ± 5.671 ton yr(-1) respectively, but the 
      discharged amount of antibiotics from S-sludge (6.945 ton yr(-1)) was lower than 
      that from L-sludge (9.234 ton yr(-1)).
CI  - Copyright © 2016 Elsevier Ltd. All rights reserved.
FAU - Ekpeghere, Kalu Ibe
AU  - Ekpeghere KI
AD  - Department of Civil and Environmental Engineering, Pusan National University, 
      Busan, 46241, Republic of Korea.
FAU - Lee, Ji-Woo
AU  - Lee JW
AD  - Department of Civil and Environmental Engineering, Pusan National University, 
      Busan, 46241, Republic of Korea.
FAU - Kim, Hee-Young
AU  - Kim HY
AD  - Department of Civil and Environmental Engineering, Pusan National University, 
      Busan, 46241, Republic of Korea.
FAU - Shin, Sun-Kyoung
AU  - Shin SK
AD  - National Institute of Environmental Research, Incheon, 404-708, Republic of 
      Korea.
FAU - Oh, Jeong-Eun
AU  - Oh JE
AD  - Department of Civil and Environmental Engineering, Pusan National University, 
      Busan, 46241, Republic of Korea. Electronic address: jeoh@pusan.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20161103
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Sewage)
RN  - 0 (Water Pollutants, Chemical)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/*analysis
MH  - Aspirin/*analysis
MH  - Livestock
MH  - Pharmaceutical Preparations/*analysis/isolation & purification
MH  - Republic of Korea
MH  - Sewage/*analysis
MH  - *Waste Disposal, Fluid
MH  - Water Pollutants, Chemical/*analysis
MH  - Water Purification
OTO - NOTNLM
OT  - Livestock wastewater treatment plant
OT  - Pharmaceuticals
OT  - Sewage treatment plant
OT  - Sludge
EDAT- 2016/11/08 06:00
MHDA- 2017/02/18 06:00
CRDT- 2016/11/08 06:00
PHST- 2016/09/06 00:00 [received]
PHST- 2016/10/17 00:00 [revised]
PHST- 2016/10/21 00:00 [accepted]
PHST- 2016/11/08 06:00 [pubmed]
PHST- 2017/02/18 06:00 [medline]
PHST- 2016/11/08 06:00 [entrez]
AID - S0045-6535(16)31461-8 [pii]
AID - 10.1016/j.chemosphere.2016.10.077 [doi]
PST - ppublish
SO  - Chemosphere. 2017 Feb;168:1211-1221. doi: 10.1016/j.chemosphere.2016.10.077. Epub 
      2016 Nov 3.

PMID- 24650313
OWN - NLM
STAT- MEDLINE
DCOM- 20141125
LR  - 20140321
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 12
IP  - 4
DP  - 2014 Apr
TI  - Contemporary antiplatelet therapy in patients undergoing percutaneous coronary 
      intervention.
PG  - 463-74
LID - 10.1586/14779072.2014.901149 [doi]
AB  - The proper use of antiplatelet agents in the cardiac catheterization laboratory 
      is important for ensuring optimal results in patients undergoing percutaneous 
      revascularization. Understanding the mechanisms by which these drugs exerts their 
      effects is important for both interventional and non-interventional 
      cardiologists. The effects of these agents on platelet function can be assessed 
      and monitored using a variety of commercially available laboratory assays but so 
      far these tests have not been adopted in routine clinical practice. Currently, 
      aspirin, thienopyridines and glycoprotein IIb/IIIa inhibitors are the primary 
      types of antiplatelet drugs being utilized. The use of these drugs and of several 
      newer antiplatelet drugs in the treatment of patients undergoing percutaneous 
      revascularization in the cardiac catheterization laboratory will be discussed, 
      especially in the light of the recently published guidelines.
FAU - Bhatty, Shaun
AU  - Bhatty S
AD  - Department of Internal Medicine, Cardiovascular Division, Virginia Commonwealth 
      University Health System/Medical College of Virginia, Richmond, VA, USA.
FAU - Ali, Asghar
AU  - Ali A
FAU - Shetty, Ranjith
AU  - Shetty R
FAU - Sumption, Kevin F
AU  - Sumption KF
FAU - Cowley, Michael J
AU  - Cowley MJ
FAU - Jovin, Ion S
AU  - Jovin IS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - *Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Treatment Outcome
EDAT- 2014/03/22 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/03/22 06:00
PHST- 2014/03/22 06:00 [entrez]
PHST- 2014/03/22 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1586/14779072.2014.901149 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2014 Apr;12(4):463-74. doi: 
      10.1586/14779072.2014.901149.

PMID- 16783994
OWN - NLM
STAT- MEDLINE
DCOM- 20060802
LR  - 20131121
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 2
IP  - 68
DP  - 2006 May 31
TI  - [The Polypill: between myths and reality in the treatment of type 2 diabetes 
      mellitus].
PG  - 1480-2, 1484-5
AB  - The Polypill: between myths and reality in the treatment of type 2 diabetes 
      mellitus The concept of "Polypill" was developed from modeling analyses and the 
      data were extracted from randomized-control trials and epidemiological studies. 
      This "Polypill" should be a combination of three antihypertensive drugs 
      associated to aspirin, a statin and folic acid. This "Polypill" would allow to 
      reduce of more than 80% the cardiovascular events. The original publication 
      suggests that all subjects of more than 55 years could benefit from this magic 
      pill. Numerous positive and negative reactions showed themselves further to this 
      publication. Other approaches based on the change of lifestyle seem so effective. 
      Nevertheless, to have a really effective approach the therapeutic educational 
      dimension should be also included in the basic strategy.
FAU - Ruiz, J
AU  - Ruiz J
AD  - Service d'endocrinologie, diabétologie et métabolisme CHUV, 101 Lausanne. 
      Juan.Ruiz@chuv.ch
FAU - Egli, M
AU  - Egli M
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - La polypill: entre mythes et réalité dans le traitement du diabète sucré.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 935E97BOY8 (Folic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Combinations
MH  - Folic Acid/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 17
EDAT- 2006/06/21 09:00
MHDA- 2006/08/03 09:00
CRDT- 2006/06/21 09:00
PHST- 2006/06/21 09:00 [pubmed]
PHST- 2006/08/03 09:00 [medline]
PHST- 2006/06/21 09:00 [entrez]
PST - ppublish
SO  - Rev Med Suisse. 2006 May 31;2(68):1480-2, 1484-5.

PMID- 8603274
OWN - NLM
STAT- MEDLINE
DCOM- 19960515
LR  - 20131121
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 75
IP  - 6 Pt 1
DP  - 1995 Dec
TI  - Leukotriene inhibitors and antagonists in asthma.
PG  - 463-70, 473; quiz 473-4
AB  - OBJECTIVE: This article reviews the literature on the effects of leukotrienes in 
      asthma. In particular, the ability of recently developed receptor antagonists and 
      synthesis inhibitors to attenuate the asthma-causing effects of leukotrienes is 
      examined. DESIGN: Published literature on the role of leukotrienes in asthma was 
      reviewed. Reports of research on agents that inhibit the synthesis of 
      leukotrienes or block leukotriene receptors were also studied. RESULTS: 
      Leukotrienes are endogenous molecules formed by the breakdown of a membrane 
      constituent, arachidonic acid, via the 5-lipoxygenase enzyme pathway. This 
      pathway ultimately produces several species of leukotrienes with various biologic 
      activities, including generalized inflammatory effects associated with asthma: 
      increased vascular permeability, enhanced mucous production, and decreased 
      mucociliary transport. Particularly important in asthma, leukotriene receptors on 
      the airways mediate a potent bronchoconstriction. Two general types of drugs have 
      been developed with the goal of attenuating the leukotrienes' effects in 
      inflammation and asthma: the leukotriene receptor blockers and the leukotriene 
      synthesis inhibitors (eg, 5-lipoxygenase inhibitors). CONCLUSIONS: The 
      antileukotriene drugs attenuated the responses to inhaled leukotrienes and 
      allergen challenges. These agents produced beneficial effects in cold-, 
      exercise-, and aspirin-induced asthma, as well as clinical asthma. Many of these 
      medications appear to be effective in the treatment of asthma; however, further 
      clinical research is needed to determine which patients would benefit most from 
      their use.
FAU - Spector, S L
AU  - Spector SL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Leukotriene Antagonists)
RN  - 0 (Leukotrienes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/immunology
MH  - Asthma/*drug therapy/etiology
MH  - Humans
MH  - *Leukotriene Antagonists
MH  - Leukotrienes/physiology
RF  - 78
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 1995 Dec;75(6 Pt 1):463-70, 473; quiz 473-4.

PMID- 8533123
OWN - NLM
STAT- MEDLINE
DCOM- 19960201
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 79
IP  - 3
DP  - 1995 Aug 1
TI  - Performance characteristics and clinical evaluation of an in vitro bleeding time 
      device--Thrombostat 4000.
PG  - 275-87
AB  - The performance characteristics of an in vitro bleeding time device--Thrombostat 
      4000 were evaluated and compared with the Simplate bleeding time in healthy 
      individuals and patients with disorders of primary hemostasis. Reference ranges 
      were established using 30 normal volunteers. Although there were variations 
      between different filter batches, reproducibility was good within a single batch. 
      There were no differences between the two channels of the instrument and between 
      male and female subjects. Hematocrit correlated negatively with the initial flow 
      (IF) and IF correlated positively with closure time (T) and bleeding volume (V). 
      Aspirin could be detected only when the traditional addition of ADP was replaced 
      with CaCl2. Both, closure time (T) or bleeding volume (V) were more sensitive 
      than Simplate bleeding time and T was more sensitive than V in detecting patients 
      with disorders of primary hemostasis. We conclude that the Thrombostat 4000 is a 
      reproducible, reliable, sensitive and easy to use instrument. It is superior to 
      the traditional in vivo bleeding times for investigations of disorders of primary 
      hemostasis (screening, diagnosis, monitoring, etc.).
FAU - Alshameeri, R S
AU  - Alshameeri RS
AD  - Department of Pathology, Wayne State University School of Medicine, Detroit, MI, 
      USA.
FAU - Mammen, E F
AU  - Mammen EF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - *Bleeding Time
MH  - Blood Platelet Disorders/blood
MH  - Blood Volume
MH  - Equipment Design
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Hematocrit
MH  - Hemostatic Techniques/*instrumentation
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Reference Values
MH  - Reproducibility of Results
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
AID - 0049-3848(95)00114-7 [pii]
AID - 10.1016/0049-3848(95)00114-7 [doi]
PST - ppublish
SO  - Thromb Res. 1995 Aug 1;79(3):275-87. doi: 10.1016/0049-3848(95)00114-7.

PMID- 6435305
OWN - NLM
STAT- MEDLINE
DCOM- 19841120
LR  - 20190829
IS  - 0165-2427 (Print)
IS  - 0165-2427 (Linking)
VI  - 7
IP  - 1
DP  - 1984 Aug
TI  - Aggregation of bovine platelets by acetyl glyceryl ether phosphorylcholine 
      (platelet activating factor).
PG  - 81-7
AB  - Platelet activating factor is a multifaceted mediator of inflammation capable of 
      stimulating platelet aggregation as well as anaphylaxis, neutropenia and numerous 
      other in vitro and in vivo cellular changes. This lipid mediator, or autocoid, is 
      released by a wide variety of inflammatory cells following an equally diverse 
      group of cellular stimuli including phagocytosis or antigenic stimulation. The 
      synthesized form of PAF is acetyl glyceryl ether phosphorylcholine (AGEPC). In 
      this study AGEPC aggregated bovine platelets in a dose dependent manner. Maximal, 
      irreversible aggregation occurred at 3.6 X 10(-11) M AGEPC with unwashed 
      platelets and at 8.8 X 10(-12) M AGEPC with washed platelets. Aggregation failed 
      to occur when platelets were tested with the biologically inactive structural 
      analog of AGEPC. The possible contribution by platelet cyclooxygenase products 
      was eliminated by showing lack of platelet aggregation to arachidonic acid and 
      also by pretreating platelets with aspirin.
FAU - Liggitt, H D
AU  - Liggitt HD
FAU - Leid, R W
AU  - Leid RW
FAU - Huston, L
AU  - Huston L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Vet Immunol Immunopathol
JT  - Veterinary immunology and immunopathology
JID - 8002006
RN  - 0 (Arachidonic Acids)
RN  - 0 (Platelet Activating Factor)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/pharmacology
MH  - Cattle
MH  - In Vitro Techniques
MH  - Inflammation/etiology
MH  - Platelet Activating Factor/*physiology
MH  - *Platelet Aggregation/drug effects
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 0165-2427(84)90030-8 [pii]
AID - 10.1016/0165-2427(84)90030-8 [doi]
PST - ppublish
SO  - Vet Immunol Immunopathol. 1984 Aug;7(1):81-7. doi: 10.1016/0165-2427(84)90030-8.

PMID- 21266809
OWN - NLM
STAT- MEDLINE
DCOM- 20110420
LR  - 20181201
IS  - 1421-9867 (Electronic)
IS  - 0012-2823 (Linking)
VI  - 83
IP  - 3
DP  - 2011
TI  - Gastrointestinal bleeding after percutaneous coronary intervention.
PG  - 153-60
LID - 10.1159/000321813 [doi]
AB  - Percutaneous coronary intervention (PCI) is now performed in a wide range of 
      patients with coronary artery disease. Complications of PCI include in-stent 
      re-stenosis and in-stent thrombosis. According to the recent 2005 guidelines of 
      the American College of Cardiology/American Heart Association/Society for 
      Cardiovascular Angiography and Interventions, dual antiplatelet therapy with 
      low-dose aspirin and thienopyridine derivatives such as ticlopidine and 
      clopidogrel should be used in patients who have undergone PCI. A serious 
      complication of dual antiplatelet therapy is bleeding, most of which arise from 
      the gastrointestinal (GI) tract. In this article we review published studies 
      about GI bleeding in patients who have undergone PCI. The prevalence of GI 
      bleeding in patients who are administered dual antiplatelet therapy following PCI 
      is approximately 2%, and GI bleeding after PCI is associated with increased 
      morbidity, mortality, duration of hospitalization and cost. Advanced age, a 
      history of peptic ulcer disease, co-administration of non-steroidal 
      anti-inflammatory drugs, co-administration of anticoagulants, and physiological 
      stress are considered to be the major risk factors for GI bleeding in patients 
      undergoing antiplatelet therapy following PCI. Recent clinical and experimental 
      studies indicate that administration of low-dose aspirin may also increase the 
      risk of adverse events in the small intestine. Although some prophylactic 
      strategies such as proton-pump inhibitor, H₂ receptor antagonist and eradication 
      of Helicobacter pylori are proposed, there are few randomized controlled trials 
      assessing the best strategy for the prevention of GI bleeding after PCI. Further 
      extensive studies are required to ascertain the beneficial effect of prophylactic 
      agents for dual antiplatelet therapy following PCI.
CI  - Copyright © 2011 S. Karger AG, Basel.
FAU - Tanigawa, Tetsuya
AU  - Tanigawa T
AD  - Department of Gastroenterology, Osaka City University Graduate School of 
      Medicine, Abeno-ku, Osaka City, Japan. ttanigawa@med.osaka-cu.ac.jp
FAU - Watanabe, Toshio
AU  - Watanabe T
FAU - Nadatani, Yuji
AU  - Nadatani Y
FAU - Otani, Koji
AU  - Otani K
FAU - Machida, Hirohisa
AU  - Machida H
FAU - Okazaki, Hirotoshi
AU  - Okazaki H
FAU - Yamagami, Hirokazu
AU  - Yamagami H
FAU - Watanabe, Kenji
AU  - Watanabe K
FAU - Tominaga, Kazunari
AU  - Tominaga K
FAU - Fujiwara, Yasuhiro
AU  - Fujiwara Y
FAU - Arakawa, Tetsuo
AU  - Arakawa T
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110121
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Gastrointestinal Hemorrhage/*chemically induced/prevention & control
MH  - Humans
MH  - Intestines
MH  - Platelet Aggregation Inhibitors/*adverse effects/pharmacology/therapeutic use
MH  - Risk Factors
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
EDAT- 2011/01/27 06:00
MHDA- 2011/04/22 06:00
CRDT- 2011/01/27 06:00
PHST- 2011/01/27 06:00 [entrez]
PHST- 2011/01/27 06:00 [pubmed]
PHST- 2011/04/22 06:00 [medline]
AID - 000321813 [pii]
AID - 10.1159/000321813 [doi]
PST - ppublish
SO  - Digestion. 2011;83(3):153-60. doi: 10.1159/000321813. Epub 2011 Jan 21.

PMID- 21189093
OWN - NLM
STAT- MEDLINE
DCOM- 20111003
LR  - 20131121
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 46
IP  - 5
DP  - 2011 May
TI  - Negative capsule endoscopy for obscure gastrointestinal bleeding is closely 
      associated with the use of low-dose aspirin.
PG  - 621-6
LID - 10.3109/00365521.2010.545833 [doi]
AB  - OBJECTIVE: Capsule endoscopy (CE) is used widely for determining the cause of 
      obscure gastrointestinal bleeding (OGIB). However, negative findings still arise 
      from CE examination. The aim of this study was to determine the factors 
      associated with negative findings on CE in patients with OGIB. MATERIAL AND 
      METHODS: A total of 134 patients who underwent CE for overt (n = 104) or occult 
      (n = 30) OGIB between October 2007 and April 2010 were included. The clinical 
      backgrounds of the patients (age; sex; the use of anti-coagulant, anti-platelet 
      drugs or NSAIDs; comorbidity and the timing of CE examination after bleeding) 
      were noted. RESULTS: The overall diagnostic yield of CE in detecting the relevant 
      findings was 50% (n = 67). Multivariate analysis revealed that the use of 
      anti-platelet drug and the timing of CE (≥ 16 days) were predictive factors for 
      negative findings on CE (odds ratio 2.69 [1.01-7.21], p = 0.048 and odds ratio 
      2.32 [1.01-5.33], p = 0.047, respectively). Among the patients with the use of 
      low-dose aspirin (LDA, n = 28) as anti-platelet drug, cessation of it before CE 
      was the only predictive factor for negative findings on CE (odds ratio 12.0 
      [1.72-83.5], p = 0.012). CONCLUSION: In the patients with OGIB, the use of LDA 
      and the cessation of it before CE made it difficult to detect the cause of 
      bleeding by CE. This might indicate that the source of OGIB related to LDA heals 
      immediately after cessation of the drugs or is a very small lesion that could not 
      be detected by CE.
FAU - Matsumura, Tomoaki
AU  - Matsumura T
AD  - Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba 
      University, Chiba-city, Japan.
FAU - Arai, Makoto
AU  - Arai M
FAU - Sazuka, Sayuri
AU  - Sazuka S
FAU - Saito, Masaya
AU  - Saito M
FAU - Takahashi, Yoshie
AU  - Takahashi Y
FAU - Maruoka, Daisuke
AU  - Maruoka D
FAU - Suzuki, Takuto
AU  - Suzuki T
FAU - Nakagawa, Tomoo
AU  - Nakagawa T
FAU - Sato, Toru
AU  - Sato T
FAU - Katsuno, Tatsuro
AU  - Katsuno T
FAU - Imazeki, Fumio
AU  - Imazeki F
FAU - Yokosuka, Osamu
AU  - Yokosuka O
LA  - eng
PT  - Journal Article
DEP - 20101229
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
MH  - Anticoagulants/administration & dosage
MH  - Aspirin/*administration & dosage/adverse effects
MH  - *Capsule Endoscopy
MH  - False Negative Reactions
MH  - Female
MH  - Gastrointestinal Hemorrhage/*diagnosis/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Sensitivity and Specificity
MH  - Time Factors
MH  - Young Adult
EDAT- 2010/12/30 06:00
MHDA- 2011/10/04 06:00
CRDT- 2010/12/30 06:00
PHST- 2010/12/30 06:00 [entrez]
PHST- 2010/12/30 06:00 [pubmed]
PHST- 2011/10/04 06:00 [medline]
AID - 10.3109/00365521.2010.545833 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2011 May;46(5):621-6. doi: 10.3109/00365521.2010.545833. 
      Epub 2010 Dec 29.

PMID- 18305387
OWN - NLM
STAT- MEDLINE
DCOM- 20080703
LR  - 20131121
IS  - 1421-9786 (Electronic)
IS  - 1015-9770 (Linking)
VI  - 25
IP  - 4
DP  - 2008
TI  - Aspirin responsiveness in acute brain ischaemia: association with stroke severity 
      and clinical outcome.
PG  - 355-61
LID - 10.1159/000118382 [doi]
AB  - PURPOSE: Platelets play a critical role in the pathogenesis of acute brain 
      ischaemia. We studied the association between the degree of inhibition of 
      platelet function by aspirin (ASA) and the severity and outcome of acute brain 
      ischaemia. METHODS: Platelet responsiveness to ASA was assessed in patients with 
      acute brain ischaemia, treated with ASA since hospital admission. The degree of 
      ASA responsiveness was assessed by optical aggregometry and categorized into 
      patients with good response, partial response and complete unresponsiveness to 
      ASA (good responders, partial responders and non-responders, respectively). An 
      additional evaluation of responsiveness to ASA was performed by Impact-R (cone 
      and platelet analyzer). Patients underwent serial clinical assessment during 
      hospitalization, at discharge and during follow-up. RESULTS: Among 105 patients 
      (mean age 63 +/- 12 years; 66% men), impaired ASA responsiveness at baseline as 
      assessed by aggregometry was associated with increased stroke severity at 
      baseline, unfavourable clinical course, and poor functional outcome during 
      follow-up (p < 0.05 for all). Age-adjusted odds ratios in non-responders compared 
      to good responders were 9.8 for severe stroke on admission (95% CI 2.8-34.9), 3.1 
      for lack of early clinical improvement (95% CI 1.1-8.8) and 8.6 for poor 
      functional outcome during follow-up (95% CI 2.4-30.4). Less robust trends were 
      observed with the Impact-R. CONCLUSIONS: Impaired responsiveness to ASA in acute 
      brain ischaemia is common and is associated with worse neurological deficits at 
      stroke onset, early clinical deterioration and poorer functional outcome. The 
      clinical significance of these findings requires further evaluation in larger 
      longitudinal studies.
CI  - (c) 2008 S. Karger AG, Basel.
FAU - Schwammenthal, Y
AU  - Schwammenthal Y
AD  - Stroke Center, Department of Neurology, Sheba Medical Center, Tel Hashomer, 
      Israel.
FAU - Tsabari, R
AU  - Tsabari R
FAU - Shenkman, B
AU  - Shenkman B
FAU - Schwartz, R
AU  - Schwartz R
FAU - Matetzky, S
AU  - Matetzky S
FAU - Lubetsky, A
AU  - Lubetsky A
FAU - Orion, D
AU  - Orion D
FAU - Israeli-Korn, S
AU  - Israeli-Korn S
FAU - Chapman, J
AU  - Chapman J
FAU - Savion, N
AU  - Savion N
FAU - Varon, D
AU  - Varon D
FAU - Tanne, D
AU  - Tanne D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20080228
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects/physiology
MH  - Brain Ischemia/complications/*drug therapy/physiopathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Severity of Illness Index
MH  - Stroke/etiology/physiopathology/*prevention & control
MH  - Treatment Outcome
EDAT- 2008/02/29 09:00
MHDA- 2008/07/04 09:00
CRDT- 2008/02/29 09:00
PHST- 2007/03/16 00:00 [received]
PHST- 2007/10/17 00:00 [accepted]
PHST- 2008/02/29 09:00 [pubmed]
PHST- 2008/07/04 09:00 [medline]
PHST- 2008/02/29 09:00 [entrez]
AID - 000118382 [pii]
AID - 10.1159/000118382 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2008;25(4):355-61. doi: 10.1159/000118382. Epub 2008 Feb 28.

PMID- 10715924
OWN - NLM
STAT- MEDLINE
DCOM- 20000330
LR  - 20220318
IS  - 0002-8177 (Print)
IS  - 0002-8177 (Linking)
VI  - 131
IP  - 3
DP  - 2000 Mar
TI  - Does low-dose aspirin therapy complicate oral surgical procedures?
PG  - 331-5
AB  - BACKGROUND: The fear of uncontrolled bleeding often prompts medical practitioners 
      to stop aspirin intake for seven to 10 days before any surgical procedure. The 
      authors initiated this study to evaluate the effect of aspirin on bleeding in 
      patients undergoing oral surgery. METHODS: The study group consisted of 39 
      patients who were scheduled to undergo dental extractions. All patients were 
      receiving 100 milligrams of aspirin daily on a regular basis. The authors 
      randomly divided the patients into two groups: those who stopped the aspirin 
      therapy before the procedure and those who continued the aspirin therapy. One 
      hour before the procedures, all patients underwent a bleeding time test. In 
      addition, the amount of bleeding during the procedure was measured. RESULTS: The 
      mean (+/- standard deviation) bleeding time was 1.8 +/- 0.47 minutes for patients 
      who stopped aspirin therapy one week before the procedure. For patients who 
      continued aspirin therapy, the bleeding time was 3.1 +/- 0.65 minutes. The 
      difference was statistically significant (P = .004). However, both groups were 
      within the normal bleeding time range, and in both groups, a local hemostatic 
      method was sufficient to control bleeding. No episodes of uncontrolled 
      intraoperative or postoperative bleeding were noted. CONCLUSION: Low-dose aspirin 
      therapy should not be stopped before oral surgery. Local hemostasis is sufficient 
      to control bleeding. CLINICAL IMPLICATIONS: Patients receiving aspirin therapy to 
      prevent blood clot formation may be subject to emboli formation if the treatment 
      is stopped. The results of this study show that aspirin therapy should be 
      continued throughout oral surgical procedures. Local measures are sufficient to 
      control any bleeding during surgery.
FAU - Ardekian, L
AU  - Ardekian L
AD  - Department of Oral and Maxillofacial Surgery, Rambam Medical Center, Haifa, 
      Israel.
FAU - Gaspar, R
AU  - Gaspar R
FAU - Peled, M
AU  - Peled M
FAU - Brener, B
AU  - Brener B
FAU - Laufer, D
AU  - Laufer D
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Dent Assoc. 2000 Oct;131(10):1398, 1401-2. PMID: 11042974
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Blood Loss, Surgical/prevention & control
MH  - Female
MH  - Humans
MH  - Intraoperative Complications/*etiology/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Oral Hemorrhage/*etiology/prevention & control
MH  - Oral Surgical Procedures/*adverse effects/methods
MH  - Postoperative Complications/*etiology/prevention & control
MH  - Time Factors
EDAT- 2000/03/15 09:00
MHDA- 2000/04/01 09:00
CRDT- 2000/03/15 09:00
PHST- 2000/03/15 09:00 [pubmed]
PHST- 2000/04/01 09:00 [medline]
PHST- 2000/03/15 09:00 [entrez]
AID - S0002-8177(14)63448-6 [pii]
AID - 10.14219/jada.archive.2000.0176 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 2000 Mar;131(3):331-5. doi: 10.14219/jada.archive.2000.0176.

PMID- 6359867
OWN - NLM
STAT- MEDLINE
DCOM- 19840126
LR  - 20201209
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 75
IP  - 5A
DP  - 1983 Nov 14
TI  - Review of the comparative analgesic efficacy of salicylates, acetaminophen, and 
      pyrazolones.
PG  - 47-52
AB  - Use of salicylates, acetaminophen, and pyrazolones has become increasingly 
      complex, extending from the treatment of acute, mild pain to chronic, moderately 
      severe pain. The intensity, rather than the nature, of the pain determines the 
      efficacy of aspirin. A clinical dose-response relationship has been established, 
      and time-effect curves indicate that the total threshold-raising effect depends 
      on dosage frequency. Contrary to popular belief, aspirin and acetaminophen appear 
      to be equipotent and equianalgesic for the relief of most pain. The combination 
      of aspirin (650 mg) plus codeine (30 mg) is only slightly more effective than 
      aspirin alone. The same holds true for acetaminophen (600 mg) plus codeine (60 
      mg); the efficacy of the combination is only slightly better than that of 
      acetaminophen alone.
FAU - Mehlisch, D R
AU  - Mehlisch DR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Pyrazoles)
RN  - 0 (Salicylates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - *Analgesics
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Aspirin/pharmacology
MH  - Codeine/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Humans
MH  - Pyrazoles/*pharmacology
MH  - Salicylates/*pharmacology
RF  - 21
EDAT- 1983/11/14 00:00
MHDA- 1983/11/14 00:01
CRDT- 1983/11/14 00:00
PHST- 1983/11/14 00:00 [pubmed]
PHST- 1983/11/14 00:01 [medline]
PHST- 1983/11/14 00:00 [entrez]
AID - 0002-9343(83)90232-2 [pii]
AID - 10.1016/0002-9343(83)90232-2 [doi]
PST - ppublish
SO  - Am J Med. 1983 Nov 14;75(5A):47-52. doi: 10.1016/0002-9343(83)90232-2.

PMID- 28425093
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20220408
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Print)
IS  - 0002-8614 (Linking)
VI  - 65
IP  - 8
DP  - 2017 Aug
TI  - Low-Dose Aspirin Use and Cognitive Function in Older Age: A Systematic Review and 
      Meta-analysis.
PG  - 1763-1768
LID - 10.1111/jgs.14883 [doi]
AB  - OBJECTIVES: To investigate whether low-dose aspirin (<300 mg/d) can influence the 
      onset of cognitive impairment or dementia in observational studies and improve 
      cognitive test scores in randomized controlled trials (RCTs) in participants 
      without dementia. DESIGN: Systematic review and meta-analysis. SETTING: 
      Observational and interventional studies. PARTICIPANTS: Individuals with no 
      dementia or cognitive impairment initially. MEASUREMENTS: Odds ratios (ORs) and 
      95% confidence intervals (CIs), adjusted for the maximum number of covariates 
      from each study, were used to summarize data on the incidence of dementia and 
      cognitive impairment in observational studies. Standardized mean differences 
      (SMDs) were used for cognitive test scores in RCTs. RESULTS: Of 2,341 potentially 
      eligible articles, eight studies were included and provided data for 36,196 
      participants without dementia or cognitive impairment at baseline (mean age 66, 
      63% female). After adjusting for a median of three potential confounders over a 
      median follow-up period of 6 years, chronic use of low-dose aspirin was not 
      associated with onset of dementia or cognitive impairment (5 studies, N = 26,159; 
      OR = 0.82, 95% CI = 0.55-1.22, P = .33, I(2) = 67%). In three RCTs (N = 10,037; 
      median follow-up 5 years), the use of low-dose aspirin was not associated with 
      significantly better global cognition (SMD=0.005, 95% CI=-0.04-0.05, P = .84, 
      I(2) = 0%) in individuals without dementia. Adherence was lower in participants 
      taking aspirin than in controls, and the incidence of adverse events was higher. 
      CONCLUSION: This review found no evidence that low-dose aspirin buffers against 
      cognitive decline or dementia or improves cognitive test scores in RCTs.
CI  - © 2017, Copyright the Authors Journal compilation © 2017, The American Geriatrics 
      Society.
FAU - Veronese, Nicola
AU  - Veronese N
AD  - Institute for Clinical Research and Education in Medicine, Padova, Italy.
AD  - Aging Section, Institute of Neurosciences, Italian Research Council, Padova, 
      Italy.
FAU - Stubbs, Brendon
AU  - Stubbs B
AD  - Faculty of Health, Social Care and Education, Anglia Ruskin University, 
      Chelmsford, UK.
AD  - South London and Maudsley National Health Service Foundation Trust, London, UK.
AD  - Institute of Psychiatry, Psychology and Neuroscience, King's College London, 
      London, UK.
FAU - Maggi, Stefania
AU  - Maggi S
AD  - Aging Section, Institute of Neurosciences, Italian Research Council, Padova, 
      Italy.
FAU - Thompson, Trevor
AU  - Thompson T
AD  - Faculty of Education and Health, University of Greenwich, London, UK.
FAU - Schofield, Patricia
AU  - Schofield P
AD  - Faculty of Health, Social Care and Education, Anglia Ruskin University, 
      Chelmsford, UK.
FAU - Muller, Christoph
AU  - Muller C
AD  - South London and Maudsley National Health Service Foundation Trust, London, UK.
AD  - Institute of Psychiatry, Psychology and Neuroscience, King's College London, 
      London, UK.
FAU - Tseng, Ping-Tao
AU  - Tseng PT
AD  - Department of Psychiatry, Tsyr-Huey Mental Hospital, Kaohsiung Jen-Ai's Home, 
      Taiwan.
FAU - Lin, Pao-Yen
AU  - Lin PY
AD  - Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung 
      University College of Medicine, Kaohsiung, Taiwan.
AD  - Institute for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung 
      Memorial Hospital, Kaohsiung, Taiwan.
FAU - Carvalho, André F
AU  - Carvalho AF
AD  - Translational Psychiatry Research Group, Department of Clinical Medicine, Faculty 
      of Medicine, Federal University of Ceara, Fortaleza, Ceara, Brazil.
FAU - Solmi, Marco
AU  - Solmi M
AD  - Institute for Clinical Research and Education in Medicine, Padova, Italy.
AD  - Department of Neuroscience, University of Padova, Padova, Italy.
LA  - eng
GR  - U01 AG029824/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20170420
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*administration & dosage
MH  - Cognition/*drug effects
MH  - Cognition Disorders/prevention & control
MH  - Dementia/prevention & control
MH  - Humans
MH  - Randomized Controlled Trials as Topic
PMC - PMC6810633
MID - NIHMS1048104
OTO - NOTNLM
OT  - aspirin
OT  - cognitive impairment
OT  - dementia
OT  - meta-analysis
EDAT- 2017/04/21 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/04/21 06:00
PHST- 2017/04/21 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
PHST- 2017/04/21 06:00 [entrez]
AID - 10.1111/jgs.14883 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2017 Aug;65(8):1763-1768. doi: 10.1111/jgs.14883. Epub 2017 Apr 
      20.

PMID- 8846553
OWN - NLM
STAT- MEDLINE
DCOM- 19961021
LR  - 20191101
IS  - 0950-3552 (Print)
IS  - 0950-3552 (Linking)
VI  - 9
IP  - 3
DP  - 1995 Sep
TI  - The pharmacological prevention of pre-eclampsia.
PG  - 509-28
AB  - The disparate results reported in the literature on the effects of low dose 
      aspirin in preventing pre-eclampsia might be caused by non-compliance in the more 
      recent large trials in low-risk patients. All the earlier small trials were done 
      on identified high-risk patients who consider themselves as patients, as do their 
      doctors. Compliance in these patients will be very high. In fact, the only study 
      in healthy subjects in which aspirin intake was controlled for (Hauth et al 1993) 
      showed a marked reduction in the incidence of pre-eclampsia. However, the recent 
      large trials have demonstrated, without any doubt, that low dose aspirin is not a 
      miracle drug. The combined literature points at a 25% reduction in the incidence 
      of pre-eclampsia in association with the use of aspirin (Collins, 1994). The 
      correct indication for the use of low-dose aspirin appears to be the patient that 
      is at very high risk of developing early-onset (less than 32 weeks gestation) 
      pre-eclampsia. Since early-onset pre-eclampsia can begin at any time after 20 
      weeks gestation, it is necessary to initiate low-dose aspirin therapy early in 
      pregnancy, preferably at 10-14 weeks gestation. The results of the recent large 
      trials emphasize the need for a reliable, sensitive method of predicting or 
      detecting pre-eclampsia at a very early gestational age (Dekker and Sibai, 1991). 
      Valensise et al (1993) recently confirmed earlier studies (McParland et al, 1990) 
      on the useful combination of uteroplacental Doppler flow velocimetry and aspirin 
      in low-risk primigravidae. Results from current large-scale trials, such as the 
      ECPPA, the BLASP, the WHO Jamaica and the second NICHHD studies, will be 
      available in the near future. The results of especially the second NICHHD study 
      on low-dose aspirin, in more than 2000 high-risk women (previous 
      pre-eclampsia/eclampsia, chronic hypertension, class B to F diabetes or multiple 
      gestation), will hopefully give us a more definitive picture on the potential 
      benificial effects of low-dose aspirin in high-risk patients. The effect of 
      aspirin on placental TXA2 deserves further studies. It might be that the optimal 
      level to inhibit placental TXA2 and lipid peroxide production is actually higher 
      than the minimal effective doses of aspirin that are needed to inhibit platelet 
      TXA2 production (Walsh, 1994). Low-dose aspirin appears to be safe for the fetus 
      and neonate. If there is an increased risk of abruptio placentae, this risk 
      appears to be minimal. The final word on the use of low-dose aspirin has not yet 
      been reached; however, we may be getting closer to profiling patients for whom 
      the therapy may be efficacious and beneficial to both mother and fetus. Further 
      studies are also necessary on combinations of aspirin and other antithrombotic 
      drugs, such as heparin or ketanserin (Tanaka et al, 1993; Bolte et al, 1994; 
      North et al, 1994). North et al (1994) demonstrated that treatment of women with 
      severe renal disease with heparin plus aspirin reduced the prevalence of 
      superimposed pre-eclampsia, compared with no treatment or aspirin alone. Next to 
      low-dose aspirin, there appear to be several new and promising pharmaceutical 
      approaches for reducing the consequences of EC dysfunction. Among these are 
      selective TXA2-synthetase or TXA2-receptor antagonists, Serotonin2-receptor 
      blockers, stable PGI2 analogues and NO donors.
FAU - Dekker, G A
AU  - Dekker GA
AD  - Department of Obstetrics and Gynaecology, Free University Hospital, Amsterdam, 
      The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Baillieres Clin Obstet Gynaecol
JT  - Bailliere's clinical obstetrics and gynaecology
JID - 8710782
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Epoprostenol/therapeutic use
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/physiopathology/*prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Thromboxane A2/therapeutic use
RF  - 109
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
AID - 10.1016/s0950-3552(05)80378-5 [doi]
PST - ppublish
SO  - Baillieres Clin Obstet Gynaecol. 1995 Sep;9(3):509-28. doi: 
      10.1016/s0950-3552(05)80378-5.

PMID- 6607158
OWN - NLM
STAT- MEDLINE
DCOM- 19840305
LR  - 20190913
IS  - 0012-6578 (Print)
IS  - 0012-6578 (Linking)
VI  - 18
IP  - 1
DP  - 1984 Jan
TI  - Other NSAIDs of choice for rheumatoid arthritis.
PG  - 39-41
AB  - Aspirin is an effective antiinflammatory and analgesic agent. Pain relief is 
      achieved with relatively modest doses, far below those necessary for inflammation 
      control. The patient reacts to the need for pain relief and will take fewer 
      aspirin than prescribed because the lower dosage is better tolerated and less 
      expensive. This often obviates the wanted effects. This pain-inflammation gap 
      does not exist for most nonsteroidal antiinflammatory drugs (NSAIDs), in which 
      analgesic and antiinflammatory doses approximate each other. The range of toxic 
      effects from aspirin is larger than that for nonsteroidal drugs. Gastric erosions 
      and bleeding are far more prevalent with aspirin. Other organ systems are 
      involved more by aspirin than by other drugs, and, in osteoarthritis, aspirin 
      actually may militate against recovery by interfering with glycosaminoglycan 
      synthesis.
FAU - Ehrlich, G E
AU  - Ehrlich GE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Drug Intell Clin Pharm
JT  - Drug intelligence & clinical pharmacy
JID - 0212457
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects
MH  - Costs and Cost Analysis
MH  - Humans
MH  - Liver Function Tests
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1177/106002808401800105 [doi]
PST - ppublish
SO  - Drug Intell Clin Pharm. 1984 Jan;18(1):39-41. doi: 10.1177/106002808401800105.

PMID- 6740559
OWN - NLM
STAT- MEDLINE
DCOM- 19840813
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 51
IP  - 2
DP  - 1984 Apr 30
TI  - Effects of acetylsalicylic acid on human platelet function in vivo at salicylate 
      steady state.
PG  - 269-71
AB  - The results of clinical trials concerning the use of acetylsalicylic acid (ASA) 
      as antithrombotic drug are contradictory. Inhibition by ASA of platelet 
      prostaglandin synthesis and aggregation is prevented by its metabolite salicylic 
      acid (SA) in animals and in human platelets in vitro. It was suggested that ASA 
      might produce its own inhibitor, thereby diminishing its efficiency in 
      thromboembolic disease. In four healthy male subjects there was no difference in 
      inhibition of collagen-induced platelet aggregation after the administration of 
      500 mg ASA alone or at salicylate steady state (3 g SA daily). But the inhibition 
      of tissue-extract-induced platelet shape change was diminished and shortened by 
      pretreatment with SA. We conclude that SA does not inhibit the effects of ASA on 
      human platelet aggregation in vivo in therapeutic dose ranges. The clinical 
      importance of the SA/ASA-interaction on tissue-extract-induced platelet shape 
      change remains to be clarified.
FAU - Simrock, R
AU  - Simrock R
FAU - Missalla, A
AU  - Missalla A
FAU - Schwidtal, P
AU  - Schwidtal P
FAU - Lischke, V
AU  - Lischke V
FAU - Breddin, H K
AU  - Breddin HK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Salicylates)
RN  - 9007-34-5 (Collagen)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Collagen/pharmacology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Function Tests
MH  - Salicylates/*pharmacology
MH  - Salicylic Acid
EDAT- 1984/04/30 00:00
MHDA- 1984/04/30 00:01
CRDT- 1984/04/30 00:00
PHST- 1984/04/30 00:00 [pubmed]
PHST- 1984/04/30 00:01 [medline]
PHST- 1984/04/30 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1984 Apr 30;51(2):269-71.

PMID- 6224670
OWN - NLM
STAT- MEDLINE
DCOM- 19831028
LR  - 20131121
IS  - 0012-0472 (Print)
IS  - 0012-0472 (Linking)
VI  - 108
IP  - 37
DP  - 1983 Sep 16
TI  - [Incidence of recurrence after successful transluminal coronary angioplasty].
PG  - 1387-90
AB  - From October, 1977 to April, 1983, a total of 500 transluminal coronary 
      angioplasties (TCA) were performed. The acute success rate averaged 71%, in 
      stenoses of the anterior interventricular branch it was 75%. Long-term results 
      were assessed on the basis of clinical findings, functional studies including 
      ergometry, radionuclide ventriculography and thallium scan, revealing a 
      recurrence rate of 13%. Repeat angiography of 213 patients with successful 
      angioplasty indicated a recurrence of 15% (lasting widening of the stenosis less 
      than 20%). All recurrences occurred within the first three months. A second 
      angiogram was performed 12 months after successful angioplasty in 66 patients who 
      three months after the origin TCA had shown no recurrence. In no case was there a 
      reduction in the widened stenosis. The reported recurrence rate is lower than 
      comparable figures in published reports. Possible reasons for this may be the 
      selection of patients, the technique of angioplasty and long-term treatment with 
      acetylsalicylic acid, nitrates and calcium antagonists.
FAU - Kaltenbach, M
AU  - Kaltenbach M
FAU - Kober, G
AU  - Kober G
FAU - Schmidt-Moritz, A
AU  - Schmidt-Moritz A
FAU - Scherer, D
AU  - Scherer D
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Rezidivhäufigkeit nach erfolgreicher transluminaler Koronarangioplastie.
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - CJ0O37KU29 (Verapamil)
RN  - IA7306519N (Isosorbide Dinitrate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon
MH  - Aspirin/therapeutic use
MH  - Coronary Disease/diagnosis/*therapy
MH  - Exercise Test
MH  - Humans
MH  - Isosorbide Dinitrate/therapeutic use
MH  - Premedication
MH  - Recurrence
MH  - Time Factors
MH  - Verapamil/therapeutic use
EDAT- 1983/09/16 00:00
MHDA- 1983/09/16 00:01
CRDT- 1983/09/16 00:00
PHST- 1983/09/16 00:00 [pubmed]
PHST- 1983/09/16 00:01 [medline]
PHST- 1983/09/16 00:00 [entrez]
AID - 10.1055/s-2008-1069754 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 1983 Sep 16;108(37):1387-90. doi: 10.1055/s-2008-1069754.

PMID- 7252808
OWN - NLM
STAT- MEDLINE
DCOM- 19810915
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 6
DP  - 1981 Jun
TI  - Spectrofluorometric determination of acetylsalicylic acid, salicylamide, and 
      salicyclic acid as an impurity in pharmaceutical preparations.
PG  - 641-6
AB  - Spectrofluorometry, either direct or in combination with a separation technique, 
      provides a sensitive and accurate method for the determination of certain extent 
      fluorescent analgesic drugs and the determination of impurities in many 
      combination preparations. A critical examination of the UV spectra of common 
      analgesics and related compounds indicates that the fluorescence inner filter 
      effect should be negligible below 10(-5) M and that selective excitation and 
      emission wavelengths should minimize interference from other fluorescent species. 
      Fluorometric procedures are presented for the determination of salicylamide, 
      acetylsalicylic acid, and salicylic acid, as an impurity, in preparations 
      containing salicylamide, acetylsalicylic acid, acetaminophen, caffeine, and 
      phenacetin as major constituents. Inner filtering is the limiting factor only for 
      the direct and indirect determination of salicylamide and the direct 
      determination of acetylsalicylic acid. Results of fluorometric determinations 
      compare favorably with other reference methods. Salicylic acid is determined in 
      the 10(-7) M concentration range after separation from salicylamide, 
      acetaminophen, and caffeine.
FAU - Street, K W
AU  - Street KW
FAU - Schenk, G H
AU  - Schenk GH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Buffers)
RN  - 0 (Drug Combinations)
RN  - 0 (Salicylamides)
RN  - 0 (Salicylates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - EM8BM710ZC (salicylamide)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen
MH  - Aspirin/*analysis
MH  - Buffers
MH  - Caffeine
MH  - Drug Combinations
MH  - Drug Contamination
MH  - Salicylamides/*analysis
MH  - Salicylates/*analysis
MH  - Salicylic Acid
MH  - Spectrometry, Fluorescence/methods
MH  - Spectrophotometry, Ultraviolet
EDAT- 1981/06/01 00:00
MHDA- 1981/06/01 00:01
CRDT- 1981/06/01 00:00
PHST- 1981/06/01 00:00 [pubmed]
PHST- 1981/06/01 00:01 [medline]
PHST- 1981/06/01 00:00 [entrez]
AID - S0022-3549(15)43754-2 [pii]
AID - 10.1002/jps.2600700617 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Jun;70(6):641-6. doi: 10.1002/jps.2600700617.

PMID- 3986859
OWN - NLM
STAT- MEDLINE
DCOM- 19850607
LR  - 20190511
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 19
IP  - 3
DP  - 1985 Mar
TI  - Effect of aspirin and indomethacin on exercise-induced changes in blood pressure 
      and limb blood flow in normal volunteers.
PG  - 177-80
AB  - To evaluate the possible role of prostaglandins in exercise-induced changes in 
      blood pressure and limb blood flow we have compared the effects of aspirin and 
      indomethacin in a double-blind placebo controlled study in a group of normal 
      volunteers. Nine men undertook treadmill exercise after pretreatment with 
      placebo, aspirin and indomethacin. Indomethacin caused a greater increase in 
      systolic blood pressure during exercise than aspirin (p less than 0.05) and a 
      smaller fall in diastolic pressure than either placebo or aspirin (p less than 
      0.02 and p less than 0.01). Compared with placebo both aspirin and indomethacin 
      attenuated to a similar degree the increase in calf blood flow (p less than 0.05 
      and p less than 0.03) and the changes in forearm blood flow following exercise. 
      These results suggest that although aspirin and indomethacin both inhibit 
      prostaglandin production they have different effects on exercise-induced changes 
      in blood pressure. They have, however, similar effects on limb blood flow.
FAU - Cowley, A J
AU  - Cowley AJ
FAU - Stainer, K
AU  - Stainer K
FAU - Rowley, J M
AU  - Rowley JM
FAU - Wilcox, R G
AU  - Wilcox RG
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Double-Blind Method
MH  - Extremities/*blood supply
MH  - Forearm/blood supply
MH  - Humans
MH  - Indomethacin/*pharmacology
MH  - Leg/blood supply
MH  - Male
MH  - *Physical Exertion
MH  - Regional Blood Flow/drug effects
MH  - Time Factors
EDAT- 1985/03/01 00:00
MHDA- 1985/03/01 00:01
CRDT- 1985/03/01 00:00
PHST- 1985/03/01 00:00 [pubmed]
PHST- 1985/03/01 00:01 [medline]
PHST- 1985/03/01 00:00 [entrez]
AID - 10.1093/cvr/19.3.177 [doi]
PST - ppublish
SO  - Cardiovasc Res. 1985 Mar;19(3):177-80. doi: 10.1093/cvr/19.3.177.

PMID- 17340057
OWN - NLM
STAT- MEDLINE
DCOM- 20071018
LR  - 20131121
IS  - 0300-8428 (Print)
IS  - 0300-8428 (Linking)
VI  - 102
IP  - 4
DP  - 2007 Jul
TI  - High dose aspirin and left ventricular remodeling after myocardial infarction: 
      aspirin and myocardial infarction.
PG  - 334-40
AB  - BACKGROUND: Proinflammatory proteins like inflammatory cytokines are implicated 
      in myocardial depression and left ventricular remodeling after myocardial 
      infarction. High-dose aspirin inhibits cytokine activation. Therefore, we tested 
      the influence of high-dose aspirin treatment on left ventricular remodeling in 
      mice after myocardial infarction. METHODS AND RESULTS: Mice were treated for 4 
      weeks with placebo or aspirin (120 mg/kg per day) by Alzet mini-osmotic pumps 
      after ligation of the left anterior descending coronary artery. Serial 
      transthoracic echocardiography was performed at days 1, 7, and 28. Over the 4 
      weeks, mortality was not different between the groups (placebo 30.8%, aspirin 
      30.8%). On echocardiography, animals after myocardial infarction exhibited left 
      ventricular dilatation (week 4, end-systolic area, placebo sham 8.9 +/- 1.7 vs. 
      placebo MI 15.9 +/- 2.5 mm(2)), which was not changed by aspirin treatment (week 
      4, end-systolic area, aspirin MI 14.5 +/- 1.3 mm(2), p= ns vs. placebo MI). The 
      expression of the proinflammatory cytokines TNF and IL-1beta were markedly 
      upregulated in mice with myocardial infarction on placebo. Cytokine expression 
      was significantly reduced by aspirin treatment while collagen deposition was not 
      influenced. CONCLUSION: Continuous aspirin treatment (120 mg/kg/d) reduces the 
      expression of proinflammatory cytokines after myocardial infarction, but does not 
      affect post-infarct cardiac remodeling and cardiac function.
FAU - Adamek, Anna
AU  - Adamek A
AD  - Medizinische Klinik und Poliklinik I der Universität Würzburg, Josef 
      Schneider-Strasse 2, 97080 Würzburg, Germany.
FAU - Hu, Kai
AU  - Hu K
FAU - Bayer, Barbara
AU  - Bayer B
FAU - Wagner, Helga
AU  - Wagner H
FAU - Ertl, Georg
AU  - Ertl G
FAU - Bauersachs, Johann
AU  - Bauersachs J
FAU - Frantz, Stefan
AU  - Frantz S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070308
PL  - Germany
TA  - Basic Res Cardiol
JT  - Basic research in cardiology
JID - 0360342
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/*pharmacology/therapeutic use
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Collagen/metabolism
MH  - Coronary Vessels/surgery
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Infusion Pumps, Implantable
MH  - Interleukin-1beta/metabolism
MH  - Ligation
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Myocardial Infarction/*drug therapy/metabolism/pathology/physiopathology
MH  - Myocardium/metabolism
MH  - Organ Size/drug effects
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Ventricular Function, Left/*drug effects
MH  - Ventricular Pressure/drug effects
MH  - Ventricular Remodeling/*drug effects
EDAT- 2007/03/07 09:00
MHDA- 2007/10/19 09:00
CRDT- 2007/03/07 09:00
PHST- 2006/12/16 00:00 [received]
PHST- 2007/02/16 00:00 [accepted]
PHST- 2007/02/12 00:00 [revised]
PHST- 2007/03/07 09:00 [pubmed]
PHST- 2007/10/19 09:00 [medline]
PHST- 2007/03/07 09:00 [entrez]
AID - 10.1007/s00395-007-0647-2 [doi]
PST - ppublish
SO  - Basic Res Cardiol. 2007 Jul;102(4):334-40. doi: 10.1007/s00395-007-0647-2. Epub 
      2007 Mar 8.

PMID- 9727553
OWN - NLM
STAT- MEDLINE
DCOM- 19980917
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 98
IP  - 8
DP  - 1998 Aug 25
TI  - Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased 
      activity in combination with aspirin.
PG  - 813-20
AB  - BACKGROUND: Inhibition of platelet aggregation by preventing the binding of 
      fibrinogen to glycoprotein (GP) IIb/IIIa on activated platelets results in 
      antithrombotic activity. We report on the antithrombotic effect of xemilofiban 
      (SC-54684A), an oral GP IIb/IIIa antagonist, administered alone or with aspirin 
      (ASA) in an acute thrombosis model. METHODS AND RESULTS: Conscious dogs were 
      treated with xemilofiban (1.25, 2.5, 5.0, or 6 mg/kg, n=6); low-dose (LD, 81 mg) 
      ASA, n=7; high-dose (HD, 162 mg) ASA, n=6; xemilofibran 1.25 mg/kg plus LD ASA, 
      n=6; xemilofibran 1.25 mg/kg plus HD ASA, n=6; or placebo, n=7. Dogs were 
      anesthetized 60 minutes later, and the effects of the treatments were evaluated 
      after electrolytic injury (250 microA for 180 minutes) in the left circumflex 
      coronary artery. Bleeding time (BT) was assessed in a separate study. Incidence 
      of thrombosis was reduced (P<0.05) by xemilofiban > or =2.5 mg/kg, HD ASA, or 
      xemilofiban 1.25 mg/kg plus HD ASA compared with placebo. Xemilofiban > or =2.5 
      mg/kg or xemilofiban 1.25 mg/kg plus HD ASA significantly increased time to 
      occlusion, inhibited ex vivo platelet aggregation to collagen >90%, and prevented 
      or decreased (P<0.05) cyclic flow variations (CFVs) compared with placebo. BT was 
      increased (P<0.05) with xemilofiban > or =2.5 mg/kg but not with xemilofiban 1.25 
      mg/kg plus HD ASA. CONCLUSIONS: Xemilofiban > or =2.5 mg/kg, HD ASA, or 
      xemilofiban 1.25 mg/kg plus HD ASA significantly reduced the incidence of 
      thrombosis. These doses of xemilofiban or xemilofiban 1.25 mg/kg plus HD ASA 
      increased time to occlusion, inhibited ex vivo platelet aggregation by >90%, and 
      prevented or reduced CFVs. Xemilofiban > or =2.5 mg/kg but not xemilofiban 1.25 
      mg/kg plus HD ASA significantly increased BT.
FAU - Frederick, L G
AU  - Frederick LG
AD  - Thrombosis Research Department, Searle, Skokie, Ill, USA.
FAU - Suleymanov, O D
AU  - Suleymanov OD
FAU - Szalony, J A
AU  - Szalony JA
FAU - Taite, B B
AU  - Taite BB
FAU - Salyers, A K
AU  - Salyers AK
FAU - King, L W
AU  - King LW
FAU - Feigen, L P
AU  - Feigen LP
FAU - Nicholson, N S
AU  - Nicholson NS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Benzamidines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - P614JI3IYK (xemilofiban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Arterial Occlusive Diseases/prevention & control
MH  - Aspirin/*therapeutic use
MH  - Benzamidines/*therapeutic use
MH  - Binding Sites
MH  - Dogs
MH  - Drug Evaluation, Preclinical
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Electric Stimulation
MH  - Female
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Templates, Genetic
MH  - Thrombosis/*drug therapy
EDAT- 1998/09/04 00:00
MHDA- 1998/09/04 00:01
CRDT- 1998/09/04 00:00
PHST- 1998/09/04 00:00 [pubmed]
PHST- 1998/09/04 00:01 [medline]
PHST- 1998/09/04 00:00 [entrez]
AID - 10.1161/01.cir.98.8.813 [doi]
PST - ppublish
SO  - Circulation. 1998 Aug 25;98(8):813-20. doi: 10.1161/01.cir.98.8.813.

PMID- 16810619
OWN - NLM
STAT- MEDLINE
DCOM- 20060825
LR  - 20161124
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 32
IP  - 4 Pt 2
DP  - 2006 Jun
TI  - Update on diagnosis and management of essential thrombocythemia.
PG  - 430-6
AB  - Patients with essential thrombocythemia carry a high risk for thromboembolic and 
      bleeding events but they have an almost normal life expectancy. A careful 
      evaluation of the medical history and an exact diagnosis is mandatory to estimate 
      each patient's risk for morbidity and to choose the most appropriate treatment 
      measure. In patients with the need of cytoreductive therapy, the benefits of 
      therapy have to outweigh the potential risks of drug toxicities. Hydroxyurea is 
      the most useful cytoreductive drug for elderly patients; in younger persons, 
      interferon alpha or anagrelide may be the drugs of choice. The combination of 
      anagrelide with acetylsalicylic acid may be contraindicated in patients with a 
      history of bleeding.
FAU - Gisslinger, Heinz
AU  - Gisslinger H
AD  - Department of Internal Medicine I, Division of Hematology and Blood Coagulation, 
      Medical University of Vienna, Vienna, Austria. heinz.gisslinger@meduniwien.ac.at
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Interferon-alpha)
RN  - 0 (Quinazolines)
RN  - K9X45X0051 (anagrelide)
RN  - R16CO5Y76E (Aspirin)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Age Factors
MH  - Antineoplastic Agents/antagonists & inhibitors/therapeutic use
MH  - Aspirin/antagonists & inhibitors/therapeutic use
MH  - Drug Antagonism
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Hydroxyurea/therapeutic use
MH  - Interferon-alpha/therapeutic use
MH  - Life Expectancy
MH  - Male
MH  - Quinazolines/antagonists & inhibitors/therapeutic use
MH  - Risk Factors
MH  - Thrombocythemia, Essential/complications/*diagnosis/*drug therapy
RF  - 38
EDAT- 2006/07/01 09:00
MHDA- 2006/08/26 09:00
CRDT- 2006/07/01 09:00
PHST- 2006/07/01 09:00 [pubmed]
PHST- 2006/08/26 09:00 [medline]
PHST- 2006/07/01 09:00 [entrez]
AID - 10.1055/s-2006-942764 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):430-6. doi: 10.1055/s-2006-942764.

PMID- 6647870
OWN - NLM
STAT- MEDLINE
DCOM- 19840127
LR  - 20190825
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 26
IP  - 2
DP  - 1983 Aug
TI  - Influence of treatment with prostaglandin synthesis inhibitor or progesterone on 
      cytotoxic activity and progesterone binding capacity of lymphocytes during 
      pregnancy.
PG  - 187-95
AB  - Cytotoxic activity and progesterone binding capacity of lymphocytes obtained from 
      women with threatened preterm labour were tested before and during treatment with 
      acetylsalicylic acid or 17-hydroxyprogesterone caproate. Cytotoxic activity of 
      the lymphocytes significantly decreased (p less than 0.001), while progesterone 
      binding capacity significantly increased (p less than 0.001) following the 
      introduction of the treatments. No changes in these parameters were observed on 
      lymphocytes of untreated women. Preterm delivery occurred more frequently among 
      untreated women than among women treated with acetylsalicylic acid (p less than 
      0.01) or those treated with 17-hydroxyprogesterone caproate (p less than 0.05).
FAU - Szekeres-Bartho, J
AU  - Szekeres-Bartho J
FAU - Csernus, V
AU  - Csernus V
FAU - Hadnagy, J
AU  - Hadnagy J
FAU - Pacsa, A S
AU  - Pacsa AS
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Hydroxyprogesterones)
RN  - 4G7DS2Q64Y (Progesterone)
RN  - 68-96-2 (17-alpha-Hydroxyprogesterone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 17-alpha-Hydroxyprogesterone
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cytotoxicity, Immunologic/*drug effects
MH  - Female
MH  - Humans
MH  - Hydroxyprogesterones/*pharmacology/therapeutic use
MH  - Lymphocytes/*drug effects/immunology/metabolism
MH  - Obstetric Labor, Premature/prevention & control
MH  - Pregnancy/*drug effects
MH  - Progesterone/blood
EDAT- 1983/08/01 00:00
MHDA- 1983/08/01 00:01
CRDT- 1983/08/01 00:00
PHST- 1983/08/01 00:00 [pubmed]
PHST- 1983/08/01 00:01 [medline]
PHST- 1983/08/01 00:00 [entrez]
AID - 0090-6980(83)90087-4 [pii]
AID - 10.1016/0090-6980(83)90087-4 [doi]
PST - ppublish
SO  - Prostaglandins. 1983 Aug;26(2):187-95. doi: 10.1016/0090-6980(83)90087-4.

PMID- 10763205
OWN - NLM
STAT- MEDLINE
DCOM- 20000427
LR  - 20201208
IS  - 0248-8663 (Print)
IS  - 0248-8663 (Linking)
VI  - 21 Suppl 1
DP  - 2000 Mar
TI  - [Digestive complications of aspirin].
PG  - 50s-59s
AB  - INTRODUCTION: This review focuses on aspirin-related gastrointestinal 
      side-effects and the mechanism by which aspirin causes gastrointestinal damage. 
      CURRENT KNOWLEDGE AND KEY POINTS: Aspirin causes direct gastric damage by topical 
      irritant effects and indirect damage via systemic inhibition of cyclooxygenase 
      synthesis and microcirculation injury. The question of a possible synergistic 
      relation between the presence of Helicobacter pylori infection and aspirin use on 
      gastric damage is not resolved. The pathogenesis of small intestinal and colonic 
      damage is less well understood; an increase in intestinal permeability and free 
      radical synthesis are suggested. Gastric damage predominates. Gastroduodenal 
      lesions from aspirin have been documented in endoscopy studies. The lesions occur 
      rapidly, even for low-dose aspirin. The association of aspirin consumption with 
      upper gastrointestinal bleeding has been well established. The main risk factors 
      are advanced age, concomitant use of nonsteroidal antiinflammatory drugs and 
      history of ulcer. Low-dose aspirin are associated with increased risk of 
      gastrointestinal bleeding and this risk is dose-dependant. Chronic aspirin 
      consumption can cause iron deficiency anaemia. Uncomplicated gastric ulcer (but 
      not uncomplicated duodenal ulcer) is associated with aspirin use, with relative 
      risk 3. Other upper gastrointestinal complications have been reported: stenosis 
      and perforation. Aspirin can also damage other areas of the gastrointestinal 
      tract. Oesophageal injuries (oesophagitis and stricture) have been reported. 
      Aspirin is associated with variceal bleeding episodes in patients with cirrhosis. 
      The adverse effects of aspirin on the small bowel are perforation, bleeding, 
      increasing permeability. The adverse effects of aspirin on the large intestine 
      are perforation, bleeding, collagenous colitis and anorectal stenosis with 
      suppositories containing aspirin. Direct clinical data regarding prophylaxis with 
      co-administration of a protective drug are not yet available for aspirin. FUTURE 
      PROSPECTS AND PROJECTS: Patients should be made aware of adverse gastrointestinal 
      effects due to aspirin. Further studies regarding prophylactic therapy of 
      low-dose aspirin induced gastroduodenal lesions, which identify a subset of 
      patients who may be at higher risk than the low-dose aspirin population as a 
      whole, are warranted.
FAU - Hochain, P
AU  - Hochain P
AD  - Groupe de recherche sur l'appareil digestif, hôpital Charles-Nicolle, Rouen, 
      France.
FAU - Capet, C
AU  - Capet C
FAU - Colin, R
AU  - Colin R
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Complications digestives de l'aspirine.
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cyclooxygenase Inhibitors/administration & dosage/*adverse effects
MH  - Digestive System/*drug effects
MH  - Esophagitis/chemically induced
MH  - Fibrinolytic Agents/administration & dosage/*adverse effects
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Helicobacter Infections/complications
MH  - Helicobacter pylori
MH  - Humans
MH  - Odds Ratio
MH  - Peptic Ulcer/chemically induced/complications/etiology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk Factors
RF  - 72
EDAT- 2000/04/14 09:00
MHDA- 2000/04/29 09:00
CRDT- 2000/04/14 09:00
PHST- 2000/04/14 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/04/14 09:00 [entrez]
AID - S0248-8663(00)88725-1 [pii]
AID - 10.1016/s0248-8663(00)88725-1 [doi]
PST - ppublish
SO  - Rev Med Interne. 2000 Mar;21 Suppl 1:50s-59s. doi: 10.1016/s0248-8663(00)88725-1.

PMID- 11757226
OWN - NLM
STAT- MEDLINE
DCOM- 20020215
LR  - 20131121
IS  - 1426-9686 (Print)
IS  - 1426-9686 (Linking)
VI  - 11
IP  - 62
DP  - 2001 Aug
TI  - [Prenatal effects of acetylsalicylic acid].
PG  - 182-6
AB  - Acetylsalicylic acid is frequently ingested over-the-counter (OTC) drug, either 
      as single or in combination with other drugs. It has been used in various 
      diseases including that complicated pregnancy, such as preeclampsia and fetal 
      grow retardation. Analgesic, antipyretic, especially anti-inflammatory activity 
      occurs in high therapeutic doses. In low-dose acetylsalicylic acid is used to 
      block production of thromboxane A2. Big epidemiological data suggest that 
      low-dose of acetylsalicylic acid, even taken chronically, is safe for mother and 
      fetus. However, animal and various human data have shown that high doses of the 
      drug could produce different congenital malformations. The current literature 
      suggests that acetylsalicylic acid should be given in pregnancy only if the 
      potential benefit justifies the potential risk to the fetus. Anti-inflammatory 
      doses should be stopped in the third trimester of gestation or given if the drug 
      is needed in life-threatening situation or for serious disease for which safer 
      drugs can not be used or are ineffective.
FAU - Burdan, F
AU  - Burdan F
AD  - Pracownia Teratologii Doświadczalnej, Katedrze i Zakładzie Anatomii Prawidłowej 
      Człowieka Akademii Medycznej w Lublinie. frank@tkt.net.pl
LA  - pol
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Ocena bezpieczeństwa stosowania kwasu acetylosalicylowego w okresie prenatalnym.
PL  - Poland
TA  - Pol Merkur Lekarski
JT  - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
JID - 9705469
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced/*etiology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Humans
MH  - Pregnancy
RF  - 64
EDAT- 2002/01/05 10:00
MHDA- 2002/02/16 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/02/16 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
PST - ppublish
SO  - Pol Merkur Lekarski. 2001 Aug;11(62):182-6.

PMID- 1702552
OWN - NLM
STAT- MEDLINE
DCOM- 19910214
LR  - 20161123
IS  - 0035-1040 (Print)
IS  - 0035-1040 (Linking)
VI  - 76
IP  - 4
DP  - 1990
TI  - [Prevention of thromboembolic disease and post-transfusional complications using 
      normovolemic hemodilution in arthroplasty surgery of the hip].
PG  - 267-71
AB  - A prospective randomized study was conducted to evaluate the effect of moderate 
      normovolemic haemodilution in arthroplastic surgery of the hip, to prevent 
      postoperative deep vein thrombosis and the need for postoperative transfusion. 
      The patients (n = 151) were divided into three groups: 48 patients received 
      Dextran + Acetylsalicylic Acid as a prevention of the thromboembolic 
      complications (Group I). 57 patients received a low dose of Heparin according to 
      the Kakkar protocol (Group II). 52 patients were operated under Haemodilution 
      (Group III). In Group I and II homologous blood transfusions were necessary in 
      83% of the cases, and in two cases posttransfusional hepatitis were observed. In 
      Group III haemodilution avoided the use of homologous blood. Therefore of the 
      three methods this study showed that haemodilution is the best way to prevent 
      postoperative thrombo-embolism, significantly more effective than Heparin and 
      Dextran, in arthroplastic hip surgery.
FAU - Vara Thorbeck, R
AU  - Vara Thorbeck R
AD  - Chaire de chirurgie, Hôpital Universitaire, Grenade, Espagne.
FAU - Rosell Pradas, J
AU  - Rosell Pradas J
FAU - Mekinassi, K L
AU  - Mekinassi KL
FAU - Prados Olleta, N
AU  - Prados Olleta N
FAU - Guerrero Fernandez-Marcote, J A
AU  - Guerrero Fernandez-Marcote JA
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Prévention de la maladie thrombo-embolique et des complications 
      post-transfusionnelles par l'hémodilution normovolémique en chirurgie 
      arthroplastique de la hanche.
PL  - France
TA  - Rev Chir Orthop Reparatrice Appar Mot
JT  - Revue de chirurgie orthopedique et reparatrice de l'appareil moteur
JID - 1272427
RN  - 0 (Dextrans)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Blood Transfusion, Autologous
MH  - Dextrans/therapeutic use
MH  - Hemodilution/*methods
MH  - Heparin/therapeutic use
MH  - *Hip Prosthesis
MH  - Humans
MH  - Postoperative Complications/*prevention & control
MH  - Prospective Studies
MH  - Thromboembolism/*prevention & control
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Chir Orthop Reparatrice Appar Mot. 1990;76(4):267-71.

PMID- 794960
OWN - NLM
STAT- MEDLINE
DCOM- 19770226
LR  - 20190911
IS  - 0300-9130 (Print)
IS  - 0300-9130 (Linking)
VI  - 169
IP  - 2
DP  - 1976 Dec 30
TI  - [The effect of antiaggregating agents - acetylsalicylic acid (ASA) and 
      dipyridamol - on the rejection of allotransplanted canine kidneys in 
      presensitized animals (author's transl)].
PG  - 109-22
AB  - The effect of antiaggregating agents - acetylsalicyclic acid (ASA) and 
      dipyridamol - on the rejection of allotransplanted canine kidneys in 
      presensitized animals were studied. Blood flow dropped more markedly in the 
      control group than in the group treated with ASA and dipyridamol. 24 hours after 
      transplantation the blood flow in this group was significantly higher than in the 
      control group (p 2,5 %) and in the third group treated with dipyridamol alone. 
      The cellular rejection started earlier and was more pronounced in the control 
      group. Only in this group vascular rejection and microthrombi were demonstrated. 
      Urine output ceased 24 to 60 hours after transplantation. The immunosuppressive, 
      antiphlogistic and platelet antiaggregating effect of the combined ASA and 
      dipyridamol therapy is thought to be responsible for the better results in this 
      group. In this experimental model the combined treatment of ASA and dipyridamol 
      results in a later onset of cellular rejection, in better blood-flow of the 
      kidney and later onset of anuria.
FAU - Wagner, W
AU  - Wagner W
FAU - Grether, U
AU  - Grether U
FAU - Maar, K
AU  - Maar K
FAU - Jacobi, E
AU  - Jacobi E
FAU - Huth, F
AU  - Huth F
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Der Einfluss von Azetylsalizylasäure und Dipridamol auf die Absotossung 
      allotransplantierter Hunderieren bei präsensibilisierten Empfängern. Eine 
      tierexperimentelle Studie.
PL  - Germany
TA  - Res Exp Med (Berl)
JT  - Research in experimental medicine. Zeitschrift fur die gesamte experimentelle 
      Medizin einschliesslich experimenteller Chirurgie
JID - 0324736
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anuria
MH  - Aspirin/*pharmacology
MH  - Dipyridamole/*pharmacology
MH  - Dogs
MH  - Female
MH  - Graft Rejection/*drug effects
MH  - Kidney/blood supply
MH  - *Kidney Transplantation
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Regional Blood Flow/drug effects
MH  - Time Factors
MH  - Transplantation, Homologous
EDAT- 1976/12/30 00:00
MHDA- 1976/12/30 00:01
CRDT- 1976/12/30 00:00
PHST- 1976/12/30 00:00 [pubmed]
PHST- 1976/12/30 00:01 [medline]
PHST- 1976/12/30 00:00 [entrez]
AID - 10.1007/BF01851172 [doi]
PST - ppublish
SO  - Res Exp Med (Berl). 1976 Dec 30;169(2):109-22. doi: 10.1007/BF01851172.

PMID- 10536315
OWN - NLM
STAT- MEDLINE
DCOM- 19991117
LR  - 20190722
IS  - 0016-5107 (Print)
IS  - 0016-5107 (Linking)
VI  - 50
IP  - 5
DP  - 1999 Nov
TI  - Relationship of low-dose aspirin to GI injury and occult bleeding: a pilot study.
PG  - 618-22
AB  - BACKGROUND: Low-dose aspirin is commonly used in patients with cardiovascular 
      disease. However, little is known about the effect of aspirin on occult blood 
      loss caused by gastrointestinal injury. Therefore, we studied endoscopic injury 
      and fecal occult blood loss in patients ingesting different quantities of 
      low-dose aspirin. METHODS: Forty healthy volunteers were enrolled in a 
      randomized, double-blind, prospective, pilot endoscopic study. Each volunteer 
      underwent 30 days of treatment with daily aspirin 30 mg, 81 mg, 325 mg, or 
      placebo. Subjects completed fecal occult blood test cards before and at the end 
      of treatment of two types: guaiac impregnated (Hemoccult and Hemoccult SENSA) and 
      immunochemical (HemeSelect and FlexSure OBT). Each volunteer underwent upper 
      endoscopy at baseline and after completing 30 days of study medication. RESULTS: 
      Aspirin did not induce significant injury as determined by endoscopy when 
      compared with placebo. Six of 30 volunteers taking aspirin developed erosions, 
      whereas 1 of 10 subjects on placebo developed a new erosion (p = 0.66). Aspirin 
      (325 mg) was associated with a higher mean symptom score than the lower aspirin 
      dosages and the placebo group (p = 0.12). Only one subject taking aspirin (325 
      mg) had fecal occult blood on a single HemeSelect card. No subject had a positive 
      fecal occult blood test with Hemoccult II, Hemoccult II SENSA, or FlexSure OBT 
      cards. CONCLUSIONS: Aspirin in dosages commonly used for cardiovascular 
      prophylaxis does not generally cause significant gastric or duodenal mucosal 
      endoscopic lesions. In the absence of frank ulceration, low-dose aspirin does not 
      result in positive fecal occult blood tests. Low-dose aspirin should not 
      interfere with fecal occult blood testing and probably should not be stopped 
      during stool collection.
FAU - Greenberg, P D
AU  - Greenberg PD
AD  - Division of Gastroenterology, Hepatology and Clinical Nutrition, San Francisco 
      General Hospital, Department of Medicine, University of California, San 
      Francisco, California, USA.
FAU - Cello, J P
AU  - Cello JP
FAU - Rockey, D C
AU  - Rockey DC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Gastrointest Endosc
JT  - Gastrointestinal endoscopy
JID - 0010505
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Biopsy
MH  - Chi-Square Distribution
MH  - Digestive System/*drug effects/pathology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Endoscopy, Digestive System/methods/statistics & numerical data
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/*adverse effects
MH  - Helicobacter pylori/isolation & purification
MH  - Humans
MH  - Male
MH  - *Occult Blood
MH  - Pilot Projects
MH  - Pyloric Antrum/microbiology/pathology
MH  - Reference Values
EDAT- 1999/10/28 00:00
MHDA- 1999/10/28 00:01
CRDT- 1999/10/28 00:00
PHST- 1999/10/28 00:00 [pubmed]
PHST- 1999/10/28 00:01 [medline]
PHST- 1999/10/28 00:00 [entrez]
AID - S0016-5107(99)80008-X [pii]
AID - 10.1016/s0016-5107(99)80008-x [doi]
PST - ppublish
SO  - Gastrointest Endosc. 1999 Nov;50(5):618-22. doi: 10.1016/s0016-5107(99)80008-x.

PMID- 1001981
OWN - NLM
STAT- MEDLINE
DCOM- 19770226
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 17
IP  - 11
DP  - 1976 Nov
TI  - Effect of paracetamol (acetaminophen) on gastric ionic fluxes and potential 
      difference in man.
PG  - 916-9
AB  - Paracetamol has replaced aspirin as the analgesic of choice in many situations. 
      The major reason is the damaging effect of aspirin on gastric mucosa. Alterations 
      in gastric ionic fluxes and potential difference provide measures of 
      aspirin-induced structural damage. We studied the effect of large doses of 
      paracetamol (acetaminophen 2-0 g) on gastric ionic fluxes in man. In addition, 
      the effect of 2-0 g paracetamol on gastric potential difference was compared with 
      that of 600 mg aspirin. In contrast with salicylates, paracetamol caused no 
      significant alteration in movement of H+ and Na+ ions over control periods. 
      Aspirin causes a significant fall in transmucosal potential difference (PD) 
      across gastric mucosa of 15 mv, while paracetamol cuased no significant change. 
      Paracetamol in a dose four times that recommended does not alter gastric ionic 
      fluxes or potential difference. These studies support choice of paracetamol as 
      analgesic over aspirin where damage to gastric mucosa may be critical.
FAU - Ivey, K J
AU  - Ivey KJ
FAU - Settree, P
AU  - Settree P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 362O9ITL9D (Acetaminophen)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Adolescent
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Depression, Chemical
MH  - Gastric Mucosa/drug effects/*metabolism
MH  - Humans
MH  - Membrane Potentials/drug effects
MH  - Sodium/metabolism
PMC - PMC1411215
EDAT- 1976/11/01 00:00
MHDA- 1976/11/01 00:01
CRDT- 1976/11/01 00:00
PHST- 1976/11/01 00:00 [pubmed]
PHST- 1976/11/01 00:01 [medline]
PHST- 1976/11/01 00:00 [entrez]
AID - 10.1136/gut.17.11.916 [doi]
PST - ppublish
SO  - Gut. 1976 Nov;17(11):916-9. doi: 10.1136/gut.17.11.916.

PMID- 35762143
OWN - NLM
STAT- MEDLINE
DCOM- 20220629
LR  - 20220716
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Print)
IS  - 1011-8934 (Linking)
VI  - 37
IP  - 25
DP  - 2022 Jun 27
TI  - Outcomes of Empirical Treatment With Intravenous Immunoglobulin G Combined With 
      Low-Dose Aspirin in Women With Unexplained Recurrent Pregnancy Loss.
PG  - e200
LID - 10.3346/jkms.2022.37.e200 [doi]
LID - e200
AB  - BACKGROUND: To assess the clinical efficacy of intravenous immunoglobulin G 
      (IVIG) administration combined with low-dose aspirin in women with unexplained 
      recurrent pregnancy loss (RPL). METHODS: We retrospectively analyzed the medical 
      records of patients who had been diagnosed with unexplained RPL and treated with 
      IVIG and low-dose aspirin between January 2000 and March 2020 at Asan Medical 
      Center. We analyzed pregnancy outcomes and their association with the percentage 
      of natural killer (NK) cells. RESULTS: The study analyzed a total of 93 patients 
      and 113 natural and assisted reproductive technology pregnancy cycles. The live 
      birth rate per cycle was 73.5% (83/113), and the term delivery rate was 86.7% 
      (72/83). The live birth rate was high regardless of the type of RPL, method of 
      pregnancy, timing of IVIG treatment, and presence or absence of autoantibodies. 
      In addition, the live birth rate was significantly higher in patients who 
      received IVIG more than once, compared with patients who received IVIG only once 
      (77.8% vs. 42.9%, P = 0.006). There was no significant association between the NK 
      cell counts and live birth rate (65.5% in the group with NK cell < 12%, and 69.7% 
      in that with NK cell ≥ 12%, P = 0.725). Among all patients, 87.6% had no 
      complications, and there were no congenital malformation among newborn babies. 
      CONCLUSION: IVIG combined with low-dose aspirin treatment showed favorable 
      pregnancy outcomes regardless of the patient's NK cell counts (%).
CI  - © 2022 The Korean Academy of Medical Sciences.
FAU - Kim, Ju Hee
AU  - Kim JH
AUID- ORCID: 0000-0001-5713-7743
AD  - Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, 
      Asan Medical Center, Seoul, Korea.
FAU - Kim, Sung Hoon
AU  - Kim SH
AUID- ORCID: 0000-0003-2567-2092
AD  - Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, 
      Asan Medical Center, Seoul, Korea. kimsung@amc.seoul.kr.
FAU - Yang, Nuri
AU  - Yang N
AUID- ORCID: 0000-0002-1458-2262
AD  - Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, 
      Asan Medical Center, Seoul, Korea.
FAU - Ko, Yuri
AU  - Ko Y
AUID- ORCID: 0000-0002-7579-6571
AD  - Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, 
      Asan Medical Center, Seoul, Korea.
FAU - Lee, Sa Ra
AU  - Lee SR
AUID- ORCID: 0000-0002-7890-8348
AD  - Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, 
      Asan Medical Center, Seoul, Korea.
FAU - Chae, Hee Dong
AU  - Chae HD
AUID- ORCID: 0000-0003-0129-9422
AD  - Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, 
      Asan Medical Center, Seoul, Korea.
LA  - eng
PT  - Journal Article
DEP - 20220627
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abortion, Habitual/drug therapy/prevention & control
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Immunoglobulin G
MH  - *Immunoglobulins, Intravenous
MH  - Infant, Newborn
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Retrospective Studies
PMC - PMC9239843
OTO - NOTNLM
OT  - Intravenous Immunoglobulin
OT  - Live Birth
OT  - Natural Killer Cell
OT  - Recurrent Pregnancy Loss
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2022/06/29 06:00
MHDA- 2022/06/30 06:00
CRDT- 2022/06/28 03:13
PHST- 2022/01/05 00:00 [received]
PHST- 2022/05/20 00:00 [accepted]
PHST- 2022/06/28 03:13 [entrez]
PHST- 2022/06/29 06:00 [pubmed]
PHST- 2022/06/30 06:00 [medline]
AID - 37.e200 [pii]
AID - 10.3346/jkms.2022.37.e200 [doi]
PST - epublish
SO  - J Korean Med Sci. 2022 Jun 27;37(25):e200. doi: 10.3346/jkms.2022.37.e200.

PMID- 23786894
OWN - NLM
STAT- MEDLINE
DCOM- 20140617
LR  - 20151119
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 132
IP  - 2
DP  - 2013 Aug
TI  - Open-label, randomized study of the effect of rivaroxaban with or without 
      acetylsalicylic acid on thrombus formation in a perfusion chamber.
PG  - 240-7
LID - S0049-3848(13)00211-9 [pii]
LID - 10.1016/j.thromres.2013.05.019 [doi]
AB  - INTRODUCTION: Rivaroxaban, a direct factor Xa inhibitor, has demonstrated 
      effectiveness for the management of both venous and arterial thrombosis. This 
      study was designed to investigate the antithrombotic effect of rivaroxaban, with 
      or without acetylsalicylic acid (ASA), in an ex vivo perfusion chamber at both 
      low and high shear rates. MATERIALS AND METHODS: Healthy subjects (N=51) were 
      enrolled in a randomized, crossover (rivaroxaban 5, 10 or 20mg with or without 
      ASA), and parallel-group (compared with ASA plus clopidogrel) study. Thrombi 
      formed on pig aorta strips were measured after a 5-minute perfusion at low and 
      high shear rates with blood from the subjects by measuring D-dimer concentration 
      (for fibrin deposition) and P-selectin content (for platelet deposition). 
      RESULTS: ASA alone had no impact on thrombus D-dimer levels, whereas rivaroxaban 
      alone at peak concentrations decreased D-dimer levels by 9%, 84% and 65% at low 
      shear rate and 37%, 73% and 74% at high shear rate after doses of 5, 10 and 20mg, 
      respectively. Steady-state ASA plus rivaroxaban 5mg caused a greater reduction in 
      D-dimer levels (63%) than monotherapy at low shear rate. Co-administration of ASA 
      with clopidogrel was associated with a 30% decrease in D-dimer levels at low 
      shear rate and a 14% decrease at high shear rate. No conclusive effect on 
      P-selectin content was observed across the treatment groups. CONCLUSIONS: 
      Rivaroxaban dose-dependently inhibited ex vivo thrombus formation under low and 
      high shear rates. Co-administration of ASA had an additional effect on the 
      antithrombotic action of low-dose rivaroxaban.
CI  - Copyright © 2013 Elsevier Ltd. All rights reserved.
FAU - Wolzt, Michael
AU  - Wolzt M
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria. Electronic address: michael.wolzt@meduniwien.ac.at.
FAU - Gouya, Ghazaleh
AU  - Gouya G
FAU - Kapiotis, Stylianos
AU  - Kapiotis S
FAU - Becka, Michael
AU  - Becka M
FAU - Mueck, Wolfgang
AU  - Mueck W
FAU - Kubitza, Dagmar
AU  - Kubitza D
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130618
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Morpholines)
RN  - 0 (Thiophenes)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Morpholines/pharmacology/*therapeutic use
MH  - Platelet Aggregation/drug effects
MH  - Rivaroxaban
MH  - Swine
MH  - Thiophenes/pharmacology/*therapeutic use
MH  - Thrombosis/blood/drug therapy
MH  - Venous Thromboembolism/blood/*drug therapy/pathology
MH  - Young Adult
OTO - NOTNLM
OT  - ACS
OT  - ANCOVA
OT  - ASA
OT  - Acetylsalicylic acid
OT  - Arterial thrombosis
OT  - C(max)
OT  - C(trough)
OT  - CI
OT  - CV
OT  - ETP
OT  - LD
OT  - LS
OT  - PT
OT  - Rivaroxaban
OT  - SD
OT  - VKA
OT  - Venous thrombosis
OT  - aPTT
OT  - acetylsalicylic acid
OT  - activated partial thromboplastin time
OT  - acute coronary syndrome
OT  - analysis of covariance
OT  - coefficient of variation
OT  - confidence interval
OT  - endogenous thrombin potential
OT  - least squares
OT  - loading dose
OT  - maximum plasma concentration
OT  - minimum plasma concentration
OT  - od
OT  - once daily
OT  - prothrombin time
OT  - standard deviation
OT  - vitamin K antagonist
EDAT- 2013/06/22 06:00
MHDA- 2014/06/18 06:00
CRDT- 2013/06/22 06:00
PHST- 2013/02/20 00:00 [received]
PHST- 2013/05/10 00:00 [revised]
PHST- 2013/05/21 00:00 [accepted]
PHST- 2013/06/22 06:00 [entrez]
PHST- 2013/06/22 06:00 [pubmed]
PHST- 2014/06/18 06:00 [medline]
AID - S0049-3848(13)00211-9 [pii]
AID - 10.1016/j.thromres.2013.05.019 [doi]
PST - ppublish
SO  - Thromb Res. 2013 Aug;132(2):240-7. doi: 10.1016/j.thromres.2013.05.019. Epub 2013 
      Jun 18.

PMID- 17525499
OWN - NLM
STAT- MEDLINE
DCOM- 20071105
LR  - 20161124
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 145
DP  - 2007 Apr
TI  - [Effectiveness of treatment and prophylactic methods in persons with ischemic 
      heart disease risk factors].
PG  - 45-9
AB  - The article investigates the effectiveness of prophylactic measures in persons 
      with risk factors of coronary arterial disease (RF CAD). For this reason 
      unorganized population (aged 30-59) was examined and CAD was diagnosed by 
      standard means of epidemiologic methods. The persons with RF were revealed. 
      Functional state of hemostasis system, as well as definition of total blood 
      cholesterol level was performed by two brevity screening systems of investigation 
      (initial and second-screening systems). Seven years of prospective research 
      proved the effectiveness of proposed prophylactic methods in men and women with 
      CAD RF. Complex prophylactic treatment considerably reduced the possibility of 
      development CAD and stroke, mortality.
FAU - Kakuliia, M Sh
AU  - Kakuliia MSh
LA  - rus
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Exercise
MH  - Feeding Behavior
MH  - Female
MH  - Humans
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*drug therapy/mortality/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Prospective Studies
MH  - Risk Factors
MH  - Survival Rate
MH  - Ticlopidine/administration & dosage/*therapeutic use
EDAT- 2007/05/26 09:00
MHDA- 2007/11/06 09:00
CRDT- 2007/05/26 09:00
PHST- 2007/05/26 09:00 [pubmed]
PHST- 2007/11/06 09:00 [medline]
PHST- 2007/05/26 09:00 [entrez]
PST - ppublish
SO  - Georgian Med News. 2007 Apr;(145):45-9.

PMID- 2906299
OWN - NLM
STAT- MEDLINE
DCOM- 19890329
LR  - 20181217
IS  - 0338-1684 (Print)
IS  - 0338-1684 (Linking)
VI  - 14
IP  - 4
DP  - 1988 Jul-Aug
TI  - Studies on the mechanism of salicylate-induced increase of insulin secretion in 
      man.
PG  - 431-6
AB  - Salicylate compounds are known to increase basal and stimulated insulin secretion 
      in man. In our studies, infusion of lysine acetylsalicylate (72 mg/min) increased 
      basal insulin levels and amplified insulin responses to glucose (5 g i.v.), 
      arginine (5 g i.v.) and tolbutamide (1 g i.v.). Verapamil, an organic calcium 
      antagonist, did not modify LAS-induced increase of basal insulin levels, but 
      reduced the effect of LAS on glucose-induced insulin secretion. Calcitonin and 
      somatostatin, two agents that inhibit basal and glucose-stimulated insulin 
      secretion, inhibited the insulin response to glucose in presence of LAS infusion. 
      The ability of salicylate compounds to augment insulin secretion might be due to 
      multiple sites of action in the Beta-cells.
FAU - Giugliano, D
AU  - Giugliano D
AD  - Cattedra di Diabetologia e Dietoterapia, Facoltà di Medicina, Università di 
      Napoli, Italia.
FAU - Cozzolino, D
AU  - Cozzolino D
FAU - Ceriello, A
AU  - Ceriello A
FAU - Cerciello, T
AU  - Cerciello T
FAU - Varano, R
AU  - Varano R
FAU - Saccomanno, F
AU  - Saccomanno F
FAU - Torella, R
AU  - Torella R
LA  - eng
PT  - Journal Article
PL  - France
TA  - Diabete Metab
JT  - Diabete & metabolisme
JID - 7604157
RN  - 0 (Insulin)
RN  - 51110-01-1 (Somatostatin)
RN  - 9007-12-9 (Calcitonin)
RN  - 94ZLA3W45F (Arginine)
RN  - 982XCM1FOI (Tolbutamide)
RN  - CJ0O37KU29 (Verapamil)
RN  - IY9XDZ35W2 (Glucose)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Arginine/pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Calcitonin/pharmacology
MH  - Female
MH  - Glucose/pharmacology
MH  - Humans
MH  - Insulin/blood/*metabolism
MH  - Insulin Secretion
MH  - Kinetics
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Male
MH  - Reference Values
MH  - Somatostatin/pharmacology
MH  - Tolbutamide/pharmacology
MH  - Verapamil/pharmacology
EDAT- 1988/07/01 00:00
MHDA- 2000/03/11 09:00
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 2000/03/11 09:00 [medline]
PHST- 1988/07/01 00:00 [entrez]
PST - ppublish
SO  - Diabete Metab. 1988 Jul-Aug;14(4):431-6.

PMID- 7129246
OWN - NLM
STAT- MEDLINE
DCOM- 19821218
LR  - 20131121
IS  - 0015-5691 (Print)
IS  - 0015-5691 (Linking)
VI  - 79
IP  - 5
DP  - 1982 May
TI  - [Studies on the pharmacological bases of fetal toxicity of drugs. (I). Relation 
      of fetal toxicity and tissue concentration of acetylsalicylic acid with pyrogen 
      in pregnant rats].
PG  - 357-67
AB  - The mechanism for the enhancing effect of pyrogen (lipopolysaccharide, LPS) on 
      the fetal toxicity of acetylsalicylic acid (ASA) was studied in pregnant rats. 
      The lethality of ASA was significantly enhanced by LPS in male rats. The fetal 
      toxicity of ASA including fetal death, resorption, growth retardation, and 
      skeletal anomalies (wavy rib and asymmetry of sternebra) was slightly observed in 
      the dams that received a single dose of ASA (125 to 500 mg/kg, p.o.) on the 15th 
      day of gestation, but it was markedly increased by LPS (20 micrograms/kg, i.v.). 
      The enhancement of the toxicity of ASA by LPS was also observed in the maternal 
      body weight gain until term. The plasma concentrations of ASA and salicylic acid 
      (SA), the major metabolite of ASA, were increased by LPS. The tissue 
      concentrations of SA were also increased in the following order: placenta, brain, 
      fetus, uterus, liver and kidney. The ATP levels of placenta and fetus were not 
      influenced by ASA alone, but markedly decreased by both LPS and ASA.
FAU - Itami, T
AU  - Itami T
FAU - Kanoh, S
AU  - Kanoh S
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Yakurigaku Zasshi
JT  - Nihon yakurigaku zasshi. Folia pharmacologica Japonica
JID - 0420550
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Pyrogens)
RN  - 0 (Salicylates)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced/etiology
MH  - Adenosine Triphosphate/metabolism
MH  - Animals
MH  - Aspirin/metabolism/*toxicity
MH  - Body Weight/drug effects
MH  - Drug Synergism
MH  - Female
MH  - Fetus/*drug effects
MH  - Humans
MH  - Infant, Newborn
MH  - Lipopolysaccharides/pharmacology
MH  - Male
MH  - Maternal-Fetal Exchange
MH  - Pregnancy
MH  - Pyrogens/*pharmacology
MH  - Rats
MH  - Salicylates/blood
MH  - Salicylic Acid
MH  - Tissue Distribution
EDAT- 1982/05/01 00:00
MHDA- 1982/05/01 00:01
CRDT- 1982/05/01 00:00
PHST- 1982/05/01 00:00 [pubmed]
PHST- 1982/05/01 00:01 [medline]
PHST- 1982/05/01 00:00 [entrez]
PST - ppublish
SO  - Nihon Yakurigaku Zasshi. 1982 May;79(5):357-67.

PMID- 321487
OWN - NLM
STAT- MEDLINE
DCOM- 19770527
LR  - 20190823
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 17
IP  - 4
DP  - 1977 Apr
TI  - Application of nonparametric procedure for bioassay data to the evaluation of 
      analgesics in man.
PG  - 177-84
AB  - Parametric tests for bioassay data are commonly applied to scores of pain 
      intensity and relief for the assessment of potency ratios of analgesic drugs. It 
      has been demonstrated, however, that scores derived from semiquantitative scales 
      often deviate from normal distribution. In addition, when scores decrease as a 
      consequence of analgesic treatment, the variances may be nonhomogenous. Both 
      parametric and nonparametric procedures have been employed in this study for the 
      evaluation of results of a double-blind multicenter trial of the analgesic effect 
      of indoprofen and ASA (both drugs at three dose levels) and placebo in episiotomy 
      pain. There was a good agreement between potency ratios obtained with the two 
      assays. Peak PID appeared a less efficient means of estimating potency ratio than 
      other measurements such as SPID and TOTPAR. The nonparametric test for 
      quantitative bioassay appears to be a valid statistical procedure for evaluating 
      results of clinical trials, and it does not imply any assumptions as to the type 
      of distribution of the data.
FAU - Fuccella, L M
AU  - Fuccella LM
FAU - Corvi, G
AU  - Corvi G
FAU - Gorini, F
AU  - Gorini F
FAU - Mandelli, V
AU  - Mandelli V
FAU - Mascellani, G
AU  - Mascellani G
FAU - Nobili, F
AU  - Nobili F
FAU - Pedronetto, S
AU  - Pedronetto S
FAU - Ragni, N
AU  - Ragni N
FAU - Vandelli, I
AU  - Vandelli I
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Analgesics)
RN  - 0 (Indoles)
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analgesics/adverse effects/*pharmacology/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation/*methods
MH  - Female
MH  - Humans
MH  - Indoles/adverse effects/pharmacology/therapeutic use
MH  - Pain, Postoperative/*drug therapy/physiopathology
MH  - Phenylpropionates/adverse effects/*pharmacology/therapeutic use
MH  - Research Design
MH  - Time Factors
EDAT- 1977/04/01 00:00
MHDA- 1977/04/01 00:01
CRDT- 1977/04/01 00:00
PHST- 1977/04/01 00:00 [pubmed]
PHST- 1977/04/01 00:01 [medline]
PHST- 1977/04/01 00:00 [entrez]
AID - 10.1177/009127007701700401 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1977 Apr;17(4):177-84. doi: 10.1177/009127007701700401.

PMID- 758460
OWN - NLM
STAT- MEDLINE
DCOM- 19790226
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 68
IP  - 1
DP  - 1979 Jan
TI  - Liquid chromatography in pharmaceutical analysis XI: determination of muscle 
      relaxant--analgesic mixture using reversed-phase and ion-pair techniques.
PG  - 32-6
AB  - High pressure liquid chromatography using reversed-phase and/or ion-pair 
      techniques was used to optimize resolution of aspirin-containing muscle relaxant 
      mixtures as well as other therapeutic agents commonly found in muscle 
      relaxant-analgesic mixtures. The compounds were chromatographed on an 
      octadecylsilane column using methanol--water solvent systems, some of which 
      contained tetrabutylammonium cation as counterion. Mixtures of 
      methocarbamol--aspirin and chlorzoxazone--acetaminophen were selected to 
      demonstrate separation and quantification. The methocarbamol--aspirin mixture was 
      chromatographed with methanol--water (40:60, pH 6.8) containing 0.01 M 
      tetrabutylammonium cation at a flow rate of 2.0 ml/min. The 
      chlorzoxazone--acetaminophen mixture was chromatographed with methanol--water 
      (50:50) at a 2.0 ml/min flow rate. The separation and quantitation of each 
      mixture were achieved in approximately 8 min with accuracy in the 2--3% range.
FAU - Stewart, J T
AU  - Stewart JT
FAU - Honigberg, I L
AU  - Honigberg IL
FAU - Coldren, J W
AU  - Coldren JW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Analgesics)
RN  - 0 (Drug Combinations)
RN  - 0 (Muscle Relaxants, Central)
RN  - 125OD7737X (Methocarbamol)
RN  - 362O9ITL9D (Acetaminophen)
RN  - H0DE420U8G (Chlorzoxazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/analysis
MH  - Analgesics/*analysis
MH  - Aspirin/analysis
MH  - Chlorzoxazone/analysis
MH  - Chromatography, High Pressure Liquid/methods
MH  - Drug Combinations
MH  - Methocarbamol/analysis
MH  - Methods
MH  - Muscle Relaxants, Central/*analysis
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - S0022-3549(15)42455-4 [pii]
AID - 10.1002/jps.2600680112 [doi]
PST - ppublish
SO  - J Pharm Sci. 1979 Jan;68(1):32-6. doi: 10.1002/jps.2600680112.

PMID- 9093785
OWN - NLM
STAT- MEDLINE
DCOM- 19970623
LR  - 20170112
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 15
IP  - 1
DP  - 1997 Jan-Feb
TI  - Erythromelalgia following influenza vaccine in a child.
PG  - 111-3
AB  - Erythromelalgia is a rare disease characterised by palmar and plantar erythema, 
      burning pain and local increases in temperature. Erythromelalgia in adults most 
      commonly appears secondary to myeloproliferative disorders, essential 
      thrombocytosis and polycythemia vera; however, in children primary forms 
      predominate. Erythromelalgia in children is characterised by a chronic relapsing 
      course, usually refractory to treatment. We describe a case of erythromelalgia 
      which developed in a 4.5 year old girl following influenza vaccination. Low dose 
      aspirin, carbamazepine and propranolol induced a rapid resolution of the 
      syndrome.
FAU - Confino, I
AU  - Confino I
AD  - Paediatric Department B, Chaim Sheba Medical Centre, Tel Hashomer, Israel.
FAU - Passwell, J H
AU  - Passwell JH
FAU - Padeh, S
AU  - Padeh S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Influenza Vaccines)
RN  - 33CM23913M (Carbamazepine)
RN  - 9Y8NXQ24VQ (Propranolol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Carbamazepine/therapeutic use
MH  - Child, Preschool
MH  - Drug Therapy, Combination
MH  - Erythromelalgia/drug therapy/*etiology
MH  - Female
MH  - Humans
MH  - Influenza Vaccines/*adverse effects
MH  - Propranolol/therapeutic use
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Rheumatol. 1997 Jan-Feb;15(1):111-3.

PMID- 19712620
OWN - NLM
STAT- MEDLINE
DCOM- 20100202
LR  - 20190917
IS  - 1579-2242 (Electronic)
IS  - 0300-8932 (Linking)
VI  - 62
IP  - 9
DP  - 2009 Sep
TI  - Long-term follow-up of atrial fibrillation patients in the NASPEAF study. 
      Prospective evaluation of different antiplatelet treatments.
PG  - 992-1000
AB  - INTRODUCTION AND OBJECTIVES: In the NASPEAF (National Study for Prevention of 
      Embolism in Atrial Fibrillation) trial, combination therapy with an anticoagulant 
      and an antiplatelet was more effective than anticoagulation alone in patients 
      with atrial fibrillation. We report long-term follow-up in these patients, 
      including prospective evaluation of different antiplatelet therapies. METHODS: 
      This analysis included 574 atrial fibrillation patients. Standard anticoagulation 
      (international normalized ratio [INR] 2.0-3.0) was used as control therapy to 
      compare with anticoagulation (INR 1.9-2.5) plus either triflusal at 600 mg/day, 
      triflusal at 300 mg/day or aspirin at 100 mg/day. The primary endpoint was 
      ischemic or hemorrhagic stroke, a systemic or coronary ischemic event, or 
      cardiovascular death. The mean follow-up was 4.92 years. RESULTS: Long-term 
      follow-up confirmed that combination therapy with an anticoagulant plus triflusal 
      at 600 mg/day gave significantly better results than anticoagulation alone 
      (hazard ratio [HR]=0.33; 95% confidence interval [CI], 0.14-0.80; P=.014). There 
      was a significantly higher incidence of ischemic events with triflusal at 300 
      mg/day (P=.031) and of severe bleeding events with aspirin at 100 mg/day 
      (P=.008). The mean INR was similar in the three combination therapy groups. The 
      incidence of severe nongastric bleeding during combination therapy with triflusal 
      was very low (0.3% of patients/year). CONCLUSIONS: Long-term follow-up confirmed 
      that combination antithrombotic therapy with triflusal at 600 mg/day gave 
      significantly better results than anticoagulant monotherapy. The results obtained 
      with combination therapy with triflusal at 300 mg/day and with aspirin at 100 
      mg/day should be considered provisional because the treatment groups were small 
      and treatment was not randomly assigned.
FAU - Bover, Ramón
AU  - Bover R
AD  - Servicio de Cardiología, Hospital Universitario Clínico San Carlos, Madrid, 
      España. ramonbover@secardiologia.es
FAU - Pérez-Gómez, Francisco
AU  - Pérez-Gómez F
FAU - Maluenda, María P
AU  - Maluenda MP
FAU - Asenjo, Susana
AU  - Asenjo S
FAU - Pérez-Saldaña, Rosario
AU  - Pérez-Saldaña R
FAU - Igea, Angel
AU  - Igea A
FAU - Suárez, Marta
AU  - Suárez M
FAU - Coleto, Dulcenombre
AU  - Coleto D
FAU - Fernández, Cristina
AU  - Fernández C
LA  - eng
LA  - spa
PT  - Comparative Study
PT  - Journal Article
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 1Z0YFI05OO (triflusal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Rev Esp Cardiol. 2009 Sep;62(9):972-5. PMID: 19712617
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Salicylates/*therapeutic use
MH  - Time Factors
EDAT- 2009/08/29 09:00
MHDA- 2010/02/03 06:00
CRDT- 2009/08/29 09:00
PHST- 2009/08/29 09:00 [entrez]
PHST- 2009/08/29 09:00 [pubmed]
PHST- 2010/02/03 06:00 [medline]
AID - 13140541 [pii]
AID - 10.1016/s1885-5857(09)73265-7 [doi]
PST - ppublish
SO  - Rev Esp Cardiol. 2009 Sep;62(9):992-1000. doi: 10.1016/s1885-5857(09)73265-7.

PMID- 9062862
OWN - NLM
STAT- MEDLINE
DCOM- 19970508
LR  - 20220318
IS  - 0303-6979 (Print)
IS  - 0303-6979 (Linking)
VI  - 24
IP  - 2
DP  - 1997 Feb
TI  - Aspirin-induced post-gingivectomy haemorrhage: a timely reminder.
PG  - 136-8
AB  - A case report is described of significant aspirin-induced haemorrhage following a 
      gingivectory procedure in an organ transplant patient. Aspirin-induced platelet 
      impairment secondary to low-dose aspirin was implicated as the cause of the 
      haemorrhage. Haemostasis was eventually achieved after platelet transfusion. The 
      case illustrates the problems that can arise when carrying out gingival surgery 
      on patients medicated with low-dose aspirin.
FAU - Thomason, J M
AU  - Thomason JM
AD  - Department of Restorative Dentistry, Dental School, Newcastle upon Tyne, UK.
FAU - Seymour, R A
AU  - Seymour RA
FAU - Murphy, P
AU  - Murphy P
FAU - Brigham, K M
AU  - Brigham KM
FAU - Jones, P
AU  - Jones P
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Clin Periodontol
JT  - Journal of clinical periodontology
JID - 0425123
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cyclosporine/adverse effects
MH  - *Dental Care for Chronically Ill
MH  - Gingival Hypertrophy/chemically induced/surgery
MH  - Gingivectomy/*adverse effects
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects
MH  - Kidney Transplantation
MH  - Male
MH  - Oral Hemorrhage/*chemically induced/therapy
MH  - Platelet Aggregation/drug effects
MH  - Platelet Transfusion
MH  - Postoperative Hemorrhage/*chemically induced/etiology/therapy
EDAT- 1997/02/01 00:00
MHDA- 1997/02/01 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1997/02/01 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
AID - 10.1111/j.1600-051x.1997.tb00480.x [doi]
PST - ppublish
SO  - J Clin Periodontol. 1997 Feb;24(2):136-8. doi: 
      10.1111/j.1600-051x.1997.tb00480.x.

PMID- 1751016
OWN - NLM
STAT- MEDLINE
DCOM- 19920127
LR  - 20150901
IS  - 1011-8934 (Print)
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Linking)
VI  - 6
IP  - 2
DP  - 1991 Jun
TI  - Sodium salicylate sensitivity in an asthmatic patient with aspirin sensitivity.
PG  - 113-7
AB  - Non-acetylated salicylates have been recommended for use as alternatives to 
      nonsteroidal anti-inflammatory drugs (NSAIDs) in aspirin and/or 
      tartrazine-sensitive patients. We experienced a case of an aspirin-sensitive 
      asthmatic patient who developed a broncho-obstructive reaction after taking 100 
      mg of sodium salicylate. The result of this study suggests that sodium salicylate 
      may cross-react with aspirin in aspirin-and tartrazine-sensitive patients.
FAU - Park, H S
AU  - Park HS
AD  - Department of Chest Medicine, National Medical Center, Seoul, Korea.
FAU - Lim, Y S
AU  - Lim YS
FAU - Suh, J E
AU  - Suh JE
FAU - Rhu, N S
AU  - Rhu NS
FAU - Cho, D I
AU  - Cho DI
FAU - Kim, J W
AU  - Kim JW
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - I753WB2F1M (Tartrazine)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/*complications/diagnosis/etiology
MH  - Bronchial Provocation Tests
MH  - Cross Reactions
MH  - Drug Hypersensitivity/*complications/diagnosis/etiology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Sodium Salicylate/*adverse effects/immunology
MH  - Tartrazine/adverse effects
PMC - PMC3049690
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
AID - 10.3346/jkms.1991.6.2.113 [doi]
PST - ppublish
SO  - J Korean Med Sci. 1991 Jun;6(2):113-7. doi: 10.3346/jkms.1991.6.2.113.

PMID- 23199511
OWN - NLM
STAT- MEDLINE
DCOM- 20130321
LR  - 20181202
IS  - 1532-1916 (Electronic)
IS  - 1521-6918 (Linking)
VI  - 26
IP  - 4
DP  - 2012 Aug
TI  - Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract.
PG  - e1-e13
LID - S1521-6918(12)00097-2 [pii]
LID - 10.1016/j.bpg.2012.10.001 [doi]
AB  - A recent clinical study showed that after five years of taking aspirin, at doses 
      of at least 75 mg once daily, death rates were 54% less for gastrointestinal (GI) 
      cancers. The finding of aspirin benefit at low-doses used for cardioprevention, 
      locates the antiplatelet effect of aspirin at the centre of its antitumour 
      efficacy. At low-doses, aspirin acts mainly by an irreversible inactivation of 
      platelet cyclooxygenase (COX)-1 activity. We propose that platelet activation is 
      involved in the early stages of colorectal carcinogenesis in man through the 
      induction of a COX-2-mediated paracrine signalling between stromal cells and 
      epithelial cells within adenomas. In this scenario, aspirin causes a 
      chemopreventive effect by countering platelet activation which seems to play a 
      role in early event in GI tumourigenesis.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Bruno, Annalisa
AU  - Bruno A
AD  - Department of Medicine and Aging, G. d'Annunzio University, School of Medicine, 
      Italy.
FAU - Dovizio, Melania
AU  - Dovizio M
FAU - Tacconelli, Stefania
AU  - Tacconelli S
FAU - Patrignani, Paola
AU  - Patrignani P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Gastroenterol
JT  - Best practice & research. Clinical gastroenterology
JID - 101120605
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/prevention & control
MH  - Anticarcinogenic Agents/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Cyclooxygenase Inhibitors/administration & dosage/*pharmacology
MH  - Gastrointestinal Neoplasms/etiology/*prevention & control
MH  - Gastrointestinal Tract/drug effects
MH  - Humans
MH  - Platelet Aggregation/drug effects/physiology
EDAT- 2012/12/04 06:00
MHDA- 2013/03/22 06:00
CRDT- 2012/12/04 06:00
PHST- 2012/02/13 00:00 [received]
PHST- 2012/03/06 00:00 [accepted]
PHST- 2012/12/04 06:00 [entrez]
PHST- 2012/12/04 06:00 [pubmed]
PHST- 2013/03/22 06:00 [medline]
AID - S1521-6918(12)00097-2 [pii]
AID - 10.1016/j.bpg.2012.10.001 [doi]
PST - ppublish
SO  - Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):e1-e13. doi: 
      10.1016/j.bpg.2012.10.001.

PMID- 7264920
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 70
IP  - 7
DP  - 1981 Jul
TI  - Improved delivery through biological membranes XD: Percutaneous absorption and 
      metabolism of methylsulfinylmethyl 2-acetoxybenzoate and related aspirin 
      prodrugs.
PG  - 756-8
AB  - Oxidative-reductive interconversion of the methylthiomethyl ester of aspirin and 
      the corresponding sulfoxide and sulfone derivatives can be detected in rat liver 
      homogenate, in addition to the extremely facile hydrolysis of these esters. The 
      methylthiomethyl and methylsulfinylmethyl 2-acetoxybenzoates penetrate freshly 
      excised hairless mice skin rather easily with the simultaneous hydrolysis of the 
      two ester functions. Contrary to in vivo observations in dogs, where significant 
      amounts of aspirin formed, the prodrugs cleave to salicylic acid and/or 
      salicylate esters rather than aspirin.
FAU - Loftsson, T
AU  - Loftsson T
FAU - Bodor, N
AU  - Bodor N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 76432-33-2 (methylsulfinylmethyl 2-acetoxybenzoate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives
MH  - Biotransformation
MH  - Female
MH  - Half-Life
MH  - In Vitro Techniques
MH  - Liver/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Rats
MH  - Salicylates/*metabolism
MH  - Skin Absorption
EDAT- 1981/07/01 00:00
MHDA- 1981/07/01 00:01
CRDT- 1981/07/01 00:00
PHST- 1981/07/01 00:00 [pubmed]
PHST- 1981/07/01 00:01 [medline]
PHST- 1981/07/01 00:00 [entrez]
AID - S0022-3549(15)43781-5 [pii]
AID - 10.1002/jps.2600700710 [doi]
PST - ppublish
SO  - J Pharm Sci. 1981 Jul;70(7):756-8. doi: 10.1002/jps.2600700710.

PMID- 3923568
OWN - NLM
STAT- MEDLINE
DCOM- 19850712
LR  - 20190824
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 29
IP  - 4
DP  - 1985 Apr
TI  - Prostaglandin synthesis by the cochlea of the guinea pig. Influence of aspirin, 
      gentamicin, and acoustic stimulation.
PG  - 589-99
AB  - This study describes the synthesis of prostaglandins (PGs) by the vascular 
      structures of the inner ear (lateral wall = stria vascularis and spiral ligament) 
      in vitro. The main PGs produced were PGI2, PGF2 alpha and PGE2. PGI2 and PGF2 
      alpha were also found in the perilymph. A 350 mg/kg ip injection of aspirin 
      decreased PG synthesis by the lateral wall and PG levels in perilymph. This 
      effect was reversed after 3 days. Gentamicin (10(-9) to 10(-5) M) decreased 
      significantly and reversibly PG synthesis in vitro, as did 100 mg/kg ip 
      injection. Acoustic stimulation increased ex vivo PGI2 and PGE2 synthesis without 
      modifying PG levels in perilymph. Results suggest that PGs could be one humoral 
      mediator of the cochlear microcirculation homeostasis, and, possibly, of the 
      circulatory disturbances reported after acoustic stimulation. The decreased PG 
      synthesis after gentamicin treatment could account for the angiotoxic component 
      observed in aminoglycoside ototoxicity.
FAU - Escoubet, B
AU  - Escoubet B
FAU - Amsallem, P
AU  - Amsallem P
FAU - Ferrary, E
AU  - Ferrary E
FAU - Tran Ba Huy, P
AU  - Tran Ba Huy P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Arachidonic Acids)
RN  - 0 (Gentamicins)
RN  - 0 (Prostaglandins)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acoustic Stimulation
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/*pharmacology
MH  - Cochlea/*metabolism
MH  - Gentamicins/*pharmacology
MH  - Guinea Pigs
MH  - Male
MH  - Prostaglandins/*biosynthesis
EDAT- 1985/04/01 00:00
MHDA- 1985/04/01 00:01
CRDT- 1985/04/01 00:00
PHST- 1985/04/01 00:00 [pubmed]
PHST- 1985/04/01 00:01 [medline]
PHST- 1985/04/01 00:00 [entrez]
AID - 0090-6980(85)90082-6 [pii]
AID - 10.1016/0090-6980(85)90082-6 [doi]
PST - ppublish
SO  - Prostaglandins. 1985 Apr;29(4):589-99. doi: 10.1016/0090-6980(85)90082-6.

PMID- 6185629
OWN - NLM
STAT- MEDLINE
DCOM- 19830324
LR  - 20131121
IS  - 0022-1317 (Print)
IS  - 0022-1317 (Linking)
VI  - 63
IP  - 2
DP  - 1982 Dec
TI  - Indomethacin and aspirin do not inhibit the antiviral or anti-proliferative 
      actions of interferon.
PG  - 505-8
AB  - Neither indomethacin nor aspirin, at concentrations which inhibited the formation 
      of prostaglandins and prevented the interferon-induced increase in the 
      intracellular concentration of cyclic GMP, had any significant effect on the 
      development of the interferon-induced antiviral state either in mouse L1210 cells 
      challenged with vesicular stomatitis virus or in mice infected with 
      encephalomyocarditis virus. Furthermore, neither drug had any significant effect 
      on the interferon-induced inhibition of cell multiplication in cultures of mouse 
      leukaemia L1210 cells. The differences in the effects of these cyclo-oxygenase 
      inhibitors on different interferon effects may provide some insight into the 
      different pathways of interferon action.
FAU - Tovey, M G
AU  - Tovey MG
FAU - Gresser, I
AU  - Gresser I
FAU - Rochette-Egly, C
AU  - Rochette-Egly C
FAU - Begon-Lours-Guymarho, J
AU  - Begon-Lours-Guymarho J
FAU - Bandu, M T
AU  - Bandu MT
FAU - Maury, C
AU  - Maury C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Gen Virol
JT  - The Journal of general virology
JID - 0077340
RN  - 9008-11-1 (Interferons)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cell Division/*drug effects
MH  - Cell Line
MH  - Encephalomyocarditis virus/physiology
MH  - Indomethacin/*pharmacology
MH  - Interferons/*antagonists & inhibitors
MH  - Leukemia L1210
MH  - Vesicular stomatitis Indiana virus/physiology
MH  - Virus Replication/*drug effects
EDAT- 1982/12/01 00:00
MHDA- 1982/12/01 00:01
CRDT- 1982/12/01 00:00
PHST- 1982/12/01 00:00 [pubmed]
PHST- 1982/12/01 00:01 [medline]
PHST- 1982/12/01 00:00 [entrez]
AID - 10.1099/0022-1317-63-2-505 [doi]
PST - ppublish
SO  - J Gen Virol. 1982 Dec;63(2):505-8. doi: 10.1099/0022-1317-63-2-505.

PMID- 24344050
OWN - NLM
STAT- MEDLINE
DCOM- 20150702
LR  - 20220321
IS  - 1945-239X (Electronic)
IS  - 0021-9665 (Linking)
VI  - 52
IP  - 10
DP  - 2014 Nov-Dec
TI  - Simultaneous quantification of paracetamol, acetylsalicylic acid and papaverine 
      with a validated HPLC method.
PG  - 1198-203
LID - 10.1093/chromsci/bmt177 [doi]
AB  - Combined drug products have the advantages of better patient compliance and 
      possible synergic effects. The simultaneous application of several active 
      ingredients at a time is therefore frequently chosen. However, the quantitative 
      analysis of such medicines can be challenging. The aim of this study is to 
      provide a validated method for the investigation of a multidose packed oral 
      powder that contained acetylsalicylic acid, paracetamol and papaverine-HCl. 
      Reversed-phase high-pressure liquid chromatography was used. The Agilent Zorbax 
      SB-C18 column was found to be the most suitable of the three different stationary 
      phases tested for the separation of the components of this sample. The key 
      parameters in the method development (apart from the nature of the column) were 
      the pH of the aqueous phase (set to 3.4) and the ratio of the organic 
      (acetonitrile) and the aqueous (25 mM phosphate buffer) phases, which was varied 
      from 7:93 (v/v) to 25:75 (v/v) in a linear gradient, preceded by an initial hold. 
      The method was validated: linearity, precision (repeatability and intermediate 
      precision), accuracy, specificity and robustness were all tested, and the results 
      met the ICH guidelines.
CI  - © The Author [2013]. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Kalmár, Eva
AU  - Kalmár E
AD  - Institute of Pharmaceutical Analysis, Faculty of Pharmacy, University of Szeged, 
      Somogyi u. 4, Szeged H-6720, Hungary.
FAU - Gyuricza, Anett
AU  - Gyuricza A
AD  - Institute of Pharmaceutical Analysis, Faculty of Pharmacy, University of Szeged, 
      Somogyi u. 4, Szeged H-6720, Hungary.
FAU - Kunos-Tóth, Erika
AU  - Kunos-Tóth E
AD  - Institute of Pharmaceutical Analysis, Faculty of Pharmacy, University of Szeged, 
      Somogyi u. 4, Szeged H-6720, Hungary.
FAU - Szakonyi, Gerda
AU  - Szakonyi G
AD  - Institute of Pharmaceutical Analysis, Faculty of Pharmacy, University of Szeged, 
      Somogyi u. 4, Szeged H-6720, Hungary gerda.szakonyi@pharm.u-szeged.hu.
FAU - Dombi, György
AU  - Dombi G
AD  - Institute of Pharmaceutical Analysis, Faculty of Pharmacy, University of Szeged, 
      Somogyi u. 4, Szeged H-6720, Hungary.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131215
PL  - United States
TA  - J Chromatogr Sci
JT  - Journal of chromatographic science
JID - 0173225
RN  - 362O9ITL9D (Acetaminophen)
RN  - DAA13NKG2Q (Papaverine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Hydrogen-Ion Concentration
MH  - Linear Models
MH  - Papaverine/*analysis
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
EDAT- 2013/12/18 06:00
MHDA- 2015/07/03 06:00
CRDT- 2013/12/18 06:00
PHST- 2013/12/18 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2015/07/03 06:00 [medline]
AID - bmt177 [pii]
AID - 10.1093/chromsci/bmt177 [doi]
PST - ppublish
SO  - J Chromatogr Sci. 2014 Nov-Dec;52(10):1198-203. doi: 10.1093/chromsci/bmt177. 
      Epub 2013 Dec 15.

PMID- 15335035
OWN - NLM
STAT- MEDLINE
DCOM- 20040915
LR  - 20191108
IS  - 1615-9306 (Print)
IS  - 1615-9306 (Linking)
VI  - 27
IP  - 7-8
DP  - 2004 May
TI  - Sequential injection chromatographic determination of paracetamol, caffeine, and 
      acetylsalicylic acid in pharmaceutical tablets.
PG  - 529-36
AB  - In this contribution, a new separation method for simultaneous determination of 
      paracetamol, caffeine, acetylsalicylic acid, and internal standard benzoic acid 
      was developed based on a novel reversed-phase sequential injection chromatography 
      (SIC) technique with UV detection. A Chromolith Flash RP-18e, 25-4.6mm column 
      (Merck, Germany) and a FIAlab 3000 system (USA) with an 8-port selection valve 
      and a 5 mL syringe were used for sequential injection chromatographic separations 
      in our study. The mobile phase used was acetonitrile-(0.01 M) phosphate buffer 
      (10:90, v/v) pH 4.05, flow rate 0.6 mL min(-1). UV detection was at 210 and 230 
      nm. The validation parameters showed good results: linearity (r >0.999) for all 
      compounds, detection limits in the range 0.3-0.8 microg mL(-1), repeatability 
      (RSD) of peak heights between runs in the range 1.10-4.30% at three concentration 
      levels and intra-day repeatability of the retention times in the range 
      0.28-0.43%. The analysis time was <6 min. The method was found to be applicable 
      for the routine analysis of the active compounds paracetamol, caffeine, and 
      acetylsalicylic acid in pharmaceutical tablets.
FAU - Satínský, Dalibor
AU  - Satínský D
AD  - The Research Centre LN00B125, Department of Analytical Chemistry, Faculty of 
      Pharmacy, Charles University, Heyrovského, Hradec Králové, Czech Republic. 
      satinsky@faf.cuni.cz
FAU - Neto, Isabel
AU  - Neto I
FAU - Solich, Petr
AU  - Solich P
FAU - Sklenákova, Hana
AU  - Sklenákova H
FAU - Conceição, M
AU  - Conceição M
FAU - Montenegro, B S M
AU  - Montenegro BS
FAU - Araújo, Alberto N
AU  - Araújo AN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - J Sep Sci
JT  - Journal of separation science
JID - 101088554
RN  - 0 (Indicators and Reagents)
RN  - 0 (Solvents)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Chromatography/methods
MH  - Indicators and Reagents
MH  - Sensitivity and Specificity
MH  - Solvents
MH  - Spectrophotometry, Ultraviolet/methods
MH  - Tablets/*chemistry
EDAT- 2004/09/01 05:00
MHDA- 2004/09/16 05:00
CRDT- 2004/09/01 05:00
PHST- 2004/09/01 05:00 [pubmed]
PHST- 2004/09/16 05:00 [medline]
PHST- 2004/09/01 05:00 [entrez]
AID - 10.1002/jssc.200301644 [doi]
PST - ppublish
SO  - J Sep Sci. 2004 May;27(7-8):529-36. doi: 10.1002/jssc.200301644.

PMID- 7650593
OWN - NLM
STAT- MEDLINE
DCOM- 19950922
LR  - 20131121
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 12
IP  - 3
DP  - 1995 May-Jun
TI  - Physico-chemical evaluation of acetylsalicylic acid-Eudragit RS100 microspheres 
      prepared using a solvent-partition method.
PG  - 287-305
AB  - Controlled release homogeneous matrix microspheres containing acetylsalicylic 
      acid (ASA) were prepared by a simple mechanical process using Eudragit RS100 as 
      the matrix polymer. A drug-polymer solution in a binary solvent of methylene 
      chloride/acetone (9:1) was prepared and infused at a rate of 15 microliters/min 
      as small droplets into a flowing stream of mineral oil where partition of the 
      solvent occurred. A series of experiments was conducted in which the polymer to 
      drug ratio in the infusion solution was fixed at 5:1, 4:1, 3:1 or 2:1 while 
      varying the infusion solution viscosity by altering the infusion solution total 
      solids concentration. Results indicate that microsphere mean particle size was 
      maintained at 200-300 microns once the infusion solution viscosity exceeded 2 
      cps. The physical state of the ASA incorporated into the microspheres, as 
      confirmed by SEM and thermal analysis, was amorphous in nature until a drug 
      loading of 24% was reached. Drug loading for each polymer to drug ratio increased 
      in a proportional manner with respect to the initial drug concentration of the 
      infusion solution. Dissolution release profiles were found to be biphasic and 
      best analysed according to the semi-empirical equation of Ritger-Peppas, Mt/Mx = 
      k2tn, for the initial phase and by the square-root model of Higuchi, Qt = k1t1/2 
      for the latter phase. This difference was attributed to the lack of a barrier 
      effect to the drug diffusion process during the latter dissolution phase when the 
      microspheres are fully hydrated.
FAU - Vachon, M G
AU  - Vachon MG
AD  - Faculty of Pharmacy, University of Toronto, Ontario, Canada.
FAU - Nairn, J G
AU  - Nairn JG
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Acrylic Resins)
RN  - 0 (Capsules)
RN  - 0 (Drug Carriers)
RN  - 0 (Polymers)
RN  - 33434-24-1 (Eudragit RS)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acrylic Resins/*chemistry
MH  - Aspirin/*chemistry
MH  - Calorimetry, Differential Scanning
MH  - Capsules/*chemistry
MH  - Diffusion
MH  - Drug Carriers/chemistry
MH  - Kinetics
MH  - Microscopy, Electron, Scanning
MH  - Particle Size
MH  - Polymers/chemistry
MH  - Solubility
MH  - Viscosity
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
AID - 10.3109/02652049509010297 [doi]
PST - ppublish
SO  - J Microencapsul. 1995 May-Jun;12(3):287-305. doi: 10.3109/02652049509010297.

PMID- 26758864
OWN - NLM
STAT- MEDLINE
DCOM- 20160620
LR  - 20181202
IS  - 1534-6315 (Electronic)
IS  - 1529-7322 (Linking)
VI  - 16
IP  - 2
DP  - 2016 Feb
TI  - Rapid Aspirin Challenge in Patients with Aspirin Allergy and Acute Coronary 
      Syndromes.
PG  - 11
LID - 10.1007/s11882-015-0593-2 [doi]
AB  - Aspirin allergy in a patient with acute coronary syndrome represents one of the 
      more urgent challenges an allergist may face. Adverse reactions to aspirin are 
      reported in 1.5% of patients with coronary artery disease. A history of adverse 
      reaction to aspirin often leads to unnecessary withholding of this medication or 
      use of alternative antiplatelet therapy which may be inferior or more costly. 
      Aspirin therapy has been shown to reduce morbidity and mortality in patients with 
      coronary artery disease. Rapid aspirin challenge/desensitization in the aspirin 
      allergic patient has been consistently shown to be both safe and successful in 
      patients with acute coronary syndromes.
FAU - Cook, Kevin A
AU  - Cook KA
AD  - Division of Allergy and Immunology, Scripps Green Hospital, La Jolla, CA, USA.
FAU - White, Andrew A
AU  - White AA
AD  - Division of Allergy and Immunology, Scripps Green Hospital, La Jolla, CA, USA. 
      white.andrew@scrippshealth.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Allergy Asthma Rep
JT  - Current allergy and asthma reports
JID - 101096440
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*complications
MH  - Aspirin/*adverse effects
MH  - Desensitization, Immunologic
MH  - *Drug Hypersensitivity/drug therapy
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Platelet Aggregation Inhibitors/*adverse effects
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Aspirin allergy
OT  - Aspirin benefit
OT  - Aspirin challenge
OT  - Aspirin desensitization
OT  - Aspirin reaction
OT  - Aspirin therapy
OT  - Coronary artery disease
EDAT- 2016/01/14 06:00
MHDA- 2016/06/21 06:00
CRDT- 2016/01/14 06:00
PHST- 2016/01/14 06:00 [entrez]
PHST- 2016/01/14 06:00 [pubmed]
PHST- 2016/06/21 06:00 [medline]
AID - 10.1007/s11882-015-0593-2 [pii]
AID - 10.1007/s11882-015-0593-2 [doi]
PST - ppublish
SO  - Curr Allergy Asthma Rep. 2016 Feb;16(2):11. doi: 10.1007/s11882-015-0593-2.

PMID- 7637720
OWN - NLM
STAT- MEDLINE
DCOM- 19950914
LR  - 20220410
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 333
IP  - 10
DP  - 1995 Sep 7
TI  - Aspirin and the risk of colorectal cancer in women.
PG  - 609-14
AB  - BACKGROUND: Most data suggest that the regular use of aspirin reduces the risk of 
      colorectal cancer, but some apparently conflicting evidence exists. The effects 
      of the dose and the duration of aspirin consumption on the risk of colorectal 
      cancer are not well understood. METHODS: We determined rates of colorectal cancer 
      according to the number of consecutive years of regular aspirin use (defined as 
      two or more tablets per week) among women in the Nurses' Health Study who 
      reported regular aspirin use on three consecutive questionnaires (1980, 1982, and 
      1984) and compared the rates in this group with the rates among women who said 
      they did not use aspirin. Cases of cancer occurring from 1984 through 1992 (the 
      eight years after the 1984 questionnaire) were included. RESULTS: From 1984 
      through 1992, we documented 331 new cases of colorectal cancer during 551,651 
      person-years of follow-up. Women who consistently took two or more aspirin 
      tablets per week had no appreciable reduction in the risk of colorectal cancer as 
      compared with nonusers after four years (relative risk, 1.06; 95 percent 
      confidence interval, 0.78 to 1.45) or after five to nine years (relative risk, 
      0.84; 95 percent confidence interval, 0.55 to 1.28). There was a slight reduction 
      in risk among women who took aspirin for 10 to 19 years, but it was not 
      statistically significant (relative risk, 0.70; 95 percent confidence interval, 
      0.41 to 1.20). However, there was a statistically significant reduction after 20 
      years of consistent use of aspirin (relative risk, 0.56; 95 percent confidence 
      interval, 0.36 to 0.90; P for trend = 0.008). The maximal reduction in risk was 
      observed among women who took four to six tablets per week; higher doses had a 
      similar apparent benefit. Controlling for risk factors for colorectal cancer, 
      including diet, did not change the results, and the earlier diagnosis and removal 
      of colorectal adenomas among aspirin users did not account for the results. 
      CONCLUSIONS: Regular aspirin use, at doses similar to those recommended for the 
      prevention of cardiovascular disease, substantially reduces the risk of 
      colorectal cancer. However, this benefit may not be evident until after at least 
      a decade of regular aspirin consumption.
FAU - Giovannucci, E
AU  - Giovannucci E
AD  - Channing Laboratory, Department of Medicine, Harvard Medical School, Boston, MA 
      02115, USA.
FAU - Egan, K M
AU  - Egan KM
FAU - Hunter, D J
AU  - Hunter DJ
FAU - Stampfer, M J
AU  - Stampfer MJ
FAU - Colditz, G A
AU  - Colditz GA
FAU - Willett, W C
AU  - Willett WC
FAU - Speizer, F E
AU  - Speizer FE
LA  - eng
GR  - CA 40356/CA/NCI NIH HHS/United States
GR  - CA 55075/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 1995 Sep 7;333(10):656-8. PMID: 7637730
CIN - N Engl J Med. 1996 Jan 11;334(2):119; author reply 121. PMID: 8531946
CIN - N Engl J Med. 1996 Jan 11;334(2):119-20; author reply 121. PMID: 8531947
CIN - N Engl J Med. 1996 Jan 11;334(2):120; author reply 121-2. PMID: 8531948
CIN - N Engl J Med. 1996 Jan 11;334(2):120; author reply 121. PMID: 8531950
CIN - N Engl J Med. 1996 Jan 11;334(2):121-2. PMID: 8531951
CIN - N Engl J Med. 1996 Mar 21;334(12):800-1. PMID: 8592564
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cohort Studies
MH  - Colonic Neoplasms/epidemiology/prevention & control
MH  - Colorectal Neoplasms/epidemiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Rectal Neoplasms/epidemiology/prevention & control
MH  - Risk
MH  - Risk Factors
MH  - Time Factors
MH  - United States/epidemiology
EDAT- 1995/09/07 00:00
MHDA- 1995/09/07 00:01
CRDT- 1995/09/07 00:00
PHST- 1995/09/07 00:00 [pubmed]
PHST- 1995/09/07 00:01 [medline]
PHST- 1995/09/07 00:00 [entrez]
AID - 10.1056/NEJM199509073331001 [doi]
PST - ppublish
SO  - N Engl J Med. 1995 Sep 7;333(10):609-14. doi: 10.1056/NEJM199509073331001.

PMID- 22142668
OWN - NLM
STAT- MEDLINE
DCOM- 20120628
LR  - 20131121
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 129
IP  - 3
DP  - 2012 Mar
TI  - Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update.
PG  - 341-4
LID - 10.1016/j.thromres.2011.11.020 [doi]
AB  - In 2004 an editorial article on the so-called "aspirin resistance" and diabetic 
      angiopathy as related to platelet turnover was published by one of us. An update 
      of this issue is now presented. The evidence of an incomplete inhibition of 
      platelet function by aspirin, despite doses of the drug proved to be clinically 
      effective are employed, was first reported in the '80s, in studies devoted to 
      platelet turnover. Based on this concept, the possibility of monitoring the entry 
      of newly formed platelets into the circulation after aspirin ingestion was 
      documented by measuring the return of thromboxane biosynthesis by platelets 
      challenged in vitro by pairs of aggregating agents. The data obtained showed that 
      platelets with intact cyclooxygenase activity could be detected into the 
      circulation of control individuals as early as 4-6hrs after aspirin ingestion, 
      but at shorter time intervals in diabetic angiopathy. In the latter setting, it 
      was concluded that "schedules of aspirin which may suffice in normals are not 
      effective in patients with diabetic angiopathy, presumably because these patients 
      have a high rate of entry of new platelets into the circulation". As many as 
      25years after its original publication, the clinical relevance of an accelerated 
      platelet turnover as to "aspirin resistance" has been confirmed and extended to 
      other clinical settings at high risk of ischemic events. Newer aspirin dosing and 
      scheduling, tailored at reducing the individual patient risk related to an 
      incomplete inhibition of platelet function by a standard aspirin dose should now 
      be defined.
CI  - Copyright © 2011 Elsevier Ltd. All rights reserved.
FAU - Di Minno, Matteo Nicola Dario
AU  - Di Minno MN
AD  - Department of Clinical Experimental Medicine, Regional Reference Centre for 
      Coagulation Disorders; Napoli, Italy. dario.diminno@hotmail.it
FAU - Lupoli, Roberta
AU  - Lupoli R
FAU - Palmieri, Nicola Macarone
AU  - Palmieri NM
FAU - Russolillo, Anna
AU  - Russolillo A
FAU - Buonauro, Agostino
AU  - Buonauro A
FAU - Di Minno, Giovanni
AU  - Di Minno G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20111203
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Diabetic Angiopathies/blood/*drug therapy
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Treatment Failure
EDAT- 2011/12/07 06:00
MHDA- 2012/06/29 06:00
CRDT- 2011/12/07 06:00
PHST- 2011/09/19 00:00 [received]
PHST- 2011/11/10 00:00 [revised]
PHST- 2011/11/10 00:00 [accepted]
PHST- 2011/12/07 06:00 [entrez]
PHST- 2011/12/07 06:00 [pubmed]
PHST- 2012/06/29 06:00 [medline]
AID - S0049-3848(11)00614-1 [pii]
AID - 10.1016/j.thromres.2011.11.020 [doi]
PST - ppublish
SO  - Thromb Res. 2012 Mar;129(3):341-4. doi: 10.1016/j.thromres.2011.11.020. Epub 2011 
      Dec 3.

PMID- 15651910
OWN - NLM
STAT- MEDLINE
DCOM- 20050512
LR  - 20181113
IS  - 0112-1642 (Print)
IS  - 0112-1642 (Linking)
VI  - 35
IP  - 1
DP  - 2005
TI  - Aggregation and activation of blood platelets in exercise and training.
PG  - 11-22
AB  - This article presents an overview of the progress that has been made in recent 
      years in our understanding of the interaction between exercise and platelets in 
      health and disease. Although platelets are important in normal haemostasis, 
      recent evidence emphasises the pivotal role of abnormal platelet function in 
      acute coronary artery diseases, myocardial infarction, unstable angina and 
      stroke. In light of the positive health benefits of exercise, interest has been 
      heightened on the association between exercise and platelet aggregation and 
      function, not only in normal healthy subjects but also in patients. However, the 
      study of exercise effects on blood platelets are highly contentious because of 
      the fact that the analytical methods employed to study platelets are bedevilled 
      by numerous methodological problems. While exercise effects on platelet 
      aggregation and function in healthy individuals have been extensively examined, 
      the evidence reported has been conflicting. Somewhat less contradictory are the 
      results generated from studies in patients with coronary heart disease, as the 
      preponderance of evidence available would strongly suggest that platelet 
      aggregation and function are increased with exercise. Several drugs are known to 
      influence platelet aggregation and function, the most examined among these 
      medications is aspirin (acetylsalicylic acid). However, aspirin appears to be 
      ineffective to attenuate exercise-induced increases in platelet aggregation and 
      activation. Few studies are available on the effect of training on blood 
      platelets and the exact effects of exercise training on platelet activation and 
      function is not as yet known. This lack of information makes further studies 
      particularly important, in order to clarify whether there are favourable effects 
      of exercise training on platelet aggregation and function in health and disease.
FAU - El-Sayed, Mahmoud S
AU  - El-Sayed MS
AD  - Faculty of Science, Liverpool John Moores University, Henry Cotton Campus, 
      Liverpool, UK. m.s.elsayed@livjm.ac.uk
FAU - Ali, Nagia
AU  - Ali N
FAU - El-Sayed Ali, Zeinab
AU  - El-Sayed Ali Z
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Sports Med
JT  - Sports medicine (Auckland, N.Z.)
JID - 8412297
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiac Rehabilitation
MH  - Cardiovascular Diseases/blood/prevention & control
MH  - Exercise/*physiology
MH  - Humans
MH  - Physical Education and Training/*methods
MH  - Platelet Activation/*physiology
MH  - Platelet Aggregation/*physiology
MH  - Platelet Aggregation Inhibitors/therapeutic use
RF  - 64
EDAT- 2005/01/18 09:00
MHDA- 2005/05/13 09:00
CRDT- 2005/01/18 09:00
PHST- 2005/01/18 09:00 [pubmed]
PHST- 2005/05/13 09:00 [medline]
PHST- 2005/01/18 09:00 [entrez]
AID - 3512 [pii]
AID - 10.2165/00007256-200535010-00002 [doi]
PST - ppublish
SO  - Sports Med. 2005;35(1):11-22. doi: 10.2165/00007256-200535010-00002.

PMID- 23809178
OWN - NLM
STAT- MEDLINE
DCOM- 20140423
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 11
IP  - 9
DP  - 2013 Sep
TI  - Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor 
      antagonists.
PG  - 1627-39
LID - 10.1111/jth.12318 [doi]
AB  - Antiplatelet agents like aspirin and adenosine diphosphate receptor antagonists 
      are effective in reducing recurrent ischemic events. Considerable 
      inter-individual variability in the platelet inhibition obtained with these drugs 
      has initiated a search for explanatory mechanisms and ways to improve treatment. 
      In recent years, numerous genetic polymorphisms have been linked with reduced 
      platelet inhibition and lack of clinical efficacy of antiplatelet drugs, 
      particularly clopidogrel and aspirin. Consequently, attempts to adjust 
      antiplatelet treatment according to genotype have been made, but the clinical 
      benefit has been modest in studies performed so far. The progress in genome 
      science over the last decade and the declining cost of sequencing technologies 
      hold the promise of enabling genetically tailored antiplatelet therapy. However, 
      more evidence is needed to clarify which polymorphisms may serve as targets to 
      improve treatment. The present review outlines the panel of polymorphisms 
      affecting the benefit of aspirin and adenosine diphosphate receptor antagonists, 
      including novel and ongoing studies evaluating whether genotyping may be 
      beneficial in tailoring antiplatelet therapy.
CI  - © 2013 International Society on Thrombosis and Haemostasis.
FAU - Würtz, M
AU  - Würtz M
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Lordkipanidzé, M
AU  - Lordkipanidzé M
FAU - Grove, E L
AU  - Grove EL
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/*genetics
MH  - Clopidogrel
MH  - Humans
MH  - *Pharmacogenetics
MH  - Purinergic P2Y Receptor Antagonists/*therapeutic use
MH  - Ticlopidine/analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - ADP receptor antagonists
OT  - aspirin
OT  - cardiovascular disease
OT  - clopidogrel
OT  - pharmacogenomics
EDAT- 2013/07/03 06:00
MHDA- 2014/04/24 06:00
CRDT- 2013/07/02 06:00
PHST- 2013/03/21 00:00 [received]
PHST- 2013/07/02 06:00 [entrez]
PHST- 2013/07/03 06:00 [pubmed]
PHST- 2014/04/24 06:00 [medline]
AID - S1538-7836(22)04778-X [pii]
AID - 10.1111/jth.12318 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2013 Sep;11(9):1627-39. doi: 10.1111/jth.12318.

PMID- 1879600
OWN - NLM
STAT- MEDLINE
DCOM- 19910927
LR  - 20190816
IS  - 0301-2115 (Print)
IS  - 0301-2115 (Linking)
VI  - 40
IP  - 3
DP  - 1991 Jul 25
TI  - Idiopathic thrombocythemia and pregnancy; a case report.
PG  - 237-8
AB  - A 28-year-old women with idiopathic thrombocytosis was treated with melphalan 
      before pregnancy, which resulted in a normal platelet count. During pregnancy 80 
      mg acetylsalicyclic acid was given daily to prevent microcirculatory thrombotic 
      complications. Fetal outcome was normal.
FAU - Minkhorst, A G
AU  - Minkhorst AG
AD  - Department of Obstetrics and Gynaecology, University Hospital Nijmegen, The 
      Netherlands.
FAU - Nováková, I R
AU  - Nováková IR
FAU - van Dongen, P W
AU  - van Dongen PW
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - Q41OR9510P (Melphalan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Eur J Obstet Gynecol Reprod Biol 1991 Nov 26;42(2):165
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Melphalan/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*drug therapy
MH  - Thrombocytosis/*drug therapy
MH  - Thrombosis/prevention & control
EDAT- 1991/07/25 00:00
MHDA- 1991/07/25 00:01
CRDT- 1991/07/25 00:00
PHST- 1991/07/25 00:00 [pubmed]
PHST- 1991/07/25 00:01 [medline]
PHST- 1991/07/25 00:00 [entrez]
AID - 0028-2243(91)90124-4 [pii]
AID - 10.1016/0028-2243(91)90124-4 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 1991 Jul 25;40(3):237-8. doi: 
      10.1016/0028-2243(91)90124-4.

PMID- 897558
OWN - NLM
STAT- MEDLINE
DCOM- 19771031
LR  - 20190907
IS  - 0036-553X (Print)
IS  - 0036-553X (Linking)
VI  - 19
IP  - 2
DP  - 1977 Aug
TI  - The investigation of collagen induced platelet aggregation by the screen 
      filtration pressure technique.
PG  - 185-91
AB  - A modification of the screen filtration pressure technique has been developed to 
      allow platelet response to collagen to be measured. Using a commercial collagen 
      suspension this method has been found to be both simple to perform and to give 
      highly reproducible results. Changes in platelet response to collagen after 
      administration of acetylsalicyclic acid were clearly detected and this suggests 
      that collagen screen filtration pressure may provide a sensitive method for 
      evaluating the effect of platelet release inhibiting drugs.
FAU - Chater, B V
AU  - Chater BV
FAU - Sanderson, J H
AU  - Sanderson JH
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Scand J Haematol
JT  - Scandinavian journal of haematology
JID - 0404507
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Cell Count
MH  - Collagen/*pharmacology
MH  - Erythrocyte Count
MH  - Filtration/*methods
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Pressure
MH  - Temperature
MH  - Time Factors
EDAT- 1977/08/01 00:00
MHDA- 1977/08/01 00:01
CRDT- 1977/08/01 00:00
PHST- 1977/08/01 00:00 [pubmed]
PHST- 1977/08/01 00:01 [medline]
PHST- 1977/08/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1977.tb02343.x [doi]
PST - ppublish
SO  - Scand J Haematol. 1977 Aug;19(2):185-91. doi: 10.1111/j.1600-0609.1977.tb02343.x.

PMID- 752611
OWN - NLM
STAT- MEDLINE
DCOM- 19790925
LR  - 20131121
IS  - 0303-6227 (Print)
IS  - 0303-6227 (Linking)
IP  - 1978
DP  - 1978
TI  - [Inhibition of thrombocyte aggregation in hemorrhagic shock using acetylsalicylic 
      acid and mechanical ventilation].
PG  - 89-93
AB  - Platelet aggregation in flowing venous and arterial blood during hypovolemic 
      hypotension is followed by a previously described photoelectric method. It is 
      shown that platelet aggregation can be inhibited by acetylsalicyclic acid (ASA) 
      and by artificial ventilation. The inhibition of platelet aggregation by 
      artificial ventilation is significantly more pronounced than that by ASA. That 
      different times are needed for platelet aggregation in venous and arterial blood 
      in dogs treated with ASA and with artificial ventilation is informative about the 
      canine lung not only as a filter for aggregates but also as a source of 
      aggregating substances.
FAU - Welter, H
AU  - Welter H
FAU - Lauterjung, K L
AU  - Lauterjung KL
FAU - Isselhard, W
AU  - Isselhard W
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Inhibition der Thrombocytenaggregation im hämorrhagischen Schock durch 
      Acetylsalicylsäure und maschinelle Beatmung.
PL  - Germany
TA  - Chir Forum Exp Klin Forsch
JT  - Chirurgisches Forum fur experimentelle und klinische Forschung
JID - 0435763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteries/physiopathology
MH  - Aspirin/*pharmacology
MH  - Blood Flow Velocity
MH  - Dogs
MH  - Platelet Aggregation/*drug effects
MH  - *Respiration, Artificial
MH  - Shock, Hemorrhagic/*physiopathology/therapy
MH  - Time Factors
MH  - Veins/physiopathology
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
PST - ppublish
SO  - Chir Forum Exp Klin Forsch. 1978;(1978):89-93.

PMID- 3967845
OWN - NLM
STAT- MEDLINE
DCOM- 19850318
LR  - 20131121
IS  - 0018-5043 (Print)
IS  - 0018-5043 (Linking)
VI  - 17
IP  - 1
DP  - 1985 Jan
TI  - Prostaglandin synthesis inhibition reduces platelet aggregation in diabetes 
      mellitus.
PG  - 42-3
AB  - Platelet aggregation, platelet prostaglandin precursor fatty acids, glycaemia and 
      lipid levels were studied in a group of insulin dependent diabetics whilst taking 
      Aspirin (900 mg daily) and Dipyridamole (300 mg daily) and again two months after 
      discontinuing this treatment.
FAU - Jones, D B
AU  - Jones DB
FAU - Haitas, B
AU  - Haitas B
FAU - Carter, R D
AU  - Carter RD
FAU - Bown, E
AU  - Bown E
FAU - Mann, J I
AU  - Mann JI
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
RN  - 0 (Prostaglandins)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Diabetes Mellitus, Type 1/*blood
MH  - Dipyridamole/pharmacology
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Prostaglandins/*biosynthesis
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1055/s-2007-1013444 [doi]
PST - ppublish
SO  - Horm Metab Res. 1985 Jan;17(1):42-3. doi: 10.1055/s-2007-1013444.

PMID- 21839960
OWN - NLM
STAT- MEDLINE
DCOM- 20111006
LR  - 20181201
IS  - 1878-8769 (Electronic)
IS  - 1878-8750 (Linking)
VI  - 76
IP  - 1-2
DP  - 2011 Jul-Aug
TI  - Emergency reversal of clopidogrel in the setting of spontaneous intracerebral 
      hemorrhage.
PG  - 100-4; discussion 59-60
LID - 10.1016/j.wneu.2011.02.010 [doi]
AB  - OBJECTIVE: To compare outcomes in the setting of spontaneous intracerebral 
      hemorrhage (ICH) in patients taking aspirin (acetylsalicylic acid [ASA]) versus 
      patients taking clopidogrel before hospitalization. METHODS: Patients admitted to 
      the neurosurgical service with a spontaneous ICH while taking an antiplatelet 
      agent were prospectively identified and retrospectively reviewed. Two groups of 
      28 consecutive patients taking ASA or clopidogrel on admission were ultimately 
      evaluated. RESULTS: Patients in the clopidogrel group had a mean age of 72.6 
      years, and patients in the ASA group had a mean age of 65.8 years (P=0.04). 
      Patients taking clopidogrel before hospitalization were significantly more likely 
      than patients taking ASA to experience an increase in hematoma volume (P=0.05). 
      Patients in the ASA group trended toward being discharged to home more frequently 
      than other destinations (P=0.07). The in-hospital mortality rates in this series 
      were 14.3% for the ASA group and 28.6% for the clopidogrel group. However, this 
      association did not reach statistical significance (P=0.19). CONCLUSIONS: In this 
      study, patients taking clopidogrel showed more hematoma expansion, higher 
      in-hospital mortality rates, and a decreased likelihood of a home discharge 
      compared with patients taking ASA alone.
CI  - Copyright © 2011 Elsevier Inc. All rights reserved.
FAU - Campbell, Peter G
AU  - Campbell PG
AD  - Department of Neurosurgery, Thomas Jefferson University, Jefferson Hospital for 
      Neurosciences, Philadelphia, Pennsylvania, USA.
FAU - Yadla, Sanjay
AU  - Yadla S
FAU - Sen, Anish N
AU  - Sen AN
FAU - Jallo, Jack
AU  - Jallo J
FAU - Jabbour, Pascal
AU  - Jabbour P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World Neurosurg
JT  - World neurosurgery
JID - 101528275
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/antagonists & inhibitors/therapeutic use
MH  - Cerebral Hemorrhage/etiology/*therapy
MH  - Clopidogrel
MH  - Data Interpretation, Statistical
MH  - Drug Therapy, Combination
MH  - Emergency Medical Services
MH  - Female
MH  - Glasgow Outcome Scale
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - *Platelet Transfusion
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Ventriculoperitoneal Shunt
MH  - Ventriculostomy
MH  - Warfarin/adverse effects/therapeutic use
EDAT- 2011/08/16 06:00
MHDA- 2011/10/07 06:00
CRDT- 2011/08/16 06:00
PHST- 2010/08/08 00:00 [received]
PHST- 2010/11/22 00:00 [revised]
PHST- 2011/02/03 00:00 [accepted]
PHST- 2011/08/16 06:00 [entrez]
PHST- 2011/08/16 06:00 [pubmed]
PHST- 2011/10/07 06:00 [medline]
AID - S1878-8750(11)00126-4 [pii]
AID - 10.1016/j.wneu.2011.02.010 [doi]
PST - ppublish
SO  - World Neurosurg. 2011 Jul-Aug;76(1-2):100-4; discussion 59-60. doi: 
      10.1016/j.wneu.2011.02.010.

PMID- 8166943
OWN - NLM
STAT- MEDLINE
DCOM- 19940601
LR  - 20190920
IS  - 1046-7408 (Print)
IS  - 1046-7408 (Linking)
VI  - 31
IP  - 1
DP  - 1994 Jan
TI  - Prevention of pregnancy-induced hypertension in twins by early administration of 
      low-dose aspirin: a preliminary report.
PG  - 19-24
AB  - PROBLEM: Effectiveness of early administered low-dose aspirin in prevention of 
      pregnancy-induced hypertension (PIH) and fetal growth retardation in twin 
      pregnancies was investigated in a randomized placebo controlled, double-blind 
      trial in 47 twin pregnancies. METHOD: Twenty-four women received 100 mg of 
      aspirin daily from mean gestational age of 17.7 wk, and 23 women ingested placebo 
      from a mean gestational age of 18 wk until delivery. The placebo and aspirin 
      group were similar in age, weight gain, zygosity, gravidity, parity, and 
      obstetrical antecedents. Treatment lasted for a mean period of 16.8 wk and 18.3 
      wk in the placebo and aspirin groups, respectively. The mean gestational age at 
      birth was 35.0 wk and 36.4 wk in the placebo and aspirin groups, respectively. 
      RESULTS: PIH was noted in six women (26%) in the placebo group, but in only one 
      woman (4%) in the aspirin treated patients (P < .05). The mean combined fetal 
      weights of both twins, and the mean weight of the second twin at delivery were 
      significantly higher in the aspirin treated mothers than in the placebo treated 
      gravidas (mean difference of 781 g, P < .02 and mean difference of 488 g, P < 
      .005, respectively). Intrauterine growth retardation (< 10th percentile) 
      concerned 11 (24%) and six (13%) fetuses in the placebo and aspirin groups, 
      respectively. No adverse effects of treatment to either the mothers or the 
      infants were noted. CONCLUSION: Low-dose aspirin reduces the incidence of PIH and 
      has a beneficial effect on fetal growth in twin pregnancies. Additional clinical 
      trials are needed in order to define and select subgroups of twins where aspirin 
      treatment is recommended.
FAU - Caspi, E
AU  - Caspi E
AD  - Department of Obstetrics and Gynecology, Assaf Harofeh Medical Center, Zerifin, 
      Israel.
FAU - Raziel, A
AU  - Raziel A
FAU - Sherman, D
AU  - Sherman D
FAU - Arieli, S
AU  - Arieli S
FAU - Bukovski, I
AU  - Bukovski I
FAU - Weinraub, Z
AU  - Weinraub Z
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Double-Blind Method
MH  - Embryonic and Fetal Development/drug effects
MH  - Female
MH  - Humans
MH  - Hypertension/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*prevention & control
MH  - Pregnancy, Multiple/*physiology
MH  - Twins
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1111/j.1600-0897.1994.tb00842.x [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 1994 Jan;31(1):19-24. doi: 
      10.1111/j.1600-0897.1994.tb00842.x.

PMID- 8173677
OWN - NLM
STAT- MEDLINE
DCOM- 19940609
LR  - 20191023
IS  - 1350-7540 (Print)
IS  - 1350-7540 (Linking)
VI  - 7
IP  - 1
DP  - 1994 Feb
TI  - Antithrombotic therapies for stroke prevention.
PG  - 48-53
AB  - Aspirin is the most widely used antiplatelet agent, reducing nonfatal ischemic 
      stroke by 22%. There is increasing evidence that the efficacy of aspirin may vary 
      with the etiologic subtype of stroke. Although the cost and side effects have 
      limited the use of ticlopidine, patients who are intolerant of aspirin and those 
      experiencing transient ischemic attack or stroke during aspirin therapy should be 
      given ticlopidine. Patients with atrial fibrillation have a five-fold increased 
      risk of stroke and require prophylactic therapy with warfarin or aspirin. Aspirin 
      is less effective than warfarin in preventing atrial fibrillation-associated 
      stroke, but the higher risk of hemorrhagic complications and frequent monitoring 
      associated with warfarin must be considered. Clinical and echocardiographic 
      predictors of increased thromboembolic risk in atrial fibrillation patients have 
      been identified and may direct the treatment choice.
FAU - Solomon, D H
AU  - Solomon DH
AD  - Department of Medicine, University of Texas Health Science Center, San Antonio 
      78284.
FAU - Hart, R G
AU  - Hart RG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Neurol
JT  - Current opinion in neurology
JID - 9319162
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Atrial Fibrillation/complications
MH  - Brain Ischemia/complications
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Ticlopidine/administration & dosage/adverse effects
RF  - 22
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
AID - 10.1097/00019052-199402000-00009 [doi]
PST - ppublish
SO  - Curr Opin Neurol. 1994 Feb;7(1):48-53. doi: 10.1097/00019052-199402000-00009.

PMID- 9835257
OWN - NLM
STAT- MEDLINE
DCOM- 19990210
LR  - 20190909
IS  - 1045-3873 (Print)
IS  - 1045-3873 (Linking)
VI  - 9
IP  - 11
DP  - 1998 Nov
TI  - Pretreatment with antithrombotic agents during radiofrequency catheter ablation: 
      a randomized comparison of aspirin versus ticlopidine.
PG  - 1144-51
AB  - INTRODUCTION: D-dimer is a product of fibrin degradation and can serve as a 
      biochemical marker of thrombus formation and reactive fibrinolysis. According to 
      our previous observations, and as reflected by elevated plasma D-dimer levels, 
      lesions produced by radiofrequency (RF) ablation have a thrombogenic effect. 
      Pretreatment with combined aspirin and ticlopidine mitigates this 
      thrombogenicity; however, the effect of either agent alone remains unknown. 
      METHODS AND RESULTS: In this study, 59 patients undergoing RF ablation were 
      randomized to pretreatment with aspirin (group I; n = 30) or ticlopidine (group 
      II; n = 29) for 3 days prior to RF ablation. D-dimer levels were measured by 
      enzyme immunoassay before and after the electrophysiologic study (EPS), and both 
      immediately and at 48 hours after RF ablation. Results also were compared with 
      those of 31 patients (nonrandomized group III) who had received both aspirin and 
      ticlopidine. At all stages, D-dimer levels were higher in groups I and II when 
      compared with group III. Baseline D-dimer (31+/-20 vs 24+/-13 vs 17+/-11 
      microg/L, respectively; P = 0.002) rose after EPS to higher levels in groups I 
      and II (91+/-100 microg/L and 51+/-35 microg/L) compared with group III (31+/-17 
      microg/L; P = 0.001). After RF ablation, D-dimer levels increased in all groups, 
      but this increase was much higher in groups I and II (214+/-210 microg/L and 
      201+/-222 microg/L) than in group III (74+/-60 microg/L; P = 0.005). At 48 hours, 
      D-dimer levels decreased in all groups, but remained higher in groups I and II 
      (91+/-100 microg/L and 95+/-99 microg/L) than in group III (35+/-31 microg/L; P = 
      0.009). There were no differences among the three groups in the number of RF 
      ablation lesions or the duration of the RF ablation procedure. CONCLUSION: 
      Pretreatment with aspirin or ticlopidine alone does not decrease the thrombogenic 
      potential of RF ablation. Only combined therapy with aspirin and ticlopidine has 
      a favorable effect, as reflected by the lower degree of D-dimer elevation.
FAU - Manolis, A S
AU  - Manolis AS
AD  - Onassis Cardiac Surgery Center, Athens, Greece.
FAU - Maounis, T
AU  - Maounis T
FAU - Vassilikos, V
AU  - Vassilikos V
FAU - Melita-Manolis, H
AU  - Melita-Manolis H
FAU - Psarros, L
AU  - Psarros L
FAU - Terzoglou, G
AU  - Terzoglou G
FAU - Cokkinos, D V
AU  - Cokkinos DV
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Cardiovasc Electrophysiol
JT  - Journal of cardiovascular electrophysiology
JID - 9010756
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Biomarkers
MH  - *Catheter Ablation
MH  - Child
MH  - Double-Blind Method
MH  - Electrophysiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Preoperative Care
MH  - Ticlopidine/*therapeutic use
EDAT- 1998/12/03 00:00
MHDA- 1998/12/03 00:01
CRDT- 1998/12/03 00:00
PHST- 1998/12/03 00:00 [pubmed]
PHST- 1998/12/03 00:01 [medline]
PHST- 1998/12/03 00:00 [entrez]
AID - 10.1111/j.1540-8167.1998.tb00085.x [doi]
PST - ppublish
SO  - J Cardiovasc Electrophysiol. 1998 Nov;9(11):1144-51. doi: 
      10.1111/j.1540-8167.1998.tb00085.x.

PMID- 35104279
OWN - NLM
STAT- MEDLINE
DCOM- 20220210
LR  - 20220210
IS  - 1549-1676 (Electronic)
IS  - 1549-1277 (Print)
IS  - 1549-1277 (Linking)
VI  - 19
IP  - 2
DP  - 2022 Feb
TI  - Evaluation of low-dose aspirin in the prevention of recurrent spontaneous preterm 
      labour (the APRIL study): A multicentre, randomised, double-blinded, 
      placebo-controlled trial.
PG  - e1003892
LID - 10.1371/journal.pmed.1003892 [doi]
LID - e1003892
AB  - BACKGROUND: Preterm birth is the leading cause of neonatal morbidity and 
      mortality. The recurrence rate of spontaneous preterm birth is high, and 
      additional preventive measures are required. Our objective was to assess the 
      effectiveness of low-dose aspirin compared to placebo in the prevention of 
      preterm birth in women with a previous spontaneous preterm birth. METHODS AND 
      FINDINGS: We performed a parallel multicentre, randomised, double-blinded, 
      placebo-controlled trial (the APRIL study). The study was performed in 8 tertiary 
      and 26 secondary care hospitals in the Netherlands. We included women with a 
      singleton pregnancy and a history of spontaneous preterm birth of a singleton 
      between 22 and 37 weeks. Participants were randomly assigned to aspirin 80 mg 
      daily or placebo initiated between 8 and 16 weeks of gestation and continued 
      until 36 weeks or delivery. Randomisation was computer generated, with allocation 
      concealment by using sequentially numbered medication containers. Participants, 
      their healthcare providers, and researchers were blinded for treatment 
      allocation. The primary outcome was preterm birth <37 weeks of gestation. 
      Secondary outcomes included a composite of poor neonatal outcome 
      (bronchopulmonary dysplasia, periventricular leukomalacia > grade 1, 
      intraventricular hemorrhage > grade 2, necrotising enterocolitis > stage 1, 
      retinopathy of prematurity, culture proven sepsis, or perinatal death). Analyses 
      were performed by intention to treat. From May 31, 2016 to June 13, 2019, 406 
      women were randomised to aspirin (n = 204) or placebo (n = 202). A total of 387 
      women (81.1% of white ethnic origin, mean age 32.5 ± SD 3.8) were included in the 
      final analysis: 194 women were allocated to aspirin and 193 to placebo. Preterm 
      birth <37 weeks occurred in 41 (21.2%) women in the aspirin group and 49 (25.4%) 
      in the placebo group (relative risk (RR) 0.83, 95% confidence interval (CI) 0.58 
      to 1.20, p = 0.32). In women with ≥80% medication adherence, preterm birth 
      occurred in 24 (19.2%) versus 30 (24.8%) women (RR 0.77, 95% CI 0.48 to 1.25, p = 
      0.29). The rate of the composite of poor neonatal outcome was 4.6% (n = 9) versus 
      2.6% (n = 5) (RR 1.79, 95% CI 0.61 to 5.25, p = 0.29). Among all randomised 
      women, serious adverse events occurred in 11 out of 204 (5.4%) women allocated to 
      aspirin and 11 out of 202 (5.4%) women allocated to placebo. None of these 
      serious adverse events was considered to be associated with treatment allocation. 
      The main study limitation is the underpowered sample size due to the lower than 
      expected preterm birth rates. CONCLUSIONS: In this study, we observed that 
      low-dose aspirin did not significantly reduce the preterm birth rate in women 
      with a previous spontaneous preterm birth. However, a modest reduction of preterm 
      birth with aspirin cannot be ruled out. Further research is required to determine 
      a possible beneficial effect of low-dose aspirin for women with a previous 
      spontaneous preterm birth. TRIAL REGISTRATION: Dutch Trial Register (NL5553, 
      NTR5675) https://www.trialregister.nl/trial/5553.
FAU - Landman, Anadeijda J E M C
AU  - Landman AJEMC
AUID- ORCID: 0000-0002-6354-3489
AD  - Department of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit 
      Amsterdam, Amsterdam Reproduction & Development Research Institute, Amsterdam, 
      the Netherlands.
FAU - de Boer, Marjon A
AU  - de Boer MA
AD  - Department of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit 
      Amsterdam, Amsterdam Reproduction & Development Research Institute, Amsterdam, 
      the Netherlands.
FAU - Visser, Laura
AU  - Visser L
AD  - Department of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit 
      Amsterdam, Amsterdam Reproduction & Development Research Institute, Amsterdam, 
      the Netherlands.
FAU - Nijman, Tobias A J
AU  - Nijman TAJ
AD  - Department of Obstetrics and Gynaecology, Haaglanden Medical Centre, Den Haag, 
      the Netherlands.
FAU - Hemels, Marieke A C
AU  - Hemels MAC
AD  - Department of Neonatal Intensive Care, Isala, Zwolle, the Netherlands.
FAU - Naaktgeboren, Christiana N
AU  - Naaktgeboren CN
AUID- ORCID: 0000-0002-0685-9989
AD  - Department of Obstetrics and Gynaecology, Amsterdam UMC, University of Amsterdam, 
      Amsterdam Reproduction & Development Research Institute, Amsterdam, the 
      Netherlands.
FAU - van der Weide, Marijke C
AU  - van der Weide MC
AUID- ORCID: 0000-0001-6979-1347
AD  - Department of Obstetrics and Gynaecology, Amsterdam UMC, University of Amsterdam, 
      Amsterdam Reproduction & Development Research Institute, Amsterdam, the 
      Netherlands.
FAU - Mol, Ben W
AU  - Mol BW
AUID- ORCID: 0000-0001-8337-550X
AD  - Department of Obstetrics and Gynaecology, School of Clinical Sciences at Monash 
      Health, Monash University, Melbourne, Victoria, Australia.
AD  - Aberdeen Centre for Women's Health Research, University of Aberdeen Aberdeen, 
      United Kingdom.
FAU - van Laar, Judith O E H
AU  - van Laar JOEH
AD  - Department of Obstetrics and Gynaecology, Máxima Medical Centre, Veldhoven, the 
      Netherlands.
FAU - Papatsonis, Dimitri N M
AU  - Papatsonis DNM
AD  - Department of Obstetrics and Gynaecology, Amphia Hospital, Breda, the 
      Netherlands.
FAU - Bekker, Mireille N
AU  - Bekker MN
AUID- ORCID: 0000-0002-7372-4291
AD  - Department of Obstetrics and Gynaecology, University Medical Centre Utrecht, 
      Utrecht, the Netherlands.
FAU - van Drongelen, Joris
AU  - van Drongelen J
AUID- ORCID: 0000-0002-4592-4288
AD  - Department of Obstetrics and Gynaecology, Radboud University Medical Center, 
      Nijmegen, the Netherlands.
FAU - van Pampus, Mariëlle G
AU  - van Pampus MG
AD  - Department of Obstetrics and Gynaecology, OLVG, Amsterdam, the Netherlands.
FAU - Sueters, Marieke
AU  - Sueters M
AD  - Department of Obstetrics and Gynaecology, Leiden University Medical Centre, 
      Leiden, the Netherlands.
FAU - van der Ham, David P
AU  - van der Ham DP
AUID- ORCID: 0000-0003-1434-2477
AD  - Department of Obstetrics and Gynaecology, Martini Hospital, Groningen, the 
      Netherlands.
FAU - Sikkema, J Marko
AU  - Sikkema JM
AD  - Department of Obstetrics and Gynaecology, Hospital Group Twente Almelo, Almelo, 
      the Netherlands.
FAU - Zwart, Joost J
AU  - Zwart JJ
AD  - Department of Obstetrics and Gynaecology, Deventer Hospital, Deventer, the 
      Netherlands.
FAU - Huisjes, Anjoke J M
AU  - Huisjes AJM
AD  - Department of Obstetrics and Gynaecology, Gelre Hospitals Apeldoorn, Apeldoorn, 
      the Netherlands.
FAU - van Huizen, Marloes E
AU  - van Huizen ME
AD  - Department of Obstetrics and Gynaecology, Haga Hospital, Den Haag, the 
      Netherlands.
FAU - Kleiverda, Gunilla
AU  - Kleiverda G
AD  - Department of Obstetrics and Gynaecology, Flevo Hospital Almere, Almere, the 
      Netherlands.
FAU - Boon, Janine
AU  - Boon J
AD  - Department of Obstetrics and Gynaecology, Diakonessenhuis, Utrecht, the 
      Netherlands.
FAU - Franssen, Maureen T M
AU  - Franssen MTM
AD  - Department of Obstetrics and Gynaecology, University Medical Centre Groningen, 
      Groningen, the Netherlands.
FAU - Hermes, Wietske
AU  - Hermes W
AD  - Department of Obstetrics and Gynaecology, Haaglanden Medical Centre, Den Haag, 
      the Netherlands.
FAU - Visser, Harry
AU  - Visser H
AUID- ORCID: 0000-0001-8471-4550
AD  - Department of Obstetrics and Gynaecology, Tergooi Hospitals, Hilversum, the 
      Netherlands.
FAU - de Groot, Christianne J M
AU  - de Groot CJM
AD  - Department of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit 
      Amsterdam, Amsterdam Reproduction & Development Research Institute, Amsterdam, 
      the Netherlands.
FAU - Oudijk, Martijn A
AU  - Oudijk MA
AD  - Department of Obstetrics and Gynaecology, Amsterdam UMC, University of Amsterdam, 
      Amsterdam Reproduction & Development Research Institute, Amsterdam, the 
      Netherlands.
LA  - eng
SI  - NTR/NL5553
SI  - NTR/NTR5675
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20220201
PL  - United States
TA  - PLoS Med
JT  - PLoS medicine
JID - 101231360
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - doi: 10.1371/journal.pmed.1003908
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Netherlands
MH  - Obstetric Labor, Premature/*prevention & control
MH  - Pregnancy
MH  - Premature Birth/prevention & control
PMC - PMC8806064
COIS- I have read the journal’s policy and the authors of this manuscript have the 
      following competing interests: BM reported an Investigator grant from the 
      National Health and Medical Research Council (NHMRC; grant no. GNT1176437); 
      receipt of research funding from Guerbet; and is a former advisory board member 
      at ObsEva. All other authors do not report any relevant financial activities 
      outside the submitted work.
EDAT- 2022/02/02 06:00
MHDA- 2022/02/11 06:00
CRDT- 2022/02/01 17:10
PHST- 2021/06/23 00:00 [received]
PHST- 2021/12/14 00:00 [accepted]
PHST- 2022/02/01 17:10 [entrez]
PHST- 2022/02/02 06:00 [pubmed]
PHST- 2022/02/11 06:00 [medline]
AID - PMEDICINE-D-21-02759 [pii]
AID - 10.1371/journal.pmed.1003892 [doi]
PST - epublish
SO  - PLoS Med. 2022 Feb 1;19(2):e1003892. doi: 10.1371/journal.pmed.1003892. 
      eCollection 2022 Feb.

PMID- 20435181
OWN - NLM
STAT- MEDLINE
DCOM- 20100524
LR  - 20131121
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 159
IP  - 5
DP  - 2010 May
TI  - Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal 
      anti-inflammatory drug use explains the lack of clinical benefit of aspirin on 
      first myocardial infarction attributed to "aspirin resistance".
PG  - 744-8
LID - 10.1016/j.ahj.2009.11.033 [doi]
AB  - BACKGROUND: "Aspirin resistance" has been defined as the occurrence of 
      cardiovascular events despite regular intake of aspirin. One major analytic study 
      suggesting that "aspirin resistance" is a clinical reality was unable to control 
      for confounding by nonadherence or nonsteroidal anti-inflammatory drugs (NSAIDs). 
      METHODS: We formulated a hypothesis from subgroup analyses in the Physicians' 
      Health Study, a randomized double-blind placebo-controlled trial testing 325 mg 
      of aspirin every other day among 22,071 apparently healthy US male physicians. We 
      classified participants by nonadherence or NSAIDs and used time-varying Cox 
      proportional hazard models to adjust for confounding. RESULTS: After 5 years, the 
      blinded aspirin component was terminated early based on the unanimous 
      recommendation of the Data and Safety Monitoring Board. Of 378 confirmed first 
      myocardial infarctions (139 aspirin and 239 placebo), the relative risk (RR) was 
      0.56 (95% CI 0.45-0.70, P < .00001). There was no statistically significant 
      reduction among aspirin <150/180 pills/y (RR = 0.91, 95% CI 0.61-1.35, P = .62) 
      or NSAID users >60 days per year (RR = 1.54, 95% CI 0.68-3.47, P = .31). There 
      was a statistically significant reduction among aspirin >150/180 pills/y and 
      NSAID users <60 days/y (RR = 0.55, 95% CI 0.44-0.70, P < or = .0001) and an 
      increase among aspirin <150/180 pills/y and NSAID users >60 days/y (RR of 3.43, 
      95% CI 1.41-8.33, P = .007). CONCLUSIONS: In subgroup analyses useful to 
      formulate hypotheses from a large randomized trial in apparently healthy men, 
      aspirin nonadherence or NSAID use explained the lack of clinical benefit of 
      aspirin on first myocardial infarction that has been attributed to "aspirin 
      resistance." Direct randomized comparisons are necessary in trials designed a 
      priori to test this hypothesis.
CI  - 2010 Mosby, Inc. All rights reserved.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - Florida Atlantic University, Boca Raton, 33431-0991, USA. profchhmd@prodigy.net
FAU - Schneider, Wendy R
AU  - Schneider WR
FAU - Hebert, Patricia R
AU  - Hebert PR
FAU - Tantry, Udaya S
AU  - Tantry US
FAU - Gurbel, Paul A
AU  - Gurbel PA
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am Heart J. 2010 May;159(5):713-5. PMID: 20435177
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/pharmacology
MH  - Drug Tolerance
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - *Patient Compliance
MH  - Proportional Hazards Models
EDAT- 2010/05/04 06:00
MHDA- 2010/05/25 06:00
CRDT- 2010/05/04 06:00
PHST- 2009/06/05 00:00 [received]
PHST- 2009/11/25 00:00 [accepted]
PHST- 2010/05/04 06:00 [entrez]
PHST- 2010/05/04 06:00 [pubmed]
PHST- 2010/05/25 06:00 [medline]
AID - S0002-8703(10)00141-9 [pii]
AID - 10.1016/j.ahj.2009.11.033 [doi]
PST - ppublish
SO  - Am Heart J. 2010 May;159(5):744-8. doi: 10.1016/j.ahj.2009.11.033.

PMID- 7336165
OWN - NLM
STAT- MEDLINE
DCOM- 19820521
LR  - 20190909
IS  - 0036-553X (Print)
IS  - 0036-553X (Linking)
VI  - 27
IP  - 2
DP  - 1981 Aug
TI  - Congenital deficiency of cyclo-oxygenase in a woman with generalized 
      atherosclerosis.
PG  - 65-9
AB  - The case of a 52-year-old woman with congenital cyclo-oxygenase deficiency, signs 
      of generalized atherosclerosis and a moderate bleeding tendency is reported. 
      Secondary platelet aggregation was absent. Platelet aggregation induced by 
      arachidonic acid failed totally while that induced by calcium ionophore was 
      normal. No malondialdehyde formation could be detected in her 
      platelet-rich-plasma. The life-long deficiency of cyclo-oxygenase had not 
      protected her from progressive vascular disease. This case suggests that the 
      chronic intake of large doses of aspirin cannot prevent arterial disorders.
FAU - Boda, Z
AU  - Boda Z
FAU - Tamás, E
AU  - Tamás E
FAU - Altorjay, I
AU  - Altorjay I
FAU - Pfliegler, G
AU  - Pfliegler G
FAU - Rak, K
AU  - Rak K
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Denmark
TA  - Scand J Haematol
JT  - Scandinavian journal of haematology
JID - 0404507
RN  - EC 1.13.- (Oxygenases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis/blood/*enzymology
MH  - Aspirin/therapeutic use
MH  - Blood Platelets/enzymology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Oxygenases/*deficiency
MH  - Platelet Aggregation
EDAT- 1981/08/01 00:00
MHDA- 1981/08/01 00:01
CRDT- 1981/08/01 00:00
PHST- 1981/08/01 00:00 [pubmed]
PHST- 1981/08/01 00:01 [medline]
PHST- 1981/08/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1981.tb00453.x [doi]
PST - ppublish
SO  - Scand J Haematol. 1981 Aug;27(2):65-9. doi: 10.1111/j.1600-0609.1981.tb00453.x.

PMID- 2486135
OWN - NLM
STAT- MEDLINE
DCOM- 19910108
LR  - 20191029
IS  - 0904-213X (Print)
IS  - 0904-213X (Linking)
VI  - 43
IP  - 8
DP  - 1989 Sep
TI  - Aspirin prodrugs: synthesis and hydrolysis of 
      2-benzyloxy-2-methyl-4H-1,3-benzodioxin-4-ones.
PG  - 793-8
AB  - Aspirin is widely used for its analgesic, antiinflammatory and antipyretic 
      properties. Among its disadvantages are the relatively narrow therapeutic margin, 
      its irritancy towards the gastric mucosa, and occasionally patient 
      hypersensitivity towards aspirin. As part of our effort to develop prodrugs 
      without these liabilities eleven new title compounds have been isolated and 
      characterized. These 'superaspirin' candidates were subjected to non-enzymatic 
      hydrolysis for a first rapid screening in vitro. Only 
      2-(2,6-dimethoxybenzyloxy)-2-methyl-4H-1,3-benzodioxin-4-one (4c) was observed to 
      act as an exclusive aspirin prodrug, while 
      2-(2-methoxybenzyloxy)-2-methyl-4H-1,3-benzodioxin-4-one (4b) and 
      2-(2-ethoxybenzyloxy)-2-methyl-4H-1,3- benzodioxin-4-one (4d) were shown to 
      release both aspirin 6 and salicylic acid 7. Subsequently, these three candidates 
      were further characterized by investigation of the pH profile of their hydrolysis 
      rates.
FAU - Ankersen, M
AU  - Ankersen M
AD  - Department of Chemistry, University of Aarhus, Denmark.
FAU - Senning, A
AU  - Senning A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Acta Chem Scand (Cph)
JT  - Acta chemica Scandinavica (Copenhagen, Denmark : 1989)
JID - 9012772
RN  - 0 (Benzyl Alcohols)
RN  - 0 (Dioxins)
RN  - 0 (Prodrugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analogs & derivatives
MH  - Benzyl Alcohols/*chemical synthesis/chemistry
MH  - Chromatography, High Pressure Liquid
MH  - Dioxins/*chemical synthesis/chemistry
MH  - Hydrolysis
MH  - Kinetics
MH  - Magnetic Resonance Spectroscopy
MH  - Molecular Structure
MH  - Prodrugs/*chemical synthesis/chemistry
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
AID - 10.3891/acta.chem.scand.43-0793 [doi]
PST - ppublish
SO  - Acta Chem Scand (Cph). 1989 Sep;43(8):793-8. doi: 
      10.3891/acta.chem.scand.43-0793.

PMID- 33118207
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1099-0801 (Electronic)
IS  - 0269-3879 (Linking)
VI  - 35
IP  - 2
DP  - 2021 Feb
TI  - Green analysis of newly approved binary omeprazole/aspirin mixture in presence of 
      aspirin impurity using ultra-high-performance liquid chromatography and 
      thin-layer chromatography methods.
PG  - e4986
LID - 10.1002/bmc.4986 [doi]
AB  - Two green, simple, and accurate chromatographic methods were developed and 
      validated for the simultaneous determination of omeprazole and aspirin mixture in 
      the presence of salicylic acid, a major impurity of aspirin. Method A is a 
      reversed-phase ultra-high-performance liquid chromatography; the separation was 
      performed on a C18 column, with a mobile phase composed of ethanol:0.1% aqueous 
      solution of triethylamine acidified with orthophosphoric acid (pH 3) (30:70, v/v) 
      at 0.15 mL/min flow rate and 230 nm. Omeprazole, aspirin, and aspirin impurity 
      retention times were 7.47, 4.40, and 5.13 min, respectively. Good linearity was 
      achieved in the concentration ranges of 5-80, 5-85, and 3-50 μg/mL for the three 
      mentioned components, respectively. Method B is thin-layer chromatography (TLC) 
      where silica gel TLC F254 plates were utilized to achieve separation using 
      ethanol:ethyl acetate (2:8, v/v) as a developing system at 240 nm. The resulted 
      R(f) values were 0.83, 0.65, and 0.23 for omeprazole, aspirin, and impurity, 
      respectively. The concentration ranges of 0.1-3 μg/band for the three drugs 
      showed good linearity. The proposed methods are eco-friendly and greener when 
      compared to the already reported method (Microchemical Journal, 152, 104350). 
      This is the first use of TLC method for the determination of the three drugs. 
      International Council for Harmonization (ICH) guidelines were followed to ensure 
      the validity of developed methods.
CI  - © 2020 John Wiley & Sons, Ltd.
FAU - Abdelaleem, Eglal A
AU  - Abdelaleem EA
AUID- ORCID: 0000-0002-6461-2490
AD  - Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Beni-Suef 
      University, Beni-Suef, Egypt.
FAU - Abou El Ella, Dalal A
AU  - Abou El Ella DA
AD  - Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain-shams University, 
      Cairo, Egypt.
FAU - Mahmoud, Alaa M
AU  - Mahmoud AM
AUID- ORCID: 0000-0002-0224-2578
AD  - Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Nahda 
      University, Beni-Suef, Egypt.
FAU - Abdelhamid, Nessreen S
AU  - Abdelhamid NS
AD  - Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Beni-Suef 
      University, Beni-Suef, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - KG60484QX9 (Omeprazole)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Chromatography, Thin Layer/*methods
MH  - *Drug Contamination
MH  - Green Chemistry Technology
MH  - Limit of Detection
MH  - Linear Models
MH  - Omeprazole/*analysis
MH  - Reproducibility of Results
MH  - Salicylic Acid/analysis
OTO - NOTNLM
OT  - aspirin
OT  - aspirin impurity
OT  - green thin-layer chromatography
OT  - green ultra-high-performance liquid chromatography
OT  - omeprazole
EDAT- 2020/10/30 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/10/29 05:56
PHST- 2020/05/20 00:00 [received]
PHST- 2020/08/22 00:00 [revised]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/10/29 05:56 [entrez]
AID - 10.1002/bmc.4986 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2021 Feb;35(2):e4986. doi: 10.1002/bmc.4986. Epub 2020 Oct 28.

PMID- 2677086
OWN - NLM
STAT- MEDLINE
DCOM- 19891114
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 14
IP  - 4
DP  - 1989 Oct
TI  - Platelet inhibitor agents in cardiovascular disease: an update.
PG  - 813-36
AB  - Platelets interact with the coagulation and fibrinolytic systems in the 
      maintenance of hemostasis. However, these physiologic mechanisms may become 
      pathologic, requiring prevention and treatment. In this review, the following 
      clinical developments are analyzed: 1) the role of platelets in thrombogenesis; 
      2) the pharmacology of platelet inhibitory agents; and, most important, 3) the 
      results of recent randomized trials of platelet inhibitor agents in different 
      cardiovascular disorders. Aspirin reduces mortality and infarction rates in 
      unstable angina and significantly decreases vascular mortality in acute 
      myocardial infarction. Platelet inhibitors decrease mortality and recurrent 
      cardiovascular events in the chronic phase after myocardial infarction. They also 
      decrease vein graft occlusion rates after coronary bypass surgery. Although 
      platelet inhibitors are beneficial in preventing acute vessel occlusion during 
      coronary angioplasty, they are ineffective in preventing chronic restenosis. 
      Antiplatelet agents, combined with warfarin, reduce thromboembolic events in 
      patients with a mechanical prosthesis. Platelet inhibitors are also effective in 
      secondary prevention of vascular events in patients with cerebrovascular disease. 
      Finally, the use of aspirin for primary prevention of cardiovascular disease is 
      still evolving, particularly in individuals at high risk. In conclusion, platelet 
      inhibitors are effective in patients with a variety of cardiovascular disorders. 
      The best studied, most inexpensive and least toxic agent is aspirin at a daily 
      dose of 160 to 325 mg. Studies using new platelet inhibitor agents with different 
      mechanisms of action are currently underway.
FAU - Stein, B
AU  - Stein B
AD  - Division of Cardiology, Mount Sinai Medical Center, New York, New York.
FAU - Fuster, V
AU  - Fuster V
FAU - Israel, D H
AU  - Israel DH
FAU - Cohen, M
AU  - Cohen M
FAU - Badimon, L
AU  - Badimon L
FAU - Badimon, J J
AU  - Badimon JJ
FAU - Chesebro, J H
AU  - Chesebro JH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Blood Platelets/physiology
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cerebrovascular Disorders/drug therapy
MH  - Coronary Disease/drug therapy
MH  - Graft Occlusion, Vascular/drug therapy
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thrombosis/etiology
RF  - 205
EDAT- 1989/10/01 00:00
MHDA- 1989/10/01 00:01
CRDT- 1989/10/01 00:00
PHST- 1989/10/01 00:00 [pubmed]
PHST- 1989/10/01 00:01 [medline]
PHST- 1989/10/01 00:00 [entrez]
AID - 0735-1097(89)90453-1 [pii]
AID - 10.1016/0735-1097(89)90453-1 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1989 Oct;14(4):813-36. doi: 10.1016/0735-1097(89)90453-1.

PMID- 30425392
OWN - NLM
STAT- MEDLINE
DCOM- 20191002
LR  - 20191002
IS  - 1827-6806 (Print)
IS  - 1827-6806 (Linking)
VI  - 19
IP  - 11
DP  - 2018 Nov
TI  - [Bleeding risk in patients with acute coronary syndromes treated with 
      antiplatelet agents: incidence, prognosis and clinical evaluation. From research 
      to clinical practice].
PG  - 628-639
LID - 10.1714/3012.30110 [doi]
AB  - Dual antiplatelet therapy (DAPT) including aspirin and a P2Y12 inhibitor is the 
      cornerstone for the treatment of patients with acute coronary syndrome (ACS). The 
      introduction of more potent drugs significantly reduced ischemic events, but with 
      an associated increased risk of bleeding. Although appropriate estimation of 
      bleeding risk by comparing the single drugs is challenging, mainly because of 
      differences in definitions, it has been consistently shown that bleeding events 
      are associated with an adverse outcome, both at short and long-term 
      follow-up.Current guidelines recommend a short DAPT in patients at high bleeding 
      risk, making appropriate risk estimation of crucial importance. Several numerical 
      scores have been proposed for use in daily clinical practice. Although an 
      objective risk assessment provides superior risk discrimination compared to 
      physician's estimation, none of these scores appear free from limitations, nor 
      have been obtained from cohorts of patients on short-tern treatment with 
      prasugrel or ticagrelor. In the present review, we report the rates of major 
      bleeding observed in the main randomized clinical trials and registries, their 
      association with mortality, differences in definitions when used as safety 
      endpoint, and finally the scores currently used for evaluation in daily clinical 
      practice.
FAU - Ferlini, Marco
AU  - Ferlini M
AD  - S.C. Cardiologia, Fondazione IRCCS Policlinico San Matteo, Pavia.
FAU - Mauri, Silvia
AU  - Mauri S
AD  - S.C. Cardiologia, Fondazione IRCCS Policlinico San Matteo, Pavia.
FAU - Demarchi, Andrea
AU  - Demarchi A
AD  - S.C. Cardiologia, Fondazione IRCCS Policlinico San Matteo, Pavia.
FAU - Portolan, Monica
AU  - Portolan M
AD  - S.C. Cardiologia, Fondazione IRCCS Policlinico San Matteo, Pavia.
FAU - Visconti, Luigi Oltrona
AU  - Visconti LO
AD  - S.C. Cardiologia, Fondazione IRCCS Policlinico San Matteo, Pavia.
LA  - ita
PT  - Journal Article
PT  - Review
TT  - Il rischio di sanguinamento nei pazienti con sindrome coronarica acuta trattati 
      con farmaci antiaggreganti: incidenza, impatto prognostico e metodi di 
      valutazione, dagli studi alla pratica clinica.
PL  - Italy
TA  - G Ital Cardiol (Rome)
JT  - Giornale italiano di cardiologia (2006)
JID - 101263411
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aspirin/administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Practice Guidelines as Topic
MH  - Prognosis
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Time Factors
EDAT- 2018/11/15 06:00
MHDA- 2019/10/03 06:00
CRDT- 2018/11/15 06:00
PHST- 2018/11/15 06:00 [entrez]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2019/10/03 06:00 [medline]
AID - 10.1714/3012.30110 [doi]
PST - ppublish
SO  - G Ital Cardiol (Rome). 2018 Nov;19(11):628-639. doi: 10.1714/3012.30110.

PMID- 21946915
OWN - NLM
STAT- MEDLINE
DCOM- 20120420
LR  - 20131121
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 106
IP  - 6
DP  - 2011 Dec
TI  - Addition of enoxaparin to aspirin for the secondary prevention of placental 
      vascular complications in women with severe pre-eclampsia. The pilot randomised 
      controlled NOH-PE trial.
PG  - 1053-61
LID - 10.1160/TH11-05-0340 [doi]
AB  - Administration of heparin in the secondary prevention of placental vascular 
      complications is still experimental. In women with a previous severe 
      pre-eclampsia, we investigated the effectiveness of enoxaparin, a 
      low-molecular-weight heparin, in preventing these complications. Between January 
      2000 and January 2010, 224 women from the NOHA First cohort, with previous severe 
      pre-eclampsia but no foetal loss during their first pregnancy and negative for 
      antiphospholipid antibodies, were randomised to either a prophylactic daily dose 
      of enoxaparin starting from the positive pregnancy test (n=112), or no enoxaparin 
      (n=112). The primary outcome was a composite of at least one of the following: 
      pre-eclampsia, abruptio placentae, birthweight ≤ 5th percentile, or foetal loss 
      after 20 weeks. Enoxaparin was associated with a lower frequency of primary 
      outcome: 8.9% (n=10/112) vs. 25 % (28/112), p=0.004, hazard ratio = 0.32, 95% 
      confidence interval (0.16-0.66), p=0.002. Enoxaparin was safe, with no obvious 
      side-effect, no thrombocytopenia nor major bleeding event excess. This pilot 
      study shows that enoxaparin given early during the second pregnancy decreases the 
      occurrence of placental vascular complications in women with a previous severe 
      pre-eclampsia during their first pregnancy.
FAU - Gris, Jean-Christophe
AU  - Gris JC
AD  - Research team EA2992, Montpellier 1 University, Nîmes, France. 
      jean.christophe.gris@chu-nimes.fr
FAU - Chauleur, Céline
AU  - Chauleur C
FAU - Molinari, Nicolas
AU  - Molinari N
FAU - Marès, Pierre
AU  - Marès P
FAU - Fabbro-Peray, Pascale
AU  - Fabbro-Peray P
FAU - Quéré, Isabelle
AU  - Quéré I
FAU - Lefrant, Jean-Yves
AU  - Lefrant JY
FAU - Haddad, Bassam
AU  - Haddad B
FAU - Dauzat, Michel
AU  - Dauzat M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110922
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cohort Studies
MH  - Disease Progression
MH  - Enoxaparin/*administration & dosage/adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Gravidity
MH  - Humans
MH  - Pilot Projects
MH  - Placenta/*pathology
MH  - Pre-Eclampsia/*physiopathology
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*prevention & control
MH  - Treatment Outcome
EDAT- 2011/09/29 06:00
MHDA- 2012/04/21 06:00
CRDT- 2011/09/28 06:00
PHST- 2011/05/20 00:00 [received]
PHST- 2011/08/19 00:00 [accepted]
PHST- 2011/09/28 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2012/04/21 06:00 [medline]
AID - 11-05-0340 [pii]
AID - 10.1160/TH11-05-0340 [doi]
PST - ppublish
SO  - Thromb Haemost. 2011 Dec;106(6):1053-61. doi: 10.1160/TH11-05-0340. Epub 2011 Sep 
      22.

PMID- 12462133
OWN - NLM
STAT- MEDLINE
DCOM- 20030507
LR  - 20131121
IS  - 1053-8569 (Print)
IS  - 1053-8569 (Linking)
VI  - 11
IP  - 7
DP  - 2002 Oct-Nov
TI  - The nature and frequency of potential warfarin drug interactions that increase 
      the risk of bleeding in patients with atrial fibrillation.
PG  - 569-76
AB  - PURPOSE: To determine the frequency with which atrial fibrillation (AF) patients 
      receiving warfarin are prescribed interacting drugs that could increase bleeding 
      risks. METHODS: We retrospectively examined medical records for 704 Medicare 
      beneficiaries > or = 65 years of age discharged from Kansas hospitals with AF. We 
      identified all patients receiving warfarin and examined discharge prescriptions 
      for drugs that could increase bleeding risk either by increasing the 
      international normalized ratio (INR) or directly inhibiting hemostasis. RESULTS: 
      Of 256 patients discharged on warfarin, 138 (54%) were prescribed another 
      medication that could increase bleeding risk. Among these patients, 106 (41%) 
      were discharged with a total of 150 prescriptions for drugs that could interact 
      with warfarin to increase the INR. Antibiotics accounted for 67% of these 
      prescriptions. Fifty-three patients (21%) received 56 prescriptions for drugs 
      which could inhibit hemostasis. These were primarily antiplatelet drugs with 61% 
      of the prescriptions for aspirin. Patients with coronary artery disease were more 
      likely than others to be prescribed warfarin plus antiplatelet agents (OR = 2.80; 
      p = 0.04). More than one interacting drug was prescribed for 20% of the patients. 
      CONCLUSIONS: AF patients discharged on warfarin were frequently prescribed 
      concomitant medications that increase bleeding risks. These patients should be 
      closely monitored and counseled to watch for signs of bleeding.
FAU - Howard, Patricia A
AU  - Howard PA
AD  - Departments of Pharmacy Practice and Cardiovascular Medicine, University of 
      Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160-7231, USA. 
      phoward@kumc.edu
FAU - Ellerbeck, Edward F
AU  - Ellerbeck EF
FAU - Engelman, Kimberly K
AU  - Engelman KK
FAU - Patterson, Kelly L
AU  - Patterson KL
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Bacterial Agents/adverse effects/therapeutic use
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Drug Interactions
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Hemostasis/drug effects
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Retrospective Studies
MH  - Warfarin/*adverse effects/therapeutic use
EDAT- 2002/12/05 04:00
MHDA- 2003/05/08 05:00
CRDT- 2002/12/05 04:00
PHST- 2002/12/05 04:00 [pubmed]
PHST- 2003/05/08 05:00 [medline]
PHST- 2002/12/05 04:00 [entrez]
AID - 10.1002/pds.748 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2002 Oct-Nov;11(7):569-76. doi: 10.1002/pds.748.

PMID- 10150183
OWN - NLM
STAT- MEDLINE
DCOM- 19950601
LR  - 20131121
IS  - 0927-5401 (Print)
IS  - 0927-5401 (Linking)
VI  - 29
IP  - 1
DP  - 1994 Apr
TI  - The trapidil restenosis trial (STARC study): background, methods and clinical 
      characteristics of the patient population.
PG  - 31-40
AB  - Restenosis remains the principal drawback of percutaneous transluminal coronary 
      angioplasty (PTCA) since 30-35% of patients still experience it 6 months after 
      the intervention. Several studies have clearly demonstrated that restenosis is a 
      complex multifactorial process that involves smooth muscle cell (SMC) migration 
      and proliferation in the intimal layer of the coronary artery. Among others, the 
      platelet-derived growth factor (PDGF) seems to play an important role in this 
      process. That is why researches have been made in finding and developing new 
      agents able to inhibit PDGF. Trapidil (triazolopyrimidine) (T), is a potent PDGF 
      inhibitor that has been efficacious in preventing restenosis after balloon 
      angioplasty in the experimental animal and after PTCA in a limited clinical 
      trial. The Trapidil Restenosis Trial (STARC study) is a double blind randomized 
      trial of T 100 mg t.i.d. vs. Aspirin (ASA) 100 mg t.i.d. 360 patients have been 
      enrolled from April 1990 until May 1992, excluding recent myocardial infarctions, 
      thrombolysis, restenotic and venous graft lesions and 302 have terminated 
      follow-up. This paper describes the clinical background, the protocol and 
      baseline data of the patient population including data regarding initial stenosis 
      and type of vessel treated.
FAU - Maresta, A
AU  - Maresta A
AD  - Servizio di Cardiologia, Ospedale per gli Infermi, Faenza (RA), Italy.
FAU - Balducelli, M
AU  - Balducelli M
FAU - Cantini, L
AU  - Cantini L
FAU - Casari, A
AU  - Casari A
FAU - Chioin, R
AU  - Chioin R
FAU - Fontanelli, A
AU  - Fontanelli A
FAU - Monici Preti, P A
AU  - Monici Preti PA
FAU - Repetto, S
AU  - Repetto S
FAU - Raffaghello, S
AU  - Raffaghello S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Clin Trials Metaanal
JT  - Clinical trials and meta-analysis
JID - 9212070
RN  - 0 (Platelet-Derived Growth Factor)
RN  - EYG5Y6355E (Trapidil)
RN  - R16CO5Y76E (Aspirin)
MH  - Adult
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clinical Protocols
MH  - Cohort Studies
MH  - Coronary Disease/pathology/*prevention & control/therapy
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle, Smooth, Vascular/pathology
MH  - Platelet-Derived Growth Factor/antagonists & inhibitors
MH  - Postoperative Complications/prevention & control
MH  - Recurrence
MH  - Trapidil/administration & dosage/*therapeutic use
MH  - Tunica Intima/pathology
EDAT- 1994/03/09 00:00
MHDA- 1994/03/09 00:01
CRDT- 1994/03/09 00:00
PHST- 1994/03/09 00:00 [pubmed]
PHST- 1994/03/09 00:01 [medline]
PHST- 1994/03/09 00:00 [entrez]
PST - ppublish
SO  - Clin Trials Metaanal. 1994 Apr;29(1):31-40.

PMID- 31586705
OWN - NLM
STAT- MEDLINE
DCOM- 20201020
LR  - 20201020
IS  - 1090-2120 (Electronic)
IS  - 0045-2068 (Linking)
VI  - 93
DP  - 2019 Dec
TI  - Oleanolic acid oxime derivatives and their conjugates with aspirin modulate the 
      NF-κB-mediated transcription in HepG2 hepatoma cells.
PG  - 103326
LID - S0045-2068(19)31151-4 [pii]
LID - 10.1016/j.bioorg.2019.103326 [doi]
AB  - The aim of this study was to evaluate the effect of new oleanolic acid oxime 
      (OAO) derivatives and their conjugates with aspirin (ASP) on the expression and 
      activation of NF-κB in human hepatoma HepG2 cells. OAO derivatives showed a 
      stronger cytotoxic effect against HepG2 cells compared with their conjugates with 
      aspirin. Moreover, conjugation of OAO with ASP led to enhanced downregulation of 
      NF-κB expression and activation. Among the hybrids with ASP, compounds: 19, 
      3-(2-acetoxy)benzoyloxyiminoolean-12-en-28-oic acid morpholide and 13, 
      3-(2-acetoxy)benzoyloxyiminoolean-12-en-28-oic acid methyl ester, differing, 
      respectively, in morpholide and methyl ester groups at the C-17 position of 
      oleanolic acid (OA) molecule were the most efficient. COX-2 transcript and 
      protein levels were also diminished after treatment with these compounds. The 
      results of this study indicate that the new derivatives of OAO and particularly 
      their conjugates with ASP, downregulate the expression of COX-2 in HepG2 cells by 
      modulating the NF-κB signaling pathway and suggest their potential application in 
      the prevention of liver inflammation and cancer.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Krajka-Kuźniak, Violetta
AU  - Krajka-Kuźniak V
AD  - Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 
      Święcickiego 4, 60-781 Poznan, Poland.
FAU - Bednarczyk-Cwynar, Barbara
AU  - Bednarczyk-Cwynar B
AD  - Department of Organic Chemistry Poznan University of Medical Sciences, 
      Grunwaldzka 6, 60-780 Poznan, Poland.
FAU - Paluszczak, Jarosław
AU  - Paluszczak J
AD  - Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 
      Święcickiego 4, 60-781 Poznan, Poland.
FAU - Szaefer, Hanna
AU  - Szaefer H
AD  - Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 
      Święcickiego 4, 60-781 Poznan, Poland.
FAU - Narożna, Maria
AU  - Narożna M
AD  - Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 
      Święcickiego 4, 60-781 Poznan, Poland.
FAU - Zaprutko, Lucjusz
AU  - Zaprutko L
AD  - Department of Organic Chemistry Poznan University of Medical Sciences, 
      Grunwaldzka 6, 60-780 Poznan, Poland.
FAU - Baer-Dubowska, Wanda
AU  - Baer-Dubowska W
AD  - Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 
      Święcickiego 4, 60-781 Poznan, Poland. Electronic address: baerw@ump.edu.pl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190927
PL  - United States
TA  - Bioorg Chem
JT  - Bioorganic chemistry
JID - 1303703
RN  - 0 (NF-kappa B)
RN  - 0 (Oximes)
RN  - 6SMK8R7TGJ (Oleanolic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Hep G2 Cells
MH  - Humans
MH  - NF-kappa B/*metabolism
MH  - Oleanolic Acid/chemistry/*pharmacology
MH  - Oximes/*chemistry
MH  - Signal Transduction/drug effects
MH  - Transcription, Genetic/*drug effects
OTO - NOTNLM
OT  - Aspirin oleanolate conjugates
OT  - HepG2 cells
OT  - NF-κB
OT  - Oleanolic acid oximes derivatives
EDAT- 2019/10/07 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/10/07 06:00
PHST- 2019/07/19 00:00 [received]
PHST- 2019/09/26 00:00 [revised]
PHST- 2019/09/26 00:00 [accepted]
PHST- 2019/10/07 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/10/07 06:00 [entrez]
AID - S0045-2068(19)31151-4 [pii]
AID - 10.1016/j.bioorg.2019.103326 [doi]
PST - ppublish
SO  - Bioorg Chem. 2019 Dec;93:103326. doi: 10.1016/j.bioorg.2019.103326. Epub 2019 Sep 
      27.

PMID- 36632735
OWN - NLM
STAT- MEDLINE
DCOM- 20230602
LR  - 20230604
IS  - 1592-8721 (Electronic)
IS  - 0390-6078 (Print)
IS  - 0390-6078 (Linking)
VI  - 108
IP  - 6
DP  - 2023 Jun 1
TI  - Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?
PG  - 1487-1499
LID - 10.3324/haematol.2022.281388 [doi]
AB  - Essential thrombocythemia (ET) is a BCR-ABL1-negative myeloproliferative 
      neoplasm, the most common clinical manifestations of which include arterial and 
      venous thrombosis, bleeding and vasomotor/microvascular disturbances. Low-dose 
      (81-100 mg) aspirin once daily, which irreversibly inhibits platelet thromboxane 
      A2 (TxA2) production by acetylating cyclo-oxygenase-1, is the recommended 
      treatment for the control of vascular events in all ET risk categories, except 
      patients at very low risk, who need aspirin for treatment of 
      vasomotor/microvascular disturbances only. Simple observation should be preferred 
      over aspirin prophylaxis in low-risk patients with platelet counts >1,000x109/L 
      or harboring CALR mutations. Plain aspirin should be preferred over enteric 
      coated aspirin because some ET patients display poor responsiveness 
      ("resistance") to the latter. When treated with a once daily aspirin regimen, 
      adequate inhibition of platelet TxA2 production (measured as serum thromboxane B2 
      level) does not persist for 24 h in most patients. This phenomenon is associated 
      with the patients' platelet count and the number (but not the fraction) of 
      circulating immature reticulated platelets with non-acetylated cyclo-oxygenase-1 
      and is therefore consequent to high platelet production (the hallmark of ET), 
      rather than increased platelet turnover (which is normal in ET). Twice daily 
      aspirin administration overcame this problem and proved safe in small studies. 
      Although additional data on gastrointestinal tolerability will be useful, the 
      twice daily regimen could already be implemented in clinical practice, 
      considering its favorable risk/benefit profile. However, patients whose platelet 
      count has been normalized could still be treated with the once daily regimen, 
      because they would otherwise be unnecessarily exposed to a potential small risk 
      of gastrointestinal discomfort.
FAU - Cattaneo, Marco
AU  - Cattaneo M
AD  - Fondazione Arianna Anticoagulazione. marco.natale.cattaneo@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230601
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - R16CO5Y76E (Aspirin)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - *Thrombocythemia, Essential/drug therapy/genetics
MH  - Prostaglandin-Endoperoxide Synthases/therapeutic use
MH  - Blood Platelets
MH  - Hemorrhage/chemically induced
MH  - Platelet Aggregation Inhibitors
PMC - PMC10230439
EDAT- 2023/01/13 06:00
MHDA- 2023/06/02 06:42
CRDT- 2023/01/12 03:25
PHST- 2022/10/06 00:00 [received]
PHST- 2023/06/02 06:42 [medline]
PHST- 2023/01/13 06:00 [pubmed]
PHST- 2023/01/12 03:25 [entrez]
AID - 10.3324/haematol.2022.281388 [doi]
PST - epublish
SO  - Haematologica. 2023 Jun 1;108(6):1487-1499. doi: 10.3324/haematol.2022.281388.

PMID- 32755413
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210903
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Print)
IS  - 0194-911X (Linking)
VI  - 76
IP  - 3
DP  - 2020 Sep
TI  - Preconception Blood Pressure and Its Change Into Early Pregnancy: Early Risk 
      Factors for Preeclampsia and Gestational Hypertension.
PG  - 922-929
LID - 10.1161/HYPERTENSIONAHA.120.14875 [doi]
AB  - Preeclampsia and gestational hypertension are common complications of pregnancy 
      associated with significant maternal and infant morbidity. Despite extensive 
      research evaluating risk factors during pregnancy, most women who develop a 
      hypertensive disorder of pregnancy are not considered high-risk and strategies 
      for prevention remain elusive. We evaluated preconception blood pressure and its 
      change into early pregnancy as novel risk markers for development of a 
      hypertensive disorder of pregnancy. The EAGeR (Effects of Aspirin in Gestation 
      and Reproduction) trial (2007-2011) randomized 1228 healthy women with a history 
      of pregnancy loss to preconception-initiated low-dose aspirin versus placebo and 
      followed participants for up to 6 menstrual cycles attempting pregnancy and 
      throughout pregnancy if they became pregnant. Blood pressure was measured during 
      preconception and throughout early gestation. The primary outcomes, preterm 
      preeclampsia, term preeclampsia, and gestational hypertension, were abstracted 
      from medical records. Among 586 women with a pregnancy >20 weeks' gestation, 
      preconception blood pressure levels were higher for preterm preeclampsia 
      (87.3±6.7 mm Hg mean arterial pressure), term preeclampsia (88.3±9.8 mm Hg), and 
      gestational hypertension (87.9±9.1 mm Hg) as compared with no hypertensive 
      disorder of pregnancy (83.9±8.6 mm Hg). Change in blood pressure from 
      preconception into very early pregnancy was associated with development of 
      preeclampsia (relative risk, 1.13 [95% CI, 1.02-1.25] per 2 mm Hg increase in 
      mean arterial pressure at 4 weeks' gestation), particularly preterm preeclampsia 
      (relative risk, 1.21 [95% CI, 1.01-1.45]). Randomization to aspirin did not alter 
      blood pressure trajectory or risk of hypertension in pregnancy. Preconception 
      blood pressure and longitudinal changes during early pregnancy are underexplored 
      but crucial windows in the detection and prevention of hypertensive disorders of 
      pregnancy. Registration- URL: http://www.clinicaltrials.gov. Unique identifier: 
      NCT00467363.
FAU - Nobles, Carrie J
AU  - Nobles CJ
AD  - From the Division of Intramural Population Health Research, Eunice Kennedy 
      Shriver National Institute of Child Health and Human Development (C.J.N., P.M., 
      S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).
FAU - Mendola, Pauline
AU  - Mendola P
AD  - From the Division of Intramural Population Health Research, Eunice Kennedy 
      Shriver National Institute of Child Health and Human Development (C.J.N., P.M., 
      S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).
FAU - Mumford, Sunni L
AU  - Mumford SL
AD  - From the Division of Intramural Population Health Research, Eunice Kennedy 
      Shriver National Institute of Child Health and Human Development (C.J.N., P.M., 
      S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).
FAU - Silver, Robert M
AU  - Silver RM
AD  - Obstetrics and Gynecology, School of Medicine, University of Utah (R.M.S.).
FAU - Kim, Keewan
AU  - Kim K
AD  - From the Division of Intramural Population Health Research, Eunice Kennedy 
      Shriver National Institute of Child Health and Human Development (C.J.N., P.M., 
      S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).
FAU - Andriessen, Victoria C
AU  - Andriessen VC
AD  - From the Division of Intramural Population Health Research, Eunice Kennedy 
      Shriver National Institute of Child Health and Human Development (C.J.N., P.M., 
      S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).
FAU - Connell, Matthew
AU  - Connell M
AD  - From the Division of Intramural Population Health Research, Eunice Kennedy 
      Shriver National Institute of Child Health and Human Development (C.J.N., P.M., 
      S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).
FAU - Sjaarda, Lindsey
AU  - Sjaarda L
AD  - From the Division of Intramural Population Health Research, Eunice Kennedy 
      Shriver National Institute of Child Health and Human Development (C.J.N., P.M., 
      S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).
FAU - Perkins, Neil J
AU  - Perkins NJ
AD  - From the Division of Intramural Population Health Research, Eunice Kennedy 
      Shriver National Institute of Child Health and Human Development (C.J.N., P.M., 
      S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).
FAU - Schisterman, Enrique F
AU  - Schisterman EF
AD  - From the Division of Intramural Population Health Research, Eunice Kennedy 
      Shriver National Institute of Child Health and Human Development (C.J.N., P.M., 
      S.L.M., K.K., V.C.A., M.C., L.S., N.J.P., E.F.S.).
LA  - eng
SI  - ClinicalTrials.gov/NCT00467363
GR  - Z01 HD008795/ImNIH/Intramural NIH HHS/United States
GR  - ZIA HD008795/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Intramural
DEP - 20200803
PL  - United States
TA  - Hypertension
JT  - Hypertension (Dallas, Tex. : 1979)
JID - 7906255
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Aspirin/administration & dosage/adverse effects
MH  - *Blood Pressure Determination/methods/statistics & numerical data
MH  - Drug Monitoring/methods/statistics & numerical data
MH  - Early Diagnosis
MH  - Female
MH  - Humans
MH  - *Hypertension, Pregnancy-Induced/diagnosis/physiopathology
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - *Pre-Eclampsia/diagnosis/physiopathology
MH  - *Preconception Care/methods/statistics & numerical data
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Preventive Health Services
PMC - PMC7456510
MID - NIHMS1605262
OTO - NOTNLM
OT  - blood pressure
OT  - hypertension
OT  - preeclampsia
OT  - pregnancy
OT  - risk factors
EDAT- 2020/08/07 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/08/07 06:00 [entrez]
AID - 10.1161/HYPERTENSIONAHA.120.14875 [doi]
PST - ppublish
SO  - Hypertension. 2020 Sep;76(3):922-929. doi: 10.1161/HYPERTENSIONAHA.120.14875. 
      Epub 2020 Aug 3.

PMID- 27465859
OWN - NLM
STAT- MEDLINE
DCOM- 20170213
LR  - 20181113
IS  - 2008-2231 (Electronic)
IS  - 1560-8115 (Print)
IS  - 1560-8115 (Linking)
VI  - 24
IP  - 1
DP  - 2016 Jul 28
TI  - Aspirin use and bleeding volume in skin cancer patients undergoing surgery: a 
      randomized controlled trial.
PG  - 20
LID - 10.1186/s40199-016-0159-4 [doi]
LID - 20
AB  - ᅟ: We investigated the occurrence of bleeding complications in patients who 
      underwent skin tumor surgery and compared it between Aspirin users and a placebo 
      control group. In this double blind randomized controlled trial, 32 patients who 
      continued taking aspirin (intervention group) and 38 patients who stopped taking 
      Aspirin (placebo group) before surgery were compared in terms of intraoprative 
      and postoperative bleeding problems, hematoma and local signs of coagulopathy. 
      There was no statistically significant difference in intraoprative bleeding 
      between the study groups (P = 0.107). We concluded that continuation of Aspirin 
      therapy had no significant effect on bleeding complications in patients who 
      underwent skin tumor surgery. TRIAL REGISTRATION: IRCT201602049768N5 Flow chart 
      of the study process and its final finding.
FAU - Engheta, Arman
AU  - Engheta A
AD  - Department of Plastic Surgery, Imam Khomeini Hospital, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Hadadi Abianeh, Shahryar
AU  - Hadadi Abianeh S
AD  - Department of Plastic Surgery, Razi Hospital, Tehran University of Medical 
      Sciences, Vahdat Eslami st, Tehran, Iran. H_abianeh@yahoo.com.
FAU - Atri, Ali
AU  - Atri A
AD  - Department of Plastic Surgery, Imam Khomeini Hospital, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Sanatkarfar, Mehdi
AU  - Sanatkarfar M
AD  - Department of Anesthesiology, Razi Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Letter
PT  - Randomized Controlled Trial
DEP - 20160728
PL  - Switzerland
TA  - Daru
JT  - Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
JID - 101125969
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Intraoperative Complications/chemically induced
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/chemically induced
MH  - Skin Neoplasms/*surgery
PMC - PMC4964271
OTO - NOTNLM
OT  - Acetyl salicylic acid
OT  - Aspirin
OT  - Bleeding
OT  - Complication
OT  - Skin cancer
OT  - Surgery
EDAT- 2016/07/29 06:00
MHDA- 2017/02/14 06:00
CRDT- 2016/07/29 06:00
PHST- 2016/05/28 00:00 [received]
PHST- 2016/07/12 00:00 [accepted]
PHST- 2016/07/29 06:00 [entrez]
PHST- 2016/07/29 06:00 [pubmed]
PHST- 2017/02/14 06:00 [medline]
AID - 10.1186/s40199-016-0159-4 [pii]
AID - 159 [pii]
AID - 10.1186/s40199-016-0159-4 [doi]
PST - epublish
SO  - Daru. 2016 Jul 28;24(1):20. doi: 10.1186/s40199-016-0159-4.

PMID- 30201406
OWN - NLM
STAT- MEDLINE
DCOM- 20190924
LR  - 20190925
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 154
IP  - 6
DP  - 2018 Dec
TI  - Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin 
      for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial 
      Population.
PG  - 1371-1378
LID - S0012-3692(18)32412-7 [pii]
LID - 10.1016/j.chest.2018.08.1059 [doi]
AB  - BACKGROUND: Using data from the Reduced-Dose Rivaroxaban in the Long-Term 
      Prevention of Recurrent Symptomatic Venous Thromboembolism (EINSTEIN-CHOICE) 
      trial, this study assessed cost impact of continued anticoagulation therapy with 
      rivaroxaban vs aspirin. METHODS: Total health-care costs (2016 USD) associated 
      with rivaroxaban and aspirin were calculated as the sum of clinical event costs 
      and drug costs from a US managed care perspective. Clinical event costs were 
      calculated by multiplying event rate by cost of care. One-year Kaplan-Meier 
      clinical event rates for recurrent pulmonary embolism, recurrent DVT, all-cause 
      mortality, and bleeding were obtained from EINSTEIN-CHOICE. Cost of care was 
      determined by literature review. Drug costs were the product of drug price 
      (wholesale acquisition cost) and treatment duration. A one-way sensitivity 
      analysis was conducted. RESULTS: Rivaroxaban users had lower per patient per 
      month (PPPM) clinical event costs compared with aspirin users ($123, $243, and 
      $381 for rivaroxaban 10 mg, rivaroxaban 20 mg, and aspirin, respectively). 
      However, vs aspirin, PPPM total health-care costs were $24 higher for patients 
      treated with rivaroxaban 10 mg ($143 higher for rivaroxaban 20 mg) due to higher 
      cost of rivaroxaban. With a 15% discount for rivaroxaban 10 mg, the lower cost of 
      clinical events for the rivaroxaban-treated patients more than fully offset the 
      higher drug costs, and yielded a $19 lower total health-care cost. CONCLUSIONS: 
      Continued therapy with rivaroxaban 10 and 20 mg vs aspirin was associated with 
      lower clinical event costs but higher total health-care costs; with a 15% drug 
      discount rivaroxaban 10 mg had lower total health-care costs than aspirin.
CI  - Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Wells, Philip S
AU  - Wells PS
AD  - Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, 
      Ottawa, ON, Canada.
FAU - Prins, Martin H
AU  - Prins MH
AD  - Department of Epidemiology and Technology Assessment, University of Maastricht, 
      Maastricht, the Netherlands.
FAU - Beyer-Westendorf, Jan
AU  - Beyer-Westendorf J
AD  - Thrombosis Research Unit, Division of Hematology, Department of Medicine I, 
      University Hospital "Carl Gustav Carus," Dresden, Germany; King's Thrombosis 
      Service, Department of Haematology, King's College London, London, UK.
FAU - Lensing, Anthonie W A
AU  - Lensing AWA
AD  - Bayer Pharma AG, Wuppertal, Germany.
FAU - Haskell, Lloyd
AU  - Haskell L
AD  - Janssen Research & Development, LLC, Raritan, NJ.
FAU - Levitan, Bennett
AU  - Levitan B
AD  - Janssen Research & Development, LLC, Titusville, NJ.
FAU - Laliberté, François
AU  - Laliberté F
AD  - Groupe d'analyse, Ltée, Montréal, QC, Canada.
FAU - Ashton, Veronica
AU  - Ashton V
AD  - Janssen Scientific Affairs, LLC, Titusville, NJ.
FAU - Xiao, Yongling
AU  - Xiao Y
AD  - Groupe d'analyse, Ltée, Montréal, QC, Canada.
FAU - Lejeune, Dominique
AU  - Lejeune D
AD  - Groupe d'analyse, Ltée, Montréal, QC, Canada. Electronic address: 
      dominique.lejeune@analysisgroup.com.
FAU - Crivera, Concetta
AU  - Crivera C
AD  - Janssen Scientific Affairs, LLC, Titusville, NJ.
FAU - Lefebvre, Patrick
AU  - Lefebvre P
AD  - Groupe d'analyse, Ltée, Montréal, QC, Canada.
FAU - Zhao, Qi
AU  - Zhao Q
AD  - Janssen Scientific Affairs, LLC, Titusville, NJ.
FAU - Yuan, Zhong
AU  - Yuan Z
AD  - Janssen Research & Development, LLC, Titusville, NJ.
FAU - Schein, Jeff
AU  - Schein J
AD  - Janssen Scientific Affairs, LLC, Titusville, NJ.
FAU - Prandoni, Paolo
AU  - Prandoni P
AD  - Department of Cardiovascular Sciences, University of Padua Medical School, Padua, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20180907
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Anticoagulants)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/adverse effects/economics
MH  - *Aspirin/administration & dosage/adverse effects/economics
MH  - Cost Savings/methods
MH  - Dose-Response Relationship, Drug
MH  - Drug Monitoring/economics
MH  - Female
MH  - Health Care Costs/*statistics & numerical data
MH  - *Hemorrhage/chemically induced/economics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pulmonary Embolism/drug therapy/economics/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - *Rivaroxaban/administration & dosage/adverse effects/economics
MH  - Secondary Prevention/economics/methods
MH  - *Venous Thromboembolism/drug therapy/economics/prevention & control
OTO - NOTNLM
OT  - anticoagulants
OT  - aspirin
OT  - cost comparison
OT  - economic analysis
OT  - extended treatment
OT  - recurrent VTE
OT  - rivaroxaban
EDAT- 2018/09/12 06:00
MHDA- 2019/09/26 06:00
CRDT- 2018/09/12 06:00
PHST- 2017/10/23 00:00 [received]
PHST- 2018/08/10 00:00 [revised]
PHST- 2018/08/15 00:00 [accepted]
PHST- 2018/09/12 06:00 [pubmed]
PHST- 2019/09/26 06:00 [medline]
PHST- 2018/09/12 06:00 [entrez]
AID - S0012-3692(18)32412-7 [pii]
AID - 10.1016/j.chest.2018.08.1059 [doi]
PST - ppublish
SO  - Chest. 2018 Dec;154(6):1371-1378. doi: 10.1016/j.chest.2018.08.1059. Epub 2018 
      Sep 7.

PMID- 28511616
OWN - NLM
STAT- MEDLINE
DCOM- 20191113
LR  - 20191113
IS  - 1477-0334 (Electronic)
IS  - 0962-2802 (Linking)
VI  - 27
IP  - 12
DP  - 2018 Dec
TI  - Bayesian meta-analysis: The role of the between-sample heterogeneity.
PG  - 3643-3657
LID - 10.1177/0962280217709837 [doi]
AB  - The random effect approach for meta-analysis was motivated by a lack of 
      consistent assessment of homogeneity of treatment effect before pooling. The 
      random effect model assumes that the distribution of the treatment effect is 
      fully heterogenous across the experiments. However, other models arising by 
      grouping some of the experiments are plausible. We illustrate on simulated binary 
      experiments that the fully heterogenous model gives a poor meta-inference when 
      fully heterogeneity is not the true model and that the knowledge of the true 
      cluster model considerably improves the inference. We propose the use of a 
      Bayesian model selection procedure for estimating the true cluster model, and 
      Bayesian model averaging to incorporate into the meta-analysis the clustering 
      estimation. A well-known meta-analysis for six major multicentre trials to assess 
      the efficacy of a given dose of aspirin in post-myocardial infarction patients is 
      reanalysed.
FAU - Moreno, Elías
AU  - Moreno E
AD  - 1 Department of Statistics, University of Granada, Granada, Spain.
FAU - Vázquez-Polo, Francisco-José
AU  - Vázquez-Polo FJ
AD  - 2 Department of Quantitative Methods and TiDES Institute, University of Las 
      Palmas de Gran Canaria, Las Palmas, Spain.
FAU - Negrín, Miguel A
AU  - Negrín MA
AD  - 2 Department of Quantitative Methods and TiDES Institute, University of Las 
      Palmas de Gran Canaria, Las Palmas, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170516
PL  - England
TA  - Stat Methods Med Res
JT  - Statistical methods in medical research
JID - 9212457
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - *Bayes Theorem
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Models, Statistical
MH  - Myocardial Infarction/*drug therapy
MH  - Research Design
OTO - NOTNLM
OT  - Clustering
OT  - copula
OT  - meta-analysis
OT  - product partition model
EDAT- 2017/05/18 06:00
MHDA- 2019/11/14 06:00
CRDT- 2017/05/18 06:00
PHST- 2017/05/18 06:00 [pubmed]
PHST- 2019/11/14 06:00 [medline]
PHST- 2017/05/18 06:00 [entrez]
AID - 10.1177/0962280217709837 [doi]
PST - ppublish
SO  - Stat Methods Med Res. 2018 Dec;27(12):3643-3657. doi: 10.1177/0962280217709837. 
      Epub 2017 May 16.

PMID- 2029080
OWN - NLM
STAT- MEDLINE
DCOM- 19910613
LR  - 20191029
IS  - 0192-8562 (Print)
IS  - 0192-8562 (Linking)
VI  - 13
IP  - 1
DP  - 1991 Spring
TI  - Essential thrombocythemia in a child: management with anagrelide.
PG  - 52-6
AB  - Essential thrombocythemia (ET) is a rare disorder in children. An 11-year-old 
      white boy was first seen in January 1986 with symptoms of abdominal pain. His 
      platelet count was 1.5 million/mm3. Other hematological values and coagulation 
      studies, including bleeding time, were normal. There was laboratory evidence of 
      mild platelet dysfunction. Using the criteria of the Polycythemia Vera Study 
      Group, a diagnosis of ET was made. He developed frequent headaches. Aspirin was 
      prescribed for the next 2 years at varying doses and frequency. During the 
      period, platelet counts ranged between 1 and 3 million/mm3. In view of 
      progressive headaches and evidence of increasing platelet dysfunction, further 
      treatment was indicated. The use of a new agent, anagrelide, reported effective 
      in adults with ET, resulted in amelioration of symptoms and improvement in 
      quantitative and qualitative platelet control with no significant untoward 
      effects.
FAU - Chintagumpala, M M
AU  - Chintagumpala MM
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
FAU - Steuber, C P
AU  - Steuber CP
FAU - Mahoney, D H Jr
AU  - Mahoney DH Jr
FAU - Ogden, A K
AU  - Ogden AK
FAU - Fernbach, D J
AU  - Fernbach DJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Pediatr Hematol Oncol
JT  - The American journal of pediatric hematology/oncology
JID - 7908071
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Quinazolines)
RN  - K9X45X0051 (anagrelide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Count/drug effects
MH  - Quinazolines/*therapeutic use
MH  - Thrombocythemia, Essential/*drug therapy
EDAT- 1991/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1097/00043426-199121000-00013 [doi]
PST - ppublish
SO  - Am J Pediatr Hematol Oncol. 1991 Spring;13(1):52-6. doi: 
      10.1097/00043426-199121000-00013.

PMID- 3423768
OWN - NLM
STAT- MEDLINE
DCOM- 19880208
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 117
IP  - 46
DP  - 1987 Nov 14
TI  - [A modified in vivo platelet retention test in the evaluation of primary 
      hemostasis].
PG  - 1814-6
AB  - A simple assay system for measuring platelet retention in a standardized 
      superficial skin wound is presented. Platelets were counted in the blood 
      collected at the site of the wound 1, 2 and 3 minutes following incision. Per 
      cent platelet retention was calculated from the difference between venous blood 
      platelet count and wound blood platelet count, divided by venous count. The time 
      course of platelet retention, measured in 20 healthy persons, reflected the 
      sequence of primary and secondary platelet aggregation. Ten patients with 
      congenital platelet defects already showed impaired platelet retention in the 
      early stage of bleeding. On the other hand, administration of aspirin to 10 
      healthy subjects inhibited only the late stage of platelet retention. In 
      comparison with the template bleeding time our platelet retention test provides 
      additional information useful for evaluating congenital and drug-induced defects 
      in platelet plug formation.
FAU - de la Cuadra, J L
AU  - de la Cuadra JL
AD  - Hämatologisches Zentrallabor, Inselspital, Bern.
FAU - Jeanneret, C
AU  - Jeanneret C
FAU - Furlan, M
AU  - Furlan M
FAU - Beck, E A
AU  - Beck EA
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Ein modifizierter In-vivo-Plättchenretentionstest zur Beurteilung der primären 
      Hämostase.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelet Disorders/blood
MH  - Blood Platelets/drug effects
MH  - Female
MH  - *Hemostasis
MH  - Humans
MH  - Male
MH  - Platelet Adhesiveness
MH  - Platelet Count
MH  - Platelet Function Tests/*methods
MH  - Skin/injuries
MH  - Time Factors
MH  - Wounds and Injuries/blood
EDAT- 1987/11/14 00:00
MHDA- 1987/11/14 00:01
CRDT- 1987/11/14 00:00
PHST- 1987/11/14 00:00 [pubmed]
PHST- 1987/11/14 00:01 [medline]
PHST- 1987/11/14 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1987 Nov 14;117(46):1814-6.

PMID- 36241001
OWN - NLM
STAT- MEDLINE
DCOM- 20221108
LR  - 20221222
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 185
DP  - 2022 Nov
TI  - The specific deletion of cyclooxygenase-1 in megakaryocytes/platelets reduces 
      intestinal polyposis in Apc(Min/+) mice.
PG  - 106506
LID - S1043-6618(22)00452-2 [pii]
LID - 10.1016/j.phrs.2022.106506 [doi]
AB  - Clinical and experimental evidence sustain the role of cyclooxygenase (COX)-1 in 
      intestinal tumorigenesis. However, the cell type expressing the enzyme involved 
      and molecular mechanism(s) have not been clarified yet. We aimed to elucidate the 
      role of platelet COX-1 (the target of low-dose aspirin in humans) in intestinal 
      tumorigenesis of Apc(Min/+) mice, considered a clinically relevant model. To 
      realize this objective, we generated an Apc(Min/+) mouse with a specific deletion 
      of Ptgs1(COX-1 gene name) in megakaryocytes/platelets 
      (Apc(Min/+);pPtgs1(-/-)mice) characterized by profound inhibition of 
      thromboxane(TX)A(2) biosynthesis ex vivo (serum TXB(2); by 99%) and in vivo 
      [urinary 2,3-dinor-TXB(2)(TXM), by 79%]. Apc(Min/+) mice with the deletion of 
      platelet COX-1 showed a significantly reduced number (67%) and size (32%) of 
      tumors in the small intestine. The intestinal adenomas of these mice had 
      decreased proliferative index associated with reduced COX-2 expression and 
      systemic prostaglandin(PG)E(2) biosynthesis (urinary PGEM) vs. Apc(Min/+)mice. 
      Extravasated platelets were detected in the intestine of Apc(Min/+)mice. Thus, we 
      explored their contribution to COX-2 induction in fibroblasts, considered the 
      primary polyp cell type expressing the protein. In the coculture of human 
      platelets and myofibroblasts, platelet-derived TXA(2) was involved in the 
      induction of COX-2-dependent PGE(2) in myofibroblasts since it was prevented by 
      the selective inhibition of platelet COX-1 by aspirin or by a specific antagonist 
      of TXA(2) receptors. In conclusion, our results support the platelet hypothesis 
      of intestinal tumorigenesis and provide experimental evidence that selective 
      inhibition of platelet COX-1 can mitigate early events of intestinal 
      tumorigenesis by restraining COX-2 induction.
CI  - Copyright © 2022 Elsevier Ltd. All rights reserved.
FAU - Bruno, Annalisa
AU  - Bruno A
AD  - Center for Advanced Studies and Technology (CAST), "G.d'Annunzio" University, 
      66100 Chieti, Italy; Department of Neuroscience, Imaging and Clinical Science, 
      "G.d'Annunzio" University, 66100 Chieti, Italy.
FAU - Contursi, Annalisa
AU  - Contursi A
AD  - Center for Advanced Studies and Technology (CAST), "G.d'Annunzio" University, 
      66100 Chieti, Italy; Department of Neuroscience, Imaging and Clinical Science, 
      "G.d'Annunzio" University, 66100 Chieti, Italy.
FAU - Tacconelli, Stefania
AU  - Tacconelli S
AD  - Center for Advanced Studies and Technology (CAST), "G.d'Annunzio" University, 
      66100 Chieti, Italy; Department of Neuroscience, Imaging and Clinical Science, 
      "G.d'Annunzio" University, 66100 Chieti, Italy.
FAU - Sacco, Angela
AU  - Sacco A
AD  - Center for Advanced Studies and Technology (CAST), "G.d'Annunzio" University, 
      66100 Chieti, Italy; Department of Neuroscience, Imaging and Clinical Science, 
      "G.d'Annunzio" University, 66100 Chieti, Italy.
FAU - Hofling, Ulrika
AU  - Hofling U
AD  - Center for Advanced Studies and Technology (CAST), "G.d'Annunzio" University, 
      66100 Chieti, Italy; Department of Neuroscience, Imaging and Clinical Science, 
      "G.d'Annunzio" University, 66100 Chieti, Italy.
FAU - Mucci, Matteo
AU  - Mucci M
AD  - Center for Advanced Studies and Technology (CAST), "G.d'Annunzio" University, 
      66100 Chieti, Italy; Department of Neuroscience, Imaging and Clinical Science, 
      "G.d'Annunzio" University, 66100 Chieti, Italy.
FAU - Lamolinara, Alessia
AU  - Lamolinara A
AD  - Center for Advanced Studies and Technology (CAST), "G.d'Annunzio" University, 
      66100 Chieti, Italy; Department of Neuroscience, Imaging and Clinical Science, 
      "G.d'Annunzio" University, 66100 Chieti, Italy.
FAU - Del Pizzo, Francesco
AU  - Del Pizzo F
AD  - Center for Advanced Studies and Technology (CAST), "G.d'Annunzio" University, 
      66100 Chieti, Italy.
FAU - Ballerini, Patrizia
AU  - Ballerini P
AD  - Center for Advanced Studies and Technology (CAST), "G.d'Annunzio" University, 
      66100 Chieti, Italy; Department of Innovative Technologies in Medicine and 
      Dentistry, "G.d'Annunzio" University, 66100 Chieti, Italy.
FAU - Di Gregorio, Patrizia
AU  - Di Gregorio P
AD  - Institute of Transfusion Medicine, "Ss. Annunziata" Hospital, 66100 Chieti, 
      Italy.
FAU - Yu, Ying
AU  - Yu Y
AD  - Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical 
      University, Tianjin 300070, China.
FAU - Patrignani, Paola
AU  - Patrignani P
AD  - Center for Advanced Studies and Technology (CAST), "G.d'Annunzio" University, 
      66100 Chieti, Italy; Department of Neuroscience, Imaging and Clinical Science, 
      "G.d'Annunzio" University, 66100 Chieti, Italy. Electronic address: 
      ppatrignani@unich.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221012
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Mice
MH  - Humans
MH  - Animals
MH  - Cyclooxygenase 1/genetics
MH  - Cyclooxygenase 2/genetics
MH  - *Megakaryocytes
MH  - *Intestinal Polyposis
MH  - Cell Transformation, Neoplastic
MH  - Carcinogenesis
MH  - Aspirin/pharmacology
OTO - NOTNLM
OT  - Apc(Min/+) mice
OT  - Cyclooxygenases
OT  - Intestinal tumors
OT  - Platelets
OT  - ProstaglandinE(2)
OT  - ThromboxaneA(2)
COIS- Conflict of interest None of the authors has any potential conflicts (financial, 
      professional, or personal) relevant to the manuscript. Declarations of interest 
      none.
EDAT- 2022/10/15 06:00
MHDA- 2022/11/09 06:00
CRDT- 2022/10/14 19:26
PHST- 2022/08/02 00:00 [received]
PHST- 2022/09/26 00:00 [revised]
PHST- 2022/10/09 00:00 [accepted]
PHST- 2022/10/15 06:00 [pubmed]
PHST- 2022/11/09 06:00 [medline]
PHST- 2022/10/14 19:26 [entrez]
AID - S1043-6618(22)00452-2 [pii]
AID - 10.1016/j.phrs.2022.106506 [doi]
PST - ppublish
SO  - Pharmacol Res. 2022 Nov;185:106506. doi: 10.1016/j.phrs.2022.106506. Epub 2022 
      Oct 12.

PMID- 15674891
OWN - NLM
STAT- MEDLINE
DCOM- 20050527
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 1
DP  - 2005 Jan 25
TI  - Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion 
      following peripheral endovascular treatment.
PG  - CD002071
AB  - BACKGROUND: Peripheral arterial disease (PAD) is frequently treated by balloon 
      angioplasty. Restenosis/reocclusion of the dilated segments occurs often 
      depending on length of occlusion, lower leg outflow, stage of disease and 
      presence of cardiovascular risk factors. To prevent reocclusion, patients are 
      treated with antithrombotic agents. OBJECTIVES: To determine whether any 
      antithrombotic drug is more effective in preventing reocclusion after peripheral 
      endovascular treatment, compared to another antithrombotic drug, no treatment, 
      placebo, or other vasoactive drugs. SEARCH STRATEGY: We searched the Cochrane 
      Peripheral Vascular Diseases Group's trials register (last searched April 2004), 
      the Cochrane Central Register of Controlled trials (CENTRAL Issue 2, 2004), 
      MEDLINE and EMBASE (last searched June 2004). SELECTION CRITERIA: Randomised 
      trials were categorised as A (double or single blinded) or B (not blinded). 
      Participants included patients with symptomatic PAD treated by endovascular 
      revascularisation of the pelvic or femoropopliteal arteries. Interventions were 
      anticoagulant, antiplatelet or other vasoactive drug therapy compared with no 
      treatment, placebo, or any other vasoactive drug. Clinical endpoints were 
      re-obstruction, amputation, death, myocardial infarction, stroke and major 
      bleeding. DATA COLLECTION AND ANALYSIS: Details of the number of randomised 
      patients, treatment, study design, study category, allocation concealment and 
      patient characteristics were extracted. Analysis was based on intention-to-treat 
      data. To examine the effects of binary outcomes such as amputation and major 
      bleeding, odds ratios were computed using a fixed effect model. The 95% 
      confidence intervals of the effect sizes were calculated. MAIN RESULTS: A 60% 
      reduction of recurrent obstruction was found with aspirin (ASA) 330 mg combined 
      with dipyridamol (DIP) as compared to placebo at 12 months follow-up. At six 
      months following endovascular treatment, a positive effect on patency was found 
      with 50 to 100 mg ASA combined with DIP (n = 356). However, this was not 
      significant. ASA/DIP tended towards showing a superior effect on patency after 
      femoropopliteal angioplasty compared with VKA at three, six, and twelve months. 
      Periinterventional treatment with LMWH in femoropopliteal obstructions resulted 
      in significantly lower restenosis/reocclusion rates than with unfractionated 
      heparin. AUTHORS' CONCLUSIONS: Aspirin 50 to 300 mg started prior to 
      femoropopliteal endovascular treatment appears to be the most effective and is 
      safe. Clopidogrel might be an alternative, but data are lacking. Abciximab might 
      be a useful adjunctive for high risk patients with long segmental femoropopliteal 
      interventions. Low molecular weight heparin seems to be more effective in 
      preventing reocclusion or restenosis than unfractionated heparin.
FAU - Dörffler-Melly, J
AU  - Dörffler-Melly J
AD  - Swiss Cardiovascular Center, Division for Angiology, University Hospital of 
      Berne, Freiburgstrasse 4, Berne, Switzerland, 3010. Janine.Doerffler@insel.ch
FAU - Koopman, M M W
AU  - Koopman MM
FAU - Prins, M H
AU  - Prins MH
FAU - Büller, H R
AU  - Büller HR
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20050125
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UIN - Cochrane Database Syst Rev. 2012;8:CD002071. PMID: 22895926
MH  - Angioplasty, Balloon
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Peripheral Vascular Diseases/*prevention & control/therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Secondary Prevention
RF  - 65
EDAT- 2005/01/28 09:00
MHDA- 2005/05/28 09:00
CRDT- 2005/01/28 09:00
PHST- 2005/01/28 09:00 [pubmed]
PHST- 2005/05/28 09:00 [medline]
PHST- 2005/01/28 09:00 [entrez]
AID - 10.1002/14651858.CD002071.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2005 Jan 25;(1):CD002071. doi: 
      10.1002/14651858.CD002071.pub2.

PMID- 23047244
OWN - NLM
STAT- MEDLINE
DCOM- 20130521
LR  - 20190720
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 35
IP  - 12
DP  - 2012
TI  - Theoretical investigation of aspirin dosage regimen to exhibit optimal 
      antiplatelet effects and decrease risk of upper gastrointestinal lesions.
PG  - 2112-8
AB  - We investigated dosage regimens for aspirin therapy in regard to antiplatelet 
      effects in patients without gastrointestinal lesions. Findings for inhibition of 
      biosynthesis of thromboxane B(2) (TXB(2)) and prostaglandin E(2) (PGE(2)) were 
      simulated based on pharmacokinetic and pharmacodynamic models using an 
      irreversible process of inhibition of cyclooxygenase-1 (COX-1) by aspirin. We 
      found that the inhibition of biosynthesis of TXB(2) at a steady state was greater 
      than 90% when the dose of aspirin administered exceeded 81 mg, which was 
      considered to exhibit a sufficient antiplatelet effect. Furthermore, it was 
      confirmed that a dose of 162 mg or more is needed to exert an immediate 
      antiplatelet effect on the initial day of administration. On the other hand, the 
      inhibition of biosynthesis of PGE(2) ranged from 40-90% when aspirin was 
      administered at a dose of 10.125-324 mg. Thus, the risk of gastrointestinal 
      lesions differed in a dosage-dependent manner. The biosynthesis inhibition of 
      PGE(2) was calculated to be 37.9%, with that value set as the target level for 
      prevention of gastrointestinal disorders. We also noted a difference between 
      platelets and gastric mucosa cells in regard to the turnover rate of COX-1, and 
      attempted to simulate the inhibition of biosynthesis of TXB(2) and PGE(2) 
      following administration of aspirin. However, it was not possible, as the 
      inhibition of biosynthesis of TXB(2) was greater than 90% and that of PGE(2) was 
      less than 37.9%, even with various dosage regimens. Our findings suggest that it 
      is difficult to determine a rational dosage regimen of aspirin to exert an 
      antiplatelet effect without inducing gastrointestinal lesions.
FAU - Yokoyama, Haruko
AU  - Yokoyama H
AD  - Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo 
      University of Pharmacy and Life Sciences, 1432–1 Horinouchi, Hachiouji, Tokyo 
      192–0392, Japan.
FAU - Yaguchi, Takehiro
AU  - Yaguchi T
FAU - Suzuki, Yuji
AU  - Suzuki Y
FAU - Tokuoka, Kentaro
AU  - Tokuoka K
FAU - Watanabe, Masayuki
AU  - Watanabe M
FAU - Kitagawa, Yasuhisa
AU  - Kitagawa Y
FAU - Yamada, Yasuhiko
AU  - Yamada Y
LA  - eng
PT  - Journal Article
DEP - 20121005
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Arachidonic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acids/*biosynthesis
MH  - Aspirin/*administration & dosage/adverse effects/pharmacology
MH  - Blood Platelets/drug effects
MH  - Cyclooxygenase 1/*metabolism
MH  - Cyclooxygenase Inhibitors/administration & dosage/adverse effects/pharmacology
MH  - Dinoprostone/biosynthesis
MH  - Dose-Response Relationship, Drug
MH  - *Gastric Mucosa/cytology/metabolism/pathology
MH  - Gastrointestinal Diseases/etiology/pathology/*prevention & control
MH  - Models, Biological
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/pharmacology
MH  - Thromboxane B2/biosynthesis
EDAT- 2012/10/11 06:00
MHDA- 2013/05/23 06:00
CRDT- 2012/10/11 06:00
PHST- 2012/10/11 06:00 [entrez]
PHST- 2012/10/11 06:00 [pubmed]
PHST- 2013/05/23 06:00 [medline]
AID - DN/JST.JSTAGE/bpb/b12-00030 [pii]
AID - 10.1248/bpb.b12-00030 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2012;35(12):2112-8. doi: 10.1248/bpb.b12-00030. Epub 2012 Oct 5.

PMID- 17339622
OWN - NLM
STAT- MEDLINE
DCOM- 20070322
LR  - 20220331
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 146
IP  - 5
DP  - 2007 Mar 6
TI  - The use of aspirin for primary prevention of colorectal cancer: a systematic 
      review prepared for the U.S. Preventive Services Task Force.
PG  - 365-75
AB  - BACKGROUND: Aspirin for prevention of colorectal cancer is controversial. 
      PURPOSE: To examine the benefits and harms of aspirin chemoprevention. DATA 
      SOURCES: MEDLINE, 1966 to December 2006; EMBASE, 1980 to April 2005; CENTRAL, 
      Cochrane Collaboration's registry of clinical trials; Cochrane Database of 
      Systematic Reviews. STUDY SELECTION: Two independent reviewers conducted 
      multilevel screening to identify randomized, controlled trials (RCTs), 
      case-control studies, and cohort studies of aspirin chemoprophylaxis. For harms, 
      systematic reviews were sought. DATA EXTRACTION: In duplicate, data were 
      abstracted and checked and quality was assessed. DATA SYNTHESIS: Regular use of 
      aspirin reduced the incidence of colonic adenomas in RCTs (relative risk [RR], 
      0.82 [95% CI, 0.7 to 0.95]), case-control studies (RR, 0.87 [CI, 0.77 to 0.98]), 
      and cohort studies (RR, 0.72 [CI, 0.61 to 0.85]). In cohort studies, regular use 
      of aspirin was associated with RR reductions of 22% for incidence of colorectal 
      cancer. Two RCTs of low-dose aspirin failed to show a protective effect. Data for 
      colorectal cancer mortality were limited. Benefits from chemoprevention were more 
      evident when aspirin was used at a high dose and for periods longer than 10 
      years. Aspirin use was associated with a dose-related increase in incidence of 
      gastrointestinal complications. LIMITATIONS: Important clinical and 
      methodological heterogeneity in the definitions of regular use, dose, and 
      duration of use of aspirin necessitated careful grouping for analysis. 
      CONCLUSIONS: Aspirin appears to be effective at reducing the incidence of colonic 
      adenoma and colorectal cancer, especially if used in high doses for more than 10 
      years. However, the possible harms of such a practice require careful 
      consideration. Further evaluation of the cost-effectiveness of chemoprevention 
      compared with, and in combination with, a screening strategy is required.
FAU - Dubé, Catherine
AU  - Dubé C
AD  - University of Calgary, Calgary, Alberta, Canada.
FAU - Rostom, Alaa
AU  - Rostom A
FAU - Lewin, Gabriela
AU  - Lewin G
FAU - Tsertsvadze, Alexander
AU  - Tsertsvadze A
FAU - Barrowman, Nicholas
AU  - Barrowman N
FAU - Code, Catherine
AU  - Code C
FAU - Sampson, Margaret
AU  - Sampson M
FAU - Moher, David
AU  - Moher D
CN  - U.S. Preventive Services Task Force
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- Ann Intern Med. 2007 Mar 6;146(5):I35. PMID: 17339615
CIN - ACP J Club. 2007 Jul-Aug;147(1):15-6. PMID: 17608380
CIN - Gastroenterology. 2007 Aug;133(2):717-8. PMID: 17681190
CIN - Ann Intern Med. 2007 Nov 6;147(9):674; author reply 674-5. PMID: 17975195
MH  - Adenoma/prevention & control
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/chemically induced
MH  - Colonic Polyps/prevention & control
MH  - Colorectal Neoplasms/epidemiology/mortality/*prevention & control
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Incidence
MH  - Male
MH  - *Primary Prevention
MH  - United States/epidemiology
RF  - 61
EDAT- 2007/03/07 09:00
MHDA- 2007/03/23 09:00
CRDT- 2007/03/07 09:00
PHST- 2007/03/07 09:00 [pubmed]
PHST- 2007/03/23 09:00 [medline]
PHST- 2007/03/07 09:00 [entrez]
AID - 146/5/365 [pii]
AID - 10.7326/0003-4819-146-5-200703060-00009 [doi]
PST - ppublish
SO  - Ann Intern Med. 2007 Mar 6;146(5):365-75. doi: 
      10.7326/0003-4819-146-5-200703060-00009.

PMID- 10502211
OWN - NLM
STAT- MEDLINE
DCOM- 19991028
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 138
IP  - 4 Pt 1
DP  - 1999 Oct
TI  - Comparison of the efficacy and safety of aspirin alone with coumadin plus aspirin 
      after provisional coronary stenting: final and follow-up results of a randomized 
      study.
PG  - 663-9
AB  - BACKGROUND: The antithrombotic benefit of the conventional treatment with 
      coumadin after coronary stenting is limited by bleeding complications. However, 
      the superiority of an antiplatelet therapy with aspirin alone compared with 
      coumadin plus aspirin has not been proven by randomized studies. The efficacy and 
      safety of treatment with aspirin alone in comparison to coumadin plus aspirin 
      were evaluated in this randomized study. METHODS: Out of 164 patients aged 59.7 
      +/- 9.2 years, 79 patients were randomly assigned to receive 100 mg aspirin daily 
      (group A) and 85 patients randomly assigned to coumadin plus aspirin (group CA) 
      after provisional coronary stenting with a high-pressure technique. The primary 
      end point was defined as the absence of death, subacute closure of the target 
      vessel, myocardial infarction, urgent coronary bypass surgery, repeated coronary 
      angioplasty, and peripheral vascular complications requiring transfusion or 
      surgery. High-pressure inflation technique was used, but ultrasound guidance was 
      not. RESULTS: During hospitalization (median 8 days), 135 patients (82. 3%) were 
      free of events (A, 84.8%; CA, 80.8%; P =.42). Eleven (6.7%) subacute closures 
      occurred (A, 10.1%; CA, 3.5%; P =.09); 2 of them were lethal in the aspirin 
      group. Emergency bypass surgery was performed in 1 patient in each group. 
      Peripheral vascular complications were observed in 13 patients (7.9%) (A, 1.3%; 
      CA, 14. 1%; P <.01). At 3-month follow-up, 15 (9.1%) elective revascularization 
      procedures (A, 7.6%; CA, 10.6%; P =.51) were performed. CONCLUSION: Aspirin alone 
      at the low dose of 100 mg administered or the combination of coumadin and aspirin 
      after high-pressure coronary stenting does not prevent adverse clinical events 
      when ultrasound guidance is not used.
FAU - Machraoui, A
AU  - Machraoui A
AD  - Department of Cardiology, Bergmannsheil, Bochum, Germany. 
      machrabj@ruhr-uni-bochum.de
FAU - Germing, A
AU  - Germing A
FAU - von Dryander, S
AU  - von Dryander S
FAU - Lange, S
AU  - Lange S
FAU - Jäger, D
AU  - Jäger D
FAU - Lemke, B
AU  - Lemke B
FAU - Barmeyer, J
AU  - Barmeyer J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am Heart J. 1999 Oct;138(4 Pt 1):602-5. PMID: 10502200
MH  - Angioplasty, Balloon, Coronary
MH  - Anticoagulants/*administration & dosage/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Coronary Angiography
MH  - Coronary Disease/surgery/therapy
MH  - Coronary Thrombosis/*prevention & control
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Safety
MH  - *Stents/adverse effects
MH  - Ultrasonography, Interventional
MH  - Warfarin/*administration & dosage/therapeutic use
EDAT- 1999/09/29 00:00
MHDA- 1999/09/29 00:01
CRDT- 1999/09/29 00:00
PHST- 1999/09/29 00:00 [pubmed]
PHST- 1999/09/29 00:01 [medline]
PHST- 1999/09/29 00:00 [entrez]
AID - S0002870399003531 [pii]
AID - 10.1016/s0002-8703(99)70180-8 [doi]
PST - ppublish
SO  - Am Heart J. 1999 Oct;138(4 Pt 1):663-9. doi: 10.1016/s0002-8703(99)70180-8.

PMID- 31241606
OWN - NLM
STAT- MEDLINE
DCOM- 20200429
LR  - 20200506
IS  - 1547-1896 (Print)
IS  - 0893-7400 (Linking)
VI  - 32
IP  - 7
DP  - 2019 Jul
TI  - Does rivaroxaban have a role in treating patients with PAD?
PG  - 16-17
LID - 10.1097/01.JAA.0000558364.85986.ad [doi]
AB  - Peripheral arterial disease can cause devastating health outcomes, and few 
      therapies are available to treat this condition. Results of a secondary analysis 
      of the COMPASS trial suggest benefit with the use of rivaroxaban 2.5 mg twice 
      daily plus aspirin 100 mg daily. This treatment regimen could change the standard 
      pharmacotherapeutic management practice for many patients with peripheral 
      arterial disease.
FAU - Thomas, Rebekah
AU  - Thomas R
AD  - Rebekah Thomas is assistant program director, Georgia campus site director, and 
      an assistant professor in the PA program at Philadelphia College of Osteopathic 
      Medicine in Suwanee, Ga. The author has disclosed no potential conflicts of 
      interest, financial or otherwise.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - JAAPA
JT  - JAAPA : official journal of the American Academy of Physician Assistants
JID - 9513102
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
CON - J Am Coll Cardiol. 2018 May 22;71(20):2306-2315. PMID: 29540326
MH  - Aspirin
MH  - Humans
MH  - *Peripheral Arterial Disease
MH  - *Rivaroxaban
EDAT- 2019/06/27 06:00
MHDA- 2020/04/30 06:00
CRDT- 2019/06/27 06:00
PHST- 2019/06/27 06:00 [entrez]
PHST- 2019/06/27 06:00 [pubmed]
PHST- 2020/04/30 06:00 [medline]
AID - 01720610-201907000-00002 [pii]
AID - 10.1097/01.JAA.0000558364.85986.ad [doi]
PST - ppublish
SO  - JAAPA. 2019 Jul;32(7):16-17. doi: 10.1097/01.JAA.0000558364.85986.ad.

PMID- 9297601
OWN - NLM
STAT- MEDLINE
DCOM- 19980107
LR  - 20190920
IS  - 0920-5063 (Print)
IS  - 0920-5063 (Linking)
VI  - 8
IP  - 10
DP  - 1997
TI  - Acetylsalicylic acid loaded poly(vinyl alcohol) hemodialysis membranes: effect of 
      drug release on blood compatibility and permeability.
PG  - 755-64
AB  - Membranes developed from poly(vinyl alcohol) (PVA) have superior permeability 
      because of the highly hydrophilic character of PVA. However, its blood 
      compatibility needs to be further improved. For this we have developed 
      acetylsalicylic acid (ASA, aspirin) loaded PVA membranes. It seems that the slow 
      release of aspirin from the membrane provides a surface concentration of aspirin 
      sufficient for partially inhibiting platelet adhesion. PVA membrane with 531 
      micrograms cm-2 of ASA loaded, may be selected for hemodialysis applications. 
      This may help to reduce the amount of heparin infused during hemodialysis, 
      thereby reducing the side-effects associated with the systemic administration of 
      heparin.
FAU - Paul, W
AU  - Paul W
AD  - Division of Biosurface Technology, Sree Chitra Tirunal Institute for Medical 
      Sciences & Technology, Trivandrum, India.
FAU - Sharma, C P
AU  - Sharma CP
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Biomater Sci Polym Ed
JT  - Journal of biomaterials science. Polymer edition
JID - 9007393
RN  - 0 (Anticoagulants)
RN  - 0 (Biocompatible Materials)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Membranes, Artificial)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9002-89-5 (Polyvinyl Alcohol)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/adverse effects
MH  - Aspirin/*metabolism/pharmacology
MH  - Biocompatible Materials/standards
MH  - Biomechanical Phenomena
MH  - Blood Platelets/drug effects
MH  - Cell Adhesion/drug effects
MH  - Cell Membrane Permeability/drug effects
MH  - Delayed-Action Preparations/metabolism
MH  - Heparin/administration & dosage/adverse effects
MH  - *Membranes, Artificial
MH  - Platelet Aggregation Inhibitors/*metabolism/pharmacology
MH  - Polyvinyl Alcohol/chemistry/*metabolism
MH  - *Renal Dialysis
MH  - Spectrophotometry, Ultraviolet
MH  - Tensile Strength
EDAT- 1997/01/01 00:00
MHDA- 1997/09/23 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/09/23 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1163/156856297x00290 [doi]
PST - ppublish
SO  - J Biomater Sci Polym Ed. 1997;8(10):755-64. doi: 10.1163/156856297x00290.

PMID- 24750015
OWN - NLM
STAT- MEDLINE
DCOM- 20151214
LR  - 20150326
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 26
IP  - 3
DP  - 2015
TI  - Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary 
      artery disease and type 2 diabetes.
PG  - 230-5
LID - 10.3109/09537104.2014.901497 [doi]
AB  - Reduced antiplatelet effect of aspirin has been reported in patients with type 2 
      diabetes, and recent studies suggest that once-daily aspirin provides 
      insufficient platelet inhibition. We investigated if the effect of aspirin 
      declined during the 24-hour dosing interval in patients with coronary artery 
      disease and type 2 diabetes, and whether this correlated with increased platelet 
      turnover. Furthermore, the intra-individual variation in platelet aggregation was 
      determined during a 28-day period. We included 47 patients with coronary artery 
      disease and type 2 diabetes treated with aspirin 75 mg daily. Blood samples were 
      obtained 1 and 24 hours after aspirin intake, and this was repeated three times 
      with a 2-week interval between each visit. Platelet aggregation was evaluated by 
      impedance aggregometry (Multiplate® Analyzer) using arachidonic acid (1.0 mM) and 
      collagen (3.2 µg/ml) as agonists. Markers of platelet turnover were measured by 
      flow cytometry. Compliance was confirmed by serum thromboxane B2. Platelet 
      aggregation levels measured 1 and 24 hours after aspirin intake were compared 
      using the mean of 1- and 24-hour measurements at the three study visits. The 
      difference in platelet aggregation was 70 ± 97 AU × min (p < 0.0001) when using 
      arachidonic acid as agonist and 33 ± 76 AU × min (p = 0.01) when using collagen. 
      Markers of platelet turnover correlated positively, though not significantly, 
      with residual platelet aggregation 24 hours after aspirin intake (p values 0.06 
      and 0.07). Median intra-individual variation of platelet aggregation was 9-16%. 
      Patients with coronary artery disease and type 2 diabetes had increased platelet 
      aggregation at the end of the 24-hour aspirin dosing interval. Platelet turnover 
      did not correlate significantly with residual platelet aggregation, although a 
      trend was observed. The intra-individual variation of platelet aggregation after 
      aspirin intake was low.
FAU - Christensen, Kristian H
AU  - Christensen KH
AD  - Department of Cardiology and.
FAU - Grove, Erik L
AU  - Grove EL
FAU - Würtz, Morten
AU  - Würtz M
FAU - Kristensen, Steen D
AU  - Kristensen SD
FAU - Hvas, Anne-Mette
AU  - Hvas AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140421
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Biomarkers/blood
MH  - Blood Platelets/*drug effects/*metabolism
MH  - Coronary Artery Disease/diagnosis/*drug therapy/*metabolism/therapy
MH  - Diabetes Mellitus, Type 2/diagnosis/*drug therapy/*metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Thromboxane B2/blood
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - coronary artery disease
OT  - diabetes mellitus
OT  - platelet aggregation
OT  - platelet function tests
OT  - platelet turnover
EDAT- 2014/04/23 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/04/23 06:00
PHST- 2014/04/23 06:00 [entrez]
PHST- 2014/04/23 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.3109/09537104.2014.901497 [doi]
PST - ppublish
SO  - Platelets. 2015;26(3):230-5. doi: 10.3109/09537104.2014.901497. Epub 2014 Apr 21.

PMID- 19922458
OWN - NLM
STAT- MEDLINE
DCOM- 20100825
LR  - 20181201
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 17
IP  - 3
DP  - 2010 Mar
TI  - Addition of cilostazol reduces biological aspirin resistance in aspirin users 
      with ischaemic stroke: a double-blind randomized clinical trial.
PG  - 434-42
LID - 10.1111/j.1468-1331.2009.02837.x [doi]
AB  - BACKGROUND AND PURPOSE: Biological aspirin resistance (AR) has been recognized as 
      an important cause of clinical AR. Recent studies have reported the beneficial 
      effects of cilostazol for the prevention of cardiovascular diseases. This study 
      investigated whether addition of cilostazol to aspirin in ischaemic stroke 
      patients can reduce AR. METHODS: In this double-blind multicenter trial, 244 
      aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 
      100 mg twice daily or to placebo. Antiplatelet function was assessed using the 
      VerifyNow Aspirin system. The primary end-point was the incidence of AR, which 
      was measured as aspirin resistance unit (ARU) > or =550 after 4-week treatment. 
      RESULTS: The incidence of AR after treatment in cilostazol group was not 
      significantly different from that in placebo (8.8% vs. 10.9%, P = 0.578). 
      However, AR decreased from 12.8% to 8.8% in cilostazol group, whereas it was not 
      changed in the placebo group. The mean ARU after treatment were also lower in the 
      cilostazol group (456.9 +/- 56.0 vs. 470.7 +/- 67.2, P = 0.081). Cilostazol 
      addition did not prolong bleeding time. CONCLUSIONS: Although this was a negative 
      study, our findings disclosed a trend toward enhanced antiplatelet effects when 
      cilostazol was added to aspirin in ischaemic stroke patients. Combination of 
      aspirin and cilostazol might be a treatment option in the ischaemic stroke 
      patients with AR.
FAU - Lee, J-H
AU  - Lee JH
AD  - Department of Neurology, Hallym University College of Medicine, Seoul, Korea.
FAU - Cha, J-K
AU  - Cha JK
FAU - Lee, S J
AU  - Lee SJ
FAU - Ha, S-W
AU  - Ha SW
FAU - Kwon, S U
AU  - Kwon SU
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20091117
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Bleeding Time
MH  - Brain Ischemia/diagnosis/*drug therapy/epidemiology
MH  - Cilostazol
MH  - Double-Blind Method
MH  - Drug Resistance/*drug effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Prognosis
MH  - Stroke/diagnosis/*drug therapy/epidemiology
MH  - Tetrazoles/administration & dosage/*therapeutic use
MH  - Treatment Outcome
EDAT- 2009/11/20 06:00
MHDA- 2010/08/26 06:00
CRDT- 2009/11/20 06:00
PHST- 2009/11/20 06:00 [entrez]
PHST- 2009/11/20 06:00 [pubmed]
PHST- 2010/08/26 06:00 [medline]
AID - ENE2837 [pii]
AID - 10.1111/j.1468-1331.2009.02837.x [doi]
PST - ppublish
SO  - Eur J Neurol. 2010 Mar;17(3):434-42. doi: 10.1111/j.1468-1331.2009.02837.x. Epub 
      2009 Nov 17.

PMID- 15990752
OWN - NLM
STAT- MEDLINE
DCOM- 20051205
LR  - 20210322
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 149
IP  - 4
DP  - 2005 Apr
TI  - The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in 
      vitro aspirin resistance in patients with intracoronary stent restenosis.
PG  - 675-80
AB  - OBJECTIVES: The aim of our study was to determine the relation between platelet 
      glycoprotein IIIa (Pl A ) polymorphism and aspirin resistance in patients with 
      intracoronary stent restenosis. BACKGROUND: Clinically, aspirin resistance is 
      defined as having thrombotic and embolic cardiovascular events despite regular 
      aspirin therapy. Platelet glycoprotein IIIa polymorphism is said to be a possible 
      mechanism of aspirin resistance. METHODS: We studied the prevalence of aspirin 
      resistance in 204 previously intracoronary stent-implanted patients with stable 
      coronary artery disease. In 102 of these patients, intracoronary stent restenosis 
      was present. Platelet functions were analyzed in a platelet function analyzer 
      (PFA-100, Dade Behring, Germany) with collagen and/or epinephrine (Col/Epi) and 
      collagen and/or adenosine diphosphate cartridges. Closure time <186 seconds was 
      defined as aspirin resistance with Col/Epi cartridges of PFA-100. The Pl A 
      polymorphisms of 43 aspirin-resistant and 51 aspirin-sensitive subjects were 
      determined with polymerase chain reaction and restriction fragments length 
      polymorphism. RESULTS: A total of 31.3% (n = 32) of patients with intracoronary 
      stent restenosis and 10.7% (n = 11) of patients with patent intracoronary stents 
      were resistant to aspirin by PFA-100. The Pl A1,A1 allele of glycoprotein IIIa 
      was present in 36 subjects (83.7.%) and the Pl A1,A2 allele was present in 7 
      subjects (16.2.%) in the aspirin-resistant patients group. The Pl A1,A1 allele of 
      glycoprotein IIIa was present in 37 subjects (72.5%) and the Pl A1,A2 allele was 
      present in 14 subjects (27.5%) in the aspirin-sensitive patients group ( P = 
      .195). CONCLUSION: Our results suggest that platelets of patients with 
      intracoronary stent restenosis with or without Pl A2 heterozygosity of 
      glycoprotein IIIa are more likely to be resistant to low-dose aspirin therapy.
FAU - Pamukcu, Burak
AU  - Pamukcu B
AD  - Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, 
      Istanbul, Turkey. burakpamukcu@istanbul.edu
FAU - Oflaz, Huseyin
AU  - Oflaz H
FAU - Nisanci, Yilmaz
AU  - Nisanci Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Antigens, Human Platelet)
RN  - 0 (ITGB3 protein, human)
RN  - 0 (Integrin beta3)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (human platelet antigen 1b)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Alleles
MH  - Antigens, Human Platelet/*genetics
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Coronary Restenosis/complications/*genetics
MH  - Coronary Stenosis/therapy
MH  - DNA Mutational Analysis
MH  - Drug Resistance/*genetics
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Integrin beta3/chemistry/*genetics/physiology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Polymerase Chain Reaction
MH  - *Polymorphism, Genetic
MH  - Polymorphism, Restriction Fragment Length
MH  - Stents
MH  - Thrombophilia/*drug therapy/etiology
EDAT- 2005/07/02 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/07/02 09:00
PHST- 2005/07/02 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/07/02 09:00 [entrez]
AID - S0002870304007525 [pii]
AID - 10.1016/j.ahj.2004.10.007 [doi]
PST - ppublish
SO  - Am Heart J. 2005 Apr;149(4):675-80. doi: 10.1016/j.ahj.2004.10.007.

PMID- 26503669
OWN - NLM
STAT- MEDLINE
DCOM- 20161006
LR  - 20181113
IS  - 1364-548X (Electronic)
IS  - 1359-7345 (Print)
IS  - 1359-7345 (Linking)
VI  - 52
IP  - 1
DP  - 2016 Jan 4
TI  - New formulation of old aspirin for better delivery.
PG  - 140-3
LID - 10.1039/c5cc07316b [doi]
AB  - For better use of cyclooxygenase dependent anti-inflammatory properties and 
      mitochondrial activities of aspirin, new hydrophobic analogues of aspirin were 
      developed and successfully encapsulated in polymeric nanoparticles (NPs). In vivo 
      anti-inflammatory effects of these NPs using a mouse model demonstrated unique 
      properties of an optimized aspirin analogue to inhibit production of 
      pro-inflammatory and enrichment of anti-inflammatory cytokines.
FAU - Kalathil, Akil A
AU  - Kalathil AA
AD  - NanoTherapeutics Research Laboratory, Department of Chemistry, University of 
      Georgia, Athens, GA 30602, USA. shanta@uga.edu.
FAU - Kumar, Anil
AU  - Kumar A
AD  - NanoTherapeutics Research Laboratory, Department of Chemistry, University of 
      Georgia, Athens, GA 30602, USA. shanta@uga.edu.
FAU - Banik, Bhabatosh
AU  - Banik B
AD  - NanoTherapeutics Research Laboratory, Department of Chemistry, University of 
      Georgia, Athens, GA 30602, USA. shanta@uga.edu.
FAU - Ruiter, Timothy A
AU  - Ruiter TA
AD  - NanoTherapeutics Research Laboratory, Department of Chemistry, University of 
      Georgia, Athens, GA 30602, USA. shanta@uga.edu.
FAU - Pathak, Rakesh K
AU  - Pathak RK
AD  - NanoTherapeutics Research Laboratory, Department of Chemistry, University of 
      Georgia, Athens, GA 30602, USA. shanta@uga.edu.
FAU - Dhar, Shanta
AU  - Dhar S
AD  - NanoTherapeutics Research Laboratory, Department of Chemistry, University of 
      Georgia, Athens, GA 30602, USA. shanta@uga.edu.
LA  - eng
GR  - R01 NS093314/NS/NINDS NIH HHS/United States
GR  - R01NS093314/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Chem Commun (Camb)
JT  - Chemical communications (Cambridge, England)
JID - 9610838
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Carriers)
RN  - 0 (Interleukin-6)
RN  - 0 (Polymers)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & 
      dosage/*chemistry/therapeutic use
MH  - Aspirin/*administration & dosage/*analogs & derivatives/therapeutic use
MH  - Drug Carriers/*chemistry
MH  - Interleukin-10/blood/immunology
MH  - Interleukin-6/blood/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Nanoparticles/*chemistry
MH  - Polymers/chemistry
MH  - Tumor Necrosis Factor-alpha/blood/immunology
PMC - PMC4679634
MID - NIHMS733682
EDAT- 2015/10/28 06:00
MHDA- 2016/10/08 06:00
CRDT- 2015/10/28 06:00
PHST- 2015/10/28 06:00 [entrez]
PHST- 2015/10/28 06:00 [pubmed]
PHST- 2016/10/08 06:00 [medline]
AID - 10.1039/c5cc07316b [doi]
PST - ppublish
SO  - Chem Commun (Camb). 2016 Jan 4;52(1):140-3. doi: 10.1039/c5cc07316b.

PMID- 1415427
OWN - NLM
STAT- MEDLINE
DCOM- 19921117
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 167
IP  - 4 Pt 1
DP  - 1992 Oct
TI  - Low-dose aspirin inhibits lipid peroxides and thromboxane but not prostacyclin in 
      pregnant women.
PG  - 926-30
AB  - OBJECTIVE: Preeclampsia is associated with an imbalance of increased thromboxane 
      and decreased prostacyclin and an abnormal increase of lipid peroxides. Lipid 
      peroxides are toxic compounds that damage cells and inhibit prostacyclin 
      synthesis. Low-dose aspirin therapy reduces the incidence of preeclampsia, 
      presumably by selective inhibition of thromboxane to restore a balance between 
      thromboxane and prostacyclin. However, the effectiveness of low-dose aspirin 
      might also relate to inhibition of lipid peroxides. STUDY DESIGN: To test this 
      hypothesis, 10 women at risk of preeclampsia were placed on low-dose aspirin 
      therapy (81 mg/day) between 9 and 34 weeks of gestation. Plasma samples were 
      collected before and after 3 to 4 days and 3 to 4 weeks of aspirin therapy. 
      Samples were analyzed for thromboxane and prostacyclin by radioimmunoassay of 
      their stable metabolites, thromboxane B2 and 6-keto-prostaglandin F1 alpha, and 
      for lipid peroxides by hydrogen peroxide equivalents. RESULTS: Low-dose aspirin 
      significantly decreased (p < 0.05) both lipid peroxides (130 +/- 18 vs 92 +/- 11 
      and 68 +/- 9 nmol/ml, mean +/- SE) and thromboxane (502 +/- 67 vs 138 +/- 67 and 
      8 +/- 5 pg/ml), but it did not affect prostacyclin (55 +/- 10 vs 41 +/- 8 and 40 
      +/- 11 pg/ml, p > 0.1). CONCLUSION: Low-dose aspirin selectively inhibits both 
      lipid peroxides and thromboxane without affecting prostacyclin. Inhibition of 
      both lipid peroxides and thromboxane by low-dose aspirin reveals a new mechanism 
      of action and may account for its effectiveness in the prevention of 
      preeclampsia.
FAU - Walsh, S W
AU  - Walsh SW
AD  - Department of Obstetrics and Gynecology, Medical College of Virginia, Richmond 
      23298-0034.
FAU - Wang, Y
AU  - Wang Y
FAU - Kay, H H
AU  - Kay HH
FAU - McCoy, M C
AU  - McCoy MC
LA  - eng
GR  - HD 20973/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Lipid Peroxides)
RN  - 0 (Thromboxanes)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Epoprostenol/*blood
MH  - Female
MH  - Humans
MH  - Lipid Peroxides/*antagonists & inhibitors/blood
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy/*blood
MH  - Radioimmunoassay
MH  - Thromboxanes/*antagonists & inhibitors/blood
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - S0002-9378(12)80013-5 [pii]
AID - 10.1016/s0002-9378(12)80013-5 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1992 Oct;167(4 Pt 1):926-30. doi: 
      10.1016/s0002-9378(12)80013-5.

PMID- 6128005
OWN - NLM
STAT- MEDLINE
DCOM- 19821221
LR  - 20181130
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 32
IP  - 8
DP  - 1982
TI  - [SKF 93479, a newly developed histamine H2-receptor antagonist. / Effect on 
      gastric potential difference in the presence and absence of acetylsalicylic 
      acid].
PG  - 840-1
AB  - Acetylsalicylic acid (ASA) alters the gastric mucosal barrier as measured by the 
      transmucosal potential difference (PD). The effect of the newly developed 
      histamine H2-receptor antagonist 
      2-(2-(5-dimethylaminoethylfuran-2-ylmethylthio)ethylamino)-5-(6-methylpyrid-3-ylmethyl)pyrimid-4-one 
      trihydrochloride (SKF 93479) on the ASA-induced drop in gastric PD was studied in 
      6 healthy volunteers. Mean basal PD was -38.5 to -39.5 mV. After 1000 mg of ASA 
      PD decreased in 10-15 min to -25 mV. In subjects pretreated orally with 0.5 mg/kg 
      SKF 93479, PD rose during 30-45 min to -53.5 mV. After ASA PD fell to -38.5 mV, 
      but did not fall below normal.
FAU - Müller, P
AU  - Müller P
FAU - Dammann, H G
AU  - Dammann HG
FAU - Kessler, R
AU  - Kessler R
FAU - Simon, B
AU  - Simon B
LA  - ger
PT  - Journal Article
TT  - SKF 93479, ein neu entwickelter Histamin H2-Rezeptor Antagonist. Wirkung auf die 
      gastrale Potentialdifferenz in An- und Abwesenheit von Acetylsalicylsäure.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Pyrimidinones)
RN  - 72716-75-7 (SK&F 93479)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Gastric Acid/metabolism
MH  - Gastric Mucosa/*drug effects
MH  - Histamine H2 Antagonists/*pharmacology
MH  - Humans
MH  - Male
MH  - Membrane Potentials/drug effects
MH  - Pyrimidinones/*pharmacology
MH  - Time Factors
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1982;32(8):840-1.

PMID- 781232
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20131121
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 2
DP  - 1976
TI  - Some problems in the interpretation of clinical trials: longterm parallel study 
      of fenoprofen in rheumatoid arthritis.
PG  - 61-5
AB  - Fenoprofen calcium was compared with acetylsalicylic acid in the treatment of 27 
      patients with definite or classic rheumatoid arthritis, over a period of one 
      year. Both drugs appeared efficacious, with a slight edge to fenoprofen in the 
      doses employed. Fewer side effects were noted with fenoprofen. Effectiveness 
      continued undiminished throughout the year, and mean values of most parameters 
      continued to improve in both groups over the entire period. Three problems which 
      influence extrapolation of results from this and similar studies to the general 
      setting are discussed. (1) Individual patients show great variation from the mean 
      and from one observation point to another. Thus, expectations developed from mean 
      values will seldom be accurate in a particular patient. (2) The relative doses 
      chosen for two drugs in the clinical trial can profoundly influence both efficacy 
      and toxicity. The qualification "at the doses employed" is seldom emphasized in 
      clinical reports. (3) Patient compliance in the general clinical setting is 
      importantly different from that in a clinical trial, and this potential problem 
      must be assessed by the physician choosing an appropriate medication for a 
      particular patient.
FAU - Fries, J F
AU  - Fries JF
FAU - Britton, M C
AU  - Britton MC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Fenoprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Phenylpropionates/*therapeutic use
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1976;2:61-5.

PMID- 17484273
OWN - NLM
STAT- MEDLINE
DCOM- 20070618
LR  - 20161020
IS  - 0884-6812 (Linking)
VI  - 29
IP  - 2
DP  - 2007 Apr
TI  - Light, electron microscopic and immunohistochemical study of the effect of 
      low-dose aspirin during the proestrus phase on rat endometrium in the 
      preimplantation period.
PG  - 95-102
AB  - OBJECTIVE: To evaluate structural alterations in rat endometrium at 
      preimplantation following treatment with aspirin beginning from proestrus by 
      light microscopy, electron microscopy and immunohistochemical techniques. STUDY 
      DESIGN: Twenty rats were divided into control (n = 10) and experimental (n = 10) 
      groups. Experimental rats were treated with low-dose aspirin daily (2 mg/kg/day) 
      during estrus, beginning from the proestrus phase, mated at end of cycle and 
      treated with aspirin. Untreated pregnant rats were the control group. Rats in 
      both groups were sacrificed at the 84th pregnancy hour; the uterus was rapidly 
      removed and dissected free of surrounding adipose tissue. Uteri specimens from 
      nonpregnant rats were transferred into fixative solution and processed for light, 
      electron microscopic and immunohistochemical study. RESULTS: Light and electron 
      microscopy of endometrium from control rats conformed to mid-diestrus phase; 
      endometrial histology of the aspirin-treated group conformed to late diestrus 
      phase. The endometrial layer was significantly thicker in the aspirin-treated 
      group compared to the untreated control group (p <0.001). No significant 
      difference was found in vessel number between groups. Staining with alphaV 
      integrin was more dense in the aspirin-treated group. CONCLUSION: Based on 
      histologic findings, we suggest low-dose aspirin has positive effects on 
      preparing endometrium before implantation.
FAU - Ateş, Utku
AU  - Ateş U
AD  - Department of Histology, Faculty of Medicine, Ege University, Izmir, Turkey.
FAU - Baka, Meral
AU  - Baka M
FAU - Turgut, Mehmet
AU  - Turgut M
FAU - Uyanikgil, Yiğit
AU  - Uyanikgil Y
FAU - Ulker, Sibel
AU  - Ulker S
FAU - Yilmaz, Ozlem
AU  - Yilmaz O
FAU - Tavmergen, Erol
AU  - Tavmergen E
FAU - Yurtseven, Mine
AU  - Yurtseven M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Anal Quant Cytol Histol
JT  - Analytical and quantitative cytology and histology
JID - 8506819
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blastocyst
MH  - Endometrium/*drug effects
MH  - Female
MH  - Immunohistochemistry/*methods
MH  - Microscopy/*methods
MH  - Microscopy, Electron/methods
MH  - Pregnancy
MH  - *Pregnancy, Animal
MH  - Proestrus/*drug effects
MH  - Rats
EDAT- 2007/05/09 09:00
MHDA- 2007/06/19 09:00
CRDT- 2007/05/09 09:00
PHST- 2007/05/09 09:00 [pubmed]
PHST- 2007/06/19 09:00 [medline]
PHST- 2007/05/09 09:00 [entrez]
PST - ppublish
SO  - Anal Quant Cytol Histol. 2007 Apr;29(2):95-102.

PMID- 10211350
OWN - NLM
STAT- MEDLINE
DCOM- 19990429
LR  - 20190501
IS  - 0032-5473 (Print)
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 74
IP  - 876
DP  - 1998 Oct
TI  - Platelets, aspirin, and cardiovascular disease.
PG  - 587-91
AB  - Aspirin was first synthesised 100 years ago and its preparation and marketing is 
      generally reckoned to have been the foundation of the pharmaceutical industry. 
      For most of the time since then it has been used for the relief of pain and 
      fever. The modern phase of aspirin use commenced with the reporting in 1974 of a 
      randomised controlled trial in the secondary prevention of death by low-dose 
      aspirin given to patients who had suffered a myocardial infarct. Reports of other 
      trials followed and an overview of the first six trials was presented to the 
      inaugural meeting of the Society for Clinical Trials in Philadelphia in 1980. 
      There have been two further major overviews and the most recent, based on 145 
      trials, established that low-dose aspirin reduces vascular events by around one 
      third. It has been estimated that, used appropriately, aspirin could prevent 
      100,000 premature deaths each year worldwide, at a cost of about 250 Pounds 
      ($400) per life saved, and about 80 Pounds ($130) per cardiovascular event 
      prevented. The evidence indicates that it is seriously underused at present. The 
      aspirin story continues and trials are in progress to test other possible uses of 
      aspirin, in vascular dementia, colorectal cancer, and cataract.
FAU - Elwood, P C
AU  - Elwood PC
AD  - MRC Epidemiology Unit, Llandough Hospital, Penarth, South Glamorgan, UK.
FAU - Hughes, C
AU  - Hughes C
FAU - O'Brien, J R
AU  - O'Brien JR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/prevention & control
MH  - Venous Thrombosis/prevention & control
PMC - PMC2361007
EDAT- 1999/04/22 00:00
MHDA- 1999/04/22 00:01
CRDT- 1999/04/22 00:00
PHST- 1999/04/22 00:00 [pubmed]
PHST- 1999/04/22 00:01 [medline]
PHST- 1999/04/22 00:00 [entrez]
AID - 10.1136/pgmj.74.876.587 [doi]
PST - ppublish
SO  - Postgrad Med J. 1998 Oct;74(876):587-91. doi: 10.1136/pgmj.74.876.587.

PMID- 24427842
OWN - NLM
STAT- MEDLINE
DCOM- 20140415
LR  - 20140115
IS  - 1167-7422 (Print)
IS  - 1167-7422 (Linking)
VI  - 22
IP  - 143
DP  - 2013 Nov
TI  - Antithrombotic drugs and ischaemic stroke.
PG  - 270-1
AB  - About 80% of strokes are ischaemic. Approximately 12% of patients die within 3 
      months following stroke, and another 20% are institutionalised or become highly 
      dependent. In early 2013, what is the harm-benefit balance of antithrombotic 
      treatments used in the acute phase of ischaemic stroke? To answer this question, 
      we reviewed the available data using the standard Prescrire methodology. Clinical 
      trials of aspirin in the acute phase of ischaemic stroke consist mainly of two 
      randomised trials including a total of 40 541 patients. After 1 to 6 months, 13 
      deaths or sequelae resulting in dependence are prevented when 1000 patients are 
      treated with aspirin during the acute phase. Aspirin increases the risk of 
      symptomatic intracranial haemorrhage when it is introduced less than 24 hours 
      after treatment with alteplase. Abciximab, an injectable antiplatelet agent, 
      showed no tangible clinical benefit in 5 randomised placebo-controlled trials in 
      a total of 1275 patients. Clopidogrel and prasugrel, two other antiplatelet 
      agents, have not been evaluated in this setting. However, in case of allergy to 
      aspirin, clopidogrel is a useful alternative in other situations associated with 
      a risk of arterial ischaemia. In a randomised trial including 458 patients, 
      cilostazol and aspirin were similarly effective after 3 months of follow-up, but 
      cilostazol caused cardiac arrhythmias. Ticlopidine has too many adverse effects 
      to consider it a useful drug. Anticoagulant therapy during the acute phase of 
      stroke has an unfavourable harm-benefit balance, including in patients with 
      stroke secondary to cardiac embolism. Low-molecular-weight heparin reduces the 
      risk of pulmonary embolism but has no impact on overall mortality. The aim of 
      thrombolysis is to unclog the affected artery. Intravenous alteplase 
      administration is the best-assessed thrombolytic method. Twelve randomised trials 
      have compared intravenous thrombolysis with alteplase versus no thrombolytic 
      therapy in 7012 patients. Among patients treated within 3 hours after stroke 
      onset, 41% survived without sequelae after alteplase administration, versus 32% 
      in the absence of thrombolysis; alteplase had no statistically significant impact 
      on mortality at the end of follow-up. Efficacy appeared to be similar in patients 
      over 80 years old.The harm-benefit balance may also be favourable when 
      thrombolysis is started more than 3 hours after stroke onset, but when it is 
      initiated more than 4.5 hours after stroke onset, it increases mortality. Four 
      randomised trials showed that intra-arterial thrombolysis with urokinase or 
      pro-urokinase had a beneficial effect, versus no thrombolysis, in a total of 356 
      patients. In a randomised trial including 362 patients, intra-arterial 
      thrombolysis did not have a better harm-benefit balance than intravenous 
      thrombolysis. Among the various physical and mechanical methods used to remove or 
      dissolve clots, the best-evaluated is ultrasound plus intravenous alteplase 
      thrombolysis; initial results with this procedure warrant further clinical 
      trials. Rapid intervention and patient selection are both crucial in optimising 
      the harm-benefit balance of intravenous alteplase thrombolysis. This treatment 
      should only be used when management begins within the first hours following 
      stroke symptom onset, and when there are no risk factors for bleeding, especially 
      intracranial bleeding. For other patients, aspirin is the only antithrombotic 
      drug known to reduce, albeit only slightly, the risk of death and sequelae 
      following ischaemic stroke.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Prescrire Int
JT  - Prescrire international
JID - 9439295
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects
MH  - Brain Ischemia/*drug therapy
MH  - Fibrinolytic Agents/*adverse effects
MH  - Humans
MH  - Stroke/*drug therapy
EDAT- 2014/01/16 06:00
MHDA- 2014/04/16 06:00
CRDT- 2014/01/16 06:00
PHST- 2014/01/16 06:00 [entrez]
PHST- 2014/01/16 06:00 [pubmed]
PHST- 2014/04/16 06:00 [medline]
PST - ppublish
SO  - Prescrire Int. 2013 Nov;22(143):270-1.

PMID- 8720968
OWN - NLM
STAT- MEDLINE
DCOM- 19961004
LR  - 20131121
IS  - 0035-3639 (Print)
IS  - 0035-3639 (Linking)
VI  - 17
IP  - 1
DP  - 1996 Feb
TI  - [Response to 6 questions apropos transient cerebral ischemia].
PG  - 11-6
AB  - The author answers to six questions relating to the cerebral transitory ischémic 
      attacks, namely definition, significance, frequency, diagnosis, causes and 
      prevention. Within this context, the actualization of antiagregation, 
      anticoagulation and endarterectomy is presented.
FAU - Sternon, J
AU  - Sternon J
AD  - Médecine Interne, Hôpital Erasme.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Six questions-réponses à propos des accidents ischémiques cérébraux transitoires.
PL  - Belgium
TA  - Rev Med Brux
JT  - Revue medicale de Bruxelles
JID - 8003474
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Endarterectomy, Carotid
MH  - Humans
MH  - Ischemic Attack, Transient/*diagnosis/etiology/prevention & control
MH  - Platelet Aggregation Inhibitors/therapeutic use
RF  - 22
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
PST - ppublish
SO  - Rev Med Brux. 1996 Feb;17(1):11-6.

PMID- 6779236
OWN - NLM
STAT- MEDLINE
DCOM- 19810324
LR  - 20161123
IS  - 0375-9393 (Print)
IS  - 0375-9393 (Linking)
VI  - 46
IP  - 2
DP  - 1980 Feb
TI  - [Delivery under general anesthesia with the sequence of althesin and lysine 
      acetylsalicylate; a clinical contribution].
PG  - 305-10
AB  - Personal experience in the use of Althesin in painless childbirth is reported. 
      The anaesthetic is held to have no effect on the foetus and the technique using 
      Althesin and acetylsalicylate of lysine is considered the correct one. If 
      properly applied, it offers the foetus complete wellbeing during labour and 
      enables the mother to overcome the psychophysical stress of an event which is too 
      often accepted with inherited feelings of ancestral fear.
FAU - Ventura, S
AU  - Ventura S
FAU - Catalano, S
AU  - Catalano S
FAU - Cianci, A
AU  - Cianci A
LA  - ita
PT  - Journal Article
TT  - Il parto in anestesia generale con la sequenza althesin acetilsalicilato di 
      lisina; contributo clinico.
PL  - Italy
TA  - Minerva Anestesiol
JT  - Minerva anestesiologica
JID - 0375272
RN  - 8067-82-1 (Alfaxalone Alfadolone Mixture)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Alfaxalone Alfadolone Mixture
MH  - Anesthesia, General/*methods
MH  - Anesthesia, Intravenous/methods
MH  - Anesthesia, Obstetrical/*methods
MH  - Aspirin/*analogs & derivatives
MH  - Delivery, Obstetric/*methods
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives
MH  - Parity
MH  - Pregnancy
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
PST - ppublish
SO  - Minerva Anestesiol. 1980 Feb;46(2):305-10.

PMID- 477965
OWN - NLM
STAT- MEDLINE
DCOM- 19791121
LR  - 20131121
IS  - 0014-8318 (Print)
IS  - 0014-8318 (Linking)
VI  - 42
IP  - 4
DP  - 1979 Jul-Aug
TI  - [Gonadotoxic action of acetylsalicylic acid].
PG  - 421-3
AB  - It has been established in experiments on white rats that administration of 
      acetylsalicylic acid (ASA) in a dose of 1/10 LD50 for 1 1/2 months is accompanied 
      by a decrease in the functional activity of spermatozoids. Repeated inhalation of 
      ASA dust at a concentration of 25 mg/m3 for 4 months produces morphological 
      changes in the spermatogenic epithelium and abnormal antenatal development of the 
      progeny of male animals under test.
FAU - Vasilenko, N M
AU  - Vasilenko NM
FAU - Manzhelaĭ, E S
AU  - Manzhelaĭ ES
FAU - Gnezdilova, A I
AU  - Gnezdilova AI
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - O gonadotoksicheskom deĭstvii atsetilsalitsilovoĭ kisloty.
PL  - Russia (Federation)
TA  - Farmakol Toksikol
JT  - Farmakologiia i toksikologiia
JID - 16920420R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Dose-Response Relationship, Drug
MH  - Embryo, Mammalian/drug effects
MH  - Environmental Exposure
MH  - Female
MH  - Male
MH  - Pregnancy
MH  - Rats
MH  - Reproduction/drug effects
MH  - Spermatogenesis/drug effects
MH  - Testis/*drug effects
MH  - Time Factors
EDAT- 1979/07/01 00:00
MHDA- 1979/07/01 00:01
CRDT- 1979/07/01 00:00
PHST- 1979/07/01 00:00 [pubmed]
PHST- 1979/07/01 00:01 [medline]
PHST- 1979/07/01 00:00 [entrez]
PST - ppublish
SO  - Farmakol Toksikol. 1979 Jul-Aug;42(4):421-3.

PMID- 26743279
OWN - NLM
STAT- MEDLINE
DCOM- 20161107
LR  - 20170103
IS  - 2066-8279 (Electronic)
IS  - 1220-0522 (Linking)
VI  - 56
IP  - 4
DP  - 2015
TI  - Orthodontic tooth movement following analgesic treatment with Aspirin and 
      Algocalmin. An experimental study.
PG  - 1339-44
AB  - The objective of this study was the tracing of the effect of Aspirin and 
      Algocalmin, two of the most frequently used analgesics after the application of 
      orthodontic appliances, on the dental displacements, starting from the hypothesis 
      according to whom any substance that inhibits prostaglandins' production will 
      have as result the inhibition of the osteoclasts' activity and of the orthodontic 
      tooth movements implicit. Twenty-four male Wistar rats, separated into three 
      groups were used. Group I (control) included eight rats in which the orthodontic 
      device was applied, without a subsequent administration of any analgesic; Group 
      II - eight rats in which after the device application Aspirin was administrated; 
      and Group III - eight animals in which Algocalmin was administrated. A 
      histological study was completed in order to establish the size of bone areola. 
      Average mesial displacement of the first left inferior maxillary molar 28 days 
      after applying the orthodontic device was of 3.61±0.29 mm for the control group. 
      The average displacement in the group in which Aspirin was administrated was 0.03 
      mm. In the group treated with Algocalmin, the dental displacement was of 
      0.19±0.08 mm. Histological examination revealed the presence of large sizes bone 
      areola in control group (244 μm), more reduced in the group treated with Aspirin 
      (74 μm), and intermediate in that treated with Algocalmin (127 μm). Treatments 
      with Aspirin and Algocalmin in experimental groups, immediately after the 
      orthodontic device application, induced a decreased dental displacement rate.
FAU - Olteanu, Cristian Doru
AU  - Olteanu CD
AD  - Department of Orthodontics, "Iuliu Hatieganu" University of Medicine and 
      Pharmacy, Cluj-Napoca, Romania; cristidolteanu@yahoo.com.
FAU - Şerbănescu, Alin
AU  - Şerbănescu A
FAU - Boşca, Adina Bianca
AU  - Boşca AB
FAU - Mihu, Carmen Mihaela
AU  - Mihu CM
LA  - eng
PT  - Journal Article
PL  - Romania
TA  - Rom J Morphol Embryol
JT  - Romanian journal of morphology and embryology = Revue roumaine de morphologie et 
      embryologie
JID - 9112454
RN  - 0 (Analgesics)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alveolar Process/drug effects/pathology
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dipyrone/*pharmacology
MH  - Male
MH  - *Orthodontic Appliances
MH  - Rats, Wistar
MH  - *Tooth Movement Techniques
EDAT- 2016/01/09 06:00
MHDA- 2016/11/08 06:00
CRDT- 2016/01/09 06:00
PHST- 2016/01/09 06:00 [entrez]
PHST- 2016/01/09 06:00 [pubmed]
PHST- 2016/11/08 06:00 [medline]
AID - 56041513391344 [pii]
PST - ppublish
SO  - Rom J Morphol Embryol. 2015;56(4):1339-44.

PMID- 2231066
OWN - NLM
STAT- MEDLINE
DCOM- 19901219
LR  - 20190515
IS  - 0884-8734 (Print)
IS  - 0884-8734 (Linking)
VI  - 5
IP  - 5 Suppl
DP  - 1990 Sep-Oct
TI  - Prevention of cardiovascular disease: risks and benefits of aspirin.
PG  - S54-7
AB  - Aspirin has been tested for its benefit in preventing cardiovascular disease in 
      randomized trials in three categories of patients. In secondary prevention among 
      those with a history of myocardial infarction (MI), stroke or transient cerebral 
      ischemia, or unstable angina pectoris, 25 randomized trials demonstrated 
      significant reductions from aspirin of 25% for the occurrence of an "important 
      vascular event" (nonfatal MI, nonfatal stroke, or vascular death), 32% for 
      nonfatal MI, 27% for nonfatal stroke, and 15% for vascular mortality. Among those 
      evolving an MI, the Second International Study of Infarct Survival (ISIS-2) 
      showed a significant reduction of 23% in five-week vascular mortality among those 
      started on a one-month regimen of daily aspirin within 24 hours of the onset of 
      symptoms of suspected MI. Aspirin also significantly reduced reinfarction, 
      nonfatal stroke, and important vascular events. Finally, in primary prevention, 
      the US Physicians' Health Study (PHS) showed a significant 44% reduction in the 
      occurrence of a first MI among apparently healthy male physicians; numbers of 
      strokes and vascular deaths were insufficient to permit conclusions for these 
      endpoints. Thus, aspirin is of clear benefit in reducing MI, stroke, and vascular 
      death in secondary prevention and among those evolving an MI. It is also 
      beneficial in the primary prevention of MI among men over 40, but data concerning 
      its effects on stroke and vascular death remain inconclusive.
FAU - Buring, J E
AU  - Buring JE
AD  - Department of Medicine, Harvard Medical School, Boston, MA.
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Review
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cerebrovascular Disorders/prevention & control
MH  - Humans
MH  - Myocardial Infarction/drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Streptokinase/therapeutic use
MH  - United States/epidemiology
RF  - 17
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
AID - 10.1007/BF02600843 [doi]
PST - ppublish
SO  - J Gen Intern Med. 1990 Sep-Oct;5(5 Suppl):S54-7. doi: 10.1007/BF02600843.

PMID- 9049576
OWN - NLM
STAT- MEDLINE
DCOM- 19970529
LR  - 20230320
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 51
IP  - 5
DP  - 1997
TI  - Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in 
      children with fever.
PG  - 367-71
AB  - OBJECTIVE: We compared efficacy and impact on the comfort of ibuprofen (7.5 mg/kg 
      per dose), aspirin (10 mg/kg/dose) and paracetamol (10 mg/kg per dose) on 
      children with fever aged 6-24 months in an open, randomised study with three 
      parallel groups. METHODS: The main criterion for efficacy was area under the 
      curve (AUC) of percentage temperature reduction. Comfort was assessed on scores 
      depending on general behaviour and degree of relief. General behaviour was 
      assessed on a verbal scale and on a visual analogue scale (VAS) and the degree of 
      relief was assessed in relation to baseline on a verbal scale. RESULTS: The 
      efficacy of ibuprofen was better than that of aspirin or paracetamol. In spite of 
      more adverse events, the comfort scores were significantly in favour of ibuprofen 
      6 h after the first dose of treatment.
FAU - Autret, E
AU  - Autret E
AD  - Clinical Pharmacology Department, Bretonneau Hospital, Tours, France.
FAU - Reboul-Marty, J
AU  - Reboul-Marty J
FAU - Henry-Launois, B
AU  - Henry-Launois B
FAU - Laborde, C
AU  - Laborde C
FAU - Courcier, S
AU  - Courcier S
FAU - Goehrs, J M
AU  - Goehrs JM
FAU - Languillat, G
AU  - Languillat G
FAU - Launois, R
AU  - Launois R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/adverse effects/pharmacokinetics/*therapeutic use
MH  - Analgesics, Non-Narcotic/adverse effects/pharmacokinetics/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse 
      effects/pharmacokinetics/*therapeutic use
MH  - Aspirin/adverse effects/pharmacokinetics/*therapeutic use
MH  - Body Temperature/*drug effects
MH  - Child, Preschool
MH  - Female
MH  - Fever/*drug therapy/metabolism
MH  - Humans
MH  - Ibuprofen/adverse effects/pharmacokinetics/*therapeutic use
MH  - Infant
MH  - Male
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1007/s002280050215 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1997;51(5):367-71. doi: 10.1007/s002280050215.

PMID- 17145791
OWN - NLM
STAT- MEDLINE
DCOM- 20070604
LR  - 20220318
IS  - 0066-4804 (Print)
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Linking)
VI  - 51
IP  - 2
DP  - 2007 Feb
TI  - Aspirin antagonism in isoniazid treatment of tuberculosis in mice.
PG  - 794-5
AB  - Salicylate has previously been shown to reduce the susceptibility of 
      Mycobacterium tuberculosis to several drugs in vitro. In this study, aspirin, a 
      salicylate anti-inflammatory, antagonized isoniazid treatment of murine pulmonary 
      tuberculosis, whereas the nonsalicylate ibuprofen did not. These results may have 
      implications on concurrent administration of anti-inflammatory and 
      antituberculosis drugs.
FAU - Byrne, Sean T
AU  - Byrne ST
AD  - Department of Molecular Microbiology and Immunology, Bloomberg School of Public 
      Health, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, MD 21205, USA.
FAU - Denkin, Steven M
AU  - Denkin SM
FAU - Zhang, Ying
AU  - Zhang Y
LA  - eng
GR  - R01 AI044063/AI/NIAID NIH HHS/United States
GR  - R01 AI049485/AI/NIAID NIH HHS/United States
GR  - AI44063/AI/NIAID NIH HHS/United States
GR  - AI49485/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20061204
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Antitubercular Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - V83O1VOZ8L (Isoniazid)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Antitubercular Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Drug Antagonism
MH  - Drug Therapy, Combination
MH  - Ibuprofen/pharmacology
MH  - Isoniazid/*pharmacology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - *Mycobacterium tuberculosis
MH  - Tuberculosis/*drug therapy
PMC - PMC1797778
EDAT- 2006/12/06 09:00
MHDA- 2007/06/05 09:00
CRDT- 2006/12/06 09:00
PHST- 2006/12/06 09:00 [pubmed]
PHST- 2007/06/05 09:00 [medline]
PHST- 2006/12/06 09:00 [entrez]
AID - AAC.01145-06 [pii]
AID - 1145-06 [pii]
AID - 10.1128/AAC.01145-06 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 2007 Feb;51(2):794-5. doi: 10.1128/AAC.01145-06. 
      Epub 2006 Dec 4.

PMID- 29571114
OWN - NLM
STAT- MEDLINE
DCOM- 20190723
LR  - 20190723
IS  - 1878-0180 (Electronic)
IS  - 1878-0180 (Linking)
VI  - 82
DP  - 2018 Jun
TI  - Mechanically strong dual responsive nanocomposite double network hydrogel for 
      controlled drug release of asprin.
PG  - 61-69
LID - S1751-6161(18)30269-8 [pii]
LID - 10.1016/j.jmbbm.2018.03.002 [doi]
AB  - Mechanically strong dual/multi-stimuli-responsive smart hydrogels have attracted 
      extensive attention in recent years. A novel tough, mechanical strong and 
      biocompatible dual pH- and temperature- responsive poly (N-isopropylacrylamide) 
      /clay (laponite XLG)/carboxymethyl chitosan (CMCTs) /genipin nanocomposite double 
      network hydrogel was synthesized through a facile, one-pot free radical 
      polymerization initiated by the ultraviolet light, using clay and the natural 
      molecular-genipin as the cross-linkers instead of toxic organic molecules. 
      Crucial factors, the content of CMCTs, clay and genipin, for synthesizing the 
      mechanical strong hydrogels were investigated. When the content of CMCTs, clay 
      and genipin were 5 wt%, 33.3 wt% and 0.175 wt%, respectively (to the weight of 
      N-isopropylacrylamide), these prepared hydrogels exhibited a high tensile 
      strength of 137.9 kPa at the failure strain of 446.1%. Furthermore, the 
      relationship between swelling and deswelling rate of the synthesized hydrogels 
      and the above crucial factors were also studied. Besides, the synthesized 
      hydrogels displayed a considerable controlled release property of asprin by 
      tuning their inner crosslink density. Owing to this property, they may have great 
      potential in the drug delivery systems.
CI  - Copyright © 2018 Elsevier Ltd. All rights reserved.
FAU - Chen, Yang
AU  - Chen Y
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China.
FAU - Song, Guocheng
AU  - Song G
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China.
FAU - Yu, Junrong
AU  - Yu J
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China. Electronic address: yjr@dhu.edu.cn.
FAU - Wang, Yan
AU  - Wang Y
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China.
FAU - Zhu, Jing
AU  - Zhu J
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China.
FAU - Hu, Zuming
AU  - Hu Z
AD  - State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, 
      College of Materials Science and Engineering, Donghua University, Shanghai 
      201620, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180308
PL  - Netherlands
TA  - J Mech Behav Biomed Mater
JT  - Journal of the mechanical behavior of biomedical materials
JID - 101322406
RN  - 0 (Acrylic Resins)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Carriers)
RN  - 0 (Hydrogels)
RN  - 25189-55-3 (poly-N-isopropylacrylamide)
RN  - R16CO5Y76E (Aspirin)
MH  - Acrylic Resins/chemistry
MH  - Aspirin/*chemistry
MH  - Delayed-Action Preparations
MH  - Drug Carriers/*chemistry
MH  - Hydrogels/*chemistry
MH  - Hydrogen-Ion Concentration
MH  - *Mechanical Phenomena
MH  - Nanocomposites/*chemistry
MH  - Temperature
MH  - Tensile Strength
OTO - NOTNLM
OT  - Biocompatible
OT  - Drug delivery systems
OT  - Dual-responsive
OT  - Mechanically strong
OT  - Nanocomposite double network
EDAT- 2018/03/24 06:00
MHDA- 2019/07/25 06:00
CRDT- 2018/03/24 06:00
PHST- 2018/01/15 00:00 [received]
PHST- 2018/03/02 00:00 [revised]
PHST- 2018/03/05 00:00 [accepted]
PHST- 2018/03/24 06:00 [pubmed]
PHST- 2019/07/25 06:00 [medline]
PHST- 2018/03/24 06:00 [entrez]
AID - S1751-6161(18)30269-8 [pii]
AID - 10.1016/j.jmbbm.2018.03.002 [doi]
PST - ppublish
SO  - J Mech Behav Biomed Mater. 2018 Jun;82:61-69. doi: 10.1016/j.jmbbm.2018.03.002. 
      Epub 2018 Mar 8.

PMID- 24662756
OWN - NLM
STAT- MEDLINE
DCOM- 20141209
LR  - 20140424
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 128
DP  - 2014 Jul 15
TI  - Application of time-resolved fluorescence to the determination of metabolites.
PG  - 82-90
LID - S1386-1425(14)00335-7 [pii]
LID - 10.1016/j.saa.2014.02.137 [doi]
AB  - A simple fluorescent methodology for the simultaneous determination of two major 
      metabolites of acetylsalicylic acid--salicylic and gentisic acids--in 
      pharmaceutical preparations and human urine is proposed. Due to the overlapping 
      between the fluorescence spectra of both analytes, the use of the more selective 
      fluorescence decay curves is proposed. Values of dependent instrumental variables 
      affecting the signal-to-noise ratio were fixed with a simplex optimization 
      procedure. A calibration matrix of thirteen standards plus two blank samples was 
      processed using a partial least-squares (PLS) analysis. To assess the goodness of 
      the proposed method, a prediction set of nine synthetic samples was analyzed, 
      obtaining recovery percentages between 95% and 106%. Limits of detection, 
      calculated by means of a new criterion, were 3.49 μg L(-1) and 1.66 μg L(-1) for 
      salicylic and gentisic acids, respectively. The method was also tested in three 
      pharmaceutical preparations containing salicylic acid, obtaining recovery 
      percentages close to 100%. Finally, the simultaneous determination of both 
      analytes in human urine samples was successfully carried out by the PLS-analysis 
      of a matrix of thirteen standards plus five analyte blanks. Although spectra of 
      analytes and urine overlap strongly, no extraction method neither prior 
      separation of the analytes were needed.
CI  - Copyright © 2014 Elsevier B.V. All rights reserved.
FAU - Murillo Pulgarín, J A
AU  - Murillo Pulgarín JA
AD  - Department of Analytical Chemistry and Foods Technology, University of 
      Castilla-La Mancha, 13071 Ciudad Real, Spain.
FAU - Alañón Molina, A
AU  - Alañón Molina A
AD  - Department of Analytical Chemistry and Foods Technology, University of 
      Castilla-La Mancha, 13071 Ciudad Real, Spain. Electronic address: 
      Aurelia.Alanon@uclm.es.
FAU - Martínez Ferreras, F
AU  - Martínez Ferreras F
AD  - Department of Analytical Chemistry and Foods Technology, University of 
      Castilla-La Mancha, 13071 Ciudad Real, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140312
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 0 (Gentisates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - VP36V95O3T (2,5-dihydroxybenzoic acid)
SB  - IM
MH  - Aspirin/*analysis
MH  - Gentisates/*analysis
MH  - Humans
MH  - Salicylic Acid/*analysis
MH  - Spectrometry, Fluorescence/methods
MH  - Urine/*chemistry
OTO - NOTNLM
OT  - Decay curves
OT  - Gentisic acid
OT  - Salicylic acid
OT  - Simplex optimization
EDAT- 2014/03/26 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/03/26 06:00
PHST- 2013/10/16 00:00 [received]
PHST- 2014/02/17 00:00 [revised]
PHST- 2014/02/21 00:00 [accepted]
PHST- 2014/03/26 06:00 [entrez]
PHST- 2014/03/26 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - S1386-1425(14)00335-7 [pii]
AID - 10.1016/j.saa.2014.02.137 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2014 Jul 15;128:82-90. doi: 
      10.1016/j.saa.2014.02.137. Epub 2014 Mar 12.

PMID- 22693711
OWN - NLM
STAT- MEDLINE
DCOM- 20121204
LR  - 20131121
IS  - 1364-5528 (Electronic)
IS  - 0003-2654 (Linking)
VI  - 137
IP  - 15
DP  - 2012 Aug 7
TI  - Detection of microscopic particles present as contaminants in latent fingerprints 
      by means of synchrotron radiation-based Fourier transform infra-red 
      micro-imaging.
PG  - 3459-65
LID - 10.1039/c2an35355e [doi]
AB  - Synchrotron radiation-based Fourier transform infra-red (SR-FTIR) micro-imaging 
      has been developed as a rapid, direct and non-destructive technique. This method, 
      taking advantage of the high brightness and small effective source size of 
      synchrotron light, is capable of exploring the molecular chemistry within the 
      microstructures of microscopic particles without their destruction at high 
      spatial resolutions. This is in contrast to traditional "wet" chemical methods, 
      which, during processing for analysis, often caused destruction of the original 
      samples. In the present study, we demonstrate the potential of SR-FTIR 
      micro-imaging as an effective way to accurately identify microscopic particles 
      deposited within latent fingerprints. These particles are present from residual 
      amounts of materials left on a person's fingers after handling such materials. 
      Fingerprints contaminated with various types of powders, creams, medications and 
      high explosive materials (3-nitrooxy-2,2-bis(nitrooxymethyl)propyl nitrate 
      (PETN), 1,3,5-trinitro-1,3,5-triazinane (RDX), 2-methyl-1,3,5-trinitrobenzene 
      (TNT)) deposited on various - daily used - substrates have been analysed herein 
      without any further sample preparation. A non-destructive method for the transfer 
      of contaminated fingerprints from hard-to-reach areas of the substrates to the 
      place of analysis is also presented. This method could have a significant impact 
      on forensic science and could dramatically enhance the amount of information that 
      can be obtained from the study of fingerprints.
FAU - Banas, A
AU  - Banas A
AD  - Singapore Synchrotron Light Source, National University of Singapore, 5 Research 
      Link, Singapore 117603. slsba@nus.edu.sg
FAU - Banas, K
AU  - Banas K
FAU - Breese, M B H
AU  - Breese MB
FAU - Loke, J
AU  - Loke J
FAU - Heng Teo, B
AU  - Heng Teo B
FAU - Lim, S K
AU  - Lim SK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120613
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - 0 (Carbohydrates)
RN  - 0 (Explosive Agents)
RN  - 0 (Powders)
RN  - 0 (Triazines)
RN  - 118-96-7 (Trinitrotoluene)
RN  - R16CO5Y76E (Aspirin)
RN  - W91SSV5831 (cyclonite)
SB  - IM
MH  - Aspirin/*analysis
MH  - Carbohydrates/analysis
MH  - *Dermatoglyphics
MH  - Explosive Agents/*analysis
MH  - Humans
MH  - Particle Size
MH  - Powders/*analysis
MH  - *Spectroscopy, Fourier Transform Infrared
MH  - *Synchrotrons
MH  - Triazines/analysis
MH  - Trinitrotoluene/analysis
EDAT- 2012/06/14 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/06/14 06:00
PHST- 2012/06/14 06:00 [entrez]
PHST- 2012/06/14 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.1039/c2an35355e [doi]
PST - ppublish
SO  - Analyst. 2012 Aug 7;137(15):3459-65. doi: 10.1039/c2an35355e. Epub 2012 Jun 13.

PMID- 21763764
OWN - NLM
STAT- MEDLINE
DCOM- 20111227
LR  - 20131121
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 416
IP  - 1
DP  - 2011 Sep 15
TI  - Combining formulation and process aspects for optimizing the high-shear wet 
      granulation of common drugs.
PG  - 229-41
LID - 10.1016/j.ijpharm.2011.06.051 [doi]
AB  - The purpose of this research was to determine the effects of some important drug 
      properties (such as particle size distribution, hygroscopicity and solubility) 
      and process variables on the granule growth behaviour and final drug distribution 
      in high shear wet granulation. Results have been analyzed in the light of widely 
      accepted theories and some recently developed approaches. A mixture composed of 
      drug, some excipients and a dry binder was processed using a lab-scale high-shear 
      mixer. Three common active pharmaceutical ingredients (paracetamol, caffeine and 
      acetylsalicylic acid) were used within the initial formulation. Drug load was 50% 
      (on weight basis). Influences of drug particle properties (e.g. particle size and 
      shape, hygroscopicity) on the granule growth behaviour were evaluated. Particle 
      size distribution (PSD) and granule morphology were monitored during the entire 
      process through sieve analysis and scanning electron microscope (SEM) image 
      analysis. Resistance of the wet mass to mixing was furthermore measured using the 
      impeller torque monitoring technique. The observed differences in the granule 
      growth behaviour as well as the discrepancies between the actual and the ideal 
      drug content in the final granules have been interpreted in terms of 
      dimensionless quantity (spray flux number, bed penetration time) and related to 
      torque measurements. Analysis highlighted the role of liquid distribution on the 
      process. It was demonstrated that where the liquid penetration time was higher 
      (e.g. paracetamol-based formulations), the liquid distribution was poorer leading 
      to retarded granule growth and selective agglomeration. On the other hand where 
      penetration time was lower (e.g. acetylsalicylic acid-based formulations), the 
      growth was much faster but uniformity content problem arose because of the onset 
      of crushing and layering phenomena.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Cavinato, Mauro
AU  - Cavinato M
AD  - Department of Chemical Engineering, University of Padova, Padova, Italy.
FAU - Andreato, Enrico
AU  - Andreato E
FAU - Bresciani, Massimo
AU  - Bresciani M
FAU - Pignatone, Isabella
AU  - Pignatone I
FAU - Bellazzi, Guido
AU  - Bellazzi G
FAU - Franceschinis, Erica
AU  - Franceschinis E
FAU - Realdon, Nicola
AU  - Realdon N
FAU - Canu, Paolo
AU  - Canu P
FAU - Santomaso, Andrea C
AU  - Santomaso AC
LA  - eng
PT  - Journal Article
DEP - 20110707
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Excipients)
RN  - 0 (Powders)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*chemistry
MH  - Aspirin/*chemistry
MH  - Caffeine/*chemistry
MH  - Chemistry, Pharmaceutical/*methods
MH  - Excipients/chemistry
MH  - Particle Size
MH  - Powders/*chemistry
MH  - Solubility
MH  - Surface Properties
MH  - Torque
MH  - Wettability
EDAT- 2011/07/19 06:00
MHDA- 2011/12/28 06:00
CRDT- 2011/07/19 06:00
PHST- 2011/03/14 00:00 [received]
PHST- 2011/06/29 00:00 [revised]
PHST- 2011/06/30 00:00 [accepted]
PHST- 2011/07/19 06:00 [entrez]
PHST- 2011/07/19 06:00 [pubmed]
PHST- 2011/12/28 06:00 [medline]
AID - S0378-5173(11)00629-6 [pii]
AID - 10.1016/j.ijpharm.2011.06.051 [doi]
PST - ppublish
SO  - Int J Pharm. 2011 Sep 15;416(1):229-41. doi: 10.1016/j.ijpharm.2011.06.051. Epub 
      2011 Jul 7.

PMID- 24656779
OWN - NLM
STAT- MEDLINE
DCOM- 20141228
LR  - 20140430
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 20
IP  - 1
DP  - 2014 May
TI  - Synergistic interaction between choline and aspirin against acute inflammation 
      induced by carrageenan and lipopolysaccharide.
PG  - 229-37
LID - S1567-5769(14)00096-4 [pii]
LID - 10.1016/j.intimp.2014.03.004 [doi]
AB  - The simultaneous use of drugs with different mechanisms of anti-inflammatory 
      action is a strategy for achieving effective control of inflammation while 
      minimizing dose-related side effects. Choline was described to potentiate the 
      antinociceptive action of aspirin at small doses in several inflammatory pain 
      models. However, these findings are only limited to alleviating pain, more 
      associated data are required to confirm the effectiveness of the combined choline 
      and aspirin therapy against inflammatory disorders. Moreover, no report is 
      available regarding the mechanism responsible for their synergism. Here, we first 
      investigated the anti-inflammatory activity and pharmacological mechanisms of 
      co-administration of choline and aspirin in 2 commonly studied inflammation 
      models, carrageenan-induced paw edema and lipopolysaccharide (LPS)-induced sepsis 
      in mice. Isobolographic analysis revealed that combined choline and aspirin 
      administration exhibited a strong synergistic interaction in reducing 
      carrageenan-mediated edema, and the estimated combination index values at 50%, 
      75%, and 90% effective dose (ED50, ED75, and ED90) were 0.25, 0.32, and 0.44. 
      Drug co-administration also afforded synergistic protection against LPS-induced 
      sepsis and mortality, since aspirin or choline alone was inadequate to improve 
      survival. The effects of choline-aspirin co-administration were blocked by 
      methyllycaconitine, suggesting that activation of alpha 7 nicotinic acetylcholine 
      receptor participates in the interaction between choline and aspirin. 
      Furthermore, co-administration of choline and aspirin was more likely to inhibit 
      the production of pro-inflammatory mediators induced by LPS. Our results 
      indicated that combined choline and aspirin therapy represented a significant 
      synergistic interaction in attenuating acute inflammatory response. This 
      preclinical relevant evidence provides a promising approach to treat 
      inflammation-based diseases such as arthritis and sepsis.
CI  - Copyright © 2014 Elsevier B.V. All rights reserved.
FAU - Pan, Zhi-Yuan
AU  - Pan ZY
AD  - Cardiovascular Drug Research Center, Institute of Health and Environmental 
      Medicine, Academy of Military Medical Sciences, Beijing 100850, PR China.
FAU - Wang, Hai
AU  - Wang H
AD  - Cardiovascular Drug Research Center, Institute of Health and Environmental 
      Medicine, Academy of Military Medical Sciences, Beijing 100850, PR China; 
      Thadweik Academy of Medicine, Beijing 100039, PR China. Electronic address: 
      wh9588@sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140319
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Chrna9 protein, mouse)
RN  - 0 (Cytokines)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Receptors, Nicotinic)
RN  - 9000-07-1 (Carrageenan)
RN  - N91BDP6H0X (Choline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Carrageenan
MH  - Choline/pharmacology/*therapeutic use
MH  - Cytokines/immunology
MH  - Drug Synergism
MH  - Edema/chemically induced/*drug therapy/immunology/pathology
MH  - Foot/pathology
MH  - Inflammation/chemically induced/*drug therapy/immunology/pathology
MH  - Lipopolysaccharides
MH  - Male
MH  - Mice
MH  - Receptors, Nicotinic/immunology
OTO - NOTNLM
OT  - Alpha 7 nicotinic acetylcholine receptor
OT  - Aspirin
OT  - Carrageenan
OT  - Choline
OT  - Lipopolysaccharide
OT  - Synergism
EDAT- 2014/03/25 06:00
MHDA- 2014/12/30 06:00
CRDT- 2014/03/25 06:00
PHST- 2014/01/26 00:00 [received]
PHST- 2014/02/19 00:00 [revised]
PHST- 2014/03/05 00:00 [accepted]
PHST- 2014/03/25 06:00 [entrez]
PHST- 2014/03/25 06:00 [pubmed]
PHST- 2014/12/30 06:00 [medline]
AID - S1567-5769(14)00096-4 [pii]
AID - 10.1016/j.intimp.2014.03.004 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2014 May;20(1):229-37. doi: 10.1016/j.intimp.2014.03.004. 
      Epub 2014 Mar 19.

PMID- 26374108
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20191027
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Print)
IS  - 1570-1611 (Linking)
VI  - 14
IP  - 1
DP  - 2016
TI  - The Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: Variation in 
      Platelet Response to Clopidogrel and Aspirin.
PG  - 116-24
AB  - Clopidogrel and aspirin are commonly prescribed anti-platelet medications 
      indicated for patients who have experienced, or are at risk for, ischemic 
      cardiovascular events. The Pharmacogenomics of Anti-Platelet Intervention (PAPI) 
      Study was designed to characterize determinants of clopidogrel and dual 
      anti-platelet therapy (DAPT) response in a healthy cohort of Old Order Amish from 
      Lancaster, PA. Following a loading dose, clopidogrel was taken once a day for 7 
      days. One hour after the last dose of clopidogrel, 325 mg of aspirin was given. 
      Ex vivo platelet aggregometry was performed at baseline, post-clopidogrel, and 
      post-DAPT. Platelet aggregation measurements were significantly lower after both 
      interventions for all agonists tested (p <0.05), although there was large 
      inter-individual variation in the magnitude of anti-platelet response. Female sex 
      and older age were associated with higher platelet aggregation at all three 
      time-points. Change in aggregation was correlated among the various agonists at 
      each time point. Heritability (h2) of change in platelet aggregation was 
      significant for most traits at all time-points (range h2=0.14-0.57). Utilization 
      of a standardized, short-term intervention provided a powerful approach to 
      investigate sources of variation in platelet aggregation response due to drug 
      therapy. Further, this short-term intervention approach may provide a useful 
      paradigm for pharmacogenomics studies.
FAU - Bozzi, Laura M
AU  - Bozzi LM
FAU - Mitchell, Braxton D
AU  - Mitchell BD
FAU - Lewis, Joshua P
AU  - Lewis JP
FAU - Ryan, Kathy A
AU  - Ryan KA
FAU - Herzog, William R
AU  - Herzog WR
FAU - O'Connell, Jeffrey R
AU  - O'Connell JR
FAU - Horenstein, Richard B
AU  - Horenstein RB
FAU - Shuldiner, Alan R
AU  - Shuldiner AR
FAU - Yerges-Armstrong, Laura M
AU  - Yerges-Armstrong LM
AD  - University of Maryland Baltimore, 685 W. Baltimore St., MSTF 357, Baltimore, MD 
      21201, USA. lyerges@medicine.umaryland.edu.
LA  - eng
GR  - U01 HL105198/HL/NHLBI NIH HHS/United States
GR  - P30 DK079637/DK/NIDDK NIH HHS/United States
GR  - T32 AG000262/AG/NIA NIH HHS/United States
GR  - P30 DK072488/DK/NIDDK NIH HHS/United States
GR  - K01 HL116770/HL/NHLBI NIH HHS/United States
GR  - K23-GM102678/GM/NIGMS NIH HHS/United States
GR  - K23 GM102678/GM/NIGMS NIH HHS/United States
GR  - P30DK072488/DK/NIDDK NIH HHS/United States
GR  - U01 GM074518/GM/NIGMS NIH HHS/United States
GR  - K01-HL116770/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Amish/genetics
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pharmacogenetics
MH  - Platelet Aggregation/drug effects/genetics
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Sex Factors
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Time Factors
PMC - PMC4842002
MID - NIHMS777797
COIS- CONFLICT OF INTEREST Alan Shuldiner is a consultant for United States Diagnostic 
      Standards, Inc and an employee of Regeneron Pharmaceuticals, Inc. All other 
      authors (LMYA, LMB, JPL, BDM, JRO, KAR, RBH, WH) report no conflict of interest.
EDAT- 2015/09/17 06:00
MHDA- 2016/09/16 06:00
CRDT- 2015/09/17 06:00
PHST- 2014/10/28 00:00 [received]
PHST- 2015/09/01 00:00 [revised]
PHST- 2015/09/14 00:00 [accepted]
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
AID - CVP-EPUB-70440 [pii]
AID - 10.2174/1570161113666150916094829 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2016;14(1):116-24. doi: 10.2174/1570161113666150916094829.

PMID- 27231076
OWN - NLM
STAT- MEDLINE
DCOM- 20171026
LR  - 20171026
IS  - 1472-0795 (Print)
IS  - 1472-0795 (Linking)
VI  - 28
IP  - 5
DP  - 2016 May 27
TI  - Aspirin can aid bandage as the best treatment for leg ulcers.
PG  - 13
LID - 10.7748/nop.28.5.13.s17 [doi]
AB  - Best practice for venous leg ulcers is a firm graduated compression bandage to 
      reduce venous hypertension, aid venous return and reduce peripheral oedema. 
      Sadly, many healed ulcers recur within three months, possibly due to prolonged 
      inflammatory response.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nurs Older People
JT  - Nursing older people
JID - 101084156
RN  - R16CO5Y76E (Aspirin)
MH  - *Aspirin
MH  - Compression Bandages
MH  - Humans
MH  - *Leg Ulcer
MH  - Varicose Ulcer
MH  - Wound Healing
EDAT- 2016/05/28 06:00
MHDA- 2017/10/27 06:00
CRDT- 2016/05/28 06:00
PHST- 2016/05/28 06:00 [entrez]
PHST- 2016/05/28 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
AID - 10.7748/nop.28.5.13.s17 [doi]
PST - ppublish
SO  - Nurs Older People. 2016 May 27;28(5):13. doi: 10.7748/nop.28.5.13.s17.

PMID- 30612091
OWN - NLM
STAT- MEDLINE
DCOM- 20190930
LR  - 20210324
IS  - 1472-0213 (Electronic)
IS  - 1472-0205 (Linking)
VI  - 36
IP  - 3
DP  - 2019 Mar
TI  - Optimising antiplatelet utilisation in the acute care setting: a novel threshold 
      for medical intervention in suspected acute coronary syndromes.
PG  - 163-170
LID - 10.1136/emermed-2018-207633 [doi]
AB  - OBJECTIVES: To construct a model to optimise and personalise recommendations for 
      antiplatelet prescription for patients with suspected acute coronary syndrome 
      (ACS). Acknowledging that emergency physicians work with diagnostic uncertainty, 
      we sought to identify the point at which the probability of ACS is sufficiently 
      high that the benefits of antiplatelet treatment outweigh the risks. Second, we 
      evaluated the projected clinical impact of this approach by using a clinical 
      prediction model (Troponin-only Manchester Acute Coronary Syndromes (T-MACS)) to 
      calculate the probability of ACS. METHODS: We conducted three systematic reviews, 
      quantifying the effects of ticagrelor, clopidogrel or aspirin-alone treatment 
      strategies for ACS (November 2017). We extracted data for (a) clinical outcomes 
      and (b) weighted patient preferences (utilities) for each outcome. We then 
      constructed utilitarian models, simulating the probability of clinical outcomes 
      with different treatment strategies. This identified the threshold probability of 
      ACS at which each treatment strategy became superior.We validated this approach 
      in a prospective diagnostic study including patients with suspected ACS that was 
      conducted at two large UK teaching hospitals (St George's Hospital London 
      recruited October 2015 to June 2017 and Manchester Royal Infirmary: February 2015 
      to August 2017). We calculated the probability of ACS using T-MACS. The diagnosis 
      of ACS was adjudicated based on serial high-sensitivity troponin testing and 
      30-day follow-up. RESULTS: We constructed three models using data from six 
      studies. Prescribing ticagrelor had greatest overall benefit when the probability 
      of ACS exceeded 8.0%. Below that threshold, aspirin alone yielded greater 
      benefit. The validation study included 660 patients, of which 87 (13.2%) had ACS. 
      Prescription of combined antiplatelet strategy to patients with >8% probability 
      of ACS had greater utility than aspirin alone. CONCLUSION: Treatment with 
      ticagrelor appears to yield greater net benefit for patients when the probability 
      of ACS >8%. The clinical and cost-effectiveness of this 'precision medicine' 
      approach warrants further study.
CI  - © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Reynard, Charles
AU  - Reynard C
AUID- ORCID: 0000-0002-7534-2668
AD  - Division of Cardiovascular Sciences, The University of Manchester, Manchester, 
      UK.
AD  - Manchester University Foundation Hospital NHS Trust, Manchester Academic Health 
      Science Centre, Manchester, UK.
FAU - Morris, Niall
AU  - Morris N
AD  - Division of Cardiovascular Sciences, The University of Manchester, Manchester, 
      UK.
AD  - Manchester University Foundation Hospital NHS Trust, Manchester Academic Health 
      Science Centre, Manchester, UK.
FAU - Moss, Phil
AU  - Moss P
AD  - St George's University Hospitals NHS Foundation Trust, London, UK.
FAU - Jarman, Heather
AU  - Jarman H
AD  - St George's University Hospitals NHS Foundation Trust, London, UK.
AD  - Faculty of Health, Social Care and Education, Kingston University and St George's 
      University, London, UK.
FAU - Body, Richard
AU  - Body R
AUID- ORCID: 0000-0001-9089-8130
AD  - Division of Cardiovascular Sciences, The University of Manchester, Manchester, 
      UK.
AD  - Manchester University Foundation Hospital NHS Trust, Manchester Academic Health 
      Science Centre, Manchester, UK.
AD  - Manchester Metropolitan University, Manchester, UK.
LA  - eng
GR  - NIHR300246/DH_/Department of Health/United Kingdom
GR  - PDF-2012-05-193/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Systematic Review
DEP - 20190105
PL  - England
TA  - Emerg Med J
JT  - Emergency medicine journal : EMJ
JID - 100963089
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/classification/diagnosis/*drug therapy
MH  - Aspirin/standards/therapeutic use
MH  - Clopidogrel/standards/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Decision Support Techniques
MH  - Humans
MH  - London
MH  - Monte Carlo Method
MH  - Platelet Aggregation Inhibitors/*standards/therapeutic use
MH  - Prospective Studies
MH  - Ticagrelor/standards/therapeutic use
MH  - *Time Factors
OTO - NOTNLM
OT  - acute coronary syndrome
OT  - cardiac care, acute coronary syndrome
OT  - clincial management
OT  - clinical
COIS- Competing interests: RB has accepted speaker fees from Singulex, Alere, Lumira Dx 
      and Siemens, and provision of travel and accommodation for conferences by Roche 
      Diagnostics and Randox Laboratories. His institution has accepted research grants 
      from Abbott Point of Care and Roche Diagnostics.
EDAT- 2019/01/07 06:00
MHDA- 2019/10/01 06:00
CRDT- 2019/01/07 06:00
PHST- 2018/03/19 00:00 [received]
PHST- 2018/11/23 00:00 [revised]
PHST- 2018/11/26 00:00 [accepted]
PHST- 2019/01/07 06:00 [pubmed]
PHST- 2019/10/01 06:00 [medline]
PHST- 2019/01/07 06:00 [entrez]
AID - emermed-2018-207633 [pii]
AID - 10.1136/emermed-2018-207633 [doi]
PST - ppublish
SO  - Emerg Med J. 2019 Mar;36(3):163-170. doi: 10.1136/emermed-2018-207633. Epub 2019 
      Jan 5.

PMID- 16144121
OWN - NLM
STAT- MEDLINE
DCOM- 20051005
LR  - 20220330
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 100
IP  - 8
DP  - 2005 Aug
TI  - NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality.
PG  - 1694-5
AB  - Although gastrointestinal (GI) morbidity and mortality from NSAIDs continues to 
      be a significant problem, this study by Lanas et al. indicates that the magnitude 
      of the concern is declining. Explanations for this reduction are more likely 
      related to the increased use of proton pump inhibitors (PPIs) than to the 
      introduction of COX-2 inhibitors. This study further reveals that one-third of 
      NSAIDs' GI mortality comes from low-dose, daily aspirin. Another important 
      contribution derived from this report is a more reliable estimate of NSAIDs' 
      lower GI clinical consequences than previously available.
FAU - Cryer, Byron
AU  - Cryer B
LA  - eng
PT  - Comment
PT  - Editorial
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Am J Gastroenterol. 2005 Aug;100(8):1685-93. PMID: 16086703
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/adverse effects
MH  - Gastrointestinal Diseases/*chemically induced/*mortality
MH  - Humans
MH  - Spain/epidemiology
EDAT- 2005/09/08 09:00
MHDA- 2005/10/06 09:00
CRDT- 2005/09/08 09:00
PHST- 2005/09/08 09:00 [pubmed]
PHST- 2005/10/06 09:00 [medline]
PHST- 2005/09/08 09:00 [entrez]
AID - 10.1111/j.1572-0241.2005.50565.x [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2005 Aug;100(8):1694-5. doi: 
      10.1111/j.1572-0241.2005.50565.x.

PMID- 7274163
OWN - NLM
STAT- MEDLINE
DCOM- 19811122
LR  - 20131121
IS  - 0013-7251 (Print)
IS  - 0013-7251 (Linking)
VI  - 77
IP  - 3
DP  - 1981 Jul
TI  - Effects of prostaglandin synthesis inhibitors on the anterior pituitary cell 
      proliferation.
PG  - 367-70
AB  - The effects of indomethacin and aspirin on the mitotic incidence in the anterior 
      pituitary in male rats was investigated. It was shown that either of the 
      inhibitors of prostaglandin synthesis used in the study suppressed the anterior 
      pituitary mitotic activity, although the effect of indomethacin was more 
      pronounced. A suppression of the mitotic activity involved the acidophilic and 
      the chromophobe cells, whereas the number of basophils in mitosis was not 
      diminished. These findings suggest an involvement of prostaglandins in the 
      control of the anterior pituitary cell proliferation.
FAU - Pawlikowski, M
AU  - Pawlikowski M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Endokrinologie
JT  - Endokrinologie
JID - 0370675
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Mitosis/*drug effects
MH  - Pituitary Gland, Anterior/*cytology/drug effects
MH  - Rats
EDAT- 1981/07/01 00:00
MHDA- 1981/07/01 00:01
CRDT- 1981/07/01 00:00
PHST- 1981/07/01 00:00 [pubmed]
PHST- 1981/07/01 00:01 [medline]
PHST- 1981/07/01 00:00 [entrez]
PST - ppublish
SO  - Endokrinologie. 1981 Jul;77(3):367-70.

PMID- 526133
OWN - NLM
STAT- MEDLINE
DCOM- 19800327
LR  - 20131121
IS  - 0098-6127 (Print)
IS  - 0098-6127 (Linking)
VI  - 5
IP  - 3
DP  - 1979 Mar
TI  - Inhibitors of platelet function and atherogenesis.
PG  - 273-84
AB  - Platelets play an important role in atherogenesis. This has given rise to the 
      speculation that inhibitors of platelet function may prevent atherosclerotic 
      changes. Two distinct therapeutic goals might be achieved by the use of 
      inhibitors of platelet function in vascular disease - one, the prevention of 
      thrombosis and, two, the prevention of atherosclerosis. The choice of inhibitor 
      may well determine the goal achieved. Thus far, the data available indicate that 
      inhibitors of platelet aggregation, such as aspirin, are the most effective in 
      the prevention of thrombosis, while inhibitors of platelet adherence, such as 
      dipyridamole, are likely to be the most effective in the prevention of 
      atherosclerosis.
FAU - Rossi, E C
AU  - Rossi EC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Artery
JT  - Artery
JID - 7508494
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteriosclerosis/*prevention & control
MH  - Aspirin/therapeutic use
MH  - Blood Platelets/*drug effects/physiology
MH  - Dipyridamole/therapeutic use
MH  - Disease Models, Animal
MH  - Humans
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Thrombosis/prevention & control
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
PST - ppublish
SO  - Artery. 1979 Mar;5(3):273-84.

PMID- 33354747
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 21
IP  - 4
DP  - 2021 Jul
TI  - Comparison of Warfarin to Dual Antiplatelet Therapy Following Transcatheter 
      Aortic Valve Replacement.
PG  - 453-458
LID - 10.1007/s40256-020-00443-9 [doi]
AB  - INTRODUCTION: Dual antiplatelet therapy (DAPT) was the initial antithrombotic 
      regimen of choice following transcatheter aortic valve replacement (TAVR). 
      Subsequent identification of subclinical valve thrombosis in high-risk patients 
      has questioned whether warfarin should be used as an alternative to DAPT for some 
      patients. OBJECTIVE: The aim of this study was to compare thromboembolic events, 
      bleeding, and all-cause mortality between DAPT and warfarin following TAVR. 
      METHODS: This was a single-center, retrospective review of TAVR patients who 
      received DAPT or warfarin following TAVR between 2008 and 2018. The primary 
      endpoint was occurrence of thromboembolic events during the hospital stay and 
      1-year follow-up, while secondary endpoints included bleeding and all-cause 
      mortality. RESULTS: Of the included 764 patients, 193 received DAPT and 571 
      received warfarin. The median Society of Thoracic Surgeons (STS) Predicted Risk 
      of Mortality (PROM) scores were 8.3% for the DAPT group and 6.5% for the warfarin 
      group. The primary endpoint occurred 30 times (3.9%) during the study timeframe. 
      No differences in thromboembolic events between the DAPT and warfarin groups were 
      found (4.14% vs. 3.85%; p = 0.857), and there was no difference in bleeding 
      (6.22% vs. 5.08%; p = 0.544) or risk of mortality (hazard ratio 0.59, 95% 
      confidence interval 0.33-1.06; p = 0.076). CONCLUSIONS: In this study, warfarin 
      had similar effectiveness and safety, compared with DAPT, for antithrombotic 
      management post-TAVR. For patients whom the provider deemed anticoagulation is 
      indicated, our data suggest warfarin is a well-tolerated option following TAVR in 
      intermediate- and high-risk STS score patients.
FAU - Nei, Scott D
AU  - Nei SD
AD  - Department of Pharmacy, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. 
      nei.scott@mayo.edu.
FAU - Wieruszewski, Patrick M
AU  - Wieruszewski PM
AD  - Department of Pharmacy, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.
AD  - Multidisciplinary Epidemiology and Translational Research in Intensive Care 
      (METRIC) Group, Mayo Clinic, Rochester, MN, USA.
FAU - Scott, Rachael
AU  - Scott R
AD  - Department of Pharmacy, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.
FAU - Greason, Kevin L
AU  - Greason KL
AD  - Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, USA.
LA  - eng
PT  - Journal Article
DEP - 20201223
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clopidogrel/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thrombosis/prevention & control
MH  - *Transcatheter Aortic Valve Replacement
MH  - Warfarin/administration & dosage/adverse effects/*therapeutic use
EDAT- 2020/12/24 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/12/23 05:51
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/12/23 05:51 [entrez]
AID - 10.1007/s40256-020-00443-9 [pii]
AID - 10.1007/s40256-020-00443-9 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2021 Jul;21(4):453-458. doi: 10.1007/s40256-020-00443-9. 
      Epub 2020 Dec 23.

PMID- 31727004
OWN - NLM
STAT- MEDLINE
DCOM- 20200214
LR  - 20200309
IS  - 1471-2350 (Electronic)
IS  - 1471-2350 (Linking)
VI  - 20
IP  - 1
DP  - 2019 Nov 14
TI  - Increased risk of aspirin-induced gastric mucosal erosion in elderly Chinese men 
      harboring SLCO1B1*1b/*1b while using aspirin and an ACEI or ARB concomitantly.
PG  - 183
LID - 10.1186/s12881-019-0918-4 [doi]
LID - 183
AB  - BACKGROUND: It is well established that long-term use of aspirin can cause 
      gastric mucosal injury. ACEIs and ARBs are inversely related to gastric ulcer 
      development. This study aimed to evaluate the relationship between SLCO1B1 
      polymorphisms, which can affect ACEI and ARB transport, and gastric mucosal 
      erosion in elderly male Chinese patients with cardiovascular disease who use 
      aspirin. METHODS: Patients taking aspirin and an ACEI or ARB concomitantly who 
      had undergone endoscopic screening for gastric erosion were analyzed for SLCO1B1 
      polymorphisms by a TaqMan assay. RESULTS: The frequency of the SLCO1B1*1b/*1b 
      diplotype (42% vs. 24%; p = 0.002) was significantly higher in the gastric 
      mucosal erosion group than in the control group. After adjustment for significant 
      factors, SLCO1B1*1b/*1b (OR, 2.64; 95% CI, 1.59-4.17; p < 0.05) was found to be 
      associated with gastric mucosal erosion in aspirin users. CONCLUSIONS: The 
      presence of the SLCO1B1*1b/*1b diplotype may be a risk factor for aspirin-induced 
      gastric mucosal erosion in elderly Chinese men taking aspirin and an ACEI or ARB 
      concomitantly.
FAU - Duan, Lei
AU  - Duan L
AD  - Medical School of Chinese PLA, Beijing, 100853, China.
AD  - Department of Geriatric Cardiology, National Clinical Research Center for 
      Geriatric Diseases, the Second Medical Center of PLA General Hospital, 28 Fuxing 
      Road, Beijing, 100853, China.
FAU - Bai, Yongyi
AU  - Bai Y
AD  - Department of Geriatric Cardiology, National Clinical Research Center for 
      Geriatric Diseases, the Second Medical Center of PLA General Hospital, 28 Fuxing 
      Road, Beijing, 100853, China.
FAU - Li, Man
AU  - Li M
AD  - Medical School of Chinese PLA, Beijing, 100853, China.
FAU - Li, Huiying
AU  - Li H
AD  - Medical School of Chinese PLA, Beijing, 100853, China.
FAU - Li, Yanping
AU  - Li Y
AD  - Medical School of Chinese PLA, Beijing, 100853, China.
FAU - Liu, Hongbin
AU  - Liu H
AUID- ORCID: 0000-0001-5356-7682
AD  - Medical School of Chinese PLA, Beijing, 100853, China. liuhb301@sina.com.
AD  - Department of Geriatric Cardiology, National Clinical Research Center for 
      Geriatric Diseases, the Second Medical Center of PLA General Hospital, 28 Fuxing 
      Road, Beijing, 100853, China. liuhb301@sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191114
PL  - England
TA  - BMC Med Genet
JT  - BMC medical genetics
JID - 100968552
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Liver-Specific Organic Anion Transporter 1)
RN  - 0 (SLCO1B1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin Receptor Antagonists/administration & dosage/*therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - China
MH  - Drug Therapy, Combination
MH  - Gastric Mucosa/*pathology
MH  - Gene Frequency
MH  - *Genetic Predisposition to Disease
MH  - Humans
MH  - Liver-Specific Organic Anion Transporter 1/*genetics
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Stomach Ulcer/*chemically induced/*genetics
PMC - PMC6857243
OTO - NOTNLM
OT  - Aspirin
OT  - Gastric mucosa erosion
OT  - Pharmacogenomics
OT  - SLCO1B1
OT  - Single nucleotide polymorphism
COIS- The authors declare that they have no competing interests.
EDAT- 2019/11/16 06:00
MHDA- 2020/02/15 06:00
CRDT- 2019/11/16 06:00
PHST- 2019/04/02 00:00 [received]
PHST- 2019/11/01 00:00 [accepted]
PHST- 2019/11/16 06:00 [entrez]
PHST- 2019/11/16 06:00 [pubmed]
PHST- 2020/02/15 06:00 [medline]
AID - 10.1186/s12881-019-0918-4 [pii]
AID - 918 [pii]
AID - 10.1186/s12881-019-0918-4 [doi]
PST - epublish
SO  - BMC Med Genet. 2019 Nov 14;20(1):183. doi: 10.1186/s12881-019-0918-4.

PMID- 33360326
OWN - NLM
STAT- MEDLINE
DCOM- 20211231
LR  - 20211231
IS  - 2468-2942 (Electronic)
IS  - 2468-2942 (Linking)
VI  - 26
DP  - 2021
TI  - The multiple effects of aspirin in prostate cancer patients.
PG  - 100267
LID - S2468-2942(20)30102-7 [pii]
LID - 10.1016/j.ctarc.2020.100267 [doi]
AB  - Aspirin is a commonly used medication with anti-inflammatory and analgesic 
      properties, and it is widely used to reduce the risk of ischaemic heart 
      disease-related events and/or cerebrovascular accidents. However, there is also 
      evidence from epidemiological and interventional studies to suggest that regular 
      aspirin use can reduce the risk of prostate cancer development and progression, 
      and can reduce the risk of disease recurrence following anti-prostate cancer 
      therapy. Aspirin use in African-American men is associated with a reduced 
      incidence of advanced PCa and reduced disease recurrence, and there is evidence 
      from other studies of an association between regular aspirin use and decreased 
      PCa-related mortality. The cyclooxygenase-2 enzyme inhibited by Aspirin and other 
      NSAIDs, and which catalyses prostaglandin synthesis and mediates inflammation, is 
      overexpressed in prostate cancer, therefore inhibition of cyclooxygenase-2 may 
      have direct, and indirect, therapeutic effects. This review explores the evidence 
      suggesting that aspirin use can modify prostate cancer biology and disease 
      characteristics, and explores the potential mechanisms underpinning the observed 
      associations between aspirin use and modification of prostate cancer risk. It 
      also summarises the potential for adjuvant aspirin use to combine with other 
      therapeutic approaches such as radical surgery and radiotherapy.
CI  - Copyright © 2020. Published by Elsevier Ltd.
FAU - Joshi, S N
AU  - Joshi SN
AD  - Medical Sciences Divisional Office, University of Oxford, Level 3, John Radcliffe 
      Hospital, Oxford OX3 9DU, United Kingdom.
FAU - Murphy, E A
AU  - Murphy EA
AD  - Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 7DQ, 
      United Kingdom.
FAU - Olaniyi, P
AU  - Olaniyi P
AD  - Department of Urology, Ipswich Hospital, East Suffolk and North Essex NHS 
      Foundation Trust, Heath Road, Ipswich IP4 5PD, United Kingdom.
FAU - Bryant, R J
AU  - Bryant RJ
AD  - Department of Urology, Ipswich Hospital, East Suffolk and North Essex NHS 
      Foundation Trust, Heath Road, Ipswich IP4 5PD, United Kingdom; Department of 
      Urology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, 
      Oxford OX3 7LE, United Kingdom. Electronic address: richard.bryant@nds.ox.ac.uk.
LA  - eng
GR  - C39297/A22748/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201208
PL  - England
TA  - Cancer Treat Res Commun
JT  - Cancer treatment and research communications
JID - 101694651
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Prostaglandins)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Chemoradiotherapy/methods
MH  - Chemotherapy, Adjuvant/methods
MH  - Cyclooxygenase 2/metabolism
MH  - Cyclooxygenase 2 Inhibitors/pharmacology/*therapeutic use
MH  - Disease Progression
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local/*epidemiology/prevention & control
MH  - Progression-Free Survival
MH  - Prostaglandins/metabolism
MH  - Prostatectomy
MH  - Prostatic Neoplasms/mortality/pathology/*therapy
OTO - NOTNLM
OT  - Aspirin
OT  - Cyclooxygenase-2
OT  - Epidemiology
OT  - Intervention
OT  - Prostate cancer
EDAT- 2020/12/29 06:00
MHDA- 2022/01/01 06:00
CRDT- 2020/12/28 11:11
PHST- 2020/10/31 00:00 [received]
PHST- 2020/12/02 00:00 [revised]
PHST- 2020/12/07 00:00 [accepted]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2022/01/01 06:00 [medline]
PHST- 2020/12/28 11:11 [entrez]
AID - S2468-2942(20)30102-7 [pii]
AID - 10.1016/j.ctarc.2020.100267 [doi]
PST - ppublish
SO  - Cancer Treat Res Commun. 2021;26:100267. doi: 10.1016/j.ctarc.2020.100267. Epub 
      2020 Dec 8.

PMID- 6117613
OWN - NLM
STAT- MEDLINE
DCOM- 19820120
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 33
IP  - 10
DP  - 1981 Oct
TI  - The prediction of the bulk densities of powder mixtures, and its relationship to 
      the filling of hard gelatin capsules.
PG  - 621-6
AB  - From measurements of the properties of individual components, it has been found 
      possible to predict the maximum tapped bulk density of two component mixtures of 
      a range of particle size fractions of acetylsalicylic acid and lactose in varying 
      proportions. This has been extended to the prediction of bulk density of such 
      mixtures when filled into hard gelatin capsules by a system which results in the 
      powders existing at the maximum tapped bulk density. Consequently the capsule 
      fill weight can also be predicted for such systems. The method is less 
      satisfactory for the prediction of the bulk density and capsule fill weight, when 
      the capsules are filled by a process involving compression of the powder within 
      the capsule shell.
FAU - Newton, J M
AU  - Newton JM
FAU - Bader, F
AU  - Bader F
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Capsules)
RN  - 0 (Powders)
RN  - 9000-70-8 (Gelatin)
RN  - J2B2A4N98G (Lactose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - *Capsules
MH  - Drug Compounding
MH  - Gelatin
MH  - Lactose
MH  - Particle Size
MH  - *Powders
EDAT- 1981/10/01 00:00
MHDA- 1981/10/01 00:01
CRDT- 1981/10/01 00:00
PHST- 1981/10/01 00:00 [pubmed]
PHST- 1981/10/01 00:01 [medline]
PHST- 1981/10/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1981.tb13887.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1981 Oct;33(10):621-6. doi: 
      10.1111/j.2042-7158.1981.tb13887.x.

PMID- 30614864
OWN - NLM
STAT- MEDLINE
DCOM- 20190429
LR  - 20200225
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 132
IP  - 2
DP  - 2019 Jan 20
TI  - De-escalation of anti-platelet therapy in patients with acute coronary syndromes 
      undergoing percutaneous coronary intervention: a narrative review.
PG  - 197-210
LID - 10.1097/CM9.0000000000000047 [doi]
AB  - OBJECTIVE: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor 
      inhibitor is the cornerstone of treatment in patients with acute coronary 
      syndromes (ACS) and in those undergoing percutaneous coronary intervention (PCI). 
      In current clinical situation, availability of different oral P2Y12 inhibitors 
      (clopidogrel, prasugrel, and ticagrelor) has enabled physicians to switch among 
      therapies owing to specific clinical scenarios. Although optimum time, loading 
      dose and interval of transition between P2Y12 inhibitors is still controversial 
      and needs further evidence, switching between oral inhibitors frequently occurs 
      in clinical practice for several reasons. DATA SOURCES: This review was based on 
      data in articles published in PubMed up to June 2018, with the following keywords 
      "antiplatelet therapy", "ACS", "PCI", "ticagrelor", and "clopidogrel". STUDY 
      SELECTION: Original articles and critical reviews on de-escalation strategy in 
      ACS patients after PCI were selected. References of the retrieved articles were 
      also screened to search for potentially relevant papers. RESULTS: Safety concerns 
      associated with switching between antiplatelet agents, has prompted the use of 
      clopidogrel for patients with ACS especially after PCI as a de-escalation 
      strategy. Practical considerations for de-escalating therapies in patients with 
      ACS such as reducing dose of P2Y12 inhibitors or shortening duration of DAPT 
      (followed by aspirin or P2Y12 receptor inhibitor monotherapy) as potential 
      options are yet to be standardized and validated. CONCLUSIONS: Current review 
      will provide an overview of the pharmacology of common P2Y12 inhibitors, 
      definitions of de-escalation and different de-escalating strategies and its 
      outcomes, along with possible direction to be explored in de-escalation.
FAU - Han, Ya-Ling
AU  - Han YL
AD  - Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, 
      Liaoning 110016, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (24-diamino-5-phenylthiazole)
RN  - 0 (Diamines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - 0 (Thiazoles)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/*therapy
MH  - Aspirin/therapeutic use
MH  - Diamines/therapeutic use
MH  - Humans
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
MH  - Thiazoles/therapeutic use
PMC - PMC6365275
EDAT- 2019/01/08 06:00
MHDA- 2019/04/30 06:00
CRDT- 2019/01/08 06:00
PHST- 2019/01/08 06:00 [pubmed]
PHST- 2019/04/30 06:00 [medline]
PHST- 2019/01/08 06:00 [entrez]
AID - CMJ-2018-187 [pii]
AID - 10.1097/CM9.0000000000000047 [doi]
PST - ppublish
SO  - Chin Med J (Engl). 2019 Jan 20;132(2):197-210. doi: 10.1097/CM9.0000000000000047.

PMID- 29475508
OWN - NLM
STAT- MEDLINE
DCOM- 20190204
LR  - 20190215
IS  - 1873-2534 (Electronic)
IS  - 0165-2427 (Linking)
VI  - 197
DP  - 2018 Mar
TI  - In vivo effects of aspirin and cyclosporine on regulatory T cells and T-cell 
      cytokine production in healthy dogs.
PG  - 63-68
LID - S0165-2427(16)30239-2 [pii]
LID - 10.1016/j.vetimm.2018.01.003 [doi]
AB  - Cyclosporine and aspirin are routinely used in combination to treat 
      immune-mediated hemolytic anemia (IMHA) in dogs. Cyclosporine is a potent 
      immunosuppressive agent that targets T cell production of the cytokines IL-2 and 
      IFN-γ. Low-dose aspirin is often used to inhibit platelet function in dogs with 
      IMHA, since these animals are prone to life-threatening thromboembolic disease. 
      In rodents and humans, aspirin and cyclosporine have both been shown to variably 
      affect T cell cytokine production, and also numbers of circulating regulatory T 
      cells (Tregs). In dogs, it has not yet been determined if concurrent aspirin 
      alters the effects of cyclosporine on T-cell cytokine expression, or if either 
      drug influences Treg numbers. In a crossover study, seven healthy young adult 
      dogs were given either oral high-dose cyclosporine (10 mg/kg Q12 h), oral 
      low-dose aspirin (1 mg/kg Q24 h), oral high-dose aspirin (10 mg/kg Q12 h), or 
      combined low-dose aspirin with cyclosporine, each for 8 days, with a washout of 
      at least 2 weeks after each treatment. Activated T cell cytokine expression (IL-2 
      & IFN-γ) and percent CD4 + CD25 + FOXP3+ Tregs were evaluated using flow 
      cytometry, both prior to and on the last day of treatment. The difference between 
      pre- and post-treatment values for each group, as well as the difference between 
      treatment groups, was evaluated. Cyclosporine significantly decreased IL-2 and 
      IFN-γ expression when used alone or in combination with low-dose aspirin. 
      High-dose aspirin, but not low-dose aspirin, also significantly decreased IL-2 
      expression, although the decrease was not as marked as that seen with 
      cyclosporine alone or in combination with aspirin. Neither low-dose nor high-dose 
      aspirin significantly affected IFN-γ expression. No drug or drug combination 
      affected Treg numbers. Low-dose aspirin given with cyclosporine creates the same 
      degree of T-cell cytokine suppression as does cyclosporine alone, suggesting that 
      the two drugs can be used concurrently without significantly altering the 
      immunosuppressive mechanism of action of cyclosporine.
CI  - Published by Elsevier B.V.
FAU - Archer, T M
AU  - Archer TM
AD  - Department of Clinical Sciences, Mississippi State University College of 
      Veterinary Medicine, 240 Wise Center Drive, Mississippi State, MS, 39762, United 
      States. Electronic address: tarcher@cvm.msstate.edu.
FAU - Stokes, J V
AU  - Stokes JV
AD  - Department of Basic Sciences, Mississippi State University College of Veterinary 
      Medicine, 240 Wise Center Drive, Mississippi State, MS, 39762, United States.
FAU - Kummari, E
AU  - Kummari E
AD  - Department of Basic Sciences, Mississippi State University College of Veterinary 
      Medicine, 240 Wise Center Drive, Mississippi State, MS, 39762, United States.
FAU - Fellman, C
AU  - Fellman C
AD  - Department of Clinical Sciences, Mississippi State University College of 
      Veterinary Medicine, 240 Wise Center Drive, Mississippi State, MS, 39762, United 
      States.
FAU - Thomason, J
AU  - Thomason J
AD  - Department of Clinical Sciences, Mississippi State University College of 
      Veterinary Medicine, 240 Wise Center Drive, Mississippi State, MS, 39762, United 
      States.
FAU - Haraschak, J
AU  - Haraschak J
AD  - Department of Clinical Sciences, Mississippi State University College of 
      Veterinary Medicine, 240 Wise Center Drive, Mississippi State, MS, 39762, United 
      States.
FAU - Wills, R
AU  - Wills R
AD  - Department of Pathobiology and Population Medicine, Mississippi State University 
      College of Veterinary Medicine, 240 Wise Center Drive, Mississippi State, MS, 
      3976, United States.
FAU - Pinchuk, L
AU  - Pinchuk L
AD  - Department of Basic Sciences, Mississippi State University College of Veterinary 
      Medicine, 240 Wise Center Drive, Mississippi State, MS, 39762, United States.
FAU - Mackin, A
AU  - Mackin A
AD  - Department of Clinical Sciences, Mississippi State University College of 
      Veterinary Medicine, 240 Wise Center Drive, Mississippi State, MS, 39762, United 
      States.
LA  - eng
PT  - Journal Article
DEP - 20180109
PL  - Netherlands
TA  - Vet Immunol Immunopathol
JT  - Veterinary immunology and immunopathology
JID - 8002006
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Interleukin-2)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anemia, Hemolytic/drug therapy
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cross-Over Studies
MH  - Cyclosporine/administration & dosage/*pharmacology
MH  - Dogs
MH  - Flow Cytometry
MH  - Immunity, Cellular
MH  - Immunosuppressive Agents/pharmacology
MH  - Interferon-gamma/*immunology
MH  - Interleukin-2/*immunology
MH  - Lymphocyte Activation
MH  - T-Lymphocytes, Regulatory/*drug effects/immunology
OTO - NOTNLM
OT  - Aspirin
OT  - Cyclosporine
OT  - Cytokine
OT  - Flow cytometry
OT  - Lymphocytes
OT  - Regulatory T cells
EDAT- 2018/02/25 06:00
MHDA- 2019/02/05 06:00
CRDT- 2018/02/25 06:00
PHST- 2016/10/27 00:00 [received]
PHST- 2018/01/06 00:00 [revised]
PHST- 2018/01/09 00:00 [accepted]
PHST- 2018/02/25 06:00 [entrez]
PHST- 2018/02/25 06:00 [pubmed]
PHST- 2019/02/05 06:00 [medline]
AID - S0165-2427(16)30239-2 [pii]
AID - 10.1016/j.vetimm.2018.01.003 [doi]
PST - ppublish
SO  - Vet Immunol Immunopathol. 2018 Mar;197:63-68. doi: 10.1016/j.vetimm.2018.01.003. 
      Epub 2018 Jan 9.

PMID- 24785356
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20140804
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Linking)
VI  - 46
IP  - 5
DP  - 2014 Aug
TI  - Myocardial infarction and gastro-intestinal bleeding risks associated with 
      aspirin use among elderly individuals with type 2 diabetes.
PG  - 335-40
LID - 10.3109/07853890.2014.902636 [doi]
AB  - INTRODUCTION: The benefit of aspirin in primary prevention of myocardial 
      infarction and the associated gastro-intestinal bleeding risks have not been well 
      established in the elderly population with diabetes. METHODS: Using Quebec 
      administrative databases, we conducted two nested case-control analyses within a 
      cohort of individuals aged ≥ 66 years newly treated with an oral antidiabetes 
      drug between 1998 and 2003. The 28,067 individuals had no cardiovascular disease 
      recorded in the database in the year prior cohort entry. They had not used 
      prescribed aspirin, antiplatelet, or anticoagulant drugs, and were not 
      hospitalized for gastro-intestinal bleeding in the year prior cohort entry. The 
      odds of myocardial infarction and gastro-intestinal bleedings were compared 
      between individuals who were current, past, or non-users of aspirin. RESULTS: 
      There were 1101 (3.9%) cases of myocardial infarction. Compared to non-users, 
      neither aspirin users (OR 0.89; 95% CI 0.71-1.13) nor aspirin past users (0.81; 
      0.62-1.06) showed a statistically significant lower risk of myocardial 
      infarction. There were 373 (1.3%) cases of gastro-intestinal bleeding. Current 
      users of aspirin had about a 2-fold greater risk of gastro-intestinal bleeding 
      compared to non-users (2.19; 1.53-3.13). CONCLUSIONS: Our results suggest that 
      individual assessment of bleeding risk and cardiovascular risk is mandatory among 
      elderly people with diabetes before introducing aspirin therapy.
FAU - Sirois, Caroline
AU  - Sirois C
AD  - Department of Nursing, UQAR , Lévis , Canada.
FAU - Moisan, Jocelyne
AU  - Moisan J
FAU - Poirier, Paul
AU  - Poirier P
FAU - Grégoire, Jean-Pierre
AU  - Grégoire JP
LA  - eng
PT  - Journal Article
DEP - 20140502
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/*complications/drug therapy
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/*epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Male
MH  - Myocardial Infarction/epidemiology/*prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Primary Prevention
MH  - Quebec/epidemiology
MH  - Risk
OTO - NOTNLM
OT  - Aspirin
OT  - diabetes mellitus
OT  - hemorrhage
OT  - myocardial infarction
EDAT- 2014/05/03 06:00
MHDA- 2015/05/12 06:00
CRDT- 2014/05/03 06:00
PHST- 2014/05/03 06:00 [entrez]
PHST- 2014/05/03 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - 10.3109/07853890.2014.902636 [doi]
PST - ppublish
SO  - Ann Med. 2014 Aug;46(5):335-40. doi: 10.3109/07853890.2014.902636. Epub 2014 May 
      2.

PMID- 24667978
OWN - NLM
STAT- MEDLINE
DCOM- 20141211
LR  - 20181202
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 48
IP  - 6
DP  - 2014 Jun
TI  - Absorption and efficacy of acetylsalicylic acid in patients with short bowel 
      syndrome.
PG  - 705-10
LID - 10.1177/1060028014526700 [doi]
AB  - BACKGROUND: The patients with a short bowel (SB) frequently require antiplatelet 
      therapy. Resection of the bowel is likely to modify the absorption and first-pass 
      effect of drugs. No data on the absorption and efficacy of the cardiovascular 
      dose of aspirin (75-160 mg) in these patients have been published. OBJECTIVE: To 
      evaluate the efficacy of a low dose of aspirin in patients with SB caused by 
      mesenteric ischemia. METHODS: The efficacy of a low dose of aspirin was assessed 
      in 10 consecutive SB patients, both 1 hour and 24 hours after administration 
      (peak and trough value, respectively). The primary criterion was the inhibition 
      of platelet aggregation, as assessed by light transmission aggregometry, 
      triggered with 0.5 mg/mL arachidonic acid. Biological efficacy of aspirin was 
      also evaluated by serum thromboxane B2 value and by platelet function 
      analyzer-100. RESULTS: At its peak value, aspirin had the expected efficacy, as 
      demonstrated both by light transmission aggregometry and the other methods. 
      However, 24 hours after administration, as many as 30% of patients had lost the 
      pharmacological efficacy of their aspirin. CONCLUSION: We show for the first time 
      that with at least 30 cm of small intestine, all patients with SB absorb 
      sufficient oral aspirin in a cardiovascular dose to rapidly exert the expected 
      level of antiplatelet activity. But given only once daily, aspirin does not 
      provide stable 24-hour antiplatelet protection in 30% of patients, because of 
      increased platelet turnover, as usually observed in patients with extensive 
      vascular pathology, diabetes, or inflammation.
FAU - Faye, Elodie
AU  - Faye E
AD  - Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne A, Hôpital 
      Lariboisière, Paris, France.
FAU - Drouet, Ludovic
AU  - Drouet L
FAU - De Raucourt, Emmanuelle
AU  - De Raucourt E
FAU - Green, Andrew
AU  - Green A
FAU - Bal-Dit-Sollier, Claire
AU  - Bal-Dit-Sollier C
FAU - Boudaoud, Larbi
AU  - Boudaoud L
FAU - Corcos, Olivier
AU  - Corcos O
FAU - Bergmann, Jean-François
AU  - Bergmann JF
FAU - Joly, Francisca
AU  - Joly F
FAU - Lloret-Linares, Célia
AU  - Lloret-Linares C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20140325
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*pharmacokinetics
MH  - Drug Administration Schedule
MH  - Drug Resistance/drug effects
MH  - Female
MH  - Humans
MH  - Intestinal Absorption
MH  - Male
MH  - Mesenteric Ischemia/complications
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*pharmacokinetics
MH  - Platelet Function Tests
MH  - Short Bowel Syndrome/*drug therapy/etiology/*metabolism
MH  - Treatment Outcome
OTO - NOTNLM
OT  - absorption
OT  - aspirin
OT  - platelet aggregation tests
OT  - platelet function assay
OT  - short bowel
EDAT- 2014/03/29 06:00
MHDA- 2014/12/17 06:00
CRDT- 2014/03/27 06:00
PHST- 2014/03/27 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
AID - 1060028014526700 [pii]
AID - 10.1177/1060028014526700 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2014 Jun;48(6):705-10. doi: 10.1177/1060028014526700. Epub 2014 
      Mar 25.

PMID- 3133976
OWN - NLM
STAT- MEDLINE
DCOM- 19880802
LR  - 20190812
IS  - 0148-7043 (Print)
IS  - 0148-7043 (Linking)
VI  - 20
IP  - 6
DP  - 1988 Jun
TI  - Successful combined medical and surgical treatment of a lower extremity 
      sclerodermal ulcer.
PG  - 582-5
AB  - Combined medical and surgical treatment of a chronic lower extremity ulcer in a 
      patient with systemic scleroderma is described. Recent pharmacological advances 
      including calcium channel blockers, meticulous surgical care, and skin grafting 
      offer promise for more consistent wound closure in sclerodermal skin ulcerations.
FAU - Grossman, J A
AU  - Grossman JA
AD  - Department of Plastic Surgery, Brown University Affiliated Hospitals, Providence, 
      RI.
FAU - Barrall, D T
AU  - Barrall DT
FAU - Dennison, A
AU  - Dennison A
FAU - Lally, E V
AU  - Lally EV
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Plast Surg
JT  - Annals of plastic surgery
JID - 7805336
RN  - 64ALC7F90C (Dipyridamole)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - M2F465ROXU (Etidronic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Combined Modality Therapy
MH  - Debridement
MH  - Dipyridamole/therapeutic use
MH  - Etidronic Acid/therapeutic use
MH  - Female
MH  - Humans
MH  - Leg Ulcer/etiology/*therapy
MH  - Nifedipine/therapeutic use
MH  - Scleroderma, Systemic/*complications
MH  - Skin Transplantation
MH  - Wound Healing
EDAT- 1988/06/01 00:00
MHDA- 1988/06/01 00:01
CRDT- 1988/06/01 00:00
PHST- 1988/06/01 00:00 [pubmed]
PHST- 1988/06/01 00:01 [medline]
PHST- 1988/06/01 00:00 [entrez]
AID - 10.1097/00000637-198806000-00016 [doi]
PST - ppublish
SO  - Ann Plast Surg. 1988 Jun;20(6):582-5. doi: 10.1097/00000637-198806000-00016.

PMID- 12621388
OWN - NLM
STAT- MEDLINE
DCOM- 20030320
LR  - 20181130
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 73
IP  - 3
DP  - 2003 Mar
TI  - Clopidogrel but not aspirin reduces P-selectin expression and formation of 
      platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
PG  - 232-41
AB  - Formation of platelet-leukocyte aggregates via the CD62 ligand represents an 
      important mechanism by which leukocytes contribute to thrombotic events. In a 
      cross-sectional study, we investigated platelet-leukocyte aggregate formation and 
      markers indicative for platelet, leukocyte, and endothelial activation (CD62, 
      activated fibrinogin receptor glycoprotein IIb/IIIA [PAC-1], CD11b/CD18 [MAC-1], 
      and soluble intercellular adhesion molecule 1) in 44 patients with 
      atherosclerotic vascular disease and peripheral occlusions receiving clopidogrel 
      (n = 12), aspirin (n = 17), their combination (n = 8), or no treatment (n = 7), 
      as well as in a group of healthy subjects (n = 9). Whole-blood flow cytometry was 
      performed before (baseline) and after stimulation with thrombin 
      receptor-activating peptide or adenosine diphosphate. Both at baseline and after 
      stimulation, untreated patients and those receiving aspirin monotherapy exhibited 
      significantly higher levels of platelet CD62 expression (baseline CD62: 
      untreated, 22% [median]; with aspirin, 16%) and had higher rates of 
      platelet-leukocyte aggregate formation (monocyte-platelet-leukocyte aggregates at 
      baseline: untreated, 27%; with aspirin, 16%) when compared with patients 
      receiving clopidogrel alone (baseline CD62: 10% [P <.05]; 
      monocyte-platelet-leukocyte aggregates: 13% [P <.05]) or combined with aspirin 
      (baseline CD62: 5% [P <.05]; monocyte-platelet-leukocyte aggregates: 7% [P 
      <.05]). Up-regulation of MAC-1 on monocytes after stimulation with thrombin 
      receptor-activating peptide and adenosine diphosphate was significantly lower in 
      patients treated with clopidogrel and aspirin. Plasma levels of soluble 
      intercellular adhesion molecule 1 were significantly lower in the group of 
      healthy subjects (median, 186 ng/mL) when compared with those in untreated 
      patients (median, 352 ng/mL) (P <.05), whereas intercellular adhesion molecule 1 
      levels in treated patients were similar for any antiplatelet regimen (aspirin, 
      262 ng/mL; clopidogrel, 274 ng/mL; combination therapy, 273 ng/mL) but 
      significantly lower than those in untreated patients. This is the first report 
      showing that platelet-leukocyte aggregate formation is enhanced in 
      atherosclerotic vascular disease but was found to be reduced in patients 
      receiving clopidogrel.
FAU - Klinkhardt, Ute
AU  - Klinkhardt U
AD  - Institute of Clinical Pharmacology and Department of Angiology, University 
      Hospital Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany.
FAU - Bauersachs, Rupert
AU  - Bauersachs R
FAU - Adams, Jan
AU  - Adams J
FAU - Graff, Jochen
AU  - Graff J
FAU - Lindhoff-Last, Edeltraud
AU  - Lindhoff-Last E
FAU - Harder, Sebastian
AU  - Harder S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 3.1.3.16 (Protein Phosphatase 2)
RN  - EC 3.1.3.48 (DUSP2 protein, human)
RN  - EC 3.1.3.48 (Dual Specificity Phosphatase 2)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatases)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Blood Platelets/*metabolism
MH  - Case-Control Studies
MH  - Clopidogrel
MH  - Coronary Artery Disease/drug therapy
MH  - Cross-Sectional Studies
MH  - Drug Therapy, Combination
MH  - Dual Specificity Phosphatase 2
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Intercellular Adhesion Molecule-1/metabolism
MH  - Leukocytes/*metabolism
MH  - Male
MH  - Middle Aged
MH  - P-Selectin/*metabolism
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology/therapeutic 
      use
MH  - Protein Phosphatase 2
MH  - Protein Tyrosine Phosphatases/metabolism
MH  - Ticlopidine/administration & dosage/analogs & 
      derivatives/*pharmacology/therapeutic use
EDAT- 2003/03/07 04:00
MHDA- 2003/03/21 04:00
CRDT- 2003/03/07 04:00
PHST- 2003/03/07 04:00 [pubmed]
PHST- 2003/03/21 04:00 [medline]
PHST- 2003/03/07 04:00 [entrez]
AID - S0009923602176144 [pii]
AID - 10.1067/mcp.2003.13 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2003 Mar;73(3):232-41. doi: 10.1067/mcp.2003.13.

PMID- 3937451
OWN - NLM
STAT- MEDLINE
DCOM- 19860307
LR  - 20181130
IS  - 0300-8924 (Print)
IS  - 0300-8924 (Linking)
VI  - 7
IP  - 3-4
DP  - 1985
TI  - Liberation of prostaglandin-like substances from the isolated coronary artery in 
      presence of angiotensin and of 4-methylesculetin.
PG  - 257-67
AB  - The aim of this work is to study the mechanism by which 4-Methylesculetin (4-ME) 
      causes the relaxation or inhibits the Angiotensin II (ATN 2) induced contraction 
      in the smooth muscle. The effect of 4-Me, alone or associated with Ascorbic Acid, 
      on basal tone and ATN 2 induced contraction of isolated coronary strips have been 
      studied. Experiments have been carried out in presence of Lysine Acetylsalicylate 
      (LAS) and Indomethacin (IN), known inhibitors of prostaglandin-synthetase. Both 
      LAS and IN decrease but not abolish, the 4-ME induced relaxation and suppressed 
      the depressive effect of 4-ME on the ATN 2 dependent contraction. From R.I.A. 
      tests results that 6-Keto PGF1 alpha (prostacyclines stable metabolite) 
      concentration increased with the addition of 4-ME to the bath. 6-Keto PGF1 alpha 
      concentration was drastically reduced after IN and LAS use. Therefore, it seems 
      reasonable to conclude that 4-ME influence could be mediated by prostacyclines 
      release in the smooth muscle.
FAU - Bettini, V
AU  - Bettini V
FAU - Calò, L
AU  - Calò L
FAU - Cantaro, S
AU  - Cantaro S
FAU - Martino, R
AU  - Martino R
FAU - Munari, L
AU  - Munari L
FAU - Salvatico, E
AU  - Salvatico E
FAU - Ton, P
AU  - Ton P
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Acta Vitaminol Enzymol
JT  - Acta vitaminologica et enzymologica
JID - 0135063
RN  - 0 (Prostaglandins)
RN  - 0 (Umbelliferones)
RN  - 11128-99-7 (Angiotensin II)
RN  - K3Z4F929H6 (Lysine)
RN  - KLF1HS0SXJ (Scopoletin)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Angiotensin II/*antagonists & inhibitors
MH  - Animals
MH  - Ascorbic Acid/pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cattle
MH  - Coronary Vessels/*drug effects/metabolism
MH  - Drug Interactions
MH  - In Vitro Techniques
MH  - Indomethacin/pharmacology
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Muscle, Smooth, Vascular/*drug effects
MH  - Prostaglandins/*metabolism
MH  - Scopoletin/*pharmacology
MH  - Umbelliferones/*pharmacology
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Vitaminol Enzymol. 1985;7(3-4):257-67.

PMID- 23425
OWN - NLM
STAT- MEDLINE
DCOM- 19780321
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 67
IP  - 2
DP  - 1978 Feb
TI  - Improved colorimetric determination of aspirin and salicylic acid concentrations 
      in human plasma.
PG  - 289-91
AB  - An improvement in a previously described method for the determination of plasma 
      salicylic acid and aspirin levels in humans is described. The procedure was 
      simplified by employing only one plasma sample for both salicylates. More 
      accurate estimation of salicylates, particularly aspirin, was achieved by using 
      two different calibration curves. Salicylic acid was estimated by reaction with 
      an aqueous solution of the Folin-Ciocalteu phenol reagent. Absorbance of the 
      blue-colored complex, which formed on addition of sodium hydroxide, was measured 
      at 670 nm. The influence of alkalinity in the formation of the colored complex is 
      discussed. The average recovery of aspirin added to plasma was 94.61%; it was 
      214.72% by the previous method.
FAU - Muni, I A
AU  - Muni IA
FAU - Leeling, J L
AU  - Leeling JL
FAU - Helms, R J
AU  - Helms RJ
FAU - Johnson, N Jr
AU  - Johnson N Jr
FAU - Bare, J J
AU  - Bare JJ
FAU - Phillips, B M
AU  - Phillips BM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*blood
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Light
MH  - Methods
MH  - Salicylates/*blood
MH  - Spectrophotometry
EDAT- 1978/02/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1978/02/01 00:00
PHST- 1978/02/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1978/02/01 00:00 [entrez]
AID - S0022-3549(15)39853-1 [pii]
AID - 10.1002/jps.2600670251 [doi]
PST - ppublish
SO  - J Pharm Sci. 1978 Feb;67(2):289-91. doi: 10.1002/jps.2600670251.

PMID- 11498517
OWN - NLM
STAT- MEDLINE
DCOM- 20011025
LR  - 20181113
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 133
IP  - 8
DP  - 2001 Aug
TI  - Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in 
      normotensive and hypertensive rats.
PG  - 1314-22
AB  - 1. Nonsteroidal anti-inflammatory drugs have been reported to exacerbate 
      hypertension and to interfere with the effectiveness of some anti-hypertensive 
      therapies. In this study, we tested the effects of a gastric-sparing, nitric 
      oxide-releasing derivative of aspirin (NCX-4016) on hypertension in rats. 2. 
      Hypertension was induced by administering L-NAME in the drinking water (400 mg 
      l(-1)). Groups of rats were treated daily with aspirin, NCX-4016 or vehicle. 3. 
      NCX-4016 significantly reduced blood pressure relative to the aspirin-treated 
      group over the 2-week period of treatment. Aspirin and, to a lesser extent, 
      NCX-4016 suppressed whole blood thromboxane synthesis. 4. In anaesthetized rats, 
      acute intravenous administration of NCX-4016 caused a significant fall in mean 
      arterial pressure in hypertensive rats, but was devoid of such effects in 
      normotensive controls. 5. In vitro, NCX-4016 relaxed phenylephrine-pre-contracted 
      aortic rings obtained from both normotensive and hypertensive rats, and 
      significantly reduced their responsiveness to the contractile effects of 
      phenylephrine. 6. These results suggest that NCX-4016 reduces blood pressure in 
      hypertensive rats, not simply through the direct vasodilatory actions of the 
      nitric oxide released by this compound, but also through possible interference 
      with the effects of endogenous pressor agents. These properties, added to its 
      anti-thrombotic effects, suggest that NCX-4016 may be a safer alternative to 
      aspirin for use by hypertensive patients.
FAU - Muscará, M N
AU  - Muscará MN
AD  - Department of Pharmacology, Institute of Biomedical Sciences, University of São 
      Paulo, Av. Prof. Lineu Prestes 1524, São Paulo, 05508-900, SP, Brazil.
FAU - Lovren, F
AU  - Lovren F
FAU - McKnight, W
AU  - McKnight W
FAU - Dicay, M
AU  - Dicay M
FAU - del Soldato, P
AU  - del Soldato P
FAU - Triggle, C R
AU  - Triggle CR
FAU - Wallace, J L
AU  - Wallace JL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nitrates)
RN  - 0 (Nitrites)
RN  - 0 (Thromboxanes)
RN  - 169D1260KM (Nitroprusside)
RN  - 1WS297W6MV (Phenylephrine)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 3.4.23.15 (Renin)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Anesthesia
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics/*pharmacology
MH  - Aorta/drug effects/metabolism/physiology/physiopathology
MH  - Aspirin/analogs & derivatives/pharmacokinetics/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Consciousness
MH  - Dose-Response Relationship, Drug
MH  - Hypertension/*physiopathology
MH  - In Vitro Techniques
MH  - Male
MH  - NG-Nitroarginine Methyl Ester/pharmacology
MH  - Nitrates/metabolism
MH  - Nitric Oxide/*metabolism
MH  - Nitrites/metabolism
MH  - Nitroprusside/pharmacology
MH  - Phenylephrine/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Renin/blood
MH  - Thromboxanes/metabolism
MH  - Vasodilation/*drug effects
PMC - PMC1621160
EDAT- 2001/08/11 10:00
MHDA- 2001/10/26 10:01
CRDT- 2001/08/11 10:00
PHST- 2001/08/11 10:00 [pubmed]
PHST- 2001/10/26 10:01 [medline]
PHST- 2001/08/11 10:00 [entrez]
AID - 0704209 [pii]
AID - 10.1038/sj.bjp.0704209 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2001 Aug;133(8):1314-22. doi: 10.1038/sj.bjp.0704209.

PMID- 29091481
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1747-4094 (Electronic)
IS  - 1747-4094 (Linking)
VI  - 11
IP  - 1
DP  - 2018 Jan
TI  - The quest for safer antithrombotic treatment regimens in patients with coronary 
      artery disease: new strategies and paradigm shifts.
PG  - 5-12
LID - 10.1080/17474086.2018.1400378 [doi]
AB  - Despite the undeniable benefits on reducing ischemic adverse events, antiplatelet 
      regimens including dual antiplatelet therapy (DAPT) with aspirin and P2Y(12) 
      receptor inhibitors are associated with an increased risk of bleeding. The 
      awareness of the unfavorable prognostic implications associated with bleeding 
      complications have somewhat hampered the enthusiasm towards the use of more 
      potent antiplatelet treatment regimens or prolonged use of DAPT. This awareness 
      also has prompted a series of investigations geared towards the identification of 
      antithrombotic treatment regimens which are efficacious at reducing ischemic 
      recurrences while also safe in terms of bleeding risk profile. Areas covered: The 
      present manuscript focuses on new approaches for improving the safety profile of 
      antithrombotic treatment regimens, including most recent updates from clinical 
      trials, as well as future perspectives in the field. Expert commentary: Results 
      of ongoing trials testing new antithrombotic treatment regimens, including new 
      drugs, new combinations, which may be used for different duration of time 
      according to the individual's risk of thrombotic and bleeding complications, may 
      lead to paradigm shifts in secondary prevention of atherothrombotic events in 
      patients with coronary artery disease.
FAU - Moon, Jae Youn
AU  - Moon JY
AD  - a Division of Cardiology , University of Florida College of Medicine-Jacksonville 
      , Jacksonville , FL , USA.
FAU - Franchi, Francesco
AU  - Franchi F
AD  - a Division of Cardiology , University of Florida College of Medicine-Jacksonville 
      , Jacksonville , FL , USA.
FAU - Rollini, Fabiana
AU  - Rollini F
AD  - a Division of Cardiology , University of Florida College of Medicine-Jacksonville 
      , Jacksonville , FL , USA.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - a Division of Cardiology , University of Florida College of Medicine-Jacksonville 
      , Jacksonville , FL , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171114
PL  - England
TA  - Expert Rev Hematol
JT  - Expert review of hematology
JID - 101485942
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Artery Disease/blood/*complications/drug therapy
MH  - Fibrinolytic Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Hemorrhage/*etiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/therapeutic use
MH  - Precision Medicine/methods
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/adverse 
      effects/therapeutic use
OTO - NOTNLM
OT  - Antiplatelet agents
OT  - anticoagulant therapy
OT  - bleeding
OT  - ischemia
OT  - safety
EDAT- 2017/11/02 06:00
MHDA- 2018/12/12 06:00
CRDT- 2017/11/02 06:00
PHST- 2017/11/02 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2017/11/02 06:00 [entrez]
AID - 10.1080/17474086.2018.1400378 [doi]
PST - ppublish
SO  - Expert Rev Hematol. 2018 Jan;11(1):5-12. doi: 10.1080/17474086.2018.1400378. Epub 
      2017 Nov 14.

PMID- 8154111
OWN - NLM
STAT- MEDLINE
DCOM- 19940512
LR  - 20131121
IS  - 0042-8787 (Print)
IS  - 0042-8787 (Linking)
IP  - 6
DP  - 1993 Nov-Dec
TI  - [Combined use of disaggregants and galvanic current in cerebrocardio-vascular 
      pathology].
PG  - 13-6
AB  - The efficiency of combined use of the disaggregant aspirin and electroplate 
      current on the precordial area was studied in 230 patients with coronary heart 
      disease concurrent with cerebral disorders. The procedure was shown to have a 
      positive action on the time course of clinical symptoms, the status of central 
      hemodynamics, physical fitness, and psychoemotional status of the patients.
FAU - Ezhova, L V
AU  - Ezhova LV
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Kombinirovannoe primenenie dezagregantov i gal'vanicheskogo toka pri 
      serdechno-mozgovoĭ sosudistoĭ patologii.
PL  - Russia (Federation)
TA  - Vopr Kurortol Fizioter Lech Fiz Kult
JT  - Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury
JID - 2984868R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cerebrovascular Disorders/diagnosis/psychology/*therapy
MH  - Chronic Disease
MH  - Combined Modality Therapy
MH  - *Electric Stimulation Therapy
MH  - Health Resorts
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Ischemia/diagnosis/psychology/*therapy
MH  - Remission Induction
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PST - ppublish
SO  - Vopr Kurortol Fizioter Lech Fiz Kult. 1993 Nov-Dec;(6):13-6.

PMID- 31951112
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr
TI  - Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a 
      systematic review.
PG  - 450-464
LID - 10.1002/alr.22520 [doi]
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) represents an 
      aggressive form of chronic rhinosinusitis with nasal polyposis that is 
      notoriously challenging to treat. There is evidence to suggest desensitization to 
      aspirin may improve symptomatology and disease control in these patients. The 
      goal of our study was to critically appraise the literature on this topic and 
      assess the effect of desensitization on sinonasal symptomatology. METHODS: We 
      searched EMBASE, CINAHL, MEDLINE, and the Cochrane Library for relevant 
      literature. Studies were included if they were observational studies or 
      randomized, controlled trials, had n > 1, and were published in English or 
      French. Studies were excluded if they were systematic reviews. We assessed study 
      for quality and presence of common sources of bias. RESULTS: Twenty-four studies 
      met the inclusion criteria. In general, polyp size, polyp recurrence, nasal 
      symptom scores, sense of smell, number of acute rhinosinusitis episodes, and 
      systemic steroid use improved when patients were desensitized. The vast majority 
      of studies recommend desensitization. CONCLUSION: There is mounting evidence that 
      aspirin desensitization is a valuable adjunct to treat sinonasal symptoms in the 
      treatment of patients who have AERD.
CI  - © 2020 ARS-AAOA, LLC.
FAU - Larivée, Natasha
AU  - Larivée N
AD  - Dalhousie Medicine New Brunswick, Saint John, NB, Canada.
FAU - Chin, Christopher J
AU  - Chin CJ
AUID- ORCID: 0000-0003-4477-764X
AD  - Dalhousie Medicine New Brunswick, Saint John, NB, Canada.
AD  - Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, Dalhousie 
      University, Saint John, NB, Canada.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200116
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Asthma, Aspirin-Induced/therapy
MH  - Desensitization, Immunologic
MH  - Humans
MH  - *Nasal Polyps/therapy
MH  - *Rhinitis/drug therapy
MH  - *Sinusitis/drug therapy
OTO - NOTNLM
OT  - ASA
OT  - aspirin
OT  - desensitization
OT  - sinusitis
EDAT- 2020/01/18 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/01/18 06:00
PHST- 2019/09/24 00:00 [received]
PHST- 2019/12/10 00:00 [revised]
PHST- 2019/12/12 00:00 [accepted]
PHST- 2020/01/18 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/01/18 06:00 [entrez]
AID - 10.1002/alr.22520 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2020 Apr;10(4):450-464. doi: 10.1002/alr.22520. Epub 
      2020 Jan 16.

PMID- 27712761
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20180124
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 36
IP  - 4
DP  - 2016 Nov
TI  - Diagnostic Evaluation in Aspirin-Exacerbated Respiratory Disease.
PG  - 657-668
LID - S0889-8561(16)30048-0 [pii]
LID - 10.1016/j.iac.2016.06.003 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is a distinct clinical condition 
      characterized by chronic sinusitis with nasal polyps, asthma, and 
      hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs). 
      Distinguishing AERD from other forms of chronic sinusitis, asthma, and NSAID 
      reactivity has important clinical implications for management. The clinical 
      history is helpful, but not adequate for confirming the diagnosis of AERD, in 
      most cases. Diagnostic provocation challenge remains the only way to confirm or 
      exclude the diagnosis of AERD. This article discusses the utility of the clinical 
      history and the current evidence regarding measures that optimize the safety of 
      performing diagnostic NSAID provocation challenges.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Williams, Adam N
AU  - Williams AN
AD  - Department of Allergy, Asthma, and Immunology, Bend Memorial Clinic, 815 
      Southwest Bond Street, Bend, OR 97702, USA; School of Medicine, Oregon Health and 
      Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. 
      Electronic address: awilliams@bmctotalcare.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160913
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Bronchial Provocation Tests
MH  - Humans
MH  - Nasal Provocation Tests
MH  - Phenotype
MH  - Respiratory Function Tests
MH  - Respiratory Tract Diseases/*diagnosis/*etiology/therapy
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - Aspirin-exacerbated respiratory disease
OT  - Asthma
OT  - Chronic rhinosinusitis with nasal polyps
OT  - Diagnosis
OT  - Intranasal ketorolac
OT  - Lysine-aspirin
OT  - NSAID hypersensitivity
OT  - Oral aspirin challenge
EDAT- 2016/10/08 06:00
MHDA- 2017/12/23 06:00
CRDT- 2016/10/08 06:00
PHST- 2016/10/08 06:00 [entrez]
PHST- 2016/10/08 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - S0889-8561(16)30048-0 [pii]
AID - 10.1016/j.iac.2016.06.003 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2016 Nov;36(4):657-668. doi: 
      10.1016/j.iac.2016.06.003. Epub 2016 Sep 13.

PMID- 26233471
OWN - NLM
STAT- MEDLINE
DCOM- 20160509
LR  - 20191210
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 37
IP  - 9
DP  - 2015 Sep
TI  - Medication Extraction from Electronic Clinical Notes in an Integrated Health 
      System: A Study on Aspirin Use in Patients with Nonvalvular Atrial Fibrillation.
PG  - 2048-2058.e2
LID - S0149-2918(15)00930-3 [pii]
LID - 10.1016/j.clinthera.2015.07.002 [doi]
AB  - PURPOSE: The purpose of this study was to investigate whether aspirin use can be 
      captured from the clinical notes in a nonvalvular atrial fibrillation population. 
      METHODS: A total of 29,507 patients with newly diagnosed nonvalvular atrial 
      fibrillation were identified from January 1, 2006, through December 31, 2011, and 
      were followed up through December 31, 2012. More than 3 million clinical notes 
      were retrieved from electronic medical records. A training data set of 2949 notes 
      was created to develop a computer-based method to automatically extract aspirin 
      use status and dosage information using natural language processing (NLP). A gold 
      standard data set of 5339 notes was created using a blinded manual review. NLP 
      results were validated against the gold standard data set. The aspirin data from 
      the structured medication databases were also compared with the results from NLP. 
      Positive and negative predictive values, along with sensitivity and specificity, 
      were calculated. FINDINGS: NLP achieved 95.5% sensitivity and 98.9% specificity 
      when compared with the gold standard data set. The positive predictive value was 
      93.0%, and the negative predictive value was 99.3%. NLP identified aspirin use 
      for 83.8% of the study population, and 70% of the low dose aspirin use was 
      identified only by the NLP method. IMPLICATIONS: We developed and validated an 
      NLP method specifically designed to identify low dose aspirin use status from the 
      clinical notes with high accuracy. This method can be a valuable tool to 
      supplement existing structured medication data.
CI  - Copyright © 2015 Elsevier HS Journals, Inc. All rights reserved.
FAU - Zheng, Chengyi
AU  - Zheng C
AD  - Department of Research and Evaluation, Kaiser Permanente Southern California, 
      Pasadena, California. Electronic address: Chengyi.X.Zheng@kp.org.
FAU - Rashid, Nazia
AU  - Rashid N
AD  - Drug Information Services, Kaiser Permanente Southern California, Downey, 
      California.
FAU - Koblick, River
AU  - Koblick R
AD  - Drug Information Services, Kaiser Permanente Southern California, Downey, 
      California.
FAU - An, JaeJin
AU  - An J
AD  - Department of Pharmacy Practice and Administration, Western University of Health 
      Sciences, Pomona, California.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20150729
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/drug therapy
MH  - California
MH  - Delivery of Health Care, Integrated
MH  - *Electronic Health Records
MH  - Humans
MH  - Information Storage and Retrieval/methods
MH  - *Natural Language Processing
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - aspirin
OT  - electronic clinical notes
OT  - electronic medical record
OT  - integrated health systems
OT  - medication status
OT  - natural language processing
EDAT- 2015/08/04 06:00
MHDA- 2016/05/10 06:00
CRDT- 2015/08/03 06:00
PHST- 2015/04/03 00:00 [received]
PHST- 2015/06/06 00:00 [revised]
PHST- 2015/07/06 00:00 [accepted]
PHST- 2015/08/03 06:00 [entrez]
PHST- 2015/08/04 06:00 [pubmed]
PHST- 2016/05/10 06:00 [medline]
AID - S0149-2918(15)00930-3 [pii]
AID - 10.1016/j.clinthera.2015.07.002 [doi]
PST - ppublish
SO  - Clin Ther. 2015 Sep;37(9):2048-2058.e2. doi: 10.1016/j.clinthera.2015.07.002. 
      Epub 2015 Jul 29.

PMID- 32366719
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Print)
IS  - 0066-4804 (Linking)
VI  - 64
IP  - 7
DP  - 2020 Jun 23
TI  - Combination Therapy Using Benznidazole and Aspirin during the Acute Phase of 
      Experimental Chagas Disease Prevents Cardiovascular Dysfunction and Decreases 
      Typical Cardiac Lesions in the Chronic Phase.
LID - 10.1128/AAC.00069-20 [doi]
LID - e00069-20
AB  - Chagas disease, caused by the protozoan Trypanosoma cruzi, is one of the main 
      causes of death due to cardiomyopathy and heart failure in Latin American 
      countries. The treatment of Chagas disease is directed at eliminating the 
      parasite, decreasing the probability of cardiomyopathy and disrupting the disease 
      transmission cycle. Benznidazole (BZ) and nifurtimox (Nfx) are recognized as 
      effective drugs for the treatment of Chagas disease by the World Health 
      Organization, but both have high toxicity and limited efficacy, especially in the 
      chronic disease phase. At low doses, aspirin (ASA) has been reported to protect 
      against T. cruzi infection. We evaluated the effectiveness of BZ in combination 
      with ASA at low doses during the acute disease phase and evaluated cardiovascular 
      aspects and cardiac lesions in the chronic phase. ASA treatment prevented the 
      cardiovascular dysfunction (hypertension and tachycardia) and typical cardiac 
      lesions. Moreover, BZ+ASA-treated mice had a smaller cardiac fibrotic area than 
      BZ-treated mice. These results were associated with an increase in numbers of 
      eosinophils and reticulocytes and levels of nitric oxide in the plasma and 
      cardiac tissue of ASA-treated mice relative to respective controls. These effects 
      of ASA and BZ+ASA in chronically infected mice were inhibited by pretreatment 
      with the lipoxin A(4) (LXA(4)) receptor antagonist Boc-2, indicating that the 
      protective effects of ASA are mediated by ASA-triggered lipoxin. These results 
      emphasize the importance of exploring new drug combinations for treatments of the 
      acute phase of Chagas disease that are beneficial for patients with chronic 
      disease.
CI  - Copyright © 2020 American Society for Microbiology.
FAU - Pereira, Rito Santo
AU  - Pereira RS
AD  - Laboratório de Imunopatologia Experimental, Departamento de Ciências Patológicas, 
      Centro de Ciências Biológicas, Universidade Estadual de Londrina, Londrina, 
      Paraná, Brazil.
FAU - Malvezi, Aparecida Donizette
AU  - Malvezi AD
AD  - Laboratório de Imunopatologia Experimental, Departamento de Ciências Patológicas, 
      Centro de Ciências Biológicas, Universidade Estadual de Londrina, Londrina, 
      Paraná, Brazil.
FAU - Lovo-Martins, Maria Isabel
AU  - Lovo-Martins MI
AD  - Laboratório de Imunopatologia Experimental, Departamento de Ciências Patológicas, 
      Centro de Ciências Biológicas, Universidade Estadual de Londrina, Londrina, 
      Paraná, Brazil.
FAU - Lucchetti, Bruno Fernando Cruz
AU  - Lucchetti BFC
AD  - Laboratório de Fisiologia e Fisiopatologia Cardiovascular, Departamento de 
      Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Estadual de 
      Londrina, Londrina, Paraná, Brazil.
FAU - Santos, Jussevania Pereira
AU  - Santos JP
AD  - Laboratório de Biologia Molecular de Microrganismos, Departamento de 
      Microbiologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, 
      Londrina, Paraná, Brazil.
FAU - Tavares, Eliandro Reis
AU  - Tavares ER
AD  - Laboratório de Biologia Molecular de Microrganismos, Departamento de 
      Microbiologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, 
      Londrina, Paraná, Brazil.
FAU - Verri, Waldiceu Aparecido Jr,
AU  - Verri WA Jr,
AD  - Laboratório de Pesquisa em Dor, Neuropatia e Inflamação, Departamento de Ciências 
      Patológicas, Centro de Ciências Biológicas, Universidade Estadual de Londrina, 
      Londrina, Paraná, Brazil.
FAU - de Almeida Araújo, Eduardo José
AU  - de Almeida Araújo EJ
AD  - Laboratório de Neurogastroenterologia, Centro de Ciências Biológicas, 
      Universidade Estadual de Londrina, CEP, Londrina, Paraná, Brazil.
FAU - Yamauchi, Lucy Megumi
AU  - Yamauchi LM
AD  - Laboratório de Biologia Molecular de Microrganismos, Departamento de 
      Microbiologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, 
      Londrina, Paraná, Brazil.
FAU - Yamada-Ogatta, Sueli Fumie
AU  - Yamada-Ogatta SF
AD  - Laboratório de Biologia Molecular de Microrganismos, Departamento de 
      Microbiologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, 
      Londrina, Paraná, Brazil.
FAU - Martins-Pinge, Marli Cardoso
AU  - Martins-Pinge MC
AD  - Laboratório de Fisiologia e Fisiopatologia Cardiovascular, Departamento de 
      Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Estadual de 
      Londrina, Londrina, Paraná, Brazil.
FAU - Pinge-Filho, Phileno
AU  - Pinge-Filho P
AUID- ORCID: 0000-0002-1500-3998
AD  - Laboratório de Imunopatologia Experimental, Departamento de Ciências Patológicas, 
      Centro de Ciências Biológicas, Universidade Estadual de Londrina, Londrina, 
      Paraná, Brazil pingefilho@uel.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200623
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Drug Combinations)
RN  - 0 (Nitroimidazoles)
RN  - 0 (Trypanocidal Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - YC42NRJ1ZD (benzonidazole)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - *Chagas Disease/drug therapy
MH  - Drug Combinations
MH  - Humans
MH  - Mice
MH  - *Nitroimidazoles/pharmacology/therapeutic use
MH  - *Trypanocidal Agents/therapeutic use
MH  - *Trypanosoma cruzi
PMC - PMC7318042
OTO - NOTNLM
OT  - Chagas disease
OT  - aspirin
OT  - benznidazole
OT  - cardioprotective effects
OT  - lipoxin
OT  - therapy
EDAT- 2020/05/06 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/01/10 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - AAC.00069-20 [pii]
AID - 00069-20 [pii]
AID - 10.1128/AAC.00069-20 [doi]
PST - epublish
SO  - Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00069-20. doi: 
      10.1128/AAC.00069-20. Print 2020 Jun 23.

PMID- 7013009
OWN - NLM
STAT- MEDLINE
DCOM- 19810623
LR  - 20191031
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - 20
IP  - 1
DP  - 1981 Feb 1
TI  - Isoxepac in rheumatoid arthritis: a double-blind comparison with aspirin.
PG  - 50-3
AB  - Nineteen patients with rheumatoid arthritis entered a double-blind cross-over 
      study, comparing a new anti-inflammatory agent isoxepac, 200 mg three times 
      daily, with aspirin 1.2 g three times daily. Eighteen patients completed 2-4 
      weeks treatment with each drug. The treatments were similar when assessed by 
      measurement of joint pain, grip strength, morning stiffness, patients' global 
      assessment and overall preference. Significantly fewer adverse effects were 
      associated with isoxepac therapy when compared with aspirin therapy.
FAU - Gerlis, L S
AU  - Gerlis LS
FAU - Gumpel, J M
AU  - Gumpel JM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Acetates)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Dibenzoxepins)
RN  - 2KH283Q0Z5 (isoxepac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dibenzoxepins/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
AID - 10.1093/rheumatology/20.1.50 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1981 Feb 1;20(1):50-3. doi: 10.1093/rheumatology/20.1.50.

PMID- 25120015
OWN - NLM
STAT- MEDLINE
DCOM- 20150708
LR  - 20211021
IS  - 1558-822X (Electronic)
IS  - 1558-8211 (Linking)
VI  - 9
IP  - 4
DP  - 2014 Dec
TI  - Antiplatelet therapy in the management of myeloproliferative neoplasms.
PG  - 319-23
LID - 10.1007/s11899-014-0226-1 [doi]
AB  - Low-dose acetylsalicylic acid (ASA) is given to most patients with polycythemia 
      vera (PV) and essential thrombocythemia (ET) although some uncertainties 
      encompass this clinical practice. In patients with history of thrombosis, the use 
      of ASA is supported on the results observed in the general population showing a 
      substantial net benefit of this treatment in preventing thrombosis. In the 
      European collaboration study on low-dose aspirin in polycythemia vera (ECLAP), 
      ASA reduced the risk of thrombosis without increasing the risk of major bleeding 
      when compared with placebo, supporting the primary prevention of thrombosis in 
      PV. In ET, the efficacy of low-dose ASA has not been tested in randomized 
      clinical trials. Two retrospective studies have shown that low-dose ASA could 
      benefit ET patients older than 60 years when combined with cytoreduction, whereas 
      in young, low-risk patients, ASA benefits to particular subgroups of patients. In 
      spite of the fact that in primary myelofibrosis the incidence of thrombosis is 
      increased, the use of ASA is not clearly recommended.
FAU - Alvarez-Larrán, Alberto
AU  - Alvarez-Larrán A
AD  - Hematology Department, Hospital del Mar, IMIM, Universitat Autònoma de Barcelona, 
      Passeig Marítim 25-29, 08003, Barcelona, Spain, 95967@parcdesalutmar.cat.
FAU - Besses, Carlos
AU  - Besses C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Hematol Malig Rep
JT  - Current hematologic malignancy reports
JID - 101262565
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Disease Management
MH  - Female
MH  - Humans
MH  - Male
MH  - Myeloproliferative Disorders/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Polycythemia Vera/*drug therapy
MH  - Thrombocythemia, Essential/*drug therapy
EDAT- 2014/08/15 06:00
MHDA- 2015/07/15 06:00
CRDT- 2014/08/15 06:00
PHST- 2014/08/15 06:00 [entrez]
PHST- 2014/08/15 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - 10.1007/s11899-014-0226-1 [doi]
PST - ppublish
SO  - Curr Hematol Malig Rep. 2014 Dec;9(4):319-23. doi: 10.1007/s11899-014-0226-1.

PMID- 3588660
OWN - NLM
STAT- MEDLINE
DCOM- 19870708
LR  - 20180214
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 34
IP  - 2-3
DP  - 1987
TI  - Aspirin, indomethacin, and tartrazine increase carotid-sinus-nerve activity and 
      arterial blood pressure in guinea pigs.
PG  - 96-103
AB  - Acetylsalicylic acid (ASA; 0.1-10 mg/kg), indomethacin (IND; 0.1-1.0 mg/kg), and 
      tartrazine (TZ; 0.1-2.0 mg/kg), given intravenously induced dose-dependent 
      increases in carotid-sinus nerve (CSN) activity, accompanied by increases in mean 
      arterial blood pressure (MABP), but only the IND-induced MABP increases were 
      dose-dependent. The MABP and CSN activity responses to all three drugs were not 
      correlated, suggesting a direct action on CSN afferents that is unrelated to the 
      pressor effects of the drugs. Sodium cromoglycate (10 mg/kg) selectively reduced 
      the increases in CSN response to ASA and IND. Phentolamine (0.2 mg/kg) inhibited 
      the increased CSN activity induced by ASA, IND, and TZ. These findings indicate 
      that ASA, IND, and TZ act directly on carotid baroreceptors to increase their 
      activity.
FAU - D'Souza, S J
AU  - D'Souza SJ
FAU - Biggs, D F
AU  - Biggs DF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Azo Compounds)
RN  - 1WS297W6MV (Phenylephrine)
RN  - I753WB2F1M (Tartrazine)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Azo Compounds/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Carotid Sinus/*innervation
MH  - Female
MH  - Guinea Pigs
MH  - Indomethacin/*pharmacology
MH  - Neurons/drug effects
MH  - Phenylephrine/pharmacology
MH  - Stimulation, Chemical
MH  - Tartrazine/*pharmacology
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1159/000138258 [doi]
PST - ppublish
SO  - Pharmacology. 1987;34(2-3):96-103. doi: 10.1159/000138258.

PMID- 1179461
OWN - NLM
STAT- MEDLINE
DCOM- 19751228
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 6
IP  - 5
DP  - 1975 Sep-Oct
TI  - Increased platelet aggregates in patients with transient ischemic attacks.
PG  - 521-4
AB  - In order to evaluate the pathogenetic importance of platelet aggregates in 
      cerebrovascular disease, a platelet count ratio method was used to study 66 
      patients with transient ischemic attacks (TIAs). Thirty normal subjects and 22 
      patients without thromboembolic disorders were also included as controls. The 
      mean platelet aggregate ratio of the TIA group was 0.75 +/- 0.03 SEM which was 
      significantly lower than that of normal subjects (0.90 +/- 0.02) or patients 
      controls (0.88 +/- 0.01) (P less than 0.01). Seventeen patients with TIA were 
      then treated with aspirin (1,200 mg) and dipyridamole (200 mg) daily. The 
      platelet aggregate ratios were normalized in 13 patients. Of four patients who 
      did not respond to this regimen, one did respond to sulfinpyrazone. When 
      sulfinpyrazone was discontinued, recurrence of symptoms was preceded by an 
      increase in platelet aggregates. These findings suggest that platelet aggregates 
      may play an important role in the pathogenesis of cerebrovascular insufficiency. 
      The determination of platelet aggregates appears useful in selecting patients for 
      antiplatelet therapy.
FAU - Wu, K K
AU  - Wu KK
FAU - Hoak, J C
AU  - Hoak JC
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*blood
MH  - Male
MH  - Middle Aged
MH  - *Platelet Aggregation
MH  - Sulfinpyrazone/therapeutic use
EDAT- 1975/09/01 00:00
MHDA- 1975/09/01 00:01
CRDT- 1975/09/01 00:00
PHST- 1975/09/01 00:00 [pubmed]
PHST- 1975/09/01 00:01 [medline]
PHST- 1975/09/01 00:00 [entrez]
AID - 10.1161/01.str.6.5.521 [doi]
PST - ppublish
SO  - Stroke. 1975 Sep-Oct;6(5):521-4. doi: 10.1161/01.str.6.5.521.

PMID- 19440925
OWN - NLM
STAT- MEDLINE
DCOM- 20090901
LR  - 20220409
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 20
IP  - 4
DP  - 2009 Jun
TI  - Measurement of platelet P-selectin for remote testing of platelet function during 
      treatment with clopidogrel and/or aspirin.
PG  - 250-9
LID - 10.1080/09537100902912451 [doi]
AB  - There is great interest in assessing the efficacy of treatment with clopidogrel 
      and aspirin in patients with cardiovascular disease using procedures that can be 
      used in a remote setting. Here we have established methods to assess the effects 
      of clopidogrel and aspirin on platelets based on measurements of platelet 
      P-selectin. Platelets were stimulated in whole blood by adding the combination of 
      adenosine diphosphate and the TXA(2) mimetic U46619 (ADP/U4, designed to assess 
      P2Y(12) inhibition) or the combination of arachidonic acid and epinephrine 
      (AA/Epi, designed to assess COX-1 inhibition). The stimulated samples were then 
      fixed using a fixative solution that provides stability for at least 9 days, and 
      sent to a central laboratory for analysis of P-selectin by flow cytometry. 
      Measurements were performed in blood from healthy volunteers and patients with 
      cardiovascular disease. The inhibitory effects of clopidogrel and aspirin were 
      assessed ex vivo and the effects of the direct acting P2Y(12) antagonist 
      cangrelor and aspirin were assessed in vitro. Measurements of platelet 
      aggregation were also performed for comparison. In healthy volunteers clopidogrel 
      ex vivo and cangrelor in vitro markedly inhibited P-selectin expression induced 
      by ADP/U4. Aspirin did not inhibit and did not interfere with the effects of 
      clopidogrel or cangrelor using this test. There was very little overlap of 
      results obtained in the absence and presence of clopidogrel or cangrelor. In 
      contrast, over half of 42 patients with cardiovascular disease did not respond 
      well to clopidogrel treatment, although cangrelor was still effective. Aspirin 
      markedly inhibited P-selectin expression induced by AA/Epi. Clopidogrel had much 
      less effect and did not interfere with the effects of aspirin. There was no 
      overlap of results obtained in the absence and presence of aspirin. Aspirin 
      provided near-complete inhibition in 29 of 30 patients with cardiovascular 
      disease. Aggregometry measurements agreed well with the P-selectin data obtained 
      ex vivo following both clopidogrel and aspirin treatment. It is concluded that 
      measurements of P-selectin performed on fixed blood samples following platelet 
      stimulation in whole blood in a remote setting can be used effectively to monitor 
      the effects of clopidogrel and aspirin.
FAU - Fox, S C
AU  - Fox SC
AD  - Cardiovascular Medicine, Queens Medical Centre, Nottingham, UK. 
      sue.fox@nottingham.ac.uk
FAU - May, J A
AU  - May JA
FAU - Shah, A
AU  - Shah A
FAU - Neubert, U
AU  - Neubert U
FAU - Heptinstall, S
AU  - Heptinstall S
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 6AQ1Y404U7 (cangrelor)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adenosine Monophosphate/analogs & derivatives/pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cardiovascular Diseases/blood/drug therapy
MH  - Case-Control Studies
MH  - Clopidogrel
MH  - Drug Monitoring/*methods
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Male
MH  - P-Selectin/*analysis
MH  - Platelet Activation
MH  - Platelet Aggregation Inhibitors
MH  - Platelet Function Tests/*methods
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Tissue Fixation
EDAT- 2009/05/15 09:00
MHDA- 2009/09/02 06:00
CRDT- 2009/05/15 09:00
PHST- 2009/05/15 09:00 [entrez]
PHST- 2009/05/15 09:00 [pubmed]
PHST- 2009/09/02 06:00 [medline]
AID - 911179139 [pii]
AID - 10.1080/09537100902912451 [doi]
PST - ppublish
SO  - Platelets. 2009 Jun;20(4):250-9. doi: 10.1080/09537100902912451.

PMID- 12187896
OWN - NLM
STAT- MEDLINE
DCOM- 20020925
LR  - 20131121
IS  - 0035-2640 (Print)
IS  - 0035-2640 (Linking)
VI  - 52
IP  - 12
DP  - 2002 Jun 15
TI  - [Antithrombotic drugs in atrial fibrillation].
PG  - 1324-8
AB  - Stroke and peripheral thrombo-embolism are common in all forms of atrial 
      fibrillation which is responsible for a hypercoagulable state. Clinical and 
      echocardiographic risk stratification allow therapeutic recommendations among the 
      different antithrombotic strategies used in randomized studies (adjusted-dose 
      oral anticoagulant, aspirin or a combination of aspirin and low-dose oral 
      anticoagulant) in agreement with recent guidelines from the European and American 
      associations of cardiology for the managMent of patients with atrial 
      fibrillation.
FAU - Hidden-Lucet, Françoise
AU  - Hidden-Lucet F
AD  - Unité de rythmologie Institut de cardiologie Groupe hospitalier la Pitié-la 
      Salpêtrière AP-HP 75651 Paris. francoise.hidden-lucet@psl.ap-hop-paris.fr
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Médicaments antithrombotiques dans la fibrillation atriale.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Risk Factors
RF  - 22
EDAT- 2002/08/22 10:00
MHDA- 2002/09/26 06:00
CRDT- 2002/08/22 10:00
PHST- 2002/08/22 10:00 [pubmed]
PHST- 2002/09/26 06:00 [medline]
PHST- 2002/08/22 10:00 [entrez]
PST - ppublish
SO  - Rev Prat. 2002 Jun 15;52(12):1324-8.

PMID- 12466747
OWN - NLM
STAT- MEDLINE
DCOM- 20030103
LR  - 20131121
IS  - 1531-0132 (Electronic)
IS  - 1531-0132 (Linking)
VI  - 4
IP  - 3
DP  - 2002 Sep 20
TI  - Air travel and venous thrombosis: how much help might aspirin be?
PG  - 4
AB  - There has been considerable attention focused recently on the risk of deep venous 
      thrombosis (DVT) associated with air travel. Despite the lack of evidence among 
      air travelers, a single dose of aspirin has been widely recommended as a means of 
      preventing such thrombosis. We have calculated the potential benefit of aspirin 
      by applying the data for aspirin in preventing DVT in hip fracture patients to 
      the estimated rates of travel-related DVT. If the rate of travel-related DVT is 
      20 per 100,000 travelers, then we will have to treat 17,000 people with aspirin 
      to prevent 1 additional DVT.
FAU - Loke, Yoon K
AU  - Loke YK
AD  - University of Oxford, Oxford, United Kingdom. yoon.loke@clinpharm.ox.ac.uk
FAU - Derry, Sheena
AU  - Derry S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20020920
PL  - United States
TA  - MedGenMed
JT  - MedGenMed : Medscape general medicine
JID - 100894134
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Aircraft
MH  - Aspirin/*therapeutic use
MH  - Evidence-Based Medicine/statistics & numerical data
MH  - Female
MH  - Humans
MH  - MEDLINE/statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Smoking/adverse effects
MH  - *Travel
MH  - Venous Thrombosis/*prevention & control
EDAT- 2002/12/06 04:00
MHDA- 2003/01/07 04:00
CRDT- 2002/12/06 04:00
PHST- 2002/12/06 04:00 [pubmed]
PHST- 2003/01/07 04:00 [medline]
PHST- 2002/12/06 04:00 [entrez]
AID - 441153 [pii]
PST - epublish
SO  - MedGenMed. 2002 Sep 20;4(3):4.

PMID- 12076987
OWN - NLM
STAT- MEDLINE
DCOM- 20020726
LR  - 20190616
IS  - 0077-8923 (Print)
IS  - 0077-8923 (Linking)
VI  - 962
DP  - 2002 May
TI  - Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic 
      agents.
PG  - 360-71
AB  - Nitric oxide (NO) deficiency has been implicated in many pathologic processes, 
      thus providing a solid biological basis for the use of NO replacement therapy. 
      Exogenous NO sources constitute a powerful way to supplement NO when the body 
      cannot generate sufficient NO for normal biological functions. This theory has 
      opened up the possibility of designing new drugs that are capable of delivering 
      NO into tissues and the bloodstream in a sustained and controlled manner. This 
      objective has been achieved by grafting an organic nitrate structure onto 
      existing drugs through chemical spacers, such as aliphatic, aromatic, or a 
      heterocyclic chain. The approach has led to the synthesis of several new chemical 
      entities whose pharmacologic profile challenges the parent drug, not only on the 
      basis of new properties, but also with respect to a better safety profile. In 
      this article, a specific class of NO donors is reviewed, the nitric 
      oxide-releasing non-steroidal antiinflammatory drugs, NO-NSAIDs. Recently 
      discovered compounds, whose action depends on the combined properties of both the 
      known drug and NO release, are illustrated. Two examples are described in detail: 
      (1) nitric oxide-releasing aspirin, which has demonstrable innovative properties 
      for treatment of vascular disorders and cancer; (2) nitro-derivatives of 
      flurbiprofen that have shown encouraging results in models of Alzheimer's 
      disease.
FAU - Burgaud, Jean-Luc
AU  - Burgaud JL
AD  - NicOx SA, Espace Gaia II - Bâtiment I BP 313, Sophia Antipolis, France.
FAU - Ongini, Ennio
AU  - Ongini E
FAU - Del Soldato, Piero
AU  - Del Soldato P
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nitric Oxide Donors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/metabolism/therapeutic use
MH  - Aspirin/chemistry/metabolism
MH  - Flurbiprofen/chemistry/metabolism/therapeutic use
MH  - Humans
MH  - Molecular Structure
MH  - Nitric Oxide/chemistry/*metabolism
MH  - Nitric Oxide Donors/chemistry/*metabolism/therapeutic use
RF  - 51
EDAT- 2002/06/22 10:00
MHDA- 2002/07/27 10:01
CRDT- 2002/06/22 10:00
PHST- 2002/06/22 10:00 [pubmed]
PHST- 2002/07/27 10:01 [medline]
PHST- 2002/06/22 10:00 [entrez]
AID - 10.1111/j.1749-6632.2002.tb04080.x [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2002 May;962:360-71. doi: 10.1111/j.1749-6632.2002.tb04080.x.

PMID- 7297912
OWN - NLM
STAT- MEDLINE
DCOM- 19820128
LR  - 20201209
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 22
IP  - 10
DP  - 1981 Oct
TI  - Changes in potential difference across the human buccal mucosa with buffered or 
      unbuffered aspirin and salicylate.
PG  - 798-803
AB  - The potential difference (PD) across the gastric mucosa is an index of mucosal 
      integrity, and is lowered by topical application of irritants such as aspirin. 
      There are basic similarities in the PD across the buccal and gastric mucosae, and 
      we have therefore investigated the actions of various salicylates in buffered or 
      un-buffered solution on buccal PD in human subjects. Aspirin (at pH 2) and 
      soluble aspirin (pH 4.4) applied topically reduced buccal PD, but this fall was 
      abolished by buffering to pH 7. Sodium salicylate likewise reduced buccal PD at 
      pH 4 and pH 6, but not when buffered to pH 7. Two other soluble aspirin mixtures 
      also reduced buccal PD, indicating insufficient buffering capacity to prevent 
      topical irritancy. Ingestion of aspirin (600 mg), avoiding topical contact with 
      the buccal mucosa, did not alter buccal PD. Paracetamol applied topically 
      likewise failed to reduce buccal PD. Measurement of buccal PD may be useful in 
      the preliminary assessment of the gastrointestinal irritation provoked by 
      anti-inflammatory and other compounds.
FAU - Whittle, B J
AU  - Whittle BJ
FAU - Makki, K A
AU  - Makki KA
FAU - O'Grady, J
AU  - O'Grady J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Buffers)
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Acetaminophen/pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Buffers
MH  - Cheek
MH  - Codeine/pharmacology
MH  - Drug Combinations
MH  - Electrophysiology
MH  - Humans
MH  - Mouth Mucosa/*drug effects
MH  - Sodium Salicylate/*pharmacology
PMC - PMC1419425
EDAT- 1981/10/01 00:00
MHDA- 1981/10/01 00:01
CRDT- 1981/10/01 00:00
PHST- 1981/10/01 00:00 [pubmed]
PHST- 1981/10/01 00:01 [medline]
PHST- 1981/10/01 00:00 [entrez]
AID - 10.1136/gut.22.10.798 [doi]
PST - ppublish
SO  - Gut. 1981 Oct;22(10):798-803. doi: 10.1136/gut.22.10.798.

PMID- 17393749
OWN - NLM
STAT- MEDLINE
DCOM- 20070503
LR  - 20131121
IS  - 1098-1861 (Print)
IS  - 1098-1861 (Linking)
VI  - 106
IP  - 1
DP  - 2007 Feb
TI  - Clinical use of evidence-based medicine--clinical questions. Is low-dose aspirin 
      a better choice in patients with coronary artery disease and bleeding risks?
PG  - 7-8
AB  - This post-hoc analysis of the large, randomized controlled trial (CURE trial) 
      shows a statistically significant increase in the risk of primary end points 
      including CVA, cardiovascular death, and myocardial infarction with the use of 
      high-dose aspirin therapy. Additionally, there was an increased incidence of 
      major and life-threatening bleeding events in the high-dose aspirin group. This 
      study should be interpreted with caution given its significant limitations: 
      patients were not randomized based on ASA dose; patients and doctors were not 
      blinded to the ASA dosage; study population groups were not equal at baseline; 
      groups were treated differently depending on geographic location. Finally, given 
      the nature of a cohort study, we would hope to see a larger magnitude of 
      treatment effect to overcome the unknown confounding variables. There is 
      currently no high quality evidence on the risk of bleeding with high-dose ASA 
      versus low-dose ASA. The current evidence does not support using high-dose ASA 
      therapy in patients with known coronary artery disease and a history of 
      gastrointestinal bleeding.
FAU - Hsu, Jennifer
AU  - Hsu J
AD  - Department of Internal Medicine, University of Wisconsin Hospital and Clinics, 
      USA.
FAU - Pack, Quinn
AU  - Pack Q
FAU - Feldstein, David A
AU  - Feldstein DA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - WMJ
JT  - WMJ : official publication of the State Medical Society of Wisconsin
JID - 9716054
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Coronary Disease/*drug therapy
MH  - Evidence-Based Medicine
MH  - Gastrointestinal Hemorrhage/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Randomized Controlled Trials as Topic
EDAT- 2007/03/31 09:00
MHDA- 2007/05/04 09:00
CRDT- 2007/03/31 09:00
PHST- 2007/03/31 09:00 [pubmed]
PHST- 2007/05/04 09:00 [medline]
PHST- 2007/03/31 09:00 [entrez]
PST - ppublish
SO  - WMJ. 2007 Feb;106(1):7-8.

PMID- 1333782
OWN - NLM
STAT- MEDLINE
DCOM- 19930112
LR  - 20190509
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 34
IP  - 4
DP  - 1992 Oct
TI  - The low-chloride cough response is not inhibited by a single, high dose of 
      aspirin.
PG  - 370-2
AB  - The effect of a single, high dose of aspirin has been assessed against low 
      chloride cough challenge. The drug does not affect the cough response, suggesting 
      that airway prostaglandin generation is not responsible for the tussive activity 
      of low chloride solution.
FAU - Stone, R A
AU  - Stone RA
AD  - Department of Thoracic Medicine, National Heart and Lung Institute, London.
FAU - Barnes, P J
AU  - Barnes PJ
FAU - Fuller, R W
AU  - Fuller RW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Bicarbonates)
RN  - 0 (Chlorides)
RN  - 8MDF5V39QO (Sodium Bicarbonate)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Bicarbonates
MH  - *Chlorides/administration & dosage
MH  - Cough/chemically induced/*physiopathology
MH  - Double-Blind Method
MH  - Humans
MH  - Sodium
MH  - Sodium Bicarbonate
PMC - PMC1381423
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1992.tb05645.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1992 Oct;34(4):370-2. doi: 
      10.1111/j.1365-2125.1992.tb05645.x.

PMID- 16714187
OWN - NLM
STAT- MEDLINE
DCOM- 20060608
LR  - 20220318
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 367
IP  - 9523
DP  - 2006 May 20
TI  - Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of 
      arterial origin (ESPRIT): randomised controlled trial.
PG  - 1665-73
AB  - BACKGROUND: Results of trials of aspirin and dipyridamole combined versus aspirin 
      alone for the secondary prevention of vascular events after ischaemic stroke of 
      presumed arterial origin are inconsistent. Our aim was to resolve this 
      uncertainty. METHODS: We did a randomised controlled trial in which we assigned 
      patients to aspirin (30-325 mg daily) with (n=1363) or without (n=1376) 
      dipyridamole (200 mg twice daily) within 6 months of a transient ischaemic attack 
      or minor stroke of presumed arterial origin. Our primary outcome event was the 
      composite of death from all vascular causes, non-fatal stroke, non-fatal 
      myocardial infarction, or major bleeding complication, whichever happened first. 
      Treatment was open, but auditing of outcome events was blinded. Primary analysis 
      was by intention to treat. This study is registered as an International Standard 
      Randomised Controlled Trial (number ISRCTN73824458) and with (NCT00161070). 
      FINDINGS: Mean follow-up was 3.5 years (SD 2.0). Median aspirin dose was 75 mg in 
      both treatment groups (range 30-325); extended-release dipyridamole was used by 
      83% (n=1131) of patients on the combination regimen. Primary outcome events arose 
      in 173 (13%) patients on aspirin and dipyridamole and in 216 (16%) on aspirin 
      alone (hazard ratio 0.80, 95% CI 0.66-0.98; absolute risk reduction 1.0% per 
      year, 95% CI 0.1-1.8). Addition of the ESPRIT data to the meta-analysis of 
      previous trials resulted in an overall risk ratio for the composite of vascular 
      death, stroke, or myocardial infarction of 0.82 (95% CI 0.74-0.91). Patients on 
      aspirin and dipyridamole discontinued trial medication more often than those on 
      aspirin alone (470 vs 184), mainly because of headache. INTERPRETATION: The 
      ESPRIT results, combined with the results of previous trials, provide sufficient 
      evidence to prefer the combination regimen of aspirin plus dipyridamole over 
      aspirin alone as antithrombotic therapy after cerebral ischaemia of arterial 
      origin.
CN  - ESPRIT Study Group
FAU - Halkes, P H A
AU  - Halkes PH
FAU - van Gijn, J
AU  - van Gijn J
FAU - Kappelle, L J
AU  - Kappelle LJ
FAU - Koudstaal, P J
AU  - Koudstaal PJ
FAU - Algra, A
AU  - Algra A
LA  - eng
SI  - ClinicalTrials.gov/NCT00161070
SI  - ISRCTN/ISRCTN73824458
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Lancet. 2007 Jan 27;369(9558):274
CIN - Lancet. 2006 May 20;367(9523):1638-9. PMID: 16714170
CIN - Lancet. 2006 Aug 5;368(9534):447-8; author reply 449. PMID: 16890823
CIN - Lancet. 2006 Aug 5;368(9534):447; author reply 449. PMID: 16890824
CIN - Lancet. 2006 Aug 5;368(9534):448; author reply 449. PMID: 16890825
CIN - Lancet. 2006 Aug 5;368(9534):448-9; author reply 449. PMID: 16890826
CIN - ACP J Club. 2006 Nov-Dec;145(3):57. PMID: 17080969
CIN - Evid Based Med. 2006 Dec;11(6):169. PMID: 17213163
CIN - Curr Neurol Neurosci Rep. 2007 Jan;7(1):4. PMID: 17217847
CIN - Curr Cardiol Rep. 2007 Mar;9(1):5-6. PMID: 17362683
CIN - Perspect Vasc Surg Endovasc Ther. 2007 Mar;19(1):87-9. PMID: 17437989
CIN - Postgrad Med. 2010 Nov;122(6):227-9. PMID: 21084797
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Dipyridamole/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/complications
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Stroke/etiology/*prevention & control
EDAT- 2006/05/23 09:00
MHDA- 2006/06/09 09:00
CRDT- 2006/05/23 09:00
PHST- 2006/05/23 09:00 [pubmed]
PHST- 2006/06/09 09:00 [medline]
PHST- 2006/05/23 09:00 [entrez]
AID - S0140-6736(06)68734-5 [pii]
AID - 10.1016/S0140-6736(06)68734-5 [doi]
PST - ppublish
SO  - Lancet. 2006 May 20;367(9523):1665-73. doi: 10.1016/S0140-6736(06)68734-5.

PMID- 25126950
OWN - NLM
STAT- MEDLINE
DCOM- 20151215
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 8
DP  - 2014
TI  - Aspirin delimits platelet life span by proteasomal inhibition.
PG  - e105049
LID - 10.1371/journal.pone.0105049 [doi]
LID - e105049
AB  - Aspirin is widely used in clinical settings as an anti-inflammatory and 
      anti-platelet drug due its inhibitory effect on cyclooxygenase activity. Although 
      the drug has long been considered to be an effective and safe therapeutic regime 
      against inflammatory and cardiovascular disorders, consequences of its 
      cyclooxygenase-independent attributes on platelets, the key players in 
      thrombogenesis, beg serious investigation. In this report we explored the effect 
      of aspirin on platelet lifespan in murine model and its possible cytotoxicity 
      against human platelets in vitro. Aspirin administration in mice led to 
      significant reduction in half-life of circulating platelets, indicative of 
      enhanced rate of platelet clearance. Aspirin-treated human platelets were found 
      to be phagocytosed more efficiently by macrophages, associated with attenuation 
      in platelet proteasomal activity and upregulation of conformationally active Bax, 
      which were consistent with enhanced platelet apoptosis. Although the dosage of 
      aspirin administered in mice was higher than the therapeutic regimen against 
      cardiovascular events, it is comparable with the recommended anti-inflammatory 
      prescription. Thus, above observations provide cautionary framework to critically 
      re-evaluate prophylactic and therapeutic dosage regime of aspirin in systemic 
      inflammatory as well as cardiovascular ailments.
FAU - Nayak, Manasa K
AU  - Nayak MK
AD  - Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu 
      University, Varanasi, India.
FAU - Dash, Ayusman
AU  - Dash A
AD  - Indian Institute of Science Education and Research, Kolkata, India.
FAU - Singh, Nitesh
AU  - Singh N
AD  - Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu 
      University, Varanasi, India.
FAU - Dash, Debabrata
AU  - Dash D
AD  - Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu 
      University, Varanasi, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140815
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proteasome Inhibitors)
RN  - EC 3.4.25.1 (Proteasome Endopeptidase Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - PLoS One. 2014;9(12):e115927
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/cytology/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Mice
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Proteasome Endopeptidase Complex/metabolism
MH  - Proteasome Inhibitors/*pharmacology
PMC - PMC4134270
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/08/16 06:00
MHDA- 2015/12/17 06:00
CRDT- 2014/08/16 06:00
PHST- 2013/11/12 00:00 [received]
PHST- 2014/07/20 00:00 [accepted]
PHST- 2014/08/16 06:00 [entrez]
PHST- 2014/08/16 06:00 [pubmed]
PHST- 2015/12/17 06:00 [medline]
AID - PONE-D-13-46964 [pii]
AID - 10.1371/journal.pone.0105049 [doi]
PST - epublish
SO  - PLoS One. 2014 Aug 15;9(8):e105049. doi: 10.1371/journal.pone.0105049. 
      eCollection 2014.

PMID- 8904056
OWN - NLM
STAT- MEDLINE
DCOM- 19970214
LR  - 20131121
IS  - 0012-835X (Print)
IS  - 0012-835X (Linking)
VI  - 72
IP  - 11
DP  - 1995 Nov
TI  - Low dose aspirin in prevention of pregnancy-induced hypertension in primigravidae 
      at the Muhimbili Medical Center, Dar es Salaam.
PG  - 690-3
AB  - There is evidence that aspirin in low doses favourably influences the course and 
      outcome of pregnancy in women at risk of developing pregnancy-induced 
      hypertension. We conducted a double blind prospective randomized study to 
      investigate the effect of low dose aspirin in preventing pregnancy-induced 
      hypertension. Two hundred and one primigravidae from twenty weeks of pregnancy 
      and above were screened using the roll-over test. Of the 127 women with an 
      increase in blood pressure during the roll-over test, 126 women entered the study 
      and were treated with a daily dose of either aspirin (80 mg) or placebo up to 10 
      days before the expected date of delivery. Samples of urine were collected for 
      detection of aspirin. The incidence of pregnancy-induced hypertension in the 
      aspirin treated group was significantly lower than in the placebo treated group; 
      3.17% versus 15.9% with a p value of 0.02. It is concluded that low daily doses 
      of aspirin taken from twenty weeks of pregnancy significantly reduce the 
      incidence of pregnancy-induced hypertension, possibly through the correction of 
      an imbalance in levels of thromboxane and prostacyclin.
FAU - Ramaiya, C
AU  - Ramaiya C
AD  - T.M.J. Medical Clinic, Dar es Salaam, Tanzania.
FAU - Mgaya, H N
AU  - Mgaya HN
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Kenya
TA  - East Afr Med J
JT  - East African medical journal
JID - 0372766
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - East Afr Med J. 1995 Nov;72(11):689. PMID: 8904055
MH  - Aspirin/*therapeutic use
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Pre-Eclampsia/diagnosis/*drug therapy
MH  - Pregnancy
MH  - Prospective Studies
MH  - Tanzania
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
PST - ppublish
SO  - East Afr Med J. 1995 Nov;72(11):690-3.

PMID- 24745726
OWN - NLM
STAT- MEDLINE
DCOM- 20141222
LR  - 20140520
IS  - 1532-1681 (Electronic)
IS  - 0268-960X (Linking)
VI  - 28
IP  - 3
DP  - 2014 May
TI  - Aspirin for prevention and treatment of venous thromboembolism.
PG  - 103-8
LID - S0268-960X(14)00029-0 [pii]
LID - 10.1016/j.blre.2014.03.003 [doi]
AB  - Venous and arterial thromboses have been regarded for many years as two different 
      diseases requiring anticoagulant or antiplatelet treatment, respectively. 
      Platelets have a role in venous thromboembolism through several mechanisms, 
      including the formation of and adhesion to the neutrophil extracellular traps, as 
      recently demonstrated. When given for antithrombotic prophylaxis in high risk 
      medical or surgical patients, aspirin was shown to reduce the incidence of venous 
      thromboembolism in clinical studies and meta-analyses. However, controversial 
      recommendations have been released on the role of aspirin for the prevention of 
      venous thromboembolism. Two randomized, double blind trials have recently shown a 
      reduction of recurrence by about 30% with aspirin compared to placebo in patients 
      who had completed treatment with vitamin K antagonists for a first episode of 
      unprovoked venous thromboembolism. The clinical value of this risk reduction in 
      comparison to that obtained with warfarin and the new oral anticoagulant agents, 
      should take into account the low risk for bleeding and costs associated with 
      aspirin. Given its safety, worldwide availability and low cost, aspirin can be 
      considered a valid alternative to oral anticoagulants for the extended treatment 
      of venous thromboembolism after a first unprovoked event.
CI  - Copyright © 2014 Elsevier Ltd. All rights reserved.
FAU - Becattini, Cecilia
AU  - Becattini C
AD  - Internal and Cardiovascular Medicine, Stroke Unit, University of Perugia, 
      Perugia, Italy. Electronic address: cecilia.becattini@unipg.it.
FAU - Agnelli, Giancarlo
AU  - Agnelli G
AD  - Internal and Cardiovascular Medicine, Stroke Unit, University of Perugia, 
      Perugia, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140401
PL  - England
TA  - Blood Rev
JT  - Blood reviews
JID - 8708558
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Venous Thromboembolism/blood/*drug therapy/*prevention & control
OTO - NOTNLM
OT  - Apixaban
OT  - Aspirin
OT  - Dabigatran
OT  - Edoxaban
OT  - Oral anticoagulants
OT  - Pulmonary embolism
OT  - Rivaroxaban
OT  - Venous thromboembolism
OT  - Venous thrombosis
EDAT- 2014/04/22 06:00
MHDA- 2014/12/23 06:00
CRDT- 2014/04/22 06:00
PHST- 2014/01/02 00:00 [received]
PHST- 2014/03/14 00:00 [accepted]
PHST- 2014/04/22 06:00 [entrez]
PHST- 2014/04/22 06:00 [pubmed]
PHST- 2014/12/23 06:00 [medline]
AID - S0268-960X(14)00029-0 [pii]
AID - 10.1016/j.blre.2014.03.003 [doi]
PST - ppublish
SO  - Blood Rev. 2014 May;28(3):103-8. doi: 10.1016/j.blre.2014.03.003. Epub 2014 Apr 
      1.

PMID- 15766098
OWN - NLM
STAT- MEDLINE
DCOM- 20100603
LR  - 20131121
IS  - 1000-0593 (Print)
IS  - 1000-0593 (Linking)
VI  - 24
IP  - 7
DP  - 2004 Jul
TI  - [Determination of three components in compound acetylsalicylic acid tablet by 
      dual-wavelength ratio spectrometry].
PG  - 883-6
AB  - The contents of three components in compound acetylsalicylic acid tablets were 
      determined by dual-wavelength ratio spectrometry. According to the feature of the 
      spectra, 213, 227, 245 and 265 nm were chosen as the determining wavelengths. It 
      is shown that for the three components good linear correlations exist for 
      acetylsalicylic acid (5-20 microg x mL(-1)), phenacetin (2-10 microg x mL(-1)), 
      and caffeine (2-20 microg x mL(-1)). The average recoveries were 100.03%, 100.23% 
      and 99.96% respectively. The results were consistent with those obtained by the 
      standard method of Health Ministry(P > 0.05). The method is simple and practical 
      with fewer determination wavelengths and powerful spectral resolution, and can be 
      performed on a lower level instrument, as well as be easily spreaded for 
      application.
FAU - Zeng-xian, Sun
AU  - Zeng-xian S
AD  - No. 1 Hospital of Lianyungang, Lianyungang 222002, China.
FAU - Qian-feng, Zhang
AU  - Qian-feng Z
FAU - Jin-yu, Zhou
AU  - Jin-yu Z
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Guang Pu Xue Yu Guang Pu Fen Xi
JT  - Guang pu xue yu guang pu fen xi = Guang pu
JID - 9424805
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Tablets)
RN  - 3G6A5W338E (Caffeine)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Caffeine/analysis
MH  - Drug Compounding
MH  - Drugs, Chinese Herbal/chemistry
MH  - Phenacetin/*analysis
MH  - Spectrometry, Fluorescence/methods
MH  - Spectrophotometry, Infrared
MH  - Spectrophotometry, Ultraviolet
MH  - Spectrum Analysis/*methods
MH  - Tablets/*analysis
EDAT- 2005/03/16 09:00
MHDA- 2010/06/04 06:00
CRDT- 2005/03/16 09:00
PHST- 2005/03/16 09:00 [pubmed]
PHST- 2010/06/04 06:00 [medline]
PHST- 2005/03/16 09:00 [entrez]
PST - ppublish
SO  - Guang Pu Xue Yu Guang Pu Fen Xi. 2004 Jul;24(7):883-6.

PMID- 2029709
OWN - NLM
STAT- MEDLINE
DCOM- 19910619
LR  - 20190510
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 25
IP  - 3
DP  - 1991 Mar
TI  - Effect of dipyridamole alone and in combination with aspirin on whole blood 
      platelet aggregation, PGI2 generation, and red cell deformability ex vivo in man.
PG  - 177-83
AB  - STUDY OBJECTIVE: The aim was to investigate the effects of dipyridamole, aspirin, 
      and a combination of dipyridamole plus aspirin on platelet aggregation in whole 
      blood, PGI2 generation, and red cell deformability ex vivo. SUBJECTS: were 16 
      male volunteers, aged 22-39 years, mean age, 26.6 years. DESIGN: This was a 
      randomised, double blind, placebo controlled trial. The volunteer received each 
      of the following treatments 10 days apart: dipyridamole 200 mg; aspirin 300 mg; 
      dipyridamole 200 mg plus aspirin 300 mg; matched placebos. MEASUREMENTS AND MAIN 
      RESULTS: Blood was taken for platelet function tests, PGI2 metabolite assay, and 
      red cell deformability before and 2 h after the trial dose was taken. Platelet 
      aggregation was quantified by measuring the fall in single platelet count after 
      stimulation with 2 micrograms.ml-1 collagen or 50 nM platelet activating factor 
      (PAF), or by rollermixing aliquots of blood to initiate spontaneous aggregation. 
      The platelet function tests were completed at 37 degrees C within 10 min of 
      venepuncture. The stable metabolite of PGI2, 6-keto PGF1 alpha, was measured in 
      serum. There was inhibition of spontaneous platelet aggregation by dipyridamole 
      (p less than 0.004), aspirin (p less than 0.005), and the combination of 
      dipyridamole plus aspirin (p less than 0.0001) as compared with placebo. PAF 
      induced platelet aggregation was inhibited by dipyridamole (p less than 0.002) 
      and the combination of dipyridamole plus aspirin (p less than 0.0001) but aspirin 
      alone had no inhibitory effect. Collagen induced platelet aggregation was 
      inhibited by all three treatments: dipyridamole (p less than 0.06), aspirin (p 
      less than 0.0001), and the combination of dipyridamole plus aspirin (p less than 
      0.0001). PGI2 generation was markedly inhibited by aspirin (p less than 0.0001) 
      and the combination doses (p less than 0.0001) but was unaffected by dipyridamole 
      alone. Of the three active treatments, only dipyridamole alone significantly (p 
      less than 0.001) increased red cell deformability; there was a modest decrease in 
      red cell deformability with aspirin. CONCLUSIONS: The results with PAF support 
      the view that dipyridamole inhibits platelet activation by more than one 
      mechanism; the effect on collagen induced and spontaneous platelet aggregation 
      suggests that the effect of the combination doses is additive and that on red 
      cell deformability the synergy is negative.
FAU - Saniabadi, A R
AU  - Saniabadi AR
AD  - Department of Medicine, University of Dundee, Ninewells Hospital, United Kingdom.
FAU - Fisher, T C
AU  - Fisher TC
FAU - McLaren, M
AU  - McLaren M
FAU - Belch, J F
AU  - Belch JF
FAU - Forbes, C D
AU  - Forbes CD
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 64ALC7F90C (Dipyridamole)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Adult
MH  - Aspirin/adverse effects/*pharmacology
MH  - Dipyridamole/adverse effects/*pharmacology
MH  - Double-Blind Method
MH  - Drug Synergism
MH  - Epoprostenol/*biosynthesis/blood
MH  - Erythrocyte Deformability/*drug effects
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology
MH  - Platelet Function Tests
EDAT- 1991/03/01 00:00
MHDA- 1991/03/01 00:01
CRDT- 1991/03/01 00:00
PHST- 1991/03/01 00:00 [pubmed]
PHST- 1991/03/01 00:01 [medline]
PHST- 1991/03/01 00:00 [entrez]
AID - 10.1093/cvr/25.3.177 [doi]
PST - ppublish
SO  - Cardiovasc Res. 1991 Mar;25(3):177-83. doi: 10.1093/cvr/25.3.177.

PMID- 22156597
OWN - NLM
STAT- MEDLINE
DCOM- 20120612
LR  - 20131121
IS  - 1468-2834 (Electronic)
IS  - 0002-0729 (Linking)
VI  - 41
IP  - 2
DP  - 2012 Mar
TI  - Aspirin versus warfarin in atrial fibrillation: decision analysis may help 
      patients' choice.
PG  - 250-4
LID - 10.1093/ageing/afr165 [doi]
AB  - BACKGROUND: the primary prevention of ischaemic stroke in chronic non-valvular 
      atrial fibrillation (AF) typically involves consideration of aspirin or warfarin. 
      CHA(2)DS(2)-VASc estimates annual stroke rates for untreated AF patients, which 
      are reduced by 60% with warfarin and by 20% with aspirin. HAS-BLED estimates 
      annual rates of major bleeding on warfarin. The latter risk with aspirin is 
      0.5-1.2% per year. HYPOTHESIS: given a 'warfarin, aspirin or no therapy' choice, 
      AF patients will prefer the option that maximises the annual probability of not 
      having a stroke and not having a major bleed. METHODS: decision tree applied to 
      the 60 possible combinations of CHA(2)DS(2)-VASc and HAS-BLED scores. RESULTS: 
      according to the pre-specified hypothesis, when CHA(2)DS(2)-VASc is <2, the 
      balance of risk and benefit would advise no treatment; when CHA(2)DS(2)-VASc is 2 
      or 3, warfarin would be best when HAS-BLED <2, otherwise no treatment would be 
      advised; for CHA(2)DS(2)-VASc =4, warfarin would be best when HAS-BLED <3, 
      otherwise no treatment would be advised and for CHA(2)DS(2)-VASc ≥5, warfarin 
      would be the preferred option if HAS-BLED <4, otherwise aspirin would be advised. 
      CONCLUSION: this theoretical exercise illustrates the potential benefit of 
      decision analysis in an area where high complexity and uncertainty still remain.
FAU - Romero-Ortuno, Roman
AU  - Romero-Ortuno R
AD  - St Vincent's University Hospital, Department of Medicine for the Elderly, Elm 
      Park, Dublin 4, Ireland. romeror@tcd.ie
FAU - O'Shea, Diarmuid
AU  - O'Shea D
LA  - eng
PT  - Journal Article
DEP - 20111211
PL  - England
TA  - Age Ageing
JT  - Age and ageing
JID - 0375655
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - *Decision Support Techniques
MH  - *Decision Trees
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Patient Selection
MH  - Primary Prevention/*methods
MH  - Risk Assessment
MH  - Risk Factors
MH  - Stroke/etiology/*prevention & control
MH  - Treatment Outcome
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2011/12/14 06:00
MHDA- 2012/06/13 06:00
CRDT- 2011/12/14 06:00
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/06/13 06:00 [medline]
AID - afr165 [pii]
AID - 10.1093/ageing/afr165 [doi]
PST - ppublish
SO  - Age Ageing. 2012 Mar;41(2):250-4. doi: 10.1093/ageing/afr165. Epub 2011 Dec 11.

PMID- 3839446
OWN - NLM
STAT- MEDLINE
DCOM- 19850911
LR  - 20190511
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 38
IP  - 2
DP  - 1985 Aug
TI  - Oral ciramadol in the treatment of postoperative pain.
PG  - 176-82
AB  - The efficacy and safety of single oral 15, 30, and 60 mg doses of ciramadol, an 
      investigational agonist/antagonist analgesic, were studied in a postoperative 
      pain model and compared with aspirin, 325 and 650 mg. Two visual analog pain 
      assessment scales were also compared. Results showed that a pain relief score of 
      moderate or better was reported at some time during the 6-hour observation period 
      by 76% of the patients who took 15 mg ciramadol, by 60% of those who took 30 mg 
      ciramadol, by 59% of those who took 60 mg ciramadol, and by 38% and 92% of the 
      patients who took the low and high doses of aspirin, respectively. From 1 to 4 
      hours after drug dosing, 15 mg ciramadol generally produced higher scores, 
      indicative of greater pain relief, on the three pain intensity efficacy scales 
      used (verbal, linear analog, and curvilinear analog) than did the other two 
      ciramadol doses, but these differences were generally not significant. The 
      differences between 15 mg ciramadol and 650 mg aspirin were generally not 
      significant, although the higher aspirin dose had some advantages over 15 mg 
      ciramadol. The most frequently reported adverse effect was dizziness/vertigo in 
      22% of patients taking 60 mg ciramadol, in 17% of those taking 30 mg ciramadol, 
      in 13% of those taking 15 mg ciramadol, in 4% of those taking high aspirin doses, 
      and in none of those who received the low aspirin doses. The correlation 
      coefficient for the linear and curvilinear pain analog intensity scales was 
      0.955, indicating a highly significant correlation (P less than 0.001).
FAU - Lasagna, L
AU  - Lasagna L
FAU - Calimlim, J F
AU  - Calimlim JF
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Amines)
RN  - 0 (Analgesics)
RN  - 0 (Benzylamines)
RN  - 9NQ109OW0G (ciramadol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Amines/*therapeutic use
MH  - Analgesics/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Benzylamines/administration & dosage/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Random Allocation
MH  - Time Factors
EDAT- 1985/08/01 00:00
MHDA- 1985/08/01 00:01
CRDT- 1985/08/01 00:00
PHST- 1985/08/01 00:00 [pubmed]
PHST- 1985/08/01 00:01 [medline]
PHST- 1985/08/01 00:00 [entrez]
AID - 0009-9236(85)90444-8 [pii]
AID - 10.1038/clpt.1985.155 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1985 Aug;38(2):176-82. doi: 10.1038/clpt.1985.155.

PMID- 10931801
OWN - NLM
STAT- MEDLINE
DCOM- 20000831
LR  - 20220330
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 102
IP  - 6
DP  - 2000 Aug 8
TI  - Double-blind study of the safety of clopidogrel with and without a loading dose 
      in combination with aspirin compared with ticlopidine in combination with aspirin 
      after coronary stenting : the clopidogrel aspirin stent international cooperative 
      study (CLASSICS).
PG  - 624-9
AB  - BACKGROUND: Combination therapy with the ADP receptor antagonist ticlopidine plus 
      aspirin has emerged as standard care after coronary stenting. Clopidogrel, a new 
      ADP receptor antagonist, has greater molar potency than ticlopidine and better 
      safety/tolerability. METHODS AND RESULTS: Patients (n=1020) were randomized after 
      successful stent placement and initiated on a 28-day regimen of either (1) 300-mg 
      clopidogrel loading dose and 325 mg/d aspirin on day 1, followed by 75 mg/d 
      clopidogrel and 325 mg/d aspirin; (2) 75 mg/d clopidogrel and 325 mg/d aspirin; 
      or (3) 250 mg BID ticlopidine and 325 mg/d aspirin. The primary end point 
      consisted of major peripheral or bleeding complications, neutropenia, 
      thrombocytopenia, or early discontinuation of study drug as the result of a 
      noncardiac adverse event during the study-drug treatment period. The primary end 
      point occurred in 9.1% of patients (n=31) in the ticlopidine group and 4.6% of 
      patients (n=31) in the combined clopidogrel group (relative risk 0.50; 95% CI 
      0.31 to 0.81; P=0.005). Overall rates of major adverse cardiac events (cardiac 
      death, myocardial infarction, target lesion revascularization) were low and 
      comparable between treatment groups (0.9% with ticlopidine, 1.5% with 75 mg/d 
      clopidogrel, 1.2% with the clopidogrel loading dose; P=NS for all comparisons). 
      CONCLUSIONS: The safety/tolerability of clopidogrel (plus aspirin) is superior to 
      that of ticlopidine (plus aspirin) (P=0.005). The 300-mg loading dose was well 
      tolerated, notably with no increased risk of bleeding. Secondary end point data 
      are consistent with the hypothesis that clopidogrel and ticlopidine have 
      comparable efficacy with regard to cardiac events after successful stenting.
FAU - Bertrand, M E
AU  - Bertrand ME
AD  - Department of Cardiology, Hôpital Cardiologique, Lille, France. 
      mbcardio@ccub.internet.fr
FAU - Rupprecht, H J
AU  - Rupprecht HJ
FAU - Urban, P
AU  - Urban P
FAU - Gershlick, A H
AU  - Gershlick AH
CN  - CLASSICS Investigators
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - *Coronary Vessels
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - International Cooperation
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - *Stents
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/*therapeutic use
MH  - Treatment Outcome
EDAT- 2000/08/10 00:00
MHDA- 2000/09/02 00:00
CRDT- 2000/08/10 00:00
PHST- 2000/08/10 00:00 [pubmed]
PHST- 2000/09/02 00:00 [medline]
PHST- 2000/08/10 00:00 [entrez]
AID - 10.1161/01.cir.102.6.624 [doi]
PST - ppublish
SO  - Circulation. 2000 Aug 8;102(6):624-9. doi: 10.1161/01.cir.102.6.624.

PMID- 1758287
OWN - NLM
STAT- MEDLINE
DCOM- 19920203
LR  - 20131121
IS  - 0195-9131 (Print)
IS  - 0195-9131 (Linking)
VI  - 23
IP  - 10
DP  - 1991 Oct
TI  - Cerebral stroke in a semi-pro football player: a case report.
PG  - 1119-21
AB  - Cervical spine trauma can clearly result in neurologic injury. An unusual 
      traumatic event is a vascular insult of the vertebral arteries, potentially 
      leading to stroke. The vertebral arteries are vulnerable to compression at 
      several sites in the cervical spine. The high degree of physiologic rotation at 
      the atlanto-axial joint places the vertebral artery at risk through normal daily 
      activities as well as following forceful trauma, including manipulative 
      treatment. Cerebrovascular insufficiency is an uncommon but serious complication 
      of cervical spinal manipulation, which can lead to posterior circulatory 
      impairment. Comprehensive diagnostic studies may be required to differentiate 
      primary intracranial pathology from cerebral symptoms secondary to vascular 
      compromise.
FAU - Weinstein, S M
AU  - Weinstein SM
AD  - Puget Sound Sports Physicians, Seattle, WA 98105.
FAU - Cantu, R C
AU  - Cantu RC
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Med Sci Sports Exerc
JT  - Medicine and science in sports and exercise
JID - 8005433
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Med Sci Sports Exerc. 1992 Sep;24(9):1066. PMID: 1406192
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/drug therapy/*etiology
MH  - Football/*injuries
MH  - Humans
MH  - Male
MH  - Manipulation, Orthopedic/*adverse effects
MH  - Vertebral Artery/injuries
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
PST - ppublish
SO  - Med Sci Sports Exerc. 1991 Oct;23(10):1119-21.

PMID- 3475542
OWN - NLM
STAT- MEDLINE
DCOM- 19870909
LR  - 20191029
IS  - 0742-2814 (Print)
IS  - 0742-2814 (Linking)
VI  - 7
IP  - 2
DP  - 1986 Mar-Apr
TI  - Asthma improved by acetylsalicylic acid and other nonsteroidal anti-inflammatory 
      agents.
PG  - 117-21
AB  - Acetylsalicylic acid (ASA) and other nonsteroidal anti-inflammatory drugs (NSAID) 
      cause a variety of symptoms in patients sensitive to these drugs. These include 
      wheezing, rhinorrhea, flushing, pruritus, urticaria, hypotension and loss of 
      consciousness. Conversely, improvement of asthma with the use of these drugs in 
      patients who do not have idiosyncratic reactions to ASA (ASA-nonsensitive) has 
      also been observed both with respect to clinical symptoms and pulmonary function 
      tests.
FAU - Nelson, R P
AU  - Nelson RP
FAU - Stablein, J J
AU  - Stablein JJ
FAU - Lockey, R F
AU  - Lockey RF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - N Engl Reg Allergy Proc
JT  - New England and regional allergy proceedings
JID - 8306562
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Peak Expiratory Flow Rate
MH  - Vital Capacity/drug effects
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
AID - 10.2500/108854186779047717 [doi]
PST - ppublish
SO  - N Engl Reg Allergy Proc. 1986 Mar-Apr;7(2):117-21. doi: 
      10.2500/108854186779047717.

PMID- 6868016
OWN - NLM
STAT- MEDLINE
DCOM- 19830817
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 49
IP  - 2
DP  - 1983 Apr 28
TI  - Influence of platelet activation of erythrocyte deformability.
PG  - 84-6
AB  - Erythrocyte deformability was demonstrated to be influenced by platelet 
      activation. Deformability of erythrocytes suspended in autologous platelet poor 
      plasma (PPP), obtained from platelet rich plasma (PRP), was significantly reduced 
      when PRP had previously been incubated with a platelet activating substance 
      (arachidonic acid, adrenaline or ADP). The possibility of a direct influence of 
      the activating substance on erythrocyte deformability was examined and 
      malondialdehyde formation was determined as an indicator of platelet activation. 
      Erythrocyte deformability was not impaired when endoperoxide formation in 
      platelets was blocked by an inhibitor of cyclooxigenase (acetylsalicylic acid). 
      Plasma viscosity was not influenced by platelet activation as demonstrated by 
      filtration and viscosimetry. Recent studies showed that prostacyclin (PGI2) 
      increases erythrocyte deformability (1). The antagonistic action between 
      prostacyclin released by vessel walls and products of platelet metabolism being 
      well known, we discuss possible mechanisms of this effect and pathophysiological 
      relevance of our results.
FAU - Palinski, W
AU  - Palinski W
FAU - Torsellini, A
AU  - Torsellini A
FAU - Doni, L
AU  - Doni L
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets/drug effects/*physiology
MH  - Blood Viscosity
MH  - Epinephrine/pharmacology
MH  - Erythrocytes/*pathology
MH  - Filtration
MH  - Humans
EDAT- 1983/04/28 00:00
MHDA- 1983/04/28 00:01
CRDT- 1983/04/28 00:00
PHST- 1983/04/28 00:00 [pubmed]
PHST- 1983/04/28 00:01 [medline]
PHST- 1983/04/28 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1983 Apr 28;49(2):84-6.

PMID- 6844375
OWN - NLM
STAT- MEDLINE
DCOM- 19830610
LR  - 20190920
IS  - 0031-6989 (Print)
IS  - 0031-6989 (Linking)
VI  - 15
IP  - 2
DP  - 1983 Feb
TI  - Protection from arrhythmias of cultured heart cells by nonsteroidal 
      antiinflammatory drugs.
PG  - 167-72
AB  - The nonsteroidal antiinflammatory drugs: acetylsalicylic acid, salicylic acid, 
      sulfinpyrazone and indomethacin were tested at 10(-10) - 10(-5) M for their 
      effect on arrhythmias of monolayer cultures of neonatal rat heart myocytes. 
      Arrhythmias produced by reoxygenation were prevented or significantly reduced (p 
      less than or equal to 0.05) by either indomethacin or salicylic acid at 10(-9) M. 
      Acetylsalicylic acid and sulfinpyrazone, while not significantly anti-arrhythmic, 
      produced consistent numerical inhibition of arrhythmias at 10(-9) M.
FAU - Wenzel, D G
AU  - Wenzel DG
FAU - Innis, J D
AU  - Innis JD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pharmacol Res Commun
JT  - Pharmacological research communications
JID - 0236354
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - *Anti-Arrhythmia Agents
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/pharmacology
MH  - Cells, Cultured
MH  - Indomethacin/pharmacology
MH  - Rats
MH  - Salicylates/pharmacology
MH  - Salicylic Acid
MH  - Sulfinpyrazone/pharmacology
MH  - Time Factors
EDAT- 1983/02/01 00:00
MHDA- 1983/02/01 00:01
CRDT- 1983/02/01 00:00
PHST- 1983/02/01 00:00 [pubmed]
PHST- 1983/02/01 00:01 [medline]
PHST- 1983/02/01 00:00 [entrez]
AID - 10.1016/s0031-6989(83)80058-7 [doi]
PST - ppublish
SO  - Pharmacol Res Commun. 1983 Feb;15(2):167-72. doi: 10.1016/s0031-6989(83)80058-7.

PMID- 7254546
OWN - NLM
STAT- MEDLINE
DCOM- 19810915
LR  - 20131121
IS  - 0026-4733 (Print)
IS  - 0026-4733 (Linking)
VI  - 36
IP  - 10
DP  - 1981 May 31
TI  - [Platelet anti-aggregants in the prevention of disseminated intravascular 
      coagulation in severe burns].
PG  - 683-90
AB  - Two groups of patients with burns involving from 40-70% of the body surface have 
      been examined. One group of 34 patients was not treated with antiaggregating 
      therapy, and one of 28 was treated with platelet antiaggregating therapy from the 
      first day of admission. It was noted that this treatment has a favourable 
      influence on burn shock by means of a mechanism which impedes the onset of D.I.C.
FAU - Raso, S M
AU  - Raso SM
FAU - Gliori, A
AU  - Gliori A
FAU - Lavagnino, G
AU  - Lavagnino G
FAU - Bersini, M
AU  - Bersini M
FAU - Ponzio, E
AU  - Ponzio E
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Gli antiaggreganti piastrinici nella profilassi della C.I.D. nei grandi 
      ustionati.
PL  - Italy
TA  - Minerva Chir
JT  - Minerva chirurgica
JID - 0400726
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Burns/*complications/drug therapy
MH  - Dipyridamole/therapeutic use
MH  - Disseminated Intravascular Coagulation/*prevention & control
MH  - Fibrin Fibrinogen Degradation Products/analysis
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Prothrombin Time
EDAT- 1981/05/31 00:00
MHDA- 1981/05/31 00:01
CRDT- 1981/05/31 00:00
PHST- 1981/05/31 00:00 [pubmed]
PHST- 1981/05/31 00:01 [medline]
PHST- 1981/05/31 00:00 [entrez]
PST - ppublish
SO  - Minerva Chir. 1981 May 31;36(10):683-90.

PMID- 6108875
OWN - NLM
STAT- MEDLINE
DCOM- 19810324
LR  - 20181217
IS  - 0430-0920 (Print)
IS  - 0430-0920 (Linking)
VI  - 35
IP  - 7
DP  - 1980 Jul
TI  - Somatostatin and insulin secretion in man. III - Lack of interaction with 
      prostaglandins.
PG  - 615-20
AB  - In order to asses potential interactions between somatostatin and prostaglandins 
      during regulation of insulin secretion in vivo, in the present investigation we 
      studied the effect of acetylsalicylic acid, an inhibitor of endogenous PG 
      synthesis, on somatostatin-mediated inhibition of glucose-induced insulin 
      secretion in normal man. Acute insulin response (mean change 3'-10') to glucose 
      was almost completely suppressed by somatostatin (500 microgram/h) and glucose 
      utilization was decreased. These somatostatin-induced changes failed to be 
      eliminated by a concurrent infusion of acetylsalicylic acid (40 mg/min). This 
      last drug, when infused alone, increased both the acute insulin response to 
      glucose and glucose tolerance. These results speak against the involvement of PGs 
      in the mediation of somatostatin-induced suppression of insulin secretion.
FAU - Giugliano, D
AU  - Giugliano D
FAU - Passariello, N
AU  - Passariello N
FAU - Torella, R
AU  - Torella R
FAU - Gentile, S
AU  - Gentile S
FAU - D'Angelo, G
AU  - D'Angelo G
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Farmaco Sci
JT  - Il Farmaco; edizione scientifica
JID - 0370716
RN  - 0 (Insulin)
RN  - 0 (Prostaglandins)
RN  - 51110-01-1 (Somatostatin)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Glucose/pharmacology
MH  - Humans
MH  - Insulin/*metabolism
MH  - Insulin Secretion
MH  - Male
MH  - Prostaglandins/*physiology
MH  - Somatostatin/*physiology
EDAT- 1980/07/01 00:00
MHDA- 1980/07/01 00:01
CRDT- 1980/07/01 00:00
PHST- 1980/07/01 00:00 [pubmed]
PHST- 1980/07/01 00:01 [medline]
PHST- 1980/07/01 00:00 [entrez]
PST - ppublish
SO  - Farmaco Sci. 1980 Jul;35(7):615-20.

PMID- 6608397
OWN - NLM
STAT- MEDLINE
DCOM- 19840524
LR  - 20190614
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 294
IP  - 2
DP  - 1984 Mar 5
TI  - The pain suppressive effect of vibratory stimulation and transcutaneous 
      electrical nerve stimulation (TENS) as compared to aspirin.
PG  - 201-9
AB  - The pain reducing effect of vibratory stimulation and transcutaneous electrical 
      nerve stimulation (TENS) as compared to aspirin and placebo was studied in 60 
      patients suffering myofascial or musculoskeletal pain. Vibratory stimulation at 
      20 Hz, 100 Hz and 200 Hz and two modes of TENS were used for peripheral 
      stimulation. In 48 patients these modes of stimulation produced pain reduction. 
      Out of these patients 29 rated vibratory stimulation or TENS as more effective 
      than aspirin while 9 patients rated aspirin as more effective. Ten patients rated 
      the pain suppressive effect of vibratory stimulation and TENS as being equal to 
      that of aspirin. Six of the patients who experienced pain reduction with 
      peripheral stimulation reported an effect only for one particular type of 
      peripheral stimulation. The present results provide evidence that vibratory 
      stimulation and TENS are as efficient and in some patients more efficient pain 
      suppressive measures as compared to aspirin. It is suggested on the basis of 
      these findings that vibratory stimulation and TENS merit consideration in the 
      choice of treatment of myofascial or musculoskeletal pain.
FAU - Lundeberg, T
AU  - Lundeberg T
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Electric Stimulation
MH  - *Electric Stimulation Therapy
MH  - Humans
MH  - Muscles/*innervation/physiopathology
MH  - Pain/*physiopathology
MH  - Pain Management
MH  - Peripheral Nerves/physiopathology
MH  - Skin/*innervation
MH  - *Transcutaneous Electric Nerve Stimulation
MH  - Vibration
EDAT- 1984/03/05 00:00
MHDA- 1984/03/05 00:01
CRDT- 1984/03/05 00:00
PHST- 1984/03/05 00:00 [pubmed]
PHST- 1984/03/05 00:01 [medline]
PHST- 1984/03/05 00:00 [entrez]
AID - 0006-8993(84)91031-X [pii]
AID - 10.1016/0006-8993(84)91031-x [doi]
PST - ppublish
SO  - Brain Res. 1984 Mar 5;294(2):201-9. doi: 10.1016/0006-8993(84)91031-x.

PMID- 15597751
OWN - NLM
STAT- MEDLINE
DCOM- 20050103
LR  - 20131121
IS  - 0022-3085 (Print)
IS  - 0022-3085 (Linking)
VI  - 101
IP  - 6
DP  - 2004 Dec
TI  - Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage.
PG  - 921-5
AB  - OBJECT: Previous studies have indicated an increased incidence of death in 
      patients with subarachnoid hemorrhage (SAH) who are currently receiving 
      anticoagulation therapy. The significance of previous aspirin use in patients 
      with SAH is unknown. The authors analyzed the effects of prior aspirin use on 
      clinical course and outcomes following aneurysmal SAH. METHODS: The medical 
      records of 305 patients with angiogram-confirmed aneurysmal SAH who consecutively 
      presented to our institution between 1990 and 1997 within 7 days of ictus were 
      analyzed. Twenty-nine (9.5%) of these patients had a history of regular aspirin 
      use before onset of the SAH. The Glasgow Outcome Scale (GOS) was used to measure 
      patient outcome at the longest available follow up. Aspirin users were older on 
      average than nonusers (59 years of age compared with 53 years; p = 0.018). The 
      mean admission Hunt and Hess grades of patients with and without aspirin use were 
      similar (2 compared with 2.3; p = 0.51). Two trends, which did not reach 
      statistical significance, were observed. 1) The rebleeding rate in aspirin users 
      was 14.3%, compared with a 4.7% rebleeding rate in nonusers (p = 0.06). 2) 
      Permanent disability from vasospasm was less common among aspirin users (23% 
      compared with 50%; p = 0.069). Outcomes did not differ between aspirin users and 
      nonusers (mean GOS Score 3.83 compared with GOS Score 3.86, respectively; p = 
      0.82). CONCLUSIONS: Despite trends indicating increased rebleeding rates and a 
      lower incidence of permanent disability due to delayed ischemic neurological 
      deficits, there was no significant effect of previous aspirin use on overall 
      outcome following aneurysmal SAH. Based on these preliminary data, the presence 
      of an intracranial aneurysm is not a strict contraindication to aspirin use.
FAU - Toussaint, L Gerard 3rd
AU  - Toussaint LG 3rd
AD  - Department of Neurologic Surgery, Mayo Graduate School of Medicine, Rochester, 
      Minnesota 55905, USA. Toussaint.Gerard@mayo.edu
FAU - Friedman, Jonathan A
AU  - Friedman JA
FAU - Wijdicks, Eelco F M
AU  - Wijdicks EF
FAU - Piepgras, David G
AU  - Piepgras DG
FAU - Pichelmann, Mark A
AU  - Pichelmann MA
FAU - McIver, Jon I
AU  - McIver JI
FAU - McClelland, Robyn L
AU  - McClelland RL
FAU - Nichols, Douglas A
AU  - Nichols DA
FAU - Meyer, Fredric B
AU  - Meyer FB
FAU - Atkinson, John L D
AU  - Atkinson JL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Neurosurg
JT  - Journal of neurosurgery
JID - 0253357
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Medical Records
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Recurrence
MH  - Risk Factors
MH  - Subarachnoid Hemorrhage/*drug therapy/epidemiology
MH  - Treatment Outcome
MH  - Vasospasm, Intracranial/*drug therapy/epidemiology
EDAT- 2004/12/16 09:00
MHDA- 2005/01/04 09:00
CRDT- 2004/12/16 09:00
PHST- 2004/12/16 09:00 [pubmed]
PHST- 2005/01/04 09:00 [medline]
PHST- 2004/12/16 09:00 [entrez]
AID - 10.3171/jns.2004.101.6.0921 [doi]
PST - ppublish
SO  - J Neurosurg. 2004 Dec;101(6):921-5. doi: 10.3171/jns.2004.101.6.0921.

PMID- 14702728
OWN - NLM
STAT- MEDLINE
DCOM- 20040810
LR  - 20131121
IS  - 1220-0875 (Print)
IS  - 1220-0875 (Linking)
VI  - 58
IP  - 3
DP  - 2003
TI  - [Branch retinal arterial occlusions--clinical case].
PG  - 26-8
AB  - Branch retinal arterial occlusion is an ophthalmological emergency, presenting 
      with features of sudden and painless loss of vision and visual field defect. Even 
      if the diagnosis is easy to make, the ophthalmologist is, most of the times, 
      unable to improve the prognosis. We present a clinical case of unilateral branch 
      retinal arterial occlusion with unusual evolution.
FAU - Gafencu, Otilia
AU  - Gafencu O
FAU - Cârstocea, B
AU  - Cârstocea B
FAU - Paiu, Maria
AU  - Paiu M
LA  - rum
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Obstrucţia de ram arterial retinian--consideraţii pe marginea unui caz clinic.
PL  - Romania
TA  - Oftalmologia
JT  - Oftalmologia (Bucharest, Romania : 1990)
JID - 9111247
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Nadroparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/therapeutic use
MH  - Fundus Oculi
MH  - Humans
MH  - Male
MH  - Nadroparin/therapeutic use
MH  - Retinal Artery Occlusion/*diagnosis/drug therapy
MH  - Treatment Outcome
EDAT- 2004/01/02 05:00
MHDA- 2004/08/11 05:00
CRDT- 2004/01/02 05:00
PHST- 2004/01/02 05:00 [pubmed]
PHST- 2004/08/11 05:00 [medline]
PHST- 2004/01/02 05:00 [entrez]
PST - ppublish
SO  - Oftalmologia. 2003;58(3):26-8.

PMID- 2303583
OWN - NLM
STAT- MEDLINE
DCOM- 19900320
LR  - 20201209
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 30
IP  - 1
DP  - 1990 Jan
TI  - Multiple-dose safety study of ibuprofen/codeine and aspirin/codeine combinations.
PG  - 65-9
AB  - This multiple-dose, double-blind, placebo-controlled, randomized, normal 
      volunteer study compared formulations of ibuprofen/codeine and aspirin/codeine 
      for systemic safety. Vital signs, hematologic, biochemical and urinary 
      parameters, side effects, mood and mental alertness, were monitored. The placebo 
      group had less gastrointestinal side effects and more frequent stools than the 
      active treatment groups. There was statistical evidence for greater adverse 
      effects of aspirin/codeine on mood and mental alertness in comparison to 
      ibuprofen/codeine and placebo. Ibuprofen/codeine had a more favorable adverse 
      effect profile than aspirin/codeine. A mild respiratory and cardiac depressant 
      effect attributable to codeine was evident in all active treatment groups after 7 
      days of frequent therapy. More work needs to be done to elucidate the factors 
      regulating the development of tolerance to the respiratory and cardiovascular 
      depressant effects of opiates in general, and for codeine in particular.
FAU - Friedman, H
AU  - Friedman H
AD  - Clinical Pharmacology Unit, Upjohn Company, Kalamazoo, MI 49001.
FAU - Seckman, C
AU  - Seckman C
FAU - Stubbs, C
AU  - Stubbs C
FAU - Oster, H
AU  - Oster H
FAU - Royer, G
AU  - Royer G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Drug Combinations)
RN  - 268B43MJ25 (Uric Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Arousal/drug effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Codeine/administration & dosage/*adverse effects
MH  - Drug Combinations
MH  - Emotions/drug effects
MH  - Feces/analysis
MH  - Humans
MH  - Ibuprofen/administration & dosage/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Pulse/drug effects
MH  - Respiration/drug effects
MH  - Uric Acid/blood
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - J Clin Pharmacol. 1990 Jan;30(1):65-9.

PMID- 7171033
OWN - NLM
STAT- MEDLINE
DCOM- 19830623
LR  - 20190909
IS  - 0567-8056 (Print)
IS  - 0567-8056 (Linking)
VI  - 23
IP  - 6
DP  - 1982
TI  - Pulmonary airflow obstruction following lymphography.
PG  - 639-42
AB  - In a series of 27 patients a significant mean decrease of forced expiratory 
      volume in one second (FEV1) was recorded at 1/2, 2, 4 and 24 hours after 
      lymphography with an oily contrast medium, with a maximum mean decrease at 4 
      hours after injection. The decrease of FEV1 was greater in patients given large 
      amounts of contrast medium at high injection speed. Furthermore, an excessive 
      decrease was observed in patients with metastatic lymph nodes, while a less 
      marked decrease of FEV1 was observed in patients treated with aspirin. No serious 
      clinical side effects were observed. It is recommended that the injection speed 
      and the total amount of contrast medium be limited as far as possible, especially 
      in patients with severe airflow obstruction or with metastases in the lymphatic 
      system. Oral administration of aspirin may limit the decrease in FEV1 following 
      lymphography.
FAU - Andersen, P E Jr
AU  - Andersen PE Jr
FAU - Heslet, L
AU  - Heslet L
FAU - Elle, B
AU  - Elle B
FAU - Bastholt, L
AU  - Bastholt L
LA  - eng
PT  - Journal Article
PL  - Sweden
TA  - Acta Radiol Diagn (Stockh)
JT  - Acta radiologica: diagnosis
JID - 0370367
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Airway Obstruction/*etiology/physiopathology
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Lymphography/*adverse effects/methods
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
EDAT- 1982/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1177/028418518202300618 [doi]
PST - ppublish
SO  - Acta Radiol Diagn (Stockh). 1982;23(6):639-42. doi: 10.1177/028418518202300618.

PMID- 15354073
OWN - NLM
STAT- MEDLINE
DCOM- 20041109
LR  - 20191108
IS  - 1057-0829 (Print)
IS  - 1057-0829 (Linking)
VI  - 13
IP  - 5
DP  - 2004 Oct
TI  - Aspirin use in advanced uncontrolled glaucoma.
PG  - 365-70
AB  - PURPOSE: To evaluate if aspirin use affects progression of primary open angle 
      glaucoma (POAG). METHODS: A retrospective review of patients with uncontrolled 
      glaucoma was performed. Incidence of aspirin use was noted by a one-time 
      self-reporting survey. Controls were medically stable patients diagnosed with 
      POAG. The primary outcome measure studied was a comparison of percentages of 
      aspirin use in patients who have and have not undergone glaucoma filtering 
      surgery (trabeculectomy). RESULTS: Forty-one percent (26/64) of the patients in 
      the trabeculectomy group and 23% (17/74) of controls were using aspirin. Patients 
      undergoing trabeculectomy were twice as likely to take aspirin (O.R., 2.29; 95% 
      C.I., 1.10-4.79). Subgroup analyses demonstrated increased aspirin use in those 
      operative patients who are current or former smokers (O.R., 3.71; 95% C.I., 
      1.10-12.56), have systemic hypertension (O.R., 3.30; 95% C.I., 1.02-22.58), or 
      have joint disease (O.R., 4.60; 95% C.I., 1.34-15.82). CONCLUSION: A higher 
      concurrence of aspirin use was observed in patients with POAG who required 
      surgical management compared with patients having relatively medically stable 
      glaucoma. This may be secondary to a higher rate of glaucoma surgery performed on 
      patients with greater systemic illnesses, more of whom use aspirin.
FAU - Bell, Nicholas P
AU  - Bell NP
AD  - Department of Ophthalmology and Visual Science, The University of Texas Medical 
      School at Houston, Houston, TX, USA. nick.bell@earthlink.net
FAU - Orengo-Nania, Silvia
AU  - Orengo-Nania S
FAU - Pietz, Kenneth
AU  - Pietz K
FAU - Gross, Ronald L
AU  - Gross RL
LA  - eng
GR  - EY02520-22/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Glaucoma
JT  - Journal of glaucoma
JID - 9300903
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/complications
MH  - Cohort Studies
MH  - Disease Progression
MH  - Female
MH  - Glaucoma, Open-Angle/complications/*physiopathology/surgery
MH  - Humans
MH  - Joint Diseases/complications
MH  - Male
MH  - Retrospective Studies
MH  - Trabeculectomy
MH  - Visual Fields
EDAT- 2004/09/09 05:00
MHDA- 2004/11/13 09:00
CRDT- 2004/09/09 05:00
PHST- 2004/09/09 05:00 [pubmed]
PHST- 2004/11/13 09:00 [medline]
PHST- 2004/09/09 05:00 [entrez]
AID - 00061198-200410000-00004 [pii]
AID - 10.1097/01.ijg.0000133148.59933.50 [doi]
PST - ppublish
SO  - J Glaucoma. 2004 Oct;13(5):365-70. doi: 10.1097/01.ijg.0000133148.59933.50.

PMID- 20022477
OWN - NLM
STAT- MEDLINE
DCOM- 20101007
LR  - 20131121
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 104
IP  - 5
DP  - 2010 May
TI  - Association of the CCR3 gene polymorphism with aspirin exacerbated respiratory 
      disease.
PG  - 626-32
LID - 10.1016/j.rmed.2009.11.024 [doi]
AB  - INTRODUCTION: Aspirin hypersensitivity represents two distinct clinical 
      syndromes, such as aspirin exacerbated respiratory disease (AERD) and 
      aspirin-intolerant chronic urticaria/angioedema (AICU) which have different 
      clinical phenotypes resulting from different genetic backgrounds in a Korean 
      population. Persistent eosinophilic inflammation in airway is a characteristic 
      feature of AERD and chemokine CC motif receptor 3 (CCR3) plays an important role 
      in eosinophilic infiltration into the asthmatic airway. OBJECTIVES: The main 
      objective of this study is to investigate the association between CCR3 gene 
      polymorphisms and aspirin hypersensitivity, including AERD and AICU. METHODS: 
      CCR3 mRNA expression was measured after an aspirin provocation test by real-time 
      PCR. In total, 330 patients with aspirin hypersensitivity (191 AERD and 139 AICU) 
      and 217 normal healthy controls (NC) were genotyped for two CCR3 promoter 
      polymorphisms (-520T/G and -174C/T), and the functional effects of the 
      polymorphisms were analyzed applying a luciferase reporter assay and an 
      electrophoretic mobility shift assay. RESULTS: CCR3 mRNA expression was 
      significantly increased after aspirin provocation in AERD patients (P=0.002) but 
      not in AICU patients. An in vitro functional study showed that the reporter 
      construct having a -520G allele exhibited significantly higher promoter activity 
      compared with the construct having a -520T allele in human myeloid (U937), 
      lymphoid (Jurkat), and mast (HMC-1) cell lines (P<0.001). We found -520G and 
      -174T specific bands on EMSA. CONCLUSION: This result suggests that the CCR3 
      genetic polymorphisms may contribute to the development of the AERD phenotype and 
      may be used as a genetic marker for differentiating between the two major aspirin 
      hypersensitivity phenotypes.
FAU - Kim, Seung-Hyun
AU  - Kim SH
AD  - Department of Allergy and Rheumatology, Ajou University School of Medicine, 
      Suwon, Republic of Korea.
FAU - Yang, Eun-Mi
AU  - Yang EM
FAU - Lee, Haet-Nim
AU  - Lee HN
FAU - Choi, Gil-Soon
AU  - Choi GS
FAU - Ye, Young-Min
AU  - Ye YM
FAU - Park, Hae-Sim
AU  - Park HS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091221
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (CCR3 protein, human)
RN  - 0 (Genetic Markers)
RN  - 0 (Receptors, CCR3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*immunology
MH  - Case-Control Studies
MH  - Drug Hypersensitivity/*genetics/immunology
MH  - Female
MH  - Gene Frequency/genetics/immunology
MH  - Genetic Markers
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Phenotype
MH  - *Polymorphism, Genetic
MH  - Receptors, CCR3/*genetics
MH  - Respiration Disorders/chemically induced/*genetics/immunology
MH  - Urticaria/chemically induced/*genetics/immunology
EDAT- 2009/12/22 06:00
MHDA- 2010/10/12 06:00
CRDT- 2009/12/22 06:00
PHST- 2009/10/08 00:00 [received]
PHST- 2009/11/25 00:00 [revised]
PHST- 2009/11/29 00:00 [accepted]
PHST- 2009/12/22 06:00 [entrez]
PHST- 2009/12/22 06:00 [pubmed]
PHST- 2010/10/12 06:00 [medline]
AID - S0954-6111(09)00388-6 [pii]
AID - 10.1016/j.rmed.2009.11.024 [doi]
PST - ppublish
SO  - Respir Med. 2010 May;104(5):626-32. doi: 10.1016/j.rmed.2009.11.024. Epub 2009 
      Dec 21.

PMID- 16716214
OWN - NLM
STAT- MEDLINE
DCOM- 20060724
LR  - 20181113
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 4
DP  - 2006 May 22
TI  - Biological efficacy of low versus medium dose aspirin after coronary surgery: 
      results from a randomized trial [NCT00262275].
PG  - 12
AB  - BACKGROUND: The beneficial effect of aspirin after coronary surgery is 
      established; however, a recent study reported the inability of low doses (100 mg) 
      to inhibit postoperative platelet function. We conducted a double-blind 
      randomised trial to establish the efficacy of low dose aspirin and to compare it 
      against medium dose aspirin. METHODS: Patients undergoing coronary surgery were 
      invited to participate and consenting patients were randomised to 100 mg or 325 
      mg of aspirin daily for 5 days. Our primary outcome was the difference in 
      platelet aggregation (day 5 - baseline) using 1 microg/ml of collagen. Secondary 
      outcomes were differences in EC50 of collagen, ADP and epinephrine (assessed 
      using the technique of Born). RESULTS: From September 2002 to April 2004, 72 
      patients were randomised; 3 patients discontinued, leaving 35 and 34 in the low 
      and medium dose aspirin arms respectively. The mean aggregation (using 1.1 
      microg/ml of collagen) was reduced in both the medium and low dose aspirin arms 
      by 37% and 36% respectively. The baseline adjusted difference (low - medium) was 
      6% (95% CI -3 to 14; p = 0.19). The directions of the results for the differences 
      in EC50 (low - medium) were consistent for collagen, ADP and epinephrine at -0.07 
      (-0.53 to 0.40), -0.08 (-0.28 to 0.11) and -4.41 (-10.56 to 1.72) respectively, 
      but none were statistically significant. CONCLUSION: Contrary to recent findings, 
      low dose aspirin is effective and medium dose aspirin did not prove superior for 
      inhibiting platelet aggregation after coronary surgery.
FAU - Lim, Eric
AU  - Lim E
AD  - Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, CB3 8RE, UK. 
      eric.lim@cvsnet.org
FAU - Cornelissen, Jacqueline
AU  - Cornelissen J
FAU - Routledge, Tom
AU  - Routledge T
FAU - Ali, Ayyaz
AU  - Ali A
FAU - Kirtland, Stephen
AU  - Kirtland S
FAU - Sharples, Linda
AU  - Sharples L
FAU - Sheridan, Kate
AU  - Sheridan K
FAU - Bellm, Sarah
AU  - Bellm S
FAU - Munday, Helen
AU  - Munday H
FAU - Large, Stephen
AU  - Large S
LA  - eng
SI  - ClinicalTrials.gov/NCT00262275
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20060522
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/blood
MH  - Aged
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Collagen/blood
MH  - *Coronary Artery Bypass
MH  - Epinephrine/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Treatment Outcome
PMC - PMC1479833
EDAT- 2006/05/24 09:00
MHDA- 2006/07/25 09:00
CRDT- 2006/05/24 09:00
PHST- 2005/11/27 00:00 [received]
PHST- 2006/05/22 00:00 [accepted]
PHST- 2006/05/24 09:00 [pubmed]
PHST- 2006/07/25 09:00 [medline]
PHST- 2006/05/24 09:00 [entrez]
AID - 1741-7015-4-12 [pii]
AID - 10.1186/1741-7015-4-12 [doi]
PST - epublish
SO  - BMC Med. 2006 May 22;4:12. doi: 10.1186/1741-7015-4-12.

PMID- 2195861
OWN - NLM
STAT- MEDLINE
DCOM- 19900816
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 66
IP  - 3
DP  - 1990 Aug 1
TI  - Effects of early intervention with low-dose aspirin (100 mg) on infarct size, 
      reinfarction and mortality in anterior wall acute myocardial infarction.
PG  - 267-70
AB  - Recently, it was shown that aspirin given early in acute myocardial infarction 
      (AMI) improves hospital survival, but the mechanisms involved are unclear. In a 
      prospective, randomized placebo-controlled trial, the influence of early 
      intervention with low-dose aspirin (100 mg/day) on infarct size and clinical 
      outcome was studied in 100 consecutive patients with first anterior wall AMI. 
      Infarct size was calculated by cumulative lactate dehydrogenase release in the 
      first 72 hours after admission and was found to be (mean +/- standard deviation) 
      1,431 +/- 782 U/liter in the aspirin group (n = 50) and 1,592 +/- 1,082 U/liter 
      in the placebo group (n = 50, p = 0.35). The study medication was given for 3 
      months, during which mortality was 10 (20%) in the aspirin patients and 12 (24%) 
      in the placebo patients (p = 0.65). However, reinfarction occurred in 2 patients 
      (4%) in the aspirin group and in 9 (18%) in the placebo group (p less than 0.03). 
      Early intervention with low-dose aspirin showed, in comparison to placebo, a 10% 
      decrease of infarct size, but this difference was not statistically significant. 
      However, early low-dose aspirin effectively decreased the risk of reinfarction. 
      Therefore, the favor able results of early aspirin on mortality in acute 
      myocardial infarction are probably due more to prevention of reinfarction than to 
      decrease of infarct size.
FAU - Verheugt, F W
AU  - Verheugt FW
AD  - Department of Cardiology, Free University Hospital, Amsterdam, The Netherlands.
FAU - van der Laarse, A
AU  - van der Laarse A
FAU - Funke-Küpper, A J
AU  - Funke-Küpper AJ
FAU - Sterkman, L G
AU  - Sterkman LG
FAU - Galema, T W
AU  - Galema TW
FAU - Roos, J P
AU  - Roos JP
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - L-Lactate Dehydrogenase/blood
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/enzymology/mortality/prevention & control
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Survival Rate
EDAT- 1990/08/01 00:00
MHDA- 1990/08/01 00:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 1990/08/01 00:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
AID - 0002-9149(90)90833-M [pii]
AID - 10.1016/0002-9149(90)90833-m [doi]
PST - ppublish
SO  - Am J Cardiol. 1990 Aug 1;66(3):267-70. doi: 10.1016/0002-9149(90)90833-m.

PMID- 11182624
OWN - NLM
STAT- MEDLINE
DCOM- 20010712
LR  - 20171101
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 30 Suppl 3
DP  - 2000
TI  - Aspirin in the treatment and prevention of cardiovascular disease.
PG  - 1-13
AB  - Randomized trials of aspirin have been conducted in three main populations: 
      patients with evolving acute myocardial infarction (MI), patients with a history 
      of cardiovascular disease and apparently healthy subjects. Initiating aspirin 
      therapy within 24 h after the onset of symptoms of an acute MI results in 
      conclusive reductions in the risk of nonfatal reinfarction, nonfatal stroke and 
      total cardiovascular death. In a wide range of patients with prior occlusive 
      cardiovascular disease, aspirin reduces the risks of nonfatal MI, nonfatal stroke 
      and vascular death. In primary prevention trials, aspirin has been shown to 
      reduce the risk of a first MI in men; limited data make it difficult to draw 
      conclusions regarding its effect on stroke and total cardiovascular death. 
      Randomized data from studies in women and other populations are lacking. Until 
      more data are available, the decision to use aspirin in primary prevention should 
      be based on the clinical judgment of the physician and it should be used as an 
      adjunct in the management of other cardiovascular disease risk factors.
FAU - Gaziano, J M
AU  - Gaziano JM
AD  - Division of Preventive Medicine, Cardiovascular Division, and Channing 
      Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard 
      Medical School, Boston, Mass 02215, USA. graziano@maveric.org
FAU - Skerrett, P J
AU  - Skerrett PJ
FAU - Buring, J E
AU  - Buring JE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Coronary Disease/drug therapy/prevention & control
MH  - Cost-Benefit Analysis
MH  - Cyclooxygenase Inhibitors/pharmacology/therapeutic use
MH  - Drug Costs
MH  - Drug Labeling
MH  - Drug Utilization
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/mortality
MH  - Myocardial Revascularization
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Postoperative Complications/prevention & control
MH  - Practice Guidelines as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Streptokinase/therapeutic use
MH  - Stroke/prevention & control
MH  - Thrombolytic Therapy
MH  - Thrombosis/prevention & control
MH  - Treatment Outcome
RF  - 57
EDAT- 2001/02/22 11:00
MHDA- 2001/07/13 10:01
CRDT- 2001/02/22 11:00
PHST- 2001/02/22 11:00 [pubmed]
PHST- 2001/07/13 10:01 [medline]
PHST- 2001/02/22 11:00 [entrez]
AID - 54193 [pii]
AID - 10.1159/000054193 [doi]
PST - ppublish
SO  - Haemostasis. 2000;30 Suppl 3:1-13. doi: 10.1159/000054193.

PMID- 9391242
OWN - NLM
STAT- MEDLINE
DCOM- 19971217
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 41
IP  - 4
DP  - 1997 Oct
TI  - Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and 
      non-steroidal anti-inflammatory drugs.
PG  - 459-62
AB  - BACKGROUND: Most ulcers are caused, one can deduce, by Helicobacter pylori or by 
      use of non-steroidal anti-inflammatory drugs (NSAIDs). Whether both together are 
      worse than one alone is something that is quite unknown. AIM: To study both 
      factors in order to see wither they interact together positively. METHOD: A case 
      control study of ulcer bleeding in elderly patients chosen without weeding. 
      RESULTS: NSAID usage increased risk substantially. So did H pylori infection (but 
      relative risk less than three). Neither seemed to interact. Their actions were 
      discretely intact. CONCLUSION: H pylori effects ulcer bleeding in an adverse 
      manner but does not make the risk of NSAIDs worse.
FAU - Cullen, D J
AU  - Cullen DJ
AD  - Division of Gastroenterology, University Hospital, Nottingham, UK.
FAU - Hawkey, G M
AU  - Hawkey GM
FAU - Greenwood, D C
AU  - Greenwood DC
FAU - Humphreys, H
AU  - Humphreys H
FAU - Shepherd, V
AU  - Shepherd V
FAU - Logan, R F
AU  - Logan RF
FAU - Hawkey, C J
AU  - Hawkey CJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Helicobacter Infections/*complications
MH  - *Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Odds Ratio
MH  - Peptic Ulcer/chemically induced
MH  - Peptic Ulcer Hemorrhage/chemically induced/*etiology/microbiology
MH  - Regression Analysis
MH  - Risk Factors
PMC - PMC1891536
EDAT- 1997/12/10 00:00
MHDA- 1997/12/10 00:01
CRDT- 1997/12/10 00:00
PHST- 1997/12/10 00:00 [pubmed]
PHST- 1997/12/10 00:01 [medline]
PHST- 1997/12/10 00:00 [entrez]
AID - 10.1136/gut.41.4.459 [doi]
PST - ppublish
SO  - Gut. 1997 Oct;41(4):459-62. doi: 10.1136/gut.41.4.459.

PMID- 22677970
OWN - NLM
STAT- MEDLINE
DCOM- 20130510
LR  - 20211021
IS  - 1435-2451 (Electronic)
IS  - 1435-2443 (Linking)
VI  - 397
IP  - 8
DP  - 2012 Dec
TI  - Risk of wound hematoma at carotid endarterectomy under dual antiplatelet therapy.
PG  - 1275-82
LID - 10.1007/s00423-012-0967-z [doi]
AB  - BACKGROUND AND PURPOSE: This study aims to assess perioperative incidence of 
      wound hematoma and bleeding in patients who underwent carotid endarterectomy 
      (CEA) under dual antiplatelet therapy. METHODS: Consecutive patients with initial 
      CEA receiving aspirin, clopidogrel, or a combination of both were subjected to 
      standard patch endarterectomy. Postoperative wound hematoma was assessed as 
      moderate (subcutaneous bleeding, nonspace-occupying hematoma, and oozing suture 
      bleeding) or severe, i.e., needing operative re-exploration. RESULTS: Six hundred 
      eighty-four (80.9%) patients with one of the three types of antiplatelet therapy 
      out of 844 patients registered from 1995 to 2010 were enrolled. Wound hematoma 
      occurred in 27 of 112 (24.1%) patients under combined aspirin and clopidogrel, 33 
      of 162 (20.4%) under clopidogrel, and 48 of 410 (11.7 %) under aspirin. Relative 
      risk compared to aspirin was 2.4 (95% CI, 1.4 to 4.1) for aspirin and clopidogrel 
      and 1.9 (95% CI, 1.2 to 3.1) for clopidogrel. Severe space-occupying hematoma 
      needing operative re-exploration occurred in four (3.6%) patients under aspirin 
      and clopidogrel, seven (4.3%) under clopidogrel, and five (1.2%) under aspirin. 
      Corresponding relative risks were 3.0 (95% CI, 0.8 to 11.4) for aspirin and 
      clopidogrel and 3.7 (95% CI, 1.1 to 11.7) for clopidogrel. Relative risks 
      remained without relevant change after adjustment for potentially confounding 
      variables. CONCLUSIONS: Dual antiplatelet therapy with combined aspirin and 
      clopidogrel as well as clopidogrel is associated with an increased incidence of 
      perioperative wound hematoma compared to aspirin but on an acceptable low level 
      of incidence. The latter may be achieved by adapting operative procedures to more 
      intensive antiplatelet regimes.
FAU - Oldag, Andreas
AU  - Oldag A
AD  - Vascular and Stroke Center, Department of Neurology, Otto-von-Guericke University 
      of Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. 
      andreas.oldag@med.ovgu.de
FAU - Schreiber, Stephan
AU  - Schreiber S
FAU - Schreiber, Stefanie
AU  - Schreiber S
FAU - Heinze, Hans-Jochen
AU  - Heinze HJ
FAU - Meyer, Frank
AU  - Meyer F
FAU - Weber, Mathias
AU  - Weber M
FAU - Halloul, Zuhir
AU  - Halloul Z
FAU - Goertler, Michael
AU  - Goertler M
LA  - eng
PT  - Journal Article
DEP - 20120608
PL  - Germany
TA  - Langenbecks Arch Surg
JT  - Langenbeck's archives of surgery
JID - 9808285
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Loss, Surgical
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Endarterectomy, Carotid/*adverse effects
MH  - Female
MH  - Hematoma/*chemically induced
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Reoperation
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
EDAT- 2012/06/09 06:00
MHDA- 2013/05/11 06:00
CRDT- 2012/06/09 06:00
PHST- 2012/01/23 00:00 [received]
PHST- 2012/05/23 00:00 [accepted]
PHST- 2012/06/09 06:00 [entrez]
PHST- 2012/06/09 06:00 [pubmed]
PHST- 2013/05/11 06:00 [medline]
AID - 10.1007/s00423-012-0967-z [doi]
PST - ppublish
SO  - Langenbecks Arch Surg. 2012 Dec;397(8):1275-82. doi: 10.1007/s00423-012-0967-z. 
      Epub 2012 Jun 8.

PMID- 19520981
OWN - NLM
STAT- MEDLINE
DCOM- 20090819
LR  - 20161122
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 40
IP  - 8
DP  - 2009 Aug
TI  - Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: 
      differential efficacy in diabetes? Subgroup analysis from S-ACCESS.
PG  - 2862-5
LID - 10.1161/STROKEAHA.109.554246 [doi]
AB  - BACKGROUND AND PURPOSE: The results of the Sarpogrelate-Aspirin Comparative 
      Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral 
      Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 
      5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been 
      reported. But S-ACCESS failed to demonstrate noninferiority of sarpogrelate to 
      aspirin for preventing the recurrence of cerebral infarction. Here we compare the 
      characteristics of sarpogrelate and aspirin in various subgroups. METHODS: 
      Subgroups were predefined from patients' baseline characteristics. Hazard ratio 
      (HR) and 95% confidence interval (CI) for sarpogrelate versus aspirin were 
      calculated for primary (cerebral infarction) and secondary (serious vascular 
      events) end points. Interactions between treatment effects and subgroup variables 
      were examined by post hoc analysis. RESULTS: No significant difference in outcome 
      between sarpogrelate and aspirin was found across multiple predefined subgroups. 
      In post hoc analysis, a qualitative treatment interaction with diabetes mellitus 
      was detected (P=0.166 for recurrence of cerebral infarction; P=0.098 for serious 
      vascular events). HR for the recurrence of cerebral infarction with sarpogrelate 
      versus that with aspirin was 0.87 (95% CI: 0.48 to 1.60) in diabetic patients and 
      1.51 (95% CI: 0.98 to 2.31) in nondiabetic patients. For serious vascular events, 
      the corresponding HRs were 0.73 (95% CI: 0.42 to 1.25) and 1.28 (95% CI: 0.89 to 
      1.83). CONCLUSIONS: No specific baseline characteristic resulting in a 
      significant difference between the effects of sarpogrelate and aspirin was 
      identified. Aspirin was superior in most subgroups, except diabetics. 
      Sarpogrelate may be a useful treatment option for Japanese patients with 
      diabetes.
FAU - Shinohara, Yukito
AU  - Shinohara Y
AD  - Department of Neurology, Federation of National Public Service Personnel Mutual 
      Aid Associations Tachikawa Hospital, 4-2-22 Nishiki-cho, Tachikawa, Tokyo 
      190-8531, Japan. yshinoha@tachikawa-hosp.gr.jp
FAU - Nishimaru, Katsuya
AU  - Nishimaru K
CN  - S-ACCESS study group
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090611
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Succinates)
RN  - 19P708E787 (sarpogrelate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebral Infarction/physiopathology/*prevention & control
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Secondary Prevention/*methods/trends
MH  - Succinates/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2009/06/13 09:00
MHDA- 2009/08/20 09:00
CRDT- 2009/06/13 09:00
PHST- 2009/06/13 09:00 [entrez]
PHST- 2009/06/13 09:00 [pubmed]
PHST- 2009/08/20 09:00 [medline]
AID - STROKEAHA.109.554246 [pii]
AID - 10.1161/STROKEAHA.109.554246 [doi]
PST - ppublish
SO  - Stroke. 2009 Aug;40(8):2862-5. doi: 10.1161/STROKEAHA.109.554246. Epub 2009 Jun 
      11.

PMID- 31845894
OWN - NLM
STAT- MEDLINE
DCOM- 20200415
LR  - 20200415
IS  - 1969-6213 (Electronic)
IS  - 1774-024X (Linking)
VI  - 15
IP  - 18
DP  - 2020 Apr 3
TI  - Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly 
      patients: a pre-specified analysis of the GLOBAL LEADERS trial.
PG  - e1605-e1614
LID - EIJ-D-19-00699 [pii]
LID - 10.4244/EIJ-D-19-00699 [doi]
AB  - AIMS: Antiplatelet treatment in the elderly post percutaneous coronary 
      interventions (PCI) remains a complex issue. Here we report the results of the 
      pre-specified subgroup analysis of the GLOBAL LEADERS trial evaluating the 
      long-term safety and cardiovascular efficacy of ticagrelor monotherapy among 
      patients categorised according to the pre-specified cut-off value of 75 years of 
      age. METHODS AND RESULTS: This was a pre-specified analysis of the randomised 
      GLOBAL LEADERS trial (n=15,991), comparing 23-month ticagrelor monotherapy (after 
      one month of DAPT) with the reference treatment (12-month DAPT followed by 12 
      months of aspirin). Among elderly patients (>75 years; n=2,565), the primary 
      endpoint (two-year all-cause mortality or new Q-wave core lab-adjudicated 
      myocardial infarction [MI]) occurred in 7.2% and 9.4% of patients in the 
      ticagrelor monotherapy and the reference group, respectively (hazard ratio [HR] 
      0.75, 95% confidence interval [CI]: 0.58-0.99, p=0.041; pint=0.23); BARC-defined 
      bleeding type 3/5 occurred in 5.2% and 4.1%, respectively (HR 1.29, 95% CI: 
      0.89-1.86; p=0.180; pint=0.06). The elderly with stable CAD had a higher rate of 
      BARC 3/5 type bleeding (HR 2.05, 95% CI: 1.18-3.55) with ticagrelor monotherapy 
      versus the reference treatment (pint=0.02). Elderly patients had a lower rate of 
      definite or probable stent thrombosis (ST) with ticagrelor monotherapy (0.4% vs 
      1.4%, p=0.015, pint=0.01), compared with the reference group. CONCLUSIONS: In 
      this pre-specified, exploratory analysis of the overall neutral trial, there was 
      no differential treatment effect of ticagrelor monotherapy (after one-month dual 
      therapy with aspirin) found in elderly patients undergoing PCI with respect to 
      the rate of the primary endpoint of all-cause death or new Q-wave MI. The lower 
      rate of ST in the elderly with ticagrelor monotherapy is hypothesis-generating. 
      ClinicalTrials.gov identifier: NCT01813435.
FAU - Tomaniak, Mariusz
AU  - Tomaniak M
AD  - Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.
FAU - Chichareon, Ply
AU  - Chichareon P
FAU - Modolo, Rodrigo
AU  - Modolo R
FAU - Takahashi, Kuniaki
AU  - Takahashi K
FAU - Chang, Chun Chin
AU  - Chang CC
FAU - Kogame, Norihiro
AU  - Kogame N
FAU - Spitzer, Ernest
AU  - Spitzer E
FAU - Buszman, Pawel E
AU  - Buszman PE
FAU - van Geuns, Robert-Jan M
AU  - van Geuns RM
FAU - Valkov, Veselin
AU  - Valkov V
FAU - Steinwender, Clemens
AU  - Steinwender C
FAU - Geisler, Tobias
AU  - Geisler T
FAU - Prokopczuk, Janusz
AU  - Prokopczuk J
FAU - Sabaté, Manel
AU  - Sabaté M
FAU - Zmudka, Krzysztof
AU  - Zmudka K
FAU - Rademaker-Havinga, Tessa
AU  - Rademaker-Havinga T
FAU - Tijssen, Jan G P
AU  - Tijssen JGP
FAU - Jüni, Peter
AU  - Jüni P
FAU - Hamm, Christian
AU  - Hamm C
FAU - Steg, Philippe Gabriel
AU  - Steg PG
FAU - Onuma, Yoshinobu
AU  - Onuma Y
FAU - Vranckx, Pascal
AU  - Vranckx P
FAU - Valgimigli, Marco
AU  - Valgimigli M
FAU - Windecker, Stephan
AU  - Windecker S
FAU - Baber, Usman
AU  - Baber U
FAU - Anderson, Richard
AU  - Anderson R
FAU - Dominici, Marcello
AU  - Dominici M
FAU - Serruys, Patrick W
AU  - Serruys PW
LA  - eng
SI  - ClinicalTrials.gov/NCT01813435
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200403
PL  - France
TA  - EuroIntervention
JT  - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on 
      Interventional Cardiology of the European Society of Cardiology
JID - 101251040
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/*therapeutic use
MH  - Ticagrelor/*therapeutic use
MH  - Time
MH  - Treatment Outcome
EDAT- 2019/12/18 06:00
MHDA- 2020/04/16 06:00
CRDT- 2019/12/18 06:00
PHST- 2019/12/18 06:00 [pubmed]
PHST- 2020/04/16 06:00 [medline]
PHST- 2019/12/18 06:00 [entrez]
AID - EIJ-D-19-00699 [pii]
AID - 10.4244/EIJ-D-19-00699 [doi]
PST - epublish
SO  - EuroIntervention. 2020 Apr 3;15(18):e1605-e1614. doi: 10.4244/EIJ-D-19-00699.

PMID- 1169029
OWN - NLM
STAT- MEDLINE
DCOM- 19750724
LR  - 20190703
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 54
IP  - 3
DP  - 1975 May-Jun
TI  - Anesthetic problems with aspirin-intolerant patients.
PG  - 376-80
AB  - Sixty-seven aspirin-sensitive asthmatic patients underwent a total of 89 
      operative procedures. Wheezing with induction, intraoperative tachycardia and 
      arrhythmias, and postoperative wheezing were the major problems in their 
      anesthetic course. Wheezing was encountered despite various induction technics. 
      Preoperative steroids, aminophylline, and ephedrine appeared necessary for 
      surgical preparation, but the presence of aminophylline and ephedrine predisposed 
      to tachycardia under anesthesia. The appearance of mild preoperative wheezing 
      allows the prediction of postoperative wheezing in a significant number of 
      patients.
FAU - Barton, M D
AU  - Barton MD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 27Y3KJK423 (Aminophylline)
RN  - GN83C131XS (Ephedrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aminophylline/pharmacology
MH  - Anesthesia/*adverse effects
MH  - Arrhythmias, Cardiac/chemically induced
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Asthma/drug therapy
MH  - Bronchial Spasm/complications
MH  - Drug Synergism
MH  - Ephedrine/pharmacology
MH  - Female
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Intubation, Intratracheal/adverse effects
MH  - Male
MH  - Pulse/adverse effects
MH  - Respiratory Hypersensitivity/*chemically induced
MH  - Rhinitis/complications
MH  - Tachycardia/chemically induced
MH  - Urticaria/complications
EDAT- 1975/05/01 00:00
MHDA- 1975/05/01 00:01
CRDT- 1975/05/01 00:00
PHST- 1975/05/01 00:00 [pubmed]
PHST- 1975/05/01 00:01 [medline]
PHST- 1975/05/01 00:00 [entrez]
AID - 10.1213/00000539-197505000-00031 [doi]
PST - ppublish
SO  - Anesth Analg. 1975 May-Jun;54(3):376-80. doi: 10.1213/00000539-197505000-00031.

PMID- 16935176
OWN - NLM
STAT- MEDLINE
DCOM- 20080417
LR  - 20151119
IS  - 0196-0709 (Print)
IS  - 0196-0709 (Linking)
VI  - 27
IP  - 5
DP  - 2006 Sep-Oct
TI  - Endoscopic dacryocystorhinostomy in patients taking aspirin perioperatively.
PG  - 323-6
AB  - PURPOSE: The aim of this study is to report the results of endoscopic 
      dacryocystorhinotomy (EDCR) in patients who did not interrupt their low-dose 
      (75-150 mg daily) aspirin regimen for the procedure. MATERIALS AND METHODS: A 
      case note review was made of all 40 patients taking aspirin who had EDCR at 
      Ipswich Hospital from May 1998 to October 2003. Age, gender, indications for 
      surgery, complications, and outcome were analyzed and the bleeding rate compared 
      to that in patients who were not on aspirin or warfarin who had an EDCR. RESULTS: 
      Of the 51 EDCRs performed in the 40 patients, 47 had complete relief of epiphora. 
      Two of the patients with a persistent watering eye are to have revision surgery, 
      1 patient was observed (75% improvement), and 1 patient has since died. A total 
      of 33 patients had no postoperative complications; 5 had epistaxis but only 1 of 
      these required a nasal pack; 1 each had minor periorbital bruising, confusion, 
      and facial pain, none of which delayed discharge. None required readmission. Of 
      257 EDCRs in patients not on aspirin or warfarin, 1.3% had epistaxis resulting in 
      delayed discharged or readmission. CONCLUSIONS: EDCR is a safe and efficacious 
      treatment in patients with distal nasolacrimal obstruction in patients taking 
      aspirin and does not require stopping the aspirin perioperatively.
FAU - Smith, Wendy
AU  - Smith W
AD  - Department of Otolaryngology, The Ipswich Hospital N.H.S.Trust, Suffolk, UK.
FAU - Merkonidis, Christos
AU  - Merkonidis C
FAU - Yung, Matthew
AU  - Yung M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Otolaryngol
JT  - American journal of otolaryngology
JID - 8000029
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dacryocystorhinostomy/*methods
MH  - Endoscopy
MH  - Epistaxis/chemically induced/epidemiology/etiology
MH  - Female
MH  - Humans
MH  - Lacrimal Apparatus Diseases/*surgery
MH  - Male
MH  - Middle Aged
MH  - Nasolacrimal Duct/pathology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Hemorrhage/chemically induced/epidemiology/etiology
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2006/08/29 09:00
MHDA- 2008/04/18 09:00
CRDT- 2006/08/29 09:00
PHST- 2005/12/05 00:00 [received]
PHST- 2006/08/29 09:00 [pubmed]
PHST- 2008/04/18 09:00 [medline]
PHST- 2006/08/29 09:00 [entrez]
AID - S0196-0709(06)00017-2 [pii]
AID - 10.1016/j.amjoto.2006.01.015 [doi]
PST - ppublish
SO  - Am J Otolaryngol. 2006 Sep-Oct;27(5):323-6. doi: 10.1016/j.amjoto.2006.01.015.

PMID- 28577622
OWN - NLM
STAT- MEDLINE
DCOM- 20170731
LR  - 20211204
IS  - 1557-9859 (Electronic)
IS  - 0025-7125 (Linking)
VI  - 101
IP  - 4
DP  - 2017 Jul
TI  - Aspirin for Primary Prevention.
PG  - 713-724
LID - S0025-7125(17)30027-5 [pii]
LID - 10.1016/j.mcna.2017.03.004 [doi]
AB  - Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the 
      risk of colorectal cancer. Aspirin increases the risk of gastrointestinal and 
      intracranial bleeding. The best available evidence supports initiating aspirin in 
      select populations. In 2016, the US Preventive Services Task Force recommended 
      initiating aspirin for the primary prevention of both cardiovascular disease and 
      colorectal cancer among adults ages 50 to 59 who are at increased risk for 
      cardiovascular disease. Adults 60 to 69 who are at increased cardiovascular 
      disease risk may also benefit. There remains considerable uncertainty about 
      whether younger and older patients may benefit.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Richman, Ilana B
AU  - Richman IB
AD  - Department of Medicine, Yale University School of Medicine, 367 Cedar Street, 
      Harkness Hall A, Room 301, New Haven, CT 06510, USA. Electronic address: 
      ilana.richman@yale.edu.
FAU - Owens, Douglas K
AU  - Owens DK
AD  - VA Palo Alto Health Care System, Palo Alto, CA, USA; Department of Medicine, 
      Stanford University School of Medicine, Center for Primary Care and Outcomes 
      Research/Center for Health Policy, 117 Encina Commons, Stanford, CA 94305, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Med Clin North Am
JT  - The Medical clinics of North America
JID - 2985236R
RN  - 0 (Lipids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Colorectal Neoplasms/prevention & control
MH  - Diabetes Mellitus/epidemiology
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Lipids/blood
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors
MH  - Practice Guidelines as Topic
MH  - Primary Prevention/*methods
MH  - Racial Groups
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
MH  - Smoking/epidemiology
MH  - Stroke/prevention & control
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease prevention
OT  - Colorectal cancer prevention
OT  - Guidelines
EDAT- 2017/06/05 06:00
MHDA- 2017/08/02 06:00
CRDT- 2017/06/05 06:00
PHST- 2017/06/05 06:00 [entrez]
PHST- 2017/06/05 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
AID - S0025-7125(17)30027-5 [pii]
AID - 10.1016/j.mcna.2017.03.004 [doi]
PST - ppublish
SO  - Med Clin North Am. 2017 Jul;101(4):713-724. doi: 10.1016/j.mcna.2017.03.004.

PMID- 9679792
OWN - NLM
STAT- MEDLINE
DCOM- 19980811
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 158
IP  - 14
DP  - 1998 Jul 27
TI  - Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose 
      warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial 
      Fibrillation, Aspirin, and Anticoagulation Study.
PG  - 1513-21
AB  - BACKGROUND: Despite the efficacy of warfarin sodium therapy for stroke prevention 
      in atrial fibrillation, many physicians hesitate to prescribe it to elderly 
      patients because of the risk for bleeding complications and because of 
      inconvenience for the patients. METHODS: The Second Copenhagen Atrial 
      Fibrillation, Aspirin, and Anticoagulation Study was a randomized, controlled 
      trial examining the following therapies: warfarin sodium, 1.25 mg/d; warfarin 
      sodium, 1.25 mg/d, plus aspirin, 300 mg/d; and aspirin, 300 mg/d. These were 
      compared with adjusted-dose warfarin therapy (international normalized ratio of 
      prothrombin time [INR], 2.0-3.0). Stroke or a systemic thromboembolic event was 
      the primary outcome event. Transient ischemic attack, acute myocardial 
      infarction, and death were secondary events. Data were handled as survival data, 
      and risk factors were identified using the Cox proportional hazards model. The 
      trial was scheduled for 6 years from May 1, 1993, but due to scientific evidence 
      of inefficiency of low-intensity warfarin plus aspirin therapy from another 
      study, our trial was prematurely terminated on October 2, 1996. RESULTS: We 
      included 677 patients (median age, 74 years). The cumulative primary event rate 
      after 1 year was 5.8% in patients receiving minidose warfarin; 7.2%, warfarin 
      plus aspirin; 3.6%, aspirin; and 2.8%, adjusted-dose warfarin (P = .67). After 3 
      years, no difference among the groups was seen. Major bleeding events were rare. 
      CONCLUSIONS: Although the difference was insignificant, adjusted-dose warfarin 
      seemed superior to minidose warfarin and to warfarin plus aspirin after 1 year of 
      treatment. The results do not justify a change in the current recommendation of 
      adjusted-dose warfarin (INR, 2.0-3.0) for stroke prevention in atrial 
      fibrillation.
FAU - Gulløv, A L
AU  - Gulløv AL
AD  - Copenhagen General Practitioners Laboratory, Denmark. gullov@dadlnet.dk
FAU - Koefoed, B G
AU  - Koefoed BG
FAU - Petersen, P
AU  - Petersen P
FAU - Pedersen, T S
AU  - Pedersen TS
FAU - Andersen, E D
AU  - Andersen ED
FAU - Godtfredsen, J
AU  - Godtfredsen J
FAU - Boysen, G
AU  - Boysen G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Intern Med. 1998 Jul 27;158(14):1487-91. PMID: 9679788
CIN - Arch Intern Med. 1999 May 10;159(9):1010-1. PMID: 10326947
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Cerebrovascular Disorders/etiology/*prevention & control
MH  - Denmark
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Warfarin/*administration & dosage/adverse effects
EDAT- 1998/07/29 00:00
MHDA- 1998/07/29 00:01
CRDT- 1998/07/29 00:00
PHST- 1998/07/29 00:00 [pubmed]
PHST- 1998/07/29 00:01 [medline]
PHST- 1998/07/29 00:00 [entrez]
AID - 10.1001/archinte.158.14.1513 [doi]
PST - ppublish
SO  - Arch Intern Med. 1998 Jul 27;158(14):1513-21. doi: 10.1001/archinte.158.14.1513.

PMID- 23298342
OWN - NLM
STAT- MEDLINE
DCOM- 20131115
LR  - 20131121
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 48
IP  - 3
DP  - 2013 Mar
TI  - Incidence and risk factors of gastrointestinal bleeding in patients on low-dose 
      aspirin therapy after percutaneous coronary intervention in Japan.
PG  - 320-5
LID - 10.3109/00365521.2012.758771 [doi]
AB  - BACKGROUND: Low-dose aspirin (LDA) is the most commonly prescribed antiplatelet 
      agent for prevention of cardiovascular events following percutaneous coronary 
      intervention (PCI). Long-term treatment with LDA has serious adverse effects, 
      including gastrointestinal (GI) hemorrhage. Most studies have focused only on 
      upper GI bleeding and few studies have evaluated the effect of LDA on total GI 
      bleeding. AIMS: The aims of this study were to investigate the incidence and risk 
      factors of total GI bleeding within 30 days after PCI in Japanese patients taking 
      LDA. METHODS: A retrospective chart review was conducted for 364 patients 
      undergoing LDA therapy following PCI at Osaka City University Hospital. A 
      retrospective case-control study evaluated risk factors using the chi-squared 
      test and logistic regression. RESULTS: The incidence of total GI bleeding after 
      PCI within 30 days was 4.3%. The source of the GI bleeding was located throughout 
      the GI tract. Risk factors identified by univariate analysis were age ≥ 75 years, 
      history of peptic ulcer disease, chronic renal failure, proton pump inhibitor 
      use, and histamine H2 receptor antagonist use. By multivariate logistic 
      regression only age ≥ 75 years (odds ratio = 5.26; 95% confidence interval: 
      1.13-24.51; p = 0.035) was found to be an independent risk factor of GI bleeding. 
      CONCLUSIONS: The incidence of GI bleeding in patients undergoing LDA therapy 
      following PCI is high. The bleeding episodes were located in the upper, middle, 
      and lower GI tract. Age of ≥ 75 years was an independent risk factor for GI 
      bleeding after PCI in patients on LDA therapy.
FAU - Nadatani, Yuji
AU  - Nadatani Y
AD  - Department of Gastroenterology, Osaka City University Graduate School of 
      Medicine, Osaka, Japan. dada@med.osaka-cu.ac.jp
FAU - Watanabe, Toshio
AU  - Watanabe T
FAU - Tanigawa, Tetsuya
AU  - Tanigawa T
FAU - Sogawa, Mitsue
AU  - Sogawa M
FAU - Yamagami, Hirokazu
AU  - Yamagami H
FAU - Shiba, Masatsugu
AU  - Shiba M
FAU - Watanabe, Kenji
AU  - Watanabe K
FAU - Tominaga, Kazunari
AU  - Tominaga K
FAU - Fujiwara, Yasuhiro
AU  - Fujiwara Y
FAU - Yoshiyama, Minoru
AU  - Yoshiyama M
FAU - Arakawa, Tetsuo
AU  - Arakawa T
LA  - eng
PT  - Journal Article
DEP - 20130108
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Chi-Square Distribution
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Japan/epidemiology
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Retrospective Studies
MH  - Risk Factors
EDAT- 2013/01/10 06:00
MHDA- 2013/11/16 06:00
CRDT- 2013/01/10 06:00
PHST- 2013/01/10 06:00 [entrez]
PHST- 2013/01/10 06:00 [pubmed]
PHST- 2013/11/16 06:00 [medline]
AID - 10.3109/00365521.2012.758771 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2013 Mar;48(3):320-5. doi: 10.3109/00365521.2012.758771. 
      Epub 2013 Jan 8.

PMID- 25501289
OWN - NLM
STAT- MEDLINE
DCOM- 20151223
LR  - 20181113
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
VI  - 50
IP  - 4
DP  - 2015 Apr
TI  - Small bowel injury in low-dose aspirin users.
PG  - 378-86
LID - 10.1007/s00535-014-1028-x [doi]
AB  - The use of low-dose aspirin (LDA) is well known to be associated with an 
      increased risk of serious upper gastrointestinal complications, such as peptic 
      ulceration and bleeding. Until recently, attention was mainly focused on 
      aspirin-induced damage of the stomach and duodenum. However, recently, there has 
      been growing interest among gastroenterologists on the adverse effects of aspirin 
      on the small bowel, especially as new endoscopic techniques, such as capsule 
      endoscopy (CE) and balloon-assisted endoscopy, have become available for the 
      evaluation of small bowel lesions. Preliminary CE studies conducted in healthy 
      subjects have shown that short-term administration of LDA can induce mild mucosal 
      inflammation of the small bowel. Furthermore, chronic use of LDA results in a 
      variety of lesions in the small bowel, including multiple petechiae, loss of 
      villi, erosions, and round, irregular, or punched-out ulcers. Some patients 
      develop circumferential ulcers with stricture. In addition, to reduce the 
      incidence of gastrointestinal lesions in LDA users, it is important for 
      clinicians to confirm the differences in the gastrointestinal toxicity between 
      different types of aspirin formulations in clinical use. Some studies suggest 
      that enteric-coated aspirin may be more injurious to the small bowel mucosa than 
      buffered aspirin. The ideal treatment for small bowel injury in patients taking 
      LDA would be withdrawal of aspirin, however, LDA is used as an antiplatelet agent 
      in the majority of patients, and its withdrawal could increase the risk of 
      cardiovascular/cerebrovascular morbidity and mortality. Thus, novel means for the 
      treatment of aspirin-induced enteropathy are urgently needed.
FAU - Endo, Hiroki
AU  - Endo H
AD  - Department of Gastroenterology and Hepatology, Yokohama City University School of 
      Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan, 
      endo1978@yokohama-cu.ac.jp.
FAU - Sakai, Eiji
AU  - Sakai E
FAU - Kato, Takayuki
AU  - Kato T
FAU - Umezawa, Shotaro
AU  - Umezawa S
FAU - Higurashi, Takuma
AU  - Higurashi T
FAU - Ohkubo, Hidenori
AU  - Ohkubo H
FAU - Nakajima, Atsushi
AU  - Nakajima A
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141214
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Capsule Endoscopy
MH  - Drug Administration Schedule
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Intestinal Diseases/*chemically induced/prevention & control
MH  - Intestine, Small/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Ulcer/chemically induced/prevention & control
EDAT- 2014/12/17 06:00
MHDA- 2015/12/24 06:00
CRDT- 2014/12/16 06:00
PHST- 2014/11/27 00:00 [received]
PHST- 2014/12/02 00:00 [accepted]
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/12/24 06:00 [medline]
AID - 10.1007/s00535-014-1028-x [doi]
PST - ppublish
SO  - J Gastroenterol. 2015 Apr;50(4):378-86. doi: 10.1007/s00535-014-1028-x. Epub 2014 
      Dec 14.

PMID- 1838974
OWN - NLM
STAT- MEDLINE
DCOM- 19920409
LR  - 20161123
IS  - 0147-958X (Print)
IS  - 0147-958X (Linking)
VI  - 14
IP  - 6
DP  - 1991 Dec
TI  - Aspirin injection test to predict angioplasty outcome in unilateral renovascular 
      hypertension: preliminary report.
PG  - 566-73
AB  - We examined the usefulness of aspirin DL-lysine for prediction of the outcome of 
      renal artery angioplasty in renovascular hypertension. The study was carried out 
      in eight hypertensive patients with unilateral renal artery stenosis: six were 
      free from azotemia and two had slight azotemia. Before and 30 min after an 
      intravenous injection of aspirin DL-lysine (18 mg/kg), renal venous and abdominal 
      aortic plasma was sampled and assayed for prostaglandin E2 and plasma renin 
      activity. Blood pressure and heart rate were serially measured at this time. 
      Renal angioplasty was later performed and was technically successful in all 
      patients. In the six patients without azotemia, aspirin inhibited renal 
      prostaglandin E2 synthesis and suppressed renin release from the ischemic kidney, 
      resulting in lowered blood pressure. Renal angioplasty caused plasma renin 
      activity to become normal and lowered high blood pressure. The reduction in blood 
      pressure by angioplasty was correlated with the responses of blood pressure and 
      renin release to aspirin. However, in the two patients with azotemia, aspirin 
      neither suppressed renin release nor lowered blood pressure. Their hypertension 
      was not reduced by the angioplasty. These results indicate that an aspirin 
      injection test could be useful for prediction of the outcome of angioplasty in 
      unilateral renovascular hypertension.
FAU - Imanishi, M
AU  - Imanishi M
AD  - Division of Hypertension and Renal Diseases, National Cardiovascular Center, 
      Osaka, Japan.
FAU - Ohta, M
AU  - Ohta M
FAU - Akabane, S
AU  - Akabane S
FAU - Kawamura, M
AU  - Kawamura M
FAU - Matsushima, Y
AU  - Matsushima Y
FAU - Kojima, S
AU  - Kojima S
FAU - Kuramochi, M
AU  - Kuramochi M
FAU - Kimura, K
AU  - Kimura K
FAU - Takamiya, M
AU  - Takamiya M
FAU - Ito, K
AU  - Ito K
AU  - et al.
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Clin Invest Med
JT  - Clinical and investigative medicine. Medecine clinique et experimentale
JID - 7804071
RN  - EC 3.4.23.15 (Renin)
RN  - K3Z4F929H6 (Lysine)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - *Angioplasty, Balloon
MH  - Aorta, Abdominal
MH  - Aspirin/administration & dosage/*analogs & derivatives
MH  - Blood Pressure
MH  - Dinoprostone/blood
MH  - Female
MH  - Humans
MH  - Hypertension, Renovascular/physiopathology/*therapy
MH  - Injections, Intravenous
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Renal Veins
MH  - Renin/blood
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
PST - ppublish
SO  - Clin Invest Med. 1991 Dec;14(6):566-73.

PMID- 27262381
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20170827
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 786
DP  - 2016 Sep 5
TI  - Prophylactic acetylsalicylic acid attenuates the inflammatory response but fails 
      to protect exercise-induced liver damage in exercised rats.
PG  - 204-211
LID - S0014-2999(16)30357-0 [pii]
LID - 10.1016/j.ejphar.2016.05.043 [doi]
AB  - This study evaluated the effects of acetylsalicylic acid (ASA) on 
      exercise-induced inflammatory response, muscle damage, and liver injury in rats. 
      Wistar-Kyoto (WKY) rats were divided into six groups: control (C), exercise (E), 
      C+20mg ASA, E+20mg ASA, C+100mg/kg ASA, and E+100mg ASA groups. ASA or a vehicle 
      was orally administered through gavage 1h before a treadmill test. Upon trial 
      completion, blood was drawn at 1, 12, and 24h for biochemical analysis, and 
      livers were excised at 24h for a histological assessment. Our results revealed 
      that 100mg/kg ASA significantly reduced interleukin (IL)-6 and tumor necrosis 
      factor (TNF)-α levels in the E groups; however, the IL-10 level was considerably 
      increased. Moreover, aspartate aminotransferase (AST), alanine aminotransferase 
      (ALT) levels and histological hepatic damage increased significantly in the 
      E+100mg ASA group compared with the corresponding changes in the E group. These 
      results suggest that the prophylactic administration of particularly high-dose 
      ASA alleviates exercise-induced inflammatory response but exacerbates liver 
      injury.
CI  - Copyright © 2016 Elsevier B.V. All rights reserved.
FAU - Huang, Kuo-Chin
AU  - Huang KC
AD  - Holistic Education Center, Mackay Medical College, New Taipei City, Taiwan, ROC. 
      Electronic address: kchsports@mmc.edu.tw.
FAU - Chiu, Yi-Han
AU  - Chiu YH
AD  - Department of Nursing, St. Mary's Medicine, Nursing and Management College, 
      Yi-Lan, Taiwan, ROC. Electronic address: chiuyiham@hotmail.com.
FAU - Liao, Kuang-Wen
AU  - Liao KW
AD  - Department of Biological Science and Technology, National Chiao Tung University, 
      Hsinchu, Taiwan, ROC. Electronic address: liaonms@mail.nctu.edu.tw.
FAU - Ke, Chun-Yen
AU  - Ke CY
AD  - Department of Biological Science and Technology, National Chiao Tung University, 
      Hsinchu, Taiwan, ROC. Electronic address: brant77123@hotmail.com.
FAU - Lee, Chung-Jen
AU  - Lee CJ
AD  - Department of Nursing, Tzu Chi University of Science and Technology, Hualien, 
      Taiwan, ROC. Electronic address: guggilee@msn.com.
FAU - Chao, Yann-Fen C
AU  - Chao YC
AD  - Department of Nursing, Mackay Medical College, New Taipei City, Taiwan, ROC. 
      Electronic address: yfchaomk@mmc.edu.tw.
FAU - Lee, Ru-Ping
AU  - Lee RP
AD  - Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan, ROC. 
      Electronic address: fish@gms.tcu.edu.tw.
LA  - eng
PT  - Journal Article
DEP - 20160601
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alanine Transaminase/blood
MH  - Animals
MH  - Aspartate Aminotransferases/blood
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Inflammation/drug therapy/etiology
MH  - Interleukin-10/blood
MH  - Liver/*drug effects/injuries/metabolism
MH  - Physical Conditioning, Animal/*adverse effects
MH  - Rats
MH  - Rats, Inbred WKY
MH  - Tumor Necrosis Factor-alpha/blood
OTO - NOTNLM
OT  - Aspirin
OT  - Exhaustion exercise
OT  - Liver injury
OT  - Nonsteroidal antiinflammatory drug
EDAT- 2016/06/06 06:00
MHDA- 2017/03/11 06:00
CRDT- 2016/06/06 06:00
PHST- 2016/01/13 00:00 [received]
PHST- 2016/05/27 00:00 [revised]
PHST- 2016/05/30 00:00 [accepted]
PHST- 2016/06/06 06:00 [entrez]
PHST- 2016/06/06 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
AID - S0014-2999(16)30357-0 [pii]
AID - 10.1016/j.ejphar.2016.05.043 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2016 Sep 5;786:204-211. doi: 10.1016/j.ejphar.2016.05.043. Epub 
      2016 Jun 1.

PMID- 19826
OWN - NLM
STAT- MEDLINE
DCOM- 19771028
LR  - 20131121
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 17
IP  - 4
DP  - 1977 Aug
TI  - Failure to observe pathology in the rat following chronic dosing with 
      acetaminophen and acetylsalicylic acid.
PG  - 663-78
AB  - Male Wistar rats were dosed daily by gavage for 200 days with either (1) aspirin, 
      200 mg/kg; (2) acetaminophen, 200 mg/kg; (3) aspirin and acetaminophen, 200 mg/kg 
      of each; (4) aspirin and acetaminophen, 100 mg/kg of each or (5) vehicle alone. 
      None of the treatments produced any marked signs of toxicity and no drug related 
      deaths were observed. The full dose combination (3) did significantly reduce the 
      weight compared to the control group (5). When urinary lactic dehydrogenase and 
      alkaline phosphatase were measured, all treatments caused some increase in 
      activity but those containing aspirin had the greatest effect. Urinary pH and 
      osmolarity were not effected by the treatments. Complete pathological examination 
      of the animals failed to detect any significant changes when compared to the 
      controls. It is concluded that there is no evidence of a toxic interaction 
      between aspirin and acetaminophen in the rat.
FAU - Thomas, B H
AU  - Thomas BH
FAU - Nera, E A
AU  - Nera EA
FAU - Zeitz, W
AU  - Zeitz W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - 362O9ITL9D (Acetaminophen)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/*adverse effects
MH  - Alanine Transaminase/blood
MH  - Alkaline Phosphatase/urine
MH  - Animals
MH  - Aspartate Aminotransferases/blood
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Body Weight/drug effects
MH  - Diuresis/drug effects
MH  - Drug Interactions
MH  - Hydrogen-Ion Concentration
MH  - L-Lactate Dehydrogenase/urine
MH  - Male
MH  - Osmolar Concentration
MH  - Rats
MH  - Time Factors
EDAT- 1977/08/01 00:00
MHDA- 1977/08/01 00:01
CRDT- 1977/08/01 00:00
PHST- 1977/08/01 00:00 [pubmed]
PHST- 1977/08/01 00:01 [medline]
PHST- 1977/08/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1977 Aug;17(4):663-78.

PMID- 31259820
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20210209
IS  - 1536-3678 (Electronic)
IS  - 1077-4114 (Linking)
VI  - 42
IP  - 6
DP  - 2020 Aug
TI  - Development and Validation of the Warfarin-Aspirin Bleeding Assessment Tool 
      (WA-BAT) in Children.
PG  - e513-e514
LID - 10.1097/MPH.0000000000001540 [doi]
AB  - Bleeding assessment tools (BATs) aim to screen and estimate bleeding risk in 
      patients with inherited bleeding disorders. However, the use of BAT as a 
      standardized measure for comparing bleeding in patients on long-term 
      thromboprophylaxis has not yet been validated. We developed a self-administrable 
      BAT to assess bleeding in patients undergoing long-term thromboprophylaxis with 
      aspirin or warfarin. Eligible participants were invited to complete the 
      warfarin-aspirin -BAT (WA-BAT) online. The WA-BAT was readministered a number of 
      weeks later to determine intrarater reliability. The WA-BAT showed substantial 
      intrarater reliability and assesses major and minor bleeding associated with 
      long-term warfarin or aspirin use.
FAU - Attard, Chantal
AU  - Attard C
AD  - Murdoch Children's Research Institute.
AD  - Royal Children's Hospital.
AD  - Department of Paediatrics, The University of Melbourne, Parkville.
FAU - Huang, Joanna
AU  - Huang J
AD  - Murdoch Children's Research Institute.
AD  - Royal Children's Hospital.
AD  - School of Clinical Sciences, Monash University, Clayton, Vic., Australia.
FAU - Newall, Fiona
AU  - Newall F
AD  - Murdoch Children's Research Institute.
AD  - Royal Children's Hospital.
AD  - Department of Paediatrics, The University of Melbourne, Parkville.
FAU - Monagle, Paul
AU  - Monagle P
AD  - Murdoch Children's Research Institute.
AD  - Royal Children's Hospital.
AD  - Department of Paediatrics, The University of Melbourne, Parkville.
FAU - d'Udekem, Yves
AU  - d'Udekem Y
AD  - Murdoch Children's Research Institute.
AD  - Royal Children's Hospital.
AD  - Department of Paediatrics, The University of Melbourne, Parkville.
FAU - Ignjatovic, Vera
AU  - Ignjatovic V
AD  - Murdoch Children's Research Institute.
AD  - Royal Children's Hospital.
LA  - eng
PT  - Journal Article
PT  - Validation Study
PL  - United States
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Blood Coagulation Disorders/*diagnosis/drug therapy
MH  - Blood Coagulation Tests/*standards
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Predictive Value of Tests
MH  - Warfarin/*therapeutic use
EDAT- 2019/07/02 06:00
MHDA- 2021/01/01 06:00
CRDT- 2019/07/02 06:00
PHST- 2019/07/02 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
PHST- 2019/07/02 06:00 [entrez]
AID - 00043426-202008000-00038 [pii]
AID - 10.1097/MPH.0000000000001540 [doi]
PST - ppublish
SO  - J Pediatr Hematol Oncol. 2020 Aug;42(6):e513-e514. doi: 
      10.1097/MPH.0000000000001540.

PMID- 15383758
OWN - NLM
STAT- MEDLINE
DCOM- 20041209
LR  - 20131121
IS  - 0257-2753 (Print)
IS  - 0257-2753 (Linking)
VI  - 22
IP  - 2
DP  - 2004
TI  - Acid suppression and chemoprevention in Barrett's oesophagus.
PG  - 171-80
AB  - Barrett's oesophagus is a pre-malignant condition affecting 1% of the population 
      in the West. Even though most patients with Barrett's will not develop 
      oesophageal cancer, the incidence of adenocarcinoma is 0.45-1%, conferring a 
      40-fold increased risk compared with the general population. The risk rises to 
      40-50% within 5 years for those with high grade dysplasia. Currently, the only 
      strategies available to diminish adenocarcinoma rates are surveillance endoscopy, 
      endoscopic thermal or photodynamic ablation or tissue resection. The latter 
      options are reserved for those who already have dysplasia. 10-50% of patients 
      undergoing oesophagectomy for high grade dysplasia have been shown to have 
      adenocarcinoma. Therefore approaches are needed to be that either remove or 
      prevent stimuli propelling patients down the dysplasia-adenocarcinoma pathway. 
      Both gastric acid and bile acids have been reported as potential insults involved 
      in the pathogenesis of Barrett's oesophagus. This is thought to be mediated by a 
      range of molecules including cyclo-oxygenase-2, c-myc and mitogen-activated 
      protein kinase signalling. Proton pump inhibitors not only suppress acid but also 
      bile reflux, although symptom control is a poor guide as to adequacy of acid 
      suppression. There is some evidence that proton pump inhibitors cause partial 
      regression in Barrett's oesophagus length, although the data is contradictory. 
      Proton pump inhibitors have also been shown to increase cell differentiation and 
      apoptosis, reduce proliferation and COX-2 levels, with the supposition that this 
      may diminish cancer risk. However this role in decreasing cancer risk has not yet 
      been evaluated. The use of NSAIDS and aspirin, most likely via inhibition of 
      COX-2 and other inflammatory pathways, is associated with a reduction of 
      adenocarcinoma rates. Both PPIs and NSAIDs/Aspirin may therefore be potential 
      chemopreventative agents but further studies are required to appraise their use.
CI  - Copyright 2004 S. Karger AG, Basel
FAU - Raj, Anita
AU  - Raj A
AD  - Digestive Diseases Centre, Leicester Royal Infirmary, Leicester, UK.
FAU - Jankowski, Janusz
AU  - Jankowski J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Dig Dis
JT  - Digestive diseases (Basel, Switzerland)
JID - 8701186
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Barrett Esophagus/pathology/*prevention & control
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Humans
MH  - Precancerous Conditions
MH  - *Proton Pump Inhibitors
RF  - 129
EDAT- 2004/09/24 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/09/24 05:00
PHST- 2004/09/24 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/09/24 05:00 [entrez]
AID - 80316 [pii]
AID - 10.1159/000080316 [doi]
PST - ppublish
SO  - Dig Dis. 2004;22(2):171-80. doi: 10.1159/000080316.

PMID- 7355383
OWN - NLM
STAT- MEDLINE
DCOM- 19800425
LR  - 20131121
IS  - 0090-3019 (Print)
IS  - 0090-3019 (Linking)
VI  - 13
IP  - 2
DP  - 1980 Feb
TI  - The influence of systemic aspirin on rat small diameter vein grafts: a scanning 
      electron microscopic study.
PG  - 99-108
AB  - Small diameter vein grafts have been shown previously to have a poor patency rate 
      unmedicated rats. Oral aspirin administered to male and female rats for one week 
      pre-operatively reduced the number of platelets laid down on the luminal surface 
      of their grafts, and resulted in a greater number of grafts remaining patent up 
      to one hour after the blood flow through them had been established. The patency 
      rate of grafts examined one to 17 weeks after operation was significantly better 
      in female rats than in males given aspirin pre- and post-operatively. The 
      different effect of aspirin in preventing thrombosis of the vein grafts of the 
      two sexes makes its clinical usefulness for this purpose suspect.
FAU - Bannister, C M
AU  - Bannister CM
FAU - Chapman, S A
AU  - Chapman SA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Surg Neurol
JT  - Surgical neurology
JID - 0367070
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - *Cerebral Revascularization
MH  - Endothelium/ultrastructure
MH  - Female
MH  - Jugular Veins/transplantation/*ultrastructure
MH  - Male
MH  - Microscopy, Electron, Scanning
MH  - Rats
MH  - Sex Factors
MH  - Thrombosis/prevention & control
MH  - Transplantation, Autologous
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
PST - ppublish
SO  - Surg Neurol. 1980 Feb;13(2):99-108.

PMID- 17676393
OWN - NLM
STAT- MEDLINE
DCOM- 20080515
LR  - 20181113
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 53
IP  - 3
DP  - 2008 Mar
TI  - Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg 
      q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week 
      trial.
PG  - 647-56
AB  - AIM: To determine the rate of endoscopic gastric/duodenal ulcers (GDUs) 
      associated with use of aspirin (81 mg q.d.) alone or coadministered with 
      celecoxib or naproxen. METHODS: In this multicenter, double-blind study, healthy 
      subjects were randomized to receive daily aspirin (81 mg q.d.) plus celecoxib 200 
      mg q.d., naproxen 500 mg b.i.d., or placebo. Upper endoscopy was performed at 
      baseline and day 7. The primary end point was incidence of GDUs >or=3 mm 
      diameter. RESULTS: Incidence of GDUs was significantly lower in subjects 
      receiving celecoxib plus aspirin (7%) compared with naproxen plus aspirin (25.3%; 
      relative risk [RR], 0.28 [95% confidence interval (CI), 0.17-0.45]; P < 0.001), 
      but significantly higher than placebo plus aspirin (1.6%; RR, 4.78 [95% CI, 
      1.12-20.32]; P = 0.016). CONCLUSION: In a healthy population taking aspirin (81 
      mg q.d.), coadministration of celecoxib resulted in fewer GDUs than naproxen, but 
      significantly more mucosal damage than aspirin alone.
FAU - Goldstein, Jay L
AU  - Goldstein JL
AD  - College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA. 
      jlgoldst@uic.edu
FAU - Aisenberg, James
AU  - Aisenberg J
FAU - Zakko, Salam F
AU  - Zakko SF
FAU - Berger, Manuela F
AU  - Berger MF
FAU - Dodge, William E
AU  - Dodge WE
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20070804
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - 57Y76R9ATQ (Naproxen)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Celecoxib
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Duodenal Ulcer/*chemically induced
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naproxen/adverse effects
MH  - Pyrazoles/adverse effects
MH  - Random Allocation
MH  - Stomach Ulcer/*chemically induced
MH  - Sulfonamides/adverse effects
EDAT- 2007/08/07 09:00
MHDA- 2008/05/16 09:00
CRDT- 2007/08/07 09:00
PHST- 2007/03/23 00:00 [received]
PHST- 2007/06/04 00:00 [accepted]
PHST- 2007/08/07 09:00 [pubmed]
PHST- 2008/05/16 09:00 [medline]
PHST- 2007/08/07 09:00 [entrez]
AID - 10.1007/s10620-007-9903-4 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2008 Mar;53(3):647-56. doi: 10.1007/s10620-007-9903-4. Epub 2007 Aug 
      4.

PMID- 27129549
OWN - NLM
STAT- MEDLINE
DCOM- 20170807
LR  - 20191210
IS  - 1432-2218 (Electronic)
IS  - 0930-2794 (Linking)
VI  - 30
IP  - 12
DP  - 2016 Dec
TI  - Is preoperative withdrawal of aspirin necessary in patients undergoing elective 
      inguinal hernia repair?
PG  - 5542-5549
AB  - BACKGROUND: Antiplatelets such as aspirin are widely used to reduce thrombotic 
      events in patients with various cardiovascular comorbidities. Continuing aspirin 
      through noncardiac surgery has been shown to reduce risk of major adverse cardiac 
      events (MACE) but may lead to higher bleeding complications. Inguinal hernia 
      repair is a commonly performed surgical procedure among such patients, but no 
      guideline exists regarding perioperative use of aspirin. OBJECTIVE: We aim to 
      investigate the safety profile of aspirin continuation in the perioperative 
      period in patients undergoing elective primary inguinal hernia repair. METHODS: 
      All patients who underwent elective primary inguinal hernia repair from 2008 to 
      2015 and were on aspirin preoperatively were identified. The patients were 
      divided into two groups: those who continued aspirin through the morning of the 
      operation and those who were advised to stop aspirin therapy 3-7 days prior to 
      operation. All patients underwent either open Lichtenstein mesh repair or 
      laparoscopic total extra-peritoneal mesh repair. Outcomes measured include 
      intraoperative blood loss, operative time, bleeding complications, wound site 
      complications and MACE. RESULTS: Among 1841 patients who underwent elective 
      primary inguinal hernia mesh repair, 142 (7.7 %) patients were on preoperative 
      aspirin. Fifty-seven patients underwent laparoscopic repair, while 85 underwent 
      open mesh repair. Twenty-seven out of fifty-seven (47.3 %) from the laparoscopic 
      group and 55/85 (64.7 %) from the open group were instructed to stop aspirin 
      (p = 0.040). There were no significant differences between those who stopped 
      aspirin and those who continued in terms of intraoperative blood loss and 
      operative timing. Immediate postoperative bleeding complications and follow-up 
      wound complications were also similar between the two groups. Overall, there were 
      no MACE among those who underwent laparoscopic repair. Three MACE were recorded 
      in the open group (2 stopped vs. 1 continued; p = 0.943). There was no 
      perioperative mortality. CONCLUSION: Continuation of aspirin is safe and should 
      be preferred in patients with higher cardiovascular risk.
FAU - Ong, Wilson
AU  - Ong W
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore. prooyf@hotmail.com.
FAU - Shen, Tong
AU  - Shen T
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Tan, Wee Boon
AU  - Tan WB
AD  - Department of Surgery, Minimally Invasive Surgical Centre, National University 
      Health System, Yong Loo Lin School of Medicine, National University of Singapore, 
      Singapore, Singapore.
FAU - Lomanto, Davide
AU  - Lomanto D
AD  - Department of Surgery, Minimally Invasive Surgical Centre, National University 
      Health System, Yong Loo Lin School of Medicine, National University of Singapore, 
      Singapore, Singapore.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20160429
PL  - Germany
TA  - Surg Endosc
JT  - Surgical endoscopy
JID - 8806653
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Loss, Surgical/prevention & control/statistics & numerical data
MH  - Drug Administration Schedule
MH  - *Elective Surgical Procedures
MH  - Female
MH  - Follow-Up Studies
MH  - Hernia, Inguinal/*surgery
MH  - *Herniorrhaphy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Operative Time
MH  - Perioperative Care/*methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Complications/chemically induced/epidemiology/prevention & control
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Withholding Treatment
OTO - NOTNLM
OT  - Antiplatelets
OT  - Aspirin
OT  - Inguinal hernia
OT  - Repair
EDAT- 2016/05/01 06:00
MHDA- 2017/08/08 06:00
CRDT- 2016/05/01 06:00
PHST- 2015/11/09 00:00 [received]
PHST- 2016/04/07 00:00 [accepted]
PHST- 2016/05/01 06:00 [pubmed]
PHST- 2017/08/08 06:00 [medline]
PHST- 2016/05/01 06:00 [entrez]
AID - 10.1007/s00464-016-4926-6 [pii]
AID - 10.1007/s00464-016-4926-6 [doi]
PST - ppublish
SO  - Surg Endosc. 2016 Dec;30(12):5542-5549. doi: 10.1007/s00464-016-4926-6. Epub 2016 
      Apr 29.

PMID- 19902063
OWN - NLM
STAT- MEDLINE
DCOM- 20100118
LR  - 20190813
IS  - 1573-8221 (Electronic)
IS  - 0007-4888 (Linking)
VI  - 147
IP  - 6
DP  - 2009 Jun
TI  - Acetylsalicylic acid as a modulator of neutrophil peroxidase system.
PG  - 708-10
AB  - Effect of acetylsalycilic acid (aspirin; Ron-Pulenk) on activity of mouse 
      neutrophil peroxydase system was investigated. Using luminol-dependent 
      chemiluminscence and cytochemical methods we demonstrated that neutrophil 
      peroxydase system in mice receiving aspirin for 14 days is probably determined by 
      stimulation of myeloperoxydase synthesis.
FAU - Mushtakova, V M
AU  - Mushtakova VM
AD  - N. N. Semenov Institute of Chemical Physics of Russian Academy of Sciences, 
      Moscow, Russia. kar12255@orc.ru
FAU - Fomina, V A
AU  - Fomina VA
FAU - Rogovin, V V
AU  - Rogovin VV
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bull Exp Biol Med
JT  - Bulletin of experimental biology and medicine
JID - 0372557
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/*pharmacology
MH  - Male
MH  - Mice
MH  - Neutrophils/*drug effects/*enzymology
MH  - Peroxidase/*metabolism
EDAT- 2009/11/11 06:00
MHDA- 2010/01/19 06:00
CRDT- 2009/11/11 06:00
PHST- 2009/11/11 06:00 [entrez]
PHST- 2009/11/11 06:00 [pubmed]
PHST- 2010/01/19 06:00 [medline]
AID - 10.1007/s10517-009-0598-8 [doi]
PST - ppublish
SO  - Bull Exp Biol Med. 2009 Jun;147(6):708-10. doi: 10.1007/s10517-009-0598-8.

PMID- 7641247
OWN - NLM
STAT- MEDLINE
DCOM- 19950918
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 15
IP  - 2
DP  - 1995 Apr
TI  - The effects of aspirin on the CNV in healthy individuals.
PG  - 129-31; discussion 78
AB  - The effects of aspirin on the contingent negative variation (CNV) of 16 healthy, 
      right-handed volunteers were studied in accordance with a placebo-controlled 
      double-blind crossover design. Early and late CNV factors were measured. Aspirin 
      caused a statistically significant decrease of the early wave and an increase of 
      mean amplitude of the late wave. A central action of aspirin, affecting 
      noradrenergic and dopaminergic structures, may be responsible for the CNV 
      changes.
FAU - Vein, A
AU  - Vein A
AD  - Department of Neurology, Sechenov's Moscow Medical Academy, Russia.
FAU - Voznesenskaya, T
AU  - Voznesenskaya T
FAU - Danilov, A
AU  - Danilov A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/*pharmacology
MH  - Contingent Negative Variation/*drug effects
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Migraine Disorders/drug therapy/physiopathology
MH  - Reference Values
EDAT- 1995/04/01 00:00
MHDA- 1995/04/01 00:01
CRDT- 1995/04/01 00:00
PHST- 1995/04/01 00:00 [pubmed]
PHST- 1995/04/01 00:01 [medline]
PHST- 1995/04/01 00:00 [entrez]
AID - 10.1046/j.1468-2982.1995.015002129.x [doi]
PST - ppublish
SO  - Cephalalgia. 1995 Apr;15(2):129-31; discussion 78. doi: 
      10.1046/j.1468-2982.1995.015002129.x.

PMID- 321177
OWN - NLM
STAT- MEDLINE
DCOM- 19770527
LR  - 20201209
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 21
IP  - 4
DP  - 1977 Apr
TI  - Naproxen, aspirin, and codeine in postpartum uterine pain.
PG  - 414-21
AB  - The analgesic efficacy of oral naproxen and its sodium salt was compared with 
      that of aspirin and codeine in two separate trials involving 140 and 90 patients, 
      respectively, with postpartum uterine pain in a single-dose, parallel, 
      stratified, randomized, placebo-controlled, double-blind design. With 300 or 600 
      mg naproxen and with 275 mg naproxen sodium, significant analgesia, measured 
      subjectively by pain intensity differences (PID), was prolonged at least 7 or 8 
      hr; onset tended to be delayed 2 hr or more. With 650 mg aspirin analgesia began 
      within 1 hr and continued until the fifth hour, while with 60 mg codeine 
      responses were indistinguishable from placebo responses throughout the 8-hr time 
      course. Although time-effect patterns with naproxen sodium and aspirin were 
      different, summed analgesic effects (SPID) showed equal efficacy and superiority 
      over placebo (p less than 0.005). With each of the 2 doses of naproxen, SPID 
      separation from placebo was comparable to that above (p less than 0.02 and 0.005, 
      respectively), but analgesic dose response, though measurable, was not 
      significant. Side effects were not significant with any of the treatments. It 
      appears that naproxen and naproxen sodium are analgesics with efficacy equal to 
      aspirin and may prove to be rational substitutes for currently available 
      analgesics in some painful states in which longer pain relief would be 
      desireable.
FAU - Bloomfield, S S
AU  - Bloomfield SS
FAU - Barden, T P
AU  - Barden TP
FAU - Mitchell, J
AU  - Mitchell J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Naphthaleneacetic Acids)
RN  - 0 (Placebos)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Codeine/adverse effects/*therapeutic use
MH  - Delivery, Obstetric/adverse effects
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Naphthaleneacetic Acids/*therapeutic use
MH  - Naproxen/adverse effects/*therapeutic use
MH  - Pain/*drug therapy
MH  - Placebos
MH  - Postnatal Care
MH  - Pregnancy
MH  - Puerperal Disorders/*drug therapy
MH  - *Uterus
EDAT- 1977/04/01 00:00
MHDA- 1977/04/01 00:01
CRDT- 1977/04/01 00:00
PHST- 1977/04/01 00:00 [pubmed]
PHST- 1977/04/01 00:01 [medline]
PHST- 1977/04/01 00:00 [entrez]
AID - 0009-9236(77)90321-6 [pii]
AID - 10.1002/cpt1977214414 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1977 Apr;21(4):414-21. doi: 10.1002/cpt1977214414.

PMID- 11592847
OWN - NLM
STAT- MEDLINE
DCOM- 20020123
LR  - 20151119
IS  - 0969-9961 (Print)
IS  - 0969-9961 (Linking)
VI  - 8
IP  - 5
DP  - 2001 Oct
TI  - Attenuation of Zn2+ neurotoxicity by aspirin: role of N-type Ca2+ channel and the 
      carboxyl acid group.
PG  - 774-83
AB  - Synaptically released Zn2+ ions enter into neurons primarily through 
      voltage-gated Ca2+ channels (VGCC) or N-methyl-d-aspartate (NMDA) receptors, 
      which can mediate pathological neuronal death. We studied the possibility (and 
      underlying mechanisms) that aspirin, known to prevent NMDA neurotoxicity, would 
      also attenuate Zn2+ neurotoxicity. Administration of 3 to 10 mM aspirin, in 
      cortical cell cultures, attenuated the evolution of neuronal death following 
      exposure to 300 microM Zn2+ for 30 min. This neuroprotective effect of aspirin 
      was attributable to the prevention of Zn2+ ion entry. Aspirin interfered with 
      inward currents and an increase in [Ca2+]i through VGCC and selective binding of 
      omega-conotoxin, sensitive to N-type Ca2+ channel. The omega-conotoxins GVIA or 
      MVIIC, the selective inhibitors of N-type Ca2+ channels, attenuated Zn2+ 
      neurotoxicity. Aspirin derivatives lacking the carboxyl acid group did not reduce 
      Zn2+ neurotoxicity. The present findings suggest that aspirin prevents 
      Zn2+-mediated neuronal death by interfering with VGCC, and its action 
      specifically requires the carboxyl acid group.
CI  - Copyright 2001 Academic Press.
FAU - Kim, E Y
AU  - Kim EY
AD  - Department of Pharmacology and Center for the Interventional Therapy of Stroke 
      and Alzheimer's Disease, Ajou University School of Medicine, Suwon, Kyunggi-do, 
      442-749, Korea.
FAU - Chang, S Y
AU  - Chang SY
FAU - Chung, J M
AU  - Chung JM
FAU - Ryu, B R
AU  - Ryu BR
FAU - Joo, C K
AU  - Joo CK
FAU - Moon, H S
AU  - Moon HS
FAU - Kang, K
AU  - Kang K
FAU - Yoon, S H
AU  - Yoon SH
FAU - Han, P L
AU  - Han PL
FAU - Gwag, B J
AU  - Gwag BJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurobiol Dis
JT  - Neurobiology of disease
JID - 9500169
RN  - 0 (2-acetoxymethylbenzoate)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Benzoates)
RN  - 0 (Calcium Channels, N-Type)
RN  - 0 (Chromans)
RN  - 0 (Excitatory Amino Acid Agonists)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (ethyl-2-acetoxyethylbenzoate)
RN  - 0 (omega-Conotoxins)
RN  - 147794-23-8 (omega-conotoxin-MVIIC)
RN  - 6384-92-5 (N-Methylaspartate)
RN  - 92078-76-7 (omega-Conotoxin GVIA)
RN  - H88EPA0A3N (Staurosporine)
RN  - J41CSQ7QDS (Zinc)
RN  - R16CO5Y76E (Aspirin)
RN  - S18UL9710X (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid)
RN  - SY7Q814VUP (Calcium)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Antioxidants/pharmacology
MH  - Apoptosis/*drug effects
MH  - Aspirin/analogs & derivatives/chemistry/*pharmacology
MH  - Benzoates/pharmacology
MH  - Calcium/metabolism
MH  - Calcium Channels, N-Type/drug effects/*physiology
MH  - Cerebral Cortex/cytology/drug effects
MH  - Chromans/pharmacology
MH  - Excitatory Amino Acid Agonists/pharmacology
MH  - Ion Channel Gating/drug effects
MH  - Ion Transport/*drug effects
MH  - Membrane Potentials/drug effects
MH  - Mice
MH  - N-Methylaspartate/pharmacology
MH  - Nerve Tissue Proteins/drug effects/*physiology
MH  - Neurons/*drug effects/metabolism
MH  - Neuroprotective Agents/*pharmacology
MH  - Staurosporine/pharmacology
MH  - Structure-Activity Relationship
MH  - Zinc/antagonists & inhibitors/pharmacology/*toxicity
MH  - omega-Conotoxin GVIA/pharmacology
MH  - omega-Conotoxins/pharmacology
EDAT- 2001/10/11 10:00
MHDA- 2002/01/24 10:01
CRDT- 2001/10/11 10:00
PHST- 2001/10/11 10:00 [pubmed]
PHST- 2002/01/24 10:01 [medline]
PHST- 2001/10/11 10:00 [entrez]
AID - S0969996101904218 [pii]
AID - 10.1006/nbdi.2001.0421 [doi]
PST - ppublish
SO  - Neurobiol Dis. 2001 Oct;8(5):774-83. doi: 10.1006/nbdi.2001.0421.

PMID- 29319492
OWN - NLM
STAT- MEDLINE
DCOM- 20180706
LR  - 20181202
IS  - 0301-0430 (Print)
IS  - 0301-0430 (Linking)
VI  - 89
IP  - 2
DP  - 2018 Feb
TI  - Risk of complications with use of aspirin during renal biopsy: A systematic 
      review.
PG  - 67-76
LID - 10.5414/CN109274 [doi]
AB  - BACKGROUND: Bleeding is a well-known complication of percutaneous renal biopsy 
      (PRB). Thus, antiplatelet agents are routinely held for most patients undergoing 
      elective PRB to decrease bleeding risk. MATERIALS AND METHODS: In this systematic 
      review, we examine the association between antiplatelet use and bleeding during 
      PRB. MEDLINE and EMBASE were searched from inception to December 2016 using terms 
      that included "renal biopsy", "antiplatelet","aspirin", and "bleeding". 
      Guidelines and systematic reviews were identified primarily through large 
      databases, including the National Guideline Clearinghouse and Cochrane Database 
      of Systematic Reviews. Two authors independently screened the results, and 
      appraised and graded the evidence using the Grading of Recommendations 
      Assessment, Development, and Evaluation (GRADE) approach. RESULTS: Out of 371 
      guidelines, 40 systematic reviews, and 709 primary studies originally identified, 
      4 guidelines, 1 systematic review, and 2 primary studies met inclusion criteria. 
      The guidelines recommend halting aspirin for elective PRB. The systematic review 
      found no difference in major outcomes for PRB in patients for whom aspirin was 
      continued versus halted, but was of low quality. The 2 nonrandomized primary 
      studies in PRB patients managed with and without aspirin found no difference in 
      major bleeds but a higher risk of minor bleeds. CONCLUSIONS: There is low-quality 
      evidence on the effect of aspirin on bleeding risk from PRB. It is reasonable to 
      discontinue aspirin 7 - 10 days prior to nonemergent biopsies, in accordance with 
      guidelines. Given the results from the primary studies, it is reasonable to 
      perform randomized controlled trials to obtain high-quality evidence to inform 
      clinical practice. .
FAU - Kumar, Vinayak
AU  - Kumar V
FAU - Mitchell, Matthew D
AU  - Mitchell MD
FAU - Umscheid, Craig A
AU  - Umscheid CA
FAU - Berns, Jeffrey S
AU  - Berns JS
FAU - Hogan, Jonathan J
AU  - Hogan JJ
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - Germany
TA  - Clin Nephrol
JT  - Clinical nephrology
JID - 0364441
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Biopsy/*adverse effects
MH  - Humans
MH  - Kidney/*pathology
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Hemorrhage/*etiology/*prevention & control
MH  - Risk
EDAT- 2018/01/11 06:00
MHDA- 2018/07/07 06:00
CRDT- 2018/01/11 06:00
PHST- 2018/01/17 00:00 [accepted]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2018/07/07 06:00 [medline]
PHST- 2018/01/11 06:00 [entrez]
AID - 16534 [pii]
AID - 10.5414/CN109274 [doi]
PST - ppublish
SO  - Clin Nephrol. 2018 Feb;89(2):67-76. doi: 10.5414/CN109274.

PMID- 28267249
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 15
IP  - 5
DP  - 2017 May
TI  - Once versus twice daily aspirin after coronary bypass surgery: a randomized 
      trial.
PG  - 889-896
LID - 10.1111/jth.13667 [doi]
AB  - Essentials Coronary artery bypass graft (CABG) failure is associated with 
      myocardial infarction and death. We tested whether more frequent dosing improves 
      aspirin (ASA) response following CABG surgery. Twice-daily compared with 
      once-daily dosing reduces ASA hyporesponsiveness after CABG surgery. The efficacy 
      of twice-daily ASA needs to be tested in a trial powered for clinical outcomes. 
      SUMMARY: Background Acetyl-salicylic acid (ASA) hyporesponsiveness occurs 
      transiently after coronary artery bypass graft (CABG) surgery and may compromise 
      the effectiveness of ASA in reducing thrombotic graft failure. A reduced response 
      to ASA 81 mg once-daily after CABG surgery is overcome by four times daily ASA 
      dosing. Objectives To determine whether ASA 325 mg once-daily or 162 mg 
      twice-daily overcomes a reduced response to ASA 81 mg once-daily after CABG 
      surgery. Methods Adults undergoing CABG surgery were randomized to ASA 81 mg 
      once-daily, 325 mg once-daily or 162 mg twice-daily. The primary outcome was 
      median serum thromboxane B(2) (TXB(2) ) level on postoperative day 4. We pooled 
      the results with those of our earlier study to obtain better estimates of the 
      effect of ASA 325 mg once-daily or in divided doses over 24 h. Results We 
      randomized 68 patients undergoing CABG surgery. On postoperative day 4, patients 
      randomized to receive ASA 81 mg once-daily had a median day 4 TXB(2) level of 4.2 
      ng mL(-1) (Q1, Q3: 1.5, 7.5 ng mL(-1) ), which was higher than in those 
      randomized to ASA 162 mg twice-daily (1.1 ng mL(-1) ; Q1, Q3: 0.7, 2.7 ng mL(-1) 
      ) and similar to those randomized to ASA 325 mg once-daily (1.9 ng mL(-1) ; Q1, 
      Q3: 0.9, 4.7 ng mL(-1) ). Pooled data showed that the median TXB(2) level on day 
      4 in groups receiving ASA 162 mg twice-daily or 81 mg four times daily was 1.1 ng 
      mL(-1) compared with 2.2 ng mL(-1) in those receiving ASA 325 mg once-daily. 
      Conclusions Multiple daily dosing of ASA is more effective than ASA 81 mg 
      once-daily or 325 mg once-daily at suppressing serum TXB(2) formation after CABG 
      surgery. A twice-daily treatment regimen needs to be tested in a clinical outcome 
      study.
CI  - © 2017 International Society on Thrombosis and Haemostasis.
FAU - Paikin, J S
AU  - Paikin JS
AD  - Hamilton General Hospital, McMaster University, Hamilton, ON, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
FAU - Hirsh, J
AU  - Hirsh J
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
AD  - Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
FAU - Ginsberg, J S
AU  - Ginsberg JS
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
AD  - Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, 
      ON, Canada.
FAU - Weitz, J I
AU  - Weitz JI
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
AD  - Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, 
      ON, Canada.
FAU - Chan, N C
AU  - Chan NC
AD  - Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
FAU - Whitlock, R P
AU  - Whitlock RP
AD  - Hamilton General Hospital, McMaster University, Hamilton, ON, Canada.
AD  - Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
FAU - Pare, G
AU  - Pare G
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
AD  - Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
FAU - Eikelboom, J W
AU  - Eikelboom JW
AD  - Hamilton General Hospital, McMaster University, Hamilton, ON, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
AD  - Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20170418
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Biomarkers/blood
MH  - Blood Platelets/*drug effects/metabolism
MH  - *Coronary Artery Bypass/adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ontario
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Platelet Function Tests
MH  - Thromboxane B2/blood
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin
OT  - coronary artery bypass
OT  - drug resistance
OT  - platelet function tests
EDAT- 2017/03/08 06:00
MHDA- 2018/03/27 06:00
CRDT- 2017/03/08 06:00
PHST- 2016/06/13 00:00 [received]
PHST- 2017/03/08 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
PHST- 2017/03/08 06:00 [entrez]
AID - S1538-7836(22)00889-3 [pii]
AID - 10.1111/jth.13667 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2017 May;15(5):889-896. doi: 10.1111/jth.13667. Epub 2017 Apr 
      18.

PMID- 14730253
OWN - NLM
STAT- MEDLINE
DCOM- 20040429
LR  - 20131121
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 17 Suppl 3
DP  - 2004
TI  - Ongoing and planned trials of antiplatelet therapy in the acute and long-term 
      management of patients with ischaemic brain syndromes: setting a new standard of 
      care.
PG  - 11-6
AB  - Among high vascular risk patients, acetylsalicylic acid (ASA) reduces the 
      relative risk of serious vascular events by about one fifth. However, because ASA 
      fails to prevent four fifths of serious vascular events, more effective, yet 
      equally safe and affordable, antiplatelet regimens are desired. Compared with 
      ASA, clopidogrel alone reduces the odds of serious vascular events by about 10%, 
      and the combination of dipyridamole and ASA reduces the odds of serious vascular 
      events by about 6%. Combining ASA with an orally administered platelet 
      glycoprotein (GP) IIb/IIIa blocker is not effective, and indeed more hazardous 
      than ASA alone. Among patients with non-ST-segment acute coronary syndromes 
      (ACS), the addition of an intravenously administered GP IIb/IIIa receptor 
      antagonist to ASA reduces the risk of vascular events by about 10% compared with 
      ASA, and the addition of clopidogrel to ASA reduces the risk of vascular events 
      by 20% compared with ASA alone. Among patients undergoing percutaneous coronary 
      intervention (PCI), both the addition of an intravenously administered GP 
      IIb/IIIa receptor antagonist to ASA, and the addition of clopidogrel to ASA 
      reduce the risk of vascular events by 30% compared with ASA alone. The greater 
      efficacy of the combinations of ASA with clopidogrel, and ASA with an 
      intravenously administered GP IIb/IIIa receptor antagonist, in patients with ACS 
      and those undergoing PCI has fostered several ongoing and planned trials of these 
      regimens in the acute and long-term management of patients with ischaemic brain 
      syndromes. The combination of ASA and clopidogrel is being compared with ASA 
      alone within 12 h of onset of symptoms of TIA in two trials (FASTER, ATARI), and 
      the use of an intravenously administered GP IIb/IIIa receptor antagonist is being 
      compared with placebo within 6 h of onset of acute ischaemic stroke in two trials 
      (AbESST, AbESST-2). Six trials are assessing the combination of clopidogrel and 
      ASA in the long-term management of patients with ischaemic brain syndromes due to 
      atherothrombosis (MATCH, CHARISMA, ARCH, CARESS, SPS3) or atrial fibrillation 
      (ACTIVE). The MATCH trial of clopidogrel and ASA versus clopidogrel alone in 
      patients with recent TIA or ischaemic stroke is the first which is likely to 
      report its results - in mid 2004. The combination of dipyridamole and ASA is 
      being compared with ASA in the ESPRIT trial and with the combination of 
      clopidogrel and ASA in the planned PRoFESS trial. These ongoing and planned 
      clinical trials of antiplatelet therapy promise to further define the role of 
      combination antiplatelet therapy in the acute and long-term management of 
      patients with ischaemic brain syndromes.
CI  - Copyright 2004 S. Karger AG, Basel
FAU - Hankey, Graeme J
AU  - Hankey GJ
AD  - Stroke Unit, Department of Neurology, Royal Perth Hospital, Perth, WA, Australia. 
      gjhankey@cyllene.uwa.edu.au
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/standards/therapeutic use
MH  - Brain Ischemia/*drug therapy/epidemiology
MH  - Disease Management
MH  - Humans
MH  - Patient Care/standards
MH  - Platelet Aggregation Inhibitors/standards/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/standards/therapeutic use
MH  - Risk Factors
MH  - Stroke/drug therapy/epidemiology
MH  - Syndrome
MH  - Time Factors
RF  - 19
EDAT- 2004/01/20 05:00
MHDA- 2004/04/30 05:00
CRDT- 2004/01/20 05:00
PHST- 2004/01/20 05:00 [pubmed]
PHST- 2004/04/30 05:00 [medline]
PHST- 2004/01/20 05:00 [entrez]
AID - 75299 [pii]
AID - 10.1159/000075299 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2004;17 Suppl 3:11-6. doi: 10.1159/000075299.

PMID- 34530594
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20220531
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 49
IP  - 9
DP  - 2021 Sep 24
TI  - [Rivaroxaban with aspirin for the secondary prevention of cardiovascular events 
      in Chinese patients with stable cardiovascular diseases: subgroup analysis of 
      COMPASS].
PG  - 873-879
LID - 10.3760/cma.j.cn112148-20210319-00247 [doi]
AB  - Objective: This analysis was performed to evaluate the efficacy and the safety of 
      rivaroxaban-aspirin combination therapy in secondary prevention of major adverse 
      cardiovascular events in Chinese patients enrolled in the COMPASS trial. Methods: 
      COMPASS was a prospective, international multi-center and randomized controlled 
      trial. From September 2014 to February 2017, 1 086 patients with stable coronary 
      artery disease and peripheral artery diseases were recruited from 31 centers in 
      China. Patients were randomly assigned to separately receive the therapy of 
      rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day,) group (n=366), 
      rivaroxaban (5 mg twice a day) alone group (n=365), and aspirin (100 mg once a 
      day) alone group (n=355). Baseline information such as age, sex, etc. of all 
      three groups was collected. Finally, 1 081 patients were followed up 
      successfully, with the follow-up rate 99.5% and the average follow-up time was 19 
      months. The primary efficacy endpoint was the composite of cardiovascular death, 
      myocardial infarction and stroke. The primary safety endpoint was major bleeding 
      evaluated by modified International Society on Thrombosis and Haemostasis 
      criteria. Results: Age of patients was (64.2±8.3) years and there were 293 male 
      in rivaroxaban plus aspirin group. Age of patients was (63.8±9.0) years, and 
      there were 301 male patients in rivaroxaban alone group. Age of patients was 
      (63.6±8.8) years, and there were 282 male patients in the aspirin alone group. 
      The incidences of primary efficacy endpoint occurred in 9 cases (1.5%) in 
      rivaroxaban with aspirin group, 21 cases (3.7%) in rivaroxaban alone group and 14 
      cases (2.5%) in aspirin alone group. Meanwhile, the incidences of primary safety 
      endpoint occurred in 6 cases (1.0%) in rivaroxaban with aspirin group, 9 cases 
      (1.6%) in rivaroxaban alone group and 7 cases (1.2%) in aspirin alone group. The 
      net clinical benefit events were 10 cases (1.7%) in rivaroxaban with aspirin 
      group, 22 cases (3.9%) in rivaroxaban alone group and 15 cases (2.7%) in aspirin 
      alone group (P>0.5%). Conclusions: The combination of rivaroxaban with aspirin 
      can be safe and effectively used for the secondary prevention in Chinese patients 
      with stable coronary artery disease and peripheral artery diseases.
FAU - Liang, Y
AU  - Liang Y
AD  - Emergency and Intensive Care Center, Cardiovascular Department, Fuwai Hospital, 
      Chinses Academy of Medical Sciences and Peking Union Medical College, Beijing 
      100037, China.
FAU - Gong, Z B
AU  - Gong ZB
AD  - Emergency and Intensive Care Center, Cardiovascular Department, Fuwai Hospital, 
      Chinses Academy of Medical Sciences and Peking Union Medical College, Beijing 
      100037, China.
FAU - Lou, K J
AU  - Lou KJ
AD  - Emergency and Intensive Care Center, Cardiovascular Department, Fuwai Hospital, 
      Chinses Academy of Medical Sciences and Peking Union Medical College, Beijing 
      100037, China.
FAU - Liu, L S
AU  - Liu LS
AD  - Emergency and Intensive Care Center, Cardiovascular Department, Fuwai Hospital, 
      Chinses Academy of Medical Sciences and Peking Union Medical College, Beijing 
      100037, China.
FAU - Zhu, J
AU  - Zhu J
AD  - Emergency and Intensive Care Center, Cardiovascular Department, Fuwai Hospital, 
      Chinses Academy of Medical Sciences and Peking Union Medical College, Beijing 
      100037, China.
LA  - chi
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/drug therapy/prevention & control
MH  - China
MH  - Drug Therapy, Combination
MH  - Factor Xa Inhibitors/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prospective Studies
MH  - *Rivaroxaban/therapeutic use
MH  - Secondary Prevention
EDAT- 2021/09/18 06:00
MHDA- 2021/09/21 06:00
CRDT- 2021/09/17 03:54
PHST- 2021/09/17 03:54 [entrez]
PHST- 2021/09/18 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
AID - 10.3760/cma.j.cn112148-20210319-00247 [doi]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2021 Sep 24;49(9):873-879. doi: 
      10.3760/cma.j.cn112148-20210319-00247.

PMID- 20224050
OWN - NLM
STAT- MEDLINE
DCOM- 20100518
LR  - 20191210
IS  - 1530-8561 (Electronic)
IS  - 0009-9147 (Linking)
VI  - 56
IP  - 5
DP  - 2010 May
TI  - Long-term aspirin and clopidogrel response evaluated by light transmission 
      aggregometry, VerifyNow, and thrombelastography in patients undergoing 
      percutaneous coronary intervention.
PG  - 839-47
LID - 10.1373/clinchem.2009.137471 [doi]
AB  - BACKGROUND: A reduced response to aspirin and clopidogrel predicts ischemic 
      events, but reliable tests are needed to identify low responders. We compared 3 
      platelet-function tests during long-term dual treatment with aspirin and 
      clopidogrel. METHODS: Patients who underwent a percutaneous coronary intervention 
      and were receiving a combination of 325 mg/day aspirin and 75 mg/day clopidogrel 
      were followed for 1 year. Blood was sampled 5 times during this period for 3 
      tests: light transmission aggregometry (LTA) assay, with 5.0 micromol/L ADP or 
      1.0 mmol/L arachidonic acid (AA) used as an agonist; VerifyNow assay, with the 
      P2Y(12) or aspirin cartridge (Accumetrics); and thrombelastography (TEG), 
      stimulated by 2.0 micromol/L ADP or 1.0 mmol/L AA. RESULTS: Twenty-six of 33 
      patients completed all scheduled visits. A low response to clopidogrel was found 
      in a few patients at variable frequencies and at different visits, depending on 
      the method and criteria used. We found a moderate correlation between the LTA 
      (ADP) and VerifyNow (P2Y(12) cartridge) results, but the TEG (ADP) results 
      correlated poorly with the LTA and VerifyNow results. A low response to aspirin 
      was found with the VerifyNow (aspirin cartridge) and TEG (AA) methods on 6 and 2 
      occasions, respectively, but not with the LTA (AA) method, except for 1 occasion 
      caused by probable noncompliance. CONCLUSIONS: Detecting a low response to 
      clopidogrel depends largely on the method used. Which method best predicts 
      ischemic events remains uncertain. A low response to aspirin is rare with 
      AA-dependent methods used at the chosen cutoffs. In some patients, the response 
      to clopidogrel or aspirin may be classified differently at different times, even 
      with the same method.
FAU - Madsen, Esben Hjorth
AU  - Madsen EH
AD  - Department of Clinical Biochemistry, Center for Cardiovascular Research, Aalborg 
      Hospital, Aarhus University Hospital, Aalborg, Denmark. ehmadsen@gmail.com
FAU - Saw, Jacqueline
AU  - Saw J
FAU - Kristensen, Søren Risom
AU  - Kristensen SR
FAU - Schmidt, Erik Berg
AU  - Schmidt EB
FAU - Pittendreigh, Cheryl
AU  - Pittendreigh C
FAU - Maurer-Spurej, Elisabeth
AU  - Maurer-Spurej E
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100311
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Platelet Function Tests
MH  - Thrombelastography
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2010/03/13 06:00
MHDA- 2010/05/19 06:00
CRDT- 2010/03/13 06:00
PHST- 2010/03/13 06:00 [entrez]
PHST- 2010/03/13 06:00 [pubmed]
PHST- 2010/05/19 06:00 [medline]
AID - clinchem.2009.137471 [pii]
AID - 10.1373/clinchem.2009.137471 [doi]
PST - ppublish
SO  - Clin Chem. 2010 May;56(5):839-47. doi: 10.1373/clinchem.2009.137471. Epub 2010 
      Mar 11.

PMID- 7986557
OWN - NLM
STAT- MEDLINE
DCOM- 19950112
LR  - 20190512
IS  - 1010-7940 (Print)
IS  - 1010-7940 (Linking)
VI  - 8
IP  - 8
DP  - 1994
TI  - Pre-operative aspirin decreases platelet aggregation and increases post-operative 
      blood loss--a prospective, randomised, placebo controlled, double-blind clinical 
      trial in 100 patients with chronic stable angina.
PG  - 404-9
AB  - Aspirin has an established benefit in reducing the incidence of coronary events 
      and vein graft occlusion. We have now assessed the risk of pre-operative aspirin 
      in a prospective, randomised, double-blind clinical trial in 100 patients 
      scheduled for elective coronary artery surgery. Any prescribed aspirin and 
      non-steroidal anti-inflammatory drugs were discontinued 2 weeks pre-operatively 
      and these were replaced by a randomly assigned tablet of either aspirin 300 mg 
      daily or placebo taken until the day of surgery. Patient compliance was confirmed 
      by serum and urinary salicylate analysis. The two groups were similar in 
      demographic characteristics, bypass time, number of grafts placed and number of 
      internal mammary arteries used. All patients survived to be discharged home (see 
      Table). Aspirin decreases platelet aggregation to arachidonic acid and to 
      collagen both pre- and post-operatively. The benefit of pre-operative aspirin has 
      to be balanced against the risk of increasing post-operative blood loss, 
      re-exploration for excessive bleeding and transfusion requirements.
FAU - Kallis, P
AU  - Kallis P
AD  - Harefield Hospital, Middlesex, UK.
FAU - Tooze, J A
AU  - Tooze JA
FAU - Talbot, S
AU  - Talbot S
FAU - Cowans, D
AU  - Cowans D
FAU - Bevan, D H
AU  - Bevan DH
FAU - Treasure, T
AU  - Treasure T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European 
      Association for Cardio-thoracic Surgery
JID - 8804069
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Coagulation Tests
MH  - Blood Loss, Surgical/*physiopathology
MH  - Blood Transfusion
MH  - *Coronary Artery Bypass
MH  - Coronary Disease/blood/*surgery
MH  - Double-Blind Method
MH  - Female
MH  - Graft Occlusion, Vascular/blood/*prevention & control
MH  - Humans
MH  - Internal Mammary-Coronary Artery Anastomosis
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Postoperative Complications/blood/*chemically induced
MH  - *Preoperative Care
MH  - Prospective Studies
MH  - Reoperation
MH  - Risk Factors
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1016/1010-7940(94)90081-7 [doi]
PST - ppublish
SO  - Eur J Cardiothorac Surg. 1994;8(8):404-9. doi: 10.1016/1010-7940(94)90081-7.

PMID- 7942522
OWN - NLM
STAT- MEDLINE
DCOM- 19941026
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 74
IP  - 7
DP  - 1994 Oct 1
TI  - Safety and anticoagulation effect of a low-dose combination of warfarin and 
      aspirin in clinically stable coronary artery disease. Coumadin Aspirin 
      Reinfarction (CARS) Pilot Study Group.
PG  - 657-61
AB  - The hypothesis that the combination of low-dose aspirin and warfarin therapy is 
      more effective than aspirin alone in secondary prophylaxis after myocardial 
      infarction is to be examined in the Coumadin Aspirin Reinfarction Study. This 
      pilot study addressed the safety and anticoagulation effect of a fixed, low-dose 
      combination in 114 patients (aged 64 +/- 8 years, 85% men) with stable coronary 
      artery disease receiving 3 mg of warfarin plus 80 mg of aspirin daily for 8 
      weeks. The international normalized ratio (INR) was measured within 72 hours of 
      initial therapy, and weekly. Of the 110 patients with evaluable INRs, 87 patients 
      (79%) maintained the 3 + 80 mg combination, 19 (17%) had the dose reduced to 1 mg 
      warfarin + 80 mg aspirin, and 4 (4%) discontinued therapy because of a confirmed 
      INR of > or = 4.5. At steady state, patients had INRs of 1.48 +/- 0.41 (3 + 80 mg 
      group) and 1.21 +/- 0.23 (1 + 80 mg group), and inter- and intra-patient 
      variability (estimated by the mean of the between- and within-patient SDs at 
      steady state) was 0.49 +/- 0.08 and 0.13 +/- 0.14, respectively. There was no 
      apparent effect of age on INR distribution. Microscopic hematuria was the most 
      frequent (20%) adverse clinical event, but was unrelated to the INR. Three 
      patients required discontinuation of therapy because of bleeding events 
      (persistent hematuria and epistaxis). A fixed low-dose combination of warfarin 
      and aspirin results in a predictable and stable increase in the INR in a large 
      proportion of patients with coronary artery disease.(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Goodman, S G
AU  - Goodman SG
AD  - Department of Medicine, St. Michael's Hospital, University of Toronto, Canada.
FAU - Langer, A
AU  - Langer A
FAU - Durica, S S
AU  - Durica SS
FAU - Raskob, G E
AU  - Raskob GE
FAU - Comp, P C
AU  - Comp PC
FAU - Gray, R J
AU  - Gray RJ
FAU - Hall, J H
AU  - Hall JH
FAU - Kelley, R P
AU  - Kelley RP
FAU - Hua, T A
AU  - Hua TA
FAU - Lee, R J
AU  - Lee RJ
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*administration & dosage
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Coagulation/*drug effects
MH  - Coronary Disease/blood/*drug therapy
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Hematuria/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Proportional Hazards Models
MH  - Warfarin/*administration & dosage/adverse effects
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 0002-9149(94)90305-0 [pii]
AID - 10.1016/0002-9149(94)90305-0 [doi]
PST - ppublish
SO  - Am J Cardiol. 1994 Oct 1;74(7):657-61. doi: 10.1016/0002-9149(94)90305-0.

PMID- 35147530
OWN - NLM
STAT- MEDLINE
DCOM- 20221227
LR  - 20230103
IS  - 1875-8622 (Electronic)
IS  - 1386-0291 (Linking)
VI  - 82
IP  - 3
DP  - 2022
TI  - Lipoxins in inflammation.
PG  - 201-216
LID - 10.3233/CH-211346 [doi]
AB  - Lipoxins and ATL appear to be the first recognized members of a new class of 
      endogenous mediator that are anti-inflammatory or serve for the "pro-resolution" 
      of inflammation. PGE2 can and may display anti-inflammatory properties in certain 
      settings, but in most cases, it enhances inflammation in vivo. This is likely the 
      result of numerous receptor isoforms and differential coupled mechanisms for PGE2 
      and its diverse role in human physiology. Since the integrated response of the 
      host is essential to health and disease, it is important to achieve a more 
      complete understanding of the molecular and cellular events governing the 
      formation and actions of endogenous mediators of resolution that appear to 
      control the magnitude and duration of inflammation. In view of the present body 
      of evidence, it is not surprising that a protective action for inhibition of 
      COX-2 was found in cardiovascular disease. Characterizing useful experimental 
      systems with clinically relevant endpoints will also take a multidisciplinary 
      approach and require a shift in our current thinking about inflammation and the 
      role of lipid mediators.
FAU - Sachdeva, Shivani
AU  - Sachdeva S
AD  - Department of Periodontology, Pravara Institute of Medical Sciences, Rdc, Loni, 
      Maharashtra, India.
FAU - Saluja, Harish
AU  - Saluja H
AD  - Department of Oral and Maxillofacial Surgery, Pravara Institute of Medical 
      Sciences, Rdc, Loni, Maharashtra, India.
FAU - Mani, Ameet
AU  - Mani A
AD  - Department of Periodontology, Pravara Institute of Medical Sciences, Rdc, Loni, 
      Maharashtra, India.
FAU - Phadnaik, M B
AU  - Phadnaik MB
AD  - Department of Periodontology, #Government Dental College Nagpur, Maharashtra, 
      India.
FAU - Mani, Shubhangi
AU  - Mani S
AD  - Department of Orthodontics, Pravara Institute of Medical Sciences, Rdc, Loni, 
      Maharashtra, India.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - 0 (Lipoxins)
RN  - R16CO5Y76E (Aspirin)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Anti-Inflammatory Agents)
SB  - IM
MH  - Humans
MH  - *Lipoxins/physiology/therapeutic use
MH  - Aspirin/pharmacology
MH  - Dinoprostone/therapeutic use
MH  - Inflammation Mediators/physiology/therapeutic use
MH  - Inflammation/drug therapy
MH  - Anti-Inflammatory Agents/therapeutic use
OTO - NOTNLM
OT  - Lipoxins
OT  - anti-inflammatory
OT  - chemical mediators
EDAT- 2022/02/12 06:00
MHDA- 2022/12/28 06:00
CRDT- 2022/02/11 12:12
PHST- 2022/02/12 06:00 [pubmed]
PHST- 2022/12/28 06:00 [medline]
PHST- 2022/02/11 12:12 [entrez]
AID - CH211346 [pii]
AID - 10.3233/CH-211346 [doi]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 2022;82(3):201-216. doi: 10.3233/CH-211346.

PMID- 35773430
OWN - NLM
STAT- MEDLINE
DCOM- 20230414
LR  - 20230414
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 149
IP  - 5
DP  - 2023 May
TI  - The protective effect of aspirin-induced temporary threshold shift in an animal 
      model of cisplatin-related ototoxicity.
PG  - 2009-2016
LID - 10.1007/s00432-022-04144-5 [doi]
AB  - PURPOSE: The purpose of this study was to evaluate whether induction of temporary 
      threshold shift (TTS) with aspirin prior to cisplatin exposure can prevent or 
      minimize cisplatin detrimental effects on hearing. METHODS: We randomly divided 
      BALB mice into three groups: (1) cisplatin only, (2) aspirin only, and (3) 
      combined aspirin/cisplatin. Cisplatin was administered as a single 
      intraperitoneal injection of 14 mg/kg. Aspirin was administered for three weeks 
      via intraperitoneal injection of 200 mg/kg sodium salicylate, twice daily. Air 
      conduction thresholds were recorded using Auditory Brainstem Responses (ABR). 
      Cochleae were harvested and cochlear hair cells were counted using a scanning 
      electron microscope (SEM). RESULTS: Aspirin-induced TTS have reached an average 
      of 30.05±16.9 dB after 2 weeks. At 60 days, cisplatin-only treated mice 
      experienced an average threshold shifts of 50.7 dB at 4 kHz, 35.16 dB at 8 kHz, 
      70 dB at 16 kHz, 53.1 dB at 32 kHz. All threshold shifts were significantly worse 
      than for cisplatin/aspirin treated mice with TTS of 11.85 dB at 4 kHz, 3.58 dB at 
      8 kHz, 16.58  dB at 16 kHz, 20.41 dB at 32 kHz (p < 0.01). Cochlear cell count 
      with SEM has shown reduction in the number of both inner and outer hair cells in 
      the mid-turn in cisplatin treated mice. CONCLUSION: Aspirin induced TTS can 
      protect from cisplatin-induced ototoxicity. This beneficial effect was 
      demonstrated by auditory thresholds as well as SEM. Larger pre-clinical and 
      clinical studies are still needed to confirm these findings.
CI  - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Tzelnick, Sharon
AU  - Tzelnick S
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Rabin Medical Center, 39 
      Jabotinsky St, Petah Tikva, Israel. tzelnicksharon@gmail.com.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 
      tzelnicksharon@gmail.com.
FAU - Mizrachi, Aviram
AU  - Mizrachi A
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Rabin Medical Center, 39 
      Jabotinsky St, Petah Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Barkan, Neta
AU  - Barkan N
AD  - Institute of Audiology and Clinical Neurophysiology, Schneider Children's Medical 
      Center of Israel, Petach Tikva, Israel.
FAU - Shivatzki, Shaked
AU  - Shivatzki S
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Rabin Medical Center, 39 
      Jabotinsky St, Petah Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Yosefof, Eyal
AU  - Yosefof E
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Rabin Medical Center, 39 
      Jabotinsky St, Petah Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Hikri, Elad
AU  - Hikri E
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Rabin Medical Center, 39 
      Jabotinsky St, Petah Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Attias, Joseph
AU  - Attias J
AD  - Institute of Audiology and Clinical Neurophysiology, Schneider Children's Medical 
      Center of Israel, Petach Tikva, Israel.
AD  - Department of Communications Sciences and Disorders, Haifa University, Haifa, 
      Israel.
FAU - Hilly, Ohad
AU  - Hilly O
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Rabin Medical Center, 39 
      Jabotinsky St, Petah Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
LA  - eng
PT  - Journal Article
DEP - 20220701
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - Q20Q21Q62J (Cisplatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *Cisplatin/toxicity
MH  - Aspirin/pharmacology
MH  - *Ototoxicity/etiology/prevention & control
MH  - Cochlea
MH  - Disease Models, Animal
OTO - NOTNLM
OT  - Animal model
OT  - Aspirin
OT  - Cisplatin
OT  - Ototoxicity
OT  - Temporary threshold shift
EDAT- 2022/07/01 06:00
MHDA- 2023/04/14 06:42
CRDT- 2022/06/30 23:28
PHST- 2022/04/20 00:00 [received]
PHST- 2022/06/13 00:00 [accepted]
PHST- 2023/04/14 06:42 [medline]
PHST- 2022/07/01 06:00 [pubmed]
PHST- 2022/06/30 23:28 [entrez]
AID - 10.1007/s00432-022-04144-5 [pii]
AID - 10.1007/s00432-022-04144-5 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2023 May;149(5):2009-2016. doi: 
      10.1007/s00432-022-04144-5. Epub 2022 Jul 1.

PMID- 28700757
OWN - NLM
STAT- MEDLINE
DCOM- 20170815
LR  - 20170815
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 66
IP  - 7
DP  - 2017 Jul
TI  - Stroke: Secondary prevention of ischemic events.
PG  - 420-427
AB  - A multifactorial approach is key to effective secondary stroke prevention. Here's 
      how to individualize your plan for your at-risk patients.
FAU - Morris, Jane G
AU  - Morris JG
AD  - Department of Neurology, Maine Medical Center, Portland, ME, USA.
FAU - Carter, Emily L
AU  - Carter EL
AD  - Department of Family Medicine, Maine Medical Center, Portland, ME, USA.
FAU - Martin, Stephen A
AU  - Martin SA
AD  - Department of Family Medicine and Community Health, University of Massachusetts 
      Medical School and Barre Family Health Center, Barre, MA, USA. E-mail: 
      stmartin@gmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Family Practice/*methods
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Secondary Prevention/*methods
MH  - Stroke/*prevention & control
EDAT- 2017/07/13 06:00
MHDA- 2017/08/16 06:00
CRDT- 2017/07/13 06:00
PHST- 2017/07/13 06:00 [entrez]
PHST- 2017/07/13 06:00 [pubmed]
PHST- 2017/08/16 06:00 [medline]
AID - jfp_6607b [pii]
PST - ppublish
SO  - J Fam Pract. 2017 Jul;66(7):420-427.

PMID- 7053513
OWN - NLM
STAT- MEDLINE
DCOM- 19820222
LR  - 20150624
IS  - 0032-1052 (Print)
IS  - 0032-1052 (Linking)
VI  - 69
IP  - 1
DP  - 1982 Jan
TI  - The effect of prostaglandin inhibitors on wound contraction and the 
      myofibroblast.
PG  - 74-85
AB  - The production and smooth muscle-like activity of the myofibroblast do not appear 
      to be diminished in a granulating wound treated with prostaglandin inhibitors. 
      Prostaglandins are mediators of inflammation and smooth-muscle stimulants, but 
      inhibition of the prostaglandins and their precursors failed to alter the course 
      of wound contraction and, by inference, the activity of the myofibroblast in this 
      experimental model.
FAU - McGrath, M H
AU  - McGrath MH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Plast Reconstr Surg
JT  - Plastic and reconstructive surgery
JID - 1306050
RN  - 0 (Prostaglandin Antagonists)
RN  - 1191-85-1 (5,8,11,14-Eicosatetraynoic Acid)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 5,8,11,14-Eicosatetraynoic Acid/pharmacology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Fibroblasts/drug effects/ultrastructure
MH  - Granulation Tissue/*drug effects
MH  - Injections, Subcutaneous
MH  - Male
MH  - Prednisolone/pharmacology
MH  - Prostaglandin Antagonists/*pharmacology
MH  - Rats
MH  - Wound Healing/*drug effects
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - Plast Reconstr Surg. 1982 Jan;69(1):74-85.

PMID- 717988
OWN - NLM
STAT- MEDLINE
DCOM- 19790126
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 89
IP  - 6
DP  - 1978 Dec
TI  - Articular manifestations of rheumatic fever in adults.
PG  - 917-20
AB  - Six adult patients had a syndrome indistinguishable from childhood rheumatic 
      fever, with few cardiac findings and an arthrutis that had a characteristic 
      pattern. The joint disease was abrupt in onset, rapidly additive, and eventually 
      symmetrical, with a lower-extremity, large-joint predominance and a profoundly 
      symptomatic tenosynovitis. Emphasizing the benign prognosis associated with a 
      lack of heart disease and a "typical" pattern of articular involvement, we have 
      reassessed the sensitivity of the traditional diagnostic Jones' criteria and 
      suggest that this syndrome in adults may be more properly termed 
      "poststreptococcal arthritis."
FAU - McDanald, E C
AU  - McDanald EC
FAU - Weisman, M H
AU  - Weisman MH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Arthritis/diagnosis
MH  - Arthritis, Infectious/drug therapy/*etiology
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Rheumatic Fever/*complications
EDAT- 1978/12/01 00:00
MHDA- 1978/12/01 00:01
CRDT- 1978/12/01 00:00
PHST- 1978/12/01 00:00 [pubmed]
PHST- 1978/12/01 00:01 [medline]
PHST- 1978/12/01 00:00 [entrez]
AID - 10.7326/0003-4819-89-6-917 [doi]
PST - ppublish
SO  - Ann Intern Med. 1978 Dec;89(6):917-20. doi: 10.7326/0003-4819-89-6-917.

PMID- 32989461
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1460-2091 (Electronic)
IS  - 0305-7453 (Linking)
VI  - 75
IP  - 12
DP  - 2020 Dec 1
TI  - Aspirin, sodium benzoate and sodium salicylate reverse resistance to colistin in 
      Enterobacteriaceae and Pseudomonas aeruginosa.
PG  - 3568-3575
LID - 10.1093/jac/dkaa371 [doi]
AB  - BACKGROUND: MDR bacterial infections are currently a serious problem for 
      clinicians worldwide. Klebsiella pneumoniae and Enterobacter spp., among 
      Enterobacteriaceae, and Pseudomonas aeruginosa, are part of the group of ESCAPE 
      pathogens or bacteria that 'escape' from common antibacterial treatments. The 
      lack of effectiveness of the first common line of antibiotics has led to the 
      search for new therapies based on older antibiotics, such as colistin. 
      OBJECTIVES: We searched for new enhancers of the action of colistin against MDR 
      Gram-negative bacteria that can be easily applicable to clinical treatments. 
      METHODS: Colistin MICs were determined alone and with the protonophores CCCP, 
      sodium benzoate, sodium salicylate and aspirin using the broth microdilution 
      method and FIC indexes were calculated to assess synergy between colistin and 
      each chemical. Time-kill assays of colistin with and without protonophores were 
      performed to determine the bactericidal action of combinations of colistin with 
      protonophores. Likewise, the effect of sucrose, l-arginine and l-glutamic acid on 
      the MICs of colistin alone and combined with each protonophore was assessed. 
      RESULTS: It was found that sodium benzoate, sodium salicylate and aspirin, at 
      concentrations allowed for human and animal use, partially or totally reversed 
      resistance to colistin in P. aeruginosa and highly resistant enterobacterial 
      strains. The mechanism of action could be related to their negative charge at a 
      physiological pH along with their lipid-soluble character. CONCLUSIONS: Sodium 
      benzoate, sodium salicylate and aspirin are good enhancers to use in antibiotic 
      therapies that include colistin.
CI  - © The Author(s) 2020. Published by Oxford University Press on behalf of the 
      British Society for Antimicrobial Chemotherapy. All rights reserved. For 
      permissions, please email: journals.permissions@oup.com.
FAU - Malla, Cristina F
AU  - Malla CF
AD  - Microbiology, Clinical Science Department, Faculty of Health Sciences, 
      Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
AD  - University Institute of Animal Health and Food Safety, Universidad de Las Palmas 
      de Gran Canaria, Las Palmas de Gran Canaria, Spain.
FAU - Mireles, Natalia A
AU  - Mireles NA
AD  - Microbiology, Clinical Science Department, Faculty of Health Sciences, 
      Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
FAU - Ramírez, Ana S
AU  - Ramírez AS
AD  - University Institute of Animal Health and Food Safety, Universidad de Las Palmas 
      de Gran Canaria, Las Palmas de Gran Canaria, Spain.
FAU - Poveda, José B
AU  - Poveda JB
AD  - University Institute of Animal Health and Food Safety, Universidad de Las Palmas 
      de Gran Canaria, Las Palmas de Gran Canaria, Spain.
FAU - Tavío, María M
AU  - Tavío MM
AD  - Microbiology, Clinical Science Department, Faculty of Health Sciences, 
      Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
AD  - University Institute of Animal Health and Food Safety, Universidad de Las Palmas 
      de Gran Canaria, Las Palmas de Gran Canaria, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
RN  - 0 (Anti-Bacterial Agents)
RN  - OJ245FE5EU (Sodium Benzoate)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
RN  - Z67X93HJG1 (Colistin)
SB  - IM
MH  - Anti-Bacterial Agents/pharmacology
MH  - Aspirin/pharmacology
MH  - *Colistin/pharmacology
MH  - Drug Resistance, Multiple, Bacterial
MH  - Enterobacteriaceae
MH  - Humans
MH  - Microbial Sensitivity Tests
MH  - *Pseudomonas aeruginosa
MH  - Sodium Benzoate
MH  - Sodium Salicylate
EDAT- 2020/09/30 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/29 05:37
PHST- 2020/04/13 00:00 [received]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/09/29 05:37 [entrez]
AID - 5912718 [pii]
AID - 10.1093/jac/dkaa371 [doi]
PST - ppublish
SO  - J Antimicrob Chemother. 2020 Dec 1;75(12):3568-3575. doi: 10.1093/jac/dkaa371.

PMID- 9456103
OWN - NLM
STAT- MEDLINE
DCOM- 19980225
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 65
IP  - 1
DP  - 1998 Jan
TI  - Thromboxane production in human lung during cardiopulmonary bypass: beneficial 
      effect of aspirin?
PG  - 101-6
AB  - BACKGROUND: Increased systemic levels of thromboxane (Tx) during cardiopulmonary 
      bypass (CPB) in humans have been reported. It is not known whether this reflects 
      a general systemic response to the surgical procedure or an increased pulmonary 
      production of Tx in response to ischemia and reperfusion. METHODS: Thromboxane B2 
      levels were measured in the right atrium and left atrium of 14 patients 
      undergoing coronary artery bypass grafting for angina. Eight patients (group 1) 
      were without aspirin for at least 15 days before operation, and 6 patients (group 
      2) were treated with aspirin (100 mg/day) for at least 1 month before operation. 
      Levels of TxB2 were determined by enzyme immunoassay after lipid extraction and 
      separation. RESULTS: Thromboxane B2 levels were elevated throughout CPB. In group 
      1, left atrial TxB2 levels were significantly higher (p < 0.05) than right atrial 
      levels at all study points during CPB. After pulmonary reperfusion, TxB2 levels 
      in both atria increased significantly (p < 0.02) compared with the levels before 
      cross-clamping of the aorta, and there was an increasing gradient between the two 
      atria (p < 0.05). Mean plasma TxB2 levels during CPB in group 2 were 
      significantly reduced (p < 0.0001) in the right atrium (by 73%) and in the left 
      atrium (by 69%) compared with levels in group 1. CONCLUSIONS: The rise in TxB2 
      levels in the left atrium after CPB in humans reflects production of Tx mainly in 
      the lungs, most probably by ischemic pulmonary tissue and intravascular 
      hematologic components. Aspirin markedly reduces Tx production during CPB, and it 
      might play a major role in preventing pulmonary injury after operations with CPB 
      in humans.
FAU - Erez, E
AU  - Erez E
AD  - Department of Cardiothoracic Surgery, Rabin Medical Center, Beilinson Campus, 
      affiliated to the Sackler School of Medicine, Tel Aviv University, Petach Tikva, 
      Israel.
FAU - Erman, A
AU  - Erman A
FAU - Snir, E
AU  - Snir E
FAU - Raanani, E
AU  - Raanani E
FAU - Abramov, D
AU  - Abramov D
FAU - Sulkes, J
AU  - Sulkes J
FAU - Boner, G
AU  - Boner G
FAU - Vidne, B A
AU  - Vidne BA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology
MH  - *Cardiopulmonary Bypass
MH  - Female
MH  - Humans
MH  - Lung/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Thromboxane B2/biosynthesis
MH  - Thromboxanes/*biosynthesis
EDAT- 1998/02/10 00:00
MHDA- 1998/02/10 00:01
CRDT- 1998/02/10 00:00
PHST- 1998/02/10 00:00 [pubmed]
PHST- 1998/02/10 00:01 [medline]
PHST- 1998/02/10 00:00 [entrez]
AID - S0003-4975(97)01040-0 [pii]
AID - 10.1016/s0003-4975(97)01040-0 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1998 Jan;65(1):101-6. doi: 10.1016/s0003-4975(97)01040-0.

PMID- 1002007
OWN - NLM
STAT- MEDLINE
DCOM- 19770224
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 5
IP  - 4
DP  - 1976
TI  - Combined administration of low dose heparin and aspirin as prophylaxis of deep 
      vein thrombosis after hip joint surgery.
PG  - 250-7
AB  - The study was carried out on 75 patients undergoing hip joint surgery. The 
      efficacy of a prophylaxis of deep vein thrombosis (DVT) by acetylsalicyclic 
      lysine (ASL) and by a low dose heparin (LDH) combined with the ASL treatment was 
      investigated using the 125I-fibrinogen test. DVT was not significantly decreased 
      by the ASL application (53%) compared to the controls (60%). DVT occurred 
      significantly less under the combined administration (27%) than in the other two 
      groups.
FAU - Schöndorf, T H
AU  - Schöndorf TH
FAU - Hey, D
AU  - Hey D
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Hip Joint/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Popliteal Vein
MH  - Pulmonary Embolism/drug therapy
MH  - Thrombophlebitis/*drug therapy
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1159/000214140 [doi]
PST - ppublish
SO  - Haemostasis. 1976;5(4):250-7. doi: 10.1159/000214140.

PMID- 21061518
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - [Epidemiology of peptic ulcer in the elderly].
PG  - 1973-7
AB  - The frequency of severe complications is higher in elderly patients than in young 
      patients. NSAIDs and low-dose aspirin are often prescribed for elderly patients. 
      Physiological functions of the stomach such as acid secretion in elderly patients 
      are also different from those in young patients. Hemorrhage and perforation can 
      suddenly occur in elderly patients even though abdominal symptoms are mild. There 
      is a tendency for the condition of such patients to deteriorate and long-term 
      hospitalization is often required. Effective prevention measures are necessary 
      since it is expected that cases of gastrointestinal injury caused by NSAIDs will 
      continue to increase.
FAU - Mizokami, Yuji
AU  - Mizokami Y
AD  - Department of Gastroenterology and Endoscopy, University of Tsukuba.
FAU - Iwamoto, Junichi
AU  - Iwamoto J
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects
MH  - Female
MH  - Humans
MH  - Japan/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/chemically induced/*epidemiology
EDAT- 2010/11/11 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Nov;68(11):1973-7.

PMID- 12829186
OWN - NLM
STAT- MEDLINE
DCOM- 20031014
LR  - 20190513
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 59
IP  - 1
DP  - 2003 Jul 1
TI  - Aspirin modifies nitric oxide synthase activity in platelets: effects of acute 
      versus chronic aspirin treatment.
PG  - 152-9
AB  - OBJECTIVE: We examined the effects of aspirin on basal and beta-adrenoceptor 
      (beta-AR)-mediated nitric oxide synthase (NOS) activity in normal platelets. 
      METHODS: NOS activity was determined from the conversion of L-[3H]arginine to 
      L-[3H]citrulline, both basally and following beta-AR stimulation, in platelets 
      from healthy human subjects following both short- and long-term aspirin 
      administration. RESULTS: Basal L-[3H]citrulline increased following aspirin 800 
      mg administered intravenously in vivo, from 0.31+/-0.12 to 0.76+/-0.14 pmol/10(8) 
      platelets (P<0.01). Isoproterenol at 1 micromol/l increased platelet NOS activity 
      before but not following intravenous aspirin. After short-term in vitro treatment 
      with aspirin 10 micromol/l, 400 micromol/l or 4 mmol/l, basal platelet 
      L-[3H]citrulline increased similarly, an effect not seen with indomethacin 100 
      micromol/l or ibuprofen 10 micromol/l. Platelet NOS activity was not increased by 
      albuterol 1 micromol/l, in the presence of indomethacin, ibuprofen or aspirin in 
      vitro. By contrast, oral aspirin 75 mg daily for 14 days did not affect basal 
      platelet NOS activity, but abolished beta-adrenergic NOS activation. CONCLUSIONS: 
      Aspirin activates basal platelet NOS acutely, but not chronically, through a 
      mechanism independent of cyclooxygenase (COX) inhibition. By contrast, both 
      short- and long-term aspirin treatment inhibit platelet beta-adrenergic NOS 
      activation by a COX-dependent mechanism. This indicates that aspirin exerts 
      divergent effects on basal and beta-AR-stimulated platelet NOS activity, which 
      are likely to be of clinical relevance.
FAU - O'Kane, Peter D
AU  - O'Kane PD
AD  - Department of Cardiology, Cardiothoracic Centre, St Thomas' Hospital, London, UK.
FAU - Queen, Lindsay R
AU  - Queen LR
FAU - Ji, Yong
AU  - Ji Y
FAU - Reebye, Vikash
AU  - Reebye V
FAU - Stratton, Paula
AU  - Stratton P
FAU - Jackson, Graham
AU  - Jackson G
FAU - Ferro, Albert
AU  - Ferro A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27JT06E6GR (omega-N-Methylarginine)
RN  - 29VT07BGDA (Citrulline)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - L628TT009W (Isoproterenol)
RN  - QF8SVZ843E (Albuterol)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adrenergic beta-Agonists/pharmacology
MH  - Adult
MH  - Albuterol/pharmacology
MH  - Analysis of Variance
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Platelets/drug effects/*enzymology
MH  - Citrulline/metabolism
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Isoproterenol/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide Synthase/antagonists & inhibitors/*metabolism
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - omega-N-Methylarginine/pharmacology
EDAT- 2003/06/28 05:00
MHDA- 2003/10/15 05:00
CRDT- 2003/06/28 05:00
PHST- 2003/06/28 05:00 [pubmed]
PHST- 2003/10/15 05:00 [medline]
PHST- 2003/06/28 05:00 [entrez]
AID - S0008636303003237 [pii]
AID - 10.1016/s0008-6363(03)00323-7 [doi]
PST - ppublish
SO  - Cardiovasc Res. 2003 Jul 1;59(1):152-9. doi: 10.1016/s0008-6363(03)00323-7.

PMID- 12741431
OWN - NLM
STAT- MEDLINE
DCOM- 20030812
LR  - 20190916
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 23
IP  - 5
DP  - 2003 May
TI  - Aspirin dosage and thromboxane synthesis in patients with vascular disease.
PG  - 579-84
AB  - STUDY OBJECTIVE: To determine whether urinary 11-dehydrothromboxane B2 (d-TXB2) 
      is a marker of aspirin resistance and define the relationship between aspirin 
      dosage and concentrations of this thromboxane metabolite. DESIGN: Randomized, 
      crossover study. SETTING: Two outpatient clinical centers. PATIENTS: Forty-eight 
      patients (mean age 70 yrs) with vascular disease (52% clinical coronary artery 
      disease, 29% cerebrovascular disease, 46% atrial fibrillation). INTERVENTION: 
      Levels of serum thromboxane B2 and d-TXB2 were measured after patients were 
      treated initially with aspirin 325 mg/day for 4 weeks, then again after random 
      assignment to receive aspirin 81, 325, or 1300 mg/day for 4 weeks, and then again 
      after resumption of 325 mg/day for 4 weeks. MEASUREMENTS AND MAIN RESULTS: During 
      treatment with aspirin 325 mg/day, the mean +/- SD serum thromboxane B2 level was 
      0.9 +/- 1.2 ng/ml and median (interquartile range) was 0.4 (0.2-0.9) ng/ml. Mean 
      urinary d-TXB2 was 16 +/- 7.9 ng/mmol creatinine, with a median of 15 (9.9-23) 
      ng/mmol creatinine with aspirin 325 mg/day. After 4 weeks of aspirin 81 mg/day, 
      levels of serum thromboxane B2 (p<0.01) and urinary d-TXB2 (p=0.04) were both 
      significantly higher compared with aspirin 325 mg/day; for urinary d-TXB2, the 
      median increase was 3.0 ng/mmol creatinine. After 4 weeks of treatment with 
      aspirin 1300 mg/day, levels of serum thromboxane B2 (p<0.01) and urinary d-TXB2 
      (p<0.01) were both significantly lower compared with aspirin 325 mg/day; the 
      median decrease in urinary d-TXB2 was 4.4 ng/mmol creatinine. CONCLUSION: 
      Different aspirin dosages significantly affect serum and urinary markers of 
      thromboxane synthesis.
FAU - Hart, Robert G
AU  - Hart RG
AD  - University of Texas Health Science Center, San Antonio 78229-3900, USA.
FAU - Leonard, Anne D
AU  - Leonard AD
FAU - Talbert, Robert L
AU  - Talbert RL
FAU - Pearce, Lesly A
AU  - Pearce LA
FAU - Cornell, Elaine
AU  - Cornell E
FAU - Bovill, Edwin
AU  - Bovill E
FAU - Feinberg, William M
AU  - Feinberg WM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Thromboxane B2/*analogs & derivatives/urine
MH  - Thromboxanes/*biosynthesis/blood/urine
MH  - Vascular Diseases/blood/*metabolism/urine
EDAT- 2003/05/14 05:00
MHDA- 2003/08/13 05:00
CRDT- 2003/05/14 05:00
PHST- 2003/05/14 05:00 [pubmed]
PHST- 2003/08/13 05:00 [medline]
PHST- 2003/05/14 05:00 [entrez]
AID - 10.1592/phco.23.5.579.32206 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2003 May;23(5):579-84. doi: 10.1592/phco.23.5.579.32206.

PMID- 11179262
OWN - NLM
STAT- MEDLINE
DCOM- 20010524
LR  - 20190503
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Print)
IS  - 1355-6037 (Linking)
VI  - 85
IP  - 3
DP  - 2001 Mar
TI  - Aspirin for primary prevention of coronary heart disease: safety and absolute 
      benefit related to coronary risk derived from meta-analysis of randomised trials.
PG  - 265-71
AB  - OBJECTIVE: To determine the cardiovascular and coronary risk thresholds at which 
      aspirin for primary prevention of coronary heart disease is safe and worthwhile. 
      DESIGN: Meta-analysis of four randomised controlled trials of aspirin for primary 
      prevention. The benefit and harm from aspirin treatment were examined to 
      determine: (1) the cardiovascular and coronary risk threshold at which benefit in 
      prevention of myocardial infarction exceeds harm from significant bleeding; and 
      (2) the absolute benefit expressed as number needed to treat (NNT) for aspirin 
      net of cerebral haemorrhage and other bleeding complications at different levels 
      of coronary risk. MAIN OUTCOME MEASURES: Benefit from aspirin, expressed as 
      reduction in cardiovascular events, myocardial infarctions, strokes, and total 
      mortality; harm caused by aspirin in relation to significant bleeds and major 
      haemorrhages. RESULTS: Aspirin for primary prevention significantly reduced all 
      cardiovascular events by 15% (95% confidence interval (CI) 6% to 22%) and 
      myocardial infarctions by 30% (95% CI 21% to 38%), and non-significantly reduced 
      all deaths by 6% (95% CI -4% to 15%). Aspirin non-significantly increased strokes 
      by 6% (95% CI -24% to 9%) and significantly increased bleeding complications by 
      69% (95% CI 38% to 107%). The risk of major bleeding balanced the reduction in 
      cardiovascular events when cardiovascular event risk was 0.22%/year. The upper 
      95% CI for this estimate suggests that harm from aspirin is unlikely to outweigh 
      benefit provided the cardiovascular event risk is 0.8%/year, equivalent to a 
      coronary risk of 0.6%/year. At coronary event risk 1.5%/year, the five year NNT 
      was 44 to prevent a myocardial infarction, and 77 to prevent a myocardial 
      infarction net of any important bleeding complication. At coronary event risk 
      1%/year the NNT was 67 to prevent a myocardial infarction, and 182 to prevent a 
      myocardial infarction net of important bleeding. CONCLUSIONS: Aspirin treatment 
      for primary prevention is safe and worthwhile at coronary event risk >/= 
      1.5%/year; safe but of limited value at coronary risk 1%/year; and unsafe at 
      coronary event risk 0.5%/year. Advice on aspirin for primary prevention requires 
      formal accurate estimation of absolute coronary event risk.
FAU - Sanmuganathan, P S
AU  - Sanmuganathan PS
AD  - Clinical Pharmacology and Therapeutics, Royal Hallamshire Hospital, Glossop Road, 
      Sheffield S10 2JF, UK.
FAU - Ghahramani, P
AU  - Ghahramani P
FAU - Jackson, P R
AU  - Jackson PR
FAU - Wallis, E J
AU  - Wallis EJ
FAU - Ramsay, L E
AU  - Ramsay LE
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Heart. 2001 Mar;85(3):245-6. PMID: 11179252
CIN - BMJ. 2013;347:f5021. PMID: 23935087
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/*prevention & control
MH  - Coronary Disease/*prevention & control
MH  - Female
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Mortality
MH  - Myocardial Infarction/epidemiology/prevention & control
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Stroke/chemically induced/epidemiology
PMC - PMC1729640
EDAT- 2001/02/17 11:00
MHDA- 2001/05/26 10:01
CRDT- 2001/02/17 11:00
PHST- 2001/02/17 11:00 [pubmed]
PHST- 2001/05/26 10:01 [medline]
PHST- 2001/02/17 11:00 [entrez]
AID - 10.1136/heart.85.3.265 [doi]
PST - ppublish
SO  - Heart. 2001 Mar;85(3):265-71. doi: 10.1136/heart.85.3.265.

PMID- 35940829
OWN - NLM
STAT- MEDLINE
DCOM- 20220810
LR  - 20220823
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 12
IP  - 8
DP  - 2022 Aug 8
TI  - Long-term outcomes following antenatal exposure to low-dose aspirin: study 
      protocol for the 4-year follow-up of the APRIL randomised controlled trial.
PG  - e060632
LID - 10.1136/bmjopen-2021-060632 [doi]
LID - e060632
AB  - INTRODUCTION: The use of low-dose aspirin by pregnant women to prevent preterm 
      pre-eclampsia is gradually increasing. The administration of aspirin during 
      pregnancy improves perinatal outcome, which could translate into improved child 
      outcome in the long term. However, antenatal exposure to aspirin could have 
      adverse effects on child development that may manifest later in life. The aim of 
      this follow-up study is to assess the long-term effects of antenatal exposure to 
      low-dose aspirin compared with placebo on survival, (neuro)development, behaviour 
      and general health at 4 years corrected age. METHODS AND ANALYSIS: This is a 
      follow-up study of the Dutch double-blind randomised controlled APRIL trial which 
      assessed the effectiveness of treatment with aspirin (80 mg daily) compared with 
      placebo for the prevention of preterm birth in women with a previous spontaneous 
      preterm birth. Treatment was initiated before 16 weeks of gestation and continued 
      until 36 weeks or birth. We aim to follow-up all 379 children born to women who 
      participated in the APRIL trial and survived the neonatal period, at the 
      corrected age of 4 years. The main outcomes are (neuro)development as assessed by 
      the Ages and Stages Questionnaire, and behaviour as assessed by the Strength and 
      Difficulties Questionnaire. Additional outcomes include mortality, growth and 
      general health from birth up to 4 years, and a composite outcome including 
      mortality, abnormal (neuro)development and problem behaviour. Analyses will be 
      performed by intention-to-treat using a superiority design. ETHICS AND 
      DISSEMINATION: Institutional Review Board approval was obtained from the Medical 
      Research Ethics Committee from Amsterdam Medical Center (no. W20 289#20.325). The 
      results will be published in a peer-reviewed journal and presented at 
      conferences. TRIAL REGISTRATION NUMBER: The APRIL trial (NTR5675, NL5553; EudraCT 
      number 2015-003220-31) and the APRIL follow-up study (NL8950) are registered in 
      the Dutch trial register. The study is funded by the Amsterdam Reproduction & 
      Development research institute.
CI  - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Landman, Anadeijda J E M C
AU  - Landman AJEMC
AUID- ORCID: 0000-0002-6354-3489
AD  - Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Obstetrics and 
      Gynaecology, De Boelelaan 1117, Amsterdam, The Netherlands 
      a.landman@amsterdamumc.nl.
AD  - Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
FAU - van Limburg Stirum, Emilie V J
AU  - van Limburg Stirum EVJ
AUID- ORCID: 0000-0003-2381-0332
AD  - Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
AD  - Amsterdam UMC location location University of Amsterdam, Department of Obstetrics 
      and Gynaecology, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - van 't Hooft, Janneke
AU  - van 't Hooft J
AUID- ORCID: 0000-0001-5303-1503
AD  - Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
AD  - Amsterdam UMC location location University of Amsterdam, Department of Obstetrics 
      and Gynaecology, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - Leemhuis, Aleid G
AU  - Leemhuis AG
AUID- ORCID: 0000-0002-4414-9451
AD  - Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, 
      Department of Neonatology and Paediatrics, Meibergdreef 9, Amsterdam, The 
      Netherlands.
FAU - Finken, Martijn J J
AU  - Finken MJJ
AUID- ORCID: 0000-0002-6589-9788
AD  - Amsterdam UMC location Vrije Universiteit Amsterdam, Emma Children's Hospital, 
      Department of Paediatric Endocrinology, De Boelelaan 1117, Amsterdam, The 
      Netherlands.
FAU - van Baar, Anneloes L
AU  - van Baar AL
AUID- ORCID: 0000-0002-3498-9019
AD  - Utrecht University, Department of Child and Adolescent Studies, Utrecht, The 
      Netherlands, Utrecht, The Netherlands.
FAU - Roseboom, Tessa J
AU  - Roseboom TJ
AUID- ORCID: 0000-0003-0564-5994
AD  - Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
AD  - Amsterdam UMC location location University of Amsterdam, Department of Obstetrics 
      and Gynaecology, Meibergdreef 9, Amsterdam, The Netherlands.
AD  - Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam 
      UMC Locatie AMC, Amsterdam, The Netherlands.
FAU - Ravelli, Anita C J
AU  - Ravelli ACJ
AUID- ORCID: 0000-0002-3447-8286
AD  - Department of Medical Informatics, Amsterdam UMC location University of 
      Amsterdam, Department of Clinical Epidemiology, Biostatistics and Bioinformatics, 
      Meibergdreef 9, Amsterdam, The Netherlands.
FAU - van Wely, Madelon
AU  - van Wely M
AUID- ORCID: 0000-0001-8263-213X
AD  - Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
AD  - Amsterdam UMC location location University of Amsterdam, Department of Obstetrics 
      and Gynaecology, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - Oosterlaan, Jaap
AU  - Oosterlaan J
AUID- ORCID: 0000-0002-0218-5630
AD  - Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
AD  - Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, 
      Department of Neonatology and Paediatrics, Meibergdreef 9, Amsterdam, The 
      Netherlands.
AD  - Amsterdam UMC location University of Amsterdam, Amsterdam UMC Follow-Me program & 
      Emma Neuroscience Group, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - Painter, Rebecca C
AU  - Painter RC
AUID- ORCID: 0000-0001-9336-6033
AD  - Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
AD  - Amsterdam UMC location location University of Amsterdam, Department of Obstetrics 
      and Gynaecology, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - Pajkrt, Eva
AU  - Pajkrt E
AUID- ORCID: 0000-0002-4432-3691
AD  - Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
AD  - Amsterdam UMC location location University of Amsterdam, Department of Obstetrics 
      and Gynaecology, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - Oudijk, Martijn A
AU  - Oudijk MA
AUID- ORCID: 0000-0001-8672-4365
AD  - Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
AD  - Amsterdam UMC location location University of Amsterdam, Department of Obstetrics 
      and Gynaecology, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - de Boer, Marjon A
AU  - de Boer MA
AUID- ORCID: 0000-0002-9386-649X
AD  - Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Obstetrics and 
      Gynaecology, De Boelelaan 1117, Amsterdam, The Netherlands.
AD  - Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220808
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (TNFSF13 protein, human)
RN  - 0 (Tumor Necrosis Factor Ligand Superfamily Member 13)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant, Newborn
MH  - Pregnancy
MH  - *Premature Birth/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Tumor Necrosis Factor Ligand Superfamily Member 13
PMC - PMC9364408
OTO - NOTNLM
OT  - EPIDEMIOLOGY
OT  - Fetal medicine
OT  - Maternal medicine
OT  - PAEDIATRICS
OT  - PERINATOLOGY
COIS- Competing interests: None declared.
EDAT- 2022/08/09 06:00
MHDA- 2022/08/11 06:00
CRDT- 2022/08/08 21:12
PHST- 2022/08/08 21:12 [entrez]
PHST- 2022/08/09 06:00 [pubmed]
PHST- 2022/08/11 06:00 [medline]
AID - bmjopen-2021-060632 [pii]
AID - 10.1136/bmjopen-2021-060632 [doi]
PST - epublish
SO  - BMJ Open. 2022 Aug 8;12(8):e060632. doi: 10.1136/bmjopen-2021-060632.

PMID- 16763985
OWN - NLM
STAT- MEDLINE
DCOM- 20061201
LR  - 20131121
IS  - 1522-1946 (Print)
IS  - 1522-1946 (Linking)
VI  - 68
IP  - 1
DP  - 2006 Jul
TI  - Short-term triple therapy with aspirin, warfarin, and a thienopyridine among 
      patients undergoing percutaneous coronary intervention.
PG  - 56-61
AB  - OBJECTIVES: To assess bleeding complications among patients undergoing 
      percutaneous coronary intervention (PCI) and receiving triple therapy of 
      warfarin, aspirin, and a thienopyridine. BACKGROUND: Triple therapy of warfarin, 
      aspirin, and a thienopyridine is strongly discouraged, given the potential risk 
      of bleeding complications. METHODS AND RESULTS: Post-PCI patients receiving 
      triple therapy thereafter underwent assessment for bleeding complications. 
      Continuous variables are presented as median (25th-75th percentiles). The study 
      group included 180 patients (80% males; age 65 (52, 75.5)). PCI was on an 
      urgent/emergent basis in 86.6%. The main indications for warfarin use were left 
      ventricular mural thrombus and atrial fibrillation (46.9 and 36.9% respectively). 
      Glycoprotein IIb/IIIa receptor antagonists were used in 47.7%. Post-PCI triple 
      therapy duration was 30 days (30, 30). During the post-triple therapy, 104 
      patients (57.8%) continued treatment with warfarin and aspirin for 376 days (150, 
      775). During the triple therapy period, 20 patients developed bleeding 
      complications, (mean INR 2.1 +/- 0.7 at 7 (6, 8.5) days post-PCI): 2 major groin 
      hematoma (initial phase of warfarin treatment during overlap with heparin) and 18 
      minor. During post-triple therapy, primarily under warfarin and aspirin, 19 
      patients developed bleeding complications: 1 major and 18 minor. CONCLUSION: 
      Short-term triple therapy after PCI was not associated with prohibitively high 
      bleeding complication rates, and thus should be favorably considered in patients 
      with a clear indication for warfarin use.
CI  - Copyright 2006 Wiley-Liss, Inc.
FAU - Porter, Avital
AU  - Porter A
AD  - Department of Cardiology, Rabin Medical Center, Petah-Tikva, Israel.
FAU - Konstantino, Yuval
AU  - Konstantino Y
FAU - Iakobishvili, Zaza
AU  - Iakobishvili Z
FAU - Shachar, Leeor
AU  - Shachar L
FAU - Battler, Alexander
AU  - Battler A
FAU - Hasdai, David
AU  - Hasdai D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Coagulation Tests
MH  - Coronary Angiography
MH  - Coronary Disease/drug therapy/mortality/*therapy
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Echocardiography, Doppler
MH  - Female
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Prognosis
MH  - Pyridines/administration & dosage/adverse effects/*therapeutic use
MH  - Research Design
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Warfarin/administration & dosage/adverse effects/*therapeutic use
EDAT- 2006/06/10 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/06/10 09:00
PHST- 2006/06/10 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/06/10 09:00 [entrez]
AID - 10.1002/ccd.20733 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2006 Jul;68(1):56-61. doi: 10.1002/ccd.20733.

PMID- 30446997
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20200518
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 74
IP  - 5
DP  - 2019 May
TI  - Prostaglandin E(2) decrease in induced sputum of hypersensitive asthmatics during 
      oral challenge with aspirin.
PG  - 922-932
LID - 10.1111/all.13671 [doi]
AB  - BACKGROUND: A special regulatory role for prostaglandin E(2) (PGE(2) ) has been 
      postulated in nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory 
      disease (NERD). OBJECTIVE: To investigate the effect of systemic aspirin 
      (acetylsalicylic acid) administration on airway PGE(2) biosynthesis in induced 
      sputum supernatant (ISS) among subjects with NERD or aspirin-tolerant asthma with 
      chronic rhinosinusitis with nasal polyposis (ATA-CRSwNP), as well as healthy 
      controls (HC). METHODS: Induced sputum (IS) was collected from patients with NERD 
      (n = 26), ATA-CRSwNP (n = 17), and HC (n = 21) at baseline and after aspirin 
      challenge. Sputum differential cell count and IS supernatant (ISS) levels of 
      prostanoids, PGE(2) , 8-iso-PGE(2) , tetranor-PGE-M, 8-iso-PGF(2) α, and 
      leukotriene C(4) , D(4) , and E(4) , were determined using mass spectrometry. 
      Urinary excretion of LTE(4) was measured by ELISA. RESULTS: NERD subjects had 
      elevated sputum eosinophilic count as compared to ATA-CRSwNP and HC (median NERD 
      9.1%, ATA-CRSwNP 2.1%, and HC 0.4%; P < 0.01). Baseline ISS levels of PGE(2) were 
      higher in asthmatics as compared to HC at baseline (NERD vs HC P = 0.04, 
      ATA-CRSwNP vs HC P < 0.05). Post-challenge ISS levels of PGE(2) compared to 
      baseline significantly decreased in NERD and HC (P < 0.01 and P = 0.01), but not 
      in ATA-CRSwNP. In NERD, a similar decrease in PGE(2) as in HC resulted from 2.8 
      times lower dose of aspirin. CONCLUSION: Aspirin-precipitated bronchoconstriction 
      is associated with a decrease in airway PGE(2) biosynthesis. These results 
      support the mechanism of PGE(2) biosynthesis inhibition as a trigger for 
      bronchoconstriction in NERD.
CI  - © 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
FAU - Mastalerz, Lucyna
AU  - Mastalerz L
AD  - Department of Internal Medicine, Jagiellonian University School of Medicine, 
      Cracow, Poland.
FAU - Tyrak, Katarzyna E
AU  - Tyrak KE
AD  - Department of Internal Medicine, Jagiellonian University School of Medicine, 
      Cracow, Poland.
FAU - Ignacak, Maria
AU  - Ignacak M
AD  - Department of Internal Medicine, Jagiellonian University School of Medicine, 
      Cracow, Poland.
FAU - Konduracka, Ewa
AU  - Konduracka E
AD  - Coronary and Heart Failure Department, Jagiellonian University School of 
      Medicine, John Paul II Hospital, Cracow, Poland.
FAU - Mejza, Filip
AU  - Mejza F
AD  - Department of Internal Medicine, Jagiellonian University School of Medicine, 
      Cracow, Poland.
FAU - Ćmiel, Adam
AU  - Ćmiel A
AD  - Department of Applied Mathematics, AGH University of Science and Technology, 
      Cracow, Poland.
FAU - Buczek, Michał
AU  - Buczek M
AD  - Department of Internal Medicine, Jagiellonian University School of Medicine, 
      Cracow, Poland.
FAU - Kot, Adrianna
AU  - Kot A
AD  - Department of Internal Medicine, Jagiellonian University School of Medicine, 
      Cracow, Poland.
FAU - Oleś, Krzysztof
AU  - Oleś K
AD  - Department of Oncological and Reconstructive Surgery, The Maria Sklodowska-Curie 
      Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, 
      Poland.
FAU - Sanak, Marek
AU  - Sanak M
AUID- ORCID: 0000-0001-7635-8103
AD  - Department of Internal Medicine, Jagiellonian University School of Medicine, 
      Cracow, Poland.
LA  - eng
GR  - UMO-2013/11/B/NZ6/02034/Narodowe Centrum Nauki/International
GR  - Faculty of Applied Mathematics AGH UST Statutory Task/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181205
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 75715-89-8 (Leukotriene E4)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects/*metabolism
MH  - Asthma/diagnosis/*etiology/*metabolism
MH  - Asthma, Aspirin-Induced/*diagnosis/*metabolism/urine
MH  - Biomarkers
MH  - Dinoprostone/*metabolism
MH  - Disease Susceptibility
MH  - Female
MH  - Humans
MH  - Leukotriene E4/urine
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Respiratory Function Tests
MH  - Sputum/*metabolism
OTO - NOTNLM
OT  - eicosanoids
OT  - induced sputum
OT  - nonsteroidal anti-inflammatory drug-exacerbated respiratory disease
OT  - oral aspirin challenge
OT  - prostaglandins
EDAT- 2018/11/18 06:00
MHDA- 2020/05/19 06:00
CRDT- 2018/11/18 06:00
PHST- 2017/10/24 00:00 [received]
PHST- 2018/11/01 00:00 [revised]
PHST- 2018/11/05 00:00 [accepted]
PHST- 2018/11/18 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
PHST- 2018/11/18 06:00 [entrez]
AID - 10.1111/all.13671 [doi]
PST - ppublish
SO  - Allergy. 2019 May;74(5):922-932. doi: 10.1111/all.13671. Epub 2018 Dec 5.

PMID- 10892889
OWN - NLM
STAT- MEDLINE
DCOM- 20000719
LR  - 20220716
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 24
IP  - 4
DP  - 1999 Oct-Dec
TI  - Mechanisms of aspirin chemoprevention of colorectal cancer.
PG  - 289-92
AB  - Good evidence indicates that the regular consumption of aspirin reduces the risk 
      of colorectal cancer by up to 50%. This paper discusses mechanisms for this 
      protection and considers carcinogen activation, cell proliferation, apoptosis and 
      immune surveillance. It is not clear, however, whether these mechanisms are dose 
      related. This question will remain to be answered until the optimum dose and 
      duration of aspirin required for protection against colorectal cancer is 
      established.
FAU - Vainio, H
AU  - Vainio H
AD  - Unit of Chemoprevention, International Agency for Research on Cancer, Lyon, 
      France.
FAU - Morgan, G
AU  - Morgan G
LA  - eng
PT  - Journal Article
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Carcinogens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/*therapeutic use
MH  - Carcinogens/metabolism
MH  - Cell Division/drug effects
MH  - Colorectal Neoplasms/*prevention & control
MH  - Humans
MH  - Neovascularization, Physiologic/drug effects
EDAT- 2000/07/13 11:00
MHDA- 2000/07/25 11:00
CRDT- 2000/07/13 11:00
PHST- 2000/07/13 11:00 [pubmed]
PHST- 2000/07/25 11:00 [medline]
PHST- 2000/07/13 11:00 [entrez]
AID - 10.1007/BF03190034 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 1999 Oct-Dec;24(4):289-92. doi: 
      10.1007/BF03190034.

PMID- 7105626
OWN - NLM
STAT- MEDLINE
DCOM- 19821029
LR  - 20190512
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 32
IP  - 3
DP  - 1982 Sep
TI  - Central nervous system effects of aspirin.
PG  - 362-5
AB  - The EEG effects of aspirin at single doses of 0.65 and 1.95 gm were studied in 
      normal adult men. Compared to placebo, 1.95 gm affected the quantitative EEG, 
      symptom self reports, and cognitive functions. The effects of 0.65 gm. were 
      similar in direction and pattern, but failed measurable significance. The EEG 
      profile of aspirin is distinct from that of other psychoactive substances. Its 
      interaction with sedative substances should be considered in routine clinical 
      use.
FAU - Fink, M
AU  - Fink M
FAU - Irwin, P
AU  - Irwin P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Brain/*drug effects
MH  - Cognition/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Electroencephalography
MH  - Flicker Fusion/drug effects
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Male
EDAT- 1982/09/01 00:00
MHDA- 1982/09/01 00:01
CRDT- 1982/09/01 00:00
PHST- 1982/09/01 00:00 [pubmed]
PHST- 1982/09/01 00:01 [medline]
PHST- 1982/09/01 00:00 [entrez]
AID - 0009-9236(82)90156-4 [pii]
AID - 10.1038/clpt.1982.172 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1982 Sep;32(3):362-5. doi: 10.1038/clpt.1982.172.

PMID- 35151209
OWN - NLM
STAT- MEDLINE
DCOM- 20220527
LR  - 20220527
IS  - 2210-7797 (Electronic)
IS  - 2210-7789 (Linking)
VI  - 28
DP  - 2022 Jun
TI  - Substantial decrease in preeclampsia prevalence and risk over two decades: A 
      population-based study of 1,153,227 deliveries in Norway.
PG  - 21-27
LID - S2210-7789(22)00015-0 [pii]
LID - 10.1016/j.preghy.2022.02.001 [doi]
AB  - OBJECTIVES: Analyze secular trends of preeclampsia in Norway based on risk 
      factors. STUDY DESIGN: Population-based cohort study of 1,153,227 women using 
      data from Medical Birth Registry of Norway from 1999 to 2018. Aggregated data 
      from Norwegian Prescription Database from 2004 to 2018 were used. Main exposure 
      variable was time period. Descriptive statistics identified the prevalence of 
      preeclampsia, labor induction and aspirin use. Multiple logistic regression 
      analysis was performed to estimate the risk of preeclampsia during the time 
      periods. MAIN OUTCOME MEASURES: Preeclampsia. RESULTS: Overall preeclampsia 
      prevalence decreased from 4.3% in 1999-2002 to 2.7% in 2015-2018. A reduction was 
      observed in all subgroups of women with known risk factors (age, nulliparity, 
      diabetes, chronic hypertension, assisted reproduction, twin pregnancy). Adjusted 
      risk of preeclampsia was reduced by 44% from 1999-2002 to 2015-2018 (aOR = 0.56, 
      95%CI 0.54, 0.58), while the net prevalence of gestational hypertension remained 
      stable over the study period. Labor induction increased 104%. Aspirin 
      prescriptions increased among fertile women in the general Norwegian population. 
      CONCLUSIONS: Preeclampsia prevalence and risk were reduced regardless of risk 
      factors and despite an increased proportion of high-risk parturients (advanced 
      age, lower parity, use of assisted reproduction). A corresponding increase in 
      aspirin prescriptions among fertile women and an overall increase in labor 
      inductions were also observed, suggesting that clinical interventions may partly 
      explain the observed reduction in preeclampsia prevalence. Lower average blood 
      pressure and improved health in the population may also explain some of the 
      reduction.
CI  - Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Sole, Kristina B
AU  - Sole KB
AD  - Institute of Clinical Medicine, University of Oslo, Postboks 1171 Blindern, 0318 
      Oslo, Norway. Electronic address: k.b.sole@medisin.uio.no.
FAU - Staff, Anne Cathrine
AU  - Staff AC
AD  - Institute of Clinical Medicine, University of Oslo, Postboks 1171 Blindern, 0318 
      Oslo, Norway; Division of Obstetrics and Gynaecology, Oslo University Hospital, 
      Postboks 4950 Nydalen, 0424 Oslo, Norway.
FAU - Räisänen, Sari
AU  - Räisänen S
AD  - School of Health, Tampere University of Applied Sciences, Kuntokatu 3, 33520 
      Tampere, Finland.
FAU - Laine, Katariina
AU  - Laine K
AD  - Institute of Clinical Medicine, University of Oslo, Postboks 1171 Blindern, 0318 
      Oslo, Norway; Norwegian Research Centre for Women's Health, Oslo University 
      Hospital, Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20220208
PL  - Netherlands
TA  - Pregnancy Hypertens
JT  - Pregnancy hypertension
JID - 101552483
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - *Hypertension, Pregnancy-Induced/epidemiology
MH  - *Pre-Eclampsia/epidemiology/etiology
MH  - Pregnancy
MH  - Prevalence
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Hypertension
OT  - Labor induction
OT  - Preeclampsia
OT  - Pregnancy
OT  - Secular trends
EDAT- 2022/02/13 06:00
MHDA- 2022/05/28 06:00
CRDT- 2022/02/12 20:16
PHST- 2021/08/16 00:00 [received]
PHST- 2022/02/04 00:00 [revised]
PHST- 2022/02/04 00:00 [accepted]
PHST- 2022/02/13 06:00 [pubmed]
PHST- 2022/05/28 06:00 [medline]
PHST- 2022/02/12 20:16 [entrez]
AID - S2210-7789(22)00015-0 [pii]
AID - 10.1016/j.preghy.2022.02.001 [doi]
PST - ppublish
SO  - Pregnancy Hypertens. 2022 Jun;28:21-27. doi: 10.1016/j.preghy.2022.02.001. Epub 
      2022 Feb 8.

PMID- 20448796
OWN - NLM
STAT- MEDLINE
DCOM- 20110127
LR  - 20220408
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Print)
IS  - 1176-6344 (Linking)
VI  - 6
DP  - 2010 Mar 24
TI  - Aspirin and clopidogrel resistance: methodological challenges and opportunities.
PG  - 109-12
AB  - Antiplatelet drug resistance is one of the urgent issues in current 
      cardiovascular medicine. Many platelet function tests have been used to define 
      responsiveness of patients with cardiovascular disease to aspirin and 
      clopidogrel. In most studies, cut-off values of platelet function tests for 
      defining responsiveness to antiplatelets were chosen arbitrarily. Different tests 
      provided wide-ranging figures of the prevalence of aspirin and clopidogrel 
      resistance, suggesting poor correlation between currently available platelet 
      function tests. Measurement of platelet size seems to be a promising approach for 
      monitoring antiplatelet drug therapy. This commentary highlights some limitations 
      of studies on aspirin and clopidogrel resistance in patients undergoing coronary 
      interventions.
FAU - Gasparyan, Armen Yuri
AU  - Gasparyan AY
AD  - Clinical Research Unit, Russell's Hall Hospital, Dudley Group of Hospitals NHS 
      Foundation Trust, West Midlands, UK. a.gasparyan@gmail.com
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100324
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clopidogrel
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
PMC - PMC2860443
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular disease
OT  - clopidogrel
OT  - platelet function tests
OT  - resistance
EDAT- 2010/05/08 06:00
MHDA- 2011/01/29 06:00
CRDT- 2010/05/08 06:00
PHST- 2010/03/01 00:00 [received]
PHST- 2010/05/08 06:00 [entrez]
PHST- 2010/05/08 06:00 [pubmed]
PHST- 2011/01/29 06:00 [medline]
AID - vhrm-6-109 [pii]
AID - 10.2147/vhrm.s9087 [doi]
PST - epublish
SO  - Vasc Health Risk Manag. 2010 Mar 24;6:109-12. doi: 10.2147/vhrm.s9087.

PMID- 20645883
OWN - NLM
STAT- MEDLINE
DCOM- 20110331
LR  - 20131121
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 10
IP  - 1
DP  - 2011 Jan
TI  - Gastrointestinal bleeding associated with low-dose aspirin use: relevance and 
      management in clinical practice.
PG  - 45-54
LID - 10.1517/14740338.2010.507629 [doi]
AB  - IMPORTANCE OF THE FIELD: Aspirin reduces the risk of cardiovascular events, but 
      it is well documented that it can also damage the gastrointestinal (GI) tract. 
      However, the reasons why some people develop serious lesions, whereas most only 
      have minor, clinically irrelevant lesions are poorly understood. AREAS COVERED IN 
      THIS REVIEW: A number of risk factors can be used to determine which patients are 
      more likely to develop aspirin-associated GI bleeding, mainly in the upper GI 
      tract; these include a previous GI ulcer, ulcer complications, dyspepsia, and 
      concomitant drug therapy with non-steroidal anti-inflammatory drugs (NSAIDs) or 
      clopidogrel. The possible role of Helicobacter pylori infection is also 
      considered. WHAT THE READER WILL GAIN: Aspirin-induced GI damage can be reduced, 
      and a number of strategies can be implemented to shift the risk-benefit ratio in 
      favour of aspirin. Proton pump inhibitors are more effective than H(2)-receptor 
      antagonists in preventing dyspeptic symptoms, peptic ulcers and bleeding ulcers 
      in aspirin users. Although H. pylori infection may be a risk factor of 
      aspirin-induced ulcer bleeding, the role of its eradication in the prevention of 
      this outcome requires further investigation. TAKE HOME MESSAGE: The individual 
      assessment of the benefits and risks with aspirin, based on the underlying GI and 
      cardiovascular risk factors, is the key to successful therapy. Understanding the 
      effect of aspirin on colorectal cancer can also alter the risk-benefit ratio in 
      at-risk aspirin users.
FAU - Lanas, Angel
AU  - Lanas A
AD  - Department of Gastroenterology, University Hospital, University of Zaragoza, 
      Servicio de Aparato Digestivo, C/Domingo Miral s/n., 50009 Zaragoza, Zaragoza, 
      Spain. alanas@unizar.es
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100720
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Diseases/chemically induced/microbiology/prevention & control
MH  - Gastrointestinal Hemorrhage/*chemically induced/microbiology/*prevention & 
      control
MH  - Gastrointestinal Tract/drug effects
MH  - Helicobacter Infections/complications
MH  - Helicobacter pylori
MH  - Humans
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Risk Factors
EDAT- 2010/07/22 06:00
MHDA- 2011/04/01 06:00
CRDT- 2010/07/22 06:00
PHST- 2010/07/22 06:00 [entrez]
PHST- 2010/07/22 06:00 [pubmed]
PHST- 2011/04/01 06:00 [medline]
AID - 10.1517/14740338.2010.507629 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2011 Jan;10(1):45-54. doi: 10.1517/14740338.2010.507629. 
      Epub 2010 Jul 20.

PMID- 11213865
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20190515
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 24
IP  - 2
DP  - 2001 Feb
TI  - Aspirin use among adults with diabetes: estimates from the Third National Health 
      and Nutrition Examination Survey.
PG  - 197-201
AB  - OBJECTIVE: Since 1997, the American Diabetes Association has recommended that 
      aspirin therapy be considered for adults with diabetes who have cardiovascular 
      disease (CVD) or CVD risk factors. We examined the prevalence of regular aspirin 
      use among adults in the U.S. with diagnosed diabetes. RESEARCH DESIGN AND 
      METHODS: The Third National Health and Nutrition Examination Survey (1988-1994) 
      used a probability sample of the U.S. population and included an interview, 
      physical examination, and laboratory studies. Among the survey participants were 
      1,503 adults (age > or =21 years) with self-reported diabetes. We defined regular 
      aspirin use as reported having taken aspirin > or = 15 times in the previous 
      month. CVD conditions were self-reported heart attack and stroke and symptoms of 
      angina and claudication. CVD risk factors included smoking, hypertension, 
      obesity, albuminuria, lipid abnormalities, and family history of heart attack. 
      RESULTS: An estimated 27% of adults with diabetes had CVD, and an additional 71% 
      had one or more CVD risk factors. Aspirin was used regularly by 37% of those with 
      CVD and by 13% of those with risk factors only Adjusted odds of regular aspirin 
      use were significantly greater for individuals with CVD than for those with one 
      CVD risk factor (odds ratio [OR] = 4.3); for non-Hispanic whites than for blacks, 
      Mexican-Americans, and others (OR = 2.5); and for individuals age 40-59 years 
      than for those <40 years (OR = 33.3). CONCLUSIONS: Nearly every adult in the U.S. 
      with diabetes has at least one risk factor for CVD and thus may be considered a 
      potential candidate for aspirin therapy. During 1988-1994, only 20% (95% CI 
      16-23) took aspirin regularly Major efforts are needed to increase aspirin use.
FAU - Rolka, D B
AU  - Rolka DB
AD  - Division of Diabetes Translation, Centers for Disease Control and Prevention, 
      Atlanta, Georgia, USA. drolka@cdc.gov
FAU - Fagot-Campagna, A
AU  - Fagot-Campagna A
FAU - Narayan, K M
AU  - Narayan KM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Diabetes Care. 2001 Feb;24(2):195-6. PMID: 11213864
CIN - Diabetes Care. 2001 Nov;24(11):2015-6. PMID: 11679489
MH  - Adult
MH  - Albuminuria
MH  - Angina Pectoris/epidemiology
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology/etiology/*prevention & control
MH  - *Diabetes Complications
MH  - Diabetes Mellitus/drug therapy
MH  - Diabetic Angiopathies/epidemiology/prevention & control
MH  - *Health Surveys
MH  - Humans
MH  - Hyperlipidemias/complications
MH  - Hypertension/complications
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology
MH  - Obesity
MH  - Risk Factors
MH  - Smoking/adverse effects
MH  - Stroke/epidemiology
EDAT- 2001/02/24 12:00
MHDA- 2001/04/03 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/04/03 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
AID - 10.2337/diacare.24.2.197 [doi]
PST - ppublish
SO  - Diabetes Care. 2001 Feb;24(2):197-201. doi: 10.2337/diacare.24.2.197.

PMID- 35647186
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220716
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2022
DP  - 2022
TI  - Clinical Effect of Nicorandil Combined with Aspirin in the Treatment of 
      Myocardial Ischemia.
PG  - 2214411
LID - 10.1155/2022/2214411 [doi]
LID - 2214411
AB  - OBJECTIVE: To investigate the clinical effect of nicorandil combined with aspirin 
      in the treatment of myocardial ischemia. METHODS: A total of 104 patients with 
      myocardial ischemia were admitted to our hospital from June 2019 to August 2020. 
      These patients were selected as the research objects and randomly divided into 
      two groups: the control group and the observation group. The control group was 
      given asilin, and the observation group was given nicorandil tablets based on the 
      control group. Both groups were given continuous treatment for 3 months. The 
      curative effect, cardiac function indexes, dynamic electrocardiogram, and the 
      occurrence of adverse reactions were observed in the two groups. RESULTS: The 
      total effective rate of the observation group was 96.15% (50/52), which was 
      higher than that of the control group (61.54%, 32/52), and the difference was 
      statistically significant (P < 0.05). After treatment, left ventricular ejection 
      fraction (LVEF) and peak early/late diastolic flow velocity (E/A) were increased 
      (P < 0.05), while peak early diastolic flow velocity to peak mitral annular root 
      movement velocity (E/Ea) was decreased (P < 0.05). After treatment, LVEF and E/A 
      in the observation group were higher than those in the control group, while E/Ea 
      was lower than that in the control group (P < 0.05). The frequency, duration of 
      ST segment, and a total load of myocardial ischemia in the ST segment within 24 h 
      after treatment were decreased compared with those before treatment (P < 0.05). 
      The frequency and duration of ST segment decreased, and the total load of 
      myocardial ischemia in the observation group was lower than those in the control 
      group within 24 h after treatment (P < 0.05). After treatment, the total 
      occurrence of adverse reactions in the observation group was lower than that in 
      the control group (P < 0.05). CONCLUSION: Nicorandil combined with aspirin in the 
      treatment of patients with myocardial ischemia has a significant effect, which 
      can effectively improve the electrocardiogram and cardiac function indicators of 
      patients and reduce the incidence of adverse reactions and is worthy of clinical 
      application.
CI  - Copyright © 2022 Yue Li et al.
FAU - Li, Yue
AU  - Li Y
AD  - Department of Cardiology, Third Hospital of Shanxi Medical University, Key 
      Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of 
      Education, China.
FAU - Zhao, Chen
AU  - Zhao C
AD  - Department of Cardiology, Third Hospital of Shanxi Medical University, Key 
      Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of 
      Education, China.
FAU - Xiong, Chengxin
AU  - Xiong C
AUID- ORCID: 0000-0002-5905-6610
AD  - School of Computer Science, Hefei University of Technology, China.
FAU - Gao, Yuping
AU  - Gao Y
AUID- ORCID: 0000-0002-9500-2361
AD  - Department of Cardiology, Third Hospital of Shanxi Medical University, Key 
      Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of 
      Education, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220518
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 260456HAM0 (Nicorandil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arrhythmias, Cardiac/drug therapy
MH  - Aspirin/therapeutic use
MH  - *Coronary Artery Disease/drug therapy
MH  - Humans
MH  - *Myocardial Ischemia/drug therapy
MH  - Nicorandil/therapeutic use
MH  - Stroke Volume
MH  - Ventricular Function, Left
PMC - PMC9132652
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/06/02 06:00
MHDA- 2022/06/07 06:00
CRDT- 2022/06/01 11:44
PHST- 2022/03/11 00:00 [received]
PHST- 2022/04/17 00:00 [revised]
PHST- 2022/05/03 00:00 [accepted]
PHST- 2022/06/01 11:44 [entrez]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
AID - 10.1155/2022/2214411 [doi]
PST - epublish
SO  - Biomed Res Int. 2022 May 18;2022:2214411. doi: 10.1155/2022/2214411. eCollection 
      2022.

PMID- 17323787
OWN - NLM
STAT- MEDLINE
DCOM- 20070315
LR  - 20190608
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 45
IP  - 2
DP  - 2007 Feb
TI  - Aspirin reduces cutaneous flushing after administration of an optimized 
      extended-release niacin formulation.
PG  - 78-88
AB  - OBJECTIVE: Niacin is an effective treatment for dyslipidemia due to its favorable 
      effects on multiple lipid parameters. Clinical utility of niacin is sometimes 
      limited, however, because of cutaneous flushing. A once-daily, extended-release 
      (ER) niacin formulation has been shown to significantly reduce flushing compared 
      to immediate-release niacin. An optimized (reformulated) version of niacin ER has 
      recently been developed and was shown in a previous study to significantly reduce 
      flushing intensity (severity) compared to the non-optimized (commercial) 
      formulation. The current study was designed to evaluate the effect of aspirin on 
      various indices of flushing when administered with the optimized niacin ER 
      formulation. METHOD: This was a randomized, double-blind, double-dummy, 
      placebo-controlled flush provocation crossover study in healthy males. To 
      increase the probability of flushing, subjects received a single dose of 
      reformulated niacin ER 2,000 mg, which is the upper limit of the approved dosage 
      range. Subjects received 650 mg aspirin orally either 30 minutes before or 
      concomitantly with niacin ER, or placebo with niacin ER, in 3-way crossover 
      fashion. The primary endpoint was the number of subjects who reported at least 
      one flushing event. Secondary endpoints included the perceived intensity and 
      duration of flushing symptoms. RESULTS: In the 148 men who completed all 
      treatments, aspirin significantly reduced flushing incidence (the primary 
      endpoint) following administration of niacin ER compared with placebo. Among 
      subjects receiving placebo, 77% of subjects reported flushing with niacin ER. 
      Among subjects receiving aspirin, 53-61% of subjects reported flushing 
      (pretreatment and concomitant treatment, respectively, both p < 0.001 compared 
      with placebo) with niacin ER. Aspirin also significantly reduced intensity and 
      duration of flushing (by 30-40%) compared with no aspirin. The two 
      aspirin-containing treatments (i.e. pre- or concomitant treatment) were similar 
      in their effects on flushing incidence, intensity and duration. Median intensity 
      on a 100 mm visual analogue scale (VAS) was reduced from 33 mm with placebo to 
      19-23 mm with aspirin. Median duration was reduced from approximately 1 hour with 
      placebo to 37-48 minutes with aspirin. CONCLUSION: Aspirin significantly reduced 
      the incidence, intensity and duration of flushing associated with reformulated 
      niacin ER. These results support the administration of aspirin prophylactically 
      to decrease niacin-induced cutaneous flushing and to improve patient adherence 
      and acceptability of chronic niacin treatment at therapeutic doses.
FAU - Cefali, E A
AU  - Cefali EA
AD  - Kos Pharmaceuticals, Inc., Cranbury, NJ, USA.
FAU - Simmons, P D
AU  - Simmons PD
FAU - Stanek, E J
AU  - Stanek EJ
FAU - McGovern, M E
AU  - McGovern ME
FAU - Kissling, C J
AU  - Kissling CJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Hypolipidemic Agents)
RN  - 2679MF687A (Niacin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cross-Over Studies
MH  - Delayed-Action Preparations
MH  - Double-Blind Method
MH  - Flushing/chemically induced/*drug therapy
MH  - Humans
MH  - Hypolipidemic Agents/administration & dosage/*adverse effects
MH  - Male
MH  - Niacin/administration & dosage/*adverse effects
MH  - Treatment Outcome
EDAT- 2007/02/28 09:00
MHDA- 2007/03/16 09:00
CRDT- 2007/02/28 09:00
PHST- 2007/02/28 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2007/02/28 09:00 [entrez]
AID - 10.5414/cpp45078 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2007 Feb;45(2):78-88. doi: 10.5414/cpp45078.

PMID- 21325111
OWN - NLM
STAT- MEDLINE
DCOM- 20110404
LR  - 20211020
IS  - 1538-3679 (Electronic)
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 171
IP  - 3
DP  - 2011 Feb 14
TI  - Cost-utility of aspirin and proton pump inhibitors for primary prevention.
PG  - 218-25
LID - 10.1001/archinternmed.2010.525 [doi]
AB  - BACKGROUND: Aspirin reduces myocardial infarction but increases gastrointestinal 
      tract (GI) bleeding. Proton pump inhibitors (PPIs) may reduce upper GI bleeding. 
      We estimate the cost-utility of aspirin treatment with or without a PPI for 
      coronary heart disease (CHD) prevention among men at different risks for CHD and 
      GI bleeding. METHODS: We updated a Markov model to compare costs and outcomes of 
      low-dose aspirin plus PPI (omeprazole, 20 mg/d), low-dose aspirin alone, or no 
      treatment for CHD prevention. We performed lifetime analyses in men with 
      different risks for cardiovascular events and GI bleeding. Aspirin reduced 
      nonfatal myocardial infarction by 30%, increased total stroke by 6%, and 
      increased GI bleeding risk 2-fold. Adding a PPI reduced upper GI bleeding by 80%. 
      Annual aspirin cost was $13.99; the generic PPI cost was $200.00. RESULTS: In 
      45-year-old men with a 10-year CHD risk of 10% and 0.8 per 1000 annual GI 
      bleeding risk, aspirin ($17,571 and 18.67 quality-adjusted life-years [QALYs]) 
      was more effective and less costly than no treatment ($18,483 and 18.44 QALYs). 
      Compared with aspirin alone, aspirin plus PPI ($21,037 and 18.68 QALYs) had an 
      incremental cost per QALY of $447,077. Results were similar in 55- and 
      65-year-old men. The incremental cost per QALY of adding a PPI was less than 
      $50,000 per QALY at annual GI bleeding probabilities greater than 4 to 6 per 
      1000. CONCLUSIONS: Treatment with aspirin for CHD prevention is less costly and 
      more effective than no treatment in men older than 45 years with greater than 
      10-year, 10% CHD risks. Adding a PPI is not cost-effective for men with average 
      GI bleeding risk but may be cost-effective for selected men at increased risk for 
      GI bleeding.
CI  - ©2011 American Medical Association. All rights reserved.
FAU - Earnshaw, Stephanie R
AU  - Earnshaw SR
AD  - RTI Health Solutions, Research Triangle Park, North Carolina 27709, USA. 
      searnshaw@rti.org
FAU - Scheiman, James
AU  - Scheiman J
FAU - Fendrick, A Mark
AU  - Fendrick AM
FAU - McDade, Cheryl
AU  - McDade C
FAU - Pignone, Michael
AU  - Pignone M
LA  - eng
GR  - K05 CA129166/CA/NCI NIH HHS/United States
GR  - K05 CA129166-04/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*economics/therapeutic use
MH  - Coronary Disease/*economics/*prevention & control
MH  - Cost-Benefit Analysis/statistics & numerical data
MH  - Drug Costs/*statistics & numerical data
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Hemorrhage/chemically induced/*economics/*prevention & control
MH  - Health Care Costs/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Myocardial Infarction/*economics/*prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*economics/therapeutic use
MH  - Proton Pump Inhibitors/adverse effects/*economics/therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Risk Assessment/economics/statistics & numerical data
MH  - United States
PMC - PMC3137269
MID - NIHMS307268
COIS- Conflicts of Interest Dr. Scheiman is Professor of Medicine in the Division of 
      Gastroenterology at the University of Michigan. Dr. Fendrick is Professor of 
      Internal Medicine and Health Management and Policy at the University of Michigan. 
      Drs. Scheiman and Fendrick are paid consultants to RTI Health Solutions. Dr. 
      Scheiman also is a consultant to AstraZeneca, Bayer Inc., Pozen, Inc., as well as 
      other pharmaceutical companies with products not relevant to this work. Dr. 
      Earnshaw and Ms. McDade are employees of RTI Health Solutions, an independent 
      contract research organization that has received research funding for this and 
      other studies from Bayer, Inc. and other pharmaceutical companies that market 
      drugs to prevent cardiovascular events and other conditions. Dr. Pignone is 
      Professor of Medicine and Division Chief for General Internal Medicine at the 
      University of North Carolina at Chapel Hill. His effort was supported by the 
      Foundation for Informed Medical Decision Making and a K05 Established 
      Investigator Award from the National Cancer Institute. Bayer, Inc. did not 
      participate in the development of the model or in the collection, management, 
      analysis, and interpretation of the data. The preparation and editing of the 
      manuscript was performed solely by the authors. Bayer received a copy of the 
      draft manuscript but had no role in decisions about submission and revision.
EDAT- 2011/02/18 06:00
MHDA- 2011/04/05 06:00
CRDT- 2011/02/18 06:00
PHST- 2011/02/18 06:00 [entrez]
PHST- 2011/02/18 06:00 [pubmed]
PHST- 2011/04/05 06:00 [medline]
AID - 171/3/218 [pii]
AID - 10.1001/archinternmed.2010.525 [doi]
PST - ppublish
SO  - Arch Intern Med. 2011 Feb 14;171(3):218-25. doi: 10.1001/archinternmed.2010.525.

PMID- 6140906
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 144
IP  - 1
DP  - 1984 Jan
TI  - Efficacy of ipecac and activated charcoal/cathartic. Prevention of salicylate 
      absorption in a simulated overdose.
PG  - 48-52
AB  - Twelve adult volunteers were given 24 81-mg aspirin tablets and were randomly 
      assigned into the following treatment groups: (1) control aspirin, (2) 30 mL of 
      ipecac repeated if vomiting not induced, (3) 60 g of activated charcoal per 15 g 
      of magnesium sulfate (MgSO4), and (4) ipecac repeated if needed, followed by 
      activated charcoal/MgSO4 given 1 1/2 hours after the last vomiting episode. All 
      treatments began 60 minutes following aspirin ingestion. Urine was collected for 
      48 hours for percent total salicylate excretion. Mean +/- SD recovery of 
      salicylate from urine was as follows: aspirin, 96.3% +/- 7.5%; ipecac 70.3% +/- 
      11.8%, activated charcoal/MgSO4, 56.4% +/- 12%; and ipecac and activated 
      charcoal/MgSO4, 72.4% +/- 14.1%. Ten subjects completed the study. In group 4, 
      eight of ten subjects vomited the activated charcoal/MgSO4 immediately, making 
      statistical analysis impossible. Analysis revealed that activated charcoal/MgSO4 
      significantly lowered the absorption of aspirin compared with the control and 
      ipecac-treated groups. Furthermore, ipecac significantly lowered aspirin 
      absorption compared with the control group. We conclude that activated 
      charcoal/MgSO4 used alone is superior to the other treatment modalities at 
      inhibiting the absorption of multiple aspirin tablets.
FAU - Curtis, R A
AU  - Curtis RA
FAU - Barone, J
AU  - Barone J
FAU - Giacona, N
AU  - Giacona N
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Cathartics)
RN  - 0 (Salicylates)
RN  - 16291-96-6 (Charcoal)
RN  - 7487-88-9 (Magnesium Sulfate)
RN  - 8012-96-2 (Ipecac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/metabolism/*poisoning
MH  - Cathartics/administration & dosage/*therapeutic use
MH  - Charcoal/administration & dosage/*therapeutic use
MH  - Drug Evaluation
MH  - Humans
MH  - Intestinal Absorption/drug effects
MH  - Ipecac/administration & dosage/*therapeutic use
MH  - Magnesium Sulfate/administration & dosage/therapeutic use
MH  - Random Allocation
MH  - Salicylates/urine
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1984 Jan;144(1):48-52.

PMID- 15242475
OWN - NLM
STAT- MEDLINE
DCOM- 20050125
LR  - 20181113
IS  - 0884-8734 (Print)
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
VI  - 19
IP  - 8
DP  - 2004 Aug
TI  - Should aspirin be continued in patients started on warfarin?
PG  - 879-86
AB  - BACKGROUND AND OBJECTIVE: Clinicians frequently face the decision of whether to 
      continue aspirin when starting patients on warfarin. We performed a meta-analysis 
      to characterize the tradeoffs involved in this common clinical dilemma. DATA 
      SOURCES: Multiple computerized databases (1966 to 2003), reference lists of 
      relevant articles, conference proceedings, and queries of primary authors. STUDY 
      SELECTION: Randomized trials comparing warfarin plus aspirin versus warfarin 
      alone. Studies with target international normalized ratios (INRs) <2 were 
      excluded. DATA EXTRACTION: Two reviewers independently extracted baseline data 
      and major outcomes: rates of thromboembolism, hemorrhage, and all-cause 
      mortality. DATA SYNTHESIS: Nine studies met the inclusion criteria. Of the five 
      that enrolled patients with mechanical heart valves, four used the same target 
      INR in both groups, while one used a reduced target INR for the warfarin plus 
      aspirin group. Pooling the results of the first four studies demonstrated that 
      combination of warfarin plus aspirin significantly decreased thromboembolic 
      events (relative risk [RR], 0.33; 95% confidence interval [CI], 0.19 to 0.58), 
      increased major bleeding (RR, 1.58; 95% CI, 1.02 to 2.44), and decreased 
      all-cause mortality (RR, 0.43; 95% CI, 0.23 to 0.81) compared to warfarin alone. 
      The one valve trial using a reduced INR in the warfarin plus aspirin group 
      reported no difference in thromboembolic outcomes but found decreased major 
      bleeding and a significant mortality benefit with combination therapy. Of the 
      remaining trials, three evaluated a warfarin indication not routinely used in the 
      United States (post-myocardial infarction), and the only trial that considered 
      atrial fibrillation was terminated early due to inadequate enrollment. 
      CONCLUSIONS: For mechanical heart valve patients, the benefits of continuing 
      aspirin when starting warfarin therapy are clear. For other routine warfarin 
      indications, there are not adequate data to guide this common clinical decision.
FAU - Larson, Robin J
AU  - Larson RJ
AD  - VA Outcomes Group, Department of Veteran Affairs Medical Center, White River 
      Junction, VT, USA. robin.j.larson@hitchcock.org
FAU - Fisher, Elliott S
AU  - Fisher ES
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Thromboembolism/*prevention & control
MH  - Warfarin/*administration & dosage/adverse effects
PMC - PMC1492499
EDAT- 2004/07/10 05:00
MHDA- 2005/01/26 09:00
CRDT- 2004/07/10 05:00
PHST- 2004/07/10 05:00 [pubmed]
PHST- 2005/01/26 09:00 [medline]
PHST- 2004/07/10 05:00 [entrez]
AID - JGI30419 [pii]
AID - 10.1111/j.1525-1497.2004.30419.x [doi]
PST - ppublish
SO  - J Gen Intern Med. 2004 Aug;19(8):879-86. doi: 10.1111/j.1525-1497.2004.30419.x.

PMID- 3968305
OWN - NLM
STAT- MEDLINE
DCOM- 19850227
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 5
IP  - 2 Pt 1
DP  - 1985 Feb
TI  - Effect of high dose aspirin on coronary hemodynamics during pacing-induced 
      myocardial ischemia.
PG  - 210-5
AB  - The effects of aspirin on coronary hemodynamics and transcardiac concentrations 
      of thromboxane B2 (the stable metabolite of thromboxane A2) were determined at 
      rest and during pacing-induced myocardial ischemia in 11 patients with coronary 
      disease. Control coronary sinus pacing increased both arterial thromboxane B2 
      (331 +/- 70 to 623 +/- 132 pg/ml, p less than 0.02) and coronary sinus 
      thromboxane B2 (184 +/- 3 to 403 +/- 156 pg/ml, p less than 0.05), but positive 
      transmyocardial gradients developed in only three patients. After 650 mg of oral 
      aspirin, more than 90% inhibition of in vitro thromboxane B2 production was 
      demonstrated and circulating thromboxane B2 was undetectable at rest and during 
      pacing in all patients. Despite these changes in thromboxane B2 concentrations, 
      coronary blood flow was unchanged by aspirin at rest (107 +/- 14 versus 112 +/- 
      13 ml/min, p = NS) and during pacing (189 +/- 29 versus 181 +/- 25 ml/min, p = 
      NS). Myocardial lactate extraction was also unchanged at rest (24 +/- 7 versus 19 
      +/- 5%, p = NS) and during pacing (5 +/- 6 versus 9 +/- 5%, p = NS). No change 
      occurred in the anginal threshold. Thus, aspirin does not have the 
      vasoconstrictive properties that have been reported with another cyclo-oxygenase 
      inhibitor, indomethacin. These findings also suggest that thromboxane A2 
      production does not play a major role in the pathogenesis of stress-induced 
      ischemia. Nonetheless, intracoronary thromboxane A2 production in some patients 
      may potentiate platelet activation and coronary thrombosis. Such patients may 
      benefit from long-term aspirin therapy and can be treated with aspirin without 
      risk of adverse coronary hemodynamic effects.
FAU - Martin, J L
AU  - Martin JL
FAU - Fisher, C A
AU  - Fisher CA
FAU - Untereker, W J
AU  - Untereker WJ
FAU - Laskey, W K
AU  - Laskey WK
FAU - Hirshfeld, J W Jr
AU  - Hirshfeld JW Jr
FAU - Harken, A H
AU  - Harken AH
FAU - Addonizio, V P
AU  - Addonizio VP
LA  - eng
GR  - HL 19055/HL/NHLBI NIH HHS/United States
GR  - HL 22315/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Lactates)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Angina Pectoris/physiopathology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cardiac Pacing, Artificial
MH  - Coronary Circulation/drug effects
MH  - Coronary Disease/etiology/*physiopathology
MH  - Female
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Lactates/blood
MH  - Lactic Acid
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/blood/*physiopathology
MH  - Thromboxane B2/blood
MH  - Vascular Resistance/drug effects
EDAT- 1985/02/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1985/02/01 00:00
PHST- 1985/02/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1985/02/01 00:00 [entrez]
AID - S0735-1097(85)80039-5 [pii]
AID - 10.1016/s0735-1097(85)80039-5 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1985 Feb;5(2 Pt 1):210-5. doi: 10.1016/s0735-1097(85)80039-5.

PMID- 8267047
OWN - NLM
STAT- MEDLINE
DCOM- 19940124
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 169
IP  - 6
DP  - 1993 Dec
TI  - Secretion of lipid peroxides by the human placenta.
PG  - 1462-6
AB  - OBJECTIVE: We attempted to determine whether the human placenta secretes lipid 
      peroxides. If it does, then it could be a source of lipid peroxides in maternal 
      blood. STUDY DESIGN: In study 1 isolated human placental cotyledons (n = 7) were 
      perfused serially for 20-minute intervals with control Krebs-Ringer-bicarbonate 
      buffer gassed with 95% oxygen and 5% carbon dioxide and Krebs-Ringer-bicarbonate 
      buffer with progressively increasing concentrations of t-butyl hydroperoxide 
      added (10, 25, 50, and 100 mumol/L) to stimulate endogenous lipid peroxide 
      production. In study 2 placental cotyledons (n = 6) were perfused serially for 
      20-minute intervals with control Krebs-Ringer-bicarbonate buffer, t-butyl 
      hydroperoxide (100 mumol/L), low-dose aspirin (5 x 10(-5) mol/L), and low-dose 
      aspirin plus t-butyl hydroperoxide. Maternal and fetal effluent samples were 
      analyzed for lipid peroxides by hydrogen peroxide equivalents. RESULTS: In study 
      1, compared with control Krebs-Ringer-bicarbonate perfusion, peroxide perfusion 
      significantly increased, in a dose-response manner, placental lipid peroxide 
      secretion. In study 2, aspirin completely blocked the ability of peroxide to 
      increase the secretion of lipid peroxides. In both studies placental secretion of 
      lipid peroxides was significantly greater toward the maternal side of the 
      placenta than toward the fetal side. CONCLUSIONS: (1) The human placenta secretes 
      lipid peroxides primarily into the maternal effluent. (2) Exogenous peroxide 
      stimulates endogenous lipid peroxide production, which is blocked by aspirin, 
      suggesting cyclooxygenase is involved in lipid peroxide production. (3) The 
      placenta could be a source of circulating lipid peroxides in pregnant women.
FAU - Walsh, S W
AU  - Walsh SW
AD  - Department of Obstetrics and Gynecology, Medical College of Virginia, Virginia 
      Commonwealth University, Richmond 23298-0034.
FAU - Wang, Y
AU  - Wang Y
LA  - eng
GR  - HD 20973/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Lipid Peroxides)
RN  - 0 (Peroxides)
RN  - 955VYL842B (tert-Butylhydroperoxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Lipid Peroxides/*metabolism
MH  - Peroxides/pharmacology
MH  - Placenta/drug effects/*metabolism
MH  - Pregnancy
MH  - tert-Butylhydroperoxide
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
AID - 0002-9378(93)90419-J [pii]
AID - 10.1016/0002-9378(93)90419-j [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1993 Dec;169(6):1462-6. doi: 10.1016/0002-9378(93)90419-j.

PMID- 8475362
OWN - NLM
STAT- MEDLINE
DCOM- 19930520
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 123
IP  - 12
DP  - 1993 Mar 27
TI  - [Acetylsalicylic acid-induced generalized pustulosis].
PG  - 542-6
AB  - We report the case of a 55-year-old patient with recurrent episodes of 
      generalized pustulosis and febrile temperatures. Histological examination 
      revealed subcorneal and spongiform pustules. After a 4 years' course acute 
      exanthematous generalized pustulosis, induced by acetylsalicylic acid was 
      diagnosed. Clinical features, differential diagnosis and causative agents of this 
      rare drug reaction are discussed.
FAU - Ballmer-Weber, B K
AU  - Ballmer-Weber BK
AD  - Dermatologische Klinik, Universität Zürich.
FAU - Widmer, M
AU  - Widmer M
FAU - Burg, G
AU  - Burg G
LA  - ger
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Acetylsalicylsäure-induzierte generalisierte Pustulose.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/*adverse effects
MH  - Diagnosis, Differential
MH  - Drug Eruptions/*diagnosis
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Psoriasis/diagnosis
MH  - Skin Diseases, Vesiculobullous/*chemically induced/diagnosis/pathology
EDAT- 1993/03/27 00:00
MHDA- 1993/03/27 00:01
CRDT- 1993/03/27 00:00
PHST- 1993/03/27 00:00 [pubmed]
PHST- 1993/03/27 00:01 [medline]
PHST- 1993/03/27 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1993 Mar 27;123(12):542-6.

PMID- 570551
OWN - NLM
STAT- MEDLINE
DCOM- 19790516
LR  - 20161123
IS  - 0378-0791 (Print)
IS  - 0378-0791 (Linking)
VI  - 6
IP  - 1
DP  - 1979
TI  - [Antithrombotic agents for the prevention of thromboses during infraclavicular 
      vena cava catheterizaiton].
PG  - 50-4
AB  - To study the suppressibility of thrombosis due to central venous catheter 
      phlebographically, groups of 25 patients were given low-dose-heparin, dextran 70 
      or salicylate (initial application preoperatively). The catheter was inserted for 
      6 to 8 days. As a control group 25 patients received no antithrombotic medication 
      whatsoever. Of these cases 35% showed evidence of thrombus formation. In 
      comparison only the patients with salicylate showed a significant reduction of 
      catheter-induced thrombosis by 67%. By comparing the heparin to the control group 
      the total of thrombotic formations when planimetrically assessed results in a 
      ration of 1:12, which is superior to dextran and salicylate.
FAU - Fassolt, A
AU  - Fassolt A
FAU - Brändli, F
AU  - Brändli F
FAU - Braun, U
AU  - Braun U
LA  - ger
PT  - Journal Article
TT  - Antithrombotika zur Prophylaxe der Begleitthrombosen bei infraklavikulären 
      Vena-Cava-Kathetern.
PL  - Switzerland
TA  - Infusionsther Klin Ernahr
JT  - Infusionstherapie und klinische Ernahrung
JID - 7613112
RN  - 0 (Dextrans)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Catheterization/*adverse effects
MH  - Dextrans/therapeutic use
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phlebography
MH  - Subclavian Vein
MH  - Thrombosis/*prevention & control
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Infusionsther Klin Ernahr. 1979;6(1):50-4.

PMID- 24121474
OWN - NLM
STAT- MEDLINE
DCOM- 20140624
LR  - 20211021
IS  - 1433-0563 (Electronic)
IS  - 0340-2592 (Linking)
VI  - 52
IP  - 11
DP  - 2013 Nov
TI  - [ASA and clopidogrel for urological operations. Perioperative management].
PG  - 1597-605
AB  - In a systematic overview and meta-analysis among more than 50,000 patients at 
      risk for coronary artery disease, not adhering to or discontinuing aspirin 
      (acetylsalicylic acid, ASA) was associated with a significantly increased risk of 
      non-fatal myocardial infarction or death. Withdrawal of low dose aspirin was 
      correlated with a threefold increase in the risk of adverse cardiovascular 
      events. This risk is present irrespective of the length of time patients had been 
      taking low dose aspirin. Therefore, in patients on chronic low dose aspirin for 
      secondary prevention of cardiovascular disease, aspirin should never be 
      discontinued. In the few available studies in urological surgery the increase in 
      bleeding does not translate into a significant increase in specific morbidity. 
      This seems to be also true for the additional administration of clopidogrel to 
      aspirin. Nevertheless, in patients with drug-eluting stents and dual antiplatelet 
      therapy, urologists should ensure a multidisciplinary management of the 
      perioperative course.
FAU - Fischer, C
AU  - Fischer C
FAU - Lümmen, G
AU  - Lümmen G
LA  - ger
PT  - Journal Article
TT  - ASS und Clopidogrel bei urologischen Operationen. Perioperatives management.
PL  - Germany
TA  - Urologe A
JT  - Der Urologe. Ausg. A
JID - 1304110
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/complications/*prevention & control
MH  - Clopidogrel
MH  - Humans
MH  - Perioperative Care
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Postoperative Hemorrhage/*etiology/*prevention & control
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Urologic Surgical Procedures/*adverse effects/*methods
EDAT- 2013/10/15 06:00
MHDA- 2014/06/25 06:00
CRDT- 2013/10/15 06:00
PHST- 2013/10/15 06:00 [entrez]
PHST- 2013/10/15 06:00 [pubmed]
PHST- 2014/06/25 06:00 [medline]
AID - 10.1007/s00120-013-3263-9 [doi]
PST - ppublish
SO  - Urologe A. 2013 Nov;52(11):1597-605. doi: 10.1007/s00120-013-3263-9.

PMID- 15861417
OWN - NLM
STAT- MEDLINE
DCOM- 20050809
LR  - 20220316
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 103
IP  - 12
DP  - 2005 Jun 15
TI  - Nuclear factor kappa B activation is a potential target for preventing pancreatic 
      carcinoma by aspirin.
PG  - 2485-90
AB  - BACKGROUND: Pancreatic carcinoma exhibits a unique genetic profile of mutations 
      that may play key roles in its progression to malignant phenotypes. Constitutive 
      activation of transcription factor nuclear factor kappa B (NF-kappaB) is a 
      frequent molecular alteration in pancreatic carcinoma, suggesting a possible link 
      between inflammation and cancer. The aims of the current study were to determine 
      the effects of aspirin on pancreatic carcinoma prevention and to reveal a 
      possible mechanism of aspirin-mediated cancer chemoprevention. METHODS: An 
      orthotopic mouse model with human pancreatic carcinoma cell lines PANC-1, 
      PANC-1/Puro, and PANC-1/IkappaBalphaM was used to study the inhibitory effects of 
      aspirin on pancreatic tumor formation. RESULTS: Aspirin inhibited constitutive 
      NF-kappaB activity in culture and, in turn, decreased the expression of the 
      NF-kappaB downstream target gene, Cox-2, in PANC-1 or PANC-1/Puro cells, without 
      significantly inhibiting the in vitro growth of PANC-1/Puro cells. All animals 
      inoculated with either PANC-1 or PANC-1/Puro cells, and not given aspirin, 
      developed pancreatic tumors, whereas none of the mice injected with 
      PANC-1/IkappaBalphaM cells showed any evidence of pancreatic tumor formation. 
      Animals given aspirin for 6 days before, or at the time of, orthotopic tumor cell 
      injection showed a significantly lower incidence of tumor formation compared with 
      those receiving aspirin 2 weeks after inoculation and controls receiving no 
      aspirin. CONCLUSIONS: Aspirin repressed tumor formation by PANC-1 cells in vivo 
      in a prophylactic setting, suggesting a possible mechanism for aspirin's 
      preventive effect in pancreatic carcinoma through inhibition of NF-kappaB 
      activation and a mechanistic link between inflammation and tumorigenesis. 
      Aspirin-mediated antiinflammatory approaches might be an effective strategy to 
      prevent pancreatic carcinoma.
CI  - Copyright 2005 American Cancer Society.
FAU - Sclabas, Guido M
AU  - Sclabas GM
AD  - Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer 
      Center, Houston, Texas 77030, USA.
FAU - Uwagawa, Tadashi
AU  - Uwagawa T
FAU - Schmidt, Christian
AU  - Schmidt C
FAU - Hess, Kenneth R
AU  - Hess KR
FAU - Evans, Douglas B
AU  - Evans DB
FAU - Abbruzzese, James L
AU  - Abbruzzese JL
FAU - Chiao, Paul J
AU  - Chiao PJ
LA  - eng
GR  - P20-CA101936/CA/NCI NIH HHS/United States
GR  - R01CA097159/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Membrane Proteins)
RN  - 0 (NF-kappa B)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenocarcinoma/genetics/metabolism/*prevention & control
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cyclooxygenase 2
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Membrane Proteins
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - NF-kappa B/genetics/*metabolism
MH  - Pancreatic Neoplasms/drug therapy/metabolism/*prevention & control
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Tumor Cells, Cultured
EDAT- 2005/04/30 09:00
MHDA- 2005/08/10 09:00
CRDT- 2005/04/30 09:00
PHST- 2005/04/30 09:00 [pubmed]
PHST- 2005/08/10 09:00 [medline]
PHST- 2005/04/30 09:00 [entrez]
AID - 10.1002/cncr.21075 [doi]
PST - ppublish
SO  - Cancer. 2005 Jun 15;103(12):2485-90. doi: 10.1002/cncr.21075.

PMID- 30918236
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20200701
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 83
IP  - 5
DP  - 2019 Apr 25
TI  - Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin 
      and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing 
      Percutaneous Coronary Intervention　- From the TWMU-AF PCI Registry.
PG  - 1000-1005
LID - 10.1253/circj.CJ-18-1113 [doi]
AB  - BACKGROUND: Using the standard maintenance dose of prasugrel (10 mg/day) as part 
      of triple therapy with aspirin and an oral anticoagulant (OAC) is not recommended 
      in the current guidelines because it increases the risk of bleeding compared with 
      clopidogrel. However, the safety and efficacy of low-dose prasugrel (3.75 mg/day) 
      as part of triple therapy has not been reported. Methods and Results: We 
      registered 816 consecutive patients with atrial fibrillation (AF) who underwent 
      percutaneous coronary intervention (PCI) from January 2011 to June 2016 at 8 
      hospitals in Japan. We examined the clinical outcomes of patients who received 
      either low-dose prasugrel (n=57) or clopidogrel (n=451) as part of triple therapy 
      after PCI. The incidences of bleeding (TIMI major and minor) and major adverse 
      cerebrocardiovascular events (MACCE; all-cause death, nonfatal myocardial 
      infarction, stent thrombosis, unplanned revascularization, and stroke) were 
      evaluated. The cumulative 1-year incidence of bleeding was not significantly 
      different (prasugrel 5.6% vs. clopidogrel 8.1%, log-rank P=0.55). In addition, 
      the cumulative 1-year incidence of MACCE was also not significantly different 
      (prasugrel 11.5% vs. clopidogrel 12.3%, log-rank P=0.88). CONCLUSIONS: Low-dose 
      prasugrel, as part of triple therapy, did not increase the risk of bleeding 
      compared with clopidogrel. Therefore, it can be an alternative to clopidogrel for 
      patients with AF undergoing PCI.
FAU - Otsuki, Hisao
AU  - Otsuki H
AD  - Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical 
      University.
FAU - Yamaguchi, Junichi
AU  - Yamaguchi J
AD  - Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical 
      University.
FAU - Kawamoto, Takanori
AU  - Kawamoto T
AD  - Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical 
      University.
FAU - Yoshikawa, Masafumi
AU  - Yoshikawa M
AD  - Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical 
      University.
FAU - Ebihara, Suguru
AU  - Ebihara S
AD  - Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical 
      University.
FAU - Tanaka, Kazuki
AU  - Tanaka K
AD  - Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical 
      University.
FAU - Nakao, Masashi
AU  - Nakao M
AD  - Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical 
      University.
FAU - Jujo, Kentaro
AU  - Jujo K
AD  - Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical 
      University.
FAU - Arashi, Hiroyuki
AU  - Arashi H
AD  - Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical 
      University.
FAU - Ota, Yoshimi
AU  - Ota Y
AD  - Department of Cardiology, Saiseikai-Kurihashi Hospital.
FAU - Saito, Katsumi
AU  - Saito K
AD  - Department of Cardiology, Nishiarai Heart Center.
FAU - Takagi, Atsushi
AU  - Takagi A
AD  - Department of Cardiology, Saiseikai-Kawaguchi General Hospital.
FAU - Tanaka, Hiroyuki
AU  - Tanaka H
AD  - Department of Cardiology, Tokyo Metropolitan Tama Medical Center.
FAU - Fujii, Shinya
AU  - Fujii S
AD  - Department of Cardiology, Sendai Cardiovascular Center.
FAU - Honda, Atsushi
AU  - Honda A
AD  - Department of Cardiology, Tokyo Women's Medical University Yachiyo Medical 
      Center.
FAU - Mori, Fumiaki
AU  - Mori F
AD  - Department of Cardiology, National Hospital Organization Yokohama Medical Center.
FAU - Hagiwara, Nobuhisa
AU  - Hagiwara N
AD  - Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical 
      University.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20190327
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Anticoagulants)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circ J. 2019 Apr 25;83(5):963-964. PMID: 30918239
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Atrial Fibrillation/epidemiology/*therapy
MH  - Female
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention
MH  - Prasugrel Hydrochloride/*administration & dosage/adverse effects
MH  - *Registries
OTO - NOTNLM
OT  - Antithrombotic therapy
OT  - Atrial fibrillation
OT  - Percutaneous coronary intervention
OT  - Prasugrel
EDAT- 2019/03/29 06:00
MHDA- 2020/07/02 06:00
CRDT- 2019/03/29 06:00
PHST- 2019/03/29 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
PHST- 2019/03/29 06:00 [entrez]
AID - 10.1253/circj.CJ-18-1113 [doi]
PST - ppublish
SO  - Circ J. 2019 Apr 25;83(5):1000-1005. doi: 10.1253/circj.CJ-18-1113. Epub 2019 Mar 
      27.

PMID- 18498081
OWN - NLM
STAT- MEDLINE
DCOM- 20081027
LR  - 20220331
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 17
IP  - 8
DP  - 2008 Aug
TI  - Positive predictive value of ICD-9 codes 410 and 411 in the identification of 
      cases of acute coronary syndromes in the Saskatchewan Hospital automated 
      database.
PG  - 842-52
LID - 10.1002/pds.1619 [doi]
AB  - BACKGROUND: Case definitions are essential to epidemiological research. 
      OBJECTIVES: To evaluate ICD-9 codes 410 and 411 to identify cases of acute 
      coronary syndromes (ACS), and the clinical information availability in the 
      administrative and hospital discharge records of Saskatchewan, Canada. METHODS: 
      In the context of a safety cohort study, we identified hospitalisations with 
      primary discharge codes 410 (2260) and 411 (799). We selected all records with 
      code 411, and a random sample (200) with code 410. Based on information obtained 
      by trained abstractors from hospital records, events were classified by two 
      cardiologists as definite or possible according to adapted AHA/ESC criteria. The 
      validity of 410 and 411 codes was assessed by calculating the positive predictive 
      value (PPV). Completeness of the recorded information on risk factors and use of 
      aspirin was explored. RESULTS: The PPVs of the codes 410 and 411 for ACS were 
      0.96 (95%CI: 0. 92-0.98) and 0.86 (95%CI: 0.83-0.88), respectively. The PPV of 
      410 for acute myocardial infarction (AMI) was 0.95 (95%CI: 0.91-0.98). The PPV of 
      411 was 0.73 (95%CI: 0.70-0.77) for primary unstable angina (UA) and 0.09 (95%CI: 
      0.07-0.11) for AMI. Hospital charts review revealed key information for clinical 
      variables, smoking, obesity and use of aspirin at admission. CONCLUSIONS: ICD-9 
      410 code has high PPV for AMI cases, likewise 411 for UA cases. Case validation 
      remains important in epidemiological studies with administrative health 
      databases. Given the pathophysiology of ACS, both AMI and UA might be used as 
      study end points. In addition to code 410, we recommend the use of 411 plus 
      validation.
FAU - Varas-Lorenzo, Cristina
AU  - Varas-Lorenzo C
AD  - RTI-Health Solutions, Epidemiology, Barcelona, Spain. cvaras@rti.org
FAU - Castellsague, Jordi
AU  - Castellsague J
FAU - Stang, Mary Rose
AU  - Stang MR
FAU - Tomas, Luis
AU  - Tomas L
FAU - Aguado, Jaume
AU  - Aguado J
FAU - Perez-Gutthann, Susana
AU  - Perez-Gutthann S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*chemically induced/*epidemiology
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Aged, 80 and over
MH  - Angina, Unstable/*classification
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cohort Studies
MH  - *Databases, Factual
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - International Classification of Diseases
MH  - Male
MH  - Medical Records
MH  - Middle Aged
MH  - Myocardial Infarction/*classification
MH  - Obesity
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Predictive Value of Tests
MH  - Risk Factors
MH  - Saskatchewan
MH  - Smoking
EDAT- 2008/05/24 09:00
MHDA- 2008/10/28 09:00
CRDT- 2008/05/24 09:00
PHST- 2008/05/24 09:00 [pubmed]
PHST- 2008/10/28 09:00 [medline]
PHST- 2008/05/24 09:00 [entrez]
AID - 10.1002/pds.1619 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):842-52. doi: 10.1002/pds.1619.

PMID- 3520978
OWN - NLM
STAT- MEDLINE
DCOM- 19860723
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 17
IP  - 3
DP  - 1986 May-Jun
TI  - A new combination therapy for selective and prolonged antiplatelet effect: 
      results in the dog.
PG  - 450-4
AB  - This study characterizes the effect of dazmegrel, a thromboxane synthetase 
      inhibitor, on platelet function in the dog and introduces its potential use in 
      combination with aspirin therapy. Ex vivo testing of dazmegrel alone was 
      performed with three dosages and three administration regimens. Platelet 
      aggregation response, malondialdehyde formation and prostaglandin metabolites 
      generation were evaluated. To maintain complete thromboxane A2 inhibition, 
      dazmegrel had to be given 3 times per day at dosages of not less than 6 mg/kg. 
      The same result was achieved with a single daily administration of combined 
      dazmegrel and aspirin in equal dosages of 3 mg/kg. Dazmegrel, both alone and with 
      aspirin, increased and sustained heightened levels of prostacyclin, unlike the 
      simultaneous inhibition of both prostaglandin metabolites seen with aspirin 
      therapy alone. Because the combination of dazmegrel and aspirin effectively 
      blocks thromboxane A2 formation and also enhances prostacyclin formation, the 
      synergistic action of these agents increases their combined antiplatelet effect 
      to a level not attainable by either agent alone. The significance of this 
      combined therapy warrants further experimental study and may soon merit clinical 
      trial for the prevention of stroke and other major thrombotic complications.
FAU - Kaplan, S
AU  - Kaplan S
FAU - Sauvage, L R
AU  - Sauvage LR
FAU - Marcoe, K F
AU  - Marcoe KF
FAU - Zammit, M
AU  - Zammit M
FAU - Wu, H D
AU  - Wu HD
FAU - Mathisen, S R
AU  - Mathisen SR
FAU - Walker, M
AU  - Walker M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Imidazoles)
RN  - 31340R8PVU (dazmegrel)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/biosynthesis
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dogs
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Epoprostenol/biosynthesis
MH  - Fibrinolytic Agents/administration & dosage/*pharmacology
MH  - Imidazoles/administration & dosage/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane A2/biosynthesis
MH  - Thromboxane B2/biosynthesis
MH  - Time Factors
EDAT- 1986/05/01 00:00
MHDA- 1986/05/01 00:01
CRDT- 1986/05/01 00:00
PHST- 1986/05/01 00:00 [pubmed]
PHST- 1986/05/01 00:01 [medline]
PHST- 1986/05/01 00:00 [entrez]
AID - 10.1161/01.str.17.3.450 [doi]
PST - ppublish
SO  - Stroke. 1986 May-Jun;17(3):450-4. doi: 10.1161/01.str.17.3.450.

PMID- 27344083
OWN - NLM
STAT- MEDLINE
DCOM- 20170810
LR  - 20220311
IS  - 1879-0828 (Electronic)
IS  - 0953-6205 (Linking)
VI  - 34
DP  - 2016 Oct
TI  - Aspirin, platelets, and cancer: The point of view of the internist.
PG  - 11-20
LID - S0953-6205(16)30173-X [pii]
LID - 10.1016/j.ejim.2016.06.004 [doi]
AB  - Growing evidence suggests the beneficial effect of aspirin against some types of 
      cancer, particularly of the gastrointestinal tract, and it has been provided for 
      an effect both in cancer prevention as well as in survival improvement of cancer 
      patients. Aspirin benefits increase with duration of treatment, especially after 
      10years of treatment. The inhibition of platelet activation at sites of 
      gastrointestinal mucosal lesions could be the primary mechanism of action of 
      low-dose aspirin. Indeed, the formation of tumor cell-induced platelet aggregates 
      may favor immune evasion, by releasing angiogenic and growth factors, and also by 
      promoting cancer cell dissemination. Moreover, platelets may contribute to 
      aberrant COX-2 expression in colon carcinoma cells, thereby contributing to 
      downregulation of oncosuppressor genes and upregulation of oncogenes, such as 
      cyclin B1. Platelet adhesion to cancer cells leads also to an increased 
      expression of genes involved in the EMT, such as the EMT-inducing transcription 
      factors ZEB1 and TWIST1 and the mesenchymal marker vimentin. The aspirin-mediated 
      inactivation of platelets may restore antitumor reactivity by blocking the 
      release of paracrine lipid and protein mediators that induce COX-2 expression in 
      adjacent nucleated cells at sites of mucosal injury. Thus, recent findings 
      suggest interesting perspectives on "old" aspirin and NSAID treatment and/or 
      "new" specific drugs to target the "evil" interactions between platelets and 
      cancer for chemoprevention.
CI  - Copyright © 2016 European Federation of Internal Medicine. Published by Elsevier 
      B.V. All rights reserved.
FAU - Santilli, F
AU  - Santilli F
AD  - Center for Aging Science (Ce.S.I.), Università G. d'Annunzio" Foundation, Italy; 
      Department of Internal Medicine, "G. d'Annunzio" University of Chieti, Italy.
FAU - Boccatonda, A
AU  - Boccatonda A
AD  - Center for Aging Science (Ce.S.I.), Università G. d'Annunzio" Foundation, Italy; 
      Department of Internal Medicine, "G. d'Annunzio" University of Chieti, Italy.
FAU - Davì, G
AU  - Davì G
AD  - Center for Aging Science (Ce.S.I.), Università G. d'Annunzio" Foundation, Italy; 
      Department of Internal Medicine, "G. d'Annunzio" University of Chieti, Italy. 
      Electronic address: gdavi@unich.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160622
PL  - Netherlands
TA  - Eur J Intern Med
JT  - European journal of internal medicine
JID - 9003220
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Transcription Factors)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Chemoprevention
MH  - Cyclooxygenase 2/*genetics
MH  - Humans
MH  - Neoplasms/drug therapy/*prevention & control
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Transcription Factors/genetics
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer
OT  - Cyclooxygenase
OT  - Metastasis
OT  - Platelet
EDAT- 2016/06/28 06:00
MHDA- 2017/08/11 06:00
CRDT- 2016/06/27 06:00
PHST- 2016/05/31 00:00 [received]
PHST- 2016/06/01 00:00 [accepted]
PHST- 2016/06/28 06:00 [pubmed]
PHST- 2017/08/11 06:00 [medline]
PHST- 2016/06/27 06:00 [entrez]
AID - S0953-6205(16)30173-X [pii]
AID - 10.1016/j.ejim.2016.06.004 [doi]
PST - ppublish
SO  - Eur J Intern Med. 2016 Oct;34:11-20. doi: 10.1016/j.ejim.2016.06.004. Epub 2016 
      Jun 22.

PMID- 28072768
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20211025
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 116
IP  - 3
DP  - 2017 Jan
TI  - Effect of low-dose aspirin use on survival of patients with gastrointestinal 
      malignancies; an observational study.
PG  - 405-413
LID - 10.1038/bjc.2016.425 [doi]
AB  - BACKGROUND: Previous studies suggested a relationship between aspirin use and 
      mortality reduction. The mechanism for the effect of aspirin on cancer outcomes 
      remains unclear. The aim of this study was to evaluate aspirin use and survival 
      in patients with gastrointestinal tract cancer. METHODS: Patients with 
      gastrointestinal tract cancer diagnosed between 1998 and 2011 were included. The 
      population-based Eindhoven Cancer Registry was linked to drug-dispensing data 
      from the PHARMO Database Network. The association between aspirin use after 
      diagnosis and overall survival was analysed using Cox regression models. RESULTS: 
      In total, 13 715 patients were diagnosed with gastrointestinal cancer. A total of 
      1008 patients were identified as aspirin users, and 8278 patients were identified 
      as nonusers. The adjusted hazard ratio for aspirin users vs nonusers was 0.52 
      (95% CI 0.44-0.63). A significant association between aspirin use and survival 
      was observed for patients with oesophageal, hepatobiliary and colorectal cancer. 
      CONCLUSIONS: Post-diagnosis use of aspirin in patients with gastrointestinal 
      tract malignancies is associated with increased survival in cancers with 
      different sites of origin and biology. This adds weight to the hypothesis that 
      the anti-cancer effects of aspirin are not tumour-site specific and may be 
      modulated through the tumour micro-environment.
FAU - Frouws, M A
AU  - Frouws MA
AD  - Department of Surgical Oncology, Leiden University Medical Center, Leiden 2300 
      RC, The Netherlands.
FAU - Bastiaannet, E
AU  - Bastiaannet E
AD  - Department of Surgical Oncology, Leiden University Medical Center, Leiden 2300 
      RC, The Netherlands.
FAU - Langley, R E
AU  - Langley RE
AD  - MRC Clinical Trials Unit, University College London, Institute of Clinical Trials 
      and Methodology, Aviation House 125 Kingsway, London WC2B 6NH, UK.
FAU - Chia, W K
AU  - Chia WK
AD  - Department of Medical Oncology, National Cancer Centre Singapore, 11 Hospital 
      Drive, Singapore 169610, Singapore.
FAU - van Herk-Sukel, M P P
AU  - van Herk-Sukel MP
AD  - PHARMO Institute for Drug Outcomes Research, Van Deventerlaan 30/40, Utrecht 3528 
      AE, The Netherlands.
FAU - Lemmens, V E P P
AU  - Lemmens VE
AD  - Comprehensive Cancer Organisation The Netherlands, Eindhoven 5600 AE, The 
      Netherlands.
AD  - Department of Public Health, Erasmus MC Medical Centre, PO Box 2040, Rotterdam 
      3000 CA, The Netherlands.
FAU - Putter, H
AU  - Putter H
AD  - Department of Medical Statistics and Bioinformatics, Leiden University Medical 
      Center, Leiden 2300 RC, The Netherlands.
FAU - Hartgrink, H H
AU  - Hartgrink HH
AD  - Department of Surgical Oncology, Leiden University Medical Center, Leiden 2300 
      RC, The Netherlands.
FAU - Bonsing, B A
AU  - Bonsing BA
AD  - Department of Surgical Oncology, Leiden University Medical Center, Leiden 2300 
      RC, The Netherlands.
FAU - Van de Velde, C J H
AU  - Van de Velde CJ
AD  - Department of Surgical Oncology, Leiden University Medical Center, Leiden 2300 
      RC, The Netherlands.
FAU - Portielje, J E A
AU  - Portielje JE
AD  - Department of Medical Oncology, Haga Hospital, Leyweg 275, The Hague 2545 CH, The 
      Netherlands.
FAU - Liefers, G J
AU  - Liefers GJ
AD  - Department of Surgical Oncology, Leiden University Medical Center, Leiden 2300 
      RC, The Netherlands.
LA  - eng
GR  - 12/01/38/DH_/Department of Health/United Kingdom
GR  - MC_UU_12023/28/MRC_/Medical Research Council/United Kingdom
GR  - CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20170110
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Neoplasms/*mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Netherlands/epidemiology
MH  - Survival Analysis
MH  - Young Adult
PMC - PMC5294482
COIS- The authors declare no conflict of interest.
EDAT- 2017/01/11 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/01/11 06:00
PHST- 2016/09/12 00:00 [received]
PHST- 2016/11/23 00:00 [revised]
PHST- 2016/11/28 00:00 [accepted]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
PHST- 2017/01/11 06:00 [entrez]
AID - bjc2016425 [pii]
AID - 10.1038/bjc.2016.425 [doi]
PST - ppublish
SO  - Br J Cancer. 2017 Jan;116(3):405-413. doi: 10.1038/bjc.2016.425. Epub 2017 Jan 
      10.

PMID- 3115287
OWN - NLM
STAT- MEDLINE
DCOM- 19871030
LR  - 20190501
IS  - 0007-1161 (Print)
IS  - 1468-2079 (Electronic)
IS  - 0007-1161 (Linking)
VI  - 71
IP  - 7
DP  - 1987 Jul
TI  - Efficacy of antiprostaglandin therapy in vernal conjunctivitis.
PG  - 497-9
AB  - Twenty-seven patients with vernal conjunctivitis who remained symptomatic 
      following treatment with corticosteroid drops and/or Opticrom drops (sodium 
      cromoglycate 2%, benzalkonium chloride 0.01%) were treated with aspirin. Aspirin 
      produced marked improvement in all patients apart from three. The possible 
      mechanism of the efficacy of aspirin in vernal conjunctivitis is discussed.
FAU - Meyer, E
AU  - Meyer E
AD  - Department of Ophthalmology, Rambam Medical Center, Haifa, Israel.
FAU - Kraus, E
AU  - Kraus E
FAU - Zonis, S
AU  - Zonis S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Ophthalmol
JT  - The British journal of ophthalmology
JID - 0421041
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Glucocorticoids)
RN  - 0 (Ophthalmic Solutions)
RN  - 0 (Prostaglandin Antagonists)
RN  - Q2WXR1I0PK (Cromolyn Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Topical
MH  - Adolescent
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Conjunctivitis, Allergic/*drug therapy
MH  - Cromolyn Sodium/therapeutic use
MH  - Drug Resistance
MH  - Female
MH  - Glucocorticoids
MH  - Humans
MH  - Male
MH  - Ophthalmic Solutions
MH  - Prostaglandin Antagonists/*therapeutic use
PMC - PMC1041213
EDAT- 1987/07/01 00:00
MHDA- 1987/07/01 00:01
CRDT- 1987/07/01 00:00
PHST- 1987/07/01 00:00 [pubmed]
PHST- 1987/07/01 00:01 [medline]
PHST- 1987/07/01 00:00 [entrez]
AID - 10.1136/bjo.71.7.497 [doi]
PST - ppublish
SO  - Br J Ophthalmol. 1987 Jul;71(7):497-9. doi: 10.1136/bjo.71.7.497.

PMID- 9784799
OWN - NLM
STAT- MEDLINE
DCOM- 19981217
LR  - 20190221
IS  - 1079-2082 (Print)
IS  - 1079-2082 (Linking)
VI  - 55
IP  - 19 Suppl 1
DP  - 1998 Oct 1
TI  - Management of peripheral arterial disease.
PG  - S21-7
AB  - The risk factors, epidemiology, diagnosis, and treatment of peripheral arterial 
      disease are reviewed. Peripheral arterial disease is characterized by a gradual 
      reduction in blood flow to one or more limbs secondary to atherosclerosis. Risk 
      factors include smoking, diabetes mellitus, hyperlipidemia, and hypertension. The 
      most common clinical manifestation is intermittent claudication. The prevalence 
      of intermittent claudication in people over the age of 50 is 2-7% for men and 
      1-2% for women. The ankle:brachial pressure index (ABPI) is a useful measure of 
      disease severity; an ABPI of 0.5-0.9 is common in intermittent claudication. The 
      goals of therapy are to relieve or reduce ischemic symptoms, alleviate 
      disability, improve in functional capacity, prevent progression that may result 
      in gangrene and limb loss, and prevent cardiovascular and cerebrovascular events. 
      Treatment includes risk-factor modification, drug therapy (primarily with 
      antiplatelet agents), and revascularization procedures. Aspirin has been shown to 
      be effective in reducing the associated risk of myocardial infarction and stroke. 
      Ticlopidine appears to be a reasonable alternative for patients who are 
      hypersensitive to aspirin. Clopidogrel has been shown to be more effective than 
      aspirin in patients with recent myocardial infarction, recent stroke, or 
      established peripheral arterial disease. There is controversy over the 
      appropriate treatment for acute arterial occlusions. Risk-factor modification and 
      antiplatelet drugs are the mainstays of therapy for patients with intermittent 
      claudication, the most common manifestation of peripheral arterial disease.
FAU - Hilleman, D E
AU  - Hilleman DE
AD  - Department of Pharmacy Practice, School of Pharmacy, Creighton University, Omaha, 
      NE 68178, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/*drug therapy/*prevention & control
MH  - Aspirin/therapeutic use
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/analogs & derivatives/therapeutic use
RF  - 69
EDAT- 1998/10/24 00:00
MHDA- 1998/10/24 00:01
CRDT- 1998/10/24 00:00
PHST- 1998/10/24 00:00 [pubmed]
PHST- 1998/10/24 00:01 [medline]
PHST- 1998/10/24 00:00 [entrez]
AID - 10.1093/ajhp/55.suppl_1.S21 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 1998 Oct 1;55(19 Suppl 1):S21-7. doi: 
      10.1093/ajhp/55.suppl_1.S21.

PMID- 1751930
OWN - NLM
STAT- MEDLINE
DCOM- 19920128
LR  - 20181113
IS  - 0820-3946 (Print)
IS  - 1488-2329 (Electronic)
IS  - 0820-3946 (Linking)
VI  - 145
IP  - 9
DP  - 1991 Nov 1
TI  - Use of acetylsalicylic acid by physicians and in the community.
PG  - 1107-16
AB  - OBJECTIVE: To determine physicians' attitudes toward prescribing acetylsalicylic 
      acid (ASA), physicians' own use of ASA and the prevalence of ASA use in the 
      community following the trials of ASA for primary prevention of coronary heart 
      disease. DESIGN: Random sample surveys of physicians and the general public by 
      mail and telephone respectively and a mail survey of a selected panel of expert 
      cardiologists and neurologists. SETTING: London, Ont., and surrounding Middlesex 
      County. PARTICIPANTS: A total of 210 physicians (77% of eligible subjects), 
      including family practitioners and most types of specialists, with an active 
      medical licence and 666 English-speaking people (75% of eligible subjects) aged 
      18 years or more living in a household with active, listed telephone service. 
      MAIN OUTCOME MEASURE: Long-term ASA use (at least 80 mg on alternate days for 4 
      or more consecutive weeks) for the treatment of atherosclerosis. MAIN RESULTS: 
      Sampled physicians and experts agreed that long-term ASA therapy was indicated in 
      patients with unstable angina, a transient ischemic episode or recent myocardial 
      infarction but not for primary prevention in healthy middle-aged men and women at 
      low risk for ischemic vascular disease. Both groups were uncertain about the role 
      of ASA in primary prevention in asymptomatic people with risk factors for 
      atherosclerosis. Nine (16%) of the 55 male physicians aged 50 years or more took 
      ASA routinely for primary prevention. In the community survey almost all those 
      who used ASA routinely were 50 years or older. The proportions of men and women 
      in this age group who used ASA routinely for any reason were 19% (95% confidence 
      limits [CLs] 11 and 28) and 14% (95% CLs 8 and 19) respectively; the proportions 
      of men and women who used ASA routinely and apparently for primary prevention 
      were 8% and 1% respectively. A total of 43% (95% CLs 30 and 57) of those with 
      apparent ischemic vascular disease took ASA routinely. Medically unsupervised 
      long-term ASA use for primary or secondary prevention of ischemic vascular 
      disease was uncommon (reported by 2% of those who used the drug routinely). 
      CONCLUSIONS: Physicians generally agree on a role for long-term ASA therapy in 
      the secondary prevention of ischemic vascular disease. However, the prevalence of 
      long-term ASA use in people with overt atherosclerosis in the community may be 
      less than optimal. The role of the drug in the primary prevention of ischemic 
      vascular disease is less accepted. Long-term ASA use in the community for primary 
      prevention is uncommon but detectable.
FAU - Mahon, J
AU  - Mahon J
AD  - Department of Medicine, University of Western Ontario, London.
FAU - Steel, K
AU  - Steel K
FAU - Feagan, B G
AU  - Feagan BG
FAU - Laupacis, A
AU  - Laupacis A
FAU - Pederson, L L
AU  - Pederson LL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - CMAJ
JT  - CMAJ : Canadian Medical Association journal = journal de l'Association medicale 
      canadienne
JID - 9711805
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Angina, Unstable/drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Community Medicine
MH  - Drug Utilization
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy
MH  - Physicians
MH  - Prevalence
MH  - Primary Prevention/methods
MH  - Random Allocation
MH  - Risk Factors
MH  - Sampling Studies
MH  - Time Factors
PMC - PMC1335868
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
PST - ppublish
SO  - CMAJ. 1991 Nov 1;145(9):1107-16.

PMID- 28807954
OWN - NLM
STAT- MEDLINE
DCOM- 20180430
LR  - 20181113
IS  - 1715-5258 (Electronic)
IS  - 0008-350X (Print)
IS  - 0008-350X (Linking)
VI  - 63
IP  - 8
DP  - 2017 Aug
TI  - Acetylsalicylic acid for children with Kawasaki disease.
PG  - 607-609
AB  - Question A 7-year-old child in my office was recently discharged from the 
      hospital after receiving intravenous immunoglobulin for Kawasaki disease. Should 
      I continue treatment with acetylsalicylic acid (ASA), and if so, what is the 
      appropriate dose? Answer The role of ASA for Kawasaki disease during the acute 
      febrile phase has recently been called into question. According to several 
      studies, ASA might reduce the duration of fever but it does not appear to 
      directly reduce the incidence of coronary artery complications. However, with no 
      high-quality randomized controlled trials, the evidence is scarce and more 
      studies with good methodology are needed to determine the value of ASA in the 
      treatment of Kawasaki disease. Currently, guidelines recommending the use of ASA 
      should be followed.
CI  - Copyright© the College of Family Physicians of Canada.
FAU - Sakulchit, Teeranai
AU  - Sakulchit T
FAU - Benseler, Susanne M
AU  - Benseler SM
FAU - Goldman, Ran D
AU  - Goldman RD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Canada
TA  - Can Fam Physician
JT  - Canadian family physician Medecin de famille canadien
JID - 0120300
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/etiology
MH  - Child
MH  - Fever/etiology/therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage
MH  - Mucocutaneous Lymph Node Syndrome/complications/*drug therapy
PMC - PMC5555326
EDAT- 2017/08/16 06:00
MHDA- 2018/05/01 06:00
CRDT- 2017/08/16 06:00
PHST- 2017/08/16 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2018/05/01 06:00 [medline]
AID - 63/8/607 [pii]
AID - 607 [pii]
PST - ppublish
SO  - Can Fam Physician. 2017 Aug;63(8):607-609.

PMID- 9799763
OWN - NLM
STAT- MEDLINE
DCOM- 19981118
LR  - 20190722
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 44
IP  - 11
DP  - 1998 Nov
TI  - Simplified interpretative format for assessing test interference: studies with 
      hemoglobin-based oxygen carrier solutions.
PG  - 2347-52
AB  - Substances such as hemoglobin that interfere with analytical processes are 
      recognized as a frequent source of error in laboratory medicine. Standard 
      guidelines for assessment of test interferences assume that interference effects 
      are not related to the concentration of the analyte being measured. However, 
      previous investigations have demonstrated that interference effects can be 
      markedly different, depending on the concentrations of interferent and analyte 
      within the specimen. An experimental protocol for investigating these different 
      types of interference effects has been developed. This protocol utilizes an 
      orthogonally arranged matrix with progressively increasing concentrations of 
      analyte and interferent. Evaluation of the measured analyte concentrations in 
      specimens within the matrix using multiple regression analysis allows the 
      magnitude, direction, and significance of each type of interference to be 
      determined. Unfortunately, implementation of the interference data derived from 
      the multiple regression analysis for judging the clinical acceptability of test 
      results when an interferent is present is difficult. We describe a 
      two-dimensional graphical format for evaluating the clinical acceptability of 
      test results, based on criteria established under the Clinical Laboratory 
      Improvement Amendments of 1988, in specimens containing hemoglobin-based oxygen 
      carrier solutions.
FAU - Kazmierczak, S C
AU  - Kazmierczak SC
AD  - Department of Pathology and Laboratory Medicine, East Carolina University School 
      of Medicine, Greenville, NC 27858-4354, USA. kaz@brody.med.ecu.edu
FAU - Catrou, P G
AU  - Catrou PG
FAU - Boudreau, D
AU  - Boudreau D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - RFM9X3LJ49 (Bilirubin)
RN  - RWP5GA015D (Potassium)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Aspirin/*analogs & derivatives/analysis
MH  - Bilirubin/*blood
MH  - Blood Substitutes/*analysis
MH  - Calcium/*blood
MH  - Cholesterol/*blood
MH  - Hemoglobins/*analysis
MH  - Humans
MH  - Potassium/*blood
MH  - Quality Control
MH  - Regression Analysis
EDAT- 1998/11/04 00:00
MHDA- 1998/11/04 00:01
CRDT- 1998/11/04 00:00
PHST- 1998/11/04 00:00 [pubmed]
PHST- 1998/11/04 00:01 [medline]
PHST- 1998/11/04 00:00 [entrez]
PST - ppublish
SO  - Clin Chem. 1998 Nov;44(11):2347-52.

PMID- 3118401
OWN - NLM
STAT- MEDLINE
DCOM- 19871216
LR  - 20131121
IS  - 0176-3679 (Print)
IS  - 0176-3679 (Linking)
VI  - 20
IP  - 5
DP  - 1987 Sep
TI  - Analgesic effect of acetylsalicylic acid (ASA) versus a lithium-ASA combination: 
      an evoked potential study employing radiant heat stimulation with a CO2 laser.
PG  - 217-21
AB  - Objective experimental algesimetry was used to assess quantitative differences in 
      analgesic properties between acetylsalicylic acid (ASA, 750 mg) and a special 
      combination of ASA, trilithium citrate and quinine-2 HCl (750 mg, 126 mg, 4.5 mg) 
      in a placebo-controlled double-blind crossover study on nine healthy subjects. 
      Radiant heat stimulation was applied with a CO2 laser and somatosensory evoked 
      vertex potentials (LSEP) were recorded while the subjects were simultaneously 
      engaged in an adaptive pursuit tracking task in order to stabilize their 
      vigilance. The N1 amplitude of the LSEP decreased under both verum medications; 
      however, the drug combination was significantly more effective. The time course 
      of this effect was attended by a marked intradiurnal variation of the LSEP 
      amplitudes. The role of lithium in the combination with ASA and quinine-2 HCl 
      (Togal) and an amplification of the analgesic potency of ASA are discussed.
FAU - Schaffler, K
AU  - Schaffler K
AD  - Institut Dr. K. Schaffler, München, FRG.
FAU - Reeh, P W
AU  - Reeh PW
FAU - Zentzis, K
AU  - Zentzis K
FAU - Hamperl, W
AU  - Hamperl W
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Pharmacopsychiatry
JT  - Pharmacopsychiatry
JID - 8402938
RN  - 0 (Citrates)
RN  - 0 (Drug Combinations)
RN  - 142M471B3J (Carbon Dioxide)
RN  - 2968PHW8QP (Citric Acid)
RN  - 9FN79X2M3F (Lithium)
RN  - A7V27PHC7A (Quinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analgesia
MH  - Arousal
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Carbon Dioxide
MH  - Citrates/pharmacology
MH  - Citric Acid
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Drug Synergism
MH  - Evoked Potentials, Somatosensory/*drug effects
MH  - Hot Temperature
MH  - Humans
MH  - Lasers
MH  - Lithium/administration & dosage/*pharmacology
MH  - Male
MH  - Pain/*drug therapy
MH  - Quinine/administration & dosage/*pharmacology
EDAT- 1987/09/01 00:00
MHDA- 1987/09/01 00:01
CRDT- 1987/09/01 00:00
PHST- 1987/09/01 00:00 [pubmed]
PHST- 1987/09/01 00:01 [medline]
PHST- 1987/09/01 00:00 [entrez]
AID - 10.1055/s-2007-1017107 [doi]
PST - ppublish
SO  - Pharmacopsychiatry. 1987 Sep;20(5):217-21. doi: 10.1055/s-2007-1017107.

PMID- 33503894
OWN - NLM
STAT- MEDLINE
DCOM- 20210415
LR  - 20210415
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 26
IP  - 3
DP  - 2021 Jan 25
TI  - Diagnosis of Agglomeration and Crystallinity of Active Pharmaceutical Ingredients 
      in Over the Counter Headache Medication by Electrospray Laser Desorption 
      Ionization Mass Spectrometry Imaging.
LID - 10.3390/molecules26030610 [doi]
LID - 610
AB  - Agglomeration of active pharmaceutical ingredients (API) in tablets can lead to 
      decreased bioavailability in some enabling formulations. In a previous study, we 
      determined that crystalline APIs can be detected as agglomeration in tablets 
      formulated with amorphous acetaminophen tablets. Multiple method advancements are 
      presented to better resolve agglomeration caused by crystallinity in standard 
      tablets. In this study, we also evaluate three "budget" over-the-counter headache 
      medications (subsequently labeled as brands A, B, and C) for agglomeration of the 
      three APIs in the formulation: Acetaminophen, aspirin, and caffeine. Electrospray 
      laser desorption ionization mass spectrometry imaging (ELDI-MSI) was used to 
      diagnose agglomeration in the tablets by creating molecular images and observing 
      the spatial distributions of the APIs. Brand A had virtually no agglomeration or 
      clustering of the active ingredients. Brand B had extensive clustering of aspirin 
      and caffeine, but acetaminophen was observed in near equal abundance across the 
      tablet. Brand C also had extensive clustering of aspirin and caffeine, and minor 
      clustering of acetaminophen. These results show that agglomeration with active 
      ingredients in over-the-counter tablets can be simultaneously detected using 
      ELDI-MS imaging.
FAU - Van Meter, Mariann Inga
AU  - Van Meter MI
AD  - Department of Chemistry, Marian University, Indianapolis, IN 46222, USA.
FAU - Khan, Salah M
AU  - Khan SM
AD  - College of Osteopathic Medicine, Marian University, Indianapolis, IN 46222, USA.
FAU - Taulbee-Cotton, Brynne V
AU  - Taulbee-Cotton BV
AD  - Department of Chemistry, Marian University, Indianapolis, IN 46222, USA.
FAU - Dimmitt, Nathan H
AU  - Dimmitt NH
AD  - Department of Chemistry, Marian University, Indianapolis, IN 46222, USA.
FAU - Hubbard, Nathan D
AU  - Hubbard ND
AD  - Department of Chemistry, Marian University, Indianapolis, IN 46222, USA.
FAU - Green, Adam M
AU  - Green AM
AD  - College of Osteopathic Medicine, Marian University, Indianapolis, IN 46222, USA.
FAU - Webster, Gregory K
AU  - Webster GK
AD  - AbbVie Inc., North Chicago, IL 60064, USA.
FAU - McVey, Patrick A
AU  - McVey PA
AD  - Department of Chemistry, Marian University, Indianapolis, IN 46222, USA.
AD  - College of Osteopathic Medicine, Marian University, Indianapolis, IN 46222, USA.
LA  - eng
GR  - 104796/AbbVie/
PT  - Journal Article
DEP - 20210125
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Nonprescription Drugs)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/chemistry
MH  - Analgesics, Non-Narcotic/*chemistry
MH  - Aspirin/chemistry
MH  - Caffeine/chemistry
MH  - Headache/drug therapy
MH  - Lasers
MH  - Nonprescription Drugs/*chemistry
MH  - Spectrometry, Mass, Electrospray Ionization/methods
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods
MH  - Tablets/*chemistry
PMC - PMC7865442
OTO - NOTNLM
OT  - ELDI
OT  - MSI
OT  - agglomeration
OT  - crystallinity
OT  - mass spectrometry imaging
OT  - pharmaceuticals
COIS- The authors declare no conflict of interest. AbbVie aided in interpretation of 
      the data and reviewed this manuscript prior to submission for peer-review.
EDAT- 2021/01/29 06:00
MHDA- 2021/04/16 06:00
CRDT- 2021/01/28 01:02
PHST- 2020/12/31 00:00 [received]
PHST- 2021/01/20 00:00 [revised]
PHST- 2021/01/21 00:00 [accepted]
PHST- 2021/01/28 01:02 [entrez]
PHST- 2021/01/29 06:00 [pubmed]
PHST- 2021/04/16 06:00 [medline]
AID - molecules26030610 [pii]
AID - molecules-26-00610 [pii]
AID - 10.3390/molecules26030610 [doi]
PST - epublish
SO  - Molecules. 2021 Jan 25;26(3):610. doi: 10.3390/molecules26030610.

PMID- 32966407
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2047-4849 (Electronic)
IS  - 2047-4830 (Linking)
VI  - 8
IP  - 21
DP  - 2020 Nov 7
TI  - The improved targeting of an aspirin prodrug albumin-based nanosystem for 
      visualizing and inhibiting lung metastasis of breast cancer.
PG  - 5941-5954
LID - 10.1039/d0bm01035a [doi]
AB  - Lung metastasis is the principal reason for the majority of deaths from breast 
      cancer. The nonsteroidal anti-inflammatory drug aspirin can prevent lung 
      metastasis in breast tumors via inhibiting heparanase. However, the lack of 
      specific targets and limited accumulation at the site of the tumor have thus far 
      hindered the use of aspirin in oncotherapy. In this study, we developed the 
      nanoplatform FA-BSA@DA and loaded it with the versatile aspirin prodrug DA to 
      visualize and inhibit breast cancer metastasis via targeting heparanase. This 
      nanosystem can be effectively targeted to folic acid (FA)-positive tumor cells, 
      and would then subsequently release a high dose of DA, whose ester bond is 
      specifically ruptured by H(2)O(2) in the tumor microenvironment to afford the 
      therapeutic drug aspirin and near-infrared (NIR) fluorescent reporter DCM. The 
      released aspirin can effectively prevent breast cancer lung metastasis through 
      the inhibition of heparanase activity, and the NIR fluorescent signals emitted 
      from DCM can be used to monitor and evaluate the metastasis levels of breast 
      cancer. Our results showed that the expression of heparanase was significantly 
      decreased, and lung metastasis from breast cancer was effectively monitored and 
      inhibited after treatment with FA-BSA@DA. Furthermore, the collaborative therapy 
      nanoplatform FA-BSA@DA/DOX exhibited strong therapeutic effects in the treatment 
      of breast cancer in vitro and in vivo via the introduction of doxorubicin (DOX) 
      to the system, which resulted in an even stronger result due to its synergistic 
      effects with aspirin. This heparanase-reliant strategy has profound significance 
      for the extended development of nanoplatforms based on versatile aspirin 
      prodrugs, which may offer a solution to clinically prevent breast cancer 
      recurrence and lung metastasis.
FAU - Zhang, Wancun
AU  - Zhang W
AD  - Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Henan 
      Neurodevelopment Engineering Research Center for Children, Children's Hospital 
      Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou 
      Children's Hospital, Zhengzhou 450018, China. wangpeng159seu@hotmail.com.
FAU - Xia, Lili
AU  - Xia L
FAU - Ren, Xiangyu
AU  - Ren X
FAU - Cui, Mengyuan
AU  - Cui M
FAU - Liu, Tianguang
AU  - Liu T
FAU - Ling, Chen
AU  - Ling C
FAU - Xu, Yanqi
AU  - Xu Y
FAU - Deng, Dawei
AU  - Deng D
FAU - Zhang, Xianwei
AU  - Zhang X
FAU - Gu, Yueqing
AU  - Gu Y
FAU - Wang, Peng
AU  - Wang P
LA  - eng
PT  - Journal Article
DEP - 20200923
PL  - England
TA  - Biomater Sci
JT  - Biomaterials science
JID - 101593571
RN  - 0 (Albumins)
RN  - 0 (Prodrugs)
RN  - 80168379AG (Doxorubicin)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Albumins
MH  - Aspirin/pharmacology
MH  - *Breast Neoplasms/drug therapy
MH  - Cell Line, Tumor
MH  - Doxorubicin/pharmacology
MH  - Humans
MH  - Hydrogen Peroxide
MH  - *Lung Neoplasms/drug therapy
MH  - *Nanoparticles
MH  - *Prodrugs/pharmacology
MH  - Tumor Microenvironment
EDAT- 2020/09/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/23 17:33
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/09/23 17:33 [entrez]
AID - 10.1039/d0bm01035a [doi]
PST - ppublish
SO  - Biomater Sci. 2020 Nov 7;8(21):5941-5954. doi: 10.1039/d0bm01035a. Epub 2020 Sep 
      23.

PMID- 25577751
OWN - NLM
STAT- MEDLINE
DCOM- 20160105
LR  - 20150401
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 182
DP  - 2015 Mar 1
TI  - Aspirin underuse, non-compliance or cessation: definition, extent, impact and 
      potential solutions in the primary and secondary prevention of cardiovascular 
      disease.
PG  - 148-54
LID - S0167-5273(14)02515-7 [pii]
LID - 10.1016/j.ijcard.2014.12.091 [doi]
AB  - Despite momentous breakthroughs in unraveling the pathophysiology of many chronic 
      conditions and developing novel therapeutic agents, everyday clinical practice is 
      still fraught with inadequate or inappropriate use of treatments with proven 
      benefits. Aspirin is a paradigmatic example, as it is used for the primary and 
      secondary prevention of cardiovascular disease and appears to have a beneficial 
      impact on cancer risk. Yet, underuse, non-compliance or cessation of aspirin are 
      not uncommon, may have an important clinical impact, and are not aggressively 
      prevented or managed. Increasing the awareness of the extent and impact of 
      aspirin underuse, non-compliance or cessation, and intensifying efforts at 
      preventing them are worthy goals likely to yield significant benefits on 
      cardiovascular morbidity and mortality worldwide, and possibly also on cancer 
      outcomes.
CI  - Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
FAU - Biondi-Zoccai, Giuseppe
AU  - Biondi-Zoccai G
AD  - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University 
      of Rome, Latina, Italy; VCU Pauley Heart Center, Virginia Commonwealth 
      University, Richmond, VA, USA. Electronic address: 
      giuseppe.biondizoccai@uniroma1.it.
FAU - Wu, Yangfeng
AU  - Wu Y
AD  - School of Public Health, Peking University, Beijing, PR China.
FAU - Serrano, Carlos V Jr
AU  - Serrano CV Jr
AD  - Department of Atherosclerosis, Heart Institute of the University of São Paulo, 
      São Paulo, Brazil.
FAU - Frati, Giacomo
AU  - Frati G
AD  - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University 
      of Rome, Latina, Italy; Department of AngioCardioNeurology, IRCCS NeuroMed, 
      Pozzilli, Italy.
FAU - Agostoni, Pierfrancesco
AU  - Agostoni P
AD  - Division of Cardiology, Utrecht University Medical Center, Utrecht, The 
      Netherlands.
FAU - Abbate, Antonio
AU  - Abbate A
AD  - VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20141227
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Health Services Misuse/*statistics & numerical data
MH  - Humans
MH  - *Patient Compliance
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Primary Prevention/*methods
MH  - *Risk Assessment
MH  - Risk Factors
MH  - Secondary Prevention/*methods
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Cessation
OT  - Compliance
OT  - Discontinuation
OT  - Underuse
EDAT- 2015/01/13 06:00
MHDA- 2016/01/06 06:00
CRDT- 2015/01/12 06:00
PHST- 2014/11/05 00:00 [received]
PHST- 2014/12/01 00:00 [revised]
PHST- 2014/12/25 00:00 [accepted]
PHST- 2015/01/12 06:00 [entrez]
PHST- 2015/01/13 06:00 [pubmed]
PHST- 2016/01/06 06:00 [medline]
AID - S0167-5273(14)02515-7 [pii]
AID - 10.1016/j.ijcard.2014.12.091 [doi]
PST - ppublish
SO  - Int J Cardiol. 2015 Mar 1;182:148-54. doi: 10.1016/j.ijcard.2014.12.091. Epub 
      2014 Dec 27.

PMID- 36495056
OWN - NLM
STAT- MEDLINE
DCOM- 20230405
LR  - 20230405
IS  - 1365-2184 (Electronic)
IS  - 0960-7722 (Print)
IS  - 0960-7722 (Linking)
VI  - 56
IP  - 4
DP  - 2023 Apr
TI  - Aspirin reverses inflammatory suppression of chondrogenesis by stabilizing YAP.
PG  - e13380
LID - 10.1111/cpr.13380 [doi]
LID - e13380
AB  - Bone marrow mesenchymal stem cells (BMMSCs) transplantation methods are promising 
      candidates for osteoarthritis (OA) treatment. However, inflammatory factors (such 
      as TNF-α) that occur at cell transplantation sites are critical factors that 
      impair the effectiveness of the treatment. Previous studies have shown that 
      aspirin (AS) had a regulatory role in stem cell differentiation. However, little 
      is known about the role of AS on the chondrogenesis of BMMSCs. The purpose of 
      this study is to explore the protective role of AS against the negative effects 
      of TNF-α on BMMSC chondrogenesis. In this study, we investigated the effects of 
      AS and TNF-α on BMMSCs chondrogenesis by performing the Alcian Blue staining, 
      safranin O-fast green staining, haematoxylin and eosin staining, and 
      immunohistochemical staining, as well as real-time RT-PCR and western blot 
      assays. Our results demonstrated that TNF-α inhibited chondrogenic 
      differentiation of BMMSCs by disrupting the balance of cartilage metabolism and 
      promoting oxidative stress in BMMSCs, while AS treatment attenuated these 
      effects. Furthermore, a detailed molecular mechanistic analysis indicated that 
      Yes-associated protein (YAP) played a critical regulatory role in this process. 
      In addition, AS treatment mitigated the progression of cartilage degeneration in 
      a mouse destabilization of the medial meniscus (DMM) model. AS alleviated the 
      inhibitory effect of TNF-α on chondrogenesis of BMMSCs by stabilizing YAP, which 
      may provide new therapeutic strategies for OA treatment.
CI  - © 2022 The Authors. Cell Proliferation published by Beijing Institute for Stem 
      Cell and Regenerative Medicine and John Wiley & Sons Ltd.
FAU - Wang, Xudong
AU  - Wang X
AD  - Department of Orthopedics, the First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
AD  - Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, the First 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
FAU - Liao, Hongyi
AU  - Liao H
AD  - Department of Orthopedics, the First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
AD  - Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, the First 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
FAU - Liu, Yong
AU  - Liu Y
AD  - Department of Orthopedics, the First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
AD  - Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, the First 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
FAU - Kang, Yunze
AU  - Kang Y
AD  - Department of Orthopedics, the First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
AD  - Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, the First 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
FAU - Tu, Qingqiang
AU  - Tu Q
AD  - Department of Orthopedics, the First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
AD  - Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, the First 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
FAU - Li, Zhiwen
AU  - Li Z
AD  - Department of Orthopedics, the First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
AD  - Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, the First 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
FAU - Kang, Yan
AU  - Kang Y
AD  - Department of Orthopedics, the First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
AD  - Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, the First 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
FAU - Sheng, Puyi
AU  - Sheng P
AD  - Department of Orthopedics, the First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
AD  - Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, the First 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
FAU - Zhang, Ziji
AU  - Zhang Z
AUID- ORCID: 0000-0002-7040-8576
AD  - Department of Orthopedics, the First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
AD  - Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, the First 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
LA  - eng
GR  - 81874014/National Natural Science Foundation of China/
GR  - 2022A1515012279/Natural Science Foundation of Guangdong Province, China/
PT  - Journal Article
DEP - 20221210
PL  - England
TA  - Cell Prolif
JT  - Cell proliferation
JID - 9105195
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Yap1 protein, mouse)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Aspirin/pharmacology
MH  - Cell Differentiation
MH  - Cells, Cultured
MH  - Chondrogenesis
MH  - *Mesenchymal Stem Cells
MH  - *Osteoarthritis/drug therapy/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
PMC - PMC10068956
COIS- All authors declare no conflict of interest.
EDAT- 2022/12/11 06:00
MHDA- 2023/04/04 06:42
CRDT- 2022/12/10 03:22
PHST- 2022/11/09 00:00 [revised]
PHST- 2022/08/03 00:00 [received]
PHST- 2022/11/29 00:00 [accepted]
PHST- 2023/04/04 06:42 [medline]
PHST- 2022/12/11 06:00 [pubmed]
PHST- 2022/12/10 03:22 [entrez]
AID - CPR13380 [pii]
AID - 10.1111/cpr.13380 [doi]
PST - ppublish
SO  - Cell Prolif. 2023 Apr;56(4):e13380. doi: 10.1111/cpr.13380. Epub 2022 Dec 10.

PMID- 8779028
OWN - NLM
STAT- MEDLINE
DCOM- 19960913
LR  - 20131121
IS  - 0036-4355 (Print)
IS  - 0036-4355 (Linking)
VI  - 41
IP  - 1
DP  - 1996 Feb
TI  - [Erythrocytes modulate the anti-aggregation effect of aspirin and dipyridamole. 
      Study under static conditions and in a flow system].
PG  - 13-8
AB  - PURPOSE: The modulating role played by red cells on platelet function is well 
      known, yet its mechanism of action in the presence of antiaggregating agents is 
      not clearly defined. We tried to assess the influence of aspirin (ASA) or 
      dipyridamole (DIP) treated red cells on platelet aggregation in plasma, with the 
      samples in static conditions and under flow in a perfusion system. MATERIAL AND 
      METHODS: Platelet-rich plasma (PRP) was adjusted to 4 x 10(9)/L. Red cells were 
      washed with a 0.9% sodium chloride and 5mM glucose solution, then resuspended in 
      PRP until a 40% haematocrit was attained. The drugs were added separately or 
      together and the mixture was incubated for 10 minutes at 37 degrees C. Three 
      series of tests were carried out: a) with reconstituted blood; b) with red cells 
      alone; c) with the red cells washed in a 10-fold volume so as to eliminate all 
      the drugs. The samples were divided in two parts: one was let to rest and the 
      other was circulated through a perfusion system with a peristaltic pump. 
      Simultaneous tests with untreated red cells and PRP were run as control in each 
      session. A multichannel aggregameter was used to assess platelet aggregation 
      according to Born's turbidimetric method. Variance analysis (ANOVA) or Student's 
      t test were used for the statistical evaluation. RESULTS: Platelets attained from 
      control samples under flow conditions showed partial inhibition of the maximal 
      aggregation (58.02 +/- 9.92%). The inhibitory power of ASA was higher than that 
      of DIP in all cases. Aggregation was totally inhibited by ASA from the beginning 
      in treated whole blood, but the inhibitory effect appeared later when working 
      with red cells alone, suggesting that red cells must retain part of the drug, 
      which cannot exert its effect until it has been released after several minutes. 
      The inhibition of platelet aggregation when working with washed treated red cells 
      was more effective under flow conditions, chiefly with combined treatment with 
      ASA+DIP. CONCLUSION: These studies stress the importance of flow conditions in 
      the red cells-platelets interaction and in the regulation of the therapeutic 
      agents used to modify platelet function.
FAU - Bozzo, J
AU  - Bozzo J
AD  - Servei d'Hemoteràpia i Hemostàsia, Hospital Clínic i Provincial, Villarroel, 
      Barcelona.
FAU - Hernández, M R
AU  - Hernández MR
FAU - Ordinas, A
AU  - Ordinas A
LA  - spa
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Los eritrocitos modulan el efecto antiagregante de la aspirina y el dipiridamol: 
      estudio bajo condiciones estáticas y en sistema de flujo.
PL  - Spain
TA  - Sangre (Barc)
JT  - Sangre
JID - 0404373
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/physiology
MH  - Aspirin/*pharmacology
MH  - Erythrocytes/*physiology
MH  - Hemorheology
MH  - Humans
MH  - Models, Biological
MH  - Perfusion
MH  - Platelet Aggregation/drug effects/*physiology
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
PST - ppublish
SO  - Sangre (Barc). 1996 Feb;41(1):13-8.

PMID- 6202972
OWN - NLM
STAT- MEDLINE
DCOM- 19840719
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 6
IP  - 3
DP  - 1984 May-Jun
TI  - Effect of aspirin on renal function and the prostaglandin-kallikrein systems 
      early after myocardial infarction.
PG  - 455-9
AB  - Using a double-blind procedure, 29 patients with a recent myocardial infarction 
      were randomly allocated to a placebo group (n = 14) and to a group receiving 
      aspirin, 300 mg three times a day (n = 15) over 7 days. No change in renal 
      function was observed in either treatment group. Compared with the placebo group, 
      the 24-h urinary excretion of prostaglandin E2 (PGE2) was significantly 
      suppressed in the aspirin group, but the urinary kallikrein activity was 
      unchanged. These results contrast with our previous study of similar patients, in 
      which sulfinpyrazone decreased renal function, as well as the urinary PGE2 and 
      kallikrein excretions. These divergent effects of aspirin and sulfinpyrazone on 
      urinary kallikrein activity could explain the different trends in renal function 
      observed early after myocardial infarction.
FAU - Lijnen, P
AU  - Lijnen P
FAU - Boelaert, J
AU  - Boelaert J
FAU - Van Eeghem, P
AU  - Van Eeghem P
FAU - Daneels, R
AU  - Daneels R
FAU - Schurgers, M
AU  - Schurgers M
FAU - De Jaegere, P
AU  - De Jaegere P
FAU - Van der Stichele, E
AU  - Van der Stichele E
FAU - Vincke, J
AU  - Vincke J
FAU - Verschueren, L J
AU  - Verschueren LJ
FAU - Amery, A
AU  - Amery A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Prostaglandins E)
RN  - EC 3.4.21.- (Kallikreins)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Dinoprostone
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Kallikreins/*urine
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/physiopathology/*urine
MH  - Prostaglandins E/*urine
MH  - Random Allocation
MH  - Time Factors
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
AID - 10.1097/00005344-198405000-00013 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1984 May-Jun;6(3):455-9. doi: 
      10.1097/00005344-198405000-00013.

PMID- 25093403
OWN - NLM
STAT- MEDLINE
DCOM- 20151109
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 8
DP  - 2014
TI  - Low-dose aspirin for prevention of cardiovascular disease in patients with 
      chronic kidney disease.
PG  - e104179
LID - 10.1371/journal.pone.0104179 [doi]
LID - e104179
AB  - BACKGROUND: Chronic kidney disease (CKD) is a major risk factor for the 
      development of cardiovascular disease (CVD). Previous trials have investigated 
      the effects of low-dose aspirin on CVD prevention in patients with diabetes; 
      however, patients with CKD were not examined. The role of aspirin in diabetics is 
      controversial, and the available literature is contradictory. Therefore, we 
      studied whether low-dose aspirin would be beneficial for patients with CKD, a 
      group that is at high risk for CVD. METHOD: From a total of 25340 patients with 
      CKD, 1884 recipients of low-dose aspirin (100 mg/day) were paired 1∶1 with 
      non-recipients for analysis using propensity score matching. The primary endpoint 
      was the development of atherosclerotic CVD, including coronary arterial disease, 
      stroke, and peripheral arterial disease. Secondary endpoints included death from 
      any cause, bleeding events, doubling of serum creatinine, and renal death. 
      RESULTS: The incidence of a primary endpoint of any atherosclerotic CVD was 
      significantly higher in the aspirin users than in the non-users (P<0.001). 
      Secondary endpoints, including all-cause mortality and composite bleeding events, 
      were not significantly different between the aspirin users and the non-users. 
      However, the doubling of serum creatinine levels (P = 0.001) and renal death 
      (P = 0.042) were significantly associated with the use of aspirin. CONCLUSION: 
      These results suggest that the use of low-dose aspirin in patients with CKD may 
      have harmful consequences related to the development of CVD and renal 
      progression.
FAU - Kim, Ae Jin
AU  - Kim AJ
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Incheon, Korea.
FAU - Lim, Hye Jin
AU  - Lim HJ
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Incheon, Korea.
FAU - Ro, Han
AU  - Ro H
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Incheon, Korea; Gachon University School of Medicine, Incheon, 
      Korea.
FAU - Ko, Kwang-Pil
AU  - Ko KP
AD  - Department of Preventive Medicine, Gachon University School of Medicine, Incheon, 
      Korea.
FAU - Han, Song Yi
AU  - Han SY
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Incheon, Korea.
FAU - Chang, Jae Hyun
AU  - Chang JH
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Incheon, Korea; Gachon University School of Medicine, Incheon, 
      Korea.
FAU - Lee, Hyun Hee
AU  - Lee HH
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Incheon, Korea; Gachon University School of Medicine, Incheon, 
      Korea.
FAU - Chung, Wookyung
AU  - Chung W
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Incheon, Korea; Gachon University School of Medicine, Incheon, 
      Korea.
FAU - Jung, Ji Yong
AU  - Jung JY
AD  - Division of Nephrology, Department of Internal Medicine, Gachon University Gil 
      Medical Center, Incheon, Korea; Gachon University School of Medicine, Incheon, 
      Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140805
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Adrenergic beta-Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/administration & dosage
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Atherosclerosis/epidemiology/etiology
MH  - Cardiovascular Diseases/epidemiology/*etiology/mortality/*prevention & control
MH  - Diabetes Mellitus
MH  - Female
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Patient Outcome Assessment
MH  - Renal Insufficiency, Chronic/*complications/epidemiology
MH  - Retrospective Studies
MH  - Risk Factors
PMC - PMC4122498
COIS- Competing Interests: The authors have read the journal’s policy and the authors 
      of this manuscript have the following competing interests: this study was 
      supported by Chong Kun Dang Pharmaceutical Corp. in Korea. This does not alter 
      the authors’ adherence to PLOS ONE policies on sharing data and materials.
EDAT- 2014/08/06 06:00
MHDA- 2015/11/10 06:00
CRDT- 2014/08/06 06:00
PHST- 2014/03/20 00:00 [received]
PHST- 2014/07/07 00:00 [accepted]
PHST- 2014/08/06 06:00 [entrez]
PHST- 2014/08/06 06:00 [pubmed]
PHST- 2015/11/10 06:00 [medline]
AID - PONE-D-14-12080 [pii]
AID - 10.1371/journal.pone.0104179 [doi]
PST - epublish
SO  - PLoS One. 2014 Aug 5;9(8):e104179. doi: 10.1371/journal.pone.0104179. eCollection 
      2014.

PMID- 8273981
OWN - NLM
STAT- MEDLINE
DCOM- 19940201
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 120
IP  - 3
DP  - 1994 Feb 1
TI  - Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury.
PG  - 184-9
AB  - OBJECTIVE: To determine if a dose of aspirin exists that might inhibit 
      thromboxane-dependent platelet function without causing gastric mucosal injury, 
      we studied the effects of a wide range of doses of aspirin (3 mg/d to 2600 mg/d) 
      on gastric juice prostaglandins (PGE2 and PGF2 alpha), on serum thromboxane B2, 
      and on stomach mucosal injury as reflected by gastric juice hemoglobin and DNA 
      concentrations. DESIGN: A randomized, placebo-controlled study. SETTING: Research 
      laboratory at a Veterans Affairs medical center. PARTICIPANTS: 16 healthy 
      volunteers (5 men and 11 women). INTERVENTION: In the first part of the study, 
      volunteers received placebo; aspirin, 324 mg/d; 1300 mg/d; or 2600 mg/d for 2 
      days. In the second part, volunteers received placebo; aspirin, 3 mg/d; 10 mg/d; 
      30 mg/d; or 81 mg/d for 8 days. MEASUREMENTS: Gastric juice PGE2 and PGF2 alpha, 
      hemoglobin and DNA concentrations; gastric juice volume and acidity; and serum 
      salicylate and thromboxane B2 concentrations. RESULTS: In the first part, 
      significant and similar (approximately 50%) inhibition of gastric juice 
      prostaglandin output was observed with daily aspirin doses of 324 to 2600 mg. 
      However, a significant increase in gastric juice hemoglobin output occurred only 
      with 2600 mg/d. In the second part, significant inhibition (approximately 50%) of 
      gastric PGE2 output was noted at a daily aspirin dose of 30 mg. Lower aspirin 
      doses did not reduce PGE2 output significantly, although these doses did 
      significantly reduce serum thromboxane B2 in a dose-related manner. CONCLUSIONS: 
      Aspirin can significantly reduce serum thromboxane B2 at doses of 3 mg/d or 10 
      mg/d, which are significantly below the threshold dose for significant gastric 
      prostaglandin inhibition and acute stomach mucosal injury.
FAU - Lee, M
AU  - Lee M
AD  - University of Texas Southwestern Medical Center, Dallas.
FAU - Cryer, B
AU  - Cryer B
FAU - Feldman, M
AU  - Feldman M
LA  - eng
GR  - R01 DK16816/DK/NIDDK NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Hemoglobins)
RN  - 0 (Prostaglandins)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 9007-49-2 (DNA)
RN  - B7IN85G1HY (Dinoprost)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 1994 Jul 1;121(1):72. PMID: 8198353
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/blood
MH  - DNA/drug effects
MH  - Dinoprost/metabolism
MH  - Dinoprostone/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastric Acidity Determination
MH  - Gastric Juice/metabolism
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Hemoglobins/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostaglandins/*metabolism
MH  - Reference Values
MH  - Thromboxane B2/blood
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
AID - 10.7326/0003-4819-120-3-199402010-00002 [doi]
PST - ppublish
SO  - Ann Intern Med. 1994 Feb 1;120(3):184-9. doi: 
      10.7326/0003-4819-120-3-199402010-00002.

PMID- 1671652
OWN - NLM
STAT- MEDLINE
DCOM- 19910327
LR  - 20190501
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 302
IP  - 6768
DP  - 1991 Jan 12
TI  - Use of secondary prophylaxis against myocardial infarction in the north of 
      England.
PG  - 91-2
AB  - OBJECTIVE: To record the use of secondary prophylactic drugs in patients 
      discharged from hospital having had a myocardial infarction. DESIGN: Prospective 
      postal questionnaire survey of a random one in two sample of general 
      practitioners in the region. SETTING: The nine family practitioner committee 
      areas within the Northern Regional Health Authority. PATIENTS: Patients who had 
      had a myocardial infarction and were discharged to their general practitioner. 
      MAIN OUTCOME MEASURE: Whether beta blockers or aspirin, or both, were given on 
      discharge. RESULTS: Of 267 patients, 158 (59%) were treated suboptimally in that 
      they did not receive a secondary prophylactic drug to which they had no 
      contraindication. For most patients this entailed underuse of one drug, but 17 
      (6%) of patients received no treatment. beta Blockers were 2.5 times less likely 
      to be used than aspirin. Treatment was not associated with the age or sex of the 
      patient, risk of further infarction, or hospital of discharge. CONCLUSIONS: 
      Secondary prophylaxis after myocardial infarction is practised haphazardly. It 
      should be offered to all patients who can tolerate it, after a trial period to 
      assess any side effects of the drugs if necessary.
FAU - Eccles, M
AU  - Eccles M
AD  - Centre for Health Services Research, University of Newcastle upon Tyne.
FAU - Bradshaw, C
AU  - Bradshaw C
LA  - eng
PT  - Journal Article
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Adrenergic beta-Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 1991 Mar 16;302(6777):656-7. PMID: 1672826
CIN - BMJ. 1991 Apr 13;302(6781):913. PMID: 1673867
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Contraindications
MH  - Death, Sudden
MH  - Drug Therapy, Combination
MH  - England
MH  - Family Practice
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC1668878
EDAT- 1991/01/12 00:00
MHDA- 1991/01/12 00:01
CRDT- 1991/01/12 00:00
PHST- 1991/01/12 00:00 [pubmed]
PHST- 1991/01/12 00:01 [medline]
PHST- 1991/01/12 00:00 [entrez]
AID - 10.1136/bmj.302.6768.91 [doi]
PST - ppublish
SO  - BMJ. 1991 Jan 12;302(6768):91-2. doi: 10.1136/bmj.302.6768.91.

PMID- 28537451
OWN - NLM
STAT- MEDLINE
DCOM- 20180426
LR  - 20180613
IS  - 1931-843X (Electronic)
IS  - 1540-9996 (Linking)
VI  - 26
IP  - 12
DP  - 2017 Dec
TI  - Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide 
      Retrospective Cohort Study in Taiwan.
PG  - 1278-1284
LID - 10.1089/jwh.2016.6040 [doi]
AB  - PURPOSE: Low-dose aspirin is commonly used for preventing cardiovascular disease 
      in people with diabetes, but its association with cancer remains controversial. 
      This study used a nationwide population-based reimbursement database to 
      investigate the relationship between low-dose aspirin use and breast cancer 
      incidence in women with diabetes. METHODS: This retrospective cohort study was 
      conducted using data retrieved from the National Health Insurance Research 
      Database in Taiwan from January 1, 1998 to December 31, 2011. Women diagnosed as 
      having diabetes with low-dose aspirin use (75-165 mg daily) were identified as 
      the study population, whereas those without low-dose aspirin use were selected as 
      the comparison group. RESULTS: We analyzed 148,739 patients with diabetes. Their 
      mean age (standard deviation) was 63.3 (12.8) years. A total of 27,378 patients 
      were taking aspirin. Overall, the use of aspirin in patients with diabetes 
      reduced the risk of breast cancer by 18% (hazard ratio [HR], 0.82; 95% confidence 
      interval [CI], 0.71-0.94) after adjustment for potential confounders, namely age 
      and comorbidities. Specifically, a cumulative dose of aspirin exceeding 88,900 mg 
      was observed to reduce the risk of breast cancer by 47% (HR, 0.53, 95% CI, 
      0.43-0.67); however, low (<8,600 mg) and medium (8,600-88,900 mg) cumulative 
      doses of aspirin did not reduce the risk of breast cancer. CONCLUSIONS: Our 
      findings suggest that a cumulative aspirin dosage of more than 88,900 mg daily 
      was associated with a reduced risk of breast cancer in women with diabetes. 
      However, additional studies are necessary to confirm these findings.
FAU - Yang, Yi-Sun
AU  - Yang YS
AD  - 1 Institute of Medicine, School of Medicine, Chung Shan Medical University , 
      Taichung, Taiwan .
AD  - 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Chung Shan Medical University Hospital , Taichung, Taiwan .
FAU - Kornelius, Edy
AU  - Kornelius E
AD  - 1 Institute of Medicine, School of Medicine, Chung Shan Medical University , 
      Taichung, Taiwan .
AD  - 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Chung Shan Medical University Hospital , Taichung, Taiwan .
FAU - Chiou, Jeng-Yuan
AU  - Chiou JY
AD  - 3 School of Health Policy and Management, Institute of Medicine, Chung Shan 
      Medical University , Taichung, Taiwan .
FAU - Lai, Yung-Rung
AU  - Lai YR
AD  - 4 Department of Pharmacy, Chung Shan Medical University Hospital , Taichung, 
      Taiwan .
FAU - Lo, Shih-Chang
AU  - Lo SC
AD  - 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Chung Shan Medical University Hospital , Taichung, Taiwan .
FAU - Peng, Chiung-Huei
AU  - Peng CH
AD  - 5 Division of Basic Medical Research, Hung Kuang University , Taichung, Taiwan .
FAU - Huang, Chien-Ning
AU  - Huang CN
AD  - 1 Institute of Medicine, School of Medicine, Chung Shan Medical University , 
      Taichung, Taiwan .
AD  - 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Chung Shan Medical University Hospital , Taichung, Taiwan .
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170524
PL  - United States
TA  - J Womens Health (Larchmt)
JT  - Journal of women's health (2002)
JID - 101159262
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hypoglycemic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Womens Health (Larchmt). 2017 Dec;26(12 ):1364. PMID: 29148880
CIN - J Womens Health (Larchmt). 2018 Jun;27(6):844. PMID: 29741979
CIN - J Womens Health (Larchmt). 2018 Jun;27(6):845. PMID: 29847742
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Breast Neoplasms/*epidemiology/prevention & control
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cohort Studies
MH  - Comorbidity
MH  - Diabetes Mellitus/drug therapy/*epidemiology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Incidence
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Taiwan/epidemiology
MH  - Time Factors
OTO - NOTNLM
OT  - aspirin
OT  - breast cancer
OT  - diabetes
OT  - nationwide cohort study
EDAT- 2017/05/26 06:00
MHDA- 2018/04/27 06:00
CRDT- 2017/05/25 06:00
PHST- 2017/05/26 06:00 [pubmed]
PHST- 2018/04/27 06:00 [medline]
PHST- 2017/05/25 06:00 [entrez]
AID - 10.1089/jwh.2016.6040 [doi]
PST - ppublish
SO  - J Womens Health (Larchmt). 2017 Dec;26(12):1278-1284. doi: 10.1089/jwh.2016.6040. 
      Epub 2017 May 24.

PMID- 1287305
OWN - NLM
STAT- MEDLINE
DCOM- 19930318
LR  - 20170310
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 32
IP  - 9-10
DP  - 1992 Sep
TI  - [Development of myocardial infarction in aspirin-treated unstable angina 
      pectoris. Repeated studies of platelet aggregation and of the 
      thromboxane-prostacyclin system].
PG  - 27-30
AB  - Platelet functional parameters (platelet aggregation, blood circulating 
      reversibly and irreversibly aggregated platelet complexes, thromboxane B2, 
      6-keto-PGF1 alpha) were examined in unstable angina treated with aspirin in a 
      daily dose of 320 mg in relation to the outcome of the disease: Group 1, 
      stabilization and Group 2, evolving myocardial infarction. Differences were found 
      in the baseline platelet functional parameters between the groups. The findings 
      suggest that platelet functional parameters show a varying response to aspirin 
      depending on the outcome of the disease. Despite the effective inhibition of 
      thromboxane A2 synthesis, aspirin was found to fail to prevent enhanced platelet 
      aggregatory activity in case of myocardial infarction developed during the 
      therapy.
FAU - Shalaev, S V
AU  - Shalaev SV
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Razvitie infarkta miokarda pri lechennoĭ aspirinom nestabil'noĭ stenokardii. 
      Povtornie issledovaniia agregatsii trombotsitov i tromboksan-prostatsiklinovoĭ 
      sistemy.
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Thromboxanes)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Angina, Unstable/blood/complications/*drug therapy
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Epoprostenol/*physiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*blood/etiology
MH  - Platelet Aggregation/drug effects/*physiology
MH  - Thromboxanes/*physiology
EDAT- 1992/09/01 00:00
MHDA- 1992/09/01 00:01
CRDT- 1992/09/01 00:00
PHST- 1992/09/01 00:00 [pubmed]
PHST- 1992/09/01 00:01 [medline]
PHST- 1992/09/01 00:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 1992 Sep;32(9-10):27-30.

PMID- 26083485
OWN - NLM
STAT- MEDLINE
DCOM- 20161012
LR  - 20181202
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 27
IP  - 1
DP  - 2016
TI  - How to test the effect of aspirin and clopidogrel in patients on dual 
      antiplatelet therapy?
PG  - 59-65
LID - 10.3109/09537104.2015.1031098 [doi]
AB  - Dual antiplatelet therapy with clopidogrel and aspirin is frequently used for the 
      prevention of recurrent ischemic events. Various laboratory methods are used to 
      detect the effect of these drugs administered in monotherapy, however their value 
      in dual therapy has not been explored. Here, we determined which methods used for 
      testing the effect of clopidogrel or aspirin are influenced by the other 
      antiplatelet agent. One arm of the study included 53 ischemic stroke patients 
      being on clopidogrel monotherapy showing effective inhibition of the P2Y12 ADP 
      receptor. Laboratory tests routinely used for the detection of aspirin resistance 
      (arachidonic acid (AA)-induced platelet aggregation/secretion, AA-induced 
      thromboxane B2 (TXB2) production in platelet-rich plasma and VerifyNow Aspirin 
      assay) were carried out on samples obtained from these patients. The other arm of 
      the study involved 52 patients with coronary artery disease being on aspirin 
      monotherapy. Methods used for testing the effect of clopidogrel (ADP-induced 
      platelet aggregation and secretion, flow cytometric analysis of 
      vasodilator-stimulated phosphoprotein (VASP) phosphorylation and a newly 
      developed P2Y12-specific platelet aggregation (ADP[PGE1] test)) were performed on 
      samples obtained from these patients. Clopidogrel monotherapy significantly 
      inhibited AA-induced platelet aggregation and secretion, moreover, AA-induced 
      TXB2 production was also significantly decreased. VASP phosphorylation and 
      AA-induced platelet aggregation showed fair correlation in patients taking 
      clopidogrel only. Clopidogrel did not inhibit the VerifyNow Aspirin test 
      significantly. Aspirin monotherapy influenced ADP-induced platelet aggregation 
      and secretion, but did not have an effect on VASP phosphorylation and on the 
      ADP[PGE1] platelet aggregation test.
FAU - Bagoly, Zsuzsa
AU  - Bagoly Z
AD  - a Division of Clinical Laboratory Sciences, Faculty of Medicine , University of 
      Debrecen , Debrecen , Hungary .
FAU - Homoródi, Nóra
AU  - Homoródi N
AD  - b Institute of Cardiology, Faculty of Medicine, University of Debrecen , Debrecen 
      , Hungary , and.
FAU - Kovács, Emese Gyöngyvér
AU  - Kovács EG
AD  - a Division of Clinical Laboratory Sciences, Faculty of Medicine , University of 
      Debrecen , Debrecen , Hungary .
FAU - Sarkady, Ferenc
AU  - Sarkady F
AD  - a Division of Clinical Laboratory Sciences, Faculty of Medicine , University of 
      Debrecen , Debrecen , Hungary .
FAU - Csiba, László
AU  - Csiba L
AD  - c Department of Neurology, Faculty of Medicine , University of Debrecen , 
      Debrecen , Hungary.
FAU - Édes, István
AU  - Édes I
AD  - b Institute of Cardiology, Faculty of Medicine, University of Debrecen , Debrecen 
      , Hungary , and.
FAU - Muszbek, László
AU  - Muszbek L
AD  - a Division of Clinical Laboratory Sciences, Faculty of Medicine , University of 
      Debrecen , Debrecen , Hungary .
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150617
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/blood
MH  - Case-Control Studies
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Drug Monitoring/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/blood
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/blood
OTO - NOTNLM
OT  - Anti-platelet drug
OT  - aspirin
OT  - clopidogrel
OT  - drug resistance
OT  - platelet aggregation
EDAT- 2015/06/18 06:00
MHDA- 2016/10/13 06:00
CRDT- 2015/06/18 06:00
PHST- 2015/06/18 06:00 [entrez]
PHST- 2015/06/18 06:00 [pubmed]
PHST- 2016/10/13 06:00 [medline]
AID - 10.3109/09537104.2015.1031098 [doi]
PST - ppublish
SO  - Platelets. 2016;27(1):59-65. doi: 10.3109/09537104.2015.1031098. Epub 2015 Jun 
      17.

PMID- 23417566
OWN - NLM
STAT- MEDLINE
DCOM- 20140130
LR  - 20161020
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 27
IP  - 4
DP  - 2013 Aug
TI  - Gastroprotection in low-dose aspirin users for primary and secondary prevention 
      of ACS: results of a cost-effectiveness analysis including compliance.
PG  - 341-57
LID - 10.1007/s10557-013-6448-y [doi]
AB  - PURPOSE: Low-dose aspirin (ASA) increases the risk of upper gastrointestinal (GI) 
      complications. Proton pump inhibitors (PPIs) reduce these upper GI side effects, 
      yet patient compliance to PPIs is low. We determined the cost-effectiveness of 
      gastroprotective strategies in low-dose ASA users considering ASA and PPI 
      compliance. METHODS: Using a Markov model we compared four strategies: no 
      medication, ASA monotherapy, ASA+PPI co-therapy and a fixed combination of ASA 
      and PPI for primary and secondary prevention of ACS. The risk of acute coronary 
      syndrome (ACS), upper GI bleeding and dyspepsia was modeled as a function of 
      compliance and the relative risk of developing these events while using 
      medication. Costs, quality adjusted life years and number of ACS events were 
      evaluated, applying a variable risk of upper GI bleeding. Probabilistic 
      sensitivity analyses were performed. RESULTS: For our base case patients using 
      ASA for primary prevention of ACS no medication was superior to ASA monotherapy. 
      PPI co-therapy was cost-effective (incremental cost-effectiveness ratio [ICER] 
      €10,314) compared to no medication. In secondary prevention, PPI co-therapy was 
      cost-effective (ICER €563) while the fixed combination yielded an ICER < €20,000 
      only in a population with elevated risk for upper GI bleeding or moderate PPI 
      compliance. PPI co-therapy had the highest probability to be cost-effective in 
      all scenarios. PPI use lowered the overall number of ACS. CONCLUSIONS: 
      Considering compliance, PPI co-therapy is likely to be cost-effective in patients 
      taking low dose ASA for primary and secondary prevention of ACS, given low PPI 
      prices. In secondary prevention, a fixed combination seems cost-effective in 
      patients with elevated risk for upper GI bleeding or in those with moderate PPI 
      compliance. Both strategies reduced the number of ACS compared to ASA 
      monotherapy.
FAU - de Groot, N L
AU  - de Groot NL
AD  - Department Gastroenterology and Hepatology, University Medical Center Utrecht, PO 
      Box (85500 internal code F02.618), 3508 GA Utrecht, The Netherlands. 
      n.l.degroot-3@umcutrecht.nl
FAU - van Haalen, H G M
AU  - van Haalen HG
FAU - Spiegel, B M R
AU  - Spiegel BM
FAU - Laine, L
AU  - Laine L
FAU - Lanas, A
AU  - Lanas A
FAU - Focks, J Jaspers
AU  - Focks JJ
FAU - Siersema, P D
AU  - Siersema PD
FAU - van Oijen, M G H
AU  - van Oijen MG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/economics/*prevention & control
MH  - Aspirin/*administration & dosage/economics
MH  - Cost-Benefit Analysis
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Hemorrhage/economics/*prevention & control
MH  - Health Care Costs
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Models, Theoretical
MH  - Patient Compliance
MH  - Platelet Aggregation Inhibitors/*administration & dosage/economics
MH  - Primary Prevention
MH  - Proton Pump Inhibitors/*administration & dosage/economics
MH  - Quality-Adjusted Life Years
MH  - Secondary Prevention
EDAT- 2013/02/19 06:00
MHDA- 2014/01/31 06:00
CRDT- 2013/02/19 06:00
PHST- 2013/02/19 06:00 [entrez]
PHST- 2013/02/19 06:00 [pubmed]
PHST- 2014/01/31 06:00 [medline]
AID - 10.1007/s10557-013-6448-y [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2013 Aug;27(4):341-57. doi: 10.1007/s10557-013-6448-y.

PMID- 16011980
OWN - NLM
STAT- MEDLINE
DCOM- 20050913
LR  - 20131211
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 16
IP  - 5
DP  - 2005 Aug
TI  - A new point-of-care method for monitoring anti-platelet therapy: application of 
      the cone and plate(let) analyzer.
PG  - 293-9
AB  - Recent studies suggest that anti-platelet agents are not equally effective in all 
      individuals. We have developed a new method to evaluate the effect of 
      anti-platelet drugs using the cone and plate(let) analyzer (CPA) test. The method 
      is based on the ability of activators to reduce platelet adhesion under flow 
      conditions. Treatment of a blood sample with arachidonic acid (AA) or ADP in 
      vitro significantly decreased platelet deposition to a surface coverage (SC) of 
      2.1+/-0.4 and 1.3+/-0.6%, respectively, compared with the basic SC of 
      12.3+/-6.8%. The effect of AA was prevented by aspirin (SC 8.1+/-3.8%) and that 
      of ADP was reduced by 2-methylthio-AMP, a P2Y12 ADP receptor inhibitor (SC 
      4.8+/-2.0%). Pre-incubation with AA of whole blood samples from untreated healthy 
      volunteers resulted in a marked decline of SC (from SC 9.8+/-2.2 to 0.6+/-0.3%). 
      In contrast, in volunteers treated with 100, 300, and 500 mg aspirin per day, AA 
      (but not ADP) decreased SC only to 3.5+/-1.3, 4.4+/-1.7, and 4.1+/-2.0%, 
      respectively (P<0.001 versus SC with AA before treatment). A good correlation was 
      observed between the modified CPA and aggregometry (R2=0.55). In conclusion, the 
      modified CPA test is a useful tool to evaluate the efficacy of anti-platelet 
      therapy.
FAU - Spectre, Galia
AU  - Spectre G
AD  - Coagulation Unit, Hematology Department, Hadassah Hebrew University Medical 
      Center, Jerusalem, Israel.
FAU - Brill, Alexander
AU  - Brill A
FAU - Gural, Alexander
AU  - Gural A
FAU - Shenkman, Boris
AU  - Shenkman B
FAU - Touretsky, Natalia
AU  - Touretsky N
FAU - Mosseri, Elinor
AU  - Mosseri E
FAU - Savion, Naphtali
AU  - Savion N
FAU - Varon, David
AU  - Varon D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Blood Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (P2RY12 protein, human)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2 Receptor Antagonists)
RN  - 0 (Receptors, Purinergic P2)
RN  - 0 (Receptors, Purinergic P2Y12)
RN  - 0 (platelet adhesion inhibitor)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/blood/pharmacology
MH  - Blood Proteins/pharmacology
MH  - Drug Monitoring/*methods
MH  - Humans
MH  - Membrane Proteins/antagonists & inhibitors/blood/pharmacology
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests/instrumentation/*methods
MH  - *Point-of-Care Systems
MH  - Purinergic P2 Receptor Antagonists
MH  - Receptors, Purinergic P2/blood
MH  - Receptors, Purinergic P2Y12
MH  - Sensitivity and Specificity
EDAT- 2005/07/14 09:00
MHDA- 2005/09/15 09:00
CRDT- 2005/07/14 09:00
PHST- 2005/07/14 09:00 [pubmed]
PHST- 2005/09/15 09:00 [medline]
PHST- 2005/07/14 09:00 [entrez]
AID - UR6W867531U16567 [pii]
AID - 10.1080/09537100400028800 [doi]
PST - ppublish
SO  - Platelets. 2005 Aug;16(5):293-9. doi: 10.1080/09537100400028800.

PMID- 2126634
OWN - NLM
STAT- MEDLINE
DCOM- 19910315
LR  - 20190828
IS  - 0167-8140 (Print)
IS  - 0167-8140 (Linking)
VI  - 19
IP  - 4
DP  - 1990 Dec
TI  - In vitro capacity of various cyclooxygenase inhibitors to revert immune 
      suppression caused by radiation therapy for breast cancer.
PG  - 329-35
AB  - Radiation therapy triggers blood monocytes to an increased secretion of 
      immunosuppressive prostaglandins (PGs), which in part can explain the 
      post-irradiation impairment of lymphocyte blastogenesis. Since low mitogen 
      responses of lymphocytes in irradiated breast cancer patients is linked to a poor 
      prognosis a clinical trial is planned to examine if treatment with inhibitors of 
      PG-synthesis during irradiation can counteract immunosuppression and increase 
      survival. In the present investigation we have compared nine different inhibitors 
      of PG-synthesis for capacity to enhance phytohemagglutinin responses of blood 
      lymphocytes before and after irradiation for breast cancer. Five of the drugs 
      (aspisol, indomethacin, meclofenamic acid, ketoprofen and diclofenac) enhanced 
      the reactivity to more than 150%. In general, the strongest enhancements were 
      observed in lymphocyte preparations obtained at completion of irradiation when 
      reactivity was most depressed followed by those obtained at one month and before 
      irradiation.
FAU - Blomgren, H
AU  - Blomgren H
AD  - Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
FAU - Rotstein, S
AU  - Rotstein S
FAU - Wasserman, J
AU  - Wasserman J
FAU - Petrini, B
AU  - Petrini B
FAU - Hammarström, S
AU  - Hammarström S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Radiother Oncol
JT  - Radiotherapy and oncology : journal of the European Society for Therapeutic 
      Radiology and Oncology
JID - 8407192
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Phytohemagglutinins)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 48I5LU4ZWD (Meclofenamic Acid)
RN  - 90Y4QC304K (Ketoprofen)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Breast Neoplasms/*radiotherapy
MH  - *Cyclooxygenase Inhibitors
MH  - Diclofenac/pharmacology
MH  - Female
MH  - Humans
MH  - Immune Tolerance/*drug effects/*radiation effects
MH  - In Vitro Techniques
MH  - Indomethacin/pharmacology
MH  - Ketoprofen/pharmacology
MH  - Lymphocyte Activation/drug effects/radiation effects
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Meclofenamic Acid/pharmacology
MH  - Middle Aged
MH  - Phytohemagglutinins
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
AID - 0167-8140(90)90033-S [pii]
AID - 10.1016/0167-8140(90)90033-s [doi]
PST - ppublish
SO  - Radiother Oncol. 1990 Dec;19(4):329-35. doi: 10.1016/0167-8140(90)90033-s.

PMID- 2620862
OWN - NLM
STAT- MEDLINE
DCOM- 19900328
LR  - 20211203
IS  - 0378-7346 (Print)
IS  - 0378-7346 (Linking)
VI  - 28
IP  - 4
DP  - 1989
TI  - Fetal demise associated with lupus anticoagulant: clinical features and results 
      of treatment.
PG  - 178-84
AB  - There are many reports in the literature associating lupus anticoagulant with 
      fetal death. Successful pregnancies have been reported following suppression of 
      the antibody by prednisone and the addition of antiaggregants and possibly 
      anticoagulants. This report describes our experience treating such patients and 
      the outcome of subsequent pregnancies. The results are less successful than the 
      figures in the literature, 13 live births out of 27 pregnancies in 19 patients. 
      This may be due to lupus anticoagulant being diagnosed as the cause for a wide 
      variety of clinical presentations including habitual first trimester abortion, 
      mid trimester fetal death, intrauterine growth retardation and placental 
      dysfunction in the third trimester. Our experience shows that steroids and 
      antiaggregants have a definite place in cases of second and third trimester fetal 
      death and in cases of clinical systemic lupus erythematosus. However, lupus 
      anticoagulant is one of a spectrum of autoantibodies whose pathophysiology has 
      not been fully elucidated. It is questionable whether this regimen of treatment 
      has a place in patients with no previous fetal loss or in cases of primary 
      habitual abortion.
FAU - Carp, H J
AU  - Carp HJ
AD  - Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, 
      Tel-Hashomer, Israel.
FAU - Frenkel, Y
AU  - Frenkel Y
FAU - Many, A
AU  - Many A
FAU - Menashe, Y
AU  - Menashe Y
FAU - Mashiach, S
AU  - Mashiach S
FAU - Nebel, L
AU  - Nebel L
FAU - Toder, V
AU  - Toder V
FAU - Serr, D M
AU  - Serr DM
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Gynecol Obstet Invest
JT  - Gynecologic and obstetric investigation
JID - 7900587
RN  - 0 (Autoantibodies)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/therapeutic use
MH  - Autoantibodies/*physiology
MH  - Blood Coagulation/drug effects/*immunology
MH  - Dipyridamole/pharmacology/therapeutic use
MH  - Female
MH  - Heparin/pharmacology/therapeutic use
MH  - Humans
MH  - *Immunosuppression Therapy
MH  - Lupus Erythematosus, Systemic/blood/*immunology/therapy
MH  - Prednisone/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/blood/*immunology/therapy
MH  - Pregnancy Outcome
MH  - Retrospective Studies
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1159/000293573 [doi]
PST - ppublish
SO  - Gynecol Obstet Invest. 1989;28(4):178-84. doi: 10.1159/000293573.

PMID- 980605
OWN - NLM
STAT- MEDLINE
DCOM- 19770103
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 58
IP  - 5
DP  - 1976 Nov
TI  - Serum enzyme abnormalities in juvenile rheumatoid arthritis.
PG  - 730-6
AB  - Elevated serum transaminases, particularly SGOT, as a result of acetylsalicylic 
      acid (ASA) therapy have been reported in patients with juvenile rheumatoid 
      arthritis (JRA). In order to evaluate the possibilities that these elevated 
      transaminases may result from JRA itself or from concomitant muscle injury, we 
      correlated liver function tests and a specific test for muscle damage, creatine 
      phosphokinase (CPK), with ASA therapy in 37 patients. These JRA patients were 
      evaluated serially; 20 took ASA continuously, 6 took it intermittently, and 11 
      were on no therapy. Thirty-five healthy children were also studied to establish 
      normal control values for the serum enzyme tests. Mean SGOT and SGPT in the 11 
      untreated subjects were significantly (P less than.001) higher than normal 
      controls while CPK and alkaline phosphatase (AP) were not elevated. Mean SGOT and 
      SGPT were also significantly (P less than .001) elevated in 20 children receiving 
      ASA continuously; CPK was normal and AP less (P less than .05) than normal. CPK 
      was elevated in 13 patients. Elevation of enzymes was sporadic and there was no 
      correlation with serum salicylate, sex, age, disease duration, type, or activity. 
      We conclude that mild abnormalities of SGOT and SGPT in JRA patients are common, 
      but that they occur sporadically and elevated values appear to be unrelated to 
      ASA therapy.
FAU - Rachelefsky, G S
AU  - Rachelefsky GS
FAU - Kar, N C
AU  - Kar NC
FAU - Coulson, A
AU  - Coulson A
FAU - Sarkissian, E
AU  - Sarkissian E
FAU - Stiehm, E R
AU  - Stiehm ER
FAU - Paulus, H E
AU  - Paulus HE
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 7440-57-5 (Gold)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - EC 2.7.3.2 (Creatine Kinase)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Alanine Transaminase/blood
MH  - Alkaline Phosphatase/blood
MH  - Arthritis, Juvenile/drug therapy/*enzymology
MH  - Aspartate Aminotransferases/blood
MH  - Aspirin/blood/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Creatine Kinase/blood
MH  - Female
MH  - Gold/therapeutic use
MH  - Humans
MH  - Infant
MH  - Liver Function Tests
MH  - Male
EDAT- 1976/11/01 00:00
MHDA- 1976/11/01 00:01
CRDT- 1976/11/01 00:00
PHST- 1976/11/01 00:00 [pubmed]
PHST- 1976/11/01 00:01 [medline]
PHST- 1976/11/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1976 Nov;58(5):730-6.

PMID- 4281540
OWN - NLM
STAT- MEDLINE
DCOM- 19750613
LR  - 20131121
IS  - 0340-5338 (Print)
IS  - 0340-5338 (Linking)
VI  - 32
IP  - 1
DP  - 1974 Sep 30
TI  - Comparative effects of proteinase inhibitors, plasminogen antiactivators, heparin 
      and acetylsalicylic acid on the experimental disseminated intravascular 
      coagulation induced by thormbin.
PG  - 171-88
AB  - In an experimental study in the rabbit, the modifications of some haemostasis 
      parameters (platelet count, platelet retention and aggregation, platelet factors 
      3 and 4, platelet and plasma plasmin inhibiting activities, fibrinogen and other 
      plasma factor levels, FDP), and histological findings are compared in both the 
      normal animal and the animal with disseminated intravascular coagulation (DIC) 
      induced by thrombin perfusion after administration of fibrinolytic inhibitors 
      (plasminogen antiactivators and proteinase inhibitors). In the normal animal, the 
      administration of fibrinolytic inhibitors is followed by haemostatic changes 
      similar to those found in thrombophilic states. The modifications are more 
      pronounced with plasminogen antiactivators than with proteinase inhibitors. In 
      the animal with DIC, the administration of fibrinolytic inhibitors enhances the 
      haemostatic and the biological disorders produced by thrombin perfusion. The 
      effect of the plasminogen antiactivators is even more evident. The preventive 
      administration of heparin reduces or abolishes the biological and histological 
      disorders induced by thrombin; its beneficial effect is considerably reduced when 
      thrombin is combined with fibrinolytic inhibitors. The administration of 
      acetylsalicylic acid appears to be ineffective for the prevention of haemostatic 
      and histological changes induced by thrombin perfusion.
FAU - Moriau, M
AU  - Moriau M
FAU - Rodhain, J
AU  - Rodhain J
FAU - Noel, H
AU  - Noel H
FAU - Beys-Col, C D
AU  - Beys-Col CD
FAU - Masure, R
AU  - Masure R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Thromb Diath Haemorrh
JT  - Thrombosis et diathesis haemorrhagica
JID - 7608420
RN  - 0 (Aminocaproates)
RN  - 0 (Cyclohexanecarboxylic Acids)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Heparin Antagonists)
RN  - 0 (Methylamines)
RN  - 0 (Protease Inhibitors)
RN  - 9001-31-4 (Fibrin)
RN  - 9001-32-5 (Fibrinogen)
RN  - 9001-91-6 (Plasminogen)
RN  - 9005-49-6 (Heparin)
RN  - 9035-58-9 (Thromboplastin)
RN  - 9087-70-1 (Aprotinin)
RN  - EC 3.4.21.5 (Thrombin)
RN  - EC 3.4.21.7 (Fibrinolysin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aminocaproates
MH  - Animals
MH  - Aprotinin/pharmacology
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Cell Count
MH  - Blood Coagulation Tests
MH  - Blood Platelets
MH  - Cyclohexanecarboxylic Acids/pharmacology
MH  - *Disseminated Intravascular Coagulation/chemically induced/prevention & control
MH  - Enzyme Activation
MH  - Enzyme Inhibitors
MH  - Fibrin/metabolism
MH  - Fibrinogen/analysis
MH  - Fibrinolysin/antagonists & inhibitors
MH  - Heparin/*pharmacology/therapeutic use
MH  - Heparin Antagonists
MH  - Kidney/pathology
MH  - Lung/pathology
MH  - Methylamines/pharmacology
MH  - *Plasminogen
MH  - Platelet Aggregation
MH  - *Protease Inhibitors
MH  - Thrombin
MH  - Thromboplastin
EDAT- 1974/09/30 00:00
MHDA- 1974/09/30 00:01
CRDT- 1974/09/30 00:00
PHST- 1974/09/30 00:00 [pubmed]
PHST- 1974/09/30 00:01 [medline]
PHST- 1974/09/30 00:00 [entrez]
PST - ppublish
SO  - Thromb Diath Haemorrh. 1974 Sep 30;32(1):171-88.

PMID- 6639221
OWN - NLM
STAT- MEDLINE
DCOM- 19831217
LR  - 20131121
IS  - 0003-9780 (Print)
IS  - 0003-9780 (Linking)
VI  - 264
IP  - 2
DP  - 1983 Aug
TI  - Effect of aspirin treatment on the hypotensive effect of clonidine in rats.
PG  - 298-304
AB  - Rats were pretreated with aspirin (5 mg/kg i.p. 5 days) or saline, anaesthetized 
      with pentobarbitone, and blood pressure recorded from the carotid artery. 
      Clonidine (30 micrograms/kg) was injected intravenously via a cannula inserted 
      into the femoral vein. Aspirin pretreatment significantly reduced the hypotensive 
      effect of clonidine. Spleen, heart brain, kidneys and lung were removed from the 
      animals 60 min after clonidine administration. Prostaglandin biosynthesis from 
      endogenous substrate was determined by homogenizing tissues (1:4 w/v) in either 
      Tris buffer (pH 7.4) or in 1 M formic acid: ethanol (1:V/v). Prostaglandins were 
      extracted into ethyl acetate and bioassayed on the rat stomach strip. Clonidine 
      administration significantly increased the prostaglandin formation in heart, 
      brain and kidney. Animals pretreated with aspirin showed a reduction in the 
      clonidine-induced increase in prostaglandin synthesis in heart, brain and spleen. 
      The results suggest that the hypotensive effect of clonidine in anaesthetized 
      rats may in part be secondary to stimulation of central prostaglandin 
      biosynthesis.
FAU - Twohig, B
AU  - Twohig B
FAU - Griffiths, R J
AU  - Griffiths RJ
FAU - Barber, N D
AU  - Barber ND
FAU - Moore, P K
AU  - Moore PK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Belgium
TA  - Arch Int Pharmacodyn Ther
JT  - Archives internationales de pharmacodynamie et de therapie
JID - 0405353
RN  - 0 (Prostaglandins)
RN  - MN3L5RMN02 (Clonidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Clonidine/*pharmacology
MH  - Drug Interactions
MH  - Heart Rate/drug effects
MH  - Male
MH  - Prostaglandins/biosynthesis
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1983/08/01 00:00
MHDA- 1983/08/01 00:01
CRDT- 1983/08/01 00:00
PHST- 1983/08/01 00:00 [pubmed]
PHST- 1983/08/01 00:01 [medline]
PHST- 1983/08/01 00:00 [entrez]
PST - ppublish
SO  - Arch Int Pharmacodyn Ther. 1983 Aug;264(2):298-304.

PMID- 7115424
OWN - NLM
STAT- MEDLINE
DCOM- 19821029
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 31
IP  - 11
DP  - 1982 Jun 1
TI  - Effects of hydrocortisone and aspirin on protein synthesis and post-translational 
      protein modification in cultured cells.
PG  - 2047-52
AB  - Arginyl-tRNA transferase is suggested to function as a post-translational 
      modifier of proteins through the addition of arginine to the NH2-terminus of 
      specific acceptor proteins. Both hydrocortisone and aspirin produced an 
      age-dependent stimulation of protein synthesis in normal human fibroblasts 
      (IMR90), while producing an inhibition of protein synthesis in SV40 
      virus-transformed IMR90 cells. The effect of aspirin was confined primarily to 
      the cytoplasmic compartment, whereas hydrocortisone produced its effect at both 
      cytoplasmic and nuclear levels. Neither hydrocortisone nor aspirin had a direct 
      effect on arginyl-tRNA transferase activity in vitro; however, hydrocortisone 
      resulted in a marked increase in the availability of chromosomal proteins subject 
      to modification by arginyl-tRNA transferase. This stimulatory effect was 
      attenuated by increasing culture age. The modified chromosomal proteins were 
      found to be dissociated from native chromatin, suggesting that arginylation 
      either triggered their release or prevented reassociation with chromatin 
      thereafter. Hydrocortisone produced a moderate decrease in the availability of 
      chromosomal proteins for arginylation in SV40 virus-transformed cells, and this 
      effect was not modulated by aging phenomena.
FAU - Lamon, K D
AU  - Lamon KD
FAU - Chiger, J L
AU  - Chiger JL
FAU - Kaji, H
AU  - Kaji H
LA  - eng
GR  - AG 00691/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Chromatin)
RN  - 0 (Proteins)
RN  - EC 2.3.- (Acyltransferases)
RN  - EC 2.3.2.- (Aminoacyltransferases)
RN  - EC 2.3.2.8 (arginyltransferase)
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Acyltransferases/metabolism
MH  - *Aminoacyltransferases
MH  - Aspirin/*pharmacology
MH  - Cells, Cultured
MH  - Chromatin/physiology
MH  - Fibroblasts
MH  - Humans
MH  - Hydrocortisone/*pharmacology
MH  - *Protein Biosynthesis
MH  - Proteins/metabolism
EDAT- 1982/06/01 00:00
MHDA- 1982/06/01 00:01
CRDT- 1982/06/01 00:00
PHST- 1982/06/01 00:00 [pubmed]
PHST- 1982/06/01 00:01 [medline]
PHST- 1982/06/01 00:00 [entrez]
AID - 0006-2952(82)90419-1 [pii]
AID - 10.1016/0006-2952(82)90419-1 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1982 Jun 1;31(11):2047-52. doi: 10.1016/0006-2952(82)90419-1.

PMID- 72910
OWN - NLM
STAT- MEDLINE
DCOM- 19780127
LR  - 20150616
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8046
DP  - 1977 Nov 12
TI  - Minimun information for sensible use of self-prescribed medicines. An 
      international consensus.
PG  - 1017-9
AB  - An independent group, mainly clinical pharmacologists and physicians from 16 
      countries, worked out what they thought was the minimum information needed by the 
      general public for the sensible use of six medicines that are widely 
      self-prescribed (aspirin, paracetamol, ferrous sulphate, aluminium hydroxide, 
      senna, and a multivitamin preparation). For each medicine the information is 
      presented under four headings: nature and purpose of the drug, dosage and 
      administration, unwanted effects, and keeping qualities. The group recommends 
      that this "minimum information" be used as the standard basic information about 
      these drugs for users in all countries. Additional items of information that may 
      be needed in some circumstances are also discussed.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Ferrous Compounds)
RN  - 0 (Nonprescription Drugs)
RN  - 0 (Vitamins)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - E1UOL152H7 (Iron)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/adverse effects/therapeutic use
MH  - Adult
MH  - Aluminum Hydroxide/administration & dosage/adverse effects/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Drug Evaluation
MH  - Ferrous Compounds/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Infant
MH  - *Information Services
MH  - Iron/*therapeutic use
MH  - *Nonprescription Drugs
MH  - Vitamins/administration & dosage/adverse effects/*therapeutic use
EDAT- 1977/11/12 00:00
MHDA- 1977/11/12 00:01
CRDT- 1977/11/12 00:00
PHST- 1977/11/12 00:00 [pubmed]
PHST- 1977/11/12 00:01 [medline]
PHST- 1977/11/12 00:00 [entrez]
AID - S0140-6736(77)92909-9 [pii]
PST - ppublish
SO  - Lancet. 1977 Nov 12;2(8046):1017-9.

PMID- 1673828
OWN - NLM
STAT- MEDLINE
DCOM- 19910531
LR  - 20190717
IS  - 0196-0644 (Print)
IS  - 0196-0644 (Linking)
VI  - 20
IP  - 5
DP  - 1991 May
TI  - The golden hours of the myocardial infarction: nonthrombolytic interventions.
PG  - 540-8
AB  - Emergency care of patients with acute myocardial infarction requires active 
      decision making to use agents that may improve morbidity and mortality. 
      Thrombolysis remains the primary tool to accomplish this goal. Other 
      pharmacologic agents, including lidocaine, nitrates, calcium channel blockers, 
      beta-blockers, and aspirin, have been used acutely in myocardial infarction in 
      the hopes of preventing death and salvaging myocardium. The decision to select 
      one or all of these agents requires a knowledge of the clinical evidence of their 
      efficacy and risk-to-benefit ratios. The clinical studies of the use of these 
      agents acutely in the management of myocardial infarction are reviewed.
FAU - Mitchell, J M
AU  - Mitchell JM
AD  - Department of Emergency Medicine, East Carolina University School of 
      Medicine/Pitt County, Memorial Hospital, Greenville, North Carolina 27858-4354.
FAU - Wheeler, W S
AU  - Wheeler WS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Nitrates)
RN  - 98PI200987 (Lidocaine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Calcium Channel Blockers/therapeutic use
MH  - Humans
MH  - Lidocaine/therapeutic use
MH  - Myocardial Infarction/*drug therapy
MH  - Nitrates/therapeutic use
RF  - 53
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
AID - S0196-0644(05)81612-9 [pii]
AID - 10.1016/s0196-0644(05)81612-9 [doi]
PST - ppublish
SO  - Ann Emerg Med. 1991 May;20(5):540-8. doi: 10.1016/s0196-0644(05)81612-9.

PMID- 588441
OWN - NLM
STAT- MEDLINE
DCOM- 19780223
LR  - 20191210
IS  - 0007-1021 (Print)
IS  - 0007-1021 (Linking)
VI  - 58
IP  - 5
DP  - 1977 Oct
TI  - The effects of treatment with aspirin and an antithrombotic agent SH1117 upon 
      platelet thrombus formation in living blood vessels.
PG  - 474-7
AB  - The work reported here describes an in vivo study, over several days in each 
      animal, of the formation and behaviour of platelet thrombi in injured living 
      blood vessels in response to topically applied adenosine diphosphate in rabbits 
      which have been treated with oral doses of SH1117 alone or together with 
      acetyl-salicylic (ASA) before and after i.v. injection of alloxan. These two 
      substances SH1117 and ASA when given together display a synergism which is 
      similar to that described for dipyridamole and ASA, but the antithrombotic action 
      of SH1117 and ASA seems to be more profound. It may be of significance that oral 
      SH1117 given alone appears to confer a degree of insensitivity of the injured 
      vessel in its response to ADP, as such an effect is not displayed by 
      dipyridamole.
FAU - Honour, A J
AU  - Honour AJ
FAU - Carter, R D
AU  - Carter RD
FAU - Mann, J I
AU  - Mann JI
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Exp Pathol
JT  - British journal of experimental pathology
JID - 0372543
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Sulfones)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 72484-97-0 (SH1117)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Biphenyl Compounds/*therapeutic use
MH  - Drug Synergism
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
MH  - Sulfones/therapeutic use
MH  - Thrombosis/*prevention & control
PMC - PMC2041264
EDAT- 1977/10/01 00:00
MHDA- 1977/10/01 00:01
CRDT- 1977/10/01 00:00
PHST- 1977/10/01 00:00 [pubmed]
PHST- 1977/10/01 00:01 [medline]
PHST- 1977/10/01 00:00 [entrez]
PST - ppublish
SO  - Br J Exp Pathol. 1977 Oct;58(5):474-7.

PMID- 37098462
OWN - NLM
STAT- MEDLINE
DCOM- 20230427
LR  - 20230428
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Apr 25
TI  - Aspirin or statin use in relation to survival after surgery for esophageal 
      cancer: a population-based cohort study.
PG  - 375
LID - 10.1186/s12885-023-10819-0 [doi]
LID - 375
AB  - BACKGROUND: Adjuvant postoperative treatment with aspirin and statins may improve 
      survival in several solid tumors. This study aimed to assess whether these 
      medications improve the survival after curatively intended treatment (including 
      esophagectomy) for esophageal cancer in an unselected setting. METHODS: This 
      nationwide cohort study included nearly all patients who underwent esophagectomy 
      for esophageal cancer in Sweden from 2006 to 2015, with complete follow-up 
      throughout 2019. Risk of 5-year disease-specific mortality in users compared to 
      non-users of aspirin and statins was analyzed using Cox regression, providing 
      hazard ratios (HR) with 95% confidence intervals (CI). The HRs were adjusted for 
      age, sex, education, calendar year, comorbidity, aspirin/statin use (mutual 
      adjustment), tumor histology, pathological tumor stage, and neoadjuvant 
      chemo(radio)therapy. RESULTS: The cohort included 838 patients who survived at 
      least 1 year after esophagectomy for esophageal cancer. Of these, 165 (19.7%) 
      used aspirin and 187 (22.3%) used statins during the first postoperative year. 
      Neither aspirin use (HR 0.92, 95% CI 0.67-1.28) nor statin use (HR 0.88, 95% CI 
      0.64-1.23) were associated with any statistically significant decreased 5-year 
      disease-specific mortality. Analyses stratified by subgroups of age, sex, tumor 
      stage, and tumor histology did not reveal any associations between aspirin or 
      statin use and 5-year disease-specific mortality. Three years of preoperative use 
      of aspirin (HR 1.26, 95% CI 0.98-1.65) or statins (HR 0.99, 95% CI 0.67-1.45) did 
      not decrease the 5-year disease-specific mortality. CONCLUSIONS: Use of aspirin 
      or statins might not improve the 5-year survival in surgically treated esophageal 
      cancer patients.
CI  - © 2023. The Author(s).
FAU - Holmberg, Dag
AU  - Holmberg D
AUID- ORCID: 0000-0003-1000-5422
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet and 
      Karolinska University Hospital, Retzius Street 13A, 4Th Floor, 171 77, Stockholm, 
      Sweden. dag.holmberg@ki.se.
FAU - Gottlieb-Vedi, Eivind
AU  - Gottlieb-Vedi E
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet and 
      Karolinska University Hospital, Retzius Street 13A, 4Th Floor, 171 77, Stockholm, 
      Sweden.
FAU - Hedberg, Jakob
AU  - Hedberg J
AD  - Department of Surgical Sciences, Uppsala University, Akademiska Sjukhuset, 
      Uppsala, Sweden.
FAU - Lindblad, Mats
AU  - Lindblad M
AD  - Department of Clinical Science, Intervention and Technology, Karolinska 
      Institutet, Stockholm, Sweden.
AD  - Department of Upper Abdominal Diseases, Karolinska University Hospital, 
      Stockholm, Sweden.
FAU - Mattsson, Fredrik
AU  - Mattsson F
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet and 
      Karolinska University Hospital, Retzius Street 13A, 4Th Floor, 171 77, Stockholm, 
      Sweden.
FAU - Lagergren, Jesper
AU  - Lagergren J
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet and 
      Karolinska University Hospital, Retzius Street 13A, 4Th Floor, 171 77, Stockholm, 
      Sweden.
AD  - School of Cancer and Pharmacological Sciences, King's College London, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20230425
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Cohort Studies
MH  - *Esophageal Neoplasms/drug therapy/surgery
MH  - Proportional Hazards Models
PMC - PMC10127395
OTO - NOTNLM
OT  - Adjuvant
OT  - Chemoprevention
OT  - Chemotherapy
OT  - Esophageal neoplasm
OT  - Non-steroidal anti-inflammatory drugs
COIS- Dr. Eivind Gottlieb-Vedi is employed by Sanofi but declares no conflict of 
      interest related to this work. Remaining authors declare no conflicts of 
      interest.
EDAT- 2023/04/26 00:41
MHDA- 2023/04/27 06:42
CRDT- 2023/04/25 23:33
PHST- 2022/09/21 00:00 [received]
PHST- 2023/04/06 00:00 [accepted]
PHST- 2023/04/27 06:42 [medline]
PHST- 2023/04/26 00:41 [pubmed]
PHST- 2023/04/25 23:33 [entrez]
AID - 10.1186/s12885-023-10819-0 [pii]
AID - 10819 [pii]
AID - 10.1186/s12885-023-10819-0 [doi]
PST - epublish
SO  - BMC Cancer. 2023 Apr 25;23(1):375. doi: 10.1186/s12885-023-10819-0.

PMID- 9932822
OWN - NLM
STAT- MEDLINE
DCOM- 19990218
LR  - 20190702
IS  - 0038-4348 (Print)
IS  - 0038-4348 (Linking)
VI  - 92
IP  - 1
DP  - 1999 Jan
TI  - Aspirin administration for cardiac-related acute chest pain/angina: increased use 
      in Medicare patients.
PG  - 23-7
AB  - BACKGROUND: Coronary heart disease (CHD), the leading cause of death in the 
      United States, accounted for approximately 490,000 deaths in 1993. Angina 
      pectoris, a manifestation of CHD, accounted for 13,586 Medicare discharges in 
      1993 in Texas. A pilot project showed aspirin prophylaxis that reduces 
      cardiovascular morbidity and mortality in individuals with acute angina is 
      underused. Texas Medical Foundation collaborated with 10 acute-care facilities to 
      improve aspirin prophylaxis. METHODS: Collaborators assessed processes of care 
      and implemented clinical pathways to improve aspirin administration. Data were 
      abstracted from medical records before and after pathway implementation to 
      evaluate impact. RESULTS: Aspirin administration during hospital stay increased 
      10.8%, aspirin administration on discharge increased 11.7%, and average time from 
      arrival to aspirin administration decreased 2.9 hours. CONCLUSIONS: Results 
      suggest collaborator-implemented clinical pathways significantly improved care 
      received by Medicare patients admitted for cardiac-related acute chest 
      pain/angina. Data suggest room for further improvement.
FAU - Bing, M
AU  - Bing M
AD  - Texas Medical Foundation, Austin 78746-5799, USA.
FAU - Abel, R L
AU  - Abel RL
FAU - Pendergrass, P
AU  - Pendergrass P
FAU - Malone, M
AU  - Malone M
FAU - Sabharwal, K
AU  - Sabharwal K
FAU - McCauley, C
AU  - McCauley C
LA  - eng
GR  - 500-94-0537/PHS HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Angina Pectoris/*drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Critical Pathways
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Medicare
MH  - *Practice Patterns, Physicians'
MH  - Texas
MH  - United States
EDAT- 1999/02/05 00:00
MHDA- 1999/02/05 00:01
CRDT- 1999/02/05 00:00
PHST- 1999/02/05 00:00 [pubmed]
PHST- 1999/02/05 00:01 [medline]
PHST- 1999/02/05 00:00 [entrez]
AID - 10.1097/00007611-199901000-00004 [doi]
PST - ppublish
SO  - South Med J. 1999 Jan;92(1):23-7. doi: 10.1097/00007611-199901000-00004.

PMID- 11286478
OWN - NLM
STAT- MEDLINE
DCOM- 20010510
LR  - 20220408
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 84
IP  - 7
DP  - 2001 Apr 6
TI  - Aspirin and risk for gastric cancer: a population-based case-control study in 
      Sweden.
PG  - 965-8
AB  - While aspirin and other non-steroid anti-inflammatory drugs (NSAIDs) are 
      associated with gastric mucosal damage, they might reduce the risk for gastric 
      cancer. In a population-based case-control study in 5 Swedish counties, we 
      interviewed 567 incident cases of gastric cancer and 1165 controls about their 
      use of pain relievers. The cases were uniformly classified to subsite 
      (cardia/non-cardia) and histological type and information collected on other 
      known risk factors for gastric cancer. Helicobacter pylori serology was tested in 
      a subset of 542 individuals. Users of aspirin had a moderately reduced risk of 
      gastric cancer compared to never users; odds ratio (OR) adjusted for age, gender 
      and socioeconomic status was 0.7 (95% CI = 0.6-1.0). Gastric cancer risk fell 
      with increasing frequency of aspirin use (P for trend = 0.02). The risk reduction 
      was apparent for both cardia and non-cardia tumours but was uncertain for the 
      diffuse histologic type. No clear association was observed between gastric cancer 
      risk and non-aspirin NSAIDs or other studied pain relievers. Our finding lends 
      support to the hypothesis that use of aspirin reduces the risk for gastric 
      cancer.
CI  - Copyright 2001 Cancer Research Campaign.
FAU - Akre, K
AU  - Akre K
AD  - Department of Medical Epidemiology, Karolinska Institutet, 171 77 Stockholm, 
      Sweden.
FAU - Ekström, A M
AU  - Ekström AM
FAU - Signorello, L B
AU  - Signorello LB
FAU - Hansson, L E
AU  - Hansson LE
FAU - Nyrén, O
AU  - Nyrén O
LA  - eng
GR  - R01 CA 50959/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenocarcinoma/epidemiology/*prevention & control
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Helicobacter Infections/complications/epidemiology
MH  - Helicobacter pylori
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Socioeconomic Factors
MH  - Stomach Neoplasms/epidemiology/*prevention & control
MH  - Sweden/epidemiology
PMC - PMC2363844
EDAT- 2001/04/05 10:00
MHDA- 2001/05/22 10:01
CRDT- 2001/04/05 10:00
PHST- 2001/04/05 10:00 [pubmed]
PHST- 2001/05/22 10:01 [medline]
PHST- 2001/04/05 10:00 [entrez]
AID - S0007092001917021 [pii]
AID - 10.1054/bjoc.2001.1702 [doi]
PST - ppublish
SO  - Br J Cancer. 2001 Apr 6;84(7):965-8. doi: 10.1054/bjoc.2001.1702.

PMID- 413839
OWN - NLM
STAT- MEDLINE
DCOM- 19780329
LR  - 20211117
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 61
IP  - 2
DP  - 1978 Feb
TI  - Inhibition of platelet prostaglandin synthetase by oral aspirin.
PG  - 314-9
AB  - Aspirin inhibits platelet function by permanently acetylating the cyclooxygenase 
      that forms prostaglandins. We determined the sensitivity of platelets to aspirin 
      in normal subjects by measuring [3H-acetyl]aspirin-susceptible cyclooxygenase in 
      washed platelets obtained at various times after aspirin ingestion. A single 
      325-mg aspirin dose inactivated 89% of platelet cyclooxygenase. The inhibition 
      persisted for 2 days suggesting that oral aspirin also inactivated megakaryocyte 
      cyclooxygenase. Thereafter, active enzyme returned with a time-course reflecting 
      platelet turnover (life-span 8.2+/-2 days). Single doses of 20-650 mg aspirin 
      resulted in 34- greater than 95% inhibition after 24 h. Daily doses of 20-325 mg 
      aspirin for brief periods produced 61- greater than 95% inactivation when 
      measured 24 h after cessation of the drug. Platelet cyclooxygenase is more 
      sensitive to inactivation by aspirin than enzyme in sheep seminal vesicles.
FAU - Burch, J W
AU  - Burch JW
FAU - Stanford, N
AU  - Stanford N
FAU - Majerus, P W
AU  - Majerus PW
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Adult
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*enzymology
MH  - *Cyclooxygenase Inhibitors
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostaglandin-Endoperoxide Synthases/blood
MH  - Seminal Vesicles/enzymology
MH  - Sheep
PMC - PMC372541
EDAT- 1978/02/01 00:00
MHDA- 1978/02/01 00:01
CRDT- 1978/02/01 00:00
PHST- 1978/02/01 00:00 [pubmed]
PHST- 1978/02/01 00:01 [medline]
PHST- 1978/02/01 00:00 [entrez]
AID - 10.1172/JCI108941 [doi]
PST - ppublish
SO  - J Clin Invest. 1978 Feb;61(2):314-9. doi: 10.1172/JCI108941.

PMID- 1304143
OWN - NLM
STAT- MEDLINE
DCOM- 19930701
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 85
IP  - 11 Suppl
DP  - 1992 Nov
TI  - [Role of antithrombotic agents after myocardial infarction].
PG  - 1703-8
AB  - Thrombosis is the causal mechanism of myocardial infarction: severe 
      atherosclerotic narrowing, ulceration of the atherosclerotic plaque and 
      disequilibrium between pro and antithrombotic factors, predispose to this 
      complication. Recurrent myocardial infarction is a common complication in the 
      year following an initial event: the risk is higher when the diseased artery has 
      been recanalized in the acute phase. Reocclusion of the recanalized artery 
      without signs of infarction is also a common occurrence. It was therefore logical 
      to have striven over the years to prevent reinfarction and/or rethrombosis after 
      reperfusion. Mechanical methods have not been crowned with resounding success and 
      antithrombotic drugs are the only products associated with real benefits in this 
      prevention. In this article, the authors review the efficacy of aspirin and 
      vitamin K antagonists in the prevention of recurrent myocardial infarction; the 
      data in favour of an efficacy of aspirin in preventing early reinfarction is also 
      analysed; finally, results suggesting a benefit of platelet antiaggregant therapy 
      (Flurbiprofen or aspirin) on the risk of reocclusion after therapeutic 
      recanalisation are also assessed.
FAU - Castaigne, A
AU  - Castaigne A
AD  - Service de cardiologie, hôpital Henri-Mondor, Créteil.
FAU - Albo, C
AU  - Albo C
FAU - Verschuren, P
AU  - Verschuren P
FAU - Perchet, H
AU  - Perchet H
FAU - Pham, I
AU  - Pham I
FAU - Saal, J P
AU  - Saal JP
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - La place des antithrombotiques après un infarctus du myocarde.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - *Thrombolytic Therapy
MH  - Vitamin K/antagonists & inhibitors
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 1992 Nov;85(11 Suppl):1703-8.

PMID- 2688036
OWN - NLM
STAT- MEDLINE
DCOM- 19900122
LR  - 20190510
IS  - 0161-8105 (Print)
IS  - 0161-8105 (Linking)
VI  - 12
IP  - 6
DP  - 1989 Dec
TI  - Aspirin and nonfebrile waking oral temperature in healthy men and women: links 
      with SWS changes?
PG  - 516-21
AB  - Previous work from our laboratory has shown that aspirin leads to a significant 
      reduction in slow wave sleep (SWS). Recently, it has been hypothesized that this 
      might be linked to alterations in body temperature around sleep onset, and during 
      the preceding wakefulness. We report unpublished findings from an earlier aspirin 
      and sleep study that help to address this issue. Seventeen healthy subjects took 
      their oral temperature on an hourly basis throughout wakefulness, during 5 
      baseline days, 4 days on drug or placebo, and 3 recovery days. A dose of 600 mg 
      of aspirin three times a day led to a small but significant fall in oral 
      temperature in both men and women. The circadian temperature trends over the 
      waking day remained unaltered. The relevance of these findings to SWS changes was 
      discussed.
FAU - Horne, J A
AU  - Horne JA
AD  - Department of Human Sciences, Loughborough University, Leicestershire, England.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Sleep
JT  - Sleep
JID - 7809084
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Body Temperature Regulation/*drug effects
MH  - Circadian Rhythm/*drug effects
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Electroencephalography/*drug effects
MH  - Evoked Potentials/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Sleep Stages/*drug effects
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
AID - 10.1093/sleep/12.6.516 [doi]
PST - ppublish
SO  - Sleep. 1989 Dec;12(6):516-21. doi: 10.1093/sleep/12.6.516.

PMID- 925948
OWN - NLM
STAT- MEDLINE
DCOM- 19780127
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 66
IP  - 12
DP  - 1977 Dec
TI  - Precautionary note for use of bisulfite in pharmaceutical formulations.
PG  - 1775-6
AB  - The effect of sodium bisulfite on aspirin hydrolysis was studied at 40 degrees in 
      the pH range of 6.5-7.5. Significant catalytic activity by the sulfite ion was 
      observed. Second-order rate constants were calculated for this catalysis and 
      compared to other buffer species. The sulfite ion was a much more efficient 
      catalyst than acetate, phosphate, or carbonate.
FAU - Munson, J W
AU  - Munson JW
FAU - Hussain, A
AU  - Hussain A
FAU - Bilous, R
AU  - Bilous R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Antioxidants)
RN  - 0 (Sulfites)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Antioxidants
MH  - *Aspirin
MH  - Catalysis
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Hydrolysis
MH  - Kinetics
MH  - *Sulfites
EDAT- 1977/12/01 00:00
MHDA- 1977/12/01 00:01
CRDT- 1977/12/01 00:00
PHST- 1977/12/01 00:00 [pubmed]
PHST- 1977/12/01 00:01 [medline]
PHST- 1977/12/01 00:00 [entrez]
AID - S0022-3549(15)39731-8 [pii]
AID - 10.1002/jps.2600661234 [doi]
PST - ppublish
SO  - J Pharm Sci. 1977 Dec;66(12):1775-6. doi: 10.1002/jps.2600661234.

PMID- 28764836
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1866-0452 (Electronic)
IS  - 1866-0452 (Linking)
VI  - 114
IP  - 27-28
DP  - 2017 Jul 10
TI  - Aspirin Before Elective Surgery-Stop or Continue?
PG  - 473-480
LID - arztebl.2017.0473 [pii]
LID - 10.3238/arztebl.2017.0473 [doi]
AB  - BACKGROUND: Cessation of long-term aspirin treatment before noncardiac surgery 
      can cause adverse cardiac events in patients at risk, particularly in those with 
      previous percutaneous coronary interventions (PCI) with stent implantation. The 
      factors influencing the clinical decision to stop aspirin treatment are currently 
      unknown. METHODS: In a single-center, cross-sectional study (retrospective 
      registration: NCT03049566) carried out from February to December 2014, we took a 
      survey among patients scheduled for noncardiac surgery who were under long-term 
      aspirin treatment, and among their treating anesthesiologists using standardized 
      questionnaires on preoperative aspirin use, comorbidities, and risk-benefit 
      assessments. The main objective was to identify factors associated with the 
      decision to stop aspirin treatment. The results of multivariable logistic 
      regressions and intraclass correlations are presented. RESULTS: 805 patients were 
      included in the study, and 636 questionnaires were returned (203 of which 
      concerned patients with coronary stents). 46.8% of the patients stopped their 
      long-term aspirin treatment before surgery; 38.7% of these patients stopped it 
      too early (>10 days before surgery) or too late (≤ 3 days before surgery). A 
      prior PCI with stent implantation lowered the probability of aspirin cessation 
      (odds ratio [OR] = 0.47 [0.31; 0.72]; p <0.001). On the other hand, patients were 
      more likely to stop their long-term aspirin treatment if it had already been 
      discontinued once before (OR = 4.58 [3.06; 6.84]; p <0.001), if there was a risk 
      of bleeding into a closed space (OR = 4.54 [2.02; 10.22]; p <0.001), if they did 
      not know why they were supposed to take aspirin (OR = 2.12 [1.05; 4.28]; p = 
      0.036), or if the preoperative consultation with the anesthesiologist occurred <2 
      days before surgery (OR = 1.60 [1.08; 2.37]; p = 0.018). Patients often assessed 
      the risks related to aspirin cessation lower than their physicians did. 
      CONCLUSION: This study reveals discordance between guideline recommendations and 
      everyday clinical practice in patients with coronary stents. The early 
      integration of cardiologists and anesthesiologists and a more widespread use of 
      stent implant cards could promote adherence to the guidelines.
FAU - Plümer, Lili
AU  - Plümer L
AD  - Department of Anesthesiology, Center for Anesthesiology and Intensive Care 
      Medicine, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; 
      Department of General and Interventional Cardiology, University Heart Center 
      Hamburg (UHZ), Hamburg, Germany; Institute of Medical Biometry and Epidemiology, 
      University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
FAU - Seiffert, Moritz
AU  - Seiffert M
FAU - Punke, Mark Andree
AU  - Punke MA
FAU - Kersten, Jan Felix
AU  - Kersten JF
FAU - Blankenberg, Stefan
AU  - Blankenberg S
FAU - Zöllner, Christian
AU  - Zöllner C
FAU - Petzoldt, Martin
AU  - Petzoldt M
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Dtsch Arztebl Int
JT  - Deutsches Arzteblatt international
JID - 101475967
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Cross-Sectional Studies
MH  - *Elective Surgical Procedures
MH  - Humans
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Stents
MH  - Treatment Outcome
PMC - PMC5545631
EDAT- 2017/08/03 06:00
MHDA- 2018/12/12 06:00
CRDT- 2017/08/03 06:00
PHST- 2016/10/02 00:00 [received]
PHST- 2016/10/02 00:00 [revised]
PHST- 2017/04/13 00:00 [accepted]
PHST- 2017/08/03 06:00 [entrez]
PHST- 2017/08/03 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
AID - arztebl.2017.0473 [pii]
AID - 10.3238/arztebl.2017.0473 [doi]
PST - ppublish
SO  - Dtsch Arztebl Int. 2017 Jul 10;114(27-28):473-480. doi: 
      10.3238/arztebl.2017.0473.

PMID- 15236176
OWN - NLM
STAT- MEDLINE
DCOM- 20040928
LR  - 20190707
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 127
IP  - 1
DP  - 2004 Jul
TI  - The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and 
      prostaglandin metabolism in cyclooxygenase knockout mice.
PG  - 94-104
AB  - BACKGROUND & AIMS: Insight into the role of the different cyclooxygenase isoforms 
      in prostaglandin biosynthesis, surface hydrophobicity, and gastric mucosal 
      barrier integrity can be gained by comparing the effects of luminal damaging 
      agents in wild-type and cyclooxygenase knockout mice. METHODS: Fasted wild-type, 
      cyclooxygenase-1, and cyclooxygenase-2 knockout mice were intragastrically 
      administered saline, 0.6N HCl, or aspirin (aspirin 20 mmol/L) in combination with 
      0.6N HCl and killed 1 hour later, at which time the gastric lesion score was 
      assessed and biopsy samples were taken for surface, biochemical, and 
      morphological analyses. RESULTS: The gastric mucosa of cyclooxygenase-1 knockout 
      mice was more severely injured by both HCl alone and aspirin/HCl than that of 
      wild-type and cyclooxygenase-2 knockout mice. HCl alone and aspirin/HCl also 
      induced a more profound decrease in surface hydrophobicity in cyclooxygenase-1 
      knockout mice than in wild-type mice, whereas this surface property was 
      unaffected in cyclooxygenase-2 knockout mice. The gastric injury induced by 
      aspirin/HCl in cyclooxygenase-1 knockout mice could be prevented if the animals 
      were treated with phosphatidylcholine-associated aspirin. Aspirin/HCl, in 
      comparison to saline or HCl alone, induced a 4-6-fold increase in gastric mucosal 
      prostaglandin E(2) concentration in the cyclooxygenase-1 knockout mice, whereas 
      it decreased prostaglandin E(2) levels in wild-type and cyclooxygenase-2 knockout 
      mice. This paradoxical aspirin-induced increase in gastric prostaglandin E(2) in 
      cyclooxygenase-1 knockout mice seemed to correspond to an increase in 
      cyclooxygenase-2 messenger RNA and protein expression. The gastric lesion score 
      seemed to be significantly associated with alterations in surface hydrophobicity 
      but not with mucosal prostaglandin E(2) concentration. CONCLUSIONS: Our evidence 
      on cyclooxygenase knockout mice suggests that aspirin predominantly causes 
      gastric injury by a non-prostaglandin mechanism, perhaps by attenuating surface 
      hydrophobicity, a possibility supported by the low gastric toxicity of 
      phosphatidylcholine/aspirin. However, prostaglandins generated by 
      cyclooxygenase-1 may play an important permissive role in maintaining gastric 
      mucosal barrier integrity. Aspirin seems to paradoxically increase the gastric 
      mucosal prostaglandin E(2) concentration in cyclooxygenase-1 knockout mice, 
      possibly by the induction of cyclooxygenase-2.
FAU - Darling, Rebecca L
AU  - Darling RL
AD  - Department of Integrative Biology & Pharmacology, The University of Texas Medical 
      School, Houston, Texas 77030, USA.
FAU - Romero, Jimmy J
AU  - Romero JJ
FAU - Dial, Elizabeth J
AU  - Dial EJ
FAU - Akunda, Jacqueline K
AU  - Akunda JK
FAU - Langenbach, Robert
AU  - Langenbach R
FAU - Lichtenberger, Lenard M
AU  - Lichtenberger LM
LA  - eng
GR  - DK 53195/DK/NIDDK NIH HHS/United States
GR  - P30 DK56338/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Phosphatidylcholines)
RN  - 0 (Prostaglandins)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 2004 Jul;127(1):341-3. PMID: 15236206
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Cyclooxygenase Inhibitors/adverse effects/pharmacology
MH  - Gastric Mucosa/*drug effects
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Mice
MH  - Mice, Knockout
MH  - Models, Animal
MH  - Peptic Ulcer/chemically induced
MH  - Phosphatidylcholines/pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Prostaglandins/metabolism
EDAT- 2004/07/06 05:00
MHDA- 2004/09/29 05:00
CRDT- 2004/07/06 05:00
PHST- 2004/07/06 05:00 [pubmed]
PHST- 2004/09/29 05:00 [medline]
PHST- 2004/07/06 05:00 [entrez]
AID - S0016508504006080 [pii]
AID - 10.1053/j.gastro.2004.04.003 [doi]
PST - ppublish
SO  - Gastroenterology. 2004 Jul;127(1):94-104. doi: 10.1053/j.gastro.2004.04.003.

PMID- 26111687
OWN - NLM
STAT- MEDLINE
DCOM- 20150925
LR  - 20190318
IS  - 1673-4254 (Print)
IS  - 1673-4254 (Linking)
VI  - 35
IP  - 6
DP  - 2015 Jun
TI  - [Early intervention with aspirin for preventing preeclampsia in high-risk women: 
      a meta-analysis].
PG  - 868-73
AB  - OBJECTIVE: To estimate the effect of early intervention with aspirin for 
      prevention of preeclampsia in high-risk women. METHODS: A systematic review and 
      meta-analysis were performed based on the principles and methods of Cochrane 
      systematic reviews. Electronic databases were searched for randomized trials 
      comparing aspirin with either placebo or no aspirin. Studies were included when 
      meeting the inclusion criteria that the participants were pregnant women at a 
      high risk of preeclampsia and started aspirin therapy at 16 gestational weeks or 
      earlier, which were assessed by two independent reviewers. Meta-analysis was 
      conducted using Review Manger 5.3 software. RESULTS: A total of 5 studies 
      involving 860 participants were included in the final analysis. In the high-risk 
      women, early use of aspirin showed an OR of 0.35 (95% CI 0.17-0.75) for 
      preventing pregnancy-induced hypertension (PIH), 0.75 (95% CI 0.47-0.98) for 
      preeclampsia, 0.53 (95% CI 0.29-0.98) for intrauterine growth retardation, and 
      0.20 (95% CI 0.08-0.48) for preterm birth; the average birth weight in aspirin 
      intervention group was 107.15 g (95% CI 76.13-138.18, P<0.001) more than that in 
      the control group. CONCLUSION: In high-risk pregnancies, early aspirin 
      intervention starting before 16 weeks of gestation can prevent PIH, preeclampsia, 
      IUGR, and preterm birth and help to increase the birth weight.
FAU - Yao, Shuo
AU  - Yao S
AD  - Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical 
      University, Guangzhou 510515, China. E-mail: yaoshuo.227@gmail.com.
FAU - Wu, Huan
AU  - Wu H
FAU - Yu, Yanhong
AU  - Yu Y
LA  - chi
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - China
TA  - Nan Fang Yi Ke Da Xue Xue Bao
JT  - Nan fang yi ke da xue xue bao = Journal of Southern Medical University
JID - 101266132
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Birth Weight
MH  - Female
MH  - Fetal Growth Retardation/prevention & control
MH  - Humans
MH  - Infant, Newborn
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Premature Birth/prevention & control
MH  - Randomized Controlled Trials as Topic
EDAT- 2015/06/27 06:00
MHDA- 2015/09/26 06:00
CRDT- 2015/06/27 06:00
PHST- 2015/06/27 06:00 [entrez]
PHST- 2015/06/27 06:00 [pubmed]
PHST- 2015/09/26 06:00 [medline]
PST - ppublish
SO  - Nan Fang Yi Ke Da Xue Xue Bao. 2015 Jun;35(6):868-73.

PMID- 6813877
OWN - NLM
STAT- MEDLINE
DCOM- 19821221
LR  - 20191031
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 9
IP  - 1
DP  - 1982 Jul
TI  - Serum levels of free fatty acids in the first trimester of pregnancy: effect of 
      acetylsalicylic acid.
PG  - 61-9
AB  - The serum levels of free fatty acids were determined before and after an oral 
      dose of 1000 mg acetylsalicylic acid (ASA) during the 7-11th weeks of pregnancy 
      in 11 women admitted to hospital for legal abortion and in 8 women admitted for 
      operative (hysterectomy) treatment because of fibroids. Thirteen healthy women of 
      reproductive age served as controls. The levels of linoleic, alpha-linolenic, 
      myristic, oleic, palmitic and palmitoleic acids were significantly lower in 
      pregnant women than in the hysterectomy group. The level of arachidonic acid was 
      higher in the pregnant and hysterectomy groups than in controls. Serum free fatty 
      acids had a negative correlation with the duration of pregnancy. ASA treatment 
      tended to increase the levels of many fatty acids in serum. Serum arachidonic 
      acid levels after ASA treatment correlated significantly with the salicylate 
      concentrations in myometrium and the levels of most other fatty acids with the 
      salicylate concentration in endometrium.
FAU - Haataja, M
AU  - Haataja M
FAU - Grönroos, M
AU  - Grönroos M
FAU - Honkonen, E
AU  - Honkonen E
FAU - Paul, R
AU  - Paul R
FAU - Nieminen, A L
AU  - Nieminen AL
FAU - Anttila, M
AU  - Anttila M
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Arachidonic Acids)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid
MH  - Arachidonic Acids/blood
MH  - Aspirin/*pharmacology
MH  - Fatty Acids, Nonesterified/*blood
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Pregnancy/drug effects
MH  - Pregnancy Trimester, First
EDAT- 1982/07/01 00:00
MHDA- 1982/07/01 00:01
CRDT- 1982/07/01 00:00
PHST- 1982/07/01 00:00 [pubmed]
PHST- 1982/07/01 00:01 [medline]
PHST- 1982/07/01 00:00 [entrez]
AID - 10.1016/0262-1746(82)90073-7 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1982 Jul;9(1):61-9. doi: 10.1016/0262-1746(82)90073-7.

PMID- 15028965
OWN - NLM
STAT- MEDLINE
DCOM- 20040427
LR  - 20220318
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 83
IP  - 2
DP  - 2004 Mar
TI  - Risk factors for cranial ischemic complications in giant cell arteritis.
PG  - 114-122
LID - 10.1097/01.md.0000119761.27564.c9 [doi]
AB  - Cranial ischemic complications (CICs) are among the presenting manifestations of 
      giant cell arteritis (GCA). Yet patients with GCA may develop CICs at a later 
      stage, despite steroid therapy. In the current report we delineate risk factors 
      for CICs, both at presentation and during follow-up, and review the relevant 
      literature. We reviewed charts of 175 patients with GCA. Follow-up data were 
      available for 166 patients. CICs at presentation or developing within 2 weeks of 
      GCA diagnosis were considered GCA related. CICs developing later were considered 
      GCA related only when associated with other GCA-related manifestations or 
      acute-phase reactions. Associations between CICs and other variables were tested 
      by multivariate analysis. At presentation, 43 patients (24.6%) had CICs. Risk 
      factors were transient cerebro-ophthalmic ischemic episodes (COIEs) (odds ratio 
      [OR] 4.3) and male sex (OR 2.5), while the presence of systemic symptoms was 
      "protective" (OR 0.3). During follow-up 8.4% of patients with GCA developed new 
      CICs. Risk factors in these cases were previous CICs at presentation (OR 5.6) and 
      transient COIEs developing during follow-up (OR 14.8). The use of low-dose 
      aspirin was protective (OR 0.2). These data, together with data from the 
      literature review, suggest that GCA patients with transient COIEs and without 
      fever or other systemic symptoms are at increased risk of presenting with CICs. 
      Risk factors for late-developing CICs were CICs at presentation and 
      late-developing transient COIEs.
FAU - Nesher, Gideon
AU  - Nesher G
AD  - From Shaare-Zedek Medical Center (GN, MM, MS), Jerusalem; Bikur-Cholim Hospital 
      (YB), Jerusalem; School of Public Health, Hadassah Medical Center (MB), 
      Jerusalem; Hadassah-Hebrew University Medical School (AR), Jerusalem; and Sapir 
      Medical Center (RN), Kfar-Saba, Israel.
FAU - Berkun, Yaakov
AU  - Berkun Y
FAU - Mates, Michal
AU  - Mates M
FAU - Baras, Mario
AU  - Baras M
FAU - Nesher, Ronit
AU  - Nesher R
FAU - Rubinow, Alan
AU  - Rubinow A
FAU - Sonnenblick, Moshe
AU  - Sonnenblick M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Brain Ischemia/*etiology
MH  - Female
MH  - Giant Cell Arteritis/*complications
MH  - Humans
MH  - Ischemic Attack, Transient/*complications/etiology
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Retrospective Studies
MH  - Risk Factors
RF  - 29
EDAT- 2004/03/19 05:00
MHDA- 2004/04/28 05:00
CRDT- 2004/03/19 05:00
PHST- 2004/03/19 05:00 [pubmed]
PHST- 2004/04/28 05:00 [medline]
PHST- 2004/03/19 05:00 [entrez]
AID - 00005792-200403000-00004 [pii]
AID - 10.1097/01.md.0000119761.27564.c9 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2004 Mar;83(2):114-122. doi: 
      10.1097/01.md.0000119761.27564.c9.

PMID- 1725363
OWN - NLM
STAT- MEDLINE
DCOM- 19920512
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 17 Suppl 7
DP  - 1991
TI  - Differential effects of endothelin-1 and big endothelin on canine kidneys.
PG  - S302-4
AB  - Renal effects of endothelin-1 (ET-1, human, 1-21) and the equivalent molar 
      concentration of big ET (human, 1-38) and the contributions of prostaglandins and 
      endothelium-derived relaxing factor to these actions were examined. Intrarenal 
      infusion of ET-1, at a dose of 0.4 pmol/kg/min, decreased renal blood flow (RBF), 
      glomerular filtration rate (GFR), and urine output (V) to 62, 70, and 45% of 
      control values, respectively. Additional aspirin-DL-lysine (ASP) treatment (25 
      mg/kg) caused marked decreases in RBF, GFR, and V to 20, 14, and 9% of control 
      values, respectively. During ET-1 infusion, intrarenal infusion of 
      NG-monomethyl-L-arginine (L-NMMA, 1 mumol/min) caused decreases in RBF, GFR, and 
      V. In another group, intrarenal infusion of big ET at a dose equivalent to that 
      of ET-1 did not significantly affect RBF, GFR, or urine output, which were 95, 
      107, and 84% of control values, respectively. Additional ASP treatment decreased 
      these values to 78, 69, and 52% of control values, respectively. L-NMMA infusion 
      during big ET infusion showed little effect on renal function. Our study 
      demonstrated that intrarenal infusion of ET-1, at a dose of 0.4 pmol/kg/min, 
      caused significant hemodynamic and functional changes in the canine kidney 
      compared with an equivalent molar concentration of big ET.
FAU - Akabane, S
AU  - Akabane S
AD  - Research Institute, National Cardiovascular Center, Suita, Japan.
FAU - Yoshimi, H
AU  - Yoshimi H
FAU - Yoshida, K
AU  - Yoshida K
FAU - Kawano, Y
AU  - Kawano Y
FAU - Ashida, T
AU  - Ashida T
FAU - Kinoshita, O
AU  - Kinoshita O
FAU - Matsushima, Y
AU  - Matsushima Y
FAU - Kawamura, M
AU  - Kawamura M
FAU - Imanishi, M
AU  - Imanishi M
FAU - Kuramochi, M
AU  - Kuramochi M
AU  - et al.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Endothelin-1)
RN  - 0 (Endothelins)
RN  - 0 (Prostaglandins)
RN  - 0 (Protein Precursors)
RN  - 27JT06E6GR (omega-N-Methylarginine)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 94ZLA3W45F (Arginine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Arginine/analogs & derivatives/pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Dogs
MH  - Endothelin-1
MH  - Endothelins/administration & dosage/*pharmacology
MH  - Female
MH  - Infusions, Intra-Arterial
MH  - Kidney/*drug effects
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Male
MH  - Nitric Oxide/physiology
MH  - Prostaglandins/physiology
MH  - Protein Precursors/administration & dosage/*pharmacology
MH  - Renal Circulation/drug effects
MH  - omega-N-Methylarginine
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1097/00005344-199100177-00086 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1991;17 Suppl 7:S302-4. doi: 
      10.1097/00005344-199100177-00086.

PMID- 15996602
OWN - NLM
STAT- MEDLINE
DCOM- 20050906
LR  - 20131121
IS  - 1078-5884 (Print)
IS  - 1078-5884 (Linking)
VI  - 30
IP  - 2
DP  - 2005 Aug
TI  - Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: 
      therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) 
      Study.
PG  - 154-9
AB  - OBJECTIVES: The beneficial effect of oral anticoagulants after infrainguinal 
      venous bypass surgery is compromised by bleeding complications. We developed a 
      model to identify patients, treated with anticoagulation, at risk of major 
      haemorrhage and estimated whether this complication could have been prevented if 
      patients had received aspirin. DESIGN: Randomised clinical trial. METHODS: Data 
      of patients who participated in the Dutch Bypass Oral Anticoagulation or Aspirin 
      Study were reanalysed using Cox regression. After infrainguinal bypass surgery 
      these patients were randomised to oral anticoagulants (n = 1326) or aspirin (n = 
      1324). RESULTS: Predictors of major haemorrhage for patients on oral 
      anticoagulants were increased systolic blood pressure (> or = 140 mmHg, hazard 
      ratio [HR] 1.62), age > or = 75 years (HR 2.77) and diabetes mellitus (HR 1.60). 
      If the 345 patients in the highest risk quartile had received aspirin, major 
      haemorrhages would have been reduced from 46 to 22, with no major changes in 
      ischemic events and graft occlusions. In the subgroup with venous bypasses major 
      haemorrhages would have been reduced from 27 to 13, at the cost of seven more 
      ischemic events (mostly fatal) and 17 more graft occlusions. CONCLUSIONS: 
      Treating patients at highest risk of major haemorrhage with aspirin instead of 
      oral anticoagulants would have resulted in a reduction of non-fatal haemorrhages, 
      but for venous bypasses this reduction was outweighed by an increase in ischemic 
      events and graft occlusions. We still recommend treatment with oral 
      anticoagulants after peripheral venous bypass surgery.
FAU - Ariesen, M J
AU  - Ariesen MJ
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center 
      Utrecht, Utrecht, The Netherlands.
FAU - Tangelder, M J D
AU  - Tangelder MJ
FAU - Lawson, J A
AU  - Lawson JA
FAU - Eikelboom, B C
AU  - Eikelboom BC
FAU - Grobbee, D E
AU  - Grobbee DE
FAU - Algra, A
AU  - Algra A
CN  - Dutch Bypass Oral Anticoagulants or Aspirin Study Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20050425
PL  - England
TA  - Eur J Vasc Endovasc Surg
JT  - European journal of vascular and endovascular surgery : the official journal of 
      the European Society for Vascular Surgery
JID - 9512728
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Arteriosclerosis/*surgery
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Graft Occlusion, Vascular/etiology/prevention & control
MH  - Humans
MH  - Inguinal Canal/*blood supply
MH  - Ischemia/etiology/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Postoperative Hemorrhage/*etiology/prevention & control
MH  - Proportional Hazards Models
MH  - Risk Assessment
MH  - Vascular Surgical Procedures/*adverse effects
EDAT- 2005/07/06 09:00
MHDA- 2005/09/07 09:00
CRDT- 2005/07/06 09:00
PHST- 2004/12/13 00:00 [received]
PHST- 2005/03/02 00:00 [accepted]
PHST- 2005/07/06 09:00 [pubmed]
PHST- 2005/09/07 09:00 [medline]
PHST- 2005/07/06 09:00 [entrez]
AID - S1078-5884(05)00150-4 [pii]
AID - 10.1016/j.ejvs.2005.03.005 [doi]
PST - ppublish
SO  - Eur J Vasc Endovasc Surg. 2005 Aug;30(2):154-9. doi: 10.1016/j.ejvs.2005.03.005. 
      Epub 2005 Apr 25.

PMID- 10344046
OWN - NLM
STAT- MEDLINE
DCOM- 19990611
LR  - 20131121
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 53
IP  - 2
DP  - 1999 Mar
TI  - Atrial fibrillation, thromboembolism and antithrombotic therapy.
PG  - 110-7
AB  - Atrial fibrillation is the commonest sustained disorder of cardiac rhythm and is 
      associated with increased risk of stroke and thromboembolic events. Warfarin 
      (dose-adjusted to a target INR of 2.0-3.0) has been well established to reduce 
      this risk of stroke by 68% (95% CI 50-79%), while aspirin provides a risk 
      reduction of 21% (95% CI 0-38%). Nevertheless, warfarin confers a risk of 
      bleeding and the inconvenience of regular monitoring checks, while aspirin seems 
      effective only for certain low-risk subgroups. Thus there have been strenuous 
      efforts to improve thromboprophylaxis in atrial fibrillation, by using 
      low-intensity anticoagulation regimens, combination antiplatelet therapy and 
      refinement of risk stratification strategies. Attempts at using a low-intensity, 
      fixed-dose warfarin regimen have, however, been disappointing. For now, a 
      strategy of risk stratification should be adopted to identify highest risk 
      patients with atrial fibrillation who would benefit from anticoagulation.
FAU - Li-Saw-Hee, F L
AU  - Li-Saw-Hee FL
AD  - University Department of Medicine, City Hospital, Birmingham, UK.
FAU - Lip, G Y
AU  - Lip GY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/complications
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Humans
MH  - Middle Aged
MH  - Thromboembolism/etiology
MH  - Warfarin/*therapeutic use
RF  - 86
EDAT- 1999/05/27 00:00
MHDA- 1999/05/27 00:01
CRDT- 1999/05/27 00:00
PHST- 1999/05/27 00:00 [pubmed]
PHST- 1999/05/27 00:01 [medline]
PHST- 1999/05/27 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pract. 1999 Mar;53(2):110-7.

PMID- 3552581
OWN - NLM
STAT- MEDLINE
DCOM- 19870619
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 32 Suppl 4
DP  - 1986
TI  - Analgesics, allergy and asthma.
PG  - 148-63
AB  - Intolerance to analgesics is common in patients with bronchial asthma, nasal 
      polyps and urticaria. Symptoms of intolerance resemble those of allergy, but the 
      events precipitating them can rarely be traced to reactions between the drug and 
      a specific antibody or sensitised T-lymphocytes. In 8 to 20% of adult asthmatics, 
      aspirin and several other analgesics provoke asthmatic attacks, probably through 
      inhibition of cyclo-oxygenase. This is a distinct and important clinical syndrome 
      with a specific history, course and clinical presentation and a number of unique 
      peculiarities which still require elucidation at the biochemical level. Up to 40% 
      of patients with chronic urticaria develop an obvious increase in weals and 
      swelling after taking aspirin. These reactions occur only when urticaria is 
      active, and though the reason for them is not known, it appears that different 
      mechanisms may be responsible in different patients. Skin reactions other than 
      exacerbation of chronic urticaria are less common, but may create serious 
      clinical problems. The clinical background of a patient often determines the type 
      of adverse response to an analgesic. Thus, in certain individuals, analgesics can 
      produce anaphylactic reactions and/or urticaria, probably through an 
      immunological mechanism, while in some asthmatics they precipitate 
      bronchoconstriction, probably through inhibition of bronchial cyclooxygenase. 
      Study of untoward reactions to analgesics not only leads to safer 
      pharmacotherapy, but it also offers a fascinating model for better understanding 
      of some diseases.
FAU - Szczeklik, A
AU  - Szczeklik A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Analgesics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/*adverse effects
MH  - Anaphylaxis/chemically induced
MH  - Aspirin/adverse effects
MH  - Asthma/*chemically induced
MH  - *Drug Hypersensitivity
MH  - Humans
RF  - 135
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.2165/00003495-198600324-00011 [doi]
PST - ppublish
SO  - Drugs. 1986;32 Suppl 4:148-63. doi: 10.2165/00003495-198600324-00011.

PMID- 23480527
OWN - NLM
STAT- MEDLINE
DCOM- 20151015
LR  - 20130410
IS  - 1944-8252 (Electronic)
IS  - 1944-8244 (Linking)
VI  - 5
IP  - 7
DP  - 2013 Apr 10
TI  - A supra-monolayer nanopattern for organic nanoparticle array deposition.
PG  - 2699-707
LID - 10.1021/am400181w [doi]
AB  - Nanopatterns have applications in many areas including sensors, optoelectronics, 
      and crystallization screening. Particle lithography is a convenient method to 
      manufacture nanoring nanopatterns based on organosilane surface chemistry. The 
      pattern thickness is generally limited to the monolayer thickness. This work is 
      focused on the chemical vapor deposition conditions that yield nanopatterns with 
      multilayer thickness. The supra-monolayer n-octadecyltrichlorosilane (OTS) 
      nanoring patterns are made using polystyrene particle lithography. The 
      supra-monolayer nanopatterns are used as "nano-flasks" to deposit and nucleate 
      nanoparticles of small organic molecules including n-docosane, aspirin, and 
      clarithromycin. The supra-monolayer OTS nanopattern is an effective template for 
      nanoparticle array deposition of all three chemicals with high degree of fidelity 
      to the substrate pattern. The nanoparticle size is varied by solution 
      concentration. The preferential deposition of the organic molecules inside the 
      nanoring is attributed to the dewetting of the liquid film on the nanopattern. 
      The dewetting process effectively distributes the liquid film among the 
      "nano-flasks" so that millions of solution experiments can be carried out in 
      isolated droplets with droplet volume as small as 1×10(-10) nL. The research 
      demonstrates a method to manufacture "nano-flask" arrays for high-throughput 
      nanoparticle deposition trials and manufacture of monodisperse organic/drug 
      nanoparticles through self-assembly.
FAU - Wang, Sunxi
AU  - Wang S
AD  - Department of Chemical Engineering and Materials Science, Wayne State University, 
      5050 Anthony Wayne Drive, Detroit, Michigan 48202, United States.
FAU - Sobczynski, Daniel J
AU  - Sobczynski DJ
FAU - Jahanian, Pedram
AU  - Jahanian P
FAU - Xhahysa, Juxhin
AU  - Xhahysa J
FAU - Mao, Guangzhao
AU  - Mao G
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130325
PL  - United States
TA  - ACS Appl Mater Interfaces
JT  - ACS applied materials & interfaces
JID - 101504991
RN  - 0 (Alkanes)
RN  - 0 (Polystyrenes)
RN  - 0 (Silanes)
RN  - 112-04-9 (octadecyltrichlorosilane)
RN  - H1250JIK0A (Clarithromycin)
RN  - OW99Q363KO (docosane)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alkanes/chemistry
MH  - Aspirin/chemistry
MH  - Clarithromycin/chemistry
MH  - Crystallization
MH  - Microscopy, Atomic Force
MH  - Nanoparticles/*chemistry
MH  - Particle Size
MH  - Polystyrenes/chemistry
MH  - Silanes/*chemistry
MH  - Surface Properties
MH  - Temperature
EDAT- 2013/03/14 06:00
MHDA- 2015/10/16 06:00
CRDT- 2013/03/14 06:00
PHST- 2013/03/14 06:00 [entrez]
PHST- 2013/03/14 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - 10.1021/am400181w [doi]
PST - ppublish
SO  - ACS Appl Mater Interfaces. 2013 Apr 10;5(7):2699-707. doi: 10.1021/am400181w. 
      Epub 2013 Mar 25.

PMID- 1940930
OWN - NLM
STAT- MEDLINE
DCOM- 19911217
LR  - 20220409
IS  - 0883-5403 (Print)
IS  - 0883-5403 (Linking)
VI  - 6
IP  - 3
DP  - 1991 Sep
TI  - Effects of hypotensive anesthesia, nonsteroidal antiinflammatory drugs, and 
      polymethylmethacrylate on bleeding in total hip arthroplasty patients.
PG  - 245-50
AB  - One hundred forty patients ranging in age from 26 to 88 years, who had primary 
      total hip arthroplasty (performed by the same surgeon and lateral surgical 
      approach), were analyzed for intraoperative and postoperative blood loss. The 
      factors affecting blood loss, which include bleeding disorders, medications, 
      duration of surgery, the mean intraoperative blood pressure, and use of cement, 
      were all recorded. A significant reduction in the intraoperative blood loss was 
      observed in the group of patients with hypotensive anesthesia (greater than 20 
      mmHg drop in the mean intraoperative blood pressure using inhalation anesthetics) 
      compared to the group of patients who did not have hypotensive anesthesia. The 
      patients who had been on aspirin or nonsteroidal antiinflammatory drugs prior to 
      surgery had increased intraoperative and postoperative blood loss compared to the 
      patients who did not take such medications. The effect of cementing with 
      methylmethacrylate on bleeding was also observed; the patients with uncemented 
      implants had a greater blood loss after operation than the patients who had 
      cemented prosthetic components.
FAU - An, H S
AU  - An HS
AD  - Department of Orthopaedic Surgery, Medical College of Wisconsin, Milwaukee 53226.
FAU - Mikhail, W E
AU  - Mikhail WE
FAU - Jackson, W T
AU  - Jackson WT
FAU - Tolin, B
AU  - Tolin B
FAU - Dodd, G A
AU  - Dodd GA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Methylmethacrylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Blood Loss, Surgical/*prevention & control
MH  - *Hip Prosthesis
MH  - Humans
MH  - *Hypotension, Controlled
MH  - *Methylmethacrylates
MH  - Middle Aged
MH  - Preoperative Care
MH  - Risk Factors
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
AID - 10.1016/s0883-5403(06)80171-3 [doi]
PST - ppublish
SO  - J Arthroplasty. 1991 Sep;6(3):245-50. doi: 10.1016/s0883-5403(06)80171-3.

PMID- 19931787
OWN - NLM
STAT- MEDLINE
DCOM- 20100106
LR  - 20131121
IS  - 1532-8171 (Electronic)
IS  - 0735-6757 (Linking)
VI  - 27
IP  - 9
DP  - 2009 Nov
TI  - Delayed salicylate toxicity with undetectable initial levels after large-dose 
      aspirin ingestion.
PG  - 1173.e1-3
LID - 10.1016/j.ajem.2009.01.013 [doi]
AB  - Aspirin (acetylsalicylic acid), the most commonly used medicinal salicylate, is 
      an antiinflammatory, antipyretic, antirheumatic, and analgesic agent. In 2005, 
      according to the Toxic Exposures Survey from the American Association of Poison 
      Control Centers' National Poisoning and Exposure Database, there were more than 
      20,000 reported aspirin and nonaspirin salicylate exposures, 64% of which 
      required treatment in a health care facility. Of these exposures, 50% were 
      reported as intentional overdoses and 60 patients died.
FAU - Herres, Joseph
AU  - Herres J
AD  - Philadelphia College of Osteopathic Medicine, Philadelphia, PA 19131, USA.
FAU - Ryan, Danielle
AU  - Ryan D
FAU - Salzman, Matthew
AU  - Salzman M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Emerg Med
JT  - The American journal of emergency medicine
JID - 8309942
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Emerg Med. 2010 Mar;28(3):383-4. PMID: 20223401
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics/*poisoning
MH  - Aspirin/*pharmacokinetics/*poisoning
MH  - Drug Overdose/blood/diagnosis/therapy
MH  - Humans
MH  - Male
MH  - Metabolic Clearance Rate
MH  - Middle Aged
MH  - Suicide, Attempted
EDAT- 2009/11/26 06:00
MHDA- 2010/01/07 06:00
CRDT- 2009/11/26 06:00
PHST- 2009/01/08 00:00 [received]
PHST- 2009/01/09 00:00 [accepted]
PHST- 2009/11/26 06:00 [entrez]
PHST- 2009/11/26 06:00 [pubmed]
PHST- 2010/01/07 06:00 [medline]
AID - S0735-6757(09)00033-3 [pii]
AID - 10.1016/j.ajem.2009.01.013 [doi]
PST - ppublish
SO  - Am J Emerg Med. 2009 Nov;27(9):1173.e1-3. doi: 10.1016/j.ajem.2009.01.013.

PMID- 37073647
OWN - NLM
STAT- MEDLINE
DCOM- 20230516
LR  - 20230516
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 21
IP  - 5
DP  - 2023 May
TI  - Antiplatelet therapy for coronary artery disease in 2023: current status and 
      future prospects.
PG  - 311-328
LID - 10.1080/14779072.2023.2201437 [doi]
AB  - INTRODUCTION: Antiplatelet therapy is the cornerstone for prevention and 
      management of ischemic complications among patients with coronary artery disease. 
      Over the past decades, advancement in stent technologies and increasing awareness 
      about the prognostic impact of major bleeding have led to evolving priorities in 
      the management of antithrombotic regimens, from exclusive concerns regarding 
      recurrent ischemic events to an individualized equipoise between ischemic and 
      bleeding risk through a patient-centered comprehensive approach. AREAS COVERED: 
      The purpose of this review is to highlight the current evidence that supports the 
      various management strategies for antiplatelet therapy and discuss future 
      directions of pharmacological regimens for coronary syndromes. We will also 
      discuss the rationale behind use of antiplatelet therapy, current guideline 
      recommendations, risk scores for ischemic and bleeding risk evaluation, and tools 
      to help assess treatment response. EXPERT OPINION: While tremendous advancements 
      have been made in antithrombotic agents and regimens, future directions for 
      antiplatelet therapy in patients with coronary artery disease would involve focus 
      on novel therapeutic targets, development of new antiplatelet agents, 
      implementation of more innovative regimens with current agents and further 
      research to validate contemporary antiplatelet strategies.
FAU - Chandiramani, Rishi
AU  - Chandiramani R
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
AD  - Department of Internal Medicine, Jacobi Medical Center/Albert Einstein College of 
      Medicine, Bronx, NY, USA.
FAU - Spirito, Alessandro
AU  - Spirito A
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Johnson, James W
AU  - Johnson JW
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Mehta, Adhya
AU  - Mehta A
AD  - Department of Internal Medicine, Jacobi Medical Center/Albert Einstein College of 
      Medicine, Bronx, NY, USA.
FAU - Vogel, Birgit
AU  - Vogel B
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Faillace, Robert T
AU  - Faillace RT
AD  - Department of Internal Medicine, Jacobi Medical Center/Albert Einstein College of 
      Medicine, Bronx, NY, USA.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230419
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Humans
MH  - Platelet Aggregation Inhibitors
MH  - *Coronary Artery Disease/therapy
MH  - Aspirin/therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - Hemorrhage/chemically induced/prevention & control
MH  - Drug Therapy, Combination
MH  - *Percutaneous Coronary Intervention/adverse effects
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - P2Y12 inhibitor
OT  - aspirin
OT  - bleeding
OT  - dual antiplatelet therapy
OT  - oral anticoagulation
OT  - pharmacology
OT  - thrombosis
EDAT- 2023/04/19 06:41
MHDA- 2023/05/16 06:42
CRDT- 2023/04/19 04:22
PHST- 2023/05/16 06:42 [medline]
PHST- 2023/04/19 06:41 [pubmed]
PHST- 2023/04/19 04:22 [entrez]
AID - 10.1080/14779072.2023.2201437 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2023 May;21(5):311-328. doi: 
      10.1080/14779072.2023.2201437. Epub 2023 Apr 19.

PMID- 24904018
OWN - NLM
STAT- MEDLINE
DCOM- 20150224
LR  - 20220408
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 3
IP  - 3
DP  - 2014 Jun 5
TI  - Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute 
      transient ischemic attack and minor stroke.
PG  - e000912
LID - 10.1161/JAHA.114.000912 [doi]
LID - e000912
AB  - BACKGROUND: Treatment with the combination of clopidogrel and aspirin taken soon 
      after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 
      90-day risk of stroke in a large trial in China, but the cost-effectiveness is 
      unknown. This study sought to estimate the cost-effectiveness of the 
      clopidogrel-aspirin regimen for acute TIA or minor stroke. METHODS AND RESULTS: A 
      Markov model was created to determine the cost-effectiveness of treatment of 
      acute TIA or minor stroke patients with clopidogrel-aspirin compared with aspirin 
      alone. Inputs for the model were obtained from clinical trial data, claims 
      databases, and the published literature. The main outcome measure was cost per 
      quality-adjusted life-years (QALYs) gained. One-way and multivariable 
      probabilistic sensitivity analyses were performed to test the robustness of the 
      findings. Compared with aspirin alone, clopidogrel-aspirin resulted in a lifetime 
      gain of 0.037 QALYs at an additional cost of CNY 1250 (US$ 192), yielding an 
      incremental cost-effectiveness ratio of CNY 33 800 (US$ 5200) per QALY gained. 
      Probabilistic sensitivity analysis showed that clopidogrel-aspirin therapy was 
      more cost-effective in 95.7% of the simulations at a willingness-to-pay threshold 
      recommended by the World Health Organization of CNY 105 000 (US$ 16 200) per 
      QALY. CONCLUSIONS: Early 90-day clopidogrel-aspirin regimen for acute TIA or 
      minor stroke is highly cost-effective in China. Although clopidogrel is generic, 
      Plavix is brand in China. If Plavix were generic, treatment with 
      clopidogrel-aspirin would have been cost saving.
CI  - © 2014 The Authors. Published on behalf of the American Heart Association, Inc., 
      by Wiley Blackwell.
FAU - Pan, Yuesong
AU  - Pan Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (Y.P., A.W., G.L., X.Z., X.M., L.L., C.W., Y.W., Y.W.).
FAU - Wang, Anxin
AU  - Wang A
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (Y.P., A.W., G.L., X.Z., X.M., L.L., C.W., Y.W., Y.W.).
FAU - Liu, Gaifen
AU  - Liu G
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (Y.P., A.W., G.L., X.Z., X.M., L.L., C.W., Y.W., Y.W.).
FAU - Zhao, Xingquan
AU  - Zhao X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (Y.P., A.W., G.L., X.Z., X.M., L.L., C.W., Y.W., Y.W.).
FAU - Meng, Xia
AU  - Meng X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (Y.P., A.W., G.L., X.Z., X.M., L.L., C.W., Y.W., Y.W.).
FAU - Zhao, Kun
AU  - Zhao K
AD  - China National Health Development Research Center, Beijing, China (K.Z.).
FAU - Liu, Liping
AU  - Liu L
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (Y.P., A.W., G.L., X.Z., X.M., L.L., C.W., Y.W., Y.W.).
FAU - Wang, Chunxue
AU  - Wang C
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (Y.P., A.W., G.L., X.Z., X.M., L.L., C.W., Y.W., Y.W.).
FAU - Johnston, S Claiborne
AU  - Johnston SC
AD  - Departments of Neurology and Epidemiology, University of California, San 
      Francisco, CA (C.J.).
FAU - Wang, Yilong
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (Y.P., A.W., G.L., X.Z., X.M., L.L., C.W., Y.W., Y.W.).
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China (Y.P., A.W., G.L., X.Z., X.M., L.L., C.W., Y.W., Y.W.).
CN  - CHANCE Investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140605
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/economics/*therapeutic use
MH  - China
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Drug Costs
MH  - Drug Therapy, Combination/economics
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/economics
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Outcome Assessment, Health Care/economics/statistics & numerical data
MH  - Platelet Aggregation Inhibitors/administration & dosage/economics/*therapeutic 
      use
MH  - Quality-Adjusted Life Years
MH  - Stroke/*drug therapy/economics
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/economics/therapeutic 
      use
PMC - PMC4309076
OTO - NOTNLM
OT  - clopidogrel
OT  - cost‐effectiveness
OT  - quality‐adjusted life‐year
OT  - stroke
FIR - Wang, Yongjun
IR  - Wang Y
FIR - Johnston, S Claiborne
IR  - Johnston SC
FIR - Wang, Yilong
IR  - Wang Y
FIR - Zhao, Xingquan
IR  - Zhao X
FIR - Wang, Zhimin
IR  - Wang Z
FIR - Xia, Haiqin
IR  - Xia H
FIR - Zhang, Guiru
IR  - Zhang G
FIR - Ren, Xudong
IR  - Ren X
FIR - Ji, Chunling
IR  - Ji C
FIR - Zhang, Guohua
IR  - Zhang G
FIR - Li, Jianhua
IR  - Li J
FIR - Lu, Bohua
IR  - Lu B
FIR - Wang, Liping
IR  - Wang L
FIR - Feng, Shutao
IR  - Feng S
FIR - Wang, Dali
IR  - Wang D
FIR - Tang, Weiguo
IR  - Tang W
FIR - Li, Juntao
IR  - Li J
FIR - Zhang, Hongtian
IR  - Zhang H
FIR - Li, Guanglai
IR  - Li G
FIR - Wang, Baojun
IR  - Wang B
FIR - Chen, Yuhua
IR  - Chen Y
FIR - Lian, Ying
IR  - Lian Y
FIR - Liu, Bin
IR  - Liu B
FIR - Teng, Junfang
IR  - Teng J
FIR - Sui, Rubo
IR  - Sui R
FIR - Li, Lejun
IR  - Li L
FIR - Yuan, Zhiling
IR  - Yuan Z
FIR - Zang, Dawei
IR  - Zang D
FIR - Lu, Zuneng
IR  - Lu Z
FIR - Sun, Li
IR  - Sun L
FIR - Wang, Dong
IR  - Wang D
FIR - Hou, Liying
IR  - Hou L
FIR - Yuan, Dongcai
IR  - Yuan D
FIR - Cao, Yongliang
IR  - Cao Y
FIR - Li, Hui
IR  - Li H
FIR - Tan, Xiuge
IR  - Tan X
FIR - Wang, Huicong
IR  - Wang H
FIR - Du, Haisong
IR  - Du H
FIR - Liu, Mingyi
IR  - Liu M
FIR - Wang, Suping
IR  - Wang S
FIR - Liu, Qiuwu
IR  - Liu Q
FIR - Zhang, Zhong
IR  - Zhang Z
FIR - Cui, Qifu
IR  - Cui Q
FIR - Wang, Runqing
IR  - Wang R
FIR - Zhao, Jialin
IR  - Zhao J
FIR - Zhang, Jiewen
IR  - Zhang J
FIR - Zhao, Jianping
IR  - Zhao J
FIR - Bi, Qi
IR  - Bi Q
FIR - Qi, Xiyou
IR  - Qi X
FIR - Liu, Junyan
IR  - Liu J
FIR - Li, Changxin
IR  - Li C
FIR - Li, Ling
IR  - Li L
FIR - Pan, Xiaoping
IR  - Pan X
FIR - Zhang, Junling
IR  - Zhang J
FIR - Jiao, Derang
IR  - Jiao D
FIR - Han, Zhao
IR  - Han Z
FIR - Qian, Dawei
IR  - Qian D
FIR - Xiao, Jin
IR  - Xiao J
FIR - Xing, Yan
IR  - Xing Y
FIR - Du, Huishan
IR  - Du H
FIR - Huang, Guang
IR  - Huang G
FIR - Cui, Yongqiang
IR  - Cui Y
FIR - Li, Yan
IR  - Li Y
FIR - Feng, Lianyuan
IR  - Feng L
FIR - Gao, Lianbo
IR  - Gao L
FIR - Xiao, Bo
IR  - Xiao B
FIR - Cao, Yibin
IR  - Cao Y
FIR - Wu, Yiping
IR  - Wu Y
FIR - Liu, Jinfeng
IR  - Liu J
FIR - Zhang, Zhiming
IR  - Zhang Z
FIR - Dong, Zhengxie
IR  - Dong Z
FIR - Wang, Limin
IR  - Wang L
FIR - He, Li
IR  - He L
FIR - Wang, Xinchen
IR  - Wang X
FIR - Guo, Xueying
IR  - Guo X
FIR - Wang, Ming
IR  - Wang M
FIR - Wang, Xiaosha
IR  - Wang X
FIR - Jiang, Jiandong
IR  - Jiang J
FIR - Zhao, Renliang
IR  - Zhao R
FIR - Zhou, Shengnian
IR  - Zhou S
FIR - Hu, Hao
IR  - Hu H
FIR - He, Maolin
IR  - He M
FIR - Yu, Fengchun
IR  - Yu F
FIR - Ouyang, Quping
IR  - Ouyang Q
FIR - Zhang, Jingbo
IR  - Zhang J
FIR - Xu, Anding
IR  - Xu A
FIR - Qi, Xiaokun
IR  - Qi X
FIR - Wang, Lei
IR  - Wang L
FIR - Shi, Fuming
IR  - Shi F
FIR - Guo, Fuqiang
IR  - Guo F
FIR - Wang, Jianfeng
IR  - Wang J
FIR - Zhao, Fengli
IR  - Zhao F
FIR - Dou, Ronghua
IR  - Dou R
FIR - Wei, Dongning
IR  - Wei D
FIR - Meng, Qingwei
IR  - Meng Q
FIR - Xia, Yilu
IR  - Xia Y
FIR - Wang, Shimin
IR  - Wang S
FIR - Xue, Zhangcang
IR  - Xue Z
FIR - Xu, Yuming
IR  - Xu Y
FIR - Ma, Liping
IR  - Ma L
FIR - Wang, Chun
IR  - Wang C
FIR - Wu, Jiang
IR  - Wu J
FIR - Du, Yifeng
IR  - Du Y
FIR - Wang, Yinzhou
IR  - Wang Y
FIR - Xiao, Lijun
IR  - Xiao L
FIR - Song, Fucong
IR  - Song F
FIR - Hu, Wenli
IR  - Hu W
FIR - Chen, Zhigang
IR  - Chen Z
FIR - Liu, Qingrui
IR  - Liu Q
FIR - Zhang, Jiemin
IR  - Zhang J
FIR - Chen, Mei
IR  - Chen M
FIR - Yuan, Xiaodong
IR  - Yuan X
FIR - Liu, Zhihui
IR  - Liu Z
FIR - Li, Guozhong
IR  - Li G
FIR - Li, Xiaohong
IR  - Li X
FIR - Tian, Tingchen
IR  - Tian T
EDAT- 2014/06/07 06:00
MHDA- 2015/02/25 06:00
CRDT- 2014/06/07 06:00
PHST- 2014/06/07 06:00 [entrez]
PHST- 2014/06/07 06:00 [pubmed]
PHST- 2015/02/25 06:00 [medline]
AID - jah3560 [pii]
AID - 10.1161/JAHA.114.000912 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2014 Jun 5;3(3):e000912. doi: 10.1161/JAHA.114.000912.

PMID- 15506665
OWN - NLM
STAT- MEDLINE
DCOM- 20050210
LR  - 20191109
IS  - 1590-8658 (Print)
IS  - 1590-8658 (Linking)
VI  - 36
IP  - 10
DP  - 2004 Oct
TI  - Helicobacter pylori infection and the prevention of peptic ulcer with proton pump 
      inhibitors in elderly subjects taking low-dose aspirin.
PG  - 666-70
AB  - INTRODUCTION: The role of Helicobacter pylori infection on the risk of low-dose 
      aspirin-related gastroduodenal damage and on the efficacy of the prevention 
      therapy in elderly chronic users of low-dose aspirin is still controversial. AIM: 
      To evaluate in symptomatic elderly chronic users of low-dose aspirin: (1) the 
      association between H. pylori infection and the prevalence of upper 
      gastrointestinal lesions; and (2) the effect of H. pylori infection on the 
      efficacy of proton pump inhibitors in the prevention of aspirin-related 
      gastroduodenal lesions. PATIENTS AND METHODS: Two hundred and forty-five 
      symptomatic elderly who were taking aspirin 75-300 mg daily, at least during the 
      last 3 months, were evaluated by endoscopy. A structured interview was carried 
      out to evaluate gastrointestinal symptoms and the use of proton pump inhibitors. 
      H. pylori infection was diagnosed according to histology and the rapid urease 
      test on gastric biopsies. RESULTS: One hundred and twelve patients were H. 
      pylori-positive and 133 patients were H. pylori-negative. A significantly higher 
      prevalence of peptic ulcers was observed in H. pylori-positive than in H. 
      pylori-negative subjects (36.6% versus 15.8%, P = 0.0002). The use of proton pump 
      inhibitors was associated with a significant decreased risk of peptic ulcer both 
      in H. pylori-positive (absolute risk reduction, ARR = -36.2, 95% confidence 
      interval: -51.2 to -21.3, P < 0.001) and H. pylori-negative patients (ARR = 
      -12.6, 95% confidence interval: -23.9 to -1.2, P = 0.03). However, the number of 
      patients who needed to be treated in order to gain a reduction of one peptic 
      ulcer (number needed to treat, NnT) was lower in H. pylori-positive than in H. 
      pylori-negative patients (NnT = 3 versus 8). CONCLUSIONS: In symptomatic elderly 
      chronic users of low-dose aspirin, H. pylori infection may influence the 
      prevalence of peptic ulcers and the cost-effectiveness of the proton pump 
      inhibitor prevention therapy.
FAU - Pilotto, A
AU  - Pilotto A
AD  - Geriatric Unit, Casa Sollievo della Sofferenza, Istituto di Ricovero e Cura a 
      Carattere Scientifico, San Giovanni Rotondo, Foggia, italy. 
      alberto.pilotto@libero.it
FAU - Franceschi, M
AU  - Franceschi M
FAU - Longoa, M G
AU  - Longoa MG
FAU - Scarcelli, C
AU  - Scarcelli C
FAU - Orsitto, G
AU  - Orsitto G
FAU - Perri, F C
AU  - Perri FC
FAU - D'Ambrosio, L P
AU  - D'Ambrosio LP
FAU - Leandro, G
AU  - Leandro G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Benzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Sulfoxides)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - D8TST4O562 (Pantoprazole)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Dig Liver Dis. 2004 Oct;36(10):655-7. PMID: 15506662
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Benzimidazoles/administration & dosage/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Endoscopes, Gastrointestinal
MH  - Helicobacter Infections/complications/*diagnosis/microbiology
MH  - Helicobacter pylori/isolation & purification
MH  - Humans
MH  - Lansoprazole
MH  - Omeprazole/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Pantoprazole
MH  - Peptic Ulcer/etiology/*prevention & control
MH  - Prospective Studies
MH  - *Proton Pump Inhibitors
MH  - Sulfoxides/administration & dosage/therapeutic use
EDAT- 2004/10/28 09:00
MHDA- 2005/02/11 09:00
CRDT- 2004/10/28 09:00
PHST- 2004/10/28 09:00 [pubmed]
PHST- 2005/02/11 09:00 [medline]
PHST- 2004/10/28 09:00 [entrez]
AID - S1590-8658(04)00272-5 [pii]
AID - 10.1016/j.dld.2004.05.011 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2004 Oct;36(10):666-70. doi: 10.1016/j.dld.2004.05.011.

PMID- 34323179
OWN - NLM
STAT- MEDLINE
DCOM- 20220328
LR  - 20220401
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 27
IP  - 40
DP  - 2021
TI  - Clinical Effects of Dual Antiplatelet Therapy or Aspirin Monotherapy after Acute 
      Minor Ischemic Stroke or Transient Ischemic Attack, a Meta-Analysis.
PG  - 4140-4146
LID - 10.2174/1381612827666210728102459 [doi]
AB  - BACKGROUND: Evidence about the use of dual antiplatelet therapy (DAPT) with 
      aspirin and P2Y12 inhibitors in patients with acute minor ischemic stroke or 
      transient ischemic attack (TIA) is emerging. The aim of our study was to provide 
      an updated and comprehensive analysis about the risks and benefits of DAPT versus 
      aspirin monotherapy in this setting. METHODS: The PubMed, Embase, Cochrane 
      Central Register of Controlled Trials, ClinicalTrials.gov databases, main 
      international conference proceedings were searched for randomized controlled 
      trials comparing DAPT versus aspirin monotherapy in patients with acute ischemic 
      stroke or TIA not eligible for thrombolysis or thrombectomy presenting in the 
      first 24 hours after the acute event. Data were pooled by meta-analysis using a 
      random-effects model. The primary efficacy endpoint was ischemic stroke 
      recurrence, and the primary safety outcome was major bleeding. Secondary 
      endpoints were intracranial hemorrhage, hemorrhagic stroke, and allcause death. 
      RESULTS: A total of 4 studies enrolling 21,459 patients were included. DAPT with 
      clopidogrel was used in 3 studies, DAPT with ticagrelor in one study. DAPT 
      duration was 21 days in one study, 1 month in one study, and 3 months in the 
      remaining studies. DAPT was associated with a significant reduction in the risk 
      of ischemic stroke recurrence (relative risk (RR), 0.74; 95% confidence interval 
      (CI), 0.67-0.82, P<0.001, number needed to treat 50 (95% CI 40-72), while it was 
      associated with a significantly higher risk of major bleeding (RR, 2.59; 95% CI 
      1.49-4.53, P=0.001, number needed to harm 330 (95% CI 149-1111), of intracranial 
      hemorrhage (RR 3.06, 95% CI 1.41-6.66, P=0.005), with a trend towards higher risk 
      of hemorrhagic stroke (RR 1.83, 95% CI 0.83-4.05, P=0.14), and a slight tendency 
      towards higher risk of all-cause death (RR 1.30, 95% CI 0.89-1.89, P=0.16). 
      CONCLUSION: Among patients with acute minor ischemic stroke or TIA, DAPT, as 
      compared with aspirin monotherapy, might offer better effectiveness in terms of 
      ischemic stroke recurrence at the expense of a higher risk of major bleeding. The 
      trade-off between ischemic benefits and bleeding risks should be assessed in 
      tailoring the therapeutic strategies.
CI  - Copyright© Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Condello, Francesco
AU  - Condello F
AD  - Department of Cardiovascular Medicine, Humanitas Research Hospital-IRCCS Via 
      Manzoni, 56, 20089 Rozzano, Milan, Italy.
FAU - Liccardo, Gaetano
AU  - Liccardo G
AD  - Department of Cardiovascular Medicine, Humanitas Research Hospital-IRCCS Via 
      Manzoni, 56, 20089 Rozzano, Milan, Italy.
FAU - Ferrante, Giuseppe
AU  - Ferrante G
AD  - Department of Cardiovascular Medicine, Humanitas Research Hospital-IRCCS Via 
      Manzoni, 56, 20089 Rozzano, Milan, Italy.
LA  - eng
PT  - Meta-Analysis
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Ischemic Attack, Transient/drug therapy
MH  - *Ischemic Stroke/drug therapy
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - *Stroke/drug therapy
OTO - NOTNLM
OT  - Acute minor ischemic stroke
OT  - aspirin
OT  - bleeding.
OT  - clopidogrel
OT  - dual antiplatelet therapy
OT  - ticagrelor
OT  - transient ischemic attack
EDAT- 2021/07/30 06:00
MHDA- 2022/03/29 06:00
CRDT- 2021/07/29 08:42
PHST- 2021/03/08 00:00 [received]
PHST- 2021/06/08 00:00 [accepted]
PHST- 2021/07/30 06:00 [pubmed]
PHST- 2022/03/29 06:00 [medline]
PHST- 2021/07/29 08:42 [entrez]
AID - CPD-EPUB-116911 [pii]
AID - 10.2174/1381612827666210728102459 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2021;27(40):4140-4146. doi: 10.2174/1381612827666210728102459.

PMID- 15328680
OWN - NLM
STAT- MEDLINE
DCOM- 20040923
LR  - 20191210
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 93
IP  - 2
DP  - 2004 Aug
TI  - Reproducibility of response to nasal lysine-aspirin challenge in patients with 
      aspirin-induced asthma.
PG  - 185-8
AB  - BACKGROUND: Peak nasal inspiratory flow (PNIF) and acoustic rhinometry 
      objectively measure the effects of nasal provocation testing. Although the latter 
      is conventionally used in nasal lysine-aspirin challenge, use of the former in 
      aspirin-induced asthma (AIA) has never been evaluated. OBJECTIVE: To evaluate the 
      reproducibility of PNIF and acoustic rhinometry following nasal lysine-aspirin 
      challenge in AIA. METHODS: Fourteen patients with a clear-cut history of AIA 
      underwent nasal lysine-aspirin challenge at 2 separate visits 1 week apart. Both 
      PNIF and minimum cross-sectional area (MCA) were measured using acoustic 
      rhinometry for 120 minutes following standard nasal lysine-aspirin challenge (25 
      mg). RESULTS: Prechallenge values were not significantly different at visit 1 vs 
      visit 2 for mean [SEM] PNIF (128 [13] vs 127 [9] L/min) and MCA (6.89 [0.51] vs 
      6.94 [0.57] cm2). The mean (SEM) maximum percent PNIF change from baseline for 
      visit 1 and visit 2 was -42 (5) and -42 (6), respectively, and the mean (SEM) 
      average percent PNIF change from baseline was -25 (4) and -25 (6), respectively. 
      The mean (SEM) maximum percent MCA change from baseline for visit 1 and visit 2 
      was -49 (4) and -48 (3), respectively, and the mean (SEM) average percent MCA 
      change from baseline was -25 (8) and -24 (4), respectively. Coefficients of 
      variation for maximum and average responses were 2.3% and 6.5%, respectively, for 
      PNIF and 7.4% and 16.1% for MCA. CONCLUSIONS: Measurement of PNIF following nasal 
      lysine-aspirin challenge is a simple and reproducible alternative to acoustic 
      rhinometry, with maximum response being a more reproducible outcome measure than 
      average response.
FAU - Lee, Daniel K C
AU  - Lee DK
AD  - Asthma & Allergy Research Group, Ninewells Hospital & Medical School, University 
      of Dundee, Dundee, Scotland.
FAU - Haggart, Kay
AU  - Haggart K
FAU - Lipworth, Brian J
AU  - Lipworth BJ
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Leukotriene Antagonists)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adrenal Cortex Hormones/administration & dosage
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects/*analogs & derivatives
MH  - Asthma/*chemically induced/drug therapy
MH  - Female
MH  - Humans
MH  - Inspiratory Capacity/drug effects
MH  - Leukotriene Antagonists/administration & dosage
MH  - Lysine/*adverse effects/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - *Nasal Provocation Tests
MH  - Peak Expiratory Flow Rate/drug effects
MH  - Reproducibility of Results
MH  - Time Factors
EDAT- 2004/08/27 05:00
MHDA- 2004/09/24 05:00
CRDT- 2004/08/27 05:00
PHST- 2004/08/27 05:00 [pubmed]
PHST- 2004/09/24 05:00 [medline]
PHST- 2004/08/27 05:00 [entrez]
AID - S1081-1206(10)61473-1 [pii]
AID - 10.1016/S1081-1206(10)61473-1 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2004 Aug;93(2):185-8. doi: 
      10.1016/S1081-1206(10)61473-1.

PMID- 23903231
OWN - NLM
STAT- MEDLINE
DCOM- 20140305
LR  - 20190724
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 133
IP  - 8
DP  - 2013
TI  - [HPLC-method for deliberation of drug mammary transfer-evaluation of 
      over-the-counter drugs (Loxonin(®)-S, Bufferin(®) A) in mother mice].
PG  - 905-11
AB  - Loxoprofen (Loxonin(®)), an antipyretic painkiller, was approved as an 
      over-the-counter (OTC) drug (Loxonin(®)-S) in January 2011. With regard to 
      self-medication using OTC drugs, the information that pharmacists provide to 
      consumers is very important. Although loxoprofen is a very versatile drug and can 
      be used during breastfeeding, information regarding its mammary gland transfer is 
      inadequate. In this study, we established a simple method to evaluate mammary 
      transfer of drugs, and compared loxoprofen's mammary gland transfer with that of 
      aspirin. Loxoprofen 12 mg/kg and aspirin 132 mg/kg was orally administered to 
      mother mice (ddY), and blood and milk samples were collected. Twenty microliters 
      of ethanol was added to the blood and milk samples (10 μL), and the mixture was 
      centrifuged for 15 min (12000 g); the supernatant was analyzed by 
      high-performance liquid chromatography. Since aspirin was immediately 
      metabolized, we analyzed salicylic acid concentrations. Maximum concentration of 
      loxoprofen was observed at around 15 min after its oral administration, with the 
      concentrations in the blood and milk being 2.9 and 0.5 μg/mL, respectively. The 
      drug was metabolized promptly thereafter. In contrast, maximum concentration of 
      salicylic acid was observed at 30 min after aspirin administration, with the 
      concentrations in the blood and milk being 187.2 and 64.4 μg/mL, respectively. 
      These concentrations remained constant from 60 to 120 min. Salicylic acid could 
      be detected 240 min after aspirin administration. Thus, mammary gland transfer of 
      loxoprofen is lower than that of aspirin, suggesting that loxoprofen does not 
      accumulate in milk.
FAU - Komori, Koji
AU  - Komori K
AD  - Department of Medical Pharmacy, Faculty of Pharmaceutical Sciences, Setsunan 
      University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan. 
      komori@pharm.setsunan.ac.jp
FAU - Komae, Ryohei
AU  - Komae R
FAU - Yamazaki, Yuki
AU  - Yamazaki Y
FAU - Nakano, Shoko
AU  - Nakano S
FAU - Mitamura, Shinobu
AU  - Mitamura S
FAU - Miyazaki, Tamami
AU  - Miyazaki T
FAU - Kikuta, Maho
AU  - Kikuta M
FAU - Takada, Masahiro
AU  - Takada M
FAU - Shuto, Makoto
AU  - Shuto M
FAU - Hane, Yumiko
AU  - Hane Y
FAU - Yamamoto, Toshiko
AU  - Yamamoto T
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - 0 (Phenylpropionates)
RN  - 3583H0GZAP (loxoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism
MH  - Aspirin/metabolism
MH  - *Chromatography, High Pressure Liquid
MH  - Female
MH  - Humans
MH  - Mammary Glands, Human/*metabolism
MH  - Mice
MH  - Nonprescription Drugs/*metabolism
MH  - Phenylpropionates/*metabolism
EDAT- 2013/08/02 06:00
MHDA- 2014/03/07 06:00
CRDT- 2013/08/02 06:00
PHST- 2013/08/02 06:00 [entrez]
PHST- 2013/08/02 06:00 [pubmed]
PHST- 2014/03/07 06:00 [medline]
AID - DN/JST.JSTAGE/yakushi/13-00053 [pii]
AID - 10.1248/yakushi.13-00053 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2013;133(8):905-11. doi: 10.1248/yakushi.13-00053.

PMID- 20718885
OWN - NLM
STAT- MEDLINE
DCOM- 20110519
LR  - 20181201
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 40
IP  - 8
DP  - 2010 Aug
TI  - Rapid and sequential desensitization to both aspirin and clopidogrel.
PG  - 596-9
LID - 10.1111/j.1445-5994.2010.02266.x [doi]
AB  - Hypersensitivity reactions to aspirin and clopidogrel are 2.5% and 1%, 
      respectively. Dual anti-platelet therapy with these drugs is effective in 
      preventing thrombosis following deployment of stents for cerebrovascular and 
      cardiovascular syndromes. Desensitization therapy with both aspirin and 
      clopidogrel may be required for patients undergoing stent implantation that have 
      experienced hypersensitivity to these agents. We report the case of a 58-year-old 
      woman who developed urticaria and angioedema following aspirin therapy for 
      ischaemic cerebrovascular disease. She developed an identical reaction after 
      clopidogrel was subsequently administered. Investigations revealed the presence 
      of an internal carotid artery aneurysm that required deployment of a stent. Rapid 
      desensitization to aspirin over 5.5 h followed 3 days later by rapid 
      desensitization to clopidogrel over 2.5 h was successfully performed prior to 
      stenting. After 4 months she has tolerated this dual anti-platelet therapy 
      without any adverse reaction. Rapid and sequential desensitization to both 
      aspirin and clopidogrel can be successfully performed for patients who require 
      stent deployment but have hypersensitivity to both these anti-platelet agents.
FAU - Fernando, S L
AU  - Fernando SL
AD  - Department of Clinical Immunology and Allergy, Royal North Shore Hospital, 
      Sydney, New South Wales, Australia. sfernando@nsccahs.health.nsw.gov.au
FAU - Assaad, N N A
AU  - Assaad NN
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioedema/chemically induced/diagnosis
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clopidogrel
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/*diagnosis/*drug therapy
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Stents
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Time Factors
MH  - Urticaria/chemically induced/diagnosis
EDAT- 2010/08/20 06:00
MHDA- 2011/05/20 06:00
CRDT- 2010/08/20 06:00
PHST- 2010/08/20 06:00 [entrez]
PHST- 2010/08/20 06:00 [pubmed]
PHST- 2011/05/20 06:00 [medline]
AID - IMJ2266 [pii]
AID - 10.1111/j.1445-5994.2010.02266.x [doi]
PST - ppublish
SO  - Intern Med J. 2010 Aug;40(8):596-9. doi: 10.1111/j.1445-5994.2010.02266.x.

PMID- 30684348
OWN - NLM
STAT- MEDLINE
DCOM- 20190606
LR  - 20190606
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 71
IP  - 8
DP  - 2018
TI  - [Acetylsalicylic acid in the prevention and treatment of cardiovascular 
      diseases].
PG  - 1608-1614
AB  - Acetylsalicylic acid (ASA) is one of the most popular medicines in the world. ASA 
      preparations have been used for over 100 years as anti-inflammatory, antipyretic 
      and analgesic drugs. Since 1971, ASA has also been used as an antiplatelet drug. 
      The main antiplatelet effect of aspirin is the irreversible inhibition of the key 
      enzyme of arachidonic acid cascade, a prostaglandin H synthetase, also called 
      cyclooxygenase (COX). ASA is a widely used drug in the prevention of 
      cardiovascular diseases. In accordance with the current European guidelines, ASA 
      is indicated in secondary prevention in all patients with established 
      cardiovascular disease (coronary heart disease, previous myocardial infarction, 
      previous stroke, peripheral atherosclerosis). Life therapy with low doses (75-150 
      mg daily) is recommended. ASA is also used to treat acute myocardial infarction, 
      unstable coronary heart disease, coronary artery bypass surgery and angioplasty, 
      as well as to treat acute stroke. Despite the proven benefits, approximately 
      10-20% of patients taking ASA are at risk for re-occurring cardiovascular events. 
      In connection with the above, the phenomenon of the so-called resistance to ASA 
      (or high on treatment platelet reactivity despite ASA). This phenomenon was 
      reported in patients after stroke (up to 60% of subjects), in atherosclerosis of 
      the lower limbs (up to 60%), in stable coronary disease (up to 70%) and in 
      patients immediately after myocardial infarction (up to 80%). Despite studies 
      conducted for several years, so far there are no clear guidelines for monitoring 
      platelet function in patients taking ASA, both in primary and secondary stroke 
      prevention.
FAU - Łabuz-Roszak, Beata
AU  - Łabuz-Roszak B
AD  - Katedra i Zakład Podstawowych Nauk Medycznych, Wydział Zdrowia Publicznego w 
      Bytomiu, Śląski Uniwersytet Medyczny w Katowicach, Katowice, Polska.
FAU - Horyniecki, Maciej
AU  - Horyniecki M
AD  - Katedra i Klinika Neurologii w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach, 
      Katowice, Polska.
FAU - Łącka-Gaździk, Beata
AU  - Łącka-Gaździk B
AD  - Katedra i Klinika Chorób Wewnętrznych, Diabetologii i Nefrologii, Śląski 
      Uniwersytet Medyczny w Katowicach, Katowice, Polska.
LA  - pol
PT  - Journal Article
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Secondary Prevention
MH  - Stroke/drug therapy/prevention & control
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - high on treatment platelet reactivity
OT  - prevention of cardiovascular diseases
OT  - stroke
EDAT- 2019/01/27 06:00
MHDA- 2019/06/07 06:00
CRDT- 2019/01/27 06:00
PHST- 2019/01/27 06:00 [entrez]
PHST- 2019/01/27 06:00 [pubmed]
PHST- 2019/06/07 06:00 [medline]
PST - ppublish
SO  - Wiad Lek. 2018;71(8):1608-1614.

PMID- 18596119
OWN - NLM
STAT- MEDLINE
DCOM- 20081118
LR  - 20211020
IS  - 1555-905X (Electronic)
IS  - 1555-9041 (Print)
IS  - 1555-9041 (Linking)
VI  - 3
IP  - 5
DP  - 2008 Sep
TI  - Consistent aspirin use associated with improved arteriovenous fistula survival 
      among incident hemodialysis patients in the dialysis outcomes and practice 
      patterns study.
PG  - 1373-8
LID - 10.2215/CJN.00130108 [doi]
AB  - BACKGROUND AND OBJECTIVES: The relationship between aspirin use and arteriovenous 
      fistula (AVF) survival has been lacking. The aim of this study was to evaluate 
      the association between AVF survival and aspirin use. DESIGN, SETTING, 
      PARTICIPANTS, & MEASUREMENTS: Data on 2815 incident hemodialysis patients (on 
      dialysis <or= 30 d) using an AVF at enrollment into the Dialysis Outcomes and 
      Practice Patterns Study between 1996 and 2004 were analyzed. Cox regression was 
      used to examine the association between aspirin use and the risk of final AVF 
      failure, first AVF failure, and a gastrointestinal bleeding event. Aspirin use 
      was determined at baseline and one year later. Patients using aspirin at baseline 
      and one year later were considered consistent aspirin users. All models accounted 
      for facility clustering effects and were adjusted for age, race, gender, body 
      mass index, prior permanent access failure, prior placement of a catheter, 10 
      comorbid conditions, laboratory data, and other medications, and stratified by 
      regions. RESULTS: Consistent aspirin use was significantly related to a lower 
      risk of final AVF failure. Facility-level analysis, which may reduce confounding 
      by indication, also showed a nearly significant trend of reduced risk of final 
      AVF failure with greater prevalence of consistent aspirin use within dialysis 
      facilities (P for trend = 0.07). The occurrence of a new gastrointestinal 
      bleeding event during the study period was not associated with aspirin use. 
      CONCLUSIONS: These results suggest that consistent aspirin use may be beneficial 
      for AVF survival among incident hemodialysis patients.
FAU - Hasegawa, Takeshi
AU  - Hasegawa T
AD  - Division of Nephrology, Fujiyoshida Municipal Hospital, Yamanashi, Japan. 
      tahasegawa-npr@umin.net
FAU - Elder, Stacey J
AU  - Elder SJ
FAU - Bragg-Gresham, Jennifer L
AU  - Bragg-Gresham JL
FAU - Pisoni, Ronald L
AU  - Pisoni RL
FAU - Yamazaki, Shin
AU  - Yamazaki S
FAU - Akizawa, Tadao
AU  - Akizawa T
FAU - Jadoul, Michel
AU  - Jadoul M
FAU - Hugh, Rayner C
AU  - Hugh RC
FAU - Port, Friedrich K
AU  - Port FK
FAU - Fukuhara, Shunichi
AU  - Fukuhara S
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20080702
PL  - United States
TA  - Clin J Am Soc Nephrol
JT  - Clinical journal of the American Society of Nephrology : CJASN
JID - 101271570
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Arteriovenous Shunt, Surgical/adverse effects
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Australia
MH  - Europe
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Graft Occlusion, Vascular/etiology/physiopathology/*prevention & control
MH  - Humans
MH  - Incidence
MH  - Japan
MH  - Kidney Failure, Chronic/*therapy
MH  - Male
MH  - Middle Aged
MH  - New Zealand
MH  - North America
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - *Renal Dialysis
MH  - Risk Assessment
MH  - Time Factors
MH  - Vascular Patency/*drug effects
PMC - PMC2518799
EDAT- 2008/07/04 09:00
MHDA- 2008/11/19 09:00
CRDT- 2008/07/04 09:00
PHST- 2008/07/04 09:00 [pubmed]
PHST- 2008/11/19 09:00 [medline]
PHST- 2008/07/04 09:00 [entrez]
AID - CJN.00130108 [pii]
AID - 0108 [pii]
AID - 10.2215/CJN.00130108 [doi]
PST - ppublish
SO  - Clin J Am Soc Nephrol. 2008 Sep;3(5):1373-8. doi: 10.2215/CJN.00130108. Epub 2008 
      Jul 2.

PMID- 24183917
OWN - NLM
STAT- MEDLINE
DCOM- 20141110
LR  - 20140219
IS  - 2210-741X (Electronic)
IS  - 2210-7401 (Linking)
VI  - 38
IP  - 1
DP  - 2014 Feb
TI  - Statin and aspirin for prevention of hepatocellular carcinoma: what are the 
      levels of evidence?
PG  - 9-11
LID - S2210-7401(13)00195-2 [pii]
LID - 10.1016/j.clinre.2013.09.007 [doi]
AB  - Recent analyses of large cohorts suggest that statins or aspirin may reduce the 
      risk of hepatocellular carcinoma (HCC). Due to their observational nature, these 
      studies may have been flawed by confounding by indication or immortal time bias. 
      Reviews of clinical trials conducted in the metabolic or cardiovascular domain 
      showed no effect of statins on cancer of any type, but identified a 20% reduction 
      of cancer with aspirin use. The effect of aspirin was concentrated to 
      adenocarcinomas. More convincing evidence is needed to support the potential 
      preventive effect of aspirin on HCC, but a clinical trial would be achievable in 
      patients who are at high risk.
CI  - Copyright © 2013 Elsevier Masson SAS. All rights reserved.
FAU - Carrat, Fabrice
AU  - Carrat F
AD  - Epidemiology of influenza and viral hepatitis: risk, prognosis and therapeutic 
      options, UMR-S 1136, INSERM and UPMC, Paris 06, Public Health Department, 
      Saint-Antoine Hospital, AP-HP, Paris, France. Electronic address: 
      carrat@u707.jussieu.fr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131030
PL  - France
TA  - Clin Res Hepatol Gastroenterol
JT  - Clinics and research in hepatology and gastroenterology
JID - 101553659
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Carcinoma, Hepatocellular/*prevention & control
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Liver Neoplasms/*prevention & control
EDAT- 2013/11/05 06:00
MHDA- 2014/11/11 06:00
CRDT- 2013/11/05 06:00
PHST- 2013/09/19 00:00 [received]
PHST- 2013/09/24 00:00 [accepted]
PHST- 2013/11/05 06:00 [entrez]
PHST- 2013/11/05 06:00 [pubmed]
PHST- 2014/11/11 06:00 [medline]
AID - S2210-7401(13)00195-2 [pii]
AID - 10.1016/j.clinre.2013.09.007 [doi]
PST - ppublish
SO  - Clin Res Hepatol Gastroenterol. 2014 Feb;38(1):9-11. doi: 
      10.1016/j.clinre.2013.09.007. Epub 2013 Oct 30.

PMID- 840541
OWN - NLM
STAT- MEDLINE
DCOM- 19770425
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 59
IP  - 1
DP  - 1977 Jan
TI  - The determination of aspirin levels in the presence of hyperbilirubinemia.
PG  - 55-7
AB  - Many major medical centers are presently utilizing a shortened method (Keller) 
      for determining serum aspirin levels which does not remove interfering compounds. 
      This report documents that the presence of even 1 mg of bilirubin/dl of serum is 
      sufficient to cause a falsely high aspirin level. It is suggested that any method 
      for determining serum bilirubin which does not remove interfering substances 
      constitutes a danger to many groups of patients and should be discontinued.
FAU - Fenton, L J
AU  - Fenton LJ
FAU - Beresford, M E
AU  - Beresford ME
FAU - Keenan, W J
AU  - Keenan WJ
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*blood
MH  - Blood Chemical Analysis/methods
MH  - False Positive Reactions
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Jaundice, Neonatal/*blood
MH  - Maternal-Fetal Exchange
MH  - Methods
MH  - Pregnancy
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1977 Jan;59(1):55-7.

PMID- 32557810
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20210729
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 105
IP  - 4
DP  - 2020 Oct
TI  - Anagrelide influences thrombotic risk, and prolongs progression-free and overall 
      survival in essential thrombocythaemia vs hydroxyurea plus aspirin.
PG  - 408-418
LID - 10.1111/ejh.13459 [doi]
AB  - OBJECTIVE: We report an extension study of patients with essential 
      thrombocythaemia (ET) in the Hungarian Myeloproliferative Neoplasm (HUMYPRON) 
      Registry, which demonstrated that over 6 years anagrelide significantly decreased 
      the number of patients experiencing minor arterial and minor venous thrombotic 
      events (TEs) vs hydroxyurea+aspirin. METHODS: Data on patients with ET were 
      collected through completion of a questionnaire developed according to 2008 WHO 
      diagnostic criteria and with regard to Landolfi, Tefferi and IPSET criteria for 
      thrombotic risk. Data were entered into the registry from 14 haematological 
      centres. TEs, secondary malignancies, disease progression and survival were 
      compared between patients with ET treated with anagrelide (n = 116) and with 
      hydroxyurea+aspirin (n = 121). RESULTS: Patients were followed for (median) 
      10 years. A between-group difference in the number of patients with TEs was 
      observed (25.9% anagrelide vs 38.0% hydroxyurea+aspirin; P = .052). Minor 
      arterial events were more frequently reported in the hydroxyurea+aspirin group 
      (P < .001); there were marginally more reports of major arterial events in the 
      anagrelide group (P = .049). TE prior to diagnosis was found to significantly 
      influence TE incidence (P > .001). Progression-free survival (P = .004) and 
      survival (P = .001) were significantly increased for the anagrelide group vs 
      hydroxyurea+aspirin. CONCLUSIONS: Anagrelide reduced TEs, and increased 
      progression-free and overall survival vs hydroxyurea+aspirin over (median) 
      10 years.
CI  - © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Kellner, Adam
AU  - Kellner A
AD  - Department of Haematology, Somogy County Kaposi Mor Teaching Hospital, Kaposvár, 
      Hungary.
FAU - Dombi, Peter
AU  - Dombi P
AD  - Szent Borbala County Hospital, Tatabánya, Hungary.
FAU - Illes, Arpad
AU  - Illes A
AD  - Department of Haematology, Faculty of Medicine, University of Debrecen, Debrecen, 
      Hungary.
FAU - Demeter, Judit
AU  - Demeter J
AD  - First Department of Internal Medicine, Division of Haematology, Semmelweis 
      University of Budapest, Budapest, Hungary.
FAU - Homor, Lajos
AU  - Homor L
AD  - Faculty of Humanities and Social Sciences, Pazmany Peter Catholic University, 
      Budapest, Hungary.
FAU - Ercsei, Ibolya
AU  - Ercsei I
AD  - Department of Haematology, Somogy County Kaposi Mor Teaching Hospital, Kaposvár, 
      Hungary.
FAU - Simon, Zsofia
AU  - Simon Z
AD  - Department of Haematology, Faculty of Medicine, University of Debrecen, Debrecen, 
      Hungary.
FAU - Karadi, Eva
AU  - Karadi E
AD  - Department of Haematology, Somogy County Kaposi Mor Teaching Hospital, Kaposvár, 
      Hungary.
FAU - Herczeg, Jozsef
AU  - Herczeg J
AD  - Department of Haematology, Somogy County Kaposi Mor Teaching Hospital, Kaposvár, 
      Hungary.
FAU - Gy Korom, Viktoria
AU  - Gy Korom V
AD  - Department of Haematology, Somogy County Kaposi Mor Teaching Hospital, Kaposvár, 
      Hungary.
FAU - Gasztonyi, Zoltan
AU  - Gasztonyi Z
AD  - Karolina General Hospital Mosonmagyarovar, Mosonmagyarovar, Hungary.
FAU - Szerafin, Laszlo
AU  - Szerafin L
AD  - Josa Andras Teaching Hospital, Nyiregyhaza, Hungary.
FAU - Udvardy, Miklos
AU  - Udvardy M
AD  - Department of Haematology, Faculty of Medicine, University of Debrecen, Debrecen, 
      Hungary.
FAU - Egyed, Miklos
AU  - Egyed M
AUID- ORCID: 0000-0002-5513-5880
AD  - Department of Haematology, Somogy County Kaposi Mor Teaching Hospital, Kaposvár, 
      Hungary.
LA  - eng
GR  - AOP Orphan Pharmaceuticals AG/
PT  - Journal Article
DEP - 20200701
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Quinazolines)
RN  - K9X45X0051 (anagrelide)
RN  - R16CO5Y76E (Aspirin)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Health Care Surveys
MH  - Humans
MH  - Hungary
MH  - Hydroxyurea/administration & dosage/therapeutic use
MH  - Quinazolines/administration & dosage/therapeutic use
MH  - Registries
MH  - Thrombocythemia, Essential/*complications/epidemiology/*mortality
MH  - Thrombosis/epidemiology/*etiology/*mortality/prevention & control
MH  - Treatment Outcome
OTO - NOTNLM
OT  - HUMYPRON registry
OT  - anagrelide
OT  - essential thrombocythaemia
OT  - hydroxyurea + aspirin
OT  - progression
OT  - risk factors
OT  - thrombosis
EDAT- 2020/06/20 06:00
MHDA- 2021/07/30 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/05/26 00:00 [revised]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1111/ejh.13459 [doi]
PST - ppublish
SO  - Eur J Haematol. 2020 Oct;105(4):408-418. doi: 10.1111/ejh.13459. Epub 2020 Jul 1.

PMID- 27561157
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20211204
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 43
IP  - 12
DP  - 2016 Dec
TI  - Beneficial effect of aspirin against interferon-α-2b-induced depressive behavior 
      in Sprague Dawley rats.
PG  - 1208-1215
LID - 10.1111/1440-1681.12660 [doi]
AB  - Accumulating data advocates that inflammatory mediators may contribute to 
      depression in experimental models as well as in humans. Nonetheless, whether 
      anti-inflammatory treatments can prevent depression still remains controversial. 
      To substantiate our hypothesis, we used an interferon-α-2b model of depression 
      using Sprague Dawley rats. Interferon-α-2b is a cytokine which activates immune 
      response and also produces depression. The animals were treated for 21 days with 
      aspirin (10 mg/kg, per oral (p.o.)) dexamethasone (1 mg/kg p.o.) and 
      amitriptyline (10 mg/kg p.o.). Amitriptyline was used as reference standard, and 
      given concurrently with aspirin and dexamethasone to examine any synergy. 
      Interferon-α-2b (6000 IU/kg, intraperitoneal (i.p.)) was administered in all the 
      above groups daily, except normal control. Tests performed included sucrose 
      preference test, behavioural tests like forced swim test, elevated plus maze, 
      light dark box and locomotor activity along with biochemical estimations like 
      serum cortisol and brain neurotransmitters. The rats in the group treated with 
      Interferon-α-2b produced depressive behaviour in rats. We found that animals 
      treated with aspirin decreased immobility time in forced swim test, increased 
      sucrose preference, decreased serum cortisol and increased brain serotonin levels 
      signifying antidepressant action. In contrast, there was no effect in groups 
      treated with dexamethasone. Our results suggest that aspirin can serve as a 
      potential antidepressant both individually and as adjuvant agent in the treatment 
      of depression. Inhibition of the cyclo-oxygenase-2 levels and prostaglandins 
      concentration or any other potential physiological and biochemical mechanisms may 
      be involved in antidepressant effect.
CI  - © 2016 John Wiley & Sons Australia, Ltd.
FAU - Bhatt, Shailendra
AU  - Bhatt S
AD  - L J Institute of Pharmacy, Ahmedabad, India.
FAU - Pundarikakshudu, Kilambi
AU  - Pundarikakshudu K
AD  - L J Institute of Pharmacy, Ahmedabad, India.
FAU - Patel, Paresh
AU  - Patel P
AD  - L J Institute of Pharmacy, Ahmedabad, India.
FAU - Patel, Nirav
AU  - Patel N
AD  - L J Institute of Pharmacy, Ahmedabad, India.
FAU - Panchal, Ashish
AU  - Panchal A
AD  - L J Institute of Pharmacy, Ahmedabad, India.
FAU - Shah, Gaurang
AU  - Shah G
AD  - Department of Pharmacology, K B Institute of Pharmaceutical Education and 
      Research, Gandhinagar, Gujarat, India.
FAU - Goswami, Sunita
AU  - Goswami S
AD  - Department of Pharmacology, L M College of Pharmacy, Navrangpura, Ahmedabad, 
      India.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interferon-alpha2b)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cyclooxygenase 2 Inhibitors/pharmacology/therapeutic use
MH  - Depression/*chemically induced/*drug therapy/metabolism
MH  - Dexamethasone/pharmacology/therapeutic use
MH  - Interferon alpha-2
MH  - Interferon-alpha/*toxicity
MH  - Locomotion/drug effects/physiology
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Treatment Outcome
OTO - NOTNLM
OT  - anti-inflammatory
OT  - aspirin
OT  - depression
OT  - dexamethasone
OT  - interferon-α-2b
OT  - neuroimmunopharmacology
EDAT- 2016/08/26 06:00
MHDA- 2017/09/12 06:00
CRDT- 2016/08/26 06:00
PHST- 2016/05/12 00:00 [received]
PHST- 2016/07/19 00:00 [revised]
PHST- 2016/07/26 00:00 [accepted]
PHST- 2016/08/26 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
PHST- 2016/08/26 06:00 [entrez]
AID - 10.1111/1440-1681.12660 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2016 Dec;43(12):1208-1215. doi: 
      10.1111/1440-1681.12660.

PMID- 25180765
OWN - NLM
STAT- MEDLINE
DCOM- 20150126
LR  - 20211021
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 111
IP  - 11
DP  - 2014 Nov 25
TI  - Relationship between aspirin use after diagnosis of colorectal cancer and patient 
      survival: a meta-analysis of observational studies.
PG  - 2172-9
LID - 10.1038/bjc.2014.481 [doi]
AB  - BACKGROUND: Epidemiological evidence suggests that use of aspirin after the 
      diagnosis of colorectal cancer can lengthen survival. However, the supporting 
      data vary between studies, and this hypothesis remains controversial. We 
      conducted a meta-analysis to provide a quantitative assessment of the association 
      between use of aspirin after diagnosis of colorectal cancer and patient survival. 
      METHODS: We searched the Medline and Embase databases up to April 2014 to 
      identify studies related to aspirin use after diagnosis and all-cause mortality 
      or colorectal cancer-specific mortality. Summary effect estimates with 95% 
      confidence intervals (CIs) were derived using a fixed or random effects model, 
      depending on the heterogeneity between the included studies. RESULTS: Seven 
      epidemiologic studies that consisted of six cohort studies and one nested 
      case-control study were included in this meta-analysis. The hazard ratio (HR) of 
      the association between aspirin use after colorectal cancer diagnosis and overall 
      mortality, which was reported in five studies, was 0.74 (95% CI, 0.62-0.89) using 
      a random model (heterogeneity test P=0.003, I(2)=75.3%), and for colorectal 
      cancer-specific mortality (four studies), it was 0.75 (95% CI, 0.51-1.10) using a 
      random model (heterogeneity test P=0.001, I(2)=84.1%). In addition, we analysed 
      postdiagnosis aspirin use according to whether aspirin was also used before 
      diagnosis. The HR for the overall mortality of patients who did not use aspirin 
      before diagnosis, which was reported in four studies, was 0.84 (95% CI, 
      0.70-1.00), and for colorectal cancer-specific mortality (three studies), it was 
      0.79 (95% CI, 0.61-1.02). For those who did use aspirin before diagnosis, the HR 
      for overall mortality (four studies) was 0.88 (95% CI, 0.83-0.93), and for 
      colorectal cancer-specific mortality (three studies), it was 0.80 (95% CI, 
      0.59-1.09). Subgroup analysis showed that use of aspirin after diagnosis was 
      associated with longer overall survival among patients with the variant PIK3CA 
      gene but not for those with wild-type PIK3CA. CONCLUSIONS: Based on current 
      evidence, the use of aspirin after diagnosis does not reduce colorectal 
      cancer-specific mortality, but it does reduce all-cause mortality for colorectal 
      cancer patients.
FAU - Ye, X-F
AU  - Ye XF
AD  - Department of Health Statistics, Second Military Medical University, Shanghai 
      200433, China.
FAU - Wang, J
AU  - Wang J
AD  - Department of Health Statistics, Second Military Medical University, Shanghai 
      200433, China.
FAU - Shi, W-T
AU  - Shi WT
AD  - Department of Health Statistics, Second Military Medical University, Shanghai 
      200433, China.
FAU - He, J
AU  - He J
AD  - Department of Health Statistics, Second Military Medical University, Shanghai 
      200433, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20140902
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Class I Phosphatidylinositol 3-Kinases
MH  - Colorectal Neoplasms/*mortality
MH  - Humans
MH  - Observational Studies as Topic
MH  - Phosphatidylinositol 3-Kinases/genetics
PMC - PMC4260025
EDAT- 2014/09/03 06:00
MHDA- 2015/01/27 06:00
CRDT- 2014/09/03 06:00
PHST- 2014/05/16 00:00 [received]
PHST- 2014/07/18 00:00 [revised]
PHST- 2014/08/07 00:00 [accepted]
PHST- 2014/09/03 06:00 [entrez]
PHST- 2014/09/03 06:00 [pubmed]
PHST- 2015/01/27 06:00 [medline]
AID - bjc2014481 [pii]
AID - 10.1038/bjc.2014.481 [doi]
PST - ppublish
SO  - Br J Cancer. 2014 Nov 25;111(11):2172-9. doi: 10.1038/bjc.2014.481. Epub 2014 Sep 
      2.

PMID- 21509719
OWN - NLM
STAT- MEDLINE
DCOM- 20120206
LR  - 20131121
IS  - 1439-1902 (Electronic)
IS  - 0171-6425 (Linking)
VI  - 59
IP  - 7
DP  - 2011 Oct
TI  - Aspirin does not increase bleeding and allogeneic blood transfusion in coronary 
      artery surgery.
PG  - 421-4
LID - 10.1055/s-0030-1270835 [doi]
AB  - BACKGROUND: Traditionally, the administration of aspirin is stopped seven days 
      before coronary artery bypass surgery to reduce the risk of postoperative 
      bleeding. The aim of this study was to evaluate the effect of preoperative 
      aspirin on bleeding in these patients. METHODS: A prospective nonrandomized 
      unblinded study was carried out at the King Abdullah University Hospital in 
      Jordan/Irbid from June 2005 to December 2009 in 756 patients. Patients were 
      divided into 2 groups: Group 1 (n = 400) consisted of patients on aspirin, 
      100 mg/day, until the day of surgery; Group 2 (n = 356) consisted of patients who 
      stopped taking aspirin seven days before surgery. The groups were compared to 
      evaluate the effect of preoperative aspirin on bleeding in patients undergoing 
      elective coronary artery bypass surgery. Data were collected and compared and 
      included total amount of postoperative chest tube drainage, number of transfused 
      units of blood and blood products, and numbers of patients who required 
      reexploration for bleeding. Results were considered significant when P < 0.05. 
      RESULTS: There was no significant increase in the amount of blood loss, units of 
      transfused blood products, or the incidence of reexploration between the two 
      groups ( P > 0.05). CONCLUSION: Aspirin does not increase bleeding or increase 
      the need for allogeneic blood transfusion in coronary artery surgery.
CI  - © Georg Thieme Verlag KG Stuttgart · New York.
FAU - Hijazi, E
AU  - Hijazi E
AD  - Division of Cardiac Surgery, Department of General Surgery, Princess Muna 
      Al-Hussein Cardiac Center, King Abdullah University Hospital - Faculty of 
      Medicine/Jordan University of Science and Technology, Irbid, Jordan. 
      emad_hijazi@hotmail.com
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110420
PL  - Germany
TA  - Thorac Cardiovasc Surg
JT  - The Thoracic and cardiovascular surgeon
JID - 7903387
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Thorac Cardiovasc Surg. 2013 Apr;61(3):270
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - *Blood Transfusion
MH  - *Coronary Artery Bypass/adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Hospitals, University
MH  - Humans
MH  - Jordan
MH  - Male
MH  - Middle Aged
MH  - Postoperative Hemorrhage/chemically induced/*prevention & control
MH  - Prospective Studies
MH  - Reoperation
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2011/04/22 06:00
MHDA- 2012/02/07 06:00
CRDT- 2011/04/22 06:00
PHST- 2011/04/22 06:00 [entrez]
PHST- 2011/04/22 06:00 [pubmed]
PHST- 2012/02/07 06:00 [medline]
AID - 10.1055/s-0030-1270835 [doi]
PST - ppublish
SO  - Thorac Cardiovasc Surg. 2011 Oct;59(7):421-4. doi: 10.1055/s-0030-1270835. Epub 
      2011 Apr 20.

PMID- 18295304
OWN - NLM
STAT- MEDLINE
DCOM- 20081007
LR  - 20191210
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 122
IP  - 3
DP  - 2008
TI  - Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane 
      A2 production.
PG  - 359-65
LID - 10.1016/j.thromres.2007.12.011 [doi]
AB  - INTRODUCTION: There is emerging evidence of a considerable variability of the 
      impact of aspirin on clinical outcome and laboratory findings. Persistent TxA2 
      production seems to be the most likely reason. Aim of this study was to determine 
      whether the mechanism responsible for TxA2 persistent production is, at least 
      partially, dependent upon aspirin-insensitive platelet COX-2 enzymatic pathway. 
      METHODS AND RESULTS: In 100 consecutive patients, under chronic aspirin 
      anti-platelet treatment (100-160 mg/day) selected on the basis of detectable 
      plasma salicylate levels, serum and Arachidonic Acid (AA)-induced platelet TxA2 
      production, immunoblot analysis of platelet COX-1/COX-2 expression and COX-2 
      activity were studied. Immunoblot revealed COX-2 expression in 46% patients, in 
      an amount that was markedly lower than COX-1. In 10 COX-2 positive patients with 
      TxA2 levels over the median, AA-induced TxA2 production performed in vitro in the 
      presence of the COX-2 inhibitor CAY10404 and aspirin demonstrated that COX-2 
      dependent TxA2 production is less than 2%. CONCLUSION: Our data demonstrate that 
      the inter-individual variability of platelet sensitivity to aspirin is due to a 
      reduced efficacy of aspirin on platelet COX-1 despite ascertained patient 
      compliance. We suggest that serum TxA2 assay might be performed in future 
      clinical studies to improve our knowledge on the residual TxA2 production in 
      aspirin-treated patients.
FAU - Riondino, Silvia
AU  - Riondino S
AD  - Department of Experimental Medicine, "Sapienza" University, Italy.
FAU - Trifirò, Elisabetta
AU  - Trifirò E
FAU - Principessa, Lorenzo
AU  - Principessa L
FAU - Mascioletti, Silvia
AU  - Mascioletti S
FAU - Di Renzo, Livia
AU  - Di Renzo L
FAU - Gaudio, Carlo
AU  - Gaudio C
FAU - Biasucci, Luigi M
AU  - Biasucci LM
FAU - Crea, Filippo
AU  - Crea F
FAU - Pulcinelli, Fabio M
AU  - Pulcinelli FM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20080304
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Algorithms
MH  - Aspirin/*administration & dosage/blood
MH  - Blood Platelets/*drug effects/enzymology
MH  - Cardiovascular Diseases/drug therapy/prevention & control
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase 2/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance/*physiology
MH  - Female
MH  - Hematology/*methods/standards
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Platelet Aggregation Inhibitors/*administration & dosage/blood
MH  - Thromboxane A2/*metabolism
EDAT- 2008/02/26 09:00
MHDA- 2008/10/08 09:00
CRDT- 2008/02/26 09:00
PHST- 2007/09/18 00:00 [received]
PHST- 2007/12/05 00:00 [revised]
PHST- 2007/12/18 00:00 [accepted]
PHST- 2008/02/26 09:00 [pubmed]
PHST- 2008/10/08 09:00 [medline]
PHST- 2008/02/26 09:00 [entrez]
AID - S0049-3848(07)00482-3 [pii]
AID - 10.1016/j.thromres.2007.12.011 [doi]
PST - ppublish
SO  - Thromb Res. 2008;122(3):359-65. doi: 10.1016/j.thromres.2007.12.011. Epub 2008 
      Mar 4.

PMID- 7508430
OWN - NLM
STAT- MEDLINE
DCOM- 19940317
LR  - 20171213
IS  - 8750-7587 (Print)
IS  - 0161-7567 (Linking)
VI  - 75
IP  - 5
DP  - 1993 Nov
TI  - Cell-free hemoglobin potentiates acetylcholine-induced coronary vasoconstriction 
      in rabbit hearts.
PG  - 2224-33
AB  - Cell-free hemoglobin (Hb) preparations have been shown to alter vascular tone in 
      vitro and in vivo. The high affinity of Hb for nitric oxide, the putative 
      endothelium-derived relaxing factor (EDRF), may be primarily responsible for this 
      activity, but the contribution of tissue-damaging oxygen-derived free radicals 
      has not been established. We investigated the effects of human Hb 
      interdimerically cross-linked with bis-(3,5-dibromosalicyl)fumarate (alpha alpha 
      Hb) on the coronary vasomotor response to acetylcholine (ACh) in isolated 
      perfused rabbit hearts. Infusion of 0.1 g/dl alpha alpha Hb altered the 
      dose-dependent response to ACh, decreasing the calculated IC50 (ACh concn at 
      which coronary pressure is 50% of its maximal value) from 3.96 +/- 0.34 to 0.85 
      +/- 0.06 microM (P < 0.01). This augmented sensitivity to ACh was only partially 
      reversed upon washout of alpha alpha Hb (IC50 1.93 +/- 0.13 microM). Simultaneous 
      infusion of 60 microM deferoxamine mesylate with alpha alpha Hb attenuated this 
      response (IC50 decreased from 3.86 +/- 0.27 to 1.73 +/- 0.38 microM), which was 
      completely reversed after removal of alpha alpha Hb (IC50 3.41 +/- 0.17 microM). 
      NG-nitro-L-arginine methyl ester (50 microM) and cross-linked cyanomethemoglobin 
      (CNmet alpha alpha Hb, 0.1 g/dl) induced a significant (P < 0.05) increase in 
      ACh-induced vasoconstriction accompanied by a reduction in myocardial functions 
      in the same range as that caused by alpha alpha Hb. Infusion of deferoxamine 
      mesylate (60 microM) with CNmet alpha alpha Hb completely prevented the reduction 
      in IC50 elicited by the infusion of CNmet alpha alpha Hb alone. These data 
      demonstrate that alpha alpha Hb can alter coronary vasomotor responsiveness and 
      suggest the involvement of at least two mechanisms, one that is related to an 
      accessible ferrous heme and is reversible and another that does not require an 
      open heme site and is irreversible.
FAU - Motterlini, R
AU  - Motterlini R
AD  - San Raffaele Scientific Institute, Milan, Italy.
FAU - Macdonald, V W
AU  - Macdonald VW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Appl Physiol (1985)
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Reactive Oxygen Species)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.4.- (Amino Acid Oxidoreductases)
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Acetylcholine/*pharmacology
MH  - Amino Acid Oxidoreductases/metabolism
MH  - Animals
MH  - Arginine/analogs & derivatives/pharmacology
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Coronary Circulation/*drug effects
MH  - Cross-Linking Reagents/pharmacology
MH  - Endothelium, Vascular/drug effects
MH  - Heart Function Tests
MH  - Hemoglobins/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - NG-Nitroarginine Methyl Ester
MH  - Nitric Oxide/pharmacology
MH  - Nitric Oxide Synthase
MH  - Oxygen Consumption/drug effects
MH  - Parasympathetic Nervous System/drug effects/physiology
MH  - Rabbits
MH  - Reactive Oxygen Species/metabolism
MH  - Vasoconstriction/*drug effects
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
AID - 10.1152/jappl.1993.75.5.2224 [doi]
PST - ppublish
SO  - J Appl Physiol (1985). 1993 Nov;75(5):2224-33. doi: 10.1152/jappl.1993.75.5.2224.

PMID- 1808626
OWN - NLM
STAT- MEDLINE
DCOM- 19920521
LR  - 20190912
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 44
IP  - 3
DP  - 1991 Nov
TI  - Two year Cottbus reinfarction study with 30 mg aspirin per day.
PG  - 159-69
AB  - All 701 heart infarction patients admitted to 15 hospitals in the district of 
      Cottbus between 1981 and 1983 were randomly administered 30, 60 or 1000 mg 
      aspirin daily according to the territorial affiliation of their local hospitals. 
      The physical and drug therapy during the 2 years follow-up was highly 
      standardized; deviations--as far as they occurred--were documented. Lower 
      all-cause mortality was statistically demonstrated in patients over 60 and a 
      lower fatal reinfarction rate in patients over 50 as well as in men. Deaths and 
      fatal reinfarctions were significantly lower among patients with a history of 
      angina pectoris, marked ST-depression, with an infarction location except for the 
      posterior wall and among hypercholesterolemic patients. The preventive effect of 
      60 mg aspirin daily was less than that of 30 mg in comparison to the 1000 mg 
      group. Side effects were seen in 4 and 8% (first and second year), respectively, 
      of the patients administered 30 mg aspirin as opposed to 22 and 17% in patients 
      allocated 1000 mg. We conclude that the optimum dose of aspirin for preventing 
      reinfarctions could be as low as 30 mg daily.
FAU - Hoffman, W
AU  - Hoffman W
AD  - District Hospital, Cottbus, Germany.
FAU - Förster, W
AU  - Förster W
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 54397-85-2 (Thromboxane B2)
RN  - B7IN85G1HY (Dinoprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Dinoprost/blood
MH  - Follow-Up Studies
MH  - Gastrointestinal Diseases/complications
MH  - Germany/epidemiology
MH  - Hospitals, District
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/epidemiology/mortality
MH  - Random Allocation
MH  - Recurrence
MH  - Survival Rate
MH  - Thromboxane B2/blood
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
AID - 10.1016/0952-3278(91)90051-6 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 1991 Nov;44(3):159-69. doi: 
      10.1016/0952-3278(91)90051-6.

PMID- 12194885
OWN - NLM
STAT- MEDLINE
DCOM- 20021001
LR  - 20220410
IS  - 0091-6765 (Print)
IS  - 0091-6765 (Linking)
VI  - 110 Suppl 4
IP  - Suppl 4
DP  - 2002 Aug
TI  - Environmental contributions to the allergic asthma epidemic.
PG  - 553-6
AB  - Current data overwhelmingly document the existence of a worldwide asthma 
      epidemic, although individual studies remain controversial. The epidemic is 
      thought to involve primarily persons with allergic asthma, and many diverse 
      theories, based on an immunopathologic understanding of disease, have recently 
      emerged to explain this involvement. In the context of recent insights into the 
      immune basis of experimental asthma, we discuss in this review the leading asthma 
      epidemic theories, including a new theory based on inhaled environmental 
      proteases. Although no single theory may yet be fully embraced, there exists 
      substantial hope that a unifying mechanism for the epidemic will be revealed 
      through additional research.
FAU - Kheradmand, Farrah
AU  - Kheradmand F
AD  - Department of Medicine, The Biology of Inflammation Center, Baylor College of 
      Medicine, Houston, Texas 77030, USA.
FAU - Rishi, Kirtee
AU  - Rishi K
FAU - Corry, David B
AU  - Corry DB
LA  - eng
GR  - K08HL03344/HL/NHLBI NIH HHS/United States
GR  - K08HL03732/HL/NHLBI NIH HHS/United States
GR  - R01HL64061/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Environ Health Perspect
JT  - Environmental health perspectives
JID - 0330411
RN  - 0 (Air Pollutants)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 3.4.- (Endopeptidases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Air Pollutants/*adverse effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Asthma/*epidemiology/*immunology
MH  - Child
MH  - *Disease Outbreaks
MH  - Endopeptidases/*adverse effects
MH  - Exercise
MH  - Humans
MH  - Hypersensitivity
MH  - Infections/complications
MH  - *Inhalation Exposure
MH  - Obesity/complications
PMC - PMC1241204
EDAT- 2002/08/27 10:00
MHDA- 2002/10/03 04:00
CRDT- 2002/08/27 10:00
PHST- 2002/08/27 10:00 [pubmed]
PHST- 2002/10/03 04:00 [medline]
PHST- 2002/08/27 10:00 [entrez]
AID - sc271_5_1835 [pii]
AID - 10.1289/ehp.02110s4553 [doi]
PST - ppublish
SO  - Environ Health Perspect. 2002 Aug;110 Suppl 4(Suppl 4):553-6. doi: 
      10.1289/ehp.02110s4553.

PMID- 8925092
OWN - NLM
STAT- MEDLINE
DCOM- 19961101
LR  - 20190914
IS  - 1572-6495 (Print)
IS  - 1572-6495 (Linking)
VI  - 677
IP  - 1
DP  - 1996 Feb 23
TI  - Simultaneous determination of acetylsalicylic acid and salicylic acid in human 
      plasma by high-performance liquid chromatography.
PG  - 172-7
AB  - A high-performance liquid chromatographic (HPLC) method is described for the 
      simultaneous determination of acetylsalicylic acid (ASA) and its main metabolite 
      salicylic acid (SA) in human plasma. Acidified plasma is deproteinized with 
      acetonitrile which is separated from the aqueous layer by adding sodium chloride. 
      ASA and SA are extracted into the acetonitrile layer with high yield, and 
      determined by reversed-phase HPLC (column: Novapak C18 4 microns silica, 150 x 4 
      mm I.D.; eluent: 740 ml water, 900 microliters 85% orthophosphoric acid, 180 ml 
      acetonitrile) and photometric detection (237 nm). 2-Methylbenzoic acid is used as 
      internal standard. The method allows the determination of ASA and SA in human 
      plasma as low as 100 ng/ml with good precision (better than 10%). The assay was 
      used to determine the pharmacokinetic parameters of ASA and SA following oral 
      administration of 100-500 mg ASA in healthy volunteers.
FAU - Kees, F
AU  - Kees F
AD  - Department of Pharmacology, University of Regensburg, Germany.
FAU - Jehnich, D
AU  - Jehnich D
FAU - Grobecker, H
AU  - Grobecker H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Netherlands
TA  - J Chromatogr B Biomed Appl
JT  - Journal of chromatography. B, Biomedical applications
JID - 9421796
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics, Non-Narcotic/*blood/pharmacokinetics
MH  - Aspirin/*blood/pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Humans
MH  - Indicators and Reagents
MH  - Quality Control
MH  - Reproducibility of Results
MH  - Salicylates/*blood
MH  - Salicylic Acid
MH  - Specimen Handling
MH  - Therapeutic Equivalency
EDAT- 1996/02/23 00:00
MHDA- 1996/02/23 00:01
CRDT- 1996/02/23 00:00
PHST- 1996/02/23 00:00 [pubmed]
PHST- 1996/02/23 00:01 [medline]
PHST- 1996/02/23 00:00 [entrez]
AID - 0378434795004645 [pii]
AID - 10.1016/0378-4347(95)00464-5 [doi]
PST - ppublish
SO  - J Chromatogr B Biomed Appl. 1996 Feb 23;677(1):172-7. doi: 
      10.1016/0378-4347(95)00464-5.

PMID- 34332946
OWN - NLM
STAT- MEDLINE
DCOM- 20211029
LR  - 20211029
IS  - 1876-7605 (Electronic)
IS  - 1936-8798 (Linking)
VI  - 14
IP  - 16
DP  - 2021 Aug 23
TI  - 1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy 
      After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial.
PG  - 1801-1811
LID - S1936-8798(21)01045-1 [pii]
LID - 10.1016/j.jcin.2021.06.003 [doi]
AB  - OBJECTIVES: The aim of this study was to determine whether 1 month of 
      dual-antiplatelet therapy (DAPT) followed by aspirin monotherapy after 
      polymer-free drug-coated stent (PF-DCS) implantation is noninferior to 6 to 
      12 months of DAPT after biodegradable-polymer drug-eluting stent (BP-DES) 
      implantation. BACKGROUND: It is necessary to determine the optimal minimal 
      duration of DAPT followed by aspirin monotherapy after percutaneous coronary 
      intervention (PCI). METHODS: In this trial, 3,020 patients with coronary artery 
      disease considered for PCI for noncomplex lesions were randomized to 1-month DAPT 
      after PF-DCS (n = 1,507) or 6- to 12-month DAPT after BP-DES (n = 1,513). The 
      primary endpoint was the 1-year composite of cardiac death, nonfatal myocardial 
      infarction, target vessel revascularization, stroke, or major bleeding 
      (noninferiority hypothesis margin of 3%). RESULTS: The primary endpoint occurred 
      in 88 patients (5.9%) in the 1-month DAPT after PF-DCS group and 98 patients 
      (6.5%) in the 6- to 12-month DAPT after BP-DES group (absolute difference -0.7%; 
      upper limit of 1-sided 97.5% confidence interval: 1.33%; P < 0.001 for 
      noninferiority). The occurrence of major bleeding was not different (1.7% vs 
      2.5%; P = 0.136). There was no difference in the occurrence of stent thrombosis 
      (0.7% vs 0.8%; P = 0.842). CONCLUSIONS: Among patients who underwent PCI for 
      noncomplex lesions, 1-month DAPT followed by aspirin monotherapy after PF-DCS 
      implantation was noninferior to 6- to 12-month DAPT after BP-DES implantation for 
      the 1-year composite of cardiovascular events or major bleeding. The present 
      findings need to be interpreted in the setting of different types of stents 
      according to antiplatelet strategy. (A Randomized Controlled Comparison Between 
      One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus 
      A9-Eluting Stent Implantation; NCT02513810).
CI  - Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Hong, Sung-Jin
AU  - Hong SJ
AD  - Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.
FAU - Kim, Jung-Sun
AU  - Kim JS
AD  - Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.
FAU - Hong, Soon Jun
AU  - Hong SJ
AD  - Korea University College of Medicine, Seoul, Korea.
FAU - Lim, Do-Sun
AU  - Lim DS
AD  - Korea University College of Medicine, Seoul, Korea.
FAU - Lee, Seung-Yul
AU  - Lee SY
AD  - Wonkwang University Hospital, Iksan, Korea.
FAU - Yun, Kyeong Ho
AU  - Yun KH
AD  - Wonkwang University Hospital, Iksan, Korea.
FAU - Park, Jong-Kwan
AU  - Park JK
AD  - National Health Insurance Service Ilsan Hospital, Goyang, Korea.
FAU - Kang, Woong Chol
AU  - Kang WC
AD  - Gachon University College of Medicine, Incheon, Korea.
FAU - Kim, Yong Hoon
AU  - Kim YH
AD  - Kangwon National University School of Medicine, Chuncheon, Korea.
FAU - Yoon, Hyuck-Jun
AU  - Yoon HJ
AD  - Keimyung University College of Medicine, Daegu, Korea.
FAU - Won, Hoyoun
AU  - Won H
AD  - Chung-Ang University College of Medicine, Seoul, Korea.
FAU - Nam, Chung-Mo
AU  - Nam CM
AD  - Department of Preventive Medicine and Biostatistics, Yonsei University College of 
      Medicine, Seoul, Korea.
FAU - Ahn, Chul-Min
AU  - Ahn CM
AD  - Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.
FAU - Kim, Byeong-Keuk
AU  - Kim BK
AD  - Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.
FAU - Ko, Young-Guk
AU  - Ko YG
AD  - Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.
FAU - Choi, Donghoon
AU  - Choi D
AD  - Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.
FAU - Jang, Yangsoo
AU  - Jang Y
AD  - Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.
FAU - Hong, Myeong-Ki
AU  - Hong MK
AD  - Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea. 
      Electronic address: mkhong61@yuhs.ac.
CN  - One-Month DAPT Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT02513810
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20210728
PL  - United States
TA  - JACC Cardiovasc Interv
JT  - JACC. Cardiovascular interventions
JID - 101467004
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polymers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JACC Cardiovasc Interv. 2021 Aug 23;14(16):1812-1814. PMID: 34332942
MH  - Aspirin/adverse effects
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Humans
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Polymers
MH  - Treatment Outcome
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - drug-eluting stent(s)
OT  - percutaneous coronary intervention
COIS- Funding Support and Author Disclosures This study was supported by the 
      Cardiovascular Research Center (Seoul, South Korea) and funded by grants from 
      DIO, Cardinal Health Korea, and Terumo Corporation. No funder or sponsor had any 
      role in the design and conduct of the study; collection, management, analysis, 
      and interpretation of the data; preparation, review, or approval of the 
      manuscript; or decision to submit the manuscript for publication. The authors 
      have reported that they have no relationships relevant to the contents of this 
      paper to disclose.
EDAT- 2021/08/02 06:00
MHDA- 2021/10/30 06:00
CRDT- 2021/08/01 20:40
PHST- 2021/03/22 00:00 [received]
PHST- 2021/05/14 00:00 [revised]
PHST- 2021/06/01 00:00 [accepted]
PHST- 2021/08/02 06:00 [pubmed]
PHST- 2021/10/30 06:00 [medline]
PHST- 2021/08/01 20:40 [entrez]
AID - S1936-8798(21)01045-1 [pii]
AID - 10.1016/j.jcin.2021.06.003 [doi]
PST - ppublish
SO  - JACC Cardiovasc Interv. 2021 Aug 23;14(16):1801-1811. doi: 
      10.1016/j.jcin.2021.06.003. Epub 2021 Jul 28.

PMID- 20819399
OWN - NLM
STAT- MEDLINE
DCOM- 20110103
LR  - 20181201
IS  - 1743-1328 (Electronic)
IS  - 0161-6412 (Linking)
VI  - 32
IP  - 7
DP  - 2010 Sep
TI  - Impact of platelet transfusion on hematoma expansion in patients receiving 
      antiplatelet agents before intracerebral hemorrhage.
PG  - 706-10
LID - 10.1179/174313209X459129 [doi]
AB  - OBJECTIVES: Patients receiving antiplatelet medications are reported to be at 
      increased risk for hematoma enlargement and worse clinical outcomes following 
      intracerebral hemorrhage (ICH). While platelet transfusions are frequently 
      administered to counteract qualitative platelet defects in the setting of ICH, 
      conclusive evidence in support of this therapeutic strategy is lacking. In fact, 
      platelet transfusions may be associated with adverse effects, and represent a 
      finite resource. We sought to determine the clinical efficacy of platelet 
      transfusion and its impact on systemic complications following ICH in a cohort of 
      patients receiving antiplatelet medications. METHODS: We retrospectively analysed 
      the medical records of 66 patients admitted to our institution from June 2003 to 
      July 2008 who suffered a primary ICH while receiving antiplatelet 
      (acetylsalicylic acid and/or clopidogrel) therapy. The primary outcome was the 
      rate of significant (>25% increase from admission) hematoma expansion in 
      transfused (n=35) versus non-transfused (n=31) patients. Discharge 
      modified-Rankin score (mRS) and the rates of systemic complications were also 
      assessed. RESULTS: There were no statistically significant differences in rates 
      of hematoma expansion between cohorts, nor were there differences in demographic 
      variables, systemic complications or discharge mRS. Subgroup analysis revealed 
      that there was a higher rate of hematoma expansion in the clopidogrel cohort 
      (p=0.034) than in the cohort of patients receiving aspirin alone. DISCUSSION: 
      This study suggests that platelet administration does not reduce the frequency of 
      hematoma expansion in ICH patients receiving antiplatelet medications. This lack 
      of efficacy may relate to transfusion timing, as a significant proportion of 
      hematoma expansion occurs within 6 hours post-ictus. Additionally, the increased 
      rates of hematoma expansion in the clopidogrel cohort may relate to its prolonged 
      half-life. A larger, prospective study is warranted.
FAU - Ducruet, Andrew F
AU  - Ducruet AF
AD  - Department of Neurological Surgery, Columbia University, New York, NY 10032, USA.
FAU - Hickman, Zachary L
AU  - Hickman ZL
FAU - Zacharia, Brad E
AU  - Zacharia BE
FAU - Grobelny, Bartosz T
AU  - Grobelny BT
FAU - DeRosa, Peter A
AU  - DeRosa PA
FAU - Landes, Elissa
AU  - Landes E
FAU - Lei, Shuang
AU  - Lei S
FAU - Khandji, Joyce
AU  - Khandji J
FAU - Gutbrod, Sarah
AU  - Gutbrod S
FAU - Connolly, E Sander Jr
AU  - Connolly ES Jr
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cerebral Hemorrhage/*therapy
MH  - Clopidogrel
MH  - Databases, Factual
MH  - Female
MH  - Hematoma/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - *Platelet Transfusion
MH  - Retrospective Studies
MH  - Statistics, Nonparametric
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2010/09/08 06:00
MHDA- 2011/01/05 06:00
CRDT- 2010/09/08 06:00
PHST- 2010/09/08 06:00 [entrez]
PHST- 2010/09/08 06:00 [pubmed]
PHST- 2011/01/05 06:00 [medline]
AID - 10.1179/174313209X459129 [doi]
PST - ppublish
SO  - Neurol Res. 2010 Sep;32(7):706-10. doi: 10.1179/174313209X459129.

PMID- 22298034
OWN - NLM
STAT- MEDLINE
DCOM- 20120710
LR  - 20211021
IS  - 1573-2630 (Electronic)
IS  - 0165-5701 (Linking)
VI  - 32
IP  - 1
DP  - 2012 Feb
TI  - Microtrauma-induced recurrent hyphema and secondary glaucoma associated with 
      chronic acetylsalicylic acid use.
PG  - 89-92
LID - 10.1007/s10792-012-9517-5 [doi]
AB  - To report a case of microtrauma-induced recurrent hyphema and secondary glaucoma 
      associated with voluntary chronic acetylsalicylic acid (ASA) use. A 43-year-old 
      male developed advanced glaucoma in his right eye after a two-month followup 
      period of recurrent microhyphema, which had been induced by strong eye-rubbing. 
      In spite of topical and systemic antiglaucoma medication, as well as topical 
      corticosteroid and cycloplegic drugs and bed rest under hospitalization, the 
      hyphema and glaucoma were not controlled. His medical history revealed that he 
      had been using ASA for 2 years in order to prevent heart attacks. We asked the 
      patient to stop ASA intake and the hyphema cleared considerably on the third day 
      after discontinuation of the drug. One week after stopping ASA, trabeculectomy 
      with mitomycin C was performed without any complications. Glaucoma and recurrent 
      hyphema were controlled after surgery without any medical treatment. Chronic ASA 
      intake may cause recurrent hyphema and secondary glaucoma even after a 
      microtrauma. Medical histories of patients must always be taken, especially in 
      cases of prolonged recurrent hyphema.
FAU - Elgin, Ufuk
AU  - Elgin U
AD  - Department of Ophthalmology, Ulucanlar Eye Research Hospital, 24 Sokak, 13/4 
      06490, Bahcelievler, Ankara, Turkey. ufukelgin@superonline.com
FAU - Sen, Emine
AU  - Sen E
FAU - Teke, Mehmet Y
AU  - Teke MY
FAU - Tirhis, Hakan
AU  - Tirhis H
FAU - Ozturk, Faruk
AU  - Ozturk F
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20120202
PL  - Netherlands
TA  - Int Ophthalmol
JT  - International ophthalmology
JID - 7904294
RN  - 0 (Antihypertensive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Angina Pectoris/prevention & control
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Diagnosis, Differential
MH  - Eye Injuries/*complications/diagnosis
MH  - Glaucoma/*chemically induced/complications/therapy
MH  - Gonioscopy
MH  - Humans
MH  - Hyphema/diagnosis/*etiology/surgery
MH  - Intraocular Pressure
MH  - Male
MH  - Recurrence
MH  - Trabeculectomy
MH  - Trauma Severity Indices
MH  - Visual Acuity
MH  - Visual Fields
EDAT- 2012/02/03 06:00
MHDA- 2012/07/11 06:00
CRDT- 2012/02/03 06:00
PHST- 2010/06/04 00:00 [received]
PHST- 2012/01/11 00:00 [accepted]
PHST- 2012/02/03 06:00 [entrez]
PHST- 2012/02/03 06:00 [pubmed]
PHST- 2012/07/11 06:00 [medline]
AID - 10.1007/s10792-012-9517-5 [doi]
PST - ppublish
SO  - Int Ophthalmol. 2012 Feb;32(1):89-92. doi: 10.1007/s10792-012-9517-5. Epub 2012 
      Feb 2.

PMID- 11978562
OWN - NLM
STAT- MEDLINE
DCOM- 20020514
LR  - 20161124
IS  - 1167-1122 (Print)
IS  - 1167-1122 (Linking)
VI  - 12
IP  - 3
DP  - 2002 May-Jun
TI  - Lysine acetylsalicylate decreases proliferation and extracellular matrix gene 
      expression rate in keloid fibroblasts in vitro.
PG  - 231-5
AB  - BACKGROUND: In genetically predisposed individuals keloids are formed as benign 
      collagenous tumors. OBJECTIVE: The purpose of this study was to investigate 
      whether the proliferation and matrix gene expression of keloid fibroblasts is 
      differently influenced by the anti-inflammatory active drug lysine 
      acetylsalicylate (LAS) when compared to normal skin fibroblasts in vitro. 
      METHODS: Normal skin and keloid fibroblasts derived from human donors were 
      compared. RESULTS: Excessive scarring and the formation of keloids are (at least 
      in part) due to an overproduction of collagen types I and III. The results show a 
      significant dose-dependent anti-proliferative effect of lysine acetylsalicylate. 
      At the level of gene expression we observed a pronounced inhibitory effect of LAS 
      on procollagen I and III mRNA synthesis, whereas matrix metalloproteinase 1 and 
      tissue inhibitor of metalloproteinases 1 were not altered. CONCLUSIONS: Further 
      clinical studies are planned to evaluate these effects of a high-dose treatment 
      of keloids with LAS.
FAU - Petri, Jean-Bernhard
AU  - Petri JB
AD  - IBFB Institut für. Biomedizinische Forschung und Beratung, Karl-Heine-Str. 99, 
      Leipzig, Germany. b.petri@ibfb.de
FAU - Haustein, Uwe-Frithjof
AU  - Haustein UF
LA  - eng
PT  - Journal Article
PL  - France
TA  - Eur J Dermatol
JT  - European journal of dermatology : EJD
JID - 9206420
RN  - 0 (RNA, Messenger)
RN  - 9007-34-5 (Collagen)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aspirin/*analogs & derivatives/*metabolism
MH  - Cell Division
MH  - Cells, Cultured
MH  - Collagen/metabolism
MH  - Extracellular Matrix/*metabolism
MH  - Fibroblasts/cytology/metabolism
MH  - Humans
MH  - Keloid/metabolism/*pathology
MH  - Lysine/*analogs & derivatives/*metabolism
MH  - RNA, Messenger/metabolism
MH  - Skin/*metabolism/pathology
MH  - Wound Healing
EDAT- 2002/04/30 10:00
MHDA- 2002/05/15 10:01
CRDT- 2002/04/30 10:00
PHST- 2002/04/30 10:00 [pubmed]
PHST- 2002/05/15 10:01 [medline]
PHST- 2002/04/30 10:00 [entrez]
PST - ppublish
SO  - Eur J Dermatol. 2002 May-Jun;12(3):231-5.

PMID- 7497193
OWN - NLM
STAT- MEDLINE
DCOM- 19960117
LR  - 20131121
IS  - 0210-0010 (Print)
IS  - 0210-0010 (Linking)
VI  - 23
IP  - 120
DP  - 1995 Mar-Apr
TI  - [Non-valvular atrial fibrillation and cerebral infarction].
PG  - 370-6
AB  - Non-valvular auricular fibrillation (NVAF) is linked to a high rate of cerebral 
      embolism (CE), being one of the main causes of cerebral infarction in elderly 
      people. The real risk of these patients suffering a cerebral embolism depends on 
      various factors such as the type of fibrillation (chronic as opposed to 
      paroxistic) and on the coexistence or not of other cerebrovascular risk factors. 
      In recent years five random essays have been published on the primary prophylaxis 
      of CE in patients with NVAF (AFASAK, SPAF, BAATAF, CAFA and SPINAF) and one on 
      its secondary prophylaxis (EAFT), which have evaluated the efficiency of oral 
      anticoagulation, acetilsalicilic acid with placebo. The results indicate that 
      oral anticoagulation is efficient and safe both in primary and secondary 
      prophylaxis. Use of acetilsalicilic acid is safe, but less efficient, although it 
      is easier to administer and more economical, and would be indicated for patients 
      with a contraindication for anticoagulation or who are not compliant to therapy. 
      Currently we need to determine which factors identify the patient subgroups with 
      high risk NVAF both as regards the appearance of CE and that of haemorrhagic 
      complications for anticoagulation. The identification of these subgroups would 
      probably make it possible to give a more exact profile of the right treatment for 
      these patients.
FAU - Martín, R
AU  - Martín R
AD  - Sección de Neurología, Hospital Universitario de San Juan, Alicante.
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Fibrilación auricular no valvular e infarto cerebral.
PL  - Spain
TA  - Rev Neurol
JT  - Revista de neurologia
JID - 7706841
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Atrial Fibrillation/drug therapy/*physiopathology
MH  - Brain/*physiopathology
MH  - Cerebral Infarction/drug therapy/*physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Heart/*physiopathology
MH  - Humans
MH  - Intracranial Embolism and Thrombosis/physiopathology
RF  - 81
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
PST - ppublish
SO  - Rev Neurol. 1995 Mar-Apr;23(120):370-6.

PMID- 20124989
OWN - NLM
STAT- MEDLINE
DCOM- 20100628
LR  - 20131121
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 21
IP  - 3
DP  - 2010 Apr
TI  - Comparison of antiplatelet potency of sarpogrelate, aspirin, and beraprost in 
      healthy volunteers according to in-vitro closure time.
PG  - 262-5
LID - 10.1097/MBC.0b013e32833700fc [doi]
AB  - This open-label prospective study compared the antiplatelet potency of 
      sarpogrelate, aspirin, and beraprost in 20 healthy volunteers according to 
      in-vitro closure time. Volunteers were assigned to receive sarpogrelate, aspirin, 
      or beraprost for 14 days, then given 14 days of washout, then switched to another 
      of these medications. We measured in-vitro closure time using a platelet function 
      analyzer with collagen/epinephrine (CEPI). We also measured bleeding time, von 
      Willebrand factor (vWF), D-dimer, high sensitivity C-reactive protein (hs-CRP), 
      and fibrinogen. Baseline parameters were normal in all individuals and were not 
      significantly different among the three groups. In patients who received 
      sarpogrelate, there was no difference in CEPI-closure time at baseline and after 
      14 days. Aspirin and beraprost significantly prolonged the day 14 CEPI-closure 
      time compared with baseline, from 145 +/- 37 to 259 +/- 41 s (P < 0.0001) and 
      from 134 +/- 37 to 150 +/- 27 s (P = 0.035), respectively. The CEPI-closure time 
      change was greater for aspirin than for beraprost (178 +/- 28 vs. 112 +/- 20%, P 
      < 0.0001). None of the drugs changed the bleeding times of levels of vWF, 
      D-dimer, hs-CRP, and fibrinogen. In conclusion, ingestion of aspirin (100 mg 
      daily) and beraprost (120 microg daily) for 14 days significantly prolonged 
      in-vitro closure time but ingestion of saprogrelate (300 mg daily) for 14 days 
      did not. Aspirin was superior to beraprost in antiplatelet potency, as assessed 
      by in-vitro closure time with CEPI.
FAU - Kim, Kyung Min
AU  - Kim KM
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
FAU - Kim, Hyunjung
AU  - Kim H
FAU - Chi, Hyun-Sook
AU  - Chi HS
FAU - Park, Jung Sik
AU  - Park JS
FAU - Kim, Soon Bae
AU  - Kim SB
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Succinates)
RN  - 19P708E787 (sarpogrelate)
RN  - 35E3NJJ4O6 (beraprost)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Epoprostenol/*analogs & derivatives/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Platelet Function Tests
MH  - Prospective Studies
MH  - Succinates/*therapeutic use
EDAT- 2010/02/04 06:00
MHDA- 2010/06/29 06:00
CRDT- 2010/02/04 06:00
PHST- 2010/02/04 06:00 [entrez]
PHST- 2010/02/04 06:00 [pubmed]
PHST- 2010/06/29 06:00 [medline]
AID - 10.1097/MBC.0b013e32833700fc [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2010 Apr;21(3):262-5. doi: 
      10.1097/MBC.0b013e32833700fc.

PMID- 9809499
OWN - NLM
STAT- MEDLINE
DCOM- 19981123
LR  - 20131121
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 81
IP  - 4
DP  - 1998 Oct
TI  - Hypothesis: decreased use of pediatric aspirin has contributed to the increasing 
      prevalence of childhood asthma.
PG  - 347-51
AB  - BACKGROUND: The prevalence of asthma, atopic eczema, and allergic rhinitis has 
      increased over the last three decades in Western countries. Speculation on the 
      causes of this trend have focused on changes in environmental factors. We 
      hypothesize that the decreased use of aspirin in favor of acetaminophen, due to 
      the association of aspirin with Reye's syndrome during febrile respiratory 
      infections, may be contributing to these trends in the United States. DATA 
      SOURCES: A detailed literature search was conducted utilizing Medline. Studies 
      considered relevant and important involving both humans and animals in English 
      language were used. HYPOTHESIS: In the United States, the documented prevalence 
      of childhood asthma has increased since 1970, but the rate of this increase 
      accelerated upward beginning in the early 1980s when the use of pediatric aspirin 
      decreased. During the resolution of common respiratory viral infections, 
      prostaglandin E2 (PGE2) is produced through the actions of cyclooxygenase-2 
      (COX-2). Aspirin, but not acetaminophen, inhibits COX-2 activity. As PGE2 
      promotes TH2 and inhibits THI type cytokine generation, we hypothesize that the 
      decreased use of aspirin may be a factor in facilitating allergic sensitization 
      and asthma by augmenting the relative TH1/TH2 cytokine imbalance in genetically 
      predisposed children. CONCLUSION: We have presented an hypothesis based upon 
      epidemiologic trends, known biologic effects of cytokines and PGE2 on allergic 
      sensitization, and a potentially relevant pharmacologic effect of aspirin to 
      explain a component of the increasing prevalence of childhood asthma in the 
      United States. We suggest this theory be examined further in animal models as 
      well as in other countries where the prevalence of childhood asthma is 
      increasing.
FAU - Varner, A E
AU  - Varner AE
AD  - Allergy Diagnostic, Beachwood, Ohio 44122, USA.
FAU - Busse, W W
AU  - Busse WW
FAU - Lemanske, R F Jr
AU  - Lemanske RF Jr
LA  - eng
GR  - AI26609/AI/NIAID NIH HHS/United States
GR  - AI34891/AI/NIAID NIH HHS/United States
GR  - HL56396/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced/epidemiology
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Prevalence
MH  - United States
RF  - 45
EDAT- 1998/11/11 03:02
MHDA- 2001/03/28 10:01
CRDT- 1998/11/11 03:02
PHST- 1998/11/11 03:02 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1998/11/11 03:02 [entrez]
AID - S1081-1206(10)63127-4 [pii]
AID - 10.1016/S1081-1206(10)63127-4 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 1998 Oct;81(4):347-51. doi: 
      10.1016/S1081-1206(10)63127-4.

PMID- 17636729
OWN - NLM
STAT- MEDLINE
DCOM- 20071018
LR  - 20200511
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 4
DP  - 2007 Jul 18
TI  - WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism 
      after major gynaecological surgery.
PG  - CD003679
AB  - BACKGROUND: The reported overall risk of deep venous thrombosis in gynaecological 
      surgery ranges from 7 to 45%. Fatal pulmonary embolism is estimated to occur in 
      nearly 1% of these women. Pharmaceutical interventions are one possible 
      prophylactic measure for preventing emboli in women undergoing major 
      gynaecological surgery. Agents include unfractionated heparin (low -dose and 
      adjusted-dose), low-molecular-weight heparins, heparinoids and warfarin. 
      OBJECTIVES: The objective of this review was to evaluate the effectiveness of 
      warfarin, heparin and aspirin in preventing thromboembolism after major 
      gynaecological surgery. SEARCH STRATEGY: We searched the Cochrane Menstrual 
      Disorders and Subfertility Group trials register (searched 15 August 2003), the 
      Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library issue 
      2, 2003), MEDLINE (1966 to April 2003), EMBASE (1985 to April 2003), and CINAHL 
      (1982 to April 2003). References from relevant articles were searched and authors 
      contacted where necessary. In addition we contacted experts in the field for 
      unpublished works. SELECTION CRITERIA: Randomised controlled trials of heparins, 
      warfarin or aspirin to prevent thromboembolism after major gynaecological surgery 
      were eligible for inclusion. DATA COLLECTION AND ANALYSIS: Thirty-three trials 
      were identified in the initial search. On careful inspection only eight of these 
      met the inclusion criteria. Trials were data extracted and assessed for quality 
      by at least two reviewers. Data were combined for meta-analysis using odds ratios 
      for dichotomous data or weighted mean difference for continuous data. A random 
      effects statistical model was used. MAIN RESULTS: The meta-analysis of heparin 
      versus placebo found a statistically significant decrease in the number of DVTs 
      in both the all women group (including those with and without malignancy) (OR 
      0.30, 95% CI 0.12 to 0.76) and the subgroup of only women with malignancy (OR 
      0.30, 95% CI 0.10 to 0.89). There was no significant difference in the incidence 
      of PE. Oral warfarin reduced DVT when compared to placebo in all women (OR 0.22, 
      95% CI 0.06 to 0.86) and in women with malignancy (OR 0.18, 95% CI 0.04 to 0.87). 
      Meta-analyses of UH and LMWH showed no statistical difference in any comparison. 
      No studies compared aspirin alone to placebo, heparin or warfarin. There was a 
      statistically significant increase in injection site haematomas associated with 
      heparin compared to placebo (OR 0.30, 95% CI 0.10 to 0.89). AUTHORS' CONCLUSIONS: 
      Women, undergoing major gynaecological surgery and without contraindications to 
      anticoagulants should be offered thromboprophylaxis. Evidence suggests that UH 
      and LMWH are equally as effective in preventing DVT and the one trial available 
      suggests that warfarin is as effective as UH. There is no evidence as yet to 
      suggest that warfarin, heparin or aspirin reduce incidence of PE.
FAU - Oates-Whitehead, R M
AU  - Oates-Whitehead RM
FAU - D'Angelo, A
AU  - D'Angelo A
FAU - Mol, B
AU  - Mol B
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20070718
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2003;(4):CD003679. PMID: 14583989
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Gynecologic Surgical Procedures
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Postoperative Complications/*prevention & control
MH  - Pulmonary Embolism/*prevention & control
MH  - Venous Thrombosis/*prevention & control
MH  - Warfarin/therapeutic use
RF  - 43
EDAT- 2007/07/20 09:00
MHDA- 2007/10/19 09:00
CRDT- 2007/07/20 09:00
PHST- 2007/07/20 09:00 [pubmed]
PHST- 2007/10/19 09:00 [medline]
PHST- 2007/07/20 09:00 [entrez]
AID - 10.1002/14651858.CD003679.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2007 Jul 18;(4):CD003679. doi: 
      10.1002/14651858.CD003679.pub2.

PMID- 30251061
OWN - NLM
STAT- MEDLINE
DCOM- 20190403
LR  - 20200225
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 75
IP  - 1
DP  - 2019 Jan
TI  - Dose reduction, oral application, and order of intake to preserve aspirin 
      antiplatelet effects in dipyrone co-medicated chronic artery disease patients.
PG  - 13-20
LID - 10.1007/s00228-018-2560-z [doi]
AB  - BACKGROUND: Dipyrone comedication in aspirin-treated patients is associated with 
      impaired pharmacodynamic response to aspirin (high on-treatment platelet 
      reactivity [HTPR]). Additionally, in small observational studies, an association 
      with impaired outcome has been described. In this uncontrolled, 
      hypothesis-generating study, we aimed to investigate strategies to prevent this 
      drug-drug interaction in patients with coronary artery disease (CAD). METHODS: We 
      analyzed pharmacodynamic response to aspirin in 80 dipyrone co-medicated CAD 
      patients. Aspirin antiplatelet effects were measured using arachidonic acid 
      (AA)-induced light-transmission aggregometry (LTA). Platelet reactivity was 
      associated with daily dose, administration form, and frequency. Additionally, we 
      conducted a time-series analysis in patients with HTPR to aspirin with 
      re-evaluation of pharmacodynamic response to aspirin after 5 days. RESULTS: 
      Patients' mean age was 75.5 ± 9.8 years. Forty-three (54%) were male, 22 (27.5%) 
      obese, and 38 (47.5%) diabetics. Baseline characteristics, cardiovascular risk 
      factors, comorbidities, comedication, or laboratory parameters did not differ 
      between patients with or without HTPR. HTPR to aspirin occurred in 34 out of 80 
      patients (42.5%). The incidence of HTPR was associated with dipyrone daily dose 
      (< 1 g/day: HTPR 20% vs. > 3 g/day: HTPR 50%, p > 0.0001) and form of 
      administration (i.v. 87.5% vs. oral 37.5%; p < 0.0001). A strict order of intake 
      (aspirin 30 min prior to dipyrone) restored aspirin antiplatelet effects in all 
      patients (HTPR before 100% vs. HTPR after 0%, p = 0.0002). CONCLUSION: This study 
      shows that dipyrone should be used with caution in aspirin-treated patients. If 
      dipyrone seems indispensable, the lowest effective dose and a strict order of 
      intake seem favorable.
FAU - Dannenberg, Lisa
AU  - Dannenberg L
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Düsseldorf, Germany. 
      lisa.dannenberg@med.uni-duesseldorf.de.
FAU - Petzold, Tobias
AU  - Petzold T
AD  - Department of Cardiology, LMU München, Munich, Germany.
AD  - DZHK (German Centre for Cardiovascular Research), Munich Heart Alliance, Munich, 
      Germany.
FAU - Achilles, Alina
AU  - Achilles A
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Düsseldorf, Germany.
FAU - Naguib, David
AU  - Naguib D
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Düsseldorf, Germany.
FAU - Zako, Saif
AU  - Zako S
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Düsseldorf, Germany.
FAU - Helten, Carolin
AU  - Helten C
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Düsseldorf, Germany.
FAU - M'Pembele, René
AU  - M'Pembele R
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Düsseldorf, Germany.
FAU - Mourikis, Philipp
AU  - Mourikis P
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Düsseldorf, Germany.
FAU - Podsvyadek, Yanina
AU  - Podsvyadek Y
AD  - Institute for Pharmacology and Clinical Pharmacology, Heinrich Heine University, 
      Düsseldorf, Germany.
FAU - Grandoch, Maria
AU  - Grandoch M
AD  - Institute for Pharmacology and Clinical Pharmacology, Heinrich Heine University, 
      Düsseldorf, Germany.
FAU - Levkau, Bodo
AU  - Levkau B
AD  - West German Heart and Vascular Center, University Hospital Essen, University of 
      Duisburg-Essen, Institute of Pathophysiology, Essen, Germany.
FAU - Zeus, Tobias
AU  - Zeus T
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Düsseldorf, Germany.
FAU - Kelm, Malte
AU  - Kelm M
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Düsseldorf, Germany.
FAU - Hohlfeld, Thomas
AU  - Hohlfeld T
AD  - Institute for Pharmacology and Clinical Pharmacology, Heinrich Heine University, 
      Düsseldorf, Germany.
FAU - Polzin, Amin
AU  - Polzin A
AD  - Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine 
      University Medical Center Dusseldorf, Düsseldorf, Germany.
LA  - eng
GR  - No. 16-2014/Medical Faculty of the Heinrich-Heine-University Düsseldorf/
GR  - No 46-2016/Medical Faculty of the Heinrich-Heine-University Düsseldorf/
PT  - Journal Article
PT  - Observational Study
DEP - 20180924
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacology
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Coronary Artery Disease/*drug therapy
MH  - Dipyrone/*administration & dosage/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Risk Factors
OTO - NOTNLM
OT  - Aggregation
OT  - Aspirin
OT  - Comedication
OT  - Dipyrone
OT  - Platelet activation
OT  - Platelet inhibition
EDAT- 2018/09/27 06:00
MHDA- 2019/04/04 06:00
CRDT- 2018/09/26 06:00
PHST- 2018/07/05 00:00 [received]
PHST- 2018/09/17 00:00 [accepted]
PHST- 2018/09/27 06:00 [pubmed]
PHST- 2019/04/04 06:00 [medline]
PHST- 2018/09/26 06:00 [entrez]
AID - 10.1007/s00228-018-2560-z [pii]
AID - 10.1007/s00228-018-2560-z [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2019 Jan;75(1):13-20. doi: 10.1007/s00228-018-2560-z. Epub 
      2018 Sep 24.

PMID- 6768397
OWN - NLM
STAT- MEDLINE
DCOM- 19800722
LR  - 20190610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 617
IP  - 3
DP  - 1980 Mar 21
TI  - Sodium n-butyrate induces prostaglandin synthetase activity in mastocytoma P-815 
      cells.
PG  - 536-9
AB  - Cultured mouse mastocytoma P-815 cells were treated with 1 mM sodium n-butyrate 
      for 40 h. The treated cell homogenate showed high activities in synthesizing 
      prostaglandin D2, E2, and F2 alpha. Such activities were virtually absent in 
      untreated cell homogenate. Direct addition of sodium n-butyrate to the homogenate 
      showed no effects. Pre-exposure of cells to acetylsalicylic acid did not diminish 
      the effect of the subsequent treatment with sodium n-butyrate. These data suggest 
      that sodium n-butyrate induces fatty acid cyclooxygenase in P-815 cells.
FAU - Koshihara, Y
AU  - Koshihara Y
FAU - Senshu, T
AU  - Senshu T
FAU - Kawamura, M
AU  - Kawamura M
FAU - Murota, S I
AU  - Murota SI
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Butyrates)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Butyrates/*pharmacology
MH  - Cells, Cultured
MH  - Enzyme Induction
MH  - Mast-Cell Sarcoma/*enzymology
MH  - Mice
MH  - Prostaglandin-Endoperoxide Synthases/*biosynthesis
EDAT- 1980/03/21 00:00
MHDA- 1980/03/21 00:01
CRDT- 1980/03/21 00:00
PHST- 1980/03/21 00:00 [pubmed]
PHST- 1980/03/21 00:01 [medline]
PHST- 1980/03/21 00:00 [entrez]
AID - 0005-2760(80)90020-X [pii]
AID - 10.1016/0005-2760(80)90020-x [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 1980 Mar 21;617(3):536-9. doi: 
      10.1016/0005-2760(80)90020-x.

PMID- 730426
OWN - NLM
STAT- MEDLINE
DCOM- 19790324
LR  - 20131121
IS  - 0340-0026 (Print)
IS  - 0340-0026 (Linking)
VI  - 16
IP  - 12
DP  - 1978 Dec
TI  - Chronopharmacokinetics of ethanol. III. Variation in rate of ethanolemia decay in 
      human subjects.
PG  - 594-9
AB  - Five male human subjects were administered repeated oral doses of ethanol 
      approximately four hours apart and were examined for venous ethanol levels during 
      the third and fourth hours after each dose. Estimates of the slopes of the 
      apparently linear ethanol disappearance curves exhibited statistically 
      significant variation along a 24-hour time scale within 4 of the 5 subjects, as 
      well as among individuals. Prior findings on one of the subjects were confirmed. 
      It is proposed in general that pharmacokinetic parameters may vary in accord with 
      the physiologic circadian phase at the time of drug challenge.
FAU - Sturtevant, R P
AU  - Sturtevant RP
FAU - Sturtevant, F M
AU  - Sturtevant FM
FAU - Pauly, J E
AU  - Pauly JE
FAU - Scheving, L E
AU  - Scheving LE
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Biopharm
JT  - International journal of clinical pharmacology and biopharmacy
JID - 7505527
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Ethanol/*blood/urine
MH  - Headache/chemically induced/drug therapy
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Middle Aged
EDAT- 1978/12/01 00:00
MHDA- 1978/12/01 00:01
CRDT- 1978/12/01 00:00
PHST- 1978/12/01 00:00 [pubmed]
PHST- 1978/12/01 00:01 [medline]
PHST- 1978/12/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Biopharm. 1978 Dec;16(12):594-9.

PMID- 21742104
OWN - NLM
STAT- MEDLINE
DCOM- 20110913
LR  - 20161125
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 162
IP  - 1
DP  - 2011 Jul
TI  - Polymorphisms associated with in vitro aspirin resistance are not associated with 
      clinical outcomes in patients with coronary artery disease who report regular 
      aspirin use.
PG  - 166-72.e1
LID - 10.1016/j.ahj.2011.03.026 [doi]
AB  - BACKGROUND: We hypothesized that single-nucleotide polymorphisms (SNPs) 
      associated with heightened in vitro platelet function during aspirin exposure 
      (which we define as "laboratory aspirin resistance") would be associated with 
      greater risk for death, myocardial infarction (MI) or stroke among patients with 
      coronary artery disease regularly using aspirin. METHODS: Duke Databank for 
      Cardiovascular Disease patients with (n = 3,449, CATHeterization GENetics cohort) 
      or without (n = 11,754, nongenetic cohort) banked DNA with ≥1 coronary stenosis 
      >75% were followed up at 6 months, then annually for death, MI, or stroke 
      occurring during periods of reported aspirin use. We evaluated associations of 
      candidate SNPs from GNB3, PEAR1, ITGB3, VAV3, ITGA2, GPVI, PTGS1, F2R, THBS1, 
      A2AR, and GP1BA with events during follow-up using Cox proportional hazards 
      modeling adjusted for clinical characteristics associated with outcomes in the 
      nongenetic cohort. RESULTS: Over a median of 3.5 years, 2,762 (24%) nongenetic 
      cohort patients and 648 (19%) CATHeterization GENetics cohort patients had the 
      composite outcome during reported aspirin use. No candidate SNPs were 
      significantly associated with death, MI, or stroke in either univariable or 
      multivariable analyses. A prospective analysis demonstrated 80% to 88% power to 
      detect a hazard ratio of ≥1.3 for minor allele carriers. CONCLUSION: Patients 
      with angiographically significant coronary artery disease regularly using aspirin 
      and carrying SNPs associated with laboratory aspirin resistance were not at 
      higher risk for death, MI, or stroke. Using these SNPs to guide more aggressive 
      antiplatelet therapy is not justified by these results. Direct extrapolation from 
      in vitro findings to the clinical setting should be avoided.
CI  - Copyright © 2011 Mosby, Inc. All rights reserved.
FAU - Voora, Deepak
AU  - Voora D
AD  - Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, 
      NC 27710, USA. deepak.voora@duke.edu
FAU - Horton, John
AU  - Horton J
FAU - Shah, Svati H
AU  - Shah SH
FAU - Shaw, Linda K
AU  - Shaw LK
FAU - Newby, L Kristin
AU  - Newby LK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9007-49-2 (DNA)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Alleles
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/*drug effects/metabolism
MH  - Coronary Angiography
MH  - Coronary Artery Disease/diagnostic imaging/drug therapy/*genetics
MH  - DNA/*genetics
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Resistance/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - *Polymorphism, Single Nucleotide
MH  - Prognosis
MH  - Severity of Illness Index
MH  - Time Factors
EDAT- 2011/07/12 06:00
MHDA- 2011/09/14 06:00
CRDT- 2011/07/12 06:00
PHST- 2010/08/17 00:00 [received]
PHST- 2011/03/17 00:00 [accepted]
PHST- 2011/07/12 06:00 [entrez]
PHST- 2011/07/12 06:00 [pubmed]
PHST- 2011/09/14 06:00 [medline]
AID - S0002-8703(11)00255-9 [pii]
AID - 10.1016/j.ahj.2011.03.026 [doi]
PST - ppublish
SO  - Am Heart J. 2011 Jul;162(1):166-72.e1. doi: 10.1016/j.ahj.2011.03.026.

PMID- 401699
OWN - NLM
STAT- MEDLINE
DCOM- 19770321
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 21
IP  - 1
DP  - 1977 Jan
TI  - Fenoprofen, aspirin, and gold induction in rheumatoid arthritis.
PG  - 52-61
AB  - Fenoprofen calcium (2,400 mg/day) or aspirin (3,900 mg/day) was administered in 
      double-blind fashion to 20 rheumatoid patients during 6 months of gold induction 
      therapy, and to 20 rheumatoid patients not receiving gold. Among both the 
      gold-treated and nongold-treated patients, the fenoprofen and aspirin groups 
      improved equally in all but one parameter of disease activity. Fenoprofen and 
      aspirin did not differ significantly in the observed prevalences of abdominal 
      discomfort, guaiac-positive stools, or peptic ulcers. Aspirin was associated with 
      significantly higher mean serum glutamic oxaloacetic transaminase (SGOT) levels 
      than fenoprofen, but only among patients undergoing gold induction. Comparison of 
      efficacy parameters between patients treated with gold and patients treated with 
      oral drugs alone revealed significant differences favoring gold.
FAU - Davis, J D
AU  - Davis JD
FAU - Turner, R A
AU  - Turner RA
FAU - Collins, R L
AU  - Collins RL
FAU - Ruchte, I R
AU  - Ruchte IR
FAU - Kaufmann, J S
AU  - Kaufmann JS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Phenylpropionates)
RN  - 12244-57-4 (Gold Sodium Thiomalate)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Aspartate Aminotransferases/blood
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fenoprofen/adverse effects/*therapeutic use
MH  - Gold Sodium Thiomalate/adverse effects/*therapeutic use
MH  - Humans
MH  - Joints/drug effects
MH  - Liver Function Tests
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Phenylpropionates/*therapeutic use
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1002/cpt197721152 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1977 Jan;21(1):52-61. doi: 10.1002/cpt197721152.

PMID- 16364011
OWN - NLM
STAT- MEDLINE
DCOM- 20060331
LR  - 20131121
IS  - 1046-7408 (Print)
IS  - 1046-7408 (Linking)
VI  - 55
IP  - 1
DP  - 2006 Jan
TI  - Aspirin desensitization in the treatment of antiphospholipid syndrome during 
      pregnancy in ASA-sensitive patients.
PG  - 45-50
AB  - PROBLEM: Antiphospholipid syndrome (APS) is associated with thrombosis and poor 
      pregnancy outcome in the presence of antiphospholipid antibodies (aPL). Patients 
      with aPL have a high risk of foetal loss. However, with low-dose aspirin 
      (acetylsalicylic acid; ASA) in combination with subcutaneous heparin, the chances 
      of full-term delivery increase. Nevertheless, ASA treatment is avoided in 
      pregnant, ASA-sensitive women with APS. METHODS: Rapid oral 
      challenge-desensitization to ASA was performed in four pregnant women with a 
      history of APS and aspirin sensitivity. In three patients, desensitization was 
      performed during pregnancy and before the next pregnancy in the fourth. 
      Desensitization was carried out in the ICU using increasing doses of aspirin 
      (0.1-125 mg) over a 24-hr period. RESULTS: Successful ASA desensitization was 
      achieved in all the patients. No severe side effects occurred during the 
      desensitization test. Only one patient required a small oral dose of 
      antihistamines. CONCLUSIONS: Aspirin desensitization may be a safe alternative 
      even during pregnancy if carefully monitored and permit patients with APS to 
      receive treatment with ASA. This would constitute a new indication in pregnant 
      women with APS and ASA sensitivity.
FAU - Alijotas-Reig, Jaume
AU  - Alijotas-Reig J
AD  - Allergy and Clinical Immunology Unit, Department of Medicine, Institut 
      Universitari Dexeus, Universitat Autónoma, Barcelona, Spain. 
      jalijotas@vhebron.net
FAU - San Miguel-Moncín, Mar
AU  - San Miguel-Moncín M
FAU - Cisteró-Bahíma, Anna
AU  - Cisteró-Bahíma A
LA  - eng
PT  - Case Reports
PT  - Clinical Trial
PT  - Journal Article
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antiphospholipid Syndrome/*therapy
MH  - Aspirin/*immunology
MH  - *Desensitization, Immunologic
MH  - Female
MH  - Fetal Death/prevention & control
MH  - Follow-Up Studies
MH  - Humans
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - Pregnancy Outcome
MH  - Treatment Outcome
EDAT- 2005/12/21 09:00
MHDA- 2006/04/01 09:00
CRDT- 2005/12/21 09:00
PHST- 2005/12/21 09:00 [pubmed]
PHST- 2006/04/01 09:00 [medline]
PHST- 2005/12/21 09:00 [entrez]
AID - AJI322 [pii]
AID - 10.1111/j.1600-0897.2005.00322.x [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 2006 Jan;55(1):45-50. doi: 10.1111/j.1600-0897.2005.00322.x.

PMID- 11467839
OWN - NLM
STAT- MEDLINE
DCOM- 20010823
LR  - 20131121
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 285
IP  - 4
DP  - 2001 Jul 27
TI  - Protective effects of aspirin and vitamin E (alpha-tocopherol) against copper- 
      and cadmium-induced toxicity.
PG  - 921-5
AB  - A 24-h exposure to copper (400 microM, 600 microM) or cadmium (5 microM, 10 
      microM) significantly reduces the viability of COS-7 cells. A 2-h preincubation 
      with vitamin E does not protect COS-7 cells from copper-induced toxicity, but 
      does protect against cadmium-induced toxicity. Preincubation with aspirin 
      protects cells from both copper- and cadmium-induced toxicity. A combination of 
      aspirin and vitamin E (10 microM and 25 microM, respectively) increases cell 
      viability in copper-exposed cells in a clearly additive manner, while in 
      cadmium-exposed cells the effects are slightly additive. These results indicate 
      that aspirin and vitamin E can protect cells from metal-induced toxicity. 
      Differences in the protective effects of aspirin and vitamin E on copper versus 
      cadmium-induced toxicity may be due to alternative mechanisms of metal toxicity 
      or antioxidant activity.
CI  - Copyright 2001 Academic Press.
FAU - Mattie, M D
AU  - Mattie MD
AD  - Nicholas School of the Environment, Duke University, Durham, North Carolina 
      27708, USA.
FAU - Freedman, J H
AU  - Freedman JH
LA  - eng
GR  - P42 ES10356/ES/NIEHS NIH HHS/United States
GR  - R01 ES09949/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Antioxidants)
RN  - 0 (Protective Agents)
RN  - 00BH33GNGH (Cadmium)
RN  - 1406-18-4 (Vitamin E)
RN  - 789U1901C5 (Copper)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antioxidants/pharmacology
MH  - Aspirin/*pharmacology
MH  - COS Cells
MH  - Cadmium/*toxicity
MH  - Copper/*toxicity
MH  - Dose-Response Relationship, Drug
MH  - Protective Agents/pharmacology
MH  - Toxicity Tests
MH  - Vitamin E/*pharmacology
EDAT- 2001/07/27 10:00
MHDA- 2001/08/24 10:01
CRDT- 2001/07/27 10:00
PHST- 2001/07/27 10:00 [pubmed]
PHST- 2001/08/24 10:01 [medline]
PHST- 2001/07/27 10:00 [entrez]
AID - S0006-291X(01)95259-3 [pii]
AID - 10.1006/bbrc.2001.5259 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2001 Jul 27;285(4):921-5. doi: 
      10.1006/bbrc.2001.5259.

PMID- 8112690
OWN - NLM
STAT- MEDLINE
DCOM- 19940328
LR  - 20190830
IS  - 0015-5691 (Print)
IS  - 0015-5691 (Linking)
VI  - 103
IP  - 2
DP  - 1994 Feb
TI  - [Effect of Y-20811, a thromboxane A2 synthetase inhibitor, on the arachidonic 
      acid-induced response in the blood-superfused canine coronary artery].
PG  - 59-66
AB  - Effects of Y-20811, a thromboxane A2 synthetase inhibitor, on the arachidonic 
      acid (AA)-induced responses were investigated in the isolated canine coronary 
      artery superfused with blood from a donor dog and Krebs-Henseleit solution. When 
      the coronary artery was superfused with Krebs-Henseleit solution, AA did not have 
      any remarkable effect on its tone. In the coronary artery superfused with blood, 
      in contrast, AA (10-100 micrograms) caused phasic constriction followed by 
      relaxation. After denudation of the endothelium, the contractile response was 
      augmented, and the relaxant effect was abolished. Y-20811 (1 mg/kg, i.v.), 
      administered into the donor dog, inhibited the contraction and augmented the 
      relaxation. Indomethacin (5 mg/kg, i.v.) and aspirin (30 mg/kg, i.v.) also 
      inhibited the AA-induced contraction. However, indomethacin inhibited the 
      relaxation induced by AA (10-100 micrograms), whereas aspirin inhibited the 
      relaxation induced by a low dose of AA (10-30 micrograms). These results suggest 
      that Y-20811 inhibits the TXA2-induced contraction and augments the production of 
      the relaxant metabolite of AA in the coronary artery.
FAU - Matsumoto, Y
AU  - Matsumoto Y
AD  - Tokyo Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd., Saitama, 
      Japan.
FAU - Noguchi, Y
AU  - Noguchi Y
FAU - Inui, J
AU  - Inui J
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Nihon Yakurigaku Zasshi
JT  - Nihon yakurigaku zasshi. Folia pharmacologica Japonica
JID - 0420550
RN  - 0 (Imidazoles)
RN  - 24A25745AD (Y 20811)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - EC 5.3.99.5 (Thromboxane-A Synthase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid/pharmacology
MH  - Arteries/drug effects
MH  - Aspirin/pharmacology
MH  - Coronary Vessels/*drug effects
MH  - Dogs
MH  - Endothelium, Vascular/drug effects
MH  - Imidazoles/*pharmacology
MH  - In Vitro Techniques
MH  - Thromboxane-A Synthase/*antagonists & inhibitors
MH  - Vasoconstriction/*drug effects
EDAT- 1994/02/01 00:00
MHDA- 1994/02/01 00:01
CRDT- 1994/02/01 00:00
PHST- 1994/02/01 00:00 [pubmed]
PHST- 1994/02/01 00:01 [medline]
PHST- 1994/02/01 00:00 [entrez]
AID - 10.1254/fpj.103.59 [doi]
PST - ppublish
SO  - Nihon Yakurigaku Zasshi. 1994 Feb;103(2):59-66. doi: 10.1254/fpj.103.59.

PMID- 36645669
OWN - NLM
STAT- MEDLINE
DCOM- 20230228
LR  - 20230516
IS  - 1531-2267 (Electronic)
IS  - 1094-8341 (Print)
IS  - 1094-8341 (Linking)
VI  - 55
IP  - 3
DP  - 2023 Mar 1
TI  - Genomic and epigenomic responses to aspirin in human colonic organoids.
PG  - 101-112
LID - 10.1152/physiolgenomics.00070.2022 [doi]
AB  - Aspirin (ASA) is a proven chemoprotective agent for colorectal cancer, though 
      mechanisms underlying these effects are incompletely understood. Human organoids 
      are an ideal system to study genomic and epigenomic host-environment 
      interactions. We use human colonic organoids to profile ASA responses on 
      genome-wide gene expression and chromatin accessibility. Human colonic organoids 
      from one individual were cultured and treated in triplicate with 3 mM ASA or 
      vehicle control (DMSO) for 24 h. Gene expression and chromatin accessibility were 
      measured using RNA- and ATAC-sequencing, respectively. Differentially expressed 
      genes were analyzed using DESeq2. Top genes were validated by qPCR. Gene set 
      enrichment was performed by SetRank. Differentially accessible peaks were 
      analyzed using DiffBind and edgeR. Peak annotation and differential transcription 
      factor motifs were determined by HOMER and diffTF. The results showed robust 
      transcriptional responses to ASA with significant enrichment for fatty acid 
      oxidation and peroxisome proliferator-activated receptor (PPAR) signaling that 
      were validated in independent organoid lines. A large number of differentially 
      accessible chromatin regions were found in response to ASA with significant 
      enrichment for Fos, Jun, and Hnf transcription factor motifs. Integrated analysis 
      of epigenomic and genomic treatment responses highlighted gene regions that could 
      mediate ASA's specific effects in the colon including those involved in 
      chemoprotection and/or toxicity. Assessment of chromatin accessibility and 
      transcriptional responses to ASA yielded new observations about genome-wide 
      effects in the colon facilitated by application of human colonic organoids. This 
      framework can be applied to study colonic ASA responses between individuals and 
      populations in future studies.
FAU - Witonsky, David
AU  - Witonsky D
AD  - Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, 
      University of Chicago, Chicago, Illinois.
FAU - Bielski, Margaret C
AU  - Bielski MC
AD  - Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, 
      University of Chicago, Chicago, Illinois.
FAU - Li, Jinchao
AU  - Li J
AD  - Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, 
      University of Chicago, Chicago, Illinois.
FAU - Lawrence, Kristi M
AU  - Lawrence KM
AD  - Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, 
      University of Chicago, Chicago, Illinois.
FAU - Mendoza, Ishmael N
AU  - Mendoza IN
AD  - Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, 
      University of Chicago, Chicago, Illinois.
FAU - Usman, Hina
AU  - Usman H
AD  - Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, 
      University of Chicago, Chicago, Illinois.
FAU - Kupfer, Sonia S
AU  - Kupfer SS
AUID- ORCID: 0000-0003-4857-2289
AD  - Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, 
      University of Chicago, Chicago, Illinois.
LA  - eng
GR  - R01 CA220329/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20230116
PL  - United States
TA  - Physiol Genomics
JT  - Physiological genomics
JID - 9815683
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Chromatin)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Humans
MH  - *Epigenomics
MH  - *Aspirin/metabolism
MH  - Colon/metabolism
MH  - Chromatin/metabolism
MH  - Transcription Factors/metabolism
MH  - Organoids
PMC - PMC10069959
OTO - NOTNLM
OT  - PPAR signaling
OT  - aspirin
OT  - chromatin accessibility
OT  - organoids
OT  - transcriptional response
COIS- No conflicts of interest, financial or otherwise, are declared by the authors.
EDAT- 2023/01/17 06:00
MHDA- 2023/03/03 06:00
PMCR- 2024/03/01
CRDT- 2023/01/16 11:32
PHST- 2024/03/01 00:00 [pmc-release]
PHST- 2023/01/17 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2023/01/16 11:32 [entrez]
AID - PG-00070-2022 [pii]
AID - 10.1152/physiolgenomics.00070.2022 [doi]
PST - ppublish
SO  - Physiol Genomics. 2023 Mar 1;55(3):101-112. doi: 
      10.1152/physiolgenomics.00070.2022. Epub 2023 Jan 16.

PMID- 32495688
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Jun 16
TI  - Antepartum Aspirin Administration Reduces Activin A and Cardiac Global 
      Longitudinal Strain in Preeclamptic Women.
PG  - e015997
LID - 10.1161/JAHA.119.015997 [doi]
LID - e015997
AB  - Background Approximately 60% of women have Stage B heart failure 1 year after a 
      preeclamptic delivery. Emerging evidence suggests that the profibrotic growth 
      factor activin A, which has been shown to induce cardiac fibrosis and 
      hypertrophy, is elevated in preeclampsia and may be inhibited by aspirin therapy. 
      We hypothesized that preeclamptic women receiving aspirin would have lower 
      activin A levels and reduced global longitudinal strain (GLS), a sensitive 
      measure of cardiac dysfunction, than women who do not receive aspirin. To test 
      our hypothesis, we performed a cohort study of women with preeclampsia or 
      superimposed preeclampsia and compared activin A levels and GLS in parturients 
      who did or did not receive aspirin. Methods and Results Ninety-two parturients 
      were enrolled, of whom 25 (27%) received aspirin (81 mg/day) therapy. GLS, plasma 
      activin A, and follistatin, which inactivates activin A, were measured. Women 
      receiving aspirin therapy had lower median (interquartile range) levels of 
      activin A (8.17 [3.70, 10.36] versus 12.77 [8.37, 31.25] ng/mL; P=0.001) and 
      lower activin/follistatin ratio (0.59 [0.31, 0.93] versus 1.01 [0.64, 2.60] 
      P=0.002) than women who did not receive aspirin, which also remained significant 
      after multivariable analysis. Furthermore, GLS was worse in patients who did not 
      receive aspirin (-19.84±2.50 versus -17.77±2.60%; P=0.03) despite no differences 
      in blood pressure between groups. Conclusions Our study suggests that antepartum 
      aspirin therapy reduced serum activin A levels and improved GLS in preeclamptic 
      patients, suggesting that aspirin may mitigate the postpartum cardiac dysfunction 
      seen in women with preeclampsia.
FAU - Naseem, Heba
AU  - Naseem H
AD  - Department of Anesthesia and Critical Care University of Chicago IL.
FAU - Dreixler, John
AU  - Dreixler J
AD  - Department of Anesthesia and Critical Care University of Chicago IL.
FAU - Mueller, Ariel
AU  - Mueller A
AD  - Department of Anesthesia and Critical Care University of Chicago IL.
AD  - Department of Anesthesia, Critical Care and Pain Medicine Massachusetts General 
      Hospital Harvard Medical School Boston MA.
FAU - Tung, Avery
AU  - Tung A
AD  - Department of Anesthesia and Critical Care University of Chicago IL.
FAU - Dhir, Rohin
AU  - Dhir R
AD  - Department of Anesthesia and Critical Care University of Chicago IL.
FAU - Chibber, Rachna
AU  - Chibber R
AD  - Department of Obstetrics and Gynecology Health Sciences Center Kuwait University 
      Kuwait.
FAU - Fazal, Abid
AU  - Fazal A
AD  - Department of Anesthesia and Critical Care University of Chicago IL.
FAU - Granger, Joey P
AU  - Granger JP
AD  - Department of Physiology and Biophysics University of Mississippi Medical Center 
      Jackson MS.
FAU - Bakrania, Bhavisha A
AU  - Bakrania BA
AD  - Department of Physiology and Biophysics University of Mississippi Medical Center 
      Jackson MS.
FAU - deMartelly, Victoria
AU  - deMartelly V
AD  - Department of Obstetrics and Gynecology University of Chicago IL.
FAU - Rana, Sarosh
AU  - Rana S
AD  - Department of Obstetrics and Gynecology University of Chicago IL.
FAU - Shahul, Sajid
AU  - Shahul S
AD  - Department of Anesthesia and Critical Care University of Chicago IL.
LA  - eng
GR  - P20 GM121334/GM/NIGMS NIH HHS/United States
GR  - R21 HL148488/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Biomarkers)
RN  - 0 (FST protein, human)
RN  - 0 (Follistatin)
RN  - 0 (Follistatin-Related Proteins)
RN  - 0 (Fstl3 protein, human)
RN  - 0 (activin A)
RN  - 104625-48-1 (Activins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Activins/*blood
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Biomarkers/blood
MH  - Down-Regulation
MH  - Drug Administration Schedule
MH  - Female
MH  - Follistatin/blood
MH  - Follistatin-Related Proteins/blood
MH  - Humans
MH  - Pre-Eclampsia/*blood/diagnosis/*physiopathology
MH  - Pregnancy
MH  - *Prenatal Care
MH  - Prospective Studies
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Function, Left/*drug effects
MH  - Young Adult
PMC - PMC7429043
OTO - NOTNLM
OT  - activin A
OT  - aspirin
OT  - cardiac dysfunction
OT  - global longitudinal strain
OT  - pregnancy
EDAT- 2020/06/05 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - JAH35225 [pii]
AID - 10.1161/JAHA.119.015997 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2020 Jun 16;9(12):e015997. doi: 10.1161/JAHA.119.015997. Epub 
      2020 Jun 4.

PMID- 8918275
OWN - NLM
STAT- MEDLINE
DCOM- 19961217
LR  - 20220410
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 348
IP  - 9038
DP  - 1996 Nov 16
TI  - A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of 
      ischaemic events (CAPRIE). CAPRIE Steering Committee.
PG  - 1329-39
AB  - BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of 
      antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin 
      and ticlopidine have been shown to be effective, but both have potentially 
      serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to 
      ticlopidine, is an inhibitor of platelet aggregation induced by adenosine 
      diphosphate. METHODS: CAPRIE was a randomised, blinded, international trial 
      designed to assess the relative efficacy of clopidogrel (75 mg once daily) and 
      aspirin (325 mg once daily) in reducing the risk of a composite outcome cluster 
      of ischaemic stroke, myocardial infarction, or vascular death; their relative 
      safety was also assessed. The population studied comprised subgroups of patients 
      with atherosclerotic vascular disease manifested as either recent ischaemic 
      stroke, recent myocardial infarction, or symptomatic peripheral arterial disease. 
      Patients were followed for 1 to 3 years. FINDINGS: 19,185 patients, with more 
      than 6300 in each of the clinical subgroups, were recruited over 3 years, with a 
      mean follow-up of 1.91 years. There were 1960 first events included in the 
      outcome cluster on which an intention-to-treat analysis showed that patients 
      treated with clopidogrel had an annual 5.32% risk of ischaemic stroke, myocardial 
      infarction, or vascular death compared with 5.83% with aspirin. These rates 
      reflect a statistically significant (p = 0.043) relative-risk reduction of 8.7% 
      in favour of clopidogrel (95% Cl 0.3-16.5). Corresponding on-treatment analysis 
      yielded a relative-risk reduction of 9.4%. There were no major differences in 
      terms of safety. Reported adverse experiences in the clopidogrel and aspirin 
      groups judged to be severe included rash (0.26% vs 0.10%), diarrhoea (0.23% vs 
      0.11%), upper gastrointestinal discomfort (0.97% vs 1.22%), intracranial 
      haemorrhage (0.33% vs 0.47%), and gastrointestinal haemorrhage (0.52% vs 0.72%), 
      respectively. There were ten (0.10%) patients in the clopidogrel group with 
      significant reductions in neutrophils (< 1.2 x 10(9)/L) and 16 (0.17%) in the 
      aspirin group. INTERPRETATION: Long-term administration of clopidogrel to 
      patients with atherosclerotic vascular disease is more effective than aspirin in 
      reducing the combined risk of ischaemic stroke, myocardial infarction, or 
      vascular death. The overall safety profile of clopidogrel is at least as good as 
      that of medium-dose aspirin.
CN  - CAPRIE Steering Committee
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 1997 Feb 1;349(9048):354; author reply 356. PMID: 9024393
CIN - Lancet. 1997 Feb 1;349(9048):354; author reply 356. PMID: 9024394
CIN - Lancet. 1997 Feb 1;349(9048):354-5; author reply 356. PMID: 9024395
CIN - Lancet. 1997 Feb 1;349(9048):355; author reply 356. PMID: 9024396
CIN - Lancet. 1997 Feb 1;349(9048):355-6. PMID: 9024397
CIN - Lancet. 1997 Mar 15;349(9054):806-7. PMID: 9074601
MH  - Adult
MH  - Arteriosclerosis/*prevention & control
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Brain Ischemia/*prevention & control
MH  - Clopidogrel
MH  - Cohort Studies
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Myocardial Ischemia/*prevention & control
MH  - Peripheral Vascular Diseases/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Treatment Outcome
FIR - Gent, M
IR  - Gent M
FIR - Beaumont, D
IR  - Beaumont D
FIR - Blanchard, J
IR  - Blanchard J
FIR - Bousser, M G
IR  - Bousser MG
FIR - Coffman, J
IR  - Coffman J
FIR - Easton, J D
IR  - Easton JD
FIR - Hampton, J R
IR  - Hampton JR
FIR - Harker, L A
IR  - Harker LA
FIR - Janzon, L
IR  - Janzon L
FIR - Kusmierek, J J
IR  - Kusmierek JJ
FIR - Panak, E
IR  - Panak E
FIR - Roberts, R S
IR  - Roberts RS
FIR - Shannon, J S
IR  - Shannon JS
FIR - Sicurella, J
IR  - Sicurella J
FIR - Tognoni, G
IR  - Tognoni G
FIR - Tool, E J
IR  - Tool EJ
FIR - Verstraete, M
IR  - Verstraete M
FIR - Warlow, C
IR  - Warlow C
FIR - Verstraete, M
IR  - Verstraete M
FIR - Easton, J D
IR  - Easton JD
FIR - Bousser, M G
IR  - Bousser MG
FIR - Cairns, J A
IR  - Cairns JA
FIR - Chesebro, J H
IR  - Chesebro JH
FIR - Hampton, J R
IR  - Hampton JR
FIR - von der Lippe, G
IR  - von der Lippe G
FIR - Ross Russell, R W
IR  - Ross Russell RW
FIR - Wolf, P A
IR  - Wolf PA
FIR - Boissel, J P
IR  - Boissel JP
FIR - Friedman, L
IR  - Friedman L
FIR - Fuster, V
IR  - Fuster V
FIR - Harrison, M G
IR  - Harrison MG
FIR - Pocock, S
IR  - Pocock S
FIR - Weksler, B B
IR  - Weksler BB
FIR - Gent, M
IR  - Gent M
FIR - Foster, G
IR  - Foster G
FIR - Lewis, G
IR  - Lewis G
FIR - Lychak, T
IR  - Lychak T
FIR - Nelson, H L
IR  - Nelson HL
FIR - Roberts, R S
IR  - Roberts RS
FIR - Sicurella, J
IR  - Sicurella J
FIR - Sicurella, J
IR  - Sicurella J
FIR - Stewart, C
IR  - Stewart C
FIR - Szechtman, B
IR  - Szechtman B
FIR - Chrolavicius, S
IR  - Chrolavicius S
FIR - Copland, I
IR  - Copland I
FIR - Jedrzojawski, B
IR  - Jedrzojawski B
FIR - McCreadie, F
IR  - McCreadie F
FIR - Wilkinson, L
IR  - Wilkinson L
FIR - Vonderveehn, S
IR  - Vonderveehn S
FIR - Boissel, J P
IR  - Boissel JP
FIR - Boutitie, F
IR  - Boutitie F
FIR - Beaumont, D
IR  - Beaumont D
FIR - Perdriset, G
IR  - Perdriset G
FIR - Thizon de Gualle, I
IR  - Thizon de Gualle I
FIR - Hoek, J
IR  - Hoek J
FIR - Besnier, M O
IR  - Besnier MO
FIR - Boddy, A
IR  - Boddy A
FIR - Brooker, D
IR  - Brooker D
FIR - Derzko, G
IR  - Derzko G
FIR - Jones, A
IR  - Jones A
FIR - Metzinger, C
IR  - Metzinger C
FIR - Novack, J
IR  - Novack J
FIR - Pratt, S
IR  - Pratt S
FIR - Roome, D
IR  - Roome D
FIR - Schulhof, J P
IR  - Schulhof JP
FIR - Vallee, E
IR  - Vallee E
FIR - Valtier, D
IR  - Valtier D
FIR - Bastida, E
IR  - Bastida E
FIR - Coy, L
IR  - Coy L
FIR - Creek, R
IR  - Creek R
FIR - Destelle, G
IR  - Destelle G
FIR - Döberl, T
IR  - Döberl T
FIR - de la Forest-Divonne, N
IR  - de la Forest-Divonne N
FIR - Gallo, G
IR  - Gallo G
FIR - Garcia, A
IR  - Garcia A
FIR - Geudelin, B
IR  - Geudelin B
FIR - Hundt, F
IR  - Hundt F
FIR - Hylkema, R
IR  - Hylkema R
FIR - Vanhove, P
IR  - Vanhove P
FIR - Amalfitano, N
IR  - Amalfitano N
FIR - Cabala, K
IR  - Cabala K
FIR - Caniglia, J
IR  - Caniglia J
FIR - Duval, I
IR  - Duval I
FIR - Forgie, L
IR  - Forgie L
FIR - Neiss, A C
IR  - Neiss AC
FIR - Wesseling, T
IR  - Wesseling T
FIR - Plehn, J F
IR  - Plehn JF
FIR - Kennedy, S J
IR  - Kennedy SJ
FIR - Zwolak, R M
IR  - Zwolak RM
FIR - Reeves, A
IR  - Reeves A
FIR - McDaniel, M D
IR  - McDaniel MD
FIR - MacDonald, G J
IR  - MacDonald GJ
FIR - Murphy, C
IR  - Murphy C
FIR - Howes, P S
IR  - Howes PS
FIR - Cornell, L K
IR  - Cornell LK
FIR - Hynes, M L
IR  - Hynes ML
FIR - Jackson, C M
IR  - Jackson CM
FIR - Lyden, P D
IR  - Lyden PD
FIR - Rothrock, J F
IR  - Rothrock JF
FIR - Hye, R J
IR  - Hye RJ
FIR - Dittrich, H C
IR  - Dittrich HC
FIR - Kelly, N M
IR  - Kelly NM
FIR - Kerridge, C M
IR  - Kerridge CM
FIR - Chippendale, T
IR  - Chippendale T
FIR - Lobatz, M
IR  - Lobatz M
FIR - Diamond, E
IR  - Diamond E
FIR - Schim, J
IR  - Schim J
FIR - Sadoff, M
IR  - Sadoff M
FIR - Logan, W
IR  - Logan W
FIR - Auer, A
IR  - Auer A
FIR - Hamilton, W
IR  - Hamilton W
FIR - Frere, R
IR  - Frere R
FIR - Schroer, S
IR  - Schroer S
FIR - Wilcox, M
IR  - Wilcox M
FIR - Naeger, C
IR  - Naeger C
FIR - Harbison, J W
IR  - Harbison JW
FIR - Makhoul, R
IR  - Makhoul R
FIR - Taylor, J R
IR  - Taylor JR
FIR - Felton, W L 3rd
IR  - Felton WL 3rd
FIR - Lee, H M
IR  - Lee HM
FIR - Massey-Makhoul, K
IR  - Massey-Makhoul K
FIR - Browne, K F
IR  - Browne KF
FIR - Tyson, G S
IR  - Tyson GS
FIR - Pineiro, E
IR  - Pineiro E
FIR - Brenner, A S
IR  - Brenner AS
FIR - Ford, R A
IR  - Ford RA
FIR - Reddy, P J
IR  - Reddy PJ
FIR - Owens, P
IR  - Owens P
FIR - Heinsimer, J
IR  - Heinsimer J
FIR - Richter, K
IR  - Richter K
FIR - Markowski, K
IR  - Markowski K
FIR - Lentini, T
IR  - Lentini T
FIR - Howell, L
IR  - Howell L
FIR - Colfer, H T
IR  - Colfer HT
FIR - Rynbrandt, D J
IR  - Rynbrandt DJ
FIR - Wendt, C D
IR  - Wendt CD
FIR - Wilmot, M
IR  - Wilmot M
FIR - Stone, B
IR  - Stone B
FIR - Touchon, R
IR  - Touchon R
FIR - Briley, D
IR  - Briley D
FIR - Adkins, L
IR  - Adkins L
FIR - Roe, K
IR  - Roe K
FIR - Harless, C
IR  - Harless C
FIR - DeWood, M A
IR  - DeWood MA
FIR - Skidmore, J A
IR  - Skidmore JA
FIR - Randall, J M
IR  - Randall JM
FIR - Davenport, J
IR  - Davenport J
FIR - Farmer, C
IR  - Farmer C
FIR - Hanson, S
IR  - Hanson S
FIR - Kuo, L C
IR  - Kuo LC
FIR - Brown, P
IR  - Brown P
FIR - DesJardins, J
IR  - DesJardins J
FIR - Halpern, N
IR  - Halpern N
FIR - Talbot, W
IR  - Talbot W
FIR - Schainfeld, R
IR  - Schainfeld R
FIR - Rosenfield, K
IR  - Rosenfield K
FIR - Isber, J M
IR  - Isber JM
FIR - Grall, E
IR  - Grall E
FIR - Lanza, S
IR  - Lanza S
FIR - Walker, P A
IR  - Walker PA
FIR - Ivanhoe, R J
IR  - Ivanhoe RJ
FIR - Milunski, M R
IR  - Milunski MR
FIR - Kereiakes, D J
IR  - Kereiakes DJ
FIR - Abbottsmith, C W
IR  - Abbottsmith CW
FIR - Lausten, D A
IR  - Lausten DA
FIR - Helgason, C M
IR  - Helgason CM
FIR - Glover, V
IR  - Glover V
FIR - Gnutek, T
IR  - Gnutek T
FIR - Clark, W M
IR  - Clark WM
FIR - Coull, B M
IR  - Coull BM
FIR - Harrison, E
IR  - Harrison E
FIR - Suh, J T
IR  - Suh JT
FIR - McBride, J W
IR  - McBride JW
FIR - Foster, B
IR  - Foster B
FIR - Vittum, K
IR  - Vittum K
FIR - Lauer, N Y
IR  - Lauer NY
FIR - Adornato, B T
IR  - Adornato BT
FIR - Adornato, M K
IR  - Adornato MK
FIR - Fisher, M
IR  - Fisher M
FIR - Ameriso, S F
IR  - Ameriso SF
FIR - Scicli, A
IR  - Scicli A
FIR - Starling, M R
IR  - Starling MR
FIR - Petrusha, J A
IR  - Petrusha JA
FIR - Devlin, W H
IR  - Devlin WH
FIR - Suter, C C
IR  - Suter CC
FIR - Tucci, J
IR  - Tucci J
FIR - Stewart, S H
IR  - Stewart SH
FIR - Sadowsky, C
IR  - Sadowsky C
FIR - Stone, R
IR  - Stone R
FIR - Tuchman, M
IR  - Tuchman M
FIR - Massin, E K
IR  - Massin EK
FIR - Anderson, H V
IR  - Anderson HV
FIR - Harlan, M
IR  - Harlan M
FIR - Abrams, J
IR  - Abrams J
FIR - Timm, C
IR  - Timm C
FIR - Rosenberg, G
IR  - Rosenberg G
FIR - Hiatt, W R
IR  - Hiatt WR
FIR - Regensteiner, J G
IR  - Regensteiner JG
FIR - Bauer, T
IR  - Bauer T
FIR - Frey, J L
IR  - Frey JL
FIR - Darbonne, C
IR  - Darbonne C
FIR - Marlor, L
IR  - Marlor L
FIR - Haire, W D
IR  - Haire WD
FIR - Stephens, L C
IR  - Stephens LC
FIR - Kotulak, G D
IR  - Kotulak GD
FIR - Iteld, B
IR  - Iteld B
FIR - VanderStappen, A
IR  - VanderStappen A
FIR - Neuman, V
IR  - Neuman V
FIR - Kleiman, N
IR  - Kleiman N
FIR - Bushman, L
IR  - Bushman L
FIR - Fischer, A
IR  - Fischer A
FIR - Clark, W M
IR  - Clark WM
FIR - Harrison, E
IR  - Harrison E
FIR - Moon, H
IR  - Moon H
FIR - Klassen, A C
IR  - Klassen AC
FIR - Berman, M E
IR  - Berman ME
FIR - Sufit, R
IR  - Sufit R
FIR - Biller, J
IR  - Biller J
FIR - Olin, J W
IR  - Olin JW
FIR - Pirzada, C A
IR  - Pirzada CA
FIR - Medical, V A
IR  - Medical VA
FIR - Hershey, L A
IR  - Hershey LA
FIR - Burch, K
IR  - Burch K
FIR - Castaldo, J
IR  - Castaldo J
FIR - Jenny, D
IR  - Jenny D
FIR - Wohlberg, C
IR  - Wohlberg C
FIR - Gaines, K
IR  - Gaines K
FIR - Cape, C
IR  - Cape C
FIR - Gupta, S K
IR  - Gupta SK
FIR - Landa, R A
IR  - Landa RA
FIR - Norcross, S R
IR  - Norcross SR
FIR - Culebras, A
IR  - Culebras A
FIR - Pastor, D C
IR  - Pastor DC
FIR - Fairman, R M
IR  - Fairman RM
FIR - Zakulec, S
IR  - Zakulec S
FIR - Sutton, J M
IR  - Sutton JM
FIR - McCullough, T
IR  - McCullough T
FIR - Fenster, P E
IR  - Fenster PE
FIR - Feinberg, W M
IR  - Feinberg WM
FIR - Pellegrino, R G
IR  - Pellegrino RG
FIR - Jeffers, C
IR  - Jeffers C
FIR - Smith, W B
IR  - Smith WB
FIR - Vargas, R
IR  - Vargas R
FIR - McCormick, T
IR  - McCormick T
FIR - Ramadan, N M
IR  - Ramadan NM
FIR - Levine, S R
IR  - Levine SR
FIR - Hirsch, A T
IR  - Hirsch AT
FIR - Wasserman, A G
IR  - Wasserman AG
FIR - Nys, A
IR  - Nys A
FIR - Breslin, D J
IR  - Breslin DJ
FIR - Labib, S B
IR  - Labib SB
FIR - Woodhead, G
IR  - Woodhead G
FIR - Matzura, T M
IR  - Matzura TM
FIR - Dunlap, S
IR  - Dunlap S
FIR - Goodman, M A
IR  - Goodman MA
FIR - Cappelli, J
IR  - Cappelli J
FIR - Stein, P
IR  - Stein P
FIR - Nadamanee, K
IR  - Nadamanee K
FIR - Havranek, E
IR  - Havranek E
FIR - Weinberger, J
IR  - Weinberger J
FIR - Lava, N S
IR  - Lava NS
FIR - Horowitz, S
IR  - Horowitz S
FIR - Byer, J
IR  - Byer J
FIR - Wentworth, D
IR  - Wentworth D
FIR - Dexter, J D
IR  - Dexter JD
FIR - Bonnett, A
IR  - Bonnett A
FIR - Vetrovec, G W
IR  - Vetrovec GW
FIR - O'Brien, R P
IR  - O'Brien RP
FIR - Easton, J D
IR  - Easton JD
FIR - Wilterdink, J L
IR  - Wilterdink JL
FIR - Gelber, D A
IR  - Gelber DA
FIR - Hemberger, S
IR  - Hemberger S
FIR - Sherman, D
IR  - Sherman D
FIR - Rogers, D
IR  - Rogers D
FIR - Alberts, M J
IR  - Alberts MJ
FIR - McClenny, C
IR  - McClenny C
FIR - Weeks, K D
IR  - Weeks KD
FIR - Whisnant, D
IR  - Whisnant D
FIR - D'Alton, J
IR  - D'Alton J
FIR - Doolittle, H
IR  - Doolittle H
FIR - Siller, K A
IR  - Siller KA
FIR - Hass, W K
IR  - Hass WK
FIR - Grines, C
IR  - Grines C
FIR - Timmis, G
IR  - Timmis G
FIR - Gorelick, P B
IR  - Gorelick PB
FIR - Robinson, D
IR  - Robinson D
FIR - Lumsden, A B
IR  - Lumsden AB
FIR - MacDonald, J
IR  - MacDonald J
FIR - Hughes, R L
IR  - Hughes RL
FIR - Noonan, V
IR  - Noonan V
FIR - Goldberg, G
IR  - Goldberg G
FIR - Costello, R
IR  - Costello R
FIR - Mohiuddin, S
IR  - Mohiuddin S
FIR - Stengel, L
IR  - Stengel L
FIR - Frankel, M R
IR  - Frankel MR
FIR - Braimah, J
IR  - Braimah J
FIR - Creager, M A
IR  - Creager MA
FIR - Baum, P
IR  - Baum P
FIR - Cooke, J P
IR  - Cooke JP
FIR - Ma, A
IR  - Ma A
FIR - Babikian, V L
IR  - Babikian VL
FIR - O'Neal, M A
IR  - O'Neal MA
FIR - Mirsen, T
IR  - Mirsen T
FIR - Bruegel, C
IR  - Bruegel C
FIR - Coffman, J D
IR  - Coffman JD
FIR - Brindley, D C
IR  - Brindley DC
FIR - Mick, M
IR  - Mick M
FIR - Korenman, S G
IR  - Korenman SG
FIR - Brass, L M
IR  - Brass LM
FIR - Asher, S W
IR  - Asher SW
FIR - Halperin, J L
IR  - Halperin JL
FIR - Schlesinger, R
IR  - Schlesinger R
FIR - Gacioch, G M
IR  - Gacioch GM
FIR - Couch, J R Jr
IR  - Couch JR Jr
FIR - Skolnick, B E
IR  - Skolnick BE
FIR - Ware, M S
IR  - Ware MS
FIR - Anderson, J
IR  - Anderson J
FIR - Knepper, L
IR  - Knepper L
FIR - Victor, M
IR  - Victor M
FIR - Ball, S
IR  - Ball S
FIR - Gurley, J C
IR  - Gurley JC
FIR - Jessup, M
IR  - Jessup M
FIR - Elkayam, U
IR  - Elkayam U
FIR - Hughes, W G
IR  - Hughes WG
FIR - Fraser, J A
IR  - Fraser JA
FIR - Potvin, E A
IR  - Potvin EA
FIR - McMillan, J
IR  - McMillan J
FIR - Grierson, J
IR  - Grierson J
FIR - Hartwick, N
IR  - Hartwick N
FIR - Musclow, S
IR  - Musclow S
FIR - Thompson, A
IR  - Thompson A
FIR - Mewett, J
IR  - Mewett J
FIR - Sivan, R
IR  - Sivan R
FIR - Turpie, A G
IR  - Turpie AG
FIR - Morino, S
IR  - Morino S
FIR - Siguenza, M
IR  - Siguenza M
FIR - Blakely, J A
IR  - Blakely JA
FIR - Styling, S
IR  - Styling S
FIR - Balleza, L
IR  - Balleza L
FIR - Beanlands, D S
IR  - Beanlands DS
FIR - Garrard, L
IR  - Garrard L
FIR - Morgan, K
IR  - Morgan K
FIR - Ruddy, T
IR  - Ruddy T
FIR - Morris, A L
IR  - Morris AL
FIR - Anderson, B A
IR  - Anderson BA
FIR - Arneja, A S
IR  - Arneja AS
FIR - Carter, S A
IR  - Carter SA
FIR - Daniels, V
IR  - Daniels V
FIR - McEwen, B
IR  - McEwen B
FIR - Ricci, A J
IR  - Ricci AJ
FIR - Swan, J H
IR  - Swan JH
FIR - Goode, J E
IR  - Goode JE
FIR - Selby, D A
IR  - Selby DA
FIR - Bozek, B
IR  - Bozek B
FIR - Shuaib, A
IR  - Shuaib A
FIR - Yeung, M
IR  - Yeung M
FIR - Press, M
IR  - Press M
FIR - Walston, L L
IR  - Walston LL
FIR - Fung, A Y
IR  - Fung AY
FIR - Henning, H
IR  - Henning H
FIR - Taylor, D C
IR  - Taylor DC
FIR - Abbey, H
IR  - Abbey H
FIR - Davies, C
IR  - Davies C
FIR - Saunders, L
IR  - Saunders L
FIR - Tanser, P H
IR  - Tanser PH
FIR - Feldman, D
IR  - Feldman D
FIR - Sullivan, B
IR  - Sullivan B
FIR - Sayles, M J
IR  - Sayles MJ
FIR - Kent, E
IR  - Kent E
FIR - Connolly, S J
IR  - Connolly SJ
FIR - Coletta, E
IR  - Coletta E
FIR - Carruthers, V
IR  - Carruthers V
FIR - Hui, W
IR  - Hui W
FIR - Klinke, P
IR  - Klinke P
FIR - Brass, N
IR  - Brass N
FIR - Kvill, L
IR  - Kvill L
FIR - Cusson, J
IR  - Cusson J
FIR - Van Nguyen, P
IR  - Van Nguyen P
FIR - Marchand, L
IR  - Marchand L
FIR - Roy, S
IR  - Roy S
FIR - Blair, J F
IR  - Blair JF
FIR - Wellington, J L
IR  - Wellington JL
FIR - Rody, K
IR  - Rody K
FIR - Poloni, S
IR  - Poloni S
FIR - Myers, M G
IR  - Myers MG
FIR - Morgan, C D
IR  - Morgan CD
FIR - Parsons, P
IR  - Parsons P
FIR - Lecours, R
IR  - Lecours R
FIR - Patanaude, J V
IR  - Patanaude JV
FIR - Turcotte, C
IR  - Turcotte C
FIR - Gutelius, J R
IR  - Gutelius JR
FIR - Pattenden, R
IR  - Pattenden R
FIR - Gagnon, R M
IR  - Gagnon RM
FIR - Racine, N
IR  - Racine N
FIR - Roy, C
IR  - Roy C
FIR - Harris, K
IR  - Harris K
FIR - Lovell, M
IR  - Lovell M
FIR - Teal, P A
IR  - Teal PA
FIR - Bloomer, J L
IR  - Bloomer JL
FIR - Thompson, C R
IR  - Thompson CR
FIR - Wong, M
IR  - Wong M
FIR - Sladen, J G
IR  - Sladen JG
FIR - MacDonald, K
IR  - MacDonald K
FIR - Heinrich, D
IR  - Heinrich D
FIR - Houde, G
IR  - Houde G
FIR - Nadeau, C
IR  - Nadeau C
FIR - Talbot, P
IR  - Talbot P
FIR - Pagé, A
IR  - Pagé A
FIR - Verdant, A
IR  - Verdant A
FIR - Smilovitch, M
IR  - Smilovitch M
FIR - Racine, N
IR  - Racine N
FIR - Steinmetz, O
IR  - Steinmetz O
FIR - Simard, D
IR  - Simard D
FIR - Benguigui, C
IR  - Benguigui C
FIR - Ouellet, C
IR  - Ouellet C
FIR - LeBrun, L H
IR  - LeBrun LH
FIR - Desrochers, M P
IR  - Desrochers MP
FIR - Finnie, K
IR  - Finnie K
FIR - McCreery, S
IR  - McCreery S
FIR - Kostuk, W J
IR  - Kostuk WJ
FIR - Pflugfelder, P W
IR  - Pflugfelder PW
FIR - Oskalns, R
IR  - Oskalns R
FIR - Bonet, J F
IR  - Bonet JF
FIR - Ilott, K
IR  - Ilott K
FIR - McConnell, J
IR  - McConnell J
FIR - Ruel, M
IR  - Ruel M
FIR - Primeau, L
IR  - Primeau L
FIR - Phillips, S
IR  - Phillips S
FIR - Coleman-Kamphuis, L
IR  - Coleman-Kamphuis L
FIR - Leclerc, J R
IR  - Leclerc JR
FIR - Solymoss, S
IR  - Solymoss S
FIR - Côté, R
IR  - Côté R
FIR - Bourque, F
IR  - Bourque F
FIR - Lee, T K
IR  - Lee TK
FIR - Kvill, L
IR  - Kvill L
FIR - Bernstein, V
IR  - Bernstein V
FIR - Doyle, L
IR  - Doyle L
FIR - Timothee, J R
IR  - Timothee JR
FIR - Chebayeb, R
IR  - Chebayeb R
FIR - Lefkowitz, C
IR  - Lefkowitz C
FIR - Hambly, P
IR  - Hambly P
FIR - Klein, G M
IR  - Klein GM
FIR - Robertson, M
IR  - Robertson M
FIR - Bayer, N
IR  - Bayer N
FIR - Couse, P
IR  - Couse P
FIR - Norris, J W
IR  - Norris JW
FIR - Medel, M J
IR  - Medel MJ
FIR - Sevitt, B
IR  - Sevitt B
FIR - Fitzsimons, J
IR  - Fitzsimons J
FIR - Fitchett, D
IR  - Fitchett D
FIR - Serpa, A
IR  - Serpa A
FIR - Marr, D
IR  - Marr D
FIR - Ouellet, B
IR  - Ouellet B
FIR - Bellavance, A
IR  - Bellavance A
FIR - Pryse-Phillips, W
IR  - Pryse-Phillips W
FIR - Howse, D C
IR  - Howse DC
FIR - Rabkin, S W
IR  - Rabkin SW
FIR - McCans, J
IR  - McCans J
FIR - Brandjes, D P
IR  - Brandjes DP
FIR - Büller, H R
IR  - Büller HR
FIR - Dÿkema, A R
IR  - Dÿkema AR
FIR - Kromhout, J G
IR  - Kromhout JG
FIR - Lawson, J A
IR  - Lawson JA
FIR - Peters, R J
IR  - Peters RJ
FIR - van der Sande, J J
IR  - van der Sande JJ
FIR - Stam, J
IR  - Stam J
FIR - Blok, L M
IR  - Blok LM
FIR - Jenner, Y
IR  - Jenner Y
FIR - Ternede, O
IR  - Ternede O
FIR - Lens, J
IR  - Lens J
FIR - Bollen, E C
IR  - Bollen EC
FIR - Welten, R J
IR  - Welten RJ
FIR - Termeulen, P
IR  - Termeulen P
FIR - Hollanders, W P
IR  - Hollanders WP
FIR - Lok, D J
IR  - Lok DJ
FIR - Groeneveld, H
IR  - Groeneveld H
FIR - Bouwens, L H
IR  - Bouwens LH
FIR - Tietge, F C
IR  - Tietge FC
FIR - van der Velden, E C
IR  - van der Velden EC
FIR - Bruggink-André, P W
IR  - Bruggink-André PW
FIR - van Iersel, G J
IR  - van Iersel GJ
FIR - Seegers, J
IR  - Seegers J
FIR - van Vliet, A C
IR  - van Vliet AC
FIR - van der Sar, P
IR  - van der Sar P
FIR - Verhoog, B D
IR  - Verhoog BD
FIR - van der Sar de Nooijer, S H
IR  - van der Sar de Nooijer SH
FIR - Verhoog-Nijhuis, I
IR  - Verhoog-Nijhuis I
FIR - Franke, C L
IR  - Franke CL
FIR - Koehler, P J
IR  - Koehler PJ
FIR - van der Meer, J
IR  - van der Meer J
FIR - van Os, J S
IR  - van Os JS
FIR - van der Heijden, M
IR  - van der Heijden M
FIR - van Wijk, L M
IR  - van Wijk LM
FIR - Kragten, J A
IR  - Kragten JA
FIR - de Warrimont-Henquet, J
IR  - de Warrimont-Henquet J
FIR - Feld, R
IR  - Feld R
FIR - Van Gemert, H M
IR  - Van Gemert HM
FIR - Dippel, D W
IR  - Dippel DW
FIR - Koudstaal, P J
IR  - Koudstaal PJ
FIR - Vanneste, J A
IR  - Vanneste JA
FIR - Linssen, W H
IR  - Linssen WH
FIR - Kruisdijk, J J
IR  - Kruisdijk JJ
FIR - Visser, J
IR  - Visser J
FIR - Van Gool, T F
IR  - Van Gool TF
FIR - Vooges, J
IR  - Vooges J
FIR - De Vries, A C
IR  - De Vries AC
FIR - Klinkert, P
IR  - Klinkert P
FIR - Bartlema, K A
IR  - Bartlema KA
FIR - Banga, J D
IR  - Banga JD
FIR - Niemeijer-Kanters, S D
IR  - Niemeijer-Kanters SD
FIR - de Groot, M G
IR  - de Groot MG
FIR - Moll, F L
IR  - Moll FL
FIR - Sybrandy, R
IR  - Sybrandy R
FIR - Buth, J
IR  - Buth J
FIR - Schol, F P
IR  - Schol FP
FIR - Donders, R C
IR  - Donders RC
FIR - Algra, A
IR  - Algra A
FIR - Pop, G A
IR  - Pop GA
FIR - van der Heijden, R
IR  - van der Heijden R
FIR - Knippenberg, B
IR  - Knippenberg B
FIR - Sier, J C
IR  - Sier JC
FIR - Berqvist, D
IR  - Berqvist D
FIR - Karacagil, S
IR  - Karacagil S
FIR - Eriksson, I
IR  - Eriksson I
FIR - Bowald, S
IR  - Bowald S
FIR - Holmberg, A
IR  - Holmberg A
FIR - Ljungman, C
IR  - Ljungman C
FIR - Westman, B
IR  - Westman B
FIR - Sivenius, J
IR  - Sivenius J
FIR - Puranen, J
IR  - Puranen J
FIR - Karinen, A
IR  - Karinen A
FIR - Onatsu, J
IR  - Onatsu J
FIR - Salmenperä, T
IR  - Salmenperä T
FIR - Kalinen, M
IR  - Kalinen M
FIR - Kaste, M
IR  - Kaste M
FIR - Tatlisumak, T
IR  - Tatlisumak T
FIR - Soinne, L
IR  - Soinne L
FIR - Kallela, M
IR  - Kallela M
FIR - Kotila, M
IR  - Kotila M
FIR - Hartford, M
IR  - Hartford M
FIR - Herlitz, J
IR  - Herlitz J
FIR - Karlson, B W
IR  - Karlson BW
FIR - Strömblad, S O
IR  - Strömblad SO
FIR - Olofsson, B O
IR  - Olofsson BO
FIR - Strand, T
IR  - Strand T
FIR - Kristensen, B
IR  - Kristensen B
FIR - Malm, J
IR  - Malm J
FIR - Melin, J H
IR  - Melin JH
FIR - Virtanen, M
IR  - Virtanen M
FIR - Olli, T
IR  - Olli T
FIR - Lindgärde, F
IR  - Lindgärde F
FIR - Pessah-Rasmussen, H
IR  - Pessah-Rasmussen H
FIR - Rendell, M
IR  - Rendell M
FIR - Ericsson, U B
IR  - Ericsson UB
FIR - Sahlman, A
IR  - Sahlman A
FIR - Savolainen, H
IR  - Savolainen H
FIR - Rämö, J
IR  - Rämö J
FIR - Lehtonen, J
IR  - Lehtonen J
FIR - Hillbom, M E
IR  - Hillbom ME
FIR - Reunanen, M
IR  - Reunanen M
FIR - Turkka, J
IR  - Turkka J
FIR - Ylönen, K
IR  - Ylönen K
FIR - Peltola, T
IR  - Peltola T
FIR - Juvonen, T
IR  - Juvonen T
FIR - Koskela, E
IR  - Koskela E
FIR - Erkinheimo, J
IR  - Erkinheimo J
FIR - Ängquist, K A
IR  - Ängquist KA
FIR - Hedberg, B
IR  - Hedberg B
FIR - Arnerlov, C
IR  - Arnerlov C
FIR - Rissanon, A
IR  - Rissanon A
FIR - Murros, K
IR  - Murros K
FIR - Idänpään-Heikkilä, U
IR  - Idänpään-Heikkilä U
FIR - Honka, L
IR  - Honka L
FIR - Heikkilä, J
IR  - Heikkilä J
FIR - Tiensuu, T
IR  - Tiensuu T
FIR - Boberg, J
IR  - Boberg J
FIR - Berggren, A L
IR  - Berggren AL
FIR - Thompson, P L
IR  - Thompson PL
FIR - Yu, E T
IR  - Yu ET
FIR - Bradshaw, P J
IR  - Bradshaw PJ
FIR - Cooke, P A
IR  - Cooke PA
FIR - Gordon, S P
IR  - Gordon SP
FIR - Loh, K S
IR  - Loh KS
FIR - McQuillan, B
IR  - McQuillan B
FIR - Moshiri, M M
IR  - Moshiri MM
FIR - Cross, D B
IR  - Cross DB
FIR - Egerton, W S
IR  - Egerton WS
FIR - Walker, P J
IR  - Walker PJ
FIR - Codd, C A
IR  - Codd CA
FIR - Kreuter, D A
IR  - Kreuter DA
FIR - Cox, S
IR  - Cox S
FIR - Naik, D
IR  - Naik D
FIR - Cavaye, D M
IR  - Cavaye DM
FIR - Harel, M C
IR  - Harel MC
FIR - Horowitz, J
IR  - Horowitz J
FIR - Rowe, C
IR  - Rowe C
FIR - Stewart, S
IR  - Stewart S
FIR - Boundy, K
IR  - Boundy K
FIR - Stringer, C F
IR  - Stringer CF
FIR - Anderson, J L
IR  - Anderson JL
FIR - Coller, D
IR  - Coller D
FIR - Aylward, P
IR  - Aylward P
FIR - Anderson, C
IR  - Anderson C
FIR - Burns, R
IR  - Burns R
FIR - Schultz, D
IR  - Schultz D
FIR - Waddy, P
IR  - Waddy P
FIR - Walsh, J
IR  - Walsh J
FIR - Davies, L
IR  - Davies L
FIR - Harris, J P
IR  - Harris JP
FIR - Wetzlar, A
IR  - Wetzlar A
FIR - McDougall, A
IR  - McDougall A
FIR - Sieunarine, K
IR  - Sieunarine K
FIR - Cremer, P
IR  - Cremer P
FIR - Donnan, G A
IR  - Donnan GA
FIR - Tonkin, A
IR  - Tonkin A
FIR - Levi, C
IR  - Levi C
FIR - Hanlan, J
IR  - Hanlan J
FIR - Ellery, F
IR  - Ellery F
FIR - White, H D
IR  - White HD
FIR - Hamer, A W
IR  - Hamer AW
FIR - Kapadia, V
IR  - Kapadia V
FIR - Ramanathan, K
IR  - Ramanathan K
FIR - Taylor, R R
IR  - Taylor RR
FIR - Hankey, G
IR  - Hankey G
FIR - Brooks, M
IR  - Brooks M
FIR - Young, T
IR  - Young T
FIR - McInerney, M
IR  - McInerney M
FIR - Sansom, J
IR  - Sansom J
FIR - Thomson, R
IR  - Thomson R
FIR - Spaulding, C
IR  - Spaulding C
FIR - Cutforth, R
IR  - Cutforth R
FIR - Thomson, A
IR  - Thomson A
FIR - Salem, H H
IR  - Salem HH
FIR - Coughlin, P
IR  - Coughlin P
FIR - Campbell, T J
IR  - Campbell TJ
FIR - Lord, R S
IR  - Lord RS
FIR - O'Sullivan, D
IR  - O'Sullivan D
FIR - Corrigan, C
IR  - Corrigan C
FIR - D'Arcy, S
IR  - D'Arcy S
FIR - Anderson, N E
IR  - Anderson NE
FIR - Charleston, A J
IR  - Charleston AJ
FIR - Davis, S M
IR  - Davis SM
FIR - Gerraty, R
IR  - Gerraty R
FIR - Bett, N
IR  - Bett N
FIR - Hewson, D J
IR  - Hewson DJ
FIR - Kester, R C
IR  - Kester RC
FIR - Scott, D J
IR  - Scott DJ
FIR - Berridge, D C
IR  - Berridge DC
FIR - Kent, P J
IR  - Kent PJ
FIR - Thornton, C A
IR  - Thornton CA
FIR - Sykes, H
IR  - Sykes H
FIR - Bennett, S
IR  - Bennett S
FIR - Blakey, D
IR  - Blakey D
FIR - Brooksby, W P
IR  - Brooksby WP
FIR - Johnston, R T
IR  - Johnston RT
FIR - Brack, M
IR  - Brack M
FIR - Hampton, J R
IR  - Hampton JR
FIR - Vowden, P
IR  - Vowden P
FIR - Gough, M J
IR  - Gough MJ
FIR - Hooper, R
IR  - Hooper R
FIR - Gough, M
IR  - Gough M
FIR - Hanley, S P
IR  - Hanley SP
FIR - MacAskill, M
IR  - MacAskill M
FIR - Miles, J
IR  - Miles J
FIR - Waywell, C
IR  - Waywell C
FIR - Mucklow, J C
IR  - Mucklow JC
FIR - Davis, C
IR  - Davis C
FIR - Harper, P
IR  - Harper P
FIR - Cooke, K
IR  - Cooke K
FIR - Lowe, G
IR  - Lowe G
FIR - Shaw, B
IR  - Shaw B
FIR - McKillop, J
IR  - McKillop J
FIR - Dormandy, J A
IR  - Dormandy JA
FIR - Chaudhry, H
IR  - Chaudhry H
FIR - Evans, J
IR  - Evans J
FIR - Bamford, J M
IR  - Bamford JM
FIR - Blundell, S
IR  - Blundell S
FIR - Venables, G
IR  - Venables G
FIR - Doyle, C
IR  - Doyle C
FIR - Shearman, C P
IR  - Shearman CP
FIR - Crow, A
IR  - Crow A
FIR - Dennis, M
IR  - Dennis M
FIR - Sandercock, P
IR  - Sandercock P
FIR - Brown, M M
IR  - Brown MM
FIR - Rogers, J
IR  - Rogers J
FIR - Boyle, R M
IR  - Boyle RM
FIR - Wiseman, B S
IR  - Wiseman BS
FIR - Humphrey, P R
IR  - Humphrey PR
FIR - Prentice, C R
IR  - Prentice CR
FIR - Moccetti, T
IR  - Moccetti T
FIR - Pasotti, E
IR  - Pasotti E
FIR - Sessa, F
IR  - Sessa F
FIR - Bertolini, A
IR  - Bertolini A
FIR - Rossi, A
IR  - Rossi A
FIR - Del, A
IR  - Del A
FIR - Malacrida, R
IR  - Malacrida R
FIR - Moccetti, D
IR  - Moccetti D
FIR - Besomi, G
IR  - Besomi G
FIR - Mattle, H P
IR  - Mattle HP
FIR - Eicher Vella, E
IR  - Eicher Vella E
FIR - Maurer, D
IR  - Maurer D
FIR - Rihs, F
IR  - Rihs F
FIR - Hoffmann, U
IR  - Hoffmann U
FIR - Bollinger, A
IR  - Bollinger A
FIR - Franzeck, U K
IR  - Franzeck UK
FIR - Mahler, F
IR  - Mahler F
FIR - Do, D
IR  - Do D
FIR - Baumgartner, I
IR  - Baumgartner I
FIR - Weder, B
IR  - Weder B
FIR - Bönig, L
IR  - Bönig L
FIR - Ludin, H P
IR  - Ludin HP
FIR - Bogousslavsky, J
IR  - Bogousslavsky J
FIR - Maeder-Ingvar, M
IR  - Maeder-Ingvar M
FIR - Regli, F
IR  - Regli F
FIR - Kappenberger, L
IR  - Kappenberger L
FIR - Depairon, M
IR  - Depairon M
FIR - Bizzini, G
IR  - Bizzini G
FIR - Beretta-Piccoli, C
IR  - Beretta-Piccoli C
FIR - Elshater-Zanetti, F
IR  - Elshater-Zanetti F
FIR - Guffi, C
IR  - Guffi C
FIR - Bertel, O
IR  - Bertel O
FIR - Deseö, T
IR  - Deseö T
FIR - Gmuer, W
IR  - Gmuer W
FIR - Bounameaux, H
IR  - Bounameaux H
FIR - Wicky, J
IR  - Wicky J
FIR - Desmarais, S
IR  - Desmarais S
FIR - Vogt, P
IR  - Vogt P
FIR - Fellay, D
IR  - Fellay D
FIR - Rhyner, K
IR  - Rhyner K
FIR - Wojtyna, W
IR  - Wojtyna W
FIR - Bonetti, T
IR  - Bonetti T
FIR - Brunner, J
IR  - Brunner J
FIR - Jäger, K A
IR  - Jäger KA
FIR - von Planta, I
IR  - von Planta I
FIR - Noseda, G
IR  - Noseda G
FIR - Pugliesi, A
IR  - Pugliesi A
FIR - Pons-Giudici, L
IR  - Pons-Giudici L
FIR - Meier, B
IR  - Meier B
FIR - Evéquoz, D
IR  - Evéquoz D
FIR - Schmidt, D
IR  - Schmidt D
FIR - Keel, H S
IR  - Keel HS
FIR - Heinrich, D
IR  - Heinrich D
FIR - Follath, F
IR  - Follath F
FIR - Brunner, H P
IR  - Brunner HP
FIR - Caduff, B
IR  - Caduff B
FIR - Wirth, M
IR  - Wirth M
FIR - Vuilliomenet, A
IR  - Vuilliomenet A
FIR - Savcic, M
IR  - Savcic M
FIR - Hürlimann, U
IR  - Hürlimann U
FIR - Bosshard, E
IR  - Bosshard E
FIR - Hacke, W
IR  - Hacke W
FIR - Brandt, T
IR  - Brandt T
FIR - Wildermuth, S
IR  - Wildermuth S
FIR - Ringleb, P
IR  - Ringleb P
FIR - Busse, O
IR  - Busse O
FIR - Straeten, V
IR  - Straeten V
FIR - Zeuner, K
IR  - Zeuner K
FIR - Vielhaber, S
IR  - Vielhaber S
FIR - Tettenborn, B
IR  - Tettenborn B
FIR - Krämer, G
IR  - Krämer G
FIR - Allardt, A
IR  - Allardt A
FIR - Schmitt-Henco, E
IR  - Schmitt-Henco E
FIR - Diener, H C
IR  - Diener HC
FIR - Schrader, V
IR  - Schrader V
FIR - Nebe, J
IR  - Nebe J
FIR - Pilger, E
IR  - Pilger E
FIR - Doder, A
IR  - Doder A
FIR - Gürtl, B
IR  - Gürtl B
FIR - Diehm, C
IR  - Diehm C
FIR - Gomer, M
IR  - Gomer M
FIR - Jansen, T
IR  - Jansen T
FIR - Kömpf, D
IR  - Kömpf D
FIR - Kaps, M
IR  - Kaps M
FIR - Vidal-Langwasser, M
IR  - Vidal-Langwasser M
FIR - Hennerici, M
IR  - Hennerici M
FIR - Daffertshofer, M
IR  - Daffertshofer M
FIR - Schminke, U
IR  - Schminke U
FIR - Osterhues, H H
IR  - Osterhues HH
FIR - Fischer, A
IR  - Fischer A
FIR - Rupprecht, H J
IR  - Rupprecht HJ
FIR - Borkowski, U
IR  - Borkowski U
FIR - Rudofsky, G
IR  - Rudofsky G
FIR - Rescher, A
IR  - Rescher A
FIR - Schwerdt, H
IR  - Schwerdt H
FIR - Hammer, B
IR  - Hammer B
FIR - Voss, R
IR  - Voss R
FIR - Grebe, M
IR  - Grebe M
FIR - Rieger, H
IR  - Rieger H
FIR - Grobe, R
IR  - Grobe R
FIR - Theiss, W
IR  - Theiss W
FIR - Schaub, F
IR  - Schaub F
FIR - Neumann, F J
IR  - Neumann FJ
FIR - Lutilsky, L
IR  - Lutilsky L
FIR - Aichner, F T
IR  - Aichner FT
FIR - Schmidauer, C
IR  - Schmidauer C
FIR - Erdlenbruch, K
IR  - Erdlenbruch K
FIR - Mórsdorf, B S
IR  - Mórsdorf BS
FIR - Hornig, C R
IR  - Hornig CR
FIR - Moulin, T
IR  - Moulin T
FIR - Chavot, D
IR  - Chavot D
FIR - Autret, A
IR  - Autret A
FIR - Lucas, C
IR  - Lucas C
FIR - Leys, D
IR  - Leys D
FIR - Henon, H
IR  - Henon H
FIR - Chedru, F
IR  - Chedru F
FIR - Ameri, A
IR  - Ameri A
FIR - Dunand, J F
IR  - Dunand JF
FIR - Dambrine, P
IR  - Dambrine P
FIR - Gabriel, A
IR  - Gabriel A
FIR - Labaki, F
IR  - Labaki F
FIR - Tran-Tranh, X
IR  - Tran-Tranh X
FIR - Jouannon, C
IR  - Jouannon C
FIR - Durup, F
IR  - Durup F
FIR - Pagès, M
IR  - Pagès M
FIR - Blard, J M
IR  - Blard JM
FIR - Giroud, M
IR  - Giroud M
FIR - Menassa, M
IR  - Menassa M
FIR - Zuber, M
IR  - Zuber M
FIR - Mas, J L
IR  - Mas JL
FIR - Hommel, M
IR  - Hommel M
FIR - Besson, G
IR  - Besson G
FIR - Laurian, C
IR  - Laurian C
FIR - Mathieu, J F
IR  - Mathieu JF
FIR - Geraud, G
IR  - Geraud G
FIR - Larrue, V
IR  - Larrue V
FIR - Ben-Hamda, K
IR  - Ben-Hamda K
FIR - Fumey, R
IR  - Fumey R
FIR - Guiraud-Chaumeil, B
IR  - Guiraud-Chaumeil B
FIR - Chollet, F
IR  - Chollet F
FIR - Pathé, M
IR  - Pathé M
FIR - Zannier-Marzari, D
IR  - Zannier-Marzari D
FIR - Chabriat, H
IR  - Chabriat H
FIR - Amarenco, P
IR  - Amarenco P
FIR - Pinel, J F
IR  - Pinel JF
FIR - Beaune, J
IR  - Beaune J
FIR - Pichard, J B
IR  - Pichard JB
FIR - Medvedowsky, A
IR  - Medvedowsky A
FIR - Becker, F
IR  - Becker F
FIR - Terriat, B
IR  - Terriat B
FIR - Woimant, F
IR  - Woimant F
FIR - Cathelineau, G
IR  - Cathelineau G
FIR - Martin Jadraque, I
IR  - Martin Jadraque I
FIR - López Sendon, J L
IR  - López Sendon JL
FIR - Gonzales Maqueda, I
IR  - Gonzales Maqueda I
FIR - Roldan Rabadan, I
IR  - Roldan Rabadan I
FIR - Cruz Fernández, J M
IR  - Cruz Fernández JM
FIR - López Garcia, V
IR  - López Garcia V
FIR - Ros Die, E
IR  - Ros Die E
FIR - Gonzáles Rios, J
IR  - Gonzáles Rios J
FIR - Del Foco, O
IR  - Del Foco O
FIR - Chamorro, A
IR  - Chamorro A
FIR - Alday, M
IR  - Alday M
FIR - Matias-Guiu, J
IR  - Matias-Guiu J
FIR - Gracia, F
IR  - Gracia F
FIR - Pomar Moya-Prats, J L
IR  - Pomar Moya-Prats JL
FIR - Mestres, C A
IR  - Mestres CA
FIR - Jiménez Cossio, J A
IR  - Jiménez Cossio JA
FIR - Riera de Cubas, L
IR  - Riera de Cubas L
FIR - Barreiro Tella, P
IR  - Barreiro Tella P
FIR - Diez Tejedor, E
IR  - Diez Tejedor E
FIR - Cunha, L
IR  - Cunha L
FIR - Goncalves, A F
IR  - Goncalves AF
FIR - Ferro, M A
IR  - Ferro MA
FIR - Barbosa, V
IR  - Barbosa V
FIR - Santiago, D
IR  - Santiago D
FIR - Ferro, J M
IR  - Ferro JM
FIR - Melo, T P
IR  - Melo TP
FIR - Oliveira, V
IR  - Oliveira V
FIR - Pinto, A N
IR  - Pinto AN
FIR - Bordalo-Sá, A L
IR  - Bordalo-Sá AL
FIR - Ferreira, D
IR  - Ferreira D
FIR - Tuna, J L
IR  - Tuna JL
FIR - Providência, L
IR  - Providência L
FIR - Morais, J
IR  - Morais J
FIR - Pimenta, A
IR  - Pimenta A
FIR - Van de Werf, F
IR  - Van de Werf F
FIR - Luyten, A
IR  - Luyten A
FIR - Luys, C
IR  - Luys C
FIR - Blecic, S A
IR  - Blecic SA
FIR - Van Blercom, N G
IR  - Van Blercom NG
FIR - Hildebrand, J G
IR  - Hildebrand JG
FIR - Sadzot, B
IR  - Sadzot B
FIR - Franck, G
IR  - Franck G
FIR - Brohet, C
IR  - Brohet C
FIR - Huyberechts, D
IR  - Huyberechts D
FIR - Zicot, M
IR  - Zicot M
FIR - Petermans, J
IR  - Petermans J
FIR - Duprez, D A
IR  - Duprez DA
FIR - Clement, D L
IR  - Clement DL
FIR - Verhaeghe, R
IR  - Verhaeghe R
FIR - Peerlinck, K
IR  - Peerlinck K
FIR - De Reuck, J
IR  - De Reuck J
FIR - Bosschaerts, T
IR  - Bosschaerts T
FIR - Wautrecht, J C
IR  - Wautrecht JC
FIR - Coccheri, S
IR  - Coccheri S
FIR - Fortunato, G
IR  - Fortunato G
FIR - Catalano, M
IR  - Catalano M
FIR - Libretti, A
IR  - Libretti A
FIR - Carolei, A
IR  - Carolei A
FIR - Mearelli, S
IR  - Mearelli S
FIR - Gresele, P
IR  - Gresele P
FIR - Selli, L
IR  - Selli L
FIR - Nenci, G G
IR  - Nenci GG
FIR - Morini, M
IR  - Morini M
FIR - Cortellaro, M
IR  - Cortellaro M
FIR - Chierchia, S L
IR  - Chierchia SL
FIR - Luca Messa, G
IR  - Luca Messa G
EDAT- 1996/11/16 00:00
MHDA- 1996/11/16 00:01
CRDT- 1996/11/16 00:00
PHST- 1996/11/16 00:00 [pubmed]
PHST- 1996/11/16 00:01 [medline]
PHST- 1996/11/16 00:00 [entrez]
AID - S0140673696094573 [pii]
AID - 10.1016/s0140-6736(96)09457-3 [doi]
PST - ppublish
SO  - Lancet. 1996 Nov 16;348(9038):1329-39. doi: 10.1016/s0140-6736(96)09457-3.

PMID- 33685558
OWN - NLM
STAT- MEDLINE
DCOM- 20211109
LR  - 20211109
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 42
IP  - 2
DP  - 2021 Mar 1
TI  - Effectiveness of endoscopic sinus surgery and aspirin therapy in the management 
      of aspirin-exacerbated respiratory disease.
PG  - 136-141
LID - 10.2500/aap.2021.42.210002 [doi]
AB  - Background: Aspirin therapy and/or type 2 (T2) biologics are used in the 
      management of aspirin-exacerbated respiratory disease (AERD). Objective: To 
      identify the number of patients with AERD who tolerated aspirin therapy, yet due 
      to persistent symptoms, incorporated T2 biologic management. Methods: A 
      retrospective review was performed between July 2016 and June 2019. Patients with 
      AERD and who underwent endoscopic sinus surgery (ESS), aspirin desensitization 
      (AD), and at least 6 months of aspirin therapy (ATAD) after AD, and who remained 
      biologic-naive up through this timepoint were included in the study. Introduction 
      of a T2 biologic while on ATAD was the primary outcome. The secondary outcome was 
      a change in a validated patient-reported outcome measure for chronic 
      rhinosinusitis score between the postoperative predesensitization timepoint, and 
      the 6-month postdesensitization timepoint, presented as means and compared by 
      using the Student's t-test. Results: A total of 103 patients met inclusion 
      criteria. Two patients (1.9%) ultimately supplemented ATAD with a T2 biologic. 
      The mean outcomes measure test score after 6 months of ATAD for patients who 
      received biologics was 40.5 versus 15 in those who did not receive biologics (p = 
      0.02). The mean differences between the postoperative predesensitization test 
      score and the 6-month postdesensitization test score for patients who went on to 
      receive biologics was an increase of 13 versus a decrease of 10 for those 
      patients who did not receive biologics (p = 0.12). Conclusion: ESS, coupled with 
      AD and ATAD, was successful in the long-term management of the majority of the 
      patients with AERD, which rarely required the incorporation of T2 biologics. 
      Patient questionnaires, such as outcomes measure test score, may identify aspirin 
      therapy failures and help guide the practitioner in deciding when to introduce T2 
      biologics into the patient's treatment regimen.
FAU - Sweis, Auddie M
AU  - Sweis AM
AD  - From the Division of Otolaryngology-Head and Neck Surgery, NorthShore University 
      Health System, University of Chicago, Pritzker School of Medicine, Evanston, 
      Illinois.
FAU - Locke, Tran B
AU  - Locke TB
AD  - Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, 
      Houston, Texas.
FAU - Ig-Izevbekhai, Kevin I
AU  - Ig-Izevbekhai KI
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
FAU - Lin, Theodore C
AU  - Lin TC
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
FAU - Kumar, Ankur
AU  - Kumar A
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
FAU - Douglas, Jennifer E
AU  - Douglas JE
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
FAU - Corr, Andrew M
AU  - Corr AM
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
FAU - Civantos, Alyssa M
AU  - Civantos AM
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
FAU - Tripathi, Siddhant H
AU  - Tripathi SH
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
FAU - Kennedy, David W
AU  - Kennedy DW
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
FAU - Kohanski, Michael A
AU  - Kohanski MA
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
FAU - Palmer, James N
AU  - Palmer JN
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
FAU - Adappa, Nithin D
AU  - Adappa ND
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
FAU - Bosso, John V
AU  - Bosso JV
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; and.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biological Products)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/immunology
MH  - Aspirin/*administration & dosage/adverse effects/immunology
MH  - Asthma, Aspirin-Induced/diagnosis/immunology/*therapy
MH  - Biological Products/adverse effects/*therapeutic use
MH  - Combined Modality Therapy
MH  - *Desensitization, Immunologic/adverse effects
MH  - *Endoscopy/adverse effects
MH  - Female
MH  - Humans
MH  - Immune Tolerance
MH  - Male
MH  - Middle Aged
MH  - *Nasal Surgical Procedures/adverse effects
MH  - Paranasal Sinuses/*surgery
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC8133012
COIS- DW Kennedy receives royalties from Medtronic, is a consultant for Faigon, is a 
      board member for NeurEnt and is an advisor for GlaxoSmithKline. JV Bosso is a 
      consultant for Sanofi, Novartis, AstraZeneca and GlaxoSmithKline. The remaining 
      authors have no conflicts of interest to declare pertaining to this article
EDAT- 2021/03/10 06:00
MHDA- 2021/11/10 06:00
CRDT- 2021/03/09 05:42
PHST- 2021/03/09 05:42 [entrez]
PHST- 2021/03/10 06:00 [pubmed]
PHST- 2021/11/10 06:00 [medline]
AID - AAP340-20 [pii]
AID - 10.2500/aap.2021.42.210002 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2021 Mar 1;42(2):136-141. doi: 10.2500/aap.2021.42.210002.

PMID- 30614246
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20200518
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 24
IP  - 4
DP  - 2019 Jul
TI  - Rapid Aspirin Desensitization is Safe and Feasible in Patients With Stable and 
      Unstable Coronary Artery Disease: A Single-Center Experience.
PG  - 359-364
LID - 10.1177/1074248418823016 [doi]
AB  - AIMS: There are limited data on aspirin (ASA) desensitization for patients with 
      coronary disease. We present our experience with a rapid nurse-led oral 
      desensitization regimen in patients with aspirin sensitivity undergoing coronary 
      angiography. METHODS: This single-center retrospective observational study 
      includes patients with a history of ASA sensitivity undergoing coronary 
      angiography with intent to perform percutaneous coronary intervention (PCI). 
      RESULTS: Between January 2012 and January 2017, 24 patients undergoing coronary 
      angiography for stable coronary disease (7 cases) or acute coronary syndromes 
      (non-ST-segment myocardial infarction [NSTEMI; 8 cases], STEMI [9 cases]) 
      underwent aspirin desensitization having reported previous reactions to aspirin. 
      At initial presentation, previous sensitivity reactions were reported as: 
      mucocutaneous reactions in 17 patients (urticaria in 3 [13%], nonurticarial rash 
      in 6 [25%], angio-oedema in 8 [33%]), respiratory sensitivity in 4 (17%), and 
      systemic anaphylactoid reactions in 3 (13%). Seventeen (71%) patients underwent 
      PCI. Desensitization was acutely successful in 22 (92%) patients and unsuccessful 
      in 2 (8%) patients who both had a single short-lived episode of acute 
      bronchospasm treated successfully with nebulized salbutamol. Fifteen successfully 
      desensitized patients completed 12 months of aspirin; no patient had recurrent 
      hypersensitivity reaction. Aspirin was stopped prior to 12 months in 7 patients 
      (replaced by warfarin [1 case], no antiplatelet or single antiplatelet clinically 
      indicated and clopidogrel chosen [4 cases], patient choice without evidence of 
      recurrent hypersensitivity [1 case], and death due to cardiogenic shock following 
      STEMI [1 case]). CONCLUSION: A rapid aspirin desensitization protocol is safe and 
      effective across a broad spectrum of hypersensitivity reactions and clinical 
      presentations.
FAU - Jackson, Matthew
AU  - Jackson M
AUID- ORCID: 0000-0002-4248-6948
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - Callaghan, Sarah
AU  - Callaghan S
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - Stapleton, John
AU  - Stapleton J
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - Bolton, Sarah
AU  - Bolton S
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - Austin, David
AU  - Austin D
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - Muir, Douglas F
AU  - Muir DF
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - Sutton, Andrew G C
AU  - Sutton AGC
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - Wright, Robert A
AU  - Wright RA
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - Williams, Paul D
AU  - Williams PD
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - Hall, Jim A
AU  - Hall JA
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - Carter, Justin
AU  - Carter J
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - de Belder, Mark A
AU  - de Belder MA
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
FAU - Swanson, Neil
AU  - Swanson N
AD  - 1 Cardiology Department, The James Cook University Hospital, Middlesbrough, 
      United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20190106
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/diagnostic imaging/*therapy
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects/immunology
MH  - *Desensitization, Immunologic/adverse effects/nursing
MH  - Drug Hypersensitivity/diagnosis/immunology/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Non-ST Elevated Myocardial Infarction/diagnostic imaging/*therapy
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/immunology
MH  - Retrospective Studies
MH  - ST Elevation Myocardial Infarction/diagnostic imaging/*therapy
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - antithrombotic—myocardial infarction
OT  - atherosclerosis
OT  - nonantiarrhythmic—cardiac pharmacology
EDAT- 2019/01/08 06:00
MHDA- 2020/05/19 06:00
CRDT- 2019/01/08 06:00
PHST- 2019/01/08 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
PHST- 2019/01/08 06:00 [entrez]
AID - 10.1177/1074248418823016 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2019 Jul;24(4):359-364. doi: 
      10.1177/1074248418823016. Epub 2019 Jan 6.

PMID- 7054250
OWN - NLM
STAT- MEDLINE
DCOM- 19820322
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 69
IP  - 1 Pt 1
DP  - 1982 Jan
TI  - Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical 
      manifestations and characterization of the refractory period.
PG  - 11-9
AB  - Thirty aspirin-sensitive asthmatic patients underwent incremental, oral aspirin 
      challenge until a "positive reaction" (delta FEV1 greater than or equal to 25%) 
      occurred. After this reaction, aspirin was readministered in an attempt to 
      achieve "desensitization." This was defined as the ability of the patient to 
      ingest 650 mg of aspirin without experiencing upper or lower respiratory-tract 
      symptoms or a decrease in lung function. To determine the "refractory period" 
      following aspirin desensitization, patients were rechallenged after various 
      intervals (days) without aspirin until a positive reaction recurred. All 30 
      aspirin-sensitive asthmatic patients were successfully desensitized to aspirin. 
      Individual patient refractory periods ranged from less than 2 days to greater 
      than 5 days, with most patients gradually returning to sensitivity between 2 to 4 
      days. Cross-densensitization with indomethacin and other nonsteroidal 
      anti-inflammatory drugs was also demonstrated. These studies show that aspirin 
      desensitization can be safely achieved in aspirin-sensitive asthmatic patients; 
      however, this desensitization will gradually disappear over several days when 
      additional aspirin is withheld.
FAU - Pleskow, W W
AU  - Pleskow WW
FAU - Stevenson, D D
AU  - Stevenson DD
FAU - Mathison, D A
AU  - Mathison DA
FAU - Simon, R A
AU  - Simon RA
FAU - Schatz, M
AU  - Schatz M
FAU - Zeiger, R S
AU  - Zeiger RS
LA  - eng
GR  - AI-10386-09/AI/NIAID NIH HHS/United States
GR  - RR 0083/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced
MH  - *Desensitization, Immunologic
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/*therapy
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Indomethacin/therapeutic use
MH  - Middle Aged
MH  - Time Factors
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 0091-6749(82)90081-1 [pii]
AID - 10.1016/0091-6749(82)90081-1 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1982 Jan;69(1 Pt 1):11-9. doi: 
      10.1016/0091-6749(82)90081-1.

PMID- 18797530
OWN - NLM
STAT- MEDLINE
DCOM- 20081203
LR  - 20181201
IS  - 0300-8495 (Print)
IS  - 0300-8495 (Linking)
VI  - 37
IP  - 9
DP  - 2008 Sep
TI  - Reducing the risk of adverse thrombotic events - The role of aspirin and 
      clopidogrel.
PG  - 721-3, 725-6
AB  - Clopidogrel and aspirin both inhibit platelet aggregation, but have differing 
      mechanisms of action that are additive in terms of antithrombotic function. The 
      additive antithrombotic effect of aspirin and clopidogrel combination therapy 
      provides additional clinical benefit compared to monotherapy in some 
      circumstances, but the risk of major bleeding with combination therapy is greater 
      than with either agent alone.
FAU - Jackowski, Leslie
AU  - Jackowski L
AD  - Sansom Institute, University of South Australia.
FAU - Stocks, Nigel
AU  - Stocks N
FAU - Rowett, Debra
AU  - Rowett D
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - Australia
TA  - Aust Fam Physician
JT  - Australian family physician
JID - 0326701
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thrombosis/*complications/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
RF  - 28
EDAT- 2008/09/18 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/09/18 09:00
PHST- 2008/09/18 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/09/18 09:00 [entrez]
PST - ppublish
SO  - Aust Fam Physician. 2008 Sep;37(9):721-3, 725-6.

PMID- 15848959
OWN - NLM
STAT- MEDLINE
DCOM- 20050630
LR  - 20181201
IS  - 0284-4311 (Print)
IS  - 0284-4311 (Linking)
VI  - 39
IP  - 1
DP  - 2005
TI  - Effects of clopidogrel and high dose aspirin on survival of skin flaps in rats.
PG  - 7-10
AB  - Clopidogrel is a new antiplatelet agent with a different mechanism of action from 
      aspirin. It is thienopyridine derivative that is chemically related to 
      ticlopidine, which irreversibly inhibits platelet aggregation by selectively 
      binding to adenylate-cyclase-coupled adenosine diphosphate receptors on the 
      platelet's surface. Aspirin is an antiplatelet agent that acetylates 
      cyclo-oxygenase and decreases the products of arachidonic acid metabolism, 
      including thromboxane and prostacyclin. Necrosis of a flap is still an important 
      complication in reconstructive surgery. To investigate the effects of clopidogrel 
      or high dose aspirin on the survival of skin flaps, 30 rats were divided into 
      three groups of 10 animals each: a control group, a clopidogrel group, and a 
      high-dose aspirin group. No pharmacological agents were used in the control 
      group. Of the two treated groups, the first was given clopidogrel 50 mg/kg/day 
      and the second aspirin 200 mg/kg/day for three days before the operation. After 
      seven days the viable areas of each flap were evaluated and the mean (SD) 
      percentage in the control group was 47 (6), in the clopidogrel group 63 (4), and 
      in the aspirin group 65 (5). Although the mean area of flaps that survived in the 
      aspirin group was slightly higher than in the clopidogrel group, the difference 
      was not significant (p = 0.54).
FAU - Akan, Mithat
AU  - Akan M
AD  - Department of Plastic and Reconstructive Surgery, Dr. Lütfi Kirdar Kartal 
      Education and Research Hospital, Istanbul, Turkey. Mithat@hotmail.com
FAU - Cakir, Bariş
AU  - Cakir B
FAU - Misirlioğlu, Aykut
AU  - Misirlioğlu A
FAU - Yildirim, Serkan
AU  - Yildirim S
FAU - Taylan, Gaye
AU  - Taylan G
FAU - Aköz, Tayfun
AU  - Aköz T
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Plast Reconstr Surg Hand Surg
JT  - Scandinavian journal of plastic and reconstructive surgery and hand surgery
JID - 8707869
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Clopidogrel
MH  - Dose-Response Relationship, Drug
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Postoperative Complications/prevention & control
MH  - Rats
MH  - Rats, Wistar
MH  - *Surgical Flaps
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/*pharmacology
MH  - Tissue Survival/drug effects
EDAT- 2005/04/26 09:00
MHDA- 2005/07/01 09:00
CRDT- 2005/04/26 09:00
PHST- 2005/04/26 09:00 [pubmed]
PHST- 2005/07/01 09:00 [medline]
PHST- 2005/04/26 09:00 [entrez]
AID - WHEM3GWJU4BW316B [pii]
AID - 10.1080/02844310410017951 [doi]
PST - ppublish
SO  - Scand J Plast Reconstr Surg Hand Surg. 2005;39(1):7-10. doi: 
      10.1080/02844310410017951.

PMID- 32627038
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210929
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 44
IP  - 2
DP  - 2020 Aug
TI  - Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo 
      via inducing cell cycle arrest and apoptosis.
PG  - 457-468
LID - 10.3892/or.2020.7630 [doi]
AB  - Aspirin, a nonsteroidal anti‑inflammatory drug (NSAID), is known to inhibit cell 
      proliferation in a variety of cancers. However, the underlying mechanism of this 
      inhibition remains unknown. We investigated the effects of aspirin on 
      hepatocellular carcinoma (HCC) cells using in vitro and in vivo models. Six HCC 
      cell lines and a liver cancer cell line including Huh‑7 were used in assays that 
      evaluated cell proliferation, cell cycle, and apoptosis. Flow cytometry, 
      enzyme‑linked immunosorbent assay (ELISA), western blot analysis, and 
      phosphorylated receptor tyrosine kinase array were used to evaluate the effects 
      of aspirin on the cells, and microRNAs (miRNAs) were analyzed by a miRNA array 
      chip. The results were validated in vivo using a nude mouse model of 
      Huh‑7‑xenografted tumors. Our results showed that aspirin exhibited an 
      antiproliferative effect on all cell lines. Moreover, aspirin induced G0/G1 cell 
      cycle arrest and modulated the levels of cell cycle‑related molecules such as 
      cyclin E, cyclin D1, and cyclin‑dependent kinase 2 (Cdk2). In addition, aspirin 
      upregulated the levels of caspase‑cleaved cytokeratin 18, increased the 
      proportion of early apoptotic cells, decreased the levels of clusterin and heat 
      shock protein 70 (HSP 70), upregulated the levels of miRNA‑137 and inhibited 
      epidermal growth factor receptor (EGFR) activation. In addition, we observed that 
      aspirin suppressed cell proliferation partially through the miRNA‑137/EGFR 
      pathway. Our in vivo results showed that aspirin reduced the growth of xenograft 
      tumors in nude mice. In conclusion, aspirin was able to inhibit the growth of HCC 
      cells by cell cycle arrest, apoptosis, and alteration of miRNA levels in in vitro 
      and in vivo models.
FAU - Shi, Tingting
AU  - Shi T
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Fujita, Koji
AU  - Fujita K
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Gong, Jian
AU  - Gong J
AD  - Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical 
      University, Dalian, Liaoning 116011, P.R. China.
FAU - Nakahara, Mai
AU  - Nakahara M
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Iwama, Hisakazu
AU  - Iwama H
AD  - Life Science Research Center, Kagawa University, Kida, Kagawa 761‑0793, Japan.
FAU - Liu, Shi
AU  - Liu S
AD  - Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical 
      University, Dalian, Liaoning 116011, P.R. China.
FAU - Yoneyama, Hirohito
AU  - Yoneyama H
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Morishita, Asahiro
AU  - Morishita A
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Nomura, Takako
AU  - Nomura T
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Tani, Joji
AU  - Tani J
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Takuma, Kei
AU  - Takuma K
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Tadokoro, Tomoko
AU  - Tadokoro T
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Himoto, Takashi
AU  - Himoto T
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Oura, Kyoko
AU  - Oura K
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Tsutsui, Kunihiko
AU  - Tsutsui K
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Kobara, Hideki
AU  - Kobara H
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
FAU - Masaki, Tsutomu
AU  - Masaki T
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa 
      University, Kida, Kagawa 761‑0793, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (MIRN137 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Carcinoma, Hepatocellular/*drug therapy/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - ErbB Receptors/genetics
MH  - Female
MH  - G1 Phase Cell Cycle Checkpoints/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Liver Neoplasms/*drug therapy/pathology
MH  - Mice
MH  - MicroRNAs/metabolism
MH  - Up-Regulation/drug effects
MH  - Xenograft Model Antitumor Assays
PMC - PMC7336451
OTO - NOTNLM
OT  - hepatocellular carcinoma
OT  - aspirin
OT  - microRNA
OT  - cell cycle
OT  - apoptosis
EDAT- 2020/07/07 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/07/07 06:00
PHST- 2019/09/23 00:00 [received]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
AID - OR-44-02-0457 [pii]
AID - 10.3892/or.2020.7630 [doi]
PST - ppublish
SO  - Oncol Rep. 2020 Aug;44(2):457-468. doi: 10.3892/or.2020.7630. Epub 2020 May 29.

PMID- 33395330
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210306
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 174
IP  - 1
DP  - 2021 Jan
TI  - Daily aspirin for primary prevention increased risk for major GI bleeding in 
      healthy older adults.
PG  - JC4
LID - 10.7326/ACPJ202101190-004 [doi]
AB  - Mahady SE, Margolis KL, Chan A, et al. Major GI bleeding in older persons using 
      aspirin: incidence and risk factors in the ASPREE randomised controlled trial. 
      Gut. 2020. [Epub ahead of print.] 32747412.
FAU - Hirsch, Calvin
AU  - Hirsch C
AD  - UC Davis Medical Center, Sacramento, California, USA (C.H.).
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20210105
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Gut. 2020 Aug 3;:null. PMID: 32747412
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aspirin/adverse effects
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Incidence
MH  - *Primary Prevention
MH  - Risk Factors
EDAT- 2021/01/05 06:00
MHDA- 2021/02/02 06:00
CRDT- 2021/01/04 17:07
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
PHST- 2021/01/04 17:07 [entrez]
AID - 10.7326/ACPJ202101190-004 [doi]
PST - ppublish
SO  - Ann Intern Med. 2021 Jan;174(1):JC4. doi: 10.7326/ACPJ202101190-004. Epub 2021 
      Jan 5.

PMID- 9035555
OWN - NLM
STAT- MEDLINE
DCOM- 19970401
LR  - 20141120
IS  - 0006-6648 (Print)
IS  - 0006-6648 (Linking)
VI  - 135
IP  - 7
DP  - 1996 Jul-Aug
TI  - Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and 
      cytoprotective activity in rats.
PG  - 421-8
AB  - Double layer 325 mg oral aspirin tablets buffered with magaldrate antacid, 100, 
      150, 175 and 200 mg (F1, F2, F3 and F4, respectively) were prepared by direct 
      compression. The new formulae were of remarkable hardness and friability. The 
      tablets complied with the requirements of the acid neutralizing capacity, 
      uniformity of dosage units, disintegration and dissolution tests (USP XXIII) for 
      buffered aspirin tablets. The in vitro release pattern of F1 and F1 followed 
      first order kinetics (r = 0.999), while F3 and F4 were released according to a 
      zero order model (r = 0.993). Formulations F2, F3 and F4 as well as the marketed 
      preparations, pure Aspro tablets (Acetylsalicylic acid 320 mg per tablet), or 
      Ascriptin tablets (aspirin 325 mg plus 150 mg Maalox per tablet) were 
      administered to fasted rats by gavage at doses that provided 400 mg aspirin kg-1 
      and the extent of the induced gastric damage was quantified 6 h later. Ascriptin, 
      F3 and F4 preparations produced significantly less gastric damage (p < 0.05, n = 
      6) when compared with pure Aspro tablets. There was a clear dose-dependent 
      decrease in the gastric damage following treatment with F2, F3 and F4 
      preparations, but there was no significant difference between the effects of F3 
      and F4 which were equipotent with Ascriptin.
FAU - al Gohary, O M
AU  - al Gohary OM
AD  - Department of Pharmaceutics, College of Pharmacy, King Saud University Riyadh, 
      Kingdom of Saudi Arabia.
FAU - el Din, K
AU  - el Din K
FAU - el Tahir, H
AU  - el Tahir H
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Boll Chim Farm
JT  - Bollettino chimico farmaceutico
JID - 0372534
RN  - 0 (Antacids)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - 6V88E24N5T (magaldrate)
RN  - NBZ3QY004S (Magnesium Hydroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aluminum Hydroxide/*administration & dosage/*therapeutic use
MH  - Animals
MH  - Antacids/*administration & dosage/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*toxicity
MH  - Aspirin/*administration & dosage/*toxicity
MH  - Drug Combinations
MH  - Drug Compounding
MH  - Magnesium Hydroxide/*administration & dosage/*therapeutic use
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Tablets
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
PST - ppublish
SO  - Boll Chim Farm. 1996 Jul-Aug;135(7):421-8.

PMID- 19351569
OWN - NLM
STAT- MEDLINE
DCOM- 20090812
LR  - 20131121
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 281
IP  - 1-2
DP  - 2009 Jun 15
TI  - Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and 
      middle-aged patients.
PG  - 2-5
LID - 10.1016/j.jns.2009.03.024 [doi]
AB  - BACKGROUND: There are very limited data on the influence of pretreatment with 
      aspirin (ASA) on the etiology of subsequent first-ever ischemic stroke. MATERIALS 
      AND METHODS: Five hundred ninety eight patients 65 years old or younger with 
      first-ever ischemic stroke either pretreated (N=167) or not treated with aspirin 
      (N=431) participated. RESULTS: The mean age was 56.5+/-6.0 years for patients 
      treated with ASA and 53.1+/-8.9 years for those not treated (p<.0001). All major 
      vascular risk factors except smoking were significantly more frequent among the 
      patients pretreated with aspirin. Logistic regression analysis adjustments for 
      age, gender, and major vascular risk factors revealed an overall significant 
      effect (p<0.0001) of aspirin treatment on the distribution of stroke etiologies. 
      Subsequent separate analyses on stroke etiology subtypes indicated that the 
      incidence of small vessel disease (SVD) related strokes was significantly reduced 
      by pretreatment with aspirin (OR=0.63). Logistic regression analysis showed no 
      influence of aspirin on the likelihood of a favorable or unfavorable outcome, as 
      expressed by Rankin scale. CONCLUSION: Pretreatment with ASA has significant 
      influence on the distribution of etiologies of first-ever ischemic stroke in 
      young and middle-aged patients, when the immediate functional stroke outcome is 
      not influenced by ASA pretreatment.
FAU - Telman, G
AU  - Telman G
AD  - Department of Neurology, Rambam Health Care Campus, Technion Faculty of Medicine, 
      Haifa, Israel. g_telman@rambam.health.gov.il
FAU - Kouperberg, E
AU  - Kouperberg E
FAU - Sprecher, E
AU  - Sprecher E
FAU - Yarnitsky, D
AU  - Yarnitsky D
LA  - eng
PT  - Journal Article
DEP - 20090405
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Brain Ischemia/*drug therapy/*etiology/prevention & control
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Registries
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Stroke/*drug therapy/*etiology/prevention & control
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2009/04/09 09:00
MHDA- 2009/08/13 09:00
CRDT- 2009/04/09 09:00
PHST- 2008/11/14 00:00 [received]
PHST- 2009/03/15 00:00 [revised]
PHST- 2009/03/20 00:00 [accepted]
PHST- 2009/04/09 09:00 [entrez]
PHST- 2009/04/09 09:00 [pubmed]
PHST- 2009/08/13 09:00 [medline]
AID - S0022-510X(09)00512-7 [pii]
AID - 10.1016/j.jns.2009.03.024 [doi]
PST - ppublish
SO  - J Neurol Sci. 2009 Jun 15;281(1-2):2-5. doi: 10.1016/j.jns.2009.03.024. Epub 2009 
      Apr 5.

PMID- 31101690
OWN - NLM
STAT- MEDLINE
DCOM- 20200414
LR  - 20200414
IS  - 1468-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 69
IP  - 3
DP  - 2020 Mar
TI  - Incidences, temporal trends and risks of hospitalisation for gastrointestinal 
      bleeding in new or chronic low-dose aspirin users after treatment for 
      Helicobacter pylori: a territory-wide cohort study.
PG  - 445-452
LID - 10.1136/gutjnl-2019-318352 [doi]
AB  - OBJECTIVE: The risk of GI bleeding (GIB) in aspirin users after Helicobacter 
      pylori (HP) eradication remains poorly defined. We characterised the incidences 
      and temporal trends of hospitalisations for all GIB in aspirin users after HP 
      eradication therapy. DESIGN: Based on a territory-wide health database, we 
      identified all patients who had received the first course of clarithromycin-based 
      triple therapy between 2003 and 2012. Patients were divided into three cohorts 
      according to aspirin use: new users (commenced after HP eradication), chronic 
      users (commenced before and resumed after HP eradication) and non-users. The 
      primary outcome was to determine the risk of hospitalisation for GIB. RESULTS: We 
      included 6985 new aspirin users, 5545 chronic users and 48 908 non-users. The 
      age-adjusted and sex-adjusted incidence of hospitalisation for all GIB in new, 
      chronic and non-users was 10.4, 7.2 and 4.6 per 1000 person-years, respectively. 
      Upper and lower GIB accounted for 34.7% and 45.3% of all bleeding, respectively. 
      Compared with chronic users, new users had a higher risk of GIB (HR with 
      propensity score matching: 1.89; 95% CI 1.29 to 2.70). Landmark analysis showed 
      that the increased risk in new aspirin users was only observed in the first 
      6 months for all GIB (HR 2.10, 95% CI 1.41 to 3.13) and upper GIB (HR 2.52, 
      95% CI 1.38 to 4.60), but not for lower GIB. CONCLUSION: New aspirin users had a 
      higher risk of GIB than chronic aspirin users, particularly during the initial 
      6 months. Lower GIB is more frequent than upper GIB in aspirin users who had HP 
      eradicated.
CI  - © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Guo, Chuan-Guo
AU  - Guo CG
AUID- ORCID: 0000-0002-0657-473X
AD  - Department of Medicine, University of Hong Kong, Hong Kong, China.
FAU - Cheung, Ka Shing
AU  - Cheung KS
AD  - Department of Medicine, University of Hong Kong, Hong Kong, China.
FAU - Zhang, Feifei
AU  - Zhang F
AD  - Usher Institute of Population Health Sciences and Informatics, University of 
      Edinburgh, Edinburgh, UK.
FAU - Chan, Esther W
AU  - Chan EW
AD  - Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong.
FAU - Chen, Lijia
AU  - Chen L
AD  - Department of Medicine, University of Hong Kong, Hong Kong, China.
FAU - Wong, Ian Ck
AU  - Wong IC
AD  - Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong.
AD  - UCL School of Pharmacy, UCL, London, UK.
FAU - Leung, Wai K
AU  - Leung WK
AUID- ORCID: 0000-0002-5993-1059
AD  - Department of Medicine, University of Hong Kong, Hong Kong, China.
LA  - eng
PT  - Journal Article
DEP - 20190517
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/*epidemiology/mortality
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Hong Kong/epidemiology
MH  - Hospital Mortality
MH  - Hospitalization/statistics & numerical data/*trends
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Protective Factors
MH  - Risk Factors
OTO - NOTNLM
OT  - aspirin
OT  - gastrointestinal bleeding
OT  - helicobacter pylori
COIS- Competing interests: None declared.
EDAT- 2019/05/19 06:00
MHDA- 2020/04/15 06:00
CRDT- 2019/05/19 06:00
PHST- 2019/01/23 00:00 [received]
PHST- 2019/04/29 00:00 [revised]
PHST- 2019/05/07 00:00 [accepted]
PHST- 2019/05/19 06:00 [pubmed]
PHST- 2020/04/15 06:00 [medline]
PHST- 2019/05/19 06:00 [entrez]
AID - gutjnl-2019-318352 [pii]
AID - 10.1136/gutjnl-2019-318352 [doi]
PST - ppublish
SO  - Gut. 2020 Mar;69(3):445-452. doi: 10.1136/gutjnl-2019-318352. Epub 2019 May 17.

PMID- 12056537
OWN - NLM
STAT- MEDLINE
DCOM- 20021125
LR  - 20190922
IS  - 0363-9045 (Print)
IS  - 0363-9045 (Linking)
VI  - 28
IP  - 4
DP  - 2002 Apr
TI  - Application of hydroalcoholic solutions of formaldehyde in preparation of 
      acetylsalicylic acid gastro-resistant capsules.
PG  - 443-9
AB  - Enteric coating of hard gelatin capsules by application of hydroalcoholic 
      solutions of formaldehyde was studied and developed in accordance with previous 
      publications. It is possible to affirm that this coating constitutes a simple, 
      stable, reproducible, and inexpensive method, being a valid alternative to those 
      which have been proposed. The aim of the present investigation is the preparation 
      of acetylsalicylic acid gelatin capsules with good conditions of 
      gastro-resistance and enteros solubility.
FAU - Pina, M E
AU  - Pina ME
AD  - Laboratory of Galenic and Pharmaceutical Technology, Faculty of Pharmacy, 
      University of Coimbra, Portugal.
FAU - Sousa, A T
AU  - Sousa AT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Capsules)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Excipients)
RN  - 0 (Fixatives)
RN  - 0 (Solvents)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 1HG84L3525 (Formaldehyde)
RN  - 3K9958V90M (Ethanol)
RN  - 9000-70-8 (Gelatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Capsules
MH  - Chemistry, Pharmaceutical
MH  - Cross-Linking Reagents/chemistry
MH  - Drug Stability
MH  - Ethanol
MH  - Excipients/chemistry
MH  - Fixatives/*chemistry
MH  - Formaldehyde/*chemistry
MH  - Gelatin/chemistry
MH  - Solubility
MH  - Solvents
MH  - Tablets, Enteric-Coated
EDAT- 2002/06/12 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/06/12 10:00
PHST- 2002/06/12 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/06/12 10:00 [entrez]
AID - 10.1081/ddc-120003005 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 2002 Apr;28(4):443-9. doi: 10.1081/ddc-120003005.

PMID- 8200272
OWN - NLM
STAT- MEDLINE
DCOM- 19940706
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 39
IP  - 6
DP  - 1994 Jun
TI  - Duodenal diaphragmlike stricture induced by acetylsalicylic acid.
PG  - 1365-9
AB  - Many reports have mentioned the role of nonsteroidal antiinflammatory drugs in 
      inducing diaphragm-like strictures in the small and large bowel. These lesions 
      are mostly seen in patients with chronic use of nonsteroidal antiinflammatory 
      drugs. We report the case of a 57-year-old man who developed a diaphragmlike 
      stricture in the second part of the duodenum. The patient had been using a 
      preparation containing acetylsalicylic acid during many years. Although a 
      congenital origin of the diaphragm is not completely excluded, we postulate that 
      this stricture probably occurred as a result of acetylsalicylic acid-induced 
      ulcerations, followed by submucosal fibrosis.
FAU - Blinder, G H
AU  - Blinder GH
AD  - Department of Internal Medicine, Middleheim General Hospital, Antwerpen, Belgium.
FAU - Hautekeete, M L
AU  - Hautekeete ML
FAU - Holvoet, J P
AU  - Holvoet JP
FAU - Kockx, M M
AU  - Kockx MM
FAU - Hubens, H K
AU  - Hubens HK
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Constriction, Pathologic
MH  - Duodenal Obstruction/*chemically induced/pathology
MH  - Duodenal Ulcer/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1994/06/01 00:00
MHDA- 1994/06/01 00:01
CRDT- 1994/06/01 00:00
PHST- 1994/06/01 00:00 [pubmed]
PHST- 1994/06/01 00:01 [medline]
PHST- 1994/06/01 00:00 [entrez]
AID - 10.1007/BF02093806 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1994 Jun;39(6):1365-9. doi: 10.1007/BF02093806.

PMID- 2658385
OWN - NLM
STAT- MEDLINE
DCOM- 19890705
LR  - 20131121
IS  - 0044-2542 (Print)
IS  - 0044-2542 (Linking)
VI  - 44
IP  - 6
DP  - 1989 Mar 15
TI  - [Anticoagulants and inhibitors of thrombocyte function in the long-term treatment 
      of arteriosclerosis].
PG  - 183-6
AB  - Oral anticoagulants are suitable for the delay of progression of 
      arteriosclerosis. The therapeutic effect is bound to the stability of the 
      hypocoagulation with values of the thromboplastin time between 15 to 20%. There 
      is a high risk of thrombosis after discontinuation of the therapy. Of the 
      inhibitors of thrombocyte function acetyl salicylic acid preparations are 
      antithrombotically effective. The controversies of dosage high (= 1,500 mg/d) or 
      low (= 20-30 mg/d) are opposed by the concept of the individual dosage via the 
      ASA-test.
FAU - Norden, C
AU  - Norden C
AD  - Zentralinstitut für Herz-Kreislauf-Forschung, Akademie der Wissenschaften, DDR 
      Berlin-Buch.
FAU - Heine, H
AU  - Heine H
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Antikoagulantien und Thrombozytenfunktionshemmer zur Langzeitbehandlung der 
      Arteriosklerose.
PL  - Germany
TA  - Z Gesamte Inn Med
JT  - Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete
JID - 21730470R
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*administration & dosage
MH  - Arteriosclerosis/*drug therapy
MH  - Aspirin/administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage
RF  - 7
EDAT- 1989/03/15 00:00
MHDA- 1989/03/15 00:01
CRDT- 1989/03/15 00:00
PHST- 1989/03/15 00:00 [pubmed]
PHST- 1989/03/15 00:01 [medline]
PHST- 1989/03/15 00:00 [entrez]
PST - ppublish
SO  - Z Gesamte Inn Med. 1989 Mar 15;44(6):183-6.

PMID- 23132
OWN - NLM
STAT- MEDLINE
DCOM- 19780329
LR  - 20131121
IS  - 0539-6115 (Print)
IS  - 0539-6115 (Linking)
VI  - 35
IP  - 1
DP  - 1978 Jan-Feb
TI  - [Salicylate poisoning. Determination of the free fraction using the 
      ultrafiltration method].
PG  - 1-12
AB  - Seventeen infants under one year of age admitted to the Emergency Service of the 
      General Hospital of the Medical Center La Raza during the year 1976 were included 
      in this study with the diagnosis of salicylate poisoning. Determination of plasma 
      salicylate by the ultrafiltrate method was practiced to all patients. A direct 
      relationship between total plasmatic salicylate and its free fraction was found 
      together with an inverse proportion between percentage of total free--salicylate 
      and plasma pH and a lineal correlation between plasma free--salicylate and 
      salicylate obtained in spinal fluid. It is concluded that determination of the 
      free fraction of plasma salicylate is an easy diagnostic method for the better 
      evaluation of salicylate acid poisoning in the infant.
FAU - Gaytán Becerril, A
AU  - Gaytán Becerril A
FAU - Franco Muñoz, P A
AU  - Franco Muñoz PA
FAU - Rivera Hidalgo, P
AU  - Rivera Hidalgo P
FAU - Gueda Baca, S
AU  - Gueda Baca S
LA  - spa
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Intoxicación por salicilatos. Determinación de la fracción libre por método de 
      ultrafiltrado.
PL  - Mexico
TA  - Bol Med Hosp Infant Mex
JT  - Boletin medico del Hospital Infantil de Mexico
JID - 0414106
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*poisoning
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Infant
MH  - Infant, Newborn
MH  - Infant, Newborn, Diseases/*diagnosis
MH  - Male
MH  - Poisoning/diagnosis
MH  - Salicylates/analysis
MH  - Ultrafiltration
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
PST - ppublish
SO  - Bol Med Hosp Infant Mex. 1978 Jan-Feb;35(1):1-12.

PMID- 1016594
OWN - NLM
STAT- MEDLINE
DCOM- 19770428
LR  - 20131121
IS  - 0021-2547 (Print)
IS  - 0021-2547 (Linking)
VI  - 55
IP  - 5
DP  - 1976
TI  - [Anti-inflammatory agents and lymphocytary reactivity].
PG  - 443-7
AB  - The acetylsalicylic acid, like other drugs with analogous properties, is an 
      anti-inflammatory drug, whose mechanism of action is still unknown. Lymphocyte 
      release, on stimulation, phlogogenic substances (lymphokines) which are 
      responsible for some phlogistic processes, above all chronic. Acetylsalicylic 
      acid inhibits some lymphocyte functions, therfore its mechanism of action may be 
      possibly accounted for by this activity. This paper dealt with the effect 
      observed that acetylsalicylic acid on mitogen-induced lymphocyte blastization. In 
      vitro it was observed that acetylsalicylic acid inhibits blastization only when 
      it is present in the incubation medium and that the inhibitor effect is dose 
      dependent. In vivo, in the rat, it was observed that acetylsalicylic acid 
      inhibits blastization only when administered some hours before lymphocyte 
      withdrawal. The Authors believe that this effect may be accounted for by a 
      metabolite of the drug itself.
FAU - Marinoni, I
AU  - Marinoni I
FAU - Torelli, L
AU  - Torelli L
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Farmaci antiinfiammatori e reattivita' linfocitaria.
PL  - Italy
TA  - Boll Ist Sieroter Milan
JT  - Bollettino dell'Istituto sieroterapico milanese
JID - 17720040R
RN  - 0 (Mitogens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antibody Formation/drug effects
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Lymphocyte Activation/*drug effects
MH  - Lymphocytes/immunology
MH  - Mitogens/pharmacology
MH  - Rats
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Boll Ist Sieroter Milan. 1976;55(5):443-7.

PMID- 8578549
OWN - NLM
STAT- MEDLINE
DCOM- 19960314
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 80
IP  - 3
DP  - 1995 Nov 1
TI  - Platelet disorders in uraemia before and after haemodialysis under the influence 
      of low dose aspirin.
PG  - 225-33
AB  - Thrombocyte dysfunction and increased bleeding time (BT) are well documented in 
      uraemic patients. However, these patients are frequently medicated with low dose 
      aspirin (ASA) in order to maintain shunt patency and prevent cardiovascular 
      events. Recently, life- threatening gastrointestinal haemorrhage in an uraemic 
      subject taking low dose aspirin has been reported. In this work ASA related 
      bleeding risk in uraemic patients and the effect of haemodialysis on their 
      bleeding tendency was studied by measuring in vitro bleeding time (BT) using the 
      Thrombostat 4000 in 34 uraemic patients on chronic haemodialysis compared to 50 
      healthy subjects. Our results indicate that low dose aspirin does not influence 
      uraemic thrombopathia 8 to 10h after ingestion but seems to increase bleeding 
      risk shortly after ingestion. Moreover, haemodialysis alters uraemic in vitro BT 
      with regard to the time after ingestion of ASA.
FAU - Tschugguel, W
AU  - Tschugguel W
AD  - Department of Anesthesiology and General Intensive Care Medicine, University of 
      Vienna, Austria.
FAU - Blaicher, A
AU  - Blaicher A
FAU - Kramer, L
AU  - Kramer L
FAU - Felfernig, M
AU  - Felfernig M
FAU - Jüngling, G
AU  - Jüngling G
FAU - Kurz, M
AU  - Kurz M
FAU - Gnant, M
AU  - Gnant M
FAU - Zimpfer, M
AU  - Zimpfer M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects
MH  - Female
MH  - Hematocrit
MH  - Hemorrhage/blood/*etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Platelet Count
MH  - Prospective Studies
MH  - *Renal Dialysis
MH  - Time Factors
MH  - Uremia/blood/complications/*therapy
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 0049-3848(95)00171-M [pii]
AID - 10.1016/0049-3848(95)00171-m [doi]
PST - ppublish
SO  - Thromb Res. 1995 Nov 1;80(3):225-33. doi: 10.1016/0049-3848(95)00171-m.

PMID- 10514159
OWN - NLM
STAT- MEDLINE
DCOM- 19991119
LR  - 20190501
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 319
IP  - 7215
DP  - 1999 Oct 9
TI  - Primary prevention of arterial thromboembolism in non-rheumatic atrial 
      fibrillation in primary care: randomised controlled trial comparing two 
      intensities of coumarin with aspirin.
PG  - 958-64
AB  - OBJECTIVE: To investigate the effectiveness of aspirin and coumarin in preventing 
      thromboembolism in patients with non-rheumatic atrial fibrillation in general 
      practice. DESIGN: Randomised controlled trial. PARTICIPANTS: 729 patients aged 
      >/=60 years with atrial fibrillation, recruited in general practice, who had no 
      established indication for coumarin. Mean age was 75 years and mean follow up 2. 
      7 years. SETTING: Primary care in the Netherlands. INTERVENTIONS: Patients 
      eligible for standard intensity coumarin (international normalised ratio 2.5-3.5) 
      were randomly assigned to standard anticoagulation, very low intensity coumarin 
      (international normalised ratio 1.1-1.6), or aspirin (150 mg/day) (stratum 1). 
      Patients ineligible for standard anticoagulation were randomly assigned to low 
      anticoagulation or aspirin (stratum 2). MAIN OUTCOME MEASURES: Stroke, systemic 
      embolism, major haemorrhage, and vascular death. RESULTS: 108 primary events 
      occurred (annual event rate 5.5%), including 13 major haemorrhages (0.7% a year). 
      The hazard ratio was 0.91 (0.61 to 1.36) for low anticoagulation versus aspirin 
      and 0.78 (0.34 to 1.81) for standard anticoagulation versus aspirin. Non-vascular 
      death was less common in the low anticoagulation group than in the aspirin group 
      (0.41, 0.20 to 0.82). There was no significant difference between the treatment 
      groups in bleeding incidence. High systolic and low diastolic blood pressure and 
      age were independent prognostic factors. CONCLUSION: In a general practice 
      population (without established indications for coumarin) neither low nor 
      standard intensity anticoagulation is better than aspirin in preventing primary 
      outcome events. Aspirin may therefore be the first choice in patients with atrial 
      fibrillation in general practice.
FAU - Hellemons, B S
AU  - Hellemons BS
AD  - Department of General Practice, University of Maastricht, 6200 MD Maastricht, 
      Netherlands. Bep.Hellemons@HAG.Unimaas.NL
FAU - Langenberg, M
AU  - Langenberg M
FAU - Lodder, J
AU  - Lodder J
FAU - Vermeer, F
AU  - Vermeer F
FAU - Schouten, H J
AU  - Schouten HJ
FAU - Lemmens, T
AU  - Lemmens T
FAU - van Ree, J W
AU  - van Ree JW
FAU - Knottnerus, J A
AU  - Knottnerus JA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Anticoagulants)
RN  - 0 (Coumarins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A4VZ22K1WT (coumarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 2000 Apr 8;320(7240):1008-9; author reply 1010-1. PMID: 10753166
CIN - BMJ. 2000 Apr 8;320(7240):1009. PMID: 10809555
CIN - BMJ. 2000 Apr 8;320(7240):1009. PMID: 10809556
CIN - BMJ. 2000 Apr 8;320(7240):1009-10. PMID: 10809557
CIN - BMJ. 2000 Apr 8;320(7240):1010. PMID: 10809558
CIN - BMJ. 2000 Apr 8;320(7240):1010. PMID: 10809559
CIN - BMJ. 2000 Aug 12;321(7258):449. PMID: 10991594
MH  - Aged
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Atrial Fibrillation/*prevention & control
MH  - Coumarins/*administration & dosage/adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Proportional Hazards Models
MH  - Survival Analysis
MH  - Thromboembolism/*prevention & control
MH  - Treatment Outcome
PMC - PMC28250
EDAT- 1999/10/08 00:00
MHDA- 1999/10/08 00:01
CRDT- 1999/10/08 00:00
PHST- 1999/10/08 00:00 [pubmed]
PHST- 1999/10/08 00:01 [medline]
PHST- 1999/10/08 00:00 [entrez]
AID - 10.1136/bmj.319.7215.958 [doi]
PST - ppublish
SO  - BMJ. 1999 Oct 9;319(7215):958-64. doi: 10.1136/bmj.319.7215.958.

PMID- 17067363
OWN - NLM
STAT- MEDLINE
DCOM- 20070319
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 5
IP  - 2
DP  - 2007 Feb
TI  - Antithrombotic therapy in patients with chronic heart failure: rationale, 
      clinical evidence and practical implications.
PG  - 224-31
AB  - Chronic heart failure (CHF) is traditionally associated with increased risk of 
      thromboembolic complications. Key features of CHF pathophysiology, such as 
      impairment of intracardiac hemodynamics, peripheral blood flow deceleration, 
      neuroendocrine activation, chronic oxidative stress and proinflammatory changes, 
      could explain the predisposition to thromboembolism. However, conclusive 
      epidemiologic data on thromboembolic event incidence in CHF are lacking. 
      Furthermore, the place of antithrombotic therapy in CHF management is still 
      uncertain. Apart from established indications for warfarin (e.g. atrial 
      fibrillation and previous embolic events), there is no robust evidence to support 
      administration of vitamin K antagonists to other patients with CHF, particularly 
      to patients in sinus rhythm. The role of aspirin in preventing thromboembolism in 
      these patients is also controversial. Large randomized trial data on the 
      effectiveness and risks of warfarin and aspirin use in CHF patients with sinus 
      rhythm are forthcoming. This article provides a brief overview of the 
      epidemiologic and pathobiological background of thromboembolism in CHF, and 
      discusses the up-to-date clinical evidence on antithrombotic therapy in detail.
FAU - Dotsenko, O
AU  - Dotsenko O
AD  - Thrombosis Research Institute, London, UK. odotsenko@tri-london.ac.uk
FAU - Kakkar, V V
AU  - Kakkar VV
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20061025
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Heart Failure/complications/*drug therapy
MH  - Humans
MH  - Thromboembolism/drug therapy/epidemiology/etiology
MH  - Warfarin/therapeutic use
RF  - 72
EDAT- 2006/10/28 09:00
MHDA- 2007/03/21 09:00
CRDT- 2006/10/28 09:00
PHST- 2006/10/28 09:00 [pubmed]
PHST- 2007/03/21 09:00 [medline]
PHST- 2006/10/28 09:00 [entrez]
AID - S1538-7836(22)10063-2 [pii]
AID - 10.1111/j.1538-7836.2007.02288.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2007 Feb;5(2):224-31. doi: 10.1111/j.1538-7836.2007.02288.x. 
      Epub 2006 Oct 25.

PMID- 1781803
OWN - NLM
STAT- MEDLINE
DCOM- 19920312
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 41
IP  - 8
DP  - 1991 Aug
TI  - [The effect of glycine on the gastroduodenal tolerability of acetylsalicylic 
      acid. An endoscopic, controlled double-blind study in healthy subjects].
PG  - 812-4
AB  - In a randomized double-blind study the gastroduodenal tolerability of daily 500 
      mg acetylsalicylic acid (ASA, CAS 50-78-2) in combination with 250 mg glycine 
      (CAS 56-40-6) (Godamed) and 500 mg ASA without addition of glycine were evaluated 
      in 20 healthy volunteers giving upper GI-endoscopy. Both ASA-preparations have 
      been taken over a period of 4 weeks. Endoscopic controls were performed at entry, 
      and repeated after 7, 14 and 28 days of treatment. Both ASA-preparations induced 
      comparable gastroduodenal damages during the whole test period: The lesions score 
      of both groups on day 7, 14 and day 28 was almost identical. In contrast to plain 
      ASA, where 9 of 10 volunteers reported gastrointestinal side effects, all 
      subjects receiving ASA in combination with glycine did not complain from any 
      dyspeptic symptoms, i.e. epigastric pain etc. The reasons for the apparent better 
      tolerability of ASA in combination with glycine are discussed.
FAU - Müller, P
AU  - Müller P
AD  - Medizinische Universitätsklinik, Gastroenterologische Abteilung, Heidelberg.
FAU - Dammann, H G
AU  - Dammann HG
FAU - Bergdolt, H
AU  - Bergdolt H
FAU - Simon, B
AU  - Simon B
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Einfluss von Glycin auf die gastroduodenale Verträglichkeit von 
      Acetylsalicylsäure. Eine endoskopisch kontrollierte Doppelblindstudie an gesunden 
      Probanden.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Double-Blind Method
MH  - Duodenum/*drug effects
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Glycine/*pharmacology
MH  - Humans
MH  - Male
MH  - Stomach/*drug effects
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1991 Aug;41(8):812-4.

PMID- 2478
OWN - NLM
STAT- MEDLINE
DCOM- 19760430
LR  - 20190813
IS  - 0340-6199 (Print)
IS  - 0340-6199 (Linking)
VI  - 121
IP  - 1
DP  - 1975 Dec 9
TI  - Oral antipyretic therapy: evaluation of benorylate, an ester of acetylsalicylic 
      acid and paracetamol.
PG  - 15-20
AB  - The capacity of benorylate, an ester of acetylsalicylic acid and paracetamol, to 
      reduce fever in children was compared with that of the components as such or as a 
      combination. The series of cases studied consisted of 66 patients between the 
      ages of 4 months and 12 years with rectal temperatures above 38.5 degrees C. 
      Temperatures were recorded at 15 and 20 min and 1, 2, 4 and 6 hrs after the 
      administration of the drug. The antipyretic effect of combined acetylsalicylic 
      acid (11 mg/kg) and paracetamol (14 mg/kg) was superior to the effect of 
      benorylate with a dose of 25 mg/kg and even of 50 mg/kg as well as better than 
      the effect of either drug alone. Acetylsalicylic acid (10 mg/kg) and paracetamol 
      (12.5 mg/kg) alone produced a significantly greater antipyretic effect than 
      benorylate with a dose of 25 mg/kg. Given in a dose of 35--40 mg/kg, benorylate 
      seems to have a significant antipyretic effect. However, this effect is clearly 
      smaller than that of either of its components, acetylsalicylic acid or 
      paracetamol. Therefore benorylate is probably not suitable to be used as a 
      general antipyretic agent in children.
FAU - Similä, S
AU  - Similä S
FAU - Keinänen, S
AU  - Keinänen S
FAU - Kouvalainen, K
AU  - Kouvalainen K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Eur J Pediatr
JT  - European journal of pediatrics
JID - 7603873
RN  - 0 (Salicylates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Body Temperature/drug effects
MH  - Child
MH  - Child, Preschool
MH  - Fever/*drug therapy
MH  - Humans
MH  - Infant
MH  - Salicylates/*therapeutic use
MH  - Time Factors
EDAT- 1975/12/09 00:00
MHDA- 1975/12/09 00:01
CRDT- 1975/12/09 00:00
PHST- 1975/12/09 00:00 [pubmed]
PHST- 1975/12/09 00:01 [medline]
PHST- 1975/12/09 00:00 [entrez]
AID - 10.1007/BF00464391 [doi]
PST - ppublish
SO  - Eur J Pediatr. 1975 Dec 9;121(1):15-20. doi: 10.1007/BF00464391.

PMID- 25678574
OWN - NLM
STAT- MEDLINE
DCOM- 20160802
LR  - 20161025
IS  - 1472-0213 (Electronic)
IS  - 1472-0205 (Linking)
VI  - 32
IP  - 11
DP  - 2015 Nov
TI  - Prehospital aspirin administration for acute coronary syndrome (ACS) in the USA: 
      an EMS quality assessment using the NEMSIS 2011 database.
PG  - 876-81
LID - 10.1136/emermed-2014-204299 [doi]
AB  - INTRODUCTION: National practice guidelines recommend early aspirin administration 
      to reduce mortality in acute coronary syndrome (ACS). Although timely 
      administration of aspirin has been shown to reduce mortality in ACS by 23%, prior 
      regional Emergency Medical Service (EMS) data have shown inadequate prehospital 
      administration of aspirin in patients with suspected cardiac ischaemia. 
      OBJECTIVES: Using the National EMS Information System (NEMSIS) database, we 
      sought to determine (1) the proportion of patients with suspected cardiac 
      ischaemia who received aspirin and (2) patient and prehospital characteristics 
      that independently predicted administration of aspirin. METHODS: Analysis of the 
      2011 NEMSIS database targeted patients aged ≥40 years with a paramedic primary 
      impression of 'chest pain'. To identify patients with chest pain of suspected 
      cardiac aetiology, we included those for whom an ECG or cardiac monitoring had 
      been performed. Trauma-related chest pain and basic life support transports were 
      excluded. The primary outcome was presence of aspirin administration. Patient 
      (age, sex, race/ethnicity and insurance status) and regional characteristics 
      where the EMS transport occurred were also obtained. Multivariate logistic 
      regression was used to assess the independent association of patient and regional 
      factors with aspirin administration for suspected cardiac ischaemia. RESULTS: Of 
      the total 14,371,941 EMS incidents in the 2011 database, 198,231 patients met our 
      inclusion criteria (1.3%). Of those, 45.4% received aspirin from the EMS 
      provider. When compared with non-Hispanic white patients, several groups had 
      greater odds of aspirin administration by EMS: non-Hispanic black patients (OR 
      1.49, 95% CI 1.44 to 1.55), non-Hispanic Asians (OR 1.62, 95% CI 1.21 to 2.18), 
      Hispanics (OR 1.71, 95% CI 1.54 to 1.91) and other non-Hispanics (OR 1.27, 95% CI 
      1.07 to 1.51). Patients living in the Southern region of the USA (OR 0.59, 95% CI 
      0.57 to 0.62) and patients with governmental (federally administered such as 
      Veteran's Health Care, but not Medicare or Medicaid) insurance (OR 0.67, 95% CI 
      0.57 to 0.78) had the lowest odds of receiving aspirin. Age and sex (OR 1.00, 95% 
      CI 1.00 to 1.00) were not associated with aspirin administration. CONCLUSIONS: It 
      is likely that prehospital aspirin administration for patients with suspected 
      cardiac ischaemia remains low nationally and could be improved. Reasons for 
      disparities among the various groups should be explored.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Tataris, Katie L
AU  - Tataris KL
AD  - Department of Emergency Medicine, University of California San Francisco, San 
      Francisco, California, USA.
FAU - Mercer, Mary P
AU  - Mercer MP
AD  - Department of Emergency Medicine, University of California San Francisco, San 
      Francisco, California, USA.
FAU - Govindarajan, Prasanthi
AU  - Govindarajan P
AD  - Department of Emergency Medicine, University of California San Francisco, San 
      Francisco, California, USA.
LA  - eng
GR  - K08 HS017965/HS/AHRQ HHS/United States
GR  - KL2 RR024130/RR/NCRR NIH HHS/United States
PT  - Journal Article
DEP - 20150212
PL  - England
TA  - Emerg Med J
JT  - Emergency medicine journal : EMJ
JID - 100963089
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Delivery of Health Care/*standards
MH  - Emergency Medical Services/*standards
MH  - Female
MH  - Humans
MH  - Ischemia/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Quality Assurance, Health Care
MH  - United States
OTO - NOTNLM
OT  - ECG
OT  - cardiac care, acute coronary syndrome
OT  - emergency ambulance systems
OT  - paramedics
OT  - prehospital care, clinical management
EDAT- 2015/02/14 06:00
MHDA- 2016/08/03 06:00
CRDT- 2015/02/14 06:00
PHST- 2014/09/04 00:00 [received]
PHST- 2015/01/24 00:00 [accepted]
PHST- 2015/02/14 06:00 [entrez]
PHST- 2015/02/14 06:00 [pubmed]
PHST- 2016/08/03 06:00 [medline]
AID - emermed-2014-204299 [pii]
AID - 10.1136/emermed-2014-204299 [doi]
PST - ppublish
SO  - Emerg Med J. 2015 Nov;32(11):876-81. doi: 10.1136/emermed-2014-204299. Epub 2015 
      Feb 12.

PMID- 16277554
OWN - NLM
STAT- MEDLINE
DCOM- 20060518
LR  - 20220330
IS  - 1549-1676 (Electronic)
IS  - 1549-1277 (Print)
IS  - 1549-1277 (Linking)
VI  - 2
IP  - 12
DP  - 2005 Dec
TI  - Underutilization of aspirin persists in US ambulatory care for the secondary and 
      primary prevention of cardiovascular disease.
PG  - e353
LID - e353
AB  - BACKGROUND: Despite the proven benefits of aspirin therapy in the primary and 
      secondary prevention of cardiovascular disease (CVD), utilization rates of 
      aspirin remain suboptimal in relation to recommendations. We studied national 
      trends of aspirin use among intermediate- to high-risk patients in the US 
      ambulatory care settings and compared the priority given to aspirin versus 
      statins for CVD risk reduction. We also examined patient and health care provider 
      contributors to the underuse of aspirin. METHODS AND FINDINGS: We used the 
      1993-2003 US National Ambulatory Medical Care Survey and National Hospital 
      Ambulatory Medical Care Survey to estimate aspirin use by cardiovascular risk. 
      Physician-noted cardiovascular diseases defined high risk. Intermediate risk was 
      defined as having diabetes mellitus or multiple major risk factors. The 
      proportion of patient visits in which aspirin was reported increased from 21.7% 
      (95% confidence interval: 18.8%-24.6%) in 1993-1994 to 32.8% (25.2%-40.4%) in 
      2003 for the high-risk category, 3.5% (2.0%-5.0%) to 11.7% (7.8%-15.7%) for 
      visits by patients diagnosed with diabetes, and 3.6% (2.6%-4.6%) to 16.3% 
      (11.4%-21.2%) for those with multiple CVD risk factors. Beginning in 1997-1998, 
      statins were prioritized over aspirin as prophylactic therapy for reducing CVD 
      risk, and the gaps remained wide through 2003. In addition to elevated CVD risk, 
      greater aspirin use was independently associated with advanced age, male gender, 
      cardiologist care, and care in hospital outpatient departments. CONCLUSION: 
      Improvements in use of aspirin in US ambulatory care for reducing risks of CVD 
      were at best modest during the period under study, particularly for secondary 
      prevention, where the strongest evidence and most explicit guidelines exist. 
      Aspirin is more underused than statins despite its more favorable 
      cost-effectiveness. Aggressive and targeted interventions are needed to enhance 
      provider and patient adherence to consensus guidelines for CVD risk reduction.
FAU - Stafford, Randall S
AU  - Stafford RS
AD  - Program on Prevention Outcomes and Practices, Stanford Prevention Research 
      Center, Stanford University School of Medicine, Stanford, California, United 
      States of America. rstafford@stanford.edu
FAU - Monti, Veronica
AU  - Monti V
FAU - Ma, Jun
AU  - Ma J
LA  - eng
GR  - R01 HS011313/HS/AHRQ HHS/United States
GR  - R01-HS11313/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20051115
PL  - United States
TA  - PLoS Med
JT  - PLoS medicine
JID - 101231360
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - PLoS Med. 2006 Feb;3(2):e110; author reply e109. PMID: 16492077
MH  - Adult
MH  - Aged
MH  - Ambulatory Care/*standards/statistics & numerical data
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Health Care Surveys
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Risk Assessment
MH  - United States
PMC - PMC1283363
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2005/11/10 09:00
MHDA- 2006/05/19 09:00
CRDT- 2005/11/10 09:00
PHST- 2005/04/21 00:00 [received]
PHST- 2005/08/25 00:00 [accepted]
PHST- 2005/11/10 09:00 [pubmed]
PHST- 2006/05/19 09:00 [medline]
PHST- 2005/11/10 09:00 [entrez]
AID - 05-PLME-RA-0169R2 [pii]
AID - 10.1371/journal.pmed.0020353 [doi]
PST - ppublish
SO  - PLoS Med. 2005 Dec;2(12):e353. doi: 10.1371/journal.pmed.0020353. Epub 2005 Nov 
      15.

PMID- 8578305
OWN - NLM
STAT- MEDLINE
DCOM- 19960314
LR  - 20170214
IS  - 0036-9330 (Print)
IS  - 0036-9330 (Linking)
VI  - 40
IP  - 5
DP  - 1995 Oct
TI  - The use of aspirin and opiates by Dumfries and Galloway general practitioners in 
      the management of acute myocardial infarction.
PG  - 151-2
AB  - In March 1994 a study in the British Medical Journal indicated a low rate of 
      administration of aspirin and opiates by general practitioners in cases of 
      suspected myocardial infarction. A retrospective analysis was made of 120 
      consecutive admissions to the medical intensive care unit of Dumfries and 
      Galloway Royal Infirmary, by general practitioners, with a primary diagnosis of 
      acute myocardial infarction. Of these 120 cases, 24% were given aspirin by their 
      G.P. prior to admission and 64% were given opiate (IV or IM). Thirty-three 
      percent were already on regular aspirin and of these 18% received further aspirin 
      prior to admission. These figures were considerably better than those previously 
      quoted and they showed that prior regular aspirin therapy did influence the GPs' 
      decision on further administration of aspirin in the acute event. A questionnaire 
      sent to all GPs in Dumfries and Galloway revealed that 100% carried aspirin in 
      their medical bags, 62% claimed to give aspirin to patients with suspected MI, 
      95% used a British Heart Foundation approved dose of aspirin and 83.3% 
      administered the aspirin using one of the approved methods.
FAU - Strachan, D A
AU  - Strachan DA
AD  - Shebburn Surgery, New Abbey, Dumfries.
FAU - Robertson, S
AU  - Robertson S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Scott Med J
JT  - Scottish medical journal
JID - 2983335R
RN  - 0 (Narcotics)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Drug Utilization
MH  - Family Practice/*methods
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Narcotics/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Practice Patterns, Physicians'
MH  - Retrospective Studies
MH  - Scotland
MH  - Surveys and Questionnaires
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - 10.1177/003693309504000509 [doi]
PST - ppublish
SO  - Scott Med J. 1995 Oct;40(5):151-2. doi: 10.1177/003693309504000509.

PMID- 14620867
OWN - NLM
STAT- MEDLINE
DCOM- 20040126
LR  - 20181113
IS  - 0830-9000 (Print)
IS  - 0830-9000 (Linking)
VI  - 67
IP  - 4
DP  - 2003 Oct
TI  - Pharmacokinetics and plasma concentrations of acetylsalicylic acid after 
      intravenous, rectal, and intragastric administration to horses.
PG  - 297-302
AB  - Six healthy adult horses (5 mares and 1 stallion) were given a single dose of 
      acetylsalicylic acid (ASA), 20 mg/kg of body weight, by intravenous (IV), rectal, 
      and intragastric (IG) routes. Serial blood samples were collected via jugular 
      venipuncture over a 36-h period, and plasma ASA and salicylic acid (SA) 
      concentrations were determined by high-performance liquid chromatography. After 
      IV administration, the mean elimination rate constant of ASA (+/- the standard 
      error of the mean) was 1.32 +/- 0.09 h(-1), the mean elimination half-life was 
      0.53 +/- 0.04 h, the area under the plasma concentration-versus-time curve (AUC) 
      was 2555 +/- 98 microg x min/mL, the plasma clearance was 472 +/- 18.9 mL/h/kg, 
      and the volume of distribution at steady state was 0.22 +/- 0.01 L/kg. After 
      rectal administration, the plasma concentration of ASA peaked at 5.05 +/- 0.80 
      microg/mL at 0.33 h, then decreased to undetectable levels by 4 h; the plasma 
      concentration of SA peaked at 17.39 +/- 5.46 microg/mL at 2 h, then decreased to 
      1.92 +/- 0.25 microg/mL by 36 h. After rectal administration, the AUC for ASA was 
      439.4 +/- 94.55 microg x min/mL and the bioavailability was 0.17 +/- 0.037. After 
      IG administration, the plasma concentration of ASA peaked at 1.26 +/- 0.10 
      microg/mL at 0.67 h, then declined to 0.37 +/- 0.37 microg/mL by 36 h; the plasma 
      concentration of SA peaked at 23.90 +/- 4.94 microg/mL at 4 h and decreased to 
      0.85 +/- 0.31 microg/mL by 36 h. After IG administration, the AUC for ASA was 
      146.70 +/- 24.90 microg x min/mL and the bioavailability was 0.059 +/- 0.013. 
      Administration of a single rectal dose of ASA of 20 mg/kg to horses results in 
      higher peak plasma ASA concentrations and greater bioavailability than the same 
      dose given IG. Plasma ASA concentrations after rectal administration should be 
      sufficient to inhibit platelet thromboxane production, and doses lower than those 
      suggested for IG administration may be adequate.
FAU - Broome, Ted A
AU  - Broome TA
AD  - Department of Large Animal Clinical Sciences, College of Veterinary Medicine, 
      University of Florida, Gainesville, Florida 32610-0136, USA.
FAU - Brown, Murray P
AU  - Brown MP
FAU - Gronwall, Ronald R
AU  - Gronwall RR
FAU - Casey, Matthew F
AU  - Casey MF
FAU - Meritt, Kelly A
AU  - Meritt KA
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can J Vet Res
JT  - Canadian journal of veterinary research = Revue canadienne de recherche 
      veterinaire
JID - 8607793
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Administration, Rectal
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/blood/*pharmacokinetics
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid/methods/veterinary
MH  - Cross-Over Studies
MH  - Female
MH  - Horses/blood/*metabolism
MH  - Infusions, Intravenous/veterinary
MH  - Infusions, Parenteral/veterinary
MH  - Male
PMC - PMC280715
EDAT- 2003/11/19 05:00
MHDA- 2004/01/27 05:00
CRDT- 2003/11/19 05:00
PHST- 2003/11/19 05:00 [pubmed]
PHST- 2004/01/27 05:00 [medline]
PHST- 2003/11/19 05:00 [entrez]
AID - 0000000-200310000-00008 [pii]
PST - ppublish
SO  - Can J Vet Res. 2003 Oct;67(4):297-302.

PMID- 23922007
OWN - NLM
STAT- MEDLINE
DCOM- 20140312
LR  - 20181202
IS  - 1744-6880 (Electronic)
IS  - 1744-6872 (Linking)
VI  - 23
IP  - 10
DP  - 2013 Oct
TI  - Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel 
      therapy in Asian patients undergoing percutaneous coronary intervention.
PG  - 558-62
LID - 10.1097/FPC.0b013e328364eb92 [doi]
AB  - The impact of the CYP2C19*17 polymorphism on the clinical outcome in Asians 
      undergoing percutaneous coronary intervention (PCI) is unknown. We sought to 
      assess the long-term impact of CYP2C19*17 on the risk for adverse clinical events 
      in 2188 Korean patients taking clopidogrel after PCI. The prevalence of the 
      CYP2C19*17 allele [*wt/*17: 2.4% (n = 53), *17/*17: 0%] was very low. The 2-year 
      cumulative event rates for bleeding [*wt/*17 vs. *wt/*wt: 2 vs. 2.3%; adjusted 
      hazard ratio (HR), 1.23; 95% confidence interval (CI), 0.16-9.45], stent 
      thrombosis (2 vs. 1.1%; HR, 3.98; 95% CI, 0.49-31.6) or composite of any death, 
      and myocardial infarction or stroke (5.4 vs. 7.1%; HR, 1.37; 95% CI, 0.32-5.73) 
      did not differ on the basis of the presence of CYP2C19*17. In conclusion, in our 
      study population of Asian patients, the CYP2C19*17 polymorphism was not 
      associated with adverse clinical outcomes after PCI because of its low 
      prevalence, the rarity of homozygotes, and the relatively low rate of adverse 
      clinical events.
FAU - Park, Mahn-Won
AU  - Park MW
AD  - aDepartment of Cardiology, Daejeon St. Mary's Hospital bDepartment of Cardiology, 
      Yeouido St. Mary's Hospital cDepartment of Cardiology, Uijeongbu St. Mary's 
      Hospital dDepartment of Cardiology, Seoul St. Mary's Hospital eDepartment of 
      Cardiology, Incheon St. Mary's Hospital fDepartment of Cardiology, St. Vincent's 
      Hospital gDepartment of Cardiology, St. Paul's Hospital hDepartment of 
      Cardiology, Bucheon St. Mary's Hospital, The Catholic University of Korea 
      iDepartment of Pharmacology, PharmacoGenomics Research Center, College of 
      Medicine jDepartment of Clinical Pharmacology, Busan Paik Hospital, Inje 
      University, Busan, Korea.
FAU - Her, Sung Ho
AU  - Her SH
FAU - Kim, Ho-Sook
AU  - Kim HS
FAU - Choi, Yun-Seok
AU  - Choi YS
FAU - Park, Chul-Soo
AU  - Park CS
FAU - Koh, Yoon-Seok
AU  - Koh YS
FAU - Park, Hun-Jun
AU  - Park HJ
FAU - Kim, Pum-Joon
AU  - Kim PJ
FAU - Kim, Chan Joon
AU  - Kim CJ
FAU - Jeon, Doo Soo
AU  - Jeon DS
FAU - Shin, Dong Il
AU  - Shin DI
FAU - Seo, Suk Min
AU  - Seo SM
FAU - Yoo, Ki-Dong
AU  - Yoo KD
FAU - Kim, Dong Bin
AU  - Kim DB
FAU - Kim, Hee Yeol
AU  - Kim HY
FAU - Lee, Jong Min
AU  - Lee JM
FAU - Chung, Wook-Sung
AU  - Chung WS
FAU - Seung, Ki-Bae
AU  - Seung KB
FAU - Shin, Jae-Gook
AU  - Shin JG
FAU - Chang, Kiyuk
AU  - Chang K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacogenet Genomics
JT  - Pharmacogenetics and genomics
JID - 101231005
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aryl Hydrocarbon Hydroxylases/*genetics
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Cytochrome P-450 CYP2C19
MH  - Drug Administration Schedule
MH  - Genetic Linkage
MH  - Genetic Variation
MH  - Genotype
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Myocardial Infarction/etiology
MH  - Myocardial Ischemia/*surgery
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Polymorphism, Genetic
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
EDAT- 2013/08/08 06:00
MHDA- 2014/03/13 06:00
CRDT- 2013/08/08 06:00
PHST- 2013/08/08 06:00 [entrez]
PHST- 2013/08/08 06:00 [pubmed]
PHST- 2014/03/13 06:00 [medline]
AID - 10.1097/FPC.0b013e328364eb92 [doi]
PST - ppublish
SO  - Pharmacogenet Genomics. 2013 Oct;23(10):558-62. doi: 
      10.1097/FPC.0b013e328364eb92.

PMID- 6344625
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 74
IP  - 6A
DP  - 1983 Jun 14
TI  - Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with 
      placebo in moderately severe headache.
PG  - 36-42
AB  - Two-hundred-sixty-nine otherwise healthy persons experiencing periodic, 
      moderately severe headache of a type that had previously responded to 
      nonprescription medications completed this randomized, parallel, double-blind 
      study. The three demographically similar subgroups took either 1,000 mg 
      acetaminophen, 650 mg aspirin, or an identical placebo, for headache. Headache 
      intensity and relief scores over the following six hours were obtained and 
      assessed by sums of pain intensity difference and values of pain relief scores 
      analyses. Responses for the group, and for the subgroup with tension headaches 
      (107 persons) showed no differences between the effects of the active 
      medications. The effects of each medication were strongly superior to placebo. 
      There were no differences in side effects among the three treatment modalities. 
      In persons experiencing tension-vascular headaches (162), only aspirin, at two 
      hours, was superior to placebo, but direct comparison with acetaminophen 
      suggested no real difference. Acetaminophen (1,000 mg) and aspirin (650 mg) are 
      clinically similar in treating the headaches for which they are commonly taken. 
      Recommendations for their use in treating headache should be based on individual 
      patient suitability and on cost factors.
FAU - Peters, B H
AU  - Peters BH
FAU - Fraim, C J
AU  - Fraim CJ
FAU - Masel, B E
AU  - Masel BE
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Headache/*drug therapy
MH  - Humans
MH  - Male
MH  - Placebos
MH  - Research Design
MH  - Vascular Headaches/drug therapy
EDAT- 1983/06/14 00:00
MHDA- 1983/06/14 00:01
CRDT- 1983/06/14 00:00
PHST- 1983/06/14 00:00 [pubmed]
PHST- 1983/06/14 00:01 [medline]
PHST- 1983/06/14 00:00 [entrez]
AID - 0002-9343(83)90526-0 [pii]
AID - 10.1016/0002-9343(83)90526-0 [doi]
PST - ppublish
SO  - Am J Med. 1983 Jun 14;74(6A):36-42. doi: 10.1016/0002-9343(83)90526-0.

PMID- 32530986
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1842-1121 (Electronic)
IS  - 1841-8724 (Linking)
VI  - 29
IP  - 2
DP  - 2020 Jun 3
TI  - Aspirin and Reducing Risk of Gastric Cancer: Systematic Review and Meta-Analysis 
      of the Observational Studies.
PG  - 191-198
LID - 10.15403/jgld-818 [doi]
AB  - BACKGROUND AND AIMS: The latest meta-analysis on the role of aspirin on various 
      cancers was published in early 2018. By including the latest and updated primary 
      observational studies, we aimed to conduct this systematic review and 
      meta-analysis to synthesize stronger evidence on the role of aspirin in reducing 
      gastric cancer (GC) risk. METHODS: The PubMed, Scopus, and MEDLINE databases were 
      systematically searched up to December 2019 to identify relevant studies. 
      Random-effects model was used to calculate summary ORs and 95%CI for I 2 >50%. If 
      the heterogeneity is not significant, the fixed-effects model was used. Overall 
      analysis of the studies, inverse variance weighting after transforming the 
      estimates of each study into log OR and its standard error were used. RESULTS: 21 
      studies were included in this meta-analysis. Results showed that aspirin 
      significantly reduced the GC risk (OR=0.64, 95%CI=0.54-0.76) with substantial 
      heterogeneity (I 2 =96%). Effect of GC risk reduction in low dose (OR=0.80, 
      95%CI=0.59-1.09) is slightly greater than high dose aspirin (OR=1.08, 
      95%CI=0.77-1.52). Protective effect of aspirin uses >5 years (OR=0.67, 
      95%CI=0.34-1.31) was greater than <5 years (OR=1.01, 95%CI=0.72-1.43) Conclusion: 
      In conclusion, this meta-analysis showed that low dose aspirin with longer 
      duration of more than 5 years were associated with a statistically significant 
      reduction in GC risk. However, due to possible confounding variables and bias, 
      these results should be cautiously treated.
FAU - Win, Thin Thin
AU  - Win TT
AD  - Pathology Division, School of Medicine, International Medical University, Kuala 
      Lumpur, Malaysia. thinthinwin@imu.edu.my.
FAU - Aye, Saint Nway
AU  - Aye SN
AD  - Pathology Division, School of Medicine, International Medical University, Kuala 
      Lumpur, Malaysia. saintnwayaye@imu.edu.my.
FAU - Lau Chui Fern, Joyce
AU  - Lau Chui Fern J
AD  - School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia. 
      JOYCE.LAUCHUI@student.imu.edu.my.
FAU - Ong Fei, Cheng
AU  - Ong Fei C
AD  - School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia. 
      CHENG.ONGFEI@student.imu.edu.my.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200603
PL  - Romania
TA  - J Gastrointestin Liver Dis
JT  - Journal of gastrointestinal and liver diseases : JGLD
JID - 101272825
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Duration of Therapy
MH  - Humans
MH  - Protective Factors
MH  - *Stomach Neoplasms/epidemiology/prevention & control
EDAT- 2020/06/13 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
AID - 10.15403/jgld-818 [doi]
PST - epublish
SO  - J Gastrointestin Liver Dis. 2020 Jun 3;29(2):191-198. doi: 10.15403/jgld-818.

PMID- 28279072
OWN - NLM
STAT- MEDLINE
DCOM- 20180618
LR  - 20180618
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 22
IP  - 6
DP  - 2017 Nov
TI  - Aspirin in Older Adults: Need for Wider Utilization in Secondary Prevention and 
      Individual Clinical Judgments in Primary Prevention.
PG  - 511-513
LID - 10.1177/1074248417696820 [doi]
AB  - In the treatment or secondary prevention of cardiovascular disease (CVD), there 
      is general consensus that the absolute benefits of aspirin far outweigh the 
      absolute risks. Despite evidence from randomized trials and their meta-analyses, 
      older adults, defined as aged 65 years or older, are less likely to be prescribed 
      aspirin than their middle-aged counterparts. In primary prevention, the optimal 
      utilization of aspirin is widely debated. There is insufficient randomized 
      evidence among apparently healthy participants at moderate to high risk of a 
      first CVD event, so general guidelines seem premature. Among older adults, 
      randomized data are even more sparse but trials are ongoing. Further, older 
      adults commonly take multiple medications due to comorbidities, which may 
      increase deleterious interactions and side effects. Older adults have higher 
      risks of occlusive events as well as bleeding. All these considerations support 
      the need for individual clinical judgments in prescribing aspirin in the context 
      of therapeutic lifestyle changes and other adjunctive drug therapies. These 
      include statins for lipids and usually multiple drugs to achieve control of high 
      blood pressure. As regards aspirin, the clinician should weigh the absolute 
      benefit on occlusion against the absolute risk of bleeding. These issues should 
      be considered with each patient to facilitate an informed and person-centered 
      individual clinical judgment. The use of aspirin in primary prevention is 
      particularly attractive because the drug is generally over the counter and, for 
      developing countries where CVD is becoming the leading cause of death, is 
      extremely inexpensive. The more widespread use of aspirin in older adults with 
      prior CVD will confer net benefits to risks and even larger net benefits to costs 
      in the United States as well as other developed and developing countries. In 
      primary prevention among older adults, individual clinical judgments should be 
      made by the health-care professional and each of his or her patients.
FAU - Sehgal, Mandi
AU  - Sehgal M
AD  - 1 Department of Integrated Medical Science, Charles E. Schmidt College of 
      Medicine, Florida Atlantic University, Boca Raton, FL, USA.
FAU - Wood, Sarah K
AU  - Wood SK
AD  - 1 Department of Integrated Medical Science, Charles E. Schmidt College of 
      Medicine, Florida Atlantic University, Boca Raton, FL, USA.
FAU - Ouslander, Joseph G
AU  - Ouslander JG
AD  - 1 Department of Integrated Medical Science, Charles E. Schmidt College of 
      Medicine, Florida Atlantic University, Boca Raton, FL, USA.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - 1 Department of Integrated Medical Science, Charles E. Schmidt College of 
      Medicine, Florida Atlantic University, Boca Raton, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170309
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/blood
MH  - Aspirin/*administration & dosage/blood
MH  - Cardiovascular Diseases/blood/*prevention & control
MH  - Clinical Decision-Making/*methods
MH  - Humans
MH  - *Judgment
MH  - Primary Prevention/*methods/standards
MH  - Secondary Prevention/*methods/standards
OTO - NOTNLM
OT  - acute myocardial infarction
OT  - cardiovascular disease
OT  - thrombosis
EDAT- 2017/03/11 06:00
MHDA- 2018/06/19 06:00
CRDT- 2017/03/11 06:00
PHST- 2017/03/11 06:00 [pubmed]
PHST- 2018/06/19 06:00 [medline]
PHST- 2017/03/11 06:00 [entrez]
AID - 10.1177/1074248417696820 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2017 Nov;22(6):511-513. doi: 
      10.1177/1074248417696820. Epub 2017 Mar 9.

PMID- 8615310
OWN - NLM
STAT- MEDLINE
DCOM- 19960605
LR  - 20221207
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 131
IP  - 5
DP  - 1996 May
TI  - Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in 
      Communities (ARIC) Study.
PG  - 915-22
AB  - To determine correlates of and recent trends in aspirin use in middle-age men and 
      women, we analyzed data from population-based samples selected in four U.S. 
      communities. Aspirin use (during a 2-week period preceding the study examination) 
      was more prevalent in whites than in blacks (30% vs 11%; p < 0.001) and in men 
      than in women among whites (31% vs 28%; p < 0.002) but not blacks (10% in both 
      sexes). In all four race and sex groups, there was a graded positive relation 
      between estimated coronary heart disease (CHD) risk and age-adjusted prevalence 
      of aspirin use. For example, 33% of CHD-free white men who reported diagnoses of 
      hypercholesterolemia and hypertension and had ever smoked reported aspirin use as 
      compared with 25% of their risk factor-free counterparts (p < 0.001). Among men 
      with symptomatic CHD or at high risk for CHD, aspirin use increased by four 
      percentage points between 1987 and 1989 in conjunction with the publication of 
      results from the aspirin primary prevention trials. However, nearly 50% of 
      participants reporting a history of myocardial infarction apparently did not take 
      aspirin regularly.
FAU - Shahar, E
AU  - Shahar E
AD  - Division of Epidemiology, School of Public Health, University of Minnesota, 
      Minneapolis 55454-1015, USA.
FAU - Folsom, A R
AU  - Folsom AR
FAU - Romm, F J
AU  - Romm FJ
FAU - Bisgard, K M
AU  - Bisgard KM
FAU - Metcalf, P A
AU  - Metcalf PA
FAU - Crum, L
AU  - Crum L
FAU - McGovern, P G
AU  - McGovern PG
FAU - Hutchinson, R G
AU  - Hutchinson RG
FAU - Heiss, G
AU  - Heiss G
LA  - eng
GR  - N01-HC-55015/HC/NHLBI NIH HHS/United States
GR  - N01-HC-55016/HC/NHLBI NIH HHS/United States
GR  - N01-HC-55018/HC/NHLBI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Black or African American
MH  - Age Factors
MH  - Aged
MH  - Arteriosclerosis/drug therapy/*mortality
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Coronary Disease/*mortality/prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Myocardial Infarction/*mortality/prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Prevalence
MH  - Risk Factors
MH  - United States/epidemiology
MH  - White People
RF  - 37
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - S0002-8703(96)90173-8 [pii]
AID - 10.1016/s0002-8703(96)90173-8 [doi]
PST - ppublish
SO  - Am Heart J. 1996 May;131(5):915-22. doi: 10.1016/s0002-8703(96)90173-8.

PMID- 3120680
OWN - NLM
STAT- MEDLINE
DCOM- 19880119
LR  - 20191029
IS  - 0276-5047 (Print)
IS  - 0276-5047 (Linking)
VI  - 7
IP  - 6
DP  - 1987 Nov-Dec
TI  - Effect of chronic low dose aspirin on platelet and vascular eicosanoid metabolism 
      in nonhuman primates (Macaca fascicularis).
PG  - 599-604
AB  - It has been suggested that inhibition of platelet cyclooxygenase by chronic low 
      dose aspirin may spare vascular prostacyclin production. Conventional doses of 
      aspirin (greater than 5 mg/kg) have been shown to inhibit the generation of both 
      thromboxane A2 and prostacyclin. Low dose aspirin inhibits prostacyclin 
      production by excised human venous tissue, thus questioning the selectivity of 
      such regimens. However, many clinical and surgical conditions requiring platelet 
      inhibition involve the arterial system. We have studied the effects of various 
      aspirin regimens on platelet, venous, and arterial cyclooxygenase activity in a 
      nonhuman primate (Macaca fascicularis). We determined the lowest chronic dose of 
      oral aspirin required to effectively inhibit platelet cyclooxygenase and 
      aggregation to be 1 mg/kg. After 14 days of 0, 1, or 2 mg/kg aspirin, intact 
      veins and arteries were surgically removed and perfused, and luminal prostacyclin 
      (6-keto-PGF1 alpha) generation was assessed. Levels of 6-keto-PGF1 alpha in 
      venous perfusates were reduced by 89% and 86% (p less than 0.05) after 1 and 2 
      mg/kg, respectively. Arterial 6-keto-PGF1 alpha levels were unchanged by 1 mg/kg 
      aspirin, but after 2 mg/kg were reduced by 66% (p less than 0.05). Preferential 
      inhibition of platelet over arterial cyclooxygenase is thus achievable, but only 
      over a narrow dose range.
FAU - Jakubowski, J A
AU  - Jakubowski JA
AD  - Boston Veterans Administration Medical Center, Massachusetts 02130.
FAU - Bush, H L Jr
AU  - Bush HL Jr
FAU - Vaillancourt, R
AU  - Vaillancourt R
FAU - Deykin, D
AU  - Deykin D
LA  - eng
GR  - HL-13262/HL/NHLBI NIH HHS/United States
GR  - HL-18586/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arteriosclerosis
JT  - Arteriosclerosis (Dallas, Tex.)
JID - 8401388
RN  - 0 (Arachidonic Acids)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - EC 1.13.11.12 (Lipoxygenase)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/metabolism
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/metabolism/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects/enzymology/metabolism
MH  - Blood Vessels/*drug effects/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Lipoxygenase/metabolism
MH  - Macaca fascicularis
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Radioimmunoassay
MH  - Thromboxane A2/biosynthesis
EDAT- 1987/11/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1987/11/01 00:00
PHST- 1987/11/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1987/11/01 00:00 [entrez]
AID - 10.1161/01.atv.7.6.599 [doi]
PST - ppublish
SO  - Arteriosclerosis. 1987 Nov-Dec;7(6):599-604. doi: 10.1161/01.atv.7.6.599.

PMID- 33214605
OWN - NLM
STAT- MEDLINE
DCOM- 20210422
LR  - 20210422
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Nov 19
TI  - Clinical factors associated with safety and efficacy in patients receiving direct 
      oral anticoagulants for non-valvular atrial fibrillation.
PG  - 20144
LID - 10.1038/s41598-020-77174-z [doi]
LID - 20144
AB  - Although patients suffering from atrial fibrillation have increased worldwide, 
      detailed information about factors associated with bleeding during direct oral 
      anticoagulant therapy remains insufficient. We studied 1086 patients for whom 
      direct oral anticoagulants were initiated for non-valvular atrial fibrillation 
      between April 2011 and June 2017. Endpoints were clinically relevant bleeding or 
      major adverse cardiac and cerebrovascular events until the end of December 2018. 
      Incidences of bleeding and thrombosis were 4.5 per 100 person-years and 4.7 per 
      100 person-years, respectively. Most bleeding events represented gastrointestinal 
      bleeding. Multivariate analysis revealed initiation of anticoagulants 
      at ≥ 85 years old as significantly associated with bleeding, particularly 
      gastrointestinal bleeding, but not major cardiac and cerebrovascular events. 
      Other significant factors included chronic kidney disease, low-dose aspirin and 
      nonsteroidal anti-inflammatory drugs. For gastrointestinal bleeding alone, 
      histories of gastrointestinal bleeding and malignancy also showed positive 
      correlations, in addition to the above-mentioned factors. Clinicians should pay 
      greater attention to the risk of gastrointestinal bleeding when considering 
      prescription of anticoagulants to patients ≥ 85 years old with atrial 
      fibrillation.
FAU - Yamato, Hiroshi
AU  - Yamato H
AD  - Division of Gastroenterology, Department of Medicine, Teikyo University School of 
      Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
FAU - Abe, Koichiro
AU  - Abe K
AD  - Division of Gastroenterology, Department of Medicine, Teikyo University School of 
      Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan. 
      abe@med.teikyo-u.ac.jp.
FAU - Osumi, Shun
AU  - Osumi S
AD  - Division of Gastroenterology, Department of Medicine, Teikyo University School of 
      Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
FAU - Yanagisawa, Daisuke
AU  - Yanagisawa D
AD  - Division of Gastroenterology, Department of Medicine, Teikyo University School of 
      Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
FAU - Kodashima, Shinya
AU  - Kodashima S
AD  - Division of Gastroenterology, Department of Medicine, Teikyo University School of 
      Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
FAU - Asaoka, Yoshinari
AU  - Asaoka Y
AD  - Division of Gastroenterology, Department of Medicine, Teikyo University School of 
      Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
FAU - Konno, Kumiko
AU  - Konno K
AD  - Division of Cardiology, Department of Medicine, Teikyo University School of 
      Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
FAU - Kozuma, Ken
AU  - Kozuma K
AD  - Division of Cardiology, Department of Medicine, Teikyo University School of 
      Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
FAU - Yamamoto, Takatsugu
AU  - Yamamoto T
AD  - Division of Gastroenterology, Department of Medicine, Teikyo University School of 
      Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
FAU - Tanaka, Atsushi
AU  - Tanaka A
AD  - Division of Gastroenterology, Department of Medicine, Teikyo University School of 
      Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201119
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Anticoagulants/*administration & dosage/*adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Atrial Fibrillation/*drug therapy/epidemiology/etiology
MH  - Comorbidity
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Male
MH  - Multivariate Analysis
MH  - Retrospective Studies
MH  - Thrombosis/chemically induced
PMC - PMC7678868
COIS- The authors declare no competing interests.
EDAT- 2020/11/21 06:00
MHDA- 2021/04/23 06:00
CRDT- 2020/11/20 05:46
PHST- 2020/07/08 00:00 [received]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2020/11/20 05:46 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/04/23 06:00 [medline]
AID - 10.1038/s41598-020-77174-z [pii]
AID - 77174 [pii]
AID - 10.1038/s41598-020-77174-z [doi]
PST - epublish
SO  - Sci Rep. 2020 Nov 19;10(1):20144. doi: 10.1038/s41598-020-77174-z.

PMID- 15936600
OWN - NLM
STAT- MEDLINE
DCOM- 20050624
LR  - 20181201
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 45
IP  - 11
DP  - 2005 Jun 7
TI  - Enhanced shear-induced platelet aggregation in patients who experience subacute 
      stent thrombosis: a case-control study.
PG  - 1753-6
AB  - OBJECTIVES: The goal of this study was to identify differences in shear-induced 
      platelet aggregation (SIPA) between patients who did or did not experience 
      subacute stent thrombosis (SAT). BACKGROUND: Despite dual antiplatelet therapy, 
      SAT after coronary stenting occurs in approximately 1% of patients. There is no 
      accepted platelet function test to identify patients at risk. METHODS: We 
      analyzed platelet aggregation in 10 patients who had experienced SAT (cases), 22 
      stented patients without SAT (controls), and 17 healthy volunteers (normals). All 
      patients except normals were treated with both aspirin and clopidogrel. RESULTS: 
      Shear-induced platelet aggregation was higher in cases than in controls at both 
      shear rates of 200 s(-1) (40.9 +/- 12.2% vs. 18.2 +/- 18%, p = 0.013) and 4,000 
      s(-1) (57.4 +/- 16.4% vs. 23.4 +/- 21.2%, p = 0.009). Moreover, SIPA in cases was 
      significantly higher than in normals both at 200 s(-1) (p = 0.013) and 4,000(-1) 
      (p = 0.009). CONCLUSIONS: Shear-induced platelet aggregation is increased in 
      patients experiencing SAT compared with controls receiving dual antiplatelet 
      therapy and to normals receiving no antiplatelet therapy, which suggests 
      increased intrinsic patient-related platelet reactivity in patients with SAT. The 
      predictive value of SIPA for SAT requires prospective investigation.
FAU - Ajzenberg, Nadine
AU  - Ajzenberg N
AD  - Hématologie et Immunologie, Hôpital Bichat, Paris, France. 
      nadine.ajzenberg@bch.ap-hop-paris.fr
FAU - Aubry, Pierre
AU  - Aubry P
FAU - Huisse, Marie-Genevieve
AU  - Huisse MG
FAU - Cachier, Agnés
AU  - Cachier A
FAU - El Amara, Walid
AU  - El Amara W
FAU - Feldman, Laurent J
AU  - Feldman LJ
FAU - Himbert, Dominique
AU  - Himbert D
FAU - Baruch, Dominique
AU  - Baruch D
FAU - Guillin, Marie-Claude
AU  - Guillin MC
FAU - Steg, Ph Gabriel
AU  - Steg PG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2005 Jun 7;45(11):1757-8. PMID: 15936601
MH  - Aged
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/pharmacology/therapeutic use
MH  - Case-Control Studies
MH  - Clopidogrel
MH  - Coronary Disease/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/physiology
MH  - Platelet Aggregation/drug effects/*physiology
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Prospective Studies
MH  - Stents/*adverse effects
MH  - Thrombosis/*physiopathology/prevention & control
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2005/06/07 09:00
MHDA- 2005/06/25 09:00
CRDT- 2005/06/07 09:00
PHST- 2004/09/03 00:00 [received]
PHST- 2004/10/11 00:00 [revised]
PHST- 2004/10/18 00:00 [accepted]
PHST- 2005/06/07 09:00 [pubmed]
PHST- 2005/06/25 09:00 [medline]
PHST- 2005/06/07 09:00 [entrez]
AID - S0735-1097(05)00634-0 [pii]
AID - 10.1016/j.jacc.2004.10.079 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2005 Jun 7;45(11):1753-6. doi: 10.1016/j.jacc.2004.10.079.

PMID- 7700286
OWN - NLM
STAT- MEDLINE
DCOM- 19950428
LR  - 20220310
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 332
IP  - 17
DP  - 1995 Apr 27
TI  - Hydroxyurea for patients with essential thrombocythemia and a high risk of 
      thrombosis.
PG  - 1132-6
AB  - BACKGROUND: Abnormalities in the number and function of platelets may contribute 
      to thromboembolic complications in patients with essential thrombocythemia. We 
      assessed whether maintaining the platelet count below 600,000 per cubic 
      millimeter with hydroxyurea reduces the incidence of thrombosis in patients with 
      essential thrombocythemia and a high risk of thrombosis. METHODS: A total of 114 
      patients with essential thrombocythemia (77 women and 37 men; median age, 68 
      years; range, 40 to 85) and a median platelet count of 788,000 per cubic 
      millimeter (range, 533,000 to 1,240,000 per cubic millimeter) were randomly 
      assigned to receive hydroxyurea (56 patients) or no myelosuppressive therapy (58 
      patients). Ninety-seven (85 percent) were over 60 years old, and 52 (46 percent) 
      had had thrombosis. The two groups were matched for age, sex, and platelet count 
      at randomization. Antiplatelet prophylaxis with aspirin or ticlopidine was not 
      stopped. Follow-up lasted a median of 27 months in both groups. RESULTS: Two 
      patients (3.6 percent) treated with hydroxyurea had thrombotic episodes (one 
      stroke and one myocardial infarction), whereas 14 patients (24 percent) in the 
      control group had thrombotic episodes (one stroke, five transient ischemic 
      attacks, five peripheral arterial occlusions, one deep-vein thrombosis, and two 
      cases of superficial thrombophlebitis). The difference (20.4 percentage points; 
      95 percent confidence interval, 8.5 to 32 percent) was statistically significant 
      (chi-square with Yates' correction, 8.3; 1 df; P = 0.003). CONCLUSIONS: 
      Hydroxyurea is effective in preventing thrombosis in high-risk patients with 
      essential thrombocythemia.
FAU - Cortelazzo, S
AU  - Cortelazzo S
AD  - Division of Hematology, Ospedali Riuniti di Bergamo, Italy.
FAU - Finazzi, G
AU  - Finazzi G
FAU - Ruggeri, M
AU  - Ruggeri M
FAU - Vestri, O
AU  - Vestri O
FAU - Galli, M
AU  - Galli M
FAU - Rodeghiero, F
AU  - Rodeghiero F
FAU - Barbui, T
AU  - Barbui T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
CIN - N Engl J Med. 1995 Sep 21;333(12):802-3. PMID: 7643898
CIN - N Engl J Med. 1995 Sep 21;333(12):803. PMID: 7643899
CIN - N Engl J Med. 1995 Sep 21;333(12):803. PMID: 7643900
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Hydroxyurea/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prospective Studies
MH  - Risk
MH  - Thrombocytosis/complications/*drug therapy
MH  - Thromboembolism/*etiology/prevention & control
MH  - Ticlopidine/adverse effects/therapeutic use
EDAT- 1995/04/27 00:00
MHDA- 1995/04/27 00:01
CRDT- 1995/04/27 00:00
PHST- 1995/04/27 00:00 [pubmed]
PHST- 1995/04/27 00:01 [medline]
PHST- 1995/04/27 00:00 [entrez]
AID - 10.1056/NEJM199504273321704 [doi]
PST - ppublish
SO  - N Engl J Med. 1995 Apr 27;332(17):1132-6. doi: 10.1056/NEJM199504273321704.

PMID- 32631716
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1877-0568 (Electronic)
IS  - 1877-0568 (Linking)
VI  - 107
IP  - 1
DP  - 2021 Feb
TI  - Aspirin versus enoxaparin for the initial prevention of venous thromboembolism 
      following elective arthroplasty of the hip or knee: A systematic review and 
      meta-analysis.
PG  - 102606
LID - S1877-0568(20)30137-7 [pii]
LID - 10.1016/j.otsr.2020.04.002 [doi]
AB  - BACKGROUND: Aspirin is perceived to be non-inferior to enoxaparin, a 
      low-molecular-weight heparin, for the prevention of venous thromboembolism (VTE) 
      following elective arthroplasty of the hip or knee and is recommended in clinical 
      guidelines internationally. Previous systematic reviews of aspirin as VTE 
      prophylaxis have been limited by the inclusion of heterogenous studies where 
      aspirin is commenced after the initial high-risk postoperative period. The 
      purpose of this systematic review and meta-analysis was to compare the efficacy 
      and associated harms of aspirin and enoxaparin when used as VTE prophylaxis in 
      the initial postoperative period following elective arthroplasty of the hip or 
      knee. We sought to: (1) to compare the use of aspirin versus enoxaparin following 
      elective joint replacement of the hip or knee on the primary outcomes of 
      incidence of VTE and mortality up to 3 months postoperatively and (2) assess the 
      efficacy of aspirin with respect to secondary outcomes such as major or minor 
      bleeding events. We hypothesised that aspirin would have equivalent efficacy for 
      the prevention of VTE when used as initial prophylactic agent, without increasing 
      harm from bleeding events. PATIENTS AND METHODS: We searched Pubmed, Embase, 
      Medline and Cochrane Central for randomized controlled trials reporting the 
      primary outcomes of VTE incidence and mortality. Secondary outcomes included 
      major (compromise of organ, limb or muscle function requiring unplanned 
      re-operation) and minor bleeding events (wound ooze, minor bleed, infection). 
      Included trials underwent a risk of bias and quality of evidence assessment using 
      the GRADE criteria. RESULTS: Four trials involving 1507 participants who 
      underwent elective lower limb arthroplasty were included. We did not detect a 
      significant difference in overall VTE rates when comparing aspirin versus 
      enoxaparin (RR, 0.84; 95% CI: 0.41 to 1.75; p=0.65). Mortality was reported by 
      one study and no events were recorded. There were no significant differences in 
      the rates of all major (RR, 0.84; 95% CI: 0.08 to 9.16) or minor (RR, 0.77; 95% 
      CI: 0.34 to 1.72) bleeding events between the aspirin and enoxaparin groups. 
      Included trials demonstrated a significant risk of bias, and Low to Very Low 
      quality of evidence for primary outcomes, and Moderate to Very Low for secondary 
      outcomes. CONCLUSION: There is currently a lack of high quality randomised 
      controlled trials supporting the use of aspirin as VTE chemoprophylaxis in the 
      initial postoperative period for both total hip and total knee arthroplasty. The 
      results of this meta-analysis provide cautious endorsement for the position that 
      aspirin is likely a safe alternative to enoxaparin for TKA patients as part of a 
      multimodal enhanced recovery protocol, but care is advised for THA patients owing 
      to a lack of data from trials. Current evidence from randomized controlled trials 
      is generally of low quality, and does not estimate critical event data for VTE 
      incidence or mortality, as well as major and minor bleeding events with 
      sufficient certainty. PROSPERO Registration CRD42018110784. LEVEL OF EVIDENCE: 
      II, systematic review.
CI  - Copyright © 2020 Elsevier Masson SAS. All rights reserved.
FAU - Farey, John E
AU  - Farey JE
AD  - Department of Orthopaedic Surgery, Royal Prince Alfred Hospital, Missenden Road, 
      2050 Camperdown NSW, Australia. Electronic address: jfar9860@uni.sydney.edu.au.
FAU - An, Vincent V G
AU  - An VVG
AD  - Department of Orthopaedic Surgery, Royal Prince Alfred Hospital, Missenden Road, 
      2050 Camperdown NSW, Australia.
FAU - Sidhu, Verinder
AU  - Sidhu V
AD  - School of Public Health, Institute for Musculoskeletal Health, University of 
      Sydney, King George V building, Missenden Road, 2050 Camperdown NSW, Australia.
FAU - Karunaratne, Sascha
AU  - Karunaratne S
AD  - Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, 
      Missenden Road, 2050 Camperdown NSW, Australia.
FAU - Harris, Ian A
AU  - Harris IA
AD  - Department of Orthopaedic Surgery, Royal Prince Alfred Hospital, Missenden Road, 
      2050 Camperdown NSW, Australia; School of Public Health, Institute for 
      Musculoskeletal Health, University of Sydney, King George V building, Missenden 
      Road, 2050 Camperdown NSW, Australia; South Western Sydney Clinical School, 
      Ingham Institute for Applied Medical Research, University of New South Wales, 
      1,Campbell Street, 2170 Liverpool NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20200704
PL  - France
TA  - Orthop Traumatol Surg Res
JT  - Orthopaedics & traumatology, surgery & research : OTSR
JID - 101494830
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - *Arthroplasty, Replacement, Hip/adverse effects
MH  - Aspirin/therapeutic use
MH  - Enoxaparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight
MH  - Humans
MH  - *Venous Thromboembolism/epidemiology/etiology/prevention & control
OTO - NOTNLM
OT  - Arthroplasty
OT  - Aspirin
OT  - Enoxaparin
OT  - Hip
OT  - Knee
OT  - Low molecular-weight heparin
OT  - Replacement
OT  - Venous thromboembolism
EDAT- 2020/07/08 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/01/23 00:00 [received]
PHST- 2020/04/07 00:00 [revised]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - S1877-0568(20)30137-7 [pii]
AID - 10.1016/j.otsr.2020.04.002 [doi]
PST - ppublish
SO  - Orthop Traumatol Surg Res. 2021 Feb;107(1):102606. doi: 
      10.1016/j.otsr.2020.04.002. Epub 2020 Jul 4.

PMID- 16787383
OWN - NLM
STAT- MEDLINE
DCOM- 20060811
LR  - 20190917
IS  - 1389-5575 (Print)
IS  - 1389-5575 (Linking)
VI  - 6
IP  - 6
DP  - 2006 Jun
TI  - Mechanisms of action and targets for actual and future antiplatelet drugs.
PG  - 719-26
AB  - Platelets are key players in arterial thrombosis and have become important 
      targets in the primary and secondary prevention of atherothrombosis. Antiplatelet 
      drugs are primarily directed against platelets and inhibit platelet activation by 
      a number of different mechanisms. They are used for the prevention and treatment 
      of thrombotic processes, especially in the arterial vascular system. Antiplatelet 
      drugs in clinical use and experimental drugs are discussed.
FAU - Freson, Kathleen
AU  - Freson K
AD  - Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium. 
      Kathleen.freson@med.kuleuven.ac.be
FAU - Thys, Chantal
AU  - Thys C
FAU - Wittevrongel, Christine
AU  - Wittevrongel C
FAU - Van Geet, Chris
AU  - Van Geet C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Mini Rev Med Chem
JT  - Mini reviews in medicinal chemistry
JID - 101094212
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Membrane Glycoprotein IIb)
RN  - 0 (Purinergic Antagonists)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - *Drug Design
MH  - Humans
MH  - Platelet Aggregation Inhibitors/chemistry/*pharmacology
MH  - Platelet Membrane Glycoprotein IIb/*drug effects
MH  - *Purinergic Antagonists
MH  - Pyridines/pharmacology
RF  - 76
EDAT- 2006/06/22 09:00
MHDA- 2006/08/12 09:00
CRDT- 2006/06/22 09:00
PHST- 2006/06/22 09:00 [pubmed]
PHST- 2006/08/12 09:00 [medline]
PHST- 2006/06/22 09:00 [entrez]
AID - 10.2174/138955706777435661 [doi]
PST - ppublish
SO  - Mini Rev Med Chem. 2006 Jun;6(6):719-26. doi: 10.2174/138955706777435661.

PMID- 8219635
OWN - NLM
STAT- MEDLINE
DCOM- 19931220
LR  - 20131121
IS  - 0941-293X (Print)
IS  - 0941-293X (Linking)
VI  - 90
IP  - 5
DP  - 1993 Oct
TI  - [Mitral valve prolapse. A possible cause of retinal vascular occlusion in young 
      patients].
PG  - 476-8
AB  - Retinal vessel occlusion in the elderly is considered to be of arteriosclerotic 
      etiology, but in young patients the reasons for retinal vessel occlusions are 
      manifold and much more obscure. We report on five patients under the age of 45 
      years who had retinal artery occlusion or retinal vein obstruction. A detailed 
      general investigation revealed nothing but an identical cardiac abnormality in 
      all five cases: mitral valve prolapse (MVP). A potential explanation for the 
      coincidence of retinal vessel occlusion and MVP might be local hyperaggregability 
      of platelets generated by the prolapsing mitral valve. In conclusion, to prevent 
      retinal vessel occlusion from recurring in patients with proven MVP, medication 
      containing platelet aggregation inhibitors should be given.
FAU - Schimkat, M
AU  - Schimkat M
AD  - Universitäts-Augenklinik Düsseldorf.
FAU - Horstkotte, D
AU  - Horstkotte D
FAU - Sundmacher, R
AU  - Sundmacher R
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Der Mitralklappenprolaps. Mögliche Ursache retinaler Gefässverschlüsse junger 
      Menschen.
PL  - Germany
TA  - Ophthalmologe
JT  - Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
JID - 9206148
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage
MH  - Female
MH  - Humans
MH  - Long-Term Care
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Prolapse/*complications
MH  - Retinal Artery Occlusion/*etiology/prevention & control
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
PST - ppublish
SO  - Ophthalmologe. 1993 Oct;90(5):476-8.

PMID- 35164195
OWN - NLM
STAT- MEDLINE
DCOM- 20220218
LR  - 20221207
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 27
IP  - 3
DP  - 2022 Jan 29
TI  - Development and Validation of a Novel HPLC Method to Analyse Metabolic Reaction 
      Products Catalysed by the CYP3A2 Isoform: In Vitro Inhibition of CYP3A2 Enzyme 
      Activity by Aspirin (Drugs Often Used Together in COVID-19 Treatment).
LID - 10.3390/molecules27030927 [doi]
LID - 927
AB  - Aspirin (also known as acetylsalicylic acid) is a drug intended to treat fever, 
      pain, or inflammation. Treatment of moderate to severe cases of COVID-19 using 
      aspirin along with dexamethasone has gained major attention globally in recent 
      times. Thus, the purpose of this study was to use High-Performance Liquid 
      Chromatography (HPLC) to evaluate the in vitro inhibition of CYP3A2 enzyme 
      activity using aspirin in rat liver microsomes (RLMs). In this study, an 
      efficient and sensitive HPLC method was developed using a reversed phase C18 
      column (X Bridge 4.6 mm × 150 mm, 3.5 µm) at 243 nm using acetonitrile and water 
      (70:30 v/v). The linearity (r(2) > 0.999), precision (<15%), accuracy and 
      recovery (80-120%), limit of detection (5.60 µM and 0.06 µM), limit of 
      quantification (16.98 µM and 0.19 µM), and stability of the newly developed 
      method were validated for dexamethasone and 6β-hydroxydexamethasone, 
      respectively, following International Conference on Harmonization (ICH) 
      guidelines. This method was applied in vitro to measure CYP3A2 activity. The 
      results showed that aspirin competitively inhibits 6β-hydroxylation (CYP3A2 
      activity) with an inhibition constant (Ki) = 95.46 µM and the concentration of 
      the inhibitor causing 50% inhibition of original enzyme activity (IC(50)) = 
      190.92 µM. This indicated that there is a minimal risk of toxicity when 
      dexamethasone and aspirin are co-administrated and a very low risk of toxicity 
      and drug interaction with drugs that are a substrate for CYP3A2 in healthcare 
      settings.
FAU - Hussain, Amira
AU  - Hussain A
AD  - School of Life Sciences, Pharmacy and Chemistry, Kingston University, 
      Kingston-upon-Thames, London KT1 2EE, UK.
FAU - Naughton, Declan P
AU  - Naughton DP
AD  - School of Life Sciences, Pharmacy and Chemistry, Kingston University, 
      Kingston-upon-Thames, London KT1 2EE, UK.
FAU - Barker, James
AU  - Barker J
AUID- ORCID: 0000-0002-5863-9400
AD  - School of Life Sciences, Pharmacy and Chemistry, Kingston University, 
      Kingston-upon-Thames, London KT1 2EE, UK.
LA  - eng
PT  - Journal Article
DEP - 20220129
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Cytochrome P-450 Enzyme Inhibitors)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Protein Isoforms)
RN  - 55879-47-5 (6-hydroxydexamethasone)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - EC 1.14.14.1 (Cyp3a2 protein, rat)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP3A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry/*pharmacology
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Cytochrome P-450 CYP3A/drug effects/*metabolism
MH  - Cytochrome P-450 Enzyme Inhibitors/metabolism
MH  - Cytochrome P-450 Enzyme System/metabolism
MH  - Dexamethasone/analogs & derivatives/pharmacology
MH  - Male
MH  - Microsomes, Liver/metabolism
MH  - Pharmaceutical Preparations/metabolism
MH  - Protein Isoforms/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reproducibility of Results
MH  - SARS-CoV-2/drug effects/pathogenicity
MH  - COVID-19 Drug Treatment
PMC - PMC8838585
OTO - NOTNLM
OT  - 6β-hydroxydexamethasone
OT  - CYP3A activity
OT  - aspirin
OT  - competitive inhibitor
OT  - cytochrome P450
OT  - dexamethasone
COIS- The authors declared that they have no conflict of financial interest.
EDAT- 2022/02/16 06:00
MHDA- 2022/02/19 06:00
CRDT- 2022/02/15 01:20
PHST- 2021/11/08 00:00 [received]
PHST- 2022/01/26 00:00 [revised]
PHST- 2022/01/27 00:00 [accepted]
PHST- 2022/02/15 01:20 [entrez]
PHST- 2022/02/16 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
AID - molecules27030927 [pii]
AID - molecules-27-00927 [pii]
AID - 10.3390/molecules27030927 [doi]
PST - epublish
SO  - Molecules. 2022 Jan 29;27(3):927. doi: 10.3390/molecules27030927.

PMID- 30221596
OWN - NLM
STAT- MEDLINE
DCOM- 20181105
LR  - 20211209
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 379
IP  - 16
DP  - 2018 Oct 18
TI  - Effect of Aspirin on Disability-free Survival in the Healthy Elderly.
PG  - 1499-1508
LID - 10.1056/NEJMoa1800722 [doi]
AB  - BACKGROUND: Information on the use of aspirin to increase healthy independent 
      life span in older persons is limited. Whether 5 years of daily low-dose aspirin 
      therapy would extend disability-free life in healthy seniors is unclear. METHODS: 
      From 2010 through 2014, we enrolled community-dwelling persons in Australia and 
      the United States who were 70 years of age or older (or ≥65 years of age among 
      blacks and Hispanics in the United States) and did not have cardiovascular 
      disease, dementia, or physical disability. Participants were randomly assigned to 
      receive 100 mg per day of enteric-coated aspirin or placebo orally. The primary 
      end point was a composite of death, dementia, or persistent physical disability. 
      Secondary end points reported in this article included the individual components 
      of the primary end point and major hemorrhage. RESULTS: A total of 19,114 persons 
      with a median age of 74 years were enrolled, of whom 9525 were randomly assigned 
      to receive aspirin and 9589 to receive placebo. A total of 56.4% of the 
      participants were women, 8.7% were nonwhite, and 11.0% reported previous regular 
      aspirin use. The trial was terminated at a median of 4.7 years of follow-up after 
      a determination was made that there would be no benefit with continued aspirin 
      use with regard to the primary end point. The rate of the composite of death, 
      dementia, or persistent physical disability was 21.5 events per 1000 person-years 
      in the aspirin group and 21.2 per 1000 person-years in the placebo group (hazard 
      ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11; P=0.79). The rate of 
      adherence to the assigned intervention was 62.1% in the aspirin group and 64.1% 
      in the placebo group in the final year of trial participation. Differences 
      between the aspirin group and the placebo group were not substantial with regard 
      to the secondary individual end points of death from any cause (12.7 events per 
      1000 person-years in the aspirin group and 11.1 events per 1000 person-years in 
      the placebo group), dementia, or persistent physical disability. The rate of 
      major hemorrhage was higher in the aspirin group than in the placebo group (3.8% 
      vs. 2.8%; hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P<0.001). CONCLUSIONS: 
      Aspirin use in healthy elderly persons did not prolong disability-free survival 
      over a period of 5 years but led to a higher rate of major hemorrhage than 
      placebo. (Funded by the National Institute on Aging and others; ASPREE 
      ClinicalTrials.gov number, NCT01038583 .).
FAU - McNeil, John J
AU  - McNeil JJ
AUID- ORCID: 0000-0002-1049-5129
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Woods, Robyn L
AU  - Woods RL
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Reid, Christopher M
AU  - Reid CM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Kirpach, Brenda
AU  - Kirpach B
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Storey, Elsdon
AU  - Storey E
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Shah, Raj C
AU  - Shah RC
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Lockery, Jessica E
AU  - Lockery JE
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Tonkin, Andrew M
AU  - Tonkin AM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Newman, Anne B
AU  - Newman AB
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Williamson, Jeff D
AU  - Williamson JD
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Margolis, Karen L
AU  - Margolis KL
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Abhayaratna, Walter P
AU  - Abhayaratna WP
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Stocks, Nigel
AU  - Stocks N
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Fitzgerald, Sharyn M
AU  - Fitzgerald SM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Orchard, Suzanne G
AU  - Orchard SG
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Trevaks, Ruth E
AU  - Trevaks RE
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Beilin, Lawrence J
AU  - Beilin LJ
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Donnan, Geoffrey A
AU  - Donnan GA
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Gibbs, Peter
AU  - Gibbs P
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Johnston, Colin I
AU  - Johnston CI
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Ryan, Joanne
AU  - Ryan J
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Radziszewska, Barbara
AU  - Radziszewska B
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Grimm, Richard
AU  - Grimm R
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
FAU - Murray, Anne M
AU  - Murray AM
AD  - From the Department of Epidemiology and Preventive Medicine, Monash University 
      (J.J.M., R.L.W., M.R.N., C.M.R., R.W., E.S., J.E.L., A.M.T., S.M.F., S.G.O., 
      R.E.T., C.I.J., J.R.), the Walter and Eliza Hall Institute of Medical Research 
      (P.G.), and the Baker Heart and Diabetes Institute (C.I.J.), Melbourne, and the 
      Florey Institute of Neuroscience and Mental Health, University of Melbourne, 
      Parkville (G.A.D.), VIC, Menzies Institute for Medical Research, University of 
      Tasmania, Hobart (M.R.N.), the School of Public Health, Curtin University 
      (C.M.R.), and the School of Medicine, Royal Perth Hospital, University of Western 
      Australia (L.J.B.), Perth, the College of Medicine, Biology, and Environment, 
      Australian National University, Canberra, ACT (W.P.A.), and Discipline of General 
      Practice, University of Adelaide, Adelaide, SA (N.S.) - all in Australia; Berman 
      Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare (B.K., R.G., A.M.M.), HealthPartners Institute 
      (K.L.M.), and the Division of Geriatrics, Department of Medicine, University of 
      Minnesota (A.M.M.) - all in Minneapolis; the Department of Family Medicine and 
      Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago 
      (R.C.S.); the Center for Aging and Population Health, University of Pittsburgh, 
      Pittsburgh (A.B.N.); Sticht Center on Aging and Alzheimer's Prevention, Section 
      on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake 
      Forest School of Medicine, Winston-Salem, NC (J.D.W.); the Department of Pharmacy 
      Practice and Science, College of Pharmacy, and the Department of Family Medicine, 
      Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the 
      Division of Geriatrics and Clinical Gerontology, National Institute on Aging, 
      Bethesda, MD (B.R.).
CN  - ASPREE Investigator Group
LA  - eng
SI  - ClinicalTrials.gov/NCT01038583
GR  - P30 AG010161/AG/NIA NIH HHS/United States
GR  - P30 AG024832/AG/NIA NIH HHS/United States
GR  - U01 AG029824/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180916
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 2019 Feb;156(3):534-538. PMID: 30529298
CIN - Ann Intern Med. 2019 Jan 15;170(2):JC3. PMID: 30641554
CIN - Internist (Berl). 2019 Feb;60(2):209-216. PMID: 30645666
CIN - MMW Fortschr Med. 2019 Feb;161(2):35. PMID: 30721495
CIN - N Engl J Med. 2019 May 2;380(18):1775. PMID: 31042833
CIN - N Engl J Med. 2019 May 2;380(18):1775. PMID: 31042834
CIN - N Engl J Med. 2019 May 2;380(18):1775-1776. PMID: 31042835
CIN - J Geriatr Oncol. 2021 Nov;12(8):1259-1260. PMID: 33785286
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Australia
MH  - Dementia/epidemiology
MH  - Disabled Persons/statistics & numerical data
MH  - *Disease-Free Survival
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Independent Living
MH  - Male
MH  - Mortality
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Treatment Failure
MH  - United States
PMC - PMC6426126
MID - NIHMS1512092
COIS- Dr. Nelson reports receiving travel support from Bayer and fees for serving on an 
      advisory board from Sanofi; Dr. Shah, receiving fees for serving as site 
      subinvestigator for a clinical trial, paid to his institution, from Eli Lilly, 
      Lundbeck, and Novartis Pharmaceuticals and fees for serving as site investigator 
      for a clinical trial, paid to his institution, from Genentech, Merck, Navidea 
      Biopharmaceuticals, and Takeda Development Center Americas; Dr. Tonkin, receiving 
      grant support, lecture fees, and fees for serving on an advisory board from Bayer 
      and lecture fees from Amgen and Pfizer; and Dr. Donnan, serving on advisory 
      panels for AstraZeneca, Bayer, Boehringer Ingelheim, Merck Sharpe & Dohme, 
      Pfizer, and Servier. No other potential conflict of interest relevant to this 
      article was reported.
FIR - Chan, Andrew
IR  - Chan A
FIR - Demons, Jamehl
IR  - Demons J
FIR - Espinoza, Sara
IR  - Espinoza S
FIR - Goetz, Matthew
IR  - Goetz M
FIR - Liew, Danny
IR  - Liew D
FIR - Meyskens, Frank
IR  - Meyskens F
FIR - Zalcberg, John
IR  - Zalcberg J
FIR - Ives, Diane
IR  - Ives D
FIR - Berk, Michael
IR  - Berk M
FIR - Bernstein, Wendy
IR  - Bernstein W
FIR - Brauer, Donna
IR  - Brauer D
FIR - Burns, Christine
IR  - Burns C
FIR - Chong, Trevor
IR  - Chong T
FIR - Cloud, Geoff
IR  - Cloud G
FIR - Eaton, Charles
IR  - Eaton C
FIR - Fitzgerald, Paul
IR  - Fitzgerald P
FIR - Haydon, Andrew
IR  - Haydon A
FIR - Jelinek, Michael
IR  - Jelinek M
FIR - Macrae, Finlay
IR  - Macrae F
FIR - Mahady, Suzanne
IR  - Mahady S
FIR - Malik, Mobin
IR  - Malik M
FIR - McLean, Catriona
IR  - McLean C
FIR - Rodriguez, Luz
IR  - Rodriguez L
FIR - Satterfield, Suzanne
IR  - Satterfield S
FIR - Tie, Jeanne
IR  - Tie J
FIR - van Londen, Gijsberta
IR  - van Londen G
FIR - Ward, Stephanie
IR  - Ward S
FIR - Wood, Erica
IR  - Wood E
FIR - Mohr, Jay
IR  - Mohr J
FIR - Anderson, Garnet
IR  - Anderson G
FIR - Connolly, Stuart
IR  - Connolly S
FIR - Friedman, Larry
IR  - Friedman L
FIR - Manson, JoAnn
IR  - Manson J
FIR - Sano, Mary
IR  - Sano M
FIR - Morrison, Sean
IR  - Morrison S
FIR - Ohman, Erik Magnus
IR  - Ohman EM
FIR - Hadley, Evan
IR  - Hadley E
FIR - Hannah, Judy
IR  - Hannah J
FIR - Romashkan, Sergei
IR  - Romashkan S
FIR - Ford, Leslie
IR  - Ford L
FIR - Richmond, Ellen
IR  - Richmond E
FIR - Umar, Asad
IR  - Umar A
FIR - Lockett, Trevor
IR  - Lockett T
FIR - Lewis, Beth
IR  - Lewis B
FIR - Obisesan, Thomas
IR  - Obisesan T
FIR - Gilbertson, Dave
IR  - Gilbertson D
FIR - Collyer, Taya
IR  - Collyer T
FIR - Rigby, Jason
IR  - Rigby J
FIR - Pruksawongsin, Kunnapoj
IR  - Pruksawongsin K
FIR - Hay, Nino
IR  - Hay N
FIR - Jachno, Kim
IR  - Jachno K
FIR - Smith, Catherine
IR  - Smith C
FIR - Ekram, A R M Saifuddin
IR  - Ekram ARMS
FIR - Gardam, Madeleine
IR  - Gardam M
FIR - Luong, Henry
IR  - Luong H
FIR - Montgomery, Tim
IR  - Montgomery T
FIR - Plate, Megan
IR  - Plate M
FIR - Rojas, Laura
IR  - Rojas L
FIR - Tominaga, Anna
IR  - Tominaga A
FIR - Wadeson, Katrina
IR  - Wadeson K
FIR - Hopkins, Sarah
IR  - Hopkins S
FIR - Nichols, Trisha
IR  - Nichols T
FIR - Johnson, Ashley
IR  - Johnson A
FIR - Prozinski, Molly
IR  - Prozinski M
FIR - Robinson-O’Brien, Ramona
IR  - Robinson-O’Brien R
FIR - Tessum, Nate
IR  - Tessum N
FIR - Aloia, John
IR  - Aloia J
FIR - Anton, Steve
IR  - Anton S
FIR - Burns, Jeffery
IR  - Burns J
FIR - Burton, Gary
IR  - Burton G
FIR - Ferris, Darron
IR  - Ferris D
FIR - Honasoge, Mahalakshmi
IR  - Honasoge M
FIR - Hsia, Daniel
IR  - Hsia D
FIR - Katzman, Steven
IR  - Katzman S
FIR - Kottam, Anupama
IR  - Kottam A
FIR - Nesbitt, Shawna
IR  - Nesbitt S
FIR - Ochoa, Augusto
IR  - Ochoa A
FIR - Pemu, Pricilla
IR  - Pemu P
FIR - Peterson, Kevin
IR  - Peterson K
FIR - Powell, James
IR  - Powell J
FIR - Pressman, Gregg
IR  - Pressman G
FIR - Robinson, William III
IR  - Robinson W III
FIR - Satterfield, Susanne
IR  - Satterfield S
FIR - Thorburn, Christine
IR  - Thorburn C
FIR - Volpi, Elena
IR  - Volpi E
FIR - Wiggins, Jocelyn
IR  - Wiggins J
FIR - Wilson, Peter
IR  - Wilson P
FIR - Womack, Catherine
IR  - Womack C
FIR - Abdullah, M
IR  - Abdullah M
FIR - Abdul-Ridha, S
IR  - Abdul-Ridha S
FIR - Aboud, E
IR  - Aboud E
FIR - Abraham, A
IR  - Abraham A
FIR - Abraham, J
IR  - Abraham J
FIR - Abraham, K
IR  - Abraham K
FIR - Abrahams, M
IR  - Abrahams M
FIR - Adad, S
IR  - Adad S
FIR - Adams, C
IR  - Adams C
FIR - Africa, N
IR  - Africa N
FIR - Afroze, S
IR  - Afroze S
FIR - Agarwal, D
IR  - Agarwal D
FIR - Agbarakwe, C
IR  - Agbarakwe C
FIR - Ah Sang, W
IR  - Ah Sang W
FIR - Ahern, T
IR  - Ahern T
FIR - Ahmad, Y
IR  - Ahmad Y
FIR - Ahmad, Z
IR  - Ahmad Z
FIR - Ahmed, L
IR  - Ahmed L
FIR - Ajam, A
IR  - Ajam A
FIR - Akhter, R
IR  - Akhter R
FIR - Akram, Z
IR  - Akram Z
FIR - Alagarswami, K
IR  - Alagarswami K
FIR - Alam, M
IR  - Alam M
FIR - Alavi, E
IR  - Alavi E
FIR - Aldridge, L
IR  - Aldridge L
FIR - Alethan, A
IR  - Alethan A
FIR - Alexander, K
IR  - Alexander K
FIR - Alexander, L
IR  - Alexander L
FIR - Alexopoulos, M
IR  - Alexopoulos M
FIR - Ali, B
IR  - Ali B
FIR - Ali, M
IR  - Ali M
FIR - Allan, J
IR  - Allan J
FIR - Allen, C
IR  - Allen C
FIR - Allen, G
IR  - Allen G
FIR - Allen, S
IR  - Allen S
FIR - Allin, P
IR  - Allin P
FIR - Al-Musawy, R
IR  - Al-Musawy R
FIR - Alpren, C
IR  - Alpren C
FIR - Al-Tawil, I
IR  - Al-Tawil I
FIR - Alwyn, T
IR  - Alwyn T
FIR - Amor, P
IR  - Amor P
FIR - Anam, T
IR  - Anam T
FIR - Anderson, G
IR  - Anderson G
FIR - Anderson, L
IR  - Anderson L
FIR - Anderson, N
IR  - Anderson N
FIR - Anderson, P
IR  - Anderson P
FIR - Anderson, R
IR  - Anderson R
FIR - Anderson-Dalheim, H
IR  - Anderson-Dalheim H
FIR - Andrada, E
IR  - Andrada E
FIR - Andre, S
IR  - Andre S
FIR - Andrews, L
IR  - Andrews L
FIR - Andric, A
IR  - Andric A
FIR - Andric, M
IR  - Andric M
FIR - Ang, J
IR  - Ang J
FIR - Ansari, A
IR  - Ansari A
FIR - Arakji, A M
IR  - Arakji AM
FIR - Arambeploa, Y
IR  - Arambeploa Y
FIR - Ark, R
IR  - Ark R
FIR - Arnaudon, F P
IR  - Arnaudon FP
FIR - Arndt, P M
IR  - Arndt PM
FIR - Aroney, T
IR  - Aroney T
FIR - Arthurson, J
IR  - Arthurson J
FIR - Arunachalam, T
IR  - Arunachalam T
FIR - Asim, N
IR  - Asim N
FIR - Aslam, I
IR  - Aslam I
FIR - Assad, S
IR  - Assad S
FIR - Astley, N
IR  - Astley N
FIR - Athari, M
IR  - Athari M
FIR - Atkins, C
IR  - Atkins C
FIR - Atkins, M
IR  - Atkins M
FIR - Aufgang, M
IR  - Aufgang M
FIR - Aung, K
IR  - Aung K
FIR - Aurora, G
IR  - Aurora G
FIR - Auteri, S
IR  - Auteri S
FIR - Avergun, A
IR  - Avergun A
FIR - Awwad, A
IR  - Awwad A
FIR - Azad, C
IR  - Azad C
FIR - Azra, S
IR  - Azra S
FIR - Babovic, A
IR  - Babovic A
FIR - Baig, M
IR  - Baig M
FIR - Baker, J
IR  - Baker J
FIR - Baker, S
IR  - Baker S
FIR - Baker, T
IR  - Baker T
FIR - Bakhilova, N
IR  - Bakhilova N
FIR - Baldam, A
IR  - Baldam A
FIR - Baldassa, A
IR  - Baldassa A
FIR - Baldi, C
IR  - Baldi C
FIR - Balkwill, C
IR  - Balkwill C
FIR - Balogun, O
IR  - Balogun O
FIR - Ban, A
IR  - Ban A
FIR - Banerjee, P
IR  - Banerjee P
FIR - Banning, M
IR  - Banning M
FIR - Bansal, S
IR  - Bansal S
FIR - Barkas, R
IR  - Barkas R
FIR - Barker, A
IR  - Barker A
FIR - Barker, D
IR  - Barker D
FIR - Barnes, A
IR  - Barnes A
FIR - Barnes, N
IR  - Barnes N
FIR - Barnetson, W
IR  - Barnetson W
FIR - Barratt, I
IR  - Barratt I
FIR - Barrett, D A
IR  - Barrett DA
FIR - Barrett, Meagan
IR  - Barrett M
FIR - Barrett, Michelle
IR  - Barrett M
FIR - Barrett, P
IR  - Barrett P
FIR - Barrett, T
IR  - Barrett T
FIR - Barson, P
IR  - Barson P
FIR - Barstad, C
IR  - Barstad C
FIR - Barton, W
IR  - Barton W
FIR - Bartram, M
IR  - Bartram M
FIR - Bartusek, P
IR  - Bartusek P
FIR - Basser, S
IR  - Basser S
FIR - Bassett, S
IR  - Bassett S
FIR - Batchelor, L
IR  - Batchelor L
FIR - Batt, D
IR  - Batt D
FIR - Batty, A
IR  - Batty A
FIR - Baum, S
IR  - Baum S
FIR - Baxter, M
IR  - Baxter M
FIR - Beaton, G
IR  - Beaton G
FIR - Beaumont, J
IR  - Beaumont J
FIR - Beavis, D
IR  - Beavis D
FIR - Beckett, V
IR  - Beckett V
FIR - Beech, M
IR  - Beech M
FIR - Beilby, J
IR  - Beilby J
FIR - Bekal, S
IR  - Bekal S
FIR - Bell, A
IR  - Bell A
FIR - Bendtsen, L
IR  - Bendtsen L
FIR - Benedict, D
IR  - Benedict D
FIR - Benjamin, T
IR  - Benjamin T
FIR - Bennett, P
IR  - Bennett P
FIR - Bennie, G
IR  - Bennie G
FIR - Bennie, S
IR  - Bennie S
FIR - Bennison, S
IR  - Bennison S
FIR - Benson, A
IR  - Benson A
FIR - Benson, R
IR  - Benson R
FIR - Benson, S
IR  - Benson S
FIR - Bergin, J
IR  - Bergin J
FIR - Bergin, S
IR  - Bergin S
FIR - Berryman, G
IR  - Berryman G
FIR - Berryman, J
IR  - Berryman J
FIR - Bertram, H
IR  - Bertram H
FIR - Bertuch, G
IR  - Bertuch G
FIR - Bettenay, G
IR  - Bettenay G
FIR - Bettiol, L
IR  - Bettiol L
FIR - Bills, R
IR  - Bills R
FIR - Birch, J
IR  - Birch J
FIR - Bird, Rachel
IR  - Bird R
FIR - Bird, Robert
IR  - Bird R
FIR - Birks, R
IR  - Birks R
FIR - Blake, R
IR  - Blake R
FIR - Blakney, A
IR  - Blakney A
FIR - Blashki, M
IR  - Blashki M
FIR - Bleach, G
IR  - Bleach G
FIR - Bloch, B
IR  - Bloch B
FIR - Bodenstein, M
IR  - Bodenstein M
FIR - Boga, V
IR  - Boga V
FIR - Bollen, C
IR  - Bollen C
FIR - Boltin, P
IR  - Boltin P
FIR - Boon, B
IR  - Boon B
FIR - Booth, G
IR  - Booth G
FIR - Borg, A
IR  - Borg A
FIR - Bornstein, D
IR  - Bornstein D
FIR - Bottcher, C
IR  - Bottcher C
FIR - Bourke, J
IR  - Bourke J
FIR - Bourke, M
IR  - Bourke M
FIR - Boutcher, S
IR  - Boutcher S
FIR - Bowden, J
IR  - Bowden J
FIR - Bowen, J
IR  - Bowen J
FIR - Bowring, B
IR  - Bowring B
FIR - Boyce, C
IR  - Boyce C
FIR - Boyd, J
IR  - Boyd J
FIR - Brack, R
IR  - Brack R
FIR - Bradshaw, A
IR  - Bradshaw A
FIR - Brady, P
IR  - Brady P
FIR - Braithwaite, J
IR  - Braithwaite J
FIR - Braude, G
IR  - Braude G
FIR - Brayshaw, N
IR  - Brayshaw N
FIR - Breen, M
IR  - Breen M
FIR - Bresnahan, R
IR  - Bresnahan R
FIR - Briddon, P
IR  - Briddon P
FIR - Bridge, A
IR  - Bridge A
FIR - Briggs, S J
IR  - Briggs SJ
FIR - Brimage, R F
IR  - Brimage RF
FIR - Britten-Jones, W
IR  - Britten-Jones W
FIR - Brkic, M
IR  - Brkic M
FIR - Broadby, M
IR  - Broadby M
FIR - Bromberger, D
IR  - Bromberger D
FIR - Brommeyer, A
IR  - Brommeyer A
FIR - Broom, I
IR  - Broom I
FIR - Brophy, T
IR  - Brophy T
FIR - Brough, J
IR  - Brough J
FIR - Brougham, J P
IR  - Brougham JP
FIR - Broun, C
IR  - Broun C
FIR - Brown, I D
IR  - Brown ID
FIR - Brown, J
IR  - Brown J
FIR - Brown, M B
IR  - Brown MB
FIR - Brown, M P
IR  - Brown MP
FIR - Brown, R
IR  - Brown R
FIR - Brownbill, C
IR  - Brownbill C
FIR - Brownbill, L
IR  - Brownbill L
FIR - Browne, M
IR  - Browne M
FIR - Brownstein, M
IR  - Brownstein M
FIR - Bruce, A
IR  - Bruce A
FIR - Brunacci, F
IR  - Brunacci F
FIR - Brunner, C
IR  - Brunner C
FIR - Bruorton, M
IR  - Bruorton M
FIR - Buccheri, V
IR  - Buccheri V
FIR - Buchanan, D
IR  - Buchanan D
FIR - Buckley, J
IR  - Buckley J
FIR - Bulle, B
IR  - Bulle B
FIR - Bundy, K
IR  - Bundy K
FIR - Burke, M
IR  - Burke M
FIR - Busch, G
IR  - Busch G
FIR - Bush, C P
IR  - Bush CP
FIR - Butrev, A
IR  - Butrev A
FIR - Bvirakare, J
IR  - Bvirakare J
FIR - Bvumbura, B F
IR  - Bvumbura BF
FIR - Bye, J
IR  - Bye J
FIR - Byrne, C
IR  - Byrne C
FIR - Byrne, P
IR  - Byrne P
FIR - Cain, M
IR  - Cain M
FIR - Calcutt, I
IR  - Calcutt I
FIR - Calder, K
IR  - Calder K
FIR - Caldwell, M
IR  - Caldwell M
FIR - Callan, C
IR  - Callan C
FIR - Cameron, A
IR  - Cameron A
FIR - Cameron, David
IR  - Cameron D
FIR - Cameron, Donald
IR  - Cameron D
FIR - Cameron, T
IR  - Cameron T
FIR - Campbell, David
IR  - Campbell D
FIR - Campbell, Donald
IR  - Campbell D
FIR - Campbell, Geoffrey
IR  - Campbell G
FIR - Campbell, Guy
IR  - Campbell G
FIR - Campbell, P H
IR  - Campbell PH
FIR - Campbell, R
IR  - Campbell R
FIR - Carroll, N
IR  - Carroll N
FIR - Carroll, V
IR  - Carroll V
FIR - Carson, J
IR  - Carson J
FIR - Carson, R
IR  - Carson R
FIR - Carter, L
IR  - Carter L
FIR - Carter, P
IR  - Carter P
FIR - Carter, R
IR  - Carter R
FIR - Carter, S
IR  - Carter S
FIR - Cartwright, P
IR  - Cartwright P
FIR - Cassidy, P
IR  - Cassidy P
FIR - Catchpole, M
IR  - Catchpole M
FIR - Cato, G
IR  - Cato G
FIR - Celada, R
IR  - Celada R
FIR - Chai, F
IR  - Chai F
FIR - Chalabi, A
IR  - Chalabi A
FIR - Chalissery, P
IR  - Chalissery P
FIR - Chalmers, M L
IR  - Chalmers ML
FIR - Chamberlain, H
IR  - Chamberlain H
FIR - Chamoun, R
IR  - Chamoun R
FIR - Chan, B
IR  - Chan B
FIR - Chan, C
IR  - Chan C
FIR - Chan, C K
IR  - Chan CK
FIR - Chan, F W
IR  - Chan FW
FIR - Chan, K
IR  - Chan K
FIR - Chandran, S
IR  - Chandran S
FIR - Chandrananth, M
IR  - Chandrananth M
FIR - Chandrananth, S
IR  - Chandrananth S
FIR - Chang, C
IR  - Chang C
FIR - Chang, V
IR  - Chang V
FIR - Chang, W
IR  - Chang W
FIR - Changakoti, A
IR  - Changakoti A
FIR - Chantler, R
IR  - Chantler R
FIR - Chao, D
IR  - Chao D
FIR - Chao, S
IR  - Chao S
FIR - Charlton, P
IR  - Charlton P
FIR - Chattersee, A
IR  - Chattersee A
FIR - Chau, G
IR  - Chau G
FIR - Chaung, Y
IR  - Chaung Y
FIR - Chawtur, V
IR  - Chawtur V
FIR - Cheah, H-H
IR  - Cheah HH
FIR - Cheah, S
IR  - Cheah S
FIR - Cheasley, A
IR  - Cheasley A
FIR - Chee, H
IR  - Chee H
FIR - Chen, D
IR  - Chen D
FIR - Cheng, W
IR  - Cheng W
FIR - Chesney, D
IR  - Chesney D
FIR - Chew, D
IR  - Chew D
FIR - Chhabra, P
IR  - Chhabra P
FIR - Chia, I
IR  - Chia I
FIR - Chia, P
IR  - Chia P
FIR - Chiang, A
IR  - Chiang A
FIR - Chiang, S
IR  - Chiang S
FIR - Chiew, I
IR  - Chiew I
FIR - Chiew, L
IR  - Chiew L
FIR - Chikarsal, A
IR  - Chikarsal A
FIR - Chin, J
IR  - Chin J
FIR - Chin, M
IR  - Chin M
FIR - Chipman, J S
IR  - Chipman JS
FIR - Chipperfield, C
IR  - Chipperfield C
FIR - Chisholm, H
IR  - Chisholm H
FIR - Chisholm, L
IR  - Chisholm L
FIR - Chiu, A
IR  - Chiu A
FIR - Chiu, C
IR  - Chiu C
FIR - Chiu, D
IR  - Chiu D
FIR - Chiu, T
IR  - Chiu T
FIR - Chizik, L
IR  - Chizik L
FIR - Choksey, H
IR  - Choksey H
FIR - Choo, E
IR  - Choo E
FIR - Chow, Amy
IR  - Chow A
FIR - Chow, Andrew
IR  - Chow A
FIR - Choy, C
IR  - Choy C
FIR - Chu, S
IR  - Chu S
FIR - Chua, A
IR  - Chua A
FIR - Chuah, T
IR  - Chuah T
FIR - Chung, J
IR  - Chung J
FIR - Cimpoescu, T
IR  - Cimpoescu T
FIR - Clapton, J
IR  - Clapton J
FIR - Clark, Benedict
IR  - Clark B
FIR - Clark, Benjamin
IR  - Clark B
FIR - Clark, M
IR  - Clark M
FIR - Clark, R
IR  - Clark R
FIR - Clarke, A
IR  - Clarke A
FIR - Clarke, D
IR  - Clarke D
FIR - Clarke, S
IR  - Clarke S
FIR - Cleary, G
IR  - Cleary G
FIR - Clerigo, L
IR  - Clerigo L
FIR - Clohesy, S
IR  - Clohesy S
FIR - Close, S
IR  - Close S
FIR - Cochrane, F
IR  - Cochrane F
FIR - Cohen, I S
IR  - Cohen IS
FIR - Cohen, J
IR  - Cohen J
FIR - Colahan, R
IR  - Colahan R
FIR - Collins, J
IR  - Collins J
FIR - Colman, W
IR  - Colman W
FIR - Colvin, R
IR  - Colvin R
FIR - Conde, S
IR  - Conde S
FIR - Connell, P
IR  - Connell P
FIR - Connellan, M
IR  - Connellan M
FIR - Connor, W
IR  - Connor W
FIR - Connors, G
IR  - Connors G
FIR - Conos, M
IR  - Conos M
FIR - Conron, D
IR  - Conron D
FIR - Conroy, J
IR  - Conroy J
FIR - Conway, C
IR  - Conway C
FIR - Cooper, M
IR  - Cooper M
FIR - Cooper, S
IR  - Cooper S
FIR - Cope, A
IR  - Cope A
FIR - Corrigan, Simon
IR  - Corrigan S
FIR - Corrigan, Sue
IR  - Corrigan S
FIR - Coughlan, P
IR  - Coughlan P
FIR - Coulter, E
IR  - Coulter E
FIR - Counsel, L
IR  - Counsel L
FIR - Court, D
IR  - Court D
FIR - Courtis, G
IR  - Courtis G
FIR - Cousens, A
IR  - Cousens A
FIR - Craig, L
IR  - Craig L
FIR - Crameri, M
IR  - Crameri M
FIR - Cranswick, M
IR  - Cranswick M
FIR - Crawford, J
IR  - Crawford J
FIR - Crawford, M
IR  - Crawford M
FIR - Crawford, P
IR  - Crawford P
FIR - Crawford, R
IR  - Crawford R
FIR - Crick, S
IR  - Crick S
FIR - Crimmins, B
IR  - Crimmins B
FIR - Cristofaro, R
IR  - Cristofaro R
FIR - Croatto, J
IR  - Croatto J
FIR - Crompton, A
IR  - Crompton A
FIR - Cronin, E
IR  - Cronin E
FIR - Crookes, J
IR  - Crookes J
FIR - Cross, B
IR  - Cross B
FIR - Cross, D
IR  - Cross D
FIR - Cross, M
IR  - Cross M
FIR - Crow, P
IR  - Crow P
FIR - Crowe, J E
IR  - Crowe JE
FIR - Crowe, P
IR  - Crowe P
FIR - Crowley, H
IR  - Crowley H
FIR - Cruickshank, J
IR  - Cruickshank J
FIR - Cummins, R
IR  - Cummins R
FIR - Cunneen, A
IR  - Cunneen A
FIR - Cunningham, A
IR  - Cunningham A
FIR - Cunningham, N
IR  - Cunningham N
FIR - Cunningham, P
IR  - Cunningham P
FIR - Curnow, D
IR  - Curnow D
FIR - Curran, J
IR  - Curran J
FIR - Curran, M
IR  - Curran M
FIR - Currie, A
IR  - Currie A
FIR - Curtis, R
IR  - Curtis R
FIR - Cusack, J
IR  - Cusack J
FIR - Dabash, K
IR  - Dabash K
FIR - Dabestani, V
IR  - Dabestani V
FIR - Dadabhay, Z
IR  - Dadabhay Z
FIR - Daglas, D
IR  - Daglas D
FIR - Dagley, P
IR  - Dagley P
FIR - Danesh, S
IR  - Danesh S
FIR - Dang, D
IR  - Dang D
FIR - Daniels, R
IR  - Daniels R
FIR - Darby, J P
IR  - Darby JP
FIR - Darko, N
IR  - Darko N
FIR - Darling, J
IR  - Darling J
FIR - Darlington, B
IR  - Darlington B
FIR - Das, J
IR  - Das J
FIR - Das, P
IR  - Das P
FIR - Date, M
IR  - Date M
FIR - Datta, C
IR  - Datta C
FIR - Datta, S
IR  - Datta S
FIR - Davenport, C
IR  - Davenport C
FIR - Davey, G
IR  - Davey G
FIR - Davey, M
IR  - Davey M
FIR - Davey, P
IR  - Davey P
FIR - Davidson, C L
IR  - Davidson CL
FIR - Davidson, D
IR  - Davidson D
FIR - Davies, M
IR  - Davies M
FIR - Davies-Hakeem, A
IR  - Davies-Hakeem A
FIR - Davis, G
IR  - Davis G
FIR - Davis, K
IR  - Davis K
FIR - Davis, Paul
IR  - Davis P
FIR - Davis, Peter
IR  - Davis P
FIR - Davis, S
IR  - Davis S
FIR - Dawe, N
IR  - Dawe N
FIR - Dawes, R
IR  - Dawes R
FIR - Dawkins, P
IR  - Dawkins P
FIR - Dawson, G
IR  - Dawson G
FIR - Dawson, P
IR  - Dawson P
FIR - Dawson, R
IR  - Dawson R
FIR - Day, P
IR  - Day P
FIR - Daya, M
IR  - Daya M
FIR - Dayasagar, D
IR  - Dayasagar D
FIR - D’Costa, L
IR  - D’Costa L
FIR - De Clifford, M
IR  - De Clifford M
FIR - De Gleria, S
IR  - De Gleria S
FIR - De Poi, C
IR  - De Poi C
FIR - De Silva, M
IR  - De Silva M
FIR - De Silva, P
IR  - De Silva P
FIR - De Steiger, R
IR  - De Steiger R
FIR - De Villiers, D
IR  - De Villiers D
FIR - De Wit, E
IR  - De Wit E
FIR - Debnath, R
IR  - Debnath R
FIR - Deery, R
IR  - Deery R
FIR - De Lanerolle, D
IR  - De Lanerolle D
FIR - Del Rio, F
IR  - Del Rio F
FIR - Delaney, S
IR  - Delaney S
FIR - Delitzsch, S S
IR  - Delitzsch SS
FIR - Demaio, F
IR  - Demaio F
FIR - Demian, M
IR  - Demian M
FIR - Demirtzoglou, J
IR  - Demirtzoglou J
FIR - Denton, T
IR  - Denton T
FIR - Derrick, L
IR  - Derrick L
FIR - Deshmukh, K
IR  - Deshmukh K
FIR - Dessauer, J
IR  - Dessauer J
FIR - Devavittiya, C
IR  - Devavittiya C
FIR - Devereux, D
IR  - Devereux D
FIR - Dewan, D
IR  - Dewan D
FIR - Dewhurst, H
IR  - Dewhurst H
FIR - Dhar, A
IR  - Dhar A
FIR - Dhillon, D
IR  - Dhillon D
FIR - Di Carlo, M
IR  - Di Carlo M
FIR - Di Dio, A
IR  - Di Dio A
FIR - Di Marco, A
IR  - Di Marco A
FIR - Dickman, J
IR  - Dickman J
FIR - Dillon, L
IR  - Dillon L
FIR - Dinh, Q-T
IR  - Dinh QT
FIR - Dissanayake, D
IR  - Dissanayake D
FIR - Dissanayake, M
IR  - Dissanayake M
FIR - Dissanayake, T
IR  - Dissanayake T
FIR - Divakaran, K
IR  - Divakaran K
FIR - Dixit, U
IR  - Dixit U
FIR - Dixon, H
IR  - Dixon H
FIR - Dixon, N
IR  - Dixon N
FIR - Djakic, E
IR  - Djakic E
FIR - Dobson, C
IR  - Dobson C
FIR - Dodd, L
IR  - Dodd L
FIR - Dodds, P
IR  - Dodds P
FIR - Dodic, A
IR  - Dodic A
FIR - Dodic, M
IR  - Dodic M
FIR - Doley, A
IR  - Doley A
FIR - Dolguina, S
IR  - Dolguina S
FIR - Dolling, C
IR  - Dolling C
FIR - Donaghy, F
IR  - Donaghy F
FIR - Donald, H
IR  - Donald H
FIR - Donelan, E
IR  - Donelan E
FIR - Donohue, M
IR  - Donohue M
FIR - Dooland, J
IR  - Dooland J
FIR - Dooley, H
IR  - Dooley H
FIR - Doslo, S
IR  - Doslo S
FIR - Douglas, A
IR  - Douglas A
FIR - Dover, P
IR  - Dover P
FIR - Downe, G
IR  - Downe G
FIR - Drake, P
IR  - Drake P
FIR - Dry, D
IR  - Dry D
FIR - Duane, P
IR  - Duane P
FIR - Dubash, A
IR  - Dubash A
FIR - Dubetz, D
IR  - Dubetz D
FIR - Duff, P
IR  - Duff P
FIR - Duke, R
IR  - Duke R
FIR - Dumitrescu, C
IR  - Dumitrescu C
FIR - Dunbar, A
IR  - Dunbar A
FIR - Dunbar, S
IR  - Dunbar S
FIR - Dunn, S
IR  - Dunn S
FIR - Duong, N H
IR  - Duong NH
FIR - Dutta, N
IR  - Dutta N
FIR - Dutton, M
IR  - Dutton M
FIR - Duval, A
IR  - Duval A
FIR - Dyson-Berry, J
IR  - Dyson-Berry J
FIR - Eade, P
IR  - Eade P
FIR - Eaton, D
IR  - Eaton D
FIR - Ebert, K
IR  - Ebert K
FIR - Edib, K
IR  - Edib K
FIR - Edillo, E
IR  - Edillo E
FIR - Edmonds, J
IR  - Edmonds J
FIR - Edwards, F
IR  - Edwards F
FIR - Edwards, P A
IR  - Edwards PA
FIR - Edwards, S
IR  - Edwards S
FIR - Eftekharuddin, M
IR  - Eftekharuddin M
FIR - Egan, A
IR  - Egan A
FIR - Egan, P
IR  - Egan P
FIR - Ehrenreich, S
IR  - Ehrenreich S
FIR - Ehsan, E
IR  - Ehsan E
FIR - Elberg, L
IR  - Elberg L
FIR - Elisha, B
IR  - Elisha B
FIR - Elisha, R
IR  - Elisha R
FIR - Elkhoury, H
IR  - Elkhoury H
FIR - Ellerton, K
IR  - Ellerton K
FIR - Elliot-Smith, A
IR  - Elliot-Smith A
FIR - Elmore, R
IR  - Elmore R
FIR - Elshenawy, I
IR  - Elshenawy I
FIR - Elsherif, S
IR  - Elsherif S
FIR - Elsouki, M
IR  - Elsouki M
FIR - Elton, P
IR  - Elton P
FIR - Emmerson, M
IR  - Emmerson M
FIR - Emmett, S I
IR  - Emmett SI
FIR - English, J
IR  - English J
FIR - Enten, P
IR  - Enten P
FIR - Entwistle, J
IR  - Entwistle J
FIR - Epa, W
IR  - Epa W
FIR - Erhardt, A
IR  - Erhardt A
FIR - Etta, J
IR  - Etta J
FIR - Evans, M
IR  - Evans M
FIR - Everitt, T
IR  - Everitt T
FIR - Ewing, J
IR  - Ewing J
FIR - Fahkok, B
IR  - Fahkok B
FIR - Faigen, M
IR  - Faigen M
FIR - Fair, A
IR  - Fair A
FIR - Fairbrother, C
IR  - Fairbrother C
FIR - Fanning, J
IR  - Fanning J
FIR - Fantasia, M
IR  - Fantasia M
FIR - Farag, E
IR  - Farag E
FIR - Fardell, K
IR  - Fardell K
FIR - Farrant, J
IR  - Farrant J
FIR - Farrell, P
IR  - Farrell P
FIR - Farrow, J
IR  - Farrow J
FIR - Fassett, M
IR  - Fassett M
FIR - Faull, P A
IR  - Faull PA
FIR - Ferguson, P
IR  - Ferguson P
FIR - Fernando, Sujeewa
IR  - Fernando S
FIR - Fernando, Sumudu
IR  - Fernando S
FIR - Ferruccio, A
IR  - Ferruccio A
FIR - Fidge, J H
IR  - Fidge JH
FIR - Field, P
IR  - Field P
FIR - Figurireo, L
IR  - Figurireo L
FIR - Fisher, H
IR  - Fisher H
FIR - Fisher, J
IR  - Fisher J
FIR - Fitzgerald, E
IR  - Fitzgerald E
FIR - Fitzgerald, M
IR  - Fitzgerald M
FIR - Fitzgerald, R
IR  - Fitzgerald R
FIR - Fitzpatrick, H
IR  - Fitzpatrick H
FIR - Fitzpatrick, J
IR  - Fitzpatrick J
FIR - Fitzpatrick, P
IR  - Fitzpatrick P
FIR - Fitzpatrick, T
IR  - Fitzpatrick T
FIR - Flaherty, P
IR  - Flaherty P
FIR - Flanagan, D
IR  - Flanagan D
FIR - Flanagan, T
IR  - Flanagan T
FIR - Flew, S
IR  - Flew S
FIR - Fonseka, P P
IR  - Fonseka PP
FIR - Foo, J
IR  - Foo J
FIR - Foo, S
IR  - Foo S
FIR - Foo, Y
IR  - Foo Y
FIR - Foong, E
IR  - Foong E
FIR - Ford, D
IR  - Ford D
FIR - Foster, D
IR  - Foster D
FIR - Fourlanos, V
IR  - Fourlanos V
FIR - Fowler, I
IR  - Fowler I
FIR - Fox, D
IR  - Fox D
FIR - Fox, F
IR  - Fox F
FIR - Fox, M
IR  - Fox M
FIR - Fox, P
IR  - Fox P
FIR - Fox-Smith, D
IR  - Fox-Smith D
FIR - Francis, J
IR  - Francis J
FIR - Francis, R
IR  - Francis R
FIR - Frank, O
IR  - Frank O
FIR - Franks, A
IR  - Franks A
FIR - Fredericks, A
IR  - Fredericks A
FIR - Freeman, E
IR  - Freeman E
FIR - French, L
IR  - French L
FIR - Frew, B
IR  - Frew B
FIR - Friebel, D
IR  - Friebel D
FIR - Friebel, T
IR  - Friebel T
FIR - Frost, S
IR  - Frost S
FIR - Fryer, D
IR  - Fryer D
FIR - Fuller, J
IR  - Fuller J
FIR - Fung, W
IR  - Fung W
FIR - Fung, W P
IR  - Fung WP
FIR - Furphy, S
IR  - Furphy S
FIR - Gabutina, C
IR  - Gabutina C
FIR - Gaggin, S
IR  - Gaggin S
FIR - Galbraith, S
IR  - Galbraith S
FIR - Gale, M
IR  - Gale M
FIR - Gall, J
IR  - Gall J
FIR - Gallichio, V
IR  - Gallichio V
FIR - Gangell, A W
IR  - Gangell AW
FIR - Garde, M A
IR  - Garde MA
FIR - Gardner, S S
IR  - Gardner SS
FIR - Gardner, T
IR  - Gardner T
FIR - Garland, J
IR  - Garland J
FIR - Garra, G
IR  - Garra G
FIR - Garrow, S
IR  - Garrow S
FIR - Garvey, J
IR  - Garvey J
FIR - Gauden, M
IR  - Gauden M
FIR - Gault, A
IR  - Gault A
FIR - Gaur, D
IR  - Gaur D
FIR - Gavralas, A
IR  - Gavralas A
FIR - George, N
IR  - George N
FIR - George, S
IR  - George S
FIR - Georgy, M
IR  - Georgy M
FIR - Gerendasi, R
IR  - Gerendasi R
FIR - Geschke, H
IR  - Geschke H
FIR - Giannakakis, J
IR  - Giannakakis J
FIR - Gidley, G
IR  - Gidley G
FIR - Gilani, M
IR  - Gilani M
FIR - Giles, P
IR  - Giles P
FIR - Gill, K
IR  - Gill K
FIR - Gill, P
IR  - Gill P
FIR - Gill, R
IR  - Gill R
FIR - Gillis, C
IR  - Gillis C
FIR - Gilmore, A
IR  - Gilmore A
FIR - Gilovitz, M
IR  - Gilovitz M
FIR - Gingold, R
IR  - Gingold R
FIR - Glaspole, D
IR  - Glaspole D
FIR - Glowinski, L
IR  - Glowinski L
FIR - Glue, A L
IR  - Glue AL
FIR - Godakumbura, P
IR  - Godakumbura P
FIR - Godavarthy, R
IR  - Godavarthy R
FIR - Goel, A
IR  - Goel A
FIR - Goeltom, C
IR  - Goeltom C
FIR - Goldberg, E
IR  - Goldberg E
FIR - Goldberg, J
IR  - Goldberg J
FIR - Golets, M
IR  - Golets M
FIR - Gong, V
IR  - Gong V
FIR - Goode, J
IR  - Goode J
FIR - Goodman, C
IR  - Goodman C
FIR - Goodwin, R J
IR  - Goodwin RJ
FIR - Gopathy, S
IR  - Gopathy S
FIR - Gordon, M
IR  - Gordon M
FIR - Gough, S
IR  - Gough S
FIR - Govender, M
IR  - Govender M
FIR - Gow, K
IR  - Gow K
FIR - Gowrie, B
IR  - Gowrie B
FIR - Goy, P
IR  - Goy P
FIR - Grabowski, C
IR  - Grabowski C
FIR - Graddon, J
IR  - Graddon J
FIR - Granek, A
IR  - Granek A
FIR - Gray, J M
IR  - Gray JM
FIR - Gray, M
IR  - Gray M
FIR - Gray, T
IR  - Gray T
FIR - Grbac, E
IR  - Grbac E
FIR - Greacen, J
IR  - Greacen J
FIR - Greculescu, E
IR  - Greculescu E
FIR - Green, J
IR  - Green J
FIR - Greenwood, E
IR  - Greenwood E
FIR - Griffin, E
IR  - Griffin E
FIR - Griffith, V
IR  - Griffith V
FIR - Griffiths, A
IR  - Griffiths A
FIR - Griffiths, G
IR  - Griffiths G
FIR - Griffiths, J
IR  - Griffiths J
FIR - Griffiths, K
IR  - Griffiths K
FIR - Grigorian, A R
IR  - Grigorian AR
FIR - Grinzi, P
IR  - Grinzi P
FIR - Grogan, H
IR  - Grogan H
FIR - Grokop, G
IR  - Grokop G
FIR - Grossman, L
IR  - Grossman L
FIR - Grove, A
IR  - Grove A
FIR - Gruzauskas, A
IR  - Gruzauskas A
FIR - Gu, M
IR  - Gu M
FIR - Guest, S
IR  - Guest S
FIR - Guindi, N
IR  - Guindi N
FIR - Guo, H
IR  - Guo H
FIR - Gurney, R
IR  - Gurney R
FIR - Guy, J
IR  - Guy J
FIR - Guymer, J
IR  - Guymer J
FIR - Gwynn, R
IR  - Gwynn R
FIR - Gyorki, J
IR  - Gyorki J
FIR - Habibi, S
IR  - Habibi S
FIR - Hachem, C
IR  - Hachem C
FIR - Hackett, A
IR  - Hackett A
FIR - Hackett, J
IR  - Hackett J
FIR - Haddad, J
IR  - Haddad J
FIR - Haddad, M
IR  - Haddad M
FIR - Hadley, E
IR  - Hadley E
FIR - Hagger, R
IR  - Hagger R
FIR - Haider, Z
IR  - Haider Z
FIR - Hain, R
IR  - Hain R
FIR - Hajicosta, T
IR  - Hajicosta T
FIR - Hales, P
IR  - Hales P
FIR - Hall, J
IR  - Hall J
FIR - Hall, P
IR  - Hall P
FIR - Hall, Robert
IR  - Hall R
FIR - Hall, Roslyn
IR  - Hall R
FIR - Hall, S
IR  - Hall S
FIR - Halliburton, K
IR  - Halliburton K
FIR - Halliday, A
IR  - Halliday A
FIR - Halliday, B
IR  - Halliday B
FIR - Halliday, J
IR  - Halliday J
FIR - Hamblen, K
IR  - Hamblen K
FIR - Hamel, J
IR  - Hamel J
FIR - Hamer, I
IR  - Hamer I
FIR - Hamilton, J
IR  - Hamilton J
FIR - Hamilton, R F
IR  - Hamilton RF
FIR - Hammond, T
IR  - Hammond T
FIR - Hanbury, R
IR  - Hanbury R
FIR - Hancock, A
IR  - Hancock A
FIR - Hand, R
IR  - Hand R
FIR - Hanna, A
IR  - Hanna A
FIR - Hanna, M
IR  - Hanna M
FIR - Hanna, S
IR  - Hanna S
FIR - Hanson, G
IR  - Hanson G
FIR - Hanson, P D
IR  - Hanson PD
FIR - Haque, E
IR  - Haque E
FIR - Haran, C
IR  - Haran C
FIR - Haran, T
IR  - Haran T
FIR - Hare, W J
IR  - Hare WJ
FIR - Harewood, A
IR  - Harewood A
FIR - Haripersad, S
IR  - Haripersad S
FIR - Harman, A
IR  - Harman A
FIR - Harmer, D
IR  - Harmer D
FIR - Harms, P
IR  - Harms P
FIR - Harnden, C
IR  - Harnden C
FIR - Harrington, M
IR  - Harrington M
FIR - Harris, A
IR  - Harris A
FIR - Harris, M
IR  - Harris M
FIR - Harrison, M
IR  - Harrison M
FIR - Harrison, S
IR  - Harrison S
FIR - Hart, E
IR  - Hart E
FIR - Hartley, D
IR  - Hartley D
FIR - Hartley, P
IR  - Hartley P
FIR - Hartnett, M
IR  - Hartnett M
FIR - Harvey, C
IR  - Harvey C
FIR - Haslam, K
IR  - Haslam K
FIR - Hassani, I
IR  - Hassani I
FIR - Hassett, R B
IR  - Hassett RB
FIR - Hastings, W
IR  - Hastings W
FIR - Hattingh, A
IR  - Hattingh A
FIR - Hawke, I
IR  - Hawke I
FIR - Hawkins, C
IR  - Hawkins C
FIR - Hayes, V
IR  - Hayes V
FIR - Heale, J
IR  - Heale J
FIR - Healy, G
IR  - Healy G
FIR - Hebblewhite, A
IR  - Hebblewhite A
FIR - Hechtman, A
IR  - Hechtman A
FIR - Hedgland, A
IR  - Hedgland A
FIR - Heffernan, C
IR  - Heffernan C
FIR - Heikkinen, M N
IR  - Heikkinen MN
FIR - Heinrich, C
IR  - Heinrich C
FIR - Henderson, J
IR  - Henderson J
FIR - Henry, F
IR  - Henry F
FIR - Herath, S
IR  - Herath S
FIR - Herbert, A
IR  - Herbert A
FIR - Herbst, D
IR  - Herbst D
FIR - Hermiz, S
IR  - Hermiz S
FIR - Herrman, J
IR  - Herrman J
FIR - Hesse, M
IR  - Hesse M
FIR - Hetherington, J
IR  - Hetherington J
FIR - Hetzel, R
IR  - Hetzel R
FIR - Hewett, R
IR  - Hewett R
FIR - Hides, R
IR  - Hides R
FIR - Higgins, C D
IR  - Higgins CD
FIR - Hildred, S
IR  - Hildred S
FIR - Hill, A
IR  - Hill A
FIR - Hilton, C
IR  - Hilton C
FIR - Hince, R
IR  - Hince R
FIR - Hines, C
IR  - Hines C
FIR - Hinton, C
IR  - Hinton C
FIR - Hipolito, A
IR  - Hipolito A
FIR - Ho, C K
IR  - Ho CK
FIR - Ho, L
IR  - Ho L
FIR - Hoar, J
IR  - Hoar J
FIR - Hocking, L
IR  - Hocking L
FIR - Hodge, A
IR  - Hodge A
FIR - Hodgkins, A
IR  - Hodgkins A
FIR - Hodgson, J
IR  - Hodgson J
FIR - Hogbin, J
IR  - Hogbin J
FIR - Hok, S
IR  - Hok S
FIR - Holder, B
IR  - Holder B
FIR - Holland, D
IR  - Holland D
FIR - Holland, M
IR  - Holland M
FIR - Hollins, B
IR  - Hollins B
FIR - Homewood, M
IR  - Homewood M
FIR - Hong Zhou, A
IR  - Hong Zhou A
FIR - Honig, J
IR  - Honig J
FIR - Honigman, S
IR  - Honigman S
FIR - Hookham, D
IR  - Hookham D
FIR - Hooper, W
IR  - Hooper W
FIR - Hope, L
IR  - Hope L
FIR - Horman, J
IR  - Horman J
FIR - Horng, T
IR  - Horng T
FIR - Hornstein, I
IR  - Hornstein I
FIR - Horriat, M
IR  - Horriat M
FIR - Horvat, J
IR  - Horvat J
FIR - Hossain, M
IR  - Hossain M
FIR - Hough, P
IR  - Hough P
FIR - Howe, J
IR  - Howe J
FIR - Howson, W
IR  - Howson W
FIR - Hubczenko, I
IR  - Hubczenko I
FIR - Hubel, M
IR  - Hubel M
FIR - Hughes, J
IR  - Hughes J
FIR - Hughes, P
IR  - Hughes P
FIR - Hunter, D
IR  - Hunter D
FIR - Huq, S
IR  - Huq S
FIR - Hussain, A
IR  - Hussain A
FIR - Hutchins, I
IR  - Hutchins I
FIR - Hutchinson, A
IR  - Hutchinson A
FIR - Hyam, P
IR  - Hyam P
FIR - Hyare, K
IR  - Hyare K
FIR - Iakovidis, B
IR  - Iakovidis B
FIR - Ibragimov, M
IR  - Ibragimov M
FIR - Idris, M
IR  - Idris M
FIR - Ierace, C
IR  - Ierace C
FIR - Ikladios, A
IR  - Ikladios A
FIR - Imgraben, P
IR  - Imgraben P
FIR - Ingham, C
IR  - Ingham C
FIR - Ip, A
IR  - Ip A
FIR - Ip, Y
IR  - Ip Y
FIR - Iqbal, A
IR  - Iqbal A
FIR - Iqbal, M
IR  - Iqbal M
FIR - Irvine, G
IR  - Irvine G
FIR - Irwin, V
IR  - Irwin V
FIR - Iser, D
IR  - Iser D
FIR - Islam, N
IR  - Islam N
FIR - Islam, S
IR  - Islam S
FIR - Isles, J K
IR  - Isles JK
FIR - Ismail, A
IR  - Ismail A
FIR - Ivanoff, G
IR  - Ivanoff G
FIR - Iwe, N
IR  - Iwe N
FIR - Jackett, R B
IR  - Jackett RB
FIR - Jackson, M
IR  - Jackson M
FIR - Jackson, N
IR  - Jackson N
FIR - Jackson, P
IR  - Jackson P
FIR - Jackson, T
IR  - Jackson T
FIR - Jacoup, M
IR  - Jacoup M
FIR - Jaensch, E
IR  - Jaensch E
FIR - Jain, P
IR  - Jain P
FIR - Jain, S
IR  - Jain S
FIR - Jaiswal, N
IR  - Jaiswal N
FIR - Jaksic, A
IR  - Jaksic A
FIR - Jakubowicz, I
IR  - Jakubowicz I
FIR - Jamel, B
IR  - Jamel B
FIR - James, J
IR  - James J
FIR - Jameson, D
IR  - Jameson D
FIR - Jansz, C
IR  - Jansz C
FIR - Jarman, E
IR  - Jarman E
FIR - Jassi, I
IR  - Jassi I
FIR - Jayasinghe, S
IR  - Jayasinghe S
FIR - Jayatilake, J
IR  - Jayatilake J
FIR - Jayaweera, V
IR  - Jayaweera V
FIR - Jeanes, R
IR  - Jeanes R
FIR - Jeanneret, C I
IR  - Jeanneret CI
FIR - Jedynak, S
IR  - Jedynak S
FIR - Jeffries, L
IR  - Jeffries L
FIR - Jegadeesh, K
IR  - Jegadeesh K
FIR - Jenkins, P
IR  - Jenkins P
FIR - Jennings, C
IR  - Jennings C
FIR - Jenny, C
IR  - Jenny C
FIR - Jiang, Y Y
IR  - Jiang YY
FIR - Jigau, C
IR  - Jigau C
FIR - Jinadasa, C
IR  - Jinadasa C
FIR - Joel, S
IR  - Joel S
FIR - John, R
IR  - John R
FIR - Johns, P
IR  - Johns P
FIR - Johnson, C
IR  - Johnson C
FIR - Johnson, J
IR  - Johnson J
FIR - Johnson, M
IR  - Johnson M
FIR - Johnson, N
IR  - Johnson N
FIR - Johnson, W
IR  - Johnson W
FIR - Johnston, B
IR  - Johnston B
FIR - Johnston, K
IR  - Johnston K
FIR - Johnston, M
IR  - Johnston M
FIR - Johnston, R
IR  - Johnston R
FIR - Johnston, T
IR  - Johnston T
FIR - Jones, G
IR  - Jones G
FIR - Jones, I
IR  - Jones I
FIR - Jones, L
IR  - Jones L
FIR - Jones, M
IR  - Jones M
FIR - Jones, S
IR  - Jones S
FIR - Jones, Tania
IR  - Jones T
FIR - Jones, Tudor
IR  - Jones T
FIR - Joshi, M
IR  - Joshi M
FIR - Joshi, Naveen
IR  - Joshi N
FIR - Joshi, Nirupama
IR  - Joshi N
FIR - Joske, F
IR  - Joske F
FIR - Joubert, C
IR  - Joubert C
FIR - Jovanovic, B
IR  - Jovanovic B
FIR - Joyce, R
IR  - Joyce R
FIR - Judd, A M
IR  - Judd AM
FIR - Judd, J
IR  - Judd J
FIR - Kaaden, J P
IR  - Kaaden JP
FIR - Kabat, L
IR  - Kabat L
FIR - Kabourakis, F
IR  - Kabourakis F
FIR - Kaippilly, A
IR  - Kaippilly A
FIR - Kajani, H
IR  - Kajani H
FIR - Kamale, A
IR  - Kamale A
FIR - Kaminsky, L
IR  - Kaminsky L
FIR - Kanapathipillai, U
IR  - Kanapathipillai U
FIR - Kanashuk, L
IR  - Kanashuk L
FIR - Kao, R
IR  - Kao R
FIR - Kapadia, P
IR  - Kapadia P
FIR - Kapadia, V
IR  - Kapadia V
FIR - Karmouche, R
IR  - Karmouche R
FIR - Kaur, K J
IR  - Kaur KJ
FIR - Kavanagh, T
IR  - Kavanagh T
FIR - Kay, A
IR  - Kay A
FIR - Kay, B
IR  - Kay B
FIR - Kaye, S
IR  - Kaye S
FIR - Keane, K
IR  - Keane K
FIR - Keating, B
IR  - Keating B
FIR - Keecha, E
IR  - Keecha E
FIR - Keecha, J
IR  - Keecha J
FIR - Keenan, P
IR  - Keenan P
FIR - Keillar, P
IR  - Keillar P
FIR - Kemp, G
IR  - Kemp G
FIR - Kemp, P
IR  - Kemp P
FIR - Kennedy, M
IR  - Kennedy M
FIR - Kennedy, U
IR  - Kennedy U
FIR - Kennett, S
IR  - Kennett S
FIR - Kesarapu, S
IR  - Kesarapu S
FIR - Khan, F
IR  - Khan F
FIR - Khan, I
IR  - Khan I
FIR - Khan, M
IR  - Khan M
FIR - Khong, C K
IR  - Khong CK
FIR - Khoo, F
IR  - Khoo F
FIR - Khoo, J
IR  - Khoo J
FIR - Khoo, S
IR  - Khoo S
FIR - Khoshghalb, A
IR  - Khoshghalb A
FIR - Kiefer, J
IR  - Kiefer J
FIR - Kiley, M
IR  - Kiley M
FIR - Kilov, G
IR  - Kilov G
FIR - Kimpton, N
IR  - Kimpton N
FIR - King, S C
IR  - King SC
FIR - Kingston, R
IR  - Kingston R
FIR - Kinsella, P
IR  - Kinsella P
FIR - Kipouridis, A
IR  - Kipouridis A
FIR - Kirwan, A
IR  - Kirwan A
FIR - Kisselev, S
IR  - Kisselev S
FIR - Kitchen, J
IR  - Kitchen J
FIR - Kloot, S
IR  - Kloot S
FIR - Knaggs, J
IR  - Knaggs J
FIR - Knight, E
IR  - Knight E
FIR - Knobel, J
IR  - Knobel J
FIR - Knowles, D
IR  - Knowles D
FIR - Knowles, P
IR  - Knowles P
FIR - Kogosowski, S
IR  - Kogosowski S
FIR - Kok, Jereth
IR  - Kok J
FIR - Kok, Joyce
IR  - Kok J
FIR - Kollios, D
IR  - Kollios D
FIR - Konopnicki, H
IR  - Konopnicki H
FIR - Koravos, A
IR  - Koravos A
FIR - Korol, P
IR  - Korol P
FIR - Kosky, A R
IR  - Kosky AR
FIR - Kote Somashekarappa, M
IR  - Kote Somashekarappa M
FIR - Kottegoda-Vithana, E
IR  - Kottegoda-Vithana E
FIR - Kotur, S
IR  - Kotur S
FIR - Kozminsky, M
IR  - Kozminsky M
FIR - Kraner, G
IR  - Kraner G
FIR - Kraus, D H
IR  - Kraus DH
FIR - Krell, I
IR  - Krell I
FIR - Kruytbosch, C
IR  - Kruytbosch C
FIR - Kuay, V
IR  - Kuay V
FIR - Kucminska, A
IR  - Kucminska A
FIR - Kulatunga, P
IR  - Kulatunga P
FIR - Kulinski, M
IR  - Kulinski M
FIR - Kumar, J
IR  - Kumar J
FIR - Kumar, R
IR  - Kumar R
FIR - Kumar, S
IR  - Kumar S
FIR - Kumarage, D
IR  - Kumarage D
FIR - Kumaraswamy, S
IR  - Kumaraswamy S
FIR - Kunze, M
IR  - Kunze M
FIR - Kurien, S
IR  - Kurien S
FIR - Kuruvilla, P
IR  - Kuruvilla P
FIR - Kwong, R
IR  - Kwong R
FIR - Kyaw, Z
IR  - Kyaw Z
FIR - Kyriacopoulos, J
IR  - Kyriacopoulos J
FIR - Lackner, P J
IR  - Lackner PJ
FIR - Lahanis, C
IR  - Lahanis C
FIR - Lajoie, D
IR  - Lajoie D
FIR - Lajoie, K
IR  - Lajoie K
FIR - Lakshmanan, A
IR  - Lakshmanan A
FIR - Lal, A
IR  - Lal A
FIR - Lalor, E
IR  - Lalor E
FIR - Lam, D
IR  - Lam D
FIR - Lambooij, C
IR  - Lambooij C
FIR - Lancaster, M
IR  - Lancaster M
FIR - Landa, L
IR  - Landa L
FIR - Landers, J
IR  - Landers J
FIR - Lane, R
IR  - Lane R
FIR - Langston, K
IR  - Langston K
FIR - Lapin, S
IR  - Lapin S
FIR - Lath, P
IR  - Lath P
FIR - Lau-Gooey, T
IR  - Lau-Gooey T
FIR - Lawlor-Smith, L
IR  - Lawlor-Smith L
FIR - Le Couteur, S
IR  - Le Couteur S
FIR - Le, P
IR  - Le P
FIR - Le Riche, M
IR  - Le Riche M
FIR - Le, V
IR  - Le V
FIR - Le, W
IR  - Le W
FIR - Leber, D
IR  - Leber D
FIR - Ledner, A
IR  - Ledner A
FIR - Lee, B
IR  - Lee B
FIR - Lee, C
IR  - Lee C
FIR - Lee, D
IR  - Lee D
FIR - Lee, F B
IR  - Lee FB
FIR - Lee, Jade
IR  - Lee J
FIR - Lee, James
IR  - Lee J
FIR - Lee, Jessicasu-Yin
IR  - Lee JY
FIR - Lee, John
IR  - Lee J
FIR - Lees, K
IR  - Lees K
FIR - Lees, R
IR  - Lees R
FIR - Lees, W
IR  - Lees W
FIR - Leffler, P
IR  - Leffler P
FIR - Lenton, J
IR  - Lenton J
FIR - Leong, R
IR  - Leong R
FIR - Leow, L
IR  - Leow L
FIR - Leow, P
IR  - Leow P
FIR - Leow, Y
IR  - Leow Y
FIR - Leslie, N
IR  - Leslie N
FIR - Lester, S E
IR  - Lester SE
FIR - Lewi, L
IR  - Lewi L
FIR - Lewis, P
IR  - Lewis P
FIR - Lewis, R
IR  - Lewis R
FIR - Li, A
IR  - Li A
FIR - Li, J
IR  - Li J
FIR - Liang, J
IR  - Liang J
FIR - Liang, Xs
IR  - Liang X
FIR - Libhaber, H
IR  - Libhaber H
FIR - Lichtblau, B
IR  - Lichtblau B
FIR - Lickiss, T
IR  - Lickiss T
FIR - Liedvogel, M
IR  - Liedvogel M
FIR - Liew, K
IR  - Liew K
FIR - Light, L
IR  - Light L
FIR - Lightfoot, W
IR  - Lightfoot W
FIR - Lim, C
IR  - Lim C
FIR - Lim, D
IR  - Lim D
FIR - Lim, H
IR  - Lim H
FIR - Lim, H S
IR  - Lim HS
FIR - Lim, J
IR  - Lim J
FIR - Lim, S G
IR  - Lim SG
FIR - Limaye, S
IR  - Limaye S
FIR - Limbu, Y
IR  - Limbu Y
FIR - Lindenmayer, J
IR  - Lindenmayer J
FIR - Lindstedt, P
IR  - Lindstedt P
FIR - Lines, A
IR  - Lines A
FIR - Ling, J
IR  - Ling J
FIR - Ling, R
IR  - Ling R
FIR - Linton, J
IR  - Linton J
FIR - Linton, S
IR  - Linton S
FIR - Linton, T
IR  - Linton T
FIR - Liow, C
IR  - Liow C
FIR - Liow, Y C
IR  - Liow YC
FIR - Lip, L
IR  - Lip L
FIR - Lipson, D
IR  - Lipson D
FIR - Liu, S
IR  - Liu S
FIR - Liu, Y
IR  - Liu Y
FIR - Liubinas, R
IR  - Liubinas R
FIR - Liveriadis, T
IR  - Liveriadis T
FIR - Lizner, S
IR  - Lizner S
FIR - Lloyd, M
IR  - Lloyd M
FIR - Lo, B
IR  - Lo B
FIR - Lo, C
IR  - Lo C
FIR - Lock, P
IR  - Lock P
FIR - Lockhart, M
IR  - Lockhart M
FIR - Logan, M
IR  - Logan M
FIR - Loke, K P
IR  - Loke KP
FIR - Long, Matthew
IR  - Long M
FIR - Long, Michael
IR  - Long M
FIR - Longworth, W
IR  - Longworth W
FIR - Loo, K H
IR  - Loo KH
FIR - Lopez-Hernandez, S
IR  - Lopez-Hernandez S
FIR - Lord, R J
IR  - Lord RJ
FIR - Louw, J
IR  - Louw J
FIR - Louw, T T
IR  - Louw TT
FIR - Low, B
IR  - Low B
FIR - Low, F
IR  - Low F
FIR - Lowe, M
IR  - Lowe M
FIR - Lowther, D
IR  - Lowther D
FIR - Loxley, P
IR  - Loxley P
FIR - Lu, P
IR  - Lu P
FIR - Lu, S
IR  - Lu S
FIR - Lucarelli, A
IR  - Lucarelli A
FIR - Lui, G
IR  - Lui G
FIR - Lui, K
IR  - Lui K
FIR - Lui, R
IR  - Lui R
FIR - Luke, C
IR  - Luke C
FIR - Lukic, N
IR  - Lukic N
FIR - Lupton, J
IR  - Lupton J
FIR - Luscombe, T
IR  - Luscombe T
FIR - Luttrell, C L
IR  - Luttrell CL
FIR - Lyall, A
IR  - Lyall A
FIR - Lynch, J
IR  - Lynch J
FIR - Lynn, K
IR  - Lynn K
FIR - Lyon, D
IR  - Lyon D
FIR - Lyon, E
IR  - Lyon E
FIR - Lyons, S
IR  - Lyons S
FIR - Macaulay, G
IR  - Macaulay G
FIR - Macaulay, K
IR  - Macaulay K
FIR - MacIndoe, A
IR  - MacIndoe A
FIR - MacIsaac, P
IR  - MacIsaac P
FIR - Maciver, R
IR  - Maciver R
FIR - Mackay, B
IR  - Mackay B
FIR - Mackay, J
IR  - Mackay J
FIR - Mackinnon, D
IR  - Mackinnon D
FIR - Mackle, R
IR  - Mackle R
FIR - Macphail, J
IR  - Macphail J
FIR - Madawala, N
IR  - Madawala N
FIR - Madden, J
IR  - Madden J
FIR - Madeley, C
IR  - Madeley C
FIR - Madhanpall, N
IR  - Madhanpall N
FIR - Magarey, J
IR  - Magarey J
FIR - Magill, M
IR  - Magill M
FIR - Mah, S
IR  - Mah S
FIR - Mahadeva, S P
IR  - Mahadeva SP
FIR - Mahendran, S
IR  - Mahendran S
FIR - Maher, J
IR  - Maher J
FIR - Maher, M
IR  - Maher M
FIR - Mahmood, Aamir
IR  - Mahmood A
FIR - Mahmood, Abbas
IR  - Mahmood A
FIR - Maier, K
IR  - Maier K
FIR - Majchrzak, W
IR  - Majchrzak W
FIR - Majeed, J
IR  - Majeed J
FIR - Makar, A
IR  - Makar A
FIR - Makohon, R
IR  - Makohon R
FIR - Malcher, P
IR  - Malcher P
FIR - Malcolm, H E
IR  - Malcolm HE
FIR - Malcolm, M
IR  - Malcolm M
FIR - Mallett, S
IR  - Mallett S
FIR - Mallik, A
IR  - Mallik A
FIR - Manderson, J
IR  - Manderson J
FIR - Mane, S
IR  - Mane S
FIR - Mangan, G
IR  - Mangan G
FIR - Manifold, M
IR  - Manifold M
FIR - Manoliadis, M
IR  - Manoliadis M
FIR - Manovel, B
IR  - Manovel B
FIR - Mansour, A
IR  - Mansour A
FIR - Manton, D
IR  - Manton D
FIR - Marano, F
IR  - Marano F
FIR - Marchant, D
IR  - Marchant D
FIR - Mariajoseph, G
IR  - Mariajoseph G
FIR - Marinos, A
IR  - Marinos A
FIR - Marinucci, D
IR  - Marinucci D
FIR - Marrows, M
IR  - Marrows M
FIR - Marsh, D
IR  - Marsh D
FIR - Martin, C
IR  - Martin C
FIR - Martin, G
IR  - Martin G
FIR - Martin, R
IR  - Martin R
FIR - Marton, F
IR  - Marton F
FIR - Martynova, L
IR  - Martynova L
FIR - Mason, N
IR  - Mason N
FIR - Masood, U
IR  - Masood U
FIR - Massaud, M
IR  - Massaud M
FIR - Massy-Westropp, P
IR  - Massy-Westropp P
FIR - Masters, B
IR  - Masters B
FIR - Mather, J
IR  - Mather J
FIR - Mathews, R A
IR  - Mathews RA
FIR - Mathieson, G
IR  - Mathieson G
FIR - Mauro, M
IR  - Mauro M
FIR - Mauviel, P A
IR  - Mauviel PA
FIR - Maxfield, N
IR  - Maxfield N
FIR - Mayhead, C
IR  - Mayhead C
FIR - Mazengiya, S
IR  - Mazengiya S
FIR - Mazhar, A
IR  - Mazhar A
FIR - Mbachilin, G
IR  - Mbachilin G
FIR - McAllan, A
IR  - McAllan A
FIR - McCallum, H
IR  - McCallum H
FIR - McCann, N
IR  - McCann N
FIR - McCarthy, A
IR  - McCarthy A
FIR - McCleary, A
IR  - McCleary A
FIR - McClelland, R
IR  - McClelland R
FIR - McConville, D S
IR  - McConville DS
FIR - McCorkell, J
IR  - McCorkell J
FIR - McCormack, G
IR  - McCormack G
FIR - McCormick, H
IR  - McCormick H
FIR - McCowan, M
IR  - McCowan M
FIR - McCutcheon, J
IR  - McCutcheon J
FIR - McDonald, A G
IR  - McDonald AG
FIR - McDonald, A S
IR  - McDonald AS
FIR - McDonald, I R
IR  - McDonald IR
FIR - McDonald, J
IR  - McDonald J
FIR - McDonald, N
IR  - McDonald N
FIR - McDonald, S
IR  - McDonald S
FIR - McEniery, A
IR  - McEniery A
FIR - McEntee, K
IR  - McEntee K
FIR - McGee, R
IR  - McGee R
FIR - McGinity, P
IR  - McGinity P
FIR - McGowan, N
IR  - McGowan N
FIR - McGowan, R
IR  - McGowan R
FIR - McGrath, L
IR  - McGrath L
FIR - McGuire, Paul
IR  - McGuire P
FIR - McGuire, Precious
IR  - McGuire P
FIR - McHardy, C
IR  - McHardy C
FIR - McHenry, K
IR  - McHenry K
FIR - McIllree, R
IR  - McIllree R
FIR - McKay, M
IR  - McKay M
FIR - McKellar, C
IR  - McKellar C
FIR - McKelvie, M
IR  - McKelvie M
FIR - McKenzie, S I
IR  - McKenzie SI
FIR - McKeown, J
IR  - McKeown J
FIR - McKeown, M
IR  - McKeown M
FIR - McKernan, S
IR  - McKernan S
FIR - McKinnon, A
IR  - McKinnon A
FIR - McLaren, G
IR  - McLaren G
FIR - McLeod, I
IR  - McLeod I
FIR - McMahon, A
IR  - McMahon A
FIR - McMaster, I
IR  - McMaster I
FIR - Mesiha, S
IR  - Mesiha S
FIR - Meyer, P L
IR  - Meyer PL
FIR - Meyer, R
IR  - Meyer R
FIR - Miceli, A
IR  - Miceli A
FIR - Michaelson, T
IR  - Michaelson T
FIR - Michail, A
IR  - Michail A
FIR - Michelmore, K
IR  - Michelmore K
FIR - Miezis, V
IR  - Miezis V
FIR - Milan, S
IR  - Milan S
FIR - Milky, S
IR  - Milky S
FIR - Miller, K
IR  - Miller K
FIR - Milner, J
IR  - Milner J
FIR - Milone, R
IR  - Milone R
FIR - Milton, C
IR  - Milton C
FIR - Milward, N
IR  - Milward N
FIR - Mirhom, R
IR  - Mirhom R
FIR - Mirranay, S
IR  - Mirranay S
FIR - Mishricky, H
IR  - Mishricky H
FIR - Misso, R
IR  - Misso R
FIR - Mitchell, A
IR  - Mitchell A
FIR - Mitchell, D
IR  - Mitchell D
FIR - Mitchell, L
IR  - Mitchell L
FIR - Mobilia, G
IR  - Mobilia G
FIR - Moffitt, M
IR  - Moffitt M
FIR - Mohr, V
IR  - Mohr V
FIR - Moller, Gary
IR  - Moller G
FIR - Moller, Graeme
IR  - Moller G
FIR - Molloy, P
IR  - Molloy P
FIR - Molloy, T
IR  - Molloy T
FIR - Molyneux, P
IR  - Molyneux P
FIR - Monaghan, C
IR  - Monaghan C
FIR - Monash, D
IR  - Monash D
FIR - Moncrieff, S
IR  - Moncrieff S
FIR - Monzon, M
IR  - Monzon M
FIR - Mooney, T
IR  - Mooney T
FIR - Moore, E
IR  - Moore E
FIR - Moran, J
IR  - Moran J
FIR - Morgan, G
IR  - Morgan G
FIR - Morgan, M
IR  - Morgan M
FIR - Morgan, N
IR  - Morgan N
FIR - Morris, N
IR  - Morris N
FIR - Morris, S
IR  - Morris S
FIR - Morrison, H
IR  - Morrison H
FIR - Morrow, S
IR  - Morrow S
FIR - Morton, R
IR  - Morton R
FIR - Moschou, C
IR  - Moschou C
FIR - Moulding, S
IR  - Moulding S
FIR - Moule, V
IR  - Moule V
FIR - Mouzakis, V
IR  - Mouzakis V
FIR - Mudunna, D
IR  - Mudunna D
FIR - Mudzi, S
IR  - Mudzi S
FIR - Mulkearns, P
IR  - Mulkearns P
FIR - Mullen, D
IR  - Mullen D
FIR - Mulvey, G
IR  - Mulvey G
FIR - Mungi, D
IR  - Mungi D
FIR - Munro, L
IR  - Munro L
FIR - Muraledaran, S
IR  - Muraledaran S
FIR - Murphy, B
IR  - Murphy B
FIR - Murphy, G
IR  - Murphy G
FIR - Murray, A
IR  - Murray A
FIR - Murray, B
IR  - Murray B
FIR - Murray, E
IR  - Murray E
FIR - Murray, H
IR  - Murray H
FIR - Murray, S
IR  - Murray S
FIR - Murtagh, C
IR  - Murtagh C
FIR - Nadarajah, M
IR  - Nadarajah M
FIR - Naiker, S
IR  - Naiker S
FIR - Naing, W
IR  - Naing W
FIR - Nandha, R
IR  - Nandha R
FIR - Nankervis, J
IR  - Nankervis J
FIR - Naoum, A
IR  - Naoum A
FIR - Nash, C
IR  - Nash C
FIR - Nashed, M
IR  - Nashed M
FIR - Nasreen, N
IR  - Nasreen N
FIR - Nath-Chand, U
IR  - Nath-Chand U
FIR - Neagle, M
IR  - Neagle M
FIR - Nelson, C
IR  - Nelson C
FIR - Nelson, M R
IR  - Nelson MR
FIR - Nesbitt, P
IR  - Nesbitt P
FIR - Neuberger, M
IR  - Neuberger M
FIR - Newman, S
IR  - Newman S
FIR - Newton, S
IR  - Newton S
FIR - Ng, D
IR  - Ng D
FIR - Ng, H
IR  - Ng H
FIR - Ng, S
IR  - Ng S
FIR - Nguyen, D
IR  - Nguyen D
FIR - Nguyen, H Q
IR  - Nguyen HQ
FIR - Nguyen, H T
IR  - Nguyen HT
FIR - Nguyen, T
IR  - Nguyen T
FIR - Nguyen-Ngoc, M
IR  - Nguyen-Ngoc M
FIR - Nice, P
IR  - Nice P
FIR - Nicholls, P
IR  - Nicholls P
FIR - Nicholson, D
IR  - Nicholson D
FIR - Nicola, N
IR  - Nicola N
FIR - Nicolettou, N
IR  - Nicolettou N
FIR - Nicolson, I
IR  - Nicolson I
FIR - Nield, S
IR  - Nield S
FIR - Nikolic, V
IR  - Nikolic V
FIR - Nikolovska-Buzevski, N
IR  - Nikolovska-Buzevski N
FIR - Nilsson, A
IR  - Nilsson A
FIR - Nimmo, A
IR  - Nimmo A
FIR - Nisselle, P
IR  - Nisselle P
FIR - Nitchingham, S
IR  - Nitchingham S
FIR - Niven, A
IR  - Niven A
FIR - Nnopu, E
IR  - Nnopu E
FIR - Noonan, L
IR  - Noonan L
FIR - Norton, C
IR  - Norton C
FIR - Norton, G
IR  - Norton G
FIR - Notini, G
IR  - Notini G
FIR - Nwaegerue, E D
IR  - Nwaegerue ED
FIR - Nylander, P
IR  - Nylander P
FIR - O’Brien, C
IR  - O’Brien C
FIR - O’Connor, A
IR  - O’Connor A
FIR - O’Connor, D A
IR  - O’Connor DA
FIR - O’Donovan, B
IR  - O’Donovan B
FIR - O’Driscoll, E
IR  - O’Driscoll E
FIR - Oechsle, G
IR  - Oechsle G
FIR - Offor, J
IR  - Offor J
FIR - Ogilvie, B
IR  - Ogilvie B
FIR - O’Halloran, J
IR  - O’Halloran J
FIR - O’Hanlon, P
IR  - O’Hanlon P
FIR - Okolie, K
IR  - Okolie K
FIR - Olaniyi, I
IR  - Olaniyi I
FIR - O’Leary, B
IR  - O’Leary B
FIR - O’Leary, K
IR  - O’Leary K
FIR - Olesen, J
IR  - Olesen J
FIR - Oliver, P
IR  - Oliver P
FIR - Olomola, O
IR  - Olomola O
FIR - Olszewski, C
IR  - Olszewski C
FIR - Olukolu, G
IR  - Olukolu G
FIR - Omarjee, A
IR  - Omarjee A
FIR - Omidiora, A A
IR  - Omidiora AA
FIR - Omifolaji, S
IR  - Omifolaji S
FIR - O’Neill, A
IR  - O’Neill A
FIR - O’Neill, C O
IR  - O’Neill CO
FIR - Ong, B P
IR  - Ong BP
FIR - Ong, M
IR  - Ong M
FIR - Ooruthiran, M
IR  - Ooruthiran M
FIR - Oppermann, B L
IR  - Oppermann BL
FIR - Orbach, E
IR  - Orbach E
FIR - Orgonas, R
IR  - Orgonas R
FIR - Orsillo, M
IR  - Orsillo M
FIR - Ostberg, M
IR  - Ostberg M
FIR - O’Sullivan, C
IR  - O’Sullivan C
FIR - O’Sullivan, J
IR  - O’Sullivan J
FIR - O’Sullivan, P J
IR  - O’Sullivan PJ
FIR - O’Toole, C
IR  - O’Toole C
FIR - O’Toole, M
IR  - O’Toole M
FIR - Otuonye, D
IR  - Otuonye D
FIR - Owen, T
IR  - Owen T
FIR - Padilla, C
IR  - Padilla C
FIR - Page, A
IR  - Page A
FIR - Pahuja, P
IR  - Pahuja P
FIR - Palmer, A
IR  - Palmer A
FIR - Pan, J
IR  - Pan J
FIR - Panozzo, D
IR  - Panozzo D
FIR - Pantillano, E
IR  - Pantillano E
FIR - Papagelis, A
IR  - Papagelis A
FIR - Papas, E
IR  - Papas E
FIR - Pape, A
IR  - Pape A
FIR - Paransothy, P
IR  - Paransothy P
FIR - Parghi, N
IR  - Parghi N
FIR - Parker, A
IR  - Parker A
FIR - Parker, J
IR  - Parker J
FIR - Parker, S
IR  - Parker S
FIR - Parkes, H
IR  - Parkes H
FIR - Parletta, E
IR  - Parletta E
FIR - Parry, B
IR  - Parry B
FIR - Pasha, M
IR  - Pasha M
FIR - Patel, G
IR  - Patel G
FIR - Patel, M
IR  - Patel M
FIR - Pathirana, A
IR  - Pathirana A
FIR - Patterson, R
IR  - Patterson R
FIR - Pattichis, I
IR  - Pattichis I
FIR - Pattison, J
IR  - Pattison J
FIR - Pava, C
IR  - Pava C
FIR - Peachey, D
IR  - Peachey D
FIR - Pearce, E
IR  - Pearce E
FIR - Pearce, R
IR  - Pearce R
FIR - Pearse, B
IR  - Pearse B
FIR - Pearson, R
IR  - Pearson R
FIR - Pech, M
IR  - Pech M
FIR - Peduru-Arachchige, A
IR  - Peduru-Arachchige A
FIR - Pellegrini, P
IR  - Pellegrini P
FIR - Pellizzari, G
IR  - Pellizzari G
FIR - Pereira, V
IR  - Pereira V
FIR - Perera, B
IR  - Perera B
FIR - Perera, L
IR  - Perera L
FIR - Perlesz, A
IR  - Perlesz A
FIR - Perraton, R
IR  - Perraton R
FIR - Perry, H
IR  - Perry H
FIR - Perry, S
IR  - Perry S
FIR - Perry, W
IR  - Perry W
FIR - Pervaiz, Z
IR  - Pervaiz Z
FIR - Peters, L
IR  - Peters L
FIR - Pham, H
IR  - Pham H
FIR - Phan, C
IR  - Phan C
FIR - Phan, T
IR  - Phan T
FIR - Phare, A
IR  - Phare A
FIR - Philip, J
IR  - Philip J
FIR - Philips, J
IR  - Philips J
FIR - Phillips, A
IR  - Phillips A
FIR - Philpot, J
IR  - Philpot J
FIR - Phiri, R
IR  - Phiri R
FIR - Pickavance, M
IR  - Pickavance M
FIR - Piekarski, D
IR  - Piekarski D
FIR - Pienkos, J
IR  - Pienkos J
FIR - Piez, W
IR  - Piez W
FIR - Pilgrim, C
IR  - Pilgrim C
FIR - Pillai, B K
IR  - Pillai BK
FIR - Pinder, R
IR  - Pinder R
FIR - Pinkstone, J
IR  - Pinkstone J
FIR - Pinson, J
IR  - Pinson J
FIR - Pither, A
IR  - Pither A
FIR - Plenderleith, J
IR  - Plenderleith J
FIR - Pliatsios, B
IR  - Pliatsios B
FIR - Plunkett, M
IR  - Plunkett M
FIR - Pokharel, C
IR  - Pokharel C
FIR - Poland, D
IR  - Poland D
FIR - Polgar, V
IR  - Polgar V
FIR - Polmear, D
IR  - Polmear D
FIR - Poologanathan, G
IR  - Poologanathan G
FIR - Pope, I
IR  - Pope I
FIR - Popp, L
IR  - Popp L
FIR - Portelli, A
IR  - Portelli A
FIR - Potter, T
IR  - Potter T
FIR - Powell, Kendra
IR  - Powell K
FIR - Powell, Kristine
IR  - Powell K
FIR - Powell, V
IR  - Powell V
FIR - Power, R
IR  - Power R
FIR - Powles, A
IR  - Powles A
FIR - Poynton, N
IR  - Poynton N
FIR - Pranavan, S
IR  - Pranavan S
FIR - Prasad, R
IR  - Prasad R
FIR - Praszkier, S
IR  - Praszkier S
FIR - Preiss, J
IR  - Preiss J
FIR - Pretorius, P
IR  - Pretorius P
FIR - Price, C
IR  - Price C
FIR - Price, I
IR  - Price I
FIR - Price, K
IR  - Price K
FIR - Price, M
IR  - Price M
FIR - Priest, C
IR  - Priest C
FIR - Pring, M
IR  - Pring M
FIR - Profitt, C
IR  - Profitt C
FIR - Protassow, A
IR  - Protassow A
FIR - Psaradellis, I J A
IR  - Psaradellis IJA
FIR - Psycharis, J
IR  - Psycharis J
FIR - Pucilowski, D
IR  - Pucilowski D
FIR - Pun, K
IR  - Pun K
FIR - Qamar, F
IR  - Qamar F
FIR - Quach, S
IR  - Quach S
FIR - Radcliff, E
IR  - Radcliff E
FIR - Radcliffe, B
IR  - Radcliffe B
FIR - Radcliffe, J
IR  - Radcliffe J
FIR - Radford, J
IR  - Radford J
FIR - Ragg, P
IR  - Ragg P
FIR - Rahel, E
IR  - Rahel E
FIR - Rahim, T
IR  - Rahim T
FIR - Rahman, F
IR  - Rahman F
FIR - Rahmanamlashi, N
IR  - Rahmanamlashi N
FIR - Rajasooriar, S
IR  - Rajasooriar S
FIR - Rajendra, I
IR  - Rajendra I
FIR - Rajini, E
IR  - Rajini E
FIR - Raman, A
IR  - Raman A
FIR - Ramsay, A
IR  - Ramsay A
FIR - Ramsey, J
IR  - Ramsey J
FIR - Rana, U
IR  - Rana U
FIR - Rankin, M
IR  - Rankin M
FIR - Rao, U V
IR  - Rao UV
FIR - Rapley, M
IR  - Rapley M
FIR - Rasaratnam, S
IR  - Rasaratnam S
FIR - Rashid, A
IR  - Rashid A
FIR - Ratnaike, L
IR  - Ratnaike L
FIR - Rattan, J
IR  - Rattan J
FIR - Ratten, K
IR  - Ratten K
FIR - Rattraywood, C
IR  - Rattraywood C
FIR - Rayner, E
IR  - Rayner E
FIR - Rea, J
IR  - Rea J
FIR - Rea, P C
IR  - Rea PC
FIR - Reddy, Sanganakal
IR  - Reddy S
FIR - Reddy, Shradhanand
IR  - Reddy S
FIR - Reed, R
IR  - Reed R
FIR - Reeves, C
IR  - Reeves C
FIR - Reichl, T
IR  - Reichl T
FIR - Reid, J
IR  - Reid J
FIR - Reid, K
IR  - Reid K
FIR - Remyn, P
IR  - Remyn P
FIR - Renfrey, S
IR  - Renfrey S
FIR - Renouf, E
IR  - Renouf E
FIR - Renshaw, P
IR  - Renshaw P
FIR - Retchford, A
IR  - Retchford A
FIR - Reynolds, F
IR  - Reynolds F
FIR - Reza, R
IR  - Reza R
FIR - Rezk, L
IR  - Rezk L
FIR - Rhee, J
IR  - Rhee J
FIR - Rhodes, F
IR  - Rhodes F
FIR - Rice, A
IR  - Rice A
FIR - Richards, J
IR  - Richards J
FIR - Richards, R
IR  - Richards R
FIR - Richardson, A
IR  - Richardson A
FIR - Richardson, G T
IR  - Richardson GT
FIR - Richardson, R
IR  - Richardson R
FIR - Richardson, T
IR  - Richardson T
FIR - Ridgers, D
IR  - Ridgers D
FIR - Ridgers, M J
IR  - Ridgers MJ
FIR - Rieger, W
IR  - Rieger W
FIR - Rienits, H
IR  - Rienits H
FIR - Rigoni, M
IR  - Rigoni M
FIR - Riley, J
IR  - Riley J
FIR - Rillstone, D
IR  - Rillstone D
FIR - Rimmer, D E
IR  - Rimmer DE
FIR - Ringelblum, D
IR  - Ringelblum D
FIR - Riseley, J
IR  - Riseley J
FIR - Roberts, A
IR  - Roberts A
FIR - Roberts, I
IR  - Roberts I
FIR - Roberts, J
IR  - Roberts J
FIR - Roberts, M
IR  - Roberts M
FIR - Roberts, S
IR  - Roberts S
FIR - Robinson, J
IR  - Robinson J
FIR - Robinson, R
IR  - Robinson R
FIR - Robson, A
IR  - Robson A
FIR - Roche, V
IR  - Roche V
FIR - Rodda, C
IR  - Rodda C
FIR - Rodway, P
IR  - Rodway P
FIR - Roebuck, R
IR  - Roebuck R
FIR - Rogers, D
IR  - Rogers D
FIR - Rogers, S
IR  - Rogers S
FIR - Roman, F
IR  - Roman F
FIR - Romas, D
IR  - Romas D
FIR - Ronan, C
IR  - Ronan C
FIR - Rope, S
IR  - Rope S
FIR - Rose, A
IR  - Rose A
FIR - Rose, D F
IR  - Rose DF
FIR - Rose, G
IR  - Rose G
FIR - Rose, K
IR  - Rose K
FIR - Rosen, N
IR  - Rosen N
FIR - Rosenblatt, J
IR  - Rosenblatt J
FIR - Ross, K
IR  - Ross K
FIR - Ross, Mary
IR  - Ross M
FIR - Ross, T
IR  - Ross T
FIR - Roth, J
IR  - Roth J
FIR - Rothfield, J
IR  - Rothfield J
FIR - Roubos, N
IR  - Roubos N
FIR - Roufael, A D
IR  - Roufael AD
FIR - Rounsevell, J
IR  - Rounsevell J
FIR - Rouse, W
IR  - Rouse W
FIR - Roushdy, B
IR  - Roushdy B
FIR - Rowe, R
IR  - Rowe R
FIR - Rowland, G
IR  - Rowland G
FIR - Roy, A
IR  - Roy A
FIR - Royston, A
IR  - Royston A
FIR - Rubin, J
IR  - Rubin J
FIR - Russell, G
IR  - Russell G
FIR - Ryan, F
IR  - Ryan F
FIR - Ryan, N
IR  - Ryan N
FIR - Ryan, S
IR  - Ryan S
FIR - Sabet, A
IR  - Sabet A
FIR - Sabetypeyman, F
IR  - Sabetypeyman F
FIR - Sachdev, A
IR  - Sachdev A
FIR - Saddik, A
IR  - Saddik A
FIR - Sadhai, R
IR  - Sadhai R
FIR - Saeed, S
IR  - Saeed S
FIR - Sahhar, C
IR  - Sahhar C
FIR - Saka, M
IR  - Saka M
FIR - Salauddin, M
IR  - Salauddin M
FIR - Salter, E
IR  - Salter E
FIR - Salter, M
IR  - Salter M
FIR - Samaddar, A
IR  - Samaddar A
FIR - Samarakkody, A
IR  - Samarakkody A
FIR - Samararatna, M
IR  - Samararatna M
FIR - Samarsekera, C
IR  - Samarsekera C
FIR - Samuel-John, D
IR  - Samuel-John D
FIR - Sandars, M
IR  - Sandars M
FIR - Sanders, J
IR  - Sanders J
FIR - Sanderson, L
IR  - Sanderson L
FIR - Sandhu, N
IR  - Sandhu N
FIR - Sandrasegaram, S
IR  - Sandrasegaram S
FIR - Sangsari, A
IR  - Sangsari A
FIR - Saprid, J
IR  - Saprid J
FIR - Sarkis, K
IR  - Sarkis K
FIR - Sasse, C
IR  - Sasse C
FIR - Satter, F
IR  - Satter F
FIR - Satyadharma, K
IR  - Satyadharma K
FIR - Saul, J
IR  - Saul J
FIR - Scaife, R
IR  - Scaife R
FIR - Schaap, M
IR  - Schaap M
FIR - Scheelings, F T
IR  - Scheelings FT
FIR - Schinckel, H
IR  - Schinckel H
FIR - Schlesinger, P
IR  - Schlesinger P
FIR - Schlicht, S
IR  - Schlicht S
FIR - Schmidt, M
IR  - Schmidt M
FIR - Schneeweiss, A
IR  - Schneeweiss A
FIR - Schroeder, E
IR  - Schroeder E
FIR - Scully, S
IR  - Scully S
FIR - Searle, R
IR  - Searle R
FIR - Sebastian, T
IR  - Sebastian T
FIR - Seeto, R
IR  - Seeto R
FIR - Segal, G
IR  - Segal G
FIR - Segal, L
IR  - Segal L
FIR - Seidel, B
IR  - Seidel B
FIR - Selga, A
IR  - Selga A
FIR - Senanayake, I
IR  - Senanayake I
FIR - Seneviratne, M
IR  - Seneviratne M
FIR - Seneviratne, T
IR  - Seneviratne T
FIR - Senini, D
IR  - Senini D
FIR - Senior, J
IR  - Senior J
FIR - Seow, L
IR  - Seow L
FIR - Sepetavc, D
IR  - Sepetavc D
FIR - Serafim, A
IR  - Serafim A
FIR - Serban, R
IR  - Serban R
FIR - Sexton, P
IR  - Sexton P
FIR - Shahat, M
IR  - Shahat M
FIR - Shamoun, Y
IR  - Shamoun Y
FIR - Shanmugarajah, K
IR  - Shanmugarajah K
FIR - Shannon, G
IR  - Shannon G
FIR - Sharif, A
IR  - Sharif A
FIR - Shariff, A
IR  - Shariff A
FIR - Sharma, A
IR  - Sharma A
FIR - Sharma, D
IR  - Sharma D
FIR - Sharma, M
IR  - Sharma M
FIR - Sharma, P
IR  - Sharma P
FIR - Sharma, R
IR  - Sharma R
FIR - Sharma, S
IR  - Sharma S
FIR - Sharma, U
IR  - Sharma U
FIR - Sharp, V
IR  - Sharp V
FIR - Sheen-Apostol, J
IR  - Sheen-Apostol J
FIR - Sheikh Mohamed, M
IR  - Sheikh Mohamed M
FIR - Sher, J
IR  - Sher J
FIR - Sherley, M
IR  - Sherley M
FIR - Shi, B
IR  - Shi B
FIR - Shimmin, M B
IR  - Shimmin MB
FIR - Shing, D
IR  - Shing D
FIR - Shires, S E
IR  - Shires SE
FIR - Shmerling, A
IR  - Shmerling A
FIR - Shortis, P
IR  - Shortis P
FIR - Shroot, A D
IR  - Shroot AD
FIR - Shute, J
IR  - Shute J
FIR - Sia, M
IR  - Sia M
FIR - Siapantas, S
IR  - Siapantas S
FIR - Sidhwarni, R
IR  - Sidhwarni R
FIR - Siemienowicz, J
IR  - Siemienowicz J
FIR - Siew, H C
IR  - Siew HC
FIR - Sigalov, E
IR  - Sigalov E
FIR - Silver, D
IR  - Silver D
FIR - Simes, L
IR  - Simes L
FIR - Simonson, F
IR  - Simonson F
FIR - Simpson, R
IR  - Simpson R
FIR - Simpson, T
IR  - Simpson T
FIR - Simpson, W
IR  - Simpson W
FIR - Singh, B
IR  - Singh B
FIR - Singh, D
IR  - Singh D
FIR - Singh, H
IR  - Singh H
FIR - Singh, M
IR  - Singh M
FIR - Singh, R
IR  - Singh R
FIR - Siow, C L
IR  - Siow CL
FIR - Sitlington, R
IR  - Sitlington R
FIR - Sivapalan, C
IR  - Sivapalan C
FIR - Skeat, J
IR  - Skeat J
FIR - Skehan, M
IR  - Skehan M
FIR - Skeklios, L
IR  - Skeklios L
FIR - Skinner, T
IR  - Skinner T
FIR - Sklovsky, C J
IR  - Sklovsky CJ
FIR - Slabbert, J
IR  - Slabbert J
FIR - Slaney, G M
IR  - Slaney GM
FIR - Slattery, C
IR  - Slattery C
FIR - Sleaby, E
IR  - Sleaby E
FIR - Sleiman, C
IR  - Sleiman C
FIR - Slesenger, J
IR  - Slesenger J
FIR - Slimming, T
IR  - Slimming T
FIR - Sloan, C
IR  - Sloan C
FIR - Sloane, R
IR  - Sloane R
FIR - Slonim, D
IR  - Slonim D
FIR - Slot, P
IR  - Slot P
FIR - Smagas, T
IR  - Smagas T
FIR - Smart, M
IR  - Smart M
FIR - Smibert, L
IR  - Smibert L
FIR - Smiley, J
IR  - Smiley J
FIR - Smith, D
IR  - Smith D
FIR - Smith, G
IR  - Smith G
FIR - Smith, J
IR  - Smith J
FIR - Smith, P
IR  - Smith P
FIR - Smith, R
IR  - Smith R
FIR - Smith, Stephen
IR  - Smith S
FIR - Smith, Stuart
IR  - Smith S
FIR - Smith, V
IR  - Smith V
FIR - Smylie, D
IR  - Smylie D
FIR - Sneyd, S
IR  - Sneyd S
FIR - Snow, S
IR  - Snow S
FIR - Sobol, G
IR  - Sobol G
FIR - Soccio, M
IR  - Soccio M
FIR - Solanki, V
IR  - Solanki V
FIR - Soloczynskiyj, A
IR  - Soloczynskiyj A
FIR - Solomon, D
IR  - Solomon D
FIR - Somerville, M
IR  - Somerville M
FIR - Song, J
IR  - Song J
FIR - Soo, D
IR  - Soo D
FIR - Soo, L
IR  - Soo L
FIR - Soo, T
IR  - Soo T
FIR - Soo, T M
IR  - Soo TM
FIR - Sood, R
IR  - Sood R
FIR - Sooknandan, S
IR  - Sooknandan S
FIR - Soon, M
IR  - Soon M
FIR - Sosnin, M
IR  - Sosnin M
FIR - Spanos, N
IR  - Spanos N
FIR - Spargo, J S
IR  - Spargo JS
FIR - Speirs, B
IR  - Speirs B
FIR - Spencer, H
IR  - Spencer H
FIR - Spencer, J
IR  - Spencer J
FIR - Spottiswood, M
IR  - Spottiswood M
FIR - Spring, M
IR  - Spring M
FIR - Squires, L
IR  - Squires L
FIR - Stabelos, G
IR  - Stabelos G
FIR - Stagg, M
IR  - Stagg M
FIR - Stanley, L
IR  - Stanley L
FIR - Stark, A
IR  - Stark A
FIR - Steel, A
IR  - Steel A
FIR - Steer, N
IR  - Steer N
FIR - Steiner, H
IR  - Steiner H
FIR - Stephanson, A
IR  - Stephanson A
FIR - Stephens, G
IR  - Stephens G
FIR - Stephenson, A
IR  - Stephenson A
FIR - Sterling, B R
IR  - Sterling BR
FIR - Stevens, B
IR  - Stevens B
FIR - Stevens, P
IR  - Stevens P
FIR - Stevenson, J
IR  - Stevenson J
FIR - Stewart, C
IR  - Stewart C
FIR - Stewart, R
IR  - Stewart R
FIR - Sticklen, E
IR  - Sticklen E
FIR - Stiebel, P
IR  - Stiebel P
FIR - Stillger, J M
IR  - Stillger JM
FIR - Stinerman, I
IR  - Stinerman I
FIR - Stobie, M
IR  - Stobie M
FIR - Stobie, T
IR  - Stobie T
FIR - Stojkovski, S
IR  - Stojkovski S
FIR - Stone, A
IR  - Stone A
FIR - Stowe, S
IR  - Stowe S
FIR - Stoyanova, V
IR  - Stoyanova V
FIR - Strasser, K
IR  - Strasser K
FIR - Strong, J
IR  - Strong J
FIR - Struk, H
IR  - Struk H
FIR - Stuart, A
IR  - Stuart A
FIR - Su, J
IR  - Su J
FIR - Sujecki, M
IR  - Sujecki M
FIR - Suka, R
IR  - Suka R
FIR - Sullivan, T
IR  - Sullivan T
FIR - Sululola, A
IR  - Sululola A
FIR - Sumathipala, A
IR  - Sumathipala A
FIR - Suntesic, L
IR  - Suntesic L
FIR - Sutherland, D
IR  - Sutherland D
FIR - Sutherland, I
IR  - Sutherland I
FIR - Sutherland, R
IR  - Sutherland R
FIR - Sutton, J
IR  - Sutton J
FIR - Swart, R
IR  - Swart R
FIR - Sweet, M
IR  - Sweet M
FIR - Sweet, R
IR  - Sweet R
FIR - Syed, Z
IR  - Syed Z
FIR - Sykes, J
IR  - Sykes J
FIR - Sylivris, A
IR  - Sylivris A
FIR - Symon, B
IR  - Symon B
FIR - Szabo, R
IR  - Szabo R
FIR - Sze, J
IR  - Sze J
FIR - Szenczy, C
IR  - Szenczy C
FIR - Sze-Tho, R
IR  - Sze-Tho R
FIR - Szymanski, I
IR  - Szymanski I
FIR - Szymanski, R
IR  - Szymanski R
FIR - Tadrous, M
IR  - Tadrous M
FIR - Taft, D
IR  - Taft D
FIR - Taine, M
IR  - Taine M
FIR - Talic, D
IR  - Talic D
FIR - Tan, Elaine
IR  - Tan E
FIR - Tan, Eng
IR  - Tan E
FIR - Tan, G
IR  - Tan G
FIR - Tan, H M
IR  - Tan HM
FIR - Tanovic, A
IR  - Tanovic A
FIR - Tasiopoulos, A
IR  - Tasiopoulos A
FIR - Tate, K
IR  - Tate K
FIR - Tattersall, I
IR  - Tattersall I
FIR - Taverna, C
IR  - Taverna C
FIR - Taylor, J
IR  - Taylor J
FIR - Taylor, R
IR  - Taylor R
FIR - Taylor, S
IR  - Taylor S
FIR - Teo, K
IR  - Teo K
FIR - Teoh, C
IR  - Teoh C
FIR - Teperman, B
IR  - Teperman B
FIR - Tereszkiewicz, W
IR  - Tereszkiewicz W
FIR - Thanenthiran, R
IR  - Thanenthiran R
FIR - Thangarajah, C
IR  - Thangarajah C
FIR - Thangavel, B
IR  - Thangavel B
FIR - Thann, Z
IR  - Thann Z
FIR - The, S
IR  - The S
FIR - Theophilos, M
IR  - Theophilos M
FIR - Theris, N
IR  - Theris N
FIR - Thiru, K
IR  - Thiru K
FIR - Thiru, M
IR  - Thiru M
FIR - Thomas, G
IR  - Thomas G
FIR - Thomas, P
IR  - Thomas P
FIR - Thompson, D
IR  - Thompson D
FIR - Thompson, L
IR  - Thompson L
FIR - Thompson, W
IR  - Thompson W
FIR - Thomson, B
IR  - Thomson B
FIR - Thorne, A
IR  - Thorne A
FIR - Thornley, J
IR  - Thornley J
FIR - Thorpe, V
IR  - Thorpe V
FIR - Thottakurichi, R
IR  - Thottakurichi R
FIR - Thurairajah, A
IR  - Thurairajah A
FIR - Thurairajah, S
IR  - Thurairajah S
FIR - Thyagarajan, T
IR  - Thyagarajan T
FIR - Tiet, Q
IR  - Tiet Q
FIR - Tillekeratne, K
IR  - Tillekeratne K
FIR - Tine, S
IR  - Tine S
FIR - Tinning, R
IR  - Tinning R
FIR - Tinston, C
IR  - Tinston C
FIR - To, E
IR  - To E
FIR - Tolentino, C
IR  - Tolentino C
FIR - Tom, H
IR  - Tom H
FIR - Tomar, D
IR  - Tomar D
FIR - Tomic, M
IR  - Tomic M
FIR - Tomyn, L
IR  - Tomyn L
FIR - Toohill, G
IR  - Toohill G
FIR - Tooth, M
IR  - Tooth M
FIR - Tormey, S
IR  - Tormey S
FIR - Toua, P
IR  - Toua P
FIR - Trainor, S
IR  - Trainor S
FIR - Tran, C
IR  - Tran C
FIR - Tran, E
IR  - Tran E
FIR - Tran, L D
IR  - Tran LD
FIR - Tran, T Q
IR  - Tran TQ
FIR - Trethowan, K
IR  - Trethowan K
FIR - Trevena, R
IR  - Trevena R
FIR - Trigg, P
IR  - Trigg P
FIR - Trivett, B
IR  - Trivett B
FIR - Try, R
IR  - Try R
FIR - Tsigopoulos, A
IR  - Tsigopoulos A
FIR - Tucker, D
IR  - Tucker D
FIR - Tunaley, S
IR  - Tunaley S
FIR - Turnbull, H
IR  - Turnbull H
FIR - Turnbull, S
IR  - Turnbull S
FIR - Turner, J
IR  - Turner J
FIR - Twycross, W
IR  - Twycross W
FIR - Tynan, D
IR  - Tynan D
FIR - Tyndall, P
IR  - Tyndall P
FIR - Tyshing, W
IR  - Tyshing W
FIR - Uchendu, F
IR  - Uchendu F
FIR - Uhlenbruch, B
IR  - Uhlenbruch B
FIR - Uluca, U
IR  - Uluca U
FIR - Unkenstein, D
IR  - Unkenstein D
FIR - Urie, J P
IR  - Urie JP
FIR - Vaiopoulos, T
IR  - Vaiopoulos T
FIR - Van Ammers, E
IR  - Van Ammers E
FIR - Van Der Merwe, D
IR  - Van Der Merwe D
FIR - Van Der Spek, A
IR  - Van Der Spek A
FIR - Van Der Vlist, R
IR  - Van Der Vlist R
FIR - Van Opstal, E
IR  - Van Opstal E
FIR - Vanderzeil, G
IR  - Vanderzeil G
FIR - Vanderzeil, T
IR  - Vanderzeil T
FIR - Vanker, L
IR  - Vanker L
FIR - Vanmali, H
IR  - Vanmali H
FIR - Varghese, A
IR  - Varghese A
FIR - Varney, W
IR  - Varney W
FIR - Vasquez, I
IR  - Vasquez I
FIR - Vasudevan, S
IR  - Vasudevan S
FIR - Veal, M
IR  - Veal M
FIR - Venables, S
IR  - Venables S
FIR - Venkatram, G
IR  - Venkatram G
FIR - Verghese, P
IR  - Verghese P
FIR - Verma, H
IR  - Verma H
FIR - Verma, R
IR  - Verma R
FIR - Verso, M
IR  - Verso M
FIR - Victor, A
IR  - Victor A
FIR - Vijayakumar, V
IR  - Vijayakumar V
FIR - Vijayanand, P
IR  - Vijayanand P
FIR - Viljoen, E
IR  - Viljoen E
FIR - Vincent, F
IR  - Vincent F
FIR - Vinci, A
IR  - Vinci A
FIR - Vinci, G
IR  - Vinci G
FIR - Viney, P
IR  - Viney P
FIR - Visvalingam, C
IR  - Visvalingam C
FIR - Von Caemmerer, A
IR  - Von Caemmerer A
FIR - Vonschmidt, J K
IR  - Vonschmidt JK
FIR - Vorich, R
IR  - Vorich R
FIR - Vrij, R
IR  - Vrij R
FIR - Vyas, S
IR  - Vyas S
FIR - Wai, T
IR  - Wai T
FIR - Waid, S
IR  - Waid S
FIR - Wakefield, B
IR  - Wakefield B
FIR - Walder, D
IR  - Walder D
FIR - Waldron, C M
IR  - Waldron CM
FIR - Waldron, M
IR  - Waldron M
FIR - Wales, S
IR  - Wales S
FIR - Walker, B
IR  - Walker B
FIR - Walker, G
IR  - Walker G
FIR - Walker, R
IR  - Walker R
FIR - Walker, W
IR  - Walker W
FIR - Wall, R
IR  - Wall R
FIR - Wallace, J
IR  - Wallace J
FIR - Wallace, K
IR  - Wallace K
FIR - Wallis, I
IR  - Wallis I
FIR - Wang, S
IR  - Wang S
FIR - Wang, X
IR  - Wang X
FIR - Wang, Z
IR  - Wang Z
FIR - Ward, C
IR  - Ward C
FIR - Ward, R
IR  - Ward R
FIR - Ward, S
IR  - Ward S
FIR - Wardlaw, P
IR  - Wardlaw P
FIR - Wark, A
IR  - Wark A
FIR - Warr, A
IR  - Warr A
FIR - Warren, M
IR  - Warren M
FIR - Waters, L
IR  - Waters L
FIR - Watson, A
IR  - Watson A
FIR - Watson, S
IR  - Watson S
FIR - Watt, G
IR  - Watt G
FIR - Watt, J
IR  - Watt J
FIR - Watterson, J
IR  - Watterson J
FIR - Waugh, R
IR  - Waugh R
FIR - Wazid, M
IR  - Wazid M
FIR - Wearne, E
IR  - Wearne E
FIR - Webb, I
IR  - Webb I
FIR - Webber, C
IR  - Webber C
FIR - Webber, E
IR  - Webber E
FIR - Webber, S
IR  - Webber S
FIR - Webster, D L
IR  - Webster DL
FIR - Webster, J
IR  - Webster J
FIR - Webster, Peter
IR  - Webster P
FIR - Webster, Philip
IR  - Webster P
FIR - Weerasinghe, S
IR  - Weerasinghe S
FIR - Weerasoorya, M
IR  - Weerasoorya M
FIR - Weinrich, J
IR  - Weinrich J
FIR - Welberry, L
IR  - Welberry L
FIR - Weller, A
IR  - Weller A
FIR - Wells, S
IR  - Wells S
FIR - Welsh, D
IR  - Welsh D
FIR - Weng, M
IR  - Weng M
FIR - Wenig, M
IR  - Wenig M
FIR - Wettesinghe, I
IR  - Wettesinghe I
FIR - Wexler, P
IR  - Wexler P
FIR - White, A
IR  - White A
FIR - White, G
IR  - White G
FIR - White, Roxana
IR  - White R
FIR - Whitehouse, J
IR  - Whitehouse J
FIR - Whitehouse, L
IR  - Whitehouse L
FIR - Whitehouse, R
IR  - Whitehouse R
FIR - Whitfield, K
IR  - Whitfield K
FIR - Whitfield, S
IR  - Whitfield S
FIR - Whitney, W
IR  - Whitney W
FIR - Wiehle, G
IR  - Wiehle G
FIR - Wight, R
IR  - Wight R
FIR - Wild, I
IR  - Wild I
FIR - Wilding, S
IR  - Wilding S
FIR - Wildman, G
IR  - Wildman G
FIR - Williams, A
IR  - Williams A
FIR - Williams, G
IR  - Williams G
FIR - Williams, J
IR  - Williams J
FIR - Williams, M
IR  - Williams M
FIR - Williams, P D
IR  - Williams PD
FIR - Williams, S
IR  - Williams S
FIR - Williams, W
IR  - Williams W
FIR - Willis, M
IR  - Willis M
FIR - Wilson, A
IR  - Wilson A
FIR - Win, N
IR  - Win N
FIR - Wiseman, J
IR  - Wiseman J
FIR - Wishart, W
IR  - Wishart W
FIR - Wivell, F
IR  - Wivell F
FIR - Wong, C
IR  - Wong C
FIR - Wong, C S
IR  - Wong CS
FIR - Wong, D
IR  - Wong D
FIR - Wong, John K
IR  - Wong JK
FIR - Wong, Johnny
IR  - Wong J
FIR - Wong, Ju-Min
IR  - Wong JM
FIR - Wong, P
IR  - Wong P
FIR - Wong, P T
IR  - Wong PT
FIR - Wong, Y
IR  - Wong Y
FIR - Wood, P
IR  - Wood P
FIR - Woods, R
IR  - Woods R
FIR - Woodward, P
IR  - Woodward P
FIR - Wooff, D
IR  - Wooff D
FIR - Woolf, S
IR  - Woolf S
FIR - Worboys, P
IR  - Worboys P
FIR - Worboys, P C
IR  - Worboys PC
FIR - Wrennall, R
IR  - Wrennall R
FIR - Wright, Adrian
IR  - Wright A
FIR - Wright, Antony
IR  - Wright A
FIR - Wright, L
IR  - Wright L
FIR - Wright, Richard
IR  - Wright R
FIR - Wright, Robert
IR  - Wright R
FIR - Wrobel, K
IR  - Wrobel K
FIR - Wu, D
IR  - Wu D
FIR - Wu, E
IR  - Wu E
FIR - Wu, L
IR  - Wu L
FIR - Xiao, M
IR  - Xiao M
FIR - Yacoub, M
IR  - Yacoub M
FIR - Yang, A
IR  - Yang A
FIR - Yang, J
IR  - Yang J
FIR - Yang, R
IR  - Yang R
FIR - Yates, D
IR  - Yates D
FIR - Yazbek, P
IR  - Yazbek P
FIR - Yeaman, C
IR  - Yeaman C
FIR - Yeo, M
IR  - Yeo M
FIR - Yeung Shi Chung, D
IR  - Yeung Shi Chung D
FIR - Yiap, D
IR  - Yiap D
FIR - Yilmaz, S
IR  - Yilmaz S
FIR - Yogaranandan, D
IR  - Yogaranandan D
FIR - Young, D
IR  - Young D
FIR - Young, R
IR  - Young R
FIR - Young, S
IR  - Young S
FIR - Yousef, M
IR  - Yousef M
FIR - Yousif, K
IR  - Yousif K
FIR - Youssef, D
IR  - Youssef D
FIR - Yu, Z
IR  - Yu Z
FIR - Yuille, R
IR  - Yuille R
FIR - Zagorksi, M
IR  - Zagorksi M
FIR - Zail, S
IR  - Zail S
FIR - Zain, M
IR  - Zain M
FIR - Zallmann, A
IR  - Zallmann A
FIR - Zeng, L
IR  - Zeng L
FIR - Zhao, S
IR  - Zhao S
FIR - Zhao, W
IR  - Zhao W
FIR - Zheng, M
IR  - Zheng M
FIR - Zhou, D
IR  - Zhou D
FIR - Ziccone, M
IR  - Ziccone M
FIR - Zimmerman, J
IR  - Zimmerman J
FIR - Zwijnenburg, A
IR  - Zwijnenburg A
FIR - McNab, N R
IR  - McNab NR
FIR - McNaughton, E L
IR  - McNaughton EL
FIR - McNiff, M
IR  - McNiff M
FIR - McPherson, C
IR  - McPherson C
FIR - Meaney, J
IR  - Meaney J
FIR - Medlicott, M
IR  - Medlicott M
FIR - Medres, R
IR  - Medres R
FIR - Megally, R
IR  - Megally R
FIR - Mehta, K
IR  - Mehta K
FIR - Mellios, O
IR  - Mellios O
FIR - Melvani, R
IR  - Melvani R
FIR - Mencel, J
IR  - Mencel J
FIR - Mendick, S
IR  - Mendick S
FIR - Mendis, L
IR  - Mendis L
FIR - Menzies, J
IR  - Menzies J
FIR - Mercado, M
IR  - Mercado M
EDAT- 2018/09/18 06:00
MHDA- 2018/11/06 06:00
CRDT- 2018/09/18 06:00
PHST- 2018/09/18 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
PHST- 2018/09/18 06:00 [entrez]
AID - 10.1056/NEJMoa1800722 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Oct 18;379(16):1499-1508. doi: 10.1056/NEJMoa1800722. Epub 
      2018 Sep 16.

PMID- 20853549
OWN - NLM
STAT- MEDLINE
DCOM- 20101227
LR  - 20131121
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 35
IP  - 4
DP  - 2010 Aug
TI  - Prophylactic use of aspirin does not induce anaemia among adults.
PG  - 415-9
AB  - BACKGROUND: Aspirin is considered one of the most prescribed drugs worldwide, 
      predominantly for its cardioprotective effects. However, its use may be precluded 
      by gastrointestinal and haematological side-effects. OBJECTIVE: To investigate 
      the association between the prophylactic use of aspirin and the prevalence of 
      anaemia among adults. Other demographic factors and co-morbid conditions such as 
      kidney or liver failure, diabetes mellitus, hypertension, hyperlipidemia, 
      coronary artery disease, ulcer, ulcer medications, and the use of non-steroidal 
      anti-inflammatory drugs, which might be associated with anaemia, were also 
      investigated. RESULTS: No association between aspirin use and prevalence of 
      anaemia was observed. Age and smoking were the only factors contributing 
      significantly to the occurrence of anaemia. Moreover, gender, age and the use of 
      peptic ulcer medication were associated with reduced haemoglobin levels. 
      CONCLUSION: The results may help in minimizing concerns about the development of 
      anaemia among patients on aspirin. They highlight the importance of age, gender, 
      smoking and ulcer medication in determining the incidence of anaemia among those 
      patients.
FAU - Al-Azzam, S I
AU  - Al-Azzam SI
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of 
      Science and Technology, Irbid, Jordan. sayerazzam@yahoo.com
FAU - AlMahasneh, F
AU  - AlMahasneh F
FAU - Mhaidat, N
AU  - Mhaidat N
FAU - Alzoubi, K H
AU  - Alzoubi KH
FAU - Khader, Y S
AU  - Khader YS
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia/*chemically induced/*epidemiology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiotonic Agents/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Female
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
MH  - Smoking
EDAT- 2010/09/22 06:00
MHDA- 2010/12/28 06:00
CRDT- 2010/09/22 06:00
PHST- 2010/09/22 06:00 [entrez]
PHST- 2010/09/22 06:00 [pubmed]
PHST- 2010/12/28 06:00 [medline]
PST - ppublish
SO  - J Clin Pharm Ther. 2010 Aug;35(4):415-9.

PMID- 10973679
OWN - NLM
STAT- MEDLINE
DCOM- 20001004
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 99
IP  - 5
DP  - 2000 Sep 1
TI  - Increased platelet aggregability during exercise in patients with previous 
      myocardial infarction. Lack of inhibition by aspirin.
PG  - 487-94
AB  - The aim of the present study was to investigate the effects of acute exercise on 
      platelet aggregability, blood coagulation, and fibrinolysis in patients with 
      recent myocardial infarction, and to examine these effects in relation to two 
      different antithrombotic regimens. Forty patients (mean age 60 years) were 
      investigated 3 months after a myocardial infarction. They were randomized to 
      antithrombotic treatment with either warfarin (INR 2.8-4.2) or aspirin 160 mg 
      daily. They performed a standardized ergometer bicycle exercise test. Blood was 
      drawn before and after the exercise. The platelet function tests included a 
      platelet aggregate ratio (PAR), which, in the presence of aggregates, is<1. The 
      coagulation products remained largely unchanged during the exercise, whereas the 
      fibrinolytic activity and the catecholamine levels increased significantly. At 
      baseline, PAR was lower in the warfarin group than in the aspirin group. During 
      exercise, PAR was significantly reduced in both study groups (0.75 vs. 0.80), 
      indicating increased platelet aggregability. Beta-thromboglobulin decreased in 
      both groups. The increased platelet aggregability after exercise despite aspirin 
      is probably due to activation by catecholamines. This implies that aspirin may 
      have a limited antithrombotic effect during physical exercise and probably also 
      in other situations with increased catecholamine levels.
FAU - Hurlen, M
AU  - Hurlen M
AD  - Dept of Cardiology, Ullevaal University Hospital, Oslo, Norway.
FAU - Seljeflot, I
AU  - Seljeflot I
FAU - Arnesen, H
AU  - Arnesen H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Blood Coagulation Factors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/pharmacology
MH  - Blood Coagulation Factors/drug effects
MH  - *Exercise
MH  - Female
MH  - Fibrinolysis/drug effects
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/blood/*drug therapy/*physiopathology
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Warfarin/administration & dosage/pharmacology
EDAT- 2000/09/06 11:00
MHDA- 2000/10/07 11:01
CRDT- 2000/09/06 11:00
PHST- 2000/09/06 11:00 [pubmed]
PHST- 2000/10/07 11:01 [medline]
PHST- 2000/09/06 11:00 [entrez]
AID - S0049-3848(00)00277-2 [pii]
AID - 10.1016/s0049-3848(00)00277-2 [doi]
PST - ppublish
SO  - Thromb Res. 2000 Sep 1;99(5):487-94. doi: 10.1016/s0049-3848(00)00277-2.

PMID- 32046972
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2291-0026 (Print)
IS  - 2291-0026 (Electronic)
IS  - 2291-0026 (Linking)
VI  - 8
IP  - 1
DP  - 2020 Jan-Mar
TI  - Development and validation of a compact on-person storage device (SMHeartCard) 
      for emergency access to acetylsalicylic acid and nitroglycerin.
PG  - E75-E82
LID - 10.9778/cmajo.20190147 [doi]
AB  - BACKGROUND: Guidelines recommend that patients with coronary artery disease (CAD) 
      carry and immediately use acetylsalicylic acid (ASA) and sublingually 
      administered nitroglycerin at the onset of chest pain; however, compliance with 
      these recommendations is poor. We designed and tested a compact on-person storage 
      device for these medications. METHODS: We designed an airtight, light-proof and 
      chemically inert holder to carry four 81-mg ASA tablets and three 0.3-mg 
      Nitrostat (nitroglycerin, Pfizer) tablets. After establishing the temperatures 
      ranges in wallets and pockets, we tested nitroglycerin dissolution and release of 
      the stored Nitrostat tablets across a range of relevant temperatures and a 
      variety of tablet enclosure systems. RESULTS: Microcalorimeter thermal conduction 
      studies as well as dissolution and release testing showed that nitroglycerin 
      tablets were stable at temperatures ranging from -20°C to 60°C for 1 week. In 
      testing up to 24 weeks, 0.3-mg Nitrostat tablets enclosed completely in 
      polytetrafluoroethylene (PTFE) performed similarly to those stored in the 
      manufacturer's borosilicate glass packaging across a wide range of temperatures 
      relevant to on-person carriage. Real-world on-person testing for 24 weeks 
      confirmed these results. Non-PTFE enclosures performed poorly. INTERPRETATION: 
      The PTFE enclosure with a PTFE-coated cap liner maintained long-term performance 
      of 0.3-mg Nitrostat tablets under laboratory and real-world conditions. This 
      storage device is now commercially available as the SMHeartCard to improve 
      compliance and provide immediate access to emergency cardiac medications.
CI  - Copyright 2020, Joule Inc. or its licensors.
FAU - Le, Tyson
AU  - Le T
AD  - Faculties of Pharmacy and Pharmaceutical Sciences (Le, Davies) and of Medicine 
      and Dentistry (Paterson), University of Alberta; Alberta Health Services 
      (Mackey), Cross Cancer Institute, Edmonton, Alta.
FAU - Paterson, D Ian
AU  - Paterson DI
AD  - Faculties of Pharmacy and Pharmaceutical Sciences (Le, Davies) and of Medicine 
      and Dentistry (Paterson), University of Alberta; Alberta Health Services 
      (Mackey), Cross Cancer Institute, Edmonton, Alta.
FAU - Davies, Neal M
AU  - Davies NM
AD  - Faculties of Pharmacy and Pharmaceutical Sciences (Le, Davies) and of Medicine 
      and Dentistry (Paterson), University of Alberta; Alberta Health Services 
      (Mackey), Cross Cancer Institute, Edmonton, Alta.
FAU - Mackey, John R
AU  - Mackey JR
AD  - Faculties of Pharmacy and Pharmaceutical Sciences (Le, Davies) and of Medicine 
      and Dentistry (Paterson), University of Alberta; Alberta Health Services 
      (Mackey), Cross Cancer Institute, Edmonton, Alta. 
      john.mackey@albertahealthservices.ca.
LA  - eng
GR  - R21 CA180764/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200211
PL  - Canada
TA  - CMAJ Open
JT  - CMAJ open
JID - 101620603
RN  - 0 (Tablets)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
MH  - *Aspirin/administration & dosage
MH  - Coronary Artery Disease
MH  - *Drug Packaging
MH  - Drug Stability
MH  - *Emergency Medical Services/methods
MH  - Humans
MH  - *Nitroglycerin/administration & dosage
MH  - Tablets
MH  - Temperature
PMC - PMC7012633
COIS- Competing interests: John Mackey holds shares in the SMHeartCard. No other 
      competing interests were declared.
EDAT- 2020/02/13 06:00
MHDA- 2020/02/13 06:01
CRDT- 2020/02/13 06:00
PHST- 2020/02/13 06:00 [entrez]
PHST- 2020/02/13 06:00 [pubmed]
PHST- 2020/02/13 06:01 [medline]
AID - 8/1/E75 [pii]
AID - cmajo.20190147 [pii]
AID - 10.9778/cmajo.20190147 [doi]
PST - epublish
SO  - CMAJ Open. 2020 Feb 11;8(1):E75-E82. doi: 10.9778/cmajo.20190147. Print 2020 
      Jan-Mar.

PMID- 26289738
OWN - NLM
STAT- MEDLINE
DCOM- 20161019
LR  - 20161230
IS  - 1365-2893 (Electronic)
IS  - 1352-0504 (Linking)
VI  - 23
IP  - 1
DP  - 2016 Jan
TI  - Aspirin inhibits hepatitis C virus entry by downregulating claudin-1.
PG  - 62-4
LID - 10.1111/jvh.12446 [doi]
AB  - Aspirin has previously been reported to inhibit hepatitis C virus (HCV) 
      replication. The aim of this study was to investigate whether aspirin is involved 
      in blocking HCV entry. We found that aspirin inhibits the entry of HCVpp and 
      infectious HCV. The level of claudin-1, an HCV receptor, is reduced by aspirin. 
      Our results extend the anti-HCV effect of aspirin to the HCV entry step and 
      further reinforce the anti-HCV role of aspirin.
CI  - © 2015 John Wiley & Sons Ltd.
FAU - Yin, P
AU  - Yin P
AD  - MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen 
      Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 
      Beijing, China.
FAU - Zhang, L
AU  - Zhang L
AD  - MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen 
      Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150820
PL  - England
TA  - J Viral Hepat
JT  - Journal of viral hepatitis
JID - 9435672
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Claudin-1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cell Line
MH  - Claudin-1/*biosynthesis
MH  - Down-Regulation/drug effects
MH  - Hepacivirus/*drug effects/growth & development
MH  - Humans
MH  - Virus Internalization/*drug effects
OTO - NOTNLM
OT  - aspirin
OT  - claudin-1
OT  - hepatitis C virus entry
EDAT- 2015/08/21 06:00
MHDA- 2016/11/12 06:00
CRDT- 2015/08/21 06:00
PHST- 2015/04/10 00:00 [received]
PHST- 2015/07/16 00:00 [accepted]
PHST- 2015/08/21 06:00 [entrez]
PHST- 2015/08/21 06:00 [pubmed]
PHST- 2016/11/12 06:00 [medline]
AID - 10.1111/jvh.12446 [doi]
PST - ppublish
SO  - J Viral Hepat. 2016 Jan;23(1):62-4. doi: 10.1111/jvh.12446. Epub 2015 Aug 20.

PMID- 1277441
OWN - NLM
STAT- MEDLINE
DCOM- 19760823
LR  - 20191021
IS  - 0009-9090 (Print)
IS  - 0009-9090 (Linking)
VI  - 6
IP  - 2
DP  - 1976 Mar
TI  - The diagnosis of aspirin idiosyncrasy by analgesic challenge.
PG  - 177-81
AB  - Analgesic challenge was employed to identify fifty patients with aspirin 
      idiosyncrasy. No serious reactions were observed using the method described. 
      Patients with a history of the condition were highly sensitive and reacted to 
      small doses of aspirin or to paracetamol. Patients with a positive challenge 
      test, but previously unaware of aspirin idiosyncrasy, were less sensitive: they 
      required larger challenge doses of aspirin and did not respond to paracetamol 
      challenge. In the absence of an in vitro test, analgesic challenge is the only 
      means of confirming the presence of aspirin idiosyncrasy.
FAU - Delaney, J C
AU  - Delaney JC
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Allergy
JT  - Clinical allergy
JID - 0311172
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Airway Obstruction
MH  - Aspirin/*adverse effects
MH  - Asthma/complications
MH  - Drug Hypersensitivity/*diagnosis
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Hypersensitivity/complications
MH  - Male
MH  - Middle Aged
MH  - Vital Capacity
EDAT- 1976/03/01 00:00
MHDA- 1976/03/01 00:01
CRDT- 1976/03/01 00:00
PHST- 1976/03/01 00:00 [pubmed]
PHST- 1976/03/01 00:01 [medline]
PHST- 1976/03/01 00:00 [entrez]
AID - 10.1111/j.1365-2222.1976.tb01896.x [doi]
PST - ppublish
SO  - Clin Allergy. 1976 Mar;6(2):177-81. doi: 10.1111/j.1365-2222.1976.tb01896.x.

PMID- 22542149
OWN - NLM
STAT- MEDLINE
DCOM- 20130320
LR  - 20211021
IS  - 1532-1916 (Electronic)
IS  - 1521-6918 (Print)
IS  - 1521-6918 (Linking)
VI  - 26
IP  - 2
DP  - 2012 Apr
TI  - Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and 
      cold.
PG  - 101-12
LID - 10.1016/j.bpg.2012.01.008 [doi]
AB  - AIMS: To analyse major sources of evidence-based information on the efficacy and 
      gastrointestinal tolerability of aspirin, used short-term, in over-the-counter 
      (OTC) doses, to relieve acute pain and cold symptoms, including associated 
      feverishness. METHODS: Evidence was largely collected from published 
      meta-analyses and systematic reviews that focused on randomised, controlled, 
      double-blind clinical trials, in which aspirin was compared to placebo and, in 
      some cases also, to active comparators such as OTC doses of paracetamol or 
      ibuprofen. RESULTS: Across a large number of comparisons, aspirin was superior to 
      placebo in treating pain, cold or fever. Efficacy was essentially similar to that 
      of comparators used in equivalent doses. There was no serious GI adverse event 
      attributed to ASA in any study, but mild-to-moderate dyspepsia in small 
      percentages of cases was commonly reported. CONCLUSION: OTC aspirin is safe and 
      effective. Safety concerns should not limit brief use to relieve acute pain, cold 
      or fever.
CI  - Copyright © 2012. Published by Elsevier Ltd.
FAU - McCarthy, Denis M
AU  - McCarthy DM
AD  - Division of Gastroenterology and Hepatology, University of New Mexico, School of 
      Medicine, USA. denis.mccarthy2@va.gov
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Gastroenterol
JT  - Best practice & research. Clinical gastroenterology
JID - 101120605
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Common Cold/*drug therapy
MH  - Dyspepsia/chemically induced/drug therapy
MH  - Fever/drug therapy
MH  - Gastrointestinal Tract/drug effects
MH  - Humans
MH  - Ibuprofen/administration & dosage/adverse effects
MH  - Nonprescription Drugs/*administration & dosage/therapeutic use
MH  - Pain/*drug therapy
PMC - PMC7185399
EDAT- 2012/05/01 06:00
MHDA- 2013/03/21 06:00
CRDT- 2012/05/01 06:00
PHST- 2011/12/02 00:00 [received]
PHST- 2012/01/07 00:00 [accepted]
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
AID - S1521-6918(12)00009-1 [pii]
AID - 10.1016/j.bpg.2012.01.008 [doi]
PST - ppublish
SO  - Best Pract Res Clin Gastroenterol. 2012 Apr;26(2):101-12. doi: 
      10.1016/j.bpg.2012.01.008.

PMID- 31845990
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20200617
IS  - 1464-3685 (Electronic)
IS  - 0300-5771 (Linking)
VI  - 49
IP  - 1
DP  - 2020 Feb 1
TI  - Low-dose aspirin use and endometrial cancer mortality-a Danish nationwide cohort 
      study.
PG  - 330-337
LID - 10.1093/ije/dyz253 [doi]
AB  - BACKGROUND: Accumulating evidence suggests that aspirin use may improve survival 
      in cancer patients, however, for endometrial cancer, epidemiological evidence is 
      limited and results are equivocal. In a nationwide cohort study, we examined the 
      association between post-diagnostic low-dose aspirin use and endometrial cancer 
      mortality. METHODS: From the Danish Cancer Registry, we identified all women with 
      a primary diagnosis of endometrial cancer. Women diagnosed between 2000 and 2012, 
      aged 30-84 years, who had no history of cancer (except non-melanoma skin cancer) 
      and were alive 1 year after the cancer diagnosis were eligible. We obtained 
      information on pre- and post-diagnostic use (≥1 prescription) of low-dose 
      aspirin, mortality and potential confounding factors from nationwide registries. 
      Using Cox regression models, we estimated adjusted hazard ratios (HRs) and 95% 
      confidence intervals (CIs) for the association between post-diagnostic low-dose 
      aspirin use and endometrial cancer mortality. The exposure was modelled as both 
      time-varying as well as time-fixed within exposure windows of 1 and 5 years. 
      RESULTS: We identified 6694 endometrial cancer patients with a maximum follow-up 
      of 13 years. In the time-varying analysis, post-diagnostic low-dose aspirin use 
      was associated with a HR of 1.10 (95% CI 0.90-1.33) for endometrial cancer 
      mortality. We found no indication of a dose-response association according to 
      increasing tablet strength, cumulative amount or duration of use, and the HRs 
      were similar for pre-diagnostic and post-diagnostic low-dose aspirin use compared 
      with non-use. CONCLUSIONS: We found no indication that post-diagnostic low-dose 
      aspirin use was associated with reduced mortality for endometrial cancer; rather 
      our findings suggested a concern for increased mortality.
CI  - © The Author(s) 2019; all rights reserved. Published by Oxford University Press 
      on behalf of the International Epidemiological Association.
FAU - Sperling, Cecilie D
AU  - Sperling CD
AD  - Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 
      Copenhagen, Denmark.
FAU - Verdoodt, Freija
AU  - Verdoodt F
AD  - Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 
      Copenhagen, Denmark.
FAU - Aalborg, Gitte L
AU  - Aalborg GL
AD  - Unit of Statistics and Pharmacoepidemiology, Danish Cancer Society Research 
      Center, Copenhagen, Denmark.
FAU - Dehlendorff, Christian
AU  - Dehlendorff C
AD  - Unit of Statistics and Pharmacoepidemiology, Danish Cancer Society Research 
      Center, Copenhagen, Denmark.
FAU - Friis, Søren
AU  - Friis S
AD  - Unit of Statistics and Pharmacoepidemiology, Danish Cancer Society Research 
      Center, Copenhagen, Denmark.
FAU - Kjaer, Susanne K
AU  - Kjaer SK
AD  - Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 
      Copenhagen, Denmark.
AD  - Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, 
      Denmark.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Epidemiol
JT  - International journal of epidemiology
JID - 7802871
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cause of Death
MH  - Cohort Studies
MH  - Denmark/epidemiology
MH  - Endometrial Neoplasms/*mortality
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Registries
MH  - Risk Factors
MH  - Survival Analysis
OTO - NOTNLM
OT  - Low-dose aspirin
OT  - anti-neoplastic drugs
OT  - cancer mortality
OT  - chemoprevention
OT  - endometrial cancer
EDAT- 2019/12/18 06:00
MHDA- 2020/06/18 06:00
CRDT- 2019/12/18 06:00
PHST- 2019/11/13 00:00 [received]
PHST- 2019/11/13 00:00 [accepted]
PHST- 2019/12/18 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PHST- 2019/12/18 06:00 [entrez]
AID - 5679830 [pii]
AID - 10.1093/ije/dyz253 [doi]
PST - ppublish
SO  - Int J Epidemiol. 2020 Feb 1;49(1):330-337. doi: 10.1093/ije/dyz253.

PMID- 21286842
OWN - NLM
STAT- MEDLINE
DCOM- 20111207
LR  - 20211020
IS  - 1863-4362 (Electronic)
IS  - 0021-1265 (Linking)
VI  - 180
IP  - 3
DP  - 2011 Sep
TI  - Aspirin for lower limb arthroplasty thromboprophylaxis: review of international 
      guidelines.
PG  - 627-32
LID - 10.1007/s11845-010-0658-0 [doi]
AB  - INTRODUCTION: Aspirin is one of the pharmacological agents used for 
      thromboprophylaxis. MATERIALS AND METHODS: National thromboprophylaxis 
      guidelines, peer-reviewed studies and data from national joint register of 
      England and Wales were analysed for evidence regarding the efficacy of aspirin 
      versus other agents in thromboprophylaxis and the recommendations of guidelines. 
      RESULTS: Two of five guidelines reviewed recommend the use of aspirin for 
      thromboprophylaxis. Aspirin is used as thromboprophylactic agent in approximately 
      25% of patients undergoing total hip and total knee arthroplasty in year 2006 in 
      England and Wales. There is no difference in mortality in these patients compared 
      to patients on other pharmacological agents. CONCLUSION: There is conflicting 
      evidence and differences in interpretation of the data from the literature. If 
      specific outcome measures and complications such as symptomatic DVT, PE and 
      bleeding were logged in arthroplasty registers, the resulting data would be 
      useful in individualised decision-making.
FAU - Donohoe, C L
AU  - Donohoe CL
AD  - Trinity College, Dublin, Ireland. donohoe.claire@gmail.com
FAU - Sayana, M K
AU  - Sayana MK
FAU - Thakral, R
AU  - Thakral R
FAU - Niall, D M
AU  - Niall DM
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20101214
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Polysaccharides)
RN  - J177FOW5JL (Fondaparinux)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - *Arthroplasty, Replacement, Hip
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/*therapeutic use
MH  - Fondaparinux
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Lower Extremity/surgery
MH  - Polysaccharides/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Pulmonary Embolism/*prevention & control
MH  - Venous Thrombosis/*prevention & control
EDAT- 2011/02/03 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/02/03 06:00
PHST- 2010/04/19 00:00 [received]
PHST- 2010/11/30 00:00 [accepted]
PHST- 2011/02/03 06:00 [entrez]
PHST- 2011/02/03 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 10.1007/s11845-010-0658-0 [doi]
PST - ppublish
SO  - Ir J Med Sci. 2011 Sep;180(3):627-32. doi: 10.1007/s11845-010-0658-0. Epub 2010 
      Dec 14.

PMID- 11508772
OWN - NLM
STAT- MEDLINE
DCOM- 20020110
LR  - 20191105
IS  - 0265-2048 (Print)
IS  - 0265-2048 (Linking)
VI  - 18
IP  - 5
DP  - 2001 Sep-Oct
TI  - Impregnation and release of aspirin from chitosan/poly(acrylic acid) graft 
      copolymer microspheres.
PG  - 679-84
AB  - The purpose of this study was to produce aspirin-impregnated microspheres of 
      chitosan/poly(acrylic acid) copolymer in order to evaluate the release 
      characteristics as a function of pH, simulating the fluids in the 
      gastrointestinal tract. Chitosan microspheres were obtained by the 
      coacervation-phase separation method, induced by the addition of a non-solvent 
      (NaOH 2.0 M solution). The microspheres were cross-linked with glutaraldehyde, 
      reduced with sodium cianoborohydride and grafted with poly(acrylic acid). The 
      impregnation of aspirin into chitosan/poly(acrylic acid) copolymer microspheres 
      was achieved by the dissolution of the drug in water:ethanol (2:1), which was 
      adsorbed by the microspheres for 24h at 25 degrees C. The efficiency of aspirin 
      impregnation was high (approximately 94%). The approach employed herein in the 
      production of aspirin-impregnated microspheres using chitosan/poly(acrylic acid) 
      can be a suitable drug-release control system.
FAU - Nascimento, A
AU  - Nascimento A
AD  - Departamento de Química, Universidade Estadual de Ponta Grossa, Brazil.
FAU - Laranjeira, M C
AU  - Laranjeira MC
FAU - Fávere, V T
AU  - Fávere VT
FAU - Josué, A
AU  - Josué A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Microencapsul
JT  - Journal of microencapsulation
JID - 8500513
RN  - 0 (Acrylic Resins)
RN  - 1398-61-4 (Chitin)
RN  - 4Q93RCW27E (carbopol 940)
RN  - 9012-76-4 (Chitosan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acrylic Resins/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Chitin/*administration & dosage/analogs & derivatives
MH  - Chitosan
MH  - *Drug Delivery Systems
MH  - Hydrogen-Ion Concentration
MH  - Microspheres
EDAT- 2001/08/18 10:00
MHDA- 2002/01/11 10:01
CRDT- 2001/08/18 10:00
PHST- 2001/08/18 10:00 [pubmed]
PHST- 2002/01/11 10:01 [medline]
PHST- 2001/08/18 10:00 [entrez]
AID - 10.1080/02652040010019451 [doi]
PST - ppublish
SO  - J Microencapsul. 2001 Sep-Oct;18(5):679-84. doi: 10.1080/02652040010019451.

PMID- 24838707
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20181202
IS  - 1552-4965 (Electronic)
IS  - 1549-3296 (Linking)
VI  - 103
IP  - 3
DP  - 2015 Mar
TI  - Nitric oxide secretion by endothelial cells in response to fluid shear stress, 
      aspirin, and temperature.
PG  - 1231-7
LID - 10.1002/jbm.a.35233 [doi]
AB  - Current vascular grafts have a high incidence of failure, especially in the 
      grafts less than 6 mm in diameter, due to thrombus formation. Nitric oxide (NO) 
      is released by endothelium and has some beneficial influences such as an 
      antithrombotic effect. We hypothesized that applying different shear stress 
      regiments and low temperature or aspirin would result in an increase in the 
      amount of NO release from human umbilical vein endothelial cells (HUVECs) and 
      decrease in platelet aggregation in the same manner as expected in vivo. HUVECs 
      were cultured into the intraluminal surface of silicone tubes. HUVECs were 
      subjected for 60 min to different parameters of shear stress, temperature, 
      aspirin, and platelets or a combination in a perfusion bioreactor by monitoring 
      NO secretion. We found that shear stress leads to an elevation of NO production 
      in HUVECS, independent of the shear stress magnitude (0.9 or 1.8 dyne/cm(2)). The 
      magnitude of this response increased with a decrease in temperature. Our results 
      also show that by addition of platelets in combination with aspirin to media 
      circulation, no thrombus formation occurred during the test time. Presence of 
      aspirin resulted in marked increase in NO levels. In conclusion, shear stresses, 
      temperature lowering, and aspirin increase the amount of NO release from HUVECs. 
      Also no thrombus formation was detected in our experimental setting.
CI  - © 2014 Wiley Periodicals, Inc.
FAU - Kabirian, Fatemeh
AU  - Kabirian F
AD  - Department of Life Science Engineering, Faculty of Interdisciplinary New Sciences 
      and Technologies, University of Tehran, Tehran, Iran.
FAU - Amoabediny, Ghassem
AU  - Amoabediny G
FAU - Haghighipour, Nooshin
AU  - Haghighipour N
FAU - Salehi-Nik, Nasim
AU  - Salehi-Nik N
FAU - Zandieh-Doulabi, Behrouz
AU  - Zandieh-Doulabi B
LA  - eng
PT  - Journal Article
DEP - 20141030
PL  - United States
TA  - J Biomed Mater Res A
JT  - Journal of biomedical materials research. Part A
JID - 101234237
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cells, Cultured
MH  - *Hot Temperature
MH  - Human Umbilical Vein Endothelial Cells/cytology/*metabolism
MH  - Humans
MH  - Nitric Oxide/*metabolism
MH  - Shear Strength
MH  - Stress, Physiological/*drug effects
OTO - NOTNLM
OT  - aspirin
OT  - endothelial cells
OT  - nitric oxide
OT  - shear stress
OT  - temperature
EDAT- 2014/05/20 06:00
MHDA- 2015/10/27 06:00
CRDT- 2014/05/20 06:00
PHST- 2013/12/17 00:00 [received]
PHST- 2014/04/18 00:00 [revised]
PHST- 2014/05/15 00:00 [accepted]
PHST- 2014/05/20 06:00 [entrez]
PHST- 2014/05/20 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
AID - 10.1002/jbm.a.35233 [doi]
PST - ppublish
SO  - J Biomed Mater Res A. 2015 Mar;103(3):1231-7. doi: 10.1002/jbm.a.35233. Epub 2014 
      Oct 30.

PMID- 36583976
OWN - NLM
STAT- MEDLINE
DCOM- 20230103
LR  - 20230404
IS  - 1558-2035 (Electronic)
IS  - 1558-2027 (Linking)
VI  - 24
IP  - 2
DP  - 2023 Feb 1
TI  - Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines 
      to clinical practice.
PG  - 77-86
LID - 10.2459/JCM.0000000000001399 [doi]
AB  - The assessment of bleeding and ischemic risk is a crucial step in establishing 
      appropriate composition and duration of dual antiplatelet therapy (DAPT) in 
      patients with acute coronary syndrome (ACS) treated with percutaneous coronary 
      angioplasty. Evidence from recent randomized clinical trials led to some paradigm 
      shifts in current guidelines recommendations. Options alternative to the standard 
      12-month DAPT duration include shorter periods of DAPT followed by single 
      antiplatelet treatment with either aspirin or P2Y12 monotherapy, guided or 
      unguided de-escalation DAPT, prolonged DAPT beyond the 12-month treatment period. 
      Although DAPT composition and duration should be selected for each ACS patient on 
      an individual basis weighing clinical and procedural variables, data from latest 
      trials and meta-analyses may permit suggesting the most appropriate DAPT strategy 
      according to the ischemic and bleeding risk assessed using validated tools and 
      scores.
CI  - Copyright © 2022 Italian Federation of Cardiology - I.F.C. All rights reserved.
FAU - De Servi, Stefano
AU  - De Servi S
AD  - Department of Molecular Medicine, University of Pavia Medical School, Pavia, 
      Italy.
FAU - Landi, Antonio
AU  - Landi A
AD  - Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale 
      (EOC), Lugano, Switzerland.
FAU - Savonitto, Stefano
AU  - Savonitto S
AD  - Division of Cardiology, Manzoni Hospital, Lecco.
FAU - De Luca, Leonardo
AU  - De Luca L
AD  - Department of Cardiovascular Sciences, A.O. San Camillo-Forlanini, Roma.
FAU - De Luca, Giuseppe
AU  - De Luca G
AD  - Clinical and Experimental Cardiology Unit, Azienda Ospedaliera-Universitaria di 
      Sassari, University of Sassari, Sassari.
AD  - Clinical and Interventional Cardiology, Istituto Clinico Sant'Ambrogio, Gruppo 
      San Donato.
FAU - Morici, Nuccia
AU  - Morici N
AD  - IRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi ONLUS.
FAU - Montalto, Claudio
AU  - Montalto C
AD  - Interventional Cardiology, De Gasperis Cardio Center, Niguarda Hospital, Milan.
FAU - Crimi, Gabriele
AU  - Crimi G
AD  - Interventional Cardiology Unit, Cardio-Thoraco Vascular Department (DICATOV), 
      IRCCS Ospedale Policlinico San Martino, Genova.
FAU - Cattaneo, Marco
AU  - Cattaneo M
AD  - Fondazione Arianna Anticoagulazione, Bologna, Italy.
LA  - eng
PT  - Journal Article
DEP - 20221115
PL  - United States
TA  - J Cardiovasc Med (Hagerstown)
JT  - Journal of cardiovascular medicine (Hagerstown, Md.)
JID - 101259752
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Platelet Aggregation Inhibitors
MH  - *Acute Coronary Syndrome/drug therapy/etiology
MH  - Aspirin/therapeutic use
MH  - Hemorrhage/etiology
MH  - Dual Anti-Platelet Therapy
MH  - Drug Therapy, Combination
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Treatment Outcome
EDAT- 2022/12/31 06:00
MHDA- 2023/01/04 06:00
CRDT- 2022/12/30 13:03
PHST- 2022/12/30 13:03 [entrez]
PHST- 2022/12/31 06:00 [pubmed]
PHST- 2023/01/04 06:00 [medline]
AID - 01244665-202302000-00001 [pii]
AID - 10.2459/JCM.0000000000001399 [doi]
PST - ppublish
SO  - J Cardiovasc Med (Hagerstown). 2023 Feb 1;24(2):77-86. doi: 
      10.2459/JCM.0000000000001399. Epub 2022 Nov 15.

PMID- 31449151
OWN - NLM
STAT- MEDLINE
DCOM- 20191220
LR  - 20201209
IS  - 1550-5111 (Electronic)
IS  - 0887-9303 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Oct/Dec
TI  - Acute Respiratory Distress Syndrome Novel Therapies.
PG  - 411-416
LID - 10.1097/CNQ.0000000000000281 [doi]
AB  - Acute respiratory distress syndrome (ARDS) was first described in 1967. Since 
      then, several landmark studies have been published that have greatly influenced 
      the way we diagnose and treat patients with ARDS. Despite extensive research and 
      advancements in ventilator strategies, moderate-severe ARDS has been associated 
      with high mortality rates. Current treatment remains primarily supportive with 
      lung-protective ventilation strategies. Pharmacological therapies that reduce the 
      severity of lung injury in vivo and in vitro have not yet translated into 
      effective clinical treatment options. Currently, the mortality rate of severe 
      ARDS remains in the range of 30% to 40%. To review, the mainstay of ARDS 
      management includes mechanical ventilation with low tidal volumes to decrease 
      barotrauma, prone ventilation, conservative fluid management, and neuromuscular 
      blockade. ARDS survivors tend to have long-term and potentially permanent 
      neuromuscular, cognitive, and psychological symptoms, affecting patient's quality 
      of life posthospitalization. These long-term effects are likely secondary to 
      prolonged hospitalizations, prolonged mechanical ventilation, utilization of 
      prone strategies, utilization of paralytic drugs, and occasionally steroids. 
      Therefore, several novel therapies outside the realm of advanced ventilation and 
      prone positioning methods are being studied. In this article, we discuss a few of 
      these novel therapies including prophylactic aspirin, inhaled nitric oxide, 
      mesenchymal stem cells, and intravenous β-agonists. Steroids and extracorporeal 
      membrane oxygenation have been discussed in a previous article.
FAU - Ma, Kiet
AU  - Ma K
AD  - Division of Pulmonary-Critical Care, Allegheny General Hospital, Allegheny Health 
      Network, Pittsburgh, Pennsylvania.
FAU - Patel, Kaushal
AU  - Patel K
FAU - Naddour, Mouhib
AU  - Naddour M
FAU - Virani, Ahmed
AU  - Virani A
FAU - Adurty, Rajashekar
AU  - Adurty R
FAU - AlhajHusain, Ahmad
AU  - AlhajHusain A
FAU - Cheema, Tariq
AU  - Cheema T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Crit Care Nurs Q
JT  - Critical care nursing quarterly
JID - 8704517
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
MH  - Administration, Inhalation
MH  - Aspirin/administration & dosage
MH  - Humans
MH  - Mesenchymal Stem Cells
MH  - Nitric Oxide
MH  - Respiration, Artificial
MH  - Respiratory Distress Syndrome/mortality/physiopathology/*therapy
EDAT- 2019/08/27 06:00
MHDA- 2019/12/21 06:00
CRDT- 2019/08/27 06:00
PHST- 2019/08/27 06:00 [entrez]
PHST- 2019/08/27 06:00 [pubmed]
PHST- 2019/12/21 06:00 [medline]
AID - 00002727-201910000-00009 [pii]
AID - 10.1097/CNQ.0000000000000281 [doi]
PST - ppublish
SO  - Crit Care Nurs Q. 2019 Oct/Dec;42(4):411-416. doi: 10.1097/CNQ.0000000000000281.

PMID- 8147629
OWN - NLM
STAT- MEDLINE
DCOM- 19940429
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 57
IP  - 3
DP  - 1994 Mar
TI  - Spontaneous closure of fenestrations in an interatrial Gore-Tex patch: 
      application to the Fontan procedure.
PG  - 611-4
AB  - The concept of the partial Fontan procedure, first described with the adjustable 
      atrial septal defect (ASD) and more recently with the fenestrated technique, has 
      become an accepted approach for the management of high-risk patients undergoing 
      the Fontan procedure. Experience with both techniques has shown that a patent ASD 
      placed in a prosthetic interatrial baffle may close spontaneously over a period 
      of weeks to months. The mechanism and timing of spontaneous closure, as well as 
      the effect of antiplatelet therapy on this process, are poorly understood. To 
      better define this process, the interatrial septum of 15 mongrel dogs was excised 
      and replaced with a fenestrated Gore-Tex (W.L. Gore, Flagstaff, AZ) patch. 
      Postoperative echocardiography confirmed the patency of the ASD and left-to-right 
      shunting. Animals were sacrificed 4 to 6 weeks postoperatively, or sooner if 
      infection or other postoperative complications developed. Eight animals underwent 
      no antiplatelet or anticoagulation therapy postoperatively, and 7 received 
      antiplatelet therapy with aspirin. Patches were removed at the end of the study 
      period and analyzed. By 6 weeks, all 2.7-mm and 4-mm holes had closed 
      spontaneously in all animals that had not received antiplatelet therapy. The 
      earliest closure occurred at 1 week. With antiplatelet therapy, hole closure was 
      found to be delayed but not prevented, and was complete by 6 weeks in all but 1 
      animal. Histologic examination of the explanted patches revealed that closure was 
      accomplished primarily through the ingrowth of fibrous tissue, accompanied by an 
      inflammatory cell infiltrate.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Pearl, J M
AU  - Pearl JM
AD  - Department of Surgery, University of California, Los Angeles Medical School.
FAU - Laks, H
AU  - Laks H
FAU - Barthell, S
AU  - Barthell S
FAU - Drinkwater, D C Jr
AU  - Drinkwater DC Jr
FAU - Capouya, E R
AU  - Capouya ER
FAU - Chang, P A
AU  - Chang PA
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Blood Platelets/drug effects
MH  - *Blood Vessel Prosthesis
MH  - Cardiac Surgical Procedures/methods
MH  - Dogs
MH  - Fibrosis
MH  - Heart Atria/*surgery
MH  - Heart Septum/pathology/surgery
MH  - *Polytetrafluoroethylene
MH  - Porosity
MH  - Pulmonary Artery/*surgery
EDAT- 1994/03/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
AID - 0003-4975(94)90553-3 [pii]
AID - 10.1016/0003-4975(94)90553-3 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1994 Mar;57(3):611-4. doi: 10.1016/0003-4975(94)90553-3.

PMID- 30994169
OWN - NLM
STAT- MEDLINE
DCOM- 20200120
LR  - 20200120
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 76
IP  - Supplement_2
DP  - 2019 May 17
TI  - Direct oral anticoagulants versus aspirin for venous thromboembolism prophylaxis 
      after orthopedic surgery.
PG  - S55-S60
LID - 10.1093/ajhp/zxy080 [doi]
AB  - PURPOSE: The risks of venous thromboembolism (VTE) and bleeding with direct oral 
      anticoagulants (DOACs) and aspirin for thromboprophylaxis after orthopedic 
      surgery were studied. METHODS: A single center, retrospective study was conducted 
      to examine patients who underwent a major orthopedic surgery from 2011 to 2015. 
      The primary endpoint evaluated was the net clinical outcome of bleeding and 
      thrombosis rates between the DOAC and aspirin groups. Secondary endpoints 
      included bleeding rates, thrombosis rates, transfusion rates, and 90-day 
      readmission rates. The primary endpoint was analyzed using adjusted logistic 
      regression model with propensity score added as an independent variable. RESULTS: 
      A total of 420 patients were included in this study. The proportion of patients 
      with composite primary outcome was similar between the groups (12.9% and 13.3%, 
      in the DOAC and aspirin groups, respectively; p > 0.5). VTE events were 
      numerically lower in the DOAC group, but the result was not statistically 
      significant. Readmission due to VTE or bleeding and bleeding events were also 
      similar between the groups. The DOAC group had a higher proportion of blood 
      transfusions of at least 2 units of blood postoperatively compared with the 
      aspirin group (p = 0.04). CONCLUSION: No difference in net clinical outcome was 
      observed in patients who received a DOAC or aspirin for VTE prophylaxis after 
      major orthopedic surgery.
CI  - © American Society of Health-System Pharmacists 2019. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Yang, Tianrui
AU  - Yang T
AD  - Houston Methodist Hospital, Houston, TX.
FAU - Murillo, Michelle
AU  - Murillo M
AD  - Houston Methodist Hospital, Houston, TX.
FAU - Vadhariya, Aisha
AU  - Vadhariya A
AD  - Department of Pharmaceutical Health Outcomes and Policy, University of Houston 
      College of Pharmacy, Houston, TX.
FAU - Wilson, Allison
AU  - Wilson A
AD  - Houston Methodist Hospital, Houston, TX.
FAU - Putney, David
AU  - Putney D
AD  - Houston Methodist Hospital, Houston, TX.
FAU - Muntz, James
AU  - Muntz J
AD  - Houston Methodist Hospital, Houston, TX.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Transfusion/statistics & numerical data
MH  - Female
MH  - Hemorrhage/chemically induced/epidemiology/therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Orthopedic Procedures/*adverse effects
MH  - Patient Readmission/statistics & numerical data
MH  - Postoperative Complications/epidemiology/etiology/*prevention & control
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Venous Thromboembolism/epidemiology/etiology/*prevention & control
OTO - NOTNLM
OT  - anticoagulant
OT  - aspirin
OT  - orthopedics
OT  - venous thromboembolism
EDAT- 2019/04/18 06:00
MHDA- 2020/01/21 06:00
CRDT- 2019/04/18 06:00
PHST- 2019/04/18 06:00 [pubmed]
PHST- 2020/01/21 06:00 [medline]
PHST- 2019/04/18 06:00 [entrez]
AID - 5474309 [pii]
AID - 10.1093/ajhp/zxy080 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2019 May 17;76(Supplement_2):S55-S60. doi: 
      10.1093/ajhp/zxy080.

PMID- 1414694
OWN - NLM
STAT- MEDLINE
DCOM- 19921120
LR  - 20190824
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 36
IP  - 1-2
DP  - 1992 May
TI  - Interaction studies of tilomisole, aspirin, and naproxen in acute and chronic 
      inflammation with assessment of gastrointestinal irritancy in the rat.
PG  - 99-106
AB  - The effect of combination NSAID therapy of tilomisole with aspirin or naproxen 
      was studied in rats with carrageenan-induced paw edema and established adjuvant 
      arthritis. Inflamed paws were measured using mercury plethysmography and the 
      arthritic paws were X-rayed to determine any bony/soft tissue changes. The 
      gastrointestinal tract was also examined for bleeding and ulceration. Tilomisole 
      had a less potent acute anti-inflammatory effect than aspirin or naproxen, but 
      produced no significant gastrointestinal damage. A significant reduction in 
      anti-inflammatory activity was observed with the tilomisole/aspirin combination 
      in acute inflammation. Only additive interactions were observed with the naproxen 
      inhibition. In the established arthritis assay, a significant synergistic 
      anti-inflammatory response, i.e. both inhibition of paw edema and bone erosion, 
      was also observed with the 80 and 93% tilomisole/naproxen combinations. The 
      gastric ulcerogenic effect of the combination paralleled its increased activity. 
      The synergism between tilomisole and naproxen in this chronic arthritic model may 
      be due to enhanced cyclooxygenase inhibitory activity. These drug interaction 
      studies suggest possible interactions in human clinical trials of rheumatoid 
      arthritis.
FAU - Calhoun, W
AU  - Calhoun W
AD  - Division of Experimental Therapeutics, Wyeth-Ayerst Research, Princeton, NJ 
      08543-8000.
FAU - Gilman, S C
AU  - Gilman SC
FAU - Datko, L J
AU  - Datko LJ
FAU - Copenhaver, T W
AU  - Copenhaver TW
FAU - Carlson, R P
AU  - Carlson RP
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Benzimidazoles)
RN  - 57Y76R9ATQ (Naproxen)
RN  - 651G60U372 (tilomisole)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Arthritis, Experimental/drug therapy
MH  - Aspirin/*pharmacology/toxicity
MH  - Benzimidazoles/*pharmacology/toxicity
MH  - Bone and Bones/drug effects/pathology
MH  - Carrageenan
MH  - Connective Tissue/drug effects/pathology
MH  - Drug Interactions
MH  - Edema/chemically induced/drug therapy
MH  - Gastrointestinal Diseases/*chemically induced/pathology
MH  - Inflammation/*drug therapy
MH  - Male
MH  - Naproxen/*pharmacology/toxicity
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
AID - 10.1007/BF01991236 [doi]
PST - ppublish
SO  - Agents Actions. 1992 May;36(1-2):99-106. doi: 10.1007/BF01991236.

PMID- 3873180
OWN - NLM
STAT- MEDLINE
DCOM- 19850614
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 248
IP  - 5 Pt 1
DP  - 1985 May
TI  - Characteristics of sudden potential drop in bullfrog gastric mucosa.
PG  - G587-93
AB  - An unusual sudden potential drop (SPD) has been described by Kidder in bullfrog 
      gastric mucosa exposed to anoxia and a serosal pH less than or equal to 7.1. We 
      found that anoxia was not a prerequisite, since under fully oxygenated conditions 
      the SPD occurred reliably in metiamide-treated tissues when the pH of the 
      nutrient solution (pHN) was below 7.1. The SPD was observed also in 
      metiamide-treated tissues exposed to 20 mM luminal or nutrient acetylsalicylic 
      acid (ASA) with pHN = 7.3, an effect that was abolished by increased nutrient 
      HCO3- concentration. The SPD occurred when NO3- but not isethionate or acetate 
      replaced Cl- in the bathing media. A marked increase in potential difference in 
      response to changing luminal Cl- concentration was observed after the SPD, uptake 
      of Cl- from the luminal solution into the tissue increased, but transmural fluxes 
      of Cl- decreased bidirectionally. Permeability to H+ was unaltered in the 
      post-SPD state. An SPD never occurred in antrum under conditions causing SPD in 
      fundus, suggesting that oxyntic cells are prerequisite. We conclude that, under 
      conditions which cause tissue or cellular acidosis and cessation of H+ secretion, 
      fundic mucosae respond with an anion-selective increase in apical permeability 
      manifest as the SPD.
FAU - Matthews, J B
AU  - Matthews JB
FAU - Rangachari, P K
AU  - Rangachari PK
FAU - Rowe, P H
AU  - Rowe PH
FAU - Lange, R
AU  - Lange R
FAU - Marrone, G
AU  - Marrone G
FAU - Silen, W
AU  - Silen W
LA  - eng
GR  - AM-15681/AM/NIADDK NIH HHS/United States
GR  - GM-07806/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Bicarbonates)
RN  - 0 (Chlorides)
RN  - 3K7670861M (Metiamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Bicarbonates/pharmacology
MH  - Chlorides/metabolism
MH  - Gastric Mucosa/*physiology
MH  - Membrane Potentials
MH  - Metiamide/pharmacology
MH  - Permeability
MH  - Rana catesbeiana
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
AID - 10.1152/ajpgi.1985.248.5.G587 [doi]
PST - ppublish
SO  - Am J Physiol. 1985 May;248(5 Pt 1):G587-93. doi: 10.1152/ajpgi.1985.248.5.G587.

PMID- 16796073
OWN - NLM
STAT- MEDLINE
DCOM- 20061010
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 29
IP  - 6
DP  - 2006 Jun
TI  - Prevention of vascular events in patients with cerebrovascular disease: efficacy 
      and appropriate duration of antiplatelet therapy.
PG  - 244-8
AB  - Antiplatelet therapy has shown consistent benefit in the prevention of secondary 
      stroke. The paucity of head-to-head studies of different antiplatelet regimens, 
      assessment of comparative efficacy, and optimal treatment duration requires 
      evaluation and comparison of clinical studies that vary extensively in design and 
      follow-up. Evidence for aspirin benefit in secondary stroke prevention is strong, 
      but existing studies provide little guidance with regard to treatment duration. 
      The efficacy of clopidogrel in secondary event prevention is significantly 
      greater than that of aspirin for patients with a history of peripheral artery 
      disease, but does not differ from that of aspirin for patients with a history of 
      stroke or myocardial infarction. Relative to clopidogrel alone, the addition of 
      aspirin to clopidogrel results in increased risk for life-threatening bleeding 
      episodes similar in absolute magnitude to the reduction of secondary event risk 
      in patients with stroke. Benefits associated with clopidogrel occur early in the 
      course of therapy; few data support clopidogrel use for longer than 1 year after 
      stroke. Monotherapy with extended-release dipyridamole (ER-DP) provides reduction 
      in secondary stroke risk similar to aspirin; however, the combination of aspirin 
      plus ER-DP significantly reduces risk relative to either agent alone. Compared 
      with placebo and monotherapy with either agent, risk reduction for the aspirin 
      plus ER-DP combination continued through 24 months, with no concomitant increase 
      in bleeding risk. Additional clinical studies should provide needed comparisons 
      of efficacy and guidance with regard to optimal duration of therapy.
FAU - Habib, Gabriel B
AU  - Habib GB
AD  - Section of Cardiology, Department of Medicine, Baylor College of Medicine, 
      Houston, Texas, USA. gabehabib@yahoo.com
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cerebrovascular Disorders/complications/*drug therapy
MH  - Clopidogrel
MH  - Dipyridamole/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Stroke/etiology/*prevention & control
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
PMC - PMC6654767
EDAT- 2006/06/27 09:00
MHDA- 2006/10/13 09:00
CRDT- 2006/06/27 09:00
PHST- 2006/06/27 09:00 [pubmed]
PHST- 2006/10/13 09:00 [medline]
PHST- 2006/06/27 09:00 [entrez]
AID - CLC4960290604 [pii]
AID - 10.1002/clc.4960290604 [doi]
PST - ppublish
SO  - Clin Cardiol. 2006 Jun;29(6):244-8. doi: 10.1002/clc.4960290604.

PMID- 2121503
OWN - NLM
STAT- MEDLINE
DCOM- 19901211
LR  - 20190824
IS  - 0014-2972 (Print)
IS  - 0014-2972 (Linking)
VI  - 20
IP  - 4
DP  - 1990 Aug
TI  - Gastric microvascular endothelium: a major target for aspirin-induced injury and 
      arachidonic acid protection. An ultrastructural analysis in the rat.
PG  - 432-40
AB  - Exposure of the gastric mucosa to aspirin results in exfoliation of the surface 
      epithelium and deep mucosal necrosis. We assessed the changes in the mucosal 
      microvessels during aspirin-induced injury and arachidonic acid protection of the 
      gastric mucosa using transmission electron microscopy. Male Sprague-Dawley rats 
      received intragastric pretreatment with either solubilizer (control) or detergent 
      solubilized arachidonic acid (148 mg kg-1). One hour later 1-ml suspension of 200 
      mg kg-1 body weight acidified aspirin was administered intragastrically. The 
      ultrastructure of mucosal microvasculature was assessed at 15 min and 4 h after 
      aspirin administration both qualitatively and quantitatively by determining the 
      number of necrotic or damaged capillaries in standardized mucosal sections. In 
      addition, mucosal specimens were immunostained with a specific antiserum against 
      vimentin, an endothelial marker, and fluorescence intensity was measured with a 
      Nikon FX microscopic photometric system. In control rats, aspirin produced 
      significant damage to both superficial and deeper microvessels consisting of: 
      rupture of capillary walls, necrosis of endothelial cells, damage to endothelial 
      organelles, deposition of fibrin and adherence of platelets to damaged 
      endothelium. Vimentin fluorescence was reduced three-fold. Microvascular injury 
      preceded the development of deep necrotic lesions. Microvascular damage and deep 
      mucosal necrosis were significantly reduced by arachidonic acid pretreatment. We 
      conclude that gastric mucosal microvessels are the major target for 
      aspirin-induced injury and arachidonic acid protection.
FAU - Tarnawski, A
AU  - Tarnawski A
AD  - Department of Veterans Affair Medical Center, Long Beach, California 90822.
FAU - Stachura, J
AU  - Stachura J
FAU - Gergely, H
AU  - Gergely H
FAU - Hollander, D
AU  - Hollander D
LA  - eng
GR  - R0I AM 32856/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Arachidonic Acids)
RN  - 0 (Vimentin)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/*therapeutic use
MH  - Aspirin/antagonists & inhibitors/*toxicity
MH  - Capillaries/drug effects/pathology
MH  - Endothelium, Vascular/*drug effects
MH  - Fluorescent Antibody Technique
MH  - Gastric Mucosa/blood supply/*drug effects/pathology
MH  - Immunohistochemistry
MH  - Male
MH  - Microscopy, Electron
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach Diseases/*chemically induced/pathology/prevention & control
MH  - Time Factors
MH  - Vimentin/analysis
EDAT- 1990/08/01 00:00
MHDA- 1990/08/01 00:01
CRDT- 1990/08/01 00:00
PHST- 1990/08/01 00:00 [pubmed]
PHST- 1990/08/01 00:01 [medline]
PHST- 1990/08/01 00:00 [entrez]
AID - 10.1111/j.1365-2362.1990.tb01881.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 1990 Aug;20(4):432-40. doi: 
      10.1111/j.1365-2362.1990.tb01881.x.

PMID- 15567446
OWN - NLM
STAT- MEDLINE
DCOM- 20050505
LR  - 20131121
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 115
IP  - 1-2
DP  - 2005
TI  - Evidence based treatment of the antiphospholipid syndrome II. Optimal 
      anticoagulant therapy for thrombosis.
PG  - 3-8
AB  - INTRODUCTION: Current consensus recommendations suggest that patients with 
      antiphospholipid antibodies (APLA) are at high risk of recurrent arterial or 
      venous thromboembolism (VTE) despite warfarin administered to achieve an 
      international normalized ratio (INR) of 2.0 to 3.0. These recommendations have 
      been called into question by three recently reported studies. METHODS: We sought 
      to determine the current "best practice" for the prevention of recurrent TE in 
      patients with APLA and TE. Data was derived from a MEDLINE search and review of 
      recent conference abstracts. The literature search was confined to studies of 
      treatment to prevent recurrent thrombosis in patients with APLA. RESULTS: The 
      overall proportion of patients suffering recurrent TE when allocated to 
      moderated-intensity warfarin (target INR of 2.0 to 3.0) was 5/113 (4.4%), and it 
      was 11/110 (10.0%) when such patients were randomized to high-intensity warfarin 
      (target INR of 3.0 to 4.0). APLA-positive patients with 
      noncardioembolic/nonatheroembolic stroke appear to have similar risks of 
      recurrent TE whether they are treated with warfarin or aspirin. DISCUSSION: 
      Patients with APLA and TE have an acceptable rate of recurrent TE if they are 
      treated with usual-intensity warfarin. Patients with APLA and stroke are probably 
      best treated with aspirin, while those with other forms of arterial TE are likely 
      best treated with moderate-intensity warfarin plus aspirin.
FAU - Crowther, Mark A
AU  - Crowther MA
AD  - Department of Medicine, McMaster University, Room L208 St Joseph's Hospital, 50 
      Charlton Avenue East, Hamilton, Ontario, Canada L8N 4A6. crowthrm@mcmaster.ca
FAU - Wisloff, Finn
AU  - Wisloff F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Antiphospholipid Syndrome/complications/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Thrombosis/*drug therapy
MH  - Treatment Outcome
MH  - Warfarin/therapeutic use
RF  - 18
EDAT- 2004/11/30 09:00
MHDA- 2005/05/06 09:00
CRDT- 2004/11/30 09:00
PHST- 2004/06/22 00:00 [received]
PHST- 2004/06/22 00:00 [revised]
PHST- 2004/06/23 00:00 [accepted]
PHST- 2004/11/30 09:00 [pubmed]
PHST- 2005/05/06 09:00 [medline]
PHST- 2004/11/30 09:00 [entrez]
AID - S0049-3848(04)00350-0 [pii]
AID - 10.1016/j.thromres.2004.06.041 [doi]
PST - ppublish
SO  - Thromb Res. 2005;115(1-2):3-8. doi: 10.1016/j.thromres.2004.06.041.

PMID- 24456320
OWN - NLM
STAT- MEDLINE
DCOM- 20140922
LR  - 20230823
IS  - 1944-706X (Electronic)
IS  - 1083-4087 (Print)
IS  - 1083-4087 (Linking)
VI  - 20
IP  - 2
DP  - 2014 Feb
TI  - Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet 
      therapy with aspirin and clopidogrel.
PG  - 187-93
LID - 10.18553/jmcp.2014.20.2.187
AB  - BACKGROUND: Dual antiplatelet therapy (DAPT) has been found to reduce the risk of 
      cardiac death, myocardial infarction, stroke, and stent thrombosis following 
      acute coronary syndrome and percutaneous coronary intervention. However, this 
      therapy has also been shown to increase the risk of gastrointestinal (GI) 
      bleeding as high as 2-fold, especially in patients with multiple risk factors. 
      Proton pump inhibitor (PPI) therapy decreases this risk. The current consensus 
      document on reducing GI risks associated with antiplatelet agents no longer 
      recommends PPI therapy for all patients receiving aspirin (ASA) and clopidogrel. 
      The consensus recommendation reserves PPI therapy for patients receiving DAPT 
      with a history of upper GI bleeding or prespecified risk factors for GI 
      bleeding.   OBJECTIVES: To (a) describe the use of GI prophylaxis in patients on 
      DAPT with ASA and clopidogrel and (b) assess the incidence of adverse outcomes 
      that occurred during readmissions within 6 months of the index hospitalization.   
      METHODS: A retrospective chart review of patients receiving DAPT between February 
      1, 2011, and October 15, 2011, was performed to assess the appropriateness of GI 
      prophylaxis based on the current consensus document. Therapy was defined as 
      appropriate if an indication for prophylaxis was present and PPI therapy was 
      prescribed, or if no indication was present and no GI prophylaxis was given. 
      Inappropriate prophylaxis was defined as no indication for GI prophylaxis yet 
      therapy received, or prophylaxis indicated but incorrect prophylaxis prescribed. 
      Incorrect prophylaxis included no prophylaxis, histamine H2 blocker therapy, 
      antacid, or combination therapy. During subsequent hospitalizations in the 
      6-month period following discharge from the index admission, patients were 
      assessed for the development of vascular-, GI-, and PPI-related adverse events.   
      RESULTS: 250 patients receiving DAPT during the study period were evaluated. 
      Gastrointestinal prophylaxis was appropriate in 48% (119/250) of patients. Of the 
      remaining patients, 56.4% (74/131) met guideline criteria for GI prophylaxis but 
      did not receive a PPI at discharge, whereas 43.5% (57/131) of patients received 
      GI prophylaxis when not indicated. Thirty-three adverse events were identified 
      during readmissions, with the most common type being vascular followed by GI and 
      PPI adverse events, respectively.   CONCLUSION: More than half of the patients 
      did not receive GI prophylaxis appropriately. The most common reason for 
      nonadherence to the consensus document was no prophylaxis when indicated. 
      Vascular events could not be directly attributed to PPI use, and GI events 
      occurred despite prophylaxis. Overall, there was a low incidence of adverse 
      events related to the use of PPI therapy. 
FAU - Morneau, Kathleen M
AU  - Morneau KM
AD  - Methodist University Hospital, Dept. of Pharmacy, 1265 Union Ave., Memphis, TN 
      38104, USA. Carrie.Oliphant@mlh.org.
FAU - Reaves, Anne B
AU  - Reaves AB
FAU - Martin, Julie B
AU  - Martin JB
FAU - Oliphant, Carrie S
AU  - Oliphant CS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Manag Care Pharm
JT  - Journal of managed care pharmacy : JMCP
JID - 9605854
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Guideline Adherence
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Readmission/statistics & numerical data
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - *Practice Guidelines as Topic
MH  - Proton Pump Inhibitors/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & 
      derivatives/therapeutic use
MH  - Treatment Outcome
PMC - PMC10437942
EDAT- 2014/01/25 06:00
MHDA- 2014/09/23 06:00
CRDT- 2014/01/25 06:00
PHST- 2014/01/25 06:00 [entrez]
PHST- 2014/01/25 06:00 [pubmed]
PHST- 2014/09/23 06:00 [medline]
AID - 2014(20)2: 187-193 [pii]
AID - 10.18553/jmcp.2014.20.2.187 [doi]
PST - ppublish
SO  - J Manag Care Pharm. 2014 Feb;20(2):187-93. doi: 10.18553/jmcp.2014.20.2.187.

PMID- 8717553
OWN - NLM
STAT- MEDLINE
DCOM- 19961129
LR  - 20190830
IS  - 0004-8666 (Print)
IS  - 0004-8666 (Linking)
VI  - 35
IP  - 4
DP  - 1995 Nov
TI  - Prevention of preeclampsia with heparin and antiplatelet drugs in women with 
      renal disease.
PG  - 357-62
AB  - In a retrospective cohort study of women with renal disease in pregnancy we 
      investigated if: 1. low dose aspirin reduced the prevalence of preeclampsia and 
      improved fetal outcome compared to no anticoagulant therapy. 2. heparin plus low 
      dose aspirin and/or dipyridamole reduced the prevalence of preeclampsia and 
      improved fetal outcome compared to i. no treatment ii. low dose aspirin alone. 
      Women with renal disease were allocated into 3 groups according to the treatment 
      received during their pregnancies: I. no prophylactic heparin or antiplatelet 
      drugs, n = 76 II. prophylactic low-dose aspirin 75(50-150)mg, n = 27 III. 
      prophylactic subcutaneous heparin 10,000 (5000-12,500) IU b.d. combined with 
      low-dose aspirin 50 (50-150)mg and/or dipyridamole 400 (200-400)mg, n = 44. 
      Preeclampsia and fetal outcome was analysed according to treatment group. 
      Preeclampsia was less common in the heparin group (2.3%) compared with 27.6% in 
      the no treatment group [O.R. 0.06 (0.01-0.30)] and 25.9% in the aspirin group 
      [O.R. 0.07 (0.01-0.38)]. Women on aspirin, who developed preeclampsia, delivered 
      later in pregnancy [35.4 (33-38.2) weeks] than preeclamptic women on no treatment 
      [29 (22-38) weeks], p = 0.04. There was a trend to reduced perinatal deaths in 
      the heparin + antiplatelet drug group, [2.3%; O.R., 0.17 (0.02-1.4)] and in the 
      aspirin group [0%, O.R., 0.13 (0.01-2.3)] compared with 11.7% perinatal deaths in 
      the no treatment group. Heparin with anti-platelet drugs may prevent preeclampsia 
      in high risk women with renal disease. Further investigation in a randomized 
      trial is indicated.
FAU - North, R A
AU  - North RA
AD  - Department of Obstetrics and Gynaecology, National Women's Hospital, Auckland, 
      New Zealand.
FAU - Ferrier, C
AU  - Ferrier C
FAU - Gamble, G
AU  - Gamble G
FAU - Fairley, K F
AU  - Fairley KF
FAU - Kincaid-Smith, P
AU  - Kincaid-Smith P
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust N Z J Obstet Gynaecol
JT  - The Australian & New Zealand journal of obstetrics & gynaecology
JID - 0001027
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - *Kidney Diseases
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 10.1111/j.1479-828x.1995.tb02141.x [doi]
PST - ppublish
SO  - Aust N Z J Obstet Gynaecol. 1995 Nov;35(4):357-62. doi: 
      10.1111/j.1479-828x.1995.tb02141.x.

PMID- 17973517
OWN - NLM
STAT- MEDLINE
DCOM- 20080103
LR  - 20181201
IS  - 1520-6106 (Print)
IS  - 1520-5207 (Linking)
VI  - 111
IP  - 46
DP  - 2007 Nov 22
TI  - Size effect on competition of two diffusion mechanisms for drug molecules in 
      amorphous polymers.
PG  - 13167-72
AB  - Diffusion of drug molecules in polymer materials is of great importance in 
      controlled drug release, and the investigation of the mechanism of drug release 
      from the polymer matrix would help us to understand the release behavior of the 
      controlled release system. In this work, molecular dynamics simulations were 
      employed to investigate the diffusion mechanisms of penetrant molecules with 
      different sizes in poly(lactic acid-co-ethylene glycol) (PLA-PEG). The size 
      effect on the diffusion mechanism of penetrant molecules in polymer matrixes was 
      discussed in detail. A competition mechanism in a two-step diffusion process-(1) 
      motion within the cavities (free volumes), and (2) jumps between cavities or 
      movement of the cavity itself originated from the wriggling of the polymer 
      chains-was observed, and the contributions of these two factors to the diffusion 
      coefficient were successfully separated. With the medium volume of penetrant 
      molecules (e.g., benzene), a competition between these two steps was observed. 
      Step (2) controlled the diffusion when penetrant molecules became bigger.
FAU - Zhao, Zhi-Jian
AU  - Zhao ZJ
AD  - Department of Chemistry, Zhejiang University, Hangzhou 310027, People's Republic 
      of China.
FAU - Wang, Qi
AU  - Wang Q
FAU - Zhang, Li
AU  - Zhang L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071101
PL  - United States
TA  - J Phys Chem B
JT  - The journal of physical chemistry. B
JID - 101157530
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Excipients)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Polymers)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - J64922108F (Benzene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Benzene/chemistry
MH  - Delayed-Action Preparations
MH  - Diffusion
MH  - Excipients
MH  - Lactic Acid
MH  - Models, Molecular
MH  - Molecular Conformation
MH  - Nifedipine/chemistry
MH  - Pharmaceutical Preparations/*chemistry
MH  - Polyglycolic Acid
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Polymers/*chemistry
EDAT- 2007/11/02 09:00
MHDA- 2008/01/04 09:00
CRDT- 2007/11/02 09:00
PHST- 2007/11/02 09:00 [pubmed]
PHST- 2008/01/04 09:00 [medline]
PHST- 2007/11/02 09:00 [entrez]
AID - 10.1021/jp074733i [doi]
PST - ppublish
SO  - J Phys Chem B. 2007 Nov 22;111(46):13167-72. doi: 10.1021/jp074733i. Epub 2007 
      Nov 1.

PMID- 10665552
OWN - NLM
STAT- MEDLINE
DCOM- 20000215
LR  - 20171116
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 355
IP  - 9201
DP  - 2000 Jan 29
TI  - Comparison of sibrafiban with aspirin for prevention of cardiovascular events 
      after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. 
      Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events 
      Post-acute Coronary Syndromes.
PG  - 337-45
AB  - BACKGROUND: Aspirin lowers risks of death and myocardial infarction in patients 
      with acute coronary syndromes. Intravenous glycoprotein IIb/IIIa receptor 
      antagonists further reduce the rates of ischaemic events in these patients, but 
      the efficacy of long-term oral glycoprotein IIb/IIIa receptor blockade has not 
      been established. We tested whether the oral glycoprotein IIb/IIIa receptor 
      antagonist sibrafiban would prevent more cardiovascular events than aspirin, when 
      given within 7 days of, and sustained for 90 days after, an acute coronary 
      syndrome event. METHODS: 9233 patients who had stabilised after an acute coronary 
      syndrome event were randomly assigned aspirin (80 mg orally twice daily) or 
      low-dose or high-dose sibrafiban. Sibrafiban doses (3.0 mg, 4.5 mg, or 6.0 mg) 
      were based on a model accounting for weight and serum creatinine and designed to 
      achieve at least 25% steady-state inhibition of platelet aggregation (low dose) 
      or at least 50% inhibition (high dose). The primary endpoint was the composite of 
      death, non-fatal infarction or reinfarction, or severe recurrent ischaemia at 90 
      days. Analysis was by intention to treat. FINDINGS: The 90-day rate of the 
      primary endpoint did not differ significantly between the groups assigned aspirin 
      (302 [9.8%]), low-dose sibrafiban (310 [10.1%]; odds ratio 1.03 [95% CI 
      0.87-1.21]), and high-dose sibrafiban (303 [10.1%]; 1.03 [0.87-1.21]). The groups 
      did not differ significantly in the rates of the component events or secondary 
      efficacy endpoints. Major bleeding was more common with high-dose sibrafiban (171 
      [5.7%]) than with aspirin (120 [3.9%]) or low-dose sibrafiban (159 [5.2%]). 
      INTERPRETATION: Sibrafiban showed no additional benefit over aspirin for 
      secondary prevention of major ischaemic events after an acute coronary syndrome, 
      and was associated with more dose-related bleeding.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Oximes)
RN  - 0 (Piperidines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
RN  - YUE443B0NF (sibrafiban)
SB  - IM
CIN - Lancet. 2000 Jan 29;355(9201):330-1. PMID: 10665546
CIN - Lancet. 2000 Oct 28;356(9240):1521-2. PMID: 11081555
CIN - Lancet. 2000 Aug 26;356(9231):768. PMID: 11085714
MH  - Administration, Oral
MH  - Aged
MH  - Angina, Unstable/*prevention & control
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Oximes/*administration & dosage/adverse effects
MH  - Piperidines/*administration & dosage/adverse effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
MH  - Recurrence
EDAT- 2000/02/09 09:00
MHDA- 2000/02/19 09:00
CRDT- 2000/02/09 09:00
PHST- 2000/02/09 09:00 [pubmed]
PHST- 2000/02/19 09:00 [medline]
PHST- 2000/02/09 09:00 [entrez]
AID - S0140673699111796 [pii]
PST - ppublish
SO  - Lancet. 2000 Jan 29;355(9201):337-45.

PMID- 25475899
OWN - NLM
STAT- MEDLINE
DCOM- 20151120
LR  - 20150302
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 40
IP  - 2
DP  - 2015 Apr
TI  - Is aspirin use associated with age-related macular degeneration? A meta-analysis.
PG  - 144-54
LID - 10.1111/jcpt.12241 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVES: Aspirin is one of the most widely used medications 
      in the world. The evidence on its effect on the risk of age-related macular 
      degeneration (AMD) appears inconsistent across different types of studies. The 
      aim of this meta-analysis was to evaluate the association between aspirin use and 
      the risk of AMD. METHODS: Relevant studies were searched using databases 
      including PubMed, EMBASE, Cochrane Library and MEDLINE up to March 2014. Summary 
      relative risks (RRs) and 95% confidence intervals (CIs) were calculated by 
      random-effects or fixed-effect models. The heterogeneity was assessed by the 
      inconsistency index (I(2) ). The publication bias was evaluated by Begg's funnel 
      plot and Egger's weighted regression. Sensitivity analysis was also performed in 
      different ways. RESULTS: Ten eligible studies including 180 834 individuals based 
      on the inclusion criteria were analysed in this meta-analysis. The pooled RR for 
      the aspirin use on the risk of AMD was 1·137 (95% CI, 1·003-1·289; I(2) , 68·4%). 
      The pooled RR for the aspirin use on the risk of early and late AMD was 1·19 (95% 
      CI, 0·92-1·53; I(2) , 82·6%) and 1·22 (95% CI, 0·87-1·72; I(2) , 55·7%), 
      respectively. In different types of late AMD, the pooled RR was 1·95 (95% CI, 
      1·40-2·72; I(2) , 27%) for neovascularization and 0·84 (95% CI, 0·62-1·15; I(2) , 
      0%) for geographic atrophy. The pooled RR in studies with standardized AMD 
      classification was 1·307 (95% CI, 1·006-1·698; I(2) , 79·2%). WHAT IS NEW AND 
      CONCLUSION: This meta-analysis updates similar reviews that included studies with 
      various types of biases. A rigorous analysis shows a weak but statistically 
      significant association between aspirin use and the risk of AMD; a result which 
      is different to that previously reported.
CI  - © 2014 John Wiley & Sons Ltd.
FAU - Li, L
AU  - Li L
AD  - Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, Hubei 
      Province, China; Department of Head and Neck Surgery, Hubei Cancer Hospital, 
      Wuhan, Hubei Province, China.
FAU - Li, W
AU  - Li W
FAU - Chen, C Z
AU  - Chen CZ
FAU - Yi, Z H Z
AU  - Yi ZH
FAU - Zhou, Y Y
AU  - Zhou YY
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20141205
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Macular Degeneration/*chemically induced/classification
MH  - Risk Assessment
OTO - NOTNLM
OT  - age-related macular degeneration
OT  - aspirin
OT  - meta-analysis
OT  - neovascularization
EDAT- 2014/12/06 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/12/06 06:00
PHST- 2014/05/26 00:00 [received]
PHST- 2014/11/11 00:00 [accepted]
PHST- 2014/12/06 06:00 [entrez]
PHST- 2014/12/06 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1111/jcpt.12241 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2015 Apr;40(2):144-54. doi: 10.1111/jcpt.12241. Epub 2014 Dec 
      5.

PMID- 25074252
OWN - NLM
STAT- MEDLINE
DCOM- 20150512
LR  - 20140820
IS  - 1941-7632 (Electronic)
IS  - 1941-7640 (Linking)
VI  - 7
IP  - 4
DP  - 2014 Aug
TI  - Aspirin reload before elective percutaneous coronary intervention: impact on 
      serum thromboxane b2 and myocardial reperfusion indexes.
PG  - 577-84
LID - 10.1161/CIRCINTERVENTIONS.113.001197 [doi]
AB  - BACKGROUND: Microvascular obstruction seems to predict poor outcome in patients 
      undergoing elective percutaneous coronary intervention (PCI), but the underlying 
      mechanism is still unclear. We analyzed whether serum thromboxane B2, a stable 
      metabolite of thromboxane A2, may be implicated in post-PCI microvascular 
      obstruction. METHODS AND RESULTS: We enrolled 91 patients (74 males, 66±10 years) 
      on chronic low-dose aspirin therapy (aspirin, 100 mg daily) scheduled for 
      elective PCI and randomly assigned to receive aspirin reload (325 mg orally, 
      n=46) or no reload (control group, n=45) ≥1 hour before elective PCI. Serum 
      levels of thromboxane B2, reperfusion indexes (corrected Thrombolysis In 
      Myocardial Infarction frame count and myocardial blush grade), and serum cardiac 
      troponin I were assessed before and after PCI. Serum thromboxane B2 significantly 
      increased after 120 minutes (P=0.0447) from PCI in control but not in aspirin 
      reload group. After PCI, both groups showed a statistically significant reduction 
      in corrected Thrombolysis In Myocardial Infarction frame count more evident in 
      aspirin reload group (P=0.0023). Moreover, after PCI, 61% of patients allocated 
      to aspirin reload and only 32% of patients allocated to control group reached 
      normal microcirculatory reperfusion (myocardial blush grade=3); patients with 
      myocardial blush grade=3 exhibited lower values of serum thromboxane B2 compared 
      with those with myocardial blush grade <3 (P=0.05). Periprocedural cardiac 
      troponin I significantly increased (F=3.64; P=0.01334) and correlated with serum 
      thromboxane B2 (ρ=0.31; P=0.0413) in control but not in aspirin reload group. In 
      addition, left ventricular ejection fraction significantly increased after PCI 
      only in the aspirin reload group (P=0.0005). CONCLUSIONS: Aspirin loading dose 
      before elective PCI improves myocardial reperfusion and injury indexes, 
      suggesting a possible role of platelet thromboxane A2 in microvascular occlusion. 
      CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique 
      identifier: NCT01374698.
CI  - © 2014 American Heart Association, Inc.
FAU - Basili, Stefania
AU  - Basili S
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.). 
      stefania.basili@uniroma1.it.
FAU - Tanzilli, Gaetano
AU  - Tanzilli G
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
FAU - Raparelli, Valeria
AU  - Raparelli V
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
FAU - Calvieri, Camilla
AU  - Calvieri C
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
FAU - Pignatelli, Pasquale
AU  - Pignatelli P
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
FAU - Carnevale, Roberto
AU  - Carnevale R
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
FAU - Dominici, Marcello
AU  - Dominici M
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
FAU - Placanica, Attilio
AU  - Placanica A
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
FAU - Arrivi, Alessio
AU  - Arrivi A
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
FAU - Farcomeni, Alessio
AU  - Farcomeni A
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
FAU - Barillà, Francesco
AU  - Barillà F
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
FAU - Mangieri, Enrico
AU  - Mangieri E
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
FAU - Violi, Francesco
AU  - Violi F
AD  - From the I Clinica Medica (S.B., V.R., P.P., R.C., F.V.), Department of the Heart 
      and Great Vessels Attilio Reale (G.T., C.C., F.B., E.M.), and Department of 
      Public Health and Infectious Diseases (A.F.), Sapienza-University of Rome, Rome, 
      Italy; and Division of Cardiology, Department of Interventional Cardiology, Santa 
      Maria University Hospital, Terni, Italy (M.D., A.P., A.A.).
LA  - eng
SI  - ClinicalTrials.gov/NCT01374698
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140729
PL  - United States
TA  - Circ Cardiovasc Interv
JT  - Circulation. Cardiovascular interventions
JID - 101499602
RN  - 0 (Troponin I)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Microvessels/*pathology/surgery
MH  - Middle Aged
MH  - Myocardial Reperfusion Injury/etiology/*prevention & control
MH  - *Percutaneous Coronary Intervention
MH  - Postoperative Complications/*prevention & control
MH  - Preoperative Period
MH  - Thrombosis/etiology/*prevention & control
MH  - Thromboxane B2/*blood
MH  - Treatment Outcome
MH  - Troponin I/blood
OTO - NOTNLM
OT  - angioplasty
OT  - aspirin
OT  - microcirculation
EDAT- 2014/07/31 06:00
MHDA- 2015/05/13 06:00
CRDT- 2014/07/31 06:00
PHST- 2014/07/31 06:00 [entrez]
PHST- 2014/07/31 06:00 [pubmed]
PHST- 2015/05/13 06:00 [medline]
AID - CIRCINTERVENTIONS.113.001197 [pii]
AID - 10.1161/CIRCINTERVENTIONS.113.001197 [doi]
PST - ppublish
SO  - Circ Cardiovasc Interv. 2014 Aug;7(4):577-84. doi: 
      10.1161/CIRCINTERVENTIONS.113.001197. Epub 2014 Jul 29.

PMID- 6784135
OWN - NLM
STAT- MEDLINE
DCOM- 19810613
LR  - 20191031
IS  - 0161-4630 (Print)
IS  - 0161-4630 (Linking)
VI  - 6
IP  - 1
DP  - 1981 Jan
TI  - Impaired insulin secretion in human diabetes mellitus. II. A possible role for 
      prostaglandins.
PG  - 41-50
AB  - Human diabetes mellitus is characterized by impaired insulin response to 
      intravenous glucose. In search of possible endogenous factors which impair 
      insulin release, we have investigated the effect of lysine acetylsalicylate 
      (LAS), an inhibitor of endogenous prostaglandin (PGs) synthesis, upon insulin 
      responses to glucose and arginine in subjects with type II (adult-on-set) 
      diabetes mellitus. Acute insulin response to glucose (20 g) was significantly 
      increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, 
      mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase 
      insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 
      min, uU/ml-min, % basal, p less than 0.01). This effect was associated with an 
      increase in glucose disappearance rates (p less than 0.01). Acute insulin 
      response to arginine (5 g iv) was also increased by LAS infusion. These results 
      suggest that endogenous PGs may be one of the factors which impair insulin 
      secretion in human diabetes.
FAU - Giugliano, D
AU  - Giugliano D
FAU - Sgamboto, S
AU  - Sgamboto S
FAU - Coppola, L
AU  - Coppola L
FAU - Misso, L
AU  - Misso L
FAU - Torella, R
AU  - Torella R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins Med
JT  - Prostaglandins and medicine
JID - 7810330
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Prostaglandins E)
RN  - 94ZLA3W45F (Arginine)
RN  - IY9XDZ35W2 (Glucose)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Arginine
MH  - Aspirin/*analogs & derivatives/blood
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus/*metabolism
MH  - Female
MH  - Glucose
MH  - Humans
MH  - Insulin/blood/*metabolism
MH  - Insulin Secretion
MH  - Lysine/*analogs & derivatives/blood
MH  - Male
MH  - Middle Aged
MH  - Prostaglandins E/*metabolism
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1016/s0161-4630(81)80008-0 [doi]
PST - ppublish
SO  - Prostaglandins Med. 1981 Jan;6(1):41-50. doi: 10.1016/s0161-4630(81)80008-0.

PMID- 18220726
OWN - NLM
STAT- MEDLINE
DCOM- 20080311
LR  - 20191110
IS  - 1871-529X (Print)
IS  - 1871-529X (Linking)
VI  - 7
IP  - 4
DP  - 2007 Dec
TI  - Variability in individual responsiveness to aspirin: clinical implications and 
      treatment.
PG  - 274-87
AB  - Aspirin protects from cardiovascular events because of its antiaggregant effect. 
      The occurrence of new events in patients who take aspirin has been called 
      clinical aspirin resistance. Many authors believe that aspirin resistance must be 
      detected by biochemical tests, although there is no agreement on which is the 
      best. Nor is there agreement on the term aspirin resistance. Tests used in 
      research laboratories are aggregometry (turbidometric and impedance), tests based 
      on activation-dependent changes in platelet surface, and tests based on 
      activation-dependent release from platelets. Point-of-care tests are PFA-100, 
      IMPACT and VerifyNow, which can detect platelet dysfunction that may be due to 
      aspirin effect, but their use for this purpose is not yet recommended. Aspirin 
      response may be modified by different factors: patient's compliance, dose, 
      smoking, hyperlipidemia, hyperglucemia, acute coronary syndrome, percutaneous 
      revascularization, recent stroke, extracorporeal circulation, heart failure, 
      exercise, circadian rhythm, absorption, concomitant medications, polymorphisms. 
      Patients with aspirin resistance may have an increased risk of cardiovascular 
      events, and possible therapeutic options are to increase the dosage, to replace 
      aspirin with another antiaggregant drug or to add another drug. In conclusion, 
      there are many reasons that explain the variability in individual responsiveness 
      to aspirin. The term resistance is probably not exact in describing this 
      phenomenon.
FAU - Coma-Canella, Isabel
AU  - Coma-Canella I
AD  - Departamento de Cardiología, Clínica Universitaria de Navarra, Avenida de Pio XII 
      36, 31008 Pamplona, Spain. icoma@unav.es
FAU - Velasc, Amelia
AU  - Velasc A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Cardiovasc Hematol Disord Drug Targets
JT  - Cardiovascular & hematological disorders drug targets
JID - 101269160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Cardiovascular Diseases/prevention & control
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation/drug effects/physiology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Point-of-Care Systems
MH  - Risk Factors
MH  - Treatment Failure
RF  - 157
EDAT- 2008/01/29 09:00
MHDA- 2008/03/12 09:00
CRDT- 2008/01/29 09:00
PHST- 2008/01/29 09:00 [pubmed]
PHST- 2008/03/12 09:00 [medline]
PHST- 2008/01/29 09:00 [entrez]
AID - 10.2174/187152907782793590 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Disord Drug Targets. 2007 Dec;7(4):274-87. doi: 
      10.2174/187152907782793590.

PMID- 26812204
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 84
DP  - 2016 Mar 10
TI  - Design and optimization of disintegrating pellets of MCC by non-aqueous extrusion 
      process using statistical tools.
PG  - 146-56
LID - S0928-0987(16)30021-5 [pii]
LID - 10.1016/j.ejps.2016.01.021 [doi]
AB  - The objective of the study was to design and optimize a disintegrating pellet 
      formulation of microcrystalline cellulose by non-aqueous extrusion process for a 
      water sensitive drug using various statistical tools. Aspirin was used as a model 
      drug. Disintegrating matrix pellets of aspirin using propylene glycol as a 
      non-aqueous granulation liquid and croscarmellose as a disintegrant was 
      developed. Plackett-Burman design was initially conducted to screen and identify 
      the significant factors. Final optimization of formula was performed by response 
      surface methodology using a central composite design. The critical attributes of 
      the pellet dosage forms (dependent variables); disintegration time, sphericity 
      and yield were predicted with adequate accuracy based on the regression model. 
      Pareto charts and contour charts were studied to understand the influence of 
      factors and predict the responses. A design space was constructed to meet the 
      desirable targets of the responses in terms of disintegration time <5min, maximum 
      yield, sphericity >0.95 and friability <1.7%. The optimized matrix pellets were 
      enteric coated using Eudragit L 100. The drug release from the enteric coated 
      pellets after 30min in the basic media was ~93% when compared to ~77% from the 
      marketed pellets. The delayed release pellets stored at 25°C/60% RH were stable 
      for a period of 10mo. In conclusion, it can be stated that the developed process 
      for disintegrating pellets using non-aqueous granulating agents can be used as an 
      alternative technique for various water sensitive drugs, circumventing the 
      application of volatile organic solvents in conventional drug layering on inert 
      cores. The scope of this study can be further extended to hydrophobic drugs, 
      which may benefit from the rapid disintegration property and the use of various 
      hydrophilic excipients used in the optimized pellet formulation to enhance 
      dissolution and in turn improve bioavailability.
CI  - Copyright © 2016 Elsevier B.V. All rights reserved.
FAU - Gurram, Rajesh Kumar
AU  - Gurram RK
AD  - Solid State Pharmaceutical Research Group (SSPRG) Department of Pharmaceutics, 
      National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad, 
      Pin Code - 500037, India.
FAU - Gandra, Suchithra
AU  - Gandra S
AD  - Solid State Pharmaceutical Research Group (SSPRG) Department of Pharmaceutics, 
      National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad, 
      Pin Code - 500037, India.
FAU - Shastri, Nalini R
AU  - Shastri NR
AD  - Solid State Pharmaceutical Research Group (SSPRG) Department of Pharmaceutics, 
      National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad, 
      Pin Code - 500037, India. Electronic address: nalini.niperhyd@gov.in.
LA  - eng
PT  - Journal Article
DEP - 20160123
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Dosage Forms)
RN  - 0 (Excipients)
RN  - 9004-34-6 (Cellulose)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Cellulose/*chemistry
MH  - Chemistry, Pharmaceutical/methods/statistics & numerical data
MH  - Dosage Forms
MH  - Excipients/*chemistry
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Models, Statistical
MH  - Solubility
MH  - Technology, Pharmaceutical/methods/statistics & numerical data
OTO - NOTNLM
OT  - Aspirin
OT  - CCD
OT  - MCC
OT  - Plackett Burman
OT  - Propylene glycol
OT  - QbD
OT  - Stability
EDAT- 2016/01/27 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/01/27 06:00
PHST- 2015/11/17 00:00 [received]
PHST- 2015/12/31 00:00 [revised]
PHST- 2016/01/22 00:00 [accepted]
PHST- 2016/01/27 06:00 [entrez]
PHST- 2016/01/27 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S0928-0987(16)30021-5 [pii]
AID - 10.1016/j.ejps.2016.01.021 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2016 Mar 10;84:146-56. doi: 10.1016/j.ejps.2016.01.021. Epub 
      2016 Jan 23.

PMID- 26980433
OWN - NLM
STAT- MEDLINE
DCOM- 20161107
LR  - 20181113
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 14
DP  - 2016 Mar 15
TI  - The lack of aspirin resistance in patients with coronary artery disease.
PG  - 74
LID - 10.1186/s12967-016-0827-7 [doi]
LID - 74
AB  - BACKGROUND: Aspirin resistance established by different laboratory methods is 
      still a debated problem. Using COX1 specific methods no aspirin resistance was 
      detected among healthy volunteers. Here we tested the effect of chronic aspirin 
      treatment on platelets from patients with stable coronary artery disease. The 
      expression of COX2 mRNA in platelets and its influences on the effect of aspirin 
      was also investigated. METHODS: One hundred and forty four patients were enrolled 
      in the study. The direct measurement of COX1 acetylation was carried out by 
      monoclonal antibodies specific to acetylated and non-acetylated COX1 (acCOX1 and 
      nacCOX1) using Western blotting technique. Arachidonic acid (AA) induced TXB2 
      production by platelets was measured by competitive immunoassay. AA induced 
      platelet aggregation, ATP secretion and VerifyNow Aspirin Assay were also 
      performed. COX2 and COX1 mRNA expression in platelets were measured in 56 
      patients by RT-qPCR. RESULTS: In 138 patients only acCOX1 was detected, in the 
      remaining six patients nacCOX1 disappeared after a compliance period. AA induced 
      TXB2 production by platelets was very low in all patients including the 6 
      patients after compliance. AA induced platelet aggregation, secretion and with a 
      few exceptions the VerifyNow Assay also demonstrated the effect of aspirin. 
      Smoking, diabetes mellitus and inflammatory conditions did not influence the 
      results. The very low amount of COX2 mRNA detected in 39 % of the investigated 
      platelets did not influence the effect of aspirin. CONCLUSIONS: No aspirin 
      resistance was detected among patients with stable coronary artery disease. COX2 
      expression in platelets did not influence the effect of aspirin.
FAU - Homoródi, Nóra
AU  - Homoródi N
AD  - Institute of Cardiology and Heart Surgery, University of Debrecen, 22 Móricz 
      Zsigmond Krt., 4032, Debrecen, Hungary.
FAU - Kovács, Emese G
AU  - Kovács EG
AD  - Institute of Cardiology and Heart Surgery, University of Debrecen, 22 Móricz 
      Zsigmond Krt., 4032, Debrecen, Hungary.
AD  - Division of Clinical Laboratory Science, Department of Laboratory Medicine, 
      University of Debrecen, 98 Nagyerdei Krt., 4032, Debrecen, Hungary.
FAU - Leé, Sarolta
AU  - Leé S
AD  - Department of Cardiology, Military Hospital, 44 Róbert Károly Krt., 1134, 
      Budapest, Hungary.
FAU - Katona, Éva
AU  - Katona É
AD  - Division of Clinical Laboratory Science, Department of Laboratory Medicine, 
      University of Debrecen, 98 Nagyerdei Krt., 4032, Debrecen, Hungary.
FAU - Shemirani, Amir H
AU  - Shemirani AH
AD  - Vascular Biology, Thrombosis and Hemostasis Research Group of the Hungarian 
      Academy of Science, University of Debrecen, 98 Nagyerdei Krt., 4032, Debrecen, 
      Hungary.
FAU - Haramura, Gizella
AU  - Haramura G
AD  - Division of Clinical Laboratory Science, Department of Laboratory Medicine, 
      University of Debrecen, 98 Nagyerdei Krt., 4032, Debrecen, Hungary.
FAU - Balogh, László
AU  - Balogh L
AD  - Institute of Cardiology and Heart Surgery, University of Debrecen, 22 Móricz 
      Zsigmond Krt., 4032, Debrecen, Hungary.
FAU - Bereczky, Zsuzsanna
AU  - Bereczky Z
AD  - Division of Clinical Laboratory Science, Department of Laboratory Medicine, 
      University of Debrecen, 98 Nagyerdei Krt., 4032, Debrecen, Hungary.
FAU - Szőke, Gabriella
AU  - Szőke G
AD  - Diagnosticum Co., Research Laboratory, 126 Attila u., 1046, Budapest, Hungary.
FAU - Péterfy, Hajna
AU  - Péterfy H
AD  - Diagnosticum Co., Research Laboratory, 126 Attila u., 1046, Budapest, Hungary.
FAU - Kiss, Róbert G
AU  - Kiss RG
AD  - Department of Cardiology, Military Hospital, 44 Róbert Károly Krt., 1134, 
      Budapest, Hungary.
FAU - Édes, István
AU  - Édes I
AD  - Institute of Cardiology and Heart Surgery, University of Debrecen, 22 Móricz 
      Zsigmond Krt., 4032, Debrecen, Hungary.
FAU - Muszbek, László
AU  - Muszbek L
AUID- ORCID: 0000-0002-3798-9962
AD  - Division of Clinical Laboratory Science, Department of Laboratory Medicine, 
      University of Debrecen, 98 Nagyerdei Krt., 4032, Debrecen, Hungary. 
      muszbek@med.unideb.hu.
AD  - Vascular Biology, Thrombosis and Hemostasis Research Group of the Hungarian 
      Academy of Science, University of Debrecen, 98 Nagyerdei Krt., 4032, Debrecen, 
      Hungary. muszbek@med.unideb.hu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160315
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - 0 (RNA, Messenger)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation/drug effects
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*pharmacology/therapeutic use
MH  - *Coronary Artery Disease/drug therapy/prevention & control
MH  - Cyclooxygenase 1/genetics/metabolism
MH  - Cyclooxygenase 2/genetics/metabolism
MH  - *Drug Resistance
MH  - Female
MH  - Gene Expression Regulation, Enzymologic/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - RNA, Messenger/genetics/metabolism
MH  - Thromboxane B2/biosynthesis
PMC - PMC4793490
OTO - NOTNLM
OT  - Aspirin
OT  - Coronary artery disease
OT  - Cyclooxygenase-1
OT  - Cyclooxygenase-2
OT  - Platelet
OT  - Thromboxane B2
EDAT- 2016/03/17 06:00
MHDA- 2016/11/08 06:00
CRDT- 2016/03/17 06:00
PHST- 2015/09/06 00:00 [received]
PHST- 2016/03/02 00:00 [accepted]
PHST- 2016/03/17 06:00 [entrez]
PHST- 2016/03/17 06:00 [pubmed]
PHST- 2016/11/08 06:00 [medline]
AID - 10.1186/s12967-016-0827-7 [pii]
AID - 827 [pii]
AID - 10.1186/s12967-016-0827-7 [doi]
PST - epublish
SO  - J Transl Med. 2016 Mar 15;14:74. doi: 10.1186/s12967-016-0827-7.

PMID- 18722299
OWN - NLM
STAT- MEDLINE
DCOM- 20090205
LR  - 20220317
IS  - 1532-8406 (Electronic)
IS  - 0883-5403 (Linking)
VI  - 23
IP  - 6 Suppl 1
DP  - 2008 Sep
TI  - Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing 
      total knee arthroplasty.
PG  - 20-4
LID - 10.1016/j.arth.2008.05.018 [doi]
AB  - Our objective of the study was to address the question: "What is the efficacy of 
      a deep venous thrombosis (DVT) and pulmonary embolus prophylaxis protocol after 
      total knee arthroplasty (TKA) in which low-risk patients had only aspirin and 
      mechanical devices for prophylaxis?" A multimodal approach to DVT prophylaxis 
      using aspirin as the primary mode of chemoprophylaxis was successful in 
      preventing DVT-related morbidity and mortality in 312 consecutive TKAs performed 
      in low-risk patients. There were no DVT-related deaths and no deaths in general 
      at 90 days of follow-up coupled with a low rate of readmission for thromboembolic 
      events and no readmissions or reoperations from bleeding in this group. This 
      low-morbidity, low-cost prophylaxis should be considered an appropriate protocol 
      for low-risk patients undergoing TKA. Of all TKAs performed during the time 
      period of the study, 73% qualified for the low-risk group.
FAU - Callaghan, John J
AU  - Callaghan JJ
AD  - University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA.
FAU - Warth, Lucian C
AU  - Warth LC
FAU - Hoballah, Jamal J
AU  - Hoballah JJ
FAU - Liu, Steve S
AU  - Liu SS
FAU - Wells, Christopher W
AU  - Wells CW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Arthroplasty, Replacement, Knee
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications
MH  - Pulmonary Embolism/prevention & control
MH  - Retrospective Studies
MH  - Venous Thrombosis/mortality/*prevention & control
EDAT- 2008/09/09 09:00
MHDA- 2009/02/06 09:00
CRDT- 2008/09/09 09:00
PHST- 2008/01/14 00:00 [received]
PHST- 2008/05/11 00:00 [accepted]
PHST- 2008/09/09 09:00 [pubmed]
PHST- 2009/02/06 09:00 [medline]
PHST- 2008/09/09 09:00 [entrez]
AID - S0883-5403(08)00490-7 [pii]
AID - 10.1016/j.arth.2008.05.018 [doi]
PST - ppublish
SO  - J Arthroplasty. 2008 Sep;23(6 Suppl 1):20-4. doi: 10.1016/j.arth.2008.05.018.

PMID- 2346237
OWN - NLM
STAT- MEDLINE
DCOM- 19900705
LR  - 20131121
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 64
IP  - 6
DP  - 1990 Jun
TI  - Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal 
      polyposis, intrinsic asthma, and intolerance to aspirin.
PG  - 513-8
AB  - Fifty-two cases of perennial rhinitis were studied, leading to the diagnosis of 
      seven cases of nonallergic rhinitis with eosinophilia syndrome (NARES) a 
      frequency of 13.5%. Symptoms of nasal hyperreactivity involving sneezing, 
      rhinorrhea, nasal obstruction and pruritus were more severe than in other types 
      of rhinitis. The frequency of hyposmia was very specific to NARES. Nasal 
      endoscopy and sinus CT revealed an evolution towards nasal polyposis in four 
      patients. The nasal challenge to house dust mites showed the absence of any 
      increase in local eosinophilia. Bronchial hyperreactivity to carbachol occurred 
      in one case. There was no case of intolerance to aspirin. There was particular 
      adrenergic hyperreactivity among the seven patients, evidenced by study of the 
      reactivity of the cardiovascular alpha and beta receptors. The authors emphasize 
      the features that are shared by NARES and by the triad, which suggest that NARES 
      is the early phase of the triad. They advance the pathogenic hypothesis of an 
      autonomic nervous system dysregulation with a predominating adrenergic 
      hyperreactivity. Inflammatory effects of local release of neurotransmitters 
      induce a switch from a neurogenic to a self-sustaining inflammation. Tissue 
      eosinophilia is regulated by chemical attractants and activating substances of 
      various origins and plays a major part in the chronic inflammatory state.
FAU - Moneret-Vautrin, D A
AU  - Moneret-Vautrin DA
AD  - Service de Médecine D-Immuno-allergologie-CHU, Vandoeuvre-les-Nancy, France.
FAU - Hsieh, V
AU  - Hsieh V
FAU - Wayoff, M
AU  - Wayoff M
FAU - Guyot, J L
AU  - Guyot JL
FAU - Mouton, C
AU  - Mouton C
FAU - Maria, Y
AU  - Maria Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Asthma/*etiology
MH  - Child
MH  - Drug Tolerance
MH  - Eosinophilia/*complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/*etiology
MH  - Rhinitis/*complications
MH  - Syndrome
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1990 Jun;64(6):513-8.

PMID- 19891963
OWN - NLM
STAT- MEDLINE
DCOM- 20100330
LR  - 20151119
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 43
IP  - 3
DP  - 2010 Feb
TI  - Effects of acetylsalicylic acid on serum paraoxonase activity, Ox-LDL, coenzyme 
      Q10 and other oxidative stress markers in healthy volunteers.
PG  - 287-90
LID - 10.1016/j.clinbiochem.2009.10.054 [doi]
AB  - OBJECTIVES: The aim of the study was to examine the effects of acetylsalicylic 
      acid (ASA) on oxidative stress in healthy volunteers. DESIGN AND METHODS: 30 
      volunteers of which 17 received ASA as 100 mg/day (Group I) and 13 received ASA 
      as 150 mg/day (Group II) for 2 months. Serum paraoxonase 1 (PON1), arylesterase, 
      total antioxidant status (TAS), total oxidant status (TOS), oxidized LDL (Ox-LDL) 
      and coenzyme Q(10) (CoQ(10)) levels were measured before and 1 and 2 months after 
      treatment. RESULTS: There was no significant differences between the measured 
      parameters of the groups. However, TOS and Ox-LDL levels of group II were 
      significantly reduced after 2 months of treatment (p<0.05). CONCLUSIONS: 
      Significantly inhibition of LDL oxidation and significantly reduction in TOS 
      levels of group II after 2 months of ASA treatment shows that ASA treatment may 
      contribute to the prevention of atherosclerosis, a beneficial effect which is 
      dose and time dependent.
CI  - (c) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. 
      All rights reserved.
FAU - Kurban, Sevil
AU  - Kurban S
AD  - University of Selcuk, Meram Faculty of Medicine, Department of Biochemistry, 
      Konya, Turkey. svlkrbn@yahoo.com
FAU - Mehmetoglu, Idris
AU  - Mehmetoglu I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091103
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - 0 (Antioxidants)
RN  - 0 (Biomarkers)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (oxidized low density lipoprotein)
RN  - 1339-63-5 (Ubiquinone)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.2 (arylesterase)
RN  - EC 3.1.8.1 (Aryldialkylphosphatase)
RN  - EJ27X76M46 (coenzyme Q10)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antioxidants/metabolism
MH  - Aryldialkylphosphatase/*metabolism
MH  - Aspirin/administration & dosage/*metabolism
MH  - Biomarkers/*blood
MH  - Carboxylic Ester Hydrolases/metabolism
MH  - Fibrinolytic Agents/administration & dosage/*metabolism
MH  - Humans
MH  - Lipoproteins, LDL/*blood
MH  - Middle Aged
MH  - *Oxidative Stress
MH  - Ubiquinone/*analogs & derivatives/blood
EDAT- 2009/11/07 06:00
MHDA- 2010/03/31 06:00
CRDT- 2009/11/07 06:00
PHST- 2009/07/10 00:00 [received]
PHST- 2009/09/24 00:00 [revised]
PHST- 2009/10/27 00:00 [accepted]
PHST- 2009/11/07 06:00 [entrez]
PHST- 2009/11/07 06:00 [pubmed]
PHST- 2010/03/31 06:00 [medline]
AID - S0009-9120(09)00504-9 [pii]
AID - 10.1016/j.clinbiochem.2009.10.054 [doi]
PST - ppublish
SO  - Clin Biochem. 2010 Feb;43(3):287-90. doi: 10.1016/j.clinbiochem.2009.10.054. Epub 
      2009 Nov 3.

PMID- 15161127
OWN - NLM
STAT- MEDLINE
DCOM- 20040706
LR  - 20191108
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 58
IP  - 4
DP  - 2004 Apr
TI  - Clopidogrel in the management of cerebrovascular events.
PG  - 402-10
AB  - The inhibition of platelet function has proved its effectiveness in the reduction 
      of vascular events in many large trials for many different compounds such as ASA, 
      ticlopinin, dipyridamole or clopidogrel. In this overview, the authors analyse 
      the results of recent trials and present ongoing or future trials with 
      clopidogrel. Clopidogrel has proved its superiority in prevention of vascular 
      events as compared to ASA, being even higher in high-risk groups such as diabetic 
      patients. For the post-interventional treatment of patients undergoing 
      stent-protected dilatation of coronary arteries, the combination of ASA and 
      clopidogrel has become a standard procedure. There is also evidence that the 
      combination of ASA and Clopidogrel is better than ASA alone in long-term 
      treatment up to at least 9 months. The long-term combination therapy seems to be 
      very promising and is currently analysed in three large trials in over 30,000 
      patients with a large number of stroke patients. These trials will also answer 
      the question, whether the combination therapy is safe in long-term secondary 
      stroke prevention. However, there is still a widespread reluctance in doctors to 
      prescribe Clopidogrel for its costs. Cost-effectiveness studies predict up to 
      tenfold higher cost in the prevention of vascular events when compared to ASA, in 
      times of shrinking health budgets a topic of interest.
FAU - Ringleb, P A
AU  - Ringleb PA
AD  - Department of Neurology, University of Heidelberg, Heidelberg, Germany. 
      Peter_Ringleb@med.uni-heidelberg.de
FAU - Schellinger, P D
AU  - Schellinger PD
FAU - Schwark, C
AU  - Schwark C
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis/etiology/prevention & control
MH  - Aspirin/economics/*therapeutic use
MH  - Clopidogrel
MH  - Drug Costs
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/economics/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/economics/*prevention & control
MH  - Thrombosis/etiology/prevention & control
MH  - Ticlopidine/*analogs & derivatives/economics/*therapeutic use
RF  - 44
EDAT- 2004/05/27 05:00
MHDA- 2004/07/09 05:00
CRDT- 2004/05/27 05:00
PHST- 2004/05/27 05:00 [pubmed]
PHST- 2004/07/09 05:00 [medline]
PHST- 2004/05/27 05:00 [entrez]
AID - 10.1111/j.1368-5031.2004.00177.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2004 Apr;58(4):402-10. doi: 10.1111/j.1368-5031.2004.00177.x.

PMID- 11744677
OWN - NLM
STAT- MEDLINE
DCOM- 20020410
LR  - 20181130
IS  - 8750-7587 (Print)
IS  - 0161-7567 (Linking)
VI  - 92
IP  - 1
DP  - 2002 Jan
TI  - Comparison of transfusion with DCLHb or pRBCs for treatment of intraoperative 
      anemia in sheep.
PG  - 343-53
AB  - Isoflurane-anesthetized sheep were transfused with packed red blood cells (pRBCs) 
      or diaspirin cross-linked hemoglobin (DCLHb) for treatment of intraoperative 
      hemorrhage. A rapid 15-min hemorrhage with lactated Ringer (LR) infusion 
      maintained filling pressure at baseline and reduced blood hemoglobin (Hb) to ~5 
      g/dl. Sheep received 2 g/kg Hb, DCLHb (n = 6), or pRBCs (n = 7); control group 
      received LR alone (n = 6). After 2 h, anesthesia was discontinued; sheep were 
      monitored in the animal intensive care unit for 48 h. DCLHb expanded blood volume 
      more, but increased total blood Hb less, than pRBCs. Lower Hb and increased 
      methemoglobin resulted in lower arterial oxygen content compared with the pRBCs. 
      DCLHb caused pulmonary hypertension (from 13 to 30 mmHg) and elevated filling 
      pressure (from 6 to 15 mmHg). Cardiac outputs (CO) were similar for all groups 
      during anesthesia; however, during recovery CO increased only in the LR and 
      packed pRBCs groups. DCLHb may limit the reflex ability to increase CO after 
      volume expansion. Hemodynamic effects of DCLHb may be exaggerated when infused 
      after large-volume LR.
FAU - Vane, Luiz A
AU  - Vane LA
AD  - Resuscitation Research Laboratories, Departments of Anesthesiology and 
      Physiology, University of Texas Medical Branch, Galveston, Texas 77555-080, USA.
FAU - Funston, J Sean
AU  - Funston JS
FAU - Kirschner, Robert
AU  - Kirschner R
FAU - Harper, Don
AU  - Harper D
FAU - Deyo, Donald J
AU  - Deyo DJ
FAU - Traber, Daniel L
AU  - Traber DL
FAU - Traber, Lillian L
AU  - Traber LL
FAU - Kramer, George C
AU  - Kramer GC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Appl Physiol (1985)
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anemia/drug therapy/etiology/*therapy
MH  - Anesthesia
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*therapeutic use
MH  - Blood Gas Analysis
MH  - Blood Pressure/drug effects/physiology
MH  - Blood Substitutes/*therapeutic use
MH  - Blood Volume
MH  - *Erythrocyte Transfusion
MH  - Heart/drug effects/physiology
MH  - Hemodynamics/drug effects/physiology
MH  - Hemoglobins/metabolism/*therapeutic use
MH  - Hemorrhage/complications/physiopathology
MH  - Intraoperative Period
MH  - Oxygen Consumption/drug effects/physiology
MH  - Pulmonary Circulation/drug effects/physiology
MH  - Sheep
EDAT- 2001/12/18 10:00
MHDA- 2002/04/11 10:01
CRDT- 2001/12/18 10:00
PHST- 2001/12/18 10:00 [pubmed]
PHST- 2002/04/11 10:01 [medline]
PHST- 2001/12/18 10:00 [entrez]
AID - 10.1152/jappl.2002.92.1.343 [doi]
PST - ppublish
SO  - J Appl Physiol (1985). 2002 Jan;92(1):343-53. doi: 10.1152/jappl.2002.92.1.343.

PMID- 3904440
OWN - NLM
STAT- MEDLINE
DCOM- 19851209
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 79
IP  - 4C
DP  - 1985 Oct 25
TI  - Modern management of rheumatoid arthritis.
PG  - 24-31
AB  - The management of rheumatoid arthritis can be challenging even to the most 
      experienced and astute physician. The rheumatoid inflammatory process can be 
      profound, ravaging, and unremitting, and the illness is notorious for its protean 
      manifestations and capricious course. Moreover, the response to therapy is 
      unpredictable, although it can be quite successful in many cases. Nevertheless, 
      the intense pain, profound disability, progressive destructive arthropathy, and 
      negative psychological milieu that haunt patients demand that something be done 
      therapeutically. Rheumatoid arthritis responds best to a symphony of therapeutic 
      modalities including drugs, rehabilitation, joint surgery, and attention to 
      psychosocial issues. The foundation of any successful therapeutic venture is an 
      educational program designed, however simply, to imbue the patient and family 
      with an understanding of the disease and its course and treatment, and with 
      realistic expectations. Drug therapy is often polypharmaceutical, employing 
      analgesics, nonsteroidal anti-inflammatory agents, both local and systemic 
      corticosteroids, and remission-inducing drugs. Pacing of lifestyle, physical 
      and/or occupational therapy, vocational guidance, psychological and sexual 
      counseling, and social intervention are as much a part of modern management in 
      rheumatoid arthritis as are drugs. The extra-articular (systemic) manifestations 
      are addressed in a variety of ways depending upon the type and severity of 
      involvement. Although most patients can be treated by their primary care 
      physician, some may require the expertise provided by a specialist. Finally, 
      despite the lack of a cure for rheumatoid arthritis, most patients respond well 
      to treatment and return to their desired activities of daily living.
FAU - Katz, W A
AU  - Katz WA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Analgesics/*therapeutic use
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/psychology/rehabilitation/surgery/*therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Counseling
MH  - Delayed-Action Preparations
MH  - Hospitalization
MH  - Humans
MH  - Indomethacin/adverse effects/*therapeutic use
MH  - Pain/drug therapy
MH  - Physical Therapy Modalities
MH  - Prognosis
RF  - 43
EDAT- 1985/10/25 00:00
MHDA- 1985/10/25 00:01
CRDT- 1985/10/25 00:00
PHST- 1985/10/25 00:00 [pubmed]
PHST- 1985/10/25 00:01 [medline]
PHST- 1985/10/25 00:00 [entrez]
AID - 0002-9343(85)90512-1 [pii]
AID - 10.1016/0002-9343(85)90512-1 [doi]
PST - ppublish
SO  - Am J Med. 1985 Oct 25;79(4C):24-31. doi: 10.1016/0002-9343(85)90512-1.

PMID- 6338971
OWN - NLM
STAT- MEDLINE
DCOM- 19830505
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 61
IP  - 4
DP  - 1983 Apr
TI  - Comparative evaluation of fifteen anti-sickling agents.
PG  - 693-704
AB  - Fifteen compounds reported to be inhibitors of gelation or sickling were studied 
      by standard methods. These tests included (1) the determination of the solubility 
      of deoxyhemoglobin S or Csat, (2) evaluation of sickling in whole SS blood at 
      various pO2s, (3) measurement of the oxygen affinity of hemoglobin and blood, and 
      (4) examination of red cell indices and morphology. Among the 4 noncovalent 
      agents tested, butylurea was the most potent inhibitor of gelation and sickling 
      in vitro; however, relatively high concentrations were required compared to the 
      covalent agents. In the latter group, bis-(3,5 dibromosalicyl)-fumarate, nitrogen 
      mustard, and dimethyladipimidate were especially effective inhibitors of gelation 
      and/or sickling. All of these compounds require further development before they 
      can be considered for clinical use.
FAU - Chang, H
AU  - Chang H
FAU - Ewert, S M
AU  - Ewert SM
FAU - Bookchin, R M
AU  - Bookchin RM
FAU - Nagel, R L
AU  - Nagel RL
LA  - eng
GR  - HL-21016-05/HL/NHLBI NIH HHS/United States
GR  - N01-HB-8-2937/HB/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antisickling Agents)
RN  - 0 (Azepines)
RN  - 0 (Cyanates)
RN  - 0 (Hemoglobins)
RN  - 0 (Imidoesters)
RN  - 0 (dibromoacetylsalicylic acid)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 13139-70-3 (Dimethyl Adipimidate)
RN  - 367-47-5 (Glyceraldehyde)
RN  - 3THM379K8A (Pyridoxal)
RN  - 47E5O17Y3R (Phenylalanine)
RN  - 50D9XSG0VR (Mechlorethamine)
RN  - 590-55-6 (Carbamyl Phosphate)
RN  - 621RT200TO (cetiedil)
RN  - 71337-52-5 (bis(3,5-dibromosalicyl)succinate)
RN  - 8W8T17847W (Urea)
RN  - 9008-02-0 (deoxyhemoglobin)
RN  - 9CPL5NR15K (butylurea)
RN  - C1O9DI6F4U (methyl acetimidate)
RN  - G9C31TWN5M (potassium cyanate)
RN  - R110LV8L02 (Cystamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anemia, Sickle Cell/*drug therapy/metabolism
MH  - Antisickling Agents/*therapeutic use
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Azepines/therapeutic use
MH  - Carbamyl Phosphate/therapeutic use
MH  - Cyanates/therapeutic use
MH  - Cystamine/therapeutic use
MH  - Dimethyl Adipimidate/therapeutic use
MH  - Drug Evaluation
MH  - Erythrocyte Indices
MH  - Glyceraldehyde/therapeutic use
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Imidoesters/therapeutic use
MH  - Mechlorethamine/therapeutic use
MH  - Oxygen Consumption
MH  - Phenylalanine/therapeutic use
MH  - Pyridoxal/therapeutic use
MH  - Solubility
MH  - Urea/analogs & derivatives/therapeutic use
RF  - 64
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - S0006-4971(20)85626-2 [pii]
PST - ppublish
SO  - Blood. 1983 Apr;61(4):693-704.

PMID- 6810642
OWN - NLM
STAT- MEDLINE
DCOM- 19821021
LR  - 20201209
IS  - 0001-5172 (Print)
IS  - 0001-5172 (Linking)
VI  - 25
IP  - 6
DP  - 1981 Dec
TI  - Postoperative analgesics for superficial surgery. Comparison of four analgesics.
PG  - 543-7
AB  - The efficacy of mild analgesics after 160 various superficial operations was 
      studied by comparing intravenous lysine-acetylsalicylate (LAS) 1.8 g, Litalgin 4 
      ml (metamizole = dipyrone 2.0 g+ pitophenone 8.0 mg) or paracetamol 0.5 g to 
      oxycodone 4 mg. At 15 min postdrug, oxycodone 4 mg had the best peak effect but 
      this significant (P less than 0.05) difference to mild analgesics disappeared at 
      30 min, and thereafter all test analgesics showed an equally low effect. 
      Two-thirds of the patients anaesthetized without peroperative analgesics needed 
      pain relief when recovering from superficial surgery. The need for pain relief 
      was lowest after varicose vein operations 40% of the patients as compared to 
      about 70% after other types of superficial surgery. In 42% of the patients 
      requiring pain relief, the test analgesics alone gave sufficient pain relief. The 
      rest needed an additional 5 mg of oxycodone, on average, to be comfortable. The 
      combined use of mild analgesics and oxycodone for adequate pain relief did not 
      seem to reduce the postdrug sedation as compared to oxycodone alone. The results 
      indicate that in traditional clinical dosages LAS, dipyrone or paracetamol can 
      substitute about 5 mg oxycodone but offer sufficient analgesia only in about 40% 
      of the patients recovering from superficial surgery.
FAU - Tigerstedt, I
AU  - Tigerstedt I
FAU - Leander, P
AU  - Leander P
FAU - Tammisto, T
AU  - Tammisto T
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Acta Anaesthesiol Scand
JT  - Acta anaesthesiologica Scandinavica
JID - 0370270
RN  - 0 (Benzilates)
RN  - 0 (Benzophenones)
RN  - 0 (Drug Combinations)
RN  - 0 (Parasympatholytics)
RN  - 01704YP3MO (Aminopyrine)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 6429L0L52Y (Dipyrone)
RN  - 80186-93-2 (litalgin)
RN  - CD35PMG570 (Oxycodone)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aminopyrine/*analogs & derivatives
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Benzilates/*therapeutic use
MH  - Benzophenones/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Codeine/*analogs & derivatives
MH  - Dipyrone/*therapeutic use
MH  - Drug Combinations/therapeutic use
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Oxycodone/*therapeutic use
MH  - Pain, Postoperative/*drug therapy
MH  - Parasympatholytics/therapeutic use
EDAT- 1981/12/01 00:00
MHDA- 1981/12/01 00:01
CRDT- 1981/12/01 00:00
PHST- 1981/12/01 00:00 [pubmed]
PHST- 1981/12/01 00:01 [medline]
PHST- 1981/12/01 00:00 [entrez]
AID - 10.1111/j.1399-6576.1981.tb01702.x [doi]
PST - ppublish
SO  - Acta Anaesthesiol Scand. 1981 Dec;25(6):543-7. doi: 
      10.1111/j.1399-6576.1981.tb01702.x.

PMID- 30637134
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 2059-8696 (Electronic)
IS  - 2059-8688 (Linking)
VI  - 3
IP  - 4
DP  - 2018 Dec
TI  - Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a parallel, 
      randomised, open-label, multicentre, prospective study.
PG  - 263-267
LID - 10.1136/svn-2018-000148 [doi]
AB  - BACKGROUND: A recent study shows that dual antiplatelet therapy with clopidogrel 
      plus aspirin is superior to aspirin monotherapy for minor stroke, which is 
      defined as a National Institutes of Health Stroke Scale (NIHSS)score of ≤3. 
      However, acute mild-moderate ischaemic stroke (4≤NIHSS≤10) still needs aggressive 
      antiplatelet intervention to prevent deterioration and recurrence of stroke. The 
      efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy in 
      the population are not clear. A multicentre clinical trial is designed to 
      evaluate the efficacy and safety of clopidogrel plus aspirin therapy versus 
      aspirin monotherapy within 48 hours of symptom onset of mild-moderate ischaemic 
      stroke. METHODS/DESIGN: The study is a randomised, open-label, multicentre, 
      prospective trial with a target enrolment of 2700 patients from 60 centres in 
      Northeast China. A treatment allocation identification number to each enrolled 
      patient will be provided by a random number generator. The follow-up time for the 
      clopidogrel plus aspirin and aspirin monotherapy groups is 90 days. The primary 
      efficacy endpoint is a stroke progression event, which is defined as ≥4 point 
      increase in the NIHSS score in 48 hours. The second efficacy endpoints include 
      new ischaemic stroke within 90 days, change in the NIHSS score within 14 days, 
      modified Rankin Scale score on day 90 and other vascular or death events within 
      90 days. The safety endpoints include mucocutaneous haemorrhage, organ 
      haemorrhage and intracranial haemorrhage, adverse events and severe adverse 
      events. χ(2) test, t-test (or Mann-Whitney test), survival analysis and Cox 
      proportional hazards models will be conducted. The findings of the study may 
      provide an important evidence for clinical practice for these patients. 
      DISCUSSION: The trial will be conducted under a rational design and will provide 
      valuable evidence on the appropriate treatment for this population. ETHICS AND 
      DISSEMINATION: The study was reviewed and approved by the Ethics Committee of the 
      General Hospital of Shen-Yang Military Region (no K(2016) 6). TRIAL REGISTRATION 
      NUMBER: NCT02869009; Pre-results.
FAU - Hou, Xiaowen
AU  - Hou X
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, Shenyang, 
      China.
FAU - Li, Xiaoqiu
AU  - Li X
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, Shenyang, 
      China.
FAU - Wang, Xinhong
AU  - Wang X
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, Shenyang, 
      China.
FAU - Chen, Huisheng
AU  - Chen H
AUID- ORCID: 0000-0002-8490-9435
AD  - Department of Neurology, General Hospital of Shen-Yang Military Region, Shenyang, 
      China.
LA  - eng
SI  - ClinicalTrials.gov/NCT02869009
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180923
PL  - England
TA  - Stroke Vasc Neurol
JT  - Stroke and vascular neurology
JID - 101689996
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects/*therapeutic use
MH  - China
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Disability Evaluation
MH  - *Dual Anti-Platelet Therapy/adverse effects
MH  - Ischemic Stroke/diagnosis/*drug therapy/physiopathology
MH  - Multicenter Studies as Topic
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Recovery of Function
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC6312068
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - aspirin
OT  - clopidogrel plus aspirin
OT  - stroke
COIS- Competing interests: None declared.
EDAT- 2019/01/15 06:00
MHDA- 2019/01/15 06:01
CRDT- 2019/01/15 06:00
PHST- 2018/01/25 00:00 [received]
PHST- 2018/07/30 00:00 [revised]
PHST- 2018/08/31 00:00 [accepted]
PHST- 2019/01/15 06:00 [entrez]
PHST- 2019/01/15 06:00 [pubmed]
PHST- 2019/01/15 06:01 [medline]
AID - svn-2018-000148 [pii]
AID - 10.1136/svn-2018-000148 [doi]
PST - epublish
SO  - Stroke Vasc Neurol. 2018 Sep 23;3(4):263-267. doi: 10.1136/svn-2018-000148. 
      eCollection 2018 Dec.

PMID- 21139290
OWN - NLM
STAT- MEDLINE
DCOM- 20111108
LR  - 20221207
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 49
IP  - 23
DP  - 2010
TI  - Low-dose aspirin-induced gastroduodenal mucosal injury in Japanese patients with 
      arteriosclerotic disease.
PG  - 2537-45
AB  - BACKGROUND: We aimed to elucidate the risk factors and preventive factors 
      associated with chronic low-dose aspirin (L-ASA)-induced gastroduodenal mucosal 
      injury in Japanese patients with arteriosclerotic disease. METHODS: This 
      retrospective observational study included 400 L-ASA users who underwent upper 
      gastrointestinal endoscopy. We investigated patients' clinical characteristics, 
      including age, peptic ulcer history, concomitant drugs [i.e. gastric agents, 
      antiplatelet drugs, anticoagulants, non-steroidal anti-inflammatory drugs 
      (NSAIDs), corticosteroids], abdominal symptoms, endoscopic findings, and 
      interruption of L-ASA before endoscopy. The severity of gastroduodenal mucosal 
      lesions was evaluated using the modified LANZA score (MLS). RESULTS: Of 400 
      patients, 249 (62%) and 41 (10%) had gastroduodenal mucosal lesions (MLS ≥1) and 
      gastroduodenal ulcers, respectively. Peptic ulcer history, abdominal symptoms, 
      proton pump inhibitor (PPI), histamine type 2-receptor antagonists (H2RA), and 
      the cessation of L-ASA before endoscopy were significantly associated with 
      L-ASA-induced gastroduodenal ulcers; the odds ratio (OR) (confidence interval 
      (CI)) was 5.49 (1.82-16.55), 4.56 (1.93-10.75), 0.12 (0.03-0.42), 0.13 
      (0.04-0.40) and 0.11 (0.04-0.29), respectively. Moreover, patients having two or 
      more of five factors [i.e. advanced age (≥75), anticoagulants, antiplatelet 
      drugs, NSAIDs and corticosteroids] had a significantly higher prevalence of 
      L-ASA-induced gastroduodenal ulcers [OR (CI): 2.39 (1.002-5.69)]. CONCLUSION: 
      Peptic ulcer history, abdominal symptoms and the summation of risk factors 
      increased the risk for L-ASA-induced gastroduodenal ulcers. H2RAs and PPIs were 
      effective for the prevention of L-ASA-induced gastroduodenal ulcers. The 
      cessation of L-ASA before endoscopy might lead to the underestimation of 
      L-ASA-induced gastroduodenal injury.
FAU - Tamura, Isamu
AU  - Tamura I
AD  - Department of Gastroenterology, Kobe University Graduate School of Medicine.
FAU - Fujita, Tsuyoshi
AU  - Fujita T
FAU - Tsumura, Hidetaka
AU  - Tsumura H
FAU - Morita, Yoshinori
AU  - Morita Y
FAU - Yoshida, Masaru
AU  - Yoshida M
FAU - Toyonaga, Takashi
AU  - Toyonaga T
FAU - Hirano, Seiichi
AU  - Hirano S
FAU - Inokuchi, Hideto
AU  - Inokuchi H
FAU - Kutsumi, Hiromu
AU  - Kutsumi H
FAU - Azuma, Takeshi
AU  - Azuma T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101201
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arteriosclerosis/*drug therapy/epidemiology
MH  - *Asian People
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Female
MH  - Histamine H2 Antagonists/therapeutic use
MH  - Humans
MH  - Intestinal Mucosa/*drug effects/pathology
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*chemically induced/diagnosis/prevention & control
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Young Adult
EDAT- 2010/12/09 06:00
MHDA- 2011/11/09 06:00
CRDT- 2010/12/09 06:00
PHST- 2010/12/09 06:00 [entrez]
PHST- 2010/12/09 06:00 [pubmed]
PHST- 2011/11/09 06:00 [medline]
AID - JST.JSTAGE/internalmedicine/49.3824 [pii]
AID - 10.2169/internalmedicine.49.3824 [doi]
PST - ppublish
SO  - Intern Med. 2010;49(23):2537-45. doi: 10.2169/internalmedicine.49.3824. Epub 2010 
      Dec 1.

PMID- 19249402
OWN - NLM
STAT- MEDLINE
DCOM- 20090609
LR  - 20131211
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
VI  - 7
IP  - 5
DP  - 2009 May
TI  - Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a 
      multidimensional assessment.
PG  - 524-9
LID - 10.1016/j.cgh.2008.12.019 [doi]
AB  - BACKGROUND & AIMS: Whether low-dose aspirin (acetylsalicylic acid [ASA]) produces 
      intestinal damage is controversial. Our aim was to determine whether the small 
      bowel is damaged by low-dose ASA on a short-term basis. METHODS: Twenty healthy 
      volunteers (age range, 19-64 years) underwent video capsule endoscopy (VCE), 
      fecal calprotectin, and permeability tests (sucrose and lactulose/mannitol 
      [lac/man] ratio) before and after ingestion of 100 mg of enteric-coated ASA daily 
      for 14 days. Video capsule images were assessed by 2 independent expert 
      endoscopists, fully blinded to the treatment group, by using an endoscopic scale. 
      RESULTS: Post-ASA VCE detected 10 cases (50%) with mucosal damage not apparent in 
      baseline studies (6 cases had petechiae, 3 had erosions, and 1 had bleeding 
      stigmata in 2 ulcers). The median baseline lac/man ratio (0.021; range, 
      0.011-0.045) increased after ASA use (0.036; range, 0.007-0.258; P = .08), and 
      the post-ASA lac/man ratio was above the upper end of normal (>0.025) in 10 of 20 
      volunteers (vs baseline, P < .02). The median baseline fecal calprotectin 
      concentration (6.05 microg/g; range, 1.9-79.2) also increased significantly after 
      ASA use (23.9 microg/g; range, 3.1-75.3; P < .0005), with 3 patients having 
      values above the cutoff (>50 microg/g). Five of 10 subjects with abnormal 
      findings at VCE also had lac/man ratios above the cutoff. Median baseline sucrose 
      urinary excretion (70.0 mg; range, 11.8-151.3) increased significantly after ASA 
      administration (107.0 mg; range, 22.9-411.3; P < .05). CONCLUSIONS: The 
      short-term administration of low-dose ASA is associated with mucosal 
      abnormalities of the small bowel mucosa, which might have implications in 
      clinical practice.
FAU - Smecuol, Edgardo
AU  - Smecuol E
AD  - Department of Medicine, Hospital de Gastroenterología Dr. Carlos Bonorino 
      Udaondo, Buenos Aires, Argentina.
FAU - Pinto Sanchez, Maria Ines
AU  - Pinto Sanchez MI
FAU - Suarez, Alejandro
AU  - Suarez A
FAU - Argonz, Julio E
AU  - Argonz JE
FAU - Sugai, Emilia
AU  - Sugai E
FAU - Vazquez, Horacio
AU  - Vazquez H
FAU - Litwin, Nestor
AU  - Litwin N
FAU - Piazuelo, Elena
AU  - Piazuelo E
FAU - Meddings, Jonathan B
AU  - Meddings JB
FAU - Bai, Julio C
AU  - Bai JC
FAU - Lanas, Angel
AU  - Lanas A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081227
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal 
      of the American Gastroenterological Association
JID - 101160775
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Leukocyte L1 Antigen Complex)
RN  - 57-50-1 (Sucrose)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Clin Gastroenterol Hepatol. 2010 Feb;8(2):223-4; author reply 224-5. PMID: 
      19665582
MH  - Adult
MH  - Anti-Inflammatory Agents/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Capsule Endoscopy
MH  - Feces/chemistry
MH  - Female
MH  - Glucose/metabolism
MH  - Healthy Volunteers
MH  - Humans
MH  - Intestinal Mucosa/*drug effects/pathology
MH  - Intestine, Small/*drug effects/pathology
MH  - Leukocyte L1 Antigen Complex/analysis
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Sucrose/metabolism
MH  - Young Adult
EDAT- 2009/03/03 09:00
MHDA- 2009/06/10 09:00
CRDT- 2009/03/03 09:00
PHST- 2008/09/14 00:00 [received]
PHST- 2008/12/07 00:00 [revised]
PHST- 2008/12/14 00:00 [accepted]
PHST- 2009/03/03 09:00 [entrez]
PHST- 2009/03/03 09:00 [pubmed]
PHST- 2009/06/10 09:00 [medline]
AID - S1542-3565(08)01250-0 [pii]
AID - 10.1016/j.cgh.2008.12.019 [doi]
PST - ppublish
SO  - Clin Gastroenterol Hepatol. 2009 May;7(5):524-9. doi: 10.1016/j.cgh.2008.12.019. 
      Epub 2008 Dec 27.

PMID- 28946463
OWN - NLM
STAT- MEDLINE
DCOM- 20180723
LR  - 20180723
IS  - 1873-2828 (Electronic)
IS  - 1350-4177 (Linking)
VI  - 40
IP  - Pt A
DP  - 2018 Jan
TI  - Ultrasound-assisted lipase catalyzed hydrolysis of aspirin methyl ester.
PG  - 587-593
LID - S1350-4177(17)30358-9 [pii]
LID - 10.1016/j.ultsonch.2017.08.004 [doi]
AB  - The ultrasound-assisted hydrolysis of aspirin methyl ester (AME) was investigated 
      using immobilized Candida antarctica lipase B (CALB) (1%) in the presence of 
      solvents like triolein, chloroform (CHCl(3)) and dichloromethane (DCM). The 
      effect of ultrasound and the role of water on the conversion rates have also been 
      investigated. Proton nuclear magnetic resonance spectroscopic ((1)H NMR) was 
      chosen to calculate hydrolysis convertion rates. We observed that 
      lipase-ultrasound assisted hydrolysis of AME in the presence of triolein and 
      water showed the highest hydrolysis conversion rate (65.3%). Herein low water 
      amount played an important role as a nucleophile being crucial for the hydrolysis 
      yields obtained. Lipase activity was affected by the conjugated action of 
      ultrasound and solvents (35.75% of decrease), however not disturbing its 
      hydrolytic efficiency. It was demonstrated that lipase is able to hydrolyse AME 
      to methyl 2-hydroxy benzoate (methyl salicylate), which applications include 
      fragrance agents in food, beverages and cosmetics, or analgesic agent in 
      liniments.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - Chiplunkar, Pranali P
AU  - Chiplunkar PP
AD  - International Joint Research Laboratory for Textile and Fiber Bioprocesses, 
      Jiangnan University, Wuxi 214122, China; Department of Oils, Oleochemicals and 
      Surfactants Technology, Institute of Chemical Technology, Matunga (E), Mumbai 
      400019, India.
FAU - Zhao, Xiaoman
AU  - Zhao X
AD  - International Joint Research Laboratory for Textile and Fiber Bioprocesses, 
      Jiangnan University, Wuxi 214122, China; Jiangsu Engineering Technology Research 
      Center for Functional Textiles, Institute of Chemical Technology, Matunga (E), 
      Mumbai 400019, India; Key Laboratory of Science and Technology of Eco-Textiles, 
      Ministry of Education, Jiangnan University, Wuxi 214122, Jiangsu, China.
FAU - Tomke, Prerana D
AU  - Tomke PD
AD  - International Joint Research Laboratory for Textile and Fiber Bioprocesses, 
      Jiangnan University, Wuxi 214122, China; Department of Chemical Engineering, 
      Institute of Chemical Technology, Matunga (E), Mumbai 400019, India.
FAU - Noro, Jennifer
AU  - Noro J
AD  - Centre of Biological Engineering, University of Minho, Campus de Gualtar, 
      4710-057, Braga, Portugal.
FAU - Xu, Bo
AU  - Xu B
AD  - International Joint Research Laboratory for Textile and Fiber Bioprocesses, 
      Jiangnan University, Wuxi 214122, China.
FAU - Wang, Qiang
AU  - Wang Q
AD  - International Joint Research Laboratory for Textile and Fiber Bioprocesses, 
      Jiangnan University, Wuxi 214122, China.
FAU - Silva, Carla
AU  - Silva C
AD  - Centre of Biological Engineering, University of Minho, Campus de Gualtar, 
      4710-057, Braga, Portugal.
FAU - Pratap, Amit P
AU  - Pratap AP
AD  - Department of Oils, Oleochemicals and Surfactants Technology, Institute of 
      Chemical Technology, Matunga (E), Mumbai 400019, India.
FAU - Cavaco-Paulo, Artur
AU  - Cavaco-Paulo A
AD  - International Joint Research Laboratory for Textile and Fiber Bioprocesses, 
      Jiangnan University, Wuxi 214122, China; Centre of Biological Engineering, 
      University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal. Electronic 
      address: artur@deb.uminho.pt.
LA  - eng
PT  - Journal Article
DEP - 20170805
PL  - Netherlands
TA  - Ultrason Sonochem
JT  - Ultrasonics sonochemistry
JID - 9433356
RN  - 0 (Enzymes, Immobilized)
RN  - 0 (Fungal Proteins)
RN  - 0 (Solvents)
RN  - EC 3.1.1.3 (Lipase)
RN  - EC 3.1.1.3 (lipase B, Candida antarctica)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - *Biocatalysis
MH  - *Enzymes, Immobilized/chemistry/metabolism
MH  - Fungal Proteins/chemistry/*metabolism
MH  - Hydrolysis
MH  - Lipase/chemistry/*metabolism
MH  - Solvents/chemistry
MH  - *Ultrasonic Waves
OTO - NOTNLM
OT  - Aspirin methyl ester
OT  - Hydrolysis
OT  - Lipase
OT  - Ultrasound
OT  - Water
EDAT- 2017/09/28 06:00
MHDA- 2018/07/24 06:00
CRDT- 2017/09/27 06:00
PHST- 2016/09/20 00:00 [received]
PHST- 2017/01/02 00:00 [revised]
PHST- 2017/08/05 00:00 [accepted]
PHST- 2017/09/27 06:00 [entrez]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2018/07/24 06:00 [medline]
AID - S1350-4177(17)30358-9 [pii]
AID - 10.1016/j.ultsonch.2017.08.004 [doi]
PST - ppublish
SO  - Ultrason Sonochem. 2018 Jan;40(Pt A):587-593. doi: 
      10.1016/j.ultsonch.2017.08.004. Epub 2017 Aug 5.

PMID- 33682036
OWN - NLM
STAT- MEDLINE
DCOM- 20210716
LR  - 20210716
IS  - 1432-1262 (Electronic)
IS  - 0179-1958 (Linking)
VI  - 36
IP  - 8
DP  - 2021 Aug
TI  - Influence of aspirin on prevention of colorectal cancer: an updated systematic 
      review and meta-analysis of randomized controlled trials.
PG  - 1711-1722
LID - 10.1007/s00384-021-03880-3 [doi]
AB  - PURPOSE: Colorectal cancer is the second most common cause of cancer death 
      worldwide. Aspirin, due to its antineoplastic effects, has been suggested to have 
      chemopreventive effects on colorectal cancer based on recent trials. We conducted 
      this systematic review and meta-analysis to provide an updated evidence about the 
      long-term efficacy of daily aspirin use in the prevention of colorectal cancer. 
      METHODS: We searched Medline/PubMed, Ovid, Web of Science, and Cochrane Library. 
      We included randomized controlled trials (RCTs) that compared the efficacy of 
      daily aspirin use to placebo in healthy individuals at the time of study entry. 
      The desired outcomes of this review were the incidence of advanced lesions (i.e., 
      adenomas with villous component, adenomas ≥1 cm in diameter, adenomas with 
      high-grade dysplasia, and/or invasive cancer) and colorectal adenomas. RESULTS: A 
      total of 15 articles representing 11 RCTs were included. Overall, the results 
      indicated that aspirin significantly reduced the risk of developing colorectal 
      adenomas but not advanced lesions at 3 years (risk ratio (RR) = 0.84, P < 0.05 
      and risk ratio = 0.82, P = 0.10, respectively). At 5 years, the risk of advanced 
      lesions but not adenomas was reduced by aspirin (RR = 0.68, P < 0.05 and 
      RR = 0.87, P = 0.22, respectively). Aspirin was not found to have an effect on 
      the risk of advanced lesions or adenomas beyond 5 years (hazard ratio 
      (HR) = 0.82, P = 0.07 and HR = 0.99, P = 0.82, respectively). CONCLUSION: 
      Overall, aspirin (particularly high dose) only reduced the risk of advanced 
      lesions up to 5 years.
CI  - © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part 
      of Springer Nature.
FAU - Ghaddaf, Abdullah A
AU  - Ghaddaf AA
AUID- ORCID: 0000-0002-0170-9754
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences, 
      Jeddah, 22384, Saudi Arabia. abdullahg.official@gmail.com.
AD  - King Abdullah International Medical Research Center, Jeddah, 22384, Saudi Arabia. 
      abdullahg.official@gmail.com.
FAU - Aziz, Muhammad
AU  - Aziz M
AD  - Division of Gastroenterology and Hepatology, University of Toledo, Toledo, OH, 
      USA.
FAU - Alomari, Mohammed S
AU  - Alomari MS
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences, 
      Jeddah, 22384, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, 22384, Saudi Arabia.
FAU - Abdulhamid, Ahmed S
AU  - Abdulhamid AS
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences, 
      Jeddah, 22384, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, 22384, Saudi Arabia.
FAU - Alharbi, Fahad A
AU  - Alharbi FA
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences, 
      Jeddah, 22384, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, 22384, Saudi Arabia.
FAU - Mullah, Abdullah N
AU  - Mullah AN
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences, 
      Jeddah, 22384, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, 22384, Saudi Arabia.
FAU - Zaidi, Syed Fasial
AU  - Zaidi SF
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences, 
      Jeddah, 22384, Saudi Arabia.
AD  - King Abdullah International Medical Research Center, Jeddah, 22384, Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210308
PL  - Germany
TA  - Int J Colorectal Dis
JT  - International journal of colorectal disease
JID - 8607899
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Adenoma/prevention & control
MH  - Aspirin/therapeutic use
MH  - *Colorectal Neoplasms/epidemiology/prevention & control
MH  - Humans
MH  - Incidence
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Advanced adenomas
OT  - Familial adenomatous polyposis
OT  - Lynch syndrome
OT  - Meta-analysis
OT  - Tubular adenomas
EDAT- 2021/03/09 06:00
MHDA- 2021/07/17 06:00
CRDT- 2021/03/08 05:59
PHST- 2021/02/03 00:00 [accepted]
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/07/17 06:00 [medline]
PHST- 2021/03/08 05:59 [entrez]
AID - 10.1007/s00384-021-03880-3 [pii]
AID - 10.1007/s00384-021-03880-3 [doi]
PST - ppublish
SO  - Int J Colorectal Dis. 2021 Aug;36(8):1711-1722. doi: 10.1007/s00384-021-03880-3. 
      Epub 2021 Mar 8.

PMID- 16565564
OWN - NLM
STAT- MEDLINE
DCOM- 20060907
LR  - 20220409
IS  - 1346-9843 (Print)
IS  - 1346-9843 (Linking)
VI  - 70
IP  - 4
DP  - 2006 Apr
TI  - Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral 
      infarction.
PG  - 453-8
AB  - BACKGROUND: The antiplatelet agent, cilostazol, is known to reduce the risk of 
      subsequent cerebral infarction. However, the cost effectiveness of such treatment 
      in comparison to aspirin has not been studied. METHODS AND RESULTS: A Markov 
      model was developed to calculate the health outcomes and associated costs for 
      65-year-old patients with cerebral infarction who were treated with 200 mg/day 
      cilostazol or 81 mg/day aspirin. Cilostazol was more effective, but also more 
      expensive than aspirin. Cilostazol would extend quality-adjusted life years 
      (QALY) by 0.64, while increasing life-time costs by approximately Yen 1.1 
      million. The incremental cost-effectiveness ratio of cilostazol in comparison 
      with aspirin was estimated to be Yen 1.8 million per QALY. CONCLUSIONS: The use 
      of cilostazol to prevent recurrence of cerebral infarction appears to be cost 
      effective.
FAU - Inoue, Tadao
AU  - Inoue T
AD  - Department of Pharmacy, St. Luke's International Hospital, Tokyo, Japan. 
      tadaoino@luke.or.jp
FAU - Kobayashi, Makoto
AU  - Kobayashi M
FAU - Uetsuka, Yoshio
AU  - Uetsuka Y
FAU - Uchiyama, Shinichiro
AU  - Uchiyama S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/economics/therapeutic use
MH  - Case-Control Studies
MH  - Cerebral Infarction/*drug therapy/economics/*prevention & control
MH  - Cilostazol
MH  - Cost-Benefit Analysis
MH  - Health Care Costs
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Models, Econometric
MH  - Models, Statistical
MH  - Platelet Aggregation Inhibitors/economics/*therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Tetrazoles/economics/*therapeutic use
MH  - Time Factors
EDAT- 2006/03/28 09:00
MHDA- 2006/09/08 09:00
CRDT- 2006/03/28 09:00
PHST- 2006/03/28 09:00 [pubmed]
PHST- 2006/09/08 09:00 [medline]
PHST- 2006/03/28 09:00 [entrez]
AID - JST.JSTAGE/circj/70.453 [pii]
AID - 10.1253/circj.70.453 [doi]
PST - ppublish
SO  - Circ J. 2006 Apr;70(4):453-8. doi: 10.1253/circj.70.453.

PMID- 9475686
OWN - NLM
STAT- MEDLINE
DCOM- 19980409
LR  - 20131121
IS  - 0735-1631 (Print)
IS  - 0735-1631 (Linking)
VI  - 15
IP  - 1
DP  - 1998 Jan
TI  - Aspirin poisoning during pregnancy: increased fetal sensitivity.
PG  - 39-41
AB  - Descriptions of salicylate poisoning during pregnancy are rare and unique 
      features of perinatal physiology predict an increased sensitivity of the fetus to 
      aspirin poisoning. A 17-year-old, 37-week pregnant woman presented to the 
      hospital stating that she had ingested 50 aspirin tablets per day for 1 month in 
      an attempt to harm her baby and herself. Ultrasound showed fetal demise. Serum 
      salicylate was 620 mg/L with an anion gap of 22.6 and the following blood gases: 
      pO2 108 mm Hg, pCO2 15mm Hg, pH 7.34, and HCO3 8.8 mmol/L. She was successfully 
      treated with alkaline diuresis followed by hemodialysis. She spontaneously 
      delivered a macerated stillborn 2380-g fetus. Autopsy revealed diffuse petechiae 
      in the lungs, heart, thymus, and kidneys. Salicylic acid was found in the cord 
      blood, but quantification was not possible due to the small volume of the blood 
      sample. Our patient supports the hypothesis that the fetus is at greater risk 
      than the mother in salicylate poisoning during pregnancy. Consideration should be 
      given to emergent delivery of term or near-term, aspirin-poisoned fetuses.
FAU - Palatnick, W
AU  - Palatnick W
AD  - Department of Family Medicine, University of Manitoba and Children's Hospital, 
      Winnipeg, Canada.
FAU - Tenenbein, M
AU  - Tenenbein M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Blood Glucose)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anti-Inflammatory Agents, Non-Steroidal/blood/*poisoning
MH  - Aspirin/blood/*poisoning
MH  - Blood Gas Analysis
MH  - Blood Glucose/analysis
MH  - Diuresis
MH  - Female
MH  - Fetal Blood/chemistry
MH  - Fetal Death/*chemically induced
MH  - Fetus/*drug effects
MH  - Humans
MH  - Male
MH  - Pregnancy
MH  - Renal Dialysis
MH  - Vitamin K/therapeutic use
EDAT- 1998/02/25 00:00
MHDA- 1998/02/25 00:01
CRDT- 1998/02/25 00:00
PHST- 1998/02/25 00:00 [pubmed]
PHST- 1998/02/25 00:01 [medline]
PHST- 1998/02/25 00:00 [entrez]
AID - 10.1055/s-2007-993896 [doi]
PST - ppublish
SO  - Am J Perinatol. 1998 Jan;15(1):39-41. doi: 10.1055/s-2007-993896.

PMID- 19955429
OWN - NLM
STAT- MEDLINE
DCOM- 20100309
LR  - 20211020
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 107
IP  - 1
DP  - 2010 Jan 5
TI  - Coxibs interfere with the action of aspirin by binding tightly to one monomer of 
      cyclooxygenase-1.
PG  - 28-33
LID - 10.1073/pnas.0909765106 [doi]
AB  - Pain associated with inflammation involves prostaglandins synthesized from 
      arachidonic acid (AA) through cyclooxygenase-2 (COX-2) pathways while thromboxane 
      A(2) formed by platelets from AA via cyclooxygenase-1 (COX-1) mediates 
      thrombosis. COX-1 and COX-2 are both targets of nonselective nonsteroidal 
      antiinflammatory drugs (nsNSAIDs) including aspirin whereas COX-2 activity is 
      preferentially blocked by COX-2 inhibitors called coxibs. COXs are homodimers 
      composed of identical subunits, but we have shown that only one subunit is active 
      at a time during catalysis; moreover, many nsNSAIDS bind to a single subunit of a 
      COX dimer to inhibit the COX activity of the entire dimer. Here, we report the 
      surprising observation that celecoxib and other coxibs bind tightly to a subunit 
      of COX-1. Although celecoxib binding to one monomer of COX-1 does not affect the 
      normal catalytic processing of AA by the second, partner subunit, celecoxib does 
      interfere with the inhibition of COX-1 by aspirin in vitro. X-ray 
      crystallographic results obtained with a celecoxib/COX-1 complex show how 
      celecoxib can bind to one of the two available COX sites of the COX-1 dimer. 
      Finally, we find that administration of celecoxib to dogs interferes with the 
      ability of a low dose of aspirin to inhibit AA-induced ex vivo platelet 
      aggregation. COX-2 inhibitors such as celecoxib are widely used for pain relief. 
      Because coxibs exhibit cardiovascular side effects, they are often prescribed in 
      combination with low-dose aspirin to prevent thrombosis. Our studies predict that 
      the cardioprotective effect of low-dose aspirin on COX-1 may be blunted when 
      taken with coxibs.
FAU - Rimon, Gilad
AU  - Rimon G
AD  - Department of Biological Chemistry, University of Michigan, Ann Arbor, MI 4810, 
      USA.
FAU - Sidhu, Ranjinder S
AU  - Sidhu RS
FAU - Lauver, D Adam
AU  - Lauver DA
FAU - Lee, Jullia Y
AU  - Lee JY
FAU - Sharma, Narayan P
AU  - Sharma NP
FAU - Yuan, Chong
AU  - Yuan C
FAU - Frieler, Ryan A
AU  - Frieler RA
FAU - Trievel, Raymond C
AU  - Trievel RC
FAU - Lucchesi, Benedict R
AU  - Lucchesi BR
FAU - Smith, William L
AU  - Smith WL
LA  - eng
SI  - PDB/3KK6
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20091201
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Protein Subunits)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/metabolism/pharmacology
MH  - Aspirin/chemistry/metabolism/pharmacology
MH  - Catalytic Domain
MH  - Crystallography, X-Ray
MH  - Cyclooxygenase 1/chemistry/*metabolism
MH  - Cyclooxygenase 2 Inhibitors/chemistry/*metabolism/pharmacology
MH  - Cyclooxygenase Inhibitors/chemistry/*metabolism/pharmacology
MH  - Dogs
MH  - Humans
MH  - Isoenzymes/chemistry/*metabolism
MH  - Models, Molecular
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/metabolism/pharmacology
MH  - Protein Binding
MH  - Protein Conformation
MH  - Protein Subunits/chemistry/metabolism
PMC - PMC2806742
COIS- The authors declare no conflict of interest.
EDAT- 2009/12/04 06:00
MHDA- 2010/03/10 06:00
CRDT- 2009/12/04 06:00
PHST- 2009/12/04 06:00 [entrez]
PHST- 2009/12/04 06:00 [pubmed]
PHST- 2010/03/10 06:00 [medline]
AID - 0909765106 [pii]
AID - 200909765 [pii]
AID - 10.1073/pnas.0909765106 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):28-33. doi: 10.1073/pnas.0909765106. 
      Epub 2009 Dec 1.

PMID- 35271538
OWN - NLM
STAT- MEDLINE
DCOM- 20220524
LR  - 20220621
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 139
IP  - 4
DP  - 2022 Apr 1
TI  - Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a 
      Subsequent Pregnancy.
PG  - 529-535
LID - 10.1097/AOG.0000000000004696 [doi]
AB  - OBJECTIVE: To estimate whether low-dose aspirin use is associated with an altered 
      risk of delivering a small-for-gestational age (SGA) neonate among women with a 
      history of having an SGA neonate in a prior pregnancy. METHODS: We performed a 
      Swedish register-based cohort study including women in their second pregnancy who 
      had a history of having an SGA neonate (birth weight less than the 10th 
      percentile). The association between use of low-dose aspirin in subsequent 
      pregnancy and birth of an SGA neonate or a severely SGA neonate (birth weight 
      less than the third percentile) were estimated using inverse propensity-weighted 
      estimation, accounting for potential confounders. RESULTS: Among 8,416 women who 
      gave birth to an SGA neonate in their first pregnancy, 801 (9.5%) used low-dose 
      aspirin during their second pregnancy. The incidence of SGA neonates was similar 
      among women using low-dose aspirin (21.7%) and those who did not use aspirin 
      (20.7%). Low-dose aspirin use in pregnancy was not associated with an altered 
      risk of having an SGA neonate (adjusted relative risk [aRR] 0.86, 95% CI 
      0.67-1.10) or a severely SGA neonate (aRR 0.98, 95% CI 0.71-1.34). Given the 
      strong association between preeclampsia and SGA, we performed subgroup analyses 
      based on preeclampsia status. Among women who had an SGA neonate and co-existing 
      preeclampsia in their first pregnancy, low-dose aspirin was not associated with 
      an altered risk of having an SGA (aRR 0.83, 95% CI 0.63-1.10) or severely SGA 
      (aRR 1.02, 95% CI 0.73-1.44) neonate. Additionally, no association was seen among 
      women who developed preeclampsia in their second pregnancy. CONCLUSION: Among 
      women with a history of having an SGA neonate, low-dose aspirin was not 
      associated with a decreased risk of having an SGA or severely SGA neonate in 
      subsequent pregnancy. These findings suggest that low-dose aspirin should not be 
      used to prevent recurrent SGA.
CI  - Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Hastie, Roxanne
AU  - Hastie R
AD  - Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden; 
      Mercy Perinatal, Mercy Hospital for Women, Melbourne, Australia; the 
      Translational Obstetrics Group, Department of Obstetrics and Gynaecology, 
      University of Melbourne, Heidelberg, Australia; the Department of Obstetrics and 
      Gynaecology, Stellenbosch University, Cape Town, South Africa; the Centre for 
      Clinical Research, Dalarna, Sweden; and the Department of Obstetrics and 
      Gynecology, Institute of Clinical Science, Sahlgrenska Academy, University of 
      Gothenburg, Gothenburg, Sweden.
FAU - Tong, Stephen
AU  - Tong S
FAU - Wikström, Anna-Karin
AU  - Wikström AK
FAU - Walker, Susan P
AU  - Walker SP
FAU - Lindquist, Anthea
AU  - Lindquist A
FAU - Cluver, Catherine A
AU  - Cluver CA
FAU - Kupka, Ellen
AU  - Kupka E
FAU - Bergman, Lina
AU  - Bergman L
FAU - Hesselman, Susanne
AU  - Hesselman S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220310
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Birth Weight
MH  - Cohort Studies
MH  - Female
MH  - Fetal Growth Retardation
MH  - Gestational Age
MH  - Humans
MH  - Infant, Newborn
MH  - *Infant, Newborn, Diseases
MH  - Infant, Small for Gestational Age
MH  - *Pre-Eclampsia/prevention & control
MH  - Pregnancy
PMC - PMC8936148
COIS- Financial Disclosure: Stephen Tong is a board member of the Menzies Research 
      Institute of Medical Research. Lina Bergman collaborates with Perkin Elmer, Roche 
      and Termo Fischer in a prediction trial of preeclampsia where the companies 
      provide the study with PlGF reagents. However, the companies have no role in the 
      design of that study and it is not related to this work. Susanne Hesselman 
      reports for serving on an advisory board for Baxter Medical AB outside the 
      submitted work. The other authors did not report any potential conflicts of 
      interest.
EDAT- 2022/03/11 06:00
MHDA- 2022/05/25 06:00
CRDT- 2022/03/10 17:14
PHST- 2021/10/19 00:00 [received]
PHST- 2021/12/09 00:00 [accepted]
PHST- 2022/03/11 06:00 [pubmed]
PHST- 2022/05/25 06:00 [medline]
PHST- 2022/03/10 17:14 [entrez]
AID - 00006250-202204000-00008 [pii]
AID - ONG-21-2106 [pii]
AID - 10.1097/AOG.0000000000004696 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2022 Apr 1;139(4):529-535. doi: 10.1097/AOG.0000000000004696. 
      Epub 2022 Mar 10.

PMID- 1637025
OWN - NLM
STAT- MEDLINE
DCOM- 19920821
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 117
IP  - 4
DP  - 1992 Aug 15
TI  - Antiphospholipid thrombosis: clinical course after the first thrombotic event in 
      70 patients.
PG  - 303-8
AB  - OBJECTIVE: To determine the clinical course and influence of antithrombotic 
      therapy in patients with lupus anticoagulant or anticardiolipin antibodies, or 
      both, after the first thromboembolic event. DESIGN: Retrospective survey of 
      consecutive patients treated according to their physician's best judgment. 
      SETTING: Secondary and tertiary referral practice. PATIENTS: Seventy patients (48 
      women [69%]) with a mean age (+/- SD) of 45.5 +/- 17.3 years. The 
      antiphospholipid syndrome was primary in 51 patients (73%) and secondary to 
      systemic lupus erythematosus in 14 patients (20%) and to chronic idiopathic 
      thrombocytopenic purpura in 5 patients (7%). MEASUREMENTS: Site of initial and 
      recurrent thrombotic events (venous or arterial), as well as kind (aspiring, 
      heparin, or warfarin) and intensity of anticoagulation. RESULTS: Total follow-up 
      after the first thrombotic event was 361.0 patient-years (mean [+/- SD], 5.2 +/- 
      5.6 years per patient). Thirty-seven patients (53%) had 54 recurrent events, with 
      2 patients experiencing fatal events. Arterial events were followed by arterial 
      events, and venous events by venous events, in 49 of 54 instances (91%). 
      Recurrence rates during "no treatment;" aspirin therapy; or low-, intermediate-, 
      or high-intensity warfarin therapy (international normalized ratios [INRs] less 
      than or equal to 1.9, 2.0 to 2.9, and greater than or equal to 3.0, respectively, 
      or rabbit brain thromboplastin prothrombin time ratios of approximately less than 
      1.3, 1.3 to 1.5, and greater than 1.5, respectively) were 0.19, 0.32, 0.57, 0.07 
      (P = 0.12), and 0.00 (P less than 0.001) per patient-year. The follow-up periods 
      for the five types of therapy were 161.2, 37.8, 11.3, 40.9, and 110.2 
      patient-years, respectively. The highest INR coincident with thrombosis was 2.6. 
      Five warfarin-treated patients had five significant bleeding events (0.031 per 
      patient-year). CONCLUSIONS: Recurrent thrombosis is a potentially serious problem 
      for patients with lupus anticoagulant or anticardiolipin antibodies or both. The 
      site of the first event (arterial or venous) tended to predict the site of 
      subsequent events. Intermediate- to high-intensity warfarin therapy may confer 
      better antithrombotic protection than low- to intermediate-intensity warfarin 
      therapy or aspirin therapy. Further studies are needed to define more precisely 
      the rethrombosis rate and optimal type, intensity, and duration of antithrombotic 
      therapy.
FAU - Rosove, M H
AU  - Rosove MH
AD  - UCLA School of Medicine.
FAU - Brewer, P M
AU  - Brewer PM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Antiphospholipid Syndrome/*drug therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Heparin/adverse effects/*therapeutic use
MH  - Humans
MH  - Lupus Erythematosus, Systemic/complications
MH  - Male
MH  - Middle Aged
MH  - Purpura, Thrombocytopenic, Idiopathic/complications
MH  - Recurrence
MH  - Retrospective Studies
MH  - Thrombosis/*immunology/prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 1992/08/15 00:00
MHDA- 1992/08/15 00:01
CRDT- 1992/08/15 00:00
PHST- 1992/08/15 00:00 [pubmed]
PHST- 1992/08/15 00:01 [medline]
PHST- 1992/08/15 00:00 [entrez]
AID - 10.7326/0003-4819-117-4-303 [doi]
PST - ppublish
SO  - Ann Intern Med. 1992 Aug 15;117(4):303-8. doi: 10.7326/0003-4819-117-4-303.

PMID- 7337551
OWN - NLM
STAT- MEDLINE
DCOM- 19820512
LR  - 20131121
IS  - 0098-6127 (Print)
IS  - 0098-6127 (Linking)
VI  - 9
IP  - 6
DP  - 1981
TI  - The effect of low-dose aspirin and dipyridamole upon atherosclerosis in the 
      rabbit.
PG  - 405-13
AB  - To examine the effect of antiplatelet therapy upon atherosclerosis in an animal 
      model, aspirin and dipyridamole were administered to female New Zealand rabbits 
      while they were fed a 2% cholesterol diet. Four experimental groups of 15 animals 
      were established: Group I (Control), no medication; Group II, aspirin, 40 mg 
      orally five days a week; Group III, dipyridamole, 25 mg orally five days a week; 
      Group IV, aspirin and dipyridamole. After seven weeks, the animals were 
      sacrificed and their aortas were removed and stained. Group means of the 
      percentage of total aortic lumenal surface occupied by gross atheromata were 
      calculated and statistically compared with the control group mean: Group I - 49%, 
      Group II 36%, p = NS, Group III - 47%, Group IV - 25%, p less than .01. 
      Histologic sections of each aorta confirmed the stained areas to be atheromata of 
      varying complexity. The lesions in animals treated with dipyridamole alone 
      exhibited a distinct increase in smooth muscle cell proliferation. For animals 
      receiving a combination of aspirin and dipyridamole the lesions were smaller and 
      less advanced than those in the control group. These findings indicate that 
      experimental atherosclerosis in rabbits is modified by the administration of 
      anti-platelet agents and that atheroma formation is significantly inhibited when 
      aspirin and dipyridamole are given in combination.
FAU - Koster, J K Jr
AU  - Koster JK Jr
FAU - Tryka, A F
AU  - Tryka AF
FAU - H'Doubler, P
AU  - H'Doubler P
FAU - Collins, J J Jr
AU  - Collins JJ Jr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Artery
JT  - Artery
JID - 7508494
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta, Thoracic/pathology
MH  - Arteriosclerosis/pathology/*prevention & control
MH  - Aspirin/*pharmacology
MH  - Dipyridamole/*pharmacology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Muscle, Smooth, Vascular/pathology
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
EDAT- 1981/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Artery. 1981;9(6):405-13.

PMID- 1787232
OWN - NLM
STAT- MEDLINE
DCOM- 19920320
LR  - 20131121
IS  - 0002-3329 (Print)
IS  - 0002-3329 (Linking)
IP  - 4
DP  - 1991 Jul-Aug
TI  - [The blood anticoagulant system in rats perorally administered a 
      heparin-acetylsalicylic acid complex].
PG  - 625-30
AB  - Heparin/acetylsalicylate complexes (1:9 and 10:1) were obtained in vitro. Single 
      or chronic (7-8 days) per os administration to white rats of 0.1% solution of the 
      heparin/acetylsalicylate complex (0.3 ml/200 g body weight) enhanced 
      anticoagulative properties of blood plasma, increased the fibrinolytic activity 
      in respect of stabilized fibrin, and diminished the thrombin-induced platelet 
      aggregation.
FAU - Kudriashov, B A
AU  - Kudriashov BA
FAU - Liapina, L A
AU  - Liapina LA
FAU - Pastorova, V E
AU  - Pastorova VE
FAU - Kondashevskaia, M V
AU  - Kondashevskaia MV
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Sostoianie protivosvertyvaiushcheĭ sistemy krovi krys pri peroral'nom vvedenii 
      kompleksa geparin--atsetilsalitsilovaia kislota.
PL  - Russia (Federation)
TA  - Izv Akad Nauk SSSR Biol
JT  - Izvestiia Akademii nauk SSSR. Seriia biologicheskaia
JID - 7505543
RN  - 0 (Drug Combinations)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage
MH  - Blood Coagulation/*drug effects
MH  - Drug Combinations
MH  - Fibrinolysis/drug effects
MH  - Heparin/*administration & dosage
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Rats
MH  - Time Factors
EDAT- 1991/07/01 00:00
MHDA- 1991/07/01 00:01
CRDT- 1991/07/01 00:00
PHST- 1991/07/01 00:00 [pubmed]
PHST- 1991/07/01 00:01 [medline]
PHST- 1991/07/01 00:00 [entrez]
PST - ppublish
SO  - Izv Akad Nauk SSSR Biol. 1991 Jul-Aug;(4):625-30.

PMID- 2748705
OWN - NLM
STAT- MEDLINE
DCOM- 19890825
LR  - 20131121
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 44
IP  - 3
DP  - 1989 Mar
TI  - [Densitometric determination of propyphenazone, paracetamol, guaiacol glycerol 
      ether, caffeine and acetylsalicylic acid in analgesic-antipyretic preparations 
      with thin-layer chromatography].
PG  - 197-8
AB  - Optimum conditions for a simultaneous determination of propyphenazone, 
      paracetamol, guaiacol glycerol ether, caffeine and acetylsalicylic acid were 
      described for preparations with analgesic-antipyretic activity, which don't allow 
      a direct determination of the active principle because of interference phenomena. 
      Using an external standard for calibration the determination was carried out by 
      adsorption measurement (reflectance detection) in situ. Beside the determination 
      of the drug content the method can be used to identify substances according to 
      their RT and RF-values as well as by on-plate spectra taken.
FAU - Tománková, H
AU  - Tománková H
AD  - Staatliches Institut für Arzneimittelkontrolle Prag, CSSR.
FAU - Vasatová, M
AU  - Vasatová M
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Densitometrische Bestimmung von Propyphenazon, Paracetamol, 
      Guajacolglycerinether, Coffein und Acetylsalicylsäure in 
      analgetisch-antipyretischen Präparaten auf Dünnschichtchromatogrammen.
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - 495W7451VQ (Guaifenesin)
RN  - OED8FV75PY (propyphenazone)
RN  - R16CO5Y76E (Aspirin)
RN  - T3CHA1B51H (Antipyrine)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Antipyrine/*analogs & derivatives/analysis
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Chromatography, Thin Layer
MH  - Densitometry
MH  - Drug Combinations
MH  - Guaifenesin/*analysis
EDAT- 1989/03/01 00:00
MHDA- 1989/03/01 00:01
CRDT- 1989/03/01 00:00
PHST- 1989/03/01 00:00 [pubmed]
PHST- 1989/03/01 00:01 [medline]
PHST- 1989/03/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1989 Mar;44(3):197-8.

PMID- 3146984
OWN - NLM
STAT- MEDLINE
DCOM- 19890322
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 38
IP  - 9
DP  - 1988 Sep
TI  - Decrease of bleeding time by a peptide fraction from bovine factor VIII in 
      laboratory animals.
PG  - 1268-70
AB  - A peptide fraction of low molecular weight prepared from bovine Factor VIII by 
      enzymatic hydrolysis (Vueffe) reduces bleeding time in laboratory animals. In 
      this study the haemostatic action in mice, rats and rabbits was investigated 
      using different experimental conditions. This action was observed in animals with 
      either normal or experimentally prolonged bleeding time, thus suggesting better 
      efficacy in pathological situations. The evidence obtained following different 
      routes of administration confirmed the activity of the compound. The efficacy was 
      present at very low doses in all animal species without interfering either with 
      platelets or with blood coagulation.
FAU - Gervasi, G B
AU  - Gervasi GB
AD  - Baldacci Research Laboratories, Pisa, Italy.
FAU - Bartoli, C
AU  - Bartoli C
FAU - Carpita, G
AU  - Carpita G
FAU - Baldacci, M
AU  - Baldacci M
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Peptide Fragments)
RN  - 9001-27-8 (Factor VIII)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Factor VIII/*analysis
MH  - Heparin/pharmacology
MH  - Mice
MH  - Peptide Fragments/isolation & purification/*pharmacology
MH  - Rabbits
MH  - Rats
EDAT- 1988/09/01 00:00
MHDA- 1988/09/01 00:01
CRDT- 1988/09/01 00:00
PHST- 1988/09/01 00:00 [pubmed]
PHST- 1988/09/01 00:01 [medline]
PHST- 1988/09/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1988 Sep;38(9):1268-70.

PMID- 1009646
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20131121
IS  - 0009-4773 (Print)
IS  - 0009-4773 (Linking)
VI  - 28
IP  - 4
DP  - 1976 Aug
TI  - [Interesting changes in blood fibrinolysis following administration of 
      acetylsalicylic acid in vascular diseases of the lower limbs].
PG  - 306-16
AB  - After reference to the results of investigations reported in literature with 
      regard to the effects of ingestion of acetylsalicylic acid on the blood 
      biochemism in normal and pathological conditions, the Authors illustrate the 
      results of their research on patients with chronic obstructive arteriopathy or 
      with post-phlebitic syndrome of the lower limbs. An accurate evaluation was made 
      of the variations induced in some important blood coagulation parameters by the 
      said drug, which was found to cause a clear increase in fibrinolytic activity and 
      which is moreover endowed with marked antithrombophilic therapeutic capacity.
FAU - Ruggiero, A
AU  - Ruggiero A
FAU - Teramo, A
AU  - Teramo A
FAU - Mauro, C
AU  - Mauro C
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Interessanti modificazioni sulla fibrinolisi ematica conseguenti a 
      somminstrazione di acido acetilsalicilico nella patologia vascolare degli arti 
      inferiori.
PL  - Italy
TA  - Chir Ital
JT  - Chirurgia italiana
JID - 0151753
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arterial Occlusive Diseases/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Blood Coagulation Tests
MH  - Fibrinolysis/*drug effects
MH  - Humans
MH  - Leg/*blood supply
MH  - Male
MH  - Middle Aged
MH  - Phlebitis/*complications
MH  - Venous Insufficiency/*drug therapy
EDAT- 1976/08/01 00:00
MHDA- 1976/08/01 00:01
CRDT- 1976/08/01 00:00
PHST- 1976/08/01 00:00 [pubmed]
PHST- 1976/08/01 00:01 [medline]
PHST- 1976/08/01 00:00 [entrez]
PST - ppublish
SO  - Chir Ital. 1976 Aug;28(4):306-16.

PMID- 23737570
OWN - NLM
STAT- MEDLINE
DCOM- 20140916
LR  - 20211021
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 2013
DP  - 2013 Jun 3
TI  - Aneurysmal coronary cameral fistula.
LID - 10.1136/bcr-2013-008649 [doi]
LID - bcr2013008649
AB  - A 26-year-old asymptomatic man, being medically managed for ventricular septal 
      defect since childhood, presented to the outpatient clinic for a second opinion. 
      Clinically, he was well built with normal vital signs. Cardiac auscultation was 
      significant for a diastolic murmur over the praecordium. An ECG showed 
      non-specific ST changes, and a subsequent transthoracic echocardiography 
      performed revealed diastolic flow from the left ventricular (LV) anteroseptal 
      wall into the LV cavity. A diagnosis of coronary-cameral fistula was confirmed by 
      a multidetector CT which showed a 2.5×2 cm aneurysmal left anterior descending 
      artery fistula to the LV. In addition to starting aspirin, transcatheter closure 
      with occlusion device was considered knowing the potential risk of thrombus 
      formation in the aneurysm and subsequent systemic embolisation. The patient 
      however refused any percutaneous or surgical intervention. He remains 
      asymptomatic 1 year after returning to his home country.
FAU - Jamil, Gohar
AU  - Jamil G
AD  - Department of Medicine, Division of Cardiology, Tawam Hospital, Al Ain, United 
      Arab Emirates. goharjamil@gmail.com
FAU - Khan, Asad
AU  - Khan A
FAU - Malik, Azhar
AU  - Malik A
FAU - Qureshi, Anwer
AU  - Qureshi A
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20130603
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Coronary Aneurysm/*diagnostic imaging/drug therapy
MH  - Diagnosis, Differential
MH  - Fistula/*diagnostic imaging/drug therapy
MH  - Humans
MH  - Male
MH  - Treatment Outcome
MH  - Ultrasonography
PMC - PMC3702796
EDAT- 2013/06/06 06:00
MHDA- 2014/09/17 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/06/06 06:00 [entrez]
PHST- 2013/06/06 06:00 [pubmed]
PHST- 2014/09/17 06:00 [medline]
AID - bcr-2013-008649 [pii]
AID - 10.1136/bcr-2013-008649 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Jun 3;2013:bcr2013008649. doi: 10.1136/bcr-2013-008649.

PMID- 23435614
OWN - NLM
STAT- MEDLINE
DCOM- 20131106
LR  - 20211021
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 69
IP  - 7
DP  - 2013 Jul
TI  - Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory 
      agents: clinical implications.
PG  - 1369-73
LID - 10.1007/s00228-013-1477-9 [doi]
AB  - PURPOSE: Pharmacogenomics investigates interindividual genetic variability in the 
      DNA sequence of drug targets, drug-metabolizing enzymes or disease genes, RNA 
      expression, or protein translation of genes affecting drug response and drug 
      safety. Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are among 
      the most commonly prescribed medications with well-documented variation in 
      patient response in terms of efficacy and safety. This variation may in part be 
      explained by pharmacogenomics. METHODS: In this paper I review data on the 
      pharmacogenomics of aspirin and other NSAIDs focusing on clinical implications. 
      RESULTS: Existing scientific evidence supports the pharmacogenomic basis of 
      interindividual variation in treatment response to aspirin and NSAIDs, with 
      clinical implications for antiplatelet action, cancer chemoprevention, and drug 
      safety. However, further research efforts are needed before knowledge on the 
      pharmacogenomics of aspirin and NSAIDs can be implemented in clinical practice. 
      CONCLUSION: The outcome of these research efforts would be anticipated to have 
      added value for both science and society, contributing to the enhanced efficacy 
      and safety of these agents through patient selection.
FAU - Yiannakopoulou, Eugenia
AU  - Yiannakopoulou E
AD  - Department of Basic Medical Lessons, Faculty of Health and Caring Professions, 
      Technological Educational Institute of Athens, Eleutheriou Benizelou 106, 
      Kallithea, Athens, 17676, Greece. nyiannak@teiath.gr
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130224
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse 
      effects/*pharmacokinetics/therapeutic use
MH  - Aryl Hydrocarbon Hydroxylases/*genetics/metabolism
MH  - Aspirin/adverse effects/*pharmacokinetics/therapeutic use
MH  - Chemical and Drug Induced Liver Injury/genetics/metabolism
MH  - *Evidence-Based Medicine
MH  - Gastrointestinal Hemorrhage/chemically induced/*genetics/metabolism
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacokinetics/therapeutic use
MH  - *Precision Medicine
EDAT- 2013/02/26 06:00
MHDA- 2013/11/07 06:00
CRDT- 2013/02/26 06:00
PHST- 2012/11/16 00:00 [received]
PHST- 2013/01/30 00:00 [accepted]
PHST- 2013/02/26 06:00 [entrez]
PHST- 2013/02/26 06:00 [pubmed]
PHST- 2013/11/07 06:00 [medline]
AID - 10.1007/s00228-013-1477-9 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2013 Jul;69(7):1369-73. doi: 10.1007/s00228-013-1477-9. 
      Epub 2013 Feb 24.

PMID- 28018108
OWN - NLM
STAT- MEDLINE
DCOM- 20170609
LR  - 20181202
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 22
IP  - 45
DP  - 2016 Dec 7
TI  - Heparin bridge therapy and post-polypectomy bleeding.
PG  - 10009-10014
LID - 10.3748/wjg.v22.i45.10009 [doi]
AB  - AIM: To identify risk factors for post-polypectomy bleeding (PPB), focusing on 
      antithrombotic agents. METHODS: This was a case-control study based on medical 
      records at a single center. PPB was defined as bleeding that occurred 6 h to 10 d 
      after colonoscopic polypectomy and required endoscopic hemostasis. As risk 
      factors for PPB, patient-related factors including anticoagulants, antiplatelets 
      and heparin bridge therapy as well as polyp- and procedure-related factors were 
      evaluated. All colonoscopic hot polypectomies, endoscopic mucosal resections and 
      endoscopic submucosal dissections performed between January 2011 and December 
      2014 were reviewed. RESULTS: PPB occurred in 29 (3.7%) of 788 polypectomies 
      performed during the study period. Antiplatelet or anticoagulant agents were 
      prescribed for 210 (26.6%) patients and were ceased before polypectomy except for 
      aspirin and cilostazol in 19 cases. Bridging therapy using intravenous 
      unfractionated heparin was adopted for 73 patients. The univariate analysis 
      revealed that anticoagulants, heparin bridge, and anticoagulants plus heparin 
      bridge were significantly associated with PPB (P < 0.0001) whereas antiplatelets 
      and antiplatelets plus heparin were not. None of the other factors including age, 
      gender, location, size, shape, number of resected polyps, prophylactic clipping 
      and resection method were correlated with PPB. The multivariate analysis 
      demonstrated that anticoagulants and anticoagulants plus heparin bridge therapy 
      were significant risk factors for PPB (P < 0.0001). Of the 29 PPB cases, 4 
      required transfusions and none required surgery. A thromboembolic event occurred 
      in a patient who took anticoagulant. CONCLUSION: Patients taking anticoagulants 
      have an increased risk of PPB, even if the anticoagulants are interrupted before 
      polypectomy. Heparin-bridge therapy might be responsible for the increased PPB in 
      patients taking anticoagulants.
FAU - Kubo, Toshiyuki
AU  - Kubo T
AD  - Toshiyuki Kubo, Kentaro Yamashita, Kei Onodera, Tomoya Iida, Hiroshi Nakase, 
      Department of Gastroenterology and Hepatology, Sapporo Medical University, 
      Sapporo 0608543, Japan.
FAU - Yamashita, Kentaro
AU  - Yamashita K
AD  - Toshiyuki Kubo, Kentaro Yamashita, Kei Onodera, Tomoya Iida, Hiroshi Nakase, 
      Department of Gastroenterology and Hepatology, Sapporo Medical University, 
      Sapporo 0608543, Japan.
FAU - Onodera, Kei
AU  - Onodera K
AD  - Toshiyuki Kubo, Kentaro Yamashita, Kei Onodera, Tomoya Iida, Hiroshi Nakase, 
      Department of Gastroenterology and Hepatology, Sapporo Medical University, 
      Sapporo 0608543, Japan.
FAU - Iida, Tomoya
AU  - Iida T
AD  - Toshiyuki Kubo, Kentaro Yamashita, Kei Onodera, Tomoya Iida, Hiroshi Nakase, 
      Department of Gastroenterology and Hepatology, Sapporo Medical University, 
      Sapporo 0608543, Japan.
FAU - Arimura, Yoshiaki
AU  - Arimura Y
AD  - Toshiyuki Kubo, Kentaro Yamashita, Kei Onodera, Tomoya Iida, Hiroshi Nakase, 
      Department of Gastroenterology and Hepatology, Sapporo Medical University, 
      Sapporo 0608543, Japan.
FAU - Nojima, Masanori
AU  - Nojima M
AD  - Toshiyuki Kubo, Kentaro Yamashita, Kei Onodera, Tomoya Iida, Hiroshi Nakase, 
      Department of Gastroenterology and Hepatology, Sapporo Medical University, 
      Sapporo 0608543, Japan.
FAU - Nakase, Hiroshi
AU  - Nakase H
AD  - Toshiyuki Kubo, Kentaro Yamashita, Kei Onodera, Tomoya Iida, Hiroshi Nakase, 
      Department of Gastroenterology and Hepatology, Sapporo Medical University, 
      Sapporo 0608543, Japan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - 9005-49-6 (Heparin)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Cilostazol
MH  - Colonic Polyps/*surgery
MH  - *Colonoscopy
MH  - Deprescriptions
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Postoperative Hemorrhage/*chemically induced/epidemiology
MH  - Retrospective Studies
MH  - Tetrazoles/adverse effects/therapeutic use
PMC - PMC5143747
OTO - NOTNLM
OT  - Anticoagulants
OT  - Antiplatelets
OT  - Colonic polypectomy
OT  - Endoscopic surgery
OT  - Heparin bridge therapy
OT  - Post-polypectomy bleeding
COIS- Conflict-of-interest statement: The authors disclose no conflicts of interest.
EDAT- 2016/12/27 06:00
MHDA- 2017/06/10 06:00
CRDT- 2016/12/27 06:00
PHST- 2016/08/29 00:00 [received]
PHST- 2016/10/07 00:00 [revised]
PHST- 2016/11/15 00:00 [accepted]
PHST- 2016/12/27 06:00 [entrez]
PHST- 2016/12/27 06:00 [pubmed]
PHST- 2017/06/10 06:00 [medline]
AID - 10.3748/wjg.v22.i45.10009 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2016 Dec 7;22(45):10009-10014. doi: 
      10.3748/wjg.v22.i45.10009.

PMID- 1285865
OWN - NLM
STAT- MEDLINE
DCOM- 19930318
LR  - 20190918
IS  - 1046-7408 (Print)
IS  - 1046-7408 (Linking)
VI  - 28
IP  - 3-4
DP  - 1992 Oct-Dec
TI  - NSAIDs: maternal and fetal considerations.
PG  - 141-7
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) gained popularity in the late 
      1970s. Inhibition of prostaglandin synthesis with indomethacin has been reported 
      to be effective for prevention of labor and for treatment for symptomatic 
      polyhydramnios. Concern about its possible constrictive effect on the fetal 
      ductus arteriosus has limited its use in pregnancy. Maternal indomethacin therapy 
      has also been associated with reduction in urine production in the fetus and with 
      oligohydramnios. Obstetricians have discouraged pregnant women from taking 
      analgesic doses of aspirin, mainly because of the availability of paracetamol 
      (acetaminophen), which causes less gastric irritation, but also because of fear 
      of maternal and fetal hemorrhage and of possible premature closure of the ductus. 
      These fears largely derive from studies on patients taking large doses and from 
      extrapolation from other NSAIDs. The likelihood that treatment with 60-75 mg/day 
      of aspirin markedly reduces the incidence of preeclampsia and fetal intrauterine 
      growth retardation makes it important to reexamine its use. This review describes 
      the pharmacology and pharmacokinetics of aspirin with particular reference to 
      pregnancy and considers teratogenesis, prolongation of pregnancy and labor, 
      maternal bleeding, fetal and neonatal bleeding, possible effects on the ductus 
      arteriosus and pulmonary circulation, and possible nonspecific effects on 
      intelligence and breast feeding and acute toxicity in the neonate.
FAU - Schoenfeld, A
AU  - Schoenfeld A
AD  - Department of Obstetrics & Gynecology, Beilinson Medical Center, Petabh-Tiqva, 
      Israel.
FAU - Bar, Y
AU  - Bar Y
FAU - Merlob, P
AU  - Merlob P
FAU - Ovadia, Y
AU  - Ovadia Y
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tocolytic Agents)
RN  - 184SNS8VUH (Sulindac)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Abnormalities, Drug-Induced/etiology
MH  - Acetaminophen/adverse effects/pharmacokinetics
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/pharmacokinetics
MH  - Drug Evaluation
MH  - Ductus Arteriosus/drug effects
MH  - Female
MH  - Fetus/*drug effects
MH  - Humans
MH  - Ibuprofen/adverse effects/pharmacokinetics
MH  - Infant, Newborn
MH  - Intelligence/drug effects
MH  - Lactation
MH  - Male
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Rheumatic Diseases/drug therapy
MH  - Sulindac/adverse effects/pharmacokinetics
MH  - Tocolytic Agents/adverse effects/therapeutic use
RF  - 140
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 10.1111/j.1600-0897.1992.tb00777.x [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 1992 Oct-Dec;28(3-4):141-7. doi: 
      10.1111/j.1600-0897.1992.tb00777.x.

PMID- 6719029
OWN - NLM
STAT- MEDLINE
DCOM- 19840620
LR  - 20131121
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 19
IP  - 2
DP  - 1984 Mar
TI  - Effect of acetylsalicylic acid on the constituents of the gastric mucosal 
      barrier.
PG  - 150-3
AB  - The effect of luminal application of acetylsalicylic acid (ASA) on the liberation 
      of gastric mucosal barrier constituents at pH 5.0 and 2.0 was investigated. The 
      Lucite chamber stomach-flap preparation was used in 18 dogs whose basal H+ 
      secretion was inhibited by cimetidine. An ASA dose of 10 mmol at pH 5.0 caused a 
      moderate increase in content of proteins, glycoproteins, and glycolipids in the 
      instillates. This was accompanied by an increase in transmucosal potential 
      difference (PD) without concomitant changes in the appearance of the gastric 
      mucosa. However, the content of mannose used as an indicator of plasma leakage 
      remained unchanged. A 20 mmol ASA dose at pH 5.0 produced further enrichment of 
      the instillates in mucus constituents, and an increase in mannose content was 
      observed, but PD still remained elevated. In contrast, the same dose of ASA at pH 
      2.0 severely depleted the gastric mucosal barrier of its mucus constituents and 
      caused a marked increase in leakage of plasma elements. These changes were 
      accompanied by a substantial drop of PD and gastric mucosal damage. These data 
      indicate that the topical application of ASA causes the liberation of mucus 
      constituents, which results in weakening of the gastric mucosal barrier and thus 
      facilitates the pepsin and acid penetration of gastric mucosa. The extent of 
      mucosal damage caused by aspirin strongly depends on the pH of luminal exposure.
FAU - Sarosiek, J
AU  - Sarosiek J
FAU - Slomiany, B L
AU  - Slomiany BL
FAU - Swierczek, J
AU  - Swierczek J
FAU - Slomiany, A
AU  - Slomiany A
FAU - Jozwiak, Z
AU  - Jozwiak Z
FAU - Konturek, S J
AU  - Konturek SJ
LA  - eng
GR  - AM 21684-06/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Glycolipids)
RN  - 0 (Glycoproteins)
RN  - 0 (Proteins)
RN  - PHA4727WTP (Mannose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dogs
MH  - Female
MH  - Gastric Mucosa/*metabolism
MH  - Glycolipids/*metabolism
MH  - Glycoproteins/*metabolism
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Mannose/metabolism
MH  - Proteins/*metabolism
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol. 1984 Mar;19(2):150-3.

PMID- 23431005
OWN - NLM
STAT- MEDLINE
DCOM- 20130417
LR  - 20211021
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Print)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 3
DP  - 2013 Mar
TI  - Challenging the FDA black box warning for high aspirin dose with ticagrelor in 
      patients with diabetes.
PG  - 669-71
LID - 10.2337/db12-0746 [doi]
AB  - Ticagrelor, a novel reversible antiplatelet agent, has a Food and Drug 
      Administration (FDA) black box warning to avoid maintenance doses of aspirin 
      (ASA) >100 mg/daily. This restriction is based on the hypothesis that ASA doses 
      >100 mg somehow decreased ticagrelor's benefit in the Platelet Inhibition and 
      Patient Outcomes (PLATO) U.S. cohort. However, these data are highly 
      postrandomized, come from a very small subgroup in PLATO (57% of patients in the 
      U.S. site), and make no biological sense. Moreover, the ticagrelor-ASA 
      interaction was not significant by any multivariate Cox regression analyses. The 
      Complete Response Review for ticagrelor indicates that for U.S. PLATO patients, 
      an ASA dose >300 mg was not a significant interaction for vascular outcomes. In 
      the ticagrelor-ASA >300 mg cohort, all-cause and vascular mortality were not 
      significantly increased (hazard ratio [HR] 1.27 [95% CI 0.84-1.93], P = 0.262 and 
      1.39 [0.87-2.2], P = 0.170), respectively. Furthermore, for major adverse 
      cardiovascular events (MACEs), 30-day all-cause mortality, and 30-day vascular 
      mortality, the strongest interaction is the diabetes-ASA interaction. That is, 
      patients who had diabetes had significantly fewer MACEs through study end (0.49 
      [0.34-0.63], P < 0.0001), significantly less 30-day all-cause mortality (0.33 
      [0.20-0.56], P < 0.0001), and significantly less 30-day vascular mortality (0.35 
      [0.22-0.55], P < 0.0001), respectively, when given high-dose (300-325 mg) ASA, 
      regardless of treatment (clopidogrel or ticagrelor) assignment. The black box 
      warning for the use of maintenance ASA doses >100 mg with ticagrelor is 
      inappropriate for patients with diabetes and not evidence based.
FAU - DiNicolantonio, James J
AU  - DiNicolantonio JJ
AD  - Wegman's Pharmacy, Ithaca, New York, USA. jjdinicol@gmail.com
FAU - Serebruany, Victor L
AU  - Serebruany VL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Diabetes. 2013 Mar;62(3):709-10. PMID: 23431018
MH  - Adenosine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Cardiovascular Abnormalities/chemically induced/etiology/prevention & control
MH  - Diabetes Mellitus/*metabolism/mortality/physiopathology
MH  - Drug Interactions
MH  - *Drug Labeling
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Ticagrelor
MH  - United States
MH  - United States Food and Drug Administration
PMC - PMC3581224
EDAT- 2013/02/23 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/02/23 06:00
PHST- 2013/02/23 06:00 [entrez]
PHST- 2013/02/23 06:00 [pubmed]
PHST- 2013/04/19 06:00 [medline]
AID - 62/3/669 [pii]
AID - 0746 [pii]
AID - 10.2337/db12-0746 [doi]
PST - ppublish
SO  - Diabetes. 2013 Mar;62(3):669-71. doi: 10.2337/db12-0746.

PMID- 25168047
OWN - NLM
STAT- MEDLINE
DCOM- 20160519
LR  - 20191113
IS  - 2233-6869 (Electronic)
IS  - 1598-9992 (Linking)
VI  - 64
IP  - 2
DP  - 2014 Aug
TI  - Helicobacter pylori infection in nonsteroidal anti-inflammatory drug users.
PG  - 70-5
AB  - NSAID-induced upper gastrointestinal (GI) damage occurs easily in people with a 
      prior history of complicated or uncomplicated ulcers. Many recent clinical 
      studies have proved the benefit of Helicobacter pylori eradication in NSAID 
      users; however, the exact pathophysiologic relationship between concomitant H. 
      pylori infection and NSAID use has not yet been fully elucidated. Testing and 
      eradication of H. pylori are generally recommended in patients who are at a high 
      risk for NSAID-induced GI damage. However, in high-risk patients, ulcer 
      prophylaxis with proton pump inhibitor or misoprostol is needed even if H. pylori 
      has been successfully eradicated. In low-risk patients, it is still questionable 
      whether or not eradication of H. pylori can reduce upper GI damage. However, in 
      western countries, due to its cost effectiveness, testing and eradication of H. 
      pylori is recommended before starting aspirin or NSAID irrespective of the risk 
      level. In regions with a high prevalence of H. pylori infection (>20%), the 
      usefulness of testing and eradication of H. pylori has not yet been determined.
FAU - Lim, Yun Jeong
AU  - Lim YJ
AD  - Department of Internal Medicine, Dongguk University College of Medicine, Goyang, 
      Digestive Disease Center and Research Institute, Bucheon, Korea.
FAU - Hong, Su Jin
AU  - Hong SJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - Korean J Gastroenterol
JT  - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JID - 101189416
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Peptic Ulcer/*etiology
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Risk Factors
EDAT- 2014/08/30 06:00
MHDA- 2016/05/20 06:00
CRDT- 2014/08/30 06:00
PHST- 2014/08/30 06:00 [entrez]
PHST- 2014/08/30 06:00 [pubmed]
PHST- 2016/05/20 06:00 [medline]
AID - 201408212 [pii]
AID - 10.4166/kjg.2014.64.2.70 [doi]
PST - ppublish
SO  - Korean J Gastroenterol. 2014 Aug;64(2):70-5. doi: 10.4166/kjg.2014.64.2.70.

PMID- 25358343
OWN - NLM
STAT- MEDLINE
DCOM- 20150615
LR  - 20181202
IS  - 1097-6817 (Electronic)
IS  - 0194-5998 (Print)
IS  - 0194-5998 (Linking)
VI  - 152
IP  - 1
DP  - 2015 Jan
TI  - Ubiquitous aspirin: a systematic review of its impact on sensorineural hearing 
      loss.
PG  - 23-41
LID - 10.1177/0194599814553930 [doi]
AB  - OBJECTIVE: This systematic review evaluates the impact of aspirin on audiometric 
      outcomes with respect to: (1) doses exceeding 325 mg daily, (2) doses of 325 mg 
      daily or less, (3) studies applicable to the general populace, and (4) studies 
      applicable to those with inflammatory conditions. It also assesses the impact of 
      aspirin on (a) self-reported hearing loss, (b) noise-induced audiometric changes, 
      and (c) the adverse otological effects of aminoglycoside therapy. DATA SOURCES: 
      Computerized searches of MEDLINE, PubMed, Cochrane, and EMBASE databases were 
      performed, updated through January 2014, and supplemented by manual searches and 
      inquiries to topic experts. REVIEW METHODS: A systematic review was performed 
      according to an a priori protocol. Data extraction was performed by 2 independent 
      parties and focused on relevant audiological measurements, potential confounders, 
      and study design elements associated with risk of bias, including utilization of 
      randomization, prospective/retrospective data collection, and incorporation of 
      blinding. RESULTS: The 37 criterion-meeting studies included a combined total of 
      185,155 participants. Aspirin ingestion ≥ 1.95 g/d was associated with worse 
      audiometric results (4-112 dB threshold shift); the effect was dose dependent and 
      reversible in the short term. There were no audiometric data that confirm that 
      long-term doses of 81 mg or 325 mg daily have no hearing consequences. 
      Paradoxically, aspirin (in doses shown to be detrimental in isolation) had a 
      protective effect when co-administered with intravenous gentamicin. CONCLUSIONS: 
      With the large-scale population utilization of aspirin for cardiovascular 
      prophylaxis, the potential risks to hearing health should be considered for 
      future longitudinal study, particularly given that short-term effects may be 
      reversible.
CI  - © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2014.
FAU - Kyle, Meghann Elizabeth
AU  - Kyle ME
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Wang, James C
AU  - Wang JC
AD  - Texas Tech Health Sciences Center, Lubbock, Texas, USA.
FAU - Shin, Jennifer J
AU  - Shin JJ
AD  - Harvard Medical School, Boston, Massachusetts, USA 
      jennifer_shin@meei.harvard.edu.
LA  - eng
GR  - U24 DC012206/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20141030
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of 
      Otolaryngology-Head and Neck Surgery
JID - 8508176
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Hearing Loss, Sensorineural/*chemically induced/diagnosis/physiopathology
MH  - Humans
PMC - PMC4472336
MID - NIHMS696481
OTO - NOTNLM
OT  - aspirin
OT  - hearing loss
OT  - public health
OT  - sensorineural hearing loss
COIS- Sponsorships or competing interests that may be relevant to content are disclosed 
      at the end of this article.
EDAT- 2014/11/02 06:00
MHDA- 2015/06/16 06:00
CRDT- 2014/11/01 06:00
PHST- 2014/11/01 06:00 [entrez]
PHST- 2014/11/02 06:00 [pubmed]
PHST- 2015/06/16 06:00 [medline]
AID - 0194599814553930 [pii]
AID - 10.1177/0194599814553930 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2015 Jan;152(1):23-41. doi: 10.1177/0194599814553930. 
      Epub 2014 Oct 30.

PMID- 27170631
OWN - NLM
STAT- MEDLINE
DCOM- 20171018
LR  - 20181202
IS  - 1532-2750 (Electronic)
IS  - 1098-612X (Linking)
VI  - 19
IP  - 6
DP  - 2017 Jun
TI  - Assessment of platelet function in healthy cats in response to commonly 
      prescribed antiplatelet drugs using three point-of-care platelet function tests.
PG  - 638-647
LID - 10.1177/1098612X16648182 [doi]
AB  - Objectives The objective was to determine if decreased platelet function could be 
      detected after treatment with aspirin and/or clopidogrel in healthy cats using 
      three point-of-care platelet function tests that evaluate platelet function by 
      different methods: Multiplate (by impedance), Platelet Function Analyzer 100 (by 
      mechanical aperture closure) and Plateletworks (by platelet counting). Methods 
      Thirty-six healthy cats were randomly assigned to receive one of three oral 
      treatments over an 8 day period: (1) aspirin 5 mg q72h; (2) aspirin 20.25 mg 
      q72h; or (3) clopidogrel 18.75 mg q24h. Cats treated with 5 and 20.25 mg aspirin 
      also received clopidogrel on days 4-8. Platelet aggregation in response to 
      adenosine diphosphate and collagen ± arachidonic acid was assessed on days 1 
      (baseline), 4 and 8. Aspirin and clopidogrel metabolites were measured by 
      high-performance liquid chromatography. Platelet function in response to 
      treatment was analyzed by ANCOVA, linear regression and Spearman correlation. 
      Results The only solitary aspirin effect was detected using Plateletworks with 
      collagen in cats treated with 20.25 mg. The only effect detected by Multiplate 
      was using arachidonic acid in cats treated with both aspirin 20.25 mg and 
      clopidogrel. All clopidogrel treatment effects were detected by Platelet Function 
      Analyzer 100, Plateletworks (adenosine diphosphate) and Plateletworks (collagen). 
      Drug metabolites were present in all cats, but concentrations were minimally 
      correlated to platelet function test results. Conclusions and relevance Platelet 
      Function Analyzer 100 and Plateletworks using adenosine diphosphate ± collagen 
      agonists may be used to detect decreased platelet function in response to 
      clopidogrel treatment. Either aspirin is not as effective an antiplatelet drug as 
      clopidogrel, or the tests used were not optimal to measure aspirin effect. Cats 
      with heart disease are commonly prescribed antiplatelet drugs to decrease the 
      risk of aortic thromboembolism. Platelet Function Analyzer 100 and Plateletworks 
      may be useful for confirming clopidogrel treatment in these cats.
FAU - Ho, Kimberly K
AU  - Ho KK
AD  - 1 Department of Clinical Studies, Ontario Veterinary College, University of 
      Guelph, Guelph, Ontario, Canada.
FAU - Abrams-Ogg, Anthony Cg
AU  - Abrams-Ogg AC
AD  - 1 Department of Clinical Studies, Ontario Veterinary College, University of 
      Guelph, Guelph, Ontario, Canada.
FAU - Wood, R Darren
AU  - Wood RD
AD  - 2 Department of Pathobiology, Ontario Veterinary College, University of Guelph, 
      Guelph, Ontario, Canada.
FAU - O'Sullivan, M Lynne
AU  - O'Sullivan ML
AD  - 1 Department of Clinical Studies, Ontario Veterinary College, University of 
      Guelph, Guelph, Ontario, Canada.
FAU - Kirby, Gordon M
AU  - Kirby GM
AD  - 3 Department of Biomedical Sciences, Ontario Veterinary College, University of 
      Guelph, Guelph, Ontario, Canada.
FAU - Blois, Shauna L
AU  - Blois SL
AD  - 1 Department of Clinical Studies, Ontario Veterinary College, University of 
      Guelph, Guelph, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160710
PL  - England
TA  - J Feline Med Surg
JT  - Journal of feline medicine and surgery
JID - 100897329
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Coagulation Tests/veterinary
MH  - Blood Platelets/*drug effects/physiology
MH  - Cats/*blood
MH  - Clopidogrel
MH  - Female
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Function Tests/veterinary
MH  - Point-of-Care Systems
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
EDAT- 2016/05/14 06:00
MHDA- 2017/10/19 06:00
CRDT- 2016/05/13 06:00
PHST- 2016/05/14 06:00 [pubmed]
PHST- 2017/10/19 06:00 [medline]
PHST- 2016/05/13 06:00 [entrez]
AID - 1098612X16648182 [pii]
AID - 10.1177/1098612X16648182 [doi]
PST - ppublish
SO  - J Feline Med Surg. 2017 Jun;19(6):638-647. doi: 10.1177/1098612X16648182. Epub 
      2016 Jul 10.

PMID- 6606504
OWN - NLM
STAT- MEDLINE
DCOM- 19840222
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 69
IP  - 2
DP  - 1984 Feb
TI  - Quantification of platelet retention in aortocoronary femoral vein bypass graft 
      in dogs treated with dipyridamole and aspirin.
PG  - 350-6
AB  - Autologous femoral vein segments were implanted as aortocoronary bypass grafts in 
      50 dogs, 25 of which were treated with dipyridamole and aspirin to inhibit 
      platelet deposition and 25 that were not. Autologous platelets labeled with 
      indium-111 were injected into some dogs 48 hr before they were killed on the 
      first day after surgery; other dogs were injected 24 hr before they were killed 
      (3, 7, 30, and 90 days after surgery). Radioactivity on the grafts and on control 
      specimens of contralateral femoral veins was converted to quantification of 
      platelets adhering to the vessel wall (platelets/cm2). The treated group had 
      fewer graft platelets per square centimeter than the untreated group on 
      postoperative days 3, 7 (p less than .01), and 30 (p less than .05). Graft and 
      control vein platelets per square centimeter were nearly equal by day 90. 
      Comparison of graft and control specimens by scanning electron microscopy nearly 
      equal by day 90. Comparison of graft and control specimens by scanning electron 
      microscopy revealed deendothelialization at 1 and 7 days after grafting and 
      reendothelialization at 30 and 90 days. The data suggest that indefinite 
      prolongation of therapy to inhibit platelet deposition after bypass grafting may 
      be unnecessary (although other atherosclerotic vessels may benefit from therapy).
FAU - Dewanjee, M K
AU  - Dewanjee MK
FAU - Tago, M
AU  - Tago M
FAU - Josa, M
AU  - Josa M
FAU - Fuster, V
AU  - Fuster V
FAU - Kaye, M P
AU  - Kaye MP
LA  - eng
GR  - HL-24602/HL/NHLBI NIH HHS/United States
GR  - HL-28974/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 045A6V3VFX (Indium)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/*pharmacology
MH  - Dogs
MH  - Endothelium/pathology
MH  - Femoral Vein/*pathology/transplantation
MH  - Indium
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Count
EDAT- 1984/02/01 00:00
MHDA- 1984/02/01 00:01
CRDT- 1984/02/01 00:00
PHST- 1984/02/01 00:00 [pubmed]
PHST- 1984/02/01 00:01 [medline]
PHST- 1984/02/01 00:00 [entrez]
AID - 10.1161/01.cir.69.2.350 [doi]
PST - ppublish
SO  - Circulation. 1984 Feb;69(2):350-6. doi: 10.1161/01.cir.69.2.350.

PMID- 36394111
OWN - NLM
STAT- MEDLINE
DCOM- 20221215
LR  - 20230512
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 57
IP  - 1
DP  - 2023 Jan
TI  - Deprescription of aspirin for primary prevention is uncommon at discharge in 
      hospitalised patients with gastrointestinal bleeding.
PG  - 94-102
LID - 10.1111/apt.17278 [doi]
AB  - BACKGROUND: Guidelines recommend against aspirin for primary prevention of 
      cardiovascular events in individuals with a history of gastrointestinal bleeding 
      (GIB). It is unknown how often patients on primary prevention aspirin 
      hospitalised with GIB have aspirin discontinued at discharge. AIMS: To determine 
      the rate of aspirin deprescription and explore long-term outcomes in patients 
      taking aspirin for primary prevention of cardiovascular events. METHODS: We 
      evaluated all patients hospitalised at Yale-New Haven Hospital between January 
      2014 and October 2021 with GIB who were on aspirin for primary prevention. Our 
      primary endpoint was the frequency of aspirin deprescription at discharge. Our 
      secondary endpoints were post-discharge hospitalisations for major adverse 
      cardiovascular events (MACE) or GIB. Time-to-event analysis was performed using 
      Kaplan-Meier curves and the log-rank test. RESULTS: We identified 320 patients 
      with GIB on aspirin for primary prevention: median age was 72 (interquartile 
      range [IQR] 61-81) years and 297 (92.8%) were on aspirin 81 mg daily. Only 25 
      (9.0%) patients surviving their hospitalisation were deprescribed aspirin at 
      discharge. Among 260 patients with follow-up (median 1103 days; IQR 367-1670), 
      MACE developed post-discharge in 2/25 (8.0%) with aspirin deprescription versus 
      37/235 (15.7%) with aspirin continuation (log-rank p = 0.28). 0/25 patients with 
      aspirin deprescription had subsequent hospitalisation for GIB versus 17/235 
      (7.2%) who continued aspirin (log-rank p = 0.13). CONCLUSIONS: Aspirin for 
      primary cardiovascular prevention was rarely deprescribed at discharge in 
      patients hospitalised with GIB. Processes designed to ensure appropriate 
      deprescription of aspirin are crucial to improve adherence to guidelines, thereby 
      improving the risk-benefit ratio in patients at high risk of subsequent GIB 
      hospitalisations with minimal increased risk of MACE.
CI  - © 2022 John Wiley & Sons Ltd.
FAU - Li, Darrick K
AU  - Li DK
AUID- ORCID: 0000-0002-1983-0165
AD  - Section of Digestive Diseases, Department of Medicine, Yale School of Medicine, 
      New Haven, Connecticut, USA.
FAU - Ong, Shawn Y
AU  - Ong SY
AD  - Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
FAU - Hughes, Michelle L
AU  - Hughes ML
AD  - Section of Digestive Diseases, Department of Medicine, Yale School of Medicine, 
      New Haven, Connecticut, USA.
FAU - Hung, Kenneth W
AU  - Hung KW
AD  - Section of Digestive Diseases, Department of Medicine, Yale School of Medicine, 
      New Haven, Connecticut, USA.
FAU - Agarwal, Ritu
AU  - Agarwal R
AD  - Joint Data Analytics Team, Information Technology Service, Yale University, New 
      Haven, Connecticut, USA.
FAU - Alexis, Jamil
AU  - Alexis J
AD  - Section of Gastroenterology, Department of Medicine, Bridgeport Hospital, 
      Bridgeport, Connecticut, USA.
FAU - Damianos, John
AU  - Damianos J
AD  - Joint Data Analytics Team, Information Technology Service, Yale University, New 
      Haven, Connecticut, USA.
FAU - Sharma, Shreyak
AU  - Sharma S
AD  - Joint Data Analytics Team, Information Technology Service, Yale University, New 
      Haven, Connecticut, USA.
FAU - Pires, Jacqueline
AU  - Pires J
AD  - Section of Cardiovascular Diseases, Department of Medicine, Yale School of 
      Medicine, New Haven, Connecticut, USA.
FAU - Nanna, Michael
AU  - Nanna M
AD  - Section of Cardiovascular Diseases, Department of Medicine, Yale School of 
      Medicine, New Haven, Connecticut, USA.
FAU - Laine, Loren
AU  - Laine L
AUID- ORCID: 0000-0002-4296-7901
AD  - Section of Digestive Diseases, Department of Medicine, Yale School of Medicine, 
      New Haven, Connecticut, USA.
AD  - VA Connecticut Healthcare System, West Haven, Connecticut, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221116
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Aliment Pharmacol Ther. 2023 Jun;57(11):1355-1356. PMID: 37161625
CIN - Aliment Pharmacol Ther. 2023 Jun;57(11):1357. PMID: 37161633
MH  - Humans
MH  - Middle Aged
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aspirin/adverse effects
MH  - Patient Discharge
MH  - Aftercare
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - *Cardiovascular Diseases/prevention & control
MH  - Primary Prevention
EDAT- 2022/11/18 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/11/17 13:16
PHST- 2022/10/17 00:00 [revised]
PHST- 2022/10/14 00:00 [received]
PHST- 2022/10/19 00:00 [accepted]
PHST- 2022/11/18 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
PHST- 2022/11/17 13:16 [entrez]
AID - 10.1111/apt.17278 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2023 Jan;57(1):94-102. doi: 10.1111/apt.17278. Epub 2022 
      Nov 16.

PMID- 17689619
OWN - NLM
STAT- MEDLINE
DCOM- 20070823
LR  - 20131121
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 197
IP  - 2
DP  - 2007 Aug
TI  - Successful pregnancy with the use of nitric oxide donors and heparin after 
      recurrent severe preeclampsia in a woman with scleroderma.
PG  - e6-7
AB  - We report the case of a woman with scleroderma who had severe, early-onset 
      preeclampsia on 2 consecutive pregnancies. With a treatment that included 
      aspirin, heparin, and a nitric oxide donor, her third pregnancy ended with a 
      healthy neonate at term. Nitric oxide donors and heparin may play a preventive 
      role on placental dysfunction in scleroderma.
FAU - Carbonne, Bruno
AU  - Carbonne B
AD  - Department of Obstetrics and Gynecology, Hôpital Saint-Antoine, Paris, France. 
      bruno.carbonne@sat.aphp.fr
FAU - Macé, Guillaume
AU  - Macé G
FAU - Cynober, Evelyne
AU  - Cynober E
FAU - Milliez, Jacques
AU  - Milliez J
FAU - Cabane, Jean
AU  - Cabane J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Nitric Oxide Donors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*administration & dosage
MH  - Humans
MH  - Nitric Oxide Donors/*administration & dosage
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - Recurrence
MH  - Scleroderma, Systemic/*complications
EDAT- 2007/08/11 09:00
MHDA- 2007/08/24 09:00
CRDT- 2007/08/11 09:00
PHST- 2006/10/03 00:00 [received]
PHST- 2007/01/06 00:00 [revised]
PHST- 2007/04/18 00:00 [accepted]
PHST- 2007/08/11 09:00 [pubmed]
PHST- 2007/08/24 09:00 [medline]
PHST- 2007/08/11 09:00 [entrez]
AID - S0002-9378(07)00546-7 [pii]
AID - 10.1016/j.ajog.2007.04.025 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2007 Aug;197(2):e6-7. doi: 10.1016/j.ajog.2007.04.025.

PMID- 36967016
OWN - NLM
STAT- MEDLINE
DCOM- 20230609
LR  - 20230619
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 151
IP  - 6
DP  - 2023 Jun
TI  - Mechanistic and clinical updates in AERD: 2021-2022.
PG  - 1448-1456
LID - S0091-6749(23)00367-6 [pii]
LID - 10.1016/j.jaci.2023.03.015 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is a unique and often clinically 
      severe disease affecting a subgroup of adults with asthma and chronic 
      rhinosinusitis with nasal polyposis. Works published in 2021-2022 confirmed the 
      critical role of lipid mediator dysregulation and mast cell activation and 
      expanded our understanding of basophils, macrophages, fibrin dysregulation, and 
      the 15-lipoxygenase pathway in disease pathogenesis. Translational studies 
      established inflammatory heterogeneity in the upper and lower airway at baseline 
      and during aspirin-induced respiratory reactions. Clinical cohorts provided 
      insights into the mechanistic actions of frequently utilized biologic therapies 
      in AERD. These advances are already changing clinical care delivery and affecting 
      patient outcomes. Despite this, further work is needed to improve clinical tools 
      to reliably diagnose AERD and identify factors that could prevent development of 
      the disease altogether. Additionally, the impact of inflammatory heterogeneity on 
      clinical trajectories and the utility and safety of combination biologic and 
      daily aspirin therapies remains unanswered.
CI  - Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Stevens, Whitney W
AU  - Stevens WW
AD  - Division of Allergy-Immunology, Northwestern University Feinberg School of 
      Medicine, Chicago, Ill.
FAU - Cahill, Katherine N
AU  - Cahill KN
AD  - Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University 
      Medical Center, Nashville, Tenn. Electronic address: Katherine.cahill@vumc.org.
LA  - eng
GR  - U01 AI155299/AI/NIAID NIH HHS/United States
GR  - UG1 HL139119/HL/NHLBI NIH HHS/United States
GR  - P01 AI145818/AI/NIAID NIH HHS/United States
GR  - K23 AI141694/AI/NIAID NIH HHS/United States
GR  - R01 HL122554/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20230324
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Asthma, Aspirin-Induced/diagnosis
MH  - Aspirin/adverse effects
MH  - *Nasal Polyps/pathology
MH  - *Asthma
MH  - Chronic Disease
MH  - *Rhinitis/therapy
PMC - PMC10272052
MID - NIHMS1885963
OTO - NOTNLM
OT  - 15-lipoxygenase
OT  - Nasal polyps
OT  - asthma
OT  - basophil
OT  - biologics
OT  - chronic rhinosinusitis
OT  - macrophage
OT  - mast cell
OT  - mechanisms
OT  - type 2 inflammation
COIS- Conflicts of interest: KN Cahill serves on scientific advisory boards for GSK, 
      AstraZeneca, and Regeneron, serves as a consultant for Third Harmonic Bio, Ribon 
      Therapeutics, and Verantos, receives royalties from UpToDate(®) and 
      ClinicalKey(®), and receives research support from NovoNordisk outside the 
      submitted work. W Stevens served on scientific advisory boards for GSK and 
      Regeneron.
EDAT- 2023/03/27 06:00
MHDA- 2023/06/09 06:42
PMCR- 2024/06/01
CRDT- 2023/03/26 20:27
PHST- 2023/02/06 00:00 [received]
PHST- 2023/03/17 00:00 [revised]
PHST- 2023/03/21 00:00 [accepted]
PHST- 2024/06/01 00:00 [pmc-release]
PHST- 2023/06/09 06:42 [medline]
PHST- 2023/03/27 06:00 [pubmed]
PHST- 2023/03/26 20:27 [entrez]
AID - S0091-6749(23)00367-6 [pii]
AID - 10.1016/j.jaci.2023.03.015 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2023 Jun;151(6):1448-1456. doi: 
      10.1016/j.jaci.2023.03.015. Epub 2023 Mar 24.

PMID- 35563226
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220716
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 9
DP  - 2022 Apr 27
TI  - The Utility of Nasal Challenges to Phenotype Asthma Patients.
LID - 10.3390/ijms23094838 [doi]
LID - 4838
AB  - Asthma is a heterogeneous disease in terms of both phenotype and response to 
      therapy. Therefore, there is a great need for clinically applicable tools 
      allowing for improved patient classification, and selection for specific 
      management approaches. Some interventions are highly helpful in selected patients 
      (e.g., allergen immunotherapy or aspirin desensitization), but they are costly 
      and/or difficult to implement. Currently available biomarkers measurable in 
      peripheral blood or exhaled air display many limitations for asthma phenotyping 
      and cannot identify properly the specific triggers of the disease (e.g., 
      aeroallergens or NSAID). The united airway concept illustrates the relevant 
      epidemiological and pathophysiological links between the upper and lower airways. 
      This concept has been largely applied to patient management and treatment, but 
      its diagnostic implications have been less often explored. Of note, a recent 
      document by the European Academy of Allergy and Clinical Immunology proposes the 
      use of nasal allergen challenge to confirm the diagnosis of allergic asthma. 
      Similarly, the nasal challenge with lysine acetylsalicylate (L-ASA) can be used 
      to identify aspirin-sensitive asthma patients. In this review, we will summarize 
      the main features of allergic asthma and aspirin-exacerbated respiratory disease 
      and will discuss the methodology of nasal allergen and L-ASA challenges with a 
      focus on their capacity to phenotype the inflammatory disease affecting both the 
      upper and lower airways.
FAU - Bentabol-Ramos, Guillermo
AU  - Bentabol-Ramos G
AD  - Pulmonology Unit, Hospital Regional Universitario de Malaga, 29010 Malaga, Spain.
FAU - Saenz de Santa Maria-Garcia, Rocio
AU  - Saenz de Santa Maria-Garcia R
AUID- ORCID: 0000-0003-0286-7217
AD  - Allergy Unit, Hospital Regional Universitario de Malaga, 29010 Malaga, Spain.
FAU - Vidal-Diaz, Monica
AU  - Vidal-Diaz M
AD  - Pulmonology Unit, Hospital Regional Universitario de Malaga, 29010 Malaga, Spain.
FAU - Eguiluz-Gracia, Ibon
AU  - Eguiluz-Gracia I
AUID- ORCID: 0000-0002-3774-931X
AD  - Allergy Unit, Hospital Regional Universitario de Malaga, 29010 Malaga, Spain.
AD  - Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA) 
      and RICORS "Enfermedades Inflamatorias", 29010 Malaga, Spain.
FAU - Testera-Montes, Almudena
AU  - Testera-Montes A
AUID- ORCID: 0000-0002-3067-0406
AD  - Allergy Unit, Hospital Regional Universitario de Malaga, 29010 Malaga, Spain.
AD  - Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA) 
      and RICORS "Enfermedades Inflamatorias", 29010 Malaga, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220427
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Allergens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Allergens
MH  - Aspirin/therapeutic use
MH  - *Asthma/chemically induced/diagnosis/therapy
MH  - *Asthma, Aspirin-Induced/diagnosis
MH  - Humans
MH  - Phenotype
PMC - PMC9104030
OTO - NOTNLM
OT  - NSAID-exacerbated respiratory disease
OT  - allergic asthma
OT  - asthma phenotypes
OT  - biomarker
OT  - nasal challenge
COIS- The authors declare no conflict of interest in relation to this work.
EDAT- 2022/05/15 06:00
MHDA- 2022/05/18 06:00
CRDT- 2022/05/14 01:04
PHST- 2022/03/30 00:00 [received]
PHST- 2022/04/20 00:00 [revised]
PHST- 2022/04/25 00:00 [accepted]
PHST- 2022/05/14 01:04 [entrez]
PHST- 2022/05/15 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
AID - ijms23094838 [pii]
AID - ijms-23-04838 [pii]
AID - 10.3390/ijms23094838 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Apr 27;23(9):4838. doi: 10.3390/ijms23094838.

PMID- 34794071
OWN - NLM
STAT- MEDLINE
DCOM- 20220111
LR  - 20220531
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 268
DP  - 2022 Jan
TI  - Low molecular weight heparin or LMWH plus aspirin in the treatment of unexplained 
      recurrent miscarriage with negative antiphospholipid antibodies: A meta-analysis 
      of randomized controlled trial.
PG  - 22-30
LID - S0301-2115(21)00533-9 [pii]
LID - 10.1016/j.ejogrb.2021.10.036 [doi]
AB  - OBJECTIVE: Unexplained recurrent miscarriage (uRM) has caused serious distress to 
      women of childbearing age, and effective treatment is particularly important. The 
      aim of this meta-analysis is to compare the efficacy of low molecular weight 
      heparin (LMWH) and LMWH combined with aspirin for uRM. METHODS: Databases 
      including PubMed, Web of Science, Embase, Scopus and the Cochrane Library 
      databases were electronically searched to identify randomized controlled trials 
      that reported the LMWH or LMWH combined with aspirin for women with uRM and 
      negative antiphospholipid antibodies (aPL). The retrieval time is limited from 
      inception to June 2021. Two reviewers independently screened literature, 
      extracted data, and assessed risk bias of included studies. Meta-analysis was 
      performed by using STATA 12.0 software. RESULTS: A total of 7 studies involving 
      1849 patients were included. The meta-analysis results showed that compared with 
      the control group, both LMWH and LMWH + aspirin interventions showed no 
      substantial influence on miscarriage rate (LMWH: RR = 0.69, 95%CI: 0.34-1.39, 
      P = 0.293, LMWH + aspirin: RR = 0.62, 95%CI: 0.30-1.27, P = 0.19) and the 
      occurrence of pre-eclampsia (LMWH: RR = 1.1, 95%CI: 0.53-2.31, P = 0.792; 
      LMWH + aspirin: RR = 1.49, 95%CI: 0.25-8.79, P = 0.662). LMWH therapy had no 
      influence on the live births (RR = 0.99, 95%CI: 0.92-1.06, P = 0.72). Subgroup 
      analysis showed that enoxaparin is not effective in women with uRM and negative 
      aPL (miscarriage rate: RR = 0.82, 95%CI: 0.31-2.19, P = 0.695; pre-eclampsia: 
      RR = 1.03, 95%CI: 0.46-2.33, P = 0.936). CONCLUSIONS: LMWH and LMWH combined with 
      aspirin therapy cannot improve the pregnancy outcome of women with uRM and 
      negative aPL. However, the above conclusions are still required to be verified 
      through more RCTs due to the limited quantity of included studies.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Yan, Xiaoli
AU  - Yan X
AD  - Department of Gynecology and Obstetrics, Southwest Hospital, Third Military 
      Medical University (Army Medical University), Chongqing, China.
FAU - Wang, Dan
AU  - Wang D
AD  - Department of Gynecology and Obstetrics, Southwest Hospital, Third Military 
      Medical University (Army Medical University), Chongqing, China.
FAU - Yan, Ping
AU  - Yan P
AD  - Department of Gynecology and Obstetrics, Southwest Hospital, Third Military 
      Medical University (Army Medical University), Chongqing, China.
FAU - Li, Hongyu
AU  - Li H
AD  - Department of Gynecology and Obstetrics, Southwest Hospital, Third Military 
      Medical University (Army Medical University), Chongqing, China. Electronic 
      address: Leerain1971@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20211110
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abortion, Habitual/drug therapy/etiology/prevention & control
MH  - Antibodies, Antiphospholipid
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin
MH  - *Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Antiphospholipid antibody
OT  - Aspirin
OT  - Low molecular weight heparin
OT  - Unexplained recurrent miscarriage
EDAT- 2021/11/19 06:00
MHDA- 2022/01/12 06:00
CRDT- 2021/11/18 20:20
PHST- 2021/06/12 00:00 [received]
PHST- 2021/09/22 00:00 [revised]
PHST- 2021/10/30 00:00 [accepted]
PHST- 2021/11/19 06:00 [pubmed]
PHST- 2022/01/12 06:00 [medline]
PHST- 2021/11/18 20:20 [entrez]
AID - S0301-2115(21)00533-9 [pii]
AID - 10.1016/j.ejogrb.2021.10.036 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2022 Jan;268:22-30. doi: 
      10.1016/j.ejogrb.2021.10.036. Epub 2021 Nov 10.

PMID- 3859595
OWN - NLM
STAT- MEDLINE
DCOM- 19850805
LR  - 20201209
IS  - 0278-2391 (Print)
IS  - 0278-2391 (Linking)
VI  - 43
IP  - 7
DP  - 1985 Jul
TI  - Comparison of meclofenamate sodium with buffered aspirin and placebo in the 
      treatment of postsurgical dental pain.
PG  - 517-22
AB  - The efficacy of meclofenamate sodium (Meclomen) at two different doses was 
      compared with that of buffered aspirin and placebo in the control of postsurgical 
      pain in a double-blind, randomized study of 205 patients. Meclofenamate sodium, 
      200 mg, was significantly better than meclofenamate sodium, 100 mg, in some 
      efficacy parameters. Both doses of meclofenamate sodium were superior to buffered 
      aspirin in most parameters of efficacy, and more effective than placebo in every 
      parameter.
FAU - Markowitz, N R
AU  - Markowitz NR
FAU - Young, S K
AU  - Young SK
FAU - Rohrer, M D
AU  - Rohrer MD
FAU - Turner, J L
AU  - Turner JL
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Oral Maxillofac Surg
JT  - Journal of oral and maxillofacial surgery : official journal of the American 
      Association of Oral and Maxillofacial Surgeons
JID - 8206428
RN  - 0 (Placebos)
RN  - 0 (ortho-Aminobenzoates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 48I5LU4ZWD (Meclofenamic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Acetaminophen/administration & dosage
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Codeine/administration & dosage
MH  - Female
MH  - Humans
MH  - Male
MH  - Meclofenamic Acid/administration & dosage/*therapeutic use
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
MH  - Time Factors
MH  - Tooth Extraction/*adverse effects
MH  - Tooth, Impacted/surgery
MH  - ortho-Aminobenzoates/*therapeutic use
EDAT- 1985/07/01 00:00
MHDA- 1985/07/01 00:01
CRDT- 1985/07/01 00:00
PHST- 1985/07/01 00:00 [pubmed]
PHST- 1985/07/01 00:01 [medline]
PHST- 1985/07/01 00:00 [entrez]
AID - S0278239185001070 [pii]
AID - 10.1016/s0278-2391(85)80030-6 [doi]
PST - ppublish
SO  - J Oral Maxillofac Surg. 1985 Jul;43(7):517-22. doi: 
      10.1016/s0278-2391(85)80030-6.

PMID- 8281347
OWN - NLM
STAT- MEDLINE
DCOM- 19940216
LR  - 20131121
IS  - 1018-9068 (Print)
IS  - 1018-9068 (Linking)
VI  - 3
IP  - 3
DP  - 1993 May-Jun
TI  - Tolerance to aspirin in aspirin-sensitive asthmatics. Methods of inducing the 
      tolerance state and its influence on the course of asthma and rhinosinusitis.
PG  - 156-9
AB  - Aspirin-sensitive asthma is a serious clinical problem, frequently involving 
      dramatic exacerbation and sometimes even death after the accidental ingestion of 
      aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). The majority of 
      such asthmatics usually suffer from chronic rhinosinusitis and nasal polyps as 
      well, and almost half of them from headaches. Widal et al. in 1922, and later, 
      Zeiss and Lockey were able to elicit tolerance to aspirin (ASA). In all the 
      studies performed so far, tolerance to ASA was achieved by giving double 
      threshold ASA doses every day or every few hours. This method elicited severe 
      dyspnea and sometimes pronounced extrabronchial sensitivity symptoms. From our 
      previous studies, it appeared that the smaller the aspirin dose, the weaker the 
      sensitivity symptoms, and that it is possible to induce tolerance after eliciting 
      only very slight sensitivity reactions. Based on this observation, we elaborated 
      a new method of eliciting aspirin tolerance by the daily administration of 
      gradually increasing doses of aspirin starting with subthreshold doses. Applying 
      this method, we achieved tolerance to aspirin without any adverse reactions. The 
      patients in a tolerance state to ASA also tolerated well other NSAIDs, i.e. 
      indomethacin and diclofenac. It is possible to maintain a tolerance state for a 
      long time by the administration of ASA at proper intervals. It was shown that 
      such a procedure may have a beneficial influence on the course of asthma and 
      rhinitis. In our opinion, inducing and maintaining aspirin tolerance in 
      aspirin-sensitive asthmatics is indicated in the following situations: 1) the 
      need to treat coexisting rheumatic diseases; 2) the need to treat coexisting 
      intractable headaches; and 3) the need for symptomatic treatment of ASA-sensitive 
      asthma and rhinitis.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Szmidt, M
AU  - Szmidt M
AD  - Department of Pneumonology and Allergology, Medical Academy of Lódź, Poland.
FAU - Grzelewska-Rzymowska, I
AU  - Grzelewska-Rzymowska I
FAU - Rozniecki, J
AU  - Rozniecki J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - J Investig Allergol Clin Immunol
JT  - Journal of investigational allergology & clinical immunology
JID - 9107858
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/chemically induced/*drug therapy
MH  - Drug Tolerance
MH  - Humans
MH  - Rhinitis/*drug therapy
MH  - Sinusitis/*drug therapy
RF  - 32
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
PST - ppublish
SO  - J Investig Allergol Clin Immunol. 1993 May-Jun;3(3):156-9.

PMID- 1378336
OWN - NLM
STAT- MEDLINE
DCOM- 19920819
LR  - 20191028
IS  - 0300-5364 (Print)
IS  - 0300-5364 (Linking)
VI  - 26
IP  - 2
DP  - 1992 Apr
TI  - Indications for aspirin as a palliative for tinnitus caused by SOAEs: a case 
      study.
PG  - 91-6
AB  - This paper explores the effect of aspirin on the tinnitus of one patient for whom 
      two contralateral spontaneous otoacoustic emissions (SOAEs) caused binaural 
      tinnitus. The relation between the SOAEs and tinnitus was explored during a 
      preliminary testing session, after which the SOAEs were measured for 7 days. 
      During days 1, 2, 5, 6 and 7 of the trial, a placebo (two 50-mg tablets of 
      ascorbic acid) was administered four times per day. During days 3 and 4, a drug 
      (two 300-mg tablets of aspirin) was administered four times per day. During day 
      2, the right ear's SOAE was low level and labile, sometimes disappearing into the 
      noise floor. The effect of aspirin on an emission which is not consistently 
      observed, cannot be assessed so this report focuses primarily on the left ear. 
      During days 1 and 2, the SOAE in the left ear was present and the tinnitus was 
      audible. By day 3 (after 2.4 g of aspirin), the SOAE in the left ear had been 
      abolished, and the tinnitus was not audible. On the fifth day (24 hours after the 
      last aspirin), both the SOAE and the tinnitus in the left ear had returned. There 
      were no reported side-effects of the aspirin. Thus, aspirin seemed to provide an 
      acceptable palliative for this patient's SOAE-caused tinnitus.
FAU - Penner, M J
AU  - Penner MJ
AD  - Department of Psychology, University of Maryland, College Park 20742.
FAU - Coles, R R
AU  - Coles RR
LA  - eng
PT  - Case Reports
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Br J Audiol
JT  - British journal of audiology
JID - 0357321
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Ear Diseases/drug therapy/etiology/physiopathology
MH  - England
MH  - Female
MH  - Hospitals, General
MH  - Humans
MH  - Male
MH  - Palliative Care/*psychology
MH  - Placebo Effect
MH  - Research Design
MH  - Tinnitus/*drug therapy/etiology
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
AID - 10.3109/03005369209077876 [doi]
PST - ppublish
SO  - Br J Audiol. 1992 Apr;26(2):91-6. doi: 10.3109/03005369209077876.

PMID- 23792301
OWN - NLM
STAT- MEDLINE
DCOM- 20131216
LR  - 20211021
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Print)
IS  - 0892-6638 (Linking)
VI  - 27
IP  - 10
DP  - 2013 Oct
TI  - Aspirin-triggered 15-epi-lipoxin A4 predicts cyclooxygenase-2 in the lungs of 
      LPS-treated mice but not in the circulation: implications for a clinical test.
PG  - 3938-46
LID - 10.1096/fj.12-215533 [doi]
AB  - Inhibition of cyclooxygenase (COX)-2 increases cardiovascular deaths. Identifying 
      a biomarker of COX-2 is desirable but difficult, since COX-1 and COX-2 ordinarily 
      catalyze formation of an identical product, prostaglandin H2. When acetylated by 
      aspirin, however, COX-2 (but not COX-1) can form 15(R)-HETE, which is metabolized 
      to aspirin-triggered lipoxin (ATL), 15-epi-lipoxin A4. Here we have used COX-1- 
      and COX-2-knockout mice to establish whether plasma ATL could be used as a 
      biomarker of vascular COX-2 in vivo. Vascular COX-2 was low but increased by LPS 
      (10 mg/kg; i.p). Aspirin (10 mg/kg; i.v.) inhibited COX-1, measured as blood 
      thromboxane and COX-2, measured as lung PGE2. Aspirin also increased the levels 
      of ATL in the lungs of LPS-treated wild-type C57Bl6 mice (vehicle: 25.5±9.3 
      ng/ml; 100 mg/kg: 112.0±7.4 ng/ml; P<0.05). Despite this, ATL was unchanged in 
      plasma after LPS and aspirin. This was true in wild-type as well as COX-1(-/-) 
      and COX-2(-/-) mice. Thus, in mice in which COX-2 has been induced by LPS 
      treatment, aspirin triggers detectable 15-epi-lipoxin A4 in lung tissue, but not 
      in plasma. This important study is the first to demonstrate that while ATL can be 
      measured in tissue, plasma ATL is not a biomarker of vascular COX-2 expression.
FAU - Kirkby, Nicholas S
AU  - Kirkby NS
AD  - 1Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College 
      London, Dovehouse St., London SW3 6LY, UK. J.A.M., j.a.mitchell@imperial.ac.uk.
FAU - Chan, Melissa V
AU  - Chan MV
FAU - Lundberg, Martina H
AU  - Lundberg MH
FAU - Massey, Karen A
AU  - Massey KA
FAU - Edmands, William M B
AU  - Edmands WM
FAU - MacKenzie, Louise S
AU  - MacKenzie LS
FAU - Holmes, Elaine
AU  - Holmes E
FAU - Nicolaou, Anna
AU  - Nicolaou A
FAU - Warner, Timothy D
AU  - Warner TD
FAU - Mitchell, Jane A
AU  - Mitchell JA
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - BHF_/British Heart Foundation/United Kingdom
GR  - 0852551Z108/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130621
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biomarkers
MH  - Cyclooxygenase 1/genetics/metabolism
MH  - Cyclooxygenase 2/genetics/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Gene Expression Regulation/*drug effects
MH  - Lipopolysaccharides/*toxicity
MH  - Lipoxins/genetics/*metabolism
MH  - Lung/drug effects/*enzymology
MH  - Mice
PMC - PMC3973905
OTO - NOTNLM
OT  - 15-HETE
OT  - COX-2 biomarker
OT  - nonsteroidal anti-inflammatory drugs
OT  - vascular inflammation
EDAT- 2013/06/25 06:00
MHDA- 2013/12/18 06:00
CRDT- 2013/06/25 06:00
PHST- 2013/06/25 06:00 [entrez]
PHST- 2013/06/25 06:00 [pubmed]
PHST- 2013/12/18 06:00 [medline]
AID - fj.12-215533 [pii]
AID - 12-215533 [pii]
AID - 10.1096/fj.12-215533 [doi]
PST - ppublish
SO  - FASEB J. 2013 Oct;27(10):3938-46. doi: 10.1096/fj.12-215533. Epub 2013 Jun 21.

PMID- 25213077
OWN - NLM
STAT- MEDLINE
DCOM- 20150318
LR  - 20211021
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 60
IP  - 2
DP  - 2015 Feb
TI  - Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's 
      esophagus.
PG  - 436-43
LID - 10.1007/s10620-014-3349-2 [doi]
AB  - BACKGROUND: The use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) 
      may decrease the risk of esophageal adenocarcinoma; however, it is unknown where 
      these agents may act in the proposed pathway from normal mucosa to Barrett's 
      esophagus to esophageal adenocarcinoma. AIM: The aim of the study was to evaluate 
      the association between aspirin and NSAID use and Barrett's esophagus in a 
      case-control study within a large community-based population. METHODS: We 
      conducted a case-control study of aspirin/NSAID use and Barrett's esophagus 
      within the Kaiser Permanente Northern California population. Cases had a new 
      diagnosis of Barrett's esophagus between October 2002 and September 2005; 
      controls were members without a diagnosis of Barrett's esophagus. RESULTS: 
      Persons with Barrett's esophagus were less likely to use aspirin than population 
      controls [odds ratio (OR) 0.59, 95 % confidence interval (CI) 0.39-0.87]; a 
      stronger association was found among cases and controls with reflux symptoms (OR 
      0.49, 95 % CI 0.32-0.75; p value interaction = 0.004). Similar associations were 
      found with the use of either aspirin and/or non-aspirin NSAIDs (OR 0.53, 95 % CI 
      0.35-0.81), although NSAID use alone was not significantly associated with 
      Barrett's esophagus (OR 0.74, 95 % CI 0.47-1.16). The strength of the association 
      was highest among persons with at least moderate-to-high total medication intake. 
      CONCLUSIONS: Regular use of aspirin or NSAIDs was associated with a decreased 
      risk of Barrett's esophagus, particularly among persons with gastroesophageal 
      reflux disease symptoms. These findings have implications for chemoprevention, as 
      some of the previously described protective association between aspirin/NSAIDs 
      and esophageal adenocarcinoma may be explained by events that occur prior to the 
      development of Barrett's esophagus.
FAU - Schneider, Jennifer L
AU  - Schneider JL
AD  - Kaiser Permanente Division of Research, 2000 Broadway, Oakland, CA, 94612, USA, 
      jennifer.l1.schneider@kp.org.
FAU - Zhao, Wei K
AU  - Zhao WK
FAU - Corley, Douglas A
AU  - Corley DA
LA  - eng
GR  - K08 DK002697/DK/NIDDK NIH HHS/United States
GR  - R01 DK063616/DK/NIDDK NIH HHS/United States
GR  - K08 DK02697/DK/NIDDK NIH HHS/United States
GR  - R01 DK63616/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20140912
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Barrett Esophagus/diagnosis/epidemiology/*prevention & control
MH  - California/epidemiology
MH  - Case-Control Studies
MH  - Cytoprotection
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Protective Factors
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Young Adult
PMC - PMC4304909
MID - NIHMS627954
COIS- Potential competing interests: None
EDAT- 2014/09/13 06:00
MHDA- 2015/03/19 06:00
CRDT- 2014/09/13 06:00
PHST- 2014/04/30 00:00 [received]
PHST- 2014/08/30 00:00 [accepted]
PHST- 2014/09/13 06:00 [entrez]
PHST- 2014/09/13 06:00 [pubmed]
PHST- 2015/03/19 06:00 [medline]
AID - 10.1007/s10620-014-3349-2 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2015 Feb;60(2):436-43. doi: 10.1007/s10620-014-3349-2. Epub 2014 Sep 
      12.

PMID- 18310750
OWN - NLM
STAT- MEDLINE
DCOM- 20080513
LR  - 20131121
IS  - 0301-620X (Print)
IS  - 0301-620X (Linking)
VI  - 90
IP  - 3
DP  - 2008 Mar
TI  - Ninety-day mortality after elective total hip replacement: 1549 patients using 
      aspirin as a thromboprophylactic agent.
PG  - 306-7
LID - 10.1302/0301-620X.90B3.19935 [doi]
AB  - Thromboprophylaxis after elective orthopaedic surgery remains controversial. 
      Recent guidelines from the National Institute for Clinical Excellence (NICE) have 
      suggested that low molecular weight heparin should be given to all patients 
      undergoing total hip replacement. The British Orthopaedic Association is 
      currently debating this guideline with NICE, as it is not clear whether published 
      evidence supports this view. We present the early mortality in our unit after 
      total hip replacement using aspirin as chemical thromboprophylaxis. The 30-day 
      and 90-day mortality after primary total hip arthroplasty was zero. We compare 
      this with that reported previously from our unit without using chemical 
      thromboprophylaxis. With the introduction of routine aspirin thromboprophylaxis, 
      deaths from cardiovascular causes have dropped from 0.75% to zero. These results 
      demonstrate that there is a strong argument for the routine administration of 
      aspirin after elective total hip replacement.
FAU - Parry, M
AU  - Parry M
AD  - University of Bristol, Avon Orthopaedic Centre, Southmead Hospital, 
      Westbury-on-Trym, Bristol BS10 5NB, UK.
FAU - Wylde, V
AU  - Wylde V
FAU - Blom, A W
AU  - Blom AW
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Bone Joint Surg Br
JT  - The Journal of bone and joint surgery. British volume
JID - 0375355
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthroplasty, Replacement, Hip/*mortality
MH  - Aspirin/*therapeutic use
MH  - England
MH  - Follow-Up Studies
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Thromboembolism/*mortality/prevention & control
EDAT- 2008/03/04 09:00
MHDA- 2008/05/14 09:00
CRDT- 2008/03/04 09:00
PHST- 2008/03/04 09:00 [pubmed]
PHST- 2008/05/14 09:00 [medline]
PHST- 2008/03/04 09:00 [entrez]
AID - 90-B/3/306 [pii]
AID - 10.1302/0301-620X.90B3.19935 [doi]
PST - ppublish
SO  - J Bone Joint Surg Br. 2008 Mar;90(3):306-7. doi: 10.1302/0301-620X.90B3.19935.

PMID- 24436316
OWN - NLM
STAT- MEDLINE
DCOM- 20150212
LR  - 20151119
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 23
IP  - 3
DP  - 2014 Mar
TI  - The non-linear threshold association between aspirin use and esophageal 
      adenocarcinoma: results of a dose-response meta-analysis.
PG  - 278-84
LID - 10.1002/pds.3560 [doi]
AB  - BACKGROUND: The role of aspirin use in chemoprevention of esophageal 
      adenocarcinoma (EAC) is still unclear. Previous meta-analyses have reported a 
      beneficial effect of aspirin use, whereas it remains still under debate whether 
      there are non-linear frequency-risk and duration-risk relations, such as a 
      "threshold" effect. METHODS: Nine observational studies reporting the association 
      between aspirin use and EAC risk were selected through a combined search with the 
      PUBMED and EMBASE electronic databases of articles published before June 2013. 
      Overall odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using 
      fixed-effects models, and the cubic spline regression models were performed for 
      the study of frequency-risk and duration-risk relations. RESULTS: A monotonically 
      decreasing relation was observed only for ≤ 4.5 times per week (OR=0.75, 95%CI 
      0.64-0.88, for twice per week; OR=0.59, 95%CI 0.45-0.78, for 4.5 times per week) 
      and ≤ 6 years (OR=0.82, 95%CI 0.76-0.91, for 1 year; OR=0.53, 95%CI 0.37-0.75, 
      for 3 years) of aspirin use using the non-users as the reference. Once the 
      frequency is more than 4.5 times/week or the duration is longer than 6 years, no 
      further benefit was observed. CONCLUSION: Our findings suggest that there may be 
      non-linear threshold relations of frequency and duration of aspirin use with the 
      risk of EAC. Further data from randomized clinical trials are required.
CI  - Copyright © 2014 John Wiley & Sons, Ltd.
FAU - Xiaohua, Ye
AU  - Xiaohua Y
AD  - School of Public Health, Guangdong Key Laboratory of Molecular Epidemiology, 
      Guangdong Pharmaceutical University, Guangzhou, China; School of Public Health 
      and Tropical Medicine, Southern Medical University, Guangzhou, China.
FAU - Zhenjiang, Yao
AU  - Zhenjiang Y
FAU - Weidong, Liu
AU  - Weidong L
FAU - Pengcheng, Xun
AU  - Pengcheng X
FAU - Sidong, Chen
AU  - Sidong C
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20140117
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - Adenocarcinoma Of Esophagus
SB  - IM
MH  - Adenocarcinoma/chemically induced/diagnosis/*epidemiology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Esophageal Neoplasms/chemically induced/diagnosis/*epidemiology
MH  - Humans
MH  - *Nonlinear Dynamics
MH  - Observational Studies as Topic/methods
OTO - NOTNLM
OT  - aspirin
OT  - epidemiology
OT  - esophageal cancer
OT  - nonsteroidal anti-inflammatory drugs
OT  - pharmacoepidemiology
EDAT- 2014/01/18 06:00
MHDA- 2015/02/13 06:00
CRDT- 2014/01/18 06:00
PHST- 2013/10/28 00:00 [received]
PHST- 2013/11/29 00:00 [revised]
PHST- 2013/12/03 00:00 [accepted]
PHST- 2014/01/18 06:00 [entrez]
PHST- 2014/01/18 06:00 [pubmed]
PHST- 2015/02/13 06:00 [medline]
AID - 10.1002/pds.3560 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):278-84. doi: 10.1002/pds.3560. Epub 
      2014 Jan 17.

PMID- 26794215
OWN - NLM
STAT- MEDLINE
DCOM- 20160804
LR  - 20190222
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 1
DP  - 2016
TI  - Aspirin Breaks the Crosstalk between 3T3-L1 Adipocytes and 4T1 Breast Cancer 
      Cells by Regulating Cytokine Production.
PG  - e0147161
LID - 10.1371/journal.pone.0147161 [doi]
LID - e0147161
AB  - Breast cancer is one of the most common cancers in women worldwide. The obesity 
      process is normally accompanied by chronic, low-grade inflammation. Infiltration 
      by inflammatory cytokines and immune cells provides a favorable microenvironment 
      for tumor growth, migration, and metastasis. Epidemiological evidence has shown 
      that aspirin is an effective agent against several types of cancer. The aim of 
      this study is to investigate the anti-inflammatory and anti-cancer effects of 
      aspirin on 3T3-L1 adipocytes, 4T1 murine breast cancer cells, and their 
      crosstalk. The results showed that aspirin treatment inhibited differentiation 
      and lipid accumulation by 3T3-L1 preadipocytes, and decreased the secretion of 
      the inflammatory adipokine MCP-1 after stimulation with tumor necrosis factor 
      (TNF)-α or conditioned medium from RAW264.7 cells. In 4T1 cells, treatment with 
      aspirin decreased cell viability and migration, possibly by suppressing MCP-1 and 
      VEGF secretion. Subsequently, culture of 4T1 cells in 3T3-L1 
      adipocyte-conditioned medium (Ad-CM) and co-culture of 3T3-L1 and 4T1 cells using 
      a transwell plate were performed to clarify the relationship between these two 
      cell lines. Aspirin exerted its inhibitory effects in the transwell co-culture 
      system, as well as the conditioned-medium model. Aspirin treatment significantly 
      inhibited the proliferation of 4T1 cells, and decreased the production of MCP-1 
      and PAI-1 in both the Ad-CM model and co-culture system. Aspirin inhibited 
      inflammatory MCP-1 adipokine production by 3T3-L1 adipocytes and the cell growth 
      and migration of 4T1 cells. It also broke the crosstalk between these two cell 
      lines, possibly contributing to its chemopreventive properties in breast cancer. 
      This is the first report that aspirin's chemopreventive activity supports the 
      potential application in auxiliary therapy against obesity-related breast cancer 
      development.
FAU - Hsieh, Chia-Chien
AU  - Hsieh CC
AD  - Department of Human Development and Family Studies, National Taiwan Normal 
      University, Taipei, Taiwan.
FAU - Huang, Yu-Shan
AU  - Huang YS
AD  - Department of Human Development and Family Studies, National Taiwan Normal 
      University, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160121
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 0 (SERPINE1 protein, human)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 3T3-L1 Cells
MH  - Adipocytes/cytology/drug effects/*metabolism
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*pharmacology
MH  - Breast Neoplasms/drug therapy/*metabolism/pathology
MH  - Cell Differentiation/drug effects
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Chemokine CCL2/*metabolism
MH  - Coculture Techniques
MH  - Culture Media, Conditioned/pharmacology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Mice
MH  - Plasminogen Activator Inhibitor 1/*metabolism
MH  - Vascular Endothelial Growth Factor A/*metabolism
PMC - PMC4721678
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2016/01/23 06:00
MHDA- 2016/08/05 06:00
CRDT- 2016/01/23 06:00
PHST- 2015/11/12 00:00 [received]
PHST- 2015/12/28 00:00 [accepted]
PHST- 2016/01/23 06:00 [entrez]
PHST- 2016/01/23 06:00 [pubmed]
PHST- 2016/08/05 06:00 [medline]
AID - PONE-D-15-47564 [pii]
AID - 10.1371/journal.pone.0147161 [doi]
PST - epublish
SO  - PLoS One. 2016 Jan 21;11(1):e0147161. doi: 10.1371/journal.pone.0147161. 
      eCollection 2016.

PMID- 9330
OWN - NLM
STAT- MEDLINE
DCOM- 19761201
LR  - 20131121
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 71
IP  - 5
DP  - 1976 Nov
TI  - Gastric mucosal lesions produced by intravenous infusion of aspirin in cats.
PG  - 754-9
AB  - Aspirin was given by continuous intravenous infusion to 35 intact cats for 7 days 
      in doses ranging from 25 to 200 mg kg-1 day-1. Gastric mucosal lesions occurred 
      in 50 to 70% of the animals in the various dosage groups, including deep ulcers 
      in 20%. All of the ulcers were in antral mucosa near its border with oxyntic 
      mucosa. The incidence of lesions, including ulcers, showed no apparent relation 
      to the dose of aspirin. With all but the highest dose, plasma salicylate levels 
      were within or below what is regarded as the therapeutic range for man. Asprin, 
      100 mg kg-1 day-1, was given for 7 days to 4 cats with pouches containing all of 
      the antral mucosa plus some oxyntic mucosa. One or more deep ulcers occurred in 
      the antral mucosa of the pouches in each of these 4 cats. The electrical 
      potential difference across the mucosa did not decrease, and net fluxes of 
      hydrogen ions out of the pouch and of sodium ions into the pouch did not increase 
      during the 7 days of aspirin administration despite the occurrence of ulcers in 
      the pouches. It is concluded that intravenous aspirin, in doses giving plasma 
      levels within or below the therapeutic range for man, causes gastric mucosal 
      lesions including deep ulcers within 7 days in cats. These lesions occur without 
      the changes in electrical potential difference and hydrogen and sodium fluxes 
      that are regarded as characteristic of the "broken barrier."
FAU - Bugat, R
AU  - Bugat R
FAU - Thompson, M R
AU  - Thompson MR
FAU - Aures, D
AU  - Aures D
FAU - Grossman, M I
AU  - Grossman MI
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Ions)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/toxicity
MH  - Body Weight/drug effects
MH  - Cats
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastric Mucosa/drug effects/metabolism/pathology
MH  - Hydrogen-Ion Concentration
MH  - Infusions, Parenteral
MH  - Ions/metabolism
MH  - Male
MH  - Membrane Potentials/drug effects
MH  - Salicylates/blood
MH  - Stomach Ulcer/*chemically induced/pathology
EDAT- 1976/11/01 00:00
MHDA- 1976/11/01 00:01
CRDT- 1976/11/01 00:00
PHST- 1976/11/01 00:00 [pubmed]
PHST- 1976/11/01 00:01 [medline]
PHST- 1976/11/01 00:00 [entrez]
AID - S0016508576002813 [pii]
PST - ppublish
SO  - Gastroenterology. 1976 Nov;71(5):754-9.

PMID- 2873955
OWN - NLM
STAT- MEDLINE
DCOM- 19860916
LR  - 20200825
IS  - 0742-8413 (Print)
IS  - 0742-8413 (Linking)
VI  - 84
IP  - 1
DP  - 1986
TI  - Effects of aspirin on gastric mucus glycoprotein in fed and fasted rats.
PG  - 7-9
AB  - Gastric lesions induced by aspirin increased the ulcer index and incidence with 
      prolongation of fasting time. Aspirin decreased gastric mucus glycoprotein in 
      both the corpus and antrum. However, the rate of decrease in mucus glycoprotein 
      induced by aspirin differed according to feeding habits and the gastric region. 
      Qualitative change in corpus mucus glycoprotein was induced by aspirin.
FAU - Ohara, S
AU  - Ohara S
FAU - Hotta, K
AU  - Hotta K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Comp Biochem Physiol C Comp Pharmacol Toxicol
JT  - Comparative biochemistry and physiology. C, Comparative pharmacology and 
      toxicology
JID - 8310013
RN  - 0 (Carbohydrates)
RN  - 0 (Glycoproteins)
RN  - 0 (gastric mucus glycoproteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Carbohydrates/analysis
MH  - Eating
MH  - Fasting
MH  - Gastric Mucosa/drug effects/*metabolism
MH  - Glycoproteins/isolation & purification/*metabolism
MH  - Kinetics
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1016/0742-8413(86)90156-8 [doi]
PST - ppublish
SO  - Comp Biochem Physiol C Comp Pharmacol Toxicol. 1986;84(1):7-9. doi: 
      10.1016/0742-8413(86)90156-8.

PMID- 3418736
OWN - NLM
STAT- MEDLINE
DCOM- 19881014
LR  - 20181113
IS  - 0027-9684 (Print)
IS  - 0027-9684 (Linking)
VI  - 80
IP  - 5
DP  - 1988 May
TI  - The effects of aspirin-like drugs on the nutritional status of pregnant rats and 
      offspring.
PG  - 545-52
AB  - Previous studies have shown that salicylates and protein-calorie malnutrition 
      independently compromise maturation and growth of infants. In the present study, 
      pregnant rats were fed normal-and low-protein diets with and without aspirinlike 
      drug treatments. The effects of a low-protein (8 percent) diet included decreases 
      in total serum proteins in both dams and their offspring. Decreases in weight 
      gains, serum albumin and globulin levels, and blood urea nitrogen (BUN) 
      concentrations were detected in dams fed the low-protein diet without evidence of 
      changes of these variables in their offspring.Salicylamide treatment was 
      associated with decreased BUN values, and aspirin treatment was associated with 
      decreased body-weight gains in both pregnant rats and offspring of dams fed the 
      normal (25 percent) protein-control diet. Although aspirin treatment decreased 
      weight gains, total serum protein and albumin levels, and BUN values, 
      salicylamide decreased only the serum albumin levels of dams fed the 
      normal-protein diet. Salicylamide treatment of dams fed the normal-protein diet 
      was associated with decreased serum globulin levels, increased serum 
      albumin-globulin ratios, and increased body-weight gains in their offspring.Both 
      aspirin and salicylamide treatments were associated with decreased total serum 
      protein levels in dams fed a low-protein diet. Aspirin treatment increased serum 
      globulin levels and decreased serum albumin-globulin ratios in off-spring of dams 
      fed the low-protein diet. The only effect of salicylamide treatment on offspring 
      of dams fed the low-protein diet was decreased BUN values.It is concluded that 
      aspirin treatment of pregnant rats was associated with more deleterious effects 
      on their offspring than salicylamide treatment. Low maternal dietary protein 
      conditions exacerbated effects associated with both salicylamide and aspirin 
      treatments.
FAU - Millis, R M
AU  - Millis RM
FAU - Ewii, M C
AU  - Ewii MC
FAU - Offiah, G U
AU  - Offiah GU
FAU - Hyde, B P
AU  - Hyde BP
FAU - Knight, E M
AU  - Knight EM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Natl Med Assoc
JT  - Journal of the National Medical Association
JID - 7503090
RN  - 0 (Salicylamides)
RN  - EM8BM710ZC (salicylamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Animals, Newborn/*metabolism
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Male
MH  - Nutritional Status/*drug effects
MH  - Pregnancy
MH  - Pregnancy, Animal/*drug effects
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Salicylamides/adverse effects
PMC - PMC2625776
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
PST - ppublish
SO  - J Natl Med Assoc. 1988 May;80(5):545-52.

PMID- 26369679
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 21
IP  - 35
DP  - 2015
TI  - New Insights into the Mechanism of Action of Aspirin in the Prevention of 
      Colorectal Neoplasia.
PG  - 5116-26
AB  - The results of clinical studies have shown that the chronic administration of 
      aspirin, even at the lowdoses (75-100 mg daily) recommended for the prevention of 
      cardiovascular disease, is associated with a reduction of cancer incidence and 
      mortality, in particular colorectal cancer (CRC). The mechanism of action of 
      aspirin as an antineoplastic agent remains controversial. However, data of 
      clinical pharmacology and several features of the chemopreventive effect of 
      aspirin, emerged from clinical trials, suggest that the antiplatelet effect of 
      aspirin plays a central role in its anticancer effects. In addition to their 
      contribution to tumor metastasis, platelets may play a role in the early phases 
      of tumorigenesis. In response to lifestyle and environment factors, intestinal 
      epithelial damage/ dysfunction may be associated with platelet activation, 
      initially as a mechanism to repair the damage. However, if the platelet response 
      is unconstrained, it may contribute to the development of chronic inflammation. 
      Altogether these events lead to alter the normal functions of intestinal 
      epithelial cells and may translate into cellular transformation through several 
      mechanisms, including the overexpression of cyclooxygenase(COX)-2 and epidermal 
      growth factor receptor (EGFR), which are considered early events in colorectal 
      tumorigenesis. Thus, antiplatelet agents may play a role in the prevention of CRC 
      by modifying epigenetic events involved in early phases of colorectal 
      tumorigenesis. Finally, we carried out a critical review of the literature on 
      off-target mechanisms of aspirin action as anticancer drug.
FAU - Di Francesco, Luigia
AU  - Di Francesco L
FAU - López Contreras, Luilli Antonio
AU  - López Contreras LA
FAU - Sacco, Angela
AU  - Sacco A
FAU - Patrignani, Paola
AU  - Patrignani P
AD  - Department of Neuroscience, Imaging and Clinical Sciences and Center of 
      Excellence on Aging .(CeSI), "G. d'Annunzio" University, Via deiVestini, 31, 
      66100, Chieti, Italy. ppatrignani@unich.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticarcinogenic Agents/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/drug effects/metabolism
MH  - Colorectal Neoplasms/genetics/pathology/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Epigenesis, Genetic
MH  - Humans
MH  - Inflammation/pathology/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology
EDAT- 2015/09/16 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/06/19 00:00 [received]
PHST- 2015/09/14 00:00 [accepted]
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - CPD-EPUB-70388 [pii]
AID - 10.2174/1381612821666150915110706 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2015;21(35):5116-26. doi: 10.2174/1381612821666150915110706.

PMID- 15969660
OWN - NLM
STAT- MEDLINE
DCOM- 20060821
LR  - 20131121
IS  - 0954-7894 (Print)
IS  - 0954-7894 (Linking)
VI  - 35
IP  - 6
DP  - 2005 Jun
TI  - Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin 
      hypersensitivity.
PG  - 717-22
AB  - Oral aspirin challenge (OAC) is used to confirm aspirin hypersensitivity (AHs) 
      but there is no consensus on a standardized protocol. As a prior clinical history 
      of adverse reactions to aspirin is poorly predictive of a positive result from 
      formal aspirin challenge, many patients have an OAC performed. We retrospectively 
      identified and prospectively validated how a 1-day OAC protocol could be 
      modified, and patient selection improved, to deliver a safe and more efficient 
      service. In a retrospective audit of 45 OACs using a 2 h dose interval, all 
      reactions occurred within 90 min of the threshold dose. Forty OACs were then 
      performed using a 90-min dose interval. This reduced the mean duration of a 
      positive and negative OAC from 6 to 5 h and from 8 to 6 h, respectively. 
      Histories of multiple manifestations of AHs were found in 91.6% (11) of those 
      with asthma, 87.5% (7) with angiooedema, 70.6% (12) with rhinosinusitis, 63.6% 
      (7) with chronic non-vasculitic urticaria and all with anaphylaxis, who developed 
      a positive OAC. None of those with anaphylaxis, 8.3% (1) with asthma and 12.5% 
      (1) with angiooedema, with a positive OAC, had a history of a single 
      manifestation of AHs. The efficiency of an OAC service can safely be improved by 
      reduction of the dose interval from 2 to 1 (1/2) h, and more targeted patient 
      selection, as the likelihood of a positive OAC increases among patients with a 
      history of asthma, angiooedoema or anaphylaxis with multiple manifestations of 
      AHs.
FAU - Cormican, L J
AU  - Cormican LJ
AD  - Department of Asthma, King's College London, Guy's Hospital, London, UK. 
      cormitron@yahoo.com
FAU - Farooque, S
AU  - Farooque S
FAU - Altmann, D R
AU  - Altmann DR
FAU - Lee, T H
AU  - Lee TH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Anaphylaxis/diagnosis
MH  - Angioedema/diagnosis
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Asthma/diagnosis
MH  - Bronchial Spasm/chemically induced
MH  - Chronic Disease
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Hypersensitivity, Immediate/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Rhinitis/diagnosis
MH  - Urticaria/diagnosis
EDAT- 2005/06/23 09:00
MHDA- 2006/08/22 09:00
CRDT- 2005/06/23 09:00
PHST- 2005/06/23 09:00 [pubmed]
PHST- 2006/08/22 09:00 [medline]
PHST- 2005/06/23 09:00 [entrez]
AID - CEA2261 [pii]
AID - 10.1111/j.1365-2222.2005.02261.x [doi]
PST - ppublish
SO  - Clin Exp Allergy. 2005 Jun;35(6):717-22. doi: 10.1111/j.1365-2222.2005.02261.x.

PMID- 15289387
OWN - NLM
STAT- MEDLINE
DCOM- 20050204
LR  - 20220408
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 110
IP  - 5
DP  - 2004 Aug 3
TI  - Comparing warfarin with aspirin after biological aortic valve replacement: a 
      prospective study.
PG  - 496-500
AB  - BACKGROUND: Patients with prosthetic heart valves have a higher risk of 
      developing valve thrombosis and arterial thromboembolism. Antithrombotic therapy 
      in the early postoperative period after biological aortic valve replacement 
      (BAVR) is controversial. The American College of Cardiology/American Heart 
      Association and European Society of Cardiology guidelines recommend the use of 
      warfarin for the first 3 months after BAVR, although the American College Chest 
      Physician guidelines suggest that the recommendations are very weak and that the 
      risk/benefit is unclear. This prospective study investigated the efficacy of 
      postoperative warfarin compared with aspirin in patients after aortic valve 
      replacement. METHODS AND RESULTS: Patients undergoing BAVR between 2001 and 2002 
      received 2 antithrombotic therapies: 141 patients received warfarin for the first 
      3 months, and 108 patients received only aspirin. The major end points evaluated 
      were the rate of cerebral ischemic events, bleeding, and survival. There were 3 
      and 5 postoperative cerebral ischemic events between 24 hours and 3 months for 
      patients treated with aspirin and warfarin, respectively. After 3 months, the 
      incidence of cerebral ischemic events did not differ between the 2 groups. The 
      rate of major bleeding events, the stroke-free survival, and the overall survival 
      rates were not statistically significant between the warfarin and aspirin groups. 
      CONCLUSIONS: There seem to be no advantages in performing early anticoagulation 
      therapy compared with a low-antiplatelet regimen with regard to early cerebral 
      ischemic events, bleeding, and survival. Currently there is no evidence to 
      support the fact that warfarin is more effective than aspirin.
FAU - Gherli, Tiziano
AU  - Gherli T
AD  - Department of Cardiac Surgery, University of Parma, Parma, Italy.
FAU - Colli, Andrea
AU  - Colli A
FAU - Fragnito, Claudio
AU  - Fragnito C
FAU - Nicolini, Francesco
AU  - Nicolini F
FAU - Borrello, Bruno
AU  - Borrello B
FAU - Saccani, Stefano
AU  - Saccani S
FAU - D'Amico, Roberto
AU  - D'Amico R
FAU - Beghi, Cesare
AU  - Beghi C
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Bioprosthesis
MH  - Brain Ischemia/etiology/*prevention & control
MH  - Disease-Free Survival
MH  - Female
MH  - *Heart Valve Prosthesis
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Life Tables
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
MH  - Prospective Studies
MH  - Survival Analysis
MH  - Thromboembolism/*prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2004/08/04 05:00
MHDA- 2005/02/05 09:00
CRDT- 2004/08/04 05:00
PHST- 2004/08/04 05:00 [pubmed]
PHST- 2005/02/05 09:00 [medline]
PHST- 2004/08/04 05:00 [entrez]
AID - 01.CIR.000013712295108.52 [pii]
AID - 10.1161/01.cir.0000137122.95108.52 [doi]
PST - ppublish
SO  - Circulation. 2004 Aug 3;110(5):496-500. doi: 10.1161/01.cir.0000137122.95108.52.

PMID- 16369762
OWN - NLM
STAT- MEDLINE
DCOM- 20060810
LR  - 20181113
IS  - 0172-8113 (Print)
IS  - 0172-8113 (Linking)
VI  - 27
IP  - 1
DP  - 2006 Feb
TI  - [NSAID-colonopathy].
PG  - 65-72
AB  - The pain-relief properties of NSAID/ASA preparations have been known for a long 
      time. In particular, the gastrointestinal tract shows side effects such as: 
      erosion, ulceration, and even perforation. In the upper gastrointestinal tract, 
      our group has shown that a correct histological diagnosis of NSAID/ASA induced 
      lesions can be made in a high percentage of cases on the basis of recognition of 
      ischemic necrosis. NSAID/ASA induced lesions are less commonly found in the lower 
      gastrointestinal tract. We could also demonstrate a correct histological 
      diagnosis of NSAID-colonopathy on the basis of finding ischemic necrosis. Besides 
      the known complications, another typical complication is diaphragm-like stenosis, 
      which must not be mistaken for tumor stenosis. The differential diagnosis of 
      NSAID-colonopathy includes ischemic colitis, which cannot be distinguished 
      histologically if the exact endoscopic description is not available. Sometimes 
      NSAID/ASA induced lesions are misdiagnosed as Crohn's disease due to the focal 
      character of the lesions. Since all of our analyses are retrospective, the 
      criteria developed by our group should be checked prospectively.
FAU - Vieth, M
AU  - Vieth M
AD  - Institut für Pathologie, Klinikum Bayreuth GmbH, Preuschwitzer Strasse 101, 95445 
      Bayreuth. vieth.lkpathol@uni-bayreuth.de
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - NSAR-Kolopathie.
PL  - Germany
TA  - Pathologe
JT  - Der Pathologe
JID - 8006541
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/adverse effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Colitis/chemically induced/pathology
MH  - Colon/drug effects/*pathology
MH  - Diagnosis, Differential
MH  - Diclofenac/adverse effects/therapeutic use
MH  - Humans
MH  - Ischemia
MH  - Microcirculation/drug effects
EDAT- 2005/12/22 09:00
MHDA- 2006/08/11 09:00
CRDT- 2005/12/22 09:00
PHST- 2005/12/22 09:00 [pubmed]
PHST- 2006/08/11 09:00 [medline]
PHST- 2005/12/22 09:00 [entrez]
AID - 10.1007/s00292-005-0810-1 [doi]
PST - ppublish
SO  - Pathologe. 2006 Feb;27(1):65-72. doi: 10.1007/s00292-005-0810-1.

PMID- 10698631
OWN - NLM
STAT- MEDLINE
DCOM- 20000404
LR  - 20151119
IS  - 0022-2836 (Print)
IS  - 0022-2836 (Linking)
VI  - 296
IP  - 5
DP  - 2000 Mar 10
TI  - Crystal structure of Lysbeta(1)82-Lysbeta(2)82 crosslinked hemoglobin: a possible 
      allosteric intermediate.
PG  - 1245-56
AB  - The crystal structure of human hemoglobin crosslinked between the Lysbeta82 
      residues has been determined at 2.30 A resolution. The crosslinking reaction was 
      performed under oxy conditions using bis(3, 5-dibromosalicyl) fumarate; the 
      modified hemoglobin has increased oxygen affinity and lacks cooperativity. Since 
      the crystallization occurred under deoxy conditions, the resulting structure 
      displays conformational characteristics of both the (oxy) R and the (deoxy) 
      T-states. beta82XLHbA does not fully reach its T-state conformation due to the 
      presence of the crosslink. The R-state-like characteristics of deoxy beta82XLHbA 
      include the position of the distal Hisbeta63 (E7) residue, indicating a possible 
      reason for the high oxygen affinity of this derivative. Other areas of the 
      molecule, particularly those thought to be important in the allosteric 
      transition, such as Tyrbeta145 (HC2) and the switch region involving 
      Proalpha(1)44 (CD2), Thralpha(1)41 (C6) and Hisbeta(2)97 (FG4), are in 
      intermediate positions between the R and T-states. Thus, the structure may 
      represent a stabilized intermediate in the allosteric transition of hemoglobin.
CI  - Copyright 2000 Academic Press.
FAU - Fernandez, E J
AU  - Fernandez EJ
AD  - Department of Chemistry, Loyola University Chicago, Chicago, IL 60626, USA.
FAU - Abad-Zapatero, C
AU  - Abad-Zapatero C
FAU - Olsen, K W
AU  - Olsen KW
LA  - eng
SI  - PDB/1BIJ
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Mol Biol
JT  - Journal of molecular biology
JID - 2985088R
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobins)
RN  - 0 (Oxyhemoglobins)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 42VZT0U6YR (Heme)
RN  - 9008-02-0 (deoxyhemoglobin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Allosteric Regulation
MH  - Amino Acid Sequence
MH  - Aspirin/analogs & derivatives/metabolism
MH  - Binding Sites
MH  - Cross-Linking Reagents/*metabolism
MH  - Crystallization
MH  - Crystallography, X-Ray
MH  - Dimerization
MH  - Heme/metabolism
MH  - Hemoglobins/*chemistry/*metabolism
MH  - Humans
MH  - Lysine/*chemistry/*metabolism
MH  - Models, Molecular
MH  - Molecular Sequence Data
MH  - Oxygen/metabolism
MH  - Oxyhemoglobins/chemistry/metabolism
MH  - Protein Structure, Tertiary
MH  - Thermodynamics
EDAT- 2000/03/04 00:00
MHDA- 2000/03/04 00:01
CRDT- 2000/03/04 00:00
PHST- 2000/03/04 00:00 [pubmed]
PHST- 2000/03/04 00:01 [medline]
PHST- 2000/03/04 00:00 [entrez]
AID - S0022-2836(00)93525-3 [pii]
AID - 10.1006/jmbi.2000.3525 [doi]
PST - ppublish
SO  - J Mol Biol. 2000 Mar 10;296(5):1245-56. doi: 10.1006/jmbi.2000.3525.

PMID- 10560153
OWN - NLM
STAT- MEDLINE
DCOM- 19991201
LR  - 20131121
IS  - 0201-7563 (Print)
IS  - 0201-7563 (Linking)
IP  - 5
DP  - 1999 Sep-Oct
TI  - [The prevention of thrombus formation and the improvement of the blood 
      rheological properties during operations with a microsurgical technic. I. The 
      possibilities for using acelysin--an acetylsalicylic acid derivative].
PG  - 51-6
AB  - Changes in the blood clotting system and rheology were studied in 39 patients 
      during reconstructive operations making use of microsurgical methods. Effects of 
      various doses of water soluble acelysine, an acetylsalicylic acid preparations 
      (DL-lysine acetylsalicylate and glycine) have been evaluated during surgery and 
      the immediate postoperative period. Clinical and laboratory changes in blood 
      coagulation were determined at different doses (1000, 500, and 250 mg). Even in 
      low doses (3.94 +/- 0.25 mg/kg) acelysine ensured chronometric and structural 
      hypocoagulation as early as 1 h after dosed infusion and throughout the entire 
      intervention, preventing thrombosis of microvascular anastomoses. Administration 
      of acelysine in doses higher than 250 mg is not recommended, because higher doses 
      involve the risk of hypocoagulation complications.
FAU - Vabishchevich, A V
AU  - Vabishchevich AV
FAU - Smirnova, L A
AU  - Smirnova LA
FAU - Roĭtman, E V
AU  - Roĭtman EV
FAU - Shibaev, E Iu
AU  - Shibaev EIu
FAU - Mikhaĭlova, O M
AU  - Mikhaĭlova OM
FAU - Svetlov, V A
AU  - Svetlov VA
LA  - rus
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Profilaktika tromboobrazovaniia i uluchshenie reologicheskikh svoĭstv krovi pri 
      operatsiiakh s mikrokhirurgicheskoĭ tekhnikoĭ--I. Vozmozhnosti ispol'zovaniia 
      atselizina--proizvodnogo atsetilsalitsilovoĭ kisloty.
PL  - Russia (Federation)
TA  - Anesteziol Reanimatol
JT  - Anesteziologiia i reanimatologiia
JID - 7705399
RN  - 0 (Anticoagulants)
RN  - 0 (Drug Combinations)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (acetylsalicylate, glycine, lysine drug combination)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*administration & dosage
MH  - Aspirin/administration & dosage/*analogs & derivatives
MH  - Child
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Glycine/*administration & dosage
MH  - Hemorheology/*drug effects/statistics & numerical data
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - *Microsurgery
MH  - Middle Aged
MH  - Postoperative Care
MH  - Postoperative Complications/*prevention & control
MH  - Thrombosis/*prevention & control
MH  - Time Factors
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
PST - ppublish
SO  - Anesteziol Reanimatol. 1999 Sep-Oct;(5):51-6.

PMID- 23074965
OWN - NLM
STAT- MEDLINE
DCOM- 20121101
LR  - 20131121
IS  - 0564-3783 (Print)
IS  - 0564-3783 (Linking)
VI  - 46
IP  - 4
DP  - 2012 Jul-Aug
TI  - [Cyclooxigenase-1 gene polymorphism and aspirin resistance].
PG  - 66-72
AB  - The literature data concerning structure of cyclo-oxigenase-1--the key enzyme in 
      prostaglandin biosynthesis and the main target of anti-platelet therapy with the 
      use of acetylsalicilic acid are presented in the review. The data on 
      cyclooxigenase-1 gene polymorphism, distribution of the revealed variants in 
      various populations and their possible correlation with biochemical and 
      functional aspirin resistance are presented.
FAU - Bondar', T N
AU  - Bondar' TN
FAU - Kravchenko, N A
AU  - Kravchenko NA
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Ukraine
TA  - Tsitol Genet
JT  - TSitologiia i genetika
JID - 0101671
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prostaglandins)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alleles
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cyclooxygenase 1/genetics/*metabolism
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Drug Resistance
MH  - Gene Frequency
MH  - Humans
MH  - Inflammation/*drug therapy/enzymology/genetics
MH  - Isoenzymes/genetics/metabolism
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - *Polymorphism, Genetic
MH  - Prostaglandins/biosynthesis
EDAT- 2012/10/19 06:00
MHDA- 2012/11/02 06:00
CRDT- 2012/10/19 06:00
PHST- 2012/10/19 06:00 [entrez]
PHST- 2012/10/19 06:00 [pubmed]
PHST- 2012/11/02 06:00 [medline]
PST - ppublish
SO  - Tsitol Genet. 2012 Jul-Aug;46(4):66-72.

PMID- 31046778
OWN - NLM
STAT- MEDLINE
DCOM- 20190604
LR  - 20200225
IS  - 1742-4755 (Electronic)
IS  - 1742-4755 (Linking)
VI  - 16
IP  - 1
DP  - 2019 May 2
TI  - Views and preferences of medical professionals and pregnant women about a novel 
      primary prevention intervention for hypertensive disorders of pregnancy: a 
      qualitative study.
PG  - 46
LID - 10.1186/s12978-019-0707-8 [doi]
LID - 46
AB  - BACKGROUND: Calcium and low-dose aspirin are two potential approaches for primary 
      prevention of hypertensive disorders of pregnancy (HDP). This study aimed to 
      explore the acceptability, views and preferences of pregnant women and primary 
      healthcare providers for a fixed-dose combined preparation of aspirin and calcium 
      (a polypill) as primary prevention of HDP in an unselected pregnant population. 
      METHODS: In this qualitative study eight in-depth semi-structured interviews were 
      conducted with Dutch primary care midwives and general practitioners. Seven focus 
      group discussions were organised with women with low-risk pregnancies. Topics 
      discussed were: perceptions of preeclampsia; information provision about 
      preeclampsia and a polypill; views on the polypill concept; preferences and needs 
      regarding implementation of a polypill. Thematic analysis of the data transcripts 
      was carried out to identify emerging themes. RESULTS: Two major themes shaped 
      medical professionals' and women's views on the polypill concept: 'Informed 
      Choice' and 'Medicalisation'. Both could be divided into subthemes related to 
      information provision, personal choice and discussions with regard to the balance 
      between 'unnecessary medicalisation' and 'scientific progress'. CONCLUSIONS: In 
      general, women and healthcare practitioners expressed a positive attitude towards 
      a polypill intervention as primary prevention strategy with aspirin and calcium, 
      providing some conditions are met. The most important conditions for 
      implementation of such a strategy were safety, effectiveness and the possibility 
      to make a well-informed autonomous decision.
FAU - Vestering, A
AU  - Vestering A
AUID- ORCID: 0000-0003-3518-7576
AD  - Julius Global Health, Julius Center for Health Sciences and Primary Care, UMC 
      Utrecht, Utrecht University, Utrecht, the Netherlands. avesteri@umcutrecht.nl.
FAU - Bekker, M N
AU  - Bekker MN
AD  - Department of Obstetrics and Gynaecology, Wilhelmina Children's Hospital, 
      University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - Grobbee, D E
AU  - Grobbee DE
AD  - Julius Global Health, Julius Center for Health Sciences and Primary Care, UMC 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - van der Graaf, R
AU  - van der Graaf R
AD  - Department of Medical Humanities, Julius Center for Health Sciences and Primary 
      Care, UMC Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - Franx, A
AU  - Franx A
AD  - Department of Obstetrics and Gynaecology, Wilhelmina Children's Hospital, 
      University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - Crombag, N M T
AU  - Crombag NMT
AD  - Department of Obstetrics and Gynaecology, Wilhelmina Children's Hospital, 
      University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
AD  - Department of development and regeneration, KU Leuven University, Leuven, 
      Belgium.
FAU - Browne, J L
AU  - Browne JL
AD  - Julius Global Health, Julius Center for Health Sciences and Primary Care, UMC 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20190502
PL  - England
TA  - Reprod Health
JT  - Reproductive health
JID - 101224380
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - *Attitude of Health Personnel
MH  - Calcium/therapeutic use
MH  - Decision Making
MH  - Female
MH  - General Practitioners/psychology
MH  - Humans
MH  - Hypertension/*prevention & control
MH  - Hypertension, Pregnancy-Induced/*prevention & control
MH  - Pregnancy
MH  - Pregnant Women/*psychology
MH  - Qualitative Research
PMC - PMC6498498
OTO - NOTNLM
OT  - Aspirin
OT  - Calcium
OT  - Hypertensive disorders of pregnancy
OT  - Patient perspective
OT  - Primary prevention
OT  - Qualitative research
OT  - Women-centred care
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This study was classified by the 
      Medical Research Ethics Committee of the UMC Utrecht as not requiring ethical 
      approval in accordance to the Dutch Act on Medical Research Involving Human 
      Subjects (WMO) (Ref. no 17–312/C). CONSENT FOR PUBLICATION: Not applicable. 
      COMPETING INTERESTS: Joyce Browne, Mireille Bekker, Diederick Grobbee, Rieke van 
      der Graaf and Arie Franx have been involved in the development of the polypill 
      and/or currently preparing for a study to determine the feasibility to implement 
      this in antenatal care in the Netherlands. Neeltje Crombag and Asra Vestering 
      declare no conflict of interest. PUBLISHER’S NOTE: Springer Nature remains 
      neutral with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2019/05/03 06:00
MHDA- 2019/06/05 06:00
CRDT- 2019/05/04 06:00
PHST- 2018/11/09 00:00 [received]
PHST- 2019/04/08 00:00 [accepted]
PHST- 2019/05/04 06:00 [entrez]
PHST- 2019/05/03 06:00 [pubmed]
PHST- 2019/06/05 06:00 [medline]
AID - 10.1186/s12978-019-0707-8 [pii]
AID - 707 [pii]
AID - 10.1186/s12978-019-0707-8 [doi]
PST - epublish
SO  - Reprod Health. 2019 May 2;16(1):46. doi: 10.1186/s12978-019-0707-8.

PMID- 36370881
OWN - NLM
STAT- MEDLINE
DCOM- 20230207
LR  - 20230402
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 151
IP  - 2
DP  - 2023 Feb
TI  - The Joint Task Force on Practice Parameters GRADE guidelines for the medical 
      management of chronic rhinosinusitis with nasal polyposis.
PG  - 386-398
LID - S0091-6749(22)01484-1 [pii]
LID - 10.1016/j.jaci.2022.10.026 [doi]
AB  - These evidence-based guidelines support patients, clinicians, and other 
      stakeholders in decisions about the use of intranasal corticosteroids (INCS), 
      biologics, and aspirin therapy after desensitization (ATAD) for the management of 
      chronic rhinosinusitis with nasal polyposis (CRSwNP). It is important to note 
      that the current evidence on surgery for CRSwNP was not assessed for this 
      guideline nor were management options other than INCS, biologics, and ATAD. The 
      Allergy-Immunology Joint Task Force on Practice Parameters formed a 
      multidisciplinary guideline panel balanced to include the views of multiple 
      stakeholders and to minimize potential biases. Systematic reviews for each 
      management option informed the guideline. The guideline panel used the Grading of 
      Recommendations Assessment, Development and Evaluation approach to inform and 
      develop recommendations. The guideline panel reached consensus on the following 
      statements: (1) In people with CRSwNP, the guideline panel suggests INCS rather 
      than no INCS (conditional recommendation, low certainty of evidence). (2) In 
      people with CRSwNP, the guideline panel suggests biologics rather than no 
      biologics (conditional recommendation, moderate certainty of evidence). (3) In 
      people with aspirin (nonsteroidal anti-inflammatory drug)-exacerbated respiratory 
      disease, the guideline panel suggests ATAD rather than no ATAD (conditional 
      recommendation, moderate certainty of evidence). The conditions for each 
      recommendation are discussed in the guideline.
CI  - Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Rank, Matthew A
AU  - Rank MA
AD  - Mayo Clinic in Arizona, Scottsdale, Ariz; Phoenix Children's Hospital, Scottsdale 
      and Phoenix, Ariz.
FAU - Chu, Derek K
AU  - Chu DK
AD  - McMaster University, Hamilton, Ontario, Canada.
FAU - Bognanni, Antonio
AU  - Bognanni A
AD  - McMaster University, Hamilton, Ontario, Canada.
FAU - Oykhman, Paul
AU  - Oykhman P
AD  - McMaster University, Hamilton, Ontario, Canada.
FAU - Bernstein, Jonathan A
AU  - Bernstein JA
AD  - University of Cincinnati, Cincinnati and Columbus, Ohio.
FAU - Ellis, Anne K
AU  - Ellis AK
AD  - Division of Allergy and Immunology, Department of Medicine, Queen's University, 
      Kingston, Ontario, Canada.
FAU - Golden, David B K
AU  - Golden DBK
AD  - Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address: 
      dbkgolden@gmail.com.
FAU - Greenhawt, Matthew
AU  - Greenhawt M
AD  - Children's Hospital Colorado and University of Colorado School of Medicine, 
      Aurora, Colo; University of Colorado School of Medicine, Aurora, Colo.
FAU - Horner, Caroline C
AU  - Horner CC
AD  - Division of Allergy and Pulmonary Medicine, Department of Pediatrics, Washington 
      University School of Medicine, St Louis, Mo.
FAU - Ledford, Dennis K
AU  - Ledford DK
AD  - Morsani College of Medicine, University of South Florida and James A. Haley 
      Veterans' Affairs Hospital, Tampa, Fla; James A. Haley Veterans' Affairs 
      Hospital, Tampa, Fla.
FAU - Lieberman, Jay
AU  - Lieberman J
AD  - University of Tennessee Health Science Center and LeBonheur Children's Hospital, 
      Memphis, Tenn; LeBonheur Children's Hospital, Memphis, Tenn.
FAU - Luong, Amber U
AU  - Luong AU
AD  - McGovern Medical School of the University of Texas Health Science Center at 
      Houston, Houston, Tex.
FAU - Orlandi, Richard R
AU  - Orlandi RR
AD  - University of Utah, Salt Lake City, Utah.
FAU - Samant, Shefali A
AU  - Samant SA
AD  - Kaiser Permanente Southern California, Los Angeles, Calif.
FAU - Shaker, Marcus S
AU  - Shaker MS
AD  - Dartmouth Geisel School of Medicine and Dartmouth Hitchcock Medical Center, 
      Section of Allergy, Lebanon, NH; Section of Allergy, Dartmouth Hitchcock Medical 
      Center, Lebanon, NH. Electronic address: marcus.s.shaker@hitchcock.org.
FAU - Soler, Zachary M
AU  - Soler ZM
AD  - Medical University of South Carolina, Charleston, SC.
FAU - Stevens, Whitney W
AU  - Stevens WW
AD  - Division of Allergy and Immunology, Northwestern University Feinberg School of 
      Medicine, Chicago, Ill.
FAU - Stukus, David R
AU  - Stukus DR
AD  - Nationwide Children's Hospital and Ohio State University College of Medicine, 
      Columbus, Ohio; Ohio State University College of Medicine, Columbus, Ohio.
FAU - Wang, Julie
AU  - Wang J
AD  - Icahn School of Medicine at Mount Sinai, New York, NY.
FAU - Peters, Anju T
AU  - Peters AT
AD  - Division of Allergy and Immunology, Northwestern University Feinberg School of 
      Medicine, Chicago, Ill.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
DEP - 20221109
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Biological Products)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Sinusitis/drug therapy
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Administration, Intranasal
MH  - *Nasal Polyps/drug therapy
MH  - Chronic Disease
MH  - *Biological Products/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Rhinitis/drug therapy
OTO - NOTNLM
OT  - Chronic rhinosinusitis
OT  - aspirin
OT  - biologics
OT  - clinical guideline
OT  - corticosteroids
OT  - nasal polyposis
EDAT- 2022/11/13 06:00
MHDA- 2023/02/08 06:00
CRDT- 2022/11/12 19:34
PHST- 2022/10/14 00:00 [received]
PHST- 2022/10/21 00:00 [accepted]
PHST- 2022/11/13 06:00 [pubmed]
PHST- 2023/02/08 06:00 [medline]
PHST- 2022/11/12 19:34 [entrez]
AID - S0091-6749(22)01484-1 [pii]
AID - 10.1016/j.jaci.2022.10.026 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2023 Feb;151(2):386-398. doi: 10.1016/j.jaci.2022.10.026. 
      Epub 2022 Nov 9.

PMID- 10072299
OWN - NLM
STAT- MEDLINE
DCOM- 19990407
LR  - 20161124
IS  - 0014-4886 (Print)
IS  - 0014-4886 (Linking)
VI  - 155
IP  - 2
DP  - 1999 Feb
TI  - Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on 
      motor performance in a transgenic model of amyotrophic lateral sclerosis.
PG  - 243-51
AB  - We have studied the effect of lysine acetylsalicylate (LAS; Aspegic), a soluble 
      salt of aspirin, on motor deficits in transgenic mice expressing a human 
      superoxide dismutase SOD1 mutation (Gly-93 --> Ala), an animal model of familial 
      amyotrophic lateral sclerosis (FALS). In nontreated FALS mice, motor impairments 
      appear at 12-14 weeks of age, whereas paralysis is not observed before 20 weeks 
      of age. Life expectancy is 140-170 days. Early treatment with LAS from 5 weeks of 
      age delayed the appearance of motor deficits in FALS mice as measured by 
      extension reflex, loaded grid, and rotarod tests. This beneficial effect of 
      treatment was maintained up to 18 weeks of age, until just before onset of 
      end-stage disease. When treatment was started at 13 weeks, no significant 
      beneficial effect was observed. These results demonstrate that chronic LAS 
      treatment is able to delay the appearance of reflex, coordination, and muscle 
      strength deficits in this animal model of ALS if the treatment is started early 
      enough. However, neither the onset of paralysis nor end-stage disease were 
      improved by the LAS treatment. In the absence of an effect on survival, the 
      functional improvement demonstrated here is probably the maximum that this 
      demanding model could allow. Although other properties of LAS may have 
      contributed to its beneficial effect, we suggest that the antioxidant properties 
      of aspirin are responsible for the positive effects in this model and support the 
      use of antioxidants as effective therapy for ALS.
CI  - Copyright 1999 Academic Press.
FAU - Barnéoud, P
AU  - Barnéoud P
AD  - CNS Research Department, Synthelabo Research, 10 rue des Carrières, 
      Rueil-Malmaison, 92500, France.
FAU - Curet, O
AU  - Curet O
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Exp Neurol
JT  - Experimental neurology
JID - 0370712
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Amyotrophic Lateral Sclerosis/*drug therapy/genetics/physiopathology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/pharmacokinetics/*pharmacology
MH  - Aspirin/administration & dosage/*analogs & 
      derivatives/pharmacokinetics/pharmacology
MH  - Body Weight/drug effects
MH  - Brain/metabolism
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & 
      derivatives/pharmacokinetics/pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - Motor Activity/*drug effects
MH  - Muscle, Skeletal/drug effects/physiopathology
MH  - Mutation
MH  - Postural Balance/drug effects
MH  - Reflex/drug effects
MH  - Salicylates/metabolism
MH  - Solubility
MH  - Superoxide Dismutase/deficiency/genetics
EDAT- 1999/03/11 00:00
MHDA- 1999/03/11 00:01
CRDT- 1999/03/11 00:00
PHST- 1999/03/11 00:00 [pubmed]
PHST- 1999/03/11 00:01 [medline]
PHST- 1999/03/11 00:00 [entrez]
AID - S0014-4886(98)96984-9 [pii]
AID - 10.1006/exnr.1998.6984 [doi]
PST - ppublish
SO  - Exp Neurol. 1999 Feb;155(2):243-51. doi: 10.1006/exnr.1998.6984.

PMID- 3119593
OWN - NLM
STAT- MEDLINE
DCOM- 19880121
LR  - 20210210
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 262
IP  - 35
DP  - 1987 Dec 15
TI  - Controlled tryptic digestion of prostaglandin H synthase. Characterization of 
      protein fragments and enhanced rate of proteolysis of oxidatively inactivated 
      enzyme.
PG  - 16892-9
AB  - Treatment of prostaglandin H (PGH) synthase (70 kDa) with trypsin generates 
      fragments of 33 and 38 kDa. Each of the fragments was purified by reverse-phase 
      high performance liquid chromatography (HPLC) using 
      acetonitrile/water/trifluoroacetic acid gradients. Amino acid sequence analysis 
      indicates that the 33-kDa protein contains the NH2 terminus of PGH synthase. 
      Neither the 33- nor 38-kDa fragment isolated by HPLC exhibits any PGH synthase 
      activity; however, cleavage of intact enzyme to 33- and 38-kDa fragments to the 
      extent of 90% only reduces cyclooxygenase activity by 40%. This implies that the 
      cleaved proteins or a complex formed between them retains the conformation 
      necessary for enzyme activity. Extensive attempts to resolve active fragments 
      from each other or from intact enzyme were unsuccessful; intact enzyme and 
      digestion fragments cochromatograph under all conditions employed. Treatment of 
      PGH synthase with [3H]acetylsalicylic acid followed by trypsin digestion 
      introduces [3H]acetyl moieties into the intact protein and the 38-kDa fragment 
      (0.8-0.9 acetyl group/subunit). Nearly complete conversion of PGH synthase to 33- 
      and 38-kDa fragments by exposure to high concentrations of trypsin prior to 
      [3H]acetylsalicylic acid treatment results in labeling of the 38-kDa fragment, 
      but not the 33-kDa fragment. The present findings are consistent with the 
      presence of a membrane-binding domain (33 kDa) and an active site domain (38 kDa) 
      in the 70-kDa subunit of PGH synthase. They also suggest that, following 
      cleavage, the 38-kDa fragment retains the structural features responsible for the 
      cyclooxygenase activity and selective aspirin labeling of PGH synthase. PGH 
      synthase undergoes self-catalyzed inactivation by oxidants generated during its 
      catalytic turnover. When PGH synthase, inactivated by treatment with arachidonic 
      acid or hydrogen peroxide, was treated with trypsin it was cleaved two to three 
      times faster than unoxidized enzyme. Addition of heme to oxidized PGH synthase 
      did not reconstitute cyclooxygenase activity or resistance to trypsin cleavage. 
      Spectrophotometric studies demonstrated that oxidatively inactivated enzyme did 
      not bind heme. This implies that oxidation of protein residues as well as the 
      heme prosthetic group is an important determinant of proteolytic sensitivity. 
      Oxidative modification may mark PGH synthase for proteolytic cleavage and 
      turnover.
FAU - Chen, Y N
AU  - Chen YN
AD  - Department of Chemistry, Wayne State University, Detroit, Michigan 48202.
FAU - Bienkowski, M J
AU  - Bienkowski MJ
FAU - Marnett, L J
AU  - Marnett LJ
LA  - eng
GR  - GM23642/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Amino Acids)
RN  - 0 (Peptide Fragments)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EC 3.4.21.4 (Trypsin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acids/analysis
MH  - Animals
MH  - Aspirin/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Male
MH  - Peptide Fragments/*analysis
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - Sheep
MH  - Trypsin/*metabolism
EDAT- 1987/12/15 00:00
MHDA- 1987/12/15 00:01
CRDT- 1987/12/15 00:00
PHST- 1987/12/15 00:00 [pubmed]
PHST- 1987/12/15 00:01 [medline]
PHST- 1987/12/15 00:00 [entrez]
AID - S0021-9258(18)45467-1 [pii]
PST - ppublish
SO  - J Biol Chem. 1987 Dec 15;262(35):16892-9.

PMID- 89124
OWN - NLM
STAT- MEDLINE
DCOM- 19791017
LR  - 20190823
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 19
IP  - 5-6
DP  - 1979 May-Jun
TI  - Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies.
PG  - 270-81
AB  - Pharmacokinetic studies with piroxicam, a nonsteroidal antiinflammatory agent, 
      have been carried out following the administration of single and multiple oral 
      doses. A plasma half-life of approximately 45 hours is observed, permitting the 
      use of single daily doses in therapy. Enterohepatic recirculation of drug is 
      suggested by the presence of multiple peaks in plasma concentration curves. 
      Piroxicam is highly bound to serum proteins. The absorption and disposition of 
      piroxicam are unaffected by the concomitant administration of aspirin and 
      antiacids. Salicylate plasma levels are similarly unaffected by piroxicam 
      administration.
FAU - Hobbs, D C
AU  - Hobbs DC
FAU - Twomey, T M
AU  - Twomey TM
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Antacids)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Pyridines)
RN  - 0 (Thiazines)
RN  - 7QID3E7BG7 (Dicumarol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antacids/*pharmacology
MH  - Anti-Inflammatory Agents/*metabolism
MH  - Aspirin/*pharmacology
MH  - Dicumarol/metabolism
MH  - Drug Interactions
MH  - Half-Life
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Protein Binding
MH  - Pyridines/*metabolism
MH  - Thiazines/*metabolism
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1979.tb02480.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1979 May-Jun;19(5-6):270-81. doi: 
      10.1002/j.1552-4604.1979.tb02480.x.

PMID- 718220
OWN - NLM
STAT- MEDLINE
DCOM- 19790115
LR  - 20190717
IS  - 0003-987X (Print)
IS  - 0003-987X (Linking)
VI  - 114
IP  - 11
DP  - 1978 Nov
TI  - Malignant atrophic papulosis: treatment with aspirin and dipyridamole.
PG  - 1687-9
AB  - On electron microscopy of the endothelial cells of a patient with cutaneous and 
      CNS symptoms of malignant atrophic papulosis, paramyxovirus-like particles could 
      be seen in the cytoplasm. These particles were interpreted as degenerative 
      changes that were due to ischemia. Coagulation studies showed increased 
      thrombocyte aggregation, and treatment with the platelet-suppressive drugs, 
      aspirin and dipyridamole, was instituted. This treatment resulted in a normal 
      thrombocyte aggregation after eight months and complete clinical remission, which 
      still persisted four months after cessation of therapy.
FAU - Stahl, D
AU  - Stahl D
FAU - Thomsen, K
AU  - Thomsen K
FAU - Hou-Jensen, K
AU  - Hou-Jensen K
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Arch Dermatol
JT  - Archives of dermatology
JID - 0372433
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Humans
MH  - Infarction/pathology
MH  - Male
MH  - Platelet Aggregation
MH  - Skin/blood supply/pathology
MH  - Skin Diseases/*drug therapy/physiopathology
MH  - Thrombosis/drug therapy/physiopathology
EDAT- 1978/11/01 00:00
MHDA- 1978/11/01 00:01
CRDT- 1978/11/01 00:00
PHST- 1978/11/01 00:00 [pubmed]
PHST- 1978/11/01 00:01 [medline]
PHST- 1978/11/01 00:00 [entrez]
AID - 10.1001/archderm.114.11.1687 [doi]
PST - ppublish
SO  - Arch Dermatol. 1978 Nov;114(11):1687-9. doi: 10.1001/archderm.114.11.1687.

PMID- 27884500
OWN - NLM
STAT- MEDLINE
DCOM- 20171003
LR  - 20171003
IS  - 1879-0828 (Electronic)
IS  - 0953-6205 (Linking)
VI  - 39
DP  - 2017 Apr
TI  - Different impact of aspirin on renal progression in patients with predialysis 
      advanced chronic kidney disease with or without previous stroke.
PG  - 63-68
LID - S0953-6205(16)30405-8 [pii]
LID - 10.1016/j.ejim.2016.11.009 [doi]
AB  - BACKGROUND: The benefit of reducing the risk of stroke against increasing the 
      risk of renal progression associated with antiplatelet therapy in patients with 
      advanced chronic kidney disease (CKD) is controversial. METHODS: We enrolled 1301 
      adult patients with advanced CKD treated with erythropoiesis stimulating agents 
      from January 1, 2002 to June 30, 2009 from the 2005 Longitudinal Health Insurance 
      Database in Taiwan. All of the patients were followed until the development of 
      the primary or secondary endpoints, or the end of the study (December 31, 2011). 
      The primary endpoint was the development of ischemic stroke, and the secondary 
      endpoints included hospitalization for bleeding events, cardiovascular mortality, 
      all-cause mortality, and renal failure. The adjusted cumulative probability of 
      events was calculated using multivariate Cox proportional regression analysis. 
      RESULTS: Adjusted survival curves showed that the usage of aspirin was not 
      associated with ischemic stroke, hospitalization for bleeding events, 
      cardiovascular mortality or all-cause mortality, however, it was significantly 
      associated with renal failure. In subgroup analysis, aspirin use was associated 
      with renal failure in the patients with no history of stroke (HR, 1.41; 95% CI, 
      1.14-1.73), and there was a borderline interaction between previous stroke and 
      the use of aspirin on renal failure (interaction p=0.0565). CONCLUSIONS: There 
      was no significant benefit in preventing ischemic stroke in the patients with 
      advanced CKD who received aspirin therapy. Furthermore, the use of aspirin was 
      associated with the risk of renal failure in the patients with advanced CKD 
      without previous stroke.
CI  - Copyright © 2016 European Federation of Internal Medicine. Published by Elsevier 
      B.V. All rights reserved.
FAU - Hsiao, Kuang-Chih
AU  - Hsiao KC
AD  - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division 
      of Nephrology, Department of Medicine, Show Chwan Memorial Hospital, Changhua, 
      Taiwan.
FAU - Huang, Jing-Yang
AU  - Huang JY
AD  - Department of Public Health and Institute of Public Health, Chung Shan Medical 
      University, Taichung City, Taiwan.
FAU - Lee, Chun-Te
AU  - Lee CT
AD  - Department of Family and Community Medicine, Chung Shan Medical University 
      Hospital, Taichung City, Taiwan.
FAU - Hung, Tung-Wei
AU  - Hung TW
AD  - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division 
      of Nephrology, Department of Medicine, Chung Shan Medical University Hospital, 
      Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, 
      Taiwan.
FAU - Liaw, Yung-Po
AU  - Liaw YP
AD  - Department of Public Health and Institute of Public Health, Chung Shan Medical 
      University, Taichung City, Taiwan; Department of Family and Community Medicine, 
      Chung Shan Medical University Hospital, Taichung City, Taiwan. Electronic 
      address: liawyp@csmu.edu.tw.
FAU - Chang, Horng-Rong
AU  - Chang HR
AD  - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division 
      of Nephrology, Department of Medicine, Chung Shan Medical University Hospital, 
      Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, 
      Taiwan. Electronic address: chrcsmu@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20161121
PL  - Netherlands
TA  - Eur J Intern Med
JT  - European journal of internal medicine
JID - 9003220
RN  - 0 (Hematinics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*mortality
MH  - Cause of Death
MH  - Comorbidity
MH  - Female
MH  - Hematinics/therapeutic use
MH  - Hemorrhage/*complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Proportional Hazards Models
MH  - Renal Insufficiency/*complications
MH  - Renal Insufficiency, Chronic/*complications/drug therapy
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Stroke/*complications/prevention & control
MH  - Taiwan
OTO - NOTNLM
OT  - Advanced chronic kidney disease
OT  - Aspirin
OT  - Ischemic stroke
OT  - Renal failure
EDAT- 2016/11/26 06:00
MHDA- 2017/10/04 06:00
CRDT- 2016/11/26 06:00
PHST- 2016/08/28 00:00 [received]
PHST- 2016/11/12 00:00 [revised]
PHST- 2016/11/13 00:00 [accepted]
PHST- 2016/11/26 06:00 [pubmed]
PHST- 2017/10/04 06:00 [medline]
PHST- 2016/11/26 06:00 [entrez]
AID - S0953-6205(16)30405-8 [pii]
AID - 10.1016/j.ejim.2016.11.009 [doi]
PST - ppublish
SO  - Eur J Intern Med. 2017 Apr;39:63-68. doi: 10.1016/j.ejim.2016.11.009. Epub 2016 
      Nov 21.

PMID- 20807171
OWN - NLM
STAT- MEDLINE
DCOM- 20110228
LR  - 20181201
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 21
IP  - 8
DP  - 2010
TI  - Individual variability of response and non-response to acetyl salicylic acid 
      after cardiac surgery.
PG  - 610-5
LID - 10.3109/09537104.2010.502981 [doi]
AB  - Insufficient inhibition of platelet function by acetyl salicylic acid (ASA) or 
      other platelet inhibitors is a risk factor for arterial thrombosis in 
      cardiovascular patients. We wanted to collect and analyse information on the 
      frequency and probable causes of non-response to ASA in patients prior to and 
      after cardiac surgery. One hundred and one patients (mean age 68 ± 9 years) 
      undergoing cardiac surgery (98 patients with coronary bypass grafting, 18 cases 
      had combined valve replacement, and three patients with only valve replacement) 
      were enrolled. Post-operatively all patients received metamizole for analgesia. 
      Platelet aggregation in platelet-rich plasma was induced by arachidonic acid (AA; 
      1.6 mM) or ADP (3 mM) in the absence and presence of exogenous ASA (100 µM). ASA 
      non-response was defined as a maximum AA-induced aggregation of >30%. Eighty 
      eight patients had pre-operative medication with ASA (100 mg/d), and ASA 
      non-response was found in 24%. Irrespective of whether or not ASA medication was 
      continued immediately after surgery, incidence of non-response increased to 55% 
      at the first post-operative day. During continuous post-operative ASA medication 
      (100 mg/d), 65% of patients were non-responder at fifth-7th post-operative day. 
      When estimated on the basis of exogenously added ASA, non-response was observed 
      pre-operative in 10%, at first post-operative day in 53% and at fifth-7th 
      post-operative day in 39% of the patients. Twenty six of the 52 patients who did 
      not adequately respond to exogenous ASA at the first post-operative day became 
      responders when tested at the fifth-7th post-operative day, and 13 of the 46 
      responders became non-responders. The conversions were not due to small changes 
      around the threshold of 30% aggregation but due to a highly significant decrease 
      or increase in the extend of aggregation. Neither extracorporal circulation nor 
      co-medication with clopidogrel had any significant influence on the platelet 
      response to ASA medication or exogenously added ASA. Some non-steroidal 
      analgesics, including metamizole, have been suggested to prevent inhibition of 
      platelet cylcooxygenase by ASA. However, in 10 healthy volunteers we did not 
      observe any interference of metamizole with the response to ASA. In conclusion, 
      platelet response to ASA is markedly decreased after cardiac surgery. The 
      underlying mechanisms and the clinical consequences of the post-operative 
      instability of non-response to ASA need further evaluation.
FAU - Börgermann, Jochen
AU  - Börgermann J
AD  - Department for Cardiothoracic Surgery, Jena University Hospital, 
      Friedrich-Schiller-University, Jena, Germany.
FAU - Kanashnik, Alena
AU  - Kanashnik A
FAU - Sossdorf, Maik
AU  - Sossdorf M
FAU - Gummert, Jan
AU  - Gummert J
FAU - Lösche, Wolfgang
AU  - Lösche W
LA  - eng
PT  - Journal Article
DEP - 20100901
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 6429L0L52Y (Dipyrone)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/physiology
MH  - *Cardiac Surgical Procedures
MH  - Clopidogrel
MH  - Dipyrone/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Count
MH  - Ticlopidine/analogs & derivatives/pharmacology
MH  - *Treatment Outcome
MH  - Young Adult
EDAT- 2010/09/03 06:00
MHDA- 2011/03/01 06:00
CRDT- 2010/09/03 06:00
PHST- 2010/09/03 06:00 [entrez]
PHST- 2010/09/03 06:00 [pubmed]
PHST- 2011/03/01 06:00 [medline]
AID - 10.3109/09537104.2010.502981 [doi]
PST - ppublish
SO  - Platelets. 2010;21(8):610-5. doi: 10.3109/09537104.2010.502981. Epub 2010 Sep 1.

PMID- 7446048
OWN - NLM
STAT- MEDLINE
DCOM- 19810219
LR  - 20220408
IS  - 0001-6470 (Print)
IS  - 0001-6470 (Linking)
VI  - 51
IP  - 4
DP  - 1980 Aug
TI  - Indomethacin and aspirin: effect of nonsteroidal anti-inflammatory agents on the 
      rate of fracture repair in the rat.
PG  - 595-600
AB  - A total of 210 male Charles River CD rats, 45 days old, were subjected to a 
      fracturing of the right radius and ulna by digital pressure while under ether 
      anesthesia. These animals were then assigned randomly to dose groups (1, 2 or 4 
      mg/kg/day of indomethacin and 100, 200, or 300 mg/kg/day of aspirin) and were 
      dosed for 21 days. Dose levels were chosen to provide approximately equipotent 
      levels of the test compounds with the highest dose approaching toxicity. 
      Radiographs were taken of control-rat fractures on days 8, 14, and 21. Three rats 
      at 4 mg/kg/day of indomethacin died of interstinal perforation prior to scheduled 
      sacrifice. On day 22, all remaining rats were sacrificed by exsanguination under 
      anesthesia. Histologic secretions of the radius and ulna were examined in random 
      sequence without knowledge of the treatment regimen. A histologic grade based on 
      the morphologic stage of fracture healing was given. There was a drug- and 
      dose-related retardation of fracture healing, which was statistically significant 
      at all dose levels of indomethacin and the highest level of aspirin, as compared 
      to controls. Decreased mean grades in the groups given 100 and 200 mg/kg/day of 
      aspirin, though not statistically significant, suggest a retarding effect on 
      fracture healing at these levels also. No statistically significant changes in 
      numbers of pseudoarthroses were found.
FAU - Allen, H L
AU  - Allen HL
FAU - Wase, A
AU  - Wase A
FAU - Bear, W T
AU  - Bear WT
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Orthop Scand
JT  - Acta orthopaedica Scandinavica
JID - 0370352
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cartilage/pathology
MH  - Dose-Response Relationship, Drug
MH  - Fractures, Bone/*physiopathology
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Pseudarthrosis/pathology
MH  - Radius Fractures/physiopathology
MH  - Rats
MH  - Ulna Fractures/physiopathology
MH  - Wound Healing/*drug effects
EDAT- 1980/08/01 00:00
MHDA- 1980/08/01 00:01
CRDT- 1980/08/01 00:00
PHST- 1980/08/01 00:00 [pubmed]
PHST- 1980/08/01 00:01 [medline]
PHST- 1980/08/01 00:00 [entrez]
AID - 10.3109/17453678008990848 [doi]
PST - ppublish
SO  - Acta Orthop Scand. 1980 Aug;51(4):595-600. doi: 10.3109/17453678008990848.

PMID- 16186468
OWN - NLM
STAT- MEDLINE
DCOM- 20051101
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 165
IP  - 17
DP  - 2005 Sep 26
TI  - Colchicine as first-choice therapy for recurrent pericarditis: results of the 
      CORE (COlchicine for REcurrent pericarditis) trial.
PG  - 1987-91
AB  - BACKGROUND: Colchicine seems to be a good drug for treating recurrences of 
      pericarditis after conventional treatment failure, but no clinical trial has 
      tested the effects of colchicine as first-line drug for the treatment of the 
      first recurrence of pericarditis. METHODS: A prospective, randomized, open-label 
      design was used to investigate the safety and efficacy of colchicine therapy as 
      adjunct to conventional therapy for the first episode of recurrent pericarditis. 
      Eighty-four consecutive patients with a first episode of recurrent pericarditis 
      were randomly assigned to receive conventional treatment with aspirin alone or 
      conventional treatment plus colchicine (1.0-2.0 mg the first day and then 0.5-1.0 
      mg/d for 6 months). When aspirin was contraindicated, prednisone (1.0-1.5 mg/kg 
      daily) was given for 1 month and then was gradually tapered. The primary end 
      point was the recurrence rate. Intention-to-treat analyses were performed by 
      treatment group. RESULTS: During 1682 patient-months (mean follow-up, 20 months), 
      treatment with colchicine significantly decreased the recurrence rate (actuarial 
      rates at 18 months were 24.0% vs 50.6%; P = .02; number needed to treat = 4.0; 
      95% confidence interval 2.5-7.1) and symptom persistence at 72 hours (10% vs 31%; 
      P = .03). In multivariate analysis, previous corticosteroid use was an 
      independent risk factor for further recurrences (odds ratio, 2.89; 95% confidence 
      interval, 1.10-8.26; P = .04). No serious adverse effects were observed. 
      CONCLUSION: Colchicine therapy led to a clinically important and statistically 
      significant benefit over conventional treatment, decreasing the recurrence rate 
      in patients with a first episode of recurrent pericarditis.
FAU - Imazio, Massimo
AU  - Imazio M
AD  - Cardiology Department, Maria Vittoria Hospital, Torino, Italy. 
      massimo_imazio@yahoo.it
FAU - Bobbio, Marco
AU  - Bobbio M
FAU - Cecchi, Enrico
AU  - Cecchi E
FAU - Demarie, Daniela
AU  - Demarie D
FAU - Pomari, Franco
AU  - Pomari F
FAU - Moratti, Mauro
AU  - Moratti M
FAU - Ghisio, Aldo
AU  - Ghisio A
FAU - Belli, Riccardo
AU  - Belli R
FAU - Trinchero, Rita
AU  - Trinchero R
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
RN  - VB0R961HZT (Prednisone)
SB  - IM
CIN - ACP J Club. 2006 Mar-Apr;144(2):31. PMID: 16539346
CIN - Arch Intern Med. 2006 Mar 27;166(6):696. PMID: 16567611
CIN - Evid Based Med. 2006 Apr;11(2):44. PMID: 17213074
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Colchicine/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pericarditis/*drug therapy
MH  - Prednisone/therapeutic use
MH  - Prospective Studies
MH  - Recurrence
MH  - Treatment Outcome
EDAT- 2005/09/28 09:00
MHDA- 2005/11/03 09:00
CRDT- 2005/09/28 09:00
PHST- 2005/09/28 09:00 [pubmed]
PHST- 2005/11/03 09:00 [medline]
PHST- 2005/09/28 09:00 [entrez]
AID - 165/17/1987 [pii]
AID - 10.1001/archinte.165.17.1987 [doi]
PST - ppublish
SO  - Arch Intern Med. 2005 Sep 26;165(17):1987-91. doi: 10.1001/archinte.165.17.1987.

PMID- 16311024
OWN - NLM
STAT- MEDLINE
DCOM- 20060523
LR  - 20161124
IS  - 0928-0987 (Print)
IS  - 0928-0987 (Linking)
VI  - 27
IP  - 2-3
DP  - 2006 Feb
TI  - Influence of cellulose powder structure on moisture-induced degradation of 
      acetylsalicylic acid.
PG  - 220-5
AB  - The stability of crystalline acetylsalicylic acid (ASA) powder in binary mixtures 
      with cellulose powders was investigated to reveal information about the influence 
      of the cellulose structural properties on the moisture-induced ASA degradation. 
      Different cellulose powder samples were manufactured and characterized by X-ray 
      diffraction and N2 BET gas adsorption. The degradation patterns in ASA/cellulose 
      mixtures were monitored as a function of salicylic acid increase versus time 
      under various relative humidity conditions at 50 degrees C. The crystallinity 
      index of cellulose samples varied between approximately 49 and 95%. The results 
      indicated that cellulose powder with the lowest crystallinity index exhibited 
      lower degradation rates than the samples with the higher crystallinity index. It 
      should be noted that higher ASA degradation rates were observed in the samples 
      with comparably lower moisture contents. This effect was most pronounced in the 
      1:3 (w/w), ASA/cellulose mixtures, whereas in 3:1 (w/w), ASA/cellulose mixtures 
      the effect was less obvious. The findings emphasise the importance of cellulose 
      structural organisation when governing the moisture's partition between cellulose 
      and ASA during the hydrolytic degradation.
FAU - Mihranyan, A
AU  - Mihranyan A
AD  - Department of Pharmacy, BMC, Uppsala University, Box 580, 75123 Uppsala, Sweden. 
      Albert.Mihranyan@farmaci.uu.se
FAU - Strømme, M
AU  - Strømme M
FAU - Ek, R
AU  - Ek R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051128
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Excipients)
RN  - 0 (Powders)
RN  - 059QF0KO0R (Water)
RN  - 9004-34-6 (Cellulose)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Cellulose/*chemistry
MH  - Crystallography
MH  - Drug Stability
MH  - Excipients/*chemistry
MH  - Humidity
MH  - Molecular Structure
MH  - Powders/chemistry
MH  - Time Factors
MH  - Water/*chemistry
EDAT- 2005/11/29 09:00
MHDA- 2006/05/24 09:00
CRDT- 2005/11/29 09:00
PHST- 2005/06/16 00:00 [received]
PHST- 2005/09/02 00:00 [revised]
PHST- 2005/10/07 00:00 [accepted]
PHST- 2005/11/29 09:00 [pubmed]
PHST- 2006/05/24 09:00 [medline]
PHST- 2005/11/29 09:00 [entrez]
AID - S0928-0987(05)00289-7 [pii]
AID - 10.1016/j.ejps.2005.10.002 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2006 Feb;27(2-3):220-5. doi: 10.1016/j.ejps.2005.10.002. Epub 
      2005 Nov 28.

PMID- 10464346
OWN - NLM
STAT- MEDLINE
DCOM- 19991021
LR  - 20190607
IS  - 0835-7900 (Print)
IS  - 0835-7900 (Linking)
VI  - 13
IP  - 6
DP  - 1999 Jul-Aug
TI  - Colonoscopy 'my way': preparation, anticoagulants, antibiotics and sedation.
PG  - 473-6
AB  - Colonoscopy was introduced in the 1960s. The facility with which this technique 
      is performed has been enhanced by vast improvements in instrumentation. In spite 
      of this, physician attitudes concerning colonoscopy have changed little over the 
      past several decades. The diet for precolonoscopic preparation has not been 
      altered for 30 years. Colonoscopists have a great reluctance to use a new 
      preparation instead of the 4 L electrolyte solution, perhaps because this was 
      such a significant advance in colonoscopic cleansing, its predecessor being 
      castor oil and enemas. Physicians continue to be wary of the patient who is 
      taking acetylsalicylic acid in the absence of any studies that show that this is 
      detrimental for polypectomy. The management of the patient on warfarin 
      anticoagulation remains a subject for debate. As for antibiotic prophylaxis, most 
      endoscopy units do not have a standardized approach, although there are good 
      guidelines that, if followed, should decrease the risk of infective endocarditis. 
      Sedation for the endoscopic examination is usually administered by the 
      colonoscopist, although anesthesiologists may, in some countries (and in some 
      defined areas of the United States) be the primary administrators of sedation and 
      analgesia. The present article is a personal approach to the following issues: 
      the preparation of the colon for an examination, current thoughts about 
      anticoagulation and acetylsalicylic acid, antibiotic prophylaxis for colonoscopy 
      and the technique for sedation out of the hospital.
FAU - Waye, J D
AU  - Waye JD
AD  - Mount Sinai Medical Center, GI Endoscopy Unit, Mount Sinai Hospital, New York, 
      New York, USA. jdwaye@aol.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Canada
TA  - Can J Gastroenterol
JT  - Canadian journal of gastroenterology = Journal canadien de gastroenterologie
JID - 8807867
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesia
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - *Antibiotic Prophylaxis
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Colonoscopy/*methods
MH  - *Conscious Sedation
MH  - Humans
RF  - 10
EDAT- 1999/08/28 00:00
MHDA- 1999/08/28 00:01
CRDT- 1999/08/28 00:00
PHST- 1999/08/28 00:00 [pubmed]
PHST- 1999/08/28 00:01 [medline]
PHST- 1999/08/28 00:00 [entrez]
AID - 10.1155/1999/837528 [doi]
PST - ppublish
SO  - Can J Gastroenterol. 1999 Jul-Aug;13(6):473-6. doi: 10.1155/1999/837528.

PMID- 2779803
OWN - NLM
STAT- MEDLINE
DCOM- 19891020
LR  - 20131121
IS  - 0026-4725 (Print)
IS  - 0026-4725 (Linking)
VI  - 37
IP  - 5
DP  - 1989 May
TI  - [Chronic treatment of vascular diseases with indobufen].
PG  - 241-50
AB  - The effects of chronic treatment with indobufen, an inhibitor of platelet 
      aggregation, was studied in a group of 1428 patients with vascular problems 
      treated in a period of about 6 years in our Units. Venous problems were the major 
      vascular problem in 313 patients, peripheral vascular diseases in 553 and 
      cerebrovascular problems in 562. In patients with venous problems the range of 
      the treatment period in different groups of patients varied from 2 to 42 months. 
      The range was from 1 to 48 months in the group of patients with peripheral 
      vascular diseases and from 2 to 48 in patients with cerebrovascular diseases. An 
      analogic score was used to evaluate the efficacy of indobufen, which was also 
      compared for the occurrence of side-effects with ASA (acetylsalicylic acid) and 
      dipyridamole. Results obtained in this large, chronic open study confirmed the 
      efficacy of indobufen in preventing (or reducing the occurrence) of vascular 
      problems which was significantly greater than that observed with the other two 
      drugs used for comparison. Indobufen also resulted in a lower incidence of 
      side-effects (particularly gastrointestinal disorders) and it was better 
      tolerated than both dipyridamole and ASA.
FAU - Belcaro, G
AU  - Belcaro G
FAU - Errichi, B M
AU  - Errichi BM
FAU - Laurora, G
AU  - Laurora G
FAU - Marinucci, R
AU  - Marinucci R
FAU - Cesarone, M R
AU  - Cesarone MR
FAU - De Cenzo, A
AU  - De Cenzo A
LA  - ita
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Trattamento cronico della patologia vascolare con indobufene.
PL  - Italy
TA  - Minerva Cardioangiol
JT  - Minerva cardioangiologica
JID - 0400725
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 6T9949G4LZ (indobufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cerebrovascular Disorders/drug therapy
MH  - Dipyridamole/*therapeutic use
MH  - Humans
MH  - Isoindoles
MH  - Middle Aged
MH  - Phenylbutyrates/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Vascular Diseases/*drug therapy
MH  - Veins
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
PST - ppublish
SO  - Minerva Cardioangiol. 1989 May;37(5):241-50.

PMID- 3095926
OWN - NLM
STAT- MEDLINE
DCOM- 19861204
LR  - 20141120
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 12
IP  - 3
DP  - 1986 Jul
TI  - Acetylation of antithrombin III by aspirin.
PG  - 213-5
AB  - Although the effect of aspirin in blood coagulation has been believed to be due 
      to its ability to interfere with platelet function, very few studies have 
      reported its effect on various blood coagulation proteins. Since aspirin 
      (acetylsalicylic acid) is known to acetylate numerous biologic macromolecules, 
      the effect of aspirin on antithrombin III was investigated. It was found that 
      antithrombin III is irreversibly inactivated by treatment with aspirin. The 
      inactivation follows pseudo first-order kinetics and incorporation of one 
      molecule of aspirin per molecule of the protein is necessary for complete 
      inactivation. Reaction with acetyl-[14C]-salicylic acid incorporated 1.4 mol of 
      acetyl group per mole of protein but reaction with carboxyl-[14C]-acetyl 
      salicylic acid incorporated only 0.03 mol of radioactive label per mole of the 
      protein. Furthermore, sodium salicylate does not inactivate the protein. This 
      suggests that the reaction occurs through the acetylation of antithrombin III. 
      Amino group analysis of aspirin-treated antithrombin III using 
      trinitrobenzenesulfonic acid revealed that one to two primary amino groups are 
      lost relative to the untreated antithrombin III. It is concluded that the 
      reaction of aspirin with antithrombin III results in specific acetylation of 
      lysine residues.
FAU - Villanueva, G B
AU  - Villanueva GB
FAU - Allen, N
AU  - Allen N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 9000-94-6 (Antithrombin III)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Antithrombin III/antagonists & inhibitors/*metabolism
MH  - Aspirin/*pharmacology
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Lysine/metabolism
EDAT- 1986/07/01 00:00
MHDA- 1986/07/01 00:01
CRDT- 1986/07/01 00:00
PHST- 1986/07/01 00:00 [pubmed]
PHST- 1986/07/01 00:01 [medline]
PHST- 1986/07/01 00:00 [entrez]
AID - 10.1055/s-2007-1003553 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 1986 Jul;12(3):213-5. doi: 10.1055/s-2007-1003553.

PMID- 16312265
OWN - NLM
STAT- MEDLINE
DCOM- 20060404
LR  - 20190608
IS  - 0301-0430 (Print)
IS  - 0301-0430 (Linking)
VI  - 64
IP  - 5
DP  - 2005 Nov
TI  - Underutilization of aspirin in hemodialysis patients for primary and secondary 
      prevention of cardiovascular disease.
PG  - 371-7
AB  - BACKGROUND: Patients on hemodialysis are at high risk for cardiovascular disease 
      (CVD). Aspirin is an established therapy for primary and secondary prevention of 
      CVD that may be underutilized in hemodialysis patients. To better understand the 
      use of aspirin in hemodialysis patients, we examined the experience of an urban 
      hemodialysis center. Guidelines for use as well as associated risks and benefits 
      are reviewed. METHODS: Medical records for patients receiving hemodialysis 
      treatment at our center (New York City, USA) in May 2004 were reviewed for 
      aspirin use, presence of CVD, and potential contraindications to aspirin therapy. 
      CVD was defined as a history of coronary artery disease, ischemic stroke, 
      transient ischemic attack, or peripheral vascular disease. Potential 
      contraindications to aspirin therapy included history of clinically significant 
      bleeding or increased risk of bleeding, aspirin allergy and routine treatment 
      with other anticoagulants. RESULTS: 176 patients were eligible for the study and 
      172 (98%) were included. Although 74 patients had a history of CVD, only 38 (51 
      %) of these were treated with aspirin. Among patients with a history of CVD who 
      were not treated with aspirin, 19 (53%) had no identifiable contraindications to 
      aspirin therapy for secondary prevention of CVD. Ninetyeight patients had no 
      history of CVD, and 18 (18%) of these were treated with aspirin. Of patients 
      without a history of CVD who were not treated with aspirin, 57 (71%) had no 
      identifiable contraindications to aspirin therapy for primary prevention of CVD. 
      CONCLUSIONS: Aspirin is underutilized in hemodialysis patients for the primary 
      and secondary prevention of CVD. Given the high risk of CVD in hemodialysis 
      patients, therapy with aspirin may be of significant benefit and prospective 
      studies of aspirin therapy are needed.
FAU - Dempster, D W
AU  - Dempster DW
AD  - Department of Medicine, Division of Nephrology, Lenox Hill Hospital, New York, 
      NY, USA.
FAU - Rosenstock, J L
AU  - Rosenstock JL
FAU - Schwimmer, J A
AU  - Schwimmer JA
FAU - Panagopoulos, G
AU  - Panagopoulos G
FAU - DeVita, M V
AU  - DeVita MV
FAU - Michelis, M F
AU  - Michelis MF
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Nephrol
JT  - Clinical nephrology
JID - 0364441
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Cyclooxygenase Inhibitors/*administration & dosage
MH  - Drug Utilization/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Renal Dialysis/adverse effects
EDAT- 2005/11/30 09:00
MHDA- 2006/04/06 09:00
CRDT- 2005/11/30 09:00
PHST- 2005/11/30 09:00 [pubmed]
PHST- 2006/04/06 09:00 [medline]
PHST- 2005/11/30 09:00 [entrez]
AID - 10.5414/cnp64371 [doi]
PST - ppublish
SO  - Clin Nephrol. 2005 Nov;64(5):371-7. doi: 10.5414/cnp64371.

PMID- 11049913
OWN - NLM
STAT- MEDLINE
DCOM- 20001116
LR  - 20190704
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 91
IP  - 5
DP  - 2000 Nov
TI  - Patient-controlled analgesia with tramadol versus tramadol plus lysine acetyl 
      salicylate.
PG  - 1226-9
AB  - By using a patient-controlled analgesia (PCA) delivery system, we compared the 
      clinical advantages and disadvantages of PCA with tramadol and PCA with a mixture 
      of tramadol plus lysine acetyl salicylate (a soluble aspirin). Fifty adult 
      patients who had undergone major orthopedic surgeries were enrolled into a 
      prospective, randomized, and double-blinded study. The general anesthesia was 
      performed in a standard manner. At the beginning of wound closure, an equal 
      volume dose of either tramadol 2.5 mg/kg (Group 1) or tramadol 1.25 mg/kg + 
      lysine acetyl salicylate 12.5 mg/kg mixture (Group 2) was administered slowly IV. 
      These solutions were continued postoperatively for IV PCA. Pain control, patient 
      satisfaction, vital signs, and adverse effects were assessed for 48 h. Visual 
      Analog Scale </=3 could be achieved with either group. Total tramadol consumption 
      was significantly less in Group 2 than in Group 1 (614 +/- 259 mg vs 923 +/- 354 
      mg) (P: < 0.05). Patients in Group 2 were more alert (P: < 0.05). Blood loss from 
      the surgical drain was similar, 865 +/- 275 mL (Group 1) vs 702 +/- 345 mL (Group 
      2). We conclude that aspirin can be used as an effective and safe adjuvant to 
      tramadol for PCA after orthopedic surgery. IMPLICATIONS: Injectable aspirin can 
      be used as an effective and safe adjuvant to tramadol for patient-controlled 
      analgesia (PCA) in orthopedic patients. The tramadol requirement is therefore 
      reduced. This combination supports the concept that drugs other than opioids can 
      be used for PCA.
FAU - Pang, W
AU  - Pang W
AD  - Departments of Anesthesia and Surgery, Show-Chwan Memorial Hospital, Changhua, 
      Taiwan, Republic of China. eddie@show.org.tw
FAU - Huang, S
AU  - Huang S
FAU - Tung, C C
AU  - Tung CC
FAU - Huang, M H
AU  - Huang MH
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Opioid)
RN  - 39J1LGJ30J (Tramadol)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Aged
MH  - *Analgesia, Patient-Controlled
MH  - Analgesics/*administration & dosage/adverse effects
MH  - Analgesics, Opioid/administration & dosage/adverse effects
MH  - Anesthesia, General
MH  - Aspirin/*administration & dosage/adverse effects/*analogs & derivatives
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Lysine/*administration & dosage/adverse effects/*analogs & derivatives
MH  - Male
MH  - Orthopedic Procedures
MH  - Pain Measurement
MH  - Patient Satisfaction
MH  - Prospective Studies
MH  - Tramadol/*administration & dosage/adverse effects
EDAT- 2000/10/26 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/26 11:00
PHST- 2000/10/26 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/26 11:00 [entrez]
AID - 10.1097/00000539-200011000-00033 [doi]
PST - ppublish
SO  - Anesth Analg. 2000 Nov;91(5):1226-9. doi: 10.1097/00000539-200011000-00033.

PMID- 10725992
OWN - NLM
STAT- MEDLINE
DCOM- 20000413
LR  - 20191103
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 5
IP  - 2
DP  - 1999 Apr
TI  - Evaluation of the Clot Signature Analyzer as a hemostasis test in healthy 
      volunteers exposed to low doses of aspirin.
PG  - 117-21
AB  - Several variables affect bleeding time that make it difficult to obtain 
      consistent measurements. The Clot Signature Analyzer (CSA) has been developed to 
      assess in vitro hemostasis using well-controlled flow chambers. In this study, 
      the equivalencies in the CSA parameters with the conventional bleeding time or 
      platelet aggregation methods were evaluated in subjects exposed to aspirin. The 
      CSA parameters, platelet hemostasis time (PHT) and collagen-induced thrombus 
      formation (CITF), were compared to bleeding time (Surgicutt2) and 
      collagen-induced platelet aggregation, respectively. Fifty-three healthy 
      volunteers were given two doses of aspirin (81 and 243 mg) in one day. Following 
      the baseline period, the volunteers took 81 mg of aspirin and then took 243 mg 2 
      hours later. The changes in each value from the baseline to that at either 
      aspirin dose (2 hours after dosing) were evaluated. Platelet hemostasis time and 
      CITF correlated well with bleeding time and aggregation, respectively, but PHT 
      was not significantly increased after 81 mg of aspirin, whereas bleeding time was 
      significantly increased. The variation in PHT was slightly higher than that of 
      bleeding time. At 81 mg, CITF was significantly increased but aggregation was 
      not, even though the variation was comparable. This suggests that PHT and CITF 
      can simulate the changes in bleeding time and aggregation, respectively, but the 
      sensitivity of PHT for detecting the changes in bleeding time was no better than 
      the conventional method. Also, CITF was more sensitive than aggregation in 
      detecting platelet response to collagen. In conclusion, the proposed CSA is not 
      always suitable for detecting hemostatic abnormalities.
FAU - Igawa, T
AU  - Igawa T
AD  - Otsuka America Pharmaceutical, Inc., Rockville, Maryland 20850, USA.
FAU - Kornhauser, R
AU  - Kornhauser R
FAU - Cilla, D D
AU  - Cilla DD
FAU - King, J O
AU  - King JO
FAU - Kambayashi, J
AU  - Kambayashi J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Salicylates)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Blood Coagulation Tests/instrumentation/methods
MH  - Collagen
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Hematologic Tests/*instrumentation/*methods
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests/instrumentation/methods
MH  - Reproducibility of Results
MH  - Salicylates/blood
MH  - Thrombosis/chemically induced/drug therapy
EDAT- 2000/03/22 09:00
MHDA- 2000/04/15 09:00
CRDT- 2000/03/22 09:00
PHST- 2000/03/22 09:00 [pubmed]
PHST- 2000/04/15 09:00 [medline]
PHST- 2000/03/22 09:00 [entrez]
AID - 10.1177/107602969900500208 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 1999 Apr;5(2):117-21. doi: 10.1177/107602969900500208.

PMID- 7505353
OWN - NLM
STAT- MEDLINE
DCOM- 19940124
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 22
IP  - 4
DP  - 1993 Oct
TI  - Superior activity of a thromboxane receptor antagonist as compared with aspirin 
      in rat models of arterial and venous thrombosis.
PG  - 526-33
AB  - We determined the effects of aspirin and a novel thromboxane A2/prostaglandin 
      endoperoxide (TP)-receptor antagonist, BMS-180291, on thrombosis and bleeding 
      times in skin and mesenteric arteries. In anesthetized rats, occlusive thrombosis 
      was induced in the carotid artery by topical application of ferrous chloride and 
      in the vena cava by blood flow stasis combined with either infusion of 
      thromboplastin or hypotonic saline. Aspirin (1, 10, and 50 mg/kg) did not reduce 
      arterial or venous thrombus weight significantly. BMS 180,291 (150 
      micrograms/kg/min) decreased arterial thrombus weight and hypotonic 
      saline-induced caval thrombus weight by 58 and 57%, respectively. BMS-180291 
      lacked antithrombotic activity at a lower dose (50 micrograms/kg/min) and failed 
      to inhibit thromboplastin-induced caval thrombosis. BMS-180291 (150 
      micrograms/kg/min) significantly reduced arterial thrombus weight by 40% when 
      plasma epinephrine concentration was increased to 5 ng/ml. BMS-180291 and aspirin 
      produced increases of only < or = 30% in bleeding times. These results 
      demonstrate that BMS-180291 has antithrombotic activity in experimental 
      aspirin-resistant arterial and venous thrombosis. Both aspirin and BMS-180291 
      have only modest effects on small artery hemostasis in rats.
FAU - Schumacher, W A
AU  - Schumacher WA
AD  - Department of Pharmacology, Bristol-Myers Squibb Pharmaceutical Research 
      Institute, Princeton, New Jersey 08543-4000.
FAU - Heran, C L
AU  - Heran CL
FAU - Steinbacher, T E
AU  - Steinbacher TE
FAU - Youssef, S
AU  - Youssef S
FAU - Ogletree, M L
AU  - Ogletree ML
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Oxazoles)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Propionates)
RN  - 0 (Receptors, Thromboxane)
RN  - E833KT807K (ifetroban)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Bleeding Time
MH  - *Bridged Bicyclo Compounds, Heterocyclic
MH  - Carotid Artery Thrombosis/*drug therapy
MH  - Disease Models, Animal
MH  - Epinephrine/blood
MH  - Male
MH  - Mesenteric Arteries/drug effects
MH  - Oxazoles/pharmacology/*therapeutic use
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Propionates/pharmacology/*therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Thromboxane/*antagonists & inhibitors
MH  - Thrombosis/*drug therapy
MH  - *Venae Cavae
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
AID - 10.1097/00005344-199310000-00004 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1993 Oct;22(4):526-33. doi: 
      10.1097/00005344-199310000-00004.

PMID- 7762021
OWN - NLM
STAT- MEDLINE
DCOM- 19950629
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 26
IP  - 6
DP  - 1995 Jun
TI  - Intravenous aspirin causes a paradoxical attenuation of cerebrovascular 
      thrombolysis.
PG  - 1039-46
AB  - BACKGROUND AND PURPOSE: Aspirin treatment is recognized as an advantageous 
      adjunct to thrombolytic agents in myocardial infarct patients. In this study we 
      examined the effects of aspirin on the rate of clot lysis and on the frequency 
      and extent of hemorrhagic transformations in rabbit models of embolic stroke. 
      METHODS: Rabbit models of ex vivo platelet aggregation and cutaneous template 
      bleeding times were used to show the anticoagulant effects of aspirin in our 
      experimental paradigm. We monitored tissue-type plasminogen activator 
      (TPA)-induced clot lysis in two rabbit models of embolic stroke by (1) 
      scintigraphically following the dissolution of a 99mTc-tagged clot or (2) using 
      roentgenography to follow the disappearance of an Sn-tagged clot. RESULTS: In 
      animals pretreated (18 hours) with a single administration of aspirin (1, 5, or 
      20 mg/kg IV) or 1 mg/kg per day for 3 days, the aggregation response of platelets 
      to collagen (3.3 micrograms/mL) or arachidonic acid (0.5 mmol/L) was attenuated. 
      High-dose aspirin also increased ear template bleeding time from 1.6 to 2.6 
      minutes. When aspirin (20 mg/kg) was administered 18 hours before embolism and 
      subsequent lysis with TPA (0.3 mg/kg bolus; 3 mg/kg per hour IV), the 
      pretreatment significantly antagonized the rate and extent of TPA-induced clot 
      lysis by up to 70%. This was confirmed in a second embolic stroke model. The 
      suppression of TPA-induced lysis was reversed by administration of the 
      prostacyclin analogue iloprost (10 micrograms/kg per hour) directly into the 
      cerebral circulation. CONCLUSIONS: We conclude that aspirin reduces the effects 
      of TPA in embolic stroke models. This effect may be the result of a loss of 
      endothelial prostacyclin production since the effect is reversed by iloprost.
FAU - Thomas, G R
AU  - Thomas GR
AD  - Department of Cardiovascular Research, Genentech Inc, South San Francisco, Calif 
      94080, USA.
FAU - Thibodeaux, H
AU  - Thibodeaux H
FAU - Errett, C J
AU  - Errett CJ
FAU - Bednar, M M
AU  - Bednar MM
FAU - Gross, C E
AU  - Gross CE
FAU - Bennett, W F
AU  - Bennett WF
LA  - eng
GR  - 1-R29-NS-31008-02/NS/NINDS NIH HHS/United States
GR  - 1-R55-NS-708-01A1/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Cerebral Hemorrhage/diagnostic imaging/physiopathology
MH  - Cerebrovascular Circulation/*drug effects
MH  - Disease Models, Animal
MH  - Injections, Intravenous
MH  - Intracranial Embolism and Thrombosis/blood/physiopathology/*prevention & control
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Premedication
MH  - Rabbits
MH  - Radionuclide Imaging
MH  - Thrombolytic Therapy
MH  - Tissue Plasminogen Activator/pharmacology
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
AID - 10.1161/01.str.26.6.1039 [doi]
PST - ppublish
SO  - Stroke. 1995 Jun;26(6):1039-46. doi: 10.1161/01.str.26.6.1039.

PMID- 24448296
OWN - NLM
STAT- MEDLINE
DCOM- 20140924
LR  - 20220410
IS  - 1537-4505 (Electronic)
IS  - 1531-7129 (Linking)
VI  - 35
IP  - 2
DP  - 2014 Feb
TI  - Aspirin intake correlates with halted growth of sporadic vestibular schwannoma in 
      vivo.
PG  - 353-7
LID - 10.1097/MAO.0000000000000189 [doi]
AB  - OBJECTIVE: Given the presence of a pathological immune response in sporadic 
      vestibular schwannoma (sVS), this study aims to explore the roles of aspirin in 
      minimizing sVS growth in vivo. STUDY DESIGN: Retrospective case review. SETTING: 
      Tertiary care hospital. PATIENTS: People diagnosed with sVS and followed at a 
      tertiary referral center by serial magnetic resonance imaging (MRI) for at least 
      4 months within the period of January 1980 through April 2012. MAIN OUTCOME 
      MEASURES: Patient use of aspirin and sVS growth rate measured by changes in the 
      largest tumor dimension as noted on serial MRIs RESULTS: Within a set of 689 
      cases, 347 were followed by serial MRI scans (50.3%); of the latter, 81 took 
      aspirin, of which, 33 demonstrated sVS growth, and 48 did not. Of the 266 
      nonaspirin users, 154 demonstrated sVS growth, and 112 did not. A significant 
      inverse association was found among aspirin users and sVS growth (odds ratio 
      [OR]: 0.50, 95% confidence interval [CI]: 0.29-0.85), which was not confounded by 
      age or sex. CONCLUSION: Our results suggest a potential therapeutic role of 
      aspirin in inhibiting sVS growth.
FAU - Kandathil, Cherian K
AU  - Kandathil CK
AD  - *Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston; 
      †Department of Otology and Laryngology, Harvard Medical School, Boston; ‡Program 
      in Speech and Hearing Bioscience and Technology, Harvard Medical School and 
      Massachusetts Institute of Technology, Cambridge; and §Biostatistics Center, 
      Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, 
      U.S.A.
FAU - Dilwali, Sonam
AU  - Dilwali S
FAU - Wu, Chen-Chi
AU  - Wu CC
FAU - Ibrahimov, Metin
AU  - Ibrahimov M
FAU - McKenna, Michael J
AU  - McKenna MJ
FAU - Lee, Hang
AU  - Lee H
FAU - Stankovic, Konstantina M
AU  - Stankovic KM
LA  - eng
GR  - K08DC010419/DC/NIDCD NIH HHS/United States
GR  - T32 DC00038/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Otol Neurotol
JT  - Otology & neurotology : official publication of the American Otological Society, 
      American Neurotology Society [and] European Academy of Otology and Neurotology
JID - 100961504
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neuroma, Acoustic/*pathology
MH  - Retrospective Studies
EDAT- 2014/01/23 06:00
MHDA- 2014/09/25 06:00
CRDT- 2014/01/23 06:00
PHST- 2014/01/23 06:00 [entrez]
PHST- 2014/01/23 06:00 [pubmed]
PHST- 2014/09/25 06:00 [medline]
AID - 00129492-201402000-00025 [pii]
AID - 10.1097/MAO.0000000000000189 [doi]
PST - ppublish
SO  - Otol Neurotol. 2014 Feb;35(2):353-7. doi: 10.1097/MAO.0000000000000189.

PMID- 35022893
OWN - NLM
STAT- MEDLINE
DCOM- 20220209
LR  - 20221224
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Linking)
VI  - 33
IP  - 3
DP  - 2022 Mar
TI  - Current regular aspirin use and mammographic breast density: a cross-sectional 
      analysis considering concurrent statin and metformin use.
PG  - 363-371
LID - 10.1007/s10552-021-01530-1 [doi]
AB  - PURPOSE: The nonsteroidal anti-inflammatory drug aspirin is an agent of interest 
      for breast cancer prevention. However, it is unclear if aspirin affects 
      mammographic breast density (MBD), a marker of elevated breast cancer risk, 
      particularly in the context of concurrent use of medications indicated for common 
      cardiometabolic conditions, which may also be associated with MBD. METHODS: We 
      used data from the New York Mammographic Density Study for 770 women age 
      40-60 years old with no history of breast cancer. We evaluated the association 
      between current regular aspirin use and MBD, using linear regression for 
      continuous measures of absolute and percent dense areas and absolute non-dense 
      area, adjusted for body mass index (BMI), sociodemographic and reproductive 
      factors, and use of statins and metformin. We assessed effect modification by BMI 
      and reproductive factors. RESULTS: After adjustment for co-medication, current 
      regular aspirin use was only positively associated with non-dense area (β = 18.1, 
      95% CI: 6.7, 29.5). Effect modification by BMI and parity showed current aspirin 
      use to only be associated with larger non-dense area among women with a BMI ≥ 30 
      (β = 28.2, 95% CI: 10.8, 45.7), and with lower percent density among parous women 
      (β = -3.3, 95% CI: -6.4, -0.3). CONCLUSIONS: Independent of co-medication use, 
      current regular aspirin users had greater non-dense area with stronger estimates 
      for women with higher BMI. We found limited support for an association between 
      current aspirin use and mammographically dense breast tissue among parous women.
CI  - © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Acheampong, Teofilia
AU  - Acheampong T
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, 
      722 West 168th street, New York, NY, 10032, USA.
FAU - Lee Argov, Erica J
AU  - Lee Argov EJ
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, 
      722 West 168th street, New York, NY, 10032, USA.
FAU - Terry, Mary Beth
AU  - Terry MB
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, 
      722 West 168th street, New York, NY, 10032, USA.
AD  - Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, 
      1130 St Nicholas Ave, New York, NY, 10032, USA.
FAU - Rodriguez, Carmen B
AU  - Rodriguez CB
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, 
      722 West 168th street, New York, NY, 10032, USA.
FAU - Agovino, Mariangela
AU  - Agovino M
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, 
      722 West 168th street, New York, NY, 10032, USA.
FAU - Wei, Ying
AU  - Wei Y
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, 
      722 West 168th street, New York, NY, 10032, USA.
AD  - Department of Biostatistics, Mailman School of Public Health, Columbia 
      University, 722 West 168th street, New York, NY, 10032, USA.
FAU - Athilat, Shweta
AU  - Athilat S
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, 
      722 West 168th street, New York, NY, 10032, USA.
FAU - Tehranifar, Parisa
AU  - Tehranifar P
AUID- ORCID: 0000-0002-0605-3934
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, 
      722 West 168th street, New York, NY, 10032, USA. pt140@cumc.columbia.edu.
AD  - Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, 
      1130 St Nicholas Ave, New York, NY, 10032, USA. pt140@cumc.columbia.edu.
LA  - eng
GR  - 1R01MD011506/MD/NIMHD NIH HHS/United States
GR  - R01 MD011506/MD/NIMHD NIH HHS/United States
GR  - T32-CA009529/CA/NCI NIH HHS/United States
GR  - T32 CA094061/CA/NCI NIH HHS/United States
GR  - 01-2015-069/Avon Foundation for Women/
PT  - Journal Article
DEP - 20220113
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Cancer Causes Control. 2023 Feb;34(2):189. PMID: 36565401
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Breast Density
MH  - *Breast Neoplasms/diagnostic imaging/epidemiology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors
MH  - Mammography
MH  - *Metformin
MH  - Middle Aged
MH  - Pregnancy
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Breast cancer
OT  - Breast density
OT  - Mammography
OT  - NSAID
EDAT- 2022/01/14 06:00
MHDA- 2022/02/10 06:00
CRDT- 2022/01/13 06:19
PHST- 2021/05/31 00:00 [received]
PHST- 2021/11/25 00:00 [accepted]
PHST- 2022/01/14 06:00 [pubmed]
PHST- 2022/02/10 06:00 [medline]
PHST- 2022/01/13 06:19 [entrez]
AID - 10.1007/s10552-021-01530-1 [pii]
AID - 10.1007/s10552-021-01530-1 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2022 Mar;33(3):363-371. doi: 10.1007/s10552-021-01530-1. 
      Epub 2022 Jan 13.

PMID- 150320
OWN - NLM
STAT- MEDLINE
DCOM- 19781018
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 24
IP  - 2
DP  - 1978 Aug
TI  - Effect of oral aspirin on "ecto-ATPase" activity of washed human platelets.
PG  - 240-2
AB  - Aspirin is a potent inhibitor of the platelet release reaction and the 
      accompanying second phase of platelet aggregation. The platelet release reaction 
      is an active, energy-dependent process which appears to require ATP. Eight men 
      ingested 0.32 gm of aspirin daily for 7 days. Although the second phase of 1.7 
      micron ADP-induced platelet aggregation was absent after aspirin ingestion, the 
      "ecto-ATPase" activities of washed human platelet suspensions were not 
      significantly different before and after ingestion of aspirin. This suggests that 
      the effect of aspirin on the second phase of platelet aggregation is not mediated 
      through inhibition of "ecto-ATPase".
FAU - Yue, K T
AU  - Yue KT
FAU - Davis, J W
AU  - Davis JW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - EC 3.6.1.- (Adenosine Triphosphatases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adenosine Triphosphatases/*blood
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/*enzymology
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Time Factors
EDAT- 1978/08/01 00:00
MHDA- 1978/08/01 00:01
CRDT- 1978/08/01 00:00
PHST- 1978/08/01 00:00 [pubmed]
PHST- 1978/08/01 00:01 [medline]
PHST- 1978/08/01 00:00 [entrez]
AID - 0009-9236(78)90017-6 [pii]
AID - 10.1002/cpt1978242240 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1978 Aug;24(2):240-2. doi: 10.1002/cpt1978242240.

PMID- 9783068
OWN - NLM
STAT- MEDLINE
DCOM- 19981130
LR  - 20131121
IS  - 0006-3029 (Print)
IS  - 0006-3029 (Linking)
VI  - 43
IP  - 4
DP  - 1998 Jul-Aug
TI  - [Effect of geomagnetic disturbances on the blood coagulation system in patients 
      with ischemic heart disease and prospects for correction with medication].
PG  - 617-22
AB  - The goals of this investigation were to study the influence of geomagnetic 
      activity on platelet aggregation, blood coagulation in venous blood. The 
      geophysical information was provided by the Institute of Terrestrial Magnetism, 
      Ionosphere and Radio Waves Propagation Russian Academy of Sciences. The most 
      significant changes were obtained in increased platelets aggregation, blood 
      coagulation during increased geomagnetic activity. All these effects may cause 
      the development of angina pectoris. The using of acetyl acetylsalicylic enable 
      decreased the negative effect of geomagnetic disturbances on patients with 
      ischemic heart disease.
FAU - Pikin, D A
AU  - Pikin DA
AD  - Central Railway Hospital N3, Moscow, Russia.
FAU - Gurfinkel', Iu I
AU  - Gurfinkel' IuI
FAU - Oraevskiĭ, V N
AU  - Oraevskiĭ VN
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Vliiane geomagnitnykh vozmushcheniĭ na svertyvaiushchuiu sistemu korvi u bol'nykh 
      ishemicheskoĭ bolezn'iu serdtsa i vozmozhnosti medikamentoznoĭ korrektsii.
PL  - Russia (Federation)
TA  - Biofizika
JT  - Biofizika
JID - 0372666
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Blood Coagulation Disorders/complications/*drug therapy
MH  - Female
MH  - Humans
MH  - *Magnetics
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*blood/complications
MH  - Platelet Aggregation
EDAT- 1998/10/23 00:00
MHDA- 1998/10/23 00:01
CRDT- 1998/10/23 00:00
PHST- 1998/10/23 00:00 [pubmed]
PHST- 1998/10/23 00:01 [medline]
PHST- 1998/10/23 00:00 [entrez]
PST - ppublish
SO  - Biofizika. 1998 Jul-Aug;43(4):617-22.

PMID- 2270377
OWN - NLM
STAT- MEDLINE
DCOM- 19910221
LR  - 20131121
IS  - 1013-2058 (Print)
IS  - 1013-2058 (Linking)
VI  - 79
IP  - 50
DP  - 1990 Dec 11
TI  - [Conservative therapy of peripheral arterial occlusive disease].
PG  - 1560-3
AB  - Strict control of risk factors and walking exercise are the basics to any medical 
      treatment of arterial obstructive disease of the extremities. The benefit of 
      platelet-aggregation inhibitors is well established. Acetylsalicylic acid slows 
      the progression of recurrence of thrombotic occlusion after endarterectomy or 
      percutaneous transluminal angioplasty in the femoral blood stream. Long-term oral 
      anticoagulants are indicated after bypass surgery. Prostaglandin E1 and 
      high-energy phosphates are of proven benefit in patients with pain at rest. 
      Vasoactive drugs such as Dipyridamole are still controversial.
FAU - Frauchiger, B
AU  - Frauchiger B
AD  - Medizinische Klinik, Kantonsspital Luzern.
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Konservative Therapie der peripheren arteriellen Verschlusskrankheit.
PL  - Switzerland
TA  - Schweiz Rundsch Med Prax
JT  - Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis
JID - 8403202
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - F5TD010360 (Alprostadil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alprostadil/therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - Arterial Occlusive Diseases/prevention & control/*therapy
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Exercise
MH  - Humans
MH  - Life Style
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 1990/12/11 00:00
MHDA- 1990/12/11 00:01
CRDT- 1990/12/11 00:00
PHST- 1990/12/11 00:00 [pubmed]
PHST- 1990/12/11 00:01 [medline]
PHST- 1990/12/11 00:00 [entrez]
PST - ppublish
SO  - Schweiz Rundsch Med Prax. 1990 Dec 11;79(50):1560-3.

PMID- 569473
OWN - NLM
STAT- MEDLINE
DCOM- 19790212
LR  - 20191021
IS  - 0004-9417 (Print)
IS  - 0004-9417 (Linking)
VI  - 31
IP  - 3
DP  - 1978 Jun
TI  - Prostaglandin F in the fallopian tube secretion of the ewe.
PG  - 275-82
AB  - Oviducal secretions were obtained from conscious unrestrained ewes throughout the 
      oestrous cycle via indwelling cannulae and the content of prostaglandin F (PGF) 
      was determined by radioimmunoassay. Levels of PGF of up to 230 ng/ml were found 
      in oviducal fluids obtained from ewes showing regular patterns of secretion and 
      normal cyclical ovarian function as indicated by plasma progesterone measurement. 
      Relatively large day to day fluctuations in content were evident, but there was 
      no consistent relationship between concentration and stage of the oestrous cycle. 
      Concentrations of PGF in excess of 100 ng/ml were common in preparations where 
      autopsy later revealed infection or tissue irritation, and the concentration of 
      PGF invariably exceeded 75 ng/ml when the concentration of protein in the 
      oviducal fluid was abnormally high.
FAU - Warnes, G M
AU  - Warnes GM
FAU - Amato, F
AU  - Amato F
FAU - Seamark, R F
AU  - Seamark RF
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust J Biol Sci
JT  - Australian journal of biological sciences
JID - 0370613
RN  - 0 (Prostaglandins F)
RN  - 0 (Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Body Fluids/*analysis/drug effects/metabolism
MH  - Estrus
MH  - Fallopian Tubes/*metabolism
MH  - Female
MH  - Pregnancy
MH  - Prostaglandins F/*analysis
MH  - Proteins/analysis
MH  - Sheep/*physiology
EDAT- 1978/06/01 00:00
MHDA- 1978/06/01 00:01
CRDT- 1978/06/01 00:00
PHST- 1978/06/01 00:00 [pubmed]
PHST- 1978/06/01 00:01 [medline]
PHST- 1978/06/01 00:00 [entrez]
AID - 10.1071/bi9780275 [doi]
PST - ppublish
SO  - Aust J Biol Sci. 1978 Jun;31(3):275-82. doi: 10.1071/bi9780275.

PMID- 17938390
OWN - NLM
STAT- MEDLINE
DCOM- 20071108
LR  - 20190619
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 147
IP  - 8
DP  - 2007 Oct 16
TI  - Effect of low-dose aspirin on the occurrence of venous thromboembolism: a 
      randomized trial.
PG  - 525-33
AB  - BACKGROUND: Short-term aspirin therapy can lower the risk for venous 
      thromboembolism (VTE) in high-risk patients, but whether the long-term use of 
      low-dose aspirin reduces risk in healthy adults is uncertain. OBJECTIVE: To test 
      the efficacy of long-term aspirin therapy for preventing VTE. DESIGN: Secondary 
      analysis of a 10-year randomized, double-blind, placebo-controlled trial. 
      SETTING: U.S. female health care professionals in the Women's Health Study. 
      PARTICIPANTS: 39,876 initially healthy women age 45 years or older (26,779 gave 
      blood samples that were evaluated for factor V Leiden, G20210A prothrombin, and 
      MTHFR 677C>T polymorphisms). MEASUREMENTS: Documented VTE (deep venous thrombosis 
      or pulmonary embolism) and unprovoked VTE (no recent surgery, trauma, or cancer 
      diagnosis) were prospectively evaluated, secondary end points. INTERVENTION: 
      Aspirin, 100 mg, or placebo on alternate days. RESULTS: Venous thromboembolism 
      occurred in 482 women during follow-up, an incidence higher than that of 
      myocardial infarction and nearly equal to that of stroke. The incidence of VTE 
      (per 1000 person-years) was 1.18 among women randomly assigned to active aspirin, 
      compared with 1.25 among women randomly assigned to placebo (relative hazard, 
      0.95 [95% CI, 0.79 to 1.13]; rate difference, -0.06 [CI, -0.28 to 0.16]). For 
      unprovoked VTE, the relative hazard was 0.90 (CI, 0.70 to 1.16) and the rate 
      difference was -0.06 (CI, -0.21 to 0.10). Relative hazards associated with 
      aspirin use in higher-risk subgroups were 0.83 (CI, 0.50 to 1.39) among women 
      with either factor V Leiden or the prothrombin mutation and 1.36 (CI, 0.77 to 
      2.41) among those with a history of VTE. LIMITATION: Venous thromboembolism was a 
      secondary end point in the Women's Health Study. CONCLUSION: These data suggest 
      that long-term, low-dose aspirin treatment has little effect on the prevention of 
      VTE in initially healthy women. ClinicalTrials.gov registration number: 
      NCT00000479.
FAU - Glynn, Robert J
AU  - Glynn RJ
AD  - Brigham and Women's Hospital, Harvard Medical School, and Harvard School of 
      Public Health, Boston, Massachusetts 02215, USA. rglynn@rics.bwh.harvard.edu .
FAU - Ridker, Paul M
AU  - Ridker PM
FAU - Goldhaber, Samuel Z
AU  - Goldhaber SZ
FAU - Buring, Julie E
AU  - Buring JE
LA  - eng
SI  - ClinicalTrials.gov/NCT00000479
GR  - CA47988/CA/NCI NIH HHS/United States
GR  - HL43851/HL/NHLBI NIH HHS/United States
GR  - HL7122/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- Ann Intern Med. 2007 Oct 16;147(8):I34. PMID: 17938386
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Peptic Ulcer/chemically induced
MH  - Prospective Studies
MH  - Risk Factors
MH  - Thromboembolism/epidemiology/*prevention & control
MH  - Venous Thrombosis/epidemiology/*prevention & control
EDAT- 2007/10/17 09:00
MHDA- 2007/11/09 09:00
CRDT- 2007/10/17 09:00
PHST- 2007/10/17 09:00 [pubmed]
PHST- 2007/11/09 09:00 [medline]
PHST- 2007/10/17 09:00 [entrez]
AID - 147/8/525 [pii]
AID - 10.7326/0003-4819-147-8-200710160-00004 [doi]
PST - ppublish
SO  - Ann Intern Med. 2007 Oct 16;147(8):525-33. doi: 
      10.7326/0003-4819-147-8-200710160-00004.

PMID- 29243497
OWN - NLM
STAT- MEDLINE
DCOM- 20190429
LR  - 20190429
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 34
IP  - 3
DP  - 2018 Mar
TI  - Preventing recurrent events in survivors of acute coronary syndromes in 
      Australia: consensus recommendations using the Delphi process.
PG  - 551-558
LID - 10.1080/03007995.2017.1418175 [doi]
AB  - OBJECTIVE: There remain substantial gaps in implementation of evidence-based care 
      in patients with acute coronary syndromes (ACS) in Australia, which contribute to 
      high recurrent event rates. Improved translation of evidence into effective 
      action is a key health-care priority. We engaged cardiovascular experts from 
      across Australia to develop straightforward, easily actionable recommendations on 
      key medications to use following ACS. METHODS: An eight-person steering committee 
      (SC) reviewed the published evidence and developed an initial set of statements 
      to be developed into consensus recommendations using a modified Delphi technique. 
      A panel of 21 expert cardiologists in the ACS field (including the SC) voted on 
      their level of agreement with the statements using a 6 point Likert scale. 
      Statements that did not reach consensus (≥80% agreement) were reviewed by the SC, 
      modified as appropriate based on input from the panel and circulated for 
      re-voting. RESULTS: Twenty-eight statements were developed by the SC across six 
      classes of medication: low-density lipoprotein (LDL) cholesterol lowering agents, 
      aspirin, dual antiplatelet therapy, renin-angiotensin-aldosterone system 
      inhibitors, beta blockers and "other". Twenty-six recommendations were endorsed 
      by the voting panel; two statements did not reach consensus. CONCLUSIONS: Despite 
      the extensive evidence base and detailed guidelines outlining best practice post 
      ACS, there remain considerable gaps in translating these into everyday care. We 
      used an internationally recognized technique to develop practical consensus 
      recommendations on medical treatment following ACS. These simple, up-to-date 
      recommendations aim to improve evidence-based medication use and thereby reduce 
      the risk of future cardiovascular events for Australian patients with ACS.
FAU - Hammett, Christopher J
AU  - Hammett CJ
AD  - a Department of Cardiology , Royal Brisbane and Women's Hospital , Brisbane , QLD 
      , Australia.
FAU - Amerena, John
AU  - Amerena J
AD  - b Geelong Cardiology Research Centre , Barwon Health , Deakin University , VIC , 
      Australia.
FAU - Brieger, David
AU  - Brieger D
AD  - c Cardiology Department , Concord Hospital and Sydney Medical School, The 
      University of Sydney , Sydney , NSW , Australia.
FAU - Sindone, Andrew
AU  - Sindone A
AD  - d Cardiology Department , Concord Hospital and Sydney Medical School, The 
      University of Sydney , Sydney , NSW , Australia.
FAU - Thompson, Peter L
AU  - Thompson PL
AD  - e Heart Research Institute, Sir Charles Gairdner Hospital and Harry Perkins 
      Institute of Medical Research, University of Western Australia , Perth , WA , 
      Australia.
FAU - Worthley, Matthew I
AU  - Worthley MI
AD  - f University of Adelaide, Royal Adelaide Hospital, and South Australian Health 
      and Medical Research Institute , Adelaide , SA , Australia.
FAU - Aylward, Philip E
AU  - Aylward PE
AD  - g South Australian Health and Medical Research Institute, and Flinders University 
      and Medical Centre , Adelaide , SA , Australia.
CN  - PERMIT Program Consensus Group
LA  - eng
PT  - Journal Article
DEP - 20180104
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Adrenergic beta-Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*prevention & control
MH  - Adrenergic beta-Antagonists/administration & dosage
MH  - Aspirin/administration & dosage
MH  - Australia
MH  - *Consensus
MH  - Delphi Technique
MH  - Humans
MH  - *Survivors
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - LDL cholesterol
OT  - angiotensin converting enzyme inhibitors
OT  - angiotensin receptor antagonists
OT  - antiplatelet agents
OT  - aspirin
OT  - beta adrenergic blockers
EDAT- 2017/12/16 06:00
MHDA- 2019/04/30 06:00
CRDT- 2017/12/16 06:00
PHST- 2017/12/16 06:00 [pubmed]
PHST- 2019/04/30 06:00 [medline]
PHST- 2017/12/16 06:00 [entrez]
AID - 10.1080/03007995.2017.1418175 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2018 Mar;34(3):551-558. doi: 10.1080/03007995.2017.1418175. 
      Epub 2018 Jan 4.

PMID- 2260137
OWN - NLM
STAT- MEDLINE
DCOM- 19910129
LR  - 20161122
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 21
IP  - 12 Suppl
DP  - 1990 Dec
TI  - Thromboxane biosynthesis in cardiovascular diseases.
PG  - IV130-3
AB  - Sudden fissuring of an atherosclerotic plaque has been suggested as the primary 
      trigger of transient spontaneous ischemia in both the coronary and cerebral 
      circulation. Measurements of urinary 11-dehydro-TXB2 and 2,3-dinor-TXB2, as well 
      as results of Aspirin trials, have suggested that episodic platelet activation at 
      the site of this acute vascular lesion is mediated, at least partly, by enhanced 
      thromboxane (TX) A2 biosynthesis. Thus, episodic increases in metabolite 
      excretion have been detected in unstable angina. Aspirin (75-325 mg/day) prevents 
      about one third of all fatal and nonfatal thrombotic events in this setting. That 
      a similar "dynamic" thrombotic process occurs during the early phase of acute 
      myocardial infarction is suggested by thromboxane metabolite measurements and by 
      the results of the ISIS-2 trial showing a similar impact of short-term Aspirin 
      therapy to that seen in unstable angina. Percutaneous transluminal coronary 
      angioplasty is associated with transiently enhanced TXA2 biosynthesis and 
      Aspirin-suppressable periprocedural thrombotic complications. On the other hand, 
      both non-insulin-dependent diabetes mellitus and type IIa hypercholesterolemia 
      are associated with a relatively reproducible and persisting abnormality of 
      TXA2-dependent platelet function. This association is likely to reflect a 
      systemic rather than localized stimulus to platelet activation and a continuous 
      rather than episodic alteration. Low-dose (50 mg/day) Aspirin can largely 
      suppress thromboxane metabolite excretion in both diseases. Thus, low-dose 
      Aspirin and/or selective prostaglandin H2/TXA2-receptor antagonists may be 
      important tools to test the hypothesis that TXA2-dependent platelet activation 
      represents an important transducer of the enhanced thrombotic risk associated 
      with these metabolic abnormalities.
FAU - Patrono, C
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.
FAU - Ciabattoni, G
AU  - Ciabattoni G
FAU - Davi, G
AU  - Davi G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*metabolism
MH  - Humans
MH  - Platelet Activation
MH  - Risk Factors
MH  - Thromboxane A2/*biosynthesis/physiology
MH  - Thromboxane B2/metabolism
RF  - 26
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
PST - ppublish
SO  - Stroke. 1990 Dec;21(12 Suppl):IV130-3.

PMID- 28489475
OWN - NLM
STAT- MEDLINE
DCOM- 20171002
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 18
IP  - 9
DP  - 2017 Jun
TI  - Antithrombotic strategies for preventing long-term major adverse cardiovascular 
      events in patients with non-valvular atrial fibrillation who undergo percutaneous 
      coronary intervention.
PG  - 875-883
LID - 10.1080/14656566.2017.1329822 [doi]
AB  - Balancing the risk of recurrent ischemia and bleeding among patients with 
      non-valvular atrial fibrillation who undergo percutaneous coronary intervention 
      (PCI) is challenging. Postprocedural antithrombotic therapy aims to reduce the 
      risk related to coronary artery disease, stent placement, and atrial 
      fibrillation, with acceptable risks of bleeding. Areas covered: This review 
      summarizes evidence and recommendations related to long-term antithrombotic 
      strategies in such patients. An overview of the findings from recent 
      meta-analyses and select observational studies is provided, and important 
      completed and ongoing randomized trials are described in detail. Recommendations 
      pertaining to treatment intensity and duration, including the choice of specific 
      anticoagulant and antiplatelet agents, are given. Expert opinion: Triple therapy 
      (oral anticoagulation with dual antiplatelet therapy) is associated with an 
      increased bleeding risk compared with double therapy (oral anticoagulation with a 
      single antiplatelet agent), but double therapy does not appear to be associated 
      with an increased risk of recurrent ischemia or death. Completed trials make a 
      compelling case for double therapy with clopidogrel, not aspirin, when compared 
      with full-intensity triple antithrombotic therapy. We believe that double therapy 
      with an anticoagulant and clopidogrel should generally be favored instead of 
      triple antithrombotic therapy.
FAU - Pareek, Manan
AU  - Pareek M
AD  - a Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School , 
      Boston , MA , USA.
AD  - b Cardiology Section, Department of Internal Medicine , Holbaek Hospital , 
      Holbaek , Denmark.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - a Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School , 
      Boston , MA , USA.
FAU - Ten Berg, Jürrien M
AU  - Ten Berg JM
AD  - c Department of Cardiology , St. Antonius Hospital , Nieuwegein , The 
      Netherlands.
FAU - Kristensen, Steen D
AU  - Kristensen SD
AD  - d Department of Cardiology , Aarhus University Hospital , Aarhus , Denmark.
AD  - e Faculty of Health , Institute of Clinical Medicine, Aarhus University , Aarhus 
      , Denmark.
FAU - Grove, Erik L
AU  - Grove EL
AUID- ORCID: 0000-0002-1466-0865
AD  - d Department of Cardiology , Aarhus University Hospital , Aarhus , Denmark.
AD  - e Faculty of Health , Institute of Clinical Medicine, Aarhus University , Aarhus 
      , Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170522
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Atrial Fibrillation/*drug therapy/therapy
MH  - Clopidogrel
MH  - Coronary Artery Disease/drug therapy
MH  - Drug Therapy, Combination
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Myocardial Ischemia/*chemically induced
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Recurrence
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & 
      derivatives/therapeutic use
OTO - NOTNLM
OT  - Anticoagulant
OT  - atrial fibrillation
OT  - bleeding
OT  - percutaneous coronary intervention
OT  - platelet inhibitors
OT  - thrombosis
EDAT- 2017/05/11 06:00
MHDA- 2017/10/03 06:00
CRDT- 2017/05/11 06:00
PHST- 2017/05/11 06:00 [pubmed]
PHST- 2017/10/03 06:00 [medline]
PHST- 2017/05/11 06:00 [entrez]
AID - 10.1080/14656566.2017.1329822 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2017 Jun;18(9):875-883. doi: 
      10.1080/14656566.2017.1329822. Epub 2017 May 22.

PMID- 33587229
OWN - NLM
STAT- MEDLINE
DCOM- 20220505
LR  - 20220531
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 36
IP  - 2
DP  - 2022 Apr
TI  - Aspirin Versus Dual Antiplatelet Therapy in Patients Undergoing Trans-Catheter 
      Aortic Valve Implantation, Updated Meta-Analysis.
PG  - 279-283
LID - 10.1007/s10557-021-07146-6 [doi]
AB  - BACKGROUND: The Antiplatelet Therapy for Patients Undergoing Transcatheter 
      Aortic-Valve Implantation (POPular TAVI) trial reported comparable composite 
      endpoints of ischemic events using aspirin compared to dual antiplatelet therapy 
      (DAPT). However, this trial was not powered to detect individual differences in 
      ischemic events. We sought to conduct a meta-analysis to compare aspirin to DAPT 
      on ischemic and bleeding events following TAVI. METHODS: The MEDLINE database was 
      searched from inception until September 2020 and only randomized clinical trials 
      of patients receiving antiplatelet therapy following TAVI were included. The 
      treatment effect was reported as rate ratios (RRs) with 95% confidence intervals. 
      RESULTS: Four randomized clinical trials of 1086 TAVI patients were included. 
      There was a 51% reduction in major or life-threatening bleeding with aspirin 
      compared with DAPT [RR 0.49, (95%CI 0.31 to 0.78)]. Aspirin was not associated 
      with an increased risk of death [RR 1.01, (95%CI 0.62 to 1.65)], cardiovascular 
      death [RR 1.15, (95%CI 0.56 to 2.36)], ischemic stroke [RR 0.93, (95%CI 0.51 to 
      1.70)], or MI [RR 0.53, (95%CI 0.18 to 1.57)]. CONCLUSIONS: This meta-analysis 
      supports the use of aspirin as the optimal antiplatelet strategy following TAVI 
      procedures in reducing bleeding without an increase in ischemic events compared 
      with dual antiplatelet therapy.
CI  - © 2021. Springer Science+Business Media, LLC, part of Springer Nature.
FAU - Alkhalil, Mohammad
AU  - Alkhalil M
AUID- ORCID: 0000-0002-3088-8878
AD  - Department of Cardiothoracic Services, Freeman Hospital, Newcastle-upon-Tyne, NE7 
      7DN, UK. mohammad.alkhalil@nhs.net.
FAU - Edwards, Richard
AU  - Edwards R
AD  - Department of Cardiothoracic Services, Freeman Hospital, Newcastle-upon-Tyne, NE7 
      7DN, UK.
FAU - Puri, Rishi
AU  - Puri R
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
FAU - Kalra, Ankur
AU  - Kalra A
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
FAU - Zaman, Azfar
AU  - Zaman A
AD  - Department of Cardiothoracic Services, Freeman Hospital, Newcastle-upon-Tyne, NE7 
      7DN, UK.
AD  - Newcastle University, Newcastle-upon-Tyne, UK.
FAU - Das, Rajiv
AU  - Das R
AD  - Department of Cardiothoracic Services, Freeman Hospital, Newcastle-upon-Tyne, NE7 
      7DN, UK.
AD  - Northumbria University, Newcastle upon Tyne, UK.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210215
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aortic Valve/surgery
MH  - *Aspirin/adverse effects
MH  - *Dual Anti-Platelet Therapy/adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - *Transcatheter Aortic Valve Replacement
OTO - NOTNLM
OT  - Aspirin
OT  - Bleeding
OT  - DAPT
OT  - TAVI
EDAT- 2021/02/16 06:00
MHDA- 2022/05/06 06:00
CRDT- 2021/02/15 12:13
PHST- 2021/01/14 00:00 [accepted]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2021/02/15 12:13 [entrez]
AID - 10.1007/s10557-021-07146-6 [pii]
AID - 10.1007/s10557-021-07146-6 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2022 Apr;36(2):279-283. doi: 10.1007/s10557-021-07146-6. 
      Epub 2021 Feb 15.

PMID- 17498004
OWN - NLM
STAT- MEDLINE
DCOM- 20071113
LR  - 20131121
IS  - 1744-9979 (Print)
IS  - 1744-9979 (Linking)
VI  - 11
IP  - 3
DP  - 2007 Jun
TI  - Iron status and the use of non-steroidal anti-inflammatory drugs in hemodialysis 
      patients.
PG  - 215-9
AB  - We examined whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) can 
      affect the anemia and iron status of hemodialysis patients. We recruited patients 
      from six dialysis centers who had undergone maintenance hemodialysis for at least 
      four months. We examined the use of NSAIDs during the past three months based on 
      their medical records and assigned the patients to three groups (group A, 
      non-NSAID group; group B, aspirin group; and group C, non-aspirin NSAID group). 
      Of the 446 patients, 95 (21.3%) were treated with aspirin and 103 (23.1%) were 
      treated with non-aspirin NSAIDs. The serum iron level and transferrin saturation 
      (TSAT) were significantly lower in group C patients than those in group A. 
      However, the ratio of the patients who were administrated iron preparations 
      during the past three months was significantly higher than that in the other two 
      groups. The incidences of positive fecal occult blood tests did not differ 
      substantially between the three groups. The ratios of the patients who were 
      administrated recombinant human erythropoietin were the same between three 
      groups. Using a multiple regression analysis, the administration of non-aspirin 
      NSAIDs was identified as an independent factor for the decreased serum iron and 
      the decreased TSAT levels. A multiple logistic regression analysis revealed that 
      the patients using non-aspirin NSAIDs had an increased the requirement for iron 
      preparation therapy (OR 2.03, 95% CI, 1.28-3.22). The use of non-aspirin NSAIDs 
      may therefore increase the risk of the iron deficiency in patients undergoing 
      hemodialysis.
FAU - Wang, Xiaoxia
AU  - Wang X
AD  - Department of Medicine, Shiga University of Medical Science, Shiga, Japan.
FAU - Uzu, Takashi
AU  - Uzu T
FAU - Isshiki, Keiji
AU  - Isshiki K
FAU - Kanasaki, Masami
AU  - Kanasaki M
FAU - Hirata, Kunio
AU  - Hirata K
FAU - Soumura, Mariko
AU  - Soumura M
FAU - Nakazawa, Jun
AU  - Nakazawa J
FAU - Kashiwagi, Atsunori
AU  - Kashiwagi A
FAU - Takaya, Kiho
AU  - Takaya K
FAU - Isono, Motohide
AU  - Isono M
FAU - Nishimura, Masataka
AU  - Nishimura M
FAU - Shikano, Tsutomu
AU  - Shikano T
FAU - Nishio, Toshiji
AU  - Nishio T
FAU - Tomita, Kobin
AU  - Tomita K
FAU - Arimura, Tetsuro
AU  - Arimura T
CN  - Lake Biwa Clinical Dialysis Meeting
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Ther Apher Dial
JT  - Therapeutic apheresis and dialysis : official peer-reviewed journal of the 
      International Society for Apheresis, the Japanese Society for Apheresis, the 
      Japanese Society for Dialysis Therapy
JID - 101181252
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Receptors, Transferrin)
RN  - 0 (Transferrin)
RN  - E1UOL152H7 (Iron)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anemia, Iron-Deficiency/blood
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Diabetes Mellitus/epidemiology
MH  - Female
MH  - Humans
MH  - Iron/*blood
MH  - Japan/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Receptors, Transferrin/blood
MH  - *Renal Dialysis
MH  - Transferrin/analysis
EDAT- 2007/05/15 09:00
MHDA- 2007/11/14 09:00
CRDT- 2007/05/15 09:00
PHST- 2007/05/15 09:00 [pubmed]
PHST- 2007/11/14 09:00 [medline]
PHST- 2007/05/15 09:00 [entrez]
AID - TAP476 [pii]
AID - 10.1111/j.1744-9987.2007.00476.x [doi]
PST - ppublish
SO  - Ther Apher Dial. 2007 Jun;11(3):215-9. doi: 10.1111/j.1744-9987.2007.00476.x.

PMID- 35908971
OWN - NLM
STAT- MEDLINE
DCOM- 20230217
LR  - 20230317
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 62
IP  - 4
DP  - 2023 Feb 15
TI  - Rabeprazole Coadministration Controls Ulcer Recurrence in Patients on Low-dose 
      Aspirin Therapy: A Multicenter Prospective Study.
PG  - 495-502
LID - 10.2169/internalmedicine.9646-22 [doi]
AB  - Objective To evaluate the efficacy and safety of rabeprazole coadministration 
      with low-dose aspirin (LDA). Methods From 2015 to 2018, we conducted a 
      large-scale, multicenter, prospective observational study to assess the safety 
      and efficacy of treatment with rabeprazole (5 or 10 mg/day) in combination with 
      LDA. Results The incidence of adverse reactions was 0.73% (11/1,513 patients), 
      with no serious adverse reactions. We found no trend toward increases in the 
      incidence of adverse reactions with increases in treatment duration. The 
      cumulative recurrence rate of ulcers by Week 52 (Kaplan-Meier estimates) was 
      3.50% (range, 1.56-7.75%). No gastrointestinal bleeding was reported. Conclusion 
      Rabeprazole in combination with LDA appears as safe and effective in real-world 
      situations as in clinical trials.
FAU - Kinoshita, Yoshikazu
AU  - Kinoshita Y
AD  - Hyogo Prefectural Harima-Himeji General Medical Center, Japan.
FAU - Kato, Mototsugu
AU  - Kato M
AD  - National Hospital Organization, Hakodate National Hospital, Japan.
FAU - Sugizaki, Katsuya
AU  - Sugizaki K
AD  - Medical HQs, Eisai, Japan.
FAU - Ikeuchi, Satoshi
AU  - Ikeuchi S
AD  - Medical HQs, Eisai, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20220729
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 32828355LL (Rabeprazole)
RN  - 0 (Anti-Ulcer Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Rabeprazole/therapeutic use
MH  - Prospective Studies
MH  - *Peptic Ulcer/drug therapy
MH  - Ulcer/drug therapy
MH  - *Anti-Ulcer Agents/adverse effects
MH  - Aspirin/adverse effects
PMC - PMC10017235
OTO - NOTNLM
OT  - low-dose aspirin
OT  - prevention of peptic ulcer
OT  - prospective study
OT  - rabeprazole
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2022/08/01 06:00
MHDA- 2023/02/18 06:00
CRDT- 2022/07/31 21:44
PHST- 2022/08/01 06:00 [pubmed]
PHST- 2023/02/18 06:00 [medline]
PHST- 2022/07/31 21:44 [entrez]
AID - 10.2169/internalmedicine.9646-22 [doi]
PST - ppublish
SO  - Intern Med. 2023 Feb 15;62(4):495-502. doi: 10.2169/internalmedicine.9646-22. 
      Epub 2022 Jul 29.

PMID- 23046071
OWN - NLM
STAT- MEDLINE
DCOM- 20130719
LR  - 20181202
IS  - 1945-0257 (Electronic)
IS  - 1945-0257 (Linking)
VI  - 16
IP  - 11
DP  - 2012 Nov
TI  - The influence of omeprazole on platelet inhibition of clopidogrel in various 
      CYP2C19 mutant alleles.
PG  - 1293-7
LID - 10.1089/gtmb.2012.0119 [doi]
AB  - Currently, concerns of clopidogrel and proton pump inhibitors (especially 
      omeprazole) interaction are raised, because they are both metabolized by CYP2C19. 
      What is more, omeprazole can also inhibit the activity of CYP2C19. The study was 
      to compare the influence of omeprazole on platelet inhibition of clopidogrel in 
      various CYP2C19 mutant alleles. One hundred forty-two consecutive patients 
      undergoing elective coronary stenting received aspirin and clopidogrel, and were 
      randomized to omeprazole or the placebo. Enrolled patients were analyzed for 
      adenosine diphosphate-induced platelet aggregation (ADP-Ag), and CYP2C19*2 and 
      CYP2C19*3 were identified by polymerase chain reaction-restriction fragment 
      length polymorphism. Of the patients included, 47 (33.1%) belonged to homozygous 
      extensive metabolizers (homEMs) (CYP2C19*1/*1), 70 (49.3%) belonged to 
      heterozygous extensive metabolizers (hetEMs) (*1/*2 or *1/*3), and 25 (17.6%) 
      belonged to poor metabolizers (PMs) (*2/*3 or *2/*2). ADP-Ag had a significant 
      difference among the three genotypic groups (p<0.01). Moreover, the present study 
      revealed that the degree of the interaction between clopidogrel and omeprazole 
      was not homogeneous within the various genotypes of CYP2C19. The difference of 
      ADP-Ag between the patients with and without omeprazole was significantly largest 
      in homEMs (45.7%±14.2% vs. 35.5%±16.0%, p<0.05). However, any significant 
      difference of ADP-Ag between the patients with and without omeprazole was not 
      observed in other two genotypic groups (hetEMs and PMs, p>0.05). In conclusion, 
      concomitant therapy with omeprazole appears to reduce the antiplatelet effect of 
      clopidogrel most significantly in homEMs of CYP2C19.
FAU - Liu, Qian
AU  - Liu Q
AD  - Department of Pharmacy, General Hospital of Shenyang Military Area Command, 
      Shenyang, China.
FAU - Dang, Da-Sheng
AU  - Dang DS
FAU - Chen, Yu-Feng
AU  - Chen YF
FAU - Yan, Ming
AU  - Yan M
FAU - Shi, Guo-Bing
AU  - Shi GB
FAU - Zhao, Qing-Chun
AU  - Zhao QC
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20121009
PL  - United States
TA  - Genet Test Mol Biomarkers
JT  - Genetic testing and molecular biomarkers
JID - 101494210
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - KG60484QX9 (Omeprazole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alleles
MH  - Aryl Hydrocarbon Hydroxylases/*genetics
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Clopidogrel
MH  - Cytochrome P-450 CYP2C19
MH  - Drug Interactions
MH  - Humans
MH  - Male
MH  - Omeprazole/*pharmacology/therapeutic use
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Young Adult
EDAT- 2012/10/11 06:00
MHDA- 2013/07/20 06:00
CRDT- 2012/10/11 06:00
PHST- 2012/10/11 06:00 [entrez]
PHST- 2012/10/11 06:00 [pubmed]
PHST- 2013/07/20 06:00 [medline]
AID - 10.1089/gtmb.2012.0119 [doi]
PST - ppublish
SO  - Genet Test Mol Biomarkers. 2012 Nov;16(11):1293-7. doi: 10.1089/gtmb.2012.0119. 
      Epub 2012 Oct 9.

PMID- 18418272
OWN - NLM
STAT- MEDLINE
DCOM- 20081113
LR  - 20181201
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 51
IP  - 5
DP  - 2008 May
TI  - Antiplatelet therapy in early management of non-ST-segment elevation acute 
      coronary syndrome: the 2002 and 2007 guidelines from North America and Europe.
PG  - 425-33
LID - 10.1097/FJC.0b013e31816a35a2 [doi]
AB  - The American College of Cardiology, American Heart Association, and the European 
      Society of Cardiology published updated guidelines in 2007 for patients with 
      non-ST elevation acute coronary syndrome. In this article, we review the 
      recommendations for antiplatelet therapy and supporting data, highlight new 
      changes, and describe differences between the European and North American 
      guidelines. The new guidelines provide more details regarding the selection of an 
      early conservative versus an early invasive approach based on the patient's 
      profile and balance between ischemic and bleeding risks. Important new 
      recommendations include wider endorsement for low-dose aspirin maintenance 
      therapy, longer duration of clopidogrel following percutaneous coronary 
      intervention, additional guidance regarding surgery in selected patients on 
      clopidogrel, identification of patients most likely to benefit from glycoprotein 
      IIb/IIIa inhibitors (with appropriate dose modification in patients with renal 
      failure), and the option to use early clopidogrel with bivalirudin in patients 
      managed invasively who are at increased risk of bleeding. The new guidelines also 
      discourage the concomitant use of nonsteroidal anti-inflammatory drugs and 
      delineate indications for adding warfarin to antiplatelet therapy. Because 
      antiplatelet therapy is the cornerstone of management of patients with non-ST 
      elevation acute coronary syndrome, health care providers should make themselves 
      familiar with the new data and latest guideline recommendations.
FAU - Thomas, Deepak
AU  - Thomas D
AD  - Department of Nuclear Cardiology, Brigham & Women's Hospital, Boston, MA, USA.
FAU - Giugliano, Robert P
AU  - Giugliano RP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clopidogrel
MH  - Contraindications
MH  - Europe
MH  - Humans
MH  - North America
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - *Practice Guidelines as Topic
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
RF  - 45
EDAT- 2008/04/18 09:00
MHDA- 2008/11/14 09:00
CRDT- 2008/04/18 09:00
PHST- 2008/04/18 09:00 [pubmed]
PHST- 2008/11/14 09:00 [medline]
PHST- 2008/04/18 09:00 [entrez]
AID - 10.1097/FJC.0b013e31816a35a2 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2008 May;51(5):425-33. doi: 10.1097/FJC.0b013e31816a35a2.

PMID- 9099195
OWN - NLM
STAT- MEDLINE
DCOM- 19970501
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 28
IP  - 4
DP  - 1997 Apr
TI  - We need stronger predictors of major vascular events in patients with a recent 
      transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group.
PG  - 774-6
AB  - BACKGROUND: It has been proposed that most prognostic factors in patients with 
      transient ischemic attack or nondisabling stroke are weak and consequently that 
      patients at high risk of recurrent major vascular events cannot be reliably 
      identified. METHODS: In the Dutch TIA trial, a multicenter, double-blind study of 
      low-dose versus medium-dose aspirin, 3127 patients were included within 3 months 
      after onset of a transient ischemic attack, amaurosis fugax, or nondisabling 
      stroke. In a previous analysis, we developed a prediction model by means of Cox 
      proportional hazards regression for the composite outcomes of fatal or nonfatal 
      stroke and for myocardial infarction, stroke, or vascular death, based on 
      clinical and demographic information as well as on the results of ancillary 
      investigations. We assessed the discriminatory power and the calibration of the 
      prediction models. RESULTS: The median numbers of prognostic factors for stroke, 
      myocardial infarction, or vascular death outcome and for stroke alone were 3 and 
      4, respectively. The proportion of patients with a predicted probability 
      exceeding 30% was less than 5% for both models; here the calibration of the 
      models was poor. Only four of the patients with stroke, myocardial infarction, or 
      vascular death were assigned a probability of greater than 50% for that outcome, 
      and only one of the patients with stroke was given such a high probability. The 
      models' discriminatory ability was a little disappointing (areas under the curve 
      of 0.73 and 0.75, respectively). CONCLUSION: This analysis indicates that we need 
      stronger predictors of recurrence risk in patients with a transient ischemic 
      attack or nondisabling stroke.
FAU - Dippel, D W
AU  - Dippel DW
AD  - Department of Neurology, University Hospital Rotterdam, Netherlands. 
      dippel@neuro.fgg.eur.nl
FAU - Koudstaal, P J
AU  - Koudstaal PJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cardiovascular Diseases/*etiology/mortality
MH  - Cerebrovascular Disorders/*complications/drug therapy/physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Forecasting
MH  - Humans
MH  - Ischemic Attack, Transient/*complications/drug therapy
MH  - Male
MH  - Myocardial Infarction/etiology/mortality
MH  - Recurrence
MH  - Survival Analysis
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - 10.1161/01.str.28.4.774 [doi]
PST - ppublish
SO  - Stroke. 1997 Apr;28(4):774-6. doi: 10.1161/01.str.28.4.774.

PMID- 2624587
OWN - NLM
STAT- MEDLINE
DCOM- 19900328
LR  - 20131121
IS  - 0300-8495 (Print)
IS  - 0300-8495 (Linking)
VI  - 18
IP  - 12
DP  - 1989 Dec
TI  - Intravenous lignocaine for migraine headache.
PG  - 1559
AB  - One per cent lignocaine injected intravenously over 90 seconds at a dose not 
      exceeding 1 mg per kg is a good alternative to existing treatment regimens for 
      classic and common migraine.
FAU - Burke, M
AU  - Burke M
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust Fam Physician
JT  - Australian family physician
JID - 0326701
RN  - 98PI200987 (Lidocaine)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Aust Fam Physician 1990 Apr;19(4):598
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Lidocaine/*administration & dosage
MH  - Metoclopramide/therapeutic use
MH  - Migraine Disorders/*drug therapy
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
PST - ppublish
SO  - Aust Fam Physician. 1989 Dec;18(12):1559.

PMID- 26491233
OWN - NLM
STAT- MEDLINE
DCOM- 20160815
LR  - 20220318
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Print)
IS  - 0962-9351 (Linking)
VI  - 2015
DP  - 2015
TI  - Multidrug Resistance Protein-4 Influences Aspirin Toxicity in Human Cell Line.
PG  - 607957
LID - 10.1155/2015/607957 [doi]
LID - 607957
AB  - Overexpression of efflux transporters, in human cells, is a mechanism of 
      resistance to drug and also to chemotherapy. We found that multidrug resistance 
      protein-4 (MRP4) overexpression has a role in reducing aspirin action in patients 
      after bypass surgery and, very recently, we found that aspirin enhances platelet 
      MRP4 levels through peroxisome proliferator activated receptor-α (PPARα). In the 
      present paper, we verified whether exposure of human embryonic kidney-293 cells 
      (Hek-293) to aspirin modifies MRP4 gene expression and its correlation with drug 
      elimination and cell toxicity. We first investigated the effect of high-dose 
      aspirin in Hek-293 and we showed that aspirin is able to increase cell toxicity 
      dose-dependently. Furthermore, aspirin effects, induced at low dose, already 
      enhance MRP4 gene expression. Based on these findings, we compared cell viability 
      in Hek-293, after high-dose aspirin treatment, in MRP4 overexpressing cells, 
      either after aspirin pretreatment or in MRP4 transfected cells; in both cases, a 
      decrease of selective aspirin cell growth inhibition was observed, in comparison 
      with the control cultures. Altogether, these data suggest that exposing cells to 
      low nontoxic aspirin dosages can induce gene expression alterations that may lead 
      to the efflux transporter protein overexpression, thus increasing cellular 
      detoxification of aspirin.
FAU - Massimi, Isabella
AU  - Massimi I
AD  - Department of Experimental Medicine, Faculty of Medicine and Surgery, Sapienza 
      University of Rome, 00161 Rome, Italy.
FAU - Ciuffetta, Ambra
AU  - Ciuffetta A
AD  - Department of Molecular Medicine, Faculty of Medicine and Surgery, Sapienza 
      University of Rome, 00161 Rome, Italy.
FAU - Temperilli, Flavia
AU  - Temperilli F
AD  - Department of Experimental Medicine, Faculty of Medicine and Surgery, Sapienza 
      University of Rome, 00161 Rome, Italy.
FAU - Ferrandino, Francesca
AU  - Ferrandino F
AD  - Department of Molecular Medicine, Faculty of Medicine and Surgery, Sapienza 
      University of Rome, 00161 Rome, Italy.
FAU - Zicari, Alessandra
AU  - Zicari A
AD  - Department of Experimental Medicine, Faculty of Medicine and Surgery, Sapienza 
      University of Rome, 00161 Rome, Italy.
FAU - Pulcinelli, Fabio M
AU  - Pulcinelli FM
AD  - Department of Experimental Medicine, Faculty of Medicine and Surgery, Sapienza 
      University of Rome, 00161 Rome, Italy.
FAU - Felli, Maria Pia
AU  - Felli MP
AD  - Department of Experimental Medicine, Faculty of Medicine and Surgery, Sapienza 
      University of Rome, 00161 Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150927
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
RN  - 0 (ABCC4 protein, human)
RN  - 0 (Multidrug Resistance-Associated Proteins)
RN  - 0 (PPAR alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Biological Transport/drug effects
MH  - Blood Platelets/drug effects
MH  - Cell Death
MH  - Cell Line
MH  - Cell Separation
MH  - Cell Survival
MH  - Chromatography, High Pressure Liquid
MH  - Drug Resistance
MH  - Flow Cytometry
MH  - Gene Expression Regulation
MH  - HEK293 Cells
MH  - Humans
MH  - Multidrug Resistance-Associated Proteins/*metabolism
MH  - PPAR alpha/metabolism
MH  - Real-Time Polymerase Chain Reaction
PMC - PMC4600549
EDAT- 2015/10/23 06:00
MHDA- 2016/08/16 06:00
CRDT- 2015/10/23 06:00
PHST- 2014/11/10 00:00 [received]
PHST- 2014/12/24 00:00 [accepted]
PHST- 2015/10/23 06:00 [entrez]
PHST- 2015/10/23 06:00 [pubmed]
PHST- 2016/08/16 06:00 [medline]
AID - 10.1155/2015/607957 [doi]
PST - ppublish
SO  - Mediators Inflamm. 2015;2015:607957. doi: 10.1155/2015/607957. Epub 2015 Sep 27.

PMID- 4023472
OWN - NLM
STAT- MEDLINE
DCOM- 19850925
LR  - 20190829
IS  - 0277-6715 (Print)
IS  - 0277-6715 (Linking)
VI  - 4
IP  - 2
DP  - 1985 Apr-Jun
TI  - The 2 x 2 factorial design: its application to a randomized trial of aspirin and 
      carotene in U.S. physicians.
PG  - 111-6
AB  - The 2 x 2 factorial design calls for randomizing each participant to treatment A 
      or B to address one question and further assignment at random within each group 
      to treatment C or D to examine a second issue, permitting the simultaneous test 
      of two different hypotheses. This design can increase the efficiency of 
      large-scale clinical trials. The Physicians' Health Study, a randomized trial of 
      aspirin and beta-carotene among U.S. physicians, illustrates some features and 
      potential problems in the design and analysis of a factorial trial. The most 
      common concern, interaction between treatments, is generally an advantage rather 
      than a limitation of this design. Although such interactions are relatively 
      uncommon, this design provides a means to measure an effect which otherwise might 
      not be apparent. If the interaction is sufficiently severe, however, then loss of 
      power is possible.
FAU - Stampfer, M J
AU  - Stampfer MJ
FAU - Buring, J E
AU  - Buring JE
FAU - Willett, W
AU  - Willett W
FAU - Rosner, B
AU  - Rosner B
FAU - Eberlein, K
AU  - Eberlein K
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA 34944/CA/NCI NIH HHS/United States
GR  - HL 01018/HL/NHLBI NIH HHS/United States
GR  - HL 26490/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Stat Med
JT  - Statistics in medicine
JID - 8215016
RN  - 36-88-4 (Carotenoids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Biometry
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Carotenoids/*therapeutic use
MH  - Clinical Trials as Topic/*methods
MH  - Humans
MH  - Neoplasms/epidemiology/*prevention & control
MH  - Research Design
MH  - United States
EDAT- 1985/04/01 00:00
MHDA- 1985/04/01 00:01
CRDT- 1985/04/01 00:00
PHST- 1985/04/01 00:00 [pubmed]
PHST- 1985/04/01 00:01 [medline]
PHST- 1985/04/01 00:00 [entrez]
AID - 10.1002/sim.4780040202 [doi]
PST - ppublish
SO  - Stat Med. 1985 Apr-Jun;4(2):111-6. doi: 10.1002/sim.4780040202.

PMID- 7452454
OWN - NLM
STAT- MEDLINE
DCOM- 19810327
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 69
IP  - 11
DP  - 1980 Nov
TI  - High-pressure liquid chromatographic determination of salicylsalicylic acid, 
      aspirin, and salicylic acid in human plasma and urine.
PG  - 1268-71
AB  - A high-pressure liquid chromatographic method was developed for the separation 
      and quantitation of salicylsalicylic acid (I), aspirin (II), and salicylic acid 
      (III) in human plasma and urine. The method for plasma involves the selective 
      extraction of I--III and an internal standard, alpha-phenylcinnamic acid, into 
      methylene chloride from acidified plasma, followed by evaporation of the organic 
      phase and dissolution of the residue in methanol. A 25-microliter aliquot is 
      analyzed on a reversed-phase column with UV detection. Urine is treated similarly 
      with hexane as the extracting solvent. If 300 nm is used as the monitoring 
      wavelength, the assays of I and III are linear over the concentration range of 
      1--150 microgram/ml in both plasma and urine. If 280 nm is used as the monitoring 
      wavelength, II can be quantitated along with I and III; however, detector 
      sensitivities of I and III are two to three times greater at 300 nm. The accuracy 
      and precision of the methods for I--III are adequate for clinical pharmacokinetic 
      studies. Following therapeutic doses of I in humans, the method was applied 
      successfully to the determination of I and III in plasma and urine.
FAU - Harrison, L I
AU  - Harrison LI
FAU - Funk, M L
AU  - Funk ML
FAU - Ober, R E
AU  - Ober RE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - V9MO595C9I (salicylsalicylic acid)
SB  - IM
MH  - Anti-Inflammatory Agents/*analysis/blood/urine
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Humans
MH  - Male
MH  - Salicylates/*analysis
EDAT- 1980/11/01 00:00
MHDA- 1980/11/01 00:01
CRDT- 1980/11/01 00:00
PHST- 1980/11/01 00:00 [pubmed]
PHST- 1980/11/01 00:01 [medline]
PHST- 1980/11/01 00:00 [entrez]
AID - S0022-3549(15)43442-2 [pii]
AID - 10.1002/jps.2600691109 [doi]
PST - ppublish
SO  - J Pharm Sci. 1980 Nov;69(11):1268-71. doi: 10.1002/jps.2600691109.

PMID- 34338761
OWN - NLM
STAT- MEDLINE
DCOM- 20220415
LR  - 20230301
IS  - 1758-535X (Electronic)
IS  - 1079-5006 (Print)
IS  - 1079-5006 (Linking)
VI  - 77
IP  - 1
DP  - 2022 Jan 7
TI  - Validation of a Deficit-Accumulation Frailty Index in the ASPirin in Reducing 
      Events in the Elderly Study and Its Predictive Capacity for Disability-Free 
      Survival.
PG  - 19-26
LID - 10.1093/gerona/glab225 [doi]
AB  - Frailty is a state of heightened vulnerability and susceptibility to physiologic 
      stressors that increases with age. It has shown increasing utility in predicting 
      a range of adverse health outcomes. Here, we characterize a 67-item 
      deficit-accumulation frailty index (FI) in 19 110 community-dwelling individuals 
      in the ASPirin in Reducing Events in the Elderly clinical trial. Participants 
      aged 65-98 years were recruited from the United States and Australia and were 
      without diagnosed dementia and cardiovascular disease, and major physical 
      disability. The median FI score was .10 (interquartile range: .07-.14) at 
      baseline, and the prevalence of frailty (FI > .21) increased from 8.1% to 17.4% 
      after 6 years. FI was positively associated with age, and women had significantly 
      higher scores than men at all ages. The FI was negatively correlated with gait 
      speed (r = -.31) and grip strength (r = -.46), and strongly associated with a 
      modified Fried's frailty phenotype (p < .0001, for all comparisons). Frailty was 
      associated with the primary composite outcome capturing independent life lived 
      free of major disability and dementia, and increased the rate of persistent 
      physical disability (hazard ratio: 21.3, 95% confidence interval: 15.6-28.9). It 
      added significantly to the predictive capacity of these outcomes above age, sex, 
      and ethnicity alone. The FI is thus a useful biomarker of aging even among 
      relatively healthy older individuals and provides important information about an 
      individual's vulnerability to and risk of disease.
CI  - © The Author(s) 2021. Published by Oxford University Press on behalf of The 
      Gerontological Society of America. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - Ryan, Joanne
AU  - Ryan J
AUID- ORCID: 0000-0002-7039-6325
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Espinoza, Sara
AU  - Espinoza S
AD  - Division of Geriatrics, Gerontology & Palliative Medicine, Sam and Ann Barshop 
      Institute for Longevity and Aging Studies, UT Health San Antonio, Texas, USA.
AD  - Geriatrics Research, Education and Clinical Center, South Texas Veterans Health 
      Care System, San Antonio, USA.
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - Department of Pharmacy Practice and Science, College of Pharmacy, University of 
      Iowa, USA.
AD  - Department of Family Medicine, Carver College of Medicine, University of Iowa, 
      USA.
FAU - Ekram, A R M Saifuddin
AU  - Ekram ARMS
AUID- ORCID: 0000-0003-4267-1286
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Murray, Anne M
AU  - Murray AM
AD  - Berman Center for Clinical Outcomes and Research, Hennepin Health Research 
      Institute and Division of Geriatrics, Department of Medicine, Hennepin Healthcare 
      and University of Minnesota, Minneapolis, USA.
FAU - Shah, Raj C
AU  - Shah RC
AD  - Department of Family Medicine and Rush Alzheimer's Disease Center, Rush 
      University Medical Center, Chicago, Illinois, USA.
FAU - Orchard, Suzanne G
AU  - Orchard SG
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Fitzgerald, Sharyn
AU  - Fitzgerald S
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Beilin, Lawrence J
AU  - Beilin LJ
AD  - School of Medicine, Royal Perth Hospital, University of Western Australia, 
      Australia.
FAU - Ward, Stephanie A
AU  - Ward SA
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Williamson, Jeff D
AU  - Williamson JD
AD  - Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest 
      School of Medicine, Winston-Salem, North Carolina, USA.
FAU - Newman, Anne B
AU  - Newman AB
AD  - Center for Aging and Population Health, University of Pittsburgh, Pennsylvania, 
      USA.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Woods, Robyn L
AU  - Woods RL
AUID- ORCID: 0000-0003-1249-6149
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
LA  - eng
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U19 AG062682/AG/NIA NIH HHS/United States
GR  - U01AG029824/NH/NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Gerontol A Biol Sci Med Sci
JT  - The journals of gerontology. Series A, Biological sciences and medical sciences
JID - 9502837
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - *Dementia/epidemiology
MH  - *Disabled Persons
MH  - Female
MH  - Frail Elderly
MH  - *Frailty/diagnosis
MH  - Geriatric Assessment
MH  - Humans
MH  - Male
MH  - United States/epidemiology
PMC - PMC8751791
OTO - NOTNLM
OT  - Biomarker
OT  - Physical function
OT  - Preventive health care
EDAT- 2021/08/03 06:00
MHDA- 2022/04/16 06:00
CRDT- 2021/08/02 12:25
PHST- 2021/04/23 00:00 [received]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2022/04/16 06:00 [medline]
PHST- 2021/08/02 12:25 [entrez]
AID - 6335588 [pii]
AID - glab225 [pii]
AID - 10.1093/gerona/glab225 [doi]
PST - ppublish
SO  - J Gerontol A Biol Sci Med Sci. 2022 Jan 7;77(1):19-26. doi: 
      10.1093/gerona/glab225.

PMID- 17847044
OWN - NLM
STAT- MEDLINE
DCOM- 20080205
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 30
IP  - 12
DP  - 2007 Dec
TI  - Antiplatelet therapy in cerebrovascular disease: implications of Management of 
      Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for 
      High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance 
      studies' results for cardiologists.
PG  - 604-14
AB  - Cardiovascular disease is prevalent among patients with stroke; thus, 
      cardiologists frequently treat patients at high risk for stroke. Results from 
      recent clinical trials of antiplatelet medications, given alone or in 
      combination, may be of special interest to cardiologists. The MATCH study 
      demonstrated no significant difference between clopidogrel alone and clopidogrel 
      plus aspirin in reducing risk of vascular events after stroke or transient 
      ischemic attack. A 1.3% increased risk of major bleeding was associated with 
      clopidogrel plus aspirin. In CHARISMA, clopidogrel plus aspirin did not reach 
      statistical significance vs. placebo plus aspirin in reducing incidence of 
      myocardial infarction (MI), stroke, or death from cardiovascular causes in 
      patients with stable atherothrombotic disease; clopidogrel was associated with an 
      increase in moderate bleeding. These results suggest that clopidogrel plus 
      aspirin may be inappropriate as first-line therapy for secondary stroke 
      prevention. In patients with established cardiovascular disease at risk for MI or 
      other vascular events, physicians must weigh the benefits and risks before 
      choosing this therapy. Selection of an antiplatelet agent must be based on 
      patient history, including previous MI and stroke, susceptibility to bleeding, 
      and other high-risk factors (e.g. advanced age and diabetes). Aspirin plus 
      extended-release dipyridamole may be more effective than clopidogrel for 
      preventing stroke in high-risk patients. This article strives to put MATCH and 
      CHARISMA results into context by providing an overview of antiplatelet therapy, 
      including relevant clinical trial results, a review of current practice 
      guidelines, and a summary of an ongoing study that will improve clinical decision 
      making.
FAU - Fintel, Dan James
AU  - Fintel DJ
AD  - Department of Medicine, Northwestern University Memorial Hospital, Chicago, 
      Illinois 60611-3008, USA. dfintel@northwestern.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Dipyridamole/therapeutic use
MH  - Drug Therapy, Combination
MH  - Embolism, Cholesterol/*drug therapy/prevention & control
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Stroke/*drug therapy/prevention & control
MH  - Ticlopidine/analogs & derivatives/therapeutic use
PMC - PMC6652940
EDAT- 2007/09/12 09:00
MHDA- 2008/02/06 09:00
CRDT- 2007/09/12 09:00
PHST- 2007/09/12 09:00 [pubmed]
PHST- 2008/02/06 09:00 [medline]
PHST- 2007/09/12 09:00 [entrez]
AID - CLC20154 [pii]
AID - 10.1002/clc.20154 [doi]
PST - ppublish
SO  - Clin Cardiol. 2007 Dec;30(12):604-14. doi: 10.1002/clc.20154.

PMID- 9542472
OWN - NLM
STAT- MEDLINE
DCOM- 19980422
LR  - 20131121
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 63
IP  - 3
DP  - 1998 Mar
TI  - Protein binding of aspirin and salicylate measured by in vivo ultrafiltration.
PG  - 285-95
AB  - OBJECTIVE: Methods for measuring protein binding of drugs generally require 
      direct measurement of the concentration of unbound drug and thus may require a 
      highly sensitive assay. In vivo ultrafiltration has been used to determine 
      protein binding of endogenous substances. We have examined its value for 
      measuring protein binding of drugs because it requires measurement of only the 
      concentration of total drug, not unbound drug, in plasma. METHODS: The protein 
      binding of aspirin and its metabolite salicylate was measured in 29 healthy 
      subjects 20 minutes after a single oral dose of 600 mg soluble aspirin, by the 
      new method, in vivo ultrafiltration, as well as by a standard method, in vitro 
      ultracentrifugation. RESULTS: The data for salicylate were examined 
      systematically to determine the optimal method of determining estimates of 
      protein binding by in vivo ultrafiltration. Estimates of protein binding of 
      salicylate were 81.7% +/- 10.1% (mean +/- SD) by the in vivo method and 81.6% +/- 
      11.3% by in vitro ultracentrifugation. Bland-Altman analysis of agreement showed 
      that within-individual differences in percentage of protein binding determined by 
      the two methods did not differ significantly from zero (mean difference, 0.07%; 
      95% confidence interval, -2.33 to +2.46). There was a highly significant 
      correlation between estimates of protein binding by the two methods (r = 0.82; p 
      = 0.001). Protein binding of aspirin was estimated of protein binding by the two 
      methods (r = 0.82; p = 0.001). Protein binding of aspirin was estimated at 58.3% 
      +/- 9.6% by in vivo ultrafiltration and could not be estimated by in vitro 
      ultracentrifugation because the concentration of unbound aspirin in plasma was 
      below the limit of detection for the assay. CONCLUSION: In vivo ultrafiltration 
      can be used to measure protein binding of drugs and has potential advantages over 
      conventional methods. A sensitive assay may not be required because the unbound 
      drug need not be measured, measurement in vivo may maintain more physiologic 
      conditions, and it may be useful in measuring protein binding of drugs that are 
      degraded rapidly in vitro.
FAU - Ghahramani, P
AU  - Ghahramani P
AD  - University Department of Medicine and Pharmacology, Royal Hallamshire Hospital, 
      Sheffield, England.
FAU - Rowland-Yeo, K
AU  - Rowland-Yeo K
FAU - Yeo, W W
AU  - Yeo WW
FAU - Jackson, P R
AU  - Jackson PR
FAU - Ramsay, L E
AU  - Ramsay LE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Blood Proteins)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics
MH  - Aspirin/blood/*pharmacokinetics
MH  - Blood Proteins/metabolism
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Protein Binding
MH  - Reference Values
MH  - Salicylates/blood/*pharmacokinetics
MH  - Salicylic Acid
MH  - *Ultrafiltration
EDAT- 1998/04/29 00:00
MHDA- 1998/04/29 00:01
CRDT- 1998/04/29 00:00
PHST- 1998/04/29 00:00 [pubmed]
PHST- 1998/04/29 00:01 [medline]
PHST- 1998/04/29 00:00 [entrez]
AID - S0009-9236(98)90160-6 [pii]
AID - 10.1016/S0009-9236(98)90160-6 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1998 Mar;63(3):285-95. doi: 10.1016/S0009-9236(98)90160-6.

PMID- 3297623
OWN - NLM
STAT- MEDLINE
DCOM- 19870730
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 33 Suppl 1
DP  - 1987
TI  - The role of arachidonic acid metabolites in cardiovascular homeostasis. 
      Biochemical, histological and clinical cardiovascular effects of non-steroidal 
      anti-inflammatory drugs and their interactions with cardiovascular drugs.
PG  - 47-55
AB  - Derivatives of arachidonic acid may be involved in atherosclerosis and its 
      clinical complications. There is much interest in pharmacologically manipulating 
      the arachidonic acid cascade as a means of preventing cardiovascular disease. The 
      development of atherosclerosis has been intensively studied and the consequences 
      of cardiovascular or cerebrovascular vessel occlusion are too familiar. Many 
      factors are probably involved, but the role of plasma lipoproteins and the 
      interactions between various constituents of blood and blood vessel walls have 
      received particular attention. The risk of cardiovascular disease associated with 
      high plasma concentrations of the low density lipoproteins and the possible 
      protective effects of high density lipoproteins have been well documented. Much 
      is now known about lipoprotein biochemistry, and the importance of controlling 
      the quantity and quality of dietary lipids has been demonstrated in 
      epidemiological studies. In studies of patients with transient ischaemic attacks, 
      aspirin reduced the risk of stroke and death in males, although these benefits 
      were not as convincingly demonstrated in women. The majority of patients were 
      given aspirin 1300 mg daily, but the optimum dosage was not properly evaluated. 
      Administering aspirin in combination with another antiplatelet drug did not 
      appear to offer any therapeutic advantage in these patients. Aspirin showed a 
      positive, but non-significant trend towards reduced numbers of cardiac events, 
      non-fatal infarcts and total mortality in patients who had experienced at least 
      one myocardial infarction. In contrast, statistically significant beneficial 
      effects were recorded when patients with unstable angina were administered 
      aspirin. The risks of myocardial infarction or coronary death were reduced by 51% 
      in 2 large studies.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Goodman, D S
AU  - Goodman DS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Eicosanoic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteriosclerosis/*drug therapy/metabolism
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/drug therapy
MH  - Eicosanoic Acids/*metabolism
MH  - Heart Valve Prosthesis
MH  - Homeostasis/drug effects
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy
MH  - Vascular Patency/drug effects
RF  - 31
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.2165/00003495-198700331-00008 [doi]
PST - ppublish
SO  - Drugs. 1987;33 Suppl 1:47-55. doi: 10.2165/00003495-198700331-00008.

PMID- 9528733
OWN - NLM
STAT- MEDLINE
DCOM- 19980408
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 104
IP  - 2
DP  - 1998 Feb
TI  - Anticoagulation for nonvalvular atrial fibrillation: effects of type of practice 
      on physicians' self-reported behavior.
PG  - 148-51
AB  - BACKGROUND: This study examines whether social and economic factors affect 
      physician practice and attitude with regard to warfarin anticoagulation in 
      patients with nonvalvular atrial fibrillation. METHODS: We identified physicians 
      in Baltimore City, Baltimore County, and Prince George's County who (1) had 
      written one or more prescriptions for a digitalis compound during the preceding 
      year, and (2) were classified as general practitioners, family practice 
      specialists, internists, or cardiologists. All 358 physicians fulfilling these 
      criteria were surveyed by questionnaire. RESULTS: The overall response rate was 
      43%. Physicians who wrote 15% or more of their digitalis prescriptions for 
      Medicaid patients said they used warfarin at significantly lower rates for 
      patients with nonvalvular AF than other (66% versus 79%, P <0.01). The opposite 
      pattern was seen with regard to aspirin. There were no significant differences in 
      practice pattern between physicians located in urban vs. suburban counties. 
      CONCLUSION: In our sample, self-reported anticoagulant practices for patients 
      with nonvalvular AF were associated with the percentage of digitalis 
      prescriptions written for Medicaid patients. In this metropolitan area, 
      anticoagulant therapy was reportedly prescribed for approximately 75% of patients 
      with nonvalvular atrial fibrillation.
FAU - Bush, D
AU  - Bush D
AD  - Department of Medicine, The Center on Aging, Johns Hopkins University School of 
      Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD 21224, USA.
FAU - Tayback, M
AU  - Tayback M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Baltimore
MH  - Drug Utilization/*statistics & numerical data
MH  - Humans
MH  - Maryland
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Warfarin/therapeutic use
EDAT- 1998/04/07 00:00
MHDA- 1998/04/07 00:01
CRDT- 1998/04/07 00:00
PHST- 1998/04/07 00:00 [pubmed]
PHST- 1998/04/07 00:01 [medline]
PHST- 1998/04/07 00:00 [entrez]
AID - S0002934397003525 [pii]
AID - 10.1016/s0002-9343(97)00352-5 [doi]
PST - ppublish
SO  - Am J Med. 1998 Feb;104(2):148-51. doi: 10.1016/s0002-9343(97)00352-5.

PMID- 23590035
OWN - NLM
STAT- MEDLINE
DCOM- 20130715
LR  - 20221207
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 96 Suppl 2
DP  - 2013 Feb
TI  - Aspirin resistance in Thai patients with chronic stable angina.
PG  - S146-51
AB  - OBJECTIVE: To determine the prevalence, clinical profile and risk factors of 
      aspirin resistance in Thai patients with chronic stable angina. MATERIAL AND 
      METHOD: The patients were prospectively recruited from the consecutive patients 
      diagnosed chronic stable angina at Siriraj Hospital during March 2011 to February 
      2012. Ten milliliter of blood samples were cautiously drawn from the antecubital 
      vein of the patients to determine the hemoglobin, platelet count and platelet 
      aggregation test performed by light transmittance aggregometry using 
      platelet-rich plasma. Platelets were stimulated with 0.5 mg/ml of arachidonic 
      acid and 10 mM adenosine diphosphate. Platelet aggregation was expressed as the 
      maximal percent change in light transmittance from baseline. Aspirin resistance 
      was defined as the mean platelet aggregation of > or = 70% with 10 mM ADP and the 
      mean platelet aggregation of > or = 20% with 0.5 mg/ml of arachidonic acid. 
      RESULTS: One-hundred and fifty seven patients diagnosed chronic stable angina 
      were enrolled in the present study. There were 34 patients (21.6%) demonstrating 
      aspirin resistance. The clinical characteristic of these patients included male 
      58.8% with mean age of 66 years, body mass index 27.5 kg/m2, diabetes mellitus 
      52.9%, smoking 8.8%, hypercholesterolemia 70.6% and proton pump inhibitor use 
      23.5%. Multivariate analysis demonstrated none of the risk factors including age, 
      female, body mass index, diabetes mellitus, hypercholesterolemia, smoking and 
      proton pump inhibitor (PPI) use had a statistically significant association with 
      aspirin resistance. CONCLUSION: Our study demonstrated that the prevalence of 
      aspirin resistance in Thai patients with chronic stable angina was 21.6%. No 
      significant association was demonstrated between age, female, body mass index, 
      diabetes mellitus, hypercholesterolemia, smoking, proton pump inhibitor (PPI) use 
      and aspirin resistance.
FAU - Phankingthongkum, Rewat
AU  - Phankingthongkum R
AD  - Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand. rewat.pha@mahidol.ac.th
FAU - Panchavinnin, Pradit
AU  - Panchavinnin P
FAU - Chinthammitr, Yingyong
AU  - Chinthammitr Y
FAU - Tresukosol, Damras
AU  - Tresukosol D
FAU - Chotinaiwattarakul, Chunhakasem
AU  - Chotinaiwattarakul C
FAU - Tungsubutra, Wiwun
AU  - Tungsubutra W
FAU - Wongpraparut, Nattawut
AU  - Wongpraparut N
FAU - Karevee, Dararat
AU  - Karevee D
FAU - Sumalee, Chansaeng
AU  - Sumalee C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/*drug therapy
MH  - Asian People
MH  - Aspirin/*therapeutic use
MH  - Chronic Disease
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Factors
EDAT- 2013/04/18 06:00
MHDA- 2013/07/17 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/18 06:00 [entrez]
PHST- 2013/04/18 06:00 [pubmed]
PHST- 2013/07/17 06:00 [medline]
PST - ppublish
SO  - J Med Assoc Thai. 2013 Feb;96 Suppl 2:S146-51.

PMID- 15991274
OWN - NLM
STAT- MEDLINE
DCOM- 20050922
LR  - 20190430
IS  - 1007-9327 (Print)
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 11
IP  - 25
DP  - 2005 Jul 7
TI  - Role of Helicobacter pylori eradication in aspirin or non-steroidal 
      anti-inflammatory drug users.
PG  - 3811-6
AB  - Helicobacter pylori (H pylori) infection and the use of non-steroidal 
      anti-inflammatory drugs (NSAIDs) including aspirin at any dosage and formulation 
      represent well-established risk factors for the development of uncomplicated and 
      complicated peptic ulcer disease accounting for the majority of such cases. 
      Although the interaction between H pylori and NSAID/aspirin use in the same 
      individuals was questioned in some epidemiological studies, it has now become 
      widely accepted that they are at least independent risk factors for peptic ulcer 
      disease. According to data from randomized intervention trials, naive NSAID users 
      certainly benefit from testing for H pylori infection and, if positive, H pylori 
      eradication therapy prior to the initiation of NSAID. A similar strategy is also 
      suggested for naive aspirin users, although the efficacy of such an approach has 
      not been evaluated yet. Strong data also support that chronic aspirin users with 
      a recent ulcer complication should be tested for H pylori infection and, if 
      positive, receive H pylori eradication therapy after ulcer healing, while they 
      appear to benefit from additional long-term therapy with a proton pump inhibitor 
      (PPI). A similar approach is often recommended to chronic aspirin users at a high 
      risk of ulcer complication. H pylori eradication alone does not efficiently 
      protect chronic NSAID users with a recent ulcer complication or those at a 
      high-risk, who certainly should be treated with long-term PPI therapy, but H 
      pylori eradication may be additionally offered even in this setting. In contrast, 
      testing for H pylori or PPI therapy is not recommended for chronic NSAID/aspirin 
      users with no ulcer complications or those at a low risk of complications.
FAU - Papatheodoridis, George-V
AU  - Papatheodoridis GV
AD  - Second Academic Department of Internal Medicine, Medical School of Athens 
      University, Hippokration General Hospital of Athens, 114 Vas. Sophias Ave., 
      Athens 115 27, Greece. gpapath@cc.uoa.gr
FAU - Archimandritis, Athanasios-J
AU  - Archimandritis AJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Gastrointestinal Diseases/*chemically induced/*prevention & control
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
PMC - PMC4504877
EDAT- 2005/07/02 09:00
MHDA- 2005/09/24 09:00
CRDT- 2005/07/02 09:00
PHST- 2005/07/02 09:00 [pubmed]
PHST- 2005/09/24 09:00 [medline]
PHST- 2005/07/02 09:00 [entrez]
AID - 10.3748/wjg.v11.i25.3811 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2005 Jul 7;11(25):3811-6. doi: 10.3748/wjg.v11.i25.3811.

PMID- 409429
OWN - NLM
STAT- MEDLINE
DCOM- 19771125
LR  - 20190613
IS  - 0006-2960 (Print)
IS  - 0006-2960 (Linking)
VI  - 16
IP  - 19
DP  - 1977 Sep 20
TI  - Acetylation of prostaglandin synthetase by aspirin. Purification and properties 
      of the acetylated protein from sheep vesicular gland.
PG  - 4244-8
AB  - We previously presented evidence that aspirin (acetylsalicylic acid) inhibits 
      prostaglandin synthetase by acetylating and active site of the enzyme. In the 
      current work, we have labeled the enzyme from an aceton-pentane powder of sheep 
      vesicular gland using [acetyl-3H]aspirin and purified the [3H]acetyl-protein to 
      near homogeneity. The final preparation contains protein of a single molecular 
      weight (85 000) and an amino-terminal sequence of Asp-Ala-Gly-Arg-Ala. The 
      [3H]acetyl-protein contained 0.5 mol of acetyl residues per mol of protein based 
      on amino acid composition but only a single sequence was found.
FAU - Roth, G J
AU  - Roth GJ
FAU - Stanford, N
AU  - Stanford N
FAU - Jacobs, J W
AU  - Jacobs JW
FAU - Majerus, P W
AU  - Majerus PW
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 0 (Amino Acids)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Amino Acid Sequence
MH  - Amino Acids/analysis
MH  - Animals
MH  - *Aspirin/metabolism
MH  - Male
MH  - *Prostaglandin-Endoperoxide Synthases/isolation & purification/metabolism
MH  - Protein Binding
MH  - Seminal Vesicles/*enzymology
MH  - Sheep
EDAT- 1977/09/20 00:00
MHDA- 1977/09/20 00:01
CRDT- 1977/09/20 00:00
PHST- 1977/09/20 00:00 [pubmed]
PHST- 1977/09/20 00:01 [medline]
PHST- 1977/09/20 00:00 [entrez]
AID - 10.1021/bi00638a018 [doi]
PST - ppublish
SO  - Biochemistry. 1977 Sep 20;16(19):4244-8. doi: 10.1021/bi00638a018.

PMID- 6393076
OWN - NLM
STAT- MEDLINE
DCOM- 19850221
LR  - 20190913
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 4
IP  - 6
DP  - 1984 Nov-Dec
TI  - Analgesic effect of fendosal, ibuprofen and aspirin in postoperative oral surgery 
      pain.
PG  - 385-91
AB  - The analgesic efficacy of a single 200-mg dose of fendosal, a nonnarcotic, 
      nonsteroidal antiinflammatory analgesic, was compared, in a double-blind study, 
      with aspirin 650 mg, ibuprofen 400 mg and placebo in outpatients who had moderate 
      or severe pain after the surgical removal of impacted third molars. Using a 
      self-rating record, patients rated their pain and its relief hourly for up to 12 
      hours after medicating. Each active medication was significantly superior to 
      placebo. The peak analgesic effect of fendosal 200 mg was similar to that of the 
      aspirin 650-mg standard. Although fendosal's onset of action was slow (3 hours), 
      its effect persisted for 8 hours, substantially longer than that of aspirin. 
      Ibuprofen 400 mg was statistically significantly superior to aspirin 650 mg and 
      fendosal 200 mg for most measures of peak and total analgesia, and its effect 
      persisted for 8 hours. The results of this study raise some questions concerning 
      the comparability of data from studies that employ different criteria for 
      remedication and/or different criteria for the inclusion of data in the analyses 
      of efficacy.
FAU - Forbes, J A
AU  - Forbes JA
FAU - Barkaszi, B A
AU  - Barkaszi BA
FAU - Ragland, R N
AU  - Ragland RN
FAU - Hankle, J J
AU  - Hankle JJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - 9Z709558TZ (fendosal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Ibuprofen/adverse effects/*therapeutic use
MH  - Male
MH  - Mouth/surgery
MH  - Pain, Postoperative/*drug therapy
MH  - Random Allocation
MH  - Salicylates/adverse effects/*therapeutic use
MH  - Time Factors
EDAT- 1984/11/01 00:00
MHDA- 1984/11/01 00:01
CRDT- 1984/11/01 00:00
PHST- 1984/11/01 00:00 [pubmed]
PHST- 1984/11/01 00:01 [medline]
PHST- 1984/11/01 00:00 [entrez]
AID - 10.1002/j.1875-9114.1984.tb03401.x [doi]
PST - ppublish
SO  - Pharmacotherapy. 1984 Nov-Dec;4(6):385-91. doi: 
      10.1002/j.1875-9114.1984.tb03401.x.

PMID- 33360345
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20210224
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 81
DP  - 2021 Jan
TI  - Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined 
      with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, 
      randomized controlled trial.
PG  - 153419
LID - S0944-7113(20)30250-6 [pii]
LID - 10.1016/j.phymed.2020.153419 [doi]
AB  - BACKGROUND: Salvia Miltiorrhiza Depside Salt (SMDS) was extracted from Salvia 
      miltiorrhiza with high-quality control of active principles. In 2005, China's FDA 
      approved the use of SMDS for stable angina pectoris (SAP), but the evidence of 
      SMDS combined with aspirin remains unclear. PURPOSE: The aim of this study was to 
      assess the clinical effectiveness and safety of SMDS combined with aspirin in 
      patients with SAP. METHODS: A multicenter, pragmatic, three-armed parallel group 
      and an individually randomized controlled superiority trial was designed. 
      Participants aged 35 to 75 years old with SAP were recruited from four "Class Ⅲ 
      Grade A" hospitals in China. Participants who were randomized into the SMDS group 
      were treated with SMDS by intravenous drip. Participants in the control group 
      received aspirin enteric-coated tablets (aspirin). Participants who were randomly 
      assigned to the combination group received SMDS combined with aspirin. All 
      participants received standard care from clinicians, without any restrictions. 
      The primary outcome measure was thromboelastography (TEG). Secondary outcome 
      measures included symptom score of the Seattle Angina Questionnaire (SAQ), visual 
      analogue scale (VAS) score of traditional Chinese medicine (TCM) symptoms, 
      platelet aggregation measured by light transmittance aggregometry (LTA), and 
      fasting blood glucose. Effectiveness evaluation data were collected at baseline 
      and ten days after treatment. Researchers followed up with participants for one 
      month after treatment to determine whether adverse events (AEs) or adverse drug 
      reactions (ADRs) such as bleeding tendency occurred. All statistical calculations 
      were carried out with R 3.5.3 statistical analysis software. RESULTS: A total of 
      135 participants completed follow-up data on the primary outcome after ten days 
      of treatment. Participants in the SMDS combined aspirin group had the highest 
      improvement rate of sensitivity in AA% [p < 0.001, 95% CI (0.00-0.00)], from 
      30.6% before treatment to 81.6% after treatment. Participants with drug 
      resistance (AA% < 20%) in the SMDS combined with aspirin group also had the 
      highest sensitivity rate [p < 0.001, 95% CI (0.00-0.00)] after treatment 
      (accounting for 81.0% of the combination group and 60.7% of the sensitive 
      participants). The improvement of TCM symptoms in participants treated with SMDS 
      combined with aspirin was significantly better than that of the aspirin group 
      [MD = 1.71, 95% CI (0.15-3.27), p = 0.032]. There were no significant differences 
      in other indexes (R, TPI, MA, K, CI, α value) of TEG, SAQ, platelet aggregation 
      and fasting blood glucose among the three groups. No bleeding tendency or ADRs 
      occurred in all participants. CONCLUSION: SMDS combined with aspirin is a 
      clinically effective and safe intervention to treat adults aged 35 and older with 
      SAP. This trial shows that SMDS combined with aspirin can significantly improve 
      the sensitivity rate of AA% in TEG and the VAS score of TCM symptoms. Further 
      large samples and high-quality research are needed to determine if certain 
      participants might benefit more from SMDS combined with aspirin. The study 
      protocol was registered in the Clinical Trials USA registry (registration No. 
      NCT02694848).
CI  - Copyright © 2020. Published by Elsevier GmbH.
FAU - Lyu, Jian
AU  - Lyu J
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Sciences, 16 Nanxiaojie, Inner Dongzhimen, Beijing 100700, China.
FAU - Xue, Mei
AU  - Xue M
AD  - XiYuan Hospital, China Academy of Chinese Medical Sciences, No.1 Xiyuan 
      playground Road, Haidian District, Beijing 100091, China.
FAU - Li, Jun
AU  - Li J
AD  - Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No.5, North Line 
      Pavilion, Xicheng District, Beijing 100053, China.
FAU - Lyu, Weihui
AU  - Lyu W
AD  - Guangdong Provincial Hospital of Traditional Chinese Medicine, No.111 Dade Road, 
      Yuexiu District, Guangzhou 510120, China.
FAU - Wen, Zehuai
AU  - Wen Z
AD  - Guangdong Provincial Hospital of Traditional Chinese Medicine, No.111 Dade Road, 
      Yuexiu District, Guangzhou 510120, China.
FAU - Yao, Ping
AU  - Yao P
AD  - Guangdong Provincial Hospital of Traditional Chinese Medicine, No.111 Dade Road, 
      Yuexiu District, Guangzhou 510120, China.
FAU - Li, Junxia
AU  - Li J
AD  - General Hospital of Beijing PLA Military Region, No.5, Nan men Cang, 
      Dongsishitiao, Dongcheng District, Beijing 100700, China.
FAU - Zhang, Yanling
AU  - Zhang Y
AD  - General Hospital of Beijing PLA Military Region, No.5, Nan men Cang, 
      Dongsishitiao, Dongcheng District, Beijing 100700, China.
FAU - Gong, Yumiao
AU  - Gong Y
AD  - General Hospital of Beijing PLA Military Region, No.5, Nan men Cang, 
      Dongsishitiao, Dongcheng District, Beijing 100700, China.
FAU - Xie, Yanming
AU  - Xie Y
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Sciences, 16 Nanxiaojie, Inner Dongzhimen, Beijing 100700, China. 
      Electronic address: ktzu2018@163.com.
FAU - Chen, Keji
AU  - Chen K
AD  - XiYuan Hospital, China Academy of Chinese Medical Sciences, No.1 Xiyuan 
      playground Road, Haidian District, Beijing 100091, China. Electronic address: 
      kjchenvip@163.com.
FAU - Wang, Lianxin
AU  - Wang L
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Sciences, 16 Nanxiaojie, Inner Dongzhimen, Beijing 100700, China. 
      Electronic address: wlxing@126.com.
FAU - Chai, Yan
AU  - Chai Y
AD  - Department of Epidemiology, University of California-Los Angeles, 405 Hilgard 
      Avenue, California 90095, USA. Electronic address: chaiyanhi@hotmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT02694848
PT  - Journal Article
PT  - Multicenter Study
PT  - Pragmatic Clinical Trial
PT  - Randomized Controlled Trial
DEP - 20201210
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Depsides)
RN  - 0 (Drugs, Chinese Herbal)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina, Stable/*drug therapy/etiology
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Creatinine/blood
MH  - Depsides/therapeutic use
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/adverse effects/chemistry/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salvia miltiorrhiza/*chemistry
MH  - Thrombelastography
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Effectiveness and safety
OT  - Randomized controlled trial
OT  - Salvia miltiorrhiza depside salt
OT  - Stable angina pectoris
OT  - Traditional Chinese medicine
EDAT- 2020/12/29 06:00
MHDA- 2021/02/25 06:00
CRDT- 2020/12/28 11:12
PHST- 2020/09/18 00:00 [received]
PHST- 2020/11/12 00:00 [revised]
PHST- 2020/11/19 00:00 [accepted]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
PHST- 2020/12/28 11:12 [entrez]
AID - S0944-7113(20)30250-6 [pii]
AID - 10.1016/j.phymed.2020.153419 [doi]
PST - ppublish
SO  - Phytomedicine. 2021 Jan;81:153419. doi: 10.1016/j.phymed.2020.153419. Epub 2020 
      Dec 10.

PMID- 32400177
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 25
IP  - 5
DP  - 2020 Sep
TI  - Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older 
      Patients With Cancer.
PG  - 456-465
LID - 10.1177/1074248420925021 [doi]
AB  - BACKGROUND: Older patients with cancer are at high risk of developing venous 
      thromboembolism (VTE) and bleeding. Aspirin may decrease VTE in the general 
      population without significant bleeding. Here, we examined whether aspirin is 
      associated with reduced rates of VTE in older patients with cancer. METHODS AND 
      RESULTS: Using the National Inpatient Sample 2016, we retrospectively identified 
      a cohort of patients with cancer ≥65 years old who received aspirin and a similar 
      cohort who did not receive aspirin (n = 31 654, each). The cohorts were matched 
      for age, sex, race, patient demographics, insurance, hospital demographics, and 9 
      comorbidities (smoking, obesity, hypertension, hyperlipidemia, diabetes, chronic 
      kidney disease, chronic obstructive pulmonary disease, congestive heart failure, 
      and history of deep venous thrombosis [DVT]/pulmonary embolism [PE]). Primary 
      outcomes were discharge diagnosis of acute PE or acute DVT. Secondary outcomes 
      were inhospital mortality, bleeding, length of hospital stay (LOS), and total 
      hospitalization cost. The aspirin group, compared with the nonaspirin group, had 
      a significantly lower incidence of acute PE (matched, 2.1% vs 2.6%, P < .001), 
      acute DVT (matched, 2.3% vs 3.2%, P < .001), and inhospital mortality (matched 
      4.0% vs 6.5%, P < .001); shorter LOS (matched, 5.29 ± 5.01 vs 6.20 ± 6.56 days, P 
      < .001); and lower total costs (matched, US$14 700 ± 15 031 vs US$16 363 ± 20 
      219, P < .001). The primary and secondary outcomes were similar before and after 
      propensity matching. We found no increase in bleeding in the aspirin group 
      compared to the nonaspirin group: gastrointestinal bleeding (matched, 3.8% vs 
      4.0%, P= .168), hematuria (matched, 3.5% vs 3.7%, P = .102), hemoptysis (matched, 
      0.9% vs 0.9%, P = .532), and hemorrhagic stroke (matched, 0.8% vs 0.8%, P = 
      .443). In subgroup analyses, aspirin was associated with decreased inhospital 
      mortality, mostly in patients with lung, colon, pancreatic, prostate, breast 
      cancer, lymphoma, and leukemia. CONCLUSIONS: Among older patients with cancer, 
      aspirin was associated with lower VTE incidence and overall inhospital mortality 
      without significantly increased bleeding.
FAU - Li, Pengyang
AU  - Li P
AUID- ORCID: 0000-0003-2272-9102
AD  - Department of Medicine, Saint Vincent Hospital, Worcester, MA, USA.
FAU - Ning, Ying
AU  - Ning Y
AD  - Department of Medicine, Saint Vincent Hospital, Worcester, MA, USA.
FAU - Li, Mu
AU  - Li M
AD  - Department of Medicine, Saint Vincent Hospital, Worcester, MA, USA.
FAU - Cai, Peng
AU  - Cai P
AD  - Department of Mathematical Sciences, Worcester Polytechnic Institute, Worcester, 
      MA, USA.
FAU - Siddiqui, Ahmad Daniyal
AU  - Siddiqui AD
AD  - Department of Hematology and Oncology, Saint Vincent Hospital, Worcester, MA, 
      USA.
FAU - Liu, Eric Yang
AU  - Liu EY
AD  - College of Professional Studies, Northeastern University, Boston, MA, USA.
FAU - Hadley, Michelle
AU  - Hadley M
AD  - Department of Cardiology, Saint Vincent Hospital, Worcester, MA, USA.
FAU - Wu, Fangcheng
AU  - Wu F
AD  - Department of Medicine, Memorial Hospital West, Pembroke Pines, FL, USA.
FAU - Pan, Su
AU  - Pan S
AD  - Wafic Said Molecular Cardiology Research Laboratory, Texas Heart Institute, 
      Houston, TX, USA.
FAU - Dixon, Richard A F
AU  - Dixon RAF
AD  - Wafic Said Molecular Cardiology Research Laboratory, Texas Heart Institute, 
      Houston, TX, USA.
FAU - Liu, Qi
AU  - Liu Q
AD  - Wafic Said Molecular Cardiology Research Laboratory, Texas Heart Institute, 
      Houston, TX, USA.
LA  - eng
PT  - Journal Article
DEP - 20200513
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Databases, Factual
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Hospital Mortality
MH  - Humans
MH  - Incidence
MH  - Inpatients
MH  - Male
MH  - Neoplasms/diagnosis/*drug therapy/mortality
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - United States/epidemiology
MH  - Venous Thromboembolism/diagnosis/mortality/*prevention & control
OTO - NOTNLM
OT  - aspirin
OT  - cancer
OT  - deep vein thrombosis
OT  - pulmonary embolism
OT  - venous thromboembolism
EDAT- 2020/05/14 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1177/1074248420925021 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2020 Sep;25(5):456-465. doi: 
      10.1177/1074248420925021. Epub 2020 May 13.

PMID- 11159653
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20190501
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 322
IP  - 7282
DP  - 2001 Feb 10
TI  - Systematic review of long term anticoagulation or antiplatelet treatment in 
      patients with non-rheumatic atrial fibrillation.
PG  - 321-6
AB  - OBJECTIVE: To examine the benefits and risks of long term anticoagulation 
      (warfarin) compared with antiplatelet treatment (aspirin/indobufen) [corrected] 
      in patients with non-rheumatic atrial fibrillation. METHODS: Meta-analysis of 
      randomised controlled trials from Cochrane library, Medline, Embase, Cinhal, and 
      Sigle from 1966 to December 1999. Odds ratios (95% confidence intervals) 
      calculated to estimate treatment effects. OUTCOME MEASURES: Fatal and non-fatal 
      cardiovascular events, reductions of which were classified as benefits. Fatal and 
      major non-fatal bleeding events classified as risks. RESULTS: No trials were 
      found from before 1989. There were five randomised controlled trials published 
      between 1989-99. There were no significant differences in mortality between the 
      two treatment options (fixed effects model: odd ratio 0.74 (95% confidence 
      interval 0.39 to 1.40) for stroke deaths; 0.86 (0.63 to 1.17) for vascular 
      deaths). There was a borderline significant difference in non-fatal stroke in 
      favour of anticoagulation (0.68 (0.46 to 0.99)); and 0.75 (0.50 to 1.13) after 
      exclusion of one trial with weak methodological design. A random effects model 
      showed no significant difference in combined fatal and non-fatal events (odds 
      ratio 0.79 (0.61 to 1.02)). There were more major bleeding events among patients 
      on anticoagulation than on antiplatelet treatment (odds ratio 1.45 (0.93 to 
      2.27)). One trial was stopped prematurely after a significant difference in 
      favour of anticoagulation was observed. The only trial to show a significant 
      difference in effect (favouring anticoagulation) was methodologically weaker in 
      design than the others. CONCLUSIONS: The heterogeneity between the trials and the 
      limited data result in considerable uncertainty about the value of long term 
      anticoagulation compared with antiplatelet treatment. The risks of bleeding and 
      the higher cost of anticoagulation make it an even less convincing treatment 
      option.
FAU - Taylor, F C
AU  - Taylor FC
AD  - Bristol Heart Institute, University of Bristol, Bristol Royal Infirmary, Bristol 
      BS2 8HW. f.c.taylor@bristol.ac.uk
FAU - Cohen, H
AU  - Cohen H
FAU - Ebrahim, S
AU  - Ebrahim S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Anticoagulants)
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 6T9949G4LZ (indobufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 2001 Sep-Oct;135(2):60
EIN - BMJ. 2001 Mar 10;322(7286):587
CIN - BMJ. 2001 Jul 28;323(7306):233-4; author reply 235-6. PMID: 11496884
CIN - BMJ. 2001 Jul 28;323(7306):233; author reply 235-6. PMID: 11496885
CIN - BMJ. 2001 Jul 28;323(7306):234-5; author reply 235-6. PMID: 11496886
CIN - BMJ. 2001 Jul 28;323(7306):234; author reply 235-6. PMID: 11496887
CIN - BMJ. 2001 Jul 28;323(7306):234; author reply 235-6. PMID: 11496888
CIN - BMJ. 2001 Jul 28;323(7306):234; author reply 235-6. PMID: 11496889
CIN - BMJ. 2001 Jul 28;323(7306):235-6. PMID: 11496890
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Isoindoles
MH  - Phenylbutyrates/adverse effects/therapeutic use
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Treatment Outcome
MH  - Warfarin/adverse effects/therapeutic use
PMC - PMC26572
EDAT- 2001/02/13 11:00
MHDA- 2001/04/03 10:01
CRDT- 2001/02/13 11:00
PHST- 2001/02/13 11:00 [pubmed]
PHST- 2001/04/03 10:01 [medline]
PHST- 2001/02/13 11:00 [entrez]
AID - 10.1136/bmj.322.7282.321 [doi]
PST - ppublish
SO  - BMJ. 2001 Feb 10;322(7282):321-6. doi: 10.1136/bmj.322.7282.321.

PMID- 24834760
OWN - NLM
STAT- MEDLINE
DCOM- 20140530
LR  - 20181202
IS  - 1565-1088 (Print)
VI  - 16
IP  - 4
DP  - 2014 Apr
TI  - Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E 
      knockout mice.
PG  - 233-8
AB  - BACKGROUND: Atherosclerosis is a complex vascular inflammatory disease. In the 
      last decade it was suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) 
      and in particular inhibition of cyclooxygenase (COX)-2 are associated with an 
      increase in cardiovascular morbidity and mortality. Aspirin is known to reduce 
      the incidence and mortality from ischemic heart disease and is a mainstay in the 
      prevention of vascular complications of atherosclerosis. OBJECTIVES: To examine 
      the effect of meloxicam, a selective COX-2 inhibitor, or low dose aspirin on the 
      development of experimental atherosclerosis in apoE knockout (KO) compared to 
      wild-type (WT) mice. We aimed to test the hypothesis that meloxicam, a potential 
      vasculitis inducer, would exacerbate atherosclerotic lesions while aspirin, which 
      is known to reduce the incidence of thrombosis occlusive events, would increase 
      protection in this model. METHODS: We randomly divided 36 male apoE KO and 36 WT 
      mice, 8 weeks old. Mice were treated for 10 weeks with 0.1 mg/ml aspirin, or 0.05 
      mg/ml meloxicam, dissolved in their drinking water. Control groups received 
      regular drinking water. At sacrifice, the hearts were removed for histochemical 
      staining and plaque size and composition were examined. RESULTS: Aspirin-treated 
      animals displayed a decreased atherosclerotic lesion area compared to the 
      untreated control mice, while meloxicam had a null effect on the extent of 
      atherosclerosis in Apo E KO mice. CONCLUSIONS: These results suggest that low 
      dose aspirin reduces early atherosclerosis, while inhibition of COX-2 by 
      meloxicam is not associated with an increase in atherosclerotic plaque size in 
      this mouse model.
FAU - Kraus, Sarah
AU  - Kraus S
FAU - Naumov, Inna
AU  - Naumov I
FAU - Shapira, Shiran
AU  - Shapira S
FAU - Kazanov, Dina
AU  - Kazanov D
FAU - Aroch, Ilan
AU  - Aroch I
FAU - Afek, Arnon
AU  - Afek A
FAU - Eisenberg, Oded
AU  - Eisenberg O
FAU - George, Jacob
AU  - George J
FAU - Arber, Nadir
AU  - Arber N
FAU - Finkelstein, Ariel
AU  - Finkelstein A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Israel
TA  - Isr Med Assoc J
JT  - The Israel Medical Association journal : IMAJ
JID - 100930740
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Apolipoproteins E)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Thiazines)
RN  - 0 (Thiazoles)
RN  - R16CO5Y76E (Aspirin)
RN  - VG2QF83CGL (Meloxicam)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology
MH  - Apolipoproteins E/*genetics
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Atherosclerosis/*prevention & control
MH  - Cyclooxygenase 2 Inhibitors/*pharmacology
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Male
MH  - Meloxicam
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Plaque, Atherosclerotic/pathology/prevention & control
MH  - Thiazines/*pharmacology
MH  - Thiazoles/*pharmacology
EDAT- 2014/05/20 06:00
MHDA- 2014/05/31 06:00
CRDT- 2014/05/20 06:00
PHST- 2014/05/20 06:00 [entrez]
PHST- 2014/05/20 06:00 [pubmed]
PHST- 2014/05/31 06:00 [medline]
PST - ppublish
SO  - Isr Med Assoc J. 2014 Apr;16(4):233-8.

PMID- 1260111
OWN - NLM
STAT- MEDLINE
DCOM- 19760706
LR  - 20191028
IS  - 0306-042X (Print)
IS  - 0306-042X (Linking)
VI  - 3
IP  - 1
DP  - 1976 Feb
TI  - A new technique for the detection of metabolites labelled by the isotope 13C 
      using mass fragmentography.
PG  - 1-3
AB  - The detection of a small amount of 13C labelled methyl benzoate and its 
      metabolites in human urine dosed 13C labelled aspirin was carried out by a new 
      mass fragmentographic technique.
FAU - Sano, M
AU  - Sano M
FAU - Yotsui, Y
AU  - Yotsui Y
FAU - Abe, H
AU  - Abe H
FAU - Sasaki, S
AU  - Sasaki S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biomed Mass Spectrom
JT  - Biomedical mass spectrometry
JID - 0430246
RN  - 0 (Benzoates)
RN  - 0 (Carbon Isotopes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/urine
MH  - Benzoates/urine
MH  - *Carbon Isotopes
MH  - Chromatography, Gas/*methods
MH  - Gas Chromatography-Mass Spectrometry/*methods
MH  - Humans
MH  - *Isotope Labeling
EDAT- 1976/02/01 00:00
MHDA- 1976/02/01 00:01
CRDT- 1976/02/01 00:00
PHST- 1976/02/01 00:00 [pubmed]
PHST- 1976/02/01 00:01 [medline]
PHST- 1976/02/01 00:00 [entrez]
AID - 10.1002/bms.1200030102 [doi]
PST - ppublish
SO  - Biomed Mass Spectrom. 1976 Feb;3(1):1-3. doi: 10.1002/bms.1200030102.

PMID- 18612542
OWN - NLM
STAT- MEDLINE
DCOM- 20080829
LR  - 20151119
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 100
IP  - 1
DP  - 2008 Jul
TI  - Increased platelet sensitivity among individuals with aspirin resistance - 
      platelet aggregation to submaximal concentration of arachidonic acid predicts 
      response to antiplatelet therapy.
PG  - 83-9
LID - 10.1160/TH07-10-0590 [doi]
AB  - Aspirin 'resistance' (AR) is a phenomenon of uncertain etiology describing 
      decreased platelet inhibition by aspirin. We studied whether (i) platelets in AR 
      demonstrate increased basal sensitivity to a lower degree of stimulation and (ii) 
      platelet aggregation with submaximal stimulation could predict responses to 
      aspirin. Serum thromboxane B(2) (TxB(2)) levels and platelet aggregation with 
      light transmission aggregometry (LTA) were measured at baseline and 24 hours 
      after 325 mg aspirin administration in 58 healthy subjects. AR was defined as the 
      upper sixth of LTA (> or = 12%) to 1.5 mM AA. Baseline platelet aggregation with 
      submaximal concentrations of agonists [ADP 2 microM, arachidonic acid (AA) 0.75 
      mM, collagen 0.375 and 0.5 microg/ml] was greater in AR subjects compared with 
      non-AR subjects, but not with higher concentrations (ADP 5 microM and 20 microM, 
      AA 1.5 mM and collagen 1 microg/ml). Post-aspirin platelet aggregation was 
      elevated in AR subjects with both submaximal and maximal stimulation. Baseline 
      and post-aspirin serum TxB(2) were higher in AR subjects and decreased further 
      with ex-vivo COX-1 inhibition, suggesting incompletely suppressed COX-1 activity. 
      Pre-aspirin platelet aggregation to 0.75 AA demonstrated a dichotomous response 
      with 29/58 subjects having aggregation < or = 15% and 29/58 subjects having 
      aggregation > or = 75%. In the high aggregation group 28% had AR compared to 6% 
      in the non-AR group (p = 0.04). In conclusion, platelets in AR subjects 
      demonstrate increased basal sensitivity to submaximal stimulation, which could 
      predict responses to antiplatelet therapy.
FAU - Guthikonda, Sasidhar
AU  - Guthikonda S
AD  - Methodist DeBakey Heart Center, 6565 Fannin, F1090, Houston, TX 77030, USA.
FAU - Mangalpally, Kirankumar
AU  - Mangalpally K
FAU - Vaduganathan, Muthiah
AU  - Vaduganathan M
FAU - Patel, Rajnikant
AU  - Patel R
FAU - Delao, Timothy
AU  - Delao T
FAU - Bergeron, Angela L
AU  - Bergeron AL
FAU - Dong, Jing-Fei
AU  - Dong JF
FAU - Lev, Eli I
AU  - Lev EI
FAU - Kleiman, Neal S
AU  - Kleiman NS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Receptors, Thromboxane)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate
MH  - Adult
MH  - *Arachidonic Acid
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/metabolism
MH  - Collagen
MH  - Cyclooxygenase 1/blood
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Predictive Value of Tests
MH  - Receptors, Thromboxane/blood/drug effects
MH  - Reference Values
MH  - Thromboxane B2/blood
MH  - Treatment Failure
EDAT- 2008/07/10 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/07/10 09:00
PHST- 2008/07/10 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/10 09:00 [entrez]
AID - 08070083 [pii]
AID - 10.1160/TH07-10-0590 [doi]
PST - ppublish
SO  - Thromb Haemost. 2008 Jul;100(1):83-9. doi: 10.1160/TH07-10-0590.

PMID- 35471505
OWN - NLM
STAT- MEDLINE
DCOM- 20220428
LR  - 20221019
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 327
IP  - 16
DP  - 2022 Apr 26
TI  - Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force 
      Recommendation Statement.
PG  - 1577-1584
LID - 10.1001/jama.2022.4983 [doi]
AB  - IMPORTANCE: Cardiovascular disease (CVD) is the leading cause of mortality in the 
      US, accounting for more than 1 in 4 deaths. Each year, an estimated 605 000 
      people in the US have a first myocardial infarction and an estimated 610 000 
      experience a first stroke. OBJECTIVE: To update its 2016 recommendation, the US 
      Preventive Services Task Force (USPSTF) commissioned a systematic review on the 
      effectiveness of aspirin to reduce the risk of CVD events (myocardial infarction 
      and stroke), cardiovascular mortality, and all-cause mortality in persons without 
      a history of CVD. The systematic review also investigated the effect of aspirin 
      use on colorectal cancer (CRC) incidence and mortality in primary CVD prevention 
      populations, as well as the harms (particularly bleeding) associated with aspirin 
      use. The USPSTF also commissioned a microsimulation modeling study to assess the 
      net balance of benefits and harms from aspirin use for primary prevention of CVD 
      and CRC, stratified by age, sex, and CVD risk level. POPULATION: Adults 40 years 
      or older without signs or symptoms of CVD or known CVD (including history of 
      myocardial infarction or stroke) who are not at increased risk for bleeding (eg, 
      no history of gastrointestinal ulcers, recent bleeding, other medical conditions, 
      or use of medications that increase bleeding risk). EVIDENCE ASSESSMENT: The 
      USPSTF concludes with moderate certainty that aspirin use for the primary 
      prevention of CVD events in adults aged 40 to 59 years who have a 10% or greater 
      10-year CVD risk has a small net benefit. The USPSTF concludes with moderate 
      certainty that initiating aspirin use for the primary prevention of CVD events in 
      adults 60 years or older has no net benefit. RECOMMENDATION: The decision to 
      initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 
      to 59 years who have a 10% or greater 10-year CVD risk should be an individual 
      one. Evidence indicates that the net benefit of aspirin use in this group is 
      small. Persons who are not at increased risk for bleeding and are willing to take 
      low-dose aspirin daily are more likely to benefit. (C recommendation) The USPSTF 
      recommends against initiating low-dose aspirin use for the primary prevention of 
      CVD in adults 60 years or older. (D recommendation).
CN  - US Preventive Services Task Force
FAU - Davidson, Karina W
AU  - Davidson KW
AD  - Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New 
      York.
FAU - Barry, Michael J
AU  - Barry MJ
AD  - Harvard Medical School, Boston, Massachusetts.
FAU - Mangione, Carol M
AU  - Mangione CM
AD  - University of California, Los Angeles.
FAU - Cabana, Michael
AU  - Cabana M
AD  - Albert Einstein College of Medicine, New York, New York.
FAU - Chelmow, David
AU  - Chelmow D
AD  - Virginia Commonwealth University, Richmond.
FAU - Coker, Tumaini Rucker
AU  - Coker TR
AD  - University of Washington, Seattle.
FAU - Davis, Esa M
AU  - Davis EM
AD  - University of Pittsburgh, Pittsburgh, Pennsylvania.
FAU - Donahue, Katrina E
AU  - Donahue KE
AD  - University of North Carolina at Chapel Hill.
FAU - Jaén, Carlos Roberto
AU  - Jaén CR
AD  - University of Texas Health Science Center, San Antonio.
FAU - Krist, Alex H
AU  - Krist AH
AD  - Virginia Commonwealth University, Richmond.
AD  - Fairfax Family Practice Residency, Fairfax, Virginia.
FAU - Kubik, Martha
AU  - Kubik M
AD  - George Mason University, Fairfax, Virginia.
FAU - Li, Li
AU  - Li L
AD  - University of Virginia, Charlottesville.
FAU - Ogedegbe, Gbenga
AU  - Ogedegbe G
AD  - New York University, New York, New York.
FAU - Pbert, Lori
AU  - Pbert L
AD  - University of Massachusetts Medical School, Worcester.
FAU - Ruiz, John M
AU  - Ruiz JM
AD  - University of Arizona, Tucson.
FAU - Stevermer, James
AU  - Stevermer J
AD  - University of Missouri, Columbia.
FAU - Tseng, Chien-Wen
AU  - Tseng CW
AD  - University of Hawaii, Honolulu.
FAU - Wong, John B
AU  - Wong JB
AD  - Tufts University School of Medicine, Boston, Massachusetts.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PT  - Systematic Review
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- JAMA. 2022 Apr 26;327(16):1624. PMID: 35471511
CIN - JAMA. 2022 Apr 26;327(16):1552-1554. PMID: 35471530
CIN - Ann Intern Med. 2022 Sep;175(9):JC98. PMID: 36063559
MH  - Adult
MH  - *Aspirin/adverse effects/therapeutic use
MH  - *Cardiovascular Diseases/diagnosis/mortality/prevention & control
MH  - Colorectal Neoplasms/mortality/prevention & control
MH  - Computer Simulation
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/prevention & control
MH  - Primary Prevention
MH  - Risk Assessment
MH  - Stroke/drug therapy/prevention & control
EDAT- 2022/04/27 06:00
MHDA- 2022/04/29 06:00
CRDT- 2022/04/26 12:52
PHST- 2022/04/26 12:52 [entrez]
PHST- 2022/04/27 06:00 [pubmed]
PHST- 2022/04/29 06:00 [medline]
AID - 2791399 [pii]
AID - 10.1001/jama.2022.4983 [doi]
PST - ppublish
SO  - JAMA. 2022 Apr 26;327(16):1577-1584. doi: 10.1001/jama.2022.4983.

PMID- 1747136
OWN - NLM
STAT- MEDLINE
DCOM- 19920114
LR  - 20190717
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 34
IP  - 12
DP  - 1991 Dec
TI  - Aspirin alters methotrexate disposition in rheumatoid arthritis patients.
PG  - 1514-20
AB  - Intravenous methotrexate (MTX) (10 mg), either alone or with oral aspirin (ASA) 
      (3,900 mg/day), was administered to 15 patients with rheumatoid arthritis. 
      Systemic and renal clearance of MTX were lower, and the unbound fraction of MTX 
      was higher when patients were also receiving ASA than when taking MTX alone. No 
      acute hematologic, renal, or hepatic toxicity was observed with either treatment. 
      The findings of this study therefore indicate that concomitant aspirin therapy 
      acutely alters the clearance of low-dose MTX in patients with rheumatoid 
      arthritis.
FAU - Stewart, C F
AU  - Stewart CF
AD  - Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee, 
      Memphis 38163.
FAU - Fleming, R A
AU  - Fleming RA
FAU - Germain, B F
AU  - Germain BF
FAU - Seleznick, M J
AU  - Seleznick MJ
FAU - Evans, W E
AU  - Evans WE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Blood Proteins)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Arthritis, Rheumatoid/*metabolism
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Proteins/metabolism
MH  - Creatinine/blood
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Kidney/pathology
MH  - Male
MH  - Metabolic Clearance Rate/drug effects/physiology
MH  - Methotrexate/blood/*pharmacokinetics/urine
MH  - Middle Aged
MH  - Protein Binding
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
AID - 10.1002/art.1780341207 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1991 Dec;34(12):1514-20. doi: 10.1002/art.1780341207.

PMID- 29753643
OWN - NLM
STAT- MEDLINE
DCOM- 20190404
LR  - 20190404
IS  - 1934-8150 (Electronic)
IS  - 1551-7411 (Linking)
VI  - 15
IP  - 3
DP  - 2019 Mar
TI  - Evaluation of community pharmacists' preparedness for the provision of 
      cardiovascular disease risk assessment and management services: A study with 
      simulated patients.
PG  - 252-259
LID - S1551-7411(18)30064-0 [pii]
LID - 10.1016/j.sapharm.2018.04.032 [doi]
AB  - BACKGROUND: Individuals who suffer from major cardiovascular events every year 
      have one or more risk factors. Cardiovascular disease (CVD) risk assessment is an 
      important strategy for the early identification of modifiable risk factors and 
      their management. There is substantial evidence that shifting the focus from 
      treatment to primary prevention reduces the burden of CVD. OBJECTIVES: To 
      evaluate the preparedness of community pharmacists in Qatar for the provision of 
      CVD risk assessment and management services; and to explore the pharmacists' 
      views on the provision of these services. METHODS: A cross-sectional study using 
      simulated-client methodology. Using standardized scenarios, community pharmacists 
      were approached for consultation on two medicines (Aspirin(®) and Crestor(®)) 
      used for managing specific CVD risk factors. Pharmacists' competency to assess 
      CVD risk was the primary outcome evaluated. Scores for each outcome were obtained 
      based on the number of predefined statements addressed during the consultation. 
      RESULTS: The mean cumulative score for all the competency outcomes assessed was 
      11.7 (SD 3.7) out of a possible score of 31. There were no differences for the 
      majority of the competencies tested between the two scenarios used. Significantly 
      more pharmacists exposed to the Aspirin(®) scenario than to the Crestor(®) 
      scenario addressed hypertension as one of the risk factors needed to assess CVD 
      risk (22% versus 11%, p = 0.03); whereas significantly more pharmacists in the 
      Crestor(®) scenario compared to the Aspirin(®) scenario, addressed dyslipidemia 
      as one of the risk factors needed to assess CVD risk (30% versus 7%, p = 0.02). 
      Significantly more pharmacists exposed to the Aspirin(®) scenario provided 
      explanation about CVD risk than those exposed to the Crestor(®) scenario 36% 
      versus 8%, p < 0.01). CONCLUSION: The results suggest that many community 
      pharmacists in Qatar are not displaying competencies that are necessary for the 
      provision of CVD prevention services.
CI  - Copyright © 2018 Elsevier Inc. All rights reserved.
FAU - Zolezzi, Monica
AU  - Zolezzi M
AD  - College of Pharmacy Qatar University, Doha, Qatar. Electronic address: 
      mzolezzi@qu.edu.qa.
FAU - Abdallah, Oraib
AU  - Abdallah O
AD  - College of Pharmacy Qatar University, Doha, Qatar. Electronic address: 
      oraibamjed@gmail.com.
FAU - Kheir, Nadir
AU  - Kheir N
AD  - College of Pharmacy Qatar University, Doha, Qatar. Electronic address: 
      nadir.kheir@gmail.com.
FAU - Abdelsalam, Abdelsalam Gomaa
AU  - Abdelsalam AG
AD  - College of Arts and Sciences, Qatar University, Doha, Qatar. Electronic address: 
      abdo@qu.edu.qa.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20180428
PL  - United States
TA  - Res Social Adm Pharm
JT  - Research in social & administrative pharmacy : RSAP
JID - 101231974
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - *Clinical Competence
MH  - *Community Pharmacy Services
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Simulation
MH  - *Pharmacists
MH  - Primary Prevention
MH  - Professional Role
MH  - Qatar
MH  - *Risk Assessment
MH  - Rosuvastatin Calcium/therapeutic use
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Community pharmacy practice
OT  - Pharmacist preparedness
OT  - Risk assessment
OT  - Simulated patient
EDAT- 2018/05/14 06:00
MHDA- 2019/04/05 06:00
CRDT- 2018/05/14 06:00
PHST- 2018/01/29 00:00 [received]
PHST- 2018/04/22 00:00 [revised]
PHST- 2018/04/26 00:00 [accepted]
PHST- 2018/05/14 06:00 [pubmed]
PHST- 2019/04/05 06:00 [medline]
PHST- 2018/05/14 06:00 [entrez]
AID - S1551-7411(18)30064-0 [pii]
AID - 10.1016/j.sapharm.2018.04.032 [doi]
PST - ppublish
SO  - Res Social Adm Pharm. 2019 Mar;15(3):252-259. doi: 10.1016/j.sapharm.2018.04.032. 
      Epub 2018 Apr 28.

PMID- 28453510
OWN - NLM
STAT- MEDLINE
DCOM- 20170907
LR  - 20190208
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 4
DP  - 2017
TI  - Is aspirin associated with diabetic retinopathy? The Singapore Epidemiology of 
      Eye Disease (SEED) study.
PG  - e0175966
LID - 10.1371/journal.pone.0175966 [doi]
LID - e0175966
AB  - BACKGROUND/AIMS: To determine the association between aspirin use and diabetic 
      retinopathy (DR) among persons with diabetes, in a population-based, 
      cross-sectional study. METHODS: Subjects with diabetes aged >40 years from the 
      Singapore Epidemiology of Eye Diseases Study were enrolled in this study. Retinal 
      photographs were graded for DR according to the modified Airlie House 
      classification system. Vision threatening diabetic retinopathy (VTDR) was defined 
      as the presence of severe non-proliferative DR, or proliferative DR, or 
      clinically significant macular oedema. The association between aspirin use and 
      the presence of DR or VTDR was assessed using multivariable logistic regression 
      models including age, gender, ethnicity, socioeconomic status, HbA1c, systolic 
      blood pressure, anti-hypertension medicine, total cholesterol, anti-cholesterol 
      medicine, BMI, current smoking status, diabetes duration, history of 
      cardiovascular disease (CVD) and chronic kidney disease (CKD.). RESULTS: A total 
      of 2,061 participants with diabetes and complete record of relevant systemic and 
      DR data were included. Of these, 711 (34.5%) had any stage of DR, and among these 
      177 (8.6%) had VTDR. After adjusting for co-variables listed, the association 
      between aspirin use and VTDR was significant (OR = 1.69, P = 0.019), while the 
      association between aspirin use and any DR was borderline (OR = 1.31, P = 0.063). 
      Aspirin use was not associated with either DR or VTDR after additional adjustment 
      of CVD and CKD. Further stratification by history of CVD or CKD showed no 
      association between aspirin use and DR/VTDR in either subgroup. CONCLUSION: 
      Aspirin use was not significantly associated with DR but might be an indicator of 
      diabetic complications (CVD, CKD) that were co-present with more severe DR type. 
      Future longitudinal studies are warranted to confirm our findings.
FAU - Shi, Yuan
AU  - Shi Y
AUID- ORCID: 0000-0002-4600-0220
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, 
      Singapore.
FAU - Tham, Yih-Chung
AU  - Tham YC
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, 
      Singapore.
AD  - Department of Ophthalmology, Yong Loo Lin School of Medicine, National University 
      of Singapore, Singapore, Singapore.
FAU - Cheung, Ning
AU  - Cheung N
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, 
      Singapore.
FAU - Chua, Jacqueline
AU  - Chua J
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, 
      Singapore.
FAU - Tan, Gavin
AU  - Tan G
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, 
      Singapore.
FAU - Mitchell, Paul
AU  - Mitchell P
AD  - Centre for Vision Research, Department of Ophthalmology and Westmead Institute 
      for Medical Research, University of Sydeney, Sydeney, Australia.
FAU - Wang, Jie Jin
AU  - Wang JJ
AD  - Centre for Vision Research, Department of Ophthalmology and Westmead Institute 
      for Medical Research, University of Sydeney, Sydeney, Australia.
AD  - Duke-NUS Medical School, Singapore, Singapore.
FAU - Cheung, Yin Bun
AU  - Cheung YB
AD  - Duke-NUS Medical School, Singapore, Singapore.
AD  - Tampere Center for Child Health Research, University of Tampere and Tampere 
      University Hospital, Tampere, Finland.
FAU - Cheng, Ching-Yu
AU  - Cheng CY
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, 
      Singapore.
AD  - Department of Ophthalmology, Yong Loo Lin School of Medicine, National University 
      of Singapore, Singapore, Singapore.
AD  - Duke-NUS Medical School, Singapore, Singapore.
FAU - Wong, Tien Yin
AU  - Wong TY
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, 
      Singapore.
AD  - Department of Ophthalmology, Yong Loo Lin School of Medicine, National University 
      of Singapore, Singapore, Singapore.
AD  - Duke-NUS Medical School, Singapore, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20170428
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Diabetic Retinopathy/*chemically induced/*epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Regression Analysis
MH  - Singapore/epidemiology
PMC - PMC5409055
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2017/04/30 06:00
MHDA- 2017/09/08 06:00
CRDT- 2017/04/29 06:00
PHST- 2016/12/26 00:00 [received]
PHST- 2017/04/03 00:00 [accepted]
PHST- 2017/04/29 06:00 [entrez]
PHST- 2017/04/30 06:00 [pubmed]
PHST- 2017/09/08 06:00 [medline]
AID - PONE-D-16-51095 [pii]
AID - 10.1371/journal.pone.0175966 [doi]
PST - epublish
SO  - PLoS One. 2017 Apr 28;12(4):e0175966. doi: 10.1371/journal.pone.0175966. 
      eCollection 2017.

PMID- 17164387
OWN - NLM
STAT- MEDLINE
DCOM- 20070409
LR  - 20131121
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 15
IP  - 12
DP  - 2006 Dec
TI  - Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic 
      cancer: a meta-analysis.
PG  - 2561-4
AB  - BACKGROUND: The association between use of nonsteroidal anti-inflammatory drugs 
      (NSAID), including aspirin, and risk of pancreatic cancer is controversial. We 
      did a meta-analysis to summarize available evidence from epidemiologic studies 
      investigating the relation between use of aspirin or other NSAIDs and the risk of 
      pancreatic cancer. METHODS: We identified potential studies by searching the 
      MEDLINE database (from 1966 to October 2006) and by reviewing the reference lists 
      of pertinent publications. Studies were eligible for inclusion if they met the 
      following criteria: (a) had a case-control or prospective design, (b) examined 
      exposure to aspirin or NSAIDs, (c) the outcome was pancreatic cancer incidence or 
      mortality, and (d) they provided a relative risk (RR) estimate with corresponding 
      confidence interval or sufficient information to permit their calculation. 
      Study-specific RR estimates were pooled using a random effects model. RESULTS: A 
      total of 11 studies (3 case-control studies, 7 cohort studies, and 1 randomized 
      trial), involving 6,386 pancreatic cancer cases, was included in the 
      meta-analysis. The summary RR estimate did not indicate any association between 
      aspirin/NSAID use and risk of pancreatic cancer [any/regular use versus 
      nonregular/never use: RR, 1.01; 95% confidence interval (95% CI), 0.91-1.11; 
      P(heterogeneity) = 0.09]. Neither use of aspirin, nonaspirin NSAIDs, nor overall 
      NSAIDs were associated with pancreatic cancer risk. There was also no overall 
      association with frequent (six or more tablets/times per week versus none: RR, 
      0.86; 95% CI, 0.61-1.23) or long-term (>or=20 years) use of aspirin (RR, 1.21; 
      95% CI, 0.74-1.96). CONCLUSIONS: Current epidemiologic evidence does not indicate 
      that use of aspirin or NSAIDs is associated with the risk of pancreatic cancer.
FAU - Larsson, Susanna C
AU  - Larsson SC
AD  - Division of Nutritional Epidemiology, The National Institute of Environmental 
      Medicine, Karolinska Institutet, P.O. Box 210, SE-17177 Stockholm, Sweden. 
      susanna.larsson@ki.se
FAU - Giovannucci, Edward
AU  - Giovannucci E
FAU - Bergkvist, Leif
AU  - Bergkvist L
FAU - Wolk, Alicja
AU  - Wolk A
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Pancreatic Neoplasms/epidemiology/*prevention & control
MH  - Risk
MH  - Sweden/epidemiology
EDAT- 2006/12/14 09:00
MHDA- 2007/04/10 09:00
CRDT- 2006/12/14 09:00
PHST- 2006/12/14 09:00 [pubmed]
PHST- 2007/04/10 09:00 [medline]
PHST- 2006/12/14 09:00 [entrez]
AID - 15/12/2561 [pii]
AID - 10.1158/1055-9965.EPI-06-0574 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2561-4. doi: 
      10.1158/1055-9965.EPI-06-0574.

PMID- 2788004
OWN - NLM
STAT- MEDLINE
DCOM- 19890921
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 27
IP  - 5
DP  - 1989 May
TI  - Comparative analgesic and anti-inflammatory properties of sodium salicylate and 
      acetylsalicylic acid (aspirin) in rheumatoid arthritis.
PG  - 607-11
AB  - 1. Enteric coated sodium salicylate 4.8 g daily was compared with the same dose 
      of enteric coated aspirin in 18 patients with rheumatoid arthritis. 2. After an 
      initial washout period lasting 3 days, patients were randomly allocated to 
      treatment with sodium salicylate or aspirin. After 2 weeks the two treatments 
      were crossed over. 3. Pain relief, reduction in articular index of joint 
      tenderness, increase in grip strength, decrease in digital joint circumference 
      and patients' assessment showed significant improvement with both treatments 
      compared with the washout period. No significant differences were found between 
      the two therapies. 4. No correlation was found in the degree of improvement in 
      any of the clinical outcomes and the salicylate concentrations at steady state.
FAU - Preston, S J
AU  - Preston SJ
AD  - Florance and Cope Professorial Department of Rheumatology, University of Sydney, 
      Royal North Shore Hospital, St Leonards, New South Wales, Australia.
FAU - Arnold, M H
AU  - Arnold MH
FAU - Beller, E M
AU  - Beller EM
FAU - Brooks, P M
AU  - Brooks PM
FAU - Buchanan, W W
AU  - Buchanan WW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Adult
MH  - *Anti-Inflammatory Agents, Non-Steroidal
MH  - Arthritis, Rheumatoid/complications/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Sodium Salicylate/*therapeutic use
PMC - PMC1379926
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1989.tb03423.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1989 May;27(5):607-11. doi: 
      10.1111/j.1365-2125.1989.tb03423.x.

PMID- 25758347
OWN - NLM
STAT- MEDLINE
DCOM- 20151217
LR  - 20220129
IS  - 1743-9159 (Electronic)
IS  - 1743-9159 (Linking)
VI  - 17
DP  - 2015 May
TI  - An observational study investigating the effect of platelet function on outcome 
      after colorectal surgery.
PG  - 28-33
LID - S1743-9191(15)00079-5 [pii]
LID - 10.1016/j.ijsu.2015.02.023 [doi]
AB  - INTRODUCTION: Previous studies have assumed patients have uniform responses to 
      aspirin, yet significant numbers are occult hypo- or hyper-responders. A new 
      validated test of platelet function measures platelet P-selectin expression, 
      which rises with increased platelet activity. This study investigated the 
      measured perioperative changes in platelet function in response to aspirin, and 
      subsequently whether quantitative variations in platelet activity affected 
      perioperative complication severity and frequency. METHODS: 107 patients 
      undergoing major colorectal surgery were recruited and assigned to either control 
      (no antiplatelet therapy) or aspirin groups. P-selectin was measured following 
      platelet stimulation at recruitment prior to cessation of medication, and at 
      surgery before intervention. Perioperative complications, hemoglobin changes and 
      blood transfusions were also recorded. RESULTS: Platelet function was higher in 
      control (n = 87) than aspirin group (n = 20) at recruitment (median 1303u [IQR 
      1102-1499] vs 77u [IQR 63.5-113.5],P < 0.01) and surgery (median 1224u [IQR 
      944-1496] vs 281.5u [IQR 106.8-943], P < 0.01). There was a positive correlation 
      between length of aspirin cessation and platelet function at surgery 
      (R(S) = 0.66, P < 0.01). Complication rates and hemorrhagic complication rates 
      (P < 0.05) were higher with aspirin than control, although complication severity 
      was not increased. Platelet function of the entire cohort at surgery was not 
      associated with complication rate, severity or transfusion use. DISCUSSION: 
      Although complication rates were higher in aspirin group, impaired platelet 
      function within ranges seen with aspirin continuation did not affect complication 
      severity or rate or blood transfusion use. Consequently, aspirin continuation may 
      not affect clinical outcome in patients undergoing major colorectal surgery and 
      requires further investigation with a large randomized trial.
CI  - Copyright © 2015. Published by Elsevier Ltd.
FAU - Keeler, Barrie D
AU  - Keeler BD
AD  - Division of Gastrointestinal Surgery, University of Nottingham, Queen's Medical 
      Centre, Derby Road, Nottingham NG7 2UH, UK; Department of Gastrointestinal 
      Surgery, Nottingham University Hospitals NHS Trust, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK. Electronic address: barriekeeler@doctors.org.uk.
FAU - Simpson, J Alastair
AU  - Simpson JA
AD  - Division of Gastrointestinal Surgery, University of Nottingham, Queen's Medical 
      Centre, Derby Road, Nottingham NG7 2UH, UK; Department of Gastrointestinal 
      Surgery, Nottingham University Hospitals NHS Trust, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Fox, Susan C
AU  - Fox SC
AD  - Division of Cardiovascular Medicine University of Nottingham, Queen's Medical 
      Centre, Derby Road, Nottingham NG7 2UH, UK.
FAU - Stavrou, Christiana L
AU  - Stavrou CL
AD  - Division of Gastrointestinal Surgery, University of Nottingham, Queen's Medical 
      Centre, Derby Road, Nottingham NG7 2UH, UK; Division of Cardiovascular Medicine 
      University of Nottingham, Queen's Medical Centre, Derby Road, Nottingham NG7 2UH, 
      UK.
FAU - Briggs, Rebecca A
AU  - Briggs RA
AD  - Division of Gastrointestinal Surgery, University of Nottingham, Queen's Medical 
      Centre, Derby Road, Nottingham NG7 2UH, UK; Division of Cardiovascular Medicine 
      University of Nottingham, Queen's Medical Centre, Derby Road, Nottingham NG7 2UH, 
      UK.
FAU - Patel, Priya
AU  - Patel P
AD  - Division of Gastrointestinal Surgery, University of Nottingham, Queen's Medical 
      Centre, Derby Road, Nottingham NG7 2UH, UK; Division of Cardiovascular Medicine 
      University of Nottingham, Queen's Medical Centre, Derby Road, Nottingham NG7 2UH, 
      UK.
FAU - Heptinstall, Stanley
AU  - Heptinstall S
AD  - Division of Cardiovascular Medicine University of Nottingham, Queen's Medical 
      Centre, Derby Road, Nottingham NG7 2UH, UK.
FAU - Acheson, Austin G
AU  - Acheson AG
AD  - Division of Gastrointestinal Surgery, University of Nottingham, Queen's Medical 
      Centre, Derby Road, Nottingham NG7 2UH, UK; Department of Gastrointestinal 
      Surgery, Nottingham University Hospitals NHS Trust, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
LA  - eng
GR  - MC_G0900866/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Observational Study
DEP - 20150307
PL  - United States
TA  - Int J Surg
JT  - International journal of surgery (London, England)
JID - 101228232
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Blood Coagulation Tests
MH  - Blood Platelets/drug effects/*physiology
MH  - *Colorectal Surgery
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Thrombosis/blood/*prevention & control
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Bleeding
OT  - Blood transfusion
OT  - Colorectal surgery
OT  - Perioperative care
OT  - Platelet activation
OT  - Postoperative complications
EDAT- 2015/03/12 06:00
MHDA- 2015/12/19 06:00
CRDT- 2015/03/12 06:00
PHST- 2014/08/07 00:00 [received]
PHST- 2015/02/08 00:00 [revised]
PHST- 2015/02/28 00:00 [accepted]
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
AID - S1743-9191(15)00079-5 [pii]
AID - 10.1016/j.ijsu.2015.02.023 [doi]
PST - ppublish
SO  - Int J Surg. 2015 May;17:28-33. doi: 10.1016/j.ijsu.2015.02.023. Epub 2015 Mar 7.

PMID- 37201625
OWN - NLM
STAT- MEDLINE
DCOM- 20230605
LR  - 20230605
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 951
DP  - 2023 Jul 15
TI  - Effects of long-term regular oral aspirin combined with atorvastatin to prevent 
      ischemic stroke on human gut microbiota.
PG  - 175800
LID - S0014-2999(23)00311-4 [pii]
LID - 10.1016/j.ejphar.2023.175800 [doi]
AB  - PURPOSE: Every year, there is a large number of people take aspirin and 
      atorvastatin to prevent ischemic stroke, but the effect of these drugs on gut 
      microbiota remains unknown. We aimed to examine the effects of long-term regular 
      oral aspirin with atorvastatin to prevent ischemic stroke on human gut 
      microbiota. METHODS: A cross-sectional study of 20 participants with the drugs 
      over one year and the other 20 gender- and age-matching participants without 
      medication were recruited from the Affiliated Hospital of Guizhou Medical 
      University. The medication habits and dietary information were obtained using a 
      questionnaire. Fecal samples collected from all participants were subjected to 
      16S rRNA sequencing of the microbiome. The datasets were analyzed using 
      bioinformatics approaches. RESULTS: The Alpha diversity showed that compared with 
      controls, medication participants had lower ACE and Chao1 index, while no 
      difference in the Shannon index and Simpson index. The Beta diversity analysis 
      revealed significant shifts in the taxonomic compositions of the two groups. 
      Linear discriminant analysis effect size (LEfSe) analysis combined with receiver 
      operating characteristic (ROC) curves revealed the marker bacteria associated 
      with taking medication were g_Parabacteroides（AUC = 0.855）, 
      g_Bifidobacterium（AUC = 0.815）, s_Bifidobacterium_longum_subsp（AUC = 0.8075）, and 
      with no taking medication was g_Prevotella_9（AUC = 0.76）. CONCLUSIONS: Our 
      findings indicated that long-term regular oral aspirin and atorvastatin modulate 
      the human gut microbiota. Taking these drugs may affect the preventive effect of 
      ischemic stroke by changing the abundance of specific gut microbiota.
CI  - Copyright © 2023. Published by Elsevier B.V.
FAU - Chen, Guangtang
AU  - Chen G
AD  - Department of Neurosurgery, Affiliated Hospital of Guizhou Medical University, 
      Guiyang, China. Electronic address: 18286089635@163.com.
FAU - Wang, Zili
AU  - Wang Z
AD  - Department of Neurosurgery, Affiliated Hospital of Guizhou Medical University, 
      Guiyang, China.
FAU - Song, Wenxue
AU  - Song W
AD  - School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
FAU - Liao, Yidong
AU  - Liao Y
AD  - School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
FAU - Wang, Xudong
AU  - Wang X
AD  - School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
FAU - Chen, Chen
AU  - Chen C
AD  - School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
FAU - Ming, Jiang
AU  - Ming J
AD  - School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
FAU - Cui, Junshuan
AU  - Cui J
AD  - Department of Neurosurgery, Affiliated Hospital of Guizhou Medical University, 
      Guiyang, China.
FAU - Xu, Kaya
AU  - Xu K
AD  - Department of Neurosurgery, Affiliated Hospital of Guizhou Medical University, 
      Guiyang, China. Electronic address: xkaya@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20230517
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - A0JWA85V8F (Atorvastatin)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (RNA, Ribosomal, 16S)
SB  - IM
MH  - Humans
MH  - *Gastrointestinal Microbiome
MH  - Atorvastatin/pharmacology/therapeutic use
MH  - *Ischemic Stroke/prevention & control
MH  - Aspirin/therapeutic use
MH  - RNA, Ribosomal, 16S/genetics
MH  - Cross-Sectional Studies
OTO - NOTNLM
OT  - Aspirin
OT  - Atorvastatin
OT  - Gut microbiota
OT  - Ischemic stroke
COIS- Declaration of competing interest No potential conflict of interest was reported 
      by all authors.
EDAT- 2023/05/19 01:04
MHDA- 2023/06/05 06:43
CRDT- 2023/05/18 19:25
PHST- 2022/12/19 00:00 [received]
PHST- 2023/05/07 00:00 [revised]
PHST- 2023/05/16 00:00 [accepted]
PHST- 2023/06/05 06:43 [medline]
PHST- 2023/05/19 01:04 [pubmed]
PHST- 2023/05/18 19:25 [entrez]
AID - S0014-2999(23)00311-4 [pii]
AID - 10.1016/j.ejphar.2023.175800 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2023 Jul 15;951:175800. doi: 10.1016/j.ejphar.2023.175800. Epub 
      2023 May 17.

PMID- 28717966
OWN - NLM
STAT- MEDLINE
DCOM- 20180801
LR  - 20181113
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 44
IP  - 3
DP  - 2017 Oct
TI  - Association between aspirin use and deep venous thrombosis in mechanically 
      ventilated ICU patients.
PG  - 330-334
LID - 10.1007/s11239-017-1525-x [doi]
AB  - Deep venous thrombosis (DVT) is common in intensive care unit (ICU) patients. It 
      is often silent and may be complicated by pulmonary embolism and death. 
      Thromboprophylaxis with heparin does not always prevent venous thromboembolism 
      (VTE). Aspirin (ASA) reduces the risk of VTE in surgical and high-risk medical 
      patients but it is unknown if ASA may prevent DVT in mechanically ventilated ICU 
      patients. We performed a retrospective chart review of critically ill patients 
      who received mechanical ventilation for >72 h and underwent venous 
      ultrasonography for suspected DVT between Jan 2012 and Dec 2013. We excluded 
      patients who were on therapeutic doses of anticoagulation or had coagulopathy. We 
      used multivariable logistic regression to evaluate association between aspirin 
      use and DVT during hospitalization. There were 193 patients. The mean ± SD age 
      was 58 ± 15.7 years. Half were male. DVT was found in 49 (25.4%). DVT was found 
      in the first 15 days of hospitalization in 67.3% of the patients. The majority 
      (82.8%) received thromboprophylaxis with unfractionated or low molecular weight 
      heparin. Fifty-six (29%) were on ASA. On multivariable regression analysis, ASA 
      use was associated with a significant reduction in the odds of finding DVT (OR 
      0.39, 95% CI 0.16-0.94; p = 0.036). DVT is common in mechanically ventilated ICU 
      patients despite the use of thromboprophylaxis. Aspirin may prevent DVT in such 
      patients.
FAU - Gupta, Ena
AU  - Gupta E
AUID- ORCID: 0000-0002-5287-299X
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Thomas Jefferson Medical 
      College, 834 Walnut Street, Suite 650, Philadelphia, PA, 19107, USA. 
      enagupta8@gmail.com.
FAU - Siddiqi, Furqan S
AU  - Siddiqi FS
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, 
      Jacksonville, FL, USA.
FAU - Kunjal, Ryan
AU  - Kunjal R
AD  - Department of Medicine, University of Florida, Jacksonville, FL, USA.
FAU - Faisal, Muhammad
AU  - Faisal M
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, 
      Jacksonville, FL, USA.
FAU - Al-Saffar, Farah
AU  - Al-Saffar F
AD  - Division of Cardiology, Mayo Clinic, Scottsdale, AZ, USA.
FAU - Bajwa, Abubakr A
AU  - Bajwa AA
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, 
      Jacksonville, FL, USA.
FAU - Jones, Lisa M
AU  - Jones LM
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, 
      Jacksonville, FL, USA.
FAU - Seeram, Vandana
AU  - Seeram V
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, 
      Jacksonville, FL, USA.
FAU - Cury, James D
AU  - Cury JD
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, 
      Jacksonville, FL, USA.
FAU - Shujaat, Adil
AU  - Shujaat A
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University at Buffalo, 
      SUNY, Buffalo, USA.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - *Intensive Care Units
MH  - Male
MH  - Middle Aged
MH  - Premedication
MH  - Regression Analysis
MH  - Respiration, Artificial/*adverse effects
MH  - Retrospective Studies
MH  - Venous Thrombosis/*prevention & control
OTO - NOTNLM
OT  - Aspirin
OT  - Deep venous thrombosis
OT  - Heparin
OT  - Intensive care unit
OT  - Thromboprophylaxis
OT  - Venous thromboembolism
EDAT- 2017/07/19 06:00
MHDA- 2018/08/02 06:00
CRDT- 2017/07/19 06:00
PHST- 2017/07/19 06:00 [pubmed]
PHST- 2018/08/02 06:00 [medline]
PHST- 2017/07/19 06:00 [entrez]
AID - 10.1007/s11239-017-1525-x [pii]
AID - 10.1007/s11239-017-1525-x [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2017 Oct;44(3):330-334. doi: 10.1007/s11239-017-1525-x.

PMID- 26330204
OWN - NLM
STAT- MEDLINE
DCOM- 20160602
LR  - 20220321
IS  - 1469-4409 (Electronic)
IS  - 0950-2688 (Print)
IS  - 0950-2688 (Linking)
VI  - 144
IP  - 4
DP  - 2016 Mar
TI  - Low-dose aspirin use does not diminish the immune response to monovalent H1N1 
      influenza vaccine in older adults.
PG  - 768-71
LID - 10.1017/S0950268815002058 [doi]
AB  - Non-steroidal anti-inflammatory drugs (NSAIDs) may inhibit antibody production by 
      peripheral blood mononuclear cells; one consequence of this could be decreased 
      effectiveness of vaccines in NSAID users. Because many older adults use low-dose 
      aspirin for primary or secondary prevention of coronary events, any inhibitory 
      effect of aspirin on vaccine immune response could reduce the benefits of 
      vaccination programmes in older adults. We tested whether immune response to 
      vaccination differed between users vs. non-users of low-dose aspirin, using data 
      from four randomized trials of monovalent 2009 pandemic influenza A(H1N1) 
      vaccine. Geometric mean haemagglutination inhibition antibody titres were not 
      significantly lower in low-dose aspirin users compared to non-users. Our results 
      provide reassurance that influenza vaccination effectiveness is probably not 
      reduced in older adults taking chronic low-dose aspirin.
FAU - Jackson, M L
AU  - Jackson ML
AD  - Group Health Research Institute,Seattle,WA,USA.
FAU - Bellamy, A
AU  - Bellamy A
AD  - The EMMES Corporation,Rockville MD,USA.
FAU - Wolff, M
AU  - Wolff M
AD  - The EMMES Corporation,Rockville MD,USA.
FAU - Hill, H
AU  - Hill H
AD  - The EMMES Corporation,Rockville MD,USA.
FAU - Jackson, L A
AU  - Jackson LA
AD  - Group Health Research Institute,Seattle,WA,USA.
LA  - eng
GR  - HHSN272200800004C/AI/NIAID NIH HHS/United States
GR  - HHSN272200800004C/PHS HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
DEP - 20150902
PL  - England
TA  - Epidemiol Infect
JT  - Epidemiology and infection
JID - 8703737
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Influenza Vaccines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*immunology
MH  - Antibodies, Viral/blood
MH  - Aspirin/administration & dosage/*immunology
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Influenza A Virus, H1N1 Subtype/*immunology
MH  - Influenza Vaccines/*immunology
MH  - Influenza, Human/*therapy
MH  - Middle Aged
PMC - PMC4737981
MID - NIHMS726884
OTO - NOTNLM
OT  - Anti-inflammatory agents
OT  - human influenza
OT  - non-steroidal
OT  - vaccines
COIS- Conflicts of Interest: The authors report no conflicts of interest.
EDAT- 2015/09/04 06:00
MHDA- 2016/06/03 06:00
PMCR- 2017/03/01
CRDT- 2015/09/03 06:00
PHST- 2017/03/01 00:00 [pmc-release]
PHST- 2015/09/03 06:00 [entrez]
PHST- 2015/09/04 06:00 [pubmed]
PHST- 2016/06/03 06:00 [medline]
AID - S0950268815002058 [pii]
AID - 10.1017/S0950268815002058 [doi]
PST - ppublish
SO  - Epidemiol Infect. 2016 Mar;144(4):768-71. doi: 10.1017/S0950268815002058. Epub 
      2015 Sep 2.

PMID- 3056785
OWN - NLM
STAT- MEDLINE
DCOM- 19890111
LR  - 20131121
IS  - 0016-867X (Print)
IS  - 0016-867X (Linking)
VI  - 43 Suppl
DP  - 1988 Dec
TI  - Antiplatelet therapy for ischemic heart disease in the elderly.
PG  - 46-56
AB  - A vast experience has developed defining an important role for blood platelets in 
      the etiology of atherosclerotic coronary disease. Antiplatelet drugs such as 
      aspirin have major therapeutic applications in various ischemic heart disease 
      syndromes. Areas of proven efficacy for antiplatelet therapy include maintenance 
      of saphenous vein graft patency and prevention of myocardial infarction and death 
      in patients with unstable angina and in survivors of myocardial infarction. Other 
      less-defined applications include primary prevention and use during acute 
      myocardial infarction with and without thrombolysis. The issues of antiplatelet 
      efficacy in women, drug doses, and risk of toxicity need further clarification.
FAU - Frishman, W H
AU  - Frishman WH
AD  - Albert Einstein College of Medicine, Bronx, New York.
FAU - Miller, K P
AU  - Miller KP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Geriatrics
JT  - Geriatrics
JID - 2985102R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Coronary Artery Bypass
MH  - Coronary Disease/*drug therapy/prevention & control
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Vascular Patency/drug effects
RF  - 106
EDAT- 1988/12/01 00:00
MHDA- 1988/12/01 00:01
CRDT- 1988/12/01 00:00
PHST- 1988/12/01 00:00 [pubmed]
PHST- 1988/12/01 00:01 [medline]
PHST- 1988/12/01 00:00 [entrez]
PST - ppublish
SO  - Geriatrics. 1988 Dec;43 Suppl:46-56.

PMID- 25467021
OWN - NLM
STAT- MEDLINE
DCOM- 20150601
LR  - 20181202
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 158
DP  - 2014
TI  - [Added value of clopidogrel in cardiology and neurology].
PG  - A7609
AB  - Platelet aggregation inhibitors reduce the risk of complications during and after 
      acute coronary syndromes and after a TIA or stroke. Acetylsalicylic acid plays a 
      major role in secondary prevention; the combination of acetylsalicylic acid and a 
      platelet ADP receptor antagonist, such as clopidogrel, may have added value. In 
      percutaneous coronary intervention, dual platelet inhibition appears to be 
      effective in the prevention of stent thrombosis. Long-term (> 1 year) use of dual 
      platelet inhibition has an unfavourable risk-benefit profile, partly due to an 
      increase in the number of bleeding events, particularly in the stomach. The use 
      of the combination of acetylsalicylic acid and clopidogrel may be helpful after a 
      TIA or minor stroke, but further research is needed to identify the group of 
      patients for whom this combination would be applicable. This article provides an 
      overview of the modern cardiological and neurological indications for platelet 
      inhibition as well as the risk factors for severe bleeding events when using dual 
      antiplatelet therapy.
FAU - Verheugt, Freek W A
AU  - Verheugt FW
AD  - Onze Lieve Vrouwe Gasthuis, Amsterdam.
FAU - Geersing, Geert-Jan
AU  - Geersing GJ
FAU - Kappelle, L Jaap
AU  - Kappelle LJ
LA  - dut
PT  - Journal Article
PT  - Review
TT  - Toegevoegde waarde van clopidogrel in cardiologie en neurologie.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/prevention & control
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - *Secondary Prevention
MH  - Stroke/prevention & control
MH  - Thrombosis/prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
EDAT- 2014/12/04 06:00
MHDA- 2015/06/02 06:00
CRDT- 2014/12/04 06:00
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2015/06/02 06:00 [medline]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2014;158:A7609.

PMID- 22161466
OWN - NLM
STAT- MEDLINE
DCOM- 20120403
LR  - 20131121
IS  - 1526-4564 (Electronic)
IS  - 1526-4564 (Linking)
VI  - 29
IP  - 6
DP  - 2011 Nov
TI  - Testing for inherited thrombophilia in recurrent miscarriage.
PG  - 540-7
LID - 10.1055/s-0031-1293207 [doi]
AB  - Approximately 1-5% of women trying to conceive experience recurrent miscarriage, 
      and in 50% of these women, the cause of the preceding miscarriages is unknown. 
      Inherited thrombophilias such as factor V Leiden mutation, prothrombin gene 
      mutation (PT 20210A), and deficiencies of natural anticoagulants protein C, 
      protein S, and antithrombin are associated with recurrent miscarriage. Knowledge 
      of the association between inherited thrombophilia and recurrent miscarriage and 
      of potential treatment options for improving chances of a live birth could tempt 
      physicians to test for inherited thrombophilia in women with recurrent 
      miscarriage. However, the strength of the association between inherited 
      thrombophilia and recurrent miscarriage is not very strong, and more importantly, 
      no evidence indicates that the use of anticoagulants improves the chance of live 
      birth in these women. With the current state of evidence, testing for inherited 
      thrombophilia should not lead to altered clinical management and therefore, 
      should not be performed routinely in women with recurrent miscarriage but only in 
      the context of scientific studies.
CI  - © Thieme Medical Publishers.
FAU - de Jong, Paulien G
AU  - de Jong PG
AD  - Department of Vascular Medicine, Center for Reproductive Medicine, Academic 
      Medical Center, Amsterdam, The Netherlands. p.g.dejong@amc.uva.nl
FAU - Goddijn, Mariëtte
AU  - Goddijn M
FAU - Middeldorp, Saskia
AU  - Middeldorp S
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20111208
PL  - United States
TA  - Semin Reprod Med
JT  - Seminars in reproductive medicine
JID - 100909394
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - Thrombophilia, hereditary
SB  - IM
MH  - Abortion, Habitual/drug therapy/*genetics/metabolism
MH  - Aspirin/adverse effects/therapeutic use
MH  - Female
MH  - Heparin/adverse effects/therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - *Thrombophilia/complications/diagnosis/drug therapy/genetics/physiopathology
MH  - Venous Thromboembolism/genetics/physiopathology
EDAT- 2011/12/14 06:00
MHDA- 2012/04/04 06:00
CRDT- 2011/12/14 06:00
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/04/04 06:00 [medline]
AID - 10.1055/s-0031-1293207 [doi]
PST - ppublish
SO  - Semin Reprod Med. 2011 Nov;29(6):540-7. doi: 10.1055/s-0031-1293207. Epub 2011 
      Dec 8.

PMID- 37233144
OWN - NLM
STAT- MEDLINE
DCOM- 20230529
LR  - 20230531
IS  - 1538-7488 (Electronic)
IS  - 0002-936X (Linking)
VI  - 123
IP  - 6
DP  - 2023 Jun 1
TI  - Aspirin Noninferior to Low-Molecular-Weight Heparin for Thromboprophylaxis After 
      Fracture.
PG  - 63
LID - 10.1097/01.NAJ.0000938752.92385.07 [doi]
AB  - According to this study: Thromboprophylaxis with aspirin was noninferior to 
      low-molecular-weight heparin for preventing fatal events in patients with 
      orthopedic trauma.The incidence of deep vein thrombosis, pulmonary embolism, and 
      death at 90 days was low in both groups.
CI  - Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Rosenberg, Karen
AU  - Rosenberg K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Nurs
JT  - The American journal of nursing
JID - 0372646
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Humans
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Aspirin/adverse effects
MH  - Anticoagulants/adverse effects
MH  - *Venous Thrombosis/drug therapy/prevention & control
MH  - *Venous Thromboembolism/prevention & control
EDAT- 2023/05/26 13:09
MHDA- 2023/05/29 06:42
CRDT- 2023/05/26 09:53
PHST- 2023/05/29 06:42 [medline]
PHST- 2023/05/26 13:09 [pubmed]
PHST- 2023/05/26 09:53 [entrez]
AID - 00000446-202306000-00026 [pii]
AID - 10.1097/01.NAJ.0000938752.92385.07 [doi]
PST - ppublish
SO  - Am J Nurs. 2023 Jun 1;123(6):63. doi: 10.1097/01.NAJ.0000938752.92385.07.

PMID- 29853716
OWN - NLM
STAT- MEDLINE
DCOM- 20191018
LR  - 20191018
IS  - 1827-6806 (Print)
IS  - 1827-6806 (Linking)
VI  - 19
IP  - 5
DP  - 2018 May
TI  - [ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term 
      antiplatelet therapy in patients with coronary artery disease].
PG  - 263-331
LID - 10.1714/2907.29280 [doi]
AB  - Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is 
      the cornerstone of the pharmacologic management of patients with acute coronary 
      syndrome (ACS) and/or receiving coronary stents. Long-term (>1 year) DAPT may 
      further reduce the risk of stent thrombosis after percutaneous coronary 
      intervention (PCI) and may decrease the occurrence of non-stent-related ischemic 
      events in patients with ACS. Nevertheless, compared with aspirin alone, extended 
      use of aspirin plus a P2Y12 receptor inhibitor may increase the risk of bleeding 
      events that have been strongly linked to adverse outcomes including recurrent 
      ischemia, repeat hospitalization, and death. Over the last years, multiple 
      randomized clinical trials have been published comparing duration of DAPT after 
      PCI and in ACS patients investigating either a shorter or prolonged DAPT 
      regimen.Although current European Society of Cardiology guidelines provide backup 
      to individualize treatment, it seems difficult to identify the ideal patient 
      profile who could safely reduce or prolong DAPT duration in daily clinical 
      practice. The aim of this consensus document is to review the contemporary 
      literature on optimal DAPT duration and to guide clinicians in tailoring 
      antiplatelet strategies in patients undergoing PCI or presenting with ACS.
FAU - Gulizia, Michele Massimo
AU  - Gulizia MM
AD  - U.O.C. Cardiologia, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e 
      Alta Specializzazione "Garibaldi", Catania.
FAU - Colivicchi, Furio
AU  - Colivicchi F
AD  - U.O.C. Cardiologia e UTIC, Presidio Ospedaliero San Filippo Neri, Roma.
FAU - Abrignani, Maurizio Giuseppe
AU  - Abrignani MG
AD  - U.O.C. Cardiologia e UTIC, Ospedale Civile Sant'Antonio Abate, Erice (TP).
FAU - Ambrosetti, Marco
AU  - Ambrosetti M
AD  - Servizio di Cardiologia Riabilitativa, Clinica Le Terrazze, Cunardo (VA).
FAU - Aspromonte, Nadia
AU  - Aspromonte N
AD  - U.O. Scompenso e Riabilitazione Cardiologica, Polo di Scienze Cardiovascolari e 
      Toraciche, Policlinico Agostino Gemelli, Roma.
FAU - Barile, Gabriella
AU  - Barile G
AD  - Poliambulatorio ASL RM C/D11, Roma.
FAU - Caporale, Roberto
AU  - Caporale R
AD  - U.O.C. Cardiologia Interventistica, Ospedale Annunziata, Cosenza.
FAU - Casolo, Giancarlo
AU  - Casolo G
AD  - S.C. Cardiologia, Nuovo Ospedale Versilia, Lido di Camaiore (LU).
FAU - Chiuini, Emilia
AU  - Chiuini E
AD  - Specialista Ambulatoriale Cardiologo, ASL Umbria 1, Perugia.
FAU - Di Lenarda, Andrea
AU  - Di Lenarda A
AD  - S.C. Cardiovascolare e Medicina dello Sport, Azienda Sanitaria Universitaria 
      Integrata di Trieste.
FAU - Faggiano, Pompilio
AU  - Faggiano P
AD  - U.O. Cardiologia, Spedali Civili, Brescia.
FAU - Gabrielli, Domenico
AU  - Gabrielli D
AD  - ASUR Marche - Area Vasta 4 Fermo, Ospedale Civile Augusto Murri, Fermo.
FAU - Geraci, Giovanna
AU  - Geraci G
AD  - U.O.C. Cardiologia, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo.
FAU - La Manna, Alessio Gaetano
AU  - La Manna AG
AD  - Divisione di Cardiologia, A.O.U. Policlinico Vittorio Emanuele, Catania.
FAU - Maggioni, Aldo Pietro
AU  - Maggioni AP
AD  - Centro Studi ANMCO della Fondazione per il Tuo Cuore, Firenze.
FAU - Marchese, Alfredo
AU  - Marchese A
AD  - U.O.C. Cardiologia Interventistica, GVM Care & Research Ospedale Santa Maria, 
      Bari.
FAU - Massari, Ferdinando Maria
AU  - Massari FM
AD  - U.O.C. Malattie Cardiovascolari, Fondazione IRCCS Ca' Granda, Ospedale Maggiore 
      Policlinico, Milano.
FAU - Mureddu, Gian Francesco
AU  - Mureddu GF
AD  - U.O.C. Cardiologia 2, A.O. San Giovanni Addolorata, Roma.
FAU - Musumeci, Giuseppe
AU  - Musumeci G
AD  - S.C. Cardiologia, A.S.O. Santa Croce e Carle, Cuneo.
FAU - Nardi, Federico
AU  - Nardi F
AD  - S.C. Cardiologia, Ospedale Santo Spirito, Casale Monferrato (AL).
FAU - Panno, Antonio Vittorio
AU  - Panno AV
AD  - Convenzione USL 6, Palermo.
FAU - Pedretti, Roberto Franco Enrico
AU  - Pedretti RFE
AD  - Dipartimento di Cardiologia Riabilitativa, Istituti Clinici Scientifici Maugeri, 
      IRCCS, Pavia.
FAU - Piredda, Massimo
AU  - Piredda M
AD  - Divisione di Cardiologia, Centro Cardiotoracico, Istituto Clinico Sant'Ambrogio, 
      Milano.
FAU - Pusineri, Enrico
AU  - Pusineri E
AD  - U.O.C. Cardiologia, Ospedale Civile di Vigevano, ASST, Pavia.
FAU - Riccio, Carmine
AU  - Riccio C
AD  - Prevenzione e Riabilitazione Cardiopatico, A.O. Sant'Anna e San Sebastiano, 
      Caserta.
FAU - Rossini, Roberta
AU  - Rossini R
AD  - S.C. Cardiologia, A.S.O. Santa Croce e Carle, Cuneo.
FAU - Scotto Di Uccio, Fortunato
AU  - Scotto Di Uccio F
AD  - U.O. Cardiologia e UTIC, Ospedale Loreto Mare, ASL NA 1, Napoli.
FAU - Urbinati, Stefano
AU  - Urbinati S
AD  - U.O.C. Cardiologia, Ospedale Bellaria, AUSL di Bologna, Bologna.
FAU - Varbella, Ferdinando
AU  - Varbella F
AD  - S.C. Cardiologia, Ospedali Riuniti di Rivoli, Rivoli (TO).
FAU - Zito, Giovanni Battista
AU  - Zito GB
AD  - Ambulatorio di Cardiologia, ASL Napoli 3 Sud, Pompei (NA).
FAU - De Luca, Leonardo
AU  - De Luca L
AD  - U.O.C. Cardiologia, Ospedale San Giovanni Evangelista, Tivoli (RM).
LA  - ita
PT  - Journal Article
PT  - Practice Guideline
TT  - Documento di consenso intersocietario ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: La 
      terapia antiaggregante a lungo termine nel paziente con malattia coronarica.
PL  - Italy
TA  - G Ital Cardiol (Rome)
JT  - Giornale italiano di cardiologia (2006)
JID - 101263411
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/therapy
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Coronary Artery Disease/*therapy
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/pharmacology
MH  - Purinergic P2Y Receptor Antagonists/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Stents
MH  - Time Factors
EDAT- 2018/06/02 06:00
MHDA- 2019/10/19 06:00
CRDT- 2018/06/02 06:00
PHST- 2018/06/02 06:00 [entrez]
PHST- 2018/06/02 06:00 [pubmed]
PHST- 2019/10/19 06:00 [medline]
AID - 10.1714/2907.29280 [doi]
PST - ppublish
SO  - G Ital Cardiol (Rome). 2018 May;19(5):263-331. doi: 10.1714/2907.29280.

PMID- 19695361
OWN - NLM
STAT- MEDLINE
DCOM- 20090915
LR  - 20181201
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 104
IP  - 5 Suppl
DP  - 2009 Sep 7
TI  - Platelet-directed therapies and coronary artery bypass grafting.
PG  - 44C-8C
LID - 10.1016/j.amjcard.2009.06.015 [doi]
AB  - Coronary artery bypass grafting (CABG) is effective in reducing cardiovascular 
      morbidity and mortality in certain high-risk groups. Despite improvement in 
      surgical technique, hemorrhagic complications are a major concern and are likely 
      to affect perioperative morbidity and mortality, length of stay, and hospital 
      expenditures. The use of platelet-directed therapies in this setting is effective 
      in decreasing ischemic complications, yet these agents simultaneously increase 
      the risk of bleeding. Concern about potential hemorrhagic risk from antiplatelet 
      agents in proximity to CABG may influence physicians to discontinue these agents. 
      The benefit of low-dose aspirin given preoperatively is likely to outweigh any 
      hemorrhagic risk. Dual antiplatelet therapy with aspirin and clopidogrel (or 
      aspirin and prasugrel) is associated with a significant increased risk of 
      bleeding and its complications. Additional research is needed to properly 
      evaluate the ischemic benefit versus bleeding risk of aspirin and clopidogrel. 
      Whether reversible P2Y(12) receptor antagonists will mitigate the bleeding risk 
      is unclear at the present time and will require large prospective studies.
FAU - Berger, Jeffrey S
AU  - Berger JS
AD  - Department of Medicine, New York University School of Medicine, 530 First Avenue, 
      New York, NY 10016, USA. jeffrey.berger@nyumc.org
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - *Coronary Artery Bypass
MH  - Humans
MH  - Myocardial Infarction/*therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
RF  - 23
EDAT- 2009/08/27 09:00
MHDA- 2009/09/16 06:00
CRDT- 2009/08/22 09:00
PHST- 2009/08/22 09:00 [entrez]
PHST- 2009/08/27 09:00 [pubmed]
PHST- 2009/09/16 06:00 [medline]
AID - S0002-9149(09)01200-4 [pii]
AID - 10.1016/j.amjcard.2009.06.015 [doi]
PST - ppublish
SO  - Am J Cardiol. 2009 Sep 7;104(5 Suppl):44C-8C. doi: 10.1016/j.amjcard.2009.06.015.

PMID- 9553645
OWN - NLM
STAT- MEDLINE
DCOM- 19980529
LR  - 20190921
IS  - 1046-7408 (Print)
IS  - 1046-7408 (Linking)
VI  - 39
IP  - 4
DP  - 1998 Apr
TI  - The use of combined heparin/aspirin and immunoglobulin G therapy in the treatment 
      of in vitro fertilization patients with antithyroid antibodies.
PG  - 223-5
AB  - PROBLEM: To compare the effect of heparin/aspirin therapy alone vs. 
      heparin/aspirin in combination with intravenous immuno-globulin (IVIg) 
      immunotherapy on in vitro fertilization (IVF) outcome of patients who test 
      positive for antithyroid antibodies (ATAs). METHOD OF STUDY: Eighty-two women 
      younger than 40 years of age whose infertility was related exclusively to female 
      causes were evaluated. All tested positive for organ-specific antithyroid 
      antibodies (antimicrosomal and/or antithyroglobulin antibodies), but negative for 
      antiphospholipid antibodies. Thirty-seven of these women (group A) received H/A 
      alone, whereas 45 (group B) received heparin/aspirin in combination with IVIg. 
      RESULTS: Ten (27%) of women in group A and 23 (51%) of women in group B achieved 
      live births after completion of a single IVF/embryo transfer cycle (P = 0.027). 
      CONCLUSION: We conclude that IVIg therapy significantly improves IVF success 
      rates in ATA+ women.
FAU - Sher, G
AU  - Sher G
AD  - Pacific Fertility Medical Centers of California, Los Angeles 90024, USA.
FAU - Maassarani, G
AU  - Maassarani G
FAU - Zouves, C
AU  - Zouves C
FAU - Feinman, M
AU  - Feinman M
FAU - Sohn, S
AU  - Sohn S
FAU - Matzner, W
AU  - Matzner W
FAU - Chong, P
AU  - Chong P
FAU - Ching, W
AU  - Ching W
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - 0 (Immunoglobulin G)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - *Embryo Transfer
MH  - Female
MH  - Fertilization in Vitro
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Infertility, Female/*drug therapy
MH  - Pregnancy
MH  - Prospective Studies
MH  - Thyroid Gland/*immunology
EDAT- 1998/04/29 00:00
MHDA- 1998/04/29 00:01
CRDT- 1998/04/29 00:00
PHST- 1998/04/29 00:00 [pubmed]
PHST- 1998/04/29 00:01 [medline]
PHST- 1998/04/29 00:00 [entrez]
AID - 10.1111/j.1600-0897.1998.tb00357.x [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 1998 Apr;39(4):223-5. doi: 
      10.1111/j.1600-0897.1998.tb00357.x.

PMID- 25744739
OWN - NLM
STAT- MEDLINE
DCOM- 20151125
LR  - 20181202
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 79
IP  - 2
DP  - 2015
TI  - Dual antiplatelet therapy for coronary artery disease.
PG  - 255-62
LID - 10.1253/circj.CJ-14-1348 [doi]
AB  - Platelets initiate the formation of a thrombus at the site of an arterial injury, 
      and the clotting cascade is activated as the thrombus matures. After coronary 
      stent placement, dual antiplatelet therapy (DAPT) with aspirin and ticlopidine 
      dramatically reduces the risk of stent thrombosis, compared with anticoagulation 
      therapy, and has become the standard of care for prevention of stent thrombosis. 
      Clopidogrel is a second-generation thienopyridine that eliminates the serious 
      side effects of ticlopidine, and new P2Y12 receptor blockers have emerged to 
      overcome the limitations of clopidogrel. Current guidelines recommend DAPT with 
      aspirin and clopidogrel for 1 month after implantation of bare-metal stents, and 
      for 6-12 months after implantation of drug-eluting stents (DES). In patients with 
      acute coronary syndrome (ACS), DAPT administration for 12 months was shown to be 
      superior to aspirin alone for the prevention of recurrent events. Treatment with 
      aspirin and new P2Y12 receptor blockers has further reduced the rate of 
      cardiovascular death, myocardial infarction or stroke after ACS compared with 
      aspirin and clopidogrel. Nonetheless, long-term DAPT increases the risk of major 
      bleeding, requiring a delicate balance between anti-ischemic benefit and bleeding 
      risk. In summary, DAPT should be maintained for at least 6-12 months after 
      implantation of DES, and for at least 12 months after ACS, unless 
      contraindicated.
FAU - Lee, Cheol Whan
AU  - Lee CW
AD  - Division of Cardiology, Heart Institute, Asan Medical Center, University of 
      Ulsan, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150107
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - Coronary Artery Disease/*therapy
MH  - Drug Therapy, Combination/methods
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Stents
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2015/03/07 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/03/07 06:00
PHST- 2015/03/07 06:00 [entrez]
PHST- 2015/03/07 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1253/circj.CJ-14-1348 [doi]
PST - ppublish
SO  - Circ J. 2015;79(2):255-62. doi: 10.1253/circj.CJ-14-1348. Epub 2015 Jan 7.

PMID- 18495263
OWN - NLM
STAT- MEDLINE
DCOM- 20090130
LR  - 20131121
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 129
IP  - 2
DP  - 2008 Sep 26
TI  - The benefit of aspirin therapy in type 2 diabetes: what is the evidence?
PG  - 172-9
LID - 10.1016/j.ijcard.2008.01.030 [doi]
AB  - Many clinical guidelines recommend aspirin therapy for the prevention of 
      cardiovascular events in individuals with type 2 diabetes. However it is unclear 
      whether the level of evidence in guidelines is derived from studies carried out 
      among individuals with diabetes. Medline and Embase databases were searched to 
      retrieve studies published since 1990, evaluating the effect of aspirin on 
      cardiovascular outcomes in subjects with type 2 diabetes. Four studies 
      corresponded to the inclusion criteria. The three clinical trials retrieved could 
      not prove from a statistical point of view, the benefits of aspirin therapy for 
      subjects with type 2 diabetes. Reduction in cardiac mortality was found only in 
      one observational study. Consequently, these findings suggest that the clinical 
      guidelines have based their recommendations upon the expected benefit previously 
      observed in other high-risk populations. Given the lack of hard evidence and the 
      different well-known platelet physiology encountered in patients with diabetes, 
      use of aspirin as a standard treatment at the highest level of evidence in 
      guidelines for subjects with type 2 diabetes should be revisited.
FAU - Sirois, Caroline
AU  - Sirois C
AD  - Faculté de pharmacie, Université Laval, Québec, Canada.
FAU - Poirier, Paul
AU  - Poirier P
FAU - Moisan, Jocelyne
AU  - Moisan J
FAU - Grégoire, Jean-Pierre
AU  - Grégoire JP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20080520
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy/etiology/*prevention & control
MH  - Diabetes Complications/drug therapy/*prevention & control
MH  - Diabetes Mellitus, Type 2/*complications/physiopathology
MH  - Disease Progression
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Practice Guidelines as Topic
RF  - 50
EDAT- 2008/05/23 09:00
MHDA- 2009/01/31 09:00
CRDT- 2008/05/23 09:00
PHST- 2007/05/04 00:00 [received]
PHST- 2007/10/11 00:00 [revised]
PHST- 2008/01/14 00:00 [accepted]
PHST- 2008/05/23 09:00 [pubmed]
PHST- 2009/01/31 09:00 [medline]
PHST- 2008/05/23 09:00 [entrez]
AID - S0167-5273(08)00332-X [pii]
AID - 10.1016/j.ijcard.2008.01.030 [doi]
PST - ppublish
SO  - Int J Cardiol. 2008 Sep 26;129(2):172-9. doi: 10.1016/j.ijcard.2008.01.030. Epub 
      2008 May 20.

PMID- 18451657
OWN - NLM
STAT- MEDLINE
DCOM- 20080729
LR  - 20190805
IS  - 0302-5144 (Print)
IS  - 0302-5144 (Linking)
VI  - 161
DP  - 2008
TI  - Trends in medication use and clinical outcomes in twelve countries: results form 
      the Dialysis Outcomes and Practice Patterns Study (DOPPS).
PG  - 48-54
LID - 10.1159/000129753 [doi]
AB  - The Dialysis Outcomes and Practice Patterns Study (DOPPS) was designed to 
      identify clinical practices of hemodialysis associated with patients longevity. 
      For more than 10 years, DOPPS has been collecting detailed information on 
      patients and facility characteristics from 12 countries across the world. 
      Multiple aspects of clinical care in hemodialysis may be associated with improved 
      outcomes. However, changes in many practices are hard to implement. One practice 
      that can be relatively easier to modify is the physician prescription of 
      medications. The associations between medication prescription and outcomes have 
      been the object of several DOPPS publications. We present here a brief summary of 
      DOPPS findings on prescription of several classes of medications and clinical 
      outcomes.
FAU - Tentori, Francesca
AU  - Tentori F
AD  - Arbor Research Collaborative for Health, Ann Arbor, Mich., USA.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Contrib Nephrol
JT  - Contributions to nephrology
JID - 7513582
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Longevity
MH  - *Practice Patterns, Physicians'
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - *Renal Dialysis
MH  - Treatment Outcome
EDAT- 2008/05/03 09:00
MHDA- 2008/07/30 09:00
CRDT- 2008/05/03 09:00
PHST- 2008/05/03 09:00 [pubmed]
PHST- 2008/07/30 09:00 [medline]
PHST- 2008/05/03 09:00 [entrez]
AID - 000129753 [pii]
AID - 10.1159/000129753 [doi]
PST - ppublish
SO  - Contrib Nephrol. 2008;161:48-54. doi: 10.1159/000129753.

PMID- 6651815
OWN - NLM
STAT- MEDLINE
DCOM- 19840127
LR  - 20131121
IS  - 0232-766X (Print)
IS  - 0232-766X (Linking)
VI  - 42
IP  - 7-8
DP  - 1983
TI  - [Distribution of salicylic acid and hydrolysis of acetylsalicylic acid in the 
      human fetus in early pregnancy].
PG  - 997-1004
AB  - The materno-fetal transfer of salicylic acid and its distribution in the fetal 
      organism was investigated in women of early pregnancy. Acetylsalicylic acid 
      (Acesal) was administered orally in a single dose or in repeated doses at 
      different times before legal interruption. The mean passage rates were about 
      6-15%. They were independent of the maternal serum concentrations of salicylic 
      acid. The distribution of salicylic acid on the fetal liver, intestine, kidneys, 
      lungs and brain was different. All fetal organs (9th to 15th week of gestation) 
      studied exhibit an acetylsalicylic acid-splitting esterase activity. The esterase 
      activity of the fetal liver was about 30% of the hydrolytic activity of the adult 
      liver. The esterase activity was mainly located in the 105 000 X g-supernatant of 
      cell homogenates.
FAU - Amon, I
AU  - Amon I
FAU - Zschiesche, A
AU  - Zschiesche A
FAU - Amon, K
AU  - Amon K
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Verteilung von Salizylsäure und Hydrolyse der Azetylsalizylsäure bei menschlichen 
      Feten in der Frühschwangerschaft.
PL  - Germany
TA  - Biomed Biochim Acta
JT  - Biomedica biochimica acta
JID - 8304435
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*metabolism
MH  - Female
MH  - Fetus/*metabolism
MH  - Humans
MH  - Hydrolysis
MH  - Maternal-Fetal Exchange
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Salicylates/*metabolism
MH  - Salicylic Acid
MH  - Tissue Distribution
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Biomed Biochim Acta. 1983;42(7-8):997-1004.

PMID- 882843
OWN - NLM
STAT- MEDLINE
DCOM- 19770917
LR  - 20190907
IS  - 0036-553X (Print)
IS  - 0036-553X (Linking)
VI  - 19
IP  - 1
DP  - 1977 Jul
TI  - Effects of acute myocardial ischaemia on platelet aggregation in the coronary 
      sinus and aorta in dogs.
PG  - 68-74
AB  - The effect of an acute myocardial ischaemia on circulating platelet aggregates 
      (CPA) in the coronary sinus and aorta was studied in open chest dogs. Even before 
      induction of myocardial ischaemia significantly more CPA were found in the 
      coronary sinus than in the aorta. Acute myocardial ischaemia produced by a 
      non-thrombotic coronary artery occlusion increased CPA in coronary sinus, but not 
      in aorta. Administration of acetylsalicylic acid (ASA) reduced the extent of the 
      myocardial ischaemia as evidenced by reduced ST-segment elevations in epicardial 
      ECG. Before induction of myocardial ischaemia, ASA significantly reduced CPA in 
      coronary sinus, but no significant effect was observed during myocardial 
      ischaemia. In the aorta no effect of ASA on CPA was found.
FAU - Vik-Mo, H
AU  - Vik-Mo H
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Scand J Haematol
JT  - Scandinavian journal of haematology
JID - 0404507
RN  - 0 (Fatty Acids, Nonesterified)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Aorta
MH  - Aspirin/pharmacology
MH  - Blood Cell Count
MH  - Coronary Disease/*blood
MH  - Coronary Vessels
MH  - Dogs
MH  - Fatty Acids, Nonesterified/blood
MH  - Female
MH  - Male
MH  - *Platelet Aggregation/drug effects
EDAT- 1977/07/01 00:00
MHDA- 1977/07/01 00:01
CRDT- 1977/07/01 00:00
PHST- 1977/07/01 00:00 [pubmed]
PHST- 1977/07/01 00:01 [medline]
PHST- 1977/07/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1977.tb02720.x [doi]
PST - ppublish
SO  - Scand J Haematol. 1977 Jul;19(1):68-74. doi: 10.1111/j.1600-0609.1977.tb02720.x.

PMID- 960008
OWN - NLM
STAT- MEDLINE
DCOM- 19761029
LR  - 20131121
IS  - 0040-3709 (Print)
IS  - 0040-3709 (Linking)
VI  - 14
IP  - 1
DP  - 1976 Aug
TI  - Teratogenicity studies with methotrexate, aminopterin, and acetylsalicylic acid 
      in domestic cats.
PG  - 21-7
AB  - Pregnancy was timed in cats following induced ovulation. Methotrexate, (0.5 
      mg/kg), aminopterin, (0.1 mg/kg), and acetylsalicylic acid, (25 or 50 mg/kg) were 
      administered orally in gelatin capsules in single daily doses on different days 
      of gestation, methotrexate (MTX) on days 11-14, 14-17, or 17-20, aminopterin on 
      day 12, 14, or 16, and acetylsalicylic acid (ASA) on days 10-15 or 15-20. 
      Maternal toxicity was produced only by MTX. MTX given on days 11-14 and 14-17 
      produced high frequencies of malformations including umbilical hernia. 
      Aminopterin caused no conclusive teratogenic response. An overall increased 
      frequency of anomalies occurred after 50 mg/kg ASA but no single anomaly 
      predominated.
FAU - Khera, K S
AU  - Khera KS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Teratology
JT  - Teratology
JID - 0153257
RN  - 0 (Teratogens)
RN  - JYB41CTM2Q (Aminopterin)
RN  - R16CO5Y76E (Aspirin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - *Abnormalities, Drug-Induced
MH  - Aminopterin/*adverse effects
MH  - Animals
MH  - Aspirin/*adverse effects
MH  - Cats
MH  - Female
MH  - Methotrexate/*adverse effects
MH  - *Teratogens
MH  - Time Factors
EDAT- 1976/08/01 00:00
MHDA- 1976/08/01 00:01
CRDT- 1976/08/01 00:00
PHST- 1976/08/01 00:00 [pubmed]
PHST- 1976/08/01 00:01 [medline]
PHST- 1976/08/01 00:00 [entrez]
AID - 10.1002/tera.1420140104 [doi]
PST - ppublish
SO  - Teratology. 1976 Aug;14(1):21-7. doi: 10.1002/tera.1420140104.

PMID- 25139873
OWN - NLM
STAT- MEDLINE
DCOM- 20150126
LR  - 20161122
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 45
IP  - 10
DP  - 2014 Oct
TI  - Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc 
      analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA 
      Thrombolysis in Ischemic Stroke trial.
PG  - 3080-2
LID - 10.1161/STROKEAHA.114.006268 [doi]
AB  - BACKGROUND AND PURPOSE: Aspirin early after intravenous thrombolysis in acute 
      ischemic stroke increases the risk of symptomatic intracranial hemorrhage (SICH), 
      without influencing functional outcome at 3 months. The effect of aspirin on 
      early neurological deterioration (END) was explored as a post hoc analysis of the 
      randomized Antiplatelet Therapy in Combination With Recombinant t-PA Thrombolysis 
      in Ischemic Stroke (ARTIS) trial. METHODS: END, defined as a ≥4 points National 
      Institutes of Health Stroke Scale worsening ≤24 hours after intravenous 
      thrombolysis, was categorized into SICH (ENDSICH) and cerebral ischemia (ENDCI). 
      Multinomial logistic regression was used to assess the effect of aspirin on END. 
      RESULTS: Of the 640 patients, 31 patients (4.8%) experienced END (14 ENDSICH, 17 
      ENDCI). Aspirin increased the risk of ENDSICH (odds ratio, 3.73; 95% confidence 
      interval, 1.03-13.49) but not of ENDCI (odds ratio, 1.14; 95% confidence 
      interval, 0.44-3.00). After adjustment for other explanatory variables, the 
      association between aspirin and ENDSICH remained significant. CONCLUSIONS: In 
      this trial, there is no evidence of an early antithrombotic effect from the 
      addition of aspirin to intravenous thrombolysis in acute ischemic stroke.
CI  - © 2014 American Heart Association, Inc.
FAU - Zinkstok, Sanne M
AU  - Zinkstok SM
AD  - From the Departments of Neurology (S.M.Z., Y.B.R.), Radiology (L.F.B., C.B.M., 
      H.A.M.), Biomedical Engineering and Physics (H.A.M.), and the Clinical Research 
      Unit (R.J.d.H.), Academic Medical Center University, Amsterdam, The Netherlands.
FAU - Beenen, Ludo F
AU  - Beenen LF
AD  - From the Departments of Neurology (S.M.Z., Y.B.R.), Radiology (L.F.B., C.B.M., 
      H.A.M.), Biomedical Engineering and Physics (H.A.M.), and the Clinical Research 
      Unit (R.J.d.H.), Academic Medical Center University, Amsterdam, The Netherlands.
FAU - Majoie, Charles B
AU  - Majoie CB
AD  - From the Departments of Neurology (S.M.Z., Y.B.R.), Radiology (L.F.B., C.B.M., 
      H.A.M.), Biomedical Engineering and Physics (H.A.M.), and the Clinical Research 
      Unit (R.J.d.H.), Academic Medical Center University, Amsterdam, The Netherlands.
FAU - Marquering, Henk A
AU  - Marquering HA
AD  - From the Departments of Neurology (S.M.Z., Y.B.R.), Radiology (L.F.B., C.B.M., 
      H.A.M.), Biomedical Engineering and Physics (H.A.M.), and the Clinical Research 
      Unit (R.J.d.H.), Academic Medical Center University, Amsterdam, The Netherlands.
FAU - de Haan, Rob J
AU  - de Haan RJ
AD  - From the Departments of Neurology (S.M.Z., Y.B.R.), Radiology (L.F.B., C.B.M., 
      H.A.M.), Biomedical Engineering and Physics (H.A.M.), and the Clinical Research 
      Unit (R.J.d.H.), Academic Medical Center University, Amsterdam, The Netherlands.
FAU - Roos, Yvo B
AU  - Roos YB
AD  - From the Departments of Neurology (S.M.Z., Y.B.R.), Radiology (L.F.B., C.B.M., 
      H.A.M.), Biomedical Engineering and Physics (H.A.M.), and the Clinical Research 
      Unit (R.J.d.H.), Academic Medical Center University, Amsterdam, The Netherlands. 
      y.b.roos@amc.uva.nl.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140819
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Humans
MH  - Intracranial Hemorrhages/*chemically induced/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Stroke/*drug therapy
MH  - Thrombolytic Therapy
MH  - Tissue Plasminogen Activator/*administration & dosage
OTO - NOTNLM
OT  - aspirin
OT  - safety
OT  - stroke
OT  - thrombolytic therapy
EDAT- 2014/08/21 06:00
MHDA- 2015/01/27 06:00
CRDT- 2014/08/21 06:00
PHST- 2014/08/21 06:00 [entrez]
PHST- 2014/08/21 06:00 [pubmed]
PHST- 2015/01/27 06:00 [medline]
AID - STROKEAHA.114.006268 [pii]
AID - 10.1161/STROKEAHA.114.006268 [doi]
PST - ppublish
SO  - Stroke. 2014 Oct;45(10):3080-2. doi: 10.1161/STROKEAHA.114.006268. Epub 2014 Aug 
      19.

PMID- 9417588
OWN - NLM
STAT- MEDLINE
DCOM- 19971229
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 127
IP  - 40
DP  - 1997 Oct 4
TI  - [Advances in therapy and prevention of ischemic myocardial infarct].
PG  - 1663-6
AB  - In the acute stage of stroke, fibrinolytics are beneficial for up to 3, and in 
      some patients up to 6, hours. If fibrinolytics are contraindicated, aspirin 
      should be given. Heparin is dangerous due to the threat of intra- and 
      extracranial hemorrhage. For secondary prevention, anticoagulants are indicated. 
      When hypercholesterolemia is present, statins should be given.
FAU - Mattle, H P
AU  - Mattle HP
AD  - Neurologische Universitätsklinik, Inselspital Bern.
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Neues in der Therapie und Prophylaxe des ischämischen Hirninfarkts.
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - Cerebral Infarction/*drug therapy/etiology/prevention & control
MH  - Clinical Trials as Topic
MH  - Drug Interactions
MH  - Fibrinolytic Agents/administration & dosage/adverse effects
MH  - Heparin/administration & dosage/adverse effects
MH  - Humans
MH  - Risk Factors
RF  - 18
EDAT- 1998/01/07 00:00
MHDA- 1998/01/07 00:01
CRDT- 1998/01/07 00:00
PHST- 1998/01/07 00:00 [pubmed]
PHST- 1998/01/07 00:01 [medline]
PHST- 1998/01/07 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1997 Oct 4;127(40):1663-6.

PMID- 4352868
OWN - NLM
STAT- MEDLINE
DCOM- 19731005
LR  - 20190511
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 47
IP  - 2
DP  - 1973 Feb
TI  - Inhibition of functional vasodilatation and prostaglandin formation in rabbit 
      adipose tissue by indomethacin and aspirin.
PG  - 305-14
AB  - 1. The epigastric adipose depot of rabbits has been used to examine the effect of 
      indomethacin, aspirin and nicotinic acid on the free fatty acid release and blood 
      flow in fat tissue.2. The prostaglandin formation which occurs in adipose tissue 
      during lipolysis is prevented by indomethacin and aspirin. The corresponding 
      functional vasodilatation which occurs after infusions of lipolytic substances is 
      also abolished by these two anti-inflammatory compounds.3. This finding is 
      consistent with the theory that prostaglandin E(2) is the mediator of functional 
      vasodilatation in adipose tissue.4. Nicotinic acid sometimes inhibits the release 
      of free fatty acids from adipose tissue by preventing activation of the tissue 
      lipase. In those experiments in which this inhibition occurred, the 
      vasodilatation was also prevented.5. This finding is consistent with the view 
      that the prostaglandin E(2) which mediates the functional vasodilatation, 
      originates in the triglycerides of the fat tissue.
FAU - Bowery, B
AU  - Bowery B
FAU - Lewis, G P
AU  - Lewis GP
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Prostaglandins)
RN  - 0 (Vasodilator Agents)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adipose Tissue/analysis/drug effects/*metabolism
MH  - Adrenocorticotropic Hormone/pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Flow Velocity
MH  - Blood Pressure/drug effects
MH  - Depression, Chemical
MH  - Fatty Acids, Nonesterified/isolation & purification/metabolism
MH  - Ileum/drug effects
MH  - In Vitro Techniques
MH  - Indomethacin/administration & dosage/*pharmacology
MH  - Male
MH  - Prostaglandins/*biosynthesis/pharmacology
MH  - Rabbits
MH  - Time Factors
MH  - Vasodilator Agents/*antagonists & inhibitors
PMC - PMC1776566
EDAT- 1973/02/01 00:00
MHDA- 1973/02/01 00:01
CRDT- 1973/02/01 00:00
PHST- 1973/02/01 00:00 [pubmed]
PHST- 1973/02/01 00:01 [medline]
PHST- 1973/02/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1973.tb08328.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1973 Feb;47(2):305-14. doi: 10.1111/j.1476-5381.1973.tb08328.x.

PMID- 28664658
OWN - NLM
STAT- MEDLINE
DCOM- 20180726
LR  - 20180726
IS  - 1365-2885 (Electronic)
IS  - 0140-7783 (Linking)
VI  - 41
IP  - 1
DP  - 2018 Feb
TI  - Effects of aspirin dose escalation on platelet function and urinary thromboxane 
      and prostacyclin levels in normal dogs.
PG  - 60-67
LID - 10.1111/jvp.12432 [doi]
AB  - Established "low" aspirin dosages inconsistently inhibit platelet function in 
      dogs. Higher aspirin dosages consistently inhibit platelet function, but are 
      associated with adverse effects. The objectives of this study were to use an 
      escalation in dosage to determine the lowest aspirin dosage that consistently 
      inhibited platelet function without inhibiting prostacyclin synthesis. Eight dogs 
      were treated with five aspirin dosages: 0.5 mg/kg q24h, 1 mg/kg q24h, 2 mg/kg 
      q24h, 4 mg/kg q24h and 10 mg/kg q12h for 7 days. Utilizing aggregometry and a 
      whole-blood platelet function analyzer (PFA-100), platelet function was evaluated 
      before and after treatment. Urine 11-dehydro-thromboxane-B(2) (11-dTXB(2) ) and 
      6-keto-prostaglandin-F(1α) (6-keto-PGF(1α) ), were measured. Compared to 
      pretreatment, there were significant post-treatment decreases in the maximum 
      aggregometry amplitude and increases in the PFA-100 closure times for all dosages 
      expect 0.5 mg/kg q24h. There was no difference in amplitude or closure time among 
      the 2 mg/kg q24h, 4 mg/kg q24h, and 10 mg/kg q12h dosages. Compared to 
      pretreatment values, there was a significant decrease in urinary 11-dTXB(2) 
      -to-creatinine and 6-keto-PGF(1α) -to-creatinine ratios, but there was no 
      dose-dependent decrease for either metabolite. An aspirin dosage of 2 mg/kg q24h 
      consistently inhibits platelet function without decreasing prostacyclin synthesis 
      significantly more than lower aspirin dosages.
CI  - © 2017 John Wiley & Sons Ltd.
FAU - McLewee, N
AU  - McLewee N
AD  - Department of Clinical Sciences, College of Veterinary Medicine, Mississippi 
      State University, Mississippi, MS, USA.
FAU - Archer, T
AU  - Archer T
AD  - Department of Clinical Sciences, College of Veterinary Medicine, Mississippi 
      State University, Mississippi, MS, USA.
FAU - Wills, R
AU  - Wills R
AD  - Department of Pathobiology and Population Medicine, College of Veterinary 
      Medicine, Mississippi State University, Mississippi, MS, USA.
FAU - Mackin, A
AU  - Mackin A
AD  - Department of Clinical Sciences, College of Veterinary Medicine, Mississippi 
      State University, Mississippi, MS, USA.
FAU - Thomason, J
AU  - Thomason J
AUID- ORCID: 0000-0001-5678-8923
AD  - Department of Clinical Sciences, College of Veterinary Medicine, Mississippi 
      State University, Mississippi, MS, USA.
LA  - eng
PT  - Journal Article
DEP - 20170630
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/urine
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Epoprostenol/*urine
MH  - Female
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests/veterinary
MH  - Thromboxane B2/analogs & derivatives/urine
MH  - Thromboxanes/*urine
OTO - NOTNLM
OT  - aggregometry
OT  - antiplatelet
OT  - canine
OT  - immune-mediated hemolytic anemia
OT  - thromboembolism
EDAT- 2017/07/01 06:00
MHDA- 2018/07/27 06:00
CRDT- 2017/07/01 06:00
PHST- 2016/09/01 00:00 [received]
PHST- 2017/06/01 00:00 [accepted]
PHST- 2017/07/01 06:00 [pubmed]
PHST- 2018/07/27 06:00 [medline]
PHST- 2017/07/01 06:00 [entrez]
AID - 10.1111/jvp.12432 [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 2018 Feb;41(1):60-67. doi: 10.1111/jvp.12432. Epub 2017 Jun 
      30.

PMID- 3050522
OWN - NLM
STAT- MEDLINE
DCOM- 19881115
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 319
IP  - 17
DP  - 1988 Oct 27
TI  - Aspirin, heparin, or both to treat acute unstable angina.
PG  - 1105-11
AB  - We tested the usefulness of aspirin (325 mg twice daily), heparin (1000 units per 
      hour by intravenous infusion), and a combination of the two in the early 
      management of acute unstable angina pectoris in a double-blind, randomized, 
      placebo-controlled trial involving 479 patients. The patients entered the study 
      as soon as possible after hospital admission (at a mean [+/- SD] of 7.9 +/- 8.0 
      hours after the last episode of pain), and the study was ended after 6 +/- 3 
      days, when definitive therapy had been selected. Major end points--refractory 
      angina, myocardial infarction, and death--occurred in 23, 12, and 1.7 percent of 
      the 118 patients receiving placebo, respectively. Heparin was associated with a 
      decrease in the occurrence of refractory angina (P = 0.002). The incidence of 
      myocardial infarction was significantly reduced in the groups receiving aspirin 
      (3 percent; P = 0.01), heparin (0.8 percent; P less than 0.001), and aspirin plus 
      heparin (1.6 percent, P = 0.003), and no deaths occurred in these groups. There 
      were too few deaths overall to permit evaluation of the effect of treatment on 
      this end point. The combination of aspirin and heparin had no greater protective 
      effect than heparin alone but was associated with slightly more serious bleeding 
      (3.3 vs. 1.7 percent). We conclude that in the acute phase of unstable angina, 
      either aspirin or heparin treatment is associated with a reduced incidence of 
      myocardial infarction, and there is a trend favoring heparin over aspirin. 
      Heparin treatment is also associated with a reduced incidence of refractory 
      angina.
FAU - Théroux, P
AU  - Théroux P
AD  - Montreal Heart Institute, Que., Canada.
FAU - Ouimet, H
AU  - Ouimet H
FAU - McCans, J
AU  - McCans J
FAU - Latour, J G
AU  - Latour JG
FAU - Joly, P
AU  - Joly P
FAU - Lévy, G
AU  - Lévy G
FAU - Pelletier, E
AU  - Pelletier E
FAU - Juneau, M
AU  - Juneau M
FAU - Stasiak, J
AU  - Stasiak J
FAU - deGuise, P
AU  - deGuise P
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 1989 Apr 13;320(15):1014-5. PMID: 2633752
MH  - Acute Disease
MH  - Angina Pectoris/*drug therapy
MH  - Angina, Unstable/complications/*drug therapy/mortality
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - Random Allocation
EDAT- 1988/10/27 00:00
MHDA- 1988/10/27 00:01
CRDT- 1988/10/27 00:00
PHST- 1988/10/27 00:00 [pubmed]
PHST- 1988/10/27 00:01 [medline]
PHST- 1988/10/27 00:00 [entrez]
AID - 10.1056/NEJM198810273191701 [doi]
PST - ppublish
SO  - N Engl J Med. 1988 Oct 27;319(17):1105-11. doi: 10.1056/NEJM198810273191701.

PMID- 26256964
OWN - NLM
STAT- MEDLINE
DCOM- 20160108
LR  - 20181202
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 56
IP  - 5
DP  - 2015 Sep
TI  - Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A 
      Double-Blind, Randomized, Crossover Trial.
PG  - 1227-34
LID - 10.3349/ymj.2015.56.5.1227 [doi]
AB  - PURPOSE: Primary vascular dysregulation (PVD) is a condition in which the 
      response to cold temperature or external stimuli is abnormal. We investigated 
      whether triflusal use results in amelioration of PVD symptoms and improvement of 
      several related parameters compared with aspirin. MATERIALS AND METHODS: 
      Eighty-eight PVD patients (54% female, 56±8 years) were randomly selected to 
      receive either triflusal (300 mg, b.i.d.) or aspirin (150 mg, b.i.d.) for a 
      period of 6 weeks followed by crossover. PVD was defined as both red-blood-cell 
      standstill in video-assisted microscopic capillaroscopy during cold stimulation 
      using carbon dioxide gas and a score of more than 7 points in a validated 
      questionnaire. Efficacy of treatment was assessed by 1) cold intolerance symptom 
      severity (CISS) score, 2) finger Doppler indices, and 3) indocyanine green 
      perfusion imaging. RESULTS: The use of triflusal resulted in a greater 
      improvement in CISS score (44.5±18.4 vs. 51.9±16.2; p<0.001) and in mean radial 
      peak systolic velocity (69.8±17.2 vs. 66.1±16.4; p=0.011) compared to aspirin. 
      Furthermore, significant differences were also observed in perfusion rates on 
      indocyanine green perfusion imaging between triflusal and aspirin (45.6±25.8 vs. 
      51.6±26.9; p=0.020). CONCLUSION: Triflusal was more effective and demonstrated a 
      more consistent impact on the improvement of symptoms and blood flow in patients 
      with PVD than aspirin.
FAU - Shin, Sanghoon
AU  - Shin S
AD  - Division of Cardiology, Department of Internal Medicine, National Health 
      Insurance Service Ilsan Hospital, Goyang, Korea.
FAU - Kim, Kwang-Joon
AU  - Kim KJ
AD  - Division of Endocrinology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Yonsei University Health System, Seoul, Korea.
AD  - Severance Check-up, Severance Hospital, Yonsei University Health System, Seoul, 
      Korea.
AD  - Severance Executive Healthcare Clinic, Severance Hospital, Yonsei University 
      Health System, Seoul, Korea.
FAU - Cho, In-Jeong
AU  - Cho IJ
AD  - Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University 
      College of Medicine, Yonsei University Health System, Seoul, Korea.
FAU - Hong, Geu-Ru
AU  - Hong GR
AD  - Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University 
      College of Medicine, Yonsei University Health System, Seoul, Korea.
FAU - Jang, Yangsoo
AU  - Jang Y
AD  - Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University 
      College of Medicine, Yonsei University Health System, Seoul, Korea.
FAU - Chung, Namsik
AU  - Chung N
AD  - Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University 
      College of Medicine, Yonsei University Health System, Seoul, Korea.
FAU - Rah, Young Min
AU  - Rah YM
AD  - Department of Internal Medicine, Eulji University Hospital, Daejeon, Korea.
FAU - Chang, Hyuk-Jae
AU  - Chang HJ
AD  - Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University 
      College of Medicine, Yonsei University Health System, Seoul, Korea. 
      hjchang@yuhs.ac.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 1Z0YFI05OO (triflusal)
RN  - IX6J1063HV (Indocyanine Green)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Indocyanine Green
MH  - Male
MH  - Middle Aged
MH  - Perfusion Imaging
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Recurrence
MH  - Salicylates/*therapeutic use
MH  - Treatment Outcome
PMC - PMC4541651
OTO - NOTNLM
OT  - Primary vascular dysregulation
OT  - endothelin-1
OT  - finger Doppler
OT  - microvascular circulation
OT  - triflusal
COIS- The authors have no financial conflicts of interest.
EDAT- 2015/08/11 06:00
MHDA- 2016/01/09 06:00
CRDT- 2015/08/11 06:00
PHST- 2014/03/06 00:00 [received]
PHST- 2014/10/13 00:00 [revised]
PHST- 2014/10/16 00:00 [accepted]
PHST- 2015/08/11 06:00 [entrez]
PHST- 2015/08/11 06:00 [pubmed]
PHST- 2016/01/09 06:00 [medline]
AID - 2015091227 [pii]
AID - 10.3349/ymj.2015.56.5.1227 [doi]
PST - ppublish
SO  - Yonsei Med J. 2015 Sep;56(5):1227-34. doi: 10.3349/ymj.2015.56.5.1227.

PMID- 16613572
OWN - NLM
STAT- MEDLINE
DCOM- 20060728
LR  - 20191109
IS  - 1871-5281 (Print)
IS  - 1871-5281 (Linking)
VI  - 5
IP  - 2
DP  - 2006 Apr
TI  - Nitric oxide, aspirin-triggered lipoxins and NO-aspirin in gastric protection.
PG  - 133-7
AB  - The use of nonsteroidal anti-inflammatory drugs is associated with an incidence 
      of severe gastrointestinal adverse events of 2-4%, the most common of which is 
      bleeding. These events are largely attributable to the ability of these drugs to 
      suppress prostaglandin and thromboxane synthesis. Prostaglandins perform a number 
      of important functions in the gastrointestinal tract, particularly with respect 
      to resistance of the mucosa to injury. Nitric oxide also appears to be a key 
      mediator of gastrointestinal mucosal defence, and this has been exploited in the 
      development of a novel class of anti-inflammatory drugs, called "NO-NSAIDs", 
      which exhibit little if any gastrointestinal toxicity. NO-NSAIDs are more 
      effective than traditional NSAIDs in reducing pain and inflammation. Another 
      class of inflammatory mediators that contribute to gastrointestinal mucosal 
      defence are the lipoxins. These products of arachidonic acid metabolism can 
      increase the resistance of the stomach to the damaging effects of aspirin. 
      Indeed, aspirin can trigger the formation of a lipoxin by the stomach which acts 
      to diminish the damaging effects of this drug. Lipoxins and nitric oxide are 
      important mediators of mucosal defence in the stomach (and elsewhere in the 
      gastrointestinal tract) and represent attractive therapeutic targets for reducing 
      the incidence of gastric ulceration.
FAU - Wallace, John L
AU  - Wallace JL
AD  - Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, 
      Calgary, Alberta, T2N 4N1, Canada. John.Wallace@ucalgary.ca
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Inflamm Allergy Drug Targets
JT  - Inflammation & allergy drug targets
JID - 101266886
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipoxins)
RN  - 0 (N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 
      4-(nitrooxy)butyl ester)
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (lipoxin A4)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation/drug effects
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/metabolism/*pharmacology
MH  - Aspirin/*adverse effects/analogs & derivatives/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Gastric Mucosa/*drug effects/metabolism/pathology
MH  - Gastrointestinal Hemorrhage/*etiology/metabolism/pathology
MH  - Humans
MH  - Lipoxins/metabolism/*pharmacology
MH  - Nitrates/metabolism/*pharmacology
MH  - Nitric Oxide/metabolism/*pharmacology
MH  - Nitric Oxide Donors/metabolism/*pharmacology
RF  - 51
EDAT- 2006/04/15 09:00
MHDA- 2006/07/29 09:00
CRDT- 2006/04/15 09:00
PHST- 2006/04/15 09:00 [pubmed]
PHST- 2006/07/29 09:00 [medline]
PHST- 2006/04/15 09:00 [entrez]
AID - 10.2174/187152806776383116 [doi]
PST - ppublish
SO  - Inflamm Allergy Drug Targets. 2006 Apr;5(2):133-7. doi: 
      10.2174/187152806776383116.

PMID- 3515927
OWN - NLM
STAT- MEDLINE
DCOM- 19860502
LR  - 20201209
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 80
IP  - 3A
DP  - 1986 Mar 24
TI  - Flurbiprofen, aspirin, codeine, and placebo for postpartum uterine pain.
PG  - 65-70
AB  - Flurbiprofen (Ansaid, Upjohn), a substituted phenyl propionic acid, is a new 
      analgesic/anti-inflammatory agent. To evaluate its relative efficacy in 
      noninflammatory pain, 159 hospitalized women with moderate or severe postpartum 
      uterine cramps were given single oral doses of 50 mg of flurbiprofen, 650 mg of 
      aspirin, 60 or 120 mg of codeine sulfate, or placebo in a parallel, stratified, 
      randomized block, placebo-controlled, double-blind trial. Patients rated pain 
      intensity, pain relief, and side effects in uniform interviews for six hours 
      after treatment. All measures of peak and summed analgesia exhibited significant 
      differences among the five treatments. Flurbiprofen and aspirin showed the 
      greatest analgesic response and were significantly superior to placebo. Results 
      of codeine treatment were equivocal with no evidence of a positive dose response. 
      Side effects were unremarkable except for dizziness and drowsiness after the 
      120-mg codeine dose. These findings suggest that flurbiprofen as an analgesic for 
      patients with postpartum uterine pain is equivalent to aspirin and superior to 
      codeine.
FAU - Bloomfield, S S
AU  - Bloomfield SS
FAU - Mitchell, J
AU  - Mitchell J
FAU - Cissell, G
AU  - Cissell G
FAU - Barden, T P
AU  - Barden TP
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Placebos)
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Codeine/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Flurbiprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
MH  - Postpartum Period
MH  - Pregnancy
MH  - Propionates/*therapeutic use
MH  - Random Allocation
MH  - Uterine Diseases/*drug therapy
EDAT- 1986/03/24 00:00
MHDA- 1986/03/24 00:01
CRDT- 1986/03/24 00:00
PHST- 1986/03/24 00:00 [pubmed]
PHST- 1986/03/24 00:01 [medline]
PHST- 1986/03/24 00:00 [entrez]
AID - 0002-9343(86)90114-2 [pii]
AID - 10.1016/0002-9343(86)90114-2 [doi]
PST - ppublish
SO  - Am J Med. 1986 Mar 24;80(3A):65-70. doi: 10.1016/0002-9343(86)90114-2.

PMID- 9397563
OWN - NLM
STAT- MEDLINE
DCOM- 19980108
LR  - 20131121
IS  - 0022-1198 (Print)
IS  - 0022-1198 (Linking)
VI  - 42
IP  - 6
DP  - 1997 Nov
TI  - GC/MS confirmation of barbiturates in blood and urine.
PG  - 1160-70
AB  - A gas chromatography-mass spectrometric method is described for the quantitative 
      measurement of 6 commonly used barbiturates in blood and urine specimens. The 
      targeted barbiturates are butalbital, amobarbital, pentobarbital, secobarbital, 
      mephobarbital and phenobarbital. They are recovered along with the internal 
      standard, tolybarb, from blood and urine using liquid extraction then alkalated 
      to form the N-ethyl derivatives. The ethylated barbiturates have symmetrical 
      peaks which are well separated from each other on a non-polar methylsilicone 
      capillary column. The derivatives on a non-polar methylsilicone capillary column. 
      The derivatives facilitate quantitations between 50 and 10,000 ng/mL. The 
      day-to-day CVs for all 6 barbiturates were between 4 and 9% at 200 and 5000 
      ng/mL. The method has been extended for identifying other acidic drugs and drug 
      metabolites. They are mainly non-steroidal anti-inflammatory drugs, diuretics, 
      and anticonvulsants. An additional 83 compounds can be qualitatively identified.
FAU - Meatherall, R
AU  - Meatherall R
AD  - Laboratory Medicine, St. Boniface General Hospital, Manitoba, Canada.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Forensic Sci
JT  - Journal of forensic sciences
JID - 0375370
RN  - 0 (Analgesics)
RN  - 0 (Barbiturates)
RN  - 0 (Drug Combinations)
RN  - 3G6A5W338E (Caffeine)
RN  - 51005-25-5 (aspirin, butalbital and caffeine drug combination)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/blood/poisoning/urine
MH  - Aspirin/blood/poisoning/urine
MH  - Barbiturates/*blood/poisoning/*urine
MH  - *Caffeine
MH  - Drug Combinations
MH  - Forensic Medicine/*methods
MH  - Gas Chromatography-Mass Spectrometry/*methods
MH  - Humans
MH  - Phenacetin/blood/poisoning/urine
EDAT- 1997/12/16 00:00
MHDA- 1997/12/16 00:01
CRDT- 1997/12/16 00:00
PHST- 1997/12/16 00:00 [pubmed]
PHST- 1997/12/16 00:01 [medline]
PHST- 1997/12/16 00:00 [entrez]
PST - ppublish
SO  - J Forensic Sci. 1997 Nov;42(6):1160-70.

PMID- 2597445
OWN - NLM
STAT- MEDLINE
DCOM- 19900206
LR  - 20191029
IS  - 0889-7190 (Print)
IS  - 0889-7190 (Linking)
VI  - 35
IP  - 3
DP  - 1989 Jul-Sep
TI  - A comparison of the antiplatelet effect of aspirin on human and bovine platelets.
PG  - 205-8
AB  - The risk of thromboembolism in human patients or animal models with blood 
      contacting prosthetic devices is well documented. Aspirin is used frequently as 
      an antiplatelet agent to minimize this risk. Although the inhibitory effect of 
      aspirin on human platelets has been clearly established, preliminary studies to 
      examine this effect on bovine platelets revealed a minimal inhibition of platelet 
      function in vivo as well as in vitro. Because a considerable amount of implant 
      research is carried out in bovine models, it was considered important to evaluate 
      carefully the antiplatelet effect of aspirin on bovine platelets. To evaluate the 
      effect of aspirin, experiments were conducted on human and bovine blood in vitro 
      as well as after the administration of aspirin up to 4,000 mg/day (p.o.) in 
      calves and 2,500 mg/day in humans. Appropriate amounts of buffered aspirin were 
      added to heparinized or citrated blood incubated for 25 min and centrifuged to 
      obtain platelet rich plasma (PRP). An aliquot of PRP was then challenged by a 
      predetermined concentration of ADP (an aggregating agent) or collagen to evaluate 
      platelet aggregation and release reaction. After aspirin was administered in 
      vivo, blood was drawn from the animal at predetermined intervals to evaluate 
      platelet function. In human blood, the inhibitory effect of aspirin was 
      discernable at 80 mg/L in vitro and 2,500 mg/day when ingested orally. Under 
      identical experimental conditions, no inhibition of bovine platelet aggregation 
      was observed using dosages of aspirin up to 1,000 mg/L in vitro or 4,000 mg/day 
      in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Swier, P
AU  - Swier P
AD  - Department of Pathology, University of Utah, Salt Lake City 84103.
FAU - Mohammad, S F
AU  - Mohammad SF
FAU - Olsen, D B
AU  - Olsen DB
FAU - Kolff, W J
AU  - Kolff WJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - ASAIO Trans
JT  - ASAIO transactions
JID - 8611947
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Triphosphate/blood
MH  - Adult
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cattle
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
EDAT- 1989/07/01 00:00
MHDA- 1989/07/01 00:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 1989/07/01 00:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
AID - 10.1097/00002480-198907000-00009 [doi]
PST - ppublish
SO  - ASAIO Trans. 1989 Jul-Sep;35(3):205-8. doi: 10.1097/00002480-198907000-00009.

PMID- 2979681
OWN - NLM
STAT- MEDLINE
DCOM- 19920305
LR  - 20190828
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 1
IP  - 5
DP  - 1987 Oct
TI  - Cimetidine decreases aspirin-induced gastric mucosal damage in humans.
PG  - 383-90
AB  - Aspirin induces gastric mucosal damage in animals and humans. The purpose of this 
      study was to examine whether cimetidine protects the human gastric mucosa from 
      acute aspirin-induced damage. Eight healthy subjects were studied on 4 separate 
      days. Cimetidine, 400 mg, or placebo was given orally 1 hour before initial 
      endoscopy. The stomach was isolated and atropine given to suppress basal acid 
      secretion. Each study consisted of four 15 min periods during which an acidic 
      test solution was instilled into the stomach. During the second period only, 
      either aspirin (1300 mg, 36 mmol) or control for aspirin (36 mmol HCl) was added 
      to the test solution. Ion fluxes and gastric mucosal potential difference were 
      measured, and endoscopy performed following each test. After placebo, aspirin 
      significantly altered hydrogen ion flux and potential difference versus basal and 
      control. Cimetidine decreased the damaging effect of aspirin. Endoscopic scores 
      increased after aspirin plus placebo, whereas they remained unchanged after 
      aspirin plus cimetidine. Therefore, cimetidine decreased aspirin-induced gastric 
      mucosal damage in humans. As gastric acidity was identical during all studies, 
      the effect of cimetidine was independent of gastric acid secretion.
FAU - Hogan, D L
AU  - Hogan DL
AD  - Department of Medicine, UCSD Medical Center 92103.
FAU - Thomas, F J
AU  - Thomas FJ
FAU - Isenberg, J I
AU  - Isenberg JI
LA  - eng
GR  - AM 17328/AM/NIADDK NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 80061L1WGD (Cimetidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Cimetidine/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Stomach Diseases/chemically induced/*prevention & control
EDAT- 1987/10/01 00:00
MHDA- 1987/10/01 00:01
CRDT- 1987/10/01 00:00
PHST- 1987/10/01 00:00 [pubmed]
PHST- 1987/10/01 00:01 [medline]
PHST- 1987/10/01 00:00 [entrez]
AID - 10.1111/j.1365-2036.1987.tb00638.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 1987 Oct;1(5):383-90. doi: 
      10.1111/j.1365-2036.1987.tb00638.x.

PMID- 23033009
OWN - NLM
STAT- MEDLINE
DCOM- 20130321
LR  - 20211021
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 107
IP  - 9
DP  - 2012 Oct 23
TI  - β-catenin negatively regulates expression of the prostaglandin transporter PGT in 
      the normal intestinal epithelium and colorectal tumour cells: a role in the 
      chemopreventive efficacy of aspirin?
PG  - 1514-7
LID - 10.1038/bjc.2012.430 [doi]
AB  - BACKGROUND: Levels of the pro-tumorigenic prostaglandin PGE(2) are increased in 
      colorectal cancer, previously attributed to increased synthesis through COX-2 
      upregulation and, more recently, to decreased catabolism. The functionally linked 
      genes 15-prostaglandin dehydrogenase (15-PGDH) and the prostaglandin transporter 
      PGT co-operate in prostaglandin degradation and are downregulated in colorectal 
      cancer. We previously reported repression of 15-PGDH expression by the 
      Wnt/β-catenin pathway, commonly deregulated during early colorectal neoplasia. 
      Here we asked whether β-catenin also regulates PGT expression. METHODS: The 
      effect of β-catenin deletion in vivo was addressed by PGT immunostaining of 
      β-catenin(-/lox)-villin-cre-ERT2 mouse tissue. The effect of siRNA-mediated 
      β-catenin knockdown and dnTCF4 induction in vitro was addressed by 
      semi-quantitative and quantitative real-time RT-PCR and immunoblotting. RESULTS: 
      This study shows for the first time that deletion of β-catenin in murine 
      intestinal epithelium in vivo upregulates PGT protein, especially in the crypt 
      epithelium. Furthermore, β-catenin knockdown in vitro increases PGT expression in 
      both colorectal adenoma- and carcinoma-derived cell lines, as does dnTCF4 
      induction in LS174T cells. CONCLUSIONS: These data suggest that β-catenin employs 
      a two-pronged approach to inhibiting prostaglandin turnover during colorectal 
      neoplasia by repressing PGT expression in addition to 15-PGDH. Furthermore, our 
      data highlight a potential mechanism that may contribute to the non-selective 
      NSAID aspirin's chemopreventive efficacy.
FAU - Smartt, H J M
AU  - Smartt HJ
AD  - Cancer Research UK Colorectal Tumour Biology Research Group, School of Cellular 
      and Molecular Medicine, University Walk, University of Bristol, Bristol BS8 1TD, 
      UK.
FAU - Greenhough, A
AU  - Greenhough A
FAU - Ordóñez-Morán, P
AU  - Ordóñez-Morán P
FAU - Al-Kharusi, M
AU  - Al-Kharusi M
FAU - Collard, T J
AU  - Collard TJ
FAU - Mariadason, J M
AU  - Mariadason JM
FAU - Huelsken, J
AU  - Huelsken J
FAU - Williams, A C
AU  - Williams AC
FAU - Paraskeva, C
AU  - Paraskeva C
LA  - eng
GR  - 11975/CRUK_/Cancer Research UK/United Kingdom
GR  - C19/A5301/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121002
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Organic Anion Transporters)
RN  - 0 (beta Catenin)
RN  - EC 1.1.1.- (Hydroxyprostaglandin Dehydrogenases)
RN  - EC 1.1.1.141 (15-hydroxyprostaglandin dehydrogenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticarcinogenic Agents/pharmacology
MH  - Aspirin/*pharmacology
MH  - Cell Line, Tumor
MH  - Colorectal Neoplasms/*metabolism/*prevention & control
MH  - HCT116 Cells
MH  - HT29 Cells
MH  - Humans
MH  - Hydroxyprostaglandin Dehydrogenases/genetics/metabolism
MH  - Intestinal Mucosa/*metabolism
MH  - Mice
MH  - Organic Anion Transporters/*biosynthesis/genetics
MH  - Signal Transduction
MH  - beta Catenin/genetics/*metabolism
PMC - PMC3493768
EDAT- 2012/10/04 06:00
MHDA- 2013/03/22 06:00
CRDT- 2012/10/04 06:00
PHST- 2012/10/04 06:00 [entrez]
PHST- 2012/10/04 06:00 [pubmed]
PHST- 2013/03/22 06:00 [medline]
AID - bjc2012430 [pii]
AID - 10.1038/bjc.2012.430 [doi]
PST - ppublish
SO  - Br J Cancer. 2012 Oct 23;107(9):1514-7. doi: 10.1038/bjc.2012.430. Epub 2012 Oct 
      2.

PMID- 29304392
OWN - NLM
STAT- MEDLINE
DCOM- 20180907
LR  - 20180907
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 221
DP  - 2018 Feb
TI  - Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia.
PG  - 144-150
LID - S0301-2115(17)30604-8 [pii]
LID - 10.1016/j.ejogrb.2017.12.052 [doi]
AB  - OBJECTIVES: Low-dose aspirin is recommended for prevention of pre-eclampsia in 
      high-risk pregnant women. Current doses provide a conservative risk reduction and 
      some individuals demonstrate 'aspirin non-responsiveness', with insufficient 
      antiplatelet effects. We aimed to determine if aspirin non-responsiveness could 
      be identified in women at high risk of pre-eclampsia and assess for potential 
      associations with placentally-mediated adverse outcomes. STUDY DESIGN: 
      Prospective cohort study. 180 women at high-risk of pre-eclampsia, by NICE 
      criteria, prescribed 75 mg dispersible aspirin daily were recruited from 
      antenatal clinics of Liverpool Women's Hospital between 17/01/14 and 31/03/16. 
      Platelet function (Multiplate™ impedance aggregometry, VerifyNow™ and 
      11-dehydrothromboxane B(2)) and aspirin metabolites (nuclear magnetic resonance 
      and liquid chromatography mass spectrometry) were assessed at 5 + (0)-20 + (6) 
      and 33 + (0)-35 + (6) weeks. Pearson's chi-square test was used to assess for 
      associations between longitudinal response to aspirin and (1) any pre-eclampsia 
      (2) composite adverse placentally-mediated outcome (one, or combination of 
      pre-eclampsia, placental abruption, IUGR and perinatal mortality). A Bonferroni 
      correction was applied to correct for multiple analyses. RESULTS: 180 women were 
      recruited, there were 4 withdrawals and no women were lost to follow-up. After 15 
      women delivered prior to the completion of follow-up, sufficient sample volumes 
      for longitudinal platelet function and aspirin adherence testing were obtained 
      from 156 women. There were no consistent aspirin non-responders in the cohort. 
      59% (n = 92) women exhibited normal response to aspirin, 34% (n = 53) variable 
      response (switching response status between study visits) and in 7% (n = 11) 
      response could not be determined as they exhibited lack of platelet response on a 
      background of undetectable aspirin metabolites. There was no significant 
      association between indeterminate or inconsistent (variable or indeterminate) 
      response to aspirin and either pre-eclampsia (p = 0.59, p = 0.84) or composite 
      outcome (p = 0.95, p = 0.65). CONCLUSIONS: When platelet function was assessed 
      with COX-specific tests that measure the antiplatelet effects of low-dose aspirin 
      and aspirin adherence is accurately accounted for aspirin non-responsiveness was 
      not identified in pregnant women at high-risk of pre-eclampsia. Response to 
      aspirin was not associated with placentally-mediated adverse outcomes. The 
      high-degree of variable and indeterminate aspirin response indicates suboptimal 
      adherence and/or dosing are more pressing factors to address to optimise aspirin 
      effectiveness.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Navaratnam, Kate
AU  - Navaratnam K
AD  - Centre for Women's Health Research, Institute of Translational Medicine, 
      University of Liverpool, Crown Street, Liverpool, L8 7SS, UK. Electronic address: 
      Kate.Navaratnam@liverpool.ac.uk.
FAU - Alfirevic, Ana
AU  - Alfirevic A
AD  - The Wolfson Centre for Personalised Medicine, Institute of Translational 
      Medicine, University of Liverpool, Brownlow Street, Liverpool, L69 3GL, UK.
FAU - Jorgensen, Andrea
AU  - Jorgensen A
AD  - Department of Biostatistics, Institute of Translational Medicine, University of 
      Liverpool, L69 3GL, UK.
FAU - Alfirevic, Zarko
AU  - Alfirevic Z
AD  - Centre for Women's Health Research, Institute of Translational Medicine, 
      University of Liverpool, Crown Street, Liverpool, L8 7SS, UK.
LA  - eng
PT  - Journal Article
DEP - 20180101
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fetal Death/prevention & control
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*drug therapy/prevention & control
MH  - Pregnancy
MH  - Prospective Studies
MH  - Risk Factors
MH  - Treatment Failure
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirin non-responsiveness
OT  - Aspirin resistance
OT  - Pre-eclampsia
OT  - Pregnancy
EDAT- 2018/01/06 06:00
MHDA- 2018/09/08 06:00
CRDT- 2018/01/06 06:00
PHST- 2017/08/21 00:00 [received]
PHST- 2017/11/21 00:00 [revised]
PHST- 2017/12/30 00:00 [accepted]
PHST- 2018/01/06 06:00 [pubmed]
PHST- 2018/09/08 06:00 [medline]
PHST- 2018/01/06 06:00 [entrez]
AID - S0301-2115(17)30604-8 [pii]
AID - 10.1016/j.ejogrb.2017.12.052 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2018 Feb;221:144-150. doi: 
      10.1016/j.ejogrb.2017.12.052. Epub 2018 Jan 1.

PMID- 440889
OWN - NLM
STAT- MEDLINE
DCOM- 19790716
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 63
IP  - 5
DP  - 1979 May
TI  - Effect of safety packaging on aspirin ingestion by children.
PG  - 687-93
AB  - The effectiveness of child-resistant closures, required under the Poison 
      Prevention Packaging Act of 1970, in reducing the incidence of accidental 
      ingestion of aspirin and aspirin-containing products among children less than 5 
      years of age has been investigated. Data from Poison Control Centers and the 
      National Center for Health Statistics were analyzed to determine the ingestion 
      level before and two to three years after safety closures were required. Baby 
      aspirin and nonbaby aspirin products were analyzed separately. For baby aspirin. 
      It is estimated that safety packaging has reduced the incidence of ingestions 45% 
      to 55%. For nonbaby aspirin products, the reduction has been 40% to 45%.
FAU - Clarke, A
AU  - Clarke A
FAU - Walton, W W
AU  - Walton WW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*poisoning
MH  - Child, Preschool
MH  - Drug Industry
MH  - Drug Packaging/*standards
MH  - Evaluation Studies as Topic
MH  - Government Agencies
MH  - Humans
MH  - Infant
MH  - Poison Control Centers
MH  - Statistics as Topic
MH  - United States
MH  - United States Food and Drug Administration
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1979 May;63(5):687-93.

PMID- 8912125
OWN - NLM
STAT- MEDLINE
DCOM- 19970219
LR  - 20131121
IS  - 0815-9319 (Print)
IS  - 0815-9319 (Linking)
VI  - 11
IP  - 10
DP  - 1996 Oct
TI  - Case report: gastrointestinal haemorrhage from jejunal diverticulosis, probably 
      induced by low dose aspirin.
PG  - 908-10
AB  - A 66-year-old female, who had been taking low dose aspirin for approximately 6 
      months, was admitted to hospital with severe gastrointestinal bleeding. The 
      source of bleeding could not be demonstrated despite gastroscopy, mesenteric 
      angiography and 99mTc-labelled red blood cell scanning. Mesenteric angiography 
      was repeated, demonstrating a site of bleeding in the proximal small intestine. 
      Laparotomy revealed blood-filled jejunal diverticulosis. Resection of the 
      affected segment resulted in cessation of haemorrhage and the patient remains 
      well in follow up. The present report illustrates a rare cause of 
      gastrointestinal haemorrhage, the possible role of aspirin in causation and the 
      difficulty in diagnosis of bleeding from jejunal diverticulosis.
FAU - Kaushik, S P
AU  - Kaushik SP
AD  - Gastroenterology Unit, Canberra Hospital, Garran, ACT, Australia.
FAU - D'Rozario, J M
AU  - D'Rozario JM
FAU - Chong, G
AU  - Chong G
FAU - Bassett, M L
AU  - Bassett ML
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Diverticulum/*complications/diagnosis/surgery
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/diagnosis/etiology
MH  - Humans
MH  - Jejunal Diseases/*complications/diagnosis/surgery
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
PST - ppublish
SO  - J Gastroenterol Hepatol. 1996 Oct;11(10):908-10.

PMID- 1853617
OWN - NLM
STAT- MEDLINE
DCOM- 19910821
LR  - 20190824
IS  - 0364-2313 (Print)
IS  - 0364-2313 (Linking)
VI  - 15
IP  - 3
DP  - 1991 May-Jun
TI  - The effect of acetylsalicylic acid on the outcome after lower limb arterial 
      surgery with special reference to cigarette smoking.
PG  - 378-82
AB  - A prospective controlled study of 144 patients with peripheral obstructive 
      arterial disease was undertaken to evaluate the efficacy of acetylsalicylic acid 
      (ASA) treatment (250 mg daily) on the outcome after lower limb arterial surgery 
      which mainly involved endarterectomy. By random enrollment, 2 groups of 72 
      patients were formed after the surgery. Patients with ASA treatment for 3 months, 
      starting from the seventh postoperative day, were compared with patients who were 
      not treated with ASA. The patients in both groups had similar characteristics as 
      to sex ratio, age, concomitant diseases, preoperative arm-ankle systolic blood 
      pressure index, and type and primary success of the reconstruction. Forty-seven 
      of the ASA-treated and 48 of the untreated patients reported to continue 
      cigarette smoking. Postoperative ASA-treatment protected against local adverse 
      events which occurred in 15 patients (21%) of the ASA-treated group compared with 
      31 patients (43%) of the untreated group (p less than 0.01). Among heavy smokers 
      (greater than 15 cigarettes/day) the efficacy of antiplatelet treatment was not 
      detectable. These results imply that, in patients with peripheral arterial 
      disease, ASA prevents platelet interaction to endarterectomized and 
      atherosclerotic lower limb arteries thereby affecting the subsequent risk of 
      occlusion; however, heavy cigarette smoking, which is very common among patients 
      with peripheral arterial disease, counteracts the local antithrombotic potency of 
      ASA.
FAU - Lassila, R
AU  - Lassila R
AD  - Fourth Department of Surgery, Helsinki University Central Hospital, Finland.
FAU - Lepäntalo, M
AU  - Lepäntalo M
FAU - Lindfors, O
AU  - Lindfors O
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - World J Surg
JT  - World journal of surgery
JID - 7704052
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/prevention & control
MH  - Female
MH  - Humans
MH  - Ischemia/*surgery
MH  - Leg/*blood supply
MH  - Male
MH  - Postoperative Complications/*prevention & control
MH  - Prospective Studies
MH  - Smoking/*adverse effects
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
AID - 10.1007/BF01658734 [doi]
PST - ppublish
SO  - World J Surg. 1991 May-Jun;15(3):378-82. doi: 10.1007/BF01658734.

PMID- 28193678
OWN - NLM
STAT- MEDLINE
DCOM- 20171107
LR  - 20181016
IS  - 1941-7632 (Electronic)
IS  - 1941-7640 (Linking)
VI  - 10
IP  - 2
DP  - 2017 Feb
TI  - Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the 
      Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary 
      Artery Disease).
LID - e004368 [pii]
LID - 10.1161/CIRCINTERVENTIONS.116.004368 [doi]
AB  - BACKGROUND: There are limited data on aspirin (ASA) desensitization for patients 
      with coronary artery disease. The aim of the present study was to assess the 
      safety and efficacy of a standard rapid desensitization protocol in patients with 
      ASA sensitivity undergoing coronary angiography. METHODS AND RESULTS: This is a 
      prospective, multicenter, observational study including 7 Italian centers 
      including patients with a history of ASA sensitivity undergoing coronary 
      angiography with intent to undergo percutaneous coronary intervention. A total of 
      330 patients with history of ASA sensitivity with known/suspected stable coronary 
      artery disease or presenting with an acute coronary syndrome, including 
      ST-segment-elevation myocardial infarction were enrolled. Adverse effects to 
      aspirin included urticaria (n=177, 53.6%), angioedema (n=69, 20.9%), asthma 
      (n=65, 19.7%), and anaphylactic reaction (n=19, 5.8%). Among patients with 
      urticaria/angioedema, 13 patients (3.9%) had a history of idiopathic chronic 
      urticaria. All patients underwent a rapid ASA (5.5 hours) desensitization 
      procedure. The desensitization procedure was performed before cardiac 
      catheterization in all patients, except for those (n=78, 23.6%) presenting with 
      ST-segment-elevation myocardial infarction who underwent the desensitization 
      after primary percutaneous coronary intervention. Percutaneous coronary 
      intervention was performed in 235 patients (71%) of the overall study population. 
      The desensitization procedure was successful in 315 patients (95.4%) and in all 
      patients with a history of anaphylactic reaction. Among the 15 patients (4.6%) 
      who did not successfully respond to the desensitization protocol, adverse 
      reactions were minor and responded to treatment with corticosteroids and 
      antihistamines. Among patients with successful in-hospital ASA desensitization, 
      253 patients (80.3%) continued ASA for at least 12 months. Discontinuation of ASA 
      in the 62 patients (19.7%) who had responded to the desensitization protocol was 
      because of medical decision and not because of hypersensitivity reactions. 
      CONCLUSIONS: A standard rapid desensitization protocol is safe and effective 
      across a broad spectrum of patients, irrespective of the type of aspirin 
      sensitivity manifestation, with indications to undergo coronary angiography with 
      intent to perform percutaneous coronary intervention. CLINICAL TRIAL 
      REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02848339.
CI  - © 2017 American Heart Association, Inc.
FAU - Rossini, Roberta
AU  - Rossini R
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.). 
      roberta.rossini2@gmail.com.
FAU - Iorio, Annamaria
AU  - Iorio A
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Pozzi, Roberto
AU  - Pozzi R
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Bianco, Matteo
AU  - Bianco M
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Musumeci, Giuseppe
AU  - Musumeci G
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Leonardi, Sergio
AU  - Leonardi S
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Lettieri, Corrado
AU  - Lettieri C
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Bossi, Irene
AU  - Bossi I
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Colombo, Paola
AU  - Colombo P
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Rigattieri, Stefano
AU  - Rigattieri S
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Dossena, Cinzia
AU  - Dossena C
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Anzuini, Angelo
AU  - Anzuini A
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Capodanno, Davide
AU  - Capodanno D
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Senni, Michele
AU  - Senni M
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy 
      (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, 
      Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, 
      Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, 
      Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST 
      Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. 
      Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi 
      di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, 
      Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, 
      Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of 
      Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
LA  - eng
SI  - ClinicalTrials.gov/NCT02848339
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - United States
TA  - Circ Cardiovasc Interv
JT  - Circulation. Cardiovascular interventions
JID - 101499602
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circ Cardiovasc Interv. 2017 Feb;10(2):. PMID: 28193681
MH  - Acute Coronary Syndrome/diagnostic imaging/*therapy
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects/immunology
MH  - Coronary Angiography
MH  - Coronary Artery Disease/diagnostic imaging/*therapy
MH  - Desensitization, Immunologic/adverse effects/*methods
MH  - Drug Hypersensitivity/diagnosis/immunology/*therapy
MH  - Female
MH  - Humans
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/immunology
MH  - Prospective Studies
MH  - Registries
MH  - Risk Factors
MH  - ST Elevation Myocardial Infarction/diagnostic imaging/*therapy
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - acute coronary syndrome
OT  - aspirin
OT  - coronary artery disease
OT  - hypersensitivity
OT  - percutaneous coronary intervention
EDAT- 2017/02/15 06:00
MHDA- 2017/11/08 06:00
CRDT- 2017/02/15 06:00
PHST- 2016/08/04 00:00 [received]
PHST- 2016/12/19 00:00 [accepted]
PHST- 2017/02/15 06:00 [entrez]
PHST- 2017/02/15 06:00 [pubmed]
PHST- 2017/11/08 06:00 [medline]
AID - CIRCINTERVENTIONS.116.004368 [pii]
AID - 10.1161/CIRCINTERVENTIONS.116.004368 [doi]
PST - ppublish
SO  - Circ Cardiovasc Interv. 2017 Feb;10(2):e004368. doi: 
      10.1161/CIRCINTERVENTIONS.116.004368.

PMID- 21409528
OWN - NLM
STAT- MEDLINE
DCOM- 20110921
LR  - 20181201
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Linking)
VI  - 22
IP  - 5
DP  - 2011 May
TI  - Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and 
      neck cancer: a systematic review.
PG  - 803-10
LID - 10.1007/s10552-011-9751-6 [doi]
AB  - BACKGROUND: Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been 
      associated with a reduced risk of several cancers. This is thought to be through 
      the inhibitory action on the cyclooxygenase (COX) enzyme, COX-2. Evidence for 
      NSAIDs preventing head and neck cancer (HNC) is conflicting. We conducted a 
      systematic literature review to investigate the association between NSAID/aspirin 
      use and risk of head and neck cancer (HNC). METHODOLOGY: MEDLINE, EMBASE, PubMed, 
      Cochrane Library, and Web of Science were systematically searched using terms for 
      NSAIDs/aspirin, HNC, and observational/intervention study designs to identify 
      studies published by December 2009. RESULTS: Of 9,268 articles identified, two 
      population-based prescribing database studies and three case-control studies met 
      the selection criteria. The studies investigated different HNC sites. Only one 
      study found a significant protective association of aspirin use with HNC risk (OR 
      0.75, 95% CI 0.58-0.96), and one showed a significantly increased risk of 
      oral/oropharyngeal cancer with non-low-dose aspirin NSAID use (OR 3.5, 95% CI 
      1.8-6.7). Many of the studies identified lacked information on important 
      confounding factors. CONCLUSION: No definitive conclusion on the effect of 
      NSAIDs/aspirin on HNC risk was possible. Aspirin may protect against HNC, 
      although further robust large-scale studies are required to clarify any possible 
      association.
FAU - Wilson, Jessica C
AU  - Wilson JC
AD  - Centre for Public Health, School of Medicine Dentistry and Biomedical Sciences, 
      Queen's University Belfast, Belfast, UK. jwilson57@qub.ac.uk
FAU - Anderson, Lesley A
AU  - Anderson LA
FAU - Murray, Liam J
AU  - Murray LJ
FAU - Hughes, Carmel M
AU  - Hughes CM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20110317
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Head and Neck Neoplasms/*epidemiology/prevention & control
MH  - Humans
MH  - Risk Factors
EDAT- 2011/03/17 06:00
MHDA- 2011/09/22 06:00
CRDT- 2011/03/17 06:00
PHST- 2010/09/20 00:00 [received]
PHST- 2011/02/26 00:00 [accepted]
PHST- 2011/03/17 06:00 [entrez]
PHST- 2011/03/17 06:00 [pubmed]
PHST- 2011/09/22 06:00 [medline]
AID - 10.1007/s10552-011-9751-6 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2011 May;22(5):803-10. doi: 10.1007/s10552-011-9751-6. 
      Epub 2011 Mar 17.

PMID- 17009567
OWN - NLM
STAT- MEDLINE
DCOM- 20070111
LR  - 20191110
IS  - 0012-6543 (Print)
IS  - 0012-6543 (Linking)
VI  - 44
IP  - 9
DP  - 2006 Sep
TI  - Dilemmas in managing Barrett's oesophagus.
PG  - 69-72
AB  - In the UK, oesophageal adenocarcinoma accounts for over 7,000 deaths per year and 
      its incidence is rising. One risk factor for this cancer is Barrett's oesophagus. 
      In this condition, reflux of acid and duodenal fluid leads to replacement of the 
      normal stratified squamous epithelium with a columnar epithelium. This new 
      epithelium includes areas of intestinal metaplasia that may develop into 
      dysplasia and ultimately carcinoma. Of people with Barrett's oesophagus, about 1% 
      per year develop adenocarcinoma, around 30-125 times the rate in the general 
      population. This carcinoma is asymptomatic until locally advanced, and has a poor 
      prognosis unless detected early. So it has been suggested that people with reflux 
      should be screened for Barrett's oesophagus, and those with the condition should 
      be kept under surveillance to detect dysplasia or adenocarcinoma in the early 
      stages. Here we discuss the problems in managing patients with Barrett's 
      oesophagus.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Barrett Esophagus/*therapy
MH  - Endoscopy, Gastrointestinal/methods
MH  - Gastroesophageal Reflux/prevention & control
MH  - Humans
MH  - Risk Factors
RF  - 72
EDAT- 2006/10/03 09:00
MHDA- 2007/01/12 09:00
CRDT- 2006/10/03 09:00
PHST- 2006/10/03 09:00 [pubmed]
PHST- 2007/01/12 09:00 [medline]
PHST- 2006/10/03 09:00 [entrez]
AID - 10.1136/dtb.2006.44969 [doi]
PST - ppublish
SO  - Drug Ther Bull. 2006 Sep;44(9):69-72. doi: 10.1136/dtb.2006.44969.

PMID- 1438023
OWN - NLM
STAT- MEDLINE
DCOM- 19921217
LR  - 20190902
IS  - 0901-9928 (Print)
IS  - 0901-9928 (Linking)
VI  - 70
IP  - 6 Pt 1
DP  - 1992 Jun
TI  - Antithrombotic activity of a new pyrazine derivative determined by the mouse 
      antithrombotic assay.
PG  - 448-52
AB  - A model of pulmonary microembolization in the mouse induced by infusion of 
      epinephrine and collagen was used to determine antithrombotic activity of 
      indomethacin and acetylsalicylic acid and of two newly synthesized pyrazine 
      derivatives. One of the new agents provided marked protection of mice from 
      thrombotic challenge with epinephrine and collagen. Its effectiveness was higher 
      than acetylsalicylic acid (especially at small doses) but smaller than that of 
      indomethacin. The same compound was similar to acetylsalicyclic acid with respect 
      to the inhibition of in vitro human blood platelet aggregation. The new class of 
      pyrazine derivatives (the so-called pyrazine CH- and NH-acids) appears 
      interesting from the view-point of the studies of platelet aggregation and may 
      yield potential antithrombotic drugs.
FAU - Petrusewicz, J
AU  - Petrusewicz J
AD  - Department of Biopharmaceutics and Pharmacodynamics, Medical Academy of Gdansk, 
      Poland.
FAU - Yilinkou, R G
AU  - Yilinkou RG
FAU - Pilarski, B
AU  - Pilarski B
FAU - Kaliszan, R
AU  - Kaliszan R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Denmark
TA  - Pharmacol Toxicol
JT  - Pharmacology & toxicology
JID - 8702180
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Pyrazines)
RN  - 99446-80-7 (BP 16)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Embolization, Therapeutic
MH  - Fibrinolytic Agents/*pharmacology
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Lung/blood supply/drug effects
MH  - Male
MH  - Mice
MH  - Platelet Aggregation/drug effects
MH  - Pyrazines/*pharmacology
EDAT- 1992/06/01 00:00
MHDA- 1992/06/01 00:01
CRDT- 1992/06/01 00:00
PHST- 1992/06/01 00:00 [pubmed]
PHST- 1992/06/01 00:01 [medline]
PHST- 1992/06/01 00:00 [entrez]
AID - 10.1111/j.1600-0773.1992.tb00506.x [doi]
PST - ppublish
SO  - Pharmacol Toxicol. 1992 Jun;70(6 Pt 1):448-52. doi: 
      10.1111/j.1600-0773.1992.tb00506.x.

PMID- 1926151
OWN - NLM
STAT- MEDLINE
DCOM- 19911030
LR  - 20190818
IS  - 0300-483X (Print)
IS  - 0300-483X (Linking)
VI  - 69
IP  - 1
DP  - 1991
TI  - Cytoprotective effect of reduced glutathione in arsenical-induced endothelial 
      cell injury.
PG  - 101-10
AB  - The effect of four arsenic compounds on cultured endothelial cell isolated from 
      bovine carotid arteries was studied. Only trivalent arsenicals (arsenic trioxide 
      and sodium m-arsenite), but not pentavalent arsenicals (arsenic acid and 
      p-arsenilic acid), induced significant cell injury. Since the intracellular 
      reduced glutathione (GSH) plays an important role in detoxication in mammalian 
      cells, its effect on arsenical-induced cell injury was then studied. Pretreatment 
      of cells with 500 microM GSH not only resulted in several-fold increase in the 
      intracellular level of GSH but also effectively protected them against the injury 
      caused by arsenic trioxide. After a pretreatment of cells with GSH for 3 h, the 
      intracellular GSH reached a plateau. A longer pretreatment for 24 h still kept 
      GSH at a very significant high level. The cell injury induced by arsenic trioxide 
      was protected by GSH, and then cellular biosynthesis of PGI2 in culture was also 
      increased. The cytoprotective effect and the stimulatory effect on PGI2 
      production, where both were dose-dependent on GSH, were in a strict reverse 
      relationship. Aspirin treatment inhibited the PGI2 biosynthesis induced by GSH in 
      the arsenic trioxide-induced cell injury, and significantly reduced the 
      cytoprotective effect induced by GSH. These results suggest that the marked 
      stimulation of endogenous PGI2 biosynthesis by GSH is the mechanism of the 
      latter's cytoprotective effect on arsenic trioxide-induced endothelial cell 
      injury.
FAU - Chang, W C
AU  - Chang WC
AD  - Department of Pharmacology, National Cheng Kung University, Tainan, Taiwan, 
      Republic of China.
FAU - Chen, S H
AU  - Chen SH
FAU - Wu, H L
AU  - Wu HL
FAU - Shi, G Y
AU  - Shi GY
FAU - Murota, S
AU  - Murota S
FAU - Morita, I
AU  - Morita I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Toxicology
JT  - Toxicology
JID - 0361055
RN  - GAN16C9B8O (Glutathione)
RN  - N712M78A8G (Arsenic)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arsenic/antagonists & inhibitors/*toxicity
MH  - Aspirin/pharmacology
MH  - Cattle
MH  - Cells
MH  - Cells, Cultured
MH  - Drug Interactions
MH  - Endothelium, Vascular/*drug effects
MH  - Glutathione/metabolism/*pharmacology
MH  - Oxidation-Reduction
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 0300-483X(91)90157-V [pii]
AID - 10.1016/0300-483x(91)90157-v [doi]
PST - ppublish
SO  - Toxicology. 1991;69(1):101-10. doi: 10.1016/0300-483x(91)90157-v.

PMID- 19692186
OWN - NLM
STAT- MEDLINE
DCOM- 20100316
LR  - 20131121
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 74
IP  - 1
DP  - 2010 Jan
TI  - Aspirin-associated iron loss as an anticancer mechanism.
PG  - 78-80
LID - 10.1016/j.mehy.2009.07.047 [doi]
AB  - A consensus view has emerged favoring an anticancer effect of long-term aspirin 
      use. Aspirin-induced loss of stored iron from chronic gastrointestinal bleeding 
      is proposed as a mechanism underlying this beneficial effect. In iron depletion, 
      less iron may be available for carcinogenesis through free-radical mediated 
      mechanisms and for promotion of tumor growth. Low-dose aspirin increases 
      gastrointestinal losses of transfused radiolabeled autologous red cells. 
      Observational studies report lower serum ferritin values with regular aspirin 
      use. A protective effect of induced iron reduction against cancer mortality has 
      been confirmed in a recent trial (FeAST) with subjects randomized to iron 
      reduction or observation. Serum ferritin reductions in the FeAST trial were 
      within conventionally normal reference ranges and were quantitatively similar to 
      ferritin reductions in observational studies in regular aspirin users. Delayed 
      anticancer effects of aspirin are compatible with the proposed mechanism, as 
      continual microbleeding has a gradual cumulative effect on stored iron.
FAU - Mascitelli, Luca
AU  - Mascitelli L
AD  - Medical Service, Comando Brigata Alpina Julia, Udine, Italy. lumasci@libero.it
FAU - Pezzetta, Francesca
AU  - Pezzetta F
FAU - Sullivan, Jerome L
AU  - Sullivan JL
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20090818
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Free Radicals)
RN  - 9007-73-2 (Ferritins)
RN  - E1UOL152H7 (Iron)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Aspirin/*adverse effects
MH  - Clinical Trials as Topic
MH  - Ferritins/metabolism
MH  - Free Radicals
MH  - Humans
MH  - Incidence
MH  - Iron/*metabolism
MH  - Models, Biological
MH  - Models, Statistical
MH  - Models, Theoretical
MH  - Neoplasms/*therapy
EDAT- 2009/08/21 09:00
MHDA- 2010/03/17 06:00
CRDT- 2009/08/21 09:00
PHST- 2009/07/23 00:00 [received]
PHST- 2009/07/26 00:00 [accepted]
PHST- 2009/08/21 09:00 [entrez]
PHST- 2009/08/21 09:00 [pubmed]
PHST- 2010/03/17 06:00 [medline]
AID - S0306-9877(09)00542-8 [pii]
AID - 10.1016/j.mehy.2009.07.047 [doi]
PST - ppublish
SO  - Med Hypotheses. 2010 Jan;74(1):78-80. doi: 10.1016/j.mehy.2009.07.047. Epub 2009 
      Aug 18.

PMID- 2247694
OWN - NLM
STAT- MEDLINE
DCOM- 19910107
LR  - 20131121
IS  - 0034-1193 (Print)
IS  - 0034-1193 (Linking)
VI  - 81
IP  - 7-8
DP  - 1990 Jul-Aug
TI  - [Still's disease in adults: diagnostic problems].
PG  - 479-81
AB  - Still's disease is a seronegative arthritis of children which, in a limited 
      number of cases, can affect adults. The diagnosis of adult-onset Still's disease 
      is characterized by high fever, arthritis and negative serologic tests for 
      rheumatoid factor and antinuclear antibodies and by at least two minor symptoms 
      (leukocytosis, evanescent rash, serositis, hepato- or splenomegaly, and 
      lympho-adenopathy). Since many diseases present analogous manifestations and the 
      adult-onset Still's disease is generally diagnosed by exclusion, we report two 
      patients, aged 26 and 39, with Still's disease, the former with a classic 
      clinical feature, the latter with a clinical feature characterized by severe 
      hepatic abnormalities. The determination of histocompatibility antigens can be 
      useful because some of them (HLA-DR4 in case 1 and HLA-DRw6 in case 2) are 
      frequently associated with the adult-onset Still's disease. The role of 
      anti-inflammatory therapy (acetylsalicylic acid, indomethacin, steroids) must be 
      emphasized, whose efficacy can constitute the pathognomonic element on which the 
      diagnosis of adult-onset Still's disease can be based in a proper clinical 
      pattern.
FAU - Foresti, V
AU  - Foresti V
AD  - Divisione medica III, Ospedale Fatebenefratelli e oftalmico, Presidio multizonale 
      ospedaliero dell'E.R.S.Z., Milano.
FAU - Casati, O
AU  - Casati O
FAU - Zubani, R
AU  - Zubani R
FAU - Parisio, E
AU  - Parisio E
FAU - Confalonieri, F
AU  - Confalonieri F
LA  - ita
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Malattia di Still dell'adulto: problemi diagnostici.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
RN  - 0 (Adrenal Cortex Hormones)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Age Factors
MH  - Arthritis, Juvenile/*diagnosis/drug therapy
MH  - Aspirin/therapeutic use
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Indomethacin/therapeutic use
MH  - Male
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
PST - ppublish
SO  - Recenti Prog Med. 1990 Jul-Aug;81(7-8):479-81.

PMID- 26556936
OWN - NLM
STAT- MEDLINE
DCOM- 20160225
LR  - 20220321
IS  - 1468-2877 (Electronic)
IS  - 0033-3549 (Print)
IS  - 0033-3549 (Linking)
VI  - 130
IP  - 6
DP  - 2015 Nov-Dec
TI  - Preventive Aspirin and Other Antiplatelet Medication Use Among U.S. Adults Aged ≥ 
      40 Years: Data from the National Health and Nutrition Examination Survey, 
      2011-2012.
PG  - 643-54
AB  - OBJECTIVE: We estimated the prevalence of preventive aspirin and/or other 
      antiplatelet medication use and the dosage of aspirin use in the U.S. adult 
      population. METHODS: We conducted cross-sectional analyses of a representative 
      sample (n=3,599) of U.S. adults aged ≥ 40 years from the National Health and 
      Nutrition Examination Survey, 2011-2012. RESULTS: In 2011-2012, one-third of U.S. 
      adults aged ≥ 40 years reported taking preventive aspirin and/or other 
      antiplatelet medications, 97% of whom indicated preventive aspirin use. 
      Preventive aspirin use increased with age (from 11% of those aged 40-49 years to 
      54% of those ≥ 80 years of age, p<0.001). Non-Hispanic white (35%) and black 
      (30%) adults were more likely to take preventive aspirin than non-Hispanic Asian 
      (20%, p<0.001) and Hispanic (22%, p=0.013) adults. Adults with, compared with 
      those without health insurance, and adults with ≥ 2 doctor visits in the past 
      year, diagnosed diabetes, hypertension, or high cholesterol were twice as likely 
      to take preventive aspirin. Among those with cardiovascular disease, 76% reported 
      taking preventive aspirin and/or other antiplatelet medications, of whom 91% were 
      taking preventive aspirin. Among adults without cardiovascular disease, 28% 
      reported taking preventive aspirin. Adherence rates to medically recommended 
      aspirin use were 82% overall, 91% for secondary prevention, and 79% for primary 
      prevention. Among current preventive aspirin users, 70% were taking 81 milligrams 
      (mg) of aspirin daily and 13% were taking 325 mg of aspirin daily. CONCLUSION: 
      The vast majority of antiplatelet therapy is preventive aspirin use. A 
      health-care provider's recommendation to take preventive aspirin is an important 
      determinant of current preventive aspirin use.
FAU - Gu, Qiuping
AU  - Gu Q
AD  - Centers for Disease Control and Prevention, National Center for Health 
      Statistics, Division of Health and Nutrition Examination Surveys, Hyattsville, 
      MD.
FAU - Dillon, Charles F
AU  - Dillon CF
AD  - Centers for Disease Control and Prevention, National Center for Health 
      Statistics, Division of Health and Nutrition Examination Surveys, Hyattsville, 
      MD.
FAU - Eberhardt, Mark S
AU  - Eberhardt MS
AD  - Centers for Disease Control and Prevention, National Center for Health 
      Statistics, Division of Health and Nutrition Examination Surveys, Hyattsville, 
      MD.
FAU - Wright, Jacqueline D
AU  - Wright JD
AD  - National Institutes of Health, National Heart, Lung, and Blood Institute, 
      Bethesda, MD.
FAU - Burt, Vicki L
AU  - Burt VL
AD  - Centers for Disease Control and Prevention, National Center for Health 
      Statistics, Division of Health and Nutrition Examination Surveys, Hyattsville, 
      MD.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Public Health Rep
JT  - Public health reports (Washington, D.C. : 1974)
JID - 9716844
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cross-Sectional Studies
MH  - *Drug Utilization Review
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Primary Prevention
MH  - Secondary Prevention
MH  - Surveys and Questionnaires
MH  - United States
PMC - PMC4612173
EDAT- 2015/11/12 06:00
MHDA- 2016/02/26 06:00
CRDT- 2015/11/12 06:00
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
AID - 14_Gu [pii]
AID - 10.1177/003335491513000614 [doi]
PST - ppublish
SO  - Public Health Rep. 2015 Nov-Dec;130(6):643-54. doi: 10.1177/003335491513000614.

PMID- 14583989
OWN - NLM
STAT- MEDLINE
DCOM- 20040504
LR  - 20220408
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 4
DP  - 2003
TI  - Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major 
      gynaecological surgery.
PG  - CD003679
AB  - BACKGROUND: The reported overall risk of deep venous thrombosis in gynaecological 
      surgery ranges from 7 to 45%. Fatal pulmonary embolism is estimated to occur in 
      nearly 1% of these women. Pharmaceutical interventions are one possible 
      prophylactic measure for preventing emboli in women undergoing major 
      gynaecological surgery. Agents include unfractionated heparin (low -dose and 
      adjusted-dose), low-molecular-weight heparins, heparinoids and warfarin. 
      OBJECTIVES: The objective of this review was to evaluate the effectiveness of 
      warfarin, heparin and aspirin in preventing thromboembolism after major 
      gynaecological surgery. SEARCH STRATEGY: We searched the Cochrane Menstrual 
      Disorders and Subfertility Group trials register (searched 15 August 2003), the 
      Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library issue 
      2, 2003), MEDLINE (1966 to April 2003), EMBASE (1985 to April 2003), and CINAHL 
      (1982 to April 2003). References from relevant articles were searched and authors 
      contacted where necessary. In addition we contacted experts in the field for 
      unpublished works. SELECTION CRITERIA: Randomised controlled trials of heparins, 
      warfarin or aspirin to prevent thromboembolism after major gynaecological surgery 
      were eligible for inclusion. DATA COLLECTION AND ANALYSIS: Thirty-three trials 
      were identified in the initial search. On careful inspection only eight of these 
      met the inclusion criteria. Trials were data extracted and assessed for quality 
      by at least two reviewers. Data were combined for meta-analysis using odds ratios 
      for dichotomous data or weighted mean difference for continuous data. A random 
      effects statistical model was used. MAIN RESULTS: The meta-analysis of heparin 
      versus placebo found a statistically significant decrease in the number of DVTs 
      in both the all women group (including those with and without malignancy) (OR 
      0.30, 95% CI 0.12 to 0.76) and the subgroup of only women with malignancy (OR 
      0.30, 95% CI 0.10 to 0.89). There was no significant difference in the incidence 
      of PE. Oral warfarin reduced DVT when compared to placebo in all women (OR 0.22, 
      95% CI 0.06 to 0.86) and in women with malignancy (OR 0.18, 95% CI 0.04 to 0.87). 
      Meta-analyses of UH and LMWH showed no statistical difference in any comparison. 
      No studies compared aspirin alone to placebo, heparin or warfarin. There was a 
      statistically significant increase in injection site haematomas associated with 
      heparin compared to placebo (OR 0.30, 95% CI 0.10 to 0.89). REVIEWER'S 
      CONCLUSIONS: Women, undergoing major gynaecological surgery and without 
      contraindications to anticoagulants should be offered thromboprophylaxis. 
      Evidence suggests that UH and LMWH are equally as effective in preventing DVT and 
      the one trial available suggests that warfarin is as effective as UH. There is no 
      evidence as yet to suggest that warfarin, heparin or aspirin reduce incidence of 
      PE.
FAU - Oates-Whitehead, R M
AU  - Oates-Whitehead RM
AD  - Research Division, Royal College of Paediatrics and Child Health, 50 Hallam 
      Street, London, UK, W1W 6DE.
FAU - D'Angelo, A
AU  - D'Angelo A
FAU - Mol, B
AU  - Mol B
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br J Perioper Nurs. 2004 Jul;14(7):285. PMID: 15704371
UIN - Cochrane Database Syst Rev. 2003;(4):CD003679. PMID: 17636729
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Gynecologic Surgical Procedures
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Postoperative Complications/*prevention & control
MH  - Pulmonary Embolism/*prevention & control
MH  - Venous Thrombosis/*prevention & control
MH  - Warfarin/therapeutic use
RF  - 43
EDAT- 2003/10/30 05:00
MHDA- 2004/05/05 05:00
CRDT- 2003/10/30 05:00
PHST- 2003/10/30 05:00 [pubmed]
PHST- 2004/05/05 05:00 [medline]
PHST- 2003/10/30 05:00 [entrez]
AID - 10.1002/14651858.CD003679 [doi]
PST - ppublish
SO  - Cochrane Database Syst Rev. 2003;(4):CD003679. doi: 10.1002/14651858.CD003679.

PMID- 29350390
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1897-4279 (Electronic)
IS  - 0022-9032 (Linking)
VI  - 76
IP  - 2
DP  - 2018
TI  - Dual antiplatelet therapy is safe and efficient after left atrial appendage 
      closure.
PG  - 459-463
LID - 10.5603/KP.a2017.0245 [doi]
AB  - BACKGROUND: Despite results of the PROTECT AF trial, many patients undergoing 
      left atrial appendage closure (LAAC) have unconditional contraindications to 
      warfarin. AIM: We sought to investigate whether double antiplatelet therapy 
      (DAPT) is safe in patients after LAAC. METHODS: Forty-four consecutive patients 
      (22 males, mean age 74 ± 7.8 years) with non-valvular atrial fibrillation (NVAF) 
      underwent LAAC procedure using a Watchman device followed by DAPT (75 mg/d 
      aspirin and 75 mg/d clopidogrel). After the procedure and during 98 days' 
      follow-up including transoesophageal echocardiography, peri-procedural 
      complications and clinical outcomes were investigated. RESULTS: Mean CHA2DS2-VASc 
      score was 4.9 ± 1.5 and mean HAS-BLED score was 3.6 ± 0.8. The main LAAC 
      indication was contraindication to anticoagulation reflected by HAS-BLED score ≥ 
      3 observed in 95.5% cases (among them history of bleeding in 38 patients, 90.5%). 
      36.4% of patients have history of stroke or transient ischaemic attack. The 
      procedure was successful in 97.7%. Peri-procedural complications were tamponade 
      (2.3%) and one death (2.3%) unrelated to the procedure with no bleeding or 
      vascular complications. During follow-up neither stroke nor bleeding were 
      observed, whereas two device related thrombi and two unrelated deaths occurred. 
      CONCLUSIONS: LAAC followed by DAPT seems to be a safe and efficient alternative 
      for stroke prevention in patients with NVAF who have contraindications to 
      anticoagulation therapy. This strategy may provide a significant reduction of 
      events such as stroke and bleeding versus the score-predicted rate.
FAU - Maksym, Jakub
AU  - Maksym J
FAU - Mazurek, Tomasz
AU  - Mazurek T
AD  - 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, 
      Poland. tmazurek@kardia.pl.
FAU - Kochman, Janusz
AU  - Kochman J
FAU - Grygier, Marek
AU  - Grygier M
FAU - Kapłon-Cieślicka, Agnieszka
AU  - Kapłon-Cieślicka A
FAU - Marchel, Michał
AU  - Marchel M
FAU - Lodziński, Piotr
AU  - Lodziński P
FAU - Piątkowski, Radosław
AU  - Piątkowski R
FAU - Wilimski, Radosław
AU  - Wilimski R
FAU - Czub, Paweł
AU  - Czub P
FAU - Fojt, Anna
AU  - Fojt A
FAU - Karolczak, Natalia
AU  - Karolczak N
FAU - Hendzel, Piotr
AU  - Hendzel P
FAU - Opolski, Grzegorz
AU  - Opolski G
LA  - eng
PT  - Journal Article
DEP - 20180119
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Appendage/*surgery
MH  - Atrial Fibrillation/complications/*surgery
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Patient Safety
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Stroke/etiology/prevention & control
MH  - Treatment Outcome
OTO - NOTNLM
OT  - atrial fibrillation
OT  - bleeding
OT  - dual antiplatelet therapy
OT  - left atrial appendage closure
OT  - stroke
EDAT- 2018/01/20 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/01/20 06:00
PHST- 2017/08/01 00:00 [received]
PHST- 2017/10/12 00:00 [accepted]
PHST- 2017/09/08 00:00 [revised]
PHST- 2018/01/20 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/01/20 06:00 [entrez]
AID - VM/OJS/KP/11549 [pii]
AID - 10.5603/KP.a2017.0245 [doi]
PST - ppublish
SO  - Kardiol Pol. 2018;76(2):459-463. doi: 10.5603/KP.a2017.0245. Epub 2018 Jan 19.

PMID- 8794671
OWN - NLM
STAT- MEDLINE
DCOM- 19961025
LR  - 20171116
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 130
IP  - 11
DP  - 1996 Jun 2
TI  - [Thrombolytic treatment for acute myocardial infarction in menstruating women].
PG  - 729-31, 800
AB  - A 44-year-old woman was admitted to the intensive cardiac care unit due to an 
      extensive anterior myocardial infarction of acute onset. Because she was 
      menstruating, thrombolytic treatment was relatively contraindicated. On primary 
      coronary angioplasty, an occluding clot was found in her proximal, left anterior 
      coronary artery. Despite menstrual bleeding, 500,000 IU/10 min of urokinase was 
      infused into the artery. After restoration of blood flow, angioplasty was 
      performed and a 90% residual stenosis was found in the artery. She was then fully 
      heparinized for 5 days and concomitantly given aspirin, 100 mg/day. There were no 
      complications, nor was menstrual bleeding excessive. She was discharged in good 
      clinical and hemodynamic status after 10 days of hospitalization. Based on our 
      experience, and reinforced by an additional 23 cases reported by others, we 
      suggest that thrombolytic treatment should not be withheld even in menstruating 
      women, when access to primary, coronary angioplasty is not available.
FAU - Avizohar, O
AU  - Avizohar O
AD  - Cardiology Dept., Tel Aviv Medical Center, Tel Aviv University.
FAU - Roth, A
AU  - Roth A
LA  - heb
PT  - Case Reports
PT  - Journal Article
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Angioplasty
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Contraindications
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - *Menstruation
MH  - Myocardial Infarction/*therapy
MH  - *Thrombolytic Therapy
MH  - Urokinase-Type Plasminogen Activator/*therapeutic use
EDAT- 1996/06/02 00:00
MHDA- 1996/06/02 00:01
CRDT- 1996/06/02 00:00
PHST- 1996/06/02 00:00 [pubmed]
PHST- 1996/06/02 00:01 [medline]
PHST- 1996/06/02 00:00 [entrez]
PST - ppublish
SO  - Harefuah. 1996 Jun 2;130(11):729-31, 800.

PMID- 6848143
OWN - NLM
STAT- MEDLINE
DCOM- 19830214
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 61
IP  - 1
DP  - 1983 Jan
TI  - Passive participation of fixed platelets in aggregation facilitated by covalently 
      bound fibrinogen.
PG  - 186-91
AB  - The role of fibrinogen in interplatelet recognition during aggregation was 
      examined by combining two cell types: fresh platelets (in limiting density) 
      activated by thrombin or A23187, and formaldehyde-fixed platelets, bearing 
      cross-linked fibrinogen. The fixed platelets did not aggregate by themselves, nor 
      with resting platelets, but were capable of interacting with activated platelets 
      and of participating passively in aggregation. The participation, expressed by 
      enhanced aggregation, was assayed by the conventional turbidometric traces and by 
      cosedimentation of fixed 3H-platelets with aggregates of fresh platelets. 
      Platelet suspensions, prepared without special means to avert spontaneous 
      activation, retained plasma fibrinogen to the extent of 50 micrograms/ml of a 
      suspension containing 10(8) platelets, and the derived fixed platelets 
      participated in aggregation, independently of added fibrinogen. The capability of 
      such fixed platelets to participate in aggregation was sensitive to proteolytic 
      digestion and to massive acetylation. When platelet separation was aided by 
      apyrase or aspirin, PGE1 and gel filtration, the residual plasma fibrinogen was 
      limited to 0.4 micrograms/ml of 10(8) platelet suspension. The derived fixed 
      platelets were incapable of participating in aggregation unless fibrinogen was 
      added prior to fixation. The affixed fibrinogen could not be replaced by soluble 
      fibrinogen or affixed albumin. It is concluded that fibrinogen, which binds to 
      platelets upon activation or is linked to them covalently, is a recognition site 
      for platelet-platelet interaction during aggregation.
FAU - Agam, G
AU  - Agam G
FAU - Livne, A
AU  - Livne A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 1HG84L3525 (Formaldehyde)
RN  - 9001-32-5 (Fibrinogen)
RN  - EC 3.4.21.5 (Thrombin)
RN  - EC 3.6.1.5 (Apyrase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apyrase/pharmacology
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cell Communication
MH  - Cell Separation
MH  - Fibrinogen/*pharmacology
MH  - Formaldehyde/*pharmacology
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Thrombin/pharmacology
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - S0006-4971(20)74346-6 [pii]
PST - ppublish
SO  - Blood. 1983 Jan;61(1):186-91.

PMID- 25994838
OWN - NLM
STAT- MEDLINE
DCOM- 20160606
LR  - 20220318
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 114
IP  - 3
DP  - 2015 Aug 31
TI  - Two doses of rivaroxaban versus aspirin for prevention of recurrent venous 
      thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
PG  - 645-50
LID - 10.1160/TH15-02-0131 [doi]
AB  - Patients with unprovoked venous thromboembolism (VTE) are at high risk for 
      recurrence. Although rivaroxaban is effective for extended VTE treatment at a 
      dose of 20 mg once daily, use of the 10 mg dose may further improve its 
      benefit-to-risk ratio. Low-dose aspirin also reduces rates of recurrent VTE, but 
      has not been compared with anticoagulant therapy. The EINSTEIN CHOICE study is a 
      multicentre, randomised, double-blind, active-controlled, event-driven study 
      comparing the efficacy and safety of two once daily doses of rivaroxaban (20 and 
      10 mg) with aspirin (100 mg daily) for the prevention of recurrent VTE in 
      patients who completed 6-12 months of anticoagulant therapy for their index acute 
      VTE event. All treatments will be given for 12 months. The primary efficacy 
      objective is to determine whether both doses of rivaroxaban are superior to 
      aspirin for the prevention of symptomatic recurrent VTE, while the principal 
      safety outcome is the incidence of major bleeding. The trial is anticipated to 
      enrol 2,850 patients from 230 sites in 31 countries over a period of 27 months. 
      In conclusion, the EINSTEIN CHOICE study will provide new insights into the 
      optimal antithrombotic strategy for extended VTE treatment by comparing two doses 
      of rivaroxaban with aspirin (clinicaltrials.gov NCT02064439).
FAU - Weitz, Jeffrey I
AU  - Weitz JI
AD  - Jeffrey I. Weitz, Thrombosis & Atherosclerosis Research Institute, and McMaster 
      University, Hamilton, Ontario, Canada, E-mail: weitzj@taari.ca.
FAU - Bauersachs, Rupert
AU  - Bauersachs R
FAU - Beyer-Westendorf, Jan
AU  - Beyer-Westendorf J
FAU - Bounameaux, Henri
AU  - Bounameaux H
FAU - Brighton, Timothy A
AU  - Brighton TA
FAU - Cohen, Alexander T
AU  - Cohen AT
FAU - Davidson, Bruce L
AU  - Davidson BL
FAU - Holberg, Gerlind
AU  - Holberg G
FAU - Kakkar, Ajay
AU  - Kakkar A
FAU - Lensing, Anthonie W A
AU  - Lensing AW
FAU - Prins, Martin
AU  - Prins M
FAU - Haskell, Lloyd
AU  - Haskell L
FAU - van Bellen, Bonno
AU  - van Bellen B
FAU - Verhamme, Peter
AU  - Verhamme P
FAU - Wells, Philip S
AU  - Wells PS
FAU - Prandoni, Paolo
AU  - Prandoni P
CN  - EINSTEIN CHOICE Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT02064439
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150521
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Fibrinolytic Agents)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clinical Protocols
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Recurrence
MH  - Research Design
MH  - Risk Assessment
MH  - Risk Factors
MH  - Rivaroxaban/*administration & dosage/adverse effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Venous Thromboembolism/diagnosis/*prevention & control
OTO - NOTNLM
OT  - Venous thrombosis
OT  - antiplatelet agents
OT  - deep-vein thrombosis
OT  - prevention
OT  - pulmonary embolism
EDAT- 2015/05/23 06:00
MHDA- 2016/06/09 06:00
CRDT- 2015/05/22 06:00
PHST- 2015/02/18 00:00 [received]
PHST- 2015/04/10 00:00 [accepted]
PHST- 2015/05/22 06:00 [entrez]
PHST- 2015/05/23 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - 15-02-0131 [pii]
AID - 10.1160/TH15-02-0131 [doi]
PST - ppublish
SO  - Thromb Haemost. 2015 Aug 31;114(3):645-50. doi: 10.1160/TH15-02-0131. Epub 2015 
      May 21.

PMID- 21613787
OWN - NLM
STAT- MEDLINE
DCOM- 20111207
LR  - 20210105
IS  - 1421-9786 (Electronic)
IS  - 1015-9770 (Linking)
VI  - 32
IP  - 1
DP  - 2011
TI  - Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized 
      double-blind non-inferiority trial.
PG  - 65-71
LID - 10.1159/000327036 [doi]
AB  - BACKGROUND: Aspirin is a proven antiplatelet agent in acute ischemic stroke, and 
      there are no current guidelines for other antiplatelet treatments. We aimed to 
      compare the efficacy and safety of cilostazol with aspirin in acute stroke. 
      METHODS: Patients with measurable neurological deficits (NIHSS score ≤15) within 
      48 h of onset were randomly assigned to cilostazol (200 mg/day) or aspirin (300 
      mg/day) for 90 days. The primary endpoint was a modified Rankin Scale (mRS) score 
      of 0-2 at 90 days. Cardiovascular events, bleeding complications, and other 
      functional outcomes were also assessed. Statistical analysis was carried out by 
      intention-to-treat and per-protocol bases. This trial is registered with 
      ClinicalTrials.gov (NCT00272454). RESULTS: In total, 458 patients were enrolled 
      (mean age of 63 years, median NIHSS of 3), and mRS at 90 days was obtained in 447 
      patients. The primary endpoint was achieved in 76% (173/228) of those randomized 
      to cilostazol and in 75% (165/219) assigned to aspirin, which supported the 
      pre-specified non-inferiority of cilostazol to aspirin (95% CI of proportion 
      difference: -6.15 to 7.22%, p = 0.0004). These results were also supported by 
      per-protocol analysis (p = 0.045). Cardiovascular events occurred in 6 patients 
      (3%) treated with cilostazol, and in 9 patients (4%) treated with aspirin (p = 
      0.41). Adverse events were more common in cilostazol-treated patients during the 
      trial (91 vs. 85%, p = 0.055), while the frequencies of bleeding complications 
      (cilostazol 11%, aspirin 13%, p = 0.43) or drug discontinuation (cilostazol 10%, 
      aspirin 7%, p = 0.32) were not different. CONCLUSION: Cilostazol is feasible in 
      acute ischemic stroke, and comparable to aspirin in its efficacy and safety.
CI  - Copyright © 2011 S. Karger AG, Basel.
FAU - Lee, Yong-Seok
AU  - Lee YS
AD  - Seoul National University Boramae Medical Center, Seoul, Korea. 
      mercades@snu.ac.kr
FAU - Bae, Hee-Joon
AU  - Bae HJ
FAU - Kang, Dong-Wha
AU  - Kang DW
FAU - Lee, Seung-Hoon
AU  - Lee SH
FAU - Yu, Kyungho
AU  - Yu K
FAU - Park, Jong-Moo
AU  - Park JM
FAU - Cho, Yong-Jin
AU  - Cho YJ
FAU - Hong, Keun-Sik
AU  - Hong KS
FAU - Kim, Dong-Eog
AU  - Kim DE
FAU - Kwon, Sun Uck
AU  - Kwon SU
FAU - Lee, Kyung Bok
AU  - Lee KB
FAU - Rha, Joung-Ho
AU  - Rha JH
FAU - Koo, Jaseong
AU  - Koo J
FAU - Han, Moon-Gu
AU  - Han MG
FAU - Lee, Soo Joo
AU  - Lee SJ
FAU - Lee, Ju-Hun
AU  - Lee JH
FAU - Jung, Sang Wook
AU  - Jung SW
FAU - Lee, Byung-Chul
AU  - Lee BC
FAU - Kim, Jong S
AU  - Kim JS
LA  - eng
SI  - ClinicalTrials.gov/NCT00272454
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110525
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cilostazol
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phosphodiesterase Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Prevalence
MH  - Risk Factors
MH  - Stroke/*drug therapy
MH  - Tetrazoles/adverse effects/pharmacology/*therapeutic use
MH  - Treatment Outcome
MH  - Vasodilation/drug effects
EDAT- 2011/05/27 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/05/27 06:00
PHST- 2010/11/21 00:00 [received]
PHST- 2011/03/03 00:00 [accepted]
PHST- 2011/05/27 06:00 [entrez]
PHST- 2011/05/27 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 000327036 [pii]
AID - 10.1159/000327036 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2011;32(1):65-71. doi: 10.1159/000327036. Epub 2011 May 25.

PMID- 7475118
OWN - NLM
STAT- MEDLINE
DCOM- 19951227
LR  - 20190830
IS  - 0378-8741 (Print)
IS  - 0378-8741 (Linking)
VI  - 46
IP  - 1
DP  - 1995 Apr
TI  - Anti-ulcerogenic evaluation of the methanolic extracts of some indigenous 
      medicinal plants of Pakistan in aspirin-ulcerated rats.
PG  - 1-6
AB  - Anti-ulcerogenic activity of the methanolic extracts of 4 medicinal plants were 
      studied in aspirin-induced gastric ulcers in rats. Their effects on the volume of 
      gastric juice secreted, acid output, peptic activity, mucin activity and curative 
      ratio were recorded. Bauhinia racemosa (flower buds) decreased the ulcer index 
      significantly, and Moringa pterygosperma (flower buds) showed some decrease in 
      the ulcer index. Trianthema pentandra (whole plant) did not show any decrease in 
      the acid or pepsin content or any increase in mucin; however, it showed a highly 
      significant decrease in the ulcer index. Cordia latifolia (ripened fruit) did not 
      however decrease the ulcer index.
FAU - Akhtar, A H
AU  - Akhtar AH
AD  - Pharmacology Section, P.C.S.I.R. Laboratories, Peshawar, Pakistan.
FAU - Ahmad, K U
AU  - Ahmad KU
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Mucins)
RN  - 0 (Plant Extracts)
RN  - R16CO5Y76E (Aspirin)
RN  - Y4S76JWI15 (Methanol)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Ulcer Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Aspirin/administration & dosage/*toxicity
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Fabaceae
MH  - Gastric Acid/metabolism
MH  - Gastric Juice/metabolism
MH  - Methanol/chemistry
MH  - Mucins/metabolism
MH  - Pakistan
MH  - Plant Extracts/administration & dosage/pharmacology/*therapeutic use
MH  - *Plants, Medicinal
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Stomach Ulcer/chemically induced/*drug therapy
EDAT- 1995/04/01 00:00
MHDA- 1995/04/01 00:01
CRDT- 1995/04/01 00:00
PHST- 1995/04/01 00:00 [pubmed]
PHST- 1995/04/01 00:01 [medline]
PHST- 1995/04/01 00:00 [entrez]
AID - 037887419401220T [pii]
AID - 10.1016/0378-8741(94)01220-t [doi]
PST - ppublish
SO  - J Ethnopharmacol. 1995 Apr;46(1):1-6. doi: 10.1016/0378-8741(94)01220-t.

PMID- 27178890
OWN - NLM
STAT- MEDLINE
DCOM- 20170227
LR  - 20170817
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 37
IP  - 3
DP  - 2016 May
TI  - Clinical benefits of aspirin desensitization in patients with nonsteroidal 
      anti-inflammatory drug exacerbated respiratory disease are not related to urinary 
      eicosanoid release and are accompanied with decreased urine creatinine.
PG  - 216-24
LID - 10.2500/aap.2016.37.3935 [doi]
AB  - BACKGROUND: Treatment with acetylsalicylic acid (ASA) after desensitization may 
      be a therapeutic option in patients with nonsteroidal anti-inflammatory drug 
      exacerbated respiratory disease (NERD). The mechanisms that lead to improvement 
      in rhinosinusitis and asthma symptoms remain unknown. AIM: To attribute the 
      documented clinical effects of ASA treatment of chronic rhinosinusitis and/or 
      asthma to the release of eicosanoid metabolites in urine. METHODS: Fourteen 
      patients with NERD were successfully desensitized, and, eventually, eight 
      patients were treated with 650 mg of ASA daily for 3 months. In addition to 
      clinical assessments, nuclear magnetic resonance imaging and smell test were 
      performed before and after treatment with ASA. Venous blood and urine were 
      collected before desensitization and after 1 and 3 months of treatment. The 
      levels of urinary leukotrienes (LT) (cysteinyl LT and LTE4) and tetranor PGDM 
      (metabolite of prostaglandin D2) were measured by enzyme-linked immunosorbent 
      assay. RESULTS: Treatment with ASA after desensitization alleviated symptoms of 
      rhinosinusitis, improved nasal patency (mean, 50% decrease in peak nasal 
      inspiratory flow) and sense of smell (fourfold increase in smell test score) in 
      as early as 4 weeks. Clinical improvements were not accompanied by any change in 
      sinonasal mucosa thickness as assessed with nuclear magnetic resonance. Urinary 
      cysteinyl LTs, LTE4, and prostaglandin D2 metabolite remained relatively stable 
      during ASA treatment and did not correlate with clinical improvements. 
      Desensitization was associated with a progressive decrease of urinary creatinine. 
      CONCLUSION: Clinical improvement in rhinosinusitis and/or asthma after ASA 
      desensitization was not related to concentrations of urinary eicosanoid 
      metabolites. A decrease of urinary creatinine requires further study to determine 
      the renal safety of long-term treatment with ASA after desensitization.
FAU - Makowska, Joanna S
AU  - Makowska JS
AD  - Department of Rheumatology, Medical University of Lodz, Poland.
FAU - Olszewska-Ziąber, Agnieszka
AU  - Olszewska-Ziąber A
FAU - Bieńkiewicz, Barbara
AU  - Bieńkiewicz B
FAU - Lewandowska-Polak, Anna
AU  - Lewandowska-Polak A
FAU - Kurowski, Marcin
AU  - Kurowski M
FAU - Woźniakowski, Bartłomiej
AU  - Woźniakowski B
FAU - Rotkiewicz, Arkadiusz
AU  - Rotkiewicz A
FAU - Kowalski, Marek L
AU  - Kowalski ML
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (11,15-dioxo-9-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Eicosanoids)
RN  - 0 (Leukotrienes)
RN  - MU72812GK0 (Creatine)
RN  - R16CO5Y76E (Aspirin)
RN  - RXY07S6CZ2 (Prostaglandin D2)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/immunology/pharmacology/*therapeutic use
MH  - Asthma/urine
MH  - Creatine/*urine
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/*therapy
MH  - Eicosanoids/*urine
MH  - Humans
MH  - Leukotrienes/urine
MH  - Prostaglandin D2/analogs & derivatives/urine
MH  - Respiratory Tract Diseases/chemically induced/immunology/urine
MH  - Sinusitis/urine
EDAT- 2016/05/15 06:00
MHDA- 2017/02/28 06:00
CRDT- 2016/05/15 06:00
PHST- 2016/05/15 06:00 [entrez]
PHST- 2016/05/15 06:00 [pubmed]
PHST- 2017/02/28 06:00 [medline]
AID - 10.2500/aap.2016.37.3935 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2016 May;37(3):216-24. doi: 10.2500/aap.2016.37.3935.

PMID- 26926089
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1743-9159 (Electronic)
IS  - 1743-9159 (Linking)
VI  - 28
DP  - 2016 Apr
TI  - Do postoperative NSAIDs improve breast cancer outcomes? A Best Evidence Topic.
PG  - 173-8
LID - S1743-9191(16)00196-5 [pii]
LID - 10.1016/j.ijsu.2016.02.086 [doi]
AB  - A Best Evidence Topic was undertaken to systematically review the evidence 
      regarding the use of NSAIDS in breast cancer patients. The search strategy 
      generated 149 titles, of which six were best placed to answer the clinical 
      question. These included three prospective cohort studies, two retrospective 
      cohort studies and one case control study, examining a total of 18,415 breast 
      cancer patients. The study methodologies were highly variable and all relied on 
      approximate measures of NSAID consumption. There is limited evidence that use of 
      aspirin and non-aspirin NSAIDs may be associated with decreased breast cancer 
      mortality and all-cause mortality in patients diagnosed with breast cancer. 
      Optimum type and dosage of NSAID for this purpose remains unclear. There is a 
      need for large-scale randomised controlled trials to further clarify.
CI  - Crown Copyright © 2016. Published by Elsevier Ltd. All rights reserved.
FAU - Sutton, Liam
AU  - Sutton L
AD  - Kingston Hospital NHS Foundation Trust, United Kingdom. Electronic address: 
      liammsutton@gmail.com.
FAU - McGlone, Emma
AU  - McGlone E
AD  - Kingston Hospital NHS Foundation Trust, United Kingdom.
FAU - Lambert, Kelly
AU  - Lambert K
AD  - Kingston Hospital NHS Foundation Trust, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20160227
PL  - United States
TA  - Int J Surg
JT  - International journal of surgery (London, England)
JID - 101228232
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Breast Neoplasms/*drug therapy/mortality/surgery
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Postoperative Period
OTO - NOTNLM
OT  - Aspirin
OT  - Breast cancer
OT  - NSAID
OT  - Non steroidal anti inflammatory
OT  - Survival
EDAT- 2016/03/02 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/03/02 06:00
PHST- 2015/12/14 00:00 [received]
PHST- 2016/02/22 00:00 [accepted]
PHST- 2016/03/02 06:00 [entrez]
PHST- 2016/03/02 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S1743-9191(16)00196-5 [pii]
AID - 10.1016/j.ijsu.2016.02.086 [doi]
PST - ppublish
SO  - Int J Surg. 2016 Apr;28:173-8. doi: 10.1016/j.ijsu.2016.02.086. Epub 2016 Feb 27.

PMID- 10489702
OWN - NLM
STAT- MEDLINE
DCOM- 19991028
LR  - 20190515
IS  - 0001-4966 (Print)
IS  - 0001-4966 (Linking)
VI  - 106
IP  - 3 Pt 1
DP  - 1999 Sep
TI  - Effects of aspirin on psychophysical measures of frequency selectivity, two-tone 
      suppression, and growth of masking.
PG  - 1436-51
AB  - Three psychophysical measures of nonlinearity were evaluated before and during a 
      course of aspirin ingestion to investigate the role of outer hair cells (OHCs) in 
      these measures, as aspirin is thought to alter the functioning of OHCs. Six 
      normal-hearing individuals received a moderate dose (3.9 g/day) of aspirin for 
      four days, producing essentially flat, temporary hearing losses that ranged from 
      5-20 dB. The losses were about 2 dB greater for a 300-ms signal than for a 15-ms 
      signal, indicating reduced temporal integration with aspirin. On the final three 
      days of aspirin use, three experiments were completed; each was designed to 
      measure one aspect of nonlinear behavior: (1) the effects of level on frequency 
      selectivity in simultaneous masking using notched-noise maskers, (2) two-tone 
      suppression using forward maskers at the signal frequency (fs) and suppressor 
      tones above fs, and (3) growth-of-masking functions in forward masking using a 
      masking tone below fs. Signal frequencies of 750 and 3000 Hz were used to 
      evaluate the effects of aspirin at relatively low- and high-frequency regions of 
      the cochlea. In experiment 1, aspirin broadened the auditory filters and reduced 
      the effect of level on frequency selectivity. In experiment 2, aspirin reduced or 
      eliminated two-tone suppression. And, in experiment 3, aspirin reduced the slopes 
      of the growth-of-masking functions. Thus, the aspirin was effective in reducing 
      nonlinearity in all three experiments, suggesting that these measures reflect the 
      same (or a similar) active, nonlinear mechanism, namely the compressive 
      nonlinearity provided by the OHCs. In all experiments, aspirin tended to have 
      larger detrimental effects on the nonlinear measures at 3000 Hz than at 750 Hz, 
      which can be explained in terms of greater involvement of nonlinear processing at 
      higher frequencies. Finally, these effects of aspirin were found to be similar to 
      those observed in preliminary measurements in two subjects with mild, permanent 
      hearing loss.
FAU - Hicks, M L
AU  - Hicks ML
AD  - Department of Speech and Hearing Science, Arizona State University, Tempe 
      85287-1908, USA. michelle.hicks@asu.edu
FAU - Bacon, S P
AU  - Bacon SP
LA  - eng
GR  - DC01376/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Acoust Soc Am
JT  - The Journal of the Acoustical Society of America
JID - 7503051
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Auditory Threshold/drug effects
MH  - Female
MH  - Hair Cells, Auditory, Outer/*drug effects
MH  - Humans
MH  - Male
MH  - *Perceptual Masking
MH  - Pitch Discrimination/*drug effects
MH  - Psychoacoustics
EDAT- 1999/09/18 00:00
MHDA- 1999/09/18 00:01
CRDT- 1999/09/18 00:00
PHST- 1999/09/18 00:00 [pubmed]
PHST- 1999/09/18 00:01 [medline]
PHST- 1999/09/18 00:00 [entrez]
AID - 10.1121/1.427146 [doi]
PST - ppublish
SO  - J Acoust Soc Am. 1999 Sep;106(3 Pt 1):1436-51. doi: 10.1121/1.427146.

PMID- 17694223
OWN - NLM
STAT- MEDLINE
DCOM- 20071004
LR  - 20181201
IS  - 0720-9355 (Print)
IS  - 0720-9355 (Linking)
VI  - 27
IP  - 3
DP  - 2007 Aug
TI  - [Modified platelet aggregation test in patients on ASA and/or clopidogrel].
PG  - 163-76
AB  - Therapy with acetylsalicylic acid (ASA) and/or clopidogrel is used to achieve 
      prophylactic inhibition of platelet aggregation in patients with arterial 
      thrombosis. We examined if aggregometry can be used to see the effect of 
      antiplatelet drugs (ASA 30, 50, 100, 300 mg/d, clopidogrel 75 mg/d or ASA 100 + 
      clopidogrel 75 mg/d). A modified platelet aggregation test was used to 
      investigate maximum aggregation in response to ADP, collagen, adrenalin and 
      arachidonic acid. Reference values were established based on healthy individuals. 
      We devised a simple scoring system for detection of inadequate platelet 
      inhibition. Compared with the control group, we detected a significant delay of 
      maximum aggregation in response to all agonists in patients on ASA and 
      combination therapy ASA + clopidogrel. Patients on clopidogrel alone were found 
      to have prolonged aggregation when induced with ADP, collagen and arachidonic 
      acid. The failure rate to achieve adequate platelet inhibition on 100 mg/d ASA, 
      75 mg/d clopidogrel or combination therapy was 27%, 26% and 7%, respectively. Our 
      results demonstrate that platelet inhibition in aggregometry is inadequate in 
      many patients with arterial thrombosis.
FAU - Eder, C
AU  - Eder C
AD  - Klinikum Löbau-Zittau, Klinik für Innere Medizin, Görlitzer Str. 8, 02763 Zittau. 
      innere.zi@kllz.de
FAU - Funke, U
AU  - Funke U
FAU - Schulze, M
AU  - Schulze M
FAU - Lutze, G
AU  - Lutze G
FAU - Zimmermann, M
AU  - Zimmermann M
FAU - Prasse, T
AU  - Prasse T
FAU - Töpfer, G
AU  - Töpfer G
LA  - ger
PT  - Journal Article
TT  - Kontrolle der Thrombozytenaggregations-hemmung unter Therapie mit 
      Azetylsalizylsäure und/oder Clopidogrel mit einem modifizierten 
      Thrombozytenaggregationstest.
PL  - Germany
TA  - Hamostaseologie
JT  - Hamostaseologie
JID - 8204531
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Aged
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Collagen/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Epinephrine/pharmacology
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Reference Values
MH  - Thrombosis/blood/*drug therapy
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2007/08/19 09:00
MHDA- 2007/10/05 09:00
CRDT- 2007/08/19 09:00
PHST- 2007/08/19 09:00 [pubmed]
PHST- 2007/10/05 09:00 [medline]
PHST- 2007/08/19 09:00 [entrez]
AID - 07030163 [pii]
PST - ppublish
SO  - Hamostaseologie. 2007 Aug;27(3):163-76.

PMID- 1268322
OWN - NLM
STAT- MEDLINE
DCOM- 19760802
LR  - 20191028
IS  - 0306-042X (Print)
IS  - 0306-042X (Linking)
VI  - 3
IP  - 2
DP  - 1976 Apr
TI  - Gas chromatographic mass spectrometric evaluation of free organic acids in human 
      saliva.
PG  - 77-80
AB  - Excellent resolution and subsequent identification of free organic acids 
      extracted from mixed, unstimulated human saliva was obtained by gas 
      chromatography using high resolution open tubular glass capillary columns coupled 
      with mass spectrometry computer instrumentation. In addition to the organic 
      acids, identified as their trimethylsilyl derivaties, the presence of 
      2,6-di-t-butylcresol--a food preservative--and cholesterol was established by 
      mass spectrometry. The effects of aspirin ingestion as well as diurnal variation 
      were studied to demonstrate the possible clinical significance of this 
      noninvasive approach to metabolic profiling.
FAU - Ward, M E
AU  - Ward ME
FAU - Politzer, I R
AU  - Politzer IR
FAU - Laseter, J L
AU  - Laseter JL
FAU - Alam, S Q
AU  - Alam SQ
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Biomed Mass Spectrom
JT  - Biomedical mass spectrometry
JID - 0430246
RN  - 0 (Acids)
RN  - 0 (Food Preservatives)
RN  - 1P9D0Z171K (Butylated Hydroxytoluene)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acids/*analysis
MH  - Aspirin/metabolism
MH  - Butylated Hydroxytoluene/analysis
MH  - Cholesterol/analysis
MH  - *Chromatography, Gas
MH  - Evaluation Studies as Topic
MH  - Food Preservatives/analysis
MH  - Humans
MH  - *Mass Spectrometry
MH  - Saliva/*analysis
EDAT- 1976/04/01 00:00
MHDA- 1976/04/01 00:01
CRDT- 1976/04/01 00:00
PHST- 1976/04/01 00:00 [pubmed]
PHST- 1976/04/01 00:01 [medline]
PHST- 1976/04/01 00:00 [entrez]
AID - 10.1002/bms.1200030207 [doi]
PST - ppublish
SO  - Biomed Mass Spectrom. 1976 Apr;3(2):77-80. doi: 10.1002/bms.1200030207.

PMID- 9694166
OWN - NLM
STAT- MEDLINE
DCOM- 19990503
LR  - 20191102
IS  - 1056-8719 (Print)
IS  - 1056-8719 (Linking)
VI  - 39
IP  - 2
DP  - 1998 Mar
TI  - Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the 
      thrombin inhibitor inogatran.
PG  - 81-9
AB  - The aim of the present study was to develop a coronary thrombolysis model using 
      the copper coil technique in closed-chest pigs. The first goal (protocol I) was 
      to obtain a reproducible size of myocardial infarction by controlling the 
      coronary occlusion period, a prerequisite for evaluation of myocardioprotective 
      interventions. The second goal (protocol II) was to study if thrombin and 
      platelet aggregation inhibitors influence the rate of thrombolysis, the degree of 
      reocclusion, and the time of coronary patency when added to a thrombolytic 
      regimen (recombinant tissue-type plasminogen activator, rt-PA). Coronary 
      thrombosis was produced by insertion of a thrombogenic copper coil into the LAD 
      of 40 anesthetized pigs. The animals were divided into six groups as follows: 
      Protocol I, group 1: Open-chest, lysis initiated with intracoronary rt-PA (50 mg) 
      concomitant with intravenous heparin and acetylsalicylic acid (ASA) (n=6). Group 
      2: Closed-chest, lysis initiated with intracoronary rt-PA concomitant with 
      intravenous heparin and ASA (n=10). Protocol II, group 3: Closed-chest, lysis 
      initiated with intravenous rt-PA (n=6). Group 4: Closed-chest, lysis initiated 
      with intravenous rt-PA concomitant with heparin (n=6). Group 5: Closed-chest, 
      lysis initiated with intravenous rt-PA concomitant with inogatran, a low 
      molecular weight thrombin inhibitor (n=6). Group 6: Closed-chest, lysis initiated 
      with intravenous rt-PA immediately after intravenous administration of ASA (n=6). 
      Protocol 1; Reperfusion was achieved in all closed- and open-chest pigs. The time 
      to thrombolysis was 5+/-1.6 and 6+/-3.0 min (mean+/-SD) for closed- and 
      open-chest pigs, respectively. Reocclusions were rare (one in group 1). The size 
      of the ischemic myocardial area was 21+/-11% of the left ventricular area in 
      group 1 and 22+/-6% in group 2. The corresponding values for infarct size as a 
      proportion of the ischemic area were 58+/-10% and 68+/-14%, respectively. The 
      closed-chest model was subsequently used to study the effect of the thrombin and 
      platelet aggregation inhibitors (inogatran, heparin, and ASA) as conjunctive 
      agents to rt-PA-induced thrombolysis (groups 3-6). To mimic its clinical use, 
      rt-PA was administered intravenously. Time to lysis after rt-PA only (group 3) 
      was 33+/-24 min. Concomitant treatment with heparin (group 4), inogatran (group 
      5), and ASA (group 6) did not significantly influence time to lysis. All 
      adjunctive compounds did, however, prolong the time to reocclusion, which 
      occurred in 100%, 75%, 67%, and 20% of the animals in groups 3, 4, 5, and 6. 
      Thus, concomitant treatment with heparin and inogatran did not shorten time to 
      lysis or reduce the reocclusion rate, and ASA turned out to be the only effective 
      adjunct to rt-PA, significantly reducing both time to and frequency of 
      reocclusion (p < 0.05). CONCLUSION: The described closed-chest pig model was 
      feasible as regards the induction and lysis of a thrombus in the left coronary 
      artery, giving reproducible areas of myocardial ischemia and infarction. This 
      model was useful for the evaluation of pharmacological interventions in the 
      thrombolysis process.
FAU - Uriuda, Y
AU  - Uriuda Y
AD  - Department of Cardiology, Karolinska Hospital, Stockholm, Sweden.
FAU - Wang, Q D
AU  - Wang QD
FAU - Hatori, N
AU  - Hatori N
FAU - Nordlander, R
AU  - Nordlander R
FAU - Sjöquist, P O
AU  - Sjöquist PO
FAU - Mattsson, C
AU  - Mattsson C
FAU - Rydén, L
AU  - Rydén L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharmacol Toxicol Methods
JT  - Journal of pharmacological and toxicological methods
JID - 9206091
RN  - 0 (Antithrombins)
RN  - 0 (Piperidines)
RN  - 428409I84L (inogatran)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Animals
MH  - Antithrombins/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Flow Velocity/drug effects
MH  - Coronary Thrombosis/drug therapy/*metabolism
MH  - Glycine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Hemodynamics/drug effects
MH  - Heparin/*pharmacology/therapeutic use
MH  - Myocardial Ischemia/physiopathology
MH  - Piperidines/*pharmacology/therapeutic use
MH  - Reperfusion Injury/physiopathology
MH  - Swine
MH  - Thrombolytic Therapy/*methods
EDAT- 1998/08/07 00:00
MHDA- 1998/08/07 00:01
CRDT- 1998/08/07 00:00
PHST- 1998/08/07 00:00 [pubmed]
PHST- 1998/08/07 00:01 [medline]
PHST- 1998/08/07 00:00 [entrez]
AID - S1056-8719(98)00006-9 [pii]
AID - 10.1016/s1056-8719(98)00006-9 [doi]
PST - ppublish
SO  - J Pharmacol Toxicol Methods. 1998 Mar;39(2):81-9. doi: 
      10.1016/s1056-8719(98)00006-9.

PMID- 21262443
OWN - NLM
STAT- MEDLINE
DCOM- 20110513
LR  - 20220410
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 127 Suppl 3
DP  - 2011 Feb
TI  - Anticoagulant therapy in pregnant women with mechanical prosthetic heart valves: 
      no easy option.
PG  - S56-60
LID - 10.1016/S0049-3848(11)70016-0 [doi]
AB  - The choice of anticoagulant agent for pregnant women with mechanical prosthetic 
      heart valves introduces a clinical dilemma for women and the clinicians caring 
      for them. Options include continuing oral anticoagulants (OAC) such as warfarin 
      throughout pregnancy, switching from warfarin to unfractionated heparin or low 
      molecular weight heparin (LMWH) in the first trimester then back to warfarin 
      until close to delivery or taking unfractionated heparin or LMWH throughout 
      pregnancy. The dilemma is that warfarin is the most effective a preventing 
      maternal thromboembolic complications but causes significant fetal morbidity and 
      mortality; unfractionated heparin and in particular LMWH have good fetal outcomes 
      but the risk of thromboembolic complications is high. What is considered to be an 
      "acceptable level" of risk to mother and infant may differ from one clinician to 
      another and of equal importance, it may also differ from one woman to the next. 
      An unbiased discussion of the pros and cons of each option is required to allow 
      women to make and informed and confident choice in this very difficult clinical 
      situation.
CI  - © 2011 Elsevier Ltd. All rights reserved.
FAU - McLintock, Claire
AU  - McLintock C
AD  - Department of Obstetrics & Gynecology, National Women's Health, Auckland City 
      Hospital, Auckland, New Zealand. claire.mclintock@adhb.govt
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Female
MH  - Heart Valve Prosthesis/*adverse effects
MH  - Heparin/adverse effects/therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*etiology/*prevention & control
MH  - Pregnancy Outcome
MH  - Thromboembolism/etiology/*prevention & control
MH  - Warfarin/adverse effects/therapeutic use
EDAT- 2011/01/26 06:00
MHDA- 2011/05/14 06:00
CRDT- 2011/01/26 06:00
PHST- 2011/01/26 06:00 [entrez]
PHST- 2011/01/26 06:00 [pubmed]
PHST- 2011/05/14 06:00 [medline]
AID - S0049-3848(11)70016-0 [pii]
AID - 10.1016/S0049-3848(11)70016-0 [doi]
PST - ppublish
SO  - Thromb Res. 2011 Feb;127 Suppl 3:S56-60. doi: 10.1016/S0049-3848(11)70016-0.

PMID- 3302653
OWN - NLM
STAT- MEDLINE
DCOM- 19870909
LR  - 20191029
IS  - 0742-2814 (Print)
IS  - 0742-2814 (Linking)
VI  - 7
IP  - 1
DP  - 1986 Jan-Feb
TI  - Effect of aspirin on hemostasis and thrombosis.
PG  - 26-31
AB  - Aspirin inhibits platelet function by acetylating platelet cyclo-oxygenase. When 
      aspirin is administered in doses as low as 40-160 mg per day, it inhibits 
      platelet cyclo-oxygenase activity by more than 80%. The effect of aspirin on 
      platelet function is maintained for the life-span of the platelet and there is 
      evidence that aspirin also acetylates platelets before they are released in the 
      circulation and while they are still within megakaryocytes. Aspirin also inhibits 
      the synthesis of PGI2 by vascular wall cells but compared to the platelet, this 
      vessel wall effect is relatively short-lived and requires slightly larger doses 
      of aspirin. In vivo studies in rabbits indicate that very high doses of aspirin 
      are thrombogenic. However, there is no evidence that aspirin is thrombogenic in 
      man even when administered in high therapeutic doses. The optimal antithrombotic 
      dose of aspirin has not yet been determined. Clinically, impressive results have 
      been obtained with low doses of aspirin (ranging from 100 to 300 mg per day) in 
      preventing aorta coronary bypass thrombosis, in patients undergoing hemodialysis, 
      and in patients with unstable angina. Aspirin is also effective in preventing 
      stroke and death in patients with cerebral ischemia when administered in doses of 
      approximately 1 gram per day. There are trends suggesting that aspirin is 
      effective when administered in doses between 300 mg per day and 1500 mg per day 
      in patients who have survived myocardial infarction. The side-effects of aspirin 
      are mainly gastrointestinal and are dose-related. Generalized bleeding is very 
      uncommon and limited mainly to patients with other hemostatic abnormalities or 
      due to the concomitant use of anticoagulant therapy.
FAU - Buchanan, M R
AU  - Buchanan MR
FAU - Hirsh, J
AU  - Hirsh J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - N Engl Reg Allergy Proc
JT  - New England and regional allergy proceedings
JID - 8306562
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Cerebrovascular Disorders/drug therapy
MH  - Coronary Artery Bypass
MH  - Coronary Disease/drug therapy
MH  - *Fibrinolytic Agents
MH  - Heart Valve Diseases/drug therapy
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Prostaglandins/biosynthesis
RF  - 29
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.2500/108854186779045539 [doi]
PST - ppublish
SO  - N Engl Reg Allergy Proc. 1986 Jan-Feb;7(1):26-31. doi: 
      10.2500/108854186779045539.

PMID- 3543298
OWN - NLM
STAT- MEDLINE
DCOM- 19870227
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 240
IP  - 1
DP  - 1987 Jan
TI  - Effects of low doses of aspirin and dipyridamole on platelet aggregation in the 
      dog coronary artery.
PG  - 37-43
AB  - The circumflex coronary artery of pentobarbital-anesthetized dogs was partially 
      obstructed with an externally applied rigid plastic band. Platelet aggregation at 
      the site of stenosis caused a gradual decline in blood flow in the artery, which 
      was monitored with an electromagnetic flow probe placed proximally to the 
      obstructor. The effects of drugs on platelet aggregation were evaluated by 
      monitoring changes in both the rate and the degree of decline in blood flow. In 
      most dogs, aspirin inhibited intravascular platelet aggregation (ED50 = 1 mg/kg). 
      Dipyridamole, even at doses that severely depressed blood pressure (1 mg/kg), had 
      no effect on platelet aggregation. However, in dogs that had been pretreated with 
      a low dose of dipyridamole (0.2 mg/kg), the antiaggregatory activity of aspirin 
      was enhanced. This potentiation was evident only at low doses of aspirin (0.03 
      and 0.1 mg/kg), where the drug was 10 times more active; at high aspirin doses, 
      which depressed vascular cyclooxygenase, no potentiation was seen. Further 
      evidence that the mechanism of this synergism may depend on endogenous 
      prostacyclin production at the site of the partial obstruction was seen when 
      cyclooxygenase inhibitors applied topically on the exposed artery eliminated the 
      antiaggregatory effect of low doses of aspirin. It is important to note that the 
      protective effect of dipyridamole and low-dose aspirin was less than that seen at 
      the high doses of aspirin alone, suggesting that the theoretical benefits of 
      platelet-specific doses of aspirin may be overstated.
FAU - Weselcouch, E O
AU  - Weselcouch EO
FAU - Humphrey, W R
AU  - Humphrey WR
FAU - Aiken, J W
AU  - Aiken JW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 54397-85-2 (Thromboxane B2)
RN  - 64ALC7F90C (Dipyridamole)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Coronary Circulation
MH  - Dipyridamole/*pharmacology
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Epoprostenol/pharmacology
MH  - Female
MH  - Indomethacin/pharmacology
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane B2/blood
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1987 Jan;240(1):37-43.

PMID- 24211052
OWN - NLM
STAT- MEDLINE
DCOM- 20150414
LR  - 20140407
IS  - 2254-8874 (Electronic)
IS  - 2254-8874 (Linking)
VI  - 214
IP  - 3
DP  - 2014 Apr
TI  - Aspirin resistant patients with recent ischemic stroke.
PG  - 145-9
LID - S0014-2565(13)00334-2 [pii]
LID - 10.1016/j.rce.2013.10.003 [doi]
AB  - Some patients with a recent ischemic stroke who are being treated with aspirin as 
      an antiaggregant suffer a new ischemic stroke. These patients (15-25%) have been 
      called unresponsive to aspirin or aspirin resistant. The aspirin-resistant 
      patients have a four-time greater risk of suffering a stroke. Furthermore, these 
      strokes are generally more severe, with increased infarct volume and greater risk 
      of recurrence. There is currently no ideal laboratory test to detect the 
      resistance to the antiaggregant effect of aspirin. The study of resistance to 
      aspirin would only be indicated in selected cases. In these patients, one should 
      first rule out any "pseudo-resistance" to aspirin (lack of compliance, 
      concomitant treatments that interfere with the action of the aspirin).
CI  - Copyright © 2013 Elsevier España, S.L. All rights reserved.
FAU - Castilla-Guerra, L
AU  - Castilla-Guerra L
AD  - Servicio de Medicina Interna, Hospital de la Merced, Osuna, Sevilla, España. 
      Electronic address: castillafernandez@hotmail.com.
FAU - Navas-Alcántara, M S
AU  - Navas-Alcántara MS
AD  - Servicio de Medicina Interna, Hospital de la Merced, Osuna, Sevilla, España.
FAU - Fernández-Moreno, M C
AU  - Fernández-Moreno MC
AD  - Servicio de Neurología, Hospital de Valme, Sevilla, España.
LA  - eng
LA  - spa
PT  - Case Reports
PT  - Journal Article
DEP - 20131108
PL  - Spain
TA  - Rev Clin Esp (Barc)
JT  - Revista clinica espanola
JID - 101632437
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Brain Ischemia/*drug therapy/prevention & control
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Recurrence
MH  - Stroke/*drug therapy/prevention & control
OTO - NOTNLM
OT  - Aspirin resistance
OT  - Ictus isquémico
OT  - Ictus recurrente
OT  - Ischemic stroke
OT  - Prevención secundaria
OT  - Recurrent stroke
OT  - Resistencia a aspirina
OT  - Secondary prevention
EDAT- 2013/11/12 06:00
MHDA- 2015/04/15 06:00
CRDT- 2013/11/12 06:00
PHST- 2013/06/27 00:00 [received]
PHST- 2013/09/24 00:00 [revised]
PHST- 2013/10/02 00:00 [accepted]
PHST- 2013/11/12 06:00 [entrez]
PHST- 2013/11/12 06:00 [pubmed]
PHST- 2015/04/15 06:00 [medline]
AID - S0014-2565(13)00334-2 [pii]
AID - 10.1016/j.rce.2013.10.003 [doi]
PST - ppublish
SO  - Rev Clin Esp (Barc). 2014 Apr;214(3):145-9. doi: 10.1016/j.rce.2013.10.003. Epub 
      2013 Nov 8.

PMID- 20717045
OWN - NLM
STAT- MEDLINE
DCOM- 20110603
LR  - 20220311
IS  - 1539-2031 (Electronic)
IS  - 0192-0790 (Linking)
VI  - 45
IP  - 3
DP  - 2011 Mar
TI  - Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel?: a 
      prospective, randomized study involving 630 biopsies.
PG  - 228-33
LID - 10.1097/MCG.0b013e3181eb5efd [doi]
AB  - GOALS: To assess prospectively the bleeding risk attributable to gastroduodenal 
      biopsy in subjects taking antiplatelet medications. BACKGROUND: No prospective 
      data exist regarding the bleeding risk attributable to endoscopic biopsy in 
      patients taking antiplatelet agents. A majority of Western endoscopists withdraw 
      antiplatelet agents before upper endoscopy, despite expert guidelines to the 
      contrary. STUDY: We performed a prospective, single-blind, randomized study in 
      healthy volunteers participating in a larger study regarding the effect of 
      antiplatelet agents on gastroduodenal mucosal healing. Multiple gastroduodenal 
      biopsies were performed during 2 esophagogastroduodenoscopy in subjects dosed 
      with aspirin enteric-coated 81 mg once daily or clopidogrel 75 mg once daily. 
      Data for endoscopic bleeding, clinical bleeding, blood vessel size, and depth of 
      biopsy in histology specimens were collected. RESULTS: Four hundred and five 
      antral biopsies and 225 duodenal biopsies were performed during 90 
      esophagogastroduodenoscopy in 45 subjects receiving aspirin or clopidogrel. 
      Median maximum blood vessel diameter per biopsy was 31.9 μ (range: 9.2 to 133.8). 
      About 50.8% of biopsy specimens breached the muscularis mucosa. In the 
      clopidogrel group, no bleeding events were noted after 350 biopsies [upper 
      confidence limit (UCL) for probability of bleeding=0.0085]. In the aspirin group, 
      there were no clinical events (UCL=0.0106) and one minor endoscopic bleeding 
      event (UCL=0.0169). CONCLUSIONS: Consistent with expert guidelines, the absolute 
      risk attributable to gastroduodenal biopsy in adults taking antiplatelet agents 
      seems to be low. Half of routine biopsies enter submucosa. The largest blood 
      vessels avulsed during biopsy correspond to midsized and large arterioles and 
      venules.
FAU - Whitson, Matthew J
AU  - Whitson MJ
AD  - Division of Gastroenterology, Department of Medicine, Mount Sinai Medical Center, 
      New York, NY 10075, USA.
FAU - Dikman, Andrew E
AU  - Dikman AE
FAU - von Althann, Caroline
AU  - von Althann C
FAU - Sanyal, Shefali
AU  - Sanyal S
FAU - Desai, Jay C
AU  - Desai JC
FAU - Bamji, Neville D
AU  - Bamji ND
FAU - Kornacki, Susan
AU  - Kornacki S
FAU - Harpaz, Noam
AU  - Harpaz N
FAU - Bodian, Carol A
AU  - Bodian CA
FAU - Cohen, Lawrence B
AU  - Cohen LB
FAU - Miller, Kenneth M
AU  - Miller KM
FAU - Aisenberg, James
AU  - Aisenberg J
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects/therapeutic use
MH  - Biopsy/*adverse effects
MH  - Clopidogrel
MH  - Duodenum/surgery
MH  - Endoscopy, Digestive System/*adverse effects
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/*epidemiology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Pyloric Antrum/surgery
MH  - Risk Factors
MH  - Single-Blind Method
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
EDAT- 2010/08/19 06:00
MHDA- 2011/06/04 06:00
CRDT- 2010/08/19 06:00
PHST- 2010/08/19 06:00 [entrez]
PHST- 2010/08/19 06:00 [pubmed]
PHST- 2011/06/04 06:00 [medline]
AID - 10.1097/MCG.0b013e3181eb5efd [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 2011 Mar;45(3):228-33. doi: 10.1097/MCG.0b013e3181eb5efd.

PMID- 29505771
OWN - NLM
STAT- MEDLINE
DCOM- 20190520
LR  - 20190520
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 218
IP  - 6
DP  - 2018 Jun
TI  - Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on 
      length of stay in the neonatal intensive care unit.
PG  - 612.e1-612.e6
LID - S0002-9378(18)30173-X [pii]
LID - 10.1016/j.ajog.2018.02.014 [doi]
AB  - BACKGROUND: Preeclampsia is a major pregnancy complication with adverse short- 
      and long-term implications for both the mother and baby. Screening for 
      preeclampsia at 11-13 weeks' gestation by a combination of maternal demographic 
      characteristics and medical history with measurements of biomarkers can identify 
      about 75% of women who develop preterm preeclampsia with delivery at <37 weeks' 
      gestation and 90% of those with early preeclampsia at <32 weeks, at a 
      screen-positive rate of 10%. A recent trial (Combined Multimarker Screening and 
      Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia 
      Prevention) has reported that in women identified by first-trimester screening as 
      being at high risk for preeclampsia, use of aspirin (150 mg/d from the first to 
      the third trimester), compared to placebo, reduced the incidence of preterm 
      preeclampsia, which was the primary outcome, by 62% (95% confidence interval, 
      26-80%) and the incidence of early preeclampsia by 89% (95% confidence interval, 
      53-97%). The surprising finding of the trial was that despite the reduction in 
      preeclampsia the incidence of admission to the neonatal intensive care unit, 
      which was one of the secondary outcomes, was not significantly affected (odds 
      ratio, 0.93; 95% confidence interval, 0.62-1.40). OBJECTIVE: We sought to examine 
      the effect of prophylactic use of aspirin during pregnancy in women at high risk 
      of preeclampsia on length of stay in the neonatal intensive care unit. STUDY 
      DESIGN: This was a secondary analysis of data from the Aspirin for Evidence-Based 
      Preeclampsia Prevention trial to assess evidence of differences in the effect of 
      aspirin on length of stay in neonatal intensive care. Bootstrapping was used for 
      the comparison of mean length of stay between the aspirin and placebo groups. 
      Logistic regression was used to assess treatment effects on stay in the neonatal 
      intensive care unit. RESULTS: In the trial there were 1620 participants and 1571 
      neonates were liveborn. The total length of stay in neonatal intensive care was 
      substantially longer in the placebo than aspirin group (1696 vs 531 days). This 
      is a reflection of significantly shorter mean lengths of stay in babies admitted 
      to the neonatal intensive care unit from the aspirin than the placebo group (11.1 
      vs 31.4 days), a reduction of 20.3 days (95% confidence interval, 7.0-38.6; P = 
      .008). Neonatal intensive care of babies born at <32 weeks' gestation contributed 
      1856 (83.3%) of the total of 2227 days in intensive care across both treatment 
      arms. These occurred in 9 (1.2%) of the 777 livebirths in the aspirin group and 
      in 23 (2.9%) of 794 in the placebo group (odds ratio, 0.42; 95% confidence 
      interval, 0.19-0.93; P = .033). Overall, in the whole population, including 0 
      lengths of stay for those not admitted to the neonatal intensive care unit, the 
      mean length of stay was longer in the placebo than aspirin group (2.06 vs 0.66 
      days; reduction of 1.4 days; 95% confidence interval, 0.45-2.81; P = .014). This 
      corresponds to a reduction in length of stay of 68% (95% confidence interval, 
      20-86%). CONCLUSION: In pregnancies at high risk of preeclampsia administration 
      of aspirin reduces the length of stay in the neonatal intensive care unit by 
      about 70%. This reduction could essentially be attributed to a decrease in the 
      rate of births at <32 weeks' gestation, mainly because of prevention of early 
      preeclampsia. The findings have implications for both short- and long-term health 
      care costs as well as infant survival and handicap.
CI  - Copyright © 2018 Elsevier Inc. All rights reserved.
FAU - Wright, David
AU  - Wright D
AD  - University of Exeter, Exeter, United Kingdom.
FAU - Rolnik, Daniel L
AU  - Rolnik DL
AD  - King's College Hospital, London, United Kingdom.
FAU - Syngelaki, Argyro
AU  - Syngelaki A
AD  - King's College Hospital, London, United Kingdom.
FAU - de Paco Matallana, Catalina
AU  - de Paco Matallana C
AD  - Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
FAU - Machuca, Mirian
AU  - Machuca M
AD  - King's College Hospital, London, United Kingdom; Medway Maritime Hospital, 
      Gillingham, United Kingdom.
FAU - de Alvarado, Mercedes
AU  - de Alvarado M
AD  - King's College Hospital, London, United Kingdom; Homerton University Hospital, 
      London, United Kingdom.
FAU - Mastrodima, Sofia
AU  - Mastrodima S
AD  - King's College Hospital, London, United Kingdom; North Middlesex University 
      Hospital, London, United Kingdom.
FAU - Tan, Min Yi
AU  - Tan MY
AD  - King's College Hospital, London, United Kingdom; Lewisham University Hospital, 
      London, United Kingdom.
FAU - Shearing, Siobhan
AU  - Shearing S
AD  - Southend University Hospital, Essex, United Kingdom.
FAU - Persico, Nicola
AU  - Persico N
AD  - Ospedale Maggiore Policlinico, Milan, Italy.
FAU - Jani, Jacques C
AU  - Jani JC
AD  - University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
FAU - Plasencia, Walter
AU  - Plasencia W
AD  - Hospiten Group, Tenerife, Canary Islands, Spain.
FAU - Papaioannou, George
AU  - Papaioannou G
AD  - Attikon University Hospital, Athens, Greece.
FAU - Molina, Francisca S
AU  - Molina FS
AD  - Hospital Universitario San Cecilio, Granada, Spain.
FAU - Poon, Liona C
AU  - Poon LC
AD  - Kings' College, London, United Kingdom.
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
AD  - King's College Hospital, London, United Kingdom. Electronic address: 
      kypros@fetalmedicine.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180302
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Evidence-Based Medicine
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - *Intensive Care Units, Neonatal
MH  - Length of Stay/*statistics & numerical data
MH  - Logistic Models
MH  - Male
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for 
      Evidence-Based Preeclampsia Prevention trial
OT  - aspirin
OT  - first-trimester screening
OT  - health economics
OT  - neonatal intensive care
OT  - preeclampsia
EDAT- 2018/03/06 06:00
MHDA- 2019/05/21 06:00
CRDT- 2018/03/06 06:00
PHST- 2018/01/02 00:00 [received]
PHST- 2018/02/14 00:00 [revised]
PHST- 2018/02/26 00:00 [accepted]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2019/05/21 06:00 [medline]
PHST- 2018/03/06 06:00 [entrez]
AID - S0002-9378(18)30173-X [pii]
AID - 10.1016/j.ajog.2018.02.014 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2018 Jun;218(6):612.e1-612.e6. doi: 
      10.1016/j.ajog.2018.02.014. Epub 2018 Mar 2.

PMID- 2661447
OWN - NLM
STAT- MEDLINE
DCOM- 19890810
LR  - 20131121
IS  - 0174-4879 (Print)
IS  - 0174-4879 (Linking)
VI  - 27
IP  - 6
DP  - 1989 Jun
TI  - A comparison of the relative safety of phenylpropanolamine, acetaminophen, 
      ibuprofen and aspirin as measured by three compendia.
PG  - 267-72
AB  - A comparison was made among phenylpropanolamine, aspirin, acetaminophen and 
      ibuprofen in terms of their relative safety, as measured by adverse reaction 
      reports published since 1980, the five semiannual reports published by the Drug 
      Abuse Warning Network during 1984-1986 and annual reports from Poison Control 
      Centers from 1983-1986. On each of the three measures, phenylpropanolamine had 
      the fewest reported adverse reactions.
FAU - Winick, C
AU  - Winick C
AD  - Training Program in Behavioral Science Research in Drug Abuse, City University of 
      New York Graduate School, NY 10036.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Int J Clin Pharmacol Ther Toxicol
JT  - International journal of clinical pharmacology, therapy, and toxicology
JID - 8003415
RN  - 33RU150WUN (Phenylpropanolamine)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Ibuprofen/*adverse effects
MH  - Phenylpropanolamine/*adverse effects
RF  - 27
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther Toxicol. 1989 Jun;27(6):267-72.

PMID- 30694883
OWN - NLM
STAT- MEDLINE
DCOM- 20200220
LR  - 20200220
IS  - 1744-6880 (Electronic)
IS  - 1744-6872 (Linking)
VI  - 29
IP  - 4
DP  - 2019 Jun
TI  - Associations between TMEM196 polymorphisms and NSAID-exacerbated respiratory 
      disease in asthma.
PG  - 69-75
LID - 10.1097/FPC.0000000000000367 [doi]
AB  - BACKGROUND: We previously found differences in the minor allele frequency (MAF) 
      of single-nucleotide polymorphisms (SNPs) in transmembrane protein 196 (TMEM196) 
      between 995 patients with aspirin-tolerant asthma (ATA) and 141 asthmatic 
      patients with NSAID-exacerbated respiratory disease (NERD). In this study, we 
      statistically analyzed the distributions of the genotypes and haplotypes of these 
      SNPs to determine the exact association between TMEM196 genetic variants and the 
      risk for NERD. MATERIALS AND METHODS: Lewontin's D' and r values were used to 
      measure linkage disequilibrium between the biallelic loci having MAFs more than 
      0.05, and haplotypes were inferred using the PHASE algorithm (version 2.0). The 
      genotype distribution was analyzed by logistic regression models using age of 
      onset, smoking status (nonsmoker=0, ex-smoker=1, smoker=2), and BMI as 
      covariates. Regression analysis of the association between SNPs and the risk of 
      NERD was analyzed using SPSS version 12.0 and PLINK version 1.9. RESULTS: The MAF 
      of rs9886152 C>T was significantly lower in NERD than in ATA [24.8 vs. 34.0%, 
      odds ratio=0.64 (0.48-0.85), P=2.07×10, Pcorr=0.048]. The rate of the rs9886152 
      C>T minor allele was significantly lower in NERD than in ATA [44.0 vs. 56.4% in 
      the codominant model, P=0.002, Pcorr=0.049, odds ratio=0.64 (0.48-0.85)]. An 
      additional three SNPs (rs9639334 A>G, rs9638765 A>G, and rs2097811 G>A) showed 
      similar associations with the risk of NERD. NERD patients had lower frequencies 
      of the rs9639334 A>G minor allele (51.1 vs. 64.4%, P=0.002, Pcorr=0.043), 
      rs9638765 A>G (49.7 vs. 64.2%, P=0.001, Pcorr=0.017), and rs2097811 G>A (51.1 vs. 
      64.5%, P=0.002, Pcorr=0.04) compared with ATA patients. Patients homozygous for 
      the minor alleles of the four SNPs showed significantly less of an 
      aspirin-induced decrease in forced expiratory volume in one second compared with 
      those homozygous for the common alleles (P=0.003-0.012). CONCLUSION: The minor 
      alleles of the four SNPs in TMEM196 may exert a protective effect against the 
      development of NERD and may be useful genetic markers to predict the risk of 
      NERD.
FAU - Lee, Jong-Uk
AU  - Lee JU
AD  - Department of Medical Bioscience, Graduate School, Soonchunhyang University, 
      Asan.
FAU - Chang, Hun Soo
AU  - Chang HS
AD  - Department of Medical Bioscience, Graduate School, Soonchunhyang University, 
      Asan.
AD  - Department of Internal Medicine, Division of Allergy and Respiratory Medicine, 
      Soonchunhyang University Bucheon Hospital, Bucheon.
FAU - Baek, Dong Gyu
AU  - Baek DG
AD  - Department of Medical Bioscience, Graduate School, Soonchunhyang University, 
      Asan.
FAU - Shin, Hyoung Doo
AU  - Shin HD
AD  - Department of Genetic Epidemiology, SNP Genetics Inc.
AD  - Department of Life Science, Sogang University, Seoul, Republic of Korea.
FAU - Park, Choon-Sik
AU  - Park CS
AD  - Department of Medical Bioscience, Graduate School, Soonchunhyang University, 
      Asan.
AD  - Department of Internal Medicine, Division of Allergy and Respiratory Medicine, 
      Soonchunhyang University Bucheon Hospital, Bucheon.
FAU - Park, Jong-Sook
AU  - Park JS
AD  - Department of Medical Bioscience, Graduate School, Soonchunhyang University, 
      Asan.
AD  - Department of Internal Medicine, Division of Allergy and Respiratory Medicine, 
      Soonchunhyang University Bucheon Hospital, Bucheon.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacogenet Genomics
JT  - Pharmacogenetics and genomics
JID - 101231005
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Membrane Proteins)
RN  - 0 (TMEM196 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma, Aspirin-Induced/*genetics/pathology
MH  - Female
MH  - Forced Expiratory Volume
MH  - Gene Frequency
MH  - *Genetic Association Studies
MH  - Genotype
MH  - Haplotypes/genetics
MH  - Homozygote
MH  - Humans
MH  - Linkage Disequilibrium
MH  - Male
MH  - Membrane Proteins/*genetics
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide/genetics
EDAT- 2019/01/30 06:00
MHDA- 2020/02/23 06:00
CRDT- 2019/01/30 06:00
PHST- 2019/01/30 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
PHST- 2019/01/30 06:00 [entrez]
AID - 10.1097/FPC.0000000000000367 [doi]
PST - ppublish
SO  - Pharmacogenet Genomics. 2019 Jun;29(4):69-75. doi: 10.1097/FPC.0000000000000367.

PMID- 26004748
OWN - NLM
STAT- MEDLINE
DCOM- 20160405
LR  - 20201216
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 136
IP  - 1
DP  - 2015 Jul
TI  - Pre-procedural dual antiplatelet therapy and bleeding events following 
      transcatheter aortic valve implantation (TAVI).
PG  - 112-7
LID - S0049-3848(15)00231-5 [pii]
LID - 10.1016/j.thromres.2015.05.004 [doi]
AB  - INTRODUCTION: Transcatheter aortic valve implantation (TAVI) is associated with 
      bleeding that increases mortality. Dual antiplatelet therapy (DAPT) is 
      recommended in TAVI, however little is known about pre-procedural DAPT use and 
      its impact on hemostasis. We sought to determine the frequency, predictors and 
      bleeding events in patients receiving DAPT before TAVI. METHODS: 
      Three-hundred-and-three (n=303, 78.6±7.6years, 49% female, EuroScore 23.1±16.9) 
      consecutive patients undergoing TAVI were prospectively analyzed and followed for 
      in-hospital events. According to pre-procedural antiplatelet status study 
      population was divided into 2 groups: patients receiving aspirin and clopidogrel 
      (DAPT) and those on aspirin only or no antiplatelet therapy (noDAPT). RESULTS: 
      Pre-procedural DAPT was used in 139 cases (46%). Previous PCI (OR 4.8, [2.8-8.3], 
      p<0.0001), implantation of self-expandable prosthesis (OR 2.2, [1.2-4], p=0.007) 
      femoral access (OR 2.2, [1.1-4.5], p=0.029) and platelet count (OR 1.006, 
      [1.002-1.01], p=0.002) were identified as independent predictors of 
      pre-procedural DAPT. No difference was observed in the rates of any bleeding (23% 
      in DAPT vs. 24.4% in noDAPT, p=0.930) or major/life-threatening bleeding (12.2% 
      in DAPT vs. 14.7% in noDAPT, p=0.715). Propensity-score matching analysis did not 
      alter the results. GFR <30ml/min was the strongest predictor of bleeding (OR 4.3, 
      [1.9-9.9], p=0.0005). There was a trend towards lower frequency of MI and 
      stroke/TIA in DAPT as compared with noDAPT (3.6% vs. 9.8%, p=0.082). CONCLUSIONS: 
      Pre-procedural DAPT is frequent and does not increase short-term bleeding 
      complications or need for transfusion following TAVI. Possible impact of DAPT use 
      before TAVI on ischemic complications needs to be investigated in larger 
      populations.
CI  - Copyright © 2015 Elsevier Ltd. All rights reserved.
FAU - Huczek, Zenon
AU  - Huczek Z
AD  - Ist Department of Cardiology, Medical University of Warsaw, Poland. Electronic 
      address: zhuczek@wp.pl.
FAU - Kochman, Janusz
AU  - Kochman J
AD  - Ist Department of Cardiology, Medical University of Warsaw, Poland.
FAU - Grygier, Marek
AU  - Grygier M
AD  - Ist Department of Cardiology, Medical University of Poznan, Poland.
FAU - Parma, Radoslaw
AU  - Parma R
AD  - IIIrd Department of Cardiology, Silesian Medical University, Poland.
FAU - Scislo, Piotr
AU  - Scislo P
AD  - Ist Department of Cardiology, Medical University of Warsaw, Poland.
FAU - Wilimski, Radoslaw
AU  - Wilimski R
AD  - Department of Cardiosurgery, Medical University of Warsaw, Poland.
FAU - Ochala, Andrzej
AU  - Ochala A
AD  - IIIrd Department of Cardiology, Silesian Medical University, Poland.
FAU - Lesiak, Maciej
AU  - Lesiak M
AD  - Ist Department of Cardiology, Medical University of Poznan, Poland.
FAU - Olasinska-Wisniewska, Anna
AU  - Olasinska-Wisniewska A
AD  - Ist Department of Cardiology, Medical University of Poznan, Poland.
FAU - Grabowski, Marcin
AU  - Grabowski M
AD  - Ist Department of Cardiology, Medical University of Warsaw, Poland.
FAU - Mazurek, Tomasz
AU  - Mazurek T
AD  - Ist Department of Cardiology, Medical University of Warsaw, Poland.
FAU - Sibbing, Dirk
AU  - Sibbing D
AD  - Medical Department, Ludwig Maximilians University, Munich, Germany.
FAU - Filipiak, Krzysztof J
AU  - Filipiak KJ
AD  - Ist Department of Cardiology, Medical University of Warsaw, Poland.
FAU - Opolski, Grzegorz
AU  - Opolski G
AD  - Ist Department of Cardiology, Medical University of Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150514
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Transcatheter Aortic Valve Replacement/adverse effects/*methods
EDAT- 2015/05/26 06:00
MHDA- 2016/04/06 06:00
CRDT- 2015/05/26 06:00
PHST- 2015/02/09 00:00 [received]
PHST- 2015/04/20 00:00 [revised]
PHST- 2015/05/10 00:00 [accepted]
PHST- 2015/05/26 06:00 [entrez]
PHST- 2015/05/26 06:00 [pubmed]
PHST- 2016/04/06 06:00 [medline]
AID - S0049-3848(15)00231-5 [pii]
AID - 10.1016/j.thromres.2015.05.004 [doi]
PST - ppublish
SO  - Thromb Res. 2015 Jul;136(1):112-7. doi: 10.1016/j.thromres.2015.05.004. Epub 2015 
      May 14.

PMID- 25895518
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20181113
IS  - 1572-0241 (Electronic)
IS  - 0002-9270 (Linking)
VI  - 110
IP  - 5
DP  - 2015 May
TI  - Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in 
      NSAID/Low-Dose Aspirin Users.
PG  - 684-9
LID - 10.1038/ajg.2015.98 [doi]
AB  - OBJECTIVES: Helicobacter pylori (H. pylori) infection and NSAID/low-dose aspirin 
      (ASA) use are associated with peptic ulcer disease. The risk of peptic ulcer 
      bleeding (PUB) associated with the interaction of these factors remains unclear. 
      The objective of this study was to determine the risk of PUB associated with the 
      interaction between H. pylori infection and current nonsteroidal 
      anti-inflammatory drugs (NSAIDs) or low-dose ASA use. METHODS: This was a 
      case-control study of consecutive patients hospitalized because of PUB. Controls 
      were matched by age, sex, and month of admission. H. pylori infection status was 
      determined in all cases and controls by serology. Drug use was determined by 
      structured questionnaire. Adjusted relative risk (RR) associated with different 
      factors, and the interaction between NSAID/ASA and H. pylori infection was 
      estimated by logistic regression analysis. RESULTS: The study included 666 cases 
      of PUB and 666 controls; 74.3% cases and 54.8% controls (RR: 2.6; 95% confidence 
      interval (CI): 2.0-3.3) tested positive for H. pylori infection; 34.5% of cases 
      had current NSAID use compared with 13.4% of controls (RR: 4.0; 95% CI: 3.0-5.4). 
      Respective proportions for low-dose ASA use were 15.8 and 12%, respectively (RR: 
      1.9; 95% CI: 1.3-2.7). The RR of PUB for concomitant NSAID use and H. pylori 
      infection suggested an additive effect (RR: 8.0; 95% CI: 5.0-12.8), whereas no 
      interaction was observed with ASA use (RR: 3.5; 95% CI: 2.0-6.1). CONCLUSIONS: 
      NSAID, low-dose ASA use, and H. pylori infection are three independent risk 
      factors for the development of PUB, but there were differences in the interaction 
      effect between low-dose ASA (no interaction) or NSAID (addition) use and H. 
      pylori infection, which may have implications for clinical practice in prevention 
      strategies.
FAU - Sostres, C
AU  - Sostres C
AD  - Universitary Hospital Lozano Blesa, Gastroenterology Unit, Zaragoza, Spain.
FAU - Carrera-Lasfuentes, P
AU  - Carrera-Lasfuentes P
AD  - CIBERehd, Madrid, Spain.
FAU - Benito, R
AU  - Benito R
AD  - Universitary Hospital Lozano Blesa, Microbiology Unit, Zaragoza, Spain.
FAU - Roncales, P
AU  - Roncales P
AD  - Health Science Institute of Aragon, Zaragoza, Spain.
FAU - Arruebo, M
AU  - Arruebo M
AD  - Health Science Institute of Aragon, Zaragoza, Spain.
FAU - Arroyo, M T
AU  - Arroyo MT
AD  - Universitary Hospital Lozano Blesa, Gastroenterology Unit, Zaragoza, Spain.
FAU - Bujanda, L
AU  - Bujanda L
AD  - Universitary Hospital of Donostia, San Sebastian, Spain.
FAU - García-Rodríguez, L A
AU  - García-Rodríguez LA
AD  - CEIFE, Madrid, Spain.
FAU - Lanas, A
AU  - Lanas A
AD  - 1] Universitary Hospital Lozano Blesa, Gastroenterology Unit, Zaragoza, Spain [2] 
      CIBERehd, Madrid, Spain [3] Health Science Institute of Aragon, Zaragoza, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150421
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Female
MH  - Helicobacter Infections/*complications
MH  - *Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer Hemorrhage/*chemically induced/*microbiology
MH  - Prospective Studies
MH  - Surveys and Questionnaires
EDAT- 2015/04/22 06:00
MHDA- 2015/07/21 06:00
CRDT- 2015/04/22 06:00
PHST- 2014/10/01 00:00 [received]
PHST- 2015/02/01 00:00 [accepted]
PHST- 2015/04/22 06:00 [entrez]
PHST- 2015/04/22 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - ajg201598 [pii]
AID - 10.1038/ajg.2015.98 [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2015 May;110(5):684-9. doi: 10.1038/ajg.2015.98. Epub 2015 
      Apr 21.

PMID- 20099710
OWN - NLM
STAT- MEDLINE
DCOM- 20100218
LR  - 20181201
IS  - 0966-8519 (Print)
IS  - 0966-8519 (Linking)
VI  - 18
IP  - 6
DP  - 2009 Nov
TI  - Initial experience with dual antiplatelet thromboprophylaxis using clopidogrel 
      and aspirin in patients with mechanical aortic prostheses.
PG  - 617-25; discussion 626
AB  - BACKGROUND AND AIM OF THE STUDY: The aortic mechanical prosthesis (AMP) generates 
      shear stress and causes erythrocyte fragmentation with ADP release that leads to 
      platelet activation, the cause of thromboembolism. Thromboprophylaxis with the 
      antiplatelet agents clopidogrel and aspirin (Clop-ASA) should reduce 
      thromboembolic events in patients receiving an AMP. METHODS: Over an eight-year 
      period at the authors' institutions, a total of 135 patients underwent aortic 
      valve replacement (AVR), with or without concomitant thoracic aortic procedures, 
      and received Clop-ASA as thromboprophylaxis. Platelet reactivity was measured 
      using the Verify Now system. Thromboelastography was commenced in August 2006, 
      and patients were followed at six-month intervals, with echocardiography and 
      assessment of platelet reactivity. RESULTS: The total follow up was 4,776 months 
      (equivalent to 398 patient-years (pt-yr)); the average follow up was 35.4 +/- 25 
      months. During follow up, 18 patients (13.3%) died, eight from coronary artery 
      disease and three from valve-related causes. Five patients (3.7%; 1.2%/pt-yr) had 
      bleeding complications, but none experienced valve thrombosis. Two patients 
      (1.5%; 0.5%/pt-yr) had a transient ischemic attack (TIA); one of these occurred 
      in a patient who discontinued Clop-ASA, and the other in a responder to Clop-ASA. 
      Seven patients (5.2%; 1.7%/pt-yr) had strokes, one of which occurred at 48.5 
      months after AVR. Of the remaining six patients who had a stroke, one was a 
      non-responder to clopidogrel and five had stopped taking Clop-ASA. The incidence 
      of strokes before using the Accumetrics and TEG devices was 2.5% per pt-yr, but 
      only 1.0% per pt-yr thereafter. CONCLUSION: Thromboprophylaxis in patients with 
      AMP receiving Clop-ASA seems to be effective. Patients had a low incidence of 
      bleeding, TIA and ischemic stroke, and no valve thrombosis. The use of assays to 
      determine platelet reactivity helped to identify those patients who were 
      resistant to clopidogrel, hyporesponders, and poorly compliant patients. Notably, 
      the incidence of strokes after implementing assays to monitor platelet reactivity 
      was reduced. Deaths were due primarily to myocardial infarction, and none of the 
      deaths was anticoagulant-related. Patients receiving Clop-ASA should undergo 
      routine testing of platelet reactivity, and also continue antiplatelet therapy so 
      as to reduce the risk of ischemic stroke.
FAU - García-Rinaldi, Raúl
AU  - García-Rinaldi R
AD  - Division of Cardiovascular Surgery and Cardiology, Advanced Cardiology Center, 
      Mayagüez, Puerto Rica. garciarinald@prtc.net
FAU - Carro-Pagán, Carlos
AU  - Carro-Pagán C
FAU - Schaff, Hartzell V
AU  - Schaff HV
FAU - McKellar, Stephen H
AU  - McKellar SH
FAU - Thompson, Jess L 3rd
AU  - Thompson JL 3rd
FAU - Quiñones, Jeannette
AU  - Quiñones J
FAU - Rodríguez-Acosta, Juan F
AU  - Rodríguez-Acosta JF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Heart Valve Dis
JT  - The Journal of heart valve disease
JID - 9312096
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Aortic Valve
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Clopidogrel
MH  - Drug Combinations
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Diseases/mortality/surgery
MH  - Heart Valve Prosthesis/*adverse effects
MH  - Heart Valve Prosthesis Implantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Puerto Rico/epidemiology
MH  - Thromboembolism/etiology/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - United States/epidemiology
EDAT- 2010/01/27 06:00
MHDA- 2010/02/19 06:00
CRDT- 2010/01/27 06:00
PHST- 2010/01/27 06:00 [entrez]
PHST- 2010/01/27 06:00 [pubmed]
PHST- 2010/02/19 06:00 [medline]
PST - ppublish
SO  - J Heart Valve Dis. 2009 Nov;18(6):617-25; discussion 626.

PMID- 16517326
OWN - NLM
STAT- MEDLINE
DCOM- 20060912
LR  - 20131121
IS  - 0952-8180 (Print)
IS  - 0952-8180 (Linking)
VI  - 18
IP  - 1
DP  - 2006 Feb
TI  - Duration of effects of aspirin on platelet function in healthy volunteers: an 
      analysis using the PFA-100.
PG  - 12-7
AB  - STUDY OBJECTIVE: The aim of the study was to determine the duration and effects 
      of aspirin on platelet function. STUDY DESIGN: Prospective investigation. 
      SETTING: Blood samples from volunteers. PATIENTS AND MONITORING: Ten healthy male 
      volunteers took part in this investigation. After having measured baseline 
      hemostatic parameters, 2000-mg aspirin was taken orally. Subsequently, the 
      hemostatic profile had been compiled daily for a duration of 4 days after 
      ingestion. MEASUREMENTS AND MAIN RESULTS: Platelet function was analyzed (1) 
      after 3 hours and (2) daily for 4 days by the platelet function analyzer 
      (PFA-100, Dade Co, Miami, Fla), which represents a sensitive investigation method 
      for measuring platelet function and dysfunction. Routine hemostatic parameters 
      were investigated. Three hours after ingestion of aspirin, abnormal PFA-100 
      values could be detected. Further detectable elevated values were found during 
      the following 3 days. CONCLUSION: Effects of single-dose aspirin 2000 mg on 
      platelet function were detected after 3 hours and had been lasting for the 
      following 3 days. This result shows that PFA-100 may help by evaluating 
      hemostasis during the preoperative period.
FAU - Konrad, Christoph J
AU  - Konrad CJ
AD  - Clinical Pain Research and Pain Clinics, Institute of Anesthesiology and 
      Intensive Care Medicine, University Clinics Mannheim, Ruprecht Karls-University 
      of Heidelberg, 68167 Mannheim, Germany. 
      christoph.konrad@anaes.ma.uni-heidelberg.de
FAU - Schuepfer, Guido K
AU  - Schuepfer GK
FAU - Gerber, Helmut
AU  - Gerber H
FAU - Rukwied, Roman
AU  - Rukwied R
FAU - Schmelz, Martin
AU  - Schmelz M
FAU - Schley, Marcus
AU  - Schley M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Anesth
JT  - Journal of clinical anesthesia
JID - 8812166
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Epinephrine/pharmacology
MH  - Hemostasis/drug effects
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests/*instrumentation
MH  - Sensitivity and Specificity
EDAT- 2006/03/07 09:00
MHDA- 2006/09/13 09:00
CRDT- 2006/03/07 09:00
PHST- 2004/06/23 00:00 [received]
PHST- 2005/05/03 00:00 [accepted]
PHST- 2006/03/07 09:00 [pubmed]
PHST- 2006/09/13 09:00 [medline]
PHST- 2006/03/07 09:00 [entrez]
AID - S0952-8180(05)00324-7 [pii]
AID - 10.1016/j.jclinane.2005.05.007 [doi]
PST - ppublish
SO  - J Clin Anesth. 2006 Feb;18(1):12-7. doi: 10.1016/j.jclinane.2005.05.007.

PMID- 8042636
OWN - NLM
STAT- MEDLINE
DCOM- 19940825
LR  - 20131121
IS  - 0002-9289 (Print)
IS  - 0002-9289 (Linking)
VI  - 51
IP  - 9
DP  - 1994 May 1
TI  - Preventing stroke in patients with nonrheumatic atrial fibrillation.
PG  - 1175-83
AB  - Published and ongoing studies of drug therapy for preventing stroke in patients 
      with nonrheumatic atrial fibrillation (AF) are discussed, and updated 
      recommendations are provided. Stroke is the most common complication of 
      nonrheumatic AF; there are more than 75,000 such strokes each year in North 
      America. Nonrheumatic AF increases the risk of stroke almost sixfold. Emboli from 
      clots that form in the left atrium because of ineffective atrial contraction and 
      turbulent blood flow may cause most of these strokes. The results of six 
      randomized trials of antithrombotic therapy in patients with nonrheumatic AF are 
      now available. In almost all of these trials, warfarin therapy significantly 
      reduced the risk of stroke. One trial showed that aspirin significantly reduced 
      the risk of stroke, but another trial did not support that finding. Ongoing 
      trials are addressing the efficacy and risks of aspirin plus low-dose warfarin 
      and very low intensity anticoagulation. Overall, the data suggest that patients 
      who are younger than 75 years of age and who lack risk factors can be adequately 
      protected against stroke with aspirin. Patients younger than 75 years who have 
      risk factors but no contraindications to warfarin should receive warfarin. 
      Patients older than 75 years appear to benefit from anticoagulation therapy, but 
      this benefit is offset by the higher risk of bleeding complications. Lone AF is 
      best managed with aspirin. Warfarin is superior to aspirin as a secondary 
      intervention in patients with a recent thromboembolic event. Strategies for 
      preventing stroke in patients with nonrheumatic atrial fibrillation continue to 
      be refined.
FAU - Nelson, K M
AU  - Nelson KM
AD  - College of Pharmacy, University of Texas at Austin.
FAU - Talbert, R L
AU  - Talbert RL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Hosp Pharm
JT  - American journal of hospital pharmacy
JID - 0370474
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Cerebrovascular Disorders/etiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Warfarin/*therapeutic use
RF  - 42
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
PST - ppublish
SO  - Am J Hosp Pharm. 1994 May 1;51(9):1175-83.

PMID- 6846549
OWN - NLM
STAT- MEDLINE
DCOM- 19830610
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 244
IP  - 5
DP  - 1983 May
TI  - Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach.
PG  - G561-8
AB  - The contact angle subtended between a droplet of aqueous fluid and nonwettable 
      surfaces provides a direct estimation of their degree of hydrophobicity. The mean 
      contact angle recorded in dogs at the oxyntic mucosal surface was 85.2 degrees, a 
      value characteristic of acid-resistant substances such as polyethylene. This 
      indicates that the mucosal surface of the stomach has a hydrophobic lining that 
      may be attributed to the surface-active phospholipids known to be present in both 
      the gastric mucosa and juice. Barrier breakers such as bile and aspirin were 
      found virtually to eliminate the hydrophobicity. Hydrophobicity was found to be 
      different in the esophagus, antrum, proximal and distal duodenum, and the colon 
      but consistent with their resistance to acid attack. Endogenous surfactants are 
      discussed for their capability to provide a cohesive and strongly adsorbed 
      protective monolayer--a physical model for the gastric mucosal barrier compatible 
      with the major properties of the gastric lining and many features of 
      ulcerogenesis, including the protection afforded by prostaglandins.
FAU - Hills, B A
AU  - Hills BA
FAU - Butler, B D
AU  - Butler BD
FAU - Lichtenberger, L M
AU  - Lichtenberger LM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Bile Acids and Salts)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Bile Acids and Salts/pharmacology
MH  - Dogs
MH  - Gastric Juice/physiology
MH  - Gastric Mucosa/cytology/drug effects/*physiology
MH  - Models, Biological
MH  - Solubility
MH  - Stomach/*physiology
OID - NASA: 83201589
EDAT- 1983/05/01 00:00
MHDA- 1983/05/01 00:01
CRDT- 1983/05/01 00:00
PHST- 1983/05/01 00:00 [pubmed]
PHST- 1983/05/01 00:01 [medline]
PHST- 1983/05/01 00:00 [entrez]
AID - 10.1152/ajpgi.1983.244.5.G561 [doi]
PST - ppublish
SO  - Am J Physiol. 1983 May;244(5):G561-8. doi: 10.1152/ajpgi.1983.244.5.G561.

PMID- 8533508
OWN - NLM
STAT- MEDLINE
DCOM- 19960126
LR  - 20161018
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 95
IP  - 4
DP  - 1995
TI  - [The effect of aspirin on the contingent negative wave in healthy subjects].
PG  - 45-6
AB  - Alterations in parameters of slow brain potentials (contingent negative 
      variation, CNV) were examined in healthy individuals under influence of aspirin 
      according to double blind method. The early and late waves of CNV were analysed. 
      The significant decrease of early wave of CNV was obtained after aspirin 
      administration. Late wave of CNV increased after aspirin and placebo intake. The 
      alterations described were explained in terms of central mechanisms of aspirin 
      action including noradrenergic and dopaminergic systems involvement.
FAU - Veĭn, A M
AU  - Veĭn AM
FAU - Voznesenskaia, T G
AU  - Voznesenskaia TG
FAU - Danilov, A B
AU  - Danilov AB
LA  - rus
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Vliianie aspirina na uslovnuiu negativnuiu volnu u zdorovykh ispytuemykh.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analysis of Variance
MH  - Aspirin/*pharmacology
MH  - Contingent Negative Variation/*drug effects
MH  - Double-Blind Method
MH  - Electrooculography/drug effects/instrumentation/methods/statistics & numerical 
      data
MH  - Female
MH  - Humans
MH  - Male
MH  - Reference Values
MH  - Time Factors
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 1995;95(4):45-6.

PMID- 1752948
OWN - NLM
STAT- MEDLINE
DCOM- 19920129
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 88
IP  - 6
DP  - 1991 Dec
TI  - Induction of omega-oxidation of monocarboxylic acids in rats by acetylsalicylic 
      acid.
PG  - 1865-72
AB  - The accumulation of dicarboxylic acids, particularly long chain, is a prominent 
      feature of Reye's syndrome and diseases of peroxisomal metabolism. We assessed 
      the omega-oxidation of a spectrum of fatty acids in rats and asked whether 
      pretreatment of rats with aspirin, which is known to predispose children to 
      Reye's syndrome, would affect omega-oxidation of long chain fatty acids. We found 
      that aspirin increased liver free fatty acids and increased the capacity for 
      omega-oxidation three- to sevenfold. Omega-oxidation of long chain substrate was 
      stimulated to a greater degree than medium chain substrate and was apparent 
      within one day of treatment, at serum aspirin concentrations below the 
      therapeutic range in humans. The apparent Km for lauric acid was 0.9 microM and 
      12 microM for palmitate. We also found a difference in the storage stability of 
      activity toward medium and long chain substrate. Saturating concentrations of 
      palmitate had no effect on the formation of dodecanedioic acid, whereas laurate 
      decreased but never eliminated the omega-oxidation of palmitate. 97% of the total 
      laurate omega-oxidative activity recovered was found in the microsomes, but 32% 
      of palmitate omega-oxidative activity was present in the cytosol. These results 
      demonstrate that aspirin is a potent stimulator of omega-oxidation and suggest 
      that there may be multiple enzymes for omega-oxidation with overlapping substrate 
      specificity.
FAU - Kundu, R K
AU  - Kundu RK
AD  - Department of Pediatrics, Pritzker Medical School, University of Chicago, 
      Illinois 60637.
FAU - Tonsgard, J H
AU  - Tonsgard JH
FAU - Getz, G S
AU  - Getz GS
LA  - eng
GR  - HD-04583/HD/NICHD NIH HHS/United States
GR  - NS2316/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Dicarboxylic Acids)
RN  - 0 (Fatty Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Dicarboxylic Acids/*metabolism
MH  - Fatty Acids/*metabolism
MH  - In Vitro Techniques
MH  - Liver/metabolism
MH  - Male
MH  - Oxidation-Reduction
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Reye Syndrome/*chemically induced
PMC - PMC295754
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
AID - 10.1172/JCI115508 [doi]
PST - ppublish
SO  - J Clin Invest. 1991 Dec;88(6):1865-72. doi: 10.1172/JCI115508.

PMID- 7054205
OWN - NLM
STAT- MEDLINE
DCOM- 19820322
LR  - 20160512
IS  - 0021-9355 (Print)
IS  - 0021-9355 (Linking)
VI  - 64
IP  - 1
DP  - 1982 Jan
TI  - High and low-dose aspirin prophylaxis against venous thromboembolic disease in 
      total hip replacement.
PG  - 63-6
AB  - Aspirin has been demonstrated to be an effective prophylactic agent against 
      postoperative venous thromboembolic disease, but the optimum dosage is unknown. 
      We compared the efficacy of daily doses of 3.6 grams of aspirin (high dose) with 
      that of 1.2 grams (low dose) in 182 patients. All patients were more than forty 
      years old and all underwent a total hip replacement. This randomized, 
      prospective, double-blind study was done using only objective dta for diagnosis. 
      Twenty-three (44 per cent) of fifty-two women who were treated with the low dose 
      had thrombi, compared with eighteen (34 per cent) of fifty-three women who were 
      given the high dose. Thrombi developed in thirteen (32 per cent) and in eighteen 
      (49 per cent) of thirty-seven men who were given the high dose. There were no 
      statistically significant differences among the four groups, nor was there a 
      significant difference among the subgroups that were determined according to 
      prior history of venous thromboembolic disease. Therefore, the higher dose of 
      aspirin was neither more nor less effective than the lower dose. Our data 
      continue to support the use of 1.2 grams in men.
FAU - Harris, W H
AU  - Harris WH
FAU - Athanasoulis, C A
AU  - Athanasoulis CA
FAU - Waltman, A C
AU  - Waltman AC
FAU - Salzman, E W
AU  - Salzman EW
LA  - eng
GR  - HL 13754/HL/NHLBI NIH HHS/United States
GR  - HL 18738-04/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Bleeding Time
MH  - Double-Blind Method
MH  - Female
MH  - *Hip Prosthesis
MH  - Humans
MH  - Male
MH  - Postoperative Complications/*prevention & control
MH  - Prospective Studies
MH  - Random Allocation
MH  - Thromboembolism/*prevention & control
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - J Bone Joint Surg Am. 1982 Jan;64(1):63-6.

PMID- 28874840
OWN - NLM
STAT- MEDLINE
DCOM- 20190501
LR  - 20200306
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 7
IP  - 1
DP  - 2017 Sep 5
TI  - UPLC-Q-TOF/MS-based metabonomic studies on the intervention effects of aspirin 
      eugenol ester in atherosclerosis hamsters.
PG  - 10544
LID - 10.1038/s41598-017-11422-7 [doi]
LID - 10544
AB  - Based on the pro-drug principle, aspirin and eugenol were used to synthesize 
      aspirin eugenol ester (AEE) by esterification reaction. In present study, the 
      anti-atherosclerosis effects of AEE were investigated in hamsters with the 
      utilization of metabonomic approach based on UPLC-Q-TOF/MS. Biochemical 
      parameters and histopathological injures in stomach, liver and aorta were 
      evaluated. In atherosclerotic hamster, oral administration of AEE normalized 
      biochemical profile such as reducing TG, TCH and LDL, and significantly reduced 
      body weight gain, alleviated hepatic steatosis and improved pathological lesions 
      in aorta. Slight damages in stomach mucous were found in AEE group. Plasma and 
      urine samples in control, model and AEE groups were scattered in the partial 
      least squares-discriminate analysis (PLS-DA) score plots. Thirteen endogenous 
      metabolites in plasma such as lysophosphatidylcholine (LysoPC), leucine and 
      valine, and seventeen endogenous metabolites in urine such as citric acid, phenol 
      sulphate and phenylacetylglycine were selected as potential biomarkers associated 
      with atherosclerosis. They were considered to be in response to 
      anti-atherosclerosis effects of AEE, mainly involved in glycerophospholipid 
      metabolism, amino acid metabolism and energy metabolism. This study extended the 
      understanding of endogenous alterations of atherosclerosis and offered insights 
      into the pharmacodynamic activity of AEE.
FAU - Ma, Ning
AU  - Ma N
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou, China.
FAU - Yang, Yajun
AU  - Yang Y
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou, China.
FAU - Liu, Xiwang
AU  - Liu X
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou, China.
FAU - Kong, Xiaojun
AU  - Kong X
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou, China.
FAU - Li, Shihong
AU  - Li S
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou, China.
FAU - Qin, Zhe
AU  - Qin Z
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou, China.
FAU - Jiao, Zenghua
AU  - Jiao Z
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou, China.
FAU - Li, Jianyong
AU  - Li J
AD  - Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary 
      Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of 
      Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, 
      Lanzhou, China. lijy1971@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170905
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Lysophosphatidylcholines)
RN  - 0 (Phenols)
RN  - 0 (aspirin eugenol ester)
RN  - 2968PHW8QP (Citric Acid)
RN  - 3T8H1794QW (Eugenol)
RN  - 500-98-1 (phenylacetylglycine)
RN  - GMW67QNF9C (Leucine)
RN  - HG18B9YRS7 (Valine)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology/therapeutic use
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Atherosclerosis/blood/*drug therapy/urine
MH  - Biomarkers/blood/urine
MH  - Citric Acid/urine
MH  - Cricetinae
MH  - Eugenol/*analogs & derivatives/pharmacology/therapeutic use
MH  - Glycine/analogs & derivatives/urine
MH  - Leucine/blood
MH  - Lysophosphatidylcholines/blood
MH  - Male
MH  - Mesocricetus
MH  - Metabolome/*drug effects
MH  - Phenols/urine
MH  - Valine/blood
PMC - PMC5585262
COIS- The authors declare that they have no competing interests.
EDAT- 2017/09/07 06:00
MHDA- 2019/05/02 06:00
CRDT- 2017/09/07 06:00
PHST- 2017/06/12 00:00 [received]
PHST- 2017/08/24 00:00 [accepted]
PHST- 2017/09/07 06:00 [entrez]
PHST- 2017/09/07 06:00 [pubmed]
PHST- 2019/05/02 06:00 [medline]
AID - 10.1038/s41598-017-11422-7 [pii]
AID - 11422 [pii]
AID - 10.1038/s41598-017-11422-7 [doi]
PST - epublish
SO  - Sci Rep. 2017 Sep 5;7(1):10544. doi: 10.1038/s41598-017-11422-7.

PMID- 18574278
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20220408
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 133
IP  - 6 Suppl
DP  - 2008 Jun
TI  - The primary and secondary prevention of coronary artery disease: American College 
      of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
PG  - 776S-814S
LID - S0012-3692(08)60130-0 [pii]
LID - 10.1378/chest.08-0685 [doi]
AB  - The following chapter devoted to antithrombotic therapy for chronic coronary 
      artery disease (CAD) is part of the Antithrombotic and Thrombolytic Therapy: 
      American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 
      (8th Edition). Grade 1 recommendations are strong and indicate that the benefits 
      do or do not outweigh risks, burden, and costs. Grade 2 suggests that individual 
      patient values may lead to different choices (for a full understanding of the 
      grading see the "Grades of Recommendation" chapter by Guyatt et al in this 
      supplement, CHEST 2008; 133[suppl]:123S-131S). Among the key recommendations in 
      this chapter are the following: for patients with non-ST-segment elevation 
      (NSTE)-acute coronary syndrome (ACS) we recommend daily oral aspirin (75-100 mg) 
      [Grade 1A]. For patients with an aspirin allergy, we recommend clopidogrel, 75 
      mg/d (Grade 1A). For patients who have received clopidogrel and are scheduled for 
      coronary bypass surgery, we suggest discontinuing clopidogrel for 5 days prior to 
      the scheduled surgery (Grade 2A). For patients after myocardial infarction, after 
      ACS, and those with stable CAD and patients after percutaneous coronary 
      intervention (PCI), we recommend daily aspirin (75-100 mg) as indefinite therapy 
      (Grade 1A). We recommend clopidogrel in combination with aspirin for patients 
      experiencing ST-segment elevation (STE) and NSTE-ACS (Grade 1A). For patients 
      with contraindications to aspirin, we recommend clopidogrel as monotherapy (Grade 
      1A). For long-term treatment after PCI in patients who receive antithrombotic 
      agents such as clopidogrel or warfarin, we recommend aspirin (75 to 100 mg/d) 
      [Grade 1B]. For patients who undergo bare metal stent placement, we recommend the 
      combination of aspirin and clopidogrel for at least 4 weeks (Grade 1A). We 
      recommend that patients receiving drug-eluting stents (DES) receive aspirin (325 
      mg/d for 3 months followed by 75-100 mg/d) and clopidogrel 75 mg/d for a minimum 
      of 12 months (Grade 2B). For primary prevention in patients with moderate risk 
      for a coronary event, we recommend aspirin, 75-100 mg/d, over either no 
      antithrombotic therapy or vitamin K antagonist (Grade 1A).
FAU - Becker, Richard C
AU  - Becker RC
AD  - Duke Clinical Research Institute, Duke University Medical Center, Durham, NC. 
      Electronic address: becke021@mc.duke.edu.
FAU - Meade, Thomas W
AU  - Meade TW
AD  - Non Comm Disease Epidemiology, London School of Hygiene Tropical, London, UK.
FAU - Berger, Peter B
AU  - Berger PB
AD  - Geisinger Center for Health Research, Danville, PA.
FAU - Ezekowitz, Michael
AU  - Ezekowitz M
AD  - Lankenau Institute for Medical Research, Wynnewood, PA.
FAU - O'Connor, Christopher M
AU  - O'Connor CM
AD  - Duke University Medical Center, Division of Cardiology, Durham, NC.
FAU - Vorchheimer, David A
AU  - Vorchheimer DA
AD  - Mount Sinai Medical Center, New York, NY.
FAU - Guyatt, Gordon H
AU  - Guyatt GH
AD  - McMaster University Health Sciences Centre, Hamilton, ON, Canada.
FAU - Mark, Daniel B
AU  - Mark DB
AD  - Duke University Medical School, Durham, NC.
FAU - Harrington, Robert A
AU  - Harrington RA
AD  - Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.
LA  - eng
GR  - G0701113/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Fibrinolytic Agents)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clopidogrel
MH  - Coronary Artery Disease/*drug therapy/*prevention & control
MH  - Drug Therapy, Combination
MH  - Evidence-Based Medicine
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Humans
MH  - *Primary Prevention
MH  - Risk Assessment
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
EDAT- 2008/07/24 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/07/24 09:00
PHST- 2008/07/24 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/24 09:00 [entrez]
AID - S0012-3692(08)60130-0 [pii]
AID - 10.1378/chest.08-0685 [doi]
PST - ppublish
SO  - Chest. 2008 Jun;133(6 Suppl):776S-814S. doi: 10.1378/chest.08-0685.

PMID- 18690939
OWN - NLM
STAT- MEDLINE
DCOM- 20080903
LR  - 20191111
IS  - 1574-8863 (Print)
IS  - 1574-8863 (Linking)
VI  - 1
IP  - 3
DP  - 2006 Aug
TI  - Oral antiplatelet agents and bleeding risk in relation to major cardiovascular 
      surgery.
PG  - 281-7
AB  - INTRODUCTION: Patients requiring major cardiovascular surgery are likely to be 
      prescribed antiplatelet agents either alone or in combination. By virtue of 
      antiplatelet agent effect, they can potentially increase bleeding complications, 
      especially if used in combination. This article aims to review the evidence and 
      make appropriate recommendations regarding these agents. ASPIRIN: 16 papers are 
      reviewed which concern surgery whilst taking aspirin. The bulk of the evidence is 
      from the coronary bypass setting. CLOPIDOGREL: 14 papers are reviewed which 
      concern surgery whilst taking clopidogrel. DIPYRIDAMOLE: 2 papers are reviewed 
      concerning dipyridamole. CILOSTAZOL: No trials are available concerning surgery 
      and cilostazol. Several relevant publications are reviewed. CONCLUSION: It is the 
      recommendation of the authors that aspirin should usually be continued 
      perioperatively, whilst clopidogrel should be stopped for seven days prior to 
      surgery if at all possible.
FAU - McCaslin, James
AU  - McCaslin J
AD  - Northern Vascular Unit, Freeman Hospital, Newcastle upon Tyne, UK.
FAU - Smout, Jonathan
AU  - Smout J
FAU - Kesteven, Patrick
AU  - Kesteven P
FAU - Stansby, Gerard
AU  - Stansby G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Saf
JT  - Current drug safety
JID - 101270895
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - *Cardiovascular Surgical Procedures
MH  - Cilostazol
MH  - Clopidogrel
MH  - Dipyridamole/adverse effects/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Postoperative Hemorrhage/*chemically induced/*epidemiology
MH  - Risk
MH  - Tetrazoles/adverse effects/therapeutic use
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
RF  - 59
EDAT- 2008/08/12 09:00
MHDA- 2008/09/04 09:00
CRDT- 2008/08/12 09:00
PHST- 2008/08/12 09:00 [pubmed]
PHST- 2008/09/04 09:00 [medline]
PHST- 2008/08/12 09:00 [entrez]
AID - 10.2174/157488606777934486 [doi]
PST - ppublish
SO  - Curr Drug Saf. 2006 Aug;1(3):281-7. doi: 10.2174/157488606777934486.

PMID- 9156914
OWN - NLM
STAT- MEDLINE
DCOM- 19970522
LR  - 20131121
IS  - 1426-9686 (Print)
IS  - 1426-9686 (Linking)
VI  - 1
IP  - 2
DP  - 1996 Aug
TI  - [Blood platelets and fibrinolysis in ischemic heart disease].
PG  - 135-8
AB  - The role of platelets and fibrinolysis in ischemic heart disease are discussed. 
      The interaction lipoproteins with platelet factors may be important in therapy of 
      ischemic heart disease.
FAU - Jastrzebska, M
AU  - Jastrzebska M
AD  - Zakładu Biochemii Klinicznej i Diagnostyki Laboratoryjnej, Centrum Badań nad 
      Miazdzyca Pomorskiej A. M. w Szczecinie.
LA  - pol
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Płytki krwi a fibrynoliza w chorobie niedokrwiennej serca.
PL  - Poland
TA  - Pol Merkur Lekarski
JT  - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
JID - 9705469
RN  - 0 (Lipoproteins)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets/drug effects/*physiology
MH  - Fibrinolysis/drug effects/*physiology
MH  - Heparin/pharmacology
MH  - Humans
MH  - Lipoproteins/metabolism
MH  - Myocardial Ischemia/*blood
RF  - 44
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
PST - ppublish
SO  - Pol Merkur Lekarski. 1996 Aug;1(2):135-8.

PMID- 19258643
OWN - NLM
STAT- MEDLINE
DCOM- 20090709
LR  - 20191210
IS  - 1557-2501 (Electronic)
IS  - 1042-3931 (Linking)
VI  - 21
IP  - 3
DP  - 2009 Mar
TI  - Association of aspirin dosage to clinical outcomes after percutaneous coronary 
      intervention: observations from the Ottawa Heart Institute PCI Registry.
PG  - 121-7
AB  - BACKGROUND: Dual antiplatelet therapy, with aspirin and a thienopyridine, is the 
      accepted treatment after percutaneous coronary intervention (PCI). No clear 
      evidence exists regarding the ideal dosage of aspirin. Recent guidelines 
      recommend higher-dose aspirin because of the possible decrease in stent 
      thrombosis. The purpose of this study was to test the hypothesis that high-dose 
      aspirin of 325 mg decreases death and myocardial infarction (MI) compared to a 
      lower dose of 81 mg in patients undergoing PCI. METHODS: An observational cohort 
      study of 1,840 consecutive patients who underwent PCI was conducted. Patients who 
      did not survive to discharge were excluded. The primary endpoint was a composite 
      of all-cause mortality and MI at 1 year. RESULTS: Nine-hundred and thirty 
      patients (50.5%) were discharged on 325 mg of aspirin and 910 (49.5%) were 
      discharged of 81 mg. The risk of all-cause mortality or MI was not significantly 
      different between patients: low-dose 5.49% (50/910) vs. high-dose 4.19% (39/930); 
      adjusted odds ratio [OR], 1.16; 95% confidence interval [CI], 0.73-1.85). In a 
      multivariable analysis, the Charlson comorbidity score (OR, 1.37; 95% CI, 
      1.18-1.58) and urgent PCI (OR, 1.75; 95% CI, 1.03-3.00) were associated with 
      increased death or MI. Among patients with drug-eluting stents, the use of 
      low-dose aspirin did not predispose them to death or MI (adjusted OR, 1.12, 95% 
      CI, 0.53-2.34). CONCLUSIONS: In this large contemporary analysis of PCI patients, 
      no differences in death or MI were observed at 1 year between patients discharged 
      on low-dose aspirin 81 mg compared to patients on a higher dose.
FAU - So, Derek
AU  - So D
AD  - University of Ottawa Heart Institute, Cardiology, Ottawa, Ontario, Canada. 
      dso@ottawaheart.ca
FAU - Cook, E Francis
AU  - Cook EF
FAU - Le May, Michel
AU  - Le May M
FAU - Glover, Chris
AU  - Glover C
FAU - Williams, William
AU  - Williams W
FAU - Ha, Andrew
AU  - Ha A
FAU - Davies, Richard
AU  - Davies R
FAU - Froeschl, Michael
AU  - Froeschl M
FAU - Marquis, Jean-Fran Cois
AU  - Marquis JF
FAU - O'Brien, Edward
AU  - O'Brien E
FAU - Labinaz, Marino
AU  - Labinaz M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Invasive Cardiol
JT  - The Journal of invasive cardiology
JID - 8917477
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary/*methods
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Canada
MH  - Combined Modality Therapy
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*therapy
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Myocardial Infarction/prevention & control/*therapy
MH  - Myocardial Ischemia/prevention & control/*therapy
MH  - Outcome Assessment, Health Care
MH  - Patient Discharge
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - *Registries
MH  - Retrospective Studies
MH  - Secondary Prevention
EDAT- 2009/03/05 09:00
MHDA- 2009/07/10 09:00
CRDT- 2009/03/05 09:00
PHST- 2009/03/05 09:00 [entrez]
PHST- 2009/03/05 09:00 [pubmed]
PHST- 2009/07/10 09:00 [medline]
PST - ppublish
SO  - J Invasive Cardiol. 2009 Mar;21(3):121-7.

PMID- 2868029
OWN - NLM
STAT- MEDLINE
DCOM- 19860304
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 7
IP  - 2
DP  - 1986 Feb
TI  - Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention 
      with persantine and aspirin.
PG  - 251-69
AB  - In the Persantine-Aspirin Reinfarction Study, Part II (PARIS II), 3,128 persons 
      who had recovered from myocardial infarction, suffered from 4 weeks to 4 months 
      previously, were randomized into two groups: dipyridamole (Persantine) plus 
      aspirin (n = 1,563) and placebo (n = 1,565). The average length of follow-up was 
      23.4 months. Prespecified primary end points were coronary incidence (definite 
      nonfatal myocardial infarction plus death due to recent or acute cardiac event), 
      coronary mortality (death due to recent or acute cardiac event) and total 
      mortality, each at 1 year of patient follow-up and at the end of the study. 
      Coronary incidence in the Persantine plus aspirin group was significantly lower 
      than in the placebo group, both at 1 year (30% reduction) and at the end of the 
      study (24% reduction). The statistically significant differences in coronary 
      incidence, at 1 year and at the end of the study, in favor of the combination 
      treatment remained after adjustment for multiple baseline variables and 
      adjustment for multiple testing (three end points for two time periods). Although 
      there were reductions for other end points, these differences were not 
      statistically significant. Coronary mortality was 20% lower in the Persantine 
      plus aspirin group compared with the placebo group at 1 year, and 6% lower 
      overall. Total mortality in the treated group compared with the placebo group was 
      11% lower at 1 year and 3% lower overall. The reduced rates of coronary incidence 
      largely reflected lower rates of definite nonfatal myocardial infarction in the 
      Persantine plus aspirin group. Several subgroups were defined a priori and at the 
      end of the study. The beneficial effect of Persantine plus aspirin compared with 
      placebo for coronary incidence tended to be greater for the following groups of 
      patients: those who had a non-Q wave infarct; those who were not taking 
      digitalis; those who were receiving beta-receptor blocking drugs at baseline; 
      those who were in New York Heart Association functional class I; those who had 
      had only one myocardial infarction; or those who were enrolled in the study 
      early, that is within 85 days of the qualifying myocardial infarction.
FAU - Klimt, C R
AU  - Klimt CR
FAU - Knatterud, G L
AU  - Knatterud GL
FAU - Stamler, J
AU  - Stamler J
FAU - Meier, P
AU  - Meier P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Digitalis Glycosides)
RN  - 0 (Drug Combinations)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Actuarial Analysis
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Digitalis Glycosides/therapeutic use
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Electrocardiography
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/mortality/*prevention & control
MH  - Patient Compliance
MH  - Random Allocation
MH  - Recurrence
EDAT- 1986/02/01 00:00
MHDA- 1986/02/01 00:01
CRDT- 1986/02/01 00:00
PHST- 1986/02/01 00:00 [pubmed]
PHST- 1986/02/01 00:01 [medline]
PHST- 1986/02/01 00:00 [entrez]
AID - S0735-1097(86)80489-2 [pii]
AID - 10.1016/s0735-1097(86)80489-2 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1986 Feb;7(2):251-69. doi: 10.1016/s0735-1097(86)80489-2.

PMID- 18193923
OWN - NLM
STAT- MEDLINE
DCOM- 20080502
LR  - 20181113
IS  - 1172-7047 (Print)
IS  - 1172-7047 (Linking)
VI  - 22
IP  - 2
DP  - 2008
TI  - Secondary stroke prevention: inside the vessels and beyond.
PG  - 113-21
AB  - Cerebral ischaemic stroke is frequently a relapsing, if not chronic, disease. Its 
      incidence is age-dependent, and with the ageing of society the need for effective 
      therapies increases. This review considers current and alternative hypotheses 
      underlying secondary prevention of stroke. Currently, secondary stroke prevention 
      is widely practiced with aspirin (acetylsalicylic acid), a drug that has been in 
      use for more than 100 years. Newer drugs such as ticlopidine and clopidogrel have 
      subsequently been developed, but their efficacy barely surpasses that of aspirin. 
      Other drugs used in secondary stroke prevention include HMG-CoA reductase 
      inhibitors and antihypertensive agents. The endovascular paradigm has shaped the 
      thinking of secondary stroke prevention, and aspirin, ticlopidine and clopidogrel 
      are known as 'platelet inhibitors'; however, their pharmacological and clinical 
      effects are not fully explained within the platelet paradigm. Moreover, in recent 
      years, reduction of stroke incidence has also been observed with HMG-CoA 
      reductase inhibitors, regardless of their lipid-lowering effects. Hence, current 
      understanding needs to be supplemented by considering mechanisms beyond platelet 
      inhibition. Evidence has shown that aspirin, ticlopidine and clopidogrel share 
      neuroprotective properties not explained by the platelet paradigm and that are 
      reminiscent of a preconditioning effect. This neuroprotective mechanism is also 
      shared with HMG-CoA reductase inhibitors.
FAU - Riepe, Matthias W
AU  - Riepe MW
AD  - Department of Psychiatry and Psychotherapy, Mental Health and Old Age Psychiatry, 
      Charité Medical University, Berlin, Germany. matthias.riepe@charite.de
FAU - Huber, Roman
AU  - Huber R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - CNS Drugs
JT  - CNS drugs
JID - 9431220
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Blood Vessels/*drug effects
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Secondary Prevention
MH  - Stroke/*pathology/*therapy
RF  - 103
EDAT- 2008/01/16 09:00
MHDA- 2008/05/03 09:00
CRDT- 2008/01/16 09:00
PHST- 2008/01/16 09:00 [pubmed]
PHST- 2008/05/03 09:00 [medline]
PHST- 2008/01/16 09:00 [entrez]
AID - 2223 [pii]
AID - 10.2165/00023210-200822020-00003 [doi]
PST - ppublish
SO  - CNS Drugs. 2008;22(2):113-21. doi: 10.2165/00023210-200822020-00003.

PMID- 6799884
OWN - NLM
STAT- MEDLINE
DCOM- 19820412
LR  - 20190712
IS  - 0030-4220 (Print)
IS  - 0030-4220 (Linking)
VI  - 53
IP  - 2
DP  - 1982 Feb
TI  - Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin.
PG  - 170-8
AB  - Aspirin and indomethacin, administered systemically by oral route, were found to 
      delay the development of hamster buccal pouch epidermoid carcinomas induced by 
      thrice weekly topical applications of a 0.5 percent solution of 
      7,12-dimethylbenz(a)anthracene (DMBA) in mineral oil. Forty male and female 
      Syrian hamsters (Mesocricetus auratus) were divided into four equal groups. In 
      Group 1 animals the left buccal pouch was painted thrice weekly with DMBA. Group 
      2 animals were painted thrice weekly with DMBA and received 12 mg. aspirin daily 
      by oral route. Group 3 animals were painted thrice weekly with DMBA and received 
      1 mg. indomethacin daily by oral route. Group 4 animals were maintained as 
      untreated controls. Two animals in each of the four groups were killed with ether 
      at 8, 10, 12, 13, and 14 weeks after the start of the experiment. At the time of 
      sacrifice the buccal pouches were photographed and the average number of tumors 
      and the average size of tumors in each group were noted. The left and right 
      buccal pouches were dissected, fixed in 10 percent formalin, sectioned in 
      paraffin, and stained with hematoxylin and eosin. Autopsies were also performed 
      on each animal. Both left and right buccal pouches and major organs were studied 
      histologically. Both aspirin and indomethacin in the dosages used were found to 
      delay DMBA buccal pouch carcinogenesis. A suggested mechanism of action is the 
      inhibition of prostaglandin synthesis by the role of both aspirin and 
      indomethacin as inhibitors of prostaglandin synthetase. Indomethacin appeared to 
      exert a greater tumor-inhibiting effect than aspirin in the dosages used.
FAU - Perkins, T M
AU  - Perkins TM
FAU - Shklar, G
AU  - Shklar G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oral Surg Oral Med Oral Pathol
JT  - Oral surgery, oral medicine, and oral pathology
JID - 0376406
RN  - 57-97-6 (9,10-Dimethyl-1,2-benzanthracene)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - 9,10-Dimethyl-1,2-benzanthracene
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Carcinoma, Squamous Cell/*etiology
MH  - Cheek/pathology
MH  - Cricetinae
MH  - Female
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Mesocricetus
MH  - Mouth Neoplasms/*etiology
MH  - Neoplasms, Experimental/etiology
MH  - Time Factors
EDAT- 1982/02/01 00:00
MHDA- 1982/02/01 00:01
CRDT- 1982/02/01 00:00
PHST- 1982/02/01 00:00 [pubmed]
PHST- 1982/02/01 00:01 [medline]
PHST- 1982/02/01 00:00 [entrez]
AID - 10.1016/0030-4220(82)90283-3 [doi]
PST - ppublish
SO  - Oral Surg Oral Med Oral Pathol. 1982 Feb;53(2):170-8. doi: 
      10.1016/0030-4220(82)90283-3.

PMID- 31479546
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1469-0705 (Electronic)
IS  - 0960-7692 (Linking)
VI  - 55
IP  - 2
DP  - 2020 Feb
TI  - Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and 
      meta-regression.
PG  - 157-169
LID - 10.1002/uog.20859 [doi]
AB  - OBJECTIVE: To perform a meta-analysis and meta-regression of randomized 
      controlled trials (RCTs) to evaluate the impact of low-dose aspirin (LDA) on 
      perinatal outcome, independent of its effect on pre-eclampsia (PE), preterm birth 
      and low birth weight. METHODS: An electronic search of EMBASE, PubMed, CENTRAL, 
      PROSPERO and Google Scholar databases was performed to identify RCTs assessing 
      the impact of LDA in pregnancy, published in English prior to May 2019, which 
      reported perinatal outcomes of interest (placental abruption, delivery mode, low 
      5-min Apgar score, neonatal acidosis, neonatal intensive care unit admission, 
      periventricular hemorrhage and perinatal death). Risk ratios (RR) and 95% CI were 
      calculated and pooled for analysis. Analysis was stratified according to 
      gestational age at commencement of treatment (≤ 16 weeks vs > 16 weeks) and 
      subgroup analysis was performed to assess the impact of aspirin dose (< 100 mg vs 
      ≥ 100 mg). Meta-regression was used to assess the impact of LDA on perinatal 
      outcome, independent of the reduction in PE, preterm birth and low birth weight. 
      RESULTS: Forty studies involving 34 807 participants were included. When LDA was 
      commenced ≤ 16 weeks' gestation, it was associated with a significant reduction 
      in the risk of perinatal death (RR, 0.47; 95% CI, 0.25-0.88; P = 0.02; number 
      needed to treat, 92); however, this risk reduction was only seen when a daily 
      dose of ≥ 100 mg was administered. If commenced > 16 weeks' gestation, LDA was 
      associated with a significant reduction in 5-min Apgar score < 7 (RR, 0.75; 
      95% CI, 0.58-0.96; P = 0.02) and periventricular hemorrhage (RR, 0.68; 95% CI, 
      0.47-0.99; P = 0.04), but a trend towards an increase in the risk of placental 
      abruption (RR, 1.20; 95% CI, 1.00-1.46; P = 0.06) was also noted. LDA was not 
      associated with any significant increase in adverse events if commenced 
      ≤ 16 weeks gestation. LDA had no effect on delivery mode, irrespective of the 
      gestational age at which it was started. Meta-regression confirmed that the 
      effect of LDA on perinatal death, when treatment was started ≤ 16 weeks' 
      gestation, was independent of any reduction in the rate of PE and preterm birth. 
      CONCLUSION: LDA improves some important perinatal outcomes, without increasing 
      adverse events such as placental abruption or periventricular hemorrhage, and its 
      utility, if commenced prior to 16 weeks' gestation, may be considered in a wider 
      context beyond the prevention of PE or fetal growth restriction. Copyright © 2019 
      ISUOG. Published by John Wiley & Sons Ltd.
CI  - Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
FAU - Turner, J M
AU  - Turner JM
AD  - Mater Research Institute, University of Queensland, South Brisbane, Queensland, 
      Australia.
AD  - Faculty of Medicine, The University of Queensland, South Brisbane, Queensland, 
      Australia.
FAU - Robertson, N T
AU  - Robertson NT
AD  - Mater Research Institute, University of Queensland, South Brisbane, Queensland, 
      Australia.
FAU - Hartel, G
AU  - Hartel G
AD  - Division of Biostatistics, QIMR Berghofer Institute of Medical Research, 
      University of Queensland, Herston, Queensland, Australia.
FAU - Kumar, S
AU  - Kumar S
AUID- ORCID: 0000-0003-0832-4811
AD  - Mater Research Institute, University of Queensland, South Brisbane, Queensland, 
      Australia.
AD  - Faculty of Medicine, The University of Queensland, South Brisbane, Queensland, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200108
PL  - England
TA  - Ultrasound Obstet Gynecol
JT  - Ultrasound in obstetrics & gynecology : the official journal of the International 
      Society of Ultrasound in Obstetrics and Gynecology
JID - 9108340
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abruptio Placentae/*chemically induced
MH  - Apgar Score
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Delivery, Obstetric/*statistics & numerical data
MH  - Female
MH  - Fetal Growth Retardation/prevention & control
MH  - Humans
MH  - Infant, Low Birth Weight
MH  - Infant, Newborn
MH  - Infant, Newborn, Diseases/*chemically induced
MH  - Intensive Care Units, Neonatal/statistics & numerical data
MH  - Perinatal Death/etiology
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Premature Birth/prevention & control
MH  - Prenatal Care/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Regression Analysis
OTO - NOTNLM
OT  - Apgar score
OT  - acetylsalicylic acid
OT  - low birth weight
OT  - neonatal intensive care unit
OT  - perinatal death
OT  - pre-eclampsia
OT  - preterm birth
EDAT- 2019/09/04 06:00
MHDA- 2021/11/25 06:00
CRDT- 2019/09/04 06:00
PHST- 2019/02/05 00:00 [received]
PHST- 2019/08/18 00:00 [revised]
PHST- 2019/08/21 00:00 [accepted]
PHST- 2019/09/04 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2019/09/04 06:00 [entrez]
AID - 10.1002/uog.20859 [doi]
PST - ppublish
SO  - Ultrasound Obstet Gynecol. 2020 Feb;55(2):157-169. doi: 10.1002/uog.20859. Epub 
      2020 Jan 8.

PMID- 17602938
OWN - NLM
STAT- MEDLINE
DCOM- 20070716
LR  - 20131121
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 120
IP  - 7
DP  - 2007 Jul
TI  - Aspirin resistance and adverse clinical events in patients with coronary artery 
      disease.
PG  - 631-5
AB  - PURPOSE: We sought to determine the clinical significance of aspirin resistance 
      measured by a point-of-care assay in stable patients with coronary artery disease 
      (CAD). METHODS: We used the VerifyNow Aspirin (Accumetrics Inc, San Diego, Calif) 
      to determine aspirin responsiveness of 468 stable CAD patients on aspirin 80 to 
      325 mg daily for > or =4 weeks. Aspirin resistance was defined as an Aspirin 
      Reaction Unit > or =550. The primary outcome was the composite of cardiovascular 
      death, myocardial infarction (MI), unstable angina requiring hospitalization, 
      stroke, and transient ischemic attack. RESULTS: Aspirin resistance was noted in 
      128 (27.4%) patients. After a mean follow-up of 379+/-200 days, patients with 
      aspirin resistance were at increased risk of the composite outcome compared to 
      patients who were aspirin-sensitive (15.6% vs 5.3%, hazard ratio [HR] 3.12, 95% 
      confidence intervals [CI], 1.65-5.91, P < .001). Cox proportional hazard 
      regression modeling identified aspirin resistance, diabetes, prior MI, and a low 
      hemoglobin to be independently associated with major adverse long-term outcomes 
      (HR for aspirin resistance 2.46, 95% CI, 1.27-4.76, P = .007). CONCLUSIONS: 
      Aspirin resistance, defined by an aggregation-based rapid platelet function 
      assay, is associated with an increased risk of adverse clinical outcomes in 
      stable patients with CAD.
FAU - Chen, Wai-Hong
AU  - Chen WH
AD  - Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong 
      Kong, China. whchen@hku.hk
FAU - Cheng, Xi
AU  - Cheng X
FAU - Lee, Pui-Yin
AU  - Lee PY
FAU - Ng, William
AU  - Ng W
FAU - Kwok, Jeanette Yat-Yin
AU  - Kwok JY
FAU - Tse, Hung-Fat
AU  - Tse HF
FAU - Lau, Chu-Pak
AU  - Lau CP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy/*mortality
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Treatment Outcome
EDAT- 2007/07/03 09:00
MHDA- 2007/07/17 09:00
CRDT- 2007/07/03 09:00
PHST- 2006/06/01 00:00 [received]
PHST- 2006/10/14 00:00 [revised]
PHST- 2006/10/30 00:00 [accepted]
PHST- 2007/07/03 09:00 [pubmed]
PHST- 2007/07/17 09:00 [medline]
PHST- 2007/07/03 09:00 [entrez]
AID - S0002-9343(06)01396-9 [pii]
AID - 10.1016/j.amjmed.2006.10.021 [doi]
PST - ppublish
SO  - Am J Med. 2007 Jul;120(7):631-5. doi: 10.1016/j.amjmed.2006.10.021.

PMID- 26657879
OWN - NLM
STAT- MEDLINE
DCOM- 20161227
LR  - 20181202
IS  - 1879-3649 (Electronic)
IS  - 1537-1891 (Linking)
VI  - 80
DP  - 2016 May
TI  - Bridge therapy or standard treatment for urgent surgery after coronary stent 
      implantation: Analysis of 314 patients.
PG  - 85-90
LID - S1537-1891(15)30022-7 [pii]
LID - 10.1016/j.vph.2015.11.085 [doi]
AB  - Intravenous administration of a short acting glycoprotein IIb/IIIa inhibitor has 
      been proposed as a bridge to surgery in patients on dual antiplatelet treatment, 
      but data in comparison with other treatment options are not available. We 
      conducted a retrospective analysis of consecutive patients who underwent 
      un-deferrable, non-emergency surgery after coronary stenting. The bridge therapy 
      was performed after discontinuation of the oral P2Y12 inhibitor by using i.v. 
      tirofiban infusion. Net Adverse Clinical Events (NACE) was the primary outcome. 
      We analyzed 314 consecutive patients: the bridge strategy was performed in 87 
      patients, whereas 227 were treated with other treatment options and represent the 
      control group. Thirty-day NACE occurred in 8% of patients in the bridge group and 
      in 22.5% in the control group (p < 0.01). Bridge therapy was associated with 
      decreased 30-day NACE rate [Odds ratio (OR) 0.30; 95% confidence interval (CI) 
      0.13-0.39; p < 0.01], particularly when the time interval between stenting and 
      surgery was ≤ 60 days (OR 0.09, 95% CI 0.01-0.72; p = 0.02). There were no cases 
      of stent thrombosis in the bridge group and 3 (1.3%) in the control group. Bridge 
      therapy was associated with decreased events rates as compared to both patients 
      with and without P2Y12 inhibitors discontinuation in the control group. After 
      adjustment for the most relevant covariates, the favorable effect of the bridge 
      therapy was not materially modified. In conclusion, perioperative bridge therapy 
      using tirofiban was associated with reduced 30-day NACE rate, particularly when 
      surgery was performed within 60 days after stent implantation.
FAU - De Servi, Stefano
AU  - De Servi S
AD  - Coronary Care Unit, IRCCS Policlinico San Matteo, Pavia, Italy. Electronic 
      address: s.deservi@smatteo.pv.it.
FAU - Morici, Nuccia
AU  - Morici N
AD  - Division of Cardiology 1-Interventional Cardiology, Azienda Ospedaliera Ospedale 
      Niguarda Ca' Granda, Milano, Italy.
FAU - Boschetti, Enrico
AU  - Boschetti E
AD  - Division of Cardiology, University Hospital, Terni, Italy.
FAU - Rossini, Roberta
AU  - Rossini R
AD  - USC Cardiologia, Dipartimento Cardiovascolare, AO Papa Giovanni XXIII, Bergamo, 
      Italy.
FAU - Martina, Paola
AU  - Martina P
AD  - Cardiovascular Department, Civic Hospital, Legnano, Italy.
FAU - Musumeci, Giuseppe
AU  - Musumeci G
AD  - USC Cardiologia, Dipartimento Cardiovascolare, AO Papa Giovanni XXIII, Bergamo, 
      Italy.
FAU - D'Urbano, Maurizio
AU  - D'Urbano M
AD  - Cardiovascular Department, Civic Hospital, Legnano, Italy.
FAU - Lazzari, Ludovico
AU  - Lazzari L
AD  - Division of Cardiology, University Hospital, Terni, Italy.
FAU - La Vecchia, Carlo
AU  - La Vecchia C
AD  - Department of Clinical Science and Community Health, University of Milan, Milano, 
      Italy.
FAU - Senni, Michele
AU  - Senni M
AD  - USC Cardiologia, Dipartimento Cardiovascolare, AO Papa Giovanni XXIII, Bergamo, 
      Italy.
FAU - Klugmann, Silvio
AU  - Klugmann S
AD  - Division of Cardiology 1-Interventional Cardiology, Azienda Ospedaliera Ospedale 
      Niguarda Ca' Granda, Milano, Italy.
FAU - Savonitto, Stefano
AU  - Savonitto S
AD  - Division of Cardiology, Azienda Ospedaliera della Provincia di Lecco, Ospedale A. 
      Manzoni, Lecco, Italy.
LA  - eng
PT  - Journal Article
DEP - 20151130
PL  - United States
TA  - Vascul Pharmacol
JT  - Vascular pharmacology
JID - 101130615
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - 42HK56048U (Tyrosine)
RN  - GGX234SI5H (Tirofiban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ambulatory Care/methods
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - *Blood Vessel Prosthesis Implantation
MH  - Coronary Stenosis/surgery
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
MH  - Postoperative Hemorrhage/metabolism/*prevention & control
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/adverse 
      effects/therapeutic use
MH  - Retrospective Studies
MH  - *Surgical Procedures, Operative
MH  - Tirofiban
MH  - Tyrosine/administration & dosage/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - ADP receptors
OT  - Coronary syndrome
OT  - Platelet glycoproteins
EDAT- 2015/12/15 06:00
MHDA- 2016/12/28 06:00
CRDT- 2015/12/15 06:00
PHST- 2015/08/31 00:00 [received]
PHST- 2015/11/02 00:00 [revised]
PHST- 2015/11/27 00:00 [accepted]
PHST- 2015/12/15 06:00 [entrez]
PHST- 2015/12/15 06:00 [pubmed]
PHST- 2016/12/28 06:00 [medline]
AID - S1537-1891(15)30022-7 [pii]
AID - 10.1016/j.vph.2015.11.085 [doi]
PST - ppublish
SO  - Vascul Pharmacol. 2016 May;80:85-90. doi: 10.1016/j.vph.2015.11.085. Epub 2015 
      Nov 30.

PMID- 36494710
OWN - NLM
STAT- MEDLINE
DCOM- 20221216
LR  - 20221221
IS  - 1465-542X (Electronic)
IS  - 1465-5411 (Print)
IS  - 1465-5411 (Linking)
VI  - 24
IP  - 1
DP  - 2022 Dec 9
TI  - Associations of aspirin and other anti-inflammatory medications with breast 
      cancer risk by the status of COX-2 expression.
PG  - 89
LID - 10.1186/s13058-022-01575-3 [doi]
LID - 89
AB  - BACKGROUND: We investigated the associations of aspirin and other nonsteroidal 
      anti-inflammatory drugs (NSAIDs) with breast cancer risk by the status of COX-2 
      protein expression. METHODS: This study included 421 cases and 3,166 controls 
      from a nested case-control study within the Nurses' Health Study (NHS) and 
      Nurses' Health Study II (NHSII) cohorts. Information on medication use was first 
      collected in 1980 (NHS) and 1989 (NHSII) and was updated biennially. Medication 
      use was defined as none, past or current; average cumulative dose and frequency 
      were calculated for all past or current users using data collected from all 
      biannual questionnaires preceding the reference date. Immunochemistry for COX-2 
      expression was performed using commercial antibody (Cayman Chemical and Thermo 
      Fisher Scientific). We used polychotomous logistic regression to quantify 
      associations of aspirin and NSAIDs with the risk of COX2+ and COX2- breast cancer 
      tumors, while adjusting for known breast cancer risk factors. All tests of 
      statistical significance were two-sided. RESULTS: In multivariate analysis, we 
      found no differences in associations of the aspirin exposures and NSAIDs with 
      breast cancer risk by COX2 expression status. In stratified analyses by COX2 
      status, significant associations of these medications with breast cancer risk 
      were observed for dosage of aspirin among current users in COX2- tumors (OR 
      for > 5 tablets per week vs. none 1.71, 95% CI 1.01-2.88, p-trend 0.04). Regular 
      aspirin use was marginally associated with the risk of COX2- tumors 
      (p-trend = 0.06). CONCLUSIONS: Our findings suggested no differences in 
      associations of aspirin and other NSAIDs with COX2+ and COX2- tumors.
CI  - © 2022. The Author(s).
FAU - Yaghjyan, Lusine
AU  - Yaghjyan L
AUID- ORCID: 0000-0002-1626-5340
AD  - Department of Epidemiology, College of Public Health and Health Professions and 
      College of Medicine, University of Florida, 2004 Mowry Rd, Gainesville, FL, 
      32610, USA. lyaghjyan@ufl.edu.
FAU - Eliassen, A Heather
AU  - Eliassen AH
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and 
      Women's Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Colditz, Graham
AU  - Colditz G
AD  - Department of Surgery, Washington University in St. Louis School of Medicine, St. 
      Louis, MO, USA.
AD  - Institute for Public Health, Washington University in St. Louis, St. Louis, MO, 
      USA.
FAU - Rosner, Bernard
AU  - Rosner B
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and 
      Women's Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Schedin, Pepper
AU  - Schedin P
AD  - Oregon Health and Science University, Portland, OR, USA.
FAU - Wijayabahu, Akemi
AU  - Wijayabahu A
AD  - Department of Epidemiology, College of Public Health and Health Professions and 
      College of Medicine, University of Florida, 2004 Mowry Rd, Gainesville, FL, 
      32610, USA.
FAU - Tamimi, Rulla M
AU  - Tamimi RM
AD  - Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, 
      USA.
LA  - eng
GR  - P01 CA087969/CA/NCI NIH HHS/United States
GR  - UM1 CA186107/CA/NCI NIH HHS/United States
GR  - U01 CA176726/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20221209
PL  - England
TA  - Breast Cancer Res
JT  - Breast cancer research : BCR
JID - 100927353
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Aspirin/therapeutic use
MH  - *Breast Neoplasms/epidemiology/etiology/drug therapy
MH  - Case-Control Studies
MH  - Breast/metabolism
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Cyclooxygenase 2
MH  - Risk Factors
PMC - PMC9733081
OTO - NOTNLM
OT  - Aspirin
OT  - Breast cancer risk
OT  - COX-2
OT  - NSAIDs
COIS- The authors declare that they have no competing interests.
EDAT- 2022/12/10 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/12/09 23:57
PHST- 2022/04/01 00:00 [received]
PHST- 2022/11/06 00:00 [accepted]
PHST- 2022/12/09 23:57 [entrez]
PHST- 2022/12/10 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
AID - 10.1186/s13058-022-01575-3 [pii]
AID - 1575 [pii]
AID - 10.1186/s13058-022-01575-3 [doi]
PST - epublish
SO  - Breast Cancer Res. 2022 Dec 9;24(1):89. doi: 10.1186/s13058-022-01575-3.

PMID- 33988836
OWN - NLM
STAT- MEDLINE
DCOM- 20220512
LR  - 20220526
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 36
IP  - 3
DP  - 2022 Jun
TI  - The Association between Multi-Vessel Coronary Artery Disease and High On-Aspirin 
      Platelet Reactivity.
PG  - 449-454
LID - 10.1007/s10557-021-07195-x [doi]
AB  - BACKGROUND: Multi-vessel coronary artery disease (MV-CAD) is correlated with 
      worse clinical outcomes compared with single-vessel CAD (SV-CAD). The aim of this 
      study was to evaluate the association between MV-CAD and high on-aspirin platelet 
      reactivity (HAPR) in patients with stable CAD treated with aspirin. METHODS: The 
      current study is an analysis of prospectively enrolled randomly selected patients 
      with known stable CAD, who were taking aspirin (75-100 mg qd) regularly for at 
      least one month, and had undergone coronary angiography at least 3 months prior 
      to the enrollment to the study. EXCLUSION CRITERIA: acute coronary syndrome at 
      the time of platelet function testing, active malignancy, acute infection, active 
      inflammatory/rheumatic disease, major surgery in the past 6 months, chronic liver 
      failure, treatment with oral anticoagulation, non-adherence with Aspirin and 
      thrombocytopenia (<100 K/micl). Blood was drawn from the participants and sent 
      for platelet function testing (VerifyNow, Instrumentation Laboratory Company, 
      Bedford, Massachusetts, United States). MV-CAD was defined as >50% stenosis in ≥2 
      separate major coronary territories per coronary angiography. HAPR was defined as 
      aspirin reaction units (ARU) >550. RESULTS: Overall, 507 patients were analyzed; 
      age 66.7 ± 11.2, 17.9% women, 223 (44%) had MV-CAD. The rate of HAPR was 
      significantly higher among patients with MV-CAD vs. SV-CAD (14.8% vs. 3.5%, 
      p < 0.001, respectively). Furthermore, a "dose response"-like association was 
      found between the number of stenotic coronary arteries and the rate of HAPR 
      (3.5%, 13.5 and 17.3% for SV-CAD, 2-vessel and 3-vessel disease, respectively). 
      In a multivariate analysis adjusted for potential confounders, MV-CAD was found 
      to be a strong independent predictor of HAPR [OR = 1.8 (95%CI: 1.05-4.7), 
      p = 0.014]. CONCLUSIONS: A significant association between MV-CAD and HAPR was 
      found. Additional studies designed to investigate the mechanisms of HAPR and 
      different therapeutic options for this subset of patients are warranted.
CI  - © 2021. Springer Science+Business Media, LLC, part of Springer Nature.
FAU - Shiyovich, Arthur
AU  - Shiyovich A
AUID- ORCID: 0000-0001-7316-1882
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      and "Sackler" Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 
      arthur.shiyovich@gmail.com.
FAU - Sasson, Liat
AU  - Sasson L
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      and "Sackler" Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Lev, Eli
AU  - Lev E
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      and "Sackler" Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Solodky, Alejandro
AU  - Solodky A
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      and "Sackler" Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Kornowski, Ran
AU  - Kornowski R
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      and "Sackler" Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Perl, Leor
AU  - Perl L
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      and "Sackler" Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
LA  - eng
PT  - Journal Article
DEP - 20210514
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - Blood Platelets
MH  - *Coronary Artery Disease/diagnostic imaging/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Platelet Function Tests
OTO - NOTNLM
OT  - Aspirin
OT  - Coronary artery disease
OT  - High on-aspirin platelet reactivity
EDAT- 2021/05/15 06:00
MHDA- 2022/05/14 06:00
CRDT- 2021/05/14 12:29
PHST- 2021/04/16 00:00 [accepted]
PHST- 2021/05/15 06:00 [pubmed]
PHST- 2022/05/14 06:00 [medline]
PHST- 2021/05/14 12:29 [entrez]
AID - 10.1007/s10557-021-07195-x [pii]
AID - 10.1007/s10557-021-07195-x [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2022 Jun;36(3):449-454. doi: 10.1007/s10557-021-07195-x. 
      Epub 2021 May 14.

PMID- 6662166
OWN - NLM
STAT- MEDLINE
DCOM- 19840302
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 25
IP  - 5
DP  - 1983
TI  - Sex differences in the pharmacokinetics of salicylates.
PG  - 679-82
AB  - The kinetics of disposition of total and free salicylic acid (SA) in blood plasma 
      was evaluated after single and multiple oral administration of acetylsalicylic 
      acid (ASA) to healthy female and male volunteers. In both single and multiple 
      dose studies significant sex differences were found in the plasma levels of SA, 
      which were due, at least in part, to individual, sex-determined differences in 
      the rate of absorption and elimination of SA; a slower absorption rate in men 
      reduced the magnitude of the peak plasma levels of SA. The corresponding area 
      under concentration-time curves were always significantly lower. The elimination 
      rate of SA in men was increased in comparison with women. The higher plasma 
      clearance in men resulted from the kinetics of absorption and elimination. The 
      sex differences appear to be clinical significance, since men achieved lower 
      plasma levels of SA than women after the same weight-adjusted dose of ASA.
FAU - Trnavská, Z
AU  - Trnavská Z
FAU - Trnavský, K
AU  - Trnavský K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/metabolism
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - Salicylates/*blood
MH  - Sex Factors
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1007/BF00542358 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1983;25(5):679-82. doi: 10.1007/BF00542358.

PMID- 7023493
OWN - NLM
STAT- MEDLINE
DCOM- 19811014
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 31
IP  - 5a
DP  - 1981
TI  - Fluproquazone: analgesic activity in outpatients with non-migrainous headache.
PG  - 914-7
AB  - The analgesic activity of 
      4-(p-fluorophenyl)-1-isopropyl-7-methyl-2(1H)-quinazolinone (fluproquazone) was 
      investigated in three separate controlled studies including 131 outpatients with 
      non-migrainous headache. By means of the patients' self-assessment of pain 
      intensity and pain relief, 25 mg and 50 mg doses were shown to be effective 
      according to some parameters of analgesic effect; a 100-mg dose was more 
      effective, being significantly different from placebo for all parameters of 
      analgesia. Fluproquazone 50 mg was as active as acetylsalicylic acid 1000 mg and 
      slightly less active than a combination of propyphenazone 220 mg and allobarbital 
      30 mg. Except for the occurrence of vomiting in one patient after fluproquazone 
      50 mg and 100 mg. the drug was well tolerated.
FAU - Wood, A J
AU  - Wood AJ
FAU - von Graffenried, B
AU  - von Graffenried B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Analgesics)
RN  - 0 (Placebos)
RN  - 0 (Quinazolines)
RN  - 0 (Quinazolinones)
RN  - R16CO5Y76E (Aspirin)
RN  - U4K85O58HD (fluproquazone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Analgesics
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Headache/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Quinazolines/*therapeutic use
MH  - Quinazolinones
MH  - Time Factors
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1981;31(5a):914-7.

PMID- 158654
OWN - NLM
STAT- MEDLINE
DCOM- 19791218
LR  - 20131121
IS  - 0380-0903 (Print)
IS  - 0380-0903 (Linking)
VI  - 5
DP  - 1979
TI  - Inhibitory effects of gold and other drugs on mononuclear cell responses: a 
      comparison.
PG  - 112-6
AB  - The effects of gold sodium thiomalate (GST) were compared with those of 
      acetylsalicylic acid (ASA), D-penicillamine (PEN), and methlyprednisolone 
      succinate (MP) on the mixed leukocyte reaction (MLR), and on cell-mediated 
      cytotoxicity (CMC) using mononuclear cells from normal human volunteers. GST and 
      MP inhibited MLR in concentrations readily achieved in the serum, or tissues of 
      patients. ASA showed only a modest effect on MLR, in high concentrations. All 
      drugs inhibited CMC; PEN inhibited CMC at doses of 100 mcg/ml which were no 
      inhibitory in MLR. ASA inhibited CMC at relatively low concentrations. The 
      effects of some of the drugs on MLR and CMC were not consistent. This may be due 
      to the preferential action of the drugs on various immunologically competent 
      cells.
FAU - Harth, M
AU  - Harth M
FAU - Stiller, C R
AU  - Stiller CR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol Suppl
JT  - The Journal of rheumatology. Supplement
JID - 7806058
RN  - 12244-57-4 (Gold Sodium Thiomalate)
RN  - GNN1DV99GX (Penicillamine)
RN  - R16CO5Y76E (Aspirin)
RN  - VC2W18DGKR (Thymidine)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Cytotoxicity, Immunologic
MH  - Gold Sodium Thiomalate/*pharmacology
MH  - Humans
MH  - Lymphocyte Culture Test, Mixed
MH  - Methylprednisolone/pharmacology
MH  - Penicillamine/pharmacology
MH  - Thymidine/metabolism
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol Suppl. 1979;5:112-6.

PMID- 31226002
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20200518
IS  - 1552-3365 (Electronic)
IS  - 0363-5465 (Linking)
VI  - 47
IP  - 9
DP  - 2019 Jul
TI  - The Perioperative Continuation of Aspirin in Patients Undergoing Arthroscopic 
      Surgery of the Knee.
PG  - 2138-2142
LID - 10.1177/0363546519855643 [doi]
AB  - BACKGROUND: The perioperative withdrawal of aspirin increases the risk of 
      cardiac, neurologic, and vascular thromboembolic events. The safety of continuing 
      aspirin in patients undergoing knee arthroscopy is unknown. HYPOTHESIS: 
      Perioperative continuation of aspirin does not increase surgical complications or 
      worsen outcomes in patients 50 years of age and older undergoing knee 
      arthroscopy. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: This is a 
      single-center, institutional review board-approved, prospective matched 
      dual-cohort study comparing the surgical complication rates and postoperative 
      outcomes of patients taking daily aspirin with those of unmedicated controls. 
      Ninety patients who were 50 years of age or older and taking 81 mg or 325 mg 
      daily aspirin were matched to 90 controls. Patients were matched on age, surgery 
      type, and the use of a tourniquet. A complication was defined as bleeding, wound 
      dehiscence, or wound infection requiring reoperation. Postoperative outcome 
      measures including hematoma formation, extent of ecchymosis (mm), visual analog 
      scale (VAS) scores for pain and swelling, and the Knee Injury and Osteoarthritis 
      Outcome Score (KOOS) were collected preoperatively and postoperatively (10-14 
      days and 4-6 weeks). RESULTS: There were no complications (0%) in either cohort. 
      There was no difference in hematoma formation (aspirin, 1.8%; controls, 2.4%; P = 
      .79), incidence of ecchymosis (aspirin, 17%; controls, 21%; P = .70), or the 
      average extent of ecchymosis (aspirin, 124.6 mm; controls, 80.3 mm; P = .36) 
      between patients taking aspirin and controls. There was no significant difference 
      in pre- or postoperative knee range of motion between controls and patients 
      taking aspirin. The KOOS subscores and VAS pain scores were similar between 
      patients taking aspirin and controls at baseline and at follow-up. CONCLUSION: 
      The perioperative continuation of daily aspirin in patients 50 years of age and 
      older undergoing arthroscopic procedures of the knee is safe and does not result 
      in an increased rate of bleeding or wound complications requiring reoperation. 
      Continued aspirin use in patients 50 years of age and older had no significant 
      effect on postoperative physical examination measures or patient-rated outcome 
      scores.
FAU - Bogunovic, Ljiljana
AU  - Bogunovic L
AD  - Department of Orthopaedics, Washington University, Chesterfield, Missouri, USA.
FAU - Haas, Amanda K
AU  - Haas AK
AD  - Department of Orthopaedics, Washington University, Chesterfield, Missouri, USA.
FAU - Brophy, Robert H
AU  - Brophy RH
AD  - Department of Orthopaedics, Washington University, Chesterfield, Missouri, USA.
FAU - Matava, Matthew J
AU  - Matava MJ
AD  - Department of Orthopaedics, Washington University, Chesterfield, Missouri, USA.
FAU - Smith, Matthew V
AU  - Smith MV
AD  - Department of Orthopaedics, Washington University, Chesterfield, Missouri, USA.
FAU - Wright, Rick W
AU  - Wright RW
AD  - Department of Orthopaedics, Washington University, Chesterfield, Missouri, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190621
PL  - United States
TA  - Am J Sports Med
JT  - The American journal of sports medicine
JID - 7609541
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arthroscopy/*methods
MH  - Aspirin/*administration & dosage
MH  - Cohort Studies
MH  - Female
MH  - Hematoma
MH  - Humans
MH  - Knee Joint/*surgery
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*epidemiology
MH  - Postoperative Period
MH  - Prospective Studies
MH  - Reoperation
MH  - Treatment Outcome
OTO - NOTNLM
OT  - antithrombotic medication
OT  - arthroscopy
OT  - aspirin
OT  - knee arthroscopy
EDAT- 2019/06/22 06:00
MHDA- 2020/05/19 06:00
CRDT- 2019/06/22 06:00
PHST- 2019/06/22 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
PHST- 2019/06/22 06:00 [entrez]
AID - 10.1177/0363546519855643 [doi]
PST - ppublish
SO  - Am J Sports Med. 2019 Jul;47(9):2138-2142. doi: 10.1177/0363546519855643. Epub 
      2019 Jun 21.

PMID- 1080251
OWN - NLM
STAT- MEDLINE
DCOM- 19751021
LR  - 20141120
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 293
IP  - 13
DP  - 1975 Sep 25
TI  - Impaired interaction (adhesion-aggregation) of platelets with the subendothelium 
      in storage-pool disease and after aspirin ingestion. A comparison with von 
      Willebrand's disease.
PG  - 619-23
AB  - Possible defects in the interaction of platelets with the subendothelial surface 
      were evaluated in six patients with storeage-pool disease, nine patients with von 
      Willebrand's disease and seven normal subjects who ingested aspirin. Citrated 
      blood was perfused through a chamber containing everted segments of rabbit aorta 
      previously denuded of endothelium by means of a ballon catheter. With normal 
      blood, 83.3 +/- 1.9 per cent (S.E.M.) of the surface was covered by adherent 
      platelets. Platelet adhesion was normal after aspirin ingestion (89.7 +/- 4.6 per 
      cent) and decreased in some patients with storage-pool disease. The most striking 
      defect in both circumstances was the virtual absence of platelet thrombi. In 
      contrast, decreased adhesion (57.3 +/- 3.4 per cent), but normal thrombus 
      formation, was characteristic of von Willebrand's disease. These types of defects 
      in platelet adhesion and aggregation may account for the hemostatic defects in a 
      variety of bleeding disorders. The findings further suggest the possible 
      usefulness of aspirin as an antithrombotic agent.
FAU - Weiss, H J
AU  - Weiss HJ
FAU - Tschopp, T B
AU  - Tschopp TB
FAU - Baumgartner, H R
AU  - Baumgartner HR
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/*metabolism
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Aorta, Abdominal
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelet Disorders/*blood
MH  - Blood Platelets/ultrastructure
MH  - Endothelium
MH  - Humans
MH  - In Vitro Techniques
MH  - Middle Aged
MH  - *Platelet Adhesiveness/drug effects
MH  - *Platelet Aggregation/drug effects
MH  - Purpura, Thrombocytopenic/blood
MH  - Rabbits
MH  - Syndrome
MH  - von Willebrand Diseases/*blood
EDAT- 1975/09/25 00:00
MHDA- 1975/09/25 00:01
CRDT- 1975/09/25 00:00
PHST- 1975/09/25 00:00 [pubmed]
PHST- 1975/09/25 00:01 [medline]
PHST- 1975/09/25 00:00 [entrez]
AID - 10.1056/NEJM197509252931301 [doi]
PST - ppublish
SO  - N Engl J Med. 1975 Sep 25;293(13):619-23. doi: 10.1056/NEJM197509252931301.

PMID- 2314974
OWN - NLM
STAT- MEDLINE
DCOM- 19900419
LR  - 20131121
IS  - 0031-4005 (Print)
IS  - 0031-4005 (Linking)
VI  - 85
IP  - 4
DP  - 1990 Apr
TI  - Repeated oral administration of activated charcoal for treating aspirin overdose 
      in young children.
PG  - 594-8
AB  - The data from our two patients indicates that gastrointestinal dialysis with 
      repeated oral doses of activated charcoal may significantly enhance the 
      elimination of overdoses of salicylate in young children. Limited experience 
      precludes precise recommendations, but current evidence suggests that 
      gastrointestinal dialysis should be evaluated further for treating pediatric 
      salicylate intoxication.
FAU - Vertrees, J E
AU  - Vertrees JE
AD  - New Mexico Poison and Drug Information Center, Division of Pulmonary/Intensive 
      Care, Albuquerque.
FAU - McWilliams, B C
AU  - McWilliams BC
FAU - Kelly, H W
AU  - Kelly HW
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (Salicylates)
RN  - 16291-96-6 (Charcoal)
RN  - 7487-88-9 (Magnesium Sulfate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/pharmacokinetics/*poisoning
MH  - Charcoal/*administration & dosage/therapeutic use
MH  - *Dialysis/methods
MH  - Half-Life
MH  - Humans
MH  - Infant
MH  - Magnesium Sulfate/administration & dosage
MH  - Male
MH  - Salicylates/pharmacokinetics/poisoning
MH  - Salicylic Acid
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
PST - ppublish
SO  - Pediatrics. 1990 Apr;85(4):594-8.

PMID- 35869616
OWN - NLM
STAT- MEDLINE
DCOM- 20220726
LR  - 20220813
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 28
DP  - 2022 Jul 23
TI  - Time of Resumption of Antiplatelet Drugs After Upper Gastrointestinal Hemorrhage.
PG  - e936953
LID - 10.12659/MSM.936953 [doi]
AB  - BACKGROUND This study aimed to investigate the optimum time to reintroduce the 
      original antiplatelet drugs after upper gastrointestinal hemorrhage in patients 
      as secondary prevention for cardiovascular and cerebrovascular diseases. MATERIAL 
      AND METHODS After the upper gastrointestinal bleeding stopped, patients were 
      randomly divided according to the oral antiplatelet drugs administered. The 
      aspirin group was further divided into 3-day and 7-day aspirin groups. The 
      patients who took aspirin and clopidogrel were randomly divided into 3 groups: 
      0-day aspirin+3-day clopidogrel; 0-day aspirin+7-day clopidogrel; and 3-day 
      aspirin+7-day clopidogrel. The recovery time, rebleeding rate, incidence of 
      cardiovascular and cerebrovascular events, and death were observed. RESULTS The 
      3-day aspirin group had more rebleeding, reduced risk of cardiovascular and 
      cerebrovascular events, and a similar mortality rate compared to the other 
      groups. In the aspirin+clopidogrel group, the 0-day aspirin+3-day clopidogrel 
      group had the highest rebleeding rate and the lowest risk of cardiovascular and 
      cerebrovascular events. The 3-day aspirin+7-day clopidogrel group had the highest 
      risk of cardiovascular and cerebrovascular events and increased hospitalization 
      time. The risk of rebleeding and cardiovascular and cerebrovascular events was 
      lower in the 0-day aspirin+7-day clopidogrel group, and the overall mortality 
      rate was the lowest in this group. CONCLUSIONS In patients receiving only 
      aspirin, this drug should be reintroduced as soon as possible after peptic ulcer 
      hemorrhage. Aspirin and clopidogrel are dual antiplatelet drugs used for the 
      secondary prevention of cardiovascular diseases. In patients under dual-drug 
      therapy, aspirin should not be stopped, while clopidogrel should be restarted in 
      about 7 days.
FAU - Ma, Huan
AU  - Ma H
AD  - Department of Gastroenterology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei, China (mainland).
FAU - Fan, Xiao
AU  - Fan X
AD  - Department of Gastroenterology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei, China (mainland).
FAU - Jiao, Li
AU  - Jiao L
AD  - Department of Gastroenterology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei, China (mainland).
FAU - Meng, Xia
AU  - Meng X
AD  - Department of Gastroenterology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei, China (mainland).
FAU - Zhao, Liwei
AU  - Zhao L
AD  - Department of Gastroenterology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei, China (mainland).
FAU - Wang, Junmin
AU  - Wang J
AD  - Department of Gastroenterology, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei, China (mainland).
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220723
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Clopidogrel/therapeutic use
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Hemorrhage/drug therapy
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/adverse effects
MH  - *Ticlopidine/therapeutic use
PMC - PMC9327622
COIS- Conflict of interest: This research was supported by the Hebei Medical Science 
      Research Project of China (No. 20210530)
EDAT- 2022/07/24 06:00
MHDA- 2022/07/27 06:00
CRDT- 2022/07/23 01:23
PHST- 2022/07/23 01:23 [entrez]
PHST- 2022/07/24 06:00 [pubmed]
PHST- 2022/07/27 06:00 [medline]
AID - 936953 [pii]
AID - 10.12659/MSM.936953 [doi]
PST - epublish
SO  - Med Sci Monit. 2022 Jul 23;28:e936953. doi: 10.12659/MSM.936953.

PMID- 105270
OWN - NLM
STAT- MEDLINE
DCOM- 19790425
LR  - 20131121
IS  - 0341-3098 (Print)
IS  - 0341-3098 (Linking)
VI  - 121
IP  - 3
DP  - 1979 Jan 19
TI  - [Iron substitution in postoperative anemia during thromboembolic prophylaxis 
      (author's transl)].
PG  - 99-102
AB  - After major operations in 246 patients it was shown that there was no greater 
      blood loss with thromboembolic prophylaxis with heparin and acetylsalicylic acid 
      and healing proceeded undisturbed in view of the demonstrated reductions of 
      hemoglobin and hematocrit which correspond to those of the gynecological 
      operations without thromboembolic prophylaxis, these patients also must be given 
      longterm iron substitution.
FAU - Riffelmacher, F
AU  - Riffelmacher F
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Eisen-Substitution bei postoperativer Anämie unter Thrombo-embolie-Prophylaxe.
PL  - Germany
TA  - MMW Munch Med Wochenschr
JT  - MMW, Munchener medizinische Wochenschrift
JID - 7801805
RN  - 9005-49-6 (Heparin)
RN  - E1UOL152H7 (Iron)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anemia, Hypochromic/drug therapy/*etiology
MH  - Aspirin/therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Iron/*therapeutic use
MH  - Postoperative Care
MH  - Postoperative Complications/drug therapy/*prevention & control
MH  - Thromboembolism/*prevention & control
EDAT- 1979/01/19 00:00
MHDA- 1979/01/19 00:01
CRDT- 1979/01/19 00:00
PHST- 1979/01/19 00:00 [pubmed]
PHST- 1979/01/19 00:01 [medline]
PHST- 1979/01/19 00:00 [entrez]
PST - ppublish
SO  - MMW Munch Med Wochenschr. 1979 Jan 19;121(3):99-102.

PMID- 27712763
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20180124
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 36
IP  - 4
DP  - 2016 Nov
TI  - Pathogenesis of Aspirin-Induced Reactions in Aspirin-Exacerbated Respiratory 
      Disease.
PG  - 681-691
LID - S0889-8561(16)30050-9 [pii]
LID - 10.1016/j.iac.2016.06.005 [doi]
AB  - The acute clinical symptoms that develop following the oral ingestion of aspirin, 
      or any other inhibitor of cyclooxygenase-1, are well established in 
      aspirin-exacerbated respiratory disease: nasal congestion, rhinorrhea, and 
      bronchospasm. Less commonly, gastrointestinal distress, rash, angioedema, or 
      urticaria also develops. However, the pathobiology that drives these clinical 
      reactions is poorly understood. Use of an intranasal aspirin challenge protocol 
      or administration of premedications inhibiting the leukotriene pathway decreases 
      the severity of clinical reaction, which suggests the involvement of both local 
      effector cells and cysteinyl leukotrienes in the pathogenesis of aspirin-induced 
      reactions.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Cahill, Katherine N
AU  - Cahill KN
AD  - Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, 
      Harvard Medical School, 1 Jimmy Fund Way, Smith Building, Room 638, Boston, MA 
      02115, USA.
FAU - Laidlaw, Tanya M
AU  - Laidlaw TM
AD  - Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, 
      Harvard Medical School, 1 Jimmy Fund Way, Smith Building, Room 638, Boston, MA 
      02115, USA. Electronic address: tlaidlaw@partners.org.
LA  - eng
GR  - K23 AI118804/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20160913
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Biomarkers
MH  - Cytokines/metabolism
MH  - Humans
MH  - Immunity, Innate
MH  - Inflammation Mediators/metabolism
MH  - Phenotype
MH  - Respiratory Tract Diseases/*diagnosis/*etiology/metabolism
OTO - NOTNLM
OT  - Aspirin-exacerbated respiratory disease
OT  - Cysteinyl leukotrienes
OT  - Mast cell
OT  - Pathogenesis
OT  - Platelet-leukocyte aggregates
OT  - Prostaglandins
EDAT- 2016/10/08 06:00
MHDA- 2017/12/23 06:00
CRDT- 2016/10/08 06:00
PHST- 2016/10/08 06:00 [entrez]
PHST- 2016/10/08 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - S0889-8561(16)30050-9 [pii]
AID - 10.1016/j.iac.2016.06.005 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2016 Nov;36(4):681-691. doi: 
      10.1016/j.iac.2016.06.005. Epub 2016 Sep 13.

PMID- 21491441
OWN - NLM
STAT- MEDLINE
DCOM- 20110909
LR  - 20181201
IS  - 1520-6017 (Electronic)
IS  - 0022-3549 (Linking)
VI  - 100
IP  - 6
DP  - 2011 Jun
TI  - Coformer selection in pharmaceutical cocrystal development: a case study of a 
      meloxicam aspirin cocrystal that exhibits enhanced solubility and 
      pharmacokinetics.
PG  - 2172-81
LID - 10.1002/jps.22434 [doi]
AB  - Meloxicam is a nonsteroidal anti-inflammatory drug with low aqueous solubility 
      and high permeability. Because of its low solubility under acidic conditions 
      (e.g., pH 1-5), it can take more than 2 h for meloxicam to reach its therapeutic 
      concentration in humans. Although the slow onset of meloxicam does not 
      necessarily impact the current label indications, the slow onset does prevent 
      meloxicam from its potential application for the relief of mild-to-medium-level 
      acute pain. Pharmaceutical cocrystallization of meloxicam, which represents a 
      promising approach to generate diverse novel crystal forms, could be used to 
      improve the aqueous solubility and accelerate the onset of action. In this 
      contribution, we describe how a novel method can be used for coformer selection 
      to enable the efficient and effective development of a pharmaceutical cocrystal 
      with desired physicochemical and pharmacokinetic properties. Aspirin was selected 
      as the coformer for meloxicam based upon this alternative route, which combines 
      the supramolecular synthon approach with findings in the previous pharmacological 
      and toxicological studies of meloxicam. The resulting cocrystal of meloxicam and 
      aspirin exhibited superior kinetic solubility and possessed the potential to 
      significantly decrease the time required to reach the human therapeutic 
      concentration compared with the parent drug, meloxicam.
CI  - Copyright © 2010 Wiley-Liss, Inc.
FAU - Cheney, Miranda L
AU  - Cheney ML
AD  - Thar Pharmaceuticals Inc, Tampa, Florida 33612, USA.
FAU - Weyna, David R
AU  - Weyna DR
FAU - Shan, Ning
AU  - Shan N
FAU - Hanna, Mazen
AU  - Hanna M
FAU - Wojtas, Lukasz
AU  - Wojtas L
FAU - Zaworotko, Michael J
AU  - Zaworotko MJ
LA  - eng
PT  - Journal Article
DEP - 20101222
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Drug Combinations)
RN  - 0 (Thiazines)
RN  - 0 (Thiazoles)
RN  - R16CO5Y76E (Aspirin)
RN  - VG2QF83CGL (Meloxicam)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry/pharmacokinetics
MH  - Aspirin/*chemistry/pharmacokinetics
MH  - Calorimetry, Differential Scanning
MH  - Chemistry, Pharmaceutical
MH  - Crystallization
MH  - Drug Combinations
MH  - Injections, Intravenous
MH  - Male
MH  - Meloxicam
MH  - Models, Molecular
MH  - Molecular Structure
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Solubility
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Technology, Pharmaceutical/*methods
MH  - Thiazines/*chemistry/pharmacokinetics
MH  - Thiazoles/*chemistry/pharmacokinetics
EDAT- 2011/04/15 06:00
MHDA- 2011/09/10 06:00
CRDT- 2011/04/15 06:00
PHST- 2010/09/14 00:00 [received]
PHST- 2010/11/16 00:00 [accepted]
PHST- 2010/11/03 00:00 [revised]
PHST- 2011/04/15 06:00 [entrez]
PHST- 2011/04/15 06:00 [pubmed]
PHST- 2011/09/10 06:00 [medline]
AID - S0022-3549(15)32097-9 [pii]
AID - 10.1002/jps.22434 [doi]
PST - ppublish
SO  - J Pharm Sci. 2011 Jun;100(6):2172-81. doi: 10.1002/jps.22434. Epub 2010 Dec 22.

PMID- 8669432
OWN - NLM
STAT- MEDLINE
DCOM- 19960808
LR  - 20190815
IS  - 0272-6386 (Print)
IS  - 0272-6386 (Linking)
VI  - 28
IP  - 1 Suppl 1
DP  - 1996 Jul
TI  - Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory 
      agents.
PG  - S63-70
AB  - Approximately 2% of the United States population consumes an analgesic, 
      antipyretic, or nonsteroidal antiinflammatory drug (NSAID) each day. Aspirin and 
      acetaminophen have been available to the public without a prescription 
      (over-the-counter) for decades, while most NSAIDs are still only available with a 
      prescription from a physician. The recent trend of switching NSAIDs from 
      prescription to over-the-counter status may be perceived by some as an indication 
      of their inherent safety. However, all these agents have been associated with a 
      unique but overlapping safety profile. In fact, significant adverse events (AEs) 
      on multiple organ systems, including the kidney and gastrointestinal tract, have 
      been reported with most of these agents. In this review, the incidence of the 
      nonrenal AEs of aspirin, acetaminophen, and selected NSAIDs are tabulated. The 
      strengths of the causative associations are highlighted, the relative risks for 
      the gastrointestinal and cardiovascular AEs are discussed, and the relationship 
      to patient risk factors and drug characteristics, such as dose and half-life, are 
      reviewed. The selection of the optimal agent for an individual patient depends on 
      the balance between the desired pharmacodynamic response, the patient's 
      pharmacotherapy history, and the degree of AE risk one is willing to accept. 
      Therapy should be initiated in all settings with the lowest possible dosage since 
      the incidence of the major AEs is dose related.
FAU - Matzke, G R
AU  - Matzke GR
AD  - Department of Pharmacy and Therapeutics, School of Pharmacy, University of 
      Pittsburgh, PA 15261, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*adverse effects/toxicity
MH  - Analgesics, Non-Narcotic/*adverse effects/toxicity
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/toxicity
MH  - Aspirin/*adverse effects/toxicity
MH  - Humans
MH  - Nonprescription Drugs/adverse effects/toxicity
RF  - 38
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
AID - S0272-6386(96)90571-5 [pii]
AID - 10.1016/s0272-6386(96)90571-5 [doi]
PST - ppublish
SO  - Am J Kidney Dis. 1996 Jul;28(1 Suppl 1):S63-70. doi: 
      10.1016/s0272-6386(96)90571-5.

PMID- 8735677
OWN - NLM
STAT- MEDLINE
DCOM- 19961017
LR  - 20190512
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 41
IP  - 5
DP  - 1996 May
TI  - Warfarin and aspirin as thromboprophylaxis in atrial fibrillation.
PG  - 369-79
AB  - 1. Anticoagulant therapy with warfarin is now established as effective 
      thromboprophylaxis against stroke in atrial fibrillation, in high-risk persons. 
      Aspirin is indicated in moderate-risk persons or if warfarin is contraindicated. 
      2. Risk stratification is suggested, using clinical factors supplemented by 
      echocardiography, to aid choice of prophylaxis. 3. Further studies are required 
      to establish how best to identify undiagnosed patients who have atrial 
      fibrillation; to develop new therapeutic strategies; and to refine risk 
      stratification to define which patients with atrial fibrillation are at the 
      highest risk of stroke.
FAU - Lip, G Y
AU  - Lip GY
AD  - University Department of Medicine, City Hospital, Birmingham, UK.
FAU - Lowe, G D
AU  - Lowe GD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*complications/drug therapy/mortality
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Thromboembolism/etiology/physiopathology/*prevention & control
MH  - *Thrombolytic Therapy
MH  - Warfarin/adverse effects/*therapeutic use
PMC - PMC2042601
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 10.1046/j.1365-2125.1996.03384.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1996 May;41(5):369-79. doi: 
      10.1046/j.1365-2125.1996.03384.x.

PMID- 1127537
OWN - NLM
STAT- MEDLINE
DCOM- 19750807
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 86
IP  - 6
DP  - 1975 Jun
TI  - Preliminary report: treatment of the hemolytic-uremic syndrome with aspirin and 
      dipyridamole.
PG  - 957-61
AB  - Three children with the hemolytic-uremic syndrome were treated with heparin, 
      aspirin, and dipyridamole. Two of the children had remained profoundly 
      thrombocytopenic in spite of platelet transfusion and heparin therapy. All three 
      patients responded with prompt elevation of their platelet counts and apparent 
      termination of the pathologic consumption of platelets. Our experience suggests 
      not only that primary platelet consumption may play a critical role in the 
      pathogenesis of the HUS, but also that such patients may benefit from therapy 
      with drugs which inhibit platelet function.
FAU - Arenson, E B Jr
AU  - Arenson EB Jr
FAU - August, C S
AU  - August CS
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9001-32-5 (Fibrinogen)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Anemia, Hemolytic
MH  - Aspirin/blood/*therapeutic use
MH  - Blood Platelet Disorders/drug therapy
MH  - Blood Platelets
MH  - Blood Transfusion
MH  - Child
MH  - Child, Preschool
MH  - Dipyridamole/blood/*therapeutic use
MH  - Diuresis
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Erythrocyte Aggregation/drug therapy
MH  - Female
MH  - Fibrinogen
MH  - Hemolytic-Uremic Syndrome/*drug therapy
MH  - Heparin/blood/*therapeutic use
MH  - Humans
MH  - Infant
MH  - Kidney Diseases/etiology
MH  - Male
MH  - Platelet Adhesiveness
MH  - Remission, Spontaneous
MH  - Thrombocytopenia
EDAT- 1975/06/11 19:15
MHDA- 2001/03/28 10:01
CRDT- 1975/06/11 19:15
PHST- 1975/06/11 19:15 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1975/06/11 19:15 [entrez]
AID - S0022-3476(75)80235-6 [pii]
AID - 10.1016/s0022-3476(75)80235-6 [doi]
PST - ppublish
SO  - J Pediatr. 1975 Jun;86(6):957-61. doi: 10.1016/s0022-3476(75)80235-6.

PMID- 239150
OWN - NLM
STAT- MEDLINE
DCOM- 19751106
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 27
IP  - 7
DP  - 1975 Jul
TI  - Prostaglandins and the anti-inflammatory activities of aspirin and sodium 
      salicylate.
PG  - 473-8
AB  - Acetylsalicylic acid (aspirin) and sodium salicylate are equally effective in 
      reducing the swelling in the carrageenan-induced paw test and the accumulation of 
      leucocytes into the inflammatory exudate produced by the subcutaneous 
      implantation of polyvinyl sponges in the rat. Aspirin but not sodium salicylate 
      caused a significant reduction in the potentiation of paw oedema found after the 
      concurrent administration of carrageenan and arachidonic acid. Some implications 
      of these findings are discussed.
FAU - Smith, M J
AU  - Smith MJ
FAU - Ford-Hutchinson, A W
AU  - Ford-Hutchinson AW
FAU - Elliott, P N
AU  - Elliott PN
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Prostaglandins)
RN  - 0 (Salicylates)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Arachidonic Acids
MH  - Aspirin/*pharmacology
MH  - Carrageenan
MH  - Cell Migration Inhibition
MH  - Female
MH  - In Vitro Techniques
MH  - Inflammation/chemically induced/physiopathology
MH  - Leukocytes/drug effects
MH  - Prostaglandins/*physiology
MH  - Rats
MH  - Salicylates/*pharmacology
MH  - Time Factors
EDAT- 1975/07/01 00:00
MHDA- 1975/07/01 00:01
CRDT- 1975/07/01 00:00
PHST- 1975/07/01 00:00 [pubmed]
PHST- 1975/07/01 00:01 [medline]
PHST- 1975/07/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1975.tb09487.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1975 Jul;27(7):473-8. doi: 10.1111/j.2042-7158.1975.tb09487.x.

PMID- 25293617
OWN - NLM
STAT- MEDLINE
DCOM- 20141023
LR  - 20181202
IS  - 0065-3411 (Print)
IS  - 0065-3411 (Linking)
VI  - 48
DP  - 2014
TI  - Aspirin, clopidogrel, and the surgeon.
PG  - 211-22
AB  - The rising use of antiplatelet therapy for primary prevention and secondary 
      prevention of cardiovascular and cerebrovascular events poses a dilemma for 
      physicians in the perioperative period. The proven benefits of aspirin in 
      preventing further thrombotic events in patients with prior ACS or stroke make it 
      difficult to withdraw this therapy. The risk of hypercoagulability associated 
      with surgery is also independent of antiplatelet withdrawal, but adds to the 
      rebound effect of platelet responsiveness. Therefore, aspirin should be continued 
      whenever feasible. Similarly, the use of thienopyridines such as clopidogrel, 
      especially for the prevention of stent thrombosis, should be maintained for at 
      least the recommended time frame, if not longer. It is recognized that 
      maintaining antiplatelet therapy is also not without risk, as bleeding 
      complications have been well documented. Unfortunately, current perioperative 
      guidelines do not often provide a simple solution for management. Therefore, the 
      risk of bleeding has to be weighed against the risk of thrombosis, and decisions 
      should be made with all providers caring for the patient on an individual basis.
FAU - Patel, Prakash A
AU  - Patel PA
FAU - Fleisher, Lee A
AU  - Fleisher LA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Surg
JT  - Advances in surgery
JID - 0045335
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thienopyridines)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Postoperative Hemorrhage/chemically induced
MH  - Practice Guidelines as Topic
MH  - *Preoperative Care
MH  - Risk Assessment
MH  - Thienopyridines/therapeutic use
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Withholding Treatment
EDAT- 2014/10/09 06:00
MHDA- 2014/10/24 06:00
CRDT- 2014/10/09 06:00
PHST- 2014/10/09 06:00 [entrez]
PHST- 2014/10/09 06:00 [pubmed]
PHST- 2014/10/24 06:00 [medline]
AID - S0065-3411(14)00006-2 [pii]
AID - 10.1016/j.yasu.2014.05.005 [doi]
PST - ppublish
SO  - Adv Surg. 2014;48:211-22. doi: 10.1016/j.yasu.2014.05.005.

PMID- 6977559
OWN - NLM
STAT- MEDLINE
DCOM- 19820527
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 22
IP  - 1
DP  - 1982 Jan
TI  - Comparative tissue absorption of oral 14C-aspirin and topical triethanolamine 
      14C-salicylate in human and canine knee joints.
PG  - 42-8
AB  - The local, articular, and systemic absorption of oral and topical salicylates was 
      studied in dogs and humans using radioisotope techniques. Topical triethanolamine 
      14C-salicylate was found capable of percutaneous absorption into the knee joint 
      and surrounding tissues. In dogs, topical salicylate application resulted in 
      higher salicylate concentrations than oral aspirin in a number of tissues, 
      despite lower blood levels. In patients with rheumatoid arthritis, intraarticular 
      14C-salicylate levels after triethanolamine 14C-salicylate cream were 60 per cent 
      of those obtained with oral aspirin. Four of six patients reported equal 
      improvement in local discomfort after oral and topical salicylates. A potential 
      role for topical salicylate cream in the treatment of localized rheumatic 
      disorders is suggested.
FAU - Rabinowitz, J L
AU  - Rabinowitz JL
FAU - Feldman, E S
AU  - Feldman ES
FAU - Weinberger, A
AU  - Weinberger A
FAU - Schumacher, H R
AU  - Schumacher HR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Salicylates)
RN  - H8O4040BHD (trolamine salicylate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Administration, Oral
MH  - Administration, Topical
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*metabolism
MH  - Aspirin/administration & dosage/*metabolism
MH  - Dogs
MH  - Humans
MH  - Knee Joint/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Salicylates/administration & dosage/*metabolism
MH  - Synovial Fluid/metabolism
MH  - Time Factors
MH  - Tissue Distribution
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1982.tb05706.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1982 Jan;22(1):42-8. doi: 10.1002/j.1552-4604.1982.tb05706.x.

PMID- 9782780
OWN - NLM
STAT- MEDLINE
DCOM- 19981119
LR  - 20131121
IS  - 0019-5189 (Print)
IS  - 0019-5189 (Linking)
VI  - 36
IP  - 7
DP  - 1998 Jul
TI  - Effect of aspirin and sodium salicylate on cataract development in diabetic rats.
PG  - 651-7
AB  - The role of acetylation in the antiglycating and anticataract effects of aspirin 
      (ASA) is explored by comparing ASA's effects with that of sodium salicylate (SS), 
      a nonacetyl analog of ASA, on cataract development in diabetic rats. Streptozocin 
      diabetic rats were provided with either ASA or SS, orally, for 24 weeks. 
      Appropriate drug controls, normal controls and diabetic controls were run in 
      parallel. Periodic estimations of blood glucose, glycated hemoglobin and 
      assessments of cataract progression were done. After 24 weeks lenses were 
      removed, homogenised and separated into water soluble fraction and urea soluble 
      fraction. The glycated lens proteins in each fraction was quantified. Results 
      were analysed statistically and interpreted in relation to serum salicylate 
      levels. Both ASA and SS did not influence blood glucose levels. In the untreated 
      diabetic groups the onset and progression of cataract was quicker and complete 
      within 16 weeks. Both ASA and SS delayed the onset and progression in diabetic 
      rats, but ASA's effect was more pronounced than that of SS. The levels of 
      glycated Hb and lens proteins in diabetic rats were significantly reduced by ASA 
      and not by SS for the same serum salicylate levels. ASA's anticataract potential 
      far exceeds that of SS and it is ASA, and not SS, that inhibits protein 
      glycation. Thus the results favour the hypothesis that acetylation plays a major 
      role in ASA's anticataract effect via inhibition of glycation.
FAU - Shastri, G V
AU  - Shastri GV
AD  - Christian Medical College & Hospital, Vellore, India.
FAU - Thomas, M
AU  - Thomas M
FAU - Victoria, A J
AU  - Victoria AJ
FAU - Selvakumar, R
AU  - Selvakumar R
FAU - Kanagasabapathy, A S
AU  - Kanagasabapathy AS
FAU - Thomas, K
AU  - Thomas K
FAU - Lakshmi
AU  - Lakshmi
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Exp Biol
JT  - Indian journal of experimental biology
JID - 0233411
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Cataract/*drug therapy
MH  - Diabetes Mellitus, Experimental/*complications
MH  - Disease Progression
MH  - Drug Evaluation, Preclinical
MH  - Female
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Sodium Salicylate/*therapeutic use
EDAT- 1998/10/23 00:00
MHDA- 1998/10/23 00:01
CRDT- 1998/10/23 00:00
PHST- 1998/10/23 00:00 [pubmed]
PHST- 1998/10/23 00:01 [medline]
PHST- 1998/10/23 00:00 [entrez]
PST - ppublish
SO  - Indian J Exp Biol. 1998 Jul;36(7):651-7.

PMID- 2664932
OWN - NLM
STAT- MEDLINE
DCOM- 19890822
LR  - 20131121
IS  - 0452-3458 (Print)
IS  - 0452-3458 (Linking)
VI  - 37
IP  - 5
DP  - 1989 May
TI  - [A case of mitral stenosis with left atrial thrombus arose and reduced in a 
      short-term].
PG  - 563-7
AB  - A case of mitral stenosis with left atrial thrombus which rapidly arose and 
      reduced within a month was reported. A 61-year-old female was admitted to our 
      hospital on November 14, 1986 because of a syncopal attack due to ventricular 
      tachycardia. On admission she had typical auscultatory signs of mitral stenosis, 
      mild hepatomegaly and no neurological abnormality. Laboratory findings included 
      coagulation studies were normal, and atrial fibrillation was noted on ECG. Heart 
      catheterization revealed low cardiac output, the mitral orifice area to be 2.4 
      cm2 and left ventriculography showed mild mitral regurgitation. Ventricular 
      tachycardia was controlled following improvement of heart failure. On 
      two-dimensional echocardiography performed on December 24, left atrial thrombus 
      was revealed which was not detected on December 3. Through the continuous 
      administration of warfarin and aspirin to prevent the thrombus' growth, it 
      markedly reduced in size, from 3 x 2 x 4.5 cm on December 24, 1986 to 1.5 x 1 x 
      2.5 cm on January 30, 1987 without systemic embolism. Then a mitral valve 
      replacement and a left atrial thrombectomy were performed on February 3, with the 
      removal of a red thrombus, partially organized, measuring 1 x 0.7 x 2.5 cm. This 
      case is unique in its clinical outcome and further investigation is necessary for 
      the management of patients as our case.
FAU - Ueda, M
AU  - Ueda M
FAU - Shibata, N
AU  - Shibata N
FAU - Miyazaki, Y
AU  - Miyazaki Y
FAU - Miura, M
AU  - Miura M
FAU - Miyazawa, Y
AU  - Miyazawa Y
FAU - Komatsu, Y
AU  - Komatsu Y
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Kokyu To Junkan
JT  - Kokyu to junkan. Respiration & circulation
JID - 0413532
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heart Atria
MH  - Heart Diseases/drug therapy/*etiology
MH  - Humans
MH  - Middle Aged
MH  - Mitral Valve Stenosis/*complications
MH  - Thrombosis/drug therapy/*etiology
MH  - Ultrasonography
MH  - Warfarin/therapeutic use
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
PST - ppublish
SO  - Kokyu To Junkan. 1989 May;37(5):563-7.

PMID- 6216623
OWN - NLM
STAT- MEDLINE
DCOM- 19830107
LR  - 20131121
IS  - 0039-6060 (Print)
IS  - 0039-6060 (Linking)
VI  - 92
IP  - 6
DP  - 1982 Dec
TI  - Enhanced patency of small-diameter, externally supported Dacron iliofemoral 
      grafts seeded with endothelial cells.
PG  - 994-1005
AB  - Fourteen adult foxhounds underwent bilateral iliofemoral bypasses with externally 
      supported, knitted Dacron grafts measured 4 mm in internal diameter and 10 cm in 
      length. These conduits were preclotted with 10 ml of blood mixed with 0.5 ml of 
      culture medium. Autologous endothelial cells, enzymatically derived from external 
      jugular veins, were added to blood and medium used to preclot one graft in each 
      dog. The other, unseeded graft served as a control. Grafts were anastomosed, end 
      to end, to the iliac and femoral arteries. All dogs received dipyridamole, 50 mg 
      twice a day for 4 days preoperatively, and aspirin, 5 grains four times a day for 
      1 day preoperatively. Both drugs were continued 14 days after operation. Grafts 
      were removed from three dogs at 2 and 4 weeks and from four dogs at 8 and 16 
      weeks. All grafts were patent at 2 weeks during drug administration. Cumulative 
      patency rates beyond 2 weeks were 73% in 11 seeded grafts and 27% in 11 control 
      grafts, a statistically significant difference (P = 0.03). Seeded grafts were 
      completely surfaced with a monolayer of endothelium between 2 and 4 weeks. 
      Small-graft patency appeared related to evolution of endothelial surfaces, the 
      development of which was clearly facilitated by seeding with autologous 
      endothelium.
FAU - Stanley, J C
AU  - Stanley JC
FAU - Burkel, W E
AU  - Burkel WE
FAU - Ford, J W
AU  - Ford JW
FAU - Vinter, D W
AU  - Vinter DW
FAU - Kahn, R H
AU  - Kahn RH
FAU - Whitehouse, W M Jr
AU  - Whitehouse WM Jr
FAU - Graham, L M
AU  - Graham LM
LA  - eng
GR  - HL 23345/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
RN  - 0 (Polyethylene Terephthalates)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - *Blood Vessel Prosthesis
MH  - Dipyridamole/therapeutic use
MH  - Dogs
MH  - Endothelium/*cytology
MH  - Evaluation Studies as Topic
MH  - Femoral Artery/*surgery
MH  - Iliac Artery/*surgery
MH  - Microscopy, Electron, Scanning
MH  - *Polyethylene Terephthalates
MH  - Thrombosis/prevention & control
EDAT- 1982/12/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1982/12/01 00:00
PHST- 1982/12/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1982/12/01 00:00 [entrez]
AID - 0039-6060(82)90161-1 [pii]
PST - ppublish
SO  - Surgery. 1982 Dec;92(6):994-1005.

PMID- 20305141
OWN - NLM
STAT- MEDLINE
DCOM- 20121108
LR  - 20211020
IS  - 1592-8721 (Electronic)
IS  - 0390-6078 (Print)
IS  - 0390-6078 (Linking)
VI  - 95
IP  - 9
DP  - 2010 Sep
TI  - Low molecular weight heparin for the treatment of retinal vein occlusion: a 
      systematic review and meta-analysis of randomized trials.
PG  - 1587-93
LID - 10.3324/haematol.2010.023614 [doi]
AB  - Retinal vein occlusion is a frequent cause of visual loss for which few effective 
      therapies are available. Anticoagulation with low molecular weight heparin might 
      be of value in its treatment. We conducted a systematic review and meta analysis 
      of randomized trials evaluating the effect of low molecular weight heparin in 
      patients with retinal vein occlusion. Data sources included MEDLINE, EMBASE, 
      HealthSTAR, the Cochrane Library, Lilacs, the Investigative Ophthalmology and 
      Visual Science database and gray literature. Main outcome was the mean difference 
      between the visual acuity measured at baseline and at six months expressed in the 
      logMAR scale. Secondary outcome was a composite of any adverse ocular outcome 
      including: worsening of visual acuity, visual fields or fluorescein angiography, 
      or development of iris neovascularization, any neovascularization or neovascular 
      glaucoma. Subgroup analyses for branch versus central retinal vein occlusion were 
      conducted. We identified 1,084 references of which 3 studies comparing low 
      molecular weight heparin with aspirin (229 evaluable patients) were included. 
      Overall, the pooled mean visual acuity difference was -0.23 logMAR (95% CI -0.38, 
      -0.09; P=0.002) in favor of low molecular weight heparin. Low molecular weight 
      heparin was associated with a 78% risk reduction for developing any adverse 
      ocular outcome (pooled RR 0.22; 95% CI 0.10, 0.46; P<0.001). In subgroup analyses 
      benefits seemed lower in branch retinal vein occlusion. No increased vitreous 
      hemorrhages were observed. In patients with retinal vein occlusion treatment with 
      low molecular weight heparin seems to be associated with improvement in the 
      visual acuity and less adverse ocular outcomes. These benefits might differ in 
      patients with central as opposed to branch retinal vein occlusion. Further 
      studies are required to confirm these findings and clarify its benefits in 
      specific subgroups of patients before definitive recommendations can be made.
FAU - Lazo-Langner, Alejandro
AU  - Lazo-Langner A
AD  - Hematology Division, London Health Sciences Centre, Victoria Hospital. 800 
      Commissioners Rd E PO Box 5010 Rm A2-401 London ON, N6A 5W9, Canada. 
      alejandro.lazolangner@lhsc.on.ca
FAU - Hawel, Jeff
AU  - Hawel J
FAU - Ageno, Walter
AU  - Ageno W
FAU - Kovacs, Michael J
AU  - Kovacs MJ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20100319
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Retinal Vein Occlusion/*drug therapy
MH  - Treatment Outcome
MH  - Visual Acuity/drug effects
PMC - PMC2930962
EDAT- 2010/03/23 06:00
MHDA- 2012/11/09 06:00
CRDT- 2010/03/23 06:00
PHST- 2010/03/23 06:00 [entrez]
PHST- 2010/03/23 06:00 [pubmed]
PHST- 2012/11/09 06:00 [medline]
AID - haematol.2010.023614 [pii]
AID - 0951587 [pii]
AID - 10.3324/haematol.2010.023614 [doi]
PST - ppublish
SO  - Haematologica. 2010 Sep;95(9):1587-93. doi: 10.3324/haematol.2010.023614. Epub 
      2010 Mar 19.

PMID- 12586131
OWN - NLM
STAT- MEDLINE
DCOM- 20031128
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 108
IP  - 1
DP  - 2002 Oct 1
TI  - PFA-100 and flow cytometry: can they challenge aggregometry to assess 
      antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?
PG  - 43-7
AB  - INTRODUCTION: Platelet response to inhibitors varies widely, leading to a higher 
      risk of abrupt closure events in insufficiently treated-coronary heart disease 
      patients. The aim of this study was to compare, in patients under various 
      antiplatelet regimens, three platelet function assays: aggregometry, PFA-100 and 
      flow cytometry. These assays stand for available tests, as "ready-to-use" device 
      (PFA-100) and sophisticated assay (cytometry). We chose the setting of 
      percutaneous coronary intervention as a standardized procedure to determine which 
      test was appropriate to detect the effect of (1) an aspirin bolus in patients 
      under long-term aspirin treatment, and (2) ticlopidin in case of stent 
      implantation. METHODS: Fifty patients under oral aspirin treatment were 
      randomized to receive a bolus of 500 mg aspirin before angioplasty (n=25). 
      Ticlopidin was given at a 500 mg loading dose in the case of stent implantation 
      (n=38). Platelet function was assessed before, at 2 and 24 h after angioplasty. 
      RESULTS: Considering aspirin antiplatelet effect, the following was observed: (1) 
      a lack of further inhibition after the bolus whatever assay was used and (2) a 
      disagreement between aggregometry and PFA-100 to classify patients as being poor 
      or good aspirin responders (kappa were 0.11 and 0.28 between ADP 4 or 6 microM 
      aggregation, respectively, and PFA-100). Another finding was the good performance 
      of flow cytometry, which evaluated GPIIbIIIa activation, and aggregometry, to 
      detect ticlopidin the day after the loading dose. In contrast, PFA-100 was 
      insensitive to ticlopidin. CONCLUSION: Current assays are not interchangeable to 
      monitor antiplatelet treatment in daily practice.
FAU - Hézard, Nathalie
AU  - Hézard N
AD  - Laboratoire Central d'Hématologie, CHU Robert Debré, 51092 Reims Cédex, France.
FAU - Metz, Damien
AU  - Metz D
FAU - Nazeyrollas, Pierre
AU  - Nazeyrollas P
FAU - Droullé, Chantal
AU  - Droullé C
FAU - Potron, Gérard
AU  - Potron G
FAU - Nguyen, Philippe
AU  - Nguyen P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Coronary Disease/blood/drug therapy/therapy
MH  - Female
MH  - Flow Cytometry/methods
MH  - Humans
MH  - Male
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Function Tests/*methods
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Ticlopidine/administration & dosage/therapeutic use
EDAT- 2003/02/15 04:00
MHDA- 2003/12/03 05:00
CRDT- 2003/02/15 04:00
PHST- 2003/02/15 04:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/02/15 04:00 [entrez]
AID - S0049384802003912 [pii]
AID - 10.1016/s0049-3848(02)00391-2 [doi]
PST - ppublish
SO  - Thromb Res. 2002 Oct 1;108(1):43-7. doi: 10.1016/s0049-3848(02)00391-2.

PMID- 35025879
OWN - NLM
STAT- MEDLINE
DCOM- 20220210
LR  - 20220210
IS  - 1549-1676 (Electronic)
IS  - 1549-1277 (Print)
IS  - 1549-1277 (Linking)
VI  - 19
IP  - 1
DP  - 2022 Jan
TI  - Low-dose aspirin and incidence of lung carcinoma in patients with chronic 
      obstructive pulmonary disease in Hong Kong: A cohort study.
PG  - e1003880
LID - 10.1371/journal.pmed.1003880 [doi]
LID - e1003880
AB  - BACKGROUND: Evidence suggests that chronic obstructive pulmonary disease (COPD) 
      is associated with a higher risk of lung carcinoma. Using a territory-wide 
      clinical electronic medical records system, we investigated the association 
      between low-dose aspirin use (≤160 mg) among patients with COPD and incidence of 
      lung carcinoma and the corresponding risk of bleeding. METHODS AND FINDINGS: This 
      is a retrospective cohort study conducted utilizing Clinical Data Analysis 
      Reporting System (CDARS), a territory-wide database developed by the Hong Kong 
      Hospital Authority. Inverse probability of treatment weighting (IPTW) was used to 
      balance baseline covariates between aspirin nonusers (35,049 patients) with new 
      aspirin users (7,679 patients) among all eligible COPD patients from 2005 to 2018 
      attending any public hospitals. The median age of the cohort was 75.7 years (SD = 
      11.5), and 80.3% were male. Competing risk regression with Cox proportional 
      hazards model were performed to estimate the subdistribution hazard ratio (SHR) 
      of lung carcinoma with low-dose aspirin and the associated bleeding events. Of 
      all eligible patients, 1,779 (4.2%, 1,526 and 253 among nonusers and users) were 
      diagnosed with lung carcinoma over a median follow-up period of 2.6 years 
      (interquartile range [IQR]: 1.4 to 4.8). Aspirin use was associated with a 25% 
      lower risk of lung carcinoma (SHR = 0.75, 95% confidence interval [CI] 0.65 to 
      0.87, p = <0.001) and 26% decrease in lung carcinoma-related mortality (SHR = 
      0.74, 95% CI 0.64 to 0.86, p = <0.001). Subgroup analysis revealed that aspirin 
      was beneficial for patients aged above or below 75 years, but was also beneficial 
      among populations who were male, nondiabetic, and nonhypertensive. Aspirin use 
      was not associated with an increased risk of upper gastrointestinal bleeding 
      (UGIB) (SHR = 1.19, 95% CI 0.94 to 1.53, p = 0.16), but was associated with an 
      increased risk of hemoptysis (SHR = 1.96, 95% CI 1.73 to 2.23, p < 0.001). The 
      main limitations of the study were (i) that one group of patients may be more 
      likely to seek additional medical attention, although this was partially 
      mitigated by the use of propensity score analysis; and (ii) the observational 
      nature of the study renders it unable to establish causality between aspirin use 
      and lung carcinoma incidence. CONCLUSIONS: In this study, we observed that 
      low-dose aspirin use was associated with a lower risk of lung carcinoma and lung 
      carcinoma-related mortality among COPD patients. While aspirin was not associated 
      with an increased risk of UGIB, the risk of hemoptysis was elevated.
FAU - Yu, Si-Yeung
AU  - Yu SY
AD  - Cardiology Division, Department of Medicine, The University of Hong Kong-Shen 
      Zhen Hospital, Shenzhen City, Guangdong Province, China.
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Ip, Mary Sau-Man
AU  - Ip MS
AUID- ORCID: 0000-0002-8692-6933
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Li, Xue
AU  - Li X
AUID- ORCID: 0000-0003-4836-7808
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Cheung, Ka-Shing
AU  - Cheung KS
AUID- ORCID: 0000-0002-4838-378X
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Ren, Qing-Wen
AU  - Ren QW
AUID- ORCID: 0000-0003-0712-9299
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Wu, Mei-Zhen
AU  - Wu MZ
AUID- ORCID: 0000-0003-2674-5097
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Li, Hang-Long
AU  - Li HL
AUID- ORCID: 0000-0002-2294-2977
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Wong, Pui-Fai
AU  - Wong PF
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Tse, Hung-Fat
AU  - Tse HF
AUID- ORCID: 0000-0002-9578-7808
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Yiu, Kai-Hang
AU  - Yiu KH
AUID- ORCID: 0000-0003-2145-3108
AD  - Cardiology Division, Department of Medicine, The University of Hong Kong-Shen 
      Zhen Hospital, Shenzhen City, Guangdong Province, China.
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
LA  - eng
PT  - Journal Article
DEP - 20220113
PL  - United States
TA  - PLoS Med
JT  - PLoS medicine
JID - 101231360
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Carcinoma/complications/*epidemiology
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hong Kong/epidemiology
MH  - Humans
MH  - Incidence
MH  - Lung Neoplasms/complications/*epidemiology
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Disease, Chronic Obstructive/complications/*epidemiology
MH  - Retrospective Studies
PMC - PMC8757901
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/01/14 06:00
MHDA- 2022/02/11 06:00
CRDT- 2022/01/13 17:26
PHST- 2021/05/13 00:00 [received]
PHST- 2021/11/30 00:00 [accepted]
PHST- 2022/01/13 17:26 [entrez]
PHST- 2022/01/14 06:00 [pubmed]
PHST- 2022/02/11 06:00 [medline]
AID - PMEDICINE-D-21-02156 [pii]
AID - 10.1371/journal.pmed.1003880 [doi]
PST - epublish
SO  - PLoS Med. 2022 Jan 13;19(1):e1003880. doi: 10.1371/journal.pmed.1003880. 
      eCollection 2022 Jan.

PMID- 7000856
OWN - NLM
STAT- MEDLINE
DCOM- 19810126
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 20
IP  - 7
DP  - 1980 Jul
TI  - Comparative analgesic effects of naproxen sodium, aspirin, and placebo.
PG  - 480-5
AB  - The analgesic efficacy of a single 550-mg dose of naproxen sodium was compared 
      with that of 650 mg aspirin and a placebo in a double-blind, parallel trial. The 
      study was carried out in an industrial setting and included 201 adult patients 
      with various acute pain states. Musculoskeletal pain was the most common type of 
      pain treated. Pain intensity differences and patients' evaluation of pain relief 
      indicated statistically significantly earlier and better analgesia with naproxen 
      sodium than with both aspirin and placebo. The summed pain intensity differences 
      (SPID) showed that naproxen sodium performed better than aspirin, which in turn 
      did better than placebo. the difference between naproxen sodium and aspirin means 
      for SPID was numerically equal to the difference between the aspirin and placebo 
      means for SPID. Further, the incidence of side effects was less with naproxen 
      sodium than with aspirin. The study demonstrated that naproxen sodium provided 
      earlier and better pain relief than aspirin, that this effect was consistent over 
      time, and that the incidence of side effects associated with naproxen sodium was 
      less than with aspirin.
FAU - Sevelius, H
AU  - Sevelius H
FAU - Segre, E
AU  - Segre E
FAU - Bursick, K
AU  - Bursick K
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Analgesics)
RN  - 0 (Placebos)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analgesics/adverse effects
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Naproxen/*therapeutic use
MH  - Pain/drug therapy
MH  - Placebos
EDAT- 1980/07/01 00:00
MHDA- 1980/07/01 00:01
CRDT- 1980/07/01 00:00
PHST- 1980/07/01 00:00 [pubmed]
PHST- 1980/07/01 00:01 [medline]
PHST- 1980/07/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1980.tb01722.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1980 Jul;20(7):480-5. doi: 10.1002/j.1552-4604.1980.tb01722.x.

PMID- 34537546
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20221105
IS  - 1872-8464 (Electronic)
IS  - 0165-5876 (Print)
IS  - 0165-5876 (Linking)
VI  - 151
DP  - 2021 Dec
TI  - Acetylsalicylic acid suppression of the PI3K pathway as a novel medical therapy 
      for head and neck lymphatic malformations.
PG  - 110869
LID - S0165-5876(21)00262-7 [pii]
LID - 10.1016/j.ijporl.2021.110869 [doi]
AB  - OBJECTIVES: Head and neck lymphatic malformations (HNLM) are caused by 
      gain-of-function somatic mutations in PIK3CA. Acetylsalicylic acid (ASA/aspirin) 
      is thought to limit growth in PIK3CA-mutated neoplasms through PI3K pathway 
      suppression. We sought to determine if ASA could be beneficial for HNLM. METHODS: 
      Retrospective case series of patients (0-18 years) offered ASA (3-5 mg/kg/day) 
      for HNLM treatment (2010-2018). Clinical and treatment characteristics, 
      patient-reported symptom improvement, medication tolerance, compliance, and 
      complications were recorded. Treatment response was determined by change in 
      patient/caregiver-reported symptoms, or HNLM size [complete (resolved), partial 
      (decreased), or stable]. RESULTS: Fifty-three patients were offered ASA, 23 (43%) 
      accepted (median age 10 years, IQR 6-14). Compared to patients who declined, 
      patients receiving ASA were more likely to have extensive malformations: ex-utero 
      intrapartum treatment procedure, bilateral malformations, oral cavity location, 
      ≥2 invasive treatments, or tracheotomy (p < 0.05). All patients with tissue 
      available had PIK3CA mutations (13/23). Treatment indications included oral 
      pain/blebs (12, 52%), recurrent pain/swelling (6, 26%), or sudden/persistent 
      swelling (5, 22%). Treatment plan was commonly one 81 mg tablet daily (19, 83%) 
      for 3-12 months (8, 42%). Therapeutic adherence was reported by 18 patients 
      (78%). Symptoms improved in 18 patients [78%; decreased pain (9, 39%) and 
      swelling (8, 35%)]. Treatment resulted in partial (14, 61%) or complete response 
      (4, 17%). Three patients developed oral bleb bleeding, which resolved with 
      medication discontinuation. CONCLUSION: ASA seems to be a well-tolerated, 
      low-risk medication for HNLM treatment. This pilot study suggests that it often 
      improves symptoms and reduces HNLM size. Further prospective, randomized studies 
      are warranted to comprehensively assess indications, safety, and efficacy. LEVEL 
      OF EVIDENCE: Level 4.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Bonilla-Velez, Juliana
AU  - Bonilla-Velez J
AD  - Division of Pediatric Otolaryngology, Seattle Children's Hospital, Seattle, WA, 
      USA; Department of Otolaryngology-Head and Neck Surgery, University of Washington 
      School of Medicine, Seattle, WA, USA. Electronic address: 
      Juliana.Bonilla-Velez@seattlechildrens.org.
FAU - Whitlock, Kathryn B
AU  - Whitlock KB
AD  - Division of Pediatric Otolaryngology, Seattle Children's Hospital, Seattle, WA, 
      USA; Center for Clinical and Translational Research, Seattle Children's Research 
      Institute, Seattle, WA, USA.
FAU - Ganti, Sheila
AU  - Ganti S
AD  - Division of Pediatric Otolaryngology, Seattle Children's Hospital, Seattle, WA, 
      USA; Center for Clinical and Translational Research, Seattle Children's Research 
      Institute, Seattle, WA, USA.
FAU - Zenner, Kaitlyn
AU  - Zenner K
AD  - Division of Pediatric Otolaryngology, Seattle Children's Hospital, Seattle, WA, 
      USA; Department of Otolaryngology-Head and Neck Surgery, University of Washington 
      School of Medicine, Seattle, WA, USA.
FAU - Cheng, Chi Vicky
AU  - Cheng CV
AD  - Center for Integrative Brain Research, Seattle Children's Research Institute, 
      Seattle, WA, USA.
FAU - Jensen, Dana M
AU  - Jensen DM
AD  - Center for Developmental Biology and Regenerative Medicine, Seattle Children's 
      Research Institute, Seattle, WA, USA.
FAU - Pham, Minh-Hang M
AU  - Pham MM
AD  - Center for Integrative Brain Research, Seattle Children's Research Institute, 
      Seattle, WA, USA.
FAU - Mitchell, Ryan M
AU  - Mitchell RM
AD  - Division of Pediatric Otolaryngology, Seattle Children's Hospital, Seattle, WA, 
      USA; Department of Otolaryngology-Head and Neck Surgery, Indiana University, 
      Indianapolis, IN, USA.
FAU - Dobyns, William
AU  - Dobyns W
AD  - Center for Integrative Brain Research, Seattle Children's Research Institute, 
      Seattle, WA, USA.
FAU - Bly, Randall A
AU  - Bly RA
AD  - Division of Pediatric Otolaryngology, Seattle Children's Hospital, Seattle, WA, 
      USA; Department of Otolaryngology-Head and Neck Surgery, University of Washington 
      School of Medicine, Seattle, WA, USA.
FAU - Bennett, James T
AU  - Bennett JT
AD  - Center for Developmental Biology and Regenerative Medicine, Seattle Children's 
      Research Institute, Seattle, WA, USA; Division of Genetic Medicine, Department of 
      Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, 
      USA.
FAU - Dahl, John P
AU  - Dahl JP
AD  - Division of Pediatric Otolaryngology, Seattle Children's Hospital, Seattle, WA, 
      USA; Department of Otolaryngology-Head and Neck Surgery, University of Washington 
      School of Medicine, Seattle, WA, USA.
FAU - Perkins, Jonathan A
AU  - Perkins JA
AD  - Division of Pediatric Otolaryngology, Seattle Children's Hospital, Seattle, WA, 
      USA; Department of Otolaryngology-Head and Neck Surgery, University of Washington 
      School of Medicine, Seattle, WA, USA; Center for Clinical and Translational 
      Research, Seattle Children's Research Institute, Seattle, WA, USA. Electronic 
      address: jonathan.perkins@seattlechildrens.org.
LA  - eng
GR  - F32 HL147398/HL/NHLBI NIH HHS/United States
GR  - R01 HL130996/HL/NHLBI NIH HHS/United States
GR  - T32 DC000018/DC/NIDCD NIH HHS/United States
PT  - Journal Article
DEP - 20210805
PL  - Ireland
TA  - Int J Pediatr Otorhinolaryngol
JT  - International journal of pediatric otorhinolaryngology
JID - 8003603
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Humans
MH  - *Lymphatic Abnormalities/drug therapy/genetics
MH  - *Phosphatidylinositol 3-Kinases
MH  - Pilot Projects
MH  - Retrospective Studies
PMC - PMC9632366
MID - NIHMS1843980
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Lymphatic abnormalities
OT  - Lymphatic malformation
OT  - PI3K
OT  - Treatment
COIS- Declaration of competing interest The authors have no conflicts of interest to 
      disclose.
EDAT- 2021/09/20 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/09/19 20:40
PHST- 2021/02/09 00:00 [received]
PHST- 2021/07/21 00:00 [revised]
PHST- 2021/08/04 00:00 [accepted]
PHST- 2021/09/20 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/09/19 20:40 [entrez]
AID - S0165-5876(21)00262-7 [pii]
AID - 10.1016/j.ijporl.2021.110869 [doi]
PST - ppublish
SO  - Int J Pediatr Otorhinolaryngol. 2021 Dec;151:110869. doi: 
      10.1016/j.ijporl.2021.110869. Epub 2021 Aug 5.

PMID- 36939486
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20230626
IS  - 1097-6817 (Electronic)
IS  - 0194-5998 (Linking)
VI  - 169
IP  - 1
DP  - 2023 Jul
TI  - Relationship Between Alcohol Intolerance and Aspirin-Exacerbated Respiratory 
      Disease (AERD): Systematic Review.
PG  - 12-20
LID - 10.1002/ohn.248 [doi]
AB  - OBJECTIVE: Previous studies have suggested that patients with aspirin-exacerbated 
      respiratory disease (AERD) have a high likelihood of alcohol intolerance. The 
      purpose of this systematic review is to identify if there is sufficient evidence 
      to confirm this correlation and the impact of medical therapy on subsequent 
      alcohol tolerance. DATA SOURCES: PubMed, EMBASE, SCOPUS, EBSCO, Google Scholar, 
      Cochrane Library, and Grey literature. We also performed snowballing on the 
      identified observational studies (OS) for additional data. REVIEW METHODS: A 
      systematic review was conducted from 1968 to 2022 to identify those studies 
      describing AERD symptomatology triggered by alcohol intake. The primary outcome 
      was to analyze the current literature for the association between alcohol 
      intolerance and AERD symptoms. The secondary outcome looked for improvement in 
      alcohol tolerance after aspirin desensitization or biological therapy. RESULTS: A 
      total of 775 studies were identified and 40 abstracts were evaluated. From these, 
      5 studies met the inclusion criteria. Of the 5 manuscripts, there was 1 
      case-control, 2 cohort, and 2 cross-sectional studies. A total of 522 
      participants with AERD and a history of alcohol consumption were included, with 
      52.8% reporting at least 1 sinopulmonary exacerbation after alcohol intake. One 
      of 3 studies noted improvement in alcohol tolerance after medical therapy with 
      aspirin desensitization. CONCLUSION: The current literature suggests that 
      patients with AERD have a high risk of alcohol intolerance. Additionally, aspirin 
      desensitization may improve alcohol tolerance in this patient population.
CI  - © 2023 American Academy of Otolaryngology-Head and Neck Surgery Foundation.
FAU - Candelo, Estephania
AU  - Candelo E
AUID- ORCID: 0000-0003-3002-7071
AD  - Department of Otolaryngology and Head-Neck Surgery, Mayo Clinic Jacksonville, 
      Jacksonville, Florida, USA.
FAU - McCalla, Monet
AU  - McCalla M
AD  - Ohio University Heritage College of Osteopathic Medicine, Athens, Ohio, USA.
FAU - Valderrama, Oriana A
AU  - Valderrama OA
AD  - Department of Medicine, Centro de Investigaciones Clinicas, Fundacion Valle del 
      Lili, Cali, Colombia.
FAU - Avila-Castano, Karol
AU  - Avila-Castano K
AD  - Department of Otolaryngology and Head-Neck Surgery, Mayo Clinic Jacksonville, 
      Jacksonville, Florida, USA.
FAU - Chelf, Cynthia
AU  - Chelf C
AD  - Mayo Clinic Libraries, Rochester, Minnesota, USA.
FAU - Olomu, Osarenoma
AU  - Olomu O
AD  - Department of Otolaryngology and Head-Neck Surgery, Mayo Clinic Jacksonville, 
      Jacksonville, Florida, USA.
FAU - Donaldson, Angela M
AU  - Donaldson AM
AUID- ORCID: 0000-0002-1442-087X
AD  - Department of Otolaryngology and Head-Neck Surgery, Mayo Clinic Jacksonville, 
      Jacksonville, Florida, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20230129
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of 
      Otolaryngology-Head and Neck Surgery
JID - 8508176
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Aspirin/adverse effects
MH  - Cross-Sectional Studies
MH  - *Asthma, Aspirin-Induced/therapy
MH  - *Sinusitis/surgery
MH  - Desensitization, Immunologic
MH  - *Nasal Polyps/complications
OTO - NOTNLM
OT  - AERD
OT  - NSAID-exacerbated respiratory disease
OT  - alcohol intake
OT  - aspirin-exacerbated respiratory disease
OT  - chronic rhinosinusitis
OT  - systematic review
EDAT- 2023/03/21 06:00
MHDA- 2023/06/26 06:42
CRDT- 2023/03/20 10:34
PHST- 2022/12/08 00:00 [revised]
PHST- 2022/09/01 00:00 [received]
PHST- 2022/12/17 00:00 [accepted]
PHST- 2023/06/26 06:42 [medline]
PHST- 2023/03/21 06:00 [pubmed]
PHST- 2023/03/20 10:34 [entrez]
AID - 10.1002/ohn.248 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2023 Jul;169(1):12-20. doi: 10.1002/ohn.248. Epub 
      2023 Jan 29.

PMID- 32342255
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1573-2630 (Electronic)
IS  - 0165-5701 (Linking)
VI  - 40
IP  - 8
DP  - 2020 Aug
TI  - Combined aspirin and clopidogrel therapy in phacoemulsification cataract surgery: 
      a risk factor for ocular hemorrhage?
PG  - 2023-2029
LID - 10.1007/s10792-020-01378-5 [doi]
AB  - PURPOSE: To evaluate the safety of phacoemulsification cataract surgery in the 
      patients undergoing dual antiplatelet therapy with aspirin and clopidogrel. 
      METHODS: Consecutive patients undergoing phacoemulsification cataract surgery 
      with a clear corneal incision under topical anesthesia were eligible for 
      inclusion in the study. Thirty-eight eyes from 38 patients on combined aspirin 
      and clopidogrel therapy who continued the treatment were classified into the 
      maintenance group, a matched group of 38 eyes from 38 patients on no 
      antiplatelet/anticoagulant therapy as the control group. The best-corrected 
      visual acuity (BCVA) and incidences of complications were compared between the 
      two groups. RESULTS: There was no significant difference in final BCVA between 
      the maintenance group and the control group (p = 0.178). No significant 
      difference existed in the incidences of hemorrhagic or non-hemorrhagic 
      complications between the two groups (p = 0.529 and p = 0.589, respectively). 
      Moreover, no surgery was postponed or cancelled due to hemorrhagic complications 
      in either group, and no cardiovascular events occurred during the follow-up. 
      There was no case of anterior chamber hemorrhage, vitreous hemorrhage, or 
      suprachoroidal hemorrhage. CONCLUSIONS: Our outcomes indicated that 
      phacoemulsification cataract surgery using a clear corneal incision with topical 
      anesthesia could be safely done without stopping dual antiplatelet therapy with 
      aspirin and clopidogrel.
FAU - Li, Qingjian
AU  - Li Q
AD  - Eye Institute of Xiamen University, School of Medicine, Xiamen University, 
      Xiamen, Fujian, China.
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, No. 12 Middle 
      Urumqi Road, Shanghai, 200040, China.
FAU - Shen, Xuzhong
AU  - Shen X
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, No. 12 Middle 
      Urumqi Road, Shanghai, 200040, China.
FAU - Wang, Shaopan
AU  - Wang S
AD  - Eye Institute of Xiamen University, School of Medicine, Xiamen University, 
      Xiamen, Fujian, China.
FAU - Su, Ting
AU  - Su T
AD  - Eye Institute of Xiamen University, School of Medicine, Xiamen University, 
      Xiamen, Fujian, China.
FAU - Yan, Ke
AU  - Yan K
AD  - Eye Institute of Xiamen University, School of Medicine, Xiamen University, 
      Xiamen, Fujian, China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, No. 12 Middle 
      Urumqi Road, Shanghai, 200040, China.
FAU - Qian, Yiwen
AU  - Qian Y
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, No. 12 Middle 
      Urumqi Road, Shanghai, 200040, China.
FAU - Jiang, Jing
AU  - Jiang J
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, No. 12 Middle 
      Urumqi Road, Shanghai, 200040, China.
FAU - Zhang, Pei
AU  - Zhang P
AD  - Department of Ophthalmology, Shanghai Gonghui Hospital, No. 6, Lane 315, Shimen 
      Road (No. 1), Shanghai, 200040, China. zhangpei7607@163.com.
FAU - Wang, Zhiliang
AU  - Wang Z
AUID- ORCID: 0000-0003-0944-8584
AD  - Department of Ophthalmology, Huashan Hospital, Fudan University, No. 12 Middle 
      Urumqi Road, Shanghai, 200040, China. ophwzl@163.com.
LA  - eng
GR  - 81670868/Natural Science Foundation of China/
GR  - 81900879/Natural Science Foundation of China/
PT  - Journal Article
DEP - 20200427
PL  - Netherlands
TA  - Int Ophthalmol
JT  - International ophthalmology
JID - 7904294
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Cataract/complications
MH  - Clopidogrel
MH  - Humans
MH  - Lens Implantation, Intraocular
MH  - *Phacoemulsification
MH  - Postoperative Complications/epidemiology/prevention & control
MH  - Risk Factors
MH  - Visual Acuity
OTO - NOTNLM
OT  - Aspirin
OT  - Cataract surgery
OT  - Clopidogrel
OT  - Complications
OT  - Topical anesthesia
EDAT- 2020/04/29 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/29 06:00
PHST- 2019/11/12 00:00 [received]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/29 06:00 [entrez]
AID - 10.1007/s10792-020-01378-5 [pii]
AID - 10.1007/s10792-020-01378-5 [doi]
PST - ppublish
SO  - Int Ophthalmol. 2020 Aug;40(8):2023-2029. doi: 10.1007/s10792-020-01378-5. Epub 
      2020 Apr 27.

PMID- 17889863
OWN - NLM
STAT- MEDLINE
DCOM- 20080717
LR  - 20220311
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Print)
IS  - 0015-0282 (Linking)
VI  - 90
IP  - 1
DP  - 2008 Jul
TI  - Evidence of absence or absence of evidence? A reanalysis of the effects of 
      low-dose aspirin in in vitro fertilization.
PG  - 71-6
AB  - OBJECTIVE: To assess the conflicting evidence whether low-dose aspirin is 
      beneficial in IVF and to evaluate the meta-analysis performed by Gelbaya et al. 
      and reported in March 2007 in Human Reproduction Update, in which they found no 
      effects of low-dose aspirin and recommended discontinuing its use in IVF. We 
      present a reanalysis of the effects of low-dose aspirin in IVF and raise 
      methodological questions regarding the analysis by Gelbaya et al. DESIGN: A 
      meta-analysis of prospective randomized trials evaluating the effects of low-dose 
      aspirin in IVF. PATIENT(S): Women undergoing IVF/intracytoplasmic sperm 
      injection. INTERVENTION(S): Low-dose acetylsalicylic acid (aspirin). MAIN OUTCOME 
      MEASURE(S): Pregnancy rates, implantation rates, miscarriage rates. RESULT(S): 
      Ten randomized clinical trials were included in the analysis. Clinical pregnancy 
      rate per ET was significant when low-dose aspirin was compared with no treatment 
      (risk ratio 1.15, 95% confidence interval 1.03-1.27). Nonsignificant estimates 
      comparing low-dose aspirin with no treatment were found for implantation and 
      miscarriage rates. CONCLUSION(S): Our results suggest that aspirin may increase 
      clinical pregnancy rates and that more data are needed to resolve the issue. At 
      this point, there is no reason to change clinical management and discontinue the 
      use of aspirin.
FAU - Ruopp, Marcus D
AU  - Ruopp MD
AD  - Division of Epidemiology, Statistics and Prevention Research, National Institute 
      of Child Health and Human Development, National Institutes of Health, Department 
      of Health and Human Services, Bethesda, Maryland 20852, USA.
FAU - Collins, Tara C
AU  - Collins TC
FAU - Whitcomb, Brian W
AU  - Whitcomb BW
FAU - Schisterman, Enrique F
AU  - Schisterman EF
LA  - eng
GR  - Z01 HD008795-01/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20070924
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Fertil Steril. 2009 May;91(5):e21; author reply e22. PMID: 19296940
MH  - Abortion, Spontaneous
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Embryo Implantation/drug effects
MH  - Evidence-Based Medicine
MH  - Female
MH  - Fertilization in Vitro/*drug effects
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Research Design
MH  - Sperm Injections, Intracytoplasmic/*drug effects
MH  - Treatment Outcome
PMC - PMC2530900
MID - NIHMS58343
EDAT- 2007/09/25 09:00
MHDA- 2008/07/18 09:00
CRDT- 2007/09/25 09:00
PHST- 2007/04/24 00:00 [received]
PHST- 2007/06/04 00:00 [revised]
PHST- 2007/06/04 00:00 [accepted]
PHST- 2007/09/25 09:00 [pubmed]
PHST- 2008/07/18 09:00 [medline]
PHST- 2007/09/25 09:00 [entrez]
AID - S0015-0282(07)01258-7 [pii]
AID - 10.1016/j.fertnstert.2007.06.033 [doi]
PST - ppublish
SO  - Fertil Steril. 2008 Jul;90(1):71-6. doi: 10.1016/j.fertnstert.2007.06.033. Epub 
      2007 Sep 24.

PMID- 2674393
OWN - NLM
STAT- MEDLINE
DCOM- 19891026
LR  - 20220408
IS  - 0891-5245 (Print)
IS  - 0891-5245 (Linking)
VI  - 3
IP  - 5
DP  - 1989 Sep-Oct
TI  - Reye's syndrome: review and update.
PG  - 246-50
AB  - Reye's syndrome is a rare but potentially fatal disease that affects all organs 
      of the body, with an especially devastating attack upon the liver and brain. It 
      is characterized by encephalopathy with severe edema of the brain, increased 
      intracranial pressure, hypoglycemia, and fatty infiltration of the liver. It is a 
      two-phase illness, almost always associated with a previous viral infection. 
      Studies strongly support a link between the use of aspirin and Reye's syndrome. 
      Reported cases are on the decline. Recent epidemiologic studies show the 
      incidence for children 10 to 19 years old to be stable, but reduced for younger 
      children. Special attention needs to be directed toward educating adolescents and 
      parents of older children about Reye's syndrome and cautioning against the use of 
      aspirin to treat influenza, upper respiratory infections, or varicella.
FAU - Maheady, D C
AU  - Maheady DC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Pediatr Health Care
JT  - Journal of pediatric health care : official publication of National Association 
      of Pediatric Nurse Associates & Practitioners
JID - 8709735
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Prognosis
MH  - *Reye Syndrome/diagnosis/nursing/therapy
RF  - 27
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
AID - 0891-5245(89)90004-7 [pii]
AID - 10.1016/0891-5245(89)90004-7 [doi]
PST - ppublish
SO  - J Pediatr Health Care. 1989 Sep-Oct;3(5):246-50. doi: 
      10.1016/0891-5245(89)90004-7.

PMID- 16321668
OWN - NLM
STAT- MEDLINE
DCOM- 20060316
LR  - 20181203
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 106
IP  - 1
DP  - 2006 Jan 4
TI  - Comparative effect of aspirin and clopidogrel on arterial function in CHF.
PG  - 61-6
AB  - BACKGROUND: By inhibiting prostaglandins, aspirin may be deleterious in 
      congestive heart failure (CHF) and/or partially counteract the efficacy of 
      angiotensin-converting enzyme inhibitors (ACEI). Conversely, clopidogrel has no 
      effect on prostaglandin metabolism. The aim of this study was to prospectively 
      investigate the effect of aspirin and clopidogrel on arterial functional 
      properties in CHF patients treated with ACEI. METHODS: Forty-five patients with 
      stable NYHA class II-IV CHF (64.0+/-15.5 years), ejection fraction <40%, were 
      included in this prospective double-blind study and randomized to receive aspirin 
      325 mg/day or clopidogrel 75 mg/day for 14 days. Reflected wave assessed by 
      radial applanation tonometry and pulse wave velocity (PWV) were measured at day 0 
      and day 14. RESULTS: Aspirin resulted in an increase in the augmentation index of 
      the reflected wave (Delta=+3.5+/-5.2%, p=0.005) and the height above the shoulder 
      of the reflected wave (Delta=+1.7+/-3.1 mm Hg, p=0.023), without statistically 
      variation in PWV. Conversely, clopidogrel had no effect on the same parameters 
      (p=0.512, p=0.677 and 0.801, respectively). Overall, variations in the 
      augmentation index of reflected wave significantly differed when compared aspirin 
      with clopidogrel (p=0.0261). CONCLUSION: This study demonstrates the existence of 
      a negative effect of aspirin 325 mg/day when compared to clopidogrel 75 mg/day on 
      arterial functional properties in CHF patients treated with ACEI.
FAU - Meune, Christophe
AU  - Meune C
AD  - Department of Cardiology, Cochin Hospital, Rene Descartes University, 27 rue du 
      Fg St-Jacques, 75014 Paris, France. christophe.meune@cch.ap-hop-paris.fr
FAU - Mahé, Isabelle
AU  - Mahé I
FAU - Solal, Alain Cohen
AU  - Solal AC
FAU - Lévy, Bernard I
AU  - Lévy BI
FAU - Duboc, Denis
AU  - Duboc D
FAU - Simoneau, Guy
AU  - Simoneau G
FAU - Champion, Karine
AU  - Champion K
FAU - Mourad, Jean-Jacques
AU  - Mourad JJ
FAU - Weber, Simon
AU  - Weber S
FAU - Bergmann, Jean-François
AU  - Bergmann JF
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Chi-Square Distribution
MH  - Clopidogrel
MH  - Double-Blind Method
MH  - Female
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Prospective Studies
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
EDAT- 2005/12/03 09:00
MHDA- 2006/03/17 09:00
CRDT- 2005/12/03 09:00
PHST- 2004/10/12 00:00 [received]
PHST- 2004/12/31 00:00 [accepted]
PHST- 2005/12/03 09:00 [pubmed]
PHST- 2006/03/17 09:00 [medline]
PHST- 2005/12/03 09:00 [entrez]
AID - S0167-5273(05)00314-1 [pii]
AID - 10.1016/j.ijcard.2004.12.059 [doi]
PST - ppublish
SO  - Int J Cardiol. 2006 Jan 4;106(1):61-6. doi: 10.1016/j.ijcard.2004.12.059.

PMID- 15034954
OWN - NLM
STAT- MEDLINE
DCOM- 20040916
LR  - 20131121
IS  - 0025-7680 (Print)
IS  - 0025-7680 (Linking)
VI  - 64
IP  - 1
DP  - 2004
TI  - [Effect of different doses of aspirin on preconditioning against stunning in 
      conscious sheep].
PG  - 30-6
AB  - Non-steroid antiinflammatory drugs, inhibitors of cyclooxigenase (COX), have been 
      postulated to have deletereous effects on the heart. Recently, COX-2 inhibitors 
      have also been found to block late preconditioning (LP) protection. Aspirin is 
      the most widely clinically used non-steroid antiinflammatory drug; yet its effect 
      on LP in big mammals has not been determined. It inhibits the two cyclooxigenase 
      isoenzymes (COX-1 and COX-2), at high doses being used as an antiinflammatory 
      drug and at low doses as an antithrombotic agent. The goal of this study was 
      thus, to analyse the effect of different aspirin doses on LP protection against 
      stunning and arrhythmias in a conscious sheep model. The animals were divided in 
      5 groups: control (C): 12 min ischemia (I)-2 hr reperfusion (R); LP: 6 periods of 
      5 min I-5 min R, 24 hr before 12 min I, and three groups same as LP, but with 1.5 
      (LPA1.5), 8 (LPA8) and 20 (LPA20) mg/kg aspirin respectively, administered 10 min 
      before the first preconditioning I. Results showed that the antiinflammatory dose 
      of aspirin (20 mg/kg) was able to inhibit LP against stunning (C vs LPA20, NS), 
      whereas low (1.5 mg/kg) and intermediate (8 mg/kg) doses did not interfere with 
      the protection (C vs LP, LPA1.5 and LPA8, p < 0.01). Moreover, no dose altered 
      the protection against arrhythmias. CONCLUSION: Antithrombotic aspirin doses 
      would not inhibit LP protection against stunning, whereas high antiinflammatory 
      doses would be potentially deletereous. Since high doses of aspirin blocked LP 
      when administered before the triggering episodes, our results show that the COX 
      pathway might be involved as a trigger of LP against stunning.
FAU - Lascano, Elena C
AU  - Lascano EC
AD  - Departamento de Fisiología, Farmacología y Bioquímica, Universidad Favaloro, 
      Solís 453, 1078 Buenos Aires, Argentina. lascano@favaloro.edu.ar
FAU - Del Valle, Héctor F
AU  - Del Valle HF
FAU - Negroni, Jorge A
AU  - Negroni JA
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Efecto de diferentes dosis de aspirina sobre el precondicionamiento contra el 
      atontamiento en ovejas.
PL  - Argentina
TA  - Medicina (B Aires)
JT  - Medicina
JID - 0204271
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Arrhythmias, Cardiac/physiopathology/prevention & control
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - *Ischemic Preconditioning, Myocardial/methods
MH  - Male
MH  - Myocardial Stunning/physiopathology/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Sheep
EDAT- 2004/03/24 05:00
MHDA- 2004/09/17 05:00
CRDT- 2004/03/24 05:00
PHST- 2004/03/24 05:00 [pubmed]
PHST- 2004/09/17 05:00 [medline]
PHST- 2004/03/24 05:00 [entrez]
PST - ppublish
SO  - Medicina (B Aires). 2004;64(1):30-6.

PMID- 826200
OWN - NLM
STAT- MEDLINE
DCOM- 19770125
LR  - 20131121
IS  - 0003-1348 (Print)
IS  - 0003-1348 (Linking)
VI  - 42
IP  - 12
DP  - 1976 Dec
TI  - Massive bleeding from the pharyngoesophageal diverticulum.
PG  - 917-9
AB  - A case of massive upper gastrointestinal bleeding secondary to an ulcer within a 
      Zenker's diverticulum is presented. The possible causes of the bleeding have been 
      discussed, but the topical effect of aspirin intake appears to be the cause of 
      bleeding in this case.
FAU - Vaghei, R
AU  - Vaghei R
FAU - Harrison, I
AU  - Harrison I
FAU - Ortiz, R A
AU  - Ortiz RA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am Surg
JT  - The American surgeon
JID - 0370522
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Diverticulum/*complications
MH  - Esophageal Diseases/*complications
MH  - Gastrointestinal Hemorrhage/chemically induced/*etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pharyngeal Diseases/*complications
EDAT- 1976/12/01 00:00
MHDA- 1976/12/01 00:01
CRDT- 1976/12/01 00:00
PHST- 1976/12/01 00:00 [pubmed]
PHST- 1976/12/01 00:01 [medline]
PHST- 1976/12/01 00:00 [entrez]
PST - ppublish
SO  - Am Surg. 1976 Dec;42(12):917-9.

PMID- 31999196
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 23
IP  - 6
DP  - 2020 Jun
TI  - Cost-effective analysis of clopidogrel versus aspirin for high risk patients with 
      established peripheral arterial disease in China.
PG  - 659-666
LID - 10.1080/13696998.2020.1724119 [doi]
AB  - Objective: To assess the cost-effectiveness of clopidogrel versus aspirin for 
      high risk patients (pre-existing symptomatic atherosclerosis or multi-vascular 
      territory involvement) with established peripheral arterial disease (PAD) for 
      secondary prevention of atherothrombotic events in a Chinese setting.Methods: A 
      Markov model with a lifetime horizon was developed from the perspective of the 
      national healthcare system in China. The primary outputs are quality adjusted 
      life years (QALYs), direct medical costs, and the incremental cost-effectiveness 
      ratios (ICERs). Clinical efficacy data were obtained from the CAPRIE trial. Drug 
      acquisition cost, other direct medical costs, and utilities were from pricing 
      records and the literature. One-way sensitivity analysis and probabilistic 
      sensitivity analysis (PSA) were conducted to test the robustness of the model on 
      all parameters.Results: In patients with pre-existing atherosclerosis, 2 years of 
      treatment with clopidogrel and aspirin would yield total QALYs of 8.776 and 8.576 
      at associated costs of ¥18,777 ($2,838) and ¥12,302 ($1,859), respectively, 
      resulting in an ICER of ¥32,382 ($4,893) per QALY gained. In patients with PVD, 
      secondary prevention with the same drugs would expect to lead to total QALYs of 
      8.836 and 8.632 at associated costs of ¥18,518 ($2,798) and ¥12,041 ($1,820), 
      respectively, resulting in a corresponding ICER of ¥31,743 ($4,797) per QALY 
      gained. The results were most sensitive to the discount rate for future outcomes 
      and costs. The PSA indicated that the probability of clopidogrel being 
      cost-effective was 100% at the willingness-to-pay threshold of 3-times 
      GDP.Conclusions: Secondary prevention with clopidogrel is an attractive 
      cost-effective option compared with aspirin for high risk patients with 
      established PAD from the perspective of the national healthcare system in Chinese 
      settings.
FAU - Lin, Ziyi
AU  - Lin Z
AD  - Health Economics Department, Shanghai Centennial Scientific, Shanghai, China.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Health Economics Department, Shanghai Centennial Scientific, Shanghai, China.
FAU - Yang, Xiaoyan
AU  - Yang X
AD  - Health Economics and Outcome Research, Sanofi, Shanghai, China.
FAU - Liu, Li
AU  - Liu L
AD  - Health Economics and Outcome Research, Sanofi, Shanghai, China.
FAU - Xuan, Jianwei
AU  - Xuan J
AD  - Health Economics Research Institute, Sun Yat-sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20200224
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*economics
MH  - Clopidogrel/administration & dosage/*economics
MH  - Cost-Benefit Analysis
MH  - Health Expenditures
MH  - Humans
MH  - Markov Chains
MH  - Models, Econometric
MH  - Peripheral Arterial Disease/*complications
MH  - Platelet Aggregation Inhibitors/administration & dosage/*economics
MH  - Quality-Adjusted Life Years
MH  - Secondary Prevention/*economics/methods
MH  - Thrombosis/etiology/prevention & control
OTO - NOTNLM
OT  - Clopidogrel
OT  - I12
OT  - I15
OT  - aspirin
OT  - cost-effectiveness analysis
OT  - peripheral arterial disease
EDAT- 2020/01/31 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/01/31 06:00
PHST- 2020/01/31 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/01/31 06:00 [entrez]
AID - 10.1080/13696998.2020.1724119 [doi]
PST - ppublish
SO  - J Med Econ. 2020 Jun;23(6):659-666. doi: 10.1080/13696998.2020.1724119. Epub 2020 
      Feb 24.

PMID- 22853743
OWN - NLM
STAT- MEDLINE
DCOM- 20130109
LR  - 20191112
IS  - 1179-1896 (Electronic)
IS  - 1175-5652 (Linking)
VI  - 10
IP  - 5
DP  - 2012 Sep 1
TI  - Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based 
      cost-effectiveness model for Greece.
PG  - 331-42
AB  - BACKGROUND: Atherothrombosis represents a leading cause of morbidity and 
      mortality worldwide. Given the prominent role of platelet aggregation in 
      atherothrombosis, antiplatelet therapy forms the cornerstone of treatment, with 
      proven efficacy in the secondary prevention of atherothrombotic events. Although 
      clopidogrel seems to be superior to aspirin in terms of risk reduction for an 
      atherothrombotic event, whether this clinical advantage is cost effective in 
      Greece is unknown. OBJECTIVE: The aim of this study was to conduct a 
      cost-effectiveness analysis comparing clopidogrel with aspirin in the secondary 
      prevention of atherothrombotic events in patients with peripheral artery disease, 
      a recent stroke or a recent myocardial infarction, from the third-party-payer 
      perspective in Greece. METHODS: A Markov model with a 6-month cycle length was 
      developed. Transition probabilities used in the model were obtained from the 
      event rates reported in the CAPRIE trial. The effect of clopidogrel was applied 
      only during the first 2 years of the model. Utility data were used to estimate 
      quality-adjusted life-years (QALYs). Costs (for the year 2012) assigned to each 
      health state included antiplatelet treatment cost, cost for the management of 
      adverse events related to antiplatelet therapy and the direct healthcare cost of 
      patients (i.e. concomitant medication, hospitalization, outpatient visits, 
      rehabilitation, laboratory and imaging diagnostic examinations as well as 
      interventions) in the acute and follow-up phase, separately. The incremental 
      cost-effectiveness ratio (ICER) was calculated for life-years (LYs) and QALYs, 
      separately. A probabilistic sensitivity analysis was conducted in order to 
      evaluate the impact of the variation that characterizes the majority of model 
      parameters to the cost-effectiveness results. RESULTS: The Markov analysis 
      revealed that the discounted survival was 11.83 (95% CI 11.40, 12.22) years and 
      12.17 (95% CI 11.75, 12.55) years in the aspirin and clopidogrel treatment 
      groups, respectively, a difference of 0.34 (95% CI 0.09, 0.618) LYs. The 
      corresponding discounted QALYs were 8.63 (95% CI 8.34, 8.90) and 8.84 (95% CI 
      8.54, 9.10), respectively, a difference of 0.21 (95% CI 0.05, 0.37) QALYs. The 
      cumulated lifetime costs per patient were €20 678 (95% CI 19 675, 21 724) and €21 
      688 (95% CI 20 649, 22 773), for aspirin and clopidogrel treatment arm, 
      respectively. The ICER for clopidogrel was calculated to be €4038 (95% CI 2743, 
      7837) for each LY saved and €5518 (95% CI 3358, 12 921) for each QALY saved. 
      CONCLUSION: The analysis indicates that clopidogrel is cost effective for the 
      secondary prevention of atherothrombotic events in the Greek setting. These 
      findings are in line with those reported in other European countries.
FAU - Kourlaba, Georgia
AU  - Kourlaba G
AD  - National School of Public Health, Department of Health Services Management, 
      Athens, Greece. kurlaba@hua.gr
FAU - Fragoulakis, Vassilis
AU  - Fragoulakis V
FAU - Maniadakis, Nikos
AU  - Maniadakis N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Appl Health Econ Health Policy
JT  - Applied health economics and health policy
JID - 101150314
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*economics/therapeutic use
MH  - Atherosclerosis/complications/drug therapy/*economics
MH  - Cardiovascular Diseases/drug therapy/economics/etiology/prevention & control
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Greece
MH  - Humans
MH  - Models, Economic
MH  - Platelet Aggregation Inhibitors/administration & dosage/economics/therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Randomized Controlled Trials as Topic
MH  - Secondary Prevention/*economics/methods
MH  - Thrombosis/complications/drug therapy/*economics
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/economics/therapeutic 
      use
MH  - Treatment Outcome
EDAT- 2012/08/03 06:00
MHDA- 2013/01/10 06:00
CRDT- 2012/08/03 06:00
PHST- 2012/08/03 06:00 [entrez]
PHST- 2012/08/03 06:00 [pubmed]
PHST- 2013/01/10 06:00 [medline]
AID - 10.1007/BF03261867 [doi]
PST - ppublish
SO  - Appl Health Econ Health Policy. 2012 Sep 1;10(5):331-42. doi: 10.1007/BF03261867.

PMID- 35283411
OWN - NLM
STAT- MEDLINE
DCOM- 20230105
LR  - 20230214
IS  - 1880-3873 (Electronic)
IS  - 1340-3478 (Print)
IS  - 1340-3478 (Linking)
VI  - 30
IP  - 1
DP  - 2023 Jan 1
TI  - Tachycardia Changes Increase Neurological Deterioration in Patients with Acute 
      Non-Cardioembolic Stroke: An ADS Post-Hoc Analysis.
PG  - 66-73
LID - 10.5551/jat.63409 [doi]
AB  - AIM: A previous randomized study showed that dual antiplatelet therapy (DAPT) 
      with aspirin and cilostazol is not superior to aspirin monotherapy for patients 
      with acute non-cardioembolic stroke; however, the reason for this remains 
      uncertain. We focused on the unusual side effects of cilostazol, namely, 
      tachycardia changes, and validated their influence on patients with acute 
      non-cardioembolic stroke. METHODS: This post-hoc study extracted data from the 
      acute aspirin plus cilostazol dual therapy study (ADS) registry, a multicenter, 
      prospective, randomized, open-label trial. Patients were randomly allocated to 
      the dual group (aspirin plus cilostazol) and the aspirin monotherapy group 
      (aspirin alone). Tachycardia changes were defined as ≥ 5% heart rate increase at 
      48 h after admission compared with that at admission. Baseline data and outcomes 
      were validated with four divided groups: aspirin-non-tachycardia changes (AN), 
      aspirin-tachycardia changes (AT), dual-non-tachycardia changes (DN), and 
      dual-tachycardia changes (DT). RESULTS: Finally, 1,188 patients were analyzed in 
      this ADS post-hoc analysis (aspirin monotherapy group, 594; dual group, 594). The 
      proportion of change in tachycardia was 19.2% in the aspirin monotherapy group 
      and 38.2% in the dual group (p＜0.001(＊＊＊)). Although the recurrences of 
      symptomatic stroke and transient ischemic attack were not significantly 
      different, the neurological deterioration was significantly different among the 
      AN, AT, DN, and DT groups (p＜0.05(＊)). CONCLUSIONS: Tachycardia changes increase 
      neurological deterioration even in patients with non-cardioembolic acute stroke. 
      DAPT consisting of aspirin and cilostazol increases the proportion of tachycardia 
      changes and is not superior to aspirin monotherapy.
FAU - Matsuzono, Kosuke
AU  - Matsuzono K
AD  - Division of Neurology, Department of Medicine, Jichi Medical University.
FAU - Fujimoto, Shigeru
AU  - Fujimoto S
AD  - Division of Neurology, Department of Medicine, Jichi Medical University.
FAU - Aoki, Junya
AU  - Aoki J
AD  - Department of Neurological Science, Graduate School of Medicine, Nippon Medical 
      School.
FAU - Ozawa, Tadashi
AU  - Ozawa T
AD  - Division of Neurology, Department of Medicine, Jichi Medical University.
FAU - Kimura, Kazumi
AU  - Kimura K
AD  - Department of Neurological Science, Graduate School of Medicine, Nippon Medical 
      School.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20220312
PL  - Japan
TA  - J Atheroscler Thromb
JT  - Journal of atherosclerosis and thrombosis
JID - 9506298
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/adverse effects
MH  - Cilostazol
MH  - Prospective Studies
MH  - Drug Therapy, Combination
MH  - Aspirin/adverse effects
MH  - *Stroke/complications/drug therapy
MH  - Treatment Outcome
PMC - PMC9899698
OTO - NOTNLM
OT  - Acute ischemic stroke
OT  - Cilostazol
OT  - DAPT
OT  - Non-cardioembolic stroke
OT  - Tachycardia
EDAT- 2022/03/15 06:00
MHDA- 2023/01/06 06:00
CRDT- 2022/03/14 05:56
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2023/01/06 06:00 [medline]
PHST- 2022/03/14 05:56 [entrez]
AID - DN/JST.JSTAGE/jat/63409 [pii]
AID - 10.5551/jat.63409 [doi]
PST - ppublish
SO  - J Atheroscler Thromb. 2023 Jan 1;30(1):66-73. doi: 10.5551/jat.63409. Epub 2022 
      Mar 12.

PMID- 1100304
OWN - NLM
STAT- MEDLINE
DCOM- 19751211
LR  - 20190509
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 18
IP  - 3
DP  - 1975 Sep
TI  - Correlation of plateau serum salicylate level with rate of salicylate metabolism.
PG  - 350-5
AB  - The range of plateau serum salicylate concentrations was 4.4 to 33 mg/100 ml in 
      patients with rheumatoid arthritis after they were treated with 50 mg/kg of 
      aspirin daily for 5 days. Individual plateau serum levels correlated better with 
      urinary excretion rates of the metabolite, salicylurate (whose maximum production 
      is capacity-limited), than with total urinary excretion of salicylates. These 
      observations suggest that large intersubject variations in plateau serum 
      salicylate levels are determined, at least in part, by similar differences in the 
      maximum rates of capacity-limited metabolic reactions. For optimal therapeutic 
      responses, individualization of aspirin dosage by following serum salicylate 
      levels is recommended.
FAU - Gupta, N
AU  - Gupta N
FAU - Sarkissian, E
AU  - Sarkissian E
FAU - Paulus, H E
AU  - Paulus HE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/drug therapy/metabolism
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Salicylates/blood/*metabolism/urine
MH  - Time Factors
EDAT- 1975/09/01 00:00
MHDA- 1975/09/01 00:01
CRDT- 1975/09/01 00:00
PHST- 1975/09/01 00:00 [pubmed]
PHST- 1975/09/01 00:01 [medline]
PHST- 1975/09/01 00:00 [entrez]
AID - 0009-9236(75)90069-7 [pii]
AID - 10.1002/cpt1975183350 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1975 Sep;18(3):350-5. doi: 10.1002/cpt1975183350.

PMID- 234262
OWN - NLM
STAT- MEDLINE
DCOM- 19750506
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 86
IP  - 2
DP  - 1975 Feb
TI  - Experimental salicylate intoxication in young baboons. A preliminary report.
PG  - 225-32
AB  - Salicylate intoxication has been investigated in young baboons. The results of 
      these studies are similar to these previously obtained in man. Acidosis appears 
      to be of considerable importance in the pathogenesis of infantile salicylism as 
      it enhances the passage of salicylate into the CSF. The CSF concentration of 
      salicylate seems to be of major physiologic importance in this condition. 
      Moreover, the serum concentration of free salicylate correlates more closely with 
      the CSF concentration of salicylate than does the total serum concentration of 
      salicylate.
FAU - Buchanan, N
AU  - Buchanan N
FAU - Kundig, H
AU  - Kundig H
FAU - Eyberg, C
AU  - Eyberg C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 0 (Bicarbonates)
RN  - 0 (Salicylates)
RN  - 0 (Serum Albumin)
RN  - 01Q9PC255D (Ammonium Chloride)
RN  - 142M471B3J (Carbon Dioxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acid-Base Equilibrium
MH  - Acidosis, Respiratory/chemically induced/complications
MH  - Alkalosis, Respiratory/chemically induced
MH  - Ammonium Chloride
MH  - Animals
MH  - Aspirin/blood/cerebrospinal fluid/toxicity
MH  - Bicarbonates/blood
MH  - Blood
MH  - Carbon Dioxide/blood
MH  - Haplorhini
MH  - Hydrogen-Ion Concentration
MH  - Medulla Oblongata/drug effects
MH  - Papio
MH  - Permeability
MH  - Protein Binding
MH  - Salicylates/blood/cerebrospinal fluid/*toxicity
MH  - Serum Albumin/metabolism
EDAT- 1975/02/01 00:00
MHDA- 1975/02/01 00:01
CRDT- 1975/02/01 00:00
PHST- 1975/02/01 00:00 [pubmed]
PHST- 1975/02/01 00:01 [medline]
PHST- 1975/02/01 00:00 [entrez]
AID - S0022-3476(75)80473-2 [pii]
AID - 10.1016/s0022-3476(75)80473-2 [doi]
PST - ppublish
SO  - J Pediatr. 1975 Feb;86(2):225-32. doi: 10.1016/s0022-3476(75)80473-2.

PMID- 21392725
OWN - NLM
STAT- MEDLINE
DCOM- 20110913
LR  - 20151119
IS  - 1933-2874 (Print)
IS  - 1876-4789 (Linking)
VI  - 5
IP  - 2
DP  - 2011 Mar-Apr
TI  - Persistent erythema with niacin is not attributable to aspirin resistance.
PG  - 114-9
LID - 10.1016/j.jacl.2011.01.002 [doi]
AB  - BACKGROUND: Niacin is suboptimally used in patients because it causes flushing 
      and erythema. These side effects have been attributed to release of the 
      vasodilating prostaglandin D2, generated in a reaction catalyzed by 
      cyclooxygenase-1. Aspirin reduces but does not completely eliminate these side 
      effects. Because some patients are resistant to its antiplatelet effects, we 
      hypothesized that patients with persistent niacin-induced erythema might be 
      aspirin resistant. METHODS: Platelet function studies (via the use of a 
      whole-blood platelet function aggregometer [VerifyNow; Accumetrics, San Diego, 
      CA] with end points of aspirin reaction unit [ARUs] and P2Y12 reaction units 
      [PRUs]) were performed on 32 healthy, drug-free subjects before and after 324 mg 
      of aspirin. A niacin skin test with the use of topical methylnicotinate was also 
      performed before and after the administration of aspirin. Responses to methyl 
      nicotinate were assessed by a reaction score and by counting the time to first 
      visible redness (TTR). RESULTS: All subjects had an expected decrease in 
      arachidonic acid induced platelet response (ARU 642.8 ± 47.20 before to 431.5 ± 
      41.1 after aspirin, P < .0001) without a significant change in the PRU. The 
      reaction score and TTR were prolonged by aspirin at methylnicotinate 
      concentrations ≥ 0.001 M. Although no subject had aspirin resistance (defined as 
      ARU > 550), there was considerable variability in skin responses with erythema 
      elicited in all subjects at the greatest concentrations. There was no difference 
      in the ARU for subjects with TTR values above and below the mean, indicating that 
      aspirin resistance does not explain the variation in skin responses to a topical 
      niacin derivative. CONCLUSION: Aspirin resistance is unlikely to be a significant 
      contributor to the persistent erythema and flushing in niacin-treated patients.
CI  - Copyright © 2011 National Lipid Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Babcock, Michael J
AU  - Babcock MJ
AD  - Department of Internal Medicine, Wake Forest University Health Sciences, 
      Winston-Salem, NC, USA.
FAU - Sane, Aneysa C
AU  - Sane AC
FAU - Eckman, Delrae M
AU  - Eckman DM
FAU - Sane, David C
AU  - Sane DC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20110119
PL  - United States
TA  - J Clin Lipidol
JT  - Journal of clinical lipidology
JID - 101300157
RN  - 2679MF687A (Niacin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Erythema/blood/*chemically induced/etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Niacin/*adverse effects
EDAT- 2011/03/12 06:00
MHDA- 2011/09/14 06:00
CRDT- 2011/03/12 06:00
PHST- 2010/03/26 00:00 [received]
PHST- 2010/12/21 00:00 [revised]
PHST- 2011/01/11 00:00 [accepted]
PHST- 2011/03/12 06:00 [entrez]
PHST- 2011/03/12 06:00 [pubmed]
PHST- 2011/09/14 06:00 [medline]
AID - S1933-2874(11)00018-3 [pii]
AID - 10.1016/j.jacl.2011.01.002 [doi]
PST - ppublish
SO  - J Clin Lipidol. 2011 Mar-Apr;5(2):114-9. doi: 10.1016/j.jacl.2011.01.002. Epub 
      2011 Jan 19.

PMID- 27542891
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20210109
IS  - 1750-2659 (Electronic)
IS  - 1750-2640 (Print)
IS  - 1750-2640 (Linking)
VI  - 11
IP  - 1
DP  - 2017 Jan
TI  - Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in 
      vitro study.
PG  - 85-92
LID - 10.1111/irv.12421 [doi]
AB  - AIM: Aspirin (acetylsalicylic acid) has been used for more than 115 years in 
      medicine. Research exists to show that aspirin has antiviral effects in vitro, 
      for example, by blocking influenza virus propagation via NF-κB inhibition when 
      used at high concentrations and short-term incubation steps. The aim of this 
      study was to confirm the antiviral activity of aspirin against influenza virus 
      and further elucidate the activity of aspirin against other respiratory viruses. 
      METHODS: Tests to detect antiviral activity were performed using plaque-reduction 
      assays. Aspirin was administered to the virus-infected cell cultures one hour 
      after infection. Prior to these assays, the non-cytotoxic concentrations of 
      aspirin on cells used for propagation of the respective viruses were determined. 
      RESULTS: Aspirin was found to be highly effective against influenza A H1N1 virus. 
      The antiviral activity against further respiratory RNA viruses was less distinct. 
      Respiratory syncytial virus was minimally inhibited. However, the activity of 
      aspirin against rhinoviruses was more pronounced. Aspirin demonstrated antiviral 
      activity against all human rhinoviruses (HRV), but the effect on members of the 
      "major group" viruses, namely HRV14 and HRV39, was greater than on those of the 
      "minor group," HRV1A and HRV2. CONCLUSIONS: These data demonstrate a specific 
      antiviral activity of aspirin against influenza A virus and HRV. The mode of 
      action against rhinoviruses is still unknown and requires further investigation, 
      as does the possibility of aspirin being effective in vivo to treat the common 
      cold.
CI  - © 2016 The Authors. Influenza and Other Respiratory Viruses Published by John 
      Wiley & Sons Ltd.
FAU - Glatthaar-Saalmüller, Bernadette
AU  - Glatthaar-Saalmüller B
AD  - Labor Dr. Glatthaar, Ochsenhausen, Germany.
AD  - Department of Pathobiology, Institute of Immunology, University of Veterinary 
      Medicine Vienna, Wien, Austria.
FAU - Mair, Kerstin H
AU  - Mair KH
AD  - Department of Pathobiology, Institute of Immunology, University of Veterinary 
      Medicine Vienna, Wien, Austria.
FAU - Saalmüller, Armin
AU  - Saalmüller A
AD  - Department of Pathobiology, Institute of Immunology, University of Veterinary 
      Medicine Vienna, Wien, Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160922
PL  - England
TA  - Influenza Other Respir Viruses
JT  - Influenza and other respiratory viruses
JID - 101304007
RN  - 0 (Antiviral Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antiviral Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Enterovirus/drug effects
MH  - Humans
MH  - Influenza A Virus, H1N1 Subtype/*drug effects
MH  - Influenza A virus/drug effects
MH  - Microbial Sensitivity Tests
MH  - RNA Viruses/*drug effects
MH  - Respiratory Syncytial Virus, Human/drug effects
MH  - Respiratory System/*virology
MH  - Rhinovirus/*drug effects
MH  - Viral Plaque Assay
PMC - PMC5155651
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - antiviral activity
OT  - aspirin
OT  - influenza
OT  - plaque-reduction assay
OT  - rhinoviruses
EDAT- 2016/08/21 06:00
MHDA- 2017/09/26 06:00
CRDT- 2016/08/21 06:00
PHST- 2016/08/13 00:00 [accepted]
PHST- 2016/08/21 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
PHST- 2016/08/21 06:00 [entrez]
AID - IRV12421 [pii]
AID - 10.1111/irv.12421 [doi]
PST - ppublish
SO  - Influenza Other Respir Viruses. 2017 Jan;11(1):85-92. doi: 10.1111/irv.12421. 
      Epub 2016 Sep 22.

PMID- 23349335
OWN - NLM
STAT- MEDLINE
DCOM- 20130516
LR  - 20211021
IS  - 1521-0103 (Electronic)
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 345
IP  - 1
DP  - 2013 Apr
TI  - Positional isomers of aspirin are equally potent in inhibiting colon cancer cell 
      growth: differences in mode of cyclooxygenase inhibition.
PG  - 85-94
LID - 10.1124/jpet.112.201970 [doi]
AB  - We compared the differential effects of positional isomers of acetylsalicylic 
      acid (o-ASA, m-ASA, and p-ASA) on cyclooxygenase (COX) inhibition, gastric 
      prostaglandin E2 (PGE2), malondialdehyde, tumor necrosis factor-alpha (TNF-α) 
      levels, superoxide dismutase (SOD) activity, human adenocarcinoma colon cancer 
      cell growth inhibition, cell proliferation, apoptosis, and cell-cycle 
      progression. We also evaluated the gastric toxicity exerted by ASA isomers. All 
      ASA isomers inhibit COX enzymes, but only the o-ASA exerted an irreversible 
      inhibitory profile. We did not observe a significant difference between ASA 
      isomers in their ability to decrease the in vivo synthesis of PGE2 and SOD 
      activity. Furthermore, all isomers increased the levels of gastric and TNF-α when 
      administered orally at equimolar doses. We observed a dose-dependent cell growth 
      inhibitory effect; the order of potency was p-ASA > m-ASA ≈ o-ASA. There was a 
      dose-dependent decrease in cell proliferation and an increase in apoptosis, with 
      a concomitant Go/G1 arrest. The ulcerogenic profile of the three ASA isomers 
      showed a significant difference between o-ASA (aspirin) and its two positional 
      isomers when administered orally at equimolar doses (1 mmol/kg); the ulcer index 
      (UI) for o-ASA indicated extensive mucosal injury (UI = 38), whereas m-ASA and 
      p-ASA produced a significantly decreased toxic response (UI = 12 and 8, 
      respectively) under the same experimental conditions. These results suggest that 
      the three positional isomers of ASA exert practically the same biologic profile 
      in vitro and in vivo but showed different safety profiles. The mechanism of 
      gastric ulcer formation exerted by aspirin and its two isomers warrants a more 
      detailed and thorough investigation.
FAU - Kodela, Ravinder
AU  - Kodela R
AD  - Department of Physiology, Pharmacology, and Neuroscience, Sophie Davis School of 
      Biomedical Education, City University of New York Medical School, New York, New 
      York 10031, USA.
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
FAU - Goswami, Satindra
AU  - Goswami S
FAU - Gan, Zong Yuan
AU  - Gan ZY
FAU - Rao, Praveen P N
AU  - Rao PP
FAU - Nia, Kamran V
AU  - Nia KV
FAU - Velázquez-Martínez, Carlos A
AU  - Velázquez-Martínez CA
FAU - Kashfi, Khosrow
AU  - Kashfi K
LA  - eng
GR  - R24 DA018055/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130124
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/chemistry/*pharmacology/toxicity
MH  - Apoptosis/drug effects
MH  - Aspirin/chemistry/*pharmacology/toxicity
MH  - Cell Cycle/drug effects
MH  - Cell Proliferation/*drug effects
MH  - Chromatography, High Pressure Liquid
MH  - Colonic Neoplasms/enzymology/pathology/*prevention & control
MH  - Cyclooxygenase Inhibitors/chemistry/*pharmacology/toxicity
MH  - Dose-Response Relationship, Drug
MH  - HT29 Cells
MH  - Humans
MH  - Isomerism
MH  - Male
MH  - Models, Molecular
MH  - Molecular Structure
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Stomach Ulcer/chemically induced
MH  - Structure-Activity Relationship
PMC - PMC3608450
EDAT- 2013/01/26 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/01/26 06:00
PHST- 2013/01/26 06:00 [entrez]
PHST- 2013/01/26 06:00 [pubmed]
PHST- 2013/05/17 06:00 [medline]
AID - jpet.112.201970 [pii]
AID - JPET_201970 [pii]
AID - 10.1124/jpet.112.201970 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2013 Apr;345(1):85-94. doi: 10.1124/jpet.112.201970. Epub 
      2013 Jan 24.

PMID- 34830128
OWN - NLM
STAT- MEDLINE
DCOM- 20211220
LR  - 20211220
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 22
DP  - 2021 Nov 12
TI  - Activated Carbon Fiber Cloth/Biomimetic Apatite: A Dual Drug Delivery System.
LID - 10.3390/ijms222212247 [doi]
LID - 12247
AB  - A biomaterial that is both bioactive and capable of controlled drug release is 
      highly attractive for bone regeneration. In previous works, we demonstrated the 
      possibility of combining activated carbon fiber cloth (ACC) and biomimetic 
      apatite (such as calcium-deficient hydroxyapatite (CDA)) to develop an efficient 
      material for bone regeneration. The aim to use the adsorption properties of an 
      activated carbon/biomimetic apatite composite to synthetize a biomaterial to be 
      used as a controlled drug release system after implantation. The adsorption and 
      desorption of tetracycline and aspirin were first investigated in the ACC and CDA 
      components and then on ACC/CDA composite. The results showed that drug adsorption 
      and release are dependent on the adsorbent material and the drug 
      polarity/hydrophilicity, leading to two distinct modes of drug adsorption and 
      release. Consequently, a double adsorption approach was successfully performed, 
      leading to a multifunctional and innovative ACC-aspirin/CDA-tetracycline 
      implantable biomaterial. In a second step, in vitro tests emphasized a better 
      affinity of the drug (tetracycline or aspirin)-loaded ACC/CDA materials towards 
      human primary osteoblast viability and proliferation. Then, in vivo experiments 
      on a large cortical bone defect in rats was carried out to test biocompatibility 
      and bone regeneration ability. Data clearly highlighted a significant 
      acceleration of bone reconstruction in the presence of the ACC/CDA patch. The 
      ability of the aspirin-loaded ACC/CDA material to release the drug in situ for 
      improving bone healing was also underlined, as a proof of concept. This work 
      highlights the possibility of bone patches with controlled (multi)drug release 
      features being used for bone tissue repair.
FAU - Olivier, Florian
AU  - Olivier F
AUID- ORCID: 0000-0001-5114-0781
AD  - ICMN, CNRS, Université d'Orléans, UMR 7374, F-45071 Orléans, France.
FAU - Bonnamy, Sylvie
AU  - Bonnamy S
AUID- ORCID: 0000-0003-0554-9716
AD  - ICMN, CNRS, Université d'Orléans, UMR 7374, F-45071 Orléans, France.
FAU - Rochet, Nathalie
AU  - Rochet N
AD  - iBV, CNRS, INSERM, Université Côte d'Azur, F-06107 Nice, France.
FAU - Drouet, Christophe
AU  - Drouet C
AUID- ORCID: 0000-0002-8471-8719
AD  - CIRIMAT, Université Toulouse, CNRS, F-31030 Toulouse, France.
LA  - eng
GR  - MatCCaP-Bio and CoMéMat projects/Région Centre-Val de Loire/
PT  - Journal Article
DEP - 20211112
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Apatites)
RN  - 0 (Bone Substitutes)
RN  - 0 (Carbon Fiber)
RN  - 16291-96-6 (Charcoal)
RN  - F8VB5M810T (Tetracycline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Animals
MH  - Anti-Bacterial Agents/administration & dosage/chemistry/pharmacokinetics
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/chemistry/pharmacokinetics
MH  - Apatites/*chemistry
MH  - Aspirin/*administration & dosage/chemistry/pharmacokinetics
MH  - Biomimetic Materials/*chemistry
MH  - Bone Regeneration/drug effects
MH  - Bone Substitutes/chemistry
MH  - Bone and Bones/metabolism
MH  - Carbon Fiber/*chemistry
MH  - Charcoal/chemistry
MH  - Drug Delivery Systems/*methods
MH  - Drug Liberation
MH  - Humans
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Tetracycline/*administration & dosage/chemistry/pharmacokinetics
PMC - PMC8624510
OTO - NOTNLM
OT  - activated carbon fiber cloth
OT  - adsorption
OT  - aspirin
OT  - biomimetic apatite
OT  - bone defect model
OT  - human osteoblast
OT  - release
OT  - tetracycline
COIS- The authors declare no conflict of interest.
EDAT- 2021/11/28 06:00
MHDA- 2021/12/21 06:00
CRDT- 2021/11/27 01:11
PHST- 2021/10/07 00:00 [received]
PHST- 2021/11/02 00:00 [revised]
PHST- 2021/11/08 00:00 [accepted]
PHST- 2021/11/27 01:11 [entrez]
PHST- 2021/11/28 06:00 [pubmed]
PHST- 2021/12/21 06:00 [medline]
AID - ijms222212247 [pii]
AID - ijms-22-12247 [pii]
AID - 10.3390/ijms222212247 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Nov 12;22(22):12247. doi: 10.3390/ijms222212247.

PMID- 7117076
OWN - NLM
STAT- MEDLINE
DCOM- 19821203
LR  - 20200304
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 27
IP  - 10
DP  - 1982 Oct
TI  - Antiinflammatory agents protect opossum esophagus during radiotherapy.
PG  - 923-8
AB  - Eighteen opossums received 2250 rad 60Co to the entire esophagus and lower 
      esophageal sphincter. Animals received treatment with 600 mg aspirin, 25 mg/kg 
      hydrocortisone, or saline before irradiation and twice daily for 1 week after 
      irradiation. At 10 days postirradiation, animals were evaluated for signs of 
      acute esophagitis by esophagoscopy and barium esophagram. Each animal was then 
      killed and the esophagus removed and evaluated histologically. Animals treated 
      with either aspirin or hydrocortisone had significantly milder esophagitis than 
      control irradiated animals.
FAU - Northway, M G
AU  - Northway MG
FAU - Eastwood, G L
AU  - Eastwood GL
FAU - Libshitz, H I
AU  - Libshitz HI
FAU - Feldman, M S
AU  - Feldman MS
FAU - Mamel, J J
AU  - Mamel JJ
FAU - Szwarc, I A
AU  - Szwarc IA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Endoscopy
MH  - Esophagus/drug effects/pathology/*radiation effects
MH  - Hydrocortisone/*therapeutic use
MH  - Opossums
MH  - Radiation Injuries/*prevention & control
EDAT- 1982/10/01 00:00
MHDA- 1982/10/01 00:01
CRDT- 1982/10/01 00:00
PHST- 1982/10/01 00:00 [pubmed]
PHST- 1982/10/01 00:01 [medline]
PHST- 1982/10/01 00:00 [entrez]
AID - 10.1007/BF01316577 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1982 Oct;27(10):923-8. doi: 10.1007/BF01316577.

PMID- 665477
OWN - NLM
STAT- MEDLINE
DCOM- 19780901
LR  - 20131121
IS  - 0002-838X (Print)
IS  - 0002-838X (Linking)
VI  - 18
IP  - 1
DP  - 1978 Jul
TI  - Rheumatoid arthritis.
PG  - 89-94
AB  - Management should help relieve symptoms, increase or maintain function, produce 
      few side effects and keep the cost to a minimum. Aspirin remains the first-line 
      drug; other nonsteroidal anti-inflammatory drugs may be useful when aspirin 
      cannot be tolerated. Symptoms and signs of rheumatoid disease may be suppressed 
      by corticosteroids, but only gold compounds, penicillamine and cytotoxic therapy 
      have been shown to decrease disease activity and lessen permanent joint damage.
FAU - Calin, A
AU  - Calin A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Fam Physician
JT  - American family physician
JID - 1272646
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 7440-57-5 (Gold)
RN  - GNN1DV99GX (Penicillamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/therapy
MH  - Aspirin/therapeutic use
MH  - Bed Rest
MH  - Gold/therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Penicillamine/therapeutic use
EDAT- 1978/07/01 00:00
MHDA- 1978/07/01 00:01
CRDT- 1978/07/01 00:00
PHST- 1978/07/01 00:00 [pubmed]
PHST- 1978/07/01 00:01 [medline]
PHST- 1978/07/01 00:00 [entrez]
PST - ppublish
SO  - Am Fam Physician. 1978 Jul;18(1):89-94.

PMID- 17364872
OWN - NLM
STAT- MEDLINE
DCOM- 20070416
LR  - 20190516
IS  - 1071-7544 (Print)
IS  - 1071-7544 (Linking)
VI  - 14
IP  - 2
DP  - 2007 Feb
TI  - Hydrogels of dextran containing nonsteroidal anti-inflammatory drugs as pendant 
      agents.
PG  - 87-93
AB  - The oral administration of nonsteroidal anti-inflammatory drugs (NSAIDs) is often 
      associated with upper gastrointestinal tract side effects. To reduce these 
      effects and improve the therapeutic efficacy, NSAIDs are often formulated as 
      controlled release systems. We have prepared a new formulation consisting of 
      dextran hydrogels containing NSAIDs as pendant agents, through ultraviolet 
      irradiation of solutions of dextran functionalized with methacrylic groups in the 
      presence of the drug derivatized in the same way. Release studies of different 
      drugs from this system, carried out in media simulating the gastrointestinal 
      tract, have demonstrated that the amount of released drug is strictly related to 
      the concentration of the polymer in the solution submitted to irradiation as well 
      as to its derivatization degree. Our obtained data confirm that the system is 
      able to realize a colon-specific drug delivery.
FAU - Feeney, Michelle
AU  - Feeney M
AD  - Dipartimento di Studi di Chimica e Tecnologia delle Sostanze Biologicamente 
      Attive, Università La Sapienza, Roma, Italy.
FAU - Giannuzzo, Maria
AU  - Giannuzzo M
FAU - Paolicelli, Patrizia
AU  - Paolicelli P
FAU - Casadei, Maria Antonietta
AU  - Casadei MA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Drug Deliv
JT  - Drug delivery
JID - 9417471
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Dextrans)
RN  - 0 (Drug Carriers)
RN  - 0 (Hydrogels)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Methacrylates)
RN  - 0 (Phenylpropionates)
RN  - 0 (Solvents)
RN  - 6E1I4IV47V (hydroxyethyl methacrylate)
RN  - CH15E393A2 (hydratropic acid)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*chemistry
MH  - Aspirin/administration & dosage/chemistry
MH  - Colon/metabolism
MH  - Dextrans/*chemistry/radiation effects
MH  - Drug Carriers
MH  - Drug Delivery Systems
MH  - Hydrogels/*chemistry/radiation effects
MH  - Ibuprofen/administration & dosage/chemistry
MH  - Indicators and Reagents
MH  - Methacrylates/chemistry
MH  - Phenylpropionates
MH  - Solvents
MH  - Spectrophotometry, Ultraviolet
MH  - Ultraviolet Rays
EDAT- 2007/03/17 09:00
MHDA- 2007/04/17 09:00
CRDT- 2007/03/17 09:00
PHST- 2007/03/17 09:00 [pubmed]
PHST- 2007/04/17 09:00 [medline]
PHST- 2007/03/17 09:00 [entrez]
AID - 770393031 [pii]
AID - 10.1080/10717540600740003 [doi]
PST - ppublish
SO  - Drug Deliv. 2007 Feb;14(2):87-93. doi: 10.1080/10717540600740003.

PMID- 12027230
OWN - NLM
STAT- MEDLINE
DCOM- 20021127
LR  - 20191106
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 30
IP  - 2
DP  - 2002 Mar
TI  - The hemodynamic effects of diaspirin cross-linked hemoglobin in 
      dopamine-resistant endotoxic shock in swine.
PG  - 83-98
AB  - As the blood substitute Diaspirin Cross-linked Hemoglobin (DCLHb) has potent 
      vasopressor activity, we assessed its hemodynamic effects in a clinically 
      relevant dopamine-resistant endotoxic shock model in swine. In a randomized and 
      controlled study, E. coli LPS was administered to anesthetized and invasively 
      monitored swine. Group I (n = 3) control pigs were not resuscitated. Groups II (n 
      = 5) and III (n = 6) pigs received dopamine (DA) after MAP decreased 30%, and 
      hetastarch and DCLHb, respectively, after dopamine-resistance occurred. 
      Progressive hemodynamic decline occurred in Group I pigs. DA failed to restore 
      MAP to baseline. However, 0% and 67% of pigs also treated with heta-starch and 
      DCLHb, respectively, achieved temporary restoration of baseline MAP (p = 0.03), 
      prompting a reduction in the dose of DA in 0% of hetastarch vs. 50% of DCLHb 
      treated pigs. Except for increased MPAP and decreased heart in DCLHb treated pigs 
      (p<0.001), hemodynamics and survival were not different (p>0.05). In conclusion, 
      although DCLHb exacerbated pulmonary hypertension and did not improve O2 
      utilization or survival, because DCLHb restored MAP to baseline and had a 
      dopamine sparing effect, further investigation of DCLHb's hemodynamic effects in 
      adrenergic agent-resistant endotoxemia is warranted.
FAU - Freilich, Erin
AU  - Freilich E
AD  - Department of Anesthesiology, University of Vermont, Burlington, USA. 
      freilichd@nmrc.navy.mil
FAU - Freilich, Daniel
AU  - Freilich D
FAU - Hacker, Miles
AU  - Hacker M
FAU - Leach, Lori
AU  - Leach L
FAU - Patel, Shilpa
AU  - Patel S
FAU - Hebert, James
AU  - Hebert J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hemoglobins)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Nitrates)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Blood Substitutes/*pharmacology
MH  - Cardiotonic Agents/pharmacology
MH  - Dopamine/pharmacology
MH  - Drug Resistance
MH  - Hemoglobins/*pharmacology
MH  - Lipopolysaccharides
MH  - Nitrates/analysis
MH  - Resuscitation
MH  - Shock, Septic/chemically induced/*drug therapy/mortality
MH  - Survival Rate
MH  - Swine
EDAT- 2002/05/25 10:00
MHDA- 2002/11/28 04:00
CRDT- 2002/05/25 10:00
PHST- 2002/05/25 10:00 [pubmed]
PHST- 2002/11/28 04:00 [medline]
PHST- 2002/05/25 10:00 [entrez]
AID - 10.1081/bio-120003190 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 2002 Mar;30(2):83-98. doi: 
      10.1081/bio-120003190.

PMID- 10409186
OWN - NLM
STAT- MEDLINE
DCOM- 19990830
LR  - 20181120
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 277
IP  - 1
DP  - 1999 Jul
TI  - Detection of a ferrylhemoglobin intermediate in an endothelial cell model after 
      hypoxia-reoxygenation.
PG  - H92-9
LID - 10.1152/ajpheart.1999.277.1.H92 [doi]
AB  - A cell culture model of bovine aortic endothelial cells attached to microcarrier 
      beads was used to study the interaction of diaspirin cross-linked hemoglobin (an 
      oxygen-carrying blood substitute) with hypoxia-reoxygenation. Hemoglobin (200 
      microM) and hypoxia-volume restriction (3-5 h), together and separately, caused 
      toxicity in this model, as measured by decreased cellular replating efficiency. 
      Hemoglobin (60 microM) caused a reduction in hydrogen peroxide concentration and 
      an increase in lipid peroxidation above that induced by hypoxia alone. Incubation 
      of hemoglobin with endothelial cells caused transient oxidation of hemoglobin to 
      its highly reactive and toxic ferryl species after >/=3 h of hypoxia, followed by 
      1 h of reoxygenation. Lipid peroxidation, which may occur in the presence of 
      ferrylhemoglobin, also occurred after 1 h of reoxygenation. Hemoglobin caused a 
      dose-dependent decrease in intracellular glutathione concentration, suggesting 
      that it caused an oxidative stress to the cells. However, addition of ascorbate, 
      alpha-tocopherol, or trolox did not decrease hemoglobin oxidation in the presence 
      of normal or hypoxic cells. It is concluded that diaspirin cross-linked 
      hemoglobin forms a ferryl intermediate in the absence of any exogenously added 
      oxidant and contributes to the oxidative burden experienced by endothelial cells 
      after hypoxia-reoxygenation, a condition that is likely to be encountered during 
      trauma and surgery when hemoglobin solutions are used as perfusion agents.
FAU - McLeod, L L
AU  - McLeod LL
AD  - Division of Hematology, Center for Biologics Evaluation and Research, Food and 
      Drug Administration, Bethesda, Maryland 20892, USA.
FAU - Alayash, A I
AU  - Alayash AI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Hemoglobins)
RN  - 0 (bis(3,5-dibromosalicyl)fumarate-crosslinked hemoglobin A(0))
RN  - 9008-37-1 (Methemoglobin)
RN  - 9034-51-9 (Hemoglobin A)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cattle
MH  - Cells, Cultured
MH  - Endothelium, Vascular/*cytology/*metabolism
MH  - Hemoglobin A/pharmacology
MH  - Hemoglobins/metabolism
MH  - Hydrogen Peroxide/metabolism
MH  - Hypoxia/*metabolism
MH  - Lipid Peroxidation
MH  - Methemoglobin/*isolation & purification/*metabolism
MH  - Oxygen/administration & dosage/*metabolism
MH  - Time Factors
EDAT- 1999/07/17 00:00
MHDA- 1999/07/17 00:01
CRDT- 1999/07/17 00:00
PHST- 1999/07/17 00:00 [pubmed]
PHST- 1999/07/17 00:01 [medline]
PHST- 1999/07/17 00:00 [entrez]
AID - 10.1152/ajpheart.1999.277.1.H92 [doi]
PST - ppublish
SO  - Am J Physiol. 1999 Jul;277(1):H92-9. doi: 10.1152/ajpheart.1999.277.1.H92.

PMID- 29464356
OWN - NLM
STAT- MEDLINE
DCOM- 20190212
LR  - 20190215
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Linking)
VI  - 20
IP  - 3
DP  - 2018 Feb 21
TI  - Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a 
      Rational Approach.
PG  - 15
LID - 10.1007/s11883-018-0717-y [doi]
AB  - PURPOSE OF REVIEW: The role of aspirin in secondary cardiovascular prevention is 
      well understood; however, the role in primary prevention is less clear, and 
      requires careful balancing of potential benefits with risks. Here, we summarize 
      the evidence base on the benefits and risks of aspirin therapy, discuss clinical 
      practice guidelines and decision support tools to assist in initiating aspirin 
      therapy, and highlight ongoing trials that may clarify the role of aspirin in 
      cardiovascular disease prevention. RECENT FINDINGS: In 2016, the USPSTF released 
      guidelines on the use of aspirin for primary prevention. Based on 11 trials 
      (n = 118,445), aspirin significantly reduced all-cause mortality and nonfatal 
      myocardial infarction, and in 7 trials that evaluated aspirin ≤ 100 mg/day, there 
      was significant reduction in nonfatal stroke. The USPSTF recommends 
      individualized use of aspirin based on factors including age, 10-year 
      atherosclerotic cardiovascular disease risk score, and bleeding risk. Several 
      ongoing trials are evaluating the role of aspirin in primary prevention, 
      secondary prevention, and in combination therapy for atrial fibrillation. 
      Evidence-based approaches to aspirin use should consider the anti-ischemic 
      benefits and bleeding risks from aspirin. In this era of precision medicine, 
      tools that provide the personalized benefit to risk assessment, such as the 
      freely available clinical decision support tool (Aspirin-Guide), can be easily 
      incorporated into the electronic health record and facilitate more informed 
      decisions about initiating aspirin therapy for primary prevention. Aspirin has a 
      complex matrix of benefits and risks, and its use in primary prevention requires 
      individualized decision-making. Results from ongoing trials may guide healthcare 
      providers in identifying appropriate candidates for aspirin therapy.
FAU - Dugani, Sagar
AU  - Dugani S
AD  - Department of Medicine, University of Toronto, Toronto, Canada.
AD  - Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
FAU - Ames, Jeffrey M
AU  - Ames JM
AD  - Department of Computer Science, Duke University, Durham, NC, USA.
FAU - Manson, JoAnn E
AU  - Manson JE
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, 
      MA, USA.
AD  - Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical 
      School, Boston, MA, USA.
FAU - Mora, Samia
AU  - Mora S
AD  - Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical 
      School, Boston, MA, USA. smora@bwh.harvard.edu.
AD  - Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's 
      Hospital and Harvard Medical School, Boston, MA, USA. smora@bwh.harvard.edu.
AD  - Center for Lipid Metabolomics, Division of Preventive Medicine, Division of 
      Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, 
      900 Commonwealth Ave E, 3rd Floor, Boston, MA, 02215, USA. smora@bwh.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180221
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/prevention & control
MH  - Hemorrhage/*etiology
MH  - Humans
MH  - Myocardial Ischemia/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention
MH  - Risk Assessment
MH  - Secondary Prevention
MH  - Stroke/prevention & control
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Cardiovascular risk reduction
OT  - Gastrointestinal bleeding
OT  - Primary prevention
OT  - Secondary prevention
EDAT- 2018/02/22 06:00
MHDA- 2019/02/13 06:00
CRDT- 2018/02/22 06:00
PHST- 2018/02/22 06:00 [entrez]
PHST- 2018/02/22 06:00 [pubmed]
PHST- 2019/02/13 06:00 [medline]
AID - 10.1007/s11883-018-0717-y [pii]
AID - 10.1007/s11883-018-0717-y [doi]
PST - epublish
SO  - Curr Atheroscler Rep. 2018 Feb 21;20(3):15. doi: 10.1007/s11883-018-0717-y.

PMID- 7970086
OWN - NLM
STAT- MEDLINE
DCOM- 19941129
LR  - 20220311
IS  - 0931-0509 (Print)
IS  - 0931-0509 (Linking)
VI  - 9
IP  - 6
DP  - 1994
TI  - Effect of aspirin and dipyridamole on proteinuria in idiopathic 
      membranoproliferative glomerulonephritis: a multicentre prospective clinical 
      trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS).
PG  - 619-22
AB  - Idiopathic membranoproliferative glomerulonephritis (MPGN) has a poor prognosis, 
      with 90% of patients requiring dialysis treatment after 20 years regardless of 
      therapy. Up to 34% of patients may die due to thrombotic complications or sepsis. 
      This study investigates the influence of aspirin plus dipyridamole on proteinuria 
      and renal function in nephrotic MPGN patients with moderately reduced glomerular 
      filtration rate. Eighteen patients with biopsy-proven MPGN (15 type I, 3 type II) 
      and nephrotic syndrome were randomly assigned to receive protein restriction, 
      antihypertensive therapy (control group) or in addition aspirin and dipyridamole 
      (treatment group). Patients were prospectively followed for a mean of 36 months. 
      Serum creatinine remained unchanged after 36 months compared to baseline in both 
      groups. In the treatment group proteinuria was reduced from 8.3 +/- 1.4 to 1.6 
      +/- 0.7 g/day (P < 0.05). In control patients proteinuria decreased from 7.1 +/- 
      1.6 to 4.3 +/- 1.1 g/day. After 36 months proteinuria was significantly lower in 
      the treatment group compared to control (P < 0.02 Mann-Whitney rank sum test). In 
      conclusion, aspirin plus dipyridamole may be of value in reversing nephrotic 
      syndrome and associated risks in patients with MPGN and moderately reduced renal 
      function.
FAU - Zäuner, I
AU  - Zäuner I
AD  - Department of Nephrology, University of Freiburg, Germany.
FAU - Böhler, J
AU  - Böhler J
FAU - Braun, N
AU  - Braun N
FAU - Grupp, C
AU  - Grupp C
FAU - Heering, P
AU  - Heering P
FAU - Schollmeyer, P
AU  - Schollmeyer P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Dietary Proteins)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Nephrol Dial Transplant 1994;9(10):1526
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antihypertensive Agents/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Pressure
MH  - Dietary Proteins/administration & dosage
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glomerulonephritis, Membranoproliferative/complications/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Proteinuria/*drug therapy/etiology
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1093/ndt/9.6.619 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 1994;9(6):619-22. doi: 10.1093/ndt/9.6.619.

PMID- 1396838
OWN - NLM
STAT- MEDLINE
DCOM- 19921118
LR  - 20190509
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 13
IP  - 9
DP  - 1992 Sep
TI  - Efficacy and safety of anticoagulant therapy started pre-operatively in 
      preventing coronary vein graft occlusion.
PG  - 1259-64
AB  - Oral anticoagulant therapy with warfarin commenced pre-operatively (n = 102) to 
      prevent coronary artery vein graft occlusions was compared in terms of efficacy 
      and safety with dipyridamole and aspirin (n = 130) in a randomized consecutive 
      series of patients. Anticoagulant therapy was started at least 2 weeks before 
      coronary artery bypass surgery (CABG) and antiplatelet therapy was started at 
      least 3 days before CABG with dipyridamole followed by a combination of 250 mg 
      aspirin once a day via a nasogastric tube 6 h after CABG. Overall, vein graft 
      patency at 3 months after surgery did not differ significantly between the 
      anticoagulant group (203/275, 74%) and dipyridamole-aspirin group (238/311, 77%), 
      but the occlusion rate for grafts with endarterectomy was higher in the 
      anticoagulant (46%) than in the dipyridamole and aspirin group (16%), (P less 
      than 0.05). The rate of peri-operative complications including deaths, 
      re-operation and myocardial infarction was higher in the anticoagulant than 
      antiplatelet group (26.5% vs 13.8%, P less than 0.05). The occurrence of 
      postoperative bleeding complications did not differ significantly between the 
      groups. Thus, oral anticoagulant therapy commenced pre-operatively has no 
      advantages over conventional antiplatelet therapy in patients who undergo CABG. 
      Neither antithrombotic regimens proved to be satisfactory for preventing acute 
      bypass vein graft occlusions in this patient population with advanced coronary 
      artery disease.
FAU - Yli-Mäyry, S
AU  - Yli-Mäyry S
AD  - Department of Medicine, Oulu University Central Hospital, Finland.
FAU - Huikuri, H V
AU  - Huikuri HV
FAU - Korhonen, U R
AU  - Korhonen UR
FAU - Airaksinen, K E
AU  - Airaksinen KE
FAU - Ikäheimo, M J
AU  - Ikäheimo MJ
FAU - Linnaluoto, M K
AU  - Linnaluoto MK
FAU - Takkunen, J T
AU  - Takkunen JT
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 1993 May;14(5):723. PMID: 8508869
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiac Catheterization
MH  - *Coronary Artery Bypass
MH  - Coronary Disease/blood/*surgery
MH  - Dipyridamole/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/blood/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Premedication
MH  - Reoperation
MH  - Warfarin/*administration & dosage/adverse effects
EDAT- 1992/09/01 00:00
MHDA- 1992/09/01 00:01
CRDT- 1992/09/01 00:00
PHST- 1992/09/01 00:00 [pubmed]
PHST- 1992/09/01 00:01 [medline]
PHST- 1992/09/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.eurheartj.a060346 [doi]
PST - ppublish
SO  - Eur Heart J. 1992 Sep;13(9):1259-64. doi: 
      10.1093/oxfordjournals.eurheartj.a060346.

PMID- 6344630
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 74
IP  - 6A
DP  - 1983 Jun 14
TI  - Aspirin and renal disease.
PG  - 97-101
AB  - Historic data has suggested a relationship between aspirin ingestion and the 
      subsequent occurrence of renal papillary necrosis. In most case reports, 
      analgesic mixtures containing aspirin, phenacetin, and caffeine were taken. This 
      resulted in the term "analgesic nephropathy." In clinical studies, phenacetin has 
      been the major common denominator, whereas experimental data in rats implicate 
      aspirin as the major nephrotoxin. Except with massive doses, attempts at 
      producing nephrotoxicity in laboratory animals with phenacetin have failed; 
      however, a high proportion of rats fed aspirin alone have developed renal 
      papillary necrosis. Acute reversible effects of aspirin on renal function in 
      patients with active lupus nephritis have been demonstrated. Data are presented 
      in 46 patients who took aspirin continuously for 10 or more years (mean total 
      dosage 35 kg) in whom there was no evidence of significant renal dysfunction. 
      These data suggest that, while aspirin may cause minor histologic or functional 
      renal abnormalities, it is unlikely that long-term salicylate consumption causes 
      serious renal disease.
FAU - Emkey, R D
AU  - Emkey RD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects
MH  - Aspirin/*adverse effects
MH  - Drug Synergism
MH  - Humans
MH  - Kidney Diseases/*chemically induced/pathology/physiopathology
MH  - Time Factors
RF  - 65
EDAT- 1983/06/14 00:00
MHDA- 1983/06/14 00:01
CRDT- 1983/06/14 00:00
PHST- 1983/06/14 00:00 [pubmed]
PHST- 1983/06/14 00:01 [medline]
PHST- 1983/06/14 00:00 [entrez]
AID - 0002-9343(83)90536-3 [pii]
AID - 10.1016/0002-9343(83)90536-3 [doi]
PST - ppublish
SO  - Am J Med. 1983 Jun 14;74(6A):97-101. doi: 10.1016/0002-9343(83)90536-3.

PMID- 2305539
OWN - NLM
STAT- MEDLINE
DCOM- 19900316
LR  - 20190713
IS  - 0090-4295 (Print)
IS  - 0090-4295 (Linking)
VI  - 35
IP  - 2
DP  - 1990 Feb
TI  - Large perirenal hematoma after extracorporeal shock-wave lithotripsy.
PG  - 151-3
AB  - We report a case of a large perirenal hematoma following extracorporeal 
      shock-wave lithotripsy (ESWL) that resulted in compromised renal blood flow and 
      function and necessitated open surgical drainage. Caution is advised and close 
      follow-up recommended in patients who have taken aspirin-containing compounds, 
      are elderly, have hypertension, or exhibit a significant drop in hematocrit 
      following ESWL.
FAU - Knorr, P A
AU  - Knorr PA
AD  - Division of Urology, University of New Mexico, School of Medicine, Albuquerque.
FAU - Woodside, J R
AU  - Woodside JR
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage
MH  - Blood Coagulation/drug effects
MH  - Hematoma/*etiology
MH  - Humans
MH  - Kidney Calculi/therapy
MH  - Kidney Diseases/*etiology
MH  - Lithotripsy/*adverse effects
MH  - Male
EDAT- 1990/02/01 00:00
MHDA- 1990/02/01 00:01
CRDT- 1990/02/01 00:00
PHST- 1990/02/01 00:00 [pubmed]
PHST- 1990/02/01 00:01 [medline]
PHST- 1990/02/01 00:00 [entrez]
AID - 0090-4295(90)80065-U [pii]
AID - 10.1016/0090-4295(90)80065-u [doi]
PST - ppublish
SO  - Urology. 1990 Feb;35(2):151-3. doi: 10.1016/0090-4295(90)80065-u.

PMID- 17546571
OWN - NLM
STAT- MEDLINE
DCOM- 20071011
LR  - 20151119
IS  - 1053-8569 (Print)
IS  - 1053-8569 (Linking)
VI  - 16
IP  - 7
DP  - 2007 Jul
TI  - Antipyretic drug use in children in French office based medical practice.
PG  - 812-7
AB  - PURPOSE: To analyse antipyretics (APs) prescriptions profile in children, 
      particularly the frequency of AP combinations. METHODS: APs (acetylsalicylic 
      acid, paracetamol, ibuprofen or ketoprofen) prescribed to children below 12 years 
      and refunded by a public health insurer in 2003, throughout France, were 
      examined. RESULTS: A total of 513 034 prescriptions were refunded for 240 720 
      children. The mean number of AP prescriptions per child was the highest in 
      children aged 6 months to 2 years. Paracetamol was the main AP prescribed, but 
      its prescription declined with age, from 90.8% below 3 months old to 57.4% 
      between 6 and 12 years old. Ibuprofen-only prescriptions were rare below 3 months 
      and maximal between 2 and 6 years. The ibuprofen/paracetamol combination was 
      prescribed from 6 months old, and its frequency was maximal between 2 and 6 years 
      old (21.7%). CONCLUSIONS: The clear predominance of paracetamol prescriptions 
      suggests that French prescribers are relatively aware of the relative 
      risk-benefit ratio of the different APs. Studies are required to determine if the 
      APs are prescribed to be used alternately or when a monotherapy fails. Guidelines 
      to manage fever in children are needed in France to restrict APs combination to 
      the case of paracetamol failure.
FAU - Deligne, Jean
AU  - Deligne J
AD  - CANAM, Caisse Nationale d'Assurance Maladie des Professions Indépendantes, 
      France.
FAU - Grimaldi, Lamiae
AU  - Grimaldi L
FAU - Jonville-Béra, Annie-Pierre
AU  - Jonville-Béra AP
FAU - Giraudeau, Bruno
AU  - Giraudeau B
FAU - Blum-Boisgard, Claudine
AU  - Blum-Boisgard C
FAU - Autret-Leca, Elisabeth
AU  - Autret-Leca E
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/adverse effects/therapeutic use
MH  - Age Factors
MH  - Analgesics, Non-Narcotic/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Drug Therapy, Combination
MH  - Fever/*drug therapy
MH  - France
MH  - Humans
MH  - Ibuprofen/adverse effects/therapeutic use
MH  - Infant
MH  - Infant, Newborn
MH  - Ketoprofen/adverse effects/therapeutic use
MH  - Physicians' Offices
MH  - Practice Guidelines as Topic
MH  - Practice Patterns, Physicians'/*statistics & numerical data
EDAT- 2007/06/05 09:00
MHDA- 2007/10/12 09:00
CRDT- 2007/06/05 09:00
PHST- 2007/06/05 09:00 [pubmed]
PHST- 2007/10/12 09:00 [medline]
PHST- 2007/06/05 09:00 [entrez]
AID - 10.1002/pds.1422 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):812-7. doi: 10.1002/pds.1422.

PMID- 15367482
OWN - NLM
STAT- MEDLINE
DCOM- 20050608
LR  - 20131121
IS  - 0263-2136 (Print)
IS  - 0263-2136 (Linking)
VI  - 21
IP  - 5
DP  - 2004 Oct
TI  - The challenge of secondary prevention for coronary heart disease in older 
      patients: findings from the British Women's Heart and Health Study and the 
      British Regional Heart Study.
PG  - 582-6
AB  - BACKGROUND: Secondary prevention of coronary heart disease (CHD) among older 
      individuals is associated with considerable benefit. METHODS: In this study, we 
      have examined the extent of secondary prevention among British women and men aged 
      60-79 years who were surveyed and examined between 1998 and 2001. RESULTS: Among 
      483 women (12.1% of the whole sample) and 831 men (19.5%) with CHD, >90% of both 
      sexes had at least one modifiable risk factor, with over two-fifths having high 
      blood pressure and over three-quarters high cholesterol. For total cholesterol 
      and body mass index, mean values in both male and female subjects were above 
      recommended levels, and a large shift in the population distributions would be 
      required for targets to be met. Less than one-quarter of subjects of either sex 
      were on a statin, and whilst the majority of men were taking an antiplatelet 
      medication, only 40% of women were. CONCLUSIONS: Most older women and men in 
      Britain were failing to meet National Service Framework standards for secondary 
      prevention in the period immediately before its implementation. Large shifts in 
      the population distributions of some risk factors would be required in this group 
      to meet these standards.
FAU - Lawlor, Debbie A
AU  - Lawlor DA
AD  - Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies 
      Road, Bristol BS8 2PR. d.a.lawlor@bristol.ac.uk
FAU - Whincup, Peter
AU  - Whincup P
FAU - Emberson, Jonathan R
AU  - Emberson JR
FAU - Rees, Karen
AU  - Rees K
FAU - Walker, Mary
AU  - Walker M
FAU - Ebrahim, Shah
AU  - Ebrahim S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Fam Pract
JT  - Family practice
JID - 8500875
RN  - 0 (Anticholesteremic Agents)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticholesteremic Agents/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Pressure
MH  - Cardiovascular Diseases/blood/epidemiology/*prevention & control
MH  - Cholesterol/blood
MH  - England/epidemiology
MH  - Female
MH  - Health Surveys
MH  - Humans
MH  - Male
MH  - Patient Compliance
MH  - Risk Factors
MH  - Scotland/epidemiology
MH  - Wales/epidemiology
EDAT- 2004/09/16 05:00
MHDA- 2005/06/09 09:00
CRDT- 2004/09/16 05:00
PHST- 2004/09/16 05:00 [pubmed]
PHST- 2005/06/09 09:00 [medline]
PHST- 2004/09/16 05:00 [entrez]
AID - 21/5/582 [pii]
AID - 10.1093/fampra/cmh516 [doi]
PST - ppublish
SO  - Fam Pract. 2004 Oct;21(5):582-6. doi: 10.1093/fampra/cmh516.

PMID- 31348582
OWN - NLM
STAT- MEDLINE
DCOM- 20191213
LR  - 20200108
IS  - 1099-0461 (Electronic)
IS  - 1095-6670 (Linking)
VI  - 33
IP  - 9
DP  - 2019 Sep
TI  - Ameliorative role of aspirin in paraquat-induced lung toxicity via mitochondrial 
      mechanisms.
PG  - e22370
LID - 10.1002/jbt.22370 [doi]
AB  - Paraquat (PQ) has accounted for numerous suicide attempts in developing 
      countries. Aspirin (ASA) as an adjuvant treatment in PQ poisoning has an 
      ameliorative role. And, it's uncoupling of mitochondrial oxidative 
      phosphorylation role has been well established. The current study aimed at 
      examining the aspirin mechanism on lung mitochondria of rats exposed to PQ. Male 
      rats were randomly allocated in five groups: Control group, PQ group (50 mg/kg; 
      orally, only on the first day), and PQ + ASA (100, 200, and 400 mg/kg; i.p.) 
      groups for 3 weeks. Mitochondrial indices and respiratory chain-complex 
      activities were determined. PQ induced lung interstitial fibrosis; however, ASA 
      (400 mg/kg) led to decrease in this abnormal alteration. In comparison with PQ 
      group, complex II and IV activity, and adenosine triphosphate content in ASA 
      groups had significantly increased; however, reactive oxygen species production, 
      mitochondrial membrane permeabilization, and mitochondrial swelling were 
      significantly reduced. In conclusion, aspirin can alleviate lung injury induced 
      by PQ poisoning by improving mitochondrial dynamics.
CI  - © 2019 Wiley Periodicals, Inc.
FAU - Marashi, Sayed Mahdi
AU  - Marashi SM
AD  - Forensic Medicine and Clinical Toxicology, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
AD  - Blood Transfusion Research Center, High Institute for Research and Education in 
      Transfusion Medicine, Tehran, Iran.
AD  - Tehran Blood Transfusion Center, Tehran, Iran.
FAU - Hosseini, Seyede Fatemeh
AU  - Hosseini SF
AD  - Department of Anatomy, School of Medicine, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Hosseinzadeh, Massood
AU  - Hosseinzadeh M
AD  - Department of Pathology, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
FAU - Qadir, Muhammad Farhan
AU  - Qadir MF
AD  - College of Animal Science and Veterinary Medicine, Shanxi Agricultural 
      University, Taigu, China.
FAU - Khodaei, Forouzan
AU  - Khodaei F
AUID- ORCID: 0000-0001-5950-4930
AD  - Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University 
      of Medical Sciences, Shiraz, Iran.
AD  - College of Animal Science and Veterinary Medicine, Shanxi Agricultural 
      University, Taigu, China.
LA  - eng
GR  - # 95-01-36-13129/Shiraz University of Medical Sciences/
PT  - Journal Article
DEP - 20190726
PL  - United States
TA  - J Biochem Mol Toxicol
JT  - Journal of biochemical and molecular toxicology
JID - 9717231
RN  - 0 (Herbicides)
RN  - 0 (Reactive Oxygen Species)
RN  - PLG39H7695 (Paraquat)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Herbicides/administration & dosage/*toxicity
MH  - Lung/*drug effects/metabolism/pathology
MH  - Male
MH  - Membrane Potential, Mitochondrial/drug effects
MH  - Mitochondria/*drug effects/enzymology/metabolism
MH  - Paraquat/administration & dosage/*toxicity
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reactive Oxygen Species/metabolism
OTO - NOTNLM
OT  - aspirin
OT  - lung injury
OT  - mitochondrial respiratory chain
OT  - oxidative stress biomarkers
OT  - paraquat poisoning
EDAT- 2019/07/28 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/07/27 06:00
PHST- 2019/02/06 00:00 [received]
PHST- 2019/05/23 00:00 [revised]
PHST- 2019/06/17 00:00 [accepted]
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/07/27 06:00 [entrez]
AID - 10.1002/jbt.22370 [doi]
PST - ppublish
SO  - J Biochem Mol Toxicol. 2019 Sep;33(9):e22370. doi: 10.1002/jbt.22370. Epub 2019 
      Jul 26.

PMID- 28695614
OWN - NLM
STAT- MEDLINE
DCOM- 20180510
LR  - 20181113
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Print)
IS  - 0269-4727 (Linking)
VI  - 42
IP  - 5
DP  - 2017 Oct
TI  - Use of anti-inflammatory analgesics in sickle-cell disease.
PG  - 656-660
LID - 10.1111/jcpt.12592 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Non-steroidal anti-inflammatory drugs (NSAIDs) have 
      been commonly used to treat pain in sickle-cell disease (SCD), but NSAID use is 
      associated with renal, gastrointestinal and cardiovascular toxicities. Our 
      objective was to evaluate the use of aspirin and non-aspirin NSAIDs in SCD. 
      COMMENT: Despite analgesic and anti-inflammatory benefits in SCD, non-aspirin 
      NSAIDs are associated with renal, cardiovascular and gastrointestinal toxicities 
      in this patient population. Aspirin may have less renal and cardiovascular 
      toxicities. The different side effect profile of NSAIDs is related to the 
      COX-1/COX-2 selectivity at their therapeutic doses. Individual risk factors and 
      genetic biomarkers should be considered when selecting appropriate NSAIDs and 
      their dose. WHAT IS NEW AND CONCLUSION: NSAIDs have the potential to be an 
      important component of pain regimens in SCD, but the use of NSAIDs should be 
      individualized based on potential side effects and patient risk factors and the 
      lowest effective dose should be prescribed with proper monitoring in patients 
      with SCD.
CI  - © 2017 John Wiley & Sons Ltd.
FAU - Han, J
AU  - Han J
AD  - Department of Pharmacy Practice, College of Pharmacy, University of Illinois at 
      Chicago, Chicago, IL, USA.
AD  - Comprehensive Sickle Cell Center, Section of Hematology/Oncology, Department of 
      Medicine, University of Illinois at Chicago, Chicago, IL, USA.
AD  - Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of 
      Illinois at Chicago, Chicago, IL, USA.
FAU - Saraf, S L
AU  - Saraf SL
AD  - Comprehensive Sickle Cell Center, Section of Hematology/Oncology, Department of 
      Medicine, University of Illinois at Chicago, Chicago, IL, USA.
FAU - Lash, J P
AU  - Lash JP
AD  - Section of Nephrology, Department of Medicine, University of Illinois at Chicago, 
      Chicago, IL, USA.
FAU - Gordeuk, V R
AU  - Gordeuk VR
AD  - Comprehensive Sickle Cell Center, Section of Hematology/Oncology, Department of 
      Medicine, University of Illinois at Chicago, Chicago, IL, USA.
LA  - eng
GR  - K23 HL125984/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20170710
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Genetic Markers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anemia, Sickle Cell/complications/*drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Monitoring/methods
MH  - Genetic Markers
MH  - Humans
MH  - Pain/*drug therapy/etiology
MH  - Risk Factors
PMC - PMC5774978
MID - NIHMS916590
OTO - NOTNLM
OT  - analgesics
OT  - anti-inflammatory
OT  - aspirin
OT  - non-steroidal anti-inflammatory
OT  - non-steroidal anti-inflammatory drugs
OT  - renal
OT  - sickle
EDAT- 2017/07/12 06:00
MHDA- 2018/05/11 06:00
CRDT- 2017/07/12 06:00
PHST- 2017/02/23 00:00 [received]
PHST- 2017/06/19 00:00 [accepted]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2018/05/11 06:00 [medline]
PHST- 2017/07/12 06:00 [entrez]
AID - 10.1111/jcpt.12592 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2017 Oct;42(5):656-660. doi: 10.1111/jcpt.12592. Epub 2017 Jul 
      10.

PMID- 37653760
OWN - NLM
STAT- MEDLINE
DCOM- 20230904
LR  - 20230905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 102
IP  - 34
DP  - 2023 Aug 25
TI  - Clinical efficacy of low-dose aspirin combined with calcium in preventing 
      preeclampsia: A systematic review and meta-analysis.
PG  - e34620
LID - 10.1097/MD.0000000000034620 [doi]
LID - e34620
AB  - OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the 
      clinical effectiveness of low-dose aspirin combined with calcium supplements for 
      the prevention of preeclampsia. METHODS: China National Knowledge Infrastructure, 
      VIP, Wanfang, PubMed, EMBASE, and Cochrane Library databases were searched from 
      inception until December 2022. Randomized controlled trials investigating the 
      preventive use of aspirin in combination with calcium supplementation for 
      preeclampsia in high-risk pregnant women were included. The quality of the 
      literature was evaluated, and a meta-analysis was conducted using RevMan 5.3 
      software to analyze the clinical efficacy of low-dose aspirin combined with 
      calcium supplementation in preventing preeclampsia. RESULTS: Seven randomized 
      controlled trials were included in this meta-analysis, and compared with the 
      control group, the experimental group had lower incidence rates of preeclampsia 
      with gestational hypertension (odds ratios [OR]: 0.17, 95% confidence interval 
      [CI]: 0.11-0.28), preeclampsia (OR: 0.20, 95% CI: 0.10-0.37), gestational 
      hypertension (OR: 0.15, 95% CI: 0.07-0.31), preterm birth (OR: 0.26, 95% CI: 
      0.16-0.44), postpartum hemorrhage (OR: 0.15, 95% CI: 0.08-0.27), and fetal growth 
      restriction (OR: 0.16, 95% CI: 0.08-0.33). CONCLUSION: Compared with aspirin 
      alone, low-dose aspirin combined with calcium supplementation was more effective 
      in preventing preeclampsia, reduced the risk of preterm birth and postpartum 
      hemorrhage, and promoted fetal growth. This intervention has clinical value and 
      should be considered for high-risk pregnant women.
CI  - Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Chen, Wen-Yue
AU  - Chen WY
AUID- ORCID: 0000-0002-8576-0935
AD  - Department of Obstetrical, Hangzhou Fuyang District First People's Hospital, 
      Hangzhou, Zhejiang, China.
FAU - Sun, Su-Fang
AU  - Sun SF
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - SY7Q814VUP (Calcium)
RN  - 0 (Calcium, Dietary)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Infant, Newborn
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - Calcium
MH  - *Pre-Eclampsia/prevention & control
MH  - *Hypertension, Pregnancy-Induced/prevention & control
MH  - *Postpartum Hemorrhage
MH  - *Premature Birth
MH  - Calcium, Dietary
MH  - Aspirin/therapeutic use
MH  - Treatment Outcome
MH  - Randomized Controlled Trials as Topic
PMC - PMC10470755
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2023/09/01 06:43
MHDA- 2023/09/04 06:42
CRDT- 2023/09/01 01:43
PHST- 2023/09/04 06:42 [medline]
PHST- 2023/09/01 06:43 [pubmed]
PHST- 2023/09/01 01:43 [entrez]
AID - 00005792-202308250-00032 [pii]
AID - 10.1097/MD.0000000000034620 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2023 Aug 25;102(34):e34620. doi: 
      10.1097/MD.0000000000034620.

PMID- 20597268
OWN - NLM
STAT- MEDLINE
DCOM- 20100816
LR  - 20161125
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 82
IP  - 5
DP  - 2010
TI  - [Recurrent thromboses and hemorrhagic complications in patients with 
      antiphospholipid syndrome during therapy with warfarin plus aspirin].
PG  - 33-9
AB  - AIM: To estimate the frequency of relapses of thrombotic and hemorrhagic 
      complications during moderately intensive therapy for antiphospholipid syndrome 
      (APS) with warfarin with and without aspirin. SUBJECTS AND METHODS: Eighty-two 
      patients diagnosed as having the antiphospholipid syndrome were examined. Group 1 
      patients (n = 49) received warfarin alone as an antithrombotic drug; Group 2 
      patients (n = 33) had a combination therapy with warfarin plus aspirin. The 
      efficiency of therapy was evaluated from the number and rate of recurrences of 
      thromboses and transient ischemic attacks (TIA) and its safety was assessed from 
      the frequency and number of hemorrhages during the study. The genetic variants of 
      cytochrome P450 CYP2C9 were determined in 52 of the 82 patients; mutations in the 
      gene for vitamin K epoxide reductase complex 1 (VCORC1) were revealed in 22 
      patients. RESULTS: During the follow-up, antithrombotic therapy was ineffective 
      in 18.4 and 36.6% of the Groups 1 and 2 patients, respectively (p = 0.07). The 
      rate of poor outcomes (thromboses and TIA) was 7 and 14.8 cases per 100 
      person-years, respectively. The first six months of warfarin therapy proved to be 
      most risky for thrombotic events to occur--this period was responsible for 37% of 
      bleedings. Hemorrhagic complications of antithrombotic therapy developed in 46.9 
      and 60.6% of Groups 1 and 2 patients, respectively (p = 0.26). Major hemorrhages 
      were observed more frequently in the combination (warfarin plus low-dose aspirin) 
      therapy group than in the warfarin monotherapy group. Mutant cytochrome P450 gene 
      variants (CYP2C9*2 and CYP2C9*3) were present in 38.5% of the patients; VCORC1 
      gene mutations were observed in 27.3%. The number of nasal and gingival 
      hemorrhages was increased in patients with CYP2C9*3 and homozygous VCORC1 gene 
      mutations. CONCLUSION: Moderately intensive warfarin therapy (international 
      normalized ratio 2.0-3.0) could generally reduce the frequency of recurrent 
      thrombotic events by at least 2-fold as compared with that before warfarin 
      administration. The efficiency of using warfarin alone or in combination with 
      aspirin in APS was found to be similar; and its safety was higher during 
      monotherapy therefore it is undesirable to combine warfarin with antiaggregants 
      in real clinical practice. The determination of CYP2C9 and VCORC1 genotypes in 
      patients with APS before warfarin use allows excessive hypocoagulation and 
      related hemorrhages to be avoided.
FAU - Kondrat'eva, L V
AU  - Kondrat'eva LV
FAU - Patrusheva, N L
AU  - Patrusheva NL
FAU - Patrushev, L I
AU  - Patrushev LI
FAU - Aleksandrova, E N
AU  - Aleksandrova EN
FAU - Kovalenko, T F
AU  - Kovalenko TF
FAU - Ostriakova, E V
AU  - Ostriakova EV
FAU - Reshetniak, T M
AU  - Reshetniak TM
LA  - rus
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - EC 1.14.13.- (CYP2C9 protein, human)
RN  - EC 1.14.13.- (Cytochrome P-450 CYP2C9)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.17.4.4 (Vitamin K Epoxide Reductases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Antiphospholipid Syndrome/complications/*drug therapy/epidemiology/genetics
MH  - Aryl Hydrocarbon Hydroxylases/genetics
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Coagulation/drug effects/genetics
MH  - Cytochrome P-450 CYP2C9
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genetic Variation
MH  - Hemorrhage/*chemically induced/epidemiology/genetics
MH  - Humans
MH  - Male
MH  - Mixed Function Oxygenases/genetics
MH  - Secondary Prevention
MH  - Thrombosis/epidemiology/etiology/genetics/*prevention & control
MH  - Vitamin K Epoxide Reductases
MH  - Warfarin/administration & dosage/adverse effects/*therapeutic use
EDAT- 2010/07/06 06:00
MHDA- 2010/08/17 06:00
CRDT- 2010/07/06 06:00
PHST- 2010/07/06 06:00 [entrez]
PHST- 2010/07/06 06:00 [pubmed]
PHST- 2010/08/17 06:00 [medline]
PST - ppublish
SO  - Ter Arkh. 2010;82(5):33-9.

PMID- 15753757
OWN - NLM
STAT- MEDLINE
DCOM- 20050408
LR  - 20191210
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 33
IP  - 3
DP  - 2005 Mar
TI  - Influence of heme-based solutions on stress protein expression and organ failure 
      after hemorrhagic shock.
PG  - 629-37
AB  - OBJECTIVE: Hemoglobin-based oxygen carriers (e.g., diaspirin-cross-linked 
      hemoglobin [DCLHb] and hemoglobin glutamer-200 [HbG]) may have potential in the 
      treatment of hemorrhagic shock. The nitric oxide scavenging and direct 
      vasoconstrictive side effects of free hemoglobin of currently available 
      preparations may increase organ injury after shock in contrast to 
      non-oxygen-carrying heme solutions (e.g., hemin arginate [HAR]). However, both 
      classes of substances might induce the protective enzyme heme oxygenase (HO)-1, 
      particularly in the liver. The aim of the study was to assess the role of 
      pretreatment with DCLHb, HbG, or HAR on HO-1 expression and organ injury after 
      hemorrhagic shock. DESIGN: Prospective controlled laboratory study. SETTING: 
      Animal research laboratory at a university hospital. SUBJECTS: Male 
      Sprague-Dawley rats (200-300 g body weight, n = 5-12/group). INTERVENTIONS: 
      Twenty-four hours after different doses of DCLHb, HbG (each 1, 2, or 3 g/kg of 
      body weight), or HAR (5, 25, or 75 mg/kg of body weight), the protein expression 
      of HO-1 and heat shock protein-70 in liver, kidney, heart, lungs, and aorta was 
      determined. Twenty-four hours after pretreatment with DCLHb, HbG, or HAR, rats 
      were subjected to hemorrhage (mean arterial blood pressure, 35-40 mm Hg for 1 or 
      2 hrs)/resuscitation (5 or 4 hrs, respectively). Animals treated with Ringer's 
      solution (30 mL/kg of body weight) served as controls. In additional experiments, 
      HO activity was blocked with tin mesoporphyrin-IX. MEASUREMENTS AND MAIN RESULTS: 
      DCLHb, HbG, and HAR dose-dependently induced HO-1 protein but not heat shock 
      protein-70. Pretreatment with DCLHb or HbG shortened the onset of decompensation 
      in shock (DCLHb, 40 +/- 11 mins; HbG, 36 +/- 4 mins) compared with vehicle (68 
      +/- 4 mins, p < .05) and HAR pretreatment (81 +/- 7 mins, p < .05). High doses of 
      DCLHb pretreatment increased mortality (2 hrs of shock, 80%; p < .05 vs. vehicle 
      or HAR). Pretreatment with HAR led to higher shed blood volumes (p < .05) and 
      higher hepatocellular ATP levels (2 hrs of shock, p < .05 vs. DCLHb and HbG). 
      Blockade of HO activity by tin mesoporphyrin-IX abolished the protection mediated 
      by HAR. CONCLUSIONS: Although DCLHb, HbG, and HAR induce HO-1 in the absence of 
      an unspecific stress response, only HAR pretreatment protects against 
      shock-induced organ failure. Although the underlying mechanisms of positive HAR 
      priming are not completely understood, the induction of HO-1 expression and the 
      lack of nitric oxide scavenging through HAR may play an important role.
FAU - Kubulus, Darius
AU  - Kubulus D
AD  - Department of Anesthesiology and Critical Care Medicine, University of the 
      Saarland, Homburg, Germany.
FAU - Rensing, Hauke
AU  - Rensing H
FAU - Paxian, Markus
AU  - Paxian M
FAU - Thierbach, Jan-Tobias
AU  - Thierbach JT
FAU - Meisel, Tanja
AU  - Meisel T
FAU - Redl, Heinz
AU  - Redl H
FAU - Bauer, Michael
AU  - Bauer M
FAU - Bauer, Inge
AU  - Bauer I
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Blood Substitutes)
RN  - 0 (HSP70 Heat-Shock Proteins)
RN  - 0 (Hemoglobins)
RN  - 0 (hemoglobin glutamer-200)
RN  - 743LRP9S7N (Hemin)
RN  - EC 1.14.14.18 (Heme Oxygenase (Decyclizing))
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Crit Care Med. 2005 Mar;33(3):694-5. PMID: 15753779
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology/*therapeutic use
MH  - Blood Substitutes/pharmacology/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - HSP70 Heat-Shock Proteins/drug effects/metabolism
MH  - Heme Oxygenase (Decyclizing)/*drug effects/metabolism
MH  - Heme Oxygenase-1
MH  - Hemin/*analogs & derivatives/pharmacology/*therapeutic use
MH  - Hemoglobins/pharmacology/*therapeutic use
MH  - Liver/drug effects/metabolism
MH  - Liver Failure/physiopathology
MH  - Male
MH  - Prospective Studies
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Shock, Hemorrhagic/*drug therapy/mortality
MH  - Survival Analysis
EDAT- 2005/03/09 09:00
MHDA- 2005/04/09 09:00
CRDT- 2005/03/09 09:00
PHST- 2005/03/09 09:00 [pubmed]
PHST- 2005/04/09 09:00 [medline]
PHST- 2005/03/09 09:00 [entrez]
AID - 00003246-200503000-00023 [pii]
AID - 10.1097/01.ccm.0000156295.48075.49 [doi]
PST - ppublish
SO  - Crit Care Med. 2005 Mar;33(3):629-37. doi: 10.1097/01.ccm.0000156295.48075.49.

PMID- 31787248
OWN - NLM
STAT- MEDLINE
DCOM- 20200429
LR  - 20200429
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 125
IP  - 3
DP  - 2020 Feb 1
TI  - Relation of Hypoalbuminemia to Response to Aspirin in Patients With Stable 
      Coronary Artery Disease.
PG  - 303-308
LID - S0002-9149(19)31248-2 [pii]
LID - 10.1016/j.amjcard.2019.10.055 [doi]
AB  - Serum albumin (SA) level is a powerful cardiovascular prognostic marker, 
      suggested to be involved in regulation of platelet function. High on-aspirin 
      platelet reactivity (HAPR) is associated with increased risk for deleterious 
      cardiovascular events. The aim of the present study was to evaluate the 
      association between HAPR and albumin levels in patients with stable coronary 
      artery disease (CAD) treated with aspirin. Patients with known stable CAD, who 
      were taking aspirin (75 to 100 mg qd) regularly for at least 1 month, were 
      screened for the present study. Exclusion criteria: cancer, sepsis or acute 
      infection, active inflammatory/rheumatic disease, recent major surgery, chronic 
      liver failure, the administration of other antiplatelet drugs, nonadherence with 
      aspirin and thrombocytopenia. Blood was drawn from the participants and sent for 
      SA level and platelet function test (VerifyNow). HAPR was defined as aspirin 
      reaction units (ARU) >550. Overall 116 patients were analyzed; age 69 ± 10, 28% 
      women. Twenty (17%) were hypoalbuminemic (≤3.5 g/dl). Hypoalbuminemic patients 
      had similar characteristics to the normal albumin group except mildly higher 
      creatinine in the former. SA levels were significantly lower in the 
      hypoalbuminemic group (3.2 ± 0.2 g/dl vs 4.2 ± 0.4 g/dl, respectively, p <0.001) 
      whereas mean ARU was significantly higher compared with the normal albumin group 
      (548 ± 45 vs 444 ± 66 ARU, respectively, p <0.001). A significant inverse 
      association was observed between SA and ARU with (R(2) = 0.67, p <0.001). 
      Multivariate analysis adjusted for potential confounders found that albumin ≤3.5 
      is the strongest predictor of HAPR in patients with stable CAD (hazards ratio 
      4.9, 95% confidence interval 2.2 to 32, p = 0.002). In conclusion, 
      hypoalbuminemia is strongly associated with HAPR in patients with stable CAD.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Shiyovich, Arthur
AU  - Shiyovich A
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      Israel; "Sackler" Faculty of Medicine, Tel-Aviv University Israel, Tel Aviv-Yafo, 
      Israel.
FAU - Sasson, Liat
AU  - Sasson L
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      Israel; "Sackler" Faculty of Medicine, Tel-Aviv University Israel, Tel Aviv-Yafo, 
      Israel.
FAU - Lev, Eli
AU  - Lev E
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      Israel; "Sackler" Faculty of Medicine, Tel-Aviv University Israel, Tel Aviv-Yafo, 
      Israel.
FAU - Solodky, Alejandro
AU  - Solodky A
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      Israel; "Sackler" Faculty of Medicine, Tel-Aviv University Israel, Tel Aviv-Yafo, 
      Israel.
FAU - Kornowski, Ran
AU  - Kornowski R
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      Israel; "Sackler" Faculty of Medicine, Tel-Aviv University Israel, Tel Aviv-Yafo, 
      Israel.
FAU - Perl, Leor
AU  - Perl L
AD  - Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 
      Israel; "Sackler" Faculty of Medicine, Tel-Aviv University Israel, Tel Aviv-Yafo, 
      Israel.
LA  - eng
PT  - Journal Article
DEP - 20191107
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Serum Albumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Biomarkers/blood
MH  - Coronary Artery Disease/blood/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypoalbuminemia/blood/*chemically induced
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
MH  - Serum Albumin/drug effects/*metabolism
EDAT- 2019/12/04 06:00
MHDA- 2020/04/30 06:00
CRDT- 2019/12/03 06:00
PHST- 2019/09/09 00:00 [received]
PHST- 2019/10/26 00:00 [revised]
PHST- 2019/10/30 00:00 [accepted]
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2020/04/30 06:00 [medline]
PHST- 2019/12/03 06:00 [entrez]
AID - S0002-9149(19)31248-2 [pii]
AID - 10.1016/j.amjcard.2019.10.055 [doi]
PST - ppublish
SO  - Am J Cardiol. 2020 Feb 1;125(3):303-308. doi: 10.1016/j.amjcard.2019.10.055. Epub 
      2019 Nov 7.

PMID- 19709095
OWN - NLM
STAT- MEDLINE
DCOM- 20100512
LR  - 20131121
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 31
IP  - 1
DP  - 2010 Jan
TI  - Predictors of gastroduodenal erosions in patients taking low-dose aspirin.
PG  - 143-9
LID - 10.1111/j.1365-2036.2009.04133.x [doi]
AB  - BACKGROUND: Gastroduodenal ulcers are common in patients taking low-dose aspirin. 
      However, the factors predisposing to mucosal erosions, the precursor lesions, are 
      not well known. AIMS: To examine the potential risk factors for the development 
      of erosions in patients chronically taking low-dose aspirin. METHODS: Patients 
      included were taking aspirin 75-325 mg daily for >28 days. Exclusion criteria 
      included use of nonsteroidal anti-inflammatory and ulcer-healing drugs. 
      Demographic data were collected at baseline, prior to endoscopy to determine the 
      frequency and number of erosions and Helicobacter pylori status. In those without 
      ulcer or other exclusions, endoscopy was repeated at 3 months. RESULTS: Fewer 
      patients had gastric erosions if they were H. pylori +ve (48.5% vs. 66.4% in H. 
      pylori-ve patients at baseline, P = 0.17; 40.0% vs. 64.1% at 3 months, P = 
      0.029). If gastric erosions were present, they were also less numerous in H. 
      pylori +ve patients (3.61 +/- 0.83 vs. 4.90 +/- 0.53 at baseline, P = 0.026; 2.17 
      +/- 0.68 vs. 5.68 +/- 0.86 at 3 months, P = 0.029). There was a trend (0.1 > P > 
      0.05) for more gastric erosions in those taking >100 mg/day aspirin. Males had 
      more duodenal erosions at baseline (25.2% vs. 7.5%, P = 0.016). Patient age did 
      not affect the presence or number of erosions. H. Pylori was not significantly 
      associated with duodenal erosion numbers. CONCLUSIONS: Helicobacter pylori 
      infection may partially protect against low-dose aspirin-induced gastric 
      erosions; damage to the stomach appears weakly dose-related; and older age does 
      not increase the risk of erosions.
FAU - Hart, J
AU  - Hart J
AD  - Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia. 
      john.hart@doctors.org.uk
FAU - Hawkey, C J
AU  - Hawkey CJ
FAU - Lanas, A
AU  - Lanas A
FAU - Naesdal, J
AU  - Naesdal J
FAU - Talley, N J
AU  - Talley NJ
FAU - Thomson, A B R
AU  - Thomson AB
FAU - Yeomans, N D
AU  - Yeomans ND
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Endoscopy
MH  - Female
MH  - Gastric Mucosa/drug effects/*pathology
MH  - Helicobacter Infections/*pathology
MH  - Helicobacter pylori
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Stomach Ulcer/*chemically induced
EDAT- 2009/08/28 09:00
MHDA- 2010/05/13 06:00
CRDT- 2009/08/28 09:00
PHST- 2009/08/28 09:00 [entrez]
PHST- 2009/08/28 09:00 [pubmed]
PHST- 2010/05/13 06:00 [medline]
AID - APT4133 [pii]
AID - 10.1111/j.1365-2036.2009.04133.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2010 Jan;31(1):143-9. doi: 
      10.1111/j.1365-2036.2009.04133.x.

PMID- 19065892
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20161018
IS  - 1003-5370 (Print)
IS  - 1003-5370 (Linking)
VI  - 28
IP  - 9
DP  - 2008 Sep
TI  - [Clinical value of protoparaxotril saporlirs combined with aspirin in the 
      secondary prevention of cerebral infarction].
PG  - 797-800
AB  - OBJECTIVE: To observe the clinical value of protoparaxotril saporlirs (PTS) 
      combined with aspirin in the secondary prevention of cerebral infarction. 
      METHODS: The 140 patients with cerebral infarction were collected, among them the 
      120 patients during recovery stage were equally assigned to three groups by 
      randomized, single blinded and open controlled principle, and they were treated 
      respectively by PTS (A), aspirin (B), and PTS plus aspirin (C) for 6 months. The 
      other 20, who couldn't or were unwilling to use aspirin, were arranged in group D 
      for control. The platelet aggregation rate, incidence of stroke recurrence, 
      gastrointestinal adverse reaction and the NIHSS scores of patients were observed 
      during the six-month period of treatment. RESULTS: As compared with group D, the 
      lowering amplitude of platelet aggregation rate after treatment in the three 
      treatment groups were significantly higher (P < 0.01). Comparison of platelet 
      aggregation rate between group A and B showed significant difference after 
      3-month treatment (P < 0.05), but the difference became insignificant after 
      6-month treatment (P > 0.05). The incidence of stroke recurrence in the group A, 
      B and C was 18.9%, 13.2% and 10.8% respectively, which showed no significant 
      difference among them, but all were significantly lower than that in the group D 
      (44.4%, P < 0.05). NIHSS scores in group A and C were significantly lower than in 
      group B (P < 0.01); and the occurrence of gastrointestinal reaction was 
      significantly lower in group A (P < 0.01). CONCLUSION: Long-term application of 
      PTS has the effects for preventing stroke recurrence, lowering gastrointestinal 
      adverse reaction and improving patients' neural function in patients with stroke. 
      As used in combination with aspirin, it shows potential practical importance in 
      the clinical secondary prevention of stroke.
FAU - Zhou, Bo-rong
AU  - Zhou BR
AD  - Department of Neurology, the Third Hospital Affiliated to Guangzhou Medical 
      College, Guangzhou. zhoubr8@yahoo.com.cn
FAU - Xu, Zhi-qiang
AU  - Xu ZQ
FAU - Liu, Zi-fan
AU  - Liu ZF
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Zhong Xi Yi Jie He Za Zhi
JT  - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese 
      journal of integrated traditional and Western medicine
JID - 9211576
RN  - 0 (Sapogenins)
RN  - 34080-08-5 (protopanaxatriol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cerebral Infarction/drug therapy/physiopathology/*prevention & control
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Sapogenins/*administration & dosage/adverse effects
MH  - *Secondary Prevention
EDAT- 2008/12/11 09:00
MHDA- 2010/06/16 06:00
CRDT- 2008/12/11 09:00
PHST- 2008/12/11 09:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
PHST- 2008/12/11 09:00 [entrez]
PST - ppublish
SO  - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Sep;28(9):797-800.

PMID- 8121085
OWN - NLM
STAT- MEDLINE
DCOM- 19940405
LR  - 20190725
IS  - 0021-5198 (Print)
IS  - 0021-5198 (Linking)
VI  - 63
IP  - 4
DP  - 1993 Dec
TI  - Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on 
      arterial thrombosis in guinea pigs.
PG  - 521-3
AB  - The antithrombotic effects of the thromboxane (TX) A2-receptor antagonist and 
      aspirin were determined using a photochemically-induced arterial thrombosis model 
      in the femoral arteries of guinea pigs. KW-3635 (sodium 
      (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,11- 
      dihydrodibenz[b,e]-oxepine-2-carboxylate monohydrate) and BM-13505, both of which 
      are TXA2-receptor antagonists, and aspirin inhibited the thrombus formation at 
      the doses that inhibited the ex vivo platelet aggregation induced by sodium 
      arachidonate (100 microM) or collagen (3 micrograms/ml). These results support 
      the notion that TXA2 is an important mediator in the present model of arterial 
      thrombogenesis.
FAU - Higo, K
AU  - Higo K
AD  - Department of Pharmacology, Pharmaceutical Research Laboratories, Kyowa Hakko 
      Kogyo Co., Ltd., Shizuoka, Japan.
FAU - Karasawa, A
AU  - Karasawa A
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Jpn J Pharmacol
JT  - Japanese journal of pharmacology
JID - 2983305R
RN  - 0 (Benzimidazoles)
RN  - 0 (Benzoxepins)
RN  - 0 (Phenylacetates)
RN  - 0 (Sulfonamides)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - S25VDY08ZC (daltroban)
RN  - WG00T3YN0T (KW 3635)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Benzimidazoles/administration & dosage/*pharmacology
MH  - Benzoxepins/administration & dosage/*pharmacology
MH  - Collagen/pharmacology
MH  - Disease Models, Animal
MH  - Femoral Artery
MH  - Guinea Pigs
MH  - Male
MH  - Phenylacetates/administration & dosage/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Sulfonamides/administration & dosage/pharmacology
MH  - Thrombosis/*drug therapy
MH  - Thromboxane A2/*antagonists & inhibitors/physiology
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
AID - 10.1254/jjp.63.521 [doi]
PST - ppublish
SO  - Jpn J Pharmacol. 1993 Dec;63(4):521-3. doi: 10.1254/jjp.63.521.

PMID- 26486090
OWN - NLM
STAT- MEDLINE
DCOM- 20160914
LR  - 20181113
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 5
DP  - 2015 Oct 21
TI  - Aspirin might reduce the incidence of pancreatic cancer: A meta-analysis of 
      observational studies.
PG  - 15460
LID - 10.1038/srep15460 [doi]
LID - 15460
AB  - Although there is evidence that non-steroidal anti-inflammatory drugs (NSAIDs) 
      might be able to prevent pancreatic cancer, the findings from epidemiological 
      studies have been inconsistent. In this paper, we conducted a meta-analysis of 
      observational studies to examine this possibility. We searched PubMed and Embase 
      for observational (cohort or case-control) studies examining the consumption of 
      aspirin and other NSAIDs and the incidence of or mortality rates associated with 
      pancreatic cancer. Twelve studies including approximately 258,000 participants in 
      total were analysed. The administration of aspirin significantly reduced the 
      incidence of pancreatic cancer (8 studies; odds ratio (OR) = 0.77; 95% confidence 
      interval (CI) = 0.62 to 0.96; I(2) = 74.2%) but not the mortality associated with 
      it (2 studies; OR = 0.94; 95% CI = 0.73 to 1.22). Specifically, frequent aspirin 
      use was associated with reduced pancreatic cancer incidence (OR = 0.57; 95% 
      CI = 0.39 to 0.83 for high frequency; OR = 0.57; 95% CI = 0.38 to 0.84 for medium 
      frequency). The summary ORs regarding the incidence of pancreatic cancer and 
      either non-aspirin NSAIDs use (OR = 1.08; 95% CI = 0.90 to 1.31) or overall 
      NSAIDs use (OR = 0.97; 95% CI = 0.86 to 1.10) were not significant. In 
      conclusion, aspirin use might reduce the incidence of pancreatic cancer; however, 
      this finding should be interpreted with caution because of study heterogeneity.
FAU - Zhang, Yan-Peng
AU  - Zhang YP
AD  - Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, 
      Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital 
      of Zhengzhou University, School of Medicine, 1 Jianshe Road, Zhengzhou 450052, 
      P.R. China.
FAU - Wan, You-Dong
AU  - Wan YD
AD  - Department of Integrated Intensive Care Unit, the First Affiliated Hospital of 
      Zhengzhou University, School of Medicine, 1 Jianshe Road, Zhengzhou 450052, P.R. 
      China.
FAU - Sun, Yu-Ling
AU  - Sun YL
AD  - Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, 
      Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital 
      of Zhengzhou University, School of Medicine, 1 Jianshe Road, Zhengzhou 450052, 
      P.R. China.
FAU - Li, Jian
AU  - Li J
AD  - Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, 
      Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital 
      of Zhengzhou University, School of Medicine, 1 Jianshe Road, Zhengzhou 450052, 
      P.R. China.
FAU - Zhu, Rong-Tao
AU  - Zhu RT
AD  - Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, 
      Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital 
      of Zhengzhou University, School of Medicine, 1 Jianshe Road, Zhengzhou 450052, 
      P.R. China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20151021
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Humans
MH  - Pancreatic Neoplasms/*mortality/pathology
MH  - PubMed
PMC - PMC4614261
EDAT- 2015/10/22 06:00
MHDA- 2016/09/15 06:00
CRDT- 2015/10/22 06:00
PHST- 2015/03/31 00:00 [received]
PHST- 2015/09/21 00:00 [accepted]
PHST- 2015/10/22 06:00 [entrez]
PHST- 2015/10/22 06:00 [pubmed]
PHST- 2016/09/15 06:00 [medline]
AID - srep15460 [pii]
AID - 10.1038/srep15460 [doi]
PST - epublish
SO  - Sci Rep. 2015 Oct 21;5:15460. doi: 10.1038/srep15460.

PMID- 23478565
OWN - NLM
STAT- MEDLINE
DCOM- 20131211
LR  - 20130312
IS  - 1537-8918 (Electronic)
IS  - 1537-890X (Linking)
VI  - 12
IP  - 2
DP  - 2013 Mar-Apr
TI  - Recognition and treatment of freezing and nonfreezing cold injuries.
PG  - 125-30
LID - 10.1249/JSR.0b013e3182877454 [doi]
AB  - This article reviews recent medical literature to provide an overview of the 
      recognition and treatment of the two broad categories of cold injuries, freezing 
      and nonfreezing. Frostbite, a freezing cold injury, is treated traditionally with 
      rapid rewarming followed by tissue care and surgical debridement of necrotic 
      tissue. Recently, newer therapies aimed at prevention of tissue necrosis have 
      shown improved outcomes compared with more traditional therapies. These newer 
      treatment regimens for frostbite include the use of various drugs such as 
      ibuprofen, aspirin, warfarin, tissue plasminogen activator, and prostacyclin. The 
      use of Tc bone scans, magnetic resonance imaging arthrogram, or angiography may 
      have prognostic value for early determination of the extent of tissue loss. The 
      more common nonfreezing cold injuries, though less severe than frostbite, may 
      lead to short- and long-term complications requiring treatment and are discussed 
      also.
FAU - Ingram, Benjamin J
AU  - Ingram BJ
AD  - Womack Army Medical Center, Fort Bragg, NC 28307, USA. 
      Benjamin.James.Ingram@us.army.mil
FAU - Raymond, Tyler J
AU  - Raymond TJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Sports Med Rep
JT  - Current sports medicine reports
JID - 101134380
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Athletic Injuries/*diagnosis/physiopathology/*therapy
MH  - Freezing/*adverse effects
MH  - Frostbite/*diagnosis/physiopathology/*therapy
MH  - Humans
MH  - Rewarming/*methods
MH  - Treatment Outcome
EDAT- 2013/03/13 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/03/13 06:00
PHST- 2013/03/13 06:00 [entrez]
PHST- 2013/03/13 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 00149619-201303000-00018 [pii]
AID - 10.1249/JSR.0b013e3182877454 [doi]
PST - ppublish
SO  - Curr Sports Med Rep. 2013 Mar-Apr;12(2):125-30. doi: 
      10.1249/JSR.0b013e3182877454.

PMID- 23399946
OWN - NLM
STAT- MEDLINE
DCOM- 20130912
LR  - 20131121
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 27
IP  - 1
DP  - 2013 Apr
TI  - Does aspirin use make it harder to collect seizures during elective video-EEG 
      telemetry?
PG  - 115-7
LID - S1525-5050(13)00008-5 [pii]
LID - 10.1016/j.yebeh.2012.12.031 [doi]
AB  - Aspirin has shown promise as an anticonvulsant drug in animal models. Whether 
      aspirin alters seizure frequency in humans remains unstudied. We retrospectively 
      looked at adults with focal onset epilepsy who took aspirin daily while 
      undergoing elective video-EEG monitoring and compared them with similar age- and 
      sex-matched controls to see if seizure frequencies were different between those 
      two populations. Significantly fewer seizures were seen on day two of monitoring 
      for patients on aspirin therapies. Higher aspirin doses were correlated with 
      fewer seizures collected during the monitoring stay. Further prospective study is 
      needed to determine whether aspirin affects more robust seizure control.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Godfred, Rachel M
AU  - Godfred RM
AD  - Department of Psychology, University of California Los Angeles, Los Angeles, CA, 
      USA.
FAU - Parikh, Mihir S
AU  - Parikh MS
FAU - Haltiner, Alan M
AU  - Haltiner AM
FAU - Caylor, Lisa M
AU  - Caylor LM
FAU - Sepkuty, Jehuda P
AU  - Sepkuty JP
FAU - Doherty, Michael J
AU  - Doherty MJ
LA  - eng
PT  - Journal Article
DEP - 20130211
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Electroencephalography
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Seizures/*drug therapy/physiopathology
MH  - *Telemetry
MH  - Treatment Outcome
MH  - Video Recording
EDAT- 2013/02/13 06:00
MHDA- 2013/09/13 06:00
CRDT- 2013/02/13 06:00
PHST- 2012/11/14 00:00 [received]
PHST- 2012/12/26 00:00 [revised]
PHST- 2012/12/28 00:00 [accepted]
PHST- 2013/02/13 06:00 [entrez]
PHST- 2013/02/13 06:00 [pubmed]
PHST- 2013/09/13 06:00 [medline]
AID - S1525-5050(13)00008-5 [pii]
AID - 10.1016/j.yebeh.2012.12.031 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2013 Apr;27(1):115-7. doi: 10.1016/j.yebeh.2012.12.031. Epub 2013 
      Feb 11.

PMID- 37112928
OWN - NLM
STAT- MEDLINE
DCOM- 20230501
LR  - 20230501
IS  - 1999-4915 (Electronic)
IS  - 1999-4915 (Linking)
VI  - 15
IP  - 4
DP  - 2023 Apr 11
TI  - Antiviral Activity of Acetylsalicylic Acid against Bunyamwera Virus in Cell 
      Culture.
LID - 10.3390/v15040948 [doi]
LID - 948
AB  - The Bunyavirales order is a large group of RNA viruses that includes important 
      pathogens for humans, animals and plants. With high-throughput screening of 
      clinically tested compounds we have looked for potential inhibitors of the 
      endonuclease domain of a bunyavirus RNA polymerase. From a list of fifteen top 
      candidates, five compounds were selected and their antiviral properties studied 
      with Bunyamwera virus (BUNV), a prototypic bunyavirus widely used for studies 
      about the biology of this group of viruses and to test antivirals. Four compounds 
      (silibinin A, myricetin, L-phenylalanine and p-aminohippuric acid) showed no 
      antiviral activity in BUNV-infected Vero cells. On the contrary, acetylsalicylic 
      acid (ASA) efficiently inhibited BUNV infection with a half maximal inhibitory 
      concentration (IC(50)) of 2.02 mM. In cell culture supernatants, ASA reduced 
      viral titer up to three logarithmic units. A significant dose-dependent reduction 
      of the expression levels of Gc and N viral proteins was also measured. 
      Immunofluorescence and confocal microscopy showed that ASA protects the Golgi 
      complex from the characteristic BUNV-induced fragmentation in Vero cells. 
      Electron microscopy showed that ASA inhibits the assembly of Golgi-associated 
      BUNV spherules that are the replication organelles of bunyaviruses. As a 
      consequence, the assembly of new viral particles is also significantly reduced. 
      Considering its availability and low cost, the potential usability of ASA to 
      treat bunyavirus infections deserves further investigation.
FAU - Fernández-Sánchez, Sara Yolanda
AU  - Fernández-Sánchez SY
AD  - Cell Structure Laboratory, Centro Nacional de Biotecnología, CSIC, Campus de 
      Cantoblanco, 28049 Madrid, Spain.
FAU - Cerón-Carrasco, José P
AU  - Cerón-Carrasco JP
AUID- ORCID: 0000-0003-0668-9227
AD  - Centro Universitario de la Defensa, Universidad Politécnica de Cartagena, 
      C/Coronel López Peña s/n, Base Aérea de San Javier, Santiago de la Ribera, 30720 
      Murcia, Spain.
FAU - Risco, Cristina
AU  - Risco C
AUID- ORCID: 0000-0001-7501-5934
AD  - Cell Structure Laboratory, Centro Nacional de Biotecnología, CSIC, Campus de 
      Cantoblanco, 28049 Madrid, Spain.
FAU - Fernández de Castro, Isabel
AU  - Fernández de Castro I
AUID- ORCID: 0000-0002-5388-8934
AD  - Cell Structure Laboratory, Centro Nacional de Biotecnología, CSIC, Campus de 
      Cantoblanco, 28049 Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230411
PL  - Switzerland
TA  - Viruses
JT  - Viruses
JID - 101509722
RN  - 0 (Antiviral Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Animals
MH  - Chlorocebus aethiops
MH  - *Bunyamwera virus/genetics
MH  - Antiviral Agents/pharmacology
MH  - Vero Cells
MH  - Aspirin/pharmacology
MH  - *Orthobunyavirus
MH  - Cell Culture Techniques
PMC - PMC10141918
OTO - NOTNLM
OT  - Bunyamwera virus
OT  - acetylsalicylic acid (ASA)
OT  - antiviral
OT  - bunyavirus
OT  - drug repurposing
OT  - electron microscopy
OT  - high-throughput screening
OT  - molecular modeling
OT  - viral RNA polymerase
OT  - viral replication organelle
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/28 06:42
MHDA- 2023/05/01 06:42
CRDT- 2023/04/28 01:54
PHST- 2023/03/02 00:00 [received]
PHST- 2023/04/05 00:00 [revised]
PHST- 2023/04/06 00:00 [accepted]
PHST- 2023/05/01 06:42 [medline]
PHST- 2023/04/28 06:42 [pubmed]
PHST- 2023/04/28 01:54 [entrez]
AID - v15040948 [pii]
AID - viruses-15-00948 [pii]
AID - 10.3390/v15040948 [doi]
PST - epublish
SO  - Viruses. 2023 Apr 11;15(4):948. doi: 10.3390/v15040948.

PMID- 9059677
OWN - NLM
STAT- MEDLINE
DCOM- 19970523
LR  - 20190201
IS  - 0001-5555 (Print)
IS  - 0001-5555 (Linking)
VI  - 77
IP  - 1
DP  - 1997 Jan
TI  - Topically applied aspirin rapidly decreases histamine-induced itch.
PG  - 46-8
AB  - The effect of topical aspirin and its model vehicle dichloromethane on itch 
      experimentally induced with histamine was studied in 16 subjects, using a visual 
      analogue scale and computerized aspirin, but not its vehicle, significantly 
      reduced itch duration (p = 0.001) and decreased itch magnitude as measured with a 
      visual analogue scale (p < 0.04). Histamine injection caused elevation of warmth 
      sensation threshold (p = 10(-8)) but did not affect cold and heat pain 
      thresholds. Aspirin and vehicle application did not affect thermal and pain 
      thresholds during histamine-induced itch. The current data suggest that topical 
      application of aspirin may be beneficial for the treatment of histamine-mediated 
      itch. Its therapeutic role in the management of clinical itch remains to be 
      determined.
FAU - Yosipovitch, G
AU  - Yosipovitch G
AD  - Department of Dermatology, UCSF Medical Center, San Francisco, USA.
FAU - Ademola, J
AU  - Ademola J
FAU - Lui, P
AU  - Lui P
FAU - Amin, S
AU  - Amin S
FAU - Maibach, H I
AU  - Maibach HI
LA  - eng
PT  - Journal Article
PL  - Sweden
TA  - Acta Derm Venereol
JT  - Acta dermato-venereologica
JID - 0370310
RN  - 820484N8I3 (Histamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Topical
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - *Histamine/administration & dosage
MH  - Humans
MH  - Injections, Intradermal
MH  - Male
MH  - Pruritus/*chemically induced
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.2340/0001555577046048 [doi]
PST - ppublish
SO  - Acta Derm Venereol. 1997 Jan;77(1):46-8. doi: 10.2340/0001555577046048.

PMID- 3285985
OWN - NLM
STAT- MEDLINE
DCOM- 19880708
LR  - 20181113
IS  - 0820-3946 (Print)
IS  - 1488-2329 (Electronic)
IS  - 0820-3946 (Linking)
VI  - 138
IP  - 12
DP  - 1988 Jun 15
TI  - Transient ischemic attacks and stroke.
PG  - 1099-105
AB  - Transient ischemic attacks (TIAs) constitute the most specific and powerful 
      warnings of impending stroke. They are defined as brief, focal neurological 
      events of sudden onset. Their proper recognition and treatment rank second only 
      to the modification of risk factors in importance for stroke prevention. Carotid 
      endarterectomy, although widely used to treat TIAs, remains unproven; randomized 
      clinical trials are attempting to define its role. Anticoagulant therapy appears 
      worth while for suspected cardiac embolism and possibly for disabling TIAs. 
      Acetylsalicylic acid is the only agent that has been found to be effective in 
      controlled trials, but questions persist about its dosage, its efficacy in women 
      and its use after stroke. Another platelet inhibitor, ticlopidine hydrochloride, 
      is being investigated and may prove to be an effective alternative.
FAU - Mirsen, T R
AU  - Mirsen TR
AD  - Department of Clinical Neurological Sciences, Faculty of Medicine, University of 
      Western Ontario, London.
FAU - Hachinski, V C
AU  - Hachinski VC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Canada
TA  - CMAJ
JT  - CMAJ : Canadian Medical Association journal = journal de l'Association medicale 
      canadienne
JID - 9711805
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/prevention & control
MH  - Humans
MH  - Ischemic Attack, Transient/diagnosis/*therapy
MH  - Risk Factors
MH  - Ticlopidine/therapeutic use
PMC - PMC1267938
EDAT- 1988/06/15 00:00
MHDA- 1988/06/15 00:01
CRDT- 1988/06/15 00:00
PHST- 1988/06/15 00:00 [pubmed]
PHST- 1988/06/15 00:01 [medline]
PHST- 1988/06/15 00:00 [entrez]
PST - ppublish
SO  - CMAJ. 1988 Jun 15;138(12):1099-105.

PMID- 1099729
OWN - NLM
STAT- MEDLINE
DCOM- 19751122
LR  - 20190713
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 20
IP  - 3
DP  - 1975 Sep
TI  - The treatment of rejection. A trial of acetylsalicylic acid, dipyridamole, and 
      heparin.
PG  - 237-40
AB  - Serial studies of platelet and fibrinogen survival were performed in 26 
      nonimmunosuppressed dogs after allogenic renal transplant operations. Treatment 
      with acetylsalicylic acid, dipyridamole, and heparin failed to improve the 
      selective platelet destruction which occurred in untreated animals, and it did 
      not improve postoperative longevity. There was a high incidence of postoperative 
      wound and intrarenal hemorrhage after heparin treatment. These results are 
      consistent with the hypothesis that platelet destruction is a consequence rather 
      than the cause of acute graft rejection, and it is concluded that antithrombotic 
      therapy is not of practical benefit in preventing acute rejection.
FAU - George, C R
AU  - George CR
FAU - Slichter, S J
AU  - Slichter SJ
FAU - Quadracci, L J
AU  - Quadracci LJ
FAU - Kenny, G M
AU  - Kenny GM
FAU - Dennis, M B Jr
AU  - Dennis MB Jr
FAU - Striker, G E
AU  - Striker GE
FAU - Harker, L A
AU  - Harker LA
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9001-32-5 (Fibrinogen)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets
MH  - Cell Survival
MH  - Dipyridamole/*therapeutic use
MH  - Dogs
MH  - Fibrinogen/analysis
MH  - Graft Rejection/*drug therapy
MH  - Heparin/*therapeutic use
MH  - Kidney/pathology
MH  - Kidney Transplantation
MH  - Transplantation, Autologous
MH  - Transplantation, Homologous
EDAT- 1975/09/11 19:15
MHDA- 2001/03/28 10:01
CRDT- 1975/09/11 19:15
PHST- 1975/09/11 19:15 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1975/09/11 19:15 [entrez]
AID - 10.1097/00007890-197509000-00008 [doi]
PST - ppublish
SO  - Transplantation. 1975 Sep;20(3):237-40. doi: 10.1097/00007890-197509000-00008.

PMID- 7025599
OWN - NLM
STAT- MEDLINE
DCOM- 19811118
LR  - 20131121
IS  - 0002-838X (Print)
IS  - 0002-838X (Linking)
VI  - 24
IP  - 4
DP  - 1981 Oct
TI  - Antiplatelet therapy.
PG  - 129-34
AB  - Much new information has been gleaned about the morphology, biochemistry and 
      function of platelets. The pathophysiology of atherosclerosis and thromboembolic 
      disorders appears to be related to abnormal platelet function. Endothelial 
      damage, thromboxane A2, Thrombin, adenosine diphospate and epinephrine may each 
      promote platelet aggregation, whereas prostacyclin impairs aggregation. Aspirin, 
      sulfinpyrazone and dipyridamole have been used as antiplatelet agents, and 
      specific indications are being developed to guide their selection.
FAU - Sloan, R W
AU  - Sloan RW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Fam Physician
JT  - American family physician
JID - 1272646
RN  - 0 (Anticoagulants)
RN  - 64ALC7F90C (Dipyridamole)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Arteriosclerosis/drug therapy/physiopathology
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/drug effects/physiology
MH  - Coronary Disease/drug therapy/physiopathology
MH  - Dipyridamole/pharmacology/*therapeutic use
MH  - Epoprostenol/adverse effects
MH  - Female
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Sulfinpyrazone/pharmacology/*therapeutic use
MH  - Thrombophlebitis/drug therapy/physiopathology
EDAT- 1981/10/01 00:00
MHDA- 1981/10/01 00:01
CRDT- 1981/10/01 00:00
PHST- 1981/10/01 00:00 [pubmed]
PHST- 1981/10/01 00:01 [medline]
PHST- 1981/10/01 00:00 [entrez]
PST - ppublish
SO  - Am Fam Physician. 1981 Oct;24(4):129-34.

PMID- 21519219
OWN - NLM
STAT- MEDLINE
DCOM- 20140219
LR  - 20181203
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
VI  - 20
IP  - 4
DP  - 2013 Jul-Aug
TI  - Ideal antiplatelet therapy for coronary artery disease: focus on adenosine 
      diphosphate receptor inhibitors.
PG  - 337-43
LID - 10.1097/MJT.0b013e31820b8668 [doi]
AB  - With the increasing prevalence of coronary artery disease, antiplatelet therapy 
      after percutaneous coronary intervention is becoming more important. As such 
      realm is still very dynamic, it is important for clinicians to understand the 
      evolution of antiplatelet therapies and current issues that are yet to be settled 
      in the search for an ideal antiplatelet agent. Electronic searches were done 
      using databases such as PubMed and Cochrane Library with appropriate keywords. 
      Randomized controlled trials and retrospective studies found were then assessed 
      for quality, and their references used to find additional studies. The field of 
      study regarding the antiplatelet therapy is still an area in which much has yet 
      to be found. Although clopidogrel and aspirin are cornerstones of therapy 
      currently, other agents such as ticagrelor offer potential alternatives. This 
      review presents an overview of current antiplatelet therapies and their relative 
      risks and benefits.
FAU - Chandrasekar, Suraj
AU  - Chandrasekar S
AD  - Chicago Medical School, North Chicago, IL, USA.
FAU - Loomba, Rohit
AU  - Loomba R
FAU - Shah, Parinda
AU  - Shah P
FAU - Arora, Rohit
AU  - Arora R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine/adverse effects/analogs & derivatives/pharmacology/therapeutic use
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Coronary Artery Disease/*drug therapy/physiopathology
MH  - Humans
MH  - Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/adverse effects/pharmacology/*therapeutic use
MH  - Ticagrelor
MH  - Ticlopidine/adverse effects/analogs & derivatives/pharmacology/therapeutic use
EDAT- 2011/04/27 06:00
MHDA- 2014/02/20 06:00
CRDT- 2011/04/27 06:00
PHST- 2011/04/27 06:00 [entrez]
PHST- 2011/04/27 06:00 [pubmed]
PHST- 2014/02/20 06:00 [medline]
AID - 10.1097/MJT.0b013e31820b8668 [doi]
PST - ppublish
SO  - Am J Ther. 2013 Jul-Aug;20(4):337-43. doi: 10.1097/MJT.0b013e31820b8668.

PMID- 35139575
OWN - NLM
STAT- MEDLINE
DCOM- 20220518
LR  - 20230728
IS  - 1806-9339 (Electronic)
IS  - 0100-7203 (Print)
IS  - 0100-7203 (Linking)
VI  - 44
IP  - 3
DP  - 2022 Mar
TI  - Could Aspirin Treatment Modify the Assessment of the Uterine Arteries?
PG  - 231-237
LID - 10.1055/s-0042-1742411 [doi]
AB  - OBJECTIVE:  To analyze whether acetylsalicylic (ASA) intake modifies the mean 
      uterine arteries pulsatility index (UtA-PI) at the 2(nd) or 3(rd) trimester in a 
      cohort of pregnant women with abnormal mean UtA-PI at between 11 and 14 weeks of 
      gestation. METHODS:  This is a retrospective cohort study. Singleton pregnancies 
      with abnormal mean UtA-PI at between 11 and 14 weeks of gestation were studied. 
      The participants were divided into 3 groups: 1) If the participant did not take 
      ASA during pregnancy; 2) If the participant took ASA before 14 weeks of 
      gestation; and 3) If the participant took ASA after 14 weeks of gestation. The 
      mean UtA-PI was evaluated at the 2(nd) and 3(rd) trimesters, and it was 
      considered to improve when it decreased below the 95(th) percentile. The 
      prevalence ratio (PR) and the number needed to treat (NNT) were calculated. 
      RESULTS:  A total of 72 participants with a mean UtA-PI > 95(th) percentile at 
      the 1(st) trimester of gestation were evaluated. Out of the 18 participants who 
      took ASA, 8 participants started it before 14 weeks of gestation and 10 after. A 
      total of 33.3% of these participants had improved the mean UtA-PI at the 2(nd) 
      and 3(rd) trimesters of gestation, although it was not statistically significant 
      (p = 0.154). The prevalence ratio was 0.95 (95% confidence interval [CI]: 
      0.31-1.89), but between the 1(st) and 2(nd) trimesters of gestation, the PR was 
      0.92 (95%CI: 0.21-0.99) and it was statistically significant. CONCLUSION:  The 
      present work demonstrates a modification of the mean UtA-PI in participants who 
      took ASA compared with those who did not. It is important to check if ASA can 
      modify the normal limits of uterine arteries because this could have an impact on 
      surveillance.
CI  - Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article 
      published by Thieme under the terms of the Creative Commons Attribution License, 
      permitting unrestricted use, distribution, and reproduction so long as the 
      original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).
FAU - Vallejo, Gabriela Marisol
AU  - Vallejo GM
AUID- ORCID: 0000-0001-9632-0428
AD  - Universidad El Bosque, El Bosque Research Group of Maternal Fetal, Medicine and 
      Gynecology, Ecodiagnóstico El Bosque SAS, Los Cobos Medical Center, Bogotá, 
      Colombia.
FAU - Uriel, Montserrat
AU  - Uriel M
AUID- ORCID: 0000-0001-5987-8633
AD  - Universidad El Bosque, El Bosque Research Group of Maternal Fetal, Medicine and 
      Gynecology, Ecodiagnóstico El Bosque SAS, Los Cobos Medical Center, Bogotá, 
      Colombia.
FAU - Porras-Ramírez, Alexandra
AU  - Porras-Ramírez A
AUID- ORCID: 0000-0002-0800-1388
AD  - Research Group Community Medicine and Collective Health, El Bosque University, 
      Los Cobos Medical Center, Bogotá, Colombia.
FAU - Romero, Ximena Carolina
AU  - Romero XC
AUID- ORCID: 0000-0002-7040-2705
AD  - Universidad El Bosque, El Bosque Research Group of Maternal Fetal, Medicine and 
      Gynecology, Ecodiagnóstico El Bosque SAS, Los Cobos Medical Center, Bogotá, 
      Colombia.
LA  - eng
PT  - Journal Article
TT  - O tratamento com aspirina pode modificar a avaliação das artérias uterinas?
DEP - 20220209
PL  - Brazil
TA  - Rev Bras Ginecol Obstet
JT  - Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira 
      das Sociedades de Ginecologia e Obstetricia
JID - 9214757
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Pre-Eclampsia/epidemiology
MH  - Pregnancy
MH  - Prospective Studies
MH  - Pulsatile Flow
MH  - Retrospective Studies
MH  - Ultrasonography, Doppler
MH  - Ultrasonography, Prenatal
MH  - *Uterine Artery/diagnostic imaging
PMC - PMC9948068
COIS- The authors have no conflict of interests to declare.
EDAT- 2022/02/10 06:00
MHDA- 2022/05/19 06:00
CRDT- 2022/02/09 20:08
PHST- 2022/02/10 06:00 [pubmed]
PHST- 2022/05/19 06:00 [medline]
PHST- 2022/02/09 20:08 [entrez]
AID - 210086 [pii]
AID - 10.1055/s-0042-1742411 [doi]
PST - ppublish
SO  - Rev Bras Ginecol Obstet. 2022 Mar;44(3):231-237. doi: 10.1055/s-0042-1742411. 
      Epub 2022 Feb 9.

PMID- 31237645
OWN - NLM
STAT- MEDLINE
DCOM- 20190710
LR  - 20210503
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 321
IP  - 24
DP  - 2019 Jun 25
TI  - Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on 
      Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: 
      The SMART-CHOICE Randomized Clinical Trial.
PG  - 2428-2437
LID - 10.1001/jama.2019.8146 [doi]
AB  - IMPORTANCE: Data on P2Y12 inhibitor monotherapy after short-duration dual 
      antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary 
      intervention are limited. OBJECTIVE: To determine whether P2Y12 inhibitor 
      monotherapy after 3 months of DAPT is noninferior to 12 months of DAPT in 
      patients undergoing PCI. DESIGN, SETTING, AND PARTICIPANTS: The SMART-CHOICE 
      trial was an open-label, noninferiority, randomized study that was conducted in 
      33 hospitals in Korea and included 2993 patients undergoing PCI with drug-eluting 
      stents. Enrollment began March 18, 2014, and follow-up was completed July 19, 
      2018. INTERVENTIONS: Patients were randomly assigned to receive aspirin plus a 
      P2Y12 inhibitor for 3 months and thereafter P2Y12 inhibitor alone (n = 1495) or 
      DAPT for 12 months (n = 1498). MAIN OUTCOMES AND MEASURES: The primary end point 
      was major adverse cardiac and cerebrovascular events (a composite of all-cause 
      death, myocardial infarction, or stroke) at 12 months after the index procedure. 
      Secondary end points included the components of the primary end point and 
      bleeding defined as Bleeding Academic Research Consortium type 2 to 5. The 
      noninferiority margin was 1.8%. RESULTS: Among 2993 patients who were randomized 
      (mean age, 64 years; 795 women [26.6%]), 2912 (97.3%) completed the trial. 
      Adherence to the study protocol was 79.3% of the P2Y12 inhibitor monotherapy 
      group and 95.2% of the DAPT group. At 12 months, major adverse cardiac and 
      cerebrovascular events occurred in 42 patients in the P2Y12 inhibitor monotherapy 
      group and in 36 patients in the DAPT group (2.9% vs 2.5%; difference, 0.4% 
      [1-sided 95% CI, -∞% to 1.3%]; P = .007 for noninferiority). There were no 
      significant differences in all-cause death (21 [1.4%] vs 18 [1.2%]; hazard ratio 
      [HR], 1.18; 95% CI, 0.63-2.21; P = .61), myocardial infarction (11 [0.8%] vs 17 
      [1.2%]; HR, 0.66; 95% CI, 0.31-1.40; P = .28), or stroke (11 [0.8%] vs 5 [0.3%]; 
      HR, 2.23; 95% CI, 0.78-6.43; P = .14) between the 2 groups. The rate of bleeding 
      was significantly lower in the P2Y12 inhibitor monotherapy group than in the DAPT 
      group (2.0% vs 3.4%; HR, 0.58; 95% CI, 0.36-0.92; P = .02). CONCLUSIONS AND 
      RELEVANCE: Among patients undergoing percutaneous coronary intervention, P2Y12 
      inhibitor monotherapy after 3 months of DAPT compared with prolonged DAPT 
      resulted in noninferior rates of major adverse cardiac and cerebrovascular 
      events. Because of limitations in the study population and adherence, further 
      research is needed in other populations. TRIAL REGISTRATION: ClinicalTrials.gov 
      Identifier: NCT02079194.
FAU - Hahn, Joo-Yong
AU  - Hahn JY
AD  - Division of Cardiology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Song, Young Bin
AU  - Song YB
AD  - Division of Cardiology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Oh, Ju-Hyeon
AU  - Oh JH
AD  - Department of Cardiology, Samsung Changwon Hospital, Sungkyunkwan University 
      School of Medicine, Changwon, Korea.
FAU - Chun, Woo Jung
AU  - Chun WJ
AD  - Department of Cardiology, Samsung Changwon Hospital, Sungkyunkwan University 
      School of Medicine, Changwon, Korea.
FAU - Park, Yong Hawn
AU  - Park YH
AD  - Department of Cardiology, Samsung Changwon Hospital, Sungkyunkwan University 
      School of Medicine, Changwon, Korea.
FAU - Jang, Woo Jin
AU  - Jang WJ
AD  - Department of Cardiology, Samsung Changwon Hospital, Sungkyunkwan University 
      School of Medicine, Changwon, Korea.
FAU - Im, Eul-Soon
AU  - Im ES
AD  - Division of Cardiology, Dongsuwon General Hospital, Suwon, Korea.
FAU - Jeong, Jin-Ok
AU  - Jeong JO
AD  - Chungnam National University Hospital, Daejeon, Korea.
FAU - Cho, Byung Ryul
AU  - Cho BR
AD  - Division of Cardiology, Kangwon National University Hospital, Chuncheon, Korea.
FAU - Oh, Seok Kyu
AU  - Oh SK
AD  - Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, 
      Wonkwang University Hospital, Iksan, Korea.
FAU - Yun, Kyeong Ho
AU  - Yun KH
AD  - Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, 
      Wonkwang University Hospital, Iksan, Korea.
FAU - Cho, Deok-Kyu
AU  - Cho DK
AD  - Division of Cardiology, Department of Internal Medicine, Myongji Hospital, 
      Goyang, Korea.
FAU - Lee, Jong-Young
AU  - Lee JY
AD  - Division of Cardiology, Department of Medicine, Kangbuk Samsung Hospital, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Koh, Young-Youp
AU  - Koh YY
AD  - Department of Internal Medicine, Chosun University Hospital, Gwangju, Korea.
FAU - Bae, Jang-Whan
AU  - Bae JW
AD  - Department of Internal Medicine, College of Medicine, Chungbuk National 
      University Hospital, Cheongju, Korea.
FAU - Choi, Jae Woong
AU  - Choi JW
AD  - Eulji General Hospital, Seoul, Korea.
FAU - Lee, Wang Soo
AU  - Lee WS
AD  - Chung-Ang University Hospital, Seoul, Korea.
FAU - Yoon, Hyuck Jun
AU  - Yoon HJ
AD  - Keimyung University Dongsan Medical Center, Daegu, Korea.
FAU - Lee, Seung Uk
AU  - Lee SU
AD  - Kwangju Christian Hospital, Gwangju, Korea.
FAU - Cho, Jang Hyun
AU  - Cho JH
AD  - St Carollo Hospital, Suncheon, Korea.
FAU - Choi, Woong Gil
AU  - Choi WG
AD  - Konkuk University Chungju Hospital, Chungju, Korea.
FAU - Rha, Seung-Woon
AU  - Rha SW
AD  - Korea University Guro Hospital, Seoul, Korea.
FAU - Lee, Joo Myung
AU  - Lee JM
AD  - Division of Cardiology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Park, Taek Kyu
AU  - Park TK
AD  - Division of Cardiology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Yang, Jeong Hoon
AU  - Yang JH
AD  - Division of Cardiology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Choi, Jin-Ho
AU  - Choi JH
AD  - Division of Cardiology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Choi, Seung-Hyuck
AU  - Choi SH
AD  - Division of Cardiology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Lee, Sang Hoon
AU  - Lee SH
AD  - Division of Cardiology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Gwon, Hyeon-Cheol
AU  - Gwon HC
AD  - Division of Cardiology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
CN  - SMART-CHOICE Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT02079194
PT  - Comparative Study
PT  - Equivalence Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2019 Jun 25;321(24):2409-2411. PMID: 31237621
EIN - JAMA. 2019 Oct 1;322(13):1316. PMID: 31461120
CIN - JAMA. 2019 Oct 22;322(16):1607. PMID: 31638667
CIN - Ann Intern Med. 2019 Nov 19;171(10):JC53. PMID: 31739336
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/adverse effects/*therapeutic use
PMC - PMC6593635
COIS- Conflict of Interest Disclosures: Dr Hahn reports receiving grants from Abbott 
      Vascular, Boston Scientific, Biotronik, Korean Society of Interventional 
      Cardiology, and Medtronic; and speaker’s fees from AstraZeneca, Daiichi Sankyo, 
      and sanofi-aventis. Dr Gwon reports receiving research grants from Abbott 
      Vascular, Boston Scientific, and Medtronic; and speaker’s fees from Abbott 
      Vascular, Boston Scientific, and Medtronic. All other authors declare that they 
      have no conflicts of interest.
EDAT- 2019/06/27 06:00
MHDA- 2019/07/11 06:00
CRDT- 2019/06/26 06:00
PHST- 2019/06/26 06:00 [entrez]
PHST- 2019/06/27 06:00 [pubmed]
PHST- 2019/07/11 06:00 [medline]
AID - 2736564 [pii]
AID - joi190061 [pii]
AID - 10.1001/jama.2019.8146 [doi]
PST - ppublish
SO  - JAMA. 2019 Jun 25;321(24):2428-2437. doi: 10.1001/jama.2019.8146.

PMID- 372242
OWN - NLM
STAT- MEDLINE
DCOM- 19790629
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 63
IP  - 3
DP  - 1979 Mar
TI  - Recovery of endothelial cell prostacyclin production after inhibition by low 
      doses of aspirin.
PG  - 532-5
AB  - Endothelial cells synthesize prostacyclin (PGI(2)), an unstable prostaglandin 
      that inhibits platelet aggregation and serotonin release. Because cyclooxygenase, 
      which is necessary for synthesis of PGI(2), is inactivated by aspirin, we 
      examined the effect of aspirin on PGI(2) production by cultured human endothelial 
      cells. Endothelial cells synthesize PGI(2) (20.1+/-7.2 ng/10(6) cells, mean+/-SD) 
      when stimulated with 20 muM sodium arachidonate for 2 min. PGI(2) production is 
      inhibited by low-dose aspirin (5 muM); the t((1/2)) of inactivation is 6.0+/-1.3 
      min (mean+/-SEM, n = 3). Thus, endothelial cell cyclooxygenase is as sensitive to 
      aspirin as the enzyme in platelets. After 1 h incubation with aspirin, 
      endothelial cell PGI(2) production was inhibited 50% by 2.1+/-0.4 muM aspirin and 
      was inhibited 90% by 6.2+/-0.9 muM aspirin (mean+/-SEM, n = 4). When endothelial 
      cells were incubated with 100 muM aspirin, washed, and recultured, their ability 
      to synthesize PGI(2) returned to control levels in 35.6+/-1.0 h (mean+/-SEM, n = 
      4). Recovery of endothelial PGI(2) production after aspirin depended on de novo 
      protein synthesis because treatment with cycloheximide (3 mug/ml) inhibited 
      recovery by 92%.These results indicate that although endothelial cell 
      cyclooxygenase in vitro is inhibited by low concentrations of aspirin, 
      endothelial cells rapidly resynthesize their cyclooxygenase after the aspirin is 
      removed. This rapid resynthesis of cyclooxygenase lessens the likelihood that 
      aspirin used in clinical doses promotes thrombosis.
FAU - Jaffe, E A
AU  - Jaffe EA
FAU - Weksler, B B
AU  - Weksler BB
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Prostaglandins)
RN  - 98600C0908 (Cycloheximide)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cycloheximide/pharmacology
MH  - Endothelium/drug effects/metabolism
MH  - Epoprostenol/*biosynthesis
MH  - Humans
MH  - In Vitro Techniques
MH  - Prostaglandins/*biosynthesis
MH  - Time Factors
PMC - PMC371983
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
AID - 10.1172/JCI109332 [doi]
PST - ppublish
SO  - J Clin Invest. 1979 Mar;63(3):532-5. doi: 10.1172/JCI109332.

PMID- 11675834
OWN - NLM
STAT- MEDLINE
DCOM- 20011101
LR  - 20131121
IS  - 1129-4728 (Print)
IS  - 1129-4728 (Linking)
VI  - 2
IP  - 9
DP  - 2001 Sep
TI  - [Prevention of thromboembolism in non-rheumatic atrial fibrillation: an update].
PG  - 972-9
AB  - Randomized clinical trials have demonstrated the efficacy and safety of oral 
      anticoagulants in the prevention of systemic thromboembolism in nonrheumatic 
      atrial fibrillation. The benefit of this treatment is particularly evident in 
      patients in whom atrial fibrillation is associated with a major risk factor for 
      systemic thromboembolism (patients > 75 years of age, history of hypertension, 
      previous left ventricular failure or previous systemic thromboembolism) or those 
      in whom two minor risk factors are present (patients between 65 and 75 years of 
      age, diabetes, ischemic heart disease). According to these recommendations, all 
      the patients > 75 years of age with chronic or paroxysmal atrial fibrillation 
      should receive oral anticoagulant treatment to maintain an INR between 2.0 and 
      3.0. However, as the risk of bleeding during oral anticoagulant treatment 
      increases with age, the benefit/risk ratio should always be evaluated in elderly 
      patients. Although high risk patients do not benefit from aspirin treatment, 
      aspirin or other antiplatelet agents might be indicated in medium risk patients 
      or in those in whom the risk of bleeding with oral anticoagulants is considered 
      too high. New antithrombotic regimens will be tested in the near future.
FAU - Pengo, V
AU  - Pengo V
AD  - Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi, Ospedale 
      Ex Busonera Via Gattamelata, 64 35128 Padova. vittorio.pengo@unipd.it
FAU - De Caterina, R
AU  - De Caterina R
LA  - ita
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Prevenzione del tromboembolismo nella fibrillazione atriale non reumatica: un 
      aggiornamento.
PL  - Italy
TA  - Ital Heart J Suppl
JT  - Italian heart journal. Supplement : official journal of the Italian Federation of 
      Cardiology
JID - 101223651
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Age Factors
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Electric Countershock
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Thromboembolism/etiology/*prevention & control
RF  - 57
EDAT- 2001/10/26 10:00
MHDA- 2001/11/03 10:01
CRDT- 2001/10/26 10:00
PHST- 2001/10/26 10:00 [pubmed]
PHST- 2001/11/03 10:01 [medline]
PHST- 2001/10/26 10:00 [entrez]
PST - ppublish
SO  - Ital Heart J Suppl. 2001 Sep;2(9):972-9.

PMID- 9575390
OWN - NLM
STAT- MEDLINE
DCOM- 19980623
LR  - 20131121
IS  - 0896-4289 (Print)
IS  - 0896-4289 (Linking)
VI  - 24
IP  - 1
DP  - 1998 Spring
TI  - Adherence to a prophylactic medication regimen in patients with symptomatic 
      versus asymptomatic ischemic heart disease.
PG  - 35-9
AB  - Although angina pectoris is the most common symptom of coronary artery disease, 
      some patients do not experience angina during ischemic episodes. The effects of 
      asymptomatic (silent) heart disease on patient self-management have rarely been 
      studied. Studies of other patient populations with asymptomatic illnesses 
      indicate that patients with silent myocardial ischemia might adhere less well to 
      a prophylactic medication regimen than would those with symptomatic ischemia. 
      Depression, a state associated with poor adherence to medical regimens is more 
      common among patients with symptomatic ischemia. For prevention of thromboembolic 
      events, 37 patients with documented ischemic heart disease who denied having 
      anginal symptoms and 28 patients who reported almost daily symptoms were given a 
      3-week supply of low-dose aspirin packaged in an unobtrusive electronic adherence 
      monitor. All other medications were provided in standard pill bottles. The 
      symptomatic patients removed their prescribed aspirin on 62.4% of the days; the 
      patients with silent ischemia took their medication on 77.3% of the days. 
      Possible explanations for these results, their clinical implications, and 
      directions for future research are discussed.
FAU - Carney, R M
AU  - Carney RM
AD  - Department of Psychiatry, Washington University School of Medicine, St. Louis, 
      Missouri, USA.
FAU - Freedland, K E
AU  - Freedland KE
FAU - Eisen, S A
AU  - Eisen SA
FAU - Rich, M W
AU  - Rich MW
FAU - Skala, J A
AU  - Skala JA
FAU - Jaffe, A S
AU  - Jaffe AS
LA  - eng
GR  - R01 HL42427-03/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Behav Med
JT  - Behavioral medicine (Washington, D.C.)
JID - 8804264
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Chi-Square Distribution
MH  - Depression/psychology
MH  - Drug Administration Schedule
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Myocardial Ischemia/*drug therapy/*psychology
MH  - *Patient Compliance
MH  - Psychological Tests
EDAT- 1998/05/12 00:00
MHDA- 1998/05/12 00:01
CRDT- 1998/05/12 00:00
PHST- 1998/05/12 00:00 [pubmed]
PHST- 1998/05/12 00:01 [medline]
PHST- 1998/05/12 00:00 [entrez]
AID - 10.1080/08964289809596379 [doi]
PST - ppublish
SO  - Behav Med. 1998 Spring;24(1):35-9. doi: 10.1080/08964289809596379.

PMID- 1126088
OWN - NLM
STAT- MEDLINE
DCOM- 19750718
LR  - 20190516
IS  - 0009-921X (Print)
IS  - 0009-921X (Linking)
IP  - 106
DP  - 1975 Jan-Feb
TI  - Comparison of the effects of steroid, aspirin and sodium salicylate on articular 
      cartilage.
PG  - 350-6
AB  - Rabbit knee joints were compressed to produce cartilage degeneration in control 
      and test animals who received intramuscular injections of prednisolone and 
      aspirin or sodium salicylate by gavage. After three weeks of compression, animals 
      were sacrificed and articular cartilage was analyzed grossly and histologically. 
      Gross and histological specimens from salicylate treated animals showed less 
      while the steroid treated rabbits showed more degenerative change. These data 
      suggest that salicylate inhibits cartilage destruction while steroids enhance it.
FAU - Roach, J E
AU  - Roach JE
FAU - Tomblin, W
AU  - Tomblin W
FAU - Eyring, E J
AU  - Eyring EJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cartilage Diseases/chemically induced/pathology
MH  - Cartilage, Articular/*drug effects/pathology
MH  - Injections, Intramuscular
MH  - Knee Joint/*drug effects
MH  - Necrosis/chemically induced
MH  - Prednisolone/administration & dosage/*adverse effects/pharmacology
MH  - Rabbits
MH  - Sodium Salicylate/administration & dosage/*pharmacology
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 10.1097/00003086-197501000-00047 [doi]
PST - ppublish
SO  - Clin Orthop Relat Res. 1975 Jan-Feb;(106):350-6. doi: 
      10.1097/00003086-197501000-00047.

PMID- 34147402
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20220131
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
VI  - 15
IP  - 6
DP  - 2021 Dec
TI  - Dashboards to reduce inappropriate prescribing of metformin and aspirin: A 
      quality assurance programme in a primary care sentinel network.
PG  - 1075-1079
LID - S1751-9918(21)00095-4 [pii]
LID - 10.1016/j.pcd.2021.06.003 [doi]
AB  - AIMS: To pilot two dashboards to monitor prescribing of metformin and aspirin 
      according to the National Institute for Health and Care Excellence (NICE) 
      'Do-Not-Do' recommendations. METHODS: This quality assurance programme was 
      conducted in twelve general practices of the Oxford-Royal College of General 
      Practitioners (RCGP) Research and Surveillance Centre (RSC) network. We developed 
      dashboards to flag inappropriate prescribing of metformin and aspirin to people 
      with type 2 diabetes mellitus (T2DM). In Phase 1, six practices (Group A) 
      received a dashboard flagging suboptimal metformin prescriptions in people with 
      reduced renal function. The other six practices (Group B) were controls. In Phase 
      2, Group B were provided a dashboard to flag inappropriate aspirin prescribing 
      and Group A were controls. We used logistic regression to explore associations 
      between dashboard exposure and inappropriate prescribing. RESULTS: The cohort 
      comprised 5644 individuals (Group A, n = 2656; Group B, n = 2988). Half (51.6%, n 
      = 2991) were prescribed metformin of which 15 (0.5%) were inappropriate (Group A, 
      n = 10; Group B, n = 5). A fifth (17.6%, n = 986) were prescribed aspirin of 
      which 828 (84.0%) were inappropriate. During Phase 1, metformin was stopped in 
      50% (n = 5) of people in Group A, compared with 20% (n = 1) in the control group 
      (Group B); in Phase 2, the odds ratio of inappropriate aspirin prescribing was 
      significantly lower in practices that received the dashboard versus control 
      (0.44, 95%CI 0.27-0.72). CONCLUSIONS: It was feasible to use a dashboard to flag 
      inappropriate prescribing. Whilst underpowered to report a change in metformin, 
      we demonstrated a reduction in inappropriate aspirin prescribing.
CI  - Copyright © 2021 Primary Care Diabetes Europe. Published by Elsevier Ltd. All 
      rights reserved.
FAU - de Lusignan, Simon
AU  - de Lusignan S
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford, 
      Oxford, UK; Royal College of General Practitioners (RCGP) Research and 
      Surveillance Centre (RSC), London, UK. Electronic address: 
      simon.delusignan@phc.ox.ac.uk.
FAU - Hinton, William
AU  - Hinton W
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford, 
      Oxford, UK; Department of Clinical and Experimental Medicine, University of 
      Surrey, Guildford, UK.
FAU - Seidu, Samuel
AU  - Seidu S
AD  - Diabetes Research Centre, University of Leicester, Leicester, UK.
FAU - Mathew, Mekha
AU  - Mathew M
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford, 
      Oxford, UK.
FAU - Feher, Michael D
AU  - Feher MD
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford, 
      Oxford, UK.
FAU - Munro, Neil
AU  - Munro N
AD  - Department of Clinical and Experimental Medicine, University of Surrey, 
      Guildford, UK.
FAU - Joy, Mark
AU  - Joy M
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford, 
      Oxford, UK.
FAU - Carinci, Fabrizio
AU  - Carinci F
AD  - Department of Clinical and Experimental Medicine, University of Surrey, 
      Guildford, UK; Department of Statistical Sciences, University of Bologna, Italy.
FAU - Hobbs, F D Richard
AU  - Hobbs FDR
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford, 
      Oxford, UK.
FAU - Khunti, Kamlesh
AU  - Khunti K
AD  - Diabetes Research Centre, University of Leicester, Leicester, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210617
PL  - England
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Humans
MH  - Inappropriate Prescribing/prevention & control
MH  - *Metformin/adverse effects
MH  - Primary Health Care
OTO - NOTNLM
OT  - Aspirin
OT  - Metformin
OT  - Primary health care
OT  - Type 2 diabetes mellitus
EDAT- 2021/06/21 06:00
MHDA- 2022/02/01 06:00
CRDT- 2021/06/20 20:32
PHST- 2021/02/09 00:00 [received]
PHST- 2021/04/01 00:00 [revised]
PHST- 2021/06/06 00:00 [accepted]
PHST- 2021/06/21 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
PHST- 2021/06/20 20:32 [entrez]
AID - S1751-9918(21)00095-4 [pii]
AID - 10.1016/j.pcd.2021.06.003 [doi]
PST - ppublish
SO  - Prim Care Diabetes. 2021 Dec;15(6):1075-1079. doi: 10.1016/j.pcd.2021.06.003. 
      Epub 2021 Jun 17.

PMID- 28706001
OWN - NLM
STAT- MEDLINE
DCOM- 20190620
LR  - 20190620
IS  - 1522-1601 (Electronic)
IS  - 8750-7587 (Print)
IS  - 0161-7567 (Linking)
VI  - 123
IP  - 6
DP  - 2017 Dec 1
TI  - Aspirin as a COX inhibitor and anti-inflammatory drug in human skeletal muscle.
PG  - 1610-1616
LID - 10.1152/japplphysiol.01119.2016 [doi]
AB  - Although aspirin is one of the most common anti-inflammatory drugs in the world, 
      the effect of aspirin on human skeletal muscle inflammation is almost completely 
      unknown. This study examined the potential effects and related time course of an 
      orally consumed aspirin dose on the inflammatory prostaglandin E(2) 
      (PGE(2))/cyclooxygenase (COX) pathway in human skeletal muscle. Skeletal muscle 
      biopsies were taken from the vastus lateralis of 10 healthy adults (5 male and 5 
      female, 25 ± 2 yr old) before (Pre) and 2, 4, and 24 h after (Post) a standard 
      dose (975mg) of aspirin and partitioned for analysis of 1) in vivo PGE(2) levels 
      in resting skeletal muscle and 2) ex vivo skeletal muscle PGE(2) production when 
      stimulated with the COX substrate arachidonic acid (5 μM). PGE(2) levels in vivo 
      and PGE(2) production ex vivo were generally unchanged at each time point after 
      aspirin consumption. However, most individuals clearly showed suppression of 
      PGE(2), but at varying time points after aspirin consumption. When the maximum 
      suppression after aspirin consumption was examined for each individual, 
      independent of time, PGE(2) levels in vivo (184 ± 17 and 104 ± 23pg/g wet wt at 
      Pre and Post, respectively) and PGE(2) production ex vivo (2.74 ± 0.17 and 
      2.09 ± 0.11pg·mg wet wt(-1)·min(-1) at Pre and Post, respectively) were reduced ( 
      P < 0.05) by 44% and 24%, respectively. These results provide evidence that 
      orally consumed aspirin can inhibit the COX pathway and reduce the inflammatory 
      mediator PGE(2) in human skeletal muscle. Findings from this study highlight the 
      need to expand our knowledge regarding the potential role for aspirin regulation 
      of the deleterious influence of inflammation on skeletal muscle health in aging 
      and exercising individuals. NEW & NOTEWORTHY This study demonstrated that orally 
      consumed aspirin can target the prostaglandin/cyclooxygenase pathway in human 
      skeletal muscle. This pathway has been shown to regulate skeletal muscle 
      metabolism and inflammation in aging and exercising individuals. Given the 
      prevalence of aspirin consumption, these findings may have implications for 
      skeletal muscle health in a large segment of the population.
FAU - Ratchford, Stephen M
AU  - Ratchford SM
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana.
FAU - Lavin, Kaleen M
AU  - Lavin KM
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana.
FAU - Perkins, Ryan K
AU  - Perkins RK
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana.
FAU - Jemiolo, Bozena
AU  - Jemiolo B
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana.
FAU - Trappe, Scott W
AU  - Trappe SW
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana.
FAU - Trappe, Todd A
AU  - Trappe TA
AD  - Human Performance Laboratory, Ball State University, Muncie, Indiana.
LA  - eng
GR  - R01 AG038576/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20170713
PL  - United States
TA  - J Appl Physiol (1985)
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Biopsy
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Dinoprostone/*biosynthesis
MH  - Female
MH  - Humans
MH  - Male
MH  - Muscle, Skeletal/*drug effects
MH  - Tissue Culture Techniques
MH  - Young Adult
PMC - PMC5814685
OTO - NOTNLM
OT  - aspirin
OT  - cyclooxygenase
OT  - inflammation
OT  - prostaglandin E2
OT  - skeletal muscle
EDAT- 2017/07/15 06:00
MHDA- 2019/06/21 06:00
CRDT- 2017/07/15 06:00
PHST- 2017/07/15 06:00 [pubmed]
PHST- 2019/06/21 06:00 [medline]
PHST- 2017/07/15 06:00 [entrez]
AID - japplphysiol.01119.2016 [pii]
AID - JAPPL-01119-2016 [pii]
AID - 10.1152/japplphysiol.01119.2016 [doi]
PST - ppublish
SO  - J Appl Physiol (1985). 2017 Dec 1;123(6):1610-1616. doi: 
      10.1152/japplphysiol.01119.2016. Epub 2017 Jul 13.

PMID- 14687165
OWN - NLM
STAT- MEDLINE
DCOM- 20040315
LR  - 20190901
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 19
IP  - 1
DP  - 2004 Jan 1
TI  - Review article: the ageing bowel and intolerance to aspirin.
PG  - 39-45
AB  - Aspirin has a role in the prevention of cardiovascular and cerebrovascular 
      disease, Alzheimer's dementia and several cancers. Encouraging all 50 year olds 
      to take low-dose aspirin doubles their chances of living a healthy life into 
      their nineties. The widespread use of aspirin, however, is limited as many older 
      subjects are currently unable to take aspirin because of gastrointestinal 
      side-effects. This review explores why gastrointestinal events occur with aspirin 
      use and how a net benefit from prophylactic aspirin might be achieved in older 
      subjects. It is suggested that, by understanding the age-related changes in upper 
      gastrointestinal physiology and the mechanisms by which aspirin leads to the risk 
      reductions associated with its use, it may be possible to direct interventions to 
      improve tolerability in older subjects. This would allow greater numbers of older 
      subjects to gain the benefits associated with aspirin use.
FAU - Newton, J L
AU  - Newton JL
AD  - Institute for Ageing and Health, University of Newcastle upon Tyne, Care of the 
      Elderly Offices, Royal Victoria Infirmary, Newcastle upon Tyne, UK. 
      julianewton@blueyonder.co.uk
FAU - Johns, C E
AU  - Johns CE
FAU - May, F E B
AU  - May FE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Forecasting
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Helicobacter Infections/prevention & control
MH  - Helicobacter pylori
MH  - Humans
MH  - Intestinal Mucosa
RF  - 68
EDAT- 2003/12/23 05:00
MHDA- 2004/03/17 05:00
CRDT- 2003/12/23 05:00
PHST- 2003/12/23 05:00 [pubmed]
PHST- 2004/03/17 05:00 [medline]
PHST- 2003/12/23 05:00 [entrez]
AID - 1811 [pii]
AID - 10.1046/j.1365-2036.2003.01811.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2004 Jan 1;19(1):39-45. doi: 
      10.1046/j.1365-2036.2003.01811.x.

PMID- 28344205
OWN - NLM
STAT- MEDLINE
DCOM- 20180322
LR  - 20180322
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 81
IP  - 7
DP  - 2017 Jun 23
TI  - Decreased Serum Albumin Predicts Bleeding Events in Patients on Antiplatelet 
      Therapy After Percutaneous Coronary Intervention.
PG  - 999-1005
LID - 10.1253/circj.CJ-17-0015 [doi]
AB  - BACKGROUND: Antiplatelet therapy (APT) after percutaneous coronary intervention 
      (PCI) prevents ischemic events with increased risk of bleeding. Little is known 
      about the relationship between hypoalbuminemia and bleeding risk in patients 
      receiving APT after PCI. This study investigated the association between serum 
      albumin level and bleeding events in this population.Methods and Results:We 
      enrolled 438 consecutive patients who were prescribed dual APT (DAPT; aspirin and 
      thienopyridine) beyond 1 month after successful PCI without adverse events. The 
      patients were divided into 3 groups according to serum albumin tertile: tertile 
      1, ≤3.7 g/dL; tertile 2, 3.8-4.1 g/dL; and tertile 3, ≥4.2 g/dL. Adverse bleeding 
      events were defined as Bleeding Academic Research Consortium criteria types 2, 3, 
      and 5. During the median follow-up of 29.5 months, a total of 30 adverse bleeding 
      events were observed. Median duration of DAPT was 14 months. The tertile 1 group 
      had the highest risk of adverse bleeding events (event-free rate, 83.1%, 94.3% 
      and 95.8%, respectively; P<0.001). On Cox proportional hazards modeling, serum 
      albumin independently predicted adverse bleeding events (HR, 0.10, 95% CI: 
      0.027-0.39, P=0.001, for tertile 3 vs. tertile 1). CONCLUSIONS: Decreased serum 
      albumin predicted bleeding events in patients with APT after PCI.
FAU - Tatami, Yosuke
AU  - Tatami Y
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Ishii, Hideki
AU  - Ishii H
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Aoki, Toshijiro
AU  - Aoki T
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Harada, Kazuhiro
AU  - Harada K
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Hirayama, Kenshi
AU  - Hirayama K
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Shibata, Yohei
AU  - Shibata Y
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Sumi, Takuya
AU  - Sumi T
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Negishi, Yosuke
AU  - Negishi Y
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Kawashima, Kazuhiro
AU  - Kawashima K
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Kunimura, Ayako
AU  - Kunimura A
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Kawamiya, Toshiki
AU  - Kawamiya T
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Yamamoto, Dai
AU  - Yamamoto D
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Suzuki, Susumu
AU  - Suzuki S
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
FAU - Murohara, Toyoaki
AU  - Murohara T
AD  - Department of Cardiology, Nagoya University Graduate School of Medicine.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Observational Study
DEP - 20170325
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
RN  - ZIF514RVZR (Serum Albumin, Human)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aspirin/administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*adverse effects
MH  - *Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - *Postoperative Hemorrhage/blood/epidemiology/etiology
MH  - *Pyridines/administration & dosage/adverse effects
MH  - Risk Factors
MH  - Serum Albumin, Human/*metabolism
MH  - Time Factors
OTO - NOTNLM
OT  - Albumin
OT  - Antiplatelet therapy
OT  - Bleeding event
OT  - Percutaneous coronary intervention
EDAT- 2017/03/28 06:00
MHDA- 2018/03/23 06:00
CRDT- 2017/03/28 06:00
PHST- 2017/03/28 06:00 [pubmed]
PHST- 2018/03/23 06:00 [medline]
PHST- 2017/03/28 06:00 [entrez]
AID - 10.1253/circj.CJ-17-0015 [doi]
PST - ppublish
SO  - Circ J. 2017 Jun 23;81(7):999-1005. doi: 10.1253/circj.CJ-17-0015. Epub 2017 Mar 
      25.

PMID- 27930430
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20181203
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 69
IP  - 2
DP  - 2017 Feb
TI  - W1, a Novel Oral Antiplatelet Agent With Less Resistance Than Clopidogrel.
PG  - 110-117
LID - 10.1097/FJC.0000000000000449 [doi]
AB  - Clopidogrel (CLO) is a clinical antiplatelet agent, about which there are major 
      concerns because its antiplatelet efficiency decreases with insufficient 
      metabolic activation, leading to "clopidogrel resistance." We aimed to determine 
      the antiplatelet effects of W1, a novel molecule composed of 2-O-clopidogrel and 
      aspirin (1:1 ratio), on platelet aggregation ex vivo and thrombus formation in 
      vivo, and its susceptibility to CLO resistance in combination with other 
      therapies in rats. Platelets were prepared, and an arteriovenous shunt thrombosis 
      model was established using Wistar rats to measure platelet aggregation and 
      thrombus formation, respectively. W1 markedly inhibited adenosine 5'-diphosphate 
      (ADP)-induced platelet aggregation and thrombus formation dose dependently (0.3, 
      1, and 3 mg/kg). W1 (3 mg/kg) acted rapidly at 0.5 hours and lasted for 72 hours. 
      W1 prolonged bleeding and clotting times in mice, confirming its antithrombotic 
      properties. Compared with CLO 10 mg/kg, the positive control, W1 3 mg/kg exerted 
      equivalent effects on the above specifications. In addition, cyclic adenosine 
      monophosphate levels, measured in rat platelets, increased rapidly after 
      prostaglandin E1 (alprostadil) stimulation of the vehicle control (0.5% methyl 
      cellulose suspension) and W1 (3 mg/kg)-treated groups. ADP (50 μm) reduced the 
      control levels more remarkably than W1 did (P < 0.05 in 3 minutes or P < 0.001 at 
      5 minutes), suggesting that W1 suppressed ADP-induced cyclic adenosine 
      monophosphate reduction. This was associated with a significant platelet 
      reactivity inhibition measured using the vasodilator-stimulated phosphoprotein 
      assay. CLO or W1 coadministration with or without omeprazole and amlodipine to 
      rats to investigate the pharmacodynamic interactions revealed that W1 exhibited 
      more stable and potent antithrombotic effects than CLO did. In conclusion, both 
      W1 and CLO showed antiplatelet and antithrombotic effects, while the former 
      exhibited less CLO resistance in combination with omeprazole or amlodipine, 2 
      drugs that inhibit CLO metabolism. Therefore, this study implies that W1 may be a 
      promising oral antiplatelet agent for reducing CLO resistance after percutaneous 
      coronary intervention.
FAU - Ge, Pengxin
AU  - Ge P
AD  - *Department of Pharmacology and Toxicology, Beijing Institute of Radiation 
      Medicine, Beijing, China; †Graduate School of Anhui Medical University, Hefei, 
      China; ‡Department of Geriatric Cardiology, Chinese PLA General Hospital, 
      Beijing, China; and §Guangzhou Health Pharmaceutical Research and Development Co, 
      Ltd, Guangzhou, China.
FAU - Du, Li
AU  - Du L
FAU - Han, Chunguang
AU  - Han C
FAU - Li, Hui
AU  - Li H
FAU - Feng, Yanguo
AU  - Feng Y
FAU - Han, Jie
AU  - Han J
FAU - Wang, Zhen
AU  - Wang Z
FAU - Xiong, Liangzhong
AU  - Xiong L
FAU - Yuan, Meiru
AU  - Yuan M
FAU - Liu, Yongxue
AU  - Liu Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage/analogs & derivatives
MH  - Clopidogrel
MH  - Drug Combinations
MH  - Drug Resistance/drug effects/physiology
MH  - Mice
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/chemistry
MH  - Random Allocation
MH  - Rats
MH  - Rats, Wistar
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/chemistry
EDAT- 2016/12/09 06:00
MHDA- 2017/11/29 06:00
CRDT- 2016/12/09 06:00
PHST- 2016/12/09 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2016/12/09 06:00 [entrez]
AID - 10.1097/FJC.0000000000000449 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2017 Feb;69(2):110-117. doi: 
      10.1097/FJC.0000000000000449.

PMID- 3287675
OWN - NLM
STAT- MEDLINE
DCOM- 19880706
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 49
IP  - 5
DP  - 1988 Mar 1
TI  - A study of bleeding time in 120 long-term aspirin trial patients.
PG  - 463-70
AB  - The bleeding time was measured in 120 patients participating in a longterm 
      randomised double-blind trial of aspirin in thromboembolic prophylaxis (UK-TIA 
      aspirin Study). In 70 patients taking aspirin 300 mg or 1,200 mg daily for a mean 
      duration of 35 months the bleeding time averaged 228 seconds. In comparison with 
      30 patients randomised to placebo and not taking aspirin whose bleeding time 
      averaged 217 seconds, there was no significant difference. Stratification of 
      bleeding time estimation by duration of treatment suggested no significant trend 
      in either placebo or aspirin groups over several years. These results suggest 
      that the longterm trials of aspirin should be looked at again from the point of 
      view of efficacy of treatment by time from randomisation.
FAU - Frith, P A
AU  - Frith PA
AD  - Department of Clinical Neurology, Radcliffe Infirmary, Oxford, U.K.
FAU - Warlow, C P
AU  - Warlow CP
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Random Allocation
MH  - Thromboembolism/blood/*prevention & control
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
AID - S0049-3848(98)90003-2 [pii]
AID - 10.1016/s0049-3848(98)90003-2 [doi]
PST - ppublish
SO  - Thromb Res. 1988 Mar 1;49(5):463-70. doi: 10.1016/s0049-3848(98)90003-2.

PMID- 6342955
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20190908
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 8
IP  - 6
DP  - 1983
TI  - Gastro-intestinal blood loss with high dose tilcotil (Ro 12-0068) and aspirin: an 
      open crossover clinical trial and pharmacokinetic assessment in normal 
      volunteers.
PG  - 412-6
AB  - An open crossover study was carried out in 8 normal volunteer subjects to compare 
      faecal blood loss resulting from tilcotil (Ro12-0068), a new anti-inflammatory 
      agent, and from enteric-coated aspirin. After a 1-week run-in period, subjects 
      were allocated at random to receive treatment for 2 weeks with either 40 mg 
      tilcotil as a single dose per day or aspirin, 900 mg 4-times daily, reduced if 
      necessary to a maximum tolerated dose. Subjects were then crossed over to the 
      alternative treatment for a further 2 weeks. The results showed that tilcotil 
      produced less blood loss, assessed by a radioactive labelling method, and was 
      better tolerated than aspirin. Plasma concentrations of tilcotil showed that the 
      drug's half-life was approximately 50 hours, compatible with once daily dosage, 
      and steady state concentrations on multiple dosing were reached after 10 to 12 
      days.
FAU - Bird, H A
AU  - Bird HA
FAU - Pickup, M E
AU  - Pickup ME
FAU - Taylor, P
AU  - Taylor P
FAU - Lowe, J R
AU  - Lowe JR
FAU - McEvoy, M
AU  - McEvoy M
FAU - Galloway, D B
AU  - Galloway DB
FAU - Wright, V
AU  - Wright V
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Thiazines)
RN  - 13T4O6VMAM (Piroxicam)
RN  - R16CO5Y76E (Aspirin)
RN  - Z1R9N0A399 (tenoxicam)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - *Piroxicam/*analogs & derivatives
MH  - Random Allocation
MH  - Thiazines/*administration & dosage/adverse effects/blood
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1185/03007998309111747 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1983;8(6):412-6. doi: 10.1185/03007998309111747.

PMID- 31238700
OWN - NLM
STAT- MEDLINE
DCOM- 20200527
LR  - 20200527
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 140
IP  - 8
DP  - 2019 Aug 20
TI  - Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient 
      Ischemic Attack and Minor Ischemic Stroke.
PG  - 658-664
LID - 10.1161/CIRCULATIONAHA.119.040713 [doi]
AB  - BACKGROUND: In patients with acute minor ischemic stroke or high-risk transient 
      ischemic attack enrolled in the POINT trial (Platelet-Oriented Inhibition in New 
      TIA and Minor Ischemic Stroke [POINT] Trial), the combination of clopidogrel and 
      aspirin for 90 days reduced major ischemic events but increased major hemorrhage 
      in comparison to aspirin alone. METHODS: In a secondary analysis of POINT 
      (N=4881), we assessed the time course for benefit and risk from the combination 
      of clopidogrel and aspirin. The primary efficacy outcome was a composite of 
      ischemic stroke, myocardial infarction, or ischemic vascular death. The primary 
      safety outcome was major hemorrhage. Risks and benefits were estimated for 
      delayed times of treatment initiation using left-truncated models. RESULTS: 
      Through 90 days, the rate of major ischemic events was initially high then 
      decreased markedly, whereas the rate of major hemorrhage remained low but 
      relatively constant throughout. With the use of a model-based approach, the 
      optimal change point for major ischemic events was 21 days (0-21 days hazard 
      ratio 0.65 for clopidogrel-aspirin versus aspirin; 95% CI, 0.50-0.85; P=0.0015, 
      in comparison to 22-90 days hazard ratio, 1.38; 95% CI, 0.81-2.35; P=0.24). 
      Models showed benefits of clopidogrel-aspirin for treatment delayed as long as 3 
      days after symptom onset. CONCLUSIONS: The benefit of clopidogrel-aspirin occurs 
      predominantly within the first 21 days, and outweighs the low, but ongoing risk 
      of major hemorrhage. When considered with the results of the CHANCE trial 
      (Clopidogrel in High-Risk Patients With Non-disabling Cerebrovascular Events), a 
      similar trial treating with clopidogrel-aspirin for 21 days and showing no 
      increase in major hemorrhage, these results suggest that limiting 
      clopidogrel-aspirin use to 21 days may maximize benefit and reduce risk after 
      high-risk transient ischemic attack or minor ischemic stroke. CLINICAL TRIAL 
      REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: 
      NCT00991029.
FAU - Johnston, S Claiborne
AU  - Johnston SC
AD  - Dean's Office, Dell Medical School, University of Texas, Austin (S.C.J.).
FAU - Elm, Jordan J
AU  - Elm JJ
AD  - Data Coordination Unit, Department of Public Health Sciences, Medical University 
      of South Carolina, Charleston (J.J.E., Y.Y.P.).
FAU - Easton, J Donald
AU  - Easton JD
AD  - Department of Neurology, University of California, San Francisco (J.D.E., M.F., 
      A.S.K., K.G.Z.).
FAU - Farrant, Mary
AU  - Farrant M
AD  - Department of Neurology, University of California, San Francisco (J.D.E., M.F., 
      A.S.K., K.G.Z.).
FAU - Barsan, William G
AU  - Barsan WG
AD  - Department of Emergency Medicine, University of Michigan, Ann Arbor (W.G.B.).
FAU - Kim, Anthony S
AU  - Kim AS
AD  - Department of Neurology, University of California, San Francisco (J.D.E., M.F., 
      A.S.K., K.G.Z.).
FAU - Lindblad, Anne S
AU  - Lindblad AS
AD  - The Emmes Corporation, Rockville, MD (A.S.L.).
FAU - Palesch, Yuko Y
AU  - Palesch YY
AD  - Dean's Office, Dell Medical School, University of Texas, Austin (S.C.J.).
FAU - Zurita, Karla G
AU  - Zurita KG
AD  - Department of Neurology, University of California, San Francisco (J.D.E., M.F., 
      A.S.K., K.G.Z.).
FAU - Albers, Gregory W
AU  - Albers GW
AD  - Department of Neurology and Neurological Sciences, Stanford Stroke Center, 
      Stanford University, Palo Alto, CA (G.W.A., N.V.).
FAU - Cucchiara, Brett L
AU  - Cucchiara BL
AD  - Department of Neurology, University of Pennsylvania, Philadelphia (B.L.C.).
FAU - Kleindorfer, Dawn O
AU  - Kleindorfer DO
AD  - Department of Neurology and Rehabilitation Medicine, University of Cincinnati 
      College of Medicine, OH (D.O.K.).
FAU - Lutsep, Helmi L
AU  - Lutsep HL
AD  - Department of Neurology, Oregon Health and Science University, Portland (H.L.L.).
FAU - Pearson, Claire
AU  - Pearson C
AD  - Department of Emergency Medicine, Wayne State University School of Medicine, 
      Detroit, MI (C.P.).
FAU - Sethi, Pramod
AU  - Sethi P
AD  - Cone Health Comprehensive Stroke Center/Guilford Neurologic Associates, 
      Greensboro, NC (P.S.).
FAU - Vora, Nirali
AU  - Vora N
AD  - Department of Neurology and Neurological Sciences, Stanford Stroke Center, 
      Stanford University, Palo Alto, CA (G.W.A., N.V.).
CN  - POINT and Neurological Emergencies Treatment Trials Network Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00991029
GR  - U01 NS062835/NS/NINDS NIH HHS/United States
GR  - U01 NS056975/NS/NINDS NIH HHS/United States
GR  - U01 NS059041/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20190626
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clinical Protocols
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination/*adverse effects
MH  - Drug-Related Side Effects and Adverse Reactions/*prevention & control
MH  - Hemorrhage/etiology/*prevention & control
MH  - Humans
MH  - Ischemia/*drug therapy
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Proportional Hazards Models
MH  - Risk
MH  - Risk Assessment
MH  - Stroke/*drug therapy
MH  - *Time Factors
OTO - NOTNLM
OT  - aspirin
OT  - clopidogrel
OT  - ischemic attack, transient
OT  - platelet aggregation inhibitors
OT  - stroke
EDAT- 2019/06/27 06:00
MHDA- 2020/05/28 06:00
CRDT- 2019/06/27 06:00
PHST- 2019/06/27 06:00 [pubmed]
PHST- 2020/05/28 06:00 [medline]
PHST- 2019/06/27 06:00 [entrez]
AID - 10.1161/CIRCULATIONAHA.119.040713 [doi]
PST - ppublish
SO  - Circulation. 2019 Aug 20;140(8):658-664. doi: 10.1161/CIRCULATIONAHA.119.040713. 
      Epub 2019 Jun 26.

PMID- 27268656
OWN - NLM
STAT- MEDLINE
DCOM- 20170202
LR  - 20170308
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 17
IP  - 5
DP  - 2016
TI  - The Efficacy of Aspirin in Preventing the Recurrence of Colorectal Adenoma: a 
      Renewed Meta-Analysis of Randomized Trials.
PG  - 2711-7
AB  - BACKGROUND: Through search the possible randomized control trials, we make a 
      renewed meta-analysis in order to assess the impact of aspirin in preventing the 
      recurrence of colorectal adenoma. MATERIALS AND METHODS: The Medicine/PubMed, 
      Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Chinese 
      biomedical literature service system (SinoMed) databases were searched for the 
      related randomized controlled trials until to the April 2016. Three different 
      authors respectively evaluated the quality of studies and extracted data, and we 
      used the STATA software to analyze, investigate heterogeneity between the data, 
      using the fixed-effects model to calculate and merge data. RESULTS: 7 papers were 
      included the renewed meta- analysis, among these studies, two pairs were 
      identified as representing the same study population, with the only difference 
      being the duration of follow-up. Thus there were only five papers included our 
      meta-analysis, and one Chinese paper were also included the work. Results were 
      categorized by the length of follow-up, different kinds of people, varied dose of 
      oral aspirin. The relative of adenoma in patients taking aspirin vs placebo were 
      0.73 (95% CI 0.55-0.98, P=0.039) with 1 year follow up; 0.84 (95% CI 0.72-0.98, 
      P=0.484) with greater than 1 year follow up; for the advanced adenoma, the RR 
      0.68 (95% CI 0.49-0.94, P=0.582),for one year; RR=0.75 (95% CI 0.52-1.07, 
      P=0.552) for greater one year. Furthermore the white population could divided 
      into two subgroups according to the different length of follow-up time. When the 
      length of follow-up time less than 3-year, The RR of two subgroups respective 
      were RR=0.86 (95% CI 0.76-0.98, P=0.332), I2=0%, RR=0.68 (95% CI 0.47-0.98, 
      P=0.552), I2=64.6%, But with the extension of follow-up time greater than 2-year, 
      with the white, oral aspirin without considering dose had no efficacy on 
      preventing the recurrence of any adenoma, the RR was 0.86 (95% CI 0.71-1.05, 
      P=0.302), I2=16.4%. CONCLUSIONS: This meta-analysis indicated that oral aspirin 
      is associated with a remarkable decrease in the recurrence of any adenoma and 
      advanced adenomas in patients follow-up for 1 year without concerning the dose of 
      aspirin, but with the extension of follow-up time for greater than 1 year, oral 
      aspirin can be effective on preventing the recurrence of any adenoma, but for the 
      advanced adenoma, the result indicated that oral aspirin had no efficacy, 
      According to the inclusion of ethnic groups, we also divided relevant papers into 
      two subgroups as the yellow and white group. Then the follow-up time was less 
      than 3 years, oral aspirin without considering the dose, had an significant 
      efficacy on preventing the recurrence of any adenoma. But with the follow-up 
      greater than 2 years, oral aspirin had no effect in the white.
FAU - Zhao, Tai-Yun
AU  - Zhao TY
AD  - Department of Gastroenterology, The people,s hospital of BoZHou Anhui province, 
      Shandong, China E-mail : yaojunwang@188.com.
FAU - Tu, Jing
AU  - Tu J
FAU - Wang, Yin
AU  - Wang Y
FAU - Cheng, Da-Wei
AU  - Cheng DW
FAU - Gao, Xian-Kui
AU  - Gao XK
FAU - Luo, Hao
AU  - Luo H
FAU - Yan, Bi-Chun
AU  - Yan BC
FAU - Xu, Xiao-Li
AU  - Xu XL
FAU - Zhang, Hong-Ling
AU  - Zhang HL
FAU - Lu, Xing-Jun
AU  - Lu XJ
FAU - Wang, Yao-Jun
AU  - Wang YJ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/*drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Humans
MH  - Neoplasm Recurrence, Local/*prevention & control
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
EDAT- 2016/06/09 06:00
MHDA- 2017/02/06 06:00
CRDT- 2016/06/09 06:00
PHST- 2016/06/09 06:00 [entrez]
PHST- 2016/06/09 06:00 [pubmed]
PHST- 2017/02/06 06:00 [medline]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2016;17(5):2711-7.

PMID- 2632446
OWN - NLM
STAT- MEDLINE
DCOM- 19900521
LR  - 20131121
IS  - 0301-4738 (Print)
IS  - 0301-4738 (Linking)
VI  - 37
IP  - 3
DP  - 1989 Jul-Sep
TI  - Methodology for studies on medical therapy of cataracts: cataract-II.
PG  - 118-20
AB  - The methodology for testing any possible effect of potential anti-cataract agents 
      is described. This is based on slit lamp and ophthalmoscopic cataract 
      classification and on visual acuity. The difficulties encountered in such studies 
      are highlighted. The presented methodology is suggested to be fairly adequate in 
      assessing usefulness of any possible medical therapy of cataracts.
FAU - Sharma, Y R
AU  - Sharma YR
FAU - Vajpayee, R B
AU  - Vajpayee RB
FAU - Bhatnagar, R
AU  - Bhatnagar R
FAU - Mohan, M
AU  - Mohan M
FAU - Azad, R V
AU  - Azad RV
FAU - Kumar, M
AU  - Kumar M
FAU - Nath, R
AU  - Nath R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Ophthalmol
JT  - Indian journal of ophthalmology
JID - 0405376
RN  - 0 (Vitamins)
RN  - 184SNS8VUH (Sulindac)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Cataract/classification/*drug therapy
MH  - Drug Evaluation/methods
MH  - Follow-Up Studies
MH  - Glutathione/therapeutic use
MH  - Humans
MH  - Sulindac/therapeutic use
MH  - Vitamins/therapeutic use
EDAT- 1989/07/01 00:00
MHDA- 1989/07/01 00:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 1989/07/01 00:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Ophthalmol. 1989 Jul-Sep;37(3):118-20.

PMID- 16235290
OWN - NLM
STAT- MEDLINE
DCOM- 20060224
LR  - 20220316
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 4
DP  - 2005 Oct 19
TI  - Antiplatelet therapy for preventing stroke in patients with non-valvular atrial 
      fibrillation and no previous history of stroke or transient ischemic attacks.
PG  - CD001925
AB  - BACKGROUND: Non-valvular atrial fibrillation (AF) carries an increased risk of 
      stroke. Antiplatelet therapy (APT) is proven effective for stroke prevention in 
      most patients at high-risk for vascular events, but its value for primary stroke 
      prevention in patients with non-valvular AF merits separate consideration because 
      of the suspected cardioembolic mechanism of most strokes in AF patients. 
      OBJECTIVES: To assess the efficacy and safety of long-term APT for primary 
      prevention of stroke in patients with chronic non-valvular AF. SEARCH STRATEGY: 
      We searched the Cochrane Stroke Group Trials Register (searched August 2004). In 
      addition, we searched the Cochrane Central Register of Controlled Trials (The 
      Cochrane Library Issue 1, 2005), MEDLINE (1966 to June 2004), and the reference 
      lists of recent review articles. We also contacted experts working in the field 
      to identify unpublished and ongoing trials. SELECTION CRITERIA: Randomized trials 
      comparing long-term APT with placebo or control in patients with non-valvular AF 
      and no history of transient ischemic attack (TIA) or stroke. A sensitivity 
      analysis included one additional randomized trial involving primary prevention 
      with aspirin plus very low dose warfarin. DATA COLLECTION AND ANALYSIS: Two 
      authors independently selected trials for inclusion and extracted data for each 
      outcome. Unpublished data were obtained from trial investigators. MAIN RESULTS: 
      Three trials tested aspirin in dosages ranging from 75 mg to 325 mg per day and 
      125 mg every other day to placebo (in two trials) or control (in one trial) in 
      1965 AF patients without prior stroke or TIA. The mean duration of follow up 
      averaged 1.3 years per participant. Aspirin was associated with non-significant 
      lower risks of all stroke (odds ratio (OR) 0.70, 95% confidence interval (CI) 
      0.47 to 1.07), ischemic stroke (OR 0.70, 95% CI 0.46 to 1.07), all disabling or 
      fatal stroke (OR 0.86, 95% CI 0.50 to 1.49) and all-cause death (OR 0.75, 95% CI 
      0.54 to 1.04). The combination of stroke, myocardial infarction or vascular death 
      was significantly reduced (OR 0.71, 95% CI 0.51 to 0.97 ). No increase in 
      intracranial hemorrhage or major extracranial hemorrhage was observed. AUTHORS' 
      CONCLUSIONS: Aspirin appears to reduce stroke and major vascular events in 
      patients with non-valvular AF similar to its effect in other high-risk patients 
      (ie by about 25%). For primary prevention among AF patients with an average 
      stroke rate of 4% per year, about 10 strokes would likely be prevented yearly for 
      every 1000 AF patients given aspirin.
FAU - Aguilar, M
AU  - Aguilar M
FAU - Hart, R
AU  - Hart R
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20051019
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2000;(2):CD001925. PMID: 10796452
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Humans
MH  - Ischemic Attack, Transient/etiology
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/etiology/*prevention & control
RF  - 26
EDAT- 2005/10/20 09:00
MHDA- 2006/02/25 09:00
CRDT- 2005/10/20 09:00
PHST- 2005/10/20 09:00 [pubmed]
PHST- 2006/02/25 09:00 [medline]
PHST- 2005/10/20 09:00 [entrez]
AID - 10.1002/14651858.CD001925.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001925. doi: 
      10.1002/14651858.CD001925.pub2.

PMID- 3948691
OWN - NLM
STAT- MEDLINE
DCOM- 19860424
LR  - 20190912
IS  - 0012-6578 (Print)
IS  - 0012-6578 (Linking)
VI  - 20
IP  - 2
DP  - 1986 Feb
TI  - Aspirin and Reye's syndrome: the change in prescribing habits of health 
      professionals.
PG  - 143-5
AB  - Epidemiological studies demonstrate the possible increased risk of Reye's 
      syndrome after aspirin ingestion in children suffering from viral influenza or 
      chicken pox. This study was conducted to determine whether the possible 
      association between aspirin and Reye's syndrome in viral influenza and chicken 
      pox deterred pediatricians and pharmacists in a large American city (Columbus, 
      Ohio) from prescribing or recommending aspirin to their pediatric patients 
      suffering from other causes of fever or pain. The results indicate that 90.6 
      percent of pediatricians and 97.8 percent of pharmacists no longer recommend 
      aspirin to their pediatric patients, and an almost identical percentage recommend 
      acetaminophen instead of aspirin. This change in prescribing habits of health 
      professionals is reflected in a drop in sales of pediatric aspirin products with 
      a simultaneous rise in sales of pediatric acetaminophen products reported by 93.3 
      percent of pharmacies. However, only 69.8 percent of pediatricians and 86.7 
      percent of pharmacists noted that their abstention from prescribing or 
      recommending aspirin to children was rooted in a belief in a possible association 
      between aspirin and Reye's syndrome.
FAU - Rahwan, G L
AU  - Rahwan GL
FAU - Rahwan, R G
AU  - Rahwan RG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Drug Intell Clin Pharm
JT  - Drug intelligence & clinical pharmacy
JID - 0212457
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects
MH  - Aspirin/*adverse effects
MH  - Child
MH  - *Drug Prescriptions
MH  - Drug Utilization
MH  - Humans
MH  - Ohio
MH  - Reye Syndrome/*chemically induced
MH  - Surveys and Questionnaires
EDAT- 1986/02/01 00:00
MHDA- 1986/02/01 00:01
CRDT- 1986/02/01 00:00
PHST- 1986/02/01 00:00 [pubmed]
PHST- 1986/02/01 00:01 [medline]
PHST- 1986/02/01 00:00 [entrez]
AID - 10.1177/106002808602000209 [doi]
PST - ppublish
SO  - Drug Intell Clin Pharm. 1986 Feb;20(2):143-5. doi: 10.1177/106002808602000209.

PMID- 1519852
OWN - NLM
STAT- MEDLINE
DCOM- 19921006
LR  - 20131121
IS  - 0003-0805 (Print)
IS  - 0003-0805 (Linking)
VI  - 146
IP  - 3
DP  - 1992 Sep
TI  - Amelioration of sleep apnea by salicylate-induced hyperventilation.
PG  - 711-5
AB  - It is well documented that upper airway (UAW) muscle activity is augmented in 
      response to increased respiratory drive, the overall effect being an improvement 
      in UAW patency. We have recently shown that salicylate-induced ventilatory 
      stimulation increased UAW muscle electrical activity and decreased UAW resistance 
      and collapsibility in anesthetized dogs. In the present study, we evaluated the 
      effect of respiratory stimulation produced by high therapeutic doses of aspirin 
      on sleep in nine patients with previously diagnosed sleep apnea. A control, 
      all-night, polysomnographic sleep study, including oximetry and ventilatory 
      monitoring by inductive plethysmography, was compared with a second study 
      undertaken after patients ingested 8 to 10 g of aspirin over a period of 4 to 5 
      h. Aspirin ingestion resulted in high therapeutic salicylate serum levels (33 +/- 
      2.5 mg/dl, mean +/- SE) the following morning and was associated with marked 
      ventilatory stimulation. Mean sleep duration and the relative partitioning of 
      sleep stages were not affected by aspirin. However, aspirin-induced 
      hyperventilation was associated with a significant non-rapid decrease in periodic 
      breathing and the frequency of both obstructive and mixed apneas in all non-rapid 
      eye movement (REM) sleep stages. The total number of apneas over the whole night 
      was reduced in all subjects and on average fell from a control rate of 42 +/- 7 
      to 28 +/- 7 apneas/h (p less than 0.01). Similarly, the mean duration of apneas 
      fell from 23 +/- 2 to 20 +/- 1 s (p less than 0.05), and the overall time spent 
      in apneas decreased from 17 +/- 3 to 10 +/- 3 min/h (p less than 0.01).(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Pillar, G
AU  - Pillar G
AD  - Department of Medicine B, Bnai Zion Medical Center, Faculty of Medicine, 
      Technion, Haifa, Israel.
FAU - Schnall, R
AU  - Schnall R
FAU - Odeh, M
AU  - Odeh M
FAU - Oliven, A
AU  - Oliven A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am Rev Respir Dis
JT  - The American review of respiratory disease
JID - 0370523
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/blood
MH  - Drug Evaluation
MH  - Humans
MH  - Hyperventilation/blood/*chemically induced/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic
MH  - Respiratory Muscles/drug effects/physiopathology
MH  - Sleep Apnea Syndromes/blood/physiopathology/*therapy
MH  - Sleep Stages/drug effects/physiology
MH  - Stimulation, Chemical
MH  - Time Factors
EDAT- 1992/09/01 00:00
MHDA- 1992/09/01 00:01
CRDT- 1992/09/01 00:00
PHST- 1992/09/01 00:00 [pubmed]
PHST- 1992/09/01 00:01 [medline]
PHST- 1992/09/01 00:00 [entrez]
AID - 10.1164/ajrccm/146.3.711 [doi]
PST - ppublish
SO  - Am Rev Respir Dis. 1992 Sep;146(3):711-5. doi: 10.1164/ajrccm/146.3.711.

PMID- 2042465
OWN - NLM
STAT- MEDLINE
DCOM- 19910711
LR  - 20190820
IS  - 0001-6470 (Print)
IS  - 0001-6470 (Linking)
VI  - 62
IP  - 3
DP  - 1991 Jun
TI  - Immobilization increases bone prostaglandin E. Effect of acetylsalicylic acid on 
      disuse osteoporosis studied in dogs.
PG  - 238-43
AB  - The effect of acetylsalicylic acid (aspirin) on bone mass and bone prostaglandin 
      E (PGE) in immobilization osteoporosis was studied in 12 growing dogs using a 
      unilateral hind limb cast-fixation model. Osteoporosis was induced by 
      fiberglass-cast immobilization of the right hind limb for 4 weeks, with the left 
      hind limb as a control. Six dogs received buffered aspirin at 25 mg/kg body 
      weight per os every 8 hours; 6 dogs received no treatment. All the dogs were 
      killed after 4 weeks, and bone samples were collected. Bone mineral content of 
      the distal tibial metaphysis was measured by single-photon absorptiometry. In 
      vitro release of PGE from the calcaneus, tibial cortical bone, tibial cancellous 
      bone, and ilium were measured using a specific radioimmunoassay for PGE. Compared 
      with the controls, the casted limb of untreated dogs had half the bone mass and a 
      twofold increase in bone PGE. Aspirin treatment was associated with a 65 percent 
      reduction in bone PGE and a 13 percent bone mass sparing effect. These results 
      provide indirect evidence that PGE plays a role in immobilization osteoporosis.
FAU - Waters, D J
AU  - Waters DJ
AD  - Department of Small Animal Clinical Sciences, College of Veterinary Medicine, 
      University of Minnesota, St. Paul.
FAU - Caywood, D D
AU  - Caywood DD
FAU - Trachte, G J
AU  - Trachte GJ
FAU - Turner, R T
AU  - Turner RT
FAU - Hodgson, S F
AU  - Hodgson SF
LA  - eng
GR  - AR 35651/AR/NIAMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Acta Orthop Scand
JT  - Acta orthopaedica Scandinavica
JID - 0370352
RN  - 0 (Minerals)
RN  - 0 (Parathyroid Hormone)
RN  - 0 (Phosphates)
RN  - 0 (Prostaglandins E)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Absorptiometry, Photon
MH  - Alkaline Phosphatase/blood
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bone and Bones/*chemistry/drug effects
MH  - Calcium/blood
MH  - Dogs
MH  - Female
MH  - *Immobilization
MH  - Minerals/analysis
MH  - Osteoporosis/etiology/*prevention & control
MH  - Parathyroid Hormone/blood
MH  - Phosphates/blood
MH  - Prostaglandins E/*analysis
MH  - Time Factors
OID - NASA: 91253385
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
AID - 10.3109/17453679108993600 [doi]
PST - ppublish
SO  - Acta Orthop Scand. 1991 Jun;62(3):238-43. doi: 10.3109/17453679108993600.

PMID- 32629007
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 318
DP  - 2020 Nov 1
TI  - Bleeding associated with low-dose aspirin: Comparison of data from the COMPASS 
      randomized controlled trial and routine clinical practice.
PG  - 21-24
LID - S0167-5273(20)33426-4 [pii]
LID - 10.1016/j.ijcard.2020.06.048 [doi]
AB  - Randomized controlled trials (RCTs) have strong internal validity but often have 
      limited external validity. Observational studies have good generalizability and 
      an increasing role in key healthcare decision making. We compared incidence rates 
      of intracranial and major gastrointestinal bleeds in the low-dose aspirin arm 
      (N = 9126) of the COMPASS double-blind RCT (conducted at 602 centres in 33 
      countries) with those from an observational cohort of preventative low-dose 
      aspirin users (N = 54,140) in a primary care database representative of the UK 
      general population - The IQVIA Medical Research Data UK (IMRD-UK). In our 
      observational study analysis, we restricted follow-up to 2 years to be comparable 
      with the duration of the COMPASS trial. Among low-dose aspirin users, incidence 
      rates per 1000 person-years (95% confidence intervals [CIs]) in the IMRD-UK 
      cohort and COMPASS trial participants, respectively, were 0.6 (0.5-0.8) vs. 1.4 
      (0.9-2.1) for intracranial bleeds, and 3.5 (3.1-3.8) vs. 3.7 (2.9-4.8) for major 
      gastrointestinal bleeds. These broadly comparable bleeding rates among COMPASS 
      trial participants and an observational cohort of low-dose aspirin users in 
      IMRD-UK support the use of the latter for generating robust therapeutic evidence, 
      and indicate that the rates from the COMPASS trial are broadly consistent with 
      realistic population-based rates.
CI  - Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - García Rodríguez, Luis A
AU  - García Rodríguez LA
AD  - Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain. 
      Electronic address: lagarcia@ceife.es.
FAU - Vora, Pareen
AU  - Vora P
AD  - Epidemiology, Bayer AG, Berlin, Germany.
FAU - Brobert, Gunnar
AU  - Brobert G
AD  - Epidemiology, Bayer AB, Stockholm, Sweden.
FAU - Soriano-Gabarró, Montse
AU  - Soriano-Gabarró M
AD  - Epidemiology, Bayer AG, Berlin, Germany.
FAU - Cea Soriano, Lucía
AU  - Cea Soriano L
AD  - Department of Public Health and Maternal and Child Health, Faculty of Medicine, 
      Complutense University of Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Randomized Controlled Trial
DEP - 20200703
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - Cohort Studies
MH  - *Gastrointestinal Hemorrhage/chemically induced/diagnosis/epidemiology
MH  - Humans
MH  - Incidence
MH  - Intracranial Hemorrhages
OTO - NOTNLM
OT  - Aspirin
OT  - Gastrointestinal bleeding
OT  - Intracranial bleeding
OT  - Observational
OT  - Trials
COIS- Declaration of Competing Interest LAGR, AR and LCS work for CEIFE, which has 
      received research funding from Bayer AG for other studies. LAGR has previously 
      received honoraria for serving on advisory boards for Bayer AG. PV and MS-G are 
      employees of Bayer AG and GB is an employee of Bayer AB.
EDAT- 2020/07/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
AID - S0167-5273(20)33426-4 [pii]
AID - 10.1016/j.ijcard.2020.06.048 [doi]
PST - ppublish
SO  - Int J Cardiol. 2020 Nov 1;318:21-24. doi: 10.1016/j.ijcard.2020.06.048. Epub 2020 
      Jul 3.

PMID- 36677668
OWN - NLM
STAT- MEDLINE
DCOM- 20230124
LR  - 20230124
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 28
IP  - 2
DP  - 2023 Jan 6
TI  - Effects of Losartan, Atorvastatin, and Aspirin on Blood Pressure and Gut 
      Microbiota in Spontaneously Hypertensive Rats.
LID - 10.3390/molecules28020612 [doi]
LID - 612
AB  - Many studies have shown that alterations in the gut microbiota are associated 
      with hypertension. Our study aimed to observe the characteristics of the gut 
      microbiota in hypertension and to further explore whether drug molecules can play 
      a therapeutic role in hypertension by interfering with the gut microbiota. We 
      evaluated the differences in the composition of the gut microbiota in 
      spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY). Meanwhile, 
      three first-line cardiovascular disease (CVD) drugs, losartan, atorvastatin, and 
      aspirin, were used to treat the SHR in order to observe their effects on the gut 
      microbiota in SHR. The 16S rDNA results showed that the diversity and richness of 
      the gut microbiota in SHR were significantly reduced compared with that of the 
      WKY, the Firmicutes/Bacteroidetes ratio was increased, the abundances of 
      Bifidobacterium and short chain fatty acids (SCFAs)-producing bacteria decreased, 
      and the abundance of lactate-producing bacteria increased. In addition to 
      lowering the blood pressure, losartan increased the abundances of Alistipes, 
      Bacteroides, and Butyricimonas in SHR, reduced the abundances of Ruminococcaceae, 
      Streptococcus, and Turicibacter, reduced the Firmicutes/Bacteroidetes ratio, and 
      rebalanced the gut microbiota. Losartan also increased the abundances of 
      Bifidobacterium and SCFAs-producing bacteria and reduced the abundance of 
      lactate-producing bacteria. However, atorvastatin and aspirin had no significant 
      effect on the gut microbiota in SHR. The above results showed that losartan could 
      change the characteristics of the gut microbiota in hypertension and rebalance 
      the gut microbiota, which may be related to lowering the blood pressure. 
      Atorvastatin and aspirin have no significant influence on the gut microbiota in 
      SHR.
FAU - Dong, Shuai
AU  - Dong S
AD  - School of Pharmacy, Minzu University of China, Beijing 100081, China.
FAU - Liu, Qi
AU  - Liu Q
AD  - School of Pharmacy, Minzu University of China, Beijing 100081, China.
FAU - Zhou, Xue
AU  - Zhou X
AD  - Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China.
FAU - Zhao, Yubo
AU  - Zhao Y
AD  - School of Pharmacy, Minzu University of China, Beijing 100081, China.
FAU - Yang, Kang
AU  - Yang K
AD  - School of Pharmacy, Minzu University of China, Beijing 100081, China.
FAU - Li, Linsen
AU  - Li L
AD  - School of Pharmacy, Minzu University of China, Beijing 100081, China.
FAU - Zhu, Dan
AU  - Zhu D
AD  - School of Pharmacy, Minzu University of China, Beijing 100081, China.
LA  - eng
GR  - 81673694/National Natural Science Foundation of China/
GR  - 2017YFC1704006/National Key Research and Development Program of China/
GR  - BZKY2021048/the Independent Scientific Research Project of Minzu University of 
      China/
PT  - Journal Article
DEP - 20230106
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - JMS50MPO89 (Losartan)
RN  - A0JWA85V8F (Atorvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Rats
MH  - Animals
MH  - Losartan/pharmacology
MH  - Blood Pressure
MH  - Rats, Inbred SHR
MH  - Atorvastatin/pharmacology
MH  - *Gastrointestinal Microbiome
MH  - Aspirin/pharmacology
MH  - *Hypertension/drug therapy
MH  - Rats, Inbred WKY
PMC - PMC9860566
OTO - NOTNLM
OT  - aspirin
OT  - atorvastatin
OT  - cardiovascular disease
OT  - gut microbiota
OT  - losartan
COIS- The authors declare no conflict of interest.
EDAT- 2023/01/22 06:00
MHDA- 2023/01/25 06:00
CRDT- 2023/01/21 01:43
PHST- 2022/11/04 00:00 [received]
PHST- 2022/12/24 00:00 [revised]
PHST- 2023/01/03 00:00 [accepted]
PHST- 2023/01/21 01:43 [entrez]
PHST- 2023/01/22 06:00 [pubmed]
PHST- 2023/01/25 06:00 [medline]
AID - molecules28020612 [pii]
AID - molecules-28-00612 [pii]
AID - 10.3390/molecules28020612 [doi]
PST - epublish
SO  - Molecules. 2023 Jan 6;28(2):612. doi: 10.3390/molecules28020612.

PMID- 32119125
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20200916
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 149
IP  - 3
DP  - 2020 Jun
TI  - Effect of current guidelines on prevention of pre-eclampsia with low-dose aspirin 
      in primary settings: A population-based case-control study.
PG  - 333-338
LID - 10.1002/ijgo.13133 [doi]
AB  - OBJECTIVE: To evaluate the effect of low-dose aspirin, which was administered at 
      or before the 16th week of pregnancy due to maternal characteristics and history 
      of a pre-existing medical condition, on prevention of pre-eclampsia, and on the 
      birth of a small-for-gestational-age (SGA) neonate without pre-eclampsia in 
      nulliparas in primary settings. METHODS: We performed a case-control study using 
      population-based data on 47 271 nulliparas with a singleton pregnancy who 
      delivered in Slovenia from 2013 to 2017. The treated group received low-dose 
      aspirin. For the untreated group, propensity score matching was used to perform a 
      1:1 matching. In the matched sample, we calculated the odds ratios (OR) with a 
      95% confidence interval (95% CI) with a two-way test for pre-eclampsia, as well 
      as SGA neonates. RESULTS: In the treated group (n=584), the odds for an SGA 
      neonate were significantly increased by 42.7% (OR 1.427, 95% CI 1.001-2.034). 
      However, we found no significant effect on the odds for pre-eclampsia (OR 1.308, 
      95% CI 0.847-2.022). CONCLUSIONS: In anticipation of more substantial 
      population-based data studies, in the Slovenian population, preventive treatment 
      with low-dose aspirin due to maternal characteristics and history of a 
      pre-existing medical condition is not beneficial for the prevention of 
      pre-eclampsia and can harm fetal growth.
CI  - © 2020 International Federation of Gynecology and Obstetrics.
FAU - Premru-Srsen, Tanja
AU  - Premru-Srsen T
AD  - Division of Obstetrics and Gynecology, Department of Perinatology, University 
      Medical Centre Ljubljana, Ljubljana, Slovenia.
AD  - Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
FAU - Kocic, Zorana
AU  - Kocic Z
AD  - Division of Obstetrics and Gynecology, Department of Perinatology, University 
      Medical Centre Ljubljana, Ljubljana, Slovenia.
FAU - Verdenik, Ivan
AU  - Verdenik I
AD  - Research Unit,, Division of Obstetrics and Gynecology, University Medical Centre 
      Ljubljana, Ljubljana, Slovenia.
LA  - eng
PT  - Journal Article
DEP - 20200320
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Case-Control Studies
MH  - Female
MH  - Guideline Adherence
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Small for Gestational Age
MH  - Odds Ratio
MH  - Pre-Eclampsia/drug therapy/*prevention & control
MH  - Pregnancy
MH  - Slovenia
OTO - NOTNLM
OT  - Aspirin
OT  - Pre-eclampsia
OT  - Pregnancy
OT  - Prevention
OT  - Propensity score matching
OT  - Small for gestational age
EDAT- 2020/03/03 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/03/03 06:00
PHST- 2019/07/10 00:00 [received]
PHST- 2019/11/26 00:00 [revised]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/03/03 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/03/03 06:00 [entrez]
AID - 10.1002/ijgo.13133 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2020 Jun;149(3):333-338. doi: 10.1002/ijgo.13133. Epub 
      2020 Mar 20.

PMID- 7030543
OWN - NLM
STAT- MEDLINE
DCOM- 19820222
LR  - 20190825
IS  - 0305-1870 (Print)
IS  - 0305-1870 (Linking)
VI  - 8
IP  - 4
DP  - 1981 Jul
TI  - Failure of aspirin to modify the hypotensive action of captopril in spontaneously 
      hypertensive rats.
PG  - 345-9
AB  - 1. Oral administration of the angiotensin converting enzyme inhibitor, captopril 
      (30 mg/kg per day) to spontaneously hypertensive rats of the Okamoto strain 
      progressively reduced arterial blood pressure by 60 mmHg over 4-5 days. 2. Oral 
      treatment of spontaneously hypertensive rats with aspirin (200 mg/kg per day) for 
      one week did not alter blood pressure, but it greatly reduced the vasodepressor 
      effects of intravenous injections of arachidonic acid (3 mg/kg). 3. The fall in 
      blood pressure of spontaneously hypertensive rats treated concurrently with both 
      aspirin (200 mg/kg per day) and captopril (30 mg/kg per day) was not different to 
      the fall observed in rats treated with captopril alone. 4. The hypotensive action 
      of captopril in spontaneously hypertensive rats does not appear to be due to 
      stimulation of vasodilator prostanoid biosynthesis.
FAU - DiNicolantonio, R
AU  - DiNicolantonio R
FAU - Dusting, G J
AU  - Dusting GJ
FAU - Hutchinson, J S
AU  - Hutchinson JS
FAU - Mendelsohn, F A
AU  - Mendelsohn FA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 9DLQ4CIU6V (Proline)
RN  - 9G64RSX1XD (Captopril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Captopril/*antagonists & inhibitors/pharmacology
MH  - Hypertension/*physiopathology
MH  - Male
MH  - Proline/*analogs & derivatives
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1981/07/01 00:00
MHDA- 1981/07/01 00:01
CRDT- 1981/07/01 00:00
PHST- 1981/07/01 00:00 [pubmed]
PHST- 1981/07/01 00:01 [medline]
PHST- 1981/07/01 00:00 [entrez]
AID - 10.1111/j.1440-1681.1981.tb00738.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 1981 Jul;8(4):345-9. doi: 
      10.1111/j.1440-1681.1981.tb00738.x.

PMID- 9376621
OWN - NLM
STAT- MEDLINE
DCOM- 19971110
LR  - 20131121
IS  - 0867-5910 (Print)
IS  - 0867-5910 (Linking)
VI  - 48
IP  - 3
DP  - 1997 Sep
TI  - Helicobacter pylori and gastric adaptation to repeated aspirin administration in 
      humans.
PG  - 383-91
AB  - The gastric irritant properties of nonsteroidal anti-inflammatory drugs (NSAID) 
      are well established but the pathogenic mechanisms by which these agents damage 
      the mucosa or delay its repair are poorly understood. The phenomenon of gastric 
      adaptation after repeated exposures to ASA is well documented but the involvement 
      of Helicobacter pylori (H. pylori) in NSAID-induced gastropathy and adaptation 
      has not been elucidated. The aim of this study was 1) to compare the gastric 
      damage in response to repeated exposures to ASA in the same subjects before and 
      after eradication of H. pylori and 2) to examine the morphological and functional 
      changes of gastric mucosa during the 14 day treatment with ASA in H. 
      pylori-infected subjects before and after eradication of this bacteria: Eight 
      healthy volunteers (age 19-28) with H. pylori infection were given ASA 1g bd 
      during 14 days before and after H. pylori eradication. Mucosal damage was 
      evaluated by endoscopy before and at 3, 7 and 14 days of ASA administration using 
      modified Lanza score. During endoscopy mucosal biopsies were obtained for 
      determination of DNA synthesis, by measuring 3H-thymidine incorporation into DNA. 
      Prior to each endoscopy gastric microbleeding was determined in three consecutive 
      gastric washings. Three months after successful eradication of H. pylori 
      confirmed by 13C-urea breath test and mucosal rapid urease test, the same 
      subjects received again 14 day treatment with ASA and underwent the same 
      examinations as prior to the therapy. In all subjects, ASA administration induced 
      acute gastric damage with endoscopic Lanza score reaching maximum at 3rd day. In 
      H. pylori-positive subjects, this damage was maintained at similar level up to 
      day 14th, whereas in H. pylori-eradicated subjects, this damage was lessened at 
      day 14th by about 60-75%. Gastric microbleeding also reached its maximum at 3rd 
      day of ASA treatment being significantly higher in H. pylori-eradicated subjects 
      than in those with H. pylori infection. This microbleeding decreased to almost 
      normal values by the end of the study in all H. pylori-negative subjects but 
      remained significantly elevated in H. pylori-infected subjects. DNA synthesis 
      before and following ASA administration was significantly higher in subjects 
      after H. pylori eradication than in those with H. pylori infection. Moreover, 
      this DNA synthesis showed significant increase at day 7 of ASA administration 
      only in H. pylori-eradicated subjects. We conclude that: 1) gastric adaptation to 
      ASA is impaired in H. pylori-positive subjects but eradication of H. pylori 
      restores this adaptation, 2) the DNA synthesis and possibly also mucosal cell 
      turnover in response to ASA are suppressed in H. pylori infection and this can be 
      reversed by eradication of H. pylori.
FAU - Konturek, J W
AU  - Konturek JW
AD  - Department of Medicine B, University of Munster, Germany.
FAU - Dembiński, A
AU  - Dembiński A
FAU - Konturek, S J
AU  - Konturek SJ
FAU - Domschke, W
AU  - Domschke W
LA  - eng
PT  - Duplicate Publication
PT  - Journal Article
PL  - Poland
TA  - J Physiol Pharmacol
JT  - Journal of physiology and pharmacology : an official journal of the Polish 
      Physiological Society
JID - 9114501
RN  - 0 (Salicylates)
RN  - 9007-49-2 (DNA)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 1999 Nov;117(5):1261. PMID: 10702018
MH  - Adaptation, Physiological
MH  - Adult
MH  - Aspirin/*adverse effects/metabolism
MH  - DNA/biosynthesis
MH  - Female
MH  - Gastric Mucosa/*drug effects/metabolism/microbiology
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Gastroscopy
MH  - Helicobacter Infections/*physiopathology
MH  - Helicobacter pylori/*pathogenicity
MH  - Humans
MH  - Male
MH  - Salicylates/blood
EDAT- 1997/10/23 22:31
MHDA- 2000/03/04 09:00
CRDT- 1997/10/23 22:31
PHST- 1997/10/23 22:31 [pubmed]
PHST- 2000/03/04 09:00 [medline]
PHST- 1997/10/23 22:31 [entrez]
PST - ppublish
SO  - J Physiol Pharmacol. 1997 Sep;48(3):383-91.

PMID- 21952617
OWN - NLM
STAT- MEDLINE
DCOM- 20120223
LR  - 20171116
IS  - 1364-5528 (Electronic)
IS  - 0003-2654 (Linking)
VI  - 136
IP  - 22
DP  - 2011 Nov 21
TI  - Competitive binding of small molecules with biopolymers: a fluorescence 
      spectroscopy and chemometrics study of the interaction of aspirin and ibuprofen 
      with BSA.
PG  - 4794-801
LID - 10.1039/c1an15550d [doi]
AB  - The interaction of aspirin and ibuprofen with bovine serum albumin (BSA) was 
      studied by spectrofluorimetry under simulated physiological conditions. Both 
      aspirin and ibuprofen quenched the intrinsic fluorescence of BSA and the binding 
      ratios obtained were 2 : 1 for aspirin-BSA and 3 : 1 for ibuprofen-BSA 
      interactions, respectively. The thermodynamic parameters (ΔH, ΔS and ΔG) obtained 
      from the fluorescence spectroscopy data showed that the binding of aspirin to BSA 
      involved van der Waals interactions and hydrogen bonds. Competitive experiments 
      using warfarin and diazepam as site markers indicated that aspirin was mainly 
      located in the hydrophobic pocket of site II of the protein as well as to a small 
      extent in site I. Furthermore, the competitive interaction of the aspirin and 
      ibuprofen with BSA, which was studied with the use of the three-way 
      excitation-emission fluorescence spectra and a parallel factor analysis (PARAFAC) 
      chemometrics method, showed that the competitive effect of ibuprofen was stronger 
      than that of aspirin, i.e. the former molecule replaced the aspirin from the 
      aspirin-BSA complex.
FAU - Ni, Yongnian
AU  - Ni Y
AD  - State Key Laboratory of Food Science and Technology, Nanchang University, 
      Nanchang, China. ynni@ncu.edu.cn
FAU - Zhu, Ruirui
AU  - Zhu R
FAU - Kokot, Serge
AU  - Kokot S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110928
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - 27432CM55Q (Serum Albumin, Bovine)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Aspirin/*metabolism
MH  - *Binding, Competitive
MH  - Cattle
MH  - Ibuprofen/*metabolism
MH  - Informatics/*methods
MH  - Models, Molecular
MH  - Protein Binding
MH  - Protein Conformation
MH  - Serum Albumin, Bovine/chemistry/*metabolism
MH  - Spectrometry, Fluorescence/*methods
MH  - Substrate Specificity
MH  - Thermodynamics
EDAT- 2011/09/29 06:00
MHDA- 2012/02/24 06:00
CRDT- 2011/09/29 06:00
PHST- 2011/09/29 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2012/02/24 06:00 [medline]
AID - 10.1039/c1an15550d [doi]
PST - ppublish
SO  - Analyst. 2011 Nov 21;136(22):4794-801. doi: 10.1039/c1an15550d. Epub 2011 Sep 28.

PMID- 28803655
OWN - NLM
STAT- MEDLINE
DCOM- 20170914
LR  - 20181202
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 120
IP  - 7
DP  - 2017 Oct 1
TI  - Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary 
      Prevention for Coronary Artery Disease.
PG  - 1118-1121
LID - S0002-9149(17)31114-1 [pii]
LID - 10.1016/j.amjcard.2017.06.052 [doi]
AB  - Aspirin has been the mainstay for secondary prevention of coronary artery disease 
      to decrease early recurrence and severity of recurrent cardiovascular events. 
      However, an increase in gastrointestinal bleeding due to aspirin is preventing 
      many patients from adhering to this daily regimen. PA32540, a combination pill 
      with aspirin and omeprazole, is a newly emerging intervention that has the 
      potential to reinforce patient compliance with the aspirin regimen due to fewer 
      gastrointestinal adverse effects. This systematic review assessed three recent 
      phase 3 clinical trials investigating the safety and efficacy of PA32540. 
      Clinical trials were chosen based on inclusion criteria such as phase 3, 
      randomized, open-label or blinded studies, utilization of enteric-coated aspirin 
      325 mg dose, and measured GI adverse effects and major adverse cardiac events 
      (MACE) as primary outcomes. Study A, a 6-month phase-3 study by Whellan et al., 
      used two identically designed, randomized, double-blind trials to compare the GI 
      adverse events and MACE after the use of PA32540 to 325mg of enteric coated 
      Aspirin (EC-ASA) in subjects at risk for aspirin-associated gastric ulcers. 
      Results showed fewer upper GI symptoms, decreased size of ulcers, and improved 
      heartburn symptoms in subjects receiving PA32540 compared to EC-ASA. Study B, a 
      12-month phase-3 study by Hatoum et al., assessed secondary cardiovascular event 
      prevention in a study population that was treated with PA32540 in comparison to a 
      community setting (CS) group that was started on a standard antiplatelet 
      treatment. Results indicated a 28% reduction of CV events in subjects treated 
      with PA32540 compared to the CS group. Study C, a phase-3 open-label study by 
      Goldstein et al., evaluating secondary prevention of 
      cardiovascular/cerebrovascular events with the use of PA32450 for 12 months found 
      that none of the 12-month completers were reported to have new-onset gastric 
      ulcers. In conclusion, PA32540 could be an effective therapy for secondary 
      prevention of coronary artery disease as studies are showing similar efficacy in 
      preventing MACE with reduced GI side effects.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Kagolanu, Deepthi
AU  - Kagolanu D
AD  - Department of Internal Medicine, Nassau University Medical Center, East Meadow, 
      USA. Electronic address: deepthi.lank@gmail.com.
FAU - Sayedy, Najia
AU  - Sayedy N
AD  - Department of Internal Medicine, Nassau University Medical Center, East Meadow, 
      USA.
FAU - Haseeb, Syed
AU  - Haseeb S
AD  - Department of Medical Education, American University of Caribbean, Coral Gables, 
      USA.
FAU - Shah, Shivani
AU  - Shah S
AD  - School of Public Health, Boston University, Boston, USA.
FAU - Lam, Paul
AU  - Lam P
AD  - Department of Infectious Diseases, Harlem Hospital Columbia, Harlem, USA.
FAU - Munnangi, Swapna
AU  - Munnangi S
AD  - Department of Gastroenterology, Albany Medical Center, Albany, USA.
FAU - Viswanathan, Prakash
AU  - Viswanathan P
AD  - Department of Research, Nassau University Medical Center, East Meadow, USA.
FAU - Stephenson, Kent
AU  - Stephenson K
AD  - Department of Cardiology, Nassau University Medical Center, East Meadow, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20170714
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Coronary Artery Disease/*prevention & control
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Humans
MH  - Omeprazole/*administration & dosage
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Proton Pump Inhibitors/administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - Secondary Prevention/*methods
EDAT- 2017/08/15 06:00
MHDA- 2017/09/15 06:00
CRDT- 2017/08/15 06:00
PHST- 2017/03/29 00:00 [received]
PHST- 2017/06/09 00:00 [revised]
PHST- 2017/06/28 00:00 [accepted]
PHST- 2017/08/15 06:00 [pubmed]
PHST- 2017/09/15 06:00 [medline]
PHST- 2017/08/15 06:00 [entrez]
AID - S0002-9149(17)31114-1 [pii]
AID - 10.1016/j.amjcard.2017.06.052 [doi]
PST - ppublish
SO  - Am J Cardiol. 2017 Oct 1;120(7):1118-1121. doi: 10.1016/j.amjcard.2017.06.052. 
      Epub 2017 Jul 14.

PMID- 33416743
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 1548-6869 (Electronic)
IS  - 1049-2089 (Linking)
VI  - 31
IP  - 4
DP  - 2020
TI  - Preeclampsia Risk and Prevention among Pregnant Medicaid Beneficiaries.
PG  - 1634-1647
LID - 10.1353/hpu.2020.0123 [doi]
AB  - Pregnancy-related hypertensive disorders can cause morbidity and mortality. 
      Low-dose aspirin (LDA) reduces risk. This paper aims to assess Medicaid 
      beneficiaries' risk factors for preeclampsia and their providers' clinical use of 
      LDA in the federal Strong Start for Mothers and Newborns II initiative. 
      Twenty-seven awardees with more than 200 care sites served almost 46,000 women. 
      This mixed-methods analysis assesses rates of risks, incidence of 
      pregnancy-related hypertensive disorders, and assessment of care teams' LDA 
      knowledge and reported prescription practices. Many Strong Start participants had 
      risk factors that merited LDA, but most practices reported inconsistent or 
      non-existent prescribing. Use varied within the three care models and among all 
      provider types. Ancillary care team members often had no knowledge of LDA's 
      benefits, resulting in lost opportunities for educating patients and assessing 
      adherence to LDA use. Clear policies and well-integrated care teams could 
      increase evidence-based use, improve pregnancy outcomes, and promote women's 
      lifelong cardiovascular health.
FAU - Cross-Barnet, Caitlin
AU  - Cross-Barnet C
FAU - Courtot, Brigette
AU  - Courtot B
FAU - Benatar, Sarah
AU  - Benatar S
FAU - Hill, Ian
AU  - Hill I
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Health Care Poor Underserved
JT  - Journal of health care for the poor and underserved
JID - 9103800
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Medicaid
MH  - Mothers
MH  - *Pre-Eclampsia/epidemiology/prevention & control
MH  - Pregnancy
MH  - Risk
MH  - United States/epidemiology
MH  - Women's Health
EDAT- 2021/01/09 06:00
MHDA- 2021/09/21 06:00
CRDT- 2021/01/08 12:12
PHST- 2021/01/08 12:12 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
AID - S1548686920400142 [pii]
AID - 10.1353/hpu.2020.0123 [doi]
PST - ppublish
SO  - J Health Care Poor Underserved. 2020;31(4):1634-1647. doi: 10.1353/hpu.2020.0123.

PMID- 20092222
OWN - NLM
STAT- MEDLINE
DCOM- 20100219
LR  - 20191111
IS  - 0888-5109 (Print)
IS  - 0888-5109 (Linking)
VI  - 24
IP  - 11
DP  - 2009 Nov
TI  - Warfarin versus aspirin: using CHADS2 to guide therapy for stroke prevention in 
      nonvalvular atrial fibrillation.
PG  - 841-4
AB  - Atrial fibrillation (AF) results in nearly a quarter of the strokes suffered in 
      patients 80 to 89 years of age. Aspirin and warfarin are primary choices for 
      preventing these ischemic strokes. CHADS2 (Congestive heart failure, 
      Hypertention, Age, Diabetes, Stroke) is a validated assessment tool for 
      cardioembolic stroke in AF. Ischemic stroke rates increase from 1.9 to 18.2 
      events per 100 patient-years with CHADS2 scores of 0 and 6, respectively. 
      Warfarin is more effective than aspirin at preventing stroke in AF, but is 
      associated with more hemorrhagic events. The American College of Chest Physicians 
      recommends the use of warfarin in patients with a CHADS2 score of 2 or higher and 
      suggests warfarin be used in patients with a score of 1. We recommend a 
      patient-specific approach to therapy in which warfarin is offered to patients 
      with a CHADS2 score of 1 or higher unless the patient is at high risk for a 
      hemorrhagic event or cannot attain regular warfarin monitoring.
FAU - Hopps, Sarah
AU  - Hopps S
AD  - University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma 73117, USA.
FAU - Marcy, Todd R
AU  - Marcy TR
LA  - eng
PT  - Case Reports
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant 
      Pharmacists
JID - 9013983
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Drug Monitoring/methods
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/therapeutic use
MH  - Humans
MH  - Male
MH  - Risk Assessment
MH  - Risk Factors
MH  - Stroke/etiology/*prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2010/01/23 06:00
MHDA- 2010/02/20 06:00
CRDT- 2010/01/23 06:00
PHST- 2010/01/23 06:00 [entrez]
PHST- 2010/01/23 06:00 [pubmed]
PHST- 2010/02/20 06:00 [medline]
AID - 10.4140/tcp.n.2009.841 [doi]
PST - ppublish
SO  - Consult Pharm. 2009 Nov;24(11):841-4. doi: 10.4140/tcp.n.2009.841.

PMID- 30986221
OWN - NLM
STAT- MEDLINE
DCOM- 20191219
LR  - 20221207
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 4
DP  - 2019
TI  - Prevention of haemoglobin glycation by acetylsalicylic acid (ASA): A new view on 
      old mechanism.
PG  - e0214725
LID - 10.1371/journal.pone.0214725 [doi]
LID - e0214725
AB  - Diabetic hyperglycemia provokes glycation of haemoglobin (Hb), an abundant 
      protein in red blood cells (RBCs), by increasing its exposure to carbohydrates. 
      Acetylsalicylic acid (ASA; Aspirin) is one of the first agents, which its 
      antiglycation effect was witnessed. Although the precise molecular mechanism of 
      action of ASA on protein glycation is not indisputably perceived, acetylation as 
      its main molecular mechanism has been proposed. This report aims to unravel the 
      meticulous mechanism of action of ASA by using two ASA analogues; benzoic acid 
      (BA) and para-nitrobenzoic acid (NBA), despite their lack of acetyl group. In 
      this regard, the inhibitory effect of these two chemicals in comparison with ASA 
      on Hb fructation is reported. UV-visible spectroscopy, intrinsic advanced 
      glycation end products (AGE) fluorescence spectroscopy, extrinsic thioflavin T 
      (ThT) binding fluorescence spectroscopy, 2,4,6-trinitrobenzenesulfonic acid 
      (TNBSA) assay, and single cell gel electrophoresis (SCGE) were used to explore 
      the effects of BA and NBA in comparison with aforementioned chemicals in the 
      context of protein glycation. In spite of the lack of acetyl substitution, NBA is 
      reported as a novel agent with prominent inhibitory efficacy than ASA on the 
      protein glycation. This fact brings up a possible new mechanism of action of ASA 
      and reconsiders acetylation as the sole mechanism of inhibition of protein 
      glycation.
FAU - Ghazanfari-Sarabi, Shabnam
AU  - Ghazanfari-Sarabi S
AD  - School of Biology, College of Science, University of Tehran, Tehran, Iran.
FAU - Habibi-Rezaei, Mehran
AU  - Habibi-Rezaei M
AD  - School of Biology, College of Science, University of Tehran, Tehran, Iran.
AD  - Nano-Biomedicine Center of Excellence, Nanoscience and Nanotechnology Research 
      Center, University of Tehran, Tehran, Iran.
FAU - Eshraghi-Naeeni, Rosheh
AU  - Eshraghi-Naeeni R
AD  - School of Biology, College of Science, University of Tehran, Tehran, Iran.
FAU - Moosavi-Movahedi, Ali Akbar
AU  - Moosavi-Movahedi AA
AD  - Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
AD  - Center of Excellence in Biothermodynamics, University of Tehran, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190415
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hemoglobins)
RN  - 0 (Nitrobenzoates)
RN  - 8SKN0B0MIM (Benzoic Acid)
RN  - G83NWR61OW (4-nitrobenzoic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Aspirin/*chemistry
MH  - Benzoic Acid/chemistry
MH  - Cattle
MH  - Glycated Hemoglobin/*analysis
MH  - Hemoglobins/*chemistry
MH  - Nitrobenzoates/chemistry
MH  - Single-Cell Analysis
MH  - Spectrometry, Fluorescence
PMC - PMC6464172
COIS- The authors have declared that no competing interests exist.
EDAT- 2019/04/16 06:00
MHDA- 2019/12/20 06:00
CRDT- 2019/04/16 06:00
PHST- 2018/10/02 00:00 [received]
PHST- 2019/03/19 00:00 [accepted]
PHST- 2019/04/16 06:00 [entrez]
PHST- 2019/04/16 06:00 [pubmed]
PHST- 2019/12/20 06:00 [medline]
AID - PONE-D-18-28527 [pii]
AID - 10.1371/journal.pone.0214725 [doi]
PST - epublish
SO  - PLoS One. 2019 Apr 15;14(4):e0214725. doi: 10.1371/journal.pone.0214725. 
      eCollection 2019.

PMID- 7660158
OWN - NLM
STAT- MEDLINE
DCOM- 19951004
LR  - 20191031
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 21 Suppl 2
DP  - 1995
TI  - Hemostaseological management of urological operations in patients taking aspirin 
      using the Thrombostat 4000.
PG  - 52-8
AB  - A clinical study was started in order to examine the suitability of the 
      Thrombostat (in vitro bleeding test) (IVBT) as a diagnostic tool to prevent 
      perioperative bleeding due to aspirin (ASA) and/or platelet function disorders of 
      other origins. This report is based on preliminary data. Eighty three patients 
      who had ingested ASA in the last two weeks and/or with a history of bleeding 
      and/or documented hemorrhagic disorders requiring distinct urological operations, 
      were included in the study. In all patients the IVBT with CaCl2, in addition to 
      common coagulation tests, were performed. Thirteen patients stopped ASA ingestion 
      until IVBT became normal and did not show any increased bleeding tendency. The 
      residual patients were classified by the various operations. The following 
      operation groups were formed: Male genitals (n = 11), inguinal/suprapubic 
      operations (n = 7), transurethral tumor resections of the bladder (TURB) (n = 
      17), transurethral prostate resection (TURP) (n = 12), tumor nephrectomy (n = 8), 
      radical prostatectomy (n = 9). Thirty six patients with a history of ASA use, but 
      normal IVBT, served as control group (C). Thirty one patients with a history of 
      ASA ingestion had normal in vivo bleeding times (BT) and abnormal IVBT with CaCl2 
      (A). Seven patients had a bleeding history and/or documented hemorrhagic 
      disorders (B). None of the patients (A) with abnormal IVBT but normal BT 
      displayed clinically relevant bleeding. However, the blood loss was somewhat 
      higher compared to the controls (C), especially in patients with TURB and radical 
      prostatectomy (not significant).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Ulshöfer, B
AU  - Ulshöfer B
AD  - Urologic Clinic, Klinikum, Philips University Marburg, Germany.
FAU - Dorst, V
AU  - Dorst V
FAU - Kretschmer, V
AU  - Kretschmer V
FAU - Köhl, H
AU  - Köhl H
FAU - Riedmiller, H
AU  - Riedmiller H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Bleeding Time
MH  - Blood Coagulation Tests/methods
MH  - Blood Loss, Surgical/*prevention & control
MH  - Hemostasis, Surgical/*methods
MH  - Humans
MH  - Male
MH  - *Prothrombin Time
MH  - Urologic Diseases/*surgery
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1055/s-0032-1313603 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 1995;21 Suppl 2:52-8. doi: 10.1055/s-0032-1313603.

PMID- 6162932
OWN - NLM
STAT- MEDLINE
DCOM- 19810521
LR  - 20190829
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 224
IP  - 4
DP  - 1981
TI  - Transient contralateral hemiplegia after ophthalmic zoster. Therapeutic problems 
      in elderly patients.
PG  - 297-300
AB  - Delayed ipsilateral carotid arteritis is a known complication of herpes zoster 
      ophthalmicus. The case of a 70-year-old man with two TIAs following ophthalmic 
      zoster is reported, and the therapeutic problems in elderly patients are 
      discussed.
FAU - Landi, G
AU  - Landi G
FAU - Calloni, M V
AU  - Calloni MV
FAU - Scarlato, G
AU  - Scarlato G
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arteritis/drug therapy
MH  - Aspirin/therapeutic use
MH  - Carotid Artery Diseases/drug therapy
MH  - Dipyridamole/therapeutic use
MH  - Hemiplegia/*etiology
MH  - Herpes Zoster Ophthalmicus/*complications
MH  - Humans
MH  - Male
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1007/BF00313294 [doi]
PST - ppublish
SO  - J Neurol. 1981;224(4):297-300. doi: 10.1007/BF00313294.

PMID- 553563
OWN - NLM
STAT- MEDLINE
DCOM- 19810324
LR  - 20131121
IS  - 0037-8771 (Print)
IS  - 0037-8771 (Linking)
VI  - 55
IP  - 18
DP  - 1979 Sep 30
TI  - [Modifications of platelet function induced by ASA. I. Effects on aggregation].
PG  - 1895-901
AB  - The inhibitory effect on platelet aggregation. induced by a single dose of 1g'per 
      os or e.v. of ASA, has been studied in normal subjects by the method of Born. The 
      results suggest the possibility of pharmacological effect control in thrombotic 
      prevention.
FAU - Piro, F
AU  - Piro F
FAU - Capetti, P
AU  - Capetti P
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Modificazioni della funcionalit'piastrinica indotte dall'ASA. Nota no 1 - Effetti 
      sull'aggregazione.
PL  - Italy
TA  - Boll Soc Ital Biol Sper
JT  - Bollettino della Societa italiana di biologia sperimentale
JID - 7506962
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Collagen/pharmacology
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Time Factors
EDAT- 1979/09/30 00:00
MHDA- 1979/09/30 00:01
CRDT- 1979/09/30 00:00
PHST- 1979/09/30 00:00 [pubmed]
PHST- 1979/09/30 00:01 [medline]
PHST- 1979/09/30 00:00 [entrez]
PST - ppublish
SO  - Boll Soc Ital Biol Sper. 1979 Sep 30;55(18):1895-901.

PMID- 2833584
OWN - NLM
STAT- MEDLINE
DCOM- 19880526
LR  - 20191101
IS  - 0270-6474 (Print)
IS  - 1529-2401 (Electronic)
IS  - 0270-6474 (Linking)
VI  - 8
IP  - 4
DP  - 1988 Apr
TI  - Prostaglandins inhibit endogenous pain control mechanisms by blocking 
      transmission at spinal noradrenergic synapses.
PG  - 1346-9
AB  - Spinal intrathecal injections of the nonsteroidal antiinflammatory analgesics 
      (NSAIAs) indomethacin and acetylsalicylic acid, which inhibit prostaglandin 
      synthesis, cause dose-dependent hypoalgesia in the rat. Intrathecal injections of 
      prostaglandin-E2 (PGE2) produce dose-dependent hyperalgesia. To determine whether 
      this action of prostaglandins on the central nervous system is mediated through 
      pain-generating or analgesia pathways, we studied the effect of intrathecal PGE2 
      on endogenous opioid-induced analgesia. Intrathecal PGE2 antagonized the 
      analgesia produced by both brain stimulation and intracerebroventricular 
      morphine. In contrast, the NSAIAs synergized with brain stimulation and 
      morphine-induced analgesia. The alpha-adrenergic antagonist phentolamine and the 
      catecholaminergic selective neurotoxin 6-hydroxydopamine, used to block tonic 
      catecholamine activity in endogenous opioid-mediated analgesia systems, prevented 
      the hyperalgesia induced by intrathecal PGE2. Phentolamine did not, however, 
      block the hyperalgesia caused by intradermal PGE2. These findings suggest that 
      prostaglandins can block endogenous opioid-mediated analgesia systems by 
      inhibiting the bulbospinal noradrenergic component of this analgesia pathway.
FAU - Taiwo, Y O
AU  - Taiwo YO
AD  - Department of Medicine, University of California, San Francisco 94143.
FAU - Levine, J D
AU  - Levine JD
LA  - eng
GR  - AI19784/AI/NIAID NIH HHS/United States
GR  - AM32634/AM/NIADDK NIH HHS/United States
GR  - NS21647/NS/NINDS NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Neurosci
JT  - The Journal of neuroscience : the official journal of the Society for 
      Neuroscience
JID - 8102140
RN  - 0 (Prostaglandins)
RN  - 0 (Prostaglandins E)
RN  - 76I7G6D29C (Morphine)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
RN  - Z468598HBV (Phentolamine)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology
MH  - Dinoprostone
MH  - Dose-Response Relationship, Drug
MH  - Indomethacin/administration & dosage/pharmacology
MH  - Injections, Spinal
MH  - Male
MH  - Morphine/pharmacology
MH  - Pain/*physiopathology
MH  - Phentolamine/pharmacology
MH  - Prostaglandins/*pharmacology
MH  - Prostaglandins E/pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Spinal Cord/*cytology
MH  - Synapses/*cytology
MH  - Synaptic Transmission/*drug effects
PMC - PMC6569250
EDAT- 1988/04/01 00:00
MHDA- 1988/04/01 00:01
CRDT- 1988/04/01 00:00
PHST- 1988/04/01 00:00 [pubmed]
PHST- 1988/04/01 00:01 [medline]
PHST- 1988/04/01 00:00 [entrez]
AID - 10.1523/JNEUROSCI.08-04-01346.1988 [doi]
PST - ppublish
SO  - J Neurosci. 1988 Apr;8(4):1346-9. doi: 10.1523/JNEUROSCI.08-04-01346.1988.

PMID- 17913265
OWN - NLM
STAT- MEDLINE
DCOM- 20090827
LR  - 20131121
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 131
IP  - 1
DP  - 2008 Dec 17
TI  - Catastrophic early drug eluting stents thrombosis and aspirin hypersensitivity.
PG  - e25-7
AB  - Stent thrombosis is a feared complication of percutaneous coronary intervention. 
      Promises and problems, late complications and early stent thrombosis have been 
      reported after drug eluting stents implantation too. Moreover some patients with 
      imperative cardiologic indications for combination therapy with aspirin and 
      clopidogrel (stent placement and/or acute coronary syndrome) have a history of 
      allergy to aspirin. We present a case of catastrophic early drug eluting stents 
      thrombosis in a 79-year-old Italian woman with aspirin hypersensitivity.
FAU - Patanè, Salvatore
AU  - Patanè S
FAU - Marte, Filippo
AU  - Marte F
FAU - Di Bella, Gianluca
AU  - Di Bella G
LA  - eng
PT  - Case Reports
PT  - Letter
DEP - 20071022
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Catastrophic Illness
MH  - Drug Hypersensitivity/complications/*diagnosis
MH  - Drug-Eluting Stents/*adverse effects
MH  - Electrocardiography/drug effects
MH  - Female
MH  - Humans
MH  - Thrombosis/chemically induced/*diagnosis/etiology
EDAT- 2007/10/05 09:00
MHDA- 2009/08/28 09:00
CRDT- 2007/10/05 09:00
PHST- 2007/05/27 00:00 [received]
PHST- 2007/07/01 00:00 [accepted]
PHST- 2007/10/05 09:00 [pubmed]
PHST- 2009/08/28 09:00 [medline]
PHST- 2007/10/05 09:00 [entrez]
AID - S0167-5273(07)01545-8 [pii]
AID - 10.1016/j.ijcard.2007.07.053 [doi]
PST - ppublish
SO  - Int J Cardiol. 2008 Dec 17;131(1):e25-7. doi: 10.1016/j.ijcard.2007.07.053. Epub 
      2007 Oct 22.

PMID- 160830
OWN - NLM
STAT- MEDLINE
DCOM- 19800425
LR  - 20131121
IS  - 0037-9026 (Print)
IS  - 0037-9026 (Linking)
VI  - 173
IP  - 4
DP  - 1979
TI  - [Role of platelets in arterial hypotension induced by arachidonic acid and in 
      carrageenan induced edema in the rat].
PG  - 843-8
AB  - When rat platelets are incubated in vitro in the presence of aspirin, the 
      formation of malonaldehyde from arachidonic acid is inhibited. The production of 
      malonaldehyde reflects the synthesis of prostaglandins and associated compounds. 
      The same inhibition is found when the platelets originate from rats pretreated 
      with aspirin. Small doses of aspirin are active in vitro and 10-20 mg/kg in vivo. 
      This dosage of aspirin does not affect the hypotensive activity of arachidonic 
      acid nor the oedematous properties of carrageenan in the rat. These two effects 
      are thus independent from the prostaglandins formed in the platelets.
FAU - Damas, J
AU  - Damas J
FAU - Volon, G
AU  - Volon G
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Rôle des plaquettes dans l'hypotension artérielle provoquée par l'acide 
      arachidonique et dans l'oedème à la carragénine, chez le rat.
PL  - France
TA  - C R Seances Soc Biol Fil
JT  - Comptes rendus des seances de la Societe de biologie et de ses filiales
JID - 7505439
RN  - 0 (Arachidonic Acids)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acids/blood
MH  - Aspirin/pharmacology
MH  - Blood Platelets/drug effects/*physiology
MH  - Carrageenan
MH  - Edema/chemically induced/*physiopathology
MH  - Hypotension/chemically induced/*physiopathology
MH  - Kinetics
MH  - Malondialdehyde/blood
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - C R Seances Soc Biol Fil. 1979;173(4):843-8.

PMID- 16168275
OWN - NLM
STAT- MEDLINE
DCOM- 20051222
LR  - 20131121
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 46
IP  - 6
DP  - 2005 Sep 20
TI  - Aspirin use in older patients with heart failure and coronary artery disease: 
      national prescription patterns and relationship with outcomes.
PG  - 955-62
AB  - OBJECTIVES: We sought to determine patterns of aspirin use and the relationship 
      between aspirin prescription and outcomes in patients with coronary artery 
      disease (CAD) and heart failure (HF). BACKGROUND: Because of the potential for 
      exacerbating hypertension or renal insufficiency and possible interactions with 
      angiotensin-converting enzyme (ACE) inhibitors, the use of aspirin for secondary 
      prevention of coronary events is controversial in patients with HF. METHODS: We 
      studied a national sample of Medicare beneficiaries > or =65 years old after 
      hospitalization for HF with CAD and without aspirin contraindications between 
      April 1998 and June 2001. We assessed factors associated with aspirin 
      prescription and the relationship between aspirin and outcomes in regression 
      models accounting for differences in patient, physician, and hospital 
      characteristics and for clustering of patients by hospital. RESULTS: Of the 
      24,012 patients, 54% received aspirin. Treated patients had lower unadjusted 
      rates of death (31% vs. 39% for those not receiving aspirin, p < 0.001). In 
      multivariable analyses, aspirin remained associated with a lower risk of death 
      (risk ratio [RR] 0.94; 95% confidence interval [CI] 0.90 to 0.99). This 
      association was similar regardless of hypertension, renal insufficiency, or 
      treatment with ACE inhibitors (p for all interactions > 0.2). Aspirin also was 
      associated with lower risks of death or all-cause readmission (RR 0.98; 95% CI 
      0.97 to 0.99) and of death or readmission for HF (RR 0.98; 95% CI 0.96 to 0.99). 
      CONCLUSIONS: Almost one-half of patients with CAD hospitalized for HF in the U.S. 
      are not treated with aspirin. This study found no evidence of harm from aspirin 
      in this population and suggests a treatment benefit. Withholding aspirin based 
      upon theoretical concerns about adverse effects appears to be unjustified.
FAU - Masoudi, Frederick A
AU  - Masoudi FA
AD  - Division of Cardiology, Department of Medicine, Denver Health Medical Center, 
      Denver, Colorado 80204, USA. fred.masoudi@uchsc.edu
FAU - Wolfe, Pam
AU  - Wolfe P
FAU - Havranek, Edward P
AU  - Havranek EP
FAU - Rathore, Saif S
AU  - Rathore SS
FAU - Foody, JoAnne M
AU  - Foody JM
FAU - Krumholz, Harlan M
AU  - Krumholz HM
LA  - eng
GR  - GM07205/GM/NIGMS NIH HHS/United States
GR  - K08-AG01011/AG/NIA NIH HHS/United States
GR  - K08-AG20623/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*complications/*drug therapy
MH  - Drug Prescriptions/*statistics & numerical data
MH  - Female
MH  - Heart Failure/*complications/*drug therapy
MH  - Humans
MH  - Male
MH  - Treatment Outcome
EDAT- 2005/09/20 09:00
MHDA- 2005/12/24 09:00
CRDT- 2005/09/20 09:00
PHST- 2004/04/13 00:00 [received]
PHST- 2004/07/20 00:00 [revised]
PHST- 2004/07/28 00:00 [accepted]
PHST- 2005/09/20 09:00 [pubmed]
PHST- 2005/12/24 09:00 [medline]
PHST- 2005/09/20 09:00 [entrez]
AID - S0735-1097(05)01521-4 [pii]
AID - 10.1016/j.jacc.2004.07.062 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2005 Sep 20;46(6):955-62. doi: 10.1016/j.jacc.2004.07.062.

PMID- 9263721
OWN - NLM
STAT- MEDLINE
DCOM- 19970922
LR  - 20131121
IS  - 1040-872X (Print)
IS  - 1040-872X (Linking)
VI  - 9
IP  - 4
DP  - 1997 Aug
TI  - Antiphospholipid antibodies, infertility and recurrent miscarriage.
PG  - 279-82
AB  - Antiphospholipid antibodies are found in 15% of women with recurrent miscarriage. 
      These women have only a 10% live birth rate in subsequent pregnancies in which no 
      pharmacological treatment is given. Pregnancy loss is often attributable to 
      uteroplacental insufficiency subsequent to placental thrombosis. Treatment with 
      low dose aspirin improves the live birth rate amongst women with antiphospholipid 
      antibodies to 40% but this is further and significantly increased to 70% when 
      they are treated with aspirin together with low-dose heparin.
FAU - Rai, R
AU  - Rai R
AD  - Department of Obstetrics and Gynaecology, Imperial College School of Medicine at 
      St Mary's, London, UK.
FAU - Regan, L
AU  - Regan L
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Curr Opin Obstet Gynecol
JT  - Current opinion in obstetrics & gynecology
JID - 9007264
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*etiology
MH  - Adult
MH  - Anticoagulants/therapeutic use
MH  - Antiphospholipid Syndrome/*complications/drug therapy
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Infertility, Female/*etiology
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Outcome
EDAT- 1997/08/01 00:00
MHDA- 1997/08/01 00:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 1997/08/01 00:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
PST - ppublish
SO  - Curr Opin Obstet Gynecol. 1997 Aug;9(4):279-82.

PMID- 7635036
OWN - NLM
STAT- MEDLINE
DCOM- 19950912
LR  - 20191031
IS  - 0012-6543 (Print)
IS  - 0012-6543 (Linking)
VI  - 32
IP  - 8
DP  - 1994 Aug 18
TI  - Warfarin or aspirin for non-rheumatic atrial fibrillation?
PG  - 57-60
AB  - Atrial fibrillation (AF) predisposes to stroke, particularly in patients with 
      rheumatic heart disease, congestive heart failure, arterial hypertension, 
      diabetes mellitus or uncontrolled thyrotoxicosis. In those with rheumatic heart 
      disease it is usual to give warfarin to reduce the incidence of stroke, although 
      there has been no randomised controlled trial on which to base this approach. 
      Whether patients with non-rheumatic AF should be anticoagulated was unclear when 
      we tackled this subject five years ago. This article reviews the evidence from 
      recent randomised controlled trials and considers whether anticoagulation with 
      warfarin, or antiplatelet therapy with aspirin, should now be routine for 
      patients with non-rheumatic AF.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Drug Ther Bull 1994 Oct 20;32(10):80
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Cerebrovascular Disorders/prevention & control
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Warfarin/*therapeutic use
RF  - 24
EDAT- 1994/08/18 00:00
MHDA- 1994/08/18 00:01
CRDT- 1994/08/18 00:00
PHST- 1994/08/18 00:00 [pubmed]
PHST- 1994/08/18 00:01 [medline]
PHST- 1994/08/18 00:00 [entrez]
AID - 10.1136/dtb.1994.32857 [doi]
PST - ppublish
SO  - Drug Ther Bull. 1994 Aug 18;32(8):57-60. doi: 10.1136/dtb.1994.32857.

PMID- 32552387
OWN - NLM
STAT- MEDLINE
DCOM- 20210421
LR  - 20210421
IS  - 2374-4243 (Electronic)
IS  - 2374-4243 (Linking)
VI  - 52
IP  - 10
DP  - 2020 Oct
TI  - Aspirin enhances the clinical efficacy of anti-tuberculosis therapy in pulmonary 
      tuberculosis in patients with type 2 diabetes mellitus.
PG  - 721-729
LID - 10.1080/23744235.2020.1778177 [doi]
AB  - Background: Tuberculosis in patients with diabetes mellitus is characterised by 
      rapid disease progression, poor treatment efficacy, poor prognosis and poses a 
      new challenge in tuberculosis treatment and control.Methods: Patients with 
      pulmonary TB and type 2 DM were recruited at Yijishan Hospital of Wannan Medical 
      College. A total of 348 patients were randomly assigned to two groups. The 
      aspirin group (aspirin + TB/DM) included 174 patients who received anti-TB 
      therapy and enteric-coated aspirin tablets (100 mg/tablet). The control group 
      (placebo + TB/DM) included 174 patients who received anti-TB therapy and 
      enteric-coated placebo tablets (an identical tablet containing no drug). 
      Eighty-two patients in the aspirin group and 86 in the control group completed 
      the trial and were included in the analysis. Clinical characteristics, laboratory 
      test results, imaging data and side effects of aspirin were monitored.Results: 
      Aspirin treatment affect certain signs and symptoms. The erythrocyte 
      sedimentation rate (ESR) and C-reactive protein (CRP) levels were lower in the 
      aspirin group than in the control group after treatment (Both p = .000). The 
      sputum-negative conversion rate was 86.7% in the aspirin group, significantly 
      higher than in the control group (53.8%) (p = .031). After two months of 
      treatment, the differences in the number of cases with cavities, the number of 
      cavities, and maximum diameter of cavities in the aspirin group were 
      statistically significant (p = .003, p = .023 and p = .015 
      respectively).Conclusion: Our findings suggest that aspirin may improve treatment 
      in patients with pulmonary TB and type 2 DM.
FAU - Wang, Wenjie
AU  - Wang W
AD  - Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, 
      Wuhu, P. R. China.
FAU - Du, Zhixiang
AU  - Du Z
AD  - Department of Infectious Diseases, The People's Hospital of Taizhou, Taizhou, P. 
      R. China.
FAU - Ni, Mingyue
AU  - Ni M
AD  - Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, 
      Wuhu, P. R. China.
FAU - Wang, Zijian
AU  - Wang Z
AD  - Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, 
      Wuhu, P. R. China.
FAU - Liang, Manman
AU  - Liang M
AD  - Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, 
      Wuhu, P. R. China.
FAU - Sheng, Haoyu
AU  - Sheng H
AD  - Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, 
      Wuhu, P. R. China.
FAU - Zhang, Aiping
AU  - Zhang A
AD  - Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, 
      Wuhu, P. R. China.
FAU - Yang, Jianghua
AU  - Yang J
AD  - Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, 
      Wuhu, P. R. China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200619
PL  - England
TA  - Infect Dis (Lond)
JT  - Infectious diseases (London, England)
JID - 101650235
RN  - 0 (Antitubercular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antitubercular Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Humans
MH  - Treatment Outcome
MH  - Tuberculosis, Pulmonary/complications/*drug therapy
OTO - NOTNLM
OT  - Pulmonary tuberculosis
OT  - aspirin
OT  - type 2 diabetes mellitus
EDAT- 2020/06/20 06:00
MHDA- 2021/04/22 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/22 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1080/23744235.2020.1778177 [doi]
PST - ppublish
SO  - Infect Dis (Lond). 2020 Oct;52(10):721-729. doi: 10.1080/23744235.2020.1778177. 
      Epub 2020 Jun 19.

PMID- 10458713
OWN - NLM
STAT- MEDLINE
DCOM- 19990913
LR  - 20220309
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 100
IP  - 8
DP  - 1999 Aug 24
TI  - Increased proinflammatory cytokines in patients with chronic stable angina and 
      their reduction by aspirin.
PG  - 793-8
AB  - BACKGROUND: Proinflammatory cytokines released by injured endothelium facilitate 
      interaction of endothelial cells with circulating leukocytes and thus may 
      contribute to development and progression of atherosclerosis. We investigated 
      whether cytokines and C-reactive protein (CRP) are indicative of myocardial 
      ischemia or of diseased vessels and whether they are influenced by aspirin 
      treatment in patients with chronic stable angina. METHODS AND RESULTS: Plasma 
      macrophage colony stimulating factor (MCSF), IL-1b, IL-6, and CRP were measured 
      in 60 stable patients after 48-hour Holter monitoring and in 24 matched controls. 
      All patients had angiographic documentation of disease and positive exercise 
      ECGs. Patients with ischemia on Holter monitoring (n=40) received aspirin or 
      placebo in a 6-week, randomized, double blind, crossover trial. Blood sampling 
      was repeated at the end of each treatment phase (3 weeks). Compared to controls, 
      patients had more than twice median MCSF (800 versus 372 pg/mL), IL-6 (3.9 versus 
      1.7 pg/mL), and CRP (1.25 versus 0.23 mg/L) levels (P<0.01 for all comparisons). 
      MCSF was related to ischemia on Holter monitoring (P<0.01), to low ischemic 
      threshold during exercise (P<0.01), and together with IL-1b to number of diseased 
      vessels (P<0.05). MCSF, IL-6, and CRP were all reduced after 6 weeks of aspirin 
      treatment (P<0.05). CONCLUSIONS: These findings suggest that cytokines are 
      associated with both ischemia and anatomic extent of disease in patients with 
      stable angina. Reduced cytokine and CRP levels by aspirin may explain part of 
      aspirin's therapeutic action.
FAU - Ikonomidis, I
AU  - Ikonomidis I
AD  - Imperial College School of Medicine, National Heart & Lung Institute, Cardiology 
      Department, Hammersmith Hospital, London, UK.
FAU - Andreotti, F
AU  - Andreotti F
FAU - Economou, E
AU  - Economou E
FAU - Stefanadis, C
AU  - Stefanadis C
FAU - Toutouzas, P
AU  - Toutouzas P
FAU - Nihoyannopoulos, P
AU  - Nihoyannopoulos P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-6)
RN  - 81627-83-0 (Macrophage Colony-Stimulating Factor)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angina Pectoris/*blood/*drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - C-Reactive Protein/analysis
MH  - Chronic Disease
MH  - Cytokines/*blood
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Interleukin-1/blood
MH  - Interleukin-6/blood
MH  - Macrophage Colony-Stimulating Factor/blood
MH  - Male
MH  - Middle Aged
EDAT- 1999/08/24 00:00
MHDA- 1999/08/24 00:01
CRDT- 1999/08/24 00:00
PHST- 1999/08/24 00:00 [pubmed]
PHST- 1999/08/24 00:01 [medline]
PHST- 1999/08/24 00:00 [entrez]
AID - 10.1161/01.cir.100.8.793 [doi]
PST - ppublish
SO  - Circulation. 1999 Aug 24;100(8):793-8. doi: 10.1161/01.cir.100.8.793.

PMID- 24857621
OWN - NLM
STAT- MEDLINE
DCOM- 20150810
LR  - 20141203
IS  - 1873-3336 (Electronic)
IS  - 0304-3894 (Linking)
VI  - 282
DP  - 2015 Jan 23
TI  - The adsorption of pharmaceutically active compounds from aqueous solutions onto 
      activated carbons.
PG  - 141-9
LID - S0304-3894(14)00331-8 [pii]
LID - 10.1016/j.jhazmat.2014.04.062 [doi]
AB  - In this study, the adsorption of pharmaceutically active compounds - salicylic 
      acid, acetylsalicylic acid, atenolol and diclofenac-Na onto activated carbons has 
      been studied. Three different commercial activated carbons, possessing ∼650, 900 
      or 1500m(2)g(-1) surface areas were used as solid adsorbents. These materials 
      were fully characterized - their textural, surface features and points of zero 
      charge have been determined. The adsorption was studied from aqueous solutions at 
      303K using batch adsorption experiments and titration microcalorimetry, which was 
      employed in order to obtain the heats evolved as a result of adsorption. The 
      maximal adsorption capacities of investigated solids for all target 
      pharmaceuticals are in the range of 10(-4)molg(-1). The obtained maximal 
      retention capacities are correlated with the textural properties of applied 
      activated carbon. The roles of acid/base features of activated carbons and of 
      molecular structures of adsorbate molecules have been discussed. The obtained 
      results enabled to estimate the possibility to use the activated carbons in the 
      removal of pharmaceuticals by adsorption.
CI  - Copyright © 2014 Elsevier B.V. All rights reserved.
FAU - Rakić, Vesna
AU  - Rakić V
AD  - Faculty of Agriculture, Department of Chemistry, University of Belgrade, 
      Nemanjina 6, 11080 Zemun, Serbia. Electronic address: vesna.rakic@ffh.bg.ac.rs.
FAU - Rac, Vladislav
AU  - Rac V
AD  - Faculty of Agriculture, Department of Chemistry, University of Belgrade, 
      Nemanjina 6, 11080 Zemun, Serbia.
FAU - Krmar, Marija
AU  - Krmar M
AD  - Institut "Goša" Milana Rakića 35, 11000 Beograd, Serbia.
FAU - Otman, Otman
AU  - Otman O
AD  - Institut de Recherches sur la Catalyse et l'Environnement de Lyon (IRCELYON) , 
      UMR 5256 CNRS/Université Lyon1, 2 av. Albert Einstein, 69626 Villeurbanne Cedex, 
      France.
FAU - Auroux, Aline
AU  - Auroux A
AD  - Institut de Recherches sur la Catalyse et l'Environnement de Lyon (IRCELYON) , 
      UMR 5256 CNRS/Université Lyon1, 2 av. Albert Einstein, 69626 Villeurbanne Cedex, 
      France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140502
PL  - Netherlands
TA  - J Hazard Mater
JT  - Journal of hazardous materials
JID - 9422688
RN  - 0 (Solutions)
RN  - 0 (Water Pollutants, Chemical)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 50VV3VW0TI (Atenolol)
RN  - 7440-44-0 (Carbon)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Aspirin/*chemistry
MH  - Atenolol/*chemistry
MH  - Carbon/*chemistry
MH  - Diclofenac/*chemistry
MH  - Salicylic Acid/*chemistry
MH  - Solutions
MH  - Surface Properties
MH  - Water Pollutants, Chemical/*chemistry
MH  - Water Purification
OTO - NOTNLM
OT  - Activated carbon
OT  - Adsorption
OT  - Emerging contaminant
OT  - Microcalorimetry
OT  - Pharmaceutically active compound
OT  - Wastewater
EDAT- 2014/05/27 06:00
MHDA- 2015/08/11 06:00
CRDT- 2014/05/27 06:00
PHST- 2013/12/21 00:00 [received]
PHST- 2014/04/25 00:00 [revised]
PHST- 2014/04/26 00:00 [accepted]
PHST- 2014/05/27 06:00 [entrez]
PHST- 2014/05/27 06:00 [pubmed]
PHST- 2015/08/11 06:00 [medline]
AID - S0304-3894(14)00331-8 [pii]
AID - 10.1016/j.jhazmat.2014.04.062 [doi]
PST - ppublish
SO  - J Hazard Mater. 2015 Jan 23;282:141-9. doi: 10.1016/j.jhazmat.2014.04.062. Epub 
      2014 May 2.

PMID- 16023118
OWN - NLM
STAT- MEDLINE
DCOM- 20060123
LR  - 20191210
IS  - 0014-827X (Print)
IS  - 0014-827X (Linking)
VI  - 60
IP  - 9
DP  - 2005 Sep
TI  - Content uniformity and dissolution tests of triplicate mixtures by a double 
      divisor-ratio spectra derivative method.
PG  - 755-62
AB  - The use of a UV double divisor-ratio spectra derivative calibration for the 
      simultaneous analysis of synthetic samples and commercial tablet preparations 
      without prior separation is proposed. The method was successfully applied to 
      quantify three ternary mixtures, chlorpheniramine maleate and caffeine combined 
      with paracetamol or acetylsalicylic acid and a mixture of acetylsalicylic acid 
      combined with paracetamol and caffeine, using the information in the absorption 
      spectra of appropriate solutions. Beer's law was obeyed in the concentration 
      range of 0.84-4.21 microg/ml for chlorpheniramine maleate, 1.60-15.96 microg/ml 
      for caffeine, 2.0-20.0 microg/ml for acetylsalicylic acid and 1.58-15.93 
      microg/ml for paracetamol. The whole procedure was applied to synthetic mixtures 
      of pure drugs as well as to commercial preparations (Algon) by using content 
      uniformity and dissolution tests (USP 24) and was found to be precise and 
      reproducible. According to the dissolution profile test more than 84% of 
      paracetamol and caffeine were dissolved within 20 min. Acetylsalicylic acid 
      dissolved more slowly, taking about 45-60 min to dissolve completely. A 
      chemometric method partial least squares (PLS) and a HPLC method were also 
      employed to evaluate the same mixtures. The results of the proposed method were 
      in excellent agreement with those obtained from PLS and HPLC methods and can be 
      satisfactorily used for routine analysis of multicomponent dosage forms.
FAU - Markopoulou, Catherine K
AU  - Markopoulou CK
AD  - Laboratory of Pharmaceutical Analysis, School of Pharmacy, Aristotelian 
      University, 54124 Thessaloniki, Greece.
FAU - Malliou, Eleftheria T
AU  - Malliou ET
FAU - Koundourellis, John E
AU  - Koundourellis JE
LA  - eng
PT  - Journal Article
PT  - Validation Study
PL  - France
TA  - Farmaco
JT  - Farmaco (Societa chimica italiana : 1989)
JID - 8912641
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - 3U6IO1965U (Chlorpheniramine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Chlorpheniramine/*analysis
MH  - Chromatography, High Pressure Liquid/methods
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Solubility
MH  - Spectrophotometry, Ultraviolet/*methods
EDAT- 2005/07/19 09:00
MHDA- 2006/01/24 09:00
CRDT- 2005/07/19 09:00
PHST- 2004/12/13 00:00 [received]
PHST- 2005/06/08 00:00 [accepted]
PHST- 2005/07/19 09:00 [pubmed]
PHST- 2006/01/24 09:00 [medline]
PHST- 2005/07/19 09:00 [entrez]
AID - S0014-827X(05)00120-5 [pii]
AID - 10.1016/j.farmac.2005.06.003 [doi]
PST - ppublish
SO  - Farmaco. 2005 Sep;60(9):755-62. doi: 10.1016/j.farmac.2005.06.003.

PMID- 20614431
OWN - NLM
STAT- MEDLINE
DCOM- 20100811
LR  - 20211020
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 2010
IP  - 7
DP  - 2010 Jul 7
TI  - Vasoactive drugs for acute stroke.
PG  - CD002839
LID - 10.1002/14651858.CD002839.pub2 [doi]
LID - CD002839
AB  - BACKGROUND: It is unclear whether blood pressure (BP) should be altered actively 
      during the acute phase of stroke. OBJECTIVES: To assess the effect of lowering or 
      elevating BP in people with acute stroke, and the effect of different vasoactive 
      drugs on BP in acute stroke. SEARCH STRATEGY: We searched the Cochrane Stroke 
      Group Trials Register (last searched June 2009), the Cochrane Central Register of 
      Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2009), MEDLINE (1966 
      to October 2009), EMBASE (1980 to October 2009), and Science Citation Index (1981 
      to October 2009). SELECTION CRITERIA: Randomised trials of interventions that 
      would be expected, on pharmacological grounds, to alter BP in patients within one 
      week of the onset of acute stroke. DATA COLLECTION AND ANALYSIS: Two review 
      authors independently applied the trial inclusion criteria, assessed trial 
      quality, and extracted data. MAIN RESULTS: We identified 131 trials involving in 
      excess of 18,000 patients; a further 13 trials are ongoing. We obtained data for 
      43 trials (7649 patients). Among BP-lowering trials, beta receptor antagonists 
      lowered BP (early systolic BP (SBP) mean difference (MD) -6.1 mmHg, 95% CI -11.4 
      to -0.9; late SBP MD -4.9 mmHg, 95% CI -10.2 to 0.4; late diastolic BP (DBP) MD 
      -4.5 mmHg, 95% CI -7.8 to -1.2). Oral calcium channel blockers (CCB) lowered BP 
      (late SBP MD -3.2 mmHg, 95% CI -5.4 to -1.1; early DBP MD -2.5, 95% CI -5.6 to 
      0.7; late DBP MD -2.1, 95% CI -3.5 to -0.7). Nitric oxide donors lowered BP 
      (early SBP MD -10.3 mmHg, 95% CI -17.6 to -3.0). Prostacyclin lowered BP (late 
      SBP MD, -7.7 mmHg, 95% CI -15.6 to 0.2; late DBP MD -3.9 mmHg, 95% CI -8.1 to 
      0.4). Among BP-increasing trials, diaspirin cross-linked haemoglobin (DCLHb) 
      increased BP (early SBP MD 15.3 mmHg, 95% CI 4.0 to 26.6; late SBP MD 15.9 mmHg, 
      95% CI 1.8 to 30.0). None of the drug classes significantly altered outcome apart 
      from DCLHb which increased combined death or dependency (odds ratio (OR) 5.41, 
      95% CI 1.87 to 15.64). AUTHORS' CONCLUSIONS: There is not enough evidence to 
      evaluate reliably the effect of altering BP on outcome after acute stroke. 
      However, treatment with DCLHb was associated with poor clinical outcomes. Beta 
      receptor antagonists, CCBs, nitric oxide, and prostacyclin each lowered BP during 
      the acute phase of stroke. In contrast, DCLHb increased BP.
FAU - Geeganage, Chamila
AU  - Geeganage C
AD  - Division of Stroke Medicine, University of Nottingham, Nottingham City Hospital 
      Campus, Hucknall Road, Nottingham, UK, NG5 1PB.
FAU - Bath, Philip Mw
AU  - Bath PM
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20100707
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hemoglobins)
RN  - 0 (Vasoconstrictor Agents)
RN  - 0 (Vasodilator Agents)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2000;(4):CD002839. PMID: 11034772
MH  - Administration, Oral
MH  - Adult
MH  - Antihypertensive Agents/*therapeutic use
MH  - Aspirin/adverse effects/analogs & derivatives
MH  - Blood Pressure/*drug effects/physiology
MH  - Hemoglobins/adverse effects
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Hypotension/*drug therapy
MH  - Injections, Intravenous
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/*drug therapy/physiopathology
MH  - Vasoconstrictor Agents/therapeutic use
MH  - Vasodilator Agents/therapeutic use
PMC - PMC7120409
COIS- PMW Bath was involved in three completed studies included in this review. He is 
      the principal investigator of the ongoing Efficacy of Nitric Oxide in Stroke 
      (ENOS) trial.
EDAT- 2010/07/09 06:00
MHDA- 2010/08/12 06:00
CRDT- 2010/07/09 06:00
PHST- 2010/07/09 06:00 [entrez]
PHST- 2010/07/09 06:00 [pubmed]
PHST- 2010/08/12 06:00 [medline]
AID - CD002839.pub2 [pii]
AID - 10.1002/14651858.CD002839.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2010 Jul 7;2010(7):CD002839. doi: 
      10.1002/14651858.CD002839.pub2.

PMID- 9473126
OWN - NLM
STAT- MEDLINE
DCOM- 19980326
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 339
IP  - 2-3
DP  - 1997 Nov 27
TI  - Acetylsalicylic acid enhances arrhythmogeneity in a model of local ischemia of 
      isolated rabbit hearts.
PG  - 129-39
AB  - Acetylsalicylic acid often is used in the treatment and prophylaxis of regional 
      myocardial ischemia and infarction. However, only little is known about its 
      electrophysiological effects and on possible proarrhythmic effects of the drug. 
      Thus, the aim of this study was to evaluate the electrophysiological effects of 
      acetylsalicylic acid in normal isolated saline perfused rabbit hearts and in 
      hearts submitted to regional ischemia. Isolated saline perfused rabbit hearts 
      were treated with increasing concentrations of acetylsalicylic acid (0.05, 0.1, 
      0.5 and 1 microM). The epicardial activation and repolarisation process were 
      analysed using an epicardial mapping (256 unipolar leads). Activation and 
      repolarisation time were determined for each electrode from which data the 
      'breakthrough-points' of epicardial activation were determined. At each electrode 
      an activation vector was calculated giving the direction and velocity of the 
      local excitation wave. The similarity of selected heart beats compared to the 
      control was evaluated by determination of the percentage of identical 
      breakthrough-points and of similar vectors (deviation < or = 5 degrees). At each 
      electrode the local epicardial action potential duration was assessed as the 
      activation recovery interval and the standard deviation of the epicardial action 
      potential duration (of 256 leads, = dispersion) was determined. In a second 
      series of experiments 30 min regional ischemia was induced by occlusion of the 
      left descendent coronary artery followed by 30 min reperfusion in the absence or 
      presence of 0.5 microM acetylsalicylic acid or 1 micro/M indomethacin. The degree 
      of ischemia was assessed by the reduction in coronary flow, by the degree of 
      ST-elevation and by the area in which ST-elevation was registered. Under 
      non-ischemic conditions acetylsalicylic acid led to an increase in the epicardial 
      action potential duration (7%), a decrease in the breakthrough-point similarity 
      (by 10%) and vectorfield similarity (by 15%). In control hearts submitted to 
      regional ischemia the similarity of the vectorfields and of the 
      breakthrough-points, as well as the duration of the epicardial action potentials 
      were markedly reduced while the dispersion was greatly increased. In the ischemic 
      region there was a significant ST-deviation from the isoelectrical line. These 
      changes of ST-segments were significantly enhanced by 0.5 microM acetylsalicylic 
      acid, so that in all (7/7) acetylsalicylic acid treated hearts sustained 
      ventricular fibrillation occurred after 20 min ischemia, whereas in the absence 
      of acetylsalicylic acid fibrillation was found in only 2/7 hearts during 
      reperfusion and not during ischemia. 1 microM indomethacin did not cause these 
      changes. In all ischemia/reperfusion series of experiments the reduction in 
      coronary flow and left ventricular pressure by ischemia was of the same degree 
      and we did not observe significant differences in the size of ischemic area. 
      Using 14C-acetylsalicylic acid, an accumulation of acetylsalicylic acid in the 
      ischemic region could be observed. From these results we conclude, that 
      acetylsalicylic acid can induce ventricular fibrillation. Thus, in acute 
      myocardial ischemia, acetylsalicylic acid may have (besides the well known and 
      desired antiaggregatory effects) electrophysiologic side effects which seem to be 
      proarrhythmic in regional ischemia at least in this model.
FAU - Dhein, S
AU  - Dhein S
AD  - Institute of Pharmacology, University of Cologne, Germany. 
      stefan.dhein@uni-koeln.de
FAU - Gottwald, M
AU  - Gottwald M
FAU - Gottwald, E
AU  - Gottwald E
FAU - Hohlfeld, T
AU  - Hohlfeld T
FAU - Salameh, A
AU  - Salameh A
FAU - Klaus, W
AU  - Klaus W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/blood/*pharmacology
MH  - Arrhythmias, Cardiac/etiology
MH  - Aspirin/blood/*pharmacology
MH  - Coronary Circulation/drug effects
MH  - Electrophysiology
MH  - Heart Rate/*drug effects/physiology
MH  - Male
MH  - Myocardial Ischemia/drug therapy/physiopathology
MH  - Myocardial Reperfusion
MH  - Rabbits
MH  - Ventricular Fibrillation/*etiology
EDAT- 1998/02/24 00:00
MHDA- 1998/02/24 00:01
CRDT- 1998/02/24 00:00
PHST- 1998/02/24 00:00 [pubmed]
PHST- 1998/02/24 00:01 [medline]
PHST- 1998/02/24 00:00 [entrez]
AID - S0014-2999(97)01382-4 [pii]
AID - 10.1016/s0014-2999(97)01382-4 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1997 Nov 27;339(2-3):129-39. doi: 10.1016/s0014-2999(97)01382-4.

PMID- 17443552
OWN - NLM
STAT- MEDLINE
DCOM- 20070717
LR  - 20220408
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 2
DP  - 2007 Apr 18
TI  - Antiplatelet agents for preventing pre-eclampsia and its complications.
PG  - CD004659
AB  - BACKGROUND: Pre-eclampsia is associated with deficient intravascular production 
      of prostacyclin, a vasodilator, and excessive production of thromboxane, a 
      vasoconstrictor and stimulant of platelet aggregation. These observations led to 
      the hypotheses that antiplatelet agents, low-dose aspirin in particular, might 
      prevent or delay development of pre-eclampsia. OBJECTIVES: To assess the 
      effectiveness and safety of antiplatelet agents for women at risk of developing 
      pre-eclampsia. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth 
      Group's Trials Register (July 2006), the Cochrane Central Register of Controlled 
      Trials (The Cochrane Library 2005, Issue 1), EMBASE (1994 to November 2005) and 
      handsearched congress proceedings of the International and European Societies for 
      the Study of Hypertension in Pregnancy. SELECTION CRITERIA: All randomised trials 
      comparing antiplatelet agents with either placebo or no antiplatelet agent were 
      included. Quasi-random studies were excluded. Participants were pregnant women at 
      risk of developing pre-eclampsia. Interventions were any comparisons of an 
      antiplatelet agent (such as low-dose aspirin or dipyridamole) with either placebo 
      or no antiplatelet. DATA COLLECTION AND ANALYSIS: Two authors assessed trials for 
      inclusion and extracted data independently. MAIN RESULTS: Fifty-nine trials 
      (37,560 women) are included. There is a 17% reduction in the risk of 
      pre-eclampsia associated with the use of antiplatelet agents ((46 trials, 32,891 
      women, relative risk (RR) 0.83, 95% confidence interval (CI) 0.77 to 0.89), 
      number needed to treat (NNT) 72 (52, 119)). Although there is no statistical 
      difference in RR based on maternal risk, there is a significant increase in the 
      absolute risk reduction of pre-eclampsia for high risk (risk difference (RD) 
      -5.2% (-7.5, -2.9), NNT 19 (13, 34)) compared with moderate risk women (RD -0.84 
      (-1.37, -0.3), NNT 119 (73, 333)). Antiplatelets were associated with an 8% 
      reduction in the relative risk of preterm birth (29 trials, 31,151 women, RR 
      0.92, 95% CI 0.88 to 0.97); NNT 72 (52, 119)), a 14% reduction in fetal or 
      neonatal deaths (40 trials, 33,098 women, RR 0.86, 95% CI 0.76 to 0.98); NNT 243 
      (131, 1,666) and a 10% reduction in small-for-gestational age babies (36 trials, 
      23,638 women, RR 0.90, 95% CI0.83 to 0.98). There were no statistically 
      significant differences between treatment and control groups for any other 
      outcomes. AUTHORS' CONCLUSIONS: Antiplatelet agents, largely low-dose aspirin, 
      have moderate benefits when used for prevention of pre-eclampsia and its 
      consequences. Further information is required to assess which women are most 
      likely to benefit, when treatment is best started, and at what dose.
FAU - Duley, L
AU  - Duley L
AD  - University of Leeds, Centre for Epidemiology and Biostatistics, Academic Unit, 
      Fieldhouse, Bradford Teaching Hospitals Foundation Trust, Bradford Royal 
      Infirmary, Duckworth Lane, Bradford, West Yorkshire, UK BD9 6RJ. 
      l.duley@leeds.ac.uk
FAU - Henderson-Smart, D J
AU  - Henderson-Smart DJ
FAU - Meher, S
AU  - Meher S
FAU - King, J F
AU  - King JF
LA  - eng
GR  - G116/98/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20070418
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2004;(1):CD004659. PMID: 14974075
UIN - Cochrane Database Syst Rev. 2019 Oct 30;2019(10):. PMID: 31684684
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Fetal Death/prevention & control
MH  - Humans
MH  - Obstetric Labor, Premature/prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
RF  - 159
EDAT- 2007/04/20 09:00
MHDA- 2007/07/18 09:00
CRDT- 2007/04/20 09:00
PHST- 2007/04/20 09:00 [pubmed]
PHST- 2007/07/18 09:00 [medline]
PHST- 2007/04/20 09:00 [entrez]
AID - 10.1002/14651858.CD004659.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004659. doi: 
      10.1002/14651858.CD004659.pub2.

PMID- 27830335
OWN - NLM
STAT- MEDLINE
DCOM- 20170503
LR  - 20181202
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Linking)
VI  - 274
IP  - 3
DP  - 2017 Mar
TI  - Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without 
      AERD: a cross-sectional and longitudinal study.
PG  - 1487-1493
LID - 10.1007/s00405-016-4366-x [doi]
AB  - Oral aspirin challenge (OAC) reveals aspirin-exacerbated respiratory disease 
      (AERD) in approximately 50% of unselected patients with chronic rhinosinusitis 
      with nasal polyposis (CRSwNP). Smell loss is one factor that predicts the outcome 
      of OAC. The present study aims to unveil differences in olfactory function 
      between patients with CRSwNP with and without AERD by means of a validated 
      reliable test for odor threshold, discrimination and identification. 
      Additionally, Beck Depression Inventory (BDI) and Sinonasal Outcome Test 22 (SNOT 
      22) were applied. 31 patients were tested before and 7 months after OAC and 
      aspirin desensitization in case of diagnosed AERD. AERD was diagnosed in 16 and 
      excluded in 15 patients. Patients with AERD demonstrated significantly more 
      olfactory loss, but no difference in BDI or SNOT 22 at baseline. Olfaction of the 
      groups equalized at follow-up. Sinonasal complaints decreased significantly in 
      patients with AERD, but not in the group without AERD. Olfactory loss is a 
      valuable marker for AERD, but due to the variance of olfactory test results 
      prediction of AERD by exclusively any of the applied olfactory tests appears 
      unreliable.
FAU - Gudziol, V
AU  - Gudziol V
AUID- ORCID: 0000-0002-9602-0983
AD  - Interdisciplinary Center "Smell and Taste", Department of Otorhinolaryngology, TU 
      Dresden, Dresden, Germany. volker.gudziol@uniklinikum-dresden.de.
AD  - Department of ORL, Dresden Medical School, Fetscherstr. 74, 01304, Dresden, 
      Germany. volker.gudziol@uniklinikum-dresden.de.
FAU - Michel, M
AU  - Michel M
AD  - Department of Otorhinolaryngology, German Armed Forces Hospital of Ulm, Ulm, 
      Germany.
FAU - Sonnefeld, C
AU  - Sonnefeld C
AD  - Interdisciplinary Center "Smell and Taste", Department of Otorhinolaryngology, TU 
      Dresden, Dresden, Germany.
FAU - Koschel, D
AU  - Koschel D
AD  - Department of Pulmonary Diseases, Fachkrankenhaus Coswig, Centre for Pulmonary 
      Diseases and Thoracic Surgery, Coswig, Germany.
FAU - Hummel, T
AU  - Hummel T
AD  - Interdisciplinary Center "Smell and Taste", Department of Otorhinolaryngology, TU 
      Dresden, Dresden, Germany.
LA  - eng
PT  - Journal Article
DEP - 20161109
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma, Aspirin-Induced/diagnosis
MH  - Chronic Disease
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/chemically induced
MH  - Olfaction Disorders/chemically induced/*diagnosis
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Prospective Studies
MH  - Rhinitis/*chemically induced/diagnosis
MH  - Sinusitis/*chemically induced/diagnosis
OTO - NOTNLM
OT  - Aspirin tolerance test
OT  - Depression
OT  - Nasal polyps
OT  - Quality of life
OT  - Smell
EDAT- 2016/11/11 06:00
MHDA- 2017/05/04 06:00
CRDT- 2016/11/11 06:00
PHST- 2016/08/03 00:00 [received]
PHST- 2016/10/31 00:00 [accepted]
PHST- 2016/11/11 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
PHST- 2016/11/11 06:00 [entrez]
AID - 10.1007/s00405-016-4366-x [pii]
AID - 10.1007/s00405-016-4366-x [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1487-1493. doi: 
      10.1007/s00405-016-4366-x. Epub 2016 Nov 9.

PMID- 22044499
OWN - NLM
STAT- MEDLINE
DCOM- 20121031
LR  - 20211020
IS  - 1742-481X (Electronic)
IS  - 1742-4801 (Print)
IS  - 1742-4801 (Linking)
VI  - 9
IP  - 3
DP  - 2012 Jun
TI  - Livedoid vasculopathy associated with sickle cell trait: significant improvement 
      on aspirin treatment.
PG  - 344-7
LID - 10.1111/j.1742-481X.2011.00882.x [doi]
AB  - Livedoid vasculopathy (LV) is a chronic, recurrent, painful cutaneous disease 
      manifesting as longstanding distal lower extremity ulcers that scar leaving 
      stellate atrophic lesions known as 'atrophie blanche'. A significant number of 
      cases have been associated with thrombophilic abnormalities. In this study, we 
      describe, to the best of our knowledge, the first report of LV only associated 
      with sickle cell trait with significant improvement on aspirin.
CI  - © 2011 The Authors. © 2011 Blackwell Publishing Ltd and Medicalhelplines.com Inc.
FAU - El Khoury, Jinane
AU  - El Khoury J
AD  - Dermatology Department, American University of Beirut Medical Center, Beirut, 
      Lebanon.
FAU - Taher, Ali
AU  - Taher A
FAU - Kurban, Mazen
AU  - Kurban M
FAU - Kibbi, Abdul-Ghani
AU  - Kibbi AG
FAU - Abbas, Ossama
AU  - Abbas O
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20111101
PL  - England
TA  - Int Wound J
JT  - International wound journal
JID - 101230907
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Biopsy
MH  - Follow-Up Studies
MH  - Humans
MH  - Livedo Reticularis/complications/diagnosis/*drug therapy
MH  - Male
MH  - Sickle Cell Trait/*complications/diagnosis
MH  - Skin/pathology
PMC - PMC7950644
EDAT- 2011/11/03 06:00
MHDA- 2012/11/01 06:00
CRDT- 2011/11/03 06:00
PHST- 2011/11/03 06:00 [entrez]
PHST- 2011/11/03 06:00 [pubmed]
PHST- 2012/11/01 06:00 [medline]
AID - IWJ882 [pii]
AID - 10.1111/j.1742-481X.2011.00882.x [doi]
PST - ppublish
SO  - Int Wound J. 2012 Jun;9(3):344-7. doi: 10.1111/j.1742-481X.2011.00882.x. Epub 
      2011 Nov 1.

PMID- 7222893
OWN - NLM
STAT- MEDLINE
DCOM- 19810623
LR  - 20131121
IS  - 0301-0481 (Print)
IS  - 0301-0481 (Linking)
VI  - 56
IP  - 6
DP  - 1981 Mar 15
TI  - [Urticaria and "aspirin intolerance"--part of an interdisciplinary pathogenetic 
      principle? (author's transl)].
PG  - 347-67
AB  - Like the so-called "aspirin asthma", the aspirin-induced provocation of chronic 
      urticaria is a symptom of the intolerance syndrome. This may also be induced by 
      various other drugs, particularly by indomethacin and food additives. The 
      intolerance syndromes of the "Aspirin type", however, must be assigned to the 
      "anaphylactoid reactions" in man which also include the non-immunologic reactions 
      to radiographic contrast media and colloids in blood substitutes. It has not yet 
      been investigated in how far the mechanisms of these three clinical types of 
      anaphylactoid reactions are similar or identical; however, this appears to be the 
      case at least with aspirin intolerance and anaphylactoid reactions to contrast 
      media. According to our observations in 150 urticaria patients, the 
      non-immunologic aspirin-induced urticaria (and probably also the "aspirin 
      asthma") should furthermore be divided into real provocation within the meaning 
      of a chemical Koebner phenomenon, and "aspirin urticaria" as a symptom of the 
      intolerance syndrome as such. A rel provocation of pre-existent urticaria is much 
      less frequent than superimposed urticaria as a mere symptom of the intolerance 
      syndrome. An exact differentiation is only possible in patients without any 
      clinical symptoms after additive-free diet as well as on the basis of the 
      phenomenon of "figuration". The most important substance as mediator for 
      intolerance urticaria is histamine. In contrast to the usual urticaria, 
      H2-antagonists are an important adjuvant to the traditional H1-antagonists in the 
      symptomatic therapy.
FAU - Illig, L
AU  - Illig L
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Urticaria und "Aspirin-Intoleranz" Teilkomplex eines fächerübergreifenden 
      pathogenetischen Prinzips?
PL  - Germany
TA  - Z Hautkr
JT  - Zeitschrift fur Hautkrankheiten
JID - 0367576
RN  - 0 (Food Additives)
RN  - 0 (Histamine Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anaphylaxis
MH  - Aspirin/*immunology
MH  - Drug Tolerance
MH  - Food Additives/adverse effects
MH  - Histamine Antagonists/therapeutic use
MH  - Humans
MH  - Intradermal Tests
MH  - Urticaria/*immunology
EDAT- 1981/03/15 00:00
MHDA- 1981/03/15 00:01
CRDT- 1981/03/15 00:00
PHST- 1981/03/15 00:00 [pubmed]
PHST- 1981/03/15 00:01 [medline]
PHST- 1981/03/15 00:00 [entrez]
PST - ppublish
SO  - Z Hautkr. 1981 Mar 15;56(6):347-67.

PMID- 21249700
OWN - NLM
STAT- MEDLINE
DCOM- 20110228
LR  - 20221207
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 2011
IP  - 1
DP  - 2011 Jan 19
TI  - Cilostazol versus aspirin for secondary prevention of vascular events after 
      stroke of arterial origin.
PG  - CD008076
LID - 10.1002/14651858.CD008076.pub2 [doi]
LID - CD008076
AB  - BACKGROUND: Aspirin is widely used for secondary prevention after stroke. 
      Cilostazol has shown promise as an alternative to aspirin in Asian people with 
      stroke. OBJECTIVES: To determine the relative effectiveness and safety of 
      cilostazol compared directly with aspirin in the prevention of stroke and other 
      serious vascular events in patients at high vascular risk for subsequent stroke, 
      those with previous transient ischaemic attack (TIA) or ischaemic stroke of 
      arterial origin. SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials 
      Register (last searched September 2010), the Cochrane Central Register of 
      Controlled Trials (CENTRAL) (The Cochrane Library 2009, Issue 4), MEDLINE (1950 
      to May 2010) and EMBASE (1980 to May 2010). In an effort to identify further 
      published, ongoing and unpublished studies we searched journals, conference 
      proceedings and ongoing trial registers, scanned reference lists from relevant 
      studies and contacted trialists and Otsuka Pharmaceutical Co Ltd. SELECTION 
      CRITERIA: We selected all randomised controlled trials (RCTs) comparing 
      cilostazol with aspirin where participants were treated for at least one month 
      and followed systematically for development of vascular events. DATA COLLECTION 
      AND ANALYSIS: Data extracted from eligible studies included: (1) a composite 
      outcome of vascular events (stroke, myocardial infarction or vascular death) 
      during follow up (primary outcome); (2) separate outcomes of stroke (ischaemic or 
      haemorrhagic, fatal or non-fatal), myocardial infarction (MI) (fatal or 
      non-fatal), vascular death and death from all causes; and (3) main outcomes of 
      safety including any intracranial, extracranial or gastrointestinal (GI) 
      haemorrhage and other outcomes during treatment follow up (secondary outcomes). 
      We computed an estimate of treatment effect and performed a test for 
      heterogeneity between trials. We analysed data on an intention-to-treat basis and 
      assessed bias for all included studies. MAIN RESULTS: We included two RCTs with 
      3477 Asian participants. Compared with aspirin, cilostazol was associated with a 
      significantly lower risk of composite outcome of vascular events (6.77% versus 
      9.39%, risk ratio (RR) 0.72, 95% confidence interval (CI) 0.57 to 0.91), and 
      lower risk of haemorrhagic stroke (0.53% versus 2.01%, RR 0.26, 95% CI 0.13 to 
      0.55). In terms of outcome of safety compared with aspirin, cilostazol was 
      significantly associated with minor adverse effects (8.22% versus 4.95%, RR 1.66, 
      95% CI 1.51 to 1.83). AUTHORS' CONCLUSIONS: Cilostazol is more effective than 
      aspirin in the prevention of vascular events secondary to stroke. Cilostazol has 
      more minor adverse effects, although there is evidence of fewer bleeds.
FAU - Kamal, Ayeesha K
AU  - Kamal AK
AD  - Stroke Service, Section of Neurology, Department of Medicine, Aga Khan University 
      Hospital, Stadium Road, PO Box 3500, Karachi, Pakistan, 74800.
FAU - Naqvi, Imama
AU  - Naqvi I
FAU - Husain, Muhammad R
AU  - Husain MR
FAU - Khealani, Bhojo A
AU  - Khealani BA
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20110119
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - doi: 10.1002/14651858.CD008076
MH  - Asian People
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/complications
MH  - Cause of Death
MH  - Cilostazol
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Secondary Prevention/*methods
MH  - Stroke/*complications/ethnology/prevention & control
MH  - Tetrazoles/adverse effects/*therapeutic use
PMC - PMC6599824
COIS- None known
EDAT- 2011/01/21 06:00
MHDA- 2011/03/01 06:00
CRDT- 2011/01/21 06:00
PHST- 2011/01/21 06:00 [entrez]
PHST- 2011/01/21 06:00 [pubmed]
PHST- 2011/03/01 06:00 [medline]
AID - CD008076 [pii]
AID - 10.1002/14651858.CD008076.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2011 Jan 19;2011(1):CD008076. doi: 
      10.1002/14651858.CD008076.pub2.

PMID- 26280541
OWN - NLM
STAT- MEDLINE
DCOM- 20161012
LR  - 20191210
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Linking)
VI  - 118
IP  - 2
DP  - 2016 Feb
TI  - Concurrent Use of Low-Dose Aspirin and Omega-3 Fatty Acids and Risk of Upper 
      Gastrointestinal Complications: A Cohort Study with Nested Case-Control Analysis.
PG  - 136-42
LID - 10.1111/bcpt.12454 [doi]
AB  - The risk of upper gastrointestinal complications (UGIC) due to low-dose aspirin 
      (LDA) can be further increased by the concurrent exposure to other antithrombotic 
      agents. Little is known on the combined therapy with LDA and medications 
      containing omega-3 (OM3) fatty acids, which also exert antiplatelet activity. The 
      aim of this study was to investigate the risk of UGIC in patients exposed to 
      LDA-OM3 combination. The Italian Health Search IMS Health Longitudinal Patients 
      Database was used to perform a population-based cohort study. Patients aged ≥18 
      years with cardio- or cerebrovascular ischaemic disease recorded between 2002 and 
      2012 (cohort entry) were selected. All UGIC cases (index date) observed up to 
      December 2013 were identified. According to a nested case-control analysis, up to 
      10 controls were matched to each case on age, sex and calendar period. The risk 
      of UGIC was investigated among current (up to 30 days preceding index date), 
      recent (31-60 days) and past users (61-365 days) of the LDA-OM3 combination. 
      Exposure assessment was lagged by 30 days to minimize reverse causation. 
      Additionally, a duration-response analysis was performed. Odds ratios (OR) and 
      95% confidence intervals (CI) were estimated using conditional logistic 
      regression. Non-users of the LDA-OM3 combination were the reference category. 
      Current (OR = 0.66; 95% CI: 0.44-1.00), recent (OR = 0.83; 95% CI: 0.52-1.33) and 
      past users (OR = 0.81; 95% CI: 0.57-1.15) did not statistically significantly 
      increase the risk of UGIC. No duration-response relationship was found. Our 
      results suggest that LDA-OM3 combination therapy does not affect the UGIC risk in 
      patients with cardio- or cerebrovascular ischaemic diseases. Given the novelty of 
      these findings, further studies are needed.
CI  - © 2015 Nordic Association for the Publication of BCPT (former Nordic 
      Pharmacological Society).
FAU - Roberto, Giuseppe
AU  - Roberto G
AD  - Regional Agency for Healthcare Services of Tuscany, Epidemiology Unit, Florence, 
      Italy.
FAU - Simonetti, Monica
AU  - Simonetti M
AD  - Health Search, Italian College of General Practitioners and Primary Care, 
      Florence, Italy.
FAU - Cricelli, Claudio
AU  - Cricelli C
AD  - Health Search, Italian College of General Practitioners and Primary Care, 
      Florence, Italy.
FAU - Cricelli, Iacopo
AU  - Cricelli I
AD  - Health Search, Italian College of General Practitioners and Primary Care, 
      Florence, Italy.
FAU - Giustini, Saffi Ettore
AU  - Giustini SE
AD  - Italian College of General Practitioners and Primary Care, Florence, Italy.
FAU - Parretti, Damiano
AU  - Parretti D
AD  - Italian College of General Practitioners and Primary Care, Florence, Italy.
FAU - Lapi, Francesco
AU  - Lapi F
AD  - Health Search, Italian College of General Practitioners and Primary Care, 
      Florence, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150911
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Aspirin/administration & dosage/adverse effects
MH  - *Cardiovascular Diseases/drug therapy/epidemiology
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - *Fatty Acids, Omega-3/administration & dosage/adverse effects
MH  - Female
MH  - *Gastrointestinal Diseases/chemically induced/diagnosis/prevention & control
MH  - Humans
MH  - Italy/epidemiology
MH  - Male
MH  - Outcome Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Risk Assessment
EDAT- 2015/08/19 06:00
MHDA- 2016/10/13 06:00
CRDT- 2015/08/18 06:00
PHST- 2015/05/12 00:00 [received]
PHST- 2015/08/10 00:00 [accepted]
PHST- 2015/08/18 06:00 [entrez]
PHST- 2015/08/19 06:00 [pubmed]
PHST- 2016/10/13 06:00 [medline]
AID - 10.1111/bcpt.12454 [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2016 Feb;118(2):136-42. doi: 10.1111/bcpt.12454. 
      Epub 2015 Sep 11.

PMID- 10523476
OWN - NLM
STAT- MEDLINE
DCOM- 19991122
LR  - 20131121
IS  - 0828-282X (Print)
IS  - 0828-282X (Linking)
VI  - 15
IP  - 10
DP  - 1999 Oct
TI  - Higher rates of coronary angiography and revascularization following myocardial 
      infarction may be associated with greater survival in the United States than in 
      Canada. The CARS Investigators (Coumadin/Aspirin Reinfarction Study).
PG  - 1095-102
AB  - BACKGROUND: Significant differences are known to exist between the United States 
      and Canada with respect to coronary catheterization and intervention. In a post 
      hoc analysis, it was hypothesized that these differences may have the greatest 
      impact on outcome in patients at risk for recurrent events such as those 
      following myocardial infarction (MI). PATIENTS AND METHODS: The hypothesis was 
      tested in a nonrandomized comparison of the catheterization and revascularization 
      patterns for patients following acute MI in 7029 patients in the United States 
      and 1774 patients in Canada who participated in the Coumadin/Aspirin Reinfarction 
      Study (CARS). CARS tested the effectiveness of low dose warfarin in combination 
      with acetylsalicylic acid (ASA) versus ASA alone in reducing cardiovascular 
      morbidity and mortality. RESULTS: Before study enrollment (median day 7 to 8), 
      84.5% of the American patients underwent coronary angiography compared with only 
      7.7% in Canada (P<0.01). CARS patients in the United States underwent 
      significantly more frequent angioplasty during their hospital admission before 
      study enrollment than their Canadian counterparts (55.8% versus 3.0%, 
      respectively, P<0.01), and there was a more frequent use of intravenous heparin 
      among American CARS patients (96% versus 88%, respectively, P<0.01) but less 
      frequent administration of thrombolytic therapy (44% versus 49%, respectively, 
      P<0.01). For follow-up of up to 32 months, American CARS patients had 
      significantly fewer primary events (cardiovascular deaths, nonfatal MI, nonfatal 
      ischemic stroke) than Canadian patients. Cumulative estimate of a primary end 
      point comparing American with Canadian patients was, respectively, 2.0% versus 
      3.1% at one month, 8.0% versus 11.3% at one year and 11.6% versus 15.0% at two 
      years. Thus, time to the primary event was significantly longer in American 
      patients (P=0.0001). All-cause mortality estimates at 12 months were 2.2% and 
      4.0%, respectively, for the American and Canadian CARS subgroups. When management 
      for the index MI (ie, angiography and angioplasty) is included in the model, the 
      risk of death for Canadian versus American subgroups of CARS is not statistically 
      different (0.9, 95% CI 0.6 to 1.2, P=0.40). CONCLUSION: Among study participants, 
      American patients experienced a better outcome than Canadian patients, which may 
      be attributable to more aggressive management based on early coronary angiography 
      and angioplasty. However, angioplasty before study enrollment in American 
      patients may have resulted in enrollment of lower risk patients. This selection 
      bias limits the scope of the comparison.
FAU - Langer, A
AU  - Langer A
AD  - St Michael's Hospital, Toronto, Canada.
FAU - Fisher, M
AU  - Fisher M
FAU - Califf, R M
AU  - Califf RM
FAU - Goodman, S
AU  - Goodman S
FAU - O'Connor, C M
AU  - O'Connor CM
FAU - Harrington, R A
AU  - Harrington RA
FAU - Fuster, V
AU  - Fuster V
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angioplasty, Balloon, Coronary
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Canada/epidemiology
MH  - Coronary Angiography
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Myocardial Infarction/drug therapy/mortality/*surgery
MH  - *Myocardial Revascularization
MH  - Survival Rate
MH  - United States/epidemiology
MH  - Warfarin/pharmacology/therapeutic use
EDAT- 1999/10/16 00:00
MHDA- 1999/10/16 00:01
CRDT- 1999/10/16 00:00
PHST- 1999/10/16 00:00 [pubmed]
PHST- 1999/10/16 00:01 [medline]
PHST- 1999/10/16 00:00 [entrez]
PST - ppublish
SO  - Can J Cardiol. 1999 Oct;15(10):1095-102.

PMID- 24004620
OWN - NLM
STAT- MEDLINE
DCOM- 20140428
LR  - 20181023
IS  - 1002-0098 (Print)
IS  - 1002-0098 (Linking)
VI  - 48
IP  - 5
DP  - 2013 May
TI  - [Clinical evaluation of influence of aspirin on post-operative bleeding after 
      tooth extraction in the elderly].
PG  - 262-5
LID - 10.3760/cma.j.issn.1002-0098.2013.05.003 [doi]
AB  - OBJECTIVE: To investigate the feasibility of continuation of aspirin before tooth 
      extraction in the elderly. METHODS: The patients enrolled in this study were the 
      elderly requiring a single non-impacted tooth extraction. 300 elderly outpatients 
      used lidocaine local infiltration anesthesia, 200 patients without using aspirin 
      before tooth extraction served as control group I, 100 patients with prolong use 
      of aspirin before tooth extraction as observation group I. 300 elderly 
      outpatients used compound articaine local infiltration anesthesia, 200 patients 
      without using aspirin before tooth extraction served as control group II, 100 
      patients with prolong use of aspirin before tooth extraction as observation group 
      II.Bleedings at 5, 10, 30 min, 24 h after tooth extraction were observed and the 
      relationship between postoperative bleeding and intake of aspirin was analyzed. 
      RESULTS: There was no significant difference at 5, 10, 30 min, 24 h in 
      postoperative bleeding after extraction between control group I and observation 
      group. The incidence of bleeding of observation group II after tooth extraction 
      at 5 min was higher than that of control group II and there was no significant 
      difference at 10, 30 min, 24 h between the two groups. CONCLUSIONS: Continuation 
      of aspirin have no influence on postoperative bleeding. Therefore we suggest that 
      there was no indication to discontinue aspirin for the elderly before a single 
      non-impacted tooth extraction.
FAU - Wang, Wen-ying
AU  - Wang WY
AD  - Department of Oral and Maxillofacial Surgery, Peking University School and 
      Hospital of Stomatology, Beijing, China.
FAU - Cui, Nian-hui
AU  - Cui NH
FAU - Wang, En-bo
AU  - Wang EB
FAU - Zhang, Wei
AU  - Zhang W
LA  - chi
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Kou Qiang Yi Xue Za Zhi
JT  - Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese 
      journal of stomatology
JID - 8711066
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 98PI200987 (Lidocaine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anesthesia, Local
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Humans
MH  - Lidocaine
MH  - Male
MH  - Middle Aged
MH  - Oral Hemorrhage/*etiology
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Postoperative Hemorrhage/*etiology
MH  - Tooth Extraction/*adverse effects
EDAT- 2013/09/06 06:00
MHDA- 2014/04/29 06:00
CRDT- 2013/09/06 06:00
PHST- 2013/09/06 06:00 [entrez]
PHST- 2013/09/06 06:00 [pubmed]
PHST- 2014/04/29 06:00 [medline]
AID - 10.3760/cma.j.issn.1002-0098.2013.05.003 [doi]
PST - ppublish
SO  - Zhonghua Kou Qiang Yi Xue Za Zhi. 2013 May;48(5):262-5. doi: 
      10.3760/cma.j.issn.1002-0098.2013.05.003.

PMID- 7502240
OWN - NLM
STAT- MEDLINE
DCOM- 19960117
LR  - 20131121
IS  - 0040-3709 (Print)
IS  - 0040-3709 (Linking)
VI  - 51
IP  - 6
DP  - 1995 Jun
TI  - Aspirin-alcohol interaction in the production of cleft palate and limb 
      malformations in the TO mouse.
PG  - 404-17
AB  - Our objective in the present study was to determine the effects of alcohol on 
      stages when the limb buds and renal primordia develop in the TO mouse and to see 
      if aspirin pretreatment would prevent these organ systems from being malformed as 
      was shown by Randall et al. ('91) in the C57 mice. On one of days 9-12 of 
      gestation, groups of TO mice were injected intraperitoneally (IP) with a single 
      dose of 200 mg/kg of aspirin, or a proportionate volume of physiological saline. 
      An hour later, half of the aspirin-treated animals received a single dose of 0.03 
      ml/g of freshly prepared 25% (v/v) solution of absolute alcohol and the other 
      half received a proportionate volume of saline. Half of the saline-treated 
      animals received a single dose of 0.03 ml/g of saline or a proportionate volume 
      of alcohol solution. All animals were killed on day 18 of gestation. Alcohol 
      significantly increased embryonic resorption and caused remarkable intrauterine 
      growth retardation (IUGR). It also induced arched palate, cleft palate and 
      deformities of the digits with haematomas in a modest number of embryos. Aspirin 
      alone did not have any teratogenic effects. Pretreatment with aspirin 
      significantly augmented alcohol-induced resorption, IUGR, cleft palate and 
      digital malformations associated with haematomas. Chronological observations on 
      the development of the treated limbs showed the occurrence of vascular stasis, 
      haematomas, edema and cell death at early stages. Subsequently, digital rays were 
      either destroyed (ectrodactyly) or remained hypoplastic (brachydactyly). It 
      appears that limb development in the aspirin- and alcohol-treated TO mouse 
      embryos is largely affected by vascular disruption. These data provide further 
      evidence to our earlier observation that alcohol and aspirin interact in the 
      production of malformations and that the teratogenic effects of alcohol in the TO 
      mouse are possibly not mediated via treatment related prostaglandin elevation.
FAU - Padmanabhan, R
AU  - Padmanabhan R
AD  - Department of Anatomy, Faculty of Medicine and Health Sciences, UAE University, 
      AL Ain, United Arab Emirates.
FAU - Pallot, D J
AU  - Pallot DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Teratology
JT  - Teratology
JID - 0153257
RN  - 0 (Teratogens)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Cleft Palate/*chemically induced
MH  - Drug Interactions
MH  - Ethanol/*toxicity
MH  - Female
MH  - *Limb Deformities, Congenital
MH  - Mice
MH  - Pregnancy
MH  - Teratogens/*toxicity
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
AID - 10.1002/tera.1420510606 [doi]
PST - ppublish
SO  - Teratology. 1995 Jun;51(6):404-17. doi: 10.1002/tera.1420510606.

PMID- 8236166
OWN - NLM
STAT- MEDLINE
DCOM- 19931202
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 71
IP  - 5
DP  - 1993 Sep 1
TI  - Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study 
      including 180 post-stroke patients.
PG  - 397-403
AB  - Aspirin is proposed to be effective in stroke-prophylaxis because it completely 
      inhibits the platelet prostanoid-pathway. In about 90% of stroke victims, 
      increased platelet reactivity (PR) can be reduced to the normal range by aspirin. 
      Twelve hours later, about one third of them show an enhanced PR again. These 
      patients are called secondary aspirin non responders (SANR). In this study the 
      potential pathogenetic and prognostic impact of this biological feature on stroke 
      recurrence was evaluated. Before discharge from the hospital, PR was determined 
      12 hours after an oral administration of 500 mg aspirin in 180 patients aged 58 
      +/- 15 years; 74 were female and 106 male. All had suffered a stroke in the 
      internal carotid artery territory. Patients were treated with 3 x 500 mg 
      aspirin/d and were followed up over a 24-month period. Major endpoints of this 
      study were stroke, myocardial infarction or vascular death. On discharge from the 
      hospital, 120 of the 180 patients showed a normal PR under aspirin treatment. 
      High test values were found in 60 patients (SANR). Six patients were lost for 
      follow-up. Because of side effects 36 (20%) of the 180 patients enrolled 
      discontinued medication. Major endpoints occurred in 4 of these 36 patients (11%) 
      and in 25 of the 138 remaining patients (18.1%); 19 patients died in consequence 
      of a vascular event during the observation period. Major endpoints were seen in 
      only 5 of 114 (4.4%) of the aspirin responders, but in 24 out of 60 SANR (40%, p 
      < 0.0001). It may be assumed that early identification of SANR's is a clinically 
      useful tool to classify patients at high risk for recurrence of vascular events.
FAU - Grotemeyer, K H
AU  - Grotemeyer KH
AD  - Department of Neurology, University of Münster, F.R.G.
FAU - Scharafinski, H W
AU  - Scharafinski HW
FAU - Husstedt, I W
AU  - Husstedt IW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/mortality
MH  - Carotid Artery, Internal
MH  - Cerebrovascular Disorders/drug therapy/*prevention & control
MH  - Drug Tolerance
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prognosis
MH  - Recurrence
MH  - Survival Rate
EDAT- 1993/09/01 00:00
MHDA- 1993/09/01 00:01
CRDT- 1993/09/01 00:00
PHST- 1993/09/01 00:00 [pubmed]
PHST- 1993/09/01 00:01 [medline]
PHST- 1993/09/01 00:00 [entrez]
AID - 0049-3848(93)90164-J [pii]
AID - 10.1016/0049-3848(93)90164-j [doi]
PST - ppublish
SO  - Thromb Res. 1993 Sep 1;71(5):397-403. doi: 10.1016/0049-3848(93)90164-j.

PMID- 991500
OWN - NLM
STAT- MEDLINE
DCOM- 19770128
LR  - 20151119
IS  - 0009-921X (Print)
IS  - 0009-921X (Linking)
IP  - 121
DP  - 1976 Nov-Dec
TI  - Complications following total knee replacement.
PG  - 181-7
AB  - Forty-two months follow-up examinations on 30 total knee arthroplasties revealed 
      the following significant complications: phlebothrombosis, 13 knees (46%); 
      pulmonary embolism 3 patients (11%); asymptomatic loosening, 8 knees (11.4%); 
      symptomatic loosening, 3 knees (4.8%); superficial infections, 4 knees (5.4%); 
      deep infections, 4 knees (5.4%); peroneal palsy, 3 patients (4.3%). Early 
      detection of thrombophlebitis by 125I fibrinogen scan and possible aspirin 
      prophylaxis were evaluated. In view of the limited number of encouraging results, 
      e.g. excellent 58.6 per cent; good 28.5 per cent; fair 5.4 per cent and poor 7.1 
      per cent, caution is advocated until extensive time elapses for more clinical 
      experience with total knee arthroplasty.
FAU - Kaushal, S P
AU  - Kaushal SP
FAU - Galante, J O
AU  - Galante JO
FAU - McKenna, R
AU  - McKenna R
FAU - Bachmann, F
AU  - Bachmann F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
RN  - 0 (Iodine Radioisotopes)
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Fibrinogen
MH  - Humans
MH  - Iodine Radioisotopes
MH  - *Joint Prosthesis
MH  - Knee Joint/*surgery
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Embolism/*etiology
MH  - Surgical Wound Infection/*etiology
MH  - Thrombophlebitis/*etiology
EDAT- 1976/11/01 00:00
MHDA- 1976/11/01 00:01
CRDT- 1976/11/01 00:00
PHST- 1976/11/01 00:00 [pubmed]
PHST- 1976/11/01 00:01 [medline]
PHST- 1976/11/01 00:00 [entrez]
PST - ppublish
SO  - Clin Orthop Relat Res. 1976 Nov-Dec;(121):181-7.

PMID- 1398238
OWN - NLM
STAT- MEDLINE
DCOM- 19921029
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 33
IP  - 8
DP  - 1992 Aug
TI  - Inhibition of human gall bladder mucus synthesis in patients undergoing 
      cholecystectomy.
PG  - 1113-7
AB  - Hypersection of gall bladder mucus is associated with gall stone formation in 
      animal models. Aspirin inhibits both mucus synthesis and secretion, prevents gall 
      stone formation in animals and reduces gall stone recurrence in man after 
      dissolution therapy. Mucus biosynthesis in human gall bladder mucosal explants is 
      inhibited by aspirin in vitro. We have studied the effects of aspirin in vivo. 
      Fifty five patients with functioning gall bladder and stones have been 
      randomised, 27 to group 1 (aspirin EC 300 mg once daily for seven days before 
      cholecystectomy) and 28 to group 2 (controls). Gall bladder bile composition was 
      analysed and mucus synthesis rates measured using 3H-glucosamine incorporation 
      into mucosal explants cultured for 24 hours. Patient age, sex, and gall bladder 
      histology were similar in both groups. There were no differences in stone 
      composition, gall bladder bile calcium concentration, cholesterol saturation and 
      cholesterol nucleation time. The mean 3H-glucosamine incorporation in aspirin 
      treated patients was 1347 fmol/g wet weight as compared with 2008 fmol/g wet 
      weight in controls (95% confidence interval 222-1100, p<0.005, unpaired t test). 
      This reduction in biosynthesis was associated with gall bladder bile mucus 
      concentrations of 7.6 mg/ml in patients and 7.1 mg/ml in controls (ns). Treatment 
      with aspirin led to a significant reduction in mucus biosynthesis by the gall 
      bladder mucosa. This action is consistent with a role for aspirin in the 
      prevention of gall stones.
FAU - Rhodes, M
AU  - Rhodes M
AD  - Department of Surgery, New Medical School, Newcastle upon Tyne.
FAU - Allen, A
AU  - Allen A
FAU - Dowling, R H
AU  - Dowling RH
FAU - Murphy, G
AU  - Murphy G
FAU - Lennard, T W
AU  - Lennard TW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Glycoproteins)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology
MH  - Bile/chemistry
MH  - Cholelithiasis/metabolism
MH  - Cholesterol/analysis
MH  - Depression, Chemical
MH  - Female
MH  - Gallbladder/*metabolism
MH  - Glycoproteins/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mucus/*metabolism
MH  - Prospective Studies
PMC - PMC1379453
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
AID - 10.1136/gut.33.8.1113 [doi]
PST - ppublish
SO  - Gut. 1992 Aug;33(8):1113-7. doi: 10.1136/gut.33.8.1113.

PMID- 480180
OWN - NLM
STAT- MEDLINE
DCOM- 19791128
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 68
IP  - 8
DP  - 1979 Aug
TI  - Effects of aspirin on 14C-pirprofen disposition in rats.
PG  - 996-8
AB  - The effects of aspirin on 14C-pirprofen disposition in the rat were studied. An 
      oral 60-mg/kg dose of aspirin significantly reduced plasma radioactivity during 
      the 1--8-hr interval after an intravenous 5-mg/kg injection of 14C-pirprofen. The 
      aspirin-treated group had only 69% as much area under the radioactivity curve as 
      the control group. The radioactive material in plasma consisted almost entirely 
      of 14C-pirprofen, as shown by GLC. The plasma clearance of 14C-pirprofen was 7.4 
      ml/hr for the aspirin-treated group and 5.1 ml/hr for the control group, while 
      the volumes of distribution were 0.32 and 0.20 liter/kg, respectively. The 
      apparent elimination half-life was unchanged at 5.9 hr. 14C-Pirprofen was 
      approximately 98.6% bound to plasma proteins, and the binding decreased to an 
      average of 97.2% in the presence of salicylate. Binding to blood cellular 
      constituents was insignificant. Rats give 14C-pirprofen by intravenous injection 
      without aspirin secreted 36.0--42.8% of the dose radioactivity into bile during 4 
      hr while a comparable group given 60 mg of aspirin/kg secreted 46.4--70.8%. TLC 
      and GLC demonstrated that the radioactivity in rat bile was 80--90% conjugated 
      14C-pirprofen. The increased radioactive material secretion into bile was 
      compensated in the intact rat by reabsorption, since the total radioactive 
      material excreted in urine was not changed by aspirin administration.
FAU - Thompson, T A
AU  - Thompson TA
FAU - Borman, C H
AU  - Borman CH
FAU - Goodblatt, R S
AU  - Goodblatt RS
FAU - Roth, W J 3rd
AU  - Roth WJ 3rd
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Blood Proteins)
RN  - 0 (Carbon Radioisotopes)
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyrroles)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bile/analysis
MH  - Blood Proteins/metabolism
MH  - Carbon Radioisotopes
MH  - Drug Interactions
MH  - Male
MH  - Phenylpropionates/*metabolism/urine
MH  - Protein Binding/drug effects
MH  - Pyrroles/metabolism/urine
MH  - Rats
EDAT- 1979/08/01 00:00
MHDA- 1979/08/01 00:01
CRDT- 1979/08/01 00:00
PHST- 1979/08/01 00:00 [pubmed]
PHST- 1979/08/01 00:01 [medline]
PHST- 1979/08/01 00:00 [entrez]
AID - S0022-3549(15)42763-7 [pii]
AID - 10.1002/jps.2600680820 [doi]
PST - ppublish
SO  - J Pharm Sci. 1979 Aug;68(8):996-8. doi: 10.1002/jps.2600680820.

PMID- 28991640
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20181202
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 35
DP  - 2017 Nov 15
TI  - The isoflavonoid tectorigenin has better antiplatelet potential than 
      acetylsalicylic acid.
PG  - 11-17
LID - S0944-7113(17)30111-3 [pii]
LID - 10.1016/j.phymed.2017.08.023 [doi]
AB  - BACKGROUND: One reason for the lower incidence of cardiovascular diseases in 
      Asian countries may be the high intake of isoflavonoids and their antiplatelet 
      effects may be an important factor. To date, there is limited comparison of a 
      range of isoflavonoids and knowledge of their effects at different levels of 
      platelet aggregation. PURPOSE: To screen the antiplatelet effects of a number of 
      isoflavonoids on the arachidonic acid based aggregation pathway and investigate 
      how the antiplatelet activity might occur. METHODS: The antiplatelet effects were 
      first screened in whole human blood where platelet aggregation was induced by 
      arachidonic acid. Further analysis was targeted at search of the mechanism of 
      action. RESULTS: Thirteen of the eighteen tested isoflavonoids had significant 
      inhibitory effect on platelet aggregation in whole human blood. Genistein had the 
      same potency as clinically used acetylsalicylic acid (ASA) while tectorigenin was 
      clearly stronger than ASA. Further analyses showed that the effect of 
      tectorigenin was not based on inhibition of cyclooxygenase-1 in contrast to ASA 
      or thromboxane synthase but by competitive antagonism at thromboxane receptors. 
      CONCLUSION: Tectorigenin is a more potent antiplatelet compound than ASA and thus 
      an interesting substance for further testing.
CI  - Copyright © 2017 Elsevier GmbH. All rights reserved.
FAU - Applová, Lenka
AU  - Applová L
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, 
      Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech 
      Republic.
FAU - Karlíčková, Jana
AU  - Karlíčková J
AD  - Department of Pharmaceutical Botany and Ecology, Faculty of Pharmacy in Hradec 
      Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, 
      Czech Republic.
FAU - Říha, Michal
AU  - Říha M
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, 
      Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech 
      Republic.
FAU - Filipský, Tomáš
AU  - Filipský T
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, 
      Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech 
      Republic.
FAU - Macáková, Kateřina
AU  - Macáková K
AD  - Department of Pharmaceutical Botany and Ecology, Faculty of Pharmacy in Hradec 
      Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, 
      Czech Republic.
FAU - Spilková, Jiřina
AU  - Spilková J
AD  - Department of Pharmacognosy, Faculty of Pharmacy in Hradec Králové, Charles 
      University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
FAU - Mladěnka, Přemysl
AU  - Mladěnka P
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, 
      Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech 
      Republic. Electronic address: mladenkap@faf.cuni.cz.
LA  - eng
PT  - Journal Article
DEP - 20170824
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 0 (Isoflavones)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 855130H9CO (tectorigenin)
RN  - DH2M523P0H (Genistein)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cyclooxygenase 1/metabolism
MH  - Genistein/pharmacology
MH  - Humans
MH  - Isoflavones/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
OTO - NOTNLM
OT  - Cyclooxygenase
OT  - Isoflavones
OT  - Platelets
OT  - Tectorigenin
EDAT- 2017/10/11 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/10/10 06:00
PHST- 2016/07/18 00:00 [received]
PHST- 2017/07/12 00:00 [revised]
PHST- 2017/08/20 00:00 [accepted]
PHST- 2017/10/10 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S0944-7113(17)30111-3 [pii]
AID - 10.1016/j.phymed.2017.08.023 [doi]
PST - ppublish
SO  - Phytomedicine. 2017 Nov 15;35:11-17. doi: 10.1016/j.phymed.2017.08.023. Epub 2017 
      Aug 24.

PMID- 11272320
OWN - NLM
STAT- MEDLINE
DCOM- 20010614
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 24
IP  - 4
DP  - 2001 Feb
TI  - Non-ionic micellar affinity capillary electrophoresis for analysis of 
      interactions between micelles and drugs.
PG  - 637-43
AB  - Micellar affinity capillary electrophoresis (MACE) was introduced to evaluate the 
      affinity of various kinds of drugs as benzoic acid, salicylic acid, 
      trinitrophenol, p-hydroxybenzoic acid and o-acetylsalicylic acid. Non-ionic 
      micelles as Brij 35 (polyethylenglycol dodecylether), Tagat (polyoxyethylene (20) 
      glycerol monooleate) and Tween 20 (polyoxyethylen sorbitan monolaurate) were used 
      as a pseudostationary phase in capillary electrophoresis. For polyvinyl alcohol 
      (PVA) coated capillary was used in this examinations. The drugs had negative 
      electrophoretic mobilities at a pH value of pH 7.2. The negatively charged drugs 
      migrated toward the anode and were related by their interaction with the 
      micelles. The difference in the mobility of the drugs owing to the presence of 
      the micelles reflected the interaction between these drugs and the micelles. 
      Equations were derived to calculate the capacity factor k' from the migration 
      times in the presence of micelles t' and in the absence of micelles t, the 
      partition coefficients Pwm and the Gibbs free energy. The drugs show different 
      interaction and affinity with the micelles in the systems. Strong interaction was 
      observed between benzoic acid and the micelles. Furthermore, a linear 
      relationship (R = 0.999) was obtained between deltaG(o) and ln Pwm in the 
      micellar solubilization of drugs. These results show that deltaG(o) can give us 
      information on the affinity and on the partition behaviour of the drugs in these 
      systems.
FAU - Mrestani, Y
AU  - Mrestani Y
AD  - Institute of Pharmaceutics and Biopharmaceutics, Martin-Luther-University 
      Halle-Wittenberg, Halle/S., Germany. mrestani@pharmazie.uni-halle.de
FAU - Neubert, R H
AU  - Neubert RH
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Micelles)
RN  - 0 (Picrates)
RN  - 8SKN0B0MIM (Benzoic Acid)
RN  - A49OS0F91S (picric acid)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Benzoic Acid/*chemistry
MH  - Chromatography, Micellar Electrokinetic Capillary
MH  - Hydroxybenzoates/*chemistry
MH  - Micelles
MH  - Picrates/*chemistry
MH  - Salicylic Acid/*chemistry
EDAT- 2001/03/29 10:00
MHDA- 2001/06/15 10:01
CRDT- 2001/03/29 10:00
PHST- 2001/03/29 10:00 [pubmed]
PHST- 2001/06/15 10:01 [medline]
PHST- 2001/03/29 10:00 [entrez]
AID - S0731-7085(00)00441-6 [pii]
AID - 10.1016/s0731-7085(00)00441-6 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2001 Feb;24(4):637-43. doi: 10.1016/s0731-7085(00)00441-6.

PMID- 10463839
OWN - NLM
STAT- MEDLINE
DCOM- 19991005
LR  - 20131121
IS  - 1386-0291 (Print)
IS  - 1386-0291 (Linking)
VI  - 20
IP  - 3
DP  - 1999
TI  - Rheological action of aspirin on human erythrocytes.
PG  - 159-65
AB  - The rheological action of aspirin on human erythrocytes was studied by in vitro 
      incubation of normal erythrocytes with aspirin at 1, 2 and 4 mg/ml for 30-60 min 
      and then measuring erythrocyte rheological properties of deformability, osmotic 
      fragility and aggregation. Aspirin (2 and/or 4 mg/ml) significantly (p<0.05) 
      prevented the loss of filterability (deformability) through 5 microm diameter 
      pores of erythrocytes dehydrated with hypertonic buffer (450 mOsm/kg water) or 
      with potassium ionophore valinomycin (18 micromol/l). When the calcium ionophore 
      A23187 (1.9 micromol/l) was used to induce cell dehydration, aspirin (4 mg/ml) 
      unexpectedly significantly (p<0.05) increased further the loss of filterability 
      (deformability). Aspirin (1, 2 and 4 mg/ml) also increased significantly (p<0.05) 
      erythrocyte osmotic fragility. Aspirin (4 mg/ml) had no effects on aggregation of 
      erythrocytes induced by dextran 70 (3%). The results suggest that aspirin could 
      play a rheologically active role on erythrocytes. The observed effects of aspirin 
      could be explained by acetylation of intracellular proteins and hence saturation 
      (concentration) of the cell interior with the osmotically active drug.
FAU - Bilto, Y Y
AU  - Bilto YY
AD  - Department of Biological Sciences, University of Jordan, Amman. 
      bilto@sci.ju.edu.jo
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Erythrocyte Aggregation/drug effects
MH  - Erythrocyte Aging/drug effects
MH  - Erythrocyte Deformability/drug effects
MH  - Erythrocytes/cytology/*drug effects/physiology
MH  - Fibrinolytic Agents/*pharmacology
MH  - Humans
EDAT- 1999/08/27 00:00
MHDA- 1999/08/27 00:01
CRDT- 1999/08/27 00:00
PHST- 1999/08/27 00:00 [pubmed]
PHST- 1999/08/27 00:01 [medline]
PHST- 1999/08/27 00:00 [entrez]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 1999;20(3):159-65.

PMID- 2330076
OWN - NLM
STAT- MEDLINE
DCOM- 19900529
LR  - 20190510
IS  - 0148-396X (Print)
IS  - 0148-396X (Linking)
VI  - 26
IP  - 4
DP  - 1990 Apr
TI  - Patterns of failure of aspirin treatment in symptomatic atherosclerotic carotid 
      artery disease.
PG  - 565-9
AB  - Over a 24-month period, 291 patients were consecutively admitted to the West 
      Haven Veterans Administration Medical Center with new ischemic neurological 
      symptoms. Of these, 90 patients (31%) developed ischemic neurological symptoms 
      while taking aspirin (aspirin treatment failure). Of those in whom aspirin 
      treatment failed, 66 patients had ischemic symptoms in the distribution of the 
      carotid artery. Aspirin treatment failed in 21 patients with severe carotid 
      stenosis (greater than 75% stenosis). Eleven of these 21 patients had cerebral 
      infarctions while taking aspirin, and 7 of these 11 infarcts occurred without the 
      prior warning of transient ischemic attacks. Aspirin treatment failed in 45 
      patients with lesser degrees of carotid stenosis. Transient ischemic attack 
      without permanent ischemia was the most common manifestation of failure in these 
      patients. Infarction occurred in only 12 of these 45 patients and in only 4 
      patients did infarction occur without warning. We conclude that patients with 
      symptomatic high-grade carotid stenosis (greater than 75%) in whom aspirin 
      treatment failed are likely to suffer an infarct without warning as the first 
      sign of treatment failure (P less than 0.033). We suggest that this subgroup of 
      patients should be considered for alternative forms of therapy.
FAU - Chyatte, D
AU  - Chyatte D
AD  - Section of Neurosurgery, Yale School of Medicine, New Haven, Connecticut.
FAU - Chen, T L
AU  - Chen TL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arteriosclerosis/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Carotid Artery Diseases/complications/*drug therapy
MH  - Cerebral Infarction/*etiology
MH  - Humans
MH  - Middle Aged
MH  - Retrospective Studies
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
AID - 10.1097/00006123-199004000-00002 [doi]
PST - ppublish
SO  - Neurosurgery. 1990 Apr;26(4):565-9. doi: 10.1097/00006123-199004000-00002.

PMID- 1439416
OWN - NLM
STAT- MEDLINE
DCOM- 19921210
LR  - 20131121
IS  - 1013-2058 (Print)
IS  - 1013-2058 (Linking)
VI  - 81
IP  - 45
DP  - 1992 Nov 3
TI  - [Current aspects of analgetics-induced asthma].
PG  - 1350-3
AB  - Up to 10% of all asthmatics are intolerant to aspirin reacting with bronchospasm 
      after intake of this drug. The triad aspirin-intolerance, 
      glucocorticoid-dependent intrinsic asthma and nasal polyps is common in these 
      patients. The reaction to aspirin is not mediated by IgE. Cross-intolerance is 
      observed with all non-steroidal antiinflammatory drugs inhibiting the enzyme 
      cyclooxygenase. If intolerance to aspirin is suspected such drugs have to be 
      strictly avoided. Paracetamol is the alternative in most instances. Only rarely 
      an adaptive desensitization with acetylsalicylic acid is indicated. This method 
      may help to overcome the intolerance. Non-acetylated salicylates occurring also 
      in some foods, preservatives, and food dyes must not generally be avoided in 
      aspirin-induced asthma.
FAU - Rothe, T
AU  - Rothe T
AD  - Luzerner Höhenklinik, Montana.
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Aktuelles zum Analgetika-Asthma-Syndrom.
PL  - Switzerland
TA  - Schweiz Rundsch Med Prax
JT  - Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis
JID - 8403202
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Angioedema/chemically induced
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced
MH  - Drug Hypersensitivity/immunology
MH  - Humans
MH  - Hypersensitivity, Immediate/chemically induced
MH  - Syndrome
EDAT- 1992/11/03 00:00
MHDA- 1992/11/03 00:01
CRDT- 1992/11/03 00:00
PHST- 1992/11/03 00:00 [pubmed]
PHST- 1992/11/03 00:01 [medline]
PHST- 1992/11/03 00:00 [entrez]
PST - ppublish
SO  - Schweiz Rundsch Med Prax. 1992 Nov 3;81(45):1350-3.

PMID- 22771679
OWN - NLM
STAT- MEDLINE
DCOM- 20130607
LR  - 20220408
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 34
IP  - 2
DP  - 2013 Jan
TI  - Long-term benefit of implantable cardioverter/defibrillator therapy after 
      elective device replacement: results of the INcidence free SUrvival after ICD 
      REplacement (INSURE) trial--a prospective multicentre study.
PG  - 130-7
LID - 10.1093/eurheartj/ehs177 [doi]
AB  - AIMS: Prevention of sudden cardiac death by means of the implantable 
      cardioverter/defibrillator (ICD) is considered to be a lifelong therapy. However, 
      it is still unresolved if patients who never experienced an appropriate ICD 
      intervention during generator longevity really need to undergo device 
      replacement. METHODS AND RESULTS: The INSURE trial was a multicentre prospective 
      observational cohort study that enrolled patients at the time of their first ICD 
      replacement. Patients with and without previous appropriate ICD therapy were 
      enrolled prospectively and were evaluated every 3-6 months after ICD replacement. 
      Primary endpoint of the study was the first occurrence of appropriate ICD therapy 
      after device replacement. Five hundred and ten patients (83% males, mean age 65 ± 
      10 years, mean ejection fraction 39 ± 16%) were enrolled between 2002 and 2007 in 
      the study after an average lifespan of their first ICD generator of 62 ± 18 
      months. Three years after elective ICD replacement, the rates of appropriate ICD 
      therapies in patients with (n = 245) and without (n = 265) former appropriate ICD 
      intervention were 48.1 and 21.4% (adjusted hazard ratio 3.08, CI: 2.15-4.39, P < 
      0.001). Notably, no predictive factors for lower need of ICD therapy could be 
      identified in patients without prior appropriate ICD intervention. CONCLUSIONS: 
      In this study, a significant number of ICD-indicated patients without the need 
      for therapy by their first device received appropriate ICD intervention after 
      generator replacement. There were no predictors for lower need of ICD therapy. 
      Hence, ICD replacement appears still necessary in patients without prior ICD 
      interventions.
FAU - Erkapic, Damir
AU  - Erkapic D
AD  - Department of Cardiology, Kerckhoff Heart and Thorax Center, Benekestr. 2-8, Bad 
      Nauheim 61231, Germany.
FAU - Sperzel, Johannes
AU  - Sperzel J
FAU - Stiller, Sascha
AU  - Stiller S
FAU - Meltendorf, Ulf
AU  - Meltendorf U
FAU - Mermi, Johann
AU  - Mermi J
FAU - Wegscheider, Karl
AU  - Wegscheider K
FAU - Hügl, Burkhard
AU  - Hügl B
CN  - INSURE Investigators
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20120706
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Arrhythmias, Cardiac/*therapy
MH  - Aspirin/therapeutic use
MH  - *Defibrillators, Implantable
MH  - Equipment Failure
MH  - Female
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Prosthesis Implantation/methods
MH  - Retreatment
EDAT- 2012/07/10 06:00
MHDA- 2013/06/08 06:00
CRDT- 2012/07/10 06:00
PHST- 2012/07/10 06:00 [entrez]
PHST- 2012/07/10 06:00 [pubmed]
PHST- 2013/06/08 06:00 [medline]
AID - ehs177 [pii]
AID - 10.1093/eurheartj/ehs177 [doi]
PST - ppublish
SO  - Eur Heart J. 2013 Jan;34(2):130-7. doi: 10.1093/eurheartj/ehs177. Epub 2012 Jul 
      6.

PMID- 32557282
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20211203
IS  - 1933-7205 (Electronic)
IS  - 1933-7191 (Print)
IS  - 1933-7191 (Linking)
VI  - 27
IP  - 12
DP  - 2020 Dec
TI  - Placental Production of Eicosanoids and Sphingolipids in Women Who Developed 
      Preeclampsia on Low-Dose Aspirin.
PG  - 2158-2169
LID - 10.1007/s43032-020-00234-2 [doi]
AB  - Low-dose aspirin, which selectively inhibits thromboxane synthesis, is now 
      standard of care for the prevention of preeclampsia in at risk women, but some 
      women still develop preeclampsia despite an aspirin regimen. To explore the 
      "aspirin failures," we undertook a comprehensive evaluation of placental lipids 
      to determine if abnormalities in non-aspirin sensitive lipids might help explain 
      why some women on low-dose aspirin develop preeclampsia. We studied placentas 
      from women with normal pregnancies and women with preeclampsia. Placental villous 
      explants were cultured and media analyzed by mass spectrometry for 
      aspirin-sensitive and non-aspirin-sensitive lipids. In women who developed severe 
      preeclampsia and delivered preterm, there were significant elevations in 
      non-aspirin-sensitive lipids with biologic actions that could cause preeclampsia. 
      There were significant increases in 15- and 20-hydroxyeicosatetraenoic acids and 
      sphingolipids: D-e-C(18:0) ceramide, D-e-C(18:0) sphingomyelin, 
      D-e-sphingosine-1-phosphate, and D-e-sphinganine-1-phosphate. With regard to 
      lipids sensitive to aspirin, there was no difference in placental production of 
      thromboxane or prostacyclin, but prostaglandins were lower. There was no 
      difference for isoprostanes, but surprisingly, anti-inflammatory omega 3 and 6 
      PUFAs were increased. In total, 10 of 30 eicosanoids and 5 of 42 sphingolipids 
      were abnormal in women with severe early onset preeclampsia. Lipid changes in 
      women with mild preeclampsia who delivered at term were of lesser magnitude with 
      few significant differences. The placenta produces many aspirin-sensitive and 
      non-aspirin-sensitive lipids. Abnormalities in eicosanoids and sphingolipids not 
      sensitive to aspirin might explain why some aspirin-treated women develop 
      preeclampsia.
FAU - Walsh, Scott W
AU  - Walsh SW
AUID- ORCID: 0000-0001-8234-025X
AD  - Departments of Obstetrics and Gynecology, Virginia Commonwealth University 
      Medical Center, P.O. Box 980034, Richmond, VA, 23298-0034, USA. 
      scott.walsh@vcuhealth.org.
AD  - Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, 23298, 
      USA. scott.walsh@vcuhealth.org.
FAU - Reep, Daniel T
AU  - Reep DT
AD  - Departments of Obstetrics and Gynecology, Virginia Commonwealth University 
      Medical Center, P.O. Box 980034, Richmond, VA, 23298-0034, USA.
AD  - Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, 23298, 
      USA.
FAU - Alam, S M Khorshed
AU  - Alam SMK
AD  - Departments of Obstetrics and Gynecology, Virginia Commonwealth University 
      Medical Center, P.O. Box 980034, Richmond, VA, 23298-0034, USA.
FAU - Washington, Sonya L
AU  - Washington SL
AD  - Departments of Obstetrics and Gynecology, Virginia Commonwealth University 
      Medical Center, P.O. Box 980034, Richmond, VA, 23298-0034, USA.
FAU - Al Dulaimi, Marwah
AU  - Al Dulaimi M
AD  - Departments of Obstetrics and Gynecology, Virginia Commonwealth University 
      Medical Center, P.O. Box 980034, Richmond, VA, 23298-0034, USA.
FAU - Lee, Stephanie M
AU  - Lee SM
AD  - Departments of Obstetrics and Gynecology, Virginia Commonwealth University 
      Medical Center, P.O. Box 980034, Richmond, VA, 23298-0034, USA.
FAU - Springel, Edward H
AU  - Springel EH
AD  - Departments of Obstetrics and Gynecology, Virginia Commonwealth University 
      Medical Center, P.O. Box 980034, Richmond, VA, 23298-0034, USA.
FAU - Strauss, Jerome F 3rd
AU  - Strauss JF 3rd
AD  - Departments of Obstetrics and Gynecology, Virginia Commonwealth University 
      Medical Center, P.O. Box 980034, Richmond, VA, 23298-0034, USA.
FAU - Stephenson, Daniel J
AU  - Stephenson DJ
AD  - Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, 
      VA, 23298, USA.
AD  - Department of Cell Biology and Molecular Biology, University of South Florida, 
      Tampa, FL, 33620, USA.
FAU - Chalfant, Charles E
AU  - Chalfant CE
AD  - Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, 
      VA, 23298, USA.
AD  - Department of Cell Biology and Molecular Biology, University of South Florida, 
      Tampa, FL, 33620, USA.
AD  - Research Service, James A. Haley Veterans Hospital, Tampa, FL, 33612, USA.
AD  - The Moffitt Cancer Center, Tampa, FL, 33620, USA.
LA  - eng
GR  - IK6 BX004603/BX/BLRD VA/United States
GR  - U01 HD087198/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200617
PL  - United States
TA  - Reprod Sci
JT  - Reproductive sciences (Thousand Oaks, Calif.)
JID - 101291249
RN  - 0 (Eicosanoids)
RN  - 0 (Sphingolipids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Eicosanoids/*biosynthesis
MH  - Female
MH  - Humans
MH  - Mass Spectrometry
MH  - Placenta/*metabolism
MH  - Pre-Eclampsia/*drug therapy/*metabolism
MH  - Pregnancy
MH  - Sphingolipids/*biosynthesis
MH  - Treatment Outcome
PMC - PMC7606383
MID - NIHMS1605086
OTO - NOTNLM
OT  - Eicosanoids
OT  - Low-dose aspirin
OT  - Placenta
OT  - Preeclampsia
OT  - Sphingolipids
COIS- Conflict of interest: The authors declared they have no conflict of interest.
EDAT- 2020/06/20 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/11/14 00:00 [received]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/05/19 00:00 [revised]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1007/s43032-020-00234-2 [pii]
AID - 10.1007/s43032-020-00234-2 [doi]
PST - ppublish
SO  - Reprod Sci. 2020 Dec;27(12):2158-2169. doi: 10.1007/s43032-020-00234-2. Epub 2020 
      Jun 17.

PMID- 34771018
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 26
IP  - 21
DP  - 2021 Oct 31
TI  - Curcumin Acetylsalicylate Extends the Lifespan of Caenorhabditis elegans.
LID - 10.3390/molecules26216609 [doi]
LID - 6609
AB  - Aspirin and curcumin have been reported to be beneficial to anti-aging in a 
      variety of biological models. Here, we synthesized a novel compound, curcumin 
      acetylsalicylate (CA), by combining aspirin and curcumin. We characterized how CA 
      affects the lifespan of Caenorhabditis elegans (C. elegans) worms. Our results 
      demonstrated that CA extended the lifespan of worms in a dose-dependent manner 
      and reached its highest anti-aging effect at the concentration of 20 μM. In 
      addition, CA reduced the deposition of lipofuscin or "age pigment" without 
      affecting the reproductivity of worms. CA also caused a rightward shift of C. 
      elegans lifespan curves in the presence of paraquat-induced (5 mM) oxidative 
      stress or 37 °C acute heat shock. Additionally, CA treatment decreased the 
      reactive oxygen species (ROS) level in C. elegans and increased the expression of 
      downstream genes superoxide dismutase (sod)-3, glutathione S-transferase (gst)-4, 
      heat shock protein (hsp)-16.2, and catalase-1 (ctl-1). Notably, CA treatment 
      resulted in nuclear translocation of the DAF-16 transcription factor, which is 
      known to stimulate the expression of SOD-3, GST-4, HSP-16, and CTL-1. CA did not 
      produce a longevity effect in daf-16 mutants. In sum, our data indicate that CA 
      delayed the aging of C. elegans without affecting reproductivity, and this effect 
      may be mediated by its activation of DAF-16 and subsequent expression of 
      antioxidative genes, such as sod-3 and gst-4. Our study suggests that novel 
      anti-aging drugs may be developed by combining two individual drugs.
FAU - Zhou, Lei
AU  - Zhou L
AD  - Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western 
      Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of 
      Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, 
      Changsha 410208, China.
FAU - Liu, Jin
AU  - Liu J
AD  - Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western 
      Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of 
      Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, 
      Changsha 410208, China.
FAU - Bu, Lan-Lan
AU  - Bu LL
AD  - Division of Stem Cell Regulation and Application, Key Laboratory for Quality 
      Evaluation of Bulk Herbs of Hunan Province, Hunan University of Chinese Medicine, 
      Changsha 410208, China.
FAU - Liao, Duan-Fang
AU  - Liao DF
AD  - Division of Stem Cell Regulation and Application, Key Laboratory for Quality 
      Evaluation of Bulk Herbs of Hunan Province, Hunan University of Chinese Medicine, 
      Changsha 410208, China.
FAU - Cheng, Shao-Wu
AU  - Cheng SW
AUID- ORCID: 0000-0001-6148-9565
AD  - Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western 
      Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of 
      Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, 
      Changsha 410208, China.
FAU - Zheng, Xi-Long
AU  - Zheng XL
AUID- ORCID: 0000-0002-0889-1827
AD  - Departments of Biochemistry & Molecular Biology and Physiology & Pharmacology, 
      Libin Cardiovascular Institute, Cumming School of Medicine, University of 
      Calgary, Calgary, AB T2N 4Z6, Canada.
LA  - eng
GR  - 81773736/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20211031
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Reactive Oxygen Species)
RN  - IT942ZTH98 (Curcumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Caenorhabditis elegans/*drug effects/metabolism
MH  - Curcumin/*pharmacology
MH  - Longevity/*drug effects
MH  - Reactive Oxygen Species/*metabolism
PMC - PMC8586958
OTO - NOTNLM
OT  - Caenorhabditis elegans
OT  - aging
OT  - antioxidation
OT  - curcumin acetylsalicylate
COIS- The authors declare no conflict of interest.
EDAT- 2021/11/14 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/11/13 01:13
PHST- 2021/08/22 00:00 [received]
PHST- 2021/10/26 00:00 [revised]
PHST- 2021/10/27 00:00 [accepted]
PHST- 2021/11/13 01:13 [entrez]
PHST- 2021/11/14 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - molecules26216609 [pii]
AID - molecules-26-06609 [pii]
AID - 10.3390/molecules26216609 [doi]
PST - epublish
SO  - Molecules. 2021 Oct 31;26(21):6609. doi: 10.3390/molecules26216609.

PMID- 22921973
OWN - NLM
STAT- MEDLINE
DCOM- 20121113
LR  - 20191210
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 60
IP  - 11
DP  - 2012 Sep 11
TI  - Early anticoagulation of bioprosthetic aortic valves in older patients: results 
      from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database.
PG  - 971-7
LID - 10.1016/j.jacc.2012.05.029 [doi]
AB  - OBJECTIVES: The aim of this study was to evaluate the risks and benefits of 
      short-term anticoagulation in patients receiving aortic valve bioprostheses. 
      BACKGROUND: Patients receiving aortic valve bioprostheses have an elevated early 
      risk of thromboembolic events; however, the risks and benefits of short-term 
      anticoagulation have been debated with limited evidence. METHODS: Our cohort 
      consisted of 25,656 patients ≥65 years of age receiving aortic valve 
      bioprostheses at 797 hospitals within the Society of Thoracic Surgeons Adult 
      Cardiac Surgery Database (2004 to 2006). The associated 3-month incidences of 
      death or readmission for embolic (cerebrovascular accident, transient ischemic 
      attack, and noncerebral arterial thromboembolism) or bleeding events were 
      compared across discharge anticoagulation strategies with propensity methods. 
      RESULTS: In this cohort (median age, 77 years), the 3 most common discharge 
      anticoagulation strategies included: aspirin-only (49%), warfarin-only (12%), and 
      warfarin plus aspirin (23%). Among those receiving aspirin-only, 3-month adverse 
      events were low (death, 3.0%; embolic events, 1.0%; bleeding events, 1.0%). 
      Relative to aspirin-only, those treated with warfarin plus aspirin had a lower 
      adjusted risk of death (relative risk [RR]: 0.80, 95% confidence interval [CI]: 
      0.66 to 0.96) and embolic event (RR: 0.52, 95% CI: 0.35 to 0.76) but a higher 
      risk of bleeding (RR: 2.80, 95% CI: 2.18 to 3.60). Relative to aspirin-only, 
      warfarin-only patients had a similar risk of death (RR: 1.01, 95% CI: 0.80 to 
      1.27), embolic events (RR: 0.95, 95% CI: 0.61 to 1.47), and bleeding (RR: 1.23, 
      95% CI: 0.85 to 1.79). These results were generally consistent across patient 
      subgroups. CONCLUSIONS: Death and embolic events were relatively rare in the 
      first 3 months after bioprosthetic aortic valve replacement. Compared with 
      aspirin-only, aspirin plus warfarin was associated with a reduced risk of death 
      and embolic events, but at the cost of an increased bleeding risk.
CI  - Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Brennan, J Matthew
AU  - Brennan JM
AD  - Duke Clinical Research Institute, Durham, North Carolina, USA. 
      brenn009@mc.duke.edu
FAU - Edwards, Fred H
AU  - Edwards FH
FAU - Zhao, Yue
AU  - Zhao Y
FAU - O'Brien, Sean
AU  - O'Brien S
FAU - Booth, Michael E
AU  - Booth ME
FAU - Dokholyan, Rachel S
AU  - Dokholyan RS
FAU - Douglas, Pamela S
AU  - Douglas PS
FAU - Peterson, Eric D
AU  - Peterson ED
CN  - DEcIDE AVR Research Team
LA  - eng
GR  - HHSA290-2005-0032-ITO2-WA3/PHS HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20120822
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2012 Sep 11;60(11):978-80. PMID: 22921974
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aortic Valve/*surgery
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Bioprosthesis/*adverse effects
MH  - Cohort Studies
MH  - Drug Therapy, Combination/adverse effects
MH  - Female
MH  - Heart Valve Prosthesis/*adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Risk Factors
MH  - Survival Analysis
MH  - Thoracic Surgery
MH  - Thromboembolism/epidemiology/*prevention & control
MH  - Treatment Outcome
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2012/08/28 06:00
MHDA- 2012/11/14 06:00
CRDT- 2012/08/28 06:00
PHST- 2011/12/30 00:00 [received]
PHST- 2012/04/18 00:00 [revised]
PHST- 2012/05/02 00:00 [accepted]
PHST- 2012/08/28 06:00 [entrez]
PHST- 2012/08/28 06:00 [pubmed]
PHST- 2012/11/14 06:00 [medline]
AID - S0735-1097(12)02335-2 [pii]
AID - 10.1016/j.jacc.2012.05.029 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2012 Sep 11;60(11):971-7. doi: 10.1016/j.jacc.2012.05.029. 
      Epub 2012 Aug 22.

PMID- 17336029
OWN - NLM
STAT- MEDLINE
DCOM- 20071109
LR  - 20131121
IS  - 0753-3322 (Print)
IS  - 0753-3322 (Linking)
VI  - 61
IP  - 5
DP  - 2007 Jun
TI  - Effect of aspirin on DNA damage induced by MMC in Drosophila.
PG  - 250-3
AB  - In our previous paper, we found that aspirin suppressed the genotoxicity of 
      mitomycin C (MMC) in a somatic mutation and recombination test (SMART) in 
      Drosophila melanogaster. In order to reveal the mechanism of antigenotoxicity of 
      aspirin, we evaluated the protective effects of aspirin against the genotoxicity 
      of MMC with the DNA repair test in Drosophila melanogaster. Three types of 
      treatment of aspirin were performed as co-, post- and pre-treatment. Aspirin 
      co-treatment suppressed effectively the genotoxicity of MMC in a dose-dependent 
      manner and the sex ratio at a dose of aspirin 10mg/bottle elevated from 0.01 
      (without aspirin) to 0.65 at sc z(1) w(+(TE)) mei-9(a) mei-41(D5)/-C(1)DX, y f 
      [mei-9 mei-41, Rec(-) male.Rec(+) female] consists of DNA repair-deficient 
      (Rec(-)) males and -proficient (Rec(+)) females. The antigenotoxic effect of 
      aspirin on [mei-41, Rec(-) male.Rec(+) female] was similar to that on [mei-9, 
      Rec(-) male.Rec(+) female]. But post- and pre-treatment by aspirin did not affect 
      the genotoxicity of MMC on [mei-9 mei-41, Rec(-) male.Rec(+) female].
FAU - Niikawa, Miki
AU  - Niikawa M
AD  - Department of Hygienics, Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, 
      Gifu 502-8585, Japan. niikawam@tim.hi-ho.ne.jp
FAU - Nagase, Hisamitsu
AU  - Nagase H
LA  - eng
PT  - Journal Article
DEP - 20070209
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antimutagenic Agents)
RN  - 50SG953SK6 (Mitomycin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antibiotics, Antineoplastic/*toxicity
MH  - Antimutagenic Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - DNA Damage/*drug effects
MH  - DNA Repair/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drosophila melanogaster
MH  - Female
MH  - Male
MH  - Mitomycin/*toxicity
MH  - Mutagenicity Tests
MH  - Mutation
EDAT- 2007/03/06 09:00
MHDA- 2007/11/10 09:00
CRDT- 2007/03/06 09:00
PHST- 2006/12/19 00:00 [received]
PHST- 2007/01/10 00:00 [accepted]
PHST- 2007/03/06 09:00 [pubmed]
PHST- 2007/11/10 09:00 [medline]
PHST- 2007/03/06 09:00 [entrez]
AID - S0753-3322(07)00009-1 [pii]
AID - 10.1016/j.biopha.2007.01.002 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2007 Jun;61(5):250-3. doi: 10.1016/j.biopha.2007.01.002. 
      Epub 2007 Feb 9.

PMID- 15836503
OWN - NLM
STAT- MEDLINE
DCOM- 20050804
LR  - 20131121
IS  - 1444-0903 (Print)
IS  - 1444-0903 (Linking)
VI  - 35
IP  - 4
DP  - 2005 Apr
TI  - Aspirin-sensitive asthma.
PG  - 240-6
AB  - Aspirin-sensitive asthma is a common and often underdiagnosed disease affecting 
      up to 20% of the adult asthmatic population. It is associated with more severe 
      asthma, requires increased use of inhaled and oral corticosteroids, more 
      presentations to hospital and a risk of life-threatening reactions with 
      aspirin/non-steroid anti-inflammatory drug (NSAID) ingestion. Aspirin-sensitive 
      asthma is often accompanied by severe rhinosinusitis and recurrent nasal 
      polyposis, causing significant impairment of patients' quality of life. The 
      pathogenesis of aspirin-sensitive asthma is complex and involves chronic 
      eosinophilic inflammatory changes, with evidence of increased mast cell 
      activation. The cyclo-oxygenase pathways play a major role in the respiratory 
      reactions that develop after aspirin ingestion. The cysteinyl-leukotrienes have 
      also been shown to play a role in the pathogenesis of aspirin-sensitive asthma. 
      The clinical management of aspirin-sensitive asthma is complicated by the lack of 
      diagnostic testing, other than challenge procedures. Other aspects of management 
      include management of the underlying asthma and avoidance of NSAID in the 
      majority of patients. Other considerations in the management of patients with 
      aspirin-sensitive asthma include the role of leukotriene modifying agents, 
      aspirin desensitization, and the use of other agents, such as roxithromycin. The 
      management of nasal polyposis in patients with aspirin-sensitive asthma often 
      needs to be considered as a separate issue, and requires a team approach.
FAU - Morwood, K
AU  - Morwood K
AD  - Queensland Health Pathology Service, Princess Alexandra Hospital Campus, 
      Brisbane, Queensland 4102, Australia. kmoorwood@acenet.net.au
FAU - Gillis, D
AU  - Gillis D
FAU - Smith, W
AU  - Smith W
FAU - Kette, F
AU  - Kette F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced/physiopathology
MH  - Humans
RF  - 60
EDAT- 2005/04/20 09:00
MHDA- 2005/08/05 09:00
CRDT- 2005/04/20 09:00
PHST- 2005/04/20 09:00 [pubmed]
PHST- 2005/08/05 09:00 [medline]
PHST- 2005/04/20 09:00 [entrez]
AID - IMJ801 [pii]
AID - 10.1111/j.1445-5994.2004.00801.x [doi]
PST - ppublish
SO  - Intern Med J. 2005 Apr;35(4):240-6. doi: 10.1111/j.1445-5994.2004.00801.x.

PMID- 25729838
OWN - NLM
STAT- MEDLINE
DCOM- 20150415
LR  - 20150302
IS  - 1167-7422 (Print)
IS  - 1167-7422 (Linking)
VI  - 24
IP  - 156
DP  - 2015 Jan
TI  - Heart failure in sinus rhythm: no routine antithrombotic therapy.
PG  - 25
AB  - Several trials have compared aspirin or warfarin with either placebo or no 
      antithrombotic drug therapy in a total of a few hundred patients with heart 
      failure in sinus rhythm and no particular thrombotic risk.There is no evidence 
      that antiplatelet or anticoagulant therapy reduces mortality or cardiovascular 
      events, but antithrombotic drugs can provoke severe bleeding.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Prescrire Int
JT  - Prescrire international
JID - 9439295
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Heart Failure/complications/diagnosis/*drug therapy/physiopathology
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Patient Safety
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Thrombosis/etiology/*prevention & control
MH  - Treatment Outcome
MH  - Unnecessary Procedures
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2015/03/03 06:00
MHDA- 2015/04/16 06:00
CRDT- 2015/03/03 06:00
PHST- 2015/03/03 06:00 [entrez]
PHST- 2015/03/03 06:00 [pubmed]
PHST- 2015/04/16 06:00 [medline]
PST - ppublish
SO  - Prescrire Int. 2015 Jan;24(156):25.

PMID- 3392791
OWN - NLM
STAT- MEDLINE
DCOM- 19880825
LR  - 20161017
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 260
IP  - 5
DP  - 1988 Aug 5
TI  - Reye's syndrome and aspirin. Evidence for a dose-response effect.
PG  - 657-61
AB  - Data collected from the Public Health Service Main Study of Reye's Syndrome and 
      Medications were analyzed to assess the relationship between the development of 
      Reye's syndrome and the dose of aspirin received during the antecedent 
      respiratory or chickenpox illness. Among those exposed to aspirin, case-patients 
      were found to have received greater average daily and maximum daily doses of 
      aspirin and greater doses of aspirin on the first four days of the antecedent 
      illness (median, 25.1 mg/kg; 33.0 mg/kg; and 65.4 mg/kg; respectively) than did 
      controls (median, 14.5 mg/kg; 19.0 mg/kg; and 27.0 mg/kg; respectively). The 
      excess risk associated with increasing aspirin doses was due primarily to 
      intermediate levels of dose (eg, 15 to 27 mg/kg per day) rather than higher 
      levels (greater than 27 mg/kg per day). The dose difference between exposed 
      case-patients and controls was greatest on days 3 and 4 of the antecedent 
      illness.
FAU - Pinsky, P F
AU  - Pinsky PF
AD  - Division of Viral Diseases, Centers for Disease Control, Atlanta, GA 30333.
FAU - Hurwitz, E S
AU  - Hurwitz ES
FAU - Schonberger, L B
AU  - Schonberger LB
FAU - Gunn, W J
AU  - Gunn WJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*adverse effects
MH  - Chickenpox/drug therapy
MH  - Child
MH  - Child, Preschool
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Infant
MH  - Regression Analysis
MH  - Respiratory Tract Diseases/drug therapy
MH  - Reye Syndrome/*chemically induced
MH  - Risk Factors
EDAT- 1988/08/05 00:00
MHDA- 1988/08/05 00:01
CRDT- 1988/08/05 00:00
PHST- 1988/08/05 00:00 [pubmed]
PHST- 1988/08/05 00:01 [medline]
PHST- 1988/08/05 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1988 Aug 5;260(5):657-61.

PMID- 19213566
OWN - NLM
STAT- MEDLINE
DCOM- 20090305
LR  - 20211028
IS  - 0080-0015 (Print)
IS  - 0080-0015 (Linking)
VI  - 181
DP  - 2009
TI  - Chemoprevention of oesophageal cancer and the AspECT trial.
PG  - 161-9
AB  - Oesophageal cancer is on the rise and often present in an advanced state. 
      Advances in surgical techniques, chemotherapy and radiotherapy have not changed 
      the prognosis of oesophageal cancer over the last 20 years. With the unravelling 
      of molecular biology of carcinogenesis in the oesophagus, there is a need for a 
      paradigm shift from cancer treatment to prevention. Barrett's oesophagus is the 
      commonest pre-malignant condition for development of oesophageal adenocarcinomas 
      and is eminently suitable for the study of chemoprevention strategies. Now in its 
      third year, the AspECT trial is the biggest, multicentre, randomised controlled 
      clinical trial looking at the long-term chemoprevention effect of esomeprazole 
      with or without aspirin. More than 85% of the participants tolerated the 
      medications at the initial intended doses, and the drop-out rate has been 7%; the 
      interim analysis is due in 2011.
FAU - Das, Debasish
AU  - Das D
AD  - Digestive Disease Centre, Leicester Royal Infirmary, UK.
FAU - Chilton, Andrew P
AU  - Chilton AP
FAU - Jankowski, Janusz A
AU  - Jankowski JA
LA  - eng
GR  - 4584/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Recent Results Cancer Res
JT  - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans 
      les recherches sur le cancer
JID - 0044671
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - N3PA6559FT (Esomeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Esomeprazole/*therapeutic use
MH  - Esophageal Neoplasms/*prevention & control
MH  - Humans
RF  - 45
EDAT- 2009/02/14 09:00
MHDA- 2009/03/06 09:00
CRDT- 2009/02/14 09:00
PHST- 2009/02/14 09:00 [entrez]
PHST- 2009/02/14 09:00 [pubmed]
PHST- 2009/03/06 09:00 [medline]
AID - 10.1007/978-3-540-69297-3_15 [doi]
PST - ppublish
SO  - Recent Results Cancer Res. 2009;181:161-9. doi: 10.1007/978-3-540-69297-3_15.

PMID- 816203
OWN - NLM
STAT- MEDLINE
DCOM- 19760602
LR  - 20181113
IS  - 0002-9440 (Print)
IS  - 1525-2191 (Electronic)
IS  - 0002-9440 (Linking)
VI  - 82
IP  - 3
DP  - 1976 Mar
TI  - Dynamics of thrombus formation on an artificial surface in vivo. Effects of 
      antithrombotic agents.
PG  - 445-56
AB  - A nonhuman primate model for in vivo evaluation of antithrombotic agents is 
      described. In this model, the formation of a thrombus on a segment of Silastic 
      tubing placed in the vena cava of a rhesus monkey is utilized to evaluate the 
      effectiveness of antithrombotic agents. Thrombus formation in this model was 
      found to occur rapidly, but this initial deposit quickly was followed by a 
      reduction in thrombus weight. Eventually, after 2 hours of implantation of the 
      test device, thrombus weight again increased and reached an apparent plateau. 
      Three different antithrombotic agents were evaluated with this model. Warfarin 
      therapy was found to decrease the thrombus weight in approximate proportion to 
      its effect on the prothrombin time. Aspirin and dextran each produced a decrease 
      in thrombus weight in 2 of 3 animals tested. Individual differences in response 
      to thrombotic agents are apparent, but despite this, the model appears to offer 
      advantages for in vivo evaluation of antithrombotic agents.
FAU - Mason, R G
AU  - Mason RG
FAU - Wolf, R H
AU  - Wolf RH
FAU - Zucker, W H
AU  - Zucker WH
FAU - Shinoda, B A
AU  - Shinoda BA
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Pathol
JT  - The American journal of pathology
JID - 0370502
RN  - 0 (Dextrans)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Silicone Elastomers)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Dextrans/therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Haplorhini
MH  - Silicone Elastomers
MH  - Thrombosis/*drug therapy/etiology
MH  - Time Factors
MH  - Venae Cavae
MH  - Warfarin/therapeutic use
PMC - PMC2032429
EDAT- 1976/03/01 00:00
MHDA- 1976/03/01 00:01
CRDT- 1976/03/01 00:00
PHST- 1976/03/01 00:00 [pubmed]
PHST- 1976/03/01 00:01 [medline]
PHST- 1976/03/01 00:00 [entrez]
PST - ppublish
SO  - Am J Pathol. 1976 Mar;82(3):445-56.

PMID- 31738897
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20210919
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 222
IP  - 5
DP  - 2020 May
TI  - Analgesic use at ovulation and implantation and human fertility.
PG  - 476.e1-476.e11
LID - S0002-9378(19)32625-0 [pii]
LID - 10.1016/j.ajog.2019.11.1251 [doi]
AB  - BACKGROUND: Studies investigating the effects of pain-relieving medication use on 
      conceiving a pregnancy have shown conflicting results. Furthermore, no previous 
      study has examined medication use around ovulation or implantation and the 
      associations with the probability of conception, fecundability. OBJECTIVE: The 
      objective of the study was to explore the association between fecundability and 
      analgesic use in 3 different menstrual cycle windows (preovulation, 
      periovulation, and implantation) as well as across the entire menstrual cycle. 
      STUDY DESIGN: We analyzed data from a prospective cohort study of women between 
      30 and 44 years of age who were trying to conceive naturally from 2008 through 
      2015. Using daily diaries, medication usage was classified as acetaminophen, 
      aspirin, or nonaspirin nonsteroidal antiinflammatory drug during 4 time periods 
      of interest (preovulatory, periovulatory, and implantation) as well as the 
      overall nonmenstrual bleeding days of the cycle. Menstrual cycles during the 
      prospective attempt to become pregnant were enumerated using daily diary 
      menstrual bleeding information. Conception was defined as a positive home 
      pregnancy test. Discrete time fecundability models were used to estimate the 
      fecundability ratio and 95% confidence interval in each of the 4 time windows of 
      interest and for each pain reliever (aspirin use, nonaspirin nonsteroidal 
      antiinflammatory drug use, acetaminophen) compared with no medication use after 
      adjustment for several covariates including age, race, education, body mass 
      index, alcohol and caffeine use, frequency of intercourse, and a history of 
      migraines or uterine fibroids. RESULTS: Medication use was infrequent in the 858 
      women and 2366 cycles in this analysis. Use of nonaspirin nonsteroidal 
      antiinflammatory drugs or acetaminophen was not associated with fecundability in 
      any of the time windows of interest. Although the sample size was small, aspirin 
      use during the implantation window was associated with increased fecundability 
      (adjusted fecundability ratio [confidence interval]: 2.05 [1.23-3.41]). This 
      association remained when limiting the analysis to cycles with minimal missing 
      data or when adjusting for gravidity. None of the other medications were 
      associated with fecundability. CONCLUSION: Aspirin use around implantation was 
      associated with increased fecundability. These results expand previous literature 
      to suggest the following: (1) implantation may be an important target for the 
      effects of aspirin on conception and (2) aspirin may be beneficial, regardless of 
      pregnancy loss history. These observations should be tested with a clinical 
      trial.
CI  - Published by Elsevier Inc.
FAU - Jukic, Anne Marie Z
AU  - Jukic AMZ
AD  - Department of Chronic Disease Epidemiology, New Haven, CT; Center for Perinatal 
      Pediatric and Environmental Epidemiology, Yale School of Public Health, New 
      Haven, CT. Electronic address: jukica@niehs.nih.gov.
FAU - Padiyara, Ponnu
AU  - Padiyara P
AD  - Department of Chronic Disease Epidemiology, New Haven, CT; Center for Perinatal 
      Pediatric and Environmental Epidemiology, Yale School of Public Health, New 
      Haven, CT.
FAU - Bracken, Michael B
AU  - Bracken MB
AD  - Department of Chronic Disease Epidemiology, New Haven, CT; Center for Perinatal 
      Pediatric and Environmental Epidemiology, Yale School of Public Health, New 
      Haven, CT.
FAU - McConnaughey, D Robert
AU  - McConnaughey DR
AD  - Westat, Durham, NC.
FAU - Steiner, Anne Z
AU  - Steiner AZ
AD  - Department of Obstetrics and Gynecology, University of North Carolina, Chapel 
      Hill, NC.
LA  - eng
GR  - R01 HD067683/HD/NICHD NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
GR  - ZIA ES103333/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
DEP - 20191115
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*administration & dosage/therapeutic use
MH  - Adult
MH  - Analgesics/*administration & dosage/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Embryo Implantation/*drug effects
MH  - Female
MH  - Fertility/*drug effects
MH  - Fertilization/*drug effects
MH  - Humans
MH  - Menstrual Cycle/drug effects
MH  - Ovulation/*drug effects
MH  - Pain/drug therapy
MH  - Pregnancy
MH  - Prospective Studies
PMC - PMC7195999
MID - NIHMS1062641
OTO - NOTNLM
OT  - acetaminophen
OT  - aspirin
OT  - conception
OT  - fertility
OT  - implantation
OT  - nonsteroidal antiinflammatory drug
OT  - ovulation
OT  - pain medication
OT  - pain reliever
OT  - time to pregnancy
EDAT- 2019/11/19 06:00
MHDA- 2020/06/23 06:00
CRDT- 2019/11/19 06:00
PHST- 2019/07/22 00:00 [received]
PHST- 2019/10/30 00:00 [revised]
PHST- 2019/11/07 00:00 [accepted]
PHST- 2019/11/19 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
PHST- 2019/11/19 06:00 [entrez]
AID - S0002-9378(19)32625-0 [pii]
AID - 10.1016/j.ajog.2019.11.1251 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2020 May;222(5):476.e1-476.e11. doi: 
      10.1016/j.ajog.2019.11.1251. Epub 2019 Nov 15.

PMID- 9894704
OWN - NLM
STAT- MEDLINE
DCOM- 19990324
LR  - 20190816
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 67
IP  - 3
DP  - 1998 Dec 31
TI  - Changing prescribing behaviour: early low dose aspirin in suspected acute 
      myocardial infarction.
PG  - 237-40
AB  - INTRODUCTION: Evidence obtained from large clinical trials would be of limited 
      value, if such evidence does not reach the provider of care, and even when it 
      reaches them, if they do not change their clinical behaviour accordingly. The aim 
      of our study was to assess the effectiveness of intervention, aimed at changing 
      prescribing behaviour of general practitioners (GPs) with regard to early low 
      dose aspirin in patients with suspected acute myocardial infarction (MI). 
      METHODS: A total of 96 GPs were sent a questionnaire assessing their knowledge 
      and practices with regard to use of low dose aspirin in acute MI in November 1995 
      (Q1), June 1996 (Q2) and September 1996 (Q3). An 'intervention' was carried out 
      with a view to changing GP prescribing of low dose aspirin is suspected acute MI 
      after the first two questionnaires were sent. RESULTS: The results of this study 
      seem to show that an intensive 'intervention' achieved success in changing 
      prescribing behaviour of GPs. Although the intervention resulted in a overall 
      significant increase in the prescription of low dose aspirin in suspected acute 
      MI, it was seen that in the GPs who were aged <40 years the success achieved with 
      the 'intervention' was greater when compared with that seen in those older than 
      40 years. CONCLUSION: Dissemination of information on new practices in medicine 
      are important in the process of continuing medical education for doctors. A 
      'personal intervention' such as is described in this study seems to have good 
      effect.
FAU - Seneviratne, S L
AU  - Seneviratne SL
AD  - Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri 
      Lanka.
FAU - Gunatilake, S B
AU  - Gunatilake SB
FAU - Adhikari, A A
AU  - Adhikari AA
FAU - Gunawardhana, P
AU  - Gunawardhana P
FAU - de Silva, H J
AU  - de Silva HJ
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - *Drug Prescriptions
MH  - Drug Utilization/statistics & numerical data
MH  - Family Practice
MH  - Humans
MH  - Myocardial Infarction/drug therapy
MH  - *Practice Patterns, Physicians'
MH  - Surveys and Questionnaires
MH  - Time Factors
EDAT- 1999/01/23 00:00
MHDA- 1999/01/23 00:01
CRDT- 1999/01/23 00:00
PHST- 1999/01/23 00:00 [pubmed]
PHST- 1999/01/23 00:01 [medline]
PHST- 1999/01/23 00:00 [entrez]
AID - S016752739800312X [pii]
AID - 10.1016/s0167-5273(98)00312-x [doi]
PST - ppublish
SO  - Int J Cardiol. 1998 Dec 31;67(3):237-40. doi: 10.1016/s0167-5273(98)00312-x.

PMID- 21993290
OWN - NLM
STAT- MEDLINE
DCOM- 20111129
LR  - 20190923
IS  - 0253-9772 (Print)
IS  - 0253-9772 (Linking)
VI  - 33
IP  - 10
DP  - 2011 Oct
TI  - [Screening of high-yield PUFAs Mortierella isabellina strain].
PG  - 1147-52
AB  - The original strain Mortierella isabellina As3.3410 was treated by microwave and 
      ultraviolet. Mutated strains were screened by acetyl salicylic acid and low 
      temperature (15°C). A high-yield strain named as A35-4 was successfully selected. 
      The biomass of this strain was 17.9 g/L, oil content was 67.8%, oil production 
      was 12.12 g/L, polyunsaturated fatty acids (PUFAs) content was 20.2%, and 
      production of PUFAs was 2.46 g/L, which increased 32.6%, 49.8%, 98.69%, 14.0%, 
      and 125.7% compared with the original A0 stain, respectively. The continuous 
      slope transmission experiments confirmed that the strain had a good genetic 
      stability. The study is beneficial for cloning high efficiency genes for PUFAs 
      and producing PUFAs in this stain, and lays the ground work for creation of 
      transgenic plants containing high levels of PUFAs.
FAU - Xu, Ben-Bo
AU  - Xu BB
AD  - Yangtze University, Jingzhou, China. benboxu@yangtzeu.edu.cn
FAU - Ba, Min
AU  - Ba M
FAU - Xie, Ling-Li
AU  - Xie LL
FAU - Tian, Zhi-Hong
AU  - Tian ZH
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Yi Chuan
JT  - Yi chuan = Hereditas
JID - 9436478
RN  - 0 (Fatty Acids, Unsaturated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Fatty Acids, Unsaturated/*biosynthesis
MH  - Microwaves
MH  - Mortierella/*genetics/metabolism/radiation effects
MH  - Mutation
MH  - Ultraviolet Rays
EDAT- 2011/10/14 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/10/14 06:00
PHST- 2011/10/14 06:00 [entrez]
PHST- 2011/10/14 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 0253-9772(2011)10-1147-06 [pii]
AID - 10.3724/sp.j.1005.2011.01147 [doi]
PST - ppublish
SO  - Yi Chuan. 2011 Oct;33(10):1147-52. doi: 10.3724/sp.j.1005.2011.01147.

PMID- 20026423
OWN - NLM
STAT- MEDLINE
DCOM- 20100614
LR  - 20211020
IS  - 1878-5875 (Electronic)
IS  - 1357-2725 (Linking)
VI  - 42
IP  - 4
DP  - 2010 Apr
TI  - Eicosanoids and the endogenous control of acute inflammatory resolution.
PG  - 524-8
LID - 10.1016/j.biocel.2009.12.013 [doi]
AB  - Inflammation is a formidable ally in the constant battle against infection, 
      cancer and tissue injury. It is a primordial response that protects against 
      injury and restores damaged tissue to its normal physiological functioning. In 
      fact, our wellbeing and survival depends upon its efficiency and carefully 
      balanced control. In general, the innate inflammatory response initiates within 
      minutes and, if all is well, resolves within hours. In contrast, chronic 
      inflammation persists for weeks, months or even years. Here, we are going to 
      discuss the key endogenous checkpoints necessary for mounting an effective yet 
      limited inflammatory response and the crucial biochemical pathways necessary to 
      prevent its persistence. In this setting, the biochemical synthesis of key 
      pro-resolution eicosanoids as well as their mode of action in self-limiting 
      inflammation will be discussed.
FAU - Gilroy, Derek W
AU  - Gilroy DW
AD  - Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, 5 
      University Street, University College London, London WC1E 6JJ, United Kingdom. 
      d.gilroy@ucl.ac.uk <d.gilroy@ucl.ac.uk>
LA  - eng
GR  - 087520/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20091222
PL  - Netherlands
TA  - Int J Biochem Cell Biol
JT  - The international journal of biochemistry & cell biology
JID - 9508482
RN  - 0 (Eicosanoids)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Eicosanoids/*immunology
MH  - *Feedback, Physiological
MH  - Humans
MH  - Immunity, Innate/drug effects
MH  - *Inflammation
MH  - Nitric Oxide/immunology
RF  - 62
EDAT- 2009/12/23 06:00
MHDA- 2010/06/15 06:00
CRDT- 2009/12/23 06:00
PHST- 2009/09/22 00:00 [received]
PHST- 2009/12/15 00:00 [accepted]
PHST- 2009/12/23 06:00 [entrez]
PHST- 2009/12/23 06:00 [pubmed]
PHST- 2010/06/15 06:00 [medline]
AID - S1357-2725(09)00366-5 [pii]
AID - 10.1016/j.biocel.2009.12.013 [doi]
PST - ppublish
SO  - Int J Biochem Cell Biol. 2010 Apr;42(4):524-8. doi: 10.1016/j.biocel.2009.12.013. 
      Epub 2009 Dec 22.

PMID- 1447236
OWN - NLM
STAT- MEDLINE
DCOM- 19921224
LR  - 20201007
IS  - 0301-620X (Print)
IS  - 0301-620X (Linking)
VI  - 74
IP  - 6
DP  - 1992 Nov
TI  - The significance of calf thrombi after total knee arthroplasty.
PG  - 799-802
AB  - We reviewed the records of 1257 patients having 1625 total knee arthroplasties; 
      all had pre-operative and postoperative perfusion lung scans and postoperative 
      venograms which were classified as showing no thrombi, calf thrombi or proximal 
      thrombi. Patients with calf thrombi were found to have a significantly greater 
      risk for both symptomatic and asymptomatic pulmonary embolism compared with 
      patients with no venographic thrombi. There were positive lung scans in 6.9% of 
      patients with calf thrombi compared with 2.0% of patients with negative venograms 
      (p < 0.001). Symptomatic pulmonary embolism occurred in 1.6% of patients with 
      calf thrombi compared with 0.2% of patients with negative venograms (p = 0.034). 
      The risk of pulmonary embolism was not significantly different between patients 
      with treated proximal thrombi, and those with calf thrombi. Patients who develop 
      deep-vein thrombosis despite prophylaxis are at increased risk for pulmonary 
      embolism; these patients should receive treatment, or undergo follow-up studies 
      to detect proximal propagation.
FAU - Haas, S B
AU  - Haas SB
AD  - Hospital for Special Surgery, New York, NY 10021.
FAU - Tribus, C B
AU  - Tribus CB
FAU - Insall, J N
AU  - Insall JN
FAU - Becker, M W
AU  - Becker MW
FAU - Windsor, R E
AU  - Windsor RE
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Bone Joint Surg Br
JT  - The Journal of bone and joint surgery. British volume
JID - 0375355
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Bone Joint Surg Br. 1993 May;75(3):507-8. PMID: 8496237
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - *Knee Prosthesis
MH  - Leg/*blood supply
MH  - *Phlebography
MH  - Postoperative Complications/diagnosis
MH  - Pulmonary Embolism/diagnostic imaging
MH  - Radionuclide Imaging
MH  - Thrombosis/*diagnostic imaging/prevention & control
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
AID - 10.1302/0301-620X.74B6.1447236 [doi]
PST - ppublish
SO  - J Bone Joint Surg Br. 1992 Nov;74(6):799-802. doi: 
      10.1302/0301-620X.74B6.1447236.

PMID- 7064887
OWN - NLM
STAT- MEDLINE
DCOM- 19820512
LR  - 20180330
IS  - 0002-9165 (Print)
IS  - 0002-9165 (Linking)
VI  - 35
IP  - 2
DP  - 1982 Feb
TI  - Effect of acetylsalicylic acid on symptoms and hydrogen excretion in the 
      disaccharide tolerance test with lactose or lactulose.
PG  - 273-6
AB  - Prostaglandins play a role in the pathogenesis of symptoms of food intolerance. 
      An alleviation of lactose intolerance by premedication with the 
      prostaglandin-synthesis inhibitor acetylsalicylic acid (ASA) has been reported. 
      We studied the effect of 900 mg of ASA and of a glucose placebo on disaccharide 
      intolerance symptoms and on breath hydrogen (H2) excretion in 16 healthy adult 
      males 12 of whom were lactose malabsorbers and received 50 g of lactose 30 to 40 
      min after ASA; the remaining four were lactose absorbers and received 30 g of 
      lactulose. Premedication with ASA had no significant effect on the severity and 
      duration of intolerance symptoms and on the timing of H2 excretion. In contrast, 
      the maximal breath H2 concentration and the total H2 excretion were significantly 
      increased after ASA administration. We conclude that prostaglandins are of minor 
      importance in causing the usually moderate symptoms of disaccharide intolerance. 
      Prostaglandin-synthesis inhibition by ASA may reduce the motility of the colon 
      thereby permitting more colonic gas (derived from unabsorbed carbohydrates) to be 
      absorbed and excreted.
FAU - Flatz, G
AU  - Flatz G
FAU - Lie, G H
AU  - Lie GH
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
RN  - 0 (Disaccharides)
RN  - 4618-18-2 (Lactulose)
RN  - 7YNJ3PO35Z (Hydrogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Breath Tests
MH  - Disaccharides/*metabolism
MH  - Humans
MH  - Hydrogen/*metabolism
MH  - Lactose Intolerance/*metabolism
MH  - Lactulose/*metabolism
MH  - Male
EDAT- 1982/02/01 00:00
MHDA- 1982/02/01 00:01
CRDT- 1982/02/01 00:00
PHST- 1982/02/01 00:00 [pubmed]
PHST- 1982/02/01 00:01 [medline]
PHST- 1982/02/01 00:00 [entrez]
AID - 10.1093/ajcn/35.2.273 [doi]
PST - ppublish
SO  - Am J Clin Nutr. 1982 Feb;35(2):273-6. doi: 10.1093/ajcn/35.2.273.

PMID- 78979
OWN - NLM
STAT- MEDLINE
DCOM- 19780925
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 93
IP  - 2
DP  - 1978 Aug
TI  - Reflex neurovascular dystrophy in childhood.
PG  - 211-5
AB  - Reflex neurovascular dystrophy has rarely been recognized in children. During the 
      past eight years we have observed 24 instances of RND in 23 children. Lower 
      extremity involvement was manifested in 20 of them and upper extremity in four. 
      The major complaint was pain; swelling and vasomotor instability were prominent, 
      and exquisite tenderness was characteristic. Chronic trophic changes were not 
      observed. Antecedent illness or trauma could be related to the RND in less than 
      half of the children, but personality factors appeared contributory to the 
      development of RND in most children. Physical therapy was the principal form of 
      treatment; therapy with a corticosteroid or by sympathetic blockade was not 
      employed. Reduction in the evidences of disease, including improvement in 
      function, were present in all children at the termination of therapy; improvement 
      was maintained in all but one child after a mean period of 2.4 years. The 
      excellent response to conservative therapy suggests that RND may be a more benign 
      condition in children than in adults.
FAU - Bernstein, B H
AU  - Bernstein BH
FAU - Singsen, B H
AU  - Singsen BH
FAU - Kent, J T
AU  - Kent JT
FAU - Kornreich, H
AU  - Kornreich H
FAU - King, K
AU  - King K
FAU - Hicks, R
AU  - Hicks R
FAU - Hanson, V
AU  - Hanson V
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Arm/innervation
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Exercise Therapy
MH  - Female
MH  - Humans
MH  - Indomethacin/therapeutic use
MH  - Leg/innervation
MH  - Male
MH  - *Reflex Sympathetic Dystrophy/diagnosis/therapy
EDAT- 1978/08/01 00:00
MHDA- 1978/08/01 00:01
CRDT- 1978/08/01 00:00
PHST- 1978/08/01 00:00 [pubmed]
PHST- 1978/08/01 00:01 [medline]
PHST- 1978/08/01 00:00 [entrez]
AID - S0022-3476(78)80498-3 [pii]
AID - 10.1016/s0022-3476(78)80498-3 [doi]
PST - ppublish
SO  - J Pediatr. 1978 Aug;93(2):211-5. doi: 10.1016/s0022-3476(78)80498-3.

PMID- 7462284
OWN - NLM
STAT- MEDLINE
DCOM- 19810421
LR  - 20160512
IS  - 0021-9355 (Print)
IS  - 0021-9355 (Linking)
VI  - 63
IP  - 2
DP  - 1981 Feb
TI  - Platelet activity (malondialdehyde production) after orthopaedic surgery: the 
      effect of aspirin.
PG  - 288-94
AB  - Using a biochemical assay of the prostaglandin endoperoxide metabolite 
      malondialdehyde, platelet activity was evaluated in 147 patients who were 
      undergoing orthopaedic surgical procedures. Assays were performed before and 
      after operation and the results were correlated with the type of operation, the 
      sex of the patient, and the use of aspirin as an antiplatelet-aggregation agent. 
      Postoperatively, statistically significant elevations of platelet activity were 
      found in patients who were not taking aspirin, while highly statistically 
      significant suppressions of this activity were found after total hip 
      arthroplasties and other surgical procedures in patients who had received 
      aspirin. Men and women had similar levels of suppression of platelet 
      aggregability with aspirin.
FAU - Stulberg, B N
AU  - Stulberg BN
FAU - Dorr, L D
AU  - Dorr LD
FAU - Ranawat, C S
AU  - Ranawat CS
FAU - Weksler, B B
AU  - Weksler BB
FAU - Schneider, R
AU  - Schneider R
LA  - eng
GR  - HL-18828/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
RN  - 0 (Malonates)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*metabolism
MH  - Female
MH  - Hemostasis
MH  - Humans
MH  - Male
MH  - Malonates/*blood
MH  - Malondialdehyde/*blood
MH  - Middle Aged
MH  - Orthopedics
MH  - Platelet Aggregation/*drug effects
MH  - Postoperative Period
MH  - Preoperative Care
MH  - *Surgical Procedures, Operative
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
PST - ppublish
SO  - J Bone Joint Surg Am. 1981 Feb;63(2):288-94.

PMID- 7258469
OWN - NLM
STAT- MEDLINE
DCOM- 19810915
LR  - 20170214
IS  - 0363-5465 (Print)
IS  - 0363-5465 (Linking)
VI  - 9
IP  - 4
DP  - 1981 Jul-Aug
TI  - The 100-mile run: preparation, performance, and recovery. A case report.
PG  - 258-61
AB  - This study analyzed the training methods and racing techniques of 12 athletes who 
      have completed 100-mile runs. It showed that use of aspirin during the race can 
      be dangerous if the run takes place in hot weather. No other consistent 
      correlation was evident, however, between the variables examined and the 
      finishing times. The findings suggest that an average marathoner can finish the 
      100-mile run without modifying his training program.
FAU - Fred, H L
AU  - Fred HL
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Sports Med
JT  - The American journal of sports medicine
JID - 7609541
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Diet
MH  - Heat Exhaustion/etiology
MH  - Hot Temperature/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Education and Training
MH  - *Running
EDAT- 1981/07/01 00:00
MHDA- 1981/07/01 00:01
CRDT- 1981/07/01 00:00
PHST- 1981/07/01 00:00 [pubmed]
PHST- 1981/07/01 00:01 [medline]
PHST- 1981/07/01 00:00 [entrez]
AID - 10.1177/036354658100900415 [doi]
PST - ppublish
SO  - Am J Sports Med. 1981 Jul-Aug;9(4):258-61. doi: 10.1177/036354658100900415.

PMID- 9890391
OWN - NLM
STAT- MEDLINE
DCOM- 19990311
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 33
IP  - 1
DP  - 1999 Jan
TI  - A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy 
      volunteers.
PG  - 12-8
AB  - Platelet inhibition significantly reduces the risk of cardiovascular mortality 
      and morbidity. However, current antiplatelet therapies have limitations, and more 
      efficacious agents are needed. E5510 is a novel compound that has multiple 
      platelet inhibitory effects in in vitro studies. We compared the in vivo, 
      pharmacodynamic effects of maximal antiplatelet doses of E5510 (20 mg) with 300 
      mg aspirin in a placebo-controlled, triple crossover trial in nine healthy 
      volunteers. Collagen-induced platelet aggregation and serum thromboxane B2 (TxB2) 
      were similarly inhibited by both compounds in the first 12 h but showed recovery 
      at 24 h in the E5510 group only (p < 0.05). Thrombin and U46619-induced platelet 
      aggregation, as well as basal and prostaglandin E2 (PGE2)-stimulated platelet 
      cyclic adenosine monophosphate (cAMP) levels were unchanged after ingestion of 
      either agent. E5510 and aspirin reduced systemic thromboxane formation without 
      affecting prostacyclin biosynthesis. Neither E5510 nor aspirin inhibited the 
      excretion of 8-epi PGF2alpha and 5,6-DHET, two indices of 
      cyclooxygenase-independent arachidonate metabolism. In conclusion, (a) E55 10 in 
      vivo most likely induces a reversible inhibition of cyclooxygenase, without 
      affecting thromboxane synthetase, phosphodiesterase, thrombin, or thromboxane 
      receptor-mediated signaling; (b) single doses of aspirin or E5510 affect 
      thromboxane/prostacyclin profiles favorably, supporting their use in acute 
      coronary syndromes. This study outlines a comprehensive and minimally invasive 
      approach for the assessment of the in vivo mechanism of action of novel 
      antiplatelet agents.
FAU - Reilly, M P
AU  - Reilly MP
AD  - Division of Cardiology, University of Pennsylvania, School of Medicine, 
      Philadelphia, USA.
FAU - Moran, N
AU  - Moran N
FAU - Meagher, E
AU  - Meagher E
FAU - Delanty, N
AU  - Delanty N
FAU - Cucchiara, A E
AU  - Cucchiara AE
FAU - Lawson, J A
AU  - Lawson JA
FAU - Catella-Lawson, F
AU  - Catella-Lawson F
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Eicosanoids)
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - E0399OZS9N (Cyclic AMP)
RN  - R16CO5Y76E (Aspirin)
RN  - XPV71VQL72 (Satigrel)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects/metabolism
MH  - Cross-Over Studies
MH  - Cyclic AMP/metabolism
MH  - Double-Blind Method
MH  - Eicosanoids/urine
MH  - Fatty Acids, Monounsaturated/pharmacokinetics/*pharmacology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/*pharmacology
MH  - Thromboxanes/blood
EDAT- 1999/01/16 00:00
MHDA- 1999/01/16 00:01
CRDT- 1999/01/16 00:00
PHST- 1999/01/16 00:00 [pubmed]
PHST- 1999/01/16 00:01 [medline]
PHST- 1999/01/16 00:00 [entrez]
AID - 10.1097/00005344-199901000-00003 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1999 Jan;33(1):12-8. doi: 
      10.1097/00005344-199901000-00003.

PMID- 3897296
OWN - NLM
STAT- MEDLINE
DCOM- 19850927
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 25
IP  - 5
DP  - 1985 Jul-Aug
TI  - A comparative oral analgesic study of indoprofen, aspirin, and placebo in 
      postpartum pain.
PG  - 374-80
AB  - The purpose of this study was to evaluate the analgesic efficacy and adverse 
      effect liability of single oral doses of indoprofen, 50 mg, 100 mg, and 200 mg, 
      compared with aspirin, 300 mg and 600 mg, and placebo in the relief of moderate 
      to severe postpartum pain. Two hundred-ten patients entered a randomized, 
      double-blind, parallel group study and were evaluated over a six-hour period by a 
      single nurse-observer. There was a significant imbalance in the distribution of 
      pain types across treatments that compromises the interpretation of the results. 
      In addition to analyzing the data from all patients, the subsets with 
      episiotomy/cesarean section pain and uterine cramp pain were examined separately. 
      The latter group had too few patients to permit distinction between drugs. The 
      100 mg and 200 mg doses of indoprofen were significantly (P less than or equal to 
      .05) more effective than placebo for many variables including the following 
      summary values: sum of pain intensity difference (SPID), sum of hourly relief 
      values (TOTPAR), and % SPID for all patients as well as in the subset of patients 
      with episiotomy/cesarean section pain. Aspirin, 600 mg, was also significantly 
      more effective than placebo for many of the same measures of analgesia in the 
      episiotomy/cesarean section subset. Pairwise differences were also seen between 
      placebo and aspirin, 300 mg, but on fewer variables. Indoprofen, 100 mg, was 
      significantly more effective than aspirin, 600 mg, at hour 6 for pain intensity 
      difference (PID) in the episiotomy/cesarean section subset. The effect of 
      indoprofen appeared to plateau above 100 mg.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Sunshine, A
AU  - Sunshine A
FAU - Zighelboim, I
AU  - Zighelboim I
FAU - Olson, N Z
AU  - Olson NZ
FAU - De Sarrazin, C
AU  - De Sarrazin C
FAU - Laska, E
AU  - Laska E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Phenylpropionates)
RN  - 0 (Placebos)
RN  - CPE46ZU14N (Indoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cesarean Section/adverse effects
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Episiotomy/adverse effects
MH  - Female
MH  - Humans
MH  - Indoprofen/administration & dosage/*therapeutic use
MH  - Pain/*drug therapy
MH  - Pain, Postoperative/drug therapy/etiology
MH  - Phenylpropionates/*therapeutic use
MH  - Placebos/*therapeutic use
MH  - Postpartum Period/*drug effects
MH  - Pregnancy
MH  - Random Allocation
EDAT- 1985/07/01 00:00
MHDA- 1985/07/01 00:01
CRDT- 1985/07/01 00:00
PHST- 1985/07/01 00:00 [pubmed]
PHST- 1985/07/01 00:01 [medline]
PHST- 1985/07/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1985.tb02858.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1985 Jul-Aug;25(5):374-80. doi: 
      10.1002/j.1552-4604.1985.tb02858.x.

PMID- 24080598
OWN - NLM
STAT- MEDLINE
DCOM- 20140626
LR  - 20220409
IS  - 1759-4782 (Electronic)
IS  - 1759-4774 (Linking)
VI  - 10
IP  - 11
DP  - 2013 Nov
TI  - Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates.
PG  - 625-42
LID - 10.1038/nrclinonc.2013.169 [doi]
AB  - Cancer risk reduction using pharmacological means is an attractive modern 
      preventive approach that supplements the classical behavioural prevention 
      recommendations. Medications that are commonly used by large populations to treat 
      a variety of common, non-cancer-related, medical situations are an attractive 
      candidate pool. This Review discusses three pharmacological agents with the most 
      evidence for their potential as cancer chemopreventive agents: 
      anti-hypercholesterolaemia medications (statins), an antidiabetic agent 
      (metformin) and antiosteoporosis drugs (bisphosphonates). Data are accumulating 
      to support a significant negative association of certain statins with cancer 
      occurrence or survival in several major tumour sites (mostly gastrointestinal 
      tumours and breast cancer), with an augmented combined effect with aspirin or 
      other non-steroidal anti-inflammatory drugs. Metformin, but not other 
      hypoglycaemic drugs, also seems to have some antitumour growth activity, but the 
      amount of evidence in human studies, mainly in breast cancer, is still limited. 
      Experimental and observational data have identified bisphosphonates as a 
      pharmacological group that could have significant impact on incidence and 
      mortality of more than one subsite of malignancy. At the current level of 
      evidence these potential chemopreventive drugs should be considered in high-risk 
      situations or using the personalized approach of maximizing individual benefits 
      and minimizing the potential for adverse effects with the aid of pharmacogenetic 
      indicators.
FAU - Gronich, Naomi
AU  - Gronich N
AD  - Pharmacoepidemiology and Pharmacogenetics Unit, Department of Community Medicine 
      and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, 
      Technion-Israel Institute of Technology and Clalit National Israeli Cancer 
      Control Center (NICCC), 7 Michal Street, Haifa 34362, Israel.
FAU - Rennert, Gad
AU  - Rennert G
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131001
PL  - England
TA  - Nat Rev Clin Oncol
JT  - Nature reviews. Clinical oncology
JID - 101500077
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Bone Density Conservation Agents/therapeutic use
MH  - Diphosphonates/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Hypoglycemic Agents/therapeutic use
MH  - Metformin/*therapeutic use
MH  - Neoplasms/*prevention & control
EDAT- 2013/10/02 06:00
MHDA- 2014/06/27 06:00
CRDT- 2013/10/02 06:00
PHST- 2013/10/02 06:00 [entrez]
PHST- 2013/10/02 06:00 [pubmed]
PHST- 2014/06/27 06:00 [medline]
AID - nrclinonc.2013.169 [pii]
AID - 10.1038/nrclinonc.2013.169 [doi]
PST - ppublish
SO  - Nat Rev Clin Oncol. 2013 Nov;10(11):625-42. doi: 10.1038/nrclinonc.2013.169. Epub 
      2013 Oct 1.

PMID- 7258043
OWN - NLM
STAT- MEDLINE
DCOM- 19810925
LR  - 20131121
IS  - 0301-0546 (Print)
IS  - 0301-0546 (Linking)
VI  - 9
IP  - 1
DP  - 1981 Jan-Feb
TI  - Functional assessment of airways bronchoconstriction with nebulized acetyl 
      salicylic acid.
PG  - 1-8
AB  - The aim of our study was to verify the functional modifications affecting central 
      and peripheral airways during bronchoconstriction induced by aerosolized aspirin, 
      so as to better understand the pathophysiologic mechanisms of the asthmatic 
      crises in A.S.A. sensitive patients. The preliminary results were presented of a 
      study carried out o 12 asthmatic A.S.A. sensitive patients, 7 of whom were 
      females and 5 males, between the ages of 22 and 57 years. A.S.A. sensitivity was 
      found in their medical history, in some cases, it had been confirmed by oral 
      A.S.A. challenge. Among these patients, 6 were also affected by nasal polyposis. 
      The method used was recently described by Bianco et al. although slightly 
      modified by us: a fresh aqueous solution (18%) of A.S.A. -L is diluted 1:3 in 
      saline; 4 ml of this solution is transferred to a glass nebulizer activated by a 
      small compressor. The patients underwent treatment for 60 sec, during which a 
      dose of approximately 1,8 mg of A.S.A. was inhaled, corresponding to about 40 mg 
      of aspirin taken orally. In comparison with the reactions induced by oral 
      challenge, those obtained with this treatment are easier, faster and confined 
      only to the respiratory system. Before giving A.S.A. to the patients, control 
      tests using saline aerosol were done. The functional assessment was performed 
      under basal conditions, and 1, 15, 30, 60, 90 and 120 minutes following 
      administration of A.S.A. since bronchoconstriction caused by nebulized A.S.A. 
      usually reaches peak values between the 60th and 90th min. after which it 
      gradually decreases over the following two hours. Our results show that, though 
      A.S.A. induced bronchoconstriction prevails at large airways, it also influences 
      the distal tracts of the tracheobronchial tree, since both SRAW, FEV1 and Vmax50C 
      are modified at the same time.
FAU - Carnimeo, N
AU  - Carnimeo N
FAU - Resta, O
AU  - Resta O
FAU - Foschino-Barbaro, M P
AU  - Foschino-Barbaro MP
FAU - Valerio, G
AU  - Valerio G
FAU - Picca, V
AU  - Picca V
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - 0 (Aerosols)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aerosols
MH  - Aspirin/*adverse effects
MH  - Bronchi/physiopathology
MH  - Bronchial Provocation Tests
MH  - Bronchial Spasm/chemically induced/*physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiratory Function Tests
MH  - Time Factors
MH  - Trachea/physiopathology
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Allergol Immunopathol (Madr). 1981 Jan-Feb;9(1):1-8.

PMID- 31624397
OWN - NLM
STAT- MEDLINE
DCOM- 20191105
LR  - 20210626
IS  - 1671-167X (Print)
IS  - 1671-167X (Linking)
VI  - 51
IP  - 5
DP  - 2019 Oct 18
TI  - [Preparation of aspirin sustained-release microsphere and its in vitro releasing 
      property].
PG  - 907-912
AB  - OBJECTIVE: It has been proven that acetylsalicylic acid (aspirin), as a kind of 
      classical non-steroidal anti-inflammatory drug, not only has the effect of 
      anti-inflammatory, but also has the function of immunity regulation and 
      mineralization. However, it needs further investigation to study how to delay 
      release of aspirin for a long time and enable to promote bone regeneration. 
      Herein, we demonstrated that the longterm delayed release pattern of aspirin 
      through the construction of microsphere scaffolds is promising to achieve the 
      excellent bone regeneration. METHODS: Here we synthesized three kinds of 
      scaffolds as follows: (1) aspirin loaded calcium silicate (CaSiO(3)) microsphere 
      (CaSiO(3)-aspirin) via simple immersion; (2) aspirin loaded 
      polylactic-co-glycolic acid (PLGA) microsphere (PLGA-aspirin) via oil/water (O/W) 
      emulsion; (3) aspirin loaded PLGA-CaSiO(3) scaffold (PLGA-CaSiO(3)-aspirin) via 
      O/W emulsion, optimal morphology and structure of PLGA-CaSiO(3)-aspirin scaffold 
      was acquired through modulating the ratio between PLGA and CaSiO(3). Furthermore, 
      spectrophotometer was used to monitor the concentration of the extract of the 
      three scaffolds for different releasing time, including 1, 2, 4, 6, 9, 13, 17, 
      21, 24, 30, 36, and 45 days, aspirin loading efficiency and its accumulation 
      releasing curves were both achieved according to the concentration of aspirin. 
      Their sustained release effects of aspirin were evaluated eventually. RESULTS: 
      Environmental scanning electron microscope (ESEM) results showed that the surface 
      structure of the three kinds of scaffolds were smooth and had uniform size 
      distribution. In addition, a small amount of PLGA-aspirin microspheres occurred 
      to aggregation, while a small amount of CaSiO(3)-aspirin microspheres were 
      broken. Moreover, the PLGA-aspirin microspheres in the PLGA-CaSiO(3)-aspirin 
      scaffolds were uniformly adhered to the surface of CaSiO(3) microspheres. The 
      aspirin loadings of CaSiO(3)-aspirin, PLGA-aspirin, and PLGA-CaSiO(3)-aspirin 
      were (1.06±0.04)%, (7.05±0.06)%, and (6.75±0.18)%, respectively. In addition, 
      their corresponding time for releasing 95% of aspirin was 3, 24, and 36 days, 
      respectively. The releasing time of PLGA-CaSiO(3)-aspirin was longer than that of 
      the others and the releasing rate was more stable. CONCLUSION: The microsphere 
      scaffold of PLGA-CaSiO(3)-aspirin composites has excellent delayedrelease effect 
      on aspirin, which is promising for using as osteogenic materials.
FAU - Chen, Y
AU  - Chen Y
AD  - Department of Prosthodontics, Peking University School and Hospital of 
      Stomatology & National Clinical Research Center for Oral Diseases & National 
      Engineering Laboratory for Digital and Material Technology of Stomatology & 
      Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.
FAU - Liu, Z N
AU  - Liu ZN
AD  - Department of Prosthodontics, Peking University School and Hospital of 
      Stomatology & National Clinical Research Center for Oral Diseases & National 
      Engineering Laboratory for Digital and Material Technology of Stomatology & 
      Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.
FAU - Li, B
AU  - Li B
AD  - Chongqing Key Laboratory of Nano/Micro Composite Materials and Devices, Chongqing 
      University of Science and Technology, Chongqing 401331, China.
FAU - Jiang, T
AU  - Jiang T
AD  - Department of Prosthodontics, Peking University School and Hospital of 
      Stomatology & National Clinical Research Center for Oral Diseases & National 
      Engineering Laboratory for Digital and Material Technology of Stomatology & 
      Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Beijing Da Xue Xue Bao Yi Xue Ban
JT  - Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health 
      sciences
JID - 101125284
RN  - 0 (Delayed-Action Preparations)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - *Delayed-Action Preparations
MH  - Lactic Acid
MH  - *Microspheres
MH  - Polyglycolic Acid
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
PMC - PMC7433526
EDAT- 2019/10/19 06:00
MHDA- 2019/11/07 06:00
CRDT- 2019/10/19 06:00
PHST- 2019/10/19 06:00 [entrez]
PHST- 2019/10/19 06:00 [pubmed]
PHST- 2019/11/07 06:00 [medline]
AID - bjdxxbyxb-51-5-907 [pii]
AID - 10.19723/j.issn.1671-167X.2019.05.019 [doi]
PST - ppublish
SO  - Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Oct 18;51(5):907-912. doi: 
      10.19723/j.issn.1671-167X.2019.05.019.

PMID- 33039837
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 254
DP  - 2020 Nov
TI  - Aspirin non-response in pregnant women at increased risk of pre-eclampsia.
PG  - 292-297
LID - S0301-2115(20)30614-X [pii]
LID - 10.1016/j.ejogrb.2020.09.036 [doi]
AB  - OBJECTIVES: Low dose aspirin (LDA) is recommended for women at increased risk of 
      preeclampsia (PE), however it is not always effective. The study sought to 
      determine the prevalence of non-response to LDA and to ascertain the effect of 
      increasing aspirin dose in non-responders. STUDY DESIGN: Single centre, cohort 
      study of 166 women at increased risk of PE was conducted in a large maternity 
      unit in the UK between 2013 and 2016. All women were prescribed 75 mg of aspirin 
      and invited to attend study visits at 18-24 weeks' and 32-36 weeks' gestation. 
      Non-response was defined as a serum thromboxane B2 (TXB(2)) ≤10 ng/mL. Aspirin 
      dose was increased to 150 mg if a bedside VerifyNow test suggested non-response 
      (test value ≥ 550 arachidonic acid reactive units [ARU]) at 18-24 weeks. 
      Adherence was assessed by self-report. RESULTS: Based on serum TXB(2), response 
      rates were 85.3 % at 18-24 weeks and 79.3 % at 32-36 weeks' gestation. Compared 
      to serum TXB(2), the VerifyNow test demonstrated moderate test performance (AUC 
      0.79 95 % CI 0.71-0.88, p < 0.0001) to detect non-response. High prevalence of 
      non-adherence (6/10) was evident in persistent non-response group. Dose change 
      from 75 to 150 mg of aspirin in adherent participants improved response 
      (VerifyNow: 598 [95 % CI 550-665] ARU at 18-24 weeks on 75 mg aspirin, 509 [95 % 
      CI 350-667] at 32-36 weeks on 150 mg of aspirin, [p < 0.0001]). CONCLUSIONS: 
      Non-response to LDA is common in pregnancy but appears to be largely attributable 
      to non-adherence. Dose change could be useful to improve response to LDA in this 
      cohort.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Vinogradov, Raya
AU  - Vinogradov R
AD  - Newcastle upon Tyne NHS Hospitals Foundation Trust, Newcastle upon Tyne, UK. 
      Electronic address: Raya.vinogradov@newcastle.ac.uk.
FAU - Boag, Clare
AU  - Boag C
AD  - Department of Nursing Midwifery and Health, Faculty of Health and Life Sciences, 
      Northumbria University, Newcastle upon Tyne, UK.
FAU - Murphy, Paul
AU  - Murphy P
AD  - Newcastle upon Tyne NHS Hospitals Foundation Trust, Newcastle upon Tyne, UK.
FAU - McGeeney, David
AU  - McGeeney D
AD  - School of Mathematics, Statistics & Physics, Newcastle University, UK.
FAU - Kunadian, Vijay
AU  - Kunadian V
AD  - Newcastle upon Tyne NHS Hospitals Foundation Trust, Newcastle upon Tyne, UK; 
      Translational and Clinical Research Institute, Newcastle University, UK.
FAU - Robson, Stephen C
AU  - Robson SC
AD  - Newcastle upon Tyne NHS Hospitals Foundation Trust, Newcastle upon Tyne, UK; 
      Population Health Sciences Institute, Newcastle University, UK.
LA  - eng
PT  - Journal Article
DEP - 20200923
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - *Pre-Eclampsia/chemically induced/epidemiology/prevention & control
MH  - Pregnancy
MH  - Pregnant Women
OTO - NOTNLM
OT  - Adherence
OT  - Aspirin
OT  - Aspirin resistance
OT  - Aspirin response
OT  - Platelet response
OT  - Pre-eclampsia
COIS- Declaration of Competing Interest All authors declare no interests that may have 
      influenced the submitted work. EliTech has provided VerifyNow consumables for 100 
      patients. EliTech has not been involved in the design, conduct, management of the 
      study, analysis or interpretation of the data, or the preparation, review or 
      approval of this manuscript.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:30
PHST- 2020/07/06 00:00 [received]
PHST- 2020/09/18 00:00 [revised]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/10/11 20:30 [entrez]
AID - S0301-2115(20)30614-X [pii]
AID - 10.1016/j.ejogrb.2020.09.036 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2020 Nov;254:292-297. doi: 
      10.1016/j.ejogrb.2020.09.036. Epub 2020 Sep 23.

PMID- 14592557
OWN - NLM
STAT- MEDLINE
DCOM- 20040701
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 110
IP  - 5-6
DP  - 2003 Jun 15
TI  - Aspirin and the fibrinolytic response.
PG  - 331-4
AB  - Apart from the anti-inflammatory action, aspirin (ASA) by inhibiting thromboxane 
      A2 synthesis, decreases platelets activity and possesses the antithrombotic 
      action. However, an ASA effect on fibrinolysis has not been yet finally 
      established. Menon [Lancet 1 (1970) 364] reported increased fibrinolytic response 
      in patients treated with high doses of ASA and this observation started a series 
      of studies to find the relation between aspirin and fibrinolysis. This review 
      comprises the results of those studies, divided into in vitro and in vivo, animal 
      and human experiments. The results of our animal studies are also included. Data 
      survey shows that the ASA effect on fibrinolysis depends on experimental 
      conditions, the dose and the time of drug administration. The results of our 
      study indicate the essential role of plasma components in the fibrinolysis 
      regulation by ASA.
FAU - Buczko, Włodzimierz
AU  - Buczko W
AD  - Department of Pharmacodynamics, Medical University of Bialystok, 15-089 
      Bialystok, Mickiewicza Str 2C, Poland. pharmdyn@amb.edu.pl
FAU - Mogielnicki, Andrzej
AU  - Mogielnicki A
FAU - Kramkowski, Karol
AU  - Kramkowski K
FAU - Chabielska, Ewa
AU  - Chabielska E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Endothelial Cells/*drug effects/*physiology
MH  - Fibrinolysis/*drug effects/*physiology
MH  - Fibrinolytic Agents/pharmacology
MH  - Humans
MH  - Platelet Activation/*drug effects/*physiology
RF  - 24
EDAT- 2003/11/01 05:00
MHDA- 2004/07/02 05:00
CRDT- 2003/11/01 05:00
PHST- 2003/11/01 05:00 [pubmed]
PHST- 2004/07/02 05:00 [medline]
PHST- 2003/11/01 05:00 [entrez]
AID - S0049384803004250 [pii]
AID - 10.1016/j.thromres.2003.08.006 [doi]
PST - ppublish
SO  - Thromb Res. 2003 Jun 15;110(5-6):331-4. doi: 10.1016/j.thromres.2003.08.006.

PMID- 16160210
OWN - NLM
STAT- MEDLINE
DCOM- 20060124
LR  - 20151119
IS  - 0272-989X (Print)
IS  - 0272-989X (Linking)
VI  - 25
IP  - 5
DP  - 2005 Sep-Oct
TI  - Preference-based antithrombotic therapy in atrial fibrillation: implications for 
      clinical decision making.
PG  - 548-59
AB  - BACKGROUND: Patient preferences and expert-generated clinical practice guidelines 
      regarding treatment decisions may not be identical. The authors compared the 
      thresholds for antithrombotic treatment from studies that determined or modeled 
      the treatment preferences of patients with atrial fibrillation with 
      recommendations from clinical practice guidelines. METHODS: Methods included 
      MEDLINE identification, systematic review, and pooling with some reanalysis of 
      primary data from relevant studies. RESULTS: Eight pertinent studies, including 
      890 patients, were identified. These studies used 3 methods (decision analysis, 
      probability tradeoff, and decision aids) to determine or model patient 
      preferences. All methods highlighted that the threshold above which warfarin was 
      preferred over aspirin was highly variable. In 6 of 8 studies, patient 
      preferences indicated that fewer patients would take warfarin compared to the 
      recommendations of the guidelines. In general, at a stroke rate of 1% with 
      aspirin, half of the participants would prefer warfarin, and at a rate of 2% with 
      aspirin, two thirds would prefer warfarin. In 3 studies, warfarin must provide at 
      least a 0.9% to 3.0% per year absolute reduction in stroke risk for patients to 
      be willing to take it, corresponding to a stroke rate of 2% to 6% on aspirin. 
      CONCLUSIONS: For patients with atrial fibrillation, treatment recommendations 
      from clinical practice guidelines often differ from patient preferences, with 
      substantial heterogeneity in their individual preferences. Since patient 
      preferences can have a substantial impact on the clinical decision-making 
      process, acknowledgment of their importance should be incorporated into clinical 
      practice guidelines. Practicing physicians need to balance the patient 
      preferences with the treatment recommendations from clinical practice guidelines.
FAU - Man-Son-Hing, Malcolm
AU  - Man-Son-Hing M
AD  - Elisabeth Bruyere Research Institute and Division of Geriatric Medicine, 
      University of Ottawa, Ottawa, Ontario, Canada. mhing@ohri.ca
FAU - Gage, Brian F
AU  - Gage BF
FAU - Montgomery, Alan A
AU  - Montgomery AA
FAU - Howitt, Alistair
AU  - Howitt A
FAU - Thomson, Richard
AU  - Thomson R
FAU - Devereaux, P J
AU  - Devereaux PJ
FAU - Protheroe, Joanne
AU  - Protheroe J
FAU - Fahey, Tom
AU  - Fahey T
FAU - Armstrong, David
AU  - Armstrong D
FAU - Laupacis, Andreas
AU  - Laupacis A
LA  - eng
GR  - R01 HS10133/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Med Decis Making
JT  - Medical decision making : an international journal of the Society for Medical 
      Decision Making
JID - 8109073
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Antithrombins/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Patient Satisfaction
MH  - Practice Guidelines as Topic
MH  - *Practice Patterns, Physicians'
MH  - Warfarin/*therapeutic use
EDAT- 2005/09/15 09:00
MHDA- 2006/01/25 09:00
CRDT- 2005/09/15 09:00
PHST- 2005/09/15 09:00 [pubmed]
PHST- 2006/01/25 09:00 [medline]
PHST- 2005/09/15 09:00 [entrez]
AID - 25/5/548 [pii]
AID - 10.1177/0272989X05280558 [doi]
PST - ppublish
SO  - Med Decis Making. 2005 Sep-Oct;25(5):548-59. doi: 10.1177/0272989X05280558.

PMID- 24575839
OWN - NLM
STAT- MEDLINE
DCOM- 20141030
LR  - 20211021
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 14
DP  - 2014 Feb 28
TI  - Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an 
      effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.
PG  - 141
LID - 10.1186/1471-2407-14-141 [doi]
AB  - BACKGROUND: The anticancer properties of aspirin are restricted by its 
      gastrointestinal toxicity and its limited efficacy. Therefore, we synthesized 
      phospho-aspirin (PA-2; MDC-22), a novel derivative of aspirin, and evaluated its 
      chemotherapeutic and chemopreventive efficacy in preclinical models of triple 
      negative breast cancer (TNBC). METHODS: Efficacy of PA-2 was evaluated in human 
      breast cancer cells in vitro, and in orthotopic and subcutaneous TNBC xenografts 
      in nude mice. Mechanistic studies were also carried out to elucidate the 
      mechanism of action of PA-2. RESULTS: PA-2 inhibited the growth of TNBC cells in 
      vitro more potently than aspirin. Treatment of established subcutaneous TNBC 
      xenografts (MDA-MB-231 and BT-20) with PA-2 induced a strong growth inhibitory 
      effect, resulting in tumor stasis (79% and 90% inhibition, respectively). PA-2, 
      but not aspirin, significantly prevented the development of orthotopic MDA-MB-231 
      xenografts (62% inhibition). Mechanistically, PA-2: 1) inhibited the activation 
      of epidermal growth factor receptor (EGFR) and suppressed its downstream 
      signaling cascades, including PI3K/AKT/mTOR and STAT3; 2) induced acetylation of 
      p53 at multiple lysine residues and enhanced its DNA binding activity, leading to 
      cell cycle arrest; and 3) induced oxidative stress by suppressing the thioredoxin 
      system, consequently inhibiting the activation of the redox sensitive 
      transcription factor NF-κB. These molecular alterations were observed in vitro 
      and in vivo, demonstrating their relevance to the anticancer effect of PA-2. 
      CONCLUSIONS: Our findings demonstrate that PA-2 possesses potent chemotherapeutic 
      efficacy against TNBC, and is also effective in its chemoprevention, warranting 
      further evaluation as an anticancer agent.
FAU - Huang, Liqun
AU  - Huang L
FAU - Wong, Chi C
AU  - Wong CC
FAU - Mackenzie, Gerardo G
AU  - Mackenzie GG
FAU - Sun, Yu
AU  - Sun Y
FAU - Cheng, Ka Wing
AU  - Cheng KW
FAU - Vrankova, Kvetoslava
AU  - Vrankova K
FAU - Alston, Ninche
AU  - Alston N
FAU - Ouyang, Nengtai
AU  - Ouyang N
FAU - Rigas, Basil
AU  - Rigas B
AD  - Division of Cancer Prevention, Department of Medicine, Stony Brook University, 
      Stony Brook, New York 11794-8173, USA. basil.rigas@stonybrookmedicine.edu.
LA  - eng
GR  - 1N01CN43302WA22/CN/NCI NIH HHS/United States
GR  - HHSN261201000109C./PHS HHS/United States
GR  - R01-CA139453/CA/NCI NIH HHS/United States
GR  - R01CA13945402/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20140228
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Organophosphates)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (phosphoaspirin)
RN  - EC 2.7.10.1 (EGFR protein, mouse)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation/drug effects
MH  - Animals
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Breast Neoplasms/metabolism/prevention & control
MH  - Cell Line, Tumor
MH  - ErbB Receptors/*antagonists & inhibitors/physiology
MH  - Female
MH  - Humans
MH  - Mammary Neoplasms, Experimental/drug therapy/metabolism/*prevention & control
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Organophosphates/administration & dosage/*therapeutic use
MH  - Oxidative Stress/drug effects/*physiology
MH  - Treatment Outcome
MH  - Tumor Suppressor Protein p53/*administration & dosage/*metabolism/therapeutic use
MH  - Xenograft Model Antitumor Assays/methods
PMC - PMC3941604
EDAT- 2014/03/01 06:00
MHDA- 2014/10/31 06:00
CRDT- 2014/03/01 06:00
PHST- 2013/12/17 00:00 [received]
PHST- 2014/02/21 00:00 [accepted]
PHST- 2014/03/01 06:00 [entrez]
PHST- 2014/03/01 06:00 [pubmed]
PHST- 2014/10/31 06:00 [medline]
AID - 1471-2407-14-141 [pii]
AID - 10.1186/1471-2407-14-141 [doi]
PST - epublish
SO  - BMC Cancer. 2014 Feb 28;14:141. doi: 10.1186/1471-2407-14-141.

PMID- 17242094
OWN - NLM
STAT- MEDLINE
DCOM- 20070315
LR  - 20220317
IS  - 1526-7598 (Electronic)
IS  - 0003-2999 (Linking)
VI  - 104
IP  - 2
DP  - 2007 Feb
TI  - Posttreatment with aspirin-triggered lipoxin A4 analog attenuates 
      lipopolysaccharide-induced acute lung injury in mice: the role of heme 
      oxygenase-1.
PG  - 369-77
AB  - BACKGROUND: We hypothesized that posttreatment with 15-epi-16-parafluoro-phenoxy 
      lipoxin A4 (ATL) could attenuate lipopolysaccharide (LPS)-induced acute lung 
      injury in mice. METHODS: All the animals were randomly assigned to one of six 
      groups (n = 6 per group). In the sham-vehicle group, mice were treated with 0.9% 
      saline 60 min after they were challenged with saline. The sham-ATL group was 
      identical to the sham-vehicle group except that ATL (0.7 mg/kg, IV) was 
      administered, and the sham-ZnPP group was identical to the sham-vehicle group 
      except that Zinc protoporphyrin IX (ZnPP, 25 mg/kg IV) was administered. In the 
      LPS-vehicle group, mice were treated with vehicle 60 min after they were 
      challenged with LPS. The LPS-ATL group was identical to the LPS-vehicle group but 
      received ATL. The ZnPP-ATL-LPS group was identical to the LPS-ATL group, but ZnPP 
      was administered 30 min before ATL. RESULTS: Inhalation of LPS increased 
      inflammatory cell counts, tumor necrosis factor-alpha, and protein concentration 
      in bronchoalveolar lavage fluid and also induced lung histological injury and 
      edema. Posttreatment with ATL inhibited tumor necrosis factor-alpha, nitric 
      oxide, and malondialdehyde production, with the outcome of decreased pulmonary 
      edema, lipid peroxidation, and the infiltration of neutrophils in lung tissues. 
      In addition, ATL promoted the formation of heme oxygenase-1 in the lung tissues. 
      Heme oxygenase-1 activity was also increased in the lung tissues after ATL 
      stimulation. The beneficial effects of ATL were abolished by ZnPP. CONCLUSIONS: 
      This study demonstrates that posttreatment with ATL significantly reduces 
      LPS-induced acute lung injury in mice.
FAU - Jin, Sheng-Wei
AU  - Jin SW
AD  - Department of Anesthesiology, Second Affiliated Hospital, Wenzhou Medical 
      College, Wenzhou, China. jinshengwei@sohu.com
FAU - Zhang, Li
AU  - Zhang L
FAU - Lian, Qin-Quan
AU  - Lian QQ
FAU - Liu, Dong
AU  - Liu D
FAU - Wu, Ping
AU  - Wu P
FAU - Yao, Shang-Long
AU  - Yao SL
FAU - Ye, Du-Yun
AU  - Ye DY
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Anesth Analg. 2007 Feb;104(2):258-9. PMID: 17242075
MH  - Acute Disease
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Heme Oxygenase-1/antagonists & inhibitors/*physiology
MH  - Lipopolysaccharides/*toxicity
MH  - Lipoxins/pharmacology/*therapeutic use
MH  - Lung Diseases/chemically induced/*enzymology/pathology/prevention & control
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Random Allocation
MH  - Time Factors
EDAT- 2007/01/24 09:00
MHDA- 2007/03/16 09:00
CRDT- 2007/01/24 09:00
PHST- 2007/01/24 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2007/01/24 09:00 [entrez]
AID - 104/2/369 [pii]
AID - 10.1213/01.ane.0000252414.00363.c4 [doi]
PST - ppublish
SO  - Anesth Analg. 2007 Feb;104(2):369-77. doi: 10.1213/01.ane.0000252414.00363.c4.

PMID- 6536418
OWN - NLM
STAT- MEDLINE
DCOM- 19850828
LR  - 20190825
IS  - 0305-1870 (Print)
IS  - 0305-1870 (Linking)
VI  - 11
IP  - 6
DP  - 1984 Nov-Dec
TI  - Canine nonresponders to alveolar hypoxic vasoconstriction and quantitative 
      restoration of the response by aspirin I-3.
PG  - 579-88
AB  - Hypoxic pulmonary vasoconstriction is characterized by considerable variability 
      in rate of response (pulmonary vascular resistance [PVR] as a function of time 
      under hypoxia). To further define this response, forty-five closed chest dogs 
      were anaesthetized (pentobarbitone sodium), intubated, and mechanically 
      ventilated. Constant left lower lobar pulmonary artery flow was maintained 
      through a balloon tipped 14F catheter via an extracorporeal pump at a rate to 
      achieve lobar pulmonary artery pressure (Plobar) equal to main pulmonary artery 
      pressure (PPA) and thereafter held constant. Left ventricular end diastolic 
      pressure (PLVED) was measured by left ventricular catheter and lobar pulmonary 
      artery flow rate (Q) by flow meter. Lobar PVR (mmHg/min per 1) was calculated 
      every 15 min. Ventilation with 10% oxygen (O2) separated two groups based on the 
      increase in PVR over time: twenty-two rapid hypoxic responders [HR] (slope= delta 
      PVR/delta min greater than 0.3) and twenty-three slow or nonresponders [NR] 
      (slope less than 0.1). The twenty-three NR were divided into two groups. Ten NR 
      dogs (NR control) had no change in mean PVR (23.9, s.d. = 8.2, to 24.1, s.d. = 
      9.6) over a mean of 78 min and were used as controls. Thirteen NR dogs (NR ASA) 
      had no change in mean PVR (32.9, s.d. = 9.5, to 32.3, s.d. = 9.8) over 75 min and 
      were given aspirin (ASA), 10-15 mg/kg intra-arterially. The NR ASA group mean PVR 
      then increased from 32.3 (s.d. = 9.8) to 59.1 (s.d. = 23.9, 82.9% increase, P 
      less than 0.01) over a mean of 54 min. The mean PVR for the twenty-two HR rose 
      from 39.8 (s.d. = 34.0) to 64.5 (s.d. = 36.6, 62.1% increase, P less than 0.01) 
      over a mean of 72 min. The slopes of rate of response for HR (0.66) and for NR 
      ASA (0.88) were not significantly different. The absolute values of PVR reached 
      after plateau for HR and for NR ASA (after ASA) were also not different. Aspirin 
      restored the NR capability to develop pulmonary vasoconstriction in response to 
      alveolar hypoxia. The rate of response and the absolute level of response reached 
      were also restored by aspirin.
FAU - Siefkin, A D
AU  - Siefkin AD
FAU - Parsons, G H
AU  - Parsons GH
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Gas Analysis
MH  - Blood Pressure/drug effects
MH  - Dogs
MH  - Female
MH  - Hypoxia/*physiopathology
MH  - Male
MH  - Oxygen Consumption/drug effects
MH  - Pulmonary Alveoli/*physiopathology
MH  - Pulmonary Circulation/drug effects
MH  - Vascular Resistance/drug effects
MH  - Vasoconstriction/*drug effects
EDAT- 1984/11/01 00:00
MHDA- 1984/11/01 00:01
CRDT- 1984/11/01 00:00
PHST- 1984/11/01 00:00 [pubmed]
PHST- 1984/11/01 00:01 [medline]
PHST- 1984/11/01 00:00 [entrez]
AID - 10.1111/j.1440-1681.1984.tb00870.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 1984 Nov-Dec;11(6):579-88. doi: 
      10.1111/j.1440-1681.1984.tb00870.x.

PMID- 16414427
OWN - NLM
STAT- MEDLINE
DCOM- 20061102
LR  - 20220408
IS  - 0749-3797 (Print)
IS  - 0749-3797 (Linking)
VI  - 30
IP  - 1
DP  - 2006 Jan
TI  - Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System.
PG  - 74-7
AB  - BACKGROUND: The role of aspirin in prevention of cardiovascular disease (CVD) and 
      cardiovascular complications among people with diabetes has been examined. A 
      Healthy People 2010 objective calls for increasing the proportion of people with 
      diabetes aged>or=40 years who take aspirin>or=15 times per month. METHODS: Data 
      from 2003 Behavioral Risk Factor Surveillance System were used to examine (1) the 
      prevalence of aspirin intake, (2) aspirin use among those with CVD, (3) aspirin 
      use among those with diabetes, (4) current status with respect to Healthy People 
      objective 5-16, and (5) changes in aspirin intake from 1999. RESULTS: Daily or 
      every-other-day aspirin use was reported by 36.2% of participants in 2003. 
      Aspirin intake among those with CVD and diabetes was 82.8% and 62.6%, 
      respectively. The Healthy People 2010 objective of increasing the proportion of 
      adults with diabetes aged>or=40 years who take aspirin to 30% was achieved. The 
      prevalence of aspirin intake was higher in 2003 compared to 1999 among all 
      participants, those with CVD, and those with diabetes (relative increase of about 
      20%, 12%, and 36%, respectively). Most participants (74%) reported cardiovascular 
      reasons for aspirin use. Among those without CVD or diabetes, the prevalence of 
      aspirin intake increased with the increasing number of CVD risk factors. 
      CONCLUSIONS: Regular aspirin use increased over a 4-year period. Greater use of 
      inexpensive and easily accessible interventions to prevent cardiovascular events 
      is encouraging. Increased efforts to continue preventive uses of available 
      treatment and reduction in risk by modifying other risk factors will help lower 
      future disease burden.
FAU - Ajani, Umed A
AU  - Ajani UA
AD  - Division of Adult and Community Health, National Center for Chronic Disease 
      Prevention and Health Promotion, Centers for Disease Control and Prevention, 
      Atlanta, Georgia 30341, USA. uajani@cdc.gov
FAU - Ford, Earl S
AU  - Ford ES
FAU - Greenland, Kurt J
AU  - Greenland KJ
FAU - Giles, Wayne H
AU  - Giles WH
FAU - Mokdad, Ali H
AU  - Mokdad AH
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Am J Prev Med
JT  - American journal of preventive medicine
JID - 8704773
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - *Behavioral Risk Factor Surveillance System
MH  - Cardiovascular Diseases/epidemiology/etiology/*prevention & control
MH  - Diabetes Complications/*prevention & control
MH  - Female
MH  - *Health Promotion
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Risk Factors
MH  - Risk Reduction Behavior
MH  - Self Medication/*statistics & numerical data
MH  - United States/epidemiology
EDAT- 2006/01/18 09:00
MHDA- 2006/11/03 09:00
CRDT- 2006/01/18 09:00
PHST- 2005/03/10 00:00 [received]
PHST- 2005/06/27 00:00 [revised]
PHST- 2005/08/25 00:00 [accepted]
PHST- 2006/01/18 09:00 [pubmed]
PHST- 2006/11/03 09:00 [medline]
PHST- 2006/01/18 09:00 [entrez]
AID - S0749-3797(05)00347-8 [pii]
AID - 10.1016/j.amepre.2005.08.042 [doi]
PST - ppublish
SO  - Am J Prev Med. 2006 Jan;30(1):74-7. doi: 10.1016/j.amepre.2005.08.042.

PMID- 6473898
OWN - NLM
STAT- MEDLINE
DCOM- 19841022
LR  - 20131121
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 45
IP  - 1
DP  - 1984 Jul
TI  - Acetyl salicylic acid-induced gastric mucosal lesions: no role of gastric 
      glutathione.
PG  - 153-6
AB  - Gastric glutathione (GSH) depletion has been implicated in the causation of 
      gastric mucosal lesions by ethanol, diethylmaleate (DEM) and acrylonitrile (VCN). 
      The purpose of the current studies was to investigate the role of gastric GSH in 
      Acetyl Salicylic acid (Aspirin; ASA) induced gastric lesions. Intragastric 
      administration of doses of ASA to rats, which caused gastric mucosal lesions, had 
      no significant influence on gastric or hepatic GSH concentrations. Furthermore, 
      pretreatment of rats with sulfhydryl-containing chemicals (e.g. L-cysteine) 
      failed to protect against the ASA- or Acid-induced gastric lesions. Our findings 
      indicate that gastric GSH plays no role in the pathogenesis of ASA-induced 
      gastric mucosal necrosis.
FAU - Ghanayem, B I
AU  - Ghanayem BI
FAU - Ahmed, A E
AU  - Ahmed AE
FAU - Boor, P J
AU  - Boor PJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - GAN16C9B8O (Glutathione)
RN  - K848JZ4886 (Cysteine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cysteine/pharmacology
MH  - Gastric Acid/metabolism
MH  - Gastric Mucosa/*drug effects
MH  - Glutathione/*metabolism
MH  - Liver/metabolism
MH  - Male
MH  - Necrosis/chemically induced
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1984 Jul;45(1):153-6.

PMID- 636506
OWN - NLM
STAT- MEDLINE
DCOM- 19780524
LR  - 20131121
IS  - 0044-2771 (Print)
IS  - 0044-2771 (Linking)
VI  - 16
IP  - 3
DP  - 1978 Mar
TI  - [Transmural electronic potential difference--a functional parameter of the 
      gastric mucosal barrier (author's transl)].
PG  - 126-36
AB  - The transmural electric potential difference represents the resultant of a 
      complex of electromotive forces across the gastric mucosal barrier. Its 
      quantitative changes correlate with other functional parameters of the gastric 
      mucosal barrier: H+-back diffusion, Na+-influx, ultrastructural changes of the 
      mucosa. Measurement of the transmural electric PD represents a convenient 
      technique to detect functional changes of the mucosa induced by aspirin, alcohol 
      and bile acids. Antacids with potent buffering capacity are able to prevent 
      reduction of PD-changes induced by aspirin and bile acids. Antacids therefore 
      seem to exhibit a protective effect against acute lesions of the gastric mucosa.
FAU - Caspary, W F
AU  - Caspary WF
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Transmurale elektrische Potentialdifferenz-Messung als Funktionsparameter der 
      Magenmukosaschranke.
PL  - Germany
TA  - Z Gastroenterol
JT  - Zeitschrift fur Gastroenterologie
JID - 0033370
RN  - 0 (Antacids)
RN  - 0 (Bile Acids and Salts)
RN  - 11041-12-6 (Cholestyramine Resin)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antacids/pharmacology
MH  - Aspirin/pharmacology
MH  - Bile Acids and Salts/pharmacology
MH  - Cholestyramine Resin/pharmacology
MH  - Ethanol/pharmacology
MH  - Gastric Mucosa/drug effects/*physiology
MH  - Humans
MH  - *Membrane Potentials
MH  - Potentiometry/methods
EDAT- 1978/03/01 00:00
MHDA- 1978/03/01 00:01
CRDT- 1978/03/01 00:00
PHST- 1978/03/01 00:00 [pubmed]
PHST- 1978/03/01 00:01 [medline]
PHST- 1978/03/01 00:00 [entrez]
PST - ppublish
SO  - Z Gastroenterol. 1978 Mar;16(3):126-36.

PMID- 7095604
OWN - NLM
STAT- MEDLINE
DCOM- 19820924
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 11
IP  - 3
DP  - 1982
TI  - Acetylsalicylic acid in combination with dihydroergotamine for preventing 
      thromboembolism.
PG  - 149-53
AB  - In a prospective randomized clinical trial involving 150 patients who underwent 
      major abdominal surgery, acetylsalicylic acid (ASA) and dihydroergotamine (DHE) 
      were examined either alone or in combination for their potential to prevent 
      thromboembolism. Combined treatment with ASA and DHE was found to be more 
      effective in preventing the spread of thrombi and their propagation to the 
      femoral veins.
FAU - Zekert, F
AU  - Zekert F
FAU - Schemper, M
AU  - Schemper M
FAU - Neumann, K
AU  - Neumann K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 436O5HM03C (Dihydroergotamine)
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Dihydroergotamine/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fibrinogen/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Embolism/drug therapy
MH  - Thromboembolism/*drug therapy
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
AID - 10.1159/000214655 [doi]
PST - ppublish
SO  - Haemostasis. 1982;11(3):149-53. doi: 10.1159/000214655.

PMID- 35366853
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220408
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Apr 2
TI  - Ultrasonography evaluation on the protective effect of combination therapy of 
      beraprost sodium and aspirin on arteries occlusion and stiffness in patients with 
      type 2 diabetes mellitus - a prospective, randomized study.
PG  - 87
LID - 10.1186/s12902-022-01007-5 [doi]
LID - 87
AB  - BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) are susceptible to 
      developing symptomatic peripheral arterial disease (PAD). As a proven vasodilator 
      and antiplatelet agent, the efficiency of Beraprost sodium (BPS) on the 
      prevention of arteries occlusion and stiffness in T2DM patients with PAD has not 
      yet been fully investigated. METHODS: From July 2010 to April 2012, 64 Patients 
      enrolled were randomly assigned to the combined therapy group (n=32), which 
      received combination therapy with BPS (60 μg/day) and aspirin (100 mg/day), or to 
      the control group (n=32), which only received aspirin (100 mg/day). After 
      randomization, the patients were followed up at years 0, 1, 2, 3, 4, and 5 with 
      the evaluation of carotid intima-media thickness (CIMT), pulse wave velocity 
      (PWV), inner artery diameter, stenosis rate, and medial arterial calcification 
      (MAC) of lower limb arteries via high-resolution ultrasound measurement. Adverse 
      events were also recorded in each visit. RESULTS: There was no significant change 
      of the CIMT during the follow-up in both groups when compared to the baseline. 
      Similar results were also observed in the PWV measurement. Significantly 
      increases in the inner artery diameter of the dorsal pedal artery and posterior 
      tibial artery were observed in patients with BPS and aspirin administration 
      during the follow-up. Patients in the combined therapy group experienced marked 
      improvement of MAC in the dorsal pedal artery and posterior tibial artery at the 
      end of the follow-up. No significant difference in the adverse events was found 
      between the combined therapy group and the aspirin group. CONCLUSION: The 
      combined therapy of BPS and aspirin showed a protective effect on arteries 
      occlusion and stiffness in T2DM patients with PAD, along with a significant 
      improvement of inner artery diameter and MAC in lower limbs. TRIAL REGISTRATION: 
      http://www.chictr.org.cn , ChiCTR-TRC-10000919. Prospectively registered on 
      2010/06/29.
CI  - © 2022. The Author(s).
FAU - Lin, Xian
AU  - Lin X
AD  - Department of Ultrasound, Guangdong Province Traditional Chinese Medical 
      Hospital, 111, Dade Road, Yuexiu District, Guangzhou, Guangdong, China.
AD  - Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen 
      University, 107, Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, PR 
      China.
FAU - Chen, Yuying
AU  - Chen Y
AD  - Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen 
      University, 107, Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, PR 
      China.
FAU - Lu, Wan
AU  - Lu W
AD  - Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen 
      University, 107, Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, PR 
      China.
FAU - Li, Jin
AU  - Li J
AD  - Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen 
      University, 107, Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, PR 
      China.
FAU - Fu, Li
AU  - Fu L
AD  - Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen 
      University, 107, Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, PR 
      China.
FAU - Yin, Jingyu
AU  - Yin J
AD  - Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen 
      University, 107, Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, PR 
      China.
FAU - Ren, Meng
AU  - Ren M
AD  - Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen 
      University, 107, Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, PR 
      China.
FAU - Yan, Li
AU  - Yan L
AD  - Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen 
      University, 107, Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, PR 
      China.
FAU - Yang, Chuan
AU  - Yang C
AD  - Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen 
      University, 107, Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, PR 
      China. yangchuangsysu@163.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220402
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 35E3NJJ4O6 (beraprost)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arteries
MH  - *Aspirin/therapeutic use
MH  - Carotid Intima-Media Thickness
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Epoprostenol/analogs & derivatives
MH  - Humans
MH  - Prospective Studies
MH  - Pulse Wave Analysis
MH  - Ultrasonography
PMC - PMC8977025
OTO - NOTNLM
OT  - Aspirin
OT  - Atherosclerosis
OT  - Beraprost Sodium
OT  - Medial Arterial Calcification
OT  - Type 2 Diabetes Mellitus
COIS- The authors have no conflicts of interest.
EDAT- 2022/04/04 06:00
MHDA- 2022/04/06 06:00
CRDT- 2022/04/03 20:21
PHST- 2021/06/12 00:00 [received]
PHST- 2022/03/30 00:00 [accepted]
PHST- 2022/04/03 20:21 [entrez]
PHST- 2022/04/04 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
AID - 10.1186/s12902-022-01007-5 [pii]
AID - 1007 [pii]
AID - 10.1186/s12902-022-01007-5 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2022 Apr 2;22(1):87. doi: 10.1186/s12902-022-01007-5.

PMID- 30582489
OWN - NLM
STAT- MEDLINE
DCOM- 20190802
LR  - 20200225
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 40
IP  - 1
DP  - 2019 Jan 1
TI  - Clinical updates in aspirin-exacerbated respiratory disease.
PG  - 4-6
LID - 10.2500/aap.2019.40.4188 [doi]
AB  - Background: Aspirin-exacerbated respiratory disease (AERD), a syndrome that 
      includes asthma, recurrent nasal polyps, and pathognomonic reactions to aspirin 
      and other nonselective cyclooxygenase inhibitors, is still not fully understood 
      and lacks specific disease-modifying therapeutic options. Objective: To review 
      the most recent clinical updates in the evaluation and treatment of patients with 
      AERD. Methods: Recent clinical research studies relevant to patients with AERD 
      were reviewed. Results: Multiple new biologics are available for the treatment of 
      severe asthma, several of which have been specifically studied and determined to 
      be efficacious in the subset of patients with asthma who are also aspirin 
      sensitive. Zileuton continues to be underprescribed for AERD and is considered to 
      be very effective by many patients with AERD. Dietary modifications toward a diet 
      that is high in omega-3 fatty acids and low in omega-6 fatty acids can reduce the 
      production of the inflammatory leukotriene and prostaglandin D₂ lipids and help 
      improve symptoms for patients with AERD. Conclusion: A lack of definitive 
      understanding of the causative mechanisms of AERD and the absence of an 
      AERD-specific patient-reported outcome measure are obstacles that remain in this 
      field, but much progress has been made over the past decade.
FAU - Laidlaw, Tanya M
AU  - Laidlaw TM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Asthma, Aspirin-Induced
MH  - Disease Management
MH  - Health Services Needs and Demand
MH  - Humans
MH  - Patient Care
MH  - Respiratory Tract Diseases/*diagnosis/*etiology/*therapy
MH  - Syndrome
PMC - PMC6313255
COIS- The author has no conflicts of interest to declare pertaining to this article
EDAT- 2018/12/26 06:00
MHDA- 2019/08/03 06:00
CRDT- 2018/12/25 06:00
PHST- 2018/12/25 06:00 [entrez]
PHST- 2018/12/26 06:00 [pubmed]
PHST- 2019/08/03 06:00 [medline]
AID - AAP094-18 [pii]
AID - 10.2500/aap.2019.40.4188 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2019 Jan 1;40(1):4-6. doi: 10.2500/aap.2019.40.4188.

PMID- 18855583
OWN - NLM
STAT- MEDLINE
DCOM- 20081212
LR  - 20191027
IS  - 1567-2050 (Print)
IS  - 1567-2050 (Linking)
VI  - 5
IP  - 5
DP  - 2008 Oct
TI  - Fatty aspirin: a new perspective in the prevention of dementia of Alzheimer's 
      type?
PG  - 422-31
AB  - Alzheimer's disease (AD) leads to a dramatic decline in cognitive abilities and 
      memory. A more modest disruption of memory often occurs in normal aging and the 
      same circuits that are devastated through degeneration in AD are vulnerable to 
      sub-lethal age-related changes that alter synaptic transmission. There are 
      numerous indications that aberrant plasticity is critically involved in 
      Alzheimer's. Is ageing itself the major risk factor for AD? Is AD an acceleration 
      of normal ageing? We assume that the ability of the brain is to modify its own 
      structural organization and functioning which is liable to become impaired in 
      ageing until it becomes dramatically impaired in Alzheimer's. Moreover, ageing 
      can compromise the conversion of dietary alpha-linolenic acid (ALA) to 
      docosahexaenoic acid (DHA). DHA regulates synaptogenesis and affects the synaptic 
      structure, and synapse density is reduced in ageing. DHA and newly identified 
      DHA-derived messenger, neuroprotecting D1 (NPD1), protect synapses and decrease 
      the number of activated microglia in the hippocampal system. Delaying AD onset by 
      a few years would reduce the number of the cases of dementia in the community. 
      DHA (and NPD1?) and aspirin induce brain-derived neurotrophic factor (BDNF) 
      protein expression and this protein has a crucial role in neuronal survival. The 
      authors--in view of the increased neuroinflammatory reaction frequently observed 
      during normal brain ageing--suggest the long-term use of "fatty aspirin", an 
      association of DHA and/or NPD1 and aspirin (or nitroaspirin), to postpone, or 
      prevent, the structural neurodegeneration of the brain.
FAU - Pomponi, M
AU  - Pomponi M
AD  - Catholic University of Sacred Heart (UCSC), Psychiatric Department, Rome, Italy. 
      m.pomponi@rm.unicatt.it
FAU - Di Gioia, A
AU  - Di Gioia A
FAU - Bria, P
AU  - Bria P
FAU - Pomponi, M F L
AU  - Pomponi MF
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Alzheimer Res
JT  - Current Alzheimer research
JID - 101208441
RN  - 0 (Antioxidants)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alzheimer Disease/*complications
MH  - Animals
MH  - Antioxidants/therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Cognition Disorders/etiology/prevention & control
MH  - Dementia/etiology/*prevention & control
MH  - Disease Models, Animal
MH  - Docosahexaenoic Acids/*therapeutic use
MH  - Hippocampus/drug effects
MH  - Memory/drug effects/physiology
MH  - Mice
MH  - Microglia/drug effects/physiology
MH  - Neurofibrillary Tangles/drug effects
MH  - Neuronal Plasticity/drug effects
MH  - Synapses/drug effects/physiology
EDAT- 2008/10/16 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/10/16 09:00
PHST- 2008/10/16 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/10/16 09:00 [entrez]
AID - 10.2174/156720508785908892 [doi]
PST - ppublish
SO  - Curr Alzheimer Res. 2008 Oct;5(5):422-31. doi: 10.2174/156720508785908892.

PMID- 9842027
OWN - NLM
STAT- MEDLINE
DCOM- 19990107
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 136
IP  - 6
DP  - 1998 Dec
TI  - Effect of intravenous heparin infusion on thrombin-antithrombin complex and 
      fibrinopeptide A in unstable angina.
PG  - 1106-13
AB  - BACKGROUND: In unstable angina, the clinical efficacy of heparin is limited in 
      time, and recurrence of adverse events has been reported after discontinuation of 
      the anticoagulant. METHODS: In 21 episodes of unstable angina, we used the plasma 
      level of fibrinopeptide A (FPA) and of thrombin-antithrombin complex (TAT) to 
      evaluate the pattern of thrombin inhibition by heparin and the effect of stopping 
      heparin and initiating aspirin. RESULTS: At admission, the plasma level of FPA 
      was increased: median value 3.7 ng/mL compared with 5.5 ng/mL in a control group 
      of 20 patients with early myocardial infarction (not significant). The following 
      findings were observed during a 4-day course of intravenous heparin infusion: (1) 
      FPA decreased significantly 6 hours after the start of therapy; (2) FPA was lower 
      when activated partial thromboplastic time (aPTT) was >1.5 times baseline; (3) 
      there was a significant negative correlation between aPTT and FPA. Twenty-four 
      hours after heparin was discontinued and aspirin initiated, a significant 
      increase in TAT and FPA in plasma was observed. CONCLUSIONS: The results confirm 
      ongoing fibrin formation in the active phase of unstable angina, indicate 
      incomplete and variable inhibition of thrombin by heparin during continuous 
      infusion, and suggest a risk of re-emergence of thrombosis (in spite of 
      initiating aspirin) 24 hours after withdrawal of heparin. Data demonstrate a 
      better control of thrombin activity when heparin is infused at rates that 
      maintain aPTT at >1.5 times baseline, as currently recommended in unstable 
      angina.
FAU - Mombelli, G
AU  - Mombelli G
AD  - Ospedale Regionale Locarno, and the Thrombosis Research Laboratory, University of 
      Bern, Switzerland.
FAU - Marchetti, O
AU  - Marchetti O
FAU - Haeberli, A
AU  - Haeberli A
FAU - Straub, P W
AU  - Straub PW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Anticoagulants)
RN  - 0 (Biomarkers)
RN  - 0 (antithrombin III-protease complex)
RN  - 25422-31-5 (Fibrinopeptide A)
RN  - 9000-94-6 (Antithrombin III)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina, Unstable/*blood/*drug therapy
MH  - Anticoagulants/*administration & dosage/therapeutic use
MH  - Antithrombin III/*analysis
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Biomarkers/blood
MH  - Female
MH  - Fibrinopeptide A/*analysis
MH  - Heparin/*administration & dosage/therapeutic use
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Peptide Hydrolases/*analysis
MH  - Prospective Studies
EDAT- 1998/12/08 00:00
MHDA- 1998/12/08 00:01
CRDT- 1998/12/08 00:00
PHST- 1998/12/08 00:00 [pubmed]
PHST- 1998/12/08 00:01 [medline]
PHST- 1998/12/08 00:00 [entrez]
AID - S0002870398000301 [pii]
AID - 10.1016/s0002-8703(98)70170-x [doi]
PST - ppublish
SO  - Am Heart J. 1998 Dec;136(6):1106-13. doi: 10.1016/s0002-8703(98)70170-x.

PMID- 365283
OWN - NLM
STAT- MEDLINE
DCOM- 19790324
LR  - 20190509
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 64
IP  - 4
DP  - 1978 Dec
TI  - Effects of sulphinpyrazone and aspirin on prostaglandin I2 (prostacyclin) 
      synthesis by endothelial cells.
PG  - 481-3
AB  - Synthesis of prostaglandin I2, (PGI2, prostacyclin) by vascular endothelium 
      (assayed by the ability of cultured endothelial cells to inhibit platelet 
      aggregation) was inhibited by aspirin. At 100 mumol/l aspirin completely blocked 
      measurable PGI2 production, but endothelial cells had substantially recovered 
      their ability to synthesize PGI2 24 h after removal of the drug. In contrast, the 
      effect of 1 mmol/l aspirin was still evident 24 h after drug withdrawal. 
      Sulphinpyrazone also inhibited PGI2 synthesis, but was about 100 fold less potent 
      than aspirin, and the effect of the drug was lost within 24 h of its addition, 
      even when endothelial cells were left in contact with the drug during this 
      period.
FAU - Gordon, J L
AU  - Gordon JL
FAU - Pearson, J D
AU  - Pearson JD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Prostaglandins)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cells, Cultured
MH  - Endothelium/cytology/drug effects/metabolism
MH  - Epoprostenol/*biosynthesis
MH  - Prostaglandins/*biosynthesis
MH  - Sulfinpyrazone/*pharmacology
PMC - PMC1668445
EDAT- 1978/12/01 00:00
MHDA- 1978/12/01 00:01
CRDT- 1978/12/01 00:00
PHST- 1978/12/01 00:00 [pubmed]
PHST- 1978/12/01 00:01 [medline]
PHST- 1978/12/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1978.tb17308.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1978 Dec;64(4):481-3. doi: 10.1111/j.1476-5381.1978.tb17308.x.

PMID- 33844134
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20220726
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 36
IP  - 4
DP  - 2022 Aug
TI  - An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes 
      Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection.
PG  - 605-618
LID - 10.1007/s10557-021-07182-2 [doi]
AB  - PURPOSE: Hypoxic microenvironment plays a vital role in myocardial ischemia 
      injury, generally leading to the resistance of chemotherapeutic drugs. This 
      induces an intriguing study on mechanism exploration and prodrug design to 
      overcome the hypoxia-induced drug resistance. METHODS: In this study, we 
      hypothesized that the overexpression of carbonic anhydrase 9 (CAIX) in myocardial 
      cells is closely related to the drug resistance. Herein, bioinformatics analysis, 
      gene knockdown, and overexpression assay certificated the correlation between 
      CAIX overexpression and hypoxia. An original aspirin-containing CAIX inhibitor 
      AcAs has been developed. RESULTS: Based on the downregulation of CAIX level, both 
      in vitro and in vivo, AcAs can overcome the acquired resistance and more 
      effectively attenuate myocardial ischemia and hypoxia injury than that of 
      aspirin. CAIX inhibitor is believed to recover the extracellular pH value so as 
      to ensure the stable effect of aspirin. CONCLUSION: Results indicate great 
      potential of CAIX inhibitor for further application in myocardial hypoxia injury 
      therapy.
CI  - © 2021. Springer Science+Business Media, LLC, part of Springer Nature.
FAU - Zhou, Wen
AU  - Zhou W
AUID- ORCID: 0000-0001-9506-1620
AD  - Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast 
      University, Nanjing, 211189, Jiangsu, People's Republic of China.
AD  - Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, 
      Southeast University, Nanjing, 211189, Jiangsu, People's Republic of China.
FAU - Zhang, Bin
AU  - Zhang B
AD  - Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, 
      Southeast University, Nanjing, 211189, Jiangsu, People's Republic of China.
FAU - Fan, Keyu
AU  - Fan K
AD  - Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, 
      Southeast University, Nanjing, 211189, Jiangsu, People's Republic of China.
FAU - Yin, Xiaojian
AU  - Yin X
AD  - State Key Laboratory of Natural Medicines, China Pharmaceutical University, 
      Nanjing, 210009, Jiangsu, People's Republic of China.
FAU - Liu, Jinfeng
AU  - Liu J
AD  - School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical 
      University, Nanjing, 211198, Jiangsu, People's Republic of China.
FAU - Gou, Shaohua
AU  - Gou S
AD  - Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast 
      University, Nanjing, 211189, Jiangsu, People's Republic of China. 
      sgou@seu.edu.cn.
AD  - Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, 
      Southeast University, Nanjing, 211189, Jiangsu, People's Republic of China. 
      sgou@seu.edu.cn.
LA  - eng
GR  - BK20180570/Natural Science Foundation of Jiangsu Province/
PT  - Journal Article
DEP - 20210412
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Carbonic Anhydrase Inhibitors)
RN  - EC 4.2.1.1 (Carbonic Anhydrase IX)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Carbonic Anhydrase IX/genetics
MH  - *Carbonic Anhydrase Inhibitors/pharmacology
MH  - Cell Line, Tumor
MH  - Drug Resistance
MH  - Humans
MH  - Hypoxia/drug therapy
MH  - *Myocardial Ischemia/drug therapy
OTO - NOTNLM
OT  - Aspirin derivative
OT  - Carbonic anhydrase 9
OT  - Drug resistance
OT  - Myocardial hypoxia injury
EDAT- 2021/04/13 06:00
MHDA- 2022/07/14 06:00
CRDT- 2021/04/12 12:48
PHST- 2021/03/31 00:00 [accepted]
PHST- 2021/04/13 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
PHST- 2021/04/12 12:48 [entrez]
AID - 10.1007/s10557-021-07182-2 [pii]
AID - 10.1007/s10557-021-07182-2 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2022 Aug;36(4):605-618. doi: 10.1007/s10557-021-07182-2. 
      Epub 2021 Apr 12.

PMID- 31117119
OWN - NLM
STAT- MEDLINE
DCOM- 20200203
LR  - 20200309
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 5
DP  - 2019
TI  - Efficacy between low and high dose aspirin for the initial treatment of Kawasaki 
      disease: Current evidence based on a meta-analysis.
PG  - e0217274
LID - 10.1371/journal.pone.0217274 [doi]
LID - e0217274
AB  - BACKGROUND: Kawasaki disease (KD) is now the leading cause of acquired heart 
      disease in children in developed countries. Intravenous immunoglobulin (IVIG) and 
      aspirin were considered as the standard initial treatment of KD for decades. 
      However, the optimal dose of aspirin has remained controversial. In recent years, 
      many studies compared the efficacy of low-dose with high-dose aspirin in the 
      acute phase of KD, but the results have not always been consistent. Therefore, we 
      performed this meta-analysis to evaluate the efficacy of low-dose aspirin 
      compared with high-dose for the initial treatment of KD. METHODS: Studies related 
      to aspirin therapy for KD were selected from PubMed, EMBASE, the Cochrane Central 
      Register of Controlled Trials, China National Knowledge Infrastructure, and 
      Google scholar through Mar 25th, 2019. Data were analyzed using STATA Version 
      15.1. Additionally, publication bias and sensitivity analysis were also performed 
      by STATA version 15.1. RESULTS: Six studies were included in our analysis of the 
      rate of coronary artery lesion (CAL), five reports for IVIG-resistant KD (rKD), 
      and four for the duration of fever and hospitalization. However, no significant 
      differences were found between low-dose and high-dose aspirin groups in the 
      incidence of CAL (risk ratio (RR), 0.85; 95%CI (0.63, 1.14); P = 0.28), the risk 
      of rKD (RR, 1.39; 95%CI (1.00, 1.93); P = 0.05), and duration of fever and 
      hospitalization (the mean standard deviation (SMD), 0.03; 95%CI (-0.16, 0.22); P 
      = 0.78). CONCLUSION: Low-dose aspirin (3-5 mg·kg-1·d-1) may be as effective as 
      the use of high-dose aspirin (≥30 mg·kg-1·d-1) for the initial treatment of KD. 
      Further well-designed randomized clinical trials are needed to evaluate the 
      efficacy of low-dose aspirin for the initial treatment of KD.
FAU - Zheng, Xiaolan
AU  - Zheng X
AUID- ORCID: 0000-0001-5971-4284
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
AD  - West China Medical School, Sichuan University, Chengdu, Sichuan, China.
FAU - Yue, Peng
AU  - Yue P
AUID- ORCID: 0000-0002-8541-0265
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
AD  - West China Medical School, Sichuan University, Chengdu, Sichuan, China.
FAU - Liu, Lei
AU  - Liu L
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
AD  - West China Medical School, Sichuan University, Chengdu, Sichuan, China.
FAU - Tang, Changqing
AU  - Tang C
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
AD  - West China Medical School, Sichuan University, Chengdu, Sichuan, China.
FAU - Ma, Fan
AU  - Ma F
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
AD  - West China Medical School, Sichuan University, Chengdu, Sichuan, China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Wang, Chuan
AU  - Wang C
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Duan, Hongyu
AU  - Duan H
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Zhou, Kaiyu
AU  - Zhou K
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
AD  - Program for Changjiang Scholars and Innovative Research Team in University, West 
      China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
FAU - Hua, Yimin
AU  - Hua Y
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
AD  - Program for Changjiang Scholars and Innovative Research Team in University, West 
      China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
FAU - Wu, Gang
AU  - Wu G
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Li, Yifei
AU  - Li Y
AUID- ORCID: 0000-0002-3096-4287
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
AD  - Ministry of Education Key Laboratory of Women and Children's Diseases and Birth 
      Defects, West China Second University Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20190522
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Child, Preschool
MH  - Coronary Aneurysm/etiology/prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage
MH  - Mucocutaneous Lymph Node Syndrome/complications/*drug therapy
MH  - Treatment Outcome
PMC - PMC6531010
COIS- The authors have declared that no competing interests exist.
EDAT- 2019/05/23 06:00
MHDA- 2020/02/06 06:00
CRDT- 2019/05/23 06:00
PHST- 2018/08/15 00:00 [received]
PHST- 2019/05/09 00:00 [accepted]
PHST- 2019/05/23 06:00 [entrez]
PHST- 2019/05/23 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
AID - PONE-D-18-23975 [pii]
AID - 10.1371/journal.pone.0217274 [doi]
PST - epublish
SO  - PLoS One. 2019 May 22;14(5):e0217274. doi: 10.1371/journal.pone.0217274. 
      eCollection 2019.

PMID- 32464321
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 1878-5921 (Electronic)
IS  - 0895-4356 (Linking)
VI  - 125
DP  - 2020 Sep
TI  - Counterfactual clinical prediction models could help to infer individualized 
      treatment effects in randomized controlled trials-An illustration with the 
      International Stroke Trial.
PG  - 47-56
LID - S0895-4356(20)30044-5 [pii]
LID - 10.1016/j.jclinepi.2020.05.022 [doi]
AB  - OBJECTIVE: Causal treatment effects are estimated at the population level in 
      randomized controlled trials, while clinical decision is often to be made at the 
      individual level in practice. We aim to show how clinical prediction models used 
      under a counterfactual framework may help to infer individualized treatment 
      effects. STUDY DESIGN AND SETTING: As an illustrative example, we reanalyze the 
      International Stroke Trial. This large, multicenter trial enrolled 19,435 adult 
      patients with suspected acute ischemic stroke from 36 countries, and reported a 
      modest average benefit of aspirin (vs. no aspirin) on a composite outcome of 
      death or dependency at 6 months. We derive and validate multivariable logistic 
      regression models that predict the patient counterfactual risks of outcome with 
      and without aspirin, conditionally on 23 predictors. RESULTS: The counterfactual 
      prediction models display good performance in terms of calibration and 
      discrimination (validation c-statistics: 0.798 and 0.794). Comparing the 
      counterfactual predicted risks on an absolute difference scale, we show that 
      aspirin-despite an average benefit-may increase the risk of death or dependency 
      at 6 months (compared with the control) in a quarter of stroke patients. 
      CONCLUSIONS: Counterfactual prediction models could help researchers and 
      clinicians (i) infer individualized treatment effects and (ii) better target 
      patients who may benefit from treatments.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Nguyen, Tri-Long
AU  - Nguyen TL
AD  - Section of Epidemiology, Department of Public Health, Faculty of Health and 
      Medical Sciences, University of Copenhagen, Copenhagen K, Denmark; Centre for 
      Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and 
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Windmill 
      Road, Oxford, UK; Laboratory of Biostatistics, Epidemiology, Clinical Research 
      and Health Economics, EA2415, Montpellier University, Montpellier, France; 
      Departments of Anesthesia & Health Research Methods, Evidence, and Impact, 
      Michael DeGroote School of Medicine, Faculty of Health Sciences, McMaster 
      University and the Perioperative Research Group, Population Health Research 
      Institute, Hamilton, Canada; Department of Pharmacy, Nîmes University Hospital, 
      University of Montpellier, Nîmes, France. Electronic address: long@sund.ku.dk.
FAU - Collins, Gary S
AU  - Collins GS
AD  - Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, 
      Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of 
      Oxford, Windmill Road, Oxford, UK; NIHR Oxford Biomedical Research Centre, John 
      Radcliffe Hospital, Oxford, UK.
FAU - Landais, Paul
AU  - Landais P
AD  - Laboratory of Biostatistics, Epidemiology, Clinical Research and Health 
      Economics, EA2415, Montpellier University, Montpellier, France.
FAU - Le Manach, Yannick
AU  - Le Manach Y
AD  - Departments of Anesthesia & Health Research Methods, Evidence, and Impact, 
      Michael DeGroote School of Medicine, Faculty of Health Sciences, McMaster 
      University and the Perioperative Research Group, Population Health Research 
      Institute, Hamilton, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200525
PL  - United States
TA  - J Clin Epidemiol
JT  - Journal of clinical epidemiology
JID - 8801383
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - *Clinical Decision Rules
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Ischemic Stroke/*drug therapy
MH  - Logistic Models
MH  - Male
MH  - Models, Theoretical
MH  - Multicenter Studies as Topic
MH  - Precision Medicine
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Causal inference
OT  - Clinical prediction models
OT  - Counterfactual framework
OT  - Heterogeneity of treatment effect
OT  - Randomized controlled trial
EDAT- 2020/05/29 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/01/17 00:00 [received]
PHST- 2020/04/17 00:00 [revised]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - S0895-4356(20)30044-5 [pii]
AID - 10.1016/j.jclinepi.2020.05.022 [doi]
PST - ppublish
SO  - J Clin Epidemiol. 2020 Sep;125:47-56. doi: 10.1016/j.jclinepi.2020.05.022. Epub 
      2020 May 25.

PMID- 35809217
OWN - NLM
STAT- MEDLINE
DCOM- 20230629
LR  - 20230630
IS  - 1868-601X (Electronic)
IS  - 1868-4483 (Linking)
VI  - 14
IP  - 4
DP  - 2023 Aug
TI  - Aspirin and Subarachnoid Haemorrhage in the UK Biobank.
PG  - 490-498
LID - 10.1007/s12975-022-01060-1 [doi]
AB  - Previous studies investigating the relationship between aspirin use and 
      subarachnoid haemorrhage (SAH) have yielded conflicting results. In this study, 
      we aimed to clarify the association between aspirin and SAH in the general 
      population. The UK Biobank is a prospective population-based cohort study. Sex, 
      age, smoking, alcohol, medication use, hypertension, blood pressure, ischaemic 
      heart disease and stroke were recorded at baseline assessments. Follow-up is 
      conducted through linkages to National Health Service data including electronic, 
      coded death certificate, hospital and primary care data. Cox proportional hazards 
      modelling was used to analyse the association between aspirin use and SAH. Of the 
      501,060 participants included in the analysis, a total of 579 suffered from 
      spontaneous SAH after their baseline assessment. There was no relationship 
      between aspirin and SAH of all causes (HR, 1.16 [0.92-1.46]), aneurysmal SAH (HR, 
      1.15 [0.91-1.47]) or non-aneurysmal SAH (HR, 1.29 [0.54-3.09]). Aspirin use was 
      associated with SAH resulting in death (HR, 1.69 [1.14-2.51]), especially out of 
      hospital death (HR, 2.10 [1.13-3.91]). Despite reports of a protective 
      association between aspirin and SAH in patients with known unruptured aneurysms, 
      this study has not demonstrated the same effect in the general population. 
      However, aspirin users were more likely to suffer SAH resulting in death, 
      especially out of hospital.
CI  - © 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Ewbank, Frederick
AU  - Ewbank F
AD  - Department of Neurosurgery, University Hospital Southampton NHS Foundation Trust, 
      Southampton, UK. f.ewbank@nhs.net.
FAU - Birks, Jacqueline
AU  - Birks J
AD  - Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
FAU - Gaastra, Benjamin
AU  - Gaastra B
AD  - Department of Neurosurgery, University Hospital Southampton NHS Foundation Trust, 
      Southampton, UK.
AD  - Faculty of Medicine, University of Southampton, Southampton, UK.
FAU - Hall, Samuel
AU  - Hall S
AD  - Department of Neurosurgery, University Hospital Southampton NHS Foundation Trust, 
      Southampton, UK.
FAU - Galea, Ian
AU  - Galea I
AD  - Faculty of Medicine, University of Southampton, Southampton, UK.
FAU - Bulters, Diederik
AU  - Bulters D
AD  - Department of Neurosurgery, University Hospital Southampton NHS Foundation Trust, 
      Southampton, UK.
AD  - Faculty of Medicine, University of Southampton, Southampton, UK.
LA  - eng
GR  - MC_PC_17228/MRC_/Medical Research Council/United Kingdom
GR  - MC_QA137853/MRC_/Medical Research Council/United Kingdom
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220709
PL  - United States
TA  - Transl Stroke Res
JT  - Translational stroke research
JID - 101517297
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Subarachnoid Hemorrhage/complications
MH  - Aspirin/adverse effects
MH  - Cohort Studies
MH  - Prospective Studies
MH  - Biological Specimen Banks
MH  - State Medicine
MH  - United Kingdom/epidemiology
MH  - Risk Factors
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - Aspirin
OT  - Stroke
OT  - Stroke prevalence
OT  - Stroke subtypes
OT  - Subarachnoid haemorrhage
EDAT- 2022/07/10 06:00
MHDA- 2023/06/29 06:43
CRDT- 2022/07/09 11:18
PHST- 2022/06/08 00:00 [received]
PHST- 2022/06/26 00:00 [accepted]
PHST- 2023/06/29 06:43 [medline]
PHST- 2022/07/10 06:00 [pubmed]
PHST- 2022/07/09 11:18 [entrez]
AID - 10.1007/s12975-022-01060-1 [pii]
AID - 10.1007/s12975-022-01060-1 [doi]
PST - ppublish
SO  - Transl Stroke Res. 2023 Aug;14(4):490-498. doi: 10.1007/s12975-022-01060-1. Epub 
      2022 Jul 9.

PMID- 27440714
OWN - NLM
STAT- MEDLINE
DCOM- 20180409
LR  - 20190318
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 116
IP  - 5
DP  - 2016 Oct 28
TI  - Patient-independent variables affecting the assessment of aspirin responsiveness 
      by serum thromboxane measurement.
PG  - 891-896
AB  - The serum TXB(2) (sTXB(2)) assay reflects the pharmacodynamics of platelet 
      inhibition by low-dose aspirin. However, different studies reported variable 
      sTXB(2) values. sTXB(2) assay requires whole blood incubation at 37 °C as a 
      condition for optimal thrombin generation, arachidonic acid release and its 
      metabolism by platelet cyclooxygenase-1 to form TXA(2). Access to 37 °C 
      incubation may be variably delayed, and different methods to quantitate sTXB(2) 
      may contribute to variable results between different Centers. We investigated 
      whether delaying 37 °C incubation and/or analytical issues affect sTXB(2) 
      concentrations, biasing the assessment of aspirin responsiveness. Sixty-eight 
      samples from 54 volunteers, on- and off-aspirin, were incubated at 37 °C 
      immediately after sampling (reference sample) or after 5, 10, 15, 20, 30 or 60 
      minutes at room temperature (RT); 8 samples remained at RT 60 minutes, without 
      subsequent incubation; 314 sera were measured by enzyme immunoassay (EIA) and 
      liquid chromatography-tandem mass-spectrometry (LC/MS-MS) methods. sTXB(2) 
      concentrations decreased exponentially as a function of the delay before 37 °C 
      incubation, ranging from 94 ± 11 % at 5 minutes to 23 ± 22 % of the reference 
      sample after 60 minutes at RT. There was high agreement between EIA and LC/MS-MS. 
      Moreover, we simulated the influence of a 15- or 30-minute delayed incubation on 
      300 sTXB2 measurements from previously-studied, aspirin-treated patients. Delayed 
      incubation reduced the percentage of aspirin 'non-responders' by 22 % to 52 %, 
      depending on the response threshold. In conclusion, a variable delay in the 37 °C 
      incubation of blood samples may affect the assessment of platelet 
      cyclooxygenase-1 inhibition by aspirin and confound the characterization of the 
      determinants of aspirin responsiveness.
FAU - Petrucci, Giovanna
AU  - Petrucci G
FAU - Rizzi, Alessandro
AU  - Rizzi A
FAU - Cavalca, Viviana
AU  - Cavalca V
FAU - Habib, Aida
AU  - Habib A
FAU - Pitocco, Dario
AU  - Pitocco D
FAU - Veglia, Fabrizio
AU  - Veglia F
FAU - Ranalli, Paola
AU  - Ranalli P
FAU - Zaccardi, Francesco
AU  - Zaccardi F
FAU - Pagliaccia, Francesca
AU  - Pagliaccia F
FAU - Tremoli, Elena
AU  - Tremoli E
FAU - Patrono, Carlo
AU  - Patrono C
FAU - Rocca, Bianca
AU  - Rocca B
AD  - Bianca Rocca, MD, PhD, Istituto di Farmacologia, Università Cattolica, Largo F. 
      Vito 1, 00168 Rome, Italy, Tel.: +39 06 30154253, E-mail: b.rocca@tiscali.it; 
      bianca.rocca@unicatt.it.
LA  - eng
PT  - Journal Article
DEP - 20160721
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Thromboxane B2/*blood
OTO - NOTNLM
OT  - *Thromboxane B2
OT  - *aspirin
OT  - *cyclooxygenase-1
OT  - *enzyme immunoassay
OT  - *liquid chromatography-tandem mass spectrometry
EDAT- 2016/10/30 06:00
MHDA- 2018/04/10 06:00
CRDT- 2016/07/22 06:00
PHST- 2016/05/06 00:00 [received]
PHST- 2016/06/15 00:00 [accepted]
PHST- 2016/10/30 06:00 [pubmed]
PHST- 2018/04/10 06:00 [medline]
PHST- 2016/07/22 06:00 [entrez]
AID - 16-05-0349 [pii]
AID - 10.1160/TH16-05-0349 [doi]
PST - ppublish
SO  - Thromb Haemost. 2016 Oct 28;116(5):891-896. doi: 10.1160/TH16-05-0349. Epub 2016 
      Jul 21.

PMID- 33524286
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 174
IP  - 2
DP  - 2021 Feb
TI  - After TAVI, aspirin vs. aspirin + clopidogrel for 3 mo reduced bleeding and a 
      composite of bleeding and thrombotic events at 1 y.
PG  - JC21
LID - 10.7326/ACPJ202102160-021 [doi]
AB  - Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel 
      after transcatheter aortic-valve implantation. N Engl J Med. 2020;383:1447-57. 
      32865376.
FAU - Moreno, Raúl
AU  - Moreno R
AD  - Hospital La Paz, IdiPAZ, CIBER-CV, Madrid, Spain (R.M.).
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20210202
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - N Engl J Med. 2020 Oct 8;383(15):1447-1457. PMID: 32865376
MH  - *Aspirin/adverse effects
MH  - Clopidogrel/adverse effects
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - *Transcatheter Aortic Valve Replacement/adverse effects
EDAT- 2021/02/02 06:00
MHDA- 2021/02/24 06:00
CRDT- 2021/02/01 20:10
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
PHST- 2021/02/01 20:10 [entrez]
AID - 10.7326/ACPJ202102160-021 [doi]
PST - ppublish
SO  - Ann Intern Med. 2021 Feb;174(2):JC21. doi: 10.7326/ACPJ202102160-021. Epub 2021 
      Feb 2.

PMID- 23518029
OWN - NLM
STAT- MEDLINE
DCOM- 20140102
LR  - 20140214
IS  - 1472-6491 (Electronic)
IS  - 1472-6483 (Linking)
VI  - 26
IP  - 6
DP  - 2013 Jun
TI  - Aspirin and heparin as adjuvants during IVF do not improve live birth rates in 
      unexplained implantation failure.
PG  - 586-94
LID - S1472-6483(13)00071-0 [pii]
LID - 10.1016/j.rbmo.2013.02.007 [doi]
AB  - This study tested the hypothesis that using aspirin and/or heparin as adjuvants 
      in IVF improves the treatment outcome. This retrospective cohort-control study 
      recruited 234 consecutive subjects aged ≤ 44 years who had previously had one or 
      more unsuccessful IVF cycle. All underwent IVF using conventional protocols. The 
      study group received aspirin and/or heparin post embryo transfer until the day of 
      pregnancy test or until 12 weeks of pregnancy. The control group did not receive 
      adjuvant treatment. The outcome measures were live birth, clinical pregnancy and 
      miscarriage rates. The outcomes were compared by chi-squared test and 
      relative-risk analysis. Analysis was performed in 206 subjects. There was no 
      statistically significant difference in the live birth rate (35.0%, 36/103 versus 
      47.6%, 49/103), clinical pregnancy rate (40.8%, 42/103 versus 53.4%, 55/103) and 
      miscarriage rate (14.3%, 6/42 versus 10.9%, 6/55) between the study group and the 
      control group. The data in this study show that low-dose aspirin and/or heparin 
      as adjuvant therapies during IVF do not improve live birth rates in an unselected 
      group of subfertile women who have previously had one or more unexplained 
      implantation failure following IVF.
CI  - Copyright © 2013 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Akhtar, Muhammad A
AU  - Akhtar MA
AD  - Nottingham University Research and Treatment Unit in Reproduction (NURTURE), 
      Division of Obstetrics and Gynaecology, School of Clinical Sciences, University 
      of Nottingham, Nottingham, Nottinghamshire NG7 2UH, United Kingdom.
FAU - Eljabu, Hanan
AU  - Eljabu H
FAU - Hopkisson, James
AU  - Hopkisson J
FAU - Raine-Fenning, Nick
AU  - Raine-Fenning N
FAU - Quenby, Siobhan
AU  - Quenby S
FAU - Jayaprakasan, Kannamannadiar
AU  - Jayaprakasan K
LA  - eng
PT  - Journal Article
DEP - 20130218
PL  - Netherlands
TA  - Reprod Biomed Online
JT  - Reproductive biomedicine online
JID - 101122473
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Reprod Biomed Online. 2013 Jun;26(6):538-41. PMID: 23602681
CIN - Reprod Biomed Online. 2014 Jan;28(1):133. PMID: 24125945
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - *Birth Rate
MH  - *Embryo Implantation
MH  - Female
MH  - *Fertilization in Vitro
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Infant, Newborn
MH  - Infertility, Female
MH  - Infertility, Male
MH  - Male
MH  - Pregnancy
MH  - Retrospective Studies
EDAT- 2013/03/23 06:00
MHDA- 2014/01/03 06:00
CRDT- 2013/03/23 06:00
PHST- 2012/10/11 00:00 [received]
PHST- 2013/02/06 00:00 [revised]
PHST- 2013/02/07 00:00 [accepted]
PHST- 2013/03/23 06:00 [entrez]
PHST- 2013/03/23 06:00 [pubmed]
PHST- 2014/01/03 06:00 [medline]
AID - S1472-6483(13)00071-0 [pii]
AID - 10.1016/j.rbmo.2013.02.007 [doi]
PST - ppublish
SO  - Reprod Biomed Online. 2013 Jun;26(6):586-94. doi: 10.1016/j.rbmo.2013.02.007. 
      Epub 2013 Feb 18.

PMID- 20578780
OWN - NLM
STAT- MEDLINE
DCOM- 20100930
LR  - 20181201
IS  - 1175-5652 (Print)
IS  - 1175-5652 (Linking)
VI  - 8
IP  - 4
DP  - 2010
TI  - Costs and consequences of clopidogrel versus aspirin for secondary prevention of 
      ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime 
      model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
PG  - 251-65
LID - 10.2165/11535520-000000000-00000 [doi]
AB  - BACKGROUND: Antiplatelet therapy plays a central role in the prevention of 
      atherothrombotic events. Both acetylsalicylic acid (aspirin) and clopidogrel have 
      been shown to reduce the risk of recurrent cardiovascular events in various 
      subgroups of patients with vascular disease. OBJECTIVE: To estimate the cost 
      effectiveness of clopidogrel versus aspirin in Sweden for the prevention of 
      atherothrombotic events based on CAPRIE trial data. The focus of this study is on 
      two high-risk subpopulations: (i) patients with pre-existing symptomatic 
      atherosclerotic disease; and (ii) patients with polyvascular disease. METHODS: A 
      Markov model combining clinical, epidemiological and cost data was used to assess 
      the economic value of clopidogrel compared with aspirin during a patient's 
      lifetime. A societal perspective was used, with costs stated in Swedish kronor 
      (SEK), year 2007 values. For the first 2 years, the clinical input for the model 
      was based on the relevant subpopulations in the CAPRIE trial. Thereafter, 
      transition probabilities were extrapolated, taking account of increased risks 
      related to age and to a history of events. Cost effectiveness of 2 years of 
      therapy is presented as cost per life-year gained (LYG) and as cost per QALY. 
      Univariate and multivariate sensitivity analyses were performed to investigate 
      robustness of results. RESULTS: For patients resembling the total CAPRIE 
      population, who were treated with clopidogrel, the expected cost per LYG was 
      SEK217,806 and the cost per QALY was estimated at SEK169,154. For the high-risk 
      CAPRIE subpopulations, costs per QALY were lowest for patients with pre-existing 
      symptomatic atherosclerotic disease (SEK38,153). Using a 'willingness-to-pay' 
      perspective indicated that treatment with clopidogrel instead of aspirin in 
      high-risk patients is associated with a high probability for cost effectiveness; 
      81% using a threshold of SEK100,000 per QALY and 98% using a threshold of 
      SEK500,000 per QALY. Overall, the results appeared to be robust over the 
      sensitivity analyses performed. CONCLUSION: When considering the 
      cost-effectiveness categorization as proposed by the Swedish National Board of 
      Health and Welfare, clopidogrel appears to be associated with costs per QALY that 
      range from intermediate in the total CAPRIE population to low in high-risk 
      atherosclerotic patients.
FAU - Logman, J Floris S
AU  - Logman JF
AD  - Pharmerit Europe BV, Rotterdam, The Netherlands. info@pharmerit.com
FAU - Heeg, Bart M S
AU  - Heeg BM
FAU - Herlitz, Johan
AU  - Herlitz J
FAU - van Hout, Ben A
AU  - van Hout BA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Appl Health Econ Health Policy
JT  - Applied health economics and health policy
JID - 101150314
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*economics/therapeutic use
MH  - Atherosclerosis/*drug therapy
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Myocardial Infarction/*economics/*prevention & control
MH  - Platelet Aggregation Inhibitors/*economics/therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Secondary Prevention/*economics
MH  - Sweden
MH  - Ticlopidine/*analogs & derivatives/economics/therapeutic use
EDAT- 2010/06/29 06:00
MHDA- 2010/10/01 06:00
CRDT- 2010/06/29 06:00
PHST- 2010/06/29 06:00 [entrez]
PHST- 2010/06/29 06:00 [pubmed]
PHST- 2010/10/01 06:00 [medline]
AID - 4 [pii]
AID - 10.2165/11535520-000000000-00000 [doi]
PST - ppublish
SO  - Appl Health Econ Health Policy. 2010;8(4):251-65. doi: 
      10.2165/11535520-000000000-00000.

PMID- 8902784
OWN - NLM
STAT- MEDLINE
DCOM- 19970212
LR  - 20170214
IS  - 0961-2033 (Print)
IS  - 0961-2033 (Linking)
VI  - 5
IP  - 5
DP  - 1996 Oct
TI  - Prevention of fetal death in the antiphospholipid antibody syndrome.
PG  - 467-72
AB  - The first treatment of pregnant women with antiphospholipid antibody syndrome 
      (APLS) employed high doses of corticosteroids, plus low dose aspirin, with the 
      goal of suppressing production of the autoantibody. Corticosteroids (usually 
      prednisone), even when much lower doses are used, and even when tapered after 
      midpregnancy, have been associated with significant maternal and obstetric risks 
      and side effects: the most important are osteomalacia and preterm delivery (often 
      precipitated by premature rupture of the membranes). Since the publication of a 
      randomized trial demonstrating equivalent live birth rates of about 75% whether 
      heparin or prednisone was used for treatment (plus low dose aspirin), the use of 
      adjusted doses of heparin, together with low dose aspirin, has replaced 
      prednisone for treatment of pregnant women; although prednisone may still be 
      needed to treat manifestations of associated autoimmune disorders. A recent 
      randomized trial has shown that the addition of heparin to aspirin is probably 
      superior to treatment with aspirin alone. To achieve prophylactic levels of 
      plasma heparin equivalent to those measured in patients who are not pregnant and 
      are treated with the usual dose of standard heparin of 5000 IU every 12 h, the 
      heparin dose required for treatment of pregnant women is usually higher. For that 
      reason, heparin doses should be adjusted using the nadir APTT, or better plasma 
      heparin measured by a factor Xa inhibition assay at the 2 h post-injection peak. 
      Although low molecular weight heparin has been shown to be useful in prevention 
      of fetal resorption in a mouse model, and appears to be equally safe for 
      treatment of pregnant women, we still have no published data to show therapeutic 
      equivalency, with respect to treatment of APLS-complicated pregnancy, to standard 
      heparin preparations, and none that demonstrate any lower risk for the 
      complication of most concern when heparin is given to pregnant women-osteopenia. 
      Similarly, intravenous infusion of gamma globulins (IVG) appears on the basis of 
      case reports to be effective additional treatment in cases where standard therapy 
      has failed. Gamma globulin preparations contain anti-idiotypic antibodies that 
      have been shown to bind to patient antiphospholipid antibodies. The place for the 
      addition of IVG to standard therapy has not been defined, but clinically 
      significant and corticosteroid-resistant thrombocytopenia complicating 
      antiphospholipid antibody syndrome might be one indication for primary treatment 
      with IVG +/- low dose aspirin. Overall, live birth rates in most treatment 
      studies are in the range of 70-80%. The reported birth rate information, however, 
      cannot be compared between studies. None of the studies reported have used tools 
      such as logistic regression analysis to allow for such significant predictors of 
      live birth as the number of prior miscarriages, maternal age, medical history, or 
      a history of fetal death (loss of a viable and chromosomally normal fetus after 
      the 10th gestational week).
FAU - Cowchock, S
AU  - Cowchock S
AD  - Jefferson Medical College, Phila., PA 19107, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Animals
MH  - Antiphospholipid Syndrome/complications/*therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Fetal Death/*prevention & control
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Mice
MH  - Pregnancy
RF  - 59
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - 10.1177/096120339600500528 [doi]
PST - ppublish
SO  - Lupus. 1996 Oct;5(5):467-72. doi: 10.1177/096120339600500528.

PMID- 9360028
OWN - NLM
STAT- MEDLINE
DCOM- 19980106
LR  - 20191024
IS  - 0742-0528 (Print)
IS  - 0742-0528 (Linking)
VI  - 14
IP  - 6
DP  - 1997 Nov
TI  - Influence of aspirin usage on blood pressure: dose and administration-time 
      dependencies.
PG  - 619-37
AB  - This study investigates the possible effects of acetylsalicylic acid (ASA; 
      aspirin) on systolic (S) and diastolic (D) blood pressure (BP) in healthy and 
      mildly hypertensive subjects receiving ASA at different times according to their 
      rest-activity cycle. A double-blind, randomized, controlled trial was conducted 
      in 73 healthy young adult volunteers and 18 previously untreated subjects with 
      mild hypertension. The BP of each subject was automatically monitored every 30 
      minutes for 48h before the trial and at the end of a one-week course of placebo 
      and a one-week course of ASA. Healthy volunteers were randomly assigned to one of 
      six groups, defined according to the dose of ASA (either 500 mg/day, the usual 
      commercial dose; or 100 mg/day) and timing of ASA and placebo (within 2h after 
      awakening, Time 1; 7h to 9h after awakening, Time 2; or within 2h of bedtime, 
      Time 3). Subjects with mild hypertension received the low dose of 100 mg/day ASA, 
      as well as one week of placebo, and were randomly assigned to one of the same 
      three groups defined above according to the time of treatment. A small 
      (approximately 2 mmHg in the 24h mean of SBP), but statistically significant, BP 
      reduction was found when 500 mg/day ASA was given to healthy volunteers at Time 
      2. With 100 mg/day, the effect of ASA in healthy subjects was comparable to the 
      BP reduction found with the higher dose for Time 2; there was again no effect on 
      BP at Time 1, but we found a statistically significant effect at Time 3 (2.3 mmHg 
      reduction in the 24h mean of SBP), larger than for Time 2. For hypertensive 
      patients, the BP reduction was again statistically significant for Time 2 and, to 
      a greater extent, for Time 3 (approximately 4.5 mmHg for both SBP and DBP); all 
      patients in these two groups showed a BP reduction after one week of ASA. The 
      effect was about three times as large as the BP reduction obtained in healthy 
      subjects treated with 100 mg/day ASA. Results indicate a statistically 
      significant time- and dose-dependent effect of ASA on BP. In any meta-analysis of 
      ASA effects, inquiries about the time when subjects took the drug are indicated 
      and may account for discrepancies in the literature. Moreover, the influence of 
      ASA on BP demonstrated here indicates the need to identify and control for ASA 
      effects in patients using ASA before and during their participation in 
      antihypertension medication trials.
FAU - Hermida, R C
AU  - Hermida RC
AD  - Bioengineering and Chronobiology Laboratories, ETSI Telecomunicación, Universidad 
      de Vigo, Campus Universitario, Spain. rhermida@tsc.uvigo.es
FAU - Fernández, J R
AU  - Fernández JR
FAU - Ayala, D E
AU  - Ayala DE
FAU - Mojón, A
AU  - Mojón A
FAU - Iglesias, M
AU  - Iglesias M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Chronobiol Int
JT  - Chronobiology international
JID - 8501362
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Blood Pressure/*drug effects
MH  - Circadian Rhythm
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy/physiopathology
MH  - Male
EDAT- 1997/11/14 00:00
MHDA- 1997/11/14 00:01
CRDT- 1997/11/14 00:00
PHST- 1997/11/14 00:00 [pubmed]
PHST- 1997/11/14 00:01 [medline]
PHST- 1997/11/14 00:00 [entrez]
AID - 10.3109/07420529709001452 [doi]
PST - ppublish
SO  - Chronobiol Int. 1997 Nov;14(6):619-37. doi: 10.3109/07420529709001452.

PMID- 19260592
OWN - NLM
STAT- MEDLINE
DCOM- 20090330
LR  - 20131121
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 147
IP  - 12
DP  - 2008 Dec
TI  - [Factors that influence the implementation of the guidelines for aspirin use by 
      diabetic patients in Israel].
PG  - 971-4, 1030
AB  - BACKGROUND: Aspirin use by diabetic patients, both as secondary and tertiary 
      prevention, significantly reduces cardiovascular events. The Israeli Diabetes 
      Association guidelines, published in 2005, recommend that all diabetic patients, 
      at increased risk for cardiovascular events, take aspirin. AIMS: The aim of this 
      study was to identify factors which influence the implementation of the 
      guidelines for aspirin use by diabetic patients in Israel. METHODS: The medical 
      records of 100 diabetic patients were reviewed in a cross sectional study 
      conducted among patients of 4 family practitioners in a primary care clinic in 
      Tel Aviv. Statistical analyses were performed to identify the relation between 
      aspirin use, and medical and personal data of the diabetic patients. RESULTS: 
      Among 100 diabetic patients, sixty one (61%) were prescribed aspirin. 
      Prescription rate among men (60%) and women (62%) was similar. Patients who were 
      not prescribed aspirin were younger on average (p < 0.02). Prescription of 
      aspirin was more common as tertiary rather than secondary prevention, i.e. among 
      patients who already showed signs of cardiovascular disease (p < 0.003). The 
      prescription rates for aspirin were lower than for statins and ACE-inhibitors. 
      CONCLUSIONS: Aspirin use among diabetic patients in Tel Aviv is relatively high 
      and similar to that in other western countries. However, the relatively lower use 
      of aspirin for secondary prevention, especially among younger patients, deserves 
      attention.
FAU - Azuz, Niva
AU  - Azuz N
AD  - Department of Family Medicine, Rabin Medical Center, Beilinson Hospital, Petach 
      Tikva, Israel.
FAU - Thomas, Kathy
AU  - Thomas K
FAU - Yaffe, Yonah
AU  - Yaffe Y
FAU - Katz, Michal
AU  - Katz M
FAU - Weingarten, Michael
AU  - Weingarten M
FAU - Matalon, Andre
AU  - Matalon A
LA  - heb
PT  - English Abstract
PT  - Journal Article
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Diabetes Complications/*prevention & control
MH  - Diabetes Mellitus/*drug therapy
MH  - Diabetic Angiopathies/drug therapy/*prevention & control
MH  - Female
MH  - Guidelines as Topic
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Physicians, Family
EDAT- 2009/03/06 09:00
MHDA- 2009/03/31 09:00
CRDT- 2009/03/06 09:00
PHST- 2009/03/06 09:00 [entrez]
PHST- 2009/03/06 09:00 [pubmed]
PHST- 2009/03/31 09:00 [medline]
PST - ppublish
SO  - Harefuah. 2008 Dec;147(12):971-4, 1030.

PMID- 35015330
OWN - NLM
STAT- MEDLINE
DCOM- 20220621
LR  - 20230510
IS  - 1471-0528 (Electronic)
IS  - 1470-0328 (Linking)
VI  - 129
IP  - 8
DP  - 2022 Jul
TI  - Serum PlGF compared with PAPP-A in first trimester screening for preterm 
      pre-eclampsia: Adjusting for the effect of aspirin treatment.
PG  - 1308-1317
LID - 10.1111/1471-0528.17096 [doi]
AB  - OBJECTIVE: To compare the predictive performance for preterm-pre-eclampsia (PE) 
      in first-trimester screening by serum placental growth factor (PlGF) versus 
      pregnancy associated plasma protein-A (PAPP-A), in combination with maternal risk 
      factors, mean arterial pressure (MAP) and uterine artery pulsatility index 
      (UtA-PI), after adjustment for the effect of aspirin in women receiving this 
      treatment. DESIGN: Non-intervention multicentre screening studies for PE in 
      singleton pregnancies. SETTING: Maternity hospitals. POPULATION: Two independent 
      prospective studies of 8775 and 16 451 women with singleton pregnancies attending 
      for routine assessment at 11(+0) -13(+6) weeks' gestation. METHODS: The competing 
      risks model was used to estimate patient-specific risks of delivery with PE at 
      <37 weeks' gestation based on maternal risk factors and combinations with MAP, 
      UtA-PI and either PlGF or PAPP-A. McNemar's test was used to compare the 
      detection rate (DR) of preterm-PE of screening utilising PlGF versus PAPP-A, 
      after adjustments for the effects of aspirin. MAIN OUTCOME MEASURE: Predictive 
      performance for preterm-PE. RESULTS: In the combined data of 25 226 women, 
      including 678 (2.7%) who developed PE, there were 194(0.8%) with preterm-PE. 
      Addition of PlGF improved the DR of preterm-PE, at 10% screen positive rate, by 
      18.4% (95% CI 12.2-24.6) in screening by maternal risk factors, by 19.9% (95% CI 
      13.6-26.2) in screening by maternal factors and MAP, and by 7.0% (95% CI 
      2.3-11.6) in screening by maternal factors, MAP and UtA-PI. PAPP-A did not 
      significantly improve the DR provided by any combination of biomarkers. 
      CONCLUSION: The predictive performance of first trimester PlGF for preterm-PE is 
      superior to that of PAPP-A.
CI  - © 2022 John Wiley & Sons Ltd.
FAU - Wright, David
AU  - Wright D
AD  - Institute of Health Research, University of Exeter, Exeter, UK.
FAU - Tan, Min Yi
AU  - Tan MY
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, 
      London, UK.
FAU - O'Gorman, Neil
AU  - O'Gorman N
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, 
      London, UK.
FAU - Syngelaki, Argyro
AU  - Syngelaki A
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, 
      London, UK.
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, 
      London, UK.
LA  - eng
GR  - Fetal Medicine Foundation/
GR  - 14/01/02/National Institute for Health Research Efficacy and Mechanism Evaluation 
      (NIHR EME) Programme/
GR  - FP7-HEALTH-2013-INNOVATION-2/European Union Seventh Framework Program/
PT  - Comparative Study
PT  - Journal Article
DEP - 20220213
PL  - England
TA  - BJOG
JT  - BJOG : an international journal of obstetrics and gynaecology
JID - 100935741
RN  - 0 (Biomarkers)
RN  - 144589-93-5 (Placenta Growth Factor)
RN  - EC 3.4.24.- (Pregnancy-Associated Plasma Protein-A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BJOG. 2022 Jul;129(8):1318. PMID: 35025143
CIN - BJOG. 2023 Jun;130(7):838. PMID: 35446469
MH  - Aspirin/therapeutic use
MH  - Biomarkers
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Placenta Growth Factor
MH  - *Pre-Eclampsia/diagnosis/prevention & control
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Pregnancy-Associated Plasma Protein-A
MH  - Prospective Studies
MH  - Pulsatile Flow
MH  - Uterine Artery/diagnostic imaging
OTO - NOTNLM
OT  - ASPRE
OT  - SPREE
OT  - aspirin
OT  - competing risk model
OT  - first trimester screening
OT  - mean arterial pressure
OT  - placental growth factor
OT  - pre-eclampsia
OT  - pregnancy associated plasma protein-a
OT  - pyramid of pregnancy care
OT  - uterine artery Doppler
EDAT- 2022/01/12 06:00
MHDA- 2022/06/22 06:00
CRDT- 2022/01/11 12:38
PHST- 2021/12/15 00:00 [revised]
PHST- 2021/11/16 00:00 [received]
PHST- 2021/12/22 00:00 [accepted]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/06/22 06:00 [medline]
PHST- 2022/01/11 12:38 [entrez]
AID - 10.1111/1471-0528.17096 [doi]
PST - ppublish
SO  - BJOG. 2022 Jul;129(8):1308-1317. doi: 10.1111/1471-0528.17096. Epub 2022 Feb 13.

PMID- 17696569
OWN - NLM
STAT- MEDLINE
DCOM- 20071102
LR  - 20181201
IS  - 1175-3277 (Print)
IS  - 1175-3277 (Linking)
VI  - 7
IP  - 4
DP  - 2007
TI  - Incremental effect of clopidogrel on important outcomes in patients with 
      cardiovascular disease: a meta-analysis of randomized trials.
PG  - 289-97
AB  - OBJECTIVES: To quantify the impact of clopidogrel plus aspirin on the individual 
      outcomes of death, myocardial infarction, or stroke in patients with established 
      cardiovascular disease, or in patients with multiple risk factors for vascular 
      disease. BACKGROUND: Randomized trials have demonstrated a reduction in composite 
      outcomes when clopidogrel is added to aspirin therapy in patients with coronary 
      artery disease; however, the magnitude of benefit on individual outcomes is 
      unknown. METHODS: We conducted a meta-analysis on randomized, controlled trials 
      that compared aspirin plus clopidogrel with aspirin plus placebo for the 
      treatment of coronary artery disease. RESULTS: This analysis included five 
      randomized trials (CURE, CREDO, CLARITY, COMMIT, and CHARISMA) in 79 624 
      patients. The incidence of all-cause mortality was 6.3% in the aspirin plus 
      clopidogrel group versus 6.7% in the aspirin group (odds ratio [OR] 0.94; 95% CI 
      0.89, 0.99; p = 0.026). The incidence of myocardial infarction was 2.7% and 3.3% 
      (OR 0.82; 95% CI 0.75, 0.89; p < 0.0001), and stroke was 1.2% and 1.4% (OR 0.82; 
      95% CI 0.73, 0.93; p = 0.002). Similarly, the incidence of major bleeding was 
      1.6% and 1.3% (OR 1.26; 95% CI 1.11, 1.41; p < 0.0001), and fatal bleeding was 
      0.28% and 0.27% (OR 1.04; 95% CI 0.76, 1.43; p = 0.79). CONCLUSION: The addition 
      of clopidogrel to aspirin results in a small reduction in all-cause mortality in 
      patients with ST-elevation myocardial infarction and a modest reduction in 
      myocardial infarction and stroke in patients with cardiovascular disease. The 
      overall incidence of major bleeding however is increased, although there is no 
      excess of fatal bleeds or hemorrhagic strokes.
FAU - Helton, Thomas J
AU  - Helton TJ
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Bavry, Anthony A
AU  - Bavry AA
FAU - Kumbhani, Dharam J
AU  - Kumbhani DJ
FAU - Duggal, Sandeep
AU  - Duggal S
FAU - Roukoz, Henri
AU  - Roukoz H
FAU - Bhatt, Deepak L
AU  - Bhatt DL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Assessment
MH  - Stroke/prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
EDAT- 2007/08/19 09:00
MHDA- 2007/11/06 09:00
CRDT- 2007/08/19 09:00
PHST- 2007/08/19 09:00 [pubmed]
PHST- 2007/11/06 09:00 [medline]
PHST- 2007/08/19 09:00 [entrez]
AID - 746 [pii]
AID - 10.2165/00129784-200707040-00006 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2007;7(4):289-97. doi: 10.2165/00129784-200707040-00006.

PMID- 28539172
OWN - NLM
STAT- MEDLINE
DCOM- 20171108
LR  - 20181202
IS  - 1873-4111 (Electronic)
IS  - 0378-5122 (Linking)
VI  - 100
DP  - 2017 Jun
TI  - Influence of aspirin and non-aspirin NSAID use on ovarian and endometrial cancer: 
      Summary of epidemiologic evidence of cancer risk and prognosis.
PG  - 1-7
LID - S0378-5122(17)30119-6 [pii]
LID - 10.1016/j.maturitas.2017.03.001 [doi]
AB  - Increasing evidence supports a role for aspirin use in reducing the incidence and 
      mortality of several cancer types. This has spurred a new wave of interest in 
      this widely used drug. In this review, we present and evaluate the epidemiologic 
      evidence of the association between the use of aspirin and other non-steroidal 
      anti-inflammatory drugs (NSAIDs) and the incidence and prognosis of ovarian and 
      endometrial cancer. The evidence of a preventive effect of NSAID use on risk of 
      ovarian or endometrial cancer is based primarily on results from observational 
      studies and, consequently, is only suggestive. Overall, observational studies 
      indicate modest reductions in risk of ovarian and endometrial cancer with aspirin 
      use, whereas the results for non-aspirin NSAID use are equivocal. The strongest 
      inverse associations have been reported for long-term consistent aspirin use, 
      notably among subgroups of users (e.g., those with high body mass index). Few 
      studies have evaluated the influence of NSAID use on the mortality of ovarian or 
      endometrial cancer, and substantial heterogeneity of study characteristics and 
      results preclude any conclusions. Additional studies of aspirin and non-aspirin 
      NSAID use and ovarian or endometrial cancer risk and prognosis are warranted. In 
      the present review, we discuss the importance of comprehensive exposure 
      definitions (i.e., duration, timing, consistency and intensity/dose) and 
      evaluation of potential effect modification according to user characteristics, 
      with the aim of identifying women who may experience the largest benefit of 
      aspirin or non-aspirin NSAID use on risk or prognosis of ovarian and endometrial 
      cancer.
CI  - Copyright © 2017 Elsevier B.V. All rights reserved.
FAU - Verdoodt, F
AU  - Verdoodt F
AD  - Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 
      Copenhagen, Denmark. Electronic address: freija@cancer.dk.
FAU - Kjaer, S K
AU  - Kjaer SK
AD  - Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 
      Copenhagen, Denmark; Department of Gynecology, Rigshospitalet, University of 
      Copenhagen, Copenhagen, Denmark.
FAU - Friis, S
AU  - Friis S
AD  - Unit of Statistics and Pharmacoepidemiology, Danish Cancer Society Research 
      Center, Copenhagen, Denmark; Department of Clinical Epidemiology, Faculty of 
      Health, Aarhus University Hospital, Aarhus, and Department of Public Health, 
      University of Copenhagen, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170307
PL  - Ireland
TA  - Maturitas
JT  - Maturitas
JID - 7807333
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Endometrial Neoplasms/*epidemiology
MH  - Female
MH  - Humans
MH  - Ovarian Neoplasms/*epidemiology
MH  - Prognosis
MH  - Risk
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer prognosis
OT  - Cancer risk
OT  - Endometrial cancer
OT  - Non-steroidal anti-inflammatory drugs
OT  - Ovarian cancer
OT  - Pharmacoepidemiology
EDAT- 2017/05/26 06:00
MHDA- 2017/11/09 06:00
CRDT- 2017/05/26 06:00
PHST- 2017/03/01 00:00 [received]
PHST- 2017/03/06 00:00 [accepted]
PHST- 2017/05/26 06:00 [entrez]
PHST- 2017/05/26 06:00 [pubmed]
PHST- 2017/11/09 06:00 [medline]
AID - S0378-5122(17)30119-6 [pii]
AID - 10.1016/j.maturitas.2017.03.001 [doi]
PST - ppublish
SO  - Maturitas. 2017 Jun;100:1-7. doi: 10.1016/j.maturitas.2017.03.001. Epub 2017 Mar 
      7.

PMID- 24074752
OWN - NLM
STAT- MEDLINE
DCOM- 20140514
LR  - 20220409
IS  - 2046-4924 (Electronic)
IS  - 1366-5278 (Print)
IS  - 1366-5278 (Linking)
VI  - 17
IP  - 43
DP  - 2013 Sep
TI  - Aspirin for prophylactic use in the primary prevention of cardiovascular disease 
      and cancer: a systematic review and overview of reviews.
PG  - 1-253
LID - 10.3310/hta17430 [doi]
AB  - BACKGROUND: Prophylactic aspirin has been considered to be beneficial in reducing 
      the risks of heart disease and cancer. However, potential benefits must be 
      balanced against the possible harm from side effects, such as bleeding and 
      gastrointestinal (GI) symptoms. It is particularly important to know the risk of 
      side effects when aspirin is used as primary prevention--that is when used by 
      people as yet free of, but at risk of developing, cardiovascular disease (CVD) or 
      cancer. In this report we aim to identify and re-analyse randomised controlled 
      trials (RCTs), systematic reviews and meta-analyses to summarise the current 
      scientific evidence with a focus on possible harms of prophylactic aspirin in 
      primary prevention of CVD and cancer. OBJECTIVES: To identify RCTs, systematic 
      reviews and meta-analyses of RCTs of the prophylactic use of aspirin in primary 
      prevention of CVD or cancer. To undertake a quality assessment of identified 
      systematic reviews and meta-analyses using meta-analysis to investigate 
      study-level effects on estimates of benefits and risks of adverse events; 
      cumulative meta-analysis; exploratory multivariable meta-regression; and to 
      quantify relative and absolute risks and benefits. METHODS: We identified RCTs, 
      meta-analyses and systematic reviews, and searched electronic bibliographic 
      databases (from 2008 September 2012) including MEDLINE, Cochrane Central Register 
      of Controlled Trials, Database of Abstracts of Reviews of Effects, NHS Centre for 
      Reviews and Dissemination, and Science Citation Index. We limited searches to 
      publications since 2008, based on timing of the most recent comprehensive 
      systematic reviews. RESULTS: In total, 2572 potentially relevant papers were 
      identified and 27 met the inclusion criteria. Benefits of aspirin ranged from 6% 
      reduction in relative risk (RR) for all-cause mortality [RR 0.94, 95% confidence 
      interval (CI) 0.88 to 1.00] and 10% reduction in major cardiovascular events 
      (MCEs) (RR 0.90, 95% CI 0.85 to 0.96) to a reduction in total coronary heart 
      disease (CHD) of 15% (RR 0.85, 95% CI 0.69 to 1.06). Reported pooled odds ratios 
      (ORs) for total cancer mortality ranged between 0.76 (95% CI 0.66 to 0.88) and 
      0.93 (95% CI 0.84 to 1.03). Inclusion of the Women's Health Study changed the 
      estimated OR to 0.82 (95% CI 0.69 to 0.97). Aspirin reduced reported colorectal 
      cancer (CRC) incidence (OR 0.66, 95% CI 0.90 to 1.02). However, including studies 
      in which aspirin was given every other day raised the OR to 0.91 (95% CI 0.74 to 
      1.11). Reported cancer benefits appeared approximately 5 years from start of 
      treatment. Calculation of absolute effects per 100,000 patient-years of follow-up 
      showed reductions ranging from 33 to 46 deaths (all-cause mortality), 60-84 MCEs 
      and 47-64 incidents of CHD and a possible avoidance of 34 deaths from CRC. 
      Reported increased RRs of adverse events from aspirin use were 37% for GI 
      bleeding (RR 1.37, 95% CI 1.15 to 1.62), between 54% (RR 1.54, 95% CI 1.30 to 
      1.82) and 62% (RR 1.62, 95% CI 1.31 to 2.00) for major bleeds, and between 32% 
      (RR 1.32, 95% CI 1.00 to 1.74) and 38% (RR 1.38, 95% CI 1.01 to 1.82) for 
      haemorrhagic stroke. Pooled estimates of increased RR for bleeding remained 
      stable across trials conducted over several decades. Estimates of absolute rates 
      of harm from aspirin use, per 100,000 patient-years of follow-up, were 99-178 for 
      non-trivial bleeds, 46-49 for major bleeds, 68-117 for GI bleeds and 8-10 for 
      haemorrhagic stroke. Meta-analyses aimed at judging risk of bleed according to 
      sex and in individuals with diabetes were insufficiently powered for firm 
      conclusions to be drawn. LIMITATIONS: Searches were date limited to 2008 because 
      of the intense interest that this subject has generated and the cataloguing of 
      all primary research in so many previous systematic reviews. A further limitation 
      was our potential over-reliance on study-level systematic reviews in which the 
      person-years of follow-up were not accurately ascertainable. However, estimates 
      of number of events averted or incurred through aspirin use calculated from data 
      in study-level meta-analyses did not differ substantially from estimates based on 
      individual patient data-level meta-analyses, for which person-years of follow-up 
      were more accurate (although based on less-than-complete assemblies of currently 
      available primary studies). CONCLUSIONS: We have found that there is a fine 
      balance between benefits and risks from regular aspirin use in primary prevention 
      of CVD. Effects on cancer prevention have a long lead time and are at present 
      reliant on post hoc analyses. All absolute effects are relatively small compared 
      with the burden of these diseases. Several potentially relevant ongoing trials 
      will be completed between 2013 and 2019, which may clarify the extent of benefit 
      of aspirin in reducing cancer incidence and mortality. Future research 
      considerations include expanding the use of IPD meta-analysis of RCTs by pooling 
      data from available studies and investigating the impact of different dose 
      regimens on cardiovascular and cancer outcomes. FUNDING: The National Institute 
      for Health Research Health Technology Assessment programme.
FAU - Sutcliffe, P
AU  - Sutcliffe P
AD  - Warwick Evidence, Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Connock, M
AU  - Connock M
FAU - Gurung, T
AU  - Gurung T
FAU - Freeman, K
AU  - Freeman K
FAU - Johnson, S
AU  - Johnson S
FAU - Kandala, N-B
AU  - Kandala NB
FAU - Grove, A
AU  - Grove A
FAU - Gurung, B
AU  - Gurung B
FAU - Morrow, S
AU  - Morrow S
FAU - Clarke, A
AU  - Clarke A
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Health Technol Assess
JT  - Health technology assessment (Winchester, England)
JID - 9706284
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Colorectal Neoplasms/mortality/prevention & control
MH  - Confidence Intervals
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/mortality/*prevention & control
MH  - Odds Ratio
MH  - Primary Prevention/*methods
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Survival Analysis
MH  - United States
PMC - PMC4781046
EDAT- 2013/10/01 06:00
MHDA- 2014/05/16 06:00
CRDT- 2013/10/01 06:00
PHST- 2013/10/01 06:00 [entrez]
PHST- 2013/10/01 06:00 [pubmed]
PHST- 2014/05/16 06:00 [medline]
AID - 10.3310/hta17430 [doi]
PST - ppublish
SO  - Health Technol Assess. 2013 Sep;17(43):1-253. doi: 10.3310/hta17430.

PMID- 36069719
OWN - NLM
STAT- MEDLINE
DCOM- 20220909
LR  - 20220913
IS  - 2159-3000 (Print)
IS  - 2159-3000 (Linking)
VI  - 520
DP  - 2022 Sep
TI  - Cardiovascular Disease Prevention: Pharmacologic Prevention.
PG  - 20-25
AB  - Several drugs have shown benefits in primary and secondary prevention of 
      cardiovascular disease (CVD). Aspirin should be used routinely for the secondary 
      prevention of CVD. Low-dose aspirin should not be used for the primary prevention 
      of CVD in adults ages 60 years and older. Aspirin can be considered for primary 
      prevention in adults ages 40 to 59 years with a 10% or greater 10-year CVD risk. 
      Moderate- to high-intensity statin therapy should be prescribed for most patients 
      with known atherosclerotic CVD, those with a low-density lipoprotein (LDL) 
      cholesterol level of 190 mg/dL or higher, and those ages 40 to 75 years with 
      diabetes or with a 10-year risk of CVD of 7.5% or greater. Newer lipid-lowering 
      drugs have shown benefits in lowering LDL cholesterol levels, but at high cost 
      and with limited evidence of reduction of CVD outcomes. Polypills provide a 
      method to deliver multiple proven drugs at lower cost and to a broader 
      population. Sodium-dependent glucose cotransporter 2 inhibitors or glucagon-like 
      peptide 1 receptor agonists should be added to metformin as the preferred 
      second-line drug in the management of diabetes because of their proven ability to 
      improve cardiovascular outcomes. No supplements have proven benefits in CVD 
      prevention. Omega-3 fatty acids and folic acid have shown benefits when consumed 
      in food.
CI  - Written permission from the American Academy of Family Physicians is required for 
      reproduction of this material in whole or in part in any form or medium.
FAU - Reamy, Brian V Jr
AU  - Reamy BV Jr
AD  - Department of Family Medicine - Uniformed Services University School of the 
      Health Sciences School of Medicine, 4301 Jones Bridge Rd, Bethesda, MD 20814.
FAU - Viera, Anthony J
AU  - Viera AJ
AD  - Department of Family Medicine and Community Health - Duke University School of 
      Medicine, DUMC 2914, Durham, NC 27710.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - FP Essent
JT  - FP essentials
JID - 101578821
RN  - 0 (Cholesterol, LDL)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/complications/prevention & control
MH  - Cholesterol, LDL
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/prevention & control
MH  - Humans
MH  - Middle Aged
EDAT- 2022/09/08 06:00
MHDA- 2022/09/11 06:00
CRDT- 2022/09/07 13:08
PHST- 2022/09/07 13:08 [entrez]
PHST- 2022/09/08 06:00 [pubmed]
PHST- 2022/09/11 06:00 [medline]
PST - ppublish
SO  - FP Essent. 2022 Sep;520:20-25.

PMID- 15242723
OWN - NLM
STAT- MEDLINE
DCOM- 20040914
LR  - 20131121
IS  - 0889-8561 (Print)
IS  - 0889-8561 (Linking)
VI  - 24
IP  - 3
DP  - 2004 Aug
TI  - Aspirin and NSAID sensitivity.
PG  - 491-505, vii
AB  - Aspirin and the older nonsteroidal anti-inflammatory drugs (NSAIDs) that block 
      cyclo-oxygenase-1 (COX-1) induce asthma attacks in patients with 
      aspirin-exacerbated respiratory disease and urticaria in patients with chronic 
      idiopathic urticaria. Weak inhibitors of COX-1, such as acetaminophen and 
      salsalate, crossreact also but only with high doses of the drugs. Partial 
      inhibitors of both COX-1 and COX-2, such as nimesulide and meloxicam, also 
      cross-react but only at high drug doses. COX-2 inhibitors do not cross-react; 
      however, all NSAIDs, including the selective COX-2 inhibitors, can sensitize 
      patients and induce urticaria or anaphylaxis on next exposure to the drug.
FAU - Stevenson, Donald D
AU  - Stevenson DD
AD  - Division of Allergy, Asthma, and Immunology, Department of Medicine, Scripps 
      Clinic and The Scripps Research Institute, W 205, 10666 North Torrey Pines Road, 
      La Jolla, CA 92037, USA. stevensn@scripps.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/*therapeutic use
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/adverse effects/therapeutic use
MH  - Desensitization, Immunologic
MH  - Drug Hypersensitivity/*immunology/*physiopathology/therapy
MH  - Humans
MH  - Isoenzymes/antagonists & inhibitors
MH  - Membrane Proteins
MH  - Prostaglandin-Endoperoxide Synthases
RF  - 62
EDAT- 2004/07/10 05:00
MHDA- 2004/09/15 05:00
CRDT- 2004/07/10 05:00
PHST- 2004/07/10 05:00 [pubmed]
PHST- 2004/09/15 05:00 [medline]
PHST- 2004/07/10 05:00 [entrez]
AID - S088985610400027X [pii]
AID - 10.1016/j.iac.2004.03.001 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2004 Aug;24(3):491-505, vii. doi: 
      10.1016/j.iac.2004.03.001.

PMID- 33082930
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210202
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 9
DP  - 2020
TI  - Recent advances in understanding, diagnosing and treating venous thrombosis.
LID - F1000 Faculty Rev-1206 [pii]
LID - 10.12688/f1000research.27115.1 [doi]
AB  - Focusing on the current state of the art, this article (a) describes recent 
      advances in the understanding of the pathogenesis of venous thromboembolism 
      (VTE), (b) discusses current approaches for the prevention, diagnosis and 
      treatment of VTE, (c) outlines the role of aspirin for VTE prevention and 
      treatment, and (d) highlights the unmet needs in VTE management and describes 
      novel approaches to address them.
CI  - Copyright: © 2020 Chan NC and Weitz JI.
FAU - Chan, Noel C
AU  - Chan NC
AUID- ORCID: 0000-0001-9491-6172
AD  - Thrombosis and Atherosclerosis Research Institute and McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Weitz, Jeffrey I
AU  - Weitz JI
AUID- ORCID: 0000-0002-1092-7550
AD  - Thrombosis and Atherosclerosis Research Institute and McMaster University, 
      Hamilton, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201006
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - *Venous Thromboembolism/diagnosis/drug therapy/prevention & control
MH  - *Venous Thrombosis/diagnosis/drug therapy/prevention & control
PMC - PMC7539078
OTO - NOTNLM
OT  - D-dimer
OT  - Venous thrombosis
OT  - advances
OT  - aspirin
OT  - clinical prediction rule
OT  - diagnosis
OT  - direct oral anticoagulants
OT  - factor XI inhibitors
OT  - thromboembolism
OT  - treatment
COIS- No competing interests were disclosed.No competing interests were disclosed.No 
      competing interests were disclosed.
EDAT- 2020/10/22 06:00
MHDA- 2021/02/03 06:00
CRDT- 2020/10/21 06:02
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/10/21 06:02 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
AID - F1000 Faculty Rev-1206 [pii]
AID - 10.12688/f1000research.27115.1 [doi]
PST - epublish
SO  - F1000Res. 2020 Oct 6;9:F1000 Faculty Rev-1206. doi: 
      10.12688/f1000research.27115.1. eCollection 2020.

PMID- 15927904
OWN - NLM
STAT- MEDLINE
DCOM- 20050927
LR  - 20190917
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 25
IP  - 6
DP  - 2005 Jun
TI  - Aspirin under fire: aspirin use in the primary prevention of coronary heart 
      disease.
PG  - 847-61
AB  - The issue of aspirin use in the primary prevention of cardiovascular disease is 
      still debated because of conflicting opinions on risks versus benefits. Recently, 
      a United States Food and Drug Administration (FDA) panel rejected the approval of 
      aspirin in the setting of primary prevention in moderate-risk patients. However, 
      the United States Preventive Services Task Force recommends that clinicians 
      discuss aspirin therapy with patients at increased risk for having a future 
      coronary event. During the past 15 years, many large randomized trials have 
      specifically addressed this issue and helped shape the decisions of the FDA panel 
      and the Preventive Services Task Force. These trials lend a handful of 
      experiences and results, with no clear recommendations for antiplatelet therapy 
      in the setting of primary prevention of coronary heart disease (CHD). Recently, 
      trial results have been assimilated into practical tools for risk stratification 
      to guide aspirin use in this setting. An overview and critical evaluation of the 
      work performed thus far is provided in order to lend insight into the ongoing 
      debate and, through use of the Framingham CHD risk prediction score sheets, to 
      better equip practitioners faced with the decision of giving aspirin to 
      "relatively" healthy individuals for CHD primary prevention.
FAU - Miller, Michael G
AU  - Miller MG
AD  - Medical Services Department, Solvay Pharmaceuticals, Inc., Allison Park, 
      Pennsylvania, USA.
FAU - Lucas, B Daniel
AU  - Lucas BD
FAU - Papademetriou, Vasilios
AU  - Papademetriou V
FAU - Elhabyan, Abdul-Karim
AU  - Elhabyan AK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Pharmacotherapy. 2005 Dec;25(12):1826-8; discussion 1827-8. PMID: 16305303
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/etiology/mortality/*prevention & control
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
RF  - 49
EDAT- 2005/06/02 09:00
MHDA- 2005/09/28 09:00
CRDT- 2005/06/02 09:00
PHST- 2005/06/02 09:00 [pubmed]
PHST- 2005/09/28 09:00 [medline]
PHST- 2005/06/02 09:00 [entrez]
AID - 10.1592/phco.2005.25.6.847 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2005 Jun;25(6):847-61. doi: 10.1592/phco.2005.25.6.847.

PMID- 24479717
OWN - NLM
STAT- MEDLINE
DCOM- 20141103
LR  - 20191112
IS  - 2212-4063 (Electronic)
IS  - 1871-529X (Linking)
VI  - 13
IP  - 3
DP  - 2013 Dec
TI  - Antiplatelet therapies: aspirin at the heart of new directions.
PG  - 173-84
AB  - When introduced over 100 years ago, aspirin was prescribed as an analgesic drug 
      to arthritic patients for pain relief. The prevalence of users grew quite rapidly 
      and to this day, aspirin remains widely used in clinical practice. The popularity 
      of aspirin resulted not only from its analgesic properties but also from a second 
      benefit recognized later as an anti-platelet effect. It was this important 
      activity of aspirin that made it one of the most recommended drugs for the 
      treatment and prevention of cardiovascular diseases. The anti-platelet effect of 
      aspirin emerged from the first few case reports published in the early 1900s and 
      was described as a mild bleeding. The molecular mechanisms involved were 
      described in 1971 and constituted the irreversible inhibition of cyclooxygenase-1 
      enzyme and prevention of platelet aggregation. Today, the contribution of aspirin 
      to our understanding of cardiovascular health persists and remains considerable. 
      Observations from large cohorts of aspirin users generate massive amount of 
      valuable information used in the identification of factors influencing the 
      potential risk for cardiovascular diseases, including sex, age and genetic 
      predisposition. Aspirin and the path of discovery leading to its anti-platelet 
      activity has taken a hundred years was based on manifestations of effects 
      observed in its users, and it remains a successful strategy for the 
      identification of new avenues to treat cardiovascular diseases associated with 
      hyper-platelet activity. The contribution of aspirin to the understanding of 
      cardiovascular diseases and to the design of effective treatment and prevention 
      strategies, remains of high importance in our society.
FAU - Bunimov, Natalia
AU  - Bunimov N
FAU - Laneuville, Odette
AU  - Laneuville O
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, 
      University of Ottawa, RGN 4108,451 Smyth Rd., Ottawa, Ontario Canada, K1H 8M5. 
      olaneuvi@uottawa.ca.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Cardiovasc Hematol Disord Drug Targets
JT  - Cardiovascular & hematological disorders drug targets
JID - 101269160
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2014/02/01 06:00
MHDA- 2014/11/05 06:00
CRDT- 2014/02/01 06:00
PHST- 2012/07/17 00:00 [received]
PHST- 2013/04/21 00:00 [revised]
PHST- 2013/04/22 00:00 [accepted]
PHST- 2014/02/01 06:00 [entrez]
PHST- 2014/02/01 06:00 [pubmed]
PHST- 2014/11/05 06:00 [medline]
AID - CHDDT-58878 [pii]
AID - 10.2174/1871529x1303140129154040 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Disord Drug Targets. 2013 Dec;13(3):173-84. doi: 
      10.2174/1871529x1303140129154040.

PMID- 23934900
OWN - NLM
STAT- MEDLINE
DCOM- 20141204
LR  - 20171206
IS  - 1724-6067 (Electronic)
IS  - 1120-7000 (Linking)
VI  - 24
IP  - 1
DP  - 2014 Jan-Feb
TI  - Prevention of venous thromboembolic events following femoroacetabular 
      osteoplasty: aspirin is enough for most.
PG  - 77-80
LID - 10.5301/hipint.5000079 [doi]
AB  - BACKGROUND: As hip-preservation surgery is performed in a particularly young and 
      active group of patients, the knowledge accrued in the fields of hip arthroplasty 
      and hip fracture care regarding postoperative thromboprophylaxis cannot be 
      extrapolated to this patient population. Recommendations based on the evidence 
      for each particular surgical procedure and population is desirable. For these 
      reasons, the purpose of our study is to describe the rate of clinically relevant 
      venous thromboembolism (VTE) and anticoagulation-related complications observed 
      in patients undergoing hip-preservation surgery through mini-open femoracetabular 
      osteoplasty (FAO) with a formal postoperative thromboprophylaxis protocol of 
      aspirin dosing. METHODS: A prospective case series of 407 consecutive FAO 
      procedures in 375 patients of mean age 34.5 ± 11.1 years (range 15-62 years) were 
      followed six weeks post operatively to document the presence of clinically 
      relevant VTE as well as major bleeding events, as defined by the most recent 
      American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 
      All patients were given aspirin 325 mg by mouth daily for two to four weeks. 
      RESULTS: There was one case of distal DVT in a 31-year-old male with no specific 
      risk factors. No cases of pulmonary embolism were observed. There were no major 
      bleeding events or reoperations due to postsurgical haematoma. There were no 
      deaths. The crude incidence of clinically relevant VTE was 1 per 407 procedures 
      (0.25%). CONCLUSION: Aspirin is a safe and effective modality to provide 
      thromboprophylaxis in patients undergoing hip-preservation surgery. The rate of 
      VTE that we observed is, thus far, the lowest in comparison to other published 
      series of hip preservation surgery that specifically focused on this 
      complication.
FAU - Tischler, Eric H
AU  - Tischler EH
AD  - The Rothman Institute, Philadelphia, Pennsylvania - USA.
FAU - Ponzio, Danielle Y
AU  - Ponzio DY
FAU - Diaz-Ledezma, Claudio
AU  - Diaz-Ledezma C
FAU - Parvizi, Javad
AU  - Parvizi J
LA  - eng
PT  - Journal Article
DEP - 20130809
PL  - United States
TA  - Hip Int
JT  - Hip international : the journal of clinical and experimental research on hip 
      pathology and therapy
JID - 9200413
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Arthroplasty, Replacement/*adverse effects
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/epidemiology/*prevention & control
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
MH  - United States/epidemiology
MH  - Venous Thromboembolism/epidemiology/etiology/*prevention & control
MH  - Young Adult
EDAT- 2013/08/13 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/08/13 06:00
PHST- 2013/06/19 00:00 [accepted]
PHST- 2013/08/13 06:00 [entrez]
PHST- 2013/08/13 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 433C604E-016A-4334-A9F8-4D9644A042D8 [pii]
AID - 10.5301/hipint.5000079 [doi]
PST - ppublish
SO  - Hip Int. 2014 Jan-Feb;24(1):77-80. doi: 10.5301/hipint.5000079. Epub 2013 Aug 9.

PMID- 15783239
OWN - NLM
STAT- MEDLINE
DCOM- 20050517
LR  - 20181201
IS  - 0114-5916 (Print)
IS  - 0114-5916 (Linking)
VI  - 28
IP  - 4
DP  - 2005
TI  - NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for 
      patient management.
PG  - 287-300
AB  - The conflicting data about the influence of Helicobacter pylori infection on the 
      ulcer risk in patients receiving NSAIDs can be accounted for by the heterogeneity 
      of study designs and the diversified host response to H. pylori. Factors that 
      will affect the outcome include the choice of H. pylori diagnostic tests, 
      previous ulcer complications, concurrent use of acid suppressants, NSAID-naive 
      versus long-term users, low-dose aspirin (acetylsalicylic acid) versus 
      non-aspirin NSAIDs and whether the result was derived from a pre-specified 
      endpoint or post hoc subgroup analysis. Current evidence suggests that H. pylori 
      eradication reduces the ulcer risk for patients who are about to start receiving 
      NSAIDs but not for those who are already on long-term NSAID therapy. Since 
      treatment with a proton pump inhibitor (PPI) worsens H. pylori-associated corpus 
      gastritis, H. pylori should be tested for, and eradicated if present, before 
      starting long-term prophylaxis with PPIs. Patients with H. pylori infection and a 
      history of ulcer complications who require NSAIDs should receive concomitant PPIs 
      or misoprostol after curing the infection. Among patients receiving low-dose 
      aspirin, who have H. pylori infection and previous ulcer complications, long-term 
      treatment with a PPI further reduces the risk of complicated ulcers if H. pylori 
      eradication fails or if patients use concomitant non-aspirin NSAIDs. Current data 
      on the gastric safety of COX-2 selective NSAIDs in H. pylori-infected patients 
      are conflicting. Limited data suggest that the gastroduodenal sparing effect of 
      rofecoxib is negated by H. pylori infection in patients who have had prior upper 
      gastrointestinal events. In light of potential cardiovascular risk with COX-2 
      selective NSAIDs, it is important to weigh the potential adverse effects against 
      the benefits for an individual patient.
FAU - Chan, Francis K L
AU  - Chan FK
AD  - Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese 
      University of Hong Kong, Hong Kong, Shatin, Hong Kong SAR. fklchan@cuhk.edu.hk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Prostaglandins)
RN  - 0E43V0BB57 (Misoprostol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Apoptosis
MH  - Aspirin/adverse effects/therapeutic use
MH  - Gastric Acid/*metabolism
MH  - *Gastritis/metabolism/microbiology
MH  - Helicobacter pylori/drug effects/*pathogenicity
MH  - Humans
MH  - Misoprostol/*therapeutic use
MH  - *Peptic Ulcer/chemically induced/drug therapy/microbiology
MH  - Prostaglandins/*metabolism/physiology
RF  - 68
EDAT- 2005/03/24 09:00
MHDA- 2005/05/18 09:00
CRDT- 2005/03/24 09:00
PHST- 2005/03/24 09:00 [pubmed]
PHST- 2005/05/18 09:00 [medline]
PHST- 2005/03/24 09:00 [entrez]
AID - 2842 [pii]
AID - 10.2165/00002018-200528040-00002 [doi]
PST - ppublish
SO  - Drug Saf. 2005;28(4):287-300. doi: 10.2165/00002018-200528040-00002.

PMID- 2506093
OWN - NLM
STAT- MEDLINE
DCOM- 19891013
LR  - 20190516
IS  - 0892-6638 (Print)
IS  - 0892-6638 (Linking)
VI  - 3
IP  - 11
DP  - 1989 Sep
TI  - Heme prosthetic group required for acetylation of prostaglandin H synthase by 
      aspirin.
PG  - 2294-7
AB  - The ability of aspirin to acetylate PGH synthase was determined by reacting 
      [3H-acetyl]-aspirin with purified enzyme followed by high pressure liquid 
      chromatography analysis of the protein components of the reaction mixture. 
      Heme-reconstituted enzyme incorporated approximately one acetyl group per 70-kDa 
      subunit, whereas apoprotein incorporated 0.1 acetyl group per subunit. The 
      ability of the heme prosthetic group to enhance acetylation of the protein was 
      correlated with its ability to protect the Arg253-Gly254 peptide bond from 
      cleavage by trypsin. Thus, heme-induced alteration of protein conformation may 
      contribute to the enhanced labeling of Ser506 by aspirin. The present results 
      indicate that irreversible inactivation of prostaglandin H synthase by aspirin 
      occurs only when the heme prosthetic group is bound to the protein. Considering 
      its short in vivo half-life, it is likely that aspirin inactivates only the 
      steady-state fraction of PGH synthase in a cell that is active but not newly 
      synthesized apoprotein. This may contribute to the differential kinetics of 
      inactivation and recovery of PGH synthase activity in platelets and vascular 
      endothelial cells after administration of low dose aspirin as a prophylactic 
      agent against cardiovascular disease.
FAU - Chen, Y N
AU  - Chen YN
AD  - Department of Chemistry, Wayne State University, Detroit, Michigan 48202.
FAU - Marnett, L J
AU  - Marnett LJ
LA  - eng
GR  - CA47479/CA/NCI NIH HHS/United States
GR  - GM23642/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (Apoproteins)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 42VZT0U6YR (Heme)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EC 3.4.21.4 (Trypsin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Apoproteins/metabolism
MH  - Aspirin/*physiology
MH  - Cyclooxygenase Inhibitors
MH  - Heme/*physiology
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - Protein Conformation
MH  - Structure-Activity Relationship
MH  - Swine
MH  - Trypsin/pharmacology
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
AID - 10.1096/fasebj.3.11.2506093 [doi]
PST - ppublish
SO  - FASEB J. 1989 Sep;3(11):2294-7. doi: 10.1096/fasebj.3.11.2506093.

PMID- 285986
OWN - NLM
STAT- MEDLINE
DCOM- 19790725
LR  - 20190708
IS  - 0002-8177 (Print)
IS  - 0002-8177 (Linking)
VI  - 98
IP  - 5
DP  - 1979 May
TI  - Aspirin idiosyncrasy.
PG  - 737-8
AB  - Aspirin idiosyncrasy is infrequently discussed in the dental literature. The 
      severity of the case described illustrates the importance of complete familiarity 
      with the syndrome. Because the patient who is sensitive to the drug may not 
      volunteer this information, the dentist must include specific questions about 
      asthma, nasal polyps, and adverse clinical reaction to aspirin in the initial 
      interview of the patient. Suspicion of this idiosyncrasy will result in avoidance 
      of aspirin; this may well prevent a life-threatening reaction. Acetaminophen is a 
      safe alternative analgesic agent for such patients.
FAU - Lewis, D P Jr
AU  - Lewis DP Jr
FAU - Casterline, C L
AU  - Casterline CL
FAU - Stein, M
AU  - Stein M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced
MH  - Drug Hypersensitivity/*etiology/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/complications
MH  - Rhinitis/complications
EDAT- 1979/05/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
AID - S0002-8177(79)85028-X [pii]
AID - 10.14219/jada.archive.1979.0157 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 1979 May;98(5):737-8. doi: 10.14219/jada.archive.1979.0157.

PMID- 1276534
OWN - NLM
STAT- MEDLINE
DCOM- 19760901
LR  - 20190509
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 57
IP  - 1
DP  - 1976 May
TI  - The effect of aspirin on 5-hydroxytryptamine uptake and release by human 
      platelets.
PG  - 149-51
AB  - The influence of aspirin on 5-hydroxytryptamine (5-HT) uptake and storage by 
      human blood platelets has been investigated. Uptake of 5-HT was strongly 
      inhibited. In 30 min aspirin released 50% of the 5-HT that had been incorporated 
      into the platelets prior to the addition of the aspirin. These results are 
      discussed in terms of possible interference with a 5-HT membrane receptor and the 
      impairment of 5-HT storage in the dense granules.
FAU - Rendu, F
AU  - Rendu F
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 333DO1RDJY (Serotonin)
RN  - H0C805XYDE (Quinacrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/*metabolism
MH  - Depression, Chemical
MH  - Humans
MH  - In Vitro Techniques
MH  - Quinacrine/pharmacology
MH  - Serotonin/*blood
MH  - Time Factors
PMC - PMC1667011
EDAT- 1976/05/01 00:00
MHDA- 1976/05/01 00:01
CRDT- 1976/05/01 00:00
PHST- 1976/05/01 00:00 [pubmed]
PHST- 1976/05/01 00:01 [medline]
PHST- 1976/05/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1976.tb07665.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1976 May;57(1):149-51. doi: 10.1111/j.1476-5381.1976.tb07665.x.

PMID- 29132875
OWN - NLM
STAT- MEDLINE
DCOM- 20180626
LR  - 20201003
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Print)
IS  - 0090-8258 (Linking)
VI  - 148
IP  - 1
DP  - 2018 Jan
TI  - Aspirin use and endometrial cancer risk and survival.
PG  - 222-232
LID - S0090-8258(17)31448-8 [pii]
LID - 10.1016/j.ygyno.2017.10.026 [doi]
AB  - The role of acetylsalicylic acid (aspirin) as a chemo-preventive and adjuvant 
      therapeutic agent for cancers is generating attention. Mounting evidence 
      indicates that aspirin reduces the incidence and mortality of certain 
      obesity-related cancers, particularly colorectal cancer. In endometrial cancer, 
      previous studies examining the effect of aspirin remain inconsistent as to the 
      reduction in the risk of endometrial cancer. While some evidence indicates 
      protective effects in obese women, other studies have showed a potential 
      deleterious effect of these medications on endometrial cancer outcomes. However, 
      exposure measurement across studies has been inconsistent in recording dose, 
      duration, and frequency of use; thus making comparisons difficult. In this 
      article, we review the evidence for the association between endometrial cancer 
      and obesity, the pharmacological differences between regular- and low-dose 
      aspirin, as well as the potential anti-tumor mechanism of aspirin, supporting a 
      possible therapeutic effect on endometrial cancer. A proposed mechanism behind 
      decreased cancer mortality in endometrial cancer may be a result of inhibition of 
      metastasis via platelet inactivation and possible prostaglandin E(2) suppression 
      by aspirin. Additionally, aspirin use in particular may have a secondary benefit 
      for obesity-related comorbidities including cardiovascular disease in women with 
      endometrial cancer. Although aspirin-related bleeding needs to be considered as a 
      possible adverse effect, the benefits of aspirin therapy may exceed the potential 
      risk in women with endometrial cancer. The current evidence reviewed herein has 
      resulted in conflicting findings regarding the potential effect on endometrial 
      cancer outcomes, thus indicating that future studies in this area are needed to 
      resolve the effects of aspirin on endometrial cancer survival, particularly to 
      identify specific populations that might benefit from aspirin use.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Takiuchi, Tsuyoshi
AU  - Takiuchi T
AD  - Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 
      University of Southern California, Los Angeles, CA, USA.
FAU - Blake, Erin A
AU  - Blake EA
AD  - Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 
      University of Southern California, Los Angeles, CA, USA.
FAU - Matsuo, Koji
AU  - Matsuo K
AD  - Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 
      University of Southern California, Los Angeles, CA, USA; Norris Comprehensive 
      Cancer Center, University of Southern California, Los Angeles, CA, USA. 
      Electronic address: koji.matsuo@med.usc.edu.
FAU - Sood, Anil K
AU  - Sood AK
AD  - Department of Gynecologic Oncology & Reproductive Medicine, The University of 
      Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, 
      The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Center for 
      RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Brasky, Theodore M
AU  - Brasky TM
AD  - Division of Cancer Prevention and Control, Department of Internal Medicine, The 
      Ohio State University College of Medicine, Columbus, OH, USA.
LA  - eng
GR  - P30 CA014089/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20171111
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Endometrial Neoplasms/drug therapy/*mortality
MH  - Female
MH  - Humans
PMC - PMC7531033
MID - NIHMS1627679
OTO - NOTNLM
OT  - Aspirin
OT  - Endometrial cancer
OT  - Review
OT  - Risk
OT  - Survival
COIS- Disclosure statement There is no conflict of interest in all the authors.
EDAT- 2017/11/15 06:00
MHDA- 2018/06/27 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/09/08 00:00 [received]
PHST- 2017/10/20 00:00 [revised]
PHST- 2017/10/23 00:00 [accepted]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2018/06/27 06:00 [medline]
PHST- 2017/11/15 06:00 [entrez]
AID - S0090-8258(17)31448-8 [pii]
AID - 10.1016/j.ygyno.2017.10.026 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2018 Jan;148(1):222-232. doi: 10.1016/j.ygyno.2017.10.026. Epub 
      2017 Nov 11.

PMID- 19301289
OWN - NLM
STAT- MEDLINE
DCOM- 20090508
LR  - 20220310
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 32
IP  - 3
DP  - 2009 Mar
TI  - The impact of aspirin resistance on the long-term cardiovascular mortality in 
      patients with non-ST segment elevation acute coronary syndromes.
PG  - 142-7
LID - 10.1002/clc.20293 [doi]
AB  - BACKGROUND: Aspirin resistance has been associated with an adverse long-term 
      outcome in patients with atherosclerotic coronary artery disease, but more 
      studies are needed. HYPOTHESIS: The aim of this study was to investigate the 
      impact of aspirin resistance, assessed by the Platelet Function Analyzer-100 
      (PFA-100) (Dade Behring Inc., Deerfield, Ill., USA) on the long-term prognosis in 
      patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS). 
      METHODS: A total of 496 consecutive patients were studied. The 1-y incidence of 
      cardiovascular death was the prespecified study endpoint. The patients were 
      divided, according to the values of PFA-100 collagen epinephrine closure time 
      (CEPI-CT) upon presentation, into aspirin sensitives (those with a PFA-100 
      CEPI-CT>193 sec) and aspirin resistants (those with a PFA-100 CEPI-CT<or=193 
      sec). RESULTS: Aspirin resistants were younger (p-value = 0.04), and less 
      frequently hypertensives (p-value=0.05) or diabetics (p-value=0.04) than aspirin 
      sensitives. By 1 y, the incidence of cardiovascular deaths in the entire cohort 
      was 12.9% (64/496), and aspirin resistants were at significantly higher risk of 
      cardiovascular death (23.1% versus 9.6%; hazard ratio [HR]=2.6; 95% confidence 
      interval [CI]=1.6-4.3; p-value<0.001), than aspirin sensitives. By multivariate 
      Cox regression analysis, aspirin resistance (a PFA-100 CEPI-CT<or=193 sec) was 
      among the most potent predictors of the 1-y incidence of cardiovascular death 
      (HR=2.8; 95% CI=1.7-4.6; p-value<0.001). CONCLUSION: According to the present 
      data, aspirin resistance, assessed by the PFA-100, is an independent predictor of 
      long-term cardiovascular mortality in patients with NSTE-ACS.
CI  - Copyright (c) 2009 Wiley Periodicals, Inc.
FAU - Foussas, Stefanos G
AU  - Foussas SG
AD  - Department of Cardiology, Tzanio Hospital, Piraeus, Greece.
FAU - Zairis, Michael N
AU  - Zairis MN
FAU - Tsirimpis, Vasilios G
AU  - Tsirimpis VG
FAU - Makrygiannis, Stamatis S
AU  - Makrygiannis SS
FAU - Patsourakos, Nikolaos G
AU  - Patsourakos NG
FAU - Adamopoulou, Evdokia N
AU  - Adamopoulou EN
FAU - Mytas, Demetrios Z
AU  - Mytas DZ
FAU - Prekates, Athanasios A
AU  - Prekates AA
FAU - Perdiou, Anna J
AU  - Perdiou AJ
FAU - Tsoukanas, Vasilios K
AU  - Tsoukanas VK
FAU - Argyrakis, Spyros K
AU  - Argyrakis SK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*mortality
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Chi-Square Distribution
MH  - *Drug Resistance
MH  - Endpoint Determination
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Statistics, Nonparametric
PMC - PMC6653184
EDAT- 2009/03/21 09:00
MHDA- 2009/05/09 09:00
CRDT- 2009/03/21 09:00
PHST- 2009/03/21 09:00 [entrez]
PHST- 2009/03/21 09:00 [pubmed]
PHST- 2009/05/09 09:00 [medline]
AID - CLC20293 [pii]
AID - 10.1002/clc.20293 [doi]
PST - ppublish
SO  - Clin Cardiol. 2009 Mar;32(3):142-7. doi: 10.1002/clc.20293.

PMID- 11419884
OWN - NLM
STAT- MEDLINE
DCOM- 20010712
LR  - 20220310
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 37
IP  - 8
DP  - 2001 Jun 15
TI  - Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 
      concentrations: a placebo-controlled study using a highly sensitive C-reactive 
      protein assay.
PG  - 2036-41
AB  - OBJECTIVES: We performed a placebo-controlled study to evaluate the effect of 
      low-dose aspirin on serum C-reactive protein (CRP) levels. BACKGROUND: Elevated 
      circulating concentrations of CRP, an inflammatory marker, increase the risk of 
      thrombotic cardiovascular diseases such as myocardial infarction (MI). Moreover, 
      low-dose aspirin therapy has been reported to be more effective in preventing MI 
      in men with higher CRP levels than it is in those with lower levels, raising the 
      possibility that aspirin prevents thrombosis by reducing vascular inflammation. 
      The effect of low-dose aspirin therapy on serum CRP levels in men has been 
      addressed recently, but the results of the two studies conflict. METHODS: Effects 
      of aspirin (81 mg every day or 325, 81 or 40 mg every-third-day given for 31 
      days) on serum CRP, using a highly-sensitive assay, and on serum 
      platelet-cyclo-oxygenase (COX)-1-derived thromboxane (Tx) B2 concentrations were 
      studied simultaneously in 57 healthy volunteers (30 men and 27 women). RESULTS: 
      Trough platelet COX-1-derived serum Tx B2 concentrations decreased by 100% with 
      daily aspirin and by 90%, 84% and 78% with 325, 81 and 40 mg aspirin 
      every-third-day (p < 0.001). However, there were no significant changes in serum 
      CRP levels from baseline with daily low-dose aspirin therapy, with any of the 
      every-third-day aspirin regimens or with placebo treatment. CONCLUSIONS: Low 
      doses of aspirin that markedly inhibit platelet COX-1 activity, as manifested by 
      a profound decline in platelet-derived serum Tx B2 concentrations, have no 
      detectable effect on serum CRP levels in healthy men and women.
FAU - Feldman, M
AU  - Feldman M
AD  - Medical Service, Dallas Department of Veterans Affairs Medical Center, Texas 
      75216, USA. mark.feldman@med.va.gov
FAU - Jialal, I
AU  - Jialal I
FAU - Devaraj, S
AU  - Devaraj S
FAU - Cryer, B
AU  - Cryer B
LA  - eng
GR  - K24AT00596/AT/NCCIH NIH HHS/United States
GR  - R01AJ00005/PHS HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 54397-85-2 (Thromboxane B2)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - C-Reactive Protein/*analysis
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Immunoassay/methods
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Thromboxane B2/*blood
EDAT- 2001/06/23 10:00
MHDA- 2001/07/13 10:01
CRDT- 2001/06/23 10:00
PHST- 2001/06/23 10:00 [pubmed]
PHST- 2001/07/13 10:01 [medline]
PHST- 2001/06/23 10:00 [entrez]
AID - S0735-1097(01)01289-X [pii]
AID - 10.1016/s0735-1097(01)01289-x [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2001 Jun 15;37(8):2036-41. doi: 10.1016/s0735-1097(01)01289-x.

PMID- 16158479
OWN - NLM
STAT- MEDLINE
DCOM- 20051214
LR  - 20161124
IS  - 0353-9504 (Print)
IS  - 0353-9504 (Linking)
VI  - 46
IP  - 5
DP  - 2005 Oct
TI  - Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine 
      artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled 
      clinical trial.
PG  - 826-31
AB  - AIM: To assess the effectiveness of low-dose aspirin in the prevention of 
      preeclampsia and intrauterine growth restriction (IUGR) in high-risk pregnant 
      women with abnormal findings at uterine artery Doppler velocimetry performed at 
      14-16 weeks. DESIGN: Randomized controlled clinical trial. SETTING: Department of 
      Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Egypt. METHODS: 
      The trial enrolled 139 women at risk of preeclampsia or IUGR, with abnormal 
      uterine artery Doppler findings that included the presence of unilateral or 
      bilateral diastolic notch, high resistance index (RI), or high pulsatility index 
      (PI) at 14-16 weeks of gestation. The women were randomly allocated into two 
      groups, one receiving aspirin since admission to hospital (n=74) and the other 
      serving as control (n=65). All women were followed up until delivery to assess 
      maternal and perinatal outcomes. T-test was used for comparison of quantitative 
      variables, and categorical variables were compared by chi2 test. OUTCOME 
      CRITERIA: Development of mild or severe preeclampsia, time of onset of 
      preeclampsia, preterm delivery, and the development of IUGR. RESULTS: 
      Preeclampsia developed in 35% of women receiving aspirin and 62% of women in the 
      control group (P=0.003), with severe preeclampsia developing in 8% and 23% of 
      women (P=0.215), respectively. Preeclampsia before 37 weeks of gestation was 
      recorded in only 4% of women receiving aspirin as opposed to 83% of controls 
      (P<0.001). In the group of women receiving aspirin, 19% of newborns suffered from 
      IUGR as opposed to 32%of newborns in the control group (P=0.106). There was no 
      significant difference between the two groups in the rate of preterm delivery 
      (P=0.080), mode of delivery (P=0.971), Apgar score <5 after one minute (P=0.273) 
      and after 5 minutes (P=0.941), maternal or neonatal bleeding (P=0.948), and 
      neonatal birth weight (P=0.399). CONCLUSION: Low-dose aspirin administered as 
      early as 14-16 weeks of gestation to pregnant women at high risk of preeclampsia 
      with abnormal uterine Doppler findings may reduce or modify the course of severe 
      preeclampsia. Its effects on the prevention of IUGR need further evaluation.
FAU - Ebrashy, Alaa
AU  - Ebrashy A
AD  - Kasr El Aini School of Medicine , Cairo University, 19 Tunis st, Maadi, PO 11435, 
      Cairo, Egypt. ebrashy@bigfoot.com
FAU - Ibrahim, Magdy
AU  - Ibrahim M
FAU - Marzook, Ayman
AU  - Marzook A
FAU - Yousef, Dalia
AU  - Yousef D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Croatia
TA  - Croat Med J
JT  - Croatian medical journal
JID - 9424324
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Croat Med J. 2006 Feb;47(1):176-8. PMID: 16489712
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Case-Control Studies
MH  - Echocardiography, Doppler
MH  - Female
MH  - Fetal Growth Retardation/diagnostic imaging/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Pregnancy Trimester, First
MH  - Pregnancy Trimester, Second
MH  - Pregnancy, High-Risk
MH  - Risk Assessment
MH  - Risk Factors
MH  - Ultrasonography, Prenatal
MH  - Umbilical Arteries/*diagnostic imaging/pathology
MH  - Uterus/blood supply
EDAT- 2005/09/15 09:00
MHDA- 2005/12/15 09:00
CRDT- 2005/09/15 09:00
PHST- 2005/09/15 09:00 [pubmed]
PHST- 2005/12/15 09:00 [medline]
PHST- 2005/09/15 09:00 [entrez]
PST - ppublish
SO  - Croat Med J. 2005 Oct;46(5):826-31.

PMID- 24767875
OWN - NLM
STAT- MEDLINE
DCOM- 20150123
LR  - 20141006
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 134
IP  - 4
DP  - 2014 Oct
TI  - Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant 
      asthma: a double-blind study.
PG  - 883-90
LID - S0091-6749(14)00355-8 [pii]
LID - 10.1016/j.jaci.2014.02.041 [doi]
AB  - BACKGROUND: Numerous open trials have demonstrated the beneficial clinical 
      effects of aspirin desensitization (AD) in patients with aspirin-induced asthma 
      (AIA). These beneficial effects might be attributable to aspirin's potent 
      anti-inflammatory properties, but that supposition requires further 
      corroboration. OBJECTIVE: We sought to compare the clinical and biochemical 
      responses to chronic oral AD in 20 patients with AIA and 14 patients with 
      aspirin-tolerant asthma (ATA). All of the patients had chronic rhinosinusitis and 
      nasal polyposis, and these responses were investigated in a pilot, double-blind, 
      placebo-controlled study. METHODS: Twelve patients with AIA and 6 patients with 
      ATA were randomly assigned to receive 624 mg of aspirin, and 8 patients with AIA 
      and 8 patients with ATA received placebo. Both aspirin and placebo were 
      administered once daily for 6 months. Nasal symptoms, Sino-Nasal Outcome Test 
      (SNOT20) scores, peak nasal inspiratory flows, Asthma Control Questionnaire 
      scores, spirometric parameters, peak expiratory flows, blood eosinophilia, and 
      corticosteroid doses were assessed on a monthly basis. Levels of urinary 
      leukotriene E4 and the stable plasma prostaglandin (PG) D2 metabolite 9α,11β-PGF2 
      were evaluated at baseline and after 1, 3, 5, and 6 months. RESULTS: Only the 
      patients with AIA subjected to AD reported improvements in smell and reductions 
      in sneezing and nasal blockade. The SNOT20 and Asthma Control Questionnaire 
      scores of these patients decreased, and their peak nasal inspiratory flows 
      increased. The dosages of inhaled corticosteroids were reduced. There were no 
      changes in leukotriene E(4) or 9α,11β-PGF(2) levels after AD. CONCLUSION: The 
      clinically beneficial effects of AD on nasal and bronchial symptoms occurred only 
      in the patients with AIA.
CI  - Copyright © 2014. Published by Elsevier Inc.
FAU - Świerczyńska-Krępa, Monika
AU  - Świerczyńska-Krępa M
AD  - Medex, Bielsko-Biała, Poland.
FAU - Sanak, Marek
AU  - Sanak M
AD  - Division of Pulmonology, Department of Medicine, Jagiellonian University School 
      of Medicine, Krakow, Poland.
FAU - Bochenek, Grażyna
AU  - Bochenek G
AD  - Division of Pulmonology, Department of Medicine, Jagiellonian University School 
      of Medicine, Krakow, Poland.
FAU - Stręk, Paweł
AU  - Stręk P
AD  - Department of Otolaryngology, Jagiellonian University School of Medicine, Krakow, 
      Poland.
FAU - Ćmiel, Adam
AU  - Ćmiel A
AD  - Department of Applied Mathematics, AGH University of Science and Technology, 
      Krakow, Poland.
FAU - Gielicz, Anna
AU  - Gielicz A
AD  - Division of Pulmonology, Department of Medicine, Jagiellonian University School 
      of Medicine, Krakow, Poland.
FAU - Plutecka, Hanna
AU  - Plutecka H
AD  - Division of Pulmonology, Department of Medicine, Jagiellonian University School 
      of Medicine, Krakow, Poland.
FAU - Szczeklik, Andrzej
AU  - Szczeklik A
AD  - Division of Pulmonology, Department of Medicine, Jagiellonian University School 
      of Medicine, Krakow, Poland.
FAU - Niżankowska-Mogilnicka, Ewa
AU  - Niżankowska-Mogilnicka E
AD  - Division of Pulmonology, Department of Medicine, Jagiellonian University School 
      of Medicine, Krakow, Poland. Electronic address: ewa.nizankowska@ghml.pl.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140424
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Allergens)
RN  - 75715-89-8 (Leukotriene E4)
RN  - B7IN85G1HY (Dinoprost)
RN  - R16CO5Y76E (Aspirin)
RN  - RXY07S6CZ2 (Prostaglandin D2)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Allergens/immunology
MH  - Aspirin/*administration & dosage/immunology
MH  - Asthma/diagnosis/immunology/*therapy
MH  - Asthma, Aspirin-Induced/diagnosis/immunology/*therapy
MH  - Chronic Disease
MH  - Desensitization, Immunologic/*methods
MH  - Dinoprost/blood
MH  - Double-Blind Method
MH  - Eosinophils/*immunology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Leukotriene E4/urine
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/diagnosis/immunology/*therapy
MH  - Pilot Projects
MH  - Prostaglandin D2/blood
MH  - Rhinitis/diagnosis/immunology/*therapy
MH  - Sinusitis/diagnosis/immunology/*therapy
MH  - Spirometry
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin-induced asthma
OT  - aspirin-tolerant asthma
OT  - oral aspirin desensitization
EDAT- 2014/04/29 06:00
MHDA- 2015/01/24 06:00
CRDT- 2014/04/29 06:00
PHST- 2013/08/02 00:00 [received]
PHST- 2014/02/23 00:00 [revised]
PHST- 2014/02/28 00:00 [accepted]
PHST- 2014/04/29 06:00 [entrez]
PHST- 2014/04/29 06:00 [pubmed]
PHST- 2015/01/24 06:00 [medline]
AID - S0091-6749(14)00355-8 [pii]
AID - 10.1016/j.jaci.2014.02.041 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2014 Oct;134(4):883-90. doi: 10.1016/j.jaci.2014.02.041. 
      Epub 2014 Apr 24.

PMID- 9049682
OWN - NLM
STAT- MEDLINE
DCOM- 19970527
LR  - 20190816
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 58
IP  - 2
DP  - 1997 Jan 31
TI  - Use of early aspirin in suspected acute myocardial infarction by General 
      Practitioners in Sri Lanka.
PG  - 171-3
AB  - Early low dose aspirin therapy is beneficial in myocardial infarction (MI). This 
      study investigated the use of early aspirin therapy in patients with suspected MI 
      by General Practitioners (GP). Patients with MI who were referred to our unit by 
      GPs were studied to see whether aspirin therapy had been initiated before 
      referral. A questionnaire was sent to GPs to test their attitudes and practices 
      regarding early aspirin therapy in suspected MI. Our results indicate that few 
      patients with MI had been given early aspirin therapy. Only a minority of GPs 
      were aware of the benefits of early aspirin therapy in MI, and very few 
      prescribed it. Even when it was prescribed, the dose and route of administration 
      were wrong in most instances.
FAU - Seneviratne, S L
AU  - Seneviratne SL
AD  - Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri 
      Lanka.
FAU - Gunatilake, S B
AU  - Gunatilake SB
FAU - de Silva, H J
AU  - de Silva HJ
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Family Practice/standards
MH  - Female
MH  - Health Care Surveys
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Practice Patterns, Physicians'/*standards
MH  - Primary Health Care/*standards
MH  - Sri Lanka
EDAT- 1997/01/31 00:00
MHDA- 1997/01/31 00:01
CRDT- 1997/01/31 00:00
PHST- 1997/01/31 00:00 [pubmed]
PHST- 1997/01/31 00:01 [medline]
PHST- 1997/01/31 00:00 [entrez]
AID - S0167-5273(96)02865-3 [pii]
AID - 10.1016/s0167-5273(96)02865-3 [doi]
PST - ppublish
SO  - Int J Cardiol. 1997 Jan 31;58(2):171-3. doi: 10.1016/s0167-5273(96)02865-3.

PMID- 35490770
OWN - NLM
STAT- MEDLINE
DCOM- 20230619
LR  - 20230619
IS  - 1535-6280 (Electronic)
IS  - 0146-2806 (Linking)
VI  - 48
IP  - 8
DP  - 2023 Aug
TI  - The Era of Polypills in the Management of Cardiovascular Diseases: Are We There 
      Yet?
PG  - 101233
LID - S0146-2806(22)00130-X [pii]
LID - 10.1016/j.cpcardiol.2022.101233 [doi]
AB  - Cardiovascular diseases (CVDs) are the leading cause of mortality globally. Wald 
      and Law proposed the idea of a "polypill"; a fixed dose combination therapy (FDC) 
      in the form of a single pill to curb the CVD epidemic. Such a drug would include 
      the combination of a broad spectrum of drugs including cholesterol lowering 
      drugs, antihypertensive drugs, antiplatelet drugs, anticoagulation drugs, and 
      antiarrhythmic drugs, which are frequently integrated to combat specific CVDs. 
      This "polypill" holds the potential to pose several advantages like increased 
      compliance, improved quality of life, risk factor control, psychological relief, 
      and cost effectiveness along with minimal side effects. Several trials (like 
      TIPS, UMPIRE, PolyIran, etc.) have tested different treatment strategies to test 
      the hypothesis of Wald and Law. Unlike the past, physicians are now highly aware 
      of this new strategy. The future of polypill in the management of CVD lies in a 
      strategy where polypills are treated supplementary to the already existing 
      preventive care, which includes lifestyle modifications and efforts to reduce 
      tobacco use.
CI  - Copyright © 2022 Elsevier Inc. All rights reserved.
FAU - Khan, Arsalan Aamir
AU  - Khan AA
AD  - Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Siddiqui, Sarush Ahmed
AU  - Siddiqui SA
AD  - Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Yasmin, Farah
AU  - Yasmin F
AD  - Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Abidi, Syeda Mahnoor
AU  - Abidi SM
AD  - Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Tariq, Rabbia
AU  - Tariq R
AD  - Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Ahmed, Hiba
AU  - Ahmed H
AD  - Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Murtaza, Noor
AU  - Murtaza N
AD  - Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Jawed, Fareeha
AU  - Jawed F
AD  - Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Lashkerwala, Sehan Siraj
AU  - Lashkerwala SS
AD  - Department of Internal Medicine, Dow University of Health Sciences, Karachi, 
      Pakistan.
FAU - Moin, Ariba
AU  - Moin A
AD  - Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Shah, Syed Muhammad Ismail
AU  - Shah SMI
AD  - Ziauddin Medical College, Karachi, Pakistan.
FAU - Ullah, Irfan
AU  - Ullah I
AD  - Department of Internal Medicine, Kabir Medical College, Gandhara University, 
      Peshawar, Pakistan.
FAU - Yousaf, Zohaib
AU  - Yousaf Z
AD  - Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
FAU - Faizan, Muhammad
AU  - Faizan M
AD  - Department of Internal Medicine, Dow University of Health Sciences, Karachi, 
      Pakistan.
FAU - Shahid, Muhammad Huzaifa
AU  - Shahid MH
AD  - Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. 
      Electronic address: muhammadhuz@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220429
PL  - Netherlands
TA  - Curr Probl Cardiol
JT  - Current problems in cardiology
JID - 7701802
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Cardiovascular Agents)
SB  - IM
MH  - Humans
MH  - *Cardiovascular Diseases/epidemiology
MH  - Aspirin/adverse effects
MH  - Quality of Life
MH  - Drug Combinations
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Antihypertensive Agents/therapeutic use
MH  - *Cardiovascular Agents/therapeutic use
EDAT- 2022/05/02 06:00
MHDA- 2023/06/19 13:08
CRDT- 2022/05/01 19:24
PHST- 2022/04/17 00:00 [received]
PHST- 2022/04/24 00:00 [accepted]
PHST- 2023/06/19 13:08 [medline]
PHST- 2022/05/02 06:00 [pubmed]
PHST- 2022/05/01 19:24 [entrez]
AID - S0146-2806(22)00130-X [pii]
AID - 10.1016/j.cpcardiol.2022.101233 [doi]
PST - ppublish
SO  - Curr Probl Cardiol. 2023 Aug;48(8):101233. doi: 10.1016/j.cpcardiol.2022.101233. 
      Epub 2022 Apr 29.

PMID- 30091133
OWN - NLM
STAT- MEDLINE
DCOM- 20181217
LR  - 20181217
IS  - 1897-4279 (Electronic)
IS  - 0022-9032 (Linking)
VI  - 76
IP  - 9
DP  - 2018
TI  - Acetylsalicylic acid and clopidogrel hyporesponsiveness following acute coronary 
      syndromes.
PG  - 1312-1319
LID - 10.5603/KP.a2018.0159 [doi]
AB  - This review discusses the response variability to acetylsalicylic acid (ASA) and 
      particularly to clopidogrel, and their relation to adverse recurrent ischaemic 
      events in patients with arterial diseases. The higher rate of ASA resistance 
      reported in the literature may be mainly due to the cyclooxygenase-1 non-specific 
      assays, non-compliance, and underdosing. Clopidogrel response variability and 
      non-responsiveness are established concepts. Moreover, high platelet reactivity 
      (HPR) to adenosine diphosphate during clopidogrel therapy is now a known risk 
      factor for recurrent ischaemic events in high-risk percutaneous coronary 
      intervention/acute coronary syndrome patients. Variable active metabolite 
      generation is the primary explanation for clopidogrel response variability and 
      non-responsivenes. Variable levels of active metabolite generation following 
      clopidogrel administration could be mainly explained by functional variability in 
      hepatic cytochrome (CYP)P450 isoenzyme activity that is influenced by drug-drug 
      interactions and single nucleotide polymorphisms of specific genes encoding 
      CYP450 isoenzymes. Treatment with more potent P2Y12 receptor blockers, such as 
      prasugrel and ticagrelor are credible alternative strategies to overcome HPR 
      during clopidogrel therapy.
FAU - Tantry, Udaya S
AU  - Tantry US
FAU - Navarese, Eliano P
AU  - Navarese EP
FAU - Bliden, Kevin P
AU  - Bliden KP
FAU - Gurbel, Paul A
AU  - Gurbel PA
AD  - Inova Center for Thrombosis Research and Drug Development, Inova Heart and 
      Vascular Institute, Falls Church, VA, USA. Paul.Gurbel@inova.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180809
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*surgery
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Clopidogrel/*pharmacology
MH  - Drug Resistance
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Postoperative Period
OTO - NOTNLM
OT  - P2Y12 receptor
OT  - acetylsalicylic acid
OT  - clopidogrel
OT  - coronary artery disease
OT  - high platelet reactivity
OT  - platelets
OT  - stent thrombosis
EDAT- 2018/08/10 06:00
MHDA- 2018/12/18 06:00
CRDT- 2018/08/10 06:00
PHST- 2018/08/03 00:00 [received]
PHST- 2018/08/03 00:00 [accepted]
PHST- 2018/08/10 06:00 [pubmed]
PHST- 2018/12/18 06:00 [medline]
PHST- 2018/08/10 06:00 [entrez]
AID - VM/OJS/KP/12519 [pii]
AID - 10.5603/KP.a2018.0159 [doi]
PST - ppublish
SO  - Kardiol Pol. 2018;76(9):1312-1319. doi: 10.5603/KP.a2018.0159. Epub 2018 Aug 9.

PMID- 22534410
OWN - NLM
STAT- MEDLINE
DCOM- 20121126
LR  - 20131121
IS  - 1532-8422 (Electronic)
IS  - 1053-0770 (Linking)
VI  - 26
IP  - 4
DP  - 2012 Aug
TI  - An evaluation of factors affecting activated coagulation time.
PG  - 563-8
LID - 10.1053/j.jvca.2012.03.011 [doi]
AB  - OBJECTIVE: Although failure to achieve an adequate activated coagulation time 
      (ACT) after full heparinization before cardiopulmonary bypass often is attributed 
      to antithrombin (AT) deficiency, it remains unclear if this is a causative 
      mechanism of decreased heparin responsiveness. Therefore, the authors determined 
      the relationship between AT and other coagulation-related factors that affect the 
      ACT measurement and heparin sensitivity index before the establishment of 
      cardiopulmonary bypass. DESIGN: Observational study. SETTING: University medical 
      center. PARTICIPANTS: Adult elective cardiac surgical patients. INTERVENTIONS: 
      Preoperative data collection included demographics, type of preoperative medical 
      therapy, hemoglobin, platelet count, and AT. Intraoperative measurements included 
      ACT and anti-Xa activity. RESULTS: Of the 203 patients enrolled in this study, 
      10% (n = 21) did not achieve an adequate ACT (≥400 seconds) after full 
      heparinization. Subnormal AT activity (55%-79%) was not related to a low ACT and 
      a low heparin sensitivity index. Preoperative low-molecular-weight heparin 
      therapy did not cause a decreased ACT response. However, preoperative low 
      hemoglobin levels and high platelet counts were associated with a decreased ACT. 
      CONCLUSIONS: All these observations suggest that failure to achieve an adequate 
      ACT is, in general, not an indicator of AT deficiency but could be affected by 
      high platelet counts and low hemoglobin levels.
CI  - Copyright © 2012 Elsevier Inc. All rights reserved.
FAU - Bosch, Yvonne P J
AU  - Bosch YP
AD  - Department of Cardiothoracic Surgery, Cardiovascular Research Institute 
      Maastricht (CARIM), Maastricht, the Netherlands. yvonne.bosch@mumc.nl
FAU - Weerwind, Patrick W
AU  - Weerwind PW
FAU - Nelemans, Patty J
AU  - Nelemans PJ
FAU - Maessen, Jos G
AU  - Maessen JG
FAU - Mochtar, Baheramsjah
AU  - Mochtar B
LA  - eng
PT  - Journal Article
DEP - 20120424
PL  - United States
TA  - J Cardiothorac Vasc Anesth
JT  - Journal of cardiothoracic and vascular anesthesia
JID - 9110208
RN  - 0 (Hemoglobins)
RN  - 0 (Lipoproteins)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Antithrombin III Deficiency/diagnosis
MH  - Aspirin/pharmacology
MH  - Female
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Lipoproteins/physiology
MH  - Male
MH  - Middle Aged
MH  - Platelet Count
MH  - *Whole Blood Coagulation Time
EDAT- 2012/04/27 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/04/27 06:00
PHST- 2011/12/16 00:00 [received]
PHST- 2012/04/27 06:00 [entrez]
PHST- 2012/04/27 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S1053-0770(12)00137-1 [pii]
AID - 10.1053/j.jvca.2012.03.011 [doi]
PST - ppublish
SO  - J Cardiothorac Vasc Anesth. 2012 Aug;26(4):563-8. doi: 
      10.1053/j.jvca.2012.03.011. Epub 2012 Apr 24.

PMID- 18700139
OWN - NLM
STAT- MEDLINE
DCOM- 20081118
LR  - 20220321
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 595
IP  - 1-3
DP  - 2008 Oct 24
TI  - Influence of combinations of acetylsalicylic acid, acetaminophen, and diclofenac 
      on platelet aggregation.
PG  - 65-8
LID - 10.1016/j.ejphar.2008.07.036 [doi]
AB  - Acetylsalicylic acid (aspirin) is often given together with other nonsteroidal 
      anti-inflammatory drugs and acetaminophen. The latter have been accused in 
      epidemiologic studies to cause an increased cardiovascular risk. We have, 
      therefore, analysed the influence of various such drug combinations on platelet 
      aggregation in vitro. Citrated blood was incubated with either 25 microg/ml 
      acetaminophen, 0.5 microg/ml aspirin, 0.04 microg/ml diclofenac, or buffer; 
      followed by a second of the above-mentioned solutions. After a 20 min incubation, 
      platelet aggregation was assessed with a platelet function analyser (PFA-100), 
      which measures the pore closure time (CT) by aggregating platelets. The length of 
      CT reflects the degree of platelet inhibition. Acetaminophen alone did not affect 
      platelet aggregation. Aspirin and diclofenac both increased CT (184+/-69 s, 
      P<0.01 and 196+/-54 s, P<0.001; control 120+/-13 s). Combinations of either 
      aspirin and diclofenac, aspirin and acetaminophen, or diclofenac and 
      acetaminophen increased CT further (290+/-22 s, 281+/-36 s, 288+/-25 s, 
      respectively, P<0.001). The time sequence of drug application was important: when 
      diclofenac or acetaminophen was added before aspirin, platelet aggregation was 
      less inhibited than when given in opposite order, i.e. aspirin prior to 
      diclofenac or acetaminophen. We conclude that acetaminophen by itself does not 
      affect platelet aggregation, but potentiates the antiaggregatory effect of 
      aspirin or diclofenac. Aspirin given before acetaminophen or diclofenac had a 
      more potent antiaggregatory effect than vice versa. These observations may have 
      clinical implications.
FAU - Galliard-Grigioni, Katja S
AU  - Galliard-Grigioni KS
AD  - Department of Internal Medicine, Kantonsspital Graubünden, Switzerland.
FAU - Fehr, Martin
AU  - Fehr M
FAU - Reinhart, Walter H
AU  - Reinhart WH
LA  - eng
PT  - Journal Article
DEP - 20080730
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Adult
MH  - Aged
MH  - Analgesics, Non-Narcotic/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Diclofenac/*pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
EDAT- 2008/08/14 09:00
MHDA- 2008/11/19 09:00
CRDT- 2008/08/14 09:00
PHST- 2008/01/28 00:00 [received]
PHST- 2008/07/17 00:00 [revised]
PHST- 2008/07/23 00:00 [accepted]
PHST- 2008/08/14 09:00 [pubmed]
PHST- 2008/11/19 09:00 [medline]
PHST- 2008/08/14 09:00 [entrez]
AID - S0014-2999(08)00791-7 [pii]
AID - 10.1016/j.ejphar.2008.07.036 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2008 Oct 24;595(1-3):65-8. doi: 10.1016/j.ejphar.2008.07.036. 
      Epub 2008 Jul 30.

PMID- 9744825
OWN - NLM
STAT- MEDLINE
DCOM- 19981001
LR  - 20190514
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 51
IP  - 3 Suppl 3
DP  - 1998 Sep
TI  - Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: a 
      review of clinical trial results.
PG  - S15-6
AB  - Publication of the results of the second European Stroke Prevention Study 
      (ESPS-2) provided the incentive for an update of the meta-analyses of aspirin and 
      dipyridamole in the secondary prevention of stroke. After review of published 
      randomized trials of prolonged treatment with aspirin, dipyridamole, or their 
      combination in patients with a history of stroke or transient ischemic attack 
      (TIA), data on the occurrence of stroke, myocardial infarction, and vascular 
      death were used to calculate overall relative risk reductions. The relative risk 
      reduction for aspirin versus placebo was 13%. The same relative risk reduction 
      was found in separate meta-analyses of trials with high (1,000-1,500 mg), medium 
      (250-500 mg), and low (50-100 mg) doses of aspirin. Trials in which different 
      doses were compared showed no difference in the occurrence of vascular events. 
      The addition of dipyridamole to low-dose aspirin further reduced the risk for 
      vascular events by 15%. We conclude from current trials that low-dose aspirin 
      alone reduced the risk of vascular events in patients with prior stroke or TIA by 
      13%. There is no evidence of a dose-effect relationship. An additional reduction 
      of the risk by 15% can be obtained by adding dipyridamole to aspirin. The overall 
      evidence for the relative effects of the combination of dipyridamole and aspirin 
      versus aspirin alone or placebo is highly consistent. The clinical evidence now 
      favors the two agents in combination over aspirin alone.
FAU - Tijssen, J G
AU  - Tijssen JG
AD  - Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, 
      University of Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Cerebrovascular Disorders/drug therapy/*prevention & control
MH  - *Controlled Clinical Trials as Topic
MH  - Dipyridamole/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
RF  - 13
EDAT- 1998/09/23 00:00
MHDA- 1998/09/23 00:01
CRDT- 1998/09/23 00:00
PHST- 1998/09/23 00:00 [pubmed]
PHST- 1998/09/23 00:01 [medline]
PHST- 1998/09/23 00:00 [entrez]
AID - 10.1212/wnl.51.3_suppl_3.s15 [doi]
PST - ppublish
SO  - Neurology. 1998 Sep;51(3 Suppl 3):S15-6. doi: 10.1212/wnl.51.3_suppl_3.s15.

PMID- 37338713
OWN - NLM
STAT- MEDLINE
DCOM- 20230713
LR  - 20230718
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 56
IP  - 2
DP  - 2023 Aug
TI  - On-treatment platelet reactivity through the thromboxane A(2) or P2Y12 platelet 
      receptor pathways is not affected by pelacarsen.
PG  - 226-232
LID - 10.1007/s11239-023-02818-6 [doi]
AB  - BACKGROUND: Pelacarsen decreases plasma levels of lipoprotein(a) [Lp(a)] and 
      oxidized phospholipids (OxPL). It was previously reported that pelacarsen does 
      not affect the platelet count. We now report the effect of pelacarsen on 
      on-treatment platelet reactivity. METHODS: Subjects with established 
      cardiovascular disease and screening Lp(a) levels ≥60 mg per deciliter (~ ≥150 
      nmol/L) were randomized to receive pelacarsen (20, 40, or 60 mg every 4 weeks; 
      20 mg every 2 weeks; or 20 mg every week), or placebo for 6-12 months. Aspirin 
      Reaction Units (ARU) and P2Y12 Reaction Units (PRU) were measured at baseline and 
      the primary analysis timepoint (PAT) at 6 months. RESULTS: Of the 286 subjects 
      randomized, 275 had either an ARU or PRU test, 159 (57.8%) were on aspirin alone 
      and 94 (34.2%) subjects were on dual anti-platelet therapy. As expected, the 
      baseline ARU and PRU were suppressed in subjects on aspirin or on dual 
      anti-platelet therapy, respectively. There were no significant differences in 
      baseline ARU in the aspirin groups or in PRU in the dual anti-platelet groups. At 
      the PAT there were no statistically significant differences in ARU in subjects on 
      aspirin or PRU in subjects on dual anti-platelet therapy among any of the 
      pelacarsen groups compared to the pooled placebo group (p > 0.05 for all 
      comparisons). CONCLUSION: Pelacarsen does not modify on-treatment platelet 
      reactivity through the thromboxane A(2) or P2Y12 platelet receptor pathways.
CI  - © 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Karwatowska-Prokopczuk, Ewa
AU  - Karwatowska-Prokopczuk E
AD  - Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.
FAU - Li, Lu
AU  - Li L
AD  - Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.
FAU - Yang, Jun
AU  - Yang J
AD  - Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.
FAU - Witztum, Joseph L
AU  - Witztum JL
AD  - Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.
FAU - Tsimikas, Sotirios
AU  - Tsimikas S
AUID- ORCID: 0000-0001-9834-9494
AD  - Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA. stsimikas@health.ucsd.edu.
AD  - Vascular Medicine Program, Sulpizio Cardiovascular Center, University of 
      California San Diego, 9500 Gilman Drive, BSB 1080, La Jolla, CA, 92093-0682, USA. 
      stsimikas@health.ucsd.edu.
LA  - eng
GR  - Ionis Pharmaceuticals/Ionis Pharmaceuticals/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20230620
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
SB  - IM
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Clopidogrel/pharmacology
MH  - *Thromboxanes
MH  - Prospective Studies
MH  - Blood Platelets
MH  - Aspirin/therapeutic use
MH  - Platelet Function Tests
MH  - Treatment Outcome
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
OTO - NOTNLM
OT  - Antisense
OT  - Cardiovascular disease
OT  - Lipoprotein(a)
OT  - Oxidized phospholipids
OT  - Platelet reactivity
OT  - Therapy
EDAT- 2023/06/20 13:10
MHDA- 2023/07/13 06:42
CRDT- 2023/06/20 11:11
PHST- 2023/04/14 00:00 [accepted]
PHST- 2023/07/13 06:42 [medline]
PHST- 2023/06/20 13:10 [pubmed]
PHST- 2023/06/20 11:11 [entrez]
AID - 10.1007/s11239-023-02818-6 [pii]
AID - 10.1007/s11239-023-02818-6 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2023 Aug;56(2):226-232. doi: 10.1007/s11239-023-02818-6. 
      Epub 2023 Jun 20.

PMID- 7695475
OWN - NLM
STAT- MEDLINE
DCOM- 19950421
LR  - 20190904
IS  - 0365-6233 (Print)
IS  - 0365-6233 (Linking)
VI  - 328
IP  - 1
DP  - 1995 Jan
TI  - New no-donors with antithrombotic and vasodilating activities, X: Antiplatelet 
      and antithrombotic effects of 3-methylsydnone-5-nitrosimine (RE 2047) in 
      combination with ASA, pentoxifylline, and ticlopidine.
PG  - 71-8
AB  - The combined effects of the NO-donor RE 2047 with ASA, pentoxifylline, 
      ticlopidine or BM 14515 were determined in vitro (Born-test) and in vivo (rat 
      thrombosis model). The inhibitory effects on platelet aggregation as well as the 
      inhibition of thrombus formation in vivo were over additive and over independent. 
      The combination of 10 mg/kg RE 2047 with the same dose of ASA in arterioles (A) 
      showed 70% inhibition of thrombosis (venoles (V): 40%). The respective values for 
      10 mg/kg RE 2047 and 10 mg/kg pentoxifylline are 70% (A) and 35% (V). It is 
      concluded that NO-donors in principle are compounds suitable for the combination 
      with antithrombotic drugs of different mechanism of action.
FAU - Rehse, K
AU  - Rehse K
AD  - Institut für Pharmazie, Freien Universität Berlin.
FAU - Ciborski, T
AU  - Ciborski T
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arch Pharm (Weinheim)
JT  - Archiv der Pharmazie
JID - 0330167
RN  - 0 (3-methylsydnone-5-nitrosimine)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Sydnones)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Drug Synergism
MH  - Fibrinolytic Agents/*pharmacology
MH  - Pentoxifylline/pharmacology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rats
MH  - Sydnones/*pharmacology
MH  - Ticlopidine/pharmacology
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1002/ardp.19953280113 [doi]
PST - ppublish
SO  - Arch Pharm (Weinheim). 1995 Jan;328(1):71-8. doi: 10.1002/ardp.19953280113.

PMID- 14636445
OWN - NLM
STAT- MEDLINE
DCOM- 20040405
LR  - 20131121
IS  - 1007-3418 (Print)
IS  - 1007-3418 (Linking)
VI  - 11
IP  - 11
DP  - 2003 Nov
TI  - [Cooperative anti-tumor effect of aspirin and TNF-related apoptosis-inducing 
      ligand].
PG  - 676-9
AB  - OBJECTIVE: To observe the anti-tumor effect of combination TNF-related 
      apoptosis-inducing ligand (TRAIL) with aspirin on liver cancer cell line, 
      SMMC-7721. METHODS: The survival fraction of SMMC-7721 cells was measured by MTT 
      assay, apoptosis rate and cell cycle was determined by flow cytometry, and the 
      expression of apoptosis-related gene was identified by western blot. RESULTS: The 
      survival fraction of SMMC-7721 cells treated with 300 ng/ml TRAIL, 3 mmol/L or 10 
      mmol/L aspirin alone was 82.76%, 81.34% and 71.29% respectively, and the survival 
      fractions of SMMC-7721 cells treated with TRAIL and 3 mmol/L or 10 mmol/L aspirin 
      were 43.54% and 37.8% respectively. The apoptosis rates of SMMC-7721 cells 
      induced by TRAIL and 3 mmol/L or 10 mmol/L aspirin were higher than that induced 
      by TRAIL or aspirin alone (34.76% and 38.56% vs 21.25%, 1.89% and 6.08%), and 
      G0/G1 arrest was observed under TRAIL and aspirin. The expression of Bcl-2 in 
      SMMC-7721 cells treated by 3 mmol/L or 10 mmol/L aspirin decreased markedly, but 
      no effect on Bax. CONCLUSION: The cooperative anti-tumor effect of aspirin and 
      TRAIL may be related to the inhibition of the expression of Bcl-2 by aspirin
FAU - Li, Xiao-an
AU  - Li XA
AD  - Department of Gastroenterology, Southwest Hospital, Third Military Medical 
      University, Chongqing 400038, China.
FAU - Fang, Dian-chun
AU  - Fang DC
FAU - Si, Pei-ren
AU  - Si PR
FAU - Zhang, Ru-gang
AU  - Zhang RG
FAU - Yang, Liu-qin
AU  - Yang LQ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Gan Zang Bing Za Zhi
JT  - Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of 
      hepatology
JID - 9710009
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (TNFSF10 protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - *Apoptosis
MH  - Apoptosis Regulatory Proteins
MH  - Aspirin/*pharmacology
MH  - Cell Survival/drug effects
MH  - Humans
MH  - Membrane Glycoproteins/*pharmacology
MH  - Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors
MH  - TNF-Related Apoptosis-Inducing Ligand
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/*pharmacology
EDAT- 2003/11/26 05:00
MHDA- 2004/04/06 05:00
CRDT- 2003/11/26 05:00
PHST- 2003/11/26 05:00 [pubmed]
PHST- 2004/04/06 05:00 [medline]
PHST- 2003/11/26 05:00 [entrez]
PST - ppublish
SO  - Zhonghua Gan Zang Bing Za Zhi. 2003 Nov;11(11):676-9.

PMID- 30081048
OWN - NLM
STAT- MEDLINE
DCOM- 20200203
LR  - 20220129
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Print)
IS  - 0163-7258 (Linking)
VI  - 193
DP  - 2019 Jan
TI  - Anti-platelet drugs and their necessary interaction with endothelial mediators 
      and platelet cyclic nucleotides for therapeutic efficacy.
PG  - 83-90
LID - S0163-7258(18)30136-0 [pii]
LID - 10.1016/j.pharmthera.2018.08.004 [doi]
AB  - For many millions of patients at secondary risk of coronary thrombosis 
      pharmaceutical protection is supplied by dual anti-platelet therapy. Despite 
      substantial therapeutic developments over the last decade recurrent thrombotic 
      events occur, highlighting the need for further optimisation of therapies. 
      Importantly, but often ignored, anti-platelet drugs interact with cyclic 
      nucleotide systems in platelets and these are the same systems that mediate key 
      endogenous pathways of platelet regulation, notably those dependent upon the 
      vascular endothelium. The aim of this review is to highlight interactions between 
      the anti-platelet drugs, aspirin and P2Y(12) receptor antagonists and endogenous 
      pathways of platelet regulation at the level of cyclic nucleotides. These 
      considerations are key to concepts such as anti-platelet drug resistance and 
      individualized anti-platelet therapy which cannot be understood by study of 
      platelets in isolation from the circulatory environment. We also explore novel 
      and emerging therapies that focus on preserving haemostasis and how the concepts 
      outlined in this review could be exploited therapeutically to improve 
      anti-thrombotic efficacy whilst reducing bleeding risk.
CI  - Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Knowles, Rebecca B
AU  - Knowles RB
AD  - The Blizard Institute, Barts and the London School of Medicine and Dentistry, 
      Queen Mary University of London, London, UK.
FAU - Warner, Timothy D
AU  - Warner TD
AD  - The Blizard Institute, Barts and the London School of Medicine and Dentistry, 
      Queen Mary University of London, London, UK. Electronic address: 
      t.d.warner@qmul.ac.uk.
LA  - eng
GR  - FS/12/53/29643/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180804
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Nucleotides, Cyclic)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Endothelium, Vascular/drug effects
MH  - Humans
MH  - Nucleotides, Cyclic/metabolism
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Purinergic P2Y Receptor Antagonists/*pharmacology
PMC - PMC6325790
OTO - NOTNLM
OT  - Cyclic nucleotide
OT  - Dual antiplatelet therapy
OT  - Endothelium
OT  - Platelet
OT  - Thrombosis
EDAT- 2018/08/07 06:00
MHDA- 2020/02/06 06:00
CRDT- 2018/08/07 06:00
PHST- 2018/08/07 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
PHST- 2018/08/07 06:00 [entrez]
AID - S0163-7258(18)30136-0 [pii]
AID - 10.1016/j.pharmthera.2018.08.004 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2019 Jan;193:83-90. doi: 10.1016/j.pharmthera.2018.08.004. Epub 
      2018 Aug 4.

PMID- 26330567
OWN - NLM
STAT- MEDLINE
DCOM- 20160112
LR  - 20210105
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 85
IP  - 13
DP  - 2015 Sep 29
TI  - Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE.
PG  - 1154-62
AB  - AB OBJECTIVE: We aimed to investigate whether the efficacy and safety of 
      clopidogrel plus aspirin vs aspirin alone were consistent between patients with 
      and without intracranial arterial stenosis (ICAS), in the Clopidogrel in 
      High-Risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) 
      trial. METHODS: We assessed the interaction of the treatment effects of the 2 
      antiplatelet therapies among patients with and without ICAS, identified by 
      magnetic resonance angiography (MRA) in CHANCE (ClinicalTrials.gov identifier 
      NCT00979589). RESULTS: Overall, 1,089 patients with MRA images available in 
      CHANCE were included in this subanalysis, 608 patients (55.8%) with ICAS and 481 
      (44.2%) without. Patients with ICAS had higher rates of recurrent stroke (12.5% 
      vs 5.4%; p<0.0001) at 90 days than those without. But there was no statistically 
      significant treatment by presence of ICAS interaction on either the primary 
      outcome of any stroke (hazard ratio for clopidogrel plus aspirin vs aspirin 
      alone: 0.79 [0.47-1.32] vs 1.12 [0.56-2.25]; interaction p=0.522) or the safety 
      outcome of any bleeding event (interaction p=0.277). CONCLUSIONS: The results 
      indicated higher rate of recurrent stroke in minor stroke or high-risk TIA 
      patients with ICAS than in those without. However, there was no significant 
      difference in the response to the 2 antiplatelet therapies between patients with 
      and without ICAS in the CHANCE trial. Classification of evidence: This study 
      provides Class II evidence that for patients with acute minor stroke or TIA with 
      and without ICAS identified by MRA, clopidogrel plus aspirin is not significantly 
      different than aspirin alone in preventing recurrent stroke.
CI  - © 2015 American Academy of Neurology.
FAU - Liu, Liping
AU  - Liu L
FAU - Wong, Ka Sing Lawrence
AU  - Wong KS
FAU - Leng, Xinyi
AU  - Leng X
FAU - Pu, Yuehua
AU  - Pu Y
FAU - Wang, Yilong
AU  - Wang Y
FAU - Jing, Jing
AU  - Jing J
FAU - Zou, Xinying
AU  - Zou X
FAU - Pan, Yuesong
AU  - Pan Y
FAU - Wang, Anxin
AU  - Wang A
FAU - Meng, Xia
AU  - Meng X
FAU - Wang, Chunxue
AU  - Wang C
FAU - Zhao, Xingquan
AU  - Zhao X
FAU - Soo, Yannie
AU  - Soo Y
FAU - Johnston, S Claiborne
AU  - Johnston SC
FAU - Wang, Yongjun
AU  - Wang Y
CN  - CHANCE Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00979589
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Clopidogrel
MH  - Constriction, Pathologic/pathology
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Intracranial Arterial Diseases/*drug therapy/prevention & control
MH  - Ischemic Attack, Transient/*drug therapy/prevention & control
MH  - Magnetic Resonance Angiography
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*pharmacology
MH  - Recurrence
MH  - Stroke/*drug therapy/prevention & control
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacology
MH  - Treatment Outcome
PMC - PMC4603889
FIR - Wang, Zhimin
IR  - Wang Z
FIR - Wang, Yongjun
IR  - Wang Y
FIR - Xia, Haiqin
IR  - Xia H
FIR - Li, Bin
IR  - Li B
FIR - Zhang, Guiru
IR  - Zhang G
FIR - Ren, Xudong
IR  - Ren X
FIR - Ji, Chunling
IR  - Ji C
FIR - Zhang, Guohua
IR  - Zhang G
FIR - Li, Jianhua
IR  - Li J
FIR - Lu, Bohua
IR  - Lu B
FIR - Wang, Liping
IR  - Wang L
FIR - Feng, Shutao
IR  - Feng S
FIR - Wang, Dali
IR  - Wang D
FIR - Tang, Weiguo
IR  - Tang W
FIR - Li, Juntao
IR  - Li J
FIR - Zhang, Hongtian
IR  - Zhang H
FIR - Li, Guanglai
IR  - Li G
FIR - Wang, Baojun
IR  - Wang B
FIR - Chen, Yuhua
IR  - Chen Y
FIR - Lian, Ying
IR  - Lian Y
FIR - Liu, Bin
IR  - Liu B
FIR - Teng, Junfang
IR  - Teng J
FIR - Sui, Rubo
IR  - Sui R
FIR - Li, Lejun
IR  - Li L
FIR - Yuan, Zhiling
IR  - Yuan Z
FIR - Zang, Dawei
IR  - Zang D
FIR - Lu, Zuneng
IR  - Lu Z
FIR - Sun, Li
IR  - Sun L
FIR - Wang, Dong
IR  - Wang D
FIR - Hou, Liying
IR  - Hou L
FIR - Yuan, Dongcai
IR  - Yuan D
FIR - Cao, Yongliang
IR  - Cao Y
FIR - Li, Hui
IR  - Li H
FIR - Tan, Xiuge
IR  - Tan X
FIR - Wang, Huicong
IR  - Wang H
FIR - Du, Haisong
IR  - Du H
FIR - Liu, Mingyi
IR  - Liu M
FIR - Wang, Suping
IR  - Wang S
FIR - Liu, Qiuwu
IR  - Liu Q
FIR - Zhang, Zhong
IR  - Zhang Z
FIR - Cui, Qifu
IR  - Cui Q
FIR - Wang, Runqing
IR  - Wang R
FIR - Zhao, Jialin
IR  - Zhao J
FIR - Zhang, Jiewen
IR  - Zhang J
FIR - Zhao, Jianping
IR  - Zhao J
FIR - Bi, Qi
IR  - Bi Q
FIR - Qi, Xiyou
IR  - Qi X
FIR - Liu, Junyan
IR  - Liu J
FIR - Li, Changxin
IR  - Li C
FIR - Li, Ling Lv
IR  - Li LL
FIR - Pan, Xiaoping
IR  - Pan X
FIR - Zhang, Junling
IR  - Zhang J
FIR - Jiao, Derang
IR  - Jiao D
FIR - Han, Zhao
IR  - Han Z
FIR - Qian, Dawei
IR  - Qian D
FIR - Xiao, Jin
IR  - Xiao J
FIR - Xing, Yan
IR  - Xing Y
FIR - Du, Huishan
IR  - Du H
FIR - Huang, Guang
IR  - Huang G
FIR - Cui, Yongqiang
IR  - Cui Y
FIR - Li, Yan
IR  - Li Y
FIR - Feng, Lianyuan
IR  - Feng L
FIR - Gao, Lianbo
IR  - Gao L
FIR - Xiao, Bo
IR  - Xiao B
FIR - Cao, Yibin
IR  - Cao Y
FIR - Wu, Yiping
IR  - Wu Y
FIR - Liu, Jinfeng
IR  - Liu J
FIR - Zhang, Zhiming
IR  - Zhang Z
FIR - Dong, Zhengxie
IR  - Dong Z
FIR - Wang, Limin
IR  - Wang L
FIR - Wang, Xinchen
IR  - Wang X
FIR - Guo, Xueying
IR  - Guo X
FIR - Wang, Ming
IR  - Wang M
FIR - Wang, Xiaosha
IR  - Wang X
FIR - Jiang, Jiandong
IR  - Jiang J
FIR - Zhao, Renliang
IR  - Zhao R
FIR - Zhou, Shengnian
IR  - Zhou S
FIR - Hu, Hao
IR  - Hu H
FIR - He, Maolin
IR  - He M
FIR - Yu, Fengchun
IR  - Yu F
FIR - Ouyang, Quping
IR  - Ouyang Q
FIR - Zhang, Jingbo
IR  - Zhang J
FIR - Xu, Anding
IR  - Xu A
FIR - Qi, Xiaokun
IR  - Qi X
FIR - Wang, Lei
IR  - Wang L
FIR - Shi, Fuming
IR  - Shi F
FIR - Guo, Fuqiang
IR  - Guo F
FIR - Wang, Jianfeng
IR  - Wang J
FIR - Zhao, Fengli
IR  - Zhao F
FIR - Dou, Ronghua
IR  - Dou R
FIR - Wei, Dongning
IR  - Wei D
FIR - Meng, Qingwei
IR  - Meng Q
FIR - Xia, Yilu
IR  - Xia Y
FIR - Wang, Shimin
IR  - Wang S
FIR - Xue, Zhangcang
IR  - Xue Z
FIR - Xu, Yuming
IR  - Xu Y
FIR - Ma, Liping
IR  - Ma L
FIR - Wang, Chun
IR  - Wang C
FIR - Wu, Jiang
IR  - Wu J
FIR - Du, Yifeng
IR  - Du Y
FIR - Wang, Yinzhou
IR  - Wang Y
FIR - Xiao, Lijun
IR  - Xiao L
FIR - Song, Fucong
IR  - Song F
FIR - Hu, Wenli
IR  - Hu W
FIR - Chen, Zhigang
IR  - Chen Z
FIR - Liu, Qingrui
IR  - Liu Q
FIR - Zhang, Jiemin
IR  - Zhang J
FIR - Chen, Mei
IR  - Chen M
FIR - Yuan, Xiaodong
IR  - Yuan X
FIR - Liu, Zhihui
IR  - Liu Z
FIR - Li, Guozhong
IR  - Li G
FIR - Li, Xiaohong
IR  - Li X
FIR - Tian, Tingchen
IR  - Tian T
EDAT- 2015/09/04 06:00
MHDA- 2016/01/13 06:00
CRDT- 2015/09/03 06:00
PHST- 2015/02/03 00:00 [received]
PHST- 2015/06/03 00:00 [accepted]
PHST- 2015/09/03 06:00 [entrez]
PHST- 2015/09/04 06:00 [pubmed]
PHST- 2016/01/13 06:00 [medline]
AID - WNL.0000000000001972 [pii]
AID - NEUROLOGY2015644500 [pii]
AID - 10.1212/WNL.0000000000001972 [doi]
PST - ppublish
SO  - Neurology. 2015 Sep 29;85(13):1154-62. doi: 10.1212/WNL.0000000000001972.

PMID- 25740863
OWN - NLM
STAT- MEDLINE
DCOM- 20150618
LR  - 20221207
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 84
IP  - 13
DP  - 2015 Mar 31
TI  - Glycated albumin predicts the effect of dual and single antiplatelet therapy on 
      recurrent stroke.
PG  - 1330-6
LID - 10.1212/WNL.0000000000001421 [doi]
AB  - OBJECTIVE: To determine the relationship of glycated albumin (GA) and the 
      recurrence of stroke in patients on either dual or single antiplatelet therapy. 
      METHODS: The Clopidogrel in High-Risk Patients with Acute Nondisabling 
      Cerebrovascular Events trial randomized minor ischemic stroke or TIA patients to 
      antiplatelet therapy of clopidogrel plus aspirin or aspirin alone. A subgroup of 
      3,044 consecutive patients with baseline GA levels from 73 (64%) prespecified 
      clinical sites was analyzed. Patients were categorized into 2 groups based on GA 
      level of 15.5%, the cut point for development of diabetes. The primary outcome 
      was stroke recurrence during 90-day follow-up. Cox proportional hazards models 
      were used to assess the interaction of GA with randomized antiplatelet therapy on 
      their risk of recurrent stroke. RESULTS: Significant interaction of GA levels 
      with the 2 antiplatelet therapy groups was found after adjustment for age, sex, 
      and other conventional confounding factors (p = 0.009). The interaction remained 
      consistent after further adjustment for history of diabetes (p = 0.010). In 
      patients with lower GA level, stroke occurred in 5.5% of patients in the 
      clopidogrel-aspirin group, and 12.7% in the aspirin group (adjusted hazard ratio 
      [HR] 0.40; 95% confidence interval [CI] 0.26-0.61; p < 0.001). Furthermore, in 
      patients with elevated GA level, stroke occurred in 9.2% of patients in the 
      clopidogrel-aspirin group, and 11.4% in the aspirin group (adjusted HR 0.79; 95% 
      CI 0.60-1.05; p = 0.103). CONCLUSIONS: GA could be a potential biomarker to 
      predict the effects of dual and single antiplatelet therapy in patients with 
      minor stroke or TIA.
CI  - © 2015 American Academy of Neurology.
FAU - Li, Jiejie
AU  - Li J
AD  - From the Department of Neurology (J.L., Y.W., J.L., A.W., X.Z., L.L., C.W., 
      Y.W.), Beijing Tiantan Hospital, Capital Medical University; China National 
      Clinical Research Center for Neurological Diseases (Y.W.), Beijing; Center of 
      Stroke (Y.W.), Beijing Institute for Brain Disorders, China; and the Illinois 
      Neurological Institute Stroke Network (D.W.), Sisters of the Third Order of St. 
      Francis Healthcare System, University of Illinois College of Medicine, Peoria.
FAU - Wang, Yilong
AU  - Wang Y
AD  - From the Department of Neurology (J.L., Y.W., J.L., A.W., X.Z., L.L., C.W., 
      Y.W.), Beijing Tiantan Hospital, Capital Medical University; China National 
      Clinical Research Center for Neurological Diseases (Y.W.), Beijing; Center of 
      Stroke (Y.W.), Beijing Institute for Brain Disorders, China; and the Illinois 
      Neurological Institute Stroke Network (D.W.), Sisters of the Third Order of St. 
      Francis Healthcare System, University of Illinois College of Medicine, Peoria.
FAU - Wang, David
AU  - Wang D
AD  - From the Department of Neurology (J.L., Y.W., J.L., A.W., X.Z., L.L., C.W., 
      Y.W.), Beijing Tiantan Hospital, Capital Medical University; China National 
      Clinical Research Center for Neurological Diseases (Y.W.), Beijing; Center of 
      Stroke (Y.W.), Beijing Institute for Brain Disorders, China; and the Illinois 
      Neurological Institute Stroke Network (D.W.), Sisters of the Third Order of St. 
      Francis Healthcare System, University of Illinois College of Medicine, Peoria.
FAU - Lin, Jinxi
AU  - Lin J
AD  - From the Department of Neurology (J.L., Y.W., J.L., A.W., X.Z., L.L., C.W., 
      Y.W.), Beijing Tiantan Hospital, Capital Medical University; China National 
      Clinical Research Center for Neurological Diseases (Y.W.), Beijing; Center of 
      Stroke (Y.W.), Beijing Institute for Brain Disorders, China; and the Illinois 
      Neurological Institute Stroke Network (D.W.), Sisters of the Third Order of St. 
      Francis Healthcare System, University of Illinois College of Medicine, Peoria.
FAU - Wang, Anxin
AU  - Wang A
AD  - From the Department of Neurology (J.L., Y.W., J.L., A.W., X.Z., L.L., C.W., 
      Y.W.), Beijing Tiantan Hospital, Capital Medical University; China National 
      Clinical Research Center for Neurological Diseases (Y.W.), Beijing; Center of 
      Stroke (Y.W.), Beijing Institute for Brain Disorders, China; and the Illinois 
      Neurological Institute Stroke Network (D.W.), Sisters of the Third Order of St. 
      Francis Healthcare System, University of Illinois College of Medicine, Peoria.
FAU - Zhao, Xingquan
AU  - Zhao X
AD  - From the Department of Neurology (J.L., Y.W., J.L., A.W., X.Z., L.L., C.W., 
      Y.W.), Beijing Tiantan Hospital, Capital Medical University; China National 
      Clinical Research Center for Neurological Diseases (Y.W.), Beijing; Center of 
      Stroke (Y.W.), Beijing Institute for Brain Disorders, China; and the Illinois 
      Neurological Institute Stroke Network (D.W.), Sisters of the Third Order of St. 
      Francis Healthcare System, University of Illinois College of Medicine, Peoria.
FAU - Liu, Liping
AU  - Liu L
AD  - From the Department of Neurology (J.L., Y.W., J.L., A.W., X.Z., L.L., C.W., 
      Y.W.), Beijing Tiantan Hospital, Capital Medical University; China National 
      Clinical Research Center for Neurological Diseases (Y.W.), Beijing; Center of 
      Stroke (Y.W.), Beijing Institute for Brain Disorders, China; and the Illinois 
      Neurological Institute Stroke Network (D.W.), Sisters of the Third Order of St. 
      Francis Healthcare System, University of Illinois College of Medicine, Peoria.
FAU - Wang, Chunxue
AU  - Wang C
AD  - From the Department of Neurology (J.L., Y.W., J.L., A.W., X.Z., L.L., C.W., 
      Y.W.), Beijing Tiantan Hospital, Capital Medical University; China National 
      Clinical Research Center for Neurological Diseases (Y.W.), Beijing; Center of 
      Stroke (Y.W.), Beijing Institute for Brain Disorders, China; and the Illinois 
      Neurological Institute Stroke Network (D.W.), Sisters of the Third Order of St. 
      Francis Healthcare System, University of Illinois College of Medicine, Peoria.
FAU - Wang, Yongjun
AU  - Wang Y
AD  - From the Department of Neurology (J.L., Y.W., J.L., A.W., X.Z., L.L., C.W., 
      Y.W.), Beijing Tiantan Hospital, Capital Medical University; China National 
      Clinical Research Center for Neurological Diseases (Y.W.), Beijing; Center of 
      Stroke (Y.W.), Beijing Institute for Brain Disorders, China; and the Illinois 
      Neurological Institute Stroke Network (D.W.), Sisters of the Third Order of St. 
      Francis Healthcare System, University of Illinois College of Medicine, Peoria. 
      yongjunwang1962@gmail.com.
CN  - CHANCE Investigators
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150304
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Biomarkers)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Serum Albumin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Glycated Serum Albumin)
SB  - IM
CIN - Neurology. 2015 Mar 31;84(13):1334. PMID: 25740866
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Biomarkers/blood
MH  - Clopidogrel
MH  - Double-Blind Method
MH  - Drug Therapy, Combination/adverse effects
MH  - Female
MH  - Glycation End Products, Advanced
MH  - Humans
MH  - Ischemic Attack, Transient/blood/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Recurrence
MH  - Serum Albumin/*metabolism
MH  - Stroke/blood/*drug therapy
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Glycated Serum Albumin
EDAT- 2015/03/06 06:00
MHDA- 2015/06/19 06:00
CRDT- 2015/03/06 06:00
PHST- 2015/03/06 06:00 [entrez]
PHST- 2015/03/06 06:00 [pubmed]
PHST- 2015/06/19 06:00 [medline]
AID - WNL.0000000000001421 [pii]
AID - 10.1212/WNL.0000000000001421 [doi]
PST - ppublish
SO  - Neurology. 2015 Mar 31;84(13):1330-6. doi: 10.1212/WNL.0000000000001421. Epub 
      2015 Mar 4.

PMID- 19122977
OWN - NLM
STAT- MEDLINE
DCOM- 20090915
LR  - 20131121
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Linking)
VI  - 20
IP  - 5
DP  - 2009 Jul
TI  - Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal 
      cancer: a Danish cohort study.
PG  - 731-40
LID - 10.1007/s10552-008-9286-7 [doi]
AB  - OBJECTIVE: The optimal duration and dose of aspirin and non-aspirin non-steroidal 
      anti-inflammatory drugs (NSAIDs) in the potential prevention of colorectal cancer 
      (CRC) have not been established. We examined this issue in the Danish Diet, 
      Cancer, and Health Study. METHODS: Self-reported NSAID use at entry (January 
      1995-May 1997) was updated through June 2006, using a nationwide prescription 
      database. CRC incidence was ascertained from nationwide registers. Cox 
      proportional hazards regression was used to compute confounder-adjusted incidence 
      rate ratios (RRs) and 95% confidence intervals (CIs). RESULTS: From 51,053 cohort 
      subjects, we identified 615 CRC cases during 1995-2006. Daily aspirin use at 
      entry was associated with a decreased risk of CRC (RR, 0.73; 95% CI, 0.49-1.10). 
      A similar risk reduction was seen among subjects with 10 or more prescriptions 
      for aspirin or non-aspirin NSAIDs and five or more years of follow-up. Most 
      aspirin prescriptions were for 75-150 mg aspirin tablets. Among non-aspirin NSAID 
      users, only those with body mass index (BMI) above 25 showed risk reductions [RR, 
      0.69 (0.47-1.03) for 10 or more prescriptions]. CONCLUSIONS: Long-term consistent 
      use of aspirin or non-aspirin NSAIDs appears necessary to achieve a protective 
      effect against CRC. Further studies of the effective dose of aspirin and the 
      potential interaction between NSAID use and BMI are warranted.
FAU - Friis, Søren
AU  - Friis S
AD  - Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, 
      2100 Copenhagen, Denmark. friis@cancer.dk
FAU - Poulsen, Aslak H
AU  - Poulsen AH
FAU - Sørensen, Henrik Toft
AU  - Sørensen HT
FAU - Tjønneland, Anne
AU  - Tjønneland A
FAU - Overvad, Kim
AU  - Overvad K
FAU - Vogel, Ulla
AU  - Vogel U
FAU - McLaughlin, Joseph K
AU  - McLaughlin JK
FAU - Blot, William J
AU  - Blot WJ
FAU - Olsen, Jørgen H
AU  - Olsen JH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090103
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cohort Studies
MH  - Colorectal Neoplasms/*epidemiology/prevention & control
MH  - Denmark
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2009/01/06 09:00
MHDA- 2009/09/16 06:00
CRDT- 2009/01/06 09:00
PHST- 2008/09/22 00:00 [received]
PHST- 2008/12/09 00:00 [accepted]
PHST- 2009/01/06 09:00 [entrez]
PHST- 2009/01/06 09:00 [pubmed]
PHST- 2009/09/16 06:00 [medline]
AID - 10.1007/s10552-008-9286-7 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2009 Jul;20(5):731-40. doi: 10.1007/s10552-008-9286-7. 
      Epub 2009 Jan 3.

PMID- 11696508
OWN - NLM
STAT- MEDLINE
DCOM- 20011221
LR  - 20190503
IS  - 1472-0205 (Print)
IS  - 1472-0213 (Electronic)
IS  - 1472-0205 (Linking)
VI  - 18
IP  - 6
DP  - 2001 Nov
TI  - Pre-hospital aspirin for suspected myocardial infarction and acute coronary 
      syndromes: a headache for paramedics?
PG  - 478-81
AB  - OBJECTIVE: To ascertain the frequency with which paramedics follow protocols for 
      the administration of aspirin to patients to whom an ambulance is called for 
      chest pain associated with suspected ischaemic heart disease. METHODS: Ambulance 
      services in England and Wales who had conducted a recent aspirin administration 
      audit were identified through the National Clinical Effectiveness Programme for 
      the Ambulance Service Association. Data were requested from each of these 
      services with a 100% return rate. RESULTS: Nine services out of a total of 35 had 
      collected appropriate data. The proportion of patients who were given aspirin by 
      a paramedic varied from 11% to 74%. The range of proportions of patients 
      receiving pre-hospital aspirin increased after adding those patients who had 
      already received aspirin from an alternative health provider, to 19% to 78%. It 
      is estimated that at least 15% to 74% of patients who should have been given 
      aspirin by the various ambulance services did not receive it. The proportion of 
      patients for whom aspirin was judged to be inappropriate ranged from 4% to 35%. 
      The reason for these widely varying and generally poor levels of compliance is 
      not known. However, the range of indications and contraindications to the 
      administration of aspirin varied considerably by ambulance service. This also 
      made the comparison of data from different sources difficult. CONCLUSIONS: 
      Aspirin has been shown to be beneficial after a myocardial infarction and for 
      other acute coronary syndromes. However, variances in the proportion of patients 
      with suspected ischaemic heart disease given aspirin in different ambulance 
      services indicates the need for a re-emphasis on the importance of this 
      treatment. A standard protocol for all UK ambulance services should be devised 
      that minimises the number of contraindications to aspirin and otherwise requires 
      its administration to all patients with acute coronary syndromes or suspected 
      myocardial infarction. Regular, standardised audits of compliance should also be 
      conducted and their results widely disseminated.
FAU - Woollard, M
AU  - Woollard M
AD  - Pre-hospital Emergency Research Unit, University of Wales College of 
      Medicine/Welsh Ambulance Services NHS Trust, Cardiff, UK. 
      Malcolm.peru@ukgateway.net
FAU - Smith, A
AU  - Smith A
FAU - Elwood, P
AU  - Elwood P
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Emerg Med J
JT  - Emergency medicine journal : EMJ
JID - 100963089
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aspirin/*therapeutic use
MH  - Clinical Protocols
MH  - Emergency Medical Services/*standards
MH  - Emergency Medical Technicians
MH  - England
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Guideline Adherence/*statistics & numerical data
MH  - Humans
MH  - Medical Audit
MH  - Myocardial Infarction/drug therapy
MH  - Myocardial Ischemia/*drug therapy
MH  - Wales
PMC - PMC1725743
EDAT- 2001/11/07 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/07 10:00
PHST- 2001/11/07 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/07 10:00 [entrez]
AID - 10.1136/emj.18.6.478 [doi]
PST - ppublish
SO  - Emerg Med J. 2001 Nov;18(6):478-81. doi: 10.1136/emj.18.6.478.

PMID- 19049546
OWN - NLM
STAT- MEDLINE
DCOM- 20090220
LR  - 20181201
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 15
IP  - 12
DP  - 2008 Dec
TI  - ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin 
      therapy.
PG  - 1304-8
LID - 10.1111/j.1468-1331.2008.02306.x [doi]
AB  - BACKGROUND AND PURPOSE: Aspirin is an important therapeutic regimen to prevent 
      the recurrent ischemic events or death after acute ischemic stroke. In this 
      study, we evaluated the relationship between the extent of adenosine diphosphate 
      (ADP)-induced platelet aggregation and outcome in acute ischemic stroke patients 
      on aspirin therapy. METHODS: We selected 107 acute ischemic stroke patients who 
      had been prescribed aspirin and evaluated platelet function test by using optic 
      platelet aggregometer test after 5 days of taking it and investigated the 
      prognosis 90 days after ischemic events. Kaplan-Meyer curve was used for survival 
      analysis. RESULTS: After stratification of the subjected patients by tertiles of 
      ADP-induced platelet aggregation, the events rates were 7.4%, 9.3% and 30.8% (P = 
      0.023). In multiple logistic regression analysis, old age over 70 years (OR, 
      13.7; 95% CI, 2.14-88.07; P = 0.001) and the increased ADP-induced platelet 
      aggregation had independent significance to the risk of primary end-points after 
      acute ischemic stroke (OR, 1.1; 95% CI 1.01 to 1.20; P = 0.026). CONCLUSIONS: 
      This study showed that the increased ADP-induced platelet aggregation under using 
      aspirin is associated with poor outcome after acute ischemic stroke.
FAU - Cha, J-K
AU  - Cha JK
AD  - Department of Neurology, College of Medicine, Dong-A University, 
      Dongdaeshin-Dong, Busan, South Korea. nrcjk@unitel.co.kr
FAU - Jeon, H-W
AU  - Jeon HW
FAU - Kang, M-J
AU  - Kang MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adenosine Diphosphate/*pharmacology
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Clopidogrel
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Endpoint Determination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Stroke/*drug therapy
MH  - Ticlopidine/analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2008/12/04 09:00
MHDA- 2009/02/21 09:00
CRDT- 2008/12/04 09:00
PHST- 2008/12/04 09:00 [pubmed]
PHST- 2009/02/21 09:00 [medline]
PHST- 2008/12/04 09:00 [entrez]
AID - ENE2306 [pii]
AID - 10.1111/j.1468-1331.2008.02306.x [doi]
PST - ppublish
SO  - Eur J Neurol. 2008 Dec;15(12):1304-8. doi: 10.1111/j.1468-1331.2008.02306.x.

PMID- 2567792
OWN - NLM
STAT- MEDLINE
DCOM- 19890803
LR  - 20190610
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8653
DP  - 1989 Jul 1
TI  - Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention 
      of aortocoronary vein graft occlusion.
PG  - 1-7
AB  - In a prospective randomised trial, 249 patients who had aortocoronary vein bypass 
      surgery were assigned either to a platelet inhibitory drug regimen or to standard 
      anticoagulant therapy. Treatment was replaced by placebo in half of the patients 
      in each group after 3 months. The platelet inhibitory drug regimen--very low-dose 
      aspirin combined with dipyridamole--was as effective as standard anticoagulant 
      therapy to prevent early and late graft occlusion. Death, myocardial infarction, 
      and severe bleeding occurred significantly more often in patients receiving 
      anticoagulants, whereas mild drug-related gastrointestinal and cerebral 
      side-effects were more common in patients taking platelet inhibitory drugs. 
      Antithrombotic treatment should be continued for at least 1 year after coronary 
      artery bypass graft surgery.
FAU - Pfisterer, M
AU  - Pfisterer M
AD  - Division of Cardiology, University Hospital, Basel, Switzerland.
FAU - Burkart, F
AU  - Burkart F
FAU - Jockers, G
AU  - Jockers G
FAU - Meyer, B
AU  - Meyer B
FAU - Regenass, S
AU  - Regenass S
FAU - Burckhardt, D
AU  - Burckhardt D
FAU - Schmitt, H E
AU  - Schmitt HE
FAU - Müller-Brand, J
AU  - Müller-Brand J
FAU - Skarvan, K
AU  - Skarvan K
FAU - Stulz, P
AU  - Stulz P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (4-Hydroxycoumarins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - Q08SIO485D (Phenprocoumon)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 1989 Aug 19;2(8660):443. PMID: 2569618
MH  - 4-Hydroxycoumarins/*administration & dosage
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - *Coronary Artery Bypass
MH  - Coronary Disease/*prevention & control
MH  - Coronary Thrombosis/*prevention & control
MH  - Dipyridamole/*administration & dosage/adverse effects/therapeutic use
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Evaluation
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenprocoumon/*administration & dosage/adverse effects/therapeutic use
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - *Premedication
MH  - Prospective Studies
MH  - Random Allocation
MH  - Saphenous Vein/transplantation
EDAT- 1989/07/01 00:00
MHDA- 1989/07/01 00:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 1989/07/01 00:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
AID - S0140-6736(89)90253-5 [pii]
AID - 10.1016/s0140-6736(89)90253-5 [doi]
PST - ppublish
SO  - Lancet. 1989 Jul 1;2(8653):1-7. doi: 10.1016/s0140-6736(89)90253-5.

PMID- 6614839
OWN - NLM
STAT- MEDLINE
DCOM- 19831008
LR  - 20200825
IS  - 0304-4602 (Print)
IS  - 0304-4602 (Linking)
VI  - 12
IP  - 2
DP  - 1983 Apr
TI  - The medical management of chronic arthritis in childhood.
PG  - 168-73
AB  - In the management of children suffering from chronic arthritis it is important to 
      note the type of disease present, complications both of the disease and from 
      previous therapy as well as the family background and location, against which 
      treatment is undertaken. Maintenance of joint position and function by 
      appropriate splinting and exercises are the mainstays of management. Despite many 
      new non-steroidal anti-inflammatory drugs, aspirin still has an important role, 
      particularly with systemic manifestations. To date Ibuprofen (Brufen), Naprosyn 
      and Tolmetin are the three non-steroidal anti-inflammatory agents which have been 
      shown to be effective in controlling arthritis and Tolmetin may have some effect 
      on systemic illness. The need for careful study of drugs in children is stressed. 
      A few, usually those with systemic illness, will need oral corticosteroid therapy 
      while an occasional child, usually with pauciarticular arthritis involving the 
      knee, will benefit from a local corticosteroid injection. Apart from those few 
      children with sero-positive disease, long-acting drugs are needed infrequently.
FAU - Ansell, B M
AU  - Ansell BM
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - Ann Acad Med Singap
JT  - Annals of the Academy of Medicine, Singapore
JID - 7503289
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 7440-57-5 (Gold)
RN  - GNN1DV99GX (Penicillamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Arthritis, Juvenile/*therapy
MH  - Aspirin/therapeutic use
MH  - Bed Rest
MH  - Child
MH  - Female
MH  - Gold/therapeutic use
MH  - Humans
MH  - Immobilization
MH  - Immunosuppressive Agents/therapeutic use
MH  - Male
MH  - Penicillamine/therapeutic use
MH  - Physical Therapy Modalities
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
PST - ppublish
SO  - Ann Acad Med Singap. 1983 Apr;12(2):168-73.

PMID- 32649352
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210204
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 35
IP  - 5
DP  - 2020 Sep
TI  - The COMPASS trial: practical considerations for application after coronary artery 
      bypass surgery.
PG  - 583-588
LID - 10.1097/HCO.0000000000000766 [doi]
AB  - PURPOSE OF REVIEW: We review the cardiovascular outcomes for people using 
      anticoagulation strategies (COMPASS) trial with particular emphasis on patients 
      with a history of remote coronary artery bypass grafting (CABG) and those who 
      were enrolled 4-14 days after CABG. We provide practical guidance for selecting 
      patients with the greatest potential to benefit who have acceptable bleeding 
      risk. In particular, we address concerns about postoperative bleeding and discuss 
      the relative merits of rivaroxaban and aspirin versus P2Y12 inhibition and 
      aspirin. RECENT FINDINGS: The COMPASS trial demonstrated that rivaroxaban and 
      aspirin reduce myocardial infarction, stroke, and cardiovascular death in 
      patients with coronary artery disease, without a demonstrated effect on bypass 
      graft patency in the first postoperative year. SUMMARY: After CABG, cardiac 
      surgeons should consider using the COMPASS regimen in patients at high risk of 
      thrombosis whose risk of bleeding is acceptable. If used, the COMPASS regimen 
      should be continued indefinitely in conjunction with other pharmacological risk 
      reduction therapies to prevent long-term atherothrombotic events.
FAU - Eikelboom, Rachel
AU  - Eikelboom R
AD  - Department of Surgery, Max Rady College of Medicine, University of Manitoba.
AD  - Cardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.
FAU - Muller Moran, Hellmuth R
AU  - Muller Moran HR
AD  - Department of Surgery, Max Rady College of Medicine, University of Manitoba.
AD  - Cardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.
FAU - Lodewyks, Carly
AU  - Lodewyks C
AD  - Department of Surgery, Max Rady College of Medicine, University of Manitoba.
AD  - Cardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.
FAU - Yan, Weiang
AU  - Yan W
AD  - Department of Surgery, Max Rady College of Medicine, University of Manitoba.
AD  - Cardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.
FAU - Zelentsov, Ivan
AU  - Zelentsov I
AD  - Department of Surgery, Max Rady College of Medicine, University of Manitoba.
AD  - Cardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.
FAU - Arora, Rakesh C
AU  - Arora RC
AD  - Department of Surgery, Max Rady College of Medicine, University of Manitoba.
AD  - Cardiac Sciences Program, St. Boniface Hospital, Winnipeg, Manitoba, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Coronary Artery Bypass
MH  - *Coronary Artery Disease/drug therapy/surgery
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Rivaroxaban/therapeutic use
MH  - Treatment Outcome
EDAT- 2020/07/11 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - 00001573-202009000-00020 [pii]
AID - 10.1097/HCO.0000000000000766 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2020 Sep;35(5):583-588. doi: 10.1097/HCO.0000000000000766.

PMID- 19931197
OWN - NLM
STAT- MEDLINE
DCOM- 20091215
LR  - 20181201
IS  - 1878-1810 (Electronic)
IS  - 1878-1810 (Linking)
VI  - 154
IP  - 6
DP  - 2009 Dec
TI  - Variable platelet responsiveness to aspirin and clopidogrel: role of platelet 
      function and genetic polymorphism testing.
PG  - 309-13
LID - 10.1016/j.trsl.2009.09.011 [doi]
AB  - Dual antiplatelet therapy with aspirin and clopidogrel is the standard treatment 
      for patients with an acute coronary syndrome or percutaneous coronary 
      intervention. However, at standard doses, many patients still experience an 
      adverse cardiovascular event. Numerous studies have demonstrated that a 
      laboratory assessment of platelet resistance to an antiplatelet medication is 
      associated with adverse outcomes. The gold standard in assessing platelet 
      function is light transmittance aggregometry. However, because of the time 
      necessary to complete the test, the need for skilled technicians, and the 
      associated costs, newer point-of-care tests have been developed to assess rapidly 
      an individual's platelet responsiveness. Although numerous studies demonstrate an 
      association with adverse outcomes and platelet resistance, currently no clinical 
      trial results demonstrate a treatment strategy to mitigate the adverse outcomes 
      associated with platelet resistance. Studies currently underway are evaluating 
      treatment options for a laboratory assessment of platelet resistance, such as 
      increasing the clopidogrel maintenance dose. Until such results are available, 
      routine testing of platelet resistance to aspirin or clopidogrel should be used 
      only in a research setting.
FAU - Azam, Salman M
AU  - Azam SM
AD  - University Hospitals Case Medical Center, Harrington-McLaughlin Heart and 
      Vascular Institute, Cleveland, Ohio 44106, USA.
FAU - Jozic, Joseph
AU  - Jozic J
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20091014
PL  - United States
TA  - Transl Res
JT  - Translational research : the journal of laboratory and clinical medicine
JID - 101280339
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/cytology/*drug effects
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - *Polymorphism, Genetic
MH  - Ticlopidine/*analogs & derivatives/pharmacology
RF  - 39
EDAT- 2009/11/26 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/11/26 06:00
PHST- 2009/08/19 00:00 [received]
PHST- 2009/09/29 00:00 [revised]
PHST- 2009/09/29 00:00 [accepted]
PHST- 2009/11/26 06:00 [entrez]
PHST- 2009/11/26 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S1931-5244(09)00298-9 [pii]
AID - 10.1016/j.trsl.2009.09.011 [doi]
PST - ppublish
SO  - Transl Res. 2009 Dec;154(6):309-13. doi: 10.1016/j.trsl.2009.09.011. Epub 2009 
      Oct 14.

PMID- 7974570
OWN - NLM
STAT- MEDLINE
DCOM- 19941229
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 25
IP  - 12
DP  - 1994 Dec
TI  - Compliance with antiplatelet therapy in patients with ischemic cerebrovascular 
      disease. Assessment by platelet aggregation testing.
PG  - 2337-42
AB  - BACKGROUND AND PURPOSE: Antiplatelet therapy is currently one of the methods for 
      preventing transient ischemic attacks and cerebral thrombosis. Because 
      antiplatelet agents are generally administered on a long-term basis, patient 
      compliance is an important factor. The purpose of this study was to determine the 
      compliance of patients during antiplatelet therapy by testing platelet 
      aggregation. METHODS: To establish the conditions for measuring platelet 
      aggregation, the platelet aggregation test was performed in patients taking 81 
      mg/d aspirin or 200 mg/d ticlopidine at the following final concentrations of 
      aggregation-inducing agents: 0.5, 1, 2, and 4 mumol/L ADP and 0.5 and 2 
      micrograms/mL collagen. The optimum measurement conditions for assessing patient 
      compliance were determined. Under the conditions determined in the first study, 
      platelet aggregation was assessed, and the effects of treatment were studied in 
      159 outpatients and 79 inpatients undergoing antiplatelet therapy. If the 
      antiplatelet effect was insufficient, compliance was checked by interview. 
      RESULTS: The agents used and the final concentrations found to be optimum for 
      assessing platelet aggregation were 2 micrograms/mL collagen for patients taking 
      aspirin 81 mg/day and 2 mumol/L ADP for patients taking ticlopidine 200 mg/d. In 
      17 (10%) of the 159 outpatients, platelet aggregation was not adequately reduced 
      because of noncompliance with their antiplatelet therapy. CONCLUSIONS: This study 
      indicated that monitoring of compliance is important for outpatients on 
      antiplatelet therapy. It is best if platelet aggregation can be checked, but when 
      this is impossible it is necessary to assess compliance periodically and provide 
      patient guidance.
FAU - Komiya, T
AU  - Komiya T
AD  - Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
FAU - Kudo, M
AU  - Kudo M
FAU - Urabe, T
AU  - Urabe T
FAU - Mizuno, Y
AU  - Mizuno Y
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/antagonists & inhibitors/pharmacology
MH  - Aged
MH  - Aspirin/administration & dosage/blood/*therapeutic use
MH  - Cerebral Infarction/prevention & control
MH  - Collagen/antagonists & inhibitors/pharmacology
MH  - Drug Monitoring
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Inpatients
MH  - Intracranial Embolism and Thrombosis/*prevention & control
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Male
MH  - Outpatients
MH  - *Patient Compliance
MH  - Platelet Aggregation/*drug effects
MH  - Ticlopidine/administration & dosage/blood/*therapeutic use
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
AID - 10.1161/01.str.25.12.2337 [doi]
PST - ppublish
SO  - Stroke. 1994 Dec;25(12):2337-42. doi: 10.1161/01.str.25.12.2337.

PMID- 8977914
OWN - NLM
STAT- MEDLINE
DCOM- 19970124
LR  - 20131121
IS  - 0369-8114 (Print)
IS  - 0369-8114 (Linking)
VI  - 44
IP  - 6
DP  - 1996 Jun
TI  - [Antiaggregant effect and tolerance of calcium carbasalate administrated 
      immediately after aorto-coronary bypass. Results of a double-blind versus placebo 
      study].
PG  - 571-80
AB  - The patency of aorto-coronary bypasses is greatly influenced by platelet 
      aggregability, and there is an associated risk of thrombosis which may occur very 
      early during surgery. It is in this context that aspirin has been the subject of 
      successful clinical studies. When administering aspirin, it is preferable to 
      choose formulations that are well tolerated by the gastro-intestinal tract. This 
      was the reason for carrying out the present randomised single-centre double-blind 
      parallel-group study aimed at confirming the platelet anti-aggregant effect and 
      tolerability of calcium carbasalate administered during the immediate 
      postoperative period. The dose prescribed was equivalent to aspirin 325 mg daily, 
      and was given as a single dose 6 hours after the end of the operation and 
      repeated for 7 days, versus placebo, in 56 patients undergoing aorto-coronary 
      bypass grafts. A clinical assessment, ECG, platelet count and measurements of CPK 
      and CPK-MB were carried out daily for the 7 days of the study. Tests of platelet 
      aggregation (to arachidonic acid, ADP and collagen), assays of serum thromboxane 
      B2, MDA and PDF, and urinary assays for beta-thromboglobulin and 6-keto-PGF-1 
      were carried out before treatment, then 1 and 7 days after the start of 
      treatment. Fifty males (89%) and 6 females, mean age 58.3 years, received 
      treatment with either calcium carbasalate (group C, n = 28) or placebo (group P, 
      n = 28). The atheromatous lesions present in most cases represented triple-vessel 
      disease (37 cases), and most operations were triple bypasses (23 cases) or double 
      bypasses (20 cases). A significant reduction in platelet aggregation to 
      arachidonic acid and collagen on D1 (p = 0.05) and D7 (p < 0.001), and to ADP on 
      D7 (p < 0.01) was observed in group C as compared with group P. Group C also 
      showed significant reductions as compared with group P in respect of serum 
      thromboxane B2 levels on D1 (p < 0.01) and D7 (p < 0.001) and MDA levels on D1 
      and D7 (p < 0.001). No significant difference was demonstrated between the two 
      groups in respect of urinary 6-keto-PFG-1 excretion. The number of patients 
      showing a rise in CPK was lower in group C but this difference did not reach 
      statistical significance. ST segments change were comparable in the two groups, 
      and no patient complained of anginal pain during the study. These results show 
      that calcium carbasalate administered at a dose equivalent to 325 mg aspirin 
      daily caused very early inhibition of platelet aggregation, specifically 
      inhibiting platelet production of thromboxane B2 without altering prostacyclin 
      levels. In addition, calcium carbasalate was found to be well tolerated. This 
      study confirms the value of early administration of aspirin at a dose of 325 mg 
      daily during the hours immediately following aorto-coronary bypass graft surgery.
FAU - Mathieu, P
AU  - Mathieu P
AD  - Services de Chirurgie Cardiaque, CHU Brabois, Vandoeuvre-Les-Nancy, France.
FAU - Villemot, J P
AU  - Villemot JP
FAU - Stoltz, J F
AU  - Stoltz JF
FAU - Scheck, F
AU  - Scheck F
FAU - Garnier, L F
AU  - Garnier LF
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Efficacité Antiagrégante et tolérance du carbasalate calcique administré dans les 
      suites immédiates des pontages aorto-coronaires. Résultats d'une étude réalisée 
      en double aveugle versus placebo.
PL  - France
TA  - Pathol Biol (Paris)
JT  - Pathologie-biologie
JID - 0265365
RN  - 0 (Analgesics)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (beta-Thromboglobulin)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 8W8T17847W (Urea)
RN  - 9000-94-6 (Antithrombin III)
RN  - N667F17JP1 (carbaspirin calcium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/urine
MH  - Aged
MH  - Analgesics/pharmacokinetics/*therapeutic use
MH  - Antithrombin III/analysis
MH  - Aspirin/*analogs & derivatives/pharmacokinetics/therapeutic use
MH  - *Coronary Artery Bypass
MH  - Double-Blind Method
MH  - Drug Tolerance
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/analysis
MH  - Humans
MH  - Male
MH  - Malondialdehyde/blood
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Postoperative Care
MH  - Thromboxane B2/blood
MH  - Urea/*analogs & derivatives/pharmacokinetics/therapeutic use
MH  - beta-Thromboglobulin/urine
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
PST - ppublish
SO  - Pathol Biol (Paris). 1996 Jun;44(6):571-80.

PMID- 3572906
OWN - NLM
STAT- MEDLINE
DCOM- 19870616
LR  - 20131121
IS  - 0024-7758 (Print)
IS  - 0024-7758 (Linking)
VI  - 32
IP  - 3
DP  - 1987 Mar
TI  - Successful pregnancy after pharmacologic suppression of a circulating 
      anticoagulant in a woman with previous pregnancy losses and pulmonary emboli. A 
      case report.
PG  - 221-4
AB  - A woman had two second-trimester fetal deaths two weeks after genetic 
      amniocenteses, and her puerperal courses were also complicated by pulmonary 
      emboli. During her next pregnancy a circulating anticoagulant was demonstrated 
      that had been absent between her pregnancies. It was suppressed with aspirin and 
      prednisone. Amniocentesis was uneventful. Despite the development of 
      steroid-induced diabetes, the pregnancy outcome was successful, with no 
      postpartum complications.
FAU - Isada, N
AU  - Isada N
FAU - Kessler, C
AU  - Kessler C
FAU - Larsen, J Jr
AU  - Larsen J Jr
FAU - Weingold, A
AU  - Weingold A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Reprod Med
JT  - The Journal of reproductive medicine
JID - 0173343
RN  - 0 (Immunoglobulins)
RN  - 0 (circulating anticoagulants)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - *Blood Coagulation
MH  - Female
MH  - Humans
MH  - Immunoglobulins/*analysis
MH  - Infant, Newborn
MH  - Partial Thromboplastin Time
MH  - Prednisone/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*drug therapy
MH  - Pulmonary Embolism/*complications
EDAT- 1987/03/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
PST - ppublish
SO  - J Reprod Med. 1987 Mar;32(3):221-4.

PMID- 24496251
OWN - NLM
STAT- MEDLINE
DCOM- 20150413
LR  - 20140205
IS  - 1538-8646 (Electronic)
IS  - 0730-4625 (Linking)
VI  - 33
IP  - 2
DP  - 2014 Mar-Apr
TI  - Bleeding risk factors affecting warfarin therapy in the elderly with atrial 
      fibrillation.
PG  - 57-63
LID - 10.1097/DCC.0000000000000022 [doi]
AB  - PURPOSE: Inadequate anticoagulation among elderly individuals with atrial 
      fibrillation (AF) is a common problem. This synthesis of the literature review 
      describes the pathophysiology of AF, explains the mechanism of action of warfarin 
      (Coumadin), identifies factors that contribute to warfarin (Coumadin)-associated 
      bleeding in the elderly population, and explores alternatives to warfarin 
      (Coumadin) therapy. Implications for advanced practice nurse practice, education, 
      and research will be discussed. METHODS: A literature search was conducted using 
      Academic Search Premier, CINAHL Plus with Full Text, and Medline from 1999 to 
      2012. Search terms included warfarin (Coumadin), warfarin (Coumadin) genetics, 
      diet, interactions, bleeding, atrial fibrillation, genetics, anticoagulation 
      clinic, dabigatran, apixaban, rivaroxaban, and elderly. RESULTS: The literature 
      indicates that the potential bleeding risk associated with warfarin (Coumadin) 
      therapy limits its use in the elderly population. However, some studies have 
      found warfarin (Coumadin) to be more effective than aspirin in preventing stroke. 
      The safety profiles of both medications were comparable; also, effective 
      alternatives to warfarin (Coumadin) that do not require routine testing are now 
      available. CONCLUSIONS: Atrial fibrillation increases the probability of an 
      embolic stroke, especially for the elderly population. Stroke risk and bleeding 
      risk tools, in conjunction with patient preference, determine the best stroke 
      prevention treatment. Anticoagulant clinics manage long-term warfarin (Coumadin) 
      therapy effectively. Newer anticoagulants offer effective alternatives to 
      warfarin (Coumadin) therapy.
FAU - Darnell, Stan W
AU  - Darnell SW
AD  - Stan W. Darnell, MS, APRN, AGPCNP-BC, CCRN, is an adult-gerontology nurse 
      practitioner at the Southeastern Neurosurgical & Spine Institute of the 
      Greenville Health System, South Carolina. Stephanie C. Davis, PhD, RN, FNP, BC, 
      is graduate coordinator and associate professor at Clemson University School of 
      Nursing, South Carolina. John J. Whitcomb, PhD, RN, CCRN, FCCM, is second degree 
      coordinator and assistant professor at Clemson University School of Nursing, 
      South Carolina. Joseph A. Manfredi, MD, is a clinical cardiac electrophysiologist 
      at AnMed Health Arrhythmia Specialists, Anderson, South Carolina. Brent T. 
      McLaurin, MD, is a cardiologist at Anderson Heart, AnMed Health, Anderson, South 
      Carolina. He also serves as director for the Research Division at Anderson Heart 
      and the AnMed Research Division.
FAU - Davis, Stephanie C
AU  - Davis SC
FAU - Whitcomb, John J
AU  - Whitcomb JJ
FAU - Manfredi, Joseph A
AU  - Manfredi JA
FAU - McLaurin, Brent T
AU  - McLaurin BT
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Dimens Crit Care Nurs
JT  - Dimensions of critical care nursing : DCCN
JID - 8211489
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Atrial Fibrillation/*drug therapy/*physiopathology
MH  - *Critical Care Nursing
MH  - Hemorrhage/*chemically induced/*prevention & control
MH  - Humans
MH  - Risk Factors
MH  - Stroke/physiopathology/prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2014/02/06 06:00
MHDA- 2015/04/14 06:00
CRDT- 2014/02/06 06:00
PHST- 2014/02/06 06:00 [entrez]
PHST- 2014/02/06 06:00 [pubmed]
PHST- 2015/04/14 06:00 [medline]
AID - 00003465-201403000-00004 [pii]
AID - 10.1097/DCC.0000000000000022 [doi]
PST - ppublish
SO  - Dimens Crit Care Nurs. 2014 Mar-Apr;33(2):57-63. doi: 
      10.1097/DCC.0000000000000022.

PMID- 21977943
OWN - NLM
STAT- MEDLINE
DCOM- 20120405
LR  - 20211020
IS  - 1472-6947 (Electronic)
IS  - 1472-6947 (Linking)
VI  - 11
DP  - 2011 Oct 6
TI  - Development of a tool to improve the quality of decision making in atrial 
      fibrillation.
PG  - 59
LID - 10.1186/1472-6947-11-59 [doi]
AB  - BACKGROUND: Decision-making about appropriate therapy to reduce the stroke risk 
      associated with non-valvular atrial fibrillation (NVAF) involves the 
      consideration of trade-offs among the benefits, risks, and inconveniences of 
      different treatment options. The objective of this paper is to describe the 
      development of a decision support tool for NVAF based on the provision of 
      individualized risk estimates for stroke and bleeding and on preparing patients 
      to communicate with their physicians about their values and potential treatment 
      options. METHODS: We developed a tool based on the principles of the 
      International Patient Decision Aids Standards. The tool focuses on the 
      patient-physician dyad as the decision-making unit and emphasizes improving the 
      interaction between the two. It is built on the recognition that the application 
      of patient values to a specific treatment decision is complex and that the final 
      treatment choice is best made through a process of patient-clinician 
      communication. RESULTS: The tool provides education incorporating patients ' 
      illness perceptions to explain the relationship between NVAF and stroke, and then 
      presents individualized risk estimates, derived using separate risk calculators 
      for stroke and bleeding over a clinically meaningful time period (5 years) 
      associated with no treatment, aspirin, and warfarin. Sequelae of both stroke and 
      bleeding outcomes are also described. Patients are encouraged to verbalize how 
      they value the incremental risks and benefits associated with each option and 
      write down specific concerns to address with their physician. A physician prompt 
      to encourage patients to discuss their opinions is included as part of the 
      decision support tool. In pilot testing with 11 participants (mean age 78 ± 9 
      years, 64% with ≤ high-school education), 8 (72%) rated ease of completion as 
      "very easy," and 9 (81%) rated amount of information as "just right." 
      CONCLUSIONS: The risks and benefits of different treatment options for reduction 
      of stroke in NVAF vary widely according to patients' comorbidities. This tool 
      facilitates the provision of individualized outcome data and encourages patients 
      to communicate with their physicians about these risks and benefits. Future 
      studies will examine whether use of the tool is associated with improved quality 
      of decision making.
FAU - Fraenkel, Liana
AU  - Fraenkel L
AD  - Department of Medicine, Yale University School of Medicine, New Haven, CT, USA. 
      liana.fraenkel@yale.edu
FAU - Street, Richard L Jr
AU  - Street RL Jr
FAU - Fried, Terri R
AU  - Fried TR
LA  - eng
GR  - K24 AG28443/AG/NIA NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20111006
PL  - England
TA  - BMC Med Inform Decis Mak
JT  - BMC medical informatics and decision making
JID - 101088682
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Atrial Fibrillation/*complications/drug therapy
MH  - *Decision Support Techniques
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Patient Participation/psychology
MH  - Physician-Patient Relations
MH  - Risk Assessment
MH  - Stroke/etiology/prevention & control
MH  - Warfarin/adverse effects/therapeutic use
PMC - PMC3207873
EDAT- 2011/10/08 06:00
MHDA- 2012/04/06 06:00
CRDT- 2011/10/08 06:00
PHST- 2010/12/07 00:00 [received]
PHST- 2011/10/06 00:00 [accepted]
PHST- 2011/10/08 06:00 [entrez]
PHST- 2011/10/08 06:00 [pubmed]
PHST- 2012/04/06 06:00 [medline]
AID - 1472-6947-11-59 [pii]
AID - 10.1186/1472-6947-11-59 [doi]
PST - epublish
SO  - BMC Med Inform Decis Mak. 2011 Oct 6;11:59. doi: 10.1186/1472-6947-11-59.

PMID- 2146720
OWN - NLM
STAT- MEDLINE
DCOM- 19901227
LR  - 20131121
IS  - 0300-8932 (Print)
IS  - 0300-8932 (Linking)
VI  - 43
IP  - 6
DP  - 1990 Jun-Jul
TI  - [Thrombosis from prosthetic materials: prevention with different antiaggregatory 
      agents. Low dose aspirin?].
PG  - 385-91
AB  - Using an ex vivo shunt in dogs, platelet deposition on 6 prosthetic materials 
      used in the construction of cardiovascular prostheses [highly porous Knitted 
      Dacron (intervascular HP 800, 1,400 ml/cm2/min/120 mmHg), Woven Dacron of low 
      porosity (intervascular LP 200, 200 ml/cm2/min/120 mmHg), Doble Velour Knitted 
      Dacron, Avcothane 51 elastomere and the mesothelial and epipericardial surfaces 
      of bovine pericardium] was quantified. The study of the prevention of platelet 
      thrombi formation on these materials was carried out in 6 groups of 8 animals: 
      group 1 (control), group 2 (5 mg/kg body weight/day acetylsalicylic acid), group 
      3 (20 mg/kg body weight/day acetylsalicylic acid), group 4 (15 mg/kg body wt/day 
      triflusal plus 5 mg/kg body wt/day dipyridamole), group 5 (15 mg/kg body wt/day 
      triflusal) and group 6 (5 mg/kg body wt/day acetylsalicylic acid plus 5 mg/kg 
      body wt/day dipyridamole). Platelets were labeled with 111In-oxine. The least 
      thrombogenic material was Avcothane 51 elastomere. The only effective treatment 
      for reduction of platelet deposition on the 6 materials was that used in group 2. 
      The treatment used in group 3 only decreased the deposition of platelets on 3 of 
      the 6 materials. The treatments employed in groups 4, 5 and 6 did not 
      significantly diminish the deposition of platelets on any of the materials when 
      compared with the control group. The platelet count was not modified in the 
      animals in groups 2 and 4 while in the rest it decreased after the test.
FAU - Escudero, M C
AU  - Escudero MC
AD  - Servicio de Cirugía Experimental y de Medicina Nuclear, Universidad Autónoma de 
      Madrid.
FAU - Alvarez, L
AU  - Alvarez L
FAU - Rodríguez, V
AU  - Rodríguez V
FAU - de Haro, J
AU  - de Haro J
FAU - Millán, I
AU  - Millán I
FAU - Torres, M T
AU  - Torres MT
FAU - Jorge, E
AU  - Jorge E
FAU - Castillo-Olivares, J L
AU  - Castillo-Olivares JL
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Trombosis sobre materiales protésicos: prevención con distintos fármacos 
      antiagregantes. Aspirina a dosis bajas?
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polyethylene Terephthalates)
RN  - 0 (Polyurethanes)
RN  - 0 (Salicylates)
RN  - 0 (Silicone Elastomers)
RN  - 1Z0YFI05OO (triflusal)
RN  - 37226-50-9 (Avcothane)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - *Cardiac Surgical Procedures
MH  - Cattle
MH  - Dogs
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Polyethylene Terephthalates/*adverse effects
MH  - Polyurethanes/*adverse effects
MH  - Prostheses and Implants/*adverse effects
MH  - Salicylates/therapeutic use
MH  - Silicone Elastomers/*adverse effects
MH  - Thrombosis/*etiology/prevention & control
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
PST - ppublish
SO  - Rev Esp Cardiol. 1990 Jun-Jul;43(6):385-91.

PMID- 31746356
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20211007
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jan
TI  - Aspirin metabolites 2,3‑DHBA and 2,5‑DHBA inhibit cancer cell growth: 
      Implications in colorectal cancer prevention.
PG  - 20-34
LID - 10.3892/mmr.2019.10822 [doi]
AB  - Although compelling evidence exists on the ability of aspirin to treat colorectal 
      cancer (CRC), and numerous theories and targets have been proposed, a consensus 
      has not been reached regarding its mechanism of action. In this regard, a 
      relatively unexplored area is the role played by aspirin metabolites 
      2,3‑dihydroxybenzoic acid (2,3‑DHBA) and 2,5‑dihydroxybenzoic acid (2,5‑DHBA) in 
      its chemopreventive actions. In a previous study, we demonstrated that 2,3‑DHBA 
      and 2,5‑DHBA inhibited CDK1 enzyme activity in vitro. The aim of the present 
      study was to understand the effect of these metabolites on the enzyme activity of 
      all CDKs involved in cell cycle regulation (CDKs 1, 2, 4 and 6) as well as their 
      effect on clonal formation in three different cancer cell lines. Additionally, 
      in silico studies were performed to determine the potential sites of interactions 
      of 2,3‑DHBA and 2,5‑DHBA with CDKs. We demonstrated that 2,3‑DHBA and 2,5‑DHBA 
      inhibits CDK‑1 enzyme activity beginning at 500 µM, while CDK2 and CDK4 activity 
      was inhibited only at higher concentrations (>750 µM). 2,3‑DHBA inhibited CDK6 
      enzyme activity from 250 µM, while 2,5‑DHBA inhibited its activity >750 µM. 
      Colony formation assays showed that 2,5‑DHBA was highly effective in inhibiting 
      clonal formation in HCT‑116 and HT‑29 CRC cell lines (250‑500 µM), and in the 
      MDA‑MB‑231 breast cancer cell line (~100 µM). In contrast 2,3‑DHBA was effective 
      only in MDA‑MB‑231 cells (~500 µM). Both aspirin and salicylic acid failed to 
      inhibit all four CDKs and colony formation. Based on the present results, it is 
      suggested that 2,3‑DHBA and 2,5‑DHBA may contribute to the chemopreventive 
      properties of aspirin, possibly through the inhibition of CDKs. The present data 
      and the proposed mechanisms should open new areas for future investigations.
FAU - Sankaranarayanan, Ranjini
AU  - Sankaranarayanan R
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      College of Pharmacy and Allied Health Professions, Avera Health and Sciences 
      Center, South Dakota State University, Brookings, SD 57007, USA.
FAU - Valiveti, Chaitanya K
AU  - Valiveti CK
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      College of Pharmacy and Allied Health Professions, Avera Health and Sciences 
      Center, South Dakota State University, Brookings, SD 57007, USA.
FAU - Dachineni, Rakesh
AU  - Dachineni R
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      College of Pharmacy and Allied Health Professions, Avera Health and Sciences 
      Center, South Dakota State University, Brookings, SD 57007, USA.
FAU - Kumar, D Ramesh
AU  - Kumar DR
AD  - Department of Entomology, University of Kentucky, Lexington, KY 40546, USA.
FAU - Lick, Tana
AU  - Lick T
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      College of Pharmacy and Allied Health Professions, Avera Health and Sciences 
      Center, South Dakota State University, Brookings, SD 57007, USA.
FAU - Bhat, G Jayarama
AU  - Bhat GJ
AD  - Department of Pharmaceutical Sciences and Translational Cancer Research Center, 
      College of Pharmacy and Allied Health Professions, Avera Health and Sciences 
      Center, South Dakota State University, Brookings, SD 57007, USA.
LA  - eng
PT  - Journal Article
DEP - 20191118
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Neoplasm Proteins)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacokinetics/pharmacology
MH  - Cell Cycle/*drug effects
MH  - *Colorectal Neoplasms/drug therapy/enzymology/pathology
MH  - Cyclin-Dependent Kinases/*antagonists & inhibitors/metabolism
MH  - HCT116 Cells
MH  - HT29 Cells
MH  - Humans
MH  - Neoplasm Proteins/*antagonists & inhibitors/metabolism
PMC - PMC6896348
OTO - NOTNLM
OT  - aspirin and salicylic acid
OT  - chemoprevention
OT  - colorectal cancer
OT  - cyclins
OT  - cdKs
OT  - cdK inhibitors
EDAT- 2019/11/21 06:00
MHDA- 2020/06/04 06:00
CRDT- 2019/11/21 06:00
PHST- 2019/07/31 00:00 [received]
PHST- 2019/10/08 00:00 [accepted]
PHST- 2019/11/21 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
PHST- 2019/11/21 06:00 [entrez]
AID - mmr-21-01-0020 [pii]
AID - 10.3892/mmr.2019.10822 [doi]
PST - ppublish
SO  - Mol Med Rep. 2020 Jan;21(1):20-34. doi: 10.3892/mmr.2019.10822. Epub 2019 Nov 18.

PMID- 29946729
OWN - NLM
STAT- MEDLINE
DCOM- 20180706
LR  - 20200225
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 319
IP  - 24
DP  - 2018 Jun 26
TI  - Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not 
      Receiving Antiplatelet Therapy.
PG  - 2507-2520
LID - 10.1001/jama.2018.8194 [doi]
AB  - IMPORTANCE: A decision to initiate aspirin therapy for primary prevention of 
      cardiovascular disease (CVD) requires consideration of both treatment benefits 
      and harms. The most significant harm associated with aspirin is major bleeding, 
      yet there is a paucity of data on bleeding risk in suitable community 
      populations. OBJECTIVE: To determine the risk of major bleeding among people 
      without CVD who are not receiving antiplatelet therapy. DESIGN, SETTING, AND 
      PARTICIPANTS: Prospective cohort study of 359 166 individuals aged 30 to 79 years 
      receiving primary care in New Zealand who had CVD risk assessment between 2002 
      and 2015. Participants were censored at the earliest date on which they had a 
      first major bleeding event, died, or met any baseline cohort exclusion criteria 
      or the study end date of December 31, 2015. Analyses were repeated after 
      excluding people with medical conditions associated with increased bleeding risk 
      (non-high-risk cohort; n=305 057) and after further excluding people receiving 
      other medications associated with increased bleeding risk (nonmedication cohort; 
      n=240 254). EXPOSURES: Sex and age group in 10-year bands from 30 to 79 years. 
      MAIN OUTCOMES AND MEASURES: Risk of a major bleeding event (hospitalization or 
      death associated with bleeding); nonfatal gastrointestinal tract bleeding; and 
      gastrointestinal tract bleeding-related case fatality. RESULTS: Mean participant 
      age was 54 years (SD, 10 years), 44% were women, and 57% were European. Among the 
      359 166 individuals in the baseline cohort, 3976 had a major bleeding event 
      during 1 281 896 person-years of follow-up. Most had gastrointestinal (GI) 
      bleeding (n=2910 [73%]). There were 274 fatal bleeding events (7%), of which 153 
      were intracerebral. The risk of a nonfatal GI bleeding event per 1000 
      person-years was 2.19 (95% CI, 2.11-2.27), 1.77 (95% CI, 1.69-1.85) and 1.61 (95% 
      CI, 1.52-1.69), in the baseline, non-high-risk, and nonmedication cohorts, 
      respectively. Case fatality associated with GI bleeding was 3.4% (95% CI, 
      2.2%-4.1%), 4.0% (95% CI, 3.2%-5.1%), and 4.6% (95% CI, 3.6%-6.0%) in the 
      baseline, non-high-risk, and nonmedication cohorts, respectively. CONCLUSIONS AND 
      RELEVANCE: In a population not receiving antiplatelet therapy, the annual risk of 
      major bleeding events and nonfatal major bleeding was estimated. These findings 
      could inform population-level guidelines for primary prevention of CVD.
FAU - Selak, Vanessa
AU  - Selak V
AD  - Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New 
      Zealand.
FAU - Kerr, Andrew
AU  - Kerr A
AD  - Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New 
      Zealand.
AD  - Middlemore Hospital, Auckland, New Zealand.
FAU - Poppe, Katrina
AU  - Poppe K
AD  - Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New 
      Zealand.
FAU - Wu, Billy
AU  - Wu B
AD  - Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New 
      Zealand.
FAU - Harwood, Matire
AU  - Harwood M
AD  - Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New 
      Zealand.
AD  - Te Kupenga Hauora Māori, University of Auckland, Auckland, New Zealand.
FAU - Grey, Corina
AU  - Grey C
AD  - Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New 
      Zealand.
FAU - Jackson, Rod
AU  - Jackson R
AD  - Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New 
      Zealand.
FAU - Wells, Sue
AU  - Wells S
AD  - Section of Epidemiology and Biostatistics, University of Auckland, Auckland, New 
      Zealand.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/epidemiology/mortality
MH  - Hemorrhage/chemically induced/*epidemiology/mortality
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - New Zealand/epidemiology
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Primary Prevention
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
PMC - PMC6583689
COIS- Conflict of Interest Disclosures: All authors have completed and submitted the 
      ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Wells has 
      received funding from the Heart Foundation of New Zealand (project grant for 
      quality improvement) and Roche Diagnostics Ltd (project grant for point-of-care 
      testing trial). No other disclosures were reported.
EDAT- 2018/06/28 06:00
MHDA- 2018/07/07 06:00
CRDT- 2018/06/28 06:00
PHST- 2018/06/28 06:00 [entrez]
PHST- 2018/06/28 06:00 [pubmed]
PHST- 2018/07/07 06:00 [medline]
AID - 2685989 [pii]
AID - joi180068 [pii]
AID - 10.1001/jama.2018.8194 [doi]
PST - ppublish
SO  - JAMA. 2018 Jun 26;319(24):2507-2520. doi: 10.1001/jama.2018.8194.

PMID- 10543686
OWN - NLM
STAT- MEDLINE
DCOM- 19991110
LR  - 20150616
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 354
IP  - 9188
DP  - 1999 Oct 23
TI  - Treatment and secondary prevention of stroke: evidence, costs, and effects on 
      individuals and populations.
PG  - 1457-63
AB  - This review of the effectiveness of treatment for acute stroke and methods of 
      secondary prevention shows that the highest priority for providers of a stroke 
      service must be to establish a stroke unit and multidisciplinary team that 
      delivers organised stroke care. Acute ischaemic stroke patients should be 
      immediately started on aspirin 300 mg daily, and, if possible, many of them 
      should be entered into further trials of thrombolysis and other promising 
      treatments. After the acute phase, aspirin should be continued in a lower dose, 
      75 mg daily; smoking should be discouraged; high blood pressure treated initially 
      with a diuretic; and fibrillating ischaemic stroke/transient ischaemic attack 
      survivors anticoagulated long-term with warfarin or given aspirin if 
      anticoagulation is not sensible. Statins are probably indicated in patients who 
      already have symptomatic coronary heart disease. Adding dipyridamole to aspirin, 
      substituting clopidogrel for aspirin, and carotid endarterectomy are all 
      expensive interventions to prevent stroke, but if ways could be found to focus 
      them on those patients at especially high risk, they would become more 
      affordable.
FAU - Hankey, G J
AU  - Hankey GJ
AD  - Royal Perth Hospital, and Department of Medicine, University of Western 
      Australia. gjhankey@cyllene.uwa.edu.au
FAU - Warlow, C P
AU  - Warlow CP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2000 Jan 22;355(9200):319-20; author reply 320-1. PMID: 10675101
CIN - Lancet. 2000 Jan 22;355(9200):320; author reply 320-1. PMID: 10675102
CIN - Lancet. 2000 Jan 22;355(9200):321. PMID: 10675103
CIN - Lancet. 2001 Jan 13;357(9250):146-7. PMID: 11197428
MH  - Aspirin/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Hospital Units
MH  - Humans
MH  - Risk Factors
MH  - Stroke/*drug therapy/economics/*prevention & control
MH  - Thrombolytic Therapy/methods
MH  - Treatment Outcome
RF  - 57
EDAT- 1999/10/30 09:00
MHDA- 2000/05/29 09:00
CRDT- 1999/10/30 09:00
PHST- 1999/10/30 09:00 [pubmed]
PHST- 2000/05/29 09:00 [medline]
PHST- 1999/10/30 09:00 [entrez]
AID - S0140-6736(99)04407-4 [pii]
AID - 10.1016/S0140-6736(99)04407-4 [doi]
PST - ppublish
SO  - Lancet. 1999 Oct 23;354(9188):1457-63. doi: 10.1016/S0140-6736(99)04407-4.

PMID- 7596310
OWN - NLM
STAT- MEDLINE
DCOM- 19950728
LR  - 20190821
IS  - 0306-9877 (Print)
IS  - 0306-9877 (Linking)
VI  - 44
IP  - 2
DP  - 1995 Feb
TI  - The mechanism of action of aspirin--is there anything beyond cyclo-oxygenase?
PG  - 77-80
AB  - Aspirin, today, is an established drug in the regime for the prevention of 
      myocardial infarction, especially in high-risk groups. This use of aspirin has 
      given it a new lease of life in its tenth decade of clinical use. Aspirin is 
      probably the oldest synthetic drug in the Pharmacopoeias today; thus one would 
      have imagined that understanding about the drug would have reached a zenith and 
      if not, that at least there should be certainty about its mechanism of action. 
      Most workers agree that aspirin inhibits the cyclo-oxygenase enzyme in the 
      platelets leading to reduced formation of prostaglandin G2, the precursor of 
      thromboxanes. This explanation does not appear to be complete, since the role of 
      the platelet activating factor (PAF) seems to have been ignored. The precursor 
      for PAF is the lysophospholipid that is almost always formed when membrane 
      phospholipid breakdown takes place. Any effective antiplatelet drug would have to 
      inhibit the formation and/or the action of PAF, if it were to prevent platelet 
      aggregation. Alternatively, the pathophysiological role attributed to PAF is 
      highly exaggerated and needs to be reassessed.
FAU - Ghooi, R B
AU  - Ghooi RB
AD  - Medical Division, Unichem Laboratories Limited, Bombay, India.
FAU - Thatte, S M
AU  - Thatte SM
FAU - Joshi, P S
AU  - Joshi PS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Membrane Lipids)
RN  - 0 (Phospholipids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Humans
MH  - Membrane Lipids/metabolism
MH  - Myocardial Infarction/prevention & control
MH  - Phospholipids/metabolism
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thrombolytic Therapy
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
AID - 0306-9877(95)90073-X [pii]
AID - 10.1016/0306-9877(95)90073-x [doi]
PST - ppublish
SO  - Med Hypotheses. 1995 Feb;44(2):77-80. doi: 10.1016/0306-9877(95)90073-x.

PMID- 2242655
OWN - NLM
STAT- MEDLINE
DCOM- 19910103
LR  - 20131121
IS  - 0278-2677 (Print)
IS  - 0278-2677 (Linking)
VI  - 9
IP  - 10
DP  - 1990 Oct
TI  - Treatment of Kawasaki disease.
PG  - 755-62
AB  - The epidemiology, etiology, diagnosis, and treatment of Kawasaki disease are 
      reviewed. Kawasaki disease, or mucocutaneous lymph node syndrome, is an acute, 
      usually self-limiting, multiple-organ-system disease of childhood that occurs 
      both epidemically and endemically worldwide. The etiology of the disease is 
      unknown but may involve an infectious agent. To be diagnosed, a patient must be 
      febrile for at least five days and show four of five additional clinical 
      features: bilateral conjunctivitis, changes in the oral mucosa, changes in the 
      extremities, rash, and cervical lymphadenopathy. The most important complications 
      are cardiac; patients may develop aneurysms or thrombosis of the coronary 
      arteries or myocarditis. Other complications include arthritis, conjunctivitis, 
      and hydrops of the gallbladder. Aspirin, intravenous immune globulin, 
      corticosteroids, and antithrombotic agents have been investigated for use in the 
      treatment of Kawasaki disease with varying results. Current recommendations 
      suggest therapy with aspirin 80-100 mg/kg/day every six hours for the first 14 
      days after diagnosis and intravenous immune globulin 400 mg/kg/day for the first 
      four days. The dose of aspirin should then be reduced and continued for six to 
      eight weeks if no coronary artery abnormalities are present. Treatment guidelines 
      for Kawasaki disease are being refined. Current evidence supports early use of 
      aspirin and intravenous immune globulin to prevent cardiac complications.
FAU - Nakashima, L
AU  - Nakashima L
AD  - Clinical Pharmacy Services, British Columbia Cancer Agency, Vancouver, Canada.
FAU - Edwards, D L
AU  - Edwards DL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Pharm
JT  - Clinical pharmacy
JID - 8207437
RN  - 0 (Antithrombins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antithrombins/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Humans
MH  - *Immunization, Passive
MH  - Infant
MH  - Mucocutaneous Lymph Node Syndrome/diagnosis/epidemiology/*therapy
RF  - 34
EDAT- 1990/10/01 00:00
MHDA- 1990/10/01 00:01
CRDT- 1990/10/01 00:00
PHST- 1990/10/01 00:00 [pubmed]
PHST- 1990/10/01 00:01 [medline]
PHST- 1990/10/01 00:00 [entrez]
PST - ppublish
SO  - Clin Pharm. 1990 Oct;9(10):755-62.

PMID- 1564752
OWN - NLM
STAT- MEDLINE
DCOM- 19920521
LR  - 20131121
IS  - 0381-6605 (Print)
IS  - 0381-6605 (Linking)
VI  - 21
IP  - 1
DP  - 1992 Feb
TI  - Nasal polyps, bronchial asthma and aspirin sensitivity.
PG  - 60-5
AB  - The ASA triad comprises bronchial asthma, acetylsalicylic acid (ASA) sensitivity 
      and nasal polyps. It presents as chronic rhinitis followed by bronchial asthma 
      and ASA sensitivity, and later nasal polyps. The pathogenesis of the ASA triad 
      may involve interrelationships between disease in the upper and lower airway and 
      hypersensitivity to cyclo-oxygenase inhibiting medications. Treatment of the 
      nasal polyps has been shown to improve the patients' asthma.
FAU - Probst, L
AU  - Probst L
AD  - Department of Otolaryngology, St. Joseph's Health Centre, Toronto, Ontario, 
      Canada.
FAU - Stoney, P
AU  - Stoney P
FAU - Jeney, E
AU  - Jeney E
FAU - Hawke, M
AU  - Hawke M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Canada
TA  - J Otolaryngol
JT  - The Journal of otolaryngology
JID - 7610513
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/*complications
MH  - Drug Hypersensitivity/*complications
MH  - Humans
MH  - Nasal Polyps/*complications
MH  - Rhinitis/complications
MH  - Syndrome
RF  - 42
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
PST - ppublish
SO  - J Otolaryngol. 1992 Feb;21(1):60-5.

PMID- 21440342
OWN - NLM
STAT- MEDLINE
DCOM- 20120321
LR  - 20191210
IS  - 1768-3122 (Electronic)
IS  - 0248-8663 (Linking)
VI  - 32
IP  - 12
DP  - 2011 Dec
TI  - [What's new in recurrent pericarditis in 2011?].
PG  - 736-41
LID - 10.1016/j.revmed.2011.02.018 [doi]
AB  - Recurrent pericarditis are common and their management remains a matter of 
      debate. Their precise pathophysiology is unclear, and both innate and adaptative 
      immunity seem involved. An extensive work-up seeking for etiology seems to be 
      unnecessary during the first episode of acute pericarditis, whereas it is 
      mandatory in recurrent pericarditis. Despite extensive investigations, up to 80 % 
      of recurrent pericarditis remains of unknown origin. Colchicin associated to non 
      steroidal antiinflammatory drugs is the first line treatment whereas 
      immunosuppressive drugs are exceptionally required.
CI  - Copyright © 2011 Société nationale française de médecine interne (SNFMI). 
      Published by Elsevier SAS. All rights reserved.
FAU - Geri, G
AU  - Geri G
AD  - Service de médecine interne II, hôpital Pitié-Salpêtrière, AP-HP, Paris cedex 13, 
      France.
FAU - Cacoub, P
AU  - Cacoub P
LA  - fre
PT  - Evaluation Study
PT  - Journal Article
PT  - Review
TT  - Péricardites aiguës récidivantes : mise au point et actualités 2011.
DEP - 20110325
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Acute Disease
MH  - Algorithms
MH  - Aspirin/administration & dosage
MH  - Colchicine/administration & dosage
MH  - Disease Progression
MH  - Humans
MH  - Pericarditis/diagnosis/epidemiology/etiology/*therapy
MH  - Recurrence
MH  - Standard of Care
EDAT- 2011/03/29 06:00
MHDA- 2012/03/22 06:00
CRDT- 2011/03/29 06:00
PHST- 2010/10/19 00:00 [received]
PHST- 2011/01/16 00:00 [revised]
PHST- 2011/02/16 00:00 [accepted]
PHST- 2011/03/29 06:00 [entrez]
PHST- 2011/03/29 06:00 [pubmed]
PHST- 2012/03/22 06:00 [medline]
AID - S0248-8663(11)00088-9 [pii]
AID - 10.1016/j.revmed.2011.02.018 [doi]
PST - ppublish
SO  - Rev Med Interne. 2011 Dec;32(12):736-41. doi: 10.1016/j.revmed.2011.02.018. Epub 
      2011 Mar 25.

PMID- 6235245
OWN - NLM
STAT- MEDLINE
DCOM- 19840907
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 74
IP  - 2
DP  - 1984 Aug
TI  - Aspirin inhibits vascular plasminogen activator activity in vivo. Studies 
      utilizing a new assay to quantify plasminogen activator activity.
PG  - 571-80
AB  - Vascular or tissue-type plasminogen activator (TPA) is a key enzyme in 
      physiologic fibrinolysis. To study the role of prostaglandins in modulating the 
      synthesis and release of TPA in vivo, we prospectively studied the effect of 
      aspirin (650 mg/d X 2) on TPA activity in 13 human subjects before and after 10 
      min of forearm venous occlusion. TPA activity was quantified by a newly developed 
      enzyme-linked immunosorbent assay that both measures and differentiates between 
      TPA and urokinase (UK)-like plasminogen activator activity. This assay is based 
      on the observation that the concentration of alpha 2-plasmin inhibitor-plasmin 
      complexes in Reptilase-clotted plasma increases linearly in proportion to the 
      amount of activator added. Resting TPA activity was higher in women than in men 
      (0.56 +/- 0.59 vs. 0.15 +/- 0.11 U/ml, P = 0.049). Venous occlusion induced an 
      eightfold rise in TPA activity in women (to 4.5 U/ml, P = 0.006) and a 15-fold 
      rise in men (to 2.28 U/ml, P = 0.004), whereas UK activity was not detected. 
      Aspirin inhibited the rise in TPA activity after venous occlusion by 69% in men 
      (P = 0.004) and 70% in women (P = 0.014). In contrast, aspirin had no effect on 
      pre- or post-occlusion hematocrits or Factor VIII-related antigen levels. There 
      was no correlation between plasma salicylate level and percentage inhibition of 
      TPA. Neither exogenous aspirin (0-1 microgram/ml) nor salicylate (0-70 
      micrograms/ml) inhibited the generation of alpha 2-plasmin inhibitor-plasmin 
      complexes by exogenous TPA or interfered with the assay system. We conclude that 
      aspirin may have an antifibrinolytic effect in man that has not been previously 
      described.
FAU - Levin, R I
AU  - Levin RI
FAU - Harpel, P C
AU  - Harpel PC
FAU - Weil, D
AU  - Weil D
FAU - Chang, T S
AU  - Chang TS
FAU - Rifkin, D B
AU  - Rifkin DB
LA  - eng
GR  - 5 K08 HL00748/HL/NHLBI NIH HHS/United States
GR  - CA 23753/CA/NCI NIH HHS/United States
GR  - HL 18828/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (alpha-2-Antiplasmin)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - EC 3.4.21.7 (Fibrinolysin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Female
MH  - Fibrinolysin/physiology
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Melanoma/physiopathology
MH  - Plasminogen Activators/*physiology
MH  - Protein Binding
MH  - Reference Values
MH  - alpha-2-Antiplasmin/physiology
PMC - PMC370509
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 10.1172/JCI111454 [doi]
PST - ppublish
SO  - J Clin Invest. 1984 Aug;74(2):571-80. doi: 10.1172/JCI111454.

PMID- 27845951
OWN - NLM
STAT- MEDLINE
DCOM- 20190219
LR  - 20190320
IS  - 1473-5709 (Electronic)
IS  - 0959-8278 (Linking)
VI  - 27
IP  - 2
DP  - 2018 Mar
TI  - Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal 
      cancer deaths? A comparison of two cohorts in the Florence district, Italy.
PG  - 134-139
LID - 10.1097/CEJ.0000000000000319 [doi]
AB  - Aspirin has been associated with reduced incidence and mortality of colorectal 
      and a few other cancers. The aim of our paper was to study the effect of low-dose 
      aspirin intake on cancer mortality in a population-based cohort study. The study 
      included inhabitants of the Florence district (Italy) at the beginning of 2007. 
      We considered two cohorts: patients who received prescriptions of low-dose 
      aspirin for the whole year and patients who did not have any prescriptions over 
      the same period. We followed the two cohorts until 31 December 2013. By linking 
      with the Tuscany Mortality Registry, we analysed cause-specific mortality. We 
      used a Cox semiparametric model to compare the mortality of the two cohorts. 
      There was an 18% higher probability [hazard ratio (HR)=1.18, 95% confidence 
      interval (CI): 1.12-1.23] for all causes of death among the cohort of aspirin 
      users, almost completely caused by cardiovascular diseases (CVDs) (HR=1.39, 95% 
      CI: 1.29-1.49). Colorectal cancer mortality was reduced by almost 30% (HR=0.71, 
      95% CI: 0.52-0.97). Death caused by major bleeding was 11% higher (HR=1.11, 95% 
      CI: 0.86-1.44), but not statistically significant. Our results support the 
      hypothesis that the use of low-dose aspirin for CVD prevention reduces colorectal 
      cancer mortality. Given the growing ability to identify subgroups of individuals 
      with an increased risk of developing cancer, further studies are needed to study 
      the effectiveness of different cancer screening strategies tailored to these 
      specific subgroups. Our study suggests the importance of focusing on this issue 
      from the opposite perspective, that is, considering subgroups of individuals at 
      decreased risk, such as the subgroup of individuals who take low-dose aspirin for 
      CVD prevention. Thus, further assessments are needed to possibly identify 
      subgroup-specific screening strategies that would be more effective than those 
      developed for average-risk individuals.
FAU - Ventura, Leonardo
AU  - Ventura L
AD  - Clinical Epidemiology and Registries.
FAU - Miccinesi, Guido
AU  - Miccinesi G
AD  - Clinical Epidemiology and Registries.
FAU - Barchielli, Alessandro
AU  - Barchielli A
AD  - Tuscany Cancer Registry.
FAU - Manneschi, Gianfranco
AU  - Manneschi G
AD  - Tuscany Cancer Registry.
FAU - Puliti, Donella
AU  - Puliti D
AD  - Clinical Epidemiology and Registries.
FAU - Mantellini, Paola
AU  - Mantellini P
AD  - Secondary Screening Prevention, Cancer Prevention and Research Institute.
FAU - Orso, Francesco
AU  - Orso F
AD  - Cardiology and Geriatric Medicine, AOU Careggi, Florence, Italy.
FAU - Zappa, Marco
AU  - Zappa M
AD  - Clinical Epidemiology and Registries.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Eur J Cancer Prev
JT  - European journal of cancer prevention : the official journal of the European 
      Cancer Prevention Organisation (ECP)
JID - 9300837
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Colorectal Neoplasms/*mortality/prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Italy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Registries/statistics & numerical data
MH  - Survival Analysis
EDAT- 2016/11/16 06:00
MHDA- 2019/03/21 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
PHST- 2016/11/16 06:00 [entrez]
AID - 10.1097/CEJ.0000000000000319 [doi]
PST - ppublish
SO  - Eur J Cancer Prev. 2018 Mar;27(2):134-139. doi: 10.1097/CEJ.0000000000000319.

PMID- 28878032
OWN - NLM
STAT- MEDLINE
DCOM- 20180524
LR  - 20181113
IS  - 1742-5662 (Electronic)
IS  - 1742-5689 (Print)
IS  - 1742-5662 (Linking)
VI  - 14
IP  - 134
DP  - 2017 Sep
TI  - Effect of aspirin on tumour cell colony formation and evolution.
LID - 10.1098/rsif.2017.0374 [doi]
LID - 20170374
AB  - Aspirin is known to reduce the risk of colorectal cancer (CRC) incidence, but the 
      underlying mechanisms are not fully understood. In a previous study, we 
      quantified the in vitro growth kinetics of different CRC tumour cell lines 
      treated with varying doses of aspirin, measuring the rate of cell division and 
      cell death. Here, we use these measured parameters to calculate the chances of 
      successful clonal expansion and to determine the evolutionary potential of the 
      tumour cell lines in the presence and absence of aspirin. The calculations 
      indicate that aspirin increases the probability that a single tumour cell fails 
      to clonally expand. Further, calculations suggest that aspirin increases the 
      evolutionary potential of an expanding tumour cell colony. An aspirin-treated 
      tumour cell population is predicted to result in the accumulation of more 
      mutations (and is thus more virulent and more difficult to treat) than a cell 
      population of the same size that grew without aspirin. This indicates a potential 
      trade-off between delaying the onset of cancer and increasing its evolutionary 
      potential through chemoprevention. Further work needs to investigate to what 
      extent these findings apply to in vivo settings, and to what degree they 
      contribute to the epidemiologically documented aspirin-mediated protection.
CI  - © 2017 The Author(s).
FAU - Wodarz, Dominik
AU  - Wodarz D
AUID- ORCID: 0000-0002-8017-3707
AD  - Department of Ecology and Evolutionary Biology, University of California, Irvine, 
      CA 92617, USA dwodarz@uci.edu.
AD  - Department of Mathematics, University of California, Rowland Hall, Irvine, CA 
      92617, USA.
FAU - Goel, Ajay
AU  - Goel A
AD  - Center for Gastroenterological Research, Baylor Research Institute and Sammons 
      Cancer Center, Baylor University Medical Center, Dallas TX, USA.
FAU - Boland, C Richard
AU  - Boland CR
AD  - University of California San Diego, 9500 Gilman Drive, La Jolla CA 92093, USA.
FAU - Komarova, Natalia L
AU  - Komarova NL
AUID- ORCID: 0000-0003-4876-0343
AD  - Department of Ecology and Evolutionary Biology, University of California, Irvine, 
      CA 92617, USA.
AD  - Department of Mathematics, University of California, Rowland Hall, Irvine, CA 
      92617, USA.
LA  - eng
GR  - U01 CA187956/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - J R Soc Interface
JT  - Journal of the Royal Society, Interface
JID - 101217269
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Caco-2 Cells
MH  - Cell Death/drug effects
MH  - Cell Division/*drug effects
MH  - Colorectal Neoplasms/*metabolism/prevention & control
MH  - Humans
MH  - *Models, Biological
MH  - Risk Factors
PMC - PMC5636273
OTO - NOTNLM
OT  - aspirin
OT  - chemoprevention
OT  - evolutionary theory
OT  - mathematical models
COIS- We declare we have no competing interests.
EDAT- 2017/09/08 06:00
MHDA- 2018/05/25 06:00
CRDT- 2017/09/08 06:00
PHST- 2017/05/20 00:00 [received]
PHST- 2017/08/14 00:00 [accepted]
PHST- 2017/09/08 06:00 [entrez]
PHST- 2017/09/08 06:00 [pubmed]
PHST- 2018/05/25 06:00 [medline]
AID - rsif.2017.0374 [pii]
AID - rsif20170374 [pii]
AID - 10.1098/rsif.2017.0374 [doi]
PST - ppublish
SO  - J R Soc Interface. 2017 Sep;14(134):20170374. doi: 10.1098/rsif.2017.0374.

PMID- 30177071
OWN - NLM
STAT- MEDLINE
DCOM- 20181114
LR  - 20181114
IS  - 2210-7797 (Electronic)
IS  - 2210-7789 (Linking)
VI  - 13
DP  - 2018 Jul
TI  - The effect of low-dose aspirin on serum placental growth factor levels in a 
      high-risk PREDO cohort.
PG  - 51-57
LID - S2210-7789(17)30422-1 [pii]
LID - 10.1016/j.preghy.2018.04.003 [doi]
AB  - OBJECTIVES: Our first aim was to study the longitudinal changes of serum 
      placental growth factor (PlGF) concentration between 12(+0) and 28(+0) weeks of 
      gestation in the prospective PREDO cohort. Our second aim was to study the effect 
      of low-dose acetylsalicylic acid (LDA; 100 mg/day), started before the 14th week 
      of gestation, on PlGF concentration. STUDY DESIGN: Blood samples were collected 
      at 12(+0)-14(+0), 18(+0)-20(+0) and 26(+0)-28(+0) weeks of gestation in 101 women 
      without and 309 with clinical risk factors for pre-eclampsia. Risk-women were 
      divided into two groups: to those who had medium risk for pre-eclampsia and to 
      those who had high risk for pre-eclampsia. Finally there were seven groups 
      according to risk, treatment (no prevention/placebo/LDA) and outcome measure 
      pre-eclampsia. Longitudinal changes in the PlGF concentration between groups were 
      compared. To investigate the effect of LDA on serum PlGF concentration, placebo 
      (N = 62) and LDA (N = 61) groups were compared. A repeated measures ANOVA was 
      used to analyze differences in PlGF levels between the groups. RESULTS: The 
      increase in serum PlGF concentration was higher in LDA than in placebo group 
      (time × group effect, p = 0.046). The increase in serum PlGF concentration during 
      pregnancy was lower in high-risk women who had placebo and developed 
      pre-eclampsia and in medium-risk women who developed pre-eclampsia compared to 
      the other women (time × group effect, p < 0.001). There were no differences in 
      PlGF change between low-risk women, medium-risk women who did not develop 
      pre-eclampsia, high-risk women in the placebo group without pre-eclampsia and 
      high-risk women in the LDA group with and without pre-eclampsia (p = 0.15). 
      CONCLUSIONS: Our finding suggests an association between LDA started before 
      14 weeks of gestation and higher increase in serum PlGF concentration.
CI  - Copyright © 2018 International Society for the Study of Hypertension in 
      Pregnancy. Published by Elsevier B.V. All rights reserved.
FAU - Murtoniemi, K
AU  - Murtoniemi K
AD  - Medical and Clinical Genetics, University of Helsinki and Helsinki University 
      Hospital, P.O. Box 63, FI-00014 University of Helsinki, Finland; Department of 
      Obstetrics and Gynaecology, University of Turku and Turku University Hospital, PO 
      Box 52, FI-20521 Turku, Finland. Electronic address: 
      katja.murtoniemi@helsinki.fi.
FAU - Vahlberg, T
AU  - Vahlberg T
AD  - Department of Clinical Medicine, Biostatistics, University of Turku and Turku 
      University Hospital, FI-20014 University of Turku, Finland. Electronic address: 
      tervah@utu.fi.
FAU - Hämäläinen, E
AU  - Hämäläinen E
AD  - Vita Healthcare Service Ltd., Laivakatu 5 F, FI-00150 Helsinki, Finland; 
      Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland. 
      Electronic address: esa.hamalainen@vita.fi.
FAU - Kajantie, E
AU  - Kajantie E
AD  - National Institute for Health and Welfare, Chronic Disease Prevention Unit, 
      FI-00271 Helsinki, Finland; Hospital for Children and Adolescents, University of 
      Helsinki and Helsinki University Hospital, Stenbäckinkatu 11, P.O. Box 281, 
      FI-00029 HUS, Finland; PEDEGO Research Unit, MRC Oulu, Oulu University Hospital 
      and University of Oulu, 90014 Oulu, Finland. Electronic address: 
      eero.kajantie@helsinki.fi.
FAU - Pesonen, A K
AU  - Pesonen AK
AD  - Department of Psychology and Logopedics, University of Helsinki, Faculty of 
      Medicine, P.O.Box 63, FI-00014 University of Helsinki, Finland. Electronic 
      address: anukatriina.pesonen@helsinki.fi.
FAU - Räikkönen, K
AU  - Räikkönen K
AD  - Department of Psychology and Logopedics, University of Helsinki, Faculty of 
      Medicine, P.O.Box 63, FI-00014 University of Helsinki, Finland. Electronic 
      address: katri.raikkonen@helsinki.fi.
FAU - Taipale, P
AU  - Taipale P
AD  - Terveystalo Oy, Asemakatu 22-24, FI-70100 Kuopio, Finland. Electronic address: 
      pekka.taipale@terveystalo.com.
FAU - Villa, P M
AU  - Villa PM
AD  - Obstetrics and Gynaecology, University of Helsinki and Helsinki University 
      Hospital, Helsinki, Haartmaninkatu 2, P.O. Box 140, FI-00029 HUS, Finland. 
      Electronic address: pia.villa@helsinki.fi.
FAU - Laivuori, H
AU  - Laivuori H
AD  - Medical and Clinical Genetics, University of Helsinki and Helsinki University 
      Hospital, P.O. Box 63, FI-00014 University of Helsinki, Finland; Institute for 
      Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University 
      of Helsinki, P.O.Box 20, FI-00014 University of Helsinki, Finland; Department of 
      Obstetrics and Gynecology, Tampere University Hospital, PO Box 2000, FI-33521 
      Tampere, Finland; Faculty of Medicine and Life Sciences, P.O. Box 100, FI-33014 
      University of Tampere, Finland. Electronic address: 
      hannele.laivuori@staff.uta.fi.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20180407
PL  - Netherlands
TA  - Pregnancy Hypertens
JT  - Pregnancy hypertension
JID - 101552483
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 144589-93-5 (Placenta Growth Factor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Finland/epidemiology
MH  - Gestational Age
MH  - Humans
MH  - Longitudinal Studies
MH  - Placenta Growth Factor/*blood
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pre-Eclampsia/blood/*drug therapy/epidemiology
MH  - Pregnancy
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Low-dose acetylsalicylic acid
OT  - Placental growth factor
OT  - Pre-eclampsia
EDAT- 2018/09/05 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/09/05 06:00
PHST- 2017/12/01 00:00 [received]
PHST- 2018/03/16 00:00 [revised]
PHST- 2018/04/06 00:00 [accepted]
PHST- 2018/09/05 06:00 [entrez]
PHST- 2018/09/05 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
AID - S2210-7789(17)30422-1 [pii]
AID - 10.1016/j.preghy.2018.04.003 [doi]
PST - ppublish
SO  - Pregnancy Hypertens. 2018 Jul;13:51-57. doi: 10.1016/j.preghy.2018.04.003. Epub 
      2018 Apr 7.

PMID- 9427177
OWN - NLM
STAT- MEDLINE
DCOM- 19980219
LR  - 20131121
IS  - 1070-8022 (Print)
IS  - 1070-8022 (Linking)
VI  - 17
IP  - 4
DP  - 1997 Dec
TI  - Aspirin reduces the incidence of second eye NAION: a retrospective study.
PG  - 250-3
AB  - The objective of this study was to determine if aspirin reduces the incidence of 
      second eye involvement after nonarteritic anterior ischemic optic neuropathy 
      (NAION) in one eye. Records were reviewed of 131 patients who sustained 
      unilateral NAION. Of these, the 33 patients who sustained second eye NAION were 
      compared to those followed for a minimum of 2 years without sustaining a second 
      eye NAION (67). Thirty-one of the 131 patients were excluded because of 
      inadequate follow-up. Except for diabetes (relative risk [RR] 1.43, p = 0.05), 
      the incidence of second eye NAION was independent of gender, age, cup/disk, 
      hypertension, anemia, and migraine. The degree of visual acuity or field 
      dysfunction in the first eye correlated poorly with the acuity (r = 0.28) and 
      field (r = 0.33) loss in the second eye. Aspirin (65-1,300 mg) taken two or more 
      times per week decreased the incidence (17.5% vs. 53.5%) and relative risk (RR = 
      0.44, p = 0.0002) of second eye AION regardless of the usual risk factors. Even 
      after eliminating those patients who had bilateral disease when first referred, 
      ASA still reduced the incidence of second eye involvement (35% vs. 13%, RR = 
      0.74, p = 0.01). Aspirin may be an effective means of reducing second eye NAION.
FAU - Kupersmith, M J
AU  - Kupersmith MJ
AD  - INN, Beth Israel Medical Center, New York, NY, USA.
FAU - Frohman, L
AU  - Frohman L
FAU - Sanderson, M
AU  - Sanderson M
FAU - Jacobs, J
AU  - Jacobs J
FAU - Hirschfeld, J
AU  - Hirschfeld J
FAU - Ku, C
AU  - Ku C
FAU - Warren, F A
AU  - Warren FA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Neuroophthalmol
JT  - Journal of neuro-ophthalmology : the official journal of the North American 
      Neuro-Ophthalmology Society
JID - 9431308
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Functional Laterality
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Optic Neuropathy, Ischemic/*drug therapy/epidemiology
MH  - Retrospective Studies
MH  - Risk Factors
EDAT- 1998/01/14 00:00
MHDA- 1998/01/14 00:01
CRDT- 1998/01/14 00:00
PHST- 1998/01/14 00:00 [pubmed]
PHST- 1998/01/14 00:01 [medline]
PHST- 1998/01/14 00:00 [entrez]
PST - ppublish
SO  - J Neuroophthalmol. 1997 Dec;17(4):250-3.

PMID- 9412879
OWN - NLM
STAT- MEDLINE
DCOM- 19980129
LR  - 20190909
IS  - 1053-0770 (Print)
IS  - 1053-0770 (Linking)
VI  - 11
IP  - 7
DP  - 1997 Dec
TI  - Effect of aspirin in coronary artery bypass grafting.
PG  - 831-4
AB  - OBJECTIVES: To evaluate the effect of aspirin (ASA) therapy on postoperative 
      blood loss, transfusion requirements, reoperation for bleeding, duration of stay 
      in the intensive care unit and in the hospital in a selected population 
      undergoing a first coronary artery bypass grafting (CABG) surgery. DESIGN: 
      Prospective observational study in consecutive patients during a 3-month period. 
      SETTING: A teaching cardiothoracic center. PARTICIPANTS: Two hundred forty 
      consecutive patients undergoing elective coronary artery bypass grafting surgery 
      for the first time. INTERVENTIONS: Two hundred forty consecutive patients 
      admitted for a first CABG the day before surgery were visited. patients with an 
      abnormal routine coagulation screen or taking drugs that might have affected 
      their coagulation mechanisms were prospectively excluded (n = 96). The date of 
      the last dose of ASA was recorded in the 144 remaining patients, and data were 
      acquired prospectively. MEASUREMENTS AND MAIN RESULTS: Total mediastinal blood 
      drainage, blood products usage, reopening, and duration of intensive care unit 
      and hospital stay were recorded. Patients were grouped by days free of ASA. There 
      were no significant differences detected between groups. CONCLUSIONS: In patients 
      undergoing a first CABG and with no known factors affecting their coagulation, 
      ASA therapy did not appear to increase blood loss, reopening for bleeding, or 
      blood products usage requirements during the hospital stay. ASA therapy did not 
      influence the duration of stay in intensive care or in the hospital.
FAU - Vuylsteke, A
AU  - Vuylsteke A
AD  - Department of Anaesthesia, Papworth Hospital, Cambridge, UK.
FAU - Oduro, A
AU  - Oduro A
FAU - Cardan, E
AU  - Cardan E
FAU - Latimer, R D
AU  - Latimer RD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiothorac Vasc Anesth
JT  - Journal of cardiothoracic and vascular anesthesia
JID - 9110208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Blood Transfusion
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Postoperative Hemorrhage/*etiology
MH  - Prospective Studies
EDAT- 1997/12/31 00:00
MHDA- 1997/12/31 00:01
CRDT- 1997/12/31 00:00
PHST- 1997/12/31 00:00 [pubmed]
PHST- 1997/12/31 00:01 [medline]
PHST- 1997/12/31 00:00 [entrez]
AID - S1053-0770(97)90115-4 [pii]
AID - 10.1016/s1053-0770(97)90115-4 [doi]
PST - ppublish
SO  - J Cardiothorac Vasc Anesth. 1997 Dec;11(7):831-4. doi: 
      10.1016/s1053-0770(97)90115-4.

PMID- 11030528
OWN - NLM
STAT- MEDLINE
DCOM- 20010315
LR  - 20191210
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 6
IP  - 4
DP  - 2000 Oct
TI  - Ticlopidine, Alka-Seltzer, or a combination of citric acid with aspirin: effects 
      on platelet aggregation in individuals with an insufficient response to aspirin 
      alone.
PG  - 222-5
AB  - Aspirin (ASA) does not effectively lower platelet aggregation in all people. The 
      platelet aggregation (PA) score is an easily used clinical method for measuring 
      the effect in individuals of antiplatelet medications. Fifteen apparently healthy 
      subjects (2 men and 13 women), selected for their resistance to ASA's 
      antiaggregation effect, completed a sequential trial of ticlopidine, 
      Alka-Seltzer, and ASA + citric acid (CTA). Ticlopidine was the strongest 
      aggregation inhibitor and the ASA + CTA combination was more inhibitory than 
      Alka-Seltzer. It was determined that measuring antiaggregation effects of a 
      particular agent in an individual prior to usage would optimize treatment. The PA 
      score methodology provides a means for testing patients prior to antiplatelet 
      therapy for prevention and treatment of the thrombotic complications of vascular 
      disease.
FAU - Kaplan, S
AU  - Kaplan S
AD  - The Hope Heart Institute, Seattle, Washington 98122, USA. kaplana@prodigy.net
FAU - Kaplan, A
AU  - Kaplan A
FAU - Marcoe, K
AU  - Marcoe K
FAU - Sauvage, L R
AU  - Sauvage LR
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Citrates)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 2968PHW8QP (Citric Acid)
RN  - 53663-74-4 (sodium acetylsalicylate, sodium bicarbonate, sodium citrate drug 
      combination)
RN  - 8MDF5V39QO (Sodium Bicarbonate)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/pharmacology
MH  - Citrates/administration & dosage/pharmacology
MH  - Citric Acid/administration & dosage/pharmacology
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*pharmacology
MH  - Sodium Bicarbonate/administration & dosage/pharmacology
MH  - Ticlopidine/administration & dosage/pharmacology
EDAT- 2000/10/13 11:00
MHDA- 2001/03/17 10:01
CRDT- 2000/10/13 11:00
PHST- 2000/10/13 11:00 [pubmed]
PHST- 2001/03/17 10:01 [medline]
PHST- 2000/10/13 11:00 [entrez]
AID - 10.1177/107602960000600407 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2000 Oct;6(4):222-5. doi: 10.1177/107602960000600407.

PMID- 24130971
OWN - NLM
STAT- MEDLINE
DCOM- 20140529
LR  - 20181202
IS  - 0300-8495 (Print)
IS  - 0300-8495 (Linking)
VI  - 42
IP  - 10
DP  - 2013 Oct
TI  - Dual antiplatelet therapy -- management in general practice.
PG  - 702-5
AB  - BACKGROUND: Prasugrel and ticagrelor are two new antiplatelet agents being used 
      in the management of acute coronary syndromes. The number of patients in the 
      community managed on these medications is growing, and thus, it is essential that 
      general practitioners have a good understanding of these agents and their 
      evidence-based applications. OBJECTIVE: The pharmacokinetic and pharmacodynamic 
      properties of common and new antiplatelet agents will be reviewed, along with the 
      evidence supporting their use. Safety and side effect profiles will be discussed, 
      and some common general practice case scenarios presented. DISCUSSION: Aspirin is 
      still the mainstay of therapy in patients with acute coronary syndromes. The 
      addition of clopidogrel, prasugrel or ticagrelor can reduce morbidity and 
      mortality in selected patients. Patient factors including bleeding risk, renal 
      function and time since coronary stent insertion must be reviewed before these 
      agents are initiated and before making any changes to the medication regimen.
FAU - Jayasinghe, Rohan
AU  - Jayasinghe R
AD  - MBBS(Hons), MSpM, PhD, FRACP, FCSANZ, MBA, is Professor of Cardiology, Griffith 
      University and Director of Cardiac Services/Cardiology, Gold Coast Health, 
      Queensland.
FAU - Markham, Ryan
AU  - Markham R
FAU - Adsett, Geoffrey
AU  - Adsett G
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Australia
TA  - Aust Fam Physician
JT  - Australian family physician
JID - 0326701
RN  - 0 (Piperazines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thiophenes)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Aust Fam Physician. 2014 Aug;43(8):503. PMID: 25252366
CIN - Aust Fam Physician. 2014 Aug;43(8):503. PMID: 25252367
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Adenosine/analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use
MH  - Aged
MH  - Aspirin/pharmacokinetics/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Piperazines/pharmacokinetics/pharmacology/therapeutic use
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/pharmacology/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Prasugrel Hydrochloride
MH  - Thiophenes/pharmacokinetics/pharmacology/therapeutic use
MH  - Ticagrelor
MH  - Ticlopidine/analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use
EDAT- 2013/10/17 06:00
MHDA- 2014/05/30 06:00
CRDT- 2013/10/17 06:00
PHST- 2013/10/17 06:00 [entrez]
PHST- 2013/10/17 06:00 [pubmed]
PHST- 2014/05/30 06:00 [medline]
PST - ppublish
SO  - Aust Fam Physician. 2013 Oct;42(10):702-5.

PMID- 1940196
OWN - NLM
STAT- MEDLINE
DCOM- 19911129
LR  - 20190817
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 13 Suppl 1
DP  - 1991
TI  - Epithelial renewal in protection and repair of gastroduodenal mucosa.
PG  - S48-53
AB  - The constant, rapid renewal of the gastroduodenal epithelium is an important 
      mechanism of mucosal protection because it maintains the functional integrity of 
      the epithelium. It also is necessary for the repair of mucosal injury. Aspirin, 
      indomethacin, and ethanol all have been shown to stimulate epithelial 
      proliferation in the experimental setting. The stimulatory effects of these 
      agents may be a compensatory reaction to mild injury and may contribute to the 
      process of mucosal adaptation. On the other hand, corticosteroids, physiologic 
      stress, and smoking appear to depress epithelial proliferation, which could 
      render the mucosa susceptible to the effects of other ulcerogens as well as 
      retard the healing of existing mucosal lesions. Epithelial proliferation in 
      mucosa adjacent to active duodenal ulcers as well as from nonulcerated duodenitis 
      is increased when compared to normal-appearing mucosa. This stimulation of 
      epithelial proliferation may be caused by inflammation; it is not known whether 
      ulcer patients have a defect in epithelial proliferation that precedes 
      ulceration. Although prostaglandins (PGs) protect ulceration. Although 
      prostaglandins (PGs) protect the gastroduodenal mucosa, the weight of evidence 
      indicates that PGs do not have a primary effect on epithelial proliferation but 
      rather retard senescence and loss of epithelial cells. The result is thickening 
      of the mucosa, which may contribute to the protective effects of PGs. Ulcerogenic 
      agents or conditions may either depress epithelial proliferation, which 
      predisposes to ulceration or the ulcerogenic effects of other ulcerogens, or 
      result in a hyperproliferative response, which may contribute to the process of 
      mucosal adaptation and protection.
FAU - Eastwood, G L
AU  - Eastwood GL
AD  - School of Medicine, Medical College of Georgia, Augusta 30912.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Prostaglandins)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adrenal Cortex Hormones/pharmacology
MH  - Aspirin/pharmacology
MH  - Epithelium/drug effects/physiology
MH  - Ethanol/pharmacology
MH  - Gastric Mucosa/drug effects/*physiology
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Prostaglandins/pharmacology
MH  - *Regeneration
RF  - 42
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1097/00004836-199112001-00008 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 1991;13 Suppl 1:S48-53. doi: 
      10.1097/00004836-199112001-00008.

PMID- 21745731
OWN - NLM
STAT- MEDLINE
DCOM- 20111219
LR  - 20131121
IS  - 1590-3729 (Electronic)
IS  - 0939-4753 (Linking)
VI  - 21
IP  - 8
DP  - 2011 Aug
TI  - Aspirin resistance and platelet turnover: a 25-year old issue.
PG  - 542-5
LID - 10.1016/j.numecd.2011.04.002 [doi]
AB  - The evidence of an incomplete inhibition of platelet function by aspirin, despite 
      therapeutic doses of the drug proved to be clinically effective are employed, was 
      first reported in the '80s, in the frame of studies devoted to platelet turnover. 
      Because inhibition of platelet aggregation by aspirin is irreversible, the return 
      after an interval of time of the ability to form thromboxane by platelets in 
      circulating blood should reflect the entry into the circulation of platelets 
      whose cyclooxygenase activity has not been affected by aspirin. Based on this 
      concept, the possibility of monitoring the entry of newly formed platelets into 
      the circulation after aspirin ingestion was documented by measuring the return of 
      thromboxane biosynthesis by platelets challenged in vitro by pairs of aggregating 
      agents. The data obtained showed that platelets with intact cyclooxygenase 
      activity could be detected into the circulation of control individuals as early 
      as 4-6 h after aspirin ingestion, and at shorter time intervals in diabetic 
      angiopathy. In the latter setting,the data allowed to conclude that "schedules of 
      aspirin which may suffice in normals are not effective in patients with diabetic 
      angiopathy, presumably because these patients have a high rate of entry of new 
      platelets into the circulation".
CI  - Copyright © 2011. Published by Elsevier B.V.
FAU - Di Minno, G
AU  - Di Minno G
AD  - Department of Clinical and Experimental Medicine, Regional Reference Centre for 
      Coagulation Disorders, Federico II University, Naples, Italy. diminno@unina.It
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110713
PL  - Netherlands
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
RN  - 0 (Thromboxanes)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Diabetic Angiopathies/*drug therapy
MH  - Disease Models, Animal
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Thromboxanes/biosynthesis
EDAT- 2011/07/13 06:00
MHDA- 2011/12/20 06:00
CRDT- 2011/07/13 06:00
PHST- 2011/03/22 00:00 [received]
PHST- 2011/04/11 00:00 [accepted]
PHST- 2011/07/13 06:00 [entrez]
PHST- 2011/07/13 06:00 [pubmed]
PHST- 2011/12/20 06:00 [medline]
AID - S0939-4753(11)00097-4 [pii]
AID - 10.1016/j.numecd.2011.04.002 [doi]
PST - ppublish
SO  - Nutr Metab Cardiovasc Dis. 2011 Aug;21(8):542-5. doi: 
      10.1016/j.numecd.2011.04.002. Epub 2011 Jul 13.

PMID- 334185
OWN - NLM
STAT- MEDLINE
DCOM- 19771130
LR  - 20190717
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 20
IP  - 7
DP  - 1977 Sep-Oct
TI  - Estimates of doses of antiinflammatory drugs in man by testing for analgesic 
      potency. I. 1-isopropyl-4 phenyl-7-methyl-2 (1H) quinazolone versus aspirin.
PG  - 1381-7
AB  - Dosage estimates of antiinflammatory drugs in human arthritis Phase II trials are 
      difficult to obtain and prolong such trials unnecessarily. Antiinflammatory drugs 
      almost always have analgesic properties in man and good dose estimates for 
      analgesic activity can be obtained. In 140 patients with surgical pain, 300, 600, 
      and 1200 mg of aspirin were compared to 75, 150, and 300 mg of 43-715 
      (1-isopropyl-4-phenyl-7-methyl-2 (1H) quinazolone), an antiinflammatory 
      quinazolone derivative, for analgesia in a double-blind trial using subjective 
      response methodology. The test drug was shown to be analgesic at a level four 
      times more potent, milligram for milligram, than aspirin, an estimate that should 
      be useful for later definitive Phase II trials in arthritis.
FAU - Kantor, T G
AU  - Kantor TG
FAU - Streem, A
AU  - Streem A
FAU - Laska, E
AU  - Laska E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Quinazolines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Humans
MH  - Pain, Postoperative/*drug therapy
MH  - Quinazolines/*administration & dosage
EDAT- 1977/09/01 00:00
MHDA- 1977/09/01 00:01
CRDT- 1977/09/01 00:00
PHST- 1977/09/01 00:00 [pubmed]
PHST- 1977/09/01 00:01 [medline]
PHST- 1977/09/01 00:00 [entrez]
AID - 10.1002/art.1780200712 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1977 Sep-Oct;20(7):1381-7. doi: 10.1002/art.1780200712.

PMID- 32535804
OWN - NLM
STAT- MEDLINE
DCOM- 20210601
LR  - 20210601
IS  - 1573-7438 (Electronic)
IS  - 0049-4747 (Linking)
VI  - 52
IP  - 6
DP  - 2020 Nov
TI  - Effect of flunixin meglumine and aspirin administration on conception rate and 
      estrous cycle characteristics of Egyptian Baladi cows during hot season.
PG  - 2969-2976
LID - 10.1007/s11250-020-02314-6 [doi]
AB  - The current investigation aims to evaluate the effects of flunixin meglumine (FM) 
      and aspirin as non-steroid anti-inflammatory drug (NSAID) administration on 
      estrous cycles characteristics and conception rate of Egyptian Baladi cows during 
      hot season. In the first phase, 30 cows were divided into 3 groups, 10 cows for 
      each treatment. The first group was treated with FM at the rate of 1.1 mg/kg body 
      weight (BW) intramuscular, while the second group was administrated aspirin 
      solution orally at the rate of 50 mg/kg BW. The third group was assigned as 
      control (CG) that has no treatment. The FM group was administrated on day 14 
      after mating, while aspirin was given on day 14 and day 15 post-mating. All cows 
      were mated naturally after showing estrus signs. Pregnancy diagnosis was carried 
      60 days after mating by rectal palpation. In the second phase, cows were 
      monitored for estrus behavior by visual observation twice a day. The length of 
      normal estrous cycles was 20, 23, and 22 days in cows treated with FM, aspirin, 
      and control cows, respectively. There was no significant effect of treatment on 
      the length of normal estrous cycles in Egyptian cows (P < 0.05). Proportions of 
      long cycles in Egyptian cows that treated with FM or aspirin and control were 75, 
      67.7, and 57.1%, respectively. Short cycles were completely absent in cows that 
      treated with FM or aspirin, but it was 29% in CG. Mounting behavior and tail 
      rising were not detected in CG compared to 0 and 33% in FM or 25 and 33% in 
      aspirin treated cows, respectively. Conception or pregnancy rate were 60, 40, and 
      30%, respectively, in FM, aspirin treated, and CG. Treatment cows whether FM or 
      aspirin group did not influence (P < 0.05) progesterone concentration during the 
      14 days and 21 days from estrous cycle in pregnant and non-pregnant Egyptian 
      Baladi cows than CG. In conclusion, the results of this study clearly indicated 
      beneficial effect of FM and aspirin administration on intense of displayed 
      estrous behavior and conception rate of Egyptian Baladi cows during the hot 
      season.
FAU - Damarany, Ahmed Ismail
AU  - Damarany AI
AD  - Department of Animal and Poultry Production Faculty of Agriculture and Natural 
      Resources, Aswan University, Aswan, Egypt. dr_damarana@yahoo.com.
FAU - Ghanem, Nasser
AU  - Ghanem N
AUID- ORCID: 0000-0002-0480-0959
AD  - Department of Animal Production, Faculty of Agriculture, Cairo University, Giza, 
      Egypt.
LA  - eng
PT  - Clinical Trial, Veterinary
PT  - Journal Article
DEP - 20200614
PL  - United States
TA  - Trop Anim Health Prod
JT  - Tropical animal health and production
JID - 1277355
RN  - 4G7DS2Q64Y (Progesterone)
RN  - 8Y3JK0JW3U (flunixin meglumine)
RN  - R16CO5Y76E (Aspirin)
RN  - V7DXN0M42R (Clonixin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage
MH  - Cattle
MH  - Clonixin/administration & dosage/*analogs & derivatives
MH  - Egypt
MH  - Estrous Cycle/*drug effects
MH  - Female
MH  - Pregnancy
MH  - Progesterone
MH  - *Seasons
OTO - NOTNLM
OT  - Aspirin
OT  - Conception rate
OT  - Egyptian Baladi cows
OT  - Flunixin meglumine
EDAT- 2020/06/15 06:00
MHDA- 2021/06/02 06:00
CRDT- 2020/06/15 06:00
PHST- 2019/08/07 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2021/06/02 06:00 [medline]
PHST- 2020/06/15 06:00 [entrez]
AID - 10.1007/s11250-020-02314-6 [pii]
AID - 10.1007/s11250-020-02314-6 [doi]
PST - ppublish
SO  - Trop Anim Health Prod. 2020 Nov;52(6):2969-2976. doi: 10.1007/s11250-020-02314-6. 
      Epub 2020 Jun 14.

PMID- 7126867
OWN - NLM
STAT- MEDLINE
DCOM- 19821216
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 60
IP  - 5
DP  - 1982 Nov
TI  - Aspirin prolongation of the template bleeding time: influence of venostasis and 
      direction of incision.
PG  - 1139-42
AB  - The template bleeding time is a measure of platelet participation in primary 
      hemostasis. Aspirin alters platelet function through interference with 
      prostaglandin biosynthesis. In many individuals, aspirin will consistently 
      prolong the bleeding time. Despite this observation, normal individuals rarely 
      develop a bleeding disorder. This prompted us to investigate the influence of 
      technical variables on the prolongation of the bleeding time by aspirin. Both 
      direction of incision and venostasis influenced the prolongation of the bleeding 
      time by aspirin. A horizontal incision with venostasis produced the most 
      pronounced prolongation, while a vertical incision without venostasis didn't 
      prolong the bleeding time despite the characteristic changes in platelet 
      aggregation and release. These studies suggest that the influence of aspirin on 
      the template bleeding time is dependent on technical variables and is minimal in 
      the normal subject.
FAU - Mielke, C H Jr
AU  - Mielke CH Jr
LA  - eng
GR  - S07 RR05566-18/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 333DO1RDJY (Serotonin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects
MH  - Female
MH  - *Hemostasis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Serotonin/blood
EDAT- 1982/11/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
AID - S0006-4971(20)84578-9 [pii]
PST - ppublish
SO  - Blood. 1982 Nov;60(5):1139-42.

PMID- 19520310
OWN - NLM
STAT- MEDLINE
DCOM- 20090827
LR  - 20181201
IS  - 1878-1594 (Electronic)
IS  - 1521-690X (Linking)
VI  - 23
IP  - 3
DP  - 2009 Jun
TI  - Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus.
PG  - 375-88
LID - 10.1016/j.beem.2008.12.001 [doi]
AB  - Diabetes mellitus patients are characterized by enhanced platelet reactivity 
      which exposes them to an increased risk of atherothrombotic events in the setting 
      of acute coronary syndromes or percutaneous coronary interventions. Although 
      aspirin and clopidogrel, used either solely or in combination, are associated 
      with improved clinical outcomes in high-risk patients, diabetics patients treated 
      with antiplatelet agents remain at higher risk of recurrent ischemic events. 
      Recent laboratory findings suggest that this observation may be related to a 
      reduced responsiveness or 'resistance' to these agents. In this chapter the 
      efficacy of currently available oral antiplatelet agents in preventing ischemic 
      events is reviewed. In addition, the antiplatelet 'resistance' phenomenon in the 
      diabetic population and its impact on clinical outcomes is summarized. Finally, 
      future developments in the field directed towards individualized treatment 
      strategies and novel antiplatelet agents are examined.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - Division of Cardiology, University of Florida College of Medicine-Jacksonville, 
      Jacksonville, FL 32209, USA. dominick.angiolillo@jax.ufl.edu
FAU - Suryadevara, Siva
AU  - Suryadevara S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Endocrinol Metab
JT  - Best practice & research. Clinical endocrinology & metabolism
JID - 101120682
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Diabetes Mellitus/*drug therapy/physiopathology
MH  - Drug Resistance
MH  - Endothelium, Vascular/drug effects/physiopathology
MH  - Humans
MH  - Ischemia/*prevention & control
MH  - Oxidative Stress/drug effects
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Thrombosis/prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
RF  - 95
EDAT- 2009/06/13 09:00
MHDA- 2009/08/28 09:00
CRDT- 2009/06/13 09:00
PHST- 2009/06/13 09:00 [entrez]
PHST- 2009/06/13 09:00 [pubmed]
PHST- 2009/08/28 09:00 [medline]
AID - S1521-690X(08)00170-X [pii]
AID - 10.1016/j.beem.2008.12.001 [doi]
PST - ppublish
SO  - Best Pract Res Clin Endocrinol Metab. 2009 Jun;23(3):375-88. doi: 
      10.1016/j.beem.2008.12.001.

PMID- 24596220
OWN - NLM
STAT- MEDLINE
DCOM- 20141110
LR  - 20140305
IS  - 2159-8290 (Electronic)
IS  - 2159-8274 (Linking)
VI  - 4
IP  - 3
DP  - 2014 Mar
TI  - Protective effect of aspirin associated with SNP.
PG  - OF5
LID - 10.1158/2159-8290.CD-NB2014-011 [doi]
AB  - According to findings of a study in the Journal of the National Cancer Institute, 
      people with a single-nucleotide polymorphism on chromosome 8q24 who regularly use 
      aspirin can cut their risk of colorectal cancer by about half.
LA  - eng
PT  - News
DEP - 20140123
PL  - United States
TA  - Cancer Discov
JT  - Cancer discovery
JID - 101561693
RN  - 0 (Antineoplastic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Chromosomes, Human, Pair 8
MH  - Colorectal Neoplasms/epidemiology/*genetics
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - *Polymorphism, Single Nucleotide
EDAT- 2014/03/07 06:00
MHDA- 2014/11/11 06:00
CRDT- 2014/03/06 06:00
PHST- 2014/03/06 06:00 [entrez]
PHST- 2014/03/07 06:00 [pubmed]
PHST- 2014/11/11 06:00 [medline]
AID - 2159-8290.CD-NB2014-011 [pii]
AID - 10.1158/2159-8290.CD-NB2014-011 [doi]
PST - ppublish
SO  - Cancer Discov. 2014 Mar;4(3):OF5. doi: 10.1158/2159-8290.CD-NB2014-011. Epub 2014 
      Jan 23.

PMID- 19179814
OWN - NLM
STAT- MEDLINE
DCOM- 20090219
LR  - 20151119
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 121
IP  - 1
DP  - 2009 Jan
TI  - The potential role of prasugrel in secondary prevention of ischemic events in 
      patients with acute coronary syndromes.
PG  - 59-72
LID - 10.3810/pgm.2009.01.1955 [doi]
AB  - Acute coronary syndromes (ACS) are life-threatening manifestations of coronary 
      artery disease, occurring when a thrombus forms at the site of atherosclerotic 
      plaque rupture or fissuring. Almost all patients discharged from the hospital 
      after an ACS (myocardial infarction or unstable angina) in the United States 
      receive antiplatelet therapy. Current recommendations for post-ACS antiplatelet 
      therapy are aspirin 75 to 162 mg/day indefinitely for all patients, plus a 
      thienopyridine (currently clopidogrel 75 mg/day) for > or = 12 months in those 
      receiving stents unless there is a high risk of bleeding. Dual antiplatelet 
      therapy is indicated because patients with ACS have a hypercoagulable state which 
      persists for at least 6 months after the acute event, and agents targeting 
      different mechanisms have synergistic antiplatelet effects. The thienopyridine 
      class includes ticlopidine, clopidogrel, and prasugrel. Clopidogrel is 
      recommended in guidelines because ticlopidine carries a higher risk of adverse 
      events including blood dyscrasias. Prasugrel is not yet available outside of a 
      research setting. Clopidogrel + aspirin reduces the risk of an adverse clinical 
      event after ACS by 15% and after percutaneous coronary intervention (PCI) by 34%. 
      However, there is considerable interpatient variability in response to 
      clopidogrel and a mean of 21% of patients (95% confidence interval [CI], 17 % - 
      25%) are nonresponsive to the drug as measured by platelet aggregation 
      inhibition. Nonresponsiveness is associated with an increased risk of secondary 
      ischemic events. Compared with clopidogrel, the newest thienopyridine, prasugrel, 
      has a faster onset of platelet inhibition and less variability of response. In 
      clinical trials, the combination of prasugrel + aspirin reduced the risk of a 
      second ischemic event by 19% compared with clopidogrel + aspirin. There is a 
      small increase in the risk of bleeding with dual antiplatelet therapy, but the 
      benefit still outweighs the risk in most patients. Patients with a history of 
      transient ischemic attack or stroke should not receive prasugrel + aspirin 
      because of increased risk of events.
FAU - Toth, Peter P
AU  - Toth PP
AD  - Department of Family and Community Medicine, University of Illinois School of 
      Medicine, Peoria, IL, USA. peter.toth@srfc.com
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Piperazines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2 Receptor Antagonists)
RN  - 0 (Thiophenes)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/complications
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Humans
MH  - Life Style
MH  - Myocardial Infarction/etiology/mortality/*prevention & control
MH  - Piperazines/pharmacology/*therapeutic use
MH  - Platelet Activation/drug effects/physiology
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prasugrel Hydrochloride
MH  - Purinergic P2 Receptor Antagonists
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Thiophenes/pharmacology/*therapeutic use
RF  - 56
EDAT- 2009/01/31 09:00
MHDA- 2009/02/20 09:00
CRDT- 2009/01/31 09:00
PHST- 2009/01/31 09:00 [entrez]
PHST- 2009/01/31 09:00 [pubmed]
PHST- 2009/02/20 09:00 [medline]
AID - 10.3810/pgm.2009.01.1955 [doi]
PST - ppublish
SO  - Postgrad Med. 2009 Jan;121(1):59-72. doi: 10.3810/pgm.2009.01.1955.

PMID- 30835844
OWN - NLM
STAT- MEDLINE
DCOM- 20191024
LR  - 20200309
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 210
IP  - 4
DP  - 2019 Mar
TI  - Recruiting general practice patients for large clinical trials: lessons from the 
      Aspirin in Reducing Events in the Elderly (ASPREE) study.
PG  - 168-173
LID - 10.5694/mja2.12060 [doi]
AB  - OBJECTIVE: To assess the factors that contributed to the successful completion of 
      recruitment for the largest clinical trial ever conducted in Australia, the 
      Aspirin in Reducing Events in the Elderly (ASPREE) study. DESIGN: Enrolment of 
      GPs; identification of potential participants in general practice databases; 
      screening of participants. SETTING, PARTICIPANTS: Selected general practices 
      across southeast Australia (Tasmania, Victoria, Australian Capital Territory, New 
      South Wales, South Australia). MAJOR OUTCOMES: Numbers of patients per GP 
      screened and randomised to participation; geographic and demographic factors that 
      influenced screening and randomising of patients. RESULTS: 2717 of 5833 GPs 
      approached (47%) enrolled to recruit patients for the study; 2053 (76%) recruited 
      at least one randomised participant. The highest randomised participant rate per 
      GP was for Tasmania (median, 5; IQR, 1-11), driven by the high rate of 
      participant inclusion at phone screening. GPs in inner regional (adjusted odds 
      ratio [aOR], 1.45; 95% CI, 1.14-1.84) and outer regional areas (aOR, 1.86; 95% 
      CI, 1.19-2.88) were more likely than GPs in major cities to recruit at least one 
      randomised participant. GPs in areas with a high proportion of people aged 70 
      years or more were more likely to randomise at least one participant (per 
      percentage point increase: aOR, 1.10; 95% CI, 1.05-1.15). The number of 
      randomised patients declined with time from GP enrolment to first randomisation. 
      CONCLUSION: General practice can be a rich environment for research when barriers 
      to recruitment are overcome. Including regional GPs and focusing efforts in areas 
      with the highest proportions of potentially eligible participants improves 
      recruitment. The success of ASPREE attests to the clinical importance of its 
      research question for Australian GPs.
CI  - © 2018 AMPCo Pty Ltd.
FAU - Lockery, Jessica E
AU  - Lockery JE
AUID- ORCID: 0000-0001-6664-1239
AD  - Monash University, Melbourne, VIC.
FAU - Collyer, Taya A
AU  - Collyer TA
AD  - Monash University, Melbourne, VIC.
FAU - Abhayaratna, Walter P
AU  - Abhayaratna WP
AD  - College of Health and Medicine, Australian National University School of Clinical 
      Medicine, Canberra, ACT.
AD  - Canberra Hospital, Canberra, ACT.
FAU - Fitzgerald, Sharyn M
AU  - Fitzgerald SM
AD  - Monash University, Melbourne, VIC.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Monash University, Melbourne, VIC.
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - University of Tasmania, Hobart, TAS.
FAU - Orchard, Suzanne G
AU  - Orchard SG
AD  - Monash University, Melbourne, VIC.
FAU - Reid, Christopher
AU  - Reid C
AD  - Curtin University, Perth, WA.
FAU - Stocks, Nigel P
AU  - Stocks NP
AD  - University of Adelaide, Adelaide, SA.
FAU - Trevaks, Ruth E
AU  - Trevaks RE
AD  - Monash University, Melbourne, VIC.
FAU - Woods, Robyn
AU  - Woods R
AD  - Monash University, Melbourne, VIC.
LA  - eng
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U19 AG062682/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20181221
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - Australia
MH  - Cardiovascular Diseases/prevention & control
MH  - Female
MH  - General Practice/*statistics & numerical data
MH  - General Practitioners/*statistics & numerical data
MH  - Geography
MH  - Humans
MH  - Male
MH  - *Patient Selection
MH  - Randomized Controlled Trials as Topic/*methods
PMC - PMC6456041
MID - NIHMS1001231
OTO - NOTNLM
OT  - General practice
OT  - Randomized controlled trial as topic
OT  - Research design
COIS- Competing interests: No relevant disclosures.
EDAT- 2019/03/06 06:00
MHDA- 2019/10/28 06:00
CRDT- 2019/03/06 06:00
PHST- 2018/06/14 00:00 [received]
PHST- 2018/10/31 00:00 [accepted]
PHST- 2019/03/06 06:00 [entrez]
PHST- 2019/03/06 06:00 [pubmed]
PHST- 2019/10/28 06:00 [medline]
AID - 10.5694/mja2.12060 [doi]
PST - ppublish
SO  - Med J Aust. 2019 Mar;210(4):168-173. doi: 10.5694/mja2.12060. Epub 2018 Dec 21.

PMID- 36846997
OWN - NLM
STAT- MEDLINE
DCOM- 20230412
LR  - 20230517
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 92
IP  - 3
DP  - 2023
TI  - Aspirin Use and Risk of Alzheimer's Disease: A 2-Sample Mendelian Randomization 
      Study.
PG  - 989-1000
LID - 10.3233/JAD-220787 [doi]
AB  - BACKGROUND: Observational studies have shown inconsistent findings of the 
      relationships between aspirin use and the risk of Alzheimer's disease (AD). 
      OBJECTIVE: Since residual confounding and reverse causality were challenging 
      issues inherent in observational studies, we conducted a 2-sample Mendelian 
      randomization analysis (MR) to investigate whether aspirin use was causally 
      associated with the risk of AD. METHODS: We conducted 2-sample MR analyses 
      utilizing summary genetic association statistics to estimate the potential causal 
      relationship between aspirin use and AD. Single-nucleotide variants associated 
      with aspirin use in a genome-wide association study (GWAS) of UK Biobank were 
      considered as genetic proxies for aspirin use. The GWAS summary-level data of AD 
      were derived from a meta-analysis of GWAS data from the International Genomics of 
      Alzheimer's Project (IGAP) stage I. RESULTS: Univariable MR analysis based on 
      these two large GWAS data sources showed that genetically proxied aspirin use was 
      associated with a decreased risk of AD (Odds Ratio (OR): 0.87; 95%CI: 0.77-0.99). 
      In multivariate MR analyses, the causal estimates remained significant after 
      adjusting for chronic pain, inflammation, heart failure (OR = 0.88, 
      95%CI = 0.78-0.98), or stroke (OR = 0.87, 95%CI = 0.77-0.99), but was attenuated 
      when adjusting for coronary heart disease, blood pressure, and blood lipids. 
      CONCLUSION: Findings from this MR analysis suggest a genetic protective effect of 
      aspirin use on AD, possibly influenced by coronary heart disease, blood pressure, 
      and lipid levels.
FAU - Ding, Pingjian
AU  - Ding P
AD  - Center for Artificial Intelligence in Drug Discovery, School of Medicine, Case 
      Western Reserve University, Cleveland, OH, USA.
FAU - Gorenflo, Maria P
AU  - Gorenflo MP
AD  - Center for Artificial Intelligence in Drug Discovery, School of Medicine, Case 
      Western Reserve University, Cleveland, OH, USA.
AD  - Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, 
      Cleveland, OH, USA.
FAU - Zhu, Xiaofeng
AU  - Zhu X
AD  - Department of Population and Quantitative Health Sciences, School of Medicine, 
      Case Western Reserve University, Cleveland, OH, USA.
FAU - Xu, Rong
AU  - Xu R
AD  - Center for Artificial Intelligence in Drug Discovery, School of Medicine, Case 
      Western Reserve University, Cleveland, OH, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Alzheimer Disease/genetics
MH  - Aspirin/adverse effects
MH  - Mendelian Randomization Analysis
MH  - Genome-Wide Association Study
MH  - Polymorphism, Single Nucleotide/genetics
MH  - *Coronary Disease/complications
OTO - NOTNLM
OT  - 2-sample Mendelian randomization analysis
OT  - Alzheimer’s disease
OT  - aspirin
OT  - blood pressure
OT  - cardiovascular disease
OT  - inflammation
OT  - lipids
OT  - pain
EDAT- 2023/02/28 06:00
MHDA- 2023/04/12 06:42
CRDT- 2023/02/27 06:31
PHST- 2023/04/12 06:42 [medline]
PHST- 2023/02/28 06:00 [pubmed]
PHST- 2023/02/27 06:31 [entrez]
AID - JAD220787 [pii]
AID - 10.3233/JAD-220787 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2023;92(3):989-1000. doi: 10.3233/JAD-220787.

PMID- 27816920
OWN - NLM
STAT- MEDLINE
DCOM- 20180222
LR  - 20181113
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 32
IP  - 1
DP  - 2017 Jan
TI  - Preconception use of pain-relievers and time-to-pregnancy: a prospective cohort 
      study.
PG  - 103-111
AB  - STUDY QUESTION: To what extent is preconception use of pain-relieving medication 
      associated with female fecundability? SUMMARY ANSWER: Women who used naproxen or 
      opioids had slightly lower fecundability than women who did not use any 
      pain-relieving medications; use of acetaminophen, aspirin and ibuprofen was not 
      appreciably associated with fecundability. WHAT IS KNOWN ALREADY: 
      Over-the-counter pain-relieving medications are commonly used by women of 
      reproductive age in the USA. Studies investigating the effects of pain-relieving 
      medication use on ovulation, implantation and fecundability have shown 
      conflicting results. STUDY DESIGN, SIZE, DURATION: We analyzed data from an 
      internet-based prospective cohort study of 2573 female pregnancy planners aged 
      21-45 years from the USA and Canada. Participants were enrolled and followed from 
      June 2013 through September 2015. Participants completed a baseline questionnaire 
      and bimonthly follow-up questionnaires until a reported pregnancy or for 12 
      months, whichever occurred first. Over 80% of participants completed at least one 
      follow-up questionnaire. PARTICIPANTS/MATERIALS, SETTING, METHODS: Use of 
      pain-relieving medication during the past month was assessed at baseline and on 
      each follow-up questionnaire. Medications were categorized according to type 
      (acetaminophen, aspirin, ibuprofen, naproxen and opioids) and total monthly dose. 
      Self-reported pregnancy was assessed at each follow-up. Multivariable-adjusted 
      fecundability ratios (FRs) and 95% CI were calculated using proportional 
      probabilities regression. Models were adjusted for demographic, lifestyle and 
      anthropometric factors; reproductive history; gynecologic morbidity; and 
      indications for use of pain medications. Models were also run with and without 
      adjustment for parity. After restricting to women with 6 or fewer months of 
      attempt time at study entry, 1763 were included in the analyses. MAIN RESULTS AND 
      THE ROLE OF CHANCE: At baseline, 1279 (73%) women reported using ≥1 
      pain-relieving medications in the previous month. When compared with non-use of 
      pain-relieving medications, FRs for use of naproxen and opioids at baseline were 
      0.78 (95% CI: 0.64-0.97) and 0.81 (95% CI: 0.60-1.10), respectively. A 
      dose-response relation was observed between naproxen use and fecundability; FRs 
      for use of <1500 and ≥1500 mg of naproxen were 0.85 (95% CI: 0.68-1.07) and 0.58 
      (95% CI: 0.36-0.94), respectively. Small numbers (n = 74) precluded the 
      examination of opioid use by dose. Overall, there was little evidence of an 
      association between fecundability and acetaminophen (FR 1.04, 95% CI: 0.92-1.18), 
      aspirin (FR 1.00, 95% CI: 0.80-1.25), or ibuprofen (FR 1.00, 95% CI: 0.89-1.11). 
      Similar results were observed when exposure information was updated over time. 
      LIMITATIONS, REASONS FOR CAUTION: Numbers of opioid users were small. Information 
      collected on reason for use of pain medications was not specific to each type of 
      pain medication. Therefore, we cannot rule out confounding by indication as an 
      explanation of these results. WIDER IMPLICATIONS OF THE FINDINGS: Use of naproxen 
      and opioids was associated with a small reduction in fecundability, but there was 
      little association between other pain-relieving medications and fecundability. 
      STUDY FUNDING/COMPETING INTERESTS: This study was supported through funds 
      provided by National Institute of Child Health and Human Development, National 
      Institute of Health (R21 HD072326, T32 HD052458). The authors have no conflicts 
      of interest to disclose. TRIAL REGISTRATION NUMBER: Not applicable.
CI  - © The Author 2016. Published by Oxford University Press on behalf of the European 
      Society of Human Reproduction and Embryology. All rights reserved. For 
      Permissions, please email: journals.permissions@oup.com.
FAU - McInerney, Kathryn A
AU  - McInerney KA
AD  - Department of Epidemiology, Boston University School of Public Health, 715 Albany 
      Street, 3rd Floor, Boston, MA 02118, USA kamci@bu.edu.
FAU - Hatch, Elizabeth E
AU  - Hatch EE
AD  - Department of Epidemiology, Boston University School of Public Health, 715 Albany 
      Street, 3rd Floor, Boston, MA 02118, USA.
FAU - Wesselink, Amelia K
AU  - Wesselink AK
AD  - Department of Epidemiology, Boston University School of Public Health, 715 Albany 
      Street, 3rd Floor, Boston, MA 02118, USA.
FAU - Rothman, Kenneth J
AU  - Rothman KJ
AD  - Department of Epidemiology, Boston University School of Public Health, 715 Albany 
      Street, 3rd Floor, Boston, MA 02118, USA.
AD  - RTI Health Solutions, PO Box 12194, Research Triangle Park, NC 27709, USA.
FAU - Mikkelsen, Ellen M
AU  - Mikkelsen EM
AD  - Department of Clinical Epidemiology, Aarhus University Hospital, Norrebrogade 44, 
      DK-8000 Aarhus, Denmark.
FAU - Wise, Lauren A
AU  - Wise LA
AD  - Department of Epidemiology, Boston University School of Public Health, 715 Albany 
      Street, 3rd Floor, Boston, MA 02118, USA.
LA  - eng
GR  - R21 HD072326/HD/NICHD NIH HHS/United States
GR  - T32 HD052458/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20161105
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Opioid)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/pharmacology/therapeutic use
MH  - Adult
MH  - Analgesics/*pharmacology/therapeutic use
MH  - Analgesics, Opioid/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Ibuprofen/pharmacology/therapeutic use
MH  - Internet
MH  - Naproxen/pharmacology/therapeutic use
MH  - Pain/*drug therapy
MH  - Pregnancy
MH  - Prospective Studies
MH  - Time-to-Pregnancy/*drug effects
PMC - PMC5165076
OTO - NOTNLM
OT  - acetaminophen
OT  - conception
OT  - fecundability
OT  - fertility
OT  - non-steroidal anti-inflammatory drugs
OT  - opioids
OT  - pain medications
OT  - time-to-pregnancy
EDAT- 2016/11/07 06:00
MHDA- 2018/02/23 06:00
CRDT- 2016/11/07 06:00
PHST- 2016/05/16 00:00 [received]
PHST- 2016/09/27 00:00 [revised]
PHST- 2016/10/19 00:00 [accepted]
PHST- 2016/11/07 06:00 [pubmed]
PHST- 2018/02/23 06:00 [medline]
PHST- 2016/11/07 06:00 [entrez]
AID - dew272 [pii]
AID - 10.1093/humrep/dew272 [doi]
PST - ppublish
SO  - Hum Reprod. 2017 Jan;32(1):103-111. doi: 10.1093/humrep/dew272. Epub 2016 Nov 5.

PMID- 35642270
OWN - NLM
STAT- MEDLINE
DCOM- 20220805
LR  - 20220805
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 37
IP  - 8
DP  - 2022 Aug
TI  - Risk factors for small-intestinal mucosal breaks beyond aspirin.
PG  - 1596-1602
LID - 10.1111/jgh.15892 [doi]
AB  - BACKGROUND AND AIM: There remains lots of unknowns for small intestinal mucosal 
      breaks (SIMBs). The application of magnetic controlled capsule endoscope (MCCE) 
      may provide a better understanding of SIMBs. The aim of our study was to 
      investigate the prevalence and characteristics of SIMBs in the general population 
      as well as risk factors for SIMBs other than aspirin. METHODS: Clinical data on 
      individuals who visited our institute between January 2019 and February 2021 for 
      MCCE examination as a health check were collected and analyzed retrospectively. 
      All study participants must have completed the small bowel inspection. 
      Multivariate analysis was employed to reveal the independent risk factors for 
      SIMBs. RESULTS: A total of 1599 participants, 103 of whom were aspirin users, 
      were finally included. The prevalence of SIMBs was 8.3% (132/1599) in all 
      participants, with 36.9% (38/103) in aspirin users and 6.3% (94/1496) in 
      non-aspirin users. The multivariate analysis showed that in addition to aspirin 
      (OR: 6.17, 95% CI: 3.25-11.58), obesity (OR: 2.30, 95% CI: 1.38-3.92) and smoking 
      (OR: 1.85, 95% CI: 1.56-3.20) were also independent risk factors for SIMBs. 
      Jejunum involvement was more common in aspirin users (20/38, 52.6%), while ilium 
      involvement was more common in non-aspirin users (58/94, 61.7%). Moderate SIMBs 
      (erosions) were more common in aspirin users (17/38, 44.7%), while severe SIMBs 
      (large erosions/ulcers) were more common in non-aspirin users (17/94, 18.1%). 
      CONCLUSIONS: The risk factors for SIMBs include aspirin as well as smoking and 
      obesity, and the severity and distributive features of SIMBs differ between 
      aspirin users and non-aspirin users.
CI  - © 2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & 
      Sons Australia, Ltd.
FAU - Sun, Xi
AU  - Sun X
AUID- ORCID: 0000-0001-9500-7288
AD  - Department of Gastroenterology and Hepatology, The Second Medical Center and 
      National Clinical Research Center for Geriatric Diseases, Chinese PLA General 
      Hospital, Beijing, China.
FAU - Wang, Fei
AU  - Wang F
AD  - Department of Health Management Institution, The Second Medical Center and 
      National Clinical Research Center for Geriatric Diseases, Chinese PLA General 
      Hospital, Beijing, China.
FAU - Liu, Jing
AU  - Liu J
AD  - Department of Gastroenterology and Hepatology, The Second Medical Center and 
      National Clinical Research Center for Geriatric Diseases, Chinese PLA General 
      Hospital, Beijing, China.
FAU - Wu, Lili
AU  - Wu L
AD  - Department of Gastroenterology and Hepatology, The Second Medical Center and 
      National Clinical Research Center for Geriatric Diseases, Chinese PLA General 
      Hospital, Beijing, China.
FAU - Wang, Zhiqiang
AU  - Wang Z
AD  - Department of Gastroenterology and Hepatology, The Second Medical Center and 
      National Clinical Research Center for Geriatric Diseases, Chinese PLA General 
      Hospital, Beijing, China.
FAU - Chen, Xiao
AU  - Chen X
AD  - Department of Gastroenterology and Hepatology, The Second Medical Center and 
      National Clinical Research Center for Geriatric Diseases, Chinese PLA General 
      Hospital, Beijing, China.
FAU - Wang, Ming
AU  - Wang M
AD  - Department of Gastroenterology and Hepatology, The Second Medical Center and 
      National Clinical Research Center for Geriatric Diseases, Chinese PLA General 
      Hospital, Beijing, China.
FAU - Zeng, Qang
AU  - Zeng Q
AUID- ORCID: 0000-0003-3758-3871
AD  - Department of Health Management Institution, The Second Medical Center and 
      National Clinical Research Center for Geriatric Diseases, Chinese PLA General 
      Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20220531
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - *Aspirin/adverse effects
MH  - *Capsule Endoscopy
MH  - Humans
MH  - Intestinal Mucosa
MH  - Obesity
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - aspirin
OT  - gut microbiota
OT  - magnetic controlled capsule endoscope
OT  - small intestinal mucosal breaks
EDAT- 2022/06/02 06:00
MHDA- 2022/08/06 06:00
CRDT- 2022/06/01 01:53
PHST- 2022/04/28 00:00 [revised]
PHST- 2022/02/18 00:00 [received]
PHST- 2022/05/10 00:00 [accepted]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/08/06 06:00 [medline]
PHST- 2022/06/01 01:53 [entrez]
AID - 10.1111/jgh.15892 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2022 Aug;37(8):1596-1602. doi: 10.1111/jgh.15892. Epub 
      2022 May 31.

PMID- 31196447
OWN - NLM
STAT- MEDLINE
DCOM- 20200410
LR  - 20200410
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 73
IP  - 23
DP  - 2019 Jun 18
TI  - Aspirin for Primary Prevention of Cardiovascular Events.
PG  - 2915-2929
LID - S0735-1097(19)34858-2 [pii]
LID - 10.1016/j.jacc.2019.03.501 [doi]
AB  - BACKGROUND: The efficacy and safety of aspirin for primary prevention of 
      cardiovascular disease (CVD) remain debatable. OBJECTIVES: The purpose of this 
      study was to examine the clinical outcomes with aspirin for primary prevention of 
      CVD after the recent publication of large trials adding >45,000 individuals to 
      the published data. METHODS: Randomized controlled trials comparing clinical 
      outcomes with aspirin versus control for primary prevention with follow-up 
      duration of ≥1 year were included. Efficacy outcomes included all-cause death, 
      cardiovascular (CV) death, myocardial infarction (MI), stroke, transient ischemic 
      attack (TIA), and major adverse cardiovascular events. Safety outcomes included 
      major bleeding, intracranial bleeding, fatal bleeding, and major gastrointestinal 
      (GI) bleeding. Random effects DerSimonian-Laird risk ratios (RRs) for outcomes 
      were calculated. RESULTS: A total of 15 randomized controlled trials including 
      165,502 participants (aspirin n = 83,529, control n = 81,973) were available for 
      analysis. Compared with control, aspirin was associated with similar all-cause 
      death (RR: 0.97; 95% confidence interval [CI]: 0.93 to 1.01), CV death (RR: 0.93; 
      95% CI: 0.86 to 1.00), and non-CV death (RR: 0.98; 95% CI: 0.92 to 1.05), but a 
      lower risk of nonfatal MI (RR: 0.82; 95% CI: 0.72 to 0.94), TIA (RR: 0.79; 
      95% CI: 0.71 to 0.89), and ischemic stroke (RR: 0.87; 95% CI: 0.79 to 0.95). 
      Aspirin was associated with a higher risk of major bleeding (RR: 1.5; 95% CI: 
      1.33 to 1.69), intracranial bleeding (RR: 1.32; 95% CI: 1.12 to 1.55), and major 
      GI bleeding (RR: 1.52; 95% CI: 1.34 to 1.73), with similar rates of fatal 
      bleeding (RR: 1.09; 95% CI: 0.78 to 1.55) compared with the control subjects. 
      Total cancer and cancer-related deaths were similar in both groups within the 
      follow-up period of the study. CONCLUSIONS: Aspirin for primary prevention 
      reduces nonfatal ischemic events but significantly increases nonfatal bleeding 
      events.
CI  - Copyright © 2019 American College of Cardiology Foundation. All rights reserved.
FAU - Abdelaziz, Hesham K
AU  - Abdelaziz HK
AD  - Lancashire Cardiac Center, Blackpool Victoria Hospital, Blackpool, United 
      Kingdom; Department of Cardiovascular Medicine, Ain Shams University, Cairo, 
      Egypt.
FAU - Saad, Marwan
AU  - Saad M
AD  - Department of Cardiovascular Medicine, Ain Shams University, Cairo, Egypt; 
      Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences 
      and The Central Arkansas Veterans Healthcare System, Little Rock, Arkansas. 
      Electronic address: https://twitter.com/MarwanSaadMD.
FAU - Pothineni, Naga Venkata K
AU  - Pothineni NVK
AD  - Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences 
      and The Central Arkansas Veterans Healthcare System, Little Rock, Arkansas.
FAU - Megaly, Michael
AU  - Megaly M
AD  - Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, 
      Minnesota; Hennepin Healthcare, Minneapolis, Minnesota.
FAU - Potluri, Rahul
AU  - Potluri R
AD  - Aston Medical School, School of Medical Sciences, Aston University, Birmingham, 
      United Kingdom.
FAU - Saleh, Mohammed
AU  - Saleh M
AD  - Department of Medicine, Creighton University, Omaha, Nebraska.
FAU - Kon, David Lai Chin
AU  - Kon DLC
AD  - Lancashire Cardiac Center, Blackpool Victoria Hospital, Blackpool, United 
      Kingdom.
FAU - Roberts, David H
AU  - Roberts DH
AD  - Lancashire Cardiac Center, Blackpool Victoria Hospital, Blackpool, United 
      Kingdom.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, 
      Boston, Massachusetts. Electronic address: https://twitter.com/DLBHATTMD.
FAU - Aronow, Herbert D
AU  - Aronow HD
AD  - Division of Cardiovascular Medicine, The Warren Alpert Medical School of Brown 
      University and Lifespan Cardiovascular Institute, Providence, Rhode Island. 
      Electronic address: https://twitter.com/herbaronowMD.
FAU - Abbott, J Dawn
AU  - Abbott JD
AD  - Division of Cardiovascular Medicine, The Warren Alpert Medical School of Brown 
      University and Lifespan Cardiovascular Institute, Providence, Rhode Island. 
      Electronic address: https://twitter.com/JDawnAbbott1.
FAU - Mehta, Jawahar L
AU  - Mehta JL
AD  - Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences 
      and The Central Arkansas Veterans Healthcare System, Little Rock, Arkansas. 
      Electronic address: MehtaJL@uams.edu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2019 Jun 18;73(23):2930-2931. PMID: 31196448
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/diagnosis/mortality/*prevention & control
MH  - Gastrointestinal Hemorrhage/*chemically induced/diagnosis/mortality
MH  - Humans
MH  - Primary Prevention/*methods/trends
MH  - Randomized Controlled Trials as Topic/*methods
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular events
OT  - primary prevention
EDAT- 2019/06/15 06:00
MHDA- 2020/04/11 06:00
CRDT- 2019/06/15 06:00
PHST- 2018/12/05 00:00 [received]
PHST- 2019/03/10 00:00 [revised]
PHST- 2019/03/12 00:00 [accepted]
PHST- 2019/06/15 06:00 [entrez]
PHST- 2019/06/15 06:00 [pubmed]
PHST- 2020/04/11 06:00 [medline]
AID - S0735-1097(19)34858-2 [pii]
AID - 10.1016/j.jacc.2019.03.501 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2019 Jun 18;73(23):2915-2929. doi: 10.1016/j.jacc.2019.03.501.

PMID- 6170208
OWN - NLM
STAT- MEDLINE
DCOM- 19811222
LR  - 20190829
IS  - 0001-6683 (Print)
IS  - 0001-6683 (Linking)
VI  - 47
IP  - 5
DP  - 1980 Nov
TI  - Is ethanol-induced damage of the gastric mucosa a hyperosmotic effect? 
      Comparative studies on the effects of ethanol, some other hyperosmotic solutions 
      and acetylsalicylic acid on rat gastric mucosa.
PG  - 321-7
AB  - The involvement of hyperosmolarity in ethanol-induced gastric mucosal damage was 
      studied by comparing the effects of ethanol on the rat gastric mucosa and those 
      caused by hyperosmotic glucose and choline chloride solutions, and by an almost 
      isosmotic solution of acetylsalicylic acid. Upon intragastric instillation, all 
      test solutions, namely 3M and 5M ethanol (3330 and 5590 mosmol/kg resp.), 3M 
      glucose (3890 mosmol/kg), 1.5 M choline chloride (2840 mosmol/kg) and 20 mM 
      acetylsalicylic acid, also containing 100 mM HCl and 50 mM NaCl, produced 
      macroscopic and microscopic lesions of the gastric mucosa. The haemorrhages 
      induced by ethanol and acetylsalicylic acid solutions were more evenly 
      distributed, whereas most lesions produced by the glucose and choline chloride 
      solutions were located at the rumeno-fundic junction. There were no qualitative 
      differences between the microscopic lesions caused by the various instillates, 
      however. All the test solutions broke the gastric mucosal barrier and increased 
      histamine release and pepsinogen output, but in the rats treated with 
      acetylsalicylic acid these effects were less pronounced. Ethanol, glucose and 
      choline chloride solutions increased gastric mucosal flow and fluid output from 
      the stomach, whereas acetylsalicylic acid had no effect on these. The similarity 
      between the ethanol-induced changes and those caused by hyperosmotic solutions of 
      glucose and choline chloride leads to the suggestion that ethanol may cause 
      damage in the gastric mucosa at least in part, via hyperosmolarity.
FAU - Puurunen, J
AU  - Puurunen J
FAU - Huttunen, P
AU  - Huttunen P
FAU - Hirvonen, J
AU  - Hirvonen J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Acta Pharmacol Toxicol (Copenh)
JT  - Acta pharmacologica et toxicologica
JID - 0370572
RN  - 0 (Hypertonic Solutions)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Ethanol/*pharmacology
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Histamine Release/drug effects
MH  - Hypertonic Solutions/*pharmacology
MH  - Male
MH  - Osmolar Concentration
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1980/11/01 00:00
MHDA- 1980/11/01 00:01
CRDT- 1980/11/01 00:00
PHST- 1980/11/01 00:00 [pubmed]
PHST- 1980/11/01 00:01 [medline]
PHST- 1980/11/01 00:00 [entrez]
AID - 10.1111/j.1600-0773.1980.tb01567.x [doi]
PST - ppublish
SO  - Acta Pharmacol Toxicol (Copenh). 1980 Nov;47(5):321-7. doi: 
      10.1111/j.1600-0773.1980.tb01567.x.

PMID- 7278087
OWN - NLM
STAT- MEDLINE
DCOM- 19811124
LR  - 20190711
IS  - 0023-2173 (Print)
IS  - 0023-2173 (Linking)
VI  - 59
IP  - 9
DP  - 1981 May 4
TI  - [Increase of pulmonary vascular resistance and permeability due to the metabolism 
      of free arachidonic acid (author's transl)].
PG  - 459-61
AB  - Release and metabolism of arachidonic acid are supposed to form the common final 
      pathway of different stimuli on the pulmonary vascular endothelium. In a model of 
      isolated, ventilated and perfused rabbit lungs we investigated the influence of 
      increased availability of free arachidonic acid on pulmonary vascular resistance 
      and permeability. Addition of arachidonic acid to the perfusion fluid or release 
      of arachidonic acid by Ca-ionophore A 23187 regularly produces a characteristic 
      biphasic increase of the pulmonary vascular resistance as well as a continuous 
      increase in permeability, followed by pulmonary edema. Inhibition of 
      cyclooxygenase by indomethacin prevents the augmentation of vascular resistance, 
      the increase of vascular permeability however is enhanced. thus the raise in 
      pulmonary vascular resistance can be ascribed to cyclooxygenase products, the 
      increased pulmonary vascular permeability to lipoxygenase products of arachidonic 
      acid.
FAU - Seeger, W
AU  - Seeger W
FAU - Wolf, H
AU  - Wolf H
FAU - Stähler, G
AU  - Stähler G
FAU - Neuhof, H
AU  - Neuhof H
FAU - Róka, L
AU  - Róka L
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Zunahme des Strömungswiderstandes und der Gefässpermeabilität in der pulmonalen 
      Strombahn als Folge des Metabolismus freier Arachidonsäure.
PL  - Germany
TA  - Klin Wochenschr
JT  - Klinische Wochenschrift
JID - 2985205R
RN  - 0 (Arachidonic Acids)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acids/*metabolism
MH  - Aspirin/pharmacology
MH  - Blood Pressure/drug effects
MH  - *Capillary Permeability/drug effects
MH  - Female
MH  - Indomethacin/pharmacology
MH  - Male
MH  - *Pulmonary Circulation/drug effects
MH  - Rabbits
MH  - *Vascular Resistance/drug effects
EDAT- 1981/05/04 00:00
MHDA- 1981/05/04 00:01
CRDT- 1981/05/04 00:00
PHST- 1981/05/04 00:00 [pubmed]
PHST- 1981/05/04 00:01 [medline]
PHST- 1981/05/04 00:00 [entrez]
AID - 10.1007/BF01695900 [doi]
PST - ppublish
SO  - Klin Wochenschr. 1981 May 4;59(9):459-61. doi: 10.1007/BF01695900.

PMID- 577447
OWN - NLM
STAT- MEDLINE
DCOM- 19770718
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 27
IP  - 3
DP  - 1977
TI  - Oral antipyretic therapy. Evaluation of mefenamic acid (short communication).
PG  - 687-8
AB  - The capacity of N-(2,3-xylyl)anthranilic acid (mefenamic acid) to reduce fever in 
      children was compared with that of acetylsalicylic acid, paracetamol and 
      amino-phenazone. The series of cases consisted of 71 patients in the age range 
      from 3 months to 15 years and with rectal temperatures above 38.5 degrees C. 
      Temperatures were recorded at 15 and 30 min, and 1, 2, 4 and 6 h after challenge 
      with the drug. The antipyretic effect of mefenamic acid in a dose of 4 mg/kg was 
      optimal: it was 2.5 times that of acetyl-salicylic acid or paracetamol and nearly 
      similar to that of aminophenazone. It seems possible that the antipyretic effect 
      of mefenamic acid is stronger than its anti-inflammatory and analgetic 
      properties.
FAU - Similä, S
AU  - Similä S
FAU - Kouvalainen, K
AU  - Kouvalainen K
FAU - Keinänen, S
AU  - Keinänen S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 01704YP3MO (Aminopyrine)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 367589PJ2C (Mefenamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Adolescent
MH  - Aminopyrine/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Drug Evaluation
MH  - Fever/*drug therapy
MH  - Humans
MH  - Infant
MH  - Mefenamic Acid/*therapeutic use
MH  - Time Factors
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1977;27(3):687-8.

PMID- 2437278
OWN - NLM
STAT- MEDLINE
DCOM- 19870609
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 110
IP  - 5
DP  - 1987 May
TI  - High-dose gammaglobulin therapy for Kawasaki disease.
PG  - 710-2
AB  - To evaluate the effectiveness of gammaglobulin in decreasing the incidence of 
      coronary artery lesions in Kawasaki disease, a randomized controlled study in 136 
      patients was conducted using high doses of gammaglobulin 400 mg/kg/d for 3 days 
      plus aspirin 30 mg/kg/d (gammaglobulin group) and aspirin alone at the same 
      dosage (aspirin group). The total febrile period and the duration of fever after 
      treatment were significantly shorter in the gammaglobulin group than in the 
      aspirin group (P less than 0.001). The incidence of coronary artery lesions and 
      of coronary artery aneurysms was significantly lower in the gammaglobulin group 
      than in the aspirin group up to 30 days after the onset of Kawasaki disease (P 
      less than 0.01 and P less than 0.05, respectively). In 16 of 69 patients given 
      gammaglobulin, fever persisted for longer than 3 days, and there was a higher 
      incidence of coronary artery lesions among them. The effectiveness of high doses 
      of gammaglobulin in preventing coronary artery lesions has been demonstrated, but 
      the indications and the optimal dose of gammaglobulin remain to be determined.
FAU - Nagashima, M
AU  - Nagashima M
FAU - Matsushima, M
AU  - Matsushima M
FAU - Matsuoka, H
AU  - Matsuoka H
FAU - Ogawa, A
AU  - Ogawa A
FAU - Okumura, N
AU  - Okumura N
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 0 (gamma-Globulins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Coronary Disease/*prevention & control
MH  - Female
MH  - Humans
MH  - *Immunization, Passive
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*therapy
MH  - Random Allocation
MH  - gamma-Globulins/administration & dosage
EDAT- 1987/05/01 00:00
MHDA- 1987/05/01 00:01
CRDT- 1987/05/01 00:00
PHST- 1987/05/01 00:00 [pubmed]
PHST- 1987/05/01 00:01 [medline]
PHST- 1987/05/01 00:00 [entrez]
AID - S0022-3476(87)80007-0 [pii]
AID - 10.1016/s0022-3476(87)80007-0 [doi]
PST - ppublish
SO  - J Pediatr. 1987 May;110(5):710-2. doi: 10.1016/s0022-3476(87)80007-0.

PMID- 9675104
OWN - NLM
STAT- MEDLINE
DCOM- 19980806
LR  - 20131121
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 248
IP  - 1
DP  - 1998 Jul 9
TI  - Neurite outgrowth of dorsal root ganglia is delayed and arrested by aspirin.
PG  - 165-7
AB  - In this study, the effect of increasing doses of aspirin on the neurite outgrowth 
      of Dorsal Root Ganglia (DRG) was investigated. DRG were cultured in complete 
      medium (DMEM + 10% FCS +100 ng/ml NGF + collagen Type1 in substratum in 96 
      multiwell plate) in the presence of concentration of 1.25, 2.5, 5 and 10 mM 
      aspirin. The neurite outgrowth of DRG was followed in comparison with controls 
      that lack aspirin. 10 mM aspirin treated DRG showed delayed neurite outgrowth and 
      after 7 days it reached the same DRG neurite outgrowth control wells after 18 
      hrs. This growth has delayed approximately one week and showed no further 
      development and in such stage the cells became apoptos. However at concentrations 
      of 1.25, 2.5, 5 mM of aspirin, outgrowth was observed after 18-24 hrs. Although 
      the rate of growth was lower than control, it was not significant. In the other 
      experiment, when DRG cultured for one week in complete medium then treated with 
      aspirin, at 10 mM, DRG neurite outgrowth was stopped, while it was continued in 
      the control. It seem that the aspirin affected DRG became apoptosis.
FAU - Sabouni, F
AU  - Sabouni F
AD  - Institute of Biochemistry and Biophysics, University of Tehran, I. R. Iran.
FAU - Firouzi, M
AU  - Firouzi M
FAU - Taghikhani, M
AU  - Taghikhani M
FAU - Ziaee, A A
AU  - Ziaee AA
FAU - Semnanian, S
AU  - Semnanian S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Chick Embryo
MH  - Culture Techniques
MH  - Dose-Response Relationship, Drug
MH  - Ganglia, Spinal/cytology/*drug effects
MH  - Neurites/*drug effects/physiology
EDAT- 1998/07/24 00:00
MHDA- 1998/07/24 00:01
CRDT- 1998/07/24 00:00
PHST- 1998/07/24 00:00 [pubmed]
PHST- 1998/07/24 00:01 [medline]
PHST- 1998/07/24 00:00 [entrez]
AID - S0006-291X(98)98932-X [pii]
AID - 10.1006/bbrc.1998.8932 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1998 Jul 9;248(1):165-7. doi: 10.1006/bbrc.1998.8932.

PMID- 5315912
OWN - NLM
STAT- MEDLINE
DCOM- 19720202
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 12
IP  - 10
DP  - 1971 Oct
TI  - Aspirin and alcohol in gastrointestinal haemorrhage.
PG  - 819-21
AB  - The intake of aspirin, of alcohol, and of a combination of both, among 817 
      patients admitted for gastrointestinal haemorrhage is reported. The incidence of 
      ingestion in six diagnostic groups is compared with that in two control groups. 
      Analysis confirms that there is a markedly significant association between overt 
      haemorrhage and the ingestion of aspirin, but this was not shown for alcohol 
      taken alone: the combination of aspirin and alcohol showed a highly significant 
      synergistic effect.
FAU - Needham, C D
AU  - Needham CD
FAU - Kyle, J
AU  - Kyle J
FAU - Jones, P F
AU  - Jones PF
FAU - Johnston, S J
AU  - Johnston SJ
FAU - Kerridge, D F
AU  - Kerridge DF
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - *Drug Synergism
MH  - Duodenal Ulcer
MH  - Esophageal and Gastric Varices
MH  - Ethanol/*adverse effects
MH  - Female
MH  - Gastritis
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Hernia, Diaphragmatic
MH  - Humans
MH  - Male
MH  - Peptic Ulcer Hemorrhage/chemically induced
MH  - Stomach Ulcer
MH  - Varicose Veins
PMC - PMC1411878
EDAT- 1971/10/01 00:00
MHDA- 1971/10/01 00:01
CRDT- 1971/10/01 00:00
PHST- 1971/10/01 00:00 [pubmed]
PHST- 1971/10/01 00:01 [medline]
PHST- 1971/10/01 00:00 [entrez]
AID - 10.1136/gut.12.10.819 [doi]
PST - ppublish
SO  - Gut. 1971 Oct;12(10):819-21. doi: 10.1136/gut.12.10.819.

PMID- 11692016
OWN - NLM
STAT- MEDLINE
DCOM- 20030320
LR  - 20190727
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 32
IP  - 11
DP  - 2001 Nov
TI  - Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in 
      pediatric ischemic stroke patients: a prospective follow-up study.
PG  - 2554-8
AB  - BACKGROUND AND PURPOSE: We sought to compare different antithrombotic secondary 
      treatments (mainly medium-dose aspirin with low-dose low-molecular-weight heparin 
      [LMWH]) in pediatric patients with a first ischemic stroke onset with regard to 
      the risk of stroke recurrence. METHODS: The population comprised 135 
      consecutively recruited children aged >/=6 months to </=18 years with a first 
      episode of ischemic stroke (idiopathic, n=79; cardiac, n=15; vascular, n=30; 
      infectious, n=11). The stroke patients enrolled received prophylactic 
      antithrombotic therapy (aspirin, n=49; LMWH, n=86) in a nonrandomized fashion and 
      were prospectively followed up for a median (range) of 36 (8 to 48) months. The 
      study end point was recurrent stroke. RESULTS: Recurrent ischemic stroke was 
      diagnosed at a median (range) of 5 (2 to 13) months after the first stroke onset 
      in 13 of the 135 children (9.6%) receiving antithrombotic therapy. In the 
      majority of cases (84.6%) the same vascular territory was involved. No 
      significant difference was found with respect to the antithrombotic medication 
      used (P=0.76, Fisher's exact test). No major drug-related side effects were 
      observed. CONCLUSIONS: This prospective multicenter follow-up study has provided 
      evidence that low-dose LMWH is not superior to aspirin and vice versa in 
      preventing recurrent stroke in white pediatric stroke patients. However, further 
      adequately sized randomized trials are required to obtain reliable information on 
      safety and efficacy with respect to the antithrombotic medications used.
FAU - Sträter, R
AU  - Sträter R
AD  - Department of Pediatrics, University of Münster, University of Munich, Germany.
FAU - Kurnik, K
AU  - Kurnik K
FAU - Heller, C
AU  - Heller C
FAU - Schobess, R
AU  - Schobess R
FAU - Luigs, P
AU  - Luigs P
FAU - Nowak-Göttl, U
AU  - Nowak-Göttl U
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 2002 Aug;33(8):1947-8; author reply 1947-8. PMID: 12154242
MH  - Adolescent
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Child
MH  - Child, Preschool
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Follow-Up Studies
MH  - Heparin, Low-Molecular-Weight/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Humans
MH  - Infant
MH  - Recurrence
MH  - Risk Factors
MH  - Stroke/classification/*drug therapy/mortality
MH  - Time Factors
EDAT- 2001/11/03 10:00
MHDA- 2003/03/21 04:00
CRDT- 2001/11/03 10:00
PHST- 2001/11/03 10:00 [pubmed]
PHST- 2003/03/21 04:00 [medline]
PHST- 2001/11/03 10:00 [entrez]
AID - 10.1161/hs1101.097379 [doi]
PST - ppublish
SO  - Stroke. 2001 Nov;32(11):2554-8. doi: 10.1161/hs1101.097379.

PMID- 26017576
OWN - NLM
STAT- MEDLINE
DCOM- 20151030
LR  - 20200511
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 5
DP  - 2015 May 28
TI  - Anti-inflammatory treatment for carditis in acute rheumatic fever.
PG  - CD003176
LID - 10.1002/14651858.CD003176.pub3 [doi]
AB  - BACKGROUND: Rheumatic heart disease remains an important cause of acquired heart 
      disease in developing countries. Although prevention of rheumatic fever and 
      management of recurrences have been well established, optimal management of 
      active rheumatic carditis remains unclear. This is an update of a review 
      published in 2003, and previously updated in 2009 and 2012. OBJECTIVES: To assess 
      the effects, both harmful and beneficial, of anti-inflammatory agents such as 
      aspirin, corticosteroids and other drugs in preventing or reducing further 
      valvular damage in patients with acute rheumatic fever. SEARCH METHODS: We 
      searched the Cochrane Central Register of Controlled Trials (2013, Issue 9 of 
      12), MEDLINE (Ovid, 1948 to 2013 October Week 1), EMBASE (Ovid, 1980 to 2013 Week 
      41) and Latin American Caribbean Health Sciences Literature (LILACS) (1982 to 17 
      October 2013). We last searched Index Medicus (1950 to April 2001) in 2001. We 
      checked reference lists of identified studies and applied no language 
      restrictions. SELECTION CRITERIA: Randomised controlled trials comparing 
      anti-inflammatory agents (e.g. aspirin, steroids, immunoglobulins, 
      pentoxifylline) versus placebo or controls, or comparing any of the 
      anti-inflammatory agents versus one another, in adults and children with acute 
      rheumatic fever diagnosed according to Jones, or modified Jones, criteria. The 
      presence of cardiac disease one year after treatment was the major outcome 
      criterion selected. DATA COLLECTION AND ANALYSIS: Two review authors extracted 
      data and assessed risk of bias using the methodology outlined in the Cochrane 
      Handbook of Systematic Reviews of Interventions. Standard methodological 
      procedures as expected by The Cochrane Collaboration were used. MAIN RESULTS: No 
      new studies were included in this update. Eight randomised controlled trials 
      involving 996 people were selected for inclusion in the review. Researchers 
      compared several steroidal agents such as corticotrophin, cortisone, 
      hydrocortisone, dexamethasone, prednisone and intravenous immunoglobulin versus 
      aspirin, placebo or no treatment. Six trials were conducted between 1950 and 
      1965; one was done in 1990 and the final study was published in 2001. Overall 
      there were no observed significant differences in risk of cardiac disease at one 
      year between corticosteroid-treated and aspirin-treated groups (six studies, 907 
      participants, risk ratio 0.87, 95% confidence interval 0.66 to 1.15). Similarly, 
      use of prednisone (two studies, 212 participants, risk ratio 1.13, 95% confidence 
      interval 0.52 to 2.45) compared with aspirin did not reduce the risk of heart 
      disease after one year. Investigators in five studies did not report adverse 
      events. The three studies reporting on adverse events reported substantial 
      adverse events. However, all results should be interpreted with caution because 
      of the age of the studies and the substantial risk of bias. AUTHORS' CONCLUSIONS: 
      Little evidence of benefit was found when corticosteroids or intravenous 
      immunoglobulins were used to reduce the risk of heart valve lesions in patients 
      with acute rheumatic fever. The antiquity of most of the trials restricted 
      adequate statistical analysis of the data and acceptable assessment of clinical 
      outcomes by current standards. In addition, risk of bias was substantial, so 
      results should be viewed with caution. New randomised controlled trials in 
      patients with acute rheumatic fever are warranted to assess the effects of 
      corticosteroids such as oral prednisone and intravenous methylprednisolone and 
      the effects of other new anti-inflammatory agents. Advances in echocardiography 
      will allow more objective and precise assessments of cardiac outcomes.
FAU - Cilliers, Antoinette
AU  - Cilliers A
AD  - Department of Paediatric Cardiology, Chris Hani Baragwanath Hospital, PO 
      Bertsham, Johannesburg, South Africa, 2013.
FAU - Adler, Alma J
AU  - Adler AJ
FAU - Saloojee, Haroon
AU  - Saloojee H
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20150528
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Steroids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2012;(6):CD003176. PMID: 22696333
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Myocarditis/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Rheumatic Heart Disease/*drug therapy
MH  - Steroids/therapeutic use
EDAT- 2015/05/29 06:00
MHDA- 2015/10/31 06:00
CRDT- 2015/05/29 06:00
PHST- 2015/05/29 06:00 [entrez]
PHST- 2015/05/29 06:00 [pubmed]
PHST- 2015/10/31 06:00 [medline]
AID - 10.1002/14651858.CD003176.pub3 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2015 May 28;(5):CD003176. doi: 
      10.1002/14651858.CD003176.pub3.

PMID- 22696333
OWN - NLM
STAT- MEDLINE
DCOM- 20120813
LR  - 20200511
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 6
DP  - 2012 Jun 13
TI  - Anti-inflammatory treatment for carditis in acute rheumatic fever.
PG  - CD003176
LID - 10.1002/14651858.CD003176.pub2 [doi]
AB  - BACKGROUND: Rheumatic heart disease remains an important cause of acquired heart 
      disease in developing countries. Although the prevention of rheumatic fever and 
      the management of recurrences is well established, the optimal management of 
      active rheumatic carditis is still unclear. This is an update of a review 
      published in 2003 and previously updated in 2009. OBJECTIVES: To assess the 
      effects of anti-inflammatory agents such as aspirin, corticosteroids, 
      immunoglobulin and pentoxifylline for preventing or reducing further heart valve 
      damage in patients with acute rheumatic fever. SEARCH METHODS: We searched the 
      Cochrane Central Register of Controlled Trials on The Cochrane Library (Issue 3, 
      2011), MEDLINE (1966 to Aug 2011), EMBASE (1998 to Sept 2011), LILACS (1982 to 
      Sept 2011), Index Medicus (1950 to April 2001) and references lists of identified 
      studies. No language restrictions were applied. SELECTION CRITERIA: Randomised 
      controlled trials comparing anti-inflammatory agents (e.g. aspirin, steroids, 
      immunoglobulins, pentoxifylline) with placebo or controls, or comparing any of 
      the anti-inflammatory agents with one another, in adults and children with acute 
      rheumatic fever diagnosed according to the Jones, or modified Jones criteria. The 
      presence of cardiac disease one year after treatment was the major outcome 
      criteria selected. DATA COLLECTION AND ANALYSIS: Two reviewers independently 
      extracted data. Risk of bias was assessed using methodology outlined in the 
      Cochrane handbook. MAIN RESULTS: No new studies were included in this update. 
      Eight randomised controlled trials involving 996 people were included. Several 
      steroidal agents corticotrophin, cortisone, hydrocortisone, dexamethasone and 
      prednisone, and intravenous immunoglobulin were compared to aspirin, placebo or 
      no treatment in the various studies. Six of the trials were conducted between 
      1950 and 1965, one study was done in 1990, and the final study was published in 
      2001. Overall there was no significant difference in the risk of cardiac disease 
      at one year between the corticosteroid-treated and aspirin-treated groups (six 
      studies, 907 participants, relative risk 0.87, 95% confidence interval 0.66 to 
      1.15). Similarly, use of prednisone (two studies, 212 participants, relative risk 
      1.13, 95% confidence interval 0.52 to 2.45) compared to aspirin did not reduce 
      the risk of developing heart disease after one year. Adverse events were not 
      reported in five studies. The three studies reporting on adverse events all 
      reported substantial adverse events. However, all results should be interpreted 
      with caution due to the age of the studies and to substantial risk of bias. 
      AUTHORS' CONCLUSIONS: There is little evidence of benefit from using 
      corticosteroids or intravenous immunoglobulins to reduce the risk of heart valve 
      lesions in patients with acute rheumatic fever. The antiquity of most of the 
      trials restricted adequate statistical analysis of the data and acceptable 
      assessment of clinical outcomes by current standards. Additionally there was 
      substantial risk of bias, so results should be viewed with caution. New 
      randomised controlled trials in patients with acute rheumatic fever to assess the 
      effects of corticosteroids such as oral prednisone and intravenous 
      methylprednisolone, and other new anti-inflammatory agents are warranted. 
      Advances in echocardiography will allow for more objective and precise 
      assessments of cardiac outcomes.
FAU - Cilliers, Antoinette
AU  - Cilliers A
AD  - Department of Paediatric Cardiology, Chris Hani Baragwanath Hospital, 
      Johannesburg, South Africa.amcilliers@icon.co.za.
FAU - Manyemba, Juliet
AU  - Manyemba J
FAU - Adler, Alma J
AU  - Adler AJ
FAU - Saloojee, Haroon
AU  - Saloojee H
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20120613
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Steroids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2003;(2):CD003176. PMID: 12804454
UIN - Cochrane Database Syst Rev. 2015;(5):CD003176. PMID: 26017576
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Myocarditis/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Rheumatic Heart Disease/*drug therapy
MH  - Steroids/therapeutic use
EDAT- 2012/06/15 06:00
MHDA- 2012/08/14 06:00
CRDT- 2012/06/15 06:00
PHST- 2012/06/15 06:00 [entrez]
PHST- 2012/06/15 06:00 [pubmed]
PHST- 2012/08/14 06:00 [medline]
AID - 10.1002/14651858.CD003176.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2012 Jun 13;(6):CD003176. doi: 
      10.1002/14651858.CD003176.pub2.

PMID- 34611892
OWN - NLM
STAT- MEDLINE
DCOM- 20220214
LR  - 20220214
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 196
IP  - 2
DP  - 2022 Jan
TI  - Intensified antiplatelet therapy in patients after percutaneous coronary 
      intervention with high on-treatment platelet reactivity: the OPTImal Management 
      of Antithrombotic Agents (OPTIMA)-2 Trial.
PG  - 424-432
LID - 10.1111/bjh.17847 [doi]
AB  - High on-treatment platelet reactivity (HOPR) is associated with increased risk of 
      cardiovascular events in patients undergoing percutaneous coronary intervention 
      (PCI). We randomised post-PCI patients with HOPR after 5 days of standard dual 
      antiplatelet therapy (DAPT) to intensified therapy with aspirin 100 mg once daily 
      in combination with either clopidogrel 150 mg once daily, clopidogrel 75 mg once 
      daily plus cilostazol 100 mg twice daily, ticagrelor 90 mg twice daily, or 
      standard therapy with clopidogrel 75 mg once daily (STD) for 1 month, after which 
      all patients were switched to standard DAPT for a further 11 months. The primary 
      outcome was residual HOPR rate at 1 month. We screened 1724 patients with light 
      transmission aggregation studies and randomised 434 with HOPR. At 1 month the 
      proportion of patients with persistent HOPR was significantly lower in the 
      intensified therapy groups compared with STD group. Compared to the group 
      receiving STD therapy, those receiving intensified therapy had significantly 
      lower rate of major adverse cardiovascular events (MACE) at both 1 month and 
      12 months with no significant increase in bleeding. In patients with post-PCI 
      HOPR, 1 month of intensified antiplatelet therapy provides greater platelet 
      inhibition and improves outcomes without increasing bleeding. Clinical Trial 
      Registration URL: http://www.clinicaltrials.gov; Unique Identifier: NCT01955200.
CI  - © 2021 British Society for Haematology and John Wiley & Sons Ltd.
FAU - Ying, Lianghong
AU  - Ying L
AUID- ORCID: 0000-0001-5676-5385
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
AD  - Department of Cardiology, the Affiliated Huai'an Hospital of Xuzhou Medical 
      University, Huai'an Second People's Hospital, Huai'an, Jiangsu, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
AD  - Department of Cardiology, the Affiliated Huaian No.1 People's Hospital of Nanjing 
      Medical University, Huai'an, Jiangsu, China.
FAU - Li, Juan
AU  - Li J
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
AD  - Cardiovascular Center, the Second Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Teng, Jianzhen
AU  - Teng J
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Zhang, Xiaofeng
AU  - Zhang X
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
AD  - Department of Cardiology, the Second Hospital of Nanjing, Nanjing University of 
      Chinese Medicine, Nanjing, Jiangsu, China.
FAU - Ullah, Inam
AU  - Ullah I
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Samee, Abdus
AU  - Samee A
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Xu, Ke
AU  - Xu K
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
AD  - Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, 
      Shanghai, China.
FAU - Chen, Jun
AU  - Chen J
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Xu, Lei
AU  - Xu L
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Zhu, Hui
AU  - Zhu H
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Li, Jimin
AU  - Li J
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Yang, Lu
AU  - Yang L
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Wang, Fei
AU  - Wang F
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Fan, Yuansheng
AU  - Fan Y
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Lu, Yi
AU  - Lu Y
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Gong, Xiaoxuan
AU  - Gong X
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Shi, Lu
AU  - Shi L
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
AD  - Thrombosis Service, Hamilton General Hospital, Hamilton, Ontario, Canada.
FAU - Li, Chunjian
AU  - Li C
AUID- ORCID: 0000-0002-2359-7570
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT01955200
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20211005
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br J Haematol. 2022 Jan;196(2):272-273. PMID: 34734417
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Clinical Decision-Making
MH  - Clopidogrel/administration & dosage/adverse effects/therapeutic use
MH  - Comorbidity
MH  - Disease Management
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic use
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - *Postoperative Care
MH  - Treatment Outcome
OTO - NOTNLM
OT  - cilostazol
OT  - clopidogrel
OT  - high on-treatment platelet reactivity
OT  - percutaneous coronary intervention
OT  - ticagrelor
EDAT- 2021/10/07 06:00
MHDA- 2022/02/15 06:00
CRDT- 2021/10/06 07:05
PHST- 2021/08/24 00:00 [revised]
PHST- 2021/05/04 00:00 [received]
PHST- 2021/09/09 00:00 [accepted]
PHST- 2021/10/07 06:00 [pubmed]
PHST- 2022/02/15 06:00 [medline]
PHST- 2021/10/06 07:05 [entrez]
AID - 10.1111/bjh.17847 [doi]
PST - ppublish
SO  - Br J Haematol. 2022 Jan;196(2):424-432. doi: 10.1111/bjh.17847. Epub 2021 Oct 5.

PMID- 1387025
OWN - NLM
STAT- MEDLINE
DCOM- 19920924
LR  - 20190509
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 106
IP  - 3
DP  - 1992 Jul
TI  - Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus 
      formation and vascular patency after thrombolysis by tissue-type plasminogen 
      activator.
PG  - 533-8
AB  - 1. A thrombus was induced in the rat femoral artery by endothelial damage due to 
      the photochemical reaction between systemically-injected Rose Bengal and 
      transillumination with green light (wavelength: 540 nm). The artery of the 
      control rat was completely occluded in 302.8 +/- 27.0 s after the initiation of 
      the reaction. 2. Pretreatment with vapiprost (0.1, 0.3 and 1.0 mg kg-1, i.v., 5 
      min before the reaction) prolonged the time required to occlude the femoral 
      artery in a dose-dependent manner. The efficacy of vapiprost on the time required 
      for occlusion was over 10 times higher than that of aspirin which was 
      administered 30 min before the reaction. 3. The thrombolytic effects of 
      tissue-type plasminogen activator (tPA) on the established arterial thrombus in 
      the presence and absence of vapiprost were also studied in the same model. When 
      vapiprost (0.3 mg kg-1, i.v.) was administered just before tPA infusion (100 
      micrograms kg-1 min-1 for 30 min), the time required to reperfuse the occluded 
      artery was reduced, the incidence of the reperfusion was increased and the 
      arterial blood flow after reperfusion was improved. 4. When vapiprost (1.0 mg 
      kg-1 daily p.o.) was administered for 1 week after the establishment of 
      reperfusion by tPA combined with vapiprost, the patency of the reperfused artery 
      was improved and the femoral arterial blood flow was better preserved than after 
      treatment with only tPA. 5. These findings suggest that this thromboxane receptor 
      antagonist may be a useful adjunct to anti-thrombotic therapy. The combination 
      therapy with tPA may be more effective than treatment with tPA alone and provides 
      greater protection against reocclusion after reperfusion.
FAU - Matsuno, H
AU  - Matsuno H
AD  - Department of Pharmacology, Hamamatsu University, School of Medicine, Japan.
FAU - Uematsu, T
AU  - Uematsu T
FAU - Umemura, K
AU  - Umemura K
FAU - Takiguchi, Y
AU  - Takiguchi Y
FAU - Wada, K
AU  - Wada K
FAU - Nakashima, M
AU  - Nakashima M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Receptors, Prostaglandin)
RN  - 0 (Receptors, Thromboxane)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - H84XT1COAU (vapiprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology
MH  - Biphenyl Compounds/administration & dosage/*pharmacology/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Heptanoic Acids/administration & dosage/*pharmacology/therapeutic use
MH  - Injections, Intravenous
MH  - Male
MH  - Microscopy, Electron
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Receptors, Prostaglandin/*antagonists & inhibitors
MH  - Receptors, Thromboxane
MH  - Thrombosis/*drug therapy
MH  - Tissue Plasminogen Activator/pharmacology
MH  - Vascular Patency/*drug effects
PMC - PMC1907568
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1992.tb14370.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1992 Jul;106(3):533-8. doi: 10.1111/j.1476-5381.1992.tb14370.x.

PMID- 31121190
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20201217
IS  - 1873-1732 (Electronic)
IS  - 0079-6107 (Linking)
VI  - 150
DP  - 2020 Jan
TI  - Biophysics and the nonlinear dynamics instigated by a special hormone.
PG  - 62-66
LID - S0079-6107(19)30063-X [pii]
LID - 10.1016/j.pbiomolbio.2019.05.005 [doi]
AB  - Calcitonin, a potent hypocalcemic hormone, plays a vital role in inhibiting 
      osteoclastic activities and suppressing bone removal. The physiological 
      characteristics of calcitonin have long been discussed, along a few recommending 
      calcitonin as a vestigial hormone. The basis for this article is to discuss the 
      role of low and high levels of calcitonin in normal and osteoprotic bone 
      turnover. The effect of calcitonin on the receptor activator of nuclear factor 
      kappa-ligand and osteoclasts has been demonstrated using numerical simulations. 
      This behavior recommends that treatment of osteoporosis via calcitonin does not 
      provide the required upshots. For effectiveness calcitonin must be advised along 
      with a combined therapy like aspirin which agrees with the experimental results 
      available in the literature.
CI  - Copyright © 2019 Elsevier Ltd. All rights reserved.
FAU - Javed, Sana
AU  - Javed S
AD  - Department of Biochemistry and Biophysics, Stockholm University, Science for Life 
      Laboratory, Box 1031, 17121, Solna, Sweden; Department of Mathematics, Comsats 
      University Islamabad, Lahore, 54000, Pakistan. Electronic address: 
      sana.javed@scilifelab.se.
FAU - Sohail, Ayesha
AU  - Sohail A
AD  - Department of Mathematics, Comsats University Islamabad, Lahore, 54000, Pakistan.
FAU - Asif, Anila
AU  - Asif A
AD  - Interdisciplinary Science, Comsats University Islamabad, Lahore, 54000, Pakistan.
FAU - Nutini, Alessandro
AU  - Nutini A
AD  - Center for Study in Motor Science, 94 via di Tiglio, loc. Arancio, 55100, Lucca, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190520
PL  - England
TA  - Prog Biophys Mol Biol
JT  - Progress in biophysics and molecular biology
JID - 0401233
RN  - 9007-12-9 (Calcitonin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Biophysical Phenomena
MH  - Bone Resorption/*drug therapy
MH  - Bone and Bones
MH  - Calcitonin/*pharmacology
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Models, Theoretical
MH  - Nonlinear Dynamics
MH  - Osteoclasts/*drug effects
MH  - Osteoporosis/*drug therapy
OTO - NOTNLM
OT  - Bone remodeling
OT  - Calcitonin
OT  - Mathematical modeling
OT  - Multiscale analysis
OT  - Osteoporosis
EDAT- 2019/05/24 06:00
MHDA- 2020/12/18 06:00
CRDT- 2019/05/24 06:00
PHST- 2019/03/22 00:00 [received]
PHST- 2019/05/08 00:00 [revised]
PHST- 2019/05/16 00:00 [accepted]
PHST- 2019/05/24 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2019/05/24 06:00 [entrez]
AID - S0079-6107(19)30063-X [pii]
AID - 10.1016/j.pbiomolbio.2019.05.005 [doi]
PST - ppublish
SO  - Prog Biophys Mol Biol. 2020 Jan;150:62-66. doi: 10.1016/j.pbiomolbio.2019.05.005. 
      Epub 2019 May 20.

PMID- 16290829
OWN - NLM
STAT- MEDLINE
DCOM- 20070531
LR  - 20171116
IS  - 0021-9797 (Print)
IS  - 0021-9797 (Linking)
VI  - 253
IP  - 1
DP  - 2002 Sep 1
TI  - Study of adsorption behavior of bilirubin on human-albumin monolayer using a 
      quartz crystal microbalance.
PG  - 47-52
AB  - The quartz crystal microbalance was employed to study the adsorption behavior of 
      bilirubin on human-albumin layer, which was chemically bound to the 
      self-assembled monolayer of 4-aminothiophenol on the surface of a gold electrode 
      of the crystal via glutaraldehyde. A long-time adsorption process of bilirubin 
      that took place on a human-albumin-modified surface was observed, and the 
      adsorption kinetic parameters were estimated from the in situ frequency 
      measurements. The amount of adsorbed bilirubin increased with increasing of both 
      hydrogen ions and bilirubin concentration and was larger than that estimated 
      based on the conclusion that there are two affinity sites for bilirubin per 
      albumin molecule. With the present method, the displacement of bilirubin from an 
      albumin layer caused by aspirin was also examined. QCM measurement provides a 
      facile method for in situ monitoring of the adsorption/desorption of bilirubin on 
      proteins layers.
FAU - Si, Shihui
AU  - Si S
AD  - Department of Chemistry, Central South University, Changsha, 410083, People's 
      Republic of China. shisi@cs.hn.cn
FAU - Si, Li
AU  - Si L
FAU - Ren, Fenglian
AU  - Ren F
FAU - Zhu, Derong
AU  - Zhu D
FAU - Fung, Yingsing
AU  - Fung Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Colloid Interface Sci
JT  - Journal of colloid and interface science
JID - 0043125
RN  - 0 (Albumins)
RN  - 0 (Aniline Compounds)
RN  - 0 (Sulfhydryl Compounds)
RN  - 14808-60-7 (Quartz)
RN  - 7440-57-5 (Gold)
RN  - 8X56V0K20X (4-aminothiophenol)
RN  - R16CO5Y76E (Aspirin)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Adsorption
MH  - Albumins/*chemistry
MH  - Aniline Compounds/chemistry
MH  - Aspirin/chemistry
MH  - Bilirubin/*chemistry
MH  - *Biosensing Techniques
MH  - Crystallization
MH  - Electrodes
MH  - Gold/chemistry
MH  - Humans
MH  - Kinetics
MH  - Quartz/chemistry
MH  - Sulfhydryl Compounds
MH  - Surface Properties
EDAT- 2005/11/18 09:00
MHDA- 2007/06/01 09:00
CRDT- 2005/11/18 09:00
PHST- 2002/03/30 00:00 [received]
PHST- 2002/05/20 00:00 [accepted]
PHST- 2002/03/30 00:00 [received]
PHST- 2002/05/20 00:00 [accepted]
PHST- 2005/11/18 09:00 [pubmed]
PHST- 2007/06/01 09:00 [medline]
PHST- 2005/11/18 09:00 [entrez]
AID - S0021-9797(02)98491-2 [pii]
AID - 10.1006/jcis.2002.8491 [doi]
PST - ppublish
SO  - J Colloid Interface Sci. 2002 Sep 1;253(1):47-52. doi: 10.1006/jcis.2002.8491.

PMID- 3909410
OWN - NLM
STAT- MEDLINE
DCOM- 19860124
LR  - 20191022
IS  - 0049-0172 (Print)
IS  - 0049-0172 (Linking)
VI  - 15
IP  - 2 Suppl 1
DP  - 1985 Nov
TI  - Worldwide clinical safety experience with diclofenac.
PG  - 105-10
AB  - Data from more than 100,000 patients in foreign and United States trials provide 
      substantial evidence of diclofenac's safety and tolerability. Adverse experiences 
      were infrequent and generally mild or transient. In United States short-term 
      trials, the frequency and severity of side effects compared favorably with rates 
      for placebo, aspirin, and other NSAIDs. The drop-out rate for therapeutic reasons 
      (adverse effects or lack of efficacy) was lower for diclofenac than for any of 
      the comparative treatments. In long-term trials, diclofenac has been taken safely 
      for a year or more. The incidence of adverse experiences reported for older 
      patients (greater than or equal to 65 years) treated with diclofenac did not 
      generally differ from that reported for younger patients. No significant 
      differences in the incidence of hepatic problems were detected between diclofenac 
      and other active treatments in U.S. trials. Finally, foreign post-marketing data 
      on adverse experiences show that diclofenac is one of the safest agents of its 
      kind for the treatment of a broad range of rheumatic conditions.
FAU - Willkens, R F
AU  - Willkens RF
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Semin Arthritis Rheum
JT  - Seminars in arthritis and rheumatism
JID - 1306053
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Diclofenac/*adverse effects
MH  - France
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Japan
MH  - Osteoarthritis/drug therapy
MH  - Rheumatic Diseases/drug therapy
MH  - United Kingdom
MH  - United States
EDAT- 1985/11/01 00:00
MHDA- 1985/11/01 00:01
CRDT- 1985/11/01 00:00
PHST- 1985/11/01 00:00 [pubmed]
PHST- 1985/11/01 00:01 [medline]
PHST- 1985/11/01 00:00 [entrez]
AID - S0049-0172(85)80022-6 [pii]
AID - 10.1016/s0049-0172(85)80022-6 [doi]
PST - ppublish
SO  - Semin Arthritis Rheum. 1985 Nov;15(2 Suppl 1):105-10. doi: 
      10.1016/s0049-0172(85)80022-6.

PMID- 6406072
OWN - NLM
STAT- MEDLINE
DCOM- 19830708
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 3
IP  - 1
DP  - 1983 Mar
TI  - Treatment of the acute migraine attack--current status.
PG  - 61-7
AB  - The main treatment of the acute migraine attack remains sleep, sedation, an 
      anti-nauseant and analgesics, and in some patients 1 or 2 mg of ergotamine 
      tartrate. Drugs containing large amounts of caffeine should not be used. 
      Absorption of drugs may be impaired in a migraine attack. Metoclopramide is 
      probably the anti-emetic of choice because it is an effective anti-nauseant and 
      promotes normal gastrointestinal activity. Domperidone has a similar action but 
      is said not to go through the blood-brain barrier, so is less likely to cause 
      extrapyramidal reactions. All drugs, including analgesics such as aspirin and 
      paracetamol, are best given in a soluble or effervescent form. Where vomiting 
      occurs early in the attack, suppositories may be indicated. Ergotamine tartrate 
      is necessary in about one third of attacks and is best given by suppository or by 
      inhalation. Doses higher than 2 mg per attack or 6 mg in one week may cause toxic 
      symptoms, the early signs of which are headache, nausea, vomiting and a feeling 
      of not being very well. The non-drug treatments of an acute attack include 
      pressing on the temporal artery, hot and cold compresses and relaxation.
FAU - Wilkinson, M
AU  - Wilkinson M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Ergotamines)
RN  - 362O9ITL9D (Acetaminophen)
RN  - L4YEB44I46 (Metoclopramide)
RN  - PR834Q503T (Ergotamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Ergotamine
MH  - Ergotamines/*therapeutic use
MH  - Humans
MH  - Metoclopramide/therapeutic use
MH  - Migraine Disorders/*drug therapy
EDAT- 1983/03/01 00:00
MHDA- 1983/03/01 00:01
CRDT- 1983/03/01 00:00
PHST- 1983/03/01 00:00 [pubmed]
PHST- 1983/03/01 00:01 [medline]
PHST- 1983/03/01 00:00 [entrez]
AID - 10.1046/j.1468-2982.1983.0301061.x [doi]
PST - ppublish
SO  - Cephalalgia. 1983 Mar;3(1):61-7. doi: 10.1046/j.1468-2982.1983.0301061.x.

PMID- 7301069
OWN - NLM
STAT- MEDLINE
DCOM- 19820109
LR  - 20131121
IS  - 0148-396X (Print)
IS  - 0148-396X (Linking)
VI  - 9
IP  - 3
DP  - 1981 Sep
TI  - Delayed thrombosis of synthetic microvascular bypass grafts.
PG  - 268-74
AB  - A 3-mm-diameter synthetic polytetrafluoroethylene (PTFE) cervical carotid bypass 
      graft 20 cm in length was implanted in 30 dogs for the evaluation of blood flow, 
      tissue response, and patency at intervals of 1 to 120 days. Although 4 of 5 
      grafts removed after 5 to 8 days were patent (80%), long term patency was 
      observed in only 1 graft (10%). Aspirin treatment did not influence patency. 
      Scanning electron microscopy demonstrated the lack of a neoendothelial layer upon 
      the luminal surfaces of patent grafts, which were covered with a fibrin-blood 
      cell lining. Subintimal fibrosis resulted in stenosis at sites of anastomosis in 
      thrombosed grafts. The graft length, its small caliber, and a 40% decrease in 
      blood flow after implantation may have contributed to thrombosis of the bypass 
      graft in this model. Synthetic PTFE microvascular grafts may not be suitable for 
      clinical use in extracranial-intracranial arterial bypass surgery.
FAU - Weinstein, P R
AU  - Weinstein PR
FAU - Reinert, R L
AU  - Reinert RL
FAU - Brittain, F
AU  - Brittain F
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - *Blood Vessel Prosthesis
MH  - Carotid Arteries/physiopathology/ultrastructure
MH  - *Cerebral Revascularization
MH  - Cerebrovascular Circulation
MH  - Dogs
MH  - Graft Rejection/drug effects
MH  - Intracranial Embolism and Thrombosis/*etiology
MH  - Microscopy, Electron, Scanning
MH  - Polytetrafluoroethylene
MH  - Postoperative Complications
EDAT- 1981/09/01 00:00
MHDA- 1981/09/01 00:01
CRDT- 1981/09/01 00:00
PHST- 1981/09/01 00:00 [pubmed]
PHST- 1981/09/01 00:01 [medline]
PHST- 1981/09/01 00:00 [entrez]
PST - ppublish
SO  - Neurosurgery. 1981 Sep;9(3):268-74.

PMID- 6825255
OWN - NLM
STAT- MEDLINE
DCOM- 19830407
LR  - 20221207
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 29
IP  - 3
DP  - 1983 Mar
TI  - Effect of aspirin on determinations of glycosylated hemoglobin.
PG  - 466-9
AB  - We investigated the in vivo and in vitro effects of aspirin on several clinical 
      assays of glycosylated hemoglobin. Acetylation of hemoglobin falsely increased 
      the glycosylated hemoglobin fraction measured by "high-performance" liquid 
      chromatography and electrophoresis, but isoelectric focusing and colorimetric 
      techniques differentiated between acetylated and glycosylated fractions. Aspirin 
      ingestion may result in an apparent increase in glycosylated hemoglobin measured 
      with common clinical assays.
FAU - Nathan, D M
AU  - Nathan DM
FAU - Francis, T B
AU  - Francis TB
FAU - Palmer, J L
AU  - Palmer JL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Glycated Hemoglobin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/*pharmacology
MH  - Chromatography, High Pressure Liquid/methods
MH  - Dose-Response Relationship, Drug
MH  - False Positive Reactions
MH  - Glycated Hemoglobin/*analysis/isolation & purification
MH  - Humans
MH  - Isoelectric Focusing/methods
MH  - Time Factors
EDAT- 1983/03/01 00:00
MHDA- 1983/03/01 00:01
CRDT- 1983/03/01 00:00
PHST- 1983/03/01 00:00 [pubmed]
PHST- 1983/03/01 00:01 [medline]
PHST- 1983/03/01 00:00 [entrez]
PST - ppublish
SO  - Clin Chem. 1983 Mar;29(3):466-9.

PMID- 1119446
OWN - NLM
STAT- MEDLINE
DCOM- 19750613
LR  - 20190509
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 63
IP  - 4
DP  - 1975 Apr
TI  - Platelet morphology after aspirin.
PG  - 554-8
AB  - Previous studies have revealed morphologic platelet abnormalities, particularly 
      inclusions, in patients who have acute malarial infections. To determine the 
      possible role of aspirin (ASA) in the etiology of these abnormalities, the 
      thrombocytes of 14 normal men were examined before and after ingestion of 2 Gm. 
      of ASA. A significant decrease in platelet size was noticed after ASA: however, 
      no ultrastructural alteration of these circulating platelets was found, although 
      functional impairment was manifested in vivo (bleeding time) and in vitro 
      (aggregation). It is concluded that inclusions and other morphologic 
      abnormalities in thrombocytes of malaria patients are not caused by aspirin 
      ingestion.
FAU - Fajardo, L F
AU  - Fajardo LF
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation Tests
MH  - Blood Platelets/*drug effects/physiology/ultrastructure
MH  - Humans
MH  - Male
MH  - Megakaryocytes/drug effects/ultrastructure
MH  - Microscopy, Electron
MH  - Platelet Aggregation/drug effects
MH  - Time Factors
EDAT- 1975/04/01 00:00
MHDA- 1975/04/01 00:01
CRDT- 1975/04/01 00:00
PHST- 1975/04/01 00:00 [pubmed]
PHST- 1975/04/01 00:01 [medline]
PHST- 1975/04/01 00:00 [entrez]
AID - 10.1093/ajcp/63.4.554 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1975 Apr;63(4):554-8. doi: 10.1093/ajcp/63.4.554.

PMID- 31527979
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 0026-6620 (Print)
IS  - 0026-6620 (Linking)
VI  - 116
IP  - 4
DP  - 2019 Jul-Aug
TI  - Update on Dual Antiplatelet Therapy for Secondary Stroke Prevention.
PG  - 303-307
AB  - Aspirin is recommended for patients with acute ischemic stroke within 24 hours of 
      symptom onset. It may be beneficial for dual antiplatelet therapy including 
      clopidogrel and aspirin to be administered in patients with minor stroke or 
      transient ischemic attack for early secondary prevention, however, bleeding risk 
      remains uncertain. This article will review the published literature concerning 
      the role of dual antiplatelet therapy for secondary stroke prevention with focus 
      on balancing both risk and benefit.
FAU - Stringberg, Alexandria
AU  - Stringberg A
AD  - Alexandria Stringberg, Pharmd, PGY2 Internal Medicine Pharmacy resident; Ryan 
      Camden, PharmD, BCPS, Clinical Pharmacy Specialist - Internal Medicine, PGY-2 
      Internal Medicine Residency Program Director; Kathryn Qualls, PharmD, BCPS, 
      BCCCP, Clinical Pharmacy Specialist-Neurology; and Syed H. Naqvi, MD, Associate 
      Professor of Clinical Medicine, Division of Hospital Medicine; all at the 
      University of Missouri Health System.
FAU - Camden, Ryan
AU  - Camden R
AD  - Alexandria Stringberg, Pharmd, PGY2 Internal Medicine Pharmacy resident; Ryan 
      Camden, PharmD, BCPS, Clinical Pharmacy Specialist - Internal Medicine, PGY-2 
      Internal Medicine Residency Program Director; Kathryn Qualls, PharmD, BCPS, 
      BCCCP, Clinical Pharmacy Specialist-Neurology; and Syed H. Naqvi, MD, Associate 
      Professor of Clinical Medicine, Division of Hospital Medicine; all at the 
      University of Missouri Health System.
FAU - Qualls, Kathryn
AU  - Qualls K
AD  - Alexandria Stringberg, Pharmd, PGY2 Internal Medicine Pharmacy resident; Ryan 
      Camden, PharmD, BCPS, Clinical Pharmacy Specialist - Internal Medicine, PGY-2 
      Internal Medicine Residency Program Director; Kathryn Qualls, PharmD, BCPS, 
      BCCCP, Clinical Pharmacy Specialist-Neurology; and Syed H. Naqvi, MD, Associate 
      Professor of Clinical Medicine, Division of Hospital Medicine; all at the 
      University of Missouri Health System.
FAU - Naqvi, Syed H
AU  - Naqvi SH
AD  - Alexandria Stringberg, Pharmd, PGY2 Internal Medicine Pharmacy resident; Ryan 
      Camden, PharmD, BCPS, Clinical Pharmacy Specialist - Internal Medicine, PGY-2 
      Internal Medicine Residency Program Director; Kathryn Qualls, PharmD, BCPS, 
      BCCCP, Clinical Pharmacy Specialist-Neurology; and Syed H. Naqvi, MD, Associate 
      Professor of Clinical Medicine, Division of Hospital Medicine; all at the 
      University of Missouri Health System.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Mo Med
JT  - Missouri medicine
JID - 0400744
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clopidogrel/administration & dosage/therapeutic use
MH  - *Dual Anti-Platelet Therapy/methods
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Prasugrel Hydrochloride/administration & dosage/therapeutic use
MH  - Secondary Prevention/*methods
MH  - Stroke/*prevention & control
MH  - Ticagrelor/administration & dosage/therapeutic use
PMC - PMC6699814
EDAT- 2019/09/19 06:00
MHDA- 2020/04/03 06:00
CRDT- 2019/09/19 06:00
PHST- 2019/09/19 06:00 [entrez]
PHST- 2019/09/19 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
AID - ms116_p0303 [pii]
PST - ppublish
SO  - Mo Med. 2019 Jul-Aug;116(4):303-307.

PMID- 17650824
OWN - NLM
STAT- MEDLINE
DCOM- 20070904
LR  - 20131121
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 99
IP  - 1
DP  - 2007 Jul
TI  - Pathogenesis, diagnosis, and treatment of aspirin intolerance.
PG  - 13-21
AB  - OBJECTIVES: To provide an overview of aspirin intolerance (AI), to summarize the 
      latest genetic and pathophysiologic findings, and to discuss the current 
      therapeutic recommendations, including aspirin desensitization. DATA SOURCES: 
      Using the PubMed database, a systematic search of articles published between 1968 
      and 2006 was performed to evaluate the current literature on AI. The 
      bibliographies of selected articles served as a source of additional literature. 
      STUDY SELECTION: Included articles were selected for their relevance to the 
      pathogenesis, diagnosis, and management of AI. RESULTS: The prevalence of AI is 
      approximately 0.3% to 0.9%, but AI is often overlooked. It can display a wide 
      range of clinical pictures, such as acute asthma attacks, urticaria, angioedema, 
      chronic rhinitis, myocardial ischemia, and anaphylactic shock. Regarding the 
      pathogenesis of AI, modifications of eicosanoid metabolism are supposed to 
      underlie AI, including aspirin-induced asthma and aspirin-induced urticaria. 
      However, the pathogenesis of AI has not yet been clearly elucidated. Associations 
      of several HLA alleles with subtypes of AI, such as aspirin-induced urticaria and 
      aspirin-induced asthma, and single nucleotide polymorphisms in genes encoding 
      enzymes involved in arachidonic acid metabolism have been shown. CONCLUSIONS: 
      Because aspirin therapy should be avoided in AI patients, the use of alternative 
      drugs is recommended. Patients intolerant of alternative drugs and those with 
      therapy-resistant asthma or sinusitis benefit from aspirin desensitization.
FAU - Jenneck, Claudia
AU  - Jenneck C
AD  - Department of Dermatology, University of Bonn, Bonn, Germany.
FAU - Juergens, Uwe
AU  - Juergens U
FAU - Buecheler, Markus
AU  - Buecheler M
FAU - Novak, Natalija
AU  - Novak N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/*adverse effects
MH  - Desensitization, Immunologic/methods
MH  - Diagnostic Techniques and Procedures
MH  - Drug Hypersensitivity/*diagnosis/etiology/*therapy
MH  - Humans
MH  - Models, Biological
RF  - 66
EDAT- 2007/07/27 09:00
MHDA- 2007/09/05 09:00
CRDT- 2007/07/27 09:00
PHST- 2007/07/27 09:00 [pubmed]
PHST- 2007/09/05 09:00 [medline]
PHST- 2007/07/27 09:00 [entrez]
AID - S1081-1206(10)60615-1 [pii]
AID - 10.1016/S1081-1206(10)60615-1 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2007 Jul;99(1):13-21. doi: 
      10.1016/S1081-1206(10)60615-1.

PMID- 2621427
OWN - NLM
STAT- MEDLINE
DCOM- 19900320
LR  - 20150901
IS  - 0371-7682 (Print)
IS  - 0371-7682 (Linking)
VI  - 88
IP  - 9
DP  - 1989 Sep
TI  - Acute effects of fever, fasting and aspirin on infant rat gastric mucosa.
PG  - 869-73
AB  - Clinical experience shows that young children with gastrointestinal bleeding have 
      frequently had some preceding febrile illness for which aspirin was administered. 
      Febrile young children often have poor food or liquid intake, or have been in a 
      fasting state because of diarrhea, vomiting or anorexia. The objective of this 
      study was to determine the acute effects of fever, fasting and oral aspirin 
      administration on the gastrointestinal mucosa. One hundred and sixty-eight infant 
      rats, from 21 to 28 days of age and weighting from 70 to 120 g were studied. 
      Random assignment was made to eight groups (Grs): Control (Gr I); aspirin 
      administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin 
      and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and 
      aspirin, fever and fasting (Gr VIII). Aspirin was given orally in a single daily 
      dose of 200 mg/kg for two days. Fever was induced by an intraperitoneal injection 
      of 0.6 ml salmonella vaccine. Fasting time lasted from 40 to 48 hours (8 hours 
      prior to the beginning of the experiment to the end of study). The severity of 
      the gastric bleeding was estimated by scoring the number of petechiae and the 
      percentage of the hemorrhagic erosion area from grade 0 to 3. Results showed that 
      rats in Grs VII and VIII had significantly more severe grades of petechiae and 
      hemorrhage than the other groups. These were the groups where the risk factors of 
      fasting and aspirin administration coexisted. In addition to fasting, Gr VIII had 
      fever, but this group did not show more gastric mucosal damage than Gr VII 
      showed.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Chen, P H
AU  - Chen PH
FAU - Chang, M H
AU  - Chang MH
FAU - Chuang, Y H
AU  - Chuang YH
FAU - Liu, Y C
AU  - Liu YC
LA  - eng
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Taiwan Yi Xue Hui Za Zhi
JT  - Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association
JID - 0413761
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - *Fasting
MH  - Fever/*physiopathology
MH  - Gastric Mucosa/drug effects/*physiopathology
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1989/09/01 00:00
MHDA- 1989/09/01 00:01
CRDT- 1989/09/01 00:00
PHST- 1989/09/01 00:00 [pubmed]
PHST- 1989/09/01 00:01 [medline]
PHST- 1989/09/01 00:00 [entrez]
PST - ppublish
SO  - Taiwan Yi Xue Hui Za Zhi. 1989 Sep;88(9):869-73.

PMID- 16133890
OWN - NLM
STAT- MEDLINE
DCOM- 20051115
LR  - 20181113
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 20
IP  - 1
DP  - 2005 Aug
TI  - The role of exercise on platelet aggregation in patients with stable coronary 
      artery disease: exercise induces aspirin resistant platelet activation.
PG  - 17-22
AB  - OBJECTIVES: The aim of our study was to determine the relation between exercise 
      stress test and aspirin resistance in patients with stable coronary artery 
      disease. BACKGROUND: Clinically aspirin resistance is defined as having 
      thrombotic and embolic cardiovascular events despite regular aspirin therapy. 
      METHODS: We studied platelet functions of 62 patients with stable coronary artery 
      disease and 20 subjects with normal coronary arteries by Platelet Function 
      Analyzer (PFA-100, Dade Behring, Germany) at rest and after exertion with 
      collagen and/or epinephrine (Col/Epi) and collagen and/or ADP cartridges. Closure 
      time (CT)<186 seconds was defined as aspirin resistance with Col/Epi cartridges 
      of PFA-100. Symptom limited treadmill stress test (protocol of Bruce) was 
      performed with Oxford Streslink TD-1 system. RESULTS: 8 (12.9%) patients were 
      aspirin resistant by PFA-100 (CT<186s despite regular aspirin therapy) at rest. 
      At the first minute of the recovery period of exercise stress test 14 (22.5%) 
      patients were aspirin resistant by PFA-100. CTs with Col/ADP were respectively 
      89+/-6 s (83--100s) and 89+/-5 s (82--104s) at rest and after exercise (p=0.107). 
      20.3% (11/54) of patients known as in vitro aspirin sensitives at rest had 
      shorter CTs and 11.1% (6/54) had aspirin resistance after exercise (p=0.004). 
      There was no statistically significiant difference in platelet functions in the 
      control group after exertion. CONCLUSION: We conclude that 11.1% of in vitro 
      aspirin sensitive subjects at rest had aspirin resistance after exercise by 
      PFA-100. In some individuals, exercise induced platelet activation is aspirin 
      insensitive at usual antiplatelet doses. We need further clinical trials to 
      optimize antiplatelet therapy in patients with coronary artery disease.
FAU - Pamukcu, Burak
AU  - Pamukcu B
AD  - Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 
      bpamukcu@istanbul.edu.tr
FAU - Oflaz, Huseyin
AU  - Oflaz H
FAU - Acar, Rezzan Deniz
AU  - Acar RD
FAU - Umman, Sabahattin
AU  - Umman S
FAU - Koylan, Nevres
AU  - Koylan N
FAU - Umman, Berrin
AU  - Umman B
FAU - Nisanci, Yilmaz
AU  - Nisanci Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/*physiology
MH  - Coronary Disease/physiopathology/*rehabilitation
MH  - *Drug Resistance
MH  - Exercise/*physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/*physiology
MH  - Reference Values
EDAT- 2005/09/01 09:00
MHDA- 2005/11/16 09:00
CRDT- 2005/09/01 09:00
PHST- 2005/09/01 09:00 [pubmed]
PHST- 2005/11/16 09:00 [medline]
PHST- 2005/09/01 09:00 [entrez]
AID - 10.1007/s11239-005-2318-1 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2005 Aug;20(1):17-22. doi: 10.1007/s11239-005-2318-1.

PMID- 30522897
OWN - NLM
STAT- MEDLINE
DCOM- 20200508
LR  - 20200508
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 73
IP  - 3
DP  - 2019 Mar
TI  - Prevalence and predictors of high-on treatment platelet reactivity during 
      prasugrel treatment in patients with acute coronary syndrome undergoing stent 
      implantation.
PG  - 198-203
LID - S0914-5087(18)30305-8 [pii]
LID - 10.1016/j.jjcc.2018.10.005 [doi]
AB  - BACKGROUND: ADP-antagonists such as prasugrel have reduced but yet not overcome 
      the phenomenon of high-on treatment platelet reactivity (HRPR), that has been 
      shown to increase the rate of major cardiovascular events after an acute coronary 
      syndrome (ACS) or percutaneous coronary intervention (PCI). However, the exact 
      prevalence and the principal determinants of suboptimal platelet inhibition in 
      patients treated with dual antiplatelet therapy (DAPT) with prasugrel have not 
      been completely clarified and were therefore the aim of the present study. 
      METHODS: We included patients (<75 years and >60kg) treated with DAPT 
      (aspirin+prasugrel) after PCI, mainly for an ACS. Platelet function test 
      evaluation was performed at 1-3 months from discharge. HRPR was assessed by 
      multiplate impedance aggregometry and defined for results above upper limit of 
      normal after ADP stimulation. RESULTS: We included 190 post-ACS patients. HRPR 
      with prasugrel was observed in 19 patients (10%). The prevalence of HRPR was 
      stable in different high-risk subgroups of patients (female gender, 
      hypercholesterolemic, and chronic kidney disease) whereas it was increased in 
      diabetic patients (p=0.045), with a significant interaction between diabetic 
      status and HRPR (p=0.04). However, at multivariate analysis, an impaired 
      metabolic status, with higher levels of glycosylated hemoglobin and low-density 
      lipoprotein (LDL) cholesterol, but not diabetic status, emerged as independent 
      predictors of HRPR with prasugrel [OR (95% CI)=2.1 (1.32-3.33), p=0.002 and OR 
      (95% CI)=1.03 (1.01-1.05), p=0.003, respectively], with a stronger linear 
      relationship between ADP-mediated platelet aggregation and glycosylated 
      hemoglobin levels (r=0.24, p=0.002), than for LDL-cholesterol (r=0.13, p=0.09). 
      CONCLUSIONS: In post-ACS patients treated with PCI and receiving DAPT with 
      prasugrel, HRPR is observed in about 10% of patients. Impaired metabolic status, 
      and especially elevated glycosylated hemoglobin, emerged as independent 
      predictors of the suboptimal effectiveness of prasugrel.
CI  - Copyright © 2018. Published by Elsevier Ltd.
FAU - Verdoia, Monica
AU  - Verdoia M
AD  - Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della 
      Carità", Eastern Piedmont University, Novara, Italy.
FAU - Pergolini, Patrizia
AU  - Pergolini P
AD  - Clinical Chemistry, Azienda Ospedaliera-Universitaria "Maggiore della Carità", 
      Eastern Piedmont University, Novara, Italy.
FAU - Nardin, Matteo
AU  - Nardin M
AD  - Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della 
      Carità", Eastern Piedmont University, Novara, Italy.
FAU - Rolla, Roberta
AU  - Rolla R
AD  - Clinical Chemistry, Azienda Ospedaliera-Universitaria "Maggiore della Carità", 
      Eastern Piedmont University, Novara, Italy.
FAU - Barbieri, Lucia
AU  - Barbieri L
AD  - Division of Cardiology, Ospedale S. Andrea, Vercelli, Italy.
FAU - Marino, Paolo
AU  - Marino P
AD  - Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della 
      Carità", Eastern Piedmont University, Novara, Italy.
FAU - Carriero, Alessandro
AU  - Carriero A
AD  - Division of Radiology Azienda Ospedaliera-Universitaria "Maggiore della Carità", 
      Eastern Piedmont University, Novara, Italy.
FAU - Suryapranata, Harry
AU  - Suryapranata H
AD  - Department of Cardiology, UMC St Radboud, Nijmegen, The Netherlands.
FAU - De Luca, Giuseppe
AU  - De Luca G
AD  - Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della 
      Carità", Eastern Piedmont University, Novara, Italy. Electronic address: 
      giuseppe.deluca@maggioreosp.novara.it.
CN  - Novara Atherosclerosis Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181203
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Platelets/drug effects
MH  - Dual Anti-Platelet Therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Platelet Function Tests
MH  - Postoperative Period
MH  - Prasugrel Hydrochloride/administration & dosage/*adverse effects
MH  - Prevalence
MH  - Stents
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Pharmacological
OT  - Platelet aggregation inhibitors
OT  - Platelet function tests
OT  - Prasugrel
EDAT- 2018/12/14 06:00
MHDA- 2020/05/10 06:00
CRDT- 2018/12/08 06:00
PHST- 2018/05/14 00:00 [received]
PHST- 2018/09/06 00:00 [revised]
PHST- 2018/10/04 00:00 [accepted]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2020/05/10 06:00 [medline]
PHST- 2018/12/08 06:00 [entrez]
AID - S0914-5087(18)30305-8 [pii]
AID - 10.1016/j.jjcc.2018.10.005 [doi]
PST - ppublish
SO  - J Cardiol. 2019 Mar;73(3):198-203. doi: 10.1016/j.jjcc.2018.10.005. Epub 2018 Dec 
      3.

PMID- 22526273
OWN - NLM
STAT- MEDLINE
DCOM- 20130506
LR  - 20211021
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
VI  - 47
IP  - 11
DP  - 2012 Nov
TI  - Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose 
      aspirin in patients with cardiovascular or cerebrovascular disease: a prospective 
      randomized active-controlled trial.
PG  - 1186-97
LID - 10.1007/s00535-012-0588-x [doi]
AB  - BACKGROUND: Patients using low-dose aspirin (LDA) have an increased risk of 
      gastroduodenal mucosal lesions and upper gastrointestinal symptoms. We aimed to 
      clarify the efficacy of rabeprazole for preventing peptic ulcer, esophagitis, and 
      gastrointestinal symptoms associated with LDA. METHODS: Patients with a history 
      of peptic ulcers who were receiving LDA for cardiovascular or cerebrovascular 
      disease were randomly assigned to receive rabeprazole at 10 mg daily, rabeprazole 
      at 20 mg daily, or gefarnate (a cytoprotective anti-ulcer agent) at 50 mg twice 
      daily. The primary endpoint was the development of gastric and/or duodenal ulcer 
      at 12 weeks. The modified Lanza score (MLS) and gastrointestinal symptoms were 
      evaluated at baseline and at 12 weeks. RESULTS: The full analysis set comprised 
      261 patients (rabeprazole 10 mg: n = 87, rabeprazole 20 mg: n = 89, gefarnate 100 
      mg: n = 85). The cumulative incidences of gastroduodenal ulcers at 12 weeks in 
      the 10 mg rabeprazole group, 20 mg rabeprazole group, and gefarnate group were 
      7.4, 3.7, and 26.7 %, respectively (rabeprazole group 5.5 % vs. gefarnate group 
      26.7 %, hazard ratio [HR] 0.179; 95 % confidence interval [CI] 0.082-0.394; p < 
      0.0001). The proportions of patients with an MLS of ≥1 and erosive esophagitis 
      were significantly lower in the rabeprazole group than in the gefarnate group at 
      12 weeks (gastric lesions 33.5 vs. 62.4 %, p < 0.0001; duodenal lesions 5.7 vs. 
      24.7 %, p < 0.0001; erosive esophagitis 5.8 vs. 19.4 %, p < 0.0001). Rabeprazole 
      was significantly more effective than gefarnate for the resolution and prevention 
      of gastrointestinal symptoms (resolution 53.6 vs. 25.0 %, p = 0.017; occurrence 
      9.2 vs. 28.3 %, p = 0.0026). CONCLUSIONS: Rabeprazole is more effective than 
      gefarnate for reducing the risk of recurrence of peptic ulcer, esophagitis, and 
      gastrointestinal symptoms in LDA users.
FAU - Sanuki, Tsuyoshi
AU  - Sanuki T
AD  - Department of Gastroenterology, Kobe University Graduate School of Medicine, 
      7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
FAU - Fujita, Tsuyoshi
AU  - Fujita T
FAU - Kutsumi, Hiromu
AU  - Kutsumi H
FAU - Hayakumo, Takanobu
AU  - Hayakumo T
FAU - Yoshida, Shun-ichi
AU  - Yoshida S
FAU - Inokuchi, Hideto
AU  - Inokuchi H
FAU - Murakami, Manabu
AU  - Murakami M
FAU - Matsubara, Yoshihiro
AU  - Matsubara Y
FAU - Kuwayama, Hajime
AU  - Kuwayama H
FAU - Kawai, Takashi
AU  - Kawai T
FAU - Miyaji, Hideki
AU  - Miyaji H
FAU - Fujisawa, Takashi
AU  - Fujisawa T
FAU - Terao, Shuichi
AU  - Terao S
FAU - Yamazaki, Yukinao
AU  - Yamazaki Y
FAU - Azuma, Takeshi
AU  - Azuma T
CN  - Care Study Group
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120417
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 1ISE2Y6ULA (Gefarnate)
RN  - 32828355LL (Rabeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Aged
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Cerebrovascular Disorders/drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Esophagitis/chemically induced/prevention & control
MH  - Female
MH  - Gefarnate/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/chemically induced/*prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Prospective Studies
MH  - Rabeprazole
MH  - Secondary Prevention
FIR - Yamashina, Akira
IR  - Yamashina A
FIR - Furuta, Takahisa
IR  - Furuta T
FIR - Dojo, Manabu
IR  - Dojo M
FIR - Inagaki, Tomoko
IR  - Inagaki T
FIR - Ito, Shigeji
IR  - Ito S
FIR - Kado, Takuo
IR  - Kado T
FIR - Otaki, Yoshie
IR  - Otaki Y
FIR - Hirai, Masamichi
IR  - Hirai M
FIR - Okuyama, Yusuke
IR  - Okuyama Y
FIR - Matsumori, Yoshinobu
IR  - Matsumori Y
FIR - Ashida, Kiyoshi
IR  - Ashida K
FIR - Shimizu, Seiji
IR  - Shimizu S
FIR - Ohno, Kyota
IR  - Ohno K
FIR - Nakamura, Akira
IR  - Nakamura A
FIR - Yoshida, Hiroshi
IR  - Yoshida H
FIR - Yamada, Hiroyuki
IR  - Yamada H
FIR - Chinzei, Ryo
IR  - Chinzei R
FIR - Hirata, Ken-ichi
IR  - Hirata K
FIR - Hirai, Midori
IR  - Hirai M
FIR - Inokuma, Tetsuro
IR  - Inokuma T
FIR - Shimada, Takao
IR  - Shimada T
FIR - Nakashima, Takatoshi
IR  - Nakashima T
FIR - Hirano, Seiichi
IR  - Hirano S
FIR - Ouchi, Sachiko
IR  - Ouchi S
FIR - Utaka, Isao
IR  - Utaka I
FIR - Takauchi, Takumi
IR  - Takauchi T
FIR - Taira, Akihiko
IR  - Taira A
FIR - Takeuchi, Koji
IR  - Takeuchi K
FIR - Watanabe, Yoshiyuki
IR  - Watanabe Y
FIR - Mizuno, Shigeto
IR  - Mizuno S
EDAT- 2012/04/25 06:00
MHDA- 2013/05/07 06:00
CRDT- 2012/04/25 06:00
PHST- 2012/01/06 00:00 [received]
PHST- 2012/03/19 00:00 [accepted]
PHST- 2012/04/25 06:00 [entrez]
PHST- 2012/04/25 06:00 [pubmed]
PHST- 2013/05/07 06:00 [medline]
AID - 10.1007/s00535-012-0588-x [doi]
PST - ppublish
SO  - J Gastroenterol. 2012 Nov;47(11):1186-97. doi: 10.1007/s00535-012-0588-x. Epub 
      2012 Apr 17.

PMID- 25388762
OWN - NLM
STAT- MEDLINE
DCOM- 20150831
LR  - 20220409
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 19
IP  - 2
DP  - 2015 Feb
TI  - Role of p38 MAPK in enhanced human cancer cells killing by the combination of 
      aspirin and ABT-737.
PG  - 408-17
LID - 10.1111/jcmm.12461 [doi]
AB  - Regular use of aspirin after diagnosis is associated with longer survival among 
      patients with mutated-PIK3CA colorectal cancer, but not among patients with 
      wild-type PIK3CA cancer. In this study, we showed that clinically achievable 
      concentrations of aspirin and ABT-737 in combination could induce a synergistic 
      growth arrest in several human PIK3CA wild-type cancer cells. In addition, our 
      results also demonstrated that long-term combination treatment with aspirin and 
      ABT-737 could synergistically induce apoptosis both in A549 and H1299 cells. In 
      the meanwhile, short-term aspirin plus ABT-737 combination treatment induced a 
      greater autophagic response than did either drug alone and the 
      combination-induced autophagy switched from a cytoprotective signal to a 
      death-promoting signal. Furthermore, we showed that p38 acted as a switch between 
      two different types of cell death (autophagy and apoptosis) induced by aspirin 
      plus ABT-737. Moreover, the increased anti-cancer efficacy of aspirin combined 
      with ABT-737 was further validated in a human lung cancer A549 xenograft model. 
      We hope that this synergy may contribute to failure of aspirin cancer therapy and 
      ultimately lead to efficacious regimens for cancer therapy.
CI  - © 2014 The Authors. Journal of Cellular and Molecular Medicine published by John 
      Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
FAU - Zhang, Chong
AU  - Zhang C
AD  - School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang, China.
FAU - Shi, Jing
AU  - Shi J
FAU - Mao, Shi-ying
AU  - Mao SY
FAU - Xu, Ya-si
AU  - Xu YS
FAU - Zhang, Dan
AU  - Zhang D
FAU - Feng, Lin-yi
AU  - Feng LY
FAU - Zhang, Bo
AU  - Zhang B
FAU - Yan, You-you
AU  - Yan YY
FAU - Wang, Si-cong
AU  - Wang SC
FAU - Pan, Jian-ping
AU  - Pan JP
FAU - Yang, You-ping
AU  - Yang YP
FAU - Lin, Neng-ming
AU  - Lin NM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141111
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (ABT-737)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Nitrophenols)
RN  - 0 (Piperazines)
RN  - 0 (Sulfonamides)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Aspirin/*pharmacology
MH  - Autophagy/*drug effects
MH  - Biphenyl Compounds/*pharmacology
MH  - Cell Line, Tumor
MH  - Humans
MH  - Neoplasms/*drug therapy/metabolism
MH  - Nitrophenols/*pharmacology
MH  - Piperazines/pharmacology
MH  - Sulfonamides/*pharmacology
MH  - p38 Mitogen-Activated Protein Kinases/*metabolism
PMC - PMC4407609
OTO - NOTNLM
OT  - ABT-737
OT  - aspirin
OT  - combination
OT  - p38
EDAT- 2014/11/13 06:00
MHDA- 2015/09/01 06:00
CRDT- 2014/11/13 06:00
PHST- 2014/05/16 00:00 [received]
PHST- 2014/09/19 00:00 [accepted]
PHST- 2014/11/13 06:00 [entrez]
PHST- 2014/11/13 06:00 [pubmed]
PHST- 2015/09/01 06:00 [medline]
AID - 10.1111/jcmm.12461 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2015 Feb;19(2):408-17. doi: 10.1111/jcmm.12461. Epub 2014 Nov 11.

PMID- 23158034
OWN - NLM
STAT- MEDLINE
DCOM- 20131125
LR  - 20190117
IS  - 1728-7731 (Electronic)
IS  - 1726-4901 (Linking)
VI  - 75
IP  - 11
DP  - 2012 Nov
TI  - Utilization of statins and aspirin among patients with diabetes and 
      hyperlipidemia: Taiwan, 1998-2006.
PG  - 567-72
LID - S1726-4901(12)00223-7 [pii]
LID - 10.1016/j.jcma.2012.08.020 [doi]
AB  - BACKGROUND: The proper use of statins and aspirin decrease the risk of coronary 
      heart disease (CHD) among patients with diabetes (DM) and hyperlipidemia. The 
      purpose of this study was to analyze the time trends and determinants of 
      prescribing statins and aspirin among patients with DM and hyperlipidemia in 
      medical practice in Taiwan. METHODS: A cohort of 21,667 patients with DM and 
      hyperlipidemia during the period from 1998 to 2006 was identified by using data 
      of ambulatory care claims from Taiwan's National Health Insurance Database. The 
      dataset was categorized into two equal calendar periods: Period 1 (September 
      1998-June 2002) and Period 2 (July 2002-April 2006). Multivariate logistic 
      regression analyses were used to determine the independent determinants 
      associated with receipt of lipid-lowering agents and aspirin among these 
      patients. RESULTS: There were significant increases in the prescribing of statins 
      (OR 1.78; 95% CI 1.66-1.91) and aspirin (OR 1.47, 95% CI 1.50-1.59) in Period 2 
      as compared with Period 1. Nevertheless, 30% of patients with coexisting CHD 
      neither received statins nor aspirin. Only 15% to 25% of DM patients with 
      hyperlipidemia and CHD received the combined treatment with aspirin and statin. 
      In multivariate logistic regression, we found that women received aspirin less 
      frequently than men. Old patients (>45 years) with concomitant CHD were more 
      likely to receive statins and aspirin. CONCLUSION: Despite the increasing trend 
      in the use of statins and aspirin in DM patients with hyperlipidemia in Taiwan, 
      the improvements were at best modest, particularly for secondary prevention. Our 
      data indicate the need for continued efforts to improve the utilization of these 
      drugs in daily practice.
CI  - Copyright © 2012. Published by Elsevier B.V.
FAU - Lin, Yi-Chun
AU  - Lin YC
AD  - Section of Endocrinology and Metabolism, Department of Medicine, Taipei City 
      Hospital, Renai Branch, Taipei, Taiwan, ROC.
FAU - Yang, Chen-Chang
AU  - Yang CC
FAU - Chen, Ying-Ju
AU  - Chen YJ
FAU - Peng, Wei-Chien
AU  - Peng WC
FAU - Li, Chung-Yi
AU  - Li CY
FAU - Hwu, Chii-Min
AU  - Hwu CM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121012
PL  - Netherlands
TA  - J Chin Med Assoc
JT  - Journal of the Chinese Medical Association : JCMA
JID - 101174817
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Coronary Disease/*prevention & control
MH  - Diabetes Mellitus/*drug therapy
MH  - Drug Utilization/*trends
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Hyperlipidemias/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Taiwan
EDAT- 2012/11/20 06:00
MHDA- 2013/12/16 06:00
CRDT- 2012/11/20 06:00
PHST- 2011/06/16 00:00 [received]
PHST- 2012/05/24 00:00 [accepted]
PHST- 2012/11/20 06:00 [entrez]
PHST- 2012/11/20 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - S1726-4901(12)00223-7 [pii]
AID - 10.1016/j.jcma.2012.08.020 [doi]
PST - ppublish
SO  - J Chin Med Assoc. 2012 Nov;75(11):567-72. doi: 10.1016/j.jcma.2012.08.020. Epub 
      2012 Oct 12.

PMID- 7962782
OWN - NLM
STAT- MEDLINE
DCOM- 19941215
LR  - 20190709
IS  - 0190-9622 (Print)
IS  - 0190-9622 (Linking)
VI  - 31
IP  - 6
DP  - 1994 Dec
TI  - Effect of aspirin and nonsteroidal antiinflammatory drug therapy on bleeding 
      complications in dermatologic surgical patients.
PG  - 988-92
AB  - BACKGROUND: Aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) inhibit 
      platelet cyclooxygenase activity, resulting in altered platelet function and thus 
      potentially enhanced bleeding. OBJECTIVE: We examined the frequency of operative 
      bleeding complications in dermatologic surgical patients taking these drugs and 
      the value of template bleeding time estimates in predicting this complication. 
      METHODS: Bleeding time was measured with and without therapy in 23 patients and 
      was correlated to bleeding complications after skin tumor or benign lesion 
      excision in 40 patients taking aspirin, 21 taking NSAIDs, and 20 taking neither 
      drug. RESULTS: Bleeding time dropped significantly (p < 0.01) when patients 
      stopped therapy for at least 5 days (median, 7 days), although bleeding time was 
      prolonged in only 6 of 16 patients taking aspirin and 2 of 7 taking NSAID. In 
      patients who continued antiplatelet drugs during surgery, bleeding time was 
      prolonged in 8 of 40 patients taking aspirin and in 1 of 21 treated with NSAIDs. 
      Excessive intraoperative bleeding occurred in three aspirin-treated patients, all 
      of whom had a prolonged bleeding time, compared with none of those with normal 
      bleeding times (p < 0.001, Fisher's exact probability test) and with none of 
      those taking NSAIDs. Postoperative ooze requiring a dressing replacement occurred 
      in one NSAID-treated patient and in three patients taking neither drug. 
      CONCLUSION: Bleeding time is increased by aspirin and NSAID therapy but is 
      prolonged beyond the normal range in only approximately 25% of aspirin-treated 
      and 10% of NSAID-treated patients. Intraoperative bleeding complications occurred 
      only in patients receiving aspirin who had a prolonged bleeding time. 
      Postoperative oozing occurred only in NSAID-treated and in untreated patients and 
      thus is probably unrelated to antiplatelet therapy. Patients with a normal 
      bleeding time can continue aspirin or NSAID therapy before dermatologic surgery.
FAU - Lawrence, C
AU  - Lawrence C
AD  - Department of Dermatology, Royal Victoria Infirmary, Newcastle, UK.
FAU - Sakuntabhai, A
AU  - Sakuntabhai A
FAU - Tiling-Grosse, S
AU  - Tiling-Grosse S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Acad Dermatol. 1995 Oct;33(4):692. PMID: 7673512
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Bandages
MH  - Blood Coagulation Tests
MH  - Blood Loss, Surgical
MH  - Female
MH  - Hemorrhage/*physiopathology
MH  - Humans
MH  - Intraoperative Complications
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/drug effects
MH  - Postoperative Complications
MH  - Prospective Studies
MH  - Skin Diseases/*surgery
MH  - Surgical Flaps
MH  - Suture Techniques
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
AID - S0190-9622(94)70269-1 [pii]
AID - 10.1016/s0190-9622(94)70269-1 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 1994 Dec;31(6):988-92. doi: 10.1016/s0190-9622(94)70269-1.

PMID- 7876837
OWN - NLM
STAT- MEDLINE
DCOM- 19950331
LR  - 20190909
IS  - 0162-0134 (Print)
IS  - 0162-0134 (Linking)
VI  - 57
IP  - 3
DP  - 1995 Feb 15
TI  - Copper(II) interactions with nonsteroidal antiinflammatory agents. I. Salicylic 
      acid and acetylsalicylic acid.
PG  - 191-207
AB  - Recently a growing body of evidence has accumulated on the beneficial effects of 
      copper compounds toward various models of inflammation, and copper complexes of 
      nonsteroidal antiinflammatory drugs (NSAIDs) have been shown to be more effective 
      in this respect than the parent agents. However, the origin of this activity 
      remains unclear: The ability of NSAIDs to influence copper metabolism is still 
      questionable, and apart from the claimed SOD-like activity of copper salts in 
      vivo, relatively little is known about how copper-NSAID interactions may help 
      regulate the inflammatory process. Before the potential role of copper-NSAID 
      complexes versus inflammation can be elucidated, speciation studies are necessary 
      (i) to analyze the overall influence of these drugs on copper metabolism and (ii) 
      to discriminate the individual complexes likely to represent the active form of 
      the drug in vivo. In this paper, copper(II) complex equilibria with salicylic and 
      acetylsalicylic acids--and benzoic acid used as a reference--as well as the 
      mixed-ligand complex equilibria generated by these binary systems and L-histidine 
      [main low-molar-mass ligand of copper(II) in blood plasma] have been investigated 
      under physiological conditions (37 degrees C; 0.15-M NaCl). Confirming previous 
      observations by others, resulting simulated plasma copper distributions virtually 
      rule out any quantitative influence of salicylate on copper tissue diffusion at 
      therapeutic levels. Even though, as is presently shown, both salicylate and 
      acetylsalicylate may favor the gastrointestinal absorption of copper, it seems 
      unlikely that salicylate can exert its antinflammatory activity predominantly 
      through copper complexation. The assertion that copper-NSAID complexes represent 
      the active forms of NSAIDs therefore seems to be of limited significance for 
      salicylate.
FAU - Brumas, V
AU  - Brumas V
AD  - INSERM U305, Equipe Bioréactifs: Spéciation et Biodisponibilité, Université Paul 
      Sabatier, Toulouse, France.
FAU - Brumas, B
AU  - Brumas B
FAU - Berthon, G
AU  - Berthon G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Inorg Biochem
JT  - Journal of inorganic biochemistry
JID - 7905788
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cations, Divalent)
RN  - 0 (Salicylates)
RN  - 789U1901C5 (Copper)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Cations, Divalent
MH  - Copper/*chemistry
MH  - Gastric Juice/chemistry
MH  - Hydrogen-Ion Concentration
MH  - In Vitro Techniques
MH  - Models, Biological
MH  - Salicylates/*chemistry
MH  - Salicylic Acid
EDAT- 1995/02/15 00:00
MHDA- 1995/02/15 00:01
CRDT- 1995/02/15 00:00
PHST- 1995/02/15 00:00 [pubmed]
PHST- 1995/02/15 00:01 [medline]
PHST- 1995/02/15 00:00 [entrez]
AID - 0162-0134(94)00024-5 [pii]
AID - 10.1016/0162-0134(94)00024-5 [doi]
PST - ppublish
SO  - J Inorg Biochem. 1995 Feb 15;57(3):191-207. doi: 10.1016/0162-0134(94)00024-5.

PMID- 12871601
OWN - NLM
STAT- MEDLINE
DCOM- 20031215
LR  - 20181113
IS  - 1471-2296 (Electronic)
IS  - 1471-2296 (Linking)
VI  - 4
DP  - 2003 Jul 18
TI  - Why are eligible patients not prescribed aspirin in primary care? A qualitative 
      study indicating measures for improvement.
PG  - 9
AB  - BACKGROUND: Despite evidence-based guidelines, aspirin prescribing for the 
      secondary prevention of stroke is sub-optimal. Little is known about why general 
      practitioners do not prescribe aspirin to indicated patients. We sought to 
      identify and describe factors that lead general practitioners (GPs) not to 
      prescribe aspirin to eligible stroke patients. This was the first stage of a 
      study exploring the need for and means of improving levels of appropriate aspirin 
      prescribing. METHOD: Qualitative interviews with 15 GPs in the West Midlands. 
      RESULTS: Initially, many GPs did not regard their prescribing as difficult or 
      sub-optimal. However on reflection, they gave several reasons that lead to them 
      not prescribing aspirin for eligible patients or being uncertain. These include: 
      difficulties in applying generic guidelines to individuals presenting in 
      consultations, patient resistance to taking aspirin, the prioritisation of other 
      issues in a time constrained consultation and problems in reviewing the 
      medication of existing stroke patients. CONCLUSION: In order to improve levels of 
      appropriate aspirin prescribing, the nature and presentation risk information 
      available to GPs and patients must be improved. GPs need support in assessing the 
      risks and benefits of prescribing for patients with combinations of complicating 
      risk factors, while means of facilitating improved GP-patient dialogue are 
      required to help address patient uncertainty. A decision analysis based support 
      system is one option. Decision analysis could synthesise current evidence and 
      identify risk data for a range of patient profiles commonly presenting in primary 
      care. These data could then be incorporated into a user-friendly computerised 
      decision support system to help facilitate improved GP-patient communication. 
      Measures of optimum prescribing based upon aggregated prescribing data must be 
      interpreted with caution. It is not possible to assess whether low levels of 
      prescribing reflect appropriate or inappropriate use of aspirin in specific 
      patients where concordance between the GP and the patient is practised.
FAU - Short, Duncan
AU  - Short D
AD  - Department of Medicines Management, University of Keele, Keele, Staffordshire, 
      UK, ST5 5BG. d.short@keele.ac.uk
FAU - Frischer, Martin
AU  - Frischer M
FAU - Bashford, James
AU  - Bashford J
FAU - Ashcroft, Darren
AU  - Ashcroft D
LA  - eng
PT  - Journal Article
DEP - 20030718
PL  - England
TA  - BMC Fam Pract
JT  - BMC family practice
JID - 100967792
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Attitude of Health Personnel
MH  - *Drug Prescriptions
MH  - Humans
MH  - Patient Compliance
MH  - *Physicians, Family
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Practice Patterns, Physicians'
MH  - Recurrence
MH  - Stroke/etiology/*prevention & control
MH  - Treatment Refusal
PMC - PMC183829
EDAT- 2003/07/23 05:00
MHDA- 2003/12/16 05:00
CRDT- 2003/07/23 05:00
PHST- 2003/03/06 00:00 [received]
PHST- 2003/07/18 00:00 [accepted]
PHST- 2003/07/23 05:00 [pubmed]
PHST- 2003/12/16 05:00 [medline]
PHST- 2003/07/23 05:00 [entrez]
AID - 1471-2296-4-9 [pii]
AID - 10.1186/1471-2296-4-9 [doi]
PST - ppublish
SO  - BMC Fam Pract. 2003 Jul 18;4:9. doi: 10.1186/1471-2296-4-9. Epub 2003 Jul 18.

PMID- 3081996
OWN - NLM
STAT- MEDLINE
DCOM- 19860421
LR  - 20190908
IS  - 0036-553X (Print)
IS  - 0036-553X (Linking)
VI  - 36
IP  - 1
DP  - 1986 Jan
TI  - Aspirin does not inhibit human megakaryocyte thromboxane synthesis in vivo.
PG  - 92-5
AB  - Cyclooxygenase activity in human platelets reappears after ingestion of aspirin 
      as a function of the platelet production rate. In different studies the activity 
      reappeared without delay or with an interval of at least 48 h after stopping the 
      drug. Because inhibition of megakaryocyte cyclooxygenase is the sole likely 
      explanation for a delay we determined thromboxane B2 in human megakaryocytes 
      obtained under local anaesthesia. We found that aspirin does not inhibit human 
      megakaryocytes in vivo but does so in vitro. Therefore, it does not seem likely 
      that there is actually a delay in platelet cyclooxygenase resurgence after 
      aspirin intake. In order to suppress platelet cyclooxygenase constantly, aspirin 
      should be given once or twice a day and not once or twice a week.
FAU - Huijgens, P C
AU  - Huijgens PC
FAU - van den Berg, C A
AU  - van den Berg CA
FAU - Imandt, L M
AU  - Imandt LM
FAU - Miltenburg, A
AU  - Miltenburg A
FAU - Langenhuijsen, M M
AU  - Langenhuijsen MM
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Scand J Haematol
JT  - Scandinavian journal of haematology
JID - 0404507
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/enzymology
MH  - Bone Marrow Cells
MH  - Cyclooxygenase Inhibitors
MH  - Humans
MH  - Megakaryocytes/drug effects/*metabolism
MH  - Platelet Count
MH  - Thromboxane B2/*biosynthesis
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1986.tb02656.x [doi]
PST - ppublish
SO  - Scand J Haematol. 1986 Jan;36(1):92-5. doi: 10.1111/j.1600-0609.1986.tb02656.x.

PMID- 9410426
OWN - NLM
STAT- MEDLINE
DCOM- 19971219
LR  - 20161206
IS  - 1210-7832 (Print)
IS  - 1210-7832 (Linking)
VI  - 62
IP  - 1
DP  - 1997 Feb
TI  - [Dosage of acetylsalicylic acid in the prevention and therapy of intrauterine 
      growth retardation].
PG  - 9-11
AB  - The authors recommend, based on their own experience, an optimal dose of 
      acetylsalicylic acid in treatment of IUGR. The therapeutic effect was not proved 
      conclusively and views are controversial. Based on a retrospective group from the 
      years 1993, 1994 and 1995 the authors assume that treatment of IUGR by 
      acetylsalicylic acid is indicated and they recommend a dose of 100 mg per day 
      (e.g. one tablet of Anopyrin).
FAU - Burnog, T
AU  - Burnog T
AD  - II. Gynek.-porod. klinika LF MU, Brno.
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Dávkování kyseliny acetylsalicylové v prevenci a terapii nitrodĕlozní růstové 
      retardace.
PL  - Czech Republic
TA  - Ceska Gynekol
JT  - Ceska gynekologie
JID - 9423768
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - Fetal Growth Retardation/*drug therapy/*prevention & control
MH  - Humans
MH  - Pregnancy
MH  - Retrospective Studies
EDAT- 1997/02/01 00:00
MHDA- 1997/12/31 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1997/12/31 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
PST - ppublish
SO  - Ceska Gynekol. 1997 Feb;62(1):9-11.

PMID- 94874
OWN - NLM
STAT- MEDLINE
DCOM- 19800815
LR  - 20131121
IS  - 0323-4347 (Print)
IS  - 0323-4347 (Linking)
VI  - 106
IP  - 5-6
DP  - 1979
TI  - [Effect of ASS on platelet function in experimental DIC].
PG  - 828-33
AB  - In thrombin-induced DIC, acetylsalicylic acid (ASA) prevents the strong initial 
      fall in platelet count and the obturation of the microvasculature of the lung 
      with platelet aggregates. During the DIC reaction increasing inhibition of 
      aggregability of circulating platelets against collagen and ADP is observed. 
      Furthermore, ASA prevents the increase in the plasma haemoglobin level caused by 
      DIC.
FAU - Nowak, G
AU  - Nowak G
FAU - Glusa, E
AU  - Glusa E
FAU - Hoffmann, A
AU  - Hoffmann A
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Einfluss von ASS auf die Plättchenfunktion bei der experimentellen DIC.
PL  - Germany
TA  - Folia Haematol Int Mag Klin Morphol Blutforsch
JT  - Folia haematologica (Leipzig, Germany : 1928)
JID - 0374615
RN  - 0 (Antifibrinolytic Agents)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antifibrinolytic Agents
MH  - Aspirin/*therapeutic use
MH  - Disseminated Intravascular Coagulation/chemically induced/*drug therapy
MH  - Female
MH  - Fibrinolysis/drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Premedication
MH  - Rats
MH  - Thrombin
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):828-33.

PMID- 22382478
OWN - NLM
STAT- MEDLINE
DCOM- 20120613
LR  - 20190101
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 69
IP  - 6
DP  - 2012 Mar 15
TI  - The role of mucoregulatory agents after continence-preserving urinary diversion 
      surgery.
PG  - 483-6
LID - 10.2146/ajhp110212 [doi]
AB  - PURPOSE: The postsurgical use of N-acetylcysteine, octreotide, and other agents 
      to reduce mucus accumulation after urinary diversion procedures is described. 
      SUMMARY: Patients undergoing continence-sparing bladder resection are at risk for 
      infection and stone formation due to mucus accumulation. In addition to 
      N-acetylcysteine, agents studied for mucoregulatory control in such patients 
      include aspirin, urea, ranitidine, and octreotide. N-acetylcysteine has high 
      mucolytic activity in vitro, and positive outcomes with instillations of 20% 
      N-acetylcysteine solution have been reported in some patients. Significant mucus 
      reductions were reported in small numbers of patients treated with oral 
      ranitidine 300 mg daily or instillations of 30 mL of urea 40% solution, while the 
      benefits of aspirin are more questionable. To date, there has been only one 
      randomized controlled trial comparing various agents for mucus reduction after 
      reconstructive bladder surgery; the results indicated no significant benefits 
      with the use of N-acetylcysteine, aspirin, or ranitidine. In one small study (n = 
      40), the use of subcutaneous octreotide immediately before and for 15 days after 
      surgery was reported to yield significant reductions in mucus production, the 
      need for bladder irrigation to clear blockages, and the mean duration of hospital 
      stays. CONCLUSION: Various agents evaluated for mucus control after urinary 
      diversion procedures (oral ranitidine or aspirin, N-acetylcysteine or urea 
      instillations, and subcutaneous octreotide), while reportedly effective for some 
      patients, remain of questionable benefit. More research is needed to define the 
      optimal role of these agents for this indication.
FAU - Covert, Wendy M
AU  - Covert WM
AD  - Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, 
      77030, USA. wmcovert@mdanderson.org
FAU - Westin, Shannon N
AU  - Westin SN
FAU - Soliman, Pamela T
AU  - Soliman PT
FAU - Langley, Ginger D
AU  - Langley GD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Expectorants)
RN  - 0 (Gastrointestinal Agents)
RN  - 884KT10YB7 (Ranitidine)
RN  - 8W8T17847W (Urea)
RN  - R16CO5Y76E (Aspirin)
RN  - RWM8CCW8GP (Octreotide)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Expectorants/therapeutic use
MH  - Gastrointestinal Agents/therapeutic use
MH  - Humans
MH  - Length of Stay
MH  - Mucus/*drug effects/metabolism
MH  - Octreotide/*therapeutic use
MH  - Ranitidine/therapeutic use
MH  - Urea/therapeutic use
MH  - Urinary Diversion/*methods
EDAT- 2012/03/03 06:00
MHDA- 2012/06/14 06:00
CRDT- 2012/03/03 06:00
PHST- 2012/03/03 06:00 [entrez]
PHST- 2012/03/03 06:00 [pubmed]
PHST- 2012/06/14 06:00 [medline]
AID - 69/6/483 [pii]
AID - 10.2146/ajhp110212 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2012 Mar 15;69(6):483-6. doi: 10.2146/ajhp110212.

PMID- 8227723
OWN - NLM
STAT- MEDLINE
DCOM- 19931215
LR  - 20190825
IS  - 0342-4642 (Print)
IS  - 0342-4642 (Linking)
VI  - 19
IP  - 6
DP  - 1993
TI  - Effects of ketoprofen on respiratory and circulatory changes in endotoxic shock.
PG  - 333-9
AB  - OBJECTIVE: To study the effects of ketoprofen, a dual inhibitor of the 
      arachidonic acid metabolism, on hemodynamic and respiratory changes during 
      endotoxic shock. DESIGN: Prospective, randomised, controlled study using an 
      established intact animal model of endotoxic shock in sheep. SETTING: An animal 
      laboratory in a university hospital. INTERVENTIONS: 4 groups were studied (n = 7 
      in each). Group K received ketoprofen and group A received aspirin 30 min before 
      start of endotoxin infusion. Group E received endotoxin, but no drug treatment. 
      Group C received neither endotoxin nor drug treatment. All the animals were 
      anaesthetised with ketamine, had controlled ventilation with FiO2 = 0.5 and 
      received Ringer's lactate at an infusion rate that would keep the pulmonary 
      capillary wedge pressure constant. RESULTS: Both ketoprofen and aspirin prevented 
      the early rise in pulmonary arterial pressure that occurred in group E a few 
      minutes after start of i.v. infusion of endotoxin. Furthermore, ketoprofen 
      prevented any significant changes in arterial blood pressure, arterial oxygen 
      tension, oxygen delivery index, oxygen extraction ratio, respiratory compliance, 
      intrapulmonary shunt fraction, and platelet counts that occurred in group E. 
      Aspirin, on the other hand, provided only partial and time limited (1-2 h) 
      protection against these changes. Wet-to-dry weight ratios of the lungs were 
      significantly lower in the ketoprofen treated than in the untreated shock 
      controls and the aspirin treated animals. CONCLUSION: Ketoprofen completely 
      prevented the changes in hemodynamics and respiratory function observed in 
      control-endotoxin-treated animals.
FAU - Sigurdsson, G H
AU  - Sigurdsson GH
AD  - Department of Anaesthesia and Intensive Care, University of Berne, Inselspital, 
      Switzerland.
FAU - Youssef, H A
AU  - Youssef HA
FAU - Banic, A
AU  - Banic A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Intensive Care Med
JT  - Intensive care medicine
JID - 7704851
RN  - 0 (Endotoxins)
RN  - 142M471B3J (Carbon Dioxide)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Circulation/*drug effects
MH  - Carbon Dioxide/blood
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Endotoxins/administration & dosage
MH  - Escherichia coli
MH  - Hemodynamics/drug effects
MH  - Ketoprofen/*pharmacology/therapeutic use
MH  - Oxygen/blood
MH  - Prospective Studies
MH  - Random Allocation
MH  - Respiration/*drug effects
MH  - Sheep
MH  - Shock, Septic/blood/drug therapy/etiology/*physiopathology
MH  - Time Factors
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1007/BF01694707 [doi]
PST - ppublish
SO  - Intensive Care Med. 1993;19(6):333-9. doi: 10.1007/BF01694707.

PMID- 2901909
OWN - NLM
STAT- MEDLINE
DCOM- 19881114
LR  - 20131121
IS  - 0733-8651 (Print)
IS  - 0733-8651 (Linking)
VI  - 6
IP  - 1
DP  - 1988 Feb
TI  - Medical prophylaxis for the post myocardial infarct patient.
PG  - 173-8
AB  - The use of beta-adrenergic blocking drugs has been shown to benefit many post 
      myocardial infarction patients. Aspirin is useful for secondary prevention and a 
      subset of patients may benefit from short term anticoagulation.
FAU - Cohen, L S
AU  - Cohen LS
AD  - Yale University School of Medicine, New Haven, Connecticut.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cardiol Clin
JT  - Cardiology clinics
JID - 8300331
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anticoagulants)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Calcium Channel Blockers/therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Recurrence
RF  - 15
EDAT- 1988/02/01 00:00
MHDA- 1988/02/01 00:01
CRDT- 1988/02/01 00:00
PHST- 1988/02/01 00:00 [pubmed]
PHST- 1988/02/01 00:01 [medline]
PHST- 1988/02/01 00:00 [entrez]
PST - ppublish
SO  - Cardiol Clin. 1988 Feb;6(1):173-8.

PMID- 838518
OWN - NLM
STAT- MEDLINE
DCOM- 19770425
LR  - 20190816
IS  - 0020-5915 (Print)
IS  - 0020-5915 (Linking)
VI  - 53
IP  - 1
DP  - 1977
TI  - Failure to demonstrate involvement of prostaglandins in the immune expulsion of 
      Trichostrongylus colubriformis from the intestine of guinea pigs.
PG  - 93-5
AB  - The intraduodenal injection of synthetic prostaglandins did not lead to the 
      expulsion of Trichostrongylus colubriformis from the intestine of guinea pigs. 
      Treatment of immune guinea pigs with aspirin and indomethacin failed to inhibit 
      the expulsion of a challenge infection with this nematode. These results suggest 
      that in this infection, unlike Nippostrongylus brasiliensis infection in the rat, 
      prostaglandins do not play an important role in the immune expulsion of the 
      parasite from the intestine.
FAU - Rothwell, T L
AU  - Rothwell TL
FAU - Love, R J
AU  - Love RJ
FAU - Goodrich, B S
AU  - Goodrich BS
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int Arch Allergy Appl Immunol
JT  - International archives of allergy and applied immunology
JID - 0404561
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Guinea Pigs
MH  - Indomethacin/pharmacology
MH  - Intestines/*microbiology
MH  - Prostaglandins/*pharmacology
MH  - Trichostrongyloidiasis/*immunology
MH  - Trichostrongylosis/*immunology
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1159/000231736 [doi]
PST - ppublish
SO  - Int Arch Allergy Appl Immunol. 1977;53(1):93-5. doi: 10.1159/000231736.

PMID- 16888270
OWN - NLM
STAT- MEDLINE
DCOM- 20060921
LR  - 20161122
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 37
IP  - 9
DP  - 2006 Sep
TI  - Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid 
      hemorrhage: the MASH Study.
PG  - 2326-30
AB  - BACKGROUND AND PURPOSE: A previous systematic review of randomized trials 
      suggested a positive effect of antiplatelet therapy in patients with aneurysmal 
      subarachnoid hemorrhage (SAH). We performed a randomized controlled trial to 
      assess whether acetylsalicylic acid (ASA) reduces the risk of delayed ischemic 
      neurological deficit (DIND) in patients with SAH. METHODS: Criteria for inclusion 
      were aneurysm treatment within 4 days after SAH. Trial medication (14 daily 
      suppositories with 100 mg ASA or placebo) was started within 12 hours after 
      aneurysm treatment. Analysis for the primary outcome event DIND was made 
      according to the "on-treatment" principle and for the secondary outcome measures 
      "poor outcome" and "nonexcellent outcome" according to the "intention-to-treat" 
      principle. RESULTS: Inclusion was stopped after the second interim analysis, when 
      161 of the planned 200 patients were included, because by then the chances of a 
      positive effect were negligible. At the final analysis, ASA did not reduce the 
      risk of DIND (hazard ratio, 1.83; 95% CI, 0.85 to 3.9). The relative risk 
      reduction for poor outcome was 21% (relative risk, 0.79; 95% CI, 0.38 to 1.6). 
      CONCLUSIONS: ASA given after aneurysm treatment does not appreciably reduce the 
      occurrence of DIND.
FAU - van den Bergh, Walter M
AU  - van den Bergh WM
AD  - MASH Study, The Netherlands. w.m.vandenbergh@umcutrecht.nl
CN  - MASH Study Group
FAU - Algra, A
AU  - Algra A
FAU - Dorhout Mees, S M
AU  - Dorhout Mees SM
FAU - van Kooten, F
AU  - van Kooten F
FAU - Dirven, C M F
AU  - Dirven CM
FAU - van Gijn, J
AU  - van Gijn J
FAU - Vermeulen, M
AU  - Vermeulen M
FAU - Rinkel, G J E
AU  - Rinkel GJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20060803
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aneurysm, Ruptured/*complications/therapy
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Intracranial Aneurysm/*complications/therapy
MH  - Male
MH  - Middle Aged
MH  - Nervous System Diseases/etiology/*prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Subarachnoid Hemorrhage/complications/*drug therapy/etiology
MH  - Time Factors
MH  - Treatment Failure
EDAT- 2006/08/05 09:00
MHDA- 2006/09/22 09:00
CRDT- 2006/08/05 09:00
PHST- 2006/08/05 09:00 [pubmed]
PHST- 2006/09/22 09:00 [medline]
PHST- 2006/08/05 09:00 [entrez]
AID - 01.STR.0000236841.16055.0f [pii]
AID - 10.1161/01.STR.0000236841.16055.0f [doi]
PST - ppublish
SO  - Stroke. 2006 Sep;37(9):2326-30. doi: 10.1161/01.STR.0000236841.16055.0f. Epub 
      2006 Aug 3.

PMID- 16378514
OWN - NLM
STAT- MEDLINE
DCOM- 20060207
LR  - 20190728
IS  - 1381-6128 (Print)
IS  - 1381-6128 (Linking)
VI  - 11
IP  - 31
DP  - 2005
TI  - Artificial O2 carriers: status in 2005.
PG  - 4099-114
AB  - Donor blood is a limited resource and its transfusion is associated with 
      significant adverse effects. Therefore, alternatives have been searched, the 
      ultimate being artificial oxygen (O2) carriers. There are two main groups of 
      artificial O2 carriers: hemoglobin based and perfluorocarbon emulsions. The 
      hemoglobin molecule in hemoglobin based artificial O2 carriers needs to be 
      stabilized to prevent dissociation of the alpha2beta2-hemoglobin tetramer into 
      alphabeta-dimers in order to prolong intravascular retention and to eliminate 
      nephrotoxicity. Other modifications serve to decrease O2 affinity in order to 
      improve O2 off-loading to tissues. In addition, polyethylene glycol may be 
      surface conjugated to increase molecular size. Finally, certain products are 
      polymerized to increase the hemoglobin concentration at physiologic colloid 
      oncotic pressure. Perfluorocarbons are carbon-fluorine compounds characterized by 
      a high gas dissolving capacity for O2 and CO2 and chemical and biologic 
      inertness. Perfluorocarbons are not miscible with water and therefore need to be 
      brought into emulsion for intravenous application. Development, product 
      specification, physiologic effects, efficacy to decrease the need for donor blood 
      in surgery and side effects of the following products are described: Diaspirin 
      cross-linked hemoglobin (HemAssist), human recombinant hemoglobin (rHb1.1 and 
      rHb2.0), polymerized bovine hemoglobin-based O2 carrier (HBOC-201), human 
      polymerized hemoglobin (PolyHeme), hemoglobin raffimer (Hemolink), 
      maleimide-activated polyethylene glycol-modified hemoglobin (MP4) and perflubron 
      emulsion (Oxygent). In addition, enzyme cross-linked poly-hemoglobin, hemoglobin 
      containing vesicles (nano-dimension artificial red blood cells) and an allosteric 
      modifier (RSR13) are discussed. The most advanced products are in clinical phase 
      III trials but no product has achieved market approval yet in the US, Europe or 
      Canada.
FAU - Spahn, Donat R
AU  - Spahn DR
AD  - Department of Anesthesiology, University Hospital Lausanne, CH - 1011 Lausanne, 
      Switzerland. donat.spahn@chuv.hospvd.ch
FAU - Kocian, Roman
AU  - Kocian R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Blood Substitutes)
RN  - 0 (Fluorocarbons)
RN  - 0 (Hemoglobins)
RN  - 0 (Liposomes)
RN  - 0 (Maleimides)
RN  - 0 (O-raffinose cross-linked human hemoglobin)
RN  - 0 (Polymers)
RN  - 0 (Recombinant Proteins)
RN  - 0 (maleimide-polyethylene glycol-modified hemoglobin, MP4)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - N5O3QU595M (Raffinose)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Allosteric Regulation
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Blood Substitutes/*pharmacology/therapeutic use
MH  - Erythrocyte Transfusion
MH  - Fluorocarbons/pharmacology
MH  - Hemoglobins/*pharmacology/therapeutic use
MH  - Humans
MH  - Liposomes
MH  - Maleimides/pharmacology
MH  - Nanotechnology
MH  - Oxygen/*administration & dosage/pharmacokinetics
MH  - Polyethylene Glycols/pharmacology
MH  - Polymers
MH  - Raffinose/analogs & derivatives/pharmacology
MH  - Recombinant Proteins/pharmacology
RF  - 190
EDAT- 2005/12/28 09:00
MHDA- 2006/02/08 09:00
CRDT- 2005/12/28 09:00
PHST- 2005/12/28 09:00 [pubmed]
PHST- 2006/02/08 09:00 [medline]
PHST- 2005/12/28 09:00 [entrez]
AID - 10.2174/138161205774913354 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2005;11(31):4099-114. doi: 10.2174/138161205774913354.

PMID- 12198588
OWN - NLM
STAT- MEDLINE
DCOM- 20021219
LR  - 20181130
IS  - 0948-2393 (Print)
IS  - 0948-2393 (Linking)
VI  - 206
IP  - 4
DP  - 2002 Jul-Aug
TI  - [Prevention of pre-eclampsia by low-dose acetylsalicylic acid--a critical 
      appraisal].
PG  - 125-30
AB  - Pre-eclampsia has been shown to be associated with platelet activation and 
      excessive release of vasoconstricting thromboxane preceding the onset of the 
      disease. Low-dose acetylsalicylic acid (ASA) substantially inhibits thromboxane 
      formation and may thus prevent pre-eclampsia from developing. In agreement with 
      this hypothesis early randomised trials reported on promising reductions in 
      pre-eclampsia risk and possible fetal growth retardation. Subsequent multicentre 
      trials during the nineties failed to confirm a large benefit, which may in part 
      be explained by late initiation of treatment, low dosages, low patient compliance 
      and wide inclusion of women with concomitant disorders such as chronic 
      hypertension, diabetes mellitus and kidney disease. A recent systematic review of 
      all randomised trials showed an acceptable safety profile and a significant but 
      only moderate reduction in the risk of pre-eclampsia regardless of gestation at 
      trial entry or dose of ASA. There is now growing evidence that the earlier ASA 
      treatment is started, the greater the reduction in the risk of pre-eclampsia is. 
      Moreover, ASA has much stronger effects at higher (80 - 150 mg/day) than at lower 
      doses in the protection against pre-eclampsia and the prevention of severe fetal 
      growth retardation. No clinically important effects, however, have been found in 
      patients with chronic hypertension, kidney disease or diabetes mellitus. In 
      contrast, low dose ASA (100 mg/day) might benefit women with unfavourable 
      obstetric history, in particular those with severe fetal growth retardation or 
      pre-eclampsia with onset at < 32 weeks. The crucial time for starting treatment 
      may be before 16 weeks and daily ingestion before bedtime appears useful. To 
      start low-dose ASA at 20 - 24 weeks gestation seems only justified in women with 
      abnormal uterine Doppler flow.
FAU - Klockenbusch, W
AU  - Klockenbusch W
AD  - Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe des 
      Universitätsklinikums Münster, Germany. wklocken@uni-muenster.de
FAU - Rath, W
AU  - Rath W
LA  - ger
PT  - Journal Article
PT  - Review
PT  - Systematic Review
TT  - Prävention der Präeklampsie mit Acetylsalicylsäure - eine kritische Analyse.
PL  - Germany
TA  - Z Geburtshilfe Neonatol
JT  - Zeitschrift fur Geburtshilfe und Neonatologie
JID - 9508901
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Fetal Growth Retardation/blood/prevention & control
MH  - Humans
MH  - Infant, Newborn
MH  - Multicenter Studies as Topic
MH  - Platelet Activation/drug effects
MH  - Pre-Eclampsia/blood/*prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Thromboxanes/blood
RF  - 39
EDAT- 2002/08/29 10:00
MHDA- 2002/12/20 04:00
CRDT- 2002/08/29 10:00
PHST- 2002/08/29 10:00 [pubmed]
PHST- 2002/12/20 04:00 [medline]
PHST- 2002/08/29 10:00 [entrez]
AID - 10.1055/s-2002-33667 [doi]
PST - ppublish
SO  - Z Geburtshilfe Neonatol. 2002 Jul-Aug;206(4):125-30. doi: 10.1055/s-2002-33667.

PMID- 9016440
OWN - NLM
STAT- MEDLINE
DCOM- 19970228
LR  - 20181130
IS  - 0898-4921 (Print)
IS  - 0898-4921 (Linking)
VI  - 9
IP  - 1
DP  - 1997 Jan
TI  - Hypervolemic-hemodilution during cerebral ischemia in rats: effect of diaspirin 
      cross-linked hemoglobin (DCLHb) on neurologic outcome and infarct volume.
PG  - 44-50
AB  - In a rat model of middle cerebral artery occlusion (MCAo) and reperfusion (120 
      min), previous studies have demonstrated that hemodilution with molecular 
      hemoglobin decreases ischemic brain injury. However, long-term recovery data on 
      the therapeutic efficacy of molecular hemoglobin for cerebral ischemia are 
      lacking. Accordingly, we assessed the effect of hemodilution, with alpha-alpha 
      diaspirin cross-linked hemoglobin (DCLHb, 10 g/dl) on neurologic outcome and 
      infarct volume after 120 min of MCAo and 72 h of reperfusion. Ischemia was 
      achieved by passing a 0.26-mm suture, via the external carotid artery, to 
      internally occlude the middle cerebral artery. Immediately after MCAo, the rats 
      were randomized to one of the following groups: Control-hematocrit not 
      manipulated (44%); 30/Hct-hematocrit maintained at 30% with DCLHb; or 
      16/Hct-hematocrit maintained at 16% with DCLHb. After 120 min of MCAo, the suture 
      was removed and the rats allowed to recover. Daily neurologic examinations were 
      performed, and after 72 h, the brains were analyzed for infarct volume with TTC 
      stain. Infarct volume (mm3) was less in the 30/Hct group (67 +/- 10; mean +/- SD) 
      than in the Control group (141 +/- 17); and less in the 16/Hct group (40 +/- 12) 
      than the other two groups (p < 0.05). Neurologic outcome was improved in both 
      hemodilution groups versus the Control group (p < 0.05). These data are 
      consistent with previous studies, performed in a model of short-term reperfusion, 
      which indicate a dose-dependent decrease in ischemic injury by DCLHb.
FAU - Cole, D J
AU  - Cole DJ
AD  - Department of Anesthesiology, Loma Linda University, CA 92161, USA.
FAU - Drummond, J C
AU  - Drummond JC
FAU - Patel, P M
AU  - Patel PM
FAU - Reynolds, L R
AU  - Reynolds LR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Neurosurg Anesthesiol
JT  - Journal of neurosurgical anesthesiology
JID - 8910749
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Substitutes/*pharmacology
MH  - *Blood Volume
MH  - Carotid Artery, External
MH  - Cerebral Arteries
MH  - Cerebral Infarction/etiology/physiopathology/*therapy
MH  - Hematocrit
MH  - *Hemodilution
MH  - Hemoglobins/*pharmacology
MH  - Humans
MH  - Ischemic Attack, Transient/*physiopathology/therapy
MH  - Male
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Reperfusion
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - J Neurosurg Anesthesiol. 1997 Jan;9(1):44-50.

PMID- 30079702
OWN - NLM
STAT- MEDLINE
DCOM- 20190730
LR  - 20200309
IS  - 2146-3131 (Electronic)
IS  - 2146-3123 (Print)
IS  - 2146-3123 (Linking)
VI  - 36
IP  - 1
DP  - 2019 Jan 1
TI  - The Prevalence and Risks of Inappropriate Combination of Aspirin and Warfarin in 
      Clinical Practice: Results From WARFARIN-TR Study.
PG  - 17-22
LID - 10.4274/balkanmedj.2017.1472 [doi]
AB  - BACKGROUND: The use of warfarin and aspirin in combination is restricted to 
      limited patients under relevant guidelines. AIMS: To evaluate the prevalence of 
      the inappropriate combination of aspirin and warfarin therapy in daily practice 
      and its risks. STUDY DESIGN: Cross-sectional study. METHODS: The awareness, 
      efficacy, safety, and time in the therapeutic range of warfarin in the Turkish 
      population study is a multi-center observational study that includes 4987 
      patients using warfarin for any reason between January 1, 2014, and December 31, 
      2014. To determine the prevalence of inappropriate combination use in daily 
      practice, all patients who had a history of atherosclerotic disease (ischemic 
      heart disease, peripheral artery disease) or cerebrovascular disease (n=1498) 
      were excluded. The data of 3489 patients were analyzed. We defined inappropriate 
      combination as all patients who received aspirin and warfarin regardless of the 
      indication for warfarin use, under the direction of the European Society of 
      Cardiology guideline recommendation. RESULTS: The mean age of patients was 
      59.2±13.8 years (41.8% male). The prevalence of the inappropriate use of warfarin 
      and aspirin combination was 20.0%. The prevalence of combination therapy in 
      patients with a primary indication for mechanical heart valve, non-valvular 
      atrial fibrillation, and other reasons was 20.5%, 18.7%, and 21.0%, respectively. 
      Multivariate logistic regression analysis revealed that age (odds ratio, 1.009; 
      95% confidence interval, 1.002-1.015; p=0.010), heart failure (odds ratio, 1.765; 
      95% confidence interval, 1.448-2.151; p<0.001), smoking (odds ratio, 1.762; 95% 
      confidence interval, 1.441-1.153; p<0.010), chronic kidney disease (odds ratio, 
      2.057; 95% confidence interval, 1.494-2.833; p<0.001), and deep vein thrombosis 
      (odds ratio, 0.463; 95% confidence interval, 0.229-0.718; p=0.001) were 
      independent predictors of combination therapy (r2=0.66). The mean time in 
      therapeutic range of patients receiving combination therapy was significantly 
      lower than in those on warfarin monotherapy (51.6±27.05 vs. 54.7±23.93; p=0.006). 
      Overall, 19.4% (n=677) of patients had a bleeding event (major bleeding 13.0%, 
      n=88) within a year. Percentages of patients with combination therapy were 
      significantly higher in patients with major bleeding than in patients without 
      major bleeding (29.5% vs. 19.7%; p=0.023). CONCLUSION: Our study demonstrated 
      that 20.0% of patients taking warfarin use concomitant aspirin inappropriately in 
      daily practice. Patients receiving aspirin with warfarin were demonstrated to 
      have more comorbidities, lower time in therapeutic range levels, and higher 
      bleeding rates.
FAU - Kılıç, Salih
AU  - Kılıç S
AUID- ORCID: 0000-0002-3579-3747
AD  - Department of Cardiology, Ege University School of Medicine, İzmir, Turkey
FAU - Çelik, Ahmet
AU  - Çelik A
AD  - Department of Cardiology, Mersin University School of Medicine, Mersin, Turkey
FAU - Çekirdekçi, Elif
AU  - Çekirdekçi E
AD  - Clinic of Cardiology, Tekirdağ Çorlu District State Hospital, Tekirdağ, Turkey
FAU - Altay, Servet
AU  - Altay S
AUID- ORCID: 0000-0001-7112-3970
AD  - Clinic of Cardiology, Edirne Sultan Murat 1. State Hospital, Edirne, Turkey
FAU - Elçik, Deniz
AU  - Elçik D
AUID- ORCID: 0000-0003-0992-1415
AD  - Clinic of Cardiology, Ankara Research and Training Hospital, Ankara, Turkey
FAU - Akboğa, Mehmet Kadri
AU  - Akboğa MK
AD  - Clinic of Cardiology, Türkiye Yüksek İhtisas Hospital, Ankara, Turkey
FAU - Durukan, Mine
AU  - Durukan M
AD  - Clinic of Cardiology, Mersin City Research and Training Hospital, Mersin, Turkey
FAU - Yayla, Çağrı
AU  - Yayla Ç
AD  - Clinic of Cardiology, Türkiye Yüksek İhtisas Hospital, Ankara, Turkey
FAU - Zoghi, Mehdi
AU  - Zoghi M
AD  - Department of Cardiology, Ege University School of Medicine, İzmir, Turkey
LA  - eng
PT  - Journal Article
DEP - 20180806
PL  - Turkey
TA  - Balkan Med J
JT  - Balkan medical journal
JID - 101571817
RN  - 0 (Anticoagulants)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
CIN - Balkan Med J. 2019 Jun 14;36(4):255-255. PMID: 31199092
CIN - Balkan Med J. 2019 Jul 11;36(4):256-256. PMID: 31291706
MH  - Aged
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Atrial Fibrillation/drug therapy
MH  - Cross-Sectional Studies
MH  - *Drug Combinations
MH  - Female
MH  - Heart Failure/drug therapy
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Prevalence
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
MH  - Turkey
MH  - Warfarin/*adverse effects/therapeutic use
PMC - PMC6335934
OTO - NOTNLM
OT  - Anticoagulants
OT  - antiplatelet drugs
OT  - aspirin
OT  - inappropriate prescribings
OT  - Warfarin
COIS- Conflict of Interest: No conflict of interest was declared by the authors.
EDAT- 2018/08/07 06:00
MHDA- 2019/07/31 06:00
CRDT- 2018/08/07 06:00
PHST- 2018/08/07 06:00 [entrez]
PHST- 2018/08/07 06:00 [pubmed]
PHST- 2019/07/31 06:00 [medline]
AID - 21311 [pii]
AID - 10.4274/balkanmedj.2017.1472 [doi]
PST - ppublish
SO  - Balkan Med J. 2019 Jan 1;36(1):17-22. doi: 10.4274/balkanmedj.2017.1472. Epub 
      2018 Aug 6.

PMID- 15979865
OWN - NLM
STAT- MEDLINE
DCOM- 20060120
LR  - 20131121
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 73
IP  - 3-4
DP  - 2005 Sep-Oct
TI  - Lipoxins and aspirin-triggered lipoxins in neutrophil adhesion and signal 
      transduction.
PG  - 257-62
AB  - Lipoxin A4 (LXA4) and aspirin-triggered 15-epi-LXA4 (ATL) are emerging as 
      endogenous braking signals for neutrophil-mediated tissue injury. LXA4 and ATL 
      and their metabolically stable analogues display potent inhibitory actions in 
      human isolated cells and blood, including attenuation of expression of adhesion 
      molecules on leukocytes and endothelial cells, neutrophil adhesion to endothelial 
      cells and platelets under shear, and IL-8 production, key events of the acute 
      inflammatory response. The underlying molecular mechanisms include interference 
      with MAPK signaling pathways, modulation of the oxidative chemistry of 
      superoxide, NO and ONOO-, inhibition of activation of NF-kappaB and AP-1, and 
      consequently the expression of interleukin-8 and likely other pro-inflammatory 
      genes. Collectively, these results add to the profile of LXA4/ATL rapid actions 
      that contribute to "stop signaling" involved in regulating neutrophil functions 
      during acute inflammation and suggest that aspirin inhibits neutrophil 
      accumulation through triggering the synthesis of 15-epi-LXA4.
FAU - Filep, János G
AU  - Filep JG
AD  - Research Center, Maisonneuve-Rosemont Hospital, University of Montreal, 5415 
      boulevard de l'Assomption, Montreal, Que., Canada H1T 2M4. 
      janos.g.filep@umontreal.ca
FAU - Khreiss, Tarek
AU  - Khreiss T
FAU - József, Levente
AU  - József L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - 14691-52-2 (Peroxynitrous Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/pharmacology
MH  - Cell Adhesion/physiology
MH  - Humans
MH  - Inflammation/physiopathology
MH  - Lipoxins/*physiology
MH  - Neutrophil Activation/physiology
MH  - Neutrophils/*physiology
MH  - Peroxynitrous Acid/physiology
MH  - Signal Transduction/*physiology
RF  - 46
EDAT- 2005/06/28 09:00
MHDA- 2006/01/21 09:00
CRDT- 2005/06/28 09:00
PHST- 2005/06/28 09:00 [pubmed]
PHST- 2006/01/21 09:00 [medline]
PHST- 2005/06/28 09:00 [entrez]
AID - S0952-3278(05)00092-X [pii]
AID - 10.1016/j.plefa.2005.05.014 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):257-62. doi: 
      10.1016/j.plefa.2005.05.014.

PMID- 27534608
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20220311
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 44
IP  - 8
DP  - 2016 Oct
TI  - Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 
      selective inhibitors with concomitant use of low-dose aspirin.
PG  - 785-95
LID - 10.1111/apt.13776 [doi]
AB  - BACKGROUND: It is uncertain whether concurrent use of low-dose aspirin removes 
      the gastrointestinal benefit displayed by COX-2 selective inhibitors (coxibs) 
      when compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs). AIM: 
      To evaluate the gastrointestinal risks associated with coxibs and traditional 
      NSAIDs and the interaction with concurrent use of low-dose aspirin. METHODS: We 
      searched MEDLINE, EMBASE and the Cochrane Library through April 2016 to identify 
      randomised trials comparing the gastrointestinal risk between coxibs and 
      traditional NSAIDs in patients taking or not taking low-dose aspirin. Results 
      were combined using random effects meta-analysis. Subgroup analyses by concurrent 
      use of aspirin were undertaken. RESULTS: Eleven trials (84 150 participants) were 
      included. The overall relative risk (RR) of coxibs vs. traditional NSAIDs for 
      complicated gastrointestinal events was 0.54 (95% CI, confidence interval 
      0.32-0.92), with a significant subgroup difference (P = 0.04) according to 
      concurrent use of aspirin (used: RR = 0.96, 95% CI 0.66-1.24; not used: RR = 
      0.33, 95% CI 0.14-0.83). The overall RR for clinical gastrointestinal events was 
      0.59 (95% CI 0.47-0.75), with a significant subgroup difference according to 
      aspirin usage (P = 0.008; used: RR = 0.77, 95% CI 0.62-0.95; not used: RR = 0.50, 
      95% CI 0.39-0.64). Overall coxibs were associated with significantly lower risk 
      of symptomatic ulcers (RR = 0.60, 95% CI 0.50-0.72) and endoscopic ulcers (RR = 
      0.29, 95% CI 0.16-0.53) than traditional NSAIDs; a significant subgroup 
      difference was shown for endoscopic ulcers (P = 0.05) but not for symptomatic 
      ulcers (P = 0.27). CONCLUSION: Concomitant use of low-dose aspirin reduces but 
      does not completely eliminate the gastrointestinal benefit of coxibs over 
      traditional NSAIDs.
CI  - © 2016 John Wiley & Sons Ltd.
FAU - Yuan, J Q
AU  - Yuan JQ
AD  - School of Public Health and Primary Care, Faculty of Medicine, The Chinese 
      University of Hong Kong, Hong Kong.
AD  - Municipal Key Laboratory for Health Risk Analysis, Shenzhen Research Institute of 
      the Chinese University of Hong Kong, Shenzhen, Guangdong, China.
AD  - School of Social and Community Medicine, University of Bristol, Bristol, UK.
FAU - Yang, M
AU  - Yang M
AD  - Department of Gastroenterology, Songgang Hospital, Shenzhen, Guangdong, China.
FAU - Threapleton, D E
AU  - Threapleton DE
AD  - School of Public Health and Primary Care, Faculty of Medicine, The Chinese 
      University of Hong Kong, Hong Kong.
FAU - Qi, X S
AU  - Qi XS
AD  - Department of Gastroenterology, General Hospital of Shenyang Military Region, 
      Liaoning, China.
FAU - Ye, D Q
AU  - Ye DQ
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Anhui 
      Medical University, Hefei, Anhui, China.
FAU - Mao, C
AU  - Mao C
AD  - School of Public Health and Primary Care, Faculty of Medicine, The Chinese 
      University of Hong Kong, Hong Kong. maochen@cuhk.edu.hk.
AD  - Municipal Key Laboratory for Health Risk Analysis, Shenzhen Research Institute of 
      the Chinese University of Hong Kong, Shenzhen, Guangdong, China. 
      maochen@cuhk.edu.hk.
FAU - Tang, J L
AU  - Tang JL
AD  - School of Public Health and Primary Care, Faculty of Medicine, The Chinese 
      University of Hong Kong, Hong Kong. jltang@cuhk.edu.hk.
AD  - Municipal Key Laboratory for Health Risk Analysis, Shenzhen Research Institute of 
      the Chinese University of Hong Kong, Shenzhen, Guangdong, China. 
      jltang@cuhk.edu.hk.
FAU - Higgins, J P T
AU  - Higgins JP
AD  - School of Social and Community Medicine, University of Bristol, Bristol, UK.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160817
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cyclooxygenase 2 Inhibitors/*administration & dosage/adverse effects
MH  - Gastrointestinal Diseases/epidemiology
MH  - Humans
MH  - Randomized Controlled Trials as Topic
EDAT- 2016/08/19 06:00
MHDA- 2017/08/23 06:00
CRDT- 2016/08/19 06:00
PHST- 2016/06/02 00:00 [received]
PHST- 2016/06/19 00:00 [revised]
PHST- 2016/07/22 00:00 [revised]
PHST- 2016/08/01 00:00 [revised]
PHST- 2016/08/01 00:00 [accepted]
PHST- 2016/08/19 06:00 [entrez]
PHST- 2016/08/19 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
AID - 10.1111/apt.13776 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2016 Oct;44(8):785-95. doi: 10.1111/apt.13776. Epub 2016 
      Aug 17.

PMID- 7795149
OWN - NLM
STAT- MEDLINE
DCOM- 19950731
LR  - 20190913
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 6
IP  - 1
DP  - 1995 Feb
TI  - Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and 
      bleeding episodes in patients with coronary artery disease.
PG  - 17-22
AB  - The long-term effects of fish-oil supplementation on haemostatic parameters and 
      bleeding episodes were investigated in patients undergoing coronary artery bypass 
      surgery. They were investigated before and 9 months after the operation. 
      Following randomization postoperatively, 260 patients received 4 g fish-oil 
      concentrate per day, whereas 251 patients comprised the control group. All 
      patients received either aspirin (300 mg/day) or warfarin (international 
      normalized ratio aimed at 2.5-4.2). Compliance was affirmed by determination of 
      serum phospholipid fatty acids. No excess of bleeding episodes could be 
      attributed to the use of fish oil, given in addition to either aspirin or 
      warfarin. The supplementation of fish oil did not affect the bleeding time or 
      plasma levels of beta-thromboglobulin, whereas an increase in the platelet count 
      after the operation was slightly less pronounced in the fish-oil group. Apart 
      from a small increase in PAI-1 antigen of borderline significance, no long-term 
      effects by fish oil on parameters of coagulation and fibrinolysis were seen.
FAU - Eritsland, J
AU  - Eritsland J
AD  - Department of Cardiology, Ullevål University Hospital, Oslo, Norway.
FAU - Arnesen, H
AU  - Arnesen H
FAU - Seljeflot, I
AU  - Seljeflot I
FAU - Kierulf, P
AU  - Kierulf P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Fatty Acids)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Fish Oils)
RN  - 0 (Phospholipids)
RN  - 0 (Triglycerides)
RN  - 0 (antithrombin III-protease complex)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9000-94-6 (Antithrombin III)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Antithrombin III/analysis
MH  - Arteriosclerosis/epidemiology
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Bleeding Time
MH  - Coronary Artery Bypass
MH  - Coronary Disease/blood/*drug therapy/surgery
MH  - Drug Therapy, Combination
MH  - Fatty Acids/blood
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/analysis
MH  - Fish Oils/administration & dosage/adverse effects/*therapeutic use
MH  - Hemorrhage/*chemically induced
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptide Hydrolases/analysis
MH  - Phospholipids/blood
MH  - Platelet Count
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Triglycerides/blood
MH  - Warfarin/administration & dosage/adverse effects/therapeutic use
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
AID - 10.1097/00001721-199502000-00003 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 1995 Feb;6(1):17-22. doi: 
      10.1097/00001721-199502000-00003.

PMID- 21119581
OWN - NLM
STAT- MEDLINE
DCOM- 20110316
LR  - 20191210
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Linking)
VI  - 16
IP  - 12
DP  - 2010 Dec
TI  - Influence of pharmacological treatment on blood flow and muscle perfusion in 
      patients with obliterative atheromatosis assessed with isotopic methods. A pilot 
      study.
PG  - CR622-7
AB  - BACKGROUND: Most of the methods don't give the comparison between blood flow at 
      rest and after exercise. Nuclear medicine allows for such assessment and 
      determination of muscle perfusion indexes. The aim of the study was the 
      comparison of the radioisotopic assessment of lower limbs perfusion at rest and 
      after exercise in patients with obliterative atheromatosis subjected to combined 
      treatment with the standard vascular examinations. MATERIAL/METHODS: 35 patients 
      with stage II according to Fontaine and claudication distance 30-500 m, subjected 
      to the combined medical treatment were included to the study. Basic examinations, 
      claudication distance measurements, standard vascular examinations, and 
      radioisotopic examinations of lower limbs perfusion with Tc99mMIBI were performed 
      in all patients. RESULTS: After 6 months of therapy the results of perfusion 
      scintigraphy showed that combined pharmacological treatment caused the 
      significant improvement of calf perfusion at rest (p<0.05), which justifies its 
      application in chronic ischemia of lower limbs. Such improvement was not observed 
      while analyzing the results of standard vascular indexes. CONCLUSIONS: The use of 
      perfusion scintigraphy allows for precise definition of the state of the limbs 
      perfusion and shows the improvement of lower limbs perfusion at rest after 
      medical treatment. It is a more precise and sensitive examination, gives more 
      information comparing to the standard vascular examinations, and completes 
      standard vascular diagnostics in patients with obliterative atheromatosis.
FAU - Tryniszewski, Wieslaw
AU  - Tryniszewski W
AD  - Department of Radiological and Isotopic Diagnostics and Therapy, Medical 
      University of Lodz, Lodz, Poland. wieslaw.tryniszewski@umed.lodz.pl
FAU - Nowak, Dariusz
AU  - Nowak D
FAU - Brocki, Marian
AU  - Brocki M
FAU - Maziarz, Zbigniew
AU  - Maziarz Z
FAU - Rysz, Jacek
AU  - Rysz J
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Organotechnetium Compounds)
RN  - 0 (Pyrrolidines)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
RN  - V7I71DQ432 (buflomedil)
SB  - IM
MH  - Analysis of Variance
MH  - Arteriosclerosis Obliterans/*drug therapy/therapy
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Flow Velocity/drug effects
MH  - Exercise/*physiology
MH  - Female
MH  - Humans
MH  - Intermittent Claudication/*physiopathology
MH  - Leg/*blood supply
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/*blood supply/drug effects
MH  - Organotechnetium Compounds/metabolism
MH  - Pentoxifylline/pharmacology/therapeutic use
MH  - Perfusion Imaging
MH  - Pilot Projects
MH  - Pyrrolidines/pharmacology/therapeutic use
MH  - Regional Blood Flow/*drug effects
MH  - Statistics, Nonparametric
EDAT- 2010/12/02 06:00
MHDA- 2011/03/17 06:00
CRDT- 2010/12/02 06:00
PHST- 2010/12/02 06:00 [entrez]
PHST- 2010/12/02 06:00 [pubmed]
PHST- 2011/03/17 06:00 [medline]
AID - 881300 [pii]
PST - ppublish
SO  - Med Sci Monit. 2010 Dec;16(12):CR622-7.

PMID- 19007460
OWN - NLM
STAT- MEDLINE
DCOM- 20081218
LR  - 20131121
IS  - 0003-7028 (Print)
IS  - 0003-7028 (Linking)
VI  - 62
IP  - 11
DP  - 2008 Nov
TI  - Quantitative determination of pharmaceutical drug formulations by near-infrared 
      spectroscopic imaging.
PG  - 1200-8
LID - 10.1366/000370208786401590 [doi]
AB  - Over the last decade Fourier transform infrared (FT-IR) and near-infrared (NIR) 
      spectroscopic imaging with focal plane array (FPA) detectors have proved powerful 
      techniques for the rapid visualization of samples by a combination of 
      spectroscopic and spatial information. Using these methods, selected sample areas 
      can be analyzed with reference to the identification and localization of chemical 
      species by FT-IR spectroscopy in the transmission or attenuated total reflection 
      (ATR) mode and by NIR spectroscopy in diffuse reflection with a lateral 
      resolution in the micrometer range. The present communication focuses on the 
      quantitative determination of the active ingredient composition of a solid drug 
      formulation by NIR spectroscopic imaging with a focal plane array detector and 
      the results obtained are compared to the quantitative data obtained by 
      conservative light-fiber NIR spectroscopic diffuse reflection measurements with a 
      single-element detector. The communication also addresses the issue of 
      penetration depth of NIR radiation into the investigated solid material.
FAU - Kolomiets, O
AU  - Kolomiets O
AD  - Department of Physical Chemistry, University of Duisburg-Essen, Schuetzenbahn 70, 
      D-45117 Essen, Germany.
FAU - Hoffmann, U
AU  - Hoffmann U
FAU - Geladi, P
AU  - Geladi P
FAU - Siesler, H W
AU  - Siesler HW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Appl Spectrosc
JT  - Applied spectroscopy
JID - 0372406
RN  - 0 (Pharmaceutical Preparations)
RN  - 3G6A5W338E (Caffeine)
RN  - 9004-34-6 (Cellulose)
RN  - 9005-25-8 (Starch)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Ascorbic Acid/analysis/chemistry
MH  - Aspirin/analysis/chemistry
MH  - Caffeine/analysis/chemistry
MH  - Cellulose/analysis/chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - Image Processing, Computer-Assisted/instrumentation/*methods
MH  - Microscopy, Electron, Scanning
MH  - Molecular Structure
MH  - Pharmaceutical Preparations/*analysis/chemistry
MH  - Pharmacy/*methods
MH  - Spectroscopy, Fourier Transform Infrared/instrumentation/*methods
MH  - Spectroscopy, Near-Infrared/instrumentation/*methods
MH  - Starch/analysis/chemistry
EDAT- 2008/11/15 09:00
MHDA- 2008/12/19 09:00
CRDT- 2008/11/15 09:00
PHST- 2008/11/15 09:00 [pubmed]
PHST- 2008/12/19 09:00 [medline]
PHST- 2008/11/15 09:00 [entrez]
AID - 10.1366/000370208786401590 [doi]
PST - ppublish
SO  - Appl Spectrosc. 2008 Nov;62(11):1200-8. doi: 10.1366/000370208786401590.

PMID- 11852294
OWN - NLM
STAT- MEDLINE
DCOM- 20020614
LR  - 20190916
IS  - 0362-5664 (Print)
IS  - 0362-5664 (Linking)
VI  - 25
IP  - 1
DP  - 2002 Jan-Feb
TI  - Clinical evidence of an interaction between imipramine and acetylsalicylic acid 
      on protein binding in depressed patients.
PG  - 32-6
AB  - The binding of imipramine to plasma proteins was studied in 20 adult patients 
      with endogenous depression, with the purpose of assessing the effect produced by 
      its simultaneous administration with an analgesic. Patients were administered 150 
      mg/day imipramine for 5 days and the binding to plasma proteins was determined. 
      This was repeated 2 days later, after simultaneous administration of imipramine 
      with 1,000 mg/day acetylsalicylic acid (ASA). Adverse effects for each patient 
      were registered during both phases and were classified as mild, moderate, or 
      severe. Results showed 84.4 +/- 7.07% of imipramine bound to plasma proteins and 
      72.18 +/- 6.5% when imipramine was administered with ASA (p < 0.05). When 
      imipramine was administered alone, 1.95 mild adverse events per patient were 
      registered. When imipramine was administered with ASA, the mild adverse events 
      increased to 3.1 (p < 0.01) and the severe adverse events increased from 0.6 to 
      1.5 (p < 0.01). The levels of free imipramine increased when ASA was 
      administered, indicating a displacement on the binding to plasma proteins. When 
      adverse events were compared for each treatment, the accumulation of the free 
      fraction of imipramine caused an increase in adverse events as well as in their 
      clinical severity.
FAU - Juárez-Olguín, Hugo
AU  - Juárez-Olguín H
AD  - Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma 
      de México, Mexico City, Mexico.
FAU - Jung-Cook, Helgi
AU  - Jung-Cook H
FAU - Flores-Pérez, Janett
AU  - Flores-Pérez J
FAU - Asseff, Ismael Lares
AU  - Asseff IL
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Neuropharmacol
JT  - Clinical neuropharmacology
JID - 7607910
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 0 (Blood Proteins)
RN  - OGG85SX4E4 (Imipramine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analgesics, Non-Narcotic/*metabolism/therapeutic use
MH  - Antidepressive Agents, Tricyclic/adverse effects/*metabolism/therapeutic use
MH  - Aspirin/*metabolism/therapeutic use
MH  - Blood Proteins/*metabolism
MH  - Depression/*drug therapy/metabolism
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Imipramine/adverse effects/*metabolism/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Protein Binding
MH  - Surveys and Questionnaires
EDAT- 2002/02/20 10:00
MHDA- 2002/06/18 10:01
CRDT- 2002/02/20 10:00
PHST- 2002/02/20 10:00 [pubmed]
PHST- 2002/06/18 10:01 [medline]
PHST- 2002/02/20 10:00 [entrez]
AID - 10.1097/00002826-200201000-00006 [doi]
PST - ppublish
SO  - Clin Neuropharmacol. 2002 Jan-Feb;25(1):32-6. doi: 
      10.1097/00002826-200201000-00006.

PMID- 7800562
OWN - NLM
STAT- MEDLINE
DCOM- 19950120
LR  - 20190726
IS  - 0147-8389 (Print)
IS  - 0147-8389 (Linking)
VI  - 17
IP  - 10
DP  - 1994 Oct
TI  - Power and temperature guided radiofrequency catheter ablation of the right atrium 
      in pigs.
PG  - 1610-20
AB  - The aim of the present study was twofold: to assess the safety of ablating the 
      atrial free wall using RF current; and to assess the effect of a single dose of 
      intravenous heparin followed by aspirin once daily to prevent thrombus formation 
      after RF ablation. Temperature and power guided catheter ablation were evaluated. 
      Twenty pigs were randomized to power or temperature guided unipolar RF catheter 
      ablation. Ten animals received a bolus of heparin (150 U/kg) followed by 150-mg 
      aspirin daily, and ten served as controls. A mid-sternal thoracotomy was 
      performed 5-7 days later. The ability of a lesion to resist an increased 
      transmural atrial pressure was examined by inflating a cuff around the pulmonal 
      artery. Transmural lesions were found in all animals. Right atrial pressure was 
      increased from 5 to 30 mmHg with no sign of perforation. In 11 of 20 (55%) 
      animals, 1-3 lesions were found in the lungs (diameter 4-18 mm). The localization 
      of these lesions corresponded to the lesions in the atria. There were no 
      differences in the energy delivery modes with regard to the number of animals 
      with lung lesions. Lesions with thrombus formation were found in four animals in 
      the heparin/aspirin group and in nine animals in the control group. The incidence 
      of thrombi was significantly smaller in the treatment group. There were no 
      differences between temperature and power guided catheter ablation with regard to 
      the size of the atrial lesions or to the incidence of thrombus formation. 
      Transmural lesions induced in the right atrium by RF energy are resistant to 
      increases in transmural pressure. However, lung tissue overlying the ablated 
      target may be injured by the RF energy delivered. The combination of a single 
      dose intravenous heparin followed by aspirin daily may reduce the incidence of 
      thrombus formation.
FAU - Kongsgaard, E
AU  - Kongsgaard E
AD  - Department of Pathology, Rikshospitalet, Oslo, Norway.
FAU - Foerster, A
AU  - Foerster A
FAU - Aass, H
AU  - Aass H
FAU - Madsen, S
AU  - Madsen S
FAU - Amlie, J P
AU  - Amlie JP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pacing Clin Electrophysiol
JT  - Pacing and clinical electrophysiology : PACE
JID - 7803944
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage
MH  - Catheter Ablation/*methods
MH  - Heart Atria/*surgery
MH  - Heart Diseases/*prevention & control
MH  - Heparin/administration & dosage
MH  - Lung Injury
MH  - Postoperative Complications/*prevention & control
MH  - Swine
MH  - Thrombosis/*prevention & control
EDAT- 1994/10/01 00:00
MHDA- 1994/10/01 00:01
CRDT- 1994/10/01 00:00
PHST- 1994/10/01 00:00 [pubmed]
PHST- 1994/10/01 00:01 [medline]
PHST- 1994/10/01 00:00 [entrez]
AID - 10.1111/j.1540-8159.1994.tb02354.x [doi]
PST - ppublish
SO  - Pacing Clin Electrophysiol. 1994 Oct;17(10):1610-20. doi: 
      10.1111/j.1540-8159.1994.tb02354.x.

PMID- 105014
OWN - NLM
STAT- MEDLINE
DCOM- 19790425
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 63
IP  - 1
DP  - 1979 Jan
TI  - Aspirin inhibits development of coronary atherosclerosis in cynomolgus monkeys 
      (Macaca fascicularis) fed an atherogenic diet.
PG  - 158-62
AB  - The effect of aspirin in the primary prevention of diet-induced atherogenesis in 
      cynomolgus monkeys was studied. The diet consisted of 2% cholesterol and 10% 
      butter by weight for 24 wk. Six monkeys received only the atherogenic diet and 
      five monkeys received the diet plus aspirin, 81 mg/monkey per day. Aspirin did 
      not affect plasma cholesterol levels or aortic atherosclerosis. Platelet 
      aggregation to arachidonic acid was almost completely suppressed. Aspirin 
      decreased significantly the number of coronary vessels with atherosclerotic 
      involvement, and the number of coronary vessels narrowed by 20% or more. Thus, 
      aspirin appears to exert a protective effect in the primary prevention of 
      diet-induced coronary atherosclerosis in a primate model.
FAU - Pick, R
AU  - Pick R
FAU - Chediak, J
AU  - Chediak J
FAU - Glick, G
AU  - Glick G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aortic Diseases/etiology
MH  - Arteriosclerosis/etiology/pathology/*prevention & control
MH  - Aspirin/*pharmacology
MH  - Coronary Disease/etiology/pathology/*prevention & control
MH  - *Diet, Atherogenic
MH  - Haplorhini
MH  - Macaca fascicularis
MH  - Male
PMC - PMC371932
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1172/JCI109272 [doi]
PST - ppublish
SO  - J Clin Invest. 1979 Jan;63(1):158-62. doi: 10.1172/JCI109272.

PMID- 6872421
OWN - NLM
STAT- MEDLINE
DCOM- 19830920
LR  - 20190511
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 34
IP  - 2
DP  - 1983 Aug
TI  - Ibuprofen, zomepirac, aspirin, and placebo in the relief of postepisiotomy pain.
PG  - 254-8
AB  - Our purpose was to compare the analgesic efficacy of single oral doses of 
      ibuprofen, zomepirac, aspirin, and placebo in severe postepisiotomy pain. One 
      hundred twenty subjects participated in a double-blind, single-dose, 
      parallel-group, 4-hr trial comparing 400 mg ibuprofen, 100 mg zomepirac sodium, 
      600 mg aspirin, and placebo. For most parameters, including the sum of the pain 
      intensity differences (SPID) and the sum of the hourly pain relief values 
      (TOTAL), which are summary variables, each of the drugs was more effective than 
      placebo. Ibuprofen was more effective than aspirin and zomepirac. Zomepirac and 
      aspirin were equally effective for most of the analgesic variables. There were no 
      adverse effects. Ibuprofen, 400 mg, is an effective oral analgesic and is more 
      effective than 100 mg zomepirac and 600 mg aspirin in most parameters of pain.
FAU - Sunshine, A
AU  - Sunshine A
FAU - Olson, N Z
AU  - Olson NZ
FAU - Laska, E M
AU  - Laska EM
FAU - Zighelboim, I
AU  - Zighelboim I
FAU - De Castro, A
AU  - De Castro A
FAU - De Sarrazin, C
AU  - De Sarrazin C
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Placebos)
RN  - 0 (Pyrroles)
RN  - 822G987U9J (zomepirac)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Episiotomy/*adverse effects
MH  - Female
MH  - Humans
MH  - Ibuprofen/*therapeutic use
MH  - Pain, Postoperative/*drug therapy/etiology
MH  - Placebos
MH  - Pyrroles/*therapeutic use
MH  - Tolmetin/analogs & derivatives/*therapeutic use
EDAT- 1983/08/01 00:00
MHDA- 1983/08/01 00:01
CRDT- 1983/08/01 00:00
PHST- 1983/08/01 00:00 [pubmed]
PHST- 1983/08/01 00:01 [medline]
PHST- 1983/08/01 00:00 [entrez]
AID - 0009-9236(83)90551-9 [pii]
AID - 10.1038/clpt.1983.162 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1983 Aug;34(2):254-8. doi: 10.1038/clpt.1983.162.

PMID- 18194417
OWN - NLM
STAT- MEDLINE
DCOM- 20080617
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 6
IP  - 3
DP  - 2008 Mar
TI  - Use of the PFA-100 closure time to predict cardiovascular events in 
      aspirin-treated cardiovascular patients: a systematic review and meta-analysis.
PG  - 444-50
LID - 10.1111/j.1538-7836.2008.02897.x [doi]
AB  - BACKGROUND: PFA-100 is a point-of-care assay that evaluates platelet reactivity 
      in high-shear-stress conditions by measuring the closure time (CT) of a membrane 
      aperture. When determined with a collagen/epinephrine cartridge (CEPI), the CT is 
      usually prolonged by aspirin. Studies of the predictive value of a short 
      PFA-100CT(CEPI) for ischemic events in aspirin-treated patients have given 
      variable results. OBJECTIVES: To conduct a systematic review and meta-analysis of 
      studies on the clinical predictive value of a short PFA-100CT(CEPI) in 
      aspirin-treated cardiovascular patients. PATIENTS AND METHODS: Relevant studies 
      were identified by scanning electronic databases. Studies were selected if they 
      included aspirin-treated patients with symptomatic atherosclerosis, measured the 
      PFA-100CT(CEPI), used a CT cut-off value to define aspirin 'responders' and 
      'non-responders', and reported ischemic events. RESULTS: We selected seven 
      non-prospective studies (1466 patients) and eight prospective studies (1227 
      patients). In non-prospective studies, the PFA-100CT(CEPI) was performed after 
      the ischemic clinical endpoint, and a publication bias was identified. In 
      prospective studies, the global odds ratio (OR) for the recurrence of an ischemic 
      event in 'aspirin non-responders' relative to 'aspirin responders' was 2.1 [95% 
      confidence interval (CI) 1.4-3.4, P < 0.001]. Pooled analysis with a random 
      effect model revealed no heterogeneity (Q Cochran P = 0.36 and I(2) = 9.4%). 
      CONCLUSIONS: A short PFA-100CT(CEPI) is associated with increased recurrence of 
      ischemic events in aspirin-treated cardiovascular patients. This finding needs to 
      be confirmed in stable ischemic patients, and the PFA-100CT(CEPI) cut-off needs 
      to be refined in these patients.
FAU - Reny, J-L
AU  - Reny JL
AD  - Department of Internal Medicine, Béziers Hospital, Béziers, France. 
      jeanluc.reny@ch-beziers.fr
FAU - De Moerloose, P
AU  - De Moerloose P
FAU - Dauzat, M
AU  - Dauzat M
FAU - Fontana, P
AU  - Fontana P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20080110
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Thromb Haemost. 2008 Jun;99(6):1129-31. PMID: 18521524
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*cytology
MH  - Cardiology/methods
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Myocardial Ischemia
MH  - Platelet Activation
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Time Factors
RF  - 46
EDAT- 2008/01/16 09:00
MHDA- 2008/06/18 09:00
CRDT- 2008/01/16 09:00
PHST- 2008/01/16 09:00 [pubmed]
PHST- 2008/06/18 09:00 [medline]
PHST- 2008/01/16 09:00 [entrez]
AID - S1538-7836(22)12828-X [pii]
AID - 10.1111/j.1538-7836.2008.02897.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2008 Mar;6(3):444-50. doi: 10.1111/j.1538-7836.2008.02897.x. 
      Epub 2008 Jan 10.

PMID- 6776176
OWN - NLM
STAT- MEDLINE
DCOM- 19810129
LR  - 20190709
IS  - 0002-8614 (Print)
IS  - 0002-8614 (Linking)
VI  - 28
IP  - 12
DP  - 1980 Dec
TI  - Aspirin absorption from a feeding jejunostomy.
PG  - 556-7
AB  - In a 67-year-old man who had a feeding jejunostomy because of dysphagia 
      paralytica, the absorption of aspirin was measured in terms of serum salicylate 
      concentration. A 975-mg dose of aspirin was given as a slurry in water directly 
      into the feeding tube. Peak serum levels of salicylate were well correlated with 
      those in previous studies of aspirin absorption by the oral route in a geriatric 
      population. However, unexpectedly, the half-life of the drug in this patient was 
      twice as long (7.5 hours) as that found in six previous studies (3.7 hours) of 
      elderly patients given similar doses.
FAU - Nelson, E B
AU  - Nelson EB
FAU - Levitt, J R
AU  - Levitt JR
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*metabolism
MH  - *Enteral Nutrition
MH  - Half-Life
MH  - Humans
MH  - *Intestinal Absorption
MH  - Jejunum/*metabolism
MH  - Male
MH  - Salicylates/blood
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
AID - 10.1111/j.1532-5415.1980.tb00008.x [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 1980 Dec;28(12):556-7. doi: 10.1111/j.1532-5415.1980.tb00008.x.

PMID- 7255511
OWN - NLM
STAT- MEDLINE
DCOM- 19810925
LR  - 20131121
IS  - 0308-051X (Print)
IS  - 0308-051X (Linking)
VI  - 2
IP  - 8
DP  - 1981
TI  - Bioavailability of aspirin in the presence of dextropropoxyphene/paracetamol 
      combination.
PG  - 543-6
AB  - The effect of 2 doses of a combination analgesic preparation (each dose 
      containing 65 mg dextropropoxyphene hydrochloride and 650 mg paracetamol) upon 
      plasma salicylate concentration after a single dose of soluble aspirin (1.2 g) or 
      enteric-coated aspirin (1.2 g) was examined in 6 normal volunteers and compared 
      with the effect of placebo. The dextropropoxyphene/paracetamol caused no 
      reduction in the plasma salicylate level after absorption of soluble aspirin 
      compared with placebo and, although a reduction in plasma salicylate was seen 
      after enteric-coated aspirin in a single subject, this may reflect erratic 
      absorption rather than a drug interaction.
FAU - Hemming, J D
AU  - Hemming JD
FAU - Bird, H A
AU  - Bird HA
FAU - Pickup, M E
AU  - Pickup ME
FAU - Saunders, A
AU  - Saunders A
FAU - Lowe, J R
AU  - Lowe JR
FAU - Dixon, J S
AU  - Dixon JS
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Pharmatherapeutica
JT  - Pharmatherapeutica
JID - 7606274
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 39400-85-6 (acetaminophen, dextropropoxyphene, drug combination)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
SB  - IM
MH  - Acetaminophen/administration & dosage/*pharmacology
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*metabolism
MH  - Biological Availability
MH  - Dextropropoxyphene/administration & dosage/*pharmacology
MH  - Drug Combinations/pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Pharmatherapeutica. 1981;2(8):543-6.

PMID- 7249281
OWN - NLM
STAT- MEDLINE
DCOM- 19810925
LR  - 20190706
IS  - 0009-7330 (Print)
IS  - 0009-7330 (Linking)
VI  - 49
IP  - 2
DP  - 1981 Aug
TI  - Preservation of platelets during extracorporeal circulation in sheep. A 
      comparison between aspirin and sulfinpyrazone.
PG  - 452-7
AB  - We studied the effect of aspirin and sulfinpyrazone on changes in platelet count, 
      thromboxane B2 production, and pulmonary vascular resistance following the onset 
      of veno-venous membrane oxygenator perfusion in sheep. Perfusion under identical 
      circumstances was performed in three groups of animals, with one group serving as 
      controls, one group receiving pretreatment with 1.5 grams of sulfinpyrazone iv, 
      and one group receiving pretreatment with aspirin 50 mg/kg, iv. Both aspirin and 
      sulfinpyrazone eliminated the rise in thromboxane B2 and the increase in 
      pulmonary vascular resistance seen in control animals. Platelet preservation was 
      improved significantly with sulfinpyrazone pretreatment, but not affected by 
      aspirin. We conclude that sulfinpyrazone and aspirin have different mechanisms of 
      action as far as platelet preservation during extracorporeal perfusion is 
      concerned. The major difference may be sulfinpyrazone's ability to reduce 
      platelet adhesion to the membrane surface. Since both aspirin and sulfinpyrazone 
      eliminated the pulmonary vascular-response, but only sulfinpyrazone preserved 
      platelets, it is apparent that the pulmonary vascular response is more closely 
      related to thromboxane synthesis than to platelet disappearance.
FAU - Townsend, E R
AU  - Townsend ER
FAU - Duffin, J
AU  - Duffin J
FAU - Ali, M
AU  - Ali M
FAU - McDonald, J W
AU  - McDonald JW
FAU - Thiesson, J J
AU  - Thiesson JJ
FAU - Masterson, J
AU  - Masterson J
FAU - Klement, P
AU  - Klement P
FAU - Cooper, J D
AU  - Cooper JD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circ Res
JT  - Circulation research
JID - 0047103
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*physiology
MH  - *Blood Preservation
MH  - Blood Pressure
MH  - *Extracorporeal Circulation
MH  - Leukocyte Count
MH  - Oxygenators
MH  - Platelet Count
MH  - Pulmonary Artery/physiology
MH  - Sheep
MH  - Sulfinpyrazone/pharmacology
MH  - Thromboxane B2/biosynthesis
EDAT- 1981/08/01 00:00
MHDA- 1981/08/01 00:01
CRDT- 1981/08/01 00:00
PHST- 1981/08/01 00:00 [pubmed]
PHST- 1981/08/01 00:01 [medline]
PHST- 1981/08/01 00:00 [entrez]
AID - 10.1161/01.res.49.2.452 [doi]
PST - ppublish
SO  - Circ Res. 1981 Aug;49(2):452-7. doi: 10.1161/01.res.49.2.452.

PMID- 16963324
OWN - NLM
STAT- MEDLINE
DCOM- 20061113
LR  - 20171116
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1764
IP  - 9
DP  - 2006 Sep
TI  - Protection against glycation and similar post-translational modifications of 
      proteins.
PG  - 1436-46
AB  - Glycation and other non-enzymic post-translational modifications of proteins have 
      been implicated in the complications of diabetes and other conditions. In recent 
      years there has been extensive progress in the search for ways to prevent the 
      modifications and prevent the consequences of the modifications. These areas are 
      covered in this review together with newer ideas on possibilities of reversing 
      the chemical modifications.
FAU - Harding, John J
AU  - Harding JJ
AD  - Nuffield Laboratory of Ophthalmology, University of Oxford, Walton Street, 
      Oxford, OX2 6AW, Great Britain. john.harding@eye.ox.ac.uk
FAU - Ganea, Elena
AU  - Ganea E
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060805
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Carbohydrates)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Proteins)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 0 (Receptors, Immunologic)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/chemistry
MH  - Carbohydrates/chemistry
MH  - Diabetes Complications/prevention & control
MH  - Diabetes Mellitus/etiology
MH  - Glycation End Products, Advanced/analysis
MH  - *Glycosylation
MH  - Humans
MH  - Ibuprofen/chemistry
MH  - *Protein Processing, Post-Translational
MH  - Proteins/chemistry
MH  - Receptor for Advanced Glycation End Products
MH  - Receptors, Immunologic/drug effects
RF  - 125
EDAT- 2006/09/12 09:00
MHDA- 2006/11/14 09:00
CRDT- 2006/09/12 09:00
PHST- 2006/04/23 00:00 [received]
PHST- 2006/07/29 00:00 [revised]
PHST- 2006/08/02 00:00 [accepted]
PHST- 2006/09/12 09:00 [pubmed]
PHST- 2006/11/14 09:00 [medline]
PHST- 2006/09/12 09:00 [entrez]
AID - S1570-9639(06)00260-3 [pii]
AID - 10.1016/j.bbapap.2006.08.001 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2006 Sep;1764(9):1436-46. doi: 
      10.1016/j.bbapap.2006.08.001. Epub 2006 Aug 5.

PMID- 12596530
OWN - NLM
STAT- MEDLINE
DCOM- 20030324
LR  - 20131121
IS  - 0869-2092 (Print)
IS  - 0869-2092 (Linking)
VI  - 65
IP  - 6
DP  - 2002 Nov-Dec
TI  - [Effect of combined administration of acetylsalicylic acid and antioxidants on 
      cellular and plasma hemostasis].
PG  - 32-6
AB  - It was found that upsovit (acetylsalicylic acid, 330 mg; ascorbic acid, 200 mg), 
      composition 1 (acetylsalicylic acid, 330 mg; ascorbic acid, 200 mg; hypoxen, 50 
      mg), and composition 2 (acetylsalicylic acid, 330 mg; ascorbic acid, 200 mg; 
      hypoxen, 100 mg) inhibit thrombocyte aggregation in vitro. Hypoxen per se induces 
      the aggregation of thrombocytes, but inhibited the ADP aggregation. Intravenous 
      injections of upsovit in rabbits did not influence the ADP aggregation, but 
      inhibited the collagen aggregation, while composition 2 inhibited the aggregation 
      processes of both types. Besides, the intravenous injections of upsovit decreased 
      the thromboplastin time and the activated partial thromboplastin time (APTT) and 
      reduced the protein C activity, while influencing neither the heparin cofactor 
      activity of antithrombin III nor the level of fibrinogen and its degradation 
      products. In contrast, composition II did not change the thromboplastin time, 
      APTT, and the protein C activity, but increased the heparin cofactor activity.
FAU - Makarov, V A
AU  - Makarov VA
AD  - Laboratory of Hemostasis Pathology and Pharmacology, Scientific Hematological 
      Center, Russian Academy of Medical Sciences, Novo-Zykovskii proezd 4a, Moscow, 
      125167 Russia.
FAU - Petrukhina, G N
AU  - Petrukhina GN
FAU - Remov, M N
AU  - Remov MN
FAU - Miftakhova, N T
AU  - Miftakhova NT
FAU - Kuz'mich, M K
AU  - Kuz'mich MK
FAU - Popov, V G
AU  - Popov VG
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Vliianie sochetannogo primeneniia atsetilsalitsilovoĭ kisloty s antioksidantami 
      na kletochnyĭ i plazmennyĭ gemostaz.
PL  - Russia (Federation)
TA  - Eksp Klin Farmakol
JT  - Eksperimental'naia i klinicheskaia farmakologiia
JID - 9215981
RN  - 0 (Antioxidants)
RN  - 0 (Drug Combinations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antioxidants/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Blood Coagulation Tests
MH  - Drug Combinations
MH  - Female
MH  - Hemostasis/*drug effects
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
EDAT- 2003/02/25 04:00
MHDA- 2003/03/26 04:00
CRDT- 2003/02/25 04:00
PHST- 2003/02/25 04:00 [pubmed]
PHST- 2003/03/26 04:00 [medline]
PHST- 2003/02/25 04:00 [entrez]
PST - ppublish
SO  - Eksp Klin Farmakol. 2002 Nov-Dec;65(6):32-6.

PMID- 6733590
OWN - NLM
STAT- MEDLINE
DCOM- 19840815
LR  - 20190720
IS  - 0008-4212 (Print)
IS  - 0008-4212 (Linking)
VI  - 62
IP  - 4
DP  - 1984 Apr
TI  - Placental drug transfer in near-term ewes: acetylsalicylic and salicylic acid.
PG  - 441-5
AB  - Radiolabelled acetylsalicylic acid (ASA) and salicylic acid (SA) were given 
      intravenously to four near-term ewes and their occurrence in both maternal and 
      fetal plasma was ascertained using a specific thin-layer chromatographic analysis 
      procedure. Findings proved that ASA and SA cross the placental barrier and reach 
      distribution equilibrium about 40 min after salicylate administration. The 
      equilibrium plasma fetal/maternal ratio for both salicylates averaged 0.4. Plasma 
      concentrations of the two compounds in the mother and the fetus accorded with a 
      two-compartment model having unusually large mean estimates (54 and 39 L) for the 
      tissue distribution space of ASA and SA, respectively. Furthermore, the mean SA 
      clearance in the ewe (358 mL X min-1) was much greater than that reported in man, 
      while the mean ASA clearance (764 mL X min-1) was similar. Since ASA is an 
      irreversible inhibitor of arachidonate cyclooxygenase, our findings reassert the 
      need for caution in the use of the drug during pregnancy.
FAU - Thiessen, J J
AU  - Thiessen JJ
FAU - Salama, R B
AU  - Salama RB
FAU - Coceani, F
AU  - Coceani F
FAU - Olley, P M
AU  - Olley PM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*metabolism
MH  - Computers
MH  - Female
MH  - Isotope Labeling
MH  - Kinetics
MH  - *Maternal-Fetal Exchange
MH  - Models, Biological
MH  - Pregnancy
MH  - Salicylates/*metabolism
MH  - Salicylic Acid
MH  - Sheep
EDAT- 1984/04/01 00:00
MHDA- 1984/04/01 00:01
CRDT- 1984/04/01 00:00
PHST- 1984/04/01 00:00 [pubmed]
PHST- 1984/04/01 00:01 [medline]
PHST- 1984/04/01 00:00 [entrez]
AID - 10.1139/y84-070 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 1984 Apr;62(4):441-5. doi: 10.1139/y84-070.

PMID- 6344315
OWN - NLM
STAT- MEDLINE
DCOM- 19830708
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 29
IP  - 4
DP  - 1983 Feb 15
TI  - The clotting time of whole blood in plastic tubes: the influence of exercise, 
      prostacyclin and acetylsalicylic acid.
PG  - 425-35
AB  - An assay for detection of a hypercoagulable state was accomplished by measuring 
      the clotting time of whole blood (without anticoagulant present) in plastic 
      tubes. This assay appeared to be quite sensitive to the activation state of 
      platelets. Thus, acetylsalicylic acid (ASA) or prostacyclin (PGI2) was found to 
      prolong significantly the whole blood clotting time (WBCT), specially under 
      conditions where the platelet might be hyperactive. When the WBCT was carried out 
      before and after exercise, a mean value of 12.95 min was obtained before as 
      compared to 7.48 min after exercise. In the presence of PGI2, the WBCT after 
      exercise was prolonged to 13.91 min. The shorter clotting time after exercise, in 
      the absence of inhibitor, might be explained by the observation in the present 
      study that platelet factor 3 became more readily available upon consecutive 
      stimuli. These results suggest that platelet release may be important for the 
      initiation of prothrombin activation in situations without already available 
      platelet factor 3 activity.
FAU - Osterud, B
AU  - Osterud B
FAU - Brox, J H
AU  - Brox JH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Prostaglandins)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - *Blood Coagulation Tests
MH  - Epoprostenol/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Prostaglandins/*pharmacology
MH  - Specimen Handling/instrumentation
MH  - *Whole Blood Coagulation Time
EDAT- 1983/02/15 00:00
MHDA- 1983/02/15 00:01
CRDT- 1983/02/15 00:00
PHST- 1983/02/15 00:00 [pubmed]
PHST- 1983/02/15 00:01 [medline]
PHST- 1983/02/15 00:00 [entrez]
AID - 10.1016/0049-3848(83)90246-3 [doi]
PST - ppublish
SO  - Thromb Res. 1983 Feb 15;29(4):425-35. doi: 10.1016/0049-3848(83)90246-3.

PMID- 7192122
OWN - NLM
STAT- MEDLINE
DCOM- 19810129
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 30
IP  - 4A
DP  - 1980
TI  - A new non-steroidal anti-inflammatory analgesic: gamma-oxo 
      (1,1'-biphenyl)-4-butanoic acid (fenbufen). Chemistry and activity of analogs.
PG  - 695-702
AB  - 100 analogs of gamma-oxo(1,1'-biphenyl)-4-butanoic acid (fenbufen) were prepared 
      and tested using the carrageenin, polyarthritis, and UV erythema 
      anti-inflammatory tests and the 2-phenyl-1,4-benzoquinone writhing and inflamed 
      paw pressure analgesic tests. Only three retained the same full spectrum of 
      activity as fenbufen: dl-4-(4-biphenyly)-4-hydroxybutyric acid, 
      dl-4-(4-biphenylyl)-1,4-butanediol, and 4-biphenylacetic acid. Fenbufen had the 
      same spectrum of activity as acetylsalicylic acid (ASA), phenylbutazone, and 
      indometacin in the five tests. In addition, dose-response derived potencies show 
      fenbufen more potent than ASA and at least as potent as phenylbutazone in all 
      five tests.
FAU - Child, R G
AU  - Child RG
FAU - Osterberg, A C
AU  - Osterberg AC
FAU - Sloboda, A E
AU  - Sloboda AE
FAU - Tomcufcik, A S
AU  - Tomcufcik AS
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Phenylbutyrates)
RN  - 0 (Propionates)
RN  - 9000-07-1 (Carrageenan)
RN  - 9815R1WR9B (fenbufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Arthritis, Experimental/drug therapy
MH  - Aspirin/pharmacology
MH  - Biphenyl Compounds/pharmacology
MH  - Carrageenan/antagonists & inhibitors
MH  - Chemical Phenomena
MH  - Chemistry
MH  - *Phenylbutyrates
MH  - Propionates/*pharmacology
MH  - Rats
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1980;30(4A):695-702.

PMID- 6449982
OWN - NLM
STAT- MEDLINE
DCOM- 19810317
LR  - 20161123
IS  - 0037-9026 (Print)
IS  - 0037-9026 (Linking)
VI  - 174
IP  - 1
DP  - 1980
TI  - [Effect of ascorbic acid during acute iterative anoxia, hypothesis of an 
      anti-oxidizing mechanism of action in comparison with the effect of 
      hydroquinone].
PG  - 45-51
AB  - Some of the problems which appear during senescence, are said to be caused by 
      cerebral oxygen deficiency and various experiments have been set up to try to 
      imitate this particular aspect of the ageing process. We have already studied the 
      action of many drugs with regard to acute repeated anoxia. Our work has given us 
      clear evidence of the activity of ascorbic acid, which delays the moment of 
      electroencephalographic silence in rats and decreases the latent period up to the 
      reappearance of electrical activity. In order to pinpoint the mechanism of 
      action, we compared the influence of lysine aceto-salicylate with that of 
      hydroquinone. Very small doses of the latter drug produce a marked effect and 
      lead us to put forward the hypothesis that it may be anti-oxydising. However, 
      although all the drugs which proved effective in these experiments may be grouped 
      together (despite their varying pharmacological profiles) and described as 
      "anabiotic" drugs, it is not possible to revert to a single mechanism of action 
      for the group as a whole.
FAU - Pape, D
AU  - Pape D
FAU - Linée, P
AU  - Linée P
FAU - Lacroix, P
AU  - Lacroix P
FAU - Allain, H
AU  - Allain H
FAU - Reymann, J M
AU  - Reymann JM
FAU - Le Pollès, J B
AU  - Le Pollès JB
FAU - Van den Driessche, J
AU  - Van den Driessche J
LA  - fre
PT  - Journal Article
TT  - Influence de l'acide ascorbique dans l'anoxie aiguë itérative, hypothèse d'un 
      méchanisme d'action anti-oxydant par comparaison avec l'hydroquinone.
PL  - France
TA  - C R Seances Soc Biol Fil
JT  - Comptes rendus des seances de la Societe de biologie et de ses filiales
JID - 7505439
RN  - 0 (Hydroquinones)
RN  - K3Z4F929H6 (Lysine)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Ascorbic Acid/*pharmacology
MH  - Aspirin/pharmacology
MH  - Brain/drug effects/*physiopathology
MH  - Electroencephalography
MH  - Hydroquinones/*pharmacology
MH  - Hypoxia/*physiopathology
MH  - Lysine/pharmacology
MH  - Rats
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - C R Seances Soc Biol Fil. 1980;174(1):45-51.

PMID- 34985465
OWN - NLM
STAT- MEDLINE
DCOM- 20220107
LR  - 20220110
IS  - 1972-6481 (Electronic)
IS  - 1827-6806 (Linking)
VI  - 23
IP  - 1
DP  - 2022 Jan
TI  - [Management of ST-elevation myocardial infarction in a patient with aspirin 
      hypersensitivity without oral P2Y12 inhibitors].
PG  - 75-77
LID - 10.1714/3715.37065 [doi]
AB  - Aspirin hypersensitivity is a neglected issue, especially in the setting of 
      ST-elevation myocardial infarction (STEMI). Nevertheless, in such context a 
      prompt platelet inhibition remains crucial. We report the case of a patient 
      presenting with STEMI, aspirin hypersensitivity and emesis causing inadequate 
      intake of P2Y12 inhibitors managed with intravenous cangrelor therapy and aspirin 
      desensitization. Possible options in the management of aspirin hypersensitivity 
      in the acute phase are discussed. In selected patients with STEMI and aspirin 
      hypersensitivity, particularly in the suspect of suboptimal enteric absorption of 
      P2Y12 inhibitors, the use of cangrelor until aspirin desensitization is completed 
      can be considered; bridge therapy to desensitization with glycoprotein IIb/IIIa 
      inhibitors can be considered on a case by case basis, despite the scarce 
      supporting evidence - bridge therapy with indobufen is not recommended due to the 
      limited literature data.
FAU - Bianco, Matteo
AU  - Bianco M
AD  - Dipartimento di Cardiologia, A.O.U. San Luigi Gonzaga, Orbassano (TO).
FAU - Biolè, Carloalberto
AU  - Biolè C
AD  - Dipartimento di Cardiologia, A.O.U. San Luigi Gonzaga, Orbassano (TO).
FAU - Spirito, Amanda
AU  - Spirito A
AD  - Dipartimento di Cardiologia, A.O.U. San Luigi Gonzaga, Orbassano (TO).
FAU - Destefanis, Paola
AU  - Destefanis P
AD  - Dipartimento di Cardiologia, A.O.U. San Luigi Gonzaga, Orbassano (TO).
FAU - Luciano, Alessia
AU  - Luciano A
AD  - Dipartimento di Cardiologia, A.O.U. San Luigi Gonzaga, Orbassano (TO).
FAU - Montagna, Laura
AU  - Montagna L
AD  - Dipartimento di Cardiologia, A.O.U. San Luigi Gonzaga, Orbassano (TO).
FAU - Cerrato, Enrico
AU  - Cerrato E
AD  - Unità di Cardiologia Interventistica, A.O.U. San Luigi Gonzaga, Orbassano (TO) e 
      Ospedale degli Infermi, Rivoli (TO).
LA  - ita
PT  - Case Reports
PT  - Journal Article
TT  - Gestione dell’infarto miocardico con sopraslivellamento del tratto ST in un 
      paziente con ipersensibilità all’aspirina senza l’uso di inibitori orali del 
      recettore P2Y12.
PL  - Italy
TA  - G Ital Cardiol (Rome)
JT  - Giornale italiano di cardiologia (2006)
JID - 101263411
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Purinergic P2Y Receptor Antagonists/adverse effects
MH  - *ST Elevation Myocardial Infarction/therapy
MH  - Treatment Outcome
EDAT- 2022/01/06 06:00
MHDA- 2022/01/08 06:00
CRDT- 2022/01/05 12:20
PHST- 2022/01/05 12:20 [entrez]
PHST- 2022/01/06 06:00 [pubmed]
PHST- 2022/01/08 06:00 [medline]
AID - 10.1714/3715.37065 [doi]
PST - ppublish
SO  - G Ital Cardiol (Rome). 2022 Jan;23(1):75-77. doi: 10.1714/3715.37065.

PMID- 2082484
OWN - NLM
STAT- MEDLINE
DCOM- 19910509
LR  - 20191029
IS  - 0896-0569 (Print)
IS  - 0896-0569 (Linking)
VI  - 12
DP  - 1990
TI  - Does low-dose aspirin prevent aortocoronary vein bypass graft occlusion? The 
      Spanish Group for Aortocoronary Bypass Follow-up (GESIC Study).
PG  - 23-6
AB  - Although the importance of antiplatelet treatment in preventing early bypass 
      occlusion has been clearly recognized, questions regarding the optimal drug 
      regimen remain. To study the efficacy of low-dose aspirin, alone or in 
      combination with dipyridamole, 927 consecutive patients were enrolled in a 
      multicenter, randomized, double-blind, placebo-controlled trial comparing 
      aspirin, 50 mg t.i.d., aspirin, 50 mg t.i.d. plus dipyridamole, 75 mg t.i.d., and 
      placebo. Both aspirin and aspirin plus dipyridamole reduced the occlusion rate of 
      distal anastomoses, but only aspirin plus dipyridamole reduced the number of 
      patients with at least one occluded graft. Logistic regression analysis 
      identified distal vessel diameter, bypassed artery, graft type, and postoperative 
      antiplatelet treatment as independent predictors of graft patency.
FAU - Sanz, G
AU  - Sanz G
AD  - Hospital Clinico y Provincial de Barcelona, Spain.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Thromb Res Suppl
JT  - Thrombosis research. Supplement
JID - 8309239
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/administration & dosage
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Saphenous Vein/transplantation
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1016/0049-3848(90)90435-f [doi]
PST - ppublish
SO  - Thromb Res Suppl. 1990;12:23-6. doi: 10.1016/0049-3848(90)90435-f.

PMID- 6230174
OWN - NLM
STAT- MEDLINE
DCOM- 19840424
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 69
IP  - 4
DP  - 1984 Apr
TI  - Coumadin and aspirin in prevention of recurrence after transluminal coronary 
      angioplasty: a randomized study.
PG  - 721-7
AB  - To determine the influence of adjunctive treatment with coumadin or aspirin on 
      recurrence rate after percutaneous transluminal coronary angioplasty (PTCA), 248 
      patients in whom PTCA was assessed to be a primary success were randomized to 
      either 325 mm aspirin daily or to coumadin treatment sufficient to maintain a 
      prothrombin time 2 to 2.5 times the control value. The follow-up protocol 
      included stress testing and coronary angiographic examinations 3 to 6 months 
      after PTCA. All patients were followed for at least 9 months. Of the 122 patients 
      randomized to coumadin 44 (36%) had recurrent stenoses as opposed to 34/126 (27%) 
      of patients on aspirin, a difference that did not reach statistical significance 
      at the .05 level. However, patients with at least a 6 month history of angina 
      demonstrated a significantly different response to adjunctive treatment in that 
      19/43 (44%) of coumadin patients as compared with 10/48 (21%) of aspirin patients 
      had recurrent stenoses (p less than .05). Thus, coumadin was not shown to be more 
      effective than aspirin as adjunctive treatment after PTCA, while aspirin was 
      shown to be superior to coumadin in patients with a longer history of angina.
FAU - Thornton, M A
AU  - Thornton MA
FAU - Gruentzig, A R
AU  - Gruentzig AR
FAU - Hollman, J
AU  - Hollman J
FAU - King, S B 3rd
AU  - King SB 3rd
FAU - Douglas, J S
AU  - Douglas JS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Coumarins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angina Pectoris/prevention & control/*therapy
MH  - Angioplasty, Balloon
MH  - Aspirin/*therapeutic use
MH  - Coumarins/*therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Compliance
MH  - Recurrence
EDAT- 1984/04/01 00:00
MHDA- 1984/04/01 00:01
CRDT- 1984/04/01 00:00
PHST- 1984/04/01 00:00 [pubmed]
PHST- 1984/04/01 00:01 [medline]
PHST- 1984/04/01 00:00 [entrez]
AID - 10.1161/01.cir.69.4.721 [doi]
PST - ppublish
SO  - Circulation. 1984 Apr;69(4):721-7. doi: 10.1161/01.cir.69.4.721.

PMID- 7000167
OWN - NLM
STAT- MEDLINE
DCOM- 19810126
LR  - 20190719
IS  - 0306-5456 (Print)
IS  - 0306-5456 (Linking)
VI  - 87
IP  - 4
DP  - 1980 Apr
TI  - Flurbiprofen in the management of dysmenorrhoea.
PG  - 326-9
AB  - The analgesic effect of flurbiprofen, aspirin and placebo in the treatment of 
      primary dysmenorrhoea was compared in 41 patients using a double blind triple 
      crossover study. No statistically significant differences were found between any 
      pair of treatments and the control for pain relief. Thirty patients had 
      assessments for all three treatment months, 11 preferred flurbiprofen, 9 
      preferred placebo, 6 preferred aspirin and 4 had no preference between any of the 
      treatments. Side effects were reported by 14 of the 41 patients: 3 during the 
      control month, 6 during the flurbiprofen month, 4 during the aspirin month and 7 
      during the placebo month.
FAU - Pogmore, J R
AU  - Pogmore JR
FAU - Filshie, G M
AU  - Filshie GM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Br J Obstet Gynaecol
JT  - British journal of obstetrics and gynaecology
JID - 7503752
RN  - 0 (Placebos)
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Dysmenorrhea/*drug therapy
MH  - Female
MH  - Flurbiprofen/*therapeutic use
MH  - Humans
MH  - Menstruation/drug effects
MH  - Placebos
MH  - Propionates/*therapeutic use
EDAT- 1980/04/01 00:00
MHDA- 1980/04/01 00:01
CRDT- 1980/04/01 00:00
PHST- 1980/04/01 00:00 [pubmed]
PHST- 1980/04/01 00:01 [medline]
PHST- 1980/04/01 00:00 [entrez]
AID - 10.1111/j.1471-0528.1980.tb04549.x [doi]
PST - ppublish
SO  - Br J Obstet Gynaecol. 1980 Apr;87(4):326-9. doi: 
      10.1111/j.1471-0528.1980.tb04549.x.

PMID- 6606810
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20180214
IS  - 0031-7012 (Print)
IS  - 0031-7012 (Linking)
VI  - 27 Suppl 1
DP  - 1983
TI  - Comparison of fecal blood loss after use of aspirin and suprofen.
PG  - 14-22
AB  - The effects of aspirin and suprofen on gastrointestinal blood loss were compared 
      in a double-blind, crossover study of 20 healthy male subjects. Fecal blood loss 
      was measured by 51Cr-labeled red cells. Subjects treated with aspirin (2,600 
      mg/day) experienced a mean fecal blood loss of 4.2 ml/day, compared with subjects 
      treated with suprofen (800 mg/day) whose mean fecal blood loss was 1.8 ml/day. 
      There was significantly greater (p less than 0.01) blood loss in the aspirin 
      group than in the suprofen group. Mean fecal blood loss in the suprofen group did 
      not differ appreciably from the fecal blood loss observed during the placebo 
      period (0.4 ml/day).
FAU - Arnold, J D
AU  - Arnold JD
FAU - Berger, A E
AU  - Berger AE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Phenylpropionates)
RN  - 988GU2F9PE (Suprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Chromium Radioisotopes
MH  - Double-Blind Method
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Occult Blood
MH  - Phenylpropionates/*adverse effects
MH  - Suprofen/*adverse effects
MH  - Time Factors
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1159/000137895 [doi]
PST - ppublish
SO  - Pharmacology. 1983;27 Suppl 1:14-22. doi: 10.1159/000137895.

PMID- 24099017
OWN - NLM
STAT- MEDLINE
DCOM- 20140703
LR  - 20161125
IS  - 1557-8224 (Electronic)
IS  - 1089-3261 (Linking)
VI  - 17
IP  - 4
DP  - 2013 Nov
TI  - Histopathologic manifestations of drug-induced hepatotoxicity.
PG  - 547-64, vii-viii
LID - S1089-3261(13)00033-0 [pii]
LID - 10.1016/j.cld.2013.07.004 [doi]
AB  - Drug-induced hepatotoxicity is underrecognized but increasingly identified as 
      causing acute and chronic liver disease. Several prescription drugs, 
      over-the-counter medications, dietary and/or supplementary agents, and herbal 
      products are hepatotoxic. Drug-induced liver injury mimics other primary acute 
      and chronic liver diseases and it should be considered in patients with 
      hepatobiliary disease. Certain drugs result in specific histopathologic patterns 
      of liver injury, which may help in sorting out the responsible drug. The 
      diagnosis of drug-induced hepatotoxicity is challenging. It involves excluding 
      other possible causes, careful medication history, the latent period between drug 
      exposure and symptom onset and/or abnormal liver tests, and histopathologic 
      findings.
CI  - Published by Elsevier Inc.
FAU - Zhang, Xuchen
AU  - Zhang X
AD  - Department of Pathology, VA Connecticut Health System and Yale University School 
      of Medicine, 310 Cedar Street, LH 108, New Haven, CT 06516, USA. Electronic 
      address: xuchen.zhang@yale.edu.
FAU - Ouyang, Jie
AU  - Ouyang J
FAU - Thung, Swan N
AU  - Thung SN
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130904
PL  - United States
TA  - Clin Liver Dis
JT  - Clinics in liver disease
JID - 9710002
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Cell Death/drug effects
MH  - Chemical and Drug Induced Liver Injury/diagnosis/*pathology
MH  - Hepatocytes/pathology
MH  - Humans
MH  - Immunohistochemistry
OTO - NOTNLM
OT  - Drug-induced hepatotoxicity
OT  - Drugs
OT  - Liver injury
OT  - Pathology
EDAT- 2013/10/09 06:00
MHDA- 2014/07/06 06:00
CRDT- 2013/10/09 06:00
PHST- 2013/10/09 06:00 [entrez]
PHST- 2013/10/09 06:00 [pubmed]
PHST- 2014/07/06 06:00 [medline]
AID - S1089-3261(13)00033-0 [pii]
AID - 10.1016/j.cld.2013.07.004 [doi]
PST - ppublish
SO  - Clin Liver Dis. 2013 Nov;17(4):547-64, vii-viii. doi: 10.1016/j.cld.2013.07.004. 
      Epub 2013 Sep 4.

PMID- 2411079
OWN - NLM
STAT- MEDLINE
DCOM- 19850917
LR  - 20131121
IS  - 0001-5555 (Print)
IS  - 0001-5555 (Linking)
VI  - 65
IP  - 3
DP  - 1985
TI  - Treatment of necrobiosis lipoidica with low-dose acetylsalicylic acid. A 
      randomized double-blind trial.
PG  - 230-4
AB  - 16 patients with clinically and histologically verified necrobiosis lipoidica 
      lesions were treated with either 40 mg acetylsalicylic acid or placebo daily for 
      24 weeks in a double-blind controlled study. The lesions became statistically 
      significantly larger in both groups in spite of inhibition of the aggregation of 
      the platelets in the acetylsalicylic group.
FAU - Beck, H I
AU  - Beck HI
FAU - Bjerring, P
AU  - Bjerring P
FAU - Rasmussen, I
AU  - Rasmussen I
FAU - Zachariae, H
AU  - Zachariae H
FAU - Stenbjerg, S
AU  - Stenbjerg S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Sweden
TA  - Acta Derm Venereol
JT  - Acta dermato-venereologica
JID - 0370310
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Necrobiosis Lipoidica/*drug therapy
MH  - Platelet Aggregation/drug effects
MH  - Random Allocation
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Derm Venereol. 1985;65(3):230-4.

PMID- 667675
OWN - NLM
STAT- MEDLINE
DCOM- 19780915
LR  - 20190902
IS  - 0008-2856 (Print)
IS  - 0008-2856 (Linking)
VI  - 25
IP  - 4
DP  - 1978 Jul
TI  - Halothane for status asthmaticus in the intensive care unit--a case report.
PG  - 329-30
AB  - A case report is presented demonstrating the beneficial beta2 stimulating effect 
      of halothane in a patient with status asthmaticus unresponsive to adequate 
      conventional therapy. Twenty-four hours after the commencement of therapy, 0.5 
      per cent of 1.0 per cent halothane was administered for one hour with sustained 
      reductions in peak inspiratory airway pressure and increases in dynamic and 
      static effective compliances.
FAU - Colaco, C M
AU  - Colaco CM
FAU - Crago, R R
AU  - Crago RR
FAU - Weisbert, A
AU  - Weisbert A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Canada
TA  - Can Anaesth Soc J
JT  - Canadian Anaesthetists' Society journal
JID - 0371163
RN  - R16CO5Y76E (Aspirin)
RN  - UQT9G45D1P (Halothane)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects
MH  - Asthma/chemically induced/*drug therapy
MH  - Halothane/*therapeutic use
MH  - Humans
MH  - Intensive Care Units
MH  - Male
EDAT- 1978/07/01 00:00
MHDA- 1978/07/01 00:01
CRDT- 1978/07/01 00:00
PHST- 1978/07/01 00:00 [pubmed]
PHST- 1978/07/01 00:01 [medline]
PHST- 1978/07/01 00:00 [entrez]
AID - 10.1007/BF03005658 [doi]
PST - ppublish
SO  - Can Anaesth Soc J. 1978 Jul;25(4):329-30. doi: 10.1007/BF03005658.

PMID- 19268256
OWN - NLM
STAT- MEDLINE
DCOM- 20090528
LR  - 20151119
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 19
IP  - 3
DP  - 2009 Mar
TI  - [Anticoagulation after renal transplantation: a multicenter survey on clinical 
      practice].
PG  - 186-91
LID - 10.1016/j.purol.2008.11.007 [doi]
AB  - OBJECTIVES: Graft thrombosis is a major complication of transplantation. However, 
      there are no recommendation on immediate postoperative thromboprophylaxis after 
      kidney transplantation. We recorded clinical practices in France. MATERIAL AND 
      METHODS: In 29 transplantation centres, four case studies were submitted to the 
      medical kidney transplantation referent (compatible graft from cadaveric donor, 
      without perioperative complication). N(o) 1: Man, 27-years-old, IgA 
      glomerulonephritis, without history of hypercoagulability or cardiovascular risk 
      factor. Hemodialysis since 12months. N(o) 2: Man, 53-years-old, with history of 
      deep venous thrombosis after cholecystectomy 15years before. Membranous 
      nephropathy. Hemodialysis since 10months. N(o) 3: Man, 58-years-old, with history 
      of myocardial infarction. On aspirin therapy. Nephroangiosclerosis and diabetic 
      nephropathy. Peritoneal dialysis since 6months. N(o) 4: Woman, 63-years-old. 
      Atrial fibrillation on vitamin K antagonists therapy. Lupus nephritis without 
      antiphospholipid syndrome. Hemodialysis since 12months. RESULTS: N(o) 1: No 
      anticoagulation therapy (62%), calcium heparin at prophylactic doses (34.5%). 
      N(o) 2: No anticoagulation therapy (38%), calcium heparin at prophylactic doses 
      (44.8%). N(o) 3: 62% interrupted aspirin of whom 22% without any immediate 
      anticoagulation and 55% replaced aspirin with calcium heparin at prophylactic 
      doses. Thirty-eight percent carried on with aspirin of whom 63.6% without other 
      prophylaxis and 27.3% in association with calcium heparin at prophylactic doses. 
      N(o) 4: Unfractionned heparin at curative dose (62%), unfractionned heparin at 
      prophylactic doses (17.2%), calcium heparin at prophylactic doses (13.8%). 
      CONCLUSION: Postoperative anticoagulation after renal transplantation is 
      established as a local dogma rather than evidence-based medicine. Guideline 
      recommendations and standardized protocols for the use of anticoagulation after 
      kidney transplantation should be developed.
FAU - Ripert, T
AU  - Ripert T
AD  - Département d'urologie-andrologie, CHU de Reims, rue du Général-Koenig, 51100 
      Reims, France. thomas_ripert@yahoo.fr
FAU - Menard, J
AU  - Menard J
FAU - Schoepen, Y
AU  - Schoepen Y
FAU - N'guyen, P
AU  - N'guyen P
FAU - Rieu, P
AU  - Rieu P
FAU - Brandt, B
AU  - Brandt B
FAU - Staerman, F
AU  - Staerman F
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
TT  - Quelle thromboprophylaxie après transplantation rénale ? Enquête sur la 
      prévention des thromboses du greffon en France.
DEP - 20090110
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la 
      Societe francaise d'urologie
JID - 9307844
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 37270-89-6 (calcium heparin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Female
MH  - France
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Kidney Transplantation/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Practice Patterns, Physicians'
MH  - Venous Thrombosis/*prevention & control
EDAT- 2009/03/10 09:00
MHDA- 2009/05/29 09:00
CRDT- 2009/03/10 09:00
PHST- 2008/07/31 00:00 [received]
PHST- 2008/11/06 00:00 [revised]
PHST- 2008/11/24 00:00 [accepted]
PHST- 2009/03/10 09:00 [entrez]
PHST- 2009/03/10 09:00 [pubmed]
PHST- 2009/05/29 09:00 [medline]
AID - S1166-7087(08)00552-6 [pii]
AID - 10.1016/j.purol.2008.11.007 [doi]
PST - ppublish
SO  - Prog Urol. 2009 Mar;19(3):186-91. doi: 10.1016/j.purol.2008.11.007. Epub 2009 Jan 
      10.

PMID- 19358313
OWN - NLM
STAT- MEDLINE
DCOM- 20091229
LR  - 20131121
IS  - 1099-0801 (Electronic)
IS  - 0269-3879 (Linking)
VI  - 23
IP  - 9
DP  - 2009 Sep
TI  - Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in 
      plasma using liquid chromatography-tandem mass spectrometry: application to 
      pharmacokinetic study.
PG  - 973-9
LID - 10.1002/bmc.1209 [doi]
AB  - A simple and sensitive analytical method using liquid chromatography-tandem mass 
      spectrometry (LC/MS/MS) for determination of acetylsalicylic acid (aspirin, ASA) 
      and its major metabolite, salicylic acid (SA), in animal plasma has been 
      developed and validated. Both ASA and SA in plasma samples containing potassium 
      fluoride were extracted using acetonitrile (protein precipitation) with 0.1% 
      formic acid in it. 6-Methoxysalicylic acid was used as the internal standard 
      (IS). The compounds were separated on a reversed-phase column. The multiple 
      reaction monitoring mode was used with ion transitions of m/z 178.9 --> 136.8, 
      137.0 --> 93.0 and 167.0 --> 123.0 for ASA, SA and IS, respectively. The lower 
      limits of quantification for ASA and SA were 3 and 30 ng/mL, respectively. The 
      developed method was successfully applied for the evaluation of pharmacokinetics 
      of ASA and SA after p.o. and i.v. administration of 1 mg/kg to rats.
CI  - Copyright (c) 2009 John Wiley & Sons, Ltd.
FAU - Xu, Xiangrong
AU  - Xu X
AD  - Eurofins/Product Safety Laboratories, 2394 US-130, Dayton, NJ 08810, USA. 
      austinxu@productsafetylabs.com
FAU - Koetzner, Lee
AU  - Koetzner L
FAU - Boulet, Jamie
AU  - Boulet J
FAU - Maselli, Harry
AU  - Maselli H
FAU - Beyenhof, Jessica
AU  - Beyenhof J
FAU - Grover, Gary
AU  - Grover G
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*blood/pharmacokinetics
MH  - Calibration
MH  - Chromatography, Liquid/*methods
MH  - Dogs
MH  - Drug Stability
MH  - Linear Models
MH  - Male
MH  - Pharmacokinetics
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reproducibility of Results
MH  - Salicylic Acid/*blood/pharmacokinetics
MH  - Sensitivity and Specificity
MH  - Tandem Mass Spectrometry/*methods
EDAT- 2009/04/10 09:00
MHDA- 2009/12/30 06:00
CRDT- 2009/04/10 09:00
PHST- 2009/04/10 09:00 [entrez]
PHST- 2009/04/10 09:00 [pubmed]
PHST- 2009/12/30 06:00 [medline]
AID - 10.1002/bmc.1209 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2009 Sep;23(9):973-9. doi: 10.1002/bmc.1209.

PMID- 17989545
OWN - NLM
STAT- MEDLINE
DCOM- 20080410
LR  - 20220317
IS  - 0952-7907 (Print)
IS  - 0952-7907 (Linking)
VI  - 20
IP  - 6
DP  - 2007 Dec
TI  - Low-dose aspirin and clopidogrel: how to act in patients scheduled for day 
      surgery.
PG  - 531-4
AB  - PURPOSE OF REVIEW: With the increasing use of antiplatelet drug treatment, 
      complications resulting from its interference with invasive procedures (surgery 
      or regional anaesthesia) have become an everyday challenge to the surgical team. 
      The purpose of this review is to examine the most recent findings and integrate 
      them into the ambulatory surgery setting. RECENT FINDINGS: Recent studies have 
      outlined the risks of withholding antiplatelet drug treatment, but it is now 
      generally considered to be preferable to withhold treatment than to maintain it. 
      The role of low molecular weight heparins or short-life NSAIDs as bridge drugs is 
      now discussed and their usefulness challenged. SUMMARY: Most ambulatory surgical 
      procedures present low bleeding risk. The current attitude in this setting is to 
      maintain aspirin therapy and possible antiplatelet drug inhibitors throughout the 
      perioperative period. High-risk patients proposed for high-risk surgery should 
      not be treated as outpatients.
FAU - Servin, Frédérique
AU  - Servin F
AD  - Department of Anaesthesia and Intensive Care, Bichat Hospital, Paris, France. 
      fservin@magic.fr
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Anaesthesiol
JT  - Current opinion in anaesthesiology
JID - 8813436
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anesthesia
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clopidogrel
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Postoperative Hemorrhage/chemically induced/*prevention & control
MH  - Practice Guidelines as Topic/standards
MH  - Risk Assessment
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
RF  - 10
EDAT- 2007/11/09 09:00
MHDA- 2008/04/11 09:00
CRDT- 2007/11/09 09:00
PHST- 2007/11/09 09:00 [pubmed]
PHST- 2008/04/11 09:00 [medline]
PHST- 2007/11/09 09:00 [entrez]
AID - 00001503-200712000-00008 [pii]
AID - 10.1097/ACO.0b013e3282f15f95 [doi]
PST - ppublish
SO  - Curr Opin Anaesthesiol. 2007 Dec;20(6):531-4. doi: 10.1097/ACO.0b013e3282f15f95.

PMID- 16649551
OWN - NLM
STAT- MEDLINE
DCOM- 20060530
LR  - 20131121
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 61
IP  - 4
DP  - 2006 Apr
TI  - ACEA (arachidonyl-2-chloroethylamide), the selective cannabinoid CB1 receptor 
      agonist, protects against aspirin-induced gastric ulceration.
PG  - 341-2
AB  - The effect of a selective cannabinoid CB1 receptor agonist, ACEA 
      (arachidonyl-2-chloroethylamide) in an aspirin-induced ulcer model was studied in 
      rats. ACEA (1.25-5 mg/kg i.p.) significantly reduced gastric ulcer formation to 
      24, 21 and 0.6% respectively. These results confirm the cytoprotective effect of 
      CB1 receptor agonists and suggest that the endocannabinoid system might be the 
      target for a novel class of anti-ulcer drugs.
FAU - Rutkowska, M
AU  - Rutkowska M
AD  - Department of Pharmacology, Medical University of Wrocław, 2 Mikulicza-Radeckiego 
      Str., 50-345 Wrocław, Poland. rutkowsk@fa.am.wroc.pl
FAU - Fereniec-Gołtbiewska, L
AU  - Fereniec-Gołtbiewska L
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Receptor, Cannabinoid, CB1)
RN  - 0 (arachidonyl-2-chloroethylamide)
RN  - 884KT10YB7 (Ranitidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*antagonists & inhibitors/toxicity
MH  - *Anti-Ulcer Agents
MH  - Arachidonic Acids/*pharmacology
MH  - Aspirin/*antagonists & inhibitors/toxicity
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/pathology
MH  - Ranitidine/therapeutic use
MH  - Rats
MH  - Receptor, Cannabinoid, CB1/*agonists
MH  - Stomach Ulcer/*chemically induced/pathology/*prevention & control
EDAT- 2006/05/03 09:00
MHDA- 2006/05/31 09:00
CRDT- 2006/05/03 09:00
PHST- 2006/05/03 09:00 [pubmed]
PHST- 2006/05/31 09:00 [medline]
PHST- 2006/05/03 09:00 [entrez]
PST - ppublish
SO  - Pharmazie. 2006 Apr;61(4):341-2.

PMID- 8909901
OWN - NLM
STAT- MEDLINE
DCOM- 19970320
LR  - 20190512
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 17
IP  - 10
DP  - 1996 Oct
TI  - Low molecular weight heparins: a valuable tool in the treatment of acute coronary 
      syndromes.
PG  - 1470-6
AB  - Standard heparin, low molecular weight heparin and aspirin are at present the 
      only antithrombotic agents of proven value in the initial treatment of patients 
      with an acute coronary syndrome. The combined use of aspirin and one of the 
      heparins for at least 6 days should be considered for all such patients. With 
      their high bio-availability after subcutaneous injection and prolonged half-life, 
      low molecular weight heparins simplify short-term treatment in the acute phase 
      and enable long-term therapy to be maintained on an outpatient basis without the 
      need for repeated laboratory monitoring of anticoagulant effects. Such long-term 
      therapy would appear to be beneficial, at least in high-risk patients, in the 
      light of increasing evidence that the underlying lesion in acute coronary 
      syndromes resolves over a period of weeks or months.
FAU - Wallentin, L
AU  - Wallentin L
AD  - Department of Cardiology, University Hospital, Uppsala, Sweden.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/*drug therapy/mortality
MH  - Aspirin/administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/adverse effects
MH  - Humans
MH  - Infusions, Intravenous
MH  - Myocardial Infarction/*drug therapy/mortality
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
RF  - 90
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.eurheartj.a014708 [doi]
PST - ppublish
SO  - Eur Heart J. 1996 Oct;17(10):1470-6. doi: 
      10.1093/oxfordjournals.eurheartj.a014708.

PMID- 8160214
OWN - NLM
STAT- MEDLINE
DCOM- 19940519
LR  - 20190819
IS  - 0378-4274 (Print)
IS  - 0378-4274 (Linking)
VI  - 71
IP  - 3
DP  - 1994 May
TI  - Protection by indomethacin against the lethality and hepatotoxicity of phalloidin 
      in mice.
PG  - 257-69
AB  - The present study examined the possible involvement of endogenous 
      cyclooxygenase-derived factors in the lethality and hepatic hemorrhagic necrosis 
      induced by phalloidin. Mice were pretreated with indomethacin, aspirin or 
      ibuprofen (all inhibitors of cyclooxygenase) and injected with phalloidin (2 
      mg/kg). The toxin induced 75% lethality and caused severe hemorrhagic necrosis of 
      the liver associated with increased serum levels of AST and ALT. Indomethacin 
      completely prevented the mortality and hepatic damage elicited by phalloidin as 
      judged by morphologic analysis and serum AST and ALT release. The in vitro 
      addition of indomethacin to suspensions of freshly-isolated hepatocytes decreased 
      plasma membrane bleb formation induced by phalloidin. In contrast to 
      indomethacin, aspirin and ibuprofen did not influence phalloidin toxicity in 
      vivo. These results suggest that inhibition of prostanoids per se may not be the 
      sole mechanism of protection by indomethacin.
FAU - Barriault, C
AU  - Barriault C
AD  - Department of Pharmacology, Université de Montréal, Quebec, Canada.
FAU - Audet, M
AU  - Audet M
FAU - Yousef, I M
AU  - Yousef IM
FAU - Tuchweber, B
AU  - Tuchweber B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Toxicol Lett
JT  - Toxicology letters
JID - 7709027
RN  - 17466-45-4 (Phalloidine)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Alanine Transaminase/blood/drug effects
MH  - Animals
MH  - Aspartate Aminotransferases/blood/drug effects
MH  - Aspirin/pharmacology/therapeutic use
MH  - Chemical and Drug Induced Liver Injury
MH  - Female
MH  - Ibuprofen/pharmacology/therapeutic use
MH  - Indomethacin/pharmacology/*therapeutic use
MH  - Liver/drug effects/pathology
MH  - Liver Diseases/enzymology/pathology/*prevention & control
MH  - Mice
MH  - Microscopy, Electron
MH  - Phalloidine/antagonists & inhibitors/*toxicity
MH  - Time Factors
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
AID - 0378-4274(94)90112-0 [pii]
AID - 10.1016/0378-4274(94)90112-0 [doi]
PST - ppublish
SO  - Toxicol Lett. 1994 May;71(3):257-69. doi: 10.1016/0378-4274(94)90112-0.

PMID- 26838691
OWN - NLM
STAT- MEDLINE
DCOM- 20170814
LR  - 20181202
IS  - 1532-2092 (Electronic)
IS  - 1099-5129 (Print)
IS  - 1099-5129 (Linking)
VI  - 18
IP  - 7
DP  - 2016 Jul
TI  - Cost effectiveness of left atrial appendage closure with the Watchman device for 
      atrial fibrillation patients with absolute contraindications to warfarin.
PG  - 979-86
LID - 10.1093/europace/euv412 [doi]
AB  - AIMS: Atrial fibrillation (AF) patients with contraindications to oral 
      anticoagulation have had few options for stroke prevention. Recently, a novel 
      oral anticoagulant, apixaban, and percutaneous left atrial appendage closure 
      (LAAC) have emerged as safe and effective therapies for stroke risk reduction in 
      these patients. This analysis assessed the cost effectiveness of LAAC with the 
      Watchman device relative to apixaban and aspirin therapy in patients with 
      non-valvular AF and contraindications to warfarin therapy. METHODS AND RESULTS: A 
      cost-effectiveness model was constructed using data from three studies on stroke 
      prevention in patients with contraindications: the ASAP study evaluating the 
      Watchman device, the ACTIVE A trial of aspirin and clopidogrel, and the AVERROES 
      trial evaluating apixaban. The cost-effectiveness analysis was conducted from a 
      German healthcare payer perspective over a 20-year time horizon. Left atrial 
      appendage closure yielded more quality-adjusted life years (QALYs) than aspirin 
      and apixaban by 2 and 4 years, respectively. At 5 years, LAAC was cost effective 
      compared with aspirin with an incremental cost-effectiveness ratio (ICER) of €16 
      971. Left atrial appendage closure was cost effective compared with apixaban at 7 
      years with an ICER of €9040. Left atrial appendage closure was cost saving and 
      more effective than aspirin and apixaban at 8 years and remained so throughout 
      the 20-year time horizon. CONCLUSIONS: This analysis demonstrates that LAAC with 
      the Watchman device is a cost-effective and cost-saving solution for stroke risk 
      reduction in patients with non-valvular AF who are at risk for stroke but have 
      contraindications to warfarin.
CI  - © The Author 2016. Published by Oxford University Press on behalf of the European 
      Society of Cardiology.
FAU - Reddy, Vivek Y
AU  - Reddy VY
AD  - Mount Sinai Medical Center, One Gustave L. Levy Place, Box 1030, New York, NY 
      10029, USA vivek.reddy@mountsinai.org.
FAU - Akehurst, Ronald L
AU  - Akehurst RL
AD  - University of Sheffield, Sheffield, UK.
FAU - Armstrong, Shannon O
AU  - Armstrong SO
AD  - GfK, Wayland, MA, USA.
FAU - Amorosi, Stacey L
AU  - Amorosi SL
AD  - Boston Scientific, Marlborough, MA, USA.
FAU - Brereton, Nic
AU  - Brereton N
AD  - BresMed, Sheffield, UK.
FAU - Hertz, Deanna S
AU  - Hertz DS
AD  - GfK, Wayland, MA, USA.
FAU - Holmes, David R Jr
AU  - Holmes DR Jr
AD  - Mayo Clinic, Rochester, MN, USA.
LA  - eng
PT  - Journal Article
DEP - 20160202
PL  - England
TA  - Europace
JT  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal 
      of the working groups on cardiac pacing, arrhythmias, and cardiac cellular 
      electrophysiology of the European Society of Cardiology
JID - 100883649
RN  - 0 (Anticoagulants)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Europace. 2017 May 1;19(5):882. PMID: 27194542
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*economics/therapeutic use
MH  - Atrial Appendage/*surgery
MH  - Atrial Fibrillation/physiopathology/*therapy
MH  - Cardiac Surgical Procedures/*instrumentation
MH  - Clopidogrel
MH  - Contraindications
MH  - Cost-Benefit Analysis
MH  - Germany
MH  - Humans
MH  - Markov Chains
MH  - Models, Theoretical
MH  - Pyrazoles/*economics/therapeutic use
MH  - Pyridones/*economics/therapeutic use
MH  - Quality of Life
MH  - Quality-Adjusted Life Years
MH  - Stroke/*prevention & control
MH  - Ticlopidine/analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Warfarin
PMC - PMC4927063
OTO - NOTNLM
OT  - Apixaban
OT  - Contraindicated
OT  - Cost-effectiveness analysis
OT  - Left atrial appendage closure
OT  - Stroke prevention
OT  - Watchman
EDAT- 2016/02/04 06:00
MHDA- 2017/08/15 06:00
CRDT- 2016/02/04 06:00
PHST- 2015/08/17 00:00 [received]
PHST- 2015/11/04 00:00 [accepted]
PHST- 2016/02/04 06:00 [entrez]
PHST- 2016/02/04 06:00 [pubmed]
PHST- 2017/08/15 06:00 [medline]
AID - euv412 [pii]
AID - 10.1093/europace/euv412 [doi]
PST - ppublish
SO  - Europace. 2016 Jul;18(7):979-86. doi: 10.1093/europace/euv412. Epub 2016 Feb 2.

PMID- 32165224
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 580
DP  - 2020 Apr 30
TI  - Insights on the role of excipients and tablet matrix porosity on aspirin 
      stability.
PG  - 119218
LID - S0378-5173(20)30202-7 [pii]
LID - 10.1016/j.ijpharm.2020.119218 [doi]
AB  - Excipient-moisture interaction can be a critical attribute in determination of 
      product stability. This study aimed to investigate influence of integrating 
      excipients having different moisture interaction into moisture sensitive drug 
      formulations. Aspirin was formulated with maize starch (MS), microcrystalline 
      cellulose (MCC) and calcium hydrogen phosphate dihydrate (DCP). The excipients 
      were evaluated for their inherent moisture content and water activity. Tablets 
      fabricated at different compression pressures were exposed to 40 °C, 75% relative 
      humidity for a stipulated period before analyzing for aspirin degradation. The 
      results revealed that while MS had higher moisture content, the water activity 
      was relatively low. Consequently, MS tablets had lower aspirin degradation than 
      MCC and DCP tablets. In contrast, high water activity of DCP resulted in greater 
      aspirin degradation. This was despite the low moisture content of DCP. Influence 
      of tablet porosity on aspirin degradation was minimal. This illustrated the 
      fugacity of moisture, possessing high thermodynamic activity and physical spatial 
      delimitation would not suppress its distribution. The findings suggested that 
      excipients possessing high water retentive capacity could potentially be useful 
      as internal tablet desiccants by acting as a moisture scavenger. This study also 
      highlights the importance of water activity in preformulation studies related to 
      the choice of excipients.
CI  - Copyright © 2020 Elsevier B.V. All rights reserved.
FAU - Veronica, Natalia
AU  - Veronica N
AD  - GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, 
      National University of Singapore, 18 Science Drive 4, Singapore 117543, 
      Singapore.
FAU - Liew, Celine Valeria
AU  - Liew CV
AD  - GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, 
      National University of Singapore, 18 Science Drive 4, Singapore 117543, 
      Singapore.
FAU - Heng, Paul Wan Sia
AU  - Heng PWS
AD  - GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, 
      National University of Singapore, 18 Science Drive 4, Singapore 117543, 
      Singapore. Electronic address: phapaulh@nus.edu.sg.
LA  - eng
PT  - Journal Article
DEP - 20200309
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Calcium Phosphates)
RN  - 0 (Excipients)
RN  - 0 (Tablets)
RN  - 059QF0KO0R (Water)
RN  - 9004-34-6 (Cellulose)
RN  - 9005-25-8 (Starch)
RN  - O7TSZ97GEP (calcium phosphate, dibasic, dihydrate)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Calcium Phosphates/chemistry
MH  - Cellulose/chemistry
MH  - Chemistry, Pharmaceutical/methods
MH  - Drug Compounding/methods
MH  - Excipients/*chemistry
MH  - Porosity
MH  - Pressure
MH  - Starch/chemistry
MH  - Tablets/*chemistry
MH  - Tensile Strength
MH  - Water/chemistry
OTO - NOTNLM
OT  - Hydrolysis
OT  - Moisture sorption
OT  - Porosity
OT  - Preformulation
OT  - Tablet
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/03/14 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/03/14 06:00
PHST- 2020/01/02 00:00 [received]
PHST- 2020/03/05 00:00 [revised]
PHST- 2020/03/08 00:00 [accepted]
PHST- 2020/03/14 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
PHST- 2020/03/14 06:00 [entrez]
AID - S0378-5173(20)30202-7 [pii]
AID - 10.1016/j.ijpharm.2020.119218 [doi]
PST - ppublish
SO  - Int J Pharm. 2020 Apr 30;580:119218. doi: 10.1016/j.ijpharm.2020.119218. Epub 
      2020 Mar 9.

PMID- 16839339
OWN - NLM
STAT- MEDLINE
DCOM- 20061006
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 4
IP  - 7
DP  - 2006 Jul
TI  - Aspirin in the prevention and treatment of venous thromboembolism.
PG  - 1470-5
AB  - This review summarizes available evidence on effects of aspirin on incidence and 
      outcomes of venous thromboembolism (VTE). From a pathophysiological point of 
      view, inhibition of platelet aggregation is associated with an impaired thrombus 
      formation both in an experimental model of venous thrombosis and in vivo. 
      Epidemiological evidence in support of a beneficial effect of acetylsalicylic 
      acid on VTE incidence is provided by the Antiplatelet Trialists' Collaboration 
      meta-analysis of studies on the use of antiplatelet agents in cardiovascular risk 
      reduction, showing a significant 25% risk reduction of pulmonary embolism. 
      Moreover, a meta-analysis on older trials of antiplatelet agents in postsurgical 
      VTE prevention and the large Pulmonary Embolism Prevention trial demonstrate a 
      protective effect of the same magnitude: 25-30%. However, as low-molecular-weight 
      heparins (LMWH) and vitamin K antagonists (VKA) have shown a superior efficacy 
      and safety profile, and no direct comparisons have been made between aspirin, 
      LMWH and VKA in prolonged use, the most recent guidelines advise against aspirin 
      monotherapy for thromboprophylaxis in the surgical patient. Currently, there is 
      no evidence to support a role for aspirin in air travel-related VTE. Regarding 
      prevention of recurrent VTE, studies are ongoing to determine the potential role 
      of aspirin after a first unprovoked VTE.
FAU - Hovens, M M C
AU  - Hovens MM
AD  - Department of General Internal Medicine, Section of Vascular Medicine, Leiden 
      University Medical Center, Leiden, the Netherlands. m.m.c.hovens@lumc.nl
FAU - Snoep, J D
AU  - Snoep JD
FAU - Tamsma, J T
AU  - Tamsma JT
FAU - Huisman, M V
AU  - Huisman MV
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Secondary Prevention
MH  - Thromboembolism/*drug therapy/etiology/prevention & control
MH  - Travel
MH  - Treatment Outcome
MH  - Venous Thrombosis/*drug therapy/etiology/prevention & control
RF  - 40
EDAT- 2006/07/15 09:00
MHDA- 2006/10/07 09:00
CRDT- 2006/07/15 09:00
PHST- 2006/07/15 09:00 [pubmed]
PHST- 2006/10/07 09:00 [medline]
PHST- 2006/07/15 09:00 [entrez]
AID - S1538-7836(22)13439-2 [pii]
AID - 10.1111/j.1538-7836.2006.01928.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2006 Jul;4(7):1470-5. doi: 10.1111/j.1538-7836.2006.01928.x.

PMID- 15193477
OWN - NLM
STAT- MEDLINE
DCOM- 20040714
LR  - 20131121
IS  - 0015-0282 (Print)
IS  - 0015-0282 (Linking)
VI  - 81
IP  - 6
DP  - 2004 Jun
TI  - Low-dose aspirin in a short regimen as standard treatment in in vitro 
      fertilization: a randomized, prospective study.
PG  - 1560-4
AB  - OBJECTIVE: To determine if treatment with low-dose aspirin in a short regimen 
      improves the outcome in a nonselected IVF population as compared with no 
      treatment. DESIGN: Prospective, randomized study where IVF patients were given 
      aspirin or received no treatment. SETTING: IVF clinic. PATIENT(S): The study 
      included 1380 consecutive IVF cycles. INTERVENTION(S): Women undergoing IVF were 
      randomly assigned to treatment with aspirin 75 mg daily from the day of embryo 
      transfer (ET) until pregnancy test or no treatment in an open study. MAIN OUTCOME 
      MEASURE(S): Birth rate per ET. RESULT(S): Background characteristics were similar 
      in the two groups studied except for a minor difference in number of embryos 
      transferred (2.1 vs. 2.0). Birth rate was 27.2% in the aspirin group as compared 
      with 23.2% in the nontreated group, giving an odds ratio, adjusted for number of 
      embryos transferred, of 1.2 (95% confidence interval, 1.0-1.6). CONCLUSION(S): 
      The increased birth rate with aspirin compared with no treatment was significant. 
      Given the importance of every birth in IVF, especially when taking into account 
      the limited number of IVF cycles that are normally performed in an individual 
      woman, any treatment to improve birth rate is important.
FAU - Waldenström, Urban
AU  - Waldenström U
AD  - In Vitro Fertilization Unit, Falun Hospital, Falun, Sweden. 
      waldenstrom@ltdalarna.se
FAU - Hellberg, Dan
AU  - Hellberg D
FAU - Nilsson, Staffan
AU  - Nilsson S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Birth Rate
MH  - Confidence Intervals
MH  - Dose-Response Relationship, Drug
MH  - Embryo Transfer
MH  - Female
MH  - Fertilization in Vitro/*methods
MH  - Humans
MH  - Odds Ratio
MH  - Pregnancy
MH  - Treatment Outcome
EDAT- 2004/06/15 05:00
MHDA- 2004/07/15 05:00
CRDT- 2004/06/15 05:00
PHST- 2003/07/22 00:00 [received]
PHST- 2004/02/12 00:00 [revised]
PHST- 2004/02/12 00:00 [accepted]
PHST- 2004/06/15 05:00 [pubmed]
PHST- 2004/07/15 05:00 [medline]
PHST- 2004/06/15 05:00 [entrez]
AID - S0015028204003450 [pii]
AID - 10.1016/j.fertnstert.2004.02.082 [doi]
PST - ppublish
SO  - Fertil Steril. 2004 Jun;81(6):1560-4. doi: 10.1016/j.fertnstert.2004.02.082.

PMID- 6971236
OWN - NLM
STAT- MEDLINE
DCOM- 19810613
LR  - 20190722
IS  - 0016-5107 (Print)
IS  - 0016-5107 (Linking)
VI  - 27
IP  - 1
DP  - 1981 Feb
TI  - Does aspirin prolong bleeding from gastric biopsies in man?
PG  - 1-5
AB  - Aspirin prolongs skin bleeding time in man by inducing abnormal platelet 
      function. Prolongation of gastric bleeding time has been postulated as a 
      mechanism for gastric hemorrhage after aspirin in man. To determine whether 
      endoscopic gastric biopsy is safe in patients taking aspirin, we studied the 
      effects of acute and chronic aspirin use on gastric bleeding time in four groups 
      of subjects. Gastric bleeding time was assessed directly following endoscopic 
      biopsy. Skin bleeding time was done by the Mielke method. Control subjects (group 
      I) were studied twice at one-week intervals to determine reproducibility of the 
      gastric bleeding time technique. The effect of aspirin on gastric and skin 
      bleeding time when given to normal volunteers for 24 hours (group II) and for two 
      weeks (group III) and to rheumatic disease patients on a chronic basis (group IV) 
      was also studied. In normal volunteers given aspirin for 24 hours or two weeks, 
      gastric bleeding time was not affected in spite of skin bleeding time being 
      significantly prolonged over baseline. Gastric bleeding time was less then skin 
      bleeding time in all groups including patients with rheumatoid arthritis (p less 
      than 0.05). We conclude that aspirin ingestion does not prolong gastric bleeding 
      time in man and that gastric biopsy is not contraindicated on th basis of recent 
      aspirin ingestion.
FAU - O'Laughlin, J C
AU  - O'Laughlin JC
FAU - Hoftiezer, J W
AU  - Hoftiezer JW
FAU - Mahoney, J P
AU  - Mahoney JP
FAU - Ivey, K J
AU  - Ivey KJ
LA  - eng
GR  - 440028712/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastrointest Endosc
JT  - Gastrointestinal endoscopy
JID - 0010505
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - *Biopsy
MH  - Bleeding Time
MH  - Gastric Mucosa/drug effects/*pathology
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Gastroscopy
MH  - Humans
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
AID - S0016-5107(81)73131-6 [pii]
AID - 10.1016/s0016-5107(81)73131-6 [doi]
PST - ppublish
SO  - Gastrointest Endosc. 1981 Feb;27(1):1-5. doi: 10.1016/s0016-5107(81)73131-6.

PMID- 30549489
OWN - NLM
STAT- MEDLINE
DCOM- 20191014
LR  - 20191014
IS  - 1555-2101 (Electronic)
IS  - 0160-6689 (Linking)
VI  - 80
IP  - 1
DP  - 2018 Dec 4
TI  - A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and 
      N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression.
LID - 18m12200 [pii]
LID - 10.4088/JCP.18m12200 [doi]
AB  - OBJECTIVE: Neuroinflammation has been implicated in the pathophysiology of 
      bipolar disorder. Some evidence shows that nonsteroidal anti-inflammatory drugs 
      (NSAIDs) have promising antidepressant effects. The antioxidant N-acetylcysteine 
      (NAC) may enhance the effects of NSAIDs. No study has, however, tested the 
      adjunctive therapeutic benefits of an NSAID and NAC in bipolar disorder. METHODS: 
      The sample included 24 medicated patients diagnosed with DSM-IV-TR bipolar 
      disorder who were aged 18-65 years and had a Montgomery-Asberg Depression Rating 
      Scale (MADRS) score ≥ 20. Participants were randomly assigned to receive either 
      aspirin (1,000 mg), NAC (1,000 mg), combined aspirin and NAC (1,000 mg each), or 
      placebo. Data were collected between 2013 and 2017. The primary outcome was a ≥ 
      50% reduction in MADRS scores. Participants completed mood and global functioning 
      questionnaires. They also underwent blood tests prior to and following 8 and 16 
      weeks of treatment. A Bayesian analytic method was adopted, and posterior 
      probability distributions were calculated to determine the probability of 
      treatment response. RESULTS: Following the first 8-week treatment phase, 
      individuals on treatment with placebo and NAC + aspirin had a similar probability 
      for successful treatment response (about 70%). Following a 16-week treatment 
      period, NAC + aspirin was associated with higher probability of treatment 
      response (67%) compared to placebo (55%), NAC (57%), and aspirin (33%). There was 
      no treatment effect on interleukin-6 and C-reactive protein levels at either 8 or 
      16 weeks. CONCLUSIONS: The coadministration of NAC and aspirin during a period of 
      16 weeks was associated with a reduction in depressive symptoms. The adverse 
      effects were minimal. These preliminary findings may serve as a starting point 
      for future studies assessing the efficacy, tolerability, and safety of 
      anti-inflammatory and antioxidant agents in the treatment of bipolar depression. 
      TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01797575.
CI  - © Copyright 2018 Physicians Postgraduate Press, Inc.
FAU - Bauer, Isabelle E
AU  - Bauer IE
AD  - University of Texas Health Science Center at Houston, McGovern Medical School, 
      Department of Psychiatry and Behavioral Sciences, 1941 East Rd, Houston, TX 
      77054. Isabelle.E.Bauer@uth.tmc.edu.
AD  - Department of Psychiatry and Behavioral Sciences, University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
FAU - Green, Charles
AU  - Green C
AD  - Department of Psychiatry and Behavioral Sciences, University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
FAU - Colpo, Gabriela D
AU  - Colpo GD
AD  - Department of Psychiatry and Behavioral Sciences, University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
FAU - Teixeira, Antonio L
AU  - Teixeira AL
AD  - Department of Psychiatry and Behavioral Sciences, University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
FAU - Selvaraj, Sudhakar
AU  - Selvaraj S
AD  - Department of Psychiatry and Behavioral Sciences, University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
FAU - Durkin, Katherine
AU  - Durkin K
AD  - Department of Psychiatry and Behavioral Sciences, University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
FAU - Zunta-Soares, Giovana B
AU  - Zunta-Soares GB
AD  - Department of Psychiatry and Behavioral Sciences, University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
FAU - Soares, Jair C
AU  - Soares JC
AD  - Department of Psychiatry and Behavioral Sciences, University of Texas Health 
      Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01797575
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20181204
PL  - United States
TA  - J Clin Psychiatry
JT  - The Journal of clinical psychiatry
JID - 7801243
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/*administration & dosage/pharmacokinetics
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Bayes Theorem
MH  - Bipolar Disorder/complications/*drug therapy
MH  - Chemotherapy, Adjuvant
MH  - Depressive Disorder/complications/*drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress/drug effects
MH  - Treatment Outcome
EDAT- 2018/12/15 06:00
MHDA- 2019/10/15 06:00
CRDT- 2018/12/15 06:00
PHST- 2018/02/20 00:00 [received]
PHST- 2018/06/08 00:00 [accepted]
PHST- 2018/12/15 06:00 [entrez]
PHST- 2018/12/15 06:00 [pubmed]
PHST- 2019/10/15 06:00 [medline]
AID - 18m12200 [pii]
AID - 10.4088/JCP.18m12200 [doi]
PST - epublish
SO  - J Clin Psychiatry. 2018 Dec 4;80(1):18m12200. doi: 10.4088/JCP.18m12200.

PMID- 17900460
OWN - NLM
STAT- MEDLINE
DCOM- 20071015
LR  - 20220316
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
VI  - 50
IP  - 4
DP  - 2007 Oct
TI  - Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes 
      and Practice Patterns Study (DOPPS).
PG  - 602-11
AB  - BACKGROUND: We investigated aspirin-prescribing patterns and potential benefits 
      on cardiovascular morbidity and mortality in hemodialysis patients. STUDY DESIGN: 
      Cohort study. SETTING & PARTICIPANTS: Data included 28,320 randomly selected 
      hemodialysis patients from the Dialysis Outcomes and Practice Patterns Study I 
      and II. PREDICTOR: Aspirin prescription at study baseline. OUTCOMES & 
      MEASUREMENTS: Prescription was investigated by means of logistic regression. 
      All-cause mortality, all-cause hospitalization, cardiac event, myocardial 
      infarction, cerebrovascular (CVA), gastrointestinal bleed, transient ischemic 
      attack, and subdural hematoma were examined. Cox regression examined the risk of 
      mortality and hospitalization. All models accounted for facility clustering and 
      demographics and comorbid conditions. RESULTS: Wide variation was found in 
      aspirin prescription, from 8% in Japan to 41% in Australia and New Zealand. 
      Characteristics significantly associated with increased odds of prescription 
      included coronary artery disease, cerebrovascular disease, diabetes, male sex, 
      nonblack race, peripheral vascular disease, age, hypertension, and absence of 
      gastrointestinal bleeding. Aspirin was associated with decreased risk of stroke 
      in all patients (relative risk [RR], 0.82; P < 0.01) and increased risk of 
      myocardial infarction (RR, 1.21; P = 0.01) and cardiac event (RR, 1.08; P < 0.01) 
      in all patients, with similar results for patients with coronary artery disease. 
      There was no increase in gastrointestinal bleeding. LIMITATIONS: Observational 
      studies are not protected from biases, despite adjustments. There is potential 
      for aspirin use to be underreported because of its availability without 
      prescription. CONCLUSIONS: The hypothesis that prescribing aspirin to 
      hemodialysis patients decreases cardiovascular disease risk is not supported. 
      Aspirin might decrease CVA and appears not to increase hemorrhagic risk. This 
      should be an incentive for randomized controlled trials.
FAU - Ethier, Jean
AU  - Ethier J
AD  - Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada. 
      ethierje@sympatico.ca
FAU - Bragg-Gresham, Jennifer L
AU  - Bragg-Gresham JL
FAU - Piera, Luis
AU  - Piera L
FAU - Akizawa, Tadao
AU  - Akizawa T
FAU - Asano, Yasushi
AU  - Asano Y
FAU - Mason, Nancy
AU  - Mason N
FAU - Gillespie, Brenda W
AU  - Gillespie BW
FAU - Young, Eric W
AU  - Young EW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Kidney Dis. 2008 Jun;51(6):1070-1; author reply 1071. PMID: 18501791
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/prevention & control
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - *Drug Prescriptions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Practice Patterns, Physicians'/*trends
MH  - Renal Dialysis/adverse effects/*trends
MH  - Treatment Outcome
EDAT- 2007/09/29 09:00
MHDA- 2007/10/16 09:00
CRDT- 2007/09/29 09:00
PHST- 2007/02/01 00:00 [received]
PHST- 2007/07/05 00:00 [accepted]
PHST- 2007/09/29 09:00 [pubmed]
PHST- 2007/10/16 09:00 [medline]
PHST- 2007/09/29 09:00 [entrez]
AID - S0272-6386(07)01036-0 [pii]
AID - 10.1053/j.ajkd.2007.07.007 [doi]
PST - ppublish
SO  - Am J Kidney Dis. 2007 Oct;50(4):602-11. doi: 10.1053/j.ajkd.2007.07.007.

PMID- 6790575
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20190606
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 68
IP  - 2
DP  - 1981 Aug
TI  - Differential effects of two doses of aspirin on platelets-vessel wall 
      introduction in vivo.
PG  - 382-7
AB  - Platelet cyclooxygenase appears to be more sensitive to aspirin than the arterial 
      endothelial cell cyclooxygenase. To investigate the dose-related effects of 
      aspirin on platelet-vessel wall interaction in acute vascular injury, male New 
      Zealand White rabbits were treated with either (a) aspirin (150 mg/kg body wt; n 
      = 6), (b) aspirin (30 mg/kg; n = 6), or (c) vehicle (n = 10). After treatment, 
      autologous 111In-platelets were injected and deendothelialization of a 10-cm long 
      segment of abdominal aorta was induced by a balloon catheter. Rabbits were killed 
      3 h after injury and radioactive counts and percentages of injected radioactivity 
      per gram dry weight of tissue or blood were determined. The 30 mg aspirin group 
      had a significantly lower radioactive count (62.13 +/- SD 6.07 x 10(3) cpm) and 
      percentage of injected radioactivity (0.024 +/- 0.003%) per gram dry weight of 
      damaged aortic tissue than the control (1,167.82 +/- 212.31 x 10(3) cpm/g tissue 
      and 0.435 +/- 0.079%, respectively). By contrast, the 150-mg aspirin group had an 
      elevation of radioactive counts (4,343.12 +/- 556.98 cpm) and percentage (1.632 
      +/- 0.246%) per gram dry weight of damaged tissue. Infusion of exogenous PGI2 was 
      associated with reduction of lesion radioactivity. These findings were supported 
      by ultrastructural findings. Examined under transmission electron microscopy, the 
      injured aortic wall of 30-mg group was covered throughout the segment by a single 
      layer of platelets without detectable platelet aggregates, while that of the 
      150-mg group was diffusely packed with multiple layers of platelets. The findings 
      demonstrate that aspirin (30 mg/kg) prevents platelet aggregate formation at the 
      injured arterial wall, whereas 150 mg/kg promotes platelet thrombus formation.
FAU - Wu, K K
AU  - Wu KK
FAU - Chen, Y C
AU  - Chen YC
FAU - Fordham, E
AU  - Fordham E
FAU - Ts'Ao, C H
AU  - Ts'Ao CH
FAU - Rayudu, G
AU  - Rayudu G
FAU - Matayoshi, D
AU  - Matayoshi D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta/enzymology/injuries
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Blood Platelets/*enzymology
MH  - *Cyclooxygenase Inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Endothelium/*enzymology
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
PMC - PMC370809
EDAT- 1981/08/01 00:00
MHDA- 1981/08/01 00:01
CRDT- 1981/08/01 00:00
PHST- 1981/08/01 00:00 [pubmed]
PHST- 1981/08/01 00:01 [medline]
PHST- 1981/08/01 00:00 [entrez]
AID - 10.1172/jci110266 [doi]
PST - ppublish
SO  - J Clin Invest. 1981 Aug;68(2):382-7. doi: 10.1172/jci110266.

PMID- 9071199
OWN - NLM
STAT- MEDLINE
DCOM- 19970409
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 48
IP  - 3
DP  - 1997 Mar
TI  - A comparison between aspirin and pentoxifylline in relieving claudication due to 
      peripheral vascular disease in the elderly.
PG  - 237-40
AB  - Peripheral vascular disease (PVD) commonly presents with leg claudication during 
      walking and eventually limits the walking distance and daily activities. Aspirin 
      or pentoxifylline are commonly prescribed to improve blood flow. Aspirin works 
      through its antiplatelet aggregation mechanism, and pentoxifylline increases the 
      red blood cell flexibility, which leads to increased tissue perfusion. Data on 
      comparative studies of these drugs for improving claudication in the elderly are 
      limited. The objective of this study was to compare pain relief offered by either 
      aspirin or pentoxifylline for walking leg pain in the elderly with PVD. Patients 
      sixty-five years or older with claudication were randomly assigned to receive 
      aspirin or pentoxifylline. Their reported level of walking claudication pain with 
      use of the visual analogue scale (0-5) and the distance walked during exercises 
      were recorded. Six weeks later the same parameters were recorded and results were 
      compared with Student's t test, and a P value less than 0.05 was considered a 
      statistically significant difference. Of the 90 patients who participated, 45 
      received aspirin (325 mg daily) and 45 were prescribed pentoxifylline (400 mg 
      tid) for six weeks. Both the aspirin and the pentoxifylline groups reported a 
      moderate level of pain (2/5) and remained about the same (2/5 for aspirin and 1/5 
      for pentoxifylline, P = 0.9, NS) after six weeks. However, the pentoxifylline 
      group reported a farther walking distance of 2 miles compared with the aspirin 
      group of 1.2 miles (P < 0.05). The level of pain did not change significantly 
      with either aspirin or pentoxifylline, but the walking distance was farther with 
      the pentoxifylline group.
FAU - Ciocon, J O
AU  - Ciocon JO
AD  - Internal Medicine/Geriatrics Department, Cleveland Clinic Florida, Fort 
      Lauderdale, Florida, USA.
FAU - Galindo-Ciocon, D
AU  - Galindo-Ciocon D
FAU - Galindo, D J
AU  - Galindo DJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Intermittent Claudication/*drug therapy/etiology
MH  - Male
MH  - Pentoxifylline/*therapeutic use
MH  - Peripheral Vascular Diseases/*complications
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Vasodilator Agents/*therapeutic use
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
AID - 10.1177/000331979704800306 [doi]
PST - ppublish
SO  - Angiology. 1997 Mar;48(3):237-40. doi: 10.1177/000331979704800306.

PMID- 1432645
OWN - NLM
STAT- MEDLINE
DCOM- 19921210
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 81
IP  - 9
DP  - 1992 Sep
TI  - Use of scavenging oxygen-derived free radicals to protect the rat against 
      aspirin- and ethanol-induced erosive gastritis.
PG  - 943-6
AB  - Oxygen-derived free radicals are cytotoxic and produce tissue damage. The effect 
      of the radical scavengers allopurinol and dimethyl sulfoxide (DMSO) on aspirin- 
      and ethanol-induced acute gastric mucosal injury was studied in the rat. 
      Orogastric instillation of aspirin at 200 mg/kg produced, after 4 h, gastric 
      mucosal injury in 30% of rats without pyloric ligation [score, 3.1 +/- 0.8 mm2, 
      mean +/- standard error of the mean (SEM); n = 10] and in 80% of rats with this 
      ligation (score, 10.4 +/- 1.2 mm2, mean +/- SEM; n = 10). Gavage with 1 mL of 2 
      or 5% allopurinol or DMSO at 24 h before and again just before aspirin 
      administration completely protected rats with or without pyloric ligation against 
      injury. Orogastric instillation of ethanol (1 mL of a 40% solution) produced, 
      after 1 h, gastric mucosal injury in all rats with or without pyloric ligation 
      (24.1 +/- 1.7 and 14.1 +/- 1.3 mm2, respectively, mean +/- SEM; n = 10). Gavage 
      with 1 mL of 5% allopurinol or DMSO at 24 h before and again just before ethanol 
      administration completely protected rats with or without pyloric ligation against 
      injury. Protection against the aspirin- and ethanol-induced injury was not 
      associated with any significant effect on the H+ output. The results suggest that 
      oxygen-derived free radicals are directly implicated in the mechanism of aspirin- 
      and ethanol-induced acute gastric mucosal injury and that scavenging these free 
      radicals protects against injury by maintaining the integrity of the gastric 
      mucosa.
FAU - Salim, A S
AU  - Salim AS
AD  - University Department of Surgery, Royal Infirmary, Glasgow, UK.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Free Radical Scavengers)
RN  - 3K9958V90M (Ethanol)
RN  - 63CZ7GJN5I (Allopurinol)
RN  - R16CO5Y76E (Aspirin)
RN  - YOW8V9698H (Dimethyl Sulfoxide)
SB  - IM
MH  - Allopurinol/pharmacology
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Dimethyl Sulfoxide/pharmacology
MH  - Ethanol/*toxicity
MH  - Female
MH  - *Free Radical Scavengers
MH  - Gastritis/chemically induced/*prevention & control
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1992/09/01 00:00
MHDA- 1992/09/01 00:01
CRDT- 1992/09/01 00:00
PHST- 1992/09/01 00:00 [pubmed]
PHST- 1992/09/01 00:01 [medline]
PHST- 1992/09/01 00:00 [entrez]
AID - S0022-3549(15)48945-2 [pii]
AID - 10.1002/jps.2600810921 [doi]
PST - ppublish
SO  - J Pharm Sci. 1992 Sep;81(9):943-6. doi: 10.1002/jps.2600810921.

PMID- 25939657
OWN - NLM
STAT- MEDLINE
DCOM- 20160303
LR  - 20150529
IS  - 1477-0377 (Electronic)
IS  - 1358-863X (Linking)
VI  - 20
IP  - 3
DP  - 2015 Jun
TI  - Effect of aspirin on acute changes in peripheral arterial stiffness and 
      endothelial function following exertional heat stress in firefighters: The 
      factorial group results of the Enhanced Firefighter Rehab Trial.
PG  - 230-6
LID - 10.1177/1358863X15571447 [doi]
AB  - Peripheral arterial stiffness and endothelial function, which are independent 
      predictors of cardiac events, are abnormal in firefighters. We examined the 
      effects of aspirin on peripheral arterial stiffness and endothelial function in 
      firefighters. Fifty-two firefighters were randomized to receive daily 81 mg 
      aspirin or placebo for 14 days before treadmill exercise in thermal protection 
      clothing, and a single dose of 325 mg aspirin or placebo immediately following 
      exertion. Peripheral arterial augmentation index adjusted for a heart rate of 75 
      (AI75) and reactive hyperemia index (RHI) were determined immediately before, and 
      30, 60, and 90 minutes after exertion. Low-dose aspirin was associated with lower 
      AI75 (-15.25±9.25 vs -8.08±10.70, p=0.014) but not RHI. On repeated measures 
      analysis, treatment with low-dose aspirin before, but not single-dose aspirin 
      after exertion, was associated with lower AI75 following exertional heat stress 
      (p=0.018). Low-dose aspirin improved peripheral arterial stiffness and wave 
      reflection but not endothelial function in firefighters.
CI  - © The Author(s) 2015.
FAU - Olafiranye, Oladipupo
AU  - Olafiranye O
AD  - The Heart and Vascular Institute, University of Pittsburgh School of Medicine, 
      Pittsburgh, PA, USA olafiranyeo@upmc.edu.
FAU - Hostler, David
AU  - Hostler D
AD  - Department of Exercise and Nutrition Sciences, SUNY University at Buffalo, 
      Buffalo, NY, USA.
FAU - Winger, Daniel G
AU  - Winger DG
AD  - Clinical and Translational Science Institute, University of Pittsburgh, 
      Pittsburgh, PA, USA.
FAU - Wang, Li
AU  - Wang L
AD  - Clinical and Translational Science Institute, University of Pittsburgh, 
      Pittsburgh, PA, USA.
FAU - Reis, Steven E
AU  - Reis SE
AD  - The Heart and Vascular Institute, University of Pittsburgh School of Medicine, 
      Pittsburgh, PA, USA Clinical and Translational Science Institute, University of 
      Pittsburgh, Pittsburgh, PA, USA.
LA  - eng
GR  - 5K12HL109068-04/HL/NHLBI NIH HHS/United States
GR  - UL1-TR-000005/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20150504
PL  - England
TA  - Vasc Med
JT  - Vascular medicine (London, England)
JID - 9610930
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Vasc Med. 2015 Jun;20(3):219-21. PMID: 25939656
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Double-Blind Method
MH  - Endothelium, Vascular/*drug effects/*physiology
MH  - Female
MH  - *Firefighters
MH  - Heat-Shock Response/*physiology
MH  - Humans
MH  - Male
MH  - Physical Exertion/*physiology
MH  - Vascular Stiffness/*drug effects/*physiology
OTO - NOTNLM
OT  - aspirin
OT  - firefighting
OT  - heat stress
OT  - subclinical vascular dysfunction
EDAT- 2015/05/06 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/05/06 06:00
PHST- 2015/05/06 06:00 [entrez]
PHST- 2015/05/06 06:00 [pubmed]
PHST- 2016/03/05 06:00 [medline]
AID - 1358863X15571447 [pii]
AID - 10.1177/1358863X15571447 [doi]
PST - ppublish
SO  - Vasc Med. 2015 Jun;20(3):230-6. doi: 10.1177/1358863X15571447. Epub 2015 May 4.

PMID- 19073976
OWN - NLM
STAT- MEDLINE
DCOM- 20081222
LR  - 20211028
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 359
IP  - 24
DP  - 2008 Dec 11
TI  - Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch 
      syndrome.
PG  - 2567-78
LID - 10.1056/NEJMoa0801297 [doi]
AB  - BACKGROUND: Observational and epidemiologic data indicate that the use of aspirin 
      reduces the risk of colorectal neoplasia; however, the effects of aspirin in the 
      Lynch syndrome (hereditary nonpolyposis colon cancer) are not known. Resistant 
      starch has been associated with an antineoplastic effect on the colon. METHODS: 
      In a randomized, placebo-controlled trial, we used a two-by-two design to 
      investigate the effects of aspirin, at a dose of 600 mg per day, and resistant 
      starch (Novelose), at a dose of 30 g per day, in reducing the risk of adenoma and 
      carcinoma among persons with the Lynch syndrome. RESULTS: Among 1071 persons in 
      43 centers, 62 were ineligible to participate in the study, 72 did not enter the 
      study, and 191 withdrew from the study. These three categories were equally 
      distributed across the study groups. Over a mean period of 29 months (range, 7 to 
      74), colonic adenoma or carcinoma developed in 141 participants. Of 693 
      participants randomly assigned to receive aspirin or placebo, neoplasia developed 
      in 66 participants receiving aspirin (18.9%), as compared with 65 receiving 
      placebo (19.0%) (relative risk, 1.0; 95% confidence interval [CI], 0.7 to 1.4). 
      There were no significant differences between the two groups with respect to the 
      development of advanced neoplasia (7.4% and 9.9%, respectively; P=0.33). Among 
      the 727 participants receiving resistant starch or placebo, neoplasia developed 
      in 67 participants receiving starch (18.7%), as compared with 68 receiving 
      placebo (18.4%) (relative risk, 1.0; 95% CI, 0.7 to 1.4). Advanced adenomas and 
      colorectal cancers were evenly distributed in the two groups. The prevalence of 
      serious adverse events was low, and the events were evenly distributed. 
      CONCLUSIONS: The use of aspirin, resistant starch, or both for up to 4 years has 
      no effect on the incidence of colorectal adenoma or carcinoma among carriers of 
      the Lynch syndrome. (Current Controlled Trials number, ISRCTN59521990.)
CI  - 2008 Massachusetts Medical Society
FAU - Burn, John
AU  - Burn J
AD  - Institute of Human Genetics, Newcastle University, International Centre for Life, 
      Central Pkwy., Newcastle upon Tyne NE1 3BZ, United Kingdom. john.burn@ncl.ac.uk.
FAU - Bishop, D Timothy
AU  - Bishop DT
FAU - Mecklin, Jukka-Pekka
AU  - Mecklin JP
FAU - Macrae, Finlay
AU  - Macrae F
FAU - Möslein, Gabriela
AU  - Möslein G
FAU - Olschwang, Sylviane
AU  - Olschwang S
FAU - Bisgaard, Marie-Luise
AU  - Bisgaard ML
FAU - Ramesar, Raj
AU  - Ramesar R
FAU - Eccles, Diana
AU  - Eccles D
FAU - Maher, Eamonn R
AU  - Maher ER
FAU - Bertario, Lucio
AU  - Bertario L
FAU - Jarvinen, Heikki J
AU  - Jarvinen HJ
FAU - Lindblom, Annika
AU  - Lindblom A
FAU - Evans, D Gareth
AU  - Evans DG
FAU - Lubinski, Jan
AU  - Lubinski J
FAU - Morrison, Patrick J
AU  - Morrison PJ
FAU - Ho, Judy W C
AU  - Ho JW
FAU - Vasen, Hans F A
AU  - Vasen HF
FAU - Side, Lucy
AU  - Side L
FAU - Thomas, Huw J W
AU  - Thomas HJ
FAU - Scott, Rodney J
AU  - Scott RJ
FAU - Dunlop, Malcolm
AU  - Dunlop M
FAU - Barker, Gail
AU  - Barker G
FAU - Elliott, Faye
AU  - Elliott F
FAU - Jass, Jeremy R
AU  - Jass JR
FAU - Fodde, Ricardo
AU  - Fodde R
FAU - Lynch, Henry T
AU  - Lynch HT
FAU - Mathers, John C
AU  - Mathers JC
CN  - CAPP2 Investigators
LA  - eng
SI  - ISRCTN/ISRCTN59521990
GR  - D20173/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
GR  - MC_U127527198/MRC_/Medical Research Council/United Kingdom
GR  - A4994/CRUK_/Cancer Research UK/United Kingdom
GR  - G0100496/MRC_/Medical Research Council/United Kingdom
GR  - C588/A4994/CRUK_/Cancer Research UK/United Kingdom
GR  - C1297/A5013/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 9005-25-8 (Starch)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - N Engl J Med. 2009 Apr 2;360(14):1470
CIN - N Engl J Med. 2009 Apr 2;360(14):1461-2; author reply 1462-3. PMID: 19339729
CIN - N Engl J Med. 2009 Apr 2;360(14):1462; author reply 1462-3. PMID: 19348022
CIN - Gastroenterology. 2009 Aug;137(2):730-2. PMID: 19563844
MH  - Adenoma/epidemiology/*prevention & control
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Carcinoma/epidemiology/*prevention & control
MH  - Colorectal Neoplasms/epidemiology/*prevention & control
MH  - Colorectal Neoplasms, Hereditary Nonpolyposis/*drug therapy/genetics
MH  - DNA Mismatch Repair/genetics
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Risk
MH  - Starch/adverse effects/*therapeutic use
MH  - Treatment Failure
FIR - Adamson, P
IR  - Adamson P
FIR - Armstrong, O
IR  - Armstrong O
FIR - Ball, J
IR  - Ball J
FIR - Baxter, L
IR  - Baxter L
FIR - Birkett, A
IR  - Birkett A
FIR - Boussioutas, A
IR  - Boussioutas A
FIR - Bradshaw, N
IR  - Bradshaw N
FIR - Brewer, C
IR  - Brewer C
FIR - Broughton, M
IR  - Broughton M
FIR - Bulman, B
IR  - Bulman B
FIR - Castiglione, M
IR  - Castiglione M
FIR - Clarke, S
IR  - Clarke S
FIR - Ching, R
IR  - Ching R
FIR - Chu, C
IR  - Chu C
FIR - Coaker, J
IR  - Coaker J
FIR - Cina, S
IR  - Cina S
FIR - Cook, J
IR  - Cook J
FIR - Coxhead, J
IR  - Coxhead J
FIR - Crawford, G
IR  - Crawford G
FIR - Cummings, C
IR  - Cummings C
FIR - Davies, R
IR  - Davies R
FIR - Debniak, T
IR  - Debniak T
FIR - de Moncuit, C
IR  - de Moncuit C
FIR - Drummond, S
IR  - Drummond S
FIR - Ellis, T
IR  - Ellis T
FIR - Farthing, K
IR  - Farthing K
FIR - Fidalgo, P
IR  - Fidalgo P
FIR - Gallinger, S
IR  - Gallinger S
FIR - Gascoyne, J
IR  - Gascoyne J
FIR - Gilroy, J
IR  - Gilroy J
FIR - Goff, S
IR  - Goff S
FIR - Goldberg, P
IR  - Goldberg P
FIR - Goodman, S
IR  - Goodman S
FIR - Harocopos, C
IR  - Harocopos C
FIR - Hodgson, S
IR  - Hodgson S
FIR - Jeffcoat, R
IR  - Jeffcoat R
FIR - Jeffers, L
IR  - Jeffers L
FIR - Jordan, S
IR  - Jordan S
FIR - Killick, P
IR  - Killick P
FIR - Krauss, C
IR  - Krauss C
FIR - Kristensen, J
IR  - Kristensen J
FIR - Langman, C
IR  - Langman C
FIR - Leite, J
IR  - Leite J
FIR - Liljegren, A
IR  - Liljegren A
FIR - Lindgren, G
IR  - Lindgren G
FIR - Lynagh, L
IR  - Lynagh L
FIR - Oliani, C
IR  - Oliani C
FIR - Marks, C
IR  - Marks C
FIR - Miller, J
IR  - Miller J
FIR - Miles, T
IR  - Miles T
FIR - Murday, V
IR  - Murday V
FIR - Perez Segura, P
IR  - Perez Segura P
FIR - Pietersen, E
IR  - Pietersen E
FIR - Platten, U
IR  - Platten U
FIR - Reed, L
IR  - Reed L
FIR - Rossi, G
IR  - Rossi G
FIR - Sala, P
IR  - Sala P
FIR - Sampson, J
IR  - Sampson J
FIR - Schmocker, B
IR  - Schmocker B
FIR - Shaw, J
IR  - Shaw J
FIR - Spigelman, A
IR  - Spigelman A
FIR - Tempesta, A
IR  - Tempesta A
FIR - Toes, R
IR  - Toes R
FIR - Velthuizen, M
IR  - Velthuizen M
FIR - Wakelen, P
IR  - Wakelen P
FIR - Walpole, I
IR  - Walpole I
FIR - Lynch, H
IR  - Lynch H
FIR - Burn, J
IR  - Burn J
FIR - Mathers, J
IR  - Mathers J
FIR - Bishop, D T
IR  - Bishop DT
FIR - Fodde, R
IR  - Fodde R
FIR - Mecklin, J-P
IR  - Mecklin JP
FIR - Macrae, F
IR  - Macrae F
FIR - Vasen, H
IR  - Vasen H
FIR - Möslein, G
IR  - Möslein G
FIR - Ramesar, R
IR  - Ramesar R
FIR - Kerr, D
IR  - Kerr D
FIR - Perkins, S
IR  - Perkins S
FIR - Cuzick, J
IR  - Cuzick J
FIR - Faulds Wood, L
IR  - Faulds Wood L
FIR - Steele, R
IR  - Steele R
FIR - Altman, D
IR  - Altman D
FIR - Paraskeva, C
IR  - Paraskeva C
FIR - Atkin, W
IR  - Atkin W
FIR - Hull, M
IR  - Hull M
EDAT- 2008/12/17 09:00
MHDA- 2008/12/23 09:00
CRDT- 2008/12/17 09:00
PHST- 2008/12/17 09:00 [entrez]
PHST- 2008/12/17 09:00 [pubmed]
PHST- 2008/12/23 09:00 [medline]
AID - 359/24/2567 [pii]
AID - 10.1056/NEJMoa0801297 [doi]
PST - ppublish
SO  - N Engl J Med. 2008 Dec 11;359(24):2567-78. doi: 10.1056/NEJMoa0801297.

PMID- 21166598
OWN - NLM
STAT- MEDLINE
DCOM- 20110421
LR  - 20131121
IS  - 1525-6006 (Electronic)
IS  - 1064-1963 (Linking)
VI  - 33
IP  - 1
DP  - 2011
TI  - The effect of aspirin on C-reactive protein in hypertensive patients.
PG  - 47-52
LID - 10.3109/10641963.2010.503302 [doi]
AB  - High level of C-reactive protein (CRP), most popular inflammatory marker, 
      increases the risk of thrombotic cardiovascular events. Aspirin, which has both 
      anti-inflammatory and anti-thrombotic effects, has the potential to influence CRP 
      release. Several studies have been reported investigating clinical effects of 
      aspirin on CRP levels. Some studies have reported aspirin reduced CRP levels, but 
      other studies did not. This study was designed to assess the effect of low-dose 
      aspirin on CRP levels in controlled hypertensive patients who had low 
      inflammatory burden. Two hundred twenty-five patients with controlled 
      hypertension were randomly divided into two groups; aspirin group (n = 122, 100 
      mg of aspirin) and the control group (n = 134). Patients with a CRP level >1 
      mg/dL (10 mg/L) were excluded because these high levels suggest infection. 
      C-reactive protein level and lipid profiles were measured before therapy and 3 
      months after therapy. There were no differences in baseline clinical 
      characteristics between the two groups. Low-dose aspirin showed no significant 
      influence on CRP levels over 3 months (from 0.10 ± 0.0099 to 0.12 ± 0.0097 mg/dL, 
      p = 0.12). Statin therapy did not influence CRP levels. Aspirin-resistance also 
      had no influence on CRP levels. We conclude that low-dose aspirin has no 
      significant effect on decreasing CRP levels in the patients with controlled 
      hypertension which had low inflammatory burden. The anti-inflammatory mechanism 
      may not play an important role in the cardioprotective effect of aspirin in the 
      population with low inflammatory burden such as controlled hypertensive patients.
FAU - Kim, Myung-A
AU  - Kim MA
AD  - Department of Internal Medicine, College of Medicine, Seoul National University 
      Boramae Medical Center, 39 Boramae-gil, Dongjak-gu, Seoul, Republic of Korea. 
      kma@brm.co.kr
FAU - Kim, Chee Jeong
AU  - Kim CJ
FAU - Seo, Jae-Bin
AU  - Seo JB
FAU - Chung, Woo-Yong
AU  - Chung WY
FAU - Kim, Sang-Hyun
AU  - Kim SH
FAU - Zo, Joo-Hee
AU  - Zo JH
FAU - Rho, Eun Yeon
AU  - Rho EY
FAU - Shin, Sue
AU  - Shin S
FAU - Yoon, Jong Hyun
AU  - Yoon JH
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20101219
PL  - England
TA  - Clin Exp Hypertens
JT  - Clinical and experimental hypertension (New York, N.Y. : 1993)
JID - 9305929
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipids)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Clin Exp Hypertens. 2012;34(5):383-4. PMID: 22681482
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - C-Reactive Protein/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology
MH  - Hypertension/*blood
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
EDAT- 2010/12/21 06:00
MHDA- 2011/04/22 06:00
CRDT- 2010/12/21 06:00
PHST- 2010/12/21 06:00 [entrez]
PHST- 2010/12/21 06:00 [pubmed]
PHST- 2011/04/22 06:00 [medline]
AID - 10.3109/10641963.2010.503302 [doi]
PST - ppublish
SO  - Clin Exp Hypertens. 2011;33(1):47-52. doi: 10.3109/10641963.2010.503302. Epub 
      2010 Dec 19.

PMID- 32534647
OWN - NLM
STAT- MEDLINE
DCOM- 20200623
LR  - 20221221
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 395
IP  - 10240
DP  - 2020 Jun 13
TI  - Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 
      10-year follow-up and registry-based 20-year data in the CAPP2 study: a 
      double-blind, randomised, placebo-controlled trial.
PG  - 1855-1863
LID - S0140-6736(20)30366-4 [pii]
LID - 10.1016/S0140-6736(20)30366-4 [doi]
AB  - BACKGROUND: Lynch syndrome is associated with an increased risk of colorectal 
      cancer and with a broader spectrum of cancers, especially endometrial cancer. In 
      2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months 
      [SD 31·4]) for participants with Lynch syndrome enrolled into a randomised trial 
      of daily aspirin versus placebo. This report completes the planned 10-year 
      follow-up to allow a longer-term assessment of the effect of taking regular 
      aspirin in this high-risk population. METHODS: In the double-blind, randomised 
      CAPP2 trial, 861 patients from 43 international centres worldwide (707 [82%] from 
      Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [<1%] from The 
      Americas) with Lynch syndrome were randomly assigned to receive 600 mg aspirin 
      daily or placebo. Cancer outcomes were monitored for at least 10 years from 
      recruitment with English, Finnish, and Welsh participants being monitored for up 
      to 20 years. The primary endpoint was development of colorectal cancer. Analysis 
      was by intention to treat and per protocol. The trial is registered with the 
      ISRCTN registry, number ISRCTN59521990. FINDINGS: Between January, 1999, and 
      March, 2005, 937 eligible patients with Lynch syndrome, mean age 45 years, 
      commenced treatment, of whom 861 agreed to be randomly assigned to the aspirin 
      group or placebo; 427 (50%) participants received aspirin and 434 (50%) placebo. 
      Participants were followed for a mean of 10 years approximating 8500 
      person-years. 40 (9%) of 427 participants who received aspirin developed 
      colorectal cancer compared with 58 (13%) of 434 who received placebo. 
      Intention-to-treat Cox proportional hazards analysis revealed a significantly 
      reduced hazard ratio (HR) of 0·65 (95% CI 0·43-0·97; p=0·035) for aspirin versus 
      placebo. Negative binomial regression to account for multiple primary events gave 
      an incidence rate ratio of 0·58 (0·39-0·87; p=0·0085). Per-protocol analyses 
      restricted to 509 who achieved 2 years' intervention gave an HR of 0·56 
      (0·34-0·91; p=0·019) and an incidence rate ratio of 0·50 (0·31-0·82; p=0·0057). 
      Non-colorectal Lynch syndrome cancers were reported in 36 participants who 
      received aspirin and 36 participants who received placebo. Intention-to-treat and 
      per-protocol analyses showed no effect. For all Lynch syndrome cancers combined, 
      the intention-to-treat analysis did not reach significance but per-protocol 
      analysis showed significantly reduced overall risk for the aspirin group 
      (HR=0·63, 0·43-0·92; p=0·018). Adverse events during the intervention phase 
      between aspirin and placebo groups were similar, and no significant difference in 
      compliance between intervention groups was observed for participants with 
      complete intervention phase data; details reported previously. INTERPRETATION: 
      The case for prevention of colorectal cancer with aspirin in Lynch syndrome is 
      supported by our results. FUNDING: Cancer Research UK, European Union, MRC, NIHR, 
      Bayer Pharma AG, Barbour Foundation.
CI  - Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access 
      article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights 
      reserved.
FAU - Burn, John
AU  - Burn J
AD  - Translational and Clinical Research Institute, Newcastle University, Newcastle 
      upon Tyne, UK. Electronic address: john.burn@newcastle.ac.uk.
FAU - Sheth, Harsh
AU  - Sheth H
AD  - Translational and Clinical Research Institute, Newcastle University, Newcastle 
      upon Tyne, UK.
FAU - Elliott, Faye
AU  - Elliott F
AD  - Division of Haematology and Immunology, Leeds Institute of Medical Research at St 
      James's, University of Leeds, Leeds, UK.
FAU - Reed, Lynn
AU  - Reed L
AD  - Translational and Clinical Research Institute, Newcastle University, Newcastle 
      upon Tyne, UK.
FAU - Macrae, Finlay
AU  - Macrae F
AD  - Colorectal Medicine and Genetics, Royal Melbourne Hospital, Melbourne, Australia.
FAU - Mecklin, Jukka-Pekka
AU  - Mecklin JP
AD  - Department of Education & Research, Jyväskylä Central Hospital, Jyväskylä, 
      Finland; Faculty of Sport and Health Sciences, University of Jyväskylä, 
      Jyväskylä, Finland.
FAU - Möslein, Gabriela
AU  - Möslein G
AD  - St Josefs-Hospital, Bochum-Linden, Germany.
FAU - McRonald, Fiona E
AU  - McRonald FE
AD  - National Cancer Registration and Analysis Service, Public Health England, London, 
      UK.
FAU - Bertario, Lucio
AU  - Bertario L
AD  - Instituto Nazionale per lo Studio e, la Cura dei Tumori, Milan, Italy.
FAU - Evans, D Gareth
AU  - Evans DG
AD  - Division of Evolution and Genomic Medicine, University of Manchester, Manchester, 
      UK; St Mary's Hospital, Manchester Universities Foundation Trust, Manchester, UK.
FAU - Gerdes, Anne-Marie
AU  - Gerdes AM
AD  - Clinical Genetics, Rigshospital, Copenhagen, Denmark.
FAU - Ho, Judy W C
AU  - Ho JWC
AD  - Hereditary GI Cancer Registry, Department of Surgery, Queen Mary Hospital, Hong 
      Kong Special Administrative Region, China.
FAU - Lindblom, Annika
AU  - Lindblom A
AD  - Department of Molecular Medicine & Surgery, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Morrison, Patrick J
AU  - Morrison PJ
AD  - Department of Medical Genetics, Queens University Belfast, Belfast City Hospital 
      HSC Trust, Belfast, UK.
FAU - Rashbass, Jem
AU  - Rashbass J
AD  - National Cancer Registration and Analysis Service, Public Health England, London, 
      UK.
FAU - Ramesar, Raj
AU  - Ramesar R
AD  - Genomic and Precision Medicine Research Unit, Division of Human Genetics, 
      Institute of Infectious Diseases and Molecular Medicine, Faculty of Health 
      Sciences, University of Cape Town, South Africa.
FAU - Seppälä, Toni
AU  - Seppälä T
AD  - Department of Gastrointestinal Surgery, Helsinki University Hospital, Helsinki, 
      Finland.
FAU - Thomas, Huw J W
AU  - Thomas HJW
AD  - St Mark's Hospital, London, UK; Faculty of Medicine, Imperial College London, 
      London, UK.
FAU - Pylvänäinen, Kirsi
AU  - Pylvänäinen K
AD  - Department of Education & Research, Jyväskylä Central Hospital, Jyväskylä, 
      Finland.
FAU - Borthwick, Gillian M
AU  - Borthwick GM
AD  - Translational and Clinical Research Institute, Newcastle University, Newcastle 
      upon Tyne, UK.
FAU - Mathers, John C
AU  - Mathers JC
AD  - Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle 
      University, Newcastle upon Tyne, UK.
FAU - Bishop, D Timothy
AU  - Bishop DT
AD  - Division of Haematology and Immunology, Leeds Institute of Medical Research at St 
      James's, University of Leeds, Leeds, UK.
CN  - CAPP2 Investigators
LA  - eng
GR  - 10589/CRUK_/Cancer Research UK/United Kingdom
GR  - G0100496/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2020 Jun 13;395(10240):1817-1818. PMID: 32534636
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Colorectal Neoplasms, Hereditary Nonpolyposis/genetics/*prevention & control
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Heterozygote
MH  - Humans
MH  - Intention to Treat Analysis
MH  - Life Tables
MH  - Medication Adherence
MH  - Proportional Hazards Models
PMC - PMC7294238
FIR - Boussioutas, Alex
IR  - Boussioutas A
FIR - Brewer, Carole
IR  - Brewer C
FIR - Cook, Jackie
IR  - Cook J
FIR - Eccles, Diana
IR  - Eccles D
FIR - Ellis, Anthony
IR  - Ellis A
FIR - Hodgson, Shirley V
IR  - Hodgson SV
FIR - Lubinski, Jan
IR  - Lubinski J
FIR - Maher, Eamonn R
IR  - Maher ER
FIR - Porteous, Mary Em
IR  - Porteous ME
FIR - Sampson, Julian
IR  - Sampson J
FIR - Scott, Rodney J
IR  - Scott RJ
FIR - Side, Lucy
IR  - Side L
EDAT- 2020/06/15 06:00
MHDA- 2020/06/24 06:00
CRDT- 2020/06/15 06:00
PHST- 2019/11/20 00:00 [received]
PHST- 2020/01/31 00:00 [revised]
PHST- 2020/02/06 00:00 [accepted]
PHST- 2020/06/15 06:00 [entrez]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2020/06/24 06:00 [medline]
AID - S0140-6736(20)30366-4 [pii]
AID - 10.1016/S0140-6736(20)30366-4 [doi]
PST - ppublish
SO  - Lancet. 2020 Jun 13;395(10240):1855-1863. doi: 10.1016/S0140-6736(20)30366-4.

PMID- 9219313
OWN - NLM
STAT- MEDLINE
DCOM- 19970819
LR  - 20191024
IS  - 0049-0172 (Print)
IS  - 0049-0172 (Linking)
VI  - 26
IP  - 6 Suppl 1
DP  - 1997 Jun
TI  - Mechanism of action of aspirin-like drugs.
PG  - 2-10
AB  - Nonsteroid antiinflammatory drugs (NSAIDs) or aspirin-like drugs act by 
      inhibiting the activity of the cyclooxygenase (COX) enzyme. Two isoforms of COX 
      exist, COX-1, which is constitutively expressed, and COX-2, which is an inducible 
      isoform. Prostaglandins synthesized by the constitutively expressed COX-1 are 
      implicated in the maintenance of normal physiological function and have a 
      'cytoprotective' action in the stomach. COX-2 expression is normally low but is 
      induced by inflammatory stimuli and cytokines. It is thought that the 
      antiinflammatory actions of NSAIDs are caused by the inhibition of COX-2, whereas 
      the unwanted side effects, such as gastrointestinal and renal toxicity, are 
      caused by the inhibition of the constitutively expressed COX-1. Individual NSAIDs 
      show different selectivities against the COX-1 and COX-2 isoforms. NSAIDs that 
      are selective towards COX-2, such as meloxicam, may have an improved side-effect 
      profile over current NSAIDs. In addition to their use as antiinflammatory agents 
      in the treatment of rheumatoid arthritis and osteoarthritis, selective COX-2 
      inhibitors may also be beneficial in inhibiting colorectal tumor cell growth and 
      in delaying premature labor.
FAU - Vane, J R
AU  - Vane JR
AD  - William Harvey Research Institute, St Bartholomew's, London, UK.
FAU - Botting, R M
AU  - Botting RM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Arthritis Rheum
JT  - Seminars in arthritis and rheumatism
JID - 1306053
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - 0 (Prostaglandins)
RN  - 0 (Thiazines)
RN  - 0 (Thiazoles)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - VG2QF83CGL (Meloxicam)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Arthritis, Rheumatoid/drug therapy/metabolism
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Humans
MH  - Isoenzymes/drug effects
MH  - Meloxicam
MH  - Membrane Proteins
MH  - Osteoarthritis/drug therapy/metabolism
MH  - Prostaglandin-Endoperoxide Synthases/drug effects
MH  - Prostaglandins/metabolism
MH  - Thiazines/therapeutic use
MH  - Thiazoles/therapeutic use
RF  - 78
EDAT- 1997/06/01 00:00
MHDA- 1997/06/01 00:01
CRDT- 1997/06/01 00:00
PHST- 1997/06/01 00:00 [pubmed]
PHST- 1997/06/01 00:01 [medline]
PHST- 1997/06/01 00:00 [entrez]
AID - S0049-0172(97)80046-7 [pii]
AID - 10.1016/s0049-0172(97)80046-7 [doi]
PST - ppublish
SO  - Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):2-10. doi: 
      10.1016/s0049-0172(97)80046-7.

PMID- 8267661
OWN - NLM
STAT- MEDLINE
DCOM- 19940124
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 46
IP  - 11
DP  - 1993 Dec 3
TI  - Alleviation of experimental cyclosporin A nephrotoxicity by low dose aspirin in 
      the rat.
PG  - 2104-8
AB  - Groups of male Sprague-Dawley rats received either cyclosporin A (CsA; 25 mg/kg 
      by gavage), low dose aspirin (ASP; 20 mg/kg by gavage), a combination of both, or 
      the appropriate drug vehicles daily for 14 days. Renal structure and function 
      were assessed on day 0 (pretreatment) and on days 7 and 14. Compared to 
      pretreatment results, CsA nephrotoxicity was characterized by increased plasma 
      urea and creatinine concentrations and by moderate to severe microcalcification 
      (MC) at the corticomedullary junction by day 14. The development of 
      nephrotoxicity was also associated with a 5-fold increase in urine thromboxane B2 
      (TxB2) excretion by day 10, while that of 6-ketoprostaglandin F1 alpha remained 
      relatively constant. Although both ASP and saline (ASP vehicle) -cotreated 
      animals demonstrated significantly lower plasma urea and creatinine 
      concentrations compared to treatment with CsA alone, the severity of MC observed 
      on day 14, was reduced only in the ASP cotreatment group. Though whole blood CsA 
      concentrations were similar at around 2400 ng/mL in all experimental groups. In 
      addition, although a 2-fold increase in urine TxB2 excretion was observed on days 
      7 and 10 following treatment with CsA/ASP, levels were significantly reduced 
      compared to treatment with either CsA alone or CsA/saline (both P < 0.05).
FAU - Adams, K E
AU  - Adams KE
AD  - Department of Clinical Biochemistry, University of Aberdeen, Foresterhill, U.K.
FAU - Brown, P A
AU  - Brown PA
FAU - Heys, S D
AU  - Heys SD
FAU - Whiting, P H
AU  - Whiting PH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 57576-52-0 (Thromboxane A2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - 8W8T17847W (Urea)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/urine
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Creatinine/blood
MH  - Cyclosporine/*toxicity
MH  - Kidney Diseases/chemically induced/*prevention & control/urine
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thromboxane A2/urine
MH  - Urea/blood
EDAT- 1993/12/03 00:00
MHDA- 1993/12/03 00:01
CRDT- 1993/12/03 00:00
PHST- 1993/12/03 00:00 [pubmed]
PHST- 1993/12/03 00:01 [medline]
PHST- 1993/12/03 00:00 [entrez]
AID - 0006-2952(93)90655-G [pii]
AID - 10.1016/0006-2952(93)90655-g [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1993 Dec 3;46(11):2104-8. doi: 10.1016/0006-2952(93)90655-g.

PMID- 24180531
OWN - NLM
STAT- MEDLINE
DCOM- 20140715
LR  - 20181202
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 9
IP  - 6
DP  - 2013 Nov
TI  - Antiplatelet therapy strategies after percutaneous coronary intervention in 
      patients needing oral anticoagulation.
PG  - 759-62
LID - 10.2217/fca.13.77 [doi]
AB  - Long-term oral anticoagulant (OAC) and dual-antiplatelet therapy are commonly 
      needed in patients with atrial fibrillation and in patients undergoing 
      percutaneous coronary intervention (PCI), respectively. The combination of atrial 
      fibrillation and PCI is frequent, and leads to a dilemma for antithrombotic 
      therapy, where risk of stroke or stent thrombosis must be balanced with bleeding 
      risk. In the WOEST study, 573 patients on OAC undergoing PCI were randomly 
      assigned to receive clopidogrel alone or clopidogrel plus aspirin. The primary 
      end point was the occurrence of any bleeding episode during 1-year follow-up. 
      Clopidogrel alone administered to patients taking OAC after PCI was associated 
      with a significantly lower rate of bleeding complications than clopidogrel plus 
      aspirin. Moreover, a composite secondary end point of death, myocardial 
      infarction and stent thrombosis was significantly lower in the dual-therapy group 
      compared with the triple-therapy group. In spite of its limitations, the WOEST 
      study constitutes a major breakthrough, showing that long-term aspirin after PCI 
      may be obsolete in certain circumstances. This needs to be confirmed in further 
      studies.
FAU - Saint Etienne, Christophe
AU  - Saint Etienne C
AD  - Cardiologie, Pôle Cœur Thorax Vasculaire, Centre Hospitalier Universitaire 
      Trousseau, 37044 Tours, France.
FAU - Angoulvant, Denis
AU  - Angoulvant D
FAU - Simeon, Edouard
AU  - Simeon E
FAU - Fauchier, Laurent
AU  - Fauchier L
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Lancet. 2013 Mar 30;381(9872):1107-15. PMID: 23415013
MH  - Anticoagulants/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Ticlopidine/*analogs & derivatives
EDAT- 2013/11/05 06:00
MHDA- 2014/07/16 06:00
CRDT- 2013/11/05 06:00
PHST- 2013/11/05 06:00 [entrez]
PHST- 2013/11/05 06:00 [pubmed]
PHST- 2014/07/16 06:00 [medline]
AID - 10.2217/fca.13.77 [doi]
PST - ppublish
SO  - Future Cardiol. 2013 Nov;9(6):759-62. doi: 10.2217/fca.13.77.

PMID- 21450510
OWN - NLM
STAT- MEDLINE
DCOM- 20110810
LR  - 20131121
IS  - 1769-6682 (Electronic)
IS  - 1297-9589 (Linking)
VI  - 39
IP  - 4
DP  - 2011 Apr
TI  - [Pregnancy and essential thrombocytemia].
PG  - 205-10
LID - 10.1016/j.gyobfe.2011.01.017 [doi]
AB  - OBJECTIVE: To evaluate the management and outcome of pregnancy in women with 
      essential thrombocytemia. PATIENTS AND METHODS: We conducted a retrospective 
      study including all the pregnant women with essential thrombocytemia followed 
      between January 2000 and January 2008 in a University Hospital (hôpital 
      Jeanne-de-Flandre, Lille, France). We report our experience of 18 pregnancies in 
      13 women. The management and the complications of these pregnancies were 
      reported. RESULTS: All the patients were treated with low dose aspirin during the 
      pregnancy. We observed one intrauterine death, one premature delivery at 29 weeks 
      of gestation and six maternal haemorrhages at delivery (33%). DISCUSSION AND 
      CONCLUSION: It is essential to treat these patients with low dose aspirin as soon 
      as the pregnancy begins. Aspirin will be continued in postpartum with 
      anticoagulant treatment. This management appears to improve the obstetric outcome 
      and decrease the thrombotic complications usually described. A national register 
      seems to be necessary to evaluate the complications occurring during pregnancy 
      and the optimum follow-up.
CI  - Copyright © 2011 Elsevier Masson SAS. All rights reserved.
FAU - Giraudet, G
AU  - Giraudet G
AD  - Pôle d'obstétrique, hôpital Jeanne-de-Flandre, CHRU de Lille, Lille cedex, 
      France.
FAU - Wibaut, B
AU  - Wibaut B
FAU - Ducloy, A-S
AU  - Ducloy AS
FAU - Deruelle, P
AU  - Deruelle P
FAU - Depret, S
AU  - Depret S
FAU - Cambier, N
AU  - Cambier N
FAU - Vaast, P
AU  - Vaast P
FAU - Houfflin-Debarge, V
AU  - Houfflin-Debarge V
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Thrombocytémie essentielle et grossesse.
DEP - 20110329
PL  - France
TA  - Gynecol Obstet Fertil
JT  - Gynecologie, obstetrique & fertilite
JID - 100936305
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Hospitals, University
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*drug therapy
MH  - Pregnancy Outcome
MH  - Retrospective Studies
MH  - Thrombocythemia, Essential/*drug therapy
MH  - Young Adult
EDAT- 2011/04/01 06:00
MHDA- 2011/08/11 06:00
CRDT- 2011/04/01 06:00
PHST- 2009/01/25 00:00 [received]
PHST- 2011/01/24 00:00 [accepted]
PHST- 2011/04/01 06:00 [entrez]
PHST- 2011/04/01 06:00 [pubmed]
PHST- 2011/08/11 06:00 [medline]
AID - S1297-9589(11)00038-5 [pii]
AID - 10.1016/j.gyobfe.2011.01.017 [doi]
PST - ppublish
SO  - Gynecol Obstet Fertil. 2011 Apr;39(4):205-10. doi: 10.1016/j.gyobfe.2011.01.017. 
      Epub 2011 Mar 29.

PMID- 5642311
OWN - NLM
STAT- MEDLINE
DCOM- 19680509
LR  - 20190618
IS  - 0036-8075 (Print)
IS  - 0036-8075 (Linking)
VI  - 160
IP  - 3823
DP  - 1968 Apr 5
TI  - Aspirin: dissolution rates of two polymorphic forms.
PG  - 76
AB  - Two polymorphic forms of aspirin were characterized; the rates of dissolution of 
      single crystals and of tablets were studied. One forms dissolves 50 percent 
      faster than the other.
FAU - Tawashi, R
AU  - Tawashi R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (Alkanes)
RN  - 0 (Solutions)
RN  - 0 (Tablets)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alkanes
MH  - *Aspirin
MH  - Crystallization
MH  - Ethanol
MH  - *Solubility
MH  - Solutions
MH  - Spectrophotometry
MH  - *Tablets
MH  - X-Ray Diffraction
EDAT- 1968/04/05 00:00
MHDA- 1968/04/05 00:01
CRDT- 1968/04/05 00:00
PHST- 1968/04/05 00:00 [pubmed]
PHST- 1968/04/05 00:01 [medline]
PHST- 1968/04/05 00:00 [entrez]
AID - 10.1126/science.160.3823.76 [doi]
PST - ppublish
SO  - Science. 1968 Apr 5;160(3823):76. doi: 10.1126/science.160.3823.76.

PMID- 17562671
OWN - NLM
STAT- MEDLINE
DCOM- 20080227
LR  - 20220316
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 28
IP  - 14
DP  - 2007 Jul
TI  - Combining warfarin and antiplatelet therapy after coronary stenting in the Global 
      Registry of Acute Coronary Events: is it safe and effective to use just one 
      antiplatelet agent?
PG  - 1717-22
AB  - AIMS: To identify factors associated with the use of single or dual antiplatelet 
      therapy in patients prescribed warfarin following coronary stenting and to 
      investigate whether single (aspirin or thienopyridine) vs. dual antiplatelet 
      therapy plus warfarin leads to an excess of adverse outcomes. METHODS AND 
      RESULTS: We analysed data from 800 patients with an acute coronary syndrome who 
      underwent coronary stenting (130 patients received a drug-eluting stent) and were 
      discharged on warfarin and either dual (n = 580) or single (n = 220) antiplatelet 
      therapy. The use of single antiplatelet therapy was more common in Europe than in 
      the USA (34 vs. 17%, P < 0.001). There was no difference in major bleeding in 
      hospital or in 6-month mortality or myocardial infarction. In the single 
      antiplatelet group, the use of either aspirin or thienopyridine (clopidogrel or 
      ticlopidine) in combination with warfarin resulted in similar outcomes. 
      CONCLUSION: Use of single vs. dual antiplatelet therapy and warfarin following 
      stenting is common. In this observational study, there was no difference in 
      mortality or myocardial infarction at 6 months; however, larger trials are needed 
      to assert any firm recommendations.
FAU - Nguyen, Michael C
AU  - Nguyen MC
AD  - Centre for Cardiovascular Therapeutics, Western Hospital, Melbourne, Australia. 
      mcnguyen@bidmc.harvard.edu
FAU - Lim, Yean L
AU  - Lim YL
FAU - Walton, Antony
AU  - Walton A
FAU - Lefkovits, Jeffrey
AU  - Lefkovits J
FAU - Agnelli, Giancarlo
AU  - Agnelli G
FAU - Goodman, Shaun G
AU  - Goodman SG
FAU - Budaj, Andrzej
AU  - Budaj A
FAU - Gulba, Dietrich C
AU  - Gulba DC
FAU - Allegrone, Jeanna
AU  - Allegrone J
FAU - Brieger, David
AU  - Brieger D
CN  - GRACE Investigators
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20070611
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Aged
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Regression Analysis
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Stents
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Warfarin/adverse effects/therapeutic use
EDAT- 2007/06/15 09:00
MHDA- 2008/02/28 09:00
CRDT- 2007/06/15 09:00
PHST- 2007/06/15 09:00 [pubmed]
PHST- 2008/02/28 09:00 [medline]
PHST- 2007/06/15 09:00 [entrez]
AID - ehm186 [pii]
AID - 10.1093/eurheartj/ehm186 [doi]
PST - ppublish
SO  - Eur Heart J. 2007 Jul;28(14):1717-22. doi: 10.1093/eurheartj/ehm186. Epub 2007 
      Jun 11.

PMID- 24358966
OWN - NLM
STAT- MEDLINE
DCOM- 20140918
LR  - 20220317
IS  - 1479-828X (Electronic)
IS  - 0004-8666 (Linking)
VI  - 54
IP  - 2
DP  - 2014 Apr
TI  - New directions in the prediction of pre-eclampsia.
PG  - 101-7
LID - 10.1111/ajo.12151 [doi]
AB  - Pre-eclampsia remains an important worldwide cause of maternal and perinatal 
      morbidity and mortality. Improved prediction of those destined to develop this 
      condition would allow for timely initiation of prophylactic therapy, appropriate 
      antenatal surveillance and better targeted research into preventive 
      interventions. This paper reviews recent research into strategies for the 
      prediction of pre-eclampsia, including the use of maternal risk factors, mean 
      maternal arterial pressure, ultrasound parameters and biomarkers. The most 
      promising strategies involve multiparametric approaches, which use a variety of 
      individual parameters in combination, as has been established in first-trimester 
      aneuploidy screening. The paper concludes with a discussion of the issues around 
      the introduction of such testing into clinical practice.
CI  - © 2013 The Royal Australian and New Zealand College of Obstetricians and 
      Gynaecologists.
FAU - Kane, Stefan C
AU  - Kane SC
AD  - Department of Perinatal Medicine, The Royal Women's Hospital, Parkville, 
      Victoria, Australia.
FAU - Da Silva Costa, Fabricio
AU  - Da Silva Costa F
FAU - Brennecke, Shaun P
AU  - Brennecke SP
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131223
PL  - Australia
TA  - Aust N Z J Obstet Gynaecol
JT  - The Australian & New Zealand journal of obstetrics & gynaecology
JID - 0001027
RN  - 0 (Biomarkers)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
CIN - Aust N Z J Obstet Gynaecol. 2014 Aug;54(4):394-5. PMID: 25117192
CIN - Aust N Z J Obstet Gynaecol. 2014 Aug;54(4):395. PMID: 25117193
CIN - Aust N Z J Obstet Gynaecol. 2014 Aug;54(4):395-6. PMID: 25117194
MH  - Aspirin/*therapeutic use
MH  - Biomarkers/blood
MH  - Calcium/therapeutic use
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*diagnosis/prevention & control
MH  - Pregnancy
MH  - Risk Factors
MH  - Ultrasonography, Prenatal
MH  - Uterine Artery/diagnostic imaging
OTO - NOTNLM
OT  - aspirin
OT  - blood pressure
OT  - mass screening
OT  - pre-eclampsia
OT  - pregnancy-induced hypertension
EDAT- 2013/12/24 06:00
MHDA- 2014/09/19 06:00
CRDT- 2013/12/24 06:00
PHST- 2013/04/30 00:00 [received]
PHST- 2013/10/09 00:00 [accepted]
PHST- 2013/12/24 06:00 [entrez]
PHST- 2013/12/24 06:00 [pubmed]
PHST- 2014/09/19 06:00 [medline]
AID - 10.1111/ajo.12151 [doi]
PST - ppublish
SO  - Aust N Z J Obstet Gynaecol. 2014 Apr;54(2):101-7. doi: 10.1111/ajo.12151. Epub 
      2013 Dec 23.

PMID- 25590184
OWN - NLM
STAT- MEDLINE
DCOM- 20160407
LR  - 20220330
IS  - 1438-8812 (Electronic)
IS  - 0013-726X (Linking)
VI  - 47
IP  - 7
DP  - 2015 Jul
TI  - Thienopyridine derivatives as risk factors for bleeding following high risk 
      endoscopic treatments: Safe Treatment on Antiplatelets (STRAP) study.
PG  - 632-7
LID - 10.1055/s-0034-1391354 [doi]
AB  - BACKGROUND AND STUDY AIMS: The optimal method of perioperative management of 
      antiplatelet agents during endoscopic procedures that carry a high risk of 
      bleeding is still controversial. The aim of this study was to evaluate the safety 
      of continuing aspirin treatment during these procedures in an Asian population. 
      PATIENTS AND METHODS: A multicenter, prospective, observational cohort study was 
      conducted at six high volume endoscopy centers in Japan. The study included 
      patients at high risk of thromboembolism who were regularly taking antiplatelet 
      agents (e. g. thienopyridine derivatives and aspirin). Enrolled patients 
      continued their aspirin therapy, and underwent endoscopic procedures that had a 
      high risk of bleeding for treatment of lesions in the upper and lower 
      gastrointestinal tracts. The primary end point was the rate of major bleeding 
      complications after endoscopic procedures. RESULTS: The study was terminated in 
      accordance with predetermined safety criteria because 7 of 28 consecutive 
      patients experienced major bleeding complications (25.0 %; 95 % confidence 
      interval 10.7 % - 44.9 %). All major bleeding complications occurred following 
      endoscopic submucosal dissection (ESD; 6 stomach, 1 colon). Univariate analysis 
      showed that postoperative administration of thienopyridine derivatives was the 
      only significant factor associated with postoperative bleeding (P = 0.01). 
      Subanalysis of gastric ESD (23 lesions in 19 patients) confirmed that the 
      administration of thienopyridine derivatives (P = 0.01) and that of multiple 
      agents (P = 0.02) were the significant factors. All bleeding complications 
      (postoperative day 11.2 ± 3.5) occurred after resuming thienopyridine derivative 
      therapy postoperatively (postoperative day 2.3 ± 2.4). CONCLUSION: In Asian 
      patients taking thienopyridine derivatives with aspirin, cautious postoperative 
      care is necessary for those undergoing endoscopic procedures that are associated 
      with a high risk of bleeding, especially gastric ESD. Continuation of aspirin 
      alone during these endoscopic procedures may be acceptable. STUDY REGISTRATION: 
      UMIN000009176.
CI  - © Georg Thieme Verlag KG Stuttgart · New York.
FAU - Ono, Satoshi
AU  - Ono S
AD  - Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, 
      Tokyo, Japan.
FAU - Fujishiro, Mitsuhiro
AU  - Fujishiro M
AD  - Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, 
      Tokyo, Japan.
FAU - Yoshida, Naohiro
AU  - Yoshida N
AD  - Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, 
      Japan.
FAU - Doyama, Hisashi
AU  - Doyama H
AD  - Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, 
      Japan.
FAU - Kamoshida, Toshiro
AU  - Kamoshida T
AD  - Department of Internal Medicine, Hitachi General Hospital, Hitachi, Japan.
FAU - Hirai, Shinji
AU  - Hirai S
AD  - Department of Internal Medicine, Hitachi General Hospital, Hitachi, Japan.
FAU - Kishihara, Teruhito
AU  - Kishihara T
AD  - Gastroenterology Center, Cancer Institute Hospital of JFCR, Tokyo, Japan.
FAU - Yamamoto, Yorimasa
AU  - Yamamoto Y
AD  - Gastroenterology Center, Cancer Institute Hospital of JFCR, Tokyo, Japan.
FAU - Sakae, Hiroyuki
AU  - Sakae H
AD  - Department of Gastroenterology, Mitoyo General Hospital, Kanonji, Japan.
FAU - Imagawa, Atsushi
AU  - Imagawa A
AD  - Department of Gastroenterology, Mitoyo General Hospital, Kanonji, Japan.
FAU - Hirano, Masaaki
AU  - Hirano M
AD  - Department of Gastroenterology, Niigata Prefectural Central Hospital, Niigata, 
      Japan.
FAU - Koike, Kazuhiko
AU  - Koike K
AD  - Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, 
      Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150115
PL  - Germany
TA  - Endoscopy
JT  - Endoscopy
JID - 0215166
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thienopyridines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Endoscopy. 2015 Jul;47(7):664. PMID: 26334064
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - *Endoscopy, Gastrointestinal
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Postoperative Care/adverse effects
MH  - Postoperative Hemorrhage/*chemically induced/epidemiology
MH  - Prospective Studies
MH  - Risk Factors
MH  - Thienopyridines/*adverse effects/therapeutic use
MH  - Thromboembolism/prevention & control
EDAT- 2015/01/16 06:00
MHDA- 2016/04/08 06:00
CRDT- 2015/01/16 06:00
PHST- 2015/01/16 06:00 [entrez]
PHST- 2015/01/16 06:00 [pubmed]
PHST- 2016/04/08 06:00 [medline]
AID - 10.1055/s-0034-1391354 [doi]
PST - ppublish
SO  - Endoscopy. 2015 Jul;47(7):632-7. doi: 10.1055/s-0034-1391354. Epub 2015 Jan 15.

PMID- 24399582
OWN - NLM
STAT- MEDLINE
DCOM- 20140324
LR  - 20140108
IS  - 1897-4279 (Electronic)
IS  - 0022-9032 (Linking)
VI  - 71
IP  - 12
DP  - 2013
TI  - Predictors of successful acetylsalicylic acid resistance suppression after 
      percutaneous coronary revascularisation.
PG  - 1229-36
LID - 10.5603/KP.2013.0323 [doi]
AB  - BACKGROUND AND AIM: There is no established management of resistance to 
      acetylsalicylic acid (ASA) in patients with coronary artery disease (CAD). We 
      hypothesised that simply doubling the usual daily dose of ASA could be effective 
      in overcoming ASA resistance. METHODS: Our study comprised 40 subjects with CAD 
      (male 67.5%, mean age 60.5 ± 8.8 years, mean body mass index 26.9 ± 2.7 kg/m² and 
      median aspirin reaction unit [ARU] value obtained with a Verify Now Aspirin Test 
      612 [573-634]) with resistance to 75 mg/daily ASA defined as ARU ≥ 550. According 
      to the overcoming of resistance or lack there of in a repeated test after four 
      weeks of 150 mg daily ASA treatment, we defined two subsets: subjects who 
      regained ASA sensitivity, and those who did not. RESULTS: Successful overcoming 
      of ASA resistance was observed in 62.5% of patients. Multivariate analysis 
      regression confirmed that two variables independently determined successful ASA 
      resistance suppression: male gender (OR 6.88; 95% CI 1.29-36.75; p = 0.024), and 
      ARU for 75 mg daily (OR 0.97 per unit at 75 mg; 95% CI 0.94-0.99; p = 0.039). ROC 
      analysis indicated that the threshold value at which ARU at 75 mg ASA treatment 
      was predictive of successful ASA resistance overcoming was ≤ 608 ARU. Using a 
      simple point score (one point for male gender and one for initial ARU ≤ 608), we 
      found that ASA resistance was overcome in 8%, 36% and 56% of patients, when zero, 
      any single, or two predictors were present. CONCLUSIONS: ASA resistance 
      overcoming by dose doubling can be achieved more often in males and in subjects 
      with lower ARU value at ASA 75 mg.
FAU - Dominiak, Marcin
AU  - Dominiak M
AD  - Chair and Department of Cardiology, Medical University of Lodz, Lodz, Poland. 
      Marcin.Dominiak@gmail.com.
FAU - Wcisło, Tomasz
AU  - Wcisło T
FAU - Krzemińska-Pakuła, Maria
AU  - Krzemińska-Pakuła M
FAU - Bednarkiewicz, Zbigniew
AU  - Bednarkiewicz Z
FAU - Figiel, Łukasz
AU  - Figiel Ł
FAU - Kasprzak, Jarosław D
AU  - Kasprzak JD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Coronary Artery Disease/*therapy
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Percutaneous Coronary Intervention
MH  - Postoperative Care/*methods
MH  - Sex Factors
EDAT- 2014/01/09 06:00
MHDA- 2014/03/25 06:00
CRDT- 2014/01/09 06:00
PHST- 2013/12/13 00:00 [received]
PHST- 2013/12/13 00:00 [accepted]
PHST- 2014/01/09 06:00 [entrez]
PHST- 2014/01/09 06:00 [pubmed]
PHST- 2014/03/25 06:00 [medline]
AID - VM/OJS/KP/8446 [pii]
AID - 10.5603/KP.2013.0323 [doi]
PST - ppublish
SO  - Kardiol Pol. 2013;71(12):1229-36. doi: 10.5603/KP.2013.0323.

PMID- 20518585
OWN - NLM
STAT- MEDLINE
DCOM- 20100810
LR  - 20230823
IS  - 1083-4087 (Print)
IS  - 1944-706X (Electronic)
IS  - 1083-4087 (Linking)
VI  - 16
IP  - 5
DP  - 2010 Jun
TI  - Intervention to increase the proportion of acute myocardial infarction or 
      coronary artery bypass graft patients receiving an order for aspirin at hospital 
      discharge.
PG  - 329-36
LID - 10.18553/jmcp.2010.16.5.329
AB  - BACKGROUND: Chronic aspirin therapy is recommended by the American College of 
      Cardiology/American Heart Association (ACC/AHA) following acute myocardial 
      infarction (AMI) and by the Society of Thoracic Surgeons(STS) following coronary 
      artery bypass graft (CABG). Aspirin therapy at discharge following a 
      hospitalization for AMI or CABG is a common pay for-performance indicator used by 
      third-party payers and was included asa quality measure in the Centers for 
      Medicare & Medicaid Services (CMS)/Premier Hospital Quality Incentive 
      Demonstration initiated in 2003. A formal prescription for aspirin, such as 
      required for other cardiovascular drugs,could serve as a reminder to all health 
      care providers (doctors, nurses, and pharmacists) to include aspirin on a 
      discharge medication list. OBJECTIVE: To evaluate if an aspirin prescription 
      placed in the patient chart shortly after hospital admission would increase 
      compliance with guidelines for aspirin use at discharge in patients with AMI or 
      CABG. METHODS: This was a single-center prospective pre-intervention to post 
      intervention comparison study in a 411-bed hospital. Patients admitted during the 
      3-month period from July through September 2008 with an AMI or undergoing CABG 
      surgery served as the pre-intervention group, and patients admitted during the 
      3-month period from January through March 2009 were in the post-intervention 
      group. The intervention included multiple educational sessions with clinical 
      staff, conducted both prior to and during the pilot, and blank pre-printed 
      aspirin prescriptions placed in the charts of patients for whom no 
      contraindication to aspirin was present. The blank prescriptions were then 
      completed by the attending physician (or physician extender), and the discharge 
      nurse used the completed aspirin prescription, with other prescriptions and 
      written orders, as a reference when creating the discharge medication list. The 
      primary outcome measure was the percentage of patients who had aspirin documented 
      on the discharge medication list. Differences in compliance rates in the 
      comparison and pilot periods were assessed using the Pearson chi-square test. 
      RESULTS: A total of 458 patients were identified with a CABG procedure and/or an 
      admitting diagnosis of AMI; 447 met inclusion criteria, and 11 were excluded (1 
      patient in each of the groups had a contraindication to aspirin due to bleeding, 
      and 9 died during hospitalization). The intervention was associated with an 
      increase in the proportion of patients with aspirin documented on the discharge 
      medication list, 266 of 269 patients (98.9%)compared with 169 of 178 patients 
      (94.9%, P = 0.012) in the pre-intervention group. In the subsample of patients 
      with CABG, 54 of 59 (91.5%)patients in the pre-intervention group had aspirin 
      documented on the discharge medication list compared with 100% of 66 patients in 
      the postintervention group (P = 0.016). In the subsample of patients with AMI, 
      aspirin was documented in 115 of 119 (96.6%) patients in the pre-intervention 
      group versus 200 of 203 (98.5%) in the post-intervention group (P = 0.263). 
      CONCLUSION: A quality improvement initiative that included clinical staff 
      education and placement of aspirin prescriptions in patient charts during the 
      hospital stay was associated with an increase in the proportion of patients who 
      had aspirin documented on the discharge medication list for the overall sample of 
      patients with AMI or CABG and for patients with CABG alone but not for the 
      quality measure for AMI patients.
FAU - Brackbill, Marcia L
AU  - Brackbill ML
AD  - BJD School of Pharmacy, Dept. of Pharmacy Practice, Shenandoah University, 1775 
      North Sector Court, Winchester, VA 22601, USA. mbrackbi@su.edu
FAU - Kline, Vanessa T
AU  - Kline VT
FAU - Sytsma, Christine S
AU  - Sytsma CS
FAU - Call, Jason T
AU  - Call JT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Manag Care Pharm
JT  - Journal of managed care pharmacy : JMCP
JID - 9605854
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Manag Care Pharm. 2010 Jun;16(5):360-6. PMID: 20518589
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Bypass
MH  - Decision Support Systems, Clinical
MH  - Female
MH  - Humans
MH  - Male
MH  - Medical Order Entry Systems
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy
MH  - Patient Discharge
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
PMC - PMC10438078
EDAT- 2010/06/04 06:00
MHDA- 2010/08/11 06:00
CRDT- 2010/06/04 06:00
PHST- 2010/06/04 06:00 [entrez]
PHST- 2010/06/04 06:00 [pubmed]
PHST- 2010/08/11 06:00 [medline]
AID - 2010(16)5: 329-336 [pii]
AID - 10.18553/jmcp.2010.16.5.329 [doi]
PST - ppublish
SO  - J Manag Care Pharm. 2010 Jun;16(5):329-36. doi: 10.18553/jmcp.2010.16.5.329.

PMID- 31813726
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 228
DP  - 2020 Mar 5
TI  - Multi spectroscopy and molecular modeling aspects related to drug interaction of 
      aspirin and warfarin with pepsin; structural change and protease activity.
PG  - 117813
LID - S1386-1425(19)31203-X [pii]
LID - 10.1016/j.saa.2019.117813 [doi]
AB  - This study evaluates the biochemical interactions between two widely used 
      anticoagulants agents, Aspirin and Warfarin, with the Pepsin as the main stomach 
      protease. These two drugs usually prescribe orally for long period daily use to 
      reduce cardiovascular and thrombi death which leads to being in close contact 
      with Pepsin. This interaction could induce related gastrointestinal problems such 
      as peptic ulcer. In this regard, the conformational changes and enzymatic 
      activity of the Pepsin induced by Aspirin and Warfarin were studied by using 
      several spectroscopic methods along with molecular modeling approaches. Results 
      confirm the formation of stable complexes between protein and drugs which leads 
      to slight subsequent conformational changes of protein structure. The quenching 
      mechanisms for both drug-Pepsin interactions are static. In the case of Warfarin, 
      the hydrophobic interactions are the most important interactions. Also for 
      Aspirin, hydrogen bond and van der Waals forces are mainly involved in the 
      binding process. The Warfarin shows the induction of some conformational changes 
      resulted in suppressing the protease activity and the Aspirin reversely enhanced 
      the enzyme activity function. This study provides useful information regarding 
      the effects of Warfarin and Aspirin on Pepsin which are helpful for the choosing 
      of therapeutics depending on the patients' condition.
CI  - Copyright © 2019. Published by Elsevier B.V.
FAU - Moradi, Sajad
AU  - Moradi S
AD  - Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah 
      University of Medical Sciences, Kermanshah, Iran.
FAU - Farhadian, Negin
AU  - Farhadian N
AD  - Substance Abuse Prevention Research Center, Health Institute, Kermanshah 
      University of Medical Sciences, Kermanshah, Iran.
FAU - Balaei, Fatemeh
AU  - Balaei F
AD  - Medical Biology Research Center, Health Technology Institute, Kermanshah 
      University of Medical Sciences, Kermanshah, Iran.
FAU - Ansari, Mohabbat
AU  - Ansari M
AD  - Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah 
      University of Medical Sciences, Kermanshah, Iran.
FAU - Shahlaei, Mohsen
AU  - Shahlaei M
AD  - Medical Biology Research Center, Health Technology Institute, Kermanshah 
      University of Medical Sciences, Kermanshah, Iran. Electronic address: 
      mshahlaei@kums.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20191119
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 5Q7ZVV76EI (Warfarin)
RN  - EC 3.4.23.1 (Pepsin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Binding Sites
MH  - Circular Dichroism
MH  - Computer Simulation
MH  - *Drug Interactions
MH  - Humans
MH  - Hydrogen Bonding
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Molecular Dynamics Simulation
MH  - Pepsin A/*chemistry
MH  - Protein Binding
MH  - Protein Conformation
MH  - Spectrometry, Fluorescence
MH  - Spectrophotometry
MH  - Spectrophotometry, Ultraviolet
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Thermodynamics
MH  - Warfarin/*pharmacology
OTO - NOTNLM
OT  - Aspirin
OT  - Molecular dynamic simulation
OT  - Pepsin
OT  - Protein-drug interaction
OT  - Spectroscopy
OT  - Warfarin
COIS- Declaration of competing interest All authors confirmed there is no any conflict 
      of interests.
EDAT- 2019/12/10 06:00
MHDA- 2021/01/05 06:00
CRDT- 2019/12/10 06:00
PHST- 2019/09/29 00:00 [received]
PHST- 2019/11/16 00:00 [revised]
PHST- 2019/11/17 00:00 [accepted]
PHST- 2019/12/10 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2019/12/10 06:00 [entrez]
AID - S1386-1425(19)31203-X [pii]
AID - 10.1016/j.saa.2019.117813 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2020 Mar 5;228:117813. doi: 
      10.1016/j.saa.2019.117813. Epub 2019 Nov 19.

PMID- 3743164
OWN - NLM
STAT- MEDLINE
DCOM- 19861003
LR  - 20201209
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 90
IP  - 3
DP  - 1986 Sep
TI  - Bronchoalveolar lavage in recurrent aspirin-induced adult respiratory distress 
      syndrome.
PG  - 452-3
AB  - Aspirin has been reported to induce the adult respiratory distress syndrome 
      (ARDS) in humans. The mechanism of injury appears to be similar to other forms of 
      experimentally induced high-permeability edema in which leukocytes play an 
      important role. In a patient who suffered two episodes of aspirin-related ARDS, 
      bronchoalveolar lavage showed a significant influx of leukocytes. This represents 
      the first reported bronchoalveolar lavage in aspirin-related ARDS, as well as the 
      first documentation of the nonhydrostatic nature of the edema in a patient with 
      recurrence of this entity.
FAU - Suarez, M
AU  - Suarez M
FAU - Krieger, B P
AU  - Krieger BP
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Leukocytes/pathology
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Alveoli/*pathology
MH  - Pulmonary Edema/chemically induced
MH  - Recurrence
MH  - Respiratory Distress Syndrome/*chemically induced/pathology
MH  - Therapeutic Irrigation
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
AID - S0012-3692(16)37134-3 [pii]
AID - 10.1378/chest.90.3.452 [doi]
PST - ppublish
SO  - Chest. 1986 Sep;90(3):452-3. doi: 10.1378/chest.90.3.452.

PMID- 18685810
OWN - NLM
STAT- MEDLINE
DCOM- 20090818
LR  - 20211020
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 28
IP  - 1
DP  - 2009 Jul
TI  - Aspirin administered to women at 100 mg every other day produces less platelet 
      inhibition than aspirin administered at 81 mg per day: implications for 
      interpreting the women's health study.
PG  - 94-100
LID - 10.1007/s11239-008-0262-6 [doi]
AB  - OBJECTIVE: We aimed to determine the relative level of platelet inhibition 
      achieved with low-dose aspirin (81 mg daily) compared with a very low-dose (100 
      mg every other day). BACKGROUND: The Womens Health Study (WHS) found that a dose 
      of 100 mg every other day of aspirin provided protection against stroke as 
      primary prophylaxis, but not myocardial infarction. In the United States, the 
      most commonly prescribed dose of aspirin for primary prophylaxis is 81 mg per 
      day. As a result, it is important to know whether these doses are equivalent 
      before extrapolating the results of the WHS to women in the U.S. METHODS: To 
      achieve this goal, we have studied the effects of these two dosing regimens on 
      platelet function in healthy women meeting the WHS inclusion criteria using a 
      randomized design. We enrolled 49 healthy female volunteers and used a 
      sequential, crossover design to compare the two regimens. The participants 
      received a 17-day course of each aspirin-dosing regimen separated by a 7-day 
      washout period. The degree of platelet inhibition was measured on days 14-17 of 
      each dosing regimen using a point-of-care platelet function assay utilizing 
      arachidonic acid to activate platelets (VerifyNow-Aspirin). RESULTS: Participants 
      platelet response, expressed as Aspirin Response Unit (ARU) attained a 
      significantly greater level of platelet inhibition on days 14-17 while taking 
      aspirin 81 mg daily compared to aspirin 100 mg every other day (31.3% vs. 12.7%, 
      P < 0.0001) with mean +/- SD ARU values of 445 +/- 50 and 570 +/- 68, P < 0.0001. 
      Significantly more daily readings in participants were >or=550 ARU, a value 
      correlated with clinical outcomes in several studies, with the 100 mg every other 
      day regimen (72.0% vs. 6.4% with 81 mg daily, P < 0.0001), and this alternate-day 
      regimen also resulted in more day-to-day variability in platelet function (P = 
      0.0002). CONCLUSION: We found significantly less inhibition of platelet function 
      with the dose used in the WHS than the usual U.S. dose. We observed that the 
      degree of platelet inhibition was significantly less with aspirin 100 mg every 
      other day compared with aspirin 81 mg daily, suggesting that results of the 
      Women's Health Study may have underestimated both the efficacy and toxicity of 
      aspirin as it is commonly administered. These data need to be considered when 
      developing recommendations about the use of aspirin in the primary prevention of 
      cardiovascular disease in women.
FAU - Swaim, Lisa
AU  - Swaim L
AD  - Accumetrics, Inc., 3985 Sorrento Valley Blvd, San Diego, CA 92121, USA.
FAU - Hillman, Robert S
AU  - Hillman RS
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
DEP - 20080807
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Platelet Activation/*drug effects
MH  - Time Factors
MH  - *Women's Health
EDAT- 2008/08/08 09:00
MHDA- 2009/08/19 09:00
CRDT- 2008/08/08 09:00
PHST- 2008/03/24 00:00 [received]
PHST- 2008/07/23 00:00 [accepted]
PHST- 2008/08/08 09:00 [pubmed]
PHST- 2009/08/19 09:00 [medline]
PHST- 2008/08/08 09:00 [entrez]
AID - 10.1007/s11239-008-0262-6 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2009 Jul;28(1):94-100. doi: 10.1007/s11239-008-0262-6. 
      Epub 2008 Aug 7.

PMID- 32251176
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 1537-2677 (Electronic)
IS  - 0740-9303 (Linking)
VI  - 36
IP  - 6
DP  - 2020 Nov/Dec
TI  - Effects of Aspirin on Postoperative Bruising and Bleeding Complications in Upper 
      Eyelid Surgery.
PG  - 575-578
LID - 10.1097/IOP.0000000000001652 [doi]
AB  - PURPOSE: We evaluated the effects of aspirin versus placebo in patients 
      undergoing upper eyelid blepharoplasty and/or levator advancement or plication 
      blepharoptosis repair in this randomized, prospective study. METHODS: Patients 
      who presented between October 2017 and April 2019 requiring blepharoptosis repair 
      and/or upper eyelid blepharoplasty who were taking 81 mg aspirin were randomized 
      to receive 1 week of aspirin tablets or 1 week of placebo tablets prior to 
      surgery. Postoperative complications, such as bleeding, hematoma, or hemorrhage, 
      were noted as well as perioperative thromboembolic complications. Photos were 
      obtained at the patient's first postoperative visit and later judged on bruising 
      severity. The 2 groups were subsequently compared. RESULTS: A total of 48 
      patients and 89 eyelids were evaluated in this study. Fifty-two eyelids were 
      included in the aspirin group and 37 eyelids were included in the placebo group. 
      There was no statistically significant difference in bruising rating between 
      groups. There was no statistically significant difference in the number of 
      patients who experienced mild postoperative bleeding. No patients experienced 
      vision loss. No patients experienced a thromboembolic event. There were no 
      patients who experienced hemorrhage, hematoma, or retrobulbar hemorrhage. 
      CONCLUSIONS: Continuation of aspirin does not appear to effect outcomes with 
      respect to postoperative bruising in patients undergoing upper eyelid 
      blepharoplasty or blepharoptosis repair. The study was not powered to determine 
      statistical significance with regard to bleeding complications and would require 
      a significantly higher sample size. We suggest changing the current guidelines to 
      recommend routine continuation of low dose 81 mg aspirin before upper eyelid 
      surgery.
FAU - Winkler, Kathryn P
AU  - Winkler KP
AD  - DuPage Medical Group Eye Specialists, Downers Grove, Illinois.
FAU - Beaulieu, Robert
AU  - Beaulieu R
AD  - Consultants in Ophthalmic and Facial Plastic Surgery, Southfield, Michigan.
AD  - Kresge Eye Institute, Detroit, Michigan.
FAU - Bevill, Lauren
AU  - Bevill L
AD  - Consultants in Ophthalmic and Facial Plastic Surgery, Southfield, Michigan.
FAU - Mishulin, Aleksey
AU  - Mishulin A
AD  - Kresge Eye Institute, Detroit, Michigan.
FAU - Black, Evan H
AU  - Black EH
AD  - Consultants in Ophthalmic and Facial Plastic Surgery, Southfield, Michigan.
AD  - Oakland University/William Beaumont Hospital School of Medicine, Beaumont Eye 
      Institute, Royal Oak, Michigan, U.S.A.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ophthalmic Plast Reconstr Surg
JT  - Ophthalmic plastic and reconstructive surgery
JID - 8508431
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Blepharoplasty/adverse effects
MH  - *Blepharoptosis/surgery
MH  - Eyelids/surgery
MH  - Humans
MH  - Postoperative Complications/prevention & control
MH  - Prospective Studies
MH  - Retrospective Studies
EDAT- 2020/04/07 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - 00002341-202011000-00010 [pii]
AID - 10.1097/IOP.0000000000001652 [doi]
PST - ppublish
SO  - Ophthalmic Plast Reconstr Surg. 2020 Nov/Dec;36(6):575-578. doi: 
      10.1097/IOP.0000000000001652.

PMID- 27355165
OWN - NLM
STAT- MEDLINE
DCOM- 20170410
LR  - 20220311
IS  - 1175-8716 (Electronic)
IS  - 0028-8446 (Linking)
VI  - 129
IP  - 1435
DP  - 2016 May 27
TI  - Dispensing data captures individual-level use of aspirin for cardiovascular 
      disease prevention, despite availability over-the-counter.
PG  - 21-8
AB  - AIM: To assess the level of agreement in aspirin use measured by self-report and 
      dispensing data. METHOD: We assessed preventive cardiovascular medication use 
      (prescription-only statins and blood pressure-lowering therapy; and aspirin-also 
      available over-the-counter) at baseline in participants in the New Zealand IMPACT 
      trial for whom these medications were prescribed by their general practitioner. A 
      trial nurse not involved in their ongoing health care obtained participants' 
      self-reported aspirin use data. We obtained dispensing data from the national 
      pharmaceutical dispensing database and assessed agreement between the two 
      measures using kappa coefficients. RESULTS: Of the 513 trial participants, 36% 
      were women, 50% were of Māori ethnicity, and 45% had a history of cardiovascular 
      disease. The level of agreement between self-reported aspirin use and dispensing 
      data was substantial (kappa 0.75, 95% CI 0.69 to 0.82). The level of agreement in 
      aspirin use measured by these two sources of data was similar to that for statin 
      and blood pressure-lowering therapy use, for all participants combined, for 
      subgroups according to ethnicity (Māori and non-Māori) and history of 
      cardiovascular disease. CONCLUSIONS: Despite its availability over-the-counter, 
      aspirin use in patients for whom cardiovascular medications are indicated can be 
      assessed accurately from dispensing data.
FAU - Selak, Vanessa
AU  - Selak V
AD  - Department of Epidemiology & Biostatistics, University of Auckland, Private Bag 
      92019, Auckland Mail Centre, Auckland 1142, New Zealand. v.selak@auckland.ac.nz.
FAU - Gu, Yulong
AU  - Gu Y
FAU - Rafter, Natasha
AU  - Rafter N
FAU - Crengle, Sue
AU  - Crengle S
FAU - Kerr, Andrew J
AU  - Kerr AJ
FAU - Bullen, Chris
AU  - Bullen C
LA  - eng
PT  - Journal Article
DEP - 20160527
PL  - New Zealand
TA  - N Z Med J
JT  - The New Zealand medical journal
JID - 0401067
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Databases, Pharmaceutical
MH  - Drug Prescriptions/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Male
MH  - New Zealand
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - *Self Report
EDAT- 2016/06/30 06:00
MHDA- 2017/04/11 06:00
CRDT- 2016/06/30 06:00
PHST- 2016/06/30 06:00 [entrez]
PHST- 2016/06/30 06:00 [pubmed]
PHST- 2017/04/11 06:00 [medline]
PST - epublish
SO  - N Z Med J. 2016 May 27;129(1435):21-8.

PMID- 11562343
OWN - NLM
STAT- MEDLINE
DCOM- 20020325
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 103
IP  - 4
DP  - 2001 Aug 15
TI  - There is synergism between high-intensity, low-frequency ultrasound and 
      streptokinase but not with eptifibatide, heparin, and aspirin. Differential 
      effects on fresh and aged blood clots. An in vitro study.
PG  - 337-44
AB  - OBJECTIVE: Ultrasound is emerging as a promising modality for recanalization of 
      acutely thrombosed blood vessels, especially when associated with fibrinolytics. 
      We assessed the efficacy of ultrasound combined with saline, heparin, 
      eptifibatide, aspirin, and streptokinase in disruption of fresh as well as aged 
      human blood clots, using an in vitro model. METHODS: Blood clots from five 
      donors, 2-4 or 48 hours old, were cut into 250-400 mg slices and immersed for 1, 
      15, or 30 min in 10 ml saline containing either heparin, eptifibatide, aspirin, 
      streptokinase, or saline alone. Clots were then randomized to 10 s of 20 kHz 
      ultrasound or immersion alone. After treatment, the percentage difference in 
      weight was calculated. RESULTS: Immersion of fresh clots without ultrasound in 
      eptifibatide and heparin resulted in significantly more clot lysis than immersion 
      in saline, aspirin, and streptokinase. Immersion of aged thrombi without 
      ultrasound in heparin, eptifibatide, and aspirin had no additive effect over 
      immersion in saline. Ultrasound enhanced clot disruption in all five solutions, 
      in each immersion time and both in fresh and aged clots. Heparin and aspirin had 
      no additive effect, compared with saline, on ultrasound disruption of both fresh 
      and aged clots, whereas eptifibatide was less effective than saline. In contrast, 
      streptokinase greatly enhanced disruption of both fresh (P=.004) and aged 
      (P<.001) thrombi by ultrasound. The combinations of ultrasound with saline, 
      heparin, eptifibatide, and aspirin were less effective on aged than fresh 
      thrombi, whereas the combination of ultrasound with streptokinase was equally 
      effective on fresh and aged thrombi. CONCLUSIONS: Using a simple in vitro model, 
      we found that the combination of streptokinase and low-frequency ultrasound had a 
      synergistic effect on disruption of both fresh and aged blood clots. Further 
      studies are needed to assess the role of heparin and antiplatelet agents in 
      augmenting clot disruption by ultrasound in in vivo models of acute and subacute 
      thrombosis.
FAU - Wyshelesky, A
AU  - Wyshelesky A
AD  - Laboratory of Cardiovascular Biology, Felsenstein Research Institute, Rabin 
      Medical Center, 49-100, Petah-Tiqwa, Israel.
FAU - Iakobishvili, Z
AU  - Iakobishvili Z
FAU - Matz, I
AU  - Matz I
FAU - Golovchiner, G
AU  - Golovchiner G
FAU - Vaturi, M
AU  - Vaturi M
FAU - Siegel, R J
AU  - Siegel RJ
FAU - Birnbaum, Y
AU  - Birnbaum Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Peptides)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Streptokinase)
RN  - NA8320J834 (Eptifibatide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Coagulation/drug effects/radiation effects
MH  - Combined Modality Therapy
MH  - Eptifibatide
MH  - Fibrinolysis/*drug effects/*radiation effects
MH  - Fibrinolytic Agents/*pharmacology
MH  - Heparin/pharmacology
MH  - Humans
MH  - Kinetics
MH  - Peptides/pharmacology
MH  - Streptokinase/pharmacology
MH  - *Ultrasonics
EDAT- 2001/09/20 10:00
MHDA- 2002/03/26 10:01
CRDT- 2001/09/20 10:00
PHST- 2001/09/20 10:00 [pubmed]
PHST- 2002/03/26 10:01 [medline]
PHST- 2001/09/20 10:00 [entrez]
AID - S0049-3848(01)00323-1 [pii]
AID - 10.1016/s0049-3848(01)00323-1 [doi]
PST - ppublish
SO  - Thromb Res. 2001 Aug 15;103(4):337-44. doi: 10.1016/s0049-3848(01)00323-1.

PMID- 8276502
OWN - NLM
STAT- MEDLINE
DCOM- 19940207
LR  - 20151119
IS  - 0019-5499 (Print)
IS  - 0019-5499 (Linking)
VI  - 37
IP  - 3
DP  - 1993 Jul
TI  - The effect of aspirin, paracetamol and analgin on pharmacokinetics of 
      chloroquine.
PG  - 229-31
AB  - The effect of Aspirin, paracetamol and analgin on the kinetic profile of a single 
      oral dose of chloroquine was studied in 8 healthy subjects. Aspirin did not alter 
      the kinetic parameters of chloroquine whereas paracetamol and analgin 
      significantly enhanced the Cmax and AUC0-alpha of chloroquine (P < 0.01, < 0.05 
      respectively).
FAU - Raina, R K
AU  - Raina RK
AD  - Department of Pharmacology and Therapeutics, Government Medical College, Jammu, 
      Tawi.
FAU - Bano, G
AU  - Bano G
FAU - Amla, V
AU  - Amla V
FAU - Kapoor, V
AU  - Kapoor V
FAU - Gupta, K L
AU  - Gupta KL
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Physiol Pharmacol
JT  - Indian journal of physiology and pharmacology
JID - 0374707
RN  - 362O9ITL9D (Acetaminophen)
RN  - 6429L0L52Y (Dipyrone)
RN  - 886U3H6UFF (Chloroquine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Chloroquine/blood/*pharmacokinetics
MH  - Dipyrone/*pharmacology
MH  - Drug Interactions
MH  - Humans
MH  - Male
MH  - Models, Biological
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Physiol Pharmacol. 1993 Jul;37(3):229-31.

PMID- 870837
OWN - NLM
STAT- MEDLINE
DCOM- 19770630
LR  - 20190725
IS  - 0028-1298 (Print)
IS  - 0028-1298 (Linking)
VI  - 297 Suppl 1
DP  - 1977
TI  - Participation of prostaglandins in pathogenesis of aspirin-sensitive asthma.
PG  - S99-10
AB  - Recent evidence suggests that the induction of bronchoconstriction in 
      aspirin-sensitive patients by analgesics is due to the inhibition of PG 
      biosynthesis in their respiratory tract. PGEs might play the main defensive role 
      in the bronchi of aspirin-sensitive asthmatics. Removal of this potent 
      bronchodilator by PG synthetase inhibitors leaves the effects of spasmogens 
      unopposed, and possibly promotes the release of histamine from its stores.
FAU - Szczeklik, A
AU  - Szczeklik A
FAU - Gryglewski, R J
AU  - Gryglewski RJ
FAU - Czerniawska-Mysik, G
AU  - Czerniawska-Mysik G
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/chemically induced/*metabolism
MH  - Drug Hypersensitivity/*metabolism
MH  - Humans
MH  - Prostaglandins/*metabolism
EDAT- 1977/03/31 00:00
MHDA- 1977/03/31 00:01
CRDT- 1977/03/31 00:00
PHST- 1977/03/31 00:00 [pubmed]
PHST- 1977/03/31 00:01 [medline]
PHST- 1977/03/31 00:00 [entrez]
AID - 10.1007/BF00587792 [doi]
PST - ppublish
SO  - Naunyn Schmiedebergs Arch Pharmacol. 1977;297 Suppl 1:S99-10. doi: 
      10.1007/BF00587792.

PMID- 27823698
OWN - NLM
STAT- MEDLINE
DCOM- 20170525
LR  - 20220310
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 181
DP  - 2016 Nov
TI  - A critical reappraisal of aspirin for secondary prevention in patients with 
      ischemic heart disease.
PG  - 92-100
LID - S0002-8703(16)30169-7 [pii]
LID - 10.1016/j.ahj.2016.08.008 [doi]
AB  - Aspirin was established more than a quarter century ago as an evidence-based 
      therapy to reduce recurrent cardiovascular events in patients with coronary 
      artery disease based on limited data by contemporary standards. Indeed it is 
      unclear how regulatory agencies would define the optimal dose or duration of 
      aspirin therapy if assessed in the current era. Subsequent clinical investigation 
      has focused on the addition of antithrombotic agents on top of baseline aspirin 
      therapy in the acute and chronic setting to reduce patient's risk of further 
      ischemic events, at the cost of increased bleeding complications. The current 
      armamentarium of potent and predictable antiplatelet and antithrombotic agents 
      has ushered in a new era where clinicians and scientists are contemplating 
      withdrawal of previously established agents to minimize bleeding risk while 
      sustaining efficacy; indeed, subtraction may lead to the next advance in the 
      treatment of acute and chronic ischemic vascular disease.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Welsh, Robert C
AU  - Welsh RC
AD  - Mazankowski Alberta Heart Institute and University of Alberta, Edmonton, Alberta, 
      Canada. Electronic address: Robert.Welsh@albertahealthservices.ca.
FAU - Roe, Matthew T
AU  - Roe MT
AD  - Division of Cardiology, Duke Clinical Research Institute, Duke Medicine, Durham, 
      NC.
FAU - Steg, Philippe Gabriel
AU  - Steg PG
AD  - Université Paris-Diderot, Sorbonne Paris Cité, FACT, DHU-FIRE, AP-HP and INSERM 
      U-1148, Paris, France; NHLI, Royal Brompton Hospital, Imperial College, London, 
      United Kingdom.
FAU - James, Stefan
AU  - James S
AD  - Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
FAU - Povsic, Thomas J
AU  - Povsic TJ
AD  - Division of Cardiology, Duke Clinical Research Institute, Duke Medicine, Durham, 
      NC.
FAU - Bode, Christoph
AU  - Bode C
AD  - University of Freiburg, Freiburg, Germany.
FAU - Gibson, Charles Michael
AU  - Gibson CM
AD  - Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical 
      Center, Harvard Medical School, Boston, MA.
FAU - Ohman, Erik Magnus
AU  - Ohman EM
AD  - Division of Cardiology, Duke Clinical Research Institute, Duke Medicine, Durham, 
      NC.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20160830
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Antithrombins)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Am Heart J. 2017 Feb;184:156. PMID: 28224931
MH  - Adenosine/analogs & derivatives/therapeutic use
MH  - Antithrombins/therapeutic use
MH  - Aspirin/history/*therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Evidence-Based Medicine
MH  - Factor Xa Inhibitors/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - History, 20th Century
MH  - History, 21st Century
MH  - History, Ancient
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy
MH  - Platelet Aggregation Inhibitors/history/*therapeutic use
MH  - Prasugrel Hydrochloride/therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/*therapeutic use
MH  - Secondary Prevention
MH  - Ticagrelor
MH  - Ticlopidine/analogs & derivatives/therapeutic use
EDAT- 2016/11/09 06:00
MHDA- 2017/05/26 06:00
CRDT- 2016/11/09 06:00
PHST- 2016/07/18 00:00 [received]
PHST- 2016/08/22 00:00 [accepted]
PHST- 2016/11/09 06:00 [entrez]
PHST- 2016/11/09 06:00 [pubmed]
PHST- 2017/05/26 06:00 [medline]
AID - S0002-8703(16)30169-7 [pii]
AID - 10.1016/j.ahj.2016.08.008 [doi]
PST - ppublish
SO  - Am Heart J. 2016 Nov;181:92-100. doi: 10.1016/j.ahj.2016.08.008. Epub 2016 Aug 
      30.

PMID- 20606449
OWN - NLM
STAT- MEDLINE
DCOM- 20101110
LR  - 20220311
IS  - 1421-9913 (Electronic)
IS  - 0014-3022 (Linking)
VI  - 64
IP  - 1
DP  - 2010
TI  - Biochemical aspirin resistance and recurrent lesions in patients with acute 
      ischemic stroke.
PG  - 51-7
LID - 10.1159/000315147 [doi]
AB  - BACKGROUND: The effect of biochemical aspirin resistance (BAR) on ischemic stroke 
      has not been well established. Early recurrent ischemic lesions (ERILs) on 
      diffusion-weighted imaging (DWI) are proposed as potential surrogate markers of 
      clinically recurrent stroke. METHODS: We included 117 consecutive patients who 
      (1) were admitted within 24 h of symptom onset; (2) had an ischemic stroke 
      confirmed by DWI; (3) underwent follow-up DWI within seven days after onset, and 
      (4) received aspirin treatment. BAR was measured using the VerifyNow(R) Aspirin 
      Assay. We analyzed the associations between BAR and any ERILs (overall ERILs), 
      and between BAR and ERILs occurring outside the vascular territories of index 
      stroke (distant ERILs). RESULTS: BAR was observed in 16 (13.7%) patients. Overall 
      ERILs were detected in 34 (29.1%), and distant ERILs in 10 (8.5%) patients. 
      Patients with BAR were more likely to develop ERILs, but the association was not 
      significant (OR 2.13; 95% CI 0.72-6.29; p = 0.234). However, BAR was 
      independently related to distant ERILs by logistic regression analysis (OR 6.01; 
      95% CI 1.29-28.09; p = 0.023). CONCLUSIONS: BAR was associated with distant ERILs 
      but not with overall ERILs during the first week after ischemic stroke.
CI  - 2010 S. Karger AG, Basel.
FAU - Jeon, Sang-Beom
AU  - Jeon SB
AD  - Stroke Center and Department of Neurology, Asan Medical Center, University of 
      Ulsan College of Medicine, Seoul, Republic of Korea.
FAU - Song, Ha-Sup
AU  - Song HS
FAU - Kim, Bum Joon
AU  - Kim BJ
FAU - Kim, Hye-Jin
AU  - Kim HJ
FAU - Kang, Dong-Wha
AU  - Kang DW
FAU - Kim, Jong S
AU  - Kim JS
FAU - Kwon, Sun U
AU  - Kwon SU
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100703
PL  - Switzerland
TA  - Eur Neurol
JT  - European neurology
JID - 0150760
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Diffusion Magnetic Resonance Imaging/methods
MH  - Drug Resistance
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Retrospective Studies
MH  - Stroke/*diagnosis/*drug therapy/physiopathology
MH  - Treatment Outcome
EDAT- 2010/07/08 06:00
MHDA- 2010/11/11 06:00
CRDT- 2010/07/08 06:00
PHST- 2010/01/24 00:00 [received]
PHST- 2010/05/18 00:00 [accepted]
PHST- 2010/07/08 06:00 [entrez]
PHST- 2010/07/08 06:00 [pubmed]
PHST- 2010/11/11 06:00 [medline]
AID - 000315147 [pii]
AID - 10.1159/000315147 [doi]
PST - ppublish
SO  - Eur Neurol. 2010;64(1):51-7. doi: 10.1159/000315147. Epub 2010 Jul 3.

PMID- 18534082
OWN - NLM
STAT- MEDLINE
DCOM- 20090311
LR  - 20161020
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 29
IP  - 3
DP  - 2008 May-Jun
TI  - Analysis of high-affinity IgE receptor (FcepsilonR1) polymorphisms in patients 
      with aspirin-intolerant chronic urticaria.
PG  - 250-7
LID - 10.2500/aap.2008.29.3116 [doi]
AB  - Chronic urticaria (CU) associated with aspirin sensitivity, termed 
      aspirin-intolerant CU (AICU), is a common condition in the general population. 
      The genetic mechanism of AICU still is not fully understood. We investigated 
      genetic polymorphisms of FcepsilonR1beta and FcepsilonR1gamma in patients with CU 
      including AICU and aspirin-tolerant CU (ATCU) by analyzing the genotypes and 
      haplotypes of four subsets of FcepsilonR1 genes in association with various 
      clinical parameters. Four polymorphisms of FcepsilonR1 (FcepsilonR1beta -109T>C, 
      FcepsilonR1beta E237G, FcepsilonR1gamma -237A>G, and FcepsilonR1gamma -54G>T) 
      were genotyped in 119 AICU patients and compared with 154 patients with ATCU and 
      224 normal healthy controls (NCs). No significant differences were observed with 
      respect to the allele and genotype frequencies of all four FcepsilonR1 
      single-nucleotide polymorphisms (SNPs; p > 0.05) in CU including AICU and ATCU 
      patients. However, two SNPs at FcepsilonR1beta E237G and FcepsilonR1gamma -237A>G 
      were associated with atopy in AICU patients but not in ATCU. AICU patients with 
      the AG/GG genotype of FcepsilonR1beta E237G and FcepsilonR1gamma -237G allele had 
      a significantly higher frequency of atopy than those with the AA genotype (p = 
      0.02 and p = 0.040), respectively. The release of histamine from basophils 
      induced by anti-IgE antibodies was significantly higher in AICU patients than in 
      NCs and was increased in atopic patients compared with nonatopic patients (p = 
      0.006 and p = 0.007, respectively). The FcepsilonR1beta E237G and 
      FcepsilonR1gamma -237T>G polymorphisms may be associated with the rate of atopy, 
      which in turn could increase the release of histamine from basophils and may lead 
      to the development of the AICU phenotype.
FAU - Palikhe, Nami
AU  - Palikhe N
AD  - Department of Allergy and Rheumatology, Ajou University School of Medicine, 
      Suwon, South Korea.
FAU - Kim, Seung-Hyun
AU  - Kim SH
FAU - Yang, Eun-Mi
AU  - Yang EM
FAU - Kang, Young Mi
AU  - Kang YM
FAU - Ye, Young-Min
AU  - Ye YM
FAU - Hur, Gyu-Young
AU  - Hur GY
FAU - Park, Hae-Sim
AU  - Park HS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Receptors, IgE)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*immunology
MH  - Chronic Disease
MH  - Drug Hypersensitivity/complications/*genetics/immunology
MH  - Female
MH  - Gene Frequency
MH  - Genotype
MH  - Histamine Release/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Genetic
MH  - Receptors, IgE/*genetics/immunology
MH  - Statistics as Topic
MH  - Urticaria/complications/*genetics/immunology
EDAT- 2008/06/07 09:00
MHDA- 2009/03/12 09:00
CRDT- 2008/06/07 09:00
PHST- 2008/06/07 09:00 [pubmed]
PHST- 2009/03/12 09:00 [medline]
PHST- 2008/06/07 09:00 [entrez]
AID - 10.2500/aap.2008.29.3116 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2008 May-Jun;29(3):250-7. doi: 10.2500/aap.2008.29.3116.

PMID- 1951937
OWN - NLM
STAT- MEDLINE
DCOM- 19911219
LR  - 20131121
IS  - 0044-6912 (Print)
IS  - 0044-6912 (Linking)
VI  - 29
IP  - 2
DP  - 1991 Jun
TI  - [Morphological changes in the lower incisor of suckling rats induced by large 
      dose of aspirin].
PG  - 245-56
AB  - Large doses of aspirin (200 mg/kg or 400 mg/kg, s.c) caused marked hypocalcemia 
      in suckling rats, two hours after administration. The hypocalcemic effect was 
      more evident in two week old rats than in one week old ones. Although the 
      mechanism of aspirin-induced hypocalcemia is not clear at this moment, the drug 
      can be a useful tool for inducing experimental hypocalcemia in suckling rats, 
      besides hormonal and/or nutritional controls. In this report, large doses of 
      aspirin were administrated to new born rats, once at one week after birth, or 
      twice at one and two weeks after birth. The morphological changes of the lower 
      incisor were examined using computer programs which have been developed for the 
      analysis of plane curves such as the traces of the side view of the incisor. 
      Aspirin administration shortened the length of the lower incisor and its labial 
      trace. The width of the incisor, especially in the middle, was also diminished by 
      aspirin administration. These observations suggest that the drug not only induced 
      hypocalcemia in suckling rats but also to some extent suppressed the activity of 
      odontoblasts which produce the dentin of the incisor. Analysis of curvature 
      variance, calculated with the labial trace of the lower incisor, also suggested 
      that large doses of aspirin had two effects. It suppressed mineralization of the 
      teeth through its hypocalcemic effect, and it inhibited synthesis of the 
      collagenous matrix. The computer programs applied in this study have proved 
      useful in determining and analyzing morphological changes of bio-materials which 
      are difficult to measure directly.
FAU - Takei, H
AU  - Takei H
AD  - Department of Pharmacology, School of Dentistry, Aichi-Gakuin University.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Aichi Gakuin Daigaku Shigakkai Shi
JT  - Aichi Gakuin Daigaku Shigakkai shi
JID - 7501066
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
MH  - Analysis of Variance
MH  - Animals
MH  - Animals, Newborn
MH  - Aspirin/*toxicity
MH  - Collagen/antagonists & inhibitors
MH  - Dentinogenesis/*drug effects
MH  - Hypocalcemia/*chemically induced
MH  - Odontoblasts/drug effects
MH  - Rats
MH  - Tooth/*drug effects
EDAT- 1991/06/01 00:00
MHDA- 1991/06/01 00:01
CRDT- 1991/06/01 00:00
PHST- 1991/06/01 00:00 [pubmed]
PHST- 1991/06/01 00:01 [medline]
PHST- 1991/06/01 00:00 [entrez]
PST - ppublish
SO  - Aichi Gakuin Daigaku Shigakkai Shi. 1991 Jun;29(2):245-56.

PMID- 22945770
OWN - NLM
STAT- MEDLINE
DCOM- 20130211
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 62
IP  - 12
DP  - 2012 Dec
TI  - Ibudilast, a phosphodiesterase inhibitor, in combination with low-dose aspirin 
      potently inhibits guinea pig carotid artery thrombosis without extending bleeding 
      time and causing gastric mucosal injury.
PG  - 545-53
LID - 10.1055/s-0032-1323699 [doi]
AB  - A combination of low-dose aspirin (ASA) and a phosphodiesterase inhibitor has 
      been clinically tried for the secondary prevention of atherothrombotic diseases. 
      The in vivo antithrombotic property of ibudilast (CAS 50847-11-5), a 
      phosphodiesterase 4 (PDE4) inhibitor, was evaluated in a photochemically-induced 
      guinea pig carotid artery thrombosis model in combination with low-dose ASA. The 
      time required to decrease the carotid artery blood flow to the reading "zero" was 
      defined as the time to occlusion (TTO) of the artery through thrombogenesis. Each 
      independent use of ASA (300 mg/kg, p.o.) and ibudilast (3 and 10 mg/kg, p.o.) 
      significantly prolonged the TTO, and ASA (300 mg/kg) significantly increased 
      bleeding time (BT) and gastric mucosal injury. A selective PDE4 inhibitor 
      rolipram (1 and 5 mg/kg, p.o.) tended to prolong the TTO without extending BT. 
      ASA (100 mg/kg) plus ibudilast (3 mg/kg) and ASA (100 mg/kg) plus rolipram 
      (5 mg/kg) markedly prolonged the TTO compared with each agent alone. 
      Interestingly, ASA (100 mg/kg) plus ibudilast (3 mg/kg) caused a longer TTO than 
      ASA (300 mg/kg) alone, without significant extension of BT and gastric mucosal 
      injury as observed in ASA (300 mg/kg). These results indicate that the 
      combination of low-dose ASA and ibudilast has a more potent antithrombotic effect 
      than ASA alone without increasing bleeding tendency and gastric mucosal injury. 
      The potent in vivo antithrombotic effect of this combination may be brought about 
      by an action that is associated with PDE4 inhibition of ibudilast.
CI  - © Georg Thieme Verlag KG Stuttgart · New York.
FAU - Matsuzawa, S
AU  - Matsuzawa S
AD  - Development Research Laboratories, Kyorin Pharmaceutical Co., Ltd. Tochigi, 
      Japan.
FAU - Hoshina, K
AU  - Hoshina K
FAU - Sueyoshi, S
AU  - Sueyoshi S
FAU - Miyata, Y
AU  - Miyata Y
FAU - Manita, S
AU  - Manita S
FAU - Ooie, T
AU  - Ooie T
FAU - Yasue, T
AU  - Yasue T
FAU - Sasahara, T
AU  - Sasahara T
LA  - eng
PT  - Journal Article
DEP - 20120903
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Indicators and Reagents)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - K676NL63N7 (Rolipram)
RN  - M0TTH61XC5 (ibudilast)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/metabolism
MH  - Animals
MH  - Aspirin/adverse effects/blood/*therapeutic use
MH  - Bleeding Time
MH  - Carotid Artery Thrombosis/*prevention & control
MH  - Drug Therapy, Combination
MH  - Gastric Mucosa/*pathology
MH  - Guinea Pigs
MH  - Immunoenzyme Techniques
MH  - Indicators and Reagents
MH  - Male
MH  - Mice
MH  - Phosphodiesterase Inhibitors/adverse effects/blood/*therapeutic use
MH  - Photochemistry
MH  - Platelet Aggregation Inhibitors/adverse effects/blood/*therapeutic use
MH  - Pyridines/adverse effects/blood/*therapeutic use
MH  - Rolipram/therapeutic use
MH  - Salicylic Acid/blood
MH  - Stomach Diseases/*chemically induced/pathology
MH  - Thromboxane B2/metabolism
EDAT- 2012/09/05 06:00
MHDA- 2013/02/12 06:00
CRDT- 2012/09/05 06:00
PHST- 2012/09/05 06:00 [entrez]
PHST- 2012/09/05 06:00 [pubmed]
PHST- 2013/02/12 06:00 [medline]
AID - 10.1055/s-0032-1323699 [doi]
PST - ppublish
SO  - Arzneimittelforschung. 2012 Dec;62(12):545-53. doi: 10.1055/s-0032-1323699. Epub 
      2012 Sep 3.

PMID- 11328262
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20220317
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 15
IP  - 5
DP  - 2001 May
TI  - Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: 
      gastroprotection by vitamin C.
PG  - 677-87
AB  - BACKGROUND: The roles of active oxygen metabolites and anti-oxidative defenses in 
      aspirin (ASA)-induced gastric damage have been little studied. AIM: We determined 
      the effects of aspirin (400 mg b.d.) with or without vitamin C (480 mg b.d.) for 
      3 days on gastric mucosa in human volunteers. METHODS: Gastric injury was 
      assessed endoscopically; gastric blood flow, reactive oxygen release (quantified 
      by chemiluminescence), lipid peroxidation, myeloperoxidase, superoxide dismutase 
      and glutathione peroxidase activity and intragastric vitamin C content were 
      measured. Expression of superoxide dismutase and glutathione peroxidase mRNAs was 
      assayed semi-quantitatively. RESULTS: ASA produced erosions, a marked increase in 
      chemiluminescence, lipid peroxidation, and myeloperoxidase activity. It also 
      resulted in a suppression of gastric blood flow, intragastric vitamin C levels, 
      superoxide dismutase and glutathione peroxidase activities. The addition of 
      vitamin C significantly attenuated gastric damage and reversed the effects of ASA 
      on these parameters. Superoxide dismutase and glutathione peroxidase mRNAs were 
      decreased in ASA-treated subjects; the addition of vitamin C restored their 
      regular levels. CONCLUSIONS: (i) free radical-induced lipid peroxidation and 
      suppression of antioxidizing enzymes play an important role in gastric damage 
      induced by aspirin; (ii) increased myeloperoxidase activity suggests activated 
      neutrophils to be the major source of these radicals; (iii) vitamin C protects 
      against ASA-induced damage due to its anti-oxidizing activity.
FAU - Pohle, T
AU  - Pohle T
AD  - Department of Medicine B, University of Münster, Münster, Germany. 
      pohley@uni-muenster.de
FAU - Brzozowski, T
AU  - Brzozowski T
FAU - Becker, J C
AU  - Becker JC
FAU - Van der Voort, I R
AU  - Van der Voort IR
FAU - Markmann, A
AU  - Markmann A
FAU - Konturek, S J
AU  - Konturek SJ
FAU - Moniczewski, A
AU  - Moniczewski A
FAU - Domschke, W
AU  - Domschke W
FAU - Konturek, J W
AU  - Konturek JW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Free Radicals)
RN  - 0 (RNA, Messenger)
RN  - 0 (Reactive Oxygen Species)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/chemistry
MH  - Ascorbic Acid/*pharmacology
MH  - Aspirin/*administration & dosage/chemistry
MH  - Biomarkers
MH  - Female
MH  - Free Radicals
MH  - Gastric Mucosa/drug effects/*pathology
MH  - Glutathione Peroxidase/biosynthesis
MH  - Humans
MH  - Lipid Peroxidation
MH  - Male
MH  - Oxidation-Reduction
MH  - RNA, Messenger/analysis
MH  - *Reactive Oxygen Species
MH  - Stomach/drug effects/*pathology
MH  - Superoxide Dismutase/biosynthesis
EDAT- 2001/05/01 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/05/01 10:00
PHST- 2001/05/01 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/05/01 10:00 [entrez]
AID - apt975 [pii]
AID - 10.1046/j.1365-2036.2001.00975.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2001 May;15(5):677-87. doi: 
      10.1046/j.1365-2036.2001.00975.x.

PMID- 22426086
OWN - NLM
STAT- MEDLINE
DCOM- 20121016
LR  - 20211021
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Print)
IS  - 1542-3565 (Linking)
VI  - 10
IP  - 7
DP  - 2012 Jul
TI  - Aspirin protects against Barrett's esophagus in a multivariate logistic 
      regression analysis.
PG  - 722-7
LID - 10.1016/j.cgh.2012.02.031 [doi]
AB  - BACKGROUND & AIMS: Better criteria are needed to identify patients who should be 
      screened for Barrett's esophagus (BE) to reduce overtesting and improve the cost 
      effectiveness. There is evidence that chemopreventive agents such as nonsteroidal 
      anti-inflammatory drugs, particularly aspirin, reduce the risk of esophageal 
      adenocarcinoma (EAC), but little is known about their effects on BE. We analyzed 
      characteristics of patients with BE for factors that might be used in screening 
      and management. METHODS: In this case-controlled study, we identified 434 
      patients with BE diagnosed at the first endoscopy (incident cases) at a single 
      institution (1997-2010). BE cases were matched with controls on the basis of 
      indication for endoscopy, year of endoscopy, and endoscopist. Risk factors 
      analyzed included age, sex, body mass index, medical and social history, and 
      medications. We performed a multivariate logistic regression analysis to identify 
      clinical risk factors for BE. RESULTS: In a multivariate regression model, men 
      had a greater risk for developing BE (odds ratio, 3.2; 95% confidence interval, 
      2.3-4.4), whereas current aspirin users had a lower risk than nonusers (odds 
      ratio, 0.56; 95% confidence interval, 0.39-0.80). A subset analysis, limited to 
      patients who had endoscopies for symptoms of gastroesophageal reflux disease, 
      yielded similar findings. No interactions were found between aspirin use and 
      smoking or use of acid-suppressive medications. CONCLUSIONS: In a case-controlled 
      study of 434 patients with BE, current aspirin use appeared to reduce the risk of 
      BE; previous studies associated aspirin use with a reduced risk of EAC. Although 
      efforts were made to minimize biases in our analysis, the possibility of residual 
      confounding remains.
CI  - Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.
FAU - Omer, Zehra B
AU  - Omer ZB
AD  - Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
FAU - Ananthakrishnan, Ashwin N
AU  - Ananthakrishnan AN
FAU - Nattinger, Kevin J
AU  - Nattinger KJ
FAU - Cole, Elisabeth B
AU  - Cole EB
FAU - Lin, Jesse J
AU  - Lin JJ
FAU - Kong, Chung Yin
AU  - Kong CY
FAU - Hur, Chin
AU  - Hur C
LA  - eng
GR  - K25 CA133141/CA/NCI NIH HHS/United States
GR  - R01 CA140574/CA/NCI NIH HHS/United States
GR  - R01-CA140574/CA/NCI NIH HHS/United States
GR  - U01 CA152926/CA/NCI NIH HHS/United States
GR  - P30 DK043351/DK/NIDDK NIH HHS/United States
GR  - U01-CA152926/CA/NCI NIH HHS/United States
GR  - K25-CA133141/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20120315
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal 
      of the American Gastroenterological Association
JID - 101160775
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Barrett Esophagus/epidemiology/*prevention & control
MH  - Case-Control Studies
MH  - Chemoprevention/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Models, Statistical
MH  - Prevalence
PMC - PMC3435144
MID - NIHMS378673
COIS- Disclosures/Conflicts of Interest: NONE
EDAT- 2012/03/20 06:00
MHDA- 2012/10/17 06:00
CRDT- 2012/03/20 06:00
PHST- 2012/01/24 00:00 [received]
PHST- 2012/02/28 00:00 [revised]
PHST- 2012/02/29 00:00 [accepted]
PHST- 2012/03/20 06:00 [entrez]
PHST- 2012/03/20 06:00 [pubmed]
PHST- 2012/10/17 06:00 [medline]
AID - S1542-3565(12)00310-2 [pii]
AID - 10.1016/j.cgh.2012.02.031 [doi]
PST - ppublish
SO  - Clin Gastroenterol Hepatol. 2012 Jul;10(7):722-7. doi: 10.1016/j.cgh.2012.02.031. 
      Epub 2012 Mar 15.

PMID- 2591268
OWN - NLM
STAT- MEDLINE
DCOM- 19900112
LR  - 20211109
IS  - 0412-4057 (Print)
IS  - 0412-4057 (Linking)
VI  - 22
IP  - 3
DP  - 1989 Jun
TI  - [The effects of ligustrazine, aspirin and beta-histine on platelet aggregation in 
      patients with acute ischemic stroke].
PG  - 148-51, 191
AB  - With a auto-balanced terbidimeter, the effects of ligustrazine, aspirin and 
      betahistine on platelet aggregation were studied in 45 patients with acute 
      ischemic stroke. The adopted parameters were: 1) the maximal aggregation (Amax), 
      2) the maximal aggregation velocity (Vmax), 3) the effective disaggregation rate 
      in 5 minutes (DA 5), 4) the inhibition rate of aggregation given by drugs (IR), 
      and 5) the concentration causing 50% inhibition of aggregation (IC 50). The 
      results indicated that these three drugs could inhibit platelet aggregation both 
      in vivo and in vitro. Aspirin could promote the aggregated platelets 
      disaggregation in vivo and ligustrazine, in vitro. Regarding the effects on 
      inhibiting platelet aggregation in vitro, ligustrazine was the most noticeable 
      among the 3 drugs and aspirin was more effective than betahistine. The IC50 of 
      ligustrazine, aspirin and betahistine were 0.568 mg/ml, 1,286 mg/ml and 1.722 
      mg/ml respectively. The authors considered that all three drugs possessed 
      anti-platelet effects but they showed some differences among them.
FAU - Gao, B T
AU  - Gao BT
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Shen Jing Jing Shen Ke Za Zhi
JT  - Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and 
      psychiatry
JID - 16210510R
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyrazines)
RN  - 0 (Pyridines)
RN  - 0 (Vasodilator Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - V80F4IA5XG (tetramethylpyrazine)
RN  - X32KK4201D (Betahistine)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology
MH  - Betahistine/*pharmacology
MH  - Cerebrovascular Disorders/*blood
MH  - Female
MH  - Fibrinolytic Agents
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Pyrazines/*pharmacology
MH  - Pyridines/*pharmacology
MH  - Vasodilator Agents
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
PST - ppublish
SO  - Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1989 Jun;22(3):148-51, 191.

PMID- 6439319
OWN - NLM
STAT- MEDLINE
DCOM- 19850125
LR  - 20190501
IS  - 0267-0623 (Print)
IS  - 0267-0623 (Linking)
VI  - 289
IP  - 6458
DP  - 1984 Dec 8
TI  - Cutaneous insulin allergy responsive to oral desensitisation and aspirin.
PG  - 1565-6
AB  - A diabetic man with no previous history of allergy began to suffer itchy, painful 
      swelling at the sites of injection after three months' treatment with bovine 
      insulin. Insulin specific IgE concentrations (1.2-2.0 U/ml) were higher than in 
      non-allergic diabetics (mean 0.4 (SD 0.06) U/ml) but lower than in most other 
      patients allergic to insulin (1.0-19.0 U/ml). Standard approaches failed to 
      overcome the allergic reaction, and four separate attempts at desensitisation 
      were unsuccessful. The patient was then given oral insulin 800 U thrice daily 
      together with enteric coated aspirin 1300 mg thrice daily for one week, and 
      subsequent desensitisation with neutral insulin injection was carried out 
      successfully. On stopping the aspirin the original reactions returned, and 
      aspirin was therefore reinstituted as a permanent part of treatment. Whatever the 
      mechanism in this patient, oral desensitisation and aspirin provided a simple 
      method for treating a difficult condition.
FAU - Holdaway, I M
AU  - Holdaway IM
FAU - Wilson, J D
AU  - Wilson JD
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br Med J (Clin Res Ed)
JT  - British medical journal (Clinical research ed.)
JID - 8302911
RN  - 0 (Insulin)
RN  - 0 (Insulin, Regular, Pork)
RN  - AVT680JB39 (insulin, neutral)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/*etiology/therapy
MH  - Humans
MH  - Insulin/administration & dosage/*adverse effects
MH  - Insulin, Regular, Pork
MH  - Male
PMC - PMC1443947
EDAT- 1984/12/08 00:00
MHDA- 1984/12/08 00:01
CRDT- 1984/12/08 00:00
PHST- 1984/12/08 00:00 [pubmed]
PHST- 1984/12/08 00:01 [medline]
PHST- 1984/12/08 00:00 [entrez]
AID - 10.1136/bmj.289.6458.1565 [doi]
PST - ppublish
SO  - Br Med J (Clin Res Ed). 1984 Dec 8;289(6458):1565-6. doi: 
      10.1136/bmj.289.6458.1565.

PMID- 23229722
OWN - NLM
STAT- MEDLINE
DCOM- 20130730
LR  - 20211021
IS  - 1420-908X (Electronic)
IS  - 1023-3830 (Linking)
VI  - 62
IP  - 3
DP  - 2013 Mar
TI  - Oral antigens induce rheumatoid arthritis-like inflammation in a rat model.
PG  - 291-7
LID - 10.1007/s00011-012-0577-9 [doi]
AB  - BACKGROUND AND AIMS: The pathogenesis of rheumatoid arthritis (RA) is to be 
      further elucidated. The present study aims to investigate the role of oral 
      antigen in the induction of RA-like inflammation in the articular joints of rats. 
      METHODS: An RA animal model was developed by gavage-feeding with antigen and 
      aspirin, and lipopolysaccharide intraperitoneal injection. The gut epithelial 
      barrier function was assessed by the absorption of mannitol and lactose. The 
      absorption of the specific antigen was observed by the immune fluorescent method. 
      The frequency of antigen specific CD4+ T cells in the peripheral system was 
      assessed by flow cytometry. The inflammation in the ankle joints was evaluated by 
      light microscopy and immunohistochemistry. RESULTS: Rats treated with aspirin 
      showed intestinal barrier dysfunction; high contents of the specific antigen were 
      absorbed into the lamina propria. The antigen specific CD4+ T cells were detected 
      in the spleen that could be activated by exposure to the specific antigen as well 
      as the extracts of joint tissue. High levels of proinflammatory cytokines were 
      detected in the sera. Antigen specific immune complexes were localized in the 
      ankle joints. Heavy extravasation was observed in the synovial cavity. The 
      histology showed an inflammatory feature in the ankle joints. CONCLUSIONS: Oral 
      antigen can induce RA-like inflammation in the articular joints under certain 
      environment such as gut epithelial barrier dysfunction.
FAU - Wu, Dandan
AU  - Wu D
AD  - Institute of Allergy and Immunology, Shenzhen University, Shenzhen, China.
FAU - Liu, Xiaoyu
AU  - Liu X
FAU - Su, Hong
AU  - Su H
FAU - Chen, Xiao
AU  - Chen X
FAU - Zhang, Huiyun
AU  - Zhang H
FAU - Hu, Dongsheng
AU  - Hu D
FAU - Huang, Zhong
AU  - Huang Z
FAU - Yang, Ping-Chang
AU  - Yang PC
FAU - Liu, Zhigang
AU  - Liu Z
LA  - eng
GR  - 177843/Canadian Institutes of Health Research/Canada
GR  - 191063/Canadian Institutes of Health Research/Canada
GR  - 220058/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121211
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Antigen-Antibody Complex)
RN  - 0 (Antigens)
RN  - 0 (Lipopolysaccharides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Antigen-Antibody Complex/metabolism
MH  - Antigens/*administration & dosage/*adverse effects/pharmacology
MH  - Arthritis, Rheumatoid/*etiology/*immunology
MH  - Aspirin/administration & dosage/adverse effects/pharmacology
MH  - CD4-Positive T-Lymphocytes/drug effects/pathology
MH  - Disease Models, Animal
MH  - Gastrointestinal Tract/drug effects/physiopathology
MH  - Inflammation/*etiology/*immunology
MH  - Injections, Intraperitoneal
MH  - Joints/drug effects/immunology/pathology
MH  - Lipopolysaccharides/administration & dosage/adverse effects/pharmacology
MH  - Rats
MH  - Rats, Wistar
EDAT- 2012/12/12 06:00
MHDA- 2013/07/31 06:00
CRDT- 2012/12/12 06:00
PHST- 2012/04/17 00:00 [received]
PHST- 2012/11/19 00:00 [accepted]
PHST- 2012/10/16 00:00 [revised]
PHST- 2012/12/12 06:00 [entrez]
PHST- 2012/12/12 06:00 [pubmed]
PHST- 2013/07/31 06:00 [medline]
AID - 10.1007/s00011-012-0577-9 [doi]
PST - ppublish
SO  - Inflamm Res. 2013 Mar;62(3):291-7. doi: 10.1007/s00011-012-0577-9. Epub 2012 Dec 
      11.

PMID- 23104955
OWN - NLM
STAT- MEDLINE
DCOM- 20141112
LR  - 20181203
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 20
IP  - 2
DP  - 2014 Mar
TI  - Monitoring residual platelet activity among patients with acute coronary 
      syndrome.
PG  - 179-83
LID - 10.1177/1076029612463425 [doi]
AB  - Several medicines are currently used to inhibit the platelet activity. We aim to 
      monitor the residual platelet activity (RPA) despite antiplatelet therapy and 
      assess its relationship with major adverse events. The impedance platelet 
      aggregation was employed to determine RPA. Totally, 202 patients with acute 
      coronary syndrome (ACS) were followed up for 10 months for major clinical events 
      of myocardial infarction, cerebrovascular accident (CVA), and all cause 
      mortality, and RPA after clopidogrel loading was assessed in 30 patients. The RPA 
      at 2 hours after 300 mg clopidogrel loading was 1 Ω (± 2.3 Ω) induced by 
      adenosine diphosphate. Residual platelet activity of patients who experienced 
      death, MI, or CVA was significantly higher than those who did not experience (P < 
      .05). Cutoff values of RPA showed optimal negative predictive values (96%-97%) 
      and poor positive predictive values (16%-29%). Therefore, RPA monitored by whole 
      blood impedance platelet aggregation may have high exclusionary predictive value 
      for the occurrence of major clinical events in patients with ACS.
FAU - Qiao, Rui
AU  - Qiao R
AD  - 1The department of Laboratory Medicine, Peking University Third Hospital, 
      Haidian, Beijing, China.
FAU - Li, Lei
AU  - Li L
FAU - Zhang, Jie
AU  - Zhang J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121026
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*blood
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Platelets/drug effects/*physiology
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Reference Values
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - acute coronary syndrome
OT  - platelet aggregation
OT  - platelet aggregation inhibitors
OT  - platelet function tests
EDAT- 2012/10/30 06:00
MHDA- 2014/11/13 06:00
CRDT- 2012/10/30 06:00
PHST- 2012/10/30 06:00 [entrez]
PHST- 2012/10/30 06:00 [pubmed]
PHST- 2014/11/13 06:00 [medline]
AID - 1076029612463425 [pii]
AID - 10.1177/1076029612463425 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2014 Mar;20(2):179-83. doi: 10.1177/1076029612463425. 
      Epub 2012 Oct 26.

PMID- 19281750
OWN - NLM
STAT- MEDLINE
DCOM- 20090508
LR  - 20190608
IS  - 0301-0430 (Print)
IS  - 0301-0430 (Linking)
VI  - 71
IP  - 3
DP  - 2009 Mar
TI  - Wunderlich syndrome during antiplatelet drug therapy.
PG  - 342-4
AB  - AIMS: Spontaneous hemorrhage in the kidney, also known as Wunderlich Syndrome, is 
      a rare clinical problem. The most common cause of spontaneous renal hemorrhage is 
      tumor. Other causes are rupture of a renal cyst, vasculitis, hydronephrosis, 
      preeclampsia, and kidney infections. CASE HISTORY: A 67-year-old man was admitted 
      complaining left flank colic pain. A contrast CT scan showed the presence of a 
      subcapsular hematoma of the left kidney extending from the upper to the lower 
      pole. He had no history of trauma and immunological screening tests for 
      vasculitis were normal. His current therapy included acetylsalicylic acid (100 
      mg/daily) and lisinopril (20 mg/ daily). The patient was hospitalized for 4 days 
      and his circulatory state remained stable. Nine months later an ultrasound 
      examination showed complete resolution of the hematoma. One year later the 
      patient was admitted again because of a spontaneous right calf hematoma and a 
      thoroughly investigation of his coagulation pattern was carried out. Laboratory 
      finding revealed a platelet defect, as the number of adenine nucleotides and 
      other marker related to platelet activation were increased: ADP 1 mcM lack 2 
      masculine wave, ADP 2 mcM lack 2 masculine wave, Adrenalina 5 mcM lack 2 
      masculine wave, Adrenalina 10 mcM lack 2 masculine wave. Platelet activation 
      markers: Gp53 in lysosomal membrane 0.48 Dpar (0 - 0.26). CONCLUSION: Our case 
      describes the recurrence of spontaneous hemorrhages (perirenal and intramuscular 
      hematoma) as a result of an underlying platelet aggregation defect worsened by 
      administration of acetylsalicylic acid. In patients on antiplatelet treatment 
      with a history of excessive bleeding a thorough investigation of coagulation 
      status appears beneficial.
FAU - Capitanini, A
AU  - Capitanini A
AD  - Division of Nephrology, Civil Hospital of Pescia (Pistoia), Italy. 
      drcapitanini@excite.it
FAU - Tavolaro, A
AU  - Tavolaro A
FAU - Rosellini, M
AU  - Rosellini M
FAU - Rossi, A
AU  - Rossi A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Germany
TA  - Clin Nephrol
JT  - Clinical nephrology
JID - 0364441
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - E7199S1YWR (Lisinopril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Hematoma/*chemically induced/diagnostic imaging
MH  - Humans
MH  - Kidney Diseases/*chemically induced/diagnostic imaging
MH  - Leg/blood supply
MH  - Lisinopril/administration & dosage/*adverse effects
MH  - Male
MH  - Tomography, X-Ray Computed
EDAT- 2009/03/14 09:00
MHDA- 2009/05/09 09:00
CRDT- 2009/03/14 09:00
PHST- 2009/03/14 09:00 [entrez]
PHST- 2009/03/14 09:00 [pubmed]
PHST- 2009/05/09 09:00 [medline]
AID - 5561 [pii]
AID - 10.5414/cnp71342 [doi]
PST - ppublish
SO  - Clin Nephrol. 2009 Mar;71(3):342-4. doi: 10.5414/cnp71342.

PMID- 17553647
OWN - NLM
STAT- MEDLINE
DCOM- 20071121
LR  - 20131121
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 44
IP  - 5
DP  - 2007 Sep 3
TI  - Degradation of high-molar-mass hyaluronan by an oxidative system comprising 
      ascorbate, Cu(II), and hydrogen peroxide: inhibitory action of antiinflammatory 
      drugs--naproxen and acetylsalicylic acid.
PG  - 1056-63
AB  - Changes in dynamic viscosity of the solutions of a high-molar-mass hyaluronan 
      (HA) were monitored using a rotational viscometer. The degradative conditions 
      generated in the HA solutions by a system comprising ascorbate plus Cu(II) plus 
      H(2)O(2) were studied either in the presence or absence of a drug--naproxen or 
      acetylsalicylic acid. Continual decrease of the dynamic viscosity of HA solution 
      was indicative of the polymer degradation. Addition of the drug 
      retarded/inhibited the HA degradation in a concentration-dependent manner. The 
      characteristics of the fragmented polymers were investigated by FT-IR 
      spectroscopy and by two different liquid chromatographic techniques, namely by 
      size-exclusion chromatography equipped with a multi-angle light scattering 
      photometric detector and by high-performance liquid chromatography connected 
      on-line to a spectrofluorometer.
FAU - Soltés, L
AU  - Soltés L
AD  - Institute of Experimental Pharmacology, Slovak Academy of Sciences, SK-84104 
      Bratislava, Slovakia.
FAU - Stankovská, M
AU  - Stankovská M
FAU - Kogan, G
AU  - Kogan G
FAU - Mendichi, R
AU  - Mendichi R
FAU - Volpi, N
AU  - Volpi N
FAU - Sasinková, V
AU  - Sasinková V
FAU - Gemeiner, P
AU  - Gemeiner P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070506
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Cations, Divalent)
RN  - 0 (Oxidants)
RN  - 0 (Solutions)
RN  - 57Y76R9ATQ (Naproxen)
RN  - 789U1901C5 (Copper)
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*pharmacology
MH  - Antioxidants/*chemistry
MH  - Ascorbic Acid/*chemistry
MH  - Aspirin/chemistry/*pharmacology
MH  - Cations, Divalent/chemistry
MH  - Chromatography, Gel
MH  - Chromatography, High Pressure Liquid
MH  - Copper/*chemistry
MH  - Hyaluronic Acid/*antagonists & inhibitors/*chemistry
MH  - Hydrogen Peroxide/chemistry
MH  - Molecular Structure
MH  - Molecular Weight
MH  - Naproxen/chemistry/*pharmacology
MH  - Oxidants/chemistry
MH  - Oxidation-Reduction
MH  - Solutions/chemistry
MH  - Spectrometry, Fluorescence
MH  - Spectrophotometry, Ultraviolet
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Viscosity/drug effects
EDAT- 2007/06/08 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/06/08 09:00
PHST- 2007/01/31 00:00 [received]
PHST- 2007/04/25 00:00 [revised]
PHST- 2007/04/26 00:00 [accepted]
PHST- 2007/06/08 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/06/08 09:00 [entrez]
AID - S0731-7085(07)00256-7 [pii]
AID - 10.1016/j.jpba.2007.04.037 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2007 Sep 3;44(5):1056-63. doi: 10.1016/j.jpba.2007.04.037. 
      Epub 2007 May 6.

PMID- 15154853
OWN - NLM
STAT- MEDLINE
DCOM- 20050125
LR  - 20161124
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 24
IP  - 6
DP  - 2004 Jun
TI  - Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is 
      inhibited by systemic administration of lysine acetylsalicylate but not of 
      sumatriptan.
PG  - 439-45
AB  - Systemic administration of nitroglycerin (NTG), a nitric oxide (NO) donor, in 
      migraineurs triggers after several hours an attack of which the precise 
      mechanisms are unknown. We found previously in rats that nitroglycerin (10 mg/kg 
      s.c.) is able to increase significantly after 4 h the number of neuronal nitric 
      oxide synthase (nNOS)-immunoreactive neurones in the cervical part of trigeminal 
      nucleus caudalis. In the present experiments, we demonstrate that the 5-HT1B/D 
      agonist sumatriptan (0.6 mg/kg s.c.) does not alter this phenomenon when given 
      before NTG. By contrast, pretreatment with lysine acetylsalicylate (50 mg/kg 
      i.m.) attenuates the NTG-induced nNOS expression in the superficial laminae of 
      trigeminal nucleus caudalis. These findings suggest that effect of NTG on nNOS at 
      a high dosage may involve the cycloxygenase pathway and that activation of the 
      peripheral 5-HT1B/D receptors is not able to modify this effect. These data could 
      help to better understand the role of NO in the pathogenesis of headaches and the 
      action of antimigraine drugs.
CI  - Copyright Blackwell Publishing Ltd.
FAU - Pardutz, A
AU  - Pardutz A
AD  - Research Centre of Cellular & Molecular Neurobiology, Headache Research Unit, 
      Universtiy og Liège, Liè, Belgium.
FAU - Szatmári, E
AU  - Szatmári E
FAU - Vecsei, L
AU  - Vecsei L
FAU - Schoenen, J
AU  - Schoenen J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 8R78F6L9VO (Sumatriptan)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type I)
RN  - EC 1.14.13.39 (Nos1 protein, rat)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Enzyme Activation/drug effects/physiology
MH  - Lysine/*analogs & derivatives/*pharmacology
MH  - Male
MH  - Nitric Oxide Synthase/*antagonists & inhibitors/*biosynthesis
MH  - Nitric Oxide Synthase Type I
MH  - Nitroglycerin/antagonists & inhibitors/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Sumatriptan/*pharmacology
MH  - Trigeminal Nucleus, Spinal/*drug effects/*enzymology
EDAT- 2004/05/25 05:00
MHDA- 2005/01/26 09:00
CRDT- 2004/05/25 05:00
PHST- 2004/05/25 05:00 [pubmed]
PHST- 2005/01/26 09:00 [medline]
PHST- 2004/05/25 05:00 [entrez]
AID - CHA699 [pii]
AID - 10.1111/j.1468-2982.2004.00699.x [doi]
PST - ppublish
SO  - Cephalalgia. 2004 Jun;24(6):439-45. doi: 10.1111/j.1468-2982.2004.00699.x.

PMID- 1617389
OWN - NLM
STAT- MEDLINE
DCOM- 19920805
LR  - 20190509
IS  - 0007-1420 (Print)
IS  - 0007-1420 (Linking)
VI  - 48
IP  - 1
DP  - 1992 Jan
TI  - Precipitating factors of asthma.
PG  - 169-78
AB  - Asthma is characterised by bronchial hyperresponsiveness. This feature of the 
      asthmatic diathesis predisposes patients to wheezing in response to a number of 
      different factors. These precipitating factors include specific allergen acting 
      via sensitised mediator cells through an IgE-dependent mechanism. There are 
      irritants which may work through a non-specific manner, or stimuli such as 
      exercise and hyperventilation, which probably also act through mediator release 
      via a non-IgE-dependent manner. The mechanism whereby physical stimuli such as 
      exercise induce bronchoconstriction is of interest, because it increases the 
      context in which the mast cell may participate in acute asthmatic 
      bronchoconstriction. Respiratory infections also commonly provoke asthma, 
      especially in infants and may, indeed, precipitate the asthmatic state itself. 
      Finally, drugs can often trigger asthma attacks and the mechanisms of asthma 
      precipitated by non-steroidal anti-inflammatory drugs such as aspirin have been 
      the subject of recent research.
FAU - Lee, T H
AU  - Lee TH
AD  - Department of Allergy & Allied Respiratory Disorders, UMDS Guy's Hospital, 
      London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br Med Bull
JT  - British medical bulletin
JID - 0376542
RN  - 0 (Allergens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Air Pollution/adverse effects
MH  - Allergens/immunology
MH  - Aspirin/adverse effects
MH  - Asthma/*etiology
MH  - Asthma, Exercise-Induced/etiology
MH  - Child
MH  - Humans
MH  - Virus Diseases/complications
RF  - 23
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.bmb.a072532 [doi]
PST - ppublish
SO  - Br Med Bull. 1992 Jan;48(1):169-78. doi: 10.1093/oxfordjournals.bmb.a072532.

PMID- 3431418
OWN - NLM
STAT- MEDLINE
DCOM- 19880307
LR  - 20190919
IS  - 0738-1085 (Print)
IS  - 0738-1085 (Linking)
VI  - 8
IP  - 4
DP  - 1987
TI  - Experimental models for evaluating antithrombotic therapies in replantation 
      microsurgery.
PG  - 230-3
AB  - A variety of anticoagulation and antiplatelet aggregation agents are in use 
      clinically, and in applications to microvascular surgery, a clear choice for the 
      most effective therapy has not been determined. Models of vascular trauma 
      combined with microvascular anastomosis have been developed for comparing the 
      efficacy of these agents in maintaining vascular patency. In a rat model of 
      microvascular thrombosis, heparin effectively prevents occlusion in both arteries 
      and veins, at clinical levels of administration. Aspirin helps prevent 
      thrombosis, but not as well as heparin. These results support the beneficial 
      effect of antithrombotic drug therapies, and suggest a more potent role of the 
      heparin-inhibited fibrin clot over platelet aggregation in creating thrombotic 
      occlusion of small vessels.
FAU - Cooley, B C
AU  - Cooley BC
AD  - Department of Orthopaedic Surgery, Medical College of Wisconsin, Milwaukee 53226.
FAU - Gould, J S
AU  - Gould JS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Microsurgery
JT  - Microsurgery
JID - 8309230
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Femoral Artery/*surgery
MH  - Femoral Vein/*surgery
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/therapeutic use
MH  - *Microsurgery
MH  - Rabbits
MH  - Rats
MH  - *Replantation
MH  - Thrombosis/prevention & control/surgery
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1002/micr.1920080412 [doi]
PST - ppublish
SO  - Microsurgery. 1987;8(4):230-3. doi: 10.1002/micr.1920080412.

PMID- 36941404
OWN - NLM
STAT- MEDLINE
DCOM- 20230322
LR  - 20230417
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Mar 20
TI  - Cardiovascular disease preventive effects of aspirin combined with different 
      statins in the United States general population.
PG  - 4585
LID - 10.1038/s41598-023-31739-w [doi]
LID - 4585
AB  - The purpose of this study was to explore the use of aspirin in conjunction with 
      various statins for cardiovascular disease (CVD) prevention in the general 
      population of the United States (U.S.). A total of 3778 people from the National 
      Health and Nutrition Examination Surveys from 2011 to 2018 were included in our 
      analysis. After adjusting for sociodemographic and common cardiovascular risk 
      factors, we used multivariable logistic regression analysis to determine aspirin 
      should be combined with which type of statin for better CVD preventive effects. 
      Subgroup analyses were carried out subsequently. In comparison to the aspirin use 
      alone, the odds ratios with 95% confidence intervals for CVD were 0.43 (0.33, 
      0.57), 0.69 (0.42, 1.13), 0.44 (0.31, 0.62), 0.34 (0.23, 0.50) and 0.64 (0.49, 
      0.84) for the combination use of aspirin and atorvastatin, lovastatin, 
      pravastatin, rosuvastatin as well as simvastatin, respectively, in the 
      fully-adjusted model. Aspirin combined with rosuvastatin was more effective in 
      the prevention of individual CVD, including congestive heart failure, coronary 
      heart disease, angina pectoris and heart attack, than aspirin combined with other 
      statins. In conclusion, statins combined with aspirin have a clear advantage over 
      aspirin alone in preventing CVD. In addition, when various sex, age, and fitness 
      levels were considered, as well as with and without diabetes mellitus, the 
      combination usage of aspirin and rosuvastatin had the greatest CVD preventive 
      effects than aspirin coupled with other statins.
CI  - © 2023. The Author(s).
FAU - Liu, Tao
AU  - Liu T
AD  - Department of Cardiology, Jinshan Branch of Shanghai Sixth People's Hospital, 
      Shanghai, 201500, China.
FAU - Zuo, Ronghua
AU  - Zuo R
AD  - Department of Anesthesiology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, 210029, Jiangsu, China.
FAU - Wang, Jia
AU  - Wang J
AD  - Department of Nephrology, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, 221000, Jiangsu, China.
FAU - Huangtao, Zixuan
AU  - Huangtao Z
AD  - School of Clinical Medicine, Hainan Medical University, Haikou, 57119, Hainan, 
      China.
FAU - Wang, Bing
AU  - Wang B
AD  - Department of Cardiology, Jinshan Branch of Shanghai Sixth People's Hospital, 
      Shanghai, 201500, China.
FAU - Sun, Lifang
AU  - Sun L
AD  - Department of Cardiology, Jinshan Branch of Shanghai Sixth People's Hospital, 
      Shanghai, 201500, China.
FAU - Wang, Shasha
AU  - Wang S
AD  - Department of Cardiology, Jinshan Branch of Shanghai Sixth People's Hospital, 
      Shanghai, 201500, China.
FAU - Li, Baoyin
AU  - Li B
AD  - Department of Cardiology, Jinshan Branch of Shanghai Sixth People's Hospital, 
      Shanghai, 201500, China.
FAU - Zhu, Zhijian
AU  - Zhu Z
AD  - Department of Cardiology, Jinshan Branch of Shanghai Sixth People's Hospital, 
      Shanghai, 201500, China.
FAU - Pan, Yesheng
AU  - Pan Y
AD  - Department of Cardiology, Jinshan Branch of Shanghai Sixth People's Hospital, 
      Shanghai, 201500, China. felixpan7519@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230320
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - R16CO5Y76E (Aspirin)
RN  - AGG2FN16EV (Simvastatin)
SB  - IM
MH  - Humans
MH  - United States/epidemiology
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Rosuvastatin Calcium/therapeutic use
MH  - *Cardiovascular Diseases/epidemiology/prevention & control/chemically induced
MH  - Aspirin/therapeutic use
MH  - Simvastatin/adverse effects
PMC - PMC10027662
COIS- The authors declare no competing interests.
EDAT- 2023/03/22 06:00
MHDA- 2023/03/23 06:00
CRDT- 2023/03/21 00:22
PHST- 2023/02/04 00:00 [received]
PHST- 2023/03/16 00:00 [accepted]
PHST- 2023/03/21 00:22 [entrez]
PHST- 2023/03/22 06:00 [pubmed]
PHST- 2023/03/23 06:00 [medline]
AID - 10.1038/s41598-023-31739-w [pii]
AID - 31739 [pii]
AID - 10.1038/s41598-023-31739-w [doi]
PST - epublish
SO  - Sci Rep. 2023 Mar 20;13(1):4585. doi: 10.1038/s41598-023-31739-w.

PMID- 8866340
OWN - NLM
STAT- MEDLINE
DCOM- 19970304
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 48
IP  - 7
DP  - 1996 Jul
TI  - The disposition of aspirin and salicylic acid in the isolated perfused rat liver: 
      the effect of normal and retrograde flow on availability and mean transit time.
PG  - 738-43
AB  - The effect of changing the direction of perfusate flow from anterograde to 
      retrograde on the disposition of acetylsalicylic acid (aspirin) and salicylic 
      acid was studied in the single pass in-situ perfused rat liver. Mixtures of 
      aspirin, [14C]salicylic acid and the inert reference solute [3H]sucrose were 
      administered as boluses into the liver using red blood cell and albumin-free 
      perfusate media at a flow rate of 30 mL min-1/liver. Hepatic availability (F), 
      mean transit time (MTT) and normalized variance (CV2) for aspirin, preformed 
      [14C]salicylic acid, salicylic acid produced from aspirin in the liver and 
      [3H]sucrose were deduced from the outflow concentration profiles using 
      statistical moment analysis. The values for F, MTT and CV2 for the solutes under 
      anterograde perfusion were: aspirin (0.73 +/- 0.04, 15.13 +/- 2.01 s, 0.33 +/- 
      0.09, n = 5), preformed [14C]salicylic acid (1.05 +/- 0.06, n = 12, 43.19 +/- 
      2.21 s, 1.08 +/- 0.08, n = 5), salicylic acid from aspirin (0.33 +/- 0.05, 42.82 
      +/- 9.16 s, 0.73 +/- 0.10, n = 5) and [3H]sucrose (1.05 +/- 0.05, 16.88 +/- 0.77 
      s, 0.74 +/- 0.10, n = 5). The corresponding values for retrograde perfusions 
      were: aspirin (0.73 +/- 0.02, 17.41 +/- 3.06 s, 0.32 +/- 0.09, n = 5), preformed 
      [14C]salicylic acid (1.14 +/- 0.02, 44.42 +/- 3.16 s, 0.95 +/- 0.07, n = 5), 
      salicylic acid from aspirin (0.33 +/- 0.09, 36.47 +/- 10.28 s, 0.58 +/- 0.05, n = 
      5) and sucrose (1.01 +/- 0.04, 18.08 +/- 1.61 s, 0.76 +/- 0.15, n = 5). No 
      significant differences in F or MTT were apparent between anterograde and 
      retrograde perfusions for all solutes. The MTT and CV2 data for [14C]salicylic 
      acid and salicylic acid produced from aspirin is suggestive of a permeability 
      limitation for salicylic acid transport.
FAU - Mellick, G D
AU  - Mellick GD
AD  - Department of Medicine, University of Queensland, Princess Alexandra Hospital, 
      Brisbane, Australia.
FAU - Roberts, M S
AU  - Roberts MS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Salicylates)
RN  - 57-50-1 (Sucrose)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*metabolism
MH  - Female
MH  - In Vitro Techniques
MH  - Liver/*metabolism
MH  - Perfusion/methods
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Salicylates/*metabolism
MH  - Salicylic Acid
MH  - Sucrose/metabolism
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1996.tb03962.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1996 Jul;48(7):738-43. doi: 
      10.1111/j.2042-7158.1996.tb03962.x.

PMID- 30654882
OWN - NLM
STAT- MEDLINE
DCOM- 20191118
LR  - 20191118
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 73
IP  - 2
DP  - 2019 Jan 22
TI  - Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: 
      The COMPASS-CABG Study.
PG  - 121-130
LID - S0735-1097(18)39066-1 [pii]
LID - 10.1016/j.jacc.2018.10.048 [doi]
AB  - BACKGROUND: Patients with recent coronary artery bypass graft (CABG) surgery are 
      at risk for early graft failure, which is associated with a risk of myocardial 
      infarction and death. In the COMPASS (Cardiovascular OutcoMes for People Using 
      Anticoagulation StrategieS) trial, rivaroxaban 2.5 mg twice daily plus aspirin 
      100 mg once daily compared with aspirin 100 mg once daily reduced the primary 
      major adverse cardiovascular events (MACE) outcome of cardiovascular death, 
      stroke, or myocardial infarction. Rivaroxaban 5 mg twice daily alone did not 
      significantly reduce MACE. OBJECTIVES: This pre-planned substudy sought to 
      determine whether the COMPASS treatments are more effective than aspirin alone 
      for preventing graft failure and MACE after CABG surgery. METHODS: The substudy 
      randomized 1,448 COMPASS trial patients 4 to 14 days after CABG surgery to 
      receive the combination of rivaroxaban plus aspirin, rivaroxaban alone, or 
      aspirin alone. The primary outcome was graft failure, diagnosed by computed 
      tomography angiogram 1 year after surgery. RESULTS: The combination of 
      rivaroxaban and aspirin and the regimen of rivaroxaban alone did not reduce the 
      graft failure rates compared with aspirin alone (combination vs. aspirin: 113 
      [9.1%] vs. 91 [8.0%] failed grafts; odds ratio [OR]: 1.13; 95% confidence 
      interval [CI]: 0.82 to 1.57; p = 0.45; rivaroxaban alone vs. aspirin: 92 [7.8%] 
      vs. 92 [8.0%] failed grafts; OR: 0.95; 95% CI: 0.67 to 1.33; p = 0.75). Compared 
      with aspirin, the combination was associated with fewer MACE (12 [2.4%] vs. 16 
      [3.5%]; hazard ratio [HR]: 0.69; 95% CI: 0.33 to 1.47; p = 0.34), whereas 
      rivaroxaban alone was not (16 [3.3%] vs. 16 [3.5%]; HR: 0.99, CI: 0.50 to 1.99; 
      p = 0.98). There was no fatal bleeding or tamponade within 30 days of 
      randomization. CONCLUSIONS: The combination of rivaroxaban 2.5 mg twice daily 
      plus aspirin or rivaroxaban 5 mg twice daily alone compared with aspirin alone 
      did not reduce graft failure in patients with recent CABG surgery, but the 
      combination of rivaroxaban 2.5 mg twice daily plus aspirin was associated with 
      similar reductions in MACE, as observed in the larger COMPASS trial. 
      (Cardiovascular OutcoMes for People Using Anticoagulation StrategieS [COMPASS]; 
      NCT01776424).
CI  - Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Lamy, Andre
AU  - Lamy A
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada; CADENCE Research Group, Hamilton Health Sciences, Hamilton, Ontario, 
      Canada; Department of Surgery, McMaster University, Hamilton, Ontario, Canada; 
      Department of Health Research Methods, Evidence, and Impact, McMaster University, 
      Hamilton, Ontario, Canada. Electronic address: alamy1@mac.com.
FAU - Eikelboom, John
AU  - Eikelboom J
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Sheth, Tej
AU  - Sheth T
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Connolly, Stuart
AU  - Connolly S
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Bosch, Jackie
AU  - Bosch J
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Fox, Keith A A
AU  - Fox KAA
AD  - Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United 
      Kingdom.
FAU - Zhu, Jun
AU  - Zhu J
AD  - FuWai Hospital, Beijing, China.
FAU - Lonn, Eva
AU  - Lonn E
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada; Department of Health Research Methods, Evidence, and Impact, McMaster 
      University, Hamilton, Ontario, Canada; Department of Medicine, McMaster 
      University, Hamilton, Ontario, Canada.
FAU - Dagenais, Gilles
AU  - Dagenais G
AD  - Institut Universitaire de Cardiologie et de Pnemologie de Québec, Quebec City, 
      Quebec, Canada.
FAU - Widimsky, Petr
AU  - Widimsky P
AD  - Cardiocenter, University Hospital Kralovske Vinohrady and Third Faculty of 
      Medicine, Charles University, Prague, Czech Republic.
FAU - Branch, Kelly R H
AU  - Branch KRH
AD  - University of Washington Medical Center, Seattle, Washington.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 
      Boston, Massachusetts.
FAU - Zheng, Zhe
AU  - Zheng Z
AD  - FuWai Hospital, Beijing, China.
FAU - Straka, Zbynek
AU  - Straka Z
AD  - Cardiocenter, University Hospital Kralovske Vinohrady and Third Faculty of 
      Medicine, Charles University, Prague, Czech Republic.
FAU - Dagenais, Francois
AU  - Dagenais F
AD  - Quebec Heart and Lung University Institute, Laval University, Quebec City, 
      Quebec, Canada.
FAU - Kong, Ye
AU  - Kong Y
AD  - Shanghai Chest Hospital Affiliated with Shanghai Jiao Tong University, Shanghai, 
      China.
FAU - Marsden, Tamara
AU  - Marsden T
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Lee, Shun Fu
AU  - Lee SF
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Copland, Ingrid
AU  - Copland I
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Yusuf, Salim
AU  - Yusuf S
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada; Department of Health Research Methods, Evidence, and Impact, McMaster 
      University, Hamilton, Ontario, Canada; Department of Medicine, McMaster 
      University, Hamilton, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT01776424
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2019 Jan 22;73(2):131-133. PMID: 30654883
CIN - J Am Coll Cardiol. 2019 May 14;73(18):2359-2360. PMID: 31072583
CIN - J Am Coll Cardiol. 2019 May 14;73(18):2360. PMID: 31072584
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Factor Xa Inhibitors/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rivaroxaban/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - anticoagulation
OT  - cardiac surgery
OT  - coronary artery disease
OT  - graft failures
EDAT- 2019/01/19 06:00
MHDA- 2019/11/19 06:00
CRDT- 2019/01/19 06:00
PHST- 2018/08/13 00:00 [received]
PHST- 2018/10/03 00:00 [revised]
PHST- 2018/10/08 00:00 [accepted]
PHST- 2019/01/19 06:00 [entrez]
PHST- 2019/01/19 06:00 [pubmed]
PHST- 2019/11/19 06:00 [medline]
AID - S0735-1097(18)39066-1 [pii]
AID - 10.1016/j.jacc.2018.10.048 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2019 Jan 22;73(2):121-130. doi: 10.1016/j.jacc.2018.10.048.

PMID- 27738237
OWN - NLM
STAT- MEDLINE
DCOM- 20170529
LR  - 20191210
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 47
IP  - 11
DP  - 2016 Nov
TI  - Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety 
      of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE 
      Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling 
      Cerebrovascular Events).
PG  - 2791-2796
AB  - BACKGROUND AND PURPOSE: Patients with chronic kidney disease (CKD) are at a 
      particularly high risk for ischemic and bleeding events. Limited data exist as to 
      the efficacy and safety of clopidogrel in stroke patients with renal dysfunction. 
      Therefore, we sought to assess the impact of decreased kidney function on 
      clinical outcomes for stroke patients on clopidogrel-aspirin treatment. METHODS: 
      Patients in the CHANCE trial (Clopidogrel in High-Risk Patients With Acute 
      Nondisabling Cerebrovascular Events) were randomized to clopidogrel-aspirin or 
      aspirin-alone treatment. The primary efficacy outcome was new stroke during 90 
      days, whereas bleeding was the safety outcome. Patients were stratified according 
      to estimated glomerular filtration rate. RESULTS: Dual clopidogrel-aspirin 
      therapy was associated with a marked reduction in new strokes compared with the 
      therapy of aspirin alone in patients with normal renal function (hazard ratio, 
      0.77; 95% confidence interval, 0.60-0.98; P=0.02) and mild CKD (hazard ratio, 
      0.60; 95% confidence interval, 0.45-0.79; P<0.01), whereas in patients with 
      moderate CKD, no significant benefit from clopidogrel therapy was detected 
      (hazard ratio, 1.00; 95% confidence interval, 0.43-2.35; P=0.99). There was no 
      clear difference in bleeding episodes by treatment assignment across categories 
      of renal impairment. CONCLUSIONS: Clopidogrel plus aspirin could decrease new 
      stroke in patients with normal kidney function and mild CKD, but no extra benefit 
      was observed in those with moderate CKD. Bleeding risk from the dual therapy did 
      not seem to increase in mild or moderate CKD patients. CLINICAL TRIAL 
      REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589.
CI  - © 2016 American Heart Association, Inc.
FAU - Zhou, Yilun
AU  - Zhou Y
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.).
FAU - Pan, Yuesong
AU  - Pan Y
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.).
FAU - Wu, Yu
AU  - Wu Y
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.).
FAU - Zhao, Xingquan
AU  - Zhao X
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.).
FAU - Li, Hao
AU  - Li H
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.).
FAU - Wang, David
AU  - Wang D
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.).
FAU - Johnston, S Claiborne
AU  - Johnston SC
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.).
FAU - Liu, Liping
AU  - Liu L
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.).
FAU - Wang, Chunxue
AU  - Wang C
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.).
FAU - Meng, Xia
AU  - Meng X
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.).
FAU - Wang, Yilong
AU  - Wang Y
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.). yilong528@gmail.com 
      yongjunwang1962@gmail.com.
FAU - Wang, Yongjun
AU  - Wang Y
AD  - From the Department of Nephrology, Beijing Tiantan Hospital (Y.Z., Y.W.), 
      Department of Neurology, Beijing Tiantan Hospital (Y.P., X.Z., H.L., L.L., C.W., 
      X.M., Yilong Wang, Yongjun Wang), and Department of Epidemiology and Health 
      Statistics, School of Public Health (Y.P.), Capital Medical University, China; 
      China National Clinical Research Center for Neurological Diseases, Beijing, China 
      (Y.P., X.Z., H.L., L.L., C.W., X.M., Yilong Wang, Yongjun Wang); Center of 
      Stroke, Beijing Institute for Brain Disorders, China (Y.P., X.Z., H.L., L.L., 
      C.W., X.M., Yilong Wang, Yongjun Wang); Beijing Key Laboratory of Translational 
      Medicine for Cerebrovascular Disease, China (Y.P., X.Z., H.L., L.L., C.W., X.M., 
      Yilong Wang, Yongjun Wang); INI Stroke Network, OSF Healthcare System, University 
      of Illinois College of Medicine, Peoria (D.W.); and Dell Medical School, 
      University of Texas at Austin (S.C.J.). yilong528@gmail.com 
      yongjunwang1962@gmail.com.
CN  - CHANCE Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00979589
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20161013
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - Cerebral Hemorrhage/chemically induced
MH  - Clopidogrel
MH  - Comorbidity
MH  - Drug Therapy, Combination
MH  - *Glomerular Filtration Rate
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/epidemiology
MH  - Middle Aged
MH  - *Outcome Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*pharmacology
MH  - *Renal Insufficiency, Chronic/epidemiology
MH  - Severity of Illness Index
MH  - Stroke/*drug therapy/epidemiology
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacology
OTO - NOTNLM
OT  - chronic kidney disease
OT  - clopidogrel
OT  - stroke
EDAT- 2016/10/26 06:00
MHDA- 2017/05/30 06:00
CRDT- 2016/10/15 06:00
PHST- 2016/07/14 00:00 [received]
PHST- 2016/09/19 00:00 [accepted]
PHST- 2016/10/26 06:00 [pubmed]
PHST- 2017/05/30 06:00 [medline]
PHST- 2016/10/15 06:00 [entrez]
AID - STROKEAHA.116.014761 [pii]
AID - 10.1161/STROKEAHA.116.014761 [doi]
PST - ppublish
SO  - Stroke. 2016 Nov;47(11):2791-2796. doi: 10.1161/STROKEAHA.116.014761. Epub 2016 
      Oct 13.

PMID- 30551280
OWN - NLM
STAT- MEDLINE
DCOM- 20190503
LR  - 20190503
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 74
IP  - 10
DP  - 2016 Oct
TI  - [Advances in aspirin-exacerbated respiratory disease (AERD)].
PG  - 1683-1687
AB  - Aspirin-exacerbated respiratory disease (AERD) is characterized by the triad of 
      asthma, eosinophilic nasal polyposis and a hypersensitivity to all medications 
      that inhibit the cyclo- oxygenase (COX) -1 enzyme. Clinical history and observed 
      aspirin provocation test remains gold standard for diagnosis of AERD. AERD 
      patients typically have more severe asthma with airflow limitation and greater 
      requirement for high-dose corticosteroid therapies. Over- production of 
      cysteinyl-leukotrienes (CysLTs) and prostaglandin D2 (PGD2) correlate with the 
      pathogenetic features of AERD, suggesting the possible involvement of mast cell 
      activation with innate type 2 immune response. Next breakthroughs in diagnosis 
      and treatment have been expected in the nearest futures.
FAU - Higashi, Noritaka
AU  - Higashi N
FAU - Mitsui, Chihiro
AU  - Mitsui C
FAU - Taniguchi, Masami
AU  - Taniguchi M
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - *Asthma, Aspirin-Induced/diagnosis/immunology/therapy
MH  - Humans
EDAT- 2016/10/01 00:00
MHDA- 2016/10/01 00:01
CRDT- 2018/12/15 06:00
PHST- 2018/12/15 06:00 [entrez]
PHST- 2016/10/01 00:00 [pubmed]
PHST- 2016/10/01 00:01 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2016 Oct;74(10):1683-1687.

PMID- 19694746
OWN - NLM
STAT- MEDLINE
DCOM- 20100309
LR  - 20220408
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 68
IP  - 2
DP  - 2009 Aug
TI  - Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse 
      methylprednisolone therapy.
PG  - 252-9
LID - 10.1111/j.1365-2125.2009.03445.x [doi]
AB  - AIMS: Whether glucocorticoids induce gastric mucosal injury remains uncertain. We 
      investigated whether very high-dose steroids caused gastric mucosal injury in 
      systemic lupus erythematous (SLE) patients and evaluated the possible risk 
      factors for mucosal injury. METHODS: In this prospective paired study, 67 SLE 
      patients who had received pulse methylprednisolone therapy were enrolled. Each 
      patient underwent endoscopic examination and tissue and blood sampling before and 
      after pulse steroid therapy. Mucosal injury was diagnosed if the follow-up injury 
      scale was higher than the initial scale. Examined parameters included 
      Helicobacter pylori infection, cyclooxygenase (COX)-1 and COX-2 activity, and 
      current nonsteroidal anti-inflammatory drug (NSAID) usage including aspirin. 
      RESULTS: Eleven (16.4%) of 67 cases who developed gastric mucosal injury after 
      pulse therapy had significantly higher rates of peptic ulcer history, 
      NSAID/aspirin use, lower gastric thromboxane B(2) and prostaglandin E(2) levels 
      when compared with cases without gastric mucosal injury (P < 0.05). Infection by 
      H. pylori was not a risk factor for gastric mucosal injury. Multivariate logistic 
      regression analysis showed that NSAID/aspirin use was the only risk factor for 
      gastric mucosal injury in these patients (odds ratio 26.99, 95% confidence 
      interval 4.91, 148.57, P < 0.0001). Pulse steroid therapy alone did not induce 
      gastric mucosal injury in fifty SLE patients without taking any NSAID/aspirin. 
      CONCLUSIONS: Use of NSAIDs/aspirin, but not H. pylori infection, increases 
      gastric mucosal injury in SLE patients receiving pulse methylprednisolone 
      therapy. Very high-dose steroids de novo seem not to induce gastric mucosal 
      injury in these patients. A larger case-controlled study enrolling a 
      heterogeneous population is needed to clarify the role of glucocorticoids in 
      gastric mucosal injury.
FAU - Luo, Jiing-Chyuan
AU  - Luo JC
AD  - Division of Gastroenterology, Department of Medicine, Taipei Veterans General 
      Hospital, Taipei 11217, Taiwan.
FAU - Chang, Full-Young
AU  - Chang FY
FAU - Chen, Tseng-Shing
AU  - Chen TS
FAU - Ng, Yee-Yung
AU  - Ng YY
FAU - Lin, Han-Chieh
AU  - Lin HC
FAU - Lu, Ching-Liang
AU  - Lu CL
FAU - Chen, Chih-Yen
AU  - Chen CY
FAU - Lin, Hsiao-Yi
AU  - Lin HY
FAU - Lee, Shou-Dong
AU  - Lee SD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 5GMR90S4KN (Methylprednisolone Hemisuccinate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Epidemiologic Methods
MH  - Female
MH  - Gastric Mucosa/*drug effects/injuries
MH  - Helicobacter Infections/*chemically induced/complications
MH  - Humans
MH  - Male
MH  - Methylprednisolone Hemisuccinate/administration & dosage/*adverse effects
PMC - PMC2767290
EDAT- 2009/08/22 09:00
MHDA- 2010/03/10 06:00
CRDT- 2009/08/22 09:00
PHST- 2009/08/22 09:00 [entrez]
PHST- 2009/08/22 09:00 [pubmed]
PHST- 2010/03/10 06:00 [medline]
AID - BCP3445 [pii]
AID - 10.1111/j.1365-2125.2009.03445.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2009 Aug;68(2):252-9. doi: 10.1111/j.1365-2125.2009.03445.x.

PMID- 19628366
OWN - NLM
STAT- MEDLINE
DCOM- 20100106
LR  - 20131121
IS  - 1532-8406 (Electronic)
IS  - 0883-5403 (Linking)
VI  - 24
IP  - 6 Suppl
DP  - 2009 Sep
TI  - Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooled 
      analysis of randomized controlled trials.
PG  - 77-83
LID - 10.1016/j.arth.2009.06.002 [doi]
AB  - The use of aspirin for venous thromboembolism (VTE) prophylaxis after major 
      orthopaedic surgery is controversial. The hypothesis of the present study is that 
      aspirin will decrease the rate of operative site bleeding without increasing 
      thromboembolic events when aspirin is used for VTE prophylaxis after major 
      orthopaedic surgery. A pooled analysis of 14 randomized controlled trials (RCTs) 
      cited by the American College of Chest Physicians (ACCP) guidelines was performed 
      to determine pooled rates of symptomatic deep vein thromboses, pulmonary emboli 
      (PE), fatal PE, and operative site bleeding rates. The VTE rates with aspirin 
      were not significantly different than the rates for vitamin K antagonists (VKA), 
      low molecular weight heparins (LMWH), and pentasaccharides. The operative site 
      bleeding relative risks of VKA, LMWH, and pentasaccharides versus aspirin, are 
      4.9, 6.4, and 4.2, respectively. A pooled analysis of RCTs supports the use of 
      aspirin for VTE prophylaxis after major orthopaedic surgery.
FAU - Brown, Greg A
AU  - Brown GA
AD  - Department of Orthopaedic Surgery, Park Nicollet Health Services, St. Louis Park, 
      Minnesota, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090722
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Orthopedic Procedures/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Venous Thromboembolism/*prevention & control
MH  - Vitamin K/antagonists & inhibitors
RF  - 28
EDAT- 2009/07/25 09:00
MHDA- 2010/01/07 06:00
CRDT- 2009/07/25 09:00
PHST- 2009/01/29 00:00 [received]
PHST- 2009/06/02 00:00 [accepted]
PHST- 2009/07/25 09:00 [entrez]
PHST- 2009/07/25 09:00 [pubmed]
PHST- 2010/01/07 06:00 [medline]
AID - S0883-5403(09)00223-X [pii]
AID - 10.1016/j.arth.2009.06.002 [doi]
PST - ppublish
SO  - J Arthroplasty. 2009 Sep;24(6 Suppl):77-83. doi: 10.1016/j.arth.2009.06.002. Epub 
      2009 Jul 22.

PMID- 15125293
OWN - NLM
STAT- MEDLINE
DCOM- 20040601
LR  - 20190724
IS  - 0022-2151 (Print)
IS  - 0022-2151 (Linking)
VI  - 107
IP  - 7
DP  - 1993 Jul
TI  - Spontaneous retropharyngeal haematoma: two cases and a review of the literature.
PG  - 649-50
AB  - Retropharyngeal haemorrhage is a rare condition. The classical picture is 
      described as a triad of features; superior mediastinal obstruction, anterior 
      displacement of the trachea on a plain X-ray of the neck and subcutaneous 
      bruising appearing on the neck and spreading on to the chest wall (Sandor and 
      Cooke, 1964). Two cases are reported here, neither of which had mediastinal 
      compression. The available literature is summarized.
FAU - al-Fallouji, H K
AU  - al-Fallouji HK
AD  - Department of Otolaryngology, Selly Oak Hospital, Birmingham.
FAU - Snow, D G
AU  - Snow DG
FAU - Kuo, M J
AU  - Kuo MJ
FAU - Johnson, P J
AU  - Johnson PJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Laryngol Otol
JT  - The Journal of laryngology and otology
JID - 8706896
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects
MH  - Aspirin/adverse effects
MH  - Female
MH  - Hematoma/*diagnosis/etiology
MH  - Humans
MH  - Middle Aged
MH  - Pharyngeal Diseases/*diagnosis/etiology
MH  - *Tomography, X-Ray Computed
RF  - 20
EDAT- 1993/07/01 00:00
MHDA- 2005/03/25 09:00
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 2005/03/25 09:00 [medline]
PHST- 1993/07/01 00:00 [entrez]
AID - 10.1017/s0022215100123990 [doi]
PST - ppublish
SO  - J Laryngol Otol. 1993 Jul;107(7):649-50. doi: 10.1017/s0022215100123990.

PMID- 6407310
OWN - NLM
STAT- MEDLINE
DCOM- 19830715
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 74
IP  - 6A
DP  - 1983 Jun 14
TI  - Aspirin in the treatment of cardiovascular disease: a review.
PG  - 43-9
AB  - Large-scale clinical trials of the use of aspirin in post-myocardial infarction 
      patients were based on the assumption that inhibition of platelet activity would 
      reduce thromboembolism associated with atherosclerosis, and that thromboembolism 
      is a major cause of the clinical complications of atherosclerosis. However, spasm 
      and occlusive thrombi may also contribute to this picture, and thus 
      thromboembolism is probably only one of the mechanisms that cause the clinical 
      complications. Aspirin inhibits thrombosis only if thromboxane A2 formation by 
      platelets plays a major part in the growth of thrombi; aspirin has little effect 
      on thrombosis when thrombin generation and fibrin formation are dominant factors. 
      Nevertheless, analysis of the combined data from the six clinical trials 
      indicates a highly significant (21 percent) reduction in reinfarction rate and a 
      16 percent reduction in cardiovascular mortality rate in patients treated with 
      aspirin. Aspirin may be most useful in treating an as-yet-unidentified subgroup 
      of patients.
FAU - Mustard, J F
AU  - Mustard JF
FAU - Kinlough-Rathbone, R L
AU  - Kinlough-Rathbone RL
FAU - Packham, M A
AU  - Packham MA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Blood Vessels/drug effects
MH  - Cell Adhesion/drug effects
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Thrombosis/blood
RF  - 56
EDAT- 1983/06/14 00:00
MHDA- 1983/06/14 00:01
CRDT- 1983/06/14 00:00
PHST- 1983/06/14 00:00 [pubmed]
PHST- 1983/06/14 00:01 [medline]
PHST- 1983/06/14 00:00 [entrez]
AID - 0002-9343(83)90527-2 [pii]
AID - 10.1016/0002-9343(83)90527-2 [doi]
PST - ppublish
SO  - Am J Med. 1983 Jun 14;74(6A):43-9. doi: 10.1016/0002-9343(83)90527-2.

PMID- 6337428
OWN - NLM
STAT- MEDLINE
DCOM- 19830311
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 14
IP  - 1
DP  - 1983 Jan-Feb
TI  - Persantine Aspirin Trial in cerebral ischemia. The American-Canadian Co-operative 
      Study Group.
PG  - 99-103
AB  - The Persantine Aspirin Trial is a double-blind multi-centered cooperative study 
      focusing primarily on the question of whether the administration of the 
      combination of aspirin and dipyridamole (Persantine) will result in a greater 
      reduction of cerebral or retinal infarction or death than the administration of 
      aspirin alone. Fifteen centers in the United States and Canada are participating. 
      More than 750 individuals with a history of recent carotid territory transient 
      ischemic attacks (TIAs) have been admitted over the past four years and randomly 
      allocated to either aspirin (325 mg) plus placebo four times daily or aspirin 
      (325 mg) plus Persantine (75 mg) four times daily. It is anticipated that the 
      study will continue through 1983. Analysis and publication of results are planned 
      for 1984.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage
MH  - Canada
MH  - Clinical Trials as Topic
MH  - Dipyridamole/*administration & dosage
MH  - Dogs
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - United States
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1161/01.str.14.1.99 [doi]
PST - ppublish
SO  - Stroke. 1983 Jan-Feb;14(1):99-103. doi: 10.1161/01.str.14.1.99.

PMID- 6812166
OWN - NLM
STAT- MEDLINE
DCOM- 19821202
LR  - 20190825
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 23
IP  - 6
DP  - 1982 Jun
TI  - Indomethacin prevents the long-lasting inhibitory effect of aspirin on human 
      platelet cyclo-oxygenase activity.
PG  - 787-96
AB  - Aspirin and indomethacin do interact with the same site on cyclo-oxygenase. This 
      suggestion is based on in vitro studies on ram seminal vesicles and in vivo drug 
      interaction studies on rat platelets. The purpose of the present study was to 
      ascertain whether the same interaction also occurred after administration of both 
      drugs to human volunteers. Platelet aggregation induced by sodium arachidonate or 
      by collagen, and formation of platelet MDA and TxB2 were measured before, two and 
      48 hours after ingestion of either indomethacin (50 mg) or aspirin (500 mg) or of 
      both drugs (30 minutes apart). While the inhibitory effect of indomethacin on 
      these parameters was short lasting, that of aspirin persisted for at least 48 
      hours. However, when both drugs were given concurrently, the long-lasting effect 
      of aspirin was no longer detectable. Since competition at levels other than 
      platelets was unlikely, this study indicates that indomethacin and aspirin 
      inhibit human platelet cyclo-oxygenase by the same basic mechanism. Acetylation 
      of the enzyme appears to be a secondary mechanism which makes the inhibitory 
      effect of aspirin persistent.
FAU - Livio, M
AU  - Livio M
FAU - Del Maschio, A
AU  - Del Maschio A
FAU - Cerletti, C
AU  - Cerletti C
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Arachidonic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Arachidonic Acid
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/*enzymology
MH  - *Cyclooxygenase Inhibitors
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Time Factors
EDAT- 1982/06/01 00:00
MHDA- 1982/06/01 00:01
CRDT- 1982/06/01 00:00
PHST- 1982/06/01 00:00 [pubmed]
PHST- 1982/06/01 00:01 [medline]
PHST- 1982/06/01 00:00 [entrez]
AID - 0090-6980(82)90123-X [pii]
AID - 10.1016/0090-6980(82)90123-x [doi]
PST - ppublish
SO  - Prostaglandins. 1982 Jun;23(6):787-96. doi: 10.1016/0090-6980(82)90123-x.

PMID- 35977833
OWN - NLM
STAT- MEDLINE
DCOM- 20221019
LR  - 20221217
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 99
IP  - 16
DP  - 2022 Oct 18
TI  - Consensus Recommendations for Managing Childhood Cancer Survivors at Risk for 
      Stroke After Cranial Irradiation: A Delphi Study.
PG  - e1755-e1766
LID - 10.1212/WNL.0000000000201014 [doi]
AB  - BACKGROUND AND OBJECTIVES: There is insufficient evidence to support stroke 
      prevention guidelines for childhood cancer survivors (CCS) treated with cranial 
      irradiation for CNS tumors or other childhood cancers involving the CNS. We used 
      a systematic consensus-building methodology to develop expert recommendations and 
      define areas of controversy in managing asymptomatic CCS at risk for stroke. 
      METHODS: A Delphi process was used to query a multispecialty panel of 45 
      physicians from the United States/Canada, with expertise in CCS, about their 
      stroke screening and management practices (imaging, referrals, laboratory 
      testing, and medications). Three iterative rounds of anonymous, scenario-based 
      questionnaires, building on panelists' aggregate responses, were used to reach 
      consensus (≥90% agreement), agreement (89%-70% agree), or to understand the 
      rationale for disagreement (<70% agree). RESULTS: All 45 physicians participated 
      in the first 2 rounds and 44 in the third. Panelists reached consensus on 
      indications for referral to neurology and laboratory screening for modifiable 
      cerebral vascular disease (CVD) risk factors in most scenarios. Panelists agreed 
      that aspirin therapy is not recommended in the scenario of normal neuroimaging 
      (86% agreed). Decisions about aspirin therapy in scenarios with abnormal 
      neuroimaging were deferred to specialists; almost all agreed with not using 
      aspirin for cavernomas with no evidence for previous hemorrhage (93%) and using 
      aspirin for both large vessel CVD (93%) and small vessel CVD with evidence of 
      previous stroke (86%). Clinical decisions that remain controversial (less than 
      70% agreement) include neuroimaging to screen asymptomatic CCS for CVD, referral 
      to neurology for cavernomas, aspirin use in the setting of cavernomas with 
      previous hemorrhage, or with evidence for small vessel CVD and no previous 
      stroke, and indications for statins. Overall, pediatric 
      neurologists/neuro-oncologists and radiation oncologists were more likely to 
      advocate for screening and interventions. DISCUSSION: Despite lack of evidence to 
      guide the management of CCS at risk for stroke, expert recommendations and 
      rationale developed by consensus methodology are helpful to support clinical 
      decision-making.
CI  - © 2022 American Academy of Neurology.
FAU - Kenney, Lisa B
AU  - Kenney LB
AD  - From the Dana-Farber/Boston Children's Cancer and Blood Disorders Center (L.B.K., 
      L.N., N.J.U.), Harvard Medical School, Boston, MA; Department of Pediatrics 
      (B.L.A.), Geisel School of Medicine at Dartmouth, Hanover, NH; Pediatric 
      Hematology/Oncology Massachusetts General Hospital for Children (M.S.H.), Harvard 
      Medical School, Boston; Radiation Oncology (T.Y.), Massachusetts General 
      Hospital, Harvard Medical School, Boston; Department of Pediatrics (D.C.B.), UT 
      Southwestern Medical School, Dallas, TX; Department of Medicine (L.N.), Brigham 
      and Women's Hospital, Boston, MA; Institutional Centers for Clinical and 
      Translational Research (D.W.) and Department of Neurology (N.J.U.), Boston 
      Children's Hospital, Harvard Medical School, MA; and Department of Oncology 
      (M.M.H.), St. Jude Children's Research Hospital, Memphis, TN. 
      lisa_kenney@dfci.harvard.edu.
FAU - Ames, Bethany L
AU  - Ames BL
AD  - From the Dana-Farber/Boston Children's Cancer and Blood Disorders Center (L.B.K., 
      L.N., N.J.U.), Harvard Medical School, Boston, MA; Department of Pediatrics 
      (B.L.A.), Geisel School of Medicine at Dartmouth, Hanover, NH; Pediatric 
      Hematology/Oncology Massachusetts General Hospital for Children (M.S.H.), Harvard 
      Medical School, Boston; Radiation Oncology (T.Y.), Massachusetts General 
      Hospital, Harvard Medical School, Boston; Department of Pediatrics (D.C.B.), UT 
      Southwestern Medical School, Dallas, TX; Department of Medicine (L.N.), Brigham 
      and Women's Hospital, Boston, MA; Institutional Centers for Clinical and 
      Translational Research (D.W.) and Department of Neurology (N.J.U.), Boston 
      Children's Hospital, Harvard Medical School, MA; and Department of Oncology 
      (M.M.H.), St. Jude Children's Research Hospital, Memphis, TN.
FAU - Huang, Mary S
AU  - Huang MS
AD  - From the Dana-Farber/Boston Children's Cancer and Blood Disorders Center (L.B.K., 
      L.N., N.J.U.), Harvard Medical School, Boston, MA; Department of Pediatrics 
      (B.L.A.), Geisel School of Medicine at Dartmouth, Hanover, NH; Pediatric 
      Hematology/Oncology Massachusetts General Hospital for Children (M.S.H.), Harvard 
      Medical School, Boston; Radiation Oncology (T.Y.), Massachusetts General 
      Hospital, Harvard Medical School, Boston; Department of Pediatrics (D.C.B.), UT 
      Southwestern Medical School, Dallas, TX; Department of Medicine (L.N.), Brigham 
      and Women's Hospital, Boston, MA; Institutional Centers for Clinical and 
      Translational Research (D.W.) and Department of Neurology (N.J.U.), Boston 
      Children's Hospital, Harvard Medical School, MA; and Department of Oncology 
      (M.M.H.), St. Jude Children's Research Hospital, Memphis, TN.
FAU - Yock, Torunn
AU  - Yock T
AD  - From the Dana-Farber/Boston Children's Cancer and Blood Disorders Center (L.B.K., 
      L.N., N.J.U.), Harvard Medical School, Boston, MA; Department of Pediatrics 
      (B.L.A.), Geisel School of Medicine at Dartmouth, Hanover, NH; Pediatric 
      Hematology/Oncology Massachusetts General Hospital for Children (M.S.H.), Harvard 
      Medical School, Boston; Radiation Oncology (T.Y.), Massachusetts General 
      Hospital, Harvard Medical School, Boston; Department of Pediatrics (D.C.B.), UT 
      Southwestern Medical School, Dallas, TX; Department of Medicine (L.N.), Brigham 
      and Women's Hospital, Boston, MA; Institutional Centers for Clinical and 
      Translational Research (D.W.) and Department of Neurology (N.J.U.), Boston 
      Children's Hospital, Harvard Medical School, MA; and Department of Oncology 
      (M.M.H.), St. Jude Children's Research Hospital, Memphis, TN.
FAU - Bowers, Daniel C
AU  - Bowers DC
AD  - From the Dana-Farber/Boston Children's Cancer and Blood Disorders Center (L.B.K., 
      L.N., N.J.U.), Harvard Medical School, Boston, MA; Department of Pediatrics 
      (B.L.A.), Geisel School of Medicine at Dartmouth, Hanover, NH; Pediatric 
      Hematology/Oncology Massachusetts General Hospital for Children (M.S.H.), Harvard 
      Medical School, Boston; Radiation Oncology (T.Y.), Massachusetts General 
      Hospital, Harvard Medical School, Boston; Department of Pediatrics (D.C.B.), UT 
      Southwestern Medical School, Dallas, TX; Department of Medicine (L.N.), Brigham 
      and Women's Hospital, Boston, MA; Institutional Centers for Clinical and 
      Translational Research (D.W.) and Department of Neurology (N.J.U.), Boston 
      Children's Hospital, Harvard Medical School, MA; and Department of Oncology 
      (M.M.H.), St. Jude Children's Research Hospital, Memphis, TN.
FAU - Nekhlyudov, Larissa
AU  - Nekhlyudov L
AD  - From the Dana-Farber/Boston Children's Cancer and Blood Disorders Center (L.B.K., 
      L.N., N.J.U.), Harvard Medical School, Boston, MA; Department of Pediatrics 
      (B.L.A.), Geisel School of Medicine at Dartmouth, Hanover, NH; Pediatric 
      Hematology/Oncology Massachusetts General Hospital for Children (M.S.H.), Harvard 
      Medical School, Boston; Radiation Oncology (T.Y.), Massachusetts General 
      Hospital, Harvard Medical School, Boston; Department of Pediatrics (D.C.B.), UT 
      Southwestern Medical School, Dallas, TX; Department of Medicine (L.N.), Brigham 
      and Women's Hospital, Boston, MA; Institutional Centers for Clinical and 
      Translational Research (D.W.) and Department of Neurology (N.J.U.), Boston 
      Children's Hospital, Harvard Medical School, MA; and Department of Oncology 
      (M.M.H.), St. Jude Children's Research Hospital, Memphis, TN.
FAU - Williams, David
AU  - Williams D
AD  - From the Dana-Farber/Boston Children's Cancer and Blood Disorders Center (L.B.K., 
      L.N., N.J.U.), Harvard Medical School, Boston, MA; Department of Pediatrics 
      (B.L.A.), Geisel School of Medicine at Dartmouth, Hanover, NH; Pediatric 
      Hematology/Oncology Massachusetts General Hospital for Children (M.S.H.), Harvard 
      Medical School, Boston; Radiation Oncology (T.Y.), Massachusetts General 
      Hospital, Harvard Medical School, Boston; Department of Pediatrics (D.C.B.), UT 
      Southwestern Medical School, Dallas, TX; Department of Medicine (L.N.), Brigham 
      and Women's Hospital, Boston, MA; Institutional Centers for Clinical and 
      Translational Research (D.W.) and Department of Neurology (N.J.U.), Boston 
      Children's Hospital, Harvard Medical School, MA; and Department of Oncology 
      (M.M.H.), St. Jude Children's Research Hospital, Memphis, TN.
FAU - Hudson, Melissa M
AU  - Hudson MM
AD  - From the Dana-Farber/Boston Children's Cancer and Blood Disorders Center (L.B.K., 
      L.N., N.J.U.), Harvard Medical School, Boston, MA; Department of Pediatrics 
      (B.L.A.), Geisel School of Medicine at Dartmouth, Hanover, NH; Pediatric 
      Hematology/Oncology Massachusetts General Hospital for Children (M.S.H.), Harvard 
      Medical School, Boston; Radiation Oncology (T.Y.), Massachusetts General 
      Hospital, Harvard Medical School, Boston; Department of Pediatrics (D.C.B.), UT 
      Southwestern Medical School, Dallas, TX; Department of Medicine (L.N.), Brigham 
      and Women's Hospital, Boston, MA; Institutional Centers for Clinical and 
      Translational Research (D.W.) and Department of Neurology (N.J.U.), Boston 
      Children's Hospital, Harvard Medical School, MA; and Department of Oncology 
      (M.M.H.), St. Jude Children's Research Hospital, Memphis, TN.
FAU - Ullrich, Nicole J
AU  - Ullrich NJ
AD  - From the Dana-Farber/Boston Children's Cancer and Blood Disorders Center (L.B.K., 
      L.N., N.J.U.), Harvard Medical School, Boston, MA; Department of Pediatrics 
      (B.L.A.), Geisel School of Medicine at Dartmouth, Hanover, NH; Pediatric 
      Hematology/Oncology Massachusetts General Hospital for Children (M.S.H.), Harvard 
      Medical School, Boston; Radiation Oncology (T.Y.), Massachusetts General 
      Hospital, Harvard Medical School, Boston; Department of Pediatrics (D.C.B.), UT 
      Southwestern Medical School, Dallas, TX; Department of Medicine (L.N.), Brigham 
      and Women's Hospital, Boston, MA; Institutional Centers for Clinical and 
      Translational Research (D.W.) and Department of Neurology (N.J.U.), Boston 
      Children's Hospital, Harvard Medical School, MA; and Department of Oncology 
      (M.M.H.), St. Jude Children's Research Hospital, Memphis, TN.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220817
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Neurology. 2022 Oct 18;99(16):685-686. PMID: 35977829
MH  - Aspirin/therapeutic use
MH  - *Cancer Survivors
MH  - Child
MH  - Consensus
MH  - Cranial Irradiation/adverse effects
MH  - Delphi Technique
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors
MH  - *Neoplasms
MH  - *Stroke/diagnosis/etiology/prevention & control
EDAT- 2022/08/18 06:00
MHDA- 2022/10/20 06:00
CRDT- 2022/08/17 21:41
PHST- 2022/01/25 00:00 [received]
PHST- 2022/06/09 00:00 [accepted]
PHST- 2022/08/18 06:00 [pubmed]
PHST- 2022/10/20 06:00 [medline]
PHST- 2022/08/17 21:41 [entrez]
AID - WNL.0000000000201014 [pii]
AID - 10.1212/WNL.0000000000201014 [doi]
PST - ppublish
SO  - Neurology. 2022 Oct 18;99(16):e1755-e1766. doi: 10.1212/WNL.0000000000201014. 
      Epub 2022 Aug 17.

PMID- 32639246
OWN - NLM
STAT- MEDLINE
DCOM- 20211217
LR  - 20221207
IS  - 1473-5830 (Electronic)
IS  - 0954-6928 (Linking)
VI  - 32
IP  - 2
DP  - 2021 Mar 1
TI  - The optimal duration of dual antiplatelet therapy in East Asian patients 
      undergoing percutaneous coronary intervention with drug-eluting stents: a 
      meta-analysis of randomized trials.
PG  - 119-130
LID - 10.1097/MCA.0000000000000921 [doi]
AB  - OBJECTIVE: The optimal duration of dual antiplatelet therapy (DAPT) is still 
      controversial among East Asians. This meta-analysis was designed to evaluate the 
      efficacy and safety of short-term (≤6 months) vs. long-term (≥12 months) DAPT in 
      East Asians undergoing percutaneous coronary intervention (PCI) with drug-eluting 
      stent (DES). METHODS: PubMed, Embase, Web of Science and the Cochrane Library 
      were searched for articles published up to 30 March 2020. Then meta-analysis was 
      performed using RevMan 5.3 software. RESULTS: Nine studies with a total of 20 177 
      East Asian patients were included in this meta-analysis. In East Asian patients, 
      short-term DAPT was associated with a lower incidence of major bleeding [odds 
      ratio (OR) = 0.70, 95% confidence interval (CI) (0.49, 0.99), P = 0.04]. In the 
      newer-generation DES subgroup, short-term DAPT was no less effective than 
      long-term DAPT and resulted in a lower incidence of major bleeding [OR = 0.69, 
      95% CI (0.49, 0.98), P = 0.04]. In the subgroup of patients with acute coronary 
      syndrome, there was no significant difference in the incidence of cardiac death, 
      net adverse clinical and cerebral events (NACCE) and major bleeding between 
      short-term and long-term DAPT. It was worth noting that in the subgroup of 
      patients with diabetes mellitus, short-term DAPT was associated with a higher 
      incidence of myocardial infarction [OR = 2.64, 95% CI (1.19, 5.88), P = 0.02] and 
      NACCE [OR = 1.92, 95% CI (1.07, 3.43), P = 0.03]. CONCLUSION: The short-term DAPT 
      (≤6 months) might be a better choice for East Asian patients undergoing PCI with 
      DES, especially the newer-generation DES. However, for high-risk patients such as 
      diabetes, the analysis supported the longer DAPT.
CI  - Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Sun, Yuchao
AU  - Sun Y
AD  - Department of Cardiology, Affiliated Hangzhou First People's Hospital, Nanjing 
      Medical University, Shangcheng District, Hangzhou, Zhejiang Province, China.
FAU - Liu, Xiaohua
AU  - Liu X
FAU - Xu, Yizhou
AU  - Xu Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - Coron Artery Dis
JT  - Coronary artery disease
JID - 9011445
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Asian People
MH  - Aspirin/*administration & dosage
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Randomized Controlled Trials as Topic
EDAT- 2020/07/09 06:00
MHDA- 2021/12/18 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/12/18 06:00 [medline]
PHST- 2020/07/09 06:00 [entrez]
AID - 00019501-202103000-00005 [pii]
AID - 10.1097/MCA.0000000000000921 [doi]
PST - ppublish
SO  - Coron Artery Dis. 2021 Mar 1;32(2):119-130. doi: 10.1097/MCA.0000000000000921.

PMID- 24706702
OWN - NLM
STAT- MEDLINE
DCOM- 20141224
LR  - 20211021
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 2014
DP  - 2014 Apr 4
TI  - A cautionary tale on the use of antiplatelet treatment following TURP.
LID - 10.1136/bcr-2013-202469 [doi]
LID - bcr2013202469
AB  - A pleasant 74-year-old man was discharged home following a complication-free 
      transurethral resection of his prostate (TURP) and successful trial without 
      catheter. Unfortunately, on postoperative day 6, he presented to A&E with chest 
      pain requiring emergency intervention for a confirmed myocardial infarction. A 
      drug-eluting stent was inserted into his right coronary artery and he was started 
      on dual antiplatelet therapy of aspirin and clopidogrel. On day 7, the patient 
      developed significant haematuria requiring transfusion and an obstructive 
      uropathy, requiring an emergency laparotomy and 1 L of organised clot evacuation 
      from his bladder. The dual antiplatelet treatment was restarted on day 4 
      postlaparotomy, following debate between both the cardiology and urology teams 
      regarding its appropriate reintroduction. On day 7, he was rushed back to the 
      theatre for a re-laparotomy after CT confirmed reaccumulation of clot following 
      an acute deterioration at ward level. The patient made an excellent recovery and 
      was discharged home with regular outpatient follow-up.
FAU - Murray, Aileen Marie
AU  - Murray AM
AD  - Respiratory Department, Royal Victoria Hospital, Belfast, UK.
FAU - Keville, Norah
AU  - Keville N
FAU - Gray, Sam
AU  - Gray S
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20140404
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - *Coronary Thrombosis/drug therapy/etiology
MH  - Drug-Eluting Stents
MH  - Hematuria
MH  - Humans
MH  - Male
MH  - *Myocardial Infarction/drug therapy/etiology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - *Postoperative Complications/drug therapy/surgery
MH  - Thrombosis/drug therapy/etiology
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - *Transurethral Resection of Prostate
MH  - Urinary Bladder/pathology/surgery
MH  - Urinary Bladder Diseases/etiology/surgery
PMC - PMC3987527
EDAT- 2014/04/08 06:00
MHDA- 2014/12/30 06:00
CRDT- 2014/04/08 06:00
PHST- 2014/04/08 06:00 [entrez]
PHST- 2014/04/08 06:00 [pubmed]
PHST- 2014/12/30 06:00 [medline]
AID - bcr-2013-202469 [pii]
AID - 10.1136/bcr-2013-202469 [doi]
PST - epublish
SO  - BMJ Case Rep. 2014 Apr 4;2014:bcr2013202469. doi: 10.1136/bcr-2013-202469.

PMID- 20924098
OWN - NLM
STAT- MEDLINE
DCOM- 20110520
LR  - 20131121
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 16
IP  - 1
DP  - 2011 Mar
TI  - Antiplatelet therapy in acute coronary syndromes.
PG  - 24-42
LID - 10.1177/1074248410381758 [doi]
AB  - Antiplatelet therapy is integral to the acute and long-term management of acute 
      coronary syndromes (ACSs) and for minimizing the thrombotic complications of 
      percutaneous coronary intervention (PCI). This article reviews the most commonly 
      used antiplatelet agents in ACS therapy--aspirin, adenosine diphosphate 
      (ADP)-receptor blockers, and glycoprotein IIb/IIIa inhibitors. More recent data 
      are also reviewed on novel ADP-receptor blockers and thrombin inhibitors before 
      addressing issues of adherence to antiplatelet regimens.
FAU - Aragam, Krishna G
AU  - Aragam KG
AD  - University of Michigan, Ann Arbor, MI, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20101005
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/therapy
MH  - Angioplasty/adverse effects
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Drug Interactions
MH  - Humans
MH  - Medication Adherence
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/administration & dosage/adverse 
      effects/antagonists & inhibitors
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/adverse 
      effects/therapeutic use
MH  - Thrombosis/etiology/prevention & control
EDAT- 2010/10/07 06:00
MHDA- 2011/05/21 06:00
CRDT- 2010/10/07 06:00
PHST- 2010/10/07 06:00 [entrez]
PHST- 2010/10/07 06:00 [pubmed]
PHST- 2011/05/21 06:00 [medline]
AID - 1074248410381758 [pii]
AID - 10.1177/1074248410381758 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2011 Mar;16(1):24-42. doi: 10.1177/1074248410381758. 
      Epub 2010 Oct 5.

PMID- 34728445
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20211214
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 11
IP  - 11
DP  - 2021 Nov 2
TI  - Effect of aspirin on HIV disease progression among HIV-infected individuals 
      initiating antiretroviral therapy: study protocol for a randomised controlled 
      trial.
PG  - e049330
LID - 10.1136/bmjopen-2021-049330 [doi]
LID - e049330
AB  - INTRODUCTION: An increase in cardiovascular disease (CVD) among people living 
      with HIV infection is linked to platelet and immune activation, a phenomenon 
      unabolished by antiretroviral (ARV) drugs alone. In small studies, aspirin 
      (acetylsalicylic acid [ASA]) has been shown to control immune activation, 
      increase CD4+ count, halt HIV disease progression and reduce HIV viral load 
      (HVL). We present a protocol for a larger ongoing randomised placebo controlled 
      trial on the effect of an addition of ASA to ARV drugs on HIV disease 
      progression. METHODS AND ANALYSIS: A single-centre phase IIA double-blind, 
      parallel-group randomised controlled trial intends to recruit 454 consenting ARV 
      drug-naïve, HIV-infected adults initiating ART. Participants are randomised in 
      blocks of 10 in a 1:1 ratio to receive, in addition to ARV drugs, 75 mg ASA or 
      placebo for 6 months. The primary outcome is the proportion of participants 
      attaining HVL of <50 copies/mL by 8, 12 and 24 weeks. Secondary outcomes include 
      proportions of participants with HVL of >1000 copies/mL at week 24, attaining a 
      >30% rise of CD4 count from baseline value at week 12, experiencing adverse 
      events, with normal levels of biomarkers of platelet and immune activation at 
      weeks 12 and 24 and rates of morbidity and all-cause mortality. 
      Intention-to-treat analysis will be done for all study outcomes. ETHICS AND 
      DISSEMINATION: Ethical approval has been obtained from institutional and national 
      ethics review committees. Findings will be submitted to peer-reviewed journals 
      and presented in scientific conferences. TRIAL REGISTRATION NUMBER: 
      PACTR202003522049711.
CI  - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mwakyandile, Tosi
AU  - Mwakyandile T
AUID- ORCID: 0000-0002-5073-1923
AD  - Department of Clinical Pharmacology, Muhimbili University of Health and Allied 
      Sciences, Dar es Salaam, Tanzania tosimwakys@gmail.com.
FAU - Shayo, Grace
AU  - Shayo G
AD  - Department of Internal Medicine, Muhimbili University of Health and Allied 
      Sciences, Dar es Salaam, Tanzania.
FAU - Mugusi, Sabina
AU  - Mugusi S
AD  - Department of Clinical Pharmacology, Muhimbili University of Health and Allied 
      Sciences, Dar es Salaam, Tanzania.
FAU - Sunguya, Bruno
AU  - Sunguya B
AUID- ORCID: 0000-0003-3625-0725
AD  - Department of Community Health, Muhimbili University of Health and Allied 
      Sciences, Dar es Salaam, Dar es Salaam, Tanzania.
FAU - Sasi, Philip
AU  - Sasi P
AD  - Department of Clinical Pharmacology, Muhimbili University of Health and Allied 
      Sciences, Dar es Salaam, Tanzania.
FAU - Moshiro, Candida
AU  - Moshiro C
AD  - Department of Epidemiology and Biostatistics, Muhimbili University of Health and 
      Allied Sciences, Dar es Salaam, Tanzania.
FAU - Mugusi, Ferdinand
AU  - Mugusi F
AD  - Department of Internal Medicine, Muhimbili University of Health and Allied 
      Sciences, Dar es Salaam, Tanzania.
FAU - Lyamuya, Eligius
AU  - Lyamuya E
AD  - Department of Microbiology and Immunology, Muhimbili University of Health and 
      Allied Sciences, Dar es Salaam, Tanzania.
LA  - eng
GR  - D43 TW009775/TW/FIC NIH HHS/United States
GR  - R25 TW011227/TW/FIC NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20211102
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Retroviral Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Retroviral Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - CD4 Lymphocyte Count
MH  - Disease Progression
MH  - *HIV Infections/drug therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
PMC - PMC8565540
OTO - NOTNLM
OT  - HIV & AIDS
OT  - clinical pharmacology
OT  - coronary heart disease
OT  - general medicine (see internal medicine)
OT  - immunology
OT  - infectious diseases
COIS- Competing interests: None declared.
EDAT- 2021/11/04 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/11/03 05:57
PHST- 2021/11/03 05:57 [entrez]
PHST- 2021/11/04 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - bmjopen-2021-049330 [pii]
AID - 10.1136/bmjopen-2021-049330 [doi]
PST - epublish
SO  - BMJ Open. 2021 Nov 2;11(11):e049330. doi: 10.1136/bmjopen-2021-049330.

PMID- 8957433
OWN - NLM
STAT- MEDLINE
DCOM- 19970109
LR  - 20220317
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 62
IP  - 6
DP  - 1996 Dec
TI  - Hemorrhage and the use of blood products after adult cardiac operations: myths 
      and realities.
PG  - 1908-17
AB  - BACKGROUND: Several patient-, procedure-, and prescriber-related factors are 
      thought to influence the decision to administer allogeneic blood products. We 
      reexamine a number of assertions applied commonly to the practice of transfusion 
      in cardiac operations. METHODS: More than 50 original articles including a total 
      of more than 10,000 patients from 70 centers were reviewed. Data from 5,426 
      patients operated on between 1990 and 1994 at the Montreal Heart Institute are 
      presented. RESULTS: From our review of the literature, we conclude that 
      postoperative mediastinal fluid drainage averages 917 mL and that aspirin therapy 
      increases drainage by less than 300 mL in most studies, which should not increase 
      use of blood products, insofar as a strict transfusional protocol is adhered to. 
      Across centers, transfusions can vary eightfold for the same postoperative 
      drainage. Data from our institution show that postoperative mediastinal drainage 
      per se is not influenced by reoperation or by the type of operation. However, 
      total blood losses and transfusion requirements remain increased in reoperative 
      and complex procedures. Excessive mediastinal drainage resulting in increased 
      transfusions occurs in 29% of patients. CONCLUSIONS: Exposure to allogeneic 
      transfusions remains institution dependent. Constant reevaluation of local 
      practice is essential to implement efficient blood conservation strategies.
FAU - Bélisle, S
AU  - Bélisle S
AD  - Department of Anesthesia, Montreal Heart Institute, Quebec, Canada.
FAU - Hardy, J F
AU  - Hardy JF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects
MH  - *Blood Loss, Surgical/prevention & control
MH  - *Blood Transfusion/statistics & numerical data
MH  - *Cardiac Surgical Procedures
MH  - Drainage
MH  - Humans
MH  - Mediastinum
MH  - Postoperative Care
MH  - Postoperative Hemorrhage/etiology/*therapy
MH  - Reoperation
RF  - 63
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - S0003-4975(96)00944-7 [pii]
AID - 10.1016/s0003-4975(96)00944-7 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1996 Dec;62(6):1908-17. doi: 10.1016/s0003-4975(96)00944-7.

PMID- 2785409
OWN - NLM
STAT- MEDLINE
DCOM- 19890613
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 73
IP  - 6
DP  - 1989 May 1
TI  - Supranormal von Willebrand factor multimers in scleroderma.
PG  - 1586-91
AB  - Platelet adhesion-aggregation reactions play an early and pivotal role in the 
      pathogenesis of systemic sclerosis in scleroderma, but the mechanisms are 
      incompletely understood. We determined whether or not plasma from 11 consecutive 
      patients with scleroderma contained a subset of larger than normal 
      ("supranormal") multimers of von Willebrand factor (vWF) that are potent inducers 
      of platelet aggregation and adhesion. Supranormal multimers were found in all 
      patients on at least one of two different occasions 9 to 12 months apart, 
      whatever the duration and severity of the disease, but in none of the normal 
      controls. Administration of low-dose aspirin (40 mg) to five of the 11 patients 
      for ten days to inhibit the platelet release reaction slightly reduced the 
      amounts of supranormal multimers suggesting that they might originate in part 
      from platelets. Supranormal multimers may contribute to the pathogenesis of 
      systemic sclerosis by inducing platelet aggregation and enhancing adhesion to 
      subendothelium under the conditions of elevated shear stress occurring in the 
      partially occluded vessels of the arterial microcirculation of scleroderma.
FAU - Mannucci, P M
AU  - Mannucci PM
AD  - Angelo Bianchi Bonomi Hemophilia, University of Milano, Italy.
FAU - Lombardi, R
AU  - Lombardi R
FAU - Lattuada, A
AU  - Lattuada A
FAU - Perticucci, E
AU  - Perticucci E
FAU - Valsecchi, R
AU  - Valsecchi R
FAU - Remuzzi, G
AU  - Remuzzi G
LA  - eng
GR  - 1R01 HL41136-01/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Macromolecular Substances)
RN  - 0 (von Willebrand Factor)
RN  - 1404-55-3 (Ristocetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Macromolecular Substances
MH  - Male
MH  - Middle Aged
MH  - Molecular Weight
MH  - Ristocetin/blood
MH  - Scleroderma, Systemic/drug therapy/*metabolism
MH  - von Willebrand Factor/*metabolism
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
AID - S0006-4971(20)78961-5 [pii]
PST - ppublish
SO  - Blood. 1989 May 1;73(6):1586-91.

PMID- 20107294
OWN - NLM
STAT- MEDLINE
DCOM- 20100225
LR  - 20151119
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 122
IP  - 1
DP  - 2010 Jan
TI  - Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online 
      questionnaire in Asia-Pacific.
PG  - 108-17
LID - 10.3810/pgm.2010.01.2104 [doi]
AB  - Mortality from cardiovascular diseases, such as myocardial infarction (MI), is 
      predicted to increase dramatically in Asia-Pacific countries. However, there are 
      few studies that estimate utilization of prophylactics, such as low-dose aspirin, 
      in these countries. To determine this, an online survey was sent to physicians in 
      18 countries worldwide, and this article reports the findings from the 
      Asia-Pacific region (N = 4372 respondents). The overall mean number of MI 
      patients per respondent was 246 in the Asia-Pacific countries, and 55% of 
      physicians (overall) rated their patient as having total compliance with aspirin. 
      The use of aspirin monotherapy or combination therapy, aspirin dosage, and 
      physician contact were all found to have a significant impact on compliance (all 
      P < 0.00001). Educational material on the role of aspirin was ranked as the most 
      effective measure to improve compliance. In conclusion, this survey indicates 
      that educational initiatives on secondary prevention are urgently needed in 
      Asia-Pacific countries.
FAU - Zaninelli, Augusto
AU  - Zaninelli A
AD  - University of Florence, School of Medicine, Florence, Italy. zaninelli@interac.it
FAU - Hu, Da-Yi
AU  - Hu DY
FAU - Kaufholz, Carola
AU  - Kaufholz C
FAU - Schwappach, David
AU  - Schwappach D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Asia
MH  - Aspirin/*therapeutic use
MH  - *Attitude of Health Personnel
MH  - Health Care Surveys
MH  - Humans
MH  - Internet
MH  - Middle East
MH  - Myocardial Infarction/*prevention & control
MH  - Pacific Ocean
MH  - *Physicians
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Practice Patterns, Physicians'
MH  - Surveys and Questionnaires
EDAT- 2010/01/29 06:00
MHDA- 2010/02/26 06:00
CRDT- 2010/01/29 06:00
PHST- 2010/01/29 06:00 [entrez]
PHST- 2010/01/29 06:00 [pubmed]
PHST- 2010/02/26 06:00 [medline]
AID - 10.3810/pgm.2010.01.2104 [doi]
PST - ppublish
SO  - Postgrad Med. 2010 Jan;122(1):108-17. doi: 10.3810/pgm.2010.01.2104.

PMID- 1669520
OWN - NLM
STAT- MEDLINE
DCOM- 19940203
LR  - 20191021
IS  - 1047-2797 (Print)
IS  - 1047-2797 (Linking)
VI  - 1
IP  - 5
DP  - 1991 Aug
TI  - Issues in the early termination of the aspirin component of the Physicians' 
      Health Study. Data Monitoring Board of the Physicians' Health Study.
PG  - 395-405
AB  - The Physicians' Health Study is a randomized, double-blind, placebo-controlled 
      prevention trial of 22,071 US physicians, using a factorial design to evaluate 
      the role of aspirin in the prevention of cardiovascular mortality and beta 
      carotene in the reduction of cancer incidence. After approximately 5 years of 
      follow-up, the aspirin component was terminated, 3 years ahead of schedule. 
      Several factors were considered in the decision to terminate, including a 
      cardiovascular mortality rate markedly lower than expected in both aspirin and 
      placebo subjects, precluding the evaluation of the primary aspirin hypothesis, 
      and a highly significant (P < .00001) and impressive (44%) reduction in the risk 
      of first myocardial infarction in the aspirin group. Issues in the decision to 
      terminate are described in this report.
FAU - Cairns, J
AU  - Cairns J
AD  - Harvard School of Public Health, Boston, MA.
FAU - Cohen, L
AU  - Cohen L
FAU - Colton, T
AU  - Colton T
FAU - DeMets, D L
AU  - DeMets DL
FAU - Deykin, D
AU  - Deykin D
FAU - Friedman, L
AU  - Friedman L
FAU - Greenwald, P
AU  - Greenwald P
FAU - Hutchison, G B
AU  - Hutchison GB
FAU - Rosner, B
AU  - Rosner B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Ann Epidemiol
JT  - Annals of epidemiology
JID - 9100013
RN  - 01YAE03M7J (beta Carotene)
RN  - 36-88-4 (Carotenoids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Carotenoids/*therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/mortality/*prevention & control
MH  - *Physicians
MH  - beta Carotene
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
AID - 1047-2797(91)90009-2 [pii]
AID - 10.1016/1047-2797(91)90009-2 [doi]
PST - ppublish
SO  - Ann Epidemiol. 1991 Aug;1(5):395-405. doi: 10.1016/1047-2797(91)90009-2.

PMID- 2764343
OWN - NLM
STAT- MEDLINE
DCOM- 19890915
LR  - 20131121
IS  - 0002-9645 (Print)
IS  - 0002-9645 (Linking)
VI  - 50
IP  - 6
DP  - 1989 Jun
TI  - Failure of aspirin to impair bovine platelet function.
PG  - 919-22
AB  - The effect of aspirin on bovine platelet function and thromboxane A2 (TXA2) 
      production in stimulated platelets was evaluated. A single dose of aspirin (100 
      mg/kg of body weight) was administered orally to Holstein cows, and blood samples 
      were obtained before and at regular intervals for 7 days after treatment. The 
      production of TXA2 was assessed by measuring the stable metabolite thromboxane 
      B2, using a specific radioimmunoassay. Within 4 hours of aspirin administration, 
      the production of TXA2 was significantly (P less than 0.05) decreased, 
      irrespective of whether collagen, adenosine diphosphate, or platelet activating 
      factor was used to initiate platelet aggregation. Despite the inhibition of TXA2 
      release from the stimulated platelets, platelet function, assessed by initial 
      rate of aggregate formation and extent of aggregation, was unaffected by aspirin 
      administration. The extent of aggregate formation in response to collagen, 
      adenosine diphosphate, or platelet activating factor was independent of the 
      amount of TXA2 released from platelets before and after aspirin treatment. The 
      results suggested that TXA2 formation is not the primary biochemical pathway 
      involved in the aggregation of stimulated bovine platelets.
FAU - Gentry, P A
AU  - Gentry PA
AD  - Department of Biomedical Studies, Ontario Veterinary College, Guelph, Ontario.
FAU - Tremblay, R R
AU  - Tremblay RR
FAU - Ross, M L
AU  - Ross ML
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cattle/*blood
MH  - Female
MH  - Platelet Aggregation/*drug effects
MH  - Thromboxane A2/analysis/*biosynthesis
MH  - Time Factors
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
PST - ppublish
SO  - Am J Vet Res. 1989 Jun;50(6):919-22.

PMID- 32114852
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
VI  - 75
IP  - 4
DP  - 2020 Apr
TI  - Clinical Influence of Nonadherence With Prophylactic Aspirin in Preventing 
      Preeclampsia in High-Risk Pregnancies: A Multicenter, Prospective, Observational 
      Cohort Study.
PG  - 1125-1132
LID - 10.1161/HYPERTENSIONAHA.119.14107 [doi]
AB  - Aspirin nonadherence and its associated increase in cardiovascular and 
      cerebrovascular events is well described; however, the prevalence of aspirin 
      nonadherence among high-risk pregnant women at risk of preeclampsia and its 
      influence on clinical outcomes remains unclear. Our study examined the prevalence 
      of aspirin nonadherence and resistance among high-risk pregnant women 
      quantitatively (platelet function analyzer 100 and plasma salicylic acid) and 
      clinical outcomes relative to adherence. High-risk pregnant women were recruited 
      across 3 centers in the South West Sydney Local Health District. Simultaneous 
      clinic data, blood sample, and self-reported adherence assessment were 
      prospectively collected at 4-week intervals from 12 to 36 weeks of gestation. 
      Nonadherence was defined as normal platelet function analyzer 100 and 
      nondetectable plasma salicylic acid in <90% of time points. Value of <90% is 
      based on current data. Two hundred twenty women were recruited over 25 months. No 
      woman was aspirin resistant, and 63 (44%) women demonstrated inadequate 
      adherence. Women with inadequate adherence had higher incidence of early-onset 
      preeclampsia (17% versus 2%; odds ratio [OR], 1.9 [95% CI, 1.1-8.7]; P=0.04), 
      late-onset preeclampsia (41% versus 5%; OR, 4.2 [95% CI, 1.4-19.8]; P=0.04), 
      intrauterine growth restriction (29% versus 5%; OR, 5.8; [95% CI, 1.2-8.3]; 
      P=0.001), preterm delivery (27% versus 10%; OR, 5.2 [95% CI, 1.5-8.7]; P=0.008), 
      and higher likelihood of increase in antihypertensives antenatally (60% versus 
      10%; OR, 4.6 [95% CI, 1.2-10.5]; P=0.003). Kaplan-Meier analysis demonstrated 
      lower incidence of premature delivery in the ≥90% adherent group (HR, 0.3 [95% 
      CI, 0.2-0.5]; P<0.001).Kappa coefficient agreement between qualitative and 
      quantitative assessment of adherence was moderate (κ=0.48; SE=0.029; P<0.0001). 
      Our data demonstrates that aspirin is an effective prophylactic agent with an 
      absolute risk reduction of 51% (number needed to treat, 2) when adherence is 
      ≥90%, compared with women with inadequate adherence. Women who were <90% adherent 
      had higher rates of preeclampsia, intrauterine growth restriction, preterm 
      delivery, and increase in antenatal antihypertensive requirements. Self-reported 
      adherence does not accurately reflect actual adherence.
FAU - Shanmugalingam, Renuka
AU  - Shanmugalingam R
AD  - From the Department of Renal Medicine (R.S., A.H., A.M.), South Western Sydney 
      Local Health District, NSW, Australia.
AD  - Women's Health Initiative Translational Unit, Ingham Institute For Applied 
      Medical Research (R.S., P.M., G.L., A.H., A.M.), South Western Sydney Local 
      Health District, NSW, Australia.
AD  - School of Medicine, Western Sydney University, NSW, Australia (R.S., A.H., A.M.).
AD  - Vascular Immunology Research Group, Heart Research Institute (R.S., A.H., A.M.).
FAU - Wang, XiaoSuo
AU  - Wang X
AD  - Bosch Mass Spectrometry Facility, Bosch Institute (X.W.), University of Sydney, 
      NSW, Australia.
FAU - Motum, Penelope
AU  - Motum P
AD  - Women's Health Initiative Translational Unit, Ingham Institute For Applied 
      Medical Research (R.S., P.M., G.L., A.H., A.M.), South Western Sydney Local 
      Health District, NSW, Australia.
AD  - Department of Haematology (P.M.), South Western Sydney Local Health District, 
      NSW, Australia.
FAU - Fulcher, Ian
AU  - Fulcher I
AD  - Department of Obstetrics and Gynaecology (I.F., G.L., R.K.), South Western Sydney 
      Local Health District, NSW, Australia.
FAU - Lee, Gaksoo
AU  - Lee G
AD  - Women's Health Initiative Translational Unit, Ingham Institute For Applied 
      Medical Research (R.S., P.M., G.L., A.H., A.M.), South Western Sydney Local 
      Health District, NSW, Australia.
AD  - Department of Obstetrics and Gynaecology (I.F., G.L., R.K.), South Western Sydney 
      Local Health District, NSW, Australia.
FAU - Kumar, Roshika
AU  - Kumar R
AD  - Department of Obstetrics and Gynaecology (I.F., G.L., R.K.), South Western Sydney 
      Local Health District, NSW, Australia.
FAU - Hennessy, Annemarie
AU  - Hennessy A
AD  - From the Department of Renal Medicine (R.S., A.H., A.M.), South Western Sydney 
      Local Health District, NSW, Australia.
AD  - Women's Health Initiative Translational Unit, Ingham Institute For Applied 
      Medical Research (R.S., P.M., G.L., A.H., A.M.), South Western Sydney Local 
      Health District, NSW, Australia.
AD  - School of Medicine, Western Sydney University, NSW, Australia (R.S., A.H., A.M.).
AD  - Vascular Immunology Research Group, Heart Research Institute (R.S., A.H., A.M.).
FAU - Makris, Angela
AU  - Makris A
AD  - From the Department of Renal Medicine (R.S., A.H., A.M.), South Western Sydney 
      Local Health District, NSW, Australia.
AD  - Women's Health Initiative Translational Unit, Ingham Institute For Applied 
      Medical Research (R.S., P.M., G.L., A.H., A.M.), South Western Sydney Local 
      Health District, NSW, Australia.
AD  - School of Medicine, Western Sydney University, NSW, Australia (R.S., A.H., A.M.).
AD  - Vascular Immunology Research Group, Heart Research Institute (R.S., A.H., A.M.).
AD  - South Western Sydney Clinical School, University of New South Wales, Australia 
      (A.M.).
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200302
PL  - United States
TA  - Hypertension
JT  - Hypertension (Dallas, Tex. : 1979)
JID - 7906255
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Hypertension. 2020 Apr;75(4):941-942. PMID: 32114845
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Incidence
MH  - *Medication Adherence
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Prospective Studies
MH  - Self Report
OTO - NOTNLM
OT  - aspirin
OT  - humans
OT  - preeclampsia
OT  - records
OT  - self-report
EDAT- 2020/03/03 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/03/03 06:00
PHST- 2020/03/03 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
PHST- 2020/03/03 06:00 [entrez]
AID - 10.1161/HYPERTENSIONAHA.119.14107 [doi]
PST - ppublish
SO  - Hypertension. 2020 Apr;75(4):1125-1132. doi: 10.1161/HYPERTENSIONAHA.119.14107. 
      Epub 2020 Mar 2.

PMID- 32558306
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep
TI  - Complete endoscopic sinus surgery followed by aspirin desensitization is 
      associated with decreased overall corticosteroid use.
PG  - 1043-1048
LID - 10.1002/alr.22604 [doi]
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is an aggressive 
      respiratory tract inflammatory disorder manifesting as asthma, chronic 
      rhinosinusitis with nasal polyposis, and a respiratory sensitivity to aspirin and 
      nonsteroidal anti-inflammatory drugs (NSAIDs). Corticosteroids, both systemic and 
      topical/inhaled, are used to treat inflammation of the upper and lower airways. 
      Our objective was to examine the potential impact of complete endoscopic sinus 
      surgery (ESS) and aspirin desensitization (AD) on short-term and long-term 
      corticosteroid use. METHODS: For this pilot study, a retrospective chart review 
      of all patients with AERD who underwent ESS followed by AD was performed. Daily 
      prednisone use, average daily prednisone dose, and inhaled corticosteroid use 
      were analyzed at the following time points: preoperative, postoperative/pre-AD, 
      and 2 to 3 months, 4 to 6 months, 7 to 12 months, and 13 to 24 months following 
      AD. RESULTS: A total of 125 patients underwent ESS followed by AD. Compared to 
      preoperatively, patients who underwent ESS and AD were less likely to be on daily 
      prednisone at all time points and upon long-term follow-up (32% preoperatively vs 
      10% at 13 to 24 months, McNemar's test = 9.00, p = 0.009). Average daily 
      prednisone dose decreased from 10.6 ± 7.9 mg preoperatively to 3.8 ± 2.6 mg at 13 
      to 24 months following AD (Mann-Whitney U; W = 122, p = 0.01). Similarly, 
      high-dose and medium-dose inhaled corticosteroid use decreased from 18% to 7% and 
      from 36% to 22% respectively (Pearson's chi-square = 8.06, p = 0.05). CONCLUSION: 
      In our AERD cohort who underwent ESS followed by AD, there was an observed 
      decrease in overall systemic and topical/inhaled corticosteroid use. These 
      findings can have implications for treatment given the potentially hazardous side 
      effects of corticosteroid use.
CI  - © 2020 ARS-AAOA, LLC.
FAU - Bosso, John V
AU  - Bosso JV
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Locke, Tran B
AU  - Locke TB
AUID- ORCID: 0000-0002-3838-3890
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Kuan, Edward C
AU  - Kuan EC
AUID- ORCID: 0000-0003-3475-0718
AD  - Department of Otolaryngology-Head and Neck Surgery, University of California, 
      Irvine, Orange, CA.
FAU - Tripathi, Siddhant H
AU  - Tripathi SH
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Ig-Izevbekhai, Kevin I
AU  - Ig-Izevbekhai KI
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Kalaf, Laila T
AU  - Kalaf LT
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Kohanski, Michael A
AU  - Kohanski MA
AUID- ORCID: 0000-0001-8399-364X
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Palmer, James N
AU  - Palmer JN
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Adappa, Nithin D
AU  - Adappa ND
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Pennsylvania, 
      Philadelphia, PA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200618
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/adverse effects
MH  - *Asthma, Aspirin-Induced
MH  - Desensitization, Immunologic
MH  - Humans
MH  - *Nasal Polyps/surgery
MH  - Pilot Projects
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin desensitization
OT  - aspirin-exacerbated respiratory disease
OT  - corticosteroids
OT  - endoscopic sinus surgery
OT  - nasal polyps
EDAT- 2020/06/20 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/08/06 00:00 [received]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1002/alr.22604 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2020 Sep;10(9):1043-1048. doi: 10.1002/alr.22604. Epub 
      2020 Jun 18.

PMID- 23796558
OWN - NLM
STAT- MEDLINE
DCOM- 20140526
LR  - 20131118
IS  - 1532-8406 (Electronic)
IS  - 0883-5403 (Linking)
VI  - 28
IP  - 10
DP  - 2013 Dec
TI  - DVT prophylaxis after TKA: routine anticoagulation vs risk screening approach - a 
      randomized study.
PG  - 1868-73
LID - S0883-5403(13)00405-1 [pii]
LID - 10.1016/j.arth.2013.05.025 [doi]
AB  - The American College of Chest Physicians (ACCP) recommended routine 
      anticoagulation for thromboprophylaxis in patients undergoing lower limb 
      arthroplasty. We compared results of routine anticoagulation Vs risk stratified 
      approach for Deep Venous Thrombosis (DVT) prophylaxis after TKA in terms of 
      symptomatic DVT and wound complications. Nine hundred TKAs done in 673 patients 
      were randomized after DVT risk screening to routine anticoagulation (n = 450) or 
      to risk stratification (n = 450) and selective anticoagulation. 194 patients in 
      the risk screening group received only Aspirin. Primary outcome was symptomatic 
      DVT and wound complication. This randomized study showed that the symptomatic DVT 
      rates after TKA were similar whether patients were routinely anticoagulated or 
      selectively anticoagulated after risk screening. However there was a 
      significantly higher incidence of wound complications (P < 0.014) after routine 
      anticoagulation.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Kulshrestha, Vikas
AU  - Kulshrestha V
AD  - Joint Replacement Centre, Army Hospital R & R, New Delhi.
FAU - Kumar, Santhosh
AU  - Kumar S
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20130621
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Ann Intern Med. 2013 Dec 17;159(12):JC5. PMID: 24343410
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Arthritis/*surgery
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Aspirin/adverse effects/therapeutic use
MH  - Chemoprevention
MH  - Female
MH  - Hematoma/etiology
MH  - Heparin, Low-Molecular-Weight/adverse effects/therapeutic use
MH  - Humans
MH  - Knee Joint/surgery
MH  - Male
MH  - *Mass Screening
MH  - Middle Aged
MH  - Risk Assessment
MH  - Risk Factors
MH  - Surgical Wound Dehiscence/etiology
MH  - Surgical Wound Infection/etiology
MH  - Venous Thrombosis/diagnosis/etiology/*prevention & control
OTO - NOTNLM
OT  - DVT
OT  - TKA
OT  - anticoagulation
OT  - aspirin
OT  - wound complication
EDAT- 2013/06/26 06:00
MHDA- 2014/05/27 06:00
CRDT- 2013/06/26 06:00
PHST- 2013/04/08 00:00 [received]
PHST- 2013/05/03 00:00 [revised]
PHST- 2013/05/20 00:00 [accepted]
PHST- 2013/06/26 06:00 [entrez]
PHST- 2013/06/26 06:00 [pubmed]
PHST- 2014/05/27 06:00 [medline]
AID - S0883-5403(13)00405-1 [pii]
AID - 10.1016/j.arth.2013.05.025 [doi]
PST - ppublish
SO  - J Arthroplasty. 2013 Dec;28(10):1868-73. doi: 10.1016/j.arth.2013.05.025. Epub 
      2013 Jun 21.

PMID- 33258764
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20211012
IS  - 2639-9636 (Print)
IS  - 2639-9636 (Linking)
VI  - 35
IP  - 12
DP  - 2020 Dec 1
TI  - Rates and Predictors of Physician-Recommended and Self-Reported Aspirin Use in 
      2015.
PG  - 556-565
LID - 10.4140/TCP.n.2020.556 [doi]
AB  - OBJECTIVE: This study assesses the rate of providerrecommended aspirin use 
      through the National Ambulatory Medical Care Survey (NAMCS) database versus 
      self-reported aspirin use through the Behavioral Risk Factor Surveillance System 
      (BRFSS) database and identifies factors that predict initiation of aspirin. This 
      study provides insight into the rate of providerrecommended aspirin use versus 
      self-reported aspirin use prior to the 2016 United States Preventive Service Task 
      Force primary prevention recommendation update.<br/> DESIGN: Retrospective, 
      cross-sectional analysis of US population data obtained from medical records 
      (NAMCS) and community-dwelling residents in four states (BRFSS) in 2015.<br/> 
      SETTING: Physician offices (NAMCS) and households or telephone (BRFSS).<br/> 
      PATIENTS, PARTICIPANTS: NAMCS: visits made by patients 40 years of age or older 
      to physicians who permitted federal employees to abstract officevisit data. 
      BRFSS: household or telephone interview respondents 40 years of age or 
      older.<br/> INTERVENTIONS: Comparisons of persons with (secondary prevention) 
      versus without (primary prevention) cardiovascular disease.<br/> MAIN OUTCOME 
      MEASURED: Recommended (NAMCS) or self-reported (BRFSS) use of aspirin.<br/> 
      RESULTS: The sample included 19 170 patients (NAMCS), with 2 205 having a history 
      of cardiovascular disease and 14 872 respondents (BRFSS) with 2 024 having a 
      history of cardiovascular disease. For both primary and secondary prevention, 
      respondents from BRFSS reported higher rates of aspirin use (27.7% primary, 65.6% 
      secondary prevention) compared with prescribed rates from NAMCS (11.7% primary, 
      45.6% secondary prevention).<br/> CONCLUSIONS: Study results highlight the value 
      of obtaining a complete medication history, including aspirin use, from all 
      patients.
FAU - Naberhaus, Taylor
AU  - Naberhaus T
FAU - Early, Nicole K
AU  - Early NK
FAU - Fairman, Kathleen A
AU  - Fairman KA
FAU - Buckley, Kelsey
AU  - Buckley K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Sr Care Pharm
JT  - The Senior care pharmacist
JID - 101737969
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Middle Aged
MH  - Nonprescription Drugs/*administration & dosage
MH  - *Physicians
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Prescriptions/*statistics & numerical data
MH  - Retrospective Studies
MH  - Self Report/*statistics & numerical data
MH  - United States
EDAT- 2020/12/02 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/01 12:27
PHST- 2020/12/01 12:27 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.4140/TCP.n.2020.556 [doi]
PST - ppublish
SO  - Sr Care Pharm. 2020 Dec 1;35(12):556-565. doi: 10.4140/TCP.n.2020.556.

PMID- 8924310
OWN - NLM
STAT- MEDLINE
DCOM- 19961101
LR  - 20190909
IS  - 1034-4810 (Print)
IS  - 1034-4810 (Linking)
VI  - 31
IP  - 6
DP  - 1995 Dec
TI  - Neonatal outcome in a randomized, controlled trial of low-dose aspirin in 
      high-risk pregnancies.
PG  - 549-52
AB  - OBJECTIVE: To determine the value of low-dose aspirin in high-risk pregnancies, 
      and assess its impact on fetal growth, as well as on perinatal mortality and 
      morbidity. METHODOLOGY: One hundred and eight women with singleton pregnancies 
      were enrolled in a randomized, double-blind, placebo-controlled trial of 100 
      mg/day aspirin from 17 to 19 week gestation. Enrolment criteria included 
      pre-existing chronic essential hypertension or renal disease, or a history of 
      previous early, severe pre-eclampsia. RESULTS: There were four stillbirths (all 
      aspirin) and two neonatal deaths (both placebo), to yield respective perinatal 
      mortality rates of 69/1000 and 40/1000 (P = 0.499). Liveborn infants in the 
      aspirin group were significantly more mature (P = 0.017) and of heavier 
      birthweight (P = 0.034) but had similar length (P = 0.091) and head circumference 
      (P = 0.257). Fewer infants in the aspirin group were liveborn prematurely (5/54 
      vs 14/50; P = 0.016) or were of low birthweight (3/54 vs 9/50; P = 0.052). There 
      were no significant between-group differences for standard deviation (Z) scores 
      for weight, length or head circumference, or for skinfold thickness measurements. 
      There was no significant difference in occurrence of low Apgar scores or in 
      neonatal intensive care unit use between the groups. CONCLUSIONS: Low-dose 
      aspirin does not appear to have a significant effect on perinatal morbidity. The 
      increase in weight at birth associated with low-dose aspirin therapy is due to 
      prolongation of pregnancy rather than prevention of intra-uterine growth 
      retardation.
FAU - Leslie, G I
AU  - Leslie GI
AD  - Department of Neonatology, Royal North Shore Hospital, St Leonards, New South 
      Wales, Australia.
FAU - Gallery, E D
AU  - Gallery ED
FAU - Arnold, J D
AU  - Arnold JD
FAU - Ross, M R
AU  - Ross MR
FAU - Gyory, A Z
AU  - Gyory AZ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Australia
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Chronic Disease
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Infant, Newborn
MH  - Kidney Diseases/*drug therapy
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*drug therapy
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - *Pregnancy Outcome
MH  - Pregnancy, High-Risk/*drug effects
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
AID - 10.1111/j.1440-1754.1995.tb00882.x [doi]
PST - ppublish
SO  - J Paediatr Child Health. 1995 Dec;31(6):549-52. doi: 
      10.1111/j.1440-1754.1995.tb00882.x.

PMID- 6374378
OWN - NLM
STAT- MEDLINE
DCOM- 19840709
LR  - 20190725
IS  - 0026-8925 (Print)
IS  - 0026-8925 (Linking)
VI  - 194
IP  - 1-2
DP  - 1984
TI  - Effect of aspirin on mitochondrial mutagens in Saccharomyces cerevisiae.
PG  - 299-302
AB  - The mitochondrial mutation petite was induced in yeast cells by ethidium bromide 
      (EB), Adriamycin (ADR) and 4-nitroquinoline-N-oxide (NQO). In the presence of 
      aspirin in concentrations ranging from 0.1 to 1.0 mg/ml, the mutagenicity of EB 
      and ADR was reversed but petite induction by NQO was unaffected. At these 
      concentrations, aspirin also reversed mitochondrial inhibition by oligomycin, a 
      non-mutagenic inhibitor of the organellar ATPase complex. Cells grown in the 
      presence of aspirin alone showed a significantly higher rate of oxygen uptake 
      than untreated control cultures when the drug concentration ranged from 0.05 to 
      1.0 mg/ml. At concentrations of 2 mg/ml and above, aspirin inhibited 
      mitochondrial respiration.
FAU - Bruce, I J
AU  - Bruce IJ
FAU - Wilkie, D
AU  - Wilkie D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Mol Gen Genet
JT  - Molecular & general genetics : MGG
JID - 0125036
RN  - 0 (DNA, Fungal)
RN  - 0 (DNA, Mitochondrial)
RN  - 0 (Mutagens)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - DNA, Fungal/*genetics
MH  - DNA, Mitochondrial/*genetics
MH  - Mitochondria/drug effects
MH  - Mutagenicity Tests
MH  - Mutagens/*pharmacology
MH  - *Mutation
MH  - Oxygen Consumption/drug effects
MH  - Saccharomyces cerevisiae/*drug effects/metabolism
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1007/BF00383531 [doi]
PST - ppublish
SO  - Mol Gen Genet. 1984;194(1-2):299-302. doi: 10.1007/BF00383531.

PMID- 33509351
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20210204
IS  - 1523-1755 (Electronic)
IS  - 0085-2538 (Linking)
VI  - 99
IP  - 2
DP  - 2021 Feb
TI  - "To take or not to take an aspirin?" The age-old question of cardiovascular 
      disease primary prevention for people with chronic kidney disease.
PG  - 308-310
LID - S0085-2538(20)31100-5 [pii]
LID - 10.1016/j.kint.2020.09.008 [doi]
AB  - Despite the higher risk of cardiovascular events in patients with chronic kidney 
      disease, the role of aspirin for primary prevention is unclear. In the current 
      issue, Wolfe et al. present a subgroup analysis of the ASPirin in Reducing Events 
      in the Elderly (ASPREE) trial that suggests there was no reduction in 
      cardiovascular events but bleeding events were doubled. Aspirin cannot be 
      recommended for primary prevention in chronic kidney disease, but the 
      continuation of ongoing research, such as the Aspirin To Target Arterial Events 
      in Chronic Kidney Disease (ATTACK trial), is warranted.
CI  - Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. 
      All rights reserved.
FAU - Major, Rupert W
AU  - Major RW
AD  - John Walls Renal Unit, University Hospitals of Leicester, Leicester General 
      Hospital, Leicester, UK; Department of Health Sciences, University of Leicester, 
      Leicester, UK. Electronic address: rwlm2@le.ac.uk.
FAU - Burton, James O
AU  - Burton JO
AD  - John Walls Renal Unit, University Hospitals of Leicester, Leicester General 
      Hospital, Leicester, UK; Department of Cardiovascular Sciences, University of 
      Leicester, Leicester, UK.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Kidney Int. 2021 Feb;99(2):466-474. PMID: 32920022
MH  - Aged
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/epidemiology/etiology/prevention & control
MH  - Hemorrhage
MH  - Humans
MH  - Primary Prevention
MH  - *Renal Insufficiency, Chronic/complications/diagnosis
EDAT- 2021/01/30 06:00
MHDA- 2021/02/05 06:00
CRDT- 2021/01/29 05:39
PHST- 2020/09/02 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2021/01/29 05:39 [entrez]
PHST- 2021/01/30 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
AID - S0085-2538(20)31100-5 [pii]
AID - 10.1016/j.kint.2020.09.008 [doi]
PST - ppublish
SO  - Kidney Int. 2021 Feb;99(2):308-310. doi: 10.1016/j.kint.2020.09.008.

PMID- 3931099
OWN - NLM
STAT- MEDLINE
DCOM- 19851119
LR  - 20191030
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 19
IP  - 2
DP  - 1985 Aug
TI  - Effect of aspirin on serum thrombin time and bleeding time.
PG  - 123-30
AB  - The present study describes and utilizes a novel method, the serum thrombin time 
      (STT), as a measure of the time for fibrin clot formation in serum following 
      addition of a supramaximal concentration of fibrinogen. The STT and bleeding time 
      (BT) are selectively prolonged in male subjects 2 hours and 24 hours after 
      ingestion of aspirin. In contrast, the STT is unchanged after aspirin ingestion 
      by female subjects. These data indicate that inhibition of cyclooxygenase product 
      formation by aspirin may alter the third stage of coagulation, specifically, 
      endogenous thrombin activity. Furthermore, the ability of aspirin to prolong the 
      STT appears to be sex-specific. Moreover, the STT may be a clinical reflection of 
      endogenous thrombin activity in vivo as well as in vitro and may be of clinical 
      value as a diagnostic probe in the assessment of medical and surgical disorders.
FAU - Philpot, V B
AU  - Philpot VB
FAU - Lippton, H L
AU  - Lippton HL
FAU - Kadowitz, P J
AU  - Kadowitz PJ
LA  - eng
GR  - HL18070/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - *Bleeding Time
MH  - Blood Coagulation/*drug effects
MH  - *Blood Coagulation Tests
MH  - Cyclooxygenase Inhibitors
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - *Platelet Function Tests
MH  - Sex Factors
MH  - Thrombin/metabolism
MH  - *Thrombin Time
EDAT- 1985/08/01 00:00
MHDA- 1985/08/01 00:01
CRDT- 1985/08/01 00:00
PHST- 1985/08/01 00:00 [pubmed]
PHST- 1985/08/01 00:01 [medline]
PHST- 1985/08/01 00:00 [entrez]
AID - 10.1016/0262-1746(85)90077-0 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1985 Aug;19(2):123-30. doi: 
      10.1016/0262-1746(85)90077-0.

PMID- 27561771
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20220318
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 68
IP  - 9
DP  - 2016 Aug 30
TI  - Aspirin and Cancer.
PG  - 967-76
LID - S0735-1097(16)33607-5 [pii]
LID - 10.1016/j.jacc.2016.05.083 [doi]
AB  - The place of aspirin in primary prevention remains controversial, with North 
      American and European organizations issuing contradictory treatment guidelines. 
      More recently, the U.S. Preventive Services Task Force recommended "initiating 
      low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) 
      and colorectal cancer in adults aged 50 to 59 years who have a 10% or greater 
      10-year CVD risk, are not at increased risk for bleeding, have a life expectancy 
      of at least 10 years, and are willing to take low-dose aspirin daily for at least 
      10 years." This recommendation reflects increasing evidence for a chemopreventive 
      effect of low-dose aspirin against colorectal (and other) cancer. The intent of 
      this paper is to review the evidence supporting a chemopreventive effect of 
      aspirin, discuss its potential mechanism(s) of action, and provide a conceptual 
      framework for assessing current guidelines in the light of ongoing studies.
CI  - Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Patrignani, Paola
AU  - Patrignani P
AD  - Department of Neuroscience, Imaging and Clinical Sciences and Center of 
      Excellence on Aging, "G. D'Annunzio" University School of Medicine, Chieti, 
      Italy.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. 
      Electronic address: carlo.patrono@rm.unicatt.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/prevention & control
MH  - Colorectal Neoplasms/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Practice Guidelines as Topic
MH  - Primary Prevention/*methods
OTO - NOTNLM
OT  - chemoprevention
OT  - colorectal neoplasms
OT  - cyclooxygenase-1
OT  - nonsteroidal anti-inflammatory agents
OT  - platelet activation
OT  - prostaglandins
EDAT- 2016/08/27 06:00
MHDA- 2017/07/01 06:00
CRDT- 2016/08/27 06:00
PHST- 2016/01/27 00:00 [received]
PHST- 2016/05/12 00:00 [revised]
PHST- 2016/05/18 00:00 [accepted]
PHST- 2016/08/27 06:00 [entrez]
PHST- 2016/08/27 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - S0735-1097(16)33607-5 [pii]
AID - 10.1016/j.jacc.2016.05.083 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2016 Aug 30;68(9):967-76. doi: 10.1016/j.jacc.2016.05.083.

PMID- 15742106
OWN - NLM
STAT- MEDLINE
DCOM- 20060104
LR  - 20181113
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 252
IP  - 3
DP  - 2005 Mar
TI  - Current treatments in neurology: stroke.
PG  - 260-7
AB  - There have been major advances in stroke treatment based on robust evidence from 
      large clinical trials. This review covers both acute treatment and secondary 
      prevention. Thrombolysis is now established as a therapy for ischaemic stroke 
      presenting within 3 hours, and the possibility of extending the time window and 
      refining the selection of suitable patients, is being addressed in further 
      trials. Anticoagulants are of proven benefit in cardioembolic stroke, and 
      particularly atrial fibrillation. For prevention of other stroke subtypes 
      antiplatelet agents appear to have a better risk-benefit ratio. Evidence for the 
      use of dual antiplatelet therapy, including the recent MATCH study, are 
      discussed. Carotid endarterectomy is of proven benefit in patients with>70% 
      symptomatic stenosis. Recent analysis has emphasised the importance of operating 
      as soon after symptom onset as possible. Operating on asymptomatic carotid 
      stenosis remains controversial; even after the recent Asymptomatic Carotid 
      Surgery Trial which showed that by operating on 32 people one disabling stroke or 
      death could be prevented over a 5 years period.
FAU - Markus, Hugh S
AU  - Markus HS
AD  - Clinical Neuroscience, St George's Hospital Medical School, Cranmer Terrace, 
      London SW17 0RE, UK. h.markus@sghms.ac.uk
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20050307
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (Neuroprotective Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Neurology
MH  - Neuroprotective Agents/therapeutic use
MH  - Neurosurgery/methods
MH  - Stents
MH  - Stroke/pathology/*therapy
MH  - Thrombolytic Therapy/methods
RF  - 43
EDAT- 2005/03/03 09:00
MHDA- 2006/01/05 09:00
CRDT- 2005/03/03 09:00
PHST- 2004/11/15 00:00 [received]
PHST- 2004/11/17 00:00 [accepted]
PHST- 2005/03/03 09:00 [pubmed]
PHST- 2006/01/05 09:00 [medline]
PHST- 2005/03/03 09:00 [entrez]
AID - 10.1007/s00415-005-0736-9 [doi]
PST - ppublish
SO  - J Neurol. 2005 Mar;252(3):260-7. doi: 10.1007/s00415-005-0736-9. Epub 2005 Mar 7.

PMID- 2903955
OWN - NLM
STAT- MEDLINE
DCOM- 19890105
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 2
IP  - 8622
DP  - 1988 Nov 26
TI  - Prevention of gallstone recurrence by non-steroidal anti-inflammatory drugs.
PG  - 1223-5
AB  - In laboratory animals, non-steroidal anti-inflammatory drugs (NSAIDs) are 
      reported to inhibit diet-induced gallstone formation. To see if these drugs had a 
      similar effect in man, 82 patients who had taken part in a comparison of 
      ursodeoxycholic acid, placebo, and diet for prevention of gallstone recurrence 
      were sent questionnaires about their use of NSAIDs during the period of the 
      trial. 75 replied. After a mean follow-up of 33 (SEM 4) months none of the 12 
      regular users of NSAIDs had had gallstone recurrences, compared with 20 of the 63 
      who never or rarely used these drugs (p less than 0.02).
FAU - Hood, K
AU  - Hood K
AD  - Gastroenterology Unit, UMDS of Guy's Hospital, London.
FAU - Gleeson, D
AU  - Gleeson D
FAU - Ruppin, D C
AU  - Ruppin DC
FAU - Dowling, R H
AU  - Dowling RH
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Cholelithiasis/*prevention & control
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Random Allocation
MH  - Recurrence
MH  - Retrospective Studies
EDAT- 1988/11/26 00:00
MHDA- 1988/11/26 00:01
CRDT- 1988/11/26 00:00
PHST- 1988/11/26 00:00 [pubmed]
PHST- 1988/11/26 00:01 [medline]
PHST- 1988/11/26 00:00 [entrez]
AID - S0140-6736(88)90812-4 [pii]
AID - 10.1016/s0140-6736(88)90812-4 [doi]
PST - ppublish
SO  - Lancet. 1988 Nov 26;2(8622):1223-5. doi: 10.1016/s0140-6736(88)90812-4.

PMID- 3423043
OWN - NLM
STAT- MEDLINE
DCOM- 19880203
LR  - 20131121
IS  - 0361-7742 (Print)
IS  - 0361-7742 (Linking)
VI  - 250
DP  - 1987
TI  - Prediction of patients with a high risk of coronary artery aneurysm in Kawasaki 
      disease: indication for immunoglobulin therapy.
PG  - 287-97
AB  - The prediction of the severity of Kawasaki disease in terms of coronary artery 
      disease is important for the evaluation of prognosis as well as for making 
      decisions on an appropriate form of treatment. Coronary artery lesions develop as 
      early as 8 days after onset of illness and immunoglobulin is known to be 
      ineffective in aneurysms which have already developed. Therefore, we advocate the 
      selection of suitable candidates for immunoglobulin therapy as early as possible 
      after disease onset. Our scoring system is composed of only 3 items which are 
      confined to the results of routine laboratory examinations, and it is desired to 
      be available for use by any hospital offering primary care for patients with 
      Kawasaki disease. However, such a simple procedure may be associated with a 
      reduced level of reliability for evaluation in clinical practice. Early and 
      simple, but reliable, predictors of coronary risk in Kawasaki disease should 
      therefore be further studied in order to reduce the morbidity and mortality 
      through appropriate treatment and care.
FAU - Nakano, H
AU  - Nakano H
AD  - Division of Pediatric Cardiology, Shizuoka Children's Hospital, Japan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prog Clin Biol Res
JT  - Progress in clinical and biological research
JID - 7605701
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Coronary Aneurysm/*etiology/therapy
MH  - Humans
MH  - *Immunization, Passive
MH  - Mucocutaneous Lymph Node Syndrome/*complications
MH  - Prognosis
MH  - Risk Factors
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Prog Clin Biol Res. 1987;250:287-97.

PMID- 6666232
OWN - NLM
STAT- MEDLINE
DCOM- 19840321
LR  - 20131121
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 72 Suppl 3
DP  - 1983
TI  - Coronary vasodilation by nitrates is not mediated by the prostaglandin system: an 
      angiographic and hemodynamic study.
PG  - 40-5
AB  - The possible role of prostaglandins in mediating coronary vasodilation by 
      nitrates was investigated in 13 patients. In nine patients (Group 1), the effects 
      of ISDN on coronary-artery diameter and (in four of the nine) coronary sinus flow 
      before and after administration of ASA were compared. In four additional patients 
      (Group 2) the first ISDN administration was omitted in order to investigate the 
      effect of ASA on resting coronary artery tone. Dosages used were 3 mg 
      intracoronary ISDN and 1.0 g intravenous and 100 mg intracoronary ASA. Coronary 
      artery diameter was analyzed by means of quantitative magnification coronary 
      angiography. Coronary sinus flow was investigated by means of coronary sinus 
      thermodilution. ASA was not able to induce significant changes in coronary artery 
      diameter when injected before administration of ISDN or to prevent ISDN-induced 
      vasodilation. At the coronary resistance level, ASA was not able to prevent the 
      relative vasodilation induced by ISDN. It is concluded that coronary vasodilation 
      by nitrates is not mediated by the prostaglandin system.
FAU - Simonetti, I
AU  - Simonetti I
FAU - de Caterina, R
AU  - de Caterina R
FAU - Marzilli, M
AU  - Marzilli M
FAU - de Nes, M
AU  - de Nes M
FAU - L'Abbate, A
AU  - L'Abbate A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - 0 (Nitrates)
RN  - 0 (Prostaglandins)
RN  - 0 (Vasodilator Agents)
RN  - IA7306519N (Isosorbide Dinitrate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Coronary Angiography
MH  - Coronary Vessels/*drug effects
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Isosorbide Dinitrate/pharmacology
MH  - Nitrates/*pharmacology
MH  - Prostaglandins/*physiology
MH  - Vasodilator Agents/*pharmacology
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Kardiol. 1983;72 Suppl 3:40-5.

PMID- 2015724
OWN - NLM
STAT- MEDLINE
DCOM- 19910522
LR  - 20190510
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 49
IP  - 4
DP  - 1991 Apr
TI  - Central analgesic effect of acetaminophen but not of aspirin.
PG  - 350-4
AB  - The central nervous system effect of acetaminophen (paracetamol) and 
      acetylsalicylic acid was investigated in healthy volunteers according to a 
      crossover, double-blind, and placebo-controlled design. Ten subjects received, by 
      intravenous route, a placebo, 1 gm acetaminophen, and 1 gm acetylsalicylic acid. 
      Analgesia was assessed by measurement of the subjective pain threshold and the 
      objective nociceptive flexion reflex threshold in response to selective 
      transcutaneous electrical stimulations. A close correlation was observed between 
      subjective and objective pain thresholds. Acetaminophen increased both thresholds 
      for more than 4 hours (24% and 23% of baseline value at 120 minutes, 
      respectively; p less than 0.001, ANOVA). In contrast, acetylsalicylic acid had no 
      noticeable effect on either threshold. These findings show that 
      acetaminophen-induced analgesia is centrally mediated, in contrast to aspirin. 
      The time delay between plasma concentration kinetics and acetaminophen analgesic 
      effect is another argument in favor of its direct action on the central nervous 
      system.
FAU - Piletta, P
AU  - Piletta P
AD  - Department of Medicine, University Hospital, Geneva, Switzerland.
FAU - Porchet, H C
AU  - Porchet HC
FAU - Dayer, P
AU  - Dayer P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/blood/*pharmacology
MH  - Adult
MH  - *Analgesia
MH  - Aspirin/*pharmacology
MH  - Double-Blind Method
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Pain Measurement
MH  - Random Allocation
MH  - Transcutaneous Electric Nerve Stimulation
EDAT- 1991/04/01 00:00
MHDA- 1991/04/01 00:01
CRDT- 1991/04/01 00:00
PHST- 1991/04/01 00:00 [pubmed]
PHST- 1991/04/01 00:01 [medline]
PHST- 1991/04/01 00:00 [entrez]
AID - 10.1038/clpt.1991.40 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1991 Apr;49(4):350-4. doi: 10.1038/clpt.1991.40.

PMID- 31696583
OWN - NLM
STAT- MEDLINE
DCOM- 20201230
LR  - 20201230
IS  - 1600-0897 (Electronic)
IS  - 1046-7408 (Linking)
VI  - 83
IP  - 2
DP  - 2020 Feb
TI  - Role of aspirin-triggered lipoxin A4, aspirin, and salicylic acid in the 
      modulation of the oxidative and inflammatory responses induced by plasma from 
      women with pre-eclampsia.
PG  - e13207
LID - 10.1111/aji.13207 [doi]
AB  - PROBLEM: Oxidative stress and inflammation are key events leading to 
      pre-eclampsia, involved in several maternal deaths. Low doses of acetylsalicylic 
      acid (ASA) are used in the prevention and treatment of pre-eclampsia. The 
      synthesis of aspirin-triggered lipoxin (ATL) by cyclooxygenase-2 acetylation is 
      an alternative mechanism of ASA, which could explain the effectiveness of ASA 
      treatments. The aim of this study was to evaluate the role of ASA, salicylates, 
      and ATL in the modulation of the oxidative and inflammatory responses induced by 
      plasma from women with pre-eclampsia. METHOD OF STUDY: Plasma from 14 women with 
      pre-eclampsia and 17 normotensive pregnant women was probed for inducing 
      oxidative and inflammatory responses on endothelial cells and U937 promonocytes. 
      The role of ATL, ASA, and salicylic acid (SA) on these events was evaluated. 
      RESULTS: Plasma from women with pre-eclampsia induced TBARS and nitrotyrosine 
      production on endothelial and U937 cells. Pre-treatment with both ATL and ASA 
      decreased the TBARS production, while ATL decreased the nitrotyrosine. 
      Pre-eclamptic plasma augmented the translocation of NF-kB on U937 cells, which 
      decreased by a high dose of ASA and SA. Finally, the pre-eclamptic plasma 
      increased the adhesion of leukocytes-PMN and monocytes-to endothelium, and we 
      were able to determine a state of resolution of inflammation, since ATL decreased 
      the PMN adhesion, and conversely, it increased the monocytes adhesion to 
      endothelium. CONCLUSION: Together, these results suggest that ATL could explain 
      the beneficial actions of ASA and support further research on mechanisms, real 
      efficacy, and rational use of ASA in pre-eclampsia.
CI  - © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Gil-Villa, Aura María
AU  - Gil-Villa AM
AUID- ORCID: 0000-0001-8575-6058
AD  - Grupo Reproducción, Departamento de Microbiología y Parasitología, Facultad de 
      Medicina, Universidad de Antioquia, Medellín, Colombia.
FAU - Alvarez, Angela M
AU  - Alvarez AM
AUID- ORCID: 0000-0002-9056-9764
AD  - Grupo Reproducción, Departamento de Microbiología y Parasitología, Facultad de 
      Medicina, Universidad de Antioquia, Medellín, Colombia.
AD  - Red Iberoamericana de Alteraciones Vasculares Asociadas a Transtornos del 
      Embarazo (RIVA-TREM), Chillán, Chile.
FAU - Velásquez-Berrío, Manuela
AU  - Velásquez-Berrío M
AUID- ORCID: 0000-0003-3348-9810
AD  - Grupo Reproducción, Departamento de Microbiología y Parasitología, Facultad de 
      Medicina, Universidad de Antioquia, Medellín, Colombia.
FAU - Rojas-López, Mauricio
AU  - Rojas-López M
AUID- ORCID: 0000-0002-7791-9328
AD  - Grupo de Inmunología Celular e Inmunogenética - Unidad de Citometría de Flujo, 
      Sede de Investigación Universitaria (SIU), Universidad de Antioquia, Medellín, 
      Colombia.
FAU - Cadavid J, Angela P
AU  - Cadavid J AP
AUID- ORCID: 0000-0003-3081-0840
AD  - Grupo Reproducción, Departamento de Microbiología y Parasitología, Facultad de 
      Medicina, Universidad de Antioquia, Medellín, Colombia.
AD  - Red Iberoamericana de Alteraciones Vasculares Asociadas a Transtornos del 
      Embarazo (RIVA-TREM), Chillán, Chile.
LA  - eng
GR  - 1115-408-20531/Administrative Department of Science and Technology and Innovation 
      - Colciencias, Colombia/International
GR  - 757-2017/Administrative Department of Science and Technology and Innovation - 
      Colciencias, Colombia/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191126
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - 0 (Lipoxins)
RN  - 0 (NF-kappa B)
RN  - 0 (Thiobarbituric Acid Reactive Substances)
RN  - 0 (lipoxin A4)
RN  - 3604-79-3 (3-nitrotyrosine)
RN  - 42HK56048U (Tyrosine)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Adolescent
MH  - Adult
MH  - Aspirin/blood/pharmacology/*therapeutic use
MH  - Cell Adhesion/drug effects
MH  - Cyclooxygenase 2/blood
MH  - Female
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Inflammation/blood
MH  - Lipoxins/biosynthesis/*blood/pharmacology
MH  - NF-kappa B/metabolism
MH  - Neutrophils/drug effects
MH  - Oxidative Stress/*drug effects
MH  - Pre-Eclampsia/*blood/drug therapy/prevention & control
MH  - Pregnancy
MH  - Protein Processing, Post-Translational/drug effects
MH  - Salicylic Acid/*blood/pharmacology
MH  - Thiobarbituric Acid Reactive Substances/analysis
MH  - Tyrosine/analogs & derivatives/biosynthesis
MH  - U937 Cells
MH  - Young Adult
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - aspirin-triggered lipoxins
OT  - inflammation
OT  - oxidative stress
OT  - pre-eclampsia
OT  - salicylic acid
EDAT- 2019/11/07 06:00
MHDA- 2020/12/31 06:00
CRDT- 2019/11/08 06:00
PHST- 2019/08/08 00:00 [received]
PHST- 2019/10/19 00:00 [revised]
PHST- 2019/10/30 00:00 [accepted]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2020/12/31 06:00 [medline]
PHST- 2019/11/08 06:00 [entrez]
AID - 10.1111/aji.13207 [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 2020 Feb;83(2):e13207. doi: 10.1111/aji.13207. Epub 2019 Nov 
      26.

PMID- 32487324
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20201117
IS  - 1873-5487 (Electronic)
IS  - 0188-4409 (Linking)
VI  - 51
IP  - 6
DP  - 2020 Aug
TI  - Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the 
      Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice.
PG  - 515-523
LID - S0188-4409(20)30042-4 [pii]
LID - 10.1016/j.arcmed.2020.05.003 [doi]
AB  - BACKGROUND: Platelet hyper adhesiveness orchestrates with inflammation and 
      vascular muscle proliferation leading to atheroma formation and endothelial 
      dysfunction. OBJECTIVES: The current study aims to compare the prophylactic role 
      of Aspirin and Clopidogrel therapy against isoproterenol-induced acute myocardial 
      infarction (AMI), in mice on high-fat, cholesterol-rich diet (HFD-C). METHODS: 
      The animals received HFD-C with Aspirin or Clopidogrel for 8 weeks and were 
      subjected to AMI by isoproterenol. The blood lipids, inflammatory cytokines, 
      myocardial enzymes, redox state, long pentraxin (PTX3), and matrix 
      metalloproteinases (MMP-2 and MMP-9) activities were investigated. RESULTS: 
      Antiplatelet therapy moderated the hyperlipidemia induced by HFD-C in the current 
      study. Essentially, the total cholesterol and LDL-C levels were lower with 
      Aspirin than with Clopidogrel therapy. Yet Aspirin and Clopidogrel each 
      comparably lowered CK-MB, AST, MMP-2, MMP-9, and the lipid peroxidation product 
      malondialdehyde (MDA) in the hyperlipidemic animals exposed to AMI. However, the 
      decline in cTn-T, LDH and PTX3 levels was greater after Clopidogrel than Aspirin 
      administration. Therefore, Clopidogrel provides greater protection against AMI 
      than Aspirin in the hyperlipidemic mice. This could be explained by the 
      suppression of the proinflammatory cytokines IL-6, TNF-α, TGF-1β and 
      stabilization of the extracellular matrix through the inhibition of MMP-2 and 
      MMP-9 activities. Furthermore, Clopidogrel demonstrated significant antioxidative 
      action in the AMI animals, resulting in diminished MDA production and preserved 
      CAT activity. CONCLUSION: Beside its therapeutic role in the thrombotic vascular 
      events, Clopidogrel confers significant protection against ischemic myocardial 
      injury by counteracting the platelet-mediated inflammation and oxidative stress 
      associated with HFD-C consumption in animals.
CI  - Copyright © 2020. Published by Elsevier Inc.
FAU - Korish, Aida A
AU  - Korish AA
AD  - Department of Physiology, College of Medicine, King Saud University, Riyadh, 
      Saudi Arabia. Electronic address: iaidakorish@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200531
PL  - United States
TA  - Arch Med Res
JT  - Archives of medical research
JID - 9312706
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel/*therapeutic use
MH  - Disease Models, Animal
MH  - Humans
MH  - Hypercholesterolemia/*drug therapy
MH  - Hyperlipidemias/*drug therapy
MH  - Inflammation/*drug therapy
MH  - Male
MH  - Mice
MH  - Myocardial Ischemia/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Atherosclerosis
OT  - Clopidogrel
OT  - High fat diet
OT  - Inflammation
OT  - Mice
OT  - Myocardial ischemia
OT  - Platelet hyper adhesiveness
EDAT- 2020/06/04 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/01/11 00:00 [received]
PHST- 2020/04/08 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - S0188-4409(20)30042-4 [pii]
AID - 10.1016/j.arcmed.2020.05.003 [doi]
PST - ppublish
SO  - Arch Med Res. 2020 Aug;51(6):515-523. doi: 10.1016/j.arcmed.2020.05.003. Epub 
      2020 May 31.

PMID- 24987182
OWN - NLM
STAT- MEDLINE
DCOM- 20150219
LR  - 20211021
IS  - 1998-3751 (Electronic)
IS  - 0253-7613 (Print)
IS  - 0253-7613 (Linking)
VI  - 46
IP  - 3
DP  - 2014 May-Jun
TI  - Use of Aspirin in normalization of recombinant human erythropoietin-mediated 
      hyper-reactivity of platelets in rats.
PG  - 328-33
LID - 10.4103/0253-7613.132187 [doi]
AB  - OBJECTIVES: The cytokine erythropoietin is the primary stimulator of 
      erythropoiesis and recombinant human erythropoietin (rHuEPO), which is widely 
      used in the treatment of anemia associated with advanced chronic kidney disease 
      (CKD). Adverse cardiovascular outcomes have been observed during clinical trials 
      of anemia correction with rHuEPO in CKD patients. We investigated the effects of 
      short-term, high-dose treatment with rHuEPO on platelet reactivity and effects of 
      aspirin on platelet reactivity in healthy rats. MATERIALS AND METHODS: Animals 
      received three daily dose of rHuEPO (25 μg/kg s.c.). Platelets were isolated 
      after 48 h of last dose of rHuEPO to study the arachidonic acid-induced platelet 
      aggregation. Aspirin (75 mg/kg p.o.) was given to animals just before 1 h of 
      isolation of platelets. RESULTS: In rats, treatment with rHuEPO increased 
      platelet reactivity and platelet count. The increased platelet reactivity was 
      paralleled by decreased time-to-occlusion (TTO) in arterial thrombosis model, and 
      decreased bleeding time after tail transection in rats. Treatment with rHuEPO 
      followed by single dose of aspirin showed significant reduction in TTO and 
      bleeding time as compared with aspirin-treated group. CONCLUSIONS: These findings 
      suggest that rHuEPO increases platelet reactivity and aspirin normalizes the 
      hyper-reactive platelet and may reduce the cardiovascular events associated with 
      rHuEPO in CKD patients.
FAU - Soni, Hitesh M
AU  - Soni HM
AD  - Departments of Pharmacology, Zyd us Research Centre, Sarkhej-Bavla, Moraiya, 
      Ahmedabad, Gujarat, India ; Department of Physiology, University of Tennessee 
      Health Science Center, Memphis, Tennessee, USA.
FAU - Vekaria, Amit M
AU  - Vekaria AM
AD  - Departments of Pharmacology, Zyd us Research Centre, Sarkhej-Bavla, Moraiya, 
      Ahmedabad, Gujarat, India ; Department of Pharmacology, School of Pharmacy and 
      Technology Management (Shirpur Campus), Narsee Monjee Institute of Management 
      Studies University, Mumbai, Maharashtra, India.
FAU - Rath, Akshyaya C
AU  - Rath AC
AD  - Departments of Pharmacology, Zyd us Research Centre, Sarkhej-Bavla, Moraiya, 
      Ahmedabad, Gujarat, India.
FAU - Belemkar, Sateesh
AU  - Belemkar S
AD  - Department of Pharmacology, School of Pharmacy and Technology Management (Shirpur 
      Campus), Narsee Monjee Institute of Management Studies University, Mumbai, 
      Maharashtra, India.
FAU - Jain, Mukul R
AU  - Jain MR
AD  - Departments of Pharmacology, Zyd us Research Centre, Sarkhej-Bavla, Moraiya, 
      Ahmedabad, Gujarat, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Pharmacol
JT  - Indian journal of pharmacology
JID - 7902477
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Recombinant Proteins)
RN  - 11096-26-7 (Erythropoietin)
RN  - 64FS3BFH5W (Epoetin Alfa)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects
MH  - Epoetin Alfa
MH  - Erythropoietin/*pharmacology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Count
MH  - Rats, Wistar
MH  - Recombinant Proteins/pharmacology
PMC - PMC4071712
OTO - NOTNLM
OT  - Aspirin
OT  - chronic kidney disease
OT  - platelet
OT  - rat
OT  - recombinant human erythropoietin
COIS- Conflict Interest: No
EDAT- 2014/07/06 06:00
MHDA- 2015/02/20 06:00
CRDT- 2014/07/03 06:00
PHST- 2014/01/09 00:00 [received]
PHST- 2014/03/05 00:00 [revised]
PHST- 2014/04/04 00:00 [accepted]
PHST- 2014/07/03 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2015/02/20 06:00 [medline]
AID - IJPharm-46-328 [pii]
AID - 10.4103/0253-7613.132187 [doi]
PST - ppublish
SO  - Indian J Pharmacol. 2014 May-Jun;46(3):328-33. doi: 10.4103/0253-7613.132187.

PMID- 16547586
OWN - NLM
STAT- MEDLINE
DCOM- 20071101
LR  - 20131121
IS  - 1360-8185 (Print)
IS  - 1360-8185 (Linking)
VI  - 11
IP  - 6
DP  - 2006 Jun
TI  - The role of PKCzeta in NMDA-induced retinal ganglion cell death: prevention by 
      aspirin.
PG  - 983-91
AB  - Intravitreal NMDA injection has been shown to induce the excitotoxic loss of 
      retinal cells. The retinal ganglion cell apoptosis induced by NMDA is thought to 
      play an important role in retinal ischemia injury and NMDA-injected rat has been 
      used as a model of neuronal loss in diseases such as glaucoma. In this 
      experimental model, we studied the early effects of NMDA leading to the 
      degeneration of retinal ganglion cells. PKCzeta regulates the NF-kappaB pathway 
      in cellular responses to various stresses and we have shown that aspirin inhibits 
      purified human PKCzeta. We therefore investigated the molecular mechanism by 
      which retinal cells limit ocular injury following NMDA treatment. We found that 
      the NMDA-induced apoptosis of ganglion cells was mediated, at least partly, by 
      PKCzeta. This enzyme was activated early in the cellular response to NMDA. 
      Prolonged activation was followed by PKCzeta cleavage, and nuclear translocation 
      of the C-terminal region of this protein-a critical event for the survival of 
      retinal cells. We also found that pretreatment with aspirin or the coinjection of 
      NMDA with a specific PKCzeta inhibitor counteracted the effects of NMDA. These 
      findings provide new insight into the role played by PKCzeta in neuronal loss in 
      glaucoma.
FAU - Crisanti, P
AU  - Crisanti P
AD  - Unité 598 de l'INSERM Physiopathologie des maladies oculaires, Innovations 
      thérapeutiques, France.
FAU - Laplace, O
AU  - Laplace O
FAU - Lecain, E
AU  - Lecain E
FAU - Jonet, L
AU  - Jonet L
FAU - Jeanny, J C
AU  - Jeanny JC
FAU - Omri, B
AU  - Omri B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Apoptosis
JT  - Apoptosis : an international journal on programmed cell death
JID - 9712129
RN  - 6384-92-5 (N-Methylaspartate)
RN  - EC 2.7.11.1 (protein kinase C zeta)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects
MH  - Aspirin/*pharmacology
MH  - Male
MH  - N-Methylaspartate/pharmacology
MH  - Protein Kinase C/*antagonists & inhibitors
MH  - Rats
MH  - Rats, Wistar
MH  - Retinal Ganglion Cells/*drug effects
EDAT- 2006/03/21 09:00
MHDA- 2007/11/02 09:00
CRDT- 2006/03/21 09:00
PHST- 2006/03/21 09:00 [pubmed]
PHST- 2007/11/02 09:00 [medline]
PHST- 2006/03/21 09:00 [entrez]
AID - 10.1007/s10495-006-6750-2 [doi]
PST - ppublish
SO  - Apoptosis. 2006 Jun;11(6):983-91. doi: 10.1007/s10495-006-6750-2.

PMID- 34554870
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20211101
IS  - 1943-5681 (Electronic)
IS  - 0002-9645 (Linking)
VI  - 82
IP  - 10
DP  - 2021 Oct
TI  - The use of impedance aggregometry to evaluate platelet function after the 
      administration of DDAVP in healthy dogs treated with aspirin or clopidogrel.
PG  - 823-828
LID - ajvr.82.10.823 [pii]
LID - 10.2460/ajvr.82.10.823 [doi]
AB  - OBJECTIVE: To evaluate the effect of 1-Desamino-8-d-arginine vasopressin (DDAVP; 
      desmopressin acetate) on platelet aggregation in healthy dogs receiving aspirin 
      or clopidogrel. ANIMALS: 7 healthy staff-owned dogs. PROCEDURES: In this 
      randomized double-blinded crossover study, impedance aggregometry was performed 
      on samples of lithium-heparinized whole blood samples from dogs before (T0) 
      treatment with aspirin (1 mg/kg, PO, q 24 h for 4 days; ASP group) or clopidogrel 
      (1 mg/kg, PO, q 24 h for 4 days; CLP group) and then before (T1) and after (T2) 
      treatment with DDAVP (0.3 μg/kg, IV, once). There was a 14-day washout period 
      before the crossover component. Aggregometry was performed with 4 different 
      assays, each of which involved a different agonist reagent to stimulate platelet 
      function: ADP, thrombin receptor activating peptide-6, arachidonic acid, or 
      collagen type 1. RESULTS: Median results for platelet aggregometry with agonist 
      reagents ADP, arachidonic acid, or thrombin receptor activating peptide-6 
      significantly decreased between T0 and T1 for the CLP group; however, no 
      meaningful difference in platelet aggregation was detected in the ASP group. 
      Results for platelet aggregometry did not differ substantially between T1 and T2 
      regardless of treatment group or assay. CONCLUSIONS AND CLINICAL RELEVANCE: 
      Findings suggested that administration of DDAVP may have no effect on platelet 
      aggregation (measured with platelet aggregometry) in healthy dogs treated with 
      clopidogrel. Because no inhibition of platelet aggregation was detected for dogs 
      in the ASP group, no conclusion could be made regarding the effects of DDAVP 
      administered to dogs treated with aspirin.
FAU - Yankin, Igor
AU  - Yankin I
FAU - Carver, Andy M
AU  - Carver AM
FAU - Koenigshof, Amy M
AU  - Koenigshof AM
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial, Veterinary
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Aspirin/pharmacology
MH  - Blood Platelets
MH  - Clopidogrel/pharmacology
MH  - Cross-Over Studies
MH  - *Deamino Arginine Vasopressin/pharmacology
MH  - Dogs
MH  - Electric Impedance
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Platelet Function Tests/veterinary
EDAT- 2021/09/24 06:00
MHDA- 2021/09/28 06:00
CRDT- 2021/09/23 17:15
PHST- 2021/09/23 17:15 [entrez]
PHST- 2021/09/24 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
AID - ajvr.82.10.823 [pii]
AID - 10.2460/ajvr.82.10.823 [doi]
PST - ppublish
SO  - Am J Vet Res. 2021 Oct;82(10):823-828. doi: 10.2460/ajvr.82.10.823.

PMID- 1514625
OWN - NLM
STAT- MEDLINE
DCOM- 19920925
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 263
IP  - 2 Pt 1
DP  - 1992 Aug
TI  - Effect of aspirin on ulcer site blood flow in cat stomachs.
PG  - G155-60
AB  - Radioactive microspheres were used to measure blood flow in the cat stomach 
      during exposure to saline, 0.075 M HCl, and then 15 and 30 min after exposure to 
      20 or 40 mM aspirin in HCl. At the end of the experiment, the stomach wall was 
      divided into ulcerated regions and adjacent nonulcerated areas. When exposed to 
      saline, both regions had similar blood flow: 27 +/- 5 and 25 +/- 5 ml.min-1.100 
      g-1 (means +/- SE). Addition of acid caused a significant increase in blood flow 
      to 41 +/- 7 ml.min-1.100 g-1 only at those sites that eventually ulcerated in the 
      presence of aspirin. In the adjacent nonulcerated regions, blood flow was 31 +/- 
      5 ml.min-1.100 g-1 and was not significantly greater than the flow recorded 
      during saline exposure. Aspirin caused ulcer site blood flow to increase 
      dramatically to 89 +/- 12 and 122 +/- 18 ml.min-1.100 g-1 after 15 and 30 min, 
      whereas the adjacent nonulcerated tissue rose to 40 +/- 6 and 44 +/- 5 
      ml.min-1.100 g-1, respectively. The ulcer site hyperemia with acid alone suggests 
      higher mucosal permeability in these regions allowing back-diffusion of acid and 
      injurious agents. The present data obtained in the cat do not support the notion 
      that ischemia plays a role in initiating nonsteroidal anti-inflammatory drug 
      (NSAID)-induced ulcers, but rather that acute NSAID ulcers are associated 
      initially with a hyperemia.
FAU - Lau, A T
AU  - Lau AT
AD  - School of Physiology and Pharmacology, University of New South Wales, Kensington, 
      Australia.
FAU - Graham, G G
AU  - Graham GG
FAU - Day, R O
AU  - Day RO
FAU - Perry, M A
AU  - Perry MA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - QTT17582CB (Hydrochloric Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cats
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hydrochloric Acid/pharmacology
MH  - Regional Blood Flow/drug effects
MH  - Stomach/*blood supply/pathology
MH  - Stomach Ulcer/pathology/*physiopathology
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
AID - 10.1152/ajpgi.1992.263.2.G155 [doi]
PST - ppublish
SO  - Am J Physiol. 1992 Aug;263(2 Pt 1):G155-60. doi: 10.1152/ajpgi.1992.263.2.G155.

PMID- 33883461
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20220323
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
VI  - 39
IP  - 8
DP  - 2021 Aug 1
TI  - Combination blood pressure lowering in the presence or absence of background 
      statin and aspirin therapy: a combined analysis of PROGRESS and ADVANCE Trials.
PG  - 1689-1696
LID - 10.1097/HJH.0000000000002862 [doi]
AB  - OBJECTIVES: To assess the effects of combination BP lowering on cardiovascular 
      events and mortality in the presence of aspirin and/or statin therapy in a 
      combined analysis of the ADVANCE and PROGRESS trials. METHODS: We conducted an 
      analysis of 14 682 participants allocated combination therapy with perindopril 
      and indapamide or placebo followed up for a mean of 4.2 years. Participants were 
      stratified into four groups defined by background use of medications at baseline: 
      statin, aspirin, both or neither. Linear mixed effect models were used to assess 
      differences in BP and Cox proportional hazard models were used to estimate the 
      risks of major cardiovascular events, all-cause mortality and treatment 
      discontinuation. RESULTS: At baseline, 14% of patients were on both aspirin and 
      statin, 35% on aspirin, 9% on statins and 42% on neither aspirin/statins. 
      Compared with placebo, combination BP therapy reduced mean SBP by 5.7 mmHg in 
      ADVANCE and 12.1 mmHg in PROGRESS, with no difference (P > 0.447) between 
      patients by baseline use of aspirin/statin. Combination BP therapy reduced the 
      risk of major cardiovascular events (hazard ratio 0.78, 95% CI 0.71-0.86), with 
      no significant difference (P = 0.600) between aspirin/statin subgroups. Rates of 
      treatment discontinuation were similar with combination BP therapy compared with 
      placebo (18.4 versus 18%), with no evidence of difference across the subgroups 
      (P = 0.340). CONCLUSION: BP lowering with perindopril and indapamide reduces the 
      risk of major cardiovascular events independent of baseline use of aspirin and/or 
      statins.
CI  - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Wang, Nelson
AU  - Wang N
AD  - The George Institute for Global Health, University of New South Wales.
AD  - Sydney Medical School, University of Sydney, Sydney.
FAU - Harris, Katie
AU  - Harris K
AD  - The George Institute for Global Health, University of New South Wales.
FAU - Chalmers, John
AU  - Chalmers J
AD  - The George Institute for Global Health, University of New South Wales.
FAU - Harrap, Stephen
AU  - Harrap S
AD  - Department of Physiology, Royal Melbourne Hospital, University of Melbourne, 
      Victoria, Australia.
FAU - Mancia, Giuseppe
AU  - Mancia G
AD  - Instituto Auxologico Italiano, University of Milan-Bicocca, Milan, Italy.
FAU - Marre, Michel
AU  - Marre M
AD  - Department of Endocrinology, Hopital Bichat-Claude Bernard, University of Paris, 
      Paris, France.
FAU - Poulter, Neil
AU  - Poulter N
AD  - Imperial Clinical Trials Unit, Imperial College London, UK.
FAU - Tzourio, Christophe
AU  - Tzourio C
AD  - Bordeaux Population Health Research Center, University of Bordeaux, France.
FAU - Williams, Bryan
AU  - Williams B
AD  - University College London, NIHR University College London, Hospitals Biomedical 
      Research Centre, London, UK.
FAU - Zoungas, Sophia
AU  - Zoungas S
AD  - The George Institute for Global Health, University of New South Wales.
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia.
FAU - Woodward, Mark
AU  - Woodward M
AD  - The George Institute for Global Health, University of New South Wales.
AD  - Department of Epidemiology and Biostatistics, Imperial College, London, UK.
AD  - Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.
FAU - Rodgers, Anthony
AU  - Rodgers A
AD  - The George Institute for Global Health, University of New South Wales.
LA  - eng
SI  - ClinicalTrials.gov/NCT00145925
GR  - MC_PC_13090/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - F089I0511L (Indapamide)
RN  - R16CO5Y76E (Aspirin)
RN  - Y5GMK36KGY (Perindopril)
SB  - IM
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/pharmacology
MH  - Blood Pressure
MH  - Drug Combinations
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/therapeutic use
MH  - *Hypertension/drug therapy
MH  - *Indapamide/pharmacology
MH  - Perindopril/pharmacology
EDAT- 2021/04/23 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/04/22 06:07
PHST- 2021/04/23 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/04/22 06:07 [entrez]
AID - 00004872-202108000-00025 [pii]
AID - 10.1097/HJH.0000000000002862 [doi]
PST - ppublish
SO  - J Hypertens. 2021 Aug 1;39(8):1689-1696. doi: 10.1097/HJH.0000000000002862.

PMID- 30562365
OWN - NLM
STAT- MEDLINE
DCOM- 20190521
LR  - 20200309
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 12
DP  - 2018
TI  - Triple therapy after PCI - Warfarin treatment quality and bleeding risk.
PG  - e0209187
LID - 10.1371/journal.pone.0209187 [doi]
LID - e0209187
AB  - BACKGROUND: A combination of warfarin, aspirin and clopidogrel is indicated after 
      percutaneous coronary intervention (PCI) in some patients, despite the higher 
      risk of bleeding inferred by this triple therapy. OBJECTIVES: Whether the 
      treatment quality of warfarin measured by iTTR (individual time within 
      therapeutic INR range) is associated with bleeding complications during triple 
      therapy after PCI. METHODS: A retrospective register study consisting of 601 
      triple treated PCI patients from the Swedish Coronary Angiography and Angioplasty 
      Registry (SCAAR). The cohort was cross-matched with the Swedish Patient Registry 
      for background characteristics and bleeding complications up to 6 months after 
      PCI using ICD10 codes, the Prescribed Drug Registry for ongoing medications, and 
      the national oral anticoagulation registry Auricula for warfarin treatment 
      quality. The patients were grouped into four iTTR groups: <50%, 50-69.9%, 
      70-84.9% and >85% as well as iTTR above or below 70%. RESULTS: Of 601 patients, 
      39 (6.5%) had a bleeding complication (type 2 according to BARC). Bleeding was 
      more common for iTTR<70% compared to iTTR>70%, 28 (9.3%) vs. 11 (3.7%) (p = 
      0.005). The bleeding frequency increased gradually from the best group, iTTR>85% 
      with four bleeders (3.3%) up to 17 bleeders (13.3%) in the worst group with 
      iTTR<50% (p = 0.003), with a corresponding bleeding rate per 100 treatment years 
      of 8.0 and 44.9, respectively. In multivariate analysis low BMI, HR 1.11 (95% CI 
      1.01-1.22), a medical history of anemia HR 3.17 (1.16-8.69) and iTTR < 70% HR 
      2.86 (1.25-6.53) increased the risk of bleeding. CONCLUSION: Triple therapy after 
      PCI confers a high risk of bleeding events. Warfarin treatment quality measured 
      by iTTR as well as a medical history of anemia are strong independent predictors 
      of bleeding in these patients. Physicians should pay more attention to iTTR after 
      PCI.
FAU - Wadell, Daniel
AU  - Wadell D
AUID- ORCID: 0000-0002-9789-2206
AD  - Department of Public Health and Clinical Medicine, Umeå University, Sundsvall, 
      Sweden.
FAU - Jensen, Jens
AU  - Jensen J
AD  - Department of Medicine, S:t Görans hospital, Karolinska Institute, Stockholm, 
      Sweden.
FAU - Englund, Erling
AU  - Englund E
AD  - Department of Research and Development, Region Västernorrland, Sundsvall, Sweden.
FAU - Själander, Anders
AU  - Själander A
AD  - Department of Public Health and Clinical Medicine, Umeå University, Sundsvall, 
      Sweden.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20181218
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Hematologic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination/adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Hematologic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention
MH  - Postoperative Hemorrhage/*epidemiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Warfarin/adverse effects/*therapeutic use
PMC - PMC6298652
COIS- The authors have declared that no competing interests exist.
EDAT- 2018/12/19 06:00
MHDA- 2019/05/22 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/05/15 00:00 [received]
PHST- 2018/12/01 00:00 [accepted]
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2019/05/22 06:00 [medline]
AID - PONE-D-18-14643 [pii]
AID - 10.1371/journal.pone.0209187 [doi]
PST - epublish
SO  - PLoS One. 2018 Dec 18;13(12):e0209187. doi: 10.1371/journal.pone.0209187. 
      eCollection 2018.

PMID- 20435198
OWN - NLM
STAT- MEDLINE
DCOM- 20100524
LR  - 20181201
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 159
IP  - 5
DP  - 2010 May
TI  - Incidence, correlates, and clinical impact of nuisance bleeding after 
      antiplatelet therapy for patients with drug-eluting stents.
PG  - 871-5
LID - 10.1016/j.ahj.2010.01.016 [doi]
AB  - BACKGROUND: Nuisance bleeding (NB) after dual antiplatelet therapy (DAPT) is not 
      well characterized despite its potential to impact patient compliance. We 
      therefore aimed to evaluate the incidence, correlates, and clinical impact of NB 
      after DAPT after drug-eluting stent (DES) implantation. METHODS: Included were 
      2,948 patients with DES implantation who were discharged on DAPT for 12 months. 
      New bleeding classifications were used: alarming bleeding, internal bleeding, and 
      NB. RESULTS: After excluding patients with alarming bleeding (9 [0.3%]) and 
      internal bleeding (128 [4.3%]), the 2,811 remaining patients were divided into 2 
      groups: those with NB (812 [28.9%]) and those without (1,999 [71.1%]). Patients 
      with NB were significantly younger (63.0 +/- 11.4 vs 65.2 +/- 11.6 years, P < 
      .001), were more often white (82.0% vs 69.6%, P < .001), had lower body mass 
      indices (29.2 +/- 6.1 vs 29.8 +/- 6.0 kg/m(2), P = .01), and a lower prevalence 
      of diabetes (25.5% vs 34.8%, P < .001) compared to those without NB. At 1 year, 
      the rate of major adverse cardiac events was higher in the NB group compared to 
      the nonbleeding group (77 [9.4%] vs 134 [6.7%], P = .02). In the NB group, 46 
      patients (5.7%) stopped 1 or both antiplatelet therapies. Thirty-five (4.3%) 
      discontinued clopidogrel, 16 (2.0%) stopped aspirin, and 5 (0.61%) stopped both 
      as a result of the reported NB. Multivariable analysis detected younger age, 
      lower body mass index, white race, and without diabetes as correlates associated 
      with NB while on clopidogrel therapy. CONCLUSION: Nuisance bleeding is common in 
      patients on prolonged DAPT post-DES implantation and can impact compliance. 
      Nuisance bleeding appears to have important clinical implications and, if 
      confirmed in prospective trials, should be added to the safety end points 
      assessing new antiplatelet agents.
CI  - 2010 Mosby, Inc. All rights reserved.
FAU - Ben-Dor, Itsik
AU  - Ben-Dor I
AD  - Washington Hospital Center, Washington, DC, USA.
FAU - Torguson, Rebecca
AU  - Torguson R
FAU - Scheinowitz, Mickey
AU  - Scheinowitz M
FAU - Li, Yanlin
AU  - Li Y
FAU - Delhaye, Cedric
AU  - Delhaye C
FAU - Wakabayashi, Kohei
AU  - Wakabayashi K
FAU - Maluenda, Gabriel
AU  - Maluenda G
FAU - Syed, Asmir I
AU  - Syed AI
FAU - Collins, Sara D
AU  - Collins SD
FAU - Gonzalez, Manuel A
AU  - Gonzalez MA
FAU - Gaglia, Michael A Jr
AU  - Gaglia MA Jr
FAU - Xue, Zhenyi
AU  - Xue Z
FAU - Kaneshige, Kimberly
AU  - Kaneshige K
FAU - Satler, Lowell F
AU  - Satler LF
FAU - Suddath, William O
AU  - Suddath WO
FAU - Kent, Kenneth M
AU  - Kent KM
FAU - Pichard, Augusto D
AU  - Pichard AD
FAU - Waksman, Ron
AU  - Waksman R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Coronary Angiography
MH  - Coronary Artery Disease/diagnostic imaging/therapy
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
EDAT- 2010/05/04 06:00
MHDA- 2010/05/25 06:00
CRDT- 2010/05/04 06:00
PHST- 2009/12/08 00:00 [received]
PHST- 2010/01/23 00:00 [accepted]
PHST- 2010/05/04 06:00 [entrez]
PHST- 2010/05/04 06:00 [pubmed]
PHST- 2010/05/25 06:00 [medline]
AID - S0002-8703(10)00150-X [pii]
AID - 10.1016/j.ahj.2010.01.016 [doi]
PST - ppublish
SO  - Am Heart J. 2010 May;159(5):871-5. doi: 10.1016/j.ahj.2010.01.016.

PMID- 2420078
OWN - NLM
STAT- MEDLINE
DCOM- 19860414
LR  - 20131121
IS  - 0301-0481 (Print)
IS  - 0301-0481 (Linking)
VI  - 61
IP  - 3
DP  - 1986 Feb 1
TI  - [Clinical and pathogenetic aspects of aspirin intolerance].
PG  - 124-7
AB  - Aspirin intolerance has become increasingly important in clinical dermatology 
      during the past decade, especially as a diagnostic aid in chronic urticaria. It 
      is recommended, to distinguish clinically between the intolerance syndrome and an 
      intolerance provocation (of preexistent asthma or urticaria). Pathogenetically, 
      various antibody-independent mechanisms are discussed of which most authors 
      favour a defective regulation of arachidonic acid metabolism.
FAU - Voigtländer, V
AU  - Voigtländer V
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Klinische und pathogenetische Aspekte der Aspirin-Intoleranz.
PL  - Germany
TA  - Z Hautkr
JT  - Zeitschrift fur Hautkrankheiten
JID - 0367576
RN  - 0 (Arachidonic Acids)
RN  - 0 (Prostaglandin Antagonists)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/*adverse effects
MH  - Asthma/chemically induced
MH  - Complement Activation/drug effects
MH  - Drug Eruptions/*etiology
MH  - Histamine Release/drug effects
MH  - Humans
MH  - Prostaglandin Antagonists
EDAT- 1986/02/01 00:00
MHDA- 1986/02/01 00:01
CRDT- 1986/02/01 00:00
PHST- 1986/02/01 00:00 [pubmed]
PHST- 1986/02/01 00:01 [medline]
PHST- 1986/02/01 00:00 [entrez]
PST - ppublish
SO  - Z Hautkr. 1986 Feb 1;61(3):124-7.

PMID- 34827566
OWN - NLM
STAT- MEDLINE
DCOM- 20220112
LR  - 20220112
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 11
IP  - 11
DP  - 2021 Oct 22
TI  - Aspirin-Based Organoiron Dendrimers as Promising Anti-Inflammatory, Anticancer, 
      and Antimicrobial Drugs.
LID - 10.3390/biom11111568 [doi]
LID - 1568
AB  - Designing nanocarriers with actions directed at a specific organ or tissue is a 
      very promising strategy since it can significantly reduce the toxicity of a 
      bioactive drug. In this study, an organometallic dendrimer was used to synthesize 
      a biocompatible drug delivery system by attaching aspirin to the periphery of the 
      dendrimer. Our goal is to enhance the bioavailability and anticancer activity of 
      aspirin and reduce its toxicity through successive generations of organoiron 
      dendrimers. The biological activity of aspirin-based dendrimer complexes was 
      evaluated. The result of antimicrobial activity of the synthesized dendrimers 
      also demonstrated an increase in their antimicrobial activity with increased 
      generation of the dendrimers for most types of microorganisms. This study reveals 
      for the first time that organoiron dendrimers linked with aspirin exhibit an 
      excellent Gram-negative activity comparable to the reference drug Gentamicin. All 
      synthesized dendrimers were tested for their anticancer activity against breast 
      cancer cell lines (MCF-7), hepatocellular cell lines (Hep-G2), and a non-cancer 
      cell line, Human Embryonic Kidney (HEK293), using the MTT cell viability assay 
      and compared against a standard anticancer drug, Doxorubicin. Compounds G3-D9-Asp 
      and G4-D12-Asp exhibited noticeable activity against both cell lines, both of 
      which were more effective than aspirin itself. In addition, the in vivo 
      anti-inflammatory activity and histopathology of swollen paws showed that the 
      designed aspirin-based dendrimers displayed significant anti-inflammatory 
      activity; however, G2-D6-Asp showed the best anti-inflammatory activity, which 
      was more potent than the reference drug aspirin during the same period. Moreover, 
      the coupling of aspirin to the periphery of organoiron dendrimers showed a 
      significant reduction in the toxicity of aspirin on the stomach.
FAU - Abd-El-Aziz, Alaa S
AU  - Abd-El-Aziz AS
AD  - Department of Chemistry, University of Prince Edward Island, 550 University 
      Avenue, Charlottetown, PE C1A 4P3, Canada.
FAU - Benaaisha, Maysun R
AU  - Benaaisha MR
AD  - Department of Chemistry, University of Prince Edward Island, 550 University 
      Avenue, Charlottetown, PE C1A 4P3, Canada.
FAU - Abdelghani, Amani A
AU  - Abdelghani AA
AUID- ORCID: 0000-0002-2499-2572
AD  - Department of Chemistry, University of Prince Edward Island, 550 University 
      Avenue, Charlottetown, PE C1A 4P3, Canada.
FAU - Bissessur, Rabin
AU  - Bissessur R
AD  - Department of Chemistry, University of Prince Edward Island, 550 University 
      Avenue, Charlottetown, PE C1A 4P3, Canada.
FAU - Abdel-Rahman, Laila H
AU  - Abdel-Rahman LH
AUID- ORCID: 0000-0001-7375-2885
AD  - Chemistry Department, Faculty of Science, Sohag University, Sohag 82524, Egypt.
FAU - Fayez, Ahmed M
AU  - Fayez AM
AD  - School of Life and Medical Sciences, University of Hertfordshire Hosted by Global 
      Academic Foundation, New Administrative Capital, Cairo 11835, Egypt.
FAU - El-Ezz, Doaa Abou
AU  - El-Ezz DA
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, October 
      University for Modern Sciences and Arts (MSA University), Giza 8655, Egypt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211022
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Dendrimers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents
MH  - Aspirin
MH  - *Dendrimers
MH  - HEK293 Cells
MH  - Humans
PMC - PMC8615929
OTO - NOTNLM
OT  - anticancer activity
OT  - aspirin
OT  - dendrimer
OT  - gastrointestinal toxicity
OT  - in vivo and in vitro anti-inflammatory activity
COIS- The authors declare no conflict of interest.
EDAT- 2021/11/28 06:00
MHDA- 2022/01/13 06:00
CRDT- 2021/11/27 01:03
PHST- 2021/09/20 00:00 [received]
PHST- 2021/10/09 00:00 [revised]
PHST- 2021/10/19 00:00 [accepted]
PHST- 2021/11/27 01:03 [entrez]
PHST- 2021/11/28 06:00 [pubmed]
PHST- 2022/01/13 06:00 [medline]
AID - biom11111568 [pii]
AID - biomolecules-11-01568 [pii]
AID - 10.3390/biom11111568 [doi]
PST - epublish
SO  - Biomolecules. 2021 Oct 22;11(11):1568. doi: 10.3390/biom11111568.

PMID- 10332118
OWN - NLM
STAT- MEDLINE
DCOM- 19990625
LR  - 20131121
IS  - 1341-1098 (Print)
IS  - 1341-1098 (Linking)
VI  - 5
IP  - 2
DP  - 1999 Apr
TI  - Ischemic heart attacks following cessation of aspirin before coronary artery 
      bypass surgery: A report of two cases.
PG  - 121-2
AB  - We present herein two patients who suffered life-threatening ischemic heart 
      attacks following the preoperative discontinuation of aspirin. Since their 
      cardiac conditions were stable in the long-term while under medication, the 
      cessation of aspirin was highly suspected to have caused or at least to have 
      contributed to their ischemic events. We thus discuss the appropriate timing for 
      discontinuation of aspirin before surgery in patients with ischemic heart 
      disease.
FAU - Matsuzaki, K
AU  - Matsuzaki K
AD  - Department of Cardiovascular Surgery, Matsuyama Red Cross Hospital, 1 Bunkyo-cho, 
      Matsuyama 790-8524.
FAU - Matsui, K
AU  - Matsui K
FAU - Haraguchi, N
AU  - Haraguchi N
FAU - Nagano, I
AU  - Nagano I
FAU - Okabe, H
AU  - Okabe H
FAU - Asou, T
AU  - Asou T
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Ann Thorac Cardiovasc Surg
JT  - Annals of thoracic and cardiovascular surgery : official journal of the 
      Association of Thoracic and Cardiovascular Surgeons of Asia
JID - 9703158
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*etiology/prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Preoperative Care
EDAT- 1999/05/20 00:00
MHDA- 1999/05/20 00:01
CRDT- 1999/05/20 00:00
PHST- 1999/05/20 00:00 [pubmed]
PHST- 1999/05/20 00:01 [medline]
PHST- 1999/05/20 00:00 [entrez]
PST - ppublish
SO  - Ann Thorac Cardiovasc Surg. 1999 Apr;5(2):121-2.

PMID- 12096151
OWN - NLM
STAT- MEDLINE
DCOM- 20020909
LR  - 20190513
IS  - 1460-2725 (Print)
IS  - 1460-2393 (Linking)
VI  - 95
IP  - 7
DP  - 2002 Jul
TI  - Antiplatelet agents versus control or anticoagulation for heart failure in sinus 
      rhythm: a Cochrane systematic review.
PG  - 461-8
AB  - BACKGROUND: Heart failure predisposes to stroke and thromboembolism, which in 
      turn contribute to the high mortality and morbidity in heart failure. OBJECTIVES: 
      To determine the effect of antiplatelet agents, compared to placebo or 
      anticoagulant therapy, on death and/or major thromboembolic events in adults with 
      heart failure who are in sinus rhythm. DESIGN: Systematic review of randomized 
      parallel group placebo or controlled trials comparing oral antiplatelet therapy 
      with control or anticoagulation therapy in adults with chronic heart failure in 
      sinus rhythm. DATA SOURCES: Reference lists of papers resulting from this search, 
      electronic database searching (MEDLINE, EMBASE, DARE), and abstracts from 
      national and international cardiovascular meetings were studied to identify 
      unpublished studies. Relevant authors of these studies were contacted to obtain 
      further data. SELECTION CRITERIA: These included duration of treatment of at 
      least 1 month, and adults with heart failure due to any underlying cause. To 
      assess any adverse effects, cohort study and non-randomized controlled studies 
      were assessed. Inclusion decisions were duplicated, disagreement resolved by 
      discussion or a third party. No meta-analyses were performed, as no data were 
      available from randomized comparisons. RESULTS: One randomized controlled trial 
      of warfarin vs. aspirin vs. no antithrombotic therapy was found, but no 
      definitive data have yet been published. Three retrospective, non-randomized 
      cohort studies from large trials examining the role of ACE inhibitors have 
      examined the role of aspirin therapy with and without anticoagulant therapy in 
      patients with heart failure and/or left ventricular systolic dysfunction were 
      identified, but the results from these trials were conflicting. A possible 
      interaction with ACE inhibitors may reduce the efficacy of aspirin, although this 
      evidence is from retrospective analyses of trial cohorts. CONCLUSIONS: At present 
      there is no evidence from long term RCTs to recommend use of aspirin to prevent 
      thromboembolism in patients with heart failure in sinus rhythm. There is also no 
      evidence to indicate superior effects from oral anticoagulation, when compared to 
      aspirin, in patients with heart failure in sinus rhythm.
FAU - Lip, G Y H
AU  - Lip GY
AD  - Haemostasis, Thrombosis and Vascular Biology Unit, University Department of 
      Medicine, City Hospital, Birmingham, UK. g.y.h.lip@bham.ac.uk
FAU - Gibbs, C R
AU  - Gibbs CR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - QJM
JT  - QJM : monthly journal of the Association of Physicians
JID - 9438285
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - QJM. 2002 Jul;95(7):419-21. PMID: 12096145
MH  - Adult
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Heart Failure/complications/*drug therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Thromboembolism/etiology/*prevention & control
MH  - Treatment Outcome
MH  - Warfarin/therapeutic use
RF  - 30
EDAT- 2002/07/04 10:00
MHDA- 2002/09/11 10:01
CRDT- 2002/07/04 10:00
PHST- 2002/07/04 10:00 [pubmed]
PHST- 2002/09/11 10:01 [medline]
PHST- 2002/07/04 10:00 [entrez]
AID - 10.1093/qjmed/95.7.461 [doi]
PST - ppublish
SO  - QJM. 2002 Jul;95(7):461-8. doi: 10.1093/qjmed/95.7.461.

PMID- 36002117
OWN - NLM
STAT- MEDLINE
DCOM- 20221109
LR  - 20221122
IS  - 0737-0806 (Print)
IS  - 0737-0806 (Linking)
VI  - 118
DP  - 2022 Nov
TI  - Effect of Acetylsalicylic Acid on Uterine Blood Flow, Gestation Length, Foal 
      Birth Weight and Placental Weight in Pregnant Thoroughbred Mares - A Clinical 
      Pilot Study.
PG  - 104107
LID - S0737-0806(22)00243-X [pii]
LID - 10.1016/j.jevs.2022.104107 [doi]
AB  - The aim of this double-blinded placebo-controlled study was to investigate the 
      effect of acetylsalicylic acid (ASA) on uterine blood flow, gestation length, 
      placental and foal weights in pregnant mares. Sixteen Thoroughbred mares of 
      different age (13.3 ± 4.1) and parity (7.4 ± 3.1) were randomly assigned to three 
      treatment groups. Mares in group C (n = 4) served as controls and received 5,000 
      mg lactose orally once daily from D 120 (D 0 = day of ovulation) until 
      parturition. Mares in group ASA1 (n = 7) received 5,000 mg ASA orally once daily 
      from D 120 until parturition. Mares in group ASA2 (n = 5) received the same dose 
      ASA as group ASA1 from D 120 to D 285, but twice daily from D 285 until 
      parturition. Mares were examined by ultrasonography on D 14, 28, and 60, and in 
      21-days intervals from D 120 until parturition. The cross-sectional area, time 
      average maximum velocity (TAMV), and pulsatility index were measured in both 
      uterine arteries and the blood flow volume was calculated for each uterine artery 
      and then summarized. All 16 mares carried a normal pregnancy and delivered live 
      foals. In group ASA2 TAMV in the ipsilateral artery was significantly higher 
      (P = .03) and these mares showed a tendency of increased total blood flow volume 
      (P = .07) during late pregnancy (D 305-346). Results indicate that oral 
      administration of 5,000 mg of ASA twice daily in pregnant mares causes a rise in 
      uterine blood flow during late pregnancy.
CI  - Copyright © 2022 Elsevier Inc. All rights reserved.
FAU - Sielhorst, Jutta
AU  - Sielhorst J
AD  - Unit for Reproductive Medicine - Clinic for Horses, University of Veterinary 
      Medicine Hanover Foundation, Hanover, Germany; Veterinary Competence Center 
      Karthaus GmbH, Duelmen, Germany. Electronic address: 
      jutta.sielhorst@reprotraining.de.
FAU - Roggel-Buecker, Ute
AU  - Roggel-Buecker U
AD  - Unit for Reproductive Medicine - Clinic for Horses, University of Veterinary 
      Medicine Hanover Foundation, Hanover, Germany; Veterinary Competence Center 
      Karthaus GmbH, Duelmen, Germany.
FAU - Neudeck, Kim-Carolin
AU  - Neudeck KC
AD  - Veterinary Competence Center Karthaus GmbH, Duelmen, Germany.
FAU - Kahler, Anne
AU  - Kahler A
AD  - Veterinary Competence Center Karthaus GmbH, Duelmen, Germany.
FAU - Rohn, Karl
AU  - Rohn K
AD  - Institute for Veterinary Epidemiology, University of Veterinary Medicine Hanover 
      Foundation, Hanover, Germany.
FAU - Luettgenau, Johannes
AU  - Luettgenau J
AD  - Clinic of Reproductive Medicine, Vetsuisse Faculty, University of Zurich, Zurich, 
      Switzerland.
FAU - Bollwein, Heinrich
AU  - Bollwein H
AD  - Clinic of Reproductive Medicine, Vetsuisse Faculty, University of Zurich, Zurich, 
      Switzerland.
FAU - Hollinshead, Fiona
AU  - Hollinshead F
AD  - College of Veterinary Medicine and Biomedical Science, Colorado State University, 
      Fort Collins, CO.
FAU - Sieme, Harald
AU  - Sieme H
AD  - Unit for Reproductive Medicine - Clinic for Horses, University of Veterinary 
      Medicine Hanover Foundation, Hanover, Germany.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial, Veterinary
DEP - 20220821
PL  - United States
TA  - J Equine Vet Sci
JT  - Journal of equine veterinary science
JID - 8216840
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Horses
MH  - Pregnancy
MH  - Animals
MH  - Female
MH  - Birth Weight
MH  - *Placental Circulation
MH  - *Uterus/diagnostic imaging
MH  - Pilot Projects
MH  - Aspirin/pharmacology
MH  - Placenta
MH  - Uterine Artery/diagnostic imaging
MH  - Parturition
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Blood flow
OT  - Doppler sonography
OT  - Equine
OT  - Foal weight
OT  - High-risk pregnancy
EDAT- 2022/08/25 06:00
MHDA- 2022/11/10 06:00
CRDT- 2022/08/24 19:24
PHST- 2022/06/21 00:00 [received]
PHST- 2022/08/15 00:00 [revised]
PHST- 2022/08/17 00:00 [accepted]
PHST- 2022/08/25 06:00 [pubmed]
PHST- 2022/11/10 06:00 [medline]
PHST- 2022/08/24 19:24 [entrez]
AID - S0737-0806(22)00243-X [pii]
AID - 10.1016/j.jevs.2022.104107 [doi]
PST - ppublish
SO  - J Equine Vet Sci. 2022 Nov;118:104107. doi: 10.1016/j.jevs.2022.104107. Epub 2022 
      Aug 21.

PMID- 1904371
OWN - NLM
STAT- MEDLINE
DCOM- 19910717
LR  - 20190620
IS  - 0014-5793 (Print)
IS  - 0014-5793 (Linking)
VI  - 283
IP  - 2
DP  - 1991 Jun 3
TI  - Isolation of a novel arachidonic acid metabolite 
      3-hydroxy-5,8,11,14-eicosatetraenoic acid (3-HETE) from the yeast Dipodascopsis 
      uninucleata UOFs-Y128.
PG  - 195-8
AB  - When arachidonic acid (AA) is added to the yeast Dipodascopsis uninucleata UOFS 
      Y128, one of the major metabolites isolated and purified with the help of thin 
      layer chromatography (TLC) and high performance liquid chromatography (HPLC) is 
      3-hydroxy-5,8,11,14-eicosatetraenoic acid (3-HETE). The structure of this new AA 
      metabolite was elucidated mainly by electron impact (EI) mass spectrometry (MS). 
      Strikingly, the formation of this new metabolite was found to be inhibited by 
      aspirin.
FAU - van Dyk, M S
AU  - van Dyk MS
AD  - Department of Microbiology and Biochemistry, University of the Orange Free State, 
      Bloemfontein, South Africa.
FAU - Kock, J L
AU  - Kock JL
FAU - Coetzee, D J
AU  - Coetzee DJ
FAU - Augustyn, O P
AU  - Augustyn OP
FAU - Nigam, S
AU  - Nigam S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - FEBS Lett
JT  - FEBS letters
JID - 0155157
RN  - 0 (Arachidonic Acids)
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - 135295-02-2 (3-hydroxy-5,8,11,14-eicosatetraenoic acid)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid
MH  - Arachidonic Acids/*metabolism
MH  - Aspirin/pharmacology
MH  - Chromatography, High Pressure Liquid
MH  - Chromatography, Thin Layer
MH  - Hydroxyeicosatetraenoic Acids/chemistry/*isolation & purification
MH  - Mass Spectrometry
MH  - Saccharomycetales/drug effects/*metabolism
MH  - Spectrophotometry
EDAT- 1991/06/03 00:00
MHDA- 1991/06/03 00:01
CRDT- 1991/06/03 00:00
PHST- 1991/06/03 00:00 [pubmed]
PHST- 1991/06/03 00:01 [medline]
PHST- 1991/06/03 00:00 [entrez]
AID - 0014-5793(91)80586-R [pii]
AID - 10.1016/0014-5793(91)80586-r [doi]
PST - ppublish
SO  - FEBS Lett. 1991 Jun 3;283(2):195-8. doi: 10.1016/0014-5793(91)80586-r.

PMID- 15077098
OWN - NLM
STAT- MEDLINE
DCOM- 20040809
LR  - 20181130
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 147
IP  - 4
DP  - 2004 Apr
TI  - A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin 
      after coronary stent implantation.
PG  - E15
AB  - BACKGROUND: The combination of a thienopyridine and aspirin has become the 
      standard of care after intracoronary stenting. Clopidogrel appears to be better 
      tolerated than ticlopidine but may be associated with more adverse cardiac 
      events. We assessed the tolerability and efficacy of 2 weeks of therapy with 
      ticlopidine and aspirin in comparison to clopidogrel and aspirin after coronary 
      stent implantation. METHODS: Patients with successful intracoronary stent 
      implantation at our institution were randomly assigned, in addition to aspirin, 
      to receive either ticlopidine or clopidogrel. Loading doses were administered 
      immediately after the procedure, and the drugs were continued for 2 weeks. 
      RESULTS: Three hundred seven patients were randomly assigned: 154 patients to 
      clopidogrel and 153 to the ticlopidine group. The primary end point of early drug 
      discontinuation occurred in 5 patients (3.3%) in the ticlopidine group and 1 
      patient (0.6%) in the clopidogrel group (P =.121). Within 30 days, thrombotic 
      stent occlusion occurred in 1 patient (0.7%) in the ticlopidine group and 3 
      patients (1.9%) in the clopidogrel group (P =.623). A major adverse cardiac event 
      occurred in 3 patients (approximately 1.9%; P = 1.00) in each group. CONCLUSIONS: 
      There was a nonsignificant trend to improved tolerability of a 2-week regimen of 
      clopidogrel and aspirin when compared with ticlopidine and aspirin in patients 
      undergoing intracoronary stent implantation. The combination of clopidogrel and 
      aspirin results in a comparably low incidence of major adverse cardiac events 
      when compared with ticlopidine and aspirin.
FAU - Juergens, Craig P
AU  - Juergens CP
AD  - Department of Cardiology, Liverpool Hospital, Liverpool, Australia. 
      C.Juergens@unsw.edu.au
FAU - Wong, Adelina M
AU  - Wong AM
FAU - Leung, Dominic Y C
AU  - Leung DY
FAU - Lowe, Harry C
AU  - Lowe HC
FAU - Lo, Sidney
AU  - Lo S
FAU - Fernandes, Clyne
AU  - Fernandes C
FAU - Newland, Elizabeth F
AU  - Newland EF
FAU - Hopkins, Andrew P
AU  - Hopkins AP
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - Coronary Stenosis/*therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Stents
MH  - Ticlopidine/*analogs & derivatives/*therapeutic use
EDAT- 2004/04/13 05:00
MHDA- 2004/08/10 05:00
CRDT- 2004/04/13 05:00
PHST- 2004/04/13 05:00 [pubmed]
PHST- 2004/08/10 05:00 [medline]
PHST- 2004/04/13 05:00 [entrez]
AID - S0002870303007877 [pii]
AID - 10.1016/j.ahj.2003.10.040 [doi]
PST - ppublish
SO  - Am Heart J. 2004 Apr;147(4):E15. doi: 10.1016/j.ahj.2003.10.040.

PMID- 1726214
OWN - NLM
STAT- MEDLINE
DCOM- 19920707
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 42 Suppl 5
DP  - 1991
TI  - Risk factors, interventions and therapeutic agents in the prevention of 
      atherosclerosis-related ischaemic diseases.
PG  - 22-38
AB  - Of the major risk factors for atherosclerosis, high factor VII and fibrinogen 
      levels, genetic predisposition, gender and age cannot be influenced. Reduction of 
      high blood pressure reduces the cerebral but not the coronary vascular risk and 
      correction of dyslipidaemia correlates with cardiovascular risk. Other major risk 
      factors (tobacco consumption, obesity, sedentary lifestyle and diabetes) can also 
      be modified. Aspirin in doses of approximately 300 mg/day may be recommended for 
      the primary prevention of myocardial infarction (MI), but only in those patients 
      with a moderate to high risk of cardiovascular disease. Aspirin reduces the risk 
      of fatal and nonfatal MI by about 50% and also decreases the overall mortality 
      rate among patients with unstable angina. A lower dose of aspirin (150 mg/day) 
      also reduces mortality by 23% in the acute phase of MI. In doses of 300 mg/day, 
      aspirin is useful in the secondary prevention of MI and reduces the overall 
      mortality rate by 15%. Various antiplatelet agents, including aspirin (alone or 
      combined with dipyridamole) and ticlopidine, have proved useful in the prevention 
      of thrombosis in aorto-coronary grafts, provided treatment begins at the latest 6 
      hours after surgery. The usefulness of antiplatelet drugs has been well 
      established in the prevention of immediate reocclusion following coronary 
      angioplasty, but not in the prevention of late reocclusion. Aspirin and 
      ticlopidine are also beneficial in extracorporeal circulation techniques. In 
      patients with a synthetic cardiac valve prosthesis, antivitamin K-anticoagulants 
      are still indispensable lifelong, but their antithrombotic effect can be 
      reinforced by dipyridamole or aspirin. Diuretics probably provide the best 
      primary protection against cerebrovascular accidents, although medium doses of 
      aspirin may be considered in elderly people at high risk of such accidents. 
      Aspirin (alone or combined with dipyridamole) and ticlopidine may be recommended 
      for the secondary prevention of cerebral ischaemic accidents. Aspirin (with or 
      without dipyridamole) and ticlopidine reinforce the treatment of obliterative 
      arterial disease in the lower limbs.
FAU - Verstraete, M
AU  - Verstraete M
AD  - Centre for Thrombosis and Vascular Research, University of Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Coronary Artery Disease/*complications
MH  - Coronary Disease/*prevention & control
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/prevention & control
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
RF  - 152
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.2165/00003495-199100425-00006 [doi]
PST - ppublish
SO  - Drugs. 1991;42 Suppl 5:22-38. doi: 10.2165/00003495-199100425-00006.

PMID- 21353610
OWN - NLM
STAT- MEDLINE
DCOM- 20110804
LR  - 20131121
IS  - 1096-7206 (Electronic)
IS  - 1096-7192 (Linking)
VI  - 103
IP  - 1
DP  - 2011 May
TI  - Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the 
      positive effect of long-term aspirin treatment.
PG  - 18-25
LID - 10.1016/j.ymgme.2011.01.015 [doi]
AB  - Sanfilippo disease (MPS IIIA) is an autosomal recessive lysosomal storage 
      disorder resulting from sulfamidase deficiency, which is characterized by severe 
      neurological impairment. Various tissues of MPS IIIA mice accumulate undegraded 
      glycosaminoglycans and mimic the human neurodegenerative disorder, and are an 
      excellent tool to both delineate disease pathogenesis and test potential 
      therapies. The relationship between abnormal glycosaminoglycan storage and 
      neurodysfunction remains ill defined. Pathways such as inflammation or oxidative 
      stress have been highlighted in many neurodegenerative disorders, including 
      lysosomal storage diseases, as major components of the neuropathology. By using 
      quantitative polymerase chain reaction, we have compared the expression of 
      selected genes in normal and MPS IIIA mouse cerebral tissues, focusing on 
      inflammation, apoptosis and oxidative stress-related genes. We have identified 
      several genes strongly over-expressed in the central nervous system of a MPS IIIA 
      mouse, reflecting a neurological deterioration state. We have used these genes as 
      markers to follow-up a long-term aspirin treatment. Aspirin treatment led to the 
      normalization of inflammation- and oxidative stress-related mRNA levels in 
      treated MPS IIIA mouse brains. A biochemical correction of an oxidative stress 
      phenomenon both in the brain and peripheral organs of treated MPS IIIA mice was 
      also obtained. These results suggest that anti-inflammatory intervention may be 
      of potential benefit in MPS IIIA disease.
CI  - Copyright © 2011 Elsevier Inc. All rights reserved.
FAU - Arfi, Audrey
AU  - Arfi A
AD  - CNRS UMR8151, Paris, F-75006, France.
FAU - Richard, Magali
AU  - Richard M
FAU - Gandolphe, Christelle
AU  - Gandolphe C
FAU - Bonnefont-Rousselot, Dominique
AU  - Bonnefont-Rousselot D
FAU - Thérond, Patrice
AU  - Thérond P
FAU - Scherman, Daniel
AU  - Scherman D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110203
PL  - United States
TA  - Mol Genet Metab
JT  - Molecular genetics and metabolism
JID - 9805456
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects/genetics
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Brain/*drug effects/metabolism
MH  - Disease Models, Animal
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation/drug effects
MH  - Glutathione/metabolism
MH  - Humans
MH  - Inflammation/*drug therapy/genetics/metabolism
MH  - Kinetics
MH  - Male
MH  - Mice
MH  - Mucopolysaccharidosis III/drug therapy/genetics/metabolism
MH  - Oxidative Stress/*drug effects/genetics
EDAT- 2011/03/01 06:00
MHDA- 2011/08/05 06:00
CRDT- 2011/03/01 06:00
PHST- 2010/12/17 00:00 [received]
PHST- 2011/01/28 00:00 [revised]
PHST- 2011/01/28 00:00 [accepted]
PHST- 2011/03/01 06:00 [entrez]
PHST- 2011/03/01 06:00 [pubmed]
PHST- 2011/08/05 06:00 [medline]
AID - S1096-7192(11)00040-0 [pii]
AID - 10.1016/j.ymgme.2011.01.015 [doi]
PST - ppublish
SO  - Mol Genet Metab. 2011 May;103(1):18-25. doi: 10.1016/j.ymgme.2011.01.015. Epub 
      2011 Feb 3.

PMID- 26850406
OWN - NLM
STAT- MEDLINE
DCOM- 20160510
LR  - 20181202
IS  - 0254-6450 (Print)
IS  - 0254-6450 (Linking)
VI  - 36
IP  - 12
DP  - 2015 Dec
TI  - [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel 
      versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic 
      attack].
PG  - 1430-5
AB  - OBJECTIVE: To present the systematic assessment on the efficacy and bleeding 
      adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus 
      aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient 
      ischemic attack. METHODS: Retrieve randomized controlled trials conformed to the 
      inclusion and exclusion criteria in Cochrane Library, Medline, Embase, and Web of 
      Science electronic database, between January 1, 1998 and April 1, 2015. Cochrane 
      Collaboration was used to assess the methodological quality of the included 
      research papers. Stratification analysis was performed on factors as: race, 
      subtypes of the disease, duration of follow-up and with or without clopidogrel 
      loading dose, of the patients. RESULTS: A total of 7 studies were eligible for 
      analysis, including 14 022 study objects. Data from Meta-analysis showed that 
      dual-antiplatelet therapy, when compared to the mono-therapy group, could reduce 
      the risk of recurrent stroke (RR=0.71, 95%CI: 0.61-0.84, P<0.001) , at the same 
      time, increase the risk of bleeding events (RR=1.60, 95%CI: 1.46-1.76, P<0.001). 
      Data derived from the Hierarchical analysis showed that the risk of stroke 
      recurrence in Chinese population (RR=0.55, 95%CI: 0.34-0.89) was lower than 
      recorded in other populations (RR=0.78, 95%CI: 0.66-0.93) , with the risks of 
      bleeding events as RR=1.41 (95%CI: 1.01-1.96) and RR=1.62 (95%CI: 1.47-1.79) , 
      respectively. Risk of recurrence among the group with clopidogrel loading dose 
      (RR=0.69, 95%CI: 0.58-0.81) was less than those without (RR=0.74, 
      95%CI:0.56-0.99). The risks of occurrence on bleeding events were RR=1.59 (95%CI: 
      1.10-2.30) and RR=1.60 (95%CI: 1.46-1.77) , respectively. CONCLUSION: The 
      combined therapy of aspirin and clopidogrel could reduce the risk of recurrence 
      of ischemic stroke and TIA patients, but increase the risk of bleeding, when 
      compared to the group that using aspirin alone for the therapy. In Chinese 
      population, the combined therapy seemed more effective than using aspirin alone 
      in reducing the recurrence of stroke, but without increasing the risk of 
      bleeding.
FAU - Yang, Cheng
AU  - Yang C
AD  - Department of Epidemiology and Biostatistics, Peking University Health Science 
      Center, Beijing 100191, China.
FAU - Qian, Jie
AU  - Qian J
AD  - Department of Epidemiology and Biostatistics, Peking University Health Science 
      Center, Beijing 100191, China.
FAU - Tang, Xun
AU  - Tang X
AD  - Department of Epidemiology and Biostatistics, Peking University Health Science 
      Center, Beijing 100191, China.
FAU - Gao, Pei
AU  - Gao P
AD  - Department of Epidemiology and Biostatistics, Peking University Health Science 
      Center, Beijing 100191, China.
FAU - Hu, Yonghua
AU  - Hu Y
AD  - Department of Epidemiology and Biostatistics, Peking University Health Science 
      Center, Beijing 100191, China; Email: yhhu@bjmu.edu.cn.
LA  - chi
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Liu Xing Bing Xue Za Zhi
JT  - Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
JID - 8208604
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Databases, Factual
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Risk
MH  - Stroke/*drug therapy
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2016/02/07 06:00
MHDA- 2016/05/11 06:00
CRDT- 2016/02/07 06:00
PHST- 2016/02/07 06:00 [entrez]
PHST- 2016/02/07 06:00 [pubmed]
PHST- 2016/05/11 06:00 [medline]
PST - ppublish
SO  - Zhonghua Liu Xing Bing Xue Za Zhi. 2015 Dec;36(12):1430-5.

PMID- 30825911
OWN - NLM
STAT- MEDLINE
DCOM- 20190409
LR  - 20190409
IS  - 2210-7797 (Electronic)
IS  - 2210-7789 (Linking)
VI  - 15
DP  - 2019 Jan
TI  - Aspirin causes endothelium-dependent vasodilation of resistance arteries from 
      non-gravid and gravid rats.
PG  - 141-145
LID - S2210-7789(18)30037-0 [pii]
LID - 10.1016/j.preghy.2019.01.001 [doi]
AB  - OBJECTIVE: The objective of this study was to understand the effect of 
      acetylsalicylic acid (aspirin) on resistance arteries from mesentery and uterus. 
      During pregnancy, the uterine vasculature undergoes consistent growth to provide 
      sufficient uteroplacental blood flow, a process whose failure is associated with 
      pregnancy complications characterized by high uterine vascular resistance. 
      METHODS: Uterine arcuate (UA) and mesenteric arteries (MA; diameter <300 µm) 
      isolated from non-gravid, mid-gravid (day 14), and late-gravid rats (day 20) were 
      exposed to aspirin (10(-12) to 10(-5) M). Further, in UA from late-gravid rats, 
      aspirin was evaluated in presence of inhibitors of nitric oxide synthases, 
      cyclooxygenase, cyclic nucleotides (cAMP, cGMP) and BK channels, and also on 
      endothelium-denuded vessels. RESULTS: Aspirin dilated both UA and MA in a dose 
      dependent manner. Pregnancy increased aspirin vasodilation in MA and UA from 
      mid-gravid rats, an effect that was reduced in vessels from late gravid animals 
      at concentrations >10(-7) M. Further, uterine vasodilation was significantly 
      reduced when the endothelium was removed (p < 0.001), and by inhibitors of nitric 
      oxide synthase (p < 0.001), cyclooxygenase synthase (p < 0.05), cyclic 
      nucleotides cGMP/cAMP and BK channels. CONCLUSION: This is the first study to 
      show a direct vasodilatory effect of aspirin on rat uterine artery that is 
      mediated by a combination of cellular - primarily endothelial - mechanisms. Our 
      results in UA suggest that the use of aspirin may be effective in enhancing 
      uteroplacental blood flow, while its vasodilation effect on MA may lower 
      peripheral resistance.
CI  - Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Helgadottir, Helga
AU  - Helgadottir H
AD  - Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, 107 
      Reykjavik, Iceland; Department of Biology, Ecology and Earth Sciences, University 
      of Calabria, Arcavacata di Rende (CS), Italy.
FAU - Tropea, Teresa
AU  - Tropea T
AD  - Department of Biology, Ecology and Earth Sciences, University of Calabria, 
      Arcavacata di Rende (CS), Italy.
FAU - Gizurarson, Sveinbjorn
AU  - Gizurarson S
AD  - Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, 107 
      Reykjavik, Iceland.
FAU - Meiri, Hamutal
AU  - Meiri H
AD  - TeleMarpe Ltd., Tel Aviv, Israel.
FAU - Mandalà, Maurizio
AU  - Mandalà M
AD  - Department of Biology, Ecology and Earth Sciences, University of Calabria, 
      Arcavacata di Rende (CS), Italy. Electronic address: m.mandala@unical.it.
LA  - eng
PT  - Journal Article
DEP - 20190110
PL  - Netherlands
TA  - Pregnancy Hypertens
JT  - Pregnancy hypertension
JID - 101552483
RN  - 0 (Vasodilator Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Mesenteric Arteries/*drug effects
MH  - Placenta/blood supply
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Uterine Artery/*drug effects
MH  - Vascular Resistance/*drug effects
MH  - *Vasodilation
MH  - Vasodilator Agents/*pharmacology
EDAT- 2019/03/04 06:00
MHDA- 2019/04/10 06:00
CRDT- 2019/03/04 06:00
PHST- 2018/02/27 00:00 [received]
PHST- 2018/12/07 00:00 [revised]
PHST- 2019/01/09 00:00 [accepted]
PHST- 2019/03/04 06:00 [entrez]
PHST- 2019/03/04 06:00 [pubmed]
PHST- 2019/04/10 06:00 [medline]
AID - S2210-7789(18)30037-0 [pii]
AID - 10.1016/j.preghy.2019.01.001 [doi]
PST - ppublish
SO  - Pregnancy Hypertens. 2019 Jan;15:141-145. doi: 10.1016/j.preghy.2019.01.001. Epub 
      2019 Jan 10.

PMID- 16923439
OWN - NLM
STAT- MEDLINE
DCOM- 20060928
LR  - 20131121
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 98
IP  - 5
DP  - 2006 Sep 1
TI  - Frequency of aspirin resistance in a community hospital.
PG  - 577-9
AB  - Aspirin resistance and its predictors were studied in community hospital patients 
      who required antiplatelet therapy for thrombotic event prophylaxis. Demographic 
      and antiplatelet medication data were collected and medication response followed. 
      Aspirin resistance was assayed with the VerifyNow System with > or = 550 aspirin 
      reaction units (ARUs) used as a dichotomous indicator of aspirin resistance. 
      Patients (n = 123) were 21 to 95 years old; 49.6% were women, 77.2% were black, 
      95.1% were hypertensive, 85.4% had coronary disease, and 30.1% were smokers. ARU 
      score for 325 versus 81 mg/day was 435.2 +/- 93.7 versus 401.9 +/- 83.9 ARU (p = 
      0.04), with a 12.1% (8 of 66 patients) nonresponse rate to 81 mg/day. Of the 8 
      patients who were unresponsive to 81 mg/day of aspirin, 7 responded to 325 
      mg/day. The 5.3% (3 of 57 patients) who were resistant to 325 mg/day received 
      clopidogrel; 2 became responders. Multivariate analysis demonstrated significant 
      associations of aspirin resistance with smoking (risk ratio 11.47, 95% confidence 
      interval 6.69 to 18.63, p < 0.0001), including a significant interaction between 
      smoking and aspirin resistance. In conclusion, this study estimates aspirin 
      resistance prevalence and shows a strong association of smoking with platelet 
      hyperactivity in a diverse community hospital population. Nonresponders to 81 
      mg/day frequently responded to 325 mg/day or to the addition of clopidogrel.
FAU - Mirkhel, Ahmadshah
AU  - Mirkhel A
AD  - Department of Internal Medicine, Prince Georges Hospital Center, Cheverly, 
      Maryland, USA.
FAU - Peyster, Eliot
AU  - Peyster E
FAU - Sundeen, James
AU  - Sundeen J
FAU - Greene, Linda
AU  - Greene L
FAU - Michelson, Alan D
AU  - Michelson AD
FAU - Hasan, Ahmed
AU  - Hasan A
FAU - Domanski, Michael
AU  - Domanski M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20060630
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology
MH  - *Drug Resistance
MH  - Female
MH  - Hospitals, Community/*statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Maryland/epidemiology
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Prognosis
MH  - Retrospective Studies
MH  - Thrombosis/drug therapy
EDAT- 2006/08/23 09:00
MHDA- 2006/09/29 09:00
CRDT- 2006/08/23 09:00
PHST- 2006/02/17 00:00 [received]
PHST- 2006/03/21 00:00 [revised]
PHST- 2006/03/21 00:00 [accepted]
PHST- 2006/08/23 09:00 [pubmed]
PHST- 2006/09/29 09:00 [medline]
PHST- 2006/08/23 09:00 [entrez]
AID - S0002-9149(06)00978-7 [pii]
AID - 10.1016/j.amjcard.2006.03.029 [doi]
PST - ppublish
SO  - Am J Cardiol. 2006 Sep 1;98(5):577-9. doi: 10.1016/j.amjcard.2006.03.029. Epub 
      2006 Jun 30.

PMID- 33099285
OWN - NLM
STAT- MEDLINE
DCOM- 20211126
LR  - 20211126
IS  - 1098-8785 (Electronic)
IS  - 0735-1631 (Print)
IS  - 0735-1631 (Linking)
VI  - 38
IP  - 6
DP  - 2021 May
TI  - Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk 
      Urban Cohort: A Prospective Cohort Study.
PG  - 544-552
LID - 10.1055/s-0040-1718580 [doi]
AB  - OBJECTIVE: This study aimed to evaluate the utilization of aspirin for 
      preeclampsia prevention before and after implementation of a screening tool 
      during nuchal translucency (NT) ultrasound. STUDY DESIGN: One-year prospective 
      cohort study of patients at high risk for preeclampsia after the implementation 
      of a screening tool (postscreen) administered to all patients at check in for NT 
      (11-13 weeks) ultrasound. Prospective cohort was compared with one-year 
      retrospective cohort (prescreen) the year prior (2017). All patients who 
      presented for NT ultrasound in both cohorts were evaluated for the presence of 
      one or more risk factor for preeclampsia with screening tool collected 
      prospectively and chart review retrospectively. Provider recommendation for 
      aspirin determined by documentation in prenatal record. Primary outcome was rate 
      of provider recommendation for aspirin pre versus post screening tool, compared 
      by Chi-square test and adjusted for potential confounders with multiple 
      regression analysis. RESULTS: Pre- (n = 156) and postscreen (n = 136) cohorts 
      were similar except for race and multifetal gestation. Prescreen, rate of 
      provider recommendation for aspirin was 74%. Of those with prior preeclampsia, 
      96% were recommended aspirin, compared with 64% of patients with other risk 
      factors (p < 0.001). Postscreen, provider recommendation of aspirin improved to 
      95% (p < 0.001). Rate of preeclampsia/gestational hypertension were similar 
      between cohorts; however, there was a reduced adjusted risk in overall preterm 
      birth <37 weeks (adjusted odds ratio [aOR] = 0.50 [0.25-0.99]) and preterm birth 
      <34 weeks (aOR = 0.33 [0.13-0.88]) postscreening tool implementation. CONCLUSION: 
      Prior to implementation of a simple screening questionnaire, approximately 25% of 
      high risk patients did not receive the recommendation of aspirin for preeclampsia 
      prevention. High-risk patients who lack a history of preeclampsia were less 
      likely to be advised of aspirin prophylaxis. Use of a simple universal screening 
      tool at time of NT ultrasound significantly improved utilization of aspirin for 
      preeclampsia prevention and may improve patient outcomes. KEY POINTS: · Despite 
      recommendations, aspirin use for preeclampsia prevention is suboptimal.. · 
      High-risk patients who lack a history preeclampsia were less likely to be advised 
      of aspirin use.. · A simple universal screening tool can significantly improve 
      aspirin utilization..
CI  - Thieme. All rights reserved.
FAU - Boelig, Rupsa C
AU  - Boelig RC
AUID- ORCID: 0000-0002-3705-6943
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, 
      Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Wanees, Mariam
AU  - Wanees M
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, 
      Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Zhan, Tingting
AU  - Zhan T
AD  - Division of Biostatistics, Department of Pharmacology and Experimental 
      Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania.
FAU - Berghella, Vincenzo
AU  - Berghella V
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, 
      Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Roman, Amanda
AU  - Roman A
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, 
      Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
LA  - eng
GR  - T32 GM008562/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201024
PL  - United States
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cohort Studies
MH  - Drug Administration Schedule
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/epidemiology
MH  - Premature Birth
MH  - Prospective Studies
MH  - Risk Assessment
PMC - PMC8491097
MID - NIHMS1737781
COIS- R.C.B. reports grants from March of Dimes Community Grant, grants from NIH (grant 
      no.: T32GM008562), grants from PhRMA Foundation Faculty Development Award, during 
      the conduct of the study. The other authors report no conflict of interest.
EDAT- 2020/10/26 06:00
MHDA- 2021/11/27 06:00
CRDT- 2020/10/25 00:11
PHST- 2020/10/26 06:00 [pubmed]
PHST- 2021/11/27 06:00 [medline]
PHST- 2020/10/25 00:11 [entrez]
AID - 10.1055/s-0040-1718580 [doi]
PST - ppublish
SO  - Am J Perinatol. 2021 May;38(6):544-552. doi: 10.1055/s-0040-1718580. Epub 2020 
      Oct 24.

PMID- 3187983
OWN - NLM
STAT- MEDLINE
DCOM- 19881215
LR  - 20131121
IS  - 0171-6425 (Print)
IS  - 0171-6425 (Linking)
VI  - 36
IP  - 4
DP  - 1988 Aug
TI  - Patency rate of small caliber fibrous polyurethane vascular prostheses implanted 
      in the dog carotid and femoral artery improved by use of acetylsalicylic acid and 
      dipyridamol.
PG  - 221-6
AB  - Segments of 3 mm diameter fibrous polyurethane vascular prosthesis of length 3-4 
      cm were prepared. They were bilaterally implanted in the carotid and femoral 
      arteries of male and female beagles. Four groups consisting of animals receiving 
      either no medication or thrombocyte aggregation drugs were studied: Group A (8 
      dogs), no medication: group B (19 dogs), 500 mg acetylsalicylic acid (ASA) once 
      daily and 25 mg dipyridamol (DIP) three times daily orally for 6 weeks after the 
      implantation operation; group C (14 dogs), 250 mg ASA and 25 mg DIP three times 
      daily orally for 6 weeks after the implantation operation; group D (12 dogs), 250 
      mg ASA and 25 mg DIP three times daily orally for 25 weeks after the implantation 
      operation. Medication was started one week prior to the implantation operation. 
      In group A, all prostheses were occluded at week 6. There was a significant 
      difference in patency rates between groups B-D and C-D. No significant 
      differences in patency rates could be found between groups B and C. The best 
      patency rates were obtained 25 weeks after implantation in group D for both the 
      right and left carotid and right and left femoral implantation sites. Highest 
      patency rates were observed when ASA and DIP were given for 25 weeks.
FAU - Hess, F
AU  - Hess F
AD  - Laboratory for Cell Biology and Histology, Catholic University of Nijmegen, The 
      Netherlands.
FAU - Steeghs, S
AU  - Steeghs S
FAU - Braun, B
AU  - Braun B
FAU - van Det, R
AU  - van Det R
FAU - Grande, P
AU  - Grande P
FAU - Jerusalem, C
AU  - Jerusalem C
FAU - Skotnicki, S
AU  - Skotnicki S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Thorac Cardiovasc Surg
JT  - The Thoracic and cardiovascular surgeon
JID - 7903387
RN  - 0 (Polyurethanes)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - *Blood Vessel Prosthesis
MH  - Carotid Arteries/*surgery
MH  - Dipyridamole/*therapeutic use
MH  - Dogs
MH  - Female
MH  - Femoral Artery/*surgery
MH  - Graft Occlusion, Vascular
MH  - Male
MH  - Microscopy, Electron, Scanning
MH  - Polyurethanes
MH  - Vascular Patency/*drug effects
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
AID - 10.1055/s-2007-1020083 [doi]
PST - ppublish
SO  - Thorac Cardiovasc Surg. 1988 Aug;36(4):221-6. doi: 10.1055/s-2007-1020083.

PMID- 6300366
OWN - NLM
STAT- MEDLINE
DCOM- 19830505
LR  - 20190913
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 5
IP  - 11
DP  - 1982 Nov
TI  - Cytoprotective effect of cyclic AMP on cultured rabbit gastric cells.
PG  - 911-5
AB  - A new experimental system with cultured gastric cells was developed to estimate 
      the cytoprotective and damaging effects of drugs. The gastric cells were 
      incubated in vitro in medium of pH 3, and their resistance to acid was determined 
      by measuring percentage of damaged cells as a function of time. Pretreatment with 
      0.5 mM acetylsalicylic acid (ASA) for 24 h decreased their resistance (26%), 
      whereas pretreatment with 0.3-3 micrograms/ml of 16,16-dimethylprostaglandin E2 
      (dimethyl PGE2) for 4 h increased their resistance (13-16%). The adenosine 
      3':5'-cyclic monophosphate (cyclic AMP) level in the cultured gastric cells was 
      decreased by 0.5 mM ASA (30%) and increased by 0.3 microgram/ml of dimethyl PGE2 
      (38%) on treatment for 24 h. These changes reflect phenomena observed in the 
      gastric mucosa, suggesting that this experimental system is valid as an in vitro 
      model. Concentrations of 0.1 mM cyclic AMP and 0.1 mM N6, O2'-dibutyryladenosine 
      3':5'-cyclic monophosphate (dibutyryl cyclic AMP) were found to exert 
      cytoprotective effects on the cells (5 and 7% increase, respectively). 
      Furthermore, 0.1 mM cyclic AMP caused partial recovery from 0.5 mM ASA-induced 
      decrease in resistance (ASA: 17%, ASA + cyclic AMP: 9%). These findings suggest 
      that cyclic AMP plays a role in protection of cultured gastric cells and 
      presumably also of gastric mucosal cells in vivo.
FAU - Matuoka, K
AU  - Matuoka K
FAU - Mitsui, Y
AU  - Mitsui Y
FAU - Murota, S I
AU  - Murota SI
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Prostaglandins)
RN  - E0399OZS9N (Cyclic AMP)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/toxicity
MH  - Cells, Cultured
MH  - Cyclic AMP/*pharmacology
MH  - Prostaglandins/pharmacology
MH  - Rabbits
MH  - Stomach/*drug effects/pathology
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
AID - 10.1248/bpb1978.5.911 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1982 Nov;5(11):911-5. doi: 10.1248/bpb1978.5.911.

PMID- 3595474
OWN - NLM
STAT- MEDLINE
DCOM- 19870730
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 33 Suppl 1
DP  - 1987
TI  - The evolution of non-steroidal anti-inflammatory drugs and their mechanisms of 
      action.
PG  - 18-27
AB  - The pro-inflammatory effects of prostaglandins have been clearly demonstrated 
      with the use of various animal models of inflammation. Furthermore, the 
      anti-inflammatory effects and some of the side effects of aspirin and other 
      non-steroidal anti-inflammatory agents have been shown to depend on their ability 
      to inhibit cyclo-oxygenase. These drugs, therefore, reduce the synthesis of 
      prostaglandins, prostacyclin and thromboxane. They do not affect leukotriene 
      production and there is no firm evidence to suggest that they alleviate 
      inflammation through any other mechanism. In contrast, the corticosteroids 
      facilitate the release of lipocortin which, through inhibition of phospholipase 
      A2 reduces arachidonic acid release. These drugs possess potent anti-inflammatory 
      properties and attempts have been made to develop non-steroidal drugs, such as 
      BW755C, that display similar anti-inflammatory activity through inhibition of the 
      2 main pathways of the arachidonic acid cascade. Administration of low dose 
      aspirin 40 mg/day selectively inhibits production of thromboxane A2 without 
      affecting prostacyclin. This may be because, firstly, about 60% of an 
      administered dose of aspirin is deacylated to salicylate during first-pass 
      metabolism and, secondly, platelets cannot regenerate cyclo-oxygenase. Thus, 
      absorbed aspirin irreversibly affects platelet thromboxane production in the 
      pre-systemic circulation, but the systemic plasma aspirin concentration is likely 
      to be too low to affect prostacyclin synthesis. Studies in experimental 
      inflammation have shown that after the administration of aspirin, the 
      concentration of salicylate in inflammatory exudate is considerably higher than 
      that of aspirin. In addition, a comparison of prostaglandin synthesis inhibitory 
      potencies shows that the concentration of salicylate, but not of aspirin, at the 
      inflammatory site is high enough to substantially inhibit prostaglandin 
      synthesis.
FAU - Vane, J
AU  - Vane J
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/pharmacology
MH  - Humans
MH  - Inflammation/*drug therapy/metabolism
MH  - Salicylates/pharmacology
MH  - Salicylic Acid
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.2165/00003495-198700331-00005 [doi]
PST - ppublish
SO  - Drugs. 1987;33 Suppl 1:18-27. doi: 10.2165/00003495-198700331-00005.

PMID- 24214182
OWN - NLM
STAT- MEDLINE
DCOM- 20140725
LR  - 20181202
IS  - 1539-3429 (Electronic)
IS  - 1470-8175 (Linking)
VI  - 41
IP  - 6
DP  - 2013 Nov-Dec
TI  - Over the counter drugs (and dietary supplement) exercise: a team-based 
      introduction to biochemistry for health professional students.
PG  - 384-7
LID - 10.1002/bmb.20738 [doi]
AB  - For successful delivery of basic science topics for health-professional students, 
      it is critical to reduce apprehension and illustrate relevance to clinical 
      settings and everyday life. At the beginning of the Biochemistry course for 
      Physician Assistants, a team-based assignment was designed to develop an 
      understanding of the mechanism of action, effectiveness, and toxicity of five 
      common over the counter (OTC) drugs and dietary supplements, and place these 
      familiar medicines in a political and historical context. The objectives of this 
      exercise were to stimulate interest in biochemistry; to provide basic information 
      on enzymes and enzyme inhibitors related to these drugs to be expanded upon later 
      in the course; and to encourage active and interactive learning. Teams of five 
      students were formed, and each student was given an information sheet on aspirin, 
      alpha-galactosidase, orlistat, dextromethorphan, or simvastatin, a low dose 
      statin, which was previously available without prescription at pharmacies in the 
      UK. After each member of the team acquired information on one OTC drug/dietary 
      supplement by reading an assigned information sheet, the team was asked to go 
      through a series of questions, and then submit answers to a quiz as a group. A 
      high rate of success on the quiz, an overwhelmingly positive response on formal 
      course evaluations, and enthusiastic exchanges during class suggested this 
      team-based session accomplished its goals.
CI  - Copyright © 2013 Wiley-Liss, Inc.
FAU - Phadtare, Sangita
AU  - Phadtare S
AD  - Department of Biochemistry and Molecular Biology, Rutgers-Robert Wood Johnson 
      Medical School, Piscataway, New Jersey, 08854.
FAU - Abali, Emine
AU  - Abali E
FAU - Brodsky, Barbara
AU  - Brodsky B
LA  - eng
PT  - Journal Article
DEP - 20131109
PL  - United States
TA  - Biochem Mol Biol Educ
JT  - Biochemistry and molecular biology education : a bimonthly publication of the 
      International Union of Biochemistry and Molecular Biology
JID - 100970605
RN  - 0 (Lactones)
RN  - 0 (Nonprescription Drugs)
RN  - 7355X3ROTS (Dextromethorphan)
RN  - 95M8R751W8 (Orlistat)
RN  - AGG2FN16EV (Simvastatin)
RN  - EC 3.2.1.22 (alpha-Galactosidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/chemistry
MH  - Biochemistry/*education
MH  - Dextromethorphan/administration & dosage/adverse effects/chemistry
MH  - Dietary Supplements
MH  - Humans
MH  - Lactones/administration & dosage/adverse effects/chemistry
MH  - Nonprescription Drugs/administration & dosage/adverse effects/*chemistry
MH  - Orlistat
MH  - Physician Assistants/*education
MH  - Problem-Based Learning/methods
MH  - Reproducibility of Results
MH  - Simvastatin/administration & dosage/adverse effects/chemistry
MH  - Students
MH  - Surveys and Questionnaires
MH  - Teaching/*methods
MH  - alpha-Galactosidase/administration & dosage/adverse effects/chemistry
OTO - NOTNLM
OT  - PBL
OT  - active learning
OT  - medical biochemistry
OT  - original models for teaching and learning
OT  - problem-based learning
OT  - teaching and learning techniques methods and approaches
EDAT- 2013/11/12 06:00
MHDA- 2014/07/26 06:00
CRDT- 2013/11/12 06:00
PHST- 2013/08/14 00:00 [revised]
PHST- 2013/08/23 00:00 [accepted]
PHST- 2013/11/12 06:00 [entrez]
PHST- 2013/11/12 06:00 [pubmed]
PHST- 2014/07/26 06:00 [medline]
AID - 10.1002/bmb.20738 [doi]
PST - ppublish
SO  - Biochem Mol Biol Educ. 2013 Nov-Dec;41(6):384-7. doi: 10.1002/bmb.20738. Epub 
      2013 Nov 9.

PMID- 21351314
OWN - NLM
STAT- MEDLINE
DCOM- 20110624
LR  - 20211020
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Print)
IS  - 1053-8569 (Linking)
VI  - 20
IP  - 3
DP  - 2011 Mar
TI  - Ascertainment of warfarin and aspirin use by medical record review compared with 
      automated pharmacy data.
PG  - 313-6
LID - 10.1002/pds.2041 [doi]
AB  - PURPOSE: Automated pharmacy databases are increasingly available for assessing 
      medication use, but research on the validity of these data is incomplete. This 
      study aimed to measure agreement on warfarin and aspirin use between medical 
      records and automated pharmacy data among patients with newly detected atrial 
      fibrillation (AF). METHODS: Patients with newly detected AF (n = 1953) were 
      previously identified in a cohort study at Group Health (GH) in Washington State. 
      Medical records were reviewed for information on risk factors and medication use, 
      as well as clinical care during the 6 months after AF onset. Medication data were 
      also obtained from the GH pharmacy database. We determined the sensitivity, 
      specificity, and positive predictive value (PPV) as measures of the validity of 
      the GH pharmacy database as compared with medical records for warfarin and 
      aspirin use during the first 6 and 3 months after AF onset. We also calculated 
      the κ statistic. RESULTS: For warfarin use, in comparison with the medical record 
      review, the sensitivity, specificity, and PPV for the GH pharmacy database were 
      excellent, and agreement was almost perfect in the 3- and 6-month periods after 
      AF onset (κ = 0.92 and 0.93, respectively). For aspirin use, the GH pharmacy 
      database had low sensitivity but high specificity, and agreement was only fair 
      for these two periods (κ = 0.28 and 0.31, respectively). CONCLUSIONS: The GH 
      pharmacy database is a valuable source of data for pharmacoepidemiologic research 
      on warfarin use among patients with AF. However, the database cannot be 
      recommended for assessment of aspirin use. Copyright © 2010 John Wiley & Sons, 
      Ltd.
CI  - Copyright © 2010 John Wiley & Sons, Ltd.
FAU - Garg, Renu K
AU  - Garg RK
AD  - Department of Epidemiology, University of Washington, Seattle, WA 98101-1448, 
      USA. rkgarg@u.washington.edu
FAU - Glazer, Nicole L
AU  - Glazer NL
FAU - Wiggins, Kerri L
AU  - Wiggins KL
FAU - Newton, Katherine M
AU  - Newton KM
FAU - Thacker, Evan L
AU  - Thacker EL
FAU - Smith, Nicholas L
AU  - Smith NL
FAU - Siscovick, David S
AU  - Siscovick DS
FAU - Psaty, Bruce M
AU  - Psaty BM
FAU - Heckbert, Susan R
AU  - Heckbert SR
LA  - eng
GR  - R01 HL068986/HL/NHLBI NIH HHS/United States
GR  - R01 HL068986-06/HL/NHLBI NIH HHS/United States
GR  - T32 HL007902/HL/NHLBI NIH HHS/United States
GR  - T32 HL007902-12/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20101223
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Atrial Fibrillation/drug therapy/epidemiology
MH  - Cohort Studies
MH  - Community Pharmacy Services/*statistics & numerical data
MH  - Databases, Factual/*statistics & numerical data
MH  - Drug Utilization Review/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Medical Records/statistics & numerical data
MH  - Medical Records Systems, Computerized/*statistics & numerical data
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Warfarin/*administration & dosage/therapeutic use
MH  - Washington
PMC - PMC3181009
MID - NIHMS264473
COIS- CONFLICT OF INTEREST All of the authors declare no financial, personal, 
      commercial, or academic conflicts of interest, and none related to study 
      interpretation. Additionally, the study sponsors had no involvement in the study 
      design, in the data collection, analysis and interpretation, in the writing of 
      the report, or in the decision to submit the report for publication.
EDAT- 2011/02/26 06:00
MHDA- 2011/06/28 06:00
CRDT- 2011/02/26 06:00
PHST- 2010/02/27 00:00 [received]
PHST- 2010/06/13 00:00 [revised]
PHST- 2010/07/26 00:00 [accepted]
PHST- 2011/02/26 06:00 [entrez]
PHST- 2011/02/26 06:00 [pubmed]
PHST- 2011/06/28 06:00 [medline]
AID - 10.1002/pds.2041 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):313-6. doi: 10.1002/pds.2041. Epub 
      2010 Dec 23.

PMID- 11919108
OWN - NLM
STAT- MEDLINE
DCOM- 20020429
LR  - 20190501
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Print)
IS  - 0003-9888 (Linking)
VI  - 86
IP  - 4
DP  - 2002 Apr
TI  - Kawasaki disease: an evidence based approach to diagnosis, treatment, and 
      proposals for future research.
PG  - 286-90
AB  - This article proposes a clinical guideline for the diagnosis and treatment of 
      Kawasaki disease in the UK based on the best available evidence to date, and 
      highlights areas of practice where evidence is anecdotal or based on 
      retrospective data. Future research as proposed by the London Kawasaki Disease 
      Research Group is outlined, and clinicians are invited to prospectively enroll 
      their suspected cases into this collaborative research project.
FAU - Brogan, P A
AU  - Brogan PA
AD  - Nephrourology Department, Institute of Child Health, London, UK. 
      pbrogan@ich.ucl.ac.uk
FAU - Bose, A
AU  - Bose A
FAU - Burgner, D
AU  - Burgner D
FAU - Shingadia, D
AU  - Shingadia D
FAU - Tulloh, R
AU  - Tulloh R
FAU - Michie, C
AU  - Michie C
FAU - Klein, N
AU  - Klein N
FAU - Booy, R
AU  - Booy R
FAU - Levin, M
AU  - Levin M
FAU - Dillon, M J
AU  - Dillon MJ
LA  - eng
PT  - Guideline
PT  - Journal Article
PT  - Practice Guideline
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arch Dis Child. 2003 Jan;88(1):91. PMID: 12495985
MH  - Adrenal Cortex Hormones
MH  - Aspirin/therapeutic use
MH  - Contraindications
MH  - Heart Diseases/etiology
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/*therapy
MH  - Research
MH  - Vaccination
PMC - PMC1719139
EDAT- 2002/03/29 10:00
MHDA- 2002/05/01 10:01
CRDT- 2002/03/29 10:00
PHST- 2002/03/29 10:00 [pubmed]
PHST- 2002/05/01 10:01 [medline]
PHST- 2002/03/29 10:00 [entrez]
AID - 10.1136/adc.86.4.286 [doi]
PST - ppublish
SO  - Arch Dis Child. 2002 Apr;86(4):286-90. doi: 10.1136/adc.86.4.286.

PMID- 8419726
OWN - NLM
STAT- MEDLINE
DCOM- 19930211
LR  - 20190817
IS  - 0025-7125 (Print)
IS  - 0025-7125 (Linking)
VI  - 77
IP  - 1
DP  - 1993 Jan
TI  - Diabetes and stroke.
PG  - 95-110
AB  - Diabetes is a major risk factor for development of ischemic cerebrovascular 
      disease. Patients with diabetes are at least two times more likely to have a 
      stroke than nondiabetics. In addition, they are more likely to suffer increased 
      morbidity and mortality after stroke. The mechanism of production of stroke 
      secondary to diabetes may be due to cerebrovascular atherosclerosis, cardiac 
      embolism, or rheologic abnormalities. The evaluation of cerebrovascular disease 
      in diabetic patients is similar to the nondiabetic patient, with particular 
      attention paid to adequate hydration prior to the administration of contrast 
      agents. Treatment options for stroke in diabetics requires individualization but 
      should include risk factor modification, and may include platelet antiaggregants, 
      anticoagulation, or, in a well-defined subgroup, carotid endarterectomy.
FAU - Biller, J
AU  - Biller J
AD  - Department of Neurology, Northwestern University Medical School, Chicago, 
      Illinois.
FAU - Love, B B
AU  - Love BB
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Med Clin North Am
JT  - The Medical clinics of North America
JID - 2985236R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Cerebrovascular Disorders/epidemiology/etiology/mortality/physiopathology
MH  - *Diabetes Complications
MH  - Humans
MH  - Risk Factors
RF  - 75
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - S0025-7125(16)30274-7 [pii]
AID - 10.1016/s0025-7125(16)30274-7 [doi]
PST - ppublish
SO  - Med Clin North Am. 1993 Jan;77(1):95-110. doi: 10.1016/s0025-7125(16)30274-7.

PMID- 2368418
OWN - NLM
STAT- MEDLINE
DCOM- 19900813
LR  - 20131121
IS  - 0043-5341 (Print)
IS  - 0043-5341 (Linking)
VI  - 140
IP  - 10-11
DP  - 1990 Jun 15
TI  - [The patient following PTCA].
PG  - 273-4
AB  - Diagnostic measures after PTCA consist of history, clinical findings, after 3 
      months and thereafter in 6 months intervals as well as ergometry in case of 
      recurrency of complaints of after 3 months and then in 6 months intervals. A 
      thallium-scintigraphy is done eventually. A repetition of a coronarography is 
      indicated only in cases of typical symptoms or registration of ischemia. Therapy 
      consists of lifelong ASS and calcium channel blockers for 3 months and treatment 
      of risk-factors. Repetition of a PTCA, atherectomy, stent-implantation, 
      laser-angioplasty or bypass-surgery varies from case to case; the decision has to 
      be made individually.
FAU - Klein, W
AU  - Klein W
AD  - Abteilung für Kardiologie, Universitätsklinik für Innere Medizin, Graz.
FAU - Luha, H
AU  - Luha H
FAU - Eber, B
AU  - Eber B
FAU - Dusleag, J
AU  - Dusleag J
FAU - Brussee, H
AU  - Brussee H
FAU - Rotman, B
AU  - Rotman B
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Der Patient nach PTCA.
PL  - Austria
TA  - Wien Med Wochenschr
JT  - Wiener medizinische Wochenschrift (1946)
JID - 8708475
RN  - 0 (Calcium Channel Blockers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/therapeutic use
MH  - Calcium Channel Blockers/therapeutic use
MH  - Coronary Disease/diagnosis/*therapy
MH  - Exercise Test
MH  - Follow-Up Studies
MH  - Humans
MH  - Radionuclide Ventriculography
MH  - Recurrence
EDAT- 1990/06/15 00:00
MHDA- 1990/06/15 00:01
CRDT- 1990/06/15 00:00
PHST- 1990/06/15 00:00 [pubmed]
PHST- 1990/06/15 00:01 [medline]
PHST- 1990/06/15 00:00 [entrez]
PST - ppublish
SO  - Wien Med Wochenschr. 1990 Jun 15;140(10-11):273-4.

PMID- 3763681
OWN - NLM
STAT- MEDLINE
DCOM- 19861103
LR  - 20141120
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 41
IP  - 6
DP  - 1986 Jun
TI  - [An ex-vivo technic for the pharmacologic evaluation of potential antiphlogistics 
      by ex-vivo determination of the rate of malondialdehyde (MDA) formation using rat 
      platelets].
PG  - 395-7
AB  - Based on a standardized in-vitro method for quantifying the activity of 
      prostaglandin-synthetase by means of coupling malondialdehyde with 
      2-thiobarbituric acid the possibility of using this method also as ex-vivo 
      technique is described. By this, more favourable prerequisites to pharmacological 
      valuation of the effects of potential antiinflammatory substances exists compared 
      to the application of in-vitro results, only.
FAU - Schmollack, W
AU  - Schmollack W
FAU - Scholz, U
AU  - Scholz U
FAU - Bekemeier, H
AU  - Bekemeier H
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Ein ex-vivo-Verfahren zur pharmakologischen Bewertung von potentiellen 
      Antiphlogistica anhand der ex-vivo-Bestimmung der Bildungsrate von Malondialdehyd 
      (MDA) unter Verwendung von Ratten-Thrombozyten.
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Malonates)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*metabolism
MH  - Depression, Chemical
MH  - Diclofenac/pharmacology
MH  - Drug Evaluation, Preclinical
MH  - Ibuprofen/pharmacology
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Malonates/*metabolism
MH  - Malondialdehyde/*metabolism
MH  - Rats
EDAT- 1986/06/01 00:00
MHDA- 1986/06/01 00:01
CRDT- 1986/06/01 00:00
PHST- 1986/06/01 00:00 [pubmed]
PHST- 1986/06/01 00:01 [medline]
PHST- 1986/06/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1986 Jun;41(6):395-7.

PMID- 566676
OWN - NLM
STAT- MEDLINE
DCOM- 19780925
LR  - 20131121
IS  - 0014-8318 (Print)
IS  - 0014-8318 (Linking)
VI  - 41
IP  - 4
DP  - 1978 Jun-Aug
TI  - [The effect of non-steroid antiphlogistic drugs on the number of antibody-forming 
      cells during the primary immune response].
PG  - 461-4
AB  - In mice immunized with sheep erythrocytes introduction of acetylsalycilic acid 
      (250 mg/kg), sodium salicylate (100 mg/kg) and mephenamic acid (100 mg/kg) 
      exerted an inhibitory effect on the synthesis of antibody-forming cells and the 
      titre of hemagglutinines in immunized animals. The acetylsalicylic acid and 
      sodium salicylate are more effective on the 3--5th post-immunization day; the 
      maximal effect of the mephenamic acid becomes apparent on the 7th day and its 
      action is more lasting.
FAU - Aleksandrova, G M
AU  - Aleksandrova GM
FAU - Komendantova, M V
AU  - Komendantova MV
FAU - Petrova, I V
AU  - Petrova IV
FAU - Monakhova, L A
AU  - Monakhova LA
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Bliianie nesterondnykh protivovospalitel'nykh preparatov na kolichestvo 
      antiteloobrazuiushchikh kletok pri pervichnom immunnom otvete.
PL  - Russia (Federation)
TA  - Farmakol Toksikol
JT  - Farmakologiia i toksikologiia
JID - 16920420R
RN  - 0 (Anti-Inflammatory Agents)
RN  - 367589PJ2C (Mefenamic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Antibody Formation/*drug effects
MH  - Antibody-Producing Cells/*drug effects
MH  - Aspirin/pharmacology
MH  - Hemagglutination Tests
MH  - Mefenamic Acid/pharmacology
MH  - Mice
MH  - Sodium Salicylate/pharmacology
EDAT- 1978/06/01 00:00
MHDA- 1978/06/01 00:01
CRDT- 1978/06/01 00:00
PHST- 1978/06/01 00:00 [pubmed]
PHST- 1978/06/01 00:01 [medline]
PHST- 1978/06/01 00:00 [entrez]
PST - ppublish
SO  - Farmakol Toksikol. 1978 Jun-Aug;41(4):461-4.

PMID- 28254010
OWN - NLM
STAT- MEDLINE
DCOM- 20170420
LR  - 20220331
IS  - 1873-7072 (Electronic)
IS  - 0308-8146 (Linking)
VI  - 226
DP  - 2017 Jul 1
TI  - Preharvest treatments with malic, oxalic, and acetylsalicylic acids affect the 
      phenolic composition and antioxidant capacity of coriander, dill and parsley.
PG  - 179-186
LID - S0308-8146(17)30079-1 [pii]
LID - 10.1016/j.foodchem.2017.01.067 [doi]
AB  - The effects of a preharvest treatment with malic (MA), oxalic (OA), or 
      acetylsalicylic (ASA) acid at three concentrations (1, 2 and 3mM) on the 
      bioactivity and antioxidant capacity of coriander, dill, and parsley were 
      investigated. The antioxidant capacity of the herbs extracts was assayed by 
      spectrophotometric methods by using three different analytical methods: ORAC, 
      FRAP, and ABTS; the effects of treatments were very positive in coriander, 
      produced intermediate results in dill, and no effects were found in parsley 
      plants. Polyphenol compounds were identified by LC-MS-QTof and quantified by 
      UPLC-PDA-FL. Thirty phenolic compounds were identified in these three herbs. The 
      major compounds were (i) coriander: dimethoxycinnamoyl hexoside and 
      quercetin-3-O-rutinoside, (ii) dill: neochlorogenic acid and quercetin 
      glucuronide, and (iii) parsley: apigenin-7-apiosylglucoside (apiin) and 
      isorhamnetin-3-O-hexoside. The application of these three organic acids favored 
      the accumulation of phenolic compounds in coriander plants, but had no 
      significant positive effects on dill and parsley. The treatments leading to the 
      best results in all three plants were the application of MA or OA at 1mM.
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - El-Zaeddi, Hussein
AU  - El-Zaeddi H
AD  - Universidad Miguel Hernández de Elche (UMH), Escuela Politécnica Superior de 
      Orihuela (EPSO), Department of Agro-Food Technology, Research Group "Food Quality 
      and Safety", Carretera Beniel, km 3.2, 03312-Orihuela, Alicante, Spain.
FAU - Calín-Sánchez, Ángel
AU  - Calín-Sánchez Á
AD  - Universidad Miguel Hernández de Elche (UMH), Escuela Politécnica Superior de 
      Orihuela (EPSO), Department of Agro-Food Technology, Research Group "Food Quality 
      and Safety", Carretera Beniel, km 3.2, 03312-Orihuela, Alicante, Spain. 
      Electronic address: acalin@umh.es.
FAU - Nowicka, Paulina
AU  - Nowicka P
AD  - Wrocław University of Environmental and Life Sciences, Department of Fruit and 
      Vegetable Technology, 37 Chełmońskiego Street, 51-630 Wrocław, Poland.
FAU - Martínez-Tomé, Juan
AU  - Martínez-Tomé J
AD  - Universidad Miguel Hernández de Elche, EPSO, Department of Plant Sciences and 
      Microbiology, Carretera de Beniel, km 3,2. 03312-Orihuela, Alicante, Spain.
FAU - Noguera-Artiaga, Luis
AU  - Noguera-Artiaga L
AD  - Universidad Miguel Hernández de Elche (UMH), Escuela Politécnica Superior de 
      Orihuela (EPSO), Department of Agro-Food Technology, Research Group "Food Quality 
      and Safety", Carretera Beniel, km 3.2, 03312-Orihuela, Alicante, Spain.
FAU - Burló, Francisco
AU  - Burló F
AD  - Universidad Miguel Hernández de Elche (UMH), Escuela Politécnica Superior de 
      Orihuela (EPSO), Department of Agro-Food Technology, Research Group "Food Quality 
      and Safety", Carretera Beniel, km 3.2, 03312-Orihuela, Alicante, Spain.
FAU - Wojdyło, Aneta
AU  - Wojdyło A
AD  - Wrocław University of Environmental and Life Sciences, Department of Fruit and 
      Vegetable Technology, 37 Chełmońskiego Street, 51-630 Wrocław, Poland.
FAU - Carbonell-Barrachina, Ángel A
AU  - Carbonell-Barrachina ÁA
AD  - Universidad Miguel Hernández de Elche (UMH), Escuela Politécnica Superior de 
      Orihuela (EPSO), Department of Agro-Food Technology, Research Group "Food Quality 
      and Safety", Carretera Beniel, km 3.2, 03312-Orihuela, Alicante, Spain.
LA  - eng
PT  - Journal Article
DEP - 20170116
PL  - England
TA  - Food Chem
JT  - Food chemistry
JID - 7702639
RN  - 0 (Antioxidants)
RN  - 0 (Malates)
RN  - 0 (Phenols)
RN  - 817L1N4CKP (malic acid)
RN  - 9E7R5L6H31 (Oxalic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anethum graveolens/*chemistry
MH  - Antioxidants
MH  - Aspirin/*chemistry
MH  - Coriandrum/*chemistry
MH  - Malates/*chemistry
MH  - Oxalic Acid/*chemistry
MH  - Petroselinum/*chemistry
MH  - Phenols
OTO - NOTNLM
OT  - Aromatic herbs
OT  - Bioactive compounds
OT  - LC-MS-QTof
OT  - Organic acids
OT  - Preharvest treatments
OT  - UPLC-PDA-FL
EDAT- 2017/03/04 06:00
MHDA- 2017/04/21 06:00
CRDT- 2017/03/04 06:00
PHST- 2016/09/16 00:00 [received]
PHST- 2016/12/23 00:00 [revised]
PHST- 2017/01/13 00:00 [accepted]
PHST- 2017/03/04 06:00 [entrez]
PHST- 2017/03/04 06:00 [pubmed]
PHST- 2017/04/21 06:00 [medline]
AID - S0308-8146(17)30079-1 [pii]
AID - 10.1016/j.foodchem.2017.01.067 [doi]
PST - ppublish
SO  - Food Chem. 2017 Jul 1;226:179-186. doi: 10.1016/j.foodchem.2017.01.067. Epub 2017 
      Jan 16.

PMID- 6849734
OWN - NLM
STAT- MEDLINE
DCOM- 19830708
LR  - 20190511
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 15
IP  - 1
DP  - 1983 Jan
TI  - Effect of sodium acetyl salicylate on cholesterol saturation of fasting gall 
      bladder bile, with and without chenic acid.
PG  - 114-6
AB  - The aims of this study were (a) to determine whether sodium acetyl salicylate by 
      itself or in combination with chenodeoxycholic (chenic) acid would decrease the 
      cholesterol saturation index (SI) of fasting gall bladder bile in man; and (b) to 
      confirm prospectively that 8 mg kg-1 day-1 chenic acid given at bedtime together 
      with a low cholesterol diet reduces gall bladder bile SI to a level where 
      consistent gallstone dissolution would be expected. Seven patients were studied 
      on each of the following regimens given in random order for 1 month each: bedtime 
      chenic acid alone 8 mg kg-1 day-1; sodium acetyl salicylate alone 600 mg four 
      times daily; bedtime chenic acid together with sodium acetyl salicylate; no 
      treatment. Gall bladder samples were taken by nasoduodenal intubation at the end 
      of each regimen and SI determined. SI (mean +/- s.e. mean) on low cholesterol 
      diet with no drug treatment was 1.14 +/- 0.06. On bedtime chenic acid 8 mg kg-1 
      day-1 plus low cholesterol diet it fell to 0.83 +/- 0.03 (P less than 0.05). 
      Sodium acetyl salicylate did not alter gall bladder bile SI. 95% confidence 
      limits for the effect of sodium acetyl salicylate on SI were +0.03 and -0.05. We 
      conclude that (a) sodium acetyl salicylate does not lower SI of gall bladder bile 
      in man; (b) an adequate fall in SI for gallstone dissolution can be achieved with 
      a reduced dose (8 mg kg-1 day-1) of chenic acid given at bedtime with a low 
      cholesterol diet.
FAU - Kupfer, R M
AU  - Kupfer RM
FAU - Northfield, T C
AU  - Northfield TC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Lipids)
RN  - 0GEI24LG0J (Chenodeoxycholic Acid)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Bile/*analysis
MH  - Chenodeoxycholic Acid/*therapeutic use
MH  - Cholelithiasis/*drug therapy
MH  - Cholesterol/*analysis
MH  - Female
MH  - Gallbladder/metabolism
MH  - Humans
MH  - Lipids/analysis
MH  - Male
MH  - Middle Aged
PMC - PMC1427840
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1983.tb01474.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1983 Jan;15(1):114-6. doi: 
      10.1111/j.1365-2125.1983.tb01474.x.

PMID- 21773589
OWN - NLM
STAT- MEDLINE
DCOM- 20120116
LR  - 20131121
IS  - 2042-650X (Electronic)
IS  - 2042-6496 (Linking)
VI  - 2
IP  - 1
DP  - 2011 Jan
TI  - Inhibitory effects of 1,3-bis-(2-substituted-phenyl)-propane-1,3-dione, 
      β-diketone structural analogues of curcumin, on chemical-induced tumor promotion 
      and inflammation in mouse skin.
PG  - 78-83
LID - 10.1039/c0fo00098a [doi]
AB  - Dibenzoylmethane (DBM), a β-diketone structural analogue of curcumin, has been 
      reported to exhibit anti-tumorigenic and chemopreventive activities. Due to the 
      structural resemblance of DBM to the anti-inflammatory curcumin and an 
      aspirin-like skeleton of DBM derivatives, we tested the anti-inflammatory effects 
      of DBM and its derivatives, 1,3-bis-(2-substituted-phenyl)-propane-1,3-dione, on 
      12-O-tetradecanoylphorbol-13-acetate (TPA)-induced tumor promotion as well as 
      TPA- and arachidonic acid-induced mouse ear edema in skin of CD-1 mice. Topical 
      application of 10 μmol DBM together with TPA on the back of mice previously 
      treated with 7,12-dimethylbenz[α]anthracene (DMBA) inhibited TPA-induced skin 
      tumor promotion significantly. In addition, 1,3-bis-(2-acetoxy 
      phenyl)-propane-1,3-dione was a superior anti-inflammatory agent to aspirin (80% 
      of inhibition), on TPA-induced mouse ear edema and reduced the production of 
      prostaglandin E2 (PGE(2)), comparable to aspirin. Taken together, 
      1,3-bis-(2-acetoxyphenyl-propane-1,3-dione merits a valuable anti-inflammatory 
      agent substituting aspirin in therapeutic treatment as well prevention of cancer.
FAU - Lin, Chuan-Chuan
AU  - Lin CC
AD  - Department of Food Science, China University of Science and Technology, 245 
      Yen-Chiu-Yuan Rd., Sec. 3, Nankang, Taipei 115, Taiwan. cclin@cc.cust.edu.tw
FAU - Liu, Yue
AU  - Liu Y
FAU - Ho, Chi-Tang
AU  - Ho CT
FAU - Huang, Mou-Tuan
AU  - Huang MT
LA  - eng
PT  - Journal Article
DEP - 20101110
PL  - England
TA  - Food Funct
JT  - Food & function
JID - 101549033
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Carcinogens)
RN  - 0 (Ketones)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 57-97-6 (9,10-Dimethyl-1,2-benzanthracene)
RN  - IT942ZTH98 (Curcumin)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 9,10-Dimethyl-1,2-benzanthracene/chemistry/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/chemistry/pharmacology
MH  - Carcinogens/chemistry/pharmacology
MH  - Curcumin/*analogs & derivatives
MH  - Dermatitis/*drug therapy
MH  - Ear, External/drug effects
MH  - Edema/chemically induced/drug therapy
MH  - Female
MH  - Ketones/chemistry/pharmacology
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Platelet Aggregation Inhibitors/chemistry/pharmacology
MH  - Skin Neoplasms/chemically induced/*drug therapy
MH  - Tetradecanoylphorbol Acetate/pharmacology
EDAT- 2011/07/21 06:00
MHDA- 2012/01/17 06:00
CRDT- 2011/07/21 06:00
PHST- 2011/07/21 06:00 [entrez]
PHST- 2011/07/21 06:00 [pubmed]
PHST- 2012/01/17 06:00 [medline]
AID - 10.1039/c0fo00098a [doi]
PST - ppublish
SO  - Food Funct. 2011 Jan;2(1):78-83. doi: 10.1039/c0fo00098a. Epub 2010 Nov 10.

PMID- 7095565
OWN - NLM
STAT- MEDLINE
DCOM- 19820917
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 23
IP  - 8
DP  - 1982 Aug
TI  - Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human 
      gastroduodenal mucosa.
PG  - 692-7
AB  - Aspirin causes gastroduodenal erosions and/or ulcers in man when taken for 
      prolonged periods. The effects of shorter periods of aspirin, Bufferin, or 
      paracetamol (acetaminophen) intake as used for self-medication are unknown. In a 
      four way, crossover, blinded endoscopic study, we compared the effects of 
      aspirin, Bufferin, paracetamol, and placebo, two tablets four times a day for 24 
      hours, on the gastroduodenal mucosa of 10 normal volunteers. Both regular aspirin 
      and bufferin produced multiple gastric (p less than 0.005) and duodenal erosions 
      (p less than 0.05, compared with baseline and placebo studies). Paracetamol did 
      not cause significant gastric or duodenal mucosal damage. Two subjects developed 
      duodenal ulcer-like lesions in the course of the study. We conclude that the use 
      of unbuffered aspirin and Bufferin, but not paracetamol, in recommended doses for 
      one day causes significant gastroduodenal mucosal damage.
FAU - Hoftiezer, J W
AU  - Hoftiezer JW
FAU - O'Laughlin, J C
AU  - O'Laughlin JC
FAU - Ivey, K J
AU  - Ivey KJ
LA  - eng
GR  - RR00287-12/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Buffers)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*adverse effects
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Buffers
MH  - Duodenum/*drug effects
MH  - Gastric Mucosa/*drug effects
MH  - Gastrointestinal Diseases/chemically induced
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Intestinal Mucosa/drug effects
PMC - PMC1419140
EDAT- 1982/08/01 00:00
MHDA- 1982/08/01 00:01
CRDT- 1982/08/01 00:00
PHST- 1982/08/01 00:00 [pubmed]
PHST- 1982/08/01 00:01 [medline]
PHST- 1982/08/01 00:00 [entrez]
AID - 10.1136/gut.23.8.692 [doi]
PST - ppublish
SO  - Gut. 1982 Aug;23(8):692-7. doi: 10.1136/gut.23.8.692.

PMID- 25453630
OWN - NLM
STAT- MEDLINE
DCOM- 20150812
LR  - 20181202
IS  - 1532-8406 (Electronic)
IS  - 0883-5403 (Linking)
VI  - 30
IP  - 3
DP  - 2015 Mar
TI  - Mobile compression devices and aspirin for VTE prophylaxis following simultaneous 
      bilateral total knee arthroplasty.
PG  - 447-50
LID - S0883-5403(14)00793-1 [pii]
LID - 10.1016/j.arth.2014.10.018 [doi]
AB  - Recently, Levy et al questioned the effectiveness of mobile compression devices 
      (MCDs) as the sole method of thromboprophylaxis following simultaneous bilateral 
      total knee arthroplasty (TKA). This study's purpose was to assess if the addition 
      of aspirin to MCDs improves venous thromboembolism (VTE) prevention following 
      simultaneous bilateral TKA. Ninety-six patients (192 TKAs) were retrospectively 
      reviewed: 47 patients received MCDs for 10 days and aspirin for 6 weeks 
      postoperatively based on a risk stratification protocol, while 49 patients 
      received warfarin for 4 weeks postoperatively. One symptomatic VTE was noted in 
      the warfarin cohort, while one patient in the MCD/aspirin cohort and three 
      patients in the warfarin cohort were readmitted within 3 months of surgery. In 
      appropriately selected patients, MCDs with aspirin shows promise in VTE 
      prevention following simultaneous bilateral TKA.
CI  - Copyright © 2014 Elsevier Inc. All rights reserved.
FAU - Nam, Denis
AU  - Nam D
AD  - Department of Orthopedic, Surgery, Washington University School of 
      Medicine/Barnes-Jewish Hospital, St. Louis, Missouri.
FAU - Nunley, Ryan M
AU  - Nunley RM
AD  - Department of Orthopedic, Surgery, Washington University School of 
      Medicine/Barnes-Jewish Hospital, St. Louis, Missouri.
FAU - Johnson, Staci R
AU  - Johnson SR
AD  - Department of Orthopedic, Surgery, Washington University School of 
      Medicine/Barnes-Jewish Hospital, St. Louis, Missouri.
FAU - Keeney, James A
AU  - Keeney JA
AD  - Department of Orthopedic, Surgery, Washington University School of 
      Medicine/Barnes-Jewish Hospital, St. Louis, Missouri.
FAU - Barrack, Robert L
AU  - Barrack RL
AD  - Department of Orthopedic, Surgery, Washington University School of 
      Medicine/Barnes-Jewish Hospital, St. Louis, Missouri.
LA  - eng
PT  - Journal Article
DEP - 20141022
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Aspirin/*therapeutic use
MH  - Chemoprevention
MH  - Female
MH  - Humans
MH  - *Intermittent Pneumatic Compression Devices
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Venous Thromboembolism/etiology/*prevention & control
MH  - Warfarin/therapeutic use
OTO - NOTNLM
OT  - aspirin
OT  - bilateral total knee arthroplasty
OT  - mobile compression devices
OT  - thromboprophylaxis
OT  - warfarin
EDAT- 2014/12/03 06:00
MHDA- 2015/08/13 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/07/02 00:00 [received]
PHST- 2014/10/08 00:00 [revised]
PHST- 2014/10/13 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/08/13 06:00 [medline]
AID - S0883-5403(14)00793-1 [pii]
AID - 10.1016/j.arth.2014.10.018 [doi]
PST - ppublish
SO  - J Arthroplasty. 2015 Mar;30(3):447-50. doi: 10.1016/j.arth.2014.10.018. Epub 2014 
      Oct 22.

PMID- 1191548
OWN - NLM
STAT- MEDLINE
DCOM- 19760227
LR  - 20190704
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 29
IP  - 2
DP  - 1975 Feb
TI  - The effect of cytotoxic and anti-inflammatory drugs on the phagocytosis of 
      neutrophil leucocytes.
PG  - 273-8
AB  - The phagocytosis of heat-killed Candida albicans by neutrophil leucocytes was 
      inhibited in vitro by phenylbutazone and acetylsalicylic acid and by the 
      cytotoxic drugs vincristine, vinblastine, cytosine arabinoside, daunorubicin and 
      busulphan, but not by mustine hydrochloride or procarbazine. In vivo studies in 
      man have shown a significant reduction in phagocytosis after phenylbutazone 
      ingestion, but not following an oral dose of aspirin. Possible explanatory 
      mechanisms of drug action on neutrophil phagocytosis are discussed.
FAU - Whittaker, J A
AU  - Whittaker JA
FAU - Hughes, H R
AU  - Hughes HR
FAU - Khurshid, M
AU  - Khurshid M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Antibiotics, Antineoplastic/*pharmacology
MH  - Aspirin/pharmacology
MH  - Cell Survival/drug effects
MH  - Humans
MH  - Neutrophils/*immunology
MH  - Phagocytosis/*drug effects
MH  - Phenylbutazone/pharmacology
MH  - Time Factors
EDAT- 1975/02/01 00:00
MHDA- 1975/02/01 00:01
CRDT- 1975/02/01 00:00
PHST- 1975/02/01 00:00 [pubmed]
PHST- 1975/02/01 00:01 [medline]
PHST- 1975/02/01 00:00 [entrez]
AID - 10.1111/j.1365-2141.1975.tb01821.x [doi]
PST - ppublish
SO  - Br J Haematol. 1975 Feb;29(2):273-8. doi: 10.1111/j.1365-2141.1975.tb01821.x.

PMID- 28947374
OWN - NLM
STAT- MEDLINE
DCOM- 20190110
LR  - 20190110
IS  - 1532-8406 (Electronic)
IS  - 0883-5403 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb
TI  - Increased Incidence of Bleeding and Wound Complications With Factor-Xa Inhibitors 
      After Total Joint Arthroplasty.
PG  - 533-536
LID - S0883-5403(17)30762-3 [pii]
LID - 10.1016/j.arth.2017.08.039 [doi]
AB  - BACKGROUND: Factor-Xa inhibitors have been introduced for prevention of venous 
      thromboembolism (VTE) after joint arthroplasty. However, these agents could also 
      be associated with bleeding or wound complications after surgery. METHODS: We 
      retrospectively reviewed a consecutive series of 59 patients (31 knees, 28 hips) 
      undergoing joint arthroplasty at a high-volume joint arthroplasty referral 
      center, both before and after implementation of a new VTE risk-stratification 
      tool at our institution. Patients with a history of VTE, bilateral procedures, or 
      medical conditions already requiring VTE chemoprophylaxis were excluded. We 
      reviewed the medical records to determine (1) type of VTE prophylaxis used, (2) 
      incidence of bleeding/wound complications in the postoperative period, (3) 
      incidence of VTE in the postoperative period, and (4) change in serum hemoglobin. 
      RESULTS: Twenty-seven patients (46%) were given aspirin for VTE prophylaxis, 
      while 32 patients (54%) received a factor-Xa inhibitor. There were no new VTE 
      complications in either group. And 6 of 32 patients (18.7%) in the Xa inhibitor 
      group had a postoperative bleeding/wound complication (4 delayed 
      healing/blistering, 1 hematoma/excessive ecchymosis, and 1 readmission for 
      cellulitis). There were no (0%) bleeding/wound complications in the aspirin group 
      (P = .03). The change in hemoglobin level was -2.76 g/dL in patients receiving 
      aspirin vs -2.84 g/dL in patients receiving a Xa inhibitor (P = .73). CONCLUSION: 
      In our study of total joint patients, factor-Xa inhibitors were associated with a 
      higher incidence of bleeding/wound complications. The choice of VTE prophylaxis 
      should be based on the perceived risks of bleeding and wound complications 
      compared to the risks of VTE in each patient.
CI  - Copyright © 2017 Elsevier Inc. All rights reserved.
FAU - Garfinkel, Jonathan H
AU  - Garfinkel JH
AD  - Georgetown University School of Medicine, Washington, DC.
FAU - Gladnick, Brian P
AU  - Gladnick BP
AD  - OrthoVirginia, Adult Hip and Knee Reconstruction, Arlington, Virginia; Virginia 
      Hospital Center, Arlington, Virginia.
FAU - Roland, Niama
AU  - Roland N
AD  - Virginia Hospital Center, Arlington, Virginia.
FAU - Romness, David W
AU  - Romness DW
AD  - OrthoVirginia, Adult Hip and Knee Reconstruction, Arlington, Virginia; Virginia 
      Hospital Center, Arlington, Virginia.
LA  - eng
PT  - Journal Article
DEP - 20170905
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Arthroplasty, Replacement/*adverse effects
MH  - Aspirin/adverse effects/therapeutic use
MH  - Chemoprevention
MH  - Electronic Health Records
MH  - Factor Xa Inhibitors/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*epidemiology/etiology
MH  - Postoperative Hemorrhage/etiology
MH  - Postoperative Period
MH  - Registries
MH  - Retrospective Studies
MH  - Venous Thromboembolism/epidemiology/etiology
OTO - NOTNLM
OT  - VTE
OT  - aspirin
OT  - bleeding
OT  - factor-Xa inhibitor
OT  - thromboprophylaxis
OT  - total joint arthroplasty
EDAT- 2017/09/28 06:00
MHDA- 2019/01/11 06:00
CRDT- 2017/09/27 06:00
PHST- 2017/06/08 00:00 [received]
PHST- 2017/08/12 00:00 [revised]
PHST- 2017/08/29 00:00 [accepted]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2019/01/11 06:00 [medline]
PHST- 2017/09/27 06:00 [entrez]
AID - S0883-5403(17)30762-3 [pii]
AID - 10.1016/j.arth.2017.08.039 [doi]
PST - ppublish
SO  - J Arthroplasty. 2018 Feb;33(2):533-536. doi: 10.1016/j.arth.2017.08.039. Epub 
      2017 Sep 5.

PMID- 25466180
OWN - NLM
STAT- MEDLINE
DCOM- 20150723
LR  - 20170919
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 24
IP  - 24
DP  - 2014 Dec 15
TI  - Gastric-sparing nitric oxide-releasable 'true' prodrugs of aspirin and naproxen.
PG  - 5587-5592
LID - S0960-894X(14)01167-6 [pii]
LID - 10.1016/j.bmcl.2014.10.096 [doi]
AB  - Nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) are 
      gaining attention as potentially gastric-sparing NSAIDs. Herein, we report a 
      novel class of '1-(nitrooxy)ethyl ester' group-containing NSAIDS as efficient NO 
      releasing 'true' prodrugs of aspirin and naproxen. While an aspirin prodrug 
      exhibited comparable oral bioavailability and antiplatelet activity (i.e., TXB2 
      inhibition) to those of aspirin, a naproxen prodrug exhibited better 
      bioavailability than naproxen. These promising NO-NSAIDs protected experimental 
      rats from gastric damage. We therefore believe that these promising NO-NSAIDs 
      could represent a new class of potentially 'Safe NSAIDs' for the treatment of 
      arthritic pain, inflammation and cardiovascular disorders in the case of 
      NO-aspirin.
CI  - Copyright © 2014 Elsevier Ltd. All rights reserved.
FAU - Gund, Machhindra
AU  - Gund M
AD  - Medicinal Chemistry Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Gaikwad, Parikshit
AU  - Gaikwad P
AD  - Pharmacology Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Borhade, Namdev
AU  - Borhade N
AD  - Medicinal Chemistry Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Burhan, Aslam
AU  - Burhan A
AD  - Pharmacology Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Desai, Dattatraya C
AU  - Desai DC
AD  - Analytical Chemistry-Medicinal Chemistry Division, Piramal Life Sciences, Piramal 
      Enterprises Limited, 1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Sharma, Ankur
AU  - Sharma A
AD  - Pharmacology Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Dhiman, Mini
AU  - Dhiman M
AD  - Analytical Chemistry-Medicinal Chemistry Division, Piramal Life Sciences, Piramal 
      Enterprises Limited, 1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Patil, Mohan
AU  - Patil M
AD  - Pharmacology Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Sheikh, Javed
AU  - Sheikh J
AD  - Medicinal Chemistry Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Thakre, Gajanan
AU  - Thakre G
AD  - Medicinal Chemistry Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Tipparam, Santhosh G
AU  - Tipparam SG
AD  - Medicinal Chemistry Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Sharma, Somesh
AU  - Sharma S
AD  - Pharmacology Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Nemmani, Kumar V S
AU  - Nemmani KVS
AD  - Pharmacology Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
FAU - Satyam, Apparao
AU  - Satyam A
AD  - Medicinal Chemistry Division, Piramal Life Sciences, Piramal Enterprises Limited, 
      1-Nirlon Complex, Goregaon East, Mumbai 400063, India. Electronic address: 
      apparaosvgk@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141105
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 
      4-(nitrooxy)butyl ester)
RN  - 0 (Nitrates)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prodrugs)
RN  - 0 (naproxen-n-butyl nitrate)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57Y76R9ATQ (Naproxen)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, 
      Non-Steroidal/chemistry/pharmacokinetics/pharmacology/toxicity
MH  - Area Under Curve
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacokinetics/pharmacology/toxicity
MH  - Blood Platelets/drug effects/enzymology
MH  - Cyclooxygenase 1/chemistry/metabolism
MH  - Cyclooxygenase 2/chemistry/metabolism
MH  - Drug Design
MH  - Drug Stability
MH  - Gastric Mucosa/drug effects
MH  - Half-Life
MH  - Humans
MH  - Naproxen/*analogs & derivatives/chemistry/pharmacokinetics/pharmacology/toxicity
MH  - Nitrates/*chemistry/pharmacokinetics/pharmacology/toxicity
MH  - Nitric Oxide/metabolism
MH  - Platelet Aggregation Inhibitors/chemistry/pharmacokinetics/pharmacology/toxicity
MH  - Prodrugs/*chemistry/pharmacokinetics/pharmacology/toxicity
MH  - ROC Curve
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thromboxane B2/metabolism
OTO - NOTNLM
OT  - Gastric-sparing NSAIDs
OT  - NO-NSAIDs
OT  - NO-aspirin
OT  - NO-naproxen
OT  - Nitric oxide donors
EDAT- 2014/12/04 06:00
MHDA- 2015/07/24 06:00
CRDT- 2014/12/04 06:00
PHST- 2014/07/19 00:00 [received]
PHST- 2014/10/18 00:00 [revised]
PHST- 2014/10/30 00:00 [accepted]
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2015/07/24 06:00 [medline]
AID - S0960-894X(14)01167-6 [pii]
AID - 10.1016/j.bmcl.2014.10.096 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2014 Dec 15;24(24):5587-5592. doi: 
      10.1016/j.bmcl.2014.10.096. Epub 2014 Nov 5.

PMID- 8427836
OWN - NLM
STAT- MEDLINE
DCOM- 19930309
LR  - 20190719
IS  - 0306-5456 (Print)
IS  - 0306-5456 (Linking)
VI  - 100
IP  - 1
DP  - 1993 Jan
TI  - Angiotensin sensitivity predicts aspirin benefit in placental insufficiency.
PG  - 46-50
AB  - OBJECTIVE: To determine whether the beneficial effects of aspirin in the 
      treatment of Doppler umbilical placental insufficiency correlate with the 
      maternal pressor response to angiotensin infusion. DESIGN: An open trial. 
      SETTING: A tertiary referral obstetric service. PATIENTS: Women identified at 
      between 25 and 36 weeks of pregnancy with an elevated umbilical artery Doppler 
      systolic/diastolic (S/D) ratio and a positive pressor response to angiotensin 
      infusion. INTERVENTION: Low dose aspirin (100mg/day) treatment of mothers. MAIN 
      OUTCOME MEASURE: Fetal and placental size at delivery in relation to subsequent 
      maternal angiotensin responsiveness. RESULTS: Women who converted from a positive 
      angiotensin pressor response to angiotensin refractoriness after aspirin 
      administration had larger infants and placentas compared with those whose 
      response remained positive. CONCLUSION: Angiotensin sensitivity predicts women 
      with umbilical Doppler detected placental insufficiency responding to aspirin 
      therapy. Loss of the normal refractory response in pregnancy may be a consequence 
      of vascular pathology in the placenta.
FAU - Cook, C M
AU  - Cook CM
FAU - Trudinger, B J
AU  - Trudinger BJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Obstet Gynaecol
JT  - British journal of obstetrics and gynaecology
JID - 7503752
RN  - 0 (Angiotensins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensins/*metabolism
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fetal Growth Retardation
MH  - Humans
MH  - Placental Insufficiency/*drug therapy/metabolism
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Risk Factors
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1111/j.1471-0528.1993.tb12949.x [doi]
PST - ppublish
SO  - Br J Obstet Gynaecol. 1993 Jan;100(1):46-50. doi: 
      10.1111/j.1471-0528.1993.tb12949.x.

PMID- 788993
OWN - NLM
STAT- MEDLINE
DCOM- 19761223
LR  - 20201209
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 20
IP  - 4
DP  - 1976 Oct
TI  - Asprin and codeine in two postpartum pain models.
PG  - 499-503
AB  - Aspirin and codeine, standard reference analgesics, are frequently used as 
      positive controls in clinical trials of new oral analgesics. In randomized 
      parallel double-blind studies, single doses of aspirin and codeine were compared 
      with placebo in episiotomy pain (99 patients) and in postpartum uterine pain (130 
      patients), common models in analgesic trials. With aspirin, 600 and 1,200 mg, in 
      episiotomy pain, analgesia as measured by pain intensity difference (PID) scores 
      began within 1 hr, peaked at the second hour (p less than 0.01), and continued to 
      the fifth hour (p less than 0.01). In uterine pain, responses with aspirin, 650 
      mg, were observed to be equally good. With codeine, 60 mg, in episiotomy pain 
      measurable analgesia was present by the second hour and was significant at the 
      fourth hour (p less than 0.05); in uterine pain, responses were indistinguishable 
      from placebo throughout an 8-hr time-course. Codeine seemed ineffective and 
      therefore umacceptable as a positive control in uterine pain. These data imply 
      that the two postpartum pain models are qualitatively different: episiotomy pain 
      seems sensitive to both aspirin and codeine, while uterine pain appears sensitive 
      to aspirin but not to codeine.
FAU - Bloomfield, S S
AU  - Bloomfield SS
FAU - Barden, T P
AU  - Barden TP
FAU - Mitchell, J
AU  - Mitchell J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Codeine/*therapeutic use
MH  - Episiotomy
MH  - Female
MH  - Humans
MH  - Models, Theoretical
MH  - Pain/*drug therapy
MH  - Pain, Postoperative/drug therapy
MH  - *Postpartum Period
MH  - Pregnancy
MH  - Time Factors
EDAT- 1976/10/01 00:00
MHDA- 1976/10/01 00:01
CRDT- 1976/10/01 00:00
PHST- 1976/10/01 00:00 [pubmed]
PHST- 1976/10/01 00:01 [medline]
PHST- 1976/10/01 00:00 [entrez]
AID - 10.1002/cpt1976204499 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1976 Oct;20(4):499-503. doi: 10.1002/cpt1976204499.

PMID- 18612428
OWN - NLM
STAT- MEDLINE
DCOM- 20081021
LR  - 20220408
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 3
IP  - 7
DP  - 2008 Jul 9
TI  - Pharmacologic stem cell based intervention as a new approach to osteoporosis 
      treatment in rodents.
PG  - e2615
LID - 10.1371/journal.pone.0002615 [doi]
LID - e2615
AB  - BACKGROUND: Osteoporosis is the most prevalent skeletal disorder, characterized 
      by a low bone mineral density (BMD) and bone structural deterioration, leading to 
      bone fragility fractures. Accelerated bone resorption by osteoclasts has been 
      established as a principal mechanism in osteoporosis. However, recent 
      experimental evidences suggest that inappropriate apoptosis of 
      osteoblasts/osteocytes accounts for, at least in part, the imbalance in bone 
      remodeling as occurs in osteoporosis. The aim of this study is to examine whether 
      aspirin, which has been reported as an effective drug improving bone mineral 
      density in human epidemiology studies, regulates the balance between bone 
      resorption and bone formation at stem cell levels. METHODS AND FINDINGS: We found 
      that T cell-mediated bone marrow mesenchymal stem cell (BMMSC) impairment plays a 
      crucial role in ovariectomized-induced osteoporosis. Ex vivo mechanistic studies 
      revealed that T cell-mediated BMMSC impairment was mainly attributed to the 
      apoptosis of BMMSCs via the Fas/Fas ligand pathway. To explore potential of using 
      pharmacologic stem cell based intervention as an approach for osteoporosis 
      treatment, we selected ovariectomy (OVX)-induced osteoporosis mouse model to 
      examine feasibility and mechanism of aspirin-mediated therapy for osteoporosis. 
      We found that aspirin can inhibit T cell activation and Fas ligand induced BMMSC 
      apoptosis in vitro. Further, we revealed that aspirin increases osteogenesis of 
      BMMSCs by aiming at telomerase activity and inhibits osteoclast activity in OVX 
      mice, leading to ameliorating bone density. CONCLUSION: Our findings have 
      revealed a novel osteoporosis mechanism in which activated T cells induce BMMSC 
      apoptosis via Fas/Fas ligand pathway and suggested that pharmacologic stem cell 
      based intervention by aspirin may be a new alternative in osteoporosis treatment 
      including activated osteoblasts and inhibited osteoclasts.
FAU - Yamaza, Takayoshi
AU  - Yamaza T
AD  - Center for Craniofacial Molecular Biology, University of Southern California 
      School of Dentistry, Los Angeles, California, United States of America.
FAU - Miura, Yasuo
AU  - Miura Y
FAU - Bi, Yanming
AU  - Bi Y
FAU - Liu, Yongzhong
AU  - Liu Y
FAU - Akiyama, Kentaro
AU  - Akiyama K
FAU - Sonoyama, Wataru
AU  - Sonoyama W
FAU - Patel, Voymesh
AU  - Patel V
FAU - Gutkind, Silvio
AU  - Gutkind S
FAU - Young, Marian
AU  - Young M
FAU - Gronthos, Stan
AU  - Gronthos S
FAU - Le, Anh
AU  - Le A
FAU - Wang, Cun-Yu
AU  - Wang CY
FAU - Chen, WanJun
AU  - Chen W
FAU - Shi, Songtao
AU  - Shi S
LA  - eng
GR  - R01 DE017449/DE/NIDCR NIH HHS/United States
GR  - ImNIH/Intramural NIH HHS/United States
GR  - R01DE17449/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20080709
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Interleukin-2 Receptor alpha Subunit)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Bone Marrow Cells/metabolism
MH  - Bone Resorption
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - Humans
MH  - Interleukin-2 Receptor alpha Subunit/immunology
MH  - Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*drug effects/metabolism
MH  - Mice
MH  - Mice, Inbred C3H
MH  - Mice, Transgenic
MH  - Osteoclasts/metabolism
MH  - Osteoporosis/*drug therapy/immunology
MH  - T-Lymphocytes/immunology
PMC - PMC2440798
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2008/07/10 09:00
MHDA- 2008/10/22 09:00
CRDT- 2008/07/10 09:00
PHST- 2008/03/18 00:00 [received]
PHST- 2008/06/05 00:00 [accepted]
PHST- 2008/07/10 09:00 [pubmed]
PHST- 2008/10/22 09:00 [medline]
PHST- 2008/07/10 09:00 [entrez]
AID - 08-PONE-RA-04003R1 [pii]
AID - 10.1371/journal.pone.0002615 [doi]
PST - epublish
SO  - PLoS One. 2008 Jul 9;3(7):e2615. doi: 10.1371/journal.pone.0002615.

PMID- 10681486
OWN - NLM
STAT- MEDLINE
DCOM- 20000613
LR  - 20131121
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 21
IP  - 6
DP  - 2000 Mar
TI  - Randomized comparative trial of triflusal and aspirin following acute myocardial 
      infarction.
PG  - 457-65
AB  - AIMS: To compare the efficacy and tolerability of the antiplatelet agent 
      triflusal with aspirin in the prevention of cardiovascular events following acute 
      myocardial infarction. METHODS AND RESULTS: In this double-blind, multicentre, 
      sequential design study, patients were randomized within 24 h of acute myocardial 
      infarction symptom onset to receive triflusal 600 mg or aspirin 300 mg once daily 
      for 35 days. The primary end-point was death, non-fatal myocardial reinfarction 
      or a non-fatal cerebrovascular event. The incidences of these individual outcomes 
      and urgent revascularization were secondary end-points. The null hypothesis of no 
      difference between treatments in the primary combined end-point was accepted with 
      80% power after recruiting 2124 validated patients (odds ratio (OR) for failure 
      [95% confidence interval (CI)]: 0.882 [0.634-1.227]). Non-fatal cerebrovascular 
      events were significantly less frequent with triflusal (OR [95% CI]: 0.364 
      [0.146-0.908]; P = 0.030). There was no significant difference between treatments 
      for death (OR [95% CI]: 0.816 [0.564-1.179]; P = 0.278), non-fatal reinfarction 
      (OR [95% CI]: 1.577 [0.873-2.848]; P = 0.131) or revascularization (OR [95% CI]: 
      0.864 [0.644-1.161]; P = 0.334). Overall, both drugs were well tolerated, 
      although there was a trend towards fewer bleeding episodes with triflusal; 
      significantly fewer central nervous system bleeding episodes were observed in 
      triflusal-treated patients (0.27% vs. 0.97%; P = 0.033). CONCLUSION: Triflusal 
      and aspirin have similar efficacy in preventing further cardiovascular events 
      after acute myocardial infarction, but triflusal showed a more favourable safety 
      profile. Triflusal significantly reduced the incidence of non-fatal 
      cerebrovascular events compared with aspirin.
CI  - Copyright 2000 The European Society of Cardiology.
FAU - Cruz-Fernández, J M
AU  - Cruz-Fernández JM
AD  - Department of Cardiology, Hospital Universitario Virgen de la Macarena, Sevilla, 
      Spain.
FAU - López-Bescós, L
AU  - López-Bescós L
FAU - García-Dorado, D
AU  - García-Dorado D
FAU - López García-Aranda, V
AU  - López García-Aranda V
FAU - Cabadés, A
AU  - Cabadés A
FAU - Martín-Jadraque, L
AU  - Martín-Jadraque L
FAU - Velasco, J A
AU  - Velasco JA
FAU - Castro-Beiras, A
AU  - Castro-Beiras A
FAU - Torres, F
AU  - Torres F
FAU - Marfil, F
AU  - Marfil F
FAU - Navarro, E
AU  - Navarro E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 1Z0YFI05OO (triflusal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2000 Mar;21(6):430-2. PMID: 10681480
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/complications/*drug therapy/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Recurrence
MH  - Salicylates/adverse effects/*therapeutic use
MH  - Spain
MH  - Treatment Outcome
EDAT- 2000/02/22 09:00
MHDA- 2000/06/17 09:00
CRDT- 2000/02/22 09:00
PHST- 2000/02/22 09:00 [pubmed]
PHST- 2000/06/17 09:00 [medline]
PHST- 2000/02/22 09:00 [entrez]
AID - S0195668X99918742 [pii]
AID - 10.1053/euhj.1999.1874 [doi]
PST - ppublish
SO  - Eur Heart J. 2000 Mar;21(6):457-65. doi: 10.1053/euhj.1999.1874.

PMID- 17599766
OWN - NLM
STAT- MEDLINE
DCOM- 20070906
LR  - 20211203
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 56
IP  - 7
DP  - 2007 Jul
TI  - Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a 
      randomized, double-blind, placebo-controlled trial in asymptomatic 
      antiphospholipid antibody-positive individuals.
PG  - 2382-91
AB  - OBJECTIVE: To determine the efficacy of a daily dose of 81 mg aspirin in primary 
      thrombosis prevention in asymptomatic, persistently antiphospholipid antibody 
      (aPL)-positive individuals (those with positive aPL but no vascular and/or 
      pregnancy events). METHODS: The Antiphospholipid Antibody Acetylsalicylic Acid 
      (APLASA) study was a multicenter, randomized, double-blind, placebo-controlled 
      clinical trial in which asymptomatic, persistently aPL-positive individuals were 
      randomized to receive a daily dose of 81 mg of aspirin or placebo. In a separate 
      observational and parallel study, asymptomatic, persistently aPL-positive 
      individuals who were taking aspirin or declined randomization were followed up 
      prospectively. RESULTS: In the APLASA study, 98 individuals were randomized to 
      receive aspirin or placebo (mean +/- SD followup period 2.30 +/- 0.95 years), of 
      whom 48 received aspirin and 50 received placebo. In the observational study, 74 
      nonrandomized individuals were followed up prospectively (mean +/- SD followup 
      period 2.46 +/- 0.76 years); 61 received aspirin and 13 did not. In the APLASA 
      study, the acute thrombosis incidence rates were 2.75 per 100 patient-years for 
      aspirin-treated subjects and 0 per 100 patient-years for the placebo-treated 
      subjects (hazard ratio 1.04, 95% confidence interval 0.69-1.56) (P = 0.83). 
      Similarly, in the observational study, the acute thrombosis incidence rates were 
      2.70 per 100 patient-years for aspirin-treated subjects and 0 per 100 
      patient-years for those not treated with aspirin. All but 1 patient with 
      thrombosis in either study had concomitant thrombosis risk factors and/or 
      systemic autoimmune disease at the time of thrombosis. CONCLUSION: Our results 
      suggest that asymptomatic, persistently aPL-positive individuals do not benefit 
      from low-dose aspirin for primary thrombosis prophylaxis, have a low overall 
      annual incidence rate of acute thrombosis, and develop vascular events when 
      additional thrombosis risk factors are present.
FAU - Erkan, Doruk
AU  - Erkan D
AD  - Hospital for Special Surgery, Weill Medical College of Cornell University, New 
      York, New York, USA. erkand@hss.edu
FAU - Harrison, Melanie J
AU  - Harrison MJ
FAU - Levy, Roger
AU  - Levy R
FAU - Peterson, Margaret
AU  - Peterson M
FAU - Petri, Michelle
AU  - Petri M
FAU - Sammaritano, Lisa
AU  - Sammaritano L
FAU - Unalp-Arida, Aynur
AU  - Unalp-Arida A
FAU - Vilela, Veronica
AU  - Vilela V
FAU - Yazici, Yusuf
AU  - Yazici Y
FAU - Lockshin, Michael D
AU  - Lockshin MD
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Nat Clin Pract Rheumatol. 2008 Jan;4(1):14-5. PMID: 18043598
CIN - Arthritis Rheum. 2008 Feb;58(2):635-6; author reply 636. PMID: 18240250
CIN - Curr Rheumatol Rep. 2008 Jan;10(1):59-61. PMID: 18457613
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Antiphospholipid Syndrome/*complications/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Ethnicity
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Selection
MH  - Placebos
MH  - Thrombosis/etiology/*prevention & control
EDAT- 2007/06/30 09:00
MHDA- 2007/09/07 09:00
CRDT- 2007/06/30 09:00
PHST- 2007/06/30 09:00 [pubmed]
PHST- 2007/09/07 09:00 [medline]
PHST- 2007/06/30 09:00 [entrez]
AID - 10.1002/art.22663 [doi]
PST - ppublish
SO  - Arthritis Rheum. 2007 Jul;56(7):2382-91. doi: 10.1002/art.22663.

PMID- 31865534
OWN - NLM
STAT- MEDLINE
DCOM- 20210526
LR  - 20210526
IS  - 1433-8726 (Electronic)
IS  - 0724-4983 (Linking)
VI  - 38
IP  - 10
DP  - 2020 Oct
TI  - Influence of regular aspirin intake on PSA values, prostate cancer incidence and 
      overall survival in a prospective screening trial (ERSPC Aarau).
PG  - 2485-2491
LID - 10.1007/s00345-019-03054-5 [doi]
AB  - OBJECTIVES: To analyze the influence of aspirin (ASA) intake on PSA values and 
      prostate cancer (PCa) development in a prospective screening study cohort. 
      METHODS: 4314 men from the Swiss section of the European Randomized Study of 
      Screening for Prostate Cancer (ERSPC) were included. A transrectal prostate 
      biopsy was performed in men with a PSA level ≥ 3 ng/ml. Mortality data were 
      obtained through registry linkages. PCa incidence and grade, total PSA, 
      free-to-total PSA and overall survival were compared between ASA users and 
      non-users. RESULTS: Median follow-up time was 9.6 years. In 789 men (18.3%) using 
      aspirin [ASA +], the overall PCa incidence was significantly lower (6.8% vs. 
      9.6%, p = 0.015), but the multivariate Cox regression analysis showed no 
      significant decrease in risk of PCa diagnosis (HR 0.84, p = 0.297). Total PSA 
      values were significantly lower in ASA users for both baseline (1.6 vs. 
      1.8 ng/ml, p = 0.007) and follow-up visits (1.75 vs. 2.1 ng/ml, p < 0.001). 
      Multivariate Cox regression analysis predicted significantly higher overall 
      mortality risk among ASA users (HR 1.46, p = 0.009). CONCLUSIONS: In our study 
      population, PCa incidence was significantly reduced among patients on aspirin. 
      While we did not observe a statistically significant PCa risk reduction during 
      the follow-up period, we found lower PSA values among ASA users compared to 
      non-users, with a more distinct difference after 4 years of ASA intake, 
      suggesting a cumulative effect and a potential protective association between 
      regular ASA intake and PCa development. As for clinical practice, lowering PSA 
      cutoff values by 0.4 ng/ml could be considered in long-term ASA users to avoid a 
      potential bias towards delayed PCa detection.
FAU - Prause, Lukas Werner
AU  - Prause LW
AUID- ORCID: 0000-0002-1563-3543
AD  - Department of Urology, University Hospital Zurich, Zurich, Switzerland. 
      lukas.prause@gmail.com.
AD  - Department of Urology, Cantonal Hospital Aarau, Aarau, Switzerland. 
      lukas.prause@gmail.com.
FAU - Manka, Lukas
AU  - Manka L
AD  - Department of Urology, Academic Hospital Braunschweig, Braunschweig, Germany. 
      l.manka@klinikum-braunschweig.de.
FAU - Millan, Christopher
AU  - Millan C
AD  - Department of Urology, University Hospital Zurich, Zurich, Switzerland.
FAU - Lang, Elena
AU  - Lang E
AD  - Department of Urology, University Hospital Zurich, Zurich, Switzerland.
FAU - Wyler, Stephen F
AU  - Wyler SF
AD  - Department of Urology, Cantonal Hospital Aarau, Aarau, Switzerland.
AD  - Faculty Member, University of Basel, Basel, Switzerland.
FAU - Grobholz, Rainer
AU  - Grobholz R
AD  - Institute of Pathology, Cantonal Hospital Aarau, Aarau, Switzerland.
FAU - Hammerer-Lercher, Angelika
AU  - Hammerer-Lercher A
AD  - Department of Laboratory Medicine, Cantonal Hospital Aarau, Aarau, Switzerland.
FAU - Sulser, Tullio
AU  - Sulser T
AD  - Department of Urology, University Hospital Zurich, Zurich, Switzerland.
FAU - Recker, Franz
AU  - Recker F
AD  - Department of Urology, Cantonal Hospital Aarau, Aarau, Switzerland.
FAU - Kwiatkowski, Maciej
AU  - Kwiatkowski M
AD  - Department of Urology, Cantonal Hospital Aarau, Aarau, Switzerland.
AD  - Department of Urology, Academic Hospital Braunschweig, Braunschweig, Germany.
AD  - Faculty Member, University of Basel, Basel, Switzerland.
FAU - Eberli, Daniel
AU  - Eberli D
AD  - Department of Urology, University Hospital Zurich, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20191221
PL  - Germany
TA  - World J Urol
JT  - World journal of urology
JID - 8307716
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology/therapeutic use
MH  - *Early Detection of Cancer
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Prostate-Specific Antigen/*blood/*drug effects
MH  - Prostatic Neoplasms/*blood/*epidemiology
MH  - Survival Rate
MH  - Switzerland/epidemiology
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Aspirin
OT  - Chemoprevention
OT  - Prostate cancer
OT  - Prostate-specific antigen
OT  - Screening
EDAT- 2019/12/23 06:00
MHDA- 2021/05/27 06:00
CRDT- 2019/12/23 06:00
PHST- 2019/07/15 00:00 [received]
PHST- 2019/12/08 00:00 [accepted]
PHST- 2019/12/23 06:00 [pubmed]
PHST- 2021/05/27 06:00 [medline]
PHST- 2019/12/23 06:00 [entrez]
AID - 10.1007/s00345-019-03054-5 [pii]
AID - 10.1007/s00345-019-03054-5 [doi]
PST - ppublish
SO  - World J Urol. 2020 Oct;38(10):2485-2491. doi: 10.1007/s00345-019-03054-5. Epub 
      2019 Dec 21.

PMID- 24692475
OWN - NLM
STAT- MEDLINE
DCOM- 20140703
LR  - 20220129
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 45
IP  - 5
DP  - 2014 May
TI  - Warfarin versus aspirin for prevention of cognitive decline in atrial 
      fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation 
      Treatment of the Aged Study).
PG  - 1381-6
LID - 10.1161/STROKEAHA.113.004009 [doi]
AB  - BACKGROUND AND PURPOSE: Atrial fibrillation is associated with decline of 
      cognitive function. Observational evidence suggests that anticoagulation might 
      protect against this decline. We report the first randomized controlled trial 
      evidence on the effect of anticoagulation on cognitive function in elderly 
      patients with atrial fibrillation. METHODS: A total of 973 patients aged≥75 years 
      with atrial fibrillation were recruited from primary care and randomly assigned 
      to warfarin (n=488; target international normalized ratio, 2-3) or aspirin 
      (n=485; 75 mg/d). Neither participants nor investigators were masked to group 
      assignment. Follow-up was for a mean of 2.7 years (SD, 1.2). Cognitive outcome 
      was assessed using the Mini-Mental State Examination at 9-, 21-, and 33-month 
      follow-up. Participants who had a stroke were censored from the analysis, which 
      was by intention to treat with imputation for missing data. RESULTS: There was no 
      difference between mean Mini-Mental State Examination scores in people assigned 
      to warfarin or aspirin at 9 or 21 months. At 33-month follow-up, there was a 
      nonsignificant difference of 0.56 in favor of warfarin that decreased to 0.49 
      (95% confidence interval, -0.01 to 0.98) after imputation. CONCLUSIONS: We found 
      no evidence that anticoagulation confers clinically important protection over 
      aspirin against cognitive decline as measured by the Mini-Mental State 
      Examination in atrial fibrillation in the first 33 months of treatment other than 
      that provided by preventing clinical stroke. CLINICAL TRIAL REGISTRATION URL: 
      http://www.controlled-trials.com. Unique identifier: ISRCTN89345269.
FAU - Mavaddat, Nahal
AU  - Mavaddat N
AD  - From the Primary Care Unit, Strangeways Laboratory, Department of Public Health 
      and Primary Care, University of Cambridge, Cambridge, United Kingdom (N.M., 
      J.M.); Primary Care Clinical Sciences, University of Birmingham, Edgbaston, 
      Birmingham, United Kingdom (A.R., K.F., D.F.); University of Birmingham Centre 
      for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom 
      (G.Y.H.L.); and Department of Primary Care Health Sciences, New Radcliffe House, 
      Radcliffe Observatory Quarter, University of Oxford, Oxford, United Kingdom 
      (F.D.R.H.).
FAU - Roalfe, Andrea
AU  - Roalfe A
FAU - Fletcher, Kate
AU  - Fletcher K
FAU - Lip, Gregory Y H
AU  - Lip GY
FAU - Hobbs, F D Richard
AU  - Hobbs FD
FAU - Fitzmaurice, David
AU  - Fitzmaurice D
FAU - Mant, Jonathan
AU  - Mant J
LA  - eng
SI  - ISRCTN/ISRCTN89345269
GR  - 632/DH_/Department of Health/United Kingdom
GR  - G9900264/MRC_/Medical Research Council/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140401
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Stroke. 2014 Sep;45(9):e191. PMID: 25096728
CIN - Stroke. 2014 Sep;45(9):e192. PMID: 25096732
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/pathology
MH  - Anticoagulants/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Cognition Disorders/diagnosis/*drug therapy/etiology/prevention & control
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*pharmacology
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Time Factors
MH  - Treatment Outcome
MH  - Warfarin/administration & dosage/*pharmacology
OTO - NOTNLM
OT  - aspirin
OT  - atrial fibrillation
OT  - cognition
OT  - warfarin
EDAT- 2014/04/03 06:00
MHDA- 2014/07/06 06:00
CRDT- 2014/04/03 06:00
PHST- 2014/04/03 06:00 [entrez]
PHST- 2014/04/03 06:00 [pubmed]
PHST- 2014/07/06 06:00 [medline]
AID - STROKEAHA.113.004009 [pii]
AID - 10.1161/STROKEAHA.113.004009 [doi]
PST - ppublish
SO  - Stroke. 2014 May;45(5):1381-6. doi: 10.1161/STROKEAHA.113.004009. Epub 2014 Apr 
      1.

PMID- 6367153
OWN - NLM
STAT- MEDLINE
DCOM- 19840425
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 15
IP  - 2
DP  - 1984 Mar-Apr
TI  - Prolongation of bleeding time and inhibition of platelet aggregation by low-dose 
      acetylsalicylic acid in patients with cerebrovascular disease.
PG  - 241-3
AB  - Platelet aggregation and bleeding time was measured in 43 cerebrovascular 
      patients participating in a controlled double-blind study of low-dose 
      acetylsalicylic acid. In 19 patients with satisfactory inhibition of the platelet 
      aggregation obtained by 50 to 70 mg acetylsalicylic acid per day the bleeding 
      time averaged 11.2 minutes in contrast to 7.0 minutes in the placebo group, p 
      less than 0.001. This study confirms our previous findings of platelet inhibition 
      by low-dose acetylsalicylic acid in patients with cerebrovascular disease. The 
      prolongation of the bleeding time demonstrates that we are dealing not merely 
      with an in vitro phenomenon but with a significant in vivo effect. The study 
      provides the rationale for clinical evaluations of low-dose acetylsalicylic acid 
      in stroke prophylaxis.
FAU - Boysen, G
AU  - Boysen G
FAU - Boss, A H
AU  - Boss AH
FAU - Odum, N
AU  - Odum N
FAU - Olsen, J S
AU  - Olsen JS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - *Bleeding Time
MH  - Cerebrovascular Disorders/*drug therapy
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Platelet Aggregation/*drug effects
MH  - *Platelet Function Tests
MH  - Random Allocation
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
AID - 10.1161/01.str.15.2.241 [doi]
PST - ppublish
SO  - Stroke. 1984 Mar-Apr;15(2):241-3. doi: 10.1161/01.str.15.2.241.

PMID- 29281929
OWN - NLM
STAT- MEDLINE
DCOM- 20181105
LR  - 20190116
IS  - 1525-6014 (Electronic)
IS  - 0148-0545 (Linking)
VI  - 41
IP  - 3
DP  - 2018 Jul
TI  - Protective effect of aspirin against mitomycin C-induced carcinogenicity, 
      assessed by the test for detection of epithelial tumor clones (warts) in 
      Drosophila melanogaster.
PG  - 330-337
LID - 10.1080/01480545.2017.1415926 [doi]
AB  - The present study assessed the protective effect of aspirin against 
      carcinogenicity induced by mitomycin C (MMC) by the test for detection of 
      warts/epithelial tumor clones in Drosophila melanogaster. Larvae were treated 
      with different concentrations of aspirin alone (10, 20 or 40 mg/mL) or aspirin in 
      association with MMC. MMC and ultrapure water were employed as the positive and 
      negative control, respectively. Antioxidant activity was determined using the 
      DPPH method. For performing cytotoxicity assay on HeLa cells, the aspirin 
      concentrations used ranged from 200 mmol/L to 3,125 mmol/L. For assessment of 
      apoptosis and necrosis, cells were incubated for 24 h with complete medium in the 
      absence (control group) or presence of aspirin (12.5 mmol/L and 25 mmol/L). The 
      results obtained in the assessment of the possible carcinogenic effects of 
      aspirin at the three concentrations tested indicate no statistically significant 
      increase in tumor frequency compared to the negative control. The 
      anticarcinogenic activity assessment, where the larvae of D. melanogaster were 
      previously induced to tumor formation by MMC and later treated with aspirin, 
      showed a statistically significant reduction in the number of tumors compared to 
      the positive control. Antioxidant activity across the three aspirin 
      concentrations (10, 20 or 40 mg/mL) ranged from 20.81% to 26.5%. It was observed 
      that aspirin reduced growth viability of HeLa cells in a concentration-dependent 
      manner in comparison with the control. These results indicate that aspirin did 
      not induce tumors in Drosophila and reduced MMC-induced carcinogenicity. The 
      antioxidant activity and apoptosis induction appear to be the main mechanisms 
      involved in reducing the frequency of tumors.
FAU - Oliveira, Victor Constante
AU  - Oliveira VC
AD  - a Genetics and Biochemistry Institute , Federal University of Uberlandia , 
      Uberlandia , Brazil.
AD  - b Laboratory of Cytogenetics and Mutagenesis , University Center of Patos de 
      Minas , Patos de Minas , Brazil.
FAU - Constante, Sarah Alves Rodrigues
AU  - Constante SAR
AD  - b Laboratory of Cytogenetics and Mutagenesis , University Center of Patos de 
      Minas , Patos de Minas , Brazil.
FAU - Polloni, Lorena
AU  - Polloni L
AD  - c Laboratory of Animal Cytogenetics , Genetics and Biochemistry Institute, 
      Federal University of Uberlândia , Uberlandia , Brazil.
FAU - Orsolin, Priscila Capelari
AU  - Orsolin PC
AD  - b Laboratory of Cytogenetics and Mutagenesis , University Center of Patos de 
      Minas , Patos de Minas , Brazil.
FAU - Silva-Oliveira, Rosiane Gomes
AU  - Silva-Oliveira RG
AD  - b Laboratory of Cytogenetics and Mutagenesis , University Center of Patos de 
      Minas , Patos de Minas , Brazil.
FAU - Machado, Nayane Moreira
AU  - Machado NM
AD  - b Laboratory of Cytogenetics and Mutagenesis , University Center of Patos de 
      Minas , Patos de Minas , Brazil.
FAU - de Oliveira-Júnior, Robson José
AU  - de Oliveira-Júnior RJ
AD  - c Laboratory of Animal Cytogenetics , Genetics and Biochemistry Institute, 
      Federal University of Uberlândia , Uberlandia , Brazil.
FAU - Nepomuceno, Júlio César
AU  - Nepomuceno JC
AD  - a Genetics and Biochemistry Institute , Federal University of Uberlandia , 
      Uberlandia , Brazil.
AD  - b Laboratory of Cytogenetics and Mutagenesis , University Center of Patos de 
      Minas , Patos de Minas , Brazil.
LA  - eng
PT  - Journal Article
DEP - 20171227
PL  - United States
TA  - Drug Chem Toxicol
JT  - Drug and chemical toxicology
JID - 7801723
RN  - 0 (Antioxidants)
RN  - 50SG953SK6 (Mitomycin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antioxidants/pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/*pharmacology
MH  - Drosophila melanogaster
MH  - HeLa Cells
MH  - Humans
MH  - Mitomycin/*toxicity
MH  - Neoplasms, Glandular and Epithelial/chemically induced/*prevention & control
OTO - NOTNLM
OT  - Anticarcinogenesis
OT  - Aspirin
OT  - Drosophila melanogaster
OT  - Mitomycin C. wts
EDAT- 2017/12/29 06:00
MHDA- 2018/11/06 06:00
CRDT- 2017/12/29 06:00
PHST- 2017/12/29 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
PHST- 2017/12/29 06:00 [entrez]
AID - 10.1080/01480545.2017.1415926 [doi]
PST - ppublish
SO  - Drug Chem Toxicol. 2018 Jul;41(3):330-337. doi: 10.1080/01480545.2017.1415926. 
      Epub 2017 Dec 27.

PMID- 25023071
OWN - NLM
STAT- MEDLINE
DCOM- 20150928
LR  - 20220330
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 3
IP  - 4
DP  - 2014 Jul 14
TI  - Use of aspirin for primary and secondary cardiovascular disease prevention in the 
      United States, 2011-2012.
LID - 10.1161/JAHA.114.000989 [doi]
LID - e000989
AB  - BACKGROUND: Aspirin use has been shown to be an effective tool in cardiovascular 
      disease (CVD) prevention among high-risk patients. The patient-reported physician 
      recommendation for aspirin as preventive therapy among high- and low-risk 
      patients is unknown. METHODS AND RESULTS: We conducted an analysis of the 
      National Health and Nutrition Examination Survey 2011-2012 to examine the use of 
      aspirin for CVD prevention. Patients without previously diagnosed CVD were 
      classified into high and low risk based on their Framingham Risk Score (10-year 
      coronary heart disease risk). Among patients without previously diagnosed CVD, 
      22.5% were classified as high risk. Of the high-risk individuals, 40.9% reported 
      being told by their physician to take aspirin, with 79.0% complying. Among those 
      who were at low risk, 26.0% were told by their physician to take aspirin, with 
      76.5% complying. Logistic regression analysis indicated that age, access to a 
      regular source of care, education, and insurance status were significant 
      predictors of patient-reported physician recommendations for aspirin use for 
      primary prevention. Among high-risk patients, age, race, and insurance status 
      were significant predictors of reported recommendations for aspirin use. Among 
      low-risk patients, age, education, obesity, and insurance status were significant 
      predictors of reported recommendations for aspirin use. CONCLUSIONS: Patient 
      reports indicate nonideal rates of being told to take aspirin, for both high- and 
      low-risk patients for primary prevention. Clinical decision support tools that 
      could assist physicians in identifying patients at risk may increase patient 
      reports of physician recommendations for aspirin use.
CI  - © 2014 The Authors. Published on behalf of the American Heart Association, Inc., 
      by Wiley Blackwell.
FAU - Mainous, Arch G
AU  - Mainous AG
AD  - Department of Health Services Research Management, and Policy, University of 
      Florida, Gainesville, FL (A.G.M., R.J.T.) Department of Community Health and 
      Family Medicine, University of Florida, Gainesville, FL (A.G.M.).
FAU - Tanner, Rebecca J
AU  - Tanner RJ
AD  - Department of Health Services Research Management, and Policy, University of 
      Florida, Gainesville, FL (A.G.M., R.J.T.).
FAU - Shorr, Ronald I
AU  - Shorr RI
AD  - Geriatric Research Education & Clinical Center, Malcom Randall VAMC and 
      Department of Epidemiology, University of Florida, Gainesville, FL (R.I.S.).
FAU - Limacher, Marian C
AU  - Limacher MC
AD  - Division of Cardiology, Department of Medicine, College of Medicine, University 
      of Florida, Gainesville, FL (M.C.L.).
LA  - eng
GR  - UL1 TR000064/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20140714
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Medication Adherence/*statistics & numerical data
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - *Primary Prevention
MH  - Risk Assessment
MH  - *Secondary Prevention
MH  - Self Report
MH  - United States
PMC - PMC4310388
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular diseases
OT  - prevention
EDAT- 2014/07/16 06:00
MHDA- 2015/09/29 06:00
CRDT- 2014/07/16 06:00
PHST- 2014/07/16 06:00 [entrez]
PHST- 2014/07/16 06:00 [pubmed]
PHST- 2015/09/29 06:00 [medline]
AID - jah3610 [pii]
AID - 10.1161/JAHA.114.000989 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2014 Jul 14;3(4):e000989. doi: 10.1161/JAHA.114.000989.

PMID- 29478129
OWN - NLM
STAT- MEDLINE
DCOM- 20180905
LR  - 20181202
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 45
IP  - 3
DP  - 2018 Apr
TI  - Gene polymorphisms in dual antiplatelet therapy and the presence of 
      hypo-attenuated leaflet thickening after transcatheter aortic valve replacement.
PG  - 463-465
LID - 10.1007/s11239-018-1636-z [doi]
AB  - The imaging finding of hypo-attenuated leaflet thickening (HALT) on bioprosthesis 
      after transcatheter aortic valve replacement (TAVR) has been reported. The 
      underlying mechanism is not clear, but leaflet thrombosis is speculated to be the 
      cause. Heterogeneous antiplatelet responses may play a role in the process. This 
      is a prospective, single-center pilot study in patients who received successful 
      TAVR from June 2012 to November 2016. HALT on post-procedural multi-detector 
      computed tomography. We thoroughly genotyped 34 SNPs and 8 SNPs that have been 
      reported for clopidogrel and aspirin resistance. A total of 148 patients were 
      enrolled. There were 15 patients demonstrating signs of HALT. Patients with HALT 
      had a higher rate of atrial fibrillation (AF) pre-TAVR (33.3 vs. 7.5%, P = 0.01). 
      We found that rs4244285 G>A polymorphism of the CYP2C19 gene was associated with 
      the risk of HALT in the overdominant model (OR 4.00 [1.15-13.97], P = 0.02 for GA 
      vs. GG+AA) adjusted by sex and the presence of pre-TAVR AF. Antiplatelet drug 
      resistance is a reasonable possibility involved in HALT. Potential directions 
      were suggested in polymorphisms of the CYP2C19 gene.
FAU - Xiong, Tian-Yuan
AU  - Xiong TY
AD  - Department of Cardiology, West China Hospital, Sichuan University, #37 Guo Xue 
      Alley, Chengdu, 610041, People's Republic of China.
FAU - Liao, Yan-Biao
AU  - Liao YB
AD  - Department of Cardiology, West China Hospital, Sichuan University, #37 Guo Xue 
      Alley, Chengdu, 610041, People's Republic of China.
FAU - Feng, Yuan
AU  - Feng Y
AD  - Department of Cardiology, West China Hospital, Sichuan University, #37 Guo Xue 
      Alley, Chengdu, 610041, People's Republic of China.
FAU - Zhao, Ming-Yue
AU  - Zhao MY
AD  - Laboratory of Cardiovascular Diseases, Regenerative Medicine Research Center, 
      West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of 
      China.
FAU - Zhao, Zhen-Gang
AU  - Zhao ZG
AD  - Department of Cardiology, West China Hospital, Sichuan University, #37 Guo Xue 
      Alley, Chengdu, 610041, People's Republic of China.
FAU - Li, Yi-Jian
AU  - Li YJ
AD  - Department of Cardiology, West China Hospital, Sichuan University, #37 Guo Xue 
      Alley, Chengdu, 610041, People's Republic of China.
FAU - Liu, Xiao-Jing
AU  - Liu XJ
AD  - Laboratory of Cardiovascular Diseases, Regenerative Medicine Research Center, 
      West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of 
      China. liuxq@scu.edu.cn.
FAU - Chen, Mao
AU  - Chen M
AD  - Department of Cardiology, West China Hospital, Sichuan University, #37 Guo Xue 
      Alley, Chengdu, 610041, People's Republic of China. hmaochen@vip.sina.com.
LA  - eng
GR  - 81370219/National Natural Science Foundation of China/
GR  - 2017TD0004/Science and Technology Innovative Research Groups Program of Sichuan 
      Province/
GR  - 2016YFC1102200/"13th Five-Year" National Key Research and Development Program of 
      China/
PT  - Journal Article
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Cytochrome P-450 CYP2C19/genetics
MH  - Drug Resistance/genetics
MH  - Female
MH  - Heart Valve Prosthesis/adverse effects
MH  - Humans
MH  - Male
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Polymorphism, Single Nucleotide
MH  - Prospective Studies
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
MH  - Transcatheter Aortic Valve Replacement/*adverse effects
OTO - NOTNLM
OT  - Hypo-attenuated leaflet thickening
OT  - Single nucleotide polymorphisms
OT  - Transcatheter aortic valve replacement
EDAT- 2018/02/27 06:00
MHDA- 2018/09/06 06:00
CRDT- 2018/02/26 06:00
PHST- 2018/02/27 06:00 [pubmed]
PHST- 2018/09/06 06:00 [medline]
PHST- 2018/02/26 06:00 [entrez]
AID - 10.1007/s11239-018-1636-z [pii]
AID - 10.1007/s11239-018-1636-z [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2018 Apr;45(3):463-465. doi: 10.1007/s11239-018-1636-z.

PMID- 27627817
OWN - NLM
STAT- MEDLINE
DCOM- 20170609
LR  - 20180102
IS  - 1528-1175 (Electronic)
IS  - 0003-3022 (Linking)
VI  - 125
IP  - 6
DP  - 2016 Dec
TI  - Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative 
      ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials.
PG  - 1121-1129
AB  - BACKGROUND: The PeriOperative ISchemia Evaluation-2 (POISE-2) trial compared 
      aspirin with placebo after noncardiac surgery. METHODS: The authors randomly 
      assigned 10,010 patients undergoing noncardiac surgery to receive 200 mg aspirin 
      or placebo 2 to 4 h before surgery and then 100 mg aspirin daily or placebo daily 
      for up to 30 days after surgery. Herein, the authors report the effect of aspirin 
      on venous thromboembolism (VTE), including deep vein thrombosis and pulmonary 
      embolism, as well as an updated pooled analysis of randomized trials of 
      antiplatelet therapy for VTE prevention in noncardiac surgery patients. RESULTS: 
      Six thousand five hundred forty-eight patients (65.4%) received anticoagulant 
      prophylaxis. VTE occurred in 53 patients (1.1%) allocated to aspirin and in 60 
      patients (1.2%) allocated to placebo (hazard ratio, 0.89; 95% CI, 0.61 to 1.28). 
      Major or life-threatening bleeding occurred in 312 patients (6.3%) allocated to 
      aspirin and in 256 patients (5.1%) allocated to placebo (hazard ratio, 1.22; 95% 
      CI, 1.04 to 1.44). Concomitant use of anticoagulant prophylaxis did not modify 
      the effect of aspirin on VTE or bleeding. Pooled analysis of the POISE-2 and 
      Pulmonary Embolism Prevention trials demonstrated that symptomatic VTE occurred 
      in 173 (1.3%) of 13,724 patients allocated to aspirin and in 246 (1.8%) of 13,730 
      patients allocated to placebo (odds ratio, 0.71; 95% CI, 0.56 to 0.89; 
      heterogeneity P = 0.27; I = 17%); the impact of aspirin was very similar in those 
      who did and did not receive pharmacologic prophylaxis. Pooled estimates for 
      symptomatic VTE were similar to the pooled estimates for any deep vein thrombosis 
      and pulmonary embolism from the POISE-2 trial, Pulmonary Embolism Prevention 
      trial, and the Antiplatelet Trialists' Collaboration meta-analysis. CONCLUSIONS: 
      Aspirin in the POISE-2 trial did not reduce VTE, but two thirds of patients 
      received anticoagulant prophylaxis, there were few VTE events, and results were 
      consistent with a wide range of aspirin effects. A pooled analysis of the 
      randomized trials demonstrates evidence for the efficacy of aspirin for VTE 
      prevention in hospitalized surgical patients.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AD  - From the Department of Medicine Hamilton, McMaster University, Hamilton, Ontario, 
      Canada (J.W.E., C.K., G.G., S.Y., D.C., J. Douketis, A.P., E.D., P.J.D.); 
      Departments of Outcomes Research and General Anesthesiology, Anesthesiology 
      Institute, Cleveland Clinic, Cleveland, Ohio (D.I.S., A.K.); Department of 
      Medicine Hamilton, St Joseph's Healthcare, Hamilton, Ontario, Canada (D.C., J. 
      Douketis); Department of Anesthesiology, Queen's University and Kingston General 
      Hospital, Kingston, Ontario, Canada (R.A.), Departments of Anesthesia and 
      Perioperative Medicine and Epidemiology and Biostatistics, University of Western 
      Ontario, London, Ontario, Canada (P.M.J.); Research Department, Fundaciòn 
      Cardioinfantil, Bogotà, Colombia (R.J.D.); Department of Anaesthesia, University 
      of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia 
      (T.W.P.); Departments of Anesthesiology and Neurological Surgery, The Ohio State 
      University Wexner Medical Center, Columbus, Ohio (S.D.B.); Department of 
      Anaesthesia and Pain Management, Royal Melbourne Hospital, Melbourne, Victoria, 
      Australia (K.L.); Toronto General Hospital, Li Ka Shing Knowledge Institute of 
      St. Michael's Hospital and Department of Anesthesia, University of Toronto, 
      Toronto, Ontario, Canada (D.N.W.); Population Health Research Institute, 
      Hamilton, Ontario, Canada (J.W.E., S.Y., K.B., E.D., S.M., J. Douketis, P.J.D.); 
      Department of Anesthesia, Wake Forest School of Medicine, Winston-Salem, North 
      Carolina (S.M.); and Department of Anaesthesiology, University of the Free State, 
      Bloemfontein, South Africa (J. Diedericks).
FAU - Kearon, Clive
AU  - Kearon C
FAU - Guyatt, Gordon
AU  - Guyatt G
FAU - Sessler, Daniel I
AU  - Sessler DI
FAU - Yusuf, Salim
AU  - Yusuf S
FAU - Cook, Deborah
AU  - Cook D
FAU - Douketis, James
AU  - Douketis J
FAU - Patel, Ameen
AU  - Patel A
FAU - Kurz, Andrea
AU  - Kurz A
FAU - Allard, Rene
AU  - Allard R
FAU - Jones, Philip M
AU  - Jones PM
FAU - Dennis, Rodolfo J
AU  - Dennis RJ
FAU - Painter, Thomas W
AU  - Painter TW
FAU - Bergese, Sergio D
AU  - Bergese SD
FAU - Leslie, Kate
AU  - Leslie K
FAU - Wijeysundera, Duminda N
AU  - Wijeysundera DN
FAU - Balasubramanian, Kumar
AU  - Balasubramanian K
FAU - Duceppe, Emmanuelle
AU  - Duceppe E
FAU - Miller, Scott
AU  - Miller S
FAU - Diedericks, Johan
AU  - Diedericks J
FAU - Devereaux, P J
AU  - Devereaux PJ
LA  - eng
GR  - 119385/CIHR/Canada
GR  - 104026/CIHR/Canada
GR  - 116349/CIHR/Canada
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesthesiology
JT  - Anesthesiology
JID - 1300217
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Anesthesiology. 2017 Aug;127(2):399-400. PMID: 28719534
CIN - Anesthesiology. 2017 Aug;127(2):401. PMID: 28719535
CIN - Anesthesiology. 2017 Aug;127(2):401-402. PMID: 28719536
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Odds Ratio
MH  - Perioperative Care/*methods
MH  - Postoperative Complications/*prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Surgical Procedures, Operative
MH  - Treatment Outcome
MH  - Venous Thromboembolism/*prevention & control
EDAT- 2016/09/15 06:00
MHDA- 2017/06/10 06:00
CRDT- 2016/09/15 06:00
PHST- 2016/09/15 06:00 [pubmed]
PHST- 2017/06/10 06:00 [medline]
PHST- 2016/09/15 06:00 [entrez]
AID - 10.1097/ALN.0000000000001352 [doi]
PST - ppublish
SO  - Anesthesiology. 2016 Dec;125(6):1121-1129. doi: 10.1097/ALN.0000000000001352.

PMID- 14981982
OWN - NLM
STAT- MEDLINE
DCOM- 20040405
LR  - 20131121
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 23
IP  - 6D
DP  - 2003 Nov-Dec
TI  - Angiogenic switch in earliest stages of human colonic tumorigenesis.
PG  - 5153-7
AB  - BACKGROUND: Angiogenesis is activated in numerous physiological and pathological 
      conditions. We examined whether new vessel formation exists in the earliest 
      stages of colonic tumorigenesis. MATERIALS AND METHODS: Microvascular density 
      (MVD) was examined in 176 formalin-fixed and paraffin-embedded aberrant crypt 
      foci (ACF) dissected from macroscopically-normal mucosa obtained from patients 
      with colorectal cancer. ACF were classified as non-hyperplastic, non-dysplastic 
      (NH-ACF, n = 80), hyperplastic (H-ACF, n = 72) and dysplastic (D-ACF, n = 24). 
      Mucosal strips were stained with methylene blue solution and screened under x 40 
      magnification for ACF. The identified ACF were microdissected and stained with an 
      anti-CD-34 monoclonal antibody. MVD in ACF were compared to that of normal 
      corresponding mucosa. RESULTS: The mean MVD for normal mucosa and ACF were 13.7 
      +/- 7.7 and 23 +/- 13, respectively. Microvessel counts increased in NH-ACF 
      versus normal mucosa (18.7 +/- 10 vs. 13.7 +/- 7.7, p = 0.05), in H-ACF versus 
      NH-ACF (24.8 +/- 14 vs. 18.7 +/- 10, p = 0.002) and in D-ACF versus H-ACF (31.7 
      +/- 10 vs. 24.8 +/- 14, p = 0.014). We further evaluated the effect of low-dose 
      aspirin on MVD in ACF. No effect of aspirin on microvessel counts could be 
      detected. CONCLUSION: Our data suggest that angiogenesis occurs in ACF which are 
      the earliest morphologically identifiable preneoplastic and early neoplastic 
      lesions in colonic mucosa. With progression from NH-ACF to D-ACF there is a 
      progressive, statistically significant increase in MVD, suggesting active 
      angiogenesis during the earliest steps of colorectal tumorigenesis.
FAU - Shpitz, Baruch
AU  - Shpitz B
AD  - Department of Surgery, Sapir Medical Center, Meir General Hospital, Laboratory of 
      Oncogenetics, Sapir Medical Center, Kfar Sava, Israel. shpitzca@post.tau.ac.il
FAU - Gochberg, Semion
AU  - Gochberg S
FAU - Neufeld, David
AU  - Neufeld D
FAU - Grankin, Mila
AU  - Grankin M
FAU - Buklan, Genadi
AU  - Buklan G
FAU - Klein, Ehud
AU  - Klein E
FAU - Bernheim, Joelle
AU  - Bernheim J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Colonic Neoplasms/*blood supply
MH  - Humans
MH  - Intestinal Mucosa/blood supply
MH  - Neovascularization, Pathologic/drug therapy/*pathology
MH  - Precancerous Conditions/*blood supply
EDAT- 2004/02/26 05:00
MHDA- 2004/04/06 05:00
CRDT- 2004/02/26 05:00
PHST- 2004/02/26 05:00 [pubmed]
PHST- 2004/04/06 05:00 [medline]
PHST- 2004/02/26 05:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2003 Nov-Dec;23(6D):5153-7.

PMID- 7240438
OWN - NLM
STAT- MEDLINE
DCOM- 19810810
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 21
IP  - 4
DP  - 1981 Apr
TI  - Gastroscopic observations following aspirin and naproxen sodium administration.
PG  - 169-72
AB  - A double-blind crossover study was conducted to compare the effects of aspirin 
      (3.25 Gm/day) and a new nonsteroidal antiinflammatory drug, naproxen sodium (1.1 
      Gm/day), on the gastric mucosa of 12 healthy volunteers. Subjects were 
      gastroscoped after one week on each drug, intragastric photographs were obtained, 
      and gastric contents were examined for blood. Ten subjects exhibited some degree 
      of gastric pathology following aspirin administration, compared with one subject 
      with gastric pathology following naproxen sodium. Naproxen sodium also induced 
      less gastrointestinal bleeding and caused fewer side effects than aspirin.
FAU - Halvorsen, L
AU  - Halvorsen L
FAU - Sevelius, H
AU  - Sevelius H
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastroscopy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Naproxen/*adverse effects
EDAT- 1981/04/01 00:00
MHDA- 1981/04/01 00:01
CRDT- 1981/04/01 00:00
PHST- 1981/04/01 00:00 [pubmed]
PHST- 1981/04/01 00:01 [medline]
PHST- 1981/04/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1981.tb05696.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1981 Apr;21(4):169-72. doi: 10.1002/j.1552-4604.1981.tb05696.x.

PMID- 24245548
OWN - NLM
STAT- MEDLINE
DCOM- 20151021
LR  - 20141107
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 25
IP  - 8
DP  - 2014
TI  - Assessment of the response to acetylsalicylic acid in patients with 
      myeloproliferative neoplasms by whole blood assays: a comparison of the PFA-100 
      with multiple electrode aggregometry.
PG  - 608-11
LID - 10.3109/09537104.2013.852661 [doi]
AB  - Since thrombotic and haemorrhagic complications are the most important causes of 
      morbidity and mortality in myeloproliferative neoplasms (MPN), establishing valid 
      techniques for the monitoring of antiaggregatory treatment would be beneficial. 
      The aim of this study was to assess the aspirin responsiveness in patients with 
      MPN by multiple electrode aggregometry (MEA) and the PFA-100, to determine the 
      concordance rate between the two techniques and to examine a potential clinical 
      impact. Twenty-two consecutive outpatients with polycythaemia vera and essential 
      thrombocythaemia receiving long-time treatment with 100 mg of aspirin were 
      included and clinically re-evaluated within six months after study entry. All 
      subjects were identified as aspirin responders using the PFA-100, whereas only 
      nine (41%) study participants were detected as responders by MEA. The difference 
      in the response rates was statistically highly significant (p < 0.0001). The 
      median aggregation result was 55.5 U (8-123) in the ASPI test, and the median 
      PFA-100 closure time (CT) was 300 sec (221 to 300) in the COL-EPI test. Within 
      the clinical observation period no thrombotic or haemorrhagic events occurred in 
      the study population. In this study we concluded that MEA and the PFA-100 are 
      suitable devices for the detection of a response to aspirin treatment in patients 
      with MPN, but differ significantly in the response rates and thus show a low 
      concordance rate.
FAU - Robier, Christoph
AU  - Robier C
AD  - Central Laboratory, Hospital of the Brothers of St. John of God , Graz-Eggenberg 
      , Austria .
FAU - Neubauer, Manfred
AU  - Neubauer M
FAU - Quehenberger, Franz
AU  - Quehenberger F
FAU - Stettin, Mariana
AU  - Stettin M
FAU - Neumeister, Peter
AU  - Neumeister P
LA  - eng
PT  - Journal Article
DEP - 20131118
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology
MH  - Biological Assay
MH  - Blood Platelets/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myeloproliferative Disorders/*blood/*drug therapy
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Function Tests/*methods
MH  - Young Adult
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Multiplate analyzer
OT  - PFA-100
OT  - myeloproliferative neoplasms
OT  - platelet aggregation
OT  - platelet function
EDAT- 2013/11/20 06:00
MHDA- 2015/10/22 06:00
CRDT- 2013/11/20 06:00
PHST- 2013/11/20 06:00 [entrez]
PHST- 2013/11/20 06:00 [pubmed]
PHST- 2015/10/22 06:00 [medline]
AID - 10.3109/09537104.2013.852661 [doi]
PST - ppublish
SO  - Platelets. 2014;25(8):608-11. doi: 10.3109/09537104.2013.852661. Epub 2013 Nov 
      18.

PMID- 6791962
OWN - NLM
STAT- MEDLINE
DCOM- 19811118
LR  - 20131121
IS  - 0430-0920 (Print)
IS  - 0430-0920 (Linking)
VI  - 36
IP  - 8
DP  - 1981 Aug
TI  - Further investigations on the antinflammatory activity of some 2-phenylpyrazolol 
      [1,5-a]pyrimidine compounds.
PG  - 682-91
AB  - The paper reports the inhibitory activity (ID50) of a series of 2-phenylpyrazolo 
      [1,5-a]pyrimidines on prostaglandin synthetase of guinea-pig lung homogenate in 
      comparison with indomethacin. In vivo studies showed that some of these compounds 
      possess interesting antiinflammatory, antipyretic and analgesic properties, as 
      compared to those of classic non steroid antiinflammatory drugs like aspirin or 
      phenylbutazone.
FAU - Pirisino, R
AU  - Pirisino R
FAU - Mangano, G
AU  - Mangano G
FAU - Ceppatelli, P
AU  - Ceppatelli P
FAU - Corrias, M
AU  - Corrias M
FAU - Ignesti, G
AU  - Ignesti G
FAU - Carla, V
AU  - Carla V
FAU - Vettori, L P
AU  - Vettori LP
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Farmaco Sci
JT  - Il Farmaco; edizione scientifica
JID - 0370716
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 9000-07-1 (Carrageenan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*chemical synthesis
MH  - Anti-Inflammatory Agents, Non-Steroidal
MH  - Aspirin/pharmacology
MH  - Carrageenan/antagonists & inhibitors
MH  - Cyclooxygenase Inhibitors
MH  - Pyrazoles/*chemical synthesis/pharmacology
MH  - Pyrimidines/*chemical synthesis/pharmacology
MH  - Rats
MH  - Time Factors
EDAT- 1981/08/01 00:00
MHDA- 1981/08/01 00:01
CRDT- 1981/08/01 00:00
PHST- 1981/08/01 00:00 [pubmed]
PHST- 1981/08/01 00:01 [medline]
PHST- 1981/08/01 00:00 [entrez]
PST - ppublish
SO  - Farmaco Sci. 1981 Aug;36(8):682-91.

PMID- 26808030
OWN - NLM
STAT- MEDLINE
DCOM- 20160802
LR  - 20160322
IS  - 2163-0763 (Electronic)
IS  - 2163-0755 (Linking)
VI  - 80
IP  - 4
DP  - 2016 Apr
TI  - Aspirin as added prophylaxis for deep vein thrombosis in trauma: A retrospective 
      case-control study.
PG  - 625-30
LID - 10.1097/TA.0000000000000977 [doi]
AB  - BACKGROUND: Current prophylaxis does not completely prevent deep vein thrombosis 
      (DVT) in trauma patients. Recent data suggest that platelets may be a major 
      contributor to hypercoagulability after trauma, indicating a potential role for 
      antiplatelet medications in prophylaxis for DVT. We sought to determine if 
      preinjury aspirin use was associated with a reduced incidence of lower extremity 
      DVT in trauma patients. METHODS: Using a retrospective case-control design, we 
      matched 110 cases of posttrauma lower extremity DVT one-to-one with controls 
      using seven covariates: age, admission date, probability of death, number of DVT 
      risk factors, sex, mechanism of injury, and presence of head injury. Data 
      collected included 26 risk factors for DVT, prehospital medications, and 
      in-hospital prophylaxis. Logistic regression models were created to examine the 
      relationship between prehospital aspirin use and posttrauma DVT. RESULTS: 
      Preinjury aspirin was used by 7.3% of cases (patients diagnosed with in-hospital 
      DVT) compared with 13.6% of controls (p = 0.1). Aspirin was associated with a 
      significant protective effect in multivariate analysis, with an odds ratio of 
      0.17 (95% confidence interval, 0.04-0.68; p = 0.012) in the most complete model. 
      When stratified by other antithrombotic use, aspirin showed a significant effect 
      only when used in combination with heparinoid prophylaxis (odds ratio, 0.35; 95% 
      confidence interval, 0.13-0.93; p = 0.036). CONCLUSION: Preinjury aspirin use 
      seems to significantly lower DVT rate following injury. This association is 
      strongest when heparinoid prophylaxis is prescribed after patients on preinjury 
      aspirin therapy are admitted. Aspirin as added prophylaxis for DVT in trauma 
      patients needs to be further evaluated. LEVEL OF EVIDENCE: Prognostic and 
      epidemiologic study, level III.
FAU - Brill, Jason B
AU  - Brill JB
AD  - From the Trauma Service, Scripps Mercy Hospital, San Diego, California.
FAU - Calvo, Richard Y
AU  - Calvo RY
FAU - Wallace, James D
AU  - Wallace JD
FAU - Lewis, Paul R
AU  - Lewis PR
FAU - Bansal, Vishal
AU  - Bansal V
FAU - Sise, Michael J
AU  - Sise MJ
FAU - Shackford, Steven R
AU  - Shackford SR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Trauma Acute Care Surg
JT  - The journal of trauma and acute care surgery
JID - 101570622
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Leg/blood supply
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Venous Thrombosis/*etiology/*prevention & control
MH  - Wounds and Injuries/*complications
EDAT- 2016/01/26 06:00
MHDA- 2016/08/03 06:00
CRDT- 2016/01/26 06:00
PHST- 2016/01/26 06:00 [entrez]
PHST- 2016/01/26 06:00 [pubmed]
PHST- 2016/08/03 06:00 [medline]
AID - 10.1097/TA.0000000000000977 [doi]
PST - ppublish
SO  - J Trauma Acute Care Surg. 2016 Apr;80(4):625-30. doi: 
      10.1097/TA.0000000000000977.

PMID- 6972566
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0085-5928 (Print)
IS  - 0085-5928 (Linking)
VI  - 67
DP  - 1981
TI  - Aspirin and bile acid induced gastric mucosal damage: protection by 
      prostaglandins and antacids.
PG  - 215-7
AB  - The importance of bile acids in causing gastric mucosal haemorrhage and the 
      protective effect of prostaglandins and antacids has been studied in a series of 
      studies using an animal model. Bile acids alone did not damage the gastric 
      mucosa, but conjugated bile acids together with aspirin and hydrochloric acid may 
      cause gastric mucosal haemorrhage. The prostaglandin analogue 15(R)15-methyl-E2 
      methyl ester protected the gastric mucosa against damage caused by conjugated 
      bile acids together with aspirin or hydrochloric acid. Gastric mucosal protection 
      was also achieved with antacids, but this effect appeared to be mainly on the 
      aspirin rather than on the bile acid component of the damage. Bile acid binding, 
      if it did occur, did not prevent the bile acid from increasing aspirin-induced 
      gastric mucosal damage.
FAU - Russell, R I
AU  - Russell RI
FAU - Carmichael, H A
AU  - Carmichael HA
FAU - Nelson, L M
AU  - Nelson LM
FAU - Morgan, R J
AU  - Morgan RJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol Suppl
JT  - Scandinavian journal of gastroenterology. Supplement
JID - 0437034
RN  - 0 (Antacids)
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antacids/*therapeutic use
MH  - Aspirin/*adverse effects
MH  - Bile Acids and Salts/*physiology
MH  - Gastric Mucosa/drug effects
MH  - Gastrointestinal Hemorrhage/etiology/*prevention & control
MH  - Male
MH  - Models, Biological
MH  - Prostaglandins/*therapeutic use
MH  - Rats
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol Suppl. 1981;67:215-7.

PMID- 820487
OWN - NLM
STAT- MEDLINE
DCOM- 19760925
LR  - 20191021
IS  - 0009-9090 (Print)
IS  - 0009-9090 (Linking)
VI  - 6
IP  - 3
DP  - 1976 May
TI  - The effect of sodium cromoglycate in preventing aspirin induced bronchospasm.
PG  - 269-75
AB  - Seventeen patients with aspirin-induced asthma were studied, the majority being 
      intolerant to more than one analgesic. In addition to asthma, eleven patients had 
      sinusitis and eight had nasal polyps. Serum IgE levels were normal with a mean of 
      295 iu/ml. However, some patients had positive cutaneous and PK tests against 
      inhalants and non-analgesic drugs. Spirometry showed the bronchial obstruction to 
      be mild. However, all patients were hyper-reactive to acetylcholine. Oral 
      provocation tests with aspirin alone and also with the prior administration of 
      sodium cromoglycate (SCG) by inhalation were performed and the results assessed 
      by spirometry and clinical examination. The results suggest that the obstruction 
      is probably due to oedema of the bronchial mucosa together with pulmonary 
      congestion rather than a simple spasm of the bronchi. SCG was found to prevent 
      significantly the ventilatory obstruction induced by aspirin. It is suggested 
      that non-immunological factors are responsible for the asthma and that SCG may 
      have an effect on the altered receptors protecting them from the action of 
      aspirin on kinins.
FAU - Basomba, A
AU  - Basomba A
FAU - Romar, A
AU  - Romar A
FAU - Peláez, A
AU  - Peláez A
FAU - Villalmanzo, I G
AU  - Villalmanzo IG
FAU - Campos, A
AU  - Campos A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Allergy
JT  - Clinical allergy
JID - 0311172
RN  - Q2WXR1I0PK (Cromolyn Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Airway Obstruction/pathology/prevention & control
MH  - Aspirin/*adverse effects
MH  - Bronchial Spasm/chemically induced/*prevention & control
MH  - Cromolyn Sodium/*therapeutic use
MH  - Drug Evaluation
MH  - Drug Hypersensitivity
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Spirometry
EDAT- 1976/05/01 00:00
MHDA- 1976/05/01 00:01
CRDT- 1976/05/01 00:00
PHST- 1976/05/01 00:00 [pubmed]
PHST- 1976/05/01 00:01 [medline]
PHST- 1976/05/01 00:00 [entrez]
AID - 10.1111/j.1365-2222.1976.tb01907.x [doi]
PST - ppublish
SO  - Clin Allergy. 1976 May;6(3):269-75. doi: 10.1111/j.1365-2222.1976.tb01907.x.

PMID- 32472363
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20201015
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Linking)
VI  - 22
IP  - 7
DP  - 2020 May 29
TI  - Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in 
      the Elderly.
PG  - 48
LID - 10.1007/s11886-020-01296-z [doi]
AB  - PURPOSE OF REVIEW: To review the clinical evidence of the effect of aspirin as 
      primary prevention for patients with diabetes mellitus and in healthy elderly. 
      RECENT FINDINGS: Two trials were performed to study these two patient 
      populations: ASCEND showed that the use of low-dose aspirin in persons with 
      diabetes, who did not have prior cardiovascular disease, led to a lower risk of 
      cardiovascular events than placebo (8.5% vs 9.6%, rate ratio 0.88, 95% CI 
      0.79-0.97; p = 0.01). However, it showed a similar magnitude of increased risk of 
      major bleeding among the aspirin group compared with placebo (4.1% vs 3.2%, rate 
      ratio 1.29, 95% CI 1.09-1.52; p = 0.003). ASPREE showed that the use of low-dose 
      aspirin in healthy elderly did not prolong disability-free survival (21.5% vs 
      21.2%, HR 1.01, 95% CI 0.92-1.11; p = 0.79); however, the rate of major 
      hemorrhage was higher in the aspirin group than in the placebo group (3.8% vs 
      2.8%, HR 1.38, 95% CI 1.18-1.62; p < 0.001). Additionally, further analyses of 
      secondary end points of death, cardiovascular disease, and major hemorrhage were 
      also studied. Higher all-cause mortality was seen among healthy elderly who 
      received aspirin compared with placebo (12.7% vs 11.1%, HR 1.14, 95% CI 
      1.01-1.29) and was primarily attributed to cancer-related deaths. Similar risk of 
      cardiovascular disease was seen among elderly who received aspirin compared with 
      placebo (10.7% vs 11.3%, HR 0.95, 95% CI 0.83-1.08) and resulted in a 
      significantly higher risk of major hemorrhage (8.6% vs 6.8%, HR 1.38, 95% CI 
      1.18-1.62; p < 0.001). These studies show that the use of low-dose aspirin as 
      primary prevention in patients with diabetes and in the elderly does not have 
      overall beneficial effect compared with its use in secondary prevention. In 
      patients with diabetes without prior cardiovascular disease, the benefits of 
      aspirin use were counterbalanced by the bleeding risk. Additionally, in healthy 
      elderly, the use of aspirin did not prolong disability-free survival and instead 
      led to a higher rate of major hemorrhage.
FAU - Patel, Neha J
AU  - Patel NJ
AD  - University of Toledo, Toledo, OH, USA.
FAU - Baliga, Ragavendra R
AU  - Baliga RR
AD  - The Ohio State University Medical Center, Columbus, OH, USA. rrbaliga@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200529
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*prevention & control
MH  - Case-Control Studies
MH  - Diabetes Complications/*prevention & control
MH  - Diabetes Mellitus
MH  - Disabled Persons
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Hypertension/prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Primary Prevention
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular disease
OT  - Diabetes mellitus
OT  - Elderly
OT  - Primary prevention
EDAT- 2020/05/31 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/05/31 06:00 [entrez]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1007/s11886-020-01296-z [pii]
AID - 10.1007/s11886-020-01296-z [doi]
PST - epublish
SO  - Curr Cardiol Rep. 2020 May 29;22(7):48. doi: 10.1007/s11886-020-01296-z.

PMID- 34028396
OWN - NLM
STAT- MEDLINE
DCOM- 20220614
LR  - 20220617
IS  - 1539-2031 (Electronic)
IS  - 0192-0790 (Linking)
VI  - 56
IP  - 6
DP  - 2022 Jul 1
TI  - No Significant Difference in Post-ERCP Bleeding Rates Between Dual Antiplatelet 
      Agents and Aspirin Alone: A Systematic Review and Meta-analysis.
PG  - 546-551
LID - 10.1097/MCG.0000000000001559 [doi]
AB  - BACKGROUND: Several professional society guidelines suggest holding antiplatelet 
      agents before high-risk procedures. However, there is lack of high-grade evidence 
      to support the recommendation as most of the studies have been single center with 
      small sample sizes. We aimed to perform the first systematic review and 
      meta-analysis comparing dual antiplatelet therapy (DAPT) versus aspirin alone in 
      terms of postendoscopic retrograde cholangiopancreatography (ERCP) bleeding. 
      METHODS: Three independent reviewers performed a comprehensive review of all 
      original articles published from inception to May 2020, evaluating the post-ERCP 
      bleeding rate in setting of DAPT. Primary outcomes were the overall post-ERCP 
      bleeding rate with the use of dual antiplatelet therapy; comparison of post-ERCP 
      bleeding rate in patients with DAPT versus aspirin alone. Secondary outcomes were 
      comparison of immediate and delayed post-ERCP bleeding outcomes in the 2 cohorts. 
      RESULTS: Six studies were included after a thorough search was concluded using 
      the key words. The pooled analysis of studies revealed an overall post-ERCP 
      bleeding rate of 5.7% (95% confidence interval: 3-10.6) on sustained DAPT. 
      Post-ERCP bleeding in DAPT Cohort was not significantly higher as compared with 
      aspirin only Cohort (odds ratio: 1.14, 95% confidence interval: 0.46-2.81). The 
      immediate bleeding and delayed bleeding rates cannot be generalized due to low 
      number of studies. CONCLUSIONS: The first systematic review and meta-analysis 
      showed that post-ERCP bleeding rates are not significantly higher in DAPT cohort 
      as compared with aspirin alone. Therefore, the risk of bleeding is less likely 
      related to the antiplatelet agents and more likely related to the procedure 
      itself.
CI  - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Bhurwal, Abhishek
AU  - Bhurwal A
AD  - Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School 
      of Medicine, New Brunswick, NJ.
FAU - Mutneja, Hemant
AU  - Mutneja H
AD  - Division of Gastroenterology and Hepatology, John H. Stroger Cook County 
      Hospital, Chicago, IL.
FAU - Goel, Akshay
AU  - Goel A
AD  - Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, 
      AR.
FAU - Bansal, Vikas
AU  - Bansal V
AD  - Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, MN.
FAU - Patel, Anish
AU  - Patel A
AD  - Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School 
      of Medicine, New Brunswick, NJ.
FAU - Brahmbhatt, Bhaumik
AU  - Brahmbhatt B
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL.
FAU - Sarkar, Avik
AU  - Sarkar A
AD  - Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School 
      of Medicine, New Brunswick, NJ.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210524
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - Cholangiopancreatography, Endoscopic Retrograde/adverse effects
MH  - Drug Therapy, Combination
MH  - Hemorrhage
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/adverse effects
EDAT- 2021/05/25 06:00
MHDA- 2022/06/15 06:00
CRDT- 2021/05/24 12:26
PHST- 2020/12/04 00:00 [received]
PHST- 2021/03/17 00:00 [accepted]
PHST- 2021/05/25 06:00 [pubmed]
PHST- 2022/06/15 06:00 [medline]
PHST- 2021/05/24 12:26 [entrez]
AID - 00004836-900000000-97424 [pii]
AID - 10.1097/MCG.0000000000001559 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 2022 Jul 1;56(6):546-551. doi: 
      10.1097/MCG.0000000000001559. Epub 2021 May 24.

PMID- 27631829
OWN - NLM
STAT- MEDLINE
DCOM- 20170920
LR  - 20211115
IS  - 1537-4505 (Electronic)
IS  - 1531-7129 (Linking)
VI  - 37
IP  - 9
DP  - 2016 Oct
TI  - Correlation Between Aspirin Intake and Reduced Growth of Human Vestibular 
      Schwannoma: Volumetric Analysis.
PG  - 1428-34
LID - 10.1097/MAO.0000000000001180 [doi]
AB  - OBJECTIVE: To determine whether people with sporadic vestibular schwannoma (VS) 
      who take aspirin for unrelated medical reasons exhibit less tumor growth than 
      nonaspirin users. We previously demonstrated the efficacy of salicylates in 
      inhibiting VS growth in vitro, corroborating the results of our retrospective 
      clinical study, which found halted VS growth (based on linear tumor measurements) 
      in aspirin users. The current study evaluates this association using more 
      accurate tumor volumetric measurements, and quantifies the degree of 
      frequency-specific, VS-induced hearing loss. STUDY DESIGN: Retrospective 
      analysis. SETTING: Tertiary care hospital. PATIENTS: Diagnosed with VS between 
      1980 and 2012, followed by serial magnetic resonance imaging for at least 1 year. 
      MAIN OUTCOME MEASURES: Patient history of aspirin intake; change in VS volume 
      over time of observation; frequency-specific, VS-induced audiometric threshold 
      shifts. RESULTS: Of the 347 patients followed by serial magnetic resonance 
      imaging scans, 86 had sequential scans available for 3D-segmented volumetric 
      analysis for up to 11 years of follow-up (median 53 mo). Twenty-five (29%) had 
      documented history of aspirin intake; 8 (32%) of these demonstrated VS growth. Of 
      the 61 (71%) nonusers, 36 (59%) demonstrated growth. A significant inverse 
      association was found among aspirin users and VS growth: odds ratio 0.32, 95% 
      confidence interval 0.11 to 0.91. VS-induced audiometric thresholds shifts were 
      larger above than below 2000 Hz. CONCLUSION: Our volumetric analysis of VS growth 
      reaffirms the results of our linear analysis and suggests that aspirin may 
      inhibit VS growth. The audiometric findings are consistent with the previously 
      reported VS-induced predominantly high-frequency sensorineural hearing loss.
FAU - Kandathil, Cherian K
AU  - Kandathil CK
AD  - *Eaton Peabody Laboratories and Department of Otolaryngology, Massachusetts Eye 
      and Ear†Department of Otology and Laryngology, Harvard Medical School‡Department 
      of Radiology, Massachusetts Eye and Ear and Harvard Medical School, Boston, 
      Massachusetts.
FAU - Cunnane, Mary E
AU  - Cunnane ME
FAU - McKenna, Michael J
AU  - McKenna MJ
FAU - Curtin, Hugh D
AU  - Curtin HD
FAU - Stankovic, Konstantina M
AU  - Stankovic KM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Otol Neurotol
JT  - Otology & neurotology : official publication of the American Otological Society, 
      American Neurotology Society [and] European Academy of Otology and Neurotology
JID - 100961504
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Hearing Loss
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neuroma, Acoustic/*pathology
MH  - Retrospective Studies
EDAT- 2016/09/16 06:00
MHDA- 2017/09/21 06:00
CRDT- 2016/09/16 06:00
PHST- 2016/09/16 06:00 [entrez]
PHST- 2016/09/16 06:00 [pubmed]
PHST- 2017/09/21 06:00 [medline]
AID - 10.1097/MAO.0000000000001180 [doi]
PST - ppublish
SO  - Otol Neurotol. 2016 Oct;37(9):1428-34. doi: 10.1097/MAO.0000000000001180.

PMID- 24687637
OWN - NLM
STAT- MEDLINE
DCOM- 20150514
LR  - 20211021
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
VI  - 46
IP  - 9
DP  - 2014 Sep
TI  - Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic 
      studies.
PG  - 1715-28
LID - 10.1007/s11255-014-0703-4 [doi]
AB  - PURPOSE: Several epidemiologic studies were performed to clarify the protective 
      effect of regular aspirin use on prostate cancer risk; however, the results 
      remain controversial. Therefore, we conducted this meta-analysis to assess the 
      association between regular aspirin use and risk of prostate cancer. METHODS: 
      Electronic databases including PubMed, EMBASE and Cochrane Library were searched 
      between January 1966 and April 2013 to identify eligible studies. Pooled relative 
      ratios (RRs) and 95 % confidence intervals (CIs) were computed to assess the 
      influence of aspirin use on prostate cancer risk. All statistical tests were 
      two-sided. RESULTS: A total of 24 observational studies including 14 case-control 
      studies and 10 cohort studies were eligible for this meta-analysis. Regular 
      aspirin use was associated with reduction in overall and advanced prostate cancer 
      risk (pooled RR 0.86, 95 % CI 0.81-0.92; pooled RR 0.83, 95 % CI 0.75-0.91, 
      respectively). When we restricted our analyses to studies with long-time regular 
      aspirin use (equal or more than 4 years), reverse association became stronger 
      (pooled RR 0.82, 95 % CI 0.72-0.93; pooled RR 0.70, 95 % CI 0.55-0.90, 
      respectively). CONCLUSIONS: Our findings suggest that regular, especially 
      long-time regular aspirin use may reduce the risk of overall and advanced 
      prostate cancer. Considering the limitation of included studies, further 
      well-designed large-scaled cohort studies and RCTs are required to draw more 
      definitive conclusions.
FAU - Huang, Tian-Bao
AU  - Huang TB
AD  - Department of Urology, Shanghai Tenth People's Hospital, Tongji University, 301 
      Yanchang Road, Shanghai, 200072, China.
FAU - Yan, Yang
AU  - Yan Y
FAU - Guo, Zhui-Feng
AU  - Guo ZF
FAU - Zhang, Xiao-Long
AU  - Zhang XL
FAU - Liu, Huan
AU  - Liu H
FAU - Geng, Jiang
AU  - Geng J
FAU - Yao, Xu-Dong
AU  - Yao XD
FAU - Zheng, Jun-Hua
AU  - Zheng JH
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20140401
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Epidemiologic Studies
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/*epidemiology/*prevention & control
MH  - Risk Assessment
EDAT- 2014/04/02 06:00
MHDA- 2015/05/15 06:00
CRDT- 2014/04/02 06:00
PHST- 2013/12/09 00:00 [received]
PHST- 2014/03/18 00:00 [accepted]
PHST- 2014/04/02 06:00 [entrez]
PHST- 2014/04/02 06:00 [pubmed]
PHST- 2015/05/15 06:00 [medline]
AID - 10.1007/s11255-014-0703-4 [doi]
PST - ppublish
SO  - Int Urol Nephrol. 2014 Sep;46(9):1715-28. doi: 10.1007/s11255-014-0703-4. Epub 
      2014 Apr 1.

PMID- 25130161
OWN - NLM
STAT- MEDLINE
DCOM- 20150730
LR  - 20181202
IS  - 1735-9694 (Electronic)
IS  - 0044-6025 (Linking)
VI  - 52
IP  - 6
DP  - 2014
TI  - Multiple giant succular and fusiform right and left coronary artery aneurysms 
      after early and adequate treatment of atypical kawasaki disease with unusual 
      presentation.
PG  - 490-2
AB  - The major complication of Kawasaki disease is coronary artery dilatation and 
      aneurysm. It occurs in approximately 15-25% of untreated children with Kawasaki 
      Disease. Early diagnosis and treatment with Intravenous immune globulin (IVIG) 
      and aspirin (ASA) can reduce the incidence of coronary artery abnormality to 
      2%-5%. We report one case of Atypical Kawasaki Disease with Multiple giant 
      coronary artery aneurysms despite early adequate treatment with IVIG and ASA.
FAU - Behjati-Ardakani, Mostafa
AU  - Behjati-Ardakani M
AD  - Yazd Cardiovascular Research Center, Faculty of Medicine, Shahid Sadoughi 
      University of Medical Sciences, Yazd, Iran. dr_behjati@yahoo.com.
FAU - Ferdosian, Farzad
AU  - Ferdosian F
AD  - Department of Pediatrics, Faculty of Medicine, Shahid Sadoughi University of 
      Medical Sciences, Yazd, Iran. ferdosianfarzad@yahoo.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Iran
TA  - Acta Med Iran
JT  - Acta medica Iranica
JID - 14540050R
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Child
MH  - Coronary Aneurysm/diagnostic imaging/*etiology
MH  - Coronary Angiography
MH  - *Early Diagnosis
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*adverse effects/therapeutic use
MH  - Immunologic Factors/adverse effects/therapeutic use
MH  - Mucocutaneous Lymph Node Syndrome/*complications/drug therapy
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Time Factors
EDAT- 2014/08/19 06:00
MHDA- 2015/08/01 06:00
CRDT- 2014/08/19 06:00
PHST- 2013/03/11 00:00 [received]
PHST- 2013/06/10 00:00 [accepted]
PHST- 2014/08/19 06:00 [entrez]
PHST- 2014/08/19 06:00 [pubmed]
PHST- 2015/08/01 06:00 [medline]
PST - ppublish
SO  - Acta Med Iran. 2014;52(6):490-2.

PMID- 20180974
OWN - NLM
STAT- MEDLINE
DCOM- 20101028
LR  - 20211020
IS  - 1824-7288 (Electronic)
IS  - 1720-8424 (Linking)
VI  - 36
DP  - 2010 Jan 19
TI  - Kawasaki disease presenting with intussusception: a case report.
PG  - 7
LID - 10.1186/1824-7288-36-7 [doi]
AB  - A 3 yr old boy presented with abdominal pain, fever and red jelly stools. 
      Intussusception was diagnosed and effectively reduced with air insufflation. 
      However, despite an improvement in his clinical condition, the child remained 
      febrile and miserable; 5 days later he developed characteristic signs of Kawasaki 
      disease and was treated with intravenous immunoglobulin and high dose aspirin 
      with good results. Intussusception prior to the typical features of Kawasaki 
      disease has not been described previously in the English literature. This case 
      illustrates a novel presentation of Kawasaki disease.
FAU - Hussain, Rumana N
AU  - Hussain RN
AD  - Northampton General Hospital, Northampton, UK. rumanahussain@hotmail.com
FAU - Ruiz, Gary
AU  - Ruiz G
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20100119
PL  - England
TA  - Ital J Pediatr
JT  - Italian journal of pediatrics
JID - 101510759
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Child, Preschool
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Enema
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Immunologic Factors/therapeutic use
MH  - Insufflation/methods
MH  - Intussusception/diagnosis/*etiology/therapy
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*complications/diagnosis/drug therapy
PMC - PMC2828460
EDAT- 2010/02/26 06:00
MHDA- 2010/10/29 06:00
CRDT- 2010/02/26 06:00
PHST- 2009/10/28 00:00 [received]
PHST- 2010/01/19 00:00 [accepted]
PHST- 2010/02/26 06:00 [entrez]
PHST- 2010/02/26 06:00 [pubmed]
PHST- 2010/10/29 06:00 [medline]
AID - 1824-7288-36-7 [pii]
AID - 10.1186/1824-7288-36-7 [doi]
PST - epublish
SO  - Ital J Pediatr. 2010 Jan 19;36:7. doi: 10.1186/1824-7288-36-7.

PMID- 20449540
OWN - NLM
STAT- MEDLINE
DCOM- 20100720
LR  - 20131121
IS  - 0212-1611 (Print)
IS  - 0212-1611 (Linking)
VI  - 25
IP  - 2
DP  - 2010 Mar-Apr
TI  - The effect of prostaglandin synthase inhibitor, aspirin on the rat intestinal 
      membrane structure and function.
PG  - 290-8
LID - S0212-16112010000200014 [pii]
AB  - Aspirin at a dose of 50 mg/kg body weight was found to decrease the activity of 
      the rat intestinal brush border membrane (BBM) - associated enzymes such as the 
      sucrase, lactase, maltase and alkaline phosphatase. Aspirin treatment also led to 
      a decrease in the microviscosity in the native as well as the benzyl alcohol 
      treated membrane which might be due to the lipid peroxidative damage in the 
      membrane. Physical correlation of the membrane oxidative damage was evident as 
      the Fourier Transformation Infra Red (FTIR) study of the Aspirin treated 
      membrane, which include an increased proportion of gauche to trans conformer, 
      shift in the methylene C-H asymmetric and symmetric stretching frequencies, C = O 
      double bond stretching, NH bending, antisymmetric (N)-CH3 bending, C-N stretching 
      and antisymmetric CNC stretching while there was no change in the CH2 wagging and 
      twisting as well as in NH-bending amide bond I and II. Aspirin treatment also 
      caused an alteration in the glucose and histidine transport, as evident by a 
      decreased Vmax value while the apparent Km remaining unchanged in the control and 
      Aspirin-treated animals confirming that there was no change in the substrate 
      affinity constant of the membrane transport proteins for the glucose and the 
      basic amino acid, although the rate of transport decreased considerably. There 
      was a decrease noted in the energy of activation of glucose and histidine 
      transport when studied at different temperature but no change in the temperature 
      of phase transition in the BBM with Aspirin treatment, thus implying that perhaps 
      the thermotropic phase transition in the membrane may have relatively little 
      effect on the transport processes. The result suggests an underlying molecular 
      mechanism indicating the implied membrane damage by Aspirin, an important member 
      of the non-steroidal antiinflammatory drug (NSAID) family which could possibly 
      through an oxidative damage may lead to an altered molecular structure, physical 
      state and biological functions of the intestinal membrane.
FAU - Kaur, G
AU  - Kaur G
AD  - Department of Biophysics, Panjab University, Chandigarh, India.
FAU - Kaur, J
AU  - Kaur J
FAU - Mittal, N
AU  - Mittal N
FAU - Nath Sanyal, S
AU  - Nath Sanyal S
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Nutr Hosp
JT  - Nutricion hospitalaria
JID - 9100365
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Intestinal Mucosa/anatomy & histology/*drug effects/physiology
MH  - Male
MH  - Microvilli/drug effects/physiology
MH  - Rats
MH  - Rats, Wistar
EDAT- 2010/05/08 06:00
MHDA- 2010/07/21 06:00
CRDT- 2010/05/08 06:00
PHST- 2009/11/17 00:00 [received]
PHST- 2009/11/22 00:00 [accepted]
PHST- 2010/05/08 06:00 [entrez]
PHST- 2010/05/08 06:00 [pubmed]
PHST- 2010/07/21 06:00 [medline]
AID - S0212-16112010000200014 [pii]
PST - ppublish
SO  - Nutr Hosp. 2010 Mar-Apr;25(2):290-8.

PMID- 6941410
OWN - NLM
STAT- MEDLINE
DCOM- 19810827
LR  - 20131121
IS  - 0085-5928 (Print)
IS  - 0085-5928 (Linking)
VI  - 67
DP  - 1981
TI  - Effect of aspirin on the human stomach in normals: endoscopic comparison of 
      damage produced one hour, 24 hours, and 2 weeks after administration.
PG  - 211-4
AB  - We studied the effects of regular aspirin on the human stomach by endoscopy in 15 
      volunteers divided equally into three groups. Each had a normal baseline 
      endoscopy. In Group I, two aspirin or placebo tablets were administered suspended 
      in 100 cc of water and endoscopic assessment made over on hour, at four hours, 
      and 24 hours. In Group II, in a two way cross-over, blinded study we compared the 
      effects of 24 hours' ingestion of 3.25 g of aspirin and placebo. Group III 
      subjects received aspirin, two tablets four times daily for two weeks. In Group 
      I, multiple petechiae (p less than 0.05) developed in the fundus and antrum by 
      one hour and were still visible at 24 hours in 80%. In Group II, aspirin produced 
      multiple antral erosions (p less than 0.05 vs. placebo) in all subjects and 
      duodenal erosions in half. Antral and duodenal petechiae were common. In Group 
      III, all subjects developed antral erosions (p less than 0.05 vs. control) and 
      50% duodenal erosions but only on subject developed petechiae. Acute aspirin 
      administration appears to cause predominantly petechial hemorrhage in the fundus 
      and antrum while longer term administration causes antral and duodenal erosions. 
      Regular aspirin in recommended doses for one hour, 24 hours and two weeks 
      produces endoscopically visible gastroduodenal damage in the majority of normal 
      subjects.
FAU - O'Laughlin, J C
AU  - O'Laughlin JC
FAU - Hoftiezer, J W
AU  - Hoftiezer JW
FAU - Ivey, K J
AU  - Ivey KJ
LA  - eng
GR  - RR0287-12/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Scand J Gastroenterol Suppl
JT  - Scandinavian journal of gastroenterology. Supplement
JID - 0437034
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Double-Blind Method
MH  - Endoscopy
MH  - Female
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Humans
MH  - Male
MH  - Purpura/*chemically induced
MH  - Time Factors
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol Suppl. 1981;67:211-4.

PMID- 21548865
OWN - NLM
STAT- MEDLINE
DCOM- 20111115
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 17
IP  - 16
DP  - 2011
TI  - Lipoxins, the novel mediators of gastroprotection and gastric adaptation to 
      ulcerogenic action of aspirin.
PG  - 1541-51
AB  - Previous studies revealed that prostaglandins contribute to the mechanism of 
      maintenance of gastrointestinal integrity and mediate various physiological 
      aspects of mucosal defense. The suppression of prostaglandin synthesis in the 
      stomach is a critical event in terms of the development of mucosal injury after 
      administration of various NSAID including aspirin (ASA). A worldwide use of ASA 
      is now accepted due to its remarkable analgesic, antipyretic and anti-thrombotic 
      prophylactics against myocardial infarct and coronary disorders despite the fact 
      that the use of NSAIDs is associated with the risk of gastrointestinal bleedings, 
      haemorrhagic lesions and ulcerations. It has become clear that other mediators 
      besides prostaglandins can similarly act to protect the gastrointestinal mucosa 
      of experimental animals and humans from injury induced by ASA. For instance, 
      nitric oxide (NO) released from vascular epithelium, epithelial cells of 
      gastrointestinal tract and sensory nerves can influence many of the same 
      components of mucosal defense as do prostaglandins. This review was designed to 
      provide an updated overview based on the experimental and clinical evidence on 
      the involvement COX-2 derived products, lipoxins in the mechanism of gastric 
      defense, gastroprotection and gastric adaptation to ASA. Lipoxins were recently 
      considered as another group of lipid mediators that can protect the stomach 
      similarly as NO-donors known to exert protective influence on the stomach from 
      the injury under condition where the mucosal prostaglandin levels are suppressed. 
      The new class of NO-releasing NSAIDs, including NO-aspirin or NO-naproxen, 
      represent a very promising approach to reducing the toxicity of their parent 
      NSAIDs. Aspirin-triggered lipoxin (ATL) synthesis, via COX-2, acts to reduce the 
      severity of damage induced by this NSAID. Lipoxin analogues may prove to be 
      useful for preventing mucosal injury and for modulating mucosal inflammation. 
      Evidence presented in this review documents that ATL also play in important role 
      in gastric adaptation during chronic ASA administration. Suppression of COX-2 
      activity by selective COX-2 inhibitors such as rofecoxib or celecoxib was shown 
      to abolish the production of ATL and to diminish the gastric tolerability of ASA 
      and gastric adaptation developed in response to repetitive administration of this 
      NSAID. Synthetic analogues of lipoxins as well as newer class of NSAIDs releasing 
      NO may be used in the future as the therapeutic approach to counteract adverse 
      effects in the stomach associated with NSAIDs ingestion.
FAU - Pajdo, Robert
AU  - Pajdo R
AD  - Department of Physiology, Jagiellonian University Medical College, Poland.
FAU - Brzozowski, Tomasz
AU  - Brzozowski T
FAU - Szlachcic, Aleksandra
AU  - Szlachcic A
FAU - Konturek, Peter C
AU  - Konturek PC
FAU - Ptak-Belowska, Agata
AU  - Ptak-Belowska A
FAU - Drozdowicz, Danuta
AU  - Drozdowicz D
FAU - Targosz, Aneta
AU  - Targosz A
FAU - Konturek, Stanislaw J
AU  - Konturek SJ
FAU - Pawlik, Wieslaw W
AU  - Pawlik WW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Lipoxins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Adaptation, Physiological
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Lipoxins/*physiology
MH  - Stomach/*drug effects/physiopathology
MH  - Stomach Ulcer/physiopathology/*prevention & control
EDAT- 2011/05/10 06:00
MHDA- 2011/11/16 06:00
CRDT- 2011/05/10 06:00
PHST- 2011/04/08 00:00 [received]
PHST- 2011/04/27 00:00 [accepted]
PHST- 2011/05/10 06:00 [entrez]
PHST- 2011/05/10 06:00 [pubmed]
PHST- 2011/11/16 06:00 [medline]
AID - BSP/CPD/E-Pub/000467 [pii]
AID - 10.2174/138161211796197043 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2011;17(16):1541-51. doi: 10.2174/138161211796197043.

PMID- 18334606
OWN - NLM
STAT- MEDLINE
DCOM- 20080711
LR  - 20220311
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 42
IP  - 4
DP  - 2008 Apr
TI  - Use of anticoagulation in elderly patients with atrial fibrillation who are at 
      risk for falls.
PG  - 523-32
LID - 10.1345/aph.1K498 [doi]
AB  - OBJECTIVE: To evaluate data addressing use of anticoagulation in elderly patients 
      with atrial fibrillation (AF), in particular those at risk of falls. DATA 
      SOURCES: Primary literature was identified through PubMed MEDLINE (1966-December 
      2007) and EMBASE (1980-December 2007) using the search terms anticoagulation, 
      warfarin, aspirin, elderly, falls, older persons, atrial fibrillation, bleeding, 
      education, stroke, and use. Additional references were obtained through review of 
      references from articles obtained. STUDY SELECTION AND DATA EXTRACTION: Clinical 
      studies evaluating warfarin and aspirin efficacy in AF, as well as studies 
      evaluating anticoagulation and falls, elderly patients, and bleeding were 
      considered for inclusion. Selection emphasis was placed on randomized studies of 
      AF and those evaluating anticoagulation and falls. DATA SYNTHESIS: Uncertainties 
      over the optimal treatment for elderly patients with AF still exist. Variance in 
      the guidelines is reflected in current practice, as some discrepancies are 
      present. Warfarin is underprescribed in elderly patients, with only about 50% of 
      eligible patients receiving therapy. Falls are most often cited as the reason for 
      not using anticoagulants in an elderly patient. Three risk-benefit analyses have 
      been performed, and all found that despite risks associated with warfarin, its 
      benefits outweigh its risks even in patients who fall. Warfarin should be used 
      rather than aspirin or no therapy in elderly patients at risk of falls. 
      Anticoagulation education has been shown to reduce the risk of bleeding in the 
      elderly and should be a vital part of warfarin management. CONCLUSIONS: The risk 
      of falls alone should not automatically disqualify a person from being treated 
      with warfarin. While falls should not dictate anticoagulant choice, assessment 
      and management of fall risk should be an important part of anticoagulation 
      management. Efforts should be made to minimize fall risk.
FAU - Garwood, Candice L
AU  - Garwood CL
AD  - Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health 
      Sciences, Wayne State University, Detroit, MI 48201, USA. cgarwood@wayne.edu
FAU - Corbett, Tia L
AU  - Corbett TL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20080311
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Accidental Falls
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Humans
MH  - Intracranial Hemorrhages/chemically induced/prevention & control
MH  - Practice Guidelines as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Stroke/prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
RF  - 59
EDAT- 2008/03/13 09:00
MHDA- 2008/07/12 09:00
CRDT- 2008/03/13 09:00
PHST- 2008/03/13 09:00 [pubmed]
PHST- 2008/07/12 09:00 [medline]
PHST- 2008/03/13 09:00 [entrez]
AID - aph.1K498 [pii]
AID - 10.1345/aph.1K498 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2008 Apr;42(4):523-32. doi: 10.1345/aph.1K498. Epub 2008 Mar 
      11.

PMID- 8826489
OWN - NLM
STAT- MEDLINE
DCOM- 19961206
LR  - 20210112
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 65
IP  - 1
DP  - 1996 Apr
TI  - Topical aspirin/diethyl ether mixture versus indomethacin and diclofenac/diethyl 
      ether mixtures for acute herpetic neuralgia and postherpetic neuralgia: a 
      double-blind crossover placebo-controlled study.
PG  - 45-51
LID - 10.1016/0304-3959(95)00155-7 [doi]
AB  - The efficacy of topical aspirin/diethyl ether (ADE) mixture in the treatment of 
      acute herpetic neuralgia and postherpetic neuralgia, suggested in a previous 
      open-label study (De Benedittis et al. 1992), has been evaluated in a 
      double-blind crossover placebo-controlled study as compared with two other NSAID 
      (indomethacin and diclofenac) drug/ether mixtures. The study included 37 patients 
      (15 with acute herpetic neuralgia (AHN) and 22 with postherpetic neuralgia 
      (PHN)). Comparative treatment results showed that only aspirin (but not 
      indomethacin and diclofenac) was significantly superior to placebo, as compared 
      with baseline and duration of pain relief (P < 0.05 and P < 0.01, respectively), 
      in both AHN and PHN groups. Good-to-excellent results were achieved by 87% of AHN 
      patients and by 82% of PHN patients treated with the ADE mixture, with no 
      significant differences between the two groups. On the whole, patients with 
      trigeminal involvement, less severe pain and with dysaesthetic quality of pain 
      yielded best results.
FAU - De Benedittis, Giuseppe
AU  - De Benedittis G
AD  - Pain Research and Treatment Unit, Institute of Neurosurgery, University of Milan, 
      Milan, Italy.
FAU - Lorenzetti, Ariberto
AU  - Lorenzetti A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Solvents)
RN  - 0F5N573A2Y (Ether)
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
CIN - Pain. 1997 Apr;70(2-3):287-9. PMID: 9150304
MH  - Acute Disease
MH  - Administration, Cutaneous
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Diclofenac/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Ether
MH  - Female
MH  - Herpes Zoster Oticus/*diet therapy
MH  - Humans
MH  - Indomethacin/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Neuralgia/*drug therapy/etiology
MH  - Pain Measurement
MH  - Solvents
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
AID - 00006396-199604000-00010 [pii]
AID - 10.1016/0304-3959(95)00155-7 [doi]
PST - ppublish
SO  - Pain. 1996 Apr;65(1):45-51. doi: 10.1016/0304-3959(95)00155-7.

PMID- 3348240
OWN - NLM
STAT- MEDLINE
DCOM- 19880420
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 84
IP  - 2A
DP  - 1988 Feb 22
TI  - Damage and protection of the human gastric mucosa. A multiparameter assessment.
PG  - 35-40
AB  - Studies in animals and humans have indicated that endogenous prostaglandins as 
      well as synthetic prostaglandin analogues can prevent gastric mucosal damage 
      induced by various agents. Methods were developed to assess induced damage and 
      the effects of potentially protective agents (synthetic prostaglandin analogues 
      and the histamine [H2]-receptor antagonist cimetidine) on the human gastric 
      mucosa by measuring ion fluxes and transmucosal potential difference, as well as 
      by observations with gastrointestinal endoscopy. Commonly ingested agents, such 
      as aspirin, 1,300 mg, and 20 percent ethanol increased hydrogen ion and sodium 
      ion fluxes, decreased potential difference, and caused gross mucosal damage, as 
      observed by endoscopy. Conversely, acetaminophen, 2,600 mg, and 10 percent 
      ethanol did not have any significant effects. Hyperosmolar solutions (1,800 and 
      3,600 mOsm/kg) also produced acute damage. Sodium taurocholate (10 mmol/liter) 
      when instilled into the stomach, either at pH 1.1 or 7.0, produced both 
      functional and structural damage. When given as a single dose, neither 
      15(R)15-methyl PGE2 nor the synthetic PGE1 analogue, misoprostol, prevented 
      mucosal damage induced by aspirin and taurocholate (pH 1.1), respectively. 
      Cimetidine, 400 mg orally, however, did reduce aspirin-induced mucosal damage, 
      and this effect was independent of gastric acid inhibition.
FAU - Hogan, D L
AU  - Hogan DL
AD  - Department of Medicine, University of California, San Diego Medical Center 92103.
LA  - eng
GR  - AM 17328/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 3K9958V90M (Ethanol)
RN  - 5E090O0G3Z (Taurocholic Acid)
RN  - 80061L1WGD (Cimetidine)
RN  - 9NEZ333N27 (Sodium)
RN  - M6B59S6MEF (Arbaprostil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arbaprostil/therapeutic use
MH  - Aspirin/antagonists & inhibitors/*toxicity
MH  - Cimetidine/*therapeutic use
MH  - Ethanol/antagonists & inhibitors/toxicity
MH  - Gastric Mucosa/*drug effects
MH  - Gastroscopy
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Sodium/metabolism
MH  - Taurocholic Acid/antagonists & inhibitors/toxicity
EDAT- 1988/02/22 00:00
MHDA- 1988/02/22 00:01
CRDT- 1988/02/22 00:00
PHST- 1988/02/22 00:00 [pubmed]
PHST- 1988/02/22 00:01 [medline]
PHST- 1988/02/22 00:00 [entrez]
AID - 10.1016/0002-9343(88)90252-5 [doi]
PST - ppublish
SO  - Am J Med. 1988 Feb 22;84(2A):35-40. doi: 10.1016/0002-9343(88)90252-5.

PMID- 19576865
OWN - NLM
STAT- MEDLINE
DCOM- 20091112
LR  - 20171116
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
VI  - 78
IP  - 10
DP  - 2009 Nov 15
TI  - Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 
      expression and Wnt/beta-catenin/TCF-4 signaling.
PG  - 1298-304
LID - 10.1016/j.bcp.2009.06.104 [doi]
AB  - There is current evidence implicating the Wnt/beta-catenin/TCF pathway in breast 
      cancer. We investigated the effect of para- and meta-positional isomers of nitric 
      oxide-releasing aspirin (NO-ASA), and aspirin (ASA) on MCF-7 human breast cancer 
      cell growth and beta-catenin/TCF signaling. The p- and m-NO-ASA isomers strongly 
      inhibited cell growth and beta-catenin/TCF transcriptional activity compared to 
      ASA; the IC50s for growth inhibition were 57+/-4, 193+/-10 and >5000microM, and 
      for transcriptional inhibition they were 12+/-1.8, 75+/-6.5 and >5000microM for 
      p-, m-NO-ASA and ASA, respectively. p-NO-ASA reduced the expression of 
      Wnt/beta-catenin downstream target gene cyclin D1, and total cellular 
      beta-catenin levels. COX-2 expression was induced by p-NO-ASA, protein kinase C 
      inhibitors reversed this induction. p-NO-ASA blocked the cell cycle transition at 
      S to G2/M phase. These studies suggest a targeted 
      chemopreventive/chemotherapeutic potential for NO-ASA against breast cancer.
FAU - Nath, Niharika
AU  - Nath N
AD  - Department of Physiology and Pharmacology, City University of New York Medical 
      School, 138th Street and Convent Avenue, New York, NY 10031, United States. 
      nnath@nyit.edu
FAU - Vassell, Rashida
AU  - Vassell R
FAU - Chattopadhyay, Mitali
AU  - Chattopadhyay M
FAU - Kogan, Marsel
AU  - Kogan M
FAU - Kashfi, Khosrow
AU  - Kashfi K
LA  - eng
GR  - R01 CA34 527/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20090702
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors)
RN  - 0 (CTNNB1 protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (TCF4 protein, human)
RN  - 0 (Transcription Factor 4)
RN  - 0 (Transcription Factors)
RN  - 0 (Wnt Proteins)
RN  - 0 (beta Catenin)
RN  - 136601-57-5 (Cyclin D1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticarcinogenic Agents/chemistry/*pharmacology
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
MH  - Breast Neoplasms/enzymology/metabolism/pathology/*prevention & control
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Cyclin D1/genetics
MH  - Cyclooxygenase 2/*biosynthesis
MH  - DNA-Binding Proteins/*biosynthesis/genetics
MH  - Down-Regulation
MH  - Enzyme Induction
MH  - Female
MH  - Genes, Reporter
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Isomerism
MH  - Signal Transduction/drug effects
MH  - Transcription Factor 4
MH  - Transcription Factors/*biosynthesis/genetics
MH  - Transcription, Genetic/drug effects
MH  - Wnt Proteins/*biosynthesis/genetics
MH  - beta Catenin/*biosynthesis/genetics
EDAT- 2009/07/07 09:00
MHDA- 2009/11/13 06:00
CRDT- 2009/07/07 09:00
PHST- 2009/05/14 00:00 [received]
PHST- 2009/06/24 00:00 [revised]
PHST- 2009/06/25 00:00 [accepted]
PHST- 2009/07/07 09:00 [entrez]
PHST- 2009/07/07 09:00 [pubmed]
PHST- 2009/11/13 06:00 [medline]
AID - S0006-2952(09)00594-2 [pii]
AID - 10.1016/j.bcp.2009.06.104 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2009 Nov 15;78(10):1298-304. doi: 10.1016/j.bcp.2009.06.104. 
      Epub 2009 Jul 2.

PMID- 14601698
OWN - NLM
STAT- MEDLINE
DCOM- 20031126
LR  - 20220317
IS  - 0025-6196 (Print)
IS  - 0025-6196 (Linking)
VI  - 78
IP  - 11
DP  - 2003 Nov
TI  - Continuation of medically necessary aspirin and warfarin during cutaneous 
      surgery.
PG  - 1392-6
AB  - Excisional cutaneous surgery is performed commonly in patients who take medically 
      necessary aspirin or warfarin. Although controversy has existed regarding the 
      appropriate perioperative management of anticoagulant therapy during cutaneous 
      surgery, recent data suggest that the risk of severe hemorrhagic complications is 
      not increased if these medications are continued. Brief perioperative 
      discontinuation does not lower this already minimal hemorrhagic risk. 
      Furthermore, life-threatening thromboembolic complications have been related 
      temporally to perioperative discontinuation of both aspirin and warfarin. In 
      light of the absence of benefit and the presence of risks associated with 
      discontinuation of warfarin and aspirin perioperatively during excisional 
      cutaneous surgery, continuation of these medications is recommended in most 
      situations. In all cases, the individual patient's medical history and risk 
      factors should be taken into account when making this clinical decision, and 
      deviation from the guidelines should be considered if clinical imperatives 
      warrant.
FAU - Otley, Clark C
AU  - Otley CC
AD  - Division of Dermatologic Surgery, Mayo Clinic, Rochester, Minn 55905, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*adverse effects
MH  - Aspirin/*adverse effects
MH  - *Dermatologic Surgical Procedures
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Intraoperative Complications/*chemically induced
MH  - Risk Factors
MH  - Warfarin/*adverse effects
RF  - 42
EDAT- 2003/11/07 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/11/07 05:00
PHST- 2003/11/07 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/11/07 05:00 [entrez]
AID - S0025-6196(11)62718-3 [pii]
AID - 10.4065/78.11.1392 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2003 Nov;78(11):1392-6. doi: 10.4065/78.11.1392.

PMID- 1031338
OWN - NLM
STAT- MEDLINE
DCOM- 19780127
LR  - 20190907
IS  - 0307-7772 (Print)
IS  - 0307-7772 (Linking)
VI  - 1
IP  - 1
DP  - 1976
TI  - Aspirin idiosyncrasy in patients admitted for nasal polypectomy.
PG  - 27-30
AB  - Investigation of 100 consecutive patients admitted for nasal polypectomy revealed 
      only 3 patients with aspirin idiosyncrasy and asthma. It is important that this 
      combination be recognized but fortunately this can be done by the history. 
      Incidental findings were that nasal polypi are much commoner in men and that the 
      incidence of atopy was the same as that in the general population.
FAU - Delaney, J C
AU  - Delaney JC
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Otolaryngol Allied Sci
JT  - Clinical otolaryngology and allied sciences
JID - 7701793
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/chemically induced/diagnosis
MH  - Drug Hypersensitivity/*diagnosis
MH  - Female
MH  - Humans
MH  - Lung Volume Measurements
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/*surgery
MH  - Skin Tests
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1111/j.1365-2273.1976.tb00638.x [doi]
PST - ppublish
SO  - Clin Otolaryngol Allied Sci. 1976;1(1):27-30. doi: 
      10.1111/j.1365-2273.1976.tb00638.x.

PMID- 12024110
OWN - NLM
STAT- MEDLINE
DCOM- 20020620
LR  - 20191106
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 139
IP  - 4
DP  - 2002 Apr
TI  - A new method for measuring inhibition of platelet function by nonsteroidal 
      antiinflammatory drugs.
PG  - 227-33
AB  - Aspirin is widely used to help prevent vascular occlusion caused by 
      atherosclerotic vascular disease. We used a platelet-aggregation assay (PAA) to 
      evaluate the reliability of a proprietary platelet agonist, platelet 
      prostaglandin agonist (PPA), to detect the amount of platelet inhibition induced 
      by four different classes of nonsteroidal antiinflammatory drugs (NSAIDs) with 
      antiplatelet effects. Twenty normal donors were evaluated before and 24 hours 
      after ingestion of 325 mg of aspirin. With 125 micromol/L PPA, the slope of the 
      PPA-PAA curve completely differentiated aspirin-treated from normal platelets. 
      The aspirin platelet slope, 27.9 +/- 2.0 (range 5.5-47), was significantly 
      decreased (P <.001) compared with the findings before administration of aspirin, 
      75 +/- 3.1 (range 50-125). Additionally, the time elapsed before 50% platelet 
      aggregation (T(50)) with aspirin, 10.1 +/- 0.7 minutes (range 4.7-17), was 
      significantly prolonged (P <.05) compared with the mean time before 
      administration of aspirin (4.2 +/- 0.2 minutes, range 1.7-6.4). Aspirin in a 
      daily dosage of 325 mg for 14 days produced significantly greater inhibition of 
      PPA-PAA than that induced by a single 325-mg dose (P <.001). The long-term 
      platelet-inhibitory effects of aspirin in 9 normal volunteers were evaluated with 
      PPA-PAA 2, 8, 24, 48, 72, and 96 hours after a single dose of aspirin, 81 or 325 
      mg. Compared with the preaspirin slope, 79.6 +/- 1.9, the maximal decrease in 
      slope occurred after 2 hours for both 81 mg (61.3 +/- 6.7) and 325 mg (12.1 +/- 
      1.8). The decreased slopes and increased T(50) observed at 2, 8, and 24 hours (P 
      <.001) reflected the greater degree of platelet inhibition with 325 mg than with 
      81 mg aspirin. Inhibition of PPA-PAA was observed with nonaspirin nonsteroidal 
      antiinflammatory drugs (NNSAIDs), but, compared with aspirin, the inhibition was 
      minimal. PPA-PAA may be used to help measure the magnitude of NSAID-induced 
      inhibition of platelets.
FAU - Schwartz, Kenneth A
AU  - Schwartz KA
AD  - Department of Medicine, Michigan State University, B-220 Life Sciences Building, 
      East Lansing, MI 48824-1317, USA.
FAU - Schwartz, Dianne E
AU  - Schwartz DE
FAU - Pittsley, Richard A
AU  - Pittsley RA
FAU - Mantz, Sandra L
AU  - Mantz SL
FAU - Ens, Gordon
AU  - Ens G
FAU - Sami, Amer
AU  - Sami A
FAU - Davis, John M
AU  - Davis JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Prostaglandins/agonists
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
EDAT- 2002/05/25 10:00
MHDA- 2002/06/21 10:01
CRDT- 2002/05/25 10:00
PHST- 2002/05/25 10:00 [pubmed]
PHST- 2002/06/21 10:01 [medline]
PHST- 2002/05/25 10:00 [entrez]
AID - S002221430263745X [pii]
AID - 10.1067/mlc.2002.121855 [doi]
PST - ppublish
SO  - J Lab Clin Med. 2002 Apr;139(4):227-33. doi: 10.1067/mlc.2002.121855.

PMID- 21835676
OWN - NLM
STAT- MEDLINE
DCOM- 20120116
LR  - 20220311
IS  - 1873-2828 (Electronic)
IS  - 1350-4177 (Linking)
VI  - 19
IP  - 2
DP  - 2012 Mar
TI  - Formulation development and optimization of a novel Cremophore EL-based 
      nanoemulsion using ultrasound cavitation.
PG  - 330-45
LID - 10.1016/j.ultsonch.2011.07.001 [doi]
AB  - In the present study, response surface methodology (RSM) based on central 
      composite design (CCD) was employed to investigate the influence of main emulsion 
      composition variables, namely drug loading, oil content, emulsifier content as 
      well as the effect of the ultrasonic operating parameters such as pre-mixing 
      time, ultrasonic amplitude, and irradiation time on the properties of 
      aspirin-loaded nanoemulsions. The two main emulsion properties studied as 
      response variables were: mean droplet size and polydispersity index. The ultimate 
      goal of the present work was to determine the optimum level of the six 
      independent variables in which an optimal aspirin nanoemulsion with desirable 
      properties could be produced. The response surface analysis results clearly 
      showed that the variability of two responses could be depicted as a linear 
      function of the content of main emulsion compositions and ultrasonic processing 
      variables. In the present investigation, it is evidently shown that ultrasound 
      cavitation is a powerful yet promising approach in the controlled production of 
      aspirin nanoemulsions with smaller average droplet size in a range of 200-300 nm 
      and with a polydispersity index (PDI) of about 0.30. This study proved that the 
      use of low frequency ultrasound is of considerable importance in the controlled 
      production of pharmaceutical nanoemulsions in the drug delivery system.
CI  - Copyright © 2011 Elsevier B.V. All rights reserved.
FAU - Tang, Siah Ying
AU  - Tang SY
AD  - Department of Chemical and Environmental Engineering, Faculty of Engineering, The 
      University of Nottingham Malaysia Campus, Jalan Broga, 43500 Semenyih, Malaysia.
FAU - Manickam, Sivakumar
AU  - Manickam S
FAU - Wei, Tan Khang
AU  - Wei TK
FAU - Nashiru, Billa
AU  - Nashiru B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110719
PL  - Netherlands
TA  - Ultrason Sonochem
JT  - Ultrasonics sonochemistry
JID - 9433356
RN  - 0 (Emulsions)
RN  - 0 (Oils)
RN  - 0 (Surface-Active Agents)
RN  - 059QF0KO0R (Water)
RN  - 6D4M1DAL6O (cremophor EL)
RN  - PDC6A3C0OX (Glycerol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Chemistry, Pharmaceutical/*methods
MH  - Drug Stability
MH  - Emulsions
MH  - Glycerol/*analogs & derivatives/chemistry
MH  - Hydrogen-Ion Concentration
MH  - Microscopy, Electron, Scanning
MH  - Models, Theoretical
MH  - Nanostructures/*chemistry
MH  - Oils/chemistry
MH  - Sonication/*methods
MH  - Surface-Active Agents/chemistry
MH  - Water/chemistry
EDAT- 2011/08/13 06:00
MHDA- 2012/01/17 06:00
CRDT- 2011/08/13 06:00
PHST- 2011/05/19 00:00 [received]
PHST- 2011/07/07 00:00 [revised]
PHST- 2011/07/07 00:00 [accepted]
PHST- 2011/08/13 06:00 [entrez]
PHST- 2011/08/13 06:00 [pubmed]
PHST- 2012/01/17 06:00 [medline]
AID - S1350-4177(11)00143-X [pii]
AID - 10.1016/j.ultsonch.2011.07.001 [doi]
PST - ppublish
SO  - Ultrason Sonochem. 2012 Mar;19(2):330-45. doi: 10.1016/j.ultsonch.2011.07.001. 
      Epub 2011 Jul 19.

PMID- 19673361
OWN - NLM
STAT- MEDLINE
DCOM- 20090924
LR  - 20131121
IS  - 1028-768X (Print)
IS  - 1028-768X (Linking)
VI  - 18
IP  - 2
DP  - 2009 Jun
TI  - The prescribing patterns of antithrombotic agents for prevention of recurrent 
      ischemic stroke.
PG  - 98-103
AB  - OBJECTIVES: Antithrombotic agents are effective in the secondary prevention of 
      ischemic strokes. In the present study, we sought to determine the antithrombotic 
      prescribing patterns of neurologists in patients with first-ever ischemic stroke 
      and also to identify the factors influencing the choice of a specific agent and 
      what changes are made when a recurrent stroke occurs in these patients. METHODS: 
      We retrospectively reviewed the medical records of neurology patients who were 
      diagnosed with first-ever ischemic stroke and were antithrombotic naive from 
      January 1, 2000 to December 31, 2000. Patients' antithrombotic agents at 
      discharge and during the follow-up period were reviewed to identify factors 
      affecting the choice of antithrombotic agents. RESULTS: A total of 376 patients 
      experienced non-fatal first-ever ischemic stroke. Of these, 351 were prescribed 
      antithrombotic agents at discharge, while the remaining 25 were not on 
      antithrombotic treatment. Low-dose aspirin was the most commonly prescribed agent 
      (65%). The most important determinant for the choice of other antiplatelet agents 
      was aspirin intolerance. Not surprisingly, only 36% of the patients with atrial 
      fibrillation were treated with oral anticoagulants at the time of hospital 
      discharge. CONCLUSION: Aspirin remains the most commonly used antithrombotic 
      agent for the prevention of recurrent stroke among antithrombotic naive patients 
      with a first-ever ischemic stroke in our institution. Our results demonstrate 
      that current recommendations find their way into clinical practice, but to a 
      limited extent. We aim that all patients discharged from our hospital after 
      strokes must receive appropriate antithrombotic drugs for prevention of recurrent 
      strokes provided if there are no contraindications to therapy.
FAU - Po, Helen L
AU  - Po HL
AD  - Department of Neurology, Mackay Memorial Hospital, Taipei, Taiwan. 
      hlpyjl@ms1.mmh.org.tw
FAU - Lin, Ya-Ju
AU  - Lin YJ
FAU - Hseuh, I-Hung
AU  - Hseuh IH
LA  - eng
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Acta Neurol Taiwan
JT  - Acta neurologica Taiwanica
JID - 9815355
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Brain Ischemia/*prevention & control
MH  - Drug Utilization
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Retrospective Studies
MH  - Stroke/*prevention & control
EDAT- 2009/08/14 09:00
MHDA- 2009/09/25 06:00
CRDT- 2009/08/14 09:00
PHST- 2009/08/14 09:00 [entrez]
PHST- 2009/08/14 09:00 [pubmed]
PHST- 2009/09/25 06:00 [medline]
PST - ppublish
SO  - Acta Neurol Taiwan. 2009 Jun;18(2):98-103.

PMID- 9236331
OWN - NLM
STAT- MEDLINE
DCOM- 19970821
LR  - 20220311
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 64
IP  - 1
DP  - 1997 Jul
TI  - Anticoagulation in children with mechanical valve prostheses.
PG  - 30-4; discussion 35-6
AB  - BACKGROUND: Clotting complications in patients with mechanical valve prostheses 
      can be prevented with either warfarin sodium (Coumadin; DuPont, Wilmington, DE) 
      or antiplatelet agents. In children, it is not known whether one treatment 
      regimen is more effective or safe than the other. METHODS: We prospectively 
      followed up 64 children and young adults (aged 18 years or younger at 
      implantation) with a mechanical valve on the left side of the heart, from October 
      1986 through October 1996. Forty-eight patients were treated with Coumadin and 16 
      with aspirin and dipyridamole. The two groups were similar in age, sex, valve 
      location and size, mean length of follow-up, and operative indication. There has 
      been a total follow-up of 272 patient-years on Coumadin and 116 patient-years on 
      aspirin and dipyridamole. RESULTS: There was no difference between the two groups 
      in survival or freedom from thromboembolism. Bleeding occurred more often in the 
      patients taking Coumadin, but this difference was not statistically significant. 
      Analysis of the literature showed thromboembolism and bleeding rates to be 
      similar in the patients receiving Coumadin and those receiving antiplatelet 
      agents. CONCLUSIONS: Coumadin and the combination of aspirin plus dipyridamole 
      provided similar protection against complications in this group of children and 
      young adults with left-sided St. Jude (St. Paul, MN) mechanical valves. The 
      choice between the two regimens may depend on other factors, such as patient 
      preference and convenience.
FAU - Bradley, S M
AU  - Bradley SM
AD  - Division of Cardio horacic Surgery, Medical University of South Carolina, 
      Charleston 29425-1095, USA.
FAU - Sade, R M
AU  - Sade RM
FAU - Crawford, F A Jr
AU  - Crawford FA Jr
FAU - Stroud, M R
AU  - Stroud MR
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Dipyridamole/*therapeutic use
MH  - Female
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Infant
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Thromboembolism/prevention & control
MH  - Warfarin/*therapeutic use
EDAT- 1997/07/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - S0003497597004530 [pii]
AID - 10.1016/s0003-4975(97)00453-0 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1997 Jul;64(1):30-4; discussion 35-6. doi: 
      10.1016/s0003-4975(97)00453-0.

PMID- 20393256
OWN - NLM
STAT- MEDLINE
DCOM- 20100610
LR  - 20181201
IS  - 0972-2823 (Electronic)
IS  - 0022-3859 (Linking)
VI  - 56
IP  - 1
DP  - 2010 Jan-Mar
TI  - A serious drug interaction leading to spontaneous total hyphema.
PG  - 46-7
LID - 10.4103/0022-3859.62420 [doi]
AB  - A 70 year-old diabetic man receiving anti-coagulant therapy (Warfarin) for 
      pulmonary embolism secondary to factor V Leiden deficiency, presented to the 
      hospital for chest pain. After initial evaluation, he was started on aspirin (300 
      mg) and clopidogrel (300 mg). Three days after he was discharged, he presented 
      with preseptal cellulitis complicating left upper eyelid chalazion. Initially, he 
      was treated with several anti-microbial agents used sequentially. Although, the 
      cellulitis resolved, he developed total hyphema of the left eye. The complication 
      seems to have resulted from a complex interaction amongst anti-microbial agents, 
      Warfarin and anti-platelet agents.
FAU - Trivedi, D
AU  - Trivedi D
AD  - Department of Ophthalmology, Northampton General Hospital, Clifftonville, 
      Northampton, United Kingdom.
FAU - Newton, J D
AU  - Newton JD
FAU - Mitra, A
AU  - Mitra A
FAU - Puri, P
AU  - Puri P
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Postgrad Med
JT  - Journal of postgraduate medicine
JID - 2985196R
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Infective Agents/*adverse effects/pharmacology
MH  - Anticoagulants/administration & dosage
MH  - Aspirin/*adverse effects/pharmacology
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Humans
MH  - Hyphema/*chemically induced
MH  - Male
MH  - Platelet Aggregation Inhibitors/*adverse effects/pharmacology
MH  - Ticlopidine/adverse effects/*analogs & derivatives/pharmacology
MH  - Warfarin/administration & dosage
EDAT- 2010/04/16 06:00
MHDA- 2010/06/11 06:00
CRDT- 2010/04/16 06:00
PHST- 2010/04/16 06:00 [entrez]
PHST- 2010/04/16 06:00 [pubmed]
PHST- 2010/06/11 06:00 [medline]
AID - jpgm_2010_56_1_46_62420 [pii]
AID - 10.4103/0022-3859.62420 [doi]
PST - ppublish
SO  - J Postgrad Med. 2010 Jan-Mar;56(1):46-7. doi: 10.4103/0022-3859.62420.

PMID- 866707
OWN - NLM
STAT- MEDLINE
DCOM- 19770729
LR  - 20190823
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 13
IP  - 5
DP  - 1977 May
TI  - Arachidonate-induced thrombosis in mice: effects of gender or testosterone and 
      estradiol administration.
PG  - 995-1002
AB  - Sodium arachidonate (i.v.) has previously been shown to induce pulmonary emboli 
      formation and a dose dependent cyanosis and respiratory depression in mice. 
      Subsequently, we found that male mice are significantly more sensitive to 
      arachidonate than females. Aspirin given orally 2 hours prior to arachidonate 
      administration inhibits the responses of both males and females. Pretreatment 
      with depo-testosterone markedly increases the effect of arachidonate in both 
      males and females and depo-estradiol pretreatment reduces the responses in all 
      mice. This exacerbation by testosterone of the arachidonate response and the 
      attenuating effects of estradiol is consistent with data reported using other 
      thrombogenic techniques.
FAU - Uzunova, A D
AU  - Uzunova AD
FAU - Ramey, E R
AU  - Ramey ER
FAU - Ramwell, P W
AU  - Ramwell PW
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Arachidonic Acids)
RN  - 0 (Delayed-Action Preparations)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Arachidonic Acids/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Delayed-Action Preparations
MH  - Drug Synergism
MH  - Estradiol/administration & dosage/*pharmacology
MH  - Female
MH  - Injections, Intramuscular
MH  - Injections, Intravenous
MH  - Male
MH  - Mice
MH  - Models, Biological
MH  - Respiration/*drug effects
MH  - Sex Factors
MH  - Testosterone/administration & dosage/*pharmacology
MH  - Thrombosis/*chemically induced
EDAT- 1977/05/01 00:00
MHDA- 1977/05/01 00:01
CRDT- 1977/05/01 00:00
PHST- 1977/05/01 00:00 [pubmed]
PHST- 1977/05/01 00:01 [medline]
PHST- 1977/05/01 00:00 [entrez]
AID - 0090-6980(77)90229-5 [pii]
AID - 10.1016/0090-6980(77)90229-5 [doi]
PST - ppublish
SO  - Prostaglandins. 1977 May;13(5):995-1002. doi: 10.1016/0090-6980(77)90229-5.

PMID- 34866173
OWN - NLM
STAT- MEDLINE
DCOM- 20220310
LR  - 20220311
IS  - 1179-1969 (Electronic)
IS  - 1170-229X (Linking)
VI  - 39
IP  - 1
DP  - 2022 Jan
TI  - The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and 
      Cerebrovascular Events in Chinese Older Adults: A Registration Study.
PG  - 97-106
LID - 10.1007/s40266-021-00906-x [doi]
AB  - BACKGROUND: Low-dose acetylsalicylic acid (aspirin) prevents stroke and 
      myocardial infarction in patients with cardiovascular disease (CVD), but whether 
      it should be used for primary CVD prevention in older Chinese adults remains 
      unclear. METHODS: This prospective study investigated Chinese people aged > 70 
      years participating in the Kadoorie Study of Chronic Disease. The subjects were 
      grouped as aspirin users and nonusers. Propensity score matching (PSM) was used 
      to achieve balanced baseline characteristics. The primary outcome was major 
      adverse cardiac and cerebrovascular events (MACCE). The secondary outcomes were 
      all-cause mortality, cardiovascular and/or cerebrovascular disease (CCVD) 
      mortality, and bleeding events. Survival curves were used to compare the outcomes 
      between groups. Cox regression was used to identify the risk factors for the 
      outcomes. RESULTS: In total, 4791 participants were categorized as aspirin users 
      (n = 257) or nonusers (n = 4534). PSM resulted in 252 and 951 participants in the 
      aspirin user and nonuser groups, respectively. Median follow-up was 8.6 years. 
      Aspirin did not influence MACCE, all-cause mortality, or bleeding events, but it 
      did influence CCVD deaths (p = 0.019). Male sex (hazard ratio [HR] 1.652; 95% 
      confidence interval [CI] 1.217-2.243; p = 0.001), body mass index (BMI) (HR 
      1.053; 95% CI 1.008-1.100; p = 0.021), and systolic blood pressure (HR 1.009; 95% 
      CI 1.003-1.016; p = 0.004) were independent risk factors for MACCE. Survival 
      analysis showed higher rates of CCVD mortality among aspirin users (HR 1.363; 95% 
      CI 1.040-1.786; p = 0.025), but this was not significant in the regression 
      analysis. CONCLUSIONS: There were no significant benefits from using aspirin as 
      primary prevention for MACCE in older Chinese adults.
CI  - © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Sun, Xiaojia
AU  - Sun X
AD  - Department of Neurology, First Affiliated Hospital of Harbin Medical University, 
      No. 23 Youzheng Street, Nangang District, Harbin, 150001, Heilongjiang, China. 
      xiaojiasun@sina.com.
FAU - Sun, Ruihong
AU  - Sun R
AD  - Department of Neurology, First Affiliated Hospital of Harbin Medical University, 
      No. 23 Youzheng Street, Nangang District, Harbin, 150001, Heilongjiang, China.
FAU - Zhang, Liming
AU  - Zhang L
AD  - Department of Neurology, First Affiliated Hospital of Harbin Medical University, 
      No. 23 Youzheng Street, Nangang District, Harbin, 150001, Heilongjiang, China.
LA  - eng
GR  - 202922/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - 088158/Z/09/Z/WT_/Wellcome Trust/United Kingdom
GR  - 104085/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211206
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/drug therapy
MH  - China/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Infarction/drug therapy
MH  - Platelet Aggregation Inhibitors
MH  - Primary Prevention/methods
MH  - Prospective Studies
EDAT- 2021/12/07 06:00
MHDA- 2022/03/11 06:00
CRDT- 2021/12/06 06:03
PHST- 2021/11/11 00:00 [accepted]
PHST- 2021/12/07 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
PHST- 2021/12/06 06:03 [entrez]
AID - 10.1007/s40266-021-00906-x [pii]
AID - 10.1007/s40266-021-00906-x [doi]
PST - ppublish
SO  - Drugs Aging. 2022 Jan;39(1):97-106. doi: 10.1007/s40266-021-00906-x. Epub 2021 
      Dec 6.

PMID- 9219700
OWN - NLM
STAT- MEDLINE
DCOM- 19970717
LR  - 20220317
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 337
IP  - 3
DP  - 1997 Jul 17
TI  - Prednisone and aspirin in women with autoantibodies and unexplained recurrent 
      fetal loss.
PG  - 148-53
AB  - BACKGROUND: Recurrent fetal loss has been well described in women with 
      antiphospholipid antibodies. Such women also often have other autoantibodies 
      commonly found in patients with systemic lupus erythematosus. Treating them with 
      prednisone and aspirin may reduce the risk of fetal loss. METHODS: We screened 
      773 nonpregnant women who had the unexplained loss of at least two fetuses for 
      antinuclear, anti-DNA, antilymphocyte, and anticardiolipin antibodies and for the 
      lupus anticoagulant. Of 385 women with at least one autoantibody, 202 who later 
      became pregnant were randomly assigned in equal numbers to receive either 
      prednisone (0.5 to 0.8 mg per kilogram of body weight per day) and aspirin (100 
      mg per day) or placebo for the duration of the pregnancy. The women were 
      stratified according to age (18 to 34 years or 35 to 39 years) and the week of 
      gestation at which the previous fetal losses had occurred (< or = 12 or > 12 
      weeks). The primary outcome measure was a successful pregnancy. RESULTS: Live 
      infants were born to 66 women in the treatment group (65 percent) and 57 women in 
      the placebo group (56 percent, P=0.19). More infants were born prematurely in the 
      treatment group than in the placebo group (62 percent vs. 12 percent, P<0.001). 
      The major side effects of therapy in the mothers were hypertension (treatment 
      group, 13 percent; placebo group, 5 percent; P=0.05) and diabetes mellitus (15 
      percent and 5 percent, P=0.02). CONCLUSIONS: Treating women who have 
      autoantibodies and recurrent fetal loss with prednisone and aspirin is not 
      effective in promoting live birth, and it increases the risk of prematurity.
FAU - Laskin, C A
AU  - Laskin CA
AD  - Department of Medicine, University of Toronto, ON, Canada.
FAU - Bombardier, C
AU  - Bombardier C
FAU - Hannah, M E
AU  - Hannah ME
FAU - Mandel, F P
AU  - Mandel FP
FAU - Ritchie, J W
AU  - Ritchie JW
FAU - Farewell, V
AU  - Farewell V
FAU - Farine, D
AU  - Farine D
FAU - Spitzer, K
AU  - Spitzer K
FAU - Fielding, L
AU  - Fielding L
FAU - Soloninka, C A
AU  - Soloninka CA
FAU - Yeung, M
AU  - Yeung M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Autoantibodies)
RN  - 0 (Glucocorticoids)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
CIN - N Engl J Med. 1997 Jul 17;337(3):197-8. PMID: 9219709
CIN - N Engl J Med. 1997 Nov 27;337(22):1629-30. PMID: 9411223
MH  - Abortion, Habitual/immunology/*prevention & control
MH  - Adolescent
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Autoantibodies/*blood
MH  - Female
MH  - Fetal Membranes, Premature Rupture/chemically induced
MH  - Glucocorticoids/adverse effects/*therapeutic use
MH  - Humans
MH  - Obstetric Labor, Premature/chemically induced
MH  - Prednisone/adverse effects/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/chemically induced
MH  - Pregnancy Outcome
EDAT- 1997/07/17 00:00
MHDA- 1997/07/17 00:01
CRDT- 1997/07/17 00:00
PHST- 1997/07/17 00:00 [pubmed]
PHST- 1997/07/17 00:01 [medline]
PHST- 1997/07/17 00:00 [entrez]
AID - 10.1056/NEJM199707173370302 [doi]
PST - ppublish
SO  - N Engl J Med. 1997 Jul 17;337(3):148-53. doi: 10.1056/NEJM199707173370302.

PMID- 22185746
OWN - NLM
STAT- MEDLINE
DCOM- 20120509
LR  - 20191210
IS  - 1945-8932 (Electronic)
IS  - 1945-8932 (Linking)
VI  - 25
IP  - 6
DP  - 2011 Nov-Dec
TI  - The prevalence of aspirin hypersensitivity in patients with nasal polyposis and 
      contributing factors.
PG  - 411-5
LID - 10.2500/ajra.2011.25.3660 [doi]
AB  - BACKGROUND: Aspirin (acetylsalicylic acid [ASA]) hypersensitivity is frequent in 
      patients with nasal polyps (NPs) and is called aspirin exacerbated respiratory 
      disease, previously known as Samter's syndrome. However, studies evaluating the 
      prevalence of ASA hypersensitivity in patients with NPs using the oral aspirin 
      provocation test (APT) are quite limited. This study was designed to determine 
      the prevalence of ASA hypersensitivity and factors associated with ASA 
      hypersensitivity in patients with NPs. METHODS: Sixty-eight patients with NPs 
      with or without asthma were recruited. Extension of NPs was evaluated by 
      endoscopic examination/paranasal CT. A 2-day, single-blind placebo-controlled APT 
      was used to detect ASA hypersensitivity. RESULTS: APT was performed in 53 (21 
      women/ 32 men) patients (mean age, 39.34 ± 1.76 years). APT resulted positive in 
      12 patients (22.6%) of whom 3 (25%) had no history of ASA hypersensitivity. Of 
      the positive APTs, three were isolated rhinitis and nine had classic responses. 
      APT was negative in 41 patients (77.4%) although three (7.3%) had a history of 
      ASA hypersensitivity. History of ASA hypersensitivity and prolonged duration of 
      NPs were associated with positive APT (p < 0.05). Advanced NP with multiple 
      operations was also correlated with APT positivity but was not statistically 
      significant. Presence of asthma was associated with age, female gender, NP 
      duration, and ASA hypersensitivity history (p < 0.05), but not with smoking, 
      atopy, NP extension, and positive APT. CONCLUSION: ASA hypersensitivity is quite 
      common in patients with NP. Patients with extensive and long-term NP with 
      multiple polyp operations require evaluation for the presence of ASA 
      hypersensitivity in terms of chronic management and future risks of the disease.
FAU - Bavbek, Sevim
AU  - Bavbek S
AD  - Division of Immunology and Allergy, Department of Pulmonary Disease, Ankara 
      University, School of Medicine, Ankara, Turkey. bavbek@medicine.ankara.edu.tr
FAU - Dursun, Berna
AU  - Dursun B
FAU - Dursun, Engin
AU  - Dursun E
FAU - Korkmaz, Hakan
AU  - Korkmaz H
FAU - Sertkaya Karasoy, Durdu
AU  - Sertkaya Karasoy D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma, Aspirin-Induced/*epidemiology
MH  - Confounding Factors, Epidemiologic
MH  - Disease Progression
MH  - Endoscopy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/*epidemiology/physiopathology/therapy
MH  - Prevalence
MH  - Recurrence
EDAT- 2011/12/22 06:00
MHDA- 2012/05/10 06:00
CRDT- 2011/12/22 06:00
PHST- 2011/12/22 06:00 [entrez]
PHST- 2011/12/22 06:00 [pubmed]
PHST- 2012/05/10 06:00 [medline]
AID - 10.2500/ajra.2011.25.3660 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2011 Nov-Dec;25(6):411-5. doi: 10.2500/ajra.2011.25.3660.

PMID- 6600785
OWN - NLM
STAT- MEDLINE
DCOM- 19830415
LR  - 20180330
IS  - 0022-3166 (Print)
IS  - 0022-3166 (Linking)
VI  - 113
IP  - 3
DP  - 1983 Mar
TI  - Effects of prostaglandin modifiers and zinc deficiency on possibly related 
      functions in rats.
PG  - 494-500
AB  - Experiments were conducted to investigate the role of prostaglandins (PG) in zinc 
      absorption and biological functions (food intake and weight gain, alkaline 
      phosphatase activity, T-cell-mediated immune response). PG levels were modified 
      by administering an inhibitor of their synthesis, aspirin or indomethacin in the 
      diet. Zinc level was modified by controlling the dietary concentration. Weanling 
      rats were fed the assigned diets for 1 month after which they were anesthetized 
      with ether. Samples of blood, gut contents and mucosa, liver, lung and tibia were 
      collected for zinc, PG, lymphocyte stimulation with T-cell mitogen, and alkaline 
      phosphatase assays. There was more than 50% inhibition of PG synthesis by 
      indomethacin and aspirin. This inhibition of PG synthesis, however, did not 
      affect the zinc status of the rats as measured by general appearance, food 
      intake, weight gain, organ weight, zinc concentration in different organs, serum 
      alkaline phosphatase activity, and cell-mediated immune response to T-cell 
      mitogens. It is concluded that under physiological conditions inhibitors of PG 
      synthesis do not alter these zinc metabolic functions.
FAU - Meydani, S N
AU  - Meydani SN
FAU - Meydani, M
AU  - Meydani M
FAU - Dupont, J
AU  - Dupont J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Nutr
JT  - The Journal of nutrition
JID - 0404243
RN  - 0 (Interleukin-2)
RN  - 0 (Prostaglandin Antagonists)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - J41CSQ7QDS (Zinc)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Alkaline Phosphatase/blood
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Body Weight
MH  - Immunity, Cellular/drug effects
MH  - Indomethacin/administration & dosage/*pharmacology
MH  - Interleukin-2/analysis/physiology
MH  - Male
MH  - Organ Size
MH  - Prostaglandin Antagonists/administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Zinc/analysis/*deficiency/metabolism
EDAT- 1983/03/01 00:00
MHDA- 1983/03/01 00:01
CRDT- 1983/03/01 00:00
PHST- 1983/03/01 00:00 [pubmed]
PHST- 1983/03/01 00:01 [medline]
PHST- 1983/03/01 00:00 [entrez]
AID - 10.1093/jn/113.3.494 [doi]
PST - ppublish
SO  - J Nutr. 1983 Mar;113(3):494-500. doi: 10.1093/jn/113.3.494.

PMID- 22876895
OWN - NLM
STAT- MEDLINE
DCOM- 20130321
LR  - 20220310
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 19
IP  - 27
DP  - 2012
TI  - Anticoagulant therapy during pregnancy for maternal and fetal acquired and 
      inherited thrombophilia.
PG  - 4562-71
AB  - Thromboembolism is an infrequent, yet serious cause of both maternal and fetal 
      morbidity and death during pregnancy and the puerperium. Antithrombotic treatment 
      and prophylaxis both before and during pregnancy are based on unfractionated 
      heparin (UH), low-molecularweight heparin (LMWH), Warfarin and Aspirin. The 
      prevalence and severity of thromboembolism during pregnancy and puerperium 
      warrant special consideration of management and therapy. Such therapy includes 
      the treatment of acute thrombotic events and prophylaxis for those at increased 
      risk of thrombotic events. This paper assesses the safety and efficacy of 
      antithrombotic therapy during pregnancy and the peripartum period. Its 
      cardiovascular and obstetric indications, the evidence of association between 
      thrombophilias and adverse pregnancy outcome, regimens and maternal and fetal 
      side-effects are also discussed.
FAU - Giannubilo, S R
AU  - Giannubilo SR
AD  - Department of Clinical Sciences, Polytechnic University of Marche, Salesi 
      Hospital via F. Corridoni 11, 60123 Ancona, Italy. s.giannubilo@univpm.it
FAU - Tranquilli, A L
AU  - Tranquilli AL
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Polysaccharides)
RN  - 24967-94-0 (Dermatan Sulfate)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - 9007-28-7 (Chondroitin Sulfates)
RN  - 9050-30-0 (Heparitin Sulfate)
RN  - BI6GY4U9CW (danaparoid)
RN  - J177FOW5JL (Fondaparinux)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*adverse effects/pharmacology/therapeutic use
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Bone Density/drug effects
MH  - Breast Feeding
MH  - Chondroitin Sulfates/adverse effects/therapeutic use
MH  - Dermatan Sulfate/adverse effects/therapeutic use
MH  - Female
MH  - Fondaparinux
MH  - Heparin/adverse effects/pharmacology/therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/therapeutic use
MH  - Heparitin Sulfate/adverse effects/therapeutic use
MH  - Humans
MH  - Infant, Newborn
MH  - Polysaccharides/adverse effects/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/drug therapy/prevention & control
MH  - Thromboembolism/drug therapy
MH  - Thrombophilia/*etiology
MH  - Warfarin/adverse effects/pharmacology/therapeutic use
EDAT- 2012/08/11 06:00
MHDA- 2013/03/22 06:00
CRDT- 2012/08/11 06:00
PHST- 2012/01/10 00:00 [received]
PHST- 2012/04/07 00:00 [revised]
PHST- 2012/05/23 00:00 [accepted]
PHST- 2012/08/11 06:00 [entrez]
PHST- 2012/08/11 06:00 [pubmed]
PHST- 2013/03/22 06:00 [medline]
AID - CMC-EPUB-20120809-15 [pii]
AID - 10.2174/092986712803306466 [doi]
PST - ppublish
SO  - Curr Med Chem. 2012;19(27):4562-71. doi: 10.2174/092986712803306466.

PMID- 7863968
OWN - NLM
STAT- MEDLINE
DCOM- 19950323
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 75
IP  - 6
DP  - 1995 Feb 23
TI  - Novel antithrombotic approaches to coronary artery disease.
PG  - 27B-33B
AB  - Current prevention or treatment of coronary thrombosis relies on antiplatelet 
      agents (aspirin), antithrombin agents (heparin), and plasminogen activators 
      (t-PA). The purpose of this review is to describe novel antithrombotic agents in 
      each of these classes and to discuss recent and future clinical trials with the 
      new agents. Whereas aspirin is a cyclo-oxygenase inhibitor, the most promising 
      new antiplatelets are directed at an integrin cell surface receptor--glycoprotein 
      (GP) IIb/IIIa--which represents the final common pathway for platelet 
      aggregation. The monoclonal F(ab) antibody c7E3, a chimeric murine-human 
      immunoglobulin G (IgG) fragment, is the most intensively studied to date. c7E3 
      was assessed by the Evaluation of Platelet Monoclonal Antibody to Prevent 
      Ischemic Complications (EPIC) trial in which 2,099 high-risk angioplasty patients 
      were randomized to bolus (placebo) plus infusion (placebo), bolus (c7E3, 0.25 
      mg/kg) plus infusion (placebo), and bolus (c7E3, 0.25 mg/kg) plus infusion (c7E3, 
      10 micrograms/min; 12 hours). The overall event rate at 30 days was significantly 
      decreased from 12.8% (placebo) to 8.3% (c7E3), a 36% relative reduction (p = 
      0.009). Integrelin is a cyclic heptapeptide with marked specificity for GP 
      IIb/IIIa integrin. It was studied during the Integrelin to Manage Platelet 
      Aggregation to Prevent Coronary Thrombosis (IMPACT) trial, which enrolled 150 
      routine coronary intervention patients. At endpoint, overall event rate was 
      reduced from 11.9% (placebo) to 5.6% (integrelin). The much larger (4,010 
      patients) IMPACT-II trial has just completed enrollment to confirm and extend 
      these encouraging results. Hirudin is the prototype of the direct antithrombins; 
      it binds to the active catalytic site and the substrate recognition site 
      (exosite) of thrombin.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Topol, E J
AU  - Topol EJ
AD  - Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Antithrombins)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antithrombins/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Coronary Disease/*drug therapy
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Plasminogen Activators/therapeutic use
MH  - Platelet Aggregation Inhibitors/therapeutic use
RF  - 24
EDAT- 1995/02/23 00:00
MHDA- 1995/02/23 00:01
CRDT- 1995/02/23 00:00
PHST- 1995/02/23 00:00 [pubmed]
PHST- 1995/02/23 00:01 [medline]
PHST- 1995/02/23 00:00 [entrez]
AID - 0002-9149(95)80007-F [pii]
AID - 10.1016/0002-9149(95)80007-f [doi]
PST - ppublish
SO  - Am J Cardiol. 1995 Feb 23;75(6):27B-33B. doi: 10.1016/0002-9149(95)80007-f.

PMID- 2720929
OWN - NLM
STAT- MEDLINE
DCOM- 19890707
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 79
IP  - 6
DP  - 1989 Jun
TI  - Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. 
      Evidence for a possible role of inhibiting platelet activity in thrombolysis.
PG  - 1309-14
AB  - The formation of thrombi in vivo includes the activation of both platelets and 
      the coagulation cascade. Conventional thrombolytic therapy is primarily directed 
      toward the dissolution of fibrin. To evaluate the possibility that platelet 
      activity impairs the lysis of thrombi, we studied the effects of aspirin and 
      platelet-deaggregating prostaglandin E1 on thrombolysis with urokinase. Combined 
      platelet and fibrin thrombi were produced in vitro by adding CaCl2 and collagen 
      (1 microgram/ml) to citrated platelet-rich plasma (250,000 platelets per 
      microliters). Urokinase (500-10,000 units/ml) caused a dose-dependent weight loss 
      of the thrombi that was maximal at 2,000 units/ml. The addition of aspirin 
      (10-200 micrograms/ml) to platelet-rich plasma before thrombus formation markedly 
      enhanced thrombolysis with urokinase. This effect was most pronounced at 20 
      micrograms/ml aspirin. However, when aspirin was added after completion of 
      thrombus formation, no significant effect on thrombolysis was noted. 
      Prostaglandin E1 (1-100 mumol/l) improved the lysis with urokinase of the 
      combined platelet and fibrin thrombi. This effect was maximal at 20 mumol/l 
      prostaglandin E1. When pure fibrin thrombi were produced in platelet-free plasma, 
      prostaglandin E1 was without effect on lysis. Thus, in vitro lysis with urokinase 
      of combined platelet and fibrin thrombi was enhanced by the addition of 
      platelet-deaggregating prostaglandin E1 and by pretreatment with aspirin.
FAU - Terres, W
AU  - Terres W
AD  - Department of Cardiology, Eppendorf University Hospital, Hamburg, FRG.
FAU - Beythien, C
AU  - Beythien C
FAU - Kupper, W
AU  - Kupper W
FAU - Bleifeld, W
AU  - Bleifeld W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - F5TD010360 (Alprostadil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Alprostadil/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Drug Synergism
MH  - Female
MH  - Fibrinolysis/*drug effects
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Thrombosis/drug therapy
MH  - Urokinase-Type Plasminogen Activator/*pharmacology
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
AID - 10.1161/01.cir.79.6.1309 [doi]
PST - ppublish
SO  - Circulation. 1989 Jun;79(6):1309-14. doi: 10.1161/01.cir.79.6.1309.

PMID- 16967147
OWN - NLM
STAT- MEDLINE
DCOM- 20070618
LR  - 20190917
IS  - 0104-4230 (Print)
IS  - 0104-4230 (Linking)
VI  - 52
IP  - 4
DP  - 2006 Jul-Aug
TI  - [Pre-menstrual cyclic mastalgia].
PG  - 265-9
AB  - OBJECTIVES: To compare therapeutic effects of placebo with intake of low doses of 
      acetyl-salysilic acid (aspirin) and a compound of retinol, pyridoxine 
      chlorhydrate and tocopherol acetate. METHODS: The study is a prospective, 
      controlled, triple blinded, randomized trial. From 259 patients, 81 were selected 
      in order to follow rigid criteria of inclusion. They were divided into three 
      groups of 27 patients, taking aspirin, vitamins or placebo respectively. The 
      number of patients in each group was considered satisfactory for statistical 
      analysis. Pain was scored as Grade 1 (without pain), Grade II (moderate pain) and 
      Grade III (severe pain). The Tukey test was applied for comparison of results 
      (statistical significance 5%). RESULTS: Clinical parameters, age, weight, BMI, 
      parity and lactation period were similar for each group. There was a decrease of 
      pain intensity in all groups, that was even more pronounced for the placebo 
      group. DISCUSSION: Emphasis was given to symptomatic treatment of cyclic 
      premenstrual mastalgia with symptoms considered to be the expression of a 
      physiological process that can be treated with simple drugs or placebo. Usual 
      therapeutic approaches with several drugs are criticized, including results and 
      contraindications. CONCLUSION: This study based upon acceptable trial methodology 
      (randomized, triple blinded, placebo controlled, prospective) did not show 
      significant differences in the treatment of cyclic mastalgia.
FAU - De Luca, Laurival A
AU  - De Luca LA
AD  - Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Botucatu, 
      UNESP.
FAU - Gonçalves, Maria de Fátima V S
AU  - Gonçalves Mde F
FAU - de Carvalho, Lídia Raquel
AU  - de Carvalho LR
LA  - por
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Mastalgia cíclica pré-menstrual: placebo versus outras drogas.
PL  - Brazil
TA  - Rev Assoc Med Bras (1992)
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Placebos)
RN  - 0 (Vitamins)
RN  - 11103-57-4 (Vitamin A)
RN  - 1406-18-4 (Vitamin E)
RN  - 8059-24-3 (Vitamin B 6)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Body Mass Index
MH  - Breast Diseases/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Menstrual Cycle/physiology
MH  - Pain Measurement
MH  - Placebos/therapeutic use
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Vitamin A/therapeutic use
MH  - Vitamin B 6/therapeutic use
MH  - Vitamin E/therapeutic use
MH  - Vitamins/*therapeutic use
EDAT- 2006/09/13 09:00
MHDA- 2007/06/19 09:00
CRDT- 2006/09/13 09:00
PHST- 2005/04/08 00:00 [received]
PHST- 2005/02/11 00:00 [accepted]
PHST- 2006/09/13 09:00 [pubmed]
PHST- 2007/06/19 09:00 [medline]
PHST- 2006/09/13 09:00 [entrez]
AID - S0104-42302006000400029 [pii]
AID - 10.1590/s0104-42302006000400029 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras (1992). 2006 Jul-Aug;52(4):265-9. doi: 
      10.1590/s0104-42302006000400029.

PMID- 32191472
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1520-6025 (Electronic)
IS  - 0163-3864 (Linking)
VI  - 83
IP  - 4
DP  - 2020 Apr 24
TI  - Synthesis of Salicaceae Acetyl Salicins Using Selective Deacetylation and Acetyl 
      Group Migration.
PG  - 888-893
LID - 10.1021/acs.jnatprod.9b00570 [doi]
AB  - In the present work, the synthesis of acetylated salicins, which occur naturally 
      in many Salicaceae species, is reported. The preparation of 2-O-acetylsalicin, 
      2-O-acetylchlorosalicin, and 2-O-acetylethylsalicin from peracetylated 
      bromosalicin with selective acid-catalyzed deacetylation and one-pot nucleophilic 
      substitution of bromine as the key steps is described. The base-catalyzed O-2 → 
      O-6 acetyl migration afforded 6-O-acetylsalicin derivatives in good yields. Thus, 
      the first synthesis of 6-O-acetylsalicin (fragilin) using acetyl group migration 
      is reported as well as the synthesis of 6-O-acetylchlorosalicin and 
      6-O-acetylethylsalicin. The NaOMe-catalyzed deacetylation of acetylated 
      glycosides gave salicin, chlorosalicin, and ethylsalicin recently reported from 
      Alangium chinense.
FAU - Romanova, Dariya A
AU  - Romanova DA
AD  - Tomsk Polytechnic University, Lenin Avenue 30, Tomsk 634050, Russian Federation.
FAU - Avetyan, David L
AU  - Avetyan DL
AD  - Tomsk Polytechnic University, Lenin Avenue 30, Tomsk 634050, Russian Federation.
AD  - Siberian State Medical University, Tomsk 634050, Russian Federation.
FAU - Belyanin, Maxim L
AU  - Belyanin ML
AD  - Tomsk Polytechnic University, Lenin Avenue 30, Tomsk 634050, Russian Federation.
FAU - Stepanova, Elena V
AU  - Stepanova EV
AUID- ORCID: 0000-0001-9617-9110
AD  - Tomsk Polytechnic University, Lenin Avenue 30, Tomsk 634050, Russian Federation.
AD  - N. D. Zelinsky Institute of Organic Chemistry of the Russian Academy of Sciences, 
      Leninsky Prospect 47, Moscow 119991, Russian Federation.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200319
PL  - United States
TA  - J Nat Prod
JT  - Journal of natural products
JID - 7906882
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemical synthesis
MH  - Aspirin/*chemical synthesis
MH  - Catalysis
MH  - Molecular Structure
MH  - Salicaceae/chemistry/*metabolism
EDAT- 2020/03/20 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/03/20 06:00
PHST- 2020/03/20 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/03/20 06:00 [entrez]
AID - 10.1021/acs.jnatprod.9b00570 [doi]
PST - ppublish
SO  - J Nat Prod. 2020 Apr 24;83(4):888-893. doi: 10.1021/acs.jnatprod.9b00570. Epub 
      2020 Mar 19.

PMID- 10703966
OWN - NLM
STAT- MEDLINE
DCOM- 20000331
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 21
IP  - 5
DP  - 1999 Dec
TI  - Simultaneous determination of paracetamol, caffeine and acetylsalicylic acid by 
      means of a FI ultraviolet pls multioptosensing device.
PG  - 983-92
AB  - A simple and rapid analytical procedure is proposed for the simultaneous 
      determination of caffeine (CF), acetylsalicylic acid (ASA) and paracetamol (PCT) 
      in pharmaceutical preparations by partial least-squares (PLS) treatment of a 
      flow-through multisensor based on the integration of the retention and UV 
      detection of the analytes on a solid support. Diode-array spectrophotometry has 
      been used to obtain spectra (240-350 nm) of the analytes retained on C18 bonded 
      phase beads packed in a flow cell. By using a 0.5% pH 1 HClO4 solution as the 
      carrier, the multisensor responds linearly in the measuring range without 
      requiring additional reagents or derivatization processes and the active 
      microzone is regenerated by using methanol as eluting agent. Spectra of the 
      corresponding analytes were used to provide multivariate data for the 
      multivariate procedure. The statistical parameters obtained by the application of 
      PLS methods at different reaction times were analysed, from which the optimum 
      reaction time for the simultaneous determination of the analytes was selected. In 
      the analysis of real and synthetic samples, precise and accurate values were 
      obtained.
FAU - Ruiz Medina, A
AU  - Ruiz Medina A
AD  - Department of Physical and Analytical Chemistry, Faculty of Experimental 
      Sciences, University of Jaén, Paraje Las Lagunillas, Spain.
FAU - Fernandez de Córdova, M L
AU  - Fernandez de Córdova ML
FAU - Molina-Diaz, A
AU  - Molina-Diaz A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*analysis
MH  - Aspirin/*analysis
MH  - Caffeine/*analysis
MH  - Electronic Data Processing
MH  - Flow Injection Analysis/instrumentation
MH  - Hydrogen-Ion Concentration
MH  - Least-Squares Analysis
MH  - Pharmaceutical Preparations/analysis/chemistry
MH  - Sensitivity and Specificity
MH  - Spectrophotometry, Ultraviolet
MH  - Tablets/analysis/chemistry
EDAT- 2000/03/07 00:00
MHDA- 2000/03/07 00:01
CRDT- 2000/03/07 00:00
PHST- 2000/03/07 00:00 [pubmed]
PHST- 2000/03/07 00:01 [medline]
PHST- 2000/03/07 00:00 [entrez]
AID - S0731-7085(99)00216-2 [pii]
AID - 10.1016/s0731-7085(99)00216-2 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1999 Dec;21(5):983-92. doi: 10.1016/s0731-7085(99)00216-2.

PMID- 9805822
OWN - NLM
STAT- MEDLINE
DCOM- 19981203
LR  - 20131121
IS  - 0003-4509 (Print)
IS  - 0003-4509 (Linking)
VI  - 56
IP  - 5
DP  - 1998
TI  - [Analgesic and anti-inflammatory activity of saponins of Argania spinoza].
PG  - 220-8
AB  - We studied analgesic and antiinflammatory actions of saponins of Argania spinosa 
      cakes in mice and rats. With oral doses of 50 to 300 mg/kg, we found peripheric 
      analgesic actions equivalent to the acetyl salicylic acid ones. The maximum 
      protection was obtained with 500 mg/kg per os. There is no morphine-like central 
      analgesic effect. Antiinflammatory studies were done in vivo using oedema due to 
      carrageenine or experimental trauma in rats. There was a decrease in the paw 
      swelling at doses of 10 mg/kg per os. At doses of 50 to 100 mg/kg per os, the 
      antiinflammatory effect was similar to the one of indomethacin at doses of 10 to 
      20 mg/kg per os. In vitro, there was an inhibition of beef synovial fluid 
      degradation by OH. radicals. The inhibition action is evaluated with an IC20 > or 
      = 6 microM. Argania spinosa saponins have also an antiradical action against DPPH 
      (IC25 = 85 mM) and against OH. radicals (IC25 = 0.56 M). Since they do not have 
      any inhibition effect on PGE2 synthesis, their antiinflammatory activity can be 
      explained by their action on leucotriens in the metabolic pathway of arachidonic 
      acid.
FAU - Alaoui, K
AU  - Alaoui K
AD  - Laboratoire de Pharmacologie et Toxicologie, Faculté de Médecine et de Pharmacie, 
      Rabat Instituts, Agdal, Maroc.
FAU - Lagorce, J F
AU  - Lagorce JF
FAU - Cherrah, Y
AU  - Cherrah Y
FAU - Hassar, M
AU  - Hassar M
FAU - Amarouch, H
AU  - Amarouch H
FAU - Roquebert, J
AU  - Roquebert J
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Activité analgésique et anti-inflammatoire des saponines d'Argania spinosa.
PL  - France
TA  - Ann Pharm Fr
JT  - Annales pharmaceutiques francaises
JID - 2985176R
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Saponins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/pharmacology
MH  - Edema
MH  - Indomethacin/pharmacology
MH  - Mice
MH  - Pain
MH  - Rats
MH  - Saponins/*pharmacology
MH  - Trees
EDAT- 1998/11/07 00:00
MHDA- 1998/11/07 00:01
CRDT- 1998/11/07 00:00
PHST- 1998/11/07 00:00 [pubmed]
PHST- 1998/11/07 00:01 [medline]
PHST- 1998/11/07 00:00 [entrez]
PST - ppublish
SO  - Ann Pharm Fr. 1998;56(5):220-8.

PMID- 8927738
OWN - NLM
STAT- MEDLINE
DCOM- 19961114
LR  - 20131121
IS  - 0033-2100 (Print)
IS  - 0033-2100 (Linking)
VI  - 50
IP  - 3
DP  - 1996
TI  - [Mucocutaneous lymph node syndrome (Kawasaki disease) in 2 children].
PG  - 273-9
AB  - Two children with Kawasaki disease (KD), a girl 3 yrs. and a boy 2.5 yrs., were 
      described. The children met all criteria for the diagnosis of KD (fever, 
      conjunctivitis, oral changes, extremity changes, rash, lymphadenopathy), and 
      other diseases were excluded. In both children or one of them other clinical and 
      laboratory findings occasionally detected in KD were observed: arthralgia, 
      hepatomegaly and splenomegaly, slight elevation of transaminases and bilirubin 
      level, slight elevation of CSF pleocytosis, sterile pyuria and hematuria. 
      Electrocardiograms revealed sinus tachycardia and transient disturbances of heart 
      repolarization. In both children changes in blood morphology and biochemical 
      disturbances typical for inflammatory processes were noted. Thrombocytosis was 
      seen in the 2nd week of the illness in the child in whom platelet counts were 
      controlled. The child in whom diagnosis of KD was established in the first week 
      of symptoms was treated with acetylsalicylic acid along with an oral penicillin. 
      A child with retrospectively diagnosed KD was treated with antibiotics and 
      corticosteroids. Clinical and laboratory findings of KD resolved in both children 
      within 4-6 weeks without complications from coronary blood vessels.
FAU - Szychowska, Z
AU  - Szychowska Z
AD  - Klinika Chorób Zakaźnych Dzieci AM we Wrocławiu.
FAU - Gruszka, J
AU  - Gruszka J
FAU - Kuchar, E
AU  - Kuchar E
LA  - pol
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Zespół skŕno - śluzówkowo - wezłowy (choroba Kawasaki)u 2 dzieci.
PL  - Poland
TA  - Przegl Epidemiol
JT  - Przeglad epidemiologiczny
JID - 0413725
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Penicillins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Child, Preschool
MH  - Electrocardiography
MH  - Female
MH  - Humans
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/drug therapy
MH  - Penicillins/therapeutic use
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
PST - ppublish
SO  - Przegl Epidemiol. 1996;50(3):273-9.

PMID- 18085095
OWN - NLM
STAT- MEDLINE
DCOM- 20080124
LR  - 20131121
IS  - 0030-1876 (Print)
IS  - 0030-1876 (Linking)
VI  - 100
IP  - 10
DP  - 2007 Oct
TI  - Aspirin use in the prevention of cardiovascular events.
PG  - 383-7
AB  - BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death in the 
      United States and Oklahoma, and Oklahoma ranks 50th in CVD deaths. This paper 
      will describe CVD and coronary heart disease (CHD) mortality in Oklahoma and 
      review current recommendations regarding aspirin use for the prevention of CHD 
      events. METHODS: The CDC Compressed Mortality File for 1999-2004 was accessed. 
      Average annual age-adjusted or age-specific death rates per 100,000 population 
      were calculated. A literature review of data and recommendations regarding 
      aspirin use was conducted. RESULTS: From 1999-2004, there were 50,170 CHD deaths 
      in Oklahoma (age-adjusted rate 232.1 per 100,000). Persons 75 years and older, 
      males, and blacks had the highest death rates; the death rates declined for all 
      persons except those aged 35-54 years. Aspirin use has been shown to be effective 
      in reducing the number of nonfatal myocardial infarction (MI) and fatal CHD, 
      though studies of aspirin effects in women have found a significant reduction in 
      ischemic stroke but no significant effect on fatal or nonfatal MI or CVD death. 
      Aspirin use slightly increases rates of gastrointestinal bleeding and hemorrhagic 
      stroke. CONCLUSION: Continued commitment to counseling patients regarding tobacco 
      cessation, nutrition and exercise, and treatment to reduce blood pressure, 
      cholesterol, tobacco use, and blood sugar are essential. The Oklahoma State 
      Medical Association Physicians Campaign for a Healthy Oklahoma has made it a 
      priority to increase awareness of the risk and benefits of aspirin use among 
      high-risk persons. Oklahoma physicians should assess patients at highest risk, 
      such as healthy men older than 40 years, postmenopausal women (especially >or= 65 
      years), and younger people with risk factors for coronary heart disease (e.g., 
      hypertension, hyperlipidemia, diabetes, or smoking) and discuss the potential 
      benefits and harms of aspirin use.
FAU - Crutcher, James M
AU  - Crutcher JM
AD  - Oklahoma State Department of Health, 1000 NE 10th St., Oklahoma City, Oklahoma 
      73117-1299, USA.
FAU - Mallonee, Sue
AU  - Mallonee S
FAU - Daniels, Carrie
AU  - Daniels C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Okla State Med Assoc
JT  - The Journal of the Oklahoma State Medical Association
JID - 7503043
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/mortality
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*prevention & control
MH  - Oklahoma/epidemiology
MH  - *Risk Reduction Behavior
MH  - Stroke/*prevention & control
MH  - United States/epidemiology
EDAT- 2007/12/19 09:00
MHDA- 2008/01/25 09:00
CRDT- 2007/12/19 09:00
PHST- 2007/12/19 09:00 [pubmed]
PHST- 2008/01/25 09:00 [medline]
PHST- 2007/12/19 09:00 [entrez]
PST - ppublish
SO  - J Okla State Med Assoc. 2007 Oct;100(10):383-7.

PMID- 6362058
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 32
IP  - 3
DP  - 1983 Nov 1
TI  - The effect of aspirin on the size of the hemostatic plug.
PG  - 267-73
AB  - The prolongation of the bleeding time by aspirin is presumably due to interfering 
      with platelet function. Direct quantitative studies evaluating the effects of 
      aspirin on the platelet component of the hemostatic plug have not been described. 
      We measured blood loss from a standard ear injury in rabbits after treatment with 
      either 5 mg or 200 mg/kg of aspirin (ASA) or sodium salicylate (SA), and related 
      this observation to the number of platelets incorporated into the hemostatic 
      plug. The high dose of aspirin was chosen since this dose inhibits PGI2 
      biosynthesis. Both doses of aspirin but not salicylate caused a significant 
      increase on blood loss from the treated ear compared to the control (ASA 5 mg/kg, 
      0.012 +/- 0.009 ml, (m +/- SE), n = 44, p = 0.03; ASA 200 mg/kg, 0.02 +/- 0.007 
      ml, n = 17, p less than 0.05). Both doses of aspirin also caused a significant 
      increase in the number of platelets incorporated into the hemostatic plug when 
      compared to the SA treated animals (ASA 5 mg/kg, 3.52 +/- 0.34 X 10(6) platelets 
      per incision, (m +/- SE), n = 59; SA 5 mg/kg, 1.9 +/- 0.15 X 10(6) platelets per 
      incision, n = 54, p less than 0.001; ASA 200 mg/kg, 3.19 +/- 0.54 X 10(6) 
      platelets per incision, n = 22; SA 200 mg/kg, 1.5 +/- 0.26 X 10(6) platelets per 
      incision, n = 23, p less than 0.001). This study suggests that following aspirin 
      administration hemostasis is achieved by the incorporation of a greater number of 
      platelets into the platelet plug.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Kelton, J G
AU  - Kelton JG
FAU - Carter, C J
AU  - Carter CJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Epoprostenol/biosynthesis/physiology
MH  - Hemorrhage/chemically induced
MH  - Hemostasis/*drug effects
MH  - Rabbits
MH  - Sodium Salicylate/pharmacology
EDAT- 1983/11/01 00:00
MHDA- 1983/11/01 00:01
CRDT- 1983/11/01 00:00
PHST- 1983/11/01 00:00 [pubmed]
PHST- 1983/11/01 00:01 [medline]
PHST- 1983/11/01 00:00 [entrez]
AID - 0049-3848(83)90161-5 [pii]
AID - 10.1016/0049-3848(83)90161-5 [doi]
PST - ppublish
SO  - Thromb Res. 1983 Nov 1;32(3):267-73. doi: 10.1016/0049-3848(83)90161-5.

PMID- 8256126
OWN - NLM
STAT- MEDLINE
DCOM- 19940111
LR  - 20140519
VI  - 46
IP  - 10
DP  - 1993 Oct
TI  - Gastrocolic fistula-secondary to aspirin abuse.
PG  - 358-60
AB  - Gastrocolic fistula is a rare complication of benign gastric ulcer disease. It 
      has been associated more commonly, in the past, with marginal ulceration 
      following gastrojejunostomy for peptic ulcer disease. We will describe a classic 
      case of gastrocolic fistula as a complication of acetylsalicylic acid abuse in a 
      middle aged female with a remote history of aspirin induced ulcer. Her 
      presentation was classic and required a surgical approach with excellent 
      recovery. We will describe the clinical, radiographic, endoscopic and surgical 
      aspects of this interesting and unusual disorder.
FAU - Gutnik, S H
AU  - Gutnik SH
AD  - Central Plains Clinic, Sioux Falls, SD.
FAU - Willmott, D
AU  - Willmott D
FAU - Ziebarth, J
AU  - Ziebarth J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - S D J Med
JT  - South Dakota journal of medicine
JID - 0040162
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Colonic Diseases/*chemically induced
MH  - Female
MH  - Gastric Fistula/*chemically induced
MH  - Humans
MH  - Intestinal Fistula/*chemically induced
MH  - Middle Aged
MH  - Stomach Ulcer/chemically induced
MH  - *Substance-Related Disorders
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
PST - ppublish
SO  - S D J Med. 1993 Oct;46(10):358-60.

PMID- 22090661
OWN - NLM
STAT- MEDLINE
DCOM- 20120131
LR  - 20211021
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 32
IP  - 23
DP  - 2011 Dec
TI  - Aspirin for primary prevention of vascular events in women: individualized 
      prediction of treatment effects.
PG  - 2962-9
LID - 10.1093/eurheartj/ehr423 [doi]
AB  - AIMS To identify women who benefit from aspirin 100 mg on alternate days for 
      primary prevention of vascular events by using treatment effect prediction based 
      on individual patient characteristics. METHODS AND RESULTS Randomized controlled 
      trial data from the Women's Health Study were used to predict treatment effects 
      for individual women in terms of absolute risk reduction for major cardiovascular 
      events (i.e. myocardial infarction, stroke, or cardiovascular death). Predictions 
      were based on existing risk scores, i.e. Framingham (FRS), and Reynolds (RRS), 
      and on a newly developed prediction model. The net benefit of different aspirin 
      treatment-strategies was compared: (i) treat no one, (ii) treat everyone, (iii) 
      treatment according to the current guidelines (i.e. selective treatment of women 
      >65 years of age or having >10% FRS), and (iv) prediction-based treatment (i.e. 
      selective treatment of patients whose predicted treatment effect exceeds a given 
      decision threshold). The predicted reduction in 10-year absolute risk for major 
      cardiovascular events was <1% in 97.8% of 27 939 study subjects when based on the 
      refitted FRS, in 97.0% when based on the refitted RRS, and in 90.0% when based on 
      the newly developed model. Of the treatment strategies considered, only 
      prediction-based treatment using the newly developed model and selective 
      treatment of women >65 years of age yielded more net benefit than treating no 
      one, provided that the 10-year number-willing-to-treat (NWT) to prevent one 
      cardiovascular event was above 50. CONCLUSION Aspirin was ineffective or even 
      harmful in the majority of patients. Age was positively related to treatment 
      effect, whereas current smoking and baseline risk for cardiovascular events were 
      not. When the NWT is 50 or lower, the aspirin treatment strategy that is 
      associated with optimal net benefit in primary prevention of vascular events in 
      women is to treat none.
FAU - Dorresteijn, Johannes A N
AU  - Dorresteijn JA
AD  - Department of Vascular Medicine, University Medical Center Utrecht, The 
      Netherlands.
FAU - Visseren, Frank L J
AU  - Visseren FL
FAU - Ridker, Paul M
AU  - Ridker PM
FAU - Paynter, Nina P
AU  - Paynter NP
FAU - Wassink, Annemarie M J
AU  - Wassink AM
FAU - Buring, Julie E
AU  - Buring JE
FAU - van der Graaf, Yolanda
AU  - van der Graaf Y
FAU - Cook, Nancy R
AU  - Cook NR
LA  - eng
GR  - CA-47988/CA/NCI NIH HHS/United States
GR  - HL-43851/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20111116
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Drug Administration Schedule
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Infarction/mortality/prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Primary Prevention
MH  - Risk Factors
MH  - Stroke/mortality/prevention & control
MH  - Treatment Outcome
PMC - PMC3227855
EDAT- 2011/11/18 06:00
MHDA- 2012/02/01 06:00
CRDT- 2011/11/18 06:00
PHST- 2011/11/18 06:00 [entrez]
PHST- 2011/11/18 06:00 [pubmed]
PHST- 2012/02/01 06:00 [medline]
AID - ehr423 [pii]
AID - 10.1093/eurheartj/ehr423 [doi]
PST - ppublish
SO  - Eur Heart J. 2011 Dec;32(23):2962-9. doi: 10.1093/eurheartj/ehr423. Epub 2011 Nov 
      16.

PMID- 37016833
OWN - NLM
STAT- MEDLINE
DCOM- 20230414
LR  - 20230414
IS  - 1463-9084 (Electronic)
IS  - 1463-9076 (Linking)
VI  - 25
IP  - 15
DP  - 2023 Apr 12
TI  - A photoelectron spectroscopic investigation of aspirin, paracetamol and ibuprofen 
      in the gas phase.
PG  - 10946-10955
LID - 10.1039/d2cp05810c [doi]
AB  - We have investigated the electronic structure of isolated molecules of 
      paracetamol, aspirin and ibuprofen using computational methods and benchmarked 
      the results against valence and core photoelectron spectra. Paracetamol, aspirin 
      and ibuprofen exist as multiple conformers, and we have calculated the free 
      energies and populations of the lowest energy conformers. We find generally good 
      agreement with previous experimental and theoretical structural results. The 
      valence band spectrum of gas phase aspirin has not been reported previously, and 
      we report it and assign the features based on calculations. The effect of 
      acetylation on the frontier orbitals of the parent molecule, salicylic acid, is 
      to increase the ionization potential of the highest occupied molecular orbital 
      (HOMO), and to exchange the energetic ordering of the following two orbitals. The 
      acetyl π bond contributes to the next orbital, which is hybridised with ring π 
      orbitals. The core level spectra of all three molecules are reported and compared 
      with calculations and with the spectra of parent molecules (salicylic acid for 
      aspirin, 4-aminophenol for paracetamol). Observed core ionization energies are in 
      agreement with theory. Although all compounds share a benzene ring, and they also 
      have a number of other chromophores in common, the spectroscopic data indicate 
      chemical diversity, suggesting that their modes of bonding under physiological 
      conditions are likely to be diverse.
FAU - Sa'adeh, Hanan
AU  - Sa'adeh H
AUID- ORCID: 0000-0002-2568-5507
AD  - Department of Physics, The University of Jordan, Amman, 11942, Jordan. 
      hanan.saadeh@ju.edu.jo.
AD  - Elettra Sincrotrone Trieste, in Area Science Park, 34149 Basovizza, Trieste, 
      Italy.
FAU - Prince, Kevin C
AU  - Prince KC
AUID- ORCID: 0000-0002-5416-7354
AD  - Elettra Sincrotrone Trieste, in Area Science Park, 34149 Basovizza, Trieste, 
      Italy.
AD  - Department of Chemistry and Biotechnology, School of Science, Computing and 
      Engineering Technologies, Swinburne University of Technology, Melbourne, Victoria 
      3122, Australia. fwang@swin.edu.au.
FAU - Richter, Robert
AU  - Richter R
AUID- ORCID: 0000-0001-8585-626X
AD  - Elettra Sincrotrone Trieste, in Area Science Park, 34149 Basovizza, Trieste, 
      Italy.
FAU - Vasilyev, Vladislav
AU  - Vasilyev V
AD  - National Computational Infrastructure, Australian National University, Canberra, 
      ACT 0200, Australia.
FAU - Chong, Delano P
AU  - Chong DP
AD  - Department of Chemistry, University of British Columbia, Canada.
FAU - Wang, Feng
AU  - Wang F
AUID- ORCID: 0000-0002-6584-0516
AD  - Department of Chemistry and Biotechnology, School of Science, Computing and 
      Engineering Technologies, Swinburne University of Technology, Melbourne, Victoria 
      3122, Australia. fwang@swin.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20230412
PL  - England
TA  - Phys Chem Chem Phys
JT  - Physical chemistry chemical physics : PCCP
JID - 100888160
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - 0 (Gases)
SB  - IM
MH  - *Acetaminophen
MH  - Aspirin
MH  - *Ibuprofen
MH  - Photoelectron Spectroscopy
MH  - Salicylic Acid
MH  - Gases
EDAT- 2023/04/06 06:00
MHDA- 2023/04/13 06:43
CRDT- 2023/04/05 03:22
PHST- 2023/04/13 06:43 [medline]
PHST- 2023/04/06 06:00 [pubmed]
PHST- 2023/04/05 03:22 [entrez]
AID - 10.1039/d2cp05810c [doi]
PST - epublish
SO  - Phys Chem Chem Phys. 2023 Apr 12;25(15):10946-10955. doi: 10.1039/d2cp05810c.

PMID- 27913581
OWN - NLM
STAT- MEDLINE
DCOM- 20170620
LR  - 20220129
IS  - 1535-9484 (Electronic)
IS  - 1535-9476 (Print)
IS  - 1535-9476 (Linking)
VI  - 16
IP  - 2
DP  - 2017 Feb
TI  - A Proteomic Approach to Analyze the Aspirin-mediated Lysine Acetylome.
PG  - 310-326
LID - 10.1074/mcp.O116.065219 [doi]
AB  - Aspirin, or acetylsalicylic acid is widely used to control pain, inflammation and 
      fever. Important to this function is its ability to irreversibly acetylate 
      cyclooxygenases at active site serines. Aspirin has the potential to acetylate 
      other amino acid side-chains, leading to the possibility that aspirin-mediated 
      lysine acetylation could explain some of its as-yet unexplained drug actions or 
      side-effects. Using isotopically labeled aspirin-d(3), in combination with 
      acetylated lysine purification and LC-MS/MS, we identified over 12000 sites of 
      lysine acetylation from cultured human cells. Although aspirin amplifies 
      endogenous acetylation signals at the majority of detectable endogenous sites, 
      cells tolerate aspirin mediated acetylation very well unless cellular 
      deacetylases are inhibited. Although most endogenous acetylations are amplified 
      by orders of magnitude, lysine acetylation site occupancies remain very low even 
      after high doses of aspirin. This work shows that while aspirin has enormous 
      potential to alter protein function, in the majority of cases aspirin-mediated 
      acetylations do not accumulate to levels likely to elicit biological effects. 
      These findings are consistent with an emerging model for cellular acetylation 
      whereby stoichiometry correlates with biological relevance, and deacetylases act 
      to minimize the biological consequences of nonspecific chemical acetylations.
CI  - © 2017 by The American Society for Biochemistry and Molecular Biology, Inc.
FAU - Tatham, Michael H
AU  - Tatham MH
AD  - From the ‡Centre for Gene Regulation and Expression, Sir James Black Centre, 
      School of Life Sciences, University of Dundee, Dow Street, Dundee, DD1 5EH. UK.
FAU - Cole, Christian
AU  - Cole C
AD  - §Computational Biology, School of Life Sciences, University of Dundee, Dow 
      Street, Dundee, DD1 5EH. UK.
FAU - Scullion, Paul
AU  - Scullion P
AD  - ¶Biological Chemistry and Drug Discovery, School of Life Sciences, University of 
      Dundee, Dow Street, Dundee, DD1 5EH. UK.
FAU - Wilkie, Ross
AU  - Wilkie R
AD  - ‖School of Chemistry and Biomedical Sciences Research Complex, University of St 
      Andrews and EaStCHEM, North Haugh, St Andrews, Fife. KY16 9ST. UK.
FAU - Westwood, Nicholas J
AU  - Westwood NJ
AD  - ‖School of Chemistry and Biomedical Sciences Research Complex, University of St 
      Andrews and EaStCHEM, North Haugh, St Andrews, Fife. KY16 9ST. UK.
FAU - Stark, Lesley A
AU  - Stark LA
AD  - **Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, 
      University of Edinburgh, EH4 2XU UK.
FAU - Hay, Ronald T
AU  - Hay RT
AD  - From the ‡Centre for Gene Regulation and Expression, Sir James Black Centre, 
      School of Life Sciences, University of Dundee, Dow Street, Dundee, DD1 5EH. UK; 
      R.T.Hay@dundee.ac.uk.
LA  - eng
SI  - PDB/1KX5
GR  - C434/A13067/CRUK_/Cancer Research UK/United Kingdom
GR  - ETM/154/CSO_/Chief Scientist Office/United Kingdom
GR  - MR/J001481/1/MRC_/Medical Research Council/United Kingdom
GR  - 10-0158/AICR_/Worldwide Cancer Research/United Kingdom
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 098391/Z/12/7/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161202
PL  - United States
TA  - Mol Cell Proteomics
JT  - Molecular & cellular proteomics : MCP
JID - 101125647
RN  - 0 (Proteome)
RN  - EC 3.5.1.98 (Histone Deacetylases)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/*pharmacology
MH  - Binding Sites
MH  - Chromatography, Liquid
MH  - HeLa Cells
MH  - Histone Deacetylases/metabolism
MH  - Humans
MH  - Isotope Labeling
MH  - Lysine/*analysis/chemistry/drug effects
MH  - Proteome/*chemistry
MH  - Proteomics/*methods
MH  - Tandem Mass Spectrometry
PMC - PMC5294217
EDAT- 2016/12/04 06:00
MHDA- 2017/06/21 06:00
CRDT- 2016/12/04 06:00
PHST- 2016/11/03 00:00 [received]
PHST- 2016/11/23 00:00 [revised]
PHST- 2016/12/04 06:00 [pubmed]
PHST- 2017/06/21 06:00 [medline]
PHST- 2016/12/04 06:00 [entrez]
AID - S1535-9476(20)32445-2 [pii]
AID - O116.065219 [pii]
AID - 10.1074/mcp.O116.065219 [doi]
PST - ppublish
SO  - Mol Cell Proteomics. 2017 Feb;16(2):310-326. doi: 10.1074/mcp.O116.065219. Epub 
      2016 Dec 2.

PMID- 9387206
OWN - NLM
STAT- MEDLINE
DCOM- 19980120
LR  - 20131121
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 23
IP  - 5
DP  - 1997
TI  - European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a 
      randomized trial.
PG  - 473-8
AB  - Thrombotic complications characterize the clinical course of polycythemia vera 
      (PV) and represent the main cause of morbidity and mortality. However, 
      uncertainty still exists as to the benefit/risk ratio of aspirin prophylaxis in 
      this setting. In vivo platelet biosynthesis of thromboxane A2 is enhanced and can 
      be suppressed by low-dose aspirin in PV, thus providing a rationale for assessing 
      the efficacy and safety of a low-dose aspirin regimen in these patients. The 
      Gruppo Italiano Studio Policitemia Vera has recently performed a pilot study on 
      112 patients randomized to receive aspirin, 40 mg daily, or placebo and followed 
      for 16 +/- 6 months (mean +/- SD). This study showed that low-dose aspirin is 
      well tolerated in PV patients, and that a large-scale efficacy trial is feasible 
      in this setting. In this article we report the protocol of the European 
      Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) study, which is a 
      randomized trial designed to assess the risk/benefit ratio of low-dose aspirin in 
      PV. To estimate the size and the follow-up duration required for the ECLAP trial, 
      a retrospective analysis of the clinical epidemiology of a large PV population 
      has recently been completed by the Gruppo Italiano Studio Policitemia Vera. On 
      this basis, approximately 3500 patients will be enrolled in the ECLAP study with 
      a follow-up of 3 to 4 years. The uncertainty principle will be used as the main 
      eligibility criterion: Polycythemic patients of any age, having no clear 
      indication for or contraindication to aspirin treatment, will be randomized in a 
      double-blind fashion to receive oral aspirin (100 mg daily) or placebo. According 
      to current therapeutic recommendations, the basic treatment of randomized 
      patients should be aimed at maintaining the hematocrit value < or = 45% in 
      subjects aged < or = 50, and hematocrit < 45% as well as platelet count < 400 x 
      10(9)/L in patients aged > 50. Randomization will be stratified by participating 
      center. The study is funded by the European Union BIOMED 2 program.
FAU - Landolfi, R
AU  - Landolfi R
AD  - Istituto di Semeiotica Medica Università Cattolica del Sacro Cuore, Roma, Italy.
FAU - Marchioli, R
AU  - Marchioli R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Europe
MH  - Feasibility Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Polycythemia Vera/*complications
MH  - Thrombosis/*prevention & control
MH  - Treatment Outcome
EDAT- 1997/01/01 00:00
MHDA- 1997/12/05 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/12/05 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1055/s-2007-996124 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 1997;23(5):473-8. doi: 10.1055/s-2007-996124.

PMID- 27914653
OWN - NLM
STAT- MEDLINE
DCOM- 20170419
LR  - 20170817
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 150
DP  - 2017 Feb
TI  - Antithrombotic therapy after bioprosthetic aortic valve implantation: Warfarin 
      versus aspirin, a randomized controlled trial.
PG  - 104-110
LID - S0049-3848(16)30641-7 [pii]
LID - 10.1016/j.thromres.2016.11.021 [doi]
AB  - BACKGROUND: The optimal medical strategy for prevention of thromboembolic events 
      after surgical bioprosthetic aortic valve replacement (BAVR) is still debated. 
      The objective of this study was to compare warfarin therapy (target INR of 2.0 to 
      3.0) with aspirin 150mg daily as antithrombotic therapy for the first three 
      months after BAVR with or without concomitant coronary artery bypass grafting 
      (CABG). The aim was to evaluate thromboembolic complications, major bleeding 
      complications and death. MATERIALS AND METHODS: Prospective, single-centre, 
      open-label, randomized controlled trial. 370 patients were enrolled, 328 were 
      available for data analysis. RESULTS: At baseline the warfarin and aspirin groups 
      were comparable. Thromboembolic events were comparable between groups 11 (6.6%) 
      vs. 12 (7.5%), p=0.83. Major bleeding events occurred numerically more often in 
      warfarin patients 9 (5.4%) vs. 3 (1.9%), p=0.14. Warfarin was in multivariate 
      analysis significantly associated with major bleeding OR 5.18 (CI 1.06-25.43), 
      p=0.043. 90-day mortality was comparable between groups 8 (4.7%) vs. 6 (3.7%), 
      p=0.79. CONCLUSIONS: Our results suggest that aspirin might be equally effective 
      as warfarin in preventing thromboembolic events after BAVR, but with less major 
      bleedings. Although this is numerically the largest trial testing this hypothesis 
      in a prospective randomized trial, further adequately powered studies are 
      warranted.
CI  - Copyright © 2016 Elsevier Ltd. All rights reserved.
FAU - Rafiq, Sulman
AU  - Rafiq S
AD  - Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, 
      Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen O, Denmark. 
      Electronic address: sulman_raf@hotmail.com.
FAU - Steinbrüchel, Daniel Andreas
AU  - Steinbrüchel DA
AD  - Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, 
      Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen O, Denmark. 
      Electronic address: dastpr@gmail.com.
FAU - Lilleør, Nikolaj Bang
AU  - Lilleør NB
AD  - Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, 
      Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen O, Denmark. 
      Electronic address: thomas.nikolaj.lilleoer@regionh.dk.
FAU - Møller, Christian Holdflod
AU  - Møller CH
AD  - Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, 
      Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen O, Denmark. 
      Electronic address: christian.moeller.02@regionh.dk.
FAU - Lund, Jens Teglgaard
AU  - Lund JT
AD  - Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, 
      Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen O, Denmark. 
      Electronic address: jlund@dadlnet.dk.
FAU - Thiis, Jens Juel
AU  - Thiis JJ
AD  - Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, 
      Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen O, Denmark. 
      Electronic address: jens.juel.thiis@regionh.dk.
FAU - Køber, Lars
AU  - Køber L
AD  - Department of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen University 
      Hospital, Blegdamsvej 9, 2100 Copenhagen O, Denmark. Electronic address: 
      lars.koeber.01@regionh.dk.
FAU - Olsen, Peter Skov
AU  - Olsen PS
AD  - Department of Cardiothoracic Surgery, The Heart Centre, Rigshospitalet, 
      Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen O, Denmark. 
      Electronic address: peter.skov.olsen@regionh.dk.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20161125
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aortic Valve/surgery
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Bioprosthesis/adverse effects
MH  - Heart Valve Prosthesis/adverse effects
MH  - Heart Valve Prosthesis Implantation/*adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Postoperative Complications/etiology/prevention & control
MH  - Prospective Studies
MH  - Thromboembolism/etiology/*prevention & control
MH  - Thrombosis/etiology/*prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - Anticoagulation
OT  - Aspirin
OT  - Bioprosthetic valve
OT  - Heart valve prosthesis
OT  - Thrombosis
EDAT- 2016/12/05 06:00
MHDA- 2017/04/20 06:00
CRDT- 2016/12/05 06:00
PHST- 2016/08/07 00:00 [received]
PHST- 2016/11/14 00:00 [revised]
PHST- 2016/11/24 00:00 [accepted]
PHST- 2016/12/05 06:00 [pubmed]
PHST- 2017/04/20 06:00 [medline]
PHST- 2016/12/05 06:00 [entrez]
AID - S0049-3848(16)30641-7 [pii]
AID - 10.1016/j.thromres.2016.11.021 [doi]
PST - ppublish
SO  - Thromb Res. 2017 Feb;150:104-110. doi: 10.1016/j.thromres.2016.11.021. Epub 2016 
      Nov 25.

PMID- 26149590
OWN - NLM
STAT- MEDLINE
DCOM- 20151015
LR  - 20190318
IS  - 1534-6315 (Electronic)
IS  - 1529-7322 (Print)
IS  - 1529-7322 (Linking)
VI  - 15
IP  - 8
DP  - 2015 Aug
TI  - Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients 
      with Chronic Rhinosinusitis.
PG  - 47
LID - 10.1007/s11882-015-0552-y [doi]
LID - 47
AB  - Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) associated with 
      chronic rhinosinusitis (CRS) and/or asthma comprises a distinct clinical syndrome 
      referred to as NSAIDs exacerbated respiratory disease (NERD). Patients with NERD 
      tend to have more severe course of both upper (CRS and nasal polyps) and lower 
      airway (asthma) diseases and are usually recalcitrant to conventional treatment 
      modalities. Diagnosing and phenotyping of patients with NERD are critical for 
      prevention of drug-induced adverse reactions and open novel options for 
      management of underlying chronic airway inflammatory diseases. Diagnosis of NERD 
      is based on detailed clinical history confirmed by challenge with aspirin, but 
      new diagnostic approaches are currently being developed. This review article 
      focuses on the diagnostic approach to a patient with CRS and hypersensitivity to 
      NSAIDs, emphasizing the importance of diagnosis for proper patient's management.
FAU - Makowska, Joanna
AU  - Makowska J
AD  - Department of Immunology, Rheumatology and Allergy, Healthy Ageing Research 
      Center, Medical University of Łódź, 251 Pomorska Str., 92-213, Łódź, Poland.
FAU - Lewandowska-Polak, Anna
AU  - Lewandowska-Polak A
FAU - Kowalski, Marek L
AU  - Kowalski ML
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Allergy Asthma Rep
JT  - Current allergy and asthma reports
JID - 101096440
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*adverse effects
MH  - Chronic Disease
MH  - *Drug Hypersensitivity/diagnosis
MH  - Humans
MH  - Rhinitis/*diagnosis
MH  - Sinusitis/*diagnosis
PMC - PMC4493793
EDAT- 2015/07/08 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/07/08 06:00
PHST- 2015/07/08 06:00 [entrez]
PHST- 2015/07/08 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - 552 [pii]
AID - 10.1007/s11882-015-0552-y [doi]
PST - ppublish
SO  - Curr Allergy Asthma Rep. 2015 Aug;15(8):47. doi: 10.1007/s11882-015-0552-y.

PMID- 20628791
OWN - NLM
STAT- MEDLINE
DCOM- 20110217
LR  - 20211020
IS  - 1573-904X (Electronic)
IS  - 0724-8741 (Linking)
VI  - 27
IP  - 11
DP  - 2010 Nov
TI  - Old and new molecular mechanisms associated with platelet resistance to 
      antithrombotics.
PG  - 2365-73
LID - 10.1007/s11095-010-0209-4 [doi]
AB  - Current available data show that about 5 to 40% of coronary patients treated with 
      conventional doses of antithrombotic drugs do not display adequate antiplatelet 
      response. Nowadays, aspirin remains the main antiplatelet therapy. However, a 
      significant number of patients show platelet resistance to aspirin therapy, and 
      recurrent thrombotic events occur. Combined antithrombotic therapies with 
      thienopyridines, such as clopidogrel have been used to resolve this problem. 
      However, clopidogrel treatment has been also associated with wide response 
      variability, and non-responsiveness to clopidogrel also occurs in some patients. 
      Therefore, the main question arising about the antithrombotic therapy is why 
      particular patients do not benefit from the therapy and how they might be 
      identified to improve their treatment. Different hypotheses have been suggested, 
      including genetic factors, platelet heterogeneity, non-compliance and others. 
      However, it is probably that many molecular mechanisms involved in platelet 
      resistance to antithrombotic therapies still remains unknown. New technologies, 
      such as proteomics and genetic, are beginning to show new unknown biological 
      biomarkers and molecular mechanisms which may be associated with platelet 
      antithrombotic drug resistance.
FAU - Farré, Antonio J López
AU  - Farré AJ
AD  - Cardiovascular Research Unit, Cardiology Department, Hospital Clínico San Carlos, 
      C/ Profesor Martín Lagos s/n, Madrid, 28040, Spain. lcarinv.hcsc@salud.madrid.org
FAU - Tamargo, Juan
AU  - Tamargo J
FAU - Mateos-Cáceres, Petra J
AU  - Mateos-Cáceres PJ
FAU - Azcona, Luís
AU  - Azcona L
FAU - Macaya, Carlos
AU  - Macaya C
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100714
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Antithrombins)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antithrombins/*pharmacology
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*drug effects
MH  - Clopidogrel
MH  - Humans
MH  - Patient Compliance
MH  - Ticlopidine/analogs & derivatives/pharmacology
EDAT- 2010/07/16 06:00
MHDA- 2011/02/18 06:00
CRDT- 2010/07/15 06:00
PHST- 2010/02/01 00:00 [received]
PHST- 2010/06/28 00:00 [accepted]
PHST- 2010/07/15 06:00 [entrez]
PHST- 2010/07/16 06:00 [pubmed]
PHST- 2011/02/18 06:00 [medline]
AID - 10.1007/s11095-010-0209-4 [doi]
PST - ppublish
SO  - Pharm Res. 2010 Nov;27(11):2365-73. doi: 10.1007/s11095-010-0209-4. Epub 2010 Jul 
      14.

PMID- 9480585
OWN - NLM
STAT- MEDLINE
DCOM- 19980224
LR  - 20191024
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 86
IP  - 11
DP  - 1997 Nov
TI  - [Current aspects of thrombolytic therapy in unstable angina pectoris].
PG  - 911-9
AB  - In the last years, several studies addressed the role of the different 
      antithrombotic therapeutics in unstable angina pectoris. Acetylsalicylic acid 
      still is the standard treatment reducing the rate of death and myocardial 
      infarction by 50% in the first six months. Ticlopidin has no clinical effect in 
      the first six days and therefore is not suited for treatment in the acute phase. 
      Unfractionated heparin has an additional favourable effect when added to aspirin. 
      Low molecular weight-heparin is at least as effective as UF-heparin. Direct 
      thrombin-inhibitors (hirudin, hirudin-analoga) seem to be comparable to 
      UF-heparin. Plasminogen-activators should not be given in unstable angina, as 
      they show a tendency to worsen the clinical outcome. GP IIb/IIIa-antagonists 
      (antibodies, synthetic antagonists) significantly improve the clinical effects of 
      aspirin. When combined with a reduced dose of heparin, their favourable effect 
      remains unchanged, while bleeding complications are reduced to a minimum.
FAU - Voss, R
AU  - Voss R
AD  - Zentrum für Innere Medizin, Abt. Innere Medizin-Kardiologie/Angiologie.
FAU - Tillmanns, H
AU  - Tillmanns H
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Neue Aspekte der antithrombotischen Therapie bei instabiler Angina pectoris.
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/therapeutic use
MH  - Thrombolytic Therapy/*methods
RF  - 60
EDAT- 1998/02/28 00:00
MHDA- 1998/02/28 00:01
CRDT- 1998/02/28 00:00
PHST- 1998/02/28 00:00 [pubmed]
PHST- 1998/02/28 00:01 [medline]
PHST- 1998/02/28 00:00 [entrez]
AID - 10.1007/s003920050131 [doi]
PST - ppublish
SO  - Z Kardiol. 1997 Nov;86(11):911-9. doi: 10.1007/s003920050131.

PMID- 6617402
OWN - NLM
STAT- MEDLINE
DCOM- 19831123
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 28
IP  - 10
DP  - 1983 Oct
TI  - Prostaglandin cytoprotection. Prostaglandin does not protect against aspirin- or 
      alcohol-induced red blood cell hemolysis.
PG  - 903-7
AB  - The hypothesis that prostaglandin cytoprotection involves cell membrane 
      stabilization was tested in vitro using rat erythrocytes. Low concentrations of 
      sodium acetylsalicylate, 0.02, 0.2, 2.0, and 20 mM, inhibited hypotonic hemolysis 
      of red blood cell suspensions. While 35, 140, and 280 mM sodium acetylsalicylate 
      had no hemolytic effect, 560 mM caused marked hemolysis. The prostaglandin E2 
      analog, 16,16-dimethyl prostaglandin E2, 0.4 X 10(-3), 10(-4), and 10(-5) M 
      concentrations, did not alter this hemolysis. Fourteen percent ethanol caused red 
      cell hemolysis, and this was unaffected by the prostaglandin. The findings do not 
      support the hypothesis.
FAU - Guth, P H
AU  - Guth PH
FAU - Paulsen, G
AU  - Paulsen G
FAU - Hirabayashi, K
AU  - Hirabayashi K
LA  - eng
GR  - AM 17328/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Prostaglandins E, Synthetic)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Cell Membrane/drug effects
MH  - Erythrocytes/*drug effects
MH  - Ethanol/*toxicity
MH  - Hemolysis/*drug effects
MH  - Male
MH  - Prostaglandins E, Synthetic/*pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1983/10/01 00:00
MHDA- 1983/10/01 00:01
CRDT- 1983/10/01 00:00
PHST- 1983/10/01 00:00 [pubmed]
PHST- 1983/10/01 00:01 [medline]
PHST- 1983/10/01 00:00 [entrez]
AID - 10.1007/BF01317041 [doi]
PST - ppublish
SO  - Dig Dis Sci. 1983 Oct;28(10):903-7. doi: 10.1007/BF01317041.

PMID- 28378909
OWN - NLM
STAT- MEDLINE
DCOM- 20171020
LR  - 20171020
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 102
IP  - 5
DP  - 2017 Nov
TI  - In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in 
      Health and Disease.
PG  - 823-831
LID - 10.1002/cpt.694 [doi]
AB  - The influence of platelet turnover on cyclooxygenase (COX-1) inhibition by 
      low-dose aspirin remains largely uncharacterized due to limited feasibility of 
      studying aspirin pharmacodynamics in bone marrow precursors. We developed an in 
      silico compartmental model describing the aspirin effects on COX-1 activity in a 
      population of megakaryocytes (MK) and in peripheral platelets. Model parameters 
      were inferred from the literature and calibrated using measurements of serum 
      thromboxane B(2) (sTXB(2) ), as proxy of COX-1 activity in peripheral platelets, 
      in 17 healthy subjects and 24 patients with essential thrombocythemia (ET). The 
      model reproduced well the average time-course of sTXB(2) inhibition in healthy 
      (accuracy = 10.4%), the reduced inhibition of sTXB(2) observed in ET, and the 
      effect of different dosing regimens. In conclusion, the in silico model 
      accurately describes COX-1 inactivation by low-dose aspirin in MK and platelets 
      in different clinical settings, and might help personalize aspirin regimens in 
      conditions of altered megakaryopoiesis.
CI  - © 2017 American Society for Clinical Pharmacology and Therapeutics.
FAU - Giaretta, A
AU  - Giaretta A
AD  - Department of Information Engineering, University of Padova, Padova, Italy.
FAU - Rocca, B
AU  - Rocca B
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.
FAU - Di Camillo, B
AU  - Di Camillo B
AD  - Department of Information Engineering, University of Padova, Padova, Italy.
FAU - Toffolo, G M
AU  - Toffolo GM
AD  - Department of Information Engineering, University of Padova, Padova, Italy.
FAU - Patrono, C
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20170530
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/*pharmacology
MH  - *Computer Simulation
MH  - Cyclooxygenase 1/metabolism
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Databases, Factual
MH  - Dose-Response Relationship, Drug
MH  - *Health Status
MH  - Humans
MH  - *Models, Theoretical
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 2017/04/06 06:00
MHDA- 2017/10/21 06:00
CRDT- 2017/04/06 06:00
PHST- 2016/12/22 00:00 [received]
PHST- 2017/03/06 00:00 [revised]
PHST- 2017/03/11 00:00 [accepted]
PHST- 2017/04/06 06:00 [pubmed]
PHST- 2017/10/21 06:00 [medline]
PHST- 2017/04/06 06:00 [entrez]
AID - 10.1002/cpt.694 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2017 Nov;102(5):823-831. doi: 10.1002/cpt.694. Epub 2017 May 
      30.

PMID- 6425868
OWN - NLM
STAT- MEDLINE
DCOM- 19840619
LR  - 20191031
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 13
IP  - 3
DP  - 1984 Mar
TI  - Maternal aspirin administration inhibits pulmonary arachidonic acid metabolism in 
      fetal rabbits.
PG  - 323-33
AB  - Pregnant rabbits were treated with aspirin (100 mg/kg/day) for ten consecutive 
      days during the last third of the pregnancy. The ability of isolated perfused 
      fetal rabbit lungs to metabolize arachidonic acid (AA) was studied on the 31st 
      day of the pregnancy. After the infusion of 14C-AA (100 nmol) into the pulmonary 
      circulation about 10% of the radioactivity was found in the nonrecirculating 
      perfusion effluent and about 80% was incorporated into the lung lipids. Aspirin 
      pretreatment of the rabbits inhibited the formation of AA metabolites in the 
      lungs of their fetuses. The inhibition was clear when the metabolites of AA were 
      extracted from the perfusion effluent at pH 7.4 (mainly lipoxygenase products) 
      but a slight inhibition was also seen in the amounts of some metabolites 
      extracted at pH 4.5 (cyclo-oxygenase products). When aspirin (1 mM) was infused 
      simultaneously with AA into the pulmonary circulation the inhibition of AA 
      metabolism was nearly complete. Aspirin pretreatment of the pregnant rabbits 
      caused a slight increase in the amount of 14C-AA incorporated into some of the 
      phospholipid and neutral lipid fractions of the perfused fetal lungs. Aspirin 
      pretreatment clearly inhibited the TXB2 formation during clotting in the blood of 
      maternal rabbits but not significantly in the blood of their fetuses.
FAU - Simberg, N
AU  - Simberg N
LA  - eng
GR  - R0I ES-01684-21/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Arachidonic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acids/*metabolism
MH  - Aspirin/*pharmacology
MH  - Chromatography, Thin Layer
MH  - Cyclooxygenase Inhibitors
MH  - Female
MH  - Fetus/*metabolism
MH  - Lipid Metabolism
MH  - Lung/*drug effects/metabolism
MH  - Maternal-Fetal Exchange
MH  - Pregnancy
MH  - Rabbits
MH  - Thromboxane B2/blood
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
AID - 10.1016/0262-1746(84)90047-7 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1984 Mar;13(3):323-33. doi: 
      10.1016/0262-1746(84)90047-7.

PMID- 33285683
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20230905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism 
      prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis.
PG  - e23055
LID - 10.1097/MD.0000000000023055 [doi]
LID - e23055
AB  - BACKGROUND: The purpose of this meta-analysis is to compare the efficacy and 
      safety of aspirin and rivaroxaban in the prevention of venous thromboembolism 
      (VTE) following either total knee arthroplasty or total hip arthroplasty. 
      METHODS: A comprehensive literature search of several electronic databases 
      (PubMed, Embase, and Web of Science) was conducted to identify relevant studies. 
      Outcomes of interest included VTE rate, deep vein thrombosis (DVT) rate, 
      pulmonary embolism rate, major bleeding events, mortality rate, blood 
      transfusion, and wound complication. Risk ratio (RR) with 95% confidence 
      intervals (95%CIs) were calculated using a fixed-effects model or random-effects 
      model. RESULTS: A total of 8 studies with 97,677 patients met the inclusion 
      criteria and were included in this meta-analysis. Compared with rivaroxaban, 
      aspirin had a significantly higher incidence of DVT (RR = 1.48, 95%CI: 1.27, 
      1.72; P < .001), and decreased risk of blood transfusion (RR = 0.94, 95%CI: 0.93, 
      0.94; P < .001). However, there were no significant differences between the 2 
      drugs in terms of total VTE rate (RR = 1.39%, 95%CI: 0.94, 2.05; P = .101), 
      pulmonary embolism rate (RR = 1.64, 95%CI: 0.92, 2.92; P = .094), mortality rate 
      (RR = 1.13, 95%CI: 0.15, 8.27; P = .907), major bleeding (RR = 1.00, 95%CI: 0.44, 
      2.27; P = .995), and wound complication rate (RR = 0.37, 95%CI: 0.07, 1.87; 
      P = .229). CONCLUSION: Our results suggested that aspirin and rivaroxaban offered 
      similar effect in the prevention of VTE after total knee arthroplasty or total 
      hip arthroplasty. However, rivaroxaban seemed to have better effect than aspirin 
      in reducing the risk of DVT, and aspirin was safer than rivaroxaban in decreasing 
      the blood transfusion rate.
FAU - Le, Guoping
AU  - Le G
AD  - Division of Traumatic Surgery, First Affiliated Hospital of Guangxi Medical 
      University, Nanning.
FAU - Yang, Chengzhi
AU  - Yang C
AD  - Department of Orthopedics, Fourth Affiliated Hospital of Guangxi Medical 
      University, Liuzhou, Guangxi, China.
FAU - Zhang, Ming
AU  - Zhang M
AD  - Department of Orthopedics, Fourth Affiliated Hospital of Guangxi Medical 
      University, Liuzhou, Guangxi, China.
FAU - Xi, Licheng
AU  - Xi L
AD  - Department of Orthopedics, Fourth Affiliated Hospital of Guangxi Medical 
      University, Liuzhou, Guangxi, China.
FAU - Luo, Hanwen
AU  - Luo H
AD  - Department of Orthopedics, Fourth Affiliated Hospital of Guangxi Medical 
      University, Liuzhou, Guangxi, China.
FAU - Tang, Jingli
AU  - Tang J
AD  - Department of Orthopedics, Fourth Affiliated Hospital of Guangxi Medical 
      University, Liuzhou, Guangxi, China.
FAU - Zhao, Jinmin
AU  - Zhao J
AUID- ORCID: 0000-0001-8917-3861
AD  - Division of Traumatic Surgery, First Affiliated Hospital of Guangxi Medical 
      University, Nanning.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anticoagulants)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Arthroplasty, Replacement, Knee/*methods
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Transfusion/statistics & numerical data
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Pulmonary Embolism/prevention & control
MH  - Research Design
MH  - Rivaroxaban/*administration & dosage/adverse effects
MH  - Surgical Wound Infection/epidemiology
MH  - Venous Thromboembolism/*prevention & control
MH  - Venous Thrombosis/prevention & control
MH  - Meta-Analysis as Topic
MH  - Systematic Review as Topic
PMC - PMC7717737
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 00005792-202012040-00020 [pii]
AID - MD-D-20-05882 [pii]
AID - 10.1097/MD.0000000000023055 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23055. doi: 10.1097/MD.0000000000023055.

PMID- 10448545
OWN - NLM
STAT- MEDLINE
DCOM- 19991013
LR  - 20220408
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 19
IP  - 6
DP  - 1999 Jul
TI  - Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to 
      subcutaneous sumatriptan and parenteral placebo in the acute treatment of 
      migraine. A double-blind, double-dummy, randomized, multicenter, parallel group 
      study. The ASASUMAMIG Study Group.
PG  - 581-8; discussion 542
AB  - Two-hundred-and-seventy-eight patients with acute migraine attacks with or 
      without aura were treated in 17 centers with 1.8 g lysine acetylsalicylate i.v. 
      (Aspisol; = 1 g acetylsalicylic acid), 6 mg sumatriptan s.c. or placebo using a 
      double-blind, double-dummy, randomized, multicenter parallel group study design. 
      Two-hundred-and-seventy-five of them fulfilled the criteria for efficacy 
      analysis, corresponding to 119 patients treated with lysine acetylsalicylate 
      (L-ASA), 114 with sumatriptan and 42 with placebo injections. Both treatments 
      were highly effective compared to placebo (p < 0.0001) in decreasing headache 
      from severe or moderate to mild or none (verbal rating scale, VRS, placebo = 
      23.8%). Sumatriptan showed a significantly (p = 0.001) better response (91.2%) 
      compared to L-ASA (response 73.9%). Of the patients in the L-ASA-group, 43.7% 
      were pain-free after 2 h; 76.3% after sumatriptan and 14.3% after placebo. It 
      took patients on average 12.6 (L-ASA), 8.2 (sumatriptan), and 19.4 h (placebo) to 
      be able to work again. There was no significant difference between treatment 
      groups in recurrence of headache in responders within 24 h (18.2% L-ASA, 23.1% 
      sumatriptan, 20% placebo). Accompanying symptoms (nausea, vomiting; photophobia, 
      phonophobia, and visual disturbances) improved with both verum treatments to a 
      similar extent. L-ASA was significantly better tolerated than sumatriptan 
      (adverse events L-ASA 7.6%, sumatriptan 37.8%). In conclusion, subcutaneous 
      sumatriptan and lysine acetylsalicylate i.v. are effective treatments for 
      patients suffering from migraine attacks. Sumatriptan is more effective, but 
      resulted in more adverse events.
FAU - Diener, H C
AU  - Diener HC
AD  - Department of Neurology, University Essen, Germany. h.diener@uni-essen.de
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Analgesics)
RN  - 0 (Vasoconstrictor Agents)
RN  - 8R78F6L9VO (Sumatriptan)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Analgesics/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects/*analogs & derivatives
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Injections, Subcutaneous
MH  - Lysine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Recurrence
MH  - Sumatriptan/*administration & dosage/adverse effects
MH  - Treatment Outcome
MH  - Vasoconstrictor Agents/*administration & dosage/adverse effects
EDAT- 1999/08/17 00:00
MHDA- 1999/08/17 00:01
CRDT- 1999/08/17 00:00
PHST- 1999/08/17 00:00 [pubmed]
PHST- 1999/08/17 00:01 [medline]
PHST- 1999/08/17 00:00 [entrez]
AID - 10.1046/j.1468-2982.1999.019006581.x [doi]
PST - ppublish
SO  - Cephalalgia. 1999 Jul;19(6):581-8; discussion 542. doi: 
      10.1046/j.1468-2982.1999.019006581.x.

PMID- 9257790
OWN - NLM
STAT- MEDLINE
DCOM- 19970903
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 100
IP  - 1
DP  - 1997 Jul
TI  - Protective effect of inhaled lysine acetylsalicylate on allergen-induced early 
      and late asthmatic reactions.
PG  - 71-7
AB  - Conflicting results have been reported on the effect of non-steroidal 
      antiinflammatory drugs on allergen-induced asthmatic responses. The aim of this 
      study was to investigate the effect of inhaled lysine acetylsalicylate (LASA) on 
      the early and late allergen-induced responses. We studied 16 patients with mild, 
      stable asthma who had an early asthmatic response and 10 patients with a dual 
      (early and late) response. Each patient underwent two challenges with a single 
      dose of allergen assessed in a preliminary test, after inhalation of either 720 
      mg of LASA in 4 ml of saline solution or placebo, according to a randomized, 
      double-blind protocol. Allergen-induced hyperreactivity to methacholine was 
      measured in six patients from each of the early and the dual response groups 2 
      hours and 24 hours after the challenge, respectively. In the patients with early 
      response, the maximum fall in FEV1 after challenge was 24% +/- 1% after 
      inhalation of placebo and 14% +/- 2% after inhalation of LASA (p < 0.005). No 
      protection was observed in four patients who received the drug orally instead of 
      by inhalation. In the patients with a dual response, the maximum FEV1 decrease 
      during the early response was 27% +/- 2% after placebo and 21% +/- 2% after LASA 
      (p < 0.025). During the late response (between 3 and 8 hours), the maximum 
      decrease in FEV1 was 28% +/- 4% after placebo and 16% +/- 4% after LASA (p < 
      0.005). In both groups allergen challenge caused a significant reduction in 
      methacholine PD20 after treatment with placebo but not with LASA. Without 
      allergen challenge, LASA had no effect on methacoline reactivity. We conclude 
      that inhaled LASA significantly reduces both the early and the late asthmatic 
      response to allergen challenge and that it prevents the allergen-induced airway 
      hyperresponsiveness that follows these responses.
FAU - Sestini, P
AU  - Sestini P
AD  - Institute of Respiratory Diseases, University of Siena, Italy.
FAU - Refini, R M
AU  - Refini RM
FAU - Pieroni, M G
AU  - Pieroni MG
FAU - Vaghi, A
AU  - Vaghi A
FAU - Robuschi, M
AU  - Robuschi M
FAU - Bianco, S
AU  - Bianco S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Allergens)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Adult
MH  - Allergens/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Asthma/*drug therapy/etiology/physiopathology
MH  - Bronchial Hyperreactivity/physiopathology
MH  - Cyclooxygenase Inhibitors/administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypersensitivity, Delayed/drug therapy/etiology/physiopathology
MH  - Lysine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Male
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - S0091674997001942 [pii]
AID - 10.1016/s0091-6749(97)70197-0 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1997 Jul;100(1):71-7. doi: 10.1016/s0091-6749(97)70197-0.

PMID- 30616398
OWN - NLM
STAT- MEDLINE
DCOM- 20200525
LR  - 20200525
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 15
IP  - 4
DP  - 2019 Apr
TI  - Management of pregnant women with antiphospholipid antibodies.
PG  - 347-358
LID - 10.1080/1744666X.2019.1565995 [doi]
AB  - Important advancements in pregnancy outcome have been reported in women with 
      antiphospholipid antibodies (aPL), despite the fact that the treatment of aPL 
      related pregnancy morbidity is not guided by consistent findings from 
      well-designed trials. Areas covered: The current study draws a picture of the 
      studies in the literature by performing a Medline search of relevant English 
      language articles and reports our experience in managing different subsets of 
      obstetric antiphospholipid syndrome (APS), defined on the basis of their clinical 
      and laboratory characteristics. The management of pregnant women with 
      non-criteria APS manifestations and that of aPL carriers during their first 
      pregnancy is also examined. Expert commentary: A heparin/aspirin combination 
      constitutes conventional treatment for APS affected pregnant women. As this 
      strategy fails in approximately 20-30% of cases, uncovering other options for 
      women refractory to conventional treatment or at high risk of pregnancy 
      complications has become an urgent undertaking. Some attempts have been made to 
      prescribe additional treatments in the effort to improve live birth rates and/or 
      reduce pregnancy complications, which often occur even in patients treated 
      conventionally. The evidence from some studies and an individual risk/benefit 
      assessment should instead guide treatment decisions for pregnant patients with 
      non-criteria APS manifestations and aPL carriers.
FAU - Ruffatti, Amelia
AU  - Ruffatti A
AD  - a Rheumatology Unit, Department of Medicine , University Hospital of Padua , 
      Padua , Italy.
FAU - Favaro, Maria
AU  - Favaro M
AD  - a Rheumatology Unit, Department of Medicine , University Hospital of Padua , 
      Padua , Italy.
FAU - Calligaro, Antonia
AU  - Calligaro A
AD  - a Rheumatology Unit, Department of Medicine , University Hospital of Padua , 
      Padua , Italy.
FAU - Zambon, Alessandra
AU  - Zambon A
AD  - b Obstetrics and Gynecology Unit, Department of Woman's and Child's Health , 
      University Hospital of Padua , Padua , Italy.
FAU - Del Ross, Teresa
AU  - Del Ross T
AD  - a Rheumatology Unit, Department of Medicine , University Hospital of Padua , 
      Padua , Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190111
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Drug Combinations)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Antiphospholipid/*metabolism
MH  - Antiphospholipid Syndrome/diagnosis/*therapy
MH  - Aspirin/*therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - *Pregnancy
MH  - Risk Assessment
MH  - Risk Factors
OTO - NOTNLM
OT  - Antiphospholipid antibodies
OT  - management
OT  - obstetric antiphospholipid syndrome
OT  - pregnancy
OT  - risk factors
EDAT- 2019/01/09 06:00
MHDA- 2020/05/26 06:00
CRDT- 2019/01/09 06:00
PHST- 2019/01/09 06:00 [pubmed]
PHST- 2020/05/26 06:00 [medline]
PHST- 2019/01/09 06:00 [entrez]
AID - 10.1080/1744666X.2019.1565995 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2019 Apr;15(4):347-358. doi: 
      10.1080/1744666X.2019.1565995. Epub 2019 Jan 11.

PMID- 9363730
OWN - NLM
STAT- MEDLINE
DCOM- 19971205
LR  - 20190512
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 12
IP  - 9
DP  - 1997 Sep
TI  - Heparin and low-dose aspirin restore placental human chorionic gonadotrophin 
      secretion abolished by antiphospholipid antibody-containing sera.
PG  - 2061-5
AB  - This study was conducted to determine whether drugs used for conventional 
      treatments of pregnant women with antiphosholipid syndrome might be able to 
      restore the gonadotrophin-releasing hormone (GnRH)-induced secretion of placental 
      human chorionic gonadotrophin (HCG) in vitro. We tested this hypothesis using a 
      modified enzyme-linked immunosorbent assay (ELISA) and an in-vitro placental 
      culture system. Pharmacological dose of low molecular weight heparin (20 IU/ml) 
      significantly (P < 0.02) reduced the antiphospholipid antibody (aPL) binding in 
      the ELISA and was able to restore GnRH-induced HCG secretion (P < 0.05) in 
      presence of aPL-containing sera. Low-dose aspirin (0.03 M) did not modify aPL 
      binding in the ELISA, but partially restored HCG secretion (P < 0.05). These 
      observations may help to explain the role of these treatments in antiphospholipid 
      syndrome.
FAU - Di Simone, N
AU  - Di Simone N
AD  - Department of Obstetrics and Gynecology, Università Cattolica S. Cuore, Rome, 
      Italy.
FAU - Ferrazzani, S
AU  - Ferrazzani S
FAU - Castellani, R
AU  - Castellani R
FAU - De Carolis, S
AU  - De Carolis S
FAU - Mancuso, S
AU  - Mancuso S
FAU - Caruso, A
AU  - Caruso A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Chorionic Gonadotropin)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
RN  - 9842X06Q6M (Betamethasone)
RN  - R16CO5Y76E (Aspirin)
RN  - T42P99266K (Methylene Blue)
SB  - IM
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Antibodies, Antiphospholipid/metabolism/*pharmacology
MH  - Antiphospholipid Syndrome/*blood
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Betamethasone/pharmacology
MH  - Cell Count
MH  - Cells, Cultured
MH  - Chorionic Gonadotropin/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gonadotropin-Releasing Hormone/pharmacology
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*pharmacology
MH  - Humans
MH  - Methylene Blue
MH  - Placenta/drug effects/*metabolism
MH  - Pregnancy
MH  - Trophoblasts/drug effects/physiology
EDAT- 1997/11/18 00:00
MHDA- 1997/11/18 00:01
CRDT- 1997/11/18 00:00
PHST- 1997/11/18 00:00 [pubmed]
PHST- 1997/11/18 00:01 [medline]
PHST- 1997/11/18 00:00 [entrez]
AID - 10.1093/humrep/12.9.2061 [doi]
PST - ppublish
SO  - Hum Reprod. 1997 Sep;12(9):2061-5. doi: 10.1093/humrep/12.9.2061.

PMID- 787015
OWN - NLM
STAT- MEDLINE
DCOM- 19761203
LR  - 20190823
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 16
IP  - 8-9
DP  - 1976 Aug-Sep
TI  - Antiinflammatory drugs and gastrointestinal bleeding: a comparison of aspirin and 
      ibuprofen.
PG  - 418-25
AB  - Gastrointestinal blood loss provoked by short-term and long-term therapy with 
      aspirin and ibuprofen was compared in patients with rheumatoid arthritis. Blood 
      loss was assessed by isotope counting of four-day stool collections after 
      infusion of 51Cr-labeled autologous erythrocytes. After two weeks on drug or 
      after one year on drug, aspirin consistently caused more bleeding than ibuprofen.
FAU - Schmid, F R
AU  - Schmid FR
FAU - Culic, D D
AU  - Culic DD
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Clinical Trials as Topic
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Ibuprofen/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Occult Blood
MH  - Phenylpropionates/*adverse effects
EDAT- 1976/08/01 00:00
MHDA- 1976/08/01 00:01
CRDT- 1976/08/01 00:00
PHST- 1976/08/01 00:00 [pubmed]
PHST- 1976/08/01 00:01 [medline]
PHST- 1976/08/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1976.tb02416.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1976 Aug-Sep;16(8-9):418-25. doi: 
      10.1002/j.1552-4604.1976.tb02416.x.

PMID- 36693142
OWN - NLM
STAT- MEDLINE
DCOM- 20230825
LR  - 20230825
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 24
IP  - 4
DP  - 2023 Mar
TI  - Advances in the available pharmacotherapy for the management of acute coronary 
      syndromes in patients presenting without persistent ST-segment elevation.
PG  - 453-471
LID - 10.1080/14656566.2023.2171788 [doi]
AB  - INTRODUCTION: Non-ST-segment elevation acute coronary syndromes (NSTE-ACS), 
      including non-ST-segment-elevation myocardial infarction (NSTEMI) and unstable 
      angina, represent a leading cause of mortality worldwide, with important 
      socio-economic consequences. NSTEMI accounts for the majority of acute coronary 
      syndromes and usually develops on the background of a nonocclusive thrombus. We 
      searched for relevant literature in the field in PubMed and clinicaltrials.gov as 
      of July 2022. AREAS COVERED: A number of pharmacotherapies are currently 
      available for treatment and secondary prevention, mainly including 
      antithrombotic, lipid-lowering and anti-inflammatory drugs. Pretreatment with 
      aspirin, anticoagulant and statin therapy is of key importance in the 
      preprocedural phase, while pretreating with an oral P2Y(12) inhibitor is not 
      routinely indicated in patients undergoing early invasive management. For 
      patients undergoing percutaneous coronary revascularization, pharmacotherapy 
      essentially consists of antithrombotic drugs, which should be carefully selected. 
      Finally, antithrombotic, lipid-lowering and anti-inflammatory drugs are important 
      components of long-term secondary prevention after a NSTE-ACS. EXPERT OPINION: 
      This article reviews the evidence supporting recommendation on pharmacotherapy in 
      patients presenting with a NSTE-ACS. Several randomized clinical trials are still 
      ongoing and are expected to further inform scientific knowledge and clinical 
      practice, with the final aim to improve the treatment of NSTE-ACS patients.
FAU - Greco, Antonio
AU  - Greco A
AUID- ORCID: 0000-0003-2926-9428
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco," University of Catania, Catania, Italy.
FAU - Finocchiaro, Simone
AU  - Finocchiaro S
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco," University of Catania, Catania, Italy.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AUID- ORCID: 0000-0001-8451-2131
AD  - Division of Cardiology, University of Florida College of Medicine, Jacksonville, 
      Florida, United States.
FAU - Capodanno, Davide
AU  - Capodanno D
AUID- ORCID: 0000-0002-5156-7723
AD  - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. 
      Rodolico - San Marco," University of Catania, Catania, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230207
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Lipids)
SB  - IM
MH  - Humans
MH  - *Acute Coronary Syndrome/drug therapy
MH  - Arrhythmias, Cardiac/drug therapy
MH  - Aspirin/therapeutic use
MH  - Fibrinolytic Agents/therapeutic use
MH  - Lipids
MH  - *Non-ST Elevated Myocardial Infarction/drug therapy
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - antiplatelet agents
OT  - antithrombotic therapy
OT  - non-ST-segment elevation myocardial infarction
OT  - percutaneous coronary intervention
OT  - pharmacotherapy
OT  - unstable angina
EDAT- 2023/01/25 06:00
MHDA- 2023/03/29 06:05
CRDT- 2023/01/24 14:22
PHST- 2023/03/29 06:05 [medline]
PHST- 2023/01/25 06:00 [pubmed]
PHST- 2023/01/24 14:22 [entrez]
AID - 10.1080/14656566.2023.2171788 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2023 Mar;24(4):453-471. doi: 
      10.1080/14656566.2023.2171788. Epub 2023 Feb 7.

PMID- 20800217
OWN - NLM
STAT- MEDLINE
DCOM- 20110429
LR  - 20131121
IS  - 1768-3181 (Electronic)
IS  - 0003-3928 (Linking)
VI  - 59
IP  - 5
DP  - 2010 Nov
TI  - [Myocardial infarction after voluntary intoxication by drug interaction between 
      dipyridamole and aspirin].
PG  - 314-7
LID - 10.1016/j.ancard.2010.07.016 [doi]
AB  - A 60-year-old male presented a myocardial infarction after a voluntary overdose 
      of Asasantine(®) started after strokes. He took chronically this association and 
      some psychotropic drugs with vasodilator effects. After an intake of 40 tablets, 
      he presented a cardiogenic shock with a myocardial infarction confirmed by 
      biological samples, EKG, echocardiography and angiocoronarographie. No recent 
      change of his treatment was found and symptoms regressed when dipyridamole was 
      stopped while other vasodilators drugs were continued. Chronological analysis of 
      events led us to suspect dipyridamole as a starter of the myocardial infarction 
      secondary to a coronary artery steal reinforced by the vasodilator effect of 
      combined treatments, in a patient at risk of ischemia. This case shows that, in 
      such particular conditions, a change in dipyridamole dosage can induce a 
      myocardial infarction even if its blood level remains in the therapeutic range.
CI  - Copyright © 2010. Published by Elsevier SAS.
FAU - Eschalier, R
AU  - Eschalier R
AD  - Service de cardiologie, centre hospitalier de Vichy, boulevard Denière, 03200 
      Vichy, France.
FAU - Eschalier, A
AU  - Eschalier A
FAU - Ravan, R
AU  - Ravan R
FAU - Brahic, H
AU  - Brahic H
FAU - Marcaggi, X
AU  - Marcaggi X
FAU - Amat, G
AU  - Amat G
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Infarctus du myocarde après intoxication volontaire par l'association acide 
      acétylsalicylique et dipyridamole.
DEP - 20100803
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*poisoning
MH  - Dipyridamole/*poisoning
MH  - Drug Interactions
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*chemically induced
MH  - *Suicide, Attempted
EDAT- 2010/08/31 06:00
MHDA- 2011/04/30 06:00
CRDT- 2010/08/31 06:00
PHST- 2010/07/05 00:00 [received]
PHST- 2010/07/10 00:00 [accepted]
PHST- 2010/08/31 06:00 [entrez]
PHST- 2010/08/31 06:00 [pubmed]
PHST- 2011/04/30 06:00 [medline]
AID - S0003-3928(10)00096-X [pii]
AID - 10.1016/j.ancard.2010.07.016 [doi]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 2010 Nov;59(5):314-7. doi: 
      10.1016/j.ancard.2010.07.016. Epub 2010 Aug 3.

PMID- 7279422
OWN - NLM
STAT- MEDLINE
DCOM- 19811122
LR  - 20210111
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 10
IP  - 3
DP  - 1981 Jun
TI  - Opiate pharmacology and individual differences. I. Psychophysical pain 
      measurements.
PG  - 357-366
LID - 10.1016/0304-3959(81)90097-X [doi]
AB  - A new electric stimulation pain assessment technique using the Tursky electrode 
      and a non-parametric analysis of subjects ratings was found sensitive to aspirin, 
      morphine and opiate antagonists in a series of double-blind cross-over trials in 
      normal adults. Stable individual differences in pain sensitivity (off medication) 
      were maintained on two testing sessions 7 months apart. Older individuals were 
      less pain sensitive than younger individuals. Men were more insensitive than 
      women under age 30. Together, these results suggest the empiric usefulness of 
      this pain measurement technique.
FAU - Buchsbaum, Monte S
AU  - Buchsbaum MS
AD  - Section on Clinical Psychophysiology, National Institute of Mental Health, 
      Clinical Center, Room 2N212, Bethesda, Md. 20205, USA Center for the Health 
      Sciences, University of Tennessee, Memphis, Tenn. 38105, USA Laboratory of 
      Psychology and Psychopathology, National Institute of Mental Health, Clinical 
      Center, Room 2N128, Bethesda, Md. 20205, U.S.A. Psychiatrische 
      Universitaetsklinik, Nussbaumstr. 7, D-8000 Munich, USA.
FAU - Davis, Glenn C
AU  - Davis GC
FAU - Coppola, Richard
AU  - Coppola R
FAU - Naber, Dieter
AU  - Naber D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - 76I7G6D29C (Morphine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Electric Stimulation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Morphine/*therapeutic use
MH  - Pain/*drug therapy
MH  - Sex Factors
EDAT- 1981/06/01 00:00
MHDA- 1981/06/01 00:01
CRDT- 1981/06/01 00:00
PHST- 1981/06/01 00:00 [pubmed]
PHST- 1981/06/01 00:01 [medline]
PHST- 1981/06/01 00:00 [entrez]
AID - 00006396-198106000-00010 [pii]
AID - 10.1016/0304-3959(81)90097-X [doi]
PST - ppublish
SO  - Pain. 1981 Jun;10(3):357-366. doi: 10.1016/0304-3959(81)90097-X.

PMID- 3241818
OWN - NLM
STAT- MEDLINE
DCOM- 19890519
LR  - 20190912
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 34
IP  - 2
DP  - 1988 Nov
TI  - PGE2 and PGF2 alpha in the nasal lavage fluid from healthy subjects: 
      methodological aspects.
PG  - 109-12
AB  - Prostaglandins E2 and F2 alpha were estimated in nasal secretions from ten 
      healthy volunteers by high performance liquid chromatography and 
      radioimmunological assay. Prostaglandin concentrations determined in five 
      consecutive nasal washes with saline at room temperature showed that the nasal 
      mucosa was stimulated after instillation. A substantial increase of basal levels 
      was associated with the second nasal lavage. In all volunteers aspirin treatment 
      inhibited prostaglandin release.
FAU - Ramis, I
AU  - Ramis I
AD  - Dept. of Neurochemistry, Centro de Investigación y Desarrollo, CSIC, Barcelona, 
      Spain.
FAU - Serra, J
AU  - Serra J
FAU - Roselló, J
AU  - Roselló J
FAU - Picado, C
AU  - Picado C
FAU - Gelpi, E
AU  - Gelpi E
FAU - Vidal, A A
AU  - Vidal AA
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - B7IN85G1HY (Dinoprost)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Chromatography, High Pressure Liquid
MH  - Dinoprost/*analysis
MH  - Dinoprostone/*analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Nasal Mucosa/drug effects/*metabolism
MH  - Radioimmunoassay
MH  - Therapeutic Irrigation
EDAT- 1988/11/01 00:00
MHDA- 1988/11/01 00:01
CRDT- 1988/11/01 00:00
PHST- 1988/11/01 00:00 [pubmed]
PHST- 1988/11/01 00:01 [medline]
PHST- 1988/11/01 00:00 [entrez]
AID - 10.1016/0952-3278(88)90071-3 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 1988 Nov;34(2):109-12. doi: 
      10.1016/0952-3278(88)90071-3.

PMID- 6682245
OWN - NLM
STAT- MEDLINE
DCOM- 19830527
LR  - 20190618
IS  - 0036-8075 (Print)
IS  - 0036-8075 (Linking)
VI  - 220
IP  - 4596
DP  - 1983 Apr 29
TI  - Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible 
      resolution of the "aspirin dilemma".
PG  - 517-9
AB  - Selective pharmacological inhibition of thromboxane A2 synthesis did not prevent 
      arachidonate-induced aggregation of human platelets in vitro. Prevention was 
      instead achieved by a combination of thromboxane A2 inhibitors with low 
      concentrations of aspirin. The latter partially reduced the proaggregatory 
      cyclooxygenase products that accumulated when thromboxane A2 synthesis was 
      blocked. The aspirin concentrations did not affect per se either platelet 
      aggregation or prostacyclin synthesis in cultured human endothelial cells. The 
      combination of thromboxane synthetase inhibitors with low doses of aspirin may 
      offer greater antithrombotic potential than either drug alone.
FAU - Bertelé, V
AU  - Bertelé V
FAU - Falanga, A
AU  - Falanga A
FAU - Tomasiak, M
AU  - Tomasiak M
FAU - Dejana, E
AU  - Dejana E
FAU - Cerletti, C
AU  - Cerletti C
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (Imidazoles)
RN  - 0 (Methacrylates)
RN  - 09ZFC7974Q (dazoxiben)
RN  - 75987-08-5 (2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid)
RN  - EC 1.- (Oxidoreductases)
RN  - EC 5.3.99.5 (Thromboxane-A Synthase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/enzymology
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Humans
MH  - Imidazoles/pharmacology
MH  - Methacrylates/pharmacology
MH  - Oxidoreductases/*antagonists & inhibitors
MH  - Platelet Aggregation/drug effects
MH  - Thromboxane-A Synthase/*antagonists & inhibitors
EDAT- 1983/04/29 00:00
MHDA- 1983/04/29 00:01
CRDT- 1983/04/29 00:00
PHST- 1983/04/29 00:00 [pubmed]
PHST- 1983/04/29 00:01 [medline]
PHST- 1983/04/29 00:00 [entrez]
AID - 10.1126/science.6682245 [doi]
PST - ppublish
SO  - Science. 1983 Apr 29;220(4596):517-9. doi: 10.1126/science.6682245.

PMID- 30241493
OWN - NLM
STAT- MEDLINE
DCOM- 20181024
LR  - 20181114
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Sep 21
TI  - Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The 
      MCC-Spain study.
PG  - 1134
LID - 10.1186/s12889-018-6019-z [doi]
LID - 1134
AB  - BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used 
      despite their risk of gastrointestinal bleeding or cardiovascular events. We 
      report the profile of people taking NSAIDs in Spain, and we include demographic 
      factors, health-related behaviours and cardiovascular disease history. METHODS: 
      Four thousand sixtyparticipants were selected using a pseudorandom number list 
      from Family Practice lists in 12 Spanish provinces. They completed a face-to-face 
      computerized interview on their NSAID consumption, demographic characteristics, 
      body mass index, alcohol and tobacco consumption and medical history. In 
      addition, participants completed a self-administered food-frequency and alcohol 
      consumption questionnaire. Factors associated with ever and current NSAID 
      consumption were identified by logistic regression. RESULTS: Women consumed more 
      non-aspirin NSAIDs (38.8% [36.7-41.0]) than men (22.3 [20.5-24.2]), but men 
      consumed more aspirin (11.7% [10.3-13.2]) than women (5.2% [4.3-6.3]). 
      Consumption of non-aspirin NSAIDs decrease with age from 44.2% (39.4-49.1) in 
      younger than 45 to 21.1% (18.3-24.2) in older than 75, but the age-pattern for 
      aspirin usage was the opposite. Aspirin was reported by about 11% patients, as 
      being twice as used in men (11.7%) than in women (5.2%); its consumption 
      increased with age from 1.7% (< 45 years old) to 12.4% (≥75 years old). Aspirin 
      was strongly associated with the presence of cardiovascular risk factors or 
      established cardiovascular disease, reaching odds ratios of 15.2 (7.4-31.2) in 
      women with acute coronary syndrome, 13.3 (6.2-28.3) in women with strokes and 
      11.1 (7.8-15.9) in men with acute coronary syndrome. Participants with 
      cardiovascular risk factors or diseases consumed as much non-aspirin NSAID as 
      participants without such conditions. CONCLUSIONS: Non-aspirin NSAIDs were more 
      consumed by women and aspirin by men. The age patterns of aspirin and non-aspirin 
      NSAIDs were opposite: the higher the age, the lower the non-aspirin NSAIDs usage 
      and the higher the aspirin consumption. People with cardiovascular risk factors 
      or diseases consumed more aspirin, but they did not decrease their non-aspirin 
      NSAIDs usage.
FAU - Gómez-Acebo, Inés
AU  - Gómez-Acebo I
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain. ines.gomez@unican.es.
AD  - Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 
      39011, Santander, Spain. ines.gomez@unican.es.
FAU - Dierssen-Sotos, Trinidad
AU  - Dierssen-Sotos T
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 
      39011, Santander, Spain.
FAU - de Pedro, María
AU  - de Pedro M
AD  - Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 
      39011, Santander, Spain.
AD  - Department of Obstetrics and Gynecology, Nuevo Belén University Hospital, Madrid, 
      Spain.
FAU - Pérez-Gómez, Beatriz
AU  - Pérez-Gómez B
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Environmental and Cancer Epidemiology Unit, National Centre for Epidemiology, 
      Carlos III Institute of Health (Instituto de Salud Carlos III-ISCIII), Avda. 
      Monforte de Lemos, 5, 28029, Madrid, Spain.
AD  - Institute of Health Research "Puerta de Hierro", IDIPHIM, Madrid, Spain.
FAU - Castaño-Vinyals, Gemma
AU  - Castaño-Vinyals G
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, 
      Spain.
AD  - Universitat Pompeu Fabra (UPF), Barcelona, Spain.
AD  - IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
FAU - Fernández-Villa, Tania
AU  - Fernández-Villa T
AD  - Institute of Biomedicine (IBIOMED), University of León, León, Spain.
FAU - Palazuelos-Calderón, Camilo
AU  - Palazuelos-Calderón C
AD  - Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 
      39011, Santander, Spain.
FAU - Amiano, Pilar
AU  - Amiano P
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Public Health Division of Gipuzkoa, BioDonostia Research Institute, San 
      Sebastian, Spain.
FAU - Etxeberria, Jaione
AU  - Etxeberria J
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Department of Statistics and O.R., INAMAT, Public University of Navarre, 
      Pamplona, Spain.
FAU - Benavente, Yolanda
AU  - Benavente Y
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, 
      Catalan Institute of Oncology, Barcelona, Spain.
FAU - Fernández-Tardón, Guillermo
AU  - Fernández-Tardón G
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - University of Oviedo, Oviedo, Spain.
FAU - Salcedo-Bellido, Inmaculada
AU  - Salcedo-Bellido I
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Universidad de Granada, Granada, Spain.
FAU - Capelo, Rocío
AU  - Capelo R
AD  - Centro de Investigación en Recursos Naturales, Salud, y Medio Ambiente. (RENSMA), 
      Universidad de Huelva, Huelva, Spain.
FAU - Peiró, Rosana
AU  - Peiró R
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Dirección General de Salud Pública, Fundación para el fomento de la investigación 
      sanitaria y biomédica de la Comunidad Valenciana, FISABIO-Salud Pública, 
      Valencia, Spain.
FAU - Marcos-Gragera, Rafael
AU  - Marcos-Gragera R
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Unitat d'Epidemiologia i Registre de Càncer de Girona (UERCG), Pla Director 
      d'Oncologia, Institut Català d'Oncologia, Institut d'Investigaciò Biomèdica de 
      Girona (IdIBGi), Universitat de Girona, Girona, Spain.
FAU - Huerta, José M
AU  - Huerta JM
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, 
      Murcia, Spain.
FAU - Tardón, Adonina
AU  - Tardón A
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - University of Oviedo, Oviedo, Spain.
FAU - Barricarte, Aurelio
AU  - Barricarte A
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Navarra Public Health Institute, Pamplona, Spain.
AD  - Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
FAU - Altzibar, Jone-Miren
AU  - Altzibar JM
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Osakidetza-Basque Health Service, BioDonostia Research Institute, Donostia, 
      Spain.
FAU - Alonso-Molero, Jessica
AU  - Alonso-Molero J
AD  - Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 
      39011, Santander, Spain.
FAU - Dávila-Batista, Verónica
AU  - Dávila-Batista V
AD  - Institute of Biomedicine (IBIOMED), University of León, León, Spain.
FAU - Aragonés, Nuria
AU  - Aragonés N
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Environmental and Cancer Epidemiology Unit, National Centre for Epidemiology, 
      Carlos III Institute of Health (Instituto de Salud Carlos III-ISCIII), Avda. 
      Monforte de Lemos, 5, 28029, Madrid, Spain.
AD  - Institute of Health Research "Puerta de Hierro", IDIPHIM, Madrid, Spain.
AD  - Epidemiology Section, Public Health Division, Department of Health of Madrid, 
      Madrid, Spain.
FAU - Pollán, Marina
AU  - Pollán M
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Environmental and Cancer Epidemiology Unit, National Centre for Epidemiology, 
      Carlos III Institute of Health (Instituto de Salud Carlos III-ISCIII), Avda. 
      Monforte de Lemos, 5, 28029, Madrid, Spain.
AD  - Institute of Health Research "Puerta de Hierro", IDIPHIM, Madrid, Spain.
FAU - Kogevinas, Manolis
AU  - Kogevinas M
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, 
      Spain.
AD  - Universitat Pompeu Fabra (UPF), Barcelona, Spain.
AD  - IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
FAU - Llorca, Javier
AU  - Llorca J
AD  - CIBER Epidemiología y Salud Pública, Madrid, Spain.
AD  - Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 
      39011, Santander, Spain.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20180921
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology
MH  - Case-Control Studies
MH  - Female
MH  - Gastrointestinal Hemorrhage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Sex Distribution
MH  - Spain/epidemiology
MH  - Surveys and Questionnaires
PMC - PMC6150967
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiovascular risk
OT  - Gastrointestinal bleeding
OT  - Non-steroidal anti-inflammatory drugs
OT  - Propionates
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Participants who agreed to partake in 
      the study signed an informed consent before the face-to-face interview, and the 
      protocol of MCC-Spain was approved by the local Ethics Committees of 
      participating institutions (Comité Ético de Investigación Clínica (CEIC) del 
      Instituto Municipal de Asistencia Sanitaria de Barcelona; CEIC del Hospital 
      Universitario de Bellvitge; CEIC de Navarra; CEIC del Hospital Universitario La 
      Paz; CEIC del Hospital Universitario Ramón y Cajal; CEIC de Cantabria; CEIC de 
      Gipuzkoa; CEIC de Granada; CEIC de Murcia; CEIC de Valencia; CEIC de Girona; 
      Comité de Ética de la Investigación de la Provincia de Huelva; CEIC de León; 
      Comité Ético de Investigación del Principado de Asturias), in conformity to the 
      principles of the Declaration of Helsinki. The database was registered in the 
      Spanish Agency for Data Protection (no. 2102672171). CONSENT FOR PUBLICATION: Not 
      applicable. COMPETING INTERESTS: The authors declare that they have no competing 
      interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to 
      jurisdictional claims in published maps and institutional affiliations.
EDAT- 2018/09/23 06:00
MHDA- 2018/10/26 06:00
CRDT- 2018/09/23 06:00
PHST- 2017/11/30 00:00 [received]
PHST- 2018/09/04 00:00 [accepted]
PHST- 2018/09/23 06:00 [entrez]
PHST- 2018/09/23 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
AID - 10.1186/s12889-018-6019-z [pii]
AID - 6019 [pii]
AID - 10.1186/s12889-018-6019-z [doi]
PST - epublish
SO  - BMC Public Health. 2018 Sep 21;18(1):1134. doi: 10.1186/s12889-018-6019-z.

PMID- 27397588
OWN - NLM
STAT- MEDLINE
DCOM- 20170831
LR  - 20181202
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 33
IP  - 9
DP  - 2016 Sep
TI  - A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment 
      Elevation Acute Coronary Syndrome in China.
PG  - 1600-11
LID - 10.1007/s12325-016-0375-9 [doi]
AB  - INTRODUCTION: There are a number of economic evaluation studies of clopidogrel 
      for patients with non-ST-segment elevation acute coronary syndrome (NSTEACS) 
      published from the perspective of multiple countries in recent years. However, 
      relevant research is quite limited in China. We aimed to estimate the long-term 
      cost effectiveness for up to 1-year treatment with clopidogrel plus 
      acetylsalicylic acid (ASA) versus ASA alone for NSTEACS from the public payer 
      perspective in China. METHODS: This analysis used a Markov model to simulate a 
      cohort of patients for quality-adjusted life years (QALYs) gained and incremental 
      cost for lifetime horizon. Based on the primary event rates, adherence rate, and 
      mortality derived from the CURE trial, hazard functions obtained from published 
      literature were used to extrapolate the overall survival to lifetime horizon. 
      Resource utilization, hospitalization, medication costs, and utility values were 
      estimated from official reports, published literature, and analysis of the 
      patient-level insurance data in China. To assess the impact of parameters' 
      uncertainty on cost-effectiveness results, one-way sensitivity analyses were 
      undertaken for key parameters, and probabilistic sensitivity analysis (PSA) was 
      conducted using the Monte Carlo simulation. RESULTS: The therapy of clopidogrel 
      plus ASA is a cost-effective option in comparison with ASA alone for the 
      treatment of NSTEACS in China, leading to 0.0548 life years (LYs) and 0.0518 
      QALYs gained per patient. From the public payer perspective in China, clopidogrel 
      plus ASA is associated with an incremental cost of 43,340 China Yuan (CNY) per 
      QALY gained and 41,030 CNY per LY gained (discounting at 3.5% per year). PSA 
      results demonstrated that 88% of simulations were lower than the 
      cost-effectiveness threshold of 150,721 CYN per QALY gained. Based on the one-way 
      sensitivity analysis, results are most sensitive to price of clopidogrel, but 
      remain well below this threshold. CONCLUSION: This analysis suggests that 
      treatment with clopidogrel plus ASA for up to 1 year for patients with NSTEACS is 
      cost effective in the local context of China from a public payers' perspective. 
      FUNDING: Sanofi China.
FAU - Cui, Ming
AU  - Cui M
AD  - Peking University Third Hospital, Beijing, China.
FAU - Tu, Chen Chen
AU  - Tu CC
AD  - Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
FAU - Chen, Er Zhen
AU  - Chen EZ
AD  - Shanghai Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, 
      Shanghai, China.
FAU - Wang, Xiao Li
AU  - Wang XL
AD  - China-Japan Friendship Hospital, Beijing, China.
FAU - Tan, Seng Chuen
AU  - Tan SC
AD  - IMS Health Asia, Singapore, Singapore.
FAU - Chen, Can
AU  - Chen C
AUID- ORCID: 0000-0002-9109-1061
AD  - IMS Health Asia, Shanghai, China. cchen1@cn.imshealth.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160711
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - *Acute Coronary Syndrome/diagnosis/drug therapy/epidemiology
MH  - *Aspirin/economics/therapeutic use
MH  - China/epidemiology
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Drug Costs
MH  - Drug Therapy, Combination/economics/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/economics/therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Ticlopidine/*analogs & derivatives/economics/therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiology
OT  - Clopidogrel
OT  - Cost effectiveness
OT  - Non-ST-segment elevation acute coronary syndrome
EDAT- 2016/07/12 06:00
MHDA- 2017/09/01 06:00
CRDT- 2016/07/12 06:00
PHST- 2016/04/26 00:00 [received]
PHST- 2016/07/12 06:00 [entrez]
PHST- 2016/07/12 06:00 [pubmed]
PHST- 2017/09/01 06:00 [medline]
AID - 10.1007/s12325-016-0375-9 [pii]
AID - 10.1007/s12325-016-0375-9 [doi]
PST - ppublish
SO  - Adv Ther. 2016 Sep;33(9):1600-11. doi: 10.1007/s12325-016-0375-9. Epub 2016 Jul 
      11.

PMID- 28782132
OWN - NLM
STAT- MEDLINE
DCOM- 20190125
LR  - 20210109
IS  - 1099-1166 (Electronic)
IS  - 0885-6230 (Print)
IS  - 0885-6230 (Linking)
VI  - 33
IP  - 2
DP  - 2018 Feb
TI  - Aspirin and incident depressive symptoms: A longitudinal cohort study over 
      8 years.
PG  - e193-e198
LID - 10.1002/gps.4767 [doi]
AB  - OBJECTIVE: Aspirin exhibits anti-atherosclerotic and anti-inflammatory 
      properties-two potential risk factors for depression. The relationship between 
      aspirin use and depression, however, remains unclear. We investigated whether the 
      aspirin use is associated with a decreased incidence of depressive symptoms in a 
      large North American cohort. METHODS: Data from the Osteoarthritis Initiative 
      dataset, a multicenter, longitudinal study on community-dwelling adults was 
      analyzed. Aspirin use was defined through self-report in the past 30 days and 
      confirmed by a trained interviewer. Incident depressive symptoms were defined as 
      a score of ≥16 in the 20-item Center for Epidemiologic Studies-Depression scale. 
      RESULTS: A total of 137 participants (mean age 65 y, 55.5% female) were using 
      aspirin at baseline. Compared with 4003 participants not taking aspirin, no 
      differences in Center for Epidemiologic Studies-Depression at baseline were 
      evident (P = .65). After a median follow-up time of 8 years, the incidence of 
      depressive symptoms was similar in those taking aspirin at baseline (43; 95% CI, 
      3-60) and in aspirin nonusers (38; 95% CI, 36-41) per 1000 y; log-rank 
      test = 0.63). Based on Cox's regression analysis adjusted for 11 potential 
      confounders, aspirin use was not significantly associated with the development of 
      depressive symptoms (hazard ratio = 1.12; 95% CI, 0.78-1.62; P = .54). Adjustment 
      for propensity scores or the use of propensity score matching did not alter the 
      results. CONCLUSION: Our study found that prescription of aspirin offered no 
      significant protection against incident depressive symptoms. Whether aspirin is 
      beneficial in a subgroup of depression with high levels of inflammation remains 
      to be investigated in future studies.
CI  - Copyright © 2017 John Wiley & Sons, Ltd.
FAU - Veronese, Nicola
AU  - Veronese N
AUID- ORCID: 0000-0002-9328-289X
AD  - National Research Council, Neuroscience Institute, Aging Branch, Padova, Italy.
AD  - Institute for clinical Research and Education in Medicine (IREM), Padova, Italy.
FAU - Koyanagi, Ai
AU  - Koyanagi A
AD  - Research and Development Unit, Parc Sanitari Sant Joan de Déu, Fundació Sant Joan 
      de Déu, Barcelona, Spain.
FAU - Stubbs, Brendon
AU  - Stubbs B
AD  - South London and Maudsley NHS FoundationTrust, London, UK.
AD  - Institute of Psychiatry, Psychology and Neuroscience, King's College London, 
      London, UK.
AD  - Faculty of Health, Social Care and Education, Anglia Ruskin University, 
      Chelmsford, UK.
FAU - Solmi, Marco
AU  - Solmi M
AD  - Institute for clinical Research and Education in Medicine (IREM), Padova, Italy.
AD  - Department of Neurosciences, University of Padova, Padova, Italy.
FAU - Fornaro, Michele
AU  - Fornaro M
AD  - New York Psychiatric Institute, Columbia University, New York, NY, USA.
FAU - Fernandes, Brisa S
AU  - Fernandes BS
AD  - IMPACT Strategic Research Centre, School of Medicine, and Barwon Health, Deakin 
      University, Geelong, Australia.
AD  - Laboratory of Calcium Binding Proteins in the Central Nervous System, Department 
      of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
FAU - Mueller, Christoph
AU  - Mueller C
AD  - Faculty of Education and Health, University of Greenwich, London, UK.
FAU - Thompson, Trevor
AU  - Thompson T
AD  - Faculty of Education and Health, University of Greenwich, London, UK.
FAU - Carvalho, André F
AU  - Carvalho AF
AD  - Translational Psychiatry Research Group, Department of Clinical Medicine, Faculty 
      of Medicine, Federal University of Ceara, Fortaleza, Brazil.
FAU - Maggi, Stefania
AU  - Maggi S
AD  - National Research Council, Neuroscience Institute, Aging Branch, Padova, Italy.
LA  - eng
GR  - N01 AR022261/AR/NIAMS NIH HHS/United States
GR  - ICA-CL-2017-03-001/DH_/Department of Health/United Kingdom
GR  - N01 AR022259/AR/NIAMS NIH HHS/United States
GR  - N01 AR022258/AR/NIAMS NIH HHS/United States
GR  - N01 AR022262/AR/NIAMS NIH HHS/United States
GR  - N01 AR022260/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20170806
PL  - England
TA  - Int J Geriatr Psychiatry
JT  - International journal of geriatric psychiatry
JID - 8710629
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Int J Geriatr Psychiatry. 2018 May;33(5):802. PMID: 29611270
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Depressive Disorder/*epidemiology
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Regression Analysis
PMC - PMC5773347
MID - NIHMS930641
OTO - NOTNLM
OT  - aspirin
OT  - cohort
OT  - depression
OT  - epidemiology
OT  - psychiatry
OT  - survey
COIS- Conflict of interest: none.
EDAT- 2017/08/07 06:00
MHDA- 2019/01/27 06:00
CRDT- 2017/08/08 06:00
PHST- 2017/03/14 00:00 [received]
PHST- 2017/06/12 00:00 [revised]
PHST- 2017/07/04 00:00 [accepted]
PHST- 2017/08/07 06:00 [pubmed]
PHST- 2019/01/27 06:00 [medline]
PHST- 2017/08/08 06:00 [entrez]
AID - 10.1002/gps.4767 [doi]
PST - ppublish
SO  - Int J Geriatr Psychiatry. 2018 Feb;33(2):e193-e198. doi: 10.1002/gps.4767. Epub 
      2017 Aug 6.

PMID- 9737474
OWN - NLM
STAT- MEDLINE
DCOM- 19980928
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 82
IP  - 5B
DP  - 1998 Sep 10
TI  - Clinical potential of antithrombotic drugs in coronary syndromes.
PG  - 11L-14L
AB  - Thrombosis is responsible for most of the acute manifestations of coronary artery 
      disease, including unstable angina and non-Q-wave myocardial infarction. 
      Antithrombotic therapy with antiplatelet agents and anticoagulants plays a major 
      role in decreasing the risk of ischemic events in such patients. As thrombin 
      generation plays a key role in the pathogenesis of thrombosis, recent studies 
      have focused on thrombin inhibition in the management of acute ischemia. Heparin 
      is the most widely used anticoagulant in the acute phase. Heparin given in 
      therapeutic doses intravenously has been shown to be more effective than aspirin 
      in decreasing the risk of death or myocardial infarction in patients with 
      unstable angina. Low-molecular-weight heparin (LMWH) has improved pharmacologic 
      and pharmacokinetic properties over standard heparin and this may provide greater 
      efficacy and safety. LMWH may be given at fixed subcutaneous dose without 
      monitoring and, therefore, is of greater clinical utility and is more 
      cost-effective than standard heparin. Several LMWHs have been evaluated in the 
      management of acute coronary syndromes and have shown equivalent or improved 
      efficacy compared with standard heparin. As heparin in combination with aspirin 
      is now the treatment of choice in acute unstable coronary syndromes, LMWH could 
      potentially improve the outcome in such patients.
FAU - Turpie, A G
AU  - Turpie AG
AD  - MacMaster University, Hamilton Health Sciences Corporation, General Division, 
      Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/*drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Coronary Thrombosis/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Electrocardiography/drug effects
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Heparin/administration & dosage/therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Syndrome
RF  - 11
EDAT- 1998/09/16 00:00
MHDA- 1998/09/16 00:01
CRDT- 1998/09/16 00:00
PHST- 1998/09/16 00:00 [pubmed]
PHST- 1998/09/16 00:01 [medline]
PHST- 1998/09/16 00:00 [entrez]
AID - S0002-9149(98)00106-4 [pii]
AID - 10.1016/s0002-9149(98)00106-4 [doi]
PST - ppublish
SO  - Am J Cardiol. 1998 Sep 10;82(5B):11L-14L. doi: 10.1016/s0002-9149(98)00106-4.

PMID- 2507549
OWN - NLM
STAT- MEDLINE
DCOM- 19891028
LR  - 20190912
IS  - 0273-8481 (Print)
IS  - 0273-8481 (Linking)
VI  - 10
IP  - 4
DP  - 1989 Jul-Aug
TI  - The effects of drugs on the arachidonate cascade in experimentally burned 
      rabbits.
PG  - 314-20
AB  - Platelet reduction and renal dysfunction may occur after major thermal injury and 
      be causally related to changes in the arachidonate cascade. In this article two 
      new drugs, prostaglandin I2 analog OP-41483 (Venopirin) and thromboxane 
      synthetase inhibitor OKY-046 (Cataclot), were tested in addition to aspirin in 
      animal experiments with rabbits. The rabbits were divided into five groups and 
      measurements made before and 8 and 24 hours after burn injury. The results 
      indicate that platelet reduction and renal dysfunction occur within 8 hours after 
      thermal injury in the no-therapy group and renal dysfunction could not be 
      prevented completely even by adequate infusion therapy, but treatment with 
      OP-41483 proved to suppress platelet reduction and improve renal function. 
      Improvement in renal function was also noted in animals treated with aspirin or 
      OKY-046, but platelet reduction could not be prevented by these drugs. Analysis 
      of the time course of changes in thromboxane B2 level and 6-keto prostaglandin F1 
      alpha level disclosed that animals treated by infusion showed an elevation in 
      thromboxane B2 and a significant elevation in the thromboxane B2/6-keto 
      prostaglandin F1 alpha ratio, whereas animals treated with these three drugs 
      showed a reduction in the thromboxane B2/6-keto prostglandin F1 alpha ratio. 
      These results indicate that an effective measure for prevention of dysfunction of 
      the organs after thermal injury is treatment with drugs that can modify the 
      arachidonate cascade and cause an absolute or relative reduction in TXA2.
FAU - Ono, I
AU  - Ono I
AD  - Department of Plastic and Reconstructive Surgery, Hokkaido University School of 
      Medicine, Sapporo, Japan.
FAU - Ohura, T
AU  - Ohura T
FAU - Azami, K
AU  - Azami K
FAU - Ogino, H
AU  - Ogino H
FAU - Sasaki, S
AU  - Sasaki S
FAU - Murazumi, M
AU  - Murazumi M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Burn Care Rehabil
JT  - The Journal of burn care & rehabilitation
JID - 8110188
RN  - 0 (Acrylates)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Methacrylates)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 9001-32-5 (Fibrinogen)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - L256JB984D (ozagrel)
RN  - M41LMG25QB (ataprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Acrylates/*therapeutic use
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/*metabolism
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Urea Nitrogen
MH  - Burns/blood/complications/*drug therapy/metabolism
MH  - Epoprostenol/pharmacology/*therapeutic use
MH  - Fibrinogen/analysis
MH  - Kidney Function Tests
MH  - Methacrylates/pharmacology/*therapeutic use
MH  - Rabbits
MH  - Thrombocytopenia/etiology
MH  - Thromboxane B2/blood
EDAT- 1989/07/01 00:00
MHDA- 1989/07/01 00:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 1989/07/01 00:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
AID - 10.1097/00004630-198907000-00005 [doi]
PST - ppublish
SO  - J Burn Care Rehabil. 1989 Jul-Aug;10(4):314-20. doi: 
      10.1097/00004630-198907000-00005.

PMID- 2492341
OWN - NLM
STAT- MEDLINE
DCOM- 19890303
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 248
IP  - 1
DP  - 1989 Jan
TI  - Differential inhibition by aspirin of platelet thromboxane and renal 
      prostaglandins in the rat.
PG  - 334-41
AB  - Aspirin (ASA) beside inhibiting platelet thromboxane A2 (TxA2) can suppress the 
      formation of renal prostacyclin (PGI2) and prostaglandin E2 (PGE2) which play a 
      crucial role in the control of renal hemodynamics. Previous studies based on 
      urinary PG measurements have suggested that p.o. ASA can spare renal 
      cyclooxygenase. We wanted to establish by direct measurement whether p.o. ASA has 
      a renal sparing effect and to establish to which extent changes in renal 
      cyclooxygenase activity can be predicted measuring urinary excretion of 
      6-keto-PGF1 alpha and PGE2. Our results showed that in normal rats 10 mg/kg of 
      ASA given p.o. partially inhibits platelet TxA2 formation (measured as serum 
      TxB2) and does not inhibit glomerular and medullary PGI2 and PGE2 synthesis. 
      Higher doses of ASA (30-200 mg/kg) effectively and completely inhibit platelet 
      TxA2 independently if given p.o. or i.v., and also inhibit glomerular and 
      medullary PG synthesis. The kinetics of the effect of ASA on platelet vs. renal 
      cyclooxygenase is different: the inhibition being irreversible in platelets, but 
      rapidly reversible in glomeruli and medulla. Six hours after the administration 
      of 10 and 30 mg/kg i.v. and 30 mg/kg p.o., kidney cyclooxygenase activity 
      recovers completely. This transient inhibition of renal cyclooxygenase is not 
      reflected by urinary excretion of 6-keto-PGF1 alpha and PGE2 (6- and 24-hr 
      collection periods). In conclusion our present results indicate that doses of ASA 
      enough to inhibit platelet TxA2, transiently inhibit glomerular and medullary 
      PGI2 and PGE2. Although the inhibitory effect on platelets is long lasting, the 
      effect on renal cyclooxygenase is transient and rapidly reversible.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Livio, M
AU  - Livio M
AD  - Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
FAU - Benigni, A
AU  - Benigni A
FAU - Zoja, C
AU  - Zoja C
FAU - Begnis, R
AU  - Begnis R
FAU - Morelli, C
AU  - Morelli C
FAU - Rossini, M
AU  - Rossini M
FAU - Garattini, S
AU  - Garattini S
FAU - Remuzzi, G
AU  - Remuzzi G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/*urine
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/analysis/*drug effects
MH  - Cyclooxygenase Inhibitors
MH  - Dinoprostone/*urine
MH  - Injections, Intravenous
MH  - Kidney/analysis/*drug effects
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Thromboxane B2/biosynthesis/*blood
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1989 Jan;248(1):334-41.

PMID- 8275764
OWN - NLM
STAT- MEDLINE
DCOM- 19940210
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 105
IP  - 1
DP  - 1994 Jan
TI  - Lethal pulmonary embolism in a patient with primary antiphospholipid syndrome and 
      a vena caval filter.
PG  - 312-3
AB  - A 61-year old Hispanic woman with a history of primary antiphospholipid syndrome 
      with pulmonary emboli and who was status post a vena caval filter placement to 
      prevent recurrent pulmonary emboli, presented with acute onset of right upper 
      quadrant abdominal pain. Acute cholecystitis was diagnosed and she underwent a 
      surgically uncomplicated cholecystectomy. The postoperative course was 
      complicated by new, massive pulmonary emboli despite prophylactic treatment with 
      aspirin and low-dose heparin. Patient died en route to surgery for emergency 
      embolectomy. This case suggests that a regimen of low-dose heparin and aspirin 
      therapy in patients with primary antiphospholipid syndrome and a previously 
      placed vena caval filter is not effective in preventing postoperative 
      thromboembolic complications; more aggressive anticoagulation therapy is 
      required.
FAU - Lee, H C
AU  - Lee HC
AD  - Department of Internal Medicine, Creighton University School of Medicine, Omaha, 
      Neb.
FAU - Laya, M B
AU  - Laya MB
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antiphospholipid Syndrome/*complications
MH  - Aspirin/therapeutic use
MH  - Cholecystectomy/adverse effects
MH  - Fatal Outcome
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Pulmonary Embolism/*etiology/prevention & control
MH  - *Vena Cava Filters
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - S0012-3692(15)43879-6 [pii]
AID - 10.1378/chest.105.1.312 [doi]
PST - ppublish
SO  - Chest. 1994 Jan;105(1):312-3. doi: 10.1378/chest.105.1.312.

PMID- 28799949
OWN - NLM
STAT- MEDLINE
DCOM- 20171025
LR  - 20200306
IS  - 1530-0293 (Electronic)
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 45
IP  - 11
DP  - 2017 Nov
TI  - Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: 
      An Individual Patient Data Meta-Analysis Using Propensity Matching.
PG  - 1871-1879
LID - 10.1097/CCM.0000000000002654 [doi]
AB  - OBJECTIVE: The primary objective was to conduct a meta-analysis on published 
      observational cohort data describing the association between acetyl-salicylic 
      acid (aspirin) use prior to the onset of sepsis and mortality in hospitalized 
      patients. STUDY SELECTION: Studies that reported mortality in patients on aspirin 
      with sepsis with a comparison group of patients with sepsis not on prior aspirin 
      therapy were included. DATA SOURCES: Fifteen studies described hospital-based 
      cohorts (n = 17,065), whereas one was a large insurance-based database (n = 
      683,421). Individual-level patient data were incorporated from all selected 
      studies. DATA EXTRACTION: Propensity analyses with 1:1 propensity score matching 
      at the study level were performed, using the most consistently available 
      covariates judged to be associated with aspirin. Meta-analyses were performed to 
      estimate the pooled average treatment effect of aspirin on sepsis-related 
      mortality. DATA SYNTHESIS: Use of aspirin was associated with a 7% (95% CI, 
      2-12%; p = 0.005) reduction in the risk of death as shown by meta-analysis with 
      considerable statistical heterogeneity (I = 61.6%). CONCLUSIONS: These results 
      are consistent with effects ranging from a 2% to 12% reduction in mortality risk 
      in patients taking aspirin prior to sepsis onset. This association anticipates 
      results of definitive studies of the use of low-dose aspirin as a strategy for 
      reduction of deaths in patients with sepsis.
FAU - Trauer, James
AU  - Trauer J
AD  - 1School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Victoria, Australia. 2Victorian Infectious Diseases Service, The Doherty 
      Institute, Melbourne, Victoria, Australia. 3Australian Institute of Tropical 
      Medicine and Hygiene, James Cook University, Douglas, Queensland, Australia. 
      4Pharmaceutical Care Department, College of Pharmacy, King Saud bin Abdulaziz 
      University for Health Sciences, King Abdulaziz Medical City, Riyadh, Saudi 
      Arabia. 5Intensive Care Department, College of Medicine, King Saud bin Abdulaziz 
      University for Health Sciences, King Abdullah International Medical Research 
      Center, Riyadh, Saudi Arabia. 6Regional Intensive Care Unit, Royal Victoria 
      Hospital, Belfast, Northern Ireland. 7Multidisciplinary Epidemiology and 
      Translational Research in Intensive Care, Mayo Clinic, Rochester, MN. 8Division 
      of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN. 9Division of 
      Pulmonary and Critical Medicine, Chiayi Christian Hospital, Chiayi, Taiwan. 
      10Department of Nephrology, Taipei City Hospital Heping Fuyou Branch, Taipei, 
      Taiwan, Republic of China. 11Department of Public Health and Infectious Diseases, 
      "Sapienza" University of Rome, Rome, Italy. 12Division of Critical Care Medicine, 
      Department of Medicine, Montefiore Medical Center, Bronx, NY. 13Department of 
      Medicine, Albert Einstein College of Medicine, Bronx, NY. 14Department of 
      Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, 
      NY. 15Department of Anesthesiology, Division of Critical Care Medicine, Mayo 
      Clinic, Rochester, MN. 16Center for Sepsis Control and Care, Jena University 
      Hospital, Jena, Germany. 17Centre for Experimental Medicine, School of Medicine, 
      Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern 
      Ireland. 18Louisiana State University Health Sciences Center, Department of 
      Medicine, Section of Pulmonary and Critical Care Medicine, Baton Rouge, LA. 
      19Division of Infectious Diseases and Hospital Epidemiology, Department of 
      Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland. 
      20Clinic for Anaesthesiology and Intensive Care Medicine, University Hospital 
      Jena, Jena, Germany. 21Department of Internal Medicine, Taipei Veterans General 
      Hospital, Taiwan, Republic of China. 22Department of Internal Medicine, Division 
      of Critical Care Medicine, San Rafael Hospital, Alajuela, Costa Rica. 23Center 
      for Experimental and Molecular Medicine, Academic Medical Center, University of 
      Amsterdam, Amsterdam, The Netherlands. 24Division of Infectious Diseases, 
      Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 
      25Department of Internal Medicine and Medical Specialties, Policlinico Umberto I, 
      "Sapienza" University of Rome, Rome, Italy. 26Division of Allergy, Pulmonary, and 
      Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN. 
      27The Center for Infection and Immunity, Academic Medical Center, University of 
      Amsterdam, Amsterdam, The Netherlands. 28College of Medicine and Dentistry, James 
      Cook University, Townsville, Queensland, Australia. 29Infectious Diseases Unit, 
      The Townsville Hospital, Douglas, Queensland, Australia.
FAU - Muhi, Stephen
AU  - Muhi S
FAU - McBryde, Emma S
AU  - McBryde ES
FAU - Al Harbi, Shmeylan A
AU  - Al Harbi SA
FAU - Arabi, Yaseen M
AU  - Arabi YM
FAU - Boyle, Andrew J
AU  - Boyle AJ
FAU - Cartin-Ceba, Rodrigo
AU  - Cartin-Ceba R
FAU - Chen, Wei
AU  - Chen W
FAU - Chen, Yung-Tai
AU  - Chen YT
FAU - Falcone, Marco
AU  - Falcone M
FAU - Gajic, Ognjen
AU  - Gajic O
FAU - Godsell, Jack
AU  - Godsell J
FAU - Gong, Michelle Ng
AU  - Gong MN
FAU - Kor, Daryl
AU  - Kor D
FAU - Lösche, Wolfgang
AU  - Lösche W
FAU - McAuley, Daniel F
AU  - McAuley DF
FAU - O'Neal, Hollis R Jr
AU  - O'Neal HR Jr
FAU - Osthoff, Michael
AU  - Osthoff M
FAU - Otto, Gordon P
AU  - Otto GP
FAU - Sossdorf, Maik
AU  - Sossdorf M
FAU - Tsai, Min-Juei
AU  - Tsai MJ
FAU - Valerio-Rojas, Juan C
AU  - Valerio-Rojas JC
FAU - van der Poll, Tom
AU  - van der Poll T
FAU - Violi, Francesco
AU  - Violi F
FAU - Ware, Lorraine
AU  - Ware L
FAU - Widmer, Andreas F
AU  - Widmer AF
FAU - Wiewel, Maryse A
AU  - Wiewel MA
FAU - Winning, Johannes
AU  - Winning J
FAU - Eisen, Damon P
AU  - Eisen DP
LA  - eng
GR  - K23 HL067197/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Crit Care Med. 2017 Nov;45(11):1959-1960. PMID: 29028704
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Observational Studies as Topic
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Propensity Score
MH  - Sepsis/*mortality
PMC - PMC5640482
MID - NIHMS891439
EDAT- 2017/08/12 06:00
MHDA- 2017/10/27 06:00
CRDT- 2017/08/12 06:00
PHST- 2017/08/12 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
PHST- 2017/08/12 06:00 [entrez]
AID - 10.1097/CCM.0000000000002654 [doi]
PST - ppublish
SO  - Crit Care Med. 2017 Nov;45(11):1871-1879. doi: 10.1097/CCM.0000000000002654.

PMID- 16032431
OWN - NLM
STAT- MEDLINE
DCOM- 20060213
LR  - 20131121
IS  - 0344-5704 (Print)
IS  - 0344-5704 (Linking)
VI  - 57
IP  - 3
DP  - 2006 Feb
TI  - Phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs (NSAIDs) 
      inhibit DNA synthesis and the growth of colon cancer cells in vitro.
PG  - 295-300
AB  - The use of NSAIDs or COX-2 inhibitors for chemoprevention of colorectal cancer 
      has been suggested for patients at high risk for this disease. However, the 
      gastrointestinal side effects of traditional NSAIDs which consist of bleeding and 
      ulceration, and the cardiovascular effects of COX-2 inhibitors may limit their 
      usefulness. In preclinical studies, our laboratory has shown that the addition of 
      phosphatidylcholine (PC) to the NSAIDs aspirin (ASA) or ibuprofen (IBU) results 
      in a NSAID-PC with fewer GI side effects and also maintained or enhanced 
      analgesic, anti-pyretic and anti-inflammatory efficacy over the unmodified NSAID. 
      Because NSAID-PCs have not been tested for anti-cancer activity, in the present 
      study, ASA-PC and IBU-PC were tested on the SW-480 human colon cancer cell line. 
      SW-480 cells were incubated in media containing 1-5 mM NSAID or NSAID-PC for 2 
      days. Measurements were made of cell number, cell proliferation (DNA synthesis), 
      and manner of cell death (necrosis and apoptosis). ASA and IBU reduced cell 
      number in a dose-dependent manner with IBU showing a greater potency than ASA. 
      The association of PC to the NSAID resulted in greater reductions of cell number 
      for both NSAIDs. Furthermore, the NSAID-PC formulation had significantly greater 
      efficacy and potency to inhibit cellular DNA synthesis than the unmodified NSAID. 
      PC alone at the doses and times used had no effect on cell number in this cell 
      line, but did have a small effect to reduce DNA synthesis. None of the drugs had 
      a clear effect on cell death by necrosis. Only IBU and IBU-PC caused cell death 
      by apoptosis in SW-480 cells. We conclude that NSAID-PCs have activity to impede 
      the growth of colon cancer cells in vitro, which is due, in major part, to a 
      marked reduction in DNA synthetic activity of these cells. This growth inhibitory 
      effect appears to be independent of COX-2 activity, since it is known that SW-480 
      cells do not have this inducible COX isoform. Due to its greater efficacy in this 
      model system, IBU-PC should be further evaluated as a chemopreventive agent that 
      is safer for the GI tract than unmodified NSAID.
FAU - Dial, Elizabeth J
AU  - Dial EJ
AD  - Department of Integrative Biology and Pharmacology, The University of Texas 
      Medical School, Houston, 77030, USA. elizabeth.j.dial@uth.tmc.edu
FAU - Doyen, J Rand
AU  - Doyen JR
FAU - Lichtenberger, Lenard M
AU  - Lichtenberger LM
LA  - eng
GR  - DK56338/DK/NIDDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20050720
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Nucleic Acid Synthesis Inhibitors)
RN  - 0 (Phosphatidylcholines)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Aspirin/chemistry/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Colonic Neoplasms/metabolism/pathology
MH  - DNA, Neoplasm/*biosynthesis
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Ibuprofen/chemistry/pharmacology
MH  - Necrosis/chemically induced
MH  - Nucleic Acid Synthesis Inhibitors/pharmacology
MH  - Phosphatidylcholines/chemistry/*pharmacology
EDAT- 2005/07/21 09:00
MHDA- 2006/02/14 09:00
CRDT- 2005/07/21 09:00
PHST- 2005/01/18 00:00 [received]
PHST- 2005/05/15 00:00 [accepted]
PHST- 2005/07/21 09:00 [pubmed]
PHST- 2006/02/14 09:00 [medline]
PHST- 2005/07/21 09:00 [entrez]
AID - 10.1007/s00280-005-0048-x [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2006 Feb;57(3):295-300. doi: 
      10.1007/s00280-005-0048-x. Epub 2005 Jul 20.

PMID- 8094168
OWN - NLM
STAT- MEDLINE
DCOM- 19930311
LR  - 20170920
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 341
IP  - 8842
DP  - 1993 Feb 13
TI  - Low-dose aspirin in prevention and treatment of intrauterine growth retardation 
      and pregnancy-induced hypertension. Italian study of aspirin in pregnancy.
PG  - 396-400
AB  - Meta-analysis of data from several controlled trials has shown that low-dose 
      aspirin reduces the risk of pregnancy-induced hypertension (PIH) and intrauterine 
      growth retardation (IUGR) in women at high risk of these disorders. We have 
      assessed the efficacy of low-dose aspirin in women judged to be at moderate risk. 
      Women were included on prophylactic criteria--age under 18 or over 40 years, mild 
      or moderate chronic hypertension (diastolic pressure between 90 and 110 mm Hg), 
      nephropathy with normal renal function and blood pressure, history of PIH or 
      IUGR, and twin pregnancy--or therapeutic criteria--PIH or early signs of IUGR in 
      current pregnancy. Eligible women were randomly assigned treatment with 50 mg 
      aspirin daily until delivery (583) or no treatment (523); 18 and 46 women, 
      respectively, were lost to follow-up. The groups were well matched for baseline 
      characteristics. We found no differences between the no-treatment and aspirin 
      groups in numbers of spontaneous (5 vs 2) or therapeutic (1 vs 2) abortions, 
      stillbirths (14 vs 13), perinatal mortality (35.7 vs 28.6 per 1000 births), mean 
      birthweight (2858 [SD 729] vs 2874 [795] g), proportion of infants with 
      birthweights below the 10th centile (95 [18.3%] vs 117 [19.0%]), or births before 
      37 weeks' gestation (184 [35.6%] vs 209 [33.9%]). Nor did the groups differ in 
      the frequency of PIH with or without proteinuria (51 [15.2%] vs 81 [19.3%]). 
      There was no difference in mean birthweight between the treatment groups in 
      separate analyses according to criteria for trial entry and week of gestation at 
      randomisation. Our study gives little support to the notion that low-dose aspirin 
      is beneficial in women at moderate risk of PIH or IUGR.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 1993 Feb 13;341(8842):412. PMID: 8094178
CIN - Lancet. 1993 Mar 20;341(8847):753. PMID: 8095642
CIN - Lancet. 1993 Mar 20;341(8847):753. PMID: 8095643
CIN - Lancet. 1993 Mar 20;341(8847):753-4. PMID: 8095644
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Birth Weight
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Risk Factors
EDAT- 1993/02/13 00:00
MHDA- 1993/02/13 00:01
CRDT- 1993/02/13 00:00
PHST- 1993/02/13 00:00 [pubmed]
PHST- 1993/02/13 00:01 [medline]
PHST- 1993/02/13 00:00 [entrez]
AID - 0140-6736(93)92988-6 [pii]
PST - ppublish
SO  - Lancet. 1993 Feb 13;341(8842):396-400.

PMID- 20040278
OWN - NLM
STAT- MEDLINE
DCOM- 20100519
LR  - 20181201
IS  - 1944-7930 (Electronic)
IS  - 1539-6509 (Linking)
VI  - 8
IP  - 43
DP  - 2009 Dec
TI  - Frontiers in platelet inhibition.
PG  - 242-6
AB  - Anti-platelet drugs play a key role in cardiovascular medicine since the 
      introduction of aspirin as an anti-thrombotic agent some 50 years ago. After many 
      years of a "monopoly" of aspirin, ADP receptor P2Y12 inhibitors were introduced 
      with a significant improvement in clinical outcome. Nowadays dual anti-platelet 
      therapy is the common practice for both acute events and secondary prevention in 
      selected groups of patients. The improved efficacy of multiple drug therapy is 
      associated with an increased risk of bleeding, which raises the issue of the 
      dosing of these drugs. Recently, numerous studies have reported a variable 
      laboratory response to aspirin and clopidogrel, which correlates with clinical 
      outcome. Several mechanisms for causing this variable response have been 
      proposed, including genetic variability, disease burden, and others. A major 
      obstacle in this field is the lack of a standardized method for testing these 
      responses. New drugs are currently under different stages of development, 
      including new P2Y12 receptors inhibitors, thrombaxane receptor blockers, direct 
      thrombin inhibitors, and inhibitors for other signaling pathways including oral 
      GPIIbIIIa inhibitors. Thus anti-platelet therapy is currently under intensive 
      developments toward multiple drug therapy and personal dose adjustment, which may 
      improve clinical outcome.
FAU - Varon, David
AU  - Varon D
AD  - Coagulation Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 
      dvaron@hadassah.org.il
FAU - Shai, Elai
AU  - Shai E
FAU - Spectre, Galia
AU  - Spectre G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Discov Med
JT  - Discovery medicine
JID - 101250006
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Receptors, Purinergic P2)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/drug therapy
MH  - Clopidogrel
MH  - Humans
MH  - Models, Biological
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Receptors, Purinergic P2/therapeutic use
MH  - Ticlopidine/analogs & derivatives/therapeutic use
EDAT- 2009/12/31 06:00
MHDA- 2010/05/21 06:00
CRDT- 2009/12/31 06:00
PHST- 2009/12/31 06:00 [entrez]
PHST- 2009/12/31 06:00 [pubmed]
PHST- 2010/05/21 06:00 [medline]
PST - ppublish
SO  - Discov Med. 2009 Dec;8(43):242-6.

PMID- 25091820
OWN - NLM
STAT- MEDLINE
DCOM- 20150611
LR  - 20220311
IS  - 1875-614X (Electronic)
IS  - 1871-5230 (Linking)
VI  - 13
IP  - 2
DP  - 2014
TI  - Augmentation of citalopram with aspirin for treating major depressive disorder, a 
      double blind randomized placebo controlled clinical trial.
PG  - 108-11
AB  - There are contradictory reports about the association of cytokines levels and 
      major depressive disorder and the possible therapeutic role of aspirin for 
      treating major depressive disorder (MDD). A clinical sample of adult out-patients 
      with MDD was recruited. At recruitment, they were interviewed face to face 
      according to DSM-IV diagnostic criteria. In addition, Hamilton depression rating 
      scale was completed by a psychiatrist. The patients were invited to receive 
      aspirin or placebo. All the 10 patients received 160mg/day aspirin plus 
      citlaopram 20 mg/day. Eight out of ten patients showed severe anxiety and 
      akathesia from early days of this trial. Except for two patients, we discontinued 
      the medication during 14 days of this trial. Three patients were hospitalized due 
      to anxiety and akathesia. Two patients reported suicidal behavior after the onset 
      of this trial. This trial of aspirin adjuvant therapy for treating MDD suggests 
      that this combination is not safe and there are some serious and intolerable 
      adverse effects. This finding is in contrast to the suggestions assuming that 
      aspirin may be effective for treating MDD. Aspirin may negatively impact on both 
      pro- and anti-inflammatory cytokines balance in depression. Aspirin may 
      antagonize the antidepressant effect of citalopram.
FAU - Ghanizadeh, Ahmad
AU  - Ghanizadeh A
FAU - Hedayati, Arvin
AU  - Hedayati A
AD  - Research Center for Psychiatry and Behavioral Sciences, Department of Psychiatry, 
      Hafez Hospital, Shiraz, Iran. ghanizad@sina.tums.ac.ir.
LA  - eng
SI  - IRCT/IRCT201306203930N27
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Antiinflamm Antiallergy Agents Med Chem
JT  - Anti-inflammatory & anti-allergy agents in medicinal chemistry
JID - 101462262
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0DHU5B8D6V (Citalopram)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Antidepressive Agents/*therapeutic use
MH  - Antidepressive Agents, Second-Generation/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Citalopram/*therapeutic use
MH  - Combined Modality Therapy
MH  - Depressive Disorder, Major/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outpatients
EDAT- 2014/08/06 06:00
MHDA- 2015/06/13 06:00
CRDT- 2014/08/06 06:00
PHST- 2014/04/09 00:00 [received]
PHST- 2014/07/24 00:00 [revised]
PHST- 2014/07/24 00:00 [accepted]
PHST- 2014/08/06 06:00 [entrez]
PHST- 2014/08/06 06:00 [pubmed]
PHST- 2015/06/13 06:00 [medline]
AID - AIAAMC-EPUB-61601 [pii]
AID - 10.2174/1871523013666140804225608 [doi]
PST - ppublish
SO  - Antiinflamm Antiallergy Agents Med Chem. 2014;13(2):108-11. doi: 
      10.2174/1871523013666140804225608.

PMID- 14641799
OWN - NLM
STAT- MEDLINE
DCOM- 20040113
LR  - 20210105
IS  - 0954-6820 (Print)
IS  - 0954-6820 (Linking)
VI  - 254
IP  - 6
DP  - 2003 Dec
TI  - Aspirin in the prevention of progressing stroke: a randomized controlled study.
PG  - 584-90
AB  - OBJECTIVES: In acute stroke, progression has a severe impact on patient outcome 
      and no effective treatment is known. The main objective was to evaluate the 
      efficacy of aspirin for prevention of stroke progression thereby improving 
      outcome. DESIGN: The trial was randomized, double-blind and placebo-controlled. 
      SETTING: The patients were treated in stroke units of four hospitals in Sweden. 
      SUBJECTS: Patients with ischaemic stroke but not complete paresis were included. 
      No antiplatelet drugs were allowed within the last 72 h before onset. Delay until 
      first trial dosage was maximized to 48 h. The trial was designed to detect a 20% 
      reduction of the rate of stroke progression, which was estimated to take place in 
      20% of cases. Totally, 441 patients (220 aspirin, 221 placebo) completed the 
      trial. Baseline comparisons between the groups showed no differences. 
      INTERVENTIONS: Aspirin (325 mg) or placebo was given once daily for five 
      consecutive days. MAIN OUTCOME MEASURES: Neurological assessments were carried 
      out three times daily during the treatment period to detect progression of at 
      least two points in the Scandinavian Stroke Supervision Scale. Patient outcome 
      was followed up at discharge and at 3 months. RESULTS: Aspirin treatment did not 
      significantly reduce the frequency of stroke progression. Amongst aspirin-treated 
      patients, stroke progression occurred in 15.9% as compared with 16.7% in the 
      placebo group, which is less frequent than expected. The relative risk was 0.95 
      (95% CI 0.62-1.45) in the treatment group. As regards patient outcome at 
      discharge and after 3 months, aspirin treatment did not show any difference. 
      CONCLUSION: No positive effect of aspirin, of the expected size, could be shown 
      on the frequency of stroke progression or patient outcome.
FAU - Rödén-Jüllig, A
AU  - Rödén-Jüllig A
AD  - Division of Internal Medicine, Karolinska Institutet, Danderyd Hospital, 
      Karolinska Institutet, Stockholm, Sweden. asa.roden@previa.se
FAU - Britton, M
AU  - Britton M
FAU - Malmkvist, K
AU  - Malmkvist K
FAU - Leijd, B
AU  - Leijd B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Disease Progression
MH  - Double-Blind Method
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Severity of Illness Index
MH  - Stroke/*drug therapy/pathology
MH  - Treatment Outcome
EDAT- 2003/12/04 05:00
MHDA- 2004/01/14 05:00
CRDT- 2003/12/04 05:00
PHST- 2003/12/04 05:00 [pubmed]
PHST- 2004/01/14 05:00 [medline]
PHST- 2003/12/04 05:00 [entrez]
AID - 1233 [pii]
AID - 10.1111/j.1365-2796.2003.01233.x [doi]
PST - ppublish
SO  - J Intern Med. 2003 Dec;254(6):584-90. doi: 10.1111/j.1365-2796.2003.01233.x.

PMID- 7200787
OWN - NLM
STAT- MEDLINE
DCOM- 19820708
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 32
IP  - 3
DP  - 1982
TI  - [Comparative pharmacokinetics and relative bioavailability of the active 
      principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine 
      tartrate in a combination product].
PG  - 289-93
AB  - Following application of Silentan coated tablets (a combination of 
      acetylsalicylic acid, caffeine, diazepam and dihydroergotamine (DHE) tartrate) in 
      six healthy male volunteers serum concentrations were determined. The estimated 
      relative bioavailabilities of these substances in the commercially available drug 
      were compared to the encapsulated single substances. For acetylsalicylic acid and 
      caffeine there were nearly no differences to be observed. Significant differences 
      of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and 
      Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated 
      preparations.
FAU - Degen, J
AU  - Degen J
FAU - Maier-Lenz, H
AU  - Maier-Lenz H
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Vergleichende Pharmakokinetik und relative Bioverfügbarkeit der Wirkstoffe 
      Diazepam, Acetylsalicylsäure, Coffein und Dihydroergotamin-tartrat in einem 
      Kombinationspräparat.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Drug Combinations)
RN  - 3G6A5W338E (Caffeine)
RN  - 436O5HM03C (Dihydroergotamine)
RN  - 79084-81-4 (Silentan)
RN  - Q3JTX2Q7TU (Diazepam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*metabolism
MH  - Biological Availability
MH  - Caffeine/*metabolism
MH  - Diazepam/*metabolism
MH  - Dihydroergotamine/*metabolism
MH  - Drug Combinations
MH  - Humans
MH  - Kinetics
MH  - Male
EDAT- 1982/01/01 00:00
MHDA- 1982/01/01 00:01
CRDT- 1982/01/01 00:00
PHST- 1982/01/01 00:00 [pubmed]
PHST- 1982/01/01 00:01 [medline]
PHST- 1982/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1982;32(3):289-93.

PMID- 7716824
OWN - NLM
STAT- MEDLINE
DCOM- 19950517
LR  - 20190515
IS  - 0300-9734 (Print)
IS  - 0300-9734 (Linking)
VI  - 99
IP  - 2
DP  - 1994
TI  - Antiaggregative therapy with acetylsalicylic acid and diclofenac in patients with 
      acute myocardial infarction.
PG  - 131-8
AB  - A total of 109 male patients with acute transmural myocardial infarction (MI) 
      were studied. 26 patients received a dose of acetylsalicylic acid (aspirin, ASA) 
      500 mg/d and 29 patients of 50 mg/d. 27 patients were given diclofenac (25 mg/d). 
      27 patients received no antiplatelet therapy. We observed thrombocyte 
      hyperaggregation on the 1st MI day, a rapid increase in platelet activity by the 
      7th day and a considerable decrease in platelet aggregation during the 3rd and 
      4th weeks of illness in the group without antiaggregative treatment. The present 
      study clearly demonstrated high antiaggregatory efficacy of ASA in dose of 50 
      mg/d which was significantly higher than that in daily dose of 500 mg ASA. 
      Low-dose aspirin had fewer side-effects than aspirin 500 mg/d. However, although 
      daily dose of 50 mg aspirin significantly inhibited platelet hyperaggregation on 
      7th day of MI, the hyperactivity of thrombocytes was not abolished. Diclofenac 25 
      mg daily had only a moderate antiaggregative efficacy in acute MI patients.
FAU - Viigimaa, M
AU  - Viigimaa M
AD  - Department of Cardiology, University Hospital, Tartu, Estonia.
FAU - Jôudu, T
AU  - Jôudu T
FAU - Hendrikson, E
AU  - Hendrikson E
FAU - Shandrik, Y
AU  - Shandrik Y
FAU - Teesalu, R
AU  - Teesalu R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Sweden
TA  - Ups J Med Sci
JT  - Upsala journal of medical sciences
JID - 0332203
RN  - 144O8QL0L1 (Diclofenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Diclofenac/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/blood/*drug therapy
MH  - Platelet Aggregation/*drug effects
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/03009739409179356 [doi]
PST - ppublish
SO  - Ups J Med Sci. 1994;99(2):131-8. doi: 10.3109/03009739409179356.

PMID- 6464745
OWN - NLM
STAT- MEDLINE
DCOM- 19840911
LR  - 20190821
IS  - 0001-656X (Print)
IS  - 0001-656X (Linking)
VI  - 73
IP  - 4
DP  - 1984 Jul
TI  - Simulated Reye's syndrome and salicylate therapy.
PG  - 562-4
AB  - A 4-year-old girl with juvenile rheumatoid arthritis developed fever, protracted 
      vomiting, disturbance of consciousness and decorticate posture following the 
      administration of salicylate. There were elevated levels of transaminases in 
      serum, hyperammonemia and a fatty liver. However, the fatty droplets were 
      different electronmicroscopically from that of Reye's syndrome. This observation 
      emphasizes the importance of electronmicroscopic observation of the liver in the 
      differential diagnosis between Reye's syndrome and aspirin-induced 
      encephalopathy, because the clinico-pathological findings of intoxication are so 
      similar.
FAU - Yoshida, I
AU  - Yoshida I
FAU - Yamashita, F
AU  - Yamashita F
FAU - Okada, S
AU  - Okada S
FAU - Horikoshi, T
AU  - Horikoshi T
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Sweden
TA  - Acta Paediatr Scand
JT  - Acta paediatrica Scandinavica
JID - 0000211
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Juvenile/drug therapy
MH  - Aspirin/*adverse effects
MH  - Child, Preschool
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Liver/*ultrastructure
MH  - Microscopy, Electron
MH  - Reye Syndrome/*pathology
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
AID - 10.1111/j.1651-2227.1984.tb09973.x [doi]
PST - ppublish
SO  - Acta Paediatr Scand. 1984 Jul;73(4):562-4. doi: 
      10.1111/j.1651-2227.1984.tb09973.x.

PMID- 3286527
OWN - NLM
STAT- MEDLINE
DCOM- 19880708
LR  - 20171206
IS  - 0391-3988 (Print)
IS  - 0391-3988 (Linking)
VI  - 11
IP  - 2
DP  - 1988 Mar
TI  - Thrombotic microangiopathy of the miscellaneous secondary type responding to 
      plasma exchange in a liver transplant recipient.
PG  - 131-3
AB  - A thrombotic microangiopathy syndrome, clinically and pathologically similar to 
      thrombotic thrombocytopenic purpura (TTP) has been reported in recipients of 
      tissue transplants, including renal and bone marrow allografts. The diagnosis is 
      made only after other causes of microangiopathic hemolytic anemia have been 
      excluded. In this case report we present the outcome of the combination of plasma 
      exchange, dipyridamole and aspirin in the management of a TTP-like syndrome that 
      complicated the post-operative course of liver transplantation.
FAU - Valbonesi, M
AU  - Valbonesi M
AD  - Immunohematology Services, San Martino University Hospital, Genova, Italy.
FAU - Valente, U
AU  - Valente U
FAU - Pellicci, R
AU  - Pellicci R
FAU - Piri, C
AU  - Piri C
FAU - Ferrari, M
AU  - Ferrari M
FAU - Frisoni, R
AU  - Frisoni R
FAU - Zia, S
AU  - Zia S
FAU - Quaratino, S
AU  - Quaratino S
FAU - Fella, M
AU  - Fella M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Int J Artif Organs
JT  - The International journal of artificial organs
JID - 7802649
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - *Liver Transplantation
MH  - Male
MH  - Middle Aged
MH  - *Plasma Exchange
MH  - Postoperative Complications/*therapy
MH  - Purpura, Thrombotic Thrombocytopenic/*etiology/therapy
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
PST - ppublish
SO  - Int J Artif Organs. 1988 Mar;11(2):131-3.

PMID- 5473609
OWN - NLM
STAT- MEDLINE
DCOM- 19701210
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 11
IP  - 9
DP  - 1970 Sep
TI  - Personality pattern and emotional stress in the genesis of gastric ulcer.
PG  - 773-7
AB  - In a group of 181 persons with a past history of chronic gastric ulcer, a greatly 
      increased incidence of domestic and financial stress has been found, when 
      compared with age-and sex-matched persons with no previous history of gastric 
      ulcer. The consumption of aspirin, alcohol, and cigarettes was also significantly 
      increased. Persons with chronic gastric ulcer were characterized by a personality 
      pattern of independence and self sufficiency, and they are prone to anxiety and 
      depression. This pattern was three times as common as in matched individuals 
      without chronic gastric ulcer. It is possible that internal conflict between a 
      genetic and an environmentally induced sex role, together with an inability to 
      externalize aggression, may be significant factors in the causation of chronic 
      gastric ulcer.
FAU - Alp, M H
AU  - Alp MH
FAU - Court, J H
AU  - Court JH
FAU - Grant, A K
AU  - Grant AK
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aggression
MH  - Alcohol Drinking
MH  - Anxiety/complications
MH  - Aspirin/adverse effects
MH  - Female
MH  - Humans
MH  - Life Style
MH  - Male
MH  - *Personality
MH  - Personality Inventory
MH  - Smoking/complications
MH  - Social Dominance
MH  - Stomach Ulcer/*etiology
MH  - Stress, Psychological/*complications
PMC - PMC1553105
EDAT- 1970/09/01 00:00
MHDA- 1970/09/01 00:01
CRDT- 1970/09/01 00:00
PHST- 1970/09/01 00:00 [pubmed]
PHST- 1970/09/01 00:01 [medline]
PHST- 1970/09/01 00:00 [entrez]
AID - 10.1136/gut.11.9.773 [doi]
PST - ppublish
SO  - Gut. 1970 Sep;11(9):773-7. doi: 10.1136/gut.11.9.773.

PMID- 24605613
OWN - NLM
STAT- MEDLINE
DCOM- 20140328
LR  - 20181202
IS  - 1019-5297 (Print)
IS  - 1019-5297 (Linking)
IP  - 2
DP  - 2013 Mar
TI  - [The effect of clopidogrel and aspigrel on myocardial ischemia in patients with 
      unstable angina pectoris].
PG  - 67-9
AB  - The modern cardiology pays much attention to research of myocardial ischemia, 
      especially painless myocardial ischemia as the problem of sudden coronary death. 
      Findings from the current study suggest that antianginal therapy which includes 
      antiaggregant and anticoagulant is effective because of decreasing general 
      myocardial ischemia and its painless form.
FAU - Zaval's'ka, T V
AU  - Zaval's'ka TV
LA  - ukr
PT  - Clinical Trial
PT  - Journal Article
PL  - Ukraine
TA  - Lik Sprava
JT  - Likars'ka sprava
JID - 9601540
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina, Unstable/complications/*drug therapy
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Ischemia/complications/*drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2014/03/13 06:00
MHDA- 2014/03/29 06:00
CRDT- 2014/03/11 06:00
PHST- 2014/03/11 06:00 [entrez]
PHST- 2014/03/13 06:00 [pubmed]
PHST- 2014/03/29 06:00 [medline]
PST - ppublish
SO  - Lik Sprava. 2013 Mar;(2):67-9.

PMID- 378501
OWN - NLM
STAT- MEDLINE
DCOM- 19790917
LR  - 20181025
IS  - 0312-5963 (Print)
IS  - 0312-5963 (Linking)
VI  - 4
IP  - 2
DP  - 1979 Mar-Apr
TI  - Concentration dependent plasma protein binding of salicylate in rheumatoid 
      patients.
PG  - 137-43
AB  - Acetylsalicylic acid in daily doses from 3 to 6g was prescribed to 8 patients 
      with rheumatoid arthritis. Various assessments of clinical effect, as well as 
      steady-state plasma concentrations and degree of plasma protein binding, were 
      determined at each dose. The unbound fraction of salicylate increased with the 
      dose, resulting in very high free concentrations of drug in some patients. No 
      statistically significant relationship between total or unbound plasma 
      concentration and the measurements of clinical efficacy were obtained. The marked 
      increase with the dose in unbound salicylate concentration is interpreted as the 
      result of the saturable elimination known to occur for this drug.
FAU - Ekstrand, R
AU  - Ekstrand R
FAU - Alvan, G
AU  - Alvan G
FAU - Borga, O
AU  - Borga O
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Clin Pharmacokinet
JT  - Clinical pharmacokinetics
JID - 7606849
RN  - 0 (Blood Proteins)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*blood/drug therapy
MH  - Aspirin/metabolism/therapeutic use
MH  - Blood Proteins/*metabolism
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Protein Binding
MH  - Salicylates/adverse effects/*blood/therapeutic use
MH  - Time Factors
EDAT- 1979/03/01 00:00
MHDA- 1979/03/01 00:01
CRDT- 1979/03/01 00:00
PHST- 1979/03/01 00:00 [pubmed]
PHST- 1979/03/01 00:01 [medline]
PHST- 1979/03/01 00:00 [entrez]
AID - 10.2165/00003088-197904020-00006 [doi]
PST - ppublish
SO  - Clin Pharmacokinet. 1979 Mar-Apr;4(2):137-43. doi: 
      10.2165/00003088-197904020-00006.

PMID- 2297456
OWN - NLM
STAT- MEDLINE
DCOM- 19900315
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 29
IP  - 1
DP  - 1990 Jan
TI  - Effects of aspirin upon the flushing reaction induced by niceritrol.
PG  - 120-2
AB  - The usefulness of niceritrol as a lipid-lowering agent is limited by a 
      prostaglandin-mediated flushing reaction after each dose occurring in the early 
      stages of treatment. We have tested the effect of premedication with aspirin on 
      the reaction to 250 mg niceritrol in 30 healthy male volunteers using both 
      subjective and observed assessments of severity. Both 300 mg and 600 mg of 
      aspirin significantly reduced the severity of flushing when compared with 
      placebo. No significant difference was seen between the two dose levels. Prior 
      dosing with aspirin may increase acceptability of niceritrol and hence improve 
      compliance.
FAU - Jay, R H
AU  - Jay RH
AD  - Department of Medicine, University College and Middlesex School of Medicine, 
      Rayne Institute, London.
FAU - Dickson, A C
AU  - Dickson AC
FAU - Betteridge, D J
AU  - Betteridge DJ
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Nicotinic Acids)
RN  - F54EHJ34MV (Niceritrol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Flushing/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Niceritrol/adverse effects/*antagonists & inhibitors
MH  - Nicotinic Acids/*antagonists & inhibitors
MH  - Random Allocation
PMC - PMC1380070
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1990.tb03611.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1990 Jan;29(1):120-2. doi: 
      10.1111/j.1365-2125.1990.tb03611.x.

PMID- 6605682
OWN - NLM
STAT- MEDLINE
DCOM- 19831217
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 75
IP  - 4B
DP  - 1983 Oct 31
TI  - Comparative study of gastrointestinal microbleeding caused by aspirin, fenbufen, 
      and placebo.
PG  - 80-3
AB  - Fifty volunteers, randomly divided into five groups, received placebo, fenbufen, 
      or aspirin at dosages used in treating osteoarthritis and rheumatoid arthritis 
      (fenbufen, 600 or 900 mg daily; aspirin, 3.6 g daily) for 28 days. Following 
      radioactive chromium labeling of red cells in each subject, stool specimens were 
      collected weekly for determination of blood loss by radioisotope procedure. 
      Statistical analyses demonstrated no significant differences in gastrointestinal 
      microbleeding between subjects who received fenbufen (600 or 900 mg daily) and 
      those who received placebo. Conversely, there were significant (p less than 0.01) 
      differences in microbleeding between subjects given aspirin and those given 
      either dosage of fenbufen or placebo.
FAU - Lussier, A
AU  - Lussier A
FAU - Tétreault, L
AU  - Tétreault L
FAU - Lebel, E
AU  - Lebel E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Phenylbutyrates)
RN  - 0 (Placebos)
RN  - 0 (Propionates)
RN  - 9815R1WR9B (fenbufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents/*toxicity
MH  - Aspirin/*toxicity
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - *Phenylbutyrates
MH  - Placebos
MH  - Propionates/*toxicity
MH  - Time Factors
EDAT- 1983/10/31 00:00
MHDA- 1983/10/31 00:01
CRDT- 1983/10/31 00:00
PHST- 1983/10/31 00:00 [pubmed]
PHST- 1983/10/31 00:01 [medline]
PHST- 1983/10/31 00:00 [entrez]
AID - 0002-9343(83)90333-9 [pii]
AID - 10.1016/0002-9343(83)90333-9 [doi]
PST - ppublish
SO  - Am J Med. 1983 Oct 31;75(4B):80-3. doi: 10.1016/0002-9343(83)90333-9.

PMID- 354637
OWN - NLM
STAT- MEDLINE
DCOM- 19781027
LR  - 20181113
IS  - 0312-5963 (Print)
IS  - 0312-5963 (Linking)
VI  - 3
IP  - 4
DP  - 1978 Jul-Aug
TI  - Migraine and drug absorption.
PG  - 313-8
AB  - The majority of migraine attacks are associated with gastrointestinal symptoms 
      which add considerably to the distress and inconvenience caused by the headache. 
      When salicylate absorption from effervescent aspirin tablets was studied during 
      migraine, the rate of absorption was found to be reduced relative to that found 
      in non-migrainous volunteers and in the same patients when headache-free. There 
      is evidence that this reduced rate of absorption is caused by gastrointestinal 
      stasis and reduced rate of gastric emptying. Patients in whom aspirin absorption 
      was delayed were more likely to take longer to respond and to require additional 
      treatment. Metoclopramide, which increases gastric emptying rate, has been shown 
      to improve the rate of absorption of aspirin during migraine and also increase 
      the rate of recovery from the attack and avoid the need for additional treatment; 
      effects which were not shown by thiethylperazine. It is likely that delayed 
      absorption during migraine affects some drugs other than aspirin, such as 
      ergotamine, and it is therefore recommended that the most rapidly absorbable 
      formulation should be used. If such treatment is ineffective, metoclopramide may 
      be a useful addition and should be tried before resorting to other routes of 
      administration.
FAU - Volans, G N
AU  - Volans GN
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Clin Pharmacokinet
JT  - Clinical pharmacokinetics
JID - 7606849
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Salicylates)
RN  - PR834Q503T (Ergotamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/metabolism
MH  - Ergotamine/metabolism
MH  - Humans
MH  - *Intestinal Absorption
MH  - Migraine Disorders/*metabolism
MH  - Pharmaceutical Preparations/*metabolism
MH  - Salicylates/metabolism
MH  - Time Factors
RF  - 23
EDAT- 1978/07/01 00:00
MHDA- 1978/07/01 00:01
CRDT- 1978/07/01 00:00
PHST- 1978/07/01 00:00 [pubmed]
PHST- 1978/07/01 00:01 [medline]
PHST- 1978/07/01 00:00 [entrez]
AID - 10.2165/00003088-197803040-00004 [doi]
PST - ppublish
SO  - Clin Pharmacokinet. 1978 Jul-Aug;3(4):313-8. doi: 
      10.2165/00003088-197803040-00004.

PMID- 11007580
OWN - NLM
STAT- MEDLINE
DCOM- 20001109
LR  - 20181130
IS  - 8750-7587 (Print)
IS  - 0161-7567 (Linking)
VI  - 89
IP  - 4
DP  - 2000 Oct
TI  - Diaspirin cross-linked hemoglobin improves oxygen extraction capabilities in 
      endotoxic shock.
PG  - 1437-44
AB  - We studied the effects of diaspirin cross-linked hemoglobin (DCLHb), a cell-free 
      hemoglobin derived from human erythrocytes, on blood flow distribution and tissue 
      oxygen extraction capabilities in endotoxic shock. Eighteen pentobarbital 
      sodium-anesthetized, mechanically ventilated dogs received 2 mg/kg of E. coli 
      endotoxin, followed by saline resuscitation to restore cardiac filling pressures 
      to baseline levels. The animals were randomly divided into three groups: six 
      served as control, six received DCLHb at a dose of 500 mg/kg (group 1) and six 
      DCLHb at a dose of 1,000 mg/kg (group 2). Cardiac tamponade was then induced by 
      saline injection in the pericardial sac to progressively reduce cardiac index and 
      thereby allow study of tissue oxygen extraction capabilities. DCLHb had a 
      dose-dependent vasopressor effect but did not significantly alter cardiac index 
      or regional blood flow. During cardiac tamponade, critical oxygen delivery was 
      12.8 +/- 0.7 ml. kg(-1). min(-1) in the control group, but 8.6 +/- 0.9 and 8.2 
      +/- 0.7 ml. kg(-1). min(-1) in groups 1 and 2, respectively (both P < 0.05 vs. 
      control group). The critical oxygen extraction ratio was 39.1 +/- 3.1% in the 
      control group but 58.7 +/- 12.8% and 60.2 +/- 9.0% in groups 1 and 2, 
      respectively. We conclude that DCLHb can improve whole body oxygen extraction 
      capabilities during endotoxic shock in dogs.
FAU - Creteur, J
AU  - Creteur J
AD  - Department of Intensive Care, Erasme University Hospital, Free University of 
      Brussels, B-1070 Brussels, Belgium.
FAU - Zhang, H
AU  - Zhang H
FAU - De Backer, D
AU  - De Backer D
FAU - Sun, Q
AU  - Sun Q
FAU - Vincent, J L
AU  - Vincent JL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Appl Physiol (1985)
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
RN  - 0 (Blood Substitutes)
RN  - 0 (Endotoxins)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Blood Substitutes/*pharmacology
MH  - Cardiac Output/drug effects
MH  - Cardiac Tamponade
MH  - Dogs
MH  - Endotoxins
MH  - Escherichia coli
MH  - Hemodynamics/*drug effects/physiology
MH  - Hemoglobins/*pharmacology
MH  - Oxygen/blood
MH  - Oxygen Consumption/*drug effects
MH  - Regional Blood Flow/drug effects
MH  - Shock, Septic/blood/*physiopathology/therapy
EDAT- 2000/09/28 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/28 11:00
PHST- 2000/09/28 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/28 11:00 [entrez]
AID - 10.1152/jappl.2000.89.4.1437 [doi]
PST - ppublish
SO  - J Appl Physiol (1985). 2000 Oct;89(4):1437-44. doi: 10.1152/jappl.2000.89.4.1437.

PMID- 8961362
OWN - NLM
STAT- MEDLINE
DCOM- 19970310
LR  - 20220316
IS  - 0167-8140 (Print)
IS  - 0167-8140 (Linking)
VI  - 41
IP  - 1
DP  - 1996 Oct
TI  - Late cosmetic results of short fractionation for breast conservation.
PG  - 7-13
AB  - BACKGROUND AND PURPOSE: The number of fractions of radiation therapy (RT) used 
      after breast conserving surgery varies widely and accounts for a significant 
      proportion of the workload in a modern radiotherapy department. Internationally, 
      'standard' therapy ranges from 3 to 7 weeks of daily treatment with or without a 
      boost. Short RT schedules have the attraction of reducing workload but raise 
      concern about an increased risk of late effects and poorer cosmetic outcome. 
      MATERIALS AND METHODS: In a randomized trial, 186 women with T1 or T2, 
      pathologically node-negative breast cancer had cosmetic and various normal tissue 
      effects data collected prospectively. The breast RT prescription was 44 Gy in 16 
      daily fractions to a tangent pair. RESULTS: Median follow-up is 6.7 years. 
      Actuarial 5-year breast recurrence was 6%. Overall cosmetic results at 5 years 
      were good or excellent in 89% and 96% as reported by physicians and patients, 
      respectively, and were stable between 2 and 5 years. Breast discomfort, erythema, 
      edema and induration were related to both surgery and RT. At 5 years, 20% had 
      breast discomfort, 18% had induration, 6% had erythema and 3% had some degree of 
      breast edema. Fewer patients had these effects at 5 years than immediately after 
      primary surgery. The presence of induration prior to starting RT was associated 
      with a greater likelihood of breast induration 3 or more years following RT (P = 
      0.02). Thirteen percent of patients, generally those with large breasts, 
      developed mild inframammary telangiectasia by 5 years. CONCLUSIONS: Results are 
      comparable to those reported from centers employing more conventional 
      fractionation. Short fractionation produces acceptable cosmetic results for the 
      majority of women if there are no contraindications to RT and in the absence of 
      significant post-operative breast induration.
FAU - Olivotto, I A
AU  - Olivotto IA
AD  - Division of Radiation Oncology, British Columbia Cancer Agency, Vancouver, 
      Canada.
FAU - Weir, L M
AU  - Weir LM
FAU - Kim-Sing, C
AU  - Kim-Sing C
FAU - Bajdik, C D
AU  - Bajdik CD
FAU - Trevisan, C H
AU  - Trevisan CH
FAU - Doll, C M
AU  - Doll CM
FAU - Lam, W Y
AU  - Lam WY
FAU - Basco, V E
AU  - Basco VE
FAU - Jackson, S M
AU  - Jackson SM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Ireland
TA  - Radiother Oncol
JT  - Radiotherapy and oncology : journal of the European Society for Therapeutic 
      Radiology and Oncology
JID - 8407192
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Breast/*radiation effects
MH  - Breast Neoplasms/*radiotherapy/surgery
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Mastectomy, Segmental
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Patient Satisfaction
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Prospective Studies
MH  - Radiation Injuries/*epidemiology/prevention & control
MH  - Radiotherapy, Adjuvant
MH  - Radiotherapy, High-Energy
MH  - Time Factors
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - S0167-8140(96)91824-1 [pii]
AID - 10.1016/s0167-8140(96)91824-1 [doi]
PST - ppublish
SO  - Radiother Oncol. 1996 Oct;41(1):7-13. doi: 10.1016/s0167-8140(96)91824-1.

PMID- 8072379
OWN - NLM
STAT- MEDLINE
DCOM- 19940923
LR  - 20190701
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 55
IP  - 10
DP  - 1994
TI  - Effect of stroma-free hemoglobin and diaspirin cross-linked hemoglobin on the 
      regional circulation and systemic hemodynamics.
PG  - 827-37
AB  - The effects of unmodified stroma-free hemoglobin (SFHb) and diaspirin 
      cross-linked hemoglobin (DCLHb) on the regional blood circulation and systemic 
      hemodynamics were studied in rats using a radioactive microsphere technique. SFHb 
      and DCLHb increased mean arterial blood pressure without affecting heart rate. 
      SFHb produced a 24.9% decrease in the cardiac output while DCLHb produced an 
      44.8% increase in the cardiac output. Stroke volume was decreased (-27.3%) by 
      SFHb and increased (+36.4%) by DCLHb. Total peripheral resistance increased with 
      both SFHb and DCLHb. DCLHb increased blood flow to the heart, spleen, stomach, 
      small intestine and skin, and had no effect on blood flow to the brain, kidneys, 
      liver, mesentery, pancreas, caecum, large intestine and musculo-skeletal system. 
      In contrast, in animals infused with SFHb, blood flow decreased to the kidneys, 
      liver and spleen, increased to the heart, small intestine and skin, and had no 
      effect to the brain, caecum, large intestine and musculo-skeletal system. DCLHb 
      had no effect on vascular resistance in any organ except for an increase in the 
      musculo-skeletal system. In contrast, SFHb increased vascular resistance in the 
      kidneys, liver, spleen, skin, mesentery and pancreas, and had no effect on 
      vascular resistance in the musculo-skeletal system, brain, heart, stomach, small 
      intestine, caecum and large intestine. SFHb had no effect on distribution of 
      cardiac output to the brain, gastrointestinal tract (GIT), kidneys, skin, 
      musculo-skeletal and portal system, while DCLHb significantly decreased the 
      percent cardiac output to the musculo-skeletal system. DCLHb did not affect the 
      distribution of cardiac output to the brain, GIT, kidneys, skin and portal 
      system. SFHb and DCLHb increased the percent cardiac output to the heart. It is 
      concluded that similar concentrations and doses of DCLHb and SFHb produce 
      different effects on the regional blood circulation and systemic hemodynamics.
FAU - Gulati, A
AU  - Gulati A
AD  - Department of Pharmaceutics and Pharmacodynamics, University of Illinois at 
      Chicago 60612.
FAU - Sharma, A C
AU  - Sharma AC
FAU - Burhop, K E
AU  - Burhop KE
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Hemoglobins)
RN  - 0 (Plasma Substitutes)
RN  - 0 (hemoglobin, stroma free)
RN  - 578-19-8 (succinyldisalicylic acid)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Blood Circulation/*drug effects/physiology
MH  - Blood Pressure/drug effects
MH  - Cardiac Output/drug effects
MH  - Cerebrovascular Circulation/drug effects
MH  - Coronary Circulation/drug effects
MH  - Heart Rate/drug effects
MH  - Hemodynamics/*drug effects/physiology
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Microspheres
MH  - Muscles/blood supply
MH  - Plasma Substitutes/pharmacology
MH  - Portal System/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/drug effects
MH  - Renal Circulation/drug effects
MH  - Skin/blood supply
MH  - Stroke Volume/drug effects
MH  - Vascular Resistance/drug effects
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 0024-3205(94)00566-4 [pii]
AID - 10.1016/0024-3205(94)00566-4 [doi]
PST - ppublish
SO  - Life Sci. 1994;55(10):827-37. doi: 10.1016/0024-3205(94)00566-4.

PMID- 35032181
OWN - NLM
STAT- MEDLINE
DCOM- 20220318
LR  - 20220318
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 78
IP  - 4
DP  - 2022 Apr
TI  - Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis 
      with particular focus on patients with chronic liver disease.
PG  - 647-656
LID - 10.1007/s00228-021-03247-1 [doi]
AB  - BACKGROUND: Previous studies have suggested a chemoprotective effect of aspirin 
      in hepatocellular carcinoma (HCC), but evidence is limited for patients with 
      chronic liver disease (CLD). Thus, we performed a meta-analysis of all 
      observational studies, and aimed to provide a comprehensive and quantitative 
      understanding of this topic. METHODS: The PubMed/MEDLINE, Scopus, Cochrane, and 
      Web of Science databases were systematically searched until September 2021. We 
      pooled the hazard ratio (HR) of HCC for aspirin use versus non-use and 
      investigated the possible dose-risk and duration-risk associations. RESULTS: Ten 
      studies involving 202,567 CLD patients were enrolled in this study. The pooled 
      results showed a significant reduction in HCC risk in aspirin users than in 
      non-users (HR = 0.64; 95% CI = 0.54-0.77; p(heterogeneity) < 0.001; 
      I(2) = 84.9%). In subgroup analyses, an aspirin dose of 100 mg/day (0.56, 
      0.44-0.72) showed a significant protective effect against HCC than 160 mg/day. 
      The linear model showed a significant inverse association between the duration of 
      aspirin use and HCC risk (exb(b) = 0.92; 95% CI = 0.90-0.94); also, a non-linear 
      model revealed a comparable association (coef(1) = 0.80, p(1) < 0.001; 
      coef(2) = 1.13, p(2) = 0.001). No significantly higher risk of gastrointestinal 
      bleeding of the aspirin-treated group was detected. CONCLUSIONS: The present 
      meta-analysis suggested a significant and duration-related association between 
      reduced HCC risk and aspirin use in a broad at-risk population. Nevertheless, 
      aspirin therapy applied to CLD patients should be carefully monitored, although 
      there was no significantly higher risk of gastrointestinal bleeding. 
      REGISTRATION: PROSPERO, CRD42021229892.
CI  - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Yi, Mengshi
AU  - Yi M
AD  - Department of Hepatic Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Feng, Xi
AU  - Feng X
AD  - Department of Hepatic Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Peng, Wei
AU  - Peng W
AD  - Department of Hepatic Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Teng, Fei
AU  - Teng F
AD  - Department of Hepatic Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Tang, Youyin
AU  - Tang Y
AD  - Department of Hepatic Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China.
FAU - Chen, Zheyu
AU  - Chen Z
AUID- ORCID: 0000-0003-4059-4774
AD  - Department of Hepatic Surgery, West China Hospital, Sichuan University, Chengdu, 
      610041, China. chenzheyu@scu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220115
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Carcinoma, Hepatocellular/prevention & control
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - *Liver Neoplasms/drug therapy
MH  - Observational Studies as Topic
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - Chronic liver disease
OT  - HCC
OT  - Meta-analysis
EDAT- 2022/01/16 06:00
MHDA- 2022/03/19 06:00
CRDT- 2022/01/15 12:07
PHST- 2021/07/25 00:00 [received]
PHST- 2021/10/23 00:00 [accepted]
PHST- 2022/01/16 06:00 [pubmed]
PHST- 2022/03/19 06:00 [medline]
PHST- 2022/01/15 12:07 [entrez]
AID - 10.1007/s00228-021-03247-1 [pii]
AID - 10.1007/s00228-021-03247-1 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2022 Apr;78(4):647-656. doi: 10.1007/s00228-021-03247-1. 
      Epub 2022 Jan 15.

PMID- 30527109
OWN - NLM
STAT- MEDLINE
DCOM- 20190201
LR  - 20190201
IS  - 2210-7797 (Electronic)
IS  - 2210-7789 (Linking)
VI  - 14
DP  - 2018 Oct
TI  - Aspirin use during pregnancy and hypoxia-related placental pathology.
PG  - 177-188
LID - S2210-7789(18)30177-6 [pii]
LID - 10.1016/j.preghy.2018.07.009 [doi]
AB  - OBJECTIVE: Aspirin has been shown to prevent preeclampsia. But the mechanisms 
      remain unclear despite that improved placental circulation is considered as an 
      underlying contributor. Our aim was to examine the hypoxia-related morphological 
      and histopathological placental measures in relation to aspirin use during 
      pregnancy. STUDY DESIGN: We used the Collaborative Perinatal Project (CPP) data, 
      which is a cohort study conducted in the U.S. from 1959 to 1976. A total of 23, 
      604 women who had information on placental pathology and aspirin intake during 
      pregnancy were included in the analysis. Among them, 1474 women had a history of 
      hypertension or preeclampsia/eclampsia and were classified as a high-risk 
      population; the rest were considered as a low-risk population. 47 placenta 
      measures considered to be relevant to hypoxia were selected to build a composite 
      hypoxia- related placenta index. The generalized linear mixed model was used to 
      fit the relationship between aspirin and placental pathology. MAIN OUTCOME 
      MEASURES: Hypoxia-related placental pathology. RESULTS: Aspirin use during 
      pregnancy was associated with a reduced risk of hypoxia-related placental 
      pathology in the high-risk population [the adjusted odds ratio and 95% confidence 
      interval in the 1st, 2nd, and 3rd trimesters: 0.55 (0.31, 1.00), 0.76 (0.49, 
      1.17), and 0.53 (0.29, 0.94), respectively]. Longer duration of aspirin use in 
      pregnancy tended to have a lower risk of hypoxia-related placental pathologies in 
      the high-risk population. CONCLUSIONS: Aspirin use during pregnancy reduced risks 
      of hypoxia-related placental pathologies in the high-risk women for preeclampsia. 
      The duration of aspirin use determined its effects.
CI  - Copyright © 2018 International Society for the Study of Hypertension in 
      Pregnancy. Published by Elsevier B.V. All rights reserved.
FAU - Ye, Jiangfeng
AU  - Ye J
AD  - Department of Clinical Epidemiology, Institute of Obstetrics and Gynecology, 
      Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
FAU - Chen, Yan
AU  - Chen Y
AD  - Department of Neonatology, Xinhua Hospital, Shanghai Jiao Tong University School 
      of Medicine, Shanghai, China.
FAU - Zhu, Jing
AU  - Zhu J
AD  - Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, 
      Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 
      China.
FAU - Chen, Chang
AU  - Chen C
AD  - Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, 
      Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 
      China.
FAU - Zhu, Xiaoyong
AU  - Zhu X
AD  - Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, 
      Shanghai, China.
FAU - Feng, Liping
AU  - Feng L
AD  - Department of Obstetrics and Gynecology, Duke University School of Medicine, 
      Durham, NC, USA. Electronic address: liping.feng@duke.edu.
FAU - Ye, Weiping
AU  - Ye W
AD  - Department of Obstetrics and Gynecology, Xinhua Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China. Electronic address: 
      yeweiping@xinhuamed.com.cn.
FAU - Zhang, Jun
AU  - Zhang J
AD  - Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, 
      Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 
      China. Electronic address: junjimzhang@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20180730
PL  - Netherlands
TA  - Pregnancy Hypertens
JT  - Pregnancy hypertension
JID - 101552483
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Hypoxia/prevention & control
MH  - Middle Aged
MH  - Placenta/blood supply/*pathology
MH  - Placental Insufficiency/prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Cohort study
OT  - Hypoxia
OT  - Placental pathology
OT  - Preeclampsia
EDAT- 2018/12/12 06:00
MHDA- 2019/02/02 06:00
CRDT- 2018/12/12 06:00
PHST- 2018/07/16 00:00 [received]
PHST- 2018/07/29 00:00 [accepted]
PHST- 2018/12/12 06:00 [entrez]
PHST- 2018/12/12 06:00 [pubmed]
PHST- 2019/02/02 06:00 [medline]
AID - S2210-7789(18)30177-6 [pii]
AID - 10.1016/j.preghy.2018.07.009 [doi]
PST - ppublish
SO  - Pregnancy Hypertens. 2018 Oct;14:177-188. doi: 10.1016/j.preghy.2018.07.009. Epub 
      2018 Jul 30.

PMID- 27379496
OWN - NLM
STAT- MEDLINE
DCOM- 20170717
LR  - 20181202
IS  - 1438-8359 (Electronic)
IS  - 0913-8668 (Linking)
VI  - 30
IP  - 5
DP  - 2016 Oct
TI  - Impact of aspirin use on morbidity and mortality in massively transfused cardiac 
      surgery patients: a propensity score matched cohort study.
PG  - 817-25
LID - 10.1007/s00540-016-2213-2 [doi]
AB  - PURPOSE: Aspirin may prevent organ dysfunction in critically ill patients and 
      mitigate transfusion associated acute lung injury. We hypothesized that aspirin 
      use might be associated with decreased morbidity and mortality in massively 
      transfused cardiac surgery patients. METHODS: A single center retrospective 
      cohort study was performed using data from an 8.5-year period (2006-2014). 
      Massive transfusion was defined as receiving at least 2400 ml (8 units) of red 
      blood cell units intraoperatively. A propensity score model was created to 
      account for the likelihood of receiving aspirin and matched pairs were identified 
      using global optimal matching. The primary endpoint, in-hospital mortality, was 
      compared between aspirin users and non-users. Secondary outcomes including: ICU 
      hours, mechanical lung ventilation hours, prolonged mechanical lung ventilation 
      (>24 h), pneumonia, stroke, acute renal failure, atrial fibrillation, deep 
      sternal wound infection, and multiple organ dysfunction syndrome were also 
      compared. RESULTS: Of 7492 cardiac surgery patients, 452 (6 %) were massively 
      transfused and mortality was 30.6 %. There were 346 patients included in the 
      matched cohort. No significant association was found between preoperative aspirin 
      use and in-hospital mortality; absolute risk reduction with aspirin = 7.5 % (95 % 
      CI -2.0 to 16.9 %, p = 0.12). Preoperative aspirin use was associated with fewer 
      total mechanical lung ventilation hours (p = 0.02) and less prolonged mechanical 
      lung ventilation; absolute risk reduction = 11.0 % (95 % CI 1.1-20.5 %, 
      p = 0.02). CONCLUSIONS: Preoperative aspirin use is not associated with decreased 
      in-hospital mortality in massively transfused cardiac surgery patients, but may 
      be associated with less mechanical lung ventilation time.
FAU - Mazzeffi, Michael
AU  - Mazzeffi M
AUID- ORCID: 0000-0003-2955-4915
AD  - University of Maryland School of Medicine, Anesthesiology, 22 South Greene Street 
      S11C00, Baltimore, MD, 21201, USA. mmazzeffi@anes.umm.edu.
FAU - Galvagno, Samuel
AU  - Galvagno S
AD  - University of Maryland School of Medicine, Anesthesiology, 22 South Greene Street 
      S11C00, Baltimore, MD, 21201, USA.
FAU - Gammie, James S
AU  - Gammie JS
AD  - University of Maryland School of Medicine, Cardiothoracic Surgery, 419 Redwood 
      Street #360, Baltimore, MD, 21201, USA.
FAU - Tanaka, Kenichi
AU  - Tanaka K
AD  - University of Maryland School of Medicine, Anesthesiology, 22 South Greene Street 
      S11C00, Baltimore, MD, 21201, USA.
LA  - eng
PT  - Journal Article
DEP - 20160705
PL  - Japan
TA  - J Anesth
JT  - Journal of anesthesia
JID - 8905667
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Lung Injury/*etiology
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - *Blood Transfusion
MH  - Cardiac Surgical Procedures/*methods
MH  - Cohort Studies
MH  - Critical Illness
MH  - Female
MH  - Hospital Mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Propensity Score
MH  - Respiration, Artificial
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Aspirin
OT  - Cardiac surgery
OT  - Lung injury
OT  - Transfusion
EDAT- 2016/07/06 06:00
MHDA- 2017/07/18 06:00
CRDT- 2016/07/06 06:00
PHST- 2016/04/28 00:00 [received]
PHST- 2016/06/28 00:00 [accepted]
PHST- 2016/07/06 06:00 [entrez]
PHST- 2016/07/06 06:00 [pubmed]
PHST- 2017/07/18 06:00 [medline]
AID - 10.1007/s00540-016-2213-2 [pii]
AID - 10.1007/s00540-016-2213-2 [doi]
PST - ppublish
SO  - J Anesth. 2016 Oct;30(5):817-25. doi: 10.1007/s00540-016-2213-2. Epub 2016 Jul 5.

PMID- 26182190
OWN - NLM
STAT- MEDLINE
DCOM- 20150922
LR  - 20181113
IS  - 1545-861X (Electronic)
IS  - 0149-2195 (Print)
IS  - 0149-2195 (Linking)
VI  - 64
IP  - 27
DP  - 2015 Jul 17
TI  - Use of Aspirin for Prevention of Recurrent Atherosclerotic Cardiovascular Disease 
      Among Adults — 20 States and the District of Columbia, 2013.
PG  - 733-7
AB  - The effectiveness of regular aspirin therapy in reducing risk (secondary 
      prevention) for myocardial infarction, ischemic stroke, and fatal coronary events 
      among persons with preexisting atherosclerotic cardiovascular disease (ASCVD) is 
      well established and recommended in current guidelines. Reported use of aspirin 
      or other antiplatelet agents for secondary ASCVD prevention has varied widely 
      across settings and data collection methods, from 54% of outpatient visits for 
      those with ischemic vascular disease to 98% at the time of discharge for acute 
      coronary syndrome. To estimate the prevalence of aspirin use for secondary ASCVD 
      prevention among community-dwelling adults, CDC analyzed 2013 Behavioral Risk 
      Factor Surveillance System (BRFSS) data from 20 states and the District of 
      Columbia. Overall, 70.8% of adult respondents with existing ASCVD reported using 
      aspirin regularly (every day or every other day). Within this group, 93.6% 
      reported using aspirin for heart attack prevention, 79.6% for stroke prevention 
      and 76.2% for both heart attack and stroke prevention. Differences in use were 
      found by age, sex, race/ethnicity, and ASCVD risk status, and state. Most of the 
      state differences were not statistically significant; however, these estimates 
      can be used to promote the use of aspirin as a low-cost and highly effective 
      intervention.
FAU - Fang, Jing
AU  - Fang J
FAU - George, Mary G
AU  - George MG
FAU - Hong, Yuling
AU  - Hong Y
FAU - Loustalot, Fleetwood
AU  - Loustalot F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - MMWR Morb Mortal Wkly Rep
JT  - MMWR. Morbidity and mortality weekly report
JID - 7802429
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Atherosclerosis/*prevention & control
MH  - Behavioral Risk Factor Surveillance System
MH  - District of Columbia
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Secondary Prevention/*methods/*statistics & numerical data
MH  - United States
MH  - Young Adult
PMC - PMC4584583
EDAT- 2015/07/17 06:00
MHDA- 2015/09/24 06:00
CRDT- 2015/07/17 06:00
PHST- 2015/07/17 06:00 [entrez]
PHST- 2015/07/17 06:00 [pubmed]
PHST- 2015/09/24 06:00 [medline]
AID - mm6427a1 [pii]
AID - 733-737 [pii]
PST - ppublish
SO  - MMWR Morb Mortal Wkly Rep. 2015 Jul 17;64(27):733-7.

PMID- 12843993
OWN - NLM
STAT- MEDLINE
DCOM- 20030808
LR  - 20151119
IS  - 0761-8417 (Print)
IS  - 0761-8417 (Linking)
VI  - 59
IP  - 2 Pt 1
DP  - 2003 Apr
TI  - [Intrinsic asthma].
PG  - 84-8
AB  - Although asthma is often regarded as a manifestation of atopy, many asthmatics 
      are not atopic. As compared to atopic ("extrinsic") asthma, nonatopic 
      ("intrinsic") asthma occurs later in life, mostly in females, and nasal 
      polyposis, aspirin sensitivity and steroid dependence are common. In this patient 
      population, there is no history of allergy, skin prick testing is negative for 
      all aeroallergens tested and total as well as specific immunoglobulin E serum 
      levels are within the normal range. Epidemiological studies and analysis of 
      bronchial mucosal expression of "pro-eosinophilic" and "pro-atopic" markers 
      demonstrate that there are more similarities than differences in immunopathology 
      between atopic and nonatopic asthma.
FAU - Humbert, M
AU  - Humbert M
AD  - Service de Pneumologie et Réanimation Respiratoire, Clinique de l'Asthme, Hôpital 
      Antoine-Béclère, 157, rue de la Porte-de-Trivaux, 92140 Clamart. 
      humbert@ipsc.u-psud.fr
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Asthme allergique et non allergique: similitudes et différences.
PL  - France
TA  - Rev Pneumol Clin
JT  - Revue de pneumologie clinique
JID - 8406312
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Steroids)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology
MH  - Aspirin/adverse effects/pharmacology
MH  - Asthma/*immunology/physiopathology
MH  - Biomarkers/analysis
MH  - Cytokines/analysis
MH  - Female
MH  - Humans
MH  - Hypersensitivity/*immunology/physiopathology
MH  - Immunoglobulin E/*analysis
MH  - Middle Aged
MH  - Nasal Polyps
MH  - Sex Factors
MH  - Skin Tests
MH  - Steroids/therapeutic use
RF  - 17
EDAT- 2003/07/05 05:00
MHDA- 2003/08/09 05:00
CRDT- 2003/07/05 05:00
PHST- 2003/07/05 05:00 [pubmed]
PHST- 2003/08/09 05:00 [medline]
PHST- 2003/07/05 05:00 [entrez]
AID - MDOI-RPC-04-2003-59-2-0761-8417-101019-ART5 [pii]
PST - ppublish
SO  - Rev Pneumol Clin. 2003 Apr;59(2 Pt 1):84-8.

PMID- 35196733
OWN - NLM
STAT- MEDLINE
DCOM- 20220225
LR  - 20220225
IS  - 2567-5761 (Electronic)
IS  - 0720-9355 (Linking)
VI  - 42
IP  - 1
DP  - 2022 Feb
TI  - When and How to Combine Antiplatelet and Anticoagulant Drugs?
PG  - 73-79
LID - 10.1055/a-1724-4922 [doi]
AB  - Antiplatelet and anticoagulant drugs work at different places in the coagulation 
      system. Antiplatelet drugs are usually indicated in patients with 
      atherosclerosis. Anticoagulant drugs are mostly used in patients with atrial 
      fibrillation, venous thromboembolism, or technical heart valves. In some clinical 
      situations, combination of antiplatelet and anticoagulant therapy can be 
      indicated. The most recent situations are a more intensive antithrombotic therapy 
      for risk reduction in patients with atherosclerosis and temporary addition of 
      antiplatelet drugs in patients with indication for long-term anticoagulation. 
      Temporary combination of antiplatelet and anticoagulant drugs is usually 
      necessary after coronary intervention in patients with atrial fibrillation. In 
      patients with high-risk atherosclerosis, the combination of low-dose rivaroxaban 
      and aspirin reduces major adverse cardiovascular events (myocardial infarction, 
      stroke, cardiovascular death) and major adverse limb events. But every 
      combination of antiplatelet and antithrombotic drugs can increase bleeding risk. 
      Therefore, a careful assessment of thrombotic versus bleeding risk is necessary 
      for each patient.
CI  - Thieme. All rights reserved.
FAU - Espinola-Klein, Christine
AU  - Espinola-Klein C
AD  - Center of Cardiology, Cardiology III - Angiology, University Medical Center of 
      the Johannes Gutenberg-University, Mainz, Germany.
LA  - eng
PT  - Journal Article
DEP - 20220223
PL  - Germany
TA  - Hamostaseologie
JT  - Hamostaseologie
JID - 8204531
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anticoagulants/adverse effects
MH  - Aspirin/therapeutic use
MH  - *Atrial Fibrillation/complications/drug therapy
MH  - Drug Therapy, Combination
MH  - Hemorrhage/etiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects
COIS- Honoraria for lectures or advisory boards from Amarin Germany GmbH, Amgen GmbH, 
      Bayer Health Care, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, 
      Leo Pharma, MSD Sharp & Dohme, Novartis Pharma, Pfizer Pharma GmbH, 
      Sanofi-Aventis GmbH.
EDAT- 2022/02/24 06:00
MHDA- 2022/02/26 06:00
CRDT- 2022/02/23 20:11
PHST- 2022/02/23 20:11 [entrez]
PHST- 2022/02/24 06:00 [pubmed]
PHST- 2022/02/26 06:00 [medline]
AID - 10.1055/a-1724-4922 [doi]
PST - ppublish
SO  - Hamostaseologie. 2022 Feb;42(1):73-79. doi: 10.1055/a-1724-4922. Epub 2022 Feb 
      23.

PMID- 6436180
OWN - NLM
STAT- MEDLINE
DCOM- 19841214
LR  - 20190919
IS  - 0360-3997 (Print)
IS  - 0360-3997 (Linking)
VI  - 8
IP  - 3
DP  - 1984 Sep
TI  - Therapeutic reduction of ongoing carrageenin-induced inflammation by 
      lipoxygenase, but not cyclooxygenase inhibitors.
PG  - 223-30
AB  - A variety of steroidal and nonsteroidal antiinflammatory agents (NSAs) were 
      compared for their effectiveness against a developing acute inflammatory 
      reaction. Only BW 755C [3-amino-1-(m-trifluoromethyl)-phenyl-2-pyrazole] was 
      immediately effective when administered 2 h after carrageenin, as the 3-h 
      swelling was significantly reduced. Dexamethasone, a steroidal antiinflammatory 
      agent, produced a delayed reduction. When administered at 2 h postcarrageenin, 
      there was no effect at 3 h; but at 6 h, dexamethasone significantly reduced the 
      swelling. In contrast, neither of the classic NSAs, aspirin or indomethacin, were 
      effective when administered after the carrageenin. The results demonstrating a 
      postcarrageenin effectiveness by BW 755C and dexamethasone are discussed as a 
      possible reflection of an action on the lipoxygenase pathways of the arachidonic 
      cascade that is not shared by the classic NSA.
FAU - Holsapple, M P
AU  - Holsapple MP
FAU - Yim, G K
AU  - Yim GK
LA  - eng
GR  - RR 0558613/RR/NCRR NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Inflammation
JT  - Inflammation
JID - 7600105
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 66000-40-6 (4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine)
RN  - 9000-07-1 (Carrageenan)
RN  - EC 1.13.11.12 (Lipoxygenase)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Carrageenan
MH  - Cyclooxygenase Inhibitors
MH  - Indomethacin/therapeutic use
MH  - Inflammation/chemically induced/*prevention & control
MH  - Lipoxygenase/*therapeutic use
MH  - Male
MH  - Pyrazoles/therapeutic use
MH  - Rats
MH  - Time Factors
EDAT- 1984/09/01 00:00
MHDA- 1984/09/01 00:01
CRDT- 1984/09/01 00:00
PHST- 1984/09/01 00:00 [pubmed]
PHST- 1984/09/01 00:01 [medline]
PHST- 1984/09/01 00:00 [entrez]
AID - 10.1007/BF00916412 [doi]
PST - ppublish
SO  - Inflammation. 1984 Sep;8(3):223-30. doi: 10.1007/BF00916412.

PMID- 6366809
OWN - NLM
STAT- MEDLINE
DCOM- 19840411
LR  - 20131121
IS  - 0308-051X (Print)
IS  - 0308-051X (Linking)
VI  - 3
IP  - 8
DP  - 1984
TI  - Naproxen and aspirin in acute musculoskeletal disorders: a double-blind, parallel 
      study in patients with sports injuries.
PG  - 531-7
AB  - Seventy-nine patients with injuries of less than 14-days' duration were treated 
      with either 750 mg naproxen or 2 g acetylsalicylic acid daily for 7 days in a 
      double-blind trial. A statistically significant improvement (p less than 0.001) 
      was noted in both treatment groups in respect of tenderness on palpation, pain on 
      movement and functional capacity. However, there were no significant differences 
      between the groups. Fresh injuries were over-represented in the acetylsalicylic 
      acid group (p less than 0.01), and when all patients were analyzed together, a 
      significantly better treatment result was obtained the shorter the interval 
      between injury and start of treatment. This might have influenced the results 
      from this study. Fifteen side-effects were reported by 11 patients, 5 in the 
      naproxen group and 6 in the acetylsalicylic acid group. None was serious, and 
      only 2 patients interrupted the treatment for this reason. It is suggested that 
      treatment with analgesics or anti-inflammatory drugs should start as early as 
      possible after the injury.
FAU - Andersen, L A
AU  - Andersen LA
FAU - Gøtzsche, P C
AU  - Gøtzsche PC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Pharmatherapeutica
JT  - Pharmatherapeutica
JID - 7606274
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Athletic Injuries/*drug therapy
MH  - Bone Diseases/*drug therapy
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscular Diseases/*drug therapy
MH  - Naproxen/*therapeutic use
MH  - Time Factors
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Pharmatherapeutica. 1984;3(8):531-7.

PMID- 23053045
OWN - NLM
STAT- MEDLINE
DCOM- 20130911
LR  - 20211021
IS  - 1619-0904 (Electronic)
IS  - 1434-7229 (Linking)
VI  - 16
IP  - 1
DP  - 2013 Mar
TI  - Evaluation of platelet aggregability during left ventricular bypass using a 
      MedTech MagLev VAD in a series of chronic calf experiments.
PG  - 34-41
LID - 10.1007/s10047-012-0664-2 [doi]
AB  - The impact of continuous flow left ventricular assist device (LVAD) pumping on 
      platelet aggregation was investigated in animal experiments utilizing six calves. 
      A single-use MagLev centrifugal blood pump, MedTech MagLev, was used to bypass 
      the calves' hearts from the left atrium to the descending aorta at a flow rate of 
      50 ml/kg/min. The LVAD's impact on blood coagulation activities was evaluated 
      based on the platelet aggregability, which was measured with a turbidimetric 
      assay method during the preoperative, operative, and postoperative periods. 
      Heparin and warfarin were used for anticoagulation, while aspirin was used for 
      the antiplatelet therapy. A decrease in platelet aggregation immediately after 
      the pump started was observed in the cases of successful long-term pump 
      operation, while the absence of such a decrease might have caused 
      coagulation-related complications to terminate the experiments. Thus, the 
      platelet aggregability was found to be significantly affected by the pump, and 
      its initial trend may be related to the long-term outcome of the mechanical 
      circulatory support.
FAU - Kimura, Taro
AU  - Kimura T
AD  - Department of Biodesign, Institute of Biomaterials and Bioengineering, Tokyo 
      Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo, 
      101-0062, Japan. t_kimura_s@hotmail.co.jp
FAU - Yokoyama, Yoshimasa
AU  - Yokoyama Y
FAU - Sakota, Daisuke
AU  - Sakota D
FAU - Nagaoka, Eiki
AU  - Nagaoka E
FAU - Kitao, Takashi
AU  - Kitao T
FAU - Takakuda, Kazuo
AU  - Takakuda K
FAU - Takatani, Setsuo
AU  - Takatani S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121003
PL  - Japan
TA  - J Artif Organs
JT  - Journal of artificial organs : the official journal of the Japanese Society for 
      Artificial Organs
JID - 9815648
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/pharmacology
MH  - Aspirin/pharmacology
MH  - Cattle
MH  - *Heart Bypass, Left
MH  - *Heart-Assist Devices
MH  - Heparin/pharmacology
MH  - Male
MH  - Platelet Aggregation/drug effects/*physiology
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Warfarin/pharmacology
EDAT- 2012/10/12 06:00
MHDA- 2013/09/12 06:00
CRDT- 2012/10/12 06:00
PHST- 2011/07/31 00:00 [received]
PHST- 2012/09/13 00:00 [accepted]
PHST- 2012/10/12 06:00 [entrez]
PHST- 2012/10/12 06:00 [pubmed]
PHST- 2013/09/12 06:00 [medline]
AID - 10.1007/s10047-012-0664-2 [doi]
PST - ppublish
SO  - J Artif Organs. 2013 Mar;16(1):34-41. doi: 10.1007/s10047-012-0664-2. Epub 2012 
      Oct 3.

PMID- 3864169
OWN - NLM
STAT- MEDLINE
DCOM- 19851125
LR  - 20191030
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 19
IP  - 3
DP  - 1985 Sep
TI  - Rat's vessel wall generates an antiaggregatory substance independent of 
      prostacyclin production.
PG  - 251-60
AB  - We have investigated whether the vessel wall may release or synthetize some 
      substance able to modify the platelet function independent of prostacyclin (PGI2) 
      production. Twenty female rats were injected with indomethacin. 18 hours after 
      the injection animals were sacrificed and rings cut from thoracic and abdominal 
      aorta were obtained. They were incubated in Krebs solution for different periods 
      of time after which an aliquot from the indomethacin treated rat's aortic ring 
      (ITRAR) was assayed on platelet aggregation induced by several agonists. The 
      supernatant from the 40 min. incubation mixture of ITRAR released a substance 
      which completely inhibits platelet aggregation induced by arachidonic acid (AA), 
      ADP, epinephrine, collagen, ristocetin and thrombin. The time of appearance of 
      the substance varied with a mean of 17 min.. It is released with and without AA 
      stimulation. Once generated it is active for at least three hours; its 
      antiaggregating activity remains even if it is boiled for 15 sec, incubated at 37 
      degrees C, or if the vessel is treated with tranylcypromine. Platelet aggregation 
      inhibition is still evident if the supernatant from ITRAR is transferred to a 
      platelet rich plasma (PRP) from a normal donor who had taken an aspirin 24 hours 
      before sampling. All these results indicate that this substance released from 
      ITRAR is not prostacyclin. Nordihydroguaiaretic or eicosatetraynoic acid which 
      are lipoxygenase inhibitors could not modify the ITRAR's release; nor did 
      mepacrine which is a phospholipase inhibitor. Since mepacrine does not completely 
      inhibit phospholipase activities we cannot exclude the possibility that the 
      substance is derived from AA. More studies are in progress to elucidate the 
      biochemical properties of this substance.
FAU - Schattner, M A
AU  - Schattner MA
FAU - Gimeno, M
AU  - Gimeno M
FAU - Lazzari, M A
AU  - Lazzari MA
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Catechols)
RN  - 1191-85-1 (5,8,11,14-Eicosatetraynoic Acid)
RN  - 7BO8G1BYQU (Masoprocol)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - 5,8,11,14-Eicosatetraynoic Acid/pharmacology
MH  - Animals
MH  - Aorta/*physiology
MH  - Aspirin/pharmacology
MH  - Catechols/pharmacology
MH  - Endothelium/physiology
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Indomethacin/pharmacology
MH  - Masoprocol
MH  - *Platelet Aggregation/drug effects
MH  - Rats
EDAT- 1985/09/01 00:00
MHDA- 1985/09/01 00:01
CRDT- 1985/09/01 00:00
PHST- 1985/09/01 00:00 [pubmed]
PHST- 1985/09/01 00:01 [medline]
PHST- 1985/09/01 00:00 [entrez]
AID - 10.1016/0262-1746(85)90138-6 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1985 Sep;19(3):251-60. doi: 
      10.1016/0262-1746(85)90138-6.

PMID- 14555260
OWN - NLM
STAT- MEDLINE
DCOM- 20040706
LR  - 20190906
IS  - 8756-3282 (Print)
IS  - 1873-2763 (Linking)
VI  - 33
IP  - 4
DP  - 2003 Oct
TI  - Long-term analgesic effect of clodronate in rodents.
PG  - 567-74
AB  - Several studies have shown that treatment with bisphosphonates can reduce the 
      pain associated with different painful diseases. In a previous study we 
      demonstrated that in mice two bisphosponates, clodronate and pamidronate, had an 
      antinociceptive effect under acute conditions not related to bone processes, 
      after in vein (iv) or intracerebroventricular (icv) injection. The present study 
      tested the time-dependent antinociceptive action of clodronate and pamidronate in 
      comparison with that of acetylsalicylic acid (ASA) and morphine after iv and icv 
      injection using the tail-flick test in acute and chronic treatment. The effects 
      of clodronate on other measures of animal behaviour were also evaluated. In the 
      tail-flick test, administration of clodronate iv produced an antinociceptive 
      effect that was greater than that of ASA and statistically significant up to 16 
      h; pamidronate iv showed a significant antinociceptive effect for only 6 h. 
      Clodronate and pamidronate icv showed an increase in tail-flick latency time that 
      was significant and lasted for 16 and 6 h, respectively, while morphine produced 
      an antinociceptive effect for 24 h. In the test we found significant differences 
      between male and female mice in the latency time values but not in the length of 
      the analgesic effect. In the chronic treatment paradigm, clodronate produced a 
      significant increase of the tail-flick latency after the first injection. The 
      analgesic effect increased up to 50% after 5 days of treatment. Significant 
      analgesic effects were still present after 3, 7, and 14 days from the end of 
      treatment. Clodronate did not produce any significant behavioural effects in the 
      Rota-rod test, pentobarbital-induced sleeping time, and locomotor activity cage. 
      These data indicate that clodronate presents a central and peripheral prolonged 
      antinociceptive effect, without any behavioural side effects.
FAU - Bonabello, A
AU  - Bonabello A
AD  - Research Department, SPA-Societa' Prodotti Antibiotici S.p.A., Milan, Italy. 
      bonabelloa@libero.it
FAU - Galmozzi, M R
AU  - Galmozzi MR
FAU - Canaparo, R
AU  - Canaparo R
FAU - Serpe, L
AU  - Serpe L
FAU - Zara, G P
AU  - Zara GP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Bone
JT  - Bone
JID - 8504048
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Diphosphonates)
RN  - 0813BZ6866 (Clodronic Acid)
RN  - 76I7G6D29C (Morphine)
RN  - OYY3447OMC (Pamidronate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics, Non-Narcotic/administration & dosage/*pharmacology
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology
MH  - Behavior, Animal/drug effects
MH  - Clodronic Acid/administration & dosage/*pharmacology
MH  - Diphosphonates/administration & dosage/pharmacology
MH  - Female
MH  - Injections, Intravenous
MH  - Injections, Intraventricular
MH  - Male
MH  - Mice
MH  - Morphine/administration & dosage/pharmacology
MH  - Pamidronate
MH  - Sex Characteristics
MH  - Time Factors
EDAT- 2003/10/14 05:00
MHDA- 2004/07/09 05:00
CRDT- 2003/10/14 05:00
PHST- 2003/10/14 05:00 [pubmed]
PHST- 2004/07/09 05:00 [medline]
PHST- 2003/10/14 05:00 [entrez]
AID - S8756328203002291 [pii]
AID - 10.1016/s8756-3282(03)00229-1 [doi]
PST - ppublish
SO  - Bone. 2003 Oct;33(4):567-74. doi: 10.1016/s8756-3282(03)00229-1.

PMID- 9277030
OWN - NLM
STAT- MEDLINE
DCOM- 19970909
LR  - 20190831
IS  - 0017-8748 (Print)
IS  - 0017-8748 (Linking)
VI  - 37
IP  - 7
DP  - 1997 Jul-Aug
TI  - Repeated doses of combined oral lysine acetylsalicylate and metoclopramide in the 
      acute treatment of migraine.
PG  - 452-4
AB  - The combination of lysine acetylsalicylate and metoclopramide is effective in the 
      treatment of migraine attacks. It was unknown whether repeated doses could 
      improve efficacy. The aim of this open trial was to evaluate the effects of a 
      second, and eventually a third dose of lysine acetylsalicylate and metoclopramide 
      when a first dose of the treatment was ineffective. Patients were asked to take a 
      second dose 2 hours after a first dose when they thought that the first dose was 
      ineffective. They were allowed to take a third dose or their rescue medication 2 
      hours after the second dose when they judged that the treatment remained 
      ineffective. Two hundred ninety-two patients were included in the study; 262 of 
      the 292 patients treated 517 attacks. Headache relief (reduction in headache 
      severity from grade 3 or 2 to grade 1 or 0) was observed in 54.8% of attacks 
      after one dose, in 48.1% of attacks after a second dose, and in 40.3% of attacks 
      after a third dose. Complete headache relief without recurrence and without use 
      of a rescue medication was reported in 37% of the total attacks. The patients 
      judged their treatment as good or excellent in 78% of attacks treated with one 
      dose, in 41% of those treated with two doses, and in 19% of those treated with 
      three doses. Tolerance, as judged by the patients, was considered good in 92% of 
      treated attacks. Minor side effects occurred in 6% of attacks after a first dose, 
      in 4.5% of attacks after a second dose, in 1.5% of attacks after a third dose, in 
      2% after unspecified delay, and in 14% overall. In conclusion, the efficacy of 
      lysine acetylsalicylate and metoclopramide in the treatment of migraine attacks 
      can be improved by repeated doses. It is well tolerated.
FAU - Hugues, F C
AU  - Hugues FC
AD  - Department of Médecine Interne II, Hôpital Laënnec, Paris, France.
FAU - Lacoste, J P
AU  - Lacoste JP
FAU - Danchot, J
AU  - Danchot J
FAU - Joire, J E
AU  - Joire JE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
RN  - 0 (Analgesics)
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Drug Combinations)
RN  - K3Z4F929H6 (Lysine)
RN  - L4YEB44I46 (Metoclopramide)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Analgesics/*administration & dosage
MH  - Aspirin/administration & dosage/*analogs & derivatives
MH  - Dopamine Antagonists/*administration & dosage
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Metoclopramide/*administration & dosage
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - 10.1046/j.1526-4610.1997.3707452.x [doi]
PST - ppublish
SO  - Headache. 1997 Jul-Aug;37(7):452-4. doi: 10.1046/j.1526-4610.1997.3707452.x.

PMID- 32134791
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1535-2811 (Electronic)
IS  - 1535-2811 (Linking)
VI  - 19
IP  - 3
DP  - 2020 Sep
TI  - Predictors of Aspirin Nonadherence in Adults With Prior Myocardial Infarction.
PG  - 115-118
LID - 10.1097/HPC.0000000000000218 [doi]
AB  - BACKGROUND: Medication nonadherence is an alarming public health concern due to 
      its effect on both individual treatment success and overall health care costs. 
      This study sought to identify the predictors of aspirin nonadherence in adults 
      with prior myocardial infarction (MI). METHODS: The 2017 Centers for Disease 
      Control's Behavioral Risk Factor Surveillance Survey, a nationally 
      representative, cross-sectional survey, was utilized to identify a cohort of 
      community-dwelling adults (age ≥ 18 years) with prior MI (n = 2173). The primary 
      outcome of interest was presence of self-reported aspirin nonadherence. RESULTS: 
      Among 2173 participants with prior MI studied, a total of 550 participants 
      (25.3%) reported aspirin nonadherence, whereas 1623 participants (74.7%) reported 
      adherence to aspirin. Adults with aspirin nonadherence were younger and more 
      likely to be female, Black, and of Hispanic ethnicity. They also had lower annual 
      income and were less likely to have health insurance or own a home. Participants 
      with aspirin nonadherence had less frequent medical checkups and lower rates of 
      multiple comorbidities including diabetes mellitus, hypertension, hyperlipidemia, 
      and obesity. In multivariable analysis, independent predictors of aspirin 
      nonadherence included female sex [odds ratio (OR), 1.42; 95% confidence interval 
      (CI), 1.14-1.83], Black race (OR, 1.64; 95% CI, 1.19-2.26), Hispanic ethnicity 
      (OR, 2.27; 95% CI, 1.60-3.21), current employment (OR, 1.74; 95% CI, 1.28-2.36), 
      and absence of homeowner status (OR, 0.71; 95% CI, 0.55-0.93). CONCLUSIONS: In 
      this observational contemporary study of adults with prior MI, predictors of 
      aspirin nonadherence included female sex, Black race, Hispanic ethnicity, 
      currently employed status, and absence of homeowner status.
FAU - Bhasin, Varun
AU  - Bhasin V
AD  - From the Division of Cardiology, Department of Medicine, Stony Brook University 
      Medical Center, Stony Brook, NY.
FAU - Mehta, Aayushi
AU  - Mehta A
FAU - Skopicki, Hal A
AU  - Skopicki HA
FAU - Parikh, Puja B
AU  - Parikh PB
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - United States
TA  - Crit Pathw Cardiol
JT  - Critical pathways in cardiology
JID - 101165286
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Medication Adherence/*statistics & numerical data
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - *Self Report
EDAT- 2020/03/07 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/03/06 06:00
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/03/06 06:00 [entrez]
AID - 00132577-202009000-00003 [pii]
AID - 10.1097/HPC.0000000000000218 [doi]
PST - ppublish
SO  - Crit Pathw Cardiol. 2020 Sep;19(3):115-118. doi: 10.1097/HPC.0000000000000218.

PMID- 25116427
OWN - NLM
STAT- MEDLINE
DCOM- 20150514
LR  - 20140908
IS  - 1421-9751 (Electronic)
IS  - 0008-6312 (Linking)
VI  - 129
IP  - 1
DP  - 2014
TI  - Safety and efficacy of warfarin plus aspirin combination therapy for giant 
      coronary artery aneurysm secondary to Kawasaki disease: a meta-analysis.
PG  - 55-64
LID - 10.1159/000363732 [doi]
AB  - OBJECTIVE: To compare the safety and efficacy of warfarin plus aspirin versus 
      aspirin alone for the treatment of children with giant coronary artery aneurysm 
      (CAA) secondary to Kawasaki disease (KD). METHODS: We searched the PubMed, 
      EMBASE, Cochrane Library, CNKI, WANFAN and VIP databases. We selected 
      case-controlled trials of warfarin plus aspirin versus aspirin alone for the 
      treatment of children with giant CAA secondary to KD. RESULTS: Six retrospective 
      studies met our inclusion criteria. There was no significant difference between 
      the warfarin plus aspirin and aspirin alone groups in the rate of CAA regression 
      (OR 1.38, 95% CI 0.52-3.68, p = 0.52) or the incidence of persistent CAA (OR 
      2.34, 95% CI 0.16-33.50, p = 0.53), coronary artery stenosis (OR 0.55, 95% CI 
      0.18-1.72, p = 0.30) or thrombus formation (OR 0.50, 95% CI 0.15-1.69, p = 0.26). 
      There was evidence that warfarin plus aspirin reduced the incidence of coronary 
      artery occlusion (OR 0.08, 95% CI 0.02-0.29, p < 0.0001), cardiac infarction (OR 
      0.27, 95% CI 0.11-0.63, p = 0.003) and death (OR 0.18, 95% CI 0.04-0.88, p = 
      0.03). CONCLUSION: Warfarin plus aspirin therapy reduced the incidence of 
      occlusion, cardiac infarction and death in children with giant CAA secondary to 
      KD.
CI  - © 2014 S. Karger AG, Basel.
FAU - Su, Danyan
AU  - Su D
AD  - Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi Autonomous Region, PR China.
FAU - Wang, Kai
AU  - Wang K
FAU - Qin, Suyuan
AU  - Qin S
FAU - Pang, Yusheng
AU  - Pang Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20140812
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Cardiology. 2014;129(3):174-7. PMID: 25300244
CIN - Cardiology. 2015;130(3):164-5. PMID: 25676566
CIN - Cardiology. 2015;130(3):166. PMID: 25676687
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Coronary Aneurysm/*drug therapy/etiology
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Mucocutaneous Lymph Node Syndrome/*complications
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Warfarin/*therapeutic use
EDAT- 2014/08/15 06:00
MHDA- 2015/05/15 06:00
CRDT- 2014/08/14 06:00
PHST- 2014/02/27 00:00 [received]
PHST- 2014/05/19 00:00 [accepted]
PHST- 2014/08/14 06:00 [entrez]
PHST- 2014/08/15 06:00 [pubmed]
PHST- 2015/05/15 06:00 [medline]
AID - 000363732 [pii]
AID - 10.1159/000363732 [doi]
PST - ppublish
SO  - Cardiology. 2014;129(1):55-64. doi: 10.1159/000363732. Epub 2014 Aug 12.

PMID- 34748282
OWN - NLM
STAT- MEDLINE
DCOM- 20220429
LR  - 20220429
IS  - 1755-148X (Electronic)
IS  - 1755-1471 (Linking)
VI  - 35
IP  - 2
DP  - 2022 Mar
TI  - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) sensitize melanoma cells to MEK 
      inhibition and inhibit metastasis and relapse by inducing degradation of AXL.
PG  - 238-251
LID - 10.1111/pcmr.13021 [doi]
AB  - Melanoma is highly heterogeneous with diverse genomic alterations and partial 
      therapeutic responses. The emergence of drug-resistant tumor cell clones 
      accompanied by a high AXL expression level is one of the major challenges for 
      anti-tumor clinical care. Recent studies have demonstrated that high AXL 
      expression in melanoma cells mediated drug resistance, epithelial-mesenchymal 
      transition (EMT), and elevated survival of cancer stem cells (CSCs). Given that 
      we have identified several non-steroidal anti-inflammatory drugs (NSAIDs) 
      including aspirin potently induce the degradation of AXL, we questioned whether 
      NSAIDs could counteract the AXL-mediated neoplastic phenotypes. In this study, we 
      found that NSAIDs downregulate PKA activity via the PGE(2) /EP2/cAMP/PKA 
      signaling pathway and interrupt the PKA-dependent interaction between CDC37 and 
      HSP90, resulting in an incorrect AXL protein folding and finally AXL degradation 
      through the ubiquitination-proteasome system (UPS) pathway. Furthermore, NSAIDs 
      not only sensitized the MEK inhibitor treatment but also reduced EMT and relapse 
      mediated by AXL in tumor tissue. Our findings suggest that the combination of 
      inhibitors and NSAIDs, especially aspirin, could be a simple but efficient 
      modality to treat melanoma in which AXL is a key factor for drug resistance, 
      metastasis, and relapse.
CI  - © 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Chen, Yingshi
AU  - Chen Y
AD  - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 
      Guangzhou, China.
FAU - Zhang, Yiwen
AU  - Zhang Y
AD  - Key Laboratory of Tropical Disease Control of Ministry of Education, Institute of 
      Human Virology, Guangdong Engineering Research Center for Antimicrobial Agent and 
      Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Chen, Siqi
AU  - Chen S
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Liu, Weiwei
AU  - Liu W
AD  - Key Laboratory of Tropical Disease Control of Ministry of Education, Institute of 
      Human Virology, Guangdong Engineering Research Center for Antimicrobial Agent and 
      Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Lin, Yingtong
AU  - Lin Y
AD  - Key Laboratory of Tropical Disease Control of Ministry of Education, Institute of 
      Human Virology, Guangdong Engineering Research Center for Antimicrobial Agent and 
      Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Zhang, Hui
AU  - Zhang H
AD  - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 
      Guangzhou, China.
AD  - Key Laboratory of Tropical Disease Control of Ministry of Education, Institute of 
      Human Virology, Guangdong Engineering Research Center for Antimicrobial Agent and 
      Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Yu, Fei
AU  - Yu F
AUID- ORCID: 0000-0003-1546-9365
AD  - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211214
PL  - England
TA  - Pigment Cell Melanoma Res
JT  - Pigment cell & melanoma research
JID - 101318927
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Cell Line, Tumor
MH  - Humans
MH  - *Melanoma/pathology
MH  - Mitogen-Activated Protein Kinase Kinases
MH  - *Neoplasm Recurrence, Local
OTO - NOTNLM
OT  - AXL
OT  - NSAID
OT  - drug resistance
OT  - melanoma
OT  - metastasis
EDAT- 2021/11/09 06:00
MHDA- 2022/04/30 06:00
CRDT- 2021/11/08 12:37
PHST- 2021/10/12 00:00 [revised]
PHST- 2021/06/01 00:00 [received]
PHST- 2021/11/04 00:00 [accepted]
PHST- 2021/11/09 06:00 [pubmed]
PHST- 2022/04/30 06:00 [medline]
PHST- 2021/11/08 12:37 [entrez]
AID - 10.1111/pcmr.13021 [doi]
PST - ppublish
SO  - Pigment Cell Melanoma Res. 2022 Mar;35(2):238-251. doi: 10.1111/pcmr.13021. Epub 
      2021 Dec 14.

PMID- 32403962
OWN - NLM
STAT- MEDLINE
DCOM- 20220317
LR  - 20220317
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 35
IP  - 8
DP  - 2022 Apr
TI  - The effect of antithrombotic therapy on the recurrence of placenta-mediated 
      diseases in pregnancy.
PG  - 1462-1468
LID - 10.1080/14767058.2020.1757065 [doi]
AB  - OBJECTIVES: To analyze the recurrence rate of placenta-mediated diseases (PMDs) 
      such as preeclampsia (PE) and/or intrauterine growth restriction (IUGR), 
      intrauterine fetal death (IUFD), and placental abruption (PA) in high-risk 
      patients on antithrombotic therapy (AT) because of a previous obstetrical history 
      for such complications. METHODS: The study group (SG) included 150 patients to 
      whom either 100 mg of aspirin or low-molecular weight heparin (LMWH) was 
      administered due to a previous history of PMDs. The AT in the SG was started 
      before 16 gestational weeks (g.w.). The patients in the first control group 
      (CG-1) were 150 who also had a previous obstetrical history of PMDs, but did not 
      receive antithrombotic therapy (AT) throughout their ongoing pregnancies. The 
      second CG (CG-2) comprised 320 patients with a previous history of normally 
      developing pregnancies and without AT throughout their ongoing pregnancies. 
      RESULTS: The total percentage of PE in pregnant patients from the SG was 25.3% 
      (38/150 patients), with 22.2% (10/45) in the SG on AT only with LDA (SG-LDA 
      group), 25% (17/68) in the SG on AT only with LMWHs (SG-LMWH group) and 29.7% 
      (11/37) in the SG on combined AT with LDA and LMWHs (SG-LDA + LMWH group), as 
      opposed to 18.67% (28/150) in CG-1 and 0.62% (2/320) in CG-2. The recurrent 
      severe PE/total PE ratio in the SG was 44.7% (17/38), with 30% (3/10) in the 
      SG-LDA group, 47% (8/17) in the SG-LMWH group and 54% (6/11) in the SG-LDA + LMWH 
      group, against 75% (21/28) in CG-1. There were no cases with severe PE in CG-2. 
      All cases with recurrent IUGR from the SG were equal to 13.3% (20/150), with 
      13.3% (6/45) in the SG-LDA group, 11.76% (8/68) in the SG-LMWH group and 16.2% 
      (6/37) in the SG-LDA + LMWH group, as compared to 30% (45/150) in CG-1 and 5% 
      (16/320) in CG-2. As a whole, the overall recurrence rate of PMDs in the SG was 
      38.67% (58/150), with 35.56% (16/45) in the SG-LDA group, 36.76% (25/68) in the 
      SG-LMWH group and 45.9% (17/37) in the SG-LDA + LMWH group, as compared to 50.67% 
      (76/150) in CG-1 and 5.94% (19/320) in CG-2. CONCLUSION: AT had a partial 
      beneficial effect on the prophylaxis of recurrent PMDs. On the one hand, AT led 
      to a significant reduction in the recurrent severe PE/total PE ratio, as well as 
      in the total PMDs' recurrence rate in the SG as compared to the one in CG-1. On 
      the other hand, the percentage of recurrent PMDs still remained significantly 
      higher in the SG as compared to CG-2. Pregnant patients with previous PMDs still 
      need close surveillance in subsequent pregnancies as they remain at a high risk 
      for complications.
FAU - Neykova, Konstantsa
AU  - Neykova K
AD  - "Maichin Dom" State University Hospital, Medical University-Sofia, Sofia, 
      Bulgaria.
FAU - Dimitrova, Violeta
AU  - Dimitrova V
AD  - "Maichin Dom" State University Hospital, Medical University-Sofia, Sofia, 
      Bulgaria.
FAU - Dimitrov, Roumen
AU  - Dimitrov R
AD  - "Maichin Dom" State University Hospital, Medical University-Sofia, Sofia, 
      Bulgaria.
LA  - eng
PT  - Journal Article
DEP - 20200514
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - *Fibrinolytic Agents/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Placenta
MH  - *Pre-Eclampsia/drug therapy/epidemiology/prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - Placenta-mediated disorders
OT  - antithrombotic therapy
OT  - low-dose aspirin
OT  - low-molecular weight heparin
OT  - ntrauterine growth restriction
OT  - pregnancy preeclampsia
EDAT- 2020/05/15 06:00
MHDA- 2022/03/18 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2022/03/18 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1080/14767058.2020.1757065 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2022 Apr;35(8):1462-1468. doi: 
      10.1080/14767058.2020.1757065. Epub 2020 May 14.

PMID- 18608260
OWN - NLM
STAT- MEDLINE
DCOM- 20090326
LR  - 20191210
IS  - 1556-9519 (Electronic)
IS  - 1556-3650 (Linking)
VI  - 47
IP  - 2
DP  - 2009 Feb
TI  - Neurotoxicity following chronic intravenous use of "Russian cocktail".
PG  - 157-60
LID - 10.1080/15563650802010388 [doi]
AB  - INTRODUCTION: Recently, neurological abnormalities in methcathinone users have 
      been attributed to manganese. We report similar toxicity in three patients 
      following the use of a mixture similar to methcathinone: potassium permanganate, 
      ephedrine, and aspirin. CASE REPORTS: Three teenagers (15 to 19 years old) 
      presented with extrapyramidal abnormalities and movement disorders following 
      chronic intravenous use of a mixture known as "Russian Cocktail". All three 
      patients had multiple movement disorders. One patient had normal blood manganese 
      concentration (<19 microg/L) and MRI. The other two had elevated blood manganese 
      (2100 microg/L and 3176 microg/L) and MRIs showing bilateral symmetric 
      hyper-intensities on T1-weighted-images in the dentate nucleus, subcortical white 
      substance of cerebellar hemisphere, globus pallidus, and putamen. Abstinence and 
      treatment with EDTA, levodopa, and para-aminosalicylic acid was associated with 
      decreasing blood manganese concentrations and subjective improvement, but no 
      change in objective findings. DISCUSSION: The "Russian Cocktail" likely contains 
      manganese as a result of the oxidation of ephedrine by potassium permanganate in 
      water acidified by acetylsalicylic acid. We believe that manganese with the 
      possible contribution of methcathinone caused the neurological impairments. 
      CONCLUSIONS: Three toxic substances have been made into a mixture administered 
      intravenously, similar to methcathinone. Our patients learned of this mixture, 
      called "Russian Cocktail", from their friends. The toxicity from repeated use of 
      this mixture is one of extrapyramidal abnormalities and movement disorders. 
      Standard therapies were unsuccessful in reversing the clinical toxicity.
FAU - Varlibas, Figen
AU  - Varlibas F
AD  - Haydarpasa Numune Educational and Research Hospital, Neurology, Istanbul, Turkey. 
      figenvar@yahoo.com
FAU - Delipoyraz, Ismail
AU  - Delipoyraz I
FAU - Yuksel, Gulbun
AU  - Yuksel G
FAU - Filiz, Gulmisal
AU  - Filiz G
FAU - Tireli, Hulya
AU  - Tireli H
FAU - Gecim, Nilgun Oto
AU  - Gecim NO
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Clin Toxicol (Phila)
JT  - Clinical toxicology (Philadelphia, Pa.)
JID - 101241654
RN  - 0 (Illicit Drugs)
RN  - 00OT1QX5U4 (Potassium Permanganate)
RN  - 42Z2K6ZL8P (Manganese)
RN  - GN83C131XS (Ephedrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/administration & dosage/metabolism/*poisoning
MH  - Basal Ganglia Diseases/chemically induced
MH  - Dyskinesia, Drug-Induced/etiology
MH  - Ephedrine/administration & dosage/metabolism/*poisoning
MH  - Humans
MH  - Illicit Drugs/metabolism/*poisoning
MH  - Injections, Intravenous
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Manganese/blood
MH  - Manganese Poisoning/blood/*complications/pathology/therapy
MH  - Oxidation-Reduction
MH  - Potassium Permanganate/administration & dosage/metabolism/*poisoning
MH  - *Substance Abuse, Intravenous
MH  - Treatment Failure
MH  - Young Adult
EDAT- 2008/07/09 09:00
MHDA- 2009/03/27 09:00
CRDT- 2008/07/09 09:00
PHST- 2008/07/09 09:00 [pubmed]
PHST- 2009/03/27 09:00 [medline]
PHST- 2008/07/09 09:00 [entrez]
AID - 794095118 [pii]
AID - 10.1080/15563650802010388 [doi]
PST - ppublish
SO  - Clin Toxicol (Phila). 2009 Feb;47(2):157-60. doi: 10.1080/15563650802010388.

PMID- 3078909
OWN - NLM
STAT- MEDLINE
DCOM- 19900621
LR  - 20201209
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 10
IP  - 3
DP  - 1988
TI  - Fiorinal with codeine in the treatment of tension headache--the contribution of 
      components to the combination drug.
PG  - 303-15
AB  - The contribution of the Fiorinal and codeine phosphate components to the 
      effectiveness of the Fiorinal with Codeine combination in the treatment of 
      tension headache symptoms was evaluated in a randomized, placebo-controlled, 
      multicenter double-blind study. Patients admitted to the trial took two capsules 
      of Fiorinal with Codeine, Fiorinal alone, codeine alone, or placebo during each 
      of two tension headache attacks. Immediately before and at intervals up to four 
      hours after drug ingestion, patients rated pain severity, pain relief, the tense 
      and uptight feeling, and muscle stiffness. The response to treatment was 
      evaluated in 154 patients. Despite a high placebo response, a factor known to 
      obscure the contribution of components, Fiorinal and codeine were each found to 
      contribute significantly to the therapeutic effect of the Fiorinal with Codeine 
      combination. Statistical or borderline superiority of the combination drug over 
      Fiorinal alone was seen most frequently at the early evaluations, a finding that 
      reflected the rapid onset of action of codeine. Statistically significant 
      differences between Fiorinal with Codeine and codeine alone seen principally at 
      the later assessments reflected the long duration of action of the Fiorinal 
      component. The frequency of adverse reactions did not differ significantly among 
      the four study groups.
FAU - Friedman, A P
AU  - Friedman AP
AD  - Sandoz Pharmaceuticals Corporation, East Hanover, New Jersey.
FAU - Boyles, W F
AU  - Boyles WF
FAU - Elkind, A H
AU  - Elkind AH
FAU - Fillingim, J
AU  - Fillingim J
FAU - Ford, R G
AU  - Ford RG
FAU - Gallagher, R M
AU  - Gallagher RM
FAU - Hobbs, D
AU  - Hobbs D
FAU - Rapoport, A
AU  - Rapoport A
FAU - Richards, B A
AU  - Richards BA
FAU - Sheftell, F D
AU  - Sheftell FD
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Barbiturates)
RN  - 0 (Drug Combinations)
RN  - 3G6A5W338E (Caffeine)
RN  - 51005-25-5 (aspirin, butalbital and caffeine drug combination)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Barbiturates/administration & dosage/adverse effects/*therapeutic use
MH  - *Caffeine
MH  - Codeine/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations/administration & dosage/adverse effects/therapeutic use
MH  - Female
MH  - Headache/complications/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscular Diseases/complications/drug therapy
MH  - Phenacetin/administration & dosage/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1988;10(3):303-15.

PMID- 32535773
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1432-2161 (Electronic)
IS  - 0364-2348 (Linking)
VI  - 49
IP  - 11
DP  - 2020 Nov
TI  - Association of aspirin and other non-steroidal anti-inflammatory drugs with 
      bleeding complications in image-guided musculoskeletal biopsies.
PG  - 1849-1854
LID - 10.1007/s00256-020-03510-z [doi]
AB  - OBJECTIVE: To evaluate the safety of continuing aspirin and other non-steroidal 
      anti-inflammatory drugs (NSAID) in patients undergoing image-guided 
      musculoskeletal biopsies. MATERIAL AND METHODS: Prior to October 2017, patients 
      undergoing image-guided musculoskeletal biopsy had aspirin and NSAIDs withheld 
      for the preceding 5-7 days. The policy changed in October 2017 based on new 
      guidelines from the Society of Interventional Radiology such that aspirin and 
      other NSAIDs were not withheld. A retrospective review of patient records was 
      performed for all biopsies prior to and after the policy change to assess for 
      differences in biopsy-related bleeding complications. Additional clinical and 
      biopsy factors including age, gender, liver disease, coagulopathy, biopsy tissue 
      type, and histological diagnosis were assessed. RESULTS: In the pre-policy change 
      group, there were 1853 total biopsies with 43 biopsy-related bleeding 
      complications (2.3%). Within this group, 362 patients were on aspirin with 7 
      bleeding complications (1.9%) and 260 patients were on NSAIDs with 5 bleeding 
      complications (1.9%). There were 409 total biopsies in the post-policy change 
      group and 7 bleeding complications (1.7%). Within this group, 71 patients were on 
      aspirin with 1 bleeding complication (1.4%). No bleeding complications were 
      recorded in patients on NSAIDs (0%). There was no significant difference in 
      bleeding complication between the pre- and post-policy change groups overall 
      (p = 0.58) and in patients on aspirin (p = 1.00) or other NSAIDs (p = 1.00). 
      CONCLUSION: Bleeding complications for musculoskeletal biopsies are rare. Leaving 
      patients on aspirin or other NSAIDs during a musculoskeletal biopsy does not 
      increase the incidence of bleeding complications.
FAU - Zandee van Rilland, Eddy
AU  - Zandee van Rilland E
AD  - Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline 
      Avenue, Boston, MA, 02215, USA. ezandee@bidmc.harvard.edu.
FAU - Kim, Stanley
AU  - Kim S
AD  - Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline 
      Avenue, Boston, MA, 02215, USA.
FAU - Ni Mhuircheartaigh, Jennifer
AU  - Ni Mhuircheartaigh J
AD  - Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline 
      Avenue, Boston, MA, 02215, USA.
FAU - Shif, Yuri
AU  - Shif Y
AD  - Department of Radiology, St. Luke's Hospital of Kansas City, 4401 Wornall Road, 
      Kansas City, MO, 64111, USA.
FAU - Kung, Justin
AU  - Kung J
AD  - Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline 
      Avenue, Boston, MA, 02215, USA.
FAU - Wu, Jim S
AU  - Wu JS
AD  - Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline 
      Avenue, Boston, MA, 02215, USA.
LA  - eng
PT  - Journal Article
DEP - 20200613
PL  - Germany
TA  - Skeletal Radiol
JT  - Skeletal radiology
JID - 7701953
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - *Aspirin/adverse effects
MH  - Biopsy
MH  - Humans
MH  - *Image-Guided Biopsy
MH  - Musculoskeletal Diseases/diagnosis
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - Antiplatelet
OT  - Aspirin
OT  - Bleeding
OT  - Musculoskeletal biopsy
OT  - NSAID
EDAT- 2020/06/15 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/15 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/06/07 00:00 [accepted]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/15 06:00 [entrez]
AID - 10.1007/s00256-020-03510-z [pii]
AID - 10.1007/s00256-020-03510-z [doi]
PST - ppublish
SO  - Skeletal Radiol. 2020 Nov;49(11):1849-1854. doi: 10.1007/s00256-020-03510-z. Epub 
      2020 Jun 13.

PMID- 2438534
OWN - NLM
STAT- MEDLINE
DCOM- 19870629
LR  - 20190918
IS  - 0738-1085 (Print)
IS  - 0738-1085 (Linking)
VI  - 8
IP  - 1
DP  - 1987
TI  - Per-operative topical administration of ZK 36 374 (Iloprost) acts favorably on 
      patency of small artery anastomoses in rats.
PG  - 17-21
AB  - Aspirin (group I, 20 mg/kg, 0.5 hour preoperatively, ip, xylocaine (group II, 
      topical administration of 1 ml of a 2% solution), and ZK 36,374 (Iloprost) either 
      pre- or per- or postoperatively (group III, 10 micrograms/kg 0.5 hour 
      peroperatively iv; group IV, topical administration of 1 ml of a solution 
      containing 25 micrograms/ml peroperatively; and group V, 10 micrograms/kg 0.5 
      hour postoperatively iv) were given to groups of BN female rats in order to 
      improve the patency rate of small artery (less than 0.5 mm) anastomoses. The rats 
      in group VI received saline peroperatively by topical application, this group 
      served as a control. The patency was established by means of arteriography and 
      macroscopical examination. Neither aspirin nor xylocaine improved the number of 
      successful anastomoses. However, Iloprost administered topically, while 
      performing the anastomosis, substantially improved the patency rate when compared 
      with group VI, the control group. In the control group only five out of 21 
      animals showed patent anastomoses, whereas in group IV (Iloprost, topical 
      administration) seven out of ten operations were successful. The results suggest 
      that Iloprost applied locally could be helpful in clinical microsurgery for 
      elective operations as well as in replantation surgery.
FAU - Kort, W J
AU  - Kort WJ
FAU - de Kam, J
AU  - de Kam J
FAU - Westbroek, D L
AU  - Westbroek DL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Microsurgery
JT  - Microsurgery
JID - 8309230
RN  - 98PI200987 (Lidocaine)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - JED5K35YGL (Iloprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteries/*surgery
MH  - Aspirin/pharmacology
MH  - Epoprostenol/*pharmacology
MH  - Female
MH  - Iloprost
MH  - *Injections, Intra-Arterial
MH  - Intraoperative Period
MH  - Lidocaine/pharmacology
MH  - *Microsurgery
MH  - Rats
MH  - Rats, Inbred BN
MH  - Vascular Patency/*drug effects
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1002/micr.1920080106 [doi]
PST - ppublish
SO  - Microsurgery. 1987;8(1):17-21. doi: 10.1002/micr.1920080106.

PMID- 6446445
OWN - NLM
STAT- MEDLINE
DCOM- 19800928
LR  - 20190908
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 6
IP  - 8
DP  - 1980
TI  - Medicines of choice in low back pain.
PG  - 540-7
AB  - The marketed formulations of 6 analgesic preparations were compared in the 
      treatment of patients suffering from acute exacerbations of low back pain using a 
      crossover trial of balanced incomplete block design. Sixty out-patients with 
      symptoms resulting from a mechanical or degenerative condition were each 
      prescribed 3 drugs which were administered consecutively for 1 week each. The 
      medications (and daily dosages) were coded as A --aspirin (3600 mg), B 
      --dextropropoxyphene plus paracetamol (260 mg plus 2600 mg), C --indomethacin 
      (150 mg), D --mefenamic acid (1500 mg), E --paracetamol (4000 mg), and F 
      --phenylbutazone (300 mg). Daily pain scores were significantly lower (p less 
      than 0.05) during treatment D than during treatments E and B, and significantly 
      lower (p less than 0.05) during treatment A than during treatment B. There were 
      large and significant differences between treatments in the percentages of 
      recommended doses acceptable to the patients and in the number of defaults from 
      the prescribed regimens. The patients chose F and D significantly more (p less 
      than 0.05) often than A. Overall, there were consistently superior performances 
      by mefenamic acid and phenylbutazone with little to choose between the two.
FAU - Evans, D P
AU  - Evans DP
FAU - Burke, M S
AU  - Burke MS
FAU - Newcombe, R G
AU  - Newcombe RG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 362O9ITL9D (Acetaminophen)
RN  - 367589PJ2C (Mefenamic Acid)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Back Pain/*drug therapy
MH  - Dextropropoxyphene/therapeutic use
MH  - Female
MH  - Humans
MH  - Indomethacin/therapeutic use
MH  - Male
MH  - Mefenamic Acid/therapeutic use
MH  - Middle Aged
MH  - Phenylbutazone/therapeutic use
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1185/03007998009109484 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1980;6(8):540-7. doi: 10.1185/03007998009109484.

PMID- 20514409
OWN - NLM
STAT- MEDLINE
DCOM- 20100927
LR  - 20211020
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 37
IP  - 1
DP  - 2010 Jul
TI  - Nanoparticulate delivery of novel drug combination regimens for the 
      chemoprevention of colon cancer.
PG  - 177-85
AB  - The purpose of this work was to assess synergistic inhibitory responses of a 
      novel chemopreventive combination regimen of drugs namely, aspirin in combination 
      with calcium and folic acid on two human colon cancer cell lines, HT-29 and 
      SW-480. Subsequently, based on positive responses, nanotechnology-based 
      formulations were developed for the targeted delivery of these combinatorial 
      regimens to the colon for the chemoprevention of colon cancer. Additionally, 
      conventional drug formulations using controlled release polymers chitosan, pectin 
      and hydroxypropyl methylcellulose (HPMC) were tested for release of the drugs, 
      for comparison purposes. Chemopreventive combination regimens demonstrated 
      significant synergistic efficacy in both cell lines from XTT assay studies, when 
      compared to the effects of individual agents. Approximately 45% decrease in cell 
      viability for aspirin (15 mM) and calcium (30 mM) mixtures was observed in HT-29 
      cell lines, compared to approximately 55% decrease by the same combination in 
      SW-480 cell lines. With combinations of aspirin (5 mM) and folic acid (1.5 mM), 
      HT-29 cells demonstrated a 30% decrease in cell viability compared to 
      approximately 38% decrease in the SW-480 cell line. Overall, all drug 
      combinations demonstrated significant synergistic responses in the cell lines 
      tested with the SW-480 cell line being more significantly affected by the drug 
      regimens than the HT-29 cell line. Drug encapsulated nanoparticles demonstrated a 
      spherical morphology, <125 nm average particle size (aspirin and folic acid) of 
      nanoparticles and encapsulation efficiencies in the range of 80-91%. Drug release 
      from nanoparticles was controlled with approximately 60% of the original amount 
      released over a 96 h period. Conventional formulations exhibited faster kinetics 
      of drug release when compared to the PLGA nanoparticles. Overall, the cell line 
      studies demonstrate, for the first time, the ability of novel chemopreventive 
      combinations to inhibit the growth of colon cancer cells whereas the 
      nanotechnology-based drug delivery system provides valuable evidence for targeted 
      therapy towards colon cancer chemoprevention.
FAU - Kanthamneni, Naveen
AU  - Kanthamneni N
AD  - College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
FAU - Chaudhary, Abhishek
AU  - Chaudhary A
FAU - Wang, Jeffrey
AU  - Wang J
FAU - Prabhu, Sunil
AU  - Prabhu S
LA  - eng
GR  - R03 CA121409/CA/NCI NIH HHS/United States
GR  - R03 CA121409-01A1/CA/NCI NIH HHS/United States
GR  - R03 CA121409-02/CA/NCI NIH HHS/United States
GR  - 5R03CA121409/CA/NCI NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 935E97BOY8 (Folic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Adenocarcinoma/*prevention & control
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Aspirin/administration & dosage/pharmacology
MH  - Calcium/administration & dosage/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Chemoprevention
MH  - Colonic Neoplasms/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Drug Compounding
MH  - Drug Delivery Systems
MH  - Drug Synergism
MH  - Folic Acid/administration & dosage/pharmacology
MH  - HT29 Cells
MH  - Humans
MH  - Lactic Acid/chemistry
MH  - Nanoparticles/chemistry/*therapeutic use
MH  - Particle Size
MH  - Polyglycolic Acid/chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
PMC - PMC2901928
MID - NIHMS209420
EDAT- 2010/06/02 06:00
MHDA- 2010/09/29 06:00
CRDT- 2010/06/02 06:00
PHST- 2010/06/02 06:00 [entrez]
PHST- 2010/06/02 06:00 [pubmed]
PHST- 2010/09/29 06:00 [medline]
AID - 10.3892/ijo_00000665 [doi]
PST - ppublish
SO  - Int J Oncol. 2010 Jul;37(1):177-85. doi: 10.3892/ijo_00000665.

PMID- 16493264
OWN - NLM
STAT- MEDLINE
DCOM- 20080630
LR  - 20131121
IS  - 1473-656X (Electronic)
IS  - 1040-872X (Linking)
VI  - 18
IP  - 1
DP  - 2006 Feb
TI  - Aspirin and NSAIDs: effects in breast and ovarian cancers.
PG  - 71-5
AB  - PURPOSE OF REVIEW: The purpose of this review is to provide clinicians with 
      current concepts regarding prevention for breast and ovarian cancers. 
      Specifically, this review will provide evidence for the chemoprevention of breast 
      and ovarian cancers with analgesics, such as aspirin, non-steroidal 
      anti-inflammatory drugs (NSAIDs), and acetaminophen. RECENT FINDINGS: Preclinical 
      investigations provide consistent evidence that NSAIDs effectively inhibit the 
      carcinogenesis of epithelial tumors, especially colon and gastrointestinal tract 
      cancers, but also breast and ovarian cancers. The anti-tumor effects of aspirin 
      and other NSAIDs are thought to arise primarily from an inhibition of 
      cyclooxygenase-2. Recent studies have also supported a link between 
      cyclooxygenase-2-mediated prostaglandin production and estrogen biosynthesis via 
      the aromatase enzyme. In addition, some epidemiologic studies have reported that 
      hormone-receptor-positive breast tumors are more responsive to aspirin, which is 
      consistent with these preclinical findings. A recent large-scale randomized trial 
      found, however, that low-dose aspirin in healthy women did not reduce the 
      incidence of either breast or ovarian cancers. SUMMARY: There is significant 
      preclinical evidence to support the chemopreventive effects of aspirin, NSAIDs, 
      and acetaminophen. Given the conflicting data from observational studies and the 
      null results from a limited number of randomized trials, it is, however, too 
      early to suggest that the regular use of these analgesics could help prevent 
      breast or ovarian cancers.
FAU - Crew, Katherine D
AU  - Crew KD
AD  - Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of 
      Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public 
      Health, Columbia University, New York, USA. kd59@columbia.edu
FAU - Neugut, Alfred I
AU  - Neugut AI
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Obstet Gynecol
JT  - Current opinion in obstetrics & gynecology
JID - 9007264
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Analgesics/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Breast Neoplasms/*prevention & control
MH  - Female
MH  - Humans
MH  - Ovarian Neoplasms/*prevention & control
RF  - 39
EDAT- 2006/02/24 09:00
MHDA- 2008/07/01 09:00
CRDT- 2006/02/24 09:00
PHST- 2006/02/24 09:00 [pubmed]
PHST- 2008/07/01 09:00 [medline]
PHST- 2006/02/24 09:00 [entrez]
AID - 00001703-200602000-00015 [pii]
AID - 10.1097/01.gco.0000192972.54105.cf [doi]
PST - ppublish
SO  - Curr Opin Obstet Gynecol. 2006 Feb;18(1):71-5. doi: 
      10.1097/01.gco.0000192972.54105.cf.

PMID- 27354081
OWN - NLM
STAT- MEDLINE
DCOM- 20171214
LR  - 20190202
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 6
IP  - 6
DP  - 2016 Jun 28
TI  - Study protocol for the randomised controlled trial: combined multimarker 
      screening and randomised patient treatment with ASpirin for evidence-based 
      PREeclampsia prevention (ASPRE).
PG  - e011801
LID - 10.1136/bmjopen-2016-011801 [doi]
LID - e011801
AB  - INTRODUCTION: Pre-eclampsia (PE) affects 2-3% of all pregnancies and is a major 
      cause of maternal and perinatal morbidity and mortality. Prophylactic use of 
      low-dose aspirin in women at risk for PE may substantially reduce the prevalence 
      of the disease. Effective screening for PE requiring delivery before 37 weeks 
      (preterm PE) can be provided by a combination of maternal factors, uterine artery 
      Doppler, mean arterial pressure, maternal serum pregnancy-associated plasma 
      protein A and placental growth factor at 11-13 weeks' gestation, with a detection 
      rate of 75% at a false-positive rate of 10%. We present a protocol (V.6, date 25 
      January 2016) for the ASpirin for evidence-based PREeclampsia prevention (ASPRE) 
      trial, which is a double-blinded, placebo-controlled, randomised controlled trial 
      (RCT) that uses an effective PE screening programme to determine whether low-dose 
      aspirin given to women from 11 to 13 weeks' gestation will reduce the incidence 
      of preterm PE. METHODS AND ANALYSIS: All eligible women attending for their first 
      trimester scan will be invited to participate in the screening study for preterm 
      PE. Those found to be at high risk of developing preterm PE will be invited to 
      participate in the RCT. Further scans will be conducted for assessment of fetal 
      growth and biomarkers. Pregnancy and neonatal outcomes will be collected and 
      analysed. The first enrolment for the pilot study was in April 2014. As of April 
      2016, 26 670 women have been screened and 1760 recruited to the RCT. The study is 
      registered on the International Standard Randomised Controlled Trial Number 
      (ISRCTN) registry. TRIAL REGISTRATION NUMBER: ISRCTN13633058.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://www.bmj.com/company/products-services/rights-and-licensing/
FAU - O'Gorman, Neil
AU  - O'Gorman N
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, 
      London, UK.
FAU - Wright, David
AU  - Wright D
AD  - Institute of Health Research, University of Exeter, Exeter, UK.
FAU - Rolnik, Daniel L
AU  - Rolnik DL
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, 
      London, UK.
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, 
      London, UK.
FAU - Poon, Liona C
AU  - Poon LC
AD  - Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, 
      London, UK.
LA  - eng
SI  - ISRCTN/ISRCTN13633058
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 144589-93-5 (Placenta Growth Factor)
RN  - EC 3.4.24.- (Pregnancy-Associated Plasma Protein-A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Infant, Newborn
MH  - Logistic Models
MH  - Mass Screening/*methods
MH  - Pilot Projects
MH  - Placenta Growth Factor/blood
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Pre-Eclampsia/diagnosis/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Pregnancy-Associated Plasma Protein-A/analysis
MH  - Research Design
MH  - United Kingdom
MH  - Young Adult
PMC - PMC4932292
EDAT- 2016/06/30 06:00
MHDA- 2017/12/15 06:00
CRDT- 2016/06/30 06:00
PHST- 2016/06/30 06:00 [entrez]
PHST- 2016/06/30 06:00 [pubmed]
PHST- 2017/12/15 06:00 [medline]
AID - bmjopen-2016-011801 [pii]
AID - 10.1136/bmjopen-2016-011801 [doi]
PST - epublish
SO  - BMJ Open. 2016 Jun 28;6(6):e011801. doi: 10.1136/bmjopen-2016-011801.

PMID- 27296055
OWN - NLM
STAT- MEDLINE
DCOM- 20170921
LR  - 20180620
IS  - 1526-4637 (Electronic)
IS  - 1526-2375 (Linking)
VI  - 17
IP  - 11
DP  - 2016 Nov
TI  - Bleeding Complications in Patients Undergoing Percutaneous Spinal Cord Stimulator 
      Trials and Implantations.
PG  - 2076-2081
AB  - INTRODUCTION: Spinal cord stimulators (SCS) are indicated for the management of 
      multiple pain states with strong evidence. Recent guidelines recommend 
      discontinuing aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) for the 
      described procedures. The goal of this investigation is to assess the rate of 
      bleeding and neurologic sequelae in patients undergoing SCS trials and 
      implantation. METHODS: This is a retrospective review from 2005 through 2014 of 
      all patients 18 years or older undergoing the following procedures: Percutaneous 
      SCS implantations, SCS revisions, and SCS trials. Baseline characteristics, 
      antiplatelet and anticoagulation medications, coagulation parameters, and 
      procedural details were extracted. The primary outcome was the presence of a 
      bleeding complication within 31 days of the procedure requiring emergency 
      medicine, neurology, or neurosurgical evaluation. The neurological complication 
      was independently categorized for its potential relationship to procedural 
      bleeding, and periprocedural red blood cell transfusion requirements were 
      analyzed as a secondary outcome. RESULTS: A total of 642 percutaneous SCS 
      procedures were performed on 421 unique patients, including 346 SCS trials, 255 
      SCS implantations, and 41 revision surgeries. Patients had received aspirin or 
      NSAIDs within 7 days of needle placement for 101 procedures (15.7%). There were 
      no bleeding or neurological complications identified in this cohort. CONCLUSION: 
      Although the incidence of epidural hematoma is low, the development of bleeding 
      complications following SCS lead placement can be devastating. In the present 
      investigation, we identified no cases of epidural hematoma following percutaneous 
      SCS lead placement, including more than 100 patients receiving aspirin or NSAIDs. 
      Future investigations with larger numbers are needed to better define the 
      relationships between periprocedural aspirin and NSAID utilization and bleeding 
      complications.
CI  - © 2016 American Academy of Pain Medicine. All rights reserved. For permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Moeschler, Susan M
AU  - Moeschler SM
AD  - Departments of *Anesthesiology moeschler.susan@mayo.edu.
AD  - Divisions of Pain Medicine and.
FAU - Warner, Nafisseh S
AU  - Warner NS
AD  - Departments of *Anesthesiology.
FAU - Lamer, Tim J
AU  - Lamer TJ
AD  - Departments of *Anesthesiology.
AD  - Divisions of Pain Medicine and.
FAU - Bendel, Markus A
AU  - Bendel MA
AD  - Departments of *Anesthesiology.
AD  - Divisions of Pain Medicine and.
FAU - Warner, Matthew A
AU  - Warner MA
AD  - Departments of *Anesthesiology.
FAU - Eldrige, Jason S
AU  - Eldrige JS
AD  - Departments of *Anesthesiology.
AD  - Divisions of Pain Medicine and.
FAU - Mauck, William D
AU  - Mauck WD
AD  - Departments of *Anesthesiology.
AD  - Divisions of Pain Medicine and.
FAU - Gazelka, Halena M
AU  - Gazelka HM
AD  - Departments of *Anesthesiology.
AD  - Divisions of Pain Medicine and.
FAU - Kor, Daryl J
AU  - Kor DJ
AD  - Departments of *Anesthesiology.
AD  - Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Hoelzer, Bryan C
AU  - Hoelzer BC
AD  - Departments of *Anesthesiology.
AD  - Divisions of Pain Medicine and.
LA  - eng
PT  - Journal Article
DEP - 20160612
PL  - England
TA  - Pain Med
JT  - Pain medicine (Malden, Mass.)
JID - 100894201
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Cohort Studies
MH  - Electrodes, Implanted/*adverse effects/trends
MH  - Female
MH  - Hemorrhage/*diagnosis/epidemiology/*etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Spinal Cord Stimulation/*adverse effects/trends
OTO - NOTNLM
OT  - Anticoagulation
OT  - Bleeding
OT  - Spinal Cord Stimulation
EDAT- 2016/06/15 06:00
MHDA- 2017/09/22 06:00
CRDT- 2016/06/15 06:00
PHST- 2016/06/15 06:00 [pubmed]
PHST- 2017/09/22 06:00 [medline]
PHST- 2016/06/15 06:00 [entrez]
AID - pnw124 [pii]
AID - 10.1093/pm/pnw124 [doi]
PST - ppublish
SO  - Pain Med. 2016 Nov;17(11):2076-2081. doi: 10.1093/pm/pnw124. Epub 2016 Jun 12.

PMID- 8225549
OWN - NLM
STAT- MEDLINE
DCOM- 19931206
LR  - 20131121
IS  - 0019-5499 (Print)
IS  - 0019-5499 (Linking)
VI  - 37
IP  - 2
DP  - 1993 Apr
TI  - Effect of anti-platelet therapy (aspirin + pentoxiphylline) on plasma lipids in 
      patients of ischaemic stroke.
PG  - 158-60
AB  - Twenty-one patients of ischaemic stroke were put on prolonged administration of 
      antiplatelet drugs (aspirin 320 mg once daily with pentoxiphylline 400 mg thrice 
      daily). The serum lipids along with other biochemical parameters were estimated 
      before starting the treatment and after completion of 2 months of therapy. No 
      significant changes were observed in any of the biochemical parameters including 
      lipid profile except in serum high density lipoprotein (HDL) which increased 
      significantly (< 0.05) after 2 months therapy. It is concluded that 2 months 
      antiplatelet therapy has no adverse metabolic effect in patients of ischaemic 
      stroke and the raised serum HDL may contribute to cerebral protective effect.
FAU - Gaur, S P
AU  - Gaur SP
AD  - Department of Pharmacology and Clinical & Experimental Medicine Central Drug 
      Research Institute, Lucknow.
FAU - Garg, R K
AU  - Garg RK
FAU - Kar, A M
AU  - Kar AM
FAU - Srimal, R C
AU  - Srimal RC
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Physiol Pharmacol
JT  - Indian journal of physiology and pharmacology
JID - 0374707
RN  - 0 (Lipids)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Blood Chemical Analysis
MH  - Brain Ischemia/*blood/drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Lipids/*blood
MH  - Male
MH  - Middle Aged
MH  - Pentoxifylline/*therapeutic use
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Physiol Pharmacol. 1993 Apr;37(2):158-60.

PMID- 7326871
OWN - NLM
STAT- MEDLINE
DCOM- 19820412
LR  - 20181113
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 44
IP  - 3
DP  - 1981 Jun
TI  - Stimulation of human NK cell activity by cultured cells. II Ingestion of aspirin 
      by blood donors suppresses induced NK activity.
PG  - 611-4
AB  - Incubation of mononuclear cells with a melanoma tumour cell. M4, induces a rapid 
      increase in NK cell activity in both normal and tumour patient cells. A marked 
      individual variation among the patient population can be attributed to the prior 
      ingestion of aspirin. Single therapeutic doses of aspirin (two tablets, 660 mg) 
      taken 12 hr prior to donation of the blood sample cause an 80-100% reduction in 
      the NK cell activity induced by M4. Since many patients coming to cancer clinics 
      take aspirin regularly, it is essential that they be questioned about their 
      recent usage of this drug if their cells are to be used in assays for NK 
      activity.
FAU - Grohmann, P H
AU  - Grohmann PH
FAU - Porzsolt, F
AU  - Porzsolt F
FAU - Quirt, I
AU  - Quirt I
FAU - Miller, R G
AU  - Miller RG
FAU - Phillips, R A
AU  - Phillips RA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibody-Dependent Cell Cytotoxicity/drug effects
MH  - Aspirin/*pharmacology
MH  - Blood Specimen Collection
MH  - Cell Line
MH  - Humans
MH  - Killer Cells, Natural/drug effects/*immunology
MH  - Melanoma/immunology
PMC - PMC1537301
EDAT- 1981/06/01 00:00
MHDA- 1981/06/01 00:01
CRDT- 1981/06/01 00:00
PHST- 1981/06/01 00:00 [pubmed]
PHST- 1981/06/01 00:01 [medline]
PHST- 1981/06/01 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Immunol. 1981 Jun;44(3):611-4.

PMID- 1215544
OWN - NLM
STAT- MEDLINE
DCOM- 19760409
LR  - 20190824
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 10
IP  - 5
DP  - 1975 Nov
TI  - Effects of aspirin on renal sodium excretion, blood pressure, and plasma and 
      extracellular fluid volume in salt-loaded rats.
PG  - 825-31
AB  - The effect of aspirin administration and presumed blockade of prostaglandin 
      synthesis on renal sodium excretion, plasma and extracellular fluid volumes, and 
      blood pressure were examined in rats on a high sodium intake. After acute salt 
      loading aspirin treated rats showed an impaired sodium excretion, while no 
      changes in glomerular filtration rate were observed. In chronically loaded rats 
      (7 weeks) administration of aspirin induced significant increases in both plasma 
      and extracellular fluid volume, but no significant changes in blood pressures 
      were found. The results are consistent with the hypothesis that prostaglandins 
      mediate renal sodium excretion and therefore participate in extracellular fluid 
      volume regulation.
FAU - Susic, D
AU  - Susic D
FAU - Sparks, J C
AU  - Sparks JC
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 451W47IQ8X (Sodium Chloride)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Extracellular Space/*drug effects
MH  - Glomerular Filtration Rate/drug effects
MH  - Male
MH  - Plasma Volume/*drug effects
MH  - Rats
MH  - Sodium/*urine
MH  - Sodium Chloride/pharmacology
EDAT- 1975/11/01 00:00
MHDA- 1975/11/01 00:01
CRDT- 1975/11/01 00:00
PHST- 1975/11/01 00:00 [pubmed]
PHST- 1975/11/01 00:01 [medline]
PHST- 1975/11/01 00:00 [entrez]
AID - 0090-6980(75)90011-8 [pii]
AID - 10.1016/0090-6980(75)90011-8 [doi]
PST - ppublish
SO  - Prostaglandins. 1975 Nov;10(5):825-31. doi: 10.1016/0090-6980(75)90011-8.

PMID- 27683757
OWN - NLM
STAT- MEDLINE
DCOM- 20180409
LR  - 20220318
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 116
IP  - 6
DP  - 2016 Nov 30
TI  - Enhanced platelet MRP4 expression and correlation with platelet function in 
      patients under chronic aspirin treatment.
PG  - 1100-1110
AB  - Platelet multidrug resistance protein4 (MRP4)-overexpression has a role in 
      reducing aspirin action. Aspirin in vivo treatment enhances platelet MRP4 
      expression and MRP4 mediated transport inhibition reduces platelet function and 
      delays thrombus formation. The aim of our work was to verify whether MRP4 
      expression is enhanced in platelets obtained from patients under chronic aspirin 
      treatment and whether it correlates with residual platelet reactivity. We 
      evaluated changes on mRNA and protein-MRP4 expression and platelet aggregation in 
      four populations: healthy volunteers (HV), aspirin-free control population (CTR), 
      patients who started the treatment less than one month ago (ASA<1 month patients) 
      and aspirinated patients who started the treatment more than two months ago 
      (ASA>2 months patients). In platelets obtained from ASA>2 months patients, it was 
      found a statistically significant MRP4 enhancement of both mRNA and protein 
      expression compared to HV, CTR and ASA<1 month patients. Platelets obtained from 
      ASA>2 months patients that present high levels of platelet MRP4, have higher 
      serum TxB(2) levels and collagen-induced platelet aggregation compared to patient 
      with low levels of MRP4 in platelets. In addition collagen induced platelet 
      aggregation is higher in in vitro aspirinated platelets obtained from patients 
      with high levels of MRP4 patients compared to those obtained from patients with 
      low MRP4 levels. We can assert that, in patients under chronic aspirin treatment, 
      platelets that present high MRP4 levels have an increase of residual platelet 
      reactivity, which is due in part to incomplete COX-1 inhibition, and in part to 
      COX-1-independent mechanism.
FAU - Massimi, Isabella
AU  - Massimi I
FAU - Lotti, Lavinia Vittoria
AU  - Lotti LV
FAU - Temperilli, Flavia
AU  - Temperilli F
FAU - Mancone, Massimo
AU  - Mancone M
FAU - Sardella, Gennaro
AU  - Sardella G
FAU - Calcagno, Simone
AU  - Calcagno S
FAU - Turriziani, Ombretta
AU  - Turriziani O
FAU - Frati, Luigi
AU  - Frati L
FAU - Pulcinelli, Fabio M
AU  - Pulcinelli FM
AD  - Fabio M. Pulcinelli, MD, Department of Experimental Medicine, "Sapienza" 
      University of Rome, Viale Regina Elena 324, 00161, Rome, Italy, Tel.: +39 06 
      49973002, Fax: +39 06 4452955, E-mail: fabio.pulcinelli@uniroma1.it.
LA  - eng
PT  - Journal Article
DEP - 20160929
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (ABCC4 protein, human)
RN  - 0 (Multidrug Resistance-Associated Proteins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multidrug Resistance-Associated Proteins/*metabolism
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors
MH  - Platelet Function Tests
OTO - NOTNLM
OT  - *MRP4
OT  - *Platelet
OT  - *aspirin
OT  - *gene expression
OT  - *platelet aggregation
EDAT- 2016/09/30 06:00
MHDA- 2018/04/10 06:00
CRDT- 2016/09/30 06:00
PHST- 2016/04/20 00:00 [received]
PHST- 2016/08/23 00:00 [accepted]
PHST- 2016/09/30 06:00 [pubmed]
PHST- 2018/04/10 06:00 [medline]
PHST- 2016/09/30 06:00 [entrez]
AID - 16-04-0316 [pii]
AID - 10.1160/TH16-04-0316 [doi]
PST - ppublish
SO  - Thromb Haemost. 2016 Nov 30;116(6):1100-1110. doi: 10.1160/TH16-04-0316. Epub 
      2016 Sep 29.

PMID- 11371024
OWN - NLM
STAT- MEDLINE
DCOM- 20010816
LR  - 20191021
IS  - 0939-5075 (Print)
IS  - 0341-0382 (Linking)
VI  - 56
IP  - 3-4
DP  - 2001 Mar-Apr
TI  - Effect of prostaglandin A1, arsenite and aspirin on stress proteins response in 
      mosquito cells.
PG  - 298-302
AB  - The stress response of eukaryotic cells is characterized by changes in the 
      metabolism of responding cells, most notably by increased synthesis of a group of 
      proteins known as heat shock (HSP) proteins In this paper the effect of 
      prostaglandin A1 (PGA1), arsenite and aspirin in Aedes albopictus cells was 
      investigated. In cells treated with PGA1 (10 microg/ml) we observed the induction 
      of several polypeptides with molecular masses of 87, 80, 70, 57, 29 and 23 kDa. 
      Immunoblot analysis revealed that arsenite induces a marked synthesis of HSP70, 
      and aspirin administered during the hyperthermic treatment caused a small 
      increase of HSP70 synthesized.
FAU - de Meneses, M D
AU  - de Meneses MD
AD  - Departamento de Virologia, Instituto de Microbiologia Professor Paulo de Goés, 
      Universidade Federal do Rio de Janeiro, Brasil.
FAU - Rebello, M A
AU  - Rebello MA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Z Naturforsch C J Biosci
JT  - Zeitschrift fur Naturforschung. C, Journal of biosciences
JID - 8912155
RN  - 0 (Arsenites)
RN  - 0 (HSP70 Heat-Shock Proteins)
RN  - 0 (Heat-Shock Proteins)
RN  - 0 (Prostaglandins A)
RN  - AE28F7PNPL (Methionine)
RN  - N5509X556J (arsenite)
RN  - R16CO5Y76E (Aspirin)
RN  - VYR271N44P (prostaglandin A1)
SB  - IM
MH  - Aedes
MH  - Animals
MH  - Arsenites/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cell Line
MH  - HSP70 Heat-Shock Proteins/*biosynthesis
MH  - Heat-Shock Proteins/*biosynthesis
MH  - Immunoblotting
MH  - Methionine/metabolism
MH  - Molecular Weight
MH  - Prostaglandins A/*pharmacology
EDAT- 2001/05/24 10:00
MHDA- 2001/08/17 10:01
CRDT- 2001/05/24 10:00
PHST- 2001/05/24 10:00 [pubmed]
PHST- 2001/08/17 10:01 [medline]
PHST- 2001/05/24 10:00 [entrez]
AID - 10.1515/znc-2001-3-421 [doi]
PST - ppublish
SO  - Z Naturforsch C J Biosci. 2001 Mar-Apr;56(3-4):298-302. doi: 
      10.1515/znc-2001-3-421.

PMID- 1208538
OWN - NLM
STAT- MEDLINE
DCOM- 19760330
LR  - 20200930
IS  - 0037-9727 (Print)
IS  - 0037-9727 (Linking)
VI  - 150
IP  - 2
DP  - 1975 Nov
TI  - Tartrazine: solid-phase radioimmunoassay studies of an azo dye implicated in 
      allergic reactions (azo dyes and allergy).
PG  - 278-81
AB  - A solid-phase radioimmunoassay procedure was adapted for the haptenic study of 
      tartrazine, an azo dye implicated in various forms of allergy. Further, the 
      haptenic relationship of tartrazine and aspirin was investigated, since 
      sensitivity of individuals to the two substances is often clinically associated. 
      The specificity of antibody to tartrazine was directed strongly toward a 
      pyrazolone intermediate of the molecule, 
      1-(4-sulfophenyl)-3-carboxy-5-hydroxy-pyrazole. Aspirin did not cross-react with 
      anti-tartrazine, suggesting that the clinical association of aspirin and 
      tartrazine sensitivity in patients is a nonimmunological phenomenon.
FAU - Johnson, H M
AU  - Johnson HM
FAU - Smith, B G
AU  - Smith BG
FAU - Kauffman, P E
AU  - Kauffman PE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Proc Soc Exp Biol Med
JT  - Proceedings of the Society for Experimental Biology and Medicine. Society for 
      Experimental Biology and Medicine (New York, N.Y.)
JID - 7505892
RN  - 0 (Antigens)
RN  - 0 (Azo Compounds)
RN  - 0 (Benzenesulfonates)
RN  - 0 (Food Coloring Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antigens
MH  - Aspirin/*immunology
MH  - Azo Compounds/*immunology
MH  - Benzenesulfonates/*immunology
MH  - Drug Hypersensitivity/*etiology
MH  - Food Coloring Agents/*immunology
MH  - Humans
MH  - Radioimmunoassay
EDAT- 1975/11/01 00:00
MHDA- 1975/11/01 00:01
CRDT- 1975/11/01 00:00
PHST- 1975/11/01 00:00 [pubmed]
PHST- 1975/11/01 00:01 [medline]
PHST- 1975/11/01 00:00 [entrez]
AID - 10.3181/00379727-150-39019 [doi]
PST - ppublish
SO  - Proc Soc Exp Biol Med. 1975 Nov;150(2):278-81. doi: 10.3181/00379727-150-39019.

PMID- 24322349
OWN - NLM
STAT- MEDLINE
DCOM- 20140611
LR  - 20131210
IS  - 0021-5252 (Print)
IS  - 0021-5252 (Linking)
VI  - 66
IP  - 13
DP  - 2013 Dec
TI  - [Can local administration of tranexamic acid reduce aspirin-induced bleeding in 
      off-pump coronary artery bypass grafting( CABG) ?].
PG  - 1119-25
AB  - OBJECTIVES: We examined the effect of local administration of tranexamic acid( 
      TA) on reducing aspirin-induced bleeding in off-pump coronary artery bypass 
      grafting(CABG). METHODS: From July 2009 to January 2011, 88 cases with off-pump 
      CABG were divided into 4 groups:group C including 19 cases without preoperative 
      aspirin or local administration of TA, group A including 23 cases with 
      preoperative aspirin alone, group T including 19 cases with local administration 
      of TA alone, and group AT including 27 cases with both preoperative aspirin and 
      local administration of TA. RESULTS: The bleeding volume after 24 hours in group 
      A was significantly larger than that in group C(p=0.0085). The bleeding volume in 
      group AT was significantly smaller than that in group A (p<0.0001), and the 
      bleeding volume in group T was also significantly smaller than that in group C 
      (p=0.0054). There was no significant difference between group T and AT. 
      CONCLUSIONS: The use of local administration of tranexamic acid indicated the 
      reduction of postoperative bleeding even in patients with preoperative aspirin 
      use.
FAU - Aoki, Masakazu
AU  - Aoki M
AD  - Department of Cardiovascular Surgery, Toyohashi Heart Center, Toyohashi, Japan.
FAU - Goto, Yoshihiro
AU  - Goto Y
FAU - Ogawa, Shinji
AU  - Ogawa S
FAU - Baba, Hiroshi
AU  - Baba H
FAU - Okawa, Yasuhide
AU  - Okawa Y
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Kyobu Geka
JT  - Kyobu geka. The Japanese journal of thoracic surgery
JID - 0413533
RN  - 0 (Antifibrinolytic Agents)
RN  - 6T84R30KC1 (Tranexamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antifibrinolytic Agents/*administration & dosage
MH  - Aspirin/*adverse effects
MH  - *Coronary Artery Bypass, Off-Pump
MH  - Female
MH  - Hemorrhage/*chemically induced/*drug therapy
MH  - Humans
MH  - Male
MH  - Tranexamic Acid/*administration & dosage
EDAT- 2013/12/11 06:00
MHDA- 2014/06/12 06:00
CRDT- 2013/12/11 06:00
PHST- 2013/12/11 06:00 [entrez]
PHST- 2013/12/11 06:00 [pubmed]
PHST- 2014/06/12 06:00 [medline]
PST - ppublish
SO  - Kyobu Geka. 2013 Dec;66(13):1119-25.

PMID- 19793502
OWN - NLM
STAT- MEDLINE
DCOM- 20100105
LR  - 20211020
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
VI  - 9
IP  - 5
DP  - 2009 Oct
TI  - What is the best treatment for prediabetes?
PG  - 335-41
AB  - Worldwide, along with the increasing prevalence of obesity, the number of people 
      with prediabetes is increasing. The diagnostic criteria for prediabetes include 
      impaired fasting glucose, impaired glucose tolerance, and metabolic syndrome. The 
      presence of two or more of these three criteria renders a person at high risk for 
      future diabetes. The treatment goal of prediabetes is to prevent future 
      development of type 2 diabetes and diabetes-related cardiovascular complications. 
      The treatment approach is twofold: glycemic control and control of cardiovascular 
      risk factors, mainly hypertension and hyperlipidemia. Intensive lifestyle 
      modification is the mainstay of treatment in low-risk patients. When lifestyle 
      modification fails and in high-risk patients, medications such as metformin 
      and/or acarbose are recommended. For high-risk patients and those who progress 
      despite intensive lifestyle modification, thiazolidinediones are also 
      recommended. The goals for cardiovascular risk factor control are similar to 
      those for patients with diabetes.
FAU - Sharma, Morali D
AU  - Sharma MD
AD  - Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, 
      1709 Dryden, Suite 1000, Houston, TX 77030, USA. msharma@bcm.edu
FAU - Garber, Alan J
AU  - Garber AJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/therapeutic use
MH  - Blood Pressure
MH  - Child
MH  - Drug Therapy/economics/methods
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prediabetic State/diagnosis/prevention & control/*therapy
EDAT- 2009/10/02 06:00
MHDA- 2010/01/06 06:00
CRDT- 2009/10/02 06:00
PHST- 2009/10/02 06:00 [entrez]
PHST- 2009/10/02 06:00 [pubmed]
PHST- 2010/01/06 06:00 [medline]
AID - 10.1007/s11892-009-0053-2 [doi]
PST - ppublish
SO  - Curr Diab Rep. 2009 Oct;9(5):335-41. doi: 10.1007/s11892-009-0053-2.

PMID- 18492127
OWN - NLM
STAT- MEDLINE
DCOM- 20080811
LR  - 20220410
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 66
IP  - 1
DP  - 2008 Jul
TI  - Adherence to statin or aspirin or both in patients with established 
      cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year 
      follow-up of outcome.
PG  - 110-6
LID - 10.1111/j.1365-2125.2008.03212.x [doi]
AB  - AIMS: To characterize adherence in patients with established cardiovascular 
      disease taking statins and aspirin and to estimate the effects of adherence due 
      to health behaviour, a lack of beneficial drug effect, or both on recurrence of 
      cardiovascular disease or all-cause mortality over 10 years. METHODS: A 
      population-based cohort study using a record-linkage database in Tayside, 
      Scotland. Subjects with cardiovascular disease (n = 7657; 4185 aspirin-alone 
      cohort, 671 statin-alone cohort and 2801 combination use cohort) were studied 
      between 1993 and 2003. The effects of adherence on recurrence of cardiovascular 
      disease or mortality were assessed using Poisson regression model. RESULTS: In 
      subjects taking both aspirin and statins, those adherent to statins but not 
      aspirin had a lower risk of recurrence [adjusted risk ratio (RR) 0.64; 95% 
      confidence interval 0.49, 0.82], but those adherent to aspirin but not statins 
      has no such effect (adjusted RR 0.91; 0.72, 1.15), suggesting that adherence 
      behaviour alone was not responsible for the beneficial effect. Within the group 
      adherent to aspirin, > or =80% adherence to statins was associated with reduced 
      recurrence compared with those poorly adherent (adjusted RR 0.76; 0.62, 0.94), 
      but no such effect of aspirin was seen in those adherent to statins. Similar 
      results were found for all-cause mortality. CONCLUSIONS: Poor health behaviour is 
      not a sufficient explanation of adverse outcome in poorly adherent patients. 
      Adverse outcome is more likely to be driven by foregone drug benefits.
FAU - Wei, Li
AU  - Wei L
AD  - Medicines Monitoring Unit (MEMO), Division of Medicine and Therapeutics, 
      Ninewells Hospital and Medical School, Dundee, UK.
FAU - Fahey, Tom
AU  - Fahey T
FAU - MacDonald, Thomas M
AU  - MacDonald TM
LA  - eng
GR  - G106/1249/MRC_/Medical Research Council/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Br J Clin Pharmacol. 2008 Jul;66(1):4-5. PMID: 18582249
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/mortality/prevention & control
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Male
MH  - *Patient Compliance
MH  - Scotland
MH  - Secondary Prevention
MH  - Treatment Outcome
PMC - PMC2485263
EDAT- 2008/05/22 09:00
MHDA- 2008/08/12 09:00
CRDT- 2008/05/22 09:00
PHST- 2008/05/22 09:00 [pubmed]
PHST- 2008/08/12 09:00 [medline]
PHST- 2008/05/22 09:00 [entrez]
AID - BCP3212 [pii]
AID - 10.1111/j.1365-2125.2008.03212.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2008 Jul;66(1):110-6. doi: 10.1111/j.1365-2125.2008.03212.x.

PMID- 18543479
OWN - NLM
STAT- MEDLINE
DCOM- 20100810
LR  - 20161018
IS  - 1003-5370 (Print)
IS  - 1003-5370 (Linking)
VI  - 28
IP  - 4
DP  - 2008 Apr
TI  - [Effects of supplementing qi and activating blood circulation method on platelet 
      aggregation rate, adhesion rate and thromboxane B2 level in patients with stable 
      angina pectoris and intolerable to aspirin].
PG  - 300-3
AB  - OBJECTIVE: To investigate the effects of supplementing qi and activating blood 
      circulation method (YQHX) on platelet aggregation rate (PAgR), platelet adhesion 
      rate (PAdR) and thromboxane B2(TXB2) level in patients with stable angina 
      pectoris and intolerable to aspirin. METHODS: Seventy-six out-patients with 
      stable angina (qi deficiency and blood stasis syndrom) pectoris intolerable to 
      aspirin were randomized into two groups, 40 in the treated group and 36 in the 
      control group. Both received conventional Western medicinal treatment with YQHX 
      to the treated group additionally, for 1 month. PAgR, PAdR, TXB2 level, platelet 
      count, hemoglobin concentration and fecal occult blood were measured before and 1 
      month after treatment, and the cardiac events as well as diges tive symptoms 
      occurred in the observation period were recorded. RESULTS: PAgR, PAdR and TXB2 
      level lowered in the treated group after 1-month treatment showed a significant 
      difference to those of baseline, and also to those in the control group (all P 
      <0.01). But no significant difference was found between pre-treatment and 
      post-treatment, also between the two groups in platelet count, hemoglobin 
      concentration, fecal figure and incidence of adverse cardiac events, as well as 
      digestive symptoms (P > 0.05). CONCLUSION: YQHX can effectively inhibit the 
      platelet function in patients with stable angina pectoris without aggravation of 
      digestive symptoms. Cardiac event reducing effect of YQHX was not seen in this 
      study, it is necessary for large sampled study for confirmation.
FAU - Gao, Lu
AU  - Gao L
AD  - Department of Cardiology, Tianjin Medical University, Tianjin. gaolu626@126.com
FAU - Li, Yong-Jian
AU  - Li YJ
FAU - Chen, Kang-Yin
AU  - Chen KY
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhongguo Zhong Xi Yi Jie He Za Zhi
JT  - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese 
      journal of integrated traditional and Western medicine
JID - 9211576
RN  - 0 (Drugs, Chinese Herbal)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/*drug therapy/metabolism/physiopathology
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Blood Circulation/*drug effects
MH  - Cell Adhesion/drug effects
MH  - Drug Tolerance
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - *Qi
MH  - Thromboxane B2/*blood
MH  - Treatment Outcome
EDAT- 2008/06/12 09:00
MHDA- 2010/08/11 06:00
CRDT- 2008/06/12 09:00
PHST- 2008/06/12 09:00 [pubmed]
PHST- 2010/08/11 06:00 [medline]
PHST- 2008/06/12 09:00 [entrez]
PST - ppublish
SO  - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Apr;28(4):300-3.

PMID- 10216644
OWN - NLM
STAT- MEDLINE
DCOM- 19990506
LR  - 20131121
IS  - 0019-6061 (Print)
IS  - 0019-6061 (Linking)
VI  - 35
IP  - 6
DP  - 1998 Jun
TI  - Effect of maternal low dose aspirin on neonatal platelet function.
PG  - 507-11
AB  - OBJECTIVE: To evaluate the effect of maternal low dose aspirin ingestion in 
      platelet function of newborn. DESIGN: Prospective randomized placebo controlled 
      study. METHODS: 25 neonates born to mothers receiving low dose aspirin and 25 
      matched neonates with no maternal exposure to aspirin were studied. 2 ml of EDTA 
      and 4.5 ml of citrate blood was collected from umbilical vein using double 
      clamped umbilical stump for hemogram, coagulation profile and platelet functions. 
      RESULTS: The platelet counts (10(9)/l) of study and control groups were 186.4 +/- 
      22.76 (116-225) and 205.28 +/- 17.34 (176-225), respectively. There was no 
      significant difference in coagulation parameters. Prothrombin time index (PTI) 
      was 86.24 +/- 6.623 and 87 +/- 6.43, respectively in the study and control group 
      while PTTK (sec) was 55.88 +/- 20.54 and 52.12 +/- 11.82 in study and control 
      subjects, respectively. The platelet aggregation studies (platelet function) with 
      various platelet agonists in study and control group did not show any significant 
      difference. Clinically, none of the babies had bleeding. CONCLUSIONS: Use of low 
      dose aspirin in pregnant women was found to be safe and had no adverse effects on 
      platelet functions of newborn.
FAU - Dasari, R
AU  - Dasari R
AD  - Department of Pediatrics, Post Graduate Institute of Medical Education and 
      Research, Chandigarh.
FAU - Narang, A
AU  - Narang A
FAU - Vasishta, K
AU  - Vasishta K
FAU - Garewal, G
AU  - Garewal G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - India
TA  - Indian Pediatr
JT  - Indian pediatrics
JID - 2985062R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Female
MH  - Fetal Blood
MH  - Humans
MH  - Infant, Newborn/*blood
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Count
MH  - Platelet Function Tests
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Prospective Studies
MH  - Time Factors
EDAT- 1999/04/27 00:00
MHDA- 1999/04/27 00:01
CRDT- 1999/04/27 00:00
PHST- 1999/04/27 00:00 [pubmed]
PHST- 1999/04/27 00:01 [medline]
PHST- 1999/04/27 00:00 [entrez]
PST - ppublish
SO  - Indian Pediatr. 1998 Jun;35(6):507-11.

PMID- 34649036
OWN - NLM
STAT- MEDLINE
DCOM- 20220208
LR  - 20220208
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
VI  - 30
IP  - 12
DP  - 2021 Dec
TI  - Under Treatment of High-Risk TIA Patients with Clopidogrel-Aspirin in the 
      Emergency Setting.
PG  - 106145
LID - S1052-3057(21)00550-4 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2021.106145 [doi]
AB  - BACKGROUND: Treating high-risk transient ischemic attack (TIA) with dual 
      antiplatelet therapy (DAPT) reduces subsequent ischemic stroke risk yet current 
      rates of clopidogrel-aspirin treatment are uncertain. MATERIALS AND METHODS: We 
      conducted a retrospective cohort study of consecutive TIA patients who presented 
      to any of the four emergency departments (ED) of a single urban health system 
      from 1/1/2018-3/1/2020. Medical record review was used to describe the cohort and 
      assess clopidogrel-aspirin treatment. Patient eligibility for clopidogrel-aspirin 
      was determined using relevant criteria from the Platelet-Oriented Inhibition in 
      New TIA and Minor Ischemic Stroke (POINT) Trial. Comparisons among eligible 
      patients who received versus did not receive clopidogrel-aspirin were conducted 
      using t-test, chi-squared, and Mann-Whitney as indicated. RESULTS: We identified 
      248 TIA patients of whom 95 met eligibility criteria for clopidogrel-aspirin 
      treatment. Among these 95 patients, mean age was 69.5 (SD: 12), 68.4% were women, 
      and median ABCD(2) score was 5 (IQR: 4-6). A total of 26/95 (27.4%) eligible 
      patients received clopidogrel-aspirin within 24 hours of symptom onset. 
      Appropriate clopidogrel-aspirin use was associated with having a stroke code 
      called upon ED arrival (88.5% vs. 34.8%; P<0.001), being evaluated by a vascular 
      neurologist (88.5% vs. 21.1%; P<0.001), and not presenting to the community ED 
      site wherein only a single patient received clopidogrel-aspirin. CONCLUSIONS: In 
      a multisite, single health system study, nearly three-fourths of high-risk TIA 
      patients eligible for clopidogrel-aspirin treatment did not receive it. 
      Appropriate clopidogrel-aspirin use was highest among patients seen by vascular 
      neurologists and lowest at the community ED, though under treatment was evident 
      at all sites.
CI  - Copyright © 2021 Elsevier Inc. All rights reserved.
FAU - Lendaris, Andrea R
AU  - Lendaris AR
AD  - Department of Neurology, Montefiore Medical Center, Albert Einstein College of 
      Medicine, Bronx, NY, United States.
FAU - Lessen, Samantha
AU  - Lessen S
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Cheng, Natalie T
AU  - Cheng NT
AD  - Department of Neurology, Montefiore Medical Center, Albert Einstein College of 
      Medicine, Bronx, NY, United States.
FAU - Friedman, Benjamin W
AU  - Friedman BW
AD  - Department of Emergency Medicine, Montefiore Medical Center, Albert Einstein 
      College of Medicine, Bronx, NY, United States.
FAU - Esenwa, Charles
AU  - Esenwa C
AD  - Department of Neurology, Montefiore Medical Center, Albert Einstein College of 
      Medicine, Bronx, NY, United States.
FAU - Labovitz, Daniel L
AU  - Labovitz DL
AD  - Department of Neurology, Montefiore Medical Center, Albert Einstein College of 
      Medicine, Bronx, NY, United States.
FAU - Prabhakaran, Shyam
AU  - Prabhakaran S
AD  - Department of Neurology, University of Chicago School of Medicine, Chicago, IL, 
      United States.
FAU - Lipton, Richard B
AU  - Lipton RB
AD  - Department of Neurology, Montefiore Medical Center, Albert Einstein College of 
      Medicine, Bronx, NY, United States.
FAU - Liberman, Ava L
AU  - Liberman AL
AD  - Weill Cornell Medicine. Electronic address: all9188@med.cornell.edu.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20211011
PL  - United States
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National 
      Stroke Association
JID - 9111633
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aspirin/therapeutic use
MH  - *Clopidogrel/therapeutic use
MH  - Drug Therapy, Combination
MH  - Eligibility Determination
MH  - *Emergency Service, Hospital
MH  - Female
MH  - Humans
MH  - *Ischemic Attack, Transient/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Assessment
OTO - NOTNLM
OT  - Acute ischemic stroke
OT  - Antiplatelet therapy
OT  - Minor stroke
OT  - Transient ischemic attack
EDAT- 2021/10/15 06:00
MHDA- 2022/02/09 06:00
CRDT- 2021/10/14 20:17
PHST- 2021/07/09 00:00 [received]
PHST- 2021/09/26 00:00 [accepted]
PHST- 2021/10/15 06:00 [pubmed]
PHST- 2022/02/09 06:00 [medline]
PHST- 2021/10/14 20:17 [entrez]
AID - S1052-3057(21)00550-4 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2021.106145 [doi]
PST - ppublish
SO  - J Stroke Cerebrovasc Dis. 2021 Dec;30(12):106145. doi: 
      10.1016/j.jstrokecerebrovasdis.2021.106145. Epub 2021 Oct 11.

PMID- 12789737
OWN - NLM
STAT- MEDLINE
DCOM- 20030619
LR  - 20191025
IS  - 1462-3935 (Print)
IS  - 1462-3935 (Linking)
VI  - 64
IP  - 5
DP  - 2003 May
TI  - Thromboprophylaxis in patients undergoing total hip replacement.
PG  - 281-7
AB  - Venous thromboembolism is a common complication following a hip replacement. It 
      was the authors' impression that prophylaxis of deep vein thrombosis has changed 
      in recent years. The authors felt that it was important to repeat a survey, done 
      in 1997, on the use of thromboembolism prophylaxis among British orthopaedic 
      surgeons.
FAU - Brenkel, I J
AU  - Brenkel IJ
AD  - Department of Orthopaedic Surgery, Queen Margaret Hospital, Dunfermline, Fife KY2 
      0TT.
FAU - Cook, R E
AU  - Cook RE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Hosp Med
JT  - Hospital medicine (London, England : 1998)
JID - 9803882
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthroplasty, Replacement, Hip/*adverse effects
MH  - Aspirin/therapeutic use
MH  - Bandages
MH  - Fibrinolytic Agents/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Thromboembolism/*prevention & control
MH  - Venous Thrombosis/*prevention & control
RF  - 43
EDAT- 2003/06/07 05:00
MHDA- 2003/06/20 05:00
CRDT- 2003/06/07 05:00
PHST- 2003/06/07 05:00 [pubmed]
PHST- 2003/06/20 05:00 [medline]
PHST- 2003/06/07 05:00 [entrez]
AID - 10.12968/hosp.2003.64.5.1760 [doi]
PST - ppublish
SO  - Hosp Med. 2003 May;64(5):281-7. doi: 10.12968/hosp.2003.64.5.1760.

PMID- 11402808
OWN - NLM
STAT- MEDLINE
DCOM- 20010927
LR  - 20131121
VI  - 70
IP  - 1-2
DP  - 1999
TI  - [Prevention of preeclampsia with low-dose acetyl salicylic acid: critical 
      assessment].
PG  - 29-35
AB  - The Authors present a critical review of the published literature about the 
      effect of low dose of acido acetilsalicilico on prevention and treatment of 
      preeclampic. Beginning from the effects of low daily dose of acido 
      acetilsalicilico on the pregnancy, the Authors present the published datas from 
      1970 until today, and suggest the present directions for use of acido 
      acetilsalicilico in pregnancy.
FAU - Verrotti, C
AU  - Verrotti C
AD  - Istituto di Clinica Ostetrica e Ginecologica Cattedra di Puericultura Prenatale 
      Università degli Studi di Parma.
FAU - Fieni, S
AU  - Fieni S
FAU - Gualdi, M
AU  - Gualdi M
FAU - Cavatorta, E
AU  - Cavatorta E
LA  - ita
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Prevenzione della preeclampsia con acido acetil salicilico a basse dosi: 
      valutazione critica.
PL  - Italy
TA  - Acta Biomed Ateneo Parmense
JT  - Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze 
      naturali di Parma
JID - 8106323
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Cyclooxygenase Inhibitors/*administration & dosage
MH  - Female
MH  - Humans
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
RF  - 17
EDAT- 2001/06/14 10:00
MHDA- 2001/09/28 10:01
CRDT- 2001/06/14 10:00
PHST- 2001/06/14 10:00 [pubmed]
PHST- 2001/09/28 10:01 [medline]
PHST- 2001/06/14 10:00 [entrez]
PST - ppublish
SO  - Acta Biomed Ateneo Parmense. 1999;70(1-2):29-35.

PMID- 6369302
OWN - NLM
STAT- MEDLINE
DCOM- 19840510
LR  - 20160725
IS  - 0375-9660 (Print)
IS  - 0375-9660 (Linking)
VI  - 30
IP  - 1
DP  - 1984 Jan-Feb
TI  - [Mechanism of the anti-aggregation action of thyroxine and insulin].
PG  - 61-5
AB  - Thyroxine and insulin inhibit the aggregation capacity of platelets. To study the 
      mechanisms of the antiaggregation action of thyroxine and insulin, platelets 
      obtained from patients with diffuse toxic goiter and from rabbits with 
      experimental hyperinsulinemia were incubated with acetylsalicylic acid and 
      indomethacin. Acetylsalicylic acid or indomethacin were found to suppress the 
      aggregation activity of thyrotoxicosis patients' platelets. Acetylsalicylic acid 
      did not inhibit the aggregation activity of platelets of the rabbits pretreated 
      with insulin. Based on the data obtained a hypothesis is advanced according to 
      which thyroxine inhibits the platelet aggregation, interfering with the release 
      of arachidonic acid from phospholipids of platelets (thrombocytopathy A), whereas 
      insulin--by blocking the cyclooxygenase activity (thrombocytopathy B).
FAU - Kirichuk, V F
AU  - Kirichuk VF
FAU - Puchin'ian, D M
AU  - Puchin'ian DM
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Mekhanizmy antiagregatsionnogo deĭstviia tiroksina i insulina.
PL  - Russia (Federation)
TA  - Probl Endokrinol (Mosk)
JT  - Problemy endokrinologii
JID - 0140673
RN  - 0 (Anticoagulants)
RN  - 0 (Hormones)
RN  - 0 (Insulin)
RN  - Q51BO43MG4 (Thyroxine)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anticoagulants
MH  - Aspirin/pharmacology
MH  - Depression, Chemical
MH  - Hormones/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Indomethacin/pharmacology
MH  - Insulin/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Rabbits
MH  - Thyroxine/*pharmacology
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Probl Endokrinol (Mosk). 1984 Jan-Feb;30(1):61-5.

PMID- 36914957
OWN - NLM
STAT- MEDLINE
DCOM- 20230413
LR  - 20230813
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 136
IP  - 5
DP  - 2023 Mar 5
TI  - Low-dose aspirin in the prevention of pre-eclampsia in China: postpartum 
      hemorrhage in subgroups of women according to their characteristics and potential 
      bleeding risk.
PG  - 550-555
LID - 10.1097/CM9.0000000000002545 [doi]
AB  - BACKGROUND: The APPEC study is a large-population randomized controlled trial in 
      China evaluating the role of low-dose aspirin prophylactic treatment for 
      pre-eclampsia. There was no statistically significant difference in postpartum 
      hemorrhage (PPH) incidence between the aspirin and control groups. This study 
      aimed to evaluate the potential bleeding risk of 100 mg aspirin in high-risk 
      pregnant women and the difference in the incidence of PPH according to maternal 
      characteristics. METHODS: This is a secondary data analysis of the APPEC study. 
      Platelet counts and coagulation test results were collected at five follow-up 
      visits. Subgroups defined by maternal age (<35 years and ≥35 years), 
      pre-pregnancy body mass index (pre-BMI, <28 kg/m 2 and ≥28 kg/m 2 ), parity, 
      gestational age at enrollment, and medical history, including pre-eclampsia, 
      chronic hypertension, and diabetes mellitus, were analyzed. Logistic regression 
      analysis was used to determine the statistical significance of the difference in 
      the incidence of PPH after aspirin administration in pregnant women in each 
      subgroup. Adjustment using multiple logistic regression models followed these 
      analyses. Binary logistic regression was used to determine the relationship 
      between pre-BMI and PPH. RESULTS: There was no significant difference between the 
      aspirin and control groups in bleeding risk (3.4% [16/464] vs. 3.0% [13/434], 
      T = 0.147, P  = 0.701). No significant difference was found in the incidence of 
      PPH in total (relative risk  = 1.220, 95% confidence interval [CI] = 0.720-2.067, 
      P  = 0.459; aspirin group vs. control group, 6.5% [30/464] vs. 5.3% [23/434], P 
       = 0.459) or in subgroup analysis. A significant correlation between pre-BMI and 
      PPH was found in the aspirin group, while in the control group there was no 
      significant correlation (aspirin group, odds ratio [OR] = 1.086, 95% 
      CI = 1.004-1.175, P  = 0.040; control group, OR = 1.060, 95% CI = 0.968-1.161, P 
       = 0.209). CONCLUSIONS: A dosage of 100 mg of aspirin per day, initiated from 12 
      to 20 gestational weeks until 34 weeks of gestation, did not increase the risk of 
      potential bleeding and PPH regardless of the maternal characteristic. In the 
      aspirin group, the positive correlation between BMI and PPH was significant. 
      TRIAL REGISTRATION: ClinicalTrials.gov, NCT01979627.
CI  - Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, 
      Inc. under the CC-BY-NC-ND license.
FAU - Chen, Jiahui
AU  - Chen J
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing 100034, China.
AD  - Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes 
      Mellitus, Beijing 100034, China.
FAU - Huai, Jing
AU  - Huai J
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing 100034, China.
AD  - Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes 
      Mellitus, Beijing 100034, China.
FAU - Lin, Li
AU  - Lin L
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing 100034, China.
AD  - Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes 
      Mellitus, Beijing 100034, China.
FAU - Li, Boya
AU  - Li B
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing 100034, China.
AD  - Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes 
      Mellitus, Beijing 100034, China.
FAU - Zhu, Yuchun
AU  - Zhu Y
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing 100034, China.
AD  - Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes 
      Mellitus, Beijing 100034, China.
FAU - Yang, Huixia
AU  - Yang H
AD  - Department of Obstetrics and Gynecology, Peking University First Hospital, 
      Beijing 100034, China.
AD  - Beijing Key Laboratory of Maternal Fetal Medicine of Gestational Diabetes 
      Mellitus, Beijing 100034, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT01979627
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20230305
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Pregnancy
MH  - Humans
MH  - Adult
MH  - *Pre-Eclampsia/drug therapy
MH  - *Postpartum Hemorrhage/drug therapy/prevention & control
MH  - Aspirin/therapeutic use
MH  - Maternal Age
MH  - Incidence
PMC - PMC10106256
COIS- None.
EDAT- 2023/03/15 06:00
MHDA- 2023/04/13 06:42
CRDT- 2023/03/14 00:52
PHST- 2023/04/13 06:42 [medline]
PHST- 2023/03/15 06:00 [pubmed]
PHST- 2023/03/14 00:52 [entrez]
AID - 00029330-202303050-00007 [pii]
AID - CMJ-2022-827 [pii]
AID - 10.1097/CM9.0000000000002545 [doi]
PST - epublish
SO  - Chin Med J (Engl). 2023 Mar 5;136(5):550-555. doi: 10.1097/CM9.0000000000002545.

PMID- 7105533
OWN - NLM
STAT- MEDLINE
DCOM- 19821012
LR  - 20161123
IS  - 0009-921X (Print)
IS  - 0009-921X (Linking)
IP  - 168
DP  - 1982 Aug
TI  - Aspirin prophylaxis for pulmonary embolism following total hip arthroplasty. An 
      incidence study.
PG  - 119-23
AB  - Although this study was performed on a relatively small number of patients 
      undergoing total hip arthroplasty in conjunction with aspirin prophylaxis for 
      postoperative pulmonary embolism, several important points are noted: the use of 
      pre- and postoperative lung perfusion scanning can eliminate a 15% rate of 
      false-positive diagnosis of pulmonary embolism, and pulmonary embolism occurred 
      in approximately 8% of patients undergoing total hip arthroplasty in conjunction 
      with aspirin prophylaxis, without fatality. This occurred despite the inclusion 
      of high-risk patients. "Silent" pulmonary embolization occurred in 4.1% of these 
      patients. Patients who have a history of a thromboembolism, a delayed 
      postoperative course, and two or more risk factors for pulmonary embolism 
      present, are at risk of developing a postoperative pulmonary embolism, despite 
      aspirin therapy, and should be managed more aggressively, i.e., early detection 
      or prophylactic anticoagulation therapy.
FAU - Stulberg, B N
AU  - Stulberg BN
FAU - Dorr, L D
AU  - Dorr LD
FAU - Ranawat, C S
AU  - Ranawat CS
FAU - Schneider, R
AU  - Schneider R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - *Hip Prosthesis
MH  - Humans
MH  - Lung/diagnostic imaging
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
MH  - Prospective Studies
MH  - Pulmonary Embolism/diagnostic imaging/*prevention & control
MH  - Radionuclide Imaging
MH  - Risk
EDAT- 1982/08/01 00:00
MHDA- 1982/08/01 00:01
CRDT- 1982/08/01 00:00
PHST- 1982/08/01 00:00 [pubmed]
PHST- 1982/08/01 00:01 [medline]
PHST- 1982/08/01 00:00 [entrez]
PST - ppublish
SO  - Clin Orthop Relat Res. 1982 Aug;(168):119-23.

PMID- 7457723
OWN - NLM
STAT- MEDLINE
DCOM- 19810324
LR  - 20190627
IS  - 0002-9610 (Print)
IS  - 0002-9610 (Linking)
VI  - 141
IP  - 1
DP  - 1981 Jan
TI  - Effect of 16, 16 dimethyl prostaglandin E2 on aspirin-induced permeability 
      changes in the pancreatic duct.
PG  - 22-7
AB  - Perfusion of the pancreatic duct with acidified aspirin in cats increased the 
      permeability of the duct to HCO3-. Intravenous administration of the synthetic 
      prostaglandin analog 16,16 dimethyl prostaglandin E2 (PGE2) prevented this 
      permeability change. The effect was dose-related and at the highest dose (50 
      microgram/kg/hour) was essentially complete. The beneficial effect of the PGE2 
      was apparent even when it was given after the duct had been exposed to aspirin. 
      PGE2 had no effect on pancreatic water or electrolyte secretion in the 
      unstimulated nonsecreting gland. No histologic changes in the pancreatic ducts 
      were seen after exposure to aspirin, PGE2 or both. The effectiveness of PGE2 in 
      restoring membrane permeability towards normal suggests the possibility of its 
      therapeutic role in pancreatitis.
FAU - Tweedie, J H
AU  - Tweedie JH
FAU - Mosley, J G
AU  - Mosley JG
FAU - Austin, J L
AU  - Austin JL
FAU - Reber, H A
AU  - Reber HA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Surg
JT  - American journal of surgery
JID - 0370473
RN  - 0 (Anions)
RN  - 0 (Bicarbonates)
RN  - 0 (Prostaglandins E, Synthetic)
RN  - M790V82VAC (16,16-Dimethylprostaglandin E2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 16,16-Dimethylprostaglandin E2/*pharmacology
MH  - Animals
MH  - Anions
MH  - Aspirin/*antagonists & inhibitors
MH  - Bicarbonates
MH  - Cats
MH  - Dose-Response Relationship, Drug
MH  - Pancreatic Ducts/*drug effects/metabolism/pathology
MH  - Perfusion
MH  - Permeability
MH  - Prostaglandins E, Synthetic/*pharmacology
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 0002-9610(81)90006-4 [pii]
AID - 10.1016/0002-9610(81)90006-4 [doi]
PST - ppublish
SO  - Am J Surg. 1981 Jan;141(1):22-7. doi: 10.1016/0002-9610(81)90006-4.

PMID- 6455910
OWN - NLM
STAT- MEDLINE
DCOM- 19811029
LR  - 20190825
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 10
IP  - 6
DP  - 1980 Dec
TI  - Aspirin, Prostaglandins and mucopolysaccharide/glycoprotein secretion.
PG  - 520-1
AB  - The object of the present study was to investigate the possibility that the 
      ulcer-protective action of prostaglandins (PGs) in eliciting mucus discharge in 
      the stomach could be due to their effect in enhancing the biosynthesis of mucus. 
      Intraperitoneal injection of 2,5 mg/kg PGE2, or the same dose of PGE2 plus 200 
      mg/kg aspirin (p.o.), both failed to cause any statistically significant changes 
      in the incorporation of radioactive sulphate into gastric mucus glycoproteins in 
      vivo compared with controls. Aspirin, under these conditions, inhibits mucus 
      synthesis in this effect may be related to the development of gastric mucosal 
      damage by this drug. In contrast, PGE2 administration reverses the gastric 
      mucosal damage induced by aspirin so that the ulcer-protective effect of PGE2 
      appears to be unrelated to mucus synthesis. PGE2 (0.125 - 1.25 microgram/ml) 
      inhibited oxygen consumption and 14CO2 output from 1-14C, and 6-14C glucose in 
      rat gastric mucosal slices in vitro. Thus the absence of effect of PGE2 on mucus 
      biosynthesis may be due to an effect of this PG in reducing the capacity of the 
      mucosa to yield energy (ATP) from the metabolism of glucose.
FAU - Rainsford, K D
AU  - Rainsford KD
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Glycoproteins)
RN  - 0 (Glycosaminoglycans)
RN  - 0 (Prostaglandins)
RN  - 0 (Prostaglandins E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Gastric Mucosa/*drug effects/metabolism
MH  - Glycoproteins/*metabolism
MH  - Glycosaminoglycans/metabolism
MH  - Prostaglandins/*pharmacology
MH  - Prostaglandins E/pharmacology
MH  - Rats
EDAT- 1980/12/01 00:00
MHDA- 1980/12/01 00:01
CRDT- 1980/12/01 00:00
PHST- 1980/12/01 00:00 [pubmed]
PHST- 1980/12/01 00:01 [medline]
PHST- 1980/12/01 00:00 [entrez]
AID - 10.1007/BF02024156 [doi]
PST - ppublish
SO  - Agents Actions. 1980 Dec;10(6):520-1. doi: 10.1007/BF02024156.

PMID- 785688
OWN - NLM
STAT- MEDLINE
DCOM- 19761101
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 35
IP  - 1
DP  - 1976 Feb 29
TI  - Clinical trials in thrombosis: secondary prevention of myocardial infarction.
PG  - 49-56
AB  - Numerous in vivo and in vitro experiments, investigating the inhibition of 
      platelet aggregation and the prevention of experimentally-induced thrombosis, 
      suggest that anti-platelet drugs, such as aspirin or the combination of aspirin, 
      and dipyridamole or sulfinpyrazone, may be effective anti-thrombotic agents in 
      man. Since 1971, seven randomized prospective trials and two case-control studies 
      have been referenced in the literature or are currently being conducted, which 
      evaluate the effects of aspirin, sulfinpyrazone, or dipyridamole in combination 
      with aspirin in the secondary prevention of myocardial infarction. A critical 
      review of these trials indicates a range of evidence from no difference to a 
      favorable trend that anti-platelet drugs may serve as anti-thrombotic agents in 
      man. To date, a definitive answer concerning the therapeutic effects of these 
      drugs in the secondary prevention of coronary heart disease is not available.
FAU - Klimt, C R
AU  - Klimt CR
FAU - Doub, P H
AU  - Doub PH
FAU - Doub, N H
AU  - Doub NH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyridamole/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/etiology/*prevention & control
MH  - Prospective Studies
MH  - Sulfinpyrazone/therapeutic use
MH  - Thromboembolism/complications
RF  - 26
EDAT- 1976/02/29 00:00
MHDA- 1976/02/29 00:01
CRDT- 1976/02/29 00:00
PHST- 1976/02/29 00:00 [pubmed]
PHST- 1976/02/29 00:01 [medline]
PHST- 1976/02/29 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1976 Feb 29;35(1):49-56.

PMID- 12086293
OWN - NLM
STAT- MEDLINE
DCOM- 20020717
LR  - 20190906
IS  - 0891-1150 (Print)
IS  - 0891-1150 (Linking)
VI  - 69 Suppl 1
DP  - 2002
TI  - Current perspective on the cardiovascular effects of coxibs.
PG  - SI47-52
AB  - Aspirin and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are widely 
      used for their anti-inflammatory and analgesic effects. In addition, aspirin is 
      documented to reduce cardiovascular events in selected populations, presumably 
      because of inhibition of platelet aggregation. Yet these drugs are not without 
      toxicity, particularly adverse effects on the gastric mucosa. The 
      gastrointestinal toxicity of nonselective NSAIDs and aspirin derives from the 
      inhibition of the cyclooxygenase (COX) enzyme, COX-1, which synthesizes 
      gastroprotective prostaglandins, while the anti-inflammatory and pain-relieving 
      effects are largely derived from inhibition of COX-2-derived prostaglandins. 
      Available data indicate that the harmful gastric effects of nonselective NSAIDs 
      are reduced by substitution of agents that only inhibit the COX-2 protein. The 
      COX-2-selective inhibitors, however, have also been shown to inhibit the 
      production of vascular prostacyclin, which has vasodilatory effects and inhibits 
      platelet aggregation; unlike nonselective NSAIDs, they do not inhibit the 
      production of thromboxane, an eicosanoid that promotes platelet aggregation. 
      Whether these effects could potentially contribute to a prothrombotic environment 
      is the subject of current, intensive debate. In the Vioxx Gastrointestinal 
      Outcomes Research (VIGOR) trial, there was a higher incidence of cardiovascular 
      thrombotic events in the rofecoxib- vs the naproxen-treated group: 1.67 vs 0.70 
      per 100 patient years. However, in a pooled analysis of rofecoxib studies, the 
      risk of sustaining a thrombotic cardiovascular event was similar when comparing 
      patients receiving rofecoxib with those receiving placebo, or when comparing 
      patients receiving rofecoxib with those receiving nonnaproxen nonselective 
      NSAIDs. These findings are likely to result, at least in part, from the 
      antiplatelet action of naproxen, which has been shown to be potent and sustained 
      during a typical dosing regimen (500 mg twice daily in VIGOR). In contrast, the 
      other NSAID comparators effect weaker and/or nonsustained antiplatelet action. In 
      the Celecoxib Long-term Arthritis Safety Study (CLASS) trial, there was no 
      difference between celecoxib and the nonselective NSAIDs explored (which did not 
      include naproxen) in cardiovascular event rates. Unlike those in VIGOR, patients 
      in the CLASS trial were allowed to take low-dose aspirin. Thus, despite concerns 
      raised by results of VIGOR, other existing data, including those pooled from 
      existing placebo-controlled trials, do not support a clinically relevant 
      prothrombotic effect of the COX-2 inhibitors. Additional placebo-controlled data, 
      from patients at both high and low risk for cardiovascular events, are warranted 
      to clarify the cardiovascular effects of this class of agents.
FAU - Konstam, Marvin A
AU  - Konstam MA
AD  - Tufts University School of Medicine and the New England Medical Center, Boston, 
      MA 02111, USA. mkonstam@lifespan.org
FAU - Weir, Matthew R
AU  - Weir MR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cleve Clin J Med
JT  - Cleveland Clinic journal of medicine
JID - 8703441
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Controlled Clinical Trials as Topic
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Isoenzymes/*antagonists & inhibitors
MH  - Male
MH  - Membrane Proteins
MH  - Prostaglandin-Endoperoxide Synthases
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sensitivity and Specificity
RF  - 19
EDAT- 2002/06/28 10:00
MHDA- 2002/07/18 10:01
CRDT- 2002/06/28 10:00
PHST- 2002/06/28 10:00 [pubmed]
PHST- 2002/07/18 10:01 [medline]
PHST- 2002/06/28 10:00 [entrez]
AID - 10.3949/ccjm.69.suppl_1.si47 [doi]
PST - ppublish
SO  - Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. doi: 10.3949/ccjm.69.suppl_1.si47.

PMID- 23830689
OWN - NLM
STAT- MEDLINE
DCOM- 20140710
LR  - 20220311
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 20
IP  - 12
DP  - 2013 Dec
TI  - Multiple electrode aggregometry in antiplatelet-related intracerebral 
      haemorrhage.
PG  - 1805-6
LID - S0967-5868(13)00192-6 [pii]
LID - 10.1016/j.jocn.2013.02.022 [doi]
AB  - As the population ages, antiplatelet agents are increasingly used in patients 
      with cardiovascular diseases. Due to impaired platelet activity, these patients 
      are at increased risk for bleeding complications and this is of particular 
      importance in patients with intracerebral haemorrhage. The multiple electrode 
      aggregometry analyser Multiplate (Roche Diagnostics, Mannheim, Germany) was 
      introduced in 2006 to monitor the effectiveness of antiplatelet drugs in 
      interventional cardiology. As a point-of-care device, it allows bedside 
      assessment of platelet activity within minutes through analysis of a sample of 
      whole blood. In patients treated with antiplatelet medication and in need of 
      urgent cardiac surgery, these devices allow prediction of intraoperative blood 
      loss and their use was implemented within respective guidelines to direct 
      transfusion strategies. We used the Multiplate analyser for rapid assessment of 
      antiplatelet activity in a patient who developed an intracerebral haemorrhage 
      after administration of aspirin and clopidogrel. Antiplatelet activity was 
      assessed within 10 minutes while the patient was transferred to the operating 
      room and after transfusion of platelet concentrates and administration of 
      desmopressin and tranexamic acid, repeated Multiplate analysis demonstrated 
      nearly normalized platelet activity. In our view, there is great potential for 
      this device to improve treatment in neurosurgery and especially the treatment of 
      antiplatelet-related intracerebral haemorrhage. Instant assessment of 
      antiplatelet activity or effectiveness of haemostatic measures is facilitated and 
      furthermore, patients with normal platelet activity despite a positive history of 
      antiplatelet medication intake can be identified. In these patients, empiric 
      administration of haemostatic substances would unnecessarily increase the risk of 
      thromboembolic events.
CI  - Copyright © 2013 Elsevier Ltd. All rights reserved.
FAU - Beynon, Christopher
AU  - Beynon C
AD  - Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany. 
      Electronic address: christopher.beynon@med.uni-heidelberg.de.
FAU - Sakowitz, Oliver W
AU  - Sakowitz OW
FAU - Unterberg, Andreas W
AU  - Unterberg AW
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20130705
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Brain Ischemia/drug therapy
MH  - Cerebral Hemorrhage/chemically induced/*surgery
MH  - Clopidogrel
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiplatelet therapy
OT  - Aspirin
OT  - Clopidogrel
OT  - Intracerebral haemorrhage
OT  - Point of care
EDAT- 2013/07/09 06:00
MHDA- 2014/07/11 06:00
CRDT- 2013/07/09 06:00
PHST- 2013/01/21 00:00 [received]
PHST- 2013/02/12 00:00 [accepted]
PHST- 2013/07/09 06:00 [entrez]
PHST- 2013/07/09 06:00 [pubmed]
PHST- 2014/07/11 06:00 [medline]
AID - S0967-5868(13)00192-6 [pii]
AID - 10.1016/j.jocn.2013.02.022 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2013 Dec;20(12):1805-6. doi: 10.1016/j.jocn.2013.02.022. Epub 
      2013 Jul 5.

PMID- 10337362
OWN - NLM
STAT- MEDLINE
DCOM- 19990615
LR  - 20191103
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 7
IP  - 1
DP  - 1999 Jan
TI  - Secondary stroke prevention in atrial fibrillation: indications, risks, and 
      benefits.
PG  - 61-5
AB  - Patients with nonrheumatic atrial fibrillation (NRAF) and a recent transient 
      ischemic attack (TIA) or nondisabling ischemic stroke have a high risk of stroke 
      recurrence of about 12% per year. Two randomized clinical trials have shown that 
      oral anticoagulant therapy reduces the risk by two thirds, very similar to the 
      benefit in primary prevention. The optimal intensity is INR 2.0-3.0. In case of a 
      containdication to AC, aspirin and ibuprofen are safe, but less effective, 
      alternatives. During the first 2 weeks following AF-related major stroke, the 
      benefit of subcutaneous heparin is offset by a higher risk of secondary cerebral 
      bleeding, and therefore cannot be recommended, at present, during that period. 
      The risk of stroke recurrence can be predicted by means of easily available 
      clinical information.
FAU - Koudstaal, P J
AU  - Koudstaal PJ
AD  - Department of Neurology, University Hospital Rotterdam, The Netherlands.
FAU - Koudstaal, A
AU  - Koudstaal A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Atrial Fibrillation/*complications/physiopathology
MH  - *Cerebrovascular Disorders/etiology/physiopathology/prevention & control
MH  - Humans
MH  - Ibuprofen/adverse effects/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
RF  - 20
EDAT- 1999/05/25 00:00
MHDA- 1999/05/25 00:01
CRDT- 1999/05/25 00:00
PHST- 1999/05/25 00:00 [pubmed]
PHST- 1999/05/25 00:01 [medline]
PHST- 1999/05/25 00:00 [entrez]
AID - 10.1023/a:1008883421367 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 1999 Jan;7(1):61-5. doi: 10.1023/a:1008883421367.

PMID- 30053218
OWN - NLM
STAT- MEDLINE
DCOM- 20191227
LR  - 20191227
IS  - 1460-2385 (Electronic)
IS  - 0931-0509 (Linking)
VI  - 34
IP  - 3
DP  - 2019 Mar 1
TI  - Acetylsalicylic acid decreases clotting in combination with enoxaparin during 
      haemodialysis in vitro.
PG  - 509-515
LID - 10.1093/ndt/gfy229 [doi]
AB  - BACKGROUND: Anticoagulation is a cornerstone in haemodialysis (HD) therapy to 
      avoid clotting of blood when it comes into contact with the dialysis membrane. 
      Although heparins are usually administered as anticoagulants, they are not always 
      sufficient to maintain adequate HD. We investigated the additional effect of 
      acetylsalicylic acid compared with standard anticoagulation on maintaining 
      adequate flow properties during HD in vitro. METHODS: We collected blood from 42 
      healthy volunteers, between 18 and 60 years of age, into bags filled with 1, 1.5 
      or 2 mg enoxaparin, with (treatment group) or without (control group) 100 mg of 
      aspirin. Blood was evaluated before, during and at the end of each experiment to 
      determine coagulation parameters, whole blood aggregation and thromboelastogram 
      measurements. Transmembrane pressure was recorded as indirect estimate of 
      dialysis patency. The primary endpoint was time to filter clotting. RESULTS: 
      Addition of acetylsalicylic acid significantly prolonged the time to circuit 
      clotting from 120 (105-150) min to >180 min (120-180) min (P = 0.047) and allowed 
      lowering the enoxaparin concentration from 2 mg per circuit to 1 mg without an 
      increase in clotting. Furthermore, it reduced the transmembrane pressure from 46 
      to 4 mmHg (P < 0.001) after 4 h of dialysis. Acetylsalicylic acid better 
      preserved the platelet count (128 versus 116 × 10E9/L, P = 0.01) and improved 
      platelet aggregation at the end of the dialysis procedure. CONCLUSION: Adding 
      acetylsalicylic acid to HD circuits lowered the transmembrane pressure, better 
      preserved platelet function and prolonged the time to circuit clotting, which in 
      sum increases haemodialyser performance and may facilitate a more effective HD.
CI  - © The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. 
      All rights reserved.
FAU - Samaha, Eslam
AU  - Samaha E
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
AD  - Department of Internal Medicine II, Division of Pulmonology, Medical University 
      of Vienna, Vienna, Austria.
FAU - Schwameis, Michael
AU  - Schwameis M
AD  - Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.
FAU - Schranz, Sabine
AU  - Schranz S
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
FAU - Watschinger, Bruno
AU  - Watschinger B
AD  - Department of Internal Medicine III, Division of Nephrology, Medical University 
      of Vienna, Vienna, Austria.
FAU - Buchmüller, Anja
AU  - Buchmüller A
AD  - Bayer Healthcare AG, Nordrhein-Westfalen, Wuppertal, Germany.
FAU - Jilma, Bernd
AU  - Jilma B
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Blood Coagulation/*drug effects
MH  - Drug Therapy, Combination
MH  - Enoxaparin/*therapeutic use
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prognosis
MH  - Renal Dialysis/*methods
MH  - Young Adult
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - anticoagulation
OT  - contact activation pathway
OT  - haemodialysis
OT  - transmembrane pressure
EDAT- 2018/07/28 06:00
MHDA- 2019/12/28 06:00
CRDT- 2018/07/28 06:00
PHST- 2018/04/07 00:00 [received]
PHST- 2018/06/16 00:00 [accepted]
PHST- 2018/07/28 06:00 [pubmed]
PHST- 2019/12/28 06:00 [medline]
PHST- 2018/07/28 06:00 [entrez]
AID - 5057653 [pii]
AID - 10.1093/ndt/gfy229 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 2019 Mar 1;34(3):509-515. doi: 10.1093/ndt/gfy229.

PMID- 26274799
OWN - NLM
STAT- MEDLINE
DCOM- 20160523
LR  - 20181202
IS  - 2042-6313 (Electronic)
IS  - 2042-6305 (Print)
IS  - 2042-6305 (Linking)
VI  - 4
IP  - 4
DP  - 2015 Aug
TI  - Antiplatelet therapies for secondary stroke prevention: an update on clinical and 
      cost-effectiveness.
PG  - 377-84
LID - 10.2217/cer.15.22 [doi]
AB  - Stroke exacts a huge toll physically, mentally and economically. Antiplatelet 
      therapy is the cornerstone of secondary stroke prevention, and proven drugs 
      available to successfully realize this therapeutic strategy for the long term 
      include aspirin, dipyridamole plus aspirin and clopidogrel. However, government 
      agencies, corporations, health plans and patients desire more information about 
      the clinical- and cost-effectiveness of these established therapies in real-world 
      settings. This paper provides an update on evidence-based secondary stroke 
      prevention with antiplatelet medications, discusses cost-related issues and 
      offers perspective about the future.
FAU - Rothlisberger, Julia M
AU  - Rothlisberger JM
AD  - Department of Neurology, Medical University of South Carolina, 96 Jonathan Lucas 
      Street, CSB 301, MSC 606, Charleston, SC 29425, USA.
FAU - Ovbiagele, Bruce
AU  - Ovbiagele B
AD  - Department of Neurology, Medical University of South Carolina, 96 Jonathan Lucas 
      Street, CSB 301, MSC 606, Charleston, SC 29425, USA.
LA  - eng
GR  - U01 NS079179/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - England
TA  - J Comp Eff Res
JT  - Journal of comparative effectiveness research
JID - 101577308
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/economics/therapeutic use
MH  - Clopidogrel
MH  - Cost-Benefit Analysis/*statistics & numerical data
MH  - Dipyridamole/economics/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*economics/*therapeutic use
MH  - Secondary Prevention/*economics/*methods/statistics & numerical data
MH  - Stroke/economics/*prevention & control
MH  - Ticlopidine/analogs & derivatives/economics/therapeutic use
PMC - PMC5549663
OTO - NOTNLM
OT  - antiplatelet
OT  - antithrombotics
OT  - cost
OT  - outcomes
OT  - prevention
OT  - stroke
COIS- Financial & competing interests disclosure B Ovbiagele is supported by Award 
      Number U01 NS079179 from the National Institute of Neurological Disorders and 
      Stroke. The authors have no other relevant affiliations or financial involvement 
      with any organization or entity with a financial interest in or financial 
      conflict with the subject matter or materials discussed in the manuscript apart 
      from those disclosed. No writing assistance was utilized in the production of 
      this manuscript.
EDAT- 2015/08/15 06:00
MHDA- 2016/05/24 06:00
CRDT- 2015/08/15 06:00
PHST- 2015/08/15 06:00 [entrez]
PHST- 2015/08/15 06:00 [pubmed]
PHST- 2016/05/24 06:00 [medline]
AID - 10.2217/cer.15.22 [doi]
PST - ppublish
SO  - J Comp Eff Res. 2015 Aug;4(4):377-84. doi: 10.2217/cer.15.22.

PMID- 7564036
OWN - NLM
STAT- MEDLINE
DCOM- 19951114
LR  - 20131121
IS  - 0021-5252 (Print)
IS  - 0021-5252 (Linking)
VI  - 48
IP  - 9
DP  - 1995 Aug
TI  - [Significance of combined use of anticoagulants and antiplatelet agents in the 
      early stage after prosthetic valve replacement].
PG  - 749-55
AB  - Patients who had undergone prosthetic valve replacement were treated with 
      warfarin (anticoagulant) alone or in combination of ticlopidine (200 mg/day) or 
      aspirin (81 mg/day) (anti-platelet agents). The study of blood coagulation 
      factors and platelet aggregation were carried out with these cases. 1) The 
      patients (n = 24) receiving warfarin for 21 days after prosthetic valve 
      replacement revealed marked increases in PIVKA-II and vitamin K1-epoxide. The 
      protein C activity was significantly lower than that before the operation. High 
      levels of more than 5 ng/ml of TAT were found before operation and after warfarin 
      administration for 21 days. 2) Warfarin did not affect platelet aggregation, 
      whereas ticlopidine inhibited ADP-induced platelet aggregation and aspirin 
      inhibited both collagen-induced and arachidonic acid-induced aggregation. In 
      conclusion, combined use of anticoagulants and antiplatelet agents after 
      prosthetic valve replacement will suppress not only the blood coagulation but 
      also the platelet aggregation systems.
FAU - Toyohira, H
AU  - Toyohira H
AD  - Second Department of Surgery, Faculty of Medicine Kagoshima University, Japan.
FAU - Nakamura, K
AU  - Nakamura K
FAU - Kariyazono, H
AU  - Kariyazono H
FAU - Yamada, K
AU  - Yamada K
FAU - Moriyama, Y
AU  - Moriyama Y
FAU - Shimokawa, S
AU  - Shimokawa S
FAU - Saigenji, H
AU  - Saigenji H
FAU - Taira, A
AU  - Taira A
LA  - jpn
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Kyobu Geka
JT  - Kyobu geka. The Japanese journal of thoracic surgery
JID - 0413533
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*administration & dosage/pharmacology
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Depression, Chemical
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heart Valve Diseases/surgery
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacology
MH  - Thrombosis/prevention & control
MH  - Ticlopidine/*administration & dosage/pharmacology
MH  - Warfarin/*administration & dosage/pharmacology
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
PST - ppublish
SO  - Kyobu Geka. 1995 Aug;48(9):749-55.

PMID- 7988089
OWN - NLM
STAT- MEDLINE
DCOM- 19950109
LR  - 20190914
IS  - 0303-8467 (Print)
IS  - 0303-8467 (Linking)
VI  - 96
IP  - 3
DP  - 1994 Aug
TI  - Silent infarction on a second CT scan in 91 patients without manifest stroke in 
      the Dutch TIA trial.
PG  - 219-21
AB  - The frequency of silent infarction is an important issue because it is a marker 
      of vascular disease. We studied the occurrence of silent infarction in a sample 
      of patients from the Dutch TIA trial, in which patients were randomized between 
      30 and 283 mg of aspirin. A total of 91 patients with TIA or non-disabling 
      ischemic stroke and who did not suffer a stroke during a period of one to four 
      years (mean 32 months) underwent CT scanning both on entry and at the end of the 
      study. A cardiac source of embolism was an exclusion criterion for the trial. We 
      found only one patient with a possibly silent infarction; in four patients a 
      previously detected symptomatic infarct on CT was no longer visible. The rarity 
      of silent infarction in this study may have several explanations; (1) the 
      relatively short period of follow-up, (2) the selection of patients (no cardiac 
      source of embolism), (3) the clinical monitoring at four monthly intervals aimed 
      at detection of focal ischemia, (4) the use of aspirin. Given these 
      circumstances, silent infarction is an infrequent problem.
FAU - Herderscheê, D
AU  - Herderscheê D
AD  - Department of Neurology, Academisch Medisch Centrum, Amsterdam, The Netherlands.
FAU - Hijdra, A
AU  - Hijdra A
FAU - Algra, A
AU  - Algra A
FAU - Kappelle, L J
AU  - Kappelle LJ
FAU - Koudstaal, P J
AU  - Koudstaal PJ
FAU - van Gijn, J
AU  - van Gijn J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
RN  - 50VV3VW0TI (Atenolol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Atenolol/administration & dosage/therapeutic use
MH  - Cerebral Infarction/*diagnosis/physiopathology
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Putamen/physiopathology
MH  - Risk Factors
MH  - *Tomography, X-Ray Computed
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
AID - 0303-8467(94)90071-X [pii]
AID - 10.1016/0303-8467(94)90071-x [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 1994 Aug;96(3):219-21. doi: 10.1016/0303-8467(94)90071-x.

PMID- 1282537
OWN - NLM
STAT- MEDLINE
DCOM- 19930208
LR  - 20190907
IS  - 0883-5403 (Print)
IS  - 0883-5403 (Linking)
VI  - 7
IP  - 4
DP  - 1992 Dec
TI  - Influence of prophylaxis on proximal venous thrombus formation after total hip 
      arthroplasty.
PG  - 471-5
AB  - Deep vein thrombosis (DVT) is the most frequent complication after total hip 
      arthroplasty, and proximal DVT is more likely to produce clinical pulmonary 
      emboli than distal DVT. The authors have assessed the incidence and anatomic 
      location of phlebographically proven fresh DVT following total hip arthroplasty 
      in 855 patients over 39 years of age. Eight different regimens (2 warfarin, 3 
      aspirin, 1 dextran, 1 external pneumatic compression, and 1 dextran combined with 
      external pneumatic compression) were evaluated and compared with an historical 
      placebo control group from the same institution. No significant difference (P < 
      .05) existed in proximal DVT incidence between the placebo group and any of the 
      three aspirin groups, the dextran group, the external pneumatic compression 
      group, or the dextran combined with external pneumatic compression group. In 
      contrast, warfarin, given both in traditional and low-dose regimens, provided a 
      significant reduction in proximal DVT compared with the placebo group (P < .001; 
      statistical power, 0.84 and 0.99, respectively). The low-dose regimen had 10 
      times fewer bleeding complications than the traditional regimen. All prophylaxis 
      regimens should be evaluated for both proximal and distal DVT formation, as well 
      as for overall incidence. Low-dose warfarin offers the best protection against 
      proximal thrombi of the agents studied, and it is also safer than traditional 
      dosages of warfarin.
FAU - Paiement, G D
AU  - Paiement GD
AD  - Orthopaedic Biomechanics Laboratory, Massachusetts General Hospital, Boston 
      02114.
FAU - Schutzer, S F
AU  - Schutzer SF
FAU - Wessinger, S J
AU  - Wessinger SJ
FAU - Harris, W H
AU  - Harris WH
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
RN  - 0 (Dextrans)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Combined Modality Therapy
MH  - Dextrans/adverse effects/*therapeutic use
MH  - Female
MH  - *Gravity Suits
MH  - Hemorrhage/etiology
MH  - *Hip Prosthesis
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Postoperative Complications/epidemiology/*prevention & control
MH  - Thrombophlebitis/epidemiology/*prevention & control
MH  - Warfarin/administration & dosage/adverse effects/*therapeutic use
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
AID - 10.1016/s0883-5403(06)80067-7 [doi]
PST - ppublish
SO  - J Arthroplasty. 1992 Dec;7(4):471-5. doi: 10.1016/s0883-5403(06)80067-7.

PMID- 11212358
OWN - NLM
STAT- MEDLINE
DCOM- 20010301
LR  - 20191104
IS  - 1420-682X (Print)
IS  - 1420-682X (Linking)
VI  - 56
IP  - 3-4
DP  - 1999 Oct 15
TI  - The pleiotropic functions of aspirin: mechanisms of action.
PG  - 305-12
AB  - Recent studies have suggested that aspirin and aspirin-like compounds have a 
      variety of actions in addition to their well-studied ability to inhibit 
      cyclooxygenases. These actions include inhibition of the uncoupling of oxidative 
      phosphorylation, decreases in adenosine triphosphate stores. increases in 
      extracellular adenosine, downregulation of the expression and activity of 
      inducible nitric oxide synthetase, inhibition and/or stimulation of various 
      mitogen-activated protein kinase activities and inhibition of nuclear factor 
      binding kappaB site (NF-kappaB) activation. Moreover, aspirin-like compounds have 
      recently been shown to have previously unappreciated clinical and biological 
      effects, some apparently independent of cyclooxygenase. In this review we discuss 
      the various mechanisms of action of aspirin-like compounds and their relevance to 
      clinical disease and therapy.
FAU - Amin, A R
AU  - Amin AR
AD  - Department of Rheumatology, Hospital for Joint Diseases, New York, New York 
      10003, USA.
FAU - Attur, M G
AU  - Attur MG
FAU - Pillinger, M
AU  - Pillinger M
FAU - Abramson, S B
AU  - Abramson SB
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Cell Mol Life Sci
JT  - Cellular and molecular life sciences : CMLS
JID - 9705402
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - EC 1.14.13.39 (NOS2 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/*pharmacology
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Fibrinolytic Agents/pharmacology
MH  - Humans
MH  - Nitric Oxide Synthase/antagonists & inhibitors
MH  - Nitric Oxide Synthase Type II
RF  - 62
EDAT- 2001/02/24 12:00
MHDA- 2001/03/07 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/03/07 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
AID - 10.1007/s000180050432 [doi]
PST - ppublish
SO  - Cell Mol Life Sci. 1999 Oct 15;56(3-4):305-12. doi: 10.1007/s000180050432.

PMID- 30565488
OWN - NLM
STAT- MEDLINE
DCOM- 20190813
LR  - 20190813
IS  - 1477-0903 (Electronic)
IS  - 0960-3271 (Linking)
VI  - 38
IP  - 5
DP  - 2019 May
TI  - Protective effect of essential oil from Citrus limon against aspirin-induced 
      toxicity in rats.
PG  - 499-509
LID - 10.1177/0960327118819044 [doi]
AB  - The present study is planned to examine the antioxidant activity (AA) and the 
      protective effect of the essential oil of Citrus limon (EOC) against 
      aspirin-induced histopathological changes in the brain, lung, and intestine of 
      female rats. For this purpose, 28 albino rats were classified to control group 
      (group C), aspirin group (group A), EOC group (group EOC), and pretreatment with 
      EOC and treated with aspirin group (group EOC + A). The antioxidant activities of 
      EOC were evaluated by three different assays including reducing power, 
      β-carotene, and scavenging of hydrogen peroxide (H(2)O(2)). Our results found 
      that EOC represents, respectively (0.064 ± 0.013 and 0.027 ± 00 mg Quer E/100 
      µL), of flavonoid and flavonol. Then, it exhibited a potential activity of 
      reducing power (at 300 mg/mL, which was found to be 0.82 ± 0.07), 
      β-carotene-linoleic acid (AA% = 69.28 ± 3.5%), and scavenging of H(2)O(2) (IC(50) 
      = 0.23 ± 0.008 mg/mL). In vivo, aspirin given to rats at the dose of 600 mg/kg 
      body weight induced histomorphological damage in brain, lung, and intestine. 
      However, our data found that the pretreatment with EOC offered a significant 
      protection against the injury induced by aspirin. It can be concluded that the 
      protective effect of EOC can be due to its antioxidant activities.
FAU - Bouzenna, H
AU  - Bouzenna H
AUID- ORCID: 0000-0003-0040-6417
AD  - 1 Unit of Macromolecular Biochemistry and Genetics, Faculty of Sciences of Gafsa, 
      Sidi Ahmed Zarrouk, Gafsa, Tunisia.
AD  - 2 Laboratory of Environmental Physiopathology, Valorization of Bioactive 
      Molecules and Mathematical Modeling, Faculty of Sciences Sfax, Sfax, Tunisia.
FAU - Samout, N
AU  - Samout N
AD  - 1 Unit of Macromolecular Biochemistry and Genetics, Faculty of Sciences of Gafsa, 
      Sidi Ahmed Zarrouk, Gafsa, Tunisia.
AD  - 2 Laboratory of Environmental Physiopathology, Valorization of Bioactive 
      Molecules and Mathematical Modeling, Faculty of Sciences Sfax, Sfax, Tunisia.
FAU - Dhibi, S
AU  - Dhibi S
AD  - 1 Unit of Macromolecular Biochemistry and Genetics, Faculty of Sciences of Gafsa, 
      Sidi Ahmed Zarrouk, Gafsa, Tunisia.
AD  - 2 Laboratory of Environmental Physiopathology, Valorization of Bioactive 
      Molecules and Mathematical Modeling, Faculty of Sciences Sfax, Sfax, Tunisia.
FAU - Mbarki, S
AU  - Mbarki S
AD  - 1 Unit of Macromolecular Biochemistry and Genetics, Faculty of Sciences of Gafsa, 
      Sidi Ahmed Zarrouk, Gafsa, Tunisia.
AD  - 2 Laboratory of Environmental Physiopathology, Valorization of Bioactive 
      Molecules and Mathematical Modeling, Faculty of Sciences Sfax, Sfax, Tunisia.
FAU - Akermi, S
AU  - Akermi S
AD  - 2 Laboratory of Environmental Physiopathology, Valorization of Bioactive 
      Molecules and Mathematical Modeling, Faculty of Sciences Sfax, Sfax, Tunisia.
FAU - Khdhiri, A
AU  - Khdhiri A
AD  - 1 Unit of Macromolecular Biochemistry and Genetics, Faculty of Sciences of Gafsa, 
      Sidi Ahmed Zarrouk, Gafsa, Tunisia.
AD  - 2 Laboratory of Environmental Physiopathology, Valorization of Bioactive 
      Molecules and Mathematical Modeling, Faculty of Sciences Sfax, Sfax, Tunisia.
FAU - Elfeki, A
AU  - Elfeki A
AD  - 2 Laboratory of Environmental Physiopathology, Valorization of Bioactive 
      Molecules and Mathematical Modeling, Faculty of Sciences Sfax, Sfax, Tunisia.
FAU - Hfaiedh, N
AU  - Hfaiedh N
AD  - 1 Unit of Macromolecular Biochemistry and Genetics, Faculty of Sciences of Gafsa, 
      Sidi Ahmed Zarrouk, Gafsa, Tunisia.
LA  - eng
PT  - Journal Article
DEP - 20181219
PL  - England
TA  - Hum Exp Toxicol
JT  - Human & experimental toxicology
JID - 9004560
RN  - 0 (Antioxidants)
RN  - 0 (Oils, Volatile)
RN  - R16CO5Y76E (Aspirin)
MH  - Animals
MH  - Antioxidants/*therapeutic use
MH  - Aspirin/*toxicity
MH  - Brain/drug effects/pathology
MH  - *Citrus
MH  - Female
MH  - Intestines/drug effects/pathology
MH  - Lung/drug effects/pathology
MH  - Oils, Volatile/*therapeutic use
MH  - Plant Leaves
MH  - Rats, Wistar
OTO - NOTNLM
OT  - antioxidant activities
OT  - aspirin
OT  - phytochemical investigation
OT  - toxicity
EDAT- 2018/12/20 06:00
MHDA- 2019/08/14 06:00
CRDT- 2018/12/20 06:00
PHST- 2018/12/20 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2018/12/20 06:00 [entrez]
AID - 10.1177/0960327118819044 [doi]
PST - ppublish
SO  - Hum Exp Toxicol. 2019 May;38(5):499-509. doi: 10.1177/0960327118819044. Epub 2018 
      Dec 19.

PMID- 10595379
OWN - NLM
STAT- MEDLINE
DCOM- 19991228
LR  - 20131121
IS  - 0036-7672 (Print)
IS  - 0036-7672 (Linking)
VI  - 129
IP  - 45
DP  - 1999 Nov 13
TI  - Dialogue with a patient with coronary artery disease.
PG  - 1697-700
AB  - A fictive dialogue between an internist and a patient with acute myocardial 
      infarction is used to highlight the role of drug therapy in coronary artery 
      disease.
FAU - Salomon, F
AU  - Salomon F
AD  - Departement für Innere Medizin, Universitätsspital Zürich.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Schweiz Med Wochenschr
JT  - Schweizerische medizinische Wochenschrift
JID - 0404401
RN  - 0 (Adrenergic beta-Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Coronary Angiography
MH  - Coronary Disease/diagnosis/*drug therapy
MH  - Exercise Test
MH  - Humans
MH  - Internal Medicine
MH  - Myocardial Infarction/complications
MH  - Physician-Patient Relations
EDAT- 1999/12/14 00:00
MHDA- 1999/12/14 00:01
CRDT- 1999/12/14 00:00
PHST- 1999/12/14 00:00 [pubmed]
PHST- 1999/12/14 00:01 [medline]
PHST- 1999/12/14 00:00 [entrez]
PST - ppublish
SO  - Schweiz Med Wochenschr. 1999 Nov 13;129(45):1697-700.

PMID- 1413251
OWN - NLM
STAT- MEDLINE
DCOM- 19921119
LR  - 20191021
IS  - 0304-3991 (Print)
IS  - 0304-3991 (Linking)
VI  - 42-44 ( Pt B)
DP  - 1992 Jul
TI  - Molecular-resolution images of aspirin crystals with atomic force microscopy.
PG  - 1148-54
AB  - The atomic force microscope was developed in order to image arrays of molecules 
      on the (001), (100) and (011) faces of aspirin crystals in water. Lattice 
      spacings and symmetries of methyl groups and the part of the phenyl groups on the 
      (001) face in water are consistent with X-ray diffraction data. Surfaces of the 
      (100) face that show the best-developed cleavage, in general, are difficult to 
      image. Although the lattice constant derived from (100) image is consistent with 
      the X-ray diffraction data, the c-glide plane symmetry is lost and diffused spots 
      are observed that are 1.8-3.1 times more elongated than (001) spots. It is not 
      possible to image the (011) surface. This initial success in imaging the 
      molecular crystal surfaces of drug compounds has clarified the different 
      submolecular structures of the three different crystal faces, and the close 
      relationship between the imaging difficulties and the differences in the 
      dissolution process in water.
FAU - Masaki, N
AU  - Masaki N
AD  - Faculty of Pharmaceutical Sciences, Kyoto University, Japan.
FAU - Machida, K
AU  - Machida K
FAU - Kado, H
AU  - Kado H
FAU - Yokoyama, K
AU  - Yokoyama K
FAU - Tohda, T
AU  - Tohda T
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Ultramicroscopy
JT  - Ultramicroscopy
JID - 7513702
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - Crystallization
MH  - Microscopy/methods
MH  - X-Ray Diffraction
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
AID - 0304-3991(92)90416-H [pii]
AID - 10.1016/0304-3991(92)90416-h [doi]
PST - ppublish
SO  - Ultramicroscopy. 1992 Jul;42-44 ( Pt B):1148-54. doi: 
      10.1016/0304-3991(92)90416-h.

PMID- 11234591
OWN - NLM
STAT- MEDLINE
DCOM- 20010412
LR  - 20131121
IS  - 0043-5341 (Print)
IS  - 0043-5341 (Linking)
VI  - 151
IP  - 1-2
DP  - 2001
TI  - [Pharmacologic interventions in primary prevention: lipid lowering drugs, 
      aspirin, antiobesity drugs, and antihypertensive agents].
PG  - 13-7
AB  - Heart disease, particularly coronary heart disease is a major cause of morbidity 
      and mortality in developed countries. Cardiovascular disease accounts for more 
      than 50% of deaths. Drug therapy is highly effective for treatment of patients 
      after a first cardiovascular event (secondary prevention). In contrast, 
      introduction of drug therapy for lowering cardiovascular risk before a first 
      cardiovascular event (primary prevention) is discussed controversially. The 
      number of persons who need to be treated for prevention of one cardiovascular 
      event is high and drug therapy in more or less "healthy" people is justified only 
      after accurate assessment of potential risks and possible beneficial effects. 
      Drug therapy combined with non-pharmacological treatment strategies is considered 
      to be appropriate in selected high-risk persons for primary prevention. The 
      following article describes potential indications of several drugs, in particular 
      cholesterol-lowering therapy, aspirin, drug therapy of obesity and hypertension, 
      for use in primary prevention of cardiovascular disease.
FAU - Auer, J
AU  - Auer J
AD  - II. Interne Abteilung mit Kardiologie und Intensivmedizin, Krankenhaus der 
      Barmherzigen Schwestern vom Hl. Kreuz, Grieskirchner Strasse 42, A-4600 Wels. 
      johann.auer@khwels.at
FAU - Berent, R
AU  - Berent R
FAU - Weber, T
AU  - Weber T
FAU - Porodko, M
AU  - Porodko M
FAU - Mayr, H
AU  - Mayr H
FAU - Maurer, E
AU  - Maurer E
FAU - Eber, B
AU  - Eber B
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Pharmakologische Massnahmen in der Primärprävention: Lipidsenker, Aspirin, 
      Antiadiposita und Antihypertensiva.
PL  - Austria
TA  - Wien Med Wochenschr
JT  - Wiener medizinische Wochenschrift (1946)
JID - 8708475
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Obesity Agents/*therapeutic use
MH  - Antihypertensive Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Hypolipidemic Agents/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Primary Prevention/*methods
MH  - Risk
MH  - Risk Factors
RF  - 36
EDAT- 2001/03/10 10:00
MHDA- 2001/04/17 10:01
CRDT- 2001/03/10 10:00
PHST- 2001/03/10 10:00 [pubmed]
PHST- 2001/04/17 10:01 [medline]
PHST- 2001/03/10 10:00 [entrez]
PST - ppublish
SO  - Wien Med Wochenschr. 2001;151(1-2):13-7.

PMID- 23359782
OWN - NLM
STAT- MEDLINE
DCOM- 20131125
LR  - 20181202
IS  - 1940-1574 (Electronic)
IS  - 0003-3197 (Linking)
VI  - 64
IP  - 7
DP  - 2013 Oct
TI  - Efficacy and safety of triple antiplatelet therapy in obese patients undergoing 
      stent implantation.
PG  - 554-8
LID - 10.1177/0003319712474113 [doi]
AB  - We evaluated the impact of triple antiplatelet therapy on platelet reactivity, 
      reducing cardiovascular events and the safety in obese patients undergoing 
      coronary stenting. Obese patients (n = 428) undergoing coronary stenting were 
      randomly assigned to 2 groups: standard dual group (clopidogrel plus aspirin, n = 
      215) and triple group (n = 213); adjunctive cilostazol was added to the dual 
      group treatment. Platelet reactivity was assessed at baseline and at 1-year 
      follow-up by conventional aggregometry. Major adverse cardiovascular events, 
      stent thrombosis, target lesion revascularization (TLR), target vessel 
      revascularization, and bleeding events were analyzed after 1-year follow-up. At 
      1-year follow-up after stenting, major adverse cardiac events including death, 
      myocardial infarction, and ischemic-driven TLR were lower in the triple group 
      than the dual group. Major bleeding was similar in both the groups. In obese 
      patients undergoing percutaneous coronary intervention, triple antiplatelet 
      therapy was superior to dual antiplatelet therapy in decreasing thrombotic events 
      in 12-month cardiac events, mainly driven by a decrease in the incidence of 
      clopidogrel resistance.
FAU - Gao, Wen
AU  - Gao W
AD  - Department of Cardiology, Bayannaoer City Hospital, Inner Mongolia, China.
FAU - Zhang, Qinghua
AU  - Zhang Q
FAU - Ge, Hailong
AU  - Ge H
FAU - Guo, Yonghe
AU  - Guo Y
FAU - Zhou, Zhiming
AU  - Zhou Z
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20130127
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - A74586SNO7 (Clopidogrel)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Angiology. 2013 Oct;64(7):559-60. PMID: 23478449
CIN - Angiology. 2013 Oct;64(7):561. PMID: 23823185
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Cilostazol
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Obesity/complications/*drug therapy/surgery
MH  - Percutaneous Coronary Intervention/*adverse effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Prosthesis Implantation
MH  - Stents
MH  - Tetrazoles/administration & dosage/adverse effects/therapeutic use
MH  - Thrombosis/*drug therapy/etiology
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & 
      derivatives/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - clopidogrel
OT  - obesity
OT  - resistance antiplatelet
EDAT- 2013/01/30 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/01/30 06:00
PHST- 2013/01/30 06:00 [entrez]
PHST- 2013/01/30 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 0003319712474113 [pii]
AID - 10.1177/0003319712474113 [doi]
PST - ppublish
SO  - Angiology. 2013 Oct;64(7):554-8. doi: 10.1177/0003319712474113. Epub 2013 Jan 27.

PMID- 9772677
OWN - NLM
STAT- MEDLINE
DCOM- 19981106
LR  - 20131121
IS  - 0253-9756 (Print)
IS  - 0253-9756 (Linking)
VI  - 17
IP  - 2
DP  - 1996 Mar
TI  - [Effects of aspirin and nifedipine alone or in combination on mesenteric 
      microcirculation of rats].
PG  - 189-92
AB  - AIM: To study the effects of the combination of aspirin (Asp) and nifedipine 
      (Nif) on mesenteric microcirculation of rats. METHODS: Acute microcirculation 
      disturbance (AMD) was produced by high molecular weight dextran (M(r) 480,000, 
      360 mg.kg-1 i.v.). Arteriole and venule blood flow velocity and diameter (ABFV, 
      VBFV, AD, VD) and blood flow state (BFS) were observed by intravital 
      microcirculation method. RESULTS: Asp 2.5, 5 mg.kg-1, Nif 0.05, 0.1 mg.kg-1, Asp 
      + Nif (1 + 0.025), (2.5 + 0.05) mg.kg-1, i.v. had the significant increase of 
      11.1%, 31.3%, 18.5%, 19.3%, 30.5%, 39.8% of ABFV and 12.5%, 25.7%, 12.6%, 15.2%, 
      29.6%, 36.1% of VBFV respectively, the marked improvement of BFS, and the 
      distinctive increase of 4.3%, 17.9%, 35.9%, 39.7%, 15.2%, 42.8% of AD and 2.2%, 
      4.2%, 26.2%, 27.4%, 3.4%, 28.9% of VD separately, and got a raise in the number 
      of capillaries. Asp + Nif (1 + 0.025), 2.5 + 0.05) mg.kg-1 i.v. could reverse 
      AMD. CONCLUSION: Asp was superior to Nif in the increase of BFV, but Nif was 
      superior to Asp in expansion of blood vessel. Asp in combination with Nif 
      produced marked synergistic action and protection againist AMD.
FAU - Song, Y M
AU  - Song YM
AD  - Cardiovascular Research Laboratory, Baotou Medical College, China.
FAU - Qin, J M
AU  - Qin JM
FAU - Li, Z X
AU  - Li ZX
FAU - Shi, S
AU  - Shi S
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Yao Li Xue Bao
JT  - Zhongguo yao li xue bao = Acta pharmacologica Sinica
JID - 8100330
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Flow Velocity/drug effects
MH  - Drug Synergism
MH  - Female
MH  - Male
MH  - Mesenteric Arteries/*drug effects
MH  - Microcirculation/drug effects
MH  - Nifedipine/*pharmacology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Vasodilator Agents/*pharmacology
EDAT- 1996/03/01 00:00
MHDA- 1998/10/17 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1998/10/17 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
PST - ppublish
SO  - Zhongguo Yao Li Xue Bao. 1996 Mar;17(2):189-92.

PMID- 36029646
OWN - NLM
STAT- MEDLINE
DCOM- 20220926
LR  - 20220926
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 106
DP  - 2022 Nov
TI  - Dengzhan Shengmai capsule versus Aspirin in the treatment of carotid 
      atherosclerotic plaque: A single-centre, non-inferiority, prospective, randomised 
      controlled trial.
PG  - 154408
LID - S0944-7113(22)00497-4 [pii]
LID - 10.1016/j.phymed.2022.154408 [doi]
AB  - BACKGROUND: Aspirin is an effective antiplatelet agent for the treatment of 
      carotid atherosclerosis. However, the high risk of bleeding events associated 
      with the drug makes it necessary to seek a safer alternative, with similar or 
      more efficacy than aspirin. Dengzhan Shengmai (DZSM) capsules have been widely 
      used to treat carotid atherosclerosis, and if proven to be non-inferior to 
      aspirin, it may be preferable over the latter for carotid atherosclerosis 
      treatment due to its numerous advantages. We conducted a randomised trial to test 
      the non-inferiority of DZSM to aspirin for the treatment of carotid 
      atherosclerotic plaques. METHODS: We performed a single-centre, prospective, 
      open-label, randomised non-inferiority trial. Patients with carotid 
      atherosclerotic plaques were enrolled and randomly assigned (1:1) to receive 
      either DZSM capsules or aspirin. The follow-up period was 12 months. The primary 
      outcome was the mean change in carotid intima-media thickness (IMT). Secondary 
      outcomes included ischaemic events, rate of lumen stenosis, lipid levels, and 
      plaque scores, length, counts, and vulnerability. Adverse events and laboratory 
      test results were recorded as safety outcomes. The non-inferiority of DZSM was 
      demonstrated when the lower limit of the one-sided 97.5% confidence interval (CI) 
      of the difference in IMT between groups was more than -0.06 mm (margin of 
      non-inferiority). This trial has been registered at ClinicalTrials.gov 
      (CHiCTR1900021365). RESULTS: From 1 April 2019 to 30 September 2019, 150 patients 
      were enrolled, and there was no statistical difference in demographics between 
      the groups. Intention-to-treat analysis showed that the decrease in IMT((∆)IMT) 
      was 0.216 ± 0.160 and 0.225 ± 0.149 mm in the DZSM and aspirin groups, 
      respectively. The one-sided 97.5% CI for the difference between (∆)IMTs was 
      (-0.0593, +∞). The non-inferiority of DZSM was demonstrated (P(non-inferiority) = 
      0.0234). There was no significant difference in the incidence of ischaemic events 
      between the groups (P = 1.0). The DZSM group had significantly reduced plaque 
      scores (P < 0.0001), length (P < 0.0001), and counts (P < 0.0001), and improved 
      plaque vulnerability (P < 0.0001). The DZSM group also had reduced levels of 
      low-density lipoprotein cholesterol (LDL-C) (P < 0.0001). Finally, the DZSM group 
      had a lower incidence of total adverse events (14.7% vs. 28%, P = 0.046), 
      especially gastrointestinal discomfort (5.3% vs. 16%, P = 0.034). Although there 
      was no significant difference in bleeding events (0 vs. 5.3%, P = 0.120), the 
      DZSM group tended to have a lower incidence. CONCLUSION: This trial demonstrated 
      that DZSM was not inferior, in efficacy, to aspirin in treating carotid 
      atherosclerotic plaques, and was found to be superior to aspirin in terms of 
      safety. This study provides a new approach for treating carotid plaques, 
      especially in aspirin-intolerant patients.
CI  - Copyright © 2022 The Authors. Published by Elsevier GmbH.. All rights reserved.
FAU - Shen, Xu
AU  - Shen X
AD  - Department of Vascular and Endovascular Surgery, Second Affiliated Hospital of 
      Naval Medical University, District of Huangpu, Fengyang Road 415, Shanghai 
      200003, China.
FAU - Zou, Sili
AU  - Zou S
AD  - Department of Vascular and Endovascular Surgery, Second Affiliated Hospital of 
      Naval Medical University, District of Huangpu, Fengyang Road 415, Shanghai 
      200003, China.
FAU - Jin, Jie
AU  - Jin J
AD  - Department of Vascular and Endovascular Surgery, Second Affiliated Hospital of 
      Naval Medical University, District of Huangpu, Fengyang Road 415, Shanghai 
      200003, China.
FAU - Liu, Yandong
AU  - Liu Y
AD  - Department of Vascular and Endovascular Surgery, Second Affiliated Hospital of 
      Naval Medical University, District of Huangpu, Fengyang Road 415, Shanghai 
      200003, China.
FAU - Wu, Jianjin
AU  - Wu J
AD  - Department of Vascular and Endovascular Surgery, Second Affiliated Hospital of 
      Naval Medical University, District of Huangpu, Fengyang Road 415, Shanghai 
      200003, China.
FAU - Qu, Lefeng
AU  - Qu L
AD  - Department of Vascular and Endovascular Surgery, Second Affiliated Hospital of 
      Naval Medical University, District of Huangpu, Fengyang Road 415, Shanghai 
      200003, China. Electronic address: qulefeng@smmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220819
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (dengzhan shengmai capsule)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Carotid Artery Diseases/chemically induced/drug therapy
MH  - Carotid Intima-Media Thickness
MH  - Cholesterol, LDL
MH  - Drugs, Chinese Herbal
MH  - Humans
MH  - *Plaque, Atherosclerotic/drug therapy
MH  - Platelet Aggregation Inhibitors
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Carotid atherosclerotic plaque
OT  - Dengzhan Shengmai Capsule
OT  - Non-inferiority
OT  - Randomized controlled trial
COIS- Declaration of Competing Interest The authors declare that there are no known 
      conflicts of interest associated with this publication, and that there has been 
      no significant medical or financial support from any pharmaceutical company for 
      this work that could have influenced its outcome.
EDAT- 2022/08/28 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/08/27 18:21
PHST- 2022/06/03 00:00 [received]
PHST- 2022/07/30 00:00 [revised]
PHST- 2022/08/17 00:00 [accepted]
PHST- 2022/08/28 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/08/27 18:21 [entrez]
AID - S0944-7113(22)00497-4 [pii]
AID - 10.1016/j.phymed.2022.154408 [doi]
PST - ppublish
SO  - Phytomedicine. 2022 Nov;106:154408. doi: 10.1016/j.phymed.2022.154408. Epub 2022 
      Aug 19.

PMID- 18349026
OWN - NLM
STAT- MEDLINE
DCOM- 20081117
LR  - 20220309
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 29
IP  - 9
DP  - 2008 May
TI  - Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens 
      after transient ischaemic attack or stroke.
PG  - 1086-92
LID - 10.1093/eurheartj/ehn106 [doi]
AB  - Network meta-analysis can provide estimates of treatment efficacy of multiple 
      treatment regimens, even when direct comparisons are unavailable. We used network 
      meta-analysis to compare commonly used antiplatelet regimens in the prevention of 
      serious vascular events after transient ischaemic attack (TIA) or stroke. We 
      performed direct meta-analyses of randomized, controlled trials evaluating 
      antiplatelet agents after TIA or stroke. We chose the endpoint stroke, myocardial 
      infarction, and vascular death. Network meta-analysis was then used to estimate 
      the relative efficacy of the various antiplatelet regimens. Twenty-four trials 
      involving 42688 TIA or stroke patients who suffered 6830 serious vascular events 
      were included. In the network meta-analysis, all antiplatelet regimens (aspirin, 
      aspirin plus dipyridamole, thienopyridines, and combination of aspirin and 
      thienopyridines) were significantly more effective than placebo. The combination 
      of aspirin and dipyridamole was more effective than thienopyridines (OR, 0.84; 
      95% CI, 0.73-0.97) and more effective than aspirin (OR, 0.78; 95% CI, 0.70-0.87). 
      Our analysis suggests that the most powerful antiplatelet regimen in the 
      prevention of serious vascular events after TIA or stroke is the combination of 
      aspirin and dipyridamole. Network meta-analysis could be used to synthesize 
      accumulating evidence from clinical trials in a broad range of vascular 
      disorders.
FAU - Thijs, Vincent
AU  - Thijs V
AD  - Department of Neurology, University Hospitals Leuven, VIB Herestraat 49, 3000 
      Leuven, Belgium. vincent.thijs@uz.kuleuven.ac.be
FAU - Lemmens, Robin
AU  - Lemmens R
FAU - Fieuws, Steffen
AU  - Fieuws S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20080317
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2008 May;29(9):1082-3. PMID: 18359758
CIN - Eur Heart J. 2008 Oct;29(20):2580. PMID: 18799521
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Stroke/*prevention & control
MH  - Treatment Outcome
RF  - 54
EDAT- 2008/03/20 09:00
MHDA- 2008/11/18 09:00
CRDT- 2008/03/20 09:00
PHST- 2008/03/20 09:00 [pubmed]
PHST- 2008/11/18 09:00 [medline]
PHST- 2008/03/20 09:00 [entrez]
AID - ehn106 [pii]
AID - 10.1093/eurheartj/ehn106 [doi]
PST - ppublish
SO  - Eur Heart J. 2008 May;29(9):1086-92. doi: 10.1093/eurheartj/ehn106. Epub 2008 Mar 
      17.

PMID- 18094457
OWN - NLM
STAT- MEDLINE
DCOM- 20080326
LR  - 20131121
IS  - 1386-0291 (Print)
IS  - 1386-0291 (Linking)
VI  - 38
IP  - 1
DP  - 2008
TI  - Platelet aggregation under high shear conditions during and after a 28-day 
      administration of 100 mg acetylsalicylic acid in healthy volunteers.
PG  - 45-50
AB  - Platelet primary hemostatic function occurs under high shear conditions. 
      Cyclooxygenase inhibitors such as ibuprofen inhibit this platelet aggregation 
      under high shear rates only to a limited extent. This prompted the present study 
      on 10 healthy volunteers treated with 100 mg aspirin for 4 weeks. The platelet 
      function analyser (PFA-100) was used to measure the closure time (CT) of a 
      membrane pore coated with collagen and epinephrine by aggregating platelets under 
      shear rates of 5000-6000 s(-1). A first dose of 100 mg aspirin prolonged the CT 
      above the normal range in 4 of 10 individuals, but the CT for the whole group 
      (153+/-42 s) was not different from baseline (112+/-18 s). After 7 and 28 days of 
      treatment, CTs were >300 s in 8 individuals and the mean values for the group 
      were significantly higher than baseline. However, one subject had an intermediate 
      response and one had an aspirin non-responsiveness, which was not overcome by 300 
      mg aspirin daily. The CT was normalized in 4 individuals 48 h after the last 
      aspirin dose and in 7 individuals after 72 h, when the mean value for the group 
      became not different from baseline. We conclude that the platelet function 
      measured with the PFA-100 is not inhibited significantly after a single dose of 
      100 mg aspirin, is thereafter inhibited consistently in the majority, but not all 
      individuals during a 4 week treatment, and returns to normal in 48-72 h. Since 
      large interindividual differences exist, monitoring of platelet inhibition at the 
      beginning of an aspirin treatment should be considered and validated in a 
      prospective study.
FAU - Tschopp, Marcel
AU  - Tschopp M
AD  - Department of Internal Medicine, Kantonsspital Graubünden, CH-7000 Chur, 
      Switzerland.
FAU - Reinhart, Walter H
AU  - Reinhart WH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Clin Hemorheol Microcirc. 2009;43(3):263-4. PMID: 19847061
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Drug Monitoring/*methods
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Perfusion
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Function Tests/instrumentation/*methods
MH  - Reproducibility of Results
MH  - Stress, Mechanical
MH  - Treatment Outcome
EDAT- 2007/12/21 09:00
MHDA- 2008/03/28 09:00
CRDT- 2007/12/21 09:00
PHST- 2007/12/21 09:00 [pubmed]
PHST- 2008/03/28 09:00 [medline]
PHST- 2007/12/21 09:00 [entrez]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 2008;38(1):45-50.

PMID- 9860155
OWN - NLM
STAT- MEDLINE
DCOM- 19990326
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 54
IP  - 8
DP  - 1998 Oct
TI  - Trends in aspirin, paracetamol and non-steroidal anti-inflammatory drug use in 
      children between 1981 and 1992 in France.
PG  - 659-64
AB  - OBJECTIVE: Antipyretic/analgesic drugs (AADs) are among the most commonly used 
      drugs in children. Their efficacy and adverse effects have often been debated and 
      new AADs have been introduced over the past few years. The aim of this study was 
      to assess the characteristics of the use of AADs in children in France, and their 
      trends. METHODS: Two surveys on household health care consumption were undertaken 
      in France, in 1981 and in 1992. They included 5060 and 4841 children, 
      respectively. The AADs studied were aspirin, paracetamol and non-steroidal 
      anti-inflammatory drugs (NSAIDs). RESULTS: The proportion of children exposed to 
      AADs increased significantly between 1981 and 1992 (+28% in 11 years). Among 
      them, the percentage of subjects treated with aspirin decreased (-27%). In 
      contrast, the percentage increased for paracetamol (+ 19%) and for NSAIDs 
      (+179%). Aspirin was the AAD most used in 1981 (57.4%) and it was replaced by 
      paracetamol in 1992 (71.6%). Nasopharyngitis was the main reason for AAD 
      prescription under the age of 11 years; for older children it was influenza-like 
      syndrome, irrespective of the study year. A change in AAD choice occurred in 
      nasopharyngitis, acute bronchitis and influenza-like syndrome irrespective of the 
      age group, and in otitis/sinusitis between 4 and 10 years. In all these cases 
      aspirin prescription decreased, in contrast with paracetamol and NSAIDs. 
      Self-medication of AAD was uncommon (8.3% for aspirin and 10.3% for paracetamol 
      in 1992) and decreased (-29% and -33%). It was used principally for 
      nasopharyngitis, influenza-like syndrome and pain. CONCLUSION: The consumption of 
      AADs in children is high and is increasing. Paracetamol and NSAIDs tend to 
      replace aspirin prescription in children and physicians have played the main role 
      in this change.
FAU - Maison, P
AU  - Maison P
AD  - INSERM Unité 21, Faculty of Medicine Paris Sud, Villejuif, France. 
      maison@vjf.inserm.fr
FAU - Guillemot, D
AU  - Guillemot D
FAU - Vauzelle-Kervroëdan, F
AU  - Vauzelle-Kervroëdan F
FAU - Balkau, B
AU  - Balkau B
FAU - Sermet, C
AU  - Sermet C
FAU - Thibult, N
AU  - Thibult N
FAU - Eschwège, E
AU  - Eschwège E
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Adolescent
MH  - Analgesics/*therapeutic use
MH  - Analgesics, Non-Narcotic/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Data Collection
MH  - Female
MH  - France
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
EDAT- 1998/12/22 00:00
MHDA- 1998/12/22 00:01
CRDT- 1998/12/22 00:00
PHST- 1998/12/22 00:00 [pubmed]
PHST- 1998/12/22 00:01 [medline]
PHST- 1998/12/22 00:00 [entrez]
AID - 10.1007/s002280050530 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1998 Oct;54(8):659-64. doi: 10.1007/s002280050530.

PMID- 2225410
OWN - NLM
STAT- MEDLINE
DCOM- 19901214
LR  - 20131121
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 82
IP  - 5 Suppl
DP  - 1990 Nov
TI  - Internal mammary artery and saphenous vein graft patency. Effects of aspirin.
PG  - IV237-42
AB  - As part of two Department of Veterans Affairs Cooperative Trials, we obtained 
      angiographic patency data for internal mammary artery (IMA) and saphenous vein 
      grafts to the left anterior descending (LAD) coronary artery at 1 year after 
      coronary artery bypass surgery. Patients received either aspirin 325 mg q.d., 
      aspirin 325 mg t.i.d., aspirin 325 mg and dipyridamole 75 mg t.i.d., or placebo. 
      Aspirin was initiated either 12 hours before or 6 hours after operation. Patients 
      were stratified preoperatively for extent of disease and randomized to the 
      therapies outlined above. There was no randomization to IMA versus saphenous vein 
      grafts to the LAD. When the patients taking placebo were compared with those 
      taking aspirin, there were no differences in the IMA (100.0% versus 92.1%, p = 
      0.385) or vein graft (88.8% versus 90.4%, p = 0.675) patency rates. The patency 
      rate, irrespective of treatment, for all IMA grafts was 92.8% (220 of 237) versus 
      90.1% (345 of 383) for all vein grafts to the LAD (p = 0.309). Thus, both the IMA 
      and vein grafts had excellent patency rates at 1 year. Aspirin did not alter this 
      at 1 year, and there were no differences between IMA and vein graft patency to 
      the LAD.
FAU - Goldman, S
AU  - Goldman S
AD  - Department of Veterans Affairs Medical Center, Tucson, AZ 85723.
FAU - Copeland, J
AU  - Copeland J
FAU - Moritz, T
AU  - Moritz T
FAU - Henderson, W
AU  - Henderson W
FAU - Zadina, K
AU  - Zadina K
FAU - Ovitt, T
AU  - Ovitt T
FAU - Kern, K B
AU  - Kern KB
FAU - Sethi, G
AU  - Sethi G
FAU - Sharma, G V
AU  - Sharma GV
FAU - Khuri, S
AU  - Khuri S
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Coronary Angiography
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/therapeutic use
MH  - Double-Blind Method
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - *Internal Mammary-Coronary Artery Anastomosis
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Saphenous Vein/*transplantation
MH  - Vascular Patency
EDAT- 1990/11/01 00:00
MHDA- 1990/11/01 00:01
CRDT- 1990/11/01 00:00
PHST- 1990/11/01 00:00 [pubmed]
PHST- 1990/11/01 00:01 [medline]
PHST- 1990/11/01 00:00 [entrez]
PST - ppublish
SO  - Circulation. 1990 Nov;82(5 Suppl):IV237-42.

PMID- 19968488
OWN - NLM
STAT- MEDLINE
DCOM- 20100616
LR  - 20131121
IS  - 1093-5266 (Print)
IS  - 1093-5266 (Linking)
VI  - 13
IP  - 2
DP  - 2010 Mar-Apr
TI  - The effects of antenatal anticoagulants (low-molecular-weight heparin and 
      aspirin) on neonatal pulmonary vasculature in rabbits.
PG  - 107-11
LID - 10.2350/09-04-0643-OA.1 [doi]
AB  - Low-molecular-weight heparin and aspirin are the most prescribed medical agents 
      as anticoagulants in pregnancy. Our objective was to investigate the effects of 
      antenatal use of low-molecular-weight heparin and aspirin on pulmonary vascular 
      development in neonatal rabbits. Seven pregnant rabbits (42 newborn rabbits) were 
      divided into 5 groups as follows: control group (group 1, n = 14), heparin 
      treated (group 2, n = 8), heparin and aspirin treated (group 3, n = 7), only 
      aspirin treated (group 4, n = 6), and high-dose heparin treated (group 5, n = 
      12). Pulmonary histologic evaluations were carried out for all groups. 
      Angiogenesis was also tested by CD34 immunostained microvessel count (mvc). 
      Pathologic examination of pulmonary vasculature revealed that pulmonary vascular 
      thickening occurred at the level of alveoli in heparin-, heparin- and aspirin-, 
      and high-dose-heparin-treated groups (groups 2, 3, and 5). The percentage of wall 
      thickness was different in groups 2 (26%), 3 (28.2%), and 5 (30.8%) compared with 
      group 1 (21.4%). Statistical differences were observed between group 1 vs 2, 3, 
      and 5. Microvessel count was also different between groups 2 (mvc = 90.5), 3 (mvc 
      = 90.2), and 5 (mvc = 96.3) vs group 1 (mvc = 86.7). The microvessel count was 
      statistically different between groups that received low-dose heparin vs 
      high-dose heparin. Antenatal administration of low-molecular-weight heparin 
      showed an effect on pulmonary vascular development. This effect may be explained 
      by the influence of heparin on angiogenesis through placental growth factors. 
      Further experiments are needed to understand the pathophysiology of these 
      findings, and clinical studies are needed to correlate of these results.
FAU - Canpolat, Fuat Emre
AU  - Canpolat FE
AD  - Department of Pediatrics, School of Medicine, Hacettepe University, Ankara, 
      Turkey. femrecan@gmail.com
FAU - Orhan, Diclehan
AU  - Orhan D
FAU - Yigit, Sule
AU  - Yigit S
FAU - Kale, Gülsev
AU  - Kale G
FAU - Yurdakök, Murat
AU  - Yurdakök M
FAU - Tekinalp, Gülsevin
AU  - Tekinalp G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatr Dev Pathol
JT  - Pediatric and developmental pathology : the official journal of the Society for 
      Pediatric Pathology and the Paediatric Pathology Society
JID - 9809673
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Anticoagulants/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Blood Vessels/drug effects
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*adverse effects
MH  - Lung/*blood supply/*drug effects
MH  - Neovascularization, Physiologic/drug effects
MH  - Pregnancy
MH  - *Prenatal Exposure Delayed Effects
MH  - Rabbits
EDAT- 2009/12/09 06:00
MHDA- 2010/06/17 06:00
CRDT- 2009/12/09 06:00
PHST- 2009/12/09 06:00 [entrez]
PHST- 2009/12/09 06:00 [pubmed]
PHST- 2010/06/17 06:00 [medline]
AID - 10.2350/09-04-0643-OA.1 [doi]
PST - ppublish
SO  - Pediatr Dev Pathol. 2010 Mar-Apr;13(2):107-11. doi: 10.2350/09-04-0643-OA.1.

PMID- 27249377
OWN - NLM
STAT- MEDLINE
DCOM- 20170616
LR  - 20181203
IS  - 1522-2683 (Electronic)
IS  - 0173-0835 (Print)
IS  - 0173-0835 (Linking)
VI  - 37
IP  - 11
DP  - 2016 Jun
TI  - Deciphering glycomics and neuroproteomic alterations in experimental traumatic 
      brain injury: Comparative analysis of aspirin and clopidogrel treatment.
PG  - 1562-76
LID - 10.1002/elps.201500583 [doi]
AB  - As populations age, the number of patients sustaining traumatic brain injury 
      (TBI) and concomitantly receiving preinjury antiplatelet therapy such as aspirin 
      (ASA) and clopidogrel (CLOP) is rising. These drugs have been linked with 
      unfavorable clinical outcomes following TBI, where the exact mechanism(s) 
      involved are still unknown. In this novel work, we aimed to identify and compare 
      the altered proteome profile imposed by ASA and CLOP when administered alone or 
      in combination, prior to experimental TBI. Furthermore, we assessed differential 
      glycosylation PTM patterns following experimental controlled cortical impact 
      model of TBI, ASA, CLOP, and ASA + CLOP. Ipsilateral cortical brain tissues were 
      harvested 48 h postinjury and were analyzed using an advanced neuroproteomics 
      LC-MS/MS platform to assess proteomic and glycoproteins alterations. Of interest, 
      differential proteins pertaining to each group (22 in TBI, 41 in TBI + ASA, 44 in 
      TBI + CLOP, and 34 in TBI + ASA + CLOP) were revealed. Advanced 
      bioinformatics/systems biology and clustering analyses were performed to evaluate 
      biological networks and protein interaction maps illustrating molecular pathways 
      involved in the experimental conditions. Results have indicated that proteins 
      involved in neuroprotective cellular pathways were upregulated in the ASA and 
      CLOP groups when given separately. However, ASA + CLOP administration revealed 
      enrichment in biological pathways relevant to inflammation and proinjury 
      mechanisms. Moreover, results showed differential upregulation of glycoproteins 
      levels in the sialylated N-glycans PTMs that can be implicated in pathological 
      changes. Omics data obtained have provided molecular insights of the underlying 
      mechanisms that can be translated into clinical bedside settings.
CI  - © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Abou-Abbass, Hussein
AU  - Abou-Abbass H
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon.
AD  - Faculty of Medicine, Beirut Arab University, Beirut, Lebanon.
FAU - Bahmad, Hisham
AU  - Bahmad H
AD  - Faculty of Medicine, Beirut Arab University, Beirut, Lebanon.
AD  - Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of 
      Medicine, American University of Beirut, Beirut, Lebanon.
FAU - Abou-El-Hassan, Hadi
AU  - Abou-El-Hassan H
AD  - Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
FAU - Zhu, Rui
AU  - Zhu R
AD  - Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX, 
      USA.
FAU - Zhou, Shiyue
AU  - Zhou S
AD  - Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX, 
      USA.
FAU - Dong, Xue
AU  - Dong X
AD  - Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX, 
      USA.
FAU - Hamade, Eva
AU  - Hamade E
AD  - ER045-Laboratory of Stem Cells, DSST, Lebanese University, Beirut, Lebanon.
AD  - Department of Biology, Faculty of Sciences-I, Lebanese University, Beirut, 
      Lebanon.
FAU - Mallah, Khalil
AU  - Mallah K
AD  - ER045-Laboratory of Stem Cells, DSST, Lebanese University, Beirut, Lebanon.
AD  - Department of Biology, Faculty of Sciences-I, Lebanese University, Beirut, 
      Lebanon.
FAU - Zebian, Abir
AU  - Zebian A
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon.
FAU - Ramadan, Naify
AU  - Ramadan N
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon.
FAU - Mondello, Stefania
AU  - Mondello S
AD  - Department of Neurosciences, University of Messina, Messina, Italy.
FAU - Fares, Jawad
AU  - Fares J
AD  - Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
FAU - Comair, Youssef
AU  - Comair Y
AD  - Department of Surgery, Division of Neurosurgery, Lebanese American University, 
      Beirut, Lebanon.
FAU - Atweh, Samir
AU  - Atweh S
AD  - Department of Neurology, Faculty of Medicine, American University of Beirut, 
      Beirut, Lebanon.
FAU - Darwish, Hala
AU  - Darwish H
AD  - Faculty of Medicine-School of Nursing, American University of Beirut, New York, 
      NY, USA.
FAU - Zibara, Kazem
AU  - Zibara K
AD  - ER045-Laboratory of Stem Cells, DSST, Lebanese University, Beirut, Lebanon.
AD  - Department of Biology, Faculty of Sciences-I, Lebanese University, Beirut, 
      Lebanon.
FAU - Mechref, Yehia
AU  - Mechref Y
AD  - Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX, 
      USA.
FAU - Kobeissy, Firas
AU  - Kobeissy F
AD  - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American 
      University of Beirut, Beirut, Lebanon.
LA  - eng
GR  - R01 GM112490/GM/NIGMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
DEP - 20160329
PL  - Germany
TA  - Electrophoresis
JT  - Electrophoresis
JID - 8204476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Brain Injuries, Traumatic/*drug therapy/metabolism
MH  - Cerebellar Cortex/pathology
MH  - Clopidogrel
MH  - Gene Expression Regulation
MH  - Glycomics/*methods
MH  - Glycosylation/drug effects
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Protein Processing, Post-Translational/drug effects
MH  - Proteomics/*methods
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
PMC - PMC4963819
MID - NIHMS804472
OTO - NOTNLM
OT  - Aspirin
OT  - Clopidogrel
OT  - Neuroproteomics
OT  - PTMs
OT  - TBI
COIS- The authors declare no conflict of interest.
EDAT- 2016/06/02 06:00
MHDA- 2017/06/18 06:00
CRDT- 2016/06/02 06:00
PHST- 2015/12/24 00:00 [received]
PHST- 2016/02/09 00:00 [revised]
PHST- 2016/02/11 00:00 [accepted]
PHST- 2016/06/02 06:00 [entrez]
PHST- 2016/06/02 06:00 [pubmed]
PHST- 2017/06/18 06:00 [medline]
AID - 10.1002/elps.201500583 [doi]
PST - ppublish
SO  - Electrophoresis. 2016 Jun;37(11):1562-76. doi: 10.1002/elps.201500583. Epub 2016 
      Mar 29.

PMID- 583016
OWN - NLM
STAT- MEDLINE
DCOM- 19791227
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 29
IP  - 8
DP  - 1979
TI  - Preliminary study of pharmacokinetics and metabolism of sodium 
      2-n-propylpentanoate in pig and human.
PG  - 1161-3
AB  - The pharmacokinetics of sodium 2-n-propyl-pentanoate have been studied in pig and 
      human. The drug is excreted in the human urine as a mixture of glucuronide and 
      other unidentified conjugates. It appears that no other conjugates can be found 
      in pig's urine. Treatment with sulfatase does not identify sulfate-conjugates in 
      human urine. Coadministration of acetyl salicylic acid (ASA) increases the 
      fraction of glucuronide and other conjugates in human urine. The rate of renal 
      excretion of the drug appears to be increased during concomitant administration 
      of ASA.
FAU - Bonora, M R
AU  - Bonora MR
FAU - Schobben, F
AU  - Schobben F
FAU - Taburet, A M
AU  - Taburet AM
FAU - Van der Kleijn, E
AU  - Van der Kleijn E
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Glucuronates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Fatty Acids, Unsaturated/blood/*metabolism/urine
MH  - Glucuronates/metabolism
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Swine
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1979;29(8):1161-3.

PMID- 36400421
OWN - NLM
STAT- MEDLINE
DCOM- 20230213
LR  - 20230311
IS  - 2589-9333 (Electronic)
IS  - 2589-9333 (Linking)
VI  - 5
IP  - 2
DP  - 2023 Feb
TI  - The Implementation of Preeclampsia Screening and Prevention (IMPRESS) Study.
PG  - 100815
LID - S2589-9333(22)00245-2 [pii]
LID - 10.1016/j.ajogmf.2022.100815 [doi]
AB  - BACKGROUND: Preeclampsia affects between 2% and 5% of pregnancies and is one of 
      the leading causes of perinatal morbidity and mortality worldwide. Despite strong 
      evidence that the combination of systematic preeclampsia screening based on the 
      Fetal Medicine Foundation preeclampsia risk calculation algorithm with treatment 
      of high-risk patients with low-dose aspirin reduces the incidence of preterm 
      preeclampsia more than currently used risk-factor-based screening, real-world 
      implementation studies have not yet been done in Canada. OBJECTIVE: This study 
      aimed to assess the operational feasibility of implementing first-trimester 
      screening and prevention of preterm preeclampsia (<37 weeks) alongside a publicly 
      funded first-trimester combined screening program for aneuploidies. STUDY DESIGN: 
      This was a prospective implementation study. Consecutive pregnant patients 
      referred for first-trimester combined screening (11-13+6 weeks) were offered 
      screening for preeclampsia based on the Fetal Medicine Foundation algorithm 
      concomitantly with their aneuploidy screen. Consenting participants were screened 
      using maternal risk factors, mean arterial pressure, uterine artery Doppler 
      pulsatility index, pregnancy-associated plasma protein-A, and placental growth 
      factor. Risk for preterm preeclampsia (<37 weeks) was calculated using the Fetal 
      Medicine Foundation algorithm, and individuals with a risk score ≥1 per 100 were 
      recommended to use aspirin (162 mg once daily at bedtime, <16-36 weeks). 
      Implementation metrics assessed included: acceptability, operational impact, 
      proportion of aspirin initiation, quality and safety measures, and screen 
      performance. RESULTS: Between December 1, 2020 and April 23, 2021, 1124 patients 
      consented to preeclampsia screening (98.3% uptake), and 92 (8.2%) screened 
      positive. Appointments for patients receiving first-trimester combined screening 
      aneuploidy and preeclampsia screening averaged 6 minutes longer than 
      first-trimester combined screening alone, and adding uterine artery Doppler 
      pulsatility index averaged 2 minutes. Of the 92 patients who screened as 
      high-risk for preeclampsia, 72 (78.3%) were successfully contacted before 16 
      weeks' gestation. Of these, 62 (86.1%) initiated aspirin, and 10 (13.9%) did not. 
      Performance audit identified a consistent negative bias with mean arterial 
      pressure measurements (median multiple of the median <1 in 10%); other variables 
      were satisfactory. There were 7 cases of preterm preeclampsia (0.69%): 5 and 2 in 
      the high- and low-risk groups, respectively. Screening detected 5 of 7 (71.4 %) 
      preterm preeclampsia cases, with improved performance after adjustment for 
      aspirin treatment effect. CONCLUSION: This study confirms the operational 
      feasibility of implementing an evidence-based preeclampsia screening and 
      prevention program in a publicly funded Canadian setting. This will facilitate 
      implementation into clinical service and the scaling up of this program at a 
      regional and provincial level.
CI  - Copyright © 2022 Elsevier Inc. All rights reserved.
FAU - Johnson, J M
AU  - Johnson JM
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset). Electronic address: jajohnso@ucalgary.ca.
FAU - Walsh, Jennifer D
AU  - Walsh JD
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset).
FAU - Okun, Nanette B
AU  - Okun NB
AD  - Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, 
      University of Toronto, Toronto, Canada (Dr Okun).
FAU - Metcalfe, Amy
AU  - Metcalfe A
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset).
FAU - Pastuck, Melanie L
AU  - Pastuck ML
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset).
FAU - Maxey, Connor M
AU  - Maxey CM
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset).
FAU - Soliman, Nancy
AU  - Soliman N
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset).
FAU - Mahallati, Houman
AU  - Mahallati H
AD  - Radiology (Drs Mahallati, Paterson, and Suchet), Cumming School of Medicine, 
      University of Calgary, Calgary, Canada.
FAU - Kuret, Verena H
AU  - Kuret VH
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset).
FAU - Dwinnell, Shannon J
AU  - Dwinnell SJ
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset).
FAU - Chada, Rati
AU  - Chada R
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset).
FAU - O'Quinn, Candace P
AU  - O'Quinn CP
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset).
FAU - Schacher, Jaime
AU  - Schacher J
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset).
FAU - Somerset, David A
AU  - Somerset DA
AD  - Departments of Obstetrics and Gynecology (Drs J Johnson and Walsh, Ms Pastuck, Dr 
      Metcalfe, Mr Maxey, and Drs Soliman, Kuret, Dwinnell, Chada, O'Quinn, Schacher, 
      and Somerset).
FAU - Paterson, Kimiko
AU  - Paterson K
AD  - Radiology (Drs Mahallati, Paterson, and Suchet), Cumming School of Medicine, 
      University of Calgary, Calgary, Canada.
FAU - Suchet, Ian B
AU  - Suchet IB
AD  - Radiology (Drs Mahallati, Paterson, and Suchet), Cumming School of Medicine, 
      University of Calgary, Calgary, Canada.
FAU - Silang, Katherine A
AU  - Silang KA
AD  - Department of Psychology, University of Calgary, Calgary, Canada (Ms Silang).
FAU - Paul, Heather
AU  - Paul H
AD  - Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, 
      Canada (Dr Paul).
FAU - Nerenberg, Kara A
AU  - Nerenberg KA
AD  - Department of Medicine, Cumming School of Medicine, University of Calgary, 
      Calgary, Canada (Dr Nerenberg).
FAU - Johnson, David W
AU  - Johnson DW
AD  - Departments of Pediatrics, Emergency Medicine, and Physiology and Pharmacology, 
      Cumming School of Medicine, University of Calgary, Calgary, Canada (Dr D 
      Johnson).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221115
PL  - United States
TA  - Am J Obstet Gynecol MFM
JT  - American journal of obstetrics & gynecology MFM
JID - 101746609
RN  - 144589-93-5 (Placenta Growth Factor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Infant, Newborn
MH  - Humans
MH  - Female
MH  - *Pre-Eclampsia/diagnosis/epidemiology/prevention & control
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Placenta Growth Factor
MH  - Canada
MH  - Aspirin/therapeutic use
MH  - Aneuploidy
OTO - NOTNLM
OT  - aspirin
OT  - biomarkers
OT  - first trimester
OT  - mean arterial blood pressure
OT  - placental growth factor
OT  - preterm preeclampsia
OT  - prevention
OT  - screening
OT  - uterine artery Doppler
EDAT- 2022/11/19 06:00
MHDA- 2023/02/14 06:00
CRDT- 2022/11/18 19:37
PHST- 2022/09/05 00:00 [received]
PHST- 2022/11/08 00:00 [revised]
PHST- 2022/11/10 00:00 [accepted]
PHST- 2022/11/19 06:00 [pubmed]
PHST- 2023/02/14 06:00 [medline]
PHST- 2022/11/18 19:37 [entrez]
AID - S2589-9333(22)00245-2 [pii]
AID - 10.1016/j.ajogmf.2022.100815 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol MFM. 2023 Feb;5(2):100815. doi: 10.1016/j.ajogmf.2022.100815. 
      Epub 2022 Nov 15.

PMID- 17430218
OWN - NLM
STAT- MEDLINE
DCOM- 20070502
LR  - 20191026
IS  - 1570-1611 (Print)
IS  - 1570-1611 (Linking)
VI  - 5
IP  - 2
DP  - 2007 Apr
TI  - Significance of aspirin and clopidogrel resistance in patients undergoing 
      percutaneous coronary interventions.
PG  - 135-40
AB  - Dual antiplatelet therapy (aspirin plus clopidogrel) is mandatory in patients 
      treated with coronary stent implantation. This strategy is highly effective in 
      prevention of stent thrombosis until its struts are covered with endothelium. 
      However, a substantial number of patients still suffer from recurrent ischemic 
      coronary events despite adequate antiplatelet therapy. These events fall into 
      three categories: stent thrombosis, in stent restenosis and events related to 
      other non-stented coronary lesions. Some data suggest that beside other local and 
      systemic factors resistance to aspirin and clopidogrel may be a possible cause of 
      stent thrombosis and ischemic events in patients after coronary interventions. 
      Several mechanisms of antiplatelet drug resistance have been reported including 
      poor compliance, interactions with other drugs, genetic polymorphism or increased 
      platelet turnover. More research is needed to adequately assess the clinical 
      significance and prognostic value of antiplatelet drug resistance detected by 
      laboratory tests in patients undergoing percutaneous intervention. We review 
      published data on mechanisms and the clinical significance of aspirin and 
      clopidogrel resistance in patients after coronary interventions.
FAU - Pregowski, Jerzy
AU  - Pregowski J
AD  - Institute of Cardiology, Warsaw, Poland.
FAU - Witkowski, Adam
AU  - Witkowski A
FAU - Sitkiewicz, Dariusz
AU  - Sitkiewicz D
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Clopidogrel
MH  - Drug Interactions
MH  - *Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Ticlopidine/*analogs & derivatives/pharmacology
RF  - 76
EDAT- 2007/04/14 09:00
MHDA- 2007/05/03 09:00
CRDT- 2007/04/14 09:00
PHST- 2007/04/14 09:00 [pubmed]
PHST- 2007/05/03 09:00 [medline]
PHST- 2007/04/14 09:00 [entrez]
AID - 10.2174/157016107780368262 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2007 Apr;5(2):135-40. doi: 10.2174/157016107780368262.

PMID- 8543644
OWN - NLM
STAT- MEDLINE
DCOM- 19960209
LR  - 20190501
IS  - 0021-9746 (Print)
IS  - 1472-4146 (Electronic)
IS  - 0021-9746 (Linking)
VI  - 48
IP  - 11
DP  - 1995 Nov
TI  - Early ultrastructural changes of antral mucosa with aspirin in the absence of 
      Helicobacter pylori.
PG  - 994-7
AB  - AIMS: To describe the ultrastructural changes that occur in human antral mucosa 
      following direct application of aspirin in volunteers without Helicobacter pylori 
      infection. METHODS: Ten healthy male volunteers without H pylori infection 
      underwent three consecutive endoscopies (at zero, one and five hours). At the 
      first endoscopy, two biopsy specimens were obtained (one for histology and the 
      other for electron microscopy (EM)). At subsequent endoscopies, a single biopsy 
      specimen was obtained for EM. A 50 ml solution of aspirin (concentration 3 mg/ml) 
      was applied to the antral mucosa at the first endoscopy in five subjects; the 
      other five subjects received 50 ml distilled water (placebo). RESULTS: The 
      ultrastructural appearance of the first biopsy specimen in all subjects and 
      subsequent biopsy specimens in the placebo treated subjects was normal. The 
      aspirin treated group had evidence of intercellular oedema, widening of capillary 
      fenestrae, rupturing of apical membranes, and dilatation of endoplasmic reticulum 
      and mitochondria after one hour; these changes were more marked at five hours. 
      Tight junctions were maintained. CONCLUSION: This is the first study to describe 
      the early ultrastructural changes in antral mucosa induced by aspirin in subjects 
      without H pylori infection.
FAU - McCarthy, C J
AU  - McCarthy CJ
AD  - Department of Gastroenterology, Meath Hospital, Dublin, Ireland.
FAU - Sweeney, E
AU  - Sweeney E
FAU - O'Morain, C
AU  - O'Morain C
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Clin Pathol
JT  - Journal of clinical pathology
JID - 0376601
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Gastric Mucosa/*drug effects/ultrastructure
MH  - Gastroscopy
MH  - Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Microscopy, Electron
MH  - Pyloric Antrum/drug effects/ultrastructure
MH  - Time Factors
PMC - PMC503000
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 10.1136/jcp.48.11.994 [doi]
PST - ppublish
SO  - J Clin Pathol. 1995 Nov;48(11):994-7. doi: 10.1136/jcp.48.11.994.

PMID- 16819430
OWN - NLM
STAT- MEDLINE
DCOM- 20061006
LR  - 20181201
IS  - 1732-2693 (Electronic)
IS  - 0032-5449 (Linking)
VI  - 60
DP  - 2006
TI  - Does pycnogenol intensify the efficacy of acetylsalicylic acid in the inhibition 
      of platelet function? In vitro experience.
PG  - 316-21
AB  - INTRODUCTION: Some compounds of herbal origin, such as Pycnogenol (PYC), have 
      been considered as an aid in antiplatelet therapy. Pycnogenol, a French maritime 
      pine bark extract, is a complex mixture of polyphenols that has the ability to 
      reduce human smoking-induced platelet aggregation. The aim of this study was to 
      evaluate the in vitro ability of PYC to improve the efficacy of acetylsalicylic 
      acid (ASA) in the inhibition of platelet function. MATERIAL/METHODS: Whole blood, 
      anticoagulated with hirudin, was drawn from 38 volunteers (40.4+/-13.8 years old) 
      and incubated with PYC (10, 50, 100 microg/ml) or/and ASA (25, 100 micromol/l) 
      for 20 min at RT.PYC was dissolved in water (water-PYC group, n=20) or ethanol 
      (ethanol-PYC group, n=18). To investigate platelet functions, PFA-100 
      closure-time determination, whole-blood electrical aggregation (WBEA), and PRP 
      aggregation were employed. Collagen (1 microg/ml) and ADP (5 micromol/l) were 
      used as platelet agonists. RESULTS: A compounding effect of ASA and PYC to 
      inhibit platelet function recorded in collagen-induced aggregation in PRP was 
      observed, but only when ethanol-dissolved PYC was used. The inhibitory effect of 
      PYC (alone) was most profound in platelets activated with ADP. At all 
      concentrations, PYC significantly inhibited platelet aggregation only in the 
      ethanol-PYC group. CONCLUSIONS: It was found that under in vitro conditions, 
      ethanol-dissolved PYC deepened the efficacy of ASA to inhibit platelet function. 
      This study confirmed the direct and compounding (with ASA) inhibitory effect of 
      PYC on platelets. These observations encourage the concept that the combined use 
      of ASA and PYC may be beneficial in patients with impaired response to ASA 
      therapy.
FAU - Golański, Jacek
AU  - Golański J
AD  - Department of Hemostasis and Hemostatic Disorders, Medical University Hospital 
      No. 2, Medical University of Łódź, Łódź, Poland.
FAU - Muchova, Jana
AU  - Muchova J
FAU - Golański, Ryszard
AU  - Golański R
FAU - Durackova, Zdenka
AU  - Durackova Z
FAU - Markuszewski, Leszek
AU  - Markuszewski L
FAU - Watała, Cezary
AU  - Watała C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Poland
TA  - Postepy Hig Med Dosw (Online)
JT  - Postepy higieny i medycyny doswiadczalnej (Online)
JID - 101206517
RN  - 0 (Flavonoids)
RN  - 0 (Plant Extracts)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 50JZ5Z98QY (pycnogenols)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/physiology
MH  - Drug Synergism
MH  - Flavonoids/*pharmacology
MH  - Humans
MH  - Plant Extracts
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
RF  - 29
EDAT- 2006/07/05 09:00
MHDA- 2006/10/07 09:00
CRDT- 2006/07/05 09:00
PHST- 2005/09/22 00:00 [received]
PHST- 2006/05/06 00:00 [accepted]
PHST- 2006/07/05 09:00 [pubmed]
PHST- 2006/10/07 09:00 [medline]
PHST- 2006/07/05 09:00 [entrez]
AID - 9431 [pii]
PST - ppublish
SO  - Postepy Hig Med Dosw (Online). 2006;60:316-21.

PMID- 22513397
OWN - NLM
STAT- MEDLINE
DCOM- 20121011
LR  - 20211021
IS  - 1744-6880 (Electronic)
IS  - 1744-6872 (Print)
IS  - 1744-6872 (Linking)
VI  - 22
IP  - 7
DP  - 2012 Jul
TI  - Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human 
      prostaglandin H synthase-1.
PG  - 525-37
LID - 10.1097/FPC.0b013e32835366f6 [doi]
AB  - OBJECTIVES: Aspirin (ASA), a major antiplatelet and cancer-preventing drug, 
      irreversibly blocks the cyclooxygenase (COX) activity of prostaglandin H 
      synthase-1 (PGHS-1). Considerable differences in ASA effectiveness are observed 
      between individuals, and some of this variability may be due to PGHS-1 protein 
      variants. Our overall aim is to determine which, if any, of the known variants in 
      the mature PGHS-1 protein lead to functional alterations in COX catalysis or 
      inhibition by ASA. The present study targeted four PGHS-1 variants: R53H, R108Q, 
      L237M, and V481I. METHODS: Wild-type human PGHS-1 and the four polymorphic 
      variants were expressed as histidine-tagged, homodimeric proteins in insect cells 
      using baculovirus vectors, solubilized with a detergent, and purified by affinity 
      chromatography. The purified proteins were characterized in vitro to evaluate COX 
      and peroxidase (POX) catalytic parameters and the kinetics of COX inhibition by 
      ASA and NS-398. RESULTS: Compared with the wild type, several variants showed a 
      higher COX/POX ratio (up to 1.5-fold, for R108Q), an elevated arachidonate Km (up 
      to 1.9-fold, for R108Q), and/or a lower ASA reactivity (up to 60% less, for 
      R108Q). The decreased ASA reactivity in R108Q reflected both a 70% increase in 
      the Ki for ASA and a 30% decrease in the rate constant for acetyl group transfer 
      to the protein. Computational modeling of the brief ASA pulses experienced by 
      PGHS-1 in circulating platelets during daily ASA dosing predicted that the 60% 
      lower ASA reactivity in R108Q yields a 15-fold increase in surviving COX 
      activity; smaller, approximately two-fold increases in surviving COX activity 
      were predicted for L237M and V481I. NS-398 competitively inhibited COX catalysis 
      of the wild type (Ki=6 µmol/l) and inhibited COX inactivation by 1.0 mmol/l ASA 
      in both the wild type (IC50=0.8 µmol/l) and R108Q (IC50=2.1 µmol/l). CONCLUSION: 
      Of the four PGHS-1 variants examined, R108Q exerts the largest functional 
      effects, with evidence for impaired interactions with a COX substrate and 
      inhibitors. As Arg108 is located on the protein surface and not in the active 
      site, the effects of R108Q suggest a novel, unsuspected mechanism for the 
      modulation of the PGHS-1 active site structure. The lower intrinsic ASA 
      reactivity of R108Q, V481I, and L237M, combined with the rapid hydrolysis of ASA 
      in the blood, suggests that these variants decrease the antiplatelet 
      effectiveness of the drug. These PGHS-1 variants are uncommon but ASA is used 
      widely; hence, a considerable number of individuals could be affected. Further 
      examination of these and other PGHS-1 variants will be needed to determine 
      whether PGHS-1 genotyping can be used to personalize anti-COX therapy.
FAU - Liu, Wen
AU  - Liu W
AD  - Department of Internal Medicine, University of Texas Health Science Center at 
      Houston, Houston, Texas, USA.
FAU - Poole, Elizabeth M
AU  - Poole EM
FAU - Ulrich, Cornelia M
AU  - Ulrich CM
FAU - Kulmacz, Richard J
AU  - Kulmacz RJ
LA  - eng
GR  - R01 CA114467/CA/NCI NIH HHS/United States
GR  - R01 CA114467-04/CA/NCI NIH HHS/United States
GR  - U01 CA074794/CA/NCI NIH HHS/United States
GR  - CA 114467/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Pharmacogenet Genomics
JT  - Pharmacogenetics and genomics
JID - 101231005
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Binding Sites
MH  - Cyclooxygenase 1/*genetics/metabolism
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - *Genetic Variation
MH  - Genotype
MH  - Humans
MH  - Hydrolysis
MH  - Kinetics
MH  - Models, Theoretical
PMC - PMC3376194
MID - NIHMS369187
EDAT- 2012/04/20 06:00
MHDA- 2012/10/12 06:00
CRDT- 2012/04/20 06:00
PHST- 2012/04/20 06:00 [entrez]
PHST- 2012/04/20 06:00 [pubmed]
PHST- 2012/10/12 06:00 [medline]
AID - 10.1097/FPC.0b013e32835366f6 [doi]
PST - ppublish
SO  - Pharmacogenet Genomics. 2012 Jul;22(7):525-37. doi: 10.1097/FPC.0b013e32835366f6.

PMID- 18718813
OWN - NLM
STAT- MEDLINE
DCOM- 20090325
LR  - 20181201
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 17
IP  - 6
DP  - 2008 Dec
TI  - Eosinophilia and coronary artery vasospasm.
PG  - 488-96
LID - 10.1016/j.hlc.2008.06.003 [doi]
AB  - OBJECTIVE: To describe the clinical features, natural history and response to 
      treatment of coronary vasospasm associated with eosinophilia. METHODS: Two 
      patients with eosinophilia who had recurrent acute coronary events due to 
      multi-vessel coronary artery spasm are described. The clinical presentation and 
      outcomes of these 2 patients and 17 additional cases of eosinophilia and coronary 
      artery vasospasm identified on a systematic literature review are presented. 
      RESULTS: Patients were usually admitted because of repeated episodes of angina at 
      rest and raised plasma markers of myocyte necrosis. Dynamic ST elevation was 
      observed in 15 (83%) patients. Coronary angiography was performed in all 
      patients. Spontaneous (n=7) or provoked (n=8) coronary artery spasm, which was 
      usually multi-focal, was observed in 15 (83%) patients. Symptoms often continued 
      despite high dose vasodilators but responded well to prednisone. Recurrent 
      coronary events were frequent, and included sudden death (n=4), resuscitated 
      cardiac arrest (n=2), myocardial infarction (n=10) and unstable angina (n=11). 
      Recurrent events were more frequent when not taking compared to when taking 
      prednisone (4.2 versus 0.4 events/year, p=0.002, hazard ratio 11, 95% confidence 
      interval 2.4-50). CONCLUSION: Published case reports suggest that coronary 
      vasospasm associated with eosinophilia responds poorly to conventional 
      vasodilator treatment and the risk of recurrent coronary events is high. Most 
      patients respond to treatment which suppresses the eosinophilia.
FAU - Wong, Chi Wing
AU  - Wong CW
AD  - Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
FAU - Luis, Sushil
AU  - Luis S
FAU - Zeng, Irene
AU  - Zeng I
FAU - Stewart, Ralph A H
AU  - Stewart RA
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20080821
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
CIN - Heart Lung Circ. 2009 Apr;18(2):163-4. PMID: 19081300
MH  - Aged
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/immunology
MH  - Aspirin/adverse effects/immunology
MH  - Coronary Vasospasm/*complications/drug therapy/physiopathology
MH  - Drug Hypersensitivity/*complications
MH  - Eosinophilia/chemically induced/*complications
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Prednisone/therapeutic use
RF  - 43
EDAT- 2008/08/23 09:00
MHDA- 2009/03/26 09:00
CRDT- 2008/08/23 09:00
PHST- 2008/03/17 00:00 [received]
PHST- 2008/06/17 00:00 [revised]
PHST- 2008/06/17 00:00 [accepted]
PHST- 2008/08/23 09:00 [pubmed]
PHST- 2009/03/26 09:00 [medline]
PHST- 2008/08/23 09:00 [entrez]
AID - S1443-9506(08)00795-6 [pii]
AID - 10.1016/j.hlc.2008.06.003 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2008 Dec;17(6):488-96. doi: 10.1016/j.hlc.2008.06.003. Epub 2008 
      Aug 21.

PMID- 18331216
OWN - NLM
STAT- MEDLINE
DCOM- 20080722
LR  - 20151119
IS  - 1527-0297 (Print)
IS  - 1527-0297 (Linking)
VI  - 9
IP  - 1
DP  - 2008 Spring
TI  - Low-dose acetylsalicylic acid analog and acetazolamide for prevention of acute 
      mountain sickness.
PG  - 15-23
LID - 10.1089/ham.2007.1037 [doi]
AB  - Analgesic drugs like acetylsalicylic acid, paracetamol, and ibuprofen are 
      frequently used by subjects suffering from headache of acute mountain sickness 
      (AMS). It is not clear if the effect is due to analgesia or prevention of AMS. We 
      performed a randomized controlled clinical trial comparing a low dose of an 
      acetylsalicylic acid analog, calcium carbasalate (380 mg /day), to placebo in a 
      cohort of altitude-naïve subjects attempting a fast climb of Mt. Kilimanjaro 
      (5896 m). A third noncontrolled open arm was proposed-the usual recommended 
      preventive treatment of acetazolamide 500 mg/day. Of 93 potential participants, 
      44 chose prevention with acetazolamide, 18 refused participation, 15 received 
      calcium carbasalate, and 16 received placebo. Mean age was 39 +/- 9 (SD) yr and 
      15% were female. AMS was quantified by the Lake Louise Symptom Score and 
      physician assessment. Calcium carbasalate at 380 mg/day did not have any 
      preventive effect on AMS and did not have any effect on the prevalence and 
      intensity of headache. Event rate of AMS in the pooled carbasalate-placebo group 
      was 84% and 55% in the acetazolamide group. The number needed to treat (NNT) at 
      500 mg/day of acetazolamide was 3. One subject on acetazolamide developed high 
      altitude cerebral edema and was treated with dexamethasone, oxygen, and descent 
      by evacuation. In conclusion, low-dose calcium carbasalate is not effective for 
      prevention of AMS. In addition, these results corroborate the contention that in 
      typical steep climbing profile settings, such as used by commercial enterprise on 
      Mt. Kilimanjaro, acetazolamide 500 mg/day may not be sufficient to prevent AMS or 
      to sufficiently reduce symptom intensity in almost half of subjects.
FAU - Kayser, Bengt
AU  - Kayser B
AD  - Institute of Movement Sciences and Sports Medicine, Faculty of Medicine, 
      University of Geneva, Switzerland. bengt.kayser@medecine.unige.ch
FAU - Hulsebosch, Ronald
AU  - Hulsebosch R
FAU - Bosch, Frank
AU  - Bosch F
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - High Alt Med Biol
JT  - High altitude medicine & biology
JID - 100901183
RN  - 0 (Carbonic Anhydrase Inhibitors)
RN  - 8W8T17847W (Urea)
RN  - N667F17JP1 (carbaspirin calcium)
RN  - O3FX965V0I (Acetazolamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - High Alt Med Biol. 2008 Winter;9(4):349; author reply 351-2. PMID: 19115924
MH  - Acetazolamide/*administration & dosage
MH  - Acute Disease
MH  - Adult
MH  - Altitude Sickness/drug therapy/*prevention & control
MH  - Aspirin/administration & dosage/*analogs & derivatives
MH  - Carbonic Anhydrase Inhibitors/administration & dosage
MH  - Cohort Studies
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Headache/drug therapy/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mountaineering
MH  - Nepal
MH  - Pulmonary Edema/prevention & control
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Urea/administration & dosage/*analogs & derivatives
EDAT- 2008/03/12 09:00
MHDA- 2008/07/23 09:00
CRDT- 2008/03/12 09:00
PHST- 2008/03/12 09:00 [pubmed]
PHST- 2008/07/23 09:00 [medline]
PHST- 2008/03/12 09:00 [entrez]
AID - 10.1089/ham.2007.1037 [doi]
PST - ppublish
SO  - High Alt Med Biol. 2008 Spring;9(1):15-23. doi: 10.1089/ham.2007.1037.

PMID- 16136412
OWN - NLM
STAT- MEDLINE
DCOM- 20060112
LR  - 20131121
IS  - 0022-9032 (Print)
IS  - 0022-9032 (Linking)
VI  - 63
IP  - 2
DP  - 2005 Aug
TI  - Oral surgery procedures in patients on anticoagulants. Preliminary report.
PG  - 137-40; discussion 141
AB  - INTRODUCTION: Patients who receive oral anticoagulants generally undergo oral 
      surgery procedures, especially teeth extractions. Because the withdrawal of 
      anticoagulant therapy may lead to severe thromboembolic complications, an attempt 
      to perform oral surgery procedures without discontinuation of anticoagulation, 
      based on the published reports, was made. AIM: To present our own experience with 
      the maintenance of anticoagulant therapy with oral coumarin-type drugs and/or 
      acetylsalicylic acid in patients with cardiovascular diseases who undergo oral 
      surgical procedures. METHODS: The group consisted of 40 patients (12 females and 
      28 males) aged 39-83 years (mean age 58 years) hospitalised in the 1st Department 
      of Oral and Maxillofacial Surgery in Zabrze from January 2000 to June 2003. The 
      following paper presents the results of the treatment of patients with 
      cardiovascular diseases, who are on oral coumarin-type anticoagulants and/or 
      acetylsalicylic acid, performed without modification of the 
      treatment/anticoagulant therapy. RESULTS: The level of anticoagulation defined as 
      the INR (International Normalized Ratio) and measured in all patients on the day 
      of surgery ranged from 1.0 to 4.0. Activated Partial Thromboplastin Time (aPTT) 
      was between 26 and 88 seconds, with a reference range in healthy subjects of 
      42-65 seconds. The prothrombin time ratio ranged from 26% to 100% (N: 80-120%). 
      Only 8% of patients developed minor bleeding complications which were promptly 
      controlled with additional haemostasis. CONCLUSIONS: Teeth extractions and other 
      oral surgical procedures may be performed without discontinuation of 
      anticoagulants.
FAU - Cieślik-Bielewska, Agata
AU  - Cieślik-Bielewska A
AD  - 1st Department of Oral and Maxillofacial Surgery, Medical University of Silesia, 
      ul. Buchenwaldczyków 19, 41-800 Zabrze, Poland. agatabielecka@poczta.onet.pl
FAU - Pelc, Ryszard
AU  - Pelc R
FAU - Cieślik, Tadeusz
AU  - Cieślik T
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Anticoagulants)
RN  - 0 (Coumarins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A4VZ22K1WT (coumarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Cardiovascular Diseases/drug therapy
MH  - Coumarins/administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - *Oral Surgical Procedures
MH  - Partial Thromboplastin Time
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Treatment Outcome
EDAT- 2005/09/02 09:00
MHDA- 2006/01/13 09:00
CRDT- 2005/09/02 09:00
PHST- 2005/09/02 09:00 [pubmed]
PHST- 2006/01/13 09:00 [medline]
PHST- 2005/09/02 09:00 [entrez]
AID - 3526 [pii]
PST - ppublish
SO  - Kardiol Pol. 2005 Aug;63(2):137-40; discussion 141.

PMID- 9844723
OWN - NLM
STAT- MEDLINE
DCOM- 19990311
LR  - 20191102
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 26
IP  - 5-6
DP  - 1998 Nov
TI  - Validation of the heat treatment step used in the production of diaspirin 
      crosslinked hemoglobin (DCLHb) for viral inactivation.
PG  - 577-82
AB  - A series of experiments was performed to assess the ability of the heat treatment 
      step used in the manufacture of diaspirin crosslinked hemoglobin (DCLHb) to 
      inactivate viruses. In-process solutions (reaction mixtures after the 
      crosslinking process) from six different manufacturing lots were used as test 
      media in a 1:680 scaled down system in which the key process parameters used in 
      the large scale production were duplicated. The inactivation of five different 
      viruses (Bovine Viral Diarrhea Virus, Pseudorabies Virus, Human Immunodeficiency 
      Virus 1, Porcine Parvovirus and Hepatitis A Virus) was evaluated. Each validation 
      experiment consisted of spiking the solution at 37 degrees C with virus, heating 
      to 74 +/- 1 degrees C over a period of 30 minutes, holding at 74 +/- 1 degrees C 
      for 90 minutes and cooling from 74 +/- 1 degrees C to less than 10 degrees C over 
      a period of 30 minutes. Duplicate experiments were performed with each of the 
      viruses with the exception of Human Immunodeficiency Virus 1, for which three 
      experiments were performed. In each experiment samples were removed before, 
      during, and after heating for the purpose of determining virus titer and 
      evaluating key process parameters. The results obtained from these experiments 
      confirmed that the key process parameters in these experiments using the scaled 
      down test system reproduced those of the large scale manufacturing process. The 
      results of the virus assays showed at least a 7 log reduction was accomplished by 
      the heat treatment for each of the viruses tested.
FAU - Azari, M
AU  - Azari M
AD  - Blood Substitutes Program, Baxter Healthcare Corporation, Round Lake, Illinois 
      60073, USA.
FAU - Ebeling, A
AU  - Ebeling A
FAU - Baker, R
AU  - Baker R
FAU - Burhop, K
AU  - Burhop K
FAU - Camacho, T
AU  - Camacho T
FAU - Estep, T
AU  - Estep T
FAU - Guzder, S
AU  - Guzder S
FAU - Marshall, T
AU  - Marshall T
FAU - Rohn, K
AU  - Rohn K
FAU - Sarajari, R
AU  - Sarajari R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Substitutes)
RN  - 0 (Hemoglobins)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/*analogs & derivatives
MH  - *Blood Substitutes/adverse effects
MH  - Diarrhea Viruses, Bovine Viral/growth & development
MH  - HIV/growth & development
MH  - *Hemoglobins/adverse effects
MH  - Hepatovirus/growth & development
MH  - Herpesvirus 1, Suid/growth & development
MH  - *Hot Temperature
MH  - Humans
MH  - Parvovirus/growth & development
MH  - Reproducibility of Results
MH  - Sterilization/methods
MH  - Swine
MH  - *Virus Activation
EDAT- 1998/12/09 00:00
MHDA- 1998/12/09 00:01
CRDT- 1998/12/09 00:00
PHST- 1998/12/09 00:00 [pubmed]
PHST- 1998/12/09 00:01 [medline]
PHST- 1998/12/09 00:00 [entrez]
AID - 10.3109/10731199809117477 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1998 Nov;26(5-6):577-82. doi: 
      10.3109/10731199809117477.

PMID- 9799060
OWN - NLM
STAT- MEDLINE
DCOM- 19990108
LR  - 20131121
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 36
IP  - 10
DP  - 1998 Oct
TI  - Interaction of omeprazole with enteric-coated salicylate tablets.
PG  - 549-53
AB  - OBJECTIVE: Enteric-coated tablets are designed to resist gastric fluids and to 
      disrupt and dissolve in the alkaline medium of the small intestine. Main 
      objective of the present study was to investigate whether the increase in gastric 
      pH due to omeprazole treatment alters the release rate of a drug from 
      enteric-coated formulation. To this end, we have compared the single dose 
      pharmacokinetics of a single-unit enteric-coated salicylate to that of uncoated 
      acetylsalicylic acid tablets in the presence and absence of omeprazole treatment. 
      METHODS: Study was carried out according to 4 x 4 Latin square design. Eight 
      healthy subjects received either uncoated acetylsalicylic acid tablets or 
      single-unit enteric-coated sodium salicylate tablets alone or following 4 days of 
      treatment with single-dose 20 mg omeprazole, and blood samples were collected for 
      24 hours. Serum salicylate levels were determined by the modified 
      spectrophotometric method of Brodie et al. [1994]. RESULTS: Salicylate was 
      absorbed rapidly from uncoated tablets but absorption of salicylate from 
      enteric-coated tablets was delayed, as expected. According to our results, 
      omeprazole treatment did not influence the bioavailability from uncoated 
      acetylsalicylic acid tablets but the absorption rate of salicylate from 
      enteric-coated tablets was increased significantly. CONCLUSION: Findings of the 
      present study demonstrate that omeprazole treatment significantly increases the 
      rate of absorption of single-unit enteric-coated medication. Enhanced rate of 
      absorption is most probably due to an early disruption of enteric coating and the 
      intragastric release of the drug secondary to an omeprazole-mediated increase in 
      gastric pH. The results of the present study also corroborate previous findings 
      which have demonstrated highly variable absorption of enteric-coated single 
      units.
FAU - Nefesoglu, F Z
AU  - Nefesoglu FZ
AD  - School of Pharmacy, Department of Pharmacology, Marmara University, Istanbul, 
      Turkey.
FAU - Ayanoglu-Dülger, G
AU  - Ayanoglu-Dülger G
FAU - Ulusoy, N B
AU  - Ulusoy NB
FAU - Imeryüz, N
AU  - Imeryüz N
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Salicylates)
RN  - 0 (Tablets, Enteric-Coated)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Anti-Ulcer Agents/*pharmacology
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biological Availability
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Omeprazole/*pharmacology
MH  - Salicylates/blood
MH  - Tablets, Enteric-Coated
EDAT- 1998/11/03 00:00
MHDA- 1998/11/03 00:01
CRDT- 1998/11/03 00:00
PHST- 1998/11/03 00:00 [pubmed]
PHST- 1998/11/03 00:01 [medline]
PHST- 1998/11/03 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 1998 Oct;36(10):549-53.

PMID- 8873235
OWN - NLM
STAT- MEDLINE
DCOM- 19970114
LR  - 20190826
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 51
IP  - 6
DP  - 1996 Jun
TI  - 5-Hydroxyeicosatetraenoic acid and human parturition.
PG  - 403-12
AB  - 5-Hydroxyeicosatetraenoic acid (5-HETE) is an arachidonic acid (AA) metabolite 
      derived from the lipoxygenase pathway which is capable of inducing uterine 
      contractions. The purpose of this study was to determine a). whether 5-HETE 
      concentrations in amniotic fluid increase before or after the onset of labor and 
      b). whether acetylsalicylic acid (ASA) could modulate the production of 5-HETE by 
      human amnion cells. 5-HETE concentrations are increased in amniotic fluid before 
      the onset of labor. Furthermore, ASA treatment as expected inhibited PGE2, but 
      also significantly increased 5-HETE production by amnion cells. 5-HETE 
      concentrations on average increased by greater than 2.5 fold (p < 0.001) in 
      amniotic fluid prior to spontaneous labor when compared with samples obtained 
      from the same patients earlier in gestation and therefore may be important in 
      mechanisms regulating the onset of labor. ASA provokes an increase in 5-HETE 
      biosynthesis by amnion cells: control media 2.60 +/- 1.5, ASA treatment alone 
      5.17 +/- 0.20, IL-1 beta alone 6.39 +/- 2.1, and ASA + IL-1 beta 8.95 +/- 1.2 
      (mean +/- SEM) picograms per microgram protein per 16 hours. These findings may 
      explain in part why cyclooxygenase inhibitors are not always successful in 
      treating women with preterm labor.
FAU - Edwin, S S
AU  - Edwin SS
AD  - Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, USA.
FAU - Romero, R J
AU  - Romero RJ
FAU - Munoz, H
AU  - Munoz H
FAU - Branch, D W
AU  - Branch DW
FAU - Mitchell, M D
AU  - Mitchell MD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - 0 (Interleukin-1)
RN  - 467RNW8T91 (5-hydroxy-6,8,11,14-eicosatetraenoic acid)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amniocentesis
MH  - Amnion/cytology/drug effects/metabolism
MH  - Amniotic Fluid/*metabolism
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Cells, Cultured
MH  - Dinoprostone/biosynthesis
MH  - Female
MH  - Humans
MH  - Hydroxyeicosatetraenoic Acids/analysis/*metabolism
MH  - Interleukin-1/pharmacology
MH  - Labor, Obstetric/drug effects/*metabolism
MH  - Pregnancy
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
AID - 0090698096000469 [pii]
AID - 10.1016/0090-6980(96)00046-9 [doi]
PST - ppublish
SO  - Prostaglandins. 1996 Jun;51(6):403-12. doi: 10.1016/0090-6980(96)00046-9.

PMID- 1498323
OWN - NLM
STAT- MEDLINE
DCOM- 19920914
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 80
IP  - 4
DP  - 1992 Aug 15
TI  - Blood platelets stimulate the expression of chondroitin sulfate proteoglycan in 
      human monocytes.
PG  - 1058-65
AB  - Mononuclear phagocytes synthesize chondroitin sulfate proteoglycan (CSPG), which 
      is constitutively secreted. Because mononuclear phagocytes are known to interact 
      with blood platelets, the effect of platelets on the release of CSPG in cultured 
      human monocytes was investigated. After 6 days in vitro, the monocytes were 
      supplied with fresh medium with different additions and subsequently exposed to 
      [35S]sulfate for 24 hours before the medium fractions were harvested and analyzed 
      for content of [35S]CSPG. Indirect evidence for the release of stimulatory 
      factors from blood platelets was found when the addition of medium containing 50% 
      serum made from platelet-rich plasma increased the expression of [35S]CSPG almost 
      sevenfold compared with serum-free medium, whereas medium containing 50% serum 
      made from platelet-depleted plasma increased the expression of [35S]CSPG about 
      fourfold. Further, direct evidence for the stimulatory effect of platelets was 
      found as the addition of autologous platelets to serum-free medium increased the 
      expression of [35S]CSPG about threefold, and addition of supernatant from a 
      corresponding number of thrombin-stimulated platelets was almost as efficient. 
      The effect of five different platelet-derived factors (which are all present in 
      serum) was investigated. Both platelet-derived growth factor (PDGF), platelet 
      factor 4 (PF 4), and prostaglandin E2 (PGE2) used in physiologic concentrations 
      were found to stimulate the expression of [35S]CSPG twofold to threefold, whereas 
      transforming growth factor-beta had a slight inhibitory effect. 
      12-Hydroxyeicosatetraenoic acid had no significant effect on the expression of 
      [35S]CSPG. Further evidence for the stimulatory effect of PDGF, PF 4, and PGE2 
      was found as serum depleted of these factors had significantly less stimulatory 
      effect than control serum. The increased incorporation of [35S]sulfate into 
      [35S]CSPG in cultures stimulated with serum or platelet-derived factors was not 
      due to differences in molecular size or extent of sulfation of the proteoglycan 
      molecules.
FAU - Uhlin-Hansen, L
AU  - Uhlin-Hansen L
AD  - Department of Biochemistry, University of Tromsø, Norway.
FAU - Langvoll, D
AU  - Langvoll D
FAU - Wik, T
AU  - Wik T
FAU - Kolset, S O
AU  - Kolset SO
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Chondroitin Sulfate Proteoglycans)
RN  - 0 (Culture Media)
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 0 (Sulfates)
RN  - 37270-94-3 (Platelet Factor 4)
RN  - EC 3.4.21.5 (Thrombin)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/blood/pharmacology
MH  - Blood
MH  - Blood Platelets/*physiology
MH  - Cells, Cultured
MH  - Chondroitin Sulfate Proteoglycans/*blood
MH  - Culture Media
MH  - Dinoprostone/pharmacology
MH  - Humans
MH  - Monocytes/*metabolism
MH  - Platelet Factor 4/pharmacology
MH  - Platelet-Derived Growth Factor/pharmacology
MH  - Sulfates/blood
MH  - Thrombin/pharmacology
EDAT- 1992/08/15 00:00
MHDA- 1992/08/15 00:01
CRDT- 1992/08/15 00:00
PHST- 1992/08/15 00:00 [pubmed]
PHST- 1992/08/15 00:01 [medline]
PHST- 1992/08/15 00:00 [entrez]
AID - S0006-4971(20)67667-4 [pii]
PST - ppublish
SO  - Blood. 1992 Aug 15;80(4):1058-65.

PMID- 2222293
OWN - NLM
STAT- MEDLINE
DCOM- 19901119
LR  - 20131121
IS  - 0300-8495 (Print)
IS  - 0300-8495 (Linking)
VI  - 19
IP  - 7
DP  - 1990 Jul
TI  - Aspirin and thrombolytic therapy in the management of acute myocardial 
      infarction.
PG  - 1003, 1006-9
AB  - The use of aspirin and thrombolytic agents in the management of acute myocardial 
      infarction is now accepted as standard clinical practice, but not all patients 
      with heart attack are suitable for such therapy. This article provides practical 
      guidelines for patient management and the background information on which these 
      recommendations are based.
FAU - Hockings, B
AU  - Hockings B
AD  - Royal Perth Hospital, Western Australia.
LA  - eng
PT  - Guideline
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Aust Fam Physician
JT  - Australian family physician
JID - 0326701
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/drug therapy
MH  - Aspirin/*therapeutic use
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy/prevention & control
MH  - *Thrombolytic Therapy
RF  - 13
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
PST - ppublish
SO  - Aust Fam Physician. 1990 Jul;19(7):1003, 1006-9.

PMID- 3583461
OWN - NLM
STAT- MEDLINE
DCOM- 19870708
LR  - 20190816
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 15
IP  - 2
DP  - 1987 May
TI  - Relapsing Kawasaki's disease.
PG  - 241-4
AB  - An 18-month-old child with Kawasaki syndrome twice developed severe recurrence of 
      symptoms when the acetylsalicylic acid (Aspirin) dosage was decreased from 80 
      mg/kg/day. Care of the patient with Kawasaki disease should be directed toward 
      control of symptoms as well as monitoring for cardiac involvement.
FAU - Feild, C
AU  - Feild C
FAU - Brady, S
AU  - Brady S
FAU - Lowe, B
AU  - Lowe B
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Dermatitis/etiology
MH  - Female
MH  - Fever/etiology
MH  - Humans
MH  - Infant
MH  - Mucocutaneous Lymph Node Syndrome/complications/drug therapy/*physiopathology
MH  - Recurrence
EDAT- 1987/05/01 00:00
MHDA- 1987/05/01 00:01
CRDT- 1987/05/01 00:00
PHST- 1987/05/01 00:00 [pubmed]
PHST- 1987/05/01 00:01 [medline]
PHST- 1987/05/01 00:00 [entrez]
AID - 0167-5273(87)90320-2 [pii]
AID - 10.1016/0167-5273(87)90320-2 [doi]
PST - ppublish
SO  - Int J Cardiol. 1987 May;15(2):241-4. doi: 10.1016/0167-5273(87)90320-2.

PMID- 24102516
OWN - NLM
STAT- MEDLINE
DCOM- 20140310
LR  - 20211021
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 56
IP  - 20
DP  - 2013 Oct 24
TI  - Synthesis and chemical and biological comparison of nitroxyl- and nitric 
      oxide-releasing diazeniumdiolate-based aspirin derivatives.
PG  - 7804-20
LID - 10.1021/jm400196q [doi]
AB  - Structural modifications of nonsteroidal anti-inflammatory drugs (NSAIDs) have 
      successfully reduced the side effect of gastrointestinal ulceration without 
      affecting anti-inflammatory activity, but they may increase the risk of 
      myocardial infarction with chronic use. The fact that nitroxyl (HNO) reduces 
      platelet aggregation, preconditions against myocardial infarction, and enhances 
      contractility led us to synthesize a diazeniumdiolate-based HNO-releasing aspirin 
      and to compare it to an NO-releasing analogue. Here, the decomposition mechanisms 
      are described for these compounds. In addition to protection against stomach 
      ulceration, these prodrugs exhibited significantly enhanced cytotoxcity compared 
      to either aspirin or the parent diazeniumdiolate toward nonsmall cell lung 
      carcinoma cells (A549), but they were not appreciably toxic toward endothelial 
      cells (HUVECs). The HNO-NSAID prodrug inhibited cylcooxgenase-2 and 
      glyceraldehyde 3-phosphate dehydrogenase activity and triggered significant 
      sarcomere shortening on murine ventricular myocytes compared to control. 
      Together, these anti-inflammatory, antineoplasic, and contractile properties 
      suggest the potential of HNO-NSAIDs in the treatment of inflammation, cancer, or 
      heart failure.
FAU - Basudhar, Debashree
AU  - Basudhar D
AD  - Department of Chemistry and Biochemistry, University of Arizona , Tucson, Arizona 
      85721, United States.
FAU - Bharadwaj, Gaurav
AU  - Bharadwaj G
FAU - Cheng, Robert Y
AU  - Cheng RY
FAU - Jain, Sarthak
AU  - Jain S
FAU - Shi, Sa
AU  - Shi S
FAU - Heinecke, Julie L
AU  - Heinecke JL
FAU - Holland, Ryan J
AU  - Holland RJ
FAU - Ridnour, Lisa A
AU  - Ridnour LA
FAU - Caceres, Viviane M
AU  - Caceres VM
FAU - Spadari-Bratfisch, Regina C
AU  - Spadari-Bratfisch RC
FAU - Paolocci, Nazareno
AU  - Paolocci N
FAU - Velázquez-Martínez, Carlos A
AU  - Velázquez-Martínez CA
FAU - Wink, David A
AU  - Wink DA
FAU - Miranda, Katrina M
AU  - Miranda KM
LA  - eng
GR  - R01 GM076247/GM/NIGMS NIH HHS/United States
GR  - ImNIH/Intramural NIH HHS/United States
GR  - R01-GM076247/GM/NIGMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20131008
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Azo Compounds)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Nitrogen Oxides)
RN  - 0 (Prodrugs)
RN  - 0 (diazeniumdiolate)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.2.1.9 (Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+))
RN  - GFQ4MMS07W (nitroxyl)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis/chemistry/pharmacology
MH  - Aspirin/*chemical synthesis/chemistry/*pharmacology
MH  - Azo Compounds/*chemistry
MH  - Carcinoma, Non-Small-Cell Lung/pathology
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Cyclooxygenase 2/metabolism
MH  - Enzyme Inhibitors/chemical synthesis/chemistry/pharmacology
MH  - Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+)/metabolism
MH  - Humans
MH  - Lung Neoplasms/pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Models, Chemical
MH  - Molecular Structure
MH  - Myocytes, Cardiac/cytology/drug effects/metabolism
MH  - Nitric Oxide/*chemistry
MH  - Nitrogen Oxides/*chemistry
MH  - Prodrugs/chemical synthesis/chemistry/pharmacology
MH  - Sarcomeres/drug effects/metabolism
PMC - PMC3880621
MID - NIHMS528488
EDAT- 2013/10/10 06:00
MHDA- 2014/03/13 06:00
CRDT- 2013/10/10 06:00
PHST- 2013/10/10 06:00 [entrez]
PHST- 2013/10/10 06:00 [pubmed]
PHST- 2014/03/13 06:00 [medline]
AID - 10.1021/jm400196q [doi]
PST - ppublish
SO  - J Med Chem. 2013 Oct 24;56(20):7804-20. doi: 10.1021/jm400196q. Epub 2013 Oct 8.

PMID- 32562573
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20210525
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 108
IP  - 6
DP  - 2020 Dec
TI  - Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a 
      Healthy Elderly Population.
PG  - 1289-1298
LID - 10.1002/cpt.1959 [doi]
AB  - The platelet endothelial aggregation receptor-1 (PEAR1) rs12041331 variant has 
      been identified as a genetic determinant of platelet aggregation in response to 
      antiplatelet therapies, including aspirin. However, association with 
      atherothrombotic cardiovascular events is less clear, with limited evidence from 
      large trials. Here, we tested association of rs12041331 with cardiovascular 
      events and aspirin use in a randomized trial population of healthy older 
      individuals. We undertook post hoc analysis of 13,547 participants of the ASPirin 
      in Reducing Events in the Elderly (ASPREE) trial, median age 74 years. 
      Participants had no previous diagnosis of atherothrombotic cardiovascular disease 
      at enrollment, and were randomized to either 100 mg daily low-dose aspirin or 
      placebo for median 4.7 years follow-up. We used Cox proportional hazard 
      regression to model the relationship between rs12041331 and the ASPREE primary 
      cardiovascular disease (CVD) end point, and composites of major adverse 
      cardiovascular events (MACE) and ischemic stroke (STROKE); and bleeding events; 
      major hemorrhage (MHEM) and intracranial bleeding (ICB). We performed 
      whole-population analysis using additive and dominant inheritance models, then 
      stratified by treatment group. Interaction effects between genotypes and 
      treatment group were examined. We observed no statistically significant 
      association (P < 0.05) in the population, or by treatment group, between 
      rs12041331 and cardiovascular or bleeding events in either model. We also found 
      no significant interaction effects between rs12041331-A and treatment group, for 
      CVD (P = 0.65), MACE (P = 0.32), STROKE (P = 0.56), MHEM (P = 0.59), or ICB 
      (P = 0.56). The genetic variant PEAR1 rs12041331 is not associated with 
      cardiovascular events in response to low-dose aspirin in a healthy elderly 
      population.
CI  - © 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society 
      for Clinical Pharmacology and Therapeutics.
FAU - Lewis, Joshua P
AU  - Lewis JP
AD  - Department of Medicine, Program for Personalized and Genomic Medicine, University 
      of Maryland School of Medicine, Baltimore, Maryland, USA.
FAU - Riaz, Moeen
AU  - Riaz M
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Xie, Sophia
AU  - Xie S
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Polekhina, Galina
AU  - Polekhina G
AD  - Department of Medicine, Program for Personalized and Genomic Medicine, University 
      of Maryland School of Medicine, Baltimore, Maryland, USA.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Nelson, Mark
AU  - Nelson M
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, 
      Australia.
FAU - Tonkin, Andrew M
AU  - Tonkin AM
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
AD  - School of Public Health, Curtin University, Perth, Western Australia, Australia.
FAU - Murray, Anne M
AU  - Murray AM
AD  - Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute, Hennepin Healthcare, Minneapolis, Minnesota, USA.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Shuldiner, Alan R
AU  - Shuldiner AR
AD  - Department of Medicine, Program for Personalized and Genomic Medicine, University 
      of Maryland School of Medicine, Baltimore, Maryland, USA.
FAU - Lacaze, Paul
AU  - Lacaze P
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
LA  - eng
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - R01 HL137922/HL/NHLBI NIH HHS/United States
GR  - P30 AG024824/AG/NIA NIH HHS/United States
GR  - U19 AG062682/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (PEAR1 protein, human)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Receptors, Cell Surface)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Australia
MH  - Blood Platelets/*drug effects/metabolism
MH  - Cardiovascular Diseases/blood/diagnosis/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Pharmacogenetics
MH  - *Pharmacogenomic Variants
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - *Polymorphism, Single Nucleotide
MH  - *Primary Prevention
MH  - Prospective Studies
MH  - Receptors, Cell Surface/*genetics/metabolism
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - United States
PMC - PMC7959328
MID - NIHMS1676973
EDAT- 2020/06/21 06:00
MHDA- 2021/05/26 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/04/06 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - 10.1002/cpt.1959 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2020 Dec;108(6):1289-1298. doi: 10.1002/cpt.1959. Epub 2020 
      Jul 20.

PMID- 24102416
OWN - NLM
STAT- MEDLINE
DCOM- 20151013
LR  - 20140804
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 27
IP  - 13
DP  - 2014 Sep
TI  - Management of chronic hypertension during pregnancy with furosemide, amlodipine 
      or aspirin: a pilot clinical trial.
PG  - 1291-4
LID - 10.3109/14767058.2013.852180 [doi]
AB  - OBJECTIVE: To determine the maternal and neonatal efficacy and safety with 
      furosemide, amlodipine or aspirin in women with mild/moderate chronic 
      hypertension during pregnancy. METHODS: A pilot clinical trial was performed in a 
      tertiary teaching hospital in Panama. Pregnant patients with mild/moderate 
      chronic hypertension at ≤20 weeks of gestation were invited to take part in the 
      study. Mild/moderate chronic hypertension was defined as a pregnancy with 
      systolic blood pressure of 140-159 mmHg or diastolic blood pressure of 
      90-109 mmHg. Women in the furosemide group received 20 mg of furosemide oral each 
      day, those in the amlodipine group received 5 mg of amlodipine oral each day and 
      those in the aspirin group received 75 mg of orally-administered acetylsalicylic 
      acid each day. RESULTS: We enrolled 63 patients during the study period, 21 women 
      were randomised to each group (aspirin, amlodipine and furosemide). We found no 
      difference in maternal complications, pre-term births, mean birth weight or in 
      the proportion of small for gestational age infants among treatment groups. 
      Severe hypertension and aggregate pre-eclampsia were similar among treatment 
      groups. CONCLUSION: This pilot trial demonstrates that both furosemide and 
      amlodipine might have the same effect during pregnancy. However, a large clinical 
      trial is necessary to prove this.
FAU - Vigil-De Gracia, Paulino
AU  - Vigil-De Gracia P
AD  - Department of Obstetrics and Gynecology, Critical Care and Maternal Fetal Unit, 
      Caja de Seguro Social , Panama City , Panama.
FAU - Dominguez, Leyvis
AU  - Dominguez L
FAU - Solis, Alcibiades
AU  - Solis A
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20131031
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Diuretics)
RN  - 1J444QC288 (Amlodipine)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Amlodipine/*therapeutic use
MH  - Antihypertensive Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Diuretics/*therapeutic use
MH  - Female
MH  - Furosemide/*therapeutic use
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/*drug therapy
MH  - Pilot Projects
MH  - Pregnancy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Amlodipine
OT  - aspirin
OT  - chronic hypertension
OT  - diuretics
OT  - furosemide
OT  - pre-eclampsia
EDAT- 2013/10/10 06:00
MHDA- 2015/10/16 06:00
CRDT- 2013/10/10 06:00
PHST- 2013/10/10 06:00 [entrez]
PHST- 2013/10/10 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - 10.3109/14767058.2013.852180 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2014 Sep;27(13):1291-4. doi: 
      10.3109/14767058.2013.852180. Epub 2013 Oct 31.

PMID- 2531943
OWN - NLM
STAT- MEDLINE
DCOM- 19900119
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 20
IP  - 12
DP  - 1989 Dec
TI  - Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia.
PG  - 1643-7
AB  - We compared combination therapy with low-dose aspirin plus ticlopidine to therapy 
      with aspirin alone or ticlopidine alone in patients suffering transient ischemic 
      attack or cerebral infarction. In 17, 24, and 23 patients, respectively, 300 
      mg/day aspirin, 200 mg/day ticlopidine, and 81 mg/day aspirin plus 100 mg/day 
      ticlopidine were administered orally. Aspirin alone markedly inhibited platelet 
      aggregation induced by arachidonic acid, partially inhibited platelet aggregation 
      induced by adenosine diphosphate, and did not inhibit platelet aggregation 
      induced by platelet activating factor. Ticlopidine alone inhibited platelet 
      aggregation induced by adenosine diphosphate and platelet activating factor, but 
      did not inhibit platelet aggregation induced by arachidonic acid. Combination 
      therapy with aspirin plus ticlopidine markedly inhibited platelet aggregation 
      induced by all three agonists. Plasma concentrations of beta-thromboglobulin and 
      platelet factor 4 remained unchanged by aspirin alone, were slightly reduced by 
      ticlopidine alone, and were markedly reduced by aspirin plus ticlopidine. Plasma 
      concentration of thromboxane B2 was reduced by aspirin alone or with ticlopidine, 
      but not by ticlopidine alone. The level of 6-ketoprostaglandin F1 alpha was 
      reduced only by aspirin alone. Bleeding time was significantly prolonged by 
      aspirin alone and by ticlopidine alone, although the greatest prolongation was 
      produced by aspirin plus ticlopidine. Our results indicate that the combination 
      of aspirin plus ticlopidine is a potent antiplatelet strategy, although the 
      clinical importance of the changes observed need to be determined by a properly 
      designed and controlled prospective study.
FAU - Uchiyama, S
AU  - Uchiyama S
AD  - Department of Neurology, Tokyo Women's Medical College, Japan.
FAU - Sone, R
AU  - Sone R
FAU - Nagayama, T
AU  - Nagayama T
FAU - Shibagaki, Y
AU  - Shibagaki Y
FAU - Kobayashi, I
AU  - Kobayashi I
FAU - Maruyama, S
AU  - Maruyama S
FAU - Kusakabe, K
AU  - Kusakabe K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (beta-Thromboglobulin)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Brain Ischemia/blood/*drug therapy
MH  - Cell Survival/drug effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Ticlopidine/adverse effects/*therapeutic use
MH  - beta-Thromboglobulin/analysis
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
AID - 10.1161/01.str.20.12.1643 [doi]
PST - ppublish
SO  - Stroke. 1989 Dec;20(12):1643-7. doi: 10.1161/01.str.20.12.1643.

PMID- 27640943
OWN - NLM
STAT- MEDLINE
DCOM- 20170531
LR  - 20220408
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 216
IP  - 2
DP  - 2017 Feb
TI  - The role of aspirin dose on the prevention of preeclampsia and fetal growth 
      restriction: systematic review and meta-analysis.
PG  - 110-120.e6
LID - S0002-9378(16)30783-9 [pii]
LID - 10.1016/j.ajog.2016.09.076 [doi]
AB  - BACKGROUND: Preeclampsia and fetal growth restriction are major causes of 
      perinatal death and handicap in survivors. Randomized clinical trials have 
      reported that the risk of preeclampsia, severe preeclampsia, and fetal growth 
      restriction can be reduced by the prophylactic use of aspirin in high-risk women, 
      but the appropriate dose of the drug to achieve this objective is not certain. 
      OBJECTIVE: We sought to estimate the impact of aspirin dosage on the prevention 
      of preeclampsia, severe preeclampsia, and fetal growth restriction. STUDY DESIGN: 
      We performed a systematic review and meta-analysis of randomized controlled 
      trials comparing the effect of daily aspirin or placebo (or no treatment) during 
      pregnancy. We searched MEDLINE, Embase, Web of Science, and Cochrane Central 
      Register of Controlled Trials up to December 2015, and study bibliographies were 
      reviewed. Authors were contacted to obtain additional data when needed. Relative 
      risks for preeclampsia, severe preeclampsia, and fetal growth restriction were 
      calculated with 95% confidence intervals using random-effect models. 
      Dose-response effect was evaluated using meta-regression and reported as adjusted 
      R(2). Analyses were stratified according to gestational age at initiation of 
      aspirin (≤16 and >16 weeks) and repeated after exclusion of studies at high risk 
      of biases. RESULTS: In all, 45 randomized controlled trials included a total of 
      20,909 pregnant women randomized to between 50-150 mg of aspirin daily. When 
      aspirin was initiated at ≤16 weeks, there was a significant reduction and a 
      dose-response effect for the prevention of preeclampsia (relative risk, 0.57; 95% 
      confidence interval, 0.43-0.75; P < .001; R(2), 44%; P = .036), severe 
      preeclampsia (relative risk, 0.47; 95% confidence interval, 0.26-0.83; P = .009; 
      R(2), 100%; P = .008), and fetal growth restriction (relative risk, 0.56; 95% 
      confidence interval, 0.44-0.70; P < .001; R(2), 100%; P = .044) with higher 
      dosages of aspirin being associated with greater reduction of the 3 outcomes. 
      Similar results were observed after the exclusion of studies at high risk of 
      biases. When aspirin was initiated at >16 weeks, there was a smaller reduction of 
      preeclampsia (relative risk, 0.81; 95% confidence interval, 0.66-0.99; P = .04) 
      without relationship with aspirin dosage (R(2), 0%; P = .941). Aspirin initiated 
      at >16 weeks was not associated with a risk reduction or a dose-response effect 
      for severe preeclampsia (relative risk, 0.85; 95% confidence interval, 0.64-1.14; 
      P = .28; R(2), 0%; P = .838) and fetal growth restriction (relative risk, 0.95; 
      95% confidence interval, 0.86-1.05; P = .34; R(2), not available; P = .563). 
      CONCLUSION: Prevention of preeclampsia and fetal growth restriction using aspirin 
      in early pregnancy is associated with a dose-response effect. Low-dose aspirin 
      initiated at >16 weeks' gestation has a modest or no impact on the risk of 
      preeclampsia, severe preeclampsia, and fetal growth restriction. Women at high 
      risk for those outcomes should be identified in early pregnancy.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Roberge, Stéphanie
AU  - Roberge S
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Université Laval, 
      Quebec City, Quebec, Canada; Harris Birthright Research Center of Fetal Medicine, 
      King's College Hospital, London, United Kingdom.
FAU - Nicolaides, Kypros
AU  - Nicolaides K
AD  - Harris Birthright Research Center of Fetal Medicine, King's College Hospital, 
      London, United Kingdom.
FAU - Demers, Suzanne
AU  - Demers S
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Université Laval, 
      Quebec City, Quebec, Canada; Harris Birthright Research Center of Fetal Medicine, 
      King's College Hospital, London, United Kingdom.
FAU - Hyett, Jon
AU  - Hyett J
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Central Clinical, 
      University of Sydney, Sydney, Australia.
FAU - Chaillet, Nils
AU  - Chaillet N
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Université Laval, 
      Quebec City, Quebec, Canada.
FAU - Bujold, Emmanuel
AU  - Bujold E
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Université Laval, 
      Quebec City, Quebec, Canada. Electronic address: 
      emmanuel.bujold@crchudequebec.ulaval.ca.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160915
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Obstet Gynecol. 2017 Feb;216(2):95-97. PMID: 28148451
MH  - Aspirin/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - aspirin
OT  - fetal growth restriction
OT  - meta-analysis
OT  - meta-regression
OT  - preeclampsia
OT  - pregnancy
OT  - systematic review
EDAT- 2016/09/20 06:00
MHDA- 2017/06/01 06:00
CRDT- 2016/09/20 06:00
PHST- 2016/07/18 00:00 [received]
PHST- 2016/08/25 00:00 [revised]
PHST- 2016/09/07 00:00 [accepted]
PHST- 2016/09/20 06:00 [pubmed]
PHST- 2017/06/01 06:00 [medline]
PHST- 2016/09/20 06:00 [entrez]
AID - S0002-9378(16)30783-9 [pii]
AID - 10.1016/j.ajog.2016.09.076 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2017 Feb;216(2):110-120.e6. doi: 10.1016/j.ajog.2016.09.076. 
      Epub 2016 Sep 15.

PMID- 9088834
OWN - NLM
STAT- MEDLINE
DCOM- 19970619
LR  - 20191101
IS  - 0952-1941 (Print)
IS  - 0952-1941 (Linking)
VI  - 14
DP  - 1997 Mar
TI  - Pharmacological prophylaxis of bleeding in surgical patients treated with 
      aspirin.
PG  - 38-41
AB  - A Medline search and subsequent meta-analysis shows that pre-operative aspirin 
      increases blood loss and transfusion requirements in patients undergoing coronary 
      artery bypass grafting. Both aprotinin and desmopressin are effective in 
      counteracting this. There are almost no data on the effects of bleeding of 
      aspirin, aprotinin and desmopressin in other procedures.
FAU - Flordal, P A
AU  - Flordal PA
AD  - Department of Surgery, Danderyd Hospital, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur J Anaesthesiol Suppl
JT  - European journal of anaesthesiology. Supplement
JID - 8804068
RN  - 0 (Hemostatics)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9087-70-1 (Aprotinin)
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aprotinin/*therapeutic use
MH  - Aspirin/*adverse effects
MH  - Blood Loss, Surgical/*prevention & control
MH  - Deamino Arginine Vasopressin/*therapeutic use
MH  - Hemostatics/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects
RF  - 29
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
AID - 10.1097/00003643-199703001-00008 [doi]
PST - ppublish
SO  - Eur J Anaesthesiol Suppl. 1997 Mar;14:38-41. doi: 
      10.1097/00003643-199703001-00008.

PMID- 6895645
OWN - NLM
STAT- MEDLINE
DCOM- 19820326
LR  - 20131121
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 3
IP  - Suppl 2
DP  - 1981
TI  - Protection of gastric mucosa by sucralfate from aspirin-induced erosions.
PG  - 175-9
AB  - The protective effect of sucralfate against aspirin caused damage to the gastric 
      mucosa was studied in healthy male volunteers (age range 18 to 44 years) with no 
      history of gastrointestinal disease. Each was randomly assigned to placebo or 
      sucralfate. As determined by endoscopic studies, 8 of 12 subjects on sucralfate 
      experienced complete protection; 3 were partially protected. The question was 
      raised whether sucralfate might have inhibited the absorption of aspirin from the 
      gastrointestinal tract, but measurement of salicylate levels showed no 
      statistically significant difference between salicylate levels achieved after 
      sucralfate and after placebo.
FAU - Tesler, M A
AU  - Tesler MA
FAU - Lim, E S
AU  - Lim ES
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Anti-Ulcer Agents)
RN  - 54182-58-0 (Sucralfate)
RN  - CPD4NFA903 (Aluminum)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aluminum/*pharmacology
MH  - Anti-Ulcer Agents/*pharmacology
MH  - Aspirin/*adverse effects
MH  - Endoscopy
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Random Allocation
MH  - Sucralfate
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - J Clin Gastroenterol. 1981;3(Suppl 2):175-9.

PMID- 33373378
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 12
DP  - 2020
TI  - Perioperative changes of response to antiplatelet medication in vascular surgery 
      patients.
PG  - e0244330
LID - 10.1371/journal.pone.0244330 [doi]
LID - e0244330
AB  - INTRODUCTION: Reduced antiplatelet activity of aspirin (ALR) or clopidogrel (CLR) 
      is associated with an increased risk of thromboembolic events. The reported 
      prevalence data for low-responders vary widely and there have been few 
      investigations in vascular surgery patients even though they are at high risk for 
      thromb-embolic complications. The aim of this prospective observational 
      monocentric study was to elucidate possible changes in ALR or CLR after common 
      vascular procedures. METHODS: Activity of aspirin and clopidogrel was measured by 
      impedance aggregometry using a multiple electrode aggregometer (Multiplate®). 
      Possible risk factors for ALR or CLR were identified by demographical, clinical 
      data and laboratory parameters. In addition, a follow-up aggregometry was 
      performed after completion of the vascular procedure to identify changes in 
      antiplatelet response. RESULTS: A total of 176 patients taking antiplatelet 
      medications aspirin and/or clopidogrel with peripheral artery disease (PAD) 
      and/or carotid stenosis (CS) were included in the study. The prevalence of ALR 
      was 13.1% and the prevalence of CLR was 32% in the aggregometry before vascular 
      treatment. Potential risk factors identified in the aspirin group were 
      concomitant insulin medication (p = 0.0006) and elevated C-reactive protein (CRP) 
      (p = 0.0021). The overall ALR increased significantly postoperatively to 27.5% (p 
      = 0.0006); however, there was no significant change in CLR that was detected. In 
      a subgroup analysis elevation of the platelet count was associated with a 
      post-procedure increase of ALR incidence. CONCLUSION: The incidence of ALR in 
      vascular surgery patients increases after vascular procedures. An elevated 
      platelet count was detected as a risk factor. Further studies are necessary to 
      analyse this potential influence on patency rates of vascular reconstructions.
FAU - Hummel, Thomas
AU  - Hummel T
AUID- ORCID: 0000-0001-6931-5930
AD  - Department of Vascular Surgery, St. Josef Hospital, Katholisches Klinikum Bochum, 
      Ruhr University Bochum, Bochum, Germany.
FAU - Meves, Saskia Hannah
AU  - Meves SH
AD  - Department of Neurology, St. Josef Hospital, Katholisches Klinikum Bochum, Ruhr 
      University Bochum, Bochum, Germany.
FAU - Breuer-Kaiser, Andreas
AU  - Breuer-Kaiser A
AD  - Department of Anaesthesiology, St. Josef Hospital, Katholisches Klinikum Bochum, 
      Ruhr University Bochum, Bochum, Germany.
FAU - Düsterwald, Jan-Ole
AU  - Düsterwald JO
AD  - Department of Vascular Surgery, St. Josef Hospital, Katholisches Klinikum Bochum, 
      Ruhr University Bochum, Bochum, Germany.
FAU - Mühlberger, Dominic
AU  - Mühlberger D
AD  - Department of Vascular Surgery, St. Josef Hospital, Katholisches Klinikum Bochum, 
      Ruhr University Bochum, Bochum, Germany.
FAU - Mumme, Achim
AU  - Mumme A
AD  - Department of Vascular Surgery, St. Josef Hospital, Katholisches Klinikum Bochum, 
      Ruhr University Bochum, Bochum, Germany.
FAU - Neubauer, Horst
AU  - Neubauer H
AD  - Department of Cardiology, St. Josef Hospital, Katholisches Klinikum Bochum, Ruhr 
      University Bochum, Bochum, Germany.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201229
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Carotid Stenosis/*surgery
MH  - Clopidogrel/*administration & dosage/therapeutic use
MH  - Empirical Research
MH  - Female
MH  - Humans
MH  - Male
MH  - Perioperative Care/instrumentation
MH  - Peripheral Arterial Disease/*surgery
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - Platelet Count
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Treatment Outcome
MH  - Vascular Surgical Procedures/*adverse effects
PMC - PMC7771706
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/30 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/12/29 17:08
PHST- 2020/08/18 00:00 [received]
PHST- 2020/12/07 00:00 [accepted]
PHST- 2020/12/29 17:08 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - PONE-D-20-25881 [pii]
AID - 10.1371/journal.pone.0244330 [doi]
PST - epublish
SO  - PLoS One. 2020 Dec 29;15(12):e0244330. doi: 10.1371/journal.pone.0244330. 
      eCollection 2020.

PMID- 4053513
OWN - NLM
STAT- MEDLINE
DCOM- 19851203
LR  - 20190820
IS  - 0143-5221 (Print)
IS  - 0143-5221 (Linking)
VI  - 69
IP  - 5
DP  - 1985 Nov
TI  - A vasopressin-mediated diminution of potassium excretion in water-loaded man.
PG  - 601-6
AB  - Intravenous vasopressin (1-3 mu-units min-1 kg-1) had an antidiuretic effect on 
      water-loaded man and also diminished potassium excretion. As noted by others, 
      aspirin (2.4 g) enhanced the antidiuretic effect of vasopressin, but the fall in 
      potassium excretion was not modified by prior administration of aspirin, which 
      makes it unlikely that the fall was due to the release of endogenous 
      prostaglandins. After terminating the infusion of vasopressin, the fall in 
      potassium output persisted longer than the antidiuresis, which makes it unlikely 
      that the antikaliuretic effect of vasopressin is secondary to its effect on urine 
      flow. The unchanged antikaliuretic effect of vasopressin after aspirin treatment, 
      together with its persistence after terminating the infusion, suggest the 
      possible existence of vasopressin-mediated potassium absorption in the distal 
      nephron in certain circumstances. Aspirin administration had specific effects of 
      its own in water-loaded man. It decreased both the water diuresis and sodium 
      excretion but did not alter potassium excretion or urine osmolality.
FAU - Buckley, J
AU  - Buckley J
FAU - Gebruers, E M
AU  - Gebruers EM
FAU - Hall, W J
AU  - Hall WJ
FAU - Harrington, N M
AU  - Harrington NM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 11000-17-2 (Vasopressins)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Diuresis/*drug effects
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osmolar Concentration
MH  - Potassium/*urine
MH  - Sodium/urine
MH  - Urine
MH  - Vasopressins/*pharmacology
EDAT- 1985/11/01 00:00
MHDA- 1985/11/01 00:01
CRDT- 1985/11/01 00:00
PHST- 1985/11/01 00:00 [pubmed]
PHST- 1985/11/01 00:01 [medline]
PHST- 1985/11/01 00:00 [entrez]
AID - 10.1042/cs0690601 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 1985 Nov;69(5):601-6. doi: 10.1042/cs0690601.

PMID- 336126
OWN - NLM
STAT- MEDLINE
DCOM- 19780127
LR  - 20190509
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 61
IP  - 2
DP  - 1977 Oct
TI  - Modification, by aspirin and indomethacin, of the haemodynamic and prostaglandin 
      releasing effects of E. coli endotoxin in the dog.
PG  - 175-81
AB  - 1 Dogs treated with aspirin (10 mg/kg) or indomethacin (1.5 mg/kg) 45 min before, 
      and 3 h after, an LD50 dose (1 mg/kg) of E. coli endotoxin were alive 72 h later. 
      2 Although all dogs in both treated groups survived, only those treated with 
      indomethacin were protected against the fall in blood pressure 1-2 min following 
      endotoxin. 3 Endotoxin increased the level of prostaglandin F2alpha in both the 
      mixed venous and arterial blood. No increase was observed in the aspirin and 
      indomethacin-treated groups. 4 Aspirin and indomethacin treatment did not modify 
      thrombocytopaenia or blood coagulation parameters following endotoxin.
FAU - Fletcher, J R
AU  - Fletcher JR
FAU - Ramwell, P W
AU  - Ramwell PW
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Endotoxins)
RN  - 0 (Prostaglandins F)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Cell Count
MH  - Blood Platelets
MH  - Dogs
MH  - Drug Interactions
MH  - Endotoxins/*pharmacology
MH  - *Escherichia coli
MH  - Hemodynamics/*drug effects
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Prostaglandins F/*blood
MH  - Time Factors
PMC - PMC1667519
EDAT- 1977/10/01 00:00
MHDA- 1977/10/01 00:01
CRDT- 1977/10/01 00:00
PHST- 1977/10/01 00:00 [pubmed]
PHST- 1977/10/01 00:01 [medline]
PHST- 1977/10/01 00:00 [entrez]
AID - 10.1111/j.1476-5381.1977.tb08402.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1977 Oct;61(2):175-81. doi: 10.1111/j.1476-5381.1977.tb08402.x.

PMID- 28395781
OWN - NLM
STAT- MEDLINE
DCOM- 20170503
LR  - 20181202
IS  - 1532-1916 (Electronic)
IS  - 1521-6918 (Linking)
VI  - 31
IP  - 1
DP  - 2017 Feb
TI  - Pharmacological secondary prevention in patients with mesenterial artery 
      atherosclerosis and arterial embolism.
PG  - 105-109
LID - S1521-6918(16)30050-6 [pii]
LID - 10.1016/j.bpg.2016.07.004 [doi]
AB  - Visceral arteries such as the coeliac (CA), superior mesenteric (SMA), and the 
      inferior mesenteric artery (IMA) might be affected by atherosclerotic occlusive 
      lesions with or without thrombosis or embolization causing ischaemic symptoms 
      from the gastrointestinal tract. After treatment of an acute event, these 
      patients should be offered both non-pharmacological and pharmacological secondary 
      prevention to reduce risk for future ischaemic arterial manifestations. Patients 
      with mesenteric ischaemia caused by atherosclerosis should be evaluated 
      concerning platelet antiaggregation with low dose aspirin or clopidogrel, and 
      those with cardioembolic disease should be recommended anticoagulant treatment 
      with either warfarin or one of the direct oral anticoagulants (DOAC; apixaban, 
      dabigatran, edoxaban, or rivaroxaban). In all patients, blood pressure should be 
      lowered to <140/90 mmHg with ACE-inhibitors, angiotensin receptor blockers, beta 
      blockers, calcium channel blockers, or thiazide diuretics, and LDL-cholesterol 
      should be kept at <1.8 mmol/l, preferably with statins. If present, diabetes 
      should be treated aiming at good metabolic control, and all smokers should be 
      recommended cessation.
CI  - Copyright © 2016 Elsevier Ltd. All rights reserved.
FAU - Gottsäter, Anders
AU  - Gottsäter A
AD  - Department of Vascular Diseases, Skåne University Hospital, 2-205 02 Malmö, 
      Sweden. Electronic address: anders.gottsater@med.lu.se.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160728
PL  - Netherlands
TA  - Best Pract Res Clin Gastroenterol
JT  - Best practice & research. Clinical gastroenterology
JID - 101120605
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Atherosclerosis/*drug therapy
MH  - Embolism/*drug therapy
MH  - Humans
MH  - Peripheral Arterial Disease/*drug therapy
MH  - Secondary Prevention
OTO - NOTNLM
OT  - Anticoagulation
OT  - Antiplatelet treatment
OT  - Atherosclerosis
OT  - Blood pressure lowering
OT  - Coeliac artery (CA)
OT  - Embolization
OT  - Inferior mesenteric artery (IMA)
OT  - Lipid lowering
OT  - Superior mesenteric artery (SMA)
OT  - Thrombosis
EDAT- 2017/04/12 06:00
MHDA- 2017/05/04 06:00
CRDT- 2017/04/12 06:00
PHST- 2016/07/18 00:00 [received]
PHST- 2016/07/20 00:00 [accepted]
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
AID - S1521-6918(16)30050-6 [pii]
AID - 10.1016/j.bpg.2016.07.004 [doi]
PST - ppublish
SO  - Best Pract Res Clin Gastroenterol. 2017 Feb;31(1):105-109. doi: 
      10.1016/j.bpg.2016.07.004. Epub 2016 Jul 28.

PMID- 33857301
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20220716
IS  - 1938-5404 (Electronic)
IS  - 0033-7587 (Print)
IS  - 0033-7587 (Linking)
VI  - 196
IP  - 1
DP  - 2021 Jul 1
TI  - Effects of Acute and Chronic Exposure to a Mixed Field of Neutrons and Photons 
      and Single or Fractionated Simulated Galactic Cosmic Ray Exposure on Behavioral 
      and Cognitive Performance in Mice.
PG  - 31-39
LID - 10.1667/RADE-20-00228.1 [doi]
AB  - During space missions, astronauts experience acute and chronic low-dose-rate 
      radiation exposures. Given the clear gap of knowledge regarding such exposures, 
      we assessed the effects acute and chronic exposure to a mixed field of neutrons 
      and photons and single or fractionated simulated galactic cosmic ray exposure 
      (GCRsim) on behavioral and cognitive performance in mice. In addition, we 
      assessed the effects of an aspirin-containing diet in the presence and absence of 
      chronic exposure to a mixed field of neutrons and photons. In C3H male mice, 
      there were effects of acute radiation exposure on activity levels in the open 
      field containing objects. In addition, there were radiation-aspirin interactions 
      for effects of chronic radiation exposure on activity levels and measures of 
      anxiety in the open field, and on activity levels in the open field containing 
      objects. There were also detrimental effects of aspirin and chronic radiation 
      exposure on the ability of mice to distinguish the familiar and novel object. 
      Finally, there were effects of acute GCRsim on activity levels in the open field 
      containing objects. Activity levels were lower in GCRsim than sham-irradiated 
      mice. Thus, acute and chronic irradiation to a mixture of neutrons and photons 
      and acute and fractionated GCRsim have differential effects on behavioral and 
      cognitive performance of C3H mice. Within the limitations of our study design, 
      aspirin does not appear to be a suitable countermeasure for effects of chronic 
      exposure to space radiation on cognitive performance.
CI  - ©2021 by Radiation Research Society. All rights of reproduction in any form 
      reserved.
FAU - Holden, Sarah
AU  - Holden S
AD  - Department of Behavioral Neuroscience, Division of Neuroscience ONPRC, Oregon 
      Health & Science University, Portland, Oregon 97239.
FAU - Perez, Ruby
AU  - Perez R
AD  - Department of Behavioral Neuroscience, Division of Neuroscience ONPRC, Oregon 
      Health & Science University, Portland, Oregon 97239.
FAU - Hall, Reed
AU  - Hall R
AD  - Department of Behavioral Neuroscience, Division of Neuroscience ONPRC, Oregon 
      Health & Science University, Portland, Oregon 97239.
FAU - Fallgren, Christina M
AU  - Fallgren CM
AD  - Department of Environmental and Radiological Health Sciences, Colorado State 
      University, Fort Collins, Colorado 80523.
FAU - Ponnaiya, Brian
AU  - Ponnaiya B
AD  - Columbia University Center for Radiological Research, New York, New York 10032.
FAU - Garty, Guy
AU  - Garty G
AD  - Columbia University Center for Radiological Research, New York, New York 10032.
FAU - Brenner, David J
AU  - Brenner DJ
AD  - Columbia University Center for Radiological Research, New York, New York 10032.
FAU - Weil, Michael M
AU  - Weil MM
AD  - Department of Environmental and Radiological Health Sciences, Colorado State 
      University, Fort Collins, Colorado 80523.
FAU - Raber, Jacob
AU  - Raber J
AD  - Department of Behavioral Neuroscience, Division of Neuroscience ONPRC, Oregon 
      Health & Science University, Portland, Oregon 97239.
AD  - Department of Neurology and Radiation Medicine, Division of Neuroscience ONPRC, 
      Oregon Health & Science University, Portland, Oregon 97239.
LA  - eng
GR  - U19 AI067773/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Radiat Res
JT  - Radiation research
JID - 0401245
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage
MH  - Behavior, Animal/*radiation effects
MH  - Cognition/*radiation effects
MH  - Conditioning, Classical
MH  - *Cosmic Radiation
MH  - Fear
MH  - Female
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C3H
MH  - *Neutrons
MH  - *Photons
PMC - PMC8297553
MID - NIHMS1723740
EDAT- 2021/04/16 06:00
MHDA- 2021/10/14 06:00
CRDT- 2021/04/15 17:29
PHST- 2020/09/30 00:00 [received]
PHST- 2021/03/19 00:00 [accepted]
PHST- 2021/04/16 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2021/04/15 17:29 [entrez]
AID - 464159 [pii]
AID - 10.1667/RADE-20-00228.1 [doi]
PST - ppublish
SO  - Radiat Res. 2021 Jul 1;196(1):31-39. doi: 10.1667/RADE-20-00228.1.

PMID- 8881182
OWN - NLM
STAT- MEDLINE
DCOM- 19961211
LR  - 20190830
IS  - 0929-693X (Print)
IS  - 0929-693X (Linking)
VI  - 3
IP  - 7
DP  - 1996 Jul
TI  - [Inaugural acute cholestasis of Kawasaki disease].
PG  - 694-6
AB  - BACKGROUND: Hepatic dysfunction with mild obstructive jaundice occurs 
      occasionally in Kawasaki disease. Acute episode of cholestasis as a presenting 
      symptom has never been reported. CASE REPORT: A 14 year-old-boy was admitted with 
      fever and cholestasis. He subsequently developed the classical manifestations of 
      Kawasaki disease. No signs of liver cell injury or hepatic failure were present. 
      Bacteriological cultures and seroimmunologic markers for viral infection remained 
      negative. There was no ultrasonic abnormality of bile ducts. The child was given 
      intravenous gamma globulins and salicylate. The outcome was favourable without 
      any cardiovascular complications. CONCLUSION: A persistent febrile cholestasis of 
      unknown etiology should evoke the diagnosis of Kawasaki disease.
FAU - Desgripes, A
AU  - Desgripes A
AD  - Service de pédiatrie, CHI de Poissy, France.
FAU - Blanc, P
AU  - Blanc P
FAU - Debray, D
AU  - Debray D
FAU - Carbajal, R
AU  - Carbajal R
FAU - Paupe, A
AU  - Paupe A
FAU - Lenclen, R
AU  - Lenclen R
FAU - Olivier-Martin, M
AU  - Olivier-Martin M
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Cholestase aiguë inaugurale d'une maladie de Kawasaki.
PL  - France
TA  - Arch Pediatr
JT  - Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
JID - 9421356
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Aspirin/therapeutic use
MH  - Cholestasis/*etiology
MH  - Humans
MH  - Immunization, Passive
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/drug therapy/therapy
EDAT- 1996/07/01 00:00
MHDA- 2000/05/05 09:00
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 2000/05/05 09:00 [medline]
PHST- 1996/07/01 00:00 [entrez]
AID - 0929693X96870928 [pii]
AID - 10.1016/0929-693x(96)87092-8 [doi]
PST - ppublish
SO  - Arch Pediatr. 1996 Jul;3(7):694-6. doi: 10.1016/0929-693x(96)87092-8.

PMID- 20159825
OWN - NLM
STAT- MEDLINE
DCOM- 20100504
LR  - 20220311
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 28
IP  - 9
DP  - 2010 Mar 20
TI  - Aspirin intake and survival after breast cancer.
PG  - 1467-72
LID - 10.1200/JCO.2009.22.7918 [doi]
AB  - PURPOSE: Animal and in vitro studies suggest that aspirin may inhibit breast 
      cancer metastasis. We studied whether aspirin use among women with breast cancer 
      decreased their risk of death from breast cancer. METHODS: This was a prospective 
      observational study based on responses from 4,164 female registered nurses in the 
      Nurses' Health Study who were diagnosed with stages I, II, or III breast cancer 
      between 1976 and 2002 and were observed until death or June 2006, whichever came 
      first. The main outcome was breast cancer mortality risk according to number of 
      days per week of aspirin use (0, 1, 2 to 5, or 6 to 7 days) first assessed at 
      least 12 months after diagnosis and updated. RESULTS: There were 341 breast 
      cancer deaths. Aspirin use was associated with a decreased risk of breast cancer 
      death. The adjusted relative risks (RRs) for 1, 2 to 5, and 6 to 7 days of 
      aspirin use per week compared with no use were 1.07 (95% CI, 0.70 to 1.63), 0.29 
      (95% CI, 0.16 to 0.52), and 0.36 (95% CI, 0.24 to 0.54), respectively (test for 
      linear trend, P < .001). This association did not differ appreciably by stage, 
      menopausal status, body mass index, or estrogen receptor status. Results were 
      similar for distant recurrence. The adjusted RRs were 0.91 (95% CI, 0.62 to 
      1.33), 0.40 (95% CI, 0.24 to 0.65), and 0.57 (95% CI, 0.39 to 0.82; test for 
      trend, P = .03) for 1, 2 to 5, and 6 to 7 days of aspirin use, respectively. 
      CONCLUSION: Among women living at least 1 year after a breast cancer diagnosis, 
      aspirin use was associated with a decreased risk of distant recurrence and breast 
      cancer death.
FAU - Holmes, Michelle D
AU  - Holmes MD
AD  - Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, MA 02115, USA. 
      michelle.holmes@channing.harvard.edu
FAU - Chen, Wendy Y
AU  - Chen WY
FAU - Li, Lisa
AU  - Li L
FAU - Hertzmark, Ellen
AU  - Hertzmark E
FAU - Spiegelman, Donna
AU  - Spiegelman D
FAU - Hankinson, Susan E
AU  - Hankinson SE
LA  - eng
GR  - P01 CA087969/CA/NCI NIH HHS/United States
GR  - CA87969/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20100216
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Midwifery Womens Health. 2010 Jul-Aug;55(4):389-90. PMID: 20630367
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Breast Neoplasms/*mortality
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk
MH  - Survival Analysis
PMC - PMC2849768
COIS- Authors' disclosures of potential conflicts of interest and author contributions 
      are found at the end of this article.
EDAT- 2010/02/18 06:00
MHDA- 2010/05/05 06:00
CRDT- 2010/02/18 06:00
PHST- 2010/02/18 06:00 [entrez]
PHST- 2010/02/18 06:00 [pubmed]
PHST- 2010/05/05 06:00 [medline]
AID - JCO.2009.22.7918 [pii]
AID - 27918 [pii]
AID - 10.1200/JCO.2009.22.7918 [doi]
PST - ppublish
SO  - J Clin Oncol. 2010 Mar 20;28(9):1467-72. doi: 10.1200/JCO.2009.22.7918. Epub 2010 
      Feb 16.

PMID- 36511820
OWN - NLM
STAT- MEDLINE
DCOM- 20230203
LR  - 20230301
IS  - 1473-0189 (Electronic)
IS  - 1473-0189 (Linking)
VI  - 23
IP  - 3
DP  - 2023 Jan 31
TI  - Studying the efficacy of antiplatelet drugs on atherosclerosis by optofluidic 
      imaging on a chip.
PG  - 410-420
LID - 10.1039/d2lc00895e [doi]
AB  - Vascular stenosis caused by atherosclerosis instigates activation and aggregation 
      of platelets, eventually resulting in thrombus formation. Although antiplatelet 
      drugs are commonly used to inhibit platelet activation and aggregation, they 
      unfortunately cannot prevent recurrent thrombotic events in patients with 
      atherosclerosis. This is partially due to the limited understanding of the 
      efficacy of antiplatelet drugs in the complex hemodynamic environment of vascular 
      stenosis. Conventional methods for evaluating the efficacy of antiplatelet drugs 
      under stenosis either fail to simulate the hemodynamic environment of vascular 
      stenosis characterized by high shear stress and recirculatory flow or lack 
      spatial resolution in their analytical techniques to statistically identify and 
      characterize platelet aggregates. Here we propose and experimentally demonstrate 
      a method comprising an in vitro 3D stenosis microfluidic chip and an optical 
      time-stretch quantitative phase imaging system for studying the efficacy of 
      antiplatelet drugs under stenosis. Our method simulates the atherogenic flow 
      environment of vascular stenosis while enabling high-resolution and statistical 
      analysis of platelet aggregates. Using our method, we distinguished the efficacy 
      of three antiplatelet drugs, acetylsalicylic acid (ASA), cangrelor, and 
      eptifibatide, for inhibiting platelet aggregation induced by stenosis. 
      Specifically, ASA failed to inhibit stenosis-induced platelet aggregation, while 
      eptifibatide and cangrelor showed high and moderate efficacy, respectively. 
      Furthermore, we demonstrated that the drugs tested also differed in their 
      efficacy for inhibiting platelet aggregation synergistically induced by stenosis 
      and agonists (e.g., adenosine diphosphate, and collagen). Taken together, our 
      method is an effective tool for investigating the efficacy of antiplatelet drugs 
      under vascular stenosis, which could assist the development of optimal 
      pharmacologic strategies for patients with atherosclerosis.
FAU - Deng, Yunjie
AU  - Deng Y
AUID- ORCID: 0000-0003-4118-9068
AD  - Department of Chemistry, University of Tokyo, Tokyo, 113-0033, Japan. 
      xiaoth@chem.s.u-tokyo.ac.jp.
FAU - Tay, Hui Min
AU  - Tay HM
AUID- ORCID: 0000-0002-4981-5994
AD  - School of Mechanical and Aerospace Engineering, Nanyang Technological University, 
      Singapore, 639798, Singapore.
FAU - Zhou, Yuqi
AU  - Zhou Y
AD  - Department of Chemistry, University of Tokyo, Tokyo, 113-0033, Japan. 
      xiaoth@chem.s.u-tokyo.ac.jp.
FAU - Fei, Xueer
AU  - Fei X
AD  - Department of Chemistry, University of Tokyo, Tokyo, 113-0033, Japan. 
      xiaoth@chem.s.u-tokyo.ac.jp.
FAU - Tang, Xuke
AU  - Tang X
AD  - Department of Chemistry, University of Tokyo, Tokyo, 113-0033, Japan. 
      xiaoth@chem.s.u-tokyo.ac.jp.
FAU - Nishikawa, Masako
AU  - Nishikawa M
AUID- ORCID: 0000-0002-3840-767X
AD  - Department of Clinical Laboratory Medicine, Graduate School of Medicine, 
      University of Tokyo, Tokyo, 113-0033, Japan.
FAU - Yatomi, Yutaka
AU  - Yatomi Y
AUID- ORCID: 0000-0003-1719-4297
AD  - Department of Clinical Laboratory Medicine, Graduate School of Medicine, 
      University of Tokyo, Tokyo, 113-0033, Japan.
FAU - Hou, Han Wei
AU  - Hou HW
AUID- ORCID: 0000-0001-6631-6321
AD  - School of Mechanical and Aerospace Engineering, Nanyang Technological University, 
      Singapore, 639798, Singapore.
AD  - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 
      308232, Singapore.
FAU - Xiao, Ting-Hui
AU  - Xiao TH
AUID- ORCID: 0000-0002-7339-152X
AD  - Department of Chemistry, University of Tokyo, Tokyo, 113-0033, Japan. 
      xiaoth@chem.s.u-tokyo.ac.jp.
FAU - Goda, Keisuke
AU  - Goda K
AUID- ORCID: 0000-0001-6302-6038
AD  - Department of Chemistry, University of Tokyo, Tokyo, 113-0033, Japan. 
      xiaoth@chem.s.u-tokyo.ac.jp.
AD  - Institute of Technological Sciences, Wuhan University, Hubei, 430072, China.
AD  - Department of Bioengineering, University of California, Los Angeles, California, 
      90095, USA.
AD  - CYBO, Tokyo 101-0022, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230131
PL  - England
TA  - Lab Chip
JT  - Lab on a chip
JID - 101128948
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - NA8320J834 (Eptifibatide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Eptifibatide/pharmacology
MH  - Constriction, Pathologic
MH  - Blood Platelets
MH  - Aspirin/pharmacology
MH  - *Atherosclerosis/diagnostic imaging/drug therapy
MH  - *Thrombosis
MH  - Lab-On-A-Chip Devices
EDAT- 2022/12/14 06:00
MHDA- 2023/02/04 06:00
CRDT- 2022/12/13 10:13
PHST- 2022/12/14 06:00 [pubmed]
PHST- 2023/02/04 06:00 [medline]
PHST- 2022/12/13 10:13 [entrez]
AID - 10.1039/d2lc00895e [doi]
PST - epublish
SO  - Lab Chip. 2023 Jan 31;23(3):410-420. doi: 10.1039/d2lc00895e.

PMID- 36215814
OWN - NLM
STAT- MEDLINE
DCOM- 20221108
LR  - 20221108
IS  - 1879-1506 (Electronic)
IS  - 0003-9969 (Linking)
VI  - 144
DP  - 2022 Dec
TI  - Acetylsalicylic-acid (ASA) regulation of osteo/odontogenic differentiation and 
      proliferation of human dental pulp stem cells (DPSCs) in vitro.
PG  - 105564
LID - S0003-9969(22)00221-7 [pii]
LID - 10.1016/j.archoralbio.2022.105564 [doi]
AB  - OBJECTIVE: The study aimed to investigate acetylsalicylic acid (ASA) effects on 
      osteo/odontogenic differentiation and proliferation of dental pulp stem cells 
      (DPSCs) in vitro and the potential involvement of adenosine 
      monophosphate-activated protein kinase (AMPK) pathway in these processes. DESIGN: 
      DPSCs were isolated from third molars pulp tissues of five patients and grown in 
      osteogenic medium alone or supplemented with ASA. Expression of DPSCs markers was 
      tested by flow-cytometry. Cytotoxicity of ASA at concentrations of 10, 50 and 
      100 µg/ml was tested by MTT and NR assays. Osteo/odontogenic differentiation was 
      analyzed via alizarin red staining and ALP activity. Quantitative PCR (qPCR) was 
      used for osteo/odontogenic markers' (DSPP, BMP2, BMP4, BSP, OCN and RUNX2) and 
      c-Myc expression analysis. AMPK inhibition of ASA-induced osteo/odontogenesis was 
      tested by qPCR of selected markers (DSPP, OCN and RUNX2). RESULTS: Cytotoxicity 
      assays showed that only the highest ASA dose decreased cell viability (89.1 %). 
      The smallest concentration of ASA applied on DPSCs resulted in a remarkable 
      enhancement of osteo/odontogenic differentiation, as judged by increased 
      mineralized nodules' formation, ALP activity and gene expression of analyzed 
      markers (increase between 2 and 30 folds), compared to untreated cells. ASA also 
      increased DPSCs proliferation. Interestingly, AMPK inhibition per se upregulated 
      DSPP, OCN and RUNX2; the gene upregulation was higher when ASA treatment was also 
      included. c-Myc expression level decreased in cultures treated with ASA, 
      indicating undergoing differentiation processes. CONCLUSIONS: Low concentrations 
      of ASA (corresponding to the standard use in cardiovascular patients), were shown 
      to stimulate osteo/odontogenic differentiation of dental pulp stem cells.
CI  - Copyright © 2022 Elsevier Ltd. All rights reserved.
FAU - Vukovic, Mladen
AU  - Vukovic M
AD  - Department of Human Genetics, School of Dental Medicine, University of 
      Belgrade, Serbia.
FAU - Lazarevic, Milos
AU  - Lazarevic M
AD  - Department of Human Genetics, School of Dental Medicine, University of 
      Belgrade, Serbia.
FAU - Mitic, Dijana
AU  - Mitic D
AD  - Department of Human Genetics, School of Dental Medicine, University of 
      Belgrade, Serbia.
FAU - Jaksic Karisik, Milica
AU  - Jaksic Karisik M
AD  - Department of Human Genetics, School of Dental Medicine, University of 
      Belgrade, Serbia.
FAU - Ilic, Branislav
AU  - Ilic B
AD  - Clinic for Oral Surgery, School of Dental Medicine, University of Belgrade, 
      Serbia.
FAU - Andric, Miroslav
AU  - Andric M
AD  - Clinic for Oral Surgery, School of Dental Medicine, University of Belgrade, 
      Serbia.
FAU - Jevtic, Bojan
AU  - Jevtic B
AD  - Department of Immunology, Institute for Biological Research "Sinisa Stankovic", 
      University of Belgrade, Serbia.
FAU - Roganovic, Jelena
AU  - Roganovic J
AD  - Department of Pharmacology in Dentistry, School of Dental Medicine, University of 
      Belgrade, Serbia.
FAU - Milasin, Jelena
AU  - Milasin J
AD  - Department of Human Genetics, School of Dental Medicine, University of 
      Belgrade, Serbia. Electronic address: jelena.milasin@stomf.bg.ac.rs.
LA  - eng
PT  - Journal Article
DEP - 20221001
PL  - England
TA  - Arch Oral Biol
JT  - Archives of oral biology
JID - 0116711
RN  - 0 (Core Binding Factor Alpha 1 Subunit)
RN  - R16CO5Y76E (Aspirin)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
SB  - IM
MH  - Humans
MH  - *Dental Pulp
MH  - *Core Binding Factor Alpha 1 Subunit
MH  - Aspirin/pharmacology
MH  - AMP-Activated Protein Kinases
MH  - Stem Cells
MH  - Odontogenesis/physiology
MH  - Cell Differentiation
MH  - Osteogenesis/physiology
MH  - Cell Proliferation
MH  - Cells, Cultured
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Adenosine monophosphate-activated protein kinase (AMPK)
OT  - Dental pulp stem cells
OT  - Osteogenic/odontogenic differentiation
OT  - Proliferation
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/10/11 06:00
MHDA- 2022/11/09 06:00
CRDT- 2022/10/10 18:21
PHST- 2022/06/13 00:00 [received]
PHST- 2022/09/28 00:00 [revised]
PHST- 2022/09/29 00:00 [accepted]
PHST- 2022/10/11 06:00 [pubmed]
PHST- 2022/11/09 06:00 [medline]
PHST- 2022/10/10 18:21 [entrez]
AID - S0003-9969(22)00221-7 [pii]
AID - 10.1016/j.archoralbio.2022.105564 [doi]
PST - ppublish
SO  - Arch Oral Biol. 2022 Dec;144:105564. doi: 10.1016/j.archoralbio.2022.105564. Epub 
      2022 Oct 1.

PMID- 35014931
OWN - NLM
STAT- MEDLINE
DCOM- 20220223
LR  - 20220430
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Print)
IS  - 1388-0209 (Linking)
VI  - 60
IP  - 1
DP  - 2022 Dec
TI  - The antithrombosis effect of dehydroandrographolide succinate: in vitro and 
      in vivo studies.
PG  - 175-184
LID - 10.1080/13880209.2021.2021948 [doi]
AB  - CONTEXT: Dehydroandrographolide succinate (DAS) is mainly used in the clinical 
      treatment of various infectious diseases. Its potential effects on platelet 
      aggregation and blood coagulation systems have not been reported systematically. 
      OBJECTIVE: To explore whether DAS exerts an antithrombotic effect and its 
      internal mechanism. MATERIALS AND METHODS: Human blood samples and Sprague-Dawley 
      (SD) rats divided into control, aspirin (30 mg/kg), and DAS groups (200, 400 and 
      600 mg/kg) were used to measure the platelet aggregation rate, coagulation 
      function, coagulation factor activity, and contents of thromboxane B(2) (TXB(2)) 
      and 6-keto-prostaglandin F(1α) (6-keto-PGF(1α)). The histopathology of the SD rat 
      gastric mucosa was also observed. All rats were administered intragastric or 
      intraperitoneal injections once a day for 3 consecutive days. RESULTS: Compared 
      to control group, DAS significantly inhibited the platelet aggregation rate 
      (ED(50) = 386.9 mg/kg) by decreasing TXB(2) levels (1531.95 ± 649.90 pg/mL to 
      511.08 ± 411.82 pg/mL) and activating antithrombin III (AT-III) (103.22 ± 16.22% 
      to 146.46 ± 8.96%) (p < 0.05). In addition, DAS significantly enhanced the 
      coagulation factors FV (304.12 ± 79.65% to 443.44 ± 75.04%), FVII 
      (324.19 ± 48.03% to 790.66 ± 225.56%), FVIII (524.79 ± 115.47% to 
      679.92 ± 143.34%), FX (34.90 ± 7.40% to 102.76 ± 29.41%) and FXI (38.12 ± 10.33% 
      to 65.47 ± 34.08%), increased the content of Fg (2.18 ± 0.39 to 3.61 ± 0.37 g/L), 
      shorten the PT (10.42 ± 0.44 to 9.22 ± 0.21 s), APTT (16.43 ± 1.4 to 
      14.07 ± 0.75 s) and TT time (37.04 ± 2.13 to 32.68 ± 1.29 s) (p < 0.05), while 
      the aspirin group showed no such effect on these items but showed reduced 
      activity of FII (89.21 ± 21.72% to 61.83 ± 8.95%) and FVIII (524.79 ± 115.47% to 
      306.60 ± 29.96%) (p < 0.05). Histopathological changes showed aspirin-induced 
      gastric mucosa haemorrhage and the protective effect of DAS in the gastric 
      mucosa. CONCLUSIONS: DAS is more suitable than aspirin in thromboprophylaxis 
      treatment, which provides a reliable theoretical and experimental basis for its 
      clinical application.
FAU - Yin, Bowen
AU  - Yin B
AUID- ORCID: 0000-0003-2444-8654
AD  - Clinical Laboratory, Jiangxi Provincial People's Hospital Affiliated to Nanchang 
      University, Nanchang, China.
FAU - Zhang, Shuhua
AU  - Zhang S
AD  - Jiangxi Cardiovascular Research Institute, Jiangxi Provincial People's Hospital 
      Affiliated to Nanchang University, Nanchang, China.
FAU - Huang, Yuxi
AU  - Huang Y
AD  - Dalian Key Laboratory of Marine Animal Disease Control and Prevention, College of 
      Fisheries and Life Science, Dalian Ocean University, Dalian, China.
FAU - Long, Yuanzhu
AU  - Long Y
AD  - Nanchang Maternal and Child Health Care Family Planning Service Centre, Nanchang, 
      China.
FAU - Chen, Yiguo
AU  - Chen Y
AD  - Clinical Laboratory, Jiangxi Provincial People's Hospital Affiliated to Nanchang 
      University, Nanchang, China.
FAU - Zhao, Shiyun
AU  - Zhao S
AD  - Chinese Medicine Research Institute, Academy of Jiangxi Provincial Traditional 
      Chinese Medicine, Nanchang.
FAU - Zhou, Aiqun
AU  - Zhou A
AD  - Clinical Laboratory, Jiangxi Provincial People's Hospital Affiliated to Nanchang 
      University, Nanchang, China.
FAU - Cao, Minghua
AU  - Cao M
AD  - Department of Biochemistry and Molecular Biology, School of Basic Medical 
      Sciences, Nanchang University, Nanchang, China.
FAU - Yin, Xiaoming
AU  - Yin X
AUID- ORCID: 0000-0003-4584-7347
AD  - Clinical Laboratory, Jiangxi Provincial People's Hospital Affiliated to Nanchang 
      University, Nanchang, China.
FAU - Luo, Daya
AU  - Luo D
AD  - Department of Biochemistry and Molecular Biology, School of Basic Medical 
      Sciences, Nanchang University, Nanchang, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
RN  - 0 (Diterpenes)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Succinates)
RN  - R16CO5Y76E (Aspirin)
RN  - TKB45D7LVX (dehydroandrographolide)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Diterpenes/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*pharmacology
MH  - Gastric Mucosa/drug effects/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Succinates
PMC - PMC8757605
OTO - NOTNLM
OT  - Platelet aggregation
OT  - andrographolide
OT  - aspirin
OT  - haemorrhage
OT  - thromboxane
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/01/12 06:00
MHDA- 2022/02/24 06:00
CRDT- 2022/01/11 12:18
PHST- 2022/01/11 12:18 [entrez]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/02/24 06:00 [medline]
AID - 2021948 [pii]
AID - 10.1080/13880209.2021.2021948 [doi]
PST - ppublish
SO  - Pharm Biol. 2022 Dec;60(1):175-184. doi: 10.1080/13880209.2021.2021948.

PMID- 34964076
OWN - NLM
STAT- MEDLINE
DCOM- 20211230
LR  - 20220314
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 23
IP  - 1
DP  - 2021 Dec 28
TI  - Solubility Study of Acetylsalicylic Acid in Ethanol + Water Mixtures: 
      Measurement, Mathematical Modeling, and Stability Discussion.
PG  - 42
LID - 10.1208/s12249-021-02192-7 [doi]
LID - 42
AB  - Solubility determination of poorly water-soluble drugs is pivotal for formulation 
      scientists when they want to develop a liquid formulation. Performing such a test 
      with different ratios of cosolvents with water is time-consuming and costly. The 
      scarcity of solubility data for poorly water-soluble drugs increases the 
      importance of developing correlation and prediction equations for these mixtures. 
      Therefore, the aim of the current research is to determine the solubility of 
      acetylsalicylic acid in binary mixtures of ethanol+water at 25 and 37°C. 
      Acetylsalicylic acid is non-stable in aqueous solutions and readily hydrolyze to 
      salicylic acid. So, the solubility of acetylsalicylic acid is measured in 
      ethanolic mixtures by HPLC to follow the concentration of produced salicylic acid 
      as well. Moreover, the solubility of acetylsalicylic acid is modeled using 
      different cosolvency equations. The measured solubility data were also predicted 
      using PC-SAFT EOS model. DSC results ruled out any changes in the polymorphic 
      form of acetylsalicylic acid after the solubility test, whereas XRPD results 
      showed some changes in crystallinity of the precipitated acetylsalicylic acid 
      after the solubility test. Fitting the solubility data to the different 
      cosolvency models showed that the mean relative deviation percentage for the 
      Jouyban-Acree model was less than 10.0% showing that this equation is able to 
      obtain accurate solubility data for acetylsalicylic acid in mixtures of ethanol 
      and water. Also, the predicted data with an average mean relative deviation 
      percentage (MRD%) of less than 29.65% show the capability of the PC-SAFT model 
      for predicting solubility data. A brief comparison of the solubilities of 
      structurally related solutes to acetylsalicylic acid was also provided.
CI  - © 2021. The Author(s).
FAU - Nokhodchi, Ali
AU  - Nokhodchi A
AD  - School of Life Sciences, University of Sussex, Brighton, BN1 9QJ, UK. 
      a.nokhodchi@sussex.ac.uk.
FAU - Ghafourian, Taravat
AU  - Ghafourian T
AD  - School of Life Sciences, Faculty of Creative Arts, Technologies and Science, 
      University of Bedfordshire, Luton, UK. tara.ghafourian@beds.ac.uk.
FAU - Nashed, Nour
AU  - Nashed N
AD  - School of Life Sciences, University of Sussex, Brighton, BN1 9QJ, UK.
FAU - Asare-Addo, Kofi
AU  - Asare-Addo K
AD  - Department of Pharmacy, University of Huddersfield, Huddersfield, UK.
FAU - Behboudi, Elmira
AU  - Behboudi E
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
AD  - Department of Physical Chemistry, Faculty of Chemistry, University of Tabriz, 
      Tabriz, Iran.
FAU - Sefid-Sefidehkhan, Yasaman
AU  - Sefid-Sefidehkhan Y
AD  - Department of Chemistry, University of Mohaghegh Ardabili, Ardabil, Iran.
FAU - Zarghampour, Aynaz
AU  - Zarghampour A
AD  - Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Rahimpour, Elaheh
AU  - Rahimpour E
AD  - Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
AD  - Food and Drug Safety Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Jouyban, Abolghasem
AU  - Jouyban A
AD  - Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
AD  - Faculty of Pharmacy, Near East University, Box 99138 Nicosia, North Cyprus, 10, 
      Mersin, PO, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20211228
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Solvents)
RN  - 059QF0KO0R (Water)
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - *Ethanol
MH  - Solubility
MH  - Solvents
MH  - *Water
PMC - PMC8816733
OTO - NOTNLM
OT  - PC-SAFT EOS
OT  - acetylsalicylic acid, solubility prediction
OT  - ethanol
OT  - thermal analysis
COIS- The authors declare no competing interests.
EDAT- 2021/12/30 06:00
MHDA- 2021/12/31 06:00
CRDT- 2021/12/29 05:40
PHST- 2021/06/04 00:00 [received]
PHST- 2021/11/29 00:00 [accepted]
PHST- 2021/12/29 05:40 [entrez]
PHST- 2021/12/30 06:00 [pubmed]
PHST- 2021/12/31 06:00 [medline]
AID - 10.1208/s12249-021-02192-7 [pii]
AID - 2192 [pii]
AID - 10.1208/s12249-021-02192-7 [doi]
PST - epublish
SO  - AAPS PharmSciTech. 2021 Dec 28;23(1):42. doi: 10.1208/s12249-021-02192-7.

PMID- 21925223
OWN - NLM
STAT- MEDLINE
DCOM- 20120320
LR  - 20181201
IS  - 1873-5487 (Electronic)
IS  - 0188-4409 (Linking)
VI  - 42
IP  - 6
DP  - 2011 Aug
TI  - Clopidogrel vs. aspirin treatment on admission improves 5-year survival after a 
      first-ever acute ischemic stroke. data from the Athens Stroke Outcome Project.
PG  - 443-50
LID - 10.1016/j.arcmed.2011.09.001 [doi]
AB  - BACKGROUND AND AIMS: We undertook this study to compare the impact of aspirin vs. 
      clopidogrel treatment on 5-year survival of patients experiencing a first-ever 
      acute ischemic noncardioembolic stroke. METHODS: This was a retrospective study 
      involving patients with an acute ischemic stroke who had an indication for 
      antiplatelet therapy (atherothrombotic, lacunar and cryptogenic stroke subtype). 
      A total of 1228 (383 women) hospitalized due to an acute first-ever stroke and 
      receiving aspirin (n = 880) or clopidogrel (n = 348) were finally involved. To 
      determine the factors that independently predict 5-year survival statistical 
      analysis including the Kaplan-Meier survival curve and multifactorial analysis 
      (Cox regression) was performed. RESULTS: Subjects treated with clopidogrel had 
      improved 5-year survival compared with those receiving aspirin (log rank test: 
      16.4, p <0.0001). The difference in survival was evident as early as 6 months 
      from index stroke: cumulative survival 93.8% for aspirin vs. 97% for clopidogrel 
      (log rank test: 4.01, p = 0.045). The composite cardiovascular event (including 
      stroke recurrence, myocardial infarction, unstable angina, coronary 
      revascularization, aortic aneurysm rupture, peripheral atherosclerotic artery 
      diseases, and sudden death) rates were lower in the clopidogrel group (n = 60, 
      17.2%) compared with the aspirin (n = 249, 28.3%) group (log rank test: 12.4, p 
      <0.0001). This preferential effect of clopidogrel over aspirin was independent of 
      age, gender, presence of cardiovascular disease other than stroke or 
      cardiovascular risk factors as well as irrespective of the severity of stroke and 
      days of hospitalization. CONCLUSIONS: This study supports that clopidogrel is 
      superior to aspirin in preventing death and cardiovascular events after an acute 
      noncardioembolic ischemic stroke.
CI  - Copyright © 2011 IMSS. Published by Elsevier Inc. All rights reserved.
FAU - Milionis, Haralampos J
AU  - Milionis HJ
AD  - Department of Internal Medicine, School of Medicine, University of Ioannina, 
      Ioannnina, Greece. hmilioni@uoi.gr
FAU - Gerotziafas, Grigorios
AU  - Gerotziafas G
FAU - Kostapanos, Michael S
AU  - Kostapanos MS
FAU - Vemmou, Anastasia
AU  - Vemmou A
FAU - Zis, Panagiotis
AU  - Zis P
FAU - Spengos, Konstantinos
AU  - Spengos K
FAU - Elisaf, Moses
AU  - Elisaf M
FAU - Vemmos, Konstantinos N
AU  - Vemmos KN
LA  - eng
PT  - Journal Article
DEP - 20110914
PL  - United States
TA  - Arch Med Res
JT  - Archives of medical research
JID - 9312706
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Greece
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Patient Admission
MH  - Retrospective Studies
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2011/09/20 06:00
MHDA- 2012/03/21 06:00
CRDT- 2011/09/20 06:00
PHST- 2011/04/16 00:00 [received]
PHST- 2011/08/23 00:00 [accepted]
PHST- 2011/09/20 06:00 [entrez]
PHST- 2011/09/20 06:00 [pubmed]
PHST- 2012/03/21 06:00 [medline]
AID - S0188-4409(11)00194-9 [pii]
AID - 10.1016/j.arcmed.2011.09.001 [doi]
PST - ppublish
SO  - Arch Med Res. 2011 Aug;42(6):443-50. doi: 10.1016/j.arcmed.2011.09.001. Epub 2011 
      Sep 14.

PMID- 19020119
OWN - NLM
STAT- MEDLINE
DCOM- 20081230
LR  - 20131121
IS  - 1526-7598 (Electronic)
IS  - 0003-2999 (Linking)
VI  - 107
IP  - 6
DP  - 2008 Dec
TI  - An evaluation of cyclooxygenase-1 inhibition before coronary artery surgery: 
      aggregometry versus patient self-reporting.
PG  - 1791-7
LID - 10.1213/ane.0b013e3181865733 [doi]
AB  - BACKGROUND: Platelet dysfunction due to antiplatelet therapy contributes to 
      perioperative bleeding. Several trials investigating the influence of aspirin 
      intake within the 5 days before surgery reported that transfusion requirements 
      were either increased or not significantly affected by aspirin intake. Our 
      objective was to compare the assessment of aspirin intake by patient 
      self-reporting and by measurement of platelet function with regard to transfusion 
      requirements. METHODS: In a prospective trial, a standardized questionnaire was 
      used in 100 patients for aspirin intake within the 5 days immediately before 
      coronary artery bypass grafting. Whole blood platelet aggregation triggered by 
      arachidonic acid was investigated using the Multiplate platelet function 
      analyzer. RESULTS: Eleven of 23 patients with aspirin intake within the 5 days 
      before the intervention showed an abnormal aggregation response. Nine of 77 
      patients who reported no aspirin intake before surgery had an abnormal 
      aggregation response. There were no significant differences in chest tube 
      drainage and red blood cell transfusion over the first 24 h postoperatively 
      between patients with and without reported aspirin intake. There was no 
      significant difference in chest tube drainage over the first 24 h postoperatively 
      between patients showing normal or abnormal aggregation response. Patients with 
      abnormal aggregation before intervention (<51 U) received significantly more 
      platelet transfusion than patients with normal aggregation (1.1 U compared to 0.3 
      U, P = 0.001). CONCLUSIONS: Our results suggest that arachidonic acid-induced 
      aggregation in whole blood may be a better predictor of platelet-related 
      coagulopathy and platelet transfusion than the assessment of aspirin intake by 
      patient self-reporting.
FAU - Rahe-Meyer, Niels
AU  - Rahe-Meyer N
AD  - Department of Anesthesiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 
      Hannover, Germany. rahe-meyer.niels@mh-hannover.de
FAU - Winterhalter, Michael
AU  - Winterhalter M
FAU - Hartmann, Julia
AU  - Hartmann J
FAU - Pattison, Albert
AU  - Pattison A
FAU - Hecker, Hartmut
AU  - Hecker H
FAU - Calatzis, Andreas
AU  - Calatzis A
FAU - Solomon, Cristina
AU  - Solomon C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*pharmacology
MH  - *Coronary Artery Bypass
MH  - Cyclooxygenase 1/*drug effects
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Erythrocyte Transfusion
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Prospective Studies
EDAT- 2008/11/21 09:00
MHDA- 2008/12/31 09:00
CRDT- 2008/11/21 09:00
PHST- 2008/11/21 09:00 [pubmed]
PHST- 2008/12/31 09:00 [medline]
PHST- 2008/11/21 09:00 [entrez]
AID - 107/6/1791 [pii]
AID - 10.1213/ane.0b013e3181865733 [doi]
PST - ppublish
SO  - Anesth Analg. 2008 Dec;107(6):1791-7. doi: 10.1213/ane.0b013e3181865733.

PMID- 20137092
OWN - NLM
STAT- MEDLINE
DCOM- 20101124
LR  - 20211020
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 9
DP  - 2010 Feb 6
TI  - Regulations of the key mediators in inflammation and atherosclerosis by aspirin 
      in human macrophages.
PG  - 16
LID - 10.1186/1476-511X-9-16 [doi]
AB  - Although its role to prevent secondary cardiovascular complications has been well 
      established, how acetyl salicylic acid (ASA, aspirin) regulates certain key 
      molecules in the atherogenesis is still not known. Considering the role of matrix 
      metalloproteinase-9 (MMP-9) to destabilize the atherosclerotic plaques, the roles 
      of the scavenger receptor class BI (SR-BI) and ATP-binding cassette transporter 
      A1 (ABCA1) to promote cholesterol efflux in the foam cells at the plaques, and 
      the role of NF-kappaB in the overall inflammation related to the atherosclerosis, 
      we addressed whether these molecules are all related to a common mechanism that 
      may be regulated by acetyl salicylic acid. We investigated the effect of ASA to 
      regulate the expressions and activities of these molecules in THP-1 macrophages. 
      Our results showed that ASA inhibited MMP-9 mRNA expression, and caused the 
      decrease in the MMP-9 activities from the cell culture supernatants. In addition, 
      it inhibited the nuclear translocation of NF-kappaB p65 subunit, thus the 
      activity of this inflammatory molecule. On the contrary, acetyl salicylic acid 
      induced the expressions of ABCA1 and SR-BI, two molecules known to reduce the 
      progression of atherosclerosis, at both mRNA and protein levels. It also 
      stimulated the cholesterol efflux out of macrophages. These data suggest that 
      acetyl salicylic acid may alleviate symptoms of atherosclerosis by two potential 
      mechanisms: maintaining the plaque stability via inhibiting activities of 
      inflammatory molecules MMP-9 and NF-kappaB, and increasing the cholesterol efflux 
      through inducing expressions of ABCA1 and SR-BI.
FAU - Lu, Li
AU  - Lu L
AD  - Department of Biochemistry and Molecular Biology, College of Basic Medical 
      Sciences, Third Military Medical University, Chongqing 400038, China.
FAU - Liu, Hong
AU  - Liu H
FAU - Peng, Jiahe
AU  - Peng J
FAU - Gan, Lin
AU  - Gan L
FAU - Shen, Lili
AU  - Shen L
FAU - Zhang, Qian
AU  - Zhang Q
FAU - Li, Liangpeng
AU  - Li L
FAU - Zhang, Li
AU  - Zhang L
FAU - Su, Chang
AU  - Su C
FAU - Jiang, Yu
AU  - Jiang Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100206
PL  - England
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
RN  - 0 (ABCA1 protein, human)
RN  - 0 (ATP Binding Cassette Transporter 1)
RN  - 0 (ATP-Binding Cassette Transporters)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (CD36 Antigens)
RN  - 0 (NF-kappa B)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - ATP Binding Cassette Transporter 1
MH  - ATP-Binding Cassette Transporters/metabolism
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/metabolism/*pharmacology
MH  - *Atherosclerosis
MH  - CD36 Antigens/metabolism
MH  - Cholesterol/metabolism
MH  - *Gene Expression Regulation
MH  - Humans
MH  - *Inflammation
MH  - Macrophages/*drug effects/metabolism
MH  - Matrix Metalloproteinase 9/metabolism
MH  - Mice
MH  - NF-kappa B/metabolism
PMC - PMC2846939
EDAT- 2010/02/09 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/02/09 06:00
PHST- 2009/12/21 00:00 [received]
PHST- 2010/02/06 00:00 [accepted]
PHST- 2010/02/09 06:00 [entrez]
PHST- 2010/02/09 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 1476-511X-9-16 [pii]
AID - 10.1186/1476-511X-9-16 [doi]
PST - epublish
SO  - Lipids Health Dis. 2010 Feb 6;9:16. doi: 10.1186/1476-511X-9-16.

PMID- 15013926
OWN - NLM
STAT- MEDLINE
DCOM- 20040521
LR  - 20190917
IS  - 1465-6566 (Print)
IS  - 1465-6566 (Linking)
VI  - 5
IP  - 3
DP  - 2004 Mar
TI  - Anti-inflammatory pharmacotherapy during pregnancy.
PG  - 571-80
AB  - NSAIDs or cyclooxygenase inhibitors (COX inhibitors), including aspirin, are 
      widely used to treat pain, fever and the articular symptoms of chronic rheumatic 
      diseases. Manifestations of connective tissue or autoimmune diseases are commonly 
      treated with glucocorticosteroids. The effect and side effects of NSAIDs depend 
      on the isoforms of cyclooxygenases that they preferentially or selectively 
      inhibit. The use of COX inhibitors has recently been associated with infertility 
      and miscarriage. The classical nonselective COX inhibitors, including aspirin, do 
      not increase the risk of congenital malformations in humans but administered in 
      the latter part of gestation, they can affect pregnancy and the fetus. The 
      ability of nonselective and selective COX inhibitors to prolong gestation has 
      been used by obstetricians to inhibit premature delivery. The vascular effects of 
      prostaglandin inhibitors can cause constriction of the fetal ductus arteriosus 
      and reduce renal blood flow. These complications have been described for most 
      nonselective COX inhibitors but are increasingly reported also for the selective 
      COX-2 inhibitors. Aspirin, which causes irreversible inhibition of 
      cyclooxygenases, differs from other NSAIDs with regard to indication, effects and 
      side effects. Prematurity, which is increased in pregnancies of women with 
      connective tissue diseases, is an additional risk factor for adverse effects of 
      antenatal exposure to NSAIDs. Therefore, treatment with COX inhibitors should be 
      discontinued at week 32 of gestation. The ability of NSAIDs to compromise 
      reproductive function by inhibition of ovulation and as causative agents for 
      miscarriage is still under debate. Glucocorticosteroids given in early pregnancy 
      are a risk factor for the development of oral clefts. Therefore, the daily dose 
      should be kept to <or= 15 mg during the first trimester. High doses of 
      glucocorticosteroids in the second and third trimester are reserved for flares of 
      autoimmune diseases. Intrauterine fetal growth restriction and premature delivery 
      are possible side effects of high doses.
FAU - Østensen, Monika E
AU  - Østensen ME
AD  - Department of Rheumatology, University Hospital of Berne, Berne, Switzerland. 
      monika.ostensen@insel.ch
FAU - Skomsvoll, Johan F
AU  - Skomsvoll JF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abnormalities, Drug-Induced
MH  - Adrenal Cortex Hormones/adverse effects/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Arthritis/drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase Inhibitors/adverse effects/*therapeutic use
MH  - Female
MH  - Fever/drug therapy
MH  - Humans
MH  - Maternal-Fetal Exchange
MH  - Pain/drug therapy
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
RF  - 95
EDAT- 2004/03/12 05:00
MHDA- 2004/05/22 05:00
CRDT- 2004/03/12 05:00
PHST- 2004/03/12 05:00 [pubmed]
PHST- 2004/05/22 05:00 [medline]
PHST- 2004/03/12 05:00 [entrez]
AID - 10.1517/14656566.5.3.571 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2004 Mar;5(3):571-80. doi: 10.1517/14656566.5.3.571.

PMID- 9292176
OWN - NLM
STAT- MEDLINE
DCOM- 19971023
LR  - 20191102
IS  - 1050-6586 (Print)
IS  - 1050-6586 (Linking)
VI  - 11
IP  - 4
DP  - 1997 Jul-Aug
TI  - Surgical treatment of aspirin triad sinusitis.
PG  - 263-70
AB  - Aspirin sensitivity, asthma, and chronic sinusitis with polyposis comprises the 
      syndrome of Aspirin Triad (AT). The sinusitis associated with this disease is 
      often fulminate and difficult to treat. In order to evaluate the surgical 
      treatment of chronic sinusitis of AT a 17-year retrospective study of 80 patients 
      was performed. Friedman Class III or IV sinus CT scans were present in 73 
      patients (90%) preoperatively. Twenty-five patients (30.1%) had steroid-dependent 
      asthma and an additional 40 (50%) required intermittent oral steroids for asthma 
      control. All patients underwent bilateral sinus surgery by either a conservative 
      or a radical approach. Patients were followed from 3 weeks to 16 years 
      postoperatively, with an average followup of 3 years. Sixty-eight patients (85%) 
      had significant improvement in their sinus symptoms and 67 (83%) had relief of 
      their asthma. The eight patients (10%) who remained steroid dependent required 
      smaller doses of steroids. Seven patients (8.8%) had nonoperative orbital 
      complications. There was a significant incidence of revision surgery after both 
      conservative and radical sinus procedures. We conclude that surgical treatment by 
      either a conservative or a radical approach controlled the sinusitis in the 
      majority of AT patients, but neither was effective in eliminating the need for 
      subsequent sinus surgery in a significant number of patients with severe sinus 
      disease (Classes III and IV). Control of the sinus disease has a definite 
      beneficial effect on steroid dependency and the need for intermittent oral 
      steroids in managing the asthma in AT. We recommend conservative surgery in the 
      surgical treatment of these patients. AT patients also require close long-term 
      followup with intense medical management of their chronic respiratory 
      inflammation that appears to put them at increased risk for nonoperative 
      complications of their severe sinusitis.
FAU - McFadden, E A
AU  - McFadden EA
AD  - Department of Otolaryngology and Human Communication, Medical College of 
      Wisconsin, Milwaukee, USA.
FAU - Woodson, B T
AU  - Woodson BT
FAU - Fink, J N
AU  - Fink JN
FAU - Toohill, R J
AU  - Toohill RJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Rhinol
JT  - American journal of rhinology
JID - 8807268
RN  - 0 (Steroids)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/adverse effects/metabolism
MH  - Asthma/complications/drug therapy
MH  - Bronchial Spasm/complications
MH  - Chronic Disease
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Inflammation/therapy
MH  - Male
MH  - Middle Aged
MH  - Orbital Diseases/complications
MH  - Polyps/complications
MH  - Recurrence
MH  - Retrospective Studies
MH  - Sinusitis/diagnostic imaging/*surgery
MH  - Steroids/administration & dosage/therapeutic use
MH  - Syndrome
MH  - Tomography, X-Ray Computed
EDAT- 1997/07/01 00:00
MHDA- 1997/09/18 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/09/18 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - 10.2500/105065897781446702 [doi]
PST - ppublish
SO  - Am J Rhinol. 1997 Jul-Aug;11(4):263-70. doi: 10.2500/105065897781446702.

PMID- 2362779
OWN - NLM
STAT- MEDLINE
DCOM- 19900808
LR  - 20190903
IS  - 0031-3025 (Print)
IS  - 0031-3025 (Linking)
VI  - 22
IP  - 1
DP  - 1990 Jan
TI  - Experimental analgesic nephropathy: changes in renal structure and urinary 
      concentrating ability in Fischer 344 rats given continuous low doses of aspirin 
      and paracetamol.
PG  - 33-44
AB  - Long-term treatment with aspirin and paracetamol produced renal papillary 
      necrosis in female Fischer 344 rats. Aspirin (230 mg/kg body weight/day) and 
      paracetamol (380 mg/kg body weight/day) were dissolved in drinking water and 
      given continuously for up to 65 weeks. Renal morphological changes were examined 
      between 21 weeks and 65 weeks of commencement of analgesic treatment using light 
      and electron microscopy, and were compared with age-matched controls. Structural 
      damage initially occurred in the mid-papillary region, and specifically involved 
      the interstitial cells and interstitial matrix. Necrosis of the epithelium of the 
      thin limbs of the loop of Henle was present only after interstitial changes were 
      well established. Cortical interstitial fibrosis and tubular atrophy occurred 
      after renal papillary changes were observed. There was no evidence of significant 
      vascular damage. Urinary concentrating ability was measured sequentially during 
      the period of analgesic treatment. A decrease in urine concentrating ability was 
      present when early changes to the interstitial cells and matrix were observed, 
      and concentrating ability continued to decrease in parallel with increasing 
      morphological damage. This study describes an animal model of analgesic-induced 
      nephropathy, enabling early morphological changes to be studied and correlated 
      with renal functional changes.
FAU - Burrell, J H
AU  - Burrell JH
AD  - Department of Histology and Embryology, University of Sydney.
FAU - Yong, J L
AU  - Yong JL
FAU - Macdonald, G J
AU  - Macdonald GJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pathology
JT  - Pathology
JID - 0175411
RN  - 0 (Proteoglycans)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/*toxicity
MH  - Animals
MH  - Aspirin/administration & dosage/*toxicity
MH  - Body Weight/drug effects
MH  - Disease Models, Animal
MH  - Female
MH  - Kidney Concentrating Ability/*drug effects
MH  - Kidney Cortex/drug effects
MH  - Kidney Diseases/chemically induced/*pathology/physiopathology
MH  - Kidney Medulla/drug effects
MH  - Kidney Tubules, Collecting/drug effects
MH  - Loop of Henle/drug effects
MH  - Microscopy, Electron
MH  - Proteoglycans/analysis
MH  - Rats
MH  - Rats, Inbred F344
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.3109/00313029009061423 [doi]
PST - ppublish
SO  - Pathology. 1990 Jan;22(1):33-44. doi: 10.3109/00313029009061423.

PMID- 22148253
OWN - NLM
STAT- MEDLINE
DCOM- 20120409
LR  - 20131121
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 55
IP  - 2
DP  - 2012 Jan 26
TI  - Nitric oxide release is not required to decrease the ulcerogenic profile of 
      nonsteroidal anti-inflammatory drugs.
PG  - 688-96
LID - 10.1021/jm200973j [doi]
AB  - The objective of this work was to evaluate the biological properties of a new 
      series of nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NO-NSAIDs) 
      possessing a tyrosol linker between the NSAID and the NO-releasing moiety 
      (PROLI/NO); however, initial screening of ester intermediates without the 
      PROLI/NO group showed the required (desirable) efficacy/safety ratio, which 
      questioned the need for NO in the design. In this regard, NSAID ester 
      intermediates were potent and selective COX-2 inhibitors in vitro, showed 
      equipotent anti-inflammatory activity compared to the corresponding parent NSAID, 
      but showed a markedly reduced gastric toxicity when administered orally. These 
      results provide complementary evidence to challenge the currently accepted notion 
      that hybrid NO-NSAIDs exert their cytoprotective effects by releasing NO. Results 
      obtained in this work constitute a good body of evidence to initiate a debate 
      about the future replacement of NSAID prodrugs for unprotected NSAIDs (possessing 
      a free carboxylic acid group) currently in clinical use.
FAU - Jain, Sarthak
AU  - Jain S
AD  - Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, 
      Alberta T6G 2N8 Canada.
FAU - Tran, Susan
AU  - Tran S
FAU - El Gendy, Mohamed A M
AU  - El Gendy MA
FAU - Kashfi, Khosrow
AU  - Kashfi K
FAU - Jurasz, Paul
AU  - Jurasz P
FAU - Velázquez-Martínez, Carlos A
AU  - Velázquez-Martínez CA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120110
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Prodrugs)
RN  - 0 (Recombinant Proteins)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - ML9LGA7468 (Phenylethyl Alcohol)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/pharmacology/*toxicity
MH  - Aspirin/analogs & derivatives/chemical synthesis/pharmacology/toxicity
MH  - Binding Sites
MH  - Cyclooxygenase 1/chemistry
MH  - Cyclooxygenase 2/chemistry
MH  - Cyclooxygenase Inhibitors/chemical synthesis/pharmacology/toxicity
MH  - Edema/drug therapy
MH  - Humans
MH  - Ibuprofen/analogs & derivatives/chemical synthesis/pharmacology/toxicity
MH  - Indomethacin/analogs & derivatives/chemical synthesis/pharmacology/toxicity
MH  - Nitric Oxide/*metabolism
MH  - Nitric Oxide Donors/chemical synthesis/pharmacology/*toxicity
MH  - Peptic Ulcer/*chemically induced
MH  - Phenylethyl Alcohol/chemistry
MH  - Prodrugs/chemical synthesis/pharmacology/*toxicity
MH  - Rats
MH  - Recombinant Proteins/antagonists & inhibitors/chemistry
MH  - Structure-Activity Relationship
EDAT- 2011/12/14 06:00
MHDA- 2012/04/10 06:00
CRDT- 2011/12/14 06:00
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/04/10 06:00 [medline]
AID - 10.1021/jm200973j [doi]
PST - ppublish
SO  - J Med Chem. 2012 Jan 26;55(2):688-96. doi: 10.1021/jm200973j. Epub 2012 Jan 10.

PMID- 32018223
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20201215
IS  - 2210-7797 (Electronic)
IS  - 2210-7789 (Linking)
VI  - 19
DP  - 2020 Jan
TI  - Aspirin modulates STOX1 expression and reverses STOX1-induced insufficient 
      proliferation and migration of trophoblast cells.
PG  - 170-176
LID - S2210-7789(19)30483-0 [pii]
LID - 10.1016/j.preghy.2019.12.011 [doi]
AB  - BACKGROUND: A major cause of preeclampsia is the placental ischemia caused by 
      insufficient trophoblast cells, invading into the spiral artery. Storkhead-box 
      protein 1 (STOX1) is highly associated with preeclampsia. Meanwhile, low-dose 
      aspirin for patients with preeclampsia is effective in reducing the incidence of 
      preeclampsia. The aim of the present study was to explore the underlying 
      mechanism, and the relationship between STOX1 and aspirin in preeclampsia. 
      METHODS: The human choriocarcinoma cell line JEG-3 was employed to mimic 
      trophoblast cells and establish a model for trophoblast cells overexpressing 
      STOX1 and knockdown of JEG cell lines, which were treated with aspirin 
      afterwards. Cell counting kit-8 (CCK-8) assay was utilized to estimate cell 
      proliferation and optimal concentration of aspirin for further experiments. 
      Meanwhile, transwell assay was used to detect migration, and flow cytometry was 
      used to measure apoptosis. Quantitative reverse transcription polymerase chain 
      reaction (RT-qPCR) and Western blotting were applied to analyze the expression 
      levels of STOX1 and related genes. RESULTS: Overexpression of STOX1 inhibited 
      proliferation of JEG-3 cells through epidermal growth factor (EGF), vascular EGF 
      (VEGF), and transforming growth factor beta 1 (TGF-β1) proteins, while suppressed 
      migration through MMP2, MMP9, and E-cadherin proteins. In contrast, apoptosis of 
      JEG-3 cells was elevated by STOX1 through Bcl-2, Bax, and Cox-2 proteins. 
      Furthermore, we found that aspirin modulated the expression level of STOX1 and 
      reversed proliferation and migration of STOX1-induced insufficient trophoblast 
      cells. CONCLUSION: The present study suggested that inhibition of the expression 
      of STOX1 could promote the effects of aspirin in the treatment of preeclampsia.
CI  - Copyright © 2020 International Society for the Study of Hypertension in 
      Pregnancy. Published by Elsevier B.V. All rights reserved.
FAU - He, Yuanying
AU  - He Y
AD  - Department of Gynecology and Obstetrics, Shanghai Tenth People's Hospital, Tongji 
      University School of Medicine, No. 301, Yanchangzhong Road, Shanghai 200072, 
      China. Electronic address: haze19841224@me.com.
FAU - Chen, Li
AU  - Chen L
AD  - Department of Gynecology and Obstetrics, Shanghai Pudong Hospital, Fudan 
      University Pudong Medical Center, 2800 Gongwei Road, Pudong, Shanghai 201399, 
      China.
FAU - Liu, Chunhong
AU  - Liu C
AD  - Department of Gynecology and Obstetrics, Shanghai Tenth People's Hospital, Tongji 
      University School of Medicine, No. 301, Yanchangzhong Road, Shanghai 200072, 
      China.
FAU - Han, Ying
AU  - Han Y
AD  - Department of Gynecology and Obstetrics, Shanghai Tenth People's Hospital, Tongji 
      University School of Medicine, No. 301, Yanchangzhong Road, Shanghai 200072, 
      China.
FAU - Liang, Chao
AU  - Liang C
AD  - Department of Gynecology and Obstetrics, Shanghai Tenth People's Hospital, Tongji 
      University School of Medicine, No. 301, Yanchangzhong Road, Shanghai 200072, 
      China.
FAU - Xie, Qigui
AU  - Xie Q
AD  - Department of Gynecology and Obstetrics, Shanghai Tenth People's Hospital, Tongji 
      University School of Medicine, No. 301, Yanchangzhong Road, Shanghai 200072, 
      China. Electronic address: cykstar@163.com.
FAU - Zhou, Jianhong
AU  - Zhou J
AD  - Department of Gynecology and Obstetrics, Shanghai Tenth People's Hospital, Tongji 
      University School of Medicine, No. 301, Yanchangzhong Road, Shanghai 200072, 
      China. Electronic address: zhoujoy0377@163.com.
FAU - Cheng, Zhongping
AU  - Cheng Z
AD  - Department of Gynecology and Obstetrics, Shanghai Tenth People's Hospital, Tongji 
      University School of Medicine, No. 301, Yanchangzhong Road, Shanghai 200072, 
      China. Electronic address: mdcheng18@263.net.
LA  - eng
PT  - Journal Article
DEP - 20200117
PL  - Netherlands
TA  - Pregnancy Hypertens
JT  - Pregnancy hypertension
JID - 101552483
RN  - 0 (Carrier Proteins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (STOX1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Aspirin/*pharmacology
MH  - Carrier Proteins/*drug effects/metabolism
MH  - Cell Line, Tumor
MH  - Cell Movement/*drug effects
MH  - Cell Proliferation/*drug effects
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Pregnancy
MH  - Trophoblasts/cytology/*drug effects
OTO - NOTNLM
OT  - Aspirin
OT  - Preeclampsia
OT  - STOX1
OT  - Trophoblast cells
EDAT- 2020/02/06 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/02/05 06:00
PHST- 2019/06/16 00:00 [received]
PHST- 2019/12/22 00:00 [revised]
PHST- 2019/12/24 00:00 [accepted]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
PHST- 2020/02/05 06:00 [entrez]
AID - S2210-7789(19)30483-0 [pii]
AID - 10.1016/j.preghy.2019.12.011 [doi]
PST - ppublish
SO  - Pregnancy Hypertens. 2020 Jan;19:170-176. doi: 10.1016/j.preghy.2019.12.011. Epub 
      2020 Jan 17.

PMID- 3176082
OWN - NLM
STAT- MEDLINE
DCOM- 19881102
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 19
IP  - 10
DP  - 1988 Oct
TI  - Baseline and activated platelet cytoplasmic ionized calcium in acute ischemic 
      stroke. Effect of aspirin.
PG  - 1234-8
AB  - We measured cytoplasmic ionized calcium concentrations [( Cai2+]) in 
      aequorin-loaded gel-filtered platelets from 38 patients with acute occlusive 
      stroke (12 treated with aspirin, 26 untreated) and 25 healthy controls. Compared 
      with controls, baseline [Cai2+] was higher in untreated patients (p less than 
      0.002), maximal 36-72 hours after the onset of neurologic dysfunction (p less 
      than 0.0001), in those patients with as well as those without major stroke risk 
      factors. The increase in [Cai2+] after stimulation with 0.5 and 1.0 unit/ml 
      thrombin (p less than 0.05), 2 and 4 micrograms/ml collagen (p less than 0.02), 
      and 0.5 and 1.0 mM platelet activating factor (p less than 0.05) were also 
      greater in untreated patients, but the profiles of these changes were parallel to 
      those in controls. Even though the platelets of stroke patients are more 
      sensitive to activation, they are functionally similar to those of controls. 
      Aspirin treatment reduced baseline [Cai2+] as well as thrombin- and 
      collagen-induced [Cai2+] changes. Platelet activating factor-induced increase in 
      [Cai2+] was not altered by aspirin treatment. Our results suggest that the 
      usefulness of aspirin in stroke is limited because aspirin does not suppress 
      platelet responsiveness to all in vivo thrombogenic stimuli. Specific platelet 
      activating factor antagonists may prove to be useful therapeutic agents in 
      stroke.
FAU - Joseph, R
AU  - Joseph R
AD  - Department of Neurology, Henry Ford Hospital, Detroit, MI 48202.
FAU - Welch, K M
AU  - Welch KM
FAU - Grunfeld, S
AU  - Grunfeld S
FAU - Oster, S B
AU  - Oster SB
FAU - D'Andrea, G
AU  - D'Andrea G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Ions)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Calcium/*metabolism
MH  - Cytoplasm/*metabolism
MH  - Female
MH  - Humans
MH  - Ions
MH  - Ischemic Attack, Transient/*metabolism
MH  - Male
MH  - Middle Aged
EDAT- 1988/10/01 00:00
MHDA- 1988/10/01 00:01
CRDT- 1988/10/01 00:00
PHST- 1988/10/01 00:00 [pubmed]
PHST- 1988/10/01 00:01 [medline]
PHST- 1988/10/01 00:00 [entrez]
AID - 10.1161/01.str.19.10.1234 [doi]
PST - ppublish
SO  - Stroke. 1988 Oct;19(10):1234-8. doi: 10.1161/01.str.19.10.1234.

PMID- 16859279
OWN - NLM
STAT- MEDLINE
DCOM- 20060811
LR  - 20191026
IS  - 1092-0684 (Electronic)
IS  - 1092-0684 (Linking)
VI  - 8
IP  - 5
DP  - 2000 May 15
TI  - Antiplatelet agents, carotid endarterectomy, and perioperative complications.
PG  - e1
AB  - Neurosurgeons are frequently involved in choosing an antiplatelet therapy for 
      their patients in the perioperative period. New data obtained from the Aspirin 
      and Carotid Endarterectomy (ACE) Trial suggest that low-dose aspirin is superior 
      to high-dose aspirin therapy in reducing rates of perioperative stroke and death. 
      The ACE-related data are reviewed, and the authors provide an update on current 
      Food and Drug Administration-approved antiplatelet therapies for secondary stroke 
      prevention, as well as a summary of antiplatelet therapies being developed.
FAU - Worrall, B B
AU  - Worrall BB
AD  - Department of Neurology, University of Virginia, Charlottesville, Virginia 22908, 
      USA. bbw9r@virginia.edu
FAU - Johnston, K C
AU  - Johnston KC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20000515
PL  - United States
TA  - Neurosurg Focus
JT  - Neurosurgical focus
JID - 100896471
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Endarterectomy, Carotid/adverse effects
MH  - Humans
MH  - Intraoperative Complications/*prevention & control
MH  - Models, Biological
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/*drug therapy/etiology/*prevention & control
RF  - 33
EDAT- 2006/07/25 09:00
MHDA- 2006/08/12 09:00
CRDT- 2006/07/25 09:00
PHST- 2006/07/25 09:00 [pubmed]
PHST- 2006/08/12 09:00 [medline]
PHST- 2006/07/25 09:00 [entrez]
AID - 080501 [pii]
AID - 10.3171/foc.2000.8.5.1 [doi]
PST - epublish
SO  - Neurosurg Focus. 2000 May 15;8(5):e1. doi: 10.3171/foc.2000.8.5.1.

PMID- 11601671
OWN - NLM
STAT- MEDLINE
DCOM- 20020325
LR  - 20190916
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 21
IP  - 10
DP  - 2001 Oct
TI  - Quantifying the interaction between angiotensin-converting enzyme inhibitors and 
      aspirin: are we using the right method?
PG  - 1247-9
AB  - Angiotensin-converting enzyme (ACE) inhibitors reduce mortality in patients with 
      heart failure and coronary artery disease. Recently, there has been growing 
      concern about the possible interaction between ACE inhibitors and aspirin. 
      Numerous investigators have addressed this issue; however, results are equivocal. 
      Most researchers used a statistical test of interaction, but the use of this 
      method has been criticized. To assess the interaction between ACE inhibitors and 
      aspirin properly, an additive model-more specifically, the Rothman Synergy 
      Index-should be used. Further investigation with this model, however, is needed.
FAU - Etminan, M
AU  - Etminan M
AD  - Department of Clinical Epidemiology, University of Toronto, Ontario, Canada. 
      m.etminan@utoronto.ca
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Algorithms
MH  - Angiotensin-Converting Enzyme Inhibitors/*adverse effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Data Interpretation, Statistical
MH  - Drug Synergism
MH  - Regression Analysis
EDAT- 2001/10/17 10:00
MHDA- 2002/03/26 10:01
CRDT- 2001/10/17 10:00
PHST- 2001/10/17 10:00 [pubmed]
PHST- 2002/03/26 10:01 [medline]
PHST- 2001/10/17 10:00 [entrez]
AID - 10.1592/phco.21.15.1247.33893 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2001 Oct;21(10):1247-9. doi: 10.1592/phco.21.15.1247.33893.

PMID- 3516752
OWN - NLM
STAT- MEDLINE
DCOM- 19860613
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 14
IP  - 2
DP  - 1986
TI  - A randomized double-blind placebo-controlled study of dipyrone and aspirin in 
      post-operative orthopaedic patients.
PG  - 63-6
AB  - Two hundred and fifty-four patients with post-operative pain following closed 
      reduction of fractured long bones completed a double-blind study of dipyrone and 
      aspirin. Compared with placebo both active treatments produced significant relief 
      of pain, which was apparent 30 minutes after ingestion and was maintained for the 
      6-hour duration of the study. Dipyrone 500 mg produced significantly greater pain 
      relief than aspirin 500 mg. Both drugs were generally well tolerated.
FAU - Mehta, S D
AU  - Mehta SD
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Placebos)
RN  - 01704YP3MO (Aminopyrine)
RN  - 6429L0L52Y (Dipyrone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aminopyrine/*analogs & derivatives
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dipyrone/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Fractures, Bone/surgery
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
MH  - Random Allocation
MH  - Time Factors
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1177/030006058601400202 [doi]
PST - ppublish
SO  - J Int Med Res. 1986;14(2):63-6. doi: 10.1177/030006058601400202.

PMID- 35152241
OWN - NLM
STAT- MEDLINE
DCOM- 20230216
LR  - 20230223
IS  - 1539-2031 (Electronic)
IS  - 0192-0790 (Linking)
VI  - 57
IP  - 3
DP  - 2023 Mar 1
TI  - Improved Survival for Patients With Acute Upper Gastrointestinal Bleeding While 
      on Antithrombotic Therapy: A Multicenter Prospective Cohort Study.
PG  - 278-284
LID - 10.1097/MCG.0000000000001674 [doi]
AB  - GOALS: Aim of the study was to determine if patients with acute upper 
      gastrointestinal bleeding (AUGIB) while on antithrombotic agents (ATs) are at 
      higher risk for worse outcomes. BACKGROUND: ATs are risk factors of AUGIB, but 
      their impact on clinical outcomes is uncertain. STUDY: Patients with AUGIB 
      (nonvariceal, NV-AUGIB or variceal, V-AUGIB) in 50 Italian hospitals were 
      prospectively enrolled from January 1, 2014 to December 31, 2015. Clinical data, 
      laboratory tests, comorbidities, prognostic scores, received therapies, and 
      outcomes (death, rebleeding, surgery/radiology, transfusions, length of 
      hospitalization) were analyzed. RESULTS: A total of 3324 patients (2764 NV-AUGIB, 
      83.2% and 560 V-AUGIB, 16.8%) were enrolled, 1399 (42.1%) on ATs. Patients taking 
      ATs were older (75.4 vs. 62.8 y, P <0.001), had higher American Society of 
      Anesthesiologists (ASA), Rockall and Glasgow-Blatchford scores ( P <0.001). At 
      multivariate analysis considering comorbidities, ATs use resulted an independent 
      protective factor against death [odds ratio (OR): 0.63, 95% confidence interval 
      (CI): 0.45-0.87, P =0.006]. Rebleeding (5.5% vs. 5.8%, P =0.71) and need for 
      salvage surgery/radiology (4.2% vs. 4.8%, P =0.41) were similar in the 2 groups. 
      Considering specific ATs, low-dose aspirin was the most powerful factor lowering 
      the death risk (OR: 0.51, 95% CI: 0.33-0.81, P =0.004). While the generic use of 
      AT therapy did not emerge as a statistically significant independent protective 
      factor considering separately NV-AUGIB (OR: 0.80, 95% CI: 0.56-1.13, P =0.21) and 
      V-AUGIB (OR: 0.40, 95% CI: 0.15-1.07, P =0.068), the protective effect of 
      low-dose aspirin was confirmed for NV-AUGIB (OR: 0.62, 95% CI: 0.41-0.94, P 
      =0.025). CONCLUSIONS: ATs use is an independent protective factor against death 
      in AUGIB. The protective effect is mainly derived from low-dose aspirin.
CI  - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Marmo, Riccardo
AU  - Marmo R
AD  - L. Curto Hospital, Gastroenterology Unit, Polla.
FAU - Occhipinti, Vincenzo
AU  - Occhipinti V
AD  - A. Manzoni Hospital, Digestive Endoscopy and Gastroenterology Unit, Lecco.
FAU - Zullo, Angelo
AU  - Zullo A
AD  - Nuovo Regina Margherita Hospital, Gastroenterology and Digestive Endoscopy, Rome.
FAU - Soncini, Marco
AU  - Soncini M
AD  - Department of Internal Medicine, A. Manzoni Hospital, Lecco, Italy.
CN  - GISED—Gruppo Italiano per lo Studio dell’Emorragia Digestiva
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20230301
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Clin Gastroenterol. 2022 Aug 1;56(7):641-642. PMID: 35357338
MH  - Humans
MH  - *Fibrinolytic Agents/adverse effects
MH  - Prospective Studies
MH  - *Gastrointestinal Hemorrhage/etiology
MH  - Risk Factors
MH  - Aspirin/adverse effects
MH  - Acute Disease
EDAT- 2022/02/14 06:00
MHDA- 2023/02/17 06:00
CRDT- 2022/02/13 20:36
PHST- 2021/08/17 00:00 [received]
PHST- 2022/01/04 00:00 [accepted]
PHST- 2022/02/14 06:00 [pubmed]
PHST- 2023/02/17 06:00 [medline]
PHST- 2022/02/13 20:36 [entrez]
AID - 00004836-900000000-97316 [pii]
AID - 10.1097/MCG.0000000000001674 [doi]
PST - epublish
SO  - J Clin Gastroenterol. 2023 Mar 1;57(3):278-284. doi: 
      10.1097/MCG.0000000000001674.

PMID- 34576080
OWN - NLM
STAT- MEDLINE
DCOM- 20211022
LR  - 20211022
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 18
DP  - 2021 Sep 14
TI  - Platelet Inhibition by Low-Dose Acetylsalicylic Acid Reduces Neuroinflammation in 
      an Animal Model of Multiple Sclerosis.
LID - 10.3390/ijms22189915 [doi]
LID - 9915
AB  - Aside from the established immune-mediated etiology of multiple sclerosis (MS), 
      compelling evidence implicates platelets as important players in disease 
      pathogenesis. Specifically, numerous studies have highlighted that activated 
      platelets promote the central nervous system (CNS)-directed adaptive immune 
      response early in the disease course. Platelets, therefore, present a novel 
      opportunity for modulating the neuroinflammatory process that characterizes MS. 
      We hypothesized that the well-known antiplatelet agent acetylsalicylic acid (ASA) 
      could inhibit neuroinflammation by affecting platelets if applied at low-dose and 
      investigated its effect during experimental autoimmune encephalomyelitis (EAE) as 
      a model to study MS. We found that oral administration of low-dose ASA alleviates 
      symptoms of EAE accompanied by reduced inflammatory infiltrates and less 
      extensive demyelination. Remarkably, the percentage of CNS-infiltrated CD4(+) T 
      cells, the major drivers of neuroinflammation, was decreased to 40.98 ± 3.28% in 
      ASA-treated mice compared to 56.11 ± 1.46% in control animals at the disease 
      maximum as revealed by flow cytometry. More interestingly, plasma levels of 
      thromboxane A(2) were decreased, while concentrations of platelet factor 4 and 
      glycoprotein VI were not affected by low-dose ASA treatment. Overall, we 
      demonstrate that low-dose ASA could ameliorate the platelet-dependent 
      neuroinflammatory response in vivo, thus indicating a potential treatment 
      approach for MS.
FAU - Vogelsang, Anna
AU  - Vogelsang A
AD  - Department of Neurology with Institute of Translational Neurology, University 
      Hospital Münster, 48149 Münster, Germany.
FAU - Eichler, Susann
AU  - Eichler S
AD  - Department of Neurology with Institute of Translational Neurology, University 
      Hospital Münster, 48149 Münster, Germany.
FAU - Huntemann, Niklas
AU  - Huntemann N
AUID- ORCID: 0000-0003-0015-8484
AD  - Department of Neurology with Institute of Translational Neurology, University 
      Hospital Münster, 48149 Münster, Germany.
AD  - Department of Neurology, University Hospital Düsseldorf, 40225 Düsseldorf, 
      Germany.
FAU - Masanneck, Lars
AU  - Masanneck L
AD  - Department of Neurology with Institute of Translational Neurology, University 
      Hospital Münster, 48149 Münster, Germany.
AD  - Department of Neurology, University Hospital Düsseldorf, 40225 Düsseldorf, 
      Germany.
FAU - Böhnlein, Hannes
AU  - Böhnlein H
AD  - Department of Neurology with Institute of Translational Neurology, University 
      Hospital Münster, 48149 Münster, Germany.
FAU - Schüngel, Lisa
AU  - Schüngel L
AD  - Department of Anesthesiology, Intensive Care and Pain Medicine, University 
      Hospital Münster, 48149 Münster, Germany.
FAU - Willison, Alice
AU  - Willison A
AD  - The Northern Foundation School, Newcastle-upon-Tyne University Hospitals, 
      Newcastle-upon-Tyne NE15 8NY, UK.
FAU - Loser, Karin
AU  - Loser K
AUID- ORCID: 0000-0002-0007-0936
AD  - Department of Human Medicine, Institute of Immunology, Carl von Ossietzky 
      University Oldenburg, 26129 Oldenburg, Germany.
FAU - Nieswandt, Bernhard
AU  - Nieswandt B
AD  - Rudolf Virchow Center, Research Center for Experimental Biomedicine, University 
      of Würzburg, 97080 Würzburg, Germany.
FAU - Kehrel, Beate E
AU  - Kehrel BE
AD  - Department of Anesthesiology, Intensive Care and Pain Medicine, University 
      Hospital Münster, 48149 Münster, Germany.
FAU - Zarbock, Alexander
AU  - Zarbock A
AD  - Department of Anesthesiology, Intensive Care and Pain Medicine, University 
      Hospital Münster, 48149 Münster, Germany.
FAU - Göbel, Kerstin
AU  - Göbel K
AUID- ORCID: 0000-0002-1579-9076
AD  - Department of Neurology with Institute of Translational Neurology, University 
      Hospital Münster, 48149 Münster, Germany.
FAU - Meuth, Sven G
AU  - Meuth SG
AD  - Department of Neurology, University Hospital Düsseldorf, 40225 Düsseldorf, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20210914
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/*pathology
MH  - Brain/*pathology
MH  - CD4-Positive T-Lymphocytes/drug effects/immunology
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Encephalomyelitis, Autoimmune, Experimental/drug therapy/pathology
MH  - Inflammation/immunology/*pathology
MH  - Mice, Inbred C57BL
MH  - Multiple Sclerosis/*blood/immunology/*pathology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thromboxane A2/biosynthesis
PMC - PMC8465626
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - experimental autoimmune encephalomyelitis
OT  - glycoprotein VI
OT  - multiple sclerosis
OT  - platelet factor 4
OT  - platelets
OT  - thromboxane
COIS- The authors declare no conflict of interest.
EDAT- 2021/09/29 06:00
MHDA- 2023/02/25 06:00
CRDT- 2021/09/28 01:18
PHST- 2021/08/10 00:00 [received]
PHST- 2021/09/09 00:00 [revised]
PHST- 2021/09/10 00:00 [accepted]
PHST- 2021/09/28 01:18 [entrez]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
AID - ijms22189915 [pii]
AID - ijms-22-09915 [pii]
AID - 10.3390/ijms22189915 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Sep 14;22(18):9915. doi: 10.3390/ijms22189915.

PMID- 33870848
OWN - NLM
STAT- MEDLINE
DCOM- 20210615
LR  - 20210615
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 19
IP  - 5
DP  - 2021 May
TI  - Clinical considerations after endovascular therapy of peripheral artery disease.
PG  - 369-378
LID - 10.1080/14779072.2021.1914590 [doi]
AB  - Introduction: Patients with peripheral artery disease (PAD) are at higher risk 
      for all-cause mortality, driven by increased cardiovascular mortality rates. In 
      this manuscript we review the literature on guideline-recommended therapies and 
      discuss the major clinical considerations after endovascular therapy of PAD.Areas 
      covered: Current guidelines recommend smoking cessation, aspirin, statin, and 
      renin-angiotensin system inhibitors in order to reduce the risk of cardiovascular 
      and limb-related adverse events. Nonetheless, studies have shown that patients 
      with PAD are undertreated with these important medical therapies. Additionally, 
      there is lack in evidence regarding the most optimal follow up imaging approach 
      for early detection of disease recurrence and re-intervention among patients 
      undergoing endovascular therapy for PAD. We also describe the benefits of 
      supervised walking exercise for patients with PAD that undergo revascularization 
      procedures and are fit for such interventions.Expert opinion: Adherence to 
      guideline recommended medical therapy is crucial for improved outcomes in PAD 
      management. Systematic assessment of risk-reduction interventions could help 
      increase adherence to clinically beneficial interventions and improve the overall 
      prognosis of patients with PAD undergoing revascularization procedures. 
      Additionally, optimization of current follow up protocols is needed, with the 
      optimal goal to develop standardized cost-effective algorithms regarding early 
      detection of disease recurrence and re-intervention.
FAU - Giannopoulos, Stefanos
AU  - Giannopoulos S
AD  - Division of Cardiology, Rocky Mountain Regional VA Medical Center, University of 
      Colorado, Denver, CO, USA.
FAU - Armstrong, Ehrin J
AU  - Armstrong EJ
AD  - Division of Cardiology, Rocky Mountain Regional VA Medical Center, University of 
      Colorado, Denver, CO, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210419
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Endovascular Procedures/*methods
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Peripheral Arterial Disease/*therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Factors
MH  - Risk Reduction Behavior
MH  - Treatment Outcome
OTO - NOTNLM
OT  - EVT
OT  - PAD
OT  - Peripheral artery disease
OT  - endovascular revascularization
OT  - endovascular therapy
EDAT- 2021/04/20 06:00
MHDA- 2021/06/16 06:00
CRDT- 2021/04/19 08:46
PHST- 2021/04/20 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2021/04/19 08:46 [entrez]
AID - 10.1080/14779072.2021.1914590 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2021 May;19(5):369-378. doi: 
      10.1080/14779072.2021.1914590. Epub 2021 Apr 19.

PMID- 6398158
OWN - NLM
STAT- MEDLINE
DCOM- 19850610
LR  - 20170112
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 1
IP  - 2
DP  - 1983 Apr-Jun
TI  - A clinical and biochemical evaluation of Clozic, a novel disease modifying drug 
      in rheumatoid arthritis.
PG  - 93-9
AB  - We have compared two dose levels of Clozic, a novel agent with potential 
      anti-rheumatoid activity, to D-penicillamine and aspirin in an observer blind 
      randomised parallel group study of 56 patients with active rheumatoid arthritis. 
      Eight clinical assessments and 26 laboratory assessments were performed on each 
      patient at each visit over a six month period. Results were analysed by 
      conventional methods and also by correlation matrices constructed between 
      clinical and laboratory variables. Patients treated with D-penicillamine (500 
      mg/day) responded adequately and the control group on aspirin (up to 3.6 g of 
      enteric coated formulation/day) performed well, though the withdrawal rate from 
      this latter group was high, predominantly because of continued disease activity. 
      Patients receiving Clozic (100 mg/day or 300 mg/day) improved more than patients 
      receiving penicillamine, particularly at the higher dose. Comparison of methods 
      of analysis validates the use of correlation matrices both for detecting 
      anti-rheumatoid activity and for determining the optimum dose of a novel 
      compound. This trial illustrates the problems of a study of this nature, with the 
      powerful effect on patients of being enrolled in such a closely monitored 
      investigation. It emphasises the greater value of biochemical changes in 
      following disease changes.
FAU - Bird, H A
AU  - Bird HA
FAU - Dixon, J S
AU  - Dixon JS
FAU - Finney, P L
AU  - Finney PL
FAU - Leatham, P A
AU  - Leatham PA
FAU - Lowe, J R
AU  - Lowe JR
FAU - Pickup, M E
AU  - Pickup ME
FAU - Rhind, V M
AU  - Rhind VM
FAU - Rushton, A
AU  - Rushton A
FAU - Sitton, N G
AU  - Sitton NG
FAU - Wright, V
AU  - Wright V
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Tablets, Enteric-Coated)
RN  - GNN1DV99GX (Penicillamine)
RN  - HPN91K7FU3 (Clofibrate)
RN  - R16CO5Y76E (Aspirin)
RN  - W3D7B06505 (clobuzarit)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy/metabolism
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Clofibrate/adverse effects/*analogs & derivatives/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Penicillamine/adverse effects/therapeutic use
MH  - Tablets, Enteric-Coated
MH  - Time Factors
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Rheumatol. 1983 Apr-Jun;1(2):93-9.

PMID- 8124800
OWN - NLM
STAT- MEDLINE
DCOM- 19940413
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 89
IP  - 3
DP  - 1994 Mar
TI  - Long-term graft patency (3 years) after coronary artery surgery. Effects of 
      aspirin: results of a VA Cooperative study.
PG  - 1138-43
AB  - BACKGROUND: The long-term success of coronary bypass surgery is dependent on 
      graft patency after surgery. This trial was designed to determine if aspirin 
      improved saphenous vein graft or internal mammary artery (IMA) graft patency 
      between 1 and 3 years after coronary artery bypass grafting (CABG). METHODS AND 
      RESULTS: After receiving aspirin 325 mg/d for 1 year after CABG and undergoing a 
      1-year postoperative cardiac catheterization, patients were randomized to receive 
      either aspirin (325 mg) or placebo for 2 additional years. Angiography was 
      performed 3 years after surgery to determine the primary end point-saphenous vein 
      graft patency in 288 patients and IMA graft patency in 167 patients. At 3 years 
      after CABG, the saphenous vein graft occlusion rate was 17.0% (62 of 365) for 
      patients treated with aspirin compared with 19.7% (74 of 376) for those who 
      received placebo (P = .404). For saphenous vein grafts that were patent at 1 
      year, the occlusion rate at 3 years was 4.8% (15 of 313) for patients treated 
      with aspirin compared with 4.2% (13 of 310) for patients who received placebo (P 
      = .757). At 3 years, the IMA graft occlusion rate was 10.3% (8 of 78) for 
      patients treated with aspirin compared with 7.9% (7 of 89) for patients who 
      received placebo (P = .594). For IMA grafts that were patent at 1 year, the 
      occlusion rate was 4.3% (3 of 70) for patients treated with aspirin compared with 
      2.5% (2 of 81) for patients who received placebo (P = .541). CONCLUSIONS: These 
      data suggest that aspirin treatment does not improve saphenous vein graft or IMA 
      graft patency between 1 and 3 years after CABG.
FAU - Goldman, S
AU  - Goldman S
AD  - VA Medical Center, Tucson, AZ.
FAU - Copeland, J
AU  - Copeland J
FAU - Moritz, T
AU  - Moritz T
FAU - Henderson, W
AU  - Henderson W
FAU - Zadina, K
AU  - Zadina K
FAU - Ovitt, T
AU  - Ovitt T
FAU - Kern, K B
AU  - Kern KB
FAU - Sethi, G
AU  - Sethi G
FAU - Sharma, G V
AU  - Sharma GV
FAU - Khuri, S
AU  - Khuri S
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiac Catheterization
MH  - Coronary Angiography
MH  - *Coronary Artery Bypass
MH  - Double-Blind Method
MH  - Follow-Up Studies
MH  - Graft Occlusion, Vascular/epidemiology/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Time Factors
MH  - Vascular Patency/*drug effects
EDAT- 1994/03/01 00:00
MHDA- 1994/03/01 00:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 1994/03/01 00:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
AID - 10.1161/01.cir.89.3.1138 [doi]
PST - ppublish
SO  - Circulation. 1994 Mar;89(3):1138-43. doi: 10.1161/01.cir.89.3.1138.

PMID- 2680158
OWN - NLM
STAT- MEDLINE
DCOM- 19891218
LR  - 20220330
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 80
IP  - 5
DP  - 1989 Nov
TI  - Saphenous vein graft patency 1 year after coronary artery bypass surgery and 
      effects of antiplatelet therapy. Results of a Veterans Administration Cooperative 
      Study.
PG  - 1190-7
AB  - To determine whether antiplatelet therapies improve saphenous vein graft patency 
      after coronary artery bypass grafting, we compared 1) aspirin (325 mg once 
      daily), 2) aspirin (325 mg three times daily), 3) aspirin and dipyridamole (325 
      mg and 75 mg, respectively, three times daily), 4) sulfinpyrazone (267 mg three 
      times daily), and 5) placebo (three times daily). Therapy with dipyridamole and 
      sulfinpyrazone was started 48 hours before bypass graft surgery, and aspirin 
      treatment was begun 12 hours before surgery as a single 325-mg dose. 
      Postoperative treatment was started 6 hours after surgery and continued for 1 
      year. Graft patency data were obtained early (median, 9 days) and late (median, 
      367 days) after surgery. The early graft occlusion rate was decreased with all 
      aspirin treatment regimens compared with that of the placebo regimen. At 1 year, 
      in 406 patients with 1,315 grafts, the graft occlusion rate in all of the aspirin 
      groups combined was 15.8% compared with 22.6% for the placebo group (p = 0.029). 
      The patients taking aspirin once daily had a lower occlusion rate (13.2%) 
      compared with the patients receiving placebo (p = 0.050). At 1 year, in the vein 
      grafts placed to vessels less than or equal to 2.0 mm in diameter (804 distal 
      sites), the graft occlusion rate in all of the aspirin groups was 20.1% compared 
      with 32.3% for the placebo group (p = 0.008). In the vein grafts placed to 
      vessels greater than 2.0 mm in diameter (511 distal sites), there was no 
      difference in the occlusion rates between aspirin and the placebo group at 1 year 
      (8.7% vs. 9.0%, p = 0.918).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Goldman, S
AU  - Goldman S
AD  - Cardiology 111C, Veterans Administration Medical Center, Tucson, AZ 85723.
FAU - Copeland, J
AU  - Copeland J
FAU - Moritz, T
AU  - Moritz T
FAU - Henderson, W
AU  - Henderson W
FAU - Zadina, K
AU  - Zadina K
FAU - Ovitt, T
AU  - Ovitt T
FAU - Doherty, J
AU  - Doherty J
FAU - Read, R
AU  - Read R
FAU - Chesler, E
AU  - Chesler E
FAU - Sako, Y
AU  - Sako Y
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/therapeutic use
MH  - Double-Blind Method
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Saphenous Vein/*transplantation
MH  - Sulfinpyrazone/therapeutic use
MH  - Time Factors
MH  - Vascular Patency
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
AID - 10.1161/01.cir.80.5.1190 [doi]
PST - ppublish
SO  - Circulation. 1989 Nov;80(5):1190-7. doi: 10.1161/01.cir.80.5.1190.

PMID- 35489625
OWN - NLM
STAT- MEDLINE
DCOM- 20220531
LR  - 20220531
IS  - 1879-0003 (Electronic)
IS  - 0141-8130 (Linking)
VI  - 210
DP  - 2022 Jun 15
TI  - Synthesis and characterization of photo-crosslinkable cinnamate-functionalized 
      pectin.
PG  - 208-217
LID - S0141-8130(22)00816-9 [pii]
LID - 10.1016/j.ijbiomac.2022.04.109 [doi]
AB  - The polysaccharide pectin (PC) was functionalized with the photo-responsive 
      cinnamic acid hydrazide (CN) to produce the photo-crosslinkable PC-CN hydrogel 
      material that was then evaluated as a carrier for encapsulation of the drug model 
      aspirin. Cinnamic acid hydrazide was first prepared and then incorporated with 
      the abundant -COOCH(3) groups on the pectin chain via hydrazide linkage. The 
      obtained polymeric derivatives have been characterized by means of instrumental 
      techniques including FTIR and NMR. The obtained PC-CN hydrogels with different 
      cinnamic functionality were also freeze-dried and examined by SEM, which 
      indicated more coherent hydrogel texture by increasing the cinnamic 
      functionalization. The effect of the photo-curing time, as well as the 
      functionalization degree, on the swelling and gelation of the obtained hydrogel 
      was also studied to evaluate the potential of the developed material in drug 
      delivery systems using aspirin as a common and available drug model. The 
      developed PC-CN hydrogel materials exhibited high potential as a drug carrier 
      that enables the control of the drug release via optimizing both the degree of 
      cinnamic functionality and the photo-curing time.
CI  - Copyright © 2022. Published by Elsevier B.V.
FAU - Almutairi, Tahani M
AU  - Almutairi TM
AD  - Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, 
      Riyadh 11451, Saudi Arabia. Electronic address: talmutari1@ksu.edu.sa.
FAU - Al-Rasheed, Hessa H
AU  - Al-Rasheed HH
AD  - Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, 
      Riyadh 11451, Saudi Arabia.
FAU - Monier, M
AU  - Monier M
AD  - Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt. 
      Electronic address: monierchem@yahoo.com.
FAU - Alatawi, Fatema S
AU  - Alatawi FS
AD  - Biochemistry Department, Faculty of Science, University of Tabuk, Tabuk 71421, 
      Saudi Arabia.
FAU - Elsayed, Nadia H
AU  - Elsayed NH
AD  - Department of Chemistry, Faculty of Science, University of Tabuk, Tabuk 71421, 
      Saudi Arabia; Department of Polymers and Pigments, National Research Centre, 
      Cairo 12311, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20220427
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
RN  - 0 (Cinnamates)
RN  - 0 (Hydrazines)
RN  - 0 (Hydrogels)
RN  - 89NA02M4RX (Pectins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - Cinnamates
MH  - Hydrazines
MH  - *Hydrogels/chemistry
MH  - *Pectins
OTO - NOTNLM
OT  - Cinnamate
OT  - Pectin
OT  - Photo-crosslinking
EDAT- 2022/05/01 06:00
MHDA- 2022/06/01 06:00
CRDT- 2022/04/30 19:26
PHST- 2022/01/02 00:00 [received]
PHST- 2022/04/12 00:00 [revised]
PHST- 2022/04/15 00:00 [accepted]
PHST- 2022/05/01 06:00 [pubmed]
PHST- 2022/06/01 06:00 [medline]
PHST- 2022/04/30 19:26 [entrez]
AID - S0141-8130(22)00816-9 [pii]
AID - 10.1016/j.ijbiomac.2022.04.109 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2022 Jun 15;210:208-217. doi: 
      10.1016/j.ijbiomac.2022.04.109. Epub 2022 Apr 27.

PMID- 32660262
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20220121
IS  - 1945-8932 (Electronic)
IS  - 1945-8924 (Print)
IS  - 1945-8932 (Linking)
VI  - 35
IP  - 2
DP  - 2021 Mar
TI  - A Comparison of Sphenoid Sinus Osteoneogenesis in Aspirin-Exacerbated Respiratory 
      Disease.
PG  - 172-178
LID - 10.1177/1945892420941732 [doi]
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is characterized by 
      excessive leukotriene production, diffuse polyp burden and osteitic bone changes. 
      These bony changes have not been previously characterized. OBJECTIVE: The aim of 
      this radiographic study is to characterize the bony changes noted on computed 
      tomography (CT) scans of the sphenoid sinus in patients with AERD compared to 
      other diseased sinonasal inflammatory states and non-diseased controls. METHODS: 
      A retrospective review of 43 patients with clinically confirmed AERD were 
      included and compared to 22 non-diseased, 9 allergic fungal sinusitis, and 43 
      chronic rhinosinusitis controls (23 without polyps and 18 with polyps). 
      Comparative measurements were performed using fine-cut CT scans. Sites of 
      comparison were the intersinus septum, the left and right lateral sphenoid wall, 
      the roof, and left and right floor of the sphenoid sinus. Standardized 
      measurements were averaged by two separate rhinologists. RESULTS: Patients with 
      AERD had an average statistically significant increase in bone thickness compared 
      to healthy and diseased controls in nearly every site with the most pronounced 
      changes in the intersinus septum (p < 0.05). CONCLUSION: Patients with AERD have 
      significantly increased thickness of the sphenoid bone compared to control groups 
      with the most pronounced difference in the intersinus septum. These findings may 
      help clinicians increase suspicion for a diagnosis of AERD who clinically have 
      diffuse nasal polyposis.
FAU - Malfitano, Madison J
AU  - Malfitano MJ
AUID- ORCID: 0000-0002-8820-1928
AD  - Department of Otolaryngology-Head and Neck Surgery, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina.
FAU - Santarelli, Griffin D
AU  - Santarelli GD
AD  - Department of Otolaryngology-Head and Neck Surgery, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina.
FAU - Gelpi, Mark
AU  - Gelpi M
AD  - Department of Otolaryngology-Head and Neck Surgery, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina.
FAU - Brown, William C
AU  - Brown WC
AUID- ORCID: 0000-0002-5305-1210
AD  - Department of Otolaryngology-Head and Neck Surgery, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina.
FAU - Stepp, Wesley H
AU  - Stepp WH
AD  - Department of Otolaryngology-Head and Neck Surgery, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina.
FAU - Hernandez, Stephen
AU  - Hernandez S
AD  - Department of Otolaryngology-Head and Neck Surgery, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina.
FAU - Kimple, Adam J
AU  - Kimple AJ
AD  - Department of Otolaryngology-Head and Neck Surgery, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina.
FAU - Thorp, Brian D
AU  - Thorp BD
AD  - Department of Otolaryngology-Head and Neck Surgery, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina.
FAU - Zanation, Adam M
AU  - Zanation AM
AD  - Department of Otolaryngology-Head and Neck Surgery, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina.
FAU - Ebert, Charles S Jr
AU  - Ebert CS Jr
AD  - Department of Otolaryngology-Head and Neck Surgery, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina.
LA  - eng
GR  - KL2 TR002490/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200713
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Asthma, Aspirin-Induced/diagnosis
MH  - Chronic Disease
MH  - Humans
MH  - *Nasal Polyps
MH  - Retrospective Studies
MH  - *Rhinitis/diagnosis
MH  - *Sinusitis
MH  - Sphenoid Sinus/diagnostic imaging
PMC - PMC7874380
OTO - NOTNLM
OT  - AERD
OT  - AFS
OT  - CRS
OT  - aspirin exacerbated respiratory disease
OT  - asthma
OT  - bone remodeling
OT  - osteogenesis
OT  - sinusitis
OT  - skull base
OT  - sphenoid sinus
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/07/15 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - 10.1177_1945892420941732 [pii]
AID - 10.1177/1945892420941732 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2021 Mar;35(2):172-178. doi: 10.1177/1945892420941732. Epub 
      2020 Jul 13.

PMID- 24246241
OWN - NLM
STAT- MEDLINE
DCOM- 20151021
LR  - 20141107
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 25
IP  - 8
DP  - 2014
TI  - Rapid evaluation of platelet function using the Multiplate® Analyzer.
PG  - 628-33
LID - 10.3109/09537104.2013.849804 [doi]
AB  - Rapid evaluation of platelet function may be advantageous in the setting of 
      surgical and interventional procedures to tailor treatment of ongoing bleeding. 
      We investigated if platelet function testing performed with the Multiplate® 
      Analyzer (Roche Diagnostics, Mannheim, Germany) only 5 minutes after blood 
      sampling yields reliable test results compared to analyses performed 30 minutes 
      after sampling as currently recommended. We included 48 patients with type II 
      diabetes and stable coronary artery disease treated with aspirin 75 mg daily and 
      50 healthy individuals not taking any medications. Platelet aggregometry by the 
      Multiplate® Analyzer was performed 5 and 30 minutes after blood sampling using 
      arachidonic acid (1.0 mM), collagen (3.2 µg/ml) and adenosine diphosphate (ADP; 
      6.5 µM) as agonists. Compliance with aspirin was verified by serum thromboxane B2 
      measurements. Aggregation levels assessed 5 minutes after blood sampling 
      correlated strongly with those assessed after 30 minutes irrespective of the 
      agonist used (r-values 0.75-0.89, p values <0.0001). Aggregation levels were 4-8% 
      lower and displayed a larger standard deviation when measured 5 minutes after 
      sampling, compared to 30 minutes after sampling. Weak, but significant 
      correlations were observed between platelet aggregation and platelet count 
      (r-values = 0.28-0.39; p values <0.01). The currently recommended 30-minute 
      standing time can be omitted, when platelet aggregation is measured using the 
      Multiplate® Analyzer. Platelet aggregation measured 5 minutes after blood 
      sampling correlates strongly with aggregation measured 30 minutes after sampling, 
      but yields slightly lower aggregation levels. The Multiplate® Analyzer enables 
      rapid on-site evaluation of platelet function.
FAU - Würtz, Morten
AU  - Würtz M
AD  - Department of Cardiology, Aarhus University Hospital , Denmark and.
FAU - Hvas, Anne-Mette
AU  - Hvas AM
FAU - Christensen, Kristian Hylleberg
AU  - Christensen KH
FAU - Rubak, Peter
AU  - Rubak P
FAU - Kristensen, Steen Dalby
AU  - Kristensen SD
FAU - Grove, Erik Lerkevang
AU  - Grove EL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131118
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Coronary Artery Disease/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Activation/*physiology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Function Tests/*methods
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - bleeding
OT  - coronary artery disease
OT  - impedance aggregometry
OT  - platelet aggregation
OT  - platelet function tests
EDAT- 2013/11/20 06:00
MHDA- 2015/10/22 06:00
CRDT- 2013/11/20 06:00
PHST- 2013/11/20 06:00 [entrez]
PHST- 2013/11/20 06:00 [pubmed]
PHST- 2015/10/22 06:00 [medline]
AID - 10.3109/09537104.2013.849804 [doi]
PST - ppublish
SO  - Platelets. 2014;25(8):628-33. doi: 10.3109/09537104.2013.849804. Epub 2013 Nov 
      18.

PMID- 25129584
OWN - NLM
STAT- MEDLINE
DCOM- 20141106
LR  - 20140818
IS  - 1097-685X (Electronic)
IS  - 0022-5223 (Linking)
VI  - 148
IP  - 3
DP  - 2014 Sep
TI  - Aspirin unresponsiveness predicts thrombosis in high-risk pediatric patients 
      after cardiac surgery.
PG  - 810-4; discussion 814-6
LID - S0022-5223(14)00761-2 [pii]
LID - 10.1016/j.jtcvs.2014.06.016 [doi]
AB  - OBJECTIVE: Thrombosis occurs in up to 26% of patients with congenital heart 
      disease after cardiac surgery and is associated with increased morbidity and 
      mortality. Aspirin is commonly administered to reduce the risk of thrombosis, yet 
      aspirin responsiveness is rarely assessed. In this study, we hypothesize that 
      inadequate response to aspirin is associated with increased risk of thrombosis 
      after selected congenital cardiac procedures considered to be high risk for 
      thrombosis. METHODS: Patients undergoing high-risk congenital cardiac surgery who 
      received postoperative aspirin (N = 95) were studied. Response to aspirin was 
      determined using the VerifyNow system several days after administration. Patients 
      were monitored prospectively for 30 days for the development of a thrombosis 
      event and the relationship between aspirin unresponsiveness and a thrombosis 
      event was determined by the Fisher exact test. RESULTS: Rate of aspirin 
      unresponsiveness (≥550 aspirin reaction units [ARU]) was 10 of 95 (10.5%) and was 
      highest in patients weighing less than 5 kg given 20.25 mg/d of aspirin. 
      Thrombosis events occurred in 7 patients (7.4%). Thrombosis was observed in 6 of 
      10 (60%) patients who were unresponsive to aspirin, compared with 1 of 85 (1.2%) 
      patients who were responsive to aspirin (P < .001). In 2 patients who were 
      unresponsive to the initial aspirin dose, an increase in dose resulted in an 
      adequate therapeutic aspirin response (ARU < 550), suggesting insufficiency 
      rather than true resistance in a subset of patients. CONCLUSIONS: Postoperative 
      thrombosis is associated with aspirin unresponsiveness in this patient 
      population. In high-risk patients, monitoring of aspirin therapy and 
      consideration of dose adjustment or alternative agents for unresponsive patients 
      may be justified and warrants further investigation in a prospective trial.
CI  - Copyright © 2014 The American Association for Thoracic Surgery. Published by 
      Mosby, Inc. All rights reserved.
FAU - Emani, Sirisha
AU  - Emani S
AD  - Boston Children's Hospital, Boston, Mass.
FAU - Trainor, Bethany
AU  - Trainor B
AD  - Boston Children's Hospital, Boston, Mass.
FAU - Zurakowski, David
AU  - Zurakowski D
AD  - Boston Children's Hospital, Boston, Mass.
FAU - Baird, Christopher W
AU  - Baird CW
AD  - Boston Children's Hospital, Boston, Mass.
FAU - Fynn-Thompson, Francis E
AU  - Fynn-Thompson FE
AD  - Boston Children's Hospital, Boston, Mass.
FAU - Pigula, Frank A
AU  - Pigula FA
AD  - Boston Children's Hospital, Boston, Mass.
FAU - Emani, Sitaram M
AU  - Emani SM
AD  - Boston Children's Hospital, Boston, Mass. Electronic address: 
      sitaram.emani@cardio.chboston.org.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140613
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Boston
MH  - Cardiac Surgical Procedures/*adverse effects
MH  - Child, Preschool
MH  - *Drug Resistance
MH  - Female
MH  - Heart Defects, Congenital/blood/diagnosis/*surgery
MH  - Humans
MH  - Infant
MH  - Male
MH  - Pilot Projects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Platelet Function Tests
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Thrombosis/blood/diagnosis/*etiology
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2014/08/19 06:00
MHDA- 2014/11/07 06:00
CRDT- 2014/08/18 06:00
PHST- 2014/04/09 00:00 [received]
PHST- 2014/06/04 00:00 [revised]
PHST- 2014/06/10 00:00 [accepted]
PHST- 2014/08/18 06:00 [entrez]
PHST- 2014/08/19 06:00 [pubmed]
PHST- 2014/11/07 06:00 [medline]
AID - S0022-5223(14)00761-2 [pii]
AID - 10.1016/j.jtcvs.2014.06.016 [doi]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 2014 Sep;148(3):810-4; discussion 814-6. doi: 
      10.1016/j.jtcvs.2014.06.016. Epub 2014 Jun 13.

PMID- 27701930
OWN - NLM
STAT- MEDLINE
DCOM- 20170303
LR  - 20181202
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 14
IP  - 11
DP  - 2016 Nov
TI  - Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
PG  - 1215-1226
LID - 10.1080/14779072.2016.1245145 [doi]
AB  - Dual antiplatelet therapy (DAPT) with aspirin combined with either a 
      thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine 
      (ticagrelor) plays a vital role in the management of acute coronary syndrome 
      (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but 
      even those being managed medically. Observational studies and some formal studies 
      have shown patients on the standard dual antiplatelet regimen (clopidogrel and 
      aspirin) continue to have further ischemic events and can suffer stent 
      thrombosis. It has been demonstrated that clopidogrel is associated with a 
      delayed onset of action with a considerable inter-individual variation to 
      treatment thus making it difficult to achieve an optimal level of platelet 
      inhibition. Areas covered: This article will review the current evidence that is 
      available regarding the effectiveness and safety of prasugrel in ACS patients 
      undergoing percutaneous coronary intervention (PCI). Expert commentary: Prasugrel 
      is an oral third-generation inhibitor of platelet activation and aggregation. 
      Laboratory studies and early phase clinical trials show prasugrel has a faster 
      onset of action, is more potent and has reduced inter-patient response 
      variability compared to clopidogrel. The published studies so far demonstrated 
      that prasugrel when compared to clopidogrel also shows a higher degree of 
      effectiveness in the prevention of platelet-initiated thrombotic events in 
      patients with ACS undergoing PCI, however these benefits are offset somewhat by 
      an increased bleeding risk.
FAU - Gunarathne, Ashan
AU  - Gunarathne A
AD  - a University Hospitals of Leicester NHS Trust, Glenfield Hospital , Leicester , 
      UK.
FAU - Hussain, Shahana
AU  - Hussain S
AD  - a University Hospitals of Leicester NHS Trust, Glenfield Hospital , Leicester , 
      UK.
FAU - Gershlick, Anthony H
AU  - Gershlick AH
AD  - b Department of Cardiovascular Sciences , University of Leicester and the 
      National Institute of Health Research (NIHR) Leicester Cardiovascular Biomedical 
      Research Unit, University Hospitals of Leicester National Health Service (NHS) 
      Trust, Glenfield Hospital , Leicester , UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/therapy
MH  - Administration, Oral
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Clopidogrel
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Prasugrel Hydrochloride/adverse effects/*therapeutic use
MH  - Thrombosis/prevention & control
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Prasugrel
OT  - acute coronary syndrome
OT  - antiplatelet
OT  - antithrombotic
OT  - percutaneous coronary intervention
OT  - thienopyridine
EDAT- 2016/10/06 06:00
MHDA- 2017/03/04 06:00
CRDT- 2016/10/06 06:00
PHST- 2016/10/06 06:00 [pubmed]
PHST- 2017/03/04 06:00 [medline]
PHST- 2016/10/06 06:00 [entrez]
AID - 10.1080/14779072.2016.1245145 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2016 Nov;14(11):1215-1226. doi: 
      10.1080/14779072.2016.1245145.

PMID- 18544253
OWN - NLM
STAT- MEDLINE
DCOM- 20080905
LR  - 20161124
IS  - 0161-6412 (Print)
IS  - 0161-6412 (Linking)
VI  - 30
IP  - 4
DP  - 2008 May
TI  - Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients 
      with ischemic cerebral vascular diseases.
PG  - 366-9
LID - 10.1179/174313208X300369 [doi]
AB  - BACKGROUND AND PURPOSE: Lysophosphatidic acid (LPA) is released from activated 
      platelets. Acetylsalicylate (aspirin) is the most commonly used antiplatelet 
      drug. The purpose of this study is to observe whether treatment with 
      acetylsalicylate decreases the LPA level in patients with ischemic 
      cerebrovascular diseases. METHODS: We performed a study examining LPA level in 
      fresh plasma in cases and controls enrolled in the LPA and Stroke Prevention 
      Study. Level of LPA was assayed by measuring its inorganic phosphorus after 
      separation by chromatography. RESULTS: An elevated LPA level was seen in cases (n 
      = 254) with ischemic cerebrovascular disease (3.11+/- 1.55 micromol/l) compared 
      with 136 healthy controls (1.77 +/- 1.04 micromol/l) (p < 0.001). Administration 
      of aspirin (100 mg q.d.) for 1 month significantly lowered LPA level in patients 
      (n = 142) (2.41 +/- 1.03 mu mol/l) compared with that before taking 
      acetylsalicylate (4.06 +/- 1.03 micromol/l) (p < 0.001). However, the LPA level 
      in patients (n = 36) who stopped acetylsalicylate after taking it for 1 month was 
      re-elevated. Before and after taking acetylsalicylate for 1 month, their LPA 
      levels were 4.23 +/- 1.15 and 1.93 +/- 0.85 micromol/l, respectively. After 1 
      month withdrawal, level was 3.90 +/- 1.09 micromol/l (p < 0.001 compared that 
      before taking acetylsalicylate). CONCLUSION: Our findings support a close 
      association between increased plasma LPA level and platelet activation. 
      Acetylsalicylate could decrease plasma LPA levels, which may be used as a 
      mechanism for acetylsalicylate in the prevention of ischemic stroke.
FAU - Li, Zhen-Guang
AU  - Li ZG
AD  - Department of Neurology, Wendeng Central Hospital, Weifang Medical College, 
      Weifang, China. lzg6598@163169.net
FAU - Yu, Zhan-Cai
AU  - Yu ZC
FAU - Wang, Dao-Zhen
AU  - Wang DZ
FAU - Ju, Wei-Ping
AU  - Ju WP
FAU - Zhan, Xia
AU  - Zhan X
FAU - Wu, Qi-Zhuan
AU  - Wu QZ
FAU - Wu, Xi-Juan
AU  - Wu XJ
FAU - Cong, Hai-Ming
AU  - Cong HM
FAU - Man, Hong-Hao
AU  - Man HH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - 0 (Biomarkers)
RN  - 0 (Lysophospholipids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YLU75U4W (Phosphorus)
RN  - PG6M3969SG (lysophosphatidic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Biomarkers/blood
MH  - Blood Platelets/*drug effects/metabolism
MH  - Brain Ischemia/*blood/*drug therapy/physiopathology
MH  - Down-Regulation/drug effects
MH  - Female
MH  - Humans
MH  - Lysophospholipids/biosynthesis/*blood
MH  - Male
MH  - Middle Aged
MH  - Phosphorus/blood
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Treatment Outcome
EDAT- 2008/06/12 09:00
MHDA- 2008/09/06 09:00
CRDT- 2008/06/12 09:00
PHST- 2008/06/12 09:00 [pubmed]
PHST- 2008/09/06 09:00 [medline]
PHST- 2008/06/12 09:00 [entrez]
AID - 10.1179/174313208X300369 [doi]
PST - ppublish
SO  - Neurol Res. 2008 May;30(4):366-9. doi: 10.1179/174313208X300369.

PMID- 14763358
OWN - NLM
STAT- MEDLINE
DCOM- 20040219
LR  - 20201208
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 32
IP  - 37 Pt 2
DP  - 2003 Nov 22
TI  - [Role of Helicobacter pylori in drug-induced gastrointestinal bleeding].
PG  - S60-3
AB  - TWO CO-FACTORS: Helicobacter pylori (Hp) infection and ingestion of NSAIDs are 
      two factors which play a major role in the occurrence of gastric and duodenal 
      ulcers, simple or complicated by perforation and GI bleeding. Hp increases the 
      risk of ulcer in patients receiving an NSAID and the effects of Hp and NSAIDs are 
      additive. Following GI bleeding in a patient receiving a conventional NSAID, the 
      eradication of Hp does not make it possible to protect the patient from another 
      episode of GI bleeding and proves to be a much less effective therapy than 
      continuous therapy with proton pump inhibitors. ROLE OF COX-2 INHIBITORS: COX-2 
      inhibitors (celecoxib, rofecoxib) are associated with a major decrease in the 
      number of symptomatic and/or complicated ulcers compared to a conventional NSAID. 
      Two randomized studies using doses four times higher than those recommended, have 
      demonstrated that serious GI complications associated with NSAIDs (perforation, 
      GI bleeding) were decreased by half compared to those by use of a conventional 
      NSAID at the usual therapeutic dosage. Considering the patient's previous history 
      of GI disorders prior to initiation of treatment and Hp(+) serology, it appears 
      that decreasing risk of symptomatic or complicated gastro-duodenal ulcer was 
      higher in treatment with Rofexocib in patients who did not have a previous 
      history of ulcer, whatever their Hp status. On the other hand, in the group with 
      a history of GI disorders, the decrease in the risk of ulcer was lower than in 
      patients who were Hp(+). ROLE OF ASPIRIN: The causal relationship between intake 
      of aspirin and Hp appear to be more complex. Thus, it appears that eradication of 
      Hp in patients who presented with GI bleeding and scheduled to resume low-dose 
      aspirin had the same efficacy as a daily dose of 20 mg of omeprazole for a 
      6-month period.
FAU - Chaussade, Stanislas
AU  - Chaussade S
AD  - Service de gastroéntérologie, Hôpital Cochin, Paris.
FAU - Abitbol, Vered
AU  - Abitbol V
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Rôle d'Helicobacter pylori dans les hémorragies digestives médicamenteuses.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cyclooxygenase Inhibitors/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Hemorrhage/*chemically induced/*microbiology
MH  - Helicobacter Infections/*complications
MH  - Helicobacter pylori/*pathogenicity
MH  - Humans
MH  - Proton Pump Inhibitors
MH  - Risk Factors
RF  - 11
EDAT- 2004/02/07 05:00
MHDA- 2004/02/20 05:00
CRDT- 2004/02/07 05:00
PHST- 2004/02/07 05:00 [pubmed]
PHST- 2004/02/20 05:00 [medline]
PHST- 2004/02/07 05:00 [entrez]
PST - ppublish
SO  - Presse Med. 2003 Nov 22;32(37 Pt 2):S60-3.

PMID- 12108311
OWN - NLM
STAT- MEDLINE
DCOM- 20020730
LR  - 20190901
IS  - 0929-693X (Print)
IS  - 0929-693X (Linking)
VI  - 9
IP  - 6
DP  - 2002 Jun
TI  - [Severe Reye syndrome: report of 14 cases managed in a pediatric intensive care 
      unit over 11 years].
PG  - 581-6
AB  - Idiopathic Reye syndrome is a rare disease revealed by unexplained encephalopathy 
      and microvesicular liver steatosis. Some clinical and epidemiological studies 
      mainly performed in English speaking countries questioned the reality of Reye 
      syndrome because numerous know inherited metabolic diseases, and some of them 
      unrecognized, could mimick this disorder. We focused in our study on severe forms 
      of Reye syndrome admitted to a pediatric intensive care unit. METHODS: 
      Retrospective study over the last eleven years (1991-2001) included all the 
      pediatric patients admitted to our tertiary referral center with the classical 
      American Reye syndrome criteria (e.g. CDC). Extensive metabolic screening was 
      performed in all cases, except for the ultimately dead patients. RESULT: Fourteen 
      patients (mean age 52 months) were included. Fever always occurred before their 
      admission and aspirin (n = 12) or acetaminophen (n = 7) was prescribed. Median 
      Glasgow scale was 7 on admission. Mean amoniac plasma level was 320 mumol/L and 
      alanine-aminotransferase peak plasma level 1475 +/- 1387 IU/L. Mechanical 
      ventilation was started in ten children and six of them underwent continuous 
      venovenous hemofiltration. Three patients ultimately died and 11 survived with a 
      mean five years follow-up without relapses or neurological impairment. Any of 
      them demonstrated inherited metabolic disease except for one infant with 
      hereditary fructose intolerance. CONCLUSION: Unlike widespread opinion, severe 
      Reye syndrome without identified metabolic disorders seems to not disappear in 
      our country. Reye syndrome remains a potentially life threatening disease and 
      raises for aggressive treatment of brain edema. If aspirin and Reye syndrome 
      association are not formally documented in France, cautiousness must be kept in 
      mind and all the aspirin adverse effects notifications should be addressed to the 
      public drugs survey network.
FAU - Thabet, F
AU  - Thabet F
AD  - Service de réanimation pédiatrique et néonatale, hôpital de Bicêtre, Assistance 
      publique-hôpitaux de Paris, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, 
      France.
FAU - Durand, P
AU  - Durand P
FAU - Chevret, L
AU  - Chevret L
FAU - Fabre, M
AU  - Fabre M
FAU - Debray, D
AU  - Debray D
FAU - Brivet, M
AU  - Brivet M
FAU - Devictor, D
AU  - Devictor D
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Syndrome de Reye sévère: à propos de 14 cas pris en charge dans une unité de 
      réanimation pédiatrique pendant 11 ans.
PL  - France
TA  - Arch Pediatr
JT  - Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
JID - 9421356
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*adverse effects/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Brain Edema/*etiology
MH  - Child
MH  - Child, Preschool
MH  - Fatal Outcome
MH  - Female
MH  - Fever/drug therapy
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Patient Admission
MH  - Prognosis
MH  - Recurrence
MH  - Reye Syndrome/etiology/*pathology
MH  - Risk Factors
MH  - Severity of Illness Index
EDAT- 2002/07/11 10:00
MHDA- 2002/07/31 10:01
CRDT- 2002/07/11 10:00
PHST- 2002/07/11 10:00 [pubmed]
PHST- 2002/07/31 10:01 [medline]
PHST- 2002/07/11 10:00 [entrez]
AID - S0929-693X(01)00924-1 [pii]
AID - 10.1016/s0929-693x(01)00924-1 [doi]
PST - ppublish
SO  - Arch Pediatr. 2002 Jun;9(6):581-6. doi: 10.1016/s0929-693x(01)00924-1.

PMID- 36096185
OWN - NLM
STAT- MEDLINE
DCOM- 20230223
LR  - 20230828
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 228
IP  - 3
DP  - 2023 Mar
TI  - Low-dose aspirin use in pregnancy and the risk of preterm birth: a Swedish 
      register-based cohort study.
PG  - 336.e1-336.e9
LID - S0002-9378(22)00728-1 [pii]
LID - 10.1016/j.ajog.2022.09.006 [doi]
AB  - BACKGROUND: Preterm birth is the leading cause of neonatal mortality and 
      morbidity. Women who have had a previous preterm birth are at increased risk for 
      preterm birth in their subsequent pregnancies. Low-dose aspirin use reduces the 
      risk for preterm birth among women at risk of developing preeclampsia, however, 
      it is unclear whether low-dose aspirin may reduce the risk of recurrent preterm 
      birth. OBJECTIVE: This study aimed to investigate the association between 
      low-dose aspirin use and preterm birth among women with a previous preterm birth. 
      STUDY DESIGN: We conducted a Swedish register-based cohort study and included 
      women who had a first and second pregnancy between 2006 and 2019, with the first 
      pregnancy ending in preterm birth (medically indicated or with spontaneous onset 
      <37 weeks of gestation). The association between low-dose aspirin use and preterm 
      birth in the second pregnancy was estimated via logistic regression via 
      standardization and expressed as marginal relative risks with the 95% confidence 
      interval. RESULTS: Among the study cohort (N=22,127), 3057 women (14%) were 
      prescribed low-dose aspirin during their second pregnancy and 3703 women (17%) 
      gave birth prematurely. Low-dose aspirin use was associated with a reduced risk 
      for preterm birth, (marginal relative risk, 0.87; 95% confidence interval, 
      0.77-0.99). There were no statistically significant associations between low-dose 
      aspirin use and an altered risk for moderate preterm birth, defined as birth 
      between 32 and 36 weeks' gestation (marginal relative risk, 0.90; 95% confidence 
      interval, 0.78-1.03), or very preterm birth, defined as birth <32 weeks' 
      gestation (marginal relative risk, 0.75; 95% confidence interval, 0.54-1.04). 
      Regarding the onset of preterm birth, low-dose aspirin use was associated with a 
      reduced risk for spontaneous preterm birth (marginal relative risk, 0.70; 95% 
      confidence interval, 0.57-0.86) but no reduction in the risk for medically 
      indicated preterm birth (marginal relative risk, 1.09; 95% confidence interval, 
      0.91-1.30) was observed. CONCLUSION: Among women with a previous preterm birth, 
      low-dose aspirin use was associated with a reduced risk for preterm birth. When 
      investigating preterm birth by onset in the second pregnancy, low-dose aspirin 
      use was associated with a reduced risk for spontaneous preterm birth. Our results 
      suggest that low-dose aspirin may be an effective prophylaxis for recurrent 
      preterm birth.
CI  - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Kupka, Ellen
AU  - Kupka E
AD  - Department of Obstetrics and Gynecology, Institute of Clinical Science, 
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of 
      Research and Higher Education, Center for Clinical Research, Dalarna, Uppsala 
      University, Falun, Sweden. Electronic address: ellen.kupka@gu.se.
FAU - Hesselman, Susanne
AU  - Hesselman S
AD  - Department of Research and Higher Education, Center for Clinical Research, 
      Dalarna, Uppsala University, Falun, Sweden; Department of Women's and Children's 
      Health, Uppsala University, Uppsala, Sweden.
FAU - Hastie, Roxanne
AU  - Hastie R
AD  - Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden; 
      Mercy Perinatal, Mercy Hospital for Women, Melbourne, Australia; Department of 
      Obstetrics and Gynaecology, University of Melbourne, Heidelberg, Australia.
FAU - Lomartire, Riccardo
AU  - Lomartire R
AD  - Department of Research and Higher Education, Center for Clinical Research, 
      Dalarna, Uppsala University, Falun, Sweden.
FAU - Wikström, Anna Karin
AU  - Wikström AK
AD  - Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
FAU - Bergman, Lina
AU  - Bergman L
AD  - Department of Obstetrics and Gynecology, Institute of Clinical Science, 
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of 
      Women's and Children's Health, Uppsala University, Uppsala, Sweden; Department of 
      Obstetrics and Gynaecology, Stellenbosch University, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220909
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Obstet Gynecol. 2023 Sep;229(3):353-354. PMID: 37068648
CIN - Am J Obstet Gynecol. 2023 Sep;229(3):354-355. PMID: 37080508
MH  - Pregnancy
MH  - Female
MH  - Infant, Newborn
MH  - Humans
MH  - *Premature Birth/epidemiology/prevention & control/drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Cohort Studies
MH  - Sweden/epidemiology
MH  - Aspirin/therapeutic use
OTO - NOTNLM
OT  - adverse pregnancy outcome
OT  - aspirin
OT  - preterm birth
OT  - prevention
EDAT- 2022/09/13 06:00
MHDA- 2023/02/25 06:00
CRDT- 2022/09/12 19:23
PHST- 2022/06/02 00:00 [received]
PHST- 2022/08/11 00:00 [revised]
PHST- 2022/09/02 00:00 [accepted]
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2022/09/12 19:23 [entrez]
AID - S0002-9378(22)00728-1 [pii]
AID - 10.1016/j.ajog.2022.09.006 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2023 Mar;228(3):336.e1-336.e9. doi: 
      10.1016/j.ajog.2022.09.006. Epub 2022 Sep 9.

PMID- 23499330
OWN - NLM
STAT- MEDLINE
DCOM- 20130627
LR  - 20140106
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 126
IP  - 5
DP  - 2013 May
TI  - Aspirin in the treatment and prevention of cardiovascular disease: past and 
      current perspectives and future directions.
PG  - 373-8
LID - S0002-9343(13)00096-X [pii]
LID - 10.1016/j.amjmed.2012.12.013 [doi]
AB  - In secondary prevention among a wide range of patients who have survived a prior 
      occlusive vascular event, as well as during acute myocardial infarction and acute 
      occlusive stroke, aspirin produces statistically significant and clinically 
      important reductions in the risk of subsequent myocardial infarction, stroke, and 
      vascular death. In primary prevention, aspirin reduces risk of a first myocardial 
      infarction, but the data on stroke and vascular deaths remain inconclusive. In 
      addition, the average absolute risk of subjects randomized in the primary 
      prevention trials was so low that it is not possible to get reliable estimates of 
      the benefit-to-risk ratio in primary prevention in subjects at moderate risk. 
      Until the results of ongoing trials are available, nobody would disagree that a 
      nonfatal myocardial infarction or stroke is more likely to be disabling than a 
      nonfatal bleed. Thus, in primary prevention at present, the appropriate and 
      judicious use of aspirin by clinicians based on individual clinical judgments 
      that weigh their absolute benefits against the absolute risks of the drug, will 
      avoid premature morbidity and possibly, mortality.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, 
      FL 33432, USA. PROFCHHMD@prodigy.net
FAU - Dalen, James E
AU  - Dalen JE
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130314
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Med. 2013 Dec;126(12):e47. PMID: 24262748
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*prevention & control
MH  - Humans
MH  - Primary Prevention/*methods
MH  - Risk Assessment
MH  - Secondary Prevention/*methods
EDAT- 2013/03/19 06:00
MHDA- 2013/06/29 06:00
CRDT- 2013/03/19 06:00
PHST- 2012/12/11 00:00 [received]
PHST- 2012/12/16 00:00 [revised]
PHST- 2012/12/17 00:00 [accepted]
PHST- 2013/03/19 06:00 [entrez]
PHST- 2013/03/19 06:00 [pubmed]
PHST- 2013/06/29 06:00 [medline]
AID - S0002-9343(13)00096-X [pii]
AID - 10.1016/j.amjmed.2012.12.013 [doi]
PST - ppublish
SO  - Am J Med. 2013 May;126(5):373-8. doi: 10.1016/j.amjmed.2012.12.013. Epub 2013 Mar 
      14.

PMID- 18577436
OWN - NLM
STAT- MEDLINE
DCOM- 20081010
LR  - 20171116
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 361
IP  - 1-2
DP  - 2008 Sep 1
TI  - Effects of particle size and cohesive properties on mixing studied by non-contact 
      NIR.
PG  - 87-91
LID - 10.1016/j.ijpharm.2008.05.030 [doi]
AB  - A scaled-down convective blender was used along with non-invasive NIR 
      spectrometry to study the mixing of citric acid, aspirin, aspartame or povidone 
      with microcrystalline cellulose. NIR mixing profiles were generated in real time 
      using measurements at the 2nd overtone wavelength of the added compounds. Trends 
      demonstrated previously for aspirin were confirmed for additions of citric acid: 
      the magnitude of the 2nd overtone NIR measurements is less affected by changes in 
      particle size than that of the 1st overtone; the peak-to-peak noise of the 2nd 
      overtone NIR mixing profile increases with the particle size of the added 
      compound. The study has demonstrated the usefulness of continuous NIR 
      measurements for rapid evaluation of the mixing process when deciding the best 
      particle size of microcrystalline cellulose to mix with compounds of different 
      particle shape and cohesive properties. Smaller particle sizes of 
      microcrystalline cellulose (53-106 microm) were better for aspirin (212-250 
      microm), whereas larger particles (212-250 microm) were better for aspartame 
      (212-250 microm). The characteristics of the compounds also need to be considered 
      when deciding the order of addition of secondary compounds when mixed with 
      microcrystalline cellulose. The time required to achieve a uniform mixture was 
      much less when povidone was added before aspirin, rather than vice versa.
FAU - Bellamy, Luke J
AU  - Bellamy LJ
AD  - WestCHEM, Department of Pure and Applied Chemistry and CPACT, University of 
      Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, UK.
FAU - Nordon, Alison
AU  - Nordon A
FAU - Littlejohn, David
AU  - Littlejohn D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080603
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Excipients)
RN  - 0 (Powders)
RN  - 2968PHW8QP (Citric Acid)
RN  - 9004-34-6 (Cellulose)
RN  - FZ989GH94E (Povidone)
RN  - OP1R32D61U (microcrystalline cellulose)
RN  - R16CO5Y76E (Aspirin)
RN  - Z0H242BBR1 (Aspartame)
SB  - IM
MH  - Aspartame/chemistry
MH  - Aspirin/chemistry
MH  - Cellulose/chemistry
MH  - Citric Acid/chemistry
MH  - Excipients/*chemistry
MH  - Particle Size
MH  - Povidone/chemistry
MH  - Powders
MH  - Spectroscopy, Near-Infrared/*methods
MH  - Technology, Pharmaceutical/*methods
EDAT- 2008/06/26 09:00
MHDA- 2008/10/11 09:00
CRDT- 2008/06/26 09:00
PHST- 2008/05/12 00:00 [received]
PHST- 2008/05/19 00:00 [accepted]
PHST- 2008/06/26 09:00 [pubmed]
PHST- 2008/10/11 09:00 [medline]
PHST- 2008/06/26 09:00 [entrez]
AID - S0378-5173(08)00398-0 [pii]
AID - 10.1016/j.ijpharm.2008.05.030 [doi]
PST - ppublish
SO  - Int J Pharm. 2008 Sep 1;361(1-2):87-91. doi: 10.1016/j.ijpharm.2008.05.030. Epub 
      2008 Jun 3.

PMID- 2310701
OWN - NLM
STAT- MEDLINE
DCOM- 19900416
LR  - 20190704
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 74
IP  - 1
DP  - 1990 Jan
TI  - Direct activation of platelets by heat is the possible trigger of the 
      coagulopathy of heat stroke.
PG  - 86-92
AB  - The trigger of the coagulopathy that complicates heat stroke is obscure, but 
      direct platelet activation by heat is a possibility we set out to study. Platelet 
      rich plasma (PRP), prepared from blood donors, was incubated at increasing 
      temperatures (38-45 degrees C) and then platelet aggregation was undertaken in 
      response to decreasing low doses of ADP (less than 2.0 mumol/l). 
      Hyperaggregability was manifested when the incubation temperature reached 43 
      degrees C and was maximum at 44 degrees C before complete inhibition of responses 
      at 45 degrees C. The platelet hyperactivity induced by heating at 44 degrees C 
      persisted after reincubating PRP samples at 37 degrees C. These platelet 
      responses could not be triggered in PRP samples prepared from subjects after the 
      overnight ingestion of aspirin or after the addition of aspirin to PRP before 
      starting the heating procedure. However, aspirin was less effective when added to 
      PRP after the appearance of the heat-induced hyperaggregability. In conclusion, 
      these results indicate that platelets can be activated directly by heat. This 
      mechanism which may be operational in heat stroke, is unaffected by cooling (body 
      cooling being basic in the management of heat stroke) but can be prevented by the 
      early administration of aspirin.
FAU - Gader, A M
AU  - Gader AM
AD  - Department of Physiology, College of Medicine, Riyadh, Saudi Arabia.
FAU - al-Mashhadani, S A
AU  - al-Mashhadani SA
FAU - al-Harthy, S S
AU  - al-Harthy SS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology
MH  - Blood Coagulation Disorders/*etiology
MH  - Cells, Cultured
MH  - Female
MH  - Heat Exhaustion/blood/*complications
MH  - *Hot Temperature
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects/*physiology
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1111/j.1365-2141.1990.tb02543.x [doi]
PST - ppublish
SO  - Br J Haematol. 1990 Jan;74(1):86-92. doi: 10.1111/j.1365-2141.1990.tb02543.x.

PMID- 15179245
OWN - NLM
STAT- MEDLINE
DCOM- 20040617
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 56
IP  - 5
DP  - 2004 May
TI  - Cerebral perfusion pressure elevation with oxygen-carrying pressor after 
      traumatic brain injury and hypotension in Swine.
PG  - 1049-57
AB  - BACKGROUND: Previously, we had shown that elevation of cerebral perfusion 
      pressure, using pressors, improved short-term outcomes after traumatic brain 
      injury and hemorrhagic shock in swine. The current study evaluates outcomes after 
      resuscitation with diaspirin cross-linked hemoglobin (DCLHb)--a hemoglobin-based 
      oxygen carrier with pressor activity--in the same swine model of traumatic brain 
      injury and hemorrhagic shock. METHODS: Anesthetized and ventilated swine received 
      traumatic brain injury via cortical fluid percussion (6-8 atm) followed by 45% 
      blood volume hemorrhage. One hour later, animals were randomized to either a 
      control group (SAL) resuscitated with normal saline equal to three times shed 
      blood volume or to one of two experimental groups resuscitated with DCLHb. The 
      two experimental groups consisted of a low-dose group, resuscitated with 250 mL 
      of DCLHb (Hb1), and a high-dose group, resuscitated with 500 mL of DCLHb (Hb2). 
      Animals were observed for 210 minutes postresuscitation. Outcomes evaluated were 
      cerebral oxygenation by measuring partial pressure and saturation of oxygen in 
      cerebrovenous blood; cerebral function by evaluating the preservation and 
      magnitude of cerebrovascular carbon dioxide reactivity; and brain structural 
      damage by semiquantitatively assessing beta amyloid precursor protein positive 
      axons. RESULTS: Postresuscitation, cerebral perfusion pressure was higher in the 
      DCLHb groups (p < 0.05, Hb1 and Hb2 vs. SAL), and intracranial pressure was lower 
      in the Hb2 group (p < 0.05 vs. SAL). Cerebrovenous oxygen level was similar in 
      all groups (p > 0.05). At baseline, 5% carbon dioxide evoked a 16 +/- 1% increase 
      in cerebrovenous oxygen saturation, indicating vasodilatation. At 210 minutes, 
      this response was nearly absent in SAL (4 +/- 4%) (p < 0.05 vs. baseline) and Hb1 
      (1 +/- 5%), but was partially preserved in Hb2 (9 +/- 5%). There was no 
      intergroup difference in beta amyloid precursor protein positive axons. Five of 
      20 SAL and 0 of 13 DCLHb animals developed brain death (flat 
      electroencephalogram) (p = 0.05, SAL vs. DCLHb). Postresuscitation, DCLHb animals 
      maintained higher mean pulmonary arterial pressure (28 +/- 1 mm Hg, SAL; 42 +/- 1 
      mm Hg, Hb1; 45 +/- 1 mm Hg, Hb2) (p < 0.05, Hb1 and Hb2 vs. SAL) and lower 
      cardiac output (3.9 +/- 1.6 L/min, SAL; 2.6 +/- 0.1 L/min, Hb1; 2.7 +/- 0.1 
      L/min, Hb2) (p < 0.05, Hb1 and Hb2 vs. SAL). Three Hb2 animals died as a result 
      of cardiac failure, and one SAL animal died as a result of irreversible shock. 
      CONCLUSION: In this swine model of traumatic brain injury and hemorrhagic shock, 
      resuscitation with DCLHb maintained a higher cerebral perfusion pressure. 
      Low-dose DCLHb (minimal increase in oxygen carriage) failed to significantly 
      improve short-term outcome. With high-dose DCLHb (significant improvement in 
      oxygen carriage), intracranial pressure was lower and cerebrovascular carbon 
      dioxide reactivity was partially preserved; however, this was at the cost of 
      poorer cardiac performance secondary to high afterload.
FAU - Malhotra, Ajai K
AU  - Malhotra AK
AD  - Department of Surgery, University of Tennessee Health Science Center, Memphis, 
      Tennessee, USA. akmalhot@hsc.vcu.edu
FAU - Schweitzer, John B
AU  - Schweitzer JB
FAU - Fox, Jeri L
AU  - Fox JL
FAU - Fabian, Timothy C
AU  - Fabian TC
FAU - Proctor, Kenneth G
AU  - Proctor KG
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Amyloid beta-Protein Precursor)
RN  - 0 (Hemoglobins)
RN  - 142M471B3J (Carbon Dioxide)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Amyloid beta-Protein Precursor/drug effects
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Blood Volume/drug effects
MH  - Brain Chemistry
MH  - Brain Death
MH  - Brain Injuries/complications/*drug therapy/metabolism/physiopathology
MH  - Carbon Dioxide/blood
MH  - Cardiac Output/drug effects
MH  - Cerebrovascular Circulation/drug effects
MH  - *Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical
MH  - Hemoglobins/pharmacology/*therapeutic use
MH  - Intracranial Pressure/*drug effects
MH  - Oxygen/blood
MH  - Pulmonary Wedge Pressure/drug effects
MH  - Random Allocation
MH  - Resuscitation/methods
MH  - Shock, Hemorrhagic/*etiology
MH  - Sodium Chloride/pharmacology/therapeutic use
MH  - Swine
EDAT- 2004/06/05 05:00
MHDA- 2004/06/18 05:00
CRDT- 2004/06/05 05:00
PHST- 2004/06/05 05:00 [pubmed]
PHST- 2004/06/18 05:00 [medline]
PHST- 2004/06/05 05:00 [entrez]
AID - 00005373-200405000-00018 [pii]
AID - 10.1097/01.ta.0000127765.75643.66 [doi]
PST - ppublish
SO  - J Trauma. 2004 May;56(5):1049-57. doi: 10.1097/01.ta.0000127765.75643.66.

PMID- 7688059
OWN - NLM
STAT- MEDLINE
DCOM- 19930830
LR  - 20131121
IS  - 0022-5223 (Print)
IS  - 0022-5223 (Linking)
VI  - 106
IP  - 2
DP  - 1993 Aug
TI  - Preoperative therapy of low-dose aspirin in internal mammary artery bypass 
      operations with and without low-dose aprotinin.
PG  - 262-7
AB  - The effect of preoperative low-dose aspirin (1 mg/kg of body weight) and 
      intraoperative low-dose aprotinin (2 million kallikrein inactivator units) 
      treatment on perioperative blood loss and blood requirements in patients who 
      undergo internal mammary artery bypass operations is unknown. Therefore, we 
      retrospectively studied 75 matching patients who underwent internal mammary 
      artery operations, and they were allocated to one of three groups: low-dose 
      aspirin and aprotinin treatment (group 1, n = 25), low-dose aspirin treatment 
      without aprotinin (group 2, n = 25), and neither aspirin nor aprotinin treatment 
      (group 3, n = 25). Although the perioperative blood loss was similar, the blood 
      requirements tended to be higher (p = 0.09) in the patients who were treated with 
      aspirin (group 2) than in the control patients (group 3). When aprotinin was 
      added to the priming solution in patients who were treated with aspirin (group 
      1), blood loss was significantly lower (p < 0.05) than that of group 2 patients 
      but not of control patients. Blood requirements were significantly lower (p < 
      0.01) than those of patients in groups 2 and 3. Blood products were needed in 
      29%, 62%, and 75% of patients in groups 1, 2, and 3, respectively.
FAU - Schönberger, J P
AU  - Schönberger JP
AD  - Department of Cardiopulmonary Surgery, Catharina Hospital, Eindhoven, The 
      Netherlands.
FAU - Bredée, J J
AU  - Bredée JJ
FAU - van Oeveren, W
AU  - van Oeveren W
FAU - van Zundert, A A
AU  - van Zundert AA
FAU - Verkroost, M
AU  - Verkroost M
FAU - Terwoorst, J
AU  - Terwoorst J
FAU - Bavinck, J H
AU  - Bavinck JH
FAU - Berreklouw, E
AU  - Berreklouw E
FAU - Wildevuur, C R
AU  - Wildevuur CR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
RN  - 9087-70-1 (Aprotinin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aprotinin/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Blood Component Transfusion
MH  - Blood Loss, Surgical/*prevention & control
MH  - Drug Therapy, Combination
MH  - Emergencies
MH  - Female
MH  - Humans
MH  - *Internal Mammary-Coronary Artery Anastomosis
MH  - Intraoperative Period
MH  - Male
MH  - Middle Aged
MH  - Plasma
MH  - Platelet Transfusion
MH  - *Premedication
MH  - Retrospective Studies
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 1993 Aug;106(2):262-7.

PMID- 2010565
OWN - NLM
STAT- MEDLINE
DCOM- 19910503
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 31
IP  - 2
DP  - 1991 Feb
TI  - The bleeding time effects of a single dose of aspirin in subjects receiving 
      omega-3 fatty acid dietary supplementation.
PG  - 185-90
AB  - Dietary supplementation with omega-3 fatty acids reduces platelet aggregation in 
      subjects who usually eat a diet low in these fatty acids. Aspirin also has an 
      antiplatelet effect. The clinical effects of the concomitant administration of 
      these agents were examined in this double-blind controlled crossover trial. 
      Twelve healthy adults were randomized to supplement their diet for 21 days with 8 
      g of omega-3 fatty acids or identical-looking olive oil capsules. At the end of 
      each treatment period, bleeding times were obtained before and after the 
      administration of one 325-mg aspirin tablet. Overall, percent change in bleeding 
      time after omega-3 fatty acid supplementation was significantly prolonged 
      compared with olive oil supplementation before aspirin administration but not 
      after. Bleeding times were influenced significantly by the order of randomization 
      in the two treatment groups. Changes in post-aspirin bleeding time varied in 
      subjects after they received olive oil. Post-aspirin bleeding times after omega-3 
      fatty acid supplementation were prolonged compared with baseline values but not 
      significantly prolonged when compared with those after olive oil administration. 
      The authors concluded that the concomitant administration of a single dose of 
      aspirin does not prolong bleeding time in subjects who eat a diet enriched by 
      omega-3 fatty acids versus a diet enriched by olive oil.
FAU - Mueller, B A
AU  - Mueller BA
AD  - Department of Pharmacy Practice, School of Pharmacy and Pharmacol Sciences, 
      Purdue University, West Lafayette, Indiana.
FAU - Talbert, R L
AU  - Talbert RL
FAU - Tegeler, C H
AU  - Tegeler CH
FAU - Prihoda, T J
AU  - Prihoda TJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Olive Oil)
RN  - 0 (Plant Oils)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - *Bleeding Time
MH  - Fatty Acids, Omega-3/*administration & dosage
MH  - Female
MH  - Food, Fortified
MH  - Humans
MH  - Olive Oil
MH  - Plant Oils/administration & dosage
MH  - Platelet Aggregation
EDAT- 1991/02/01 00:00
MHDA- 1991/02/01 00:01
CRDT- 1991/02/01 00:00
PHST- 1991/02/01 00:00 [pubmed]
PHST- 1991/02/01 00:01 [medline]
PHST- 1991/02/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1991.tb03706.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1991 Feb;31(2):185-90. doi: 10.1002/j.1552-4604.1991.tb03706.x.

PMID- 3570034
OWN - NLM
STAT- MEDLINE
DCOM- 19870605
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 28
IP  - 3
DP  - 1987 Mar
TI  - Molecular weight of gastric mucus glycoprotein is a determinant of the degree of 
      subsequent aspirin induced chronic gastric ulceration in the rat.
PG  - 287-93
AB  - Mucus was sampled from the gastric mucosal surface of anaesthetised rats. Three 
      weeks later these rats were orally dosed each day with aspirin (375 mg/kg) for 
      six months. Then the number and size of the aspirin induced chronic gastric 
      ulcers were assessed. Gel filtration chromatography of the mucus samples showed 
      that mucus glycoprotein was present in both high and low molecular weight forms. 
      There was a natural variation between individual rats in the percentage of 
      glycoprotein in the high molecular weight form (mean = 58.9%; SD = 9.6%; n = 23). 
      This variation correlated strongly with the degree of subsequent aspirin induced 
      chronic gastric ulceration (r = -0.85, p less than 0.001). This is the first time 
      that a pre-existent variability in a mucosal defence factor has been shown to 
      predict susceptibility of the stomach to chronic ulceration.
FAU - Bagshaw, P F
AU  - Bagshaw PF
FAU - Munster, D J
AU  - Munster DJ
FAU - Wilson, J G
AU  - Wilson JG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Amino Acids)
RN  - 0 (Carbohydrates)
RN  - 0 (Glycoproteins)
RN  - 0 (gastric mucus glycoproteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acids/analysis
MH  - Animals
MH  - Aspirin/*adverse effects
MH  - Carbohydrates/analysis
MH  - Chromatography, Gel
MH  - Chronic Disease
MH  - Gastric Mucosa/*analysis
MH  - Glycoproteins/*analysis
MH  - Molecular Weight
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach Ulcer/*chemically induced
PMC - PMC1432709
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 10.1136/gut.28.3.287 [doi]
PST - ppublish
SO  - Gut. 1987 Mar;28(3):287-93. doi: 10.1136/gut.28.3.287.

PMID- 15346090
OWN - NLM
STAT- MEDLINE
DCOM- 20050208
LR  - 20191026
IS  - 0954-6928 (Print)
IS  - 0954-6928 (Linking)
VI  - 15
IP  - 6
DP  - 2004 Sep
TI  - The role of platelet inhibition in the drug-eluting stent era.
PG  - 327-9
AB  - The use of antiplatelet agents in the management of patients undergoing 
      percutaneous coronary interventions involves the administration of aspirin, 
      thienopyridines, and in high-risk patients, GPIIb-IIIa antagonists. Drug-eluting 
      stents now account for greater than 50% of stenting procedures. This review 
      focuses on the limited available data describing the use of antiplatelet agents 
      in patients undergoing drug-eluting stent implantation.
FAU - Tamberella, Michael R
AU  - Tamberella MR
AD  - Department of Medicine and the Center for Platelet Function Studies, UMass 
      Memorial Medical Center and University of Massachusetts Medical School, 
      Worcester, MA 01655, USA.
FAU - Furman, Mark I
AU  - Furman MI
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Coron Artery Dis
JT  - Coronary artery disease
JID - 9011445
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Coronary Stenosis/drug therapy/*therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Pyridines/*therapeutic use
MH  - *Stents
RF  - 21
EDAT- 2004/09/04 05:00
MHDA- 2005/02/09 09:00
CRDT- 2004/09/04 05:00
PHST- 2004/09/04 05:00 [pubmed]
PHST- 2005/02/09 09:00 [medline]
PHST- 2004/09/04 05:00 [entrez]
AID - 00019501-200409000-00005 [pii]
AID - 10.1097/00019501-200409000-00005 [doi]
PST - ppublish
SO  - Coron Artery Dis. 2004 Sep;15(6):327-9. doi: 10.1097/00019501-200409000-00005.

PMID- 2431396
OWN - NLM
STAT- MEDLINE
DCOM- 19870109
LR  - 20131121
IS  - 0391-5387 (Print)
IS  - 0391-5387 (Linking)
VI  - 8
IP  - 2
DP  - 1986 Mar-Apr
TI  - [Kawasaki's disease. 3 problems: incomplete clinical forms, steroid treatment, 
      low doses of aspirin].
PG  - 233-41
AB  - After a brief review of the recent literature and the description of the clinical 
      and echocardiographic follow-up of 9 cases observed from 1976 to 1985, the 
      authors stress the relative importance to recognize patients who do not fulfill 
      the classic criteria for the diagnosis of Kawasaki disease, in order to treat 
      with antiaggregants those affected by coronary aneurysms. Moreover they discuss 
      the beneficial effects of steroids, in association with salicylates, given only 
      in the first two weeks of disease when the production and deposit of 
      immunocomplexes and the release of lysosomal enzymes from macrophage cells occur. 
      Finally the authors point out that the treatment with low doses of salicylates 
      selectively acting on thromboxane A2 and not on Pgl2, as shown in experimental 
      studies, remains to be confirmed by clinical trials.
FAU - Di Piero, G
AU  - Di Piero G
FAU - Cupini, V
AU  - Cupini V
FAU - Isola, M L
AU  - Isola ML
FAU - Stirpe, S
AU  - Stirpe S
FAU - Bellisario, G
AU  - Bellisario G
FAU - Garibaldi, G
AU  - Garibaldi G
FAU - Proia, R
AU  - Proia R
LA  - ita
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Malattia di Kawasaki. Tre problemi: le forme cliniche incomplete, il trattamento 
      steroideo, le basse dosi di aspirina.
PL  - Italy
TA  - Pediatr Med Chir
JT  - La Pediatria medica e chirurgica : Medical and surgical pediatrics
JID - 8100625
RN  - 0 (Glucocorticoids)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Coronary Aneurysm/etiology
MH  - Dipyridamole/therapeutic use
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Infant
MH  - Male
MH  - *Mucocutaneous Lymph Node Syndrome/complications/diagnosis
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
PST - ppublish
SO  - Pediatr Med Chir. 1986 Mar-Apr;8(2):233-41.

PMID- 1798955
OWN - NLM
STAT- MEDLINE
DCOM- 19920415
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 64
IP  - 6
DP  - 1991 Dec 15
TI  - Action of some salicylate derivatives on in vitro platelet aggregation. 
      Inhibitory and inhibition antagonistic effects.
PG  - 631-6
AB  - Twenty salicylate derivatives were tested for their antagonistic activity on the 
      inhibitory effect of aspirin on platelet aggregation. The blocking effect was not 
      limited to the salicylate but also characterised some of its substituted 
      compounds. The substituant influence did not seem to be related to electronic or 
      size parameters. This antagonistic activity of these derivatives decreased as 
      concentrations increased, owing to the emergence of their own inhibitory 
      activity: several salicylate derivatives showed dual inhibitory and inhibition 
      antagonistic activity, with both properties present at the same concentration. A 
      mechanism involving dissociated activities on the two enzymatic sites of 
      cyclooxygenase is proposed.
FAU - Casadebaig, F
AU  - Casadebaig F
AD  - Faculté de Pharmacie, Université de Bordeaux II, France.
FAU - Dupin, J P
AU  - Dupin JP
FAU - Gravier, D
AU  - Gravier D
FAU - Hou, G
AU  - Hou G
FAU - Daret, D
AU  - Daret D
FAU - Bernard, H
AU  - Bernard H
FAU - Larrue, J
AU  - Larrue J
FAU - Boisseau, M
AU  - Boisseau M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/*antagonists & inhibitors
MH  - Humans
MH  - In Vitro Techniques
MH  - Molecular Structure
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Salicylates/*pharmacology
MH  - Structure-Activity Relationship
EDAT- 1991/12/15 00:00
MHDA- 1991/12/15 00:01
CRDT- 1991/12/15 00:00
PHST- 1991/12/15 00:00 [pubmed]
PHST- 1991/12/15 00:01 [medline]
PHST- 1991/12/15 00:00 [entrez]
AID - 10.1016/0049-3848(91)90063-3 [doi]
PST - ppublish
SO  - Thromb Res. 1991 Dec 15;64(6):631-6. doi: 10.1016/0049-3848(91)90063-3.

PMID- 3110026
OWN - NLM
STAT- MEDLINE
DCOM- 19870730
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 17
IP  - 1-2
DP  - 1987
TI  - Influence of heparin, aspirin, streptokinase and factor VIII (AHF) on amorphous 
      electron-dense substance, a mediator of platelet and thrombus adhesion in vivo.
PG  - 59-65
AB  - Platelet adherence and aggregation on vessel walls are the first crucial steps in 
      thrombogenesis and atherosclerosis. Whether platelets can be activated on damaged 
      endothelial cells or their activation is achieved only when subendothelial 
      structures are exposed was controversially discussed in the past. Recently, an 
      electron-microscopic study has revealed an amorphous electron-dense substance 
      (AEDS) after endothelial cell damage and has discussed its role as a possible 
      trigger of thrombogenesis. The aim of the present study is to elucidate the role 
      and origin of this substance and to investigate the influence which inhibitors of 
      platelet function (acetylsalicylic acid), coagulation (heparin), stimulation of 
      fibrinolysis (streptokinase) and addition of factor VIII (AHF) have on AEDS.
FAU - Herrmann, K S
AU  - Herrmann KS
FAU - Voigt, W H
AU  - Voigt WH
FAU - Kreuzer, H
AU  - Kreuzer H
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 9001-27-8 (Factor VIII)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adhesiveness
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - *Blood Coagulation
MH  - Blood Platelets/*metabolism
MH  - Cricetinae
MH  - Endothelium/metabolism
MH  - Factor VIII/*pharmacology
MH  - Heparin/*pharmacology
MH  - Mesocricetus
MH  - *Platelet Adhesiveness
MH  - Streptokinase/*pharmacology
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
AID - 10.1159/000215559 [doi]
PST - ppublish
SO  - Haemostasis. 1987;17(1-2):59-65. doi: 10.1159/000215559.

PMID- 25269896
OWN - NLM
STAT- MEDLINE
DCOM- 20150409
LR  - 20141001
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 127
IP  - 19
DP  - 2014
TI  - Platelet function monitoring guided antiplatelet therapy in patients receiving 
      high-risk coronary interventions.
PG  - 3364-70
AB  - BACKGROUND: Large-scale clinical trials have shown that routine monitoring of the 
      platelet function in patients after percutanous coronary intervention (PCI) is 
      not necessary. However, it is still unclear whether patients received high-risk 
      PCI would benefit from a therapy which is guided by a selective platelet function 
      monitoring. This explanatory study sought to assess the benefit of a therapy 
      guided by platelet function monitoring for these patients. METHODS: Acute 
      coronary syndrome (ACS) patients (n = 384) who received high-risk, complex PCI 
      were randomized into two groups. PCI in the two types of lesions described below 
      was defined as high-risk, complex PCI: lesions that could result in severe 
      clinical outcomes if stent thrombosis occurred or lesions at high risk for stent 
      thrombosis. The patients in the conventionally treated group received standard 
      dual antiplatelet therapy. The patients in the platelet function monitoring 
      guided group received an antiplated therapy guided by a modified 
      thromboelastography (TEG) platelet mapping: If inhibition of platelet aggregation 
      (IPA) induced by arachidonic acid (AA) was less than 50% the aspirin dosage was 
      raised to 200 mg/d; if IPA induced by adenosine diphosphate (ADP) was less than 
      30% the clopidogrel dosage was raised to 150 mg/d, for three months. The primary 
      efficacy endpoint was a composite of myocardial infarction, emergency target 
      vessel revascularization (eTVR), stent thrombosis, and death in six months. 
      RESULTS: This study included 384 patients; 191 and 193 in the conventionally 
      treated group and platelet function monitoring guided group, respectively. No 
      significant differences were observed in the baseline clinical characteristics 
      and interventional data between the two groups. In the platelet function 
      monitoring guided group, the mean IPA induced by AA and ADP were (69.2 ± 24.5)% 
      (range, 4.8% to 100.0%) and (51.4 ± 29.8)% (range, 0.2% to 100.0%), respectively. 
      The AA-induced IPA of forty-three (22.2%) patients was less than 50% and the 
      ADP-induced IPA of fifty-seven (29.5%) patients was less than 30%; therefore, 
      their drug dosages were adjusted. The TEG was rechecked one to four weeks after 
      PCI, and the results indicated that the IPAs had significantly improved (P < 
      0.01). However, no significant differences were found in the rates of the primary 
      efficacy endpoint. Rates in the conventionally treated group and platelet 
      function monitoring guided group were 4.7% and 5.2%, respectively (hazard ratio: 
      1.13; P = 0.79). CONCLUSION: An antiplatelet therapy guided by TEG monitored 
      platelet function could not improve clinical efficacy even in ACS patients 
      treated with high-risk complex PCI.
FAU - Xu, Li
AU  - Xu L
AD  - Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 
      100020, China.
FAU - Wang, Lefeng
AU  - Wang L
AD  - Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 
      100020, China.
FAU - Yang, Xinchun
AU  - Yang X
AD  - Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 
      100020, China. Email: imxuli@hotmail.com.
FAU - Li, Kuibao
AU  - Li K
AD  - Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 
      100020, China.
FAU - Sun, Hao
AU  - Sun H
AD  - Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 
      100020, China.
FAU - Zhang, Dapeng
AU  - Zhang D
AD  - Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 
      100020, China.
FAU - Wang, Hongshi
AU  - Wang H
AD  - Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 
      100020, China.
FAU - Li, Weiming
AU  - Li W
AD  - Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 
      100020, China.
FAU - Ni, Zhuhua
AU  - Ni Z
AD  - Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 
      100020, China.
FAU - Xia, Kun
AU  - Xia K
AD  - Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 
      100020, China.
FAU - Liu, Yu
AU  - Liu Y
AD  - Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 
      100020, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aged
MH  - Arachidonic Acid/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2014/10/02 06:00
MHDA- 2015/04/10 06:00
CRDT- 2014/10/02 06:00
PHST- 2014/10/02 06:00 [entrez]
PHST- 2014/10/02 06:00 [pubmed]
PHST- 2015/04/10 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2014;127(19):3364-70.

PMID- 9141257
OWN - NLM
STAT- MEDLINE
DCOM- 19970529
LR  - 20190914
IS  - 0374-5600 (Print)
IS  - 0374-5600 (Linking)
VI  - 39
IP  - 2
DP  - 1997 Apr
TI  - Evaluation of sponging and antipyretic medication to reduce body temperature in 
      febrile children.
PG  - 215-7
AB  - Two hundred and twenty-four children aged 6 months to 5 years, with rectal 
      temperatures greater than or equal to 30 degrees (104 degrees F), were randomly 
      treated with sponging alone or with medication including a single oral dose of 
      aspirin 15 mg/kg, or paracetamol 15 mg/kg, or ibuprofen 8 mg/kg. Twenty-three 
      children were excluded from the final analysis because they did not complete the 
      study. Demographic characteristics of the patients were found to be comparable in 
      all groups. Rectal temperatures were recorded every 30 min for a 3 h period. 
      During the first 30 min of intervention, sponging was found to be more effective 
      than all of the three medications. After 60 min, the effects of each medication 
      became superior to sponging with tepid water in reducing body temperature. 
      Twenty-three children were excluded from the final analysis because they did not 
      complete the study. Comparing the effect of the three different medications, it 
      was seen that the antipyretic efficacy of aspirin and ibuprofen were 
      significantly more than paracetamol 3 h after intervention (P < 0.05). For the 
      management of fever over 39 degrees C, it is therefore recommended to give 
      children an antipyretic drug, preferably ibuprofen, and at the same time to begin 
      sponging to provide a rapid and sustained antipyresis
FAU - Aksoylar, S
AU  - Aksoylar S
AD  - Department of Pediatrics, SSK Tepecik Teaching Hospital, Yenisehir, Izmir, 
      Turkey.
FAU - Akşit, S
AU  - Akşit S
FAU - Cağlayan, S
AU  - Cağlayan S
FAU - Yaprak, I
AU  - Yaprak I
FAU - Bakiler, R
AU  - Bakiler R
FAU - Cetin, F
AU  - Cetin F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Australia
TA  - Acta Paediatr Jpn
JT  - Acta paediatrica Japonica : Overseas edition
JID - 0370357
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 059QF0KO0R (Water)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Analgesics, Non-Narcotic/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Baths
MH  - Child, Preschool
MH  - Female
MH  - Fever/*therapy
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Infant
MH  - Male
MH  - Temperature
MH  - Treatment Outcome
MH  - Water
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - 10.1111/j.1442-200x.1997.tb03584.x [doi]
PST - ppublish
SO  - Acta Paediatr Jpn. 1997 Apr;39(2):215-7. doi: 10.1111/j.1442-200x.1997.tb03584.x.

PMID- 18617299
OWN - NLM
STAT- MEDLINE
DCOM- 20081209
LR  - 20220311
IS  - 0268-960X (Print)
IS  - 0268-960X (Linking)
VI  - 22
IP  - 5
DP  - 2008 Sep
TI  - Management of Philadelphia negative chronic myeloproliferative disorders in 
      pregnancy.
PG  - 235-45
LID - 10.1016/j.blre.2008.03.007 [doi]
AB  - The management of pregnancy in Philadelphia negative chronic myeloproliferative 
      disorders (CMPDs) is an increasingly frequent problem. In the literature, most 
      pregnancies are reported for women with essential thrombocythemia (ET) with about 
      400 pregnancies in about 200 women. In ET, first trimester abortion is the most 
      frequent complication occurring in about one third of pregnancies. Interestingly, 
      the incidence of maternal complications is relatively low with 3% for major 
      thromboembolic and 2% for major bleeding events. The presence of the Jak2 
      mutation seems to be an independent predictor of pregnancy complications. 
      Pregnancies in ET should be stratified according to underlying risk factors in 
      low, high and highest risk pregnancies. Women with low risk pregnancies are 
      treated with low-dose aspirin, whereas women with high and higher risk 
      pregnancies may benefit from low-dose aspirin plus interferon alpha +/- low 
      molecular weight heparin throughout pregnancy and at least for six weeks 
      post-partum. In polycythemia vera (PV) there is only very few information on 
      pregnancy outcome with 36 pregnancies reported in the literature. According to 
      these data pregnancy in PV is per se a high risk situation. Accordingly, all 
      women with PV should be treated with low-dose aspirin. Some pregnant PV patients 
      may benefit from a more intensive therapy including interferon alpha +/- low 
      molecular weight heparin throughout pregnancy and at least for six weeks 
      post-partum.
FAU - Griesshammer, Martin
AU  - Griesshammer M
AD  - Department of Medicine III, Robert-Koch-Strasse 8, D-89081 Ulm, Federal Republic 
      of Germany. martin.griesshammer@medizin.uni-ulm.de
FAU - Struve, Sabine
AU  - Struve S
FAU - Barbui, Tiziano
AU  - Barbui T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20080709
PL  - England
TA  - Blood Rev
JT  - Blood reviews
JID - 8708558
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Polycythemia Vera/*drug therapy
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*drug therapy
MH  - Thrombocythemia, Essential/*drug therapy
RF  - 38
EDAT- 2008/07/12 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/07/12 09:00
PHST- 2008/07/12 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/07/12 09:00 [entrez]
AID - S0268-960X(08)00026-X [pii]
AID - 10.1016/j.blre.2008.03.007 [doi]
PST - ppublish
SO  - Blood Rev. 2008 Sep;22(5):235-45. doi: 10.1016/j.blre.2008.03.007. Epub 2008 Jul 
      9.

PMID- 16110127
OWN - NLM
STAT- MEDLINE
DCOM- 20060127
LR  - 20191109
IS  - 0098-8243 (Print)
IS  - 0098-8243 (Linking)
VI  - 31
IP  - 3
DP  - 2005 Fall
TI  - Aspirin for the primary prevention of cardiovascular disease: a comprehensive 
      review.
PG  - 186-93
AB  - Aspirin use for the primary prevention of cardiovascular disease should be 
      targeted to patients with a high cardiovascular risk. Physicians should assess 
      the risks and benefits of aspirin therapy for primary prevention and incorporate 
      patient preferences.
FAU - Rodondi, Nicolas
AU  - Rodondi N
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco, CA, USA. Nicolas.Rodondi@hospvd.ch
FAU - Cornuz, Jacques
AU  - Cornuz J
FAU - Bauer, Douglas C
AU  - Bauer DC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Compr Ther
JT  - Comprehensive therapy
JID - 7605837
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cerebral Hemorrhage/etiology
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Hemorrhage/etiology
MH  - Humans
MH  - Patient Participation
MH  - *Primary Prevention
MH  - Risk Assessment
RF  - 67
EDAT- 2005/08/20 09:00
MHDA- 2006/01/28 09:00
CRDT- 2005/08/20 09:00
PHST- 2005/04/06 00:00 [received]
PHST- 2005/04/18 00:00 [accepted]
PHST- 2005/08/20 09:00 [pubmed]
PHST- 2006/01/28 09:00 [medline]
PHST- 2005/08/20 09:00 [entrez]
AID - COMP:31:3:186 [pii]
AID - 10.1385/comp:31:3:186 [doi]
PST - ppublish
SO  - Compr Ther. 2005 Fall;31(3):186-93. doi: 10.1385/comp:31:3:186.

PMID- 3086120
OWN - NLM
STAT- MEDLINE
DCOM- 19860714
LR  - 20141120
IS  - 0430-0920 (Print)
IS  - 0430-0920 (Linking)
VI  - 41
IP  - 3
DP  - 1986 Mar
TI  - Relationship between structure and activity of aspirin-related compounds on the 
      inhibition of in vitro platelet aggregation.
PG  - 205-14
AB  - Thirteen aspirin-related compounds were tested for inhibitory activity on 
      platelet aggregation in human platelet rich plasma (PRP) induced with ADP, 
      collagen and arachidonic acid. The following structure-activity relationships 
      were found: none of the functional groups used to replace the acetyl group 
      retained the significant antiaggregant activity of aspirin; anti-aggregant 
      activity was enhanced when the carboxylic group was replaced with a hydroxyl or 
      an acetylated hydroxyl group. The activity of these mono and diacetylated 
      pyrocatechol derivatives was unaffected by incubation of PRP with sodium 
      salicylate.
FAU - Dupin, J P
AU  - Dupin JP
FAU - Gravier, D
AU  - Gravier D
FAU - Casadebaig, F
AU  - Casadebaig F
FAU - Boisseau, M R
AU  - Boisseau MR
FAU - Bernard, H
AU  - Bernard H
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Farmaco Sci
JT  - Il Farmaco; edizione scientifica
JID - 0370716
RN  - 0 (Arachidonic Acids)
RN  - 0 (Salicylates)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Arachidonic Acid
MH  - Arachidonic Acids/pharmacology
MH  - Aspirin/*pharmacology
MH  - Collagen/pharmacology
MH  - Drug Interactions
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Aggregation/*drug effects
MH  - Salicylates/pharmacology
MH  - Structure-Activity Relationship
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
PST - ppublish
SO  - Farmaco Sci. 1986 Mar;41(3):205-14.

PMID- 26156378
OWN - NLM
STAT- MEDLINE
DCOM- 20170419
LR  - 20181202
IS  - 1478-6427 (Electronic)
IS  - 1478-6419 (Linking)
VI  - 30
IP  - 13
DP  - 2016 Jul
TI  - Enhanced daidzin production from jasmonic and acetyl salicylic acid elicited 
      hairy root cultures of Psoralea corylifolia L. (Fabaceae).
PG  - 1542-7
LID - 10.1080/14786419.2015.1054823 [doi]
AB  - Daidzin (7-O-glucoside of daidzein) has several pharmacological benefits in 
      herbal remedy, as antioxidant and shown antidipsotropic activity. Hairy root 
      culture of Psoralea corylifolia L. was developed for biomass and enhanced daidzin 
      production using signalling compounds such as jasmonic acid (JA) and acetyl 
      salicylic acid (ASA). Best response of 2.8-fold daidzin (5.09% DW) with 1 μM JA 
      treatment after second week and 7.3-fold (3.43% DW) with 10 μM JA elicitation 
      after 10th week was obtained from hairy roots compared to untreated control. ASA 
      at 10 μM promoted 1.7-fold increase in daidzin (1.49% DW) content after seventh 
      week compared to control (0.83% DW). Addition of 25 μM ASA resulted in 1.44% DW 
      daidzin (1.5-fold increase) with 0.91% DW in control after fifth week and 1.44% 
      DW daidzin (2.3-fold increase) after eighth week when compared to untreated 
      control (0.62% DW). Reduced biomass with increased daidzin content was 
      facilitated by elicited hairy root cultures.
FAU - Zaheer, Mohd
AU  - Zaheer M
AD  - a Centre for Plant Molecular Biology (CPMB) , Osmania University , Hyderabad 
      500007 , Telangana , India.
FAU - Reddy, Vudem Dashavantha
AU  - Reddy VD
AD  - a Centre for Plant Molecular Biology (CPMB) , Osmania University , Hyderabad 
      500007 , Telangana , India.
FAU - Giri, Charu Chandra
AU  - Giri CC
AD  - a Centre for Plant Molecular Biology (CPMB) , Osmania University , Hyderabad 
      500007 , Telangana , India.
LA  - eng
PT  - Journal Article
DEP - 20150708
PL  - England
TA  - Nat Prod Res
JT  - Natural product research
JID - 101167924
RN  - 0 (Cyclopentanes)
RN  - 0 (Isoflavones)
RN  - 0 (Oxylipins)
RN  - 4R2X91A5M5 (daidzin)
RN  - 6RI5N05OWW (jasmonic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Biomass
MH  - Cyclopentanes/*pharmacology
MH  - Isoflavones/*biosynthesis
MH  - Oxylipins/*pharmacology
MH  - Plant Roots/metabolism
MH  - Psoralea/*metabolism
OTO - NOTNLM
OT  - acetyl salicylic acid
OT  - daidzin
OT  - elicitation
OT  - hairy root culture
OT  - jasmonic acid
OT  - yield enhancement
EDAT- 2015/07/15 06:00
MHDA- 2017/04/20 06:00
CRDT- 2015/07/10 06:00
PHST- 2015/07/10 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2017/04/20 06:00 [medline]
AID - 10.1080/14786419.2015.1054823 [doi]
PST - ppublish
SO  - Nat Prod Res. 2016 Jul;30(13):1542-7. doi: 10.1080/14786419.2015.1054823. Epub 
      2015 Jul 8.

PMID- 15386703
OWN - NLM
STAT- MEDLINE
DCOM- 20050721
LR  - 20131121
IS  - 1053-8569 (Print)
IS  - 1053-8569 (Linking)
VI  - 14
IP  - 4
DP  - 2005 Apr
TI  - Frequent monthly use of selected non-prescription and prescription non-narcotic 
      analgesics among U.S. adults.
PG  - 257-66
AB  - PURPOSE: Analgesics offer many benefits, however, chronic, long-term use may pose 
      risks of adverse drug events. The objective of this study was to estimate 
      frequent monthly non-narcotic analgesic use among U.S. adults, identifying 
      socio-demographic trends and potentially at-risk groups. METHODS: Analysis of 
      adult medication use data from the 1999-2000 National Health and Nutrition 
      Examination Survey household interview (n = 4880). RESULTS: Some 20% of U.S. 
      adults used non-prescription or prescription non-narcotic analgesics on a 
      frequent basis, that is nearly every day for a month, at some point during their 
      lifetime. Also, 14% of U.S. adults were currently using analgesics frequently. 
      Aspirin was most commonly used (8%), followed by non-aspirin non-steroidal 
      anti-inflammatory drugs (NANSAID, 3%) and acetaminophen (3%). Three-quarters of 
      aspirin, 46% of NANSAID and 63% of acetaminophen users were long-term frequent 
      monthly users (1+ years). Seven percent of frequent monthly analgesic users 
      reported using two or more analgesics nearly every day during the month. Frequent 
      analgesic use was most common among older adults and non-Hispanic whites with no 
      differences by gender or education. Use patterns, however, varied by analgesic 
      subgroups. CONCLUSIONS: Frequent monthly non-narcotic analgesic use, especially 
      of over-the-counter analgesics, is widely prevalent among U.S. adults. 
      Health-care providers should heighten their awareness of this trend, and 
      routinely monitor both non-prescription and prescription analgesic use in their 
      patients to prevent adverse drug effects and inappropriate use.
FAU - Paulose-Ram, Ryne
AU  - Paulose-Ram R
AD  - Division of Health and Nutrition Examination Surveys, National Center for Health 
      Statistics, Centers for Disease Control and Prevention, Hyattsville, MD 20782, 
      USA. RPaulose@cdc.gov
FAU - Hirsch, Rosemarie
AU  - Hirsch R
FAU - Dillon, Charles
AU  - Dillon C
FAU - Gu, Qiuping
AU  - Gu Q
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Analgesics, Non-Narcotic/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Utilization/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nonprescription Drugs/*therapeutic use
MH  - Nutrition Surveys
MH  - United States
EDAT- 2004/09/24 05:00
MHDA- 2005/07/22 09:00
CRDT- 2004/09/24 05:00
PHST- 2004/09/24 05:00 [pubmed]
PHST- 2005/07/22 09:00 [medline]
PHST- 2004/09/24 05:00 [entrez]
AID - 10.1002/pds.983 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2005 Apr;14(4):257-66. doi: 10.1002/pds.983.

PMID- 28134659
OWN - NLM
STAT- MEDLINE
DCOM- 20180406
LR  - 20181202
IS  - 1538-943X (Electronic)
IS  - 1058-2916 (Linking)
VI  - 63
IP  - 5
DP  - 2017 Sep/Oct
TI  - Assessment of Bleeding and Thrombosis Based on Aspirin Responsiveness after 
      Continuous-Flow Left Ventricular Assist Device Placement.
PG  - 578-587
LID - 10.1097/MAT.0000000000000535 [doi]
AB  - Pump thrombosis (PT) is a severe complication of left ventricular assist device 
      (LVAD) support. This study evaluated PT and bleeding after LVAD placement in 
      patients responsive to a standard aspirin dose of 81 mg using platelet inhibition 
      monitoring compared with initial nonresponders who were then titrated upward to 
      achieve therapeutic response. Patients ≥ 18 years of age with initial placement 
      of HeartMate II LVAD at our institution and at least one VerifyNow Aspirin test 
      performed during initial hospitalization were included. The primary endpoints 
      were bleeding and PT compared between initial aspirin responders and 
      nonresponders. Of 85 patients, 19 (22%) were nonresponsive to initial aspirin 
      therapy. Responders and nonresponders showed similar survival (p = 0.082), 
      freedom from suspected/confirmed PT (p = 0.941), confirmed PT (p = 0.273), 
      bleeding (p = 0.401), and incidence rates in PT and bleeding. Among the initial 
      responders (<500 vs. 500-549 aspirin reaction units), there were no significant 
      differences in survival (p = 0.177), freedom from suspected/confirmed PT (p = 
      0.542), confirmed PT (p = 0.159), bleeding (p = 0.879), and incidence of PT and 
      bleeding. Platelet function testing may detect resistance to standard aspirin 
      regimens used in LVAD patients. Dose escalation in initially nonresponsive 
      patients to achieve responsiveness may confer a similar PT risk to patients 
      initially responsive to standard aspirin dosing without increased bleeding risk.
FAU - Floroff, Catherine K
AU  - Floroff CK
AD  - From the *Department of Pharmacy Services, Medical University of South Carolina, 
      Charleston, South Carolina; Divisions of †Division of Cardiothoracic Surgery, 
      Medical University of South Carolina and ‡Cardiology, Medical University of South 
      Carolina, Charleston, South Carolina; §Heart Failure and Cardiac Transplantation, 
      The Lewis Katz School of Medicine at Temple University, Philadelphia, 
      Pennsylvania; ¶Sarver Heart Center, University of Arizona, Tucson, Arizona; and 
      ‖Department of Pathology and Laboratory Medicine, Medical University of South 
      Carolina, Charleston, South Carolina.
FAU - Rieger, Krista L
AU  - Rieger KL
FAU - Veasey, Tara M
AU  - Veasey TM
FAU - Strout, Sara E
AU  - Strout SE
FAU - DeNino, Walter F
AU  - DeNino WF
FAU - Meadows, Holly B
AU  - Meadows HB
FAU - Stroud, Martha R
AU  - Stroud MR
FAU - Toole, John M
AU  - Toole JM
FAU - Heyward, Dawn P
AU  - Heyward DP
FAU - Brisco-Bacik, Meredith A
AU  - Brisco-Bacik MA
FAU - Cook, Jennifer L
AU  - Cook JL
FAU - Lazarchick, John
AU  - Lazarchick J
FAU - Uber, Walter E
AU  - Uber WE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - ASAIO J
JT  - ASAIO journal (American Society for Artificial Internal Organs : 1992)
JID - 9204109
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Heart Failure/therapy
MH  - Heart-Assist Devices/*adverse effects
MH  - Hemorrhage/*epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Retrospective Studies
MH  - Thrombosis/*epidemiology
MH  - Young Adult
EDAT- 2017/01/31 06:00
MHDA- 2018/04/07 06:00
CRDT- 2017/01/31 06:00
PHST- 2017/01/31 06:00 [pubmed]
PHST- 2018/04/07 06:00 [medline]
PHST- 2017/01/31 06:00 [entrez]
AID - 10.1097/MAT.0000000000000535 [doi]
PST - ppublish
SO  - ASAIO J. 2017 Sep/Oct;63(5):578-587. doi: 10.1097/MAT.0000000000000535.

PMID- 17455339
OWN - NLM
STAT- MEDLINE
DCOM- 20070614
LR  - 20131121
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 96
IP  - 5
DP  - 2007 May
TI  - Dielectric relaxation and crystallization of ultraviscous melt and glassy states 
      of aspirin, ibuprofen, progesterone, and quinidine.
PG  - 1159-75
AB  - Molecular relaxation in ultraviscous melt and glassy states of aspirin, 
      ibuprofen, progesterone, and quinidine has been studied by dielectric 
      spectroscopy. The asymmetric relaxation spectra is characterized by the 
      Kohlrausch distribution parameter of 0.46 +/- 0.02 for aspirin to 0.67 +/- 0.02 
      for progesterone. The dielectric relaxation time varies with the temperature, T, 
      according to the Vogel-Fulcher-Tammann Equation, log(10)(tau(0)) = A(VFT) + 
      [B(VFT)/(T - T(0))], where A(VFT), B(VFT), and T(0) are empirical constants. The 
      extrapolated tau(0) at calorimetric glass-softening temperature is close to the 
      value expected. The equilibrium permittivity, epsilon(0), is lowest for ibuprofen 
      which indicates an antiparallel orientation of dipoles in its liquid's 
      hydrogen-bonded structure. A decrease in epsilon(0) with time shows that 
      ultraviscous aspirin, progesterone, and quinidine begin to cold-crystallize at a 
      relatively lower temperature than ibuprofen. epsilon(0) of the cold-crystallized 
      phases are, 4.7 for aspirin at 290 K, 2.55 for ibuprofen at 287 K, 2.6 for 
      progesterone at 320 K, and 3.2 for quinidine at 375 K. It is argued that 
      hydrogen-bonding, the Kohlrausch parameter, extent of localized motions and the 
      long-range diffusion times all determine the physical and chemical stability of 
      an amorphous pharmaceutical during storage.
CI  - (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.
FAU - Johari, G P
AU  - Johari GP
AD  - Department of Materials Science and Engineering, McMaster University, Hamilton, 
      Ontario, Canada L8S 4L7. joharig@mcmaster.ca
FAU - Kim, S
AU  - Kim S
FAU - Shanker, Ravi M
AU  - Shanker RM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Solutions)
RN  - 4G7DS2Q64Y (Progesterone)
RN  - ITX08688JL (Quinidine)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aspirin/*chemistry
MH  - Chemistry, Pharmaceutical
MH  - Drug Stability
MH  - Drug Storage
MH  - Hydrogen Bonding
MH  - Ibuprofen/*chemistry
MH  - Models, Chemical
MH  - Molecular Conformation
MH  - Motion
MH  - *Phase Transition
MH  - Progesterone/*chemistry
MH  - Quinidine/*chemistry
MH  - Solutions
MH  - Spectrum Analysis/*methods
MH  - Technology, Pharmaceutical/*methods
MH  - Temperature
MH  - Viscosity
EDAT- 2007/04/25 09:00
MHDA- 2007/06/15 09:00
CRDT- 2007/04/25 09:00
PHST- 2007/04/25 09:00 [pubmed]
PHST- 2007/06/15 09:00 [medline]
PHST- 2007/04/25 09:00 [entrez]
AID - S0022-3549(16)32262-6 [pii]
AID - 10.1002/jps.20921 [doi]
PST - ppublish
SO  - J Pharm Sci. 2007 May;96(5):1159-75. doi: 10.1002/jps.20921.

PMID- 10697085
OWN - NLM
STAT- MEDLINE
DCOM- 20000328
LR  - 20190711
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 48
IP  - 2
DP  - 2000 Feb
TI  - Deep vein thrombosis prophylaxis in hip fractures: a comparison of the 
      arteriovenous impulse system and aspirin.
PG  - 268-72
AB  - BACKGROUND: A prospective, randomized controlled trial was used to compare the 
      efficacy of the arteriovenous (AV) impulse system and aspirin in reducing venous 
      thrombosis after fracture to the femoral neck. METHODS: A total of 143 patients 
      underwent hemiarthroplasty, after which 70 patients were treated with the AV pump 
      and a second group of 73 patients were commenced on 325 mg of aspirin. Duplex 
      ultrasound was used to assess both proximal and distal venous thrombi on days 7 
      to 10. Calf and thigh circumferences were also measured. RESULTS: Thrombi 
      developed in seven of the patients treated with aspirin and in four patients 
      treated with the AV pump. No statistically significant difference could be 
      established (p = 0.109). There was a significant reduction in both calf (p = 
      0.003) and thigh (p = 0.002) swelling in the group treated with the AV pump. 
      Neither treatment group was a significant predictor of a poorer outcome by using 
      logistical regression analysis (p = 0.258). CONCLUSIONS: Both aspirin and the AV 
      pump are effective in reducing thromboembolic events after hemiarthroplasty of 
      the hip.
FAU - Kennedy, J G
AU  - Kennedy JG
AD  - Department of Orthopaedic Surgery, Mater Misericordiae Hospital, University 
      College of Dublin, Ireland.
FAU - Soffe, K E
AU  - Soffe KE
FAU - Rogers, B W
AU  - Rogers BW
FAU - Kumar, S
AU  - Kumar S
FAU - Griffen, D R
AU  - Griffen DR
FAU - Dallo Vedova, P A
AU  - Dallo Vedova PA
FAU - Sullivan, R J
AU  - Sullivan RJ
FAU - Sheehan, L J
AU  - Sheehan LJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiology/instrumentation
MH  - Female
MH  - Femoral Neck Fractures/*complications
MH  - Humans
MH  - Leg/blood supply
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Venous Thrombosis/*etiology/*prevention & control
EDAT- 2000/03/04 09:00
MHDA- 2000/04/01 09:00
CRDT- 2000/03/04 09:00
PHST- 2000/03/04 09:00 [pubmed]
PHST- 2000/04/01 09:00 [medline]
PHST- 2000/03/04 09:00 [entrez]
AID - 10.1097/00005373-200002000-00012 [doi]
PST - ppublish
SO  - J Trauma. 2000 Feb;48(2):268-72. doi: 10.1097/00005373-200002000-00012.

PMID- 2237968
OWN - NLM
STAT- MEDLINE
DCOM- 19901220
LR  - 20161122
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 21
IP  - 11 Suppl
DP  - 1990 Nov
TI  - Progress report of the Stroke Prevention in Atrial Fibrillation Study.
PG  - III12-7
AB  - The Stroke Prevention in Atrial Fibrillation Study recently found and reported 
      (SPAF Investigators, N Engl J Med, 1990;322:863-868) a beneficial effect of both 
      warfarin and aspirin compared with placebo in the primary prevention of ischemic 
      stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 
      Among warfarin-eligible patients, the event rates were 1.6%/yr for those 
      receiving active antithrombotic therapy (warfarin or aspirin) and 8.3%/yr for 
      those receiving placebo (p less than 0.00005) (risk reduction 81%, 95% confidence 
      interval 56-91). Ironically, we did not find a beneficial effect of aspirin in 
      warfarin-ineligible patients. On the basis of these results, the study has been 
      reshaped to directly compare these two antithrombotic agents. Insight into the 
      apparent aspirin unresponsiveness noted in some patients also is being sought. 
      Interpretation of the preliminary results and the reshaping of the study have 
      been made more complex by the continued blinding of the investigators to certain 
      portions of the data. Presented is an account of the study from its inception 
      through its recent redesign.
FAU - Anderson, D C
AU  - Anderson DC
AD  - Department of Neurology, Hennepin County Medical Center, Minneapolis, Minn 55415.
LA  - eng
GR  - R01-NS-24224/NS/NINDS NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Placebos)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/complications/*prevention & control
MH  - Cerebrovascular Disorders/etiology/*prevention & control
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Placebos
MH  - Warfarin/therapeutic use
EDAT- 1990/11/01 00:00
MHDA- 1990/11/01 00:01
CRDT- 1990/11/01 00:00
PHST- 1990/11/01 00:00 [pubmed]
PHST- 1990/11/01 00:01 [medline]
PHST- 1990/11/01 00:00 [entrez]
PST - ppublish
SO  - Stroke. 1990 Nov;21(11 Suppl):III12-7.

PMID- 2716205
OWN - NLM
STAT- MEDLINE
DCOM- 19890622
LR  - 20131121
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 30
IP  - 1
DP  - 1989 Jan
TI  - [Clinical evaluation of the control of antiplatelet therapy through platelet 
      aggregation rate on polycythemia vera associated with thrombocytosis and 
      erythromelalgia].
PG  - 99-104
AB  - A 60-years-old woman with polycythemia vera with marked thrombocytosis and 
      intolerable erythromelalgia was presented. A single dose of 400 mg aspirin was 
      effective to improve the pain and cyanosis. And we studied the relationship 
      between platelet aggregation rate and symptoms after administration of several 
      antiplatelet drugs. A single dose of 100, 200, 400 and 800 mg aspirin, 25 mg 
      indomethacin (Id), 200 mg OKY-046, and daily dose of 300 and 600 mg dipyridamole 
      (Dp) and 300 mg ticlopidine (Tc) were given. Aspirin, Id and OKY-046 were 
      effective for the improvement of finger pain. The complete inhibition of 
      spontaneous aggregation (SPA) and aggregation by 2.0 micrograms/ml of collagen 
      were well parallel with the improvement of symptoms. But duration of effect of 
      LKY-046 were only 6 hours. Dp and Tc were not effective for the improvement of 
      pain, had no relation with platelet aggregation rate. The concentration level of 
      aspirin in vivo which suppresses the platelet aggregation induced by SPA and 2.0 
      micrograms/ml of collagen coincided well with the concentration level of this 
      drug which suppresses the same platelet aggregation in vitro. It seems to be 
      useful to suppress the platelet aggregation induced by SPA and 2.0 micrograms/ml 
      of collagen with aspirin and Id for controlling the platelet aggregation induced 
      circulatory disturbance in patient with thrombocytosis.
FAU - Kurihara, A
AU  - Kurihara A
FAU - Kobayashi, I
AU  - Kobayashi I
FAU - Tamura, K
AU  - Tamura K
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Drug Evaluation
MH  - Erythromelalgia/*drug therapy/etiology
MH  - Female
MH  - Fingers
MH  - Humans
MH  - Indomethacin/therapeutic use
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Polycythemia Vera/*complications
MH  - Thrombocytosis/*etiology
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Rinsho Ketsueki. 1989 Jan;30(1):99-104.

PMID- 6465177
OWN - NLM
STAT- MEDLINE
DCOM- 19840907
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 77
IP  - 2
DP  - 1984 Aug
TI  - Physician beliefs, attitudes, and prescribing behavior for anti-inflammatory 
      drugs.
PG  - 313-8
AB  - Psychologists have distinguished between "beliefs" and "attitudes" to help 
      explain human behavior. To investigate the relationship between physician 
      beliefs, attitudes, and their prescribing behavior for anti-inflammatory 
      medication, 30 doctors in two Veterans Administration clinics were surveyed by 
      questionnaire, and 1,265 of their prescriptions were collected. Their estimates 
      of drug costs and the percent of patients who would have response to therapy or 
      side effects were considered "beliefs." The "attitudes" measured were the 
      relative importance physicians placed on six factors when choosing therapy: 
      effectiveness, side effects, likelihood of compliance, placebo effect, cost, and 
      the patient's perception of the physician. Physicians believed that efficacy of 
      the different proprietary nonsteroidal anti-inflammatory agents and aspirin 
      compounds was comparable. They perceived indomethacin as more toxic than other 
      nonsteroidal anti-inflammatory drugs (p less than 0.01), and enteric-coated 
      aspirin as less toxic than plain aspirin (p less than 0.01). Physicians wrote 5.7 
      times as many prescriptions for proprietary nonsteroidal anti-inflammatory agents 
      as for aspirin compounds. A correlation was not observed between relative use of 
      proprietary agents versus aspirin compounds and beliefs about costs, response 
      rates, or side effects rates; however, attitudes regarding the importance of cost 
      and placebo effects were correlated with prescribing behavior (p less than 0.05).
FAU - Epstein, A M
AU  - Epstein AM
FAU - Read, J L
AU  - Read JL
FAU - Winickoff, R
AU  - Winickoff R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Aspirin/administration & dosage
MH  - *Attitude of Health Personnel
MH  - Costs and Cost Analysis
MH  - Decision Making
MH  - *Drug Prescriptions/economics
MH  - Humans
MH  - Physician-Patient Relations
MH  - Physicians/*psychology
MH  - Self-Assessment
MH  - Surveys and Questionnaires
MH  - United States
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 0002-9343(84)90709-5 [pii]
AID - 10.1016/0002-9343(84)90709-5 [doi]
PST - ppublish
SO  - Am J Med. 1984 Aug;77(2):313-8. doi: 10.1016/0002-9343(84)90709-5.

PMID- 3904438
OWN - NLM
STAT- MEDLINE
DCOM- 19851126
LR  - 20190626
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 79
IP  - 4B
DP  - 1985 Oct 18
TI  - Six-month, double-blind comparison of isoxicam with buffered aspirin in 
      rheumatoid arthritis.
PG  - 7-11
AB  - The results of a six-month, double-blind comparison of isoxicam (Maxicam), 200 mg 
      once a day, with buffered aspirin, 3,600 mg per day (900 mg four times a day), 
      showed that isoxicam was statistically significantly better than aspirin in eight 
      of 12 measures of efficacy. The study was carried out in 15 centers around the 
      United States in 191 patients with classic or definite rheumatoid arthritis. The 
      measures for which improvement with isoxicam was significantly better than 
      aspirin were number of tender joints, sum of tenderness scores, number of swollen 
      joints, sum of swelling scores, number of joints involved, grip strength, and 
      overall assessment of the patient's condition by physician and patient. The 
      measures for which the difference favoring isoxicam was not statistically 
      significant were duration of morning stiffness, time to walk 50 feet, and global 
      assessment of change in the patient's condition by physician and patient. The 
      results indicate that 200 mg of isoxicam once daily is effective for treating 
      rheumatoid arthritis. Compared with 3,600 mg of buffered aspirin daily, isoxicam 
      is better in relief of symptoms and at least as effective regarding improvement 
      in function.
FAU - Simson, J
AU  - Simson J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Thiazines)
RN  - 13T4O6VMAM (Piroxicam)
RN  - 8XU734C4NG (isoxicam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Piroxicam/*analogs & derivatives
MH  - Thiazines/*therapeutic use
EDAT- 1985/10/18 00:00
MHDA- 1985/10/18 00:01
CRDT- 1985/10/18 00:00
PHST- 1985/10/18 00:00 [pubmed]
PHST- 1985/10/18 00:01 [medline]
PHST- 1985/10/18 00:00 [entrez]
AID - 0002-9343(85)90174-3 [pii]
AID - 10.1016/0002-9343(85)90174-3 [doi]
PST - ppublish
SO  - Am J Med. 1985 Oct 18;79(4B):7-11. doi: 10.1016/0002-9343(85)90174-3.

PMID- 6635325
OWN - NLM
STAT- MEDLINE
DCOM- 19831220
LR  - 20131121
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 41
IP  - 2
DP  - 1983 Aug
TI  - The effect of 3-methoxy-5,7,3',4'-tetrahydroxyflavan on the restraint induced 
      gastric ulceration augmented by aspirin, a gastric mucosal barrier breaker.
PG  - 337-40
AB  - The gastric anti-ulcer activity of 3-methoxy-5,7,3',4'-tetrahydroxyflavan (ME), a 
      specific histidine decarboxylase inhibitor, has been studied on a new 
      experimental restraint rat model in which the ulcerogenic effect of 6 h restraint 
      stress was augmented by the prior treatment with 50mg/kg p.o. dose of aspirin. 
      Aspirin is a known gastric mucosal barrier breaker and it produces a significant 
      increase of the ulcer index in the restraint rat model. ME (ED50 22mg/kg) was 
      found to be more potent than cimetidine (ED50 31mg/kg) in this model. The results 
      of this study indicate that ME, which has been shown to possess significant 
      anti-ulcer activity against 24 h restraint, 19 h pylorus ligation and 
      phenylbutazone, aspirin and reserpine induced gastric ulcers, also possesses the 
      potential of protecting the gastric mucosal barrier. The restraint-aspirin model 
      described in this study is simple as compared to other models of stress induced 
      ulceration, moreover, it also implicates the damage of gastric mucosal barrier 
      and thus it can be used for screening the gastric anti-ulcer activity of drugs 
      providing more useful information.
FAU - Parmar, N S
AU  - Parmar NS
FAU - Hennings, G
AU  - Hennings G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Flavonoids)
RN  - 2H64SE2UXS (meciadanol)
RN  - 80061L1WGD (Cimetidine)
RN  - 8R1V1STN48 (Catechin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Anti-Ulcer Agents
MH  - Aspirin/pharmacology
MH  - Catechin/analogs & derivatives
MH  - Cimetidine/pharmacology
MH  - Flavonoids/*pharmacology
MH  - Gastric Mucosa/drug effects
MH  - Male
MH  - Rats
MH  - Restraint, Physical
MH  - Stomach Ulcer/*prevention & control
EDAT- 1983/08/01 00:00
MHDA- 1983/08/01 00:01
CRDT- 1983/08/01 00:00
PHST- 1983/08/01 00:00 [pubmed]
PHST- 1983/08/01 00:01 [medline]
PHST- 1983/08/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1983 Aug;41(2):337-40.

PMID- 15767819
OWN - NLM
STAT- MEDLINE
DCOM- 20050329
LR  - 20190717
IS  - 0002-9629 (Print)
IS  - 0002-9629 (Linking)
VI  - 329
IP  - 3
DP  - 2005 Mar
TI  - Retinal vein thrombosis as the presenting symptom of essential thrombocythemia.
PG  - 139-40
AB  - Visual loss resulting from retinal vascular disorders can be the presenting sign 
      of serious systemic disease. Associations between retinal vein thrombosis and 
      other systemic disorders have been well documented, but a comprehensive 
      literature search failed to reveal any report of essential thrombocythemia as a 
      cause of central retinal vein thrombosis. We describe the first young female 
      patient with symptomatic visual loss due to central retinal vein thrombosis as 
      her presenting symptom of essential thrombocythemia.
FAU - Tache, Jason Eli
AU  - Tache JE
AD  - Division of Hematology and Medical Oncology, Department of Medicine, Maimonides 
      Medical Center, Brooklyn, New York 11219, USA.
FAU - Saffra, Norman
AU  - Saffra N
FAU - Marshak, Harry
AU  - Marshak H
FAU - Aithal, Sramila
AU  - Aithal S
FAU - Novetsky, Allan
AU  - Novetsky A
FAU - Huang, Yi-Wu
AU  - Huang YW
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Diagnosis, Differential
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Retinal Vein Occlusion/*diagnosis/drug therapy
MH  - Thrombocytosis/*diagnosis
MH  - Vision Disorders/*etiology
EDAT- 2005/03/16 09:00
MHDA- 2005/03/30 09:00
CRDT- 2005/03/16 09:00
PHST- 2005/03/16 09:00 [pubmed]
PHST- 2005/03/30 09:00 [medline]
PHST- 2005/03/16 09:00 [entrez]
AID - S0002-9629(15)33895-7 [pii]
AID - 10.1097/00000441-200503000-00005 [doi]
PST - ppublish
SO  - Am J Med Sci. 2005 Mar;329(3):139-40. doi: 10.1097/00000441-200503000-00005.

PMID- 10501346
OWN - NLM
STAT- MEDLINE
DCOM- 19991103
LR  - 20191103
IS  - 0933-3657 (Print)
IS  - 0933-3657 (Linking)
VI  - 17
IP  - 1
DP  - 1999 Sep
TI  - Refining instructional text generation after evaluation.
PG  - 1-36
AB  - In this paper, we describe how user-adapted explanations about drug prescriptions 
      can be generated from already existing data sources. We start by illustrating the 
      two-step approach employed in the first version of the natural language generator 
      and the limitations of generated texts, that we discovered through analytical and 
      empirical evaluations. We claim that, although style refinement would be needed 
      in these texts, particular care should be devoted to implementing some of the 
      persuasion techniques that doctors employ in their explanations. This would 
      require either thoroughly revising the text planning techniques employed or 
      converting to a multistep generation architecture. We justify why we selected 
      this second alternative and propose some heuristics to repair problems found in 
      the first version of the generator. Some final considerations about the 
      advantages of this approach and the possibility of generalizing it to other 
      domains conclude the paper.
FAU - de Rosis, F
AU  - de Rosis F
AD  - Dipartimento di Informatica, Università di Bari, Italy. derosis@gauss.uniba.it
FAU - Grasso, F
AU  - Grasso F
FAU - Berry, D C
AU  - Berry DC
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Artif Intell Med
JT  - Artificial intelligence in medicine
JID - 8915031
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 50VV3VW0TI (Atenolol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Angina Pectoris/drug therapy
MH  - *Artificial Intelligence
MH  - Aspirin/therapeutic use
MH  - Atenolol/therapeutic use
MH  - *Decision Making, Computer-Assisted
MH  - *Drug Prescriptions
MH  - Evaluation Studies as Topic
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1999/09/29 00:00
MHDA- 1999/09/29 00:01
CRDT- 1999/09/29 00:00
PHST- 1999/09/29 00:00 [pubmed]
PHST- 1999/09/29 00:01 [medline]
PHST- 1999/09/29 00:00 [entrez]
AID - S0933-3657(99)00014-7 [pii]
AID - 10.1016/s0933-3657(99)00014-7 [doi]
PST - ppublish
SO  - Artif Intell Med. 1999 Sep;17(1):1-36. doi: 10.1016/s0933-3657(99)00014-7.

PMID- 8828290
OWN - NLM
STAT- MEDLINE
DCOM- 19961108
LR  - 20141120
IS  - 0301-1208 (Print)
IS  - 0301-1208 (Linking)
VI  - 33
IP  - 3
DP  - 1996 Jun
TI  - Influence of pentoxifylline and dispirin on aggregation and deformability of 
      erythrocytes under in vitro conditions.
PG  - 199-205
AB  - Aggregation mechanism and deformability in pentoxifylline- and dispirin-treated 
      erythrocytes are measured and compared with that of normal cells. The aggregation 
      process is analyzed in terms of parameters which are obtained from the sequential 
      recording of the transmitted light signal throughout the aggregate formation and 
      sedimentation process. Erythrocyte deformability is determined by measurement of 
      passage time through cellulose membrane. The variations in aggregation parameters 
      in pentoxifylline-treated samples show that the formed aggregates are of larger 
      size which sediment faster. In dispirin-treated cells, the formation of large 
      size aggregates is delayed. The entire process is completed faster in 
      pentoxifylline-treated compared to that of dispirin-treated cell whereas the 
      normal sample shows an intermediate value. The deformability of erythrocytes 
      treated with these drugs is increased.
FAU - Singh, M
AU  - Singh M
AD  - Biomedical Engineering Division, Indian Institute of Technology, Madras, India.
FAU - Kumaravel, M
AU  - Kumaravel M
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Biochem Biophys
JT  - Indian journal of biochemistry & biophysics
JID - 0310774
RN  - 0 (Vasodilator Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cell Aggregation/drug effects
MH  - Erythrocyte Deformability/*drug effects
MH  - Erythrocytes/cytology/*drug effects/physiology
MH  - Humans
MH  - In Vitro Techniques
MH  - Pentoxifylline/*pharmacology
MH  - Vasodilator Agents/*pharmacology
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Biochem Biophys. 1996 Jun;33(3):199-205.

PMID- 2030553
OWN - NLM
STAT- MEDLINE
DCOM- 19910617
LR  - 20190817
IS  - 0047-1828 (Print)
IS  - 0047-1828 (Linking)
VI  - 55
IP  - 3
DP  - 1991 Mar
TI  - Experimental studies on the mechanism of reversible pressor response in pulmonary 
      microembolism in the dog.
PG  - 271-80
AB  - In the present study, we examined the difference in hemodynamic responses between 
      groups of canine lung lobes which received latex particles of different sizes (50 
      microns and 300 microns in diameter). We also assayed prostaglandin I2 (PGI2) and 
      thromboxane A2 in the effluent blood of the lobes. Reversible pressor response 
      was clear in embolization by 50 micron particles whereas it was not in that by 
      300 microns. No difference in PGI2 between two embolizations was seen. We 
      conclude that a local contractile mechanism exists in the pulmonary arterial wall 
      of about 50 microns in diameter whereas participation of the same mechanism is 
      minimal in 300 microns, and that this difference cannot be explained from the 
      change in PGI2.
FAU - Kawamura, Y
AU  - Kawamura Y
AD  - First Department of Internal Medicine, Asahikawa Medical College, Japan.
FAU - Hasebe, N
AU  - Hasebe N
FAU - Matsuhashi, H
AU  - Matsuhashi H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Jpn Circ J
JT  - Japanese circulation journal
JID - 7806868
RN  - 0 (Latex)
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - *Blood Pressure
MH  - Dogs
MH  - Latex
MH  - Particle Size
MH  - Prostaglandins/pharmacology
MH  - Pulmonary Embolism/*physiopathology
MH  - Vasomotor System/drug effects/*physiopathology
EDAT- 1991/03/01 00:00
MHDA- 1991/03/01 00:01
CRDT- 1991/03/01 00:00
PHST- 1991/03/01 00:00 [pubmed]
PHST- 1991/03/01 00:01 [medline]
PHST- 1991/03/01 00:00 [entrez]
AID - 10.1253/jcj.55.271 [doi]
PST - ppublish
SO  - Jpn Circ J. 1991 Mar;55(3):271-80. doi: 10.1253/jcj.55.271.

PMID- 6457315
OWN - NLM
STAT- MEDLINE
DCOM- 19811222
LR  - 20131121
IS  - 0033-8419 (Print)
IS  - 0033-8419 (Linking)
VI  - 141
IP  - 2
DP  - 1981 Nov
TI  - Transluminal angioplasty of the iliac and femoral arteries: follow-up results 
      without anticoagulation.
PG  - 347-50
AB  - With the advent of the angiographic balloon catheter, transluminal angioplasty 
      has become a more effective procedure for the alleviation of symptoms of 
      peripheral ischemia. In the past two and a half years we have performed this 
      procedure on over 208 iliac and femoral arteries. One hundred twenty iliac 
      arteries were dilated. Of these, 86% remained patent at one year and 83% at two 
      years. Eighty-eight femoral arteries were dilated. Of these, 75% remained patent 
      at one year and 67% at two years. These vessel survival rates are slightly less 
      than those following surgery. However, the morbidity from transluminal 
      angioplasty is very low and the mortality is essentially zero.
FAU - Freiman, D B
AU  - Freiman DB
FAU - Spence, R
AU  - Spence R
FAU - Gatenby, R
AU  - Gatenby R
FAU - Gertner, M
AU  - Gertner M
FAU - Roberts, B
AU  - Roberts B
FAU - Berkowitz, H D
AU  - Berkowitz HD
FAU - Ring, E J
AU  - Ring EJ
FAU - Oleaga, J A
AU  - Oleaga JA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Radiology
JT  - Radiology
JID - 0401260
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Angioplasty, Balloon
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Female
MH  - *Femoral Artery
MH  - Follow-Up Studies
MH  - Humans
MH  - *Iliac Artery
MH  - Intermittent Claudication/*therapy
MH  - Male
MH  - Middle Aged
MH  - Vascular Resistance
MH  - Warfarin/therapeutic use
EDAT- 1981/11/01 00:00
MHDA- 1981/11/01 00:01
CRDT- 1981/11/01 00:00
PHST- 1981/11/01 00:00 [pubmed]
PHST- 1981/11/01 00:01 [medline]
PHST- 1981/11/01 00:00 [entrez]
AID - 10.1148/radiology.141.2.6457315 [doi]
PST - ppublish
SO  - Radiology. 1981 Nov;141(2):347-50. doi: 10.1148/radiology.141.2.6457315.

PMID- 7194074
OWN - NLM
STAT- MEDLINE
DCOM- 19810513
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 30
IP  - 12
DP  - 1980
TI  - Gastroprotective and anti-inflammatory properties of green lipped mussel (Perna 
      canaliculus) preparation.
PG  - 2128-32
AB  - Freeze-dried powdered preparations of whole (i.e. without shell) green-lipped 
      mussel (Perna canaliculus) from New Zealand given orally to rats showed some 
      modest anti-inflammatory activity (carrageenan paw oedema). This material 
      strikingly reduced the gastric ulcerogenicity of several non-steroid 
      anti-inflammatory drugs in rats and pigs. The gastroprotective activity in rats 
      was primarily associated with particular lipid fractions, which exhibited 
      differential protective activity against acetylsalicylic acid on the one hand and 
      indometacin on the other.
FAU - Rainsford, K D
AU  - Rainsford KD
FAU - Whitehouse, M W
AU  - Whitehouse MW
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/pharmacology
MH  - Bivalvia/*analysis
MH  - Female
MH  - Freeze Drying
MH  - Indomethacin/pharmacology
MH  - Male
MH  - Rats
MH  - Stomach Ulcer/chemically induced/*prevention & control
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1980;30(12):2128-32.

PMID- 483935
OWN - NLM
STAT- MEDLINE
DCOM- 19791129
LR  - 20131121
IS  - 0044-2542 (Print)
IS  - 0044-2542 (Linking)
VI  - 34
IP  - 9
DP  - 1979 May 1
TI  - [Functional peripheral ischemia].
PG  - 1-3-6
AB  - The terminal circulation which plays an important role in the thermoregulation 
      particularly at the periphery of the extremities is not infrequently irritated by 
      false multifactorial regulations. As their sequela an increased tonus of 
      vasoconstrictors and pathological vasodilatation lead to idiopathic and 
      symptomatic functional angiolopathies. Transitions into organic vascular 
      processes are no rarity. From the extreme functional behaviour patterns 
      complaints and symptoms of the individual angiolopathies may be derived. Clinic, 
      differential diagnostics and therapeutic possibilities of the angiopathic 
      reaction position, of the acrocyanosis and its variants, of the intermittent 
      functional acrosyndromes and of the erythromelalgia are treated from practical 
      points of view. In contrast to the secondary functional angiolopathies, in which 
      the basic disease is of decisive importance in questions concerning expertise, 
      the idiopathic forms alone are scarcely of high significance concerning the 
      restriction of the physical function.
FAU - Preuss, E G
AU  - Preuss EG
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Funktionelle periphere Durchblutungsstörungen.
PL  - Germany
TA  - Z Gesamte Inn Med
JT  - Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete
JID - 21730470R
RN  - 436O5HM03C (Dihydroergotamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/*complications/therapy
MH  - Aspirin/therapeutic use
MH  - Cyanosis/etiology
MH  - Dihydroergotamine/therapeutic use
MH  - Erythromelalgia/etiology
MH  - Hot Temperature
MH  - Humans
MH  - Neurocirculatory Asthenia/*etiology
MH  - Psychotherapy
MH  - Raynaud Disease/etiology
EDAT- 1979/05/01 00:00
MHDA- 1979/05/01 00:01
CRDT- 1979/05/01 00:00
PHST- 1979/05/01 00:00 [pubmed]
PHST- 1979/05/01 00:01 [medline]
PHST- 1979/05/01 00:00 [entrez]
PST - ppublish
SO  - Z Gesamte Inn Med. 1979 May 1;34(9):1-3-6.

PMID- 906524
OWN - NLM
STAT- MEDLINE
DCOM- 19771125
LR  - 20131121
IS  - 0043-5325 (Print)
IS  - 0043-5325 (Linking)
VI  - 89
IP  - 17
DP  - 1977 Sep 16
TI  - [Transport of salicylates from blood to joint fluid (author's transl)].
PG  - 599-602
AB  - Samples of blood and joint fluid from thirty patients who had taken 
      acetyl-salicylic acid were examined for occurrence of salicylates. The data were 
      arranged in groups according to the diagnosis of the joint disease and did not 
      show significant differences in the kinetics of salicylates into blood; the time 
      of the first appearance averaged 6.4 minutes, and levels "close to maximum 
      concentration" averaged 23 mg/l. In joint fluid, the time of first appearance of 
      salicylates ranged from 10 to 31 minutes, and levels of maximum concentration of 
      salicylates averaged 14.8 mg/l. Transport of salicylates from blood to joint 
      fluid showed a pattern consistent with the type of joint disease. Support was 
      found for the assumption that diffusion was the major factor in the movement of 
      salicylates from blood to joint fluid.
FAU - Soren, A
AU  - Soren A
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Transport von Salizylaten aus dem Blut in die Gelenkflüssigkeit.
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/metabolism
MH  - Aspirin/*metabolism
MH  - Biological Transport
MH  - Humans
MH  - Osteoarthritis/metabolism
MH  - Synovial Fluid/*metabolism
MH  - Synovitis/metabolism
EDAT- 1977/09/16 00:00
MHDA- 1977/09/16 00:01
CRDT- 1977/09/16 00:00
PHST- 1977/09/16 00:00 [pubmed]
PHST- 1977/09/16 00:01 [medline]
PHST- 1977/09/16 00:00 [entrez]
PST - ppublish
SO  - Wien Klin Wochenschr. 1977 Sep 16;89(17):599-602.

PMID- 847393
OWN - NLM
STAT- MEDLINE
DCOM- 19770520
LR  - 20151119
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 12
IP  - 2
DP  - 1977
TI  - Acetylsalicyclic acid and gastrointestinal propulsion in the rat.
PG  - 249-52
AB  - The possible influence of moderate amounts of acetylsalicyclic acid (ASA) on 
      gastric emptying, duodeno-gastric reflux and small bowel propulsion was studied 
      in rats with permanent gastric and duodenal tubes. The ASA-containing or the 
      control solution was introduced intra-gastrically half an hour before the 
      simultaneous administration of differently labeled radioactive test meals into 
      the stomach and the duodenum. ASA was given as 7.5 or 15.0 mM solution in 100 mM 
      hydrochloric acid or in 100 mM sodium chloride. After 15 minutes the 
      gastrointestinal propulsion was examined. No effect of the ASA treatment was 
      noted. No increase in duodeno-gastric reflux was found in the ASA-treated 
      animals.
FAU - Frenning, B
AU  - Frenning B
FAU - Johansson, H
AU  - Johansson H
FAU - Nilsson, F
AU  - Nilsson F
FAU - Ohrn, P G
AU  - Ohrn PG
FAU - Olazabal, A
AU  - Olazabal A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 451W47IQ8X (Sodium Chloride)
RN  - QTT17582CB (Hydrochloric Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Body Weight/drug effects
MH  - Duodenum/physiology
MH  - Gastrointestinal Motility/*drug effects
MH  - Hydrochloric Acid/pharmacology
MH  - Male
MH  - Rats
MH  - Sodium Chloride/pharmacology
MH  - Stomach/physiology
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol. 1977;12(2):249-52.

PMID- 818536
OWN - NLM
STAT- MEDLINE
DCOM- 19760803
LR  - 20131121
IS  - 0341-3098 (Print)
IS  - 0341-3098 (Linking)
VI  - 118
IP  - 20
DP  - 1976 May 14
TI  - [The problems of the various characteristics of drug abuse (author's transl)].
PG  - 629-32
AB  - An analysis of the epidemiology and health policy factors of drug abuse calls for 
      a differentiation of various types of abuse. From the total of habitually used 
      drugs, a steady increase is seen in the quota of tranquilizers, while there has 
      been a regressive trend with analgesics. It is difficult to objectify the 
      dependence potential of powerful analgesics and to assess the general 
      significance of their abuse since there are no well-founded epidemiological 
      studies. In order to guarantee the proper use of such substances, it is necessary 
      to strictly consider possible hazards to individual health and the risk factors 
      for public health on the one hand and of the therapeutic benefit on the other.
FAU - Fenner, H
AU  - Fenner H
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Zur Problematik der unterschiedlichen Missbrauchs-Charakteristik von 
      Arzneimitteln.
PL  - Germany
TA  - MMW Munch Med Wochenschr
JT  - MMW, Munchener medizinische Wochenschrift
JID - 7801805
RN  - 0 (Analgesics)
RN  - 0 (Hypnotics and Sedatives)
RN  - 0 (Nonprescription Drugs)
RN  - 0 (Tranquilizing Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alcoholism/complications
MH  - Analgesics
MH  - Animals
MH  - Aspirin/adverse effects
MH  - Humans
MH  - Hypnotics and Sedatives
MH  - Nonprescription Drugs
MH  - Primates
MH  - Self Medication
MH  - Substance Withdrawal Syndrome
MH  - *Substance-Related Disorders/complications
MH  - Tranquilizing Agents
EDAT- 1976/05/14 00:00
MHDA- 1976/05/14 00:01
CRDT- 1976/05/14 00:00
PHST- 1976/05/14 00:00 [pubmed]
PHST- 1976/05/14 00:01 [medline]
PHST- 1976/05/14 00:00 [entrez]
PST - ppublish
SO  - MMW Munch Med Wochenschr. 1976 May 14;118(20):629-32.

PMID- 29402422
OWN - NLM
STAT- MEDLINE
DCOM- 20190520
LR  - 20190520
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 121
IP  - 6
DP  - 2018 Mar 15
TI  - Comparison of Outcomes and Costs Associated With Aspirin ± Clopidogrel After 
      Coronary Artery Bypass Grafting.
PG  - 709-714
LID - S0002-9149(17)31926-4 [pii]
LID - 10.1016/j.amjcard.2017.12.010 [doi]
AB  - Optimal antiplatelet therapy after coronary artery bypass graft (CABG) surgery 
      remains controversial. This study evaluated the role of dual antiplatelet therapy 
      using aspirin and clopidogrel (DAPT) versus antiplatelet therapy using aspirin 
      only (ASA) on post-CABG clinical outcomes and costs. In the Department of 
      Veterans Affairs Randomized On/Off Bypass (ROOBY) trial, clopidogrel use after 
      CABG was prospectively collected beginning in year 2 of this study to include 
      1,525 of the 2,203 original ROOBY patients who received aspirin after CABG. 
      Discretionarily, surgeons after CABG administered either DAPT or ASA treatments. 
      The ROOBY trial's primary 30-day composite (mortality or perioperative 
      morbidity), 1-year composite (all-cause death, repeat revascularization, or 
      nonfatal myocardial infarction), and costs were compared for these 2 strategies. 
      Of the 1,525 subjects, 511 received DAPT and 1,014 received ASA. DAPT subjects, 
      compared with ASA subjects, had lower rates of preoperative left ventricular 
      ejection fraction of ≥45% (78.8% vs 85.7%, p <0.001), on-pump CABG (36.6% vs 
      57.1%, p = 0.001), and endoscopic vein harvesting (30.0% vs 42.8%, p <0.001). ASA 
      patients were more likely to have earlier aspirin administration and receive 325 
      versus 81 mg dosages. The 30-day composite outcome rate was significantly lower 
      for DAPT patients compared with ASA patients (3.3% vs 7.1%, p = 0.003), but the 
      1-year composite outcome was equal between the 2 groups (12.0% vs12.0%, p = 1.0). 
      At 1 year, there were no cost differences between the 2 groups. Propensity 
      analyses did not significantly alter the results. In conclusion, DAPT appeared 
      safe and was associated with fewer 30-day adverse outcomes than aspirin only and 
      with no 1-year outcome or cost differences.
CI  - Published by Elsevier Inc.
FAU - Ebrahimi, Ramin
AU  - Ebrahimi R
AD  - Department of Cardiology, Veterans Affairs Greater Los Angeles Healthcare System, 
      Los Angeles, California; Department of Medicine, University of California Los 
      Angeles, Los Angeles, California. Electronic address: ebrahimi@ucla.edu.
FAU - Gupta, Sandeep
AU  - Gupta S
AD  - Research Service, Northport VA Medical Center, Northport, New York.
FAU - Carr, Brendan M
AU  - Carr BM
AD  - Research Service, Northport VA Medical Center, Northport, New York; Department of 
      Emergency Medicine, Mayo Clinic, Rochester, Minnesota.
FAU - Bishawi, Muath
AU  - Bishawi M
AD  - Research Service, Northport VA Medical Center, Northport, New York; 
      Cardiovascular and Thoracic Surgery, Duke University Medical Center, Durham, 
      North Carolina.
FAU - Bakaeen, Faisal G
AU  - Bakaeen FG
AD  - Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, 
      Ohio.
FAU - Almassi, G Hossein
AU  - Almassi GH
AD  - Milwaukee VA Medical Center, Milwaukee, Wisconsin; Cardiothoracic Surgery, 
      Medical College of Wisconsin, Milwaukee, Wisconsin.
FAU - Collins, Joseph
AU  - Collins J
AD  - Cooperative Studies Program Coordinating Center, Perry Point, Maryland.
FAU - Grover, Frederick L
AU  - Grover FL
AD  - Research Service, VA Eastern Colorado Healthcare System, Denver, Colorado; 
      Cardiothoracic Surgery, the University of Colorado School of Medicine at the 
      Anschutz Medical Campus, Aurora, Colorado.
FAU - Quin, Jacquelyn A
AU  - Quin JA
AD  - Cardiac Surgery, VA Boston Healthcare System, West Roxbury, Massachusetts.
FAU - Wagner, Todd H
AU  - Wagner TH
AD  - VA Palo Alto Health Economics Resource Center, Menlo Park, California; Department 
      of Health Research and Policy, Stanford University, Stanford, California.
FAU - Shroyer, A Laurie W
AU  - Shroyer ALW
AD  - Research Service, Northport VA Medical Center, Northport, New York; Research 
      Service, VA Eastern Colorado Healthcare System, Denver, Colorado.
FAU - Hattler, Brack
AU  - Hattler B
AD  - Cardiology, VA Eastern Colorado Health Care System, Denver, Colorado; Department 
      of Medicine, Division of Cardiology, University of Colorado School of Medicine at 
      the Anschutz Medical Campus, Aurora, Colorado.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20180102
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/economics
MH  - Clopidogrel/*administration & dosage/economics
MH  - Comorbidity
MH  - *Coronary Artery Bypass
MH  - Coronary Disease/mortality/*surgery
MH  - Costs and Cost Analysis
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hospitals, Veterans
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/economics
MH  - Postoperative Complications/*economics/epidemiology/*prevention & control
MH  - Prospective Studies
MH  - Treatment Outcome
EDAT- 2018/02/07 06:00
MHDA- 2019/05/21 06:00
CRDT- 2018/02/07 06:00
PHST- 2017/06/23 00:00 [received]
PHST- 2017/12/04 00:00 [revised]
PHST- 2017/12/11 00:00 [accepted]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2019/05/21 06:00 [medline]
PHST- 2018/02/07 06:00 [entrez]
AID - S0002-9149(17)31926-4 [pii]
AID - 10.1016/j.amjcard.2017.12.010 [doi]
PST - ppublish
SO  - Am J Cardiol. 2018 Mar 15;121(6):709-714. doi: 10.1016/j.amjcard.2017.12.010. 
      Epub 2018 Jan 2.

PMID- 26889740
OWN - NLM
STAT- MEDLINE
DCOM- 20160620
LR  - 20211204
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 2
IP  - 2
DP  - 2016 Feb 18
TI  - Oral aspirin for treating venous leg ulcers.
PG  - CD009432
LID - 10.1002/14651858.CD009432.pub2 [doi]
LID - CD009432
AB  - BACKGROUND: Venous leg ulcers (VLUs) or varicose ulcers are the final stage of 
      chronic venous insufficiency (CVI), and are the most common type of leg ulcer. 
      The development of VLUs on ankles and lower legs can occur spontaneously or after 
      minor trauma. The ulcers are often painful and exudative, healing is often 
      protracted and recurrence is common. This cycle of healing and recurrence has a 
      considerable impact on the health and quality of life of individuals, and 
      healthcare and socioeconomic costs. VLUs are a common and costly problem 
      worldwide; prevalence is estimated to be between 1.65% to 1.74% in the western 
      world and is more common in adults aged 65 years and older. The main treatment 
      for a VLU is a firm compression bandage. Compression assists by reducing venous 
      hypertension, enhancing venous return and reducing peripheral oedema. However, 
      studies show that it only has moderate effects on healing, with up to 50% of VLUs 
      unhealed after two years of compression. Non-adherence may be the principal cause 
      of these poor results, but presence of inflammation in people with CVI may be 
      another factor, so a treatment that suppresses inflammation (healing ulcers more 
      quickly) and reduces the frequency of ulcer recurrence (thereby prolonging time 
      between recurrent episodes) would be an invaluable intervention to complement 
      compression treatments. Oral aspirin may have a significant impact on VLU 
      clinical practice worldwide. Evidence for the effectiveness of aspirin on ulcer 
      healing and recurrence in high quality RCTs is currently lacking. OBJECTIVES: To 
      assess the benefits and harms of oral aspirin on the healing and recurrence of 
      venous leg ulcers. SEARCH METHODS: In May 2015 we searched: The Cochrane Wounds 
      Specialised Register; The Cochrane Central Register of Controlled Trials 
      (CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other 
      Non-Indexed Citations); Ovid EMBASE and EBSCO CINAHL. Additional searches were 
      made in trial registers and reference lists of relevant publications for 
      published or ongoing trials. There were no language or publication date 
      restrictions. SELECTION CRITERIA: We included randomised controlled trials (RCTs) 
      that compared oral aspirin with placebo or no drug intervention (in the presence 
      or absence of compression therapy) for treating people with venous leg ulcers. 
      Our main outcomes were time to complete ulcer healing, rate of change in the area 
      of the ulcer, proportion of ulcers healed in the trial period, major bleeding, 
      pain, mortality, adverse events and ulcer recurrence (time for recurrence and 
      proportion of recurrence). DATA COLLECTION AND ANALYSIS: Two review authors 
      independently selected studies for inclusion, extracted data, assessed the risk 
      of bias of each included trial and assessed overall quality of evidence for the 
      main outcomes in the 'Summary of findings' table. MAIN RESULTS: The electronic 
      search located 62 studies. We included two RCTs of oral aspirin (300 mg/daily) 
      given in addition to compression compared with compression and placebo, or 
      compression alone. To date, the impact of aspirin on VLUs has been examined by 
      only two randomised clinical trials, both with a small number of participants. 
      The first RCT was conducted in the United Kingdom (n=20) and reported that daily 
      administration of aspirin (300mg) in addition to compression bandages increased 
      both the rate of healing, and the number of participants healed when compared to 
      placebo in addition to compression bandaging over a four month period. 
      Thirty-eight per cent of the participants given aspirin reported complete healing 
      compared with 0% in the placebo group . Improvement (assessed by reduction in 
      wound size) occurred in 52% of the participants taking aspirin compared with 26% 
      in those taking placebo). The study identified potential benefits of taking 
      aspirin as an adjunct to compression but the sample size was small, and neither 
      the mechanism by which aspirin improved healing nor its effects on recurrence 
      were investigated.In 2012 an RCT in Spain (n=51) compared daily administration of 
      aspirin (300mg) in addition to compression bandages with compression alone over a 
      five month period. There was little difference in complete healing rates between 
      groups (21/28 aspirin and 17/23 compression bandages alone) but the average time 
      to healing was shorter (12 weeks in the treated group vs 22 weeks in the 
      compression only group) and the average time for recurrence was longer in the 
      aspirin group (39 days: [SD 6.0] compared with 16.3 days [SD 7.5] in the 
      compression only group). Although this trial provides some limited data about the 
      potential use of aspirin therapy, the sample size (only 20 patients) was too 
      small for us to draw meaningful conclusions. In addition, patients were only 
      followed up for 4 months and no information on placebo was reported. AUTHORS' 
      CONCLUSIONS: Low quality evidence from two trials indicate that there is 
      currently insufficient evidence for us to draw definitive conclusions about the 
      benefits and harms of oral aspirin on the healing and recurrence of venous leg 
      ulcers. We downgraded the evidence to low quality due to potential selection bias 
      and imprecision due to the small sample size. The small number of participants 
      may have a hidden real benefit, or an increase in harm. Due to the lack of 
      reliable evidence, we are unable to draw conclusions about the benefits and harms 
      of oral daily aspirin as an adjunct to compression in VLU healing or recurrence. 
      Further high quality studies are needed in this area.
FAU - de Oliveira Carvalho, Paulo Eduardo
AU  - de Oliveira Carvalho PE
AD  - Evidence Based Health Actions Department and Thoracic Surgery Department, Marilia 
      Medical School, Avenida Monte Carmelo, 800, Bairro Fragata, Marilia, Sao Paulo, 
      Brazil, 17519-030.
FAU - Magolbo, Natiara G
AU  - Magolbo NG
FAU - De Aquino, Rebeca F
AU  - De Aquino RF
FAU - Weller, Carolina D
AU  - Weller CD
LA  - eng
GR  - Department of Health/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20160218
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - doi: 10.1002/14651858.CD009432
MH  - Administration, Oral
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Compression Bandages
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Varicose Ulcer/*drug therapy
MH  - Wound Healing/*drug effects
PMC - PMC8627253
COIS- Paolo Eduardo de Oliveira Carvalho: none known.  Natiara Magolbo: none known.  
      Rebeca De Aquino: none known.  Carolina Weller: none known.
EDAT- 2016/02/19 06:00
MHDA- 2016/06/21 06:00
CRDT- 2016/02/19 06:00
PHST- 2016/02/19 06:00 [entrez]
PHST- 2016/02/19 06:00 [pubmed]
PHST- 2016/06/21 06:00 [medline]
AID - CD009432.pub2 [pii]
AID - 10.1002/14651858.CD009432.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2016 Feb 18;2(2):CD009432. doi: 
      10.1002/14651858.CD009432.pub2.

PMID- 3354570
OWN - NLM
STAT- MEDLINE
DCOM- 19880512
LR  - 20190815
IS  - 0272-6386 (Print)
IS  - 0272-6386 (Linking)
VI  - 11
IP  - 4
DP  - 1988 Apr
TI  - Influence of antacid administrations on aspirin absorption in patients with 
      chronic renal failure on maintenance hemodialysis.
PG  - 338-42
AB  - In order to investigate the possible interaction between oral aspirin and 
      antacids in uremic patients on chronic hemodialysis, we administered to 5 uremic 
      patients: (1) aspirin alone; (2) aluminum-magnesium hydroxide with aspirin; (3) 
      aluminum-magnesium hydroxide followed (two hours) by aspirin; (4) calcium 
      carbonate simultaneously with aspirin; and (5) calcium carbonate followed (two 
      hours) by aspirin. In all the occasions, aspirin was given two hours after a 
      standard lunch. Both antacid preparations induced comparable changes in aspirin 
      mean peak plasma concentration (Cmax), if given simultaneously with aspirin, 
      whereas no difference was found in other pharmacokinetic parameters. When 
      antacids were followed (two hours) by aspirin, both Cmax and time of maximum 
      concentration (Tmax) were significantly altered in respect to the value with 
      aspirin alone. No changes in the time course of post aspirin serum thromboxane B2 
      were detected when aspirin and antacids were administered simultaneously, but the 
      inhibition of serum thromboxane B2 was delayed when antacids were followed (two 
      hours) by aspirin. These results indicate that the administration of antacids to 
      uremic patients interferes with absorption of oral aspirin. This interference can 
      be minimized if aspirin and antacids are given simultaneously.
FAU - Gaspari, F
AU  - Gaspari F
AD  - Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
FAU - Viganò, G
AU  - Viganò G
FAU - Locatelli, M
AU  - Locatelli M
FAU - Remuzzi, G
AU  - Remuzzi G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - 0 (Antacids)
RN  - 0 (Drug Combinations)
RN  - 37317-08-1 (aluminum hydroxide, magnesium hydroxide, drug combination)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - H0G9379FGK (Calcium Carbonate)
RN  - NBZ3QY004S (Magnesium Hydroxide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Absorption
MH  - Adult
MH  - Aluminum Hydroxide/administration & dosage/pharmacology
MH  - Antacids/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/blood/*pharmacokinetics
MH  - Calcium Carbonate/administration & dosage/pharmacology
MH  - Drug Administration Schedule
MH  - Drug Combinations/administration & dosage/pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Kidney Failure, Chronic/blood/*metabolism/therapy
MH  - Magnesium Hydroxide/administration & dosage/pharmacology
MH  - Male
MH  - Middle Aged
MH  - *Renal Dialysis
MH  - Thromboxane B2/blood
EDAT- 1988/04/01 00:00
MHDA- 2000/06/01 09:00
CRDT- 1988/04/01 00:00
PHST- 1988/04/01 00:00 [pubmed]
PHST- 2000/06/01 09:00 [medline]
PHST- 1988/04/01 00:00 [entrez]
AID - S0272638688000587 [pii]
AID - 10.1016/s0272-6386(88)80140-9 [doi]
PST - ppublish
SO  - Am J Kidney Dis. 1988 Apr;11(4):338-42. doi: 10.1016/s0272-6386(88)80140-9.

PMID- 7008711
OWN - NLM
STAT- MEDLINE
DCOM- 19810424
LR  - 20190503
IS  - 0003-4967 (Print)
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 40
IP  - 1
DP  - 1981 Feb
TI  - Effect of aspirin treatment on chondromalacia patellae.
PG  - 37-41
AB  - Twenty-nine patients (21 females and 8 males) with chondromalacia patellae 
      diagnosed by arthroscopy were randomly allocated to receive aspirin or placebo 
      for 3 months. Clinical and arthroscopic examination after 3 months showed no 
      significant change in symptoms, signs, or macroscopic appearances in either 
      group. Surgical treatment was performed in 14 patients for deteriorating 
      symptoms.
FAU - Bentley, G
AU  - Bentley G
FAU - Leslie, I J
AU  - Leslie IJ
FAU - Fischer, D
AU  - Fischer D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Cartilage Diseases/*drug therapy/surgery
MH  - Cartilage, Articular
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Endoscopy
MH  - Female
MH  - Humans
MH  - Male
MH  - Patella/surgery
MH  - Prospective Studies
MH  - Random Allocation
PMC - PMC1000652
EDAT- 1981/02/01 00:00
MHDA- 1981/02/01 00:01
CRDT- 1981/02/01 00:00
PHST- 1981/02/01 00:00 [pubmed]
PHST- 1981/02/01 00:01 [medline]
PHST- 1981/02/01 00:00 [entrez]
AID - 10.1136/ard.40.1.37 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 1981 Feb;40(1):37-41. doi: 10.1136/ard.40.1.37.

PMID- 33999375
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 1865-7265 (Electronic)
IS  - 1865-7257 (Print)
IS  - 1865-7265 (Linking)
VI  - 14
IP  - 4
DP  - 2021 Aug
TI  - Isolated angioedema of the bowel caused by aspirin.
PG  - 1096-1102
LID - 10.1007/s12328-021-01430-6 [doi]
AB  - Angioedema is a self-limited, localized tissue swelling, resulting from fluid 
      extravasation into interstitial spaces. It may occur in isolation or be 
      accompanied by urticaria and/or anaphylaxis. The phenomenon has been linked to 
      multiple medications, including non-steroidal anti-inflammatory drugs (NSAIDs) 
      and angiotensin-converting enzyme inhibitors (ACEIs). NSAID-induced angioedema is 
      observed in < 0.3% of patients taking NSAIDs. While isolated visceral angioedema 
      has been reported from ACEIs, it has not been documented from NSAID use, 
      particularly aspirin usage. Here, we report a case of isolated visceral 
      angioedema attributed to aspirin use.
CI  - © 2021. Japanese Society of Gastroenterology.
FAU - Osman, Karim
AU  - Osman K
AUID- ORCID: 0000-0003-0453-9831
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St. SW, 
      Rochester, MN, 55902, USA. Ktarek.osman@gmail.com.
AD  - Department of Internal Medicine, Beth Israel Lahey Clinic, Burlington, MA, 01803, 
      USA. Ktarek.osman@gmail.com.
FAU - Kendi, Ayse Tuba
AU  - Kendi AT
AD  - Department of Radiology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55902, USA.
FAU - Maselli, Daniel
AU  - Maselli D
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St. SW, 
      Rochester, MN, 55902, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20210517
PL  - Japan
TA  - Clin J Gastroenterol
JT  - Clinical journal of gastroenterology
JID - 101477246
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioedema/chemically induced
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/adverse effects
MH  - *Drug Hypersensitivity
MH  - Humans
MH  - *Urticaria/chemically induced
PMC - PMC8127855
OTO - NOTNLM
OT  - Angioedema
OT  - Aspirin
OT  - Non-steroidal anti-inflammatory drugs
OT  - Small bowel
COIS- The authors declare that there is no conflict of interest.
EDAT- 2021/05/18 06:00
MHDA- 2021/07/27 06:00
CRDT- 2021/05/17 12:47
PHST- 2021/02/10 00:00 [received]
PHST- 2021/04/29 00:00 [accepted]
PHST- 2021/05/18 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
PHST- 2021/05/17 12:47 [entrez]
AID - 10.1007/s12328-021-01430-6 [pii]
AID - 1430 [pii]
AID - 10.1007/s12328-021-01430-6 [doi]
PST - ppublish
SO  - Clin J Gastroenterol. 2021 Aug;14(4):1096-1102. doi: 10.1007/s12328-021-01430-6. 
      Epub 2021 May 17.

PMID- 8240031
OWN - NLM
STAT- MEDLINE
DCOM- 19931217
LR  - 20131121
IS  - 0098-6127 (Print)
IS  - 0098-6127 (Linking)
VI  - 20
IP  - 3
DP  - 1993
TI  - Effect of aspirin on the contractility of aortic rings in vitro from 
      spontaneously hypertensive rats.
PG  - 135-46
AB  - The effect of Acetylsalicylic acid (ASA) on the responsiveness of rat aortic 
      smooth muscle was investigated by comparing the contractility of aortic rings 
      from SHR and WKY rats in response to alpha-agonist, phenylephrine (PE). 
      Cumulative dose response curves for PE were generated from aortic rings of SHR 
      and WKY rats in the presence and absence of 0.2mM ASA. To investigate the 
      involvement of endothelium on ASA mediated effects, active tension was recorded 
      for denuded and non-denuded rings from SHR animals in response to KCl and PE. 
      Denuded and non-denuded aortic rings from SHR animals in the presence of ASA 
      produced significantly higher active tension than in the absence of ASA. The 
      reactivity of aortic rings from WKY control animals was not altered significantly 
      in the presence of ASA. These studies suggest that ASA can also modulate aortic 
      contractility through other mechanism(s) in addition to its effect on the 
      metabolites of arachidonic acid. Significance of these observations is discussed 
      below.
FAU - Rahmani, M A
AU  - Rahmani MA
AD  - Division of Science and Mathematics, Bethune-Cookman College, Daytona Beach, Fl 
      32115.
FAU - Mangroo, T
AU  - Mangroo T
FAU - Neves, M
AU  - Neves M
FAU - Bienaime, M
AU  - Bienaime M
FAU - Wiggins, S
AU  - Wiggins S
FAU - Williams, J
AU  - Williams J
LA  - eng
GR  - GM 08119/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Artery
JT  - Artery
JID - 7508494
RN  - 1WS297W6MV (Phenylephrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta, Thoracic/drug effects
MH  - Aspirin/*pharmacology
MH  - Hypertension/*prevention & control
MH  - Male
MH  - Muscle, Smooth, Vascular/*drug effects
MH  - Phenylephrine/*pharmacology
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Rats, Inbred WKY
MH  - Vasoconstriction/*drug effects
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Artery. 1993;20(3):135-46.

PMID- 20485708
OWN - NLM
STAT- MEDLINE
DCOM- 20101008
LR  - 20131121
IS  - 0300-8495 (Print)
IS  - 0300-8495 (Linking)
VI  - 39
IP  - 5
DP  - 2010 May
TI  - Aspirin, flu and general practice research.
PG  - 263
AB  - A few weeks ago I received an invitation on a stiff white card to a morning tea 
      function at Government House in Melbourne. Being unaccustomed to the world of 
      posh functions and stiff white invitations, and never having been inside 
      Government House, I decided to go along. The occasion was the launch of the 
      ASPirin in Reducing Events in the Elderly (ASPREE) trial into general practice. 
      The cucumber sandwiches, served in dainty triangles (naturally with crusts 
      removed) were indeed a treat. However, the importance of a large clinical trial 
      undertaken in general practice and designed to answer a really important question 
      that may result in a change in clinical practice, was really the star of the 
      show.
FAU - Parsons, Jenni
AU  - Parsons J
LA  - eng
PT  - Editorial
PL  - Australia
TA  - Aust Fam Physician
JT  - Australian family physician
JID - 0326701
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Australia
MH  - Biomedical Research/standards/trends
MH  - Cardiovascular Diseases/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Family Practice/standards/trends
MH  - Forecasting
MH  - Humans
MH  - Influenza, Human/*drug therapy
MH  - Randomized Controlled Trials as Topic
EDAT- 2010/05/21 06:00
MHDA- 2010/10/12 06:00
CRDT- 2010/05/21 06:00
PHST- 2010/05/21 06:00 [entrez]
PHST- 2010/05/21 06:00 [pubmed]
PHST- 2010/10/12 06:00 [medline]
PST - ppublish
SO  - Aust Fam Physician. 2010 May;39(5):263.

PMID- 2556779
OWN - NLM
STAT- MEDLINE
DCOM- 19900116
LR  - 20131121
IS  - 0035-2640 (Print)
IS  - 0035-2640 (Linking)
VI  - 39
IP  - 25
DP  - 1989 Nov 1
TI  - [Mechanism of platelet aggregation and mode of action of platelet 
      antiaggregants].
PG  - 2219-22
AB  - Platelets play an important role in arterial thrombosis. Following the adhesion 
      of platelets to an injured vascular wall, platelet activation occurs, involving 
      calcium fluxes, phosphoinositol metabolism, protein phosphorylation, arachidonate 
      cascade. This leads to the formation of the fibrinogen membrane receptor, the 
      IIb/IIIa glycoprotein complex. Platelet aggregation results from the binding of 
      fibrinogen and other adhesive proteins to the IIb/IIIa complex between several 
      platelets. Numerous drugs can interfere with platelet function. Among these, only 
      aspirin and ticlopidine have been shown to be effective in controlled trials. 
      Aspirin, by inhibiting cyclo-oxygenase, blocks thromboxane A2 formation. 
      Ticlopidine, by inhibiting fibrinogen binding to the complex, is a potent 
      antiaggregation agent.
FAU - Tobelem, G
AU  - Tobelem G
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Mécanisme de l'agrégation plaquettaire et mode d'action des antiagrégants 
      plaquettaires.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
RN  - 0 (Arachidonic Acids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - E0399OZS9N (Cyclic AMP)
RN  - R16CO5Y76E (Aspirin)
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/pharmacology
MH  - Blood Vessels/physiopathology
MH  - Cyclic AMP/blood
MH  - Humans
MH  - Platelet Adhesiveness
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
PST - ppublish
SO  - Rev Prat. 1989 Nov 1;39(25):2219-22.

PMID- 3149194
OWN - NLM
STAT- MEDLINE
DCOM- 19890428
LR  - 20181130
IS  - 0232-766X (Print)
IS  - 0232-766X (Linking)
VI  - 47
IP  - 8
DP  - 1988
TI  - Acetylsalicylate-induced cholestasis, unrelated to biliary bile acid excretion, 
      in the rabbit.
PG  - 767-73
AB  - Administration of lysine acetylsalicylate to anaesthetized rabbits induced a 
      marked decrease in bile flow and biliary secretion rates of sodium, potassium, 
      chloride and bicarbonate. Bile acid concentrations were increased but biliary 
      bile acid outputs were similar to those observed in control animals after i.v. 
      injection of saline or lysine. Our results confirm that different species have 
      different susceptibilities to salicylates since in other species this group of 
      drugs is choleretic. It is suggested that the cholestatic effect of 
      acetylsalicylate in the rabbit is due to acetylsalicylate and that it is 
      associated with a reduction in the bile acid-independent bile flow since bile 
      acid outputs remained constant after administration of the drug.
FAU - Monte, M J
AU  - Monte MJ
AD  - Department of Physiology and Pharmacology, University of Salamanca, Spain.
FAU - Esteller, A
AU  - Esteller A
FAU - Jimenez, R
AU  - Jimenez R
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Biomed Biochim Acta
JT  - Biomedica biochimica acta
JID - 8304435
RN  - 0 (Analgesics)
RN  - 0 (Bicarbonates)
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Chlorides)
RN  - 9NEZ333N27 (Sodium)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Analgesics/*toxicity
MH  - Animals
MH  - Aspirin/*analogs & derivatives/toxicity
MH  - Bicarbonates/metabolism
MH  - Bile/drug effects/*metabolism
MH  - Bile Acids and Salts/*metabolism
MH  - Chlorides/metabolism
MH  - Cholestasis/*chemically induced
MH  - Lysine/*analogs & derivatives/pharmacology/toxicity
MH  - Male
MH  - Potassium/metabolism
MH  - Rabbits
MH  - Reference Values
MH  - Sodium/metabolism
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Biomed Biochim Acta. 1988;47(8):767-73.

PMID- 7976985
OWN - NLM
STAT- MEDLINE
DCOM- 19941214
LR  - 20171116
IS  - 0002-838X (Print)
IS  - 0002-838X (Linking)
VI  - 50
IP  - 7
DP  - 1994 Nov 15
TI  - Eight underused prescriptions.
PG  - 1497-504
AB  - Eight currently underused therapeutic regimens are reviewed on the basis of their 
      potential to have a major impact on morbidity and mortality in adults. The 
      criteria for the selection of these regimens included their safety, effectiveness 
      and cost-effectiveness, the availability of substantial data to support their 
      efficacy, and the existence of evidence that the regimens are underused in 
      clinical practice. The eight regimens that meet these criteria are prophylactic 
      aspirin therapy, estrogen replacement therapy, nicotine substitutes as adjunctive 
      therapy in smoking cessation, beta-blocker therapy following myocardial 
      infarction, anti-inflammatory agents in the treatment of asthma, antidepressant 
      drugs as therapy for mild depression, increased fiber intake and regular 
      exercise.
FAU - Kerr, C P
AU  - Kerr CP
AD  - Hamburg Center for Developmental Disabilities, Pennsylvania.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am Fam Physician
JT  - American family physician
JID - 1272646
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Dietary Fiber)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am Fam Physician. 1995 Sep 1;52(3):761, 766. PMID: 7653415
CIN - Am Fam Physician. 1995 Sep 1;52(3):766, 768, 775. PMID: 7653416
CIN - Am Fam Physician. 1994 Nov 15;50(7):1461. PMID: 7976978
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Antidepressive Agents/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Dietary Fiber/therapeutic use
MH  - Drug Prescriptions/*statistics & numerical data
MH  - Estrogen Replacement Therapy
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Smoking Cessation/methods
RF  - 76
EDAT- 1994/11/15 00:00
MHDA- 1994/11/15 00:01
CRDT- 1994/11/15 00:00
PHST- 1994/11/15 00:00 [pubmed]
PHST- 1994/11/15 00:01 [medline]
PHST- 1994/11/15 00:00 [entrez]
PST - ppublish
SO  - Am Fam Physician. 1994 Nov 15;50(7):1497-504.

PMID- 2589449
OWN - NLM
STAT- MEDLINE
DCOM- 19900104
LR  - 20220317
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 161
IP  - 5
DP  - 1989 Nov
TI  - Successful treatment in two women with antiphospholipid antibodies and refractory 
      pregnancy losses with intravenous immunoglobulin infusions.
PG  - 1271-2
AB  - In two women with antiphospholipid antibodies and recurrent fetal losses 
      refractory to usual treatments, therapy consisting of aspirin, heparin, and 
      intravenous gamma-globulin infusions was successful. Production of 
      antiphospholipid antibodies was not suppressed. The transient decrease in 
      anticoagulant activity noted in one case was not reproduced in vitro and was 
      probably not physiologically important.
FAU - Wapner, R J
AU  - Wapner RJ
AD  - Department of Obstetrics and Gynecology, Jefferson Medical College, Philadelphia, 
      PA 10107.
FAU - Cowchock, F S
AU  - Cowchock FS
FAU - Shapiro, S S
AU  - Shapiro SS
LA  - eng
GR  - 1 RO1 HD21657-01A1/HD/NICHD NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Antibodies)
RN  - 0 (Phospholipids)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/drug therapy/*therapy
MH  - Adult
MH  - Antibodies/*analysis
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - *Immunization, Passive
MH  - Infusions, Intravenous
MH  - Phospholipids/*immunology
MH  - Pregnancy
MH  - Pregnancy Outcome
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
AID - 0002-9378(89)90681-9 [pii]
AID - 10.1016/0002-9378(89)90681-9 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1989 Nov;161(5):1271-2. doi: 10.1016/0002-9378(89)90681-9.

PMID- 1262333
OWN - NLM
STAT- MEDLINE
DCOM- 19760706
LR  - 20210210
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 251
IP  - 8
DP  - 1976 Apr 25
TI  - Mechanism of the thrombin-mediated burst in oxygen consumption by human 
      platelets.
PG  - 2536-8
AB  - We present evidence that added thrombin stimulates release of endogenous 
      arachidonic acid by suspensions of human platelets. We also show that added 
      arachidonic acid causes a burst in O2 consumption that mimics one of the well 
      described effects of thrombin on these cells. Further, added aspirin, a known 
      inhibitor of the burst in O2 consumption caused by thrombin, also blunted the 
      stimulatory effect of arachidonate on O2 consumption, and eicosatetraynoate, a 
      known inhibitor of arachidonate oxygenation, blunted the burst in O2 consumption 
      initiated by both thrombin and arachidonate. We conclude that rapid oxygenation 
      of endogenously released arachidonic acid accounts for the thrombin-mediated 
      burst in oxygen consumption by platelets.
FAU - Pickett, W C
AU  - Pickett WC
FAU - Cohen, P
AU  - Cohen P
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Arachidonic Acids)
RN  - 1191-85-1 (5,8,11,14-Eicosatetraynoic Acid)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 5,8,11,14-Eicosatetraynoic Acid/pharmacology
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/pharmacology
MH  - Blood Platelets/drug effects/*metabolism
MH  - Humans
MH  - *Oxygen Consumption/drug effects
MH  - Thrombin/*metabolism
EDAT- 1976/04/25 00:00
MHDA- 1976/04/25 00:01
CRDT- 1976/04/25 00:00
PHST- 1976/04/25 00:00 [pubmed]
PHST- 1976/04/25 00:01 [medline]
PHST- 1976/04/25 00:00 [entrez]
AID - S0021-9258(17)33621-9 [pii]
PST - ppublish
SO  - J Biol Chem. 1976 Apr 25;251(8):2536-8.

PMID- 35776157
OWN - NLM
STAT- MEDLINE
DCOM- 20220812
LR  - 20221005
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 78
IP  - 9
DP  - 2022 Sep
TI  - Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data 
      from VigiBase.
PG  - 1521-1526
LID - 10.1007/s00228-022-03357-4 [doi]
AB  - PURPOSE: The aim of this study was to analyze the clinical characteristics of 
      fatal adverse events (AEs) of rivaroxaban combined with aspirin and to underline 
      the importance of the rational use of drugs. METHODS: The WHO global database of 
      reported potential side effects of medicinal products (VigiBase) was searched for 
      fatal AEs in the combined use of rivaroxaban and aspirin, and the clinical 
      characteristics of those cases with sufficient information (vigiGrade 
      completeness score ≥ 0.80) were analyzed. RESULTS: By January 19, 2020, 2309 
      fatal adverse event reports of rivaroxaban combined with aspirin from 21 
      countries were entered in VigiBase. One hundred and twenty cases contained 
      further information, of which 42 were female (35%) and 78 were male (65%). The 
      median age was 75 (range 34 to 93) years, and 109 cases (91%) were elderly 
      patients (≥ 65 years). The AEs listed in the fatal case reports included bleeding 
      in 114 cases (mainly intracranial hemorrhage and gastrointestinal hemorrhage, 59 
      and 46 respectively, accounting for 88%) and ischemic events in six cases 
      (ischemic stroke in three, acute myocardial infarction in two, myocardial 
      infarction combined with acute liver failure in one). Among the patients with 
      bleeding events, 108 (95%) had existing risk factors for bleeding or for 
      interacting with aspirin or rivaroxaban. These may be divided into the following: 
      diseases (hypertension, renal impairment, history of stroke, peptic ulcer, or 
      previous bleeding), drugs (high dose aspirin, antiplatelet drugs, anticoagulants, 
      P-gp inhibitors/CYP3A4 inhibitors, non-steroidal anti-inflammatory drugs, 
      steroids, and selective serotonin reuptake inhibitors), or other factors (e.g., 
      elderly, low body weight, or excessive intake of ginger, fish oil, or alcohol). 
      There were 45 cases with two or more of these risk factors in addition to 
      rivaroxaban and aspirin. Patients with ischemic events are often in very 
      high-risk groups of atherosclerotic cardiovascular disease (ASCVD) or 
      self-discontinuation of treated drugs. Medication errors occurred in 24 patients 
      (20%): excessive treatment in 17 cases, contraindication in three, frequency 
      error in two, excessive treatment combined with contraindication in one, and 
      self-discontinuation in one. CONCLUSIONS: Fatal AEs related to rivaroxaban 
      combined with aspirin, including bleeding and ischemic events, have been reported 
      mostly in the elderly, and sometimes involved medication errors. The fatal AEs 
      mainly manifested as serious bleeding, and most of them occurred in patients with 
      concurrent multiple risk factors. Monitoring coagulation during rivaroxaban 
      treatment is recommended in very high-risk ASCVD populations, and attention 
      should be paid to prevention of medication errors.
CI  - © 2022. The Author(s).
FAU - Zhang, Qingxia
AU  - Zhang Q
AUID- ORCID: 0000-0002-3843-8767
AD  - Department of Pharmacy, National Clinical Research Center for Geriatric Disease, 
      Xuanwu Hospital Capital Medical University, Beijing, China. WL7322681@sina.com.
FAU - Ding, Qian
AU  - Ding Q
AUID- ORCID: 0000-0001-5323-9996
AD  - School of Pharmaceutical Science, Capital Medical University, Beijing, China.
FAU - Yan, Suying
AU  - Yan S
AD  - Department of Pharmacy, National Clinical Research Center for Geriatric Disease, 
      Xuanwu Hospital Capital Medical University, Beijing, China.
FAU - Yue, Qun-Ying
AU  - Yue QY
AUID- ORCID: 0000-0003-2475-2621
AD  - Uppsala Monitoring Centre, Uppsala, Sweden. qun-ying.yue@who-umc.org.
LA  - eng
PT  - Journal Article
DEP - 20220701
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Factor Xa Inhibitors/therapeutic use
MH  - Female
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Ischemia/chemically induced
MH  - Male
MH  - *Myocardial Infarction/drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Rivaroxaban/therapeutic use
PMC - PMC9365742
OTO - NOTNLM
OT  - Adverse drug events
OT  - Aspirin
OT  - Fatal
OT  - Medication errors
OT  - Rivaroxaban
OT  - VigiBase
COIS- The authors declare no competing interests.
EDAT- 2022/07/02 06:00
MHDA- 2022/08/13 06:00
CRDT- 2022/07/01 11:13
PHST- 2022/02/14 00:00 [received]
PHST- 2022/06/16 00:00 [accepted]
PHST- 2022/07/02 06:00 [pubmed]
PHST- 2022/08/13 06:00 [medline]
PHST- 2022/07/01 11:13 [entrez]
AID - 10.1007/s00228-022-03357-4 [pii]
AID - 3357 [pii]
AID - 10.1007/s00228-022-03357-4 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2022 Sep;78(9):1521-1526. doi: 10.1007/s00228-022-03357-4. 
      Epub 2022 Jul 1.

PMID- 9606899
OWN - NLM
STAT- MEDLINE
DCOM- 19980625
LR  - 20161018
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 98
IP  - 4
DP  - 1998
TI  - [Acetylsalicylic acid in therapy of migraine].
PG  - 44-6
AB  - The paper reports the results of preventive therapy of 105 patients with migraine 
      without aura by acetylsalicylic acid in doses 1000, 500 and 100 mg (in 3 groups 
      of patients). The data were presented about the efficiency of these schemes of 
      treatment as well as about the predictors and contra-indications for their 
      prescription. Central and peripheral mechanisms of drug's action were considered.
FAU - Kolosova, O A
AU  - Kolosova OA
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Atsetilsalitsilovaia kislota v lechenii migreni.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - Chronic Disease
MH  - Cyclooxygenase Inhibitors/*administration & dosage/pharmacokinetics
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Middle Aged
MH  - Migraine Disorders/diagnosis/metabolism/*prevention & control
MH  - Predictive Value of Tests
MH  - Quality of Life
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 1998/06/02 00:00
MHDA- 1998/06/02 00:01
CRDT- 1998/06/02 00:00
PHST- 1998/06/02 00:00 [pubmed]
PHST- 1998/06/02 00:01 [medline]
PHST- 1998/06/02 00:00 [entrez]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 1998;98(4):44-6.

PMID- 19103366
OWN - NLM
STAT- MEDLINE
DCOM- 20090122
LR  - 20131121
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 60
IP  - 1
DP  - 2009 Jan
TI  - Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and 
      systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki 
      disease.
PG  - 146-9
LID - 10.1016/j.jaad.2008.07.044 [doi]
AB  - Drug-induced hypersensitivity syndrome (DIHS), also known as drug reaction with 
      eosinophilia and systemic symptoms (DRESS), is a severe multiple-organ condition 
      caused by drug treatment. The current report describes a Japanese boy who 
      underwent aspirin treatment for Kawasaki disease, and who subsequently presented 
      with the manifestations of DIHS/DRESS syndrome. He had been treated with a single 
      high dose of intravenous immunoglobulin and aspirin orally for Kawasaki disease. 
      One month after the onset of Kawasaki disease, he developed a generalized 
      maculopapular eruption, high-grade fever, leukocytosis with eosinophilia, and an 
      increased number of atypical lymphocytes, severe liver dysfunction, 
      lymphadenopathy, and prominent increases in antihuman herpesvirus-6 
      immunoglobulin G titer. The activity of 2',5'-oligoadenylate synthetase was 
      elevated at the onset stage. Hypersensitivity to aspirin was confirmed by skin 
      patch test and by lymphocyte stimulation test. Based on these findings, the 
      patient was diagnosed with DIHS/DRESS caused by aspirin. To our knowledge, there 
      have been no previous reports of aspirin-induced hypersensitivity syndrome 
      subsequent to Kawasaki disease. The activity of 2',5'-oligoadenylate synthetase 
      might be useful as a diagnostic marker of DIHS/DRESS syndrome and for exploring 
      its pathogenesis.
FAU - Kawakami, Tamihiro
AU  - Kawakami T
AD  - Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, 
      Kanagawa, Japan.
FAU - Fujita, Ayumi
AU  - Fujita A
FAU - Takeuchi, Sora
AU  - Takeuchi S
FAU - Muto, Shinji
AU  - Muto S
FAU - Soma, Yoshinao
AU  - Soma Y
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Child, Preschool
MH  - Drug Hypersensitivity/*etiology
MH  - Eosinophilia/*chemically induced
MH  - Humans
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*drug therapy
EDAT- 2008/12/24 09:00
MHDA- 2009/01/23 09:00
CRDT- 2008/12/24 09:00
PHST- 2008/04/29 00:00 [received]
PHST- 2008/07/29 00:00 [revised]
PHST- 2008/07/30 00:00 [accepted]
PHST- 2008/12/24 09:00 [entrez]
PHST- 2008/12/24 09:00 [pubmed]
PHST- 2009/01/23 09:00 [medline]
AID - S0190-9622(08)00935-3 [pii]
AID - 10.1016/j.jaad.2008.07.044 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2009 Jan;60(1):146-9. doi: 10.1016/j.jaad.2008.07.044.

PMID- 17604291
OWN - NLM
STAT- MEDLINE
DCOM- 20080403
LR  - 20131121
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 28
IP  - 16
DP  - 2007 Aug
TI  - AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy 
      in people with diabetes: how the same data generate divergent conclusions.
PG  - 1925-7
AB  - Recently, major scientific societies in Europe and USA have issued guidelines on 
      diabetes and cardiovascular (CV) disease. The conclusions of the two panels of 
      experts regarding the use of aspirin for the primary prevention of CV disease in 
      individuals with diabetes are totally divergent. The US statement recommends the 
      use of aspirin for primary prevention in all individuals aged > 40 or with 
      additional risk factors. In contrast, in the European guidelines there is no 
      mention of aspirin for the primary prevention of myocardial infarction or CV 
      death, while it is recommended for the prevention of stroke. Both recommendations 
      seem mainly based on extrapolations from data on other high-risk groups, rather 
      than on a comprehensive review of pertinent data. Actually, a body of evidence 
      suggests that the efficacy of aspirin in patients with diabetes is substantially 
      lower than in individuals without diabetes. Nevertheless, existing knowledge is 
      mainly derived from dated trials, including small numbers of patients, and hardly 
      representing current strategies for the management of CV risk factors. The high 
      level of uncertainty regarding the balance between benefits and risks of aspirin 
      therapy have important implications for clinical practice, auditing activities, 
      and the design and conduct of randomized clinical trials.
FAU - Nicolucci, Antonio
AU  - Nicolucci A
AD  - Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, 
      Via Nazionale, 66030 S. Maria Imbaro (CH), Italy. nicolucci@negrisud.it
FAU - De Berardis, Giorgia
AU  - De Berardis G
FAU - Sacco, Michele
AU  - Sacco M
FAU - Tognoni, Gianni
AU  - Tognoni G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070629
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Data Collection
MH  - Data Interpretation, Statistical
MH  - Diabetic Angiopathies/*prevention & control
MH  - Europe
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Practice Guidelines as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Societies, Medical
MH  - United States
EDAT- 2007/07/03 09:00
MHDA- 2008/04/04 09:00
CRDT- 2007/07/03 09:00
PHST- 2007/07/03 09:00 [pubmed]
PHST- 2008/04/04 09:00 [medline]
PHST- 2007/07/03 09:00 [entrez]
AID - ehm248 [pii]
AID - 10.1093/eurheartj/ehm248 [doi]
PST - ppublish
SO  - Eur Heart J. 2007 Aug;28(16):1925-7. doi: 10.1093/eurheartj/ehm248. Epub 2007 Jun 
      29.

PMID- 11712038
OWN - NLM
STAT- MEDLINE
DCOM- 20011228
LR  - 20131121
IS  - 0190-9622 (Print)
IS  - 0190-9622 (Linking)
VI  - 45
IP  - 6
DP  - 2001 Dec
TI  - The effect of topically applied aspirin on localized circumscribed 
      neurodermatitis.
PG  - 910-3
AB  - BACKGROUND: Lichen simplex chronicus is a troublesome intractable itchy 
      dermatosis, which may persist despite intensive topical treatments. Recently it 
      has been demonstrated that topical aspirin solution with dichloromethane has a 
      significant antipruritic effect in an experimentally induced itch. OBJECTIVE: The 
      aim of this double-blind, crossover placebo trial was to evaluate the efficacy of 
      this solution in the treatment of lichen simplex chronicus. METHODS: Twenty-nine 
      patients with lichen simplex chronicus of at least 3 months' duration that did 
      not respond to topical corticosteroids were randomized in a double-blind fashion 
      to receive aspirin/dichloromethane solution in treatment period 1 for 2 weeks 
      followed by placebo in treatment period 2 or placebo followed by aspirin in 
      period 2 with a crossover design after a 2-week washout. The patients rated the 
      pruritus intensity before and during therapy with a visual analog scale; a 
      blinded investigator performed photographic assessment. RESULTS: A significant 
      therapeutic response was achieved in 11 (46%) of the patients who completed the 
      study compared with 3 patients (12%) receiving placebo. Overall, aspirin-treated 
      patients experienced an average decrease in the visual analog scale of 2.18 +/- 
      2.86 versus 0.69 +/- 2.31 of those receiving placebo. The difference between the 
      2 treatments for week 2 was significant (P =.03). CONCLUSION: The study suggests 
      that topical aspirin/dichloromethane might be a practical treatment for lichen 
      simplex chronicus.
FAU - Yosipovitch, G
AU  - Yosipovitch G
AD  - National Skin Center, National Medical Research Council, Ministry of Health, 
      Singapore.
FAU - Sugeng, M W
AU  - Sugeng MW
FAU - Chan, Y H
AU  - Chan YH
FAU - Goon, A
AU  - Goon A
FAU - Ngim, S
AU  - Ngim S
FAU - Goh, C L
AU  - Goh CL
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Solutions)
RN  - 588X2YUY0A (Methylene Chloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Topical
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Methylene Chloride/administration & dosage
MH  - Middle Aged
MH  - Neurodermatitis/*drug therapy
MH  - Solutions
MH  - Treatment Outcome
EDAT- 2001/11/17 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/17 10:00
PHST- 2001/11/17 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/17 10:00 [entrez]
AID - S0190-9622(01)43106-9 [pii]
AID - 10.1067/mjd.2001.117399 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2001 Dec;45(6):910-3. doi: 10.1067/mjd.2001.117399.

PMID- 20218297
OWN - NLM
STAT- MEDLINE
DCOM- 20110111
LR  - 20131121
IS  - 1001-4454 (Print)
IS  - 1001-4454 (Linking)
VI  - 32
IP  - 11
DP  - 2009 Nov
TI  - [Effects of danhong injection on experimental atherosclerosis rabbit model and 
      its mechanism].
PG  - 1720-2
AB  - OBJECTIVE: To observe the effects of Danhong injection on experimental 
      atherosclerosis rabbits and explore its possible mechanism. METHODS: Forty 
      New-Zealand male rabbits were randomly divided into four groups: normal control 
      group, high-cholesterol group, danhong injection group and aspirin group, all 
      rabbits were administered for fourteen weeks. The plaque area of aorta in each 
      group was determined by image analysis. The blood lipid level was tested by ELISA 
      method, malonaldehyde (MDA) in aorta wall was analyzed with thiobarbituric acid 
      method, the iNOS and COX-2 in aorta wall was tested with RT-PCR method. RESULT: 
      There were significant difference between danhong injection group and other 
      groups (P < 0.5), danhong injection and Aspirin decreased the TG, TC and LDL-C 
      level in plasma of rabbit model and decreased the expression of inflammatory 
      cytokines and the oxidative stress level in aorta wall. CONCLUSION: Danhong 
      injection can inhibit the formation of experimental atherosclerosis in rabbits, 
      which may be related to decreasing blood lipid, plaque inflammation and oxidative 
      stress level.
FAU - Fu, Ting-ting
AU  - Fu TT
AD  - Guangdong Provincial People's Hospital, Guangzhou 510080, China. 
      tien404@hotmail.com
FAU - Wang, Chang-jun
AU  - Wang CJ
FAU - Min, Cun-yun
AU  - Min CY
FAU - Huang, Xu-hui
AU  - Huang XH
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhong Yao Cai
JT  - Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials
JID - 9426370
RN  - 0 (Drug Combinations)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Triglycerides)
RN  - 0 (danhong)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta/*drug effects/metabolism/pathology
MH  - Aspirin/pharmacology/therapeutic use
MH  - Atherosclerosis/*drug therapy/metabolism/prevention & control
MH  - Carthamus tinctorius/chemistry
MH  - Cholesterol/blood
MH  - Disease Models, Animal
MH  - Drug Combinations
MH  - Drugs, Chinese Herbal/chemistry/*pharmacology/therapeutic use
MH  - Injections
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Nitric Oxide Synthase/metabolism
MH  - Oxidative Stress/drug effects
MH  - *Phytotherapy
MH  - Rabbits
MH  - Random Allocation
MH  - Triglycerides/blood
EDAT- 2010/03/12 06:00
MHDA- 2011/01/12 06:00
CRDT- 2010/03/12 06:00
PHST- 2010/03/12 06:00 [entrez]
PHST- 2010/03/12 06:00 [pubmed]
PHST- 2011/01/12 06:00 [medline]
PST - ppublish
SO  - Zhong Yao Cai. 2009 Nov;32(11):1720-2.

PMID- 11787522
OWN - NLM
STAT- MEDLINE
DCOM- 20020626
LR  - 20190921
IS  - 0920-5063 (Print)
IS  - 0920-5063 (Linking)
VI  - 12
IP  - 9
DP  - 2001
TI  - A vanadium/aspirin complex controlled release using a poly(beta-propiolactone) 
      film. Effects on osteosarcoma cells.
PG  - 945-59
AB  - A delivery system for vanadium was developed using poly(beta-propiolactone) 
      (PbetaPL) films. The release kinetics of a complex of vanadium (IV) with aspirin 
      (VOAspi) was evaluated with films prepared from polymers of different molecular 
      weights, as well as with variable drug load. A sustained release of vanadium over 
      7 days was achieved. The drug release kinetics depends on contributions from two 
      factors: (a) diffusion of the drug; and (b) erosion of the PbetaPL film. The 
      experimental data at an early stage of release were fitted with a diffusion 
      model, which allowed determination of the diffusion coefficient of the drug. 
      VOAspi does not show strong interaction with the polymer, as demonstrated by the 
      low apparent partition coefficient (approximately 10(-2)). UMR106 osteosarcoma 
      cells were used as a model to evaluate the anticarcinogenic effects of the VOAspi 
      released from the PbetaPPL film. VOAspi-PbetaPL film inhibited cell proliferation 
      in a dose-response manner and induced formation of approximately half of the 
      thiobarbituric acid reactive substances (TBARS), an index of lipid peroxidation. 
      compared to that with free VOAspi in solution. The unloaded PbetaPL film did not 
      generate cytotoxicity, as evaluated by cell growth and TBARS. Thus, the 
      polymer-embedded VOAspi retained the antiproliferative effects showing lower 
      cytotoxicity than the free drug. Results with VOAspi-PbetaPL films suggest that 
      this delivery system may have promising biomedical and therapeutic applications.
FAU - Cortizo, M S
AU  - Cortizo MS
AD  - INIFTA, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, 
      Argentina. cortizo@biol.unlp.edu.ar
FAU - Alessandrini, J L
AU  - Alessandrini JL
FAU - Etcheverr, S B
AU  - Etcheverr SB
FAU - Cortizo, A M
AU  - Cortizo AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Biomater Sci Polym Ed
JT  - Journal of biomaterials science. Polymer edition
JID - 9007393
RN  - 0 (Drug Combinations)
RN  - 0 (Thiobarbituric Acid Reactive Substances)
RN  - 00J9J9XKDE (Vanadium)
RN  - 059QF0KO0R (Water)
RN  - 6RC3ZT4HB0 (Propiolactone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - Bone Neoplasms/drug therapy
MH  - Cell Division/drug effects
MH  - Drug Combinations
MH  - *Drug Delivery Systems
MH  - Kinetics
MH  - Lipid Peroxidation/drug effects
MH  - Osteoblasts/drug effects
MH  - Osteosarcoma/drug therapy
MH  - Oxidative Stress/drug effects
MH  - Propiolactone/administration & dosage/*pharmacology
MH  - Rats
MH  - Thiobarbituric Acid Reactive Substances/metabolism
MH  - Tumor Cells, Cultured
MH  - Vanadium/*administration & dosage/pharmacokinetics
MH  - Water
EDAT- 2002/01/15 10:00
MHDA- 2002/06/27 10:01
CRDT- 2002/01/15 10:00
PHST- 2002/01/15 10:00 [pubmed]
PHST- 2002/06/27 10:01 [medline]
PHST- 2002/01/15 10:00 [entrez]
AID - 10.1163/156856201753252499 [doi]
PST - ppublish
SO  - J Biomater Sci Polym Ed. 2001;12(9):945-59. doi: 10.1163/156856201753252499.

PMID- 16783270
OWN - NLM
STAT- MEDLINE
DCOM- 20060804
LR  - 20191026
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 35
IP  - 6 Pt 2
DP  - 2006 Jun
TI  - [Management of hypertension in patients with diabetes].
PG  - 1041-6
AB  - Cardiovascular risk is generally high in patients with both hypertension and 
      diabetes and should be specifically assessed for each individual. The blood 
      pressure target is<130/80 mm Hg. Two or even three different drugs are often 
      necessary to reach this rather difficult goal. Angiotensin-converting enzyme 
      (ACE) inhibitors are preferred for patients with renal damage. Proteinuria should 
      be reduced to less than 0.5 g/day. Associated risk factors should be treated with 
      equal effectiveness. In particular, LDL cholesterol should be lowered to less 
      than 1 g/L when additional risk factors are present. Aspirin (0.75 mg a day) 
      should be given routinely as soon as blood pressure is controlled.
FAU - Mignot, Aude
AU  - Mignot A
AD  - Département de Cardiologie, CHU Poitiers.
FAU - Sosner, Philippe
AU  - Sosner P
FAU - Llaty, Pierre
AU  - Llaty P
FAU - Herpin, Daniel
AU  - Herpin D
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Prise en charge de l'hypertension artérielle chez le patient diabétique.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Sodium Chloride Symporter Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cholesterol, LDL/blood
MH  - Diabetes Mellitus/*epidemiology
MH  - Diagnosis, Differential
MH  - Drug Administration Schedule
MH  - Humans
MH  - Hypertension/blood/*drug therapy/*epidemiology
MH  - Sodium Chloride Symporter Inhibitors/therapeutic use
RF  - 36
EDAT- 2006/06/20 09:00
MHDA- 2006/08/05 09:00
CRDT- 2006/06/20 09:00
PHST- 2006/06/20 09:00 [pubmed]
PHST- 2006/08/05 09:00 [medline]
PHST- 2006/06/20 09:00 [entrez]
AID - S0755-4982(06)74745-5 [pii]
AID - 10.1016/s0755-4982(06)74745-5 [doi]
PST - ppublish
SO  - Presse Med. 2006 Jun;35(6 Pt 2):1041-6. doi: 10.1016/s0755-4982(06)74745-5.

PMID- 1474533
OWN - NLM
STAT- MEDLINE
DCOM- 19930202
LR  - 20181130
IS  - 0380-0903 (Print)
IS  - 0380-0903 (Linking)
VI  - 36
DP  - 1992 Nov
TI  - Clinical efficacy and safety of nabumetone in rheumatoid arthritis and 
      osteoarthritis.
PG  - 32-40
AB  - The efficacy and safety of nabumetone were evaluated in short term (up to 6 
      months), double blind, comparative trials and a longterm (up to 8 years), open 
      label, noncomparative trial. In the short term trials, nabumetone was determined 
      to be significantly more effective than placebo and as effective as naproxen and 
      aspirin. The most common adverse effects that occurred were related to the 
      gastrointestinal tract, nervous system, skin, and special senses. In the longterm 
      trial, nabumetone was effective in 62% of patients, without complicating effects, 
      for at least 1 year. This beneficial response was maintained in a fair percentage 
      of patients for up to 5 years or more. The average treatment duration before 
      withdrawal was at least 1.1 years. Therefore, most patients in the longterm 
      trials experienced a beneficial response for a significant duration of therapy.
FAU - Fleischmann, R M
AU  - Fleischmann RM
AD  - St. Paul Medical Center, Dallas, TX 75235.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - J Rheumatol Suppl
JT  - The Journal of rheumatology. Supplement
JID - 7806058
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Butanones)
RN  - 57Y76R9ATQ (Naproxen)
RN  - LW0TIW155Z (Nabumetone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aging/physiology
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Butanones/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Nabumetone
MH  - Naproxen/adverse effects/therapeutic use
MH  - Osteoarthritis/*drug therapy
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol Suppl. 1992 Nov;36:32-40.

PMID- 16751928
OWN - NLM
STAT- MEDLINE
DCOM- 20070306
LR  - 20191026
IS  - 0102-8650 (Print)
IS  - 0102-8650 (Linking)
VI  - 21
IP  - 3
DP  - 2006 May-Jun
TI  - Effects of acetylsalicylic acid and acetic acid solutions in VX2 carcinoma cells: 
      in vitro analysis.
PG  - 151-4
AB  - PURPOSE: To analyze, in vitro, the effects of acetylsalicylic acid (aspirin) and 
      acetic acid solutions on VX2 carcinoma cells in suspension and to examine the 
      correlation between these effects and neoplastic cell death. METHODS: The VX2 
      tumor cells (10(7) cells/ml) were incubated in solutions containing differing 
      concentrations (2.5% and 5%) of either acetylsalicylic acid or acetic acid, or in 
      saline solution (controls). Every five minutes, cell viability was tested (using 
      the trypan blue test) and analyzed under light microscopy. RESULTS: Tumor cell 
      viability (in %) decreased progressively and, by 30 minutes, neoplastic cell 
      death had occurred in all solutions. CONCLUSION: Based on this experimental model 
      and the methodology employed, we conclude that these solutions cause neoplastic 
      cell death in vitro.
FAU - Saad-Hossne, Rogério
AU  - Saad-Hossne R
AD  - Department of Surgery and Orthopedics, Botucatu Medical School, Paulista State 
      University, Brazil. saad@fmb.unesp.br
FAU - Prado, René Gamberini
AU  - Prado RG
FAU - Hossne, William Saad
AU  - Hossne WS
LA  - eng
PT  - Journal Article
DEP - 20060526
PL  - Brazil
TA  - Acta Cir Bras
JT  - Acta cirurgica brasileira
JID - 9103983
RN  - 0 (Drug Combinations)
RN  - 0 (Indicators and Reagents)
RN  - Q40Q9N063P (Acetic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetic Acid/*therapeutic use
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - *Cell Death
MH  - Cell Survival/drug effects
MH  - Drug Combinations
MH  - Drug Screening Assays, Antitumor/methods
MH  - In Vitro Techniques
MH  - Indicators and Reagents/*therapeutic use
MH  - Microscopy, Fluorescence
MH  - Neoplasms, Experimental/*drug therapy/pathology
MH  - Rabbits
EDAT- 2006/06/06 09:00
MHDA- 2007/03/07 09:00
CRDT- 2006/06/06 09:00
PHST- 2006/06/06 09:00 [pubmed]
PHST- 2007/03/07 09:00 [medline]
PHST- 2006/06/06 09:00 [entrez]
AID - S0102-86502006000300006 [pii]
AID - 10.1590/s0102-86502006000300006 [doi]
PST - ppublish
SO  - Acta Cir Bras. 2006 May-Jun;21(3):151-4. doi: 10.1590/s0102-86502006000300006. 
      Epub 2006 May 26.

PMID- 3891304
OWN - NLM
STAT- MEDLINE
DCOM- 19850813
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 29
IP  - 5
DP  - 1985 May
TI  - Transient ischaemic attacks. Current treatment concepts.
PG  - 474-82
AB  - Transient ischaemic attacks are common, having an incidence of at least 50 per 
      100,000 population per annum, and the risk of stroke and/or death is about 10% 
      per annum. Death is more often due to the complications of coronary artery 
      disease than cerebrovascular disease. The most important issues in management are 
      distinguishing transient ischaemic attacks from several other causes of 
      'transient focal neurological attacks', and managing the risk factors for 
      vascular disease in general, particularly hypertension. The utility of specific 
      'antithrombotic' treatments is still uncertain, but for long term use aspirin 
      seems to be the most promising. The only dose so far tested in clinical trials 
      has been about 600mg twice daily but lower doses may theoretically be as, or 
      more, effective. Trials of aspirin and other antiplatelet agents, and also of 
      carotid endarterectomy and extracranial-to-intracranial bypass surgery are 
      continuing and should be strongly encouraged. Although transient ischaemic 
      attacks recover - by definition - in 24 hours, the pathophysiology, natural 
      history, and treatment of focal cerebral ischaemia which recovers in a matter of 
      days or weeks is probably rather similar.
FAU - Warlow, C
AU  - Warlow C
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Blood Platelets/drug effects
MH  - Carotid Arteries/surgery
MH  - Humans
MH  - Ischemic Attack, Transient/physiopathology/surgery/*therapy
RF  - 15
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
AID - 10.2165/00003495-198529050-00003 [doi]
PST - ppublish
SO  - Drugs. 1985 May;29(5):474-82. doi: 10.2165/00003495-198529050-00003.

PMID- 31815652
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20200727
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 20
IP  - 1
DP  - 2019 Dec 9
TI  - Overcoming challenges to data quality in the ASPREE clinical trial.
PG  - 686
LID - 10.1186/s13063-019-3789-2 [doi]
LID - 686
AB  - BACKGROUND: Large-scale studies risk generating inaccurate and missing data due 
      to the complexity of data collection. Technology has the potential to improve 
      data quality by providing operational support to data collectors. However, this 
      potential is under-explored in community-based trials. The Aspirin in reducing 
      events in the elderly (ASPREE) trial developed a data suite that was specifically 
      designed to support data collectors: the ASPREE Web Accessible Relational 
      Database (AWARD). This paper describes AWARD and the impact of system design on 
      data quality. METHODS: AWARD's operational requirements, conceptual design, key 
      challenges and design solutions for data quality are presented. Impact of design 
      features is assessed through comparison of baseline data collected prior to 
      implementation of key functionality (n = 1000) with data collected post 
      implementation (n = 18,114). Overall data quality is assessed according to data 
      category. RESULTS: At baseline, implementation of user-driven functionality 
      reduced staff error (from 0.3% to 0.01%), out-of-range data entry (from 0.14% to 
      0.04%) and protocol deviations (from 0.4% to 0.08%). In the longitudinal data 
      set, which contained more than 39 million data values collected within AWARD, 
      96.6% of data values were entered within specified query range or found to be 
      accurate upon querying. The remaining data were missing (3.4%). Participant 
      non-attendance at scheduled study activity was the most common cause of missing 
      data. Costs associated with cleaning data in ASPREE were lower than expected 
      compared with reports from other trials. CONCLUSIONS: Clinical trials undertake 
      complex operational activity in order to collect data, but technology rarely 
      provides sufficient support. We find the AWARD suite provides proof of principle 
      that designing technology to support data collectors can mitigate known causes of 
      poor data quality and produce higher-quality data. Health information technology 
      (IT) products that support the conduct of scheduled activity in addition to 
      traditional data entry will enhance community-based clinical trials. A 
      standardised framework for reporting data quality would aid comparisons across 
      clinical trials. TRIAL REGISTRATION: International Standard Randomized Controlled 
      Trial Number Register, ISRCTN83772183. Registered on 3 March 2005.
FAU - Lockery, Jessica E
AU  - Lockery JE
AUID- ORCID: 0000-0001-6664-1239
AD  - Department of Epidemiology & Preventive Medicine, Monash University, ASPREE 
      Co-ordinating Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia. 
      jessica.lockery@monash.edu.
FAU - Collyer, Taya A
AU  - Collyer TA
AD  - Department of Epidemiology & Preventive Medicine, Monash University, ASPREE 
      Co-ordinating Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - Department of Epidemiology & Preventive Medicine, Monash University, ASPREE 
      Co-ordinating Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
AD  - School of Public Health, Curtin University, Perth, WA, Australia.
FAU - Ernst, Michael E
AU  - Ernst ME
AD  - Department of Pharmacy Practice and Science, College of Pharmacy and Department 
      of Family Medicine, Carver College of Medicine, The University of Iowa, Iowa 
      City, USA.
FAU - Gilbertson, David
AU  - Gilbertson D
AD  - Chronic Disease Research Group, Minneapolis Medical Research Foundation, 
      Minneapolis, Minnesota, USA.
FAU - Hay, Nino
AU  - Hay N
AD  - Department of Epidemiology & Preventive Medicine, Monash University, ASPREE 
      Co-ordinating Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
FAU - Kirpach, Brenda
AU  - Kirpach B
AD  - Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research 
      Institute (HHRI), Hennepin Healthcare, Minneapolis, MN, USA.
FAU - McNeil, John J
AU  - McNeil JJ
AD  - Department of Epidemiology & Preventive Medicine, Monash University, ASPREE 
      Co-ordinating Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
FAU - Nelson, Mark R
AU  - Nelson MR
AD  - Department of Epidemiology & Preventive Medicine, Monash University, ASPREE 
      Co-ordinating Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 
      Australia.
FAU - Orchard, Suzanne G
AU  - Orchard SG
AD  - Department of Epidemiology & Preventive Medicine, Monash University, ASPREE 
      Co-ordinating Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
FAU - Pruksawongsin, Kunnapoj
AU  - Pruksawongsin K
AD  - Department of Epidemiology & Preventive Medicine, Monash University, ASPREE 
      Co-ordinating Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
FAU - Shah, Raj C
AU  - Shah RC
AD  - Department of Family Medicine and Rush Alzheimer's Disease Center, Rush 
      University Medical Center, Chicago, IL, USA.
FAU - Wolfe, Rory
AU  - Wolfe R
AD  - Department of Epidemiology & Preventive Medicine, Monash University, ASPREE 
      Co-ordinating Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
FAU - Woods, Robyn L
AU  - Woods RL
AD  - Department of Epidemiology & Preventive Medicine, Monash University, ASPREE 
      Co-ordinating Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
CN  - ASPREE Investigator Group
LA  - eng
GR  - U19 AG062682/AG/NIA NIH HHS/United States
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U10AG029824/Division of Cancer Prevention, National Cancer Institute/
GR  - 1127060/National Health and Medical Research Council of Australia/
GR  - U10AG029824/AG/NIA NIH HHS/United States
GR  - 334047/National Health and Medical Research Council of Australia/
PT  - Journal Article
DEP - 20191209
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - *Clinical Trials as Topic/economics
MH  - Cost-Benefit Analysis
MH  - *Data Accuracy
MH  - Data Collection
MH  - Databases, Factual
MH  - Humans
MH  - Medical Informatics
PMC - PMC6902598
OTO - NOTNLM
OT  - Clinical trial
OT  - Data quality
OT  - Health data
OT  - Health technology
COIS- The authors declare that they have no competing interests.
EDAT- 2019/12/10 06:00
MHDA- 2020/07/28 06:00
CRDT- 2019/12/10 06:00
PHST- 2019/03/04 00:00 [received]
PHST- 2019/10/05 00:00 [accepted]
PHST- 2019/12/10 06:00 [entrez]
PHST- 2019/12/10 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - 10.1186/s13063-019-3789-2 [pii]
AID - 3789 [pii]
AID - 10.1186/s13063-019-3789-2 [doi]
PST - epublish
SO  - Trials. 2019 Dec 9;20(1):686. doi: 10.1186/s13063-019-3789-2.

PMID- 24492939
OWN - NLM
STAT- MEDLINE
DCOM- 20140624
LR  - 20211021
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 35
IP  - 5
DP  - 2014 May
TI  - Efficacy of acetylsalicylic acid (aspirin) in skin B16-F0 melanoma tumor-bearing 
      C57BL/6 mice.
PG  - 4967-76
LID - 10.1007/s13277-014-1654-1 [doi]
AB  - Several epidemiological studies show that aspirin can act as a chemopreventive 
      agent and decrease the incidences of various cancers including melanoma. In this 
      work, we investigated the in vitro and in vivo efficacy of acetylsalicylic acid 
      (ASA) as an antimelanoma agent in B16-F0 cells and skin B16-F0 melanoma tumor 
      mouse model. Our findings indicate that the IC50 (48 h) for ASA in B16-F0 
      melanoma cells was 100 μM and that ASA caused a dose- and time-dependent GSH 
      depletion and increase in reactive oxygen species (ROS) formation in B16-F0 
      melanoma cells. Male C57BL/6 mice were inoculated s.c. with 1 × 10(6) B16-F0 
      melanoma cells. ASA (80, 100, and 150 mg/kg) was initiated on day 1 or day 7, or 
      day 9 after cell inoculation and continued daily for 13, 7, and 5 days, 
      respectively. Animals were weighed daily and sacrificed on day 13. The tumors 
      were excised and weighed. The animals receiving 13 days of ASA therapy at 80, 
      100, and 150 mg/kg demonstrated tumor growth inhibition by 1 ± 12%, 19 ± 22%, and 
      50 ± 29%, respectively. Animals receiving 7 days of therapy at 80, 100, and 150 
      mg/kg demonstrated tumor growth inhibition by 12 ± 14%, 27 ± 14%, and 40 ± 14%, 
      respectively. No significant tumor growth inhibition was observed with 5 days of 
      therapy. ASA at 100 and 150 mg/kg caused significant tumor growth inhibition in 
      C57BL/6 mice when administered for 13 and 7 days, respectively. The results 
      obtained in this study are consistent with the recent epidemiologically based 
      report that aspirin is associated with lower melanoma risk in humans.
FAU - Vad, Nikhil M
AU  - Vad NM
AD  - Department of Pharmaceutical and Department of Biomedical Sciences, School of 
      Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
FAU - Kudugunti, Shashi K
AU  - Kudugunti SK
FAU - Wang, Hezhen
AU  - Wang H
FAU - Bhat, G Jayarama
AU  - Bhat GJ
FAU - Moridani, Majid Y
AU  - Moridani MY
LA  - eng
GR  - 1R15CA122044-01A1/CA/NCI NIH HHS/United States
GR  - 5R03CA133061-02/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140204
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Reactive Oxygen Species)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alanine Transaminase/blood
MH  - Animals
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use/toxicity
MH  - Glutathione/metabolism
MH  - Kidney/metabolism
MH  - Lipid Peroxidation/drug effects
MH  - Liver/drug effects/metabolism
MH  - Male
MH  - Melanoma, Experimental/pathology/*prevention & control
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Reactive Oxygen Species/metabolism
MH  - Skin Neoplasms/pathology/*prevention & control
EDAT- 2014/02/05 06:00
MHDA- 2014/06/25 06:00
CRDT- 2014/02/05 06:00
PHST- 2013/12/12 00:00 [received]
PHST- 2014/01/13 00:00 [accepted]
PHST- 2014/02/05 06:00 [entrez]
PHST- 2014/02/05 06:00 [pubmed]
PHST- 2014/06/25 06:00 [medline]
AID - 10.1007/s13277-014-1654-1 [doi]
PST - ppublish
SO  - Tumour Biol. 2014 May;35(5):4967-76. doi: 10.1007/s13277-014-1654-1. Epub 2014 
      Feb 4.

PMID- 18042592
OWN - NLM
STAT- MEDLINE
DCOM- 20080401
LR  - 20131121
IS  - 0961-2033 (Print)
IS  - 0961-2033 (Linking)
VI  - 16
IP  - 12
DP  - 2007
TI  - Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus.
PG  - 981-6
AB  - Incomplete suppression of thromboxane biosynthesis during aspirin therapy is 
      associated with increased cardiovascular risk. Since systemic lupus erythematosus 
      (SLE) is associated with platelet activation and increased cardiovascular 
      mortality, we compared thromboxane and prostacyclin biosynthesis in patients with 
      SLE and control subjects, and measured inhibition of thromboxane excretion in 
      aspirin-treated subjects. We measured the urinary excretion of 11-dehydro 
      thromboxane B( 2) (TXB(2)) and 2,3-dinor 6-ketoPGF(1alpha) (PGI-M), the stable 
      metabolites of thromboxane A(2) and prostacyclin, respectively, in 74 patients 
      with SLE and 70 controls. In subjects who were not receiving aspirin, TXB(2) 
      excretion was higher in patients with SLE [0.40 ng/mg creatinine (0.26-0.64), 
      median (interquartile range)] than controls [0.31 ng/mg creatinine (0.23-0.44)] 
      (P = 0.04), and in these patients, TXB(2) excretion correlated with disease 
      activity (rho = 0.28, P = 0.03) and tumor necrosis factor alpha (rho = 0.48, P < 
      0.001). Aspirin therapy resulted in significantly lower TXB(2) excretion in 
      controls (P = 0.01), but not in patients with SLE (P = 0.10), compared with 
      subjects not receiving aspirin. Prostacyclin biosynthesis did not differ among 
      patients and controls, and was not affected by aspirin (P all >0.35). Thromboxane 
      biosynthesis is increased in SLE and is associated with disease activity. 
      Additionally, response to aspirin may be attenuated in some patients with SLE.
FAU - Avalos, Ingrid
AU  - Avalos I
AD  - Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 
      37232-2681, USA. ingrid.avalos@vanderbilt.edu
FAU - Chung, Cecilia P
AU  - Chung CP
FAU - Oeser, Annette
AU  - Oeser A
FAU - Milne, Ginger L
AU  - Milne GL
FAU - Borntrager, Holly
AU  - Borntrager H
FAU - Morrow, Jason D
AU  - Morrow JD
FAU - Raggi, Paolo
AU  - Raggi P
FAU - Solus, Joseph
AU  - Solus J
FAU - Stein, C Michael
AU  - Stein CM
LA  - eng
GR  - 5 M01 RR00095/RR/NCRR NIH HHS/United States
GR  - DK48831/DK/NIDDK NIH HHS/United States
GR  - ES13125/ES/NIEHS NIH HHS/United States
GR  - GM15431/GM/NIGMS NIH HHS/United States
GR  - HL04012/HL/NHLBI NIH HHS/United States
GR  - HL65082/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - *Drug Resistance
MH  - Epoprostenol/metabolism
MH  - Female
MH  - Humans
MH  - Lupus Erythematosus, Systemic/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Thromboxane A2/*metabolism
EDAT- 2007/11/29 09:00
MHDA- 2008/04/02 09:00
CRDT- 2007/11/29 09:00
PHST- 2007/11/29 09:00 [pubmed]
PHST- 2008/04/02 09:00 [medline]
PHST- 2007/11/29 09:00 [entrez]
AID - 16/12/981 [pii]
AID - 10.1177/0961203307083313 [doi]
PST - ppublish
SO  - Lupus. 2007;16(12):981-6. doi: 10.1177/0961203307083313.

PMID- 31155427
OWN - NLM
STAT- MEDLINE
DCOM- 20200127
LR  - 20200127
IS  - 0210-5705 (Print)
IS  - 0210-5705 (Linking)
VI  - 42
IP  - 7
DP  - 2019 Aug-Sep
TI  - Periendoscopic management of antiplatelet therapy: Prospective evaluation of 
      adherence to guidelines.
PG  - 423-428
LID - S0210-5705(19)30121-9 [pii]
LID - 10.1016/j.gastrohep.2019.03.010 [doi]
AB  - INTRODUCCIóN: Adherence to guidelines on the periendoscopic management of 
      antiplatelet therapy (APT) has not been analyzed in detail. Our aim was to assess 
      adherence to guidelines in patients referred to our Endoscopy Unit on a 
      case-by-case basis, describing in detail the detected deviations and identifying 
      areas of improvement. PATIENTS AND METHODS: Cross-sectional study of outpatients 
      consecutively scheduled for an unsedated upper or lower gastrointestinal 
      endoscopy between January and June 2015. Patients on anticoagulant therapy were 
      excluded. RESULTS: 675 patients were evaluated, including 91 (13.5%) patients on 
      APT [upper GI endoscopy 25 (27.5%), lower GI endoscopy 66 (72.5%)]. Contrary to 
      the clinical guidelines, aspirin was discontinued in 25 of the 77 patients 
      previously prescribed the drug (32.5%) but this modification was patient's own 
      decision in 11 cases. Most of the apparent deviations in the management of 
      clopidogrel and dual antiplatelet therapy (DAPT) were not true non-adherence 
      cases. The Primary Care physician modified an APT prescribed by another physician 
      in 8 of 9 cases (88.9%), always in cases with aspirin. No relationship was found 
      between the endoscopic procedure's predicted risk of bleeding or the patient's 
      thrombotic risk and modification of therapy. DISCUSSION: In many patients, the 
      peri-procedural management of APT goes against current guidelines, but some of 
      these inconsistencies cannot be considered true deviations from practice. 
      Identified areas for improvement are increasing patient awareness about APT, 
      disseminating the guidelines in Primary Care, and underscoring the significance 
      of thrombotic risk related to APT withdrawal.
CI  - Copyright © 2019 Elsevier España, S.L.U. All rights reserved.
FAU - Plumé, Gema
AU  - Plumé G
AD  - Hematology Department, La Fe Polytechnic University Hospital, Avda. Fernando 
      Abril Martorell, 106, Valencia 46026, Spain.
FAU - Satorres, Carla
AU  - Satorres C
AD  - Gastrointestinal Endoscopy Unit, Digestive Diseases Department, La Fe Polytechnic 
      University Hospital, Avda. Fernando Abril Martorell, 106, Valencia 46026, Spain; 
      Gastrointestinal Endoscopy Research Group, IIS Hospital La Fe, Avda. Fernando 
      Abril Martorell, 106, Valencia 46026, Spain.
FAU - Diaz, Francia C
AU  - Diaz FC
AD  - Gastrointestinal Endoscopy Unit, Digestive Diseases Department, La Fe Polytechnic 
      University Hospital, Avda. Fernando Abril Martorell, 106, Valencia 46026, Spain.
FAU - Alonso, Noelia
AU  - Alonso N
AD  - Gastrointestinal Endoscopy Unit, Digestive Diseases Department, La Fe Polytechnic 
      University Hospital, Avda. Fernando Abril Martorell, 106, Valencia 46026, Spain; 
      Gastrointestinal Endoscopy Research Group, IIS Hospital La Fe, Avda. Fernando 
      Abril Martorell, 106, Valencia 46026, Spain.
FAU - Navarro, Belén
AU  - Navarro B
AD  - Gastrointestinal Endoscopy Unit, Digestive Diseases Department, La Fe Polytechnic 
      University Hospital, Avda. Fernando Abril Martorell, 106, Valencia 46026, Spain.
FAU - Ponce, Marta
AU  - Ponce M
AD  - Gastrointestinal Endoscopy Unit, Digestive Diseases Department, La Fe Polytechnic 
      University Hospital, Avda. Fernando Abril Martorell, 106, Valencia 46026, Spain; 
      Gastrointestinal Endoscopy Research Group, IIS Hospital La Fe, Avda. Fernando 
      Abril Martorell, 106, Valencia 46026, Spain.
FAU - Pons-Beltrán, Vicente
AU  - Pons-Beltrán V
AD  - Gastrointestinal Endoscopy Unit, Digestive Diseases Department, La Fe Polytechnic 
      University Hospital, Avda. Fernando Abril Martorell, 106, Valencia 46026, Spain; 
      Gastrointestinal Endoscopy Research Group, IIS Hospital La Fe, Avda. Fernando 
      Abril Martorell, 106, Valencia 46026, Spain.
FAU - Argüello, Lidia
AU  - Argüello L
AD  - Gastrointestinal Endoscopy Unit, Digestive Diseases Department, La Fe Polytechnic 
      University Hospital, Avda. Fernando Abril Martorell, 106, Valencia 46026, Spain; 
      Gastrointestinal Endoscopy Research Group, IIS Hospital La Fe, Avda. Fernando 
      Abril Martorell, 106, Valencia 46026, Spain.
FAU - Bustamante-Balén, Marco
AU  - Bustamante-Balén M
AD  - Gastrointestinal Endoscopy Unit, Digestive Diseases Department, La Fe Polytechnic 
      University Hospital, Avda. Fernando Abril Martorell, 106, Valencia 46026, Spain; 
      Gastrointestinal Endoscopy Research Group, IIS Hospital La Fe, Avda. Fernando 
      Abril Martorell, 106, Valencia 46026, Spain. Electronic address: 
      bustamante_mar@gva.es.
LA  - eng
LA  - spa
PT  - Journal Article
DEP - 20190530
PL  - Spain
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects
MH  - Clopidogrel/administration & dosage/adverse effects
MH  - Colonoscopy
MH  - Contraindications, Drug
MH  - Cross-Sectional Studies
MH  - *Endoscopy, Gastrointestinal
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - *Guideline Adherence
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - *Practice Guidelines as Topic
MH  - Prospective Studies
OTO - NOTNLM
OT  - Adecuación
OT  - Adequacy
OT  - Aspirin
OT  - Aspirina
OT  - Clopidogrel
OT  - Endoscopia
OT  - Endoscopy
OT  - Guidelines
OT  - Guías clínicas
OT  - Oral antiplatelet therapy
OT  - Tratamiento antiagregante plaquetario
EDAT- 2019/06/04 06:00
MHDA- 2020/01/28 06:00
CRDT- 2019/06/04 06:00
PHST- 2018/09/19 00:00 [received]
PHST- 2019/01/28 00:00 [revised]
PHST- 2019/03/12 00:00 [accepted]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2020/01/28 06:00 [medline]
PHST- 2019/06/04 06:00 [entrez]
AID - S0210-5705(19)30121-9 [pii]
AID - 10.1016/j.gastrohep.2019.03.010 [doi]
PST - ppublish
SO  - Gastroenterol Hepatol. 2019 Aug-Sep;42(7):423-428. doi: 
      10.1016/j.gastrohep.2019.03.010. Epub 2019 May 30.

PMID- 35943473
OWN - NLM
STAT- MEDLINE
DCOM- 20220811
LR  - 20230210
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 328
IP  - 6
DP  - 2022 Aug 9
TI  - Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure 
      After Coronary Artery Bypass Graft Surgery: A Systematic Review and 
      Meta-analysis.
PG  - 554-562
LID - 10.1001/jama.2022.11966 [doi]
AB  - IMPORTANCE: The role of ticagrelor with or without aspirin after coronary artery 
      bypass graft surgery remains unclear. OBJECTIVE: To compare the risks of vein 
      graft failure and bleeding associated with ticagrelor dual antiplatelet therapy 
      (DAPT) or ticagrelor monotherapy vs aspirin among patients undergoing coronary 
      artery bypass graft surgery. DATA SOURCES: MEDLINE, Embase, and Cochrane Library 
      databases from inception to June 1, 2022, without language restriction. STUDY 
      SELECTION: Randomized clinical trials (RCTs) comparing the effects of ticagrelor 
      DAPT or ticagrelor monotherapy vs aspirin on saphenous vein graft failure. DATA 
      EXTRACTION AND SYNTHESIS: Individual patient data provided by each trial were 
      synthesized into a combined data set for independent analysis. Multilevel 
      logistic regression models were used. MAIN OUTCOMES AND MEASURES: The primary 
      analysis assessed the incidence of saphenous vein graft failure per graft 
      (primary outcome) in RCTs comparing ticagrelor DAPT with aspirin. Secondary 
      outcomes were saphenous vein graft failure per patient and Bleeding Academic 
      Research Consortium (BARC) type 2, 3, or 5 bleeding events. A supplementary 
      analysis included RCTs comparing ticagrelor monotherapy with aspirin. RESULTS: A 
      total of 4 RCTs were included in the meta-analysis, involving 1316 patients and 
      1668 saphenous vein grafts. Of the 871 patients in the primary analysis, 435 
      received ticagrelor DAPT (median age, 67 years [IQR, 60-72 years]; 65 women 
      [14.9%]; 370 men [85.1%]) and 436 received aspirin (median age, 66 years [IQR, 
      61-73 years]; 63 women [14.5%]; 373 men [85.5%]). Ticagrelor DAPT was associated 
      with a significantly lower incidence of saphenous vein graft failure (11.2%) per 
      graft than was aspirin (20%; difference, -8.7% [95% CI, -13.5% to -3.9%]; OR, 
      0.51 [95% CI, 0.35 to 0.74]; P < .001) and was associated with a significantly 
      lower incidence of saphenous vein graft failure per patient (13.2% vs 23.0%, 
      difference, -9.7% [95% CI, -14.9% to -4.4%]; OR, 0.51 [95% CI, 0.35 to 0.74]; 
      P < .001). Ticagrelor DAPT (22.1%) was associated with a significantly higher 
      incidence of BARC type 2, 3, or 5 bleeding events than was aspirin (8.7%; 
      difference, 13.3% [95% CI, 8.6% to 18.0%]; OR, 2.98 [95% CI, 1.99 to 4.47]; 
      P < .001), but not BARC type 3 or 5 bleeding events (1.8% vs 1.8%, difference, 0% 
      [95% CI, -1.8% to 1.8%]; OR, 1.00 [95% CI, 0.37 to 2.69]; P = .99). Compared with 
      aspirin, ticagrelor monotherapy was not significantly associated with saphenous 
      vein graft failure (19.3% vs 21.7%, difference, -2.6% [95% CI, -9.1% to 3.9%]; 
      OR, 0.86 [95% CI, 0.58 to 1.27]; P = .44) or BARC type 2, 3, or 5 bleeding events 
      (8.9% vs 7.3%, difference, 1.7% [95% CI, -2.8% to 6.1%]; OR, 1.25 [95% CI, 0.69 
      to 2.29]; P = .46). CONCLUSIONS AND RELEVANCE: Among patients undergoing coronary 
      artery bypass graft surgery, adding ticagrelor to aspirin was associated with a 
      significantly decreased risk of vein graft failure. However, this was accompanied 
      by a significantly increased risk of clinically important bleeding.
FAU - Sandner, Sigrid
AU  - Sandner S
AD  - Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
AD  - Weill Cornell Medicine, New York, New York.
FAU - Redfors, Björn
AU  - Redfors B
AD  - Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - Division of Cardiology, University of Florida College of Medicine, Jacksonville.
FAU - Audisio, Katia
AU  - Audisio K
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.
FAU - Fremes, Stephen E
AU  - Fremes SE
AD  - Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, 
      Toronto, Ontario, Canada.
AD  - Institute of Health Policy Management and Evaluation, University of Toronto, 
      Toronto, Ontario, Canada.
FAU - Janssen, Paul W A
AU  - Janssen PWA
AD  - Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands.
FAU - Kulik, Alexander
AU  - Kulik A
AD  - Division of Cardiac Surgery, Boca Raton Regional Hospital and Florida Atlantic 
      Hospital, Boca Raton.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at 
      Mount Sinai, New York, New York.
FAU - Peper, Joyce
AU  - Peper J
AD  - Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands.
FAU - Ruel, Marc
AU  - Ruel M
AD  - Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, 
      Ontario, Canada.
FAU - Saw, Jacqueline
AU  - Saw J
AD  - Division of Cardiology, Vancouver General Hospital, British Columbia, Canada.
AD  - Division of Cardiology St Paul's Hospital, University of British Columbia, 
      Vancouver, Canada.
FAU - Soletti, Giovanni Jr
AU  - Soletti GJ
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.
FAU - Starovoytov, Andrew
AU  - Starovoytov A
AD  - Division of Cardiology, Vancouver General Hospital, British Columbia, Canada.
FAU - Ten Berg, Jurrien M
AU  - Ten Berg JM
AD  - Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands.
FAU - Willemsen, Laura M
AU  - Willemsen LM
AD  - Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands.
FAU - Zhao, Qiang
AU  - Zhao Q
AD  - Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, 
      China.
FAU - Zhu, Yunpeng
AU  - Zhu Y
AD  - Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, 
      China.
FAU - Gaudino, Mario
AU  - Gaudino M
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2022 Aug 9;328(6):532-533. PMID: 35943481
CIN - Eur Heart J. 2022 Nov 7;43(42):4456-4457. PMID: 36101473
CIN - JAMA. 2022 Dec 13;328(22):2273. PMID: 36511930
MH  - Aged
MH  - *Aspirin/adverse effects/therapeutic use
MH  - *Coronary Artery Bypass/adverse effects/methods
MH  - Female
MH  - Graft Occlusion, Vascular/etiology/prevention & control
MH  - Hemorrhage/chemically induced/etiology
MH  - Humans
MH  - Male
MH  - Percutaneous Coronary Intervention
MH  - *Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - *Saphenous Vein/transplantation
MH  - *Ticagrelor/adverse effects/therapeutic use
MH  - Treatment Outcome
PMC - PMC9364127
COIS- Conflict of Interest Disclosures: Dr Sandner reported receiving institutional 
      research grants from Vascular Grafts Solutions outside the submitted work. Dr 
      Angiolillo reported receiving consulting fees or honoraria from Abbott, Amgen, 
      AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, 
      Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx 
      Pharma, Pfizer, and Sanofi; and research grants to his institution from Amgen, 
      AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli 
      Lilly, Gilead, Janssen, Matsutani Chemical Industry Co, Merck, Novartis, Osprey 
      Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. Dr Janssen 
      reported receiving grants from AstraZeneca funding for the POPular CABG trial 
      during the conduct of the study. Dr Kulik reported receiving grants from 
      AstraZeneca during the conduct of the study. Dr Mehran reported receiving 
      research grants from Abbott, Abiomed, Alleviant Medical, AM-Pharma, Applied 
      Therapeutics, Arena, AstraZeneca, Bayer, Beth Israel Deaconess, Biosensors, 
      Biotronik, Bristol Myers Squibb, Boston Scientific Research, CardiaWave Research, 
      CellAegis, CeloNova, CERC, Chiesi, Concept Medical, CSL Behring, Daiichi Sankyo 
      Inc, Duke University, Humacyte, Idorsa Pharmaceuticals, Insel Gruppe AG, Janssen, 
      Medtronic, Novartis, OrbusNeich, Philips, Vivasure, and Zoll, all to her 
      institution; serving as a consultant to the California Institute for Regenerative 
      Medicine; serving on the scientific advisory board of the American Medical 
      Association; serving on the advisory boards of CERC (Biosnsors), Abbott, Arena, 
      Biotronik, CardiaWave, Chiesi, Concept Medical, Humacyte, Magenta, Novartis, and 
      Philips, all to her institution; serving on the board of the American College of 
      Cardiology, and as a committee member of the Women in Innovations of the Society 
      for Cardiovascular Angiography, all to her institution; serving as an unpaid 
      faculty of the Cardiovascular Research Foundation; receiving personal fees from 
      Cine-Med, Janssen, and WebMD; receiving less than 1% of equity in Applied 
      Therapeutics Equity, Elixir Medical, Stel, and ControlRad Equity (spouse) outside 
      the submitted work; and having other financial or nonfinancial interests in 
      Boston Scientific Corp and divested final stock options of less than 1% in Claret 
      Medical. Dr Saw reported receiving grants from AstraZeneca outside the submitted 
      work and serving as the principal investigator for the TAP-CABG study. Dr ten 
      Berg reported receiving speaker fees from AstraZeneca, Bayer, Boehringer 
      Ingelheim, and Celecor and institutional research grants from AstraZeneca and 
      ZonMw. Dr Willemsen reported receiving grants from AstraZeneca funding of the 
      POPular CABG trial during the conduct of the study. Dr Zhao reported receiving 
      grants from AstraZeneca during the conduct of the study and from Chugai Pharma 
      China outside the submitted work. Dr Zhu reported receiving personal fees from 
      Chugai Pharma China outside the submitted work. No other disclosures were 
      reported.
EDAT- 2022/08/10 06:00
MHDA- 2022/08/12 06:00
CRDT- 2022/08/09 11:03
PHST- 2022/08/09 11:03 [entrez]
PHST- 2022/08/10 06:00 [pubmed]
PHST- 2022/08/12 06:00 [medline]
AID - 2795029 [pii]
AID - joi220074 [pii]
AID - 10.1001/jama.2022.11966 [doi]
PST - ppublish
SO  - JAMA. 2022 Aug 9;328(6):554-562. doi: 10.1001/jama.2022.11966.

PMID- 33278804
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
VI  - 30
IP  - 2
DP  - 2021 Feb
TI  - Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in 
      TOAST Subtypes: ADS Post-Hoc Analysis.
PG  - 105494
LID - S1052-3057(20)30912-5 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2020.105494 [doi]
AB  - BACKGROUND: Our previous trial acute dual study (ADS) reported that dual 
      antiplatelet therapy (DAPT) using cilostazol and aspirin did not reduce the rate 
      of short-term neurological worsening in non-cardioembolic stroke patients. 
      Present post-hoc analysis investigated whether the impact of combined cilostazol 
      and aspirin differed among stroke subtypes and factors associated with 
      neurological deterioration and/or stroke recurrence. METHODS: Using the ADS 
      registry, the rate of neurological deterioration, defined as clinical worsening 
      and/or recurrent stroke, including transient ischemic attack was calculated. 
      Stroke subtypes included large-artery atherosclerosis (LAA), small vessel 
      occlusion (SVO), other determined etiology (Others), and undetermined etiology of 
      stroke (Undetermined). RESULTS: Data of 1022 patients were analyzed. 
      Deterioration was seen in 104 (10%) patients, and the rates were not markedly 
      different between patients treated with DAPT vs. aspirin in any stroke subtypes: 
      LAA, 19% vs. 11%, (p=0.192); SVO, 10% vs. 10% (p=1.000); Others, 6% vs. 6% 
      (p=1.000); Undetermined, 11% vs. 8% (p=0.590). Diabetes mellitus was the 
      independent factor associated with deterioration (odds ratio 4.360, 95% 
      confidence interval 1.139-16.691, p=0.032) in the LAA group. Age (1.030 
      [1.004-1.057], p=0.026), systolic blood pressure (1.012 [1.003-1.022], p=0.010), 
      and infarct size (2.550 [1.488-4.371], p=0.001) were associated with 
      deterioration in SVO group, and intracranial stenosis/occlusion was associated 
      with it in the Undetermined group (3.744 [1.138-12.318], p=0.030). CONCLUSIONS: 
      Combined cilostazol and aspirin did not reduce the rate of short-term 
      neurological deterioration in any clinical stroke subtype. The characteristics of 
      patients whose condition deteriorates in the acute period may differ based on the 
      stroke subtypes.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Aoki, Junya
AU  - Aoki J
AD  - Department of Neurological Science, Nippon Medical School Graduate School of 
      Medicine, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan; Department of Stroke 
      Medicine, Kawasaki Medical School, Kurashiki, Japan. Electronic address: 
      aokijy@gmail.com.
FAU - Iguchi, Yasuyuki
AU  - Iguchi Y
AD  - Department of Neurology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Urabe, Takao
AU  - Urabe T
AD  - Department of Neurology, Juntendo University Urayasu Hospital, Chiba, Japan.
FAU - Yamagami, Hiroshi
AU  - Yamagami H
AD  - Department of Neurology, Stroke Center, Kobe City Medical Center General 
      Hospital, Hyogo.
FAU - Todo, Kenichi
AU  - Todo K
AD  - Department of Neurology, Stroke Center, Kobe City Medical Center General 
      Hospital, Hyogo.
FAU - Fujimoto, Shigeru
AU  - Fujimoto S
AD  - Department of Cerebrovascular Medicine, Stroke Center, Steel Memorial Yawata 
      Hospital, Fukuoka, Japan.
FAU - Idomari, Koji
AU  - Idomari K
AD  - Department of Stroke Medicine, Okinawa Kyodo Hospital, Okinawa, Japan.
FAU - Kaneko, Nobuyuki
AU  - Kaneko N
AD  - Department of Stroke Medicine, Okinawa Kyodo Hospital, Okinawa, Japan.
FAU - Iwanaga, Takeshi
AU  - Iwanaga T
AD  - Department of Stroke Medicine, Okayama Red Cross Hospital, Okayama, Japan.
FAU - Terasaki, Tadashi
AU  - Terasaki T
AD  - Department of Neurology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
FAU - Tanaka, Ryota
AU  - Tanaka R
AD  - Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
FAU - Yamamoto, Nobuaki
AU  - Yamamoto N
AD  - Department of Clinical Neurosciences, Institute of Biomedical Sciences, Tokushima 
      University, Tokushima, Japan.
FAU - Tsujino, Akira
AU  - Tsujino A
AD  - Department of Neurology and Strokology, Nagasaki University Hospital, Nagasaki, 
      Japan.
FAU - Nomura, Koichi
AU  - Nomura K
AD  - Department of Neurology, Shioda Hospital, Chiba, Japan.
FAU - Abe, Koji
AU  - Abe K
AD  - Department of Neurology, Okayama University Medical School. Okayama, Japan.
FAU - Uno, Masaaki
AU  - Uno M
AD  - Department of Neurosurgery, Kawasaki Medical School, Okayama, Japan.
FAU - Okada, Yasushi
AU  - Okada Y
AD  - Department of Cerebrovascular Medicine and Neurology, Clinical Research 
      Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.
FAU - Matsuoka, Hideki
AU  - Matsuoka H
AD  - Department of Cerebrovascular Medicine, NHO Kagoshima Medical Center, Kagoshima, 
      Japan.
FAU - Yamagata, Sen
AU  - Yamagata S
AD  - Department of Neurosurgery, Kurashiki Central Hospital, Okayama, Japan.
FAU - Yamamoto, Yasumasa
AU  - Yamamoto Y
AD  - Department of Neurology, Kyoto Second Red Cross Hospital, Kyoto, Japan.
FAU - Yonehara, Toshiro
AU  - Yonehara T
AD  - Department of Neurology, Stroke Center, Saiseikai Kumamoto Hospital, Kumamoto, 
      Japan.
FAU - Inoue, Takeshi
AU  - Inoue T
AD  - Department of Stroke Medicine, Kawasaki Medical School General Medical Center, 
      Kawasaki Medical School, Okayama, Japan.
FAU - Yagita, Yoshiki
AU  - Yagita Y
AD  - Department of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan.
FAU - Kimura, Kazumi
AU  - Kimura K
AD  - Department of Neurological Science, Nippon Medical School Graduate School of 
      Medicine, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan; Department of Stroke 
      Medicine, Kawasaki Medical School, Kurashiki, Japan.
CN  - ADS investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20201202
PL  - United States
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National 
      Stroke Association
JID - 9111633
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cilostazol/adverse effects/*therapeutic use
MH  - Disease Progression
MH  - *Dual Anti-Platelet Therapy/adverse effects
MH  - Female
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Registries
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stroke/diagnosis/*drug therapy/physiopathology
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiplatelet drug
OT  - Clinical outcome
OT  - Ischemic stroke
OT  - Stroke management
COIS- Declaration of Competing Interest The authors have no conflicts of interest or 
      funding sources to disclose.
EDAT- 2020/12/06 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/05 20:14
PHST- 2020/09/21 00:00 [received]
PHST- 2020/11/15 00:00 [revised]
PHST- 2020/11/20 00:00 [accepted]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/12/05 20:14 [entrez]
AID - S1052-3057(20)30912-5 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2020.105494 [doi]
PST - ppublish
SO  - J Stroke Cerebrovasc Dis. 2021 Feb;30(2):105494. doi: 
      10.1016/j.jstrokecerebrovasdis.2020.105494. Epub 2020 Dec 2.

PMID- 15383481
OWN - NLM
STAT- MEDLINE
DCOM- 20041026
LR  - 20141120
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 126
IP  - 3 Suppl
DP  - 2004 Sep
TI  - Antithrombotic therapy in valvular heart disease--native and prosthetic: the 
      Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
PG  - 457S-482S
AB  - This chapter about antithrombotic therapy in native and prosthetic valvular heart 
      disease is part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic 
      Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and 
      indicate that the benefits do, or do not, outweigh risks, burden, and costs. 
      Grade 2 suggests that individual patients' values may lead to different choices 
      (for a full understanding of the grading see Guyatt et al, CHEST 2004; 
      126:179S-187S). Among the key recommendations in this chapter are the following: 
      For patients with rheumatic mitral valve disease and atrial fibrillation (AF), or 
      a history of previous systemic embolism, we recommend long-term oral 
      anticoagulant (OAC) therapy (target international normalized ratio [INR], 2.5; 
      range, 2.0 to 3.0) [Grade 1C+]. For patients with rheumatic mitral valve disease 
      with AF or a history of systemic embolism who suffer systemic embolism while 
      receiving OACs at a therapeutic INR, we recommend adding aspirin, 75 to 100 mg/d 
      (Grade 1C). For those patients unable to take aspirin, we recommend adding 
      dipyridamole, 400 mg/d, or clopidogrel (Grade 1C). In people with mitral valve 
      prolapse (MVP) without history of systemic embolism, unexplained transient 
      ischemic attacks (TIAs), or AF, we recommended against any antithrombotic therapy 
      (Grade 1C). In patients with MVP and documented but unexplained TIAs, we 
      recommend long-term aspirin therapy, 50 to 162 mg/d (Grade 1A). For all patients 
      with mechanical prosthetic heart valves, we recommend vitamin K antagonists 
      (Grade 1C+). For patients with a St. Jude Medical (St. Paul, MN) bileaflet valve 
      in the aortic position, we recommend a target INR of 2.5 (range, 2.0 to 3.0) 
      [Grade 1A]. For patients with tilting disk valves and bileaflet mechanical valves 
      in the mitral position, we recommend a target INR of 3.0 (range, 2.5 to 3.5) 
      [Grade 1C+]. For patients with caged ball or caged disk valves, we suggest a 
      target INR of 3.0 (range, 2.5 to 3.5) in combination with aspirin, 75 to 100 mg/d 
      (Grade 2A). For patients with bioprosthetic valves, we recommend vitamin K 
      antagonists with a target INR of 2.5 (range, 2.0 to 3.0) for the first 3 months 
      after valve insertion in the mitral position (Grade 1C+) and in the aortic 
      position (Grade 2C). For patients with bioprosthetic valves who are in sinus 
      rhythm and do not have AF, we recommend long-term (> 3 months) therapy with 
      aspirin, 75 to 100 mg/d (Grade 1C+).
FAU - Salem, Deeb N
AU  - Salem DN
AD  - Tufts New England Medical Center, 750 Washington St, Boston, MA 02111, USA. 
      dsalem@tufts.org
FAU - Stein, Paul D
AU  - Stein PD
FAU - Al-Ahmad, Amin
AU  - Al-Ahmad A
FAU - Bussey, Henry I
AU  - Bussey HI
FAU - Horstkotte, Dieter
AU  - Horstkotte D
FAU - Miller, Nancy
AU  - Miller N
FAU - Pauker, Stephen G
AU  - Pauker SG
LA  - eng
PT  - Comparative Study
PT  - Guideline
PT  - Journal Article
PT  - Practice Guideline
PT  - Review
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Fibrinolytic Agents)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Bioprosthesis
MH  - Evidence-Based Medicine
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Heart Valve Diseases/blood/complications/*drug therapy
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - International Normalized Ratio
MH  - Postoperative Complications/blood/*drug therapy
MH  - Prosthesis Design
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Secondary Prevention
MH  - Thromboembolism/blood/*drug therapy
MH  - Vitamin K/antagonists & inhibitors
RF  - 234
EDAT- 2004/09/24 05:00
MHDA- 2004/10/27 09:00
CRDT- 2004/09/24 05:00
PHST- 2004/09/24 05:00 [pubmed]
PHST- 2004/10/27 09:00 [medline]
PHST- 2004/09/24 05:00 [entrez]
AID - S0012-3692(15)31500-2 [pii]
AID - 10.1378/chest.126.3_suppl.457S [doi]
PST - ppublish
SO  - Chest. 2004 Sep;126(3 Suppl):457S-482S. doi: 10.1378/chest.126.3_suppl.457S.

PMID- 15013280
OWN - NLM
STAT- MEDLINE
DCOM- 20040603
LR  - 20191210
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 112
IP  - 1-2
DP  - 2003
TI  - Augmentation of in-stent clot dissolution by low frequency ultrasound combined 
      with aspirin and heparin. An ex-vivo canine shunt study.
PG  - 99-104
AB  - INTRODUCTION: Ultrasound can accelerate clot dissolution in vitro and in vivo. We 
      used an ex vivo canine shunt to investigate low frequency ultrasound effects on 
      platelet-rich stent thrombosis. METHODS AND RESULTS: Nitinol stents were expanded 
      to 2 mm in diameter in two perfusion chambers in a parallel shunt and exposed to 
      flowing arterial blood at 2100 s(-1) to generate stent thrombi (n=224 perfusion 
      runs). Dethrombotic effects were assessed during treatment with saline and 
      combined treatment with aspirin and heparin. One stent was exposed to ultrasound 
      (27 kHz, 1.4 W/cm2), while the other was not. Stent thrombi were weighed before 
      and after treatment. There was no significant effect of ultrasound during saline 
      infusion. Treatment with aspirin+heparin alone reduced thrombus weight by 
      37+/-25% (18.9+/-6.1 to 11.8+/-7.7 mg, p<0.0001). Combined treatment with 
      aspirin+heparin+ultrasound produced a 49+/-23% reduction in thrombus weight 
      (19.0+/-6.3 to 9.6+/-7.8 mg, p<0.0001). The reduction in thrombus weight was 
      significantly greater in aspirin+heparin+ultrasound compared with aspirin+heparin 
      alone (p=0.04). CONCLUSIONS: Transcutaneous ultrasound significantly enhances 
      dethrombotic effect of aspirin plus heparin on preformed stent thrombi. These 
      findings suggest the potential of ultrasound as an adjunct to antithrombotic 
      therapy to improve effectiveness without increasing the risk of bleeding 
      complications during treatment of vascular thrombosis.
FAU - Neuman, Yoram
AU  - Neuman Y
AD  - Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis 
      Research Center, Cedars-Sinai Medical Center, Division of Cardiology, Room 5314, 
      8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
FAU - Rukshin, Vladimir
AU  - Rukshin V
FAU - Tsang, Vivian
AU  - Tsang V
FAU - Atar, Shaul
AU  - Atar S
FAU - Miyamoto, Takashi
AU  - Miyamoto T
FAU - Luo, Huai
AU  - Luo H
FAU - Kobal, Sergio
AU  - Kobal S
FAU - Thompson, Todd
AU  - Thompson T
FAU - Birnbaum, Yochai
AU  - Birnbaum Y
FAU - Horzewski, Mike
AU  - Horzewski M
FAU - Siegel, Robert J
AU  - Siegel RJ
FAU - Kaul, Sanjay
AU  - Kaul S
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Blood Vessel Prosthesis/*adverse effects
MH  - Combined Modality Therapy/methods
MH  - Dogs
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Stents/*adverse effects
MH  - Treatment Outcome
MH  - Ultrasonic Therapy/*methods
MH  - Venous Thrombosis/drug therapy/*etiology/*therapy
EDAT- 2004/03/12 05:00
MHDA- 2004/06/04 05:00
CRDT- 2004/03/12 05:00
PHST- 2003/07/08 00:00 [received]
PHST- 2003/10/22 00:00 [revised]
PHST- 2003/10/23 00:00 [accepted]
PHST- 2004/03/12 05:00 [pubmed]
PHST- 2004/06/04 05:00 [medline]
PHST- 2004/03/12 05:00 [entrez]
AID - S0049384803005437 [pii]
AID - 10.1016/j.thromres.2003.10.023 [doi]
PST - ppublish
SO  - Thromb Res. 2003;112(1-2):99-104. doi: 10.1016/j.thromres.2003.10.023.

PMID- 31044378
OWN - NLM
STAT- MEDLINE
DCOM- 20190816
LR  - 20190816
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 26
IP  - 18
DP  - 2019 Jun
TI  - Toxicity of three emerging contaminants to non-target marine organisms.
PG  - 18354-18364
LID - 10.1007/s11356-019-05151-9 [doi]
AB  - Coastal areas are continually impacted by anthropic activities because they 
      shelter large urban conglomerates. Urban effluents directly or indirectly end up 
      reaching the marine environment, releasing a large number of pollutants which 
      include the so-called contaminants of emerging concern (CECs), since the 
      conventional treatment plants are not effective in removing these compounds from 
      the effluents. These substances include hormones, pharmaceuticals and personal 
      care products, nanoparticles, biocides, among others. The aim of this study was 
      to evaluate the toxicity of the 17α-ethinylestradiol (EE2), acetylsalicylic acid 
      (ASA), and bisphenol-A (BPA) to two marine crustaceans and one echinoderm, 
      evaluating the following parameters: survival (Artemia sp. and Mysidopsis 
      juniae), embryo-larval development (Echinometra lucunter). The LC(50) values 
      calculated in the acute toxicity tests showed that the compounds were more toxic 
      to M. juniae than to the Artemia sp. Among the three contaminants, EE2 was the 
      most toxic (LC(50-48h) = 18.4 ± 2.7 mg L(-1) to Artemia sp.; LC(50-96h) = 0.36 ± 
      0.07 mg L(-1) to M. juniae). The three tested compounds affected significantly 
      the embryonic development of the sea urchin in all tested concentrations, 
      including ecologically relevant concentrations, indicating the potential risk 
      that these contaminants may present to the marine biota.
FAU - da Silva, Allyson Q
AU  - da Silva AQ
AUID- ORCID: 0000-0002-7756-1426
AD  - Instituto de Ciências do Mar (LABOMAR), Universidade Federal do Ceará, Av. da 
      Abolição, 3207, Bairro Meireles, Fortaleza, Ceará, CEP 60165-081, Brazil. 
      allyson_queiroz@hotmail.com.
FAU - de Souza Abessa, Denis Moledo
AU  - de Souza Abessa DM
AD  - Núcleo de Estudos em Poluição e Ecotoxicologia Aquática (NEPEA), Campus 
      Experimental do Litoral Paulista (UNESP), Praça Infante Dom Henrique s/n, Parque 
      Bitaru, São Vicente, SP, 11330-90, Brazil. denis.abessa@unesp.br.
LA  - eng
PT  - Journal Article
DEP - 20190501
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Phenols)
RN  - 0 (Water Pollutants, Chemical)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - MLT3645I99 (bisphenol A)
RN  - R16CO5Y76E (Aspirin)
MH  - Animals
MH  - Aquatic Organisms/*drug effects
MH  - Artemia/*drug effects
MH  - Aspirin/analysis/*toxicity
MH  - Benzhydryl Compounds/analysis/*toxicity
MH  - Ethinyl Estradiol/analysis/*toxicity
MH  - Lethal Dose 50
MH  - Phenols/analysis/*toxicity
MH  - Toxicity Tests, Acute
MH  - Water Pollutants, Chemical/analysis/*toxicity
OTO - NOTNLM
OT  - ASA
OT  - Acute toxicity
OT  - BPA
OT  - Chronic toxicity
OT  - EE2
EDAT- 2019/05/03 06:00
MHDA- 2019/08/17 06:00
CRDT- 2019/05/03 06:00
PHST- 2019/01/14 00:00 [received]
PHST- 2019/04/09 00:00 [accepted]
PHST- 2019/05/03 06:00 [pubmed]
PHST- 2019/08/17 06:00 [medline]
PHST- 2019/05/03 06:00 [entrez]
AID - 10.1007/s11356-019-05151-9 [pii]
AID - 10.1007/s11356-019-05151-9 [doi]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2019 Jun;26(18):18354-18364. doi: 
      10.1007/s11356-019-05151-9. Epub 2019 May 1.

PMID- 12110391
OWN - NLM
STAT- MEDLINE
DCOM- 20021003
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 29
IP  - 6
DP  - 2002 Aug 1
TI  - In vitro metabolism of a nitroderivative of acetylsalicylic acid (NCX4016) by rat 
      liver: LC and LC-MS studies.
PG  - 1061-71
AB  - The metabolism of a nitroderivative of acetylsalicylic acid, benzoic acid, 
      2-(acetyloxy)-3-[(nitrooxy)methyl]phenyl ester (NCX4016), the lead compound of a 
      new class of NO-releasing non steroidal-antiinflammatory drugs has been studied 
      in vitro in rat liver subcellular fractions (S 9000xg, microsomes, cytosol). 
      Samples were extracted with CH3CN (2 vol.) containing 1% H3PO4 (2 M), vortexed 
      for 3 min and then centrifuged for 5 min at 5000 rpm. Supernatants were diluted 
      with 0.02 M phosphoric acid and analysed by reverse-phase LC. Linearity of 
      calibration for NCX4016 and metabolites was observed over the range 0.25-50 
      microg/ml with coefficients of determination greater than 0.9996. Extraction 
      efficiency from spiked liver samples ranged from 85 to 95% for all the analytes. 
      In the S 9000xg fraction, NCX4016 undergoes rapid metabolization, with the 
      formation of salicylic acid (SA) and [3-(nitrooxymethyl)phenol] (HBN). HBN is 
      then rapidly metabolised to 3-hydroxybenzylalcohol (HBA), and mainly to a new 
      metabolic species, whose formation takes place specifically in the liver cell 
      cytosol. LC-MS analysis (electrospray ionisation) of the cytosol extract in 
      negative and positive-ion modes furnished deprotonated [M-H]- and protonated 
      [M+H]+ molecular ions at m/z 412 and 414, respectively, accompanied by the 
      typical clusters with sodium. MS/MS analysis in negative-ion mode, by selection 
      and collision of the ion at m/z 412, gave a fragmentation pattern characterized 
      by the ions at m/z 272 and 254, which allowed to assign the structure of 
      1-(glutathion-S-yl)methylene-3-hydroxy-benzene, a conjugated product between GSH 
      and the benzyl carbon atom of HBN. In rat liver cytosol HBN is completely 
      metabolised to this thioether adduct within 30 min incubation; the process is 
      enzymatically mediated by GSH transferase and strictly dependent on GSH 
      availability. The relevance of this new metabolic pathway in NCX4016 
      detoxification by rat liver is discussed.
FAU - Carini, Marina
AU  - Carini M
AD  - Istituto Chimico Farmaceutico Tossicologico, Viale Abruzzi 42, Milan, Italy. 
      marina.carini@unimi.it
FAU - Aldini, Giancarlo
AU  - Aldini G
FAU - Orioli, Marica
AU  - Orioli M
FAU - Maffei Facino, Roberto
AU  - Maffei Facino R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 2.5.1.18 (Glutathione Transferase)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics
MH  - Aspirin/analogs & derivatives/*pharmacokinetics
MH  - Chromatography, High Pressure Liquid
MH  - Cytosol/enzymology/metabolism
MH  - Glutathione Transferase/metabolism
MH  - In Vitro Techniques
MH  - Inactivation, Metabolic
MH  - Male
MH  - Microsomes, Liver/enzymology/*metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Spectrometry, Mass, Electrospray Ionization
EDAT- 2002/07/12 10:00
MHDA- 2002/10/04 04:00
CRDT- 2002/07/12 10:00
PHST- 2002/07/12 10:00 [pubmed]
PHST- 2002/10/04 04:00 [medline]
PHST- 2002/07/12 10:00 [entrez]
AID - S0731708502001474 [pii]
AID - 10.1016/s0731-7085(02)00147-4 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2002 Aug 1;29(6):1061-71. doi: 
      10.1016/s0731-7085(02)00147-4.

PMID- 11345689
OWN - NLM
STAT- MEDLINE
DCOM- 20010726
LR  - 20131121
IS  - 0032-0943 (Print)
IS  - 0032-0943 (Linking)
VI  - 67
IP  - 3
DP  - 2001 Apr
TI  - Effect of salicis cortex extract on human platelet aggregation.
PG  - 209-12
AB  - The bark of Salix species contains several prodrugs of salicylate, mainly 
      salicin. The aim of this study was to investigate if during pain treatment with 
      Salicis cortex extract platelet aggregation was affected. A total of 51 patients 
      were enrolled in the study. Thirty-five patients suffering from acute 
      exacerbations of chronic low back pain received randomly and double-blind either 
      Salicis cortex extract with 240 mg salicin/day (n = 19) or placebo (n = 16). 
      Further sixteen patients with stable chronic ischemic heart disease were given 
      100 mg acetylsalicylate per day. Platelet aggregation was studied using an 
      aggregometer. As aggregating agents, arachidonic acid (500 micrograms/ml), 
      adenosine di-phosphate (2 x 10(-5) M) and collagen (0.18 microgram/ml) were used. 
      The mean maximal arachidonic acid induced platelet aggregation was 61%, 78% and 
      13% in the Salicis cortex extract, placebo and acetylsalicylate groups. 
      Acetylsalicylate had a significant inhibitory effect on platelet aggregation 
      compared to Salicis cortex extract (p = 0.001) and placebo (p = 0.001). There was 
      also a significant difference between the placebo and the willow bark-treated 
      groups in the maximal platelet aggregation induced by arachidonic acid (p = 0.04) 
      and ADP (p = 0.01). No statistical difference was found between the groups when 
      collagen was applied to the human platelets. Daily consumption of Salicis cortex 
      extract with 240 mg salicin per day affects platelet aggregation to a far lesser 
      extent than acetylsalicylate. Further investigation needs to clarify if this 
      finding is of clinical relevance in patients with impaired thrombocyte function.
FAU - Krivoy, N
AU  - Krivoy N
AD  - Clinical Pharmacology Unit, Rambam Medical Center and B. Rappaport Faculty of 
      Medicine, Haifa, Israel. N_Krivoy@rambam.health.gov.il
FAU - Pavlotzky, E
AU  - Pavlotzky E
FAU - Chrubasik, S
AU  - Chrubasik S
FAU - Eisenberg, E
AU  - Eisenberg E
FAU - Brook, G
AU  - Brook G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Planta Med
JT  - Planta medica
JID - 0066751
RN  - 0 (Plant Extracts)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Aged
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/pharmacology/therapeutic use
MH  - Collagen/pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Furosemide/*pharmacology/therapeutic use
MH  - Humans
MH  - Low Back Pain/drug therapy/physiopathology
MH  - Male
MH  - Medicine, Traditional
MH  - Middle Aged
MH  - Phytotherapy
MH  - Plant Extracts/pharmacology/therapeutic use
MH  - Plant Stems
MH  - Plants, Medicinal/therapeutic use
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Platelet Count
MH  - Portugal
EDAT- 2001/05/11 10:00
MHDA- 2001/07/28 10:01
CRDT- 2001/05/11 10:00
PHST- 2001/05/11 10:00 [pubmed]
PHST- 2001/07/28 10:01 [medline]
PHST- 2001/05/11 10:00 [entrez]
AID - 10.1055/s-2001-12000 [doi]
PST - ppublish
SO  - Planta Med. 2001 Apr;67(3):209-12. doi: 10.1055/s-2001-12000.

PMID- 10444491
OWN - NLM
STAT- MEDLINE
DCOM- 19990923
LR  - 20181201
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 277
IP  - 2
DP  - 1999 Aug
TI  - Modified hemoglobins produce venular interendothelial gaps and albumin leakage in 
      the rat mesentery.
PG  - H650-9
LID - 10.1152/ajpheart.1999.277.2.H650 [doi]
AB  - Cross-linked hemoglobin (alphaalpha-Hb) and polyethylene glycol (PEG)-conjugated 
      Hb have both been considered as possible "blood substitutes." Previously, we 
      showed that PEG-Hb extravasates rapidly in the intestinal mucosa and causes 
      transient epithelial sloughing, resulting in temporary opening of the intestinal 
      epithelial barrier. In the present study, the rat mesenteric preparation was used 
      to quantify the effects of the two Hbs on microvascular leakage to albumin and to 
      investigate possible changes in the integrity of the interendothelial cell 
      junctions and the endothelial actin cytoskeleton. In anesthetized Sprague-Dawley 
      rats, the microvasculature of a mesenteric window was perfused with 
      HEPES-buffered saline (HBS) containing 0.5 mg/ml BSA and 2 mg/ml alphaalpha-Hb (n 
      = 16) or PEG-Hb (n = 5) for 2 or 10 min. Controls (n = 4) just received HBS-BSA. 
      In some experiments (n = 9 for alphaalpha-Hb; n = 5 for PEG-Hb), the perfusate 
      was then replaced by FITC-albumin in HBS-BSA for the next 3 min. The vasculature 
      was then perfusion fixed, stained for filamentous actin and for mast cells, and 
      viewed microscopically. In the remaining experiments, the mesenteric 
      microvasculature was stained with silver nitrate to determine the number of 
      endothelial junctional gaps per length of venules. Both Hbs increased the number 
      and area of leaks per micrometer of venular length compared with control, but 
      alphaalpha-Hb increased to a greater extent than PEG-Hb. Formation of leaks was 
      accompanied by changes in the endothelial actin cytoskeleton and by an increased 
      number of endothelial gaps. Mast cell degranulation was significantly greater (P 
      < 0.05) in Hb-treated preparations compared with controls, but there was no 
      direct correlation between sites of degranulation and albumin leakage. These Hbs 
      appear to induce venular leakage in the mesentery by mechanisms similar to those 
      previously observed after treatment with histamine or nitric oxide synthase 
      inhibitors.
FAU - Baldwin, A L
AU  - Baldwin AL
AD  - Department of Physiology, College of Medicine, University of Arizona, Tucson, 
      Arizona 85724-5051, USA. abaldwin@u.arizona.edu
LA  - eng
GR  - HL-53047-04/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Actins)
RN  - 0 (Hemoglobins)
RN  - 0 (PEG-hemoglobin)
RN  - 0 (Serum Albumin)
RN  - 0 (hemoglobin XL99alpha)
RN  - 3M4G523W1G (Silver)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Actins/physiology
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Capillary Permeability/*physiology
MH  - Cell Degranulation/physiology
MH  - Cytoskeleton/physiology
MH  - Endothelium, Vascular/*drug effects/physiology
MH  - Hemoglobins/*pharmacology
MH  - Male
MH  - Mast Cells/drug effects/physiology
MH  - Polyethylene Glycols/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serum Albumin/*metabolism
MH  - Silver
MH  - Splanchnic Circulation/*physiology
MH  - Staining and Labeling
MH  - Venules/*drug effects/physiology
EDAT- 1999/08/13 00:00
MHDA- 1999/08/13 00:01
CRDT- 1999/08/13 00:00
PHST- 1999/08/13 00:00 [pubmed]
PHST- 1999/08/13 00:01 [medline]
PHST- 1999/08/13 00:00 [entrez]
AID - 10.1152/ajpheart.1999.277.2.H650 [doi]
PST - ppublish
SO  - Am J Physiol. 1999 Aug;277(2):H650-9. doi: 10.1152/ajpheart.1999.277.2.H650.

PMID- 7394058
OWN - NLM
STAT- MEDLINE
DCOM- 19800926
LR  - 20191031
IS  - 0161-4630 (Print)
IS  - 0161-4630 (Linking)
VI  - 4
IP  - 3
DP  - 1980 Mar
TI  - The effect of anti-inflammatory drugs on glycosaminoglycan sulphation in pig 
      cartilage.
PG  - 133-40
AB  - Indomethacin, aspirin and hydrocortisone have been shown to inhibit 
      glycosaminoglycan sulphation in pig costal cartilage discs. The doses at which 
      inhibition was observed varied from pig to pig from 0.1 - 50 microgram/ml for 
      indomethacin, 40 - 150 microgram/ml for aspirin and 0.5 - 1 mg/ml for 
      hydrocortisone, doses which are achieved clinically in the treatment of joint 
      diseases. In a minority of experiments a significant stimulation of 
      glycosaminoglycan sulphation was observed at lower doses of indomethacin and 
      hydrocortisone but not aspirin. THe results suggest that in rheumatoid arthritis 
      but more especially osteoarthritis, treatment with these drugs should aim at 
      finding the lowest doses which have a therapeutic effect. As importantly the 
      clinician should always consider using lower doses just as much as higher doses 
      when the first dose regimen is unsatisfactory.
FAU - Dekel, S
AU  - Dekel S
FAU - Falconer, J
AU  - Falconer J
FAU - Francis, M J
AU  - Francis MJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins Med
JT  - Prostaglandins and medicine
JID - 7810330
RN  - 0 (Glycosaminoglycans)
RN  - 0 (Sulfates)
RN  - 0 (Sulfur Radioisotopes)
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cartilage/drug effects/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Glycosaminoglycans/*biosynthesis
MH  - Hydrocortisone/*pharmacology
MH  - Indomethacin/*pharmacology
MH  - Sulfates/*metabolism
MH  - Sulfur Radioisotopes
MH  - Swine
EDAT- 1980/03/01 00:00
MHDA- 1980/03/01 00:01
CRDT- 1980/03/01 00:00
PHST- 1980/03/01 00:00 [pubmed]
PHST- 1980/03/01 00:01 [medline]
PHST- 1980/03/01 00:00 [entrez]
AID - 10.1016/0161-4630(80)90074-9 [doi]
PST - ppublish
SO  - Prostaglandins Med. 1980 Mar;4(3):133-40. doi: 10.1016/0161-4630(80)90074-9.

PMID- 18759522
OWN - NLM
STAT- MEDLINE
DCOM- 20090825
LR  - 20131121
IS  - 1735-3947 (Electronic)
IS  - 1029-2977 (Linking)
VI  - 11
IP  - 5
DP  - 2008 Sep
TI  - Long-term effect of dalteparin in the prevention of neovascularization of iris in 
      recent-onset central retinal vein occlusion.
PG  - 539-43
AB  - BACKGROUND: To compare the long-term effect of dalteparin in the prevention of 
      neovascularization of iris in recent-onset central retinal vein occlusion with 
      that of aspirin. METHODS: A randomized controlled clinical trial was conducted on 
      patients with central retinal vein occlusion of less than 30 days duration. 
      Patients in the dalteparin group received subcutaneous dalteparin 100 IU/kg twice 
      a day for 10 days, and then 100 IU/kg once a day for another ten days. In the 
      aspirin group the patients received 100 mg aspirin daily throughout the study. 
      RESULTS: Forty seven patients were enrolled, 24 in the dalteparin group and 23 in 
      the aspirin group, and were followed up for one year. One (4.1%) of the 24 
      patients in dalteparin group, and 9 (39.1%) of 23 patients in aspirin group 
      developed iris neovascularization. the difference was significant (P=0.0001). The 
      visual outcomes of the two groups were compared, and a significant difference was 
      found (P=0.016). CONCLUSION: Patients treated with dalteparin within 30 days of 
      the onset of central retinal vein occlusion were less likely to develop 
      neovascularization of iris. There was also a significant difference in the visual 
      acuity between two groups.
FAU - Farahvash, Mohammad Sadegh
AU  - Farahvash MS
AD  - Department of Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran. 
      Farahva@yahoo.com
FAU - Farahvash, Mohammad Mehdi
AU  - Farahvash MM
FAU - Moradimogadam, Marzieh
AU  - Moradimogadam M
FAU - Mohammadzadeh, Shiva
AU  - Mohammadzadeh S
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Iran
TA  - Arch Iran Med
JT  - Archives of Iranian medicine
JID - 100889644
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Dalteparin/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Iris/*blood supply
MH  - Male
MH  - Middle Aged
MH  - Neovascularization, Pathologic/*prevention & control
MH  - Retinal Vein Occlusion/complications/*physiopathology
EDAT- 2008/09/02 09:00
MHDA- 2009/08/26 09:00
CRDT- 2008/09/02 09:00
PHST- 2008/09/02 09:00 [pubmed]
PHST- 2009/08/26 09:00 [medline]
PHST- 2008/09/02 09:00 [entrez]
AID - 0011 [pii]
PST - ppublish
SO  - Arch Iran Med. 2008 Sep;11(5):539-43.

PMID- 23965959
OWN - NLM
STAT- MEDLINE
DCOM- 20140318
LR  - 20220408
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 14
IP  - 8
DP  - 2013 Aug 7
TI  - Molecular pathways involved in colorectal cancer: implications for disease 
      behavior and prevention.
PG  - 16365-85
LID - 10.3390/ijms140816365 [doi]
AB  - Research conducted during the past 30 years has increased our understanding of 
      the mechanisms involved in colorectal cancer initiation and development. The 
      findings have demonstrated the existence of at least three pathways: chromosomal 
      instability, microsatellite instability and CpG island methylator phenotype. 
      Importantly, new studies have shown that inflammation and microRNAs contribute to 
      colorectal carcinogenesis. Recent data have demonstrated that several genetic and 
      epigenetic changes are important in determining patient prognosis and survival. 
      Furthermore, some of these mechanisms are related to patients' response to drugs, 
      such as aspirin, which could be used for both chemoprevention and treatment in 
      specific settings. Thus, in the near future, we could be able to predict disease 
      behavior based on molecular markers found on tumors, and direct the best 
      treatment options for patients.
FAU - Colussi, Dora
AU  - Colussi D
AD  - Department of Medical and Surgical Sciences, University of Bologna, Via 
      Massarenti 9, Pad 5, Bologna 40138, Italy. dora.colussi86@gmail.com
FAU - Brandi, Giovanni
AU  - Brandi G
FAU - Bazzoli, Franco
AU  - Bazzoli F
FAU - Ricciardiello, Luigi
AU  - Ricciardiello L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130807
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Inflammation Mediators)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenocarcinoma/*genetics/metabolism/prevention & control
MH  - Animals
MH  - Anticarcinogenic Agents/pharmacology/therapeutic use
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - *Chromosomal Instability
MH  - Colorectal Neoplasms/*genetics/metabolism/prevention & control
MH  - DNA Methylation
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Microsatellite Repeats
MH  - Wnt Signaling Pathway
PMC - PMC3759916
EDAT- 2013/08/24 06:00
MHDA- 2014/03/19 06:00
CRDT- 2013/08/23 06:00
PHST- 2013/07/22 00:00 [received]
PHST- 2013/07/25 00:00 [revised]
PHST- 2013/07/26 00:00 [accepted]
PHST- 2013/08/23 06:00 [entrez]
PHST- 2013/08/24 06:00 [pubmed]
PHST- 2014/03/19 06:00 [medline]
AID - ijms140816365 [pii]
AID - ijms-14-16365 [pii]
AID - 10.3390/ijms140816365 [doi]
PST - epublish
SO  - Int J Mol Sci. 2013 Aug 7;14(8):16365-85. doi: 10.3390/ijms140816365.

PMID- 22839518
OWN - NLM
STAT- MEDLINE
DCOM- 20120919
LR  - 20170310
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 52
IP  - 4
DP  - 2012
TI  - [Acetylsalicylic acid in patients with planned (elective) interventions on the 
      coronary arteries. Risks and benefits].
PG  - 60-7
AB  - In a review of the literature describes the risks and benefits of surgical 
      interventions, in particular, coronary artery bypass grafting in patients with 
      coronary artery disease receiving antiplatelet therapy with no cancellation or 
      late withdrawal of acetylsalicylic acid (ASA). The data supporting a moderate - 
      without increasing the frequency of reoperation and blood transfusion - an 
      increased risk of perioperative bleeding in cases where operations are conducted 
      against a background of aspirin therapy. At the same time showed a significant 
      reduction in the risk of perioperative cardiovascular complications and improve 
      survival after intervention, which did not occur before the removal of the drug 
      ASA.
FAU - Altarev, S S
AU  - Altarev SS
FAU - Barbarash, O L
AU  - Barbarash OL
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/administration & dosage/adverse effects
MH  - Blood Loss, Surgical/*prevention & control
MH  - Blood Transfusion
MH  - *Coronary Artery Bypass/adverse effects/methods
MH  - Coronary Artery Disease/*therapy
MH  - Humans
MH  - Perioperative Care/methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - *Postoperative Hemorrhage/chemically induced/prevention & control
MH  - Reoperation
MH  - Risk Adjustment
MH  - Risk Assessment
MH  - Risk Factors
MH  - Survival Rate
MH  - *Withholding Treatment
EDAT- 2012/07/31 06:00
MHDA- 2012/09/20 06:00
CRDT- 2012/07/31 06:00
PHST- 2012/07/31 06:00 [entrez]
PHST- 2012/07/31 06:00 [pubmed]
PHST- 2012/09/20 06:00 [medline]
PST - ppublish
SO  - Kardiologiia. 2012;52(4):60-7.

PMID- 36273931
OWN - NLM
STAT- MEDLINE
DCOM- 20230120
LR  - 20230215
IS  - 1873-2607 (Electronic)
IS  - 0749-3797 (Print)
IS  - 0749-3797 (Linking)
VI  - 64
IP  - 2
DP  - 2023 Feb
TI  - The First Year of the COVID-19 Pandemic: Changes in Preventive Services in 
      Community Health Centers.
PG  - 184-193
LID - S0749-3797(22)00462-7 [pii]
LID - 10.1016/j.amepre.2022.08.023 [doi]
AB  - INTRODUCTION: Community Health Centers provide comprehensive primary healthcare 
      services to many underserved populations. It is unknown how routine preventive 
      and chronic care services in Community Health Centers may have changed nationwide 
      during the COVID-19 pandemic. METHODS: The 2014-2020 Health Resources and 
      Services Administration Uniform Data System of Community Health Centers was used, 
      and data analysis was conducted from November 2021 to May 2022. Data for clinical 
      quality measures in 2020 were treated as during the pandemic, whereas receipt of 
      care in 2019 and before were treated as before the pandemic. Outcomes included 6 
      clinical quality measures of being up to date for colorectal cancer screening, 
      cervical cancer screening, tobacco screening and cessation counseling, BMI 
      screening and follow-up, depression screening and follow-up, and aspirin use for 
      ischemic vascular disease. A mixed effects regression model was used to estimate 
      changes in measures by year. RESULTS: Between 2019 and 2020, receipt of 
      preventive services declined for each of the 6 clinical quality measures: from 
      40.8% to 37.7% for colorectal cancer screening, from 48.8% to 44.9% for cervical 
      cancer screening, from 85.8% to 83.4% for tobacco screening and cessation 
      counseling, from 70.7% to 65.4% for BMI screening and follow-up, from 71.1% to 
      64.9% for depression screening and follow-up, and from 81.5% to 79.4% for aspirin 
      use for ischemic vascular disease. CONCLUSIONS: Receipt of preventive services in 
      Community Health Centers declined during the COVID-19 pandemic for each of the 6 
      clinical quality measures considered in the study. Immediate action is required 
      to support ongoing high-quality, primary healthcare services in Community Health 
      Centers across the nation.
CI  - Copyright © 2022 American Journal of Preventive Medicine. Published by Elsevier 
      Inc. All rights reserved.
FAU - Star, Jessica
AU  - Star J
AD  - Surveillance & Health Equity Science Department, American Cancer Society, 
      Kennesaw, Georgia. Electronic address: jessica.star@cancer.org.
FAU - Han, Xuesong
AU  - Han X
AD  - Surveillance & Health Equity Science Department, American Cancer Society, 
      Kennesaw, Georgia.
FAU - Makaroff, Laura A
AU  - Makaroff LA
AD  - Prevention and Early Detection, American Cancer Society, Kennesaw, Georgia.
FAU - Minihan, Adair K
AU  - Minihan AK
AD  - Surveillance & Health Equity Science Department, American Cancer Society, 
      Kennesaw, Georgia.
FAU - Jemal, Ahmedin
AU  - Jemal A
AD  - Surveillance & Health Equity Science Department, American Cancer Society, 
      Kennesaw, Georgia.
FAU - Bandi, Priti
AU  - Bandi P
AD  - Surveillance & Health Equity Science Department, American Cancer Society, 
      Kennesaw, Georgia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221021
PL  - Netherlands
TA  - Am J Prev Med
JT  - American journal of preventive medicine
JID - 8704773
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Humans
MH  - Pandemics
MH  - *Uterine Cervical Neoplasms/prevention & control
MH  - Early Detection of Cancer
MH  - *COVID-19
MH  - Preventive Health Services
MH  - Community Health Centers
MH  - *Vascular Diseases
MH  - *Colorectal Neoplasms/diagnosis
MH  - Aspirin/therapeutic use
PMC - PMC9584826
EDAT- 2022/10/24 06:00
MHDA- 2023/01/21 06:00
CRDT- 2022/10/23 22:03
PHST- 2022/05/26 00:00 [received]
PHST- 2022/08/26 00:00 [revised]
PHST- 2022/08/29 00:00 [accepted]
PHST- 2022/10/24 06:00 [pubmed]
PHST- 2023/01/21 06:00 [medline]
PHST- 2022/10/23 22:03 [entrez]
AID - S0749-3797(22)00462-7 [pii]
AID - 10.1016/j.amepre.2022.08.023 [doi]
PST - ppublish
SO  - Am J Prev Med. 2023 Feb;64(2):184-193. doi: 10.1016/j.amepre.2022.08.023. Epub 
      2022 Oct 21.

PMID- 12106925
OWN - NLM
STAT- MEDLINE
DCOM- 20020726
LR  - 20220408
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 40
IP  - 2
DP  - 2002 Jul 17
TI  - The effect of clopidogrel in combination with aspirin when given before coronary 
      artery bypass grafting.
PG  - 231-7
AB  - OBJECTIVES: This study was designed to evaluate the effect of preoperative 
      clopidogrel on coronary artery bypass graft surgery (CABG) outcomes. BACKGROUND: 
      Clopidogrel in combination with aspirin, given before percutaneous coronary 
      intervention, has become the standard for stent thrombosis prevention. Some 
      premedicated patients, however, are found to have surgical disease on 
      angiography, and irreversible platelet inhibition becomes a concern for upcoming 
      CABG. METHODS: We prospectively studied 224 consecutive patients undergoing 
      nonemergent first-time CABG, and compared those with preoperative clopidogrel 
      exposure within seven days (n = 59) to those without exposure (n = 165). RESULTS: 
      The groups were comparable in age, gender, body surface area, preoperative 
      hematocrit, preoperative prothrombin time and prior myocardial infarction. The 
      clopidogrel group had higher 24-h mean chest tube output (1,224 ml vs. 840 ml, p 
      = 0.001), and more transfusions of red blood cells (2.51 U vs. 1.74 U, p = 
      0.036), platelets (0.86 U vs. 0.24 U, p = 0.001) and fresh frozen plasma (0.68 U 
      vs. 0.24 U, p = 0.015). Moreover, reoperation for bleeding was 10-fold higher in 
      the clopidogrel group (6.8% vs. 0.6%, p = 0.018). The clopidogrel group also had 
      less extubation within 8 h (54.2% vs. 75.8%, p = 0.002) and a trend towards less 
      hospital discharge within five days (33.9% vs. 46.7%, p = 0.094). CONCLUSIONS: 
      Clopidogrel in combination with aspirin before CABG is associated with higher 
      postoperative bleeding and morbidity. These findings raise concern regarding the 
      routine administration of clopidogrel before anticipated coronary stent 
      implantation.
FAU - Hongo, Richard H
AU  - Hongo RH
AD  - Division of Cardiology, California Pacific Medical Center, 2333 Buchanan Street, 
      San Francisco, CA 94115, USA.
FAU - Ley, Jill
AU  - Ley J
FAU - Dick, Stuart E
AU  - Dick SE
FAU - Yee, Rupsa R
AU  - Yee RR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2002 Jul 17;40(2):218-9. PMID: 12106922
CIN - J Am Coll Cardiol. 2003 Apr 16;41(8):1421-2; author reply 1422-3. PMID: 12706946
MH  - Aged
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Clopidogrel
MH  - *Coronary Artery Bypass
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*adverse effects
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Prospective Studies
MH  - Research Design
MH  - Ticlopidine/*administration & dosage/*adverse effects/analogs & derivatives
MH  - Treatment Outcome
EDAT- 2002/07/11 10:00
MHDA- 2002/07/27 10:01
CRDT- 2002/07/11 10:00
PHST- 2002/07/11 10:00 [pubmed]
PHST- 2002/07/27 10:01 [medline]
PHST- 2002/07/11 10:00 [entrez]
AID - S073510970201954X [pii]
AID - 10.1016/s0735-1097(02)01954-x [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2002 Jul 17;40(2):231-7. doi: 10.1016/s0735-1097(02)01954-x.

PMID- 8923025
OWN - NLM
STAT- MEDLINE
DCOM- 19970220
LR  - 20131121
IS  - 0300-5038 (Print)
IS  - 0300-5038 (Linking)
IP  - 139
DP  - 1996
TI  - Adverse effects of preventive therapy in humans.
PG  - 135-42
AB  - The main adverse effects of tamoxifen, aspirin, oral contraceptives (OCs) and 
      retinoids used as chemopreventive agents in humans are reviewed and quantified 
      here. With regard to tamoxifen, there are suggestions of some excess risk of 
      liver, and perhaps gastrointestinal, cancers. The public health impact of such 
      associations, if any, is still unclear. Tamoxifen use is associated with 
      endometrial and myometrial hyperplasia. Data from five studies based on 174 cases 
      indicate that the overall relative risk (RR) of endometrial cancer in ever 
      tamoxifen users is 1.73 (95% confidence interval = 1.1-2.6). However, there is a 
      significant difference between the results of American and European studies, so 
      the relationship between tamoxifen and endometrial cancer remains open to debate. 
      The major side-effect of aspirin is gastrointestinal lesions; the risk of these 
      is increased two- to tenfold, depending on the dose. Aspirin is also associated 
      with an increased risk of haemorrhagic stroke, although its protection against 
      other types of stroke and against myocardial infarction leads to a favourable 
      pattern of risk for all cardiovascular conditions. Short-term side-effects of OCs 
      include vascular diseases and a moderately increased risk of breast cancer. The 
      RR of cervical cancer and hepatocellular carcinoma are also increased in OC 
      users, although the public health impact of such associations is small. Toxicity 
      associated with retinoid treatment is rarely serious as most effects observed are 
      reversible on stopping use. Side-effects include changes in the skin and mucous 
      membranes (dry skin, hair loss, dry nose, conjunctivitis), musculoskeletal 
      symptoms, ophthalmological effects, changes in transaminase activity, changes in 
      clinical chemistry markers (increase in serum triglycerides and decrease in 
      high-density lipoproteins) and, rarely, central nervous system effects. A serious 
      toxicological aspect of retinoid treatment is teratogenesis; its use should 
      therefore be avoided in women with childbearing potential, and, in cases of use, 
      conception should be delayed for a long time after stopping treatment. Thus, when 
      considering side-effects of chemoprevention, the major issues of concern are the 
      rare long-term effects (chiefly neoplasms), and the need for more precise overall 
      risk-and cost-benefit assessment, particularly for healthy people.
FAU - La Vecchia, C
AU  - La Vecchia C
AD  - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
FAU - Tavani, A
AU  - Tavani A
FAU - Garattini, S
AU  - Garattini S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - France
TA  - IARC Sci Publ
JT  - IARC scientific publications
JID - 8009542
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Contraceptives, Oral)
RN  - 0 (Retinoids)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticarcinogenic Agents/*adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Contraceptives, Oral/adverse effects/therapeutic use
MH  - Humans
MH  - Neoplasms/prevention & control
MH  - Retinoids/adverse effects/therapeutic use
MH  - Tamoxifen/adverse effects/therapeutic use
RF  - 56
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
PST - ppublish
SO  - IARC Sci Publ. 1996;(139):135-42.

PMID- 7197641
OWN - NLM
STAT- MEDLINE
DCOM- 19820120
LR  - 20190816
IS  - 0301-2115 (Print)
IS  - 0301-2115 (Linking)
VI  - 12
IP  - 3
DP  - 1981 Sep
TI  - Seral, uterine and fetal salicylate concentrations after oral administration.
PG  - 167-70
AB  - Salicylate concentrations in serum, endometrium, myometrium and fetus were 
      determined 3 h after an oral dose of 1 000 mg of acetylsalicylic acid. The 
      material consisted of 19 females (11 for legal abortion and 8 for operative 
      treatment of fibroids). Tissue salicylate concentrations were at a level at which 
      prostaglandin synthetase is inhibited.
FAU - Grönroos, M
AU  - Grönroos M
FAU - Haataja, M
AU  - Haataja M
FAU - Honkonen, E
AU  - Honkonen E
FAU - Anttila, M
AU  - Anttila M
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/*metabolism
MH  - Endometrium/metabolism
MH  - Female
MH  - Fetus/*metabolism
MH  - Humans
MH  - Kinetics
MH  - Maternal-Fetal Exchange
MH  - Myometrium/metabolism
MH  - Pregnancy
MH  - Uterus/*metabolism
EDAT- 1981/09/01 00:00
MHDA- 1981/09/01 00:01
CRDT- 1981/09/01 00:00
PHST- 1981/09/01 00:00 [pubmed]
PHST- 1981/09/01 00:01 [medline]
PHST- 1981/09/01 00:00 [entrez]
AID - 0028-2243(81)90072-1 [pii]
AID - 10.1016/0028-2243(81)90072-1 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 1981 Sep;12(3):167-70. doi: 
      10.1016/0028-2243(81)90072-1.

PMID- 33104910
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20220102
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Print)
IS  - 0957-5243 (Linking)
VI  - 32
IP  - 1
DP  - 2021 Jan
TI  - Associations between daily aspirin use and cancer risk across strata of major 
      cancer risk factors in two large U.S. cohorts.
PG  - 57-65
LID - 10.1007/s10552-020-01357-2 [doi]
AB  - PURPOSE: Daily aspirin use has been shown to reduce risk of colorectal, and 
      possibly other, cancers, but it is unknown if these benefits are consistent 
      across subgroups of people with differing cancer risk factors. We investigated 
      whether age, body mass index (BMI), smoking status, physical inactivity, and 
      family history of cancer modify the effect of daily aspirin use on colorectal, 
      ovarian, breast, endometrial and aggressive prostate cancer risk. METHODS: We 
      pooled 423,495 individuals from two prospective, U.S.-based studies: the NIH-AARP 
      Diet and Health Study (1995-2011) and the Prostate, Lung, Colorectal, and Ovarian 
      Cancer Screening Trial (1993-2009). Using Cox proportional hazards regression, we 
      examined associations between daily aspirin use (≥ 5 days/week) and risk of 
      colorectal, ovarian, breast, endometrial, and aggressive prostate cancer, overall 
      and across strata of risk factors. RESULTS: Daily aspirin use was associated with 
      a 15% reduction in colorectal cancer risk (hazard ratio [HR]: 0.85, 95% 
      confidence interval [CI] 0.80-0.89). Risk reductions were generally consistent 
      across strata of risk factors but attenuated with increasing BMI 
      (p-interaction = 0.16). For ovarian cancer, there was no significant association 
      overall (HR: 0.93, 95% CI 0.80-1.08) but reduced risk among obese women (HR: 
      0.73, 95% CI 0.52-0.98, p-interaction = 0.12). Weak or null associations were 
      observed for breast, endometrial, and aggressive prostate cancer, with no strong 
      effect modification observed. CONCLUSIONS: Daily aspirin use appears to reduce 
      colorectal cancer risk regardless of other risk factors, though the potential 
      modifying effect of BMI warrants further investigation and may need to be 
      considered in risk-benefit calculations for aspirin use.
FAU - Hurwitz, Lauren M
AU  - Hurwitz LM
AUID- ORCID: 0000-0001-8932-5028
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, 9609 Medical Center Drive, Rockville, MD, 20850, USA. 
      lauren.hurwitz@nih.gov.
FAU - Michels, Kara A
AU  - Michels KA
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, 9609 Medical Center Drive, Rockville, MD, 20850, USA.
FAU - Cook, Michael B
AU  - Cook MB
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, 9609 Medical Center Drive, Rockville, MD, 20850, USA.
FAU - Pfeiffer, Ruth M
AU  - Pfeiffer RM
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, 9609 Medical Center Drive, Rockville, MD, 20850, USA.
FAU - Trabert, Britton
AU  - Trabert B
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
      Institutes of Health, 9609 Medical Center Drive, Rockville, MD, 20850, USA.
LA  - eng
GR  - ZIA CP010128/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
DEP - 20201026
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Body Mass Index
MH  - Diet
MH  - Early Detection of Cancer
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*prevention & control
MH  - Obesity
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Smoking
PMC - PMC7855934
MID - NIHMS1641315
OTO - NOTNLM
OT  - Anti-inflammatory agents
OT  - Aspirin
OT  - Cancer risk
OT  - Chemoprevention
OT  - Effect modification
OT  - Non-steroidal
COIS- Conflicts of interest: The authors have no conflicts of interest to disclose.
EDAT- 2020/10/27 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/10/26 17:15
PHST- 2020/06/01 00:00 [received]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
PHST- 2020/10/26 17:15 [entrez]
AID - 10.1007/s10552-020-01357-2 [pii]
AID - 10.1007/s10552-020-01357-2 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2021 Jan;32(1):57-65. doi: 10.1007/s10552-020-01357-2. 
      Epub 2020 Oct 26.

PMID- 26755572
OWN - NLM
STAT- MEDLINE
DCOM- 20160923
LR  - 20230804
IS  - 1941-7632 (Electronic)
IS  - 1941-7640 (Linking)
VI  - 9
IP  - 1
DP  - 2016 Jan
TI  - Efficacy and Safety of Available Protocols for Aspirin Hypersensitivity for 
      Patients Undergoing Percutaneous Coronary Intervention: A Survey and Systematic 
      Review.
PG  - e002896
LID - 10.1161/CIRCINTERVENTIONS.115.002896 [doi]
AB  - BACKGROUND: The most suitable approach for patients with aspirin hypersensitivity 
      undergoing percutaneous coronary intervention remains to be assessed. METHODS AND 
      RESULTS: Pubmed, Google Scholar, and Cochrane were systematically searched for 
      papers describing protocols about aspirin hypersensitivity in the percutaneous 
      coronary intervention setting. Discharge from hospital with aspirin was the 
      primary end point, whereas rates of adverse reactions being a secondary outcome. 
      An online international survey was performed to critically analyze rates of 
      aspirin hypersensitivity and its medical and interventional management. Eleven 
      studies with 283 patients were included. An endovenous desensitization protocol 
      was performed on one of them, with high efficacy rate (98%) and a low adverse 
      reaction rate when compared with oral administration. No significant differences 
      were reported among the oral protocols in terms of efficacy (less versus more 
      fractionated [95.8% {95.4%-96.2%} versus 95.9% {95.2-96.5%}]), whereas higher 
      incidence of rash and angioedema were reported for protocols with <6 doses 
      escalation (2.6% [1.1%-4.1%] versus 2.6% [1.9%-3.2%]). In the survey, we 
      collected answer from 86 physician of the 100 interviewed. Fifty-six percent of 
      them managed aspirin hypersensitivity changing the therapeutic regimen (eg, 
      clopidogrel monotherapy and indobufen). Despite the previous safety data, 
      desensitization protocols were adopted by only 42% of surveyed cardiologist. 
      CONCLUSIONS: Available protocols for aspirin hypersensitivity are effective and 
      safe, representing a feasible approach for patients needing dual antiplatelet 
      therapy.
CI  - © 2016 American Heart Association, Inc.
FAU - Bianco, Matteo
AU  - Bianco M
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.). matteo.bianco87@gmail.com.
FAU - Bernardi, Alessandro
AU  - Bernardi A
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
FAU - D'Ascenzo, Fabrizio
AU  - D'Ascenzo F
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
FAU - Cerrato, Enrico
AU  - Cerrato E
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
FAU - Omedè, Pierluigi
AU  - Omedè P
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
FAU - Montefusco, Antonio
AU  - Montefusco A
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
FAU - DiNicolantonio, James J
AU  - DiNicolantonio JJ
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
FAU - Zoccai, Giuseppe Biondi
AU  - Zoccai GB
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
FAU - Varbella, Ferdinando
AU  - Varbella F
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
FAU - Carini, Giovanni
AU  - Carini G
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
FAU - Moretti, Claudio
AU  - Moretti C
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
FAU - Pozzi, Roberto
AU  - Pozzi R
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
FAU - Gaita, Fiorenzo
AU  - Gaita F
AD  - From the Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy 
      (M.B., G.C., R.P.); Division of Cardiology, Città della Salute e della Scienza 
      Hospital, University of Turin, Turin, Italy (A.B., F.D.A., P.O., A.M., C.M., 
      F.G.); Department of Medico-Surgical Sciences and Biotechnologies, Sapienza 
      University of Roma, Latina, Italy (G.B.Z.); Division of Cardiology, Infermi 
      Hospital, Rivoli, Turin, Italy (E.C., F.V.); and Saint Luke's Mid America Heart 
      Institute, Kansas City, MO (J.J.D.N.).
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Circ Cardiovasc Interv
JT  - Circulation. Cardiovascular interventions
JID - 101499602
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - *Clinical Protocols
MH  - Coronary Artery Disease/*therapy
MH  - Drug Hypersensitivity/*epidemiology
MH  - Humans
MH  - Incidence
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - *Preoperative Care
MH  - *Surveys and Questionnaires
OTO - NOTNLM
OT  - angioplasty
OT  - aspirin
OT  - hypersensitivity
OT  - indobufen
OT  - percutaneous coronary intervention
EDAT- 2016/01/13 06:00
MHDA- 2016/09/24 06:00
CRDT- 2016/01/13 06:00
PHST- 2016/01/13 06:00 [entrez]
PHST- 2016/01/13 06:00 [pubmed]
PHST- 2016/09/24 06:00 [medline]
AID - CIRCINTERVENTIONS.115.002896 [pii]
AID - 10.1161/CIRCINTERVENTIONS.115.002896 [doi]
PST - ppublish
SO  - Circ Cardiovasc Interv. 2016 Jan;9(1):e002896. doi: 
      10.1161/CIRCINTERVENTIONS.115.002896.

PMID- 36781928
OWN - NLM
STAT- MEDLINE
DCOM- 20230215
LR  - 20230320
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Feb 13
TI  - A multicenter, randomized, open-labelled, non-inferiority trial of 
      sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery 
      intervention.
PG  - 2502
LID - 10.1038/s41598-023-29006-z [doi]
LID - 2502
AB  - Optimal antiplatelet therapy after endovascular therapy (EVT) for peripheral 
      artery disease is controversial. This trial aimed to evaluate whether 
      sarpogrelate plus aspirin was non-inferior for preventing early restenosis after 
      femoropopliteal (FP) EVT compared to clopidogrel plus aspirin. In this 
      open-label, prospective randomized trial, 272 patients were enrolled after 
      successful EVT for FP lesions. Patients in each group received aspirin 100 mg and 
      clopidogrel 75 mg or sarpogrelate 300 mg orally once per day for 6 months. The 
      primary outcome was target lesion restenosis at 6 months, tested for 
      noninferiority. Patient characteristics and EVT patterns were similar, except for 
      increased inflow procedures in the sarpogrelate group and increased outflow 
      procedures in the clopidogrel group. The sarpogrelate group showed a tendency of 
      less restenosis at 6 months than the clopidogrel group (13.0% vs. 19.1%, 
      difference 6.1 percentage points, 95% CI for noninferiority - 0.047 to 0.169). 
      Secondary endpoints related to safety outcomes were rare in both groups. Risks of 
      target lesion restenosis of the two intervention arm were uniform across most 
      major subgroups except for those with coronary artery disease. In conclusion, 
      Sarpogrelate plus aspirin is non-inferior to clopidogrel plus aspirin in 
      preventing early restenosis after FP EVT. Larger multi-ethnic trials are required 
      to generalize these findings. Trial registration: National Institutes of Health 
      Clinical Trials Registry (ClinicalTrials.gov identifier: NCT02959606; 
      09/11/2016).
CI  - © 2023. The Author(s).
FAU - Han, Ahram
AU  - Han A
AD  - Division of Vascular Surgery, Department of Surgery, Seoul National University 
      Hospital, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, Korea.
AD  - Seoul National University College of Medicine, Seoul, South Korea.
FAU - Lee, Taeseung
AU  - Lee T
AD  - Seoul National University College of Medicine, Seoul, South Korea.
AD  - Division of Vascular Surgery, Bundang Seoul National University Hospital, 
      Seongnam, South Korea.
FAU - Lee, Joongyub
AU  - Lee J
AD  - Department of Preventive Medicine, Seoul National University College of Medicine, 
      Seoul, South Korea.
FAU - Song, Suk-Won
AU  - Song SW
AD  - Department of Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei 
      University College of Medicine, Seoul, South Korea.
FAU - Lee, Sang-Su
AU  - Lee SS
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Yangsan 
      Hospital, Pusan National University, Yangsan, South Korea.
FAU - Jung, In Mok
AU  - Jung IM
AD  - Seoul National University College of Medicine, Seoul, South Korea.
AD  - Department of Surgery, Seoul Metropolitan Government-Seoul National University 
      Boramae Medical Center, Seoul, South Korea.
FAU - Kang, Jin Mo
AU  - Kang JM
AD  - Department of Surgery, Gil Hospital, Gachon University of Medicine and Science, 
      Incheon, South Korea.
FAU - Gwon, Jun Gyo
AU  - Gwon JG
AD  - Department of Surgery, Korea University Hospital, Seoul, South Korea.
FAU - Yun, Woo-Sung
AU  - Yun WS
AD  - Department of Surgery, Yeungnam University Medical Center, Daegu, South Korea.
FAU - Cho, Yong-Pil
AU  - Cho YP
AD  - Division of Vascular Surgery, Department of Surgery, Asan Medical Center, Seoul, 
      South Korea.
FAU - Ko, Hyunmin
AU  - Ko H
AD  - Department of Surgery, College of Medicine, Kyung Hee University, Seoul, South 
      Korea.
FAU - Park, Yang-Jin
AU  - Park YJ
AD  - Division of Vascular Surgery, Department of Surgery, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 
      06351, South Korea. yjpark1974@skku.edu.
FAU - Min, Seung-Kee
AU  - Min SK
AD  - Division of Vascular Surgery, Department of Surgery, Seoul National University 
      Hospital, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, Korea. docmin88@snu.ac.kr.
AD  - Seoul National University College of Medicine, Seoul, South Korea. 
      docmin88@snu.ac.kr.
LA  - eng
SI  - ClinicalTrials.gov/NCT02959606
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20230213
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - A74586SNO7 (Clopidogrel)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 19P708E787 (sarpogrelate)
RN  - 0 (Delayed-Action Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Clopidogrel/therapeutic use
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - Prospective Studies
MH  - Delayed-Action Preparations
MH  - Aspirin/therapeutic use
MH  - Femoral Artery/surgery
MH  - *Peripheral Arterial Disease/drug therapy
MH  - Treatment Outcome
MH  - Drug Therapy, Combination
PMC - PMC9925771
COIS- The authors declare no competing interests.
EDAT- 2023/02/14 06:00
MHDA- 2023/02/16 06:00
CRDT- 2023/02/13 23:48
PHST- 2022/10/25 00:00 [received]
PHST- 2023/01/30 00:00 [accepted]
PHST- 2023/02/13 23:48 [entrez]
PHST- 2023/02/14 06:00 [pubmed]
PHST- 2023/02/16 06:00 [medline]
AID - 10.1038/s41598-023-29006-z [pii]
AID - 29006 [pii]
AID - 10.1038/s41598-023-29006-z [doi]
PST - epublish
SO  - Sci Rep. 2023 Feb 13;13(1):2502. doi: 10.1038/s41598-023-29006-z.

PMID- 10851364
OWN - NLM
STAT- MEDLINE
DCOM- 20000713
LR  - 20190514
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 54
IP  - 11
DP  - 2000 Jun 13
TI  - Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the 
      Cache County study.
PG  - 2066-71
AB  - OBJECTIVE: To test the hypothesis that nonsteroidal anti-inflammatory drugs 
      (NSAIDs) and histamine H2 receptor antagonists (H2RAs) are associated with a 
      decreased risk of AD in late life. BACKGROUND: Sustained use of non-aspirin 
      NSAIDs has been repeatedly associated with a reduced occurrence of AD. Similar 
      effects with aspirin have been weaker. One prior study showed a strong 
      association between use of H2RAs and reduced AD prevalence. METHODS: In a 
      population study of AD in Cache County, UT, we used a sequenced plan of sampling 
      and case ascertainment to identify 201 cases of AD and 4425 participants with no 
      indication of cognitive impairment. Independently, an interview and medicine 
      chest inventory assessed use of several medicines including aspirin, non-aspirin 
      NSAIDs, H2RAs, and three classes of "control" drugs not thought to be associated 
      with AD. Follow-up questioning probed possible indications for use of these 
      drugs. RESULTS: Compared with cognitively intact individuals, the AD cases had 
      significantly less reported current use of NSAIDs, aspirin, and H2RAs. Stronger 
      associations appeared when subjects reported use of both NSAIDs and aspirin (no 
      H2RAs), two different NSAIDs (no H2RAs), or two different H2RAs (with neither 
      aspirin nor NSAIDs). There was little or no such association with use of the 
      control medicines. Adjustment for usage indication did not influence these 
      findings, and there was no appreciable variation with number of APOE epsilon4 
      alleles. CONCLUSIONS: As predicted, use of NSAIDs and aspirin were specifically 
      associated with reduced occurrence of AD. Notably, a previous observation of an 
      inverse association of AD and use of H2RAs was also affirmed. Definitive evidence 
      for a preventive action of these agents will require randomized prevention 
      trials.
FAU - Anthony, J C
AU  - Anthony JC
AD  - Department of Mental Hygiene, School of Hygiene and Public Health, Johns Hopkins 
      University, Baltimore, MD 21205, USA. janthony@jhu.edu
FAU - Breitner, J C
AU  - Breitner JC
FAU - Zandi, P P
AU  - Zandi PP
FAU - Meyer, M R
AU  - Meyer MR
FAU - Jurasova, I
AU  - Jurasova I
FAU - Norton, M C
AU  - Norton MC
FAU - Stone, S V
AU  - Stone SV
LA  - eng
GR  - R01-AG-11380/AG/NIA NIH HHS/United States
GR  - T32-MH-14592/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Histamine H2 Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*prevention & control
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Data Collection
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Logistic Models
EDAT- 2000/06/14 09:00
MHDA- 2000/07/15 11:00
CRDT- 2000/06/14 09:00
PHST- 2000/06/14 09:00 [pubmed]
PHST- 2000/07/15 11:00 [medline]
PHST- 2000/06/14 09:00 [entrez]
AID - 10.1212/wnl.54.11.2066 [doi]
PST - ppublish
SO  - Neurology. 2000 Jun 13;54(11):2066-71. doi: 10.1212/wnl.54.11.2066.

PMID- 31039217
OWN - NLM
STAT- MEDLINE
DCOM- 20191210
LR  - 20220318
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Print)
IS  - 0094-3509 (Linking)
VI  - 68
IP  - 3
DP  - 2019 Apr
TI  - PURL: Should you switch the DAPT agent one month after ACS?
PG  - 162;164
AB  - A randomized controlled trial says Yes, but current guidelines say No.
FAU - Ashby, Drew
AU  - Ashby D
AD  - University of Colorado Family Medicine Residency, Denver, USA.
FAU - Lyon, Corey
AU  - Lyon C
AD  - University of Colorado Family Medicine Residency, Denver, USA.
LA  - eng
GR  - UL1 RR024999/RR/NCRR NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Eur Heart J. 2017 Nov 1;38(41):3070-3078. PMID: 28510646
MH  - *Acute Coronary Syndrome
MH  - Aspirin
MH  - Humans
MH  - Platelet Aggregation Inhibitors
MH  - Ticlopidine
PMC - PMC6597198
EDAT- 2019/05/01 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/05/01 06:00
PHST- 2019/05/01 06:00 [entrez]
PHST- 2019/05/01 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
AID - jfp_6803f [pii]
PST - ppublish
SO  - J Fam Pract. 2019 Apr;68(3):162;164.

PMID- 32926821
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 173
IP  - 6
DP  - 2020 Sep 15
TI  - In established atherosclerosis, P2Y12 inhibitor vs. aspirin monotherapy reduces 
      MI but not stroke or mortality.
PG  - JC26
LID - 10.7326/ACPJ202009150-026 [doi]
AB  - Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor 
      or aspirin for secondary prevention in patients with established atherosclerosis: 
      a systematic review and meta-analysis. Lancet. 2020;395;1487-95. 32386592.
FAU - Elgendy, Islam Y
AU  - Elgendy IY
AD  - Weill Cornell Medicine-Qatar, Doha, Qatar (I.Y.E.).
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Lancet. 2020 May 9;395(10235):1487-1495. PMID: 32386592
MH  - Aspirin/therapeutic use
MH  - *Atherosclerosis/drug therapy/prevention & control
MH  - Hemorrhage
MH  - Humans
MH  - Patients
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
MH  - Secondary Prevention
MH  - *Stroke/prevention & control
EDAT- 2020/09/15 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/14 20:11
PHST- 2020/09/14 20:11 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.7326/ACPJ202009150-026 [doi]
PST - ppublish
SO  - Ann Intern Med. 2020 Sep 15;173(6):JC26. doi: 10.7326/ACPJ202009150-026.

PMID- 7220654
OWN - NLM
STAT- MEDLINE
DCOM- 19810613
LR  - 20191031
IS  - 0161-4630 (Print)
IS  - 0161-4630 (Linking)
VI  - 6
IP  - 1
DP  - 1981 Jan
TI  - Prostaglandins /PGs/ and peristalsis.
PG  - 13-6
AB  - The effect of some inhibitors of PG-synthesis /Aspirin, Indomethacin and 
      Suprofen/ on the small intestine peristalsis and the PG-like activity in mice was 
      investigated. It was found that the three drugs examined in the applied doses did 
      not affect the small intestine peristalsis but they significantly decreased the 
      PG-like activity. The role of PGs in the physiological peristalsis of the small 
      intestine is discussed.
FAU - Borowska, A
AU  - Borowska A
FAU - Maćkowiak, J
AU  - Maćkowiak J
FAU - Wiśniewski, K
AU  - Wiśniewski K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prostaglandins Med
JT  - Prostaglandins and medicine
JID - 7810330
RN  - 0 (Prostaglandins)
RN  - 988GU2F9PE (Suprofen)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Gastrointestinal Motility/*drug effects
MH  - Indomethacin/pharmacology
MH  - Intestine, Small/*analysis/drug effects
MH  - Male
MH  - Mice
MH  - Peristalsis/*drug effects
MH  - Prostaglandins/metabolism/*physiology
MH  - Suprofen/pharmacology
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1016/s0161-4630(81)80004-3 [doi]
PST - ppublish
SO  - Prostaglandins Med. 1981 Jan;6(1):13-6. doi: 10.1016/s0161-4630(81)80004-3.

PMID- 1593410
OWN - NLM
STAT- MEDLINE
DCOM- 19920702
LR  - 20131121
IS  - 0022-3492 (Print)
IS  - 0022-3492 (Linking)
VI  - 63
IP  - 3
DP  - 1992 Mar
TI  - Effects of sodium meclofenamate on postoperative pain following periodontal 
      surgery.
PG  - 166-8
AB  - The analgesic activity of single doses of meclofenamate (100 mg) was compared to 
      aspirin (500 mg) and to placebo on 99 outpatients with moderate to severe pain 
      following periodontal surgery under double-blind conditions. Pain intensity 
      differences scores (PID) at the first, second, and third hour after the ingestion 
      of the first capsule of each medication were used to determine the analgesic 
      efficacy of the studied drugs. Kruskal Wallis test followed by the Mann-Whitney 
      rank sum test were used in the statistical analysis of results. Meclofenamate was 
      statistically superior to placebo and superior to aspirin in the second hour of 
      evaluation, while aspirin was not superior to placebo during the 3-hour period of 
      pain evaluation. It is concluded that meclofenamate is a non-steroidal 
      antiinflammatory drug with interesting analgesic properties which can be used as 
      directed as an alternative to aspirin or acetaminophen for the control of 
      postoperative pain following periodontal surgery.
FAU - Gallardo, F
AU  - Gallardo F
AD  - Department of Pharmacology, School of Medicine, University of Chile, Santiago.
FAU - Rossi, E
AU  - Rossi E
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Periodontol
JT  - Journal of periodontology
JID - 8000345
RN  - 0 (Placebos)
RN  - 48I5LU4ZWD (Meclofenamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Meclofenamic Acid/*therapeutic use
MH  - Middle Aged
MH  - Pain Measurement
MH  - Pain, Postoperative/*prevention & control
MH  - Periodontal Diseases/*surgery
MH  - Placebos
MH  - Surgical Flaps/methods
MH  - Time Factors
EDAT- 1992/03/01 00:00
MHDA- 1992/03/01 00:01
CRDT- 1992/03/01 00:00
PHST- 1992/03/01 00:00 [pubmed]
PHST- 1992/03/01 00:01 [medline]
PHST- 1992/03/01 00:00 [entrez]
AID - 10.1902/jop.1992.63.3.166 [doi]
PST - ppublish
SO  - J Periodontol. 1992 Mar;63(3):166-8. doi: 10.1902/jop.1992.63.3.166.

PMID- 19771482
OWN - NLM
STAT- MEDLINE
DCOM- 20100825
LR  - 20211020
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Print)
IS  - 0884-8734 (Linking)
VI  - 24
IP  - 11
DP  - 2009 Nov
TI  - Use of aspirin among diabetics in the primary prevention of cardiovascular 
      disease: need for reliable randomized evidence and astute clinical judgment.
PG  - 1248-50
LID - 10.1007/s11606-009-1095-5 [doi]
AB  - BACKGROUND: The American Heart Association Guidelines recommend aspirin for all 
      apparently healthy individuals whose 10-year risk of a first coronary heart 
      disease (CHD) event is >10%. METHODS: The United States (US) Preventive Services 
      Task Force (USPSTF) has recently updated its guidelines to encourage men 45 to 79 
      years and women 55 to 79 years to use aspirin when the potential benefit 
      outweighs the potential harm. In addition, in some US guidelines, diabetes is 
      considered to be a CHD risk equivalent. RESULTS: Two recently published trials, 
      the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes 
      (JPAD) and the Prevention of Progression of Arterial Disease and Diabetes 
      (POPADAD), concluded that aspirin did not reduce risks of CHD. Both JPAD and 
      POPADAD had inadequate statistical power. Reliable randomized evidence is 
      necessary to provide a sufficient totality of evidence about benefits and risks 
      among diabetics. CONCLUSION: At present, astute individual clinical judgments are 
      necessary.
FAU - Hebert, Patricia R
AU  - Hebert PR
AD  - Florida Atlantic University, 777 Glades Road, Boca Raton, FL 33431, USA. 
      pat.hebert.fl@comcast.net
FAU - Schneider, Wendy R
AU  - Schneider WR
FAU - Hennekens, Charles H
AU  - Hennekens CH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20090922
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Diabetes Mellitus/*drug therapy
MH  - Female
MH  - Humans
MH  - *Judgment
MH  - Male
MH  - Primary Prevention/*standards
MH  - Randomized Controlled Trials as Topic/*standards
MH  - Reproducibility of Results
PMC - PMC2771233
EDAT- 2009/09/23 06:00
MHDA- 2010/08/26 06:00
CRDT- 2009/09/23 06:00
PHST- 2009/02/16 00:00 [received]
PHST- 2009/08/07 00:00 [accepted]
PHST- 2009/06/25 00:00 [revised]
PHST- 2009/09/23 06:00 [entrez]
PHST- 2009/09/23 06:00 [pubmed]
PHST- 2010/08/26 06:00 [medline]
AID - 1095 [pii]
AID - 10.1007/s11606-009-1095-5 [doi]
PST - ppublish
SO  - J Gen Intern Med. 2009 Nov;24(11):1248-50. doi: 10.1007/s11606-009-1095-5. Epub 
      2009 Sep 22.

PMID- 3540874
OWN - NLM
STAT- MEDLINE
DCOM- 19870202
LR  - 20190912
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 6
IP  - 5
DP  - 1986 Sep-Oct
TI  - Analgesic efficacy of amfenac, aspirin and placebo after extraction of impacted 
      teeth.
PG  - 236-40
AB  - Amfenac, an arylacetic acid derivative, is a new investigational, nonsteroidal 
      antiinflammatory agent that has exhibited analgesic properties superior to those 
      of phenylbutazone in animals. This double-blind, randomized, parallel study was 
      an early clinical trial to evaluate the analgesic efficacy of one oral dose of 
      amfenac 100 mg compared to aspirin 600 mg and placebo in 120 subjects with 
      moderate to severe pain after extraction of impacted molar teeth. Self-evaluated 
      subjective pain intensity and relief reports for 4 hours were used as indexes of 
      response. Analgesic effects of amfenac were significantly superior to those of 
      placebo (p less than 0.001) and aspirin (p less than 0.05) by most measurements. 
      Aspirin 600 mg was superior to placebo based on total pain relief and global 
      scores (p less than 0.05). Compared with aspirin 600 mg, amfenac 100 mg provided 
      greater and faster analgesia, lasting at least for 4 hours. Ordinal pain 
      intensity scores correlated well with the visual pain analog scale. Seven (17.5%) 
      patients taking amfenac compared to 5 (12.5%) taking placebo reported minor 
      adverse effects).
FAU - Jain, A K
AU  - Jain AK
FAU - Hunley, C C
AU  - Hunley CC
FAU - Kuebel, J
AU  - Kuebel J
FAU - McMahon, F G
AU  - McMahon FG
FAU - Ryan, J J
AU  - Ryan JJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Phenylacetates)
RN  - 28O5C1J38A (amfenac)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/*drug therapy
MH  - Phenylacetates/adverse effects/*therapeutic use
MH  - Random Allocation
MH  - *Tooth Extraction
MH  - Tooth, Impacted/*surgery
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
AID - 10.1002/j.1875-9114.1986.tb03482.x [doi]
PST - ppublish
SO  - Pharmacotherapy. 1986 Sep-Oct;6(5):236-40. doi: 
      10.1002/j.1875-9114.1986.tb03482.x.

PMID- 3925465
OWN - NLM
STAT- MEDLINE
DCOM- 19850812
LR  - 20191030
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 18
IP  - 2
DP  - 1985 May
TI  - Aspirin enhances the sensitivity of human platelet 12-lipoxygenase to inhibition 
      by 15-HETE, an endogenous regulator.
PG  - 255-9
AB  - Human platelets metabolize arachidonic acid via cyclooxygenase (E.C. 1.14.99.1) 
      to thromboxane A2 and the 12-lipoxygenase to 12-hydroxyeicosatetraenoic acid 
      (12-HETE). Aspirin inhibits cyclooxygenase while the neutrophil product 
      15-Hydroxyeicosatetraenoic acid (15-HETE) is a selective inhibitor of platelet 
      12-lipoxygenase. The unexpected observation was made that the platelet 
      12-lipoxygenase of individuals who had ingested aspirin showed up to a 
      twenty-fold increase in sensitivity to inhibition by 15-HETE. This observation 
      was confirmed in platelets treated with aspirin in vitro. Aspirin pretreatment 
      consistently resulted in a decrease in the I50 for 15-HETE from an average of 
      21.5 microM to only 5.2 +/- 1.5 microM, indicating a probable interaction between 
      the cyclooxygenase and lipoxygenase pathways.
FAU - Fletcher-Cieutat, M
AU  - Fletcher-Cieutat M
FAU - Vanderhoek, J Y
AU  - Vanderhoek JY
FAU - Bryant, R W
AU  - Bryant RW
FAU - Bailey, J M
AU  - Bailey JM
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 467RNW8T91 (5-hydroxy-6,8,11,14-eicosatetraenoic acid)
RN  - 59985-28-3 (12-Hydroxy-5,8,10,14-eicosatetraenoic Acid)
RN  - 73945-47-8 (15-hydroxy-5,8,11,13-eicosatetraenoic acid)
RN  - EC 1.13.11.- (Arachidonate Lipoxygenases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid
MH  - Arachidonate Lipoxygenases
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/*enzymology
MH  - Drug Synergism
MH  - Humans
MH  - Hydroxyeicosatetraenoic Acids/biosynthesis/*pharmacology
MH  - *Lipoxygenase Inhibitors
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
AID - 10.1016/0262-1746(85)90025-3 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1985 May;18(2):255-9. doi: 
      10.1016/0262-1746(85)90025-3.

PMID- 8770694
OWN - NLM
STAT- MEDLINE
DCOM- 19961025
LR  - 20220408
IS  - 0884-0431 (Print)
IS  - 0884-0431 (Linking)
VI  - 11
IP  - 1
DP  - 1996 Jan
TI  - Aspirin and NSAID use in older women: effect on bone mineral density and fracture 
      risk. Study of Osteoporotic Fractures Research Group.
PG  - 29-35
AB  - Prostaglandin inhibition by aspirin or nonsteroidal anti-inflammatory drug 
      (NSAIDs) may inhibit bone loss and preserve bone mineral density (BMD) in vitro 
      and in animal models. The effect of these agents on BMD and fracture risk in 
      postmenopausal women in unknown. We assessed the risk factors for osteoporosis 
      and the use of aspirin and NSAIDs in 7786 white women over age 65. Axial BMD was 
      measured at the same time, and fractures were prospectively documented over the 
      subsequent 4 years of follow-up. In age-adjusted analyses, daily use of aspirin 
      or NSAIDs was associated with a 2.3-5.8% increase in BMD of the hip and spine. 
      The relationship persisted even after adjustment for weight, a variety of 
      medications, self-reported arthritis, and for radiographic findings of 
      osteoarthritis, but the multiply adjusted increase in BMD was only 1.0-3.1%. 
      Fracture risk was similar among daily users of aspirin and NSAIDs and nonusers. 
      After adjustment for potential confounders, among daily aspirin users the 
      relative risk of hip fracture was 1.1 (95% confidence interval [CI]: 0.7, 1.6), 
      and among daily NSAID users the risk was 0.9 (CI: 0.6, 1.4). Considering all 
      nonspine fractures together, the risk among aspirin users was 1.0 (CI: 0.8. 1.2), 
      and among NSAID users the risk was also 1.0 (CI; 0.8, 1.2). Regular use of 
      aspirin or NSAIDs may have a modest beneficial effect on BMD in postmenopausal 
      women. This effect persists after adjustment for obesity and the presence of 
      osteoarthritis. However, among women who take aspirin or NSAIDs regularly, there 
      is no clinically significant protective effect on the subsequent risk of 
      fractures.
FAU - Bauer, D C
AU  - Bauer DC
AD  - Division of General Internal Medicine, University of California, San Francisco, 
      USA.
FAU - Orwoll, E S
AU  - Orwoll ES
FAU - Fox, K M
AU  - Fox KM
FAU - Vogt, T M
AU  - Vogt TM
FAU - Lane, N E
AU  - Lane NE
FAU - Hochberg, M C
AU  - Hochberg MC
FAU - Stone, K
AU  - Stone K
FAU - Nevitt, M C
AU  - Nevitt MC
LA  - eng
GR  - 1-R01-AG05407/AG/NIA NIH HHS/United States
GR  - 1-R01-AG05934/AG/NIA NIH HHS/United States
GR  - 1-R01-AM35584/AM/NIADDK NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Bone Miner Res
JT  - Journal of bone and mineral research : the official journal of the American 
      Society for Bone and Mineral Research
JID - 8610640
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandin Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Bone Density/*drug effects
MH  - Female
MH  - Fractures, Bone/*prevention & control
MH  - Hip Fractures/prevention & control
MH  - Humans
MH  - Prospective Studies
MH  - Prostaglandin Antagonists/pharmacology
MH  - Risk Factors
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1002/jbmr.5650110106 [doi]
PST - ppublish
SO  - J Bone Miner Res. 1996 Jan;11(1):29-35. doi: 10.1002/jbmr.5650110106.

PMID- 15337620
OWN - NLM
STAT- MEDLINE
DCOM- 20041115
LR  - 20131121
IS  - 0022-510X (Print)
IS  - 0022-510X (Linking)
VI  - 223
IP  - 2
DP  - 2004 Aug 30
TI  - Dipyridamole and headache--a pilot study of initial dose titration.
PG  - 179-84
AB  - Headache is reported by about one third of patients using dipyridamole (DP) after 
      stroke or TIA. No study has systematically examined if initial dipyridamole 
      titration may affect this headache. We therefore randomised patients to (1) 
      standard aspirin and dipyridamole treatment b.i.d. for 2 weeks or (2) titration 
      with aspirin only in the morning and aspirin and dipyridamole in the evening for 
      5 days, followed by 9 days of standard aspirin and dipyridamole treatment. Among 
      57 patients included for analysis, moderate to severe headache was reported by 
      28% in the standard treatment group and 25% in the titration group (n.s.). 
      Headache for more than two consecutive days occurred in 24% and 11%, 
      respectively. Rescue medication because of headache for more than 2 days was used 
      by 14% and 0% in the respective groups. The cumulative number of days with 
      headache was more than twice as high in the standard treatment group. The total 
      numbers of other side effects were 25 and 11 in the two groups. The observed 
      differences in this pilot study were not statistically significant, but 
      nevertheless suggest that titration with an initially lower dose of dipyridamole 
      may be considered to reduce headache and thereby increase compliance. A larger 
      study is needed to clarify this with sufficient statistical power.
FAU - Lindgren, Arne
AU  - Lindgren A
AD  - Department of Clinical Neuroscience, Division of Neurology, Lund University 
      Hospital, S-221 85 Lund, Sweden. arne.lindgren@neurol.lu.se
FAU - Husted, Steen
AU  - Husted S
FAU - Staaf, Gert
AU  - Staaf G
FAU - Ziegler, Birgitte
AU  - Ziegler B
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Vasodilator Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Headache/*drug therapy/etiology
MH  - Humans
MH  - Ischemia/complications/diet therapy
MH  - Pilot Projects
MH  - Time Factors
MH  - Titrimetry/methods
MH  - Vasodilator Agents/*therapeutic use
EDAT- 2004/09/01 05:00
MHDA- 2004/11/16 09:00
CRDT- 2004/09/01 05:00
PHST- 2003/11/24 00:00 [received]
PHST- 2004/05/06 00:00 [revised]
PHST- 2004/05/19 00:00 [accepted]
PHST- 2004/09/01 05:00 [pubmed]
PHST- 2004/11/16 09:00 [medline]
PHST- 2004/09/01 05:00 [entrez]
AID - S0022510X04001704 [pii]
AID - 10.1016/j.jns.2004.05.011 [doi]
PST - ppublish
SO  - J Neurol Sci. 2004 Aug 30;223(2):179-84. doi: 10.1016/j.jns.2004.05.011.

PMID- 14984560
OWN - NLM
STAT- MEDLINE
DCOM- 20040930
LR  - 20190819
IS  - 0042-9007 (Print)
IS  - 0042-9007 (Linking)
VI  - 86
IP  - 1
DP  - 2004 Jan
TI  - Platelet function abnormalities in qualified whole-blood donors: effects of 
      medication and recent food intake.
PG  - 48-53
AB  - BACKGROUND AND OBJECTIVES: Platelet function abnormalities have been reported in 
      blood donors who have not consumed aspirin. Our objective was to identify factors 
      other than aspirin that may contribute to impaired platelet function in qualified 
      volunteer blood donors. MATERIALS AND METHODS: Blood samples were obtained from 
      24 donors following routine blood donation. Donors completed a study 
      questionnaire that included questions about recent food consumption, medication 
      and medical history. Platelet activation was measured using monoclonal antibodies 
      and flow cytometry. CD62P expression and PAC-1 binding on platelets were used as 
      indicators of platelet activation. Platelet function was measured on a platelet 
      function analyser (PFA-100) using both collagen/epinephrine (cEPI) and 
      collagen/ADP (cADP) cartridges. RESULTS: Fifty-four per cent of donors (13 of 24) 
      had normal platelet function. Thirty-eight per cent (nine of 24) had prolonged 
      cEPI closure times, of whom four (17%) had no cEPI closure (> 300 seconds). No 
      closure was associated with aspirin use (two donors) or chocolate consumption 
      (two donors) before donation. Two donors (8%) had either a shortened cEPI or cADP 
      closure time. CONCLUSIONS: Platelet dysfunction in qualified blood donors is 
      underestimated. Platelet function screening can identify donors with diet-related 
      platelet dysfunction or with poor recollection of aspirin use.
FAU - Paglieroni, T G
AU  - Paglieroni TG
AD  - BloodSource-Center for Blood Research, Sacramento, CA, USA University of 
      California Davis Medical Center, Sacramento, CA, USA. 
      teresa.paglieroni@bloodsource.org
FAU - Janatpour, K
AU  - Janatpour K
FAU - Gosselin, R
AU  - Gosselin R
FAU - Crocker, V
AU  - Crocker V
FAU - Dwyre, D M
AU  - Dwyre DM
FAU - MacKenzie, M R
AU  - MacKenzie MR
FAU - Holland, P V
AU  - Holland PV
FAU - Larkin, E C
AU  - Larkin EC
LA  - eng
PT  - Journal Article
PL  - England
TA  - Vox Sang
JT  - Vox sanguinis
JID - 0413606
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology
MH  - *Blood Donors
MH  - Blood Transfusion/*standards
MH  - Cacao/adverse effects
MH  - Female
MH  - Food/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Platelet Activation
MH  - Platelet Function Tests
MH  - Surveys and Questionnaires
EDAT- 2004/02/27 05:00
MHDA- 2004/10/01 05:00
CRDT- 2004/02/27 05:00
PHST- 2004/02/27 05:00 [pubmed]
PHST- 2004/10/01 05:00 [medline]
PHST- 2004/02/27 05:00 [entrez]
AID - 384 [pii]
AID - 10.1111/j.0042-9007.2004.00384.x [doi]
PST - ppublish
SO  - Vox Sang. 2004 Jan;86(1):48-53. doi: 10.1111/j.0042-9007.2004.00384.x.

PMID- 6631685
OWN - NLM
STAT- MEDLINE
DCOM- 19831217
LR  - 20220316
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 72
IP  - 9
DP  - 1983 Sep
TI  - High-performance liquid chromatographic determination of aspirin and its 
      metabolites in plasma and urine.
PG  - 1020-3
AB  - A simple quantitative method for the rapid determination of aspirin and its 
      metabolites, salicylic acid, salicyluric acid, and gentisic acid, in plasma and 
      urine using o-toluic and o-anisic acids, respectively, as internal standards was 
      developed. Plasma proteins were precipitated by the addition of acetonitrile and, 
      after centrifugation, the supernatant fluid was injected directly onto a 
      reverse-phase column. The mobile phase consisted of an isocratic mixture of 
      water, methanol, and glacial acetic acid (64:25:1, v/v/v) and the separated 
      components were detected at 238 nm using a UV detector. Concentrations greater 
      than or equal to 0.5 microgram/ml could be quantitated for aspirin or its 
      metabolites in plasma. The peak heights and peak height ratios to the internal 
      standard, o-toluic acid, were linear for the concentration range of 0.5-200 
      micrograms/ml. The aspirin metabolites in urine were isolated by extracting the 
      acidified urine with either and then reextracting the material into an aqueous 
      buffer solution at pH 7.0. Twenty microliters of the buffer extract was directly 
      injected onto the column. The separated components were detected and quantitated 
      at 305 nm. Concentrations greater than or equal to 5 micrograms/ml of salicyluric 
      acid, salicylic acid, and gentisic acid could be determined accurately. The peak 
      heights and peak height ratios to the internal standard, o-anisic acid, were 
      found to be linear for the concentration range of 5-200 micrograms/ml in urine.
FAU - Bakar, S K
AU  - Bakar SK
FAU - Niazi, S
AU  - Niazi S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Gentisates)
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analysis
MH  - Biotransformation
MH  - Chromatography, High Pressure Liquid/methods
MH  - Gentisates/analysis
MH  - Hippurates/analysis
MH  - Humans
MH  - Rats
MH  - Salicylates/analysis
MH  - Salicylic Acid
EDAT- 1983/09/01 00:00
MHDA- 1983/09/01 00:01
CRDT- 1983/09/01 00:00
PHST- 1983/09/01 00:00 [pubmed]
PHST- 1983/09/01 00:01 [medline]
PHST- 1983/09/01 00:00 [entrez]
AID - S0022-3549(15)44752-5 [pii]
AID - 10.1002/jps.2600720913 [doi]
PST - ppublish
SO  - J Pharm Sci. 1983 Sep;72(9):1020-3. doi: 10.1002/jps.2600720913.

PMID- 6710478
OWN - NLM
STAT- MEDLINE
DCOM- 19840511
LR  - 20190727
IS  - 0041-008X (Print)
IS  - 0041-008X (Linking)
VI  - 72
IP  - 1
DP  - 1984 Jan
TI  - Teratological evaluation of trimethyl phosphite in the rat.
PG  - 119-23
AB  - Trimethyl phosphite (TMP) is an organophosphorus alkylating agent used primarily 
      in the synthesis of organophosphate compounds. To evaluate teratogenic potential, 
      TMP was administered by gavage to pregnant rats at rates of 16, 49, or 164 
      mg/kg/day, on gestation Days 6 through 15. Acetyl salicylic acid (250 mg/kg/day) 
      was also administered to a group of rats as a positive control. Teratologic 
      evaluation revealed gross fetal abnormalities, skeletal defects, and soft tissue 
      defects at a dose rate of 164 mg/kg/day of trimethyl phosphite, but not at the 
      two lesser rates. An increased frequency of fetal resorption was also observed at 
      164 mg/kg/day.
FAU - Mehlman, M A
AU  - Mehlman MA
FAU - Craig, P H
AU  - Craig PH
FAU - Gallo, M A
AU  - Gallo MA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Toxicol Appl Pharmacol
JT  - Toxicology and applied pharmacology
JID - 0416575
RN  - 0 (Alkylating Agents)
RN  - 0 (Organophosphorus Compounds)
RN  - 0 (Phosphites)
RN  - 26Q0321ZDG (trimethyl phosphite)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Abnormalities, Drug-Induced
MH  - Alkylating Agents/*toxicity
MH  - Animals
MH  - Aspirin/toxicity
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Organophosphorus Compounds/*toxicity
MH  - *Phosphites
MH  - Pregnancy
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 0041-008X(84)90255-2 [pii]
AID - 10.1016/0041-008x(84)90255-2 [doi]
PST - ppublish
SO  - Toxicol Appl Pharmacol. 1984 Jan;72(1):119-23. doi: 10.1016/0041-008x(84)90255-2.

PMID- 6485393
OWN - NLM
STAT- MEDLINE
DCOM- 19841115
LR  - 20131121
IS  - 0303-657X (Print)
IS  - 0303-657X (Linking)
VI  - 163
IP  - 1
DP  - 1984
TI  - [Types of bronchial reaction to analgesics].
PG  - 32-5
AB  - Bronchial reaction of asthma bronchiale patients (n = 102) to analgesics was 
      tested by oral exposure to acetylsalicylic acid. 73 patients produced no changed 
      bronchial response to the exposure test. Ventilation parameters improved in 12 
      patients. In cases in which analgesics intolerance had been recordable from case 
      histories (n = 17), acetylsalicylic acid doses were carefully increased in a 
      stepwise approach to identify the threshold dose required for inset of 
      bronchoconstriction. The average triggering threshold dose was found to be 200 
      mg. In patients with normal analgesics tolerance products of arachidonic acid 
      metabolism seem to have no effect on bronchial tonus. The observed dilating 
      effect of analgesics may, possibly, be associated with elimination of a 
      cyclooxygenase metabolite with relevance to bronchoconstriction. Inducer of 
      analgesics intolerance is the shift of arachidonic acid metabolism in favour of 
      the route of lipoxygenase. Of importance is possibly a free proteolytic activity 
      (inhibitor deficiency) with increased basic release of arachidonic acid.
FAU - Hummel, S
AU  - Hummel S
FAU - Slapke, J
AU  - Slapke J
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Typen bronchialer Reaktion auf Analgetika.
PL  - Germany
TA  - Z Erkr Atmungsorgane
JT  - Zeitschrift fur Erkrankungen der Atmungsorgane
JID - 7503239
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*immunology
MH  - Asthma/*immunology
MH  - Bronchi/immunology
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/*immunology
MH  - Humans
MH  - Lung Volume Measurements
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Erkr Atmungsorgane. 1984;163(1):32-5.

PMID- 28055284
OWN - NLM
STAT- MEDLINE
DCOM- 20170222
LR  - 20181202
IS  - 1525-6006 (Electronic)
IS  - 1064-1963 (Linking)
VI  - 39
IP  - 1
DP  - 2017
TI  - Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats 
      by suppressing the ERK/MAPK pathway.
PG  - 34-41
LID - 10.1080/10641963.2016.1210620 [doi]
AB  - This study aimed to investigate the therapeutic effects of aspirin (ASA) and its 
      potential mechanisms of action in monocrotaline (MCT)-induced pulmonary arterial 
      hypertension (PAH) in rats. PAH was induced in a rat model by a single 
      intraperitoneal (IP) injection of MCT. Saline was injected in a control group. 
      Two weeks following MCT injection, right ventricular systolic pressure (RVSP) and 
      systolic blood pressure (SBP) were measured in six rats from each group to 
      confirm establishment of a PAH model. The remaining MCT-treated rats were 
      randomly allocated to receive IP injection of saline, ASA, or ERK1/2 inhibitor 
      PD98059. Four weeks following treatment, RVSP was measured and all rats were 
      sacrificed for histological study. There was no significant difference in SBP in 
      any group two weeks following MCT administration. Nonetheless RVSP was 
      significantly increased in the MCT group compared with the control group. At 6 
      weeks, ASA treatment remarkably attenuated MCT-induced increased RVSP, RV 
      hypertrophy, and pulmonary artery remodeling compared with the MCT group. The 
      density of pulmonary capillaries in ASA-treated rats was also dramatically 
      increased. Treatment with ASA significantly inhibited the increased p-ERK1/2 and 
      restored the impaired endothelial nitric oxide synthase (eNOS) in MCT-treated 
      rats. This study demonstrated that ASA distinctively attenuates MCT-induced PAH 
      by inhibition of the ERK1/2 signaling pathway.
FAU - Gao, Hua
AU  - Gao H
AD  - a Department of Respiration , First Affiliated Hospital of Bengbu Medical 
      College, Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease , 
      Bengbu , Anhui , P.R. China.
FAU - Cheng, Yuqing
AU  - Cheng Y
AD  - a Department of Respiration , First Affiliated Hospital of Bengbu Medical 
      College, Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease , 
      Bengbu , Anhui , P.R. China.
FAU - Zong, Liguo
AU  - Zong L
AD  - b Department of Intensive Care Unit , Zaozhuang Municipal Hospital , Zaozhuang , 
      Shandong , P.R. China.
FAU - Huang, Linian
AU  - Huang L
AD  - a Department of Respiration , First Affiliated Hospital of Bengbu Medical 
      College, Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease , 
      Bengbu , Anhui , P.R. China.
FAU - Qiao, Chenchen
AU  - Qiao C
AD  - c Department of Cardiology , First Municipal Hospital of Bengbu , Bengbu , Anhui 
      , P.R. China.
FAU - Li, Wei
AU  - Li W
AD  - a Department of Respiration , First Affiliated Hospital of Bengbu Medical 
      College, Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease , 
      Bengbu , Anhui , P.R. China.
FAU - Gong, Beilei
AU  - Gong B
AD  - a Department of Respiration , First Affiliated Hospital of Bengbu Medical 
      College, Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease , 
      Bengbu , Anhui , P.R. China.
FAU - Hu, Junfeng
AU  - Hu J
AD  - a Department of Respiration , First Affiliated Hospital of Bengbu Medical 
      College, Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease , 
      Bengbu , Anhui , P.R. China.
FAU - Liu, Haitao
AU  - Liu H
AD  - a Department of Respiration , First Affiliated Hospital of Bengbu Medical 
      College, Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease , 
      Bengbu , Anhui , P.R. China.
FAU - Wang, Xiaojing
AU  - Wang X
AD  - a Department of Respiration , First Affiliated Hospital of Bengbu Medical 
      College, Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease , 
      Bengbu , Anhui , P.R. China.
FAU - Zhao, Chengling
AU  - Zhao C
AD  - a Department of Respiration , First Affiliated Hospital of Bengbu Medical 
      College, Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease , 
      Bengbu , Anhui , P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170105
PL  - England
TA  - Clin Exp Hypertens
JT  - Clinical and experimental hypertension (New York, N.Y. : 1993)
JID - 9305929
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Flavonoids)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 73077K8HYV (Monocrotaline)
RN  - EC 1.14.13.39 (NOS3 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - R16CO5Y76E (Aspirin)
RN  - SJE1IO5E3I (2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Flavonoids/pharmacology
MH  - Hypertension, Pulmonary/chemically induced/*drug therapy
MH  - Hypertrophy, Right Ventricular/chemically induced/*drug therapy
MH  - MAP Kinase Signaling System/*drug effects
MH  - Male
MH  - Monocrotaline
MH  - Nitric Oxide Synthase Type III/drug effects
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Pulmonary Artery/drug effects/pathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Systole
MH  - Vascular Remodeling/drug effects
OTO - NOTNLM
OT  - Aspirin
OT  - ERK1/2
OT  - nonsteroidal anti-inflammatory drugs
OT  - pulmonary arterial hypertension
EDAT- 2017/01/06 06:00
MHDA- 2017/02/23 06:00
CRDT- 2017/01/06 06:00
PHST- 2017/01/06 06:00 [pubmed]
PHST- 2017/02/23 06:00 [medline]
PHST- 2017/01/06 06:00 [entrez]
AID - 10.1080/10641963.2016.1210620 [doi]
PST - ppublish
SO  - Clin Exp Hypertens. 2017;39(1):34-41. doi: 10.1080/10641963.2016.1210620. Epub 
      2017 Jan 5.

PMID- 21061525
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - [The risk factors for aspirin induced peptic ulcer].
PG  - 2015-9
AB  - Older age, prior GI events, chronic renal failure, use of other injurious 
      medicine such as NSAIDs, antithrombotic medicine, especially thienopyridine, and 
      corticosteroids seem to be factors associated with an increased risk for upper GI 
      ulcer and bleeding among the patients taking low dose aspirin. We have previously 
      shown that hypoacidity related with corpus atrophy as well as taking PPI and 
      co-treatment of angiotensin type 1 receptor blocker seem to reduce peptic ulcer 
      among aspirin users. In addition, the polymorphisms of interleukin-1beta -511/-31 
      and angiotensinogen -20CC were significantly associated with ulcer or ulcer 
      bleeding. The further prospective studies are needed to identify specific risk 
      factors for upper GI ulcer and its complications in Japanese patients.
FAU - Shiotani, Akiko
AU  - Shiotani A
AD  - Division of Gastroenterology, Kawasaki Medical School.
FAU - Kamada, Tomoari
AU  - Kamada T
FAU - Manabe, Noriaki
AU  - Manabe N
FAU - Imamura, Hiroshi
AU  - Imamura H
FAU - Haruma, Ken
AU  - Haruma K
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Peptic Ulcer/*chemically induced
MH  - Risk Factors
EDAT- 2010/11/11 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Nov;68(11):2015-9.

PMID- 3365912
OWN - NLM
STAT- MEDLINE
DCOM- 19880616
LR  - 20190510
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 43
IP  - 5
DP  - 1988 May
TI  - Hepatic safety of two analgesics used over the counter: ibuprofen and aspirin.
PG  - 473-9
AB  - We evaluated the potential hepatic toxicity of ibuprofen, aspirin, and oxaprozin 
      in 1468 patients with rheumatoid arthritis and osteoarthritis by slightly 
      modifying an algorithm that was developed to evaluate the drug relatedness of 
      renal toxicity associated with therapeutic doses of these agents in the same 
      population. Ibuprofen proved to be the safest of these nonsteroidal 
      antiinflammatory drugs; it was associated with no AST elevation that was 
      considered probably drug related as determined by application of the algorithm to 
      laboratory values and information from case report forms. The frequency of 
      probably drug-related AST elevations was highest (5%) with aspirin; with 
      oxaprozin, an investigational nonsteroidal antiinflammatory drug, the incidence 
      (3%) fell between that for the other two agents. Thus our findings on the hepatic 
      safety of ibuprofen are consistent with those in the medical literature.
FAU - Freeland, G R
AU  - Freeland GR
AD  - Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia 
      19104.
FAU - Northington, R S
AU  - Northington RS
FAU - Hedrich, D A
AU  - Hedrich DA
FAU - Walker, B R
AU  - Walker BR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Propionates)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - MHJ80W9LRB (Oxaprozin)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Alanine Transaminase/blood
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Ibuprofen/*adverse effects
MH  - Liver/*drug effects
MH  - Oxaprozin
MH  - Propionates/adverse effects
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
AID - 0009-9236(88)90363-3 [pii]
AID - 10.1038/clpt.1988.61 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1988 May;43(5):473-9. doi: 10.1038/clpt.1988.61.

PMID- 3529925
OWN - NLM
STAT- MEDLINE
DCOM- 19861008
LR  - 20190510
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 86
IP  - 3
DP  - 1986 Sep
TI  - Transient effect of aspirin on collagen-induced platelet accumulation.
PG  - 311-6
AB  - A piece of collagen fiber (catgut) was placed into polyethylene tubing and 
      perfused with heparinized blood. The perfusion pressure was monitored, and the 
      pressure rise indicated platelet accumulation around collagen leading to 
      occlusion of the tubing. Continuous slow infusion of prostacyclin into the blood 
      or monoclonal antibody against von Willebrand factor completely prevented 
      thrombus formation. Aspirinization of blood (0.1-2 mM) resulted in a 
      concentration-dependent delay of the onset of thrombus growth, but even at the 
      highest aspirin concentration, the thrombus did finally grow and at the same rate 
      as that of the nonaspirinated control platelets. These findings question the 
      clinical anti-thrombotic benefit of aspirin as platelet release inhibitor.
FAU - Görög, P
AU  - Görög P
FAU - Kakkar, V V
AU  - Kakkar VV
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (von Willebrand Factor)
RN  - 9007-34-5 (Collagen)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Collagen/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Epoprostenol/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Microscopy, Electron, Scanning
MH  - Thrombosis/chemically induced
MH  - von Willebrand Factor/antagonists & inhibitors
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
AID - 10.1093/ajcp/86.3.311 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1986 Sep;86(3):311-6. doi: 10.1093/ajcp/86.3.311.

PMID- 4049328
OWN - NLM
STAT- MEDLINE
DCOM- 19851112
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 39
IP  - 4
DP  - 1985 Aug 15
TI  - Antihemostatic and antithrombotic effects of XC386.
PG  - 501-10
AB  - XC386 prolonged the tail bleeding time in the conscious mice. This effect was 
      dose-dependent and persisted for at least six hours after the oral 
      administration. XC386 was effective in preventing ADP-induced acute pulmonary 
      thromboembolic death in mice at dose of 100 mg/kg. Aspirin and indomethacin had 
      no effect on this model. XC386 also reduced the mortality rate in collagen- 
      induced thromboembolic death at the same dose as aspirin and indomethacin (200 
      mg/kg). All three drugs caused no significant protection in endotoxin shock. 
      XC386 was found to suppress collagen-induced platelet aggregation, but did not 
      affect blood coagulation. In conclusion, XC386 was proved to be as effective as 
      aspirin and indomethacin in preventing the death of acute pulmonary 
      thromboembolism.
FAU - Wang, J P
AU  - Wang JP
FAU - Hsu, M F
AU  - Hsu MF
FAU - Huang, L J
AU  - Huang LJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Pyrazoles)
RN  - 5203-98-5 (XC 386)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Hematocrit
MH  - Heparin/pharmacology
MH  - Indomethacin/pharmacology
MH  - Mice
MH  - Platelet Aggregation/*drug effects
MH  - Pyrazoles/*pharmacology
MH  - Shock, Septic/physiopathology
MH  - Thrombosis/*prevention & control
MH  - Time Factors
EDAT- 1985/08/15 00:00
MHDA- 1985/08/15 00:01
CRDT- 1985/08/15 00:00
PHST- 1985/08/15 00:00 [pubmed]
PHST- 1985/08/15 00:01 [medline]
PHST- 1985/08/15 00:00 [entrez]
AID - 0049-3848(85)90173-2 [pii]
AID - 10.1016/0049-3848(85)90173-2 [doi]
PST - ppublish
SO  - Thromb Res. 1985 Aug 15;39(4):501-10. doi: 10.1016/0049-3848(85)90173-2.

PMID- 8889436
OWN - NLM
STAT- MEDLINE
DCOM- 19970214
LR  - 20190826
IS  - 0014-2972 (Print)
IS  - 0014-2972 (Linking)
VI  - 26
IP  - 9
DP  - 1996 Sep
TI  - Red blood cell aggregability is increased by aspirin and flow stress, whereas 
      dipyridamole induces cell shape alterations: measurements by digital image 
      analysis.
PG  - 747-54
AB  - We evaluated the influence of pretreatment with aspirin in vitro, alone or 
      combined with dipyridamole, on red cell aggregability. Samples were tested before 
      and after being exposed to well-defined flow conditions. An aggregation rate was 
      estimated through digital analysis of light microscopy images. Red cells of 
      untreated blood that had been exposed to flow showed a higher aggregation rate 
      (38.54 +/- 1.63 vs. 27.52 +/- 1.36; P < 0.05). This effect was not observed in 
      the absence of platelets. Treatment with aspirin induced a high aggregation rate, 
      with or without exposure to flow conditions. Dipyridamole alone or combined with 
      aspirin provoked echinocytosis, disturbing the rouleaux arrangement (rates 
      ranging from 11.25 +/- 1.91 - 13.62 +/- 1.62). Washing red cells after treatment 
      restored about 90% of echinocytes to their biconcave shape, but aggregation rate 
      did not recover in parallel. These results highlight the influence of red 
      cell-platelet interactions in the regulation of haemostasis and show how 
      therapeutic agents can interfere with rheological phenomena.
FAU - Bozzo, J
AU  - Bozzo J
AD  - Servei d'Hemoteràpia i Hemostàsia, Hospital Clínic i Provincial de Barcelona, 
      Villarroel, Spain.
FAU - Hernández, M R
AU  - Hernández MR
FAU - Del Giorgio, A
AU  - Del Giorgio A
FAU - Ordinas, A
AU  - Ordinas A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cell Size/drug effects
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Dipyridamole/*pharmacology
MH  - Drug Interactions
MH  - Erythrocyte Aggregation/drug effects
MH  - Erythrocytes/cytology/*drug effects
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - 10.1046/j.1365-2362.1996.1960540.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 1996 Sep;26(9):747-54. doi: 
      10.1046/j.1365-2362.1996.1960540.x.

PMID- 27550399
OWN - NLM
STAT- MEDLINE
DCOM- 20170912
LR  - 20181113
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
VI  - 11
IP  - 7
DP  - 2016 Oct
TI  - Safety ad efficacy of direct oral anticoagulants for extended treatment of venous 
      thromboembolism.
PG  - 895-900
LID - 10.1007/s11739-016-1521-8 [doi]
AB  - Currently available anticoagulants have limitations for long-term treatment of 
      venous thromboembolism (VTE). We have evaluated the efficacy and safety of direct 
      oral anticoagulants (DOACs) for extended treatment of VTE. Four randomized 
      controlled trials (RCTs) comparing DOACs (apixaban, rivaroxaban, and dabigatran) 
      with placebo or warfarin for extended treatment of VTE were published. Primary 
      efficacy outcome was recurrent VTE or VTE-related death, and primary safety 
      outcome was major bleeding. DOACs significantly lower the risk of recurrent VTE 
      or VTE-related death compared to placebo/warfarin, as well as all-cause 
      mortality. Risk of major bleeding is not different with DOACs compared to 
      placebo/warfarin. However, DOACs are associated with a significantly higher rate 
      of the composite of major and clinically relevant bleeding compared to placebo. 
      In conclusion, DOACs are effective and safe for the extended treatment of VTE, 
      and may reduce the risk of all-cause mortality.
FAU - Imberti, Davide
AU  - Imberti D
AD  - Haemostasis and Thrombosis Center, Internal Medicine Department, Piacenza 
      Hospital, Via Taverna 49, Piacenza, Italy. d.imberti@ausl.pc.it.
FAU - Pomero, Fulvio
AU  - Pomero F
AD  - Internal Medicine Department, Hospital 'Santa Croce e Carle', Cuneo, Italy.
FAU - Benedetti, Raffaella
AU  - Benedetti R
AD  - Haemostasis and Thrombosis Center, Internal Medicine Department, Piacenza 
      Hospital, Via Taverna 49, Piacenza, Italy.
FAU - Fenoglio, Luigi
AU  - Fenoglio L
AD  - Internal Medicine Department, Hospital 'Santa Croce e Carle', Cuneo, Italy.
LA  - eng
PT  - Journal Article
DEP - 20160822
PL  - Italy
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
RN  - 0 (Anticoagulants)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 12001-79-5 (Vitamin K)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Administration, Oral
MH  - Anticoagulants/*pharmacology/therapeutic use
MH  - Aspirin/adverse effects/pharmacology/therapeutic use
MH  - Dabigatran/adverse effects/pharmacology/therapeutic use
MH  - Humans
MH  - Italy
MH  - Pyrazoles/adverse effects/pharmacology/therapeutic use
MH  - Pyridones/adverse effects/pharmacology/therapeutic use
MH  - Rivaroxaban/adverse effects/pharmacology/therapeutic use
MH  - *Time Factors
MH  - Venous Thromboembolism/*drug therapy/physiopathology
MH  - Vitamin K/pharmacology/therapeutic use
MH  - Warfarin/adverse effects/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Deep vein thrombosis
OT  - Direct oral anticoagulants
OT  - Extended treatment
OT  - Pulmonary embolism
OT  - Venous thromboembolism
EDAT- 2016/08/24 06:00
MHDA- 2017/09/13 06:00
CRDT- 2016/08/24 06:00
PHST- 2016/03/30 00:00 [received]
PHST- 2016/08/09 00:00 [accepted]
PHST- 2016/08/24 06:00 [entrez]
PHST- 2016/08/24 06:00 [pubmed]
PHST- 2017/09/13 06:00 [medline]
AID - 10.1007/s11739-016-1521-8 [pii]
AID - 10.1007/s11739-016-1521-8 [doi]
PST - ppublish
SO  - Intern Emerg Med. 2016 Oct;11(7):895-900. doi: 10.1007/s11739-016-1521-8. Epub 
      2016 Aug 22.

PMID- 36550920
OWN - NLM
STAT- MEDLINE
DCOM- 20221226
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 50
DP  - 2022 Dec 16
TI  - Diagnostic efficacy of aneuploidy markers correlated with early onset 
      preeclampsia.
PG  - e32319
LID - 10.1097/MD.0000000000032319 [doi]
LID - e32319
AB  - Low-dose aspirin administration before 16 weeks of gestation can prevent 
      preeclampsia (PE) more effectively. In order to determine if aspirin should be 
      administered, this study aimed to investigate the predictive value of 
      pregnancy-associated plasma protein A (PAPP-A) and aneuploidy markers for the 
      onset period of PE. 1053 singleton pregnant women were included in the study, and 
      serum PAPPA-A and aneuploidy markers were analyzed between 3 group (normotensive, 
      late-onset PE, and early-onset PE). The utility of these markers for predicting 
      early-onset preeclampsia (EOPE) was compared using each marker and their 
      combination. Alpha-fetoprotein (AFP)/PAPP-A > 6.89 and human chorionic 
      gonadotropin (hCG)/PAPP-A > 7.94 were associated with EOPE with a positive 
      likelihood ratio (LR) (6.52, 95% confidence interval [CI] 4.9-7.1), and (5.77, 
      95% CI 3.9-6.4). The combination of markers could predict EOPE more accurately 
      compared to the single markers. AFP/PAPP-A > 6.89 and hCG/PAPP-A > 7.94had a 
      predictive ability for EOPE, and these cutoff values can help determine the use 
      of aspirin at an earlier gestational age (GA).
CI  - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Pyeon, Seung Yeon
AU  - Pyeon SY
AD  - Department of Obstetrics and Gynecology, Kyung Hee University Hospital at 
      Gangdong, Gangdong-gu, Seoul, Republic of Korea.
FAU - Kwon, Byung Su
AU  - Kwon BS
AD  - Department of Obstetrics and Gynecology, Kyung Hee University Medical Center, 
      Dongdaemun-gu, Seoul, Republic of Korea.
FAU - Kim, Young Sun
AU  - Kim YS
AD  - Department of Obstetrics and Gynecology, Kyung Hee University Medical Center, 
      Dongdaemun-gu, Seoul, Republic of Korea.
FAU - Lee, Young Joo
AU  - Lee YJ
AUID- ORCID: 0000-0001-5294-7368
AD  - Department of Obstetrics and Gynecology, Kyung Hee University Medical Center, 
      Dongdaemun-gu, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (alpha-Fetoproteins)
RN  - EC 3.4.24.- (Pregnancy-Associated Plasma Protein-A)
RN  - 0 (Biomarkers)
RN  - 0 (eosinylphosphatidylethanolamine)
RN  - 0 (Chorionic Gonadotropin)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Chorionic Gonadotropin, beta Subunit, Human)
SB  - IM
MH  - Pregnancy
MH  - Humans
MH  - Female
MH  - *Pre-Eclampsia/diagnosis
MH  - alpha-Fetoproteins
MH  - Pregnancy-Associated Plasma Protein-A/metabolism
MH  - Biomarkers
MH  - Chorionic Gonadotropin
MH  - Pregnancy Trimester, First
MH  - Aneuploidy
MH  - Aspirin/therapeutic use
MH  - Chorionic Gonadotropin, beta Subunit, Human
PMC - PMC9771328
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/27 06:00
CRDT- 2022/12/23 01:07
PHST- 2022/12/23 01:07 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/27 06:00 [medline]
AID - 00005792-202212160-00128 [pii]
AID - 10.1097/MD.0000000000032319 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Dec 16;101(50):e32319. doi: 
      10.1097/MD.0000000000032319.

PMID- 10564709
OWN - NLM
STAT- MEDLINE
DCOM- 20000127
LR  - 20131121
IS  - 0958-0670 (Print)
IS  - 0958-0670 (Linking)
VI  - 84
IP  - 6
DP  - 1999 Nov
TI  - L-arginine transport at the fetal side of human placenta: effect of aspirin in 
      pregnancy.
PG  - 1127-36
AB  - L-Arginine transport by the fetal side of human placenta was investigated through 
      the characterization of L-[3H]arginine uptake in isolated perfused cotyledon. 
      Competitive inhibition experiments suggest the presence of at least two transport 
      systems: a Na+-independent, pH-insensitive system inhibitable by cationic amino 
      acids, similar to system y+, and a Na+-dependent system which recognizes both 
      cationic and neutral amino acids only in the presence of Na+, i.e. a Bo,+-like 
      system. The kinetic analysis of L-arginine uptake in the presence of Na+ revealed 
      that the process is mediated by saturable components: a high-affinity system (Km 
      = 167 +/- 18.0 microM; Vmax = 0.174 +/- 0.012 micromol min-1) and a low-affinity 
      carrier (Km = 980 +/- 112 microM; Vmax = 1.60 +/- 0.12 micromol min-1). In the 
      absence of Na+, L-arginine uptake was fitted by one model with a Michaelis-Menten 
      constant of 200 +/- 24.8 microM. These results suggest that the high-affinity 
      component corresponds to the Na+-independent system y+, whilst the low-affinity 
      system may represent the activity of the Na+-dependent Bo,+ transporter. Kinetic 
      studies in placentae taken from aspirin-treated pregnancies showed that 
      L-arginine is transported with a significantly higher affinity (Km = 42.5 +/- 5.7 
      microM), but with a lower capacity (Vmax = 0.064 +/- 0.003 micromol min-1) than 
      in the non-treated group. The latter finding suggests that aspirin would 
      facilitate the uptake of the NO precursor only at very low arginine 
      concentrations.
FAU - Acevedo, C G
AU  - Acevedo CG
AD  - Department of Physiology Faculty of Biological Sciences, University of 
      Concepcion, PO Box 160-C, Concepcion, Chile. cacevedo@udec.cl
FAU - Rojas, S
AU  - Rojas S
FAU - Bravo, I
AU  - Bravo I
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Exp Physiol
JT  - Experimental physiology
JID - 9002940
RN  - 0 (Amino Acids)
RN  - 94ZLA3W45F (Arginine)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Amino Acids/pharmacology
MH  - Arginine/*metabolism
MH  - Aspirin/*pharmacology
MH  - Biological Transport/drug effects
MH  - Chile
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Kinetics
MH  - Placenta/drug effects/*metabolism
MH  - Pre-Eclampsia/drug therapy
MH  - Pregnancy
MH  - Sodium/pharmacology
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
AID - PHY_1875 [pii]
PST - ppublish
SO  - Exp Physiol. 1999 Nov;84(6):1127-36.

PMID- 6203397
OWN - NLM
STAT- MEDLINE
DCOM- 19840703
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 53
IP  - 11
DP  - 1984 Jun 1
TI  - Effect of dextran and aspirin on platelet adherence after transluminal 
      angioplasty of normal canine coronary arteries.
PG  - 1695-8
AB  - The effect of low-molecular-weight dextran and aspirin on platelet deposition 
      after transluminal coronary angioplasty was studied in a normal canine model. 
      Eighteen anesthetized, open-chest dogs were separated into 4 groups. All dogs 
      received 3,000 units of intravenous heparin 10 to 20 minutes before the 
      procedure. Dogs in Group 1 served as controls and were given no further 
      treatment. Dogs in Group 2 received low-molecular-weight dextran by continuous 
      intravenous infusion at a rate of 20 ml/hour for 1 hour before balloon inflation. 
      Dogs in Group 3 were given 500 ml of low-molecular-weight dextran as an 
      intravenous bolus over 1 hour, beginning 4 hours before the procedure. Dogs in 
      Group 4 were fed 20 mg/kg of aspirin 3 hours before angioplasty. The dogs were 
      killed 10 minutes after angioplasty and the arterial segments subjected to 
      balloon inflation submitted for electron microscopic analysis. An additional 
      group of 10 dogs was used to assess the bleeding times and platelet counts from 
      control and drug-treated dogs. Drug treatment was associated with significant 
      prolongation of the bleeding time and reduction in platelet number. Extensive 
      endothelial desquamation in the area of balloon angioplasty was observed in all 
      dogs. However, no appreciable qualitative difference in either the degree or 
      extent of rapid platelet deposition to the exposed subendothelium was discernible 
      between the control and any of the treatment groups. These results do not confirm 
      previous observations with low-molecular-weight dextran. Further work on the 
      initial and long-term platelet response after endothelial injury should be 
      undertaken in a primate atherosclerotic model.
FAU - O'Gara, P T
AU  - O'Gara PT
FAU - Guerrero, J L
AU  - Guerrero JL
FAU - Feldman, B
AU  - Feldman B
FAU - Fallon, J T
AU  - Fallon JT
FAU - Block, P C
AU  - Block PC
LA  - eng
GR  - HL 26215/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Dextrans)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - Coronary Vessels/*cytology
MH  - Dextrans/*pharmacology
MH  - Dogs
MH  - Endothelium/cytology
MH  - Infusions, Parenteral
MH  - Microscopy, Electron, Scanning
MH  - Molecular Weight
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Count
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
AID - 0002-9149(84)90604-0 [pii]
AID - 10.1016/0002-9149(84)90604-0 [doi]
PST - ppublish
SO  - Am J Cardiol. 1984 Jun 1;53(11):1695-8. doi: 10.1016/0002-9149(84)90604-0.

PMID- 12042732
OWN - NLM
STAT- MEDLINE
DCOM- 20020712
LR  - 20190822
IS  - 0741-5214 (Print)
IS  - 0741-5214 (Linking)
VI  - 35
IP  - 6
DP  - 2002 Jun
TI  - Combined therapy with clopidogrel and aspirin significantly increases the 
      bleeding time through a synergistic antiplatelet action.
PG  - 1204-9
AB  - OBJECTIVE: Many thromboembolic events occur in patients taking aspirin. Dual 
      therapy with aspirin and clopidogrel may prove effective at reduction of 
      thromboembolic complications. However, the extent to which these two drugs 
      interact may significantly increase the risk of bleeding in open surgery. Because 
      of the increased use of combination antiplatelet therapy in populations with 
      significant atherosclerotic disease, this risk needs to be evaluated by the 
      assessment of the combined effect in vivo of clopidogrel and aspirin on bleeding 
      time and platelet function. OUTCOMES: In seven healthy subjects, addition of low 
      dose clopidogrel (2 x 75 mg) to aspirin (150 mg) therapy significantly increased 
      bleeding time (from 7.6 +/- 3.4 minutes to 17.5 +/- 8.6 minutes; P <.05), with 
      concomitant falls in adenosine diphosphate (ADP)-induced platelet fibrinogen 
      binding and aggregation (P <.05). Increasing the dose of clopidogrel to 300 mg 
      increased bleeding time (to 24.9 +/- 8.5 minutes; P <.05) without significant 
      additional platelet inhibition. There was considerable variability in the 
      individual subject platelet response to the lower dose of clopidogrel. Those 
      patients with the highest ADP response at baseline had the least response, and 
      subjects with a weak response to ADP at baseline achieved maximal platelet 
      inhibition with the low dose of clopidogrel. CONCLUSION: The increases in 
      bleeding times should be considered in combination antiplatelet therapy in 
      patients who undergo open vascular surgery.
FAU - Payne, D A
AU  - Payne DA
AD  - Departments of Surgery and Pathology, University of Leicester, Leicester, UK.
FAU - Hayes, P D
AU  - Hayes PD
FAU - Jones, C I
AU  - Jones CI
FAU - Belham, P
AU  - Belham P
FAU - Naylor, A R
AU  - Naylor AR
FAU - Goodall, A H
AU  - Goodall AH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Bleeding Time
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Ticlopidine/analogs & derivatives/*pharmacology
MH  - Time Factors
EDAT- 2002/06/04 10:00
MHDA- 2002/07/13 10:01
CRDT- 2002/06/04 10:00
PHST- 2002/06/04 10:00 [pubmed]
PHST- 2002/07/13 10:01 [medline]
PHST- 2002/06/04 10:00 [entrez]
AID - S0741521402139450 [pii]
AID - 10.1067/mva.2002.122027 [doi]
PST - ppublish
SO  - J Vasc Surg. 2002 Jun;35(6):1204-9. doi: 10.1067/mva.2002.122027.

PMID- 1885260
OWN - NLM
STAT- MEDLINE
DCOM- 19911007
LR  - 20140603
VI  - 15
IP  - 5
DP  - 1991 May
TI  - Aspirin potentiates the effect of ephedrine on the thermogenic response to a meal 
      in obese but not lean women.
PG  - 359-66
AB  - The effect of ephedrine (30 mg) and aspirin (300 mg) on the acute thermogenic 
      response to a liquid meal (250 kcal) was investigated in lean and obese women (n 
      = 10 each group). Resting metabolic rate (RMR) was measured prior to each of the 
      following treatments: meal only (M), meal plus ephedrine (ME) or meal plus 
      ephedrine and aspirin (MEA). Eight post-treatment measurements of metabolic rate 
      were made over a total of 160 minutes. Rise in post-treatment metabolic rate was 
      compared to the baseline RMR. Following the M treatment, the mean increase in 
      metabolic rate was 0.17 +/- 0.01 and 0.13 +/- 0.02 kcal/min in the lean and obese 
      groups respectively, with the corresponding rises being 0.21 +/- 0.02 and 0.19 
      +/- 0.02 kcal/min following the ME, and 0.23 +/- 0.03 and 0.23 +/- 0.01 kcal/min 
      following the MEA. The increase in post-prandial thermogenesis with the ephedrine 
      or ephedrine plus aspirin was significant in the obese group (P less than 0.03 
      and P less than 0.001 respectively) but not the lean. Furthermore, the 
      post-treatment rise in metabolic rate, following the MEA treatment compared to 
      the ME, was significantly greater for the obese group (P less than 0.05) but not 
      the lean. It was concluded that aspirin potentiates the stimulatory effect of 
      ephedrine on the thermogenic response to a meal in obese but not lean women.
FAU - Horton, T J
AU  - Horton TJ
AD  - Department of Food and Nutritional Sciences, King's College (KQC), Kensington, 
      London, UK.
FAU - Geissler, C A
AU  - Geissler CA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Obes
JT  - International journal of obesity
JID - 7703240
RN  - GN83C131XS (Ephedrine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Anthropometry
MH  - Aspirin/*pharmacology
MH  - Basal Metabolism
MH  - Body Temperature Regulation/*drug effects
MH  - Drug Synergism
MH  - Eating/*physiology
MH  - Ephedrine/*pharmacology
MH  - Female
MH  - Humans
MH  - Obesity/*metabolism
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
PST - ppublish
SO  - Int J Obes. 1991 May;15(5):359-66.

PMID- 16957642
OWN - NLM
STAT- MEDLINE
DCOM- 20070109
LR  - 20220330
IS  - 0009-921X (Print)
IS  - 0009-921X (Linking)
VI  - 452
DP  - 2006 Nov
TI  - The benefit of aspirin chemoprophylaxis for thromboembolism after total knee 
      arthroplasty.
PG  - 175-80
AB  - The threat of thromboembolic events after total knee arthroplasty has been 
      substantially reduced during the past decade. Currently, the risk of fatal 
      pulmonary embolism is approximately 0.1%. This is due to a confluence of changes 
      in our medical practices, including early mobilization, less traumatic surgery, 
      increased use of regional anesthesia, pneumatic compression devices, and 
      chemoprophylactic agents. Because many chemoprophylactic agents are associated 
      with an increased risk of bleeding, we have chosen aspirin as our preferred 
      method of chemoprophylaxis. This study seeks to determine if aspirin is as 
      effective as newer chemoprophylactic agents as judged by the prevalence of fatal 
      or nonfatal pulmonary embolus, readmission for deep venous thrombosis, and risk 
      of bleeding. Aspirin was the principle chemoprophylactic agent for 3473 
      consecutive patients having total knee arthroplasty. All patients were followed 
      for a minimum of 6 weeks. There were nine deaths: two from pulmonary embolism, 
      five cardiac events, one stroke, and one fat embolism. Three cardiac-related 
      deaths occurred in patients for whom pulmonary embolism could not definitively be 
      ruled out. Therefore, the best case and worst case scenarios for fatal pulmonary 
      embolism were 0.06% and 0.14%, respectively. Thirteen patients underwent 
      reoperation for hematoma (0.4%). Therefore, we have demonstrated aspirin combined 
      with early mobilization, regional anesthesia, foot pumps, and improved surgical 
      techniques is safer than and equally efficacious as other chemoprophylaxis 
      agents.
FAU - Lotke, Paul A
AU  - Lotke PA
AD  - Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 
      paul.lotke@uphs.upenn.edu
FAU - Lonner, Jess H
AU  - Lonner JH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Pulmonary Embolism/*etiology/*prevention & control
MH  - Thromboembolism/*etiology/*prevention & control
EDAT- 2006/09/08 09:00
MHDA- 2007/01/11 09:00
CRDT- 2006/09/08 09:00
PHST- 2006/09/08 09:00 [pubmed]
PHST- 2007/01/11 09:00 [medline]
PHST- 2006/09/08 09:00 [entrez]
AID - 10.1097/01.blo.0000238822.78895.95 [doi]
PST - ppublish
SO  - Clin Orthop Relat Res. 2006 Nov;452:175-80. doi: 
      10.1097/01.blo.0000238822.78895.95.

PMID- 8972450
OWN - NLM
STAT- MEDLINE
DCOM- 19970306
LR  - 20131121
IS  - 1059-1052 (Print)
IS  - 1059-1052 (Linking)
VI  - 5
IP  - 4
DP  - 1996 Winter
TI  - Pneumatic compression or aspirin prophylaxis against thromboembolism in total hip 
      arthroplasty.
PG  - 272-80
AB  - We prospectively studied the use of either aspirin or intermittent pneumatic 
      compression (IPC) as prophylaxis against thromboembolism after 330 consecutive 
      total hip arthroplasties. Duplex ultrasonography of the veins of both lower 
      extremities and ventilation-perfusion lung scans were done preoperatively and 7 
      to 14 days postoperatively. Eight patients in the IPC group (5%) had asymptomatic 
      deep vein thrombosis; there were no symptomatic thrombi. In the aspirin group, 10 
      patients (7%) had asymptomatic deep vein thrombosis and two patients (1%) had 
      symptomatic deep vein thrombosis. This difference was not statistically 
      significant. There were no fatal pulmonary emboli in either group. In the IPC 
      group, only one patient had symptomatic pulmonary embolism and 20 patients (22 
      hips [12%]) had asymptomatic pulmonary embolism. In the aspirin group, two 
      patients (1%) had symptomatic pulmonary embolism and 26 patients (18%) had 
      asymptomatic pulmonary embolism. This difference in asymptomatic pulmonary 
      embolism between the two groups was statistically significant. Both groups had a 
      low incidence of deep vein thrombosis, as shown by Duplex ultrasonography, but 
      IPC was more effective than aspirin in preventing asymptomatic pulmonary embolism 
      after total hip arthroplasty.
FAU - Lachiewicz, P F
AU  - Lachiewicz PF
AD  - Division of Orthopaedic Surgery, University of North Carolina School of Medicine, 
      Chapel Hill 27599-7055, USA.
FAU - Klein, J A
AU  - Klein JA
FAU - Holleman, J B Jr
AU  - Holleman JB Jr
FAU - Kelley, S
AU  - Kelley S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J South Orthop Assoc
JT  - Journal of the Southern Orthopaedic Association
JID - 9211289
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - *Gravity Suits
MH  - *Hip Prosthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Prospective Studies
MH  - Pulmonary Embolism/prevention & control
MH  - Thrombosis/*prevention & control
EDAT- 1996/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
PST - ppublish
SO  - J South Orthop Assoc. 1996 Winter;5(4):272-80.

PMID- 2404020
OWN - NLM
STAT- MEDLINE
DCOM- 19900221
LR  - 20160512
IS  - 0021-9355 (Print)
IS  - 0021-9355 (Linking)
VI  - 72
IP  - 1
DP  - 1990 Jan
TI  - Pneumatic sequential-compression boots compared with aspirin prophylaxis of 
      deep-vein thrombosis after total knee arthroplasty.
PG  - 27-31
AB  - This prospective, randomized study was undertaken to compare the effectiveness of 
      pneumatic sequential-compression boots with that of aspirin in preventing 
      deep-vein thrombosis after total knee arthroplasty. Patients were randomly 
      assigned to one of two prophylactic regimens: compression boots or aspirin. One 
      hundred and nineteen patients completed the study. Seventy-two patients had 
      unilateral arthroplasty and forty-seven, one-stage bilateral arthroplasty. In the 
      unilateral group, the incidence of deep-vein thrombosis was 22 per cent for the 
      patients who used compression boots compared with 47 per cent for those who 
      received aspirin (p less than 0.03). In the bilateral group, the incidence of 
      deep-vein thrombosis was 48 per cent for the patients who used compression boots 
      compared with 68 per cent for those who received aspirin (p less than 0.20). The 
      results confirm the effectiveness of compression boots in the treatment of 
      patients who have had unilateral total knee arthroplasty. Despite the use of 
      compression boots, however, patients who had bilateral arthroplasty were at 
      greater risk for the development of deep-vein thrombosis.
FAU - Haas, S B
AU  - Haas SB
AD  - Hospital for Special Surgery, New York, NY 10021.
FAU - Insall, J N
AU  - Insall JN
FAU - Scuderi, G R
AU  - Scuderi GR
FAU - Windsor, R E
AU  - Windsor RE
FAU - Ghelman, B
AU  - Ghelman B
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Bandages
MH  - Female
MH  - Humans
MH  - Knee Joint/surgery
MH  - *Knee Prosthesis
MH  - Male
MH  - Postoperative Complications/*prevention & control
MH  - Pressure
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Thrombophlebitis/etiology/*prevention & control
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - J Bone Joint Surg Am. 1990 Jan;72(1):27-31.

PMID- 10426674
OWN - NLM
STAT- MEDLINE
DCOM- 19990811
LR  - 20190719
IS  - 0306-5456 (Print)
IS  - 0306-5456 (Linking)
VI  - 106
IP  - 2
DP  - 1999 Feb
TI  - Pregnancy complications in women with recurrent miscarriage associated with 
      antiphospholipid antibodies treated with low dose aspirin and heparin.
PG  - 102-7
AB  - OBJECTIVE: To study the obstetric course of women with a history of recurrent 
      miscarriage associated with antiphospholipid antibodies, lupus anticoagulant and 
      anticardiolipin antibodies, treated with low dose aspirin and low dose heparin. 
      DESIGN: Prospective observational study. SETTING: University based tertiary 
      referral clinic. POPULATION: One hundred and fifty pregnant women with a history 
      of recurrent miscarriage associated with persistently positive tests for 
      antiphospholipid antibodies. METHODS: Lupus anticoagulant was detected using the 
      dilute Russell's viper venom time together with a platelet neutralisation 
      procedure. IgG and IgM anticardiolipin antibodies were detected using a 
      standardised enzyme linked immunosorbent assay. An IgG anticardiolipin level > or 
      = 5 per litre units and an IgM anticardiolipin level > or = 3 per litre units was 
      considered positive. Aspirin (75 mg daily) was commenced at the time of a 
      positive pregnancy test and heparin (5000 units subcutaneously 12 hourly, or 
      enoxaparin 20 mg daily) was started when fetal heart activity was demonstrated on 
      ultrasound. Treatment was stopped at the time of miscarriage or at 34 weeks of 
      gestation. RESULTS: One hundred and seven pregnancies (71%) resulted in a live 
      birth. Forty-one pregnancies (27%) miscarried, the majority in the first 
      trimester. One woman had a stillbirth, and one a premature baby who died in the 
      neonatal period. One pregnancy was terminated for a fetal anomaly. Gestational 
      hypertension complicated 17% (18/108) of ongoing pregnancies and antepartum 
      haemorrhage 7% (8/108). Twenty-six babies (24%) were delivered before 37 weeks of 
      gestation. Fifty women (46%) were delivered by caesarean section. The median 
      birthweight of all live born infants was 3069 g (range 531-4300); however 15% 
      (16/108) of the infants were small for gestational age. CONCLUSION: Combination 
      treatment with aspirin and heparin leads to a high live birth rate among women 
      with recurrent miscarriage and antiphospholipid antibodies. However, successful 
      pregnancies are prone to a high risk of complications during all trimesters. 
      Close antenatal surveillance and planned delivery of these pregnancies in a unit 
      with specialist obstetric and neonatal intensive care facilities are indicated.
FAU - Backos, M
AU  - Backos M
AD  - Department of Obstetrics and Gynaecology, Imperial College School of Medicine at 
      St Mary's, London, UK.
FAU - Rai, R
AU  - Rai R
FAU - Baxter, N
AU  - Baxter N
FAU - Chilcott, I T
AU  - Chilcott IT
FAU - Cohen, H
AU  - Cohen H
FAU - Regan, L
AU  - Regan L
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br J Obstet Gynaecol
JT  - British journal of obstetrics and gynaecology
JID - 7503752
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/etiology/*prevention & control
MH  - Adult
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Antiphospholipid Syndrome/complications/*drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cesarean Section
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Heparin/administration & dosage/therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/drug therapy
MH  - Pregnancy Outcome
MH  - Prenatal Care/*methods
MH  - Prospective Studies
EDAT- 1999/07/30 00:00
MHDA- 1999/07/30 00:01
CRDT- 1999/07/30 00:00
PHST- 1999/07/30 00:00 [pubmed]
PHST- 1999/07/30 00:01 [medline]
PHST- 1999/07/30 00:00 [entrez]
AID - 10.1111/j.1471-0528.1999.tb08208.x [doi]
PST - ppublish
SO  - Br J Obstet Gynaecol. 1999 Feb;106(2):102-7. doi: 
      10.1111/j.1471-0528.1999.tb08208.x.

PMID- 10390914
OWN - NLM
STAT- MEDLINE
DCOM- 19990914
LR  - 20170303
IS  - 0017-0011 (Print)
IS  - 0017-0011 (Linking)
VI  - 70
IP  - 3
DP  - 1999 Mar
TI  - [Evaluation of the effectiveness of a low-dose aspirin in the treatment of 
      intrauterine growth retardation (IUGR)].
PG  - 126-34
AB  - OBJECTIVE: To evaluate the benefits of IUGR treatment by low doses of 
      acetylsalicylic acid (ASA) (1.5 mg/kg) compared to the standard method. The study 
      was based on the reports that aspirin at low doses shifts prostacyclin/tromboxan 
      A2 balance to the dominance of prostacyclin by inhibiting cyclooxygenase activity 
      in platelets, which results in the improvement of the utero-placental 
      circulation. MATERIAL AND METHOD: 31 pregnant women with diagnosed fetal IUGR 
      were randomly assigned to two groups, receiving either low-dose ASA (n = 22) or 
      the standard treatment (Sadamin, Partusisten, glucose i.v., amino acids i.v.) for 
      10 days. Ultrasound examination of the biometric parameters of the fetus (BPD, 
      AC, FL) was performed and estimated fetal weight (EFW) calculated before and 
      after treatment. The birthweight of infants in the two examined groups was 
      compared. RESULTS: The mean increase in EFW was higher in the aspirin-treated 
      group compared to that receiving standard treatment (478 g vs 246 g, p < 0.05). 
      In all the biometric parameters under study a higher increase was noted in the 
      group with aspirin treatment; however, the difference was not statistically 
      significant. The mean birthweight was found to be higher in the ASA group as well 
      (2856 g vs 2511 g). The frequency of small-for-gestational-age (SGA) infants 
      (birth weight below 10th percentile) was lower in the ASA group than in the 
      controls (27% vs 55%). The low-dose aspirin therapy did not produce any adverse 
      side-effects either among mothers of infants. CONCLUSION: The treatment with low 
      doses of aspirin reduces the proportion of SGA babies and increases birthweight 
      in the case of a diagnosed fetal growth retardation. Since the number of subjects 
      in this study was relatively small, further clinical trials are necessary to 
      evaluate the effectiveness of IUGR treatment by low-dose aspirin.
FAU - Kalinka, J
AU  - Kalinka J
AD  - Kliniki Perinatologii Instytutu Ginekologii i Połoznictwa AM w Lodzi.
FAU - Sieroszewski, P
AU  - Sieroszewski P
FAU - Hanke, W
AU  - Hanke W
FAU - Laudański, T
AU  - Laudański T
FAU - Suzin, J
AU  - Suzin J
LA  - pol
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Ocena skuteczności leczenia hipotrofii płodu przy uzyciu małych dawek kwasu 
      acetylosalicylowego.
PL  - Poland
TA  - Ginekol Pol
JT  - Ginekologia polska
JID - 0374641
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fetal Growth Retardation/*diagnosis/*drug therapy
MH  - Humans
MH  - Pregnancy
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 1999/07/03 00:00
MHDA- 1999/07/03 00:01
CRDT- 1999/07/03 00:00
PHST- 1999/07/03 00:00 [pubmed]
PHST- 1999/07/03 00:01 [medline]
PHST- 1999/07/03 00:00 [entrez]
PST - ppublish
SO  - Ginekol Pol. 1999 Mar;70(3):126-34.

PMID- 33741292
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20220127
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 21
IP  - 6
DP  - 2021 Dec
TI  - Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies 
      from 1989 to 2019.
PG  - 552-565
LID - S1526-8209(21)00047-1 [pii]
LID - 10.1016/j.clbc.2021.02.005 [doi]
AB  - BACKGROUND: Some evidence shows that aspirin can reduce the morbidity and 
      mortality of different cancers, including breast cancer. Aspirin has become a new 
      focus of cancer prevention and treatment research at present, however, clinical 
      studies found conflicting conclusions of its anticancer characteristics. 
      MATERIALS AND METHODS: A systematic literature search was performed in 8 
      electronic databases. The pooled relative risk (RR) with 95% confidence interval 
      (CI) was calculated using the random effects model to estimate the effect of 
      aspirin on breast cancer. RESULTS: Forty-two published articles with 99,769 
      patients were identified. The meta-analysis showed a significant decrease in 
      breast cancer risk with aspirin use (RR, 0.92; 95% CI, 0.89-0.96; I(2) = 72%). 
      Aspirin use decreased the risk of hormone receptor-positive tumors (estrogen 
      receptor [ER]-positive RR, 0.89; 95% CI, 0.82-0.97; I(2)=54%; progesterone 
      receptor [PR]-positive RR, 0.86; 95% CI, 0.78-0.95; I(2)=32%; ER- and PR-positive 
      RR, 0.92; 95% CI, 0.85-1.00; I(2)=45%) and reduced the risk of breast cancer in 
      postmenopausal women (RR, 0.92; 95% CI, 0.86-0.98; I(2)=59%). Further analysis 
      showed that for the in situ breast cancer, regular-dose and more than 3 years use 
      of aspirin were associated with the reduced risk of breast cancer. CONCLUSION: 
      This meta-analysis suggested that aspirin may reduce the overall risk of breast 
      cancer, reduce the risk of breast cancer in postmenopausal women, hormone 
      receptor-positive tumors, and in situ breast cancer. Larger, multicenter clinical 
      studies are needed to find the optimal dose range, frequency, and duration of the 
      aspirin use to explore the best benefit-risk ratio.
CI  - Copyright © 2021. Published by Elsevier Inc.
FAU - Ma, Shaodi
AU  - Ma S
AD  - Department of Epidemiology and Health Statistics, School of Public Health, Anhui 
      Medical University, Anhui, China.
FAU - Guo, Cijuan
AU  - Guo C
AD  - Nursing Department, First People's Hospital of Suzhou, Anhui, China.
FAU - Sun, Chenyu
AU  - Sun C
AD  - AMITA Health Saint Joseph Hospital Chicago, Chicago, IL, USA.
FAU - Han, Tiantian
AU  - Han T
AD  - Department of Epidemiology and Health Statistics, School of Public Health, Anhui 
      Medical University, Anhui, China.
FAU - Zhang, Huimei
AU  - Zhang H
AD  - Department of Epidemiology and Health Statistics, School of Public Health, Anhui 
      Medical University, Anhui, China.
FAU - Qu, Guangbo
AU  - Qu G
AD  - Department of Epidemiology and Health Statistics, School of Public Health, Anhui 
      Medical University, Anhui, China.
FAU - Jiang, Yuemeng
AU  - Jiang Y
AD  - Department of Infectious Diseases, the First Affiliated Hospital of Anhui Medical 
      University, Anhui, China.
FAU - Zhou, Qin
AU  - Zhou Q
AD  - Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
FAU - Sun, Yehuan
AU  - Sun Y
AD  - Department of Epidemiology and Health Statistics, School of Public Health, Anhui 
      Medical University, Anhui, China; Center for Evidence-Based Practice, Anhui 
      Medical University, Anhui, China. Electronic address: yhsun_ahmu_edu@yeah.net.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210217
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Breast Neoplasms/*prevention & control
MH  - Female
MH  - Humans
MH  - Observational Studies as Topic
MH  - Postmenopause
MH  - Prognosis
MH  - Risk Assessment
MH  - Risk Factors
OTO - NOTNLM
OT  - Cancer stages
OT  - Hormone receptors
OT  - Nonsteroidal anti-inflammatory drugs (NSAIDs)
EDAT- 2021/03/21 06:00
MHDA- 2022/01/28 06:00
CRDT- 2021/03/20 05:55
PHST- 2020/06/23 00:00 [received]
PHST- 2021/02/15 00:00 [accepted]
PHST- 2021/03/21 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
PHST- 2021/03/20 05:55 [entrez]
AID - S1526-8209(21)00047-1 [pii]
AID - 10.1016/j.clbc.2021.02.005 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2021 Dec;21(6):552-565. doi: 10.1016/j.clbc.2021.02.005. Epub 
      2021 Feb 17.

PMID- 18678294
OWN - NLM
STAT- MEDLINE
DCOM- 20080919
LR  - 20181201
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 102
IP  - 4
DP  - 2008 Aug 15
TI  - Comparison of increased aspirin dose versus combined aspirin plus clopidogrel 
      therapy in patients with diabetes mellitus and coronary heart disease and 
      impaired antiplatelet response to low-dose aspirin.
PG  - 396-400
LID - 10.1016/j.amjcard.2008.03.074 [doi]
AB  - The effects of therapy with aspirin 300 mg/day and with combined aspirin 100 
      mg/day plus clopidogrel 75 mg/day on platelet function were compared in patients 
      with diabetes mellitus and coronary artery disease and impaired antiplatelet 
      responses to aspirin 100 mg/day. The study population consisted of 151 
      outpatients with type II diabetes mellitus and coronary artery disease who were 
      taking aspirin 100 mg/day. Of the 151 patients, a subgroup of subjects with 
      impaired aspirin response were selected on the basis of the results of platelet 
      aggregometry. Nonresponsiveness to aspirin was defined as mean aggregation > or 
      =69% with 3 micromol/L adenosine diphosphate and mean aggregation > or =70% with 
      2 micromol/L collagen. Aspirin semiresponders were defined as meeting 1 but not 
      both of these criteria. Nonresponders and semiresponders were randomized equally 
      to aspirin 300 mg/day and aspirin 100 mg/day plus clopidogrel 75 mg/day, and 
      aggregation tests were repeated after 2 weeks. Sixty of the 151 patients with 
      diabetes (40%) were found to respond to aspirin inadequately. Platelet 
      aggregation induced by adenosine diphosphate and collagen decreased significantly 
      after aspirin 300 mg/day or combined therapy. Combined treatment was found to 
      have a stronger inhibitory effect on platelet aggregation induced by adenosine 
      diphosphate than aspirin 300 mg/day (p = 0.002). Impaired aspirin response was 
      resolved by increasing the aspirin dose or adding clopidogrel to aspirin (p 
      <0.0001 for each). However, desired platelet inhibition was achieved in 
      significantly more patients by combined treatment than by aspirin 300 mg/day (p 
      <0.05). In conclusion, aspirin 100 mg/day does not inhibit platelet function 
      adequately in a significant number of patients with diabetes mellitus and 
      coronary artery disease. Increasing the aspirin dose to 300 mg/day or adding 
      clopidogrel to aspirin can provide adequate platelet inhibition in a significant 
      number of those patients with impaired responses to low-dose aspirin.
FAU - Duzenli, Mehmet Akif
AU  - Duzenli MA
AD  - Department of Cardiology, Faculty of Medicine, Selcuk University, Konya, Turkey. 
      akifduzenli@hotmail.com
FAU - Ozdemir, Kurtulus
AU  - Ozdemir K
FAU - Aygul, Nazif
AU  - Aygul N
FAU - Soylu, Ahmet
AU  - Soylu A
FAU - Tokac, Mehmet
AU  - Tokac M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20080522
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Clopidogrel
MH  - Coronary Artery Disease/blood/complications/*drug therapy
MH  - Diabetes Mellitus, Type 2/blood/*complications
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
MH  - Treatment Failure
EDAT- 2008/08/06 09:00
MHDA- 2008/09/20 09:00
CRDT- 2008/08/06 09:00
PHST- 2008/01/19 00:00 [received]
PHST- 2008/03/24 00:00 [revised]
PHST- 2008/03/24 00:00 [accepted]
PHST- 2008/08/06 09:00 [pubmed]
PHST- 2008/09/20 09:00 [medline]
PHST- 2008/08/06 09:00 [entrez]
AID - S0002-9149(08)00647-4 [pii]
AID - 10.1016/j.amjcard.2008.03.074 [doi]
PST - ppublish
SO  - Am J Cardiol. 2008 Aug 15;102(4):396-400. doi: 10.1016/j.amjcard.2008.03.074. 
      Epub 2008 May 22.

PMID- 26458895
OWN - NLM
STAT- MEDLINE
DCOM- 20160608
LR  - 20220311
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 15
DP  - 2015 Oct 12
TI  - Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events 
      (TRACE): study protocol for a randomized controlled trial.
PG  - 195
LID - 10.1186/s12883-015-0453-7 [doi]
LID - 195
AB  - BACKGROUND: Transient ischemic attack (TIA) or minor ischemic stroke represents 
      the largest group of cerebrovascular disease, and those patients have a high risk 
      of early recurrent stroke. Over decades, anticoagulation therapy has been used 
      prudently in them for likely increasing the risk of intra-/extra-cranial 
      hemorrhagic complications. However, recently rivaroxaban, a new oral 
      anticoagulant, is proved to be as effective as traditional anticoagulants, while 
      carrying significantly less risk of intracranial hemorrhage. Therefore, we 
      assumed that patients may benefit from rivaroxaban if treated soon after TIA or 
      minor stroke, and designed this adequately powered randomized study, TRACE. 
      METHODS AND DESIGN: The Treatment of Rivaroxaban versus Aspirin in Non-disabling 
      Cerebrovascular Events (TRACE) study is a randomized, double-blind clinical trial 
      with a target enrollment of 4400 patients. A 14-days regimen of rivaroxaban 10 mg 
      daily or a 14-days regimen of aspirin 100 mg daily will be administrated to 
      randomized participants with acute TIA or minor stroke, defined as National 
      Institute of Health Stroke Scale scores ≤ 3. The primary efficacy end point is 
      percentage of patients with any stroke (ischemic or hemorrhage) at 14 days. Study 
      visits will be performed at the day of randomization, day 14 and day 90. 
      DISCUSSION: Even though the new oral anticoagulants seem to be both safe and 
      effective, few clinical trials have been carried out to test their effect on 
      non-disabling cerebrovascular events. Treatment with rivaroxaban may prevent more 
      cerebrovascular events with an acceptable risk profile after TIA or minor stroke, 
      compared with aspirin, thus helping to improve the outcome of the disease. TRIAL 
      REGISTRATION: No. NCT01923818.
FAU - Yang, Fang
AU  - Yang F
AD  - Department of Neurology, Xijing Hospital, No. 15 West Changle Road, Xi'an, 
      710032, China. fyangx@fmmu.edu.cn.
FAU - Jiang, Wenrui
AU  - Jiang W
AD  - Emergency Department, Xijing Hospital, No. 15 West Changle Road, Xi'an, 710032, 
      China. jiangwr@fmmu.edu.cn.
FAU - Bai, Ya
AU  - Bai Y
AD  - Department of Neurology, Xijing Hospital, No. 15 West Changle Road, Xi'an, 
      710032, China. xiabing616@163.com.
FAU - Han, Junliang
AU  - Han J
AD  - Department of Neurology, Xijing Hospital, No. 15 West Changle Road, Xi'an, 
      710032, China. hanjunliang@gmail.com.
FAU - Liu, Xuedong
AU  - Liu X
AD  - Department of Neurology, Xijing Hospital, No. 15 West Changle Road, Xi'an, 
      710032, China. liuxued@fmmu.edu.cn.
FAU - Zhang, Guangyun
AU  - Zhang G
AD  - Department of Neurology, Xijing Hospital, No. 15 West Changle Road, Xi'an, 
      710032, China. zhgyun@fmmu.edu.cn.
FAU - Zhao, Gang
AU  - Zhao G
AD  - Department of Neurology, Xijing Hospital, No. 15 West Changle Road, Xi'an, 
      710032, China. zhaogang@fmmu.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT01923818
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20151012
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Clinical Protocols
MH  - Factor Xa Inhibitors/administration & dosage/*pharmacology
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/prevention & control/*therapy
MH  - Male
MH  - *Outcome Assessment, Health Care
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Recurrence
MH  - Rivaroxaban/administration & dosage/*pharmacology
MH  - Stroke/prevention & control/*therapy
PMC - PMC4603584
EDAT- 2015/10/16 06:00
MHDA- 2016/06/09 06:00
CRDT- 2015/10/14 06:00
PHST- 2014/10/22 00:00 [received]
PHST- 2015/10/01 00:00 [accepted]
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - 10.1186/s12883-015-0453-7 [pii]
AID - 453 [pii]
AID - 10.1186/s12883-015-0453-7 [doi]
PST - epublish
SO  - BMC Neurol. 2015 Oct 12;15:195. doi: 10.1186/s12883-015-0453-7.

PMID- 1783044
OWN - NLM
STAT- MEDLINE
DCOM- 19920317
LR  - 20191028
IS  - 0232-1513 (Print)
IS  - 0232-1513 (Linking)
VI  - 43
IP  - 1-2
DP  - 1991
TI  - The effect of acetylsalicylic acid on the development of the skeletal system in 
      rats.
PG  - 33-6
AB  - The authors wished to clarify the cause of micro- and phocomelia developing in 
      rat fetuses following administration of acetylsalicylic acid. It has been proved 
      by histological examinations that the positive ground substance of the epiphyseal 
      cartilage, detected by Rivanol reaction, became disarranged or negative. The 
      sulphation of glycosaminoglycans was diminished or inhibited by acetylsalicylic 
      acid in the chondrocytes depending on the dose applied. The conclusion has been 
      drawn that the malformation developed is due to the reduced production of 
      sulphated mucopolysaccharides.
FAU - Tátrai, E
AU  - Tátrai E
AD  - National Institute of Occupational Health, Budapest, Hungary.
FAU - Ungváry, G
AU  - Ungváry G
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Exp Pathol
JT  - Experimental pathology
JID - 8108218
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects
MH  - Cartilage/*drug effects
MH  - Femur/drug effects/*embryology
MH  - Osteogenesis/*drug effects
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1016/s0232-1513(11)80138-6 [doi]
PST - ppublish
SO  - Exp Pathol. 1991;43(1-2):33-6. doi: 10.1016/s0232-1513(11)80138-6.

PMID- 7267469
OWN - NLM
STAT- MEDLINE
DCOM- 19811025
LR  - 20190713
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 70
IP  - 3
DP  - 1981 Sep
TI  - Rheumatoid arthritis. Guidelines for office management.
PG  - 143-9
AB  - Since this chronic inflammatory disease is characterized by a combination of 
      destruction and healing, a two-pronged approach to management that incorporates 
      antiinflammatory drug therapy and physiotherapy is advised. More toxic drugs or 
      even surgery may be tried in stepwise fashion if initial measures fail to relieve 
      symptoms.
FAU - Plotz, C M
AU  - Plotz CM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Anti-Inflammatory Agents)
RN  - 7440-57-5 (Gold)
RN  - GNN1DV99GX (Penicillamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Arthritis, Rheumatoid/diagnosis/drug therapy/*therapy
MH  - Aspirin/therapeutic use
MH  - Gold/therapeutic use
MH  - Humans
MH  - Penicillamine/therapeutic use
MH  - Physical Therapy Modalities
EDAT- 1981/09/01 00:00
MHDA- 1981/09/01 00:01
CRDT- 1981/09/01 00:00
PHST- 1981/09/01 00:00 [pubmed]
PHST- 1981/09/01 00:01 [medline]
PHST- 1981/09/01 00:00 [entrez]
AID - 10.1080/00325481.1981.11715860 [doi]
PST - ppublish
SO  - Postgrad Med. 1981 Sep;70(3):143-9. doi: 10.1080/00325481.1981.11715860.

PMID- 1283397
OWN - NLM
STAT- MEDLINE
DCOM- 19930301
LR  - 20131121
IS  - 0368-2315 (Print)
IS  - 0150-9918 (Linking)
VI  - 21
IP  - 8
DP  - 1992
TI  - [Fetal growth retardation: prevention. Review of the literature].
PG  - 857-67
AB  - The principle underlying preventive treatment of fetal intrauterine growth 
      retardation can only be considered after defining various groups that are at risk 
      and early screening based on the obstetric history, biological tests, and 
      recently using flow rates with Doppler techniques. The use of aspirin in 
      preventive treatment of growth retardation originates in the pharmacological 
      properties of its molecule which allow the re-establishment of a balance of the 
      prostoglandins. Numerous authors have studied clinical effects, its harmlessness 
      as well as the true indications for its use. As there have been no control 
      studies the theoretical possibilities of using Beta-Mimetic drugs has not been 
      tested. The use of ultrasound has made it possible to try to see whether there is 
      an improvement in the fetal state of well-being when oxygen therapy is used by 
      the mother as it is in certain extremes to see what effect it has on placental 
      function. Its use as an effective prophylactic has not yet been demonstrated. 
      Promising lines of research could be assessing the effects of immunological 
      treatments that have already been suggested (especially gammaglobulin 
      transfusions). They have been used prophylactically with success but the series 
      are small for well defined immunological indications.
FAU - Boulot, P
AU  - Boulot P
AD  - Service de Gynécologie-Obstétrique, CHRU Montpellier, Faculté de Médecine, 
      Université Montpellier I.
FAU - Giacalone, P L
AU  - Giacalone PL
FAU - Hedon, B
AU  - Hedon B
FAU - Laffargue, F
AU  - Laffargue F
FAU - Viala, J L
AU  - Viala JL
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Hypotrophie foetale: prévention. Revue de la littérature.
PL  - France
TA  - J Gynecol Obstet Biol Reprod (Paris)
JT  - Journal de gynecologie, obstetrique et biologie de la reproduction
JID - 0322206
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (gamma-Globulins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Agonists/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Fetal Growth Retardation/diagnosis/epidemiology/*prevention & control
MH  - Humans
MH  - Mass Screening/methods/standards
MH  - Oxygen Inhalation Therapy/standards
MH  - Pregnancy
MH  - Risk Factors
MH  - Ultrasonography, Prenatal
MH  - gamma-Globulins/pharmacology/therapeutic use
RF  - 60
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - J Gynecol Obstet Biol Reprod (Paris). 1992;21(8):857-67.

PMID- 25461472
OWN - NLM
STAT- MEDLINE
DCOM- 20150526
LR  - 20220330
IS  - 1873-0183 (Electronic)
IS  - 1568-9972 (Linking)
VI  - 14
IP  - 3
DP  - 2015 Mar
TI  - Patient-level analysis of five international cohorts further confirms the 
      efficacy of aspirin for the primary prevention of thrombosis in patients with 
      antiphospholipid antibodies.
PG  - 192-200
LID - S1568-9972(14)00240-7 [pii]
LID - 10.1016/j.autrev.2014.10.019 [doi]
AB  - We performed an individual patient meta-analysis to determine whether aspirin has 
      a significant protective effect on the risk of first thrombosis among patients 
      with antiphospholipid antibodies (aPL). Five international cohort studies with 
      available individual patient-level data, reporting on primary prophylaxis with 
      continuous treatment with low-dose aspirin in patients with aPL were included. 
      The main outcome was the occurrence of a first thrombotic in patients with aPL 
      treated with low-dose aspirin compared to those not treated with low-dose 
      aspirin. Pooled Hazard Ratios (HRs) and 95%CIs were calculated using frailty 
      models. We pooled data from 497 subjects and 79 first thrombotic events (3469 
      patient-years of follow-up). After adjustment on cardiovascular risk factors, aPL 
      profiles, and treatment with hydroxychloroquine, the HR for the risk of a first 
      thrombosis of any type in aPL carriers treated with low-dose aspirin versus those 
      not treated with aspirin was 0.43 (95%CI 0.25-0.75). Subgroup analysis showed a 
      protective effect of aspirin against arterial (HR: 0.43 [95%CI: 0.20-0.93]) but 
      not venous (HR: 0.49 [95%CI: 0.22-1.11]) thrombosis. Subgroup analysis according 
      to underlying disease revealed a protective effect of aspirin against arterial 
      thrombosis for systemic lupus erythematosus (SLE) (HR: 0.43 [95%CI: 0.20-0.94]) 
      and asymptomatic aPL carriers (HR: 0.43 [95%CI 0.20-0.93]). We found no 
      independent protective effect of hydroxychloroquine. This individual patient data 
      meta-analysis shows that the risk of first thrombotic event as well of first 
      arterial thrombotic event is significantly decreased among SLE patients and 
      asymptomatic aPL individuals treated by low-dose aspirin.
CI  - Copyright © 2014 Elsevier B.V. All rights reserved.
FAU - Arnaud, Laurent
AU  - Arnaud L
AD  - AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Institut E3M, Department of Internal 
      Medicine & French National Reference Center For Systemic Lupus and 
      Antiphospholipid Syndrome, F-75013, Paris; Inserm UMR-S 1136, Institut Pierre 
      Louis d'Epidémiologie et de Santé Publique (iPLESP), F-75013 Paris, France; 
      Sorbonne Universités, UPMC Univ Paris 06, F-75013 Paris, France. Electronic 
      address: Laurent.arnaud@psl.aphp.fr.
FAU - Mathian, Alexis
AU  - Mathian A
AD  - AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Institut E3M, Department of Internal 
      Medicine & French National Reference Center For Systemic Lupus and 
      Antiphospholipid Syndrome, F-75013, Paris; Sorbonne Universités, UPMC Univ Paris 
      06, F-75013 Paris, France.
FAU - Devilliers, Hervé
AU  - Devilliers H
AD  - Service de médecine interne et maladies systémiques, Dijon, France.
FAU - Ruffatti, Amelia
AU  - Ruffatti A
AD  - Rheumatology Unit, Department of Clinical and Experimental Medicine, University 
      of Padua, Padua, Italy.
FAU - Tektonidou, Maria
AU  - Tektonidou M
AD  - First Department of Internal Medicine, School of Medicine, National University of 
      Athens, Athens, Greece.
FAU - Forastiero, Ricardo
AU  - Forastiero R
AD  - Department of Physiology, Favaloro University, Buenos Aires, Argentina.
FAU - Pengo, Vittorio
AU  - Pengo V
AD  - Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, 
      University of Padova, Padova, Italy.
FAU - Lambert, Marc
AU  - Lambert M
AD  - Internal Medicine Department, Universitary Hospital, Lille, France.
FAU - Lefevre, Guillaume
AU  - Lefevre G
AD  - Internal Medicine Department, Universitary Hospital, Lille, France.
FAU - Martinez-Zamora, Maria Angeles
AU  - Martinez-Zamora MA
AD  - Institut Clínic of Gynecology, Obstetrics and Neonatology, Hospital 
      Clínic-Institut d´Investigacions Biomèdiques August Pi i Sunyer, Faculty of 
      Medicine-University of Barcelona, Barcelona, Spain.
FAU - Balasch, Juan
AU  - Balasch J
AD  - Institut Clínic of Gynecology, Obstetrics and Neonatology, Hospital 
      Clínic-Institut d´Investigacions Biomèdiques August Pi i Sunyer, Faculty of 
      Medicine-University of Barcelona, Barcelona, Spain.
FAU - Wahl, Denis
AU  - Wahl D
AD  - Nancy University Hospital, Université de Lorraine & INSERM U1116, 
      Vandœuvre-Les-Nancy, France.
FAU - Amoura, Zahir
AU  - Amoura Z
AD  - AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Institut E3M, Department of Internal 
      Medicine & French National Reference Center For Systemic Lupus and 
      Antiphospholipid Syndrome, F-75013, Paris; Sorbonne Universités, UPMC Univ Paris 
      06, F-75013 Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141022
PL  - Netherlands
TA  - Autoimmun Rev
JT  - Autoimmunity reviews
JID - 101128967
RN  - 0 (Antibodies, Antiphospholipid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Antiphospholipid/*immunology
MH  - Aspirin/*therapeutic use
MH  - Cohort Studies
MH  - Humans
MH  - Primary Prevention
MH  - Risk Factors
MH  - Thrombosis/immunology/*prevention & control
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiphospholipid antibodies
OT  - Aspirin
OT  - Meta-analysis
OT  - Primary prevention
OT  - Thrombosis
EDAT- 2014/12/03 06:00
MHDA- 2015/05/27 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/10/02 00:00 [received]
PHST- 2014/10/12 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/05/27 06:00 [medline]
AID - S1568-9972(14)00240-7 [pii]
AID - 10.1016/j.autrev.2014.10.019 [doi]
PST - ppublish
SO  - Autoimmun Rev. 2015 Mar;14(3):192-200. doi: 10.1016/j.autrev.2014.10.019. Epub 
      2014 Oct 22.

PMID- 36341885
OWN - NLM
STAT- MEDLINE
DCOM- 20230124
LR  - 20230524
IS  - 1523-1755 (Electronic)
IS  - 0085-2538 (Linking)
VI  - 103
IP  - 2
DP  - 2023 Feb
TI  - Effects of aspirin on cardiovascular outcomes in patients with chronic kidney 
      disease.
PG  - 403-410
LID - S0085-2538(22)00848-1 [pii]
LID - 10.1016/j.kint.2022.09.023 [doi]
AB  - Patients with chronic kidney disease (CKD) carry a high cardiovascular (CV) risk. 
      Since whether this risk is reduced by aspirin is unclear, we examined if the 
      effect of aspirin on cardiovascular outcomes varied by baseline kidney function 
      in a primary cardiovascular disease prevention trial. The International Polycap 
      Study-3 (TIPS-3) trial had randomized people without previous cardiovascular 
      disease to aspirin (75 mg daily) or placebo. We now examined aspirin versus 
      placebo on cardiovascular events in participants grouped by estimated glomerular 
      filtration rate (eGFR), using a threshold of 60 ml/min/1.73 m(2), and by using 
      tertiles of eGFR. The primary outcome was a composite of non-fatal myocardial 
      infarction, non-fatal stroke or cardiovascular death. A total of 5712 
      participants were randomized with a mean follow-up of 4.6 years. Of these, 983 
      (17.2%) had an eGFR under 60 ml/min/1.73 m(2) (mean eGFR 49 ml/min/1.73 m(2)) and 
      4,729 over 60 ml/min/1.73 m(2) (mean 84 ml/min/1.73 m(2)). In participants with 
      an eGFR under 60 ml/min/1.73 m(2) there were 26 primary outcomes in 502 
      participants on aspirin and 39/481 on placebo (hazard ratio 0.57; 95% confidence 
      interval 0.34-0.94). In participants with an eGFR over 60 ml/min/1.73 m(2) there 
      were 90 primary outcomes in 2357 participants on aspirin and 95/2372 on placebo 
      (0.95; 0.71-1.27). With tertiles of eGFR under 70, 70-90, and over 90 ml/min/1.73 
      m(2), risk reductions with aspirin for the primary outcome were larger at lower 
      eGFR levels (0.62; 0.43-0.91) for the lowest tertile, (0.96; 0.62-1.49) for the 
      middle, and (1.30; 0.77-2.18) for the highest tertile. Thus, our findings support 
      aspirin may reduce cardiovascular events in people with moderate to advanced 
      stage CKD.
CI  - Copyright © 2022 International Society of Nephrology. Published by Elsevier Inc. 
      All rights reserved.
FAU - Mann, Johannes F E
AU  - Mann JFE
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada; KfH Kidney Center, Munich, Germany. Electronic address: 
      prof.j.mann@gmail.com.
FAU - Joseph, Philip
AU  - Joseph P
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Gao, Peggy
AU  - Gao P
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Pais, Prem
AU  - Pais P
AD  - St. John's Research Institute, Bangalore, Karnataka, India.
FAU - Tyrwhitt, Jessica
AU  - Tyrwhitt J
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Xavier, Denis
AU  - Xavier D
AD  - St. John's Medical College, Bangalore, Karnataka, India.
FAU - Dans, Tony
AU  - Dans T
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Jaramillo, Patricio Lopez
AU  - Jaramillo PL
AD  - Universidad de Santander, Bucaramaga, Colombia.
FAU - Gamra, Habib
AU  - Gamra H
AD  - Bourguiba University Hospital, Monastir, Tunisia.
FAU - Yusuf, Salim
AU  - Yusuf S
AD  - Population Health Research Institute, McMaster University, Hamilton, Ontario, 
      Canada.
CN  - TIPS-3 investigators
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20221027
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Kidney Int. 2023 Jun;103(6):1201. PMID: 37210198
MH  - Humans
MH  - Aspirin/adverse effects
MH  - *Cardiovascular Diseases/etiology/prevention & control
MH  - *Renal Insufficiency, Chronic/drug therapy
MH  - *Myocardial Infarction
MH  - Glomerular Filtration Rate
MH  - *Stroke/etiology/prevention & control
OTO - NOTNLM
OT  - antiplatelet agent
OT  - blood pressure
OT  - cardiovascular death
OT  - glomerular filtration rate
OT  - myocardial infarction
OT  - stroke
EDAT- 2022/11/08 06:00
MHDA- 2023/01/25 06:00
CRDT- 2022/11/07 06:26
PHST- 2022/05/13 00:00 [received]
PHST- 2022/09/14 00:00 [revised]
PHST- 2022/09/22 00:00 [accepted]
PHST- 2022/11/08 06:00 [pubmed]
PHST- 2023/01/25 06:00 [medline]
PHST- 2022/11/07 06:26 [entrez]
AID - S0085-2538(22)00848-1 [pii]
AID - 10.1016/j.kint.2022.09.023 [doi]
PST - ppublish
SO  - Kidney Int. 2023 Feb;103(2):403-410. doi: 10.1016/j.kint.2022.09.023. Epub 2022 
      Oct 27.

PMID- 32106237
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20200518
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 2
DP  - 2020
TI  - Factors that influence adherence to aspirin therapy in the prevention of 
      preeclampsia amongst high-risk pregnant women: A mixed method analysis.
PG  - e0229622
LID - 10.1371/journal.pone.0229622 [doi]
LID - e0229622
AB  - BACKGROUND: Non-adherence with medications in pregnancy is increasingly 
      recognized and often results in a higher rate of preventable maternal and fetal 
      morbidity and mortality. Non-adherence with prophylactic aspirin amongst 
      high-risk pregnant women is associated with higher incidence of preeclampsia, 
      preterm delivery and intrauterine growth restriction. Yet, the factors that 
      influences adherence with aspirin in pregnancy, from the women's perspective, 
      remains poorly understood. OBJECTIVE: The study is aimed at understanding the 
      factors, from the women's perspective, that influenced adherence with 
      prophylactic aspirin in their pregnancy. STUDY DESIGN: A sequential-exploratory 
      designed mixed methods quantitative (n = 122) and qualitative (n = 6) survey of 
      women with recent high-risk pregnancy necessitating antenatal prophylactic 
      aspirin was utilized. Women recruited underwent their antenatal care in one of 
      three high-risk pregnancy clinics within the South Western Sydney Local Health 
      District, Australia. The quantitative study was done through an electronic 
      anonymous survey and the qualitative study was conducted through a face-to-face 
      interview. Data obtained was analysed against women's adherence with aspirin 
      utilizing phi correlation (φ) with significance set at <0.05. RESULTS: Two key 
      themes, from the women's perspective, that influenced their adherence with 
      aspirin in pregnancy were identified; (1) pill burden and non-intention omission 
      (2) communication and relationship with health care provider (HCP). Pill burden 
      and its associated non-intentional omission, both strongly corelated with reduced 
      adherence (Φ = 0.8, p = 0.02, Φ = 0.8, p<0.01) whilst the use of reminder 
      strategies minimized accidental omission and improved adherence (Φ = 0.9, 
      p<0.01). Consistent communication between HCPs and a good patient-HCP 
      relationship was strongly associated with improved adherence (Φ = 0.7, p = 0.04, 
      Φ = 0.9, p = <0.01) and more importantly was found to play an important role in 
      alleviating factors that had potentials to negatively influence adherence with 
      aspirin in pregnancy. CONCLUSION: This study identified factors that both 
      positively and negatively influenced adherence with aspirin amongst high-risk 
      pregnant women. Is highlights the importance in recognizing the impact of pill 
      burden in pregnancy and the need to counsel women on the utility of reminder 
      strategies to minimize non-intentional omission. Importantly, it emphasizes on 
      the importance of a positive patient-HCP relationship through effective and 
      consistent communication to achieve the desired maternal and fetal outcomes.
FAU - Shanmugalingam, Renuka
AU  - Shanmugalingam R
AUID- ORCID: 0000-0002-2255-8369
AD  - Department of Renal Medicine, South Western Sydney Local Health District, 
      Liverpool, NSW, Australia.
AD  - School of Medicine, Western Sydney University, Penrith, NSW, Australia.
AD  - Vascular Immunology Group, Heart Research Institute, University of Sydney, 
      Newtown, NSW, Australia.
AD  - Women's Health Initiative Translational Unit (WHITU), Ingham Institute For 
      Applied Medical Research and South Western Sydney Local Health District, 
      Liverpool, NSW, Australia.
FAU - Mengesha, Zelalem
AU  - Mengesha Z
AD  - Research and Social Policy Team, Uniting Australia, Sydney, NSW, Australia.
FAU - Notaras, Stephanie
AU  - Notaras S
AD  - School of Medicine, Western Sydney University, Penrith, NSW, Australia.
FAU - Liamputtong, Pranee
AU  - Liamputtong P
AD  - School of Health Sciences and Translational Health Research Institute, Western 
      Sydney University, Penrith, NSW, Australia.
FAU - Fulcher, Ian
AU  - Fulcher I
AD  - Department of Obstetrics and Gynaecology, Liverpool Hospital, Liverpool, NSW, 
      Australia.
FAU - Lee, Gaksoo
AU  - Lee G
AD  - Women's Health Initiative Translational Unit (WHITU), Ingham Institute For 
      Applied Medical Research and South Western Sydney Local Health District, 
      Liverpool, NSW, Australia.
AD  - Department of Obstetrics and Gynaecology, Liverpool Hospital, Liverpool, NSW, 
      Australia.
FAU - Kumar, Roshika
AU  - Kumar R
AD  - Department of Obstetrics and Gynaecology, Liverpool Hospital, Liverpool, NSW, 
      Australia.
FAU - Hennessy, Annemarie
AU  - Hennessy A
AD  - Department of Renal Medicine, South Western Sydney Local Health District, 
      Liverpool, NSW, Australia.
AD  - School of Medicine, Western Sydney University, Penrith, NSW, Australia.
AD  - Vascular Immunology Group, Heart Research Institute, University of Sydney, 
      Newtown, NSW, Australia.
AD  - Women's Health Initiative Translational Unit (WHITU), Ingham Institute For 
      Applied Medical Research and South Western Sydney Local Health District, 
      Liverpool, NSW, Australia.
FAU - Makris, Angela
AU  - Makris A
AUID- ORCID: 0000-0002-1636-3493
AD  - Department of Renal Medicine, South Western Sydney Local Health District, 
      Liverpool, NSW, Australia.
AD  - School of Medicine, Western Sydney University, Penrith, NSW, Australia.
AD  - Vascular Immunology Group, Heart Research Institute, University of Sydney, 
      Newtown, NSW, Australia.
AD  - Women's Health Initiative Translational Unit (WHITU), Ingham Institute For 
      Applied Medical Research and South Western Sydney Local Health District, 
      Liverpool, NSW, Australia.
AD  - School of Medicine, University of New South Wales, Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200227
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Australia
MH  - Communication
MH  - Female
MH  - Humans
MH  - *Medication Adherence/psychology/statistics & numerical data
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy, High-Risk
MH  - Professional-Patient Relations
MH  - Qualitative Research
MH  - Surveys and Questionnaires
PMC - PMC7046289
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/02/28 06:00
MHDA- 2020/05/19 06:00
CRDT- 2020/02/28 06:00
PHST- 2019/11/13 00:00 [received]
PHST- 2020/02/10 00:00 [accepted]
PHST- 2020/02/28 06:00 [entrez]
PHST- 2020/02/28 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
AID - PONE-D-19-31649 [pii]
AID - 10.1371/journal.pone.0229622 [doi]
PST - epublish
SO  - PLoS One. 2020 Feb 27;15(2):e0229622. doi: 10.1371/journal.pone.0229622. 
      eCollection 2020.

PMID- 8506454
OWN - NLM
STAT- MEDLINE
DCOM- 19930702
LR  - 20190512
IS  - 0161-8105 (Print)
IS  - 0161-8105 (Linking)
VI  - 16
IP  - 3
DP  - 1993 Apr
TI  - Sleep deprivation in the rat: XVII. Effect of aspirin on elevated body 
      temperature.
PG  - 221-5
AB  - Previous studies of total sleep deprivation (TSD) in the rat have shown an 
      elevation of waking body temperature (Tb) early in the deprivation period. TSD 
      rats defend this rise behaviorally by selecting warm ambient temperatures and 
      autonomically by increasing heat production, thus indicating an elevation of 
      thermoregulatory setpoint. Prostaglandins (PGs) can elevate setpoint and Tb. To 
      investigate whether the TSD-induced rise in setpoint and Tb was mediated by PGs, 
      aspirin, which blocks the synthesis of PGs, was administered 100 mg/kg s.q. to 11 
      TSD and 13 control (TSC) rats in baseline and deprivation. During baseline, 
      aspirin produced a nonsignificant (0.16 degrees C) rise across all rats in waking 
      Tb. For the sampled time period, waking Tb during deprivation day 3 was 
      significantly elevated in TSD rats (0.64 degrees C, p < 0.01) but not in TSC rats 
      (0.27 degrees C). Aspirin was administered on deprivation day 4. It produced a 
      fall in waking Tb in TSD rats from its deprivation-induced elevation. The 
      difference between the response to aspirin during baseline and during deprivation 
      was significant (-0.25 degrees C, p < 0.05) for TSD rats but not TSC rats (-0.17 
      degrees C). Time awake after aspirin increased significantly (16.2%, p < 0.05) 
      during baseline and declined nonsignificantly (1.1%) during deprivation. These 
      data imply that at least part of the rise in Tb that is characteristic of TSD is 
      mediated by PGs. To the extent that PGD2 promotes lower Tb and sleep in rats but 
      PGE2 has opposite effects, the results are consistent with a shift from PGD2 
      predominance in baseline toward PGE2 predominance during TSD.(ABSTRACT TRUNCATED 
      AT 250 WORDS)
FAU - Bergmann, B M
AU  - Bergmann BM
AD  - Department of Psychiatry, University of Chicago, Illinois.
FAU - Landis, C A
AU  - Landis CA
FAU - Zenko, C E
AU  - Zenko CE
FAU - Rechtschaffen, A
AU  - Rechtschaffen A
LA  - eng
GR  - MH18428/MH/NIMH NIH HHS/United States
GR  - MH4151/MH/NIMH NIH HHS/United States
GR  - T32 MH18825/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Sleep
JT  - Sleep
JID - 7809084
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Body Temperature/*drug effects
MH  - Body Temperature Regulation/drug effects
MH  - Male
MH  - Prostaglandins/biosynthesis/physiology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - *Sleep Deprivation
MH  - Wakefulness
RF  - 29
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
AID - 10.1093/sleep/16.3.221 [doi]
PST - ppublish
SO  - Sleep. 1993 Apr;16(3):221-5. doi: 10.1093/sleep/16.3.221.

PMID- 1830520
OWN - NLM
STAT- MEDLINE
DCOM- 19910830
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 84
IP  - 2
DP  - 1991 Aug
TI  - Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of 
      common platelet inhibition compared with thrombin inhibition in pigs.
PG  - 814-20
AB  - BACKGROUND: Platelet-thrombus formation is a complication of arterial wall deep 
      injury by balloon angioplasty that may lead to acute arterial occlusion and may 
      contribute to restenosis. METHODS AND RESULTS: Because common platelet-inhibitor 
      drugs with a heparin bolus (100 units/kg) may be effective in inhibiting 
      platelet-thrombus formation after arterial angioplasty, these were compared with 
      a bolus of heparin alone (control), the specific thrombin inhibitor hirudin (1.0 
      mg/kg), and saline (hirudin control) in normal pigs after angioplasty of the 
      common carotid arteries. In the presence of deep arterial wall injury (injury 
      exposing the media), indium-111-labeled platelet deposition (x 10(6)/cm2) was 
      68.8 +/- 12.3 and 48.1 +/- 16.9 in the control animals. This was significantly 
      reduced by pretreatment with low-dose aspirin (1 mg/kg/day), by high-dose aspirin 
      (20 mg/kg/day) plus dipyridamole, and especially by thrombin inhibition with 
      hirudin. Treatment regimens with aspirin alone (20 mg/kg/day), dipyridamole 
      alone, or sulfinpyrazone were ineffective. Likewise, the incidence of mural 
      thrombosis was 75% and 80% in deeply injured arteries of controls and was 
      significantly reduced to 46% with aspirin plus dipyridamole, 25% with low-dose 
      aspirin, and 0% with hirudin. The incidence of mural thrombosis was unchanged 
      with high-dose aspirin (69%), dipyridamole (90%), or sulfinpyrazone (92%). This 
      mural thrombosis could not be identified by angiography. In the presence of mild 
      injury (deendothelialization), platelet deposition was low (less than 10 x 
      10(6)/cm2, a single layer) and was not changed by any therapy, including hirudin. 
      CONCLUSIONS: These therapies do not affect platelet adhesion to deeply or mildly 
      injured artery. These data suggest a greater role for thrombin inhibition than 
      with thromboxane or cyclooxygenase inhibition in the pathogenesis of 
      platelet-rich mural thrombosis after deep injury during angioplasty. 
      Antithrombotic therapy for arterial thrombosis by thrombin inhibition appears 
      promising.
FAU - Lam, J Y
AU  - Lam JY
AD  - Division of Cardiovascular Disease and Internal Medicine, Mayo Clinic, Rochester, 
      MN 55905.
FAU - Chesebro, J H
AU  - Chesebro JH
FAU - Steele, P M
AU  - Steele PM
FAU - Heras, M
AU  - Heras M
FAU - Webster, M W
AU  - Webster MW
FAU - Badimon, L
AU  - Badimon L
FAU - Fuster, V
AU  - Fuster V
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hirudins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon
MH  - Animals
MH  - Arteries/*injuries/pathology
MH  - Aspirin/pharmacology
MH  - Dipyridamole/pharmacology
MH  - Fibrinolytic Agents/*pharmacology
MH  - Heart Diseases/physiopathology
MH  - Heparin/pharmacology
MH  - Hirudins/pharmacology
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Swine
MH  - Thrombosis/physiopathology
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
AID - 10.1161/01.cir.84.2.814 [doi]
PST - ppublish
SO  - Circulation. 1991 Aug;84(2):814-20. doi: 10.1161/01.cir.84.2.814.

PMID- 8348760
OWN - NLM
STAT- MEDLINE
DCOM- 19930913
LR  - 20190512
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 16
IP  - 7
DP  - 1993 Jul
TI  - Stroke and atrial fibrillation: to anticoagulate or not.
PG  - 529-30
AB  - After reviewing these published studies, I think one can conclude that in the 
      patient population with chronic and/or paroxysmal atrial fibrillation, warfarin 
      is beneficial and the benefits outweigh the risks. However, it is important to 
      point out that patients at high risk for embolic disease, for example, dilated 
      cardiomyopathy patients, were rarely included in these trials. The five trials 
      mentioned above do not address this patient population. Current opinion is that 
      these individuals should receive anticoagulation despite the lack of objective 
      evidence that anticoagulation is beneficial if the risk of bleeding is not 
      excessive. The five trials also do not address the population of patients 
      categorized as having "lone atrial fibrillation," that is, atrial fibrillation 
      occurring in patients with no structural heart disease. The general consensus in 
      the low embolic risk patient, (i.e., the patient < 60 years of age who has lone 
      atrial fibrillation) is that the risk of anticoagulation is greater than the 
      benefit. My final thought on the subject concerns the risk of pulmonary emboli in 
      this patient population. My guess is that this group of patients is at high risk 
      for small pulmonary emboli, which in many instances may be subclinical--for 
      example, clots too small to result in persistent tachypnea or tachycardia. As far 
      as I can tell, there are no randomized trials on the prevention of pulmonary 
      emboli in patients with chronic or paroxysmal atrial fibrillation using 
      anticoagulation or aspirin. I guess the systemic emboli trial data are sufficient 
      to indicate a protective effect on the lungs as well as on the brain.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Conti, C R
AU  - Conti CR
LA  - eng
PT  - Editorial
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Warfarin/*therapeutic use
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
AID - 10.1002/clc.4960160703 [doi]
PST - ppublish
SO  - Clin Cardiol. 1993 Jul;16(7):529-30. doi: 10.1002/clc.4960160703.

PMID- 1541338
OWN - NLM
STAT- MEDLINE
DCOM- 19920408
LR  - 20190816
IS  - 0014-4835 (Print)
IS  - 0014-4835 (Linking)
VI  - 54
IP  - 1
DP  - 1992 Jan
TI  - Internal acidification modulates membrane and junctional resistance in the 
      isolated lens of the frog Rana pipiens.
PG  - 33-9
AB  - The normal internal pH (pHi) of the amphibian lens, measured using ion-sensitive 
      microelectrodes, is 7.1 (pHo = 7.4) and the membranes appear to be relatively 
      impermeable to hydrogen ions. Perifusing the lens with 100% CO2 appeared to be 
      the most efficient way of decreasing pHi, which fell to 6.3 after an exposure 
      lasting 30 min. Accompanying this acidification, there was a rapid depolarization 
      of membrane potential (Em), a decrease in membrane resistance (Rm) and increase 
      in internal or bulk resistance (Ri). These changes did not occur if the external 
      pH alone was decreased. All changes were reversible, although the time course of 
      Ri recovery was faster than the others. The decrease in membrane resistance could 
      be prevented if the chloride concentration in the external solution was reduced, 
      suggesting that internal acidification opens chloride channels in the amphibian 
      lens. Since chloride ions are normally close to equilibrium across amphibian lens 
      membranes, it is suggested that the pH-induced depolarization is due to a 
      decrease in potassium conductance. The increase in internal resistance on 
      perifusing with CO2 is most likely due to a closing of gap junctions between the 
      fibre cells. The relationship between internal conductance and pHi was very 
      similar to that obtained in other tissues and could be fitted by the Hill 
      equation with n = 6 and pK = 6.9. Fibre junctional conductance seems sensitive to 
      small changes in hydrogen ion concentration around the resting pH. Two agents, 
      aspirin and cyanate, that are believed to influence cataract development, slowed 
      the recovery of Em, Rm and Ri during recovery from an acid load.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Emptage, N J
AU  - Emptage NJ
AD  - School of Biological Sciences, University of East Anglia, Norwich, U.K.
FAU - Duncan, G
AU  - Duncan G
FAU - Croghan, P C
AU  - Croghan PC
LA  - eng
PT  - Journal Article
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 0 (Cyanates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Culture Techniques
MH  - Cyanates/pharmacology
MH  - Electric Conductivity/drug effects/physiology
MH  - Electrophysiology
MH  - Hydrogen-Ion Concentration
MH  - Lens, Crystalline/*physiology
MH  - Membrane Potentials/drug effects/physiology
MH  - Rana pipiens/*physiology
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1016/0014-4835(92)90066-2 [doi]
PST - ppublish
SO  - Exp Eye Res. 1992 Jan;54(1):33-9. doi: 10.1016/0014-4835(92)90066-2.

PMID- 22165713
OWN - NLM
STAT- MEDLINE
DCOM- 20120104
LR  - 20131121
IS  - 0301-4894 (Print)
IS  - 0301-4894 (Linking)
VI  - 112
IP  - 6
DP  - 2011 Nov
TI  - [Review of major randomized clinical trials: carotid endarterectomy versus drug 
      therapy].
PG  - 386-9
AB  - Several randomized clinical trials (RCTs) were performed to compare carotid 
      endarterectomy (CEA) and drug therapy for the treatment of significant carotid 
      stenosis. CEA was recommended for symptomatic patients with significant carotid 
      stenosis if the risks of postoperative stroke and death were less than 6%. In 
      asymptomatic patients, immediate CEA halved the net 5-year stroke risk, resulting 
      in long-term benefits if the risks of postoperative stroke and death were less 
      than 3%. The annual risk reduction was 1% in asymptomatic patients. RCTs 
      conducted to compare treatment with aspirin and new antiplatelet drugs concluded 
      that a risk reduction was achieved in patients who received new antiplatelet 
      drugs.
FAU - Inoue, Yoshinori
AU  - Inoue Y
AD  - Department of Vascular Surgery, Tokyo Medical and Dental University, Tokyo, 
      Japan.
LA  - jpn
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Geka Gakkai Zasshi
JT  - Nihon Geka Gakkai zasshi
JID - 0405405
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Carotid Stenosis/*therapy
MH  - *Endarterectomy, Carotid
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/prevention & control
EDAT- 2011/12/15 06:00
MHDA- 2012/01/05 06:00
CRDT- 2011/12/15 06:00
PHST- 2011/12/15 06:00 [entrez]
PHST- 2011/12/15 06:00 [pubmed]
PHST- 2012/01/05 06:00 [medline]
PST - ppublish
SO  - Nihon Geka Gakkai Zasshi. 2011 Nov;112(6):386-9.

PMID- 16093807
OWN - NLM
STAT- MEDLINE
DCOM- 20051108
LR  - 20191109
IS  - 1070-5287 (Print)
IS  - 1070-5287 (Linking)
VI  - 11
IP  - 5
DP  - 2005 Sep
TI  - Anticoagulation therapy in the antiphospholipid syndrome: recent advances.
PG  - 368-72
AB  - PURPOSE OF REVIEW: The antiphospholipid syndrome is currently best treated with 
      anticoagulation. This review discusses the recent literature addressing the 
      duration, intensity, and appropriateness of anticoagulation or antiplatelet 
      therapy in various clinical subcategories of this syndrome. RECENT FINDINGS: 
      Several recent articles reaffirm the benefits of long-term anticoagulation in 
      patients with venous thromboembolism or undergoing renal transplantation and 
      support recommendations for usual International Normalized Ratio targets. Aspirin 
      seems to confer benefits similar to those of anticoagulation in arterial stroke. 
      Appropriate anticoagulation strategies for pregnancy are controversial. SUMMARY: 
      Anticoagulation will remain the mainstay of treatment for most patients with 
      antiphospholipid syndrome. The optimal therapy for specific subgroups of patients 
      will, however, require further good-quality studies.
FAU - Ng, Heng Joo
AU  - Ng HJ
AD  - Department of Medicine, Singapore General Hospital, Singapore.
FAU - Crowther, Mark A
AU  - Crowther MA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Pulm Med
JT  - Current opinion in pulmonary medicine
JID - 9503765
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Antiphospholipid Syndrome/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Kidney Transplantation
MH  - Pregnancy
MH  - Pregnancy Complications/immunology/physiopathology
MH  - Recurrence
MH  - Thrombosis/prevention & control
MH  - Warfarin/therapeutic use
RF  - 35
EDAT- 2005/08/12 09:00
MHDA- 2005/11/09 09:00
CRDT- 2005/08/12 09:00
PHST- 2005/08/12 09:00 [pubmed]
PHST- 2005/11/09 09:00 [medline]
PHST- 2005/08/12 09:00 [entrez]
AID - 00063198-200509000-00003 [pii]
AID - 10.1097/01.mcp.0000174229.24854.2e [doi]
PST - ppublish
SO  - Curr Opin Pulm Med. 2005 Sep;11(5):368-72. doi: 
      10.1097/01.mcp.0000174229.24854.2e.

PMID- 12524129
OWN - NLM
STAT- MEDLINE
DCOM- 20030815
LR  - 20190922
IS  - 1386-1425 (Print)
IS  - 1386-1425 (Linking)
VI  - 59
IP  - 3
DP  - 2003 Feb
TI  - Surface-enhanced Raman scattering of some water insoluble drugs in silver 
      hydrosols.
PG  - 589-94
AB  - An extraction method has been used to obtain surface-enhanced Raman scattering 
      (SERS) spectra of water insoluble drugs such as aspirin, salicylic acid, 
      acetaminophen, and vitamin A acid. This method is based on the strong affinity of 
      the sample molecules to the silver particle surfaces. Results from the present 
      study indicate that the method can be extended to identify and analyze many other 
      water insoluble compounds by SERS. The high sensitivity of SERS and the linear 
      calibration curve make it feasible in the trace quantitative analysis; the low 
      limit of detection is comparable or better than those of calorimetric and 
      spectrophotometric methods.
FAU - Wang, Yu
AU  - Wang Y
AD  - Jiangsu Institute for Drug Quality Control, Jiangsu 210008, Nanjing, People's 
      Republic of China.
FAU - Li, Ying-Sing
AU  - Li YS
FAU - Zhang, Zenxin
AU  - Zhang Z
FAU - An, Dengqui
AU  - An D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Powders)
RN  - 059QF0KO0R (Water)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3M4G523W1G (Silver)
RN  - 5688UTC01R (Tretinoin)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/chemistry
MH  - Aspirin/chemistry
MH  - Pharmaceutical Preparations/*chemistry
MH  - Powders
MH  - Salicylic Acid/chemistry
MH  - Silver
MH  - Solubility
MH  - Spectrum Analysis, Raman
MH  - Surface Properties
MH  - Tretinoin/chemistry
MH  - Water
EDAT- 2003/01/14 04:00
MHDA- 2003/08/16 05:00
CRDT- 2003/01/14 04:00
PHST- 2003/01/14 04:00 [pubmed]
PHST- 2003/08/16 05:00 [medline]
PHST- 2003/01/14 04:00 [entrez]
AID - S1386142502002135 [pii]
AID - 10.1016/s1386-1425(02)00213-5 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2003 Feb;59(3):589-94. doi: 
      10.1016/s1386-1425(02)00213-5.

PMID- 33306311
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20210204
IS  - 1678-9741 (Electronic)
IS  - 0102-7638 (Print)
IS  - 0102-7638 (Linking)
VI  - 35
IP  - 6
DP  - 2020 Dec 1
TI  - Impact of Preoperative Aspirin on Long-Term Outcomes in Diabetic Patients 
      Following Coronary Artery Bypass Grafting: a Propensity Score Matched Study.
PG  - 859-868
LID - 10.21470/1678-9741-2020-0313 [doi]
AB  - INTRODUCTION: This study aimed to determine the effect of preoperative aspirin 
      administration on early and long-term clinical outcomes in patients suffering 
      from diabetes mellitus (DM) undergoing coronary artery bypass grafting (CABG). 
      METHODS: In this observational study, a total of 315 patients were included and 
      grouped according to the time interval between their last aspirin dose and the 
      time of surgery; patients who had been continued aspirin intake with last 
      administered dose ≤ 24-hours before CABG (n=144) and those who had been given the 
      last dose of aspirin between 24 to 48 hours before CABG (n=171). RESULTS: 
      Multivariable analysis showed that the continuation of preoperative aspirin 
      intake ≤ 24 hours before CABG in patients with DM is associated with reduced 
      incidence of 30-day major adverse cardiac and cerebral events (MACCE) (P=0.004) 
      as well as reduced incidence of composite 30-day mortality/MACCE (P=0.012). 
      During mean follow-up of 37±17.5 months, the unadjusted hazard ratio (HR) showed 
      that aspirin ≤ 24 hours prior CABG in patients with DM significantly reduced the 
      incidence of MACCE and composite of mortality/MACCE during follow-up (HR: 0.50; 
      95% confidence interval [CI]: 0.29-0.87; P=0.014 and HR: 0.61; 95% CI: 0.38-0.97; 
      P=0.039, respectively). However, after propensity score (PS) matching, the 
      PS-adjusted HR showed a non-significant trend towards the reduction of MACCE 
      during follow-up (HR: 0.58; 95% CI: 0.31-1.06; P=0.081). CONCLUSION: Continuation 
      of preoperative aspirin intake ≤ 24 hours before CABG in patients with DM is 
      associated with reduced incidence of early MACCE, but without significant 
      influence on long-term outcomes.
FAU - Aboul-Hassan, Sleiman Sebastian
AU  - Aboul-Hassan SS
AUID- ORCID: 0000-0003-4544-7466
AD  - Department of Cardiac Surgery, Medinet Heart Center Ltd, Nowa Sol, Poland.
FAU - Stankowski, Tomasz
AU  - Stankowski T
AD  - Department of Cardiac Surgery, Sana-Heart Center Cottbus, Cottbus, Germany.
FAU - Marczak, Jakub
AU  - Marczak J
AD  - Department of Cardiac Surgery, Trent Cardiac Centre, Nottingham University 
      Hospital, Nottingham, United Kingdom.
FAU - Peksa, Maciej
AU  - Peksa M
AD  - Department of Cardiac Surgery, Medinet Heart Center Ltd, Nowa Sol, Poland.
FAU - Nawotka, Marcin
AU  - Nawotka M
AD  - Department of Cardiac Surgery, Medinet Heart Center Ltd, Nowa Sol, Poland.
FAU - Stanislawski, Ryszard
AU  - Stanislawski R
AD  - Department of Cardiac Surgery, Medinet Heart Center Ltd, Nowa Sol, Poland.
FAU - Moskal, Lukasz
AU  - Moskal L
AD  - Department of Cardiac Surgery, Medinet Heart Center Ltd, Wroclaw, Poland.
FAU - Lipowski, Adam
AU  - Lipowski A
AD  - Department of Vascular Surgery, Nowa Sol Multidisciplinary Hospital, Nowa Sol, 
      Poland.
FAU - Sá, Michel Pompeu B O
AU  - Sá MPBO
AD  - Division of Cardiovascular Surgery of Pronto Socorro Cardiologico de Pernambuco, 
      PROCAPE, Universidade de Pernambuco, Recife, Pernambuco, Brazil.
FAU - Cichon, Romuald
AU  - Cichon R
AD  - Department of Cardiac Surgery, Medinet Heart Center Ltd, Nowa Sol, Poland.
AD  - Department of Cardiac Surgery, Warsaw Medical University, Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201201
PL  - Brazil
TA  - Braz J Cardiovasc Surg
JT  - Brazilian journal of cardiovascular surgery
JID - 101677045
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - *Coronary Artery Bypass
MH  - Coronary Artery Disease/surgery
MH  - *Diabetes Mellitus/drug therapy
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC7731840
OTO - NOTNLM
OT  - Aspirin
OT  - Coronary Artery Bypass
OT  - Diabetes Mellitus
OT  - Incidence
OT  - Propensity Score
COIS- No conflict of interest.
EDAT- 2020/12/12 06:00
MHDA- 2021/02/05 06:00
CRDT- 2020/12/11 14:22
PHST- 2020/12/11 14:22 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
AID - 10.21470/1678-9741-2020-0313 [doi]
PST - epublish
SO  - Braz J Cardiovasc Surg. 2020 Dec 1;35(6):859-868. doi: 
      10.21470/1678-9741-2020-0313.

PMID- 15674407
OWN - NLM
STAT- MEDLINE
DCOM- 20050531
LR  - 20181201
IS  - 0950-9240 (Print)
IS  - 0950-9240 (Linking)
VI  - 19
IP  - 3
DP  - 2005 Mar
TI  - Antithrombotic therapy in hypertension: a Cochrane Systematic review.
PG  - 185-96
AB  - Although elevated systemic blood pressure (BP) results in high intravascular 
      pressure, the main complications of hypertension are related to thrombosis rather 
      than haemorrhage. It therefore seemed plausible that use of antithrombotic 
      therapy may be useful in preventing thrombosis-related complications of elevated 
      BP. The objectives were to conduct a systematic review of the role of 
      antiplatelet therapy and anticoagulation in patients with BP, to address the 
      following hypotheses: (i) antiplatelet agents reduce total deaths and/or major 
      thrombotic events when compared to placebo or other active treatment; and (ii) 
      oral anticoagulants reduce total deaths and/or major thromboembolic events when 
      compared to placebo or other active treatment. A systematic review of randomised 
      studies in patients with elevated BP was performed. Studies were included if they 
      were >3 months in duration and compared antithrombotic therapy with control or 
      other active treatment. One meta-analysis of antiplatelet therapy for secondary 
      prevention in patients with elevated BP reported an absolute reduction in 
      vascular events of 4.1% as compared to placebo. Acetylsalicylic acid (ASA) did 
      not reduce stroke or 'all cardiovascular events' compared to placebo in primary 
      prevention patients with elevated BP and no prior cardiovascular disease. Based 
      on one large trial, ASA taken for 5 years reduced myocardial infarction (ARR, 
      0.5%, NNT 200 for 5 years), increased major haemorrhage (ARI, 0.7%, NNT 154), and 
      did not reduce all cause mortality or cardiovascular mortality. In two small 
      trials, warfarin alone or in combination with ASA did not reduce stroke or 
      coronary events. Glycoprotein IIb/IIIa inhibitors as well as ticlopidine and 
      clopidogrel have not been sufficiently evaluated in patients with elevated BP. To 
      conclude for primary prevention in patients with elevated BP, antiplatelet 
      therapy with ASA cannot be recommended since the magnitude of benefit, a 
      reduction in myocardial infarction, is negated by a harm of similar magnitude, an 
      increase in major haemorrhage. For secondary prevention in patients with elevated 
      BP, antiplatelet therapy is recommended because the magnitude of the absolute 
      benefit is many times greater. Warfarin therapy alone or in combination with 
      aspirin in patients with elevated BP cannot be recommended because of lack of 
      demonstrated benefit. Further trials of antithrombotic therapy are required in 
      patients with elevated BP.
FAU - Felmeden, D C
AU  - Felmeden DC
AD  - Haemostasis, Thrombosis, and Vascular Biology Unit, University Department of 
      Medicine, City Hospital, Birmingham, UK.
FAU - Lip, G Y H
AU  - Lip GY
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - J Hum Hypertens
JT  - Journal of human hypertension
JID - 8811625
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Evid Based Cardiovasc Med. 2005 Sep;9(3):162-5. PMID: 16380019
CIN - Evid Based Cardiovasc Med. 2005 Sep;9(3):162-3, 166-7. PMID: 16380020
MH  - Aspirin/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Middle Aged
MH  - Thrombosis/*prevention & control
MH  - Warfarin/therapeutic use
RF  - 98
EDAT- 2005/01/28 09:00
MHDA- 2005/06/01 09:00
CRDT- 2005/01/28 09:00
PHST- 2005/01/28 09:00 [pubmed]
PHST- 2005/06/01 09:00 [medline]
PHST- 2005/01/28 09:00 [entrez]
AID - 1001807 [pii]
AID - 10.1038/sj.jhh.1001807 [doi]
PST - ppublish
SO  - J Hum Hypertens. 2005 Mar;19(3):185-96. doi: 10.1038/sj.jhh.1001807.

PMID- 11941384
OWN - NLM
STAT- MEDLINE
DCOM- 20020617
LR  - 20191105
IS  - 1075-2765 (Print)
IS  - 1075-2765 (Linking)
VI  - 9
IP  - 3
DP  - 2002 May-Jun
TI  - Over-the-counter analgesics: a toxicology perspective.
PG  - 245-57
AB  - The decision to use any analgesic is a balance of benefit and risk. In the case 
      of analgesics, it is important to balance the therapeutic benefit against both 
      the risk in therapeutic use and the risk (and ease of treatment) in overdose. 
      Paracetamol in therapeutic dose carries little risk of adverse events. Less than 
      0.1% of the estimated 30 million paracetamol users in the United Kingdom attend 
      hospital with a paracetamol overdose each year, and approximately 200 people die, 
      most of whom presented late or did not receive antidote, N-acetylcysteine, within 
      12 hours. Nonsteriodal anti-inflammatory drugs (NSAIDs) have greater adverse 
      effects in therapeutic use than paracetamol but also have a lower incidence of 
      severe features or death in overdose. There is no antidote available for NSAID 
      poisoning. Aspirin carries both significant adverse effects in therapeutic dose 
      and a substantial risk in overdose, for which there is no antidote. Its 
      risk-benefit profile is probably the poorest of all analgesics currently 
      available over-the-counter (OTC); this is reflected in current trends both in 
      analgesic use and overdose figures. Although a number of options to reduce deaths 
      from poisoning by OTC analgesics have been considered, few are practical, and all 
      must take account of the public health benefits provided by these drugs. A 
      perspective should be retained that the vast majority of the population in 
      Australia, the United States, the United Kingdom, and Denmark derive therapeutic 
      benefit from OTC analgesics and do not take them in overdose. The majority of 
      those who do take overdoses come to little or no harm. Management of serious 
      poisoning by paracetamol, aspirin, or NSAIDs remains a medical challenge.
FAU - Jones, Alison
AU  - Jones A
AD  - National Poisons Information Service, Guy's and St Thomas' NHS Trust, United 
      Kingdom. allison.jones@gstt.sthames.nhs.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/adverse effects/therapeutic use
MH  - Analgesics/*adverse effects/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/adverse effects/therapeutic use
MH  - Australia
MH  - Denmark
MH  - Drug Labeling
MH  - Drug Overdose/prevention & control
MH  - Drug Packaging
MH  - Health Education
MH  - Humans
MH  - Nonprescription Drugs/*adverse effects/therapeutic use
MH  - *Patient Education as Topic
MH  - Risk
MH  - United Kingdom
MH  - United States/epidemiology
RF  - 81
EDAT- 2002/04/10 10:00
MHDA- 2002/06/18 10:01
CRDT- 2002/04/10 10:00
PHST- 2002/04/10 10:00 [pubmed]
PHST- 2002/06/18 10:01 [medline]
PHST- 2002/04/10 10:00 [entrez]
AID - 10.1097/00045391-200205000-00010 [doi]
PST - ppublish
SO  - Am J Ther. 2002 May-Jun;9(3):245-57. doi: 10.1097/00045391-200205000-00010.

PMID- 27581316
OWN - NLM
STAT- MEDLINE
DCOM- 20170301
LR  - 20170817
IS  - 1092-0684 (Electronic)
IS  - 1092-0684 (Linking)
VI  - 41
IP  - 3
DP  - 2016 Sep
TI  - Low-dose acetylsalicylic acid and bleeding risks with ventriculoperitoneal shunt 
      placement.
PG  - E4
LID - 10.3171/2016.6.FOCUS16173 [doi]
AB  - OBJECTIVE Ventriculoperitoneal (VP) shunt placement is a common procedure for the 
      treatment of hydrocephalus following diverse neurosurgical conditions. Most of 
      the patients present with other comorbidities and receive antiplatelet therapy, 
      usually acetylsalicylic acid (ASA). Despite its clinical relevance, the 
      perioperative management of these patients has not been sufficiently 
      investigated. The aim of this study was to compare the peri- and postoperative 
      bleeding complication rates associated with ASA intake in patients undergoing VP 
      shunt placement. METHODS Of 172 consecutive patients undergoing VP shunt 
      placement between June 2009 and December 2015, 40 (23.3%) patients were receiving 
      low-dose ASA treatment. The primary outcome measure was bleeding events in ASA 
      users versus nonusers, whereas secondary outcome measures were postoperative 
      cardiovascular events, hematological findings, morbidity, and mortality. A 
      subgroup analysis was conducted in patients who discontinued ASA treatment for < 
      7 days (n = 4, ASA Group 1) and for ≥ 7 days (n = 36, ASA Group 2). RESULTS No 
      statistically significant difference for bleeding events was observed between ASA 
      users and nonusers (p = 0.30). Cardiovascular complications, surgical morbidity, 
      and mortality did not differ significantly between the groups either. Moreover, 
      there was no association between ASA discontinuation regimens (< 7 days and ≥ 7 
      days) and hemorrhagic events. CONCLUSIONS Given the lack of guidelines regarding 
      perioperative management of neurosurgical patients with antiplatelet therapy, 
      these findings elucidate one issue, showing comparable bleeding rates in ASA 
      users and nonusers undergoing VP shunt placement.
FAU - Kamenova, Maria
AU  - Kamenova M
AD  - Department of Neurosurgery, University Hospital of Basel, Switzerland.
FAU - Croci, Davide
AU  - Croci D
AD  - Department of Neurosurgery, University Hospital of Basel, Switzerland.
FAU - Guzman, Raphael
AU  - Guzman R
AD  - Department of Neurosurgery, University Hospital of Basel, Switzerland.
FAU - Mariani, Luigi
AU  - Mariani L
AD  - Department of Neurosurgery, University Hospital of Basel, Switzerland.
FAU - Soleman, Jehuda
AU  - Soleman J
AD  - Department of Neurosurgery, University Hospital of Basel, Switzerland.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosurg Focus
JT  - Neurosurgical focus
JID - 100896471
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Female
MH  - Humans
MH  - Intraoperative Complications/chemically induced/diagnosis/etiology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Postoperative Hemorrhage/*chemically induced/diagnosis/*etiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Ventriculoperitoneal Shunt/*adverse effects/trends
OTO - NOTNLM
OT  - ASA = acetylsalicylic acid
OT  - CAD = coronary artery disease
OT  - Hb = hemoglobin
OT  - LMWH = low-molecular-weight heparin
OT  - NPH = normal-pressure hydrocephalus
OT  - PBC = packed blood cells
OT  - Tc = thrombocyte
OT  - VP = ventriculoperitoneal
OT  - aSAH = aneurysmal subarachnoid hemorrhage
OT  - acetylsalicylic acid
OT  - antithrombotic therapy
OT  - bleeding events
OT  - cSDH = chronic subdural hematoma
OT  - ventriculoperitoneal shunt
EDAT- 2016/09/02 06:00
MHDA- 2017/03/03 06:00
CRDT- 2016/09/02 06:00
PHST- 2016/09/02 06:00 [entrez]
PHST- 2016/09/02 06:00 [pubmed]
PHST- 2017/03/03 06:00 [medline]
AID - 10.3171/2016.6.FOCUS16173 [doi]
PST - ppublish
SO  - Neurosurg Focus. 2016 Sep;41(3):E4. doi: 10.3171/2016.6.FOCUS16173.

PMID- 21357797
OWN - NLM
STAT- MEDLINE
DCOM- 20110726
LR  - 20211020
IS  - 1538-3679 (Electronic)
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 171
IP  - 10
DP  - 2011 May 23
TI  - Effects of benefits and harms on older persons' willingness to take medication 
      for primary cardiovascular prevention.
PG  - 923-8
LID - 10.1001/archinternmed.2011.32 [doi]
AB  - BACKGROUND: Quality-assurance initiatives encourage adherence to evidenced-based 
      guidelines based on a consideration of treatment benefit. We examined older 
      persons' willingness to take medication for primary cardiovascular disease 
      prevention according to benefits and harms. METHODS: In-person interviews were 
      performed with 356 community-living older persons. Participants were asked about 
      their willingness to take medication for primary prevention of myocardial 
      infarction (MI) with varying benefits in terms of absolute 5-year risk reduction 
      and varying harms in terms of type and severity of adverse effects. RESULTS: Most 
      (88%) would take medication, providing an absolute benefit of 6 fewer persons 
      with MI out of 100, approximating the average risk reduction of currently 
      available medications. Of participants who would not take it, 17% changed their 
      preference if the absolute benefit was increased to 10 fewer persons with MI, 
      and, of participants who would take it, 82% remained willing if the absolute 
      benefit was decreased to 3 fewer persons with MI. In contrast, large proportions 
      (48%-69%) were unwilling or uncertain about taking medication with average 
      benefit causing mild fatigue, nausea, or fuzzy thinking, and only 3% would take 
      medication with adverse effects severe enough to affect functioning. CONCLUSIONS: 
      Older persons' willingness to take medication for primary cardiovascular disease 
      prevention is relatively insensitive to its benefit but highly sensitive to its 
      adverse effects. These results suggest that clinical guidelines and decisions 
      about prescribing these medications to older persons need to place emphasis on 
      both benefits and harms.
FAU - Fried, Terri R
AU  - Fried TR
AD  - Department of Medicine, Yale University School of Medicine, New Haven, 
      Connecticut, USA. terri.fried@yale.edu
FAU - Tinetti, Mary E
AU  - Tinetti ME
FAU - Towle, Virginia
AU  - Towle V
FAU - O'Leary, John R
AU  - O'Leary JR
FAU - Iannone, Lynne
AU  - Iannone L
LA  - eng
GR  - K24 AG028443/AG/NIA NIH HHS/United States
GR  - K24 AG028443-01A2/AG/NIA NIH HHS/United States
GR  - P30 AG021342/AG/NIA NIH HHS/United States
GR  - P30AG21342/AG/NIA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20110228
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Pharmaceutical Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/adverse effects
MH  - Cardiotonic Agents/administration & dosage/adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Patient Compliance
MH  - *Patient Participation
MH  - Patient Selection
MH  - Pharmaceutical Preparations/administration & dosage
MH  - Primary Prevention/*methods
MH  - Risk Assessment
MH  - Surveys and Questionnaires
PMC - PMC3101287
MID - NIHMS279847
EDAT- 2011/03/02 06:00
MHDA- 2011/07/27 06:00
CRDT- 2011/03/02 06:00
PHST- 2011/03/02 06:00 [entrez]
PHST- 2011/03/02 06:00 [pubmed]
PHST- 2011/07/27 06:00 [medline]
AID - archinternmed.2011.32 [pii]
AID - 10.1001/archinternmed.2011.32 [doi]
PST - ppublish
SO  - Arch Intern Med. 2011 May 23;171(10):923-8. doi: 10.1001/archinternmed.2011.32. 
      Epub 2011 Feb 28.

PMID- 18753700
OWN - NLM
STAT- MEDLINE
DCOM- 20081231
LR  - 20190819
IS  - 1346-9843 (Print)
IS  - 1346-9843 (Linking)
VI  - 72
IP  - 10
DP  - 2008 Oct
TI  - Effect of intracoronary tirofiban in patients undergoing percutaneous coronary 
      intervention for acute coronary syndrome.
PG  - 1605-9
AB  - BACKGROUND: To investigate the efficacy of intracoronary tirofiban during primary 
      percutaneous coronary intervention (PCI) for patients with acute coronary 
      syndrome (ACS). METHODS AND RESULTS: The 118 patients aged 70 years and above 
      (average age 75+/-2) were divided into study (n = 58, intracoronary bolus 
      tirofiban) and control (n = 57, intravenous tirofiban) groups. The culprit 
      vessels were targeted with primary PCI in all patients. Compared with the control 
      group, the study group showed better Thrombolysis In Myocardial Infarction (TIMI) 
      flow grades and TIMI myocardial perfusion grades (TMPG) immediately after PCI (p 
      = 0.016 and 0.026, respectively). The 14-day composite major adverse cardiac 
      events rate was lower in the study group (3.5% vs 17.5%, p = 0.030), but was 
      similar between the 2 groups at 30 days following PCI (7.0% vs 1.7%, p = 0.350). 
      The left ventricular ejection fraction in the study group was higher than in the 
      control group 30 days following PCI (67.4+/-6.2% vs 60.7+/-4.6%, p = 0.033). The 
      14-day bleeding complication (p = 0.201) and platelet reduction rates (p = 0.984) 
      were similar between the 2 groups. CONCLUSION: In patients with ACS undergoing 
      primary PCI, intracoronary bolus administration of tirofiban is superior to 
      intravenous bolus injection for improving coronary flow, myocardial perfusion and 
      short-term clinical outcomes.
FAU - Wu, Tong-Guo
AU  - Wu TG
AD  - Department of Cardiology, The Red Cross Hospital of Guangzhou City, Fourth 
      Affiliated Hospital of Jinan University, Guangzhou, PR China.
FAU - Zhao, Qiang
AU  - Zhao Q
FAU - Huang, Wei-Guang
AU  - Huang WG
FAU - Wei, Jian-Rui
AU  - Wei JR
FAU - Chen, Si-Wei
AU  - Chen SW
FAU - Zhao, Jin
AU  - Zhao J
FAU - Huang, Li-Ping
AU  - Huang LP
FAU - Wang, Le-Xin
AU  - Wang LX
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20080828
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 42HK56048U (Tyrosine)
RN  - GGX234SI5H (Tirofiban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy/*therapy
MH  - Administration, Oral
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/therapeutic use
MH  - *Coronary Vessels
MH  - Drug Administration Routes
MH  - Hemorrhage/epidemiology/etiology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Thrombolytic Therapy
MH  - Tirofiban
MH  - Tyrosine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
EDAT- 2008/08/30 09:00
MHDA- 2009/01/01 09:00
CRDT- 2008/08/30 09:00
PHST- 2008/08/30 09:00 [pubmed]
PHST- 2009/01/01 09:00 [medline]
PHST- 2008/08/30 09:00 [entrez]
AID - JST.JSTAGE/circj/CJ-08-0357 [pii]
AID - 10.1253/circj.cj-08-0357 [doi]
PST - ppublish
SO  - Circ J. 2008 Oct;72(10):1605-9. doi: 10.1253/circj.cj-08-0357. Epub 2008 Aug 28.

PMID- 16255675
OWN - NLM
STAT- MEDLINE
DCOM- 20060331
LR  - 20190917
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 14
IP  - 11
DP  - 2005 Nov
TI  - Nitric oxide-modulating agents for gastrointestinal disorders.
PG  - 1347-58
AB  - Almost 20 years after the identification of the biological role of nitric oxide 
      (NO), the full therapeutic potential of novel agents that mimic the activity of 
      NO or interfere with its synthesis has yet to be realised for utilities involving 
      the gastrointestinal tract. New utilities for classical NO donors, which were 
      used as vasodilators for decades, in the treatment of motility disorders have 
      been explored and a product for treating anal fissure was recently launched. New 
      classes of compounds incorporating a NO-donating moiety into standard 
      non-steroidal anti-inflammatory drugs, the NO-non-steroidal anti-inflammatory 
      drugs (NO-NSAIDs) or COX-inhibiting nitric oxide donors (CINODs) have also been 
      developed. These have been shown to exhibit reduced gastrointestinal injury in 
      experimental models, and reports on their efficacy and safety in Phase I and II 
      studies are now available. Modulation of the inducible NO synthase isoform that 
      generates excessive NO that can lead to subsequent cytotoxic moieties, such as 
      peroxynitrite, may have therapeutic possibilities in a range of inflammatory 
      diseases of the gut. Likewise, agents that promote the decomposition of 
      peroxynitrite or removal of its other component, superoxide, may also prove to be 
      of use. Further targets for pharmaceutical exploitation are likely to come from 
      both genomic and molecular insights into the processes that regulate the NO 
      system.
FAU - Whittle, Brendan J R
AU  - Whittle BJ
AD  - William Harvey Research Institute, Bart's and The London, Queen Mary's School of 
      Medicine, Charterhouse Square, London, EC1M 6BQ, UK. b.j.whittle@qmul.ac.uk
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 
      4-(nitrooxy)butyl ester)
RN  - 0 (Nitrates)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (naproxen-n-butyl nitrate)
RN  - 14691-52-2 (Peroxynitrous Acid)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 57Y76R9ATQ (Naproxen)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Enteritis/etiology
MH  - Esophagus/drug effects/physiology
MH  - Fissure in Ano/drug therapy
MH  - Gastric Emptying/drug effects
MH  - Gastrointestinal Diseases/*drug therapy
MH  - Gastrointestinal Motility/drug effects
MH  - Humans
MH  - Naproxen/analogs & derivatives/therapeutic use
MH  - Nitrates/therapeutic use
MH  - Nitric Oxide/physiology/therapeutic use
MH  - Nitric Oxide Donors/*therapeutic use
MH  - Nitric Oxide Synthase Type II/drug effects
MH  - Peroxynitrous Acid/physiology
RF  - 86
EDAT- 2005/11/01 09:00
MHDA- 2006/04/01 09:00
CRDT- 2005/11/01 09:00
PHST- 2005/11/01 09:00 [pubmed]
PHST- 2006/04/01 09:00 [medline]
PHST- 2005/11/01 09:00 [entrez]
AID - 10.1517/13543784.14.11.1347 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2005 Nov;14(11):1347-58. doi: 
      10.1517/13543784.14.11.1347.

PMID- 8922231
OWN - NLM
STAT- MEDLINE
DCOM- 19970304
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 24
IP  - 6
DP  - 1996 Nov
TI  - Diaspirin cross-linked hemoglobin does not alter isolated human umbilical artery 
      or vein tone.
PG  - 621-8
AB  - Diaspirin cross-linked hemoglobin (DCLHbTM; Baxter Healthcare Corp., Round Lake, 
      IL, USA) is undergoing clinical trials as a blood substitute. Administration of 
      DCLHb is associated with an increase of mean arterial pressure in vivo and 
      contraction of selected adult isolated blood vessels of from certain species in 
      vitro. The mechanisms of these pressor effects may be due to scavenging of the 
      endothelium derived relaxing factor, nitric oxide (NO), by hemoglobin. Unlike 
      adult blood vessels, prostacyclin (PGI2) rather than EDNO is the important 
      relaxing agent in human umbilical vessels. In this study, we examined if DCLHb 
      had vasoconstrictor effects on isolated human umbilical vessels. Human umbilical 
      veins and arteries were excised, cut into rings and placed in organ chambers 
      filled with 25 ml Krebs-Ringer solution (37 degrees C). 5-hydroxytryptamine 
      (5-HT, 0.01-10 microM) increased the tension of human umbilical arteries (HUA, 
      from 0.4 +/- 0.2 g to 2.6 +/- 0.4g) and veins (HUV, from 0.8 +/- 0.4g to 2.5 +/- 
      0.4g) in a dose-dependent manner. DCLHb (0.01-10 microM) did not have a 
      significant effect on HUA and HUV. Substance P (1 microM, via prostanoid 
      synthesis) and nitroglycerin (NG, 1 microM) but not acetylcholine (ACh, 1 microM) 
      caused relaxation of both HUA and HUV. The NO synthase inhibitor L-NA did not 
      have significant effects on HUA and HUV. DCLHb did not alter 5-HT preconstricted 
      tension of HUA and HUV. The basal cGMP contents of HUA and HUV were low. These 
      results support our previous finding that DCLHb-induced vasoconstriction in 
      isolated vessels is dependent primarily on the binding of NO by hemoglobin.
FAU - Jing, M
AU  - Jing M
AD  - Department of Anesthesiology, Uniformed Services University of the Health 
      Sciences, Bethesda, Maryland 20814, USA.
FAU - Panico, F G
AU  - Panico FG
FAU - Panico, J L
AU  - Panico JL
FAU - Ledvina, M A
AU  - Ledvina MA
FAU - Bina, S
AU  - Bina S
FAU - Muldoon, S M
AU  - Muldoon SM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Hemoglobins)
RN  - 0 (Vasoconstrictor Agents)
RN  - 0 (Vasodilator Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 333DO1RDJY (Serotonin)
RN  - 33507-63-0 (Substance P)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - H2D2X058MU (Cyclic GMP)
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylcholine/pharmacology
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cyclic GMP/analysis
MH  - Dose-Response Relationship, Drug
MH  - Hemoglobins/*pharmacology
MH  - Humans
MH  - Muscle Tonus/drug effects
MH  - Muscle, Smooth, Vascular/drug effects
MH  - Nitric Oxide/metabolism
MH  - Nitroglycerin/pharmacology
MH  - Serotonin/pharmacology
MH  - Substance P/pharmacology
MH  - Swine
MH  - Umbilical Arteries/*drug effects
MH  - Umbilical Veins/*drug effects
MH  - Vasoconstriction/*drug effects
MH  - Vasoconstrictor Agents/pharmacology
MH  - Vasodilator Agents/pharmacology
EDAT- 1996/11/01 00:00
MHDA- 1996/11/01 00:01
CRDT- 1996/11/01 00:00
PHST- 1996/11/01 00:00 [pubmed]
PHST- 1996/11/01 00:01 [medline]
PHST- 1996/11/01 00:00 [entrez]
AID - 10.3109/10731199609118887 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1996 Nov;24(6):621-8. doi: 
      10.3109/10731199609118887.

PMID- 14555553
OWN - NLM
STAT- MEDLINE
DCOM- 20031201
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 124
IP  - 4
DP  - 2003 Oct
TI  - Aspirin does not adversely affect survival in patients with stable congestive 
      heart failure treated with Angiotensin-converting enzyme inhibitors.
PG  - 1250-8
AB  - BACKGROUND: Experimental studies and retrospective analyses of mortality trials 
      with angiotensin-converting enzyme inhibitors (ACE-Is) have suggested that 
      aspirin may reduce the beneficial effect of these drugs. The aim of this study 
      was to assess a possible detrimental effect of aspirin on survival in stable 
      patients with left ventricular systolic dysfunction who had congestive heart 
      failure and had been treated with ACE-Is. METHODS AND RESULTS: We performed a 
      retrospective analysis in 755 consecutive stable patients with left ventricular 
      systolic dysfunction. A Cox regression model was used to select independent 
      predictors of survival and to test for a possible interaction between aspirin and 
      ACE-Is with an adjustment to differences in clinical characteristics in subgroups 
      of patients. Of the 755 patients, 328 (43.4%) had proven ischemic cardiomyopathy, 
      693 patients (91.8%) were receiving ACE-Is, and 317 patients were receiving 
      aspirin (mean [+/- SD] dose, 183 +/- 65 mg/d; 74% of the patients receiving < or 
      = 200 mg/d). During a median follow-up period of 1,996 days, there were 273 
      cardiac-related deaths, 14 urgent transplantations, 71 nonurgent 
      transplantations, and 46 noncardiac-related deaths, and 3 patients were lost to 
      follow-up. The cardiovascular mortality rates were 11.5% and 19.0%, respectively, 
      at 1 and 2 years. There were no interactions among aspirin, ACE-Is, and survival 
      in the overall population (p = 0.21), or in subgroups of patients with ischemic 
      cardiomyopathy (p = 0.41) or with nonischemic cardiomyopathy (p = 0.74). 
      CONCLUSIONS: In this population of stable patients with left ventricular systolic 
      dysfunction, our retrospective analysis did not demonstrate any interaction 
      between the use of aspirin and survival in patients receiving ACE-Is.
FAU - Aumégeat, Valérie
AU  - Aumégeat V
AD  - Service de Cardiologie C, Hôpital Cardiologique, CHRU Lille, Bd Prof J Leclercq, 
      59037 Lille Cedex, France.
FAU - Lamblin, Nicolas
AU  - Lamblin N
FAU - de Groote, Pascal
AU  - de Groote P
FAU - Mc Fadden, Eugène P
AU  - Mc Fadden EP
FAU - Millaire, Alain
AU  - Millaire A
FAU - Bauters, Christophe
AU  - Bauters C
FAU - Lablanche, Jean-Marc
AU  - Lablanche JM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Chest. 2003 Oct;124(4):1192-4. PMID: 14555544
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/*adverse effects
MH  - Female
MH  - Heart Failure/*drug therapy/*mortality/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2003/10/14 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/10/14 05:00
PHST- 2003/10/14 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/10/14 05:00 [entrez]
AID - S0012-3692(16)48666-6 [pii]
AID - 10.1378/chest.124.4.1250 [doi]
PST - ppublish
SO  - Chest. 2003 Oct;124(4):1250-8. doi: 10.1378/chest.124.4.1250.

PMID- 8507222
OWN - NLM
STAT- MEDLINE
DCOM- 19930708
LR  - 20190718
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 36
IP  - 6
DP  - 1993 Jun
TI  - Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic 
      transaminase elevations in patients with rheumatoid arthritis and osteoarthritis.
PG  - 804-10
AB  - OBJECTIVE: To examine elevations in levels of serum glutamic oxaloacetic 
      transaminase (SGOT) in patients with rheumatoid arthritis (RA) and osteoarthritis 
      (OA) taking placebo, aspirin, or diclofenac, and to seek possible explanations 
      for the occurrence of these elevations. METHODS: We conducted a meta-analysis of 
      individual case reports from 3 RA protocols and 5 OA protocols, encompassing 814 
      diclofenac-treated patients, 443 aspirin-treated patients, and 359 
      placebo-treated patients. All of the RA protocols had nearly identical inclusion 
      and exclusion criteria, as well as safety studies and followup; the same was true 
      for the OA protocols. Analysis included correlation analysis and multiple linear 
      and logistic regression, accounting for numerous potential confounding variables, 
      with the SGOT as the dependent variable. F tests were used for hypothesis 
      testing. RESULTS: By several analytic approaches, the principal determinants of 
      SGOT concentrations were found to be baseline SGOT value, the use of aspirin in 
      RA patients, and the use of diclofenac in OA patients. Other significant factors 
      contributing to an increase in SGOT concentrations were duration of therapy and, 
      perhaps, daily dosage (mg/lb). Hypothesis testing supported these results. Given 
      a statistically average patient, we predicted a 1-2% chance of a mildly elevated 
      SGOT level occurring among placebo-treated patients, a 6-7% chance among 
      diclofenac- or aspirin-treated patients with RA, a 12% chance among 
      diclofenac-treated patients with OA, and a 2% chance among aspirin-treated 
      patients with OA. CONCLUSION: This study demonstrates a powerful method for 
      performing meta-analysis, using available individual patient data to examine 
      numerous factors that may affect an outcome of interest. In this case, mild 
      elevations of SGOT were examined and found to be related to baseline SGOT levels, 
      diclofenac use (in OA), and aspirin use (in RA). Of numerous other potential 
      factors examined, including age, sex, alcohol use, concomitant medications, and 
      concomitant diagnoses, only duration of therapy and, to a small extent, daily 
      dosage, were also consistent determinants of SGOT elevation. The SGOT elevations 
      were minimal and were not related to the occurrence of clinical hepatitis: No 
      clinical hepatitis occurred.
FAU - Furst, D E
AU  - Furst DE
AD  - University of Washington, Seattle.
FAU - Anderson, W
AU  - Anderson W
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Meta-Analysis
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 144O8QL0L1 (Diclofenac)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arthritis, Rheumatoid/*blood
MH  - Aspartate Aminotransferases/*blood
MH  - Aspirin/*pharmacology
MH  - Diclofenac/*pharmacology
MH  - Humans
MH  - Osteoarthritis/*blood
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - 10.1002/art.1780360610 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1993 Jun;36(6):804-10. doi: 10.1002/art.1780360610.

PMID- 35766813
OWN - NLM
STAT- MEDLINE
DCOM- 20220728
LR  - 20220728
IS  - 2047-4849 (Electronic)
IS  - 2047-4830 (Linking)
VI  - 10
IP  - 15
DP  - 2022 Jul 26
TI  - Structure and properties of nanoparticles: DES-lignin-g-PNVCL coated aspirin by 
      self-assembly.
PG  - 4284-4292
LID - 10.1039/d2bm00325b [doi]
AB  - This work was carried out in order to broaden the application field of lignin and 
      improve its additional value. The degraded deep eutectic solvent lignin-grafted 
      poly(N-vinyl caprolactam) (DES-lignin-g-PNVCL) was synthesized by using modified 
      DES-lignin and NVCL via activators regenerated by electron transfer-atom transfer 
      radical polymerization (ARGET-ATRP). Aspirin was coated with DES-lignin-g-PNVCL 
      through self-assembly by an ethanol/water anti-solvent method to obtain lignin 
      thermosensitive polymer nanoparticle coated aspirin (aspirin@LTNP). X-ray 
      electron spectroscopy (XPS), elemental analysis, scanning electron microscopy 
      (SEM), transmission electron microscopy (TEM), Fourier transform infrared 
      spectroscopy (FT-IR), dynamic light scattering (DLS), and ultraviolet visible 
      spectroscopy (UV) were used to characterize the composition, structure and 
      morphology of DES-lignin-g-PNVCL and aspirin@LTNP. The releasing behavior of 
      aspirin@LTNP at different temperatures and pH values was investigated. The safety 
      was evaluated by cytotoxicity tests. The results indicated that aspirin@LTNP was 
      mainly accumulated by the hydrophobic effect and π-π interaction in the process 
      of self-assembly, and its morphology was an ellipsoid stacked layer by layer. The 
      aspirin@LTNP hydrophilic chains were increased and had externally hydrophilic and 
      internally hydrophobic structures. The particle size decreased slightly during 
      the self-assembly process. The red-shift occurred at the π-π interaction 
      wavelength of the lignin aromatic ring, which indicated a physical coating 
      process. The coating rate of aspirin@LTNP was 88.87%. Aspirin@LTNP showed an 
      obvious temperature response; the 96 h cumulative release rate at the LCST was 
      73.75 ± 1.16%, while the 96 h cumulative release rate above the LCST was 28.10 ± 
      0.92%. The 96 h cumulative release rate was 63.21 ± 0.57% at pH = 1.5 and 49.56 ± 
      0.48% at pH = 7.4. The dosage of aspirin@LTNP used in the experiment was safe. 
      This study provided a strategy for drug coating and controlled release.
FAU - Liu, Ruixia
AU  - Liu R
AUID- ORCID: 0000-0002-0190-2781
AD  - College of Materials Science and Engineering, Central South University of 
      Forestry and Technology, Changsha, Hunan 410004, China. 1920651708@qq.com.
FAU - Ding, Tingting
AU  - Ding T
AD  - College of Materials Science and Engineering, Central South University of 
      Forestry and Technology, Changsha, Hunan 410004, China. 1920651708@qq.com.
FAU - Deng, Pingping
AU  - Deng P
AD  - College of Materials Science and Engineering, Central South University of 
      Forestry and Technology, Changsha, Hunan 410004, China. 1920651708@qq.com.
FAU - Yan, Xiaofan
AU  - Yan X
AD  - College of Materials Science and Engineering, Central South University of 
      Forestry and Technology, Changsha, Hunan 410004, China. 1920651708@qq.com.
FAU - Xiong, Fuquan
AU  - Xiong F
AUID- ORCID: 0000-0001-7289-198X
AD  - College of Materials Science and Engineering, Central South University of 
      Forestry and Technology, Changsha, Hunan 410004, China. 1920651708@qq.com.
FAU - Chen, Jienan
AU  - Chen J
AD  - College of Materials Science and Engineering, Central South University of 
      Forestry and Technology, Changsha, Hunan 410004, China. 1920651708@qq.com.
FAU - Wu, Zhiping
AU  - Wu Z
AUID- ORCID: 0000-0001-8022-4837
AD  - College of Materials Science and Engineering, Central South University of 
      Forestry and Technology, Changsha, Hunan 410004, China. 1920651708@qq.com.
LA  - eng
PT  - Journal Article
DEP - 20220726
PL  - England
TA  - Biomater Sci
JT  - Biomaterials science
JID - 101593571
RN  - 0 (Polymers)
RN  - 9005-53-2 (Lignin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - *Lignin
MH  - *Nanoparticles
MH  - Polymers/chemistry
MH  - Spectroscopy, Fourier Transform Infrared
EDAT- 2022/06/30 06:00
MHDA- 2022/07/29 06:00
CRDT- 2022/06/29 09:43
PHST- 2022/06/30 06:00 [pubmed]
PHST- 2022/07/29 06:00 [medline]
PHST- 2022/06/29 09:43 [entrez]
AID - 10.1039/d2bm00325b [doi]
PST - epublish
SO  - Biomater Sci. 2022 Jul 26;10(15):4284-4292. doi: 10.1039/d2bm00325b.

PMID- 23639705
OWN - NLM
STAT- MEDLINE
DCOM- 20131118
LR  - 20131121
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 33
IP  - 2
DP  - 2013 May
TI  - Aspirin-exacerbated respiratory disease: clinical disease and diagnosis.
PG  - 147-61
LID - S0889-8561(12)00113-0 [pii]
LID - 10.1016/j.iac.2012.10.002 [doi]
AB  - This article summarizes the current knowledge in the field of clinical 
      presentation and diagnosis of aspirin-exacerbated respiratory disease (AERD). The 
      definition, prevalence, natural history, and clinical presentation of this 
      distinct clinical syndrome are described. The classification and tolerance of 
      particular groups of cyclooxygenase inhibitors by patients with AERD are 
      presented. The authors comprehensively discuss provocation tests with aspirin as 
      the most reliable method to confirm the diagnosis of AERD.
CI  - Copyright © 2013 Elsevier Inc. All rights reserved.
FAU - Bochenek, Grażyna
AU  - Bochenek G
AD  - Department of Pulmonology, Jagiellonian University School of Medicine, 
      Jagiellonian University Medical College, Krakow, Poland. graboch@tlen.pl
FAU - Niżankowska-Mogilnicka, Ewa
AU  - Niżankowska-Mogilnicka E
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20121106
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Drug Hypersensitivity/diagnosis/epidemiology
MH  - Humans
MH  - Prevalence
MH  - Respiratory Tract Diseases/*chemically induced/*diagnosis/epidemiology
EDAT- 2013/05/04 06:00
MHDA- 2013/11/19 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/05/04 06:00 [entrez]
PHST- 2013/05/04 06:00 [pubmed]
PHST- 2013/11/19 06:00 [medline]
AID - S0889-8561(12)00113-0 [pii]
AID - 10.1016/j.iac.2012.10.002 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2013 May;33(2):147-61. doi: 
      10.1016/j.iac.2012.10.002. Epub 2012 Nov 6.

PMID- 21061522
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20201209
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - [Pathologic characteristics of gastric ulcer in the aged].
PG  - 1995-2000
AB  - The use of aspirin continues to increase as a result of accumulation of evidence 
      of benefits in treatment strategies for cardiovascular disease. These 
      antiplatelet agents, however, have recognizable risks of gastrointestinal 
      complications such as ulceration and related bleeding. Based on the published 
      guidelines in Japan, the cause of gastric ulcer is divided roughly into 
      Helicobacter pylori infection and nonsteroidal antiinflammatory drug (NSAID) 
      including aspirin. With the decrease of H. pylori infection rate in a young and 
      that of ulcer recurrence by H. pylori eradication therapy, the cases with peptic 
      ulcer that is come from H. pylori infection have decreased in Japan. On the other 
      hand, gastric ulcer based on the use of aspirin and NSAID have increased. The 
      author reviewed pathologic characteristics of gastric ulcer in the aged in this 
      report.
FAU - Uemura, Naomi
AU  - Uemura N
AD  - Kohnodai Hospital, National Center for Global Health and Medicine.
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects
MH  - Helicobacter Infections/complications
MH  - Helicobacter pylori
MH  - Humans
MH  - Stomach Ulcer/chemically induced/etiology/*pathology
EDAT- 2010/11/11 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Nov;68(11):1995-2000.

PMID- 8758043
OWN - NLM
STAT- MEDLINE
DCOM- 19961025
LR  - 20190512
IS  - 1460-2725 (Print)
IS  - 1460-2393 (Linking)
VI  - 89
IP  - 6
DP  - 1996 Jun
TI  - Anti-thrombotic therapy for non-rheumatic atrial fibrillation.
PG  - 409-14
AB  - Recent randomized trials of antithrombotic therapy in non-rheumatic atrial 
      fibrillation have helped to clarify the benefits of warfarin and aspirin. 
      Low-risk patients (normotensives aged < 60 with normal left ventricular function) 
      have a small risk of thromboembolic events and are unlikely to benefit 
      significantly from anticoagulants, but may benefit from aspirin with little 
      increase in risk of bleeding. High-risk patients (> 75 years, impaired left 
      ventricular function, previous thromboembolism and/or associated conditions such 
      as hypertension and diabetes mellitus) have an increased risk of thromboembolism, 
      and benefit from long-term anticoagulant therapy to a greater degree than with 
      aspirin, although at a risk of increased bleeding complications.
FAU - More, R S
AU  - More RS
AD  - Academic Department of Cardiology, St Mary's Hospital, London, UK.
FAU - Chauhan, A
AU  - Chauhan A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - QJM
JT  - QJM : monthly journal of the Association of Physicians
JID - 9438285
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - QJM. 1996 Oct;89(10):799-800; author reply 801-2. PMID: 8944236
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Thromboembolism/etiology/prevention & control
MH  - *Thrombolytic Therapy
MH  - Warfarin/therapeutic use
RF  - 34
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
AID - 10.1093/qjmed/89.6.409 [doi]
PST - ppublish
SO  - QJM. 1996 Jun;89(6):409-14. doi: 10.1093/qjmed/89.6.409.

PMID- 27765727
OWN - NLM
STAT- MEDLINE
DCOM- 20170906
LR  - 20181005
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
VI  - 15
IP  - 3
DP  - 2017 Mar
TI  - Aspirin Use Is Associated With Reduced Risk of Occlusion of Metallic Biliary 
      Stents.
PG  - 446-453
LID - S1542-3565(16)30930-2 [pii]
LID - 10.1016/j.cgh.2016.10.013 [doi]
AB  - BACKGROUND & AIMS: Biliary self-expandable metallic stents (SEMSs) are widely 
      used to treat malignant and benign conditions of bile duct. Despite their lower 
      rate of occlusion and longer patency than plastic stents, SEMSs still have 
      significant rates of occlusion. We aimed to identify factors associated with 
      occlusion of biliary SEMS. METHODS: We performed a retrospective study of 
      consecutive patients who underwent endoscopic retrograde cholangiopancreatography 
      with biliary SEMS placement at the Cleveland Clinic Foundation from March 2011 to 
      April 2016. We collected clinical, endoscopic, radiographic, and surgical data 
      from medical records and performed multivariable analysis to identify factors 
      associated with SEMS patency. Subjects that received minimal daily dose of 81 mg 
      at the time of stent placement until the end of follow-up were assigned to the 
      aspirin exposure group (n = 157) and compared with subjects with no aspirin 
      exposure (n = 436). Patients were followed for a median 81 days. The primary 
      outcome was hazard ratio for SEMS occlusion requiring an interventional maneuver 
      for biliary drainage. RESULTS: We analyzed data from patients receiving a total 
      of 593 biliary SEMS for treatment of malignant and benign conditions of bile 
      duct. Stent occlusion was observed in 126 cases. Multivariable analysis showed 
      that daily use of aspirin (81 mg or more) was associated with 51% lower risk of 
      stent occlusion than in patients without daily use of aspirin (hazard ratio, 
      0.49; 95% confidence interval, 0.32-0.75). Furthermore, SEMSs had a longer 
      duration of stent patency in patients in the aspirin exposure group (434.4 days) 
      versus the no aspirin exposure group (339.9 days) (P < .001). Stricture location 
      limited to distal bile duct (in comparison with strictures involving proximal 
      extrahepatic duct) was associated with lower risk of stent occlusion (hazard 
      ratio, 0.39; 95% CI, 0.22-0.71). CONCLUSIONS: In an analysis of a large cohort of 
      subjects with metallic biliary stent placement for malignant and benign 
      conditions of bile duct, we associated daily use of aspirin (81 mg or more) with 
      lower risk of SEMS occlusion and longer stent patency duration.
CI  - Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.
FAU - Jang, Sunguk
AU  - Jang S
AD  - Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio. 
      Electronic address: jangs@ccf.org.
FAU - Stevens, Tyler
AU  - Stevens T
AD  - Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio.
FAU - Parsi, Mansour A
AU  - Parsi MA
AD  - Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio.
FAU - Lopez, Rocio
AU  - Lopez R
AD  - Department of Quantitative Sciences, Cleveland Clinic, Cleveland, Ohio.
FAU - Vargo, John J
AU  - Vargo JJ
AD  - Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio.
LA  - eng
PT  - Journal Article
DEP - 20161017
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal 
      of the American Gastroenterological Association
JID - 101160775
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Biliary Tract Surgical Procedures/*adverse effects
MH  - Cholestasis/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ohio
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Stents/*adverse effects
OTO - NOTNLM
OT  - Blockage
OT  - Comparative Study
OT  - ERCP
OT  - Surgery
EDAT- 2016/10/22 06:00
MHDA- 2017/09/07 06:00
CRDT- 2016/10/22 06:00
PHST- 2016/08/19 00:00 [received]
PHST- 2016/09/20 00:00 [revised]
PHST- 2016/10/05 00:00 [accepted]
PHST- 2016/10/22 06:00 [pubmed]
PHST- 2017/09/07 06:00 [medline]
PHST- 2016/10/22 06:00 [entrez]
AID - S1542-3565(16)30930-2 [pii]
AID - 10.1016/j.cgh.2016.10.013 [doi]
PST - ppublish
SO  - Clin Gastroenterol Hepatol. 2017 Mar;15(3):446-453. doi: 
      10.1016/j.cgh.2016.10.013. Epub 2016 Oct 17.

PMID- 16052194
OWN - NLM
STAT- MEDLINE
DCOM- 20051028
LR  - 20131121
IS  - 0954-3007 (Print)
IS  - 0954-3007 (Linking)
VI  - 59 Suppl 1
DP  - 2005 Aug
TI  - Prospects and possible pitfalls of a preventive Polypill: confessions of a health 
      promotion convert.
PG  - S4-8; discussion S9
AB  - A proposal by Wald and Law (2003) for a single pill containing a statin, three 
      half-dose antihypertensives, aspirin, and folic acid, met with a storm of 
      controversy and seemed to have been relegated as much to the fanciful as to the 
      accolades it might have deserved. The benefits such a Polypill could confer on 
      people age 55+y were to reduce both cardiovascular and stroke events by 80% or 
      more. Considering the daunting and, at best, slow process of changing the same 
      risk factors through health promotion interventions on food policy, dietary and 
      physical activity behaviors, and urban planning to make less prevalent the 
      sedentary lifestyles developed over decades, the argument here is to view the 
      Polypill as a harm reduction strategy that would complement health promotion, as 
      Nicotine Replacement Therapy did for tobacco control, seat belts did for traffic 
      injuries, and needle exchange programs did for secondary complications of 
      injection drug use.
FAU - Green, L W
AU  - Green LW
AD  - School of Medicine, University of California, San Francisco, CA 94127, USA. 
      lwgreen@comcast.net
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Clin Nutr
JT  - European journal of clinical nutrition
JID - 8804070
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 935E97BOY8 (Folic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - *Drug Combinations
MH  - Female
MH  - Folic Acid/administration & dosage/adverse effects
MH  - Health Promotion/methods
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverse 
      effects
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention/*methods
MH  - Risk Factors
EDAT- 2005/07/30 09:00
MHDA- 2005/10/29 09:00
CRDT- 2005/07/30 09:00
PHST- 2005/07/30 09:00 [pubmed]
PHST- 2005/10/29 09:00 [medline]
PHST- 2005/07/30 09:00 [entrez]
AID - 1602167 [pii]
AID - 10.1038/sj.ejcn.1602167 [doi]
PST - ppublish
SO  - Eur J Clin Nutr. 2005 Aug;59 Suppl 1:S4-8; discussion S9. doi: 
      10.1038/sj.ejcn.1602167.

PMID- 15942266
OWN - NLM
STAT- MEDLINE
DCOM- 20060515
LR  - 20131121
IS  - 0301-1569 (Print)
IS  - 0301-1569 (Linking)
VI  - 67
IP  - 3
DP  - 2005
TI  - Current concepts in therapy of chronic rhinosinusitis and nasal polyposis.
PG  - 125-36
AB  - The exact pathophysiological mechanisms leading to chronic rhinosinusitis (CRS) 
      still to a large extent remain obscure. However, recently there has been some 
      progress in elucidating the etiology of nasal polyposis, especially regarding 
      tissue eosinophilia as well as the role of aspirin intolerance and eicosanoid 
      mediators. Endonasal sinus surgery has evolved to be the treatment of choice in 
      CRS and nasal polyposis in all cases where conservative treatment has failed or 
      resulted in only a partial or temporary relief. Today, state of the art in 
      surgical technique includes the ability to combine microscopic and endoscopic 
      procedures. Regardless of technical advances like powered instrumentation or 
      computer-aided surgery, in a modern protocol, surgical therapy can offer only one 
      option within a complex and individually tailored therapeutical concept. This 
      review discusses current concepts and new developments in the diagnosis and 
      treatment of CRS and nasal polyposis.
FAU - Gosepath, Jan
AU  - Gosepath J
AD  - Department of Otolaryngology, Head and Neck Surgery, School of Medicine, 
      University of Mainz, Mainz, Germany. gosepath@hno.klinik.uni-mainz.de
FAU - Mann, Wolf J
AU  - Mann WJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - ORL J Otorhinolaryngol Relat Spec
JT  - ORL; journal for oto-rhino-laryngology and its related specialties
JID - 0334721
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antifungal Agents)
RN  - 0 (Histamine H1 Antagonists)
RN  - 0 (Steroids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Antifungal Agents/therapeutic use
MH  - Aspirin/adverse effects/immunology
MH  - Chronic Disease
MH  - Endoscopy
MH  - Eosinophilia/complications/immunology
MH  - Histamine H1 Antagonists/therapeutic use
MH  - Humans
MH  - Nasal Polyps/*diagnosis/etiology/*therapy
MH  - Paranasal Sinuses/surgery
MH  - Postoperative Complications
MH  - Rhinitis/*diagnosis/etiology/*therapy
MH  - Sinusitis/*diagnosis/etiology/*therapy
MH  - Steroids/therapeutic use
MH  - Surgery, Computer-Assisted
MH  - Treatment Outcome
RF  - 130
EDAT- 2005/06/09 09:00
MHDA- 2006/05/16 09:00
CRDT- 2005/06/09 09:00
PHST- 2004/02/18 00:00 [received]
PHST- 2004/07/01 00:00 [accepted]
PHST- 2005/06/09 09:00 [pubmed]
PHST- 2006/05/16 09:00 [medline]
PHST- 2005/06/09 09:00 [entrez]
AID - 86075 [pii]
AID - 10.1159/000086075 [doi]
PST - ppublish
SO  - ORL J Otorhinolaryngol Relat Spec. 2005;67(3):125-36. doi: 10.1159/000086075.

PMID- 37649039
OWN - NLM
STAT- MEDLINE
DCOM- 20230901
LR  - 20230905
IS  - 1465-542X (Electronic)
IS  - 1465-5411 (Print)
IS  - 1465-5411 (Linking)
VI  - 25
IP  - 1
DP  - 2023 Aug 30
TI  - Low-dose aspirin, statins, and metformin and survival in patients with breast 
      cancers: a Norwegian population-based cohort study.
PG  - 101
LID - 10.1186/s13058-023-01697-2 [doi]
LID - 101
AB  - BACKGROUND: Previous studies assessed the prognostic effect of aspirin, statins, 
      and metformin in breast cancer (BC) patients, with inconclusive results. METHODS: 
      We performed a nationwide population-based cohort study to evaluate if 
      post-diagnostic use of low-dose aspirin, statins, and metformin was associated 
      with BC-specific survival. Women aged ≥ 50 years and diagnosed with BC in 
      2004-2017, who survived ≥ 12 months after diagnosis (follow-up started 12 months 
      after diagnosis), were identified in the Cancer Registry of Norway. The Norwegian 
      Prescription Database provided information on prescriptions. Multivariable Cox 
      proportional hazard models were used to estimate hazard ratios (HR) and 95% 
      confidence intervals (CI) for the association between post-diagnostic use and 
      BC-specific survival, overall and by oestrogen receptor (ER) status. RESULTS: A 
      total of 26,190 patients were included. Of these, 5324 (20%), 7591 (29%), and 
      1495 (6%) were post-diagnostic users of low-dose aspirin, statins, and metformin, 
      respectively. The median follow-up was 6.1 years, and 2169 (8%) patients died 
      from BC. HRs for use, compared to no use, were estimated at 0.96 (95% CI 
      0.85-1.08) for low-dose aspirin (ER+: HR = 0.97, 95% CI 0.83-1.13; ER-: 
      HR = 0.97, 95% CI 0.73-1.29, p value for interaction = 0.562), 0.84 (95% CI 
      0.75-0.94) for statins (ER+: HR = 0.95, 95% CI 0.82-1.09; ER-: HR = 0.77, 95% CI 
      0.60-1.00, p value for interaction = 0.259), and 0.70 (95% CI 0.51-0.96) for 
      metformin (compared to use of non-metformin antidiabetics) (ER+: HR = 0.67, 95% 
      CI 0.45-1.01; ER-: HR = 1.62, 95% CI 0.72-3.62, p value for interaction = 0.077). 
      CONCLUSION: We found evidence supporting an association between post-diagnostic 
      use of statins and metformin and survival, in patients with BC. Our findings 
      indicate potential differences according to ER status.
CI  - © 2023. BioMed Central Ltd., part of Springer Nature.
FAU - Löfling, L Lukas
AU  - Löfling LL
AUID- ORCID: 0000-0002-2731-8532
AD  - Department of Research, Cancer Registry of Norway, Postboks 5313 Majorstuen, 
      0304, Oslo, Norway.
FAU - Støer, Nathalie C
AU  - Støer NC
AUID- ORCID: 0000-0001-8994-9332
AD  - Department of Research, Cancer Registry of Norway, Postboks 5313 Majorstuen, 
      0304, Oslo, Norway.
FAU - Andreassen, Bettina Kulle
AU  - Andreassen BK
AUID- ORCID: 0000-0001-5087-2913
AD  - Department of Research, Cancer Registry of Norway, Postboks 5313 Majorstuen, 
      0304, Oslo, Norway.
FAU - Ursin, Giske
AU  - Ursin G
AUID- ORCID: 0000-0002-0835-9507
AD  - Cancer Registry of Norway, Oslo, Norway.
AD  - Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, 
      Oslo, Norway.
AD  - Department of Preventive Medicine, University of Southern California, Los 
      Angeles, USA.
FAU - Botteri, Edoardo
AU  - Botteri E
AUID- ORCID: 0000-0002-9023-8068
AD  - Department of Research, Cancer Registry of Norway, Postboks 5313 Majorstuen, 
      0304, Oslo, Norway. edoardo.botteri@kreftregisteret.no.
AD  - Section for Colorectal Cancer Screening, Cancer Registry of Norway, Oslo, Norway. 
      edoardo.botteri@kreftregisteret.no.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230830
PL  - England
TA  - Breast Cancer Res
JT  - Breast cancer research : BCR
JID - 100927353
RN  - 9100L32L2N (Metformin)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Metformin/therapeutic use
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - *Breast Neoplasms/drug therapy/epidemiology
MH  - Cohort Studies
MH  - Aspirin/therapeutic use
MH  - Norway/epidemiology
MH  - Receptors, Estrogen
PMC - PMC10466817
OTO - NOTNLM
OT  - Breast cancer
OT  - Cohort
OT  - Low-dose aspirin
OT  - Metformin
OT  - Population-based
OT  - Statins
OT  - Survival
COIS- LLL’s spouse is employed by MSD Norway AS.
EDAT- 2023/08/31 00:42
MHDA- 2023/09/01 06:43
CRDT- 2023/08/30 23:41
PHST- 2023/06/15 00:00 [received]
PHST- 2023/08/14 00:00 [accepted]
PHST- 2023/09/01 06:43 [medline]
PHST- 2023/08/31 00:42 [pubmed]
PHST- 2023/08/30 23:41 [entrez]
AID - 10.1186/s13058-023-01697-2 [pii]
AID - 1697 [pii]
AID - 10.1186/s13058-023-01697-2 [doi]
PST - epublish
SO  - Breast Cancer Res. 2023 Aug 30;25(1):101. doi: 10.1186/s13058-023-01697-2.

PMID- 22435901
OWN - NLM
STAT- MEDLINE
DCOM- 20130521
LR  - 20171116
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 41
IP  - 10
DP  - 2011 Oct
TI  - Safety of withholding anticoagulation in patients with mechanical prosthetic 
      valves and intracranial haemorrhage.
PG  - 750-4
LID - 10.1111/j.1445-5994.2011.02579.x [doi]
AB  - Patients with prosthetic heart valves require lifelong anticoagulation to prevent 
      thromboembolism. When they have intracranial haemorrhage, anticoagulation has to 
      be withheld. This study was aimed to identify safety duration and complications 
      of anticoagulation withholding in patients with prosthetic heart valves and 
      intracranial haemorrhage. This was a retrospective descriptive study in 26 
      prosthetic heart valve patients hospitalised in Srinagarind Hospital, Khon Kaen 
      University because of intracranial haemorrhage from 2003 to 2008. Range of 
      anticoagulation withholding was 1 to 26 days with mean 8.5 ± 7.7 days. Most 
      patients (84.6%) were withheld anticoagulation for less than 14 days. There were 
      five in-hospital deaths mostly within 3 days of admission from severe 
      intracranial haemorrhage. No data of reintroduction of anticoagulation was found 
      in three patients because they were lost to follow up. One patient had right 
      basal ganglia infarction after 7 days of anticoagulation withholding. Prosthetic 
      heart valve dysfunction was suspected in one patient who withheld anticoagulant 
      for 76 days. Discontinuation of anticoagulation in patients with prosthetic heart 
      valves and intracranial haemorrhage for less than 7 days was associated with low 
      thromboembolic risk and there was no clinical evidence of prosthetic heart valve 
      dysfunction when anticoagulation was withheld for less than 14 days.
CI  - © 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College 
      of Physicians.
FAU - Krittalak, K
AU  - Krittalak K
AD  - Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Sawanyawisuth, K
AU  - Sawanyawisuth K
FAU - Tiamkao, S
AU  - Tiamkao S
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Atrial Fibrillation/epidemiology
MH  - Combined Modality Therapy
MH  - Comorbidity
MH  - Contraindications
MH  - Craniotomy
MH  - Female
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - International Normalized Ratio
MH  - Intracranial Hemorrhages/*complications/drug therapy/mortality/surgery
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
MH  - Retrospective Studies
MH  - Thailand/epidemiology
MH  - Thromboembolism/prevention & control
MH  - Time Factors
MH  - Vitamin K/therapeutic use
MH  - Warfarin/administration & dosage/adverse effects
EDAT- 2012/03/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2012/03/23 06:00
PHST- 2012/03/23 06:00 [entrez]
PHST- 2012/03/23 06:00 [pubmed]
PHST- 2013/05/23 06:00 [medline]
AID - 10.1111/j.1445-5994.2011.02579.x [doi]
PST - ppublish
SO  - Intern Med J. 2011 Oct;41(10):750-4. doi: 10.1111/j.1445-5994.2011.02579.x.

PMID- 8686313
OWN - NLM
STAT- MEDLINE
DCOM- 19960822
LR  - 20131121
IS  - 0043-5325 (Print)
IS  - 0043-5325 (Linking)
VI  - 108
IP  - 8
DP  - 1996
TI  - [Effectiveness of fixed analgesic combinations exemplified by thomapyrin].
PG  - 219-33
AB  - Thomapyrin has been on the German market as analgesic for the past 50 years. It 
      is the prescription-free preparation with the highest sales there. This is an 
      occasion to survey current state of scientific knowledge concerning combination 
      analgesics with acetyl salicylic acid, paracetamol and caffeine. For the 
      assessment and registration of fixed preparations authorities of different 
      European countries and also USA have defined special criteria. Analgesic 
      preparations must agree with these defined criteria. The importance of these 
      combination analgesics in pain therapy is described with the respect to the 
      latest scientific results. Combination analgesics represent an important area of 
      self-medication by the patient. The properties of the active substances alone and 
      in combination are set forth, with respect to pharmacokinetics and efficacy. The 
      experimental and especially clinical results clearly show a broader spectrum of 
      action in consequence of the different modes of action of the individual active 
      substances. Analgesic action is 1.4 fold higher owing to added caffeine. The 
      fixed combination of active substances does not change the profile of side 
      effects. The conclusion is that combination analgesics such as Thomapyrine show a 
      positive benefit/risk ratio. Furthermore such combination analgesics are 
      appropriate for self-medications and suited to combat pain of different kinds.
FAU - Aicher, B
AU  - Aicher B
AD  - Abteilung Medizinische Wissenschaft, Dr. Karl Thomae GmbH, Biberach, 
      Bundesrepublik Deutschland.
FAU - Kraupp, O
AU  - Kraupp O
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Zweckmässigkeit fixer Analgetikakombinationen am Beispiel von Thomapyrin.
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 3G6A5W338E (Caffeine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Wien Klin Wochenschr. 1997 Apr 11;109(7):247-8; author reply 249-54. PMID: 
      9206904
CIN - Wien Klin Wochenschr. 1997 Apr 11;109(7):255-6. PMID: 9206905
MH  - Acetaminophen/adverse effects/pharmacokinetics/*therapeutic use
MH  - Analgesics, Non-Narcotic/adverse effects/pharmacokinetics/*therapeutic use
MH  - Aspirin/adverse effects/pharmacokinetics/*therapeutic use
MH  - Caffeine/adverse effects/pharmacokinetics/*therapeutic use
MH  - Drug Combinations
MH  - Germany
MH  - Humans
MH  - Pain/blood/*drug therapy/etiology
MH  - Pain Measurement
MH  - Product Surveillance, Postmarketing
MH  - Treatment Outcome
RF  - 104
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
PST - ppublish
SO  - Wien Klin Wochenschr. 1996;108(8):219-33.

PMID- 22488125
OWN - NLM
STAT- MEDLINE
DCOM- 20130311
LR  - 20201216
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 131
IP  - 6
DP  - 2012 Sep 15
TI  - Cardiovascular medications in angiogenesis--how to avoid the sting in the tail.
PG  - 1249-59
LID - 10.1002/ijc.27576 [doi]
AB  - Cancer and cardiovascular disease are the leading causes of death worldwide. 
      Cardiovascular medications have recently been found to have favorable effects 
      also for the treatment of noncardiovascular diseases, including cancer. In this 
      review, we use a reverse bedside-to-bench approach to investigate the effects of 
      common cardiovascular medications on tumor angiogenesis and vascular 
      angiogenesis. Aspirin seems to reduce the risk of developing cancer, particularly 
      colon cancer. However, whether the protective influence of aspirin is due to 
      antiangiogenesis effect is still unclear. β-Blockers, which are normally used to 
      reduce heart rate and prolong diastole, trigger an increase in stretch-associated 
      release of proangiogenic growth factors thereby inducing angiogenesis. However, 
      according to other studies β-blockers are able to inhibit angiogenesis via 
      multiplicate mechanisms. Similarly, angiotensin converting enzyme inhibitor and 
      angiotensin II type 1 receptor blocker have controversial effects for the 
      regulation of cell proliferation and angiogenesis. Statins can augment collateral 
      vascular growth in ischemic tissues and restrict the development of cancer. So 
      this topical anti-inflammatory drug seems to be of high value for further 
      therapy. Finally, suggestions on how this pilot experience may guide the conduct 
      of future preclinical investigations, and clinical trials are discussed.
CI  - Copyright © 2012 UICC.
FAU - Ma, Chenming
AU  - Ma C
AD  - Research Group Surgical Oncology, Experimental and Clinical Research Center, Max 
      Delbrueck Center and Charité Campus Buch, Berlin, Germany.
FAU - Wang, Qing
AU  - Wang Q
FAU - Man, Yicun
AU  - Man Y
FAU - Kemmner, Wolfgang
AU  - Kemmner W
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120529
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/pharmacology
MH  - Angiotensin-Converting Enzyme Inhibitors/pharmacology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Calcium Channel Blockers/pharmacology
MH  - Cardiovascular Agents/*pharmacology
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology
MH  - Neovascularization, Pathologic/*prevention & control
MH  - Neovascularization, Physiologic/*drug effects
EDAT- 2012/04/11 06:00
MHDA- 2013/03/12 06:00
CRDT- 2012/04/11 06:00
PHST- 2011/10/22 00:00 [received]
PHST- 2012/03/19 00:00 [accepted]
PHST- 2012/04/11 06:00 [entrez]
PHST- 2012/04/11 06:00 [pubmed]
PHST- 2013/03/12 06:00 [medline]
AID - 10.1002/ijc.27576 [doi]
PST - ppublish
SO  - Int J Cancer. 2012 Sep 15;131(6):1249-59. doi: 10.1002/ijc.27576. Epub 2012 May 
      29.

PMID- 8150930
OWN - NLM
STAT- MEDLINE
DCOM- 19940512
LR  - 20190512
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 8
IP  - 12
DP  - 1993 Dec
TI  - Low-dose aspirin for prevention of pregnancy losses in women with primary 
      antiphospholipid syndrome.
PG  - 2234-9
AB  - Pregnancy loss, often recurrent, is one of the most important clinical 
      manifestations associated with the primary antiphospholipid syndrome. In these 
      cases, pregnancy wastage is related to the presence of antiphospholipid 
      antibodies, namely lupus anticoagulant and anticardiolipin antibodies, but 
      patients do not have features of systemic lupus erythematosus or any other 
      well-defined autoimmune disease. We report here on the outcome of 21 consecutive 
      pregnancies in 18 patients with the syndrome who were treated with low-dose 
      aspirin (100 mg/day) from 1 month before attempting conception and throughout the 
      pregnancy. Low-dose prednisone (15-30 mg/day) was added for potentially 
      non-obstetric (autoimmune-related) reasons in six pregnancies. Patients were 
      monitored as having high-risk pregnancies. Prior to therapy, the rate of 
      live-born babies was 6.1% (46 previous fetal losses and three live-born babies), 
      and after therapy, it was 90.5% (21 pregnancies and 19 live-born babies). 
      Pre-term delivery due to maternal or fetal indications was required in 15% (3/20) 
      of the viable pregnancies. Except for prematurity (20% of viable pregnancies) and 
      its potential associated complications, there were no significant adverse effects 
      to either mothers or babies. Our treatment modality is advocated for prevention 
      of pregnancy losses in patients with the 'obstetric' primary antiphospholipid 
      syndrome.
FAU - Balasch, J
AU  - Balasch J
AD  - Department of Obstetrics and Gynaecology, Faculty of Medicine, University of 
      Barcelona, Hospital Clínic i Provincial, Spain.
FAU - Carmona, F
AU  - Carmona F
FAU - López-Soto, A
AU  - López-Soto A
FAU - Font, J
AU  - Font J
FAU - Creus, M
AU  - Creus M
FAU - Fábregues, F
AU  - Fábregues F
FAU - Ingelmo, M
AU  - Ingelmo M
FAU - Vanrell, J A
AU  - Vanrell JA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Hum Reprod. 1994 Jul;9(7):1359-62. PMID: 7962450
MH  - Abortion, Habitual/etiology/*prevention & control
MH  - Adolescent
MH  - Adult
MH  - Antiphospholipid Syndrome/*drug therapy
MH  - Aspirin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Prospective Studies
MH  - Risk Factors
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.humrep.a138009 [doi]
PST - ppublish
SO  - Hum Reprod. 1993 Dec;8(12):2234-9. doi: 10.1093/oxfordjournals.humrep.a138009.

PMID- 8996290
OWN - NLM
STAT- MEDLINE
DCOM- 19970211
LR  - 20220330
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 29
IP  - 1
DP  - 1997 Jan
TI  - High pressure assisted coronary stent implantation accomplished without 
      intravascular ultrasound guidance and subsequent anticoagulation.
PG  - 21-7
AB  - OBJECTIVES: The purpose of this study was to determine the efficacy of treatment 
      with antiplatelet therapy and no anticoagulation after high pressure assisted 
      coronary stent implantation performed without intravascular ultrasound (IVUS) 
      guidance. BACKGROUND: Previous studies have shown that during IVUS-guided 
      Palmaz-Schatz coronary stenting, it is safe to withhold anticoagulation when 
      stent expansion has been optimized by high pressure balloon dilation. METHODS: 
      Patients that had successful coronary stenting without IVUS guidance were treated 
      with ticlopidine, 500 mg/day, and aspirin, 325 mg/day, for 1 month and then 
      received only aspirin, 325 mg/day, indefinitely. Patients were not treated with 
      warfarin (Coumadin) or heparin after successful stenting. Clinical and 
      angiographic events were assessed at 1 month. RESULTS: A total of 201 
      intracoronary stents were implanted in 127 patients with 137 lesions. The average 
      number of stents per lesion was 1.4 +/- 0.8, and the average number of stents per 
      patient was 1.6 +/- 1.1. Stent deployment was performed for elective indications 
      in 79% of procedures and for emergency indications in 21%. There were four stent 
      thrombosis events for a per patient event rate of 3.1% and a per lesion event 
      rate of 2.9%. CONCLUSIONS: After high pressure assisted stenting performed 
      without IVUS guidance, there was an acceptable incidence of 3.1% of stent 
      thrombosis with the combination of short-term ticlopidine and aspirin therapy and 
      no anticoagulation. Although the study involved only 127 patients, the results 
      support the relative safety of stenting without IVUS guidance and with 
      antiplatelet therapy only in comparison to historical trials on stenting 
      performed with postprocedure anticoagulation.
FAU - Nakamura, S
AU  - Nakamura S
AD  - Ohta General Hospital, Division of Cardiology, Japan.
FAU - Hall, P
AU  - Hall P
FAU - Gaglione, A
AU  - Gaglione A
FAU - Tiecco, F
AU  - Tiecco F
FAU - Di Maggio, M
AU  - Di Maggio M
FAU - Maiello, L
AU  - Maiello L
FAU - Martini, G
AU  - Martini G
FAU - Colombo, A
AU  - Colombo A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Case-Control Studies
MH  - Coronary Angiography
MH  - Coronary Disease/diagnostic imaging/*therapy
MH  - Coronary Thrombosis/epidemiology/prevention & control
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/therapeutic use
MH  - *Stents
MH  - Ticlopidine/*administration & dosage/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - *Ultrasonography, Interventional
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - S0735109796004317 [pii]
AID - 10.1016/s0735-1097(96)00431-7 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1997 Jan;29(1):21-7. doi: 10.1016/s0735-1097(96)00431-7.

PMID- 36725971
OWN - NLM
STAT- MEDLINE
DCOM- 20230203
LR  - 20230316
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Feb 1
TI  - NHANES cross sectional study of aspirin and fractures in the elderly.
PG  - 1879
LID - 10.1038/s41598-023-29029-6 [doi]
LID - 1879
AB  - Bone fractures are a global public health concern, yet no thorough investigation 
      of low-dose aspirin usage to prevent fractures in the elderly has been conducted. 
      Many interventional human and animal studies have tried to detect the correct 
      role of low-dose aspirin on fractures in elderly persons. The literature doesn't 
      consist of a retrospective observational study that includes a large number of 
      older individuals and evaluates the accurate effect of aspirin on the fractures 
      post falling from low heights. This cross-sectional includes 7132 elderly persons 
      and aimed to detect if there was a link between taking low-dose aspirin to 
      prevent fractures in the elderly. Data was extracted from the National Health and 
      Nutrition Examination Survey (NHANES) database for 2017-2020 and 2013-2014. 
      Demographic and examination data were collected during in-home interviews and 
      study visits to a mobile examination center. Standardized questionnaires were 
      used to collect information such as age, gender, race, educational level, and 
      family income-to-poverty ratio. Body mass index (BMI), weight, standing height, 
      upper leg length, upper arm length, arm circumference, and wrist circumference 
      were all measured during the examination. The study examined 8127 patients, with 
      7132 elderly patients suitable for data analysis. The odds ratio of fractures due 
      to a fall from standing height or less was 0.963 (95 percent confidence interval 
      0.08-1.149) in low-dose aspirin users, while having parents with osteoporosis had 
      a related risk of 1.23. (95 percent confidence interval 0.81-1.8). The total 
      number of fractures was 1295; with hip fractures constituting up to 13.82%, wrist 
      fractures of 66.56%, and spine fractures of 19.61%. There was no significant 
      difference in femur and spine bone mineral density (BMD) in the two groups (use 
      low dose aspirin and don't use). Females had a 5.6 times greater fracture risk 
      related to a fall from standing height or less (1 time or more) than males 
      (P-value < 0.001). Furthermore, taking aspirin had no effect on the occurrence of 
      fractures from standing height or less in older people (P-value = 0.468). In 
      addition, the logistic regression after performing the propensity matching score 
      confirmed that there was no impact of taking aspirin on the occurrence of 
      fractures (P-value > 0.05). This cross-sectional study reveals that taking 
      low-dose aspirin to prevent fractures in the elderly is statistically 
      insignificant. However, fractures are more common in older persons, especially in 
      older women; thus, more widespread injury prevention initiatives and access to 
      osteoporosis prevention and diagnosis for older people should improve to minimize 
      the overall burden.
CI  - © 2023. The Author(s).
FAU - Swed, Sarya
AU  - Swed S
AUID- ORCID: 0000-0002-9983-2020
AD  - Faculty of Medicine, Aleppo University, Aleppo, 22743, Syria. 
      saryaswed1@gmail.com.
FAU - El-Sakka, Amro A
AU  - El-Sakka AA
AD  - Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
FAU - Abouainain, Yasmeen
AU  - Abouainain Y
AD  - Faculty of Medicine, University of Jordan, Amman, Jordan.
FAU - Lee, Ka Yiu
AU  - Lee KY
AD  - Department of Health Sciences, Swedish Winter Sports Research Centre, Mid Sweden 
      University, Östersund, Sweden.
FAU - Sawaf, Bisher
AU  - Sawaf B
AD  - Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
FAU - Albuni, Mhd Kutaiba
AU  - Albuni MK
AD  - Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
FAU - Battikh, Elias
AU  - Battikh E
AD  - Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
FAU - Ahmad, Eman Mohammed Sharif
AU  - Ahmad EMS
AD  - Nile Valley University, Atbra, Sudan.
FAU - Elkalagi, Nashaat Kamal Hamdy
AU  - Elkalagi NKH
AD  - Internal Medicine and Tropical Medicine at Faculty of Medicine Al Arish 
      University, Al Arish, Egypt.
FAU - Abbas, Kirellos Said
AU  - Abbas KS
AD  - Faculty of Medicine, Alexandria University, Alexandria, Egypt.
FAU - Hafez, Wael
AU  - Hafez W
AD  - NMC Royal Hospital, 16th Street, Khalifa City, Abu Dhabi, UAE.
AD  - Medical Research Division, Department of Internal Medicine, The National Research 
      Centre, Cairo, Egypt.
FAU - Rakab, Amine
AU  - Rakab A
AD  - Assistant Professor of Clinical Medicine, Medicine, Weill Cornell Medical 
      College, Ar Rayyān, Qatar.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20230201
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Male
MH  - Humans
MH  - Female
MH  - Aged
MH  - Aged, 80 and over
MH  - Cross-Sectional Studies
MH  - Nutrition Surveys
MH  - Aspirin/adverse effects
MH  - Risk Factors
MH  - *Fractures, Bone/epidemiology/prevention & control
MH  - *Osteoporosis/epidemiology
MH  - Bone Density
MH  - *Hip Fractures
PMC - PMC9892582
COIS- The authors declare no competing interests.
EDAT- 2023/02/02 06:00
MHDA- 2023/02/04 06:00
CRDT- 2023/02/01 23:54
PHST- 2022/05/10 00:00 [received]
PHST- 2023/01/30 00:00 [accepted]
PHST- 2023/02/01 23:54 [entrez]
PHST- 2023/02/02 06:00 [pubmed]
PHST- 2023/02/04 06:00 [medline]
AID - 10.1038/s41598-023-29029-6 [pii]
AID - 29029 [pii]
AID - 10.1038/s41598-023-29029-6 [doi]
PST - epublish
SO  - Sci Rep. 2023 Feb 1;13(1):1879. doi: 10.1038/s41598-023-29029-6.

PMID- 16034448
OWN - NLM
STAT- MEDLINE
DCOM- 20051209
LR  - 20220311
IS  - 0950-9240 (Print)
IS  - 0950-9240 (Linking)
VI  - 19
IP  - 9
DP  - 2005 Sep
TI  - Effects of low-dose aspirin on blood pressure and endothelial function of treated 
      hypertensive hypercholesterolaemic subjects.
PG  - 667-73
AB  - The main objective of this study was to assess whether aspirin 100 mg QD can 
      improve blood pressure (BP) control and endothelial function in subjects with 
      arterial hypertension (AH) and hypercholesterolaemia. In total, 21 patients of 
      both sexes (52.1+/-11.5 years) with treated AH and hypercholesterolaemia on 
      antihypertensive and statin therapy were included in the treatment group. In the 
      control group, 20 matched patients of both sexes (51.3+/-12.7 years), but without 
      statin therapy, were recruited. Treatment group subjects received aspirin (100 mg 
      QD) for a duration of 12 weeks at randomization (Treatment phase-1), followed by 
      single blind matching placebo for 12 weeks (Placebo phase) and then again 
      received aspirin (100 mg QD) for an additional 12 weeks (Treatment phase-2). The 
      control group participated in Treatment phase-1, but did not continue Placebo 
      phase and Treatment phase-2. At randomization and at the end of each study phase, 
      mean 24-h systolic BP (SBP) and diastolic BP (DBP) were assessed by 24-h 
      ambulatory blood pressure monitoring (ABPM) and endothelium-dependent (flow 
      mediated, FMD) and -independent (nitroglycerin induced, NTG) vasodilatations of 
      brachial artery were measured using high-resolution ultrasound. In Treatment 
      phase-1, reduction of SBP and DBP (DeltaSBP 5.7+/-2.6 mmHg, P=0.008; DeltaDBP 
      3.8+/-1.7 mmHg, P=0.014) and improvement of FMD (4.1+/-0.6%, P=0.019), in Placebo 
      phase an elevation of SBP and DBP (DeltaSBP -6.2+/-2.9 mmHg, P=0.002; DeltaDBP 
      -4.2+/-1.9 mmHg, P=0.031) and worsening of FMD (-3.8+/-0.9%, P=0.027), and in 
      Treatment phase-2 reduction of SBP and DBP (DeltaSBP 4.9+/-2.3 mmHg, P=0.005; 
      DeltaDBP 4.1+/-1.3 mmHg, P=0.024) and improvement of FMD (4.5+/-1.3%, P=0.009) 
      were observed in the treatment Group but not in the control group. Addition of 
      low-dose aspirin to antihypertensive medications and statins in hypertensive and 
      hypercholesterolaemic subjects can reduce both SBP and DBP by improvement of 
      endothelial function.
FAU - Magen, E
AU  - Magen E
AD  - 1WHO Collaborative Center for Prevention of CVD, Barzilai Medical Center, Ben 
      Gurion University of Negev, Ashkelon, Israel.
FAU - Viskoper, J R
AU  - Viskoper JR
FAU - Mishal, J
AU  - Mishal J
FAU - Priluk, R
AU  - Priluk R
FAU - London, D
AU  - London D
FAU - Yosefy, C
AU  - Yosefy C
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Hum Hypertens
JT  - Journal of human hypertension
JID - 8811625
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Hum Hypertens. 2005 Sep;19(9):663-5. PMID: 15905886
MH  - Adult
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Blood Pressure Monitoring, Ambulatory
MH  - Brachial Artery/diagnostic imaging/physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Endothelium, Vascular/*drug effects/*physiopathology
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Hypercholesterolemia/complications/*drug therapy
MH  - Hypertension/complications/*drug therapy/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Nitroglycerin/therapeutic use
MH  - Regional Blood Flow
MH  - Single-Blind Method
MH  - Ultrasonography
MH  - Vasodilation
MH  - Vasodilator Agents/therapeutic use
EDAT- 2005/07/22 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/07/22 09:00
PHST- 2005/07/22 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/07/22 09:00 [entrez]
AID - 1001910 [pii]
AID - 10.1038/sj.jhh.1001910 [doi]
PST - ppublish
SO  - J Hum Hypertens. 2005 Sep;19(9):667-73. doi: 10.1038/sj.jhh.1001910.

PMID- 21755814
OWN - NLM
STAT- MEDLINE
DCOM- 20110819
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 61
IP  - 5
DP  - 2011
TI  - Simultaneous extraction of acetylsalicylic acid and salicylic acid from human 
      plasma and simultaneous estimation by liquid chromatography and atmospheric 
      pressure chemical ionization/tandem mass spectrometry detection. Application to a 
      pharmacokinetic study.
PG  - 301-11
LID - 10.1055/s-0031-1296203 [doi]
AB  - A simple analytical method using liquid chromatography-tandem mass spectrometry 
      (LC-MS/MS) in atmospheric chemical ionization mode (APCI) for the simultaneous 
      estimation of acetylsalicylic acid (ASA, CAS 50-78-2) and its active metabolite 
      salicylic acid (SA, CAS 69-72-7) in human plasma has been developed and 
      validated. ASA and SA were analyzed simultaneously despite differences in plasma 
      concentration ranges of ASA and SA after oral administration of ASA. In spite of 
      having different chemical, ionization and chromatographic properties, ASA and SA 
      were extracted simultaneously from the plasma sample using acetonitrile protein 
      precipitation followed by liquid-liquid extraction. The analytes were separated 
      on a reversed phase column with rapid gradient program using mobile phase 
      consisting of ammonium acetate buffer and methanol. The structural analogue 
      diclofenac was used as an internal standard. The multiple reaction monitoring 
      (MRM) transitions m/z 179 --> 137 for ASA, m/z 137 --> 65 for SA and m/z 294 --> 
      250 for IS were used. The assay exhibited a linear dynamic range of 0.02-10 
      microg/mL for ASA and 0.1-50 microg/mL for SA. The between-batch precision (%CV) 
      ranged from 2.1 to 7.9% for ASA and from 0.2 to 5.2% for SA. The between-batch 
      accuracy ranged from 95.4 to 96.7% for ASA and from 94.6 to 111.3% for SA. The 
      validated method was successfully applied for the evaluation of pharmacokinetics 
      of ASA after single oral administration of 650 mg test formulation versus two 325 
      mg reference formulations of ASA in human subjects.
FAU - Nirogi, Ramakrishna
AU  - Nirogi R
AD  - Discovery Research, Suven Life Sciences Ltd, Serene Chambers, Hyderabad, India. 
      ramakrishna_nirogi@yahoo.co.in
FAU - Kandikere, Vishwottam
AU  - Kandikere V
FAU - Mudigonda, Koteshwara
AU  - Mudigonda K
FAU - Ajjala, Devender
AU  - Ajjala D
FAU - Suraneni, Ramakrishna
AU  - Suraneni R
FAU - Thoddi, Parthasarathi
AU  - Thoddi P
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Indicators and Reagents)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Area Under Curve
MH  - Aspirin/*blood/pharmacokinetics
MH  - Calibration
MH  - Chromatography, High Pressure Liquid
MH  - Cross-Over Studies
MH  - Drug Stability
MH  - Half-Life
MH  - Humans
MH  - Indicators and Reagents
MH  - Reference Standards
MH  - Reproducibility of Results
MH  - Salicylic Acid/*blood/pharmacokinetics
MH  - Spectrometry, Mass, Electrospray Ionization
MH  - Tandem Mass Spectrometry
EDAT- 2011/07/16 06:00
MHDA- 2011/08/20 06:00
CRDT- 2011/07/16 06:00
PHST- 2011/07/16 06:00 [entrez]
PHST- 2011/07/16 06:00 [pubmed]
PHST- 2011/08/20 06:00 [medline]
AID - 10.1055/s-0031-1296203 [doi]
PST - ppublish
SO  - Arzneimittelforschung. 2011;61(5):301-11. doi: 10.1055/s-0031-1296203.

PMID- 21463909
OWN - NLM
STAT- MEDLINE
DCOM- 20130606
LR  - 20181201
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 160
IP  - 1
DP  - 2012 Sep 20
TI  - Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is 
      associated with increased risk of fracture.
PG  - 36-40
LID - 10.1016/j.ijcard.2011.03.026 [doi]
AB  - BACKGROUND: Platelet inhibitors are widely used in the treatment and prevention 
      of coronary artery disease. In addition to acetylsalicylic acid, two major groups 
      of platelet inhibitors are used; phosphodiesterase inhibitors including 
      dipyridamole, and thienopyridines (ticlopidine and clopidogrel). Clopidogrel is 
      the most widely used, and in combination with acetylsalicylic acid it is the 
      standard of care for acute coronary syndromes and percutaneous coronary 
      interventions. However, the modes of action involve pathways that are involved in 
      the metabolic activity in bone cells and pharmacologic modulation of these 
      pathways may therefore have effects on bone. METHODS: In the current study, we 
      assessed the association between platelet inhibitor use and fracture incidence in 
      a population-based epidemiological study performed within the Danish population 
      consisting of approximately 5.3 million individuals, where all patients 
      sustaining a fracture during the year of 2000 were included (124,655 cases). The 
      hypotheses were to investigate if use of thienopyridines or phosphodiesterase 
      inhibitors were associated with increased risk of fractures after adjustment for 
      potential confounders. RESULTS: We found that treatment with dipyridamole is 
      associated with increased overall fracture risk, but not to the risk of 
      osteoporotic fractures. In contrast, low-dose acetylsalicylic acid is associated 
      to increased risk of overall fractures and fractures of the hip. Finally, in the 
      current study clopidogrel is not associated with increased fracture risk. 
      CONCLUSIONS: Use of some oral platelet inhibitors is associated with increased 
      risk of fractures, and more studies are warranted to determine the potential 
      effect of platelet inhibitors on bone metabolism in vivo.
CI  - Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Vestergaard, Peter
AU  - Vestergaard P
AD  - The Osteoporosis Clinic, Department of Endocrinology and Internal Medicine, 
      Aarhus University Hospital, Denmark.
FAU - Steinberg, Thomas H
AU  - Steinberg TH
FAU - Schwarz, Peter
AU  - Schwarz P
FAU - Jørgensen, Niklas Rye
AU  - Jørgensen NR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110403
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Clopidogrel
MH  - Dipyridamole/*adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fractures, Bone/*chemically induced/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoporosis/*chemically induced/complications
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Risk
MH  - Ticlopidine/analogs & derivatives/therapeutic use
EDAT- 2011/04/06 06:00
MHDA- 2013/06/07 06:00
CRDT- 2011/04/06 06:00
PHST- 2010/10/05 00:00 [received]
PHST- 2011/03/08 00:00 [revised]
PHST- 2011/03/11 00:00 [accepted]
PHST- 2011/04/06 06:00 [entrez]
PHST- 2011/04/06 06:00 [pubmed]
PHST- 2013/06/07 06:00 [medline]
AID - S0167-5273(11)00294-4 [pii]
AID - 10.1016/j.ijcard.2011.03.026 [doi]
PST - ppublish
SO  - Int J Cardiol. 2012 Sep 20;160(1):36-40. doi: 10.1016/j.ijcard.2011.03.026. Epub 
      2011 Apr 3.

PMID- 23633335
OWN - NLM
STAT- MEDLINE
DCOM- 20131105
LR  - 20200511
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 4
DP  - 2013 Apr 30
TI  - Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
PG  - CD006503
LID - 10.1002/14651858.CD006503.pub3 [doi]
AB  - BACKGROUND: Polycythaemia vera and essential thrombocythaemia are chronic 
      Philadelphia-negative myeloproliferative neoplasms that increase the risk of 
      arterial and venous thrombosis, as well as bleeding. In addition to the different 
      therapeutic strategies available, an antiplatelet drug is often used to reduce 
      thrombotic risk. OBJECTIVES: To quantify the benefit and harm of antiplatelet 
      drugs for long-term primary and secondary prophylaxis of arterial and venous 
      thrombotic events in patients with polycythaemia vera or essential 
      thrombocythaemia. SEARCH METHODS: We searched the Cochrane Central Register of 
      Controlled Trials (CENTRAL), The Cochrane Library (Issue 1 2012), MEDLINE (1966 
      to 2012), and EMBASE (1980 to 2012), as well as online registers of ongoing 
      trials and conference proceedings. The date of the last search was October 2012. 
      SELECTION CRITERIA: We included all randomised controlled trials (RCTs) comparing 
      long-term (>6 months) use of an antiplatelet drug versus placebo or no treatment 
      in participants with polycythaemia vera or essential thrombocythaemia, as 
      diagnosed by established international criteria, with data for at least one of 
      the selected outcomes. DATA COLLECTION AND ANALYSIS: Using a pre-defined 
      extraction form, two review authors independently screened results, extracted 
      data, and assessed quality. We planned to analyse the following outcomes: 
      mortality from arterial and venous thrombotic events (primary efficacy outcome), 
      mortality from bleeding episodes (primary safety outcome), fatal and non-fatal 
      arterial thrombotic events, fatal and non-fatal venous thrombotic events, 
      micro-circulation events, transient neurological and ocular manifestations, major 
      and minor bleeding episodes, and all-cause mortality and any adverse events. We 
      based quantitative analysis of outcome data on an intention-to-treat principle. 
      We used the pooled odds ratio (OR) with 95% confidence interval (CI) with a 
      fixed-effect model (Mantel-Haenszel) to estimate the overall treatment effect. 
      MAIN RESULTS: We identified no new studies from the updated searches. We included 
      in this review two RCTs for a total of 630 participants. Both RCTs included 
      participants with an established diagnosis of polycythaemia vera and with no 
      clear indication or contraindication to aspirin therapy. We judged both studies 
      to be of moderate quality. Published data from both studies were insufficient for 
      a time-to-event data analysis and for some of the primary and secondary outcomes 
      that we planned. The use of low-dose aspirin, compared with placebo, was 
      associated with a lower risk of fatal thrombotic events (although this benefit 
      was not statistically significant (OR 0.20, 95% CI 0.03 to 1.14; P = 0.07). No 
      data on mortality from bleeding episodes were available. A non-significant 
      benefit of aspirin was shown for all-cause mortality (OR 0.46, 95% CI 0.21 to 
      1.01; P = 0.05). No increase in the risk of major bleeding was reported in 
      participants taking aspirin compared with those given placebo (OR 0.99, 95% CI 
      0.23 to 4.36; P = 0.99), and a non-significant increase with aspirin treatment 
      was shown for minor bleeding (OR 1.85, 95% CI 0.90 to 3.79; P = 0.09). No 
      published studies have reported findings in participants with essential 
      thrombocythaemia or in the study of other antiplatelet drugs. AUTHORS' 
      CONCLUSIONS: For patients with polycythaemia vera who have no clear indication or 
      contraindication to aspirin therapy, available evidence suggests that the use of 
      low-dose aspirin, when compared with no treatment, is associated with a 
      statistically non-significant reduction in the risk of fatal thrombotic events 
      and all-cause mortality, without an increased risk of major bleeding.
FAU - Squizzato, Alessandro
AU  - Squizzato A
AD  - Research Center on Thromboembolic Disorders and Antithrombotic Therapies, 
      Department of Clinical and ExperimentalMedicine,School of Medicine, University of 
      Insubria, Varese, Italy. alexsquizzo@libero.it
FAU - Romualdi, Erica
AU  - Romualdi E
FAU - Passamonti, Francesco
AU  - Passamonti F
FAU - Middeldorp, Saskia
AU  - Middeldorp S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20130430
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - Cochrane Database Syst Rev. 2008;(2):CD006503. PMID: 18425953
MH  - Anticoagulants/administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Polycythemia Vera/*drug therapy/mortality
MH  - Randomized Controlled Trials as Topic
MH  - Thrombocythemia, Essential/*drug therapy/mortality
MH  - Thrombosis/*prevention & control
EDAT- 2013/05/02 06:00
MHDA- 2013/11/06 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/05/02 06:00 [entrez]
PHST- 2013/05/02 06:00 [pubmed]
PHST- 2013/11/06 06:00 [medline]
AID - 10.1002/14651858.CD006503.pub3 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006503. doi: 
      10.1002/14651858.CD006503.pub3.

PMID- 6997792
OWN - NLM
STAT- MEDLINE
DCOM- 19801120
LR  - 20190712
IS  - 0030-4220 (Print)
IS  - 0030-4220 (Linking)
VI  - 50
IP  - 3
DP  - 1980 Sep
TI  - Control of pain resulting from endodontic therapy: a double-blind, 
      placebo-controlled study.
PG  - 257-63
AB  - The efficacy of mefenamic acid, aspirin, and a placebo for control of 
      postendodontic pain was compared in a double-blind, randomized study of 150 
      patients. Medication was begun immediately prior to the endodontic therapy and 
      continued for a total of eight doses. The results were analyzed in terms of the 
      patients' assessments of postendodontic pain, the need for additional analgesic 
      medication, and the patients' and investigator's evaluations of drug efficacy. 
      The results indicate that mefenamic acid was well tolerated. Mefenamic acid was 
      equal to, or exceeded, aspirin in ability to control postendodontic pain in every 
      comparison made. The converse was never true. Mefenamic acid was statistically 
      superior to placebo in every comparison made. Aspirin was not consistently 
      superior to the placebo. Under the conditions of this trial, it can be stated 
      that, for control of pain following simple endodontic therapy, mefenamic acid 
      rather than aspirin is the drug of choice.
FAU - Rowe, N H
AU  - Rowe NH
FAU - Shekter, M A
AU  - Shekter MA
FAU - Turner, J L
AU  - Turner JL
FAU - Spencer, J
AU  - Spencer J
FAU - Dowson, J
AU  - Dowson J
FAU - Petrick, T J
AU  - Petrick TJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Oral Surg Oral Med Oral Pathol
JT  - Oral surgery, oral medicine, and oral pathology
JID - 0376406
RN  - 0 (Placebos)
RN  - 367589PJ2C (Mefenamic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Mefenamic Acid/*therapeutic use
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Placebos
MH  - Root Canal Therapy/*adverse effects
EDAT- 1980/09/01 00:00
MHDA- 1980/09/01 00:01
CRDT- 1980/09/01 00:00
PHST- 1980/09/01 00:00 [pubmed]
PHST- 1980/09/01 00:01 [medline]
PHST- 1980/09/01 00:00 [entrez]
AID - 10.1016/0030-4220(80)90381-3 [doi]
PST - ppublish
SO  - Oral Surg Oral Med Oral Pathol. 1980 Sep;50(3):257-63. doi: 
      10.1016/0030-4220(80)90381-3.

PMID- 21144578
OWN - NLM
STAT- MEDLINE
DCOM- 20110111
LR  - 20220408
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 377
IP  - 9759
DP  - 2011 Jan 1
TI  - Effect of daily aspirin on long-term risk of death due to cancer: analysis of 
      individual patient data from randomised trials.
PG  - 31-41
LID - 10.1016/S0140-6736(10)62110-1 [doi]
AB  - BACKGROUND: Treatment with daily aspirin for 5 years or longer reduces subsequent 
      risk of colorectal cancer. Several lines of evidence suggest that aspirin might 
      also reduce risk of other cancers, particularly of the gastrointestinal tract, 
      but proof in man is lacking. We studied deaths due to cancer during and after 
      randomised trials of daily aspirin versus control done originally for prevention 
      of vascular events. METHODS: We used individual patient data from all randomised 
      trials of daily aspirin versus no aspirin with mean duration of scheduled trial 
      treatment of 4 years or longer to determine the effect of allocation to aspirin 
      on risk of cancer death in relation to scheduled duration of trial treatment for 
      gastrointestinal and non-gastrointestinal cancers. In three large UK trials, 
      long-term post-trial follow-up of individual patients was obtained from death 
      certificates and cancer registries. RESULTS: In eight eligible trials (25 570 
      patients, 674 cancer deaths), allocation to aspirin reduced death due to cancer 
      (pooled odds ratio [OR] 0·79, 95% CI 0·68-0·92, p=0·003). On analysis of 
      individual patient data, which were available from seven trials (23 535 patients, 
      657 cancer deaths), benefit was apparent only after 5 years' follow-up (all 
      cancers, hazard ratio [HR] 0·66, 0·50-0·87; gastrointestinal cancers, 0·46, 
      0·27-0·77; both p=0·003). The 20-year risk of cancer death (1634 deaths in 12 659 
      patients in three trials) remained lower in the aspirin groups than in the 
      control groups (all solid cancers, HR 0·80, 0·72-0·88, p<0·0001; gastrointestinal 
      cancers, 0·65, 0·54-0·78, p<0·0001), and benefit increased (interaction p=0·01) 
      with scheduled duration of trial treatment (≥7·5 years: all solid cancers, 0·69, 
      0·54-0·88, p=0·003; gastrointestinal cancers, 0·41, 0·26-0·66, p=0·0001). The 
      latent period before an effect on deaths was about 5 years for oesophageal, 
      pancreatic, brain, and lung cancer, but was more delayed for stomach, colorectal, 
      and prostate cancer. For lung and oesophageal cancer, benefit was confined to 
      adenocarcinomas, and the overall effect on 20-year risk of cancer death was 
      greatest for adenocarcinomas (HR 0·66, 0·56-0·77, p<0·0001). Benefit was 
      unrelated to aspirin dose (75 mg upwards), sex, or smoking, but increased with 
      age-the absolute reduction in 20-year risk of cancer death reaching 7·08% 
      (2·42-11·74) at age 65 years and older. INTERPRETATION: Daily aspirin reduced 
      deaths due to several common cancers during and after the trials. Benefit 
      increased with duration of treatment and was consistent across the different 
      study populations. These findings have implications for guidelines on use of 
      aspirin and for understanding of carcinogenesis and its susceptibility to drug 
      intervention. FUNDING: None.
CI  - Copyright Â© 2011 Elsevier Ltd. All rights reserved.
FAU - Rothwell, Peter M
AU  - Rothwell PM
AD  - Stroke Prevention Research Unit, Department of Clinical Neurology, University of 
      Oxford, Oxford, UK. peter.rothwell@clneuro.ox.ac.uk
FAU - Fowkes, F Gerald R
AU  - Fowkes FG
FAU - Belch, Jill F F
AU  - Belch JF
FAU - Ogawa, Hisao
AU  - Ogawa H
FAU - Warlow, Charles P
AU  - Warlow CP
FAU - Meade, Tom W
AU  - Meade TW
LA  - eng
GR  - G0701113/MRC_/Medical Research Council/United Kingdom
GR  - G9534799/MRC_/Medical Research Council/United Kingdom
GR  - RP-PG-0606-1146/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20101206
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet. 2011 Jan 1;377(9759):3-4. PMID: 21195237
CIN - Ann Intern Med. 2011 Mar 15;154(6):JC3-2. PMID: 21403065
CIN - Evid Based Nurs. 2011 Jul;14(3):71. PMID: 21555322
CIN - Lancet. 2011 May 14;377(9778):1649-50; author reply 1651-2. PMID: 21571137
CIN - Lancet. 2011 May 14;377(9778):1649; author reply 1651-2. PMID: 21571138
CIN - Lancet. 2011 May 14;377(9778):1650; author reply 1651-2. PMID: 21571139
CIN - Lancet. 2011 May 14;377(9778):1650-1; author reply 1651-2. PMID: 21571140
CIN - Lancet. 2011 May 14;377(9778):1651; author reply 1651-2. PMID: 21571142
CIN - Can J Surg. 2013 Dec;56(6):427-9. PMID: 24284152
MH  - Aspirin/*administration & dosage
MH  - Cyclooxygenase 2 Inhibitors/*administration & dosage
MH  - Drug Administration Schedule
MH  - Humans
MH  - Neoplasms/*prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Survival Analysis
EDAT- 2010/12/15 06:00
MHDA- 2011/01/12 06:00
CRDT- 2010/12/15 06:00
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/01/12 06:00 [medline]
AID - S0140-6736(10)62110-1 [pii]
AID - 10.1016/S0140-6736(10)62110-1 [doi]
PST - ppublish
SO  - Lancet. 2011 Jan 1;377(9759):31-41. doi: 10.1016/S0140-6736(10)62110-1. Epub 2010 
      Dec 6.

PMID- 23198725
OWN - NLM
STAT- MEDLINE
DCOM- 20130702
LR  - 20131121
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 43
IP  - 1
DP  - 2013 Jan
TI  - Vascular and platelet responses to aspirin in patients with coronary artery 
      disease.
PG  - 91-9
LID - 10.1111/eci.12021 [doi]
AB  - BACKGROUND: Variability in the response to aspirin (sometimes known as aspirin 
      resistance) in modulating platelet activity is a potentially important clinical 
      issue in coronary artery disease (CAD), but may be also be important in other 
      areas of pathophysiology. MATERIALS AND METHODS: Testing the hypothesis of a 
      relationship between aspirin resistance and vascular function, inflammation and 
      coagulation, we recruited 175 stable CAD outpatients taking 75 mg aspirin daily. 
      Indices were compared to 58 controls not taking aspirin. Platelet activity was 
      assessed by light transmission aggregometry (LTA) to 0·5 mg/mL arachidonic acid 
      (AA), plasma markers soluble P selectin and thromboxane (ELISA), and resting and 
      AA stimulated membrane P selectin and PAC-1 expression (flow cytometry). Vascular 
      function was assessed by arterial stiffness (Sphygmocor system), von Willebrand 
      factor and soluble E selectin (ELISA), inflammation by high sensitivity CRP and 
      interleukin-6, and coagulation by tissue factor and fibrin d-dimers levels (all 
      immunoassay). RESULTS: The 5-min LTA response AA was superior to flow cytometry 
      in discriminating the response of platelets to aspirin. Using the cut-off of 20% 
      LTA response to AA, 32·6% of patients were aspirin resistant. The latter had 
      higher soluble P selectin (P = 0·03), CRP (P = 0·029) and fibrin d-dimers 
      (P = 0·01) compared to those who were aspirin sensitive. There was no 
      relationship between aspirin response status and any vascular index. CONCLUSION: 
      We conclude that LTA is a more sensitive marker of aspirin resistance than is 
      flow cytometry for P-selectin and PCA-1, and that aspirin response has no 
      influence on vascular function.
CI  - © 2012 The Authors. European Journal of Clinical Investigation © 2012 Stichting 
      European Society for Clinical Investigation Journal Foundation.
FAU - Blann, Andrew D
AU  - Blann AD
AD  - Centre for Cardiovascular Sciences, University of Birmingham, Birmingham, UK. 
      a.blann@bham.ac.uk
FAU - Kuzniatsova, Nadya
AU  - Kuzniatsova N
FAU - Lip, Gregory Y H
AU  - Lip GY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121202
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Interleukin-6)
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Analysis of Variance
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/metabolism
MH  - Case-Control Studies
MH  - Coronary Artery Disease/*blood/drug therapy
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Flow Cytometry/methods
MH  - Humans
MH  - Interleukin-6/metabolism
MH  - Male
MH  - Middle Aged
MH  - P-Selectin/*blood
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Platelet Function Tests/methods
MH  - Vascular Stiffness/*drug effects
EDAT- 2012/12/04 06:00
MHDA- 2013/07/03 06:00
CRDT- 2012/12/04 06:00
PHST- 2012/09/06 00:00 [received]
PHST- 2012/10/21 00:00 [accepted]
PHST- 2012/12/04 06:00 [entrez]
PHST- 2012/12/04 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - 10.1111/eci.12021 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2013 Jan;43(1):91-9. doi: 10.1111/eci.12021. Epub 2012 Dec 2.

PMID- 19658002
OWN - NLM
STAT- MEDLINE
DCOM- 20100617
LR  - 20191210
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 20
IP  - 6
DP  - 2009 Sep
TI  - Evaluation of aspirin response by Multiplate whole blood aggregometry and light 
      transmission aggregometry.
PG  - 415-20
LID - 10.1080/09537100903100643 [doi]
AB  - Several studies indicate that a biochemically reduced response to aspirin 
      increases the risk of cardiovascular events. This study was designed to 
      investigate the performance of Multiplate whole blood aggregometry as regards 
      assessment of platelet function prior to and after aspirin treatment, and to 
      compare it with light transmission aggregometry (LTA). We included 21 healthy 
      individuals and 43 patients with documented coronary artery disease (CAD). 
      Platelet aggregation induced by arachidonic acid 0.5 mM was measured in duplicate 
      by Multiplate aggregometry and LTA in healthy individuals before aspirin 
      treatment and in all participants on four consecutive days during treatment with 
      75 mg aspirin daily. Optimal compliance was confirmed by complete suppression of 
      serum thromboxane B(2) in all participants. Employing the Multiplate, the 
      coefficient of variation (CV) was lower at baseline (CV = 8%) than during aspirin 
      treatment in both healthy individuals (CV = 46%) and patients (CV = 46%). During 
      aspirin treatment, the repeatability of LTA was superior to Multiplate 
      measurements. However, the Multiplate was superior to LTA as regards the ability 
      to discriminate platelet response before and after aspirin treatment. In 
      conclusion, the repeatability of Multiplate aggregometry was good before aspirin 
      treatment, whereas the CV was quite high during aspirin treatment in both healthy 
      individuals and patients. However, the Multiplate device was fully capable of 
      assessing platelet function prior to and after treatment with aspirin. Clinical 
      studies are needed to investigate whether a high platelet aggregation level 
      measured by Multiplate whole blood aggregometry during aspirin treatment is 
      associated with a poor clinical outcome.
FAU - Pedersen, Susanne B
AU  - Pedersen SB
AD  - Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.
FAU - Grove, Erik L
AU  - Grove EL
FAU - Nielsen, Helle L
AU  - Nielsen HL
FAU - Mortensen, Jette
AU  - Mortensen J
FAU - Kristensen, Steen D
AU  - Kristensen SD
FAU - Hvas, Anne-Mette
AU  - Hvas AM
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Platelets/*drug effects/physiology
MH  - Coronary Artery Disease/blood
MH  - Electric Impedance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Platelet Count
MH  - Platelet Function Tests/*methods
MH  - Young Adult
EDAT- 2009/08/07 09:00
MHDA- 2010/06/18 06:00
CRDT- 2009/08/07 09:00
PHST- 2009/08/07 09:00 [entrez]
PHST- 2009/08/07 09:00 [pubmed]
PHST- 2010/06/18 06:00 [medline]
AID - 913563206 [pii]
AID - 10.1080/09537100903100643 [doi]
PST - ppublish
SO  - Platelets. 2009 Sep;20(6):415-20. doi: 10.1080/09537100903100643.

PMID- 31063574
OWN - NLM
STAT- MEDLINE
DCOM- 20190528
LR  - 20200225
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 321
IP  - 17
DP  - 2019 May 7
TI  - Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test 
      Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical 
      Trial.
PG  - 1686-1692
LID - 10.1001/jama.2019.4755 [doi]
AB  - IMPORTANCE: Fecal immunochemical tests for hemoglobin are widely used for 
      colorectal cancer (CRC) screening. Observational studies suggested that 
      sensitivity of fecal immunochemical tests for detecting advanced neoplasms could 
      be increased by acetylsalicylic acid (aspirin), especially among men. OBJECTIVE: 
      To evaluate the potential to increase sensitivity of fecal immunochemical tests 
      by administering a single 300-mg oral aspirin dose 2 days before stool sampling. 
      DESIGN, SETTING, AND PARTICIPANTS: A randomized, placebo-controlled, double-blind 
      trial was conducted in 14 gastroenterology practices and 4 hospitals in Germany, 
      and included 2422 men and women aged 40 to 80 years scheduled for colonoscopy, 
      with no recent use of aspirin or other drugs with antithrombotic effects 
      (enrollment from June 2013 to November 2016, and final follow-up January 27, 
      2017). INTERVENTIONS: Administration of a single tablet containing 300 mg of 
      aspirin (n = 1208) or placebo (n = 1214) 2 days before fecal sampling for fecal 
      immunochemical test. MAIN OUTCOME AND MEASURES: The primary outcome was 
      sensitivity of a quantitative fecal immunochemical test at 2 predefined cutoffs 
      (10.2 and 17-μg Hb/g stool) for detecting advanced neoplasms (colorectal cancer 
      or advanced adenoma). RESULTS: Among 2422 randomized patients (mean [SD] age, 
      59.6 [7.9] years; 1219, 50%, men), 2134 were included in the analysis (78% for 
      primary screening colonoscopy, 22% for diagnostic colonoscopy). Advanced 
      neoplasms were identified in 224 participants (10.5%), including 8 participants 
      (0.4%) with CRC and 216 participants (10.1%) with advanced adenoma. Sensitivity 
      was 40.2% in the aspirin group and 30.4% in the placebo group (difference 9.8%, 
      95% CI, -3.1% to 22.2%, P = .14) at cutoff 10.2-μg Hb/g stool and 28.6% in the 
      aspirin and 22.5% in the placebo group (difference 6.0%, 95% CI, -5.7% to 17.5%, 
      P = .32) at cutoff 17-μg Hb/g stool. CONCLUSIONS AND RELEVANCE: Among adults aged 
      40 to 80 years not using aspirin or other antithrombotic medications, 
      administration of a single dose of oral aspirin prior to fecal immunochemical 
      testing, compared with placebo, did not significantly increase test sensitivity 
      for detecting advanced colorectal neoplasms at 2 predefined cutoffs of a 
      quantitative fecal immunochemical test. TRIAL REGISTRATION: Deutsches Register 
      Klinischer Studien Identifier: DRKS00003252; EudraCT Identifier: 
      2011-005603-32/DE.
FAU - Brenner, Hermann
AU  - Brenner H
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research 
      Center (DKFZ), Heidelberg, Germany.
AD  - Division of Preventive Oncology, German Cancer Research Center (DKFZ) and 
      National Center for Tumor Diseases (NCT), Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Calderazzo, Silvia
AU  - Calderazzo S
AD  - Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, 
      Germany.
FAU - Seufferlein, Thomas
AU  - Seufferlein T
AD  - Department of Internal Medicine I, Ulm University, Ulm, Germany.
FAU - Ludwig, Leopold
AU  - Ludwig L
AD  - Practice of Gastroenterology, Dornstadt, Germany.
FAU - Dikopoulos, Nektarios
AU  - Dikopoulos N
AD  - Practice of Gastroenterology, Dornstadt, Germany.
FAU - Mangold, Jörg
AU  - Mangold J
AD  - Practice of Internal Medicine, Ulm, Germany.
FAU - Böck, Wolfgang
AU  - Böck W
AD  - Practice of Internal Medicine, Ulm, Germany.
FAU - Stolz, Thomas
AU  - Stolz T
AD  - Practice of Gastroenterology, Völklingen, Germany.
FAU - Eisenbach, Thomas
AU  - Eisenbach T
AD  - Practice of Gastroenterology, Leverkusen, Germany.
FAU - Block, Thomas
AU  - Block T
AD  - Practice of Gastroenterology, Leverkusen, Germany.
FAU - Kopp-Schneider, Annette
AU  - Kopp-Schneider A
AD  - Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, 
      Germany.
FAU - Czock, David
AU  - Czock D
AD  - Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital 
      Heidelberg, Heidelberg, Germany.
FAU - Tikk, Kaja
AU  - Tikk K
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research 
      Center (DKFZ), Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 2019 Oct;157(4):1158-1159. PMID: 31400365
CIN - Ann Intern Med. 2019 Aug 20;171(4):JC20. PMID: 31426063
MH  - Adenoma/diagnosis
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage
MH  - Colorectal Neoplasms/*diagnosis
MH  - Double-Blind Method
MH  - Early Detection of Cancer/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Occult Blood
MH  - Sensitivity and Specificity
PMC - PMC6506873
COIS- Conflict of Interest Disclosures: Dr Brenner reported receiving grants from the 
      German Federal Ministry of Education and Research, the German Cancer Aid, the 
      European Commission, the US National Institutes of Health, Applied Proteomics, 
      Roche Diagnostics, Volition, and Goodgut during the conduct of the study. Dr 
      Calderazzo reported receiving grants from the German Federal Ministry of 
      Education and Research and Deutsche Forschungsgemeinschaft during the conduct of 
      the study. Dr Seufferlein reported receiving grants and personal fees from 
      Celgene and Sanofi-Genzyme; personal fees from Roche, Bayer, Merck-Serono, and 
      Novartis; and grants from Amgen and Boehringer Ingelheim outside the submitted 
      work. Dr Kopp-Schneider reported receiving grants from the Deutsche 
      Forschungsgemeinschaft and the German Federal Ministry of Education and Research 
      during the conduct of the study. No other disclosures were reported.
EDAT- 2019/05/08 06:00
MHDA- 2019/05/29 06:00
CRDT- 2019/05/08 06:00
PHST- 2019/05/08 06:00 [entrez]
PHST- 2019/05/08 06:00 [pubmed]
PHST- 2019/05/29 06:00 [medline]
AID - 2732573 [pii]
AID - joi190039 [pii]
AID - 10.1001/jama.2019.4755 [doi]
PST - ppublish
SO  - JAMA. 2019 May 7;321(17):1686-1692. doi: 10.1001/jama.2019.4755.

PMID- 3077101
OWN - NLM
STAT- MEDLINE
DCOM- 19891113
LR  - 20131121
IS  - 0196-6383 (Print)
IS  - 0196-6383 (Linking)
VI  - 25
DP  - 1988
TI  - Transient ischaemic attacks: controversies in treatment. A review.
PG  - 33-42
AB  - The methods available to treat transient ischaemic episodes and to prevent stroke 
      are discussed, with particular reference to the use of aspirin.
FAU - Gilligan, B S
AU  - Gilligan BS
AD  - Department of Neurology, Alfred Hospital, Melbourne, Vic.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Clin Exp Neurol
JT  - Clinical and experimental neurology
JID - 7909724
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/complications/*surgery
MH  - Aspirin/therapeutic use
MH  - Carotid Artery Diseases/complications/*surgery
MH  - *Endarterectomy
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy/*etiology
RF  - 23
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Neurol. 1988;25:33-42.

PMID- 10406241
OWN - NLM
STAT- MEDLINE
DCOM- 19990727
LR  - 20131121
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 94
IP  - 7
DP  - 1999 Jul
TI  - Phospholipid association reduces the gastric mucosal toxicity of aspirin in human 
      subjects.
PG  - 1818-22
AB  - OBJECTIVE: In previous studies on rats, we have shown that aspirin (ASA)-induced 
      injury to the gastric mucosa is markedly reduced or completely abolished if ASA 
      is chemically associated with the phospholipid, phosphatidylcholine (PC). We have 
      also shown that the protective effect of PC does not influence the ability of ASA 
      to inhibit mucosal cyclooxygenase (COX) activity in the stomach and other 
      tissues. We therefore sought to assess the effect of PC-associated ASA (ASA/PC) 
      on the gastric mucosa of normal volunteers and to compare the results with the 
      use of ASA alone. METHODS: Sixteen normal healthy subjects were administered ASA 
      or ASA/PC in a randomized, double-blind, crossover study. The subjects received 
      ASA in a dose of 650 mg three times a day for 3 days or an equivalent dose of ASA 
      chemically associated with PC. Endoscopy was performed at baseline and again on 
      the morning of day 4, after the subjects had taken the final dose of the test 
      drug. On both occasions, antral biopsy specimens were obtained for the assessment 
      of mucosal COX activity and prostaglandin concentration. RESULTS: The number 
      (mean +/- SD) of gastric erosions seen with the ASA/PC formulation was 
      significantly less than when ASA was used alone (8.7 +/- 10.7 vs 2.9 +/- 4.3; p < 
      0.025). A similar trend was seen in the duodenum but the difference was 
      statistically not significant. The antral mucosal COX activity, as well as the 
      level of prostaglandin 6-keto PGF1alpha, were reduced significantly (80-88%) and 
      to a similar extent by both ASA and ASA/PC. CONCLUSIONS: The present study shows 
      that acute aspirin-induced damage to the gastric mucosa can be reduced by 
      chemically associating ASA with PC. The mechanism of mucosal protection provided 
      by this compound is not related to any alteration in the ability of ASA to 
      inhibit mucosal COX activity. We believe this protection is attributable to the 
      maintenance of the defensive hydrophobic barrier of the gastric mucosa.
FAU - Anand, B S
AU  - Anand BS
AD  - Department of Medicine, Baylor College of Medicine and Houston VA Medical Center, 
      Texas, USA.
FAU - Romero, J J
AU  - Romero JJ
FAU - Sanduja, S K
AU  - Sanduja SK
FAU - Lichtenberger, L M
AU  - Lichtenberger LM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Phosphatidylcholines)
RN  - 0 (Suspensions)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/metabolism
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*toxicity
MH  - Aspirin/administration & dosage/*toxicity
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Gastric Mucosa/*drug effects/metabolism
MH  - Humans
MH  - Male
MH  - Phosphatidylcholines/*administration & dosage
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Suspensions
EDAT- 1999/07/16 00:00
MHDA- 1999/07/16 00:01
CRDT- 1999/07/16 00:00
PHST- 1999/07/16 00:00 [pubmed]
PHST- 1999/07/16 00:01 [medline]
PHST- 1999/07/16 00:00 [entrez]
AID - S0002927099002671 [pii]
AID - 10.1111/j.1572-0241.1999.01211.x [doi]
PST - ppublish
SO  - Am J Gastroenterol. 1999 Jul;94(7):1818-22. doi: 
      10.1111/j.1572-0241.1999.01211.x.

PMID- 22294277
OWN - NLM
STAT- MEDLINE
DCOM- 20121204
LR  - 20211021
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 33
IP  - 3
DP  - 2012 Apr
TI  - Time-dependent changes in non-COX-1-dependent platelet function with daily 
      aspirin therapy.
PG  - 246-57
LID - 10.1007/s11239-012-0683-0 [doi]
AB  - To develop an integrated metric of non-COX-1-dependent platelet function (NCDPF) 
      to measure the temporal response to aspirin in healthy volunteers and diabetics. 
      NCDPF on aspirin demonstrates wide variability, despite suppression of COX-1. 
      Although a variety of NCDPF assays are available, no standard exists and their 
      reproducibility is not established. We administered 325 mg/day aspirin to two 
      cohorts of volunteers (HV1, n = 52, and HV2, n = 96) and diabetics (DM, n = 74) 
      and measured NCDPF using epinephrine, collagen, and ADP aggregometry and PFA100 
      (collagen/epi) before (Pre), after one dose (Post), and after several weeks 
      (Final). COX-1 activity was assessed with arachidonic acid aggregometry (AAA). 
      The primary outcome of the study, the platelet function score (PFS), was derived 
      from a principal components analysis of NCDPF measures. The PFS strongly 
      correlated with each measure of NCDPF in each cohort. After 2 or 4 weeks of daily 
      aspirin the Final PFS strongly correlated (r > 0.7, P < 0.0001) and was higher (P 
      < 0.01) than the Post PFS. The magnitude and direction of the change in PFS 
      (Final–Post) in an individual subject was moderately inversely proportional to 
      the Post PFS in HV1 (r = -0.45), HV2 (r = -0.54), DM (r = -0.68), P < 0.0001 for 
      all. AAA remained suppressed during aspirin therapy. The PFS summarizes multiple 
      measures of NCDPF. Despite suppression of COX-1 activity, NCDPF during aspirin 
      therapy is predictably dynamic: those with heightened NCDPF continue to decline 
      whereas those with low/normal NCDPF return to pre-aspirin levels over time.
FAU - Voora, Deepak
AU  - Voora D
AD  - Institute for Genome Sciences and Policy, Duke University, 905 S. Lasalle Dr., 
      DUMC Box 3445, Durham, NC 27710, USA. deepak.voora@duke.edu
FAU - Ortel, Thomas L
AU  - Ortel TL
FAU - Lucas, Joseph E
AU  - Lucas JE
FAU - Chi, Jen-Tsan
AU  - Chi JT
FAU - Becker, Richard C
AU  - Becker RC
FAU - Ginsburg, Geoffrey S
AU  - Ginsburg GS
LA  - eng
GR  - U01 DD000014/DD/NCBDD CDC HHS/United States
GR  - 5UL1RR024128/RR/NCRR NIH HHS/United States
GR  - T32 HL007101/HL/NHLBI NIH HHS/United States
GR  - RC1 GM091083-02/GM/NIGMS NIH HHS/United States
GR  - 5RC1GM091083/GM/NIGMS NIH HHS/United States
GR  - 5U01DD000014-06/DD/NCBDD CDC HHS/United States
GR  - UL1 RR024128/RR/NCRR NIH HHS/United States
GR  - RC1 GM091083/GM/NIGMS NIH HHS/United States
GR  - 5T32HL007101/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Blood Platelets/*drug effects/*physiology
MH  - Cohort Studies
MH  - *Cyclooxygenase 1
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Function Tests/methods
MH  - Time Factors
MH  - Young Adult
PMC - PMC3337886
MID - NIHMS365582
EDAT- 2012/02/02 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/02/02 06:00
PHST- 2012/02/02 06:00 [entrez]
PHST- 2012/02/02 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.1007/s11239-012-0683-0 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2012 Apr;33(3):246-57. doi: 10.1007/s11239-012-0683-0.

PMID- 18848103
OWN - NLM
STAT- MEDLINE
DCOM- 20081106
LR  - 20220318
IS  - 1531-5053 (Electronic)
IS  - 0278-2391 (Linking)
VI  - 66
IP  - 10
DP  - 2008 Oct
TI  - Exodontia and antiplatelet therapy.
PG  - 2063-6
LID - 10.1016/j.joms.2008.06.027 [doi]
AB  - PURPOSE: The fear of excessive bleeding often prompts the physician to stop 
      long-term, low-dose antiplatelet therapy before any surgical procedure. This may 
      put the patient at risk of an adverse thromboembolic event. We undertook an 
      assessment of the incidence of prolonged postoperative bleeding after dental 
      extractions among patients on uninterrupted antiplatelet therapy, and evaluated 
      the need to stop such medications before dental extractions. PATIENTS AND 
      METHODS: Eighty-two patients requiring dental extractions were included in this 
      study, of whom 57 were on antiplatelet therapy (aspirin). Patients were divided 
      into 3 groups. Group 1 consisted of patients in whom antiplatelet therapy was 
      interrupted (n = 25), group 2 consisted of those continuing their medication (n = 
      32), and group 3 comprised healthy patients not on antiplatelet therapy (n = 25). 
      Preoperative bleeding time and clotting time were determined in all patients. The 
      surgical procedure involved single or multiple teeth extractions under local 
      anesthesia with a vasoconstrictor. All patient groups were similar regarding age, 
      gender distribution, dosage of antiplatelet drug, and medical condition for which 
      the drug was prescribed. Events of single or multiple teeth extractions were also 
      comparable among the 3 groups. Pressure packing was performed in all cases as in 
      routine dental extractions. One-way analysis of variance was performed to 
      determine the significance of prolonged bleeding among groups. RESULTS: The mean 
      bleeding times in groups 1, 2, and 3 were 3 minutes, 2 minutes and 45 seconds, 
      and 1 minute and 49 seconds, respectively. The mean clotting times in groups 1, 
      2, and 3 were 5 minutes and 4 seconds, 4 minutes and 52 seconds, and 3 minutes 
      and 42 seconds, respectively. No patient in any group had any episode of 
      prolonged or significant bleeding from the extraction sites. Local hemostasis had 
      been satisfactorily obtained in all cases with the use of a pressure pack for 30 
      minutes. CONCLUSIONS: Routine dental extractions can be safely performed in 
      patients on long-term antiplatelet medication, with no interruption or alteration 
      of their medication. Such patients do not have an increased risk of prolonged or 
      excessive postoperative bleeding.
FAU - Krishnan, Balasubramanian
AU  - Krishnan B
AD  - Department of Oral and Maxillofacial Surgery, Mahatma Gandhi Postgraduate 
      Institute of Dental Sciences, Indira Nagar, Pondicherry, India.
FAU - Shenoy, Nithin A
AU  - Shenoy NA
FAU - Alexander, Mohan
AU  - Alexander M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Oral Maxillofac Surg
JT  - Journal of oral and maxillofacial surgery : official journal of the American 
      Association of Oral and Maxillofacial Surgeons
JID - 8206428
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage
MH  - Bleeding Time
MH  - *Dental Care for Chronically Ill
MH  - *Heart Diseases
MH  - Hemostatic Techniques
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Postoperative Hemorrhage/*prevention & control
MH  - Pressure
MH  - Tooth Extraction/*methods
EDAT- 2008/10/14 09:00
MHDA- 2008/11/07 09:00
CRDT- 2008/10/14 09:00
PHST- 2007/08/23 00:00 [received]
PHST- 2008/03/05 00:00 [revised]
PHST- 2008/06/16 00:00 [accepted]
PHST- 2008/10/14 09:00 [pubmed]
PHST- 2008/11/07 09:00 [medline]
PHST- 2008/10/14 09:00 [entrez]
AID - S0278-2391(08)01084-7 [pii]
AID - 10.1016/j.joms.2008.06.027 [doi]
PST - ppublish
SO  - J Oral Maxillofac Surg. 2008 Oct;66(10):2063-6. doi: 10.1016/j.joms.2008.06.027.

PMID- 14534763
OWN - NLM
STAT- MEDLINE
DCOM- 20040422
LR  - 20181113
IS  - 0172-0643 (Print)
IS  - 0172-0643 (Linking)
VI  - 25
IP  - 1
DP  - 2004 Jan-Feb
TI  - Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of 
      illness.
PG  - 31-4
AB  - We evaluated the efficacy of treating Kawasaki disease earlier than Day 5 of 
      illness with a standard dose of immunoglobulin and aspirin. We performed a 
      case-control study of patients with Kawasaki disease admitted to Princess 
      Margaret Hospital from 1994 to 1999. Patients with pretreatment coronary aneurysm 
      or those treated after day 10 of illness were excluded. All patients received 
      immunoglobulin (2 g/kg) and aspirin (80-100 mg/kg/day) until fever subsided for 
      48 hours. Immunoglobulin retreatment was given for persistent fever 48 hours 
      after the first dose of immunoglobulin or recrudescent fever. The case group 
      consisted of 15 patients who received treatment earlier than day 5 of illness, 
      and the control group consisted of 66 patients who were treated on or after day 
      5. Patients' sex, age, duration of posttreatment fever, need for additional 
      immunoglobulin, and coronary artery status were noted. Treatment efficacy was 
      assessed by the duration of posttreatment fever and the prevalence of coronary 
      artery aneurysms. Eighty-one patients were included in this study. There were 15 
      patients in the case group and 66 in the control group. No significant difference 
      was noted in age and sex between the case and control groups. Thirty-three 
      percent (5/15) and 8% (5/66) of the case and control groups, respectively, had 
      persistent/ recrudescent fever 48 hours after the first dose of immunoglobulin 
      that required retreatment ( p = 0.017). Thirteen percent (2/15) and 5% (3/66) of 
      the case and control groups, respectively, had coronary aneurysms ( p = 0.158). 
      Treatment of Kawasaki disease before day 5 of illness was associated with 
      persistent/recrudescent fever that required retreatment. However, there was no 
      significant increase in the prevalence of coronary aneurysm if retreatment was 
      given.
FAU - Fong, N C
AU  - Fong NC
AD  - Department of Paediatrics, Princess Margaret Hospital, Lai King Hill Road, 
      Kowloon, Hong Kong SAR, The People's Republic of China. naichungf@hotmail.com
FAU - Hui, Y W
AU  - Hui YW
FAU - Li, C K
AU  - Li CK
FAU - Chiu, M C
AU  - Chiu MC
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20031013
PL  - United States
TA  - Pediatr Cardiol
JT  - Pediatric cardiology
JID - 8003849
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - *Immunization, Passive
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*drug therapy
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2003/10/10 05:00
MHDA- 2004/04/23 05:00
CRDT- 2003/10/10 05:00
PHST- 2003/10/10 05:00 [pubmed]
PHST- 2004/04/23 05:00 [medline]
PHST- 2003/10/10 05:00 [entrez]
AID - 10.1007/s00246-003-0558-4 [doi]
PST - ppublish
SO  - Pediatr Cardiol. 2004 Jan-Feb;25(1):31-4. doi: 10.1007/s00246-003-0558-4. Epub 
      2003 Oct 13.

PMID- 31327202
OWN - NLM
STAT- MEDLINE
DCOM- 20190910
LR  - 20190910
IS  - 2096-7993 (Print)
IS  - 2096-7993 (Linking)
VI  - 33
IP  - 7
DP  - 2019 Jul
TI  - [Clinical study on asthma and aspirin asthma affecting chronic rhinosinusitis].
PG  - 635-638
LID - 10.13201/j.issn.1001-1781.2019.07.014 [doi]
AB  - Objective:The aim of this study is to observe the effects of asthma and aspirin 
      asthma on chronic rhinosinusitis and to explore the corresponding clinical value. 
      Method: Eighty-six patients with CRS and asthma who were treated in the 
      outpatient clinic during March 2015 to January 2018 were divided into asthma 
      group(52 cases) and aspirin asthma group(34 cases) according to asthma and 
      aspirin asthma. The clinical symptoms of the two groups were analyzed by 
      symptomatic VAS score, Lund-Mackay score of sinus CT, and Lund-Kennedy score by 
      nasal endoscopy.The scores of the two groups were compared under different lung 
      function. Enzyme-linked immunosorbent assay the levels of inflammatory markers 
      IL-5,IL-17,IFN-γ and TNF-α in the sinus secretions of the two groups were 
      detected.Result:There were no significant differences in age, gender, smoking 
      history, allergy history, surgical history and course of disease between the two 
      groups(P<0.05), suggesting that the data were comparable. The sinus CT results 
      showed that compared with the aspirin asthma group, the asthmatic group had 
      irregular turbinates and a large turbinate,as shown in Figure 1. There were 
      significant differences between the two groups in VAS score,Lund-Mackay score of 
      sinus CT and Lund-Kennedy score by nasal endoscopy.The difference was 
      statistically significant(P<0.05). And the forehead and/or facial pain or pain in 
      the symptomatic VAS score(P<0.05), the Lund-Mackay score of the sinus 
      CT(P<0.05),and intranasal.The difference in the Lund-Kennedy score(P<0.05) was 
      statistically significant.There were significant differences in the distribution 
      of lung function levels between the two groups of patients with mild airway 
      obstructive respiratory dysfunction and pulmonary ventilation obstructive 
      disorder(P<0.05).The average levels of IL-5,IL-17,IFN-γ and TNF-α in the aspirin 
      asthma group were significantly lower than those in the asthma 
      group(P<0.05).Conclusion:Aspirin-induced CRS produces asthma symptoms more 
      severely than traditional asthma symptoms, but the induced local inflammatory 
      response is relatively weak, and the mechanism may be closely related to 
      IL-5,IL-17,IFN-γ and TNF-α levels.
CI  - Copyright© by the Editorial Department of Journal of Clinical Otorhinolaryngology 
      Head and Neck Surgery.
FAU - Li, W L
AU  - Li WL
AD  - Department of Otorhinolaryngology Head and Neck Surgery, General Hospital of 
      Jianghan Oilfield, Qianjiang, 433124, China.
FAU - Ye, C G
AU  - Ye CG
FAU - Hu, H L
AU  - Hu HL
FAU - Zhou, L W
AU  - Zhou LW
LA  - chi
PT  - Journal Article
PL  - China
TA  - Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
JT  - Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical 
      otorhinolaryngology, head, and neck surgery
JID - 101303164
RN  - 0 (Cytokines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced
MH  - Chronic Disease
MH  - Cytokines/analysis
MH  - Endoscopy
MH  - Humans
MH  - Inflammation
MH  - Rhinitis/*physiopathology
MH  - Sinusitis/*physiopathology
OTO - NOTNLM
OT  - aspirin
OT  - asthma
OT  - sinusitis
COIS- The authors of this article and the planning committee members and staff have no 
      relevant financial relationships with commercial interests to disclose.
EDAT- 2019/07/23 06:00
MHDA- 2019/09/11 06:00
CRDT- 2019/07/23 06:00
PHST- 2018/02/14 00:00 [received]
PHST- 2019/07/23 06:00 [entrez]
PHST- 2019/07/23 06:00 [pubmed]
PHST- 2019/09/11 06:00 [medline]
AID - 10.13201/j.issn.1001-1781.2019.07.014 [doi]
PST - ppublish
SO  - Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019 Jul;33(7):635-638. doi: 
      10.13201/j.issn.1001-1781.2019.07.014.

PMID- 12916550
OWN - NLM
STAT- MEDLINE
DCOM- 20030826
LR  - 20131121
IS  - 0038-4348 (Print)
IS  - 0038-4348 (Linking)
VI  - 96
IP  - 4
DP  - 2003 Apr
TI  - The 5 Ps of acute ischemic stroke treatment: parenchyma, pipes, perfusion, 
      penumbra, and prevention of complications.
PG  - 336-42
AB  - Stroke is a treatable disease. Despite the therapeutic nihilism of the past, the 
      advent of thrombolysis has changed the way stroke is approached. Acute ischemic 
      stroke is a challenging and heterogeneous disease. Treatment needs to be based on 
      an understanding of the underlying pathophysiology of ischemia. Interventions are 
      designed to improve neuronal salvage and outcome. The underlying tenets of stroke 
      therapy focus on the brain parenchyma, arterial flow (pipes), perfusion, the 
      ischemic milieu or penumbra, and prevention of complications. This article 
      focuses on the practical issues of ischemic stroke care, with a brief review of 
      supporting literature.
FAU - Felberg, Robert A
AU  - Felberg RA
AD  - Department of Neurology, Ochsner Foundation Clinic and Hospital, New Orleans, LA 
      70121, USA. rfelberg@Ochsner.org
FAU - Naidech, Andrew M
AU  - Naidech AM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - *Stroke/classification/drug therapy/physiopathology
MH  - Thrombolytic Therapy
RF  - 40
EDAT- 2003/08/15 05:00
MHDA- 2003/08/27 05:00
CRDT- 2003/08/15 05:00
PHST- 2003/08/15 05:00 [pubmed]
PHST- 2003/08/27 05:00 [medline]
PHST- 2003/08/15 05:00 [entrez]
AID - 10.1097/01.SMJ.0000063573.56033.A6 [doi]
PST - ppublish
SO  - South Med J. 2003 Apr;96(4):336-42. doi: 10.1097/01.SMJ.0000063573.56033.A6.

PMID- 8361987
OWN - NLM
STAT- MEDLINE
DCOM- 19930927
LR  - 20190914
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 49
IP  - 1
DP  - 1993 Jul
TI  - The effect of regular and enteric-coated aspirin on bleeding time, thromboxane, 
      and prostacyclin.
PG  - 515-20
AB  - We compared the effect of different aspirin schedules, dosages, and formulations 
      on various bleeding time parameters including bleeding time, plasma and total 
      blood volume, and levels of the stable metabolites of thromboxane A2 (TXA2) and 
      prostacyclin (PGI2) (respectively, TXB2 and 6-keto-prostaglandin F1 alpha 
      (6-keto-PGF1 alpha)) to determine the optimal dosage and formulation of aspirin 
      to inhibit TXA2 production while sparing PGI2. In a randomized, parallel study, 
      52 healthy male volunteers (62 independent observations) with no history of 
      bleeding disorders were given 80 mg or 325 mg of regular aspirin, or 325 mg of 
      enteric-coated aspirin to ingest daily (14 pills) or every other day (7 pills) 
      for a continuous 14 day period. Bleeding times were performed on day 1 before 
      aspirin, 6 h after aspirin on day 1, and before aspirin on day 14. Bleeding 
      times, plasma volume, and total volume increased significantly from before 
      aspirin to after 6 h and 14 days (p < 0.0001 for all parameters) for all aspirin 
      formulations. For day 1 before aspirin ingestion to 6 h later, both TX and PGI2 
      (p < 0.008) decreased significantly. 6 h after ingestion of aspirin on day 1 to 
      day 14, both TX and PGI2 levels also significantly decreased (p < 0.0001). There 
      was a highly significant decrease in PGI2 production on every other day aspirin 
      schedules (p = 0.0001) particularly with 80 mg of aspirin, while the decrease in 
      PGI2 production on daily aspirin was not significant (p = 0.10). The most 
      favourable ratio of 6-keto-PGF1 alpha to TXB2 occurred with 80 mg daily.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Gow, J A
AU  - Gow JA
AD  - Manitoba Institute of Cell Biology, Faculty of Medicine, University of Manitoba, 
      Winnipeg.
FAU - Ebbeling, L
AU  - Ebbeling L
FAU - Gerrard, J M
AU  - Gerrard JM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Dosage Forms)
RN  - 0 (Eicosanoids)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/blood
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/pharmacology
MH  - *Bleeding Time
MH  - Dosage Forms
MH  - Eicosanoids/*blood
MH  - Epoprostenol/blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tablets, Enteric-Coated/administration & dosage/pharmacology
MH  - Thromboxane A2/blood
MH  - Thromboxane B2/blood
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
AID - 10.1016/0952-3278(93)90040-4 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 1993 Jul;49(1):515-20. doi: 
      10.1016/0952-3278(93)90040-4.

PMID- 32134406
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201119
IS  - 1972-6481 (Electronic)
IS  - 1827-6806 (Linking)
VI  - 21
IP  - 2 Suppl 1
DP  - 2020 Feb
TI  - [Management of antithrombotic therapy in patients with bleeding after 
      percutaneous coronary intervention].
PG  - 34S-41S
LID - 10.1714/3311.32819 [doi]
AB  - Bleeding is a frequently encountered complication in patients undergoing 
      percutaneous coronary intervention (PCI) treated with a dual antiplatelet therapy 
      regimen with aspirin plus an oral inhibitor of the P2Y12 platelet receptor 
      (clopidogrel, prasugrel, ticagrelor) or with the combination of antiplatelet 
      drugs and an anticoagulant in patients who have a specific indication for chronic 
      anticoagulation therapy such as atrial fibrillation. The management of 
      antithrombotic therapy during post-PCI bleeding is considerably challenging due 
      to the intrinsic difficulty in estimating the balance between the bleeding risk - 
      increased by antiplatelet and/or anticoagulant therapy - and the thrombotic risk 
      associated with the possible discontinuation of these drugs. Currently, there are 
      no data derived from dedicated studies in this setting and therefore the 
      management of antithrombotic therapy in patients who suffer a hemorrhagic 
      complication after PCI is guided by consensus documents that provide suggestions 
      for the different types of bleeding, based on the severity of the latter. In 
      light of the European documents available, this article will discuss the possible 
      management strategies of antithrombotic therapy (antiplatelet and/or 
      anticoagulant) in the different types of bleeding that can occur in patients 
      undergoing PCI.
FAU - Capranzano, Piera
AU  - Capranzano P
AD  - Divisione di Cardiologia, Azienda Ospedaliero-Universitaria "Policlinico-Vittorio 
      Emanuele", Università degli Studi, Catania.
FAU - Francaviglia, Bruno
AU  - Francaviglia B
AD  - Divisione di Cardiologia, Azienda Ospedaliero-Universitaria "Policlinico-Vittorio 
      Emanuele", Università degli Studi, Catania.
FAU - Capodanno, Davide
AU  - Capodanno D
AD  - Divisione di Cardiologia, Azienda Ospedaliero-Universitaria "Policlinico-Vittorio 
      Emanuele", Università degli Studi, Catania.
FAU - Tamburino, Corrado
AU  - Tamburino C
AD  - Divisione di Cardiologia, Azienda Ospedaliero-Universitaria "Policlinico-Vittorio 
      Emanuele", Università degli Studi, Catania.
LA  - ita
PT  - Journal Article
TT  - Gestione della terapia antitrombotica nei pazienti con sanguinamento dopo 
      angioplastica coronarica.
PL  - Italy
TA  - G Ital Cardiol (Rome)
JT  - Giornale italiano di cardiologia (2006)
JID - 101263411
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Atrial Fibrillation/complications/drug therapy
MH  - Dual Anti-Platelet Therapy/adverse effects/methods
MH  - Hemorrhage/chemically induced/*prevention & control
MH  - Humans
MH  - Percutaneous Coronary Intervention/adverse effects/methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Thrombosis/etiology/prevention & control
EDAT- 2020/03/07 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/03/06 06:00
PHST- 2020/03/06 06:00 [entrez]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 10.1714/3311.32819 [doi]
PST - ppublish
SO  - G Ital Cardiol (Rome). 2020 Feb;21(2 Suppl 1):34S-41S. doi: 10.1714/3311.32819.

PMID- 25216111
OWN - NLM
STAT- MEDLINE
DCOM- 20150609
LR  - 20141007
IS  - 1531-7056 (Electronic)
IS  - 0267-1379 (Linking)
VI  - 30
IP  - 6
DP  - 2014 Nov
TI  - Gastrointestinal bleeding in cardiac patients: epidemiology and evolving clinical 
      paradigms.
PG  - 609-14
LID - 10.1097/MOG.0000000000000122 [doi]
AB  - PURPOSE OF REVIEW: Cardiac patients are a fast emerging population vulnerable to 
      gastrointestinal bleeding (GIB) due to their use of antithrombotic medications. 
      This review will quantify the GIB risk of cardiac patients prescribed 
      antithrombotic medications, summarize risk-management strategies and highlight 
      knowledge gaps. RECENT FINDINGS: As the American population ages, it is 
      anticipated that there will be an increased incidence of upper and lower GIB 
      related to age-specific disease, higher burden of comorbidity and increased use 
      of anticoagulants, antiplatelets and aspirin to treat cardiac disease. New 
      evidence has highlighted the significant and clinically relevant GIB risk. The 
      increased use of aggressive antiplatelet and anticoagulant therapies will alter 
      our current understanding of the epidemiology of GIB. SUMMARY: The magnitude of 
      gastrointestinal risk in this vulnerable patient population is still relatively 
      unexplored due to a paucity of literature. This review will highlight changing 
      GIB trends and explore current knowledge regarding GIB risk in cardiac patients. 
      An emphasis on a multidisciplinary approach to the care of these patients will be 
      supported, which involves active patient participation and collaboration between 
      cardiologists and gastroenterologists. Finally, risk-minimization strategies will 
      be suggested and knowledge gaps will be identified.
FAU - Abraham, Neena S
AU  - Abraham NS
AD  - aDivision of Gastroenterology, Department of Medicine, Scottsdale, Arizona 
      bDivision of Healthcare Policy and Research, Department of Health Services 
      Research, Rochester, Minnesota, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Gastroenterol
JT  - Current opinion in gastroenterology
JID - 8506887
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Anticoagulants/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology/prevention & control
MH  - Heart Diseases/*drug therapy/epidemiology
MH  - Hemostasis, Endoscopic
MH  - Humans
MH  - Incidence
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Risk Assessment
MH  - Risk Factors
MH  - United States/epidemiology
EDAT- 2014/09/13 06:00
MHDA- 2015/06/10 06:00
CRDT- 2014/09/13 06:00
PHST- 2014/09/13 06:00 [entrez]
PHST- 2014/09/13 06:00 [pubmed]
PHST- 2015/06/10 06:00 [medline]
AID - 10.1097/MOG.0000000000000122 [doi]
PST - ppublish
SO  - Curr Opin Gastroenterol. 2014 Nov;30(6):609-14. doi: 
      10.1097/MOG.0000000000000122.

PMID- 8044989
OWN - NLM
STAT- MEDLINE
DCOM- 19940830
LR  - 20190722
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 40
IP  - 8
DP  - 1994 Aug
TI  - Mechanism and elimination of aspirin-induced interference in Emit II d.a.u. 
      assays.
PG  - 1512-6
AB  - The presence of salicylates in urine reduces the signal in Emit assays (Syva), 
      potentially yielding false-negative drugs-of-abuse screening results. We 
      demonstrate that the principal urinary metabolite of salicylate, salicyluric acid 
      (SUA; 2-hydroxybenzoylaminoacetic acid), interferes with the measurement of NADH 
      formed in the assay by reducing the molar absorptivity of NADH at 340 nm. Thus, 
      for a given concentration of d.a.u. analyte the change in absorbance over the 
      assay time interval is less in the presence of SUA. With the Emit cocaine assay 
      on the Hitachi 704 analyzer, the rate of absorbance change (delta AR) monitored 
      at 340 nm for a specimen containing approximately 270 micrograms/L 
      benzoylecgonine (BE) was 57 +/- 1.9 mA/min without SUA and 29 +/- 2.7 mA/min with 
      5 g/L SUA (n = 20). In contrast, delta AR determined at 376 nm was 18.6 +/- 0.5 
      mA/min with and 17.9 +/- 0.8 mA/min without 5 g/L SUA (n = 20). Measuring the 
      Emit assay signal at wavelengths where SUA has no absorbance (376 nm) eliminates 
      the interference due to SUA while maintaining the precision of the assay near the 
      cutoff concentration for BE (300 micrograms/L).
FAU - Linder, M W
AU  - Linder MW
AD  - Department of Pathology, University of Louisville School of Medicine, University 
      of Louisville Hospital, KY 40292.
FAU - Valdes, R Jr
AU  - Valdes R Jr
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Hippurates)
RN  - 0U46U6E8UK (NAD)
RN  - 487-54-7 (salicylurate)
RN  - EC 1.1.1.49 (Glucosephosphate Dehydrogenase)
RN  - I5Y540LHVR (Cocaine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*urine
MH  - Cocaine/urine
MH  - Enzyme Multiplied Immunoassay Technique/*statistics & numerical data
MH  - False Negative Reactions
MH  - Glucosephosphate Dehydrogenase/antagonists & inhibitors
MH  - Hippurates/pharmacology/urine
MH  - Hydrogen-Ion Concentration
MH  - NAD/analysis
MH  - Sensitivity and Specificity
MH  - Spectrophotometry
MH  - Substance Abuse Detection/*methods/statistics & numerical data
EDAT- 1994/08/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
PST - ppublish
SO  - Clin Chem. 1994 Aug;40(8):1512-6.

PMID- 8199369
OWN - NLM
STAT- MEDLINE
DCOM- 19940706
LR  - 20191023
IS  - 0268-4705 (Print)
IS  - 0268-4705 (Linking)
VI  - 9
IP  - 1
DP  - 1994 Jan
TI  - Current management of atrial fibrillation.
PG  - 30-9
AB  - A resurgence of interest in atrial fibrillation has led to research in several 
      avenues. Observations on the behavior of the atrium during atrial fibrillation 
      demonstrate that electrical activity is not entirely random and that sinus node 
      activity persists despite surrounding fibrillation. Anticoagulation therapy for 
      chronic atrial fibrillation is now accepted as optimal treatment, but randomized 
      trials have excluded the majority of patients screened and the risk-benefit ratio 
      of therapy in the average patient therefore remains unclear. This is being 
      addressed in comparative trials of warfarin and aspirin and in an analysis of 
      risk factors for stroke derived from a major trial. Assessment of the efficacy of 
      therapy for the control of ventricular rate in atrial fibrillation has 
      underscored the slow action of digoxin and raised the issue of suboptimal dosing. 
      With the recognition that improvement of exercise capacity following 
      cardioversion may be postponed for weeks, several studies have evaluated serial 
      changes in ventricular function and shown that in some patients sinus rhythm is 
      associated with an improved ejection fraction. Transesophageal echocardiography 
      is an area of intense interest for the identification of patients at high risk of 
      thromboembolism following cardioversion, and the significance of left atrial 
      spontaneous echo contrast as well as the left atrial appendage contractile 
      function are being investigated. Finally, new methods of arrhythmia termination 
      are being evaluated and developed, and surgical approaches to atrial fibrillation 
      are being expanded and refined.
FAU - Falk, R H
AU  - Falk RH
AD  - Boston University School of Medicine, Massachusetts.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Arrhythmia Agents/administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Atrial Fibrillation/physiopathology/*therapy
MH  - Cerebrovascular Disorders/physiopathology/prevention & control
MH  - Electric Countershock
MH  - Electrocardiography
MH  - Heart Atria/physiopathology
MH  - Humans
MH  - Sinoatrial Node/physiopathology
MH  - Warfarin/administration & dosage/adverse effects
RF  - 47
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1097/00001573-199401000-00005 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 1994 Jan;9(1):30-9. doi: 10.1097/00001573-199401000-00005.

PMID- 18440328
OWN - NLM
STAT- MEDLINE
DCOM- 20080527
LR  - 20220321
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 155
IP  - 5
DP  - 2008 May
TI  - The genetic response to short-term interventions affecting cardiovascular 
      function: rationale and design of the Heredity and Phenotype Intervention (HAPI) 
      Heart Study.
PG  - 823-8
LID - 10.1016/j.ahj.2008.01.019 [doi]
AB  - BACKGROUND: The etiology of cardiovascular disease (CVD) is multifactorial. 
      Efforts to identify genes influencing CVD risk have met with limited success to 
      date, likely because of the small effect sizes of common CVD risk alleles and the 
      presence of gene by gene and gene by environment interactions. METHODS: The HAPI 
      Heart Study was initiated in 2002 to measure the cardiovascular response to 4 
      short-term interventions affecting cardiovascular risk factors and to identify 
      the genetic and environmental determinants of these responses. The measurements 
      included blood pressure responses to the cold pressor stress test and to a high 
      salt diet, triglyceride excursion in response to a high-fat challenge, and 
      response in platelet aggregation to aspirin therapy. RESULTS: The interventions 
      were carried out in 868 relatively healthy Amish adults from large families. The 
      heritabilities of selected response traits for each intervention ranged from 8% 
      to 38%, suggesting that some of the variation associated with response to each 
      intervention can be attributed to the additive effects of genes. CONCLUSIONS: 
      Identifying these response genes may identify new mechanisms influencing CVD and 
      may lead to individualized preventive strategies and improved early detection of 
      high-risk individuals.
FAU - Mitchell, Braxton D
AU  - Mitchell BD
AD  - Division of Endocrinology, Department of Medicine, Diabetes and Nutrition, 
      University of Maryland School of Medicine, Baltimore, MD 21201, USA. 
      bmitchel@medicine.umaryland.edu
FAU - McArdle, Patrick F
AU  - McArdle PF
FAU - Shen, Haiqing
AU  - Shen H
FAU - Rampersaud, Evadnie
AU  - Rampersaud E
FAU - Pollin, Toni I
AU  - Pollin TI
FAU - Bielak, Lawrence F
AU  - Bielak LF
FAU - Jaquish, Cashell
AU  - Jaquish C
FAU - Douglas, Julie A
AU  - Douglas JA
FAU - Roy-Gagnon, Marie-Hélène
AU  - Roy-Gagnon MH
FAU - Sack, Paul
AU  - Sack P
FAU - Naglieri, Rosalie
AU  - Naglieri R
FAU - Hines, Scott
AU  - Hines S
FAU - Horenstein, Richard B
AU  - Horenstein RB
FAU - Chang, Yen-Pei C
AU  - Chang YP
FAU - Post, Wendy
AU  - Post W
FAU - Ryan, Kathleen A
AU  - Ryan KA
FAU - Brereton, Nga Hong
AU  - Brereton NH
FAU - Pakyz, Ruth E
AU  - Pakyz RE
FAU - Sorkin, John
AU  - Sorkin J
FAU - Damcott, Coleen M
AU  - Damcott CM
FAU - O'Connell, Jeffrey R
AU  - O'Connell JR
FAU - Mangano, Charles
AU  - Mangano C
FAU - Corretti, Mary
AU  - Corretti M
FAU - Vogel, Robert
AU  - Vogel R
FAU - Herzog, William
AU  - Herzog W
FAU - Weir, Matthew R
AU  - Weir MR
FAU - Peyser, Patricia A
AU  - Peyser PA
FAU - Shuldiner, Alan R
AU  - Shuldiner AR
LA  - eng
GR  - U01 HL72515/HL/NHLBI NIH HHS/United States
GR  - T32 HL072751/HL/NHLBI NIH HHS/United States
GR  - R01 HL088120/HL/NHLBI NIH HHS/United States
GR  - T32HL072751/HL/NHLBI NIH HHS/United States
GR  - U01 HL072515/HL/NHLBI NIH HHS/United States
GR  - U01 HL072515-05/HL/NHLBI NIH HHS/United States
GR  - M01 RR000052-45/RR/NCRR NIH HHS/United States
GR  - M01 RR 16500/RR/NCRR NIH HHS/United States
GR  - M01 RR016500-040042/RR/NCRR NIH HHS/United States
GR  - P30 DK072488/DK/NIDDK NIH HHS/United States
GR  - T32 HL072751-05/HL/NHLBI NIH HHS/United States
GR  - M01 RR 000052/RR/NCRR NIH HHS/United States
GR  - M01 RR000052/RR/NCRR NIH HHS/United States
GR  - P30 DK072488-029001/DK/NIDDK NIH HHS/United States
GR  - M01 RR016500/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20080305
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Triglycerides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Blood Pressure
MH  - Cardiovascular Diseases/*genetics
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Male
MH  - Phenotype
MH  - Platelet Aggregation/*drug effects
MH  - Risk Factors
MH  - Triglycerides/*blood
PMC - PMC2443415
MID - NIHMS49712
EDAT- 2008/04/29 09:00
MHDA- 2008/05/28 09:00
CRDT- 2008/04/29 09:00
PHST- 2007/09/19 00:00 [received]
PHST- 2008/01/08 00:00 [accepted]
PHST- 2008/04/29 09:00 [pubmed]
PHST- 2008/05/28 09:00 [medline]
PHST- 2008/04/29 09:00 [entrez]
AID - S0002-8703(08)00066-5 [pii]
AID - 10.1016/j.ahj.2008.01.019 [doi]
PST - ppublish
SO  - Am Heart J. 2008 May;155(5):823-8. doi: 10.1016/j.ahj.2008.01.019. Epub 2008 Mar 
      5.

PMID- 6354535
OWN - NLM
STAT- MEDLINE
DCOM- 19831220
LR  - 20190825
IS  - 0305-1870 (Print)
IS  - 0305-1870 (Linking)
VI  - 10
IP  - 3
DP  - 1983 May-Jun
TI  - Differences in arachidonic acid metabolism and effects of aspirin between one- 
      and two-kidney Goldblatt hypertensive rats.
PG  - 355-60
AB  - Vasodepressor responses to prostacyclin, nitroprusside and arachidonic acid were 
      compared in two groups of anaesthetized, two-kidney, one-clip Goldblatt rats. The 
      groups were composed of rats which had high blood pressure (greater than 150 mmHg 
      systolic) or normal blood pressure (less than 140 mmHg systolic). The 
      vasodepressor effects of prostacyclin and nitroprusside and arachidonic acid did 
      not differ significantly between hypertensive and normotensive groups when 
      measured as percentages of resting blood pressure. Thus, in contrast to 
      one-kidney Goldblatt hypertensive rats, there is no evidence for increased 
      vascular conversion of arachidonic acid to prostacyclin in the two-kidney 
      hypertensive model. The effect of cyclo-oxygenase inhibition on development of 
      hypertension in one- and two-kidney Goldblatt rats was also studied by treating 
      them daily with aspirin (200 mg/kg orally) from 3 days before until 3 weeks after 
      clipping the renal artery. Aspirin-treated two-kidney rats developed 
      significantly higher blood pressures than vehicle-treated controls, but the blood 
      pressures of aspirin-treated one-kidney rats increased less after clipping than 
      those of vehicle-treated controls. It appears paradoxical that transformation of 
      arachidonic acid to prostacyclin is increased, while aspirin has a blood pressure 
      lowering effect in one-kidney Goldblatt rats. It is suggested that there might be 
      a more fundamental disturbance in arachidonate metabolism in hypertension which 
      might contribute to increased vascular reactivity.
FAU - Dusting, G J
AU  - Dusting GJ
FAU - Drysdale, T
AU  - Drysdale T
FAU - Veroni, M
AU  - Veroni M
FAU - Doyle, A E
AU  - Doyle AE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Arachidonic Acids)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acids/*metabolism
MH  - Aspirin/*pharmacology
MH  - Epoprostenol/biosynthesis
MH  - Hypertension, Renovascular/*metabolism
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1983/05/01 00:00
MHDA- 1983/05/01 00:01
CRDT- 1983/05/01 00:00
PHST- 1983/05/01 00:00 [pubmed]
PHST- 1983/05/01 00:01 [medline]
PHST- 1983/05/01 00:00 [entrez]
AID - 10.1111/j.1440-1681.1983.tb00212.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 1983 May-Jun;10(3):355-60. doi: 
      10.1111/j.1440-1681.1983.tb00212.x.

PMID- 21358342
OWN - NLM
STAT- MEDLINE
DCOM- 20120427
LR  - 20151119
IS  - 1536-0237 (Electronic)
IS  - 0883-5993 (Linking)
VI  - 27
IP  - 1
DP  - 2012 Jan
TI  - Tracheal varix in portal hypertension.
PG  - W10-2
LID - 10.1097/RTI.0b013e318205a4a5 [doi]
AB  - A 56-year-old female nonsmoker presented with episodic hemoptysis, without any 
      other associated respiratory symptoms. Her medical history was notable for 
      polycythemia rubra vera with portal vein thrombosis, which was treated with 
      warfarin, but was complicated by portal hypertension. Esophageal varices were 
      controlled by endoscopic band ligation. Chest radiograph and 64-slice computed 
      tomography scanning failed to identify a culprit lesion. Bronchoscopy identified 
      a vascular structure in the proximal trachea. A contrast-enhanced 
      320-multidetector row computed tomography scan of the neck showed a tortuous 
      vascular channel in the trachea, which changed in appearance over time, 
      consistent with a tracheal varix. The patient was changed to aspirin therapy and 
      was evaluated by a cardiothoracic surgeon. A conservative approach was adopted, 
      and the patient has had no recurrence of symptoms.
FAU - MacDonald, Martin
AU  - MacDonald M
AD  - Monash Medical Centre, Clayton, Melbourne, Victoria, Australia. 
      tinomacd@hotmail.com
FAU - Bardin, Philip
AU  - Bardin P
FAU - Lau, Kenneth K
AU  - Lau KK
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Thorac Imaging
JT  - Journal of thoracic imaging
JID - 8606160
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Contrast Media)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiography
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Bronchoscopy
MH  - Contrast Media
MH  - Female
MH  - Humans
MH  - Hypertension, Portal/*complications
MH  - Middle Aged
MH  - Multidetector Computed Tomography
MH  - Tracheal Diseases/*diagnosis/*etiology
MH  - Varicose Veins/*diagnosis/*etiology
EDAT- 2011/03/02 06:00
MHDA- 2012/04/28 06:00
CRDT- 2011/03/02 06:00
PHST- 2011/03/02 06:00 [entrez]
PHST- 2011/03/02 06:00 [pubmed]
PHST- 2012/04/28 06:00 [medline]
AID - 10.1097/RTI.0b013e318205a4a5 [doi]
PST - ppublish
SO  - J Thorac Imaging. 2012 Jan;27(1):W10-2. doi: 10.1097/RTI.0b013e318205a4a5.

PMID- 19396586
OWN - NLM
STAT- MEDLINE
DCOM- 20090818
LR  - 20211020
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 28
IP  - 1
DP  - 2009 Jul
TI  - Spontaneous recanalization of a completely occluded saphenous vein graft two 
      months following acute myocardial infarction with persistent one year patency.
PG  - 101-5
LID - 10.1007/s11239-009-0339-x [doi]
AB  - Acute myocardial infarction resulting from saphenous vein graft occlusion occurs 
      not infrequently in patients who have undergone coronary artery bypass graft 
      surgery. In this case report, we present a novel case of spontaneous 
      recanalization of a thrombotic graft occlusion in a patient who presented with a 
      subacute myocardial infarction. The patient was treated medically with aspirin as 
      the only anti-platelet agent. Interestingly, he presented 2 months later with new 
      onset angina. Coronary angiography demonstrated complete resolution of thrombus 
      but a severe focal stenosis in the distal anastomoses. Following drug eluting 
      stent placement, a favorable clinical course has ensued and patency confirmed on 
      follow up angiography at 1 year.
FAU - Hu, Patrick P
AU  - Hu PP
AD  - Division of Cardiovascular Diseases, University of California, San Diego, CA 
      92093-0682, USA.
FAU - Peterson, Kirk L
AU  - Peterson KL
FAU - Tsimikas, Sotirios
AU  - Tsimikas S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - *Coronary Artery Bypass
MH  - *Drug-Eluting Stents
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Graft Occlusion, Vascular/*therapy
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*therapy
MH  - Saphenous Vein
PMC - PMC2694324
EDAT- 2009/04/28 09:00
MHDA- 2009/08/19 09:00
CRDT- 2009/04/28 09:00
PHST- 2009/04/28 09:00 [entrez]
PHST- 2009/04/28 09:00 [pubmed]
PHST- 2009/08/19 09:00 [medline]
AID - 339 [pii]
AID - 10.1007/s11239-009-0339-x [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2009 Jul;28(1):101-5. doi: 10.1007/s11239-009-0339-x.

PMID- 6617057
OWN - NLM
STAT- MEDLINE
DCOM- 19831123
LR  - 20170214
IS  - 0009-9228 (Print)
IS  - 0009-9228 (Linking)
VI  - 22
IP  - 11
DP  - 1983 Nov
TI  - House officer management of the febrile child. A survey.
PG  - 766-9
AB  - Questionnaires were used to survey 95 pediatric house officers in order to 
      determine their reasons and methods for treating fever, as well as their 
      knowledge of fever physiology. The reasons given for treating fever were to make 
      the child comfortable (99%), to prevent seizures (63%), and to satisfy parents 
      (44%). The average temperature at which antipyretic medication was started was 
      38.6 +/- 0.3 C. Alternating doses of aspirin and acetaminophen were used by 53 
      per cent, and sponging was recommended by 76 per cent of the residents. The 
      average temperature at which sponging was started was 39.5 +/- 0.6 C. The 
      percentage of house officers who use sponging and/or alternating doses of 
      antipyretics differed greatly from hospital to hospital. Sixty-one per cent of 
      the residents felt that fever is a defense mechanism which does not require 
      treatment. Despite this belief, the majority of these residents use vigorous 
      means to lower fever in children.
FAU - Weiss, J
AU  - Weiss J
FAU - Herskowitz, L
AU  - Herskowitz L
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Clin Pediatr (Phila)
JT  - Clinical pediatrics
JID - 0372606
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Brain Damage, Chronic/prevention & control
MH  - Fever/drug therapy/etiology/*therapy
MH  - Humans
MH  - Infant
MH  - Seizures/prevention & control
MH  - Surveys and Questionnaires
EDAT- 1983/11/01 00:00
MHDA- 1983/11/01 00:01
CRDT- 1983/11/01 00:00
PHST- 1983/11/01 00:00 [pubmed]
PHST- 1983/11/01 00:01 [medline]
PHST- 1983/11/01 00:00 [entrez]
AID - 10.1177/000992288302201106 [doi]
PST - ppublish
SO  - Clin Pediatr (Phila). 1983 Nov;22(11):766-9. doi: 10.1177/000992288302201106.

PMID- 16343666
OWN - NLM
STAT- MEDLINE
DCOM- 20061102
LR  - 20131121
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 110
IP  - 2
DP  - 2006 Jun 16
TI  - Antiplatelet versus anticoagulant therapies in advanced age: an unfinished task.
PG  - 271-2
AB  - We have read with great interest a retrospective cohort study recently published 
      by Blich and Gross. In our opinion, this article renews the controversy of the 
      best antithrombotic therapy in patients with AF. The use of anticoagulant 
      treatment to prevent the occurrence of stroke in patients with AF is supported by 
      several randomized controlled clinical trials. Aspirin is also effective in 
      preventing stroke in AF, but both direct and indirect comparisons with oral 
      anticoagulation suggest less effectiveness. However, very probably these patients 
      are quite different than those seen in the clinical practice. The role of 
      antiplatelet therapy is not completely established, and the selection between 
      aspirin or warfarin in advanced age remains an unfinished task.
FAU - García-Honrubia, Antonio
AU  - García-Honrubia A
FAU - Roldán, Vanessa
AU  - Roldán V
FAU - Climent, Vicente
AU  - Climent V
FAU - Sogorb, Francisco
AU  - Sogorb F
FAU - Marín, Francisco
AU  - Marín F
LA  - eng
PT  - Comment
PT  - Comparative Study
PT  - Letter
DEP - 20051215
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Int J Cardiol. 2004 Jul;96(1):89-95. PMID: 15203266
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/drug therapy
MH  - Cohort Studies
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Retrospective Studies
MH  - Stroke/prevention & control
MH  - Warfarin/*therapeutic use
EDAT- 2005/12/14 09:00
MHDA- 2006/11/03 09:00
CRDT- 2005/12/14 09:00
PHST- 2005/09/04 00:00 [received]
PHST- 2005/09/20 00:00 [accepted]
PHST- 2005/12/14 09:00 [pubmed]
PHST- 2006/11/03 09:00 [medline]
PHST- 2005/12/14 09:00 [entrez]
AID - S0167-5273(05)01269-6 [pii]
AID - 10.1016/j.ijcard.2005.09.034 [doi]
PST - ppublish
SO  - Int J Cardiol. 2006 Jun 16;110(2):271-2. doi: 10.1016/j.ijcard.2005.09.034. Epub 
      2005 Dec 15.

PMID- 11352790
OWN - NLM
STAT- MEDLINE
DCOM- 20020207
LR  - 20191104
IS  - 1523-3774 (Print)
IS  - 1523-3774 (Linking)
VI  - 3
IP  - 3
DP  - 2001 Jun
TI  - Update on the management of the pregnant patient with antiphospholipid antibody.
PG  - 213-21
AB  - Management of the pregnant patient with antiphospholipid antibody (aPL) is 
      reviewed, with emphasis on recent randomized controlled clinical trials. These 
      support the use of subcutaneous heparin and low dose aspirin, current standard 
      therapy for women with aPL and a history of fetal loss. Prednisone is rarely used 
      due to high risk of maternal and fetal morbidity. Intravenous immunoglobulin may 
      represent an important additional therapy for women who fail aspirin and heparin. 
      Patients with a history of thrombosis require full, therapeutic anticoagulation 
      during pregnancy. Recommendations are less clear for newly described antibodies 
      to phospholipid-binding protein, for low titer antibodies, and for infertility 
      treatment in the setting of aPL.
FAU - Sammaritano, L R
AU  - Sammaritano LR
AD  - Hospital for Special Surgery, Weill Medical College of Cornell University, 535 
      East 70th Street (777W), New York, NY 10021, USA. sammaritan@hss.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Rheumatol Rep
JT  - Current rheumatology reports
JID - 100888970
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Antiphospholipid Syndrome/complications/diagnosis/*therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/diagnosis/*therapy
MH  - Prenatal Care
MH  - Prognosis
MH  - Risk Factors
RF  - 56
EDAT- 2001/05/16 10:00
MHDA- 2002/02/08 10:01
CRDT- 2001/05/16 10:00
PHST- 2001/05/16 10:00 [pubmed]
PHST- 2002/02/08 10:01 [medline]
PHST- 2001/05/16 10:00 [entrez]
AID - 10.1007/s11926-001-0021-6 [doi]
PST - ppublish
SO  - Curr Rheumatol Rep. 2001 Jun;3(3):213-21. doi: 10.1007/s11926-001-0021-6.

PMID- 2945550
OWN - NLM
STAT- MEDLINE
DCOM- 19861030
LR  - 20190612
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 139
IP  - 1
DP  - 1986 Aug 29
TI  - Aspirin inhibits phospholipase C.
PG  - 115-21
AB  - We have shown previously that aspirin (ASA) ingestion by normal human volunteers 
      inhibits peripheral blood monocyte phospholipase C (PLC) activities ex vivo. In 
      order to explore further the mechanism of action of ASA, normal human monocytes 
      and differentiated human U937 cells were treated with ASA and other salicylates. 
      Cells preincubated with ASA were found to have decreased PLC activities. 
      Phospholipase A2 activities were not affected by salicylates. Sodium salicylate 
      and salicylic acid, nonacetylated relatives of ASA also inhibited PLC activity. 
      This effect was dose and time dependent and addition of cycloheximide or 
      actinomycin D to the preincubation mixture abrogated the inhibitory effect of 
      salicylates on PLC. This PLC inhibitory protein induced by ASA appears distinct 
      from lipocortin, a phospholipase A2 inhibitory protein inducible by 
      corticosteroids.
FAU - Bomalaski, J S
AU  - Bomalaski JS
FAU - Hirata, F
AU  - Hirata F
FAU - Clark, M A
AU  - Clark MA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Annexins)
RN  - 0 (Glycoproteins)
RN  - 0 (Salicylates)
RN  - 1CC1JFE158 (Dactinomycin)
RN  - 98600C0908 (Cycloheximide)
RN  - EC 3.1.4.- (Type C Phospholipases)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Annexins
MH  - Aspirin/*pharmacology
MH  - Cycloheximide/pharmacology
MH  - Dactinomycin/pharmacology
MH  - Glycoproteins/analysis
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Salicylates/pharmacology
MH  - Type C Phospholipases/*antagonists & inhibitors
EDAT- 1986/08/29 00:00
MHDA- 1986/08/29 00:01
CRDT- 1986/08/29 00:00
PHST- 1986/08/29 00:00 [pubmed]
PHST- 1986/08/29 00:01 [medline]
PHST- 1986/08/29 00:00 [entrez]
AID - S0006-291X(86)80087-0 [pii]
AID - 10.1016/s0006-291x(86)80087-0 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1986 Aug 29;139(1):115-21. doi: 
      10.1016/s0006-291x(86)80087-0.

PMID- 845612
OWN - NLM
STAT- MEDLINE
DCOM- 19770520
LR  - 20190501
IS  - 0022-3050 (Print)
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
VI  - 40
IP  - 1
DP  - 1977 Jan
TI  - Transient ischaemic attacks and increased platelet aggregability associated with 
      oral contraceptives. Treatment with dipyridamole and aspirin.
PG  - 9-10
AB  - A 24-year old woman after using birth control pills for two months began to 
      suffer from frequent migraine-like attacks, which turned eventually into typical 
      transient ischaemic attacks (TIAs). A significant increase in spontaneous 
      platelet aggregation was found, and combined treatment with dipridamole and 
      aspirin was started. After two months of treatment spontaneous platelet 
      aggregation rate fell to normal limits and TIAs disappeared. A causal 
      relationship between increased platelet aggregability and TIAs is supposed.
FAU - Mazal, S
AU  - Mazal S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
RN  - 0 (Contraceptives, Oral)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Contraceptives, Oral/*adverse effects
MH  - Dipyridamole/*therapeutic use
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*chemically induced/drug therapy
MH  - Platelet Aggregation/*drug effects
PMC - PMC492597
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1136/jnnp.40.1.9 [doi]
PST - ppublish
SO  - J Neurol Neurosurg Psychiatry. 1977 Jan;40(1):9-10. doi: 10.1136/jnnp.40.1.9.

PMID- 1258959
OWN - NLM
STAT- MEDLINE
DCOM- 19760525
LR  - 20190627
IS  - 0002-9394 (Print)
IS  - 0002-9394 (Linking)
VI  - 81
IP  - 3
DP  - 1976 Mar
TI  - Increased intraocular pressure after third ventricle injections of prostaglandin 
      E1 and arachidonic acid.
PG  - 346-50
AB  - Prostaglandin E1 administered into the third ventricle of rabbits produced 
      increased intraocular pressure and body temperature. Similar responses were 
      observed after third ventricle instillation of arachidonic acid, a precursor of 
      prostaglandin E2. Increase of body temperature occurred with lower doses of 
      prostaglandin E1 and arachidonic acid while the intraocular pressure response 
      required larger amounts of these drugs. Pretreatment with aspirin rectal 
      suppositories had no effect on the third ventricle responses induced by 
      prostaglandin E1. Aspirin pretreatment before third ventricle instillation of 
      arachidonic acid blocked the increases of intraocular pressure and temperature.
FAU - Krupin, T
AU  - Krupin T
FAU - Oestrich, C
AU  - Oestrich C
FAU - Podos, S M
AU  - Podos SM
FAU - Becker, B
AU  - Becker B
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Arachidonic Acids)
RN  - 0 (Prostaglandins E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acids/*administration & dosage/pharmacology
MH  - Aspirin/pharmacology
MH  - *Cerebral Ventricles
MH  - Dose-Response Relationship, Drug
MH  - Injections
MH  - Intraocular Pressure/*drug effects
MH  - Male
MH  - Prostaglandins E/*administration & dosage/pharmacology
MH  - Rabbits
EDAT- 1976/03/01 00:00
MHDA- 1976/03/01 00:01
CRDT- 1976/03/01 00:00
PHST- 1976/03/01 00:00 [pubmed]
PHST- 1976/03/01 00:01 [medline]
PHST- 1976/03/01 00:00 [entrez]
AID - 0002-9394(76)90252-X [pii]
AID - 10.1016/0002-9394(76)90252-x [doi]
PST - ppublish
SO  - Am J Ophthalmol. 1976 Mar;81(3):346-50. doi: 10.1016/0002-9394(76)90252-x.

PMID- 36706919
OWN - NLM
STAT- MEDLINE
DCOM- 20230403
LR  - 20230407
IS  - 2589-9333 (Electronic)
IS  - 2589-9333 (Linking)
VI  - 5
IP  - 4
DP  - 2023 Apr
TI  - Low-dose asprin use during pregnancy may be a potential risk for postpartum 
      hemorrhage and increased blood loss: a systematic review and meta-analysis.
PG  - 100878
LID - S2589-9333(23)00020-4 [pii]
LID - 10.1016/j.ajogmf.2023.100878 [doi]
AB  - OBJECTIVE: The association between aspirin use during pregnancy and the risk of 
      postpartum hemorrhage remains unclear. This study aimed to explore the incidence 
      of postpartum hemorrhage and the amount of postpartum blood loss among women who 
      used aspirin during pregnancy. DATA SOURCES: From inception to October 2022, this 
      study searched the following databases: MEDLINE, Web of Science, Embase, and the 
      Cochrane Central Register of Controlled Trials. STUDY ELIGIBILITY CRITERIA: 
      Studies comparing pregnancy outcomes that covered the incidence of postpartum 
      hemorrhage or the amount of postpartum blood loss in pregnancies with aspirin vs 
      placebo (or no aspirin) were included. METHODS: Reviewers separately ascertained 
      studies, obtained data, and gauged study quality. The meta-analysis was conducted 
      using a random effects model owing to the probable heterogeneity of the included 
      studies. The rates of postpartum hemorrhage or the mean amounts of postpartum 
      blood loss were compared, and the odds ratios or mean differences with 95% 
      confidence intervals were estimated. Of note, 2 parts performed both a pooled 
      analysis of randomized controlled trials and cohort studies and a separate 
      analysis of randomized controlled trials. RESULTS: Overall, 21 studies with 
      373,926 women were included in the postpartum hemorrhage part, and 7 studies with 
      10,163 women were included in the postpartum blood loss part. The results 
      suggested that aspirin (dose 60-150mg a day) use during pregnancy was associated 
      with an increased incidence of postpartum hemorrhage (odds ratio, 1.20; 95% 
      confidence interval, 1.07-1.34). When only randomized controlled trials were 
      retained, the results remained significant (odds ratio, 1.12; 95% confidence 
      interval, 1.00-1.25). In the second part, higher total blood loss after delivery 
      was obtained (mean difference, 12.85 mL; 95% confidence interval, 3.28-22.42), 
      and the result was unaltered when cohort studies were eliminated (mean 
      difference, 13.72 mL; 95% confidence interval, 4.63-22.81). The conclusions are 
      more likely to be obtained in developed countries. CONCLUSION: Low-dose aspirin 
      use during pregnancy is a potential risk of postpartum hemorrhage and does 
      slightly increase the amount of postpartum blood loss. Without denying the 
      combined value of aspirin, our conclusions raised an alarm for clinicians about 
      postpartum hemorrhage in women using aspirin during pregnancy.
CI  - Copyright © 2023 Elsevier Inc. All rights reserved.
FAU - Jiang, Yi
AU  - Jiang Y
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Chen, Zhuoru
AU  - Chen Z
AD  - Children's Hospital of Fudan University, Shanghai, China (Miss Chen).
FAU - Chen, Yuting
AU  - Chen Y
AD  - Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, 
      Wuhan, China (Dr Chen).
FAU - Wei, Lijie
AU  - Wei L
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Gao, Peng
AU  - Gao P
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Zhang, Jingyi
AU  - Zhang J
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Zhou, Xuan
AU  - Zhou X
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Zhu, Shenglan
AU  - Zhu S
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Zhang, Huiting
AU  - Zhang H
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Du, Yuanyuan
AU  - Du Y
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Fang, Chenyun
AU  - Fang C
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Su, Rui
AU  - Su R
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Wang, Shaoshuai
AU  - Wang S
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Yu, Jun
AU  - Yu J
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - He, Mengzhou
AU  - He M
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng).
FAU - Ding, Wencheng
AU  - Ding W
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng). Electronic address: 
      dingwencheng326@163.com.
FAU - Feng, Ling
AU  - Feng L
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China (Dr Jiang, Dr 
      Wei, Dr Gao, Dr Zhang, Dr Zhou, Dr Zhu, Dr H Zhang, Dr Du, Miss Fang, Miss Su, Dr 
      Wang, Dr Yu, Dr He, Dr Ding, and Dr Feng). Electronic address: fltj007@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20230125
PL  - United States
TA  - Am J Obstet Gynecol MFM
JT  - American journal of obstetrics & gynecology MFM
JID - 101746609
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - *Postpartum Hemorrhage/chemically induced/diagnosis/epidemiology
MH  - Aspirin/adverse effects
MH  - Pregnancy Outcome
OTO - NOTNLM
OT  - aspirin
OT  - blood loss
OT  - postpartum hemorrhage
OT  - pregnancy
EDAT- 2023/01/28 06:00
MHDA- 2023/04/03 06:42
CRDT- 2023/01/27 19:24
PHST- 2023/01/10 00:00 [received]
PHST- 2023/01/14 00:00 [revised]
PHST- 2023/01/18 00:00 [accepted]
PHST- 2023/04/03 06:42 [medline]
PHST- 2023/01/28 06:00 [pubmed]
PHST- 2023/01/27 19:24 [entrez]
AID - S2589-9333(23)00020-4 [pii]
AID - 10.1016/j.ajogmf.2023.100878 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol MFM. 2023 Apr;5(4):100878. doi: 10.1016/j.ajogmf.2023.100878. 
      Epub 2023 Jan 25.

PMID- 10796426
OWN - NLM
STAT- MEDLINE
DCOM- 20000706
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 2
DP  - 2000
TI  - Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for 
      preventing stroke and other serious vascular events in high vascular risk 
      patients.
PG  - CD001246
AB  - BACKGROUND: The most widely studied and prescribed antiplatelet agent for the 
      prevention of stroke and other serious vascular events among high vascular risk 
      patients is aspirin. Aspirin inhibits platelet activation by inhibiting platelet 
      cyclooxygenase and thromboxane production, and reduces the odds of a serious 
      vascular event by about a quarter. The thienopyridines (ticlopidine and 
      clopidogrel) inhibit platelet activation by a different mechanism to aspirin 
      (blocking the ADP receptor on platelets), and so may be more effective than 
      aspirin. OBJECTIVES: The objective of this review was to determine the 
      effectiveness and safety of thienopyridine derivatives (ticlopidine and 
      clopidogrel) versus aspirin for the prevention of serious vascular events 
      (stroke, myocardial infarction (MI) or vascular death) in patients at high risk 
      of such events, and specifically in patients with a previous TIA or ischaemic 
      stroke. SEARCH STRATEGY: We searched the Cochrane Stroke Group trials register 
      (most recent search: March 1999) and the Antithrombotic Trialists' database, and 
      also contacted Sanofi pharmaceutical company. SELECTION CRITERIA: All 
      unconfounded, double blind, randomised trials directly comparing ticlopidine or 
      clopidogrel with aspirin in high vascular risk patients. DATA COLLECTION AND 
      ANALYSIS: Two reviewers independently extracted data and assessed trial quality. 
      Additional data were sought from the principal investigators of the largest 
      trial. MAIN RESULTS: Four trials involving a total of 22,656 high vascular risk 
      patients were included. The trials were of high quality and comparable. Aspirin 
      was compared with ticlopidine in three trials (3471 patients) and with 
      clopidogrel in one trial (19,185 patients). Allocation to a thienopyridine was 
      associated with a modest, yet statistically significant, reduction in the odds of 
      a serious vascular event (12. 0% vs 13.0%; OR: 0.91, 95% CI: 0.84 to 0.98; 2p = 
      0.01), corresponding to the avoidance of 11 (95% CI: 2 to 19) serious vascular 
      events per 1000 patients treated for about two years. There was also a reduction 
      in stroke (5.7% vs 6.4%; OR: 0.88, 95% CI: 0.79 to 0.98; 7 [95% CI: 1 to 13] 
      strokes avoided per 1000 patients treated for two years). Compared with aspirin, 
      thienopyridines produced a significant reduction in the odds of gastrointestinal 
      haemorrhage and other upper gastrointestinal upset, but a significant increase in 
      the odds of skin rash and of diarrhoea. However, the increased odds of skin rash 
      and diarrhoea were greater for ticlopidine than for clopidogrel. Allocation to 
      ticlopidine, but not clopidogrel, was associated with a significant increase in 
      the odds of neutropenia (2.3% vs 0.8%; OR: 2.7, 95% CI: 1.5 to 4.8). In the 
      subset of patients with TIA/ischaemic stroke, the results were similar to those 
      for all patients combined. However, since these patients are at particularly high 
      risk of stroke, allocation to a thienopyridine was associated with a larger 
      absolute reduction in stroke (10.4% vs 12.0%; OR: 0.86, 95% CI: 0.75 to 0.97; 16 
      [95% CI: 3 to 28] strokes avoided per 1000 patients treated for two years). 
      REVIEWER'S CONCLUSIONS: The available randomised evidence shows that the 
      thienopyridine derivatives are modestly but significantly more effective than 
      aspirin in preventing serious vascular events in patients at high risk (and 
      specifically in TIA/ischaemic stroke patients), but there is uncertainty about 
      the size of the additional benefit. The thienopyridines are also associated with 
      less gastrointestinal haemorrhage and other upper gastrointestinal upset than 
      aspirin, but an excess of skin rash and diarrhoea. The risk of skin rash and 
      diarrhoea is greater with ticlopidine than with clopidogrel. Ticlopidine, but not 
      clopidogrel, is associated with an excess of neutropenia and of thrombotic 
      thrombocytopenic purpura.
FAU - Hankey, G J
AU  - Hankey GJ
AD  - Stroke Unit, Department of Neurology, Royal Perth Hospital, Wellington Street, 
      Perth, Western Australia, Australia, 6001. gjhankey@cyllene.uwa.edu.au
FAU - Sudlow, C L
AU  - Sudlow CL
FAU - Dunbabin, D W
AU  - Dunbabin DW
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UIN - Cochrane Database Syst Rev. 2009;(4):CD001246. PMID: 19821273
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clopidogrel
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/*therapeutic use
RF  - 9
EDAT- 2000/05/05 09:00
MHDA- 2000/07/08 11:00
CRDT- 2000/05/05 09:00
PHST- 2000/05/05 09:00 [pubmed]
PHST- 2000/07/08 11:00 [medline]
PHST- 2000/05/05 09:00 [entrez]
AID - CD001246 [pii]
AID - 10.1002/14651858.CD001246 [doi]
PST - ppublish
SO  - Cochrane Database Syst Rev. 2000;(2):CD001246. doi: 10.1002/14651858.CD001246.

PMID- 23532687
OWN - NLM
STAT- MEDLINE
DCOM- 20131030
LR  - 20171116
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 13
IP  - 2
DP  - 2013 Apr
TI  - Predicting the impact of polypill use in a metabolic syndrome population: an 
      effectiveness and cost-effectiveness analysis.
PG  - 121-8
LID - 10.1007/s40256-013-0019-2 [doi]
AB  - BACKGROUND: Individuals with metabolic syndrome (MetS) are at increased risk of 
      cardiovascular disease (CVD), often requiring combination drug therapy for 
      control of risk factors and subsequent risk reduction. This study aims to compare 
      the long-term effectiveness and cost effectiveness of the polypill (a 
      multi-component tablet), and its components (alone or in combination), in a MetS 
      population. METHODS AND RESULTS: A Markov state transition model, using 
      individual subject data from the Australian Diabetes, Obesity and Lifestyle 
      study, was constructed to simulate the effects of the treatment versus no 
      treatment on CVD events, and costs over 10 years. In 1,991 individuals classified 
      as MetS and free of existing diabetes mellitus or CVD, treatment with the 
      polypill (or its components) was effective at reducing cardiovascular events 
      [statin: 171, aspirin (actetylsalicylic acid): 201, antihypertensive: 186 per 
      1,000 individuals]. The more drug therapies employed the greater the reduction, 
      with the polypill reducing up to 351 cardiovascular events per 10,000 
      individuals. Cost-effectiveness analyses were sensitive to drug treatment costs 
      and effectiveness of treatment. At a cost of AUD$42 per person per annum, aspirin 
      was considered cost saving. All other treatment strategies, including the 
      polypill, were not cost effective. CONCLUSION: The polypill is likely to be 
      effective in the reduction of cardiovascular events in a MetS population. It is, 
      however, not cost effective. Nevertheless, in a high-risk population, among whom 
      combination therapy is often prescribed, the polypill is likely to be more cost 
      effective than antihypertensive therapy alone or dual therapy with a statin and 
      antihypertensive combination.
FAU - Zomer, Ella
AU  - Zomer E
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, The Alfred Centre, and Royal Melbourne 
      Hospital, Melbourne, VIC, Australia. ella.zomer@monash.edu
FAU - Owen, Alice
AU  - Owen A
FAU - Magliano, Dianna J
AU  - Magliano DJ
FAU - Ademi, Zanfina
AU  - Ademi Z
FAU - Reid, Christopher M
AU  - Reid CM
FAU - Liew, Danny
AU  - Liew D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - AGG2FN16EV (Simvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/*administration & dosage/adverse effects/therapeutic use
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/epidemiology/prevention & control
MH  - Cost-Benefit Analysis
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Male
MH  - Metabolic Syndrome/complications/*drug therapy/economics
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Risk Factors
MH  - Simvastatin/*administration & dosage/adverse effects/therapeutic use
MH  - Treatment Outcome
EDAT- 2013/03/28 06:00
MHDA- 2013/10/31 06:00
CRDT- 2013/03/28 06:00
PHST- 2013/03/28 06:00 [entrez]
PHST- 2013/03/28 06:00 [pubmed]
PHST- 2013/10/31 06:00 [medline]
AID - 10.1007/s40256-013-0019-2 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2013 Apr;13(2):121-8. doi: 10.1007/s40256-013-0019-2.

PMID- 7083734
OWN - NLM
STAT- MEDLINE
DCOM- 19820826
LR  - 20190512
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 32
IP  - 1
DP  - 1982 Jul
TI  - Flurbiprofen in dysmenorrhea.
PG  - 76-80
AB  - Reports on the efficacy of flurbiprofen for dysmenorrhea conflict. We gave 59 
      dysmenorrheic patients flurbiprofen (50 mg), aspirin (650 mg), or placebo. Paired 
      drug comparisons showed that patients preferred flurbiprofen and that it was more 
      effective in relief of pain, in allowing patients to pursue normal daily 
      function, and in reducing the need for additional analgesics. Except in patient 
      preference, aspirin was only marginally superior to placebo, There was an 
      increase in minor side effects in the flurbiprofen group, but our results 
      indicate therapeutic utility for flurbiprofen in dysmenorrhea.
FAU - DeLia, J E
AU  - DeLia JE
FAU - Emery, M G
AU  - Emery MG
FAU - Taylor, R H
AU  - Taylor RH
FAU - Scott, J R
AU  - Scott JR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Propionates)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Drug Evaluation
MH  - Dysmenorrhea/*drug therapy
MH  - Female
MH  - Flurbiprofen/adverse effects/*therapeutic use
MH  - Humans
MH  - Propionates/*therapeutic use
EDAT- 1982/07/01 00:00
MHDA- 1982/07/01 00:01
CRDT- 1982/07/01 00:00
PHST- 1982/07/01 00:00 [pubmed]
PHST- 1982/07/01 00:01 [medline]
PHST- 1982/07/01 00:00 [entrez]
AID - 10.1038/clpt.1982.129 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1982 Jul;32(1):76-80. doi: 10.1038/clpt.1982.129.

PMID- 455388
OWN - NLM
STAT- MEDLINE
DCOM- 19790925
LR  - 20190720
IS  - 0302-766X (Print)
IS  - 0302-766X (Linking)
VI  - 196
IP  - 3
DP  - 1979 Feb 28
TI  - Phagocytosis of cells in the gastric surface epithelium of the rat.
PG  - 449-54
AB  - Gastric surface epithelial cells (SEC) from fed rats, from rats fasted for 16 h 
      and from mucosae exposed in an ex-vivo chamber to 16 mM aspirin for 5 min were 
      examined by transmission electron microscopy. SEC have the capability to 
      phagocytose adjacent epithelial cells and parietal cells. Phagocytosis is rare in 
      mucosae from fasted animals but common in fed animals or after brief exposure to 
      aspirin. Phagocytic capabilities are not restricted to the progenitor zone but 
      exist throughout the surface epithelium. Phagocytosis may provide a mechanism for 
      the removal of damaged or senescent cells from the surface epithelium.
FAU - Morris, G P
AU  - Morris GP
FAU - Harding, R K
AU  - Harding RK
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Cell Tissue Res
JT  - Cell and tissue research
JID - 0417625
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Epithelial Cells
MH  - Epithelium/physiology/ultrastructure
MH  - Fasting
MH  - Female
MH  - Gastric Mucosa/drug effects/*physiology/ultrastructure
MH  - *Phagocytosis/drug effects
MH  - Rats
EDAT- 1979/02/28 00:00
MHDA- 1979/02/28 00:01
CRDT- 1979/02/28 00:00
PHST- 1979/02/28 00:00 [pubmed]
PHST- 1979/02/28 00:01 [medline]
PHST- 1979/02/28 00:00 [entrez]
AID - 10.1007/BF00234739 [doi]
PST - ppublish
SO  - Cell Tissue Res. 1979 Feb 28;196(3):449-54. doi: 10.1007/BF00234739.

PMID- 871137
OWN - NLM
STAT- MEDLINE
DCOM- 19770630
LR  - 20190716
IS  - 0002-9629 (Print)
IS  - 0002-9629 (Linking)
VI  - 273
IP  - 2
DP  - 1977 Mar-Apr
TI  - Aspirin therapy in microangiopathic hemolytic anemia and renal failure.
PG  - 227-32
AB  - An 18-year-old man presented initially with findings compatible with disseminated 
      intravascular coagulation. Following a brief partial response to intravenous 
      heparin therapy rapid deterioration of renal function was associated with 
      evidence of a hypercoagulable state characterized primarily by excessive platelet 
      aggregation and sequestration. Initiation of aspirin therapy led to a prompt rise 
      in the platelet count and permanent improvement in renal function.
FAU - Raich, P C
AU  - Raich PC
FAU - Bozdech, M J
AU  - Bozdech MJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Kidney Injury/complications/*drug therapy
MH  - Adolescent
MH  - Anemia, Hemolytic/complications/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Male
MH  - Microcirculation
MH  - Thrombocytopenia/complications/drug therapy
EDAT- 1977/03/01 00:00
MHDA- 1977/03/01 00:01
CRDT- 1977/03/01 00:00
PHST- 1977/03/01 00:00 [pubmed]
PHST- 1977/03/01 00:01 [medline]
PHST- 1977/03/01 00:00 [entrez]
AID - 10.1097/00000441-197703000-00014 [doi]
PST - ppublish
SO  - Am J Med Sci. 1977 Mar-Apr;273(2):227-32. doi: 10.1097/00000441-197703000-00014.

PMID- 24531782
OWN - NLM
STAT- MEDLINE
DCOM- 20140515
LR  - 20150828
IS  - 0080-0015 (Print)
IS  - 0080-0015 (Linking)
VI  - 202
DP  - 2014
TI  - Aspirin and prostate cancer prevention.
PG  - 93-100
LID - 10.1007/978-3-642-45195-9_11 [doi]
AB  - Aspirin has been associated to a reduced risk of colorectal, and possibly of 
      other cancers. Data from at least 25 observational studies also suggest a modest 
      reduced risk of prostate cancer in regular aspirin users, with a summary relative 
      risk, RR, of 0.91 (95 % confidence interval, CI, 0.86-0.96) overall, 0.87 (95 % 
      CI 0.74-1.02) from nine case-control studies, and 0.92 (95 % CI 0.87-0.97) from 
      16 cohort studies. However, risk estimates are heterogeneous and there is no 
      relation with frequency, dose, or duration of aspirin use. Data from randomized 
      controlled trials of aspirin for the prevention of vascular events showed a 
      nonsignificant reduced risk of death from prostate cancer after a latent period 
      of five or more years (RR 0.52, 95 % CI 0.20-1.24) based on 37 deaths from 
      prostate cancer from seven trials. The RR was 0.81 (95 % CI 0.61-1.06) after 20 
      years of follow-up, based on 210 cases from three trials with long-term 
      follow-up. Thus, data from observational studies and clinical trials are 
      compatible with a modest favorable effect of aspirin on prostate cancer. 
      Inference for causality and public health implications are, however, far from 
      conclusive given the heterogeneity of results and the lack of dose and 
      duration-risk relationships. Data on prostate cancer survival are still limited 
      and inconsistent.
FAU - Bosetti, Cristina
AU  - Bosetti C
AD  - Department of Epidemiology, IRCCS-Istituto di Ricerche Farmacologiche "Mario 
      Negri", Via La Masa 19, 20156, Milan, Italy, cristina.bosetti@marionegri.it.
FAU - Rosato, Valentina
AU  - Rosato V
FAU - Gallus, Silvano
AU  - Gallus S
FAU - La Vecchia, Carlo
AU  - La Vecchia C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Recent Results Cancer Res
JT  - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans 
      les recherches sur le cancer
JID - 0044671
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/*drug therapy/*prevention & control
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2014/02/18 06:00
MHDA- 2014/05/16 06:00
CRDT- 2014/02/18 06:00
PHST- 2014/02/18 06:00 [entrez]
PHST- 2014/02/18 06:00 [pubmed]
PHST- 2014/05/16 06:00 [medline]
AID - 10.1007/978-3-642-45195-9_11 [doi]
PST - ppublish
SO  - Recent Results Cancer Res. 2014;202:93-100. doi: 10.1007/978-3-642-45195-9_11.

PMID- 12891533
OWN - NLM
STAT- MEDLINE
DCOM- 20030925
LR  - 20220330
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 125
IP  - 2
DP  - 2003 Aug
TI  - Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year 
      results of the APACC trial.
PG  - 328-36
AB  - BACKGROUND & AIMS: Epidemiologic and experimental studies have suggested that 
      aspirin intake reduces the risk for colorectal carcinogenesis. However, the 
      available data are not sufficient to serve as the basis for firm recommendations. 
      METHODS: We randomly assigned 272 patients with a history of colorectal adenomas 
      (at least one more than 5 mm in diameter, or more than 3) to daily lysine 
      acetylsalicylate (160 or 300 mg/day) or placebo for 4 years. The primary end 
      points were adenoma recurrence after 1 and 4 years. These results are those of 
      the year 1 colonoscopy. RESULTS: Among the 238 patients who completed the year 1 
      colonoscopy, at least one adenoma was observed in 38 patients of the 126 (30%) in 
      the aspirin group and in 46 of the 112 (41%) in the placebo group; relative risk 
      was 0.73 (95% confidence interval [CI]: 0.52-1.04; P = 0.08). At least one 
      adenoma of more than 5 mm diameter was observed in 13 patients (10%) in the 
      aspirin group and 26 (23%) in the placebo group (P = 0.01). The corresponding 
      numbers for adenomas more than 10 mm in diameter were one (1%) and 7 (6%) (P = 
      0.05). Stepwise regression showed that independent factors associated with lower 
      adenoma recurrence are aspirin treatment (adenoma >5 mm, P = 0.01), absence of 
      personal history of adenoma before the entry colonoscopy (P = 0.01), and initial 
      adenomatous polyp burden less than 10 mm (P = 0.001). CONCLUSIONS: Daily soluble 
      aspirin is associated with a reduction in the risk for recurrent adenomas found 
      at colonoscopy 1 year after starting treatment.
FAU - Benamouzig, Robert
AU  - Benamouzig R
AD  - Department of Gastroenterology, Avicenne Hospital, AP-HP, Paris 13 University, 
      Bobigny Cedex, France.
FAU - Deyra, Jacques
AU  - Deyra J
FAU - Martin, Antoine
AU  - Martin A
FAU - Girard, Bernard
AU  - Girard B
FAU - Jullian, Eric
AU  - Jullian E
FAU - Piednoir, Benoit
AU  - Piednoir B
FAU - Couturier, Daniel
AU  - Couturier D
FAU - Coste, Thierry
AU  - Coste T
FAU - Little, Julian
AU  - Little J
FAU - Chaussade, Stanislas
AU  - Chaussade S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gastroenterology. 2003 Aug;125(2):612-4. PMID: 12891566
MH  - Adenoma/*prevention & control
MH  - Aspirin/*administration & dosage
MH  - Colorectal Neoplasms/*prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*prevention & control
MH  - Patient Compliance
EDAT- 2003/08/02 05:00
MHDA- 2003/09/26 05:00
CRDT- 2003/08/02 05:00
PHST- 2003/08/02 05:00 [pubmed]
PHST- 2003/09/26 05:00 [medline]
PHST- 2003/08/02 05:00 [entrez]
AID - S0016508503008874 [pii]
AID - 10.1016/s0016-5085(03)00887-4 [doi]
PST - ppublish
SO  - Gastroenterology. 2003 Aug;125(2):328-36. doi: 10.1016/s0016-5085(03)00887-4.

PMID- 24671522
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20140707
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 112
IP  - 1
DP  - 2014 Jul 3
TI  - In vivo prostacyclin biosynthesis and effects of different aspirin regimens in 
      patients with essential thrombocythaemia.
PG  - 118-27
LID - 10.1160/TH13-10-0844 [doi]
AB  - Essential thrombocythaemia (ET) is characterised by enhanced platelet generation 
      and thrombosis. Once daily (od) aspirin incompletely inhibits platelet 
      thromboxane (TX)A2 production in ET. A twice daily (bid) dosing is necessary to 
      fully inhibit TXA2. Whether this dosing regimen affects in vivo prostacyclin 
      (PGI2) biosynthesis is unknown. PGI2 biosynthesis was characterised in 50 ET 
      patients on enteric-coated (EC) aspirin 100 mg od, by measuring its urinary 
      metabolite, 2,3-dinor-6-keto-PGF1α (PGI-M). Moreover, in a crossover study 22 
      patients poorly responsive to standard aspirin based on serum TXB2 levels (≥4 
      ng/ml) were randomised to different seven-day aspirin regimens: EC aspirin 100 mg 
      od, 100 mg bid, 200 mg od, or plain aspirin 100 mg od. PGI-M measured 24 hours 
      after the last aspirin intake (EC, 100 mg od) was similar in patients and healthy 
      subjects both on (n=10) and off (n=30) aspirin. PGI-M was unrelated to in vivo 
      TXA2 biosynthesis, and not affected by EC aspirin 100 mg bid or 200 mg od as 
      compared to EC 100 mg od. PGI2 biosynthesis in aspirin-treated ET patients 
      appears unrelated to TXA2 biosynthesis, and not affected by an improved aspirin 
      regimen, demonstrating its vascular safety for future trials.
FAU - Cavalca, V
AU  - Cavalca V
AD  - Viviana Cavalca, Dipartimento di Scienze Cliniche e di Comunità, Università degli 
      Studi di Milano, Via Parea 4, 20138 Milan, Italy, Tel.: +39 02 58002345, Fax: +39 
      02 58002750, E-mail: viviana.cavalca@unimi.it.
FAU - Rocca, B
AU  - Rocca B
FAU - Squellerio, I
AU  - Squellerio I
FAU - Dragani, A
AU  - Dragani A
FAU - Veglia, F
AU  - Veglia F
FAU - Pagliaccia, F
AU  - Pagliaccia F
FAU - Porro, B
AU  - Porro B
FAU - Barbieri, S S
AU  - Barbieri SS
FAU - Tremoli, E
AU  - Tremoli E
FAU - Patrono, C
AU  - Patrono C
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140327
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 57576-52-0 (Thromboxane A2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 64700-71-6 (2,3-dinor-6-ketoprostaglandin F1alpha)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/analogs & derivatives/urine
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Blood Platelets/*drug effects/physiology
MH  - Clinical Protocols
MH  - Drug Dosage Calculations
MH  - Epoprostenol/*biosynthesis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Thrombocythemia, Essential/diagnosis/*drug therapy
MH  - Thromboxane A2/*metabolism
OTO - NOTNLM
OT  - Aspirin
OT  - essential thrombocythaemia
OT  - platelets
OT  - prostacyclin
OT  - thromboxane
EDAT- 2014/03/29 06:00
MHDA- 2015/05/12 06:00
CRDT- 2014/03/28 06:00
PHST- 2013/10/14 00:00 [received]
PHST- 2014/01/24 00:00 [accepted]
PHST- 2014/03/28 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - 13-10-0844 [pii]
AID - 10.1160/TH13-10-0844 [doi]
PST - ppublish
SO  - Thromb Haemost. 2014 Jul 3;112(1):118-27. doi: 10.1160/TH13-10-0844. Epub 2014 
      Mar 27.

PMID- 18265459
OWN - NLM
STAT- MEDLINE
DCOM- 20080321
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 66
IP  - 2
DP  - 2008 Feb
TI  - [Prevention of thrombosis of coronary aneurysms in patients with a history of 
      Kawasaki disease].
PG  - 355-9
AB  - Patients with coronary artery aneurysms caused by Kawasaki disease are at 
      increased risk of coronary thrombosis and ischemia. To prevent coronary 
      thrombosis, long-term anti-thrombosis using anti-platelet drugs, such as aspirin, 
      dipyridamole, ticlopidine, clopidogrel, and abciximab, with or without warfarin 
      is recommended by official guidelines. In fact, aspirin or aspirin with warfarin 
      are the most frequently administered regimen in these patients with coronary 
      aneurysms. However, there has been paucity of data and no randomized controlled 
      study to determine the efficacy of these drugs. This short article attempts to 
      summarize the efficacy and safety of these drugs based on currently available 
      literatures and our multi-institutional experience.
FAU - Suda, Kenji
AU  - Suda K
AD  - Department of Pediatrics and Child Health, Kurume University School of Medicine.
FAU - Kudo, Yoshiyuki
AU  - Kudo Y
FAU - Sugawara, Yoko
AU  - Sugawara Y
FAU - Ishii, Masahiro
AU  - Ishii M
FAU - Matsuishi, Toyojiro
AU  - Matsuishi T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child, Preschool
MH  - Coronary Aneurysm/*drug therapy
MH  - Coronary Thrombosis/*prevention & control
MH  - Humans
MH  - Infant
MH  - Mucocutaneous Lymph Node Syndrome/*complications
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Warfarin/therapeutic use
RF  - 20
EDAT- 2008/02/12 09:00
MHDA- 2008/03/22 09:00
CRDT- 2008/02/12 09:00
PHST- 2008/02/12 09:00 [pubmed]
PHST- 2008/03/22 09:00 [medline]
PHST- 2008/02/12 09:00 [entrez]
PST - ppublish
SO  - Nihon Rinsho. 2008 Feb;66(2):355-9.

PMID- 8291746
OWN - NLM
STAT- MEDLINE
DCOM- 19940224
LR  - 20151119
IS  - 0003-4738 (Print)
IS  - 0003-4738 (Linking)
VI  - 72
IP  - 1
DP  - 1994 Jan
TI  - Tolerability of nimesulide in aspirin-sensitive patients.
PG  - 29-32
AB  - In most patients with aspirin and nonsteroidal antiinflammatory drug (NSAID) 
      intolerance, antiinflammatory treatment is a clinical problem. In this study we 
      evaluated the tolerance to a new nonsteroidal antiinflammatory drug, nimesulide 
      (Aulin, Boehringer Mannheim, Italia), in 429 patients presenting with clear 
      histories of intolerance to NSAIDs. Nimesulide has been chosen due to its weak 
      inhibitory action on cyclooxygenase and its peculiar mechanism of action. We 
      carried out a single-blind challenge with cumulative doses of nimesulide 
      administered on three different days, until the therapeutic dose of 200 mg or 
      intolerance symptoms were reached. Nimesulide has been well tolerated in 418 
      subjects and only 11 patients (3.3%) showed a positive test. Our study 
      demonstrates that nimesulide seems to be a suitable drug in aspirin 
      hypersensitivity.
FAU - Andri, L
AU  - Andri L
AD  - Allergology Unit, Main Hospital, Verona, Italy.
FAU - Senna, G
AU  - Senna G
FAU - Betteli, C
AU  - Betteli C
FAU - Givanni, S
AU  - Givanni S
FAU - Scaricabarozzi, I
AU  - Scaricabarozzi I
FAU - Mezzelani, P
AU  - Mezzelani P
FAU - Andri, G
AU  - Andri G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Allergy
JT  - Annals of allergy
JID - 0372346
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Sulfonamides)
RN  - R16CO5Y76E (Aspirin)
RN  - V4TKW1454M (nimesulide)
SB  - IM
CIN - Ann Allergy Asthma Immunol. 1995 Feb;74(2):193-4. PMID: 7697484
CIN - Ann Allergy. 1994 Nov;73(5):455-6. PMID: 7978542
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - *Drug Hypersensitivity
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Single-Blind Method
MH  - Sulfonamides/*adverse effects
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Ann Allergy. 1994 Jan;72(1):29-32.

PMID- 1285641
OWN - NLM
STAT- MEDLINE
DCOM- 19930305
LR  - 20190827
IS  - 0003-6072 (Print)
IS  - 0003-6072 (Linking)
VI  - 62
IP  - 4
DP  - 1992 Nov
TI  - Evidence for, and taxonomic value of, an arachidonic acid cascade in the 
      Lipomycetaceae.
PG  - 251-9
AB  - By using specific inhibitors of the lipoxygenase and cyclo-oxygenase pathways, 
      arachidonic acid metabolites with similar sensitivities towards these inhibitors 
      as in humans, were detected in Dipodascopsis uninucleata. The taxonomic value of 
      aspirin sensitive arachidonic acid metabolites in the Lipomycetaceae was next 
      assessed. No metabolites of which the production is inhibited by aspirin were 
      detected in strains representing the following species: Lipomyces starkeyi, 
      Lipomyces kononenkoae, Lipomyces tetrasporus, Myxozyma melibiosi, Myxozyma 
      mucilagina, Myxozyma kluyveri, Waltomyces lipofer, Zygozyma oligophaga and 
      Zygozyma arxii. The detection of such aspirin sensitive arachidonic acid 
      metabolites in representative strains of Lipomyces anomalus and the genus 
      Dipodascopsis, emphasises the isolated position of these taxa in the genus 
      Lipomyces and the family Lipomycetaceae, respectively. Finally using long chain 
      fatty acid analyses, electrophoretic karyotyping and other phenotypic characters, 
      a phylogenetic scheme is proposed for some genera in the Lipomycetaceae.
FAU - Kock, J L
AU  - Kock JL
AD  - Department of Microbiology, University of the Orange Free State, Bloemfontein, 
      South Africa.
FAU - Coetzee, D J
AU  - Coetzee DJ
FAU - van Dyk, M S
AU  - van Dyk MS
FAU - Truscott, M
AU  - Truscott M
FAU - Botha, A
AU  - Botha A
FAU - Augustyn, O P
AU  - Augustyn OP
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Antonie Van Leeuwenhoek
JT  - Antonie van Leeuwenhoek
JID - 0372625
RN  - 0 (Fatty Acids)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid/*metabolism
MH  - Aspirin/*pharmacology
MH  - Fatty Acids/classification
MH  - Humans
MH  - Karyotyping
MH  - Lipoxygenase Inhibitors/chemistry
MH  - Phenotype
MH  - Phylogeny
MH  - Prostaglandin-Endoperoxide Synthases/chemistry
MH  - Saccharomycetales/*classification/genetics/metabolism
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
AID - 10.1007/BF00572592 [doi]
PST - ppublish
SO  - Antonie Van Leeuwenhoek. 1992 Nov;62(4):251-9. doi: 10.1007/BF00572592.

PMID- 3706054
OWN - NLM
STAT- MEDLINE
DCOM- 19860603
LR  - 20190824
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 17
IP  - 5-6
DP  - 1986 Mar
TI  - Contribution of ADP to the amplification of primary platelet aggregation by 
      platelet activating factor (PAF): modulatory role of aspirin.
PG  - 506-11
AB  - Platelet Activating Factor (PAF)-induced human platelet aggregation in citrated 
      plasma is accompanied by activation of the cyclo-oxygenase pathway and release of 
      intracellular constituents including Adenosine-5'-diphosphate (ADP). Inhibition 
      of the cyclo-oxygenase pathway by aspirin prevented the amplification of primary 
      platelet aggregation induced by threshold concentrations of PAF. Removal of ADP 
      by enzymatic systems had little or no effect on PAF-induced full aggregation, but 
      reversed the aggregating effect of PAF (at 10 times threshold concentrations) on 
      'aspirinated' platelets. Aspirin also prevented the synergism between PAF and ADP 
      when subthreshold concentrations of both compounds were combined. Similar results 
      were obtained in heparinized platelet-rich plasma. Thus, ADP may amplify the 
      primary response to PAF but its role is modulated by the availability of the 
      cyclo-oxygenase pathway products.
FAU - Lauri, D
AU  - Lauri D
FAU - Cerletti, C
AU  - Cerletti C
FAU - de Gaetano, G
AU  - de Gaetano G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Platelet Activating Factor)
RN  - 020IUV4N33 (Phosphocreatine)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - EC 2.7.3.2 (Creatine Kinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Creatine Kinase/pharmacology
MH  - Drug Interactions
MH  - Humans
MH  - Kinetics
MH  - Phosphocreatine/pharmacology
MH  - Platelet Activating Factor/*pharmacology
MH  - Platelet Aggregation/*drug effects
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
AID - 10.1007/BF01965522 [doi]
PST - ppublish
SO  - Agents Actions. 1986 Mar;17(5-6):506-11. doi: 10.1007/BF01965522.

PMID- 7256361
OWN - NLM
STAT- MEDLINE
DCOM- 19810925
LR  - 20161123
IS  - 0125-1562 (Print)
IS  - 0125-1562 (Linking)
VI  - 12
IP  - 1
DP  - 1981 Mar
TI  - Hypoxaemia and the effect of aspirin in thalassaemia.
PG  - 90-3
AB  - Blood gas analysis of arterial blood was performed in 34 patients with beta 
      o-thalassaemia/haemoglobin E disease and homozygous beta o-thalassaemia. Among 
      the 22 splenectomised patients 19 had PaO2 lower than the normal expected value, 
      and 18 of these had PaO2 lower than 80 mmHg. Of the 12 non-splenectomised 
      patients 5 had PaO2 lower than the expected normal value but only in one case it 
      was lower than 80 mmHg. After aspirin or Persantin administration there was a 
      definite rise in the PaO2 in 10 out of 12 patients. The hypoxaemia is believed to 
      occur from increased platelet aggregation leading to pulmonary artery occlusion. 
      The rise of the arterial PaO2 after aspirin administration indicates that the 
      observed hypoxaemia is due to reversible platelet aggregation in the majority of 
      cases.
FAU - Fucharoen, S
AU  - Fucharoen S
FAU - Youngchaiyud, P
AU  - Youngchaiyud P
FAU - Wasi, P
AU  - Wasi P
LA  - eng
GR  - AM 09805/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Thailand
TA  - Southeast Asian J Trop Med Public Health
JT  - The Southeast Asian journal of tropical medicine and public health
JID - 0266303
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Female
MH  - Humans
MH  - Hypoxia/*complications/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Splenectomy
MH  - Thalassemia/*complications/drug therapy
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
PST - ppublish
SO  - Southeast Asian J Trop Med Public Health. 1981 Mar;12(1):90-3.

PMID- 645106
OWN - NLM
STAT- MEDLINE
DCOM- 19780617
LR  - 20190907
IS  - 0049-8254 (Print)
IS  - 0049-8254 (Linking)
VI  - 8
IP  - 4
DP  - 1978 Apr
TI  - Biotransformation of chlormezanone, 
      2-(4-chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide, a muscle-relaxing and 
      tranquillizing agent: the effect of combination with aspirin on its metabolic 
      fate in rats and mice.
PG  - 229-38
AB  - 1. After oral administration of [14C]chlormezanone, about 74% of the dose was 
      excreted into the urine of rats within 24 h and 21% into urine of mice within 2 
      h. 2. Biliary excretion of radioactivity was about 10% of the dose in rats. 3. 
      Six metabolites in the urine of rats and mice were identified as p-chlorobenzoic 
      acid, p-chlorohippuric acid, N-methyl-p-chlorobenzamide, 
      2-[N-methyl-N-(p-chlorobenzoyl)]carbamoylethylsulphonic acid, 3-sulphopropionic 
      acid and the glucuronide of p-chlorobenzoid acid. 4. The effect of combination 
      with aspirin on the metabolic fate of chlormezanone was investigated in rats and 
      mice. Aspirin had no effect on the metabolite pattern in either species but 
      reduced the rate of excretion, particularly in the mouse.
FAU - Hakusui, H
AU  - Hakusui H
FAU - Tachizawa, H
AU  - Tachizawa H
FAU - Sano, M
AU  - Sano M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Xenobiotica
JT  - Xenobiotica; the fate of foreign compounds in biological systems
JID - 1306665
RN  - GP568V9G19 (Chlormezanone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bile/metabolism
MH  - Biotransformation/drug effects
MH  - Chlormezanone/*metabolism/urine
MH  - Chromatography, Gas
MH  - Chromatography, Thin Layer
MH  - Drug Interactions
MH  - Male
MH  - Mass Spectrometry
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Rats
EDAT- 1978/04/01 00:00
MHDA- 1978/04/01 00:01
CRDT- 1978/04/01 00:00
PHST- 1978/04/01 00:00 [pubmed]
PHST- 1978/04/01 00:01 [medline]
PHST- 1978/04/01 00:00 [entrez]
AID - 10.3109/00498257809056144 [doi]
PST - ppublish
SO  - Xenobiotica. 1978 Apr;8(4):229-38. doi: 10.3109/00498257809056144.

PMID- 31673755
OWN - NLM
STAT- MEDLINE
DCOM- 20200714
LR  - 20210813
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 146
IP  - 8
DP  - 2020 Aug
TI  - The evidence strength of a meta-analysis of aspirin for primary prevention of 
      cancer.
PG  - 2173-2175
LID - 10.1007/s00432-019-03069-w [doi]
AB  - Dr. Tarek Haykal et al. (145:1795-1809, 2019) reported a meta-analysis of aspirin 
      for the primary prevention of cancer in individuals without known cancer. The 
      authors found that aspirin use was not associated with significant reduction in 
      cancer mortality or incidence, but with higher rates of bleeding. The findings of 
      this study added some evidence to the clinical practice. However, several issues 
      might have compromised the strength of the evidence of this systematic review. If 
      the investigators could have further clarified the inclusion and exclusion 
      criteria, included all eligible studies, extracted data more meticulously, and 
      performed more necessary sensitivity analyses to confirm the robustness of their 
      findings, the strength of evidence of this meta-analysis would have been 
      stronger.
FAU - Wu, Qibiao
AU  - Wu Q
AUID- ORCID: 0000-0002-1670-1050
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Faculty of Chinese 
      Medicine, Macau Institute for Applied Research in Medicine and Health, Macau 
      University of Science and Technology, Macau, China. qbwu@must.edu.mo.
FAU - Leung, Elaine Laihan
AU  - Leung EL
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Faculty of Chinese 
      Medicine, Macau Institute for Applied Research in Medicine and Health, Macau 
      University of Science and Technology, Macau, China.
LA  - eng
GR  - 130/2017/A3/The Science and Technology Development Fund, Macau SAR/International
GR  - 0099/2018/A3/The Science and Technology Development Fund, Macau SAR/International
GR  - 0096/2018/A3/The Science and Technology Development Fund, Macau SAR/International
PT  - Comment
PT  - Letter
DEP - 20191031
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - J Cancer Res Clin Oncol. 2019 Jul;145(7):1795-1809. PMID: 31098750
MH  - *Aspirin
MH  - Hemorrhage
MH  - Humans
MH  - Incidence
MH  - *Neoplasms
MH  - Primary Prevention
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer
OT  - Evidence
OT  - Letter to the editors
OT  - Meta-analysis
OT  - Primary prevention
OT  - Strength
EDAT- 2019/11/02 06:00
MHDA- 2020/07/15 06:00
CRDT- 2019/11/02 06:00
PHST- 2019/10/17 00:00 [received]
PHST- 2019/10/24 00:00 [accepted]
PHST- 2019/11/02 06:00 [pubmed]
PHST- 2020/07/15 06:00 [medline]
PHST- 2019/11/02 06:00 [entrez]
AID - 10.1007/s00432-019-03069-w [pii]
AID - 10.1007/s00432-019-03069-w [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2020 Aug;146(8):2173-2175. doi: 
      10.1007/s00432-019-03069-w. Epub 2019 Oct 31.

PMID- 18398040
OWN - NLM
STAT- MEDLINE
DCOM- 20080724
LR  - 20211020
IS  - 1055-9965 (Print)
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
VI  - 17
IP  - 4
DP  - 2008 Apr
TI  - Transcription factor 7-like 2 polymorphism and colon cancer.
PG  - 978-82
LID - 10.1158/1055-9965.EPI-07-2687 [doi]
AB  - Polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene have been 
      associated with insulin sensitivity and diabetes, and the TCF7L2 gene is involved 
      in the Wnt/beta-catenin signaling pathway, all factors thought to be important in 
      the etiology of colon cancer. In this confirmatory study, we evaluated the 
      rs7903146 TCF7L2 polymorphism with colon cancer using previously collected data 
      on 1,578 cases and 1,966 controls. We did not observe a statistically significant 
      association between the rs7903146 polymorphisms and risk of colon cancer [odds 
      ratio (OR), 1.12; 95% confidence interval (95% CI), 0.98-1.28] when evaluating 
      the total population. We did, however, observe a statistically significant 
      interaction between the rs7903146 TCF7L2 polymorphism and recent use of 
      aspirin/nonsteroidal anti-inflammatory drugs (NSAID; P = 0.001). Increased colon 
      cancer risk associated with the T allele was restricted to those without recent 
      use of aspirin/NSAIDs (OR, 1.65; 95% CI, 1.35-2.02, relative to recent aspirin 
      users, i.e., use of aspirin/NSAIDS within the 2 years before diagnosis, with the 
      CC genotype). Among individuals who reported recent use of aspirin/NSAIDs, the T 
      allele reduced risk of colon cancer (OR, 0.78; 95% CI, 0.62-0.98) in a 
      dose-response fashion (P for linear trend across genotypes = 0.03). These data 
      suggest that colon cancer risk associated with the rs7903146 TCF7L2 polymorphism 
      is modified by use of aspirin/NSAIDs.
FAU - Slattery, Martha L
AU  - Slattery ML
AD  - Department of Internal Medicine, University of Utah School of Medicine, Salt Lake 
      City, UT 84108, USA. mslattery@hrc.utah.edu
FAU - Folsom, Aaron R
AU  - Folsom AR
FAU - Wolff, Roger
AU  - Wolff R
FAU - Herrick, Jenifer
AU  - Herrick J
FAU - Caan, Bette J
AU  - Caan BJ
FAU - Potter, John D
AU  - Potter JD
LA  - eng
GR  - R01 CA085846/CA/NCI NIH HHS/United States
GR  - R01 CA048998/CA/NCI NIH HHS/United States
GR  - CA 61757/CA/NCI NIH HHS/United States
GR  - M01 RR000064-350473/RR/NCRR NIH HHS/United States
GR  - U01 CA048998/CA/NCI NIH HHS/United States
GR  - M01 RR000064-340473/RR/NCRR NIH HHS/United States
GR  - N01 PC 67000/PC/NCI NIH HHS/United States
GR  - CA 85846/CA/NCI NIH HHS/United States
GR  - R01 CA048998-12A2/CA/NCI NIH HHS/United States
GR  - R01 CA085846-06/CA/NCI NIH HHS/United States
GR  - CA 48998/CA/NCI NIH HHS/United States
GR  - M01 RR000064/RR/NCRR NIH HHS/United States
GR  - R01 CA061757-11/CA/NCI NIH HHS/United States
GR  - R01 CA061757/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (TCF Transcription Factors)
RN  - 0 (TCF7L2 protein, human)
RN  - 0 (Transcription Factor 7-Like 2 Protein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Colonic Neoplasms/chemically induced/*genetics/pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Polymorphism, Genetic/*drug effects
MH  - TCF Transcription Factors/*genetics
MH  - Transcription Factor 7-Like 2 Protein
PMC - PMC2587179
MID - NIHMS50716
EDAT- 2008/04/10 09:00
MHDA- 2008/07/25 09:00
CRDT- 2008/04/10 09:00
PHST- 2008/04/10 09:00 [pubmed]
PHST- 2008/07/25 09:00 [medline]
PHST- 2008/04/10 09:00 [entrez]
AID - 17/4/978 [pii]
AID - 10.1158/1055-9965.EPI-07-2687 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):978-82. doi: 
      10.1158/1055-9965.EPI-07-2687.

PMID- 8928091
OWN - NLM
STAT- MEDLINE
DCOM- 19961029
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 81
IP  - 3
DP  - 1996 Feb 1
TI  - Plasma glycocalicin levels are not elevated in patients with a history of 
      transient ischaemic event and are normal in aspirinated normal volunteers.
PG  - 339-43
AB  - Glycocalicin (GC) is the soluble portion of platelet membrane protein GP1b, and 
      may be cleaved from the platelet surface during platelet activation. Previous 
      study has indicated that plasma glycocalicin/platelet (GC/plt) levels are 
      elevated in patients presenting with acute stroke. The present study was 
      undertaken to determine the GC/plt levels in patients being treated for transient 
      ischaemic episodes, to assess whether the elevated GC/plt level in acute stroke 
      is due to a detectable, constitutive premorbid state of platelet activation. In 
      sixteen consecutive patients attending a vascular surgery clinic, GC levels were 
      measured on a citrated plasma sample, and corrected for circulating platelet 
      count. Since 15 of 16 patients were taking aspirin when seen at clinic, a control 
      study was undertaken to assess the effect of aspirin on sequential plasma GC/plt 
      levels measured over 10 days--5 pre and post daily aspirin for 5 days, 4 acting 
      as non-aspirinated controls. Plasma GC/plt levels in normal plasma were 21.6 +/- 
      8.0 fg; mean +/- SD. In the 16 patients the GC/plt levels were 13.1 fg/plt; SD 
      5.4, range 2.9-24.3. All platelet counts were in the normal range in all patients 
      involved. While a masking effect due to aspirin cannot be completely ruled out, 
      these studies indicate that plasma GC/plt level is not useful as a predictor of 
      acute stroke in the premorbid population.
FAU - Huggan, P J
AU  - Huggan PJ
AD  - Faculty of Medicine, University of Edinburgh, Scotland.
FAU - Milne, A A
AU  - Milne AA
FAU - Bessos, H
AU  - Bessos H
FAU - Atkinson, A
AU  - Atkinson A
FAU - Murphy, W G
AU  - Murphy WG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIb-IX Complex)
RN  - 0 (glycocalicin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Case-Control Studies
MH  - Cerebrovascular Disorders/*blood
MH  - Humans
MH  - Platelet Aggregation Inhibitors/blood/*pharmacology
MH  - Platelet Glycoprotein GPIb-IX Complex/*metabolism
MH  - Reference Values
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - 0049-3848(96)00005-9 [pii]
AID - 10.1016/0049-3848(96)00005-9 [doi]
PST - ppublish
SO  - Thromb Res. 1996 Feb 1;81(3):339-43. doi: 10.1016/0049-3848(96)00005-9.

PMID- 28658522
OWN - NLM
STAT- MEDLINE
DCOM- 20180515
LR  - 20181202
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 7
IP  - 9
DP  - 2017 Sep
TI  - Platelet activation by crushed and uncrushed muscle: a flow cytometry analysis.
PG  - 916-919
LID - 10.1002/alr.21977 [doi]
AB  - BACKGROUND: Crushed autologous muscle is used in skull base surgery in the acute 
      phase of major arterial hemorrhage to stop bleeding. The mechanism of this is not 
      yet clear, but is thought to involve the formation of a platelet plug, which 
      seals the vessel wall defect but still allows ongoing blood flow to the brain. 
      METHODS: In this study we use flow cytometry to replicate the in-vivo actions of 
      crushed muscle on platelets in whole blood. We compare the ratio of activation of 
      platelets exposed to crushed and uncrushed muscle supernatant in control patients 
      and in patients on antiplatelet agents. RESULTS: Crushed muscle activated 
      platelets to a higher degree than uncrushed muscle: 5.18-fold greater in control 
      blood (p = 0.002); 6.53-fold greater in aspirin-exposed blood (p < 0.0001); and 
      9.4-fold greater in clopidogrel-exposed blood (p < 0.0001). CONCLUSION: Crushed 
      muscle caused a consistently increased ratio of platelet activation when compared 
      with uncrushed muscle across all groups, adding to the evidence that at least 
      part of its clinical effect is the result of platelet activation.
CI  - © 2017 ARS-AAOA, LLC.
FAU - Jukes, Alistair
AU  - Jukes A
AD  - Department of Otolaryngology, Head and Neck Surgery, Queen Elizabeth Hospital, 
      Woodville South, Adelaide, SA, Australia.
AD  - Department of Neurosurgery, Royal Adelaide Hospital, Adelaide, SA, Australia.
AD  - Department of Medicine, University of Adelaide, Queen Elizabeth Hospital, 
      Woodville South, Adelaide, SA, Australia.
FAU - Miljkovic, Dijana
AU  - Miljkovic D
AD  - Department of Otolaryngology, Head and Neck Surgery, Queen Elizabeth Hospital, 
      Woodville South, Adelaide, SA, Australia.
AD  - Department of Medicine, University of Adelaide, Queen Elizabeth Hospital, 
      Woodville South, Adelaide, SA, Australia.
FAU - Wormald, P J
AU  - Wormald PJ
AD  - Department of Otolaryngology, Head and Neck Surgery, Queen Elizabeth Hospital, 
      Woodville South, Adelaide, SA, Australia.
AD  - Department of Medicine, University of Adelaide, Queen Elizabeth Hospital, 
      Woodville South, Adelaide, SA, Australia.
FAU - Psaltis, Alkis J
AU  - Psaltis AJ
AD  - Department of Otolaryngology, Head and Neck Surgery, Queen Elizabeth Hospital, 
      Woodville South, Adelaide, SA, Australia.
AD  - Department of Medicine, University of Adelaide, Queen Elizabeth Hospital, 
      Woodville South, Adelaide, SA, Australia.
LA  - eng
PT  - Journal Article
DEP - 20170628
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Clopidogrel
MH  - Flow Cytometry
MH  - Humans
MH  - *Muscle, Skeletal
MH  - *Platelet Activation
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Ticlopidine/analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - anterior skull base
OT  - endoscopic minimally invasive surgery of the skull base
OT  - endoscopic skull base surgery
OT  - endoscopy
OT  - hemorrhagic disorders
EDAT- 2017/06/29 06:00
MHDA- 2018/05/16 06:00
CRDT- 2017/06/29 06:00
PHST- 2017/03/04 00:00 [received]
PHST- 2017/05/11 00:00 [revised]
PHST- 2017/05/23 00:00 [accepted]
PHST- 2017/06/29 06:00 [pubmed]
PHST- 2018/05/16 06:00 [medline]
PHST- 2017/06/29 06:00 [entrez]
AID - 10.1002/alr.21977 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2017 Sep;7(9):916-919. doi: 10.1002/alr.21977. Epub 
      2017 Jun 28.

PMID- 12709922
OWN - NLM
STAT- MEDLINE
DCOM- 20031212
LR  - 20131121
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 29
IP  - 2
DP  - 2003 Apr
TI  - Inherited thrombophilia and gestational vascular complications.
PG  - 185-94
AB  - Severe obstetric complications, including preeclampsia, intrauterine growth 
      retardation, abruptio placentae, and stillbirth, constitute a major cause of 
      maternal and perinatal morbidity and death. The etiology of these severe 
      obstetric complications is still unknown. However, the frequent finding of 
      structural and thrombotic changes in placental capillaries, which lead to 
      inadequate fetomaternal circulation and decreased placental perfusion, and the 
      high prevalence of heritable or acquired risk factors for thrombosis found in 
      women with these complications strongly suggest a cause-and-effect relationship. 
      This review describes the recent findings on the association between these 
      obstetric complications and the various thrombophilias, and recent therapeutic 
      approaches. Aspirin, which was regarded as the drug of choice for the prevention 
      of such obstetric complications, has proved to be ineffective in a large clinical 
      trial. The encouraging observations on the efficacy of low-molecular-weight 
      heparins, which are also included in the recently published guidelines of The 
      American College of Chest Physicians, are summarized in this review. However, 
      controlled clinical trials are still necessary to allow the development of better 
      clinical standards.
FAU - Kupferminc, Michael J
AU  - Kupferminc MJ
AD  - Maternal Fetal Medicine Unit, Department of Obstetrics and Gynecology, Lis 
      Maternity Hospital, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of 
      Medicine, Tel-Aviv University, Israel. tmcobgyn@tasmc.health.gov.il
FAU - Eldor, Amiram
AU  - Eldor A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/etiology
MH  - Pregnancy Complications, Cardiovascular/drug therapy/*etiology/prevention & 
      control
MH  - Thrombophilia/*complications/drug therapy
RF  - 86
EDAT- 2003/04/24 05:00
MHDA- 2003/12/13 05:00
CRDT- 2003/04/24 05:00
PHST- 2003/04/24 05:00 [pubmed]
PHST- 2003/12/13 05:00 [medline]
PHST- 2003/04/24 05:00 [entrez]
AID - 10.1055/s-2003-38834 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2003 Apr;29(2):185-94. doi: 10.1055/s-2003-38834.

PMID- 3767696
OWN - NLM
STAT- MEDLINE
DCOM- 19861107
LR  - 20191030
IS  - 0276-5047 (Print)
IS  - 0276-5047 (Linking)
VI  - 6
IP  - 5
DP  - 1986 Sep-Oct
TI  - Iliac artery mural thrombus formation. Effect of antiplatelet therapy on 
      111In-platelet deposition in baboons.
PG  - 511-8
AB  - To measure the rate, extent, and time course of arterial mural thrombus formation 
      in vivo and to assess the effects of antiplatelet therapy in that setting, we 
      have studied autologous 111In-platelet deposition induced by experimental iliac 
      artery aneurysms in baboons. Scintillation camera imaging analyses were performed 
      at 1, 24, 48, and 72 hours after implantation of the device. Correction for 
      tissue attenuation was determined by using a small, comparably located 111In 
      source implanted at the time of surgery. In five animals, 111In-platelet activity 
      accumulated progressively after device implantation, reaching a maximum after the 
      third day. Repeat image analysis carried out 2 weeks after the surgical procedure 
      also showed progressive accumulation of 111In-platelets over 3 days but at 
      markedly reduced amounts as compared with the initial study. In five additional 
      animals, treatment with a combination of aspirin and dipyridamole begun 1 hour 
      after surgical implantation reduced 111In-platelet deposition to negligible 
      levels by the third day. Although platelet survival time was shortened and 
      platelet turnover was reciprocally increased in all operated animals, platelet 
      survival and turnover were not affected by antiplatelet therapy. We conclude 
      that, in contrast to platelet survival and turnover measurements, 111In-platelet 
      imaging is a reliable and sensitive method for localizing and quantifying focal 
      arterial thrombi and for assessing the effects of antiplatelet therapy.
FAU - Hanson, S R
AU  - Hanson SR
FAU - Paxton, L D
AU  - Paxton LD
FAU - Harker, L A
AU  - Harker LA
LA  - eng
GR  - HL 31469/HL/NHLBI NIH HHS/United States
GR  - HL 31950/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arteriosclerosis
JT  - Arteriosclerosis (Dallas, Tex.)
JID - 8401388
RN  - 0 (Radioisotopes)
RN  - 045A6V3VFX (Indium)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Platelets/drug effects
MH  - Cell Survival/drug effects
MH  - Dipyridamole/pharmacology
MH  - Indium
MH  - Male
MH  - Papio
MH  - *Platelet Aggregation/drug effects
MH  - Platelet Count
MH  - Radioisotopes
MH  - Radionuclide Imaging
MH  - Thrombosis/diagnostic imaging/*etiology
EDAT- 1986/09/01 00:00
MHDA- 1986/09/01 00:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 1986/09/01 00:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
AID - 10.1161/01.atv.6.5.511 [doi]
PST - ppublish
SO  - Arteriosclerosis. 1986 Sep-Oct;6(5):511-8. doi: 10.1161/01.atv.6.5.511.

PMID- 14972424
OWN - NLM
STAT- MEDLINE
DCOM- 20040520
LR  - 20131121
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 25
IP  - 3
DP  - 2004 Feb
TI  - Effect of fixed low-dose warfarin added to aspirin in the long term after acute 
      myocardial infarction; the LoWASA Study.
PG  - 232-9
AB  - AIM: To evaluate whether long-term treatment with a fixed low dose of warfarin in 
      combination with aspirin improves the prognosis compared with aspirin treatment 
      alone after an acute myocardial infarction (AMI). METHODS: Patients who were 
      hospitalized for AMI were randomized to either 1.25mg of warfarin plus 75mg of 
      aspirin (n=1659) daily or 75mg of aspirin alone (n=1641). The study was performed 
      according to the PROBE (Prospective Open Treatment and Blinded End Point 
      Evaluation) design and was conducted at 31 hospitals in Sweden. The median 
      follow-up time was 5.0 years. In the aspirin+warfarin group, 30.2% were 
      permanently withdrawn as opposed to 14.0% in the aspirin group (P<0.0001). 
      Analyses were performed on an intention-to-treat basis. RESULTS: The combination 
      of cardiovascular death, reinfarction or stroke was registered in 28.1% in the 
      aspirin+warfarin group versus 28.8% in the aspirin group (NS). Cardiovascular 
      deaths occurred in 14.2% in the aspirin+warfarin group vs 15.7% in the aspirin 
      group (NS). Whereas no difference was found with regard to total mortality or 
      reinfarction, those randomized to aspirin+warfarin had a reduced occurrence of 
      stroke (4.7% vs 7.1%; P=0.004). The percentage of patients who suffered a serious 
      bleed was 1.0% in the aspirin group vs 2.2% in the combination group (P=0.0006). 
      CONCLUSION: A fixed low dose of warfarin added to aspirin in the long term after 
      AMI did not reduce the combined risk of cardiovascular death, reinfarction or 
      stroke. The results did, however, indicate that a fixed low dose of warfarin 
      added to aspirin reduced the risk of stroke, but this was a secondary end point. 
      The combination of aspirin and warfarin was associated with an increased risk of 
      bleeding.
FAU - Herlitz, Johan
AU  - Herlitz J
AD  - Division of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden. 
      johan.herlitz@hjl.gu.se
FAU - Holm, Johan
AU  - Holm J
FAU - Peterson, Magnus
AU  - Peterson M
FAU - Karlson, Björn W
AU  - Karlson BW
FAU - Haglid Evander, Maria
AU  - Haglid Evander M
FAU - Erhardt, Leif
AU  - Erhardt L
CN  - LoWASA study group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - International Normalized Ratio
MH  - Long-Term Care
MH  - Male
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Prospective Studies
MH  - Recurrence
MH  - Stroke/etiology
MH  - Treatment Outcome
MH  - Warfarin/*administration & dosage/adverse effects
EDAT- 2004/02/20 05:00
MHDA- 2004/05/21 05:00
CRDT- 2004/02/20 05:00
PHST- 2003/04/16 00:00 [received]
PHST- 2003/09/24 00:00 [revised]
PHST- 2003/10/23 00:00 [accepted]
PHST- 2004/02/20 05:00 [pubmed]
PHST- 2004/05/21 05:00 [medline]
PHST- 2004/02/20 05:00 [entrez]
AID - S0195668X03007255 [pii]
AID - 10.1016/j.ehj.2003.10.026 [doi]
PST - ppublish
SO  - Eur Heart J. 2004 Feb;25(3):232-9. doi: 10.1016/j.ehj.2003.10.026.

PMID- 444675
OWN - NLM
STAT- MEDLINE
DCOM- 19790816
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 54
IP  - 1
DP  - 1979 Jul
TI  - Release of platelet fibronectin (cold-insoluble globulin) from alpha granules 
      induced by thrombin or collagen; lack of requirement for plasma fibronectin in 
      ADP-induced platelet aggregation.
PG  - 8-12
AB  - Platelets lysed with Triton X-100 contain 3.44 +/- 1.27 (SD) microgram of 
      fibronectin (cold-insoluble globulin) per 10(9) platelets. Fibronectin was 
      partially released from washed whole platelets by collagen or thrombin, and its 
      release by collagen was inhibited by aspirin. Analysis of subcellular fractions 
      obtained by density-gradient centrifugation of disrupted platelets indicated that 
      fibronectin was contained in the alpha granules. Fibrinogen depleted of 
      fibronectin (less than 2 microgram/mg) supported ADP-induced aggregation as 
      effectively as fibrinogen contaminated with this protein, thus reinforcing the 
      generally held view that fibrinogen itself is the necessary protein cofactor in 
      this reaction.
FAU - Zucker, M B
AU  - Zucker MB
FAU - Mosesson, M W
AU  - Mosesson MW
FAU - Broekman, M J
AU  - Broekman MJ
FAU - Kaplan, K L
AU  - Kaplan KL
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Serum Globulins)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate
MH  - Aspirin/pharmacology
MH  - Blood Platelets/metabolism
MH  - Collagen
MH  - Cytoplasmic Granules/*metabolism
MH  - Humans
MH  - *Platelet Aggregation/drug effects
MH  - Serum Globulins/*metabolism
MH  - Thrombin
EDAT- 1979/07/01 00:00
MHDA- 1979/07/01 00:01
CRDT- 1979/07/01 00:00
PHST- 1979/07/01 00:00 [pubmed]
PHST- 1979/07/01 00:01 [medline]
PHST- 1979/07/01 00:00 [entrez]
AID - S0006-4971(20)72622-4 [pii]
PST - ppublish
SO  - Blood. 1979 Jul;54(1):8-12.

PMID- 36967017
OWN - NLM
STAT- MEDLINE
DCOM- 20230620
LR  - 20230620
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 151
IP  - 6
DP  - 2023 Jun
TI  - Omalizumab ameliorates extrarespiratory symptoms in patients with 
      aspirin-exacerbated respiratory disease.
PG  - 1667-1672.e2
LID - S0091-6749(23)00366-4 [pii]
LID - 10.1016/j.jaci.2023.03.014 [doi]
AB  - BACKGROUND: Omalizumab, an anti-IgE antibody, has clinical efficacy against 
      respiratory symptoms of aspirin-exacerbated respiratory disease (AERD). However, 
      some patients with AERD also present with extrarespiratory (chest, 
      gastrointestinal, and/or cutaneous) symptoms, which are resistant to conventional 
      treatment but can be alleviated by systemic corticosteroids. OBJECTIVE: We 
      evaluated the efficacy of omalizumab on extrarespiratory symptoms related to 
      AERD. METHODS: In study 1, a total of 27 consecutive patients with AERD initially 
      prescribed omalizumab at Sagamihara National Hospital between July 2009 and March 
      2019 were retrospectively studied. Frequency of exacerbations of AERD-related 
      extrarespiratory symptoms was compared before and after omalizumab treatment. In 
      study 2, we reported 3 AERD cases with aspirin challenge-induced extrarespiratory 
      symptoms among patients studied in our previous randomized trial (registration 
      UMIN000018777), which evaluated the effects of omalizumab on hypersensitivity 
      reactions during aspirin challenge to AERD patients. Extrarespiratory symptoms 
      induced during the aspirin challenge were compared between placebo and omalizumab 
      phases. RESULTS: In study 1, omalizumab treatment was associated with decrease in 
      frequency of exacerbation of chest pain (no. [%] of patients with exacerbation 
      frequency ≥1 time per year, 6 [22.2%] vs 0; P < .001), gastrointestinal symptoms 
      (9 [33.3%] vs 2 [7.4%]; P = .016), and cutaneous symptoms (16 [59.3%] vs 2 
      [7.4%]; P < .001), even under conditions of treatment-related reduction in 
      systemic corticosteroid dose. Omalizumab also attenuated all the extrarespiratory 
      symptoms during aspirin challenge in study 2. CONCLUSION: Omalizumab ameliorated 
      extrarespiratory symptoms at baseline (without aspirin exposure) and during 
      aspirin challenge.
CI  - Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Hayashi, Hiroaki
AU  - Hayashi H
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization, Sagamihara National Hospital, Sagamihara, Japan; Department of 
      Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Fukutomi, Yuma
AU  - Fukutomi Y
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization, Sagamihara National Hospital, Sagamihara, Japan.
FAU - Mitsui, Chihiro
AU  - Mitsui C
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization, Sagamihara National Hospital, Sagamihara, Japan.
FAU - Kajiwara, Keiichi
AU  - Kajiwara K
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization, Sagamihara National Hospital, Sagamihara, Japan.
FAU - Watai, Kentaro
AU  - Watai K
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization, Sagamihara National Hospital, Sagamihara, Japan; Center for 
      Immunology and Allergology, Shonan Kamakura General Hospital, Kamakura, Japan.
FAU - Tomita, Yasuhiro
AU  - Tomita Y
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization, Sagamihara National Hospital, Sagamihara, Japan; Department of 
      Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Kamide, Yosuke
AU  - Kamide Y
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization, Sagamihara National Hospital, Sagamihara, Japan.
FAU - Tsuburai, Takahiro
AU  - Tsuburai T
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization, Sagamihara National Hospital, Sagamihara, Japan; Department of 
      Respiratory Medicine, St Marianna University School of Medicine, Yokohama City 
      Seibu Hospital, Yokohama, Japan.
FAU - Sekiya, Kiyoshi
AU  - Sekiya K
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization, Sagamihara National Hospital, Sagamihara, Japan.
FAU - Ishii, Makoto
AU  - Ishii M
AD  - Department of Respiratory Medicine, Nagoya University Graduate School of 
      Medicine, Nagoya, Japan.
FAU - Hasegawa, Yoshinori
AU  - Hasegawa Y
AD  - Department of Respiratory Medicine, Nagoya University Graduate School of 
      Medicine, Nagoya, Japan; National Hospital Organization of Nagoya Medical Center, 
      Nagoya, Japan.
FAU - Taniguchi, Masami
AU  - Taniguchi M
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization, Sagamihara National Hospital, Sagamihara, Japan; Center for 
      Immunology and Allergology, Shonan Kamakura General Hospital, Kamakura, Japan. 
      Electronic address: m_taniguchi@shonankamakura.or.jp.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20230324
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Humans
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/adverse effects
MH  - *Asthma, Aspirin-Induced
MH  - Omalizumab/therapeutic use
MH  - Retrospective Studies
MH  - *Sinusitis/drug therapy
OTO - NOTNLM
OT  - 11,15-dioxo-9a-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid 
      (tetranor–prostaglandin D(2) metabolite)
OT  - Aspirin-exacerbated respiratory disease
OT  - extrarespiratory symptom
OT  - leukotriene E(4)
OT  - omalizumab
EDAT- 2023/03/27 06:00
MHDA- 2023/06/09 06:42
CRDT- 2023/03/26 20:27
PHST- 2022/11/28 00:00 [received]
PHST- 2023/03/12 00:00 [revised]
PHST- 2023/03/16 00:00 [accepted]
PHST- 2023/06/09 06:42 [medline]
PHST- 2023/03/27 06:00 [pubmed]
PHST- 2023/03/26 20:27 [entrez]
AID - S0091-6749(23)00366-4 [pii]
AID - 10.1016/j.jaci.2023.03.014 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2023 Jun;151(6):1667-1672.e2. doi: 
      10.1016/j.jaci.2023.03.014. Epub 2023 Mar 24.

PMID- 25376662
OWN - NLM
STAT- MEDLINE
DCOM- 20150707
LR  - 20141118
IS  - 1423-0208 (Electronic)
IS  - 0251-5350 (Linking)
VI  - 43
IP  - 2
DP  - 2014
TI  - Non-steroidal anti-inflammatory drug use and essential tremor.
PG  - 145-9
LID - 10.1159/000366424 [doi]
AB  - BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to be 
      inversely related to Parkinson's disease and Alzheimer's disease, both of which 
      may share common mechanisms with essential tremor (ET). Use of these medications 
      has not been studied in ET cases vs. controls. OBJECTIVE: To investigate the 
      relationships between NSAID (esp. ibuprofen) and aspirin use and ET. METHODS: 
      Subjects were enrolled in a case-control study of the environmental epidemiology 
      of ET at the Columbia University Medical Center (CUMC; 2009-2014). We compared 92 
      ET cases to 107 controls (∼1:1 matching) in terms of self-reported NSAID (esp. 
      ibuprofen) and aspirin use. RESULTS: The proportion of NSAID or aspirin users 
      (current or past) was similar in ET cases and controls (for current user, p = 
      0.66; for past user, p = 0.90). Among users, however, the total dosage of 
      ibuprofen (frequency in past year × number of tablets taken at a time × typical 
      average strength of tablets) was higher in controls than ET cases (p = 0.04). ET 
      cases and controls did not differ with respect to aspirin use in the past year. 
      CONCLUSION: The proportion of NSAID or aspirin users did not differ in ET cases 
      or controls; yet interestingly, ibuprofen use was less in ET cases than in 
      controls. The latter raises the possibility that ibuprofen use could have a 
      potential protective role in ET.
CI  - © 2014 S. Karger AG, Basel.
FAU - Pan, Jie
AU  - Pan J
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, 
      New York, N.Y., USA.
FAU - Michalec, Monika
AU  - Michalec M
FAU - Louis, Elan D
AU  - Louis ED
LA  - eng
PT  - Journal Article
DEP - 20141105
PL  - Switzerland
TA  - Neuroepidemiology
JT  - Neuroepidemiology
JID - 8218700
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Case-Control Studies
MH  - Essential Tremor/*drug therapy
MH  - Female
MH  - Humans
MH  - Ibuprofen/*administration & dosage
MH  - Male
EDAT- 2014/11/08 06:00
MHDA- 2015/07/08 06:00
CRDT- 2014/11/08 06:00
PHST- 2014/07/02 00:00 [received]
PHST- 2014/07/31 00:00 [accepted]
PHST- 2014/11/08 06:00 [entrez]
PHST- 2014/11/08 06:00 [pubmed]
PHST- 2015/07/08 06:00 [medline]
AID - 000366424 [pii]
AID - 10.1159/000366424 [doi]
PST - ppublish
SO  - Neuroepidemiology. 2014;43(2):145-9. doi: 10.1159/000366424. Epub 2014 Nov 5.

PMID- 8291501
OWN - NLM
STAT- MEDLINE
DCOM- 19940218
LR  - 20190717
IS  - 0002-9629 (Print)
IS  - 0002-9629 (Linking)
VI  - 307
IP  - 1
DP  - 1994 Jan
TI  - Quantitative assessment of platelet function and clot structure in patients with 
      severe coronary artery disease.
PG  - 15-20
AB  - The prothrombotic state of patients with coronary artery disease (CAD) can be 
      attributed partially to platelet activity. Management of such patients is 
      hindered by a lack of techniques to assess hemostatic function. This study used a 
      sensitive technique to monitor platelet function by measuring platelet force 
      development during clot retraction. This technique allowed simultaneous 
      measurement of clot elastic modulus on the same sample. Fibrin mass-length ratio 
      (mu), fibrinopeptide A, D-Dimer, von Willebrand's factor, thromboxane A2, 
      platelet aggregation studies, and bleeding times also were performed. Fourteen 
      patients with CAD were compared with 10 healthy volunteers. Despite more than 95% 
      suppression of thromboxane B2 and prolongation bleeding times in patients taking 
      aspirin, force development remained significantly elevated over healthy control 
      patients (8,279 +/- 476 dynes versus 4,857 +/- 380 dynes, p < 0.0006). Patients 
      not taking aspirin had normal bleeding times and force development of 19,110 +/- 
      3,700 dynes. Clot elastic moduli were enhanced in patients with CAD whether 
      taking or not taking aspirin. Adenosine diphosphate and ristocetin-induced 
      platelet aggregation were insensitive to the effect of aspirin in patients with 
      CAD. Fibrinopeptide A, von Willebrand's factor, and D-Dimer levels were 
      significantly elevated, and fibrin mass-length ratios were significantly larger 
      in patients with CAD. Therefore, despite aspirin therapy, patients with severe 
      CAD have evidence of persistent platelet activation and rigid clot structure. 
      Monitoring of platelet force development may prove useful in delineating enhanced 
      platelet function.
FAU - Greilich, P E
AU  - Greilich PE
AD  - Coagulation Special Studies Laboratory, Department of Anesthesiology, Walter Reed 
      Army Medical Center, Washington, DC.
FAU - Carr, M E
AU  - Carr ME
FAU - Zekert, S L
AU  - Zekert SL
FAU - Dent, R M
AU  - Dent RM
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 9001-31-4 (Fibrin)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Blood Coagulation
MH  - Blood Platelets/drug effects/*physiology
MH  - Coronary Disease/*blood
MH  - *Fibrin/chemistry
MH  - Humans
MH  - Platelet Activation
MH  - Thrombin/metabolism
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - S0002-9629(15)35370-2 [pii]
AID - 10.1097/00000441-199401000-00003 [doi]
PST - ppublish
SO  - Am J Med Sci. 1994 Jan;307(1):15-20. doi: 10.1097/00000441-199401000-00003.

PMID- 2405628
OWN - NLM
STAT- MEDLINE
DCOM- 19900315
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 65
IP  - 6
DP  - 1990 Feb 2
TI  - Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic 
      heart disease.
PG  - 7C-11C
AB  - The thrombotic component in ischemic heart disease (IHD) is now universally 
      recognized. It is therefore logical to consider modifying both fibrin formation 
      and platelet function in primary (as well as secondary) prevention. The 
      scientific case for evaluating lower-dose warfarin in primary prevention rests on 
      the implications of the secondary prevention trials, increasing evidence of an 
      association between the level of factor VII coagulant activity, VIIc, and the 
      incidence of IHD, and the results of short-term lower-dose trials for the 
      prevention of venous thrombosis and thromboembolism. The general case for 
      considering aspirin in primary prevention is well known, but the potential value 
      of low-dose aspirin in men at high risk needs to be established. Currently 
      available evidence suggests that the combination of lower doses of both warfarin 
      and aspirin in primary prevention may be effective and safe. The objective of the 
      factorial Thrombosis Prevention Trial is to demonstrate a reduction in the 
      incidence of IHD in men at high risk attributable to low-dose warfarin or 
      low-dose aspirin, or both, with 1 group receiving both active treatments. The 
      feasibility of this trial has been demonstrated. An International Normalized 
      Ratio of about 1.5, achieved with an average daily dose of 4.6 mg warfarin, has 
      resulted in no increase in the number of men ever reporting minor bleeding 
      episodes, although rectal bleeding occurs more frequently in those men who do 
      report this symptom.
FAU - Meade, T W
AU  - Meade TW
AD  - MRC Epidemiology and Medical Care Unit, Northwick Park Hospital, Harrow England.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Coronary Disease/epidemiology/*prevention & control
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Incidence
MH  - Randomized Controlled Trials as Topic
MH  - Warfarin/*administration & dosage
RF  - 27
EDAT- 1990/02/02 00:00
MHDA- 1990/02/02 00:01
CRDT- 1990/02/02 00:00
PHST- 1990/02/02 00:00 [pubmed]
PHST- 1990/02/02 00:01 [medline]
PHST- 1990/02/02 00:00 [entrez]
AID - 0002-9149(90)90108-D [pii]
AID - 10.1016/0002-9149(90)90108-d [doi]
PST - ppublish
SO  - Am J Cardiol. 1990 Feb 2;65(6):7C-11C. doi: 10.1016/0002-9149(90)90108-d.

PMID- 1328344
OWN - NLM
STAT- MEDLINE
DCOM- 19921106
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 90
IP  - 4 Pt 1
DP  - 1992 Oct
TI  - Arachidonic acid metabolism in monocytes of aspirin-sensitive asthmatic patients 
      before and after oral aspirin challenge.
PG  - 636-45
AB  - Aspirin and nonsteroidal antiinflammatory drugs induce bronchospastic reactions 
      in patients with aspirin-sensitive respiratory disease. Although the mechanism of 
      this reaction is unknown, all drugs that induce the respiratory reaction also 
      inhibit the cyclooxygenase enzyme. The ensuing changes in arachidonate metabolism 
      are presumed to play a role in the pathogenesis of the reaction. We measured 
      generation of leukotrienes and thromboxane by calcium ionophore stimulated blood 
      monocytes. Before aspirin challenge, monocytes released significantly more 
      thromboxane B2 in patients with aspirin sensitivity than in patients without 
      aspirin sensitivity or in healthy control subjects (p < 0.02). During 
      aspirin-induced bronchospasm, release of leukotriene B4 increased significantly 
      (45.5%, p = 0.018), whereas release of thromboxane B2 decreased (-46.9%, p = 
      0.028). Two hours after ingestion of 60 mg aspirin, normal monocyte release of 
      thromboxane B2 did not drop, whereas leukotriene B4 release increased. Monocytes 
      formed only minimal amounts of leukotriene C4. We conclude that the profile of 
      released eicosanoids from aspirin-sensitive monocytes is distinct from 
      non-aspirin-sensitive subjects, and that these differences could contribute to 
      the development of bronchospasm after aspirin ingestion.
FAU - Juergens, U R
AU  - Juergens UR
AD  - Molecular and Experimental Medicine Research Institute Scripps Clinic, La Jolla, 
      CA.
FAU - Christiansen, S C
AU  - Christiansen SC
FAU - Stevenson, D D
AU  - Stevenson DD
FAU - Zuraw, B L
AU  - Zuraw BL
LA  - eng
GR  - AI10386/AI/NIAID NIH HHS/United States
GR  - RR00833/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Eicosanoids)
RN  - 1HGW4DR56D (Leukotriene B4)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 37H9VM9WZL (Calcimycin)
RN  - 54397-85-2 (Thromboxane B2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Arachidonic Acid/*metabolism
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/*metabolism
MH  - Bronchial Spasm/chemically induced
MH  - Calcimycin/pharmacology
MH  - Eicosanoids/metabolism
MH  - Female
MH  - Humans
MH  - Leukotriene B4/metabolism
MH  - Male
MH  - Middle Aged
MH  - Monocytes/drug effects/*metabolism
MH  - Thromboxane B2/metabolism
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 0091-6749(92)90137-Q [pii]
AID - 10.1016/0091-6749(92)90137-q [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1992 Oct;90(4 Pt 1):636-45. doi: 
      10.1016/0091-6749(92)90137-q.

PMID- 14610494
OWN - NLM
STAT- MEDLINE
DCOM- 20031219
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 112
IP  - 5
DP  - 2003 Nov
TI  - Nasal versus bronchial and nasal response to oral aspirin challenge: Clinical and 
      biochemical differences between patients with aspirin-induced asthma/rhinitis.
PG  - 995-1001
AB  - BACKGROUND: Aspirin-induced asthma/rhinitis (AIAR) is characterized by the 
      altered metabolism of leukotrienes and proinflammatory prostaglandins. The basal 
      and postchallenge levels of eicosanoids might reflect the clinical and 
      biochemical characteristics of patients with distinct types of hypersensitive 
      responses to aspirin. OBJECTIVE: We compared clinical and eicosanoid profiles of 
      patients with AIAR showing both bronchial and nasal versus isolated nasal 
      responses to aspirin challenge. METHODS: Twenty-three patients with AIAR 
      underwent the single-blind, oral, placebo-controlled aspirin challenge. The 
      bronchial response (BR) was evidenced by dyspnea and spirometry, whereas the 
      nasal response (NR) was evidenced by nasal symptoms and acoustic rhinometry 
      and/or rhinomanometry. Urinary leukotriene E4 (uLTE4), serum and urinary stable 
      prostaglandin D2 metabolite, and 9alpha,11beta-prostaglandin F2 
      (9alpha,11beta-PGF2), were determined at baseline and after the aspirin 
      challenge. RESULTS: Fifteen subjects showed BR and NR (BNR), whereas 8 showed NR 
      only. Basal uLTE4 in the BNR group was significantly higher than in the NR group. 
      After aspirin challenge, it increased significantly in both groups. Serum 
      9alpha,11beta-PGF2 increased after aspirin challenge in the BNR group only. The 
      patients with BNR had more severe AIAR. CONCLUSIONS: BNR to aspirin in AIAR 
      indicates a more advanced disease and more profound underlying eicosanoid 
      metabolism disturbances.
FAU - Swierczynska, Monika
AU  - Swierczynska M
AD  - Department of Medicine, Jagiellonian University School of Medicine, Krakow, 
      Poland.
FAU - Nizankowska-Mogilnicka, Ewa
AU  - Nizankowska-Mogilnicka E
FAU - Zarychta, Jacek
AU  - Zarychta J
FAU - Gielicz, Anna
AU  - Gielicz A
FAU - Szczeklik, Andrzej
AU  - Szczeklik A
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 75715-89-8 (Leukotriene E4)
RN  - B7IN85G1HY (Dinoprost)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/*chemically induced/*physiopathology
MH  - Bronchi/*physiopathology
MH  - Dinoprost/blood
MH  - Female
MH  - Humans
MH  - Leukotriene E4/urine
MH  - Male
MH  - Nasal Cavity/*physiopathology
MH  - Rhinitis/*chemically induced/*physiopathology
MH  - Severity of Illness Index
MH  - Single-Blind Method
EDAT- 2003/11/12 05:00
MHDA- 2003/12/20 05:00
CRDT- 2003/11/12 05:00
PHST- 2003/11/12 05:00 [pubmed]
PHST- 2003/12/20 05:00 [medline]
PHST- 2003/11/12 05:00 [entrez]
AID - S0091674903020153 [pii]
AID - 10.1016/s0091-6749(03)02015-3 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2003 Nov;112(5):995-1001. doi: 
      10.1016/s0091-6749(03)02015-3.

PMID- 3975872
OWN - NLM
STAT- MEDLINE
DCOM- 19850329
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 37
IP  - 2
DP  - 1985 Jan 15
TI  - Antithrombotic effect of ticlopidine in a platelet-independent model of venous 
      thrombosis.
PG  - 279-85
AB  - The antithrombotic activity of ticlopidine demonstrated in a variety of 
      experimental models of thrombosis has been explained by its antiaggregating 
      properties. This study describes the antithrombotic effect of ticlopidine in a 
      platelet independent model of venous thrombosis. In the rat, ligature of the 
      inferior vena cava induces thrombosis. Antiaggregating drugs (acetylsalicylic 
      acid, dipyridamole, sulfinpyrazone) are inactive while anticoagulants (heparin, 
      acenocoumarol) are highly antithrombotic. Ticlopidine reduces thrombus weight 
      significantly and dose-dependently (ED 50 = 150 mg/kg/day X 3 days). 
      Thrombocytopenia induced by injection of anti-platelet anti-serum was found not 
      to modify thrombus formation. Yet, even in these conditions, ticlopidine remains 
      active. Acetylsalicylic acid treatment does not prevent the antithrombotic effect 
      of ticlopidine, indicating that its action is independent of PGI2 synthesis. 
      These results demonstrate that ticlopidine acts as an antithrombotic agent in a 
      venous thrombosis model in which platelets play a minor role.
FAU - Bernat, A
AU  - Bernat A
FAU - Vallée, E
AU  - Vallée E
FAU - Maffrand, J P
AU  - Maffrand JP
FAU - Roncucci, R
AU  - Roncucci R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Thiophenes)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Platelets/drug effects
MH  - Fibrinolytic Agents/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Thiophenes/*pharmacology
MH  - Thrombophlebitis/*prevention & control
MH  - Ticlopidine
EDAT- 1985/01/15 00:00
MHDA- 1985/01/15 00:01
CRDT- 1985/01/15 00:00
PHST- 1985/01/15 00:00 [pubmed]
PHST- 1985/01/15 00:01 [medline]
PHST- 1985/01/15 00:00 [entrez]
AID - 10.1016/0049-3848(85)90016-7 [doi]
PST - ppublish
SO  - Thromb Res. 1985 Jan 15;37(2):279-85. doi: 10.1016/0049-3848(85)90016-7.

PMID- 7213041
OWN - NLM
STAT- MEDLINE
DCOM- 19810521
LR  - 20131121
IS  - 0098-6127 (Print)
IS  - 0098-6127 (Linking)
VI  - 8
IP  - 4
DP  - 1980
TI  - Growth rate differences between arterial smooth muscle cells cultivated from rat 
      impaired by short--or long--term hypertension respectively.
PG  - 348-54
AB  - In former studies short-term renal hypertension (2 weeks) in rats led to a 
      remarkable increase of arterial smooth muscle cells (ASMC) proliferation in 
      cultures and subcultures, examined by cell counting and 3H-thymidine indices 
      /flasks in cultures or subcultures of hypertensive rats. The activated cell 
      growth was observed up to the 6th subcultures. The proliferation of ASMC 
      cultivated from short-term hypertensive rats is suppressed or eliminated 
      respectively by antirheumatic drugs up to the 6th subcultures. Long-term renal 
      hypertension (4-6 weeks) in rats showed the same increase in ASMC proliferation 
      rate up to the 2nd subcultures but in the higher passages e.g. in the 6th 
      subcultures the ASMC growth increase was not existing anymore. The limited 
      reduplication capacity of postmitotic cells, we assume, is the cause of this 
      difference.
FAU - Mey, J
AU  - Mey J
FAU - Grünwald, J
AU  - Grünwald J
FAU - Hauss, W H
AU  - Hauss WH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Artery
JT  - Artery
JID - 7508494
RN  - 40GP35YQ49 (Desoxycorticosterone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta, Thoracic/cytology
MH  - Aspirin/pharmacology
MH  - Cell Division
MH  - Desoxycorticosterone/pharmacology
MH  - Hypertension/*etiology/physiopathology
MH  - Muscle, Smooth, Vascular/*cytology
MH  - Rats
MH  - Time Factors
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Artery. 1980;8(4):348-54.

PMID- 468096
OWN - NLM
STAT- MEDLINE
DCOM- 19791024
LR  - 20131121
IS  - 0015-8178 (Print)
IS  - 0015-8178 (Linking)
VI  - 97
IP  - 30-31
DP  - 1979 Aug 16
TI  - [Acetlysalicylic acid, protective antacid effect and lesions of the gastric 
      mucosa. Effect of acetylsalicylic acid and an antacid drug (Gastropulgit Tabs) on 
      the transmural electric potential in the human stomach].
PG  - 1333-6
AB  - Antacids are able to prevent acetylsalicylic acid-induced functional and 
      morphological changes of the gastric mucosa. In order to test whether a new 
      antacid in chewing-tablet form (Gastropulgit Tabs) might be able to protect the 
      gastric mucosa from acetylsalicylic acid-induced functional changes similarly to 
      liquid antacids the effect of this antacid on acetylsalicylic acid-induced 
      changes of transmural gastric potential difference was measured in healthy 
      volunteers. The decrease of transmural potential differences induced by 640 mg 
      acetylsalicylic acid could be prevented by simultaneous addition of 2 tablets of 
      Gastropulgit Tabs. Thus the antacid in tablet form is able-like liquid 
      antacids-to protect the gastric mucosa against acetylsalicylic acid-induced 
      functional changes.
FAU - Caspary, W F
AU  - Caspary WF
FAU - Kausch, H
AU  - Kausch H
LA  - ger
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Azetylsalizylsäure, protektive Antazida-Wirkung und Schädigung der 
      Magenschleimhaut. Beeinflussung der transmuralen elektrischen Potentialdifferenz 
      des menschlichen Magens durch Azetylsalizylsäure und eine Antazida-Präparation 
      (Gastropulgit Tabs).
PL  - Germany
TA  - Fortschr Med
JT  - Fortschritte der Medizin
JID - 2984763R
RN  - 0 (Alum Compounds)
RN  - 0 (Antacids)
RN  - I38ZP9992A (Magnesium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alum Compounds/therapeutic use
MH  - Antacids/*therapeutic use
MH  - Aspirin/*adverse effects
MH  - Drug Evaluation
MH  - Gastric Mucosa/drug effects
MH  - Humans
MH  - Magnesium/therapeutic use
MH  - Membrane Potentials/*drug effects
EDAT- 1979/08/16 00:00
MHDA- 1979/08/16 00:01
CRDT- 1979/08/16 00:00
PHST- 1979/08/16 00:00 [pubmed]
PHST- 1979/08/16 00:01 [medline]
PHST- 1979/08/16 00:00 [entrez]
PST - ppublish
SO  - Fortschr Med. 1979 Aug 16;97(30-31):1333-6.

PMID- 35762083
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20220923
IS  - 1735-546X (Electronic)
IS  - 1735-1308 (Linking)
VI  - 19
IP  - 4
DP  - 2022 Jun 26
TI  - The Safety of Continuing Low-dose Aspirin Therapy Perioperatively in the Patients 
      had Undergone Percutaneous Nephrolithotomy: A Systematic Review and 
      Meta-analysis.
PG  - 253-261
LID - 10.22037/uj.v19i.7170 [doi]
AB  - PURPOSE: Aspirin (ASA) is often stopped prior to percutaneous nephrolithotomy 
      (PCNL) due to the surgical bleeding risk. However, this practice is based on 
      expert opinion only, and mounting evidence suggests holding aspirin 
      perioperatively can be more harmful than once thought. In our review we aimed to 
      discuss the safety of low dose aspirin continued or discontinued in the whole 
      perioperative period of PCNL. PATIENTS AND METHOD: We performed a computerized 
      PubMed, EMBASE and Cochrane Library search of relevant studies. Study 
      identification satisfied the PRISMA guidelines. Newcastle-Ottawa scale (NOS) was 
      used to evaluate the quality of including studies. Favored outcomes such as 
      operative time, complications and change in hemoglobin were extracted. 
      Statistical analysis was performed with Rev-Man software 5.3 and forest plots 
      were used to illustrate our findings. RESULTS: After screening, four studies were 
      included in the present systematic review. There was no difference in the number 
      of total complications (OR:1.25; 95 % CI 0.82-1.90; p=0.30), major complications 
      (OR: 1.24; 95 % CI 0.53-2.93; p=0.62) and blood transfusion rate (OR:0.99; 95 % 
      CI 0.46-2.12; p=0.98) between the continuing low dose aspirin group and 
      discontinuing group. Moreover, the overall stone-free rate was also not 
      statistically significant (OR:3.17; 95 % CI 0.89-11.25; p=0.07). It was similar 
      about the change in hemoglobin, hematocrit and creatinine levels between two 
      groups. CONCLUSION: Based on our findings, transient cessation of aspirin 
      perioperatively seems not to be necessary for patients who need PCNL complicated 
      with the necessity of aspirin therapy. However, further well-designed prospective 
      studies with large sample size are needed to confirm and validate our findings.
FAU - Pan, Yang
AU  - Pan Y
AD  - Department of Urology, Tianjin Medical University General hospital, Tianjin, 
      China. panyang361@163.com.
FAU - Xu, Mingming
AU  - Xu M
AD  - Department of Urology, Tianjin Medical University General hospital, Tianjin, 
      China. x18670053557mm@163.com.
FAU - Kang, Jiaqi
AU  - Kang J
AD  - Department of Urology, Tianjin Medical University General hospital, Tianjin, 
      China. kangjiaqi@tmu.edu.cn.
FAU - Wang, Shangren
AU  - Wang S
AD  - Department of Urology, Tianjin Medical University General hospital, Tianjin, 
      China. wangshangren89@126.com.
FAU - Liu, Xiaoqiang
AU  - Liu X
AD  - Department of Urology, Tianjin Medical University General hospital, Tianjin, 
      China. liuxiaoqiang2308@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220626
PL  - Iran
TA  - Urol J
JT  - Urology journal
JID - 101286676
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Creatinine
MH  - Humans
MH  - *Kidney Calculi/surgery
MH  - *Nephrolithotomy, Percutaneous/adverse effects
MH  - Prospective Studies
MH  - Treatment Outcome
EDAT- 2022/06/29 06:00
MHDA- 2022/09/24 06:00
CRDT- 2022/06/28 02:33
PHST- 2022/06/29 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/06/28 02:33 [entrez]
AID - 7170 [pii]
AID - 10.22037/uj.v19i.7170 [doi]
PST - epublish
SO  - Urol J. 2022 Jun 26;19(4):253-261. doi: 10.22037/uj.v19i.7170.

PMID- 26134597
OWN - NLM
STAT- MEDLINE
DCOM- 20160513
LR  - 20181202
IS  - 1524-4040 (Electronic)
IS  - 0148-396X (Print)
IS  - 0148-396X (Linking)
VI  - 77
IP  - 4
DP  - 2015 Oct
TI  - Paradoxical Increase in Mortality and Rupture of Intracranial Aneurysms in 
      Microsomal Prostaglandin E2 Synthase Type 1-Deficient Mice: Attenuation by 
      Aspirin.
PG  - 613-20
LID - 10.1227/NEU.0000000000000883 [doi]
AB  - BACKGROUND: Inflammation plays an important role in formation and rupture of 
      intracranial aneurysms. Expression of microsomal prostaglandin E2 (PGE2) synthase 
      type 1 (mPGES-1) is increased in the wall of intracranial aneurysms in humans. 
      PGE2, a by-product of mPGES-1, is associated with inflammation and 
      cerebrovascular dysfunction. OBJECTIVE: To test the hypothesis that deletion of 
      mPGES-1 decreases the formation and rupture of intracranial aneurysms in a murine 
      model. METHODS: Intracranial aneurysms were induced in wild-type and mPGES-1 
      knockout (mPGES-1 KO) mice by using a combination of deoxycorticosterone 
      acetate-salt-induced hypertension and intracranial injection of elastase in the 
      basal cistern. Prevalence of aneurysms, subarachnoid hemorrhage, and mortality 
      were assessed. We also tested the effects of administration of aspirin (6 
      mg/kg/d) by gavage and PGE2 (1 mg/kg/d) by subcutaneous infusion. RESULTS: 
      Systolic blood pressure and prevalence of aneurysm were similar in wild-type and 
      mPGES-1 KO mice. However, mortality and the prevalence of subarachnoid hemorrhage 
      were markedly increased in mPGES-1 KO mice (P < .05). Bone marrow reconstitution 
      studies suggest that mPGES-1 derived from leukocytes does not appear to increase 
      rupture of intracranial aneurysms. Aspirin, but not PGE2, attenuated the 
      increased mortality in mPGES-1 KO mice (P < .05). CONCLUSION: Vascular mPGES-1 
      plays a protective role in blood vessels and attenuates rupture of cerebral 
      aneurysms. In contrast to effects on abdominal aneurysms, mPGES-1 deficiency is 
      associated with an increase in rupture of cerebral aneurysms and mortality, which 
      are attenuated by low-dose aspirin.
FAU - Peña Silva, Ricardo A
AU  - Peña Silva RA
AD  - *Universidad de los Andes, Bogotá, Colombia; ‡Departments of Internal Medicine, 
      §Neurosurgery, ¶Microbiology, and ‖Pharmacology, University of Iowa, Iowa City, 
      Iowa.
FAU - Mitchell, Ian J
AU  - Mitchell IJ
FAU - Kung, David K
AU  - Kung DK
FAU - Pewe, Lecia L
AU  - Pewe LL
FAU - Granja, Manuel F
AU  - Granja MF
FAU - Harty, John T
AU  - Harty JT
FAU - Faraci, Frank M
AU  - Faraci FM
FAU - Heistad, Donald D
AU  - Heistad DD
FAU - Hasan, David M
AU  - Hasan DM
LA  - eng
GR  - NS082363/NS/NINDS NIH HHS/United States
GR  - P01 HL062984/HL/NHLBI NIH HHS/United States
GR  - I01 BX001399/BX/BLRD VA/United States
GR  - HL-62984/HL/NHLBI NIH HHS/United States
GR  - K08 NS082363/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - EC 5.3.- (Intramolecular Oxidoreductases)
RN  - EC 5.3.99.3 (PTGES protein, human)
RN  - EC 5.3.99.3 (Prostaglandin-E Synthases)
RN  - EC 5.3.99.3 (Ptges protein, mouse)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aneurysm, Ruptured/*drug therapy/*enzymology/mortality
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Humans
MH  - Intracranial Aneurysm/*drug therapy/*enzymology/mortality
MH  - Intramolecular Oxidoreductases/*deficiency
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Microsomes/drug effects/*enzymology
MH  - Mortality/trends
MH  - Prostaglandin-E Synthases
PMC - PMC4846385
MID - NIHMS775850
EDAT- 2015/07/03 06:00
MHDA- 2016/05/14 06:00
CRDT- 2015/07/03 06:00
PHST- 2015/07/03 06:00 [entrez]
PHST- 2015/07/03 06:00 [pubmed]
PHST- 2016/05/14 06:00 [medline]
AID - 10.1227/NEU.0000000000000883 [doi]
PST - ppublish
SO  - Neurosurgery. 2015 Oct;77(4):613-20. doi: 10.1227/NEU.0000000000000883.

PMID- 1906468
OWN - NLM
STAT- MEDLINE
DCOM- 19910820
LR  - 20160512
IS  - 0021-9355 (Print)
IS  - 0021-9355 (Linking)
VI  - 73
IP  - 6
DP  - 1991 Jul
TI  - Effect of aspirin on heterotopic ossification after total hip arthroplasty in men 
      who have osteoarthrosis.
PG  - 924-9
AB  - The severity of heterotopic ossification was determined from the radiographs of 
      eighty-three men in whom osteoarthrosis had been treated with a primary total hip 
      arthroplasty with cement. The medical records of these patients were then 
      reviewed, with the reviewer having no knowledge of the radiographic findings. A 
      similar operative approach and technique had been used in all patients. There was 
      no association between the amount of intraoperative loss of blood or the duration 
      of the operation and the severity of formation of heterotopic bone. The over-all 
      rate of occurrence of heterotopic ossification was 72 per cent. Of the 
      fifty-eight patients who had received aspirin throughout their course in the 
      hospital, two (3 per cent) had severe ectopic ossification (grade III or IV8). In 
      contrast, twelve (48 per cent) of the twenty-five patients who had received no 
      aspirin or in whom aspirin had been discontinued so that anticoagulation could be 
      begun had severe heterotopic ossification. The difference in the severity of the 
      ossification between the two groups is significant (p less than 0.0001).
FAU - Pagnani, M J
AU  - Pagnani MJ
AD  - Hip Service, Hospital for Special Surgery, Cornell University Medical College, 
      New York City, NY 10021.
FAU - Pellicci, P M
AU  - Pellicci PM
FAU - Salvati, E A
AU  - Salvati EA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - *Hip Prosthesis/adverse effects
MH  - Humans
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Ossification, Heterotopic/etiology/*prevention & control
MH  - Osteoarthritis/*surgery
MH  - Regression Analysis
MH  - Thrombophlebitis/prevention & control
EDAT- 1991/07/01 00:00
MHDA- 1991/07/01 00:01
CRDT- 1991/07/01 00:00
PHST- 1991/07/01 00:00 [pubmed]
PHST- 1991/07/01 00:01 [medline]
PHST- 1991/07/01 00:00 [entrez]
PST - ppublish
SO  - J Bone Joint Surg Am. 1991 Jul;73(6):924-9.

PMID- 16168277
OWN - NLM
STAT- MEDLINE
DCOM- 20051222
LR  - 20181113
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 46
IP  - 6
DP  - 2005 Sep 20
TI  - Prior aspirin use and outcomes in elderly patients hospitalized with acute 
      myocardial infarction.
PG  - 967-74
AB  - OBJECTIVES: We sought to assess the association between prior aspirin use and 
      mortality, all-cause readmission, and condition-specific readmission at one month 
      and six months in a national sample of Medicare beneficiaries hospitalized with a 
      confirmed myocardial infarction (MI). BACKGROUND: Prior aspirin use is considered 
      a marker of higher risk in patients with MI, yet the prognostic significance of 
      this factor has been debated. METHODS: Medicare beneficiaries > or =65 years old 
      hospitalized with MI were evaluated to determine whether there was an association 
      between prior aspirin use and mortality (n = 118,992), all-cause readmission, and 
      condition-specific readmission (n = 78,975) at one month and six months. RESULTS: 
      One-third of the patients (n = 39,531, 33.2%) were using aspirin before 
      admission. Those with prior aspirin use had significantly lower mortality at one 
      month (16.1% vs. 19.0%, p < 0.0001) and six months (24.7% vs. 27.5%, p < 0.0001). 
      After multivariable adjustment, prior aspirin use was found to be associated with 
      a lower risk of one-month (relative risk ratio 0.93, 95% confidence interval [CI] 
      0.90 to 0.96) and six-month mortality (hazard ratio 0.94, 95% CI 0.91 to 0.96). 
      Prior aspirin use tended to reduce all-cause or coronary artery disease 
      readmissions at one month or six months. CONCLUSIONS: Prior aspirin use is not a 
      marker of increased mortality in patients > or =65 years old hospitalized with 
      MI.
FAU - Portnay, Edward L
AU  - Portnay EL
AD  - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale 
      University School of Medicine, New Haven, Connecticut 06520, USA.
FAU - Foody, JoAnne M
AU  - Foody JM
FAU - Rathore, Saif S
AU  - Rathore SS
FAU - Wang, Yongfei
AU  - Wang Y
FAU - Masoudi, Frederick A
AU  - Masoudi FA
FAU - Curtis, Jeptha P
AU  - Curtis JP
FAU - Krumholz, Harlan M
AU  - Krumholz HM
LA  - eng
GR  - K08 AG001011/AG/NIA NIH HHS/United States
GR  - K08-AG20623-01/AG/NIA NIH HHS/United States
GR  - GM07205/GM/NIGMS NIH HHS/United States
GR  - K08-AG01011/AG/NIA NIH HHS/United States
GR  - T32 GM007205/GM/NIGMS NIH HHS/United States
GR  - T32 GM007205-35/GM/NIGMS NIH HHS/United States
GR  - K08 AG020623/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*drug therapy/*mortality
MH  - Patient Readmission/statistics & numerical data
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC2790536
MID - NIHMS155301
EDAT- 2005/09/20 09:00
MHDA- 2005/12/24 09:00
CRDT- 2005/09/20 09:00
PHST- 2004/07/30 00:00 [received]
PHST- 2005/04/11 00:00 [revised]
PHST- 2005/04/19 00:00 [accepted]
PHST- 2005/09/20 09:00 [pubmed]
PHST- 2005/12/24 09:00 [medline]
PHST- 2005/09/20 09:00 [entrez]
AID - S0735-1097(05)01559-7 [pii]
AID - 10.1016/j.jacc.2005.06.049 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2005 Sep 20;46(6):967-74. doi: 10.1016/j.jacc.2005.06.049.

PMID- 1576718
OWN - NLM
STAT- MEDLINE
DCOM- 19920605
LR  - 20190509
IS  - 0143-3334 (Print)
IS  - 0143-3334 (Linking)
VI  - 13
IP  - 4
DP  - 1992 Apr
TI  - Direct O-acetylation of N-hydroxy arylamines by acetylsalicylic acid to form 
      carcinogen-DNA adducts.
PG  - 663-7
AB  - Acetylsalicylic acid (aspirin) has been shown to acetylate a number of drugs and 
      biological macromolecules. Since enzymatic O-acetylation of N-hydroxy arylamines 
      is regarded as an important activation step for DNA adduct formation, we 
      initially examined the ability of aspirin to serve as an acetyl donor for this 
      reaction, using rabbit liver cytosol. Instead, a direct non-enzymatic reaction 
      was observed. Arylamine-DNA binding was enhanced from 3- to 25-fold at pH 7 by 
      addition of aspirin to reactions containing the N-hydroxy derivatives of 
      2-aminofluorene (AF), 4-aminobiphenyl, 
      2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline and 
      2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, but not for 
      2-amino-3-methylimidazo[4,5-f]quinoline or 
      2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole. Further studies with 
      N-hydroxy-AF showed that reaction rates were first order with respect to both 
      aspirin (0.1-10 mM) and N-hydroxy-AF (0.01-0.1 mM) concentrations. In contrast, 
      aspirin had no effect on reactions conducted at pH 5 where N-hydroxy-AF is known 
      to undergo protonation and react with DNA to form high levels of 
      N-(deoxyguanosin-8-yl)-AF. N-Acetylation of AF by aspirin under these conditions 
      was also negligible. However, the formation of the adduct from N-hydroxy-AF 
      occurred at high yield (64-82%) at pH 7 with either DNA or 2'-deoxyguanosine. 
      HPLC analyses showed only an aspirin-dependent loss of N-hydroxy-AF and 
      concomitant adduct formation, with no detectable formation of solvolysis 
      products. This indicated that the reaction proceeds to a significant extent only 
      upon addition of the nucleophile, and suggests the formation of an O-tetrahedral 
      intermediate that is in equilibrium with both the N-hydroxy derivative and the 
      reactive N-acetoxy arylamine. Thus, the apparent O-acetylation of certain 
      N-hydroxy arylamines selectively by aspirin offers a convenient route for the 
      synthesis of arylamine-DNA adducts. The potential biological significance of this 
      reaction in vivo is also discussed.
FAU - Minchin, R F
AU  - Minchin RF
AD  - Department of Pharmacology, University of Western Australia, Nedlands.
FAU - Ilett, K F
AU  - Ilett KF
FAU - Teitel, C H
AU  - Teitel CH
FAU - Reeves, P T
AU  - Reeves PT
FAU - Kadlubar, F F
AU  - Kadlubar FF
LA  - eng
PT  - Journal Article
PL  - England
TA  - Carcinogenesis
JT  - Carcinogenesis
JID - 8008055
RN  - 0 (Aminobiphenyl Compounds)
RN  - 0 (Carcinogens)
RN  - 0 (Fluorenes)
RN  - 0 (Imidazoles)
RN  - 0 (Quinolines)
RN  - 0 (Quinoxalines)
RN  - 16054949HJ (4-biphenylamine)
RN  - 30GL3D3T0G (2-amino-3-methylimidazo(4,5-f)quinoline)
RN  - 61M94X4V24 (N-hydroxy-2-aminofluorene)
RN  - 77500-04-0 (2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline)
RN  - 9007-49-2 (DNA)
RN  - 909C6UN66T (2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aminobiphenyl Compounds/metabolism
MH  - Aspirin/*metabolism
MH  - Carcinogens/*metabolism
MH  - DNA/*metabolism
MH  - Fluorenes/metabolism
MH  - Imidazoles/metabolism
MH  - Quinolines/metabolism
MH  - Quinoxalines/metabolism
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
AID - 10.1093/carcin/13.4.663 [doi]
PST - ppublish
SO  - Carcinogenesis. 1992 Apr;13(4):663-7. doi: 10.1093/carcin/13.4.663.

PMID- 4521198
OWN - NLM
STAT- MEDLINE
DCOM- 19740328
LR  - 20190501
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 70
IP  - 12
DP  - 1973 Dec
TI  - The effect of aspirin on sickling and oxygen affinity of erythrocytes.
PG  - 3707-10
AB  - The recent suggestion that the administration of aspirin might be useful in the 
      treatment of sickle-cell anemia has been further studied and found to be without 
      basis. After incubation with aspirin, sickle-cell erythrocytes are not inhibited 
      from sickling after deoxygenation. In addition, although aspirin does transfer 
      the acetyl group to hemoglobin both in vitro and in vivo, in our experiments the 
      reaction does not result in any alteration in the oxygen equilibrium of either 
      intact erythrocytes or hemoglobin in solution. Furthermore, patients maintained 
      on long-term aspirin administration also showed no shift in the oxygen affinity 
      of their blood.
FAU - De Furia, F G
AU  - De Furia FG
FAU - Cerami, A
AU  - Cerami A
FAU - Bunn, H F
AU  - Bunn HF
FAU - Lu, Y S
AU  - Lu YS
FAU - Peterson, C M
AU  - Peterson CM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Carbon Radioisotopes)
RN  - 0 (Diphosphoglyceric Acids)
RN  - 0 (Hemoglobins)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Anemia, Sickle Cell/*blood
MH  - Animals
MH  - Arthritis, Rheumatoid/blood/drug therapy
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Carbon Radioisotopes
MH  - Diphosphoglyceric Acids/blood
MH  - Erythrocytes, Abnormal/*drug effects
MH  - Female
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Oxygen/*blood
MH  - Rats
MH  - Rheumatic Heart Disease/blood
PMC - PMC427311
EDAT- 1973/12/01 00:00
MHDA- 1973/12/01 00:01
CRDT- 1973/12/01 00:00
PHST- 1973/12/01 00:00 [pubmed]
PHST- 1973/12/01 00:01 [medline]
PHST- 1973/12/01 00:00 [entrez]
AID - 10.1073/pnas.70.12.3707 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1973 Dec;70(12):3707-10. doi: 10.1073/pnas.70.12.3707.

PMID- 36075073
OWN - NLM
STAT- MEDLINE
DCOM- 20221202
LR  - 20230129
IS  - 1940-6215 (Electronic)
IS  - 1940-6215 (Linking)
VI  - 15
IP  - 12
DP  - 2022 Dec 1
TI  - Aspirin-Mediated Prevention of Colorectal Adenomas Recurrence is Affected by 
      Blood Biochemistry and Nutritional Intake.
PG  - 837-846
LID - 10.1158/1940-6207.CAPR-22-0144 [doi]
AB  - Aspirin has been shown to prevent the onset of colorectal adenoma and cancer. 
      This study aimed to identify patient characteristics and blood chemistry factors 
      related to the effect of aspirin. A total of 231 men and 59 women who 
      participated in our previous randomized clinical study in 2007-2009 using aspirin 
      or placebo (J-CAPP study) were analyzed. Interaction of aspirin with age at 
      entry, body mass index (BMI), alcohol intake, blood biochemistry, and nutrients 
      calculated from a semiquantitative food frequency questionnaire were analyzed on 
      the basis of the presence of adenomas 2 years later. Our study showed that 
      suppression of adenoma by aspirin was not affected by age or BMI. Among men, 
      significant suppression of adenoma by aspirin was seen with triglyceride (TG) 
      <167 mg/dL (P = 0.02), total cholesterol (T-cho) ≥220 mg/dL (P = 0.01), 
      high-density lipoprotein (HDL) ≥60 mg/dL (P < 0.01), and low-density lipoprotein 
      (LDL) ≥140 mg/dL (P = 0.01), aspartate aminotransferase (AST) <30 IU/L (P = 
      0.01), alanine aminotransferase <30 IU/L (P = 0.04), and gamma-glutamyl 
      transpeptidase <60 IU/L (P = 0.04). In addition, the interaction was significant 
      with TG ≥/<167 mg/dL (P = 0.02), T-cho ≥/<220 mg/dL (P = 0.03), HDL ≥/<60 mg/dL 
      (P = 0.02), LDL ≥/<140 mg/dL (P = 0.03), and AST ≥/<30 IU/L (P = 0.01). Daily 
      nutrient intake associated with aspirin was <2,000 mg sodium (P = 0.06) and ≥850 
      μg retinol equivalent (P = 0.05) among men, indicating a marginal effect on 
      adenoma suppression. No significant differences were detected among women due to 
      the small sample size. In conclusion, lipid metabolism and liver function were 
      correlated with the suppressive effect of aspirin on the recurrence of colorectal 
      adenoma. PREVENTION RELEVANCE: Aspirin has been shown to prevent the onset of 
      colorectal adenoma and cancer, and its effect modifications have been analyzed. 
      Lipid metabolism and liver function were correlated with the suppressive effect 
      of aspirin on the recurrence of colorectal adenoma.
CI  - ©2022 American Association for Cancer Research.
FAU - Yoshida, Naohisa
AU  - Yoshida N
AUID- ORCID: 0000-0001-6167-9705
AD  - Department of Molecular Gastroenterology and Hepatology, Graduate School of 
      Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
FAU - Ishikawa, Hideki
AU  - Ishikawa H
AUID- ORCID: 0000-0001-5980-698X
AD  - Department of Molecular-Targeting Prevention, Graduate School of Medical Science, 
      Kyoto Prefectural University of Medicine, Kyoto, Japan.
FAU - Otani, Takahiro
AU  - Otani T
AUID- ORCID: 0000-0002-4007-7817
AD  - Department of Public Health, Graduate School of Medical Sciences, Nagoya City 
      University, Aichi, Japan.
FAU - Goto, Chiho
AU  - Goto C
AUID- ORCID: 0000-0001-5645-8852
AD  - Department of Health and Nutrition, Nagoya Bunri University, Aichi, Japan.
FAU - Matsuda, Takahisa
AU  - Matsuda T
AUID- ORCID: 0000-0002-9244-2820
AD  - Division of Gastroenterology and Hepatology, Toho University Omori Medical 
      Center, Tokyo, Japan.
FAU - Takeuchi, Yoji
AU  - Takeuchi Y
AUID- ORCID: 0000-0003-3814-298X
AD  - Department of Gastrointestinal Oncology and Department of Genetic Oncology, 
      Division of Hereditary Tumors, Osaka International Cancer Institute, Osaka, 
      Japan.
FAU - Sano, Yasushi
AU  - Sano Y
AUID- ORCID: 0000-0002-3352-5757
AD  - Gastrointestinal Center and Institute of Minimally Invasive Endoscopic Care 
      (iMEC), Sano Hospital, Hyogo, Japan.
FAU - Itoh, Yoshito
AU  - Itoh Y
AUID- ORCID: 0000-0001-9890-3635
AD  - Department of Molecular Gastroenterology and Hepatology, Graduate School of 
      Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
FAU - Suzuki, Sadao
AU  - Suzuki S
AUID- ORCID: 0000-0001-5988-4849
AD  - Department of Public Health, Graduate School of Medical Sciences, Nagoya City 
      University, Aichi, Japan.
FAU - Mutoh, Michihiro
AU  - Mutoh M
AUID- ORCID: 0000-0003-2054-7655
AD  - Department of Molecular-Targeting Prevention, Graduate School of Medical Science, 
      Kyoto Prefectural University of Medicine, Kyoto, Japan.
CN  - J-CAPP Study group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Triglycerides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Male
MH  - Humans
MH  - Female
MH  - *Adenoma/prevention & control/drug therapy
MH  - *Colorectal Neoplasms/epidemiology/prevention & control
MH  - Triglycerides
MH  - Aspirin/therapeutic use
MH  - Eating
EDAT- 2022/09/09 06:00
MHDA- 2022/12/03 06:00
CRDT- 2022/09/08 17:03
PHST- 2022/03/25 00:00 [received]
PHST- 2022/06/03 00:00 [revised]
PHST- 2022/09/02 00:00 [accepted]
PHST- 2022/09/09 06:00 [pubmed]
PHST- 2022/12/03 06:00 [medline]
PHST- 2022/09/08 17:03 [entrez]
AID - 709135 [pii]
AID - 10.1158/1940-6207.CAPR-22-0144 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2022 Dec 1;15(12):837-846. doi: 
      10.1158/1940-6207.CAPR-22-0144.

PMID- 21450601
OWN - NLM
STAT- MEDLINE
DCOM- 20120120
LR  - 20151119
IS  - 1741-8275 (Electronic)
IS  - 1741-8267 (Linking)
VI  - 18
IP  - 5
DP  - 2011 Oct
TI  - A national survey on aspirin patterns of use and persistence in community 
      outpatients in Italy.
PG  - 695-703
LID - 10.1177/1741826710397850 [doi]
AB  - BACKGROUND: Aspirin is recommended as preventive therapy in patients with 
      cardiovascular diseases (CVD), diabetes mellitus, and high cardiovascular risk 
      due to multiple risk factors. However, the benefits of aspirin might be affected 
      by its inappropriate use. Real-life information on aspirin use is therefore 
      needed as an audit tool aimed to maximize the benefits and minimize the risks. 
      DESIGN: Retrospective cross-sectional and cohort study. METHODS: Primary care 
      data were obtained from 400 Italian general practitioners (GPs) providing 
      information to the Health Search/CDS Longitudinal Patients Database. Prevalence 
      of use was assessed in individuals aged 18 years and older, registered in the 
      GP's list at the beginning of the observation period (year 2005). As potential 
      correlates of aspirin use, clinical and demographic variables were also recorded. 
      Logistic regression analysis was conducted to assess the relationship between 
      such covariates and aspirin use. Persistence to aspirin treatment was examined 
      among newly prescribed aspirin users during the years 2000-04. RESULTS: On a 
      total sample of 540,984 patients, 45,271 (8.3%) were prescribed at least once 
      with aspirin. On 35,473 patients with previous CVD, 51.7% were treated with 
      aspirin, whereas only 15.2% of 151,526 eligible patients free of CVD received an 
      aspirin prescription. In primary prevention, prevalence of aspirin use was 
      significantly associated with the increased number of cardiovascular risk factors 
      either among diabetic (p < 0.001) or non-diabetic (p < 0.001) patients. A 
      negative association has been observed among patients with contraindication to 
      aspirin use. Only 23.4% of patients at 1 year and 12.2% at 2 years remained 
      persistent with aspirin use, although most of first-time users reported an 
      intermittent use. CONCLUSION: Underuse and discontinuation of aspirin treatment 
      is common among eligible patients. Increased cardiovascular risk only partially 
      influences aspirin management. An effort aimed to improve appropriate aspirin use 
      is likely to provide major benefits.
FAU - Filippi, Alessandro
AU  - Filippi A
AD  - Italian College of General Practitioners, Florence, Italy.
FAU - Bianchi, Cosetta
AU  - Bianchi C
FAU - Parazzini, Fabio
AU  - Parazzini F
FAU - Cricelli, Claudio
AU  - Cricelli C
FAU - Sessa, Emiliano
AU  - Sessa E
FAU - Mazzaglia, Giampiero
AU  - Mazzaglia G
LA  - eng
PT  - Journal Article
DEP - 20110301
PL  - England
TA  - Eur J Cardiovasc Prev Rehabil
JT  - European journal of cardiovascular prevention and rehabilitation : official 
      journal of the European Society of Cardiology, Working Groups on Epidemiology & 
      Prevention and Cardiac Rehabilitation and Exercise Physiology
JID - 101192000
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Ambulatory Care/*statistics & numerical data
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Cross-Sectional Studies
MH  - Drug Prescriptions/statistics & numerical data
MH  - Drug Utilization/statistics & numerical data
MH  - Female
MH  - Guideline Adherence
MH  - Health Care Surveys
MH  - Humans
MH  - Inappropriate Prescribing/statistics & numerical data
MH  - Italy
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Practice Guidelines as Topic
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Preventive Health Services/*standards
MH  - Primary Health Care/*statistics & numerical data
MH  - Proportional Hazards Models
MH  - Registries
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Young Adult
EDAT- 2011/04/01 06:00
MHDA- 2012/01/21 06:00
CRDT- 2011/04/01 06:00
PHST- 2011/04/01 06:00 [entrez]
PHST- 2011/04/01 06:00 [pubmed]
PHST- 2012/01/21 06:00 [medline]
AID - 1741826710397850 [pii]
AID - 10.1177/1741826710397850 [doi]
PST - ppublish
SO  - Eur J Cardiovasc Prev Rehabil. 2011 Oct;18(5):695-703. doi: 
      10.1177/1741826710397850. Epub 2011 Mar 1.

PMID- 15188250
OWN - NLM
STAT- MEDLINE
DCOM- 20041227
LR  - 20230120
IS  - 0173-0835 (Print)
IS  - 0173-0835 (Linking)
VI  - 25
IP  - 10-11
DP  - 2004 Jun
TI  - Monitoring of drugs and metabolites in body fluids by capillary electrophoresis 
      with XeHg lamp-based and laser-induced fluorescence detection.
PG  - 1623-31
AB  - Commercial capillary electrophoresis instrumentation with XeHg lamp-based and 
      laser induced fluorescence (LIF) detection is employed for analysis of urinary 
      3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its major metabolites, 
      urinary metabolites of acetylsalicylic acid, urinary benzoylecgonine in an 
      immunoassay format, and albendazole sulfoxide and albendazole sulfone in plasma. 
      For the examples studied, the data suggest that the lamp-based detector can be 
      employed for the monitoring of pharmacological and toxicological relevant solute 
      concentrations, and thus represents an attractive alternative to LIF detection.
FAU - Caslavska, Jitka
AU  - Caslavska J
AD  - Department of Clinical Pharmacology, University of Bern, Murtenstrasse 35, 
      CH-3010 Bern, Switzerland.
FAU - Thormann, Wolfgang
AU  - Thormann W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Electrophoresis
JT  - Electrophoresis
JID - 8204476
RN  - 1UIC88380G (albendazole sulfone)
RN  - 5353I8I6YS (benzoylecgonine)
RN  - F4216019LN (Albendazole)
RN  - I5Y540LHVR (Cocaine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Albendazole/*analogs & derivatives/analysis/blood
MH  - Aspirin/*analysis/urine
MH  - Body Fluids/*chemistry
MH  - Cocaine/*analogs & derivatives/*analysis/urine
MH  - Electrophoresis, Capillary/*instrumentation
MH  - Lasers
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*analysis/urine
MH  - Spectrometry, Fluorescence/instrumentation
EDAT- 2004/06/10 05:00
MHDA- 2004/12/28 09:00
CRDT- 2004/06/10 05:00
PHST- 2004/06/10 05:00 [pubmed]
PHST- 2004/12/28 09:00 [medline]
PHST- 2004/06/10 05:00 [entrez]
AID - 10.1002/elps.200305821 [doi]
PST - ppublish
SO  - Electrophoresis. 2004 Jun;25(10-11):1623-31. doi: 10.1002/elps.200305821.

PMID- 3938942
OWN - NLM
STAT- MEDLINE
DCOM- 19860527
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 78 Spec No
DP  - 1985 Dec
TI  - [Eicosanoids, myocardial ischemia and sudden death].
PG  - 49-55
AB  - An activation of the arachidonic acid cascade has long been reported in coronary 
      artery diseases. However, no clear-cut connection has been demonstrated between 
      this activation and the clinical manifestations of myocardial ischemia. 
      Controlled trials with the available cyclooxygenase inhibitory drugs support the 
      view that these agents might be useful in subgroups of patients. However, these 
      are not known. The peculiar pharmacologic properties of prostacyclin and PGE1 
      have been documented to improve experimental and clinical acute myocardial 
      ischemia. Further efforts are needed to elucidate the usefulness of some PGs in 
      the management of patients with ischemic heart disease and their contributory 
      role to the disease.
FAU - Jouve, R
AU  - Jouve R
FAU - Larrue, J
AU  - Larrue J
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Icosanoïdes, ischémie myocardique et mort subite.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Animals
MH  - Arrhythmias, Cardiac/drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/*drug therapy
MH  - *Cyclooxygenase Inhibitors
MH  - Death, Sudden/*prevention & control
MH  - Dipyridamole/administration & dosage
MH  - Dogs
MH  - Epoprostenol/administration & dosage/pharmacology/*therapeutic use
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Myocardial Infarction/prevention & control
MH  - Random Allocation
MH  - Sulfinpyrazone/administration & dosage
EDAT- 1985/12/01 00:00
MHDA- 1985/12/01 00:01
CRDT- 1985/12/01 00:00
PHST- 1985/12/01 00:00 [pubmed]
PHST- 1985/12/01 00:01 [medline]
PHST- 1985/12/01 00:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 1985 Dec;78 Spec No:49-55.

PMID- 29629845
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20190128
IS  - 1477-0377 (Electronic)
IS  - 1358-863X (Linking)
VI  - 23
IP  - 6
DP  - 2018 Dec
TI  - Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): 
      Challenges in clinical trial execution.
PG  - 513-522
LID - 10.1177/1358863X18760996 [doi]
AB  - There is limited evidence to guide clinical decision-making for antiplatelet 
      therapy in peripheral artery disease (PAD) in the setting of lower extremity 
      endovascular treatment. The Ticagrelor in Peripheral Artery Disease Endovascular 
      Revascularization Study (TI-PAD) evaluated the role of ticagrelor versus aspirin 
      as monotherapy in the management of patients following lower extremity 
      endovascular revascularization. The trial failed to recruit the targeted number 
      of patients, likely due to aspects of the design including the lack of option for 
      dual antiplatelet therapy, and inability to identify suitable patients at study 
      sites. In response, the protocol underwent amendments, but these changes did not 
      adequately stimulate recruitment, and thus TI-PAD was prematurely terminated. 
      This article describes the rationale for TI-PAD and challenges in trial design, 
      subject recruitment and trial operations to better inform the conduct of future 
      trials in PAD revascularization. ClinicalTrials.gov Identifier: NCT02227368.
FAU - Rogers, R Kevin
AU  - Rogers RK
AUID- ORCID: 0000-0002-5811-6829
AD  - 1 Department of Medicine, Division of Cardiology, University of Colorado School 
      of Medicine, Aurora, CO, USA.
FAU - Hiatt, William R
AU  - Hiatt WR
AD  - 1 Department of Medicine, Division of Cardiology, University of Colorado School 
      of Medicine, Aurora, CO, USA.
AD  - 2 CPC Clinical Research, Aurora, CO, USA.
FAU - Patel, Manesh R
AU  - Patel MR
AD  - 3 Duke University Health System and Duke Clinical Research Institute, Durham, NC, 
      USA.
FAU - Shishehbor, Mehdi H
AU  - Shishehbor MH
AD  - 4 Harrington Heart & Vascular Institute, University Hospitals of Cleveland, 
      Cleveland, OH, USA.
FAU - White, Robin
AU  - White R
AD  - 2 CPC Clinical Research, Aurora, CO, USA.
FAU - Khan, Naeem D
AU  - Khan ND
AD  - 5 AstraZeneca, Wilmington, DE, USA.
FAU - Bhalla, Narinder P
AU  - Bhalla NP
AD  - 5 AstraZeneca, Wilmington, DE, USA.
FAU - Jones, W Schuyler
AU  - Jones WS
AD  - 3 Duke University Health System and Duke Clinical Research Institute, Durham, NC, 
      USA.
FAU - Low Wang, Cecilia C
AU  - Low Wang CC
AUID- ORCID: 0000-0001-8557-5417
AD  - 2 CPC Clinical Research, Aurora, CO, USA.
AD  - 6 Department of Medicine, Division of Endocrinology, University of Colorado 
      School of Medicine, Aurora, CO, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02227368
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180409
PL  - England
TA  - Vasc Med
JT  - Vascular medicine (London, England)
JID - 9610930
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - *Early Termination of Clinical Trials
MH  - *Endovascular Procedures/adverse effects
MH  - Female
MH  - Humans
MH  - Lower Extremity/*blood supply
MH  - Male
MH  - Middle Aged
MH  - *Patient Selection
MH  - Peripheral Arterial Disease/diagnosis/physiopathology/*therapy
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - *Sample Size
MH  - Ticagrelor/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - United States
OTO - NOTNLM
OT  - antiplatelet
OT  - aspirin
OT  - peripheral artery disease (PAD)
OT  - ticagrelor
OT  - trial design
EDAT- 2018/04/10 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/04/10 06:00
PHST- 2018/04/10 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/04/10 06:00 [entrez]
AID - 10.1177/1358863X18760996 [doi]
PST - ppublish
SO  - Vasc Med. 2018 Dec;23(6):513-522. doi: 10.1177/1358863X18760996. Epub 2018 Apr 9.

PMID- 3562385
OWN - NLM
STAT- MEDLINE
DCOM- 19870521
LR  - 20190713
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 81
IP  - 5
DP  - 1987 Apr
TI  - Kawasaki disease in a 4-year-old boy.
PG  - 95-8, 101-2
AB  - A 4-year-old boy experienced sudden fever, followed by a rash on the trunk and 
      extremities and erythema of the pharynx. Five days later, the fever remained and 
      erythema appeared on the oropharynx, tongue, and lips. The skin of the palms and 
      soles became erythematous and indurated, and both conjunctivae became injected. 
      Desquamation of the skin occurred on both thumbs and one finger, and an anterior 
      cervical lymph node was found to be enlarged. The patient was diagnosed as having 
      Kawasaki disease, and treatment with aspirin was started. The desquamation 
      progressed to involve the entire surface of the palms and soles, and then 
      symptoms resolved. Twenty years after recognition of Kawasaki disease, this 
      enigmatic illness continues to defy attempts to understand its etiology and 
      pathogenesis. Most experts agree that the cause is either an environmental toxin 
      or an infectious agent, but other possible causative agents may need to be 
      proposed and investigated.
FAU - Haines, J D Jr
AU  - Haines JD Jr
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child, Preschool
MH  - Humans
MH  - Lymph Nodes/pathology
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/etiology/pathology
MH  - Skin/pathology
EDAT- 1987/04/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1987/04/01 00:00
PHST- 1987/04/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1987/04/01 00:00 [entrez]
AID - 10.1080/00325481.1987.11699784 [doi]
PST - ppublish
SO  - Postgrad Med. 1987 Apr;81(5):95-8, 101-2. doi: 10.1080/00325481.1987.11699784.

PMID- 3927912
OWN - NLM
STAT- MEDLINE
DCOM- 19850916
LR  - 20190612
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 130
IP  - 2
DP  - 1985 Jul 31
TI  - Prostaglandin H synthase: an example of enzymic symbiosis.
PG  - 918-23
AB  - Reaction conditions which promote the heme-dependent peroxidase activity of 
      prostaglandin H synthase appear to stimulate the heme-dependent cyclooxygenase 
      activity also present in the synthase, even though the cyclooxygenase requires 
      hydroperoxide for activity. However, aspirin-treated synthase, which retains only 
      peroxidase activity, inhibited the cyclooxygenase activity of untreated synthase 
      in the manner observed with similar levels of glutathione peroxidase. Any 
      stimulatory effect of the synthase peroxidase on the synthase cyclooxygenase is 
      thus likely to involve an intramolecular mechanism. Participation of peroxidase 
      intermediates (Compounds I and II) in the initiation of a cyclooxygenase free 
      radical chain reaction may provide an intramolecular mechanism for stimulation of 
      the synthase cyclooxygenase by the synthase peroxidase.
FAU - Kulmacz, R J
AU  - Kulmacz RJ
FAU - Miller, J F Jr
AU  - Miller JF Jr
FAU - Lands, W E
AU  - Lands WE
LA  - eng
GR  - GM30509/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Free Radicals)
RN  - 42VZT0U6YR (Heme)
RN  - EC 1.11.1.- (Peroxidases)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Free Radicals
MH  - Glutathione Peroxidase/metabolism
MH  - Heme/metabolism
MH  - Models, Chemical
MH  - Peroxidases/*metabolism
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
EDAT- 1985/07/31 00:00
MHDA- 2001/03/28 10:01
CRDT- 1985/07/31 00:00
PHST- 1985/07/31 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1985/07/31 00:00 [entrez]
AID - 0006-291X(85)90504-2 [pii]
AID - 10.1016/0006-291x(85)90504-2 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1985 Jul 31;130(2):918-23. doi: 
      10.1016/0006-291x(85)90504-2.

PMID- 37039835
OWN - NLM
STAT- MEDLINE
DCOM- 20230417
LR  - 20230804
IS  - 1873-734X (Electronic)
IS  - 1010-7940 (Linking)
VI  - 63
IP  - 4
DP  - 2023 Apr 3
TI  - Comparative effectiveness of clopidogrel versus aspirin as a maintenance 
      monotherapy 1 year after coronary artery bypass grafting.
LID - ezad128 [pii]
LID - 10.1093/ejcts/ezad128 [doi]
AB  - OBJECTIVES: Data on the safety and efficacy of clopidogrel (CPD) monotherapy 
      after coronary artery bypass grafting (CABG) are limited. We compared the 
      clinical outcomes and graft patency rates during 4 years in CABG patients who 
      maintained CPD or aspirin after 1 year of dual antiplatelet therapy (DAPT) use. 
      METHODS: A total of 671 patients who maintained 1-year DAPT after CABG with all 
      grafts patent on one-year follow-up angiography and switched to single 
      antiplatelet therapy (SAPT) using CPD (n = 272) or aspirin (n = 399) between 
      January 2009 and December 2015 were enrolled. Propensity score matching analysis 
      was used, and 227 pairs were matched in a 1:1 ratio. Overall mortality, cardiac 
      mortality, and major adverse events, including all-cause mortality, acute 
      myocardial infarction, coronary reintervention or reoperation, ischaemic stroke, 
      and major bleeding, were compared. Graft patency was evaluated using graft 
      angiography 5 years post-surgery. RESULTS: Overall survival and the incidence of 
      major adverse events during the 4-year follow-up did not differ significantly 
      between the groups when un-matched (hazard ratio [HR], 95% confidence interval 
      [CI]=1.24, 0.71 to 2.15, P = 0.46 and HR, 95% CI = 1.22, 0.77 to 1.92, P = 0.41, 
      respectively) or matched (HR, 95% CI = 1.05, 0.55 to 2.01, P = 0.89 and HR, 95% 
      CI = 1.01, 0.60 to 1.73, P = 0.96, respectively). In the postoperative 5-year 
      graft angiography, new graft occlusion was found in 3.2% and 4.7% of patients and 
      newly occurred graft occlusion rates of distal anastomoses were 1.2% and 1.6% in 
      the CPD and aspirin groups, respectively, and were not statistically different 
      between the 2 groups (P = 0.39 and 0.63, respectively). Changes of antiplatelet 
      regimen were needed in 22.8% (91 of 399) of aspirin group and in 2.2% (6 of 272) 
      of CPD group from the initiation of SAPT (P < 0.001). CONCLUSIONS: In this series 
      of patients undergoing CABG who received DAPT and remained stable for 1 year, 
      SAPT maintenance with CPD or aspirin did not show any significant differences in 
      4-year outcomes such as all-cause mortality, major adverse events, and newly 
      occurring graft occlusion. However, more patients taking aspirin required changes 
      in antiplatelet regimens to other antiplatelet or anticoagulation therapies.
CI  - © The Author(s) 2023. Published by Oxford University Press on behalf of the 
      European Association for Cardio-Thoracic Surgery. All rights reserved.
FAU - Kim, Ji Seong
AU  - Kim JS
AUID- ORCID: 0000-0003-2908-7130
AD  - Department of Thoracic and Cardiovascular Surgery, Seoul National University 
      Hospital, Seoul National University College of Medicine, Seoul, Republic of 
      Korea.
FAU - Kang, Yoonjin
AU  - Kang Y
AUID- ORCID: 0000-0002-2528-173X
AD  - Department of Thoracic and Cardiovascular Surgery, Seoul National University 
      Hospital, Seoul National University College of Medicine, Seoul, Republic of 
      Korea.
FAU - Sohn, Suk Ho
AU  - Sohn SH
AUID- ORCID: 0000-0001-7391-3415
AD  - Department of Thoracic and Cardiovascular Surgery, Seoul National University 
      Hospital, Seoul National University College of Medicine, Seoul, Republic of 
      Korea.
FAU - Hwang, Ho Young
AU  - Hwang HY
AUID- ORCID: 0000-0002-8935-8118
AD  - Department of Thoracic and Cardiovascular Surgery, Seoul National University 
      Hospital, Seoul National University College of Medicine, Seoul, Republic of 
      Korea.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European 
      Association for Cardio-thoracic Surgery
JID - 8804069
RN  - R16CO5Y76E (Aspirin)
RN  - A74586SNO7 (Clopidogrel)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - Aspirin/therapeutic use
MH  - Clopidogrel/therapeutic use
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Brain Ischemia/etiology
MH  - *Stroke/etiology
MH  - Drug Therapy, Combination
MH  - Coronary Artery Bypass/adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Clopidogrel
OT  - Coronary Artery Bypass
OT  - Coronary Artery Disease
EDAT- 2023/04/12 06:00
MHDA- 2023/04/17 06:41
CRDT- 2023/04/11 11:13
PHST- 2022/10/26 00:00 [received]
PHST- 2023/03/21 00:00 [revised]
PHST- 2023/04/17 06:41 [medline]
PHST- 2023/04/12 06:00 [pubmed]
PHST- 2023/04/11 11:13 [entrez]
AID - 7114037 [pii]
AID - 10.1093/ejcts/ezad128 [doi]
PST - ppublish
SO  - Eur J Cardiothorac Surg. 2023 Apr 3;63(4):ezad128. doi: 10.1093/ejcts/ezad128.

PMID- 9914987
OWN - NLM
STAT- MEDLINE
DCOM- 19990219
LR  - 20141120
IS  - 1026-3543 (Print)
IS  - 1026-3543 (Linking)
VI  - 114
IP  - 5
DP  - 1998
TI  - [Long-term morphofunctional preservation of guinea pig hippocampal slices 
      following short-term treatment with cyclooxygenase inhibitors].
PG  - 30-4
AB  - Hippocampal slices treated with cyclooxygenase inhibitor indomethacin for three 
      min during the sectioning (45 min) or aspirin (0.5 min) in long term (up to 5 
      days) preservation in periodic nocturnal hypothermia were studied 
      morphofunctionally using light microscopy and electrophysiological registration 
      of induced population responses of area CAI to stimulation of Schaffers 
      collaterals. Structural disorders were revealed in control slices as early as the 
      third hour of incubation and they were destroyed following the first hypothermal 
      challenge (24 hrs following preparation). The structure in slices treated with 
      blockers remained more stable as compared to control ones and the activity was 
      registered until d 3 (aspirin) and 5 (indomethacin). Morphological changes were 
      not immediately, followed by electric activity decline. On the whole it may be 
      suggested that essential viability increase occurred due to destructive processes 
      inhibition mediated by short living cyclooxygenase metabolites.
FAU - Pakhotin, P I
AU  - Pakhotin PI
AD  - Ecological Acoustics Group, Biocrystalophysics Group, Russian Academy of 
      Sciences, Pushchino, Moscow District.
FAU - Pavlik, L L
AU  - Pavlik LL
FAU - Pakhotina, I D
AU  - Pakhotina ID
FAU - Andreev, A A
AU  - Andreev AA
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Dlitel'naia morfofunktsional'naia sokhrannost' srezov gippokampa morskoĭ svinki 
      posle kratkoĭ obrabotki ingibitorami tsiklooksigenaz.
PL  - Russia (Federation)
TA  - Morfologiia
JT  - Morfologiia (Saint Petersburg, Russia)
JID - 9317610
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cryopreservation
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Guinea Pigs
MH  - Hippocampus/*drug effects/ultrastructure
MH  - In Vitro Techniques
MH  - Indomethacin/*pharmacology
MH  - Time Factors
EDAT- 1999/01/23 00:00
MHDA- 1999/01/23 00:01
CRDT- 1999/01/23 00:00
PHST- 1999/01/23 00:00 [pubmed]
PHST- 1999/01/23 00:01 [medline]
PHST- 1999/01/23 00:00 [entrez]
PST - ppublish
SO  - Morfologiia. 1998;114(5):30-4.

PMID- 2337898
OWN - NLM
STAT- MEDLINE
DCOM- 19900620
LR  - 20190720
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 51
IP  - 1
DP  - 1990 May 15
TI  - Suppression of x-ray induced transformation by Valium and aspirin in mouse 
      C3H10T1/2 cells.
PG  - 49-57
AB  - Two commonly used drugs, Valium (diazepam) and Aspirin (acetylsalicyclic acid), 
      were shown to suppress X-ray induced transformation in mouse C3H/10T1/2 cells. 
      Valium was studied in an ethanol solution. Aspirin, which is soluble in both 
      water and ethanol, was active only in the ethanol solution. Both drugs were 
      effective only when present throughout the entire assay period.
FAU - Radner, B S
AU  - Radner BS
AD  - Harvard School of Public Health, Boston, MA 02115.
FAU - Kennedy, A R
AU  - Kennedy AR
LA  - eng
GR  - CA-22704/CA/NCI NIH HHS/United States
GR  - CA-34680/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Solutions)
RN  - 3K9958V90M (Ethanol)
RN  - Q3JTX2Q7TU (Diazepam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cell Line/drug effects/radiation effects
MH  - Cell Survival/drug effects
MH  - Cell Transformation, Neoplastic/*drug effects/radiation effects
MH  - Diazepam/*pharmacology/toxicity
MH  - Dose-Response Relationship, Drug
MH  - Embryo, Mammalian
MH  - Ethanol
MH  - Mice
MH  - Solutions
MH  - Time Factors
EDAT- 1990/05/15 00:00
MHDA- 1990/05/15 00:01
CRDT- 1990/05/15 00:00
PHST- 1990/05/15 00:00 [pubmed]
PHST- 1990/05/15 00:01 [medline]
PHST- 1990/05/15 00:00 [entrez]
AID - 0304-3835(90)90230-U [pii]
AID - 10.1016/0304-3835(90)90230-u [doi]
PST - ppublish
SO  - Cancer Lett. 1990 May 15;51(1):49-57. doi: 10.1016/0304-3835(90)90230-u.

PMID- 7547179
OWN - NLM
STAT- MEDLINE
DCOM- 19951109
LR  - 20191031
IS  - 0952-3480 (Print)
IS  - 0952-3480 (Linking)
VI  - 8
IP  - 1
DP  - 1995 Feb
TI  - Salicylate poisoning: two-dimensional J-resolved NMR urinalysis.
PG  - 19-24
AB  - Identification of a case of acute salicylate intoxication using 300 MHz 1H NMR 
      spectroscopy of a urine sample is reported. It has been achieved by using a 
      combination of a one-dimensional experiment with water presaturation and a 
      two-dimensional homonuclear J-resolved experiment. By these means, lysine and the 
      three major metabolites of acetylsalicylic acid have been assigned in the crude 
      urine. The results are compared with those obtained at 600 MHz and with classical 
      biochemical methods. The use of this method for routine diagnosis in biological 
      analysis is discussed.
FAU - Maschke, S
AU  - Maschke S
AD  - Laboratoire de Biochimie, Hôpital Calmette, CHR et U de Lille, France.
FAU - Azaroual, N
AU  - Azaroual N
FAU - Imbenotte, M
AU  - Imbenotte M
FAU - Vermeersch, G
AU  - Vermeersch G
FAU - Leclerc, F
AU  - Leclerc F
FAU - Lhermitte, M
AU  - Lhermitte M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - NMR Biomed
JT  - NMR in biomedicine
JID - 8915233
RN  - 0 (Gentisates)
RN  - 0 (Hippurates)
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Salicylates)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - VP36V95O3T (2,5-dihydroxybenzoic acid)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*poisoning/*urine
MH  - Female
MH  - *Gentisates
MH  - Hippurates/urine
MH  - Humans
MH  - Hydroxybenzoates/urine
MH  - Magnetic Resonance Spectroscopy/methods
MH  - Poisoning/urine
MH  - Salicylates/urine
MH  - Salicylic Acid
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
AID - 10.1002/nbm.1940080105 [doi]
PST - ppublish
SO  - NMR Biomed. 1995 Feb;8(1):19-24. doi: 10.1002/nbm.1940080105.

PMID- 4008177
OWN - NLM
STAT- MEDLINE
DCOM- 19850726
LR  - 20131121
IS  - 0250-0868 (Print)
IS  - 0250-0868 (Linking)
VI  - 7
IP  - 1
DP  - 1985
TI  - Differentiation of peripheral and central effects of analgesic drugs.
PG  - 79-83
AB  - The nonsteroidal antiphlogistic and antinociceptive agents acetylsalicylic acid, 
      diclofenac-Na and paracetamol, and the centrally acting analgesic morphine, were 
      tested in the isolated perfused rabbit ear. This model allows for the distinction 
      between centrally and peripherally acting analgesic drugs. It was found that 
      local acetylsalicylic acid, diclofenac-Na and paracetamol inhibited the pain 
      reflexes (blood pressure change, "head-flick" response) induced by bradykinin, 
      whereas local morphine proved to be inactive. In contrast, after systemic 
      administration, only morphine, but not acetylsalicylic acid, diclofenac-Na and 
      paracetamol, was active in a therapeutic dose range. Thus, the isolated rabbit 
      ear model is useful for differentiating peripheral from central sites of action 
      of an analgesic agent.
FAU - Schweizer, A
AU  - Schweizer A
FAU - Brom, R
AU  - Brom R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Int J Tissue React
JT  - International journal of tissue reactions
JID - 8302116
RN  - 0 (Analgesics)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 76I7G6D29C (Morphine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/pharmacology
MH  - Analgesics/administration & dosage/*pharmacology
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology
MH  - Diclofenac/administration & dosage/pharmacology
MH  - Male
MH  - Morphine/administration & dosage/pharmacology
MH  - Pain/*physiopathology
MH  - Rabbits
MH  - Reflex/drug effects
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Tissue React. 1985;7(1):79-83.

PMID- 11336593
OWN - NLM
STAT- MEDLINE
DCOM- 20020919
LR  - 20220410
IS  - 1465-6566 (Print)
IS  - 1465-6566 (Linking)
VI  - 2
IP  - 3
DP  - 2001 Mar
TI  - Current treatment practice for essential thrombocythaemia in adults.
PG  - 385-93
AB  - Essential thrombocythaemia (ET) is a relatively benign chronic myeloproliferative 
      disorder that occurs primarily in middle-aged patients. Its clinical course is 
      characterised by thomboembolic and, less frequently, by haemorrhagic 
      complications. Life expectancy of ET is generally of normal length and 
      progression to acute leukaemia is a rare event. About one third of all patients 
      are asymptomatic at diagnosis and many of them remain without complications for 
      years. Therefore, the main challenge for treating patients with ET is to select 
      patients who will benefit from a cytoreductive or antiplatelet therapy, because 
      it is doubtful whether the beneficial effects of therapy outweigh the potential 
      hazards in all cases. For this reason a risk stratification in high and low risk 
      ET patients is essential. The treatment of ET has evolved from alkylating agents 
      to hydroxyurea (HU) or pipobroman and more recently to agents such as IFN-alpha 
      and anagrelide. Aspirin as an antiplatelet therapy is also expected to play a 
      part in the treatment of ET. HU is first-line therapy for elderly patients with 
      high risk ET. In young ET patients without ET related complications and a 
      platelet count << 1000 - 1500 x 10(9)/l abstention from cytoreductive therapy or 
      therapy with low-dose aspirin alone seems to be appropriate. The aim of this 
      review is to address the current treatment practice for ET in adults.
FAU - Griesshammer, M
AU  - Griesshammer M
AD  - Department of Medicine III, Robert-Koch-Strasse 8, D-89081 Ulm, Federal Republic 
      of Germany. martin.griesshammer@medizin.uni-ulm.de
FAU - Bangerter, M
AU  - Bangerter M
FAU - Grünewald, M
AU  - Grünewald M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Interferon-alpha)
RN  - 0 (Quinazolines)
RN  - 6Q99RDT97R (Pipobroman)
RN  - K9X45X0051 (anagrelide)
RN  - R16CO5Y76E (Aspirin)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Hydroxyurea/therapeutic use
MH  - Interferon-alpha/therapeutic use
MH  - Pipobroman/therapeutic use
MH  - Prognosis
MH  - Quinazolines/therapeutic use
MH  - Thrombocythemia, Essential/diagnosis/*drug therapy
RF  - 55
EDAT- 2001/05/05 10:00
MHDA- 2002/09/20 10:01
CRDT- 2001/05/05 10:00
PHST- 2001/05/05 10:00 [pubmed]
PHST- 2002/09/20 10:01 [medline]
PHST- 2001/05/05 10:00 [entrez]
AID - 10.1517/14656566.2.3.385 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2001 Mar;2(3):385-93. doi: 10.1517/14656566.2.3.385.

PMID- 8667430
OWN - NLM
STAT- MEDLINE
DCOM- 19960807
LR  - 20190512
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 88
IP  - 14
DP  - 1996 Jul 17
TI  - Prospective study of regular aspirin use and the risk of breast cancer.
PG  - 988-93
AB  - BACKGROUND: Evidence suggests that aspirin and other nonsteroidal 
      anti-inflammatory drugs (NSAIDs) can inhibit tumor development in the large 
      bowel. An inverse association between the use of NSAIDs and the incidence of 
      breast cancer has been observed, but this association has not been statistically 
      significant in all studies. PURPOSE: We analyzed data from the prospective 
      Nurses' Health Study to evaluate the influence of aspirin use on breast cancer 
      risk. METHODS: We studied a population of 89,528 female registered nurses who 
      reported no history of breast or other cancers (excluding nonmelanoma skin 
      cancer) and who returned a mailed questionnaire in 1980 that elicited information 
      concerning breast cancer risk factors and current and past aspirin use. Follow-up 
      questionnaires were mailed to the participants every 2 years; the women were 
      followed through 1992. Information concerning current aspirin use was obtained 
      from each biennial questionnaire, except in 1986. Cases of breast cancer were 
      identified through questionnaire responses, and permission was sought for a 
      review of medical records to confirm the diagnoses. Our analysis was based on 
      2414 cases of invasive breast cancer, which included 2303 cases confirmed with 
      medical records and 111 cases for which no records were obtained. Relative risks 
      (RRs) with 95% confidence intervals (CIs), adjusted for age or age plus other 
      known or potential breast cancer risk factors (i.e., multivariate), were 
      calculated. RESULTS: Regular aspirin use (two or more tablets per week) in 1980 
      was unrelated to breast cancer incidence during the succeeding 12-year period 
      (with no regular aspirin use as the referent, multivariate RR = 1.03; 95% CI = 
      0.95-1.12). The corresponding risk estimate for consistent regular aspirin use 
      during the period from 1980 through 1988 was 1.01 (95% CI = 0.80-1.27). The risks 
      were similar for heavy aspirin use (for more than two tablets per day [i.e., > 14 
      per week] in 1980 and in 1980 through 1988, the multivariate RRs [95% CIs] were 
      1.05 [0.89-1.23] and 1.09 [0.75-1.60], respectively) and for extended durations 
      of regular use (e.g., for 20 years or more of regular use, multivariate RR = 
      1.00; 95% CI = 0.71-1.41). CONCLUSION: Our results indicate that regular aspirin 
      use does not reduce the risk of breast cancer.
FAU - Egan, K M
AU  - Egan KM
AD  - Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
FAU - Stampfer, M J
AU  - Stampfer MJ
FAU - Giovannucci, E
AU  - Giovannucci E
FAU - Rosner, B A
AU  - Rosner BA
FAU - Colditz, G A
AU  - Colditz GA
LA  - eng
GR  - CA 40935/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Natl Cancer Inst. 1996 Jul 17;88(14):941-2. PMID: 8667422
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Breast Neoplasms/*prevention & control
MH  - Drug Utilization/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk
MH  - Risk Factors
EDAT- 1996/07/17 00:00
MHDA- 1996/07/17 00:01
CRDT- 1996/07/17 00:00
PHST- 1996/07/17 00:00 [pubmed]
PHST- 1996/07/17 00:01 [medline]
PHST- 1996/07/17 00:00 [entrez]
AID - 10.1093/jnci/88.14.988 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 1996 Jul 17;88(14):988-93. doi: 10.1093/jnci/88.14.988.

PMID- 8667211
OWN - NLM
STAT- MEDLINE
DCOM- 19960806
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 277
IP  - 3
DP  - 1996 Jun
TI  - Nonsteroidal anti-inflammatory drugs activate carbonic anhydrase by a direct 
      mechanism of action.
PG  - 1464-6
AB  - Previous studies by this research team proved that vasodilating prostaglandins 
      (PGs) E1, E2 and I2 inhibit carbonic anhydrase (CA) in vitro and in vivo, which 
      suggested involvement of CA in gastric acid secretion inhibition and the increase 
      of gastric mucosa blood flow produced by this group of PGs. Relying on these 
      findings, as well as on our clinical observations, we studied in vitro and in 
      vivo the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on CA I and CA 
      II. We also followed in vitro the effects on these isozymes of NSAIDs associated 
      to histamine, Ca, PGE2 and acetazolamide. The results show that the NSAIDs used 
      here, which reduce the activity of cyclooxygenase and PG production, activated CA 
      I and CA II in a dose-dependent manner by a mechanism of the noncompetitive type. 
      Histamine and Ca added to NSAIDs amplified the activating effect of the latter on 
      CA II. Association of PGE2 or acetazolamide to NSAIDs reduced NSAID-induced 
      activation of CA I and CA II. Indomethacin abolished the inhibitory effect of 
      acetazolamide on CA I and CA II. Our data imply that between CA and 
      cyclooxygenase there is an inverse relationship, CA activation being accompanied 
      by reduction of cyclooxygenase activity, a reduction achieved by the pH 
      modifications induced by CA activation. In this way, cyclooxygenase, inhibition 
      occurs "via CA," with the pH variations it brings about.
FAU - Puscas, I
AU  - Puscas I
AD  - Center for Medical Research and Assistance, Simleu Silvaniei, Salaj, Romania.
FAU - Coltau, M
AU  - Coltau M
FAU - Pasca, R
AU  - Pasca R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 13T4O6VMAM (Piroxicam)
RN  - 57Y76R9ATQ (Naproxen)
RN  - EC 4.2.1.1 (Carbonic Anhydrases)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/pharmacology
MH  - Carbonic Anhydrases/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Naproxen/pharmacology
MH  - Piroxicam/pharmacology
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1996 Jun;277(3):1464-6.

PMID- 3768359
OWN - NLM
STAT- MEDLINE
DCOM- 19861210
LR  - 20190609
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 862
IP  - 1
DP  - 1986 Nov 6
TI  - Membrane protein phosphorylation during stomatocyte-echinocyte transformation of 
      human erythrocytes.
PG  - 1-7
AB  - The normal, discoid shape of red blood cells represents an equilibrium between 
      two opposing factors, i.e., stomatocytic and echinocytic transformations. Most 
      stomatocytic agents were found to be inhibitors of calmodulin, a regulator of the 
      phosphorylation of membrane proteins. We determined whether red cell shape 
      transformations could be caused by changes in phosphorylation of membrane 
      proteins, specifically the cAMP-dependent phosphorylation of ankyrin and band 
      4.1. Red blood cells were incubated with 32P and 100 microM chlorpromazine 
      (stomatocytic transformation) or 30 mM sodium salicylate (echinocytic 
      transformation) for various time intervals. Ghost membrane proteins were examined 
      by polyacrylamide gel electrophoresis and autoradiography. Spectrin (beta-chain), 
      ankyrin, band 3, band 4.1 and 4.9 were phosphorylated. No change was found in the 
      degree and pattern of phosphorylation after stomatocytic transformation. 
      Salicylate caused a reversible inhibition of transmembranous phosphate transport 
      in both directions. The results indicate that the stomatocytic transformation 
      induced by chlorpromazine and the echinocytic transformation induced by 
      salicylate do not involve a change in phosphorylation, but that the echinocytic 
      transformation induced by salicylate is associated with an inhibition of 
      transmembranous transport of phosphate. Studies with salicylate suggest that the 
      phosphorylation sites of band 3 are found mainly on the endofacial side of the 
      membrane.
FAU - Reinhart, W H
AU  - Reinhart WH
FAU - Sung, L A
AU  - Sung LA
FAU - Schuessler, G B
AU  - Schuessler GB
FAU - Chien, S
AU  - Chien S
LA  - eng
GR  - HL-07114/HL/NHLBI NIH HHS/United States
GR  - HL-16851/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Membrane Proteins)
RN  - R16CO5Y76E (Aspirin)
RN  - U42B7VYA4P (Chlorpromazine)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Chlorpromazine/pharmacology
MH  - Erythrocytes/cytology/drug effects/*metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Membrane Proteins/*metabolism
MH  - Phosphorylation
EDAT- 1986/11/06 00:00
MHDA- 1986/11/06 00:01
CRDT- 1986/11/06 00:00
PHST- 1986/11/06 00:00 [pubmed]
PHST- 1986/11/06 00:01 [medline]
PHST- 1986/11/06 00:00 [entrez]
AID - 0005-2736(86)90462-1 [pii]
AID - 10.1016/0005-2736(86)90462-1 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 1986 Nov 6;862(1):1-7. doi: 10.1016/0005-2736(86)90462-1.

PMID- 3714284
OWN - NLM
STAT- MEDLINE
DCOM- 19860707
LR  - 20210111
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 25
IP  - 1
DP  - 1986 Apr
TI  - Dissociation between antinociceptive and anti-inflammatory effects of 
      acetylsalicylic acid and indomethacin in the formalin test.
PG  - 125-132
LID - 10.1016/0304-3959(86)90014-X [doi]
AB  - It is assumed that the mild analgesia produced by acetylsalicylic acid (ASA) and 
      indomethacin is due to a common mode of action, namely inhibition of the 
      cyclo-oxygenase reaction in the synthesis of prostaglandins. It has, however, 
      been difficult to separate the influence of the anti-inflammatory activity from 
      pure analgesia in standard animal tests using a fully developed inflammatory 
      state. In the present experiments a modification of the formalin test in mice is 
      used. Licking of the injected paw is recorded after the injection of a small 
      nociceptive amount of formalin (20 microliters, 1%). The results show that the 
      response to formalin is biphasic with an early (0-5 min) and a late (20-30 min) 
      phase of high licking activity. ASA had a dose-dependent antinociceptive effect 
      during both the early and the late phases. In contrast, antinociceptive effect of 
      indomethacin was found only during the late phase. On the basis of these results 
      it may be suggested that inhibition of the cyclo-oxygenase reaction has no major 
      effect on the early phase in the formalin test. This also suggests that ASA and 
      indomethacin are antinociceptive through partially different modes of action. In 
      addition to an anti-inflammatory effect common to both drugs, ASA may have a 
      direct antinociceptive action.
FAU - Hunskaar, Steinar
AU  - Hunskaar S
AD  - Department of Physiology, University of Bergen, Årstadveien 19, N-5000 
      BergenNorway.
FAU - Berge, Odd-Geir
AU  - Berge OG
FAU - Hole, Kjell
AU  - Hole K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - 1HG84L3525 (Formaldehyde)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Formaldehyde/*toxicity
MH  - Hindlimb/innervation
MH  - Indomethacin/*pharmacology
MH  - Inflammation/*chemically induced
MH  - Injections, Intraperitoneal
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Nociceptors/*drug effects
EDAT- 1986/04/01 00:00
MHDA- 1986/04/01 00:01
CRDT- 1986/04/01 00:00
PHST- 1986/04/01 00:00 [pubmed]
PHST- 1986/04/01 00:01 [medline]
PHST- 1986/04/01 00:00 [entrez]
AID - 00006396-198604000-00013 [pii]
AID - 10.1016/0304-3959(86)90014-X [doi]
PST - ppublish
SO  - Pain. 1986 Apr;25(1):125-132. doi: 10.1016/0304-3959(86)90014-X.

PMID- 6089187
OWN - NLM
STAT- MEDLINE
DCOM- 19841003
LR  - 20190501
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 81
IP  - 16
DP  - 1984 Aug
TI  - Dose-related effect of acetylsalicylic acid on replication of varicella zoster 
      virus in vitro.
PG  - 5223-6
AB  - Cultivation of human embryonic lung (HEL) cells in media containing 
      acetylsalicylic acid (ASA) at 100 micrograms/ml and maintenance at this level 
      after inoculation with either cell-free varicella zoster virus (VZV) or 
      virus-infected cells resulted in a 2- to 4-fold increase in yields of cell-free 
      virus released by sonication. The degree of enhancement was dependent upon 
      multiplicity of infection and time of harvest. Enhanced viral yields were not 
      consistently accompanied by an increase in the number of infected cells, nor was 
      VZV plaque formation in HEL indicator cells significantly increased in the 
      presence of ASA at 100 micrograms/ml. In the presence of ASA at 500-1000 
      micrograms/ml, VZV plaque formation was inhibited; this inhibition was partially 
      reversible, depending on concentration and period of exposure to ASA. These 
      findings may bear on the apparent association between ASA ingestion and the 
      development of Reye syndrome after infection with varicella virus.
FAU - Walz-Cicconi, M A
AU  - Walz-Cicconi MA
FAU - Weller, T H
AU  - Weller TH
LA  - eng
GR  - AI 16154/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Cell Line
MH  - DNA Replication/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Herpesvirus 3, Human/drug effects/*genetics
MH  - Humans
MH  - Lung/embryology
MH  - Viral Plaque Assay
MH  - Virus Replication/drug effects
PMC - PMC391670
EDAT- 1984/08/01 00:00
MHDA- 1984/08/01 00:01
CRDT- 1984/08/01 00:00
PHST- 1984/08/01 00:00 [pubmed]
PHST- 1984/08/01 00:01 [medline]
PHST- 1984/08/01 00:00 [entrez]
AID - 10.1073/pnas.81.16.5223 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1984 Aug;81(16):5223-6. doi: 10.1073/pnas.81.16.5223.

PMID- 6109235
OWN - NLM
STAT- MEDLINE
DCOM- 19810327
LR  - 20131121
IS  - 0026-4970 (Print)
IS  - 0026-4970 (Linking)
VI  - 29
IP  - 5
DP  - 1980 Sep-Oct
TI  - [Use of floctafenine in toothaches in adults and children (a controlled study). 
      II].
PG  - 345-58
AB  - A double-blind study was made of the activity and tolerance of 400 mg 
      Floctaphenine versus 400 mg Acetylsalicylic Acid (ASA) on ordinary random 
      administration. 48 patients received Floctaphenine and 50 ASA. Menstruating women 
      were included, but not children aged less than 12 yr. Periodontitis, pulpitis, 
      abscesses, extractions and dysodontiasis were the most frequently represented 
      sources of pain. Subjects completing the study were divided into groups: those 
      already treated with other analgesics in the previous 24 hr, those with 
      uninterrupted pain, those with attacks of pain, those for whom one administration 
      was sufficient, menstruating women. Account was also taken of the effect of 
      treatment before or after meals, and the influence of a simultaneously 
      administered antibiotic (the same one in each case). Statistical assessment 
      showed that both drugs were analgesic, but that Floctaphenine was significantly 
      (P < 0.01) better than ASA. The same was true with regard to latency time, 
      duration of the effect, clinical assessment, need for support from other 
      analgesics. The antibiotic appeared to have no appreciable influence of the 
      activity of the two drugs, nor did the time of administration (before or after 
      meals). Much the same picture was apparent in each group. Menstrual status was 
      devoid of influence, though it cannot be stated with equal certainty that whether 
      secondary effects were more frequent. Floctaphenine was very well tolerated. 
      There were 4 somewhat doubtful cases of somnolence (8.33%). It was not certain, 
      in fact, whether this was not an outcome of the relief from pain. ASA was 
      accompanied by stomach pain in 9 cases (18%). This was much more common when it 
      was taken on an empty stomach.
FAU - Di Blasi, F
AU  - Di Blasi F
FAU - Gnudi, A
AU  - Gnudi A
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Impiego della floctafenina nei dolori odontostomatologici degli adulti e dei 
      bambini (studio controllato). Seconda parte.
PL  - Italy
TA  - Minerva Stomatol
JT  - Minerva stomatologica
JID - 0421071
RN  - 0 (ortho-Aminobenzoates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Toothache/*drug therapy
MH  - ortho-Aminobenzoates/*therapeutic use
EDAT- 1980/09/01 00:00
MHDA- 1980/09/01 00:01
CRDT- 1980/09/01 00:00
PHST- 1980/09/01 00:00 [pubmed]
PHST- 1980/09/01 00:01 [medline]
PHST- 1980/09/01 00:00 [entrez]
PST - ppublish
SO  - Minerva Stomatol. 1980 Sep-Oct;29(5):345-58.

PMID- 9169251
OWN - NLM
STAT- MEDLINE
DCOM- 19970805
LR  - 20190909
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 13
IP  - 9
DP  - 1997
TI  - Comparative bioavailability of aspirin and paracetamol following single dose 
      administration of soluble and plain tablets.
PG  - 491-500
AB  - In this study, the bioavailability of aspirin and paracetamol was compared in 
      plain and soluble combination formulations in fasting, healthy volunteers. Blood 
      samples were taken and Cmax, Tmax and AUC measured at various times following 
      administration of single doses of the two formulations in 12 subjects. The 
      rapidity of uptake of aspirin following administration of a soluble formulation 
      suggests significant absorption from the stomach. There was no significant 
      difference in the pharmacokinetic parameters of paracetamol derived from a 
      soluble or plain formulation. A comparison of the uptake of aspirin from the 
      soluble aspirin formulation with paracetamol from either plain or soluble tablets 
      showed that aspirin entered the plasma and achieved peak levels significantly 
      more quickly. However, the half life of paracetamol was significantly longer than 
      that of aspirin. These findings suggest that onset of analgesia should be more 
      rapid following dosing with soluble aspirin, a conclusion supported by 
      comparative efficacy studies conducted with differing formulations of aspirin.
FAU - Muir, N
AU  - Muir N
AD  - Reckitt & Colman Plc, Hull, UK.
FAU - Nichols, J D
AU  - Nichols JD
FAU - Stillings, M R
AU  - Stillings MR
FAU - Sykes, J
AU  - Sykes J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*administration & dosage/*pharmacokinetics
MH  - Adult
MH  - Analgesics, Non-Narcotic/*administration & dosage/*pharmacokinetics
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & 
      dosage/*pharmacokinetics
MH  - Aspirin/*administration & dosage/*pharmacokinetics
MH  - Biological Availability
MH  - Female
MH  - Humans
MH  - Male
MH  - Solubility
MH  - Tablets
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1185/03007999709113322 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 1997;13(9):491-500. doi: 10.1185/03007999709113322.

PMID- 29569284
OWN - NLM
STAT- MEDLINE
DCOM- 20191023
LR  - 20210109
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 73
IP  - 10
DP  - 2018 Oct
TI  - Low frequency of acetyl salicylic acid hypersensitivity in mastocytosis: The 
      results of a double-blind, placebo-controlled challenge study.
PG  - 2055-2062
LID - 10.1111/all.13445 [doi]
AB  - BACKGROUND: Patients with mastocytosis are at increased risk of anaphylaxis. The 
      use of nonsteroidal anti-inflammatory drugs (NSAIDs) is often discouraged because 
      of this reason. However, the actual prevalence and severity of NSAID-related 
      hypersensitivity among patients with mastocytosis is unknown. METHODS: A 
      double-blind, placebo-controlled acetylsalicylic acid (ASA) challenge up to a 
      cumulative dose of 520 mg was performed among adult patients with mastocytosis. 
      In addition, a retrospective search of the entire outpatient cohort was performed 
      to obtain "real-life" data on NSAID hypersensitivity. RESULTS: Fifty patients 
      underwent an ASA challenge. Seventy percent had indolent systemic mastocytosis, 
      18% had mastocytosis in the skin, and 12% had advanced mastocytosis. The ASA 
      challenge was positive in 1 patient who developed urticaria. The additional 
      retrospective chart review revealed that 8 of 191 patients had a history of 
      NSAID-related hypersensitivity reaction(s), of whom 3 reported severe systemic 
      reactions. All 8 patients had already experienced NSAID-related hypersensitivity 
      reactions before mastocytosis was diagnosed. CONCLUSIONS: The frequency of ASA 
      hypersensitivity was 2% in a prospective challenge study and 4.1% in a 
      retrospective chart review of 191 patients with mastocytosis. NSAIDs can be 
      administered safely to most patients with mastocytosis. Extra caution should be 
      taken in patients with a history of hypersensitivity reactions to other drugs, or 
      traditional risk factors for NSAID hypersensitivity.
CI  - © 2018 The Authors. Allergy Published by John Wiley & Sons Ltd.
FAU - Hermans, M A W
AU  - Hermans MAW
AUID- ORCID: 0000-0002-1643-8387
AD  - Department of Internal Medicine, Section of Clinical Immunology, Erasmus 
      University Medical Center, Rotterdam, The Netherlands.
AD  - Department of Internal Medicine, Section of Allergy, Erasmus MC, Rotterdam, The 
      Netherlands.
FAU - van der Vet, S Q A
AU  - van der Vet SQA
AD  - Department of Internal Medicine, Section of Clinical Immunology, Erasmus 
      University Medical Center, Rotterdam, The Netherlands.
AD  - Department of Internal Medicine, Section of Allergy, Erasmus MC, Rotterdam, The 
      Netherlands.
FAU - van Hagen, P M
AU  - van Hagen PM
AD  - Department of Internal Medicine, Section of Clinical Immunology, Erasmus 
      University Medical Center, Rotterdam, The Netherlands.
FAU - van Wijk, R Gerth
AU  - van Wijk RG
AUID- ORCID: 0000-0002-9608-8742
AD  - Department of Internal Medicine, Section of Allergy, Erasmus MC, Rotterdam, The 
      Netherlands.
FAU - van Daele, P L A
AU  - van Daele PLA
AD  - Department of Internal Medicine, Section of Clinical Immunology, Erasmus 
      University Medical Center, Rotterdam, The Netherlands.
AD  - Department of Internal Medicine, Section of Allergy, Erasmus MC, Rotterdam, The 
      Netherlands.
LA  - eng
PT  - Clinical Study
PT  - Journal Article
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/immunology
MH  - Aspirin/adverse effects/*immunology
MH  - Double-Blind Method
MH  - Drug Hypersensitivity/*diagnosis
MH  - Humans
MH  - Mastocytosis/complications/*drug therapy
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Urticaria/chemically induced
PMC - PMC6220989
OTO - NOTNLM
OT  - drug challenge
OT  - epidemiology
OT  - hypersensitivity
OT  - mastocytosis
OT  - nonsteroidal anti-inflammatory drugs
EDAT- 2018/03/24 06:00
MHDA- 2019/10/24 06:00
CRDT- 2018/03/24 06:00
PHST- 2018/03/08 00:00 [accepted]
PHST- 2018/03/24 06:00 [pubmed]
PHST- 2019/10/24 06:00 [medline]
PHST- 2018/03/24 06:00 [entrez]
AID - ALL13445 [pii]
AID - 10.1111/all.13445 [doi]
PST - ppublish
SO  - Allergy. 2018 Oct;73(10):2055-2062. doi: 10.1111/all.13445.

PMID- 21371292
OWN - NLM
STAT- MEDLINE
DCOM- 20110711
LR  - 20211020
IS  - 1471-2482 (Electronic)
IS  - 1471-2482 (Linking)
VI  - 11
DP  - 2011 Mar 3
TI  - A randomised controlled trial to evaluate and optimize the use of antiplatelet 
      agents in the perioperative management in patients undergoing general and 
      abdominal surgery--the APAP trial (ISRCTN45810007).
PG  - 7
LID - 10.1186/1471-2482-11-7 [doi]
AB  - BACKGROUND: Due to the increase of cardiovascular diseases acetylsalicylic acid 
      (ASA) has become one of the most frequently prescribed drugs these days. Despite 
      the rising number of patients with ASA medication presenting for elective general 
      and abdominal surgery and the potentially increased risk of hemorrhage in these 
      patients, there are no clear, evidence-based guidelines for the perioperative use 
      of antiplatelet agents. The present randomised controlled trial was designed to 
      evaluate the safety and optimize the use of ASA in the perioperative management 
      of patients undergoing general and abdominal surgery. METHODS/DESIGN: This is a 
      two-arm, monocenter randomised controlled trial. Patients scheduled for elective 
      surgical treatment (i.e. inguinal hernia repair, cholecystectomy and colorectal 
      resections) with ASA as a permanent medication are randomised equally to 
      perioperative continuation or discontinuation of ASA. Patients who are randomised 
      in the discontinuation group stop the administration of ASA five days prior to 
      surgical treatment and start intake of ASA on postoperative day 5. Fifty-two 
      patients will be enrolled in this trial. The primary outcome is the incidence of 
      postoperative bleeding and cardiovascular events at 30 days after surgery. In 
      addition a set of general as well as surgical variables are analysed. DISCUSSION: 
      This is a randomised controlled two-group parallel trial designed to assess the 
      safety and optimize the use of ASA in the perioperative management of patients 
      undergoing general and abdominal surgery. The results of this pilot study build 
      the basis for a confirmative randomised controlled trial that may help to clarify 
      the use and potential risk/benefits of perioperative ASA medication in patients 
      undergoing elective surgery. TRIAL REGISTRATION: The trial is registered with 
      Current Controlled Trials ISRCTN45810007.
FAU - Antolovic, Dalibor
AU  - Antolovic D
AD  - Department of Surgery, University of Heidelberg, Germany. 
      dalibor.antolovic@kssg.ch
FAU - Reissfelder, Christoph
AU  - Reissfelder C
FAU - Rakow, Anastasia
AU  - Rakow A
FAU - Contin, Pietro
AU  - Contin P
FAU - Rahbari, Nuh N
AU  - Rahbari NN
FAU - Büchler, Markus W
AU  - Büchler MW
FAU - Weitz, Jürgen
AU  - Weitz J
FAU - Koch, Moritz
AU  - Koch M
LA  - eng
SI  - ISRCTN/ISRCTN45810007
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20110303
PL  - England
TA  - BMC Surg
JT  - BMC surgery
JID - 100968567
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cholecystectomy
MH  - Clinical Protocols
MH  - Colectomy
MH  - *Elective Surgical Procedures
MH  - Female
MH  - Hernia, Inguinal/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Perioperative Care
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Hemorrhage/chemically induced
MH  - Prospective Studies
MH  - Rectum/surgery
MH  - Thromboembolism/etiology
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC3056734
EDAT- 2011/03/05 06:00
MHDA- 2011/07/12 06:00
CRDT- 2011/03/05 06:00
PHST- 2010/09/26 00:00 [received]
PHST- 2011/03/03 00:00 [accepted]
PHST- 2011/03/05 06:00 [entrez]
PHST- 2011/03/05 06:00 [pubmed]
PHST- 2011/07/12 06:00 [medline]
AID - 1471-2482-11-7 [pii]
AID - 10.1186/1471-2482-11-7 [doi]
PST - epublish
SO  - BMC Surg. 2011 Mar 3;11:7. doi: 10.1186/1471-2482-11-7.

PMID- 17697147
OWN - NLM
STAT- MEDLINE
DCOM- 20071102
LR  - 20131121
IS  - 0906-6705 (Print)
IS  - 0906-6705 (Linking)
VI  - 16
IP  - 9
DP  - 2007 Sep
TI  - Suppressive effect of orally administered copper(II)-aspirinate (Cu2(asp)4) 
      complex on the generation of reactive oxygen species in the skin of animals 
      subjected to UVA exposure.
PG  - 746-52
AB  - As reactive oxygen species (ROS) are involved in the pathogenesis of various 
      diseases, superoxide dismutase (SOD) and its mimetic complexes have been 
      intensively studied. Recently, we found that Cu(2)(aspirinate)(4) (Cu(2)(asp)(4)) 
      has both in vitro and in vivo antioxidative activities. We investigated the 
      suppressive effect of Cu(2)(asp)(4) on ROS generation in the skin of hairless 
      mice that were orally administered Cu(2)(asp)(4) and followed by UVA exposure. 
      The results were compared with those obtained from mice that were orally 
      administered Cu(salicylate)(2) (Cu(sal)(2)) or Cu(acetate)(2), (Cu(ace)(2)) and 
      followed by UVA exposure. After confirming that Cu(2)(asp)(4) suppressed ROS 
      generation in the skin, we measured both SOD activity and metallothionein (MT) 
      and SOD protein levels in the whole proteins extracted from the skin of ICR mice 
      that were orally administered Cu(II) compounds. The Cu(2)Zn(2)-SOD activity was 
      enhanced by the administration of Cu(II) compounds; however, no alterations in 
      the protein levels of MT and SOD were observed. Metallokinetics of the 
      paramagnetic Cu(II) species in the circulating blood of rats, as estimated by 
      electron spin resonance (ESR), revealed that among the Cu(II) compounds, the 
      residence time of the Cu(II) species from Cu(2)(asp)(4) was the longest. On the 
      basis of these results, we conclude that Cu(2)(asp)(4) is an orally potent 
      antioxidative compound that suppresses ROS generation in the skin. The residence 
      time of Cu(II) in the blood and the enhanced SOD activity in the skin following 
      the oral administration of Cu(2)(asp)(4) support this conclusion. Here, we 
      propose that Cu(2)(asp)(4) may be used to protect the skin against ROS 
      generation.
FAU - Fujimori, Takako
AU  - Fujimori T
AD  - Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical 
      University, 5 Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto, Japan.
FAU - Yasui, Hiroyuki
AU  - Yasui H
FAU - Hiromura, Makoto
AU  - Hiromura M
FAU - Sakurai, Hiromu
AU  - Sakurai H
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Exp Dermatol
JT  - Experimental dermatology
JID - 9301549
RN  - 0 (Antioxidants)
RN  - 0 (Reactive Oxygen Species)
RN  - 23642-01-5 (tetrakis-mu-acetylsalicylato-dicopper(II))
RN  - 789U1901C5 (Copper)
RN  - 9038-94-2 (Metallothionein)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Antioxidants/*pharmacology
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Copper/metabolism
MH  - Male
MH  - Metallothionein/metabolism
MH  - Mice
MH  - Mice, Hairless
MH  - Mice, Inbred ICR
MH  - Rats
MH  - Rats, Wistar
MH  - Reactive Oxygen Species/*metabolism
MH  - Skin/drug effects/*metabolism/radiation effects
MH  - Superoxide Dismutase/metabolism
MH  - Ultraviolet Rays/*adverse effects
EDAT- 2007/08/19 09:00
MHDA- 2007/11/06 09:00
CRDT- 2007/08/19 09:00
PHST- 2007/08/19 09:00 [pubmed]
PHST- 2007/11/06 09:00 [medline]
PHST- 2007/08/19 09:00 [entrez]
AID - EXD595 [pii]
AID - 10.1111/j.1600-0625.2007.00595.x [doi]
PST - ppublish
SO  - Exp Dermatol. 2007 Sep;16(9):746-52. doi: 10.1111/j.1600-0625.2007.00595.x.

PMID- 21529769
OWN - NLM
STAT- MEDLINE
DCOM- 20110811
LR  - 20131121
IS  - 1552-6259 (Electronic)
IS  - 0003-4975 (Linking)
VI  - 91
IP  - 6
DP  - 2011 Jun
TI  - Thoracic aortic mobile thrombus: is there a role for early surgical intervention?
PG  - 1875-81
LID - 10.1016/j.athoracsur.2011.02.011 [doi]
AB  - BACKGROUND: The diagnosis of thoracic aortic mobile thrombus (TAMT) is rare and 
      is usually made after debilitating embolic events. The optimal treatment strategy 
      is unknown. We report 14 patients with TAMT and aim to better define the role of 
      early (less than 2 weeks) surgical thrombectomy. METHODS: Between February 1996 
      and February 2010, we treated 14 patients (9 women; aged 32 to 84 years, mean age 
      51 years) with TAMT. Hypercoagulable disorders or a strong family history of 
      vascular thrombosis, or both, occurred in 9 patients. Diagnosis was made by 
      transesophageal echocardiogram in 6, computed tomography angiography in 7, and 
      digital subtraction angiography in 1. Embolic locations were extremities (n=9), 
      cerebral (n=6), and abdominal (n=6). Aortic thrombi (n=17) locations were 
      ascending/arch (n=7), descending (n=8), and thoracoabdominal (n=2). RESULTS: All 
      patients were initially treated with heparin and aspirin. Thoracic aortic 
      thrombectomies were performed in 8 patients within 2 weeks of diagnosis: left 
      thoracotomy (n=5), thoracoabdominal (n=1), and median sternotomy (n=2). Left 
      atrial-femoral bypass was used in 5 patients, cardiopulmonary bypass in 2, and no 
      support in 1. Additional procedures were celiac artery (n=1) and left subclavian 
      artery (n=2) thrombectomies. Procedures for embolic complications were performed 
      in 7 patients before aortic thrombectomy. Operative mortality was 0%, with no 
      recurrent embolic events after 24±16 months. One patient had thrombectomy of the 
      ascending aorta and medical therapy with warfarin and aspirin for a second 
      concurrent small thrombus in the descending aorta. One patient presented with 
      multiorgan failure and died shortly after admission. Six patients treated 
      medically were discharged on a regimen of oral warfarin and aspirin (14±11 months 
      follow-up), with 2 fatal recurrent embolic events within 6 weeks (p=0.09). 
      CONCLUSIONS: Thoracic aortic mobile thrombus is rare and is commonly associated 
      with morbid thromboembolic events. In our experience, early surgical aortic 
      thrombectomy had a low operative risk and may prevent fatal recurrent embolic 
      events.
CI  - Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All 
      rights reserved.
FAU - Pagni, Sebastian
AU  - Pagni S
AD  - Division of Thoracic and Cardiovascular Surgery, Department of Surgery, 
      University of Louisville, Louisville, Kentucky 40202, USA. 
      spagni@louisvilleheartsurgery.com
FAU - Trivedi, Jaimin
AU  - Trivedi J
FAU - Ganzel, Brian L
AU  - Ganzel BL
FAU - Williams, Matthew
AU  - Williams M
FAU - Kapoor, Nick
AU  - Kapoor N
FAU - Ross, Charles
AU  - Ross C
FAU - Slater, A David
AU  - Slater AD
LA  - eng
PT  - Journal Article
DEP - 20110506
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aorta, Thoracic/*surgery
MH  - Aortic Diseases/diagnosis/*surgery
MH  - Aspirin/therapeutic use
MH  - Echocardiography, Transesophageal
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Thrombosis/diagnosis/*surgery
MH  - Tomography, X-Ray Computed
EDAT- 2011/05/03 06:00
MHDA- 2011/08/13 06:00
CRDT- 2011/05/03 06:00
PHST- 2010/11/08 00:00 [received]
PHST- 2011/01/28 00:00 [revised]
PHST- 2011/02/04 00:00 [accepted]
PHST- 2011/05/03 06:00 [entrez]
PHST- 2011/05/03 06:00 [pubmed]
PHST- 2011/08/13 06:00 [medline]
AID - S0003-4975(11)00435-8 [pii]
AID - 10.1016/j.athoracsur.2011.02.011 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 2011 Jun;91(6):1875-81. doi: 10.1016/j.athoracsur.2011.02.011. 
      Epub 2011 May 6.

PMID- 19594072
OWN - NLM
STAT- MEDLINE
DCOM- 20090825
LR  - 20190917
IS  - 0370-8179 (Print)
IS  - 0370-8179 (Linking)
VI  - 137
IP  - 5-6
DP  - 2009 May-Jun
TI  - [Gastro-duodenal ulcers with perforation caused by short-term acetylsalicylic 
      acid ingestion: case report].
PG  - 282-4
AB  - INTRODUCTION: Acetylsalicylic acid ingestion may cause serious gastrointestinal 
      toxicity, in particular bleeding or perforated peptic ulcer. CASE OUTLINE: A 
      72-year-old male patient presented with diffuse abdominal pain, malaise, and dark 
      stools. Several days before hospitalization, he had cerebrovascular insult and 
      began to use acetylsalicylic acid of 100 mg per day. In physical findings a 
      diffusely painful sensitivity of the abdomen was detected on palpation. 
      Laboratory findings revealed hyposideremic anaemia with inflammatory syndrome. 
      Native abdominal x-ray did not show the presence of pneumoperitoneum. Upper 
      endoscopy of the gastric corpus and antrum revealed several ulcerations 10-11 mm 
      in diameter covered with fibrin, with bleeding ulceration in the angulus region 
      of the lesser gastric curvature. The bulbus was oedematous and hyperaemic with a 
      perforated ulcer on the anterior wall. Upper central laparotomy showed a 
      perforated duodenal bulbus. The posterior wall of the bulbus was normal, while 
      the anterior wall was without scarring. Given the general condition of the 
      patient and local findings, interrupted suture of the ulcer was performed with 
      omentoplasty. Postoperative course was uneventful. A peroral diet was initiated 
      on the 4th postoperative day, and the patient was discharged on the 8th 
      postoperative day. CONCLUSION: Elderly people who use acetylsalicylic acid in 
      prophylaxis should take it in lower doses, with proton pump inhibitors, 
      especially during the first two months.
FAU - Culafić, Djordje
AU  - Culafić D
FAU - Matejić, Olivera
AU  - Matejić O
FAU - Rudić, Jelena
AU  - Rudić J
LA  - srp
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Serbia
TA  - Srp Arh Celok Lek
JT  - Srpski arhiv za celokupno lekarstvo
JID - 0027440
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Humans
MH  - Male
MH  - Peptic Ulcer Perforation/*chemically induced
EDAT- 2009/07/15 09:00
MHDA- 2009/08/26 09:00
CRDT- 2009/07/15 09:00
PHST- 2009/07/15 09:00 [entrez]
PHST- 2009/07/15 09:00 [pubmed]
PHST- 2009/08/26 09:00 [medline]
AID - 10.2298/sarh0906282c [doi]
PST - ppublish
SO  - Srp Arh Celok Lek. 2009 May-Jun;137(5-6):282-4. doi: 10.2298/sarh0906282c.

PMID- 22995532
OWN - NLM
STAT- MEDLINE
DCOM- 20130603
LR  - 20131121
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 130
IP  - 5
DP  - 2012 Nov
TI  - Shear-induced platelet aggregation in aspirin-treated patients: initial 
      experience with the novel PlaCor PRT device.
PG  - 753-8
LID - S0049-3848(12)00688-3 [pii]
LID - 10.1016/j.thromres.2012.08.312 [doi]
AB  - INTRODUCTION: Whole blood platelet function testing is widely used to evaluate 
      the effect of antiplatelet agents. Most platelet function tests employ agonists 
      to evaluate drug-specific platelet-activating pathways. Shear-based tests may 
      better reflect physiological conditions in vivo compared with agonist-based 
      tests. The novel PlaCor PRT provides a global platelet reactivity test based on 
      shear-induced platelet aggregation. We evaluated the PlaCor PRT and its agreement 
      with two widely used platelet function tests. MATERIALS AND METHODS: We evaluated 
      platelet function in 85 patients with angiographically verified coronary artery 
      disease on aspirin mono-therapy. Blood sampling was performed one hour after 
      aspirin ingestion. The following platelet function tests were used: PlaCor PRT, 
      multiple electrode aggregometry (Multiplate, agonists: arachidonic acid 1.0 
      mmol/L and collagen 1.0 μg/mL) and VerifyNow Aspirin. RESULTS: PlaCor PRT results 
      correlated significantly with multiple electrode aggregometry induced by 
      arachidonic acid (r=-0.38, p<0.001), but not with multiple electrode aggregometry 
      induced by collagen (r=-0.05, p=0.64) or with turbidimetric aggregometry 
      performed with VerifyNow Aspirin (r=-0.13, p=0.23). There was a strong 
      correlation between PlaCor PRT results and platelet count (r=-0.60, p<0.0001), 
      whereas no correlation with haematocrit or von Willebrand factor antigen was 
      found. A relatively large number of instrument errors occurred with the PlaCor 
      PRT device in this initial testing. CONCLUSIONS: PlaCor PRT is a portable, rapid 
      and user-friendly point-of-care test. It shows a modest agreement with comparable 
      tests, and results depend considerably on platelet count. Further validation of 
      the PlaCor PRT is warranted.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Würtz, Morten
AU  - Würtz M
AD  - Department of Cardiology, Aarhus University Hospital, Denmark.
FAU - Hvas, Anne-Mette
AU  - Hvas AM
FAU - Wulff, Lise N
AU  - Wulff LN
FAU - Kristensen, Steen D
AU  - Kristensen SD
FAU - Grove, Erik L
AU  - Grove EL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120917
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*cytology/*drug effects
MH  - Blood Specimen Collection/methods
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Function Tests/*instrumentation/methods
MH  - Shear Strength
EDAT- 2012/09/22 06:00
MHDA- 2013/06/05 06:00
CRDT- 2012/09/22 06:00
PHST- 2012/06/05 00:00 [received]
PHST- 2012/08/02 00:00 [revised]
PHST- 2012/08/28 00:00 [accepted]
PHST- 2012/09/22 06:00 [entrez]
PHST- 2012/09/22 06:00 [pubmed]
PHST- 2013/06/05 06:00 [medline]
AID - S0049-3848(12)00688-3 [pii]
AID - 10.1016/j.thromres.2012.08.312 [doi]
PST - ppublish
SO  - Thromb Res. 2012 Nov;130(5):753-8. doi: 10.1016/j.thromres.2012.08.312. Epub 2012 
      Sep 17.

PMID- 24346771
OWN - NLM
STAT- MEDLINE
DCOM- 20140602
LR  - 20221207
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 135
IP  - 1
DP  - 2014 Jul 1
TI  - Anticoagulant medication at time of needle biopsy for breast cancer in relation 
      to risk of lymph node metastasis.
PG  - 238-41
LID - 10.1002/ijc.28671 [doi]
AB  - Anticoagulant treatment might enhance the natural defense against tumor cell 
      dissemination caused by diagnostic needle biopsy by counteracting thrombocyte 
      coating of such cells. To clarify whether women using anticoagulant treatment at 
      the time of biopsy have a lower occurrence of lymph node metastasis, we conducted 
      a nationwide Swedish cohort study of 26,528 female incident breast cancer 
      patients in 2006-2011. Point risk ratio (RR) of risk of lymph node metastasis 
      among users of anticoagulant treatment adjusted for age, T-stage, socioeconomic 
      factors, and concomitant medication was RR = 0.94, (95% CI: 0.87-1.03), and lower 
      in younger women (RR = 0.80, 95% CI 0.50-1.29). Although nonsignificant, these 
      associations may underestimate a true negative association since women using 
      anticoagulant treatment are likely to have more concomitant diseases, lead an 
      unhealthier lifestyle, and have lower participation in mammography screening. 
      These findings provide some support for the hypothesis that anticoagulant 
      medications might counteract breast cancer spread caused by needle biopsy.
CI  - © 2013 UICC.
FAU - Ljung, Rickard
AU  - Ljung R
AD  - Upper Gastrointestinal Surgery Department of Molecular Medicine and Surgery, 
      Karolinska Institutet, Stockholm, Sweden; Unit of Epidemiology, Institute of 
      Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
FAU - Sennerstam, Roland
AU  - Sennerstam R
FAU - Mattsson, Fredrik
AU  - Mattsson F
FAU - Auer, Gert
AU  - Auer G
FAU - Lagergren, Jesper
AU  - Lagergren J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131231
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Biopsy, Needle
MH  - Blood Coagulation/drug effects
MH  - Blood Platelets/drug effects/*pathology
MH  - Breast Neoplasms/complications/*diagnosis/pathology
MH  - Early Detection of Cancer
MH  - Female
MH  - Humans
MH  - Lymphatic Metastasis/pathology/prevention & control
MH  - Mammography
MH  - Middle Aged
MH  - Sweden
MH  - White People
OTO - NOTNLM
OT  - Sweden
OT  - anticoagulantia
OT  - aspirin
OT  - biopsy
OT  - breast cancer
OT  - clotting
OT  - mammography
OT  - metastasis
OT  - stage
EDAT- 2013/12/19 06:00
MHDA- 2014/06/03 06:00
CRDT- 2013/12/19 06:00
PHST- 2013/09/16 00:00 [received]
PHST- 2013/12/05 00:00 [accepted]
PHST- 2013/12/19 06:00 [entrez]
PHST- 2013/12/19 06:00 [pubmed]
PHST- 2014/06/03 06:00 [medline]
AID - 10.1002/ijc.28671 [doi]
PST - ppublish
SO  - Int J Cancer. 2014 Jul 1;135(1):238-41. doi: 10.1002/ijc.28671. Epub 2013 Dec 31.

PMID- 18201436
OWN - NLM
STAT- MEDLINE
DCOM- 20080304
LR  - 20161020
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 28
IP  - 6
DP  - 2007 Nov-Dec
TI  - Cytokine expression in peripheral blood lymphocytes before and after aspirin 
      desensitization in aspirin-exacerbated respiratory disease.
PG  - 706-10
LID - 10.2500/aap.2007.28.3052 [doi]
AB  - Aspirin intolerance is the hallmark of aspirin-exacerbated respiratory disease 
      (AERD). Overproduction of cysteinyl-leukotrienes (Cys-LTs) has been implicated as 
      major mediators of AERD; however, the LT receptor antagonist montelukast is only 
      partially effective in inhibiting aspirin responses. Several studies have 
      documented the importance of cytokine production by T lymphocytes in asthma. 
      Peripheral blood lymphocyte (PBL) cytokine expression and its relation to aspirin 
      desensitization in aspirin-sensitive patients with asthma have not been studied. 
      This study was performed to examine PBL cytokine expression in aspirin-sensitive 
      patients who have asthma before and after aspirin desensitization. A 42-year-old 
      white woman with a history of severe asthma, nasal polyps, aspirin sensitivity, 
      and chronic sinusitis was treated with aspirin desensitization. Blood was taken 
      before and after aspirin desensitization, and PBL cytokine expression was studied 
      by flow cytometry. Aspirin desensitization differentially affects interferon 
      (IFN) gamma expression. This effect results in an increase in IFN-gamma 
      expression by CD4(+) lymphocytes and a decrease in IFN-gamma expression by CD8(+) 
      lymphocytes. Aspirin desensitization in an aspirin-sensitive patient with asthma 
      resulted in an increase in IFN-gamma expression by CD4(+) lymphocytes and a 
      decrease in IFN-gamma expression by CD8(+) lymphocytes, the significance of which 
      needs additional investigation.
FAU - Shome, Goutam P
AU  - Shome GP
AD  - Division of Allergy and Immunology, Texas Tech University Health Sciences Center, 
      Lubbock, Texas 79410, USA. goutham.shome@ttuhsc.edu
FAU - Tarbox, James
AU  - Tarbox J
FAU - Shearer, Michael
AU  - Shearer M
FAU - Kennedy, Ronald
AU  - Kennedy R
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Cytokines)
RN  - 82115-62-6 (Interferon-gamma)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*adverse effects/immunology
MH  - Asthma/immunology/*therapy
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cytokines/*blood/immunology
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/etiology/*therapy
MH  - Female
MH  - Humans
MH  - Interferon-gamma/blood/immunology
MH  - Nasal Polyps/immunology/therapy
MH  - Sinusitis/immunology/therapy
MH  - T-Lymphocytes/*immunology
EDAT- 2008/01/19 09:00
MHDA- 2008/03/05 09:00
CRDT- 2008/01/19 09:00
PHST- 2008/01/19 09:00 [pubmed]
PHST- 2008/03/05 09:00 [medline]
PHST- 2008/01/19 09:00 [entrez]
AID - 10.2500/aap.2007.28.3052 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2007 Nov-Dec;28(6):706-10. doi: 10.2500/aap.2007.28.3052.

PMID- 1541161
OWN - NLM
STAT- MEDLINE
DCOM- 19920408
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 101
IP  - 3
DP  - 1992 Mar
TI  - Flurbiprofen (Ansaid) cross-sensitivity in an aspirin-sensitive asthmatic 
      patient.
PG  - 856-8
AB  - Flurbiprofen (Ansaid) is a newly released nonsteroidal antiinflammatory drug 
      (NSAID) that is a potent inhibitor of prostaglandin synthesis. We report the 
      first case (to our knowledge) of a flurbiprofen-induced asthmatic reaction 
      confirmed by single-blind oral challenges. Cross-sensitivity and 
      cross-desensitization between aspirin (ASA) and flurbiprofen were also 
      demonstrated in this patient with rhinosinusitis and asthma, thus reinforcing the 
      observation that NSAIDs capable of cyclooxygenase inhibition crossreact with ASA 
      in producing characteristic respiratory reactions.
FAU - Bosso, J V
AU  - Bosso JV
AD  - Department of Molecular and Experimental Medicine, Scripps Clinic and Research 
      Foundation, La Jolla, Cal.
FAU - Creighton, D
AU  - Creighton D
FAU - Stevenson, D D
AU  - Stevenson DD
LA  - eng
GR  - M01RR00833/RR/NCRR NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 5GRO578KLP (Flurbiprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced/diagnosis
MH  - *Drug Hypersensitivity/diagnosis
MH  - Flurbiprofen/*adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1992/03/01 00:00
MHDA- 1992/03/01 00:01
CRDT- 1992/03/01 00:00
PHST- 1992/03/01 00:00 [pubmed]
PHST- 1992/03/01 00:01 [medline]
PHST- 1992/03/01 00:00 [entrez]
AID - S0012-3692(16)31972-9 [pii]
AID - 10.1378/chest.101.3.856 [doi]
PST - ppublish
SO  - Chest. 1992 Mar;101(3):856-8. doi: 10.1378/chest.101.3.856.

PMID- 18535024
OWN - NLM
STAT- MEDLINE
DCOM- 20081104
LR  - 20171114
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
VI  - 79
IP  - 11
DP  - 2008 Nov
TI  - Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA 
      or stroke: a meta-analysis by risk.
PG  - 1218-23
LID - 10.1136/jnnp.2008.143875 [doi]
AB  - OBJECTIVES: To study the effect of combination therapy with aspirin and 
      dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after 
      transient ischaemic attack (TIA) or minor stroke of presumed arterial origin and 
      to perform subgroup analyses to identify patients that might benefit most from 
      secondary prevention with A+D. DATA SOURCES: The previously published 
      meta-analysis of individual patient data was updated with data from ESPRIT (n = 
      2,739); trials without data on the comparison of A+D versus ASA were excluded. 
      REVIEW METHODS: A meta-analysis was performed using Cox regression, including 
      several subgroup analyses and following baseline risk stratification. RESULTS: A 
      total of 7612 patients (five trials) were included in the analyses, 3800 
      allocated to A+D and 3812 to ASA alone. The trial-adjusted hazard ratio (HR) for 
      the composite event of vascular death, non-fatal myocardial infarction and 
      non-fatal stroke was 0.82 (95% confidence interval (CI) 0.72 to 0.92). HRs did 
      not differ in subgroup analyses based on age, sex, qualifying event, 
      hypertension, diabetes, previous stroke, ischaemic heart disease, aspirin dose, 
      type of vessel disease and dipyridamole formulation, nor across baseline risk 
      strata as assessed with two different risk scores. A+D were also more effective 
      than ASA alone in preventing recurrent stroke; HR 0.78 (95% CI 0.68 to 0.90). 
      CONCLUSION: The combination of aspirin and dipyridamole is more effective than 
      aspirin alone in patients with TIA or ischaemic stroke of presumed arterial 
      origin in the secondary prevention of stroke and other vascular events. This 
      superiority was found in all subgroups and was independent of baseline risk.
FAU - Halkes, P H A
AU  - Halkes PH
AD  - Department of Neurology, Rudolf Magnus Institute of Neuroscience and Julius 
      Center for Health Sciences and Primary Care, University Medical Center Utrecht, 
      Utrecht, The Netherlands.
FAU - Gray, L J
AU  - Gray LJ
FAU - Bath, P M W
AU  - Bath PM
FAU - Diener, H-C
AU  - Diener HC
FAU - Guiraud-Chaumeil, B
AU  - Guiraud-Chaumeil B
FAU - Yatsu, F M
AU  - Yatsu FM
FAU - Algra, A
AU  - Algra A
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20080605
PL  - England
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Factors
MH  - Stroke/*prevention & control
EDAT- 2008/06/07 09:00
MHDA- 2008/11/05 09:00
CRDT- 2008/06/07 09:00
PHST- 2008/06/07 09:00 [pubmed]
PHST- 2008/11/05 09:00 [medline]
PHST- 2008/06/07 09:00 [entrez]
AID - jnnp.2008.143875 [pii]
AID - 10.1136/jnnp.2008.143875 [doi]
PST - ppublish
SO  - J Neurol Neurosurg Psychiatry. 2008 Nov;79(11):1218-23. doi: 
      10.1136/jnnp.2008.143875. Epub 2008 Jun 5.

PMID- 32385610
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210802
IS  - 1432-086X (Electronic)
IS  - 0174-1551 (Print)
IS  - 0174-1551 (Linking)
VI  - 43
IP  - 8
DP  - 2020 Aug
TI  - Acute Thrombus Burden on Coated Flow Diverters Assessed by High Frequency Optical 
      Coherence Tomography.
PG  - 1218-1223
LID - 10.1007/s00270-020-02482-w [doi]
AB  - PURPOSE: The implantation of flow diverters requires administration of dual 
      anti-platelet therapy, posing the potential for complications. The p48MW HPC 
      (phenox, Bochüm, Germany) hydrophilic-coated flow diverting stent is designed to 
      be anti-thrombotic, thus opening the potential for single anti-platelet therapy. 
      We deploy a novel intravascular high-resolution imaging technique, high-frequency 
      optical coherence tomography (HF-OCT), to study in an animal model the acute 
      thrombus formation on coated p48MW devices versus uncoated control devices. 
      METHODS: Three pigs were implanted with 4 flow diverters each, two test 
      hydrophilic-coated devices, and two control uncoated devices (p48MW). Each pig 
      was treated with a different anti-platelet regime: no anti-platelet therapy, 
      aspirin only, aspirin and clopidogrel. Twenty minutes after the flow diverter was 
      implanted, an HF-OCT data set was acquired. Acute clot formed on the flow 
      diverter at each covered side branch was measured from the HF-OCT slices. Factors 
      considered to be important were the device type (pHPC versus bare metal), 
      aspirin, clopidogrel, and vessel location. A linear model was constructed from 
      the significant factors. RESULTS: Both coating (p < 0.001) and aspirin 
      (p = 0.003) were significantly related to reduction in clot burden, leading to an 
      approximate 100-fold and 50-fold reduction in clot, respectively. CONCLUSIONS: 
      This study shows the power of HF-OCT not only in the detection of clot but also 
      the quantification of clot burden. In an animal model, the pHPC-coated p48MW 
      significantly reduced acute thrombus formation over jailed side branches as 
      compared to the bare metal p48MW that was nearly eliminated when combined with 
      aspirin administration.
FAU - King, Robert M
AU  - King RM
AUID- ORCID: 0000-0002-5144-9110
AD  - New England Center for Stroke Research, Department of Radiology, University of 
      Massachusetts Medical School, 55 Lake Ave N, SA-107R, Worcester, MA, 01655, USA.
AD  - Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, 
      MA, USA.
FAU - Langan, Erin T
AU  - Langan ET
AD  - New England Center for Stroke Research, Department of Radiology, University of 
      Massachusetts Medical School, 55 Lake Ave N, SA-107R, Worcester, MA, 01655, USA.
FAU - Ughi, Giovanni J
AU  - Ughi GJ
AD  - New England Center for Stroke Research, Department of Radiology, University of 
      Massachusetts Medical School, 55 Lake Ave N, SA-107R, Worcester, MA, 01655, USA.
FAU - Raskett, Christopher M
AU  - Raskett CM
AD  - New England Center for Stroke Research, Department of Radiology, University of 
      Massachusetts Medical School, 55 Lake Ave N, SA-107R, Worcester, MA, 01655, USA.
FAU - Puri, Ajit S
AU  - Puri AS
AD  - New England Center for Stroke Research, Department of Radiology, University of 
      Massachusetts Medical School, 55 Lake Ave N, SA-107R, Worcester, MA, 01655, USA.
FAU - Henkes, Hans
AU  - Henkes H
AD  - Neuroradiologische Klinik, Klinikum Stuttgart, Stuttgart, Germany.
FAU - Gounis, Matthew J
AU  - Gounis MJ
AD  - New England Center for Stroke Research, Department of Radiology, University of 
      Massachusetts Medical School, 55 Lake Ave N, SA-107R, Worcester, MA, 01655, USA. 
      matt.gounis@umassmed.edu.
LA  - eng
GR  - R43 NS100163/NS/NINDS NIH HHS/United States
GR  - R44 NS100163/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20200508
PL  - United States
TA  - Cardiovasc Intervent Radiol
JT  - Cardiovascular and interventional radiology
JID - 8003538
RN  - 0 (Coated Materials, Biocompatible)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Cardiovasc Intervent Radiol. 2020 Aug;43(8):1224-1225. PMID: 32529334
MH  - Acute Disease
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel/*therapeutic use
MH  - Coated Materials, Biocompatible
MH  - Disease Models, Animal
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Stents
MH  - Swine
MH  - Thrombosis/*diagnostic imaging/prevention & control
MH  - Tomography, Optical Coherence/*methods
PMC - PMC8209672
MID - NIHMS1707642
OTO - NOTNLM
OT  - Flow diverter
OT  - Hydrophilic coating
OT  - Optical coherence tomography
OT  - Stents
OT  - Thrombus
COIS- Compliance with Ethical Standards Conflict of interest Robert M. King, Erin T. 
      Langan, Chris M. Raskett declare that they have no conflicts of interest. 
      Giovanni J. Ughi declares he is an employee of Gentuity LLC and holds stock. Hans 
      Henkes declares he is a founder of phenox GmbH. Ajit S. Puri declares he has been 
      a consultant for Stryker, Cerenovus, Medtronic, Cerevasc, and Microvention; holds 
      stock in InNeuroCo; and has received research support from National Institutes of 
      Health (NIH). Matthew J. Gounis declares he has been a consultant on a 
      fee-per-hour basis for Cerenovus, Imperative Care, phenox, Medtronic 
      Neurovascular, Route 92 Medical, Stryker Neurovascular; holds stock in Imperative 
      Care and Neurogami; and has received research support from the National 
      Institutes of Health (NIH), the United States – Israel Binational Science 
      Foundation, Anaconda, ApicBio, Axovant, Cerenovus, Cook Medical, Gentuity, 
      Imperative Care, InNeuroCo, Magneto, MicroVention, Medtronic Neurovascular, MIVI 
      Neurosciences, Neuravi, Neurogami, Philips Healthcare, Rapid Medical, Route 92 
      Medical, Stryker Neurovascular, Syntheon, and the Wyss Institute.
EDAT- 2020/05/10 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/05/10 06:00
PHST- 2020/01/13 00:00 [received]
PHST- 2020/04/04 00:00 [accepted]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/05/10 06:00 [entrez]
AID - 10.1007/s00270-020-02482-w [pii]
AID - 10.1007/s00270-020-02482-w [doi]
PST - ppublish
SO  - Cardiovasc Intervent Radiol. 2020 Aug;43(8):1218-1223. doi: 
      10.1007/s00270-020-02482-w. Epub 2020 May 8.

PMID- 36228641
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20221222
IS  - 2213-2619 (Electronic)
IS  - 2213-2600 (Print)
IS  - 2213-2600 (Linking)
VI  - 10
IP  - 12
DP  - 2022 Dec
TI  - Colchicine and the combination of rivaroxaban and aspirin in patients 
      hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, 
      controlled trial.
PG  - 1169-1177
LID - S2213-2600(22)00298-3 [pii]
LID - 10.1016/S2213-2600(22)00298-3 [doi]
AB  - BACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and 
      hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to 
      evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy 
      with the combination of rivaroxaban and aspirin for prevention of disease 
      progression in patients hospitalised with COVID-19. METHODS: The ACT inpatient, 
      open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical 
      centres in 11 countries. Patients aged at least 18 years with symptomatic, 
      laboratory confirmed COVID-19 who were within 72 h of hospitalisation or 
      worsening clinically if already hospitalised were randomly assigned (1:1) to 
      receive colchicine 1·2 mg followed by 0·6 mg 2 h later and then 0·6 mg twice 
      daily for 28 days versus usual care; and in a second (1:1) randomisation, to the 
      combination of rivaroxaban 2·5 mg twice daily plus aspirin 100 mg once daily for 
      28 days versus usual care. Investigators and patients were not masked to 
      treatment allocation. The primary outcome, assessed at 45 days in the 
      intention-to-treat population, for the colchicine randomisation was the composite 
      of the need for high-flow oxygen, mechanical ventilation, or death; and for the 
      rivaroxaban plus aspirin randomisation was the composite of major thrombosis 
      (myocardial infarction, stroke, acute limb ischaemia, or pulmonary embolism), the 
      need for high-flow oxygen, mechanical ventilation, or death. The trial is 
      registered at www. CLINICALTRIALS: gov, NCT04324463 and is ongoing. FINDINGS: 
      Between Oct 2, 2020, and Feb 10, 2022, at 62 sites in 11 countries, 2749 patients 
      were randomly assigned to colchicine or control and the combination of 
      rivaroxaban and aspirin or to the control. 2611 patients were included in the 
      analysis of colchicine (n=1304) versus control (n=1307); 2119 patients were 
      included in the analysis of rivaroxaban and aspirin (n=1063) versus control 
      (n=1056). Follow-up was more than 98% complete. Overall, 368 (28·2%) of 1304 
      patients allocated to colchicine and 356 (27·2%) of 1307 allocated to control had 
      a primary outcome (hazard ratio [HR] 1·04, 95% CI 0·90-1·21, p=0·58); and 281 
      (26·4%) of 1063 patients allocated to the combination of rivaroxaban and aspirin 
      and 300 (28·4%) of 1056 allocated to control had a primary outcome (HR 0·92, 95% 
      CI 0·78-1·09, p=0·32). Results were consistent in subgroups defined by 
      vaccination status, disease severity at baseline, and timing of randomisation in 
      relation to onset of symptoms. There was no increase in the number of patients 
      who had at least one serious adverse event for colchicine versus control groups 
      (87 [6·7%] of 1304 vs 90 [6·9%] of 1307) or with rivaroxaban and aspirin versus 
      control groups (85 [8·0%] vs 91 [8·6%]). Among patients assigned to colchicine, 8 
      (0·61%) had adverse events that led to discontinuation of study drug, mostly 
      gastrointestinal in nature. 17 (1·6%) patients assigned to the combination of 
      rivaroxaban and aspirin had bleeding compared with seven (0·66%) of those 
      allocated to control (p=0·042); the number of serious bleeding events was two 
      (0·19%) versus six (0·57%), respectively (p=0·18). No patients assigned to 
      rivaroxaban and aspirin had serious adverse events that led to discontinuation of 
      study drug. INTERPRETATION: Among patients hospitalised with COVID-19, neither 
      colchicine nor the combination of rivaroxaban and aspirin prevent disease 
      progression or death. FUNDING: Canadian Institutes for Health Research, Bayer, 
      Population Health Research Institute, Hamilton Health Sciences Research 
      Institute, Thistledown Foundation. TRANSLATIONS: For the Portuguese, Russian and 
      Spanish translations of the abstract see Supplementary Materials section.
CI  - Copyright © 2022 Elsevier Ltd. All rights reserved.
FAU - Eikelboom, John W
AU  - Eikelboom JW
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada; Department of Medicine, McMaster University, Hamilton, 
      ON, Canada. Electronic address: eikelbj@mcmaster.ca.
FAU - Jolly, Sanjit S
AU  - Jolly SS
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada; Department of Medicine, McMaster University, Hamilton, 
      ON, Canada.
FAU - Belley-Cote, Emilie P
AU  - Belley-Cote EP
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada; Department of Medicine, McMaster University, Hamilton, 
      ON, Canada.
FAU - Whitlock, Richard P
AU  - Whitlock RP
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada; Department of Surgery, McMaster University, Hamilton, 
      ON, Canada.
FAU - Rangarajan, Sumathy
AU  - Rangarajan S
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada.
FAU - Xu, Lizhen
AU  - Xu L
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada.
FAU - Heenan, Laura
AU  - Heenan L
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada.
FAU - Bangdiwala, Shrikant I
AU  - Bangdiwala SI
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada.
FAU - Luz Diaz, Maria
AU  - Luz Diaz M
AD  - Estudios Clínicos Latino América, Instituto Cardiovascular de Rosario, Rosario, 
      Argentina.
FAU - Diaz, Rafael
AU  - Diaz R
AD  - Estudios Clínicos Latino América, Instituto Cardiovascular de Rosario, Rosario, 
      Argentina.
FAU - Yusufali, Afzalhussein
AU  - Yusufali A
AD  - Hatta Hospital, Dubai Medical College, Dubai Health Authority, Dubai, United Arab 
      Emirates.
FAU - Kumar Sharma, Sanjib
AU  - Kumar Sharma S
AD  - BP Koirala Institute of Health Sciences, Dharan, Nepal.
FAU - Tarhuni, Wadea M
AU  - Tarhuni WM
AD  - Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; 
      Department of Medicine, Western University, Clinical Skills Building London, ON, 
      Canada; Windsor Cardiac Centre, Windsor, ON, Canada.
FAU - Hassany, Mohamed
AU  - Hassany M
AD  - National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
FAU - Avezum, Alvaro
AU  - Avezum A
AD  - International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
FAU - Harper, William
AU  - Harper W
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada.
FAU - Wasserman, Sean
AU  - Wasserman S
AD  - Wellcome Centre for Infectious Diseases Research in Africa, Institute for 
      Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, 
      South Africa; Division of Infectious Diseases and HIV Medicine, Groote Schuur 
      Hospital, University of Cape Town, Cape Town, South Africa.
FAU - Almas, Aysha
AU  - Almas A
AD  - Section of Internal Medicine, Department of Medicine, Aga Khan University, 
      Karachi, Pakistan.
FAU - Drapkina, Oxana
AU  - Drapkina O
AD  - National Medical Research Center for Therapy and Preventive Medicine, Moscow, 
      Russia.
FAU - Felix, Camilo
AU  - Felix C
AD  - Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Ecuador.
FAU - Lopes, Renato D
AU  - Lopes RD
AD  - Division of Cardiology, Duke University Medical Center, Duke Clinical Research 
      Institute, NC, USA.
FAU - Berwanger, Otavio
AU  - Berwanger O
AD  - Hospital Israelita Albert Einstein, São Paulo, Brazil.
FAU - Lopez-Jaramillo, Patricio
AU  - Lopez-Jaramillo P
AD  - Masira Research Institute, Medical School, Universidad de Santander, Bucaramanga, 
      Colombia.
FAU - Anand, Sonia S
AU  - Anand SS
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada; Department of Medicine, McMaster University, Hamilton, 
      ON, Canada.
FAU - Bosch, Jackie
AU  - Bosch J
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada; School of Rehabilitation Science, McMaster University, 
      Hamilton, ON, Canada.
FAU - Choudhri, Shurjeel
AU  - Choudhri S
AD  - Bayer, Medical & Scientific Affairs, Mississauga, ON, Canada.
FAU - Farkouh, Michael E
AU  - Farkouh ME
AD  - Peter Munk Cardiac Centre, University of Toronto, Toronto, ON, Canada.
FAU - Loeb, Mark
AU  - Loeb M
AD  - Departments of Pathology and Molecular Medicine and Health Evidence Methods, 
      Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
FAU - Yusuf, Salim
AU  - Yusuf S
AD  - Population Health Research Institute, McMaster University and Hamilton Health 
      Sciences Hamilton, Canada; Department of Surgery, McMaster University, Hamilton, 
      ON, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04324463
GR  - VR3-172627/CIHR/Canada
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20221010
PL  - England
TA  - Lancet Respir Med
JT  - The Lancet. Respiratory medicine
JID - 101605555
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
RN  - S88TT14065 (Oxygen)
SB  - IM
CIN - Lancet Respir Med. 2022 Dec;10(12):1106-1108. PMID: 36228642
MH  - Humans
MH  - Adolescent
MH  - Adult
MH  - *Rivaroxaban/therapeutic use/adverse effects
MH  - Aspirin/therapeutic use
MH  - Colchicine/adverse effects
MH  - Canada
MH  - Disease Progression
MH  - Oxygen
MH  - Treatment Outcome
MH  - *COVID-19 Drug Treatment
PMC - PMC9635892
COIS- Declaration of interests JWE reports grant or in-kind support from AstraZeneca, 
      Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Pfizer, 
      Janssen, Sanofi-Aventis and honoraria from Astra-Zeneca, Bayer, 
      Boehringer-Ingelheim, Bristol-Myer-Squibb, Daiichi-Sankyo, Eli-Lilly, 
      Glaxo-Smith-Kline, Merck, Pfizer, Janssen, Sanofi-Aventis, Servier. SSJ reports 
      grant support from Boston Scientific, honoraria from Medtronic, Penumbra. EPB-C 
      reports grant support from Bayer, Roche, BMS-Pfizer. RPW reports grant support 
      from Bayer, Roche, BMS-Pfizer, grant and honorarium from Boehringer-Ingelheim, 
      and consultancy fees from Atricure and Phasebio. MLD reports grant support from 
      the Population Health Research Institute (PHRI) to manage the ACT study in 
      Argentina. RD reports grant support from PHRI to manage the ACT study in 
      Argentina. AA reports institutional grant support from Bayer and EMS, and lecture 
      fees from Bayer and Sanofi-Aventis. SW reports grant support from NIH, honoraria 
      from Pfizer, and safety monitoring committee of an AIDS Clinical Trial Group. RDL 
      reports institutional grant support from Bristol Myers Squibb, Glaxo Smith Kline, 
      Medtronic, Pfizer, and Sanofi, consulting fees from Bristol Myers Squibb, 
      GlaxoSmithKline, Medtronic, Pfizer, Sanofi, Bayer, Boehringer Ingelheim, Daiichi 
      Sankyo, Merck, and Portola, honoraria from Pfizer and meeting travel support from 
      IQVIA. OB reports grant support from Astra Zeneca, Bayer, Amgen, Novartis, 
      Servier, Pfizer. SSA reports grants from CIHR and PHAC, honoraria and consulting 
      fees from Bayer and Janssen Pharma, meeting support from Heart and Stroke Canada, 
      is committee member at the American Heart Association, the Canadian 
      Cardiovascular Society, and Heart and Stroke Canada. JB reports consulting fees 
      from Bayer. SC reports ACT study funding from Bayer, owns Bayer stock, is a board 
      member of Canadian Arrhythmia Network, is an institutional advisory board member 
      at the Institute of Circulatory and Respiratory Health, Canadian Institutes for 
      Health Research. MEF reports institutional grants from Amgen, Astra Zeneca, 
      Novartis, and Novo Nordisk and consulting fees from Otitopic. ML reports 
      participation in vaccine advisory boards for Medicago, Pfizer, and Sanofi and is 
      on the data safety and monitoring board for CanSino Biologics. SY reports 
      institutional grant support from Bayer and honoraria, and travel costs for 
      lectures from Bayer. SR, LX, LH, SIB, AY, SKS, WMT, MH, WH, AA, OD, CF, and PL-J 
      have no disclosures to report.
EDAT- 2022/10/14 06:00
MHDA- 2022/12/07 06:00
CRDT- 2022/10/13 19:02
PHST- 2022/06/30 00:00 [received]
PHST- 2022/08/03 00:00 [revised]
PHST- 2022/08/04 00:00 [accepted]
PHST- 2022/10/14 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/10/13 19:02 [entrez]
AID - S2213-2600(22)00298-3 [pii]
AID - 10.1016/S2213-2600(22)00298-3 [doi]
PST - ppublish
SO  - Lancet Respir Med. 2022 Dec;10(12):1169-1177. doi: 10.1016/S2213-2600(22)00298-3. 
      Epub 2022 Oct 10.

PMID- 11578715
OWN - NLM
STAT- MEDLINE
DCOM- 20011218
LR  - 20190816
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 80
IP  - 2-3
DP  - 2001 Sep-Oct
TI  - Prior aspirin use in unstable angina predisposes to higher risk: the aspirin 
      paradox.
PG  - 201-7
AB  - BACKGROUND: Aspirin is the most widely prescribed agent used in prevention of 
      coronary thrombosis. Thus, many patients presenting with acute coronary syndromes 
      have a history of aspirin usage. METHODS: To assess response to medical therapy 
      in patients taking aspirin prior to admission with an acute coronary syndrome, we 
      reviewed outcomes data from the Efficacy and Safety of Subcutaneous Enoxaparin in 
      Non-Q-wave Coronary Events (ESSENCE) and Platelet Receptor Inhibition in Ischemic 
      Syndrome Management in Patients Limited by Unstable Signs and Symptoms 
      (PRISM-PLUS) studies. RESULTS: Patients with acute coronary syndromes who had 
      taken aspirin prior to enrollment were less likely to have non-Q-wave myocardial 
      infarction on admission (ESSENCE: 16.0% vs. 29.2%, p<0.001; PRISM-PLUS: 34.2% vs. 
      57.7%, p<0.001). However, prior aspirin users were more likely to be failed by 
      standard medical therapy with unfractionated heparin than non-prior aspirin users 
      (ESSENCE: 21.5% vs. 16.5%, p=0.017; PRISM-PLUS: 23.5% vs. 12.1%, p<0.001). Prior 
      aspirin users received greater benefit from both enoxaparin (21.5% vs. 16.8%, 
      p=0.009) and tirofiban with unfractionated heparin (23.5% vs. 16.0%, p=0.007) 
      than from unfractionated heparin alone. Non-prior aspirin users presented with 
      higher rates of non-Q-wave myocardial infarction. CONCLUSIONS: Prior aspirin 
      users admitted with acute coronary syndromes may have a more benign presentation, 
      but are more likely to be failed by medical therapy with unfractionated heparin 
      and should be considered as a high-risk group. Enoxaparin or the combination of 
      tirofiban and unfractionated heparin are both more effective than unfractionated 
      heparin in this group.
FAU - Lancaster, G I
AU  - Lancaster GI
AD  - Danbury Hospital Cardiology Department, 24 Hospital Avenue, Danbury, CT 0681. 
      gil.lancaster@danhosp.org
FAU - Lancaster, C J
AU  - Lancaster CJ
FAU - Radley, D
AU  - Radley D
FAU - Cohen, M
AU  - Cohen M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina, Unstable/complications/*drug therapy/prevention & control
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/complications/*drug therapy/prevention & control
MH  - Risk Factors
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2001/10/02 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/02 10:00
PHST- 2001/10/02 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/02 10:00 [entrez]
AID - S0167527301004958 [pii]
AID - 10.1016/s0167-5273(01)00495-8 [doi]
PST - ppublish
SO  - Int J Cardiol. 2001 Sep-Oct;80(2-3):201-7. doi: 10.1016/s0167-5273(01)00495-8.

PMID- 32594508
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 120
IP  - 8
DP  - 2020 Aug
TI  - Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic 
      Disease: Rationale and Review of the Evidence.
PG  - 1147-1158
LID - 10.1055/s-0040-1713376 [doi]
AB  - Despite advances in secondary prevention strategies in patients with 
      cardiovascular disease, the residual risk of recurrent atherothrombotic events 
      remains high. Dual-antiplatelet therapy is the standard of care for secondary 
      prevention in patients with acute coronary syndrome (ACS), whereas single 
      antiplatelet therapy, generally with aspirin, is the standard of care for 
      secondary prevention in stable patients with coronary artery disease (CAD), 
      peripheral artery disease (PAD), or cerebrovascular disease. However, 
      atherosclerotic plaque disruption not only triggers platelet activation but also 
      results in thrombin generation because of tissue factor exposure. Therefore, 
      blocking both pathways by combining antiplatelet therapy with an anticoagulant, 
      or dual pathway inhibition (DPI), has the potential to be more effective than 
      inhibiting either pathway alone. The benefit of DPI has been demonstrated in the 
      ATLAS ACS 2-TIMI 51, COMPASS, and VOYAGER PAD trials, where the combination of 
      rivaroxaban vascular dose (2.5 mg twice daily) plus aspirin significantly reduced 
      the risk of atherothrombotic events compared with aspirin across a broad range of 
      patients, including those with recent ACS, those with chronic CAD and/or PAD, and 
      patients with PAD who have undergone peripheral revascularization. This article 
      provides the rationale for this regimen in more detail, including why the DPI 
      regimen with the rivaroxaban vascular dose was developed for vascular protection 
      in a broad spectrum of patients with atherosclerotic disease.
CI  - Georg Thieme Verlag KG Stuttgart · New York.
FAU - Weitz, Jeffrey Ian
AU  - Weitz JI
AD  - Thrombosis and Atherosclerosis Research Institute and McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - Division of Cardiology, University of Florida College of Medicine, Jacksonville, 
      Florida, United States.
FAU - Geisler, Tobias
AU  - Geisler T
AD  - Department of Cardiology and Angiology, University Hospital Tübingen, Tübingen, 
      Germany.
FAU - Heitmeier, Stefan
AU  - Heitmeier S
AD  - Research and Development Pharmaceuticals, Bayer AG, Wuppertal, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200628
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/prevention & control
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Atherosclerosis/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Forecasting
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Peripheral Arterial Disease/complications/surgery
MH  - Platelet Activation
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Recurrence
MH  - Rivaroxaban/administration & dosage/adverse effects/therapeutic use
MH  - Secondary Prevention/methods
MH  - Thrombin/biosynthesis
COIS- J.I.W. received honoraria from Anthos, Bayer AG, Boehringer Ingelheim, 
      Bristol-Myers Squibb, Daiichi Sankyo, Ionis, Janssen, Novartis, Pfizer, PhaseBio, 
      Portola, Servier, and Tetherex Pharmaceuticals and institutional grants from 
      Bayer AG and Boehringer Ingelheim. D.J.A. has received payment as an individual 
      for: (a) consulting fee or honorarium from Amgen, Aralez Pharmaceuticals, 
      AstraZeneca, Bayer AG, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, 
      Chiesi, Daiichi Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, Pfizer, PhaseBio, 
      PLx Pharma, Sanofi, and The Medicines Company; (b) participation in review 
      activities from CeloNova BioSciences and St. Jude Medical; (c) institutional 
      payments for grants from Amgen, AstraZeneca, Bayer AG, Biosensors, CeloNova 
      BioSciences, CSL Behring, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Idorsia 
      Pharmaceuticals, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, 
      Osprey Medical RenalGuard Solutions, and the Scott R. MacKenzie Foundation. T.G. 
      received grants and personal fees from Bayer AG, Bristol-Myers Squibb, Daiichi 
      Sankyo, and The Medicines Company, personal fees from AstraZeneca, Boehringer 
      Ingelheim, Chiesi, Ferrer, MSD, and Pfizer, grants from Siemens Healthcare and 
      Spartan Bioscience outside the submitted work. S.H. is an employee of Bayer AG. 
      D.J.A. reports grants and personal fees from Amgen, grants and personal fees from 
      Aralez, grants and personal fees from Bayer, grants and personal fees from 
      Biosensors, grants and personal fees from Boehringer Ingelheim, grants and 
      personal fees from Bristol-Myers Squibb, grants and personal fees from Chiesi, 
      grants and personal fees from Daiichi-Sankyo, grants and personal fees from Eli 
      Lilly, personal fees from Haemonetics, grants and personal fees from Janssen, 
      grants and personal fees from Merck, personal fees from PhaseBio, personal fees 
      from PLx Pharma, personal fees from Pfizer, grants and personal fees from Sanofi, 
      personal fees from The Medicines company, grants and personal fees from CeloNova, 
      personal fees from St Jude Medical, grants from CSL Behring, grants from Eisai, 
      grants from Gilead, grants from Idorsia Pharmaceuticals Ltd, grants from 
      Matsutani Chemical Industry Co., grants from Novartis, grants from Osprey 
      Medical, grants from Renal Guard Solutions, grants from Scott R. MacKenzie 
      Foundation, grants from NIH/NCATS Clinical and Translational Science Award to the 
      University of Florida UL1 TR000064 and NIH/NHGRI U01 HG007269, grants and 
      personal fees from Astra Zeneca, outside the submitted work. T.G. reports 
      personal fees from Astra Zeneca, personal fees from Boehringer Ingelheim, 
      personal fees from Pfizer, grants and personal fees from Bayer AG, grants and 
      personal fees from Bristol Myers Squibb, grants and personal fees from Daiichi 
      Sankyo, grants and personal fees from Eli Lilly, personal fees from Ferrer, 
      outside the submitted work. J.I.W. reports personal fees from Bayer, personal 
      fees from Boehringer Ingelheim, personal fees from Bristol-Myers Squibb, personal 
      fees from Daiichi-Sankyo, personal fees from Ionis, personal fees from Janssen, 
      personal fees from Merck, personal fees from Novartis, personal fees from Pfizer, 
      personal fees from Portola, outside the submitted work.
EDAT- 2020/07/01 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/29 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/06/29 06:00 [entrez]
AID - 10.1055/s-0040-1713376 [doi]
PST - ppublish
SO  - Thromb Haemost. 2020 Aug;120(8):1147-1158. doi: 10.1055/s-0040-1713376. Epub 2020 
      Jun 28.

PMID- 11321515
OWN - NLM
STAT- MEDLINE
DCOM- 20010830
LR  - 20161124
IS  - 0867-5910 (Print)
IS  - 0867-5910 (Linking)
VI  - 52
IP  - 1
DP  - 2001 Mar
TI  - Nonsteroidal anti-inflammatory drugs impair oral mucosal repair by eliciting 
      disturbances in endothelin-converting enzyme-1 and constitutive nitric oxide 
      synthase.
PG  - 81-92
AB  - Although the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is known to 
      cause the impairment in mucosal defenses that are well recognized and clinically 
      emphasized with respect to the gastrointestinal tract, less apparent is the 
      extent of their interference with the repair of soft oral tissue. As the 
      disturbances in nitric oxide generation and the release of endothelin-1 (ET-1) 
      are the early signs of injury by NSAIDs, we investigated oral mucosal ulcer 
      healing in the presence of NSAID administration by analyzing the expression of 
      endothelin-converting enzyme-1(ECE-1), responsible for ET-1 generation, and the 
      mucosal activity of inducible (NOS-2) and constitutive (cNOS) nitric oxide 
      synthase responsible for nitric oxide production. Groups of rats with 
      acetic-induced buccal mucosal ulcers were subjected twice daily for up to 10 days 
      to intragastric administration of either indomethacin (5 mg/kg), aspirin (20 
      mg/kg), or the vehicle and their mucosal tissue subjected to macroacopic 
      assessment of ulcer healing rate and biochemical measurements. While in the 
      control group the ulcer healed by the tenth day, only a 57.2% reduction in the 
      ulcer crater area was attained in the animals subjected to indomethacin and a 
      54.8% reduction in ulcer occurred in the presence of aspirin administration. 
      Futhermore, by the tenth day, the delay in healing in the presence of 
      indomethacin was manifested by a 4.9-fold higher rate of apoptosis, a 2.7-fold 
      higher expression of ECE-1 activity, a 3.9-fold higher expression of NOS-2 
      activity and a 2.2-fold decline in cNOS activity, while the interference in ulcer 
      healing by aspirin was characterized by a 5.6-fold higher rate of apoptosis, a 
      2.8-fold expressiom of ECE-1 activity, a 3.7-fold higher expression of NOS-2 
      activity and a 2.3-fold lower expression of cNOS activity. Our findings 
      demonstrate that NSAIDs not only pose a well-known risk of gastrointestinal 
      injury, but also interfere with soft oral tissue repair. The impairment in buccal 
      mucosal ulcer healing by NSAID ingestion is manifested in up-regulation in the 
      expression of ECE-1 responsible for ET-1 generation, suppression in cNOS, and 
      amplification of apoptotic events that delay the healing process.
FAU - Slomiany, B L
AU  - Slomiany BL
AD  - Research Center, University of Medicine and Dentistry of New Jersey, Newark 
      07103-2400, USA. slomiabr@umdnj.edu
FAU - Slomiany, A
AU  - Slomiany A
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - J Physiol Pharmacol
JT  - Journal of physiology and pharmacology : an official journal of the Polish 
      Physiological Society
JID - 9114501
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 3.4.23.- (Aspartic Acid Endopeptidases)
RN  - EC 3.4.24.- (Metalloendopeptidases)
RN  - EC 3.4.24.71 (Endothelin-Converting Enzymes)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*pharmacology
MH  - Apoptosis
MH  - Aspartic Acid Endopeptidases/*metabolism
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology
MH  - DNA Fragmentation
MH  - Endothelin-Converting Enzymes
MH  - Epithelial Cells/drug effects/metabolism
MH  - Indomethacin/administration & dosage/adverse effects/*pharmacology
MH  - Metalloendopeptidases
MH  - Mouth Mucosa/*drug effects/enzymology/pathology/physiology
MH  - Nitric Oxide Synthase/*metabolism
MH  - Nitric Oxide Synthase Type II
MH  - Oral Ulcer/chemically induced/pathology/*physiopathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Time Factors
EDAT- 2001/04/26 10:00
MHDA- 2001/08/31 10:01
CRDT- 2001/04/26 10:00
PHST- 2001/04/26 10:00 [pubmed]
PHST- 2001/08/31 10:01 [medline]
PHST- 2001/04/26 10:00 [entrez]
PST - ppublish
SO  - J Physiol Pharmacol. 2001 Mar;52(1):81-92.

PMID- 1409218
OWN - NLM
STAT- MEDLINE
DCOM- 19921113
LR  - 20171116
IS  - 0032-5473 (Print)
IS  - 0032-5473 (Linking)
VI  - 68 Suppl 1
DP  - 1992
TI  - Anticoagulant treatment of atrial fibrillation in the elderly.
PG  - S57-60
AB  - There is now adequate clinical evidence that the most appropriate treatment of 
      elderly patients with non-valvular atrial fibrillation is with low dose warfarin. 
      Patients may have contraindications to therapy with this agent, but should not be 
      denied treatment based on age alone. Withholding treatment based on age places 
      patients at unwarranted risk for severely disabling thromboembolic complications.
FAU - Dunn, M
AU  - Dunn M
AD  - Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas 
      City 66103.
FAU - Blackburn, T
AU  - Blackburn T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Contraindications
MH  - Humans
MH  - Risk Factors
MH  - Thromboembolism/drug therapy/*etiology
MH  - Warfarin/*administration & dosage
RF  - 21
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Postgrad Med J. 1992;68 Suppl 1:S57-60.

PMID- 1087743
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20191028
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - Suppl
DP  - 1976
TI  - Gastro-intestinal microbleeding under acetylsalicylic acid, ketoprofen and 
      placebo.
PG  - 87-93
AB  - A quantitative comparison of gastro-intestinal microbleeding induced by 
      acetylsalicylic acid (ASA), 3.6 g daily, ketoprofen (KETO), 200 mg daily and 
      placebo (P) was undertaken in 12 normal volunteers using a double-blind factorial 
      design with repeated measures. We conclude that KETO induces less 
      gastro-intestinal bleeding than ASA but more than placebo and that there is a 
      significant residual bleeding under placebo following ASA.
FAU - Arsenault, A
AU  - Arsenault A
FAU - Lussier, A
AU  - Lussier A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Benzophenones)
RN  - 0 (Placebos)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Anti-Inflammatory Agents
MH  - Aspirin/*adverse effects
MH  - Benzophenones/*adverse effects
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Ketoprofen/*adverse effects
MH  - Male
MH  - Placebos
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.1093/rheumatology/15.5.87 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1976;Suppl:87-93. doi: 10.1093/rheumatology/15.5.87.

PMID- 6738085
OWN - NLM
STAT- MEDLINE
DCOM- 19840813
LR  - 20191031
IS  - 0160-5402 (Print)
IS  - 0160-5402 (Linking)
VI  - 11
IP  - 4
DP  - 1984 Jul
TI  - Phenol red as volume marker in rat stomach with mucosal damage.
PG  - 299-303
AB  - Phenol red, long considered an acceptable volume marker in gastrointestinal 
      experiments, has been tested in rat stomach damaged by exposure to aspirin. 
      Significantly more phenol red was lost from stomachs damaged by aspirin than from 
      control stomachs. Phenol red, therefore, should not be used as a volume marker in 
      damaged stomachs. Volumes of fluid in the stomachs, which increased during the 
      experiment, were calculated from inulin concentrations. Changes in volume of 
      stomach fluid in experimental animals were not significantly different from those 
      in controls.
FAU - Alich, A A
AU  - Alich AA
FAU - Tan, R
AU  - Tan R
FAU - Wittmers, L E Jr
AU  - Wittmers LE Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharmacol Methods
JT  - Journal of pharmacological methods
JID - 7806596
RN  - 0 (Phenolphthaleins)
RN  - 9005-80-5 (Inulin)
RN  - I6G9Y0J1OJ (Phenolsulfonphthalein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/toxicity
MH  - Gastric Mucosa/drug effects/*physiopathology
MH  - Inulin
MH  - Male
MH  - *Phenolphthaleins
MH  - *Phenolsulfonphthalein
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Stomach/*physiopathology
EDAT- 1984/07/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
AID - 0160-5402(84)90048-2 [pii]
AID - 10.1016/0160-5402(84)90048-2 [doi]
PST - ppublish
SO  - J Pharmacol Methods. 1984 Jul;11(4):299-303. doi: 10.1016/0160-5402(84)90048-2.

PMID- 27576774
OWN - NLM
STAT- MEDLINE
DCOM- 20170425
LR  - 20181207
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 134
IP  - 14
DP  - 2016 Oct 4
TI  - Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
PG  - 989-998
AB  - BACKGROUND: Continued dual antiplatelet therapy and optimal medical therapy (OMT) 
      improve outcomes in selected patient populations with established coronary heart 
      disease, but whether OMT modifies the treatment effect of dual antiplatelet 
      therapy is unknown. METHODS: The DAPT (Dual Antiplatelet Therapy) Study, a 
      double-blind trial, randomly assigned 11 648 patients who had undergone coronary 
      stenting and completed 1 year of dual antiplatelet therapy without major bleeding 
      or ischemic events to an additional 18 months of continued thienopyridine or 
      placebo. OMT was defined as a combination of statin, β-blocker, and 
      angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use in 
      patients with an American College of Cardiology/American Heart Association class 
      I indication for each medication. Per protocol, all patients were treated with 75 
      to 325 mg aspirin daily. End points included myocardial infarction, major adverse 
      cardiovascular and cerebrovascular events, and Global Utilization of 
      Streptokinase and Tissue Plasminogen Activator for Occluded Arteries moderate or 
      severe bleeding events. RESULTS: Of 11 643 randomly assigned patients with 
      complete medication data, 63% were on OMT. Between 12 and 30 months, continued 
      thienopyridine reduced myocardial infarction in comparison with placebo in both 
      groups (on OMT 2.1% versus 3.3%, hazard ratio [HR], 0.64; 95% confidence interval 
      [CI], 0.48-0.86; P=0.003; off OMT 2.2% versus 5.2%, HR, 0.41; CI, 0.29-0.58; 
      P<0.001; interaction P=0.103). Comparing continued thienopyridine versus placebo, 
      rates of major adverse cardiovascular and cerebrovascular events were 4.2% versus 
      5.0% among patients on OMT (HR, 0.82; CI, 0.66-1.02; P=0.077) and 4.5% versus 
      7.0% among those off OMT (HR, 0.63; CI, 0.49-0.82; P<0.001; interaction P=0.250); 
      rates of bleeding for thienopyridine versus placebo in patients on OMT were 2.2% 
      versus 1.0% (HR, 2.13; CI, 1.43-3.17; P<0.001), and in patients off OMT were 2.8% 
      versus 2.2% (HR, 1.30; CI, 0.88-1.92; P=0.189; interaction P=0.073). Overall, 
      patients on OMT had lower rates of myocardial infarction (2.7% versus 3.7%, 
      P=0.003), major adverse cardiovascular and cerebrovascular events (4.6% versus 
      5.7%, P=0.007), and bleeding (1.6% versus 2.5%, P<0.001) in comparison with 
      patients off OMT. Rates of stent thrombosis (0.8% versus 1.0%, P=0.171) and death 
      (1.6% versus 1.9%, P=0.155) did not differ. CONCLUSIONS: Continued thienopyridine 
      therapy reduced the rate of myocardial infarction regardless of OMT status and 
      had consistent effects on reduction in major adverse cardiovascular and 
      cerebrovascular events and increased bleeding. CLINICAL TRIAL REGISTRATION: URL: 
      http://clinicaltrials.gov. Unique identifier: NCT00977938.
CI  - © 2016 American Heart Association, Inc.
FAU - Resor, Charles D
AU  - Resor CD
AD  - From Division of Cardiology and Center for Clinical Biometrics, Department of 
      Medicine, Brigham and Women's Hospital, Boston, MA (C.D.R., L.M.); Harvard 
      Clinical Research Institute, Boston, MA (R.W.Y., D.E.C., W.-H.H., L.M.); Harvard 
      Medical School, Boston, MA (R.W.Y., L.M.); Division of Cardiology, University of 
      Pennsylvania Medical Center, Philadelphia (A.N.); Smith Center for Outcomes 
      Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y., 
      D.E.C.); Department of Biostatistics, Boston University School of Public Heath, 
      MA (J.M.M.); The Christ Hospital Heart and Vascular Center and The Lindner Center 
      for Research and Education, Cincinnati, OH (D.J.K.); Université Paris-Diderot, 
      INSERM U-1148, Hôpital Bichat, Département Hospitalo-Universitaire Fibrosis, 
      Inflammation, and Remodeling, Assistance Publique-Hôpitaux de Paris, Paris, 
      France (P.G.S.); and National Heart and Lung Institute, Institute of 
      Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, 
      London, UK (P.G.S.).
FAU - Nathan, Ashwin
AU  - Nathan A
AD  - From Division of Cardiology and Center for Clinical Biometrics, Department of 
      Medicine, Brigham and Women's Hospital, Boston, MA (C.D.R., L.M.); Harvard 
      Clinical Research Institute, Boston, MA (R.W.Y., D.E.C., W.-H.H., L.M.); Harvard 
      Medical School, Boston, MA (R.W.Y., L.M.); Division of Cardiology, University of 
      Pennsylvania Medical Center, Philadelphia (A.N.); Smith Center for Outcomes 
      Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y., 
      D.E.C.); Department of Biostatistics, Boston University School of Public Heath, 
      MA (J.M.M.); The Christ Hospital Heart and Vascular Center and The Lindner Center 
      for Research and Education, Cincinnati, OH (D.J.K.); Université Paris-Diderot, 
      INSERM U-1148, Hôpital Bichat, Département Hospitalo-Universitaire Fibrosis, 
      Inflammation, and Remodeling, Assistance Publique-Hôpitaux de Paris, Paris, 
      France (P.G.S.); and National Heart and Lung Institute, Institute of 
      Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, 
      London, UK (P.G.S.).
FAU - Kereiakes, Dean J
AU  - Kereiakes DJ
AD  - From Division of Cardiology and Center for Clinical Biometrics, Department of 
      Medicine, Brigham and Women's Hospital, Boston, MA (C.D.R., L.M.); Harvard 
      Clinical Research Institute, Boston, MA (R.W.Y., D.E.C., W.-H.H., L.M.); Harvard 
      Medical School, Boston, MA (R.W.Y., L.M.); Division of Cardiology, University of 
      Pennsylvania Medical Center, Philadelphia (A.N.); Smith Center for Outcomes 
      Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y., 
      D.E.C.); Department of Biostatistics, Boston University School of Public Heath, 
      MA (J.M.M.); The Christ Hospital Heart and Vascular Center and The Lindner Center 
      for Research and Education, Cincinnati, OH (D.J.K.); Université Paris-Diderot, 
      INSERM U-1148, Hôpital Bichat, Département Hospitalo-Universitaire Fibrosis, 
      Inflammation, and Remodeling, Assistance Publique-Hôpitaux de Paris, Paris, 
      France (P.G.S.); and National Heart and Lung Institute, Institute of 
      Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, 
      London, UK (P.G.S.).
FAU - Yeh, Robert W
AU  - Yeh RW
AD  - From Division of Cardiology and Center for Clinical Biometrics, Department of 
      Medicine, Brigham and Women's Hospital, Boston, MA (C.D.R., L.M.); Harvard 
      Clinical Research Institute, Boston, MA (R.W.Y., D.E.C., W.-H.H., L.M.); Harvard 
      Medical School, Boston, MA (R.W.Y., L.M.); Division of Cardiology, University of 
      Pennsylvania Medical Center, Philadelphia (A.N.); Smith Center for Outcomes 
      Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y., 
      D.E.C.); Department of Biostatistics, Boston University School of Public Heath, 
      MA (J.M.M.); The Christ Hospital Heart and Vascular Center and The Lindner Center 
      for Research and Education, Cincinnati, OH (D.J.K.); Université Paris-Diderot, 
      INSERM U-1148, Hôpital Bichat, Département Hospitalo-Universitaire Fibrosis, 
      Inflammation, and Remodeling, Assistance Publique-Hôpitaux de Paris, Paris, 
      France (P.G.S.); and National Heart and Lung Institute, Institute of 
      Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, 
      London, UK (P.G.S.).
FAU - Massaro, Joseph M
AU  - Massaro JM
AD  - From Division of Cardiology and Center for Clinical Biometrics, Department of 
      Medicine, Brigham and Women's Hospital, Boston, MA (C.D.R., L.M.); Harvard 
      Clinical Research Institute, Boston, MA (R.W.Y., D.E.C., W.-H.H., L.M.); Harvard 
      Medical School, Boston, MA (R.W.Y., L.M.); Division of Cardiology, University of 
      Pennsylvania Medical Center, Philadelphia (A.N.); Smith Center for Outcomes 
      Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y., 
      D.E.C.); Department of Biostatistics, Boston University School of Public Heath, 
      MA (J.M.M.); The Christ Hospital Heart and Vascular Center and The Lindner Center 
      for Research and Education, Cincinnati, OH (D.J.K.); Université Paris-Diderot, 
      INSERM U-1148, Hôpital Bichat, Département Hospitalo-Universitaire Fibrosis, 
      Inflammation, and Remodeling, Assistance Publique-Hôpitaux de Paris, Paris, 
      France (P.G.S.); and National Heart and Lung Institute, Institute of 
      Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, 
      London, UK (P.G.S.).
FAU - Cutlip, Donald E
AU  - Cutlip DE
AD  - From Division of Cardiology and Center for Clinical Biometrics, Department of 
      Medicine, Brigham and Women's Hospital, Boston, MA (C.D.R., L.M.); Harvard 
      Clinical Research Institute, Boston, MA (R.W.Y., D.E.C., W.-H.H., L.M.); Harvard 
      Medical School, Boston, MA (R.W.Y., L.M.); Division of Cardiology, University of 
      Pennsylvania Medical Center, Philadelphia (A.N.); Smith Center for Outcomes 
      Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y., 
      D.E.C.); Department of Biostatistics, Boston University School of Public Heath, 
      MA (J.M.M.); The Christ Hospital Heart and Vascular Center and The Lindner Center 
      for Research and Education, Cincinnati, OH (D.J.K.); Université Paris-Diderot, 
      INSERM U-1148, Hôpital Bichat, Département Hospitalo-Universitaire Fibrosis, 
      Inflammation, and Remodeling, Assistance Publique-Hôpitaux de Paris, Paris, 
      France (P.G.S.); and National Heart and Lung Institute, Institute of 
      Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, 
      London, UK (P.G.S.).
FAU - Gabriel Steg, P
AU  - Gabriel Steg P
AD  - From Division of Cardiology and Center for Clinical Biometrics, Department of 
      Medicine, Brigham and Women's Hospital, Boston, MA (C.D.R., L.M.); Harvard 
      Clinical Research Institute, Boston, MA (R.W.Y., D.E.C., W.-H.H., L.M.); Harvard 
      Medical School, Boston, MA (R.W.Y., L.M.); Division of Cardiology, University of 
      Pennsylvania Medical Center, Philadelphia (A.N.); Smith Center for Outcomes 
      Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y., 
      D.E.C.); Department of Biostatistics, Boston University School of Public Heath, 
      MA (J.M.M.); The Christ Hospital Heart and Vascular Center and The Lindner Center 
      for Research and Education, Cincinnati, OH (D.J.K.); Université Paris-Diderot, 
      INSERM U-1148, Hôpital Bichat, Département Hospitalo-Universitaire Fibrosis, 
      Inflammation, and Remodeling, Assistance Publique-Hôpitaux de Paris, Paris, 
      France (P.G.S.); and National Heart and Lung Institute, Institute of 
      Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, 
      London, UK (P.G.S.).
FAU - Hsieh, Wen-Hua
AU  - Hsieh WH
AD  - From Division of Cardiology and Center for Clinical Biometrics, Department of 
      Medicine, Brigham and Women's Hospital, Boston, MA (C.D.R., L.M.); Harvard 
      Clinical Research Institute, Boston, MA (R.W.Y., D.E.C., W.-H.H., L.M.); Harvard 
      Medical School, Boston, MA (R.W.Y., L.M.); Division of Cardiology, University of 
      Pennsylvania Medical Center, Philadelphia (A.N.); Smith Center for Outcomes 
      Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y., 
      D.E.C.); Department of Biostatistics, Boston University School of Public Heath, 
      MA (J.M.M.); The Christ Hospital Heart and Vascular Center and The Lindner Center 
      for Research and Education, Cincinnati, OH (D.J.K.); Université Paris-Diderot, 
      INSERM U-1148, Hôpital Bichat, Département Hospitalo-Universitaire Fibrosis, 
      Inflammation, and Remodeling, Assistance Publique-Hôpitaux de Paris, Paris, 
      France (P.G.S.); and National Heart and Lung Institute, Institute of 
      Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, 
      London, UK (P.G.S.).
FAU - Mauri, Laura
AU  - Mauri L
AD  - From Division of Cardiology and Center for Clinical Biometrics, Department of 
      Medicine, Brigham and Women's Hospital, Boston, MA (C.D.R., L.M.); Harvard 
      Clinical Research Institute, Boston, MA (R.W.Y., D.E.C., W.-H.H., L.M.); Harvard 
      Medical School, Boston, MA (R.W.Y., L.M.); Division of Cardiology, University of 
      Pennsylvania Medical Center, Philadelphia (A.N.); Smith Center for Outcomes 
      Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y., 
      D.E.C.); Department of Biostatistics, Boston University School of Public Heath, 
      MA (J.M.M.); The Christ Hospital Heart and Vascular Center and The Lindner Center 
      for Research and Education, Cincinnati, OH (D.J.K.); Université Paris-Diderot, 
      INSERM U-1148, Hôpital Bichat, Département Hospitalo-Universitaire Fibrosis, 
      Inflammation, and Remodeling, Assistance Publique-Hôpitaux de Paris, Paris, 
      France (P.G.S.); and National Heart and Lung Institute, Institute of 
      Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, 
      London, UK (P.G.S.). lmauri1@partners.org.
CN  - Dual Antiplatelet Therapy Study Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00977938
GR  - K23 HL118138/HL/NHLBI NIH HHS/United States
GR  - R01 FD003870/FD/FDA HHS/United States
GR  - T32 HL007604/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160830
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 2017 Apr 4;135(14):e864-e865. PMID: 28373532
CIN - Circulation. 2017 Apr 4;135(14):e866. PMID: 28373533
CIN - Cardiovasc Diagn Ther. 2017 Jun;7(Suppl 2):S102-S106. PMID: 28748159
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Artery Disease/drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination/methods
MH  - Drug-Eluting Stents
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC5421387
MID - NIHMS856354
OTO - NOTNLM
OT  - antiplatelet agents
OT  - medical therapy
OT  - stents
EDAT- 2016/09/01 06:00
MHDA- 2017/04/26 06:00
CRDT- 2016/09/01 06:00
PHST- 2016/07/15 00:00 [received]
PHST- 2016/08/12 00:00 [accepted]
PHST- 2016/09/01 06:00 [pubmed]
PHST- 2017/04/26 06:00 [medline]
PHST- 2016/09/01 06:00 [entrez]
AID - CIRCULATIONAHA.116.024531 [pii]
AID - 10.1161/CIRCULATIONAHA.116.024531 [doi]
PST - ppublish
SO  - Circulation. 2016 Oct 4;134(14):989-998. doi: 10.1161/CIRCULATIONAHA.116.024531. 
      Epub 2016 Aug 30.

PMID- 32652834
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 96
IP  - 1
DP  - 2020 Jul
TI  - Ticagrelor monotherapy in patients undergoing percutaneous coronary intervention 
      for bifurcation lesions.
PG  - 112-113
LID - 10.1002/ccd.29082 [doi]
AB  - Ticagrelor monotherapy after a short course of aspirin is emerging as the 
      predominant aspirin-free strategy among patients undergoing percutaneous coronary 
      intervention. In patients included in the GLOBAL-LEADERS trial, the treatment 
      effect of the experimental (dual antiplatelet therapy with aspirin and ticagrelor 
      for 1 month followed by ticagrelor monotherapy) versus control strategy remained 
      consistent irrespective of the presence or absence of coronary bifurcation. 
      Ticagrelor monotherapy represents a safe and effective antiplatelet strategy for 
      the treatment of patients who undergo percutaneous coronary intervention of 
      bifurcation lesions.
CI  - © 2020 Wiley Periodicals LLC.
FAU - Piccolo, Raffaele
AU  - Piccolo R
AD  - Division of Cardiology, Department of Advanced Biomedical Sciences, University of 
      Naples Federico II, Naples, Italy.
FAU - Esposito, Giovanni
AU  - Esposito G
AUID- ORCID: 0000-0003-0565-7127
AD  - Division of Cardiology, Department of Advanced Biomedical Sciences, University of 
      Naples Federico II, Naples, Italy.
LA  - eng
PT  - Comment
PT  - Editorial
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - Catheter Cardiovasc Interv. 2020 Jul;96(1):100-111. PMID: 31410968
MH  - Aspirin/adverse effects
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - *Platelet Aggregation Inhibitors/adverse effects
MH  - Ticagrelor/adverse effects
MH  - Treatment Outcome
EDAT- 2020/07/12 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/06/05 00:00 [received]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/07/12 06:00 [entrez]
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.1002/ccd.29082 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2020 Jul;96(1):112-113. doi: 10.1002/ccd.29082.

PMID- 19520658
OWN - NLM
STAT- MEDLINE
DCOM- 20090929
LR  - 20181201
IS  - 1308-0032 (Electronic)
IS  - 1302-8723 (Linking)
VI  - 9
IP  - 3
DP  - 2009 Jun
TI  - [Clopidogrel resistance].
PG  - 231-7
AB  - Platelets play a critical role in pathogenesis of atherothrombotic diseases such 
      as acute coronary syndromes and ischemic stroke. Clopidogrel, a thienopyridine 
      derivative is an effective antiplatelet drug mostly used in combination with 
      aspirin or as a single drug in aspirin intolerant patients. However, despite its 
      proven efficacy in various clinical trials, some patients exhibit impaired 
      response to clopidogrel and have activated platelets while on usual clopidogrel 
      treatment. Although definition and mechanism(s) of this therapeutic failure are 
      poorly understood, it is associated with higher morbidity and mortality as in 
      aspirin resistance. Various causes have been implicated in clopidogrel resistance 
      and alternative therapies are recommended. The aim of this review is to evaluate 
      possible mechanisms, its clinical relevance and alternative treatments of this 
      significant issue.
FAU - Güray, Yeşim
AU  - Güray Y
AD  - Türkiye Yüksek Ihtisas Eğitim ve Araştirma Hastanesi, Kardiyoloji Kliniği, 
      Ankara, Türkiye. yesimguray@gmail.com
FAU - Güray, Umit
AU  - Güray U
FAU - Korkmaz, Sule
AU  - Korkmaz S
LA  - tur
PT  - Journal Article
PT  - Review
TT  - Klopidogrel direnci.
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Clopidogrel
MH  - Coronary Thrombosis/*drug therapy
MH  - *Drug Resistance
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
RF  - 67
EDAT- 2009/06/13 09:00
MHDA- 2009/09/30 06:00
CRDT- 2009/06/13 09:00
PHST- 2009/06/13 09:00 [entrez]
PHST- 2009/06/13 09:00 [pubmed]
PHST- 2009/09/30 06:00 [medline]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2009 Jun;9(3):231-7.

PMID- 10909284
OWN - NLM
STAT- MEDLINE
DCOM- 20001019
LR  - 20161124
IS  - 0033-2240 (Print)
IS  - 0033-2240 (Linking)
VI  - 57
IP  - 3
DP  - 2000
TI  - [Point scale quantification of changes in computed tomography of chronic 
      hyperplastic rhinosinusitis].
PG  - 150-3
AB  - Coronal CT scans have dramatically improved imaging of the nasal cavity and 
      paranasal sinuses. However, quantification of the extent of chronic sinusitis is 
      not possible by simple reviewing of the CT images. The aim of the study was to 
      introduce a CT scoring scale to assess the extend of sinusal pathology. Seventeen 
      patients with clinically recognized aspirin-sensitive rhinosinusitis asthma 
      syndrome (aspirin triad) were studied. The CT scans were reviewed and scored for 
      extent of the disease by two independent radiologists. Repeated readings of the 
      scans showed close correlation between the two assessments. The authors conclude, 
      that CT scoring system for quantitation of the disease extent is reproducible and 
      may be useful in clinical practice.
FAU - Kordek, P
AU  - Kordek P
AD  - Zakładu Diagnostyki Obrazowej Instytutu Radiologii Akademii Medycznej w Lodzi.
FAU - Kowalski, M L
AU  - Kowalski ML
FAU - Studniarek, M
AU  - Studniarek M
FAU - Kośny, B
AU  - Kośny B
FAU - Bieńkiewicz, B
AU  - Bieńkiewicz B
LA  - pol
PT  - Clinical Trial
PT  - Journal Article
TT  - Punktowa ocenia zmian w tomografii komputerowej w przewlekłym przerostowym 
      zapaleniu błony śluzowej nosa i zatok przynosowych.
PL  - Poland
TA  - Przegl Lek
JT  - Przeglad lekarski
JID - 19840720R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Chronic Disease
MH  - Humans
MH  - *Image Processing, Computer-Assisted
MH  - Middle Aged
MH  - Paranasal Sinuses/diagnostic imaging
MH  - Rhinitis/*diagnostic imaging/drug therapy
MH  - Sinusitis/diagnostic imaging
MH  - Tomography, X-Ray Computed/*methods
EDAT- 2000/07/26 11:00
MHDA- 2000/10/21 11:01
CRDT- 2000/07/26 11:00
PHST- 2000/07/26 11:00 [pubmed]
PHST- 2000/10/21 11:01 [medline]
PHST- 2000/07/26 11:00 [entrez]
PST - ppublish
SO  - Przegl Lek. 2000;57(3):150-3.

PMID- 8445256
OWN - NLM
STAT- MEDLINE
DCOM- 19930402
LR  - 20190723
IS  - 0022-1759 (Print)
IS  - 0022-1759 (Linking)
VI  - 159
IP  - 1-2
DP  - 1993 Feb 26
TI  - A colorimetric assay to evaluate the immune reactivity of blood platelets based 
      on the reduction of a tetrazolium salt.
PG  - 253-9
AB  - Since the first report in 1983, blood platelet reactivity from patients with 
      immediate hypersensitivity reactions, and particularly allergic asthma and 
      aspirin-sensitive asthma, has been evaluated by the release of cytotoxic 
      mediators able to induce the death of parasite larvae, and by the generation of 
      oxygen derived free radicals, measurable by chemiluminescence. We demonstrate 
      here that platelets are able to reduce MTT tetrazolium salt proportionally to the 
      stimulation level in two models of platelet triggering, one IgE-dependent and one 
      aspirin-dependent. This method correlated significantly with the cytotoxicity 
      assay of platelet stimulation (r = 0.965, p < 10(-5) for IgE-dependent 
      stimulation; r = 0.723, p < 10(-4) for aspirin-dependent stimulation). The MTT 
      colorimetric assay should complement or possibly replace previous methods of 
      assessing platelet activation which were of limited use allowing broader 
      investigations on the involvement of platelets in immune processes and in 
      allergic or pseudoallergic reactions.
FAU - Vanhée, D
AU  - Vanhée D
AD  - Institut Pasteur, Lille, France.
FAU - Joseph, M
AU  - Joseph M
FAU - Vorng, H
AU  - Vorng H
FAU - Tonnel, A B
AU  - Tonnel AB
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Immunol Methods
JT  - Journal of immunological methods
JID - 1305440
RN  - 0 (Tetrazolium Salts)
RN  - 0 (Thiazoles)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EUY85H477I (thiazolyl blue)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*immunology
MH  - Colorimetry
MH  - Cytotoxicity, Immunologic
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Oxidation-Reduction
MH  - Tetrazolium Salts/*metabolism
MH  - Thiazoles/*metabolism
EDAT- 1993/02/26 00:00
MHDA- 1993/02/26 00:01
CRDT- 1993/02/26 00:00
PHST- 1993/02/26 00:00 [pubmed]
PHST- 1993/02/26 00:01 [medline]
PHST- 1993/02/26 00:00 [entrez]
AID - 0022-1759(93)90164-3 [pii]
AID - 10.1016/0022-1759(93)90164-3 [doi]
PST - ppublish
SO  - J Immunol Methods. 1993 Feb 26;159(1-2):253-9. doi: 10.1016/0022-1759(93)90164-3.

PMID- 1456220
OWN - NLM
STAT- MEDLINE
DCOM- 19930107
LR  - 20161123
IS  - 0889-5406 (Print)
IS  - 0889-5406 (Linking)
VI  - 102
IP  - 4
DP  - 1992 Oct
TI  - The effect of acetylsalicylic acid on orthodontic tooth movement in the guinea 
      pig.
PG  - 360-5
AB  - This study examined the influence of acetylsalicylic acid an inhibitor of 
      prostaglandin synthesis, on orthodontic tooth movement induced with light spring 
      forces in the guinea pig. The animal model was shown to permit reliable and 
      accurate recording of tooth movement up to 28 days. Tooth movement was found to 
      be highly correlated with spring forces, indicating that the model provided a 
      sensitive test of the effect of aspirin on tooth movement. Aspirin was 
      administered orally at the rate of 65 mg/kg per day in three divided doses and 
      was found to effectively inhibit prostaglandin synthesis at the level of the 
      bronchioles. However, aspirin did not appear to significantly affect tooth 
      movement. Thus prostaglandins may not be the only mediators of the bone 
      resorption associated with tooth movement induced by light orthodontic forces 
      under these experimental conditions.
FAU - Wong, A
AU  - Wong A
AD  - Department of Preventive and Community Dentistry, Faculty of Dental Science, 
      University of Melbourne, Australia.
FAU - Reynolds, E C
AU  - Reynolds EC
FAU - West, V C
AU  - West VC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Orthod Dentofacial Orthop
JT  - American journal of orthodontics and dentofacial orthopedics : official 
      publication of the American Association of Orthodontists, its constituent 
      societies, and the American Board of Orthodontics
JID - 8610224
RN  - 0 (Prostaglandins)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*pharmacology
MH  - Bone Remodeling/*drug effects
MH  - Bone Resorption
MH  - Bronchoconstriction
MH  - Dental Stress Analysis
MH  - Guinea Pigs
MH  - Maxilla
MH  - Prostaglandins/biosynthesis
MH  - Regression Analysis
MH  - *Tooth Movement Techniques
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 0889-5406(92)70052-C [pii]
AID - 10.1016/0889-5406(92)70052-C [doi]
PST - ppublish
SO  - Am J Orthod Dentofacial Orthop. 1992 Oct;102(4):360-5. doi: 
      10.1016/0889-5406(92)70052-C.

PMID- 18041807
OWN - NLM
STAT- MEDLINE
DCOM- 20080417
LR  - 20191210
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 17
IP  - 4
DP  - 2008 Apr
TI  - Lung cancer and regular use of aspirin and nonaspirin nonsteroidal 
      anti-inflammatory drugs.
PG  - 322-7
AB  - PURPOSE: Lung cancer is the leading cause of cancer death in the US. There is 
      evidence of a reduced risk of some cancer sites associated with use of aspirin 
      (ASA) and nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs). Our 
      objective was to examine the association of regular use of ASA and NANSAIDs with 
      lung cancer. METHODS: A hospital-based case-control study of 1884 incident cases 
      of lung cancer and 6251 controls with noncancer diagnoses. Use of ASA and 
      NANSAIDs was considered 'regular' if it occurred on > or =4 days/week and lasted 
      for > or =3 months. Logistic regression was used to estimate odds ratios (OR) and 
      95% confidence intervals. RESULTS: The OR for regular use of ASA was 1.1 
      (0.9-1.4), and the corresponding estimate for regular NANSAID use was 1.0 
      (0.7-1.3). There was no evidence of decreased risk within strata of age, sex, 
      years of education, or interview year. Examining the association within strata of 
      duration of use, recency of use, cigarette smoking status, pack-years of 
      cigarette smoking, or histologic type of cancer produced no ORs significantly 
      different from 1.0. CONCLUSIONS: The hypothesis that regular use of ASA or 
      NANSAIDs reduces the risk of lung cancer is not supported by the present data.
FAU - Kelly, Judith P
AU  - Kelly JP
AD  - Slone Epidemiology Center of Boston University, Boston, MA 02215, USA. 
      jkelly@slone.bu.edu
FAU - Coogan, Patricia
AU  - Coogan P
FAU - Strom, Brian L
AU  - Strom BL
FAU - Rosenberg, Lynn
AU  - Rosenberg L
LA  - eng
GR  - R01 CA45762/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Logistic Models
MH  - Lung Neoplasms/epidemiology/etiology/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Pharmacoepidemiology/methods
MH  - Smoking/adverse effects/epidemiology
MH  - United States/epidemiology
EDAT- 2007/11/29 09:00
MHDA- 2008/04/18 09:00
CRDT- 2007/11/29 09:00
PHST- 2007/11/29 09:00 [pubmed]
PHST- 2008/04/18 09:00 [medline]
PHST- 2007/11/29 09:00 [entrez]
AID - 10.1002/pds.1532 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):322-7. doi: 10.1002/pds.1532.

PMID- 12141814
OWN - NLM
STAT- MEDLINE
DCOM- 20020808
LR  - 20190721
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 47
IP  - 7
DP  - 2002 Jul
TI  - Prevention by parenteral aspirin of indomethacin-induced gastric lesions in rats: 
      mediation by salicylic acid.
PG  - 1538-45
AB  - Nonsteroidal antiinflammatory drugs (NSAIDs) produce gastric damage in 
      experimental animals, irrespective of the route of administration. However, 
      aspirin (ASA) causes damage only when it is given orally. In the present study, 
      we examined the gastric ulcerogenic effect of subcutaneously administered ASA in 
      rats, in comparison with various NSAIDs, and investigated the reason why ASA does 
      not cause damage in the stomach, in relation to its metabolite salicylic acid 
      (SA). Since the antiinflammatory action of SA is known to be mediated, partly, by 
      endogenous adenosine (AD), we also examined the possible involvement of AD in the 
      protective action of SA. Various NSAIDs (indomethacin, flurbiprofen, naproxen, 
      diclrofenac, ASA, SA) were administered subcutaneously, and the gastric mucosa 
      was examined macroscopically 4 hr later. All NSAIDs tested, except ASA and SA, 
      caused hemorrhagic lesions in the stomach, with a marked gastric hypermotility 
      and a decrease of mucosal PGE2 contents. These ulcerogenic and motility responses 
      caused by NSAIDs were blocked by pretreatment with atropine or PGE2. ASA, 
      although inhibiting PGE2 generation, caused neither hypermotility nor damage in 
      the stomach. On the other hand, SA alone inhibited basal gastric motility without 
      any effect on mucosal PGE2 contents, and this agent, when given together with 
      indomethacin, prevented gastric hypermotility and lesion formation in response to 
      indomethacin, without affecting the reduced PGE2 contents. Likewise, ASA 
      inhibited these responses to indomethacin, yet the effects appeared later than 
      those of SA. Following administration of ASA, the blood SA levels reached a peak 
      within 30 min and remained elevated for 4 hr. In addition, the protective effect 
      of SA was not significantly influenced by either the AD deaminase or the 
      AD-receptor antagonists. These results suggest that the failure of parenteral ASA 
      to induce gastric damage may be explained by a protective action of SA 
      metabolized from ASA. SA has a cytoprotective action against NSAID-induced 
      gastric lesions, and this action is not mediated by endogenous AD but may be 
      functionally associated with inhibition of the gastric motility response.
FAU - Komoike, Yusaku
AU  - Komoike Y
AD  - Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical 
      University, Misasagi, Yamashina, Japan.
FAU - Takeeda, Masanori
AU  - Takeeda M
FAU - Tanaka, Akiko
AU  - Tanaka A
FAU - Kato, Shinichi
AU  - Kato S
FAU - Takeuchi, Koji
AU  - Takeuchi K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K72T3FS567 (Adenosine)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adenosine/physiology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastrointestinal Motility/drug effects
MH  - Indomethacin/administration & dosage/adverse effects
MH  - Injections, Subcutaneous
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Salicylic Acid/*pharmacology
EDAT- 2002/07/27 10:00
MHDA- 2002/08/09 10:01
CRDT- 2002/07/27 10:00
PHST- 2002/07/27 10:00 [pubmed]
PHST- 2002/08/09 10:01 [medline]
PHST- 2002/07/27 10:00 [entrez]
AID - 10.1023/a:1015867119014 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2002 Jul;47(7):1538-45. doi: 10.1023/a:1015867119014.

PMID- 1803283
OWN - NLM
STAT- MEDLINE
DCOM- 19920424
LR  - 20131121
IS  - 0026-4725 (Print)
IS  - 0026-4725 (Linking)
VI  - 39
IP  - 10
DP  - 1991 Oct
TI  - [Platelet antiaggregants in the treatment of arterial thrombosis].
PG  - 375-89
AB  - The paper contains a critical review of the major clinical controlled trials 
      which have been carried out on the use of platelet anti-aggregating agents in the 
      prophylactic treatment of arterial thrombosis. The drugs studied to date include 
      aspirin, sulphinpyrazone, dipyridamole and ticlopidine. These drugs have been 
      used in primary infarction prophylaxis and secondary prophylaxis of arterial 
      thrombosis at a cardiac (reinfarction, instable angina, valvular prosthesis, 
      aortocoronary bypass, coronary angioplasty), cerebral (TIA, ictus) and peripheral 
      (obliterating arteriopathy, thromboendarterectomy, arteriovenous shunt) level. 
      The most frequently studied end-points are non-fatal reinfarction, cardiovascular 
      mortality (fatal reinfarction, sudden death, fatal ictus), non-fatal ictus, 
      vascular re-occlusion after arterio-lesive surgery, and some 
      clinico-radiographical parameters at a peripheral level. The best results, which 
      are statistically significant, have been obtained in the prophylaxis of instable 
      angina and re-occlusion following aortocoronary by-pass; results obtained in 
      cerebrovascular disease and peripheral obliterating arteriopathy are less 
      statistically significant but equally successful and worthy of attention, 
      especially in the case of ticlopidine which showed a greater number of advantages 
      than aspirin. Positive but statistically not reliable findings were reported 
      regarding the secondary prophylaxis of reinfarction, whereas non-significant data 
      were reported for secondary prophylaxis of reocclusion of coronary angioplasty, 
      thromboendarterectomy and arterio-venous shunt, and for the primary prophylaxis 
      of reinfarction. The Author confirms that the clinical trials carried out for the 
      long-term prophylaxis of still asymptomatic subjects are the only way of 
      evaluating the clinical efficacy of a platelet anti-aggregating agent; the 
      results of these trials must however be carefully and critically assessed from a 
      clinical and statistical point of view and at all events can only act as a 
      guideline for the doctor; the latter continues to be solely responsible for the 
      choice of the drug and he must be aware of possible collateral effects and the 
      risk/benefit ratio as well as the personal characteristics of the patient.
FAU - Ferlito, S
AU  - Ferlito S
AD  - Istituto di Clinica Medica, Università di Catania.
LA  - ita
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Gli antiaggreganti piastrinici nel trattamento delle trombosi arteriose.
PL  - Italy
TA  - Minerva Cardioangiol
JT  - Minerva cardioangiologica
JID - 0400725
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Angina Pectoris/drug therapy
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cerebrovascular Disorders/drug therapy
MH  - Coronary Artery Bypass
MH  - Coronary Disease/surgery/therapy
MH  - Dipyridamole/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Follow-Up Studies
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Myocardial Infarction/drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Sulfinpyrazone/therapeutic use
MH  - Thrombosis/*drug therapy/prevention & control
RF  - 102
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
PST - ppublish
SO  - Minerva Cardioangiol. 1991 Oct;39(10):375-89.

PMID- 3204049
OWN - NLM
STAT- MEDLINE
DCOM- 19890209
LR  - 20131121
IS  - 0003-1488 (Print)
IS  - 0003-1488 (Linking)
VI  - 193
IP  - 10
DP  - 1988 Nov 15
TI  - Effect of aspirin, furosemide, and commercial low-salt diet on digoxin 
      pharmacokinetic properties in clinically normal cats.
PG  - 1264-8
AB  - Steady-state serum digoxin concentration ([digoxin]) was measured for 48 hours in 
      6 healthy cats after they were treated with digoxin tablets (0.01 mg/kg of body 
      weight, q 48 h) for 10 days and again after concurrent treatment of identical 
      duration with orally administered digoxin, aspirin (80 mg, q 48 h), furosemide (2 
      mg/kg, q 12 h), and a commercial low-salt diet. The concurrent treatment 
      substantially altered digoxin pharmacokinetic properties, with a resultant 
      increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour 
      (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 
      2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during 
      which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); 
      and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg). Of 
      these differences, all but the 8-hour serum [digoxin] were significant at P less 
      than 0.05. Similar sampling procedures were performed in 3 cats after 
      administration of digoxin alone (0.01 mg/kg, q 48 h) until steady-state 
      conditions were reached (10 days) and again after an additional 10 days of 
      treatment. Differences were not noticed in digoxin pharmacokinetic properties. 
      Eight-hour serum [digoxin] was shown to correlate closely with the mean serum 
      [digoxin] at steady-state conditions when digoxin was administered every 48 
      hours. Variation in digoxin pharmacokinetic properties was noticed between 
      cats.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Atkins, C E
AU  - Atkins CE
AD  - Department of Medical Sciences, School of Veterinary Medicine, University of 
      Wisconsin-Madison 53706.
FAU - Snyder, P S
AU  - Snyder PS
FAU - Keene, B W
AU  - Keene BW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Vet Med Assoc
JT  - Journal of the American Veterinary Medical Association
JID - 7503067
RN  - 0 (Drug Combinations)
RN  - 73K4184T59 (Digoxin)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Cats/*blood
MH  - *Diet, Sodium-Restricted
MH  - Digoxin/administration & dosage/blood/*pharmacokinetics
MH  - Drug Combinations
MH  - Female
MH  - Furosemide/administration & dosage/*pharmacology
MH  - Male
EDAT- 1988/11/15 00:00
MHDA- 1988/11/15 00:01
CRDT- 1988/11/15 00:00
PHST- 1988/11/15 00:00 [pubmed]
PHST- 1988/11/15 00:01 [medline]
PHST- 1988/11/15 00:00 [entrez]
PST - ppublish
SO  - J Am Vet Med Assoc. 1988 Nov 15;193(10):1264-8.

PMID- 6414516
OWN - NLM
STAT- MEDLINE
DCOM- 19831220
LR  - 20190613
IS  - 0006-2960 (Print)
IS  - 0006-2960 (Linking)
VI  - 22
IP  - 20
DP  - 1983 Sep 27
TI  - Isolation and covalent structure of the aspirin-modified, active-site region of 
      prostaglandin synthetase.
PG  - 4672-5
AB  - Aspirin (acetylsalicylic acid) inhibits prostaglandin synthesis by acetylating a 
      single internal serine residue of the initial enzyme in the biosynthetic pathway, 
      prostaglandin synthetase. In this study, the region of the enzyme that is 
      modified by aspirin has been isolated, and its amino acid sequence has been 
      determined. Sheep vesicular gland [acetyl-3H]prostaglandin synthetase was 
      purified following treatment with [acetyl-3H]aspirin and digest with pepsin. An 
      acetyl-3H-labeled peptic peptide of approximately 25 residues was isolated by 
      high-pressure liquid chromatography, and its amino acid sequence was determined 
      to be 
      Ile-Glu-Met-Gly-Ala-Pro-Phe-Ser-Leu-Lys-Gly-Leu-Gly-Asn-Pro-Ile-Glu-Ser-Pro-Glu-Tyr. 
      The acetylated serine residue was located at position 8 in this sequence. The 
      current study marks this polypeptide sequence as a region related to an active 
      site of the enzyme.
FAU - Roth, G J
AU  - Roth GJ
FAU - Machuga, E T
AU  - Machuga ET
FAU - Ozols, J
AU  - Ozols J
LA  - eng
GR  - HL-27506/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 0 (Peptide Fragments)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EC 3.4.21.4 (Trypsin)
RN  - EC 3.4.23.1 (Pepsin A)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Binding Sites
MH  - Kinetics
MH  - Male
MH  - Microsomes/enzymology
MH  - Pepsin A
MH  - Peptide Fragments/isolation & purification
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - Protein Binding
MH  - Seminal Vesicles/enzymology
MH  - Sheep
MH  - Trypsin
EDAT- 1983/09/27 00:00
MHDA- 1983/09/27 00:01
CRDT- 1983/09/27 00:00
PHST- 1983/09/27 00:00 [pubmed]
PHST- 1983/09/27 00:01 [medline]
PHST- 1983/09/27 00:00 [entrez]
AID - 10.1021/bi00289a010 [doi]
PST - ppublish
SO  - Biochemistry. 1983 Sep 27;22(20):4672-5. doi: 10.1021/bi00289a010.

PMID- 15943849
OWN - NLM
STAT- MEDLINE
DCOM- 20050815
LR  - 20131121
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 21 Suppl 2
DP  - 2005 Jun
TI  - A clinical study of Japanese patients with ulcer induced by low-dose aspirin and 
      other non-steroidal anti-inflammatory drugs.
PG  - 60-6
AB  - BACKGROUND: The incidence and severity of non-steroidal anti-inflammatory drugs 
      (NSAIDs)-induced gastro-duodenal ulcer have not been extensively studied in 
      Japan. AIM: We performed a prospective study to clarify NSAIDs-induced 
      gastro-duodenal injury, focusing especially on low-dose aspirin (L-A). METHODS: 
      Two hundred and thirty-eight patients with bleeding peptic ulcers admitted to our 
      hospital. History of taking NSAIDs and anti-ulcer drugs was obtained from all 
      patients who underwent endoscopic examinations. The lesion scores of patients 
      taking L-A were classified numerically from zero (no lesion) to five (ulcer). 
      RESULTS: The NSAIDs were associated with 28.2% of hemorrhagic ulcers. The rates 
      of patients using L-A, loxoprofen, diclofenac, and combination of two of these 
      drugs were 27, 16, 10 and 9%, respectively. Co-administered anti-ulcer drugs were 
      cytoprotective anti-ulcer drugs (27%), H2 receptor antagonists (16%), PPI (4%), 
      and none (53%). In patients taking L-A, H2 receptor antagonists were used most 
      frequently. The HP was positive in 63% of L-A-induced ulcer cases and in 69% of 
      NSAIDs other than low-dose aspirin-induced ulcer cases. The lesion scores of 
      patients taking L-A with H2 receptor antagonists or PPI were significantly lower 
      than those of patients who were taking only L-A (P < 0.05). CONCLUSIONS: 
      Approximately one-third of hospitalized patients with NSAIDs-induced hemorrhagic 
      ulcer showed an association with L-A. Prospective randomized controlled trials 
      including H2 receptor antagonists are required to establish preventive efforts 
      aimed at L-A-induced gastro-duodenal injury.
FAU - Nakashima, S
AU  - Nakashima S
AD  - Department of Gastroenterology & Hepatology, Saitama Medical School, Iruma-gun, 
      Saitama, Japan. sayaka-n@coffee.ocn.ne.jp
FAU - Arai, S
AU  - Arai S
FAU - Mizuno, Y
AU  - Mizuno Y
FAU - Yoshino, K
AU  - Yoshino K
FAU - Ando, S
AU  - Ando S
FAU - Nakamura, Y
AU  - Nakamura Y
FAU - Sugawara, K
AU  - Sugawara K
FAU - Koike, M
AU  - Koike M
FAU - Saito, E
AU  - Saito E
FAU - Naito, M
AU  - Naito M
FAU - Nakao, M
AU  - Nakao M
FAU - Ito, H
AU  - Ito H
FAU - Hamaoka, K
AU  - Hamaoka K
FAU - Rai, F
AU  - Rai F
FAU - Asakura, Y
AU  - Asakura Y
FAU - Akamatu, M
AU  - Akamatu M
FAU - Fujimori, K
AU  - Fujimori K
FAU - Inao, M
AU  - Inao M
FAU - Imai, Y
AU  - Imai Y
FAU - Ota, S
AU  - Ota S
FAU - Fujiwara, K
AU  - Fujiwara K
FAU - Shiibashi, M
AU  - Shiibashi M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Histamine H2 Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Helicobacter Infections/complications
MH  - Helicobacter pylori
MH  - Hemostasis, Endoscopic
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer Hemorrhage/chemically induced/*prevention & control
MH  - Prospective Studies
MH  - Recurrence
EDAT- 2005/06/10 09:00
MHDA- 2005/08/16 09:00
CRDT- 2005/06/10 09:00
PHST- 2005/06/10 09:00 [pubmed]
PHST- 2005/08/16 09:00 [medline]
PHST- 2005/06/10 09:00 [entrez]
AID - APT2476 [pii]
AID - 10.1111/j.1365-2036.2005.02476.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:60-6. doi: 
      10.1111/j.1365-2036.2005.02476.x.

PMID- 14984383
OWN - NLM
STAT- MEDLINE
DCOM- 20040416
LR  - 20190901
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 19
IP  - 3
DP  - 2004 Feb 1
TI  - Clopidogrel plus omeprazole compared with aspirin plus omeprazole for 
      aspirin-induced symptomatic peptic ulcers/erosions with low to moderate 
      bleeding/re-bleeding risk -- a single-blind, randomized controlled study.
PG  - 359-65
AB  - BACKGROUND: Clopidogrel causes significantly less symptomatic peptic ulcer 
      disease and gastrointestinal bleeding than low-dose aspirin in average-risk 
      patients. The gastrotoxicity of clopidogrel in patients with active peptic ulcer 
      disease is unknown. AIM: To compare the incidence of unhealed ulcers in patients 
      receiving clopidogrel or aspirin. METHODS: Patients with aspirin-induced peptic 
      ulcer disease treated with omeprazole (20 mg/day) were randomized to receive 
      clopidogrel (75 mg/day) or to continue with low-dose aspirin. Success was defined 
      as ulcer/erosion healing at the eighth week. RESULTS: One hundred and twenty-nine 
      patients were recruited (69 received clopidogrel and 60 continued with aspirin). 
      Thirty-one (45%) in the clopidogrel group and 25 (42%) in the aspirin group had a 
      minor gastrointestinal bleed. No ulcer showed an adherent clot or visible vessel. 
      The distributions of peptic ulcer disease were similar in the clopidogrel and 
      aspirin groups (gastric ulcer: 41% vs. 40%; duodenal ulcer: 10% vs. 12%; gastric 
      ulcer + duodenal ulcer: 6% vs. 3%; gastritis: 32% vs. 37%; duodenitis: 4% vs. 7%; 
      gastritis + duodenitis: 0% vs. 2%). Clopidogrel and aspirin were re-started after 
      0.86 +/- 1.79 and 0.44 +/- 1.60 days, respectively (P = 0.170). Three (4%) 
      patients stopped clopidogrel due to drug rash. Using per protocol analysis, the 
      treatment success rates of clopidogrel and aspirin were 94% (62/66) and 95% 
      (57/60), respectively. CONCLUSIONS: In patients with aspirin-associated peptic 
      ulcer disease of low to moderate grade, both early conversion from aspirin to 
      clopidogrel and continuation of aspirin are safe.
FAU - Ng, F-H
AU  - Ng FH
AD  - Department of Medicine, Ruttonjee Hospital, Hong Kong. ngfhong@ctimail3.com
FAU - Wong, B C-Y
AU  - Wong BC
FAU - Wong, S-Y
AU  - Wong SY
FAU - Chen, W-H
AU  - Chen WH
FAU - Chang, C-M
AU  - Chang CM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Ulcer Agents)
RN  - A74586SNO7 (Clopidogrel)
RN  - KG60484QX9 (Omeprazole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/*administration & dosage
MH  - Peptic Ulcer/*chemically induced/drug therapy
MH  - Peptic Ulcer Hemorrhage/*chemically induced/drug therapy
MH  - Risk Factors
MH  - Single-Blind Method
MH  - Ticlopidine/*administration & dosage/*analogs & derivatives
EDAT- 2004/02/27 05:00
MHDA- 2004/04/17 05:00
CRDT- 2004/02/27 05:00
PHST- 2004/02/27 05:00 [pubmed]
PHST- 2004/04/17 05:00 [medline]
PHST- 2004/02/27 05:00 [entrez]
AID - 1857 [pii]
AID - 10.1111/j.1365-2036.2004.01857.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2004 Feb 1;19(3):359-65. doi: 
      10.1111/j.1365-2036.2004.01857.x.

PMID- 21898115
OWN - NLM
STAT- MEDLINE
DCOM- 20120914
LR  - 20131121
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 131
IP  - 2
DP  - 2012 Jan
TI  - Aspirin use and breast cancer risk: a meta-analysis.
PG  - 581-7
LID - 10.1007/s10549-011-1747-0 [doi]
AB  - Animal and in vitro studies suggest that the use of aspirin may be associated 
      with reduced risk for breast cancer, but results from these studies of the 
      association have been inconsistent. The objective of this meta-analysis was to 
      quantitatively summarize the current evidence for such a relationship. We 
      searched MEDLINE for studies of aspirin use and breast cancer risk that were 
      published in any language, from January 1, 1966, to July 1, 2011. A total of 33 
      studies (19 cohort studies, 13 case-control studies, and 1 randomized controlled 
      trial [RCT]) that included 1,916,448 subjects were identified. We pooled the 
      relative risks from individual studies using a random-effects model, 
      heterogeneity, and publication bias analyses. In a pooled analysis of all 
      studies, aspirin use was associated with reduced risk for breast cancer (odds 
      ratio [OR] = 0.86, 95% confidence interval [CI] = 0.81, 0.92). In the subgroup 
      analysis by study design, results were similar except for RCT (OR = 0.98, 95% CI 
      = 0.87, 1.09). In conclusion, this meta-analysis indicated that regular use of 
      aspirin may be associated with reduced risk of breast cancer. More RCT were 
      needed to confirm this association in the future.
FAU - Luo, Ting
AU  - Luo T
AD  - Department of Head & Neck and Mammary Oncology, Cancer Center and State Key 
      Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China 
      Hospital, Sichuan University, 37 Guoxue Street, Chengdu 610041, China.
FAU - Yan, Hua-Mei
AU  - Yan HM
FAU - He, Ping
AU  - He P
FAU - Luo, Yong
AU  - Luo Y
FAU - Yang, Yuan-Fu
AU  - Yang YF
FAU - Zheng, Hong
AU  - Zheng H
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20110904
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Breast Neoplasms/*epidemiology/*etiology
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Risk
EDAT- 2011/09/08 06:00
MHDA- 2012/09/15 06:00
CRDT- 2011/09/08 06:00
PHST- 2011/08/10 00:00 [received]
PHST- 2011/08/16 00:00 [accepted]
PHST- 2011/09/08 06:00 [entrez]
PHST- 2011/09/08 06:00 [pubmed]
PHST- 2012/09/15 06:00 [medline]
AID - 10.1007/s10549-011-1747-0 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2012 Jan;131(2):581-7. doi: 10.1007/s10549-011-1747-0. 
      Epub 2011 Sep 4.

PMID- 20556571
OWN - NLM
STAT- MEDLINE
DCOM- 20130124
LR  - 20211020
IS  - 1672-0733 (Print)
IS  - 1672-0733 (Linking)
VI  - 30
IP  - 3
DP  - 2010 Jun
TI  - Revaluation of clopidogrel: let the data speak for themselves.
PG  - 299-306
LID - 10.1007/s11596-010-0346-3 [doi]
AB  - Clopidogrel was believed to be superior to aspirin by the well-known CAPRIE 
      trial. However, no other large clinical trials demonstrated the same results, but 
      all focused on the combination use of clopidogrel with aspirin, and combination 
      therapy in CREDO was called the "Emperor's New Clothes". However, no one 
      overturned the results of these clinical trials by quantitatively analyzing them. 
      We reviewed ten large-scale clinical trials about clopidogrel. On the basis of 
      results of CAPRIE, CREDO and CHARISMA trials, we re-estimated their minimal 
      sample sizes and their powers by three well-established statistical 
      methodologies. From the results of CAPRIE, we inferred that the minimal sample 
      size should be 85 086 or 84 968 but its power was only 30.70%. A huge gap 
      existed. The same was also true of CREDO and CHARISMA trials. Moreover, in CAPRIE 
      trial, 0 was included in the 95% confidence interval and 1 was included in the 
      95% confidence interval for the relative risk. There were some paradoxical data 
      in CAPRIE trial. We are led to conclude that the results in CAPRIE, CREDO, and 
      from the subgroup analysis in CHARISMA trials were questionable. These results 
      failed to demonstrate that clopidogrel was superior to aspirin or that 
      clopidogrel used in combination with aspirin was better than aspirin alone. The 
      cost-effectiveness analyses by some previous studies were not reliable.
FAU - Liu, Li
AU  - Liu L
AD  - Institute of Clinical Pharmacology, Department of Pharmacology, Tongji Medical 
      College, Huazhong University of Science and Technology, and Department of 
      Radiology, Renmin Hospital, Wuhan, 430030, China. LLsunrising@126.com
FAU - Zeng, Fandian
AU  - Zeng F
FAU - Zeng, Xiaohua
AU  - Zeng X
FAU - Xue, Qingmei
AU  - Xue Q
FAU - Nie, Shaoping
AU  - Nie S
FAU - Kang, Cailian
AU  - Kang C
FAU - Wu, Jianhong
AU  - Wu J
FAU - Kang, Qingyun
AU  - Kang Q
FAU - Wang, Xingao
AU  - Wang X
FAU - Liu, Xiaoqing
AU  - Liu X
FAU - Li, Tao
AU  - Li T
FAU - Chen, Jun
AU  - Chen J
FAU - Li, Qing
AU  - Li Q
FAU - Xu, Rong
AU  - Xu R
FAU - Yang, Xiaoyan
AU  - Yang X
FAU - Kang, Hui
AU  - Kang H
FAU - Jiang, Fagang
AU  - Jiang F
FAU - Li, Zongtao
AU  - Li Z
FAU - Wang, Xuwu
AU  - Wang X
FAU - Zhang, Li
AU  - Zhang L
FAU - Long, Yu
AU  - Long Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20100617
PL  - China
TA  - J Huazhong Univ Sci Technolog Med Sci
JT  - Journal of Huazhong University of Science and Technology. Medical sciences = Hua 
      zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. 
      Yixue Yingdewen ban
JID - 101169627
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/*drug therapy/prevention & control
MH  - Aspirin/therapeutic use
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2010/06/18 06:00
MHDA- 2013/01/25 06:00
CRDT- 2010/06/18 06:00
PHST- 2010/03/10 00:00 [received]
PHST- 2010/06/18 06:00 [entrez]
PHST- 2010/06/18 06:00 [pubmed]
PHST- 2013/01/25 06:00 [medline]
AID - 10.1007/s11596-010-0346-3 [doi]
PST - ppublish
SO  - J Huazhong Univ Sci Technolog Med Sci. 2010 Jun;30(3):299-306. doi: 
      10.1007/s11596-010-0346-3. Epub 2010 Jun 17.

PMID- 19903188
OWN - NLM
STAT- MEDLINE
DCOM- 20100120
LR  - 20181201
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
VI  - 27
IP  - 4
DP  - 2009 Winter
TI  - Gender and responses to aspirin and clopidogrel: insights using short 
      thrombelastography.
PG  - 246-52
LID - 10.1111/j.1755-5922.2009.00106.x [doi]
AB  - There is significant variability in both baseline clotting tendency and response 
      to antiplatelet therapy. Responses are associated with outcome. We have 
      investigated whether differences could explain the increased risk observed in 
      women presenting with coronary artery disease. We have utilized short 
      thrombelastography to assess (i) baseline clotting responses, (ii) response to 
      aspirin and clopidogrel, and (iii) post-treatment platelet reactivity in 48 young 
      volunteers, 22 older patients and 18 patients with previous stent thrombosis. 
      Baseline responses were significantly higher in young women than in men. While 
      there was no difference in response to aspirin, platelet reactivity on aspirin 
      remained higher in women (area under curve at 15 min [AUC15] of arachidonic acid 
      channel 332 +/- 122 vs. 172 +/- 80, P= 0.04). Young women had less response to 
      clopidogrel (% reduction in AUC15 with adenosine diphosphate [ADP] 36.4 +/- 12.4 
      vs. 64.0 +/- 13.2, P < 0.01) in addition to higher post-treatment reactivity 
      (AUC15 of ADP 714 +/- 161 vs. 311 +/- 146, P < 0.01) compared to men. There were 
      no such differences between male and female patients over 50. However, young 
      women with previous stent thrombosis had among the highest platelet reactivity 
      observed. Compared to men, young women have greater baseline clotting tendency, 
      reduced response to clopidogrel, and greater post-treatment reactivity while on 
      both aspirin and clopidogrel. Differences in clotting tendency and response to 
      antiplatelet therapy may contribute to the excess risk observed in young women 
      but are not observed in older female patients.
FAU - Hobson, Alex R
AU  - Hobson AR
AD  - Wessex Cardiothoracic Unit, Southampton University Hospital, UK.
FAU - Qureshi, Zeshan
AU  - Qureshi Z
FAU - Banks, Phil
AU  - Banks P
FAU - Curzen, Nick
AU  - Curzen N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Sex Characteristics
MH  - Thrombelastography/*methods
MH  - Ticlopidine/*analogs & derivatives/pharmacology
EDAT- 2009/11/12 06:00
MHDA- 2010/01/21 06:00
CRDT- 2009/11/12 06:00
PHST- 2009/11/12 06:00 [entrez]
PHST- 2009/11/12 06:00 [pubmed]
PHST- 2010/01/21 06:00 [medline]
AID - CDR106 [pii]
AID - 10.1111/j.1755-5922.2009.00106.x [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2009 Winter;27(4):246-52. doi: 10.1111/j.1755-5922.2009.00106.x.

PMID- 2546469
OWN - NLM
STAT- MEDLINE
DCOM- 19890811
LR  - 20151119
IS  - 0003-0805 (Print)
IS  - 0003-0805 (Linking)
VI  - 140
IP  - 1
DP  - 1989 Jul
TI  - Airway responsiveness to histamine and leukotriene E4 in subjects with 
      aspirin-induced asthma.
PG  - 148-53
AB  - Airway responsiveness to histamine and leukotriene E4 (LTE4) has been compared 
      between five subjects with aspirin-induced asthma (AIA) and 15 asthmatic subjects 
      without aspirin sensitivity (non-AIA). In the AIA group, the geometric mean doses 
      of histamine and LTE4 causing a 35% fall in specific airway conductance (PD35) 
      were 0.31 mumol and 0.17 nmol, respectively, and LTE4 was 1,870 times more potent 
      than histamine. In the non-AIA group, the histamine and LTE4 PD35 doses were 0.40 
      mumol (non-AIA versus AIA, NS) and 2.8 nmol (non-AIA versus AIA, p = 0.002), 
      respectively, and LTE4 was 145 times more potent than histamine in eliciting 
      bronchoconstriction (non-AIA versus AIA, p = 0.001). After desensitization to 
      aspirin the geometric mean histamine and LTE4 PD 35 in the AIA group changed to 
      0.19 mumol (NS) and 3.3 nmol (p = 0.007), respectively, and there was an average 
      33-fold reduction in the responsiveness of the airways to LTE4 relative to 
      histamine (p less than 0.001). In five non-AIA subjects. Ingestion of 600 mg of 
      aspirin daily did not lead to any significant change in airway responsiveness to 
      histamine or to LTE4. These results demonstrate a selective and marked increase 
      in airway responsiveness to LTE4 in subjects with AIA. The efficacy of 
      desensitization may relate in part to a selective down-regulation of LTE4 
      receptors within the airways.
FAU - Arm, J P
AU  - Arm JP
AD  - Department of Allergy and Allied Respiratory Disorders, UMDS, Guy's Hospital, 
      London, United Kingdom.
FAU - O'Hickey, S P
AU  - O'Hickey SP
FAU - Spur, B W
AU  - Spur BW
FAU - Lee, T H
AU  - Lee TH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am Rev Respir Dis
JT  - The American review of respiratory disease
JID - 0370523
RN  - 1HGW4DR56D (Leukotriene B4)
RN  - 820484N8I3 (Histamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced/diagnosis
MH  - Bronchial Provocation Tests
MH  - Female
MH  - *Histamine
MH  - Humans
MH  - *Leukotriene B4
MH  - Male
MH  - Middle Aged
MH  - Time Factors
EDAT- 1989/07/01 00:00
MHDA- 1989/07/01 00:01
CRDT- 1989/07/01 00:00
PHST- 1989/07/01 00:00 [pubmed]
PHST- 1989/07/01 00:01 [medline]
PHST- 1989/07/01 00:00 [entrez]
AID - 10.1164/ajrccm/140.1.148 [doi]
PST - ppublish
SO  - Am Rev Respir Dis. 1989 Jul;140(1):148-53. doi: 10.1164/ajrccm/140.1.148.

PMID- 22502946
OWN - NLM
STAT- MEDLINE
DCOM- 20130211
LR  - 20131121
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 317
IP  - 1-2
DP  - 2012 Jun 15
TI  - Revisiting cerebral thromboangiitis obliterans.
PG  - 141-5
LID - 10.1016/j.jns.2012.03.011 [doi]
AB  - We describe a 56-year-old patient with progressive cognitive decline in the 
      context of heavy tobacco use and migraine, and imaging evidence of an occlusive 
      terminal cerebral vasculopathy. The results of brain biopsy recapitulated the 
      pathological features described by Lindenberg and Spatz in their classic 1939 
      treatise on cerebral thromboangiitis obliterans, or cerebral Buerger's disease. 
      Although the condition is associated with heavy smoking, the identification of a 
      hypercoagulable state in our patient suggests a multifactorial pathogenesis. The 
      diagnosis of cerebral thromboangiitis obliterans in life is facilitated by modern 
      neuroimaging and should prompt immediate cessation of smoking and a search for an 
      underlying prothrombotic tendency.
CI  - Copyright © 2012 Elsevier B.V. All rights reserved.
FAU - Hurelbrink, Carrie B
AU  - Hurelbrink CB
AD  - Department of Neurology, Royal Prince Alfred Hospital, Missenden Road, Camperdown 
      NSW 2050, Australia.
FAU - Barnett, Yael
AU  - Barnett Y
FAU - Buckland, Michael E
AU  - Buckland ME
FAU - Wilkinson, Mark
AU  - Wilkinson M
FAU - Leicester, Jon
AU  - Leicester J
FAU - Anderson, Craig
AU  - Anderson C
FAU - Brennan, Jeffrey
AU  - Brennan J
FAU - Barnett, Michael
AU  - Barnett M
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20120412
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Smoking/adverse effects/pathology
MH  - Smoking Cessation/methods
MH  - Thromboangiitis Obliterans/*diagnosis/etiology/*therapy
EDAT- 2012/04/17 06:00
MHDA- 2013/02/12 06:00
CRDT- 2012/04/17 06:00
PHST- 2011/12/20 00:00 [received]
PHST- 2012/03/15 00:00 [revised]
PHST- 2012/03/15 00:00 [accepted]
PHST- 2012/04/17 06:00 [entrez]
PHST- 2012/04/17 06:00 [pubmed]
PHST- 2013/02/12 06:00 [medline]
AID - S0022-510X(12)00152-9 [pii]
AID - 10.1016/j.jns.2012.03.011 [doi]
PST - ppublish
SO  - J Neurol Sci. 2012 Jun 15;317(1-2):141-5. doi: 10.1016/j.jns.2012.03.011. Epub 
      2012 Apr 12.

PMID- 1632294
OWN - NLM
STAT- MEDLINE
DCOM- 19920820
LR  - 20191028
IS  - 0379-0363 (Print)
IS  - 0379-0363 (Linking)
VI  - 37
DP  - 1992
TI  - Platelet PGI2-receptor behaviour change after treatment with acetylsalicylic acid 
      in healthy volunteers.
PG  - 197-203
AB  - After treatment of human platelet membrane fractions with different 
      concentrations of acetylsalicylic acid (ASA) the Iloprost binding capacity (Bmax) 
      and also the dissociation constant (Kd) of the high-affinity PGI2-receptor 
      increased significantly (p less than 0.01, low-affinity receptor only an increase 
      of Bmax, p less than 0.01), whereas only a significant (p less than 0.05) 
      increase of the Kd of the high-affinity receptor was observed for intact 
      platelets.
FAU - Böhm, T
AU  - Böhm T
AD  - Wilhelm Auerswald Atherosclerosis Research Group (ASF) Vienna, Austria.
FAU - Virgolini, I
AU  - Virgolini I
FAU - Sinzinger, H
AU  - Sinzinger H
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions Suppl
JT  - Agents and actions. Supplements
JID - 7801014
RN  - 0 (Receptors, Epoprostenol)
RN  - 0 (Receptors, Prostaglandin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/*metabolism
MH  - Cell Membrane/drug effects/metabolism
MH  - Chromatography, Thin Layer
MH  - Humans
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Receptors, Epoprostenol
MH  - Receptors, Prostaglandin/*drug effects
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1007/978-3-0348-7262-1_27 [doi]
PST - ppublish
SO  - Agents Actions Suppl. 1992;37:197-203. doi: 10.1007/978-3-0348-7262-1_27.

PMID- 9834303
OWN - NLM
STAT- MEDLINE
DCOM- 19981204
LR  - 20131121
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 339
IP  - 23
DP  - 1998 Dec 3
TI  - A clinical trial comparing three antithrombotic-drug regimens after 
      coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
PG  - 1665-71
AB  - BACKGROUND: Antithrombotic drugs are used after coronary-artery stenting to 
      prevent stent thrombosis. We compared the efficacy and safety of three 
      antithrombotic-drug regimens - aspirin alone, aspirin and warfarin, and aspirin 
      and ticlopidine - after coronary stenting. METHODS: Of 1965 patients who 
      underwent coronary stenting at 50 centers, 1653 (84.1 percent) met angiographic 
      criteria for successful placement of the stent and were randomly assigned to one 
      of three regimens: aspirin alone (557 patients), aspirin and warfarin (550 
      patients), or aspirin and ticlopidine (546 patients). All clinical events 
      reflecting stent thrombosis were included in the prespecified primary end point: 
      death, revascularization of the target lesion, angiographically evident 
      thrombosis, or myocardial infarction within 30 days. RESULTS: The primary end 
      point was observed in 38 patients: 20 (3.6 percent) assigned to receive aspirin 
      alone, 15 (2.7 percent) assigned to receive aspirin and warfarin, and 3 (0.5 
      percent) assigned to receive aspirin and ticlopidine (P=0.001 for the comparison 
      of all three groups). Hemorrhagic complications occurred in 10 patients (1.8 
      percent) who received aspirin alone, 34 (6.2 percent) who received aspirin and 
      warfarin, and 30 (5.5 percent) who received aspirin and ticlopidine (P<0.001 for 
      the comparison of all three groups); the incidence of vascular surgical 
      complications was 0.4 percent (2 patients), 2.0 percent (11 patients), and 2.0 
      percent (11 patients), respectively (P=0.01). There were no significant 
      differences in the incidence of neutropenia or thrombocytopenia (overall 
      incidence, 0.3 percent) among the three treatment groups. CONCLUSIONS: As 
      compared with aspirin alone and a combination of aspirin and warfarin, treatment 
      with aspirin and ticlopidine resulted in a lower rate of stent thrombosis, 
      although there were more hemorrhagic complications than with aspirin alone. After 
      coronary stenting, aspirin and ticlopidine should be considered for the 
      prevention of the serious complication of stent thrombosis.
FAU - Leon, M B
AU  - Leon MB
AD  - Cardiology Research Foundation, Washington Hospital Center, DC 20010, USA.
FAU - Baim, D S
AU  - Baim DS
FAU - Popma, J J
AU  - Popma JJ
FAU - Gordon, P C
AU  - Gordon PC
FAU - Cutlip, D E
AU  - Cutlip DE
FAU - Ho, K K
AU  - Ho KK
FAU - Giambartolomei, A
AU  - Giambartolomei A
FAU - Diver, D J
AU  - Diver DJ
FAU - Lasorda, D M
AU  - Lasorda DM
FAU - Williams, D O
AU  - Williams DO
FAU - Pocock, S J
AU  - Pocock SJ
FAU - Kuntz, R E
AU  - Kuntz RE
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 1998 Dec 3;339(23):1702-4. PMID: 9834311
CIN - N Engl J Med. 1999 Apr 29;340(17):1365; author reply 1367. PMID: 10223873
MH  - Aged
MH  - Angioplasty, Balloon, Coronary
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Coronary Disease/mortality/*therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Single-Blind Method
MH  - *Stents
MH  - Thrombosis/*prevention & control
MH  - Ticlopidine/adverse effects/*therapeutic use
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 1998/12/03 00:00
MHDA- 1998/12/03 00:01
CRDT- 1998/12/03 00:00
PHST- 1998/12/03 00:00 [pubmed]
PHST- 1998/12/03 00:01 [medline]
PHST- 1998/12/03 00:00 [entrez]
AID - 10.1056/NEJM199812033392303 [doi]
PST - ppublish
SO  - N Engl J Med. 1998 Dec 3;339(23):1665-71. doi: 10.1056/NEJM199812033392303.

PMID- 27246782
OWN - NLM
STAT- MEDLINE
DCOM- 20170912
LR  - 20181113
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Print)
IS  - 0066-4804 (Linking)
VI  - 60
IP  - 8
DP  - 2016 Aug
TI  - Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs.
PG  - 4799-808
LID - 10.1128/AAC.02810-15 [doi]
AB  - The usage of fluconazole and amphotericin B in clinical settings is often limited 
      by, among other things, drug resistance development and undesired side effects. 
      Thus, there is a constant need to find new drugs to better manage fungal 
      infections. Toward this end, the study described in this paper considered the 
      repurposing of aspirin (acetylsalicylic acid) and ibuprofen as alternative drugs 
      to control the growth of cryptococcal cells. In vitro susceptibility tests, 
      including a checkerboard assay, were performed to assess the response of 
      Cryptococcus neoformans and Cryptococcus gattii to the above-mentioned 
      anti-inflammatory drugs. Next, the capacity of these two drugs to induce stress 
      as well as their mode of action in the killing of cryptococcal cells was 
      determined. The studied fungal strains revealed a response to both aspirin and 
      ibuprofen that was dose dependent, with ibuprofen exerting greater antimicrobial 
      action. More importantly, the MICs of these drugs did not negatively (i) affect 
      growth or (ii) impair the functioning of macrophages; rather, they enhanced the 
      ability of these immune cells to phagocytose cryptococcal cells. Ibuprofen was 
      also shown to act in synergy with fluconazole and amphotericin B. The treatment 
      of cryptococcal cells with aspirin or ibuprofen led to stress induction via 
      activation of the high-osmolarity glycerol (HOG) pathway, and cell death was 
      eventually achieved through reactive oxygen species (ROS)-mediated membrane 
      damage. The presented data highlight the potential clinical application of 
      aspirin and ibuprofen as candidate anti-Cryptococcus drugs.
CI  - Copyright © 2016, American Society for Microbiology. All Rights Reserved.
FAU - Ogundeji, Adepemi O
AU  - Ogundeji AO
AD  - Department of Microbial, Biochemical and Food Biotechnology, University of the 
      Free State, Bloemfontein, South Africa.
FAU - Pohl, Carolina H
AU  - Pohl CH
AD  - Department of Microbial, Biochemical and Food Biotechnology, University of the 
      Free State, Bloemfontein, South Africa.
FAU - Sebolai, Olihile M
AU  - Sebolai OM
AD  - Department of Microbial, Biochemical and Food Biotechnology, University of the 
      Free State, Bloemfontein, South Africa sebolaiom@ufs.ac.za.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160722
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Antifungal Agents)
RN  - 7XU7A7DROE (Amphotericin B)
RN  - 8VZV102JFY (Fluconazole)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Amphotericin B/pharmacology
MH  - Animals
MH  - Antifungal Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cell Death/drug effects
MH  - Cell Line
MH  - Cryptococcosis/*drug therapy
MH  - Cryptococcus/*drug effects
MH  - Drug Repositioning/methods
MH  - Drug Resistance, Fungal/drug effects
MH  - Fluconazole/pharmacology
MH  - Ibuprofen/*pharmacology
MH  - Mice
MH  - RAW 264.7 Cells
PMC - PMC4958236
EDAT- 2016/06/02 06:00
MHDA- 2017/09/13 06:00
CRDT- 2016/06/02 06:00
PHST- 2015/11/20 00:00 [received]
PHST- 2016/05/19 00:00 [accepted]
PHST- 2016/06/02 06:00 [entrez]
PHST- 2016/06/02 06:00 [pubmed]
PHST- 2017/09/13 06:00 [medline]
AID - AAC.02810-15 [pii]
AID - 02810-15 [pii]
AID - 10.1128/AAC.02810-15 [doi]
PST - epublish
SO  - Antimicrob Agents Chemother. 2016 Jul 22;60(8):4799-808. doi: 
      10.1128/AAC.02810-15. Print 2016 Aug.

PMID- 18604318
OWN - NLM
STAT- MEDLINE
DCOM- 20081022
LR  - 20151119
IS  - 0212-1611 (Print)
IS  - 0212-1611 (Linking)
VI  - 23
IP  - 4
DP  - 2008 Jul-Aug
TI  - Effect of different non-steroidal anti-inflammatory drugs, aspirin, nimesulide 
      and celecoxib on the disaccharide hydrolases and histoarchitecture of the rat 
      intestinal brush border membrane.
PG  - 326-31
AB  - Non-steroidal anti-inflammatory drugs (NSAIDs) are known to cause 
      gastrointestinal damage. New anti-inflammatory drugs have been developed in an 
      attempt to improve their gastrointestinal side effect profile which however 
      failed to do so. Therefore, the objective of the present study was to compare the 
      effect of three different NSAIDs, aspirin, nimesulide and celecoxib on the 
      intestinal brush border membrane (BBM) marker enzymes and correlate these 
      alterations to the histoarchitecture of the intestine using electron microscopic 
      study. Female Wistar rats were divided into four different groups viz: Group I 
      (Control), Group II (aspirin treated), Group III (nimesulide treated) and Group 
      IV (celecoxib treated). The Group II, III and IV received the corresponding drugs 
      dissolved in water orally at a dose of 40 mg/kg body weight, while the control 
      received the vehicle only. After 28 days, all the treatment groups demonstrated 
      significant alterations in the activities of intestinal disaccharide hydrolases 
      and alkaline phosphatase in both the crude homogenates and BBM preparations as 
      well. The histopathological observations also showed considerable changes in the 
      intestinal mucosa. It was suggested that NSAIDs like aspirin, nimesulide and 
      celecoxib pose intestinal side effects due to initial changes in the enzymatic 
      composition of the intestinal apical membranes. It was further concluded that 
      newly discovered NSAIDs such as celecoxib has better safety profiles but studies 
      are still required to comment decisively on the suitability of various NSAIDs 
      depending upon their cyclooxygenase enzyme specificity.
FAU - Sood, N
AU  - Sood N
AD  - Department of Biophysics, Panjab University, Chandigarth, 160014, India.
FAU - Kaushal, N
AU  - Kaushal N
FAU - Sanyal, S N
AU  - Sanyal SN
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Nutr Hosp
JT  - Nutricion hospitalaria
JID - 9100365
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - EC 3.2.1.- (Disaccharidases)
RN  - JCX84Q7J1L (Celecoxib)
RN  - R16CO5Y76E (Aspirin)
RN  - V4TKW1454M (nimesulide)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Celecoxib
MH  - Disaccharidases/*drug effects
MH  - Female
MH  - Intestines/*drug effects/*ultrastructure
MH  - Microscopy, Electron, Scanning
MH  - Microvilli/drug effects
MH  - Pyrazoles/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Sulfonamides/*pharmacology
EDAT- 2008/07/08 09:00
MHDA- 2008/10/23 09:00
CRDT- 2008/07/08 09:00
PHST- 2007/07/05 00:00 [received]
PHST- 2007/09/06 00:00 [accepted]
PHST- 2008/07/08 09:00 [pubmed]
PHST- 2008/10/23 09:00 [medline]
PHST- 2008/07/08 09:00 [entrez]
AID - S0212-16112008000500004 [pii]
PST - ppublish
SO  - Nutr Hosp. 2008 Jul-Aug;23(4):326-31.

PMID- 10686454
OWN - NLM
STAT- MEDLINE
DCOM- 20000623
LR  - 20171101
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 10
IP  - 2
DP  - 2000 Mar-Apr
TI  - Design of ESPRIT: an international randomized trial for secondary prevention 
      after non-disabling cerebral ischaemia of arterial origin. European/Australian 
      Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group.
PG  - 147-50
AB  - The ESPRIT trial addresses the problem that aspirin, the standard therapy for 
      secondary prevention of vascular complications after a transient ischaemic attack 
      (TIA) or ischaemic stroke of arterial origin, reduces the risk of serious 
      vascular events by only about 13%. Anticoagulants may be an alternative, as these 
      have proved highly efficacious in trials after myocardial infarction and after 
      cerebral ischaemia with atrial fibrillation. After cerebral ischaemia of presumed 
      arterial origin, high-intensity anticoagulation (INR 3.0-4.5) is not safe, but 
      the value of anticoagulation with an INR between 2.0 and 3.0 is still unknown. 
      Secondly, a recent, large trial showed that the combination of aspirin and 
      dipyridamole prevents more major vascular events than aspirin alone, but several 
      earlier trials did not find such an advantage. In ESPRIT, patients with a TIA or 
      minor ischaemic stroke (Rankin grade </=3) will be randomized between oral 
      anticoagulation (INR 2.0-3.0), the combination of dipyridamole (400 mg daily) 
      plus aspirin (in any dose between 30 and 325 mg daily) and aspirin only. Primary 
      outcome is the composite event 'death from all vascular causes, non-fatal stroke, 
      non-fatal myocardial infarction or major bleeding complication', whichever occurs 
      first. Outcome assessment will be blinded. The recruitment of a total of 4,500 
      patients from more than 10 countries is planned; the mean follow-up will be 3 
      years.
CI  - Copyright 2000 S. Karger AG, Basel.
FAU - De Schryver, E L
AU  - De Schryver EL
AD  - Trial Office Neurology, University Hospital, Utrecht, The Netherlands.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Anticoagulants)
RN  - 0 (Vasodilator Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Myocardial Infarction/complications
MH  - Research Design
MH  - Vasodilator Agents/*therapeutic use
EDAT- 2000/02/25 09:00
MHDA- 2000/07/06 11:00
CRDT- 2000/02/25 09:00
PHST- 2000/02/25 09:00 [pubmed]
PHST- 2000/07/06 11:00 [medline]
PHST- 2000/02/25 09:00 [entrez]
AID - 16044 [pii]
AID - 10.1159/000016044 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2000 Mar-Apr;10(2):147-50. doi: 10.1159/000016044.

PMID- 34301348
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220308
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
VI  - 226
IP  - 2S
DP  - 2022 Feb
TI  - Low-molecular-weight heparin for prevention of preeclampsia and other 
      placenta-mediated complications: a systematic review and meta-analysis.
PG  - S1126-S1144.e17
LID - S0002-9378(20)31288-6 [pii]
LID - 10.1016/j.ajog.2020.11.006 [doi]
AB  - BACKGROUND: Evidence on the impact of low-molecular-weight heparin, alone or in 
      combination with low-dose aspirin, for the prevention for preeclampsia in 
      high-risk patients is conflicting. OBJECTIVE: We conducted a meta-analysis of 
      studies published to assess the effectiveness of low-molecular-weight heparin for 
      the prevention of preeclampsia and other placenta-related complications in 
      high-risk women. DATA SOURCES: A systematic search was performed to identify 
      relevant studies, using the databases PubMed and Cochrane Central Register of 
      Controlled Trials, without publication time restrictions. STUDY ELIGIBILITY 
      CRITERIA: Randomized controlled trials comparing treatment with 
      low-molecular-weight heparin or unfractionated heparin (with or without low-dose 
      aspirin), in high-risk women, defined as either history of preeclampsia, 
      intrauterine growth restriction, fetal demise, or miscarriage or being at high 
      risk after first-trimester screening of preeclampsia. STUDY APPRAISAL AND 
      SYNTHESIS METHODS: The systematic review was conducted according to the Cochrane 
      Handbook guidelines. The primary outcome was the development of preeclampsia. We 
      performed prespecified subgroup analyses according to combination with low-dose 
      aspirin, low-molecular-weight heparin type, gestational age when treatment was 
      started, and study population (patients with thrombophilia, at high risk of 
      preeclampsia or miscarriage). Secondary outcomes included small for gestational 
      age, perinatal death, miscarriage, and placental abruption. Pooled odds ratios 
      with 95% confidence intervals were calculated using a random-effects model. 
      Quality of evidence was assessed using the grading of recommendations assessment, 
      development, and evaluation methodology. RESULTS: A total of 15 studies (2795 
      participants) were included. In high-risk women, treatment with 
      low-molecular-weight heparin was associated with a reduction in the development 
      of preeclampsia (odds ratio, 0.62; 95% confidence interval, 0.43-0.90; P=.010); 
      small for gestational age (odds ratio, 0.61; 95% confidence interval, 0.44-0.85; 
      P=.003), and perinatal death (odds ratio, 0.49; 95% confidence interval, 
      0.25-0.94; P=.030). This reduction was stronger if low-molecular-weight heparin 
      was started before 16 weeks' gestation (13 studies, 2474 participants) for 
      preeclampsia (odds ratio, 0.55; 95% confidence interval, 0.39-0.76; P=.0004). 
      When only studies including low-dose aspirin as an intervention were analyzed (6 
      randomized controlled trials, 920 participants), a significant reduction was 
      observed in those with combined treatment (low-molecular-weight heparin plus 
      low-dose aspirin) compared with low-dose aspirin alone (odds ratio, 0.62; 95% 
      confidence interval, 0.41-0.95; P=.030). Overall, adverse events were neither 
      serious nor significantly different. Quality of evidence ranged from very low to 
      moderate, mostly because of the lack of blinding, imprecision, and inconsistency. 
      CONCLUSION: Low-molecular-weight heparin use was associated with a significant 
      reduction in the risk of preeclampsia and other placenta-mediated complications 
      in high-risk women and when treatment was started before 16 weeks' gestation. 
      Combined treatment with low-dose aspirin was associated with a significant 
      reduction in the risk of preeclampsia compared with low-dose aspirin alone. 
      However, there exists important clinical and statistical heterogeneity, and 
      therefore, these results merit confirmation in large well-designed clinical 
      trials.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Cruz-Lemini, Monica
AU  - Cruz-Lemini M
AD  - Maternal and Fetal Medicine Unit, Department of Obstetrics and Gynecology, Sant 
      Pau University Hospital, Barcelona, Spain.
FAU - Vázquez, Juan Carlos
AU  - Vázquez JC
AD  - Iberoamerican Cochrane Center, Sant Pau University Hospital, Barcelona, Spain; 
      Department of Paediatrics, Obstetrics and Gynaecology and Preventative Medicine, 
      Universitat Autònoma de Barcelona, Barcelona, Spain.
FAU - Ullmo, Johana
AU  - Ullmo J
AD  - Maternal and Fetal Medicine Unit, Department of Obstetrics and Gynecology, Sant 
      Pau University Hospital, Barcelona, Spain.
FAU - Llurba, Elisa
AU  - Llurba E
AD  - Maternal and Fetal Medicine Unit, Department of Obstetrics and Gynecology, Sant 
      Pau University Hospital, Barcelona, Spain; Maternal and Child Health and 
      Development Network (SAMID), RD16/0022/0015, Instituto de Salud Carlos III, 
      Barcelona, Spain. Electronic address: ellurba@santpau.cat.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20210420
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fetal Growth Retardation/prevention & control
MH  - Gestational Age
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Small for Gestational Age
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - aspirin
OT  - fetal growth restriction
OT  - low-molecular-weight heparin
OT  - placental insufficiency
OT  - preeclampsia
OT  - prevention
EDAT- 2021/07/25 06:00
MHDA- 2022/03/09 06:00
CRDT- 2021/07/24 05:29
PHST- 2020/08/11 00:00 [received]
PHST- 2020/11/04 00:00 [revised]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2021/07/25 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2021/07/24 05:29 [entrez]
AID - S0002-9378(20)31288-6 [pii]
AID - 10.1016/j.ajog.2020.11.006 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 2022 Feb;226(2S):S1126-S1144.e17. doi: 
      10.1016/j.ajog.2020.11.006. Epub 2021 Apr 20.

PMID- 7413706
OWN - NLM
STAT- MEDLINE
DCOM- 19801120
LR  - 20131121
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 34
IP  - 5-6
DP  - 1980
TI  - [Criteria for the use of the linear allothermal short-time test in predicting 
      stability (author's transl)].
PG  - 302-6
AB  - Three selected model substances of varying activation energy (naphazoline, 109 
      kJ/mole; acetylsalicylic acid, 72 kJ/mole; and phenobarbital, 60 kJ/mole) were 
      studied to determine the conditions under which the allothermal short-time test 
      according to Zoglio (linear increase in temperature) will yield stability 
      predictions which are consistent with those provided by the isothermal short- or 
      long-time test. The error of the determination method should be less than or 
      equal to 1%. It is advantageous to use for the calculation as many data as the 
      analytical facilities will permit to obtain. The actual value for the respective 
      temperature should differ from the desired value by < +/- 0.2%. The increase in 
      temperature should be very slow 1-2 degrees C/h at best). This is particularly 
      true for substances of low activation energy, because more the energy values 
      calculated on the basis of the allothermal test differ from the isothermally 
      determined values, the flatter is the curve provided by the arrhenius equation. 
      The temperature range should be chosen as large as possible, from 30-90 degress 
      C, and the experiment should be continued until at least a 10% decomposition is 
      achieved. On calculating the collision factor A and the reaction-rate constant 
      for any temperature, it has proved useful to continue the experiment isothermally 
      at the final point of the allothermal test.
FAU - Beyrich, T
AU  - Beyrich T
FAU - Stahlkopf, W
AU  - Stahlkopf W
FAU - Lichtnow, K H
AU  - Lichtnow KH
FAU - Schmidt, W
AU  - Schmidt W
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Kriterien zur Anwendung des linearen allothermen Kurzzeittestes nach Zoglio zur 
      Stabilitätsvorhersage.
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - H231GF11BV (Naphazoline)
RN  - R16CO5Y76E (Aspirin)
RN  - YQE403BP4D (Phenobarbital)
SB  - IM
MH  - Aspirin
MH  - *Drug Stability
MH  - Models, Chemical
MH  - Naphazoline
MH  - Phenobarbital
MH  - Thermodynamics
MH  - Time Factors
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Pharmazie. 1980;34(5-6):302-6.

PMID- 31199427
OWN - NLM
STAT- MEDLINE
DCOM- 20191212
LR  - 20220716
IS  - 1680-0745 (Electronic)
IS  - 1995-1892 (Print)
IS  - 1015-9657 (Linking)
VI  - 29
IP  - 6
DP  - 2018 Nov/Dec
TI  - Pre-eclampsia and the foetus: a cardiovascular perspective.
PG  - 387-393
LID - 10.5830/CVJA-2017-039 [doi]
AB  - Pre-eclampsia is the leading cause of perinatal morbidity and mortality. A full 
      understanding of the pathogenesis of this enigmatic condition is essential if we 
      are to develop new prophylactic and therapeutic interventions. Central to our 
      understanding of the pathogenesis of early-onset preeclampsia is absolute 
      utero-placental ischaemia, which is lack of placental vascular transformation in 
      early pregnancy. By contrast, relative utero-placental ischaemia, due to a 
      mismatch between utero-placental blood flow and increased demand for nutrients 
      occurring later in pregnancy, may be central to the development of late-onset 
      pre-eclampsia. These pathogenic mechanisms have advanced our understanding of 
      this condition, leading to better prediction, screening and intervention 
      modalities. Screening for pre-eclampsia in the first and second trimesters by 
      investigating the maternoplacental circulation and placental hormones could 
      identify a high-risk subgroup. The advantage of screening in the first trimester 
      is that a prophylactic intervention is available in the form of low-dose aspirin, 
      if started before 16 weeks' gestation in the high-risk group, resulting in a 
      substantial reduction in severe early-onset pre-eclampsia, while identification 
      of a high-risk group in the second trimester will lead to focused management in 
      this group. Using a combination of cardiac Doppler, multi-vessel Doppler 
      assessment of the foetal circulation and biomarkers in established pre-eclampsia 
      in the third trimester could predict adverse outcomes and guide clinicians to 
      timeous delivery. Hopefully, advances in our understanding of this enigmatic 
      disease will lead to further prophylactic and new therapeutic interventions.
FAU - Bhorat, Ismail
AU  - Bhorat I
AD  - College of Health Sciences Durban, University of KwaZulu-Natal, Durban, South 
      Africa. Email: bhorat@worldonline.co.za.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - South Africa
TA  - Cardiovasc J Afr
JT  - Cardiovascular journal of Africa
JID - 101313864
RN  - 0 (Biomarkers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Biomarkers/*blood
MH  - Female
MH  - Humans
MH  - Placenta/drug effects
MH  - Pre-Eclampsia/diagnosis/*drug therapy
MH  - Pregnancy
MH  - Treatment Outcome
MH  - Ultrasonography, Doppler/methods
MH  - Ultrasonography, Prenatal/methods
PMC - PMC9048241
OTO - NOTNLM
OT  - Doppler of foetal circulation
OT  - cardiac Doppler
OT  - foetus
OT  - placental hormones
OT  - pre‐eclampsia
OT  - utero‐placental ischaemia
EDAT- 2019/06/15 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/06/15 06:00
PHST- 2016/11/19 00:00 [received]
PHST- 2017/08/12 00:00 [accepted]
PHST- 2019/06/15 06:00 [entrez]
PHST- 2019/06/15 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
AID - 10.5830/CVJA-2017-039 [doi]
PST - ppublish
SO  - Cardiovasc J Afr. 2018 Nov/Dec;29(6):387-393. doi: 10.5830/CVJA-2017-039.

PMID- 2677087
OWN - NLM
STAT- MEDLINE
DCOM- 19891114
LR  - 20190708
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 14
IP  - 4
DP  - 1989 Oct
TI  - After coronary thrombolysis and reperfusion, what next?
PG  - 837-49
AB  - Thrombolytic therapy for the removal of intravascular thrombi was introduced when 
      streptokinase was first given to humans 40 years ago, the same year the American 
      College of Cardiology was founded. Streptokinase was first administered to 
      patients with acute myocardial infarction in 1959. Today, thrombolytic therapy 
      has been established to offer significant benefits to patients with acute 
      myocardial infarction provided they are brought to medical attention early enough 
      after the onset of symptoms. The two major agents, streptokinase and recombinant 
      tissue-type plasminogen activator (rt-PA), have been shown to result in 
      reperfusion of infarct-related arteries, to salvage ischemic myocardium, to 
      improve myocardial performance and to reduce mortality. In spite of these 
      impressive gains, this novel therapy has shortcomings. The interval from the 
      start of thrombolytic treatment to coronary reperfusion varies significantly from 
      patient to patient and may, at times, be too long to produce a real benefit in 
      terms of salvage of ischemic myocardium. The rate of reocclusion lies somewhere 
      between 10% and 20% and appears not to be influenced by concomitant heparin 
      anticoagulation. The rate of bleeding complications even with the 
      "fibrin-specific" rt-PA is higher than anticipated and may range from 10% to 30%. 
      As a consequence, intensive efforts are being directed at the development of 
      improved thrombolytic agents and for adjunctive therapy evaluating better 
      anticoagulants than heparin and better antiplatelet agents than aspirin. This 
      review is a status report summarizing where we are in thrombolytic therapy in 
      acute myocardial infarction, where we need to improve treatment results and what 
      is being done mainly at the preclinical level to bring about such improvements.
FAU - Bang, N U
AU  - Bang NU
AD  - Lilly Laboratory for Clinical Research, Eli Lilly and Company, Indianapolis, 
      Indiana.
FAU - Wilhelm, O G
AU  - Wilhelm OG
FAU - Clayman, M D
AU  - Clayman MD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - *Myocardial Reperfusion
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Recurrence
MH  - *Thrombolytic Therapy
RF  - 107
EDAT- 1989/10/01 00:00
MHDA- 1989/10/01 00:01
CRDT- 1989/10/01 00:00
PHST- 1989/10/01 00:00 [pubmed]
PHST- 1989/10/01 00:01 [medline]
PHST- 1989/10/01 00:00 [entrez]
AID - 0735-1097(89)90454-3 [pii]
AID - 10.1016/0735-1097(89)90454-3 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 1989 Oct;14(4):837-49. doi: 10.1016/0735-1097(89)90454-3.

PMID- 32040035
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20210208
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 75
IP  - 4
DP  - 2020 Apr
TI  - Monitoring Antiplatelet Aggregation In Vivo and In Vitro by Microtiter Plate 
      Method.
PG  - 314-320
LID - 10.1097/FJC.0000000000000801 [doi]
AB  - BACKGROUND: The current light transmission aggregation method is a recognized 
      conventional method for platelet function evaluation, but it is time-consuming 
      and poor in parallelism and cannot simultaneously monitor multiple inducers at 
      multiple levels. The microtiter plate method has been established because of the 
      high-throughput characteristic, but it needs more practical applications. 
      OBJECTIVES: To evaluate the microtiter plate method by using aspirin and 
      clopidogrel in vivo and in vitro. METHODS: In vitro, the platelet aggregations 
      inhibited by aspirin (0.3, 1, 3, 10, 30, 90 μM) and clopidogrel (1, 3, 10, 30, 
      100, 300 μM) were evaluated with the presence of arachidonic acid (AA) and 
      adenosine diphosphate (ADP) agonists. Using the combination index (CI), the 
      effect of the combination of aspirin and clopidogrel on platelet aggregation was 
      evaluated. In vivo, New Zealand rabbits (n = 18) were randomly divided into 3 
      groups, aspirin group (5 mg/kg, intragastrical gavage [i.g.]), clopidogrel group 
      (14 mg/kg at the first day, followed by 4 mg/kg, i.g.), and the combination of 
      these two drugs, administered (i.g.) continuously for 7 days. Then, the blood was 
      collected to measure platelet aggregation. RESULTS: Different concentrations of 
      AA (12.5, 25, 50, 100 μM) and ADP (1.25, 2.5, 5, 10 μM) could promote platelet 
      aggregation in concentration-dependent manner, and the most stable induction 
      concentrations of AA and ADP were 50 and 5 μM. In vitro, with the above optimized 
      detection system, aspirin and clopidogrel alone or in combination had 
      concentration-dependent antiplatelet aggregation. The combination of aspirin and 
      clopidogrel also showed synergistic inhibition effect within the concentration 
      range studied. In vivo, aspirin and clopidogrel alone or in combination inhibited 
      platelet aggregation induced by multiple concentrations of AA and ADP agonists, 
      and the combined inhibition was more significant during the administration than 
      aspirin or clopidogrel alone. CONCLUSIONS: The improved microtiter plate method 
      combining the use of multiple levels of multiple agonists avoids the variation of 
      the effective inducer concentrations due to individual different response of 
      platelets to agonists. It may be a potential approach in the detection of 
      platelet aggregation.
FAU - Wu, Qiu-Ling
AU  - Wu QL
AD  - School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 
      China.
AD  - Department of Phytochemistry, School of Pharmacy, Second Military Medical 
      University, Shanghai, China.
FAU - Dong, Jun
AU  - Dong J
AD  - Department of Orthopaedics, Provincial Hospital Affiliated to Shandong 
      University, Jinan, China.
FAU - Zeng, Hua-Wu
AU  - Zeng HW
AD  - Department of Phytochemistry, School of Pharmacy, Second Military Medical 
      University, Shanghai, China.
FAU - Lv, Chao
AU  - Lv C
AD  - Institute of Interdisciplinary Integrative Medicine Research, Shanghai University 
      of Traditional Chinese Medicine, Shanghai, China.
FAU - Liu, Ai-Jun
AU  - Liu AJ
AD  - Department of Pharmacology, School of Pharmacy, Second Military Medical 
      University, Shanghai, China; and.
AD  - Department of Pharmacy Research, Yueyang Hospital of Integrated Traditional 
      Chinese and Western Medicine, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Zhang, Wei-Dong
AU  - Zhang WD
AD  - School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 
      China.
AD  - Department of Phytochemistry, School of Pharmacy, Second Military Medical 
      University, Shanghai, China.
AD  - Institute of Interdisciplinary Integrative Medicine Research, Shanghai University 
      of Traditional Chinese Medicine, Shanghai, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Clopidogrel/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Monitoring/*instrumentation
MH  - Dual Anti-Platelet Therapy
MH  - High-Throughput Screening Assays/*instrumentation
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests/*instrumentation
MH  - Predictive Value of Tests
MH  - Rabbits
MH  - Time Factors
EDAT- 2020/02/11 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/02/11 06:00
PHST- 2020/02/11 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2020/02/11 06:00 [entrez]
AID - 00005344-202004000-00007 [pii]
AID - 10.1097/FJC.0000000000000801 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2020 Apr;75(4):314-320. doi: 
      10.1097/FJC.0000000000000801.

PMID- 12876526
OWN - NLM
STAT- MEDLINE
DCOM- 20030826
LR  - 20211203
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 32
IP  - 21
DP  - 2003 Jun 14
TI  - [The effectiveness of leukotriene antagonists in the treatment of 
      aspirin-intolerant asthmatic patients].
PG  - 978-84
AB  - INTRODUCTION: The aim of this study was to assess the efficacy of leucotrien- 
      antagonists in aspirin-intolerant asthma (AIA). The severity of asthma was 
      evaluated according to GINA guidelines. On each consultation, the patients 
      filled-in a simplified self-assessment questionnaire on rhinitis and quality of 
      life (QOL). METHODS: Montelukast was administered during the inclusion visit. 
      Patients' general state of health was assessed, FEV1 and MMEF25-75 were measured 
      and the QOL and rhinitis scores and therapeutic impact were analysed at 3 and 6 
      months. RESULTS: Sixteen patients were included. FEV1 was initially recorded at 
      62% +/- 23 of theoretical values and then improved to 73% +/- 26.8 (p<0.002), and 
      77.2% +/- 17. Initial rhinitis score was 13 +/- 3.7 then 9 +/-5 (p<0.006) and 5.7 
      +/- 3.5 (p<0.03). Oral corticosteroids were required in 12 patients (8.5 +/- 5.6 
      mg). This dose was tapered to 3.4 +/- 6.4 mg (p<0.04) and 2.1 +/- 4.4 mg and 
      stopped in 8 patients. The initial QOL score was of 4.36 +/- 1.4 and improved to 
      5.87 +/- 1.06 (p<0.002), and to 5.90 +/- 1.12. DISCUSSION: Aspirin-induced asthma 
      is a challenging issue. Rhinitis is a major feature of discomfort. Following 
      montelukast administration, we noted an improvement in the QOL and rhinitis 
      subjective parameters, and an objective improvement in spirometrical measurements 
      and in the doses of oral corticosteroids. CONCLUSION: Early recognition of these 
      asthmatic patients is required in order to optimise their management. 
      Administration of montelukast could be envisaged as unofficial first-line therapy 
      in these patients combined with the recommended treatments.
FAU - Paganin, Fabrice
AU  - Paganin F
AD  - Unité de consultation, service de réanimation. CHD Félix Guyon, St Denis de la 
      Réunion (97). f.paganin@wanadoo.fr
FAU - Poubeau, Patrice
AU  - Poubeau P
FAU - Yvin, Jean-Luc
AU  - Yvin JL
FAU - Arvin-Berod, Claude
AU  - Arvin-Berod C
LA  - fre
PT  - Clinical Trial
PT  - Journal Article
TT  - Intérêt des anti-leucotriènes dans la prise en charge des asthmatiques 
      intolérants à l'aspirine.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Acetates)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclopropanes)
RN  - 0 (Leukotriene Antagonists)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - MHM278SD3E (montelukast)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates/*therapeutic use
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Asthma/diagnosis/*drug therapy
MH  - Bleeding Time
MH  - Cyclopropanes
MH  - Female
MH  - Humans
MH  - Leukotriene Antagonists/*therapeutic use
MH  - Male
MH  - Quality of Life
MH  - Quinolines/*therapeutic use
MH  - Rhinitis/diagnosis
MH  - Severity of Illness Index
MH  - Spirometry/methods
MH  - Sulfides
MH  - Surveys and Questionnaires
EDAT- 2003/07/24 05:00
MHDA- 2003/08/27 05:00
CRDT- 2003/07/24 05:00
PHST- 2003/07/24 05:00 [pubmed]
PHST- 2003/08/27 05:00 [medline]
PHST- 2003/07/24 05:00 [entrez]
AID - MDOI-PM-06-2003-32-21-0755-4982-101019-ART5 [pii]
PST - ppublish
SO  - Presse Med. 2003 Jun 14;32(21):978-84.

PMID- 24935675
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20220321
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 134
IP  - 2
DP  - 2014 Aug
TI  - Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke 
      prevention in patients with atrial fibrillation.
PG  - 278-87
LID - S0049-3848(14)00293-X [pii]
LID - 10.1016/j.thromres.2014.05.027 [doi]
AB  - INTRODUCTION: Atrial fibrillation (AF), one of the major risk factors for stroke, 
      imposing a substantial burden to the Swedish health care system. Apixaban has 
      demonstrated superiority to warfarin and aspirin in stroke prevention amongst 
      patients with AF in two large randomised clinical trials. The aim of this study 
      was to assess the economic implications of apixaban against warfarin and aspirin 
      in these patients from a Swedish societal perspective. MATERIALS AND METHODS: A 
      Markov cohort model was constructed to characterise the consequences of 
      anticoagulant treatment with regards to thromboembolic and bleeding events, as 
      well as the associated health care costs, life-years and quality-adjusted life 
      years (QALYs) for patients with AF treated with apixaban, warfarin or aspirin. 
      Incremental cost-effectiveness ratios (ICERs) per QALY gained of apixaban 
      relative to warfarin (among patients suitable for warfarin treatment) and aspirin 
      (among patients unsuitable for warfarin treatment) were calculated. Costs (in 
      2011 SEKs) and QALYs were discounted at 3% per annum. RESULTS: The model 
      estimated the ICER of apixaban versus warfarin amongst patients who are suitable 
      for warfarin therapy to be SEK 33,458/QALY gained and that of apixaban versus 
      aspirin amongst those unsuitable for warfarin therapy to be SEK 41,453/QALY 
      gained. Probabilistic sensitivity analyses indicate that apixaban is an optimal 
      treatment option compared with warfarin and aspirin, when the willingness-to-pay 
      is above SEK 35,000 and SEK 45,000 per QALY, respectively. CONCLUSIONS: Apixaban 
      was found to be a cost-effective alternative to warfarin and aspirin for stroke 
      prevention in patients with AF in Sweden.
CI  - Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Lanitis, Tereza
AU  - Lanitis T
AD  - Evidera, 1 Butterwick, London, W6 8DL, United Kingdom. Electronic address: 
      tereza.lanitis@evidera.com.
FAU - Kongnakorn, Thitima
AU  - Kongnakorn T
AD  - Evidera, 1 Butterwick, London, W6 8DL, United Kingdom. Electronic address: 
      thitima.kongnakorn@evidera.com.
FAU - Jacobson, Lena
AU  - Jacobson L
AD  - BMS, Hemvärnsgatan 9, SE-171 54 Solna, Sweden. Electronic address: 
      lena.jacobson@bms.com.
FAU - De Geer, Anna
AU  - De Geer A
AD  - Pfizer, Pfizer AB, Vetenskapsvägen 10, SE-191 90 Sollentuna. Electronic address: 
      anna.degeer@pfizer.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140526
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*economics/therapeutic use
MH  - Aspirin/*economics/therapeutic use
MH  - Atrial Fibrillation/*complications/economics/epidemiology
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pyrazoles/*economics/therapeutic use
MH  - Pyridones/*economics/therapeutic use
MH  - Stroke/economics/epidemiology/*prevention & control
MH  - Sweden/epidemiology
MH  - Warfarin/*economics/therapeutic use
OTO - NOTNLM
OT  - Apixaban
OT  - Aspirin
OT  - Atrial fibrillation
OT  - Cost-effectiveness
OT  - Warfarin
EDAT- 2014/06/18 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/06/18 06:00
PHST- 2014/04/07 00:00 [received]
PHST- 2014/05/09 00:00 [revised]
PHST- 2014/05/16 00:00 [accepted]
PHST- 2014/06/18 06:00 [entrez]
PHST- 2014/06/18 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - S0049-3848(14)00293-X [pii]
AID - 10.1016/j.thromres.2014.05.027 [doi]
PST - ppublish
SO  - Thromb Res. 2014 Aug;134(2):278-87. doi: 10.1016/j.thromres.2014.05.027. Epub 
      2014 May 26.

PMID- 34714341
OWN - NLM
STAT- MEDLINE
DCOM- 20220112
LR  - 20221031
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 4
IP  - 10
DP  - 2021 Oct 1
TI  - Use of a Smartphone App to Explore Potential Underuse of Prophylactic Aspirin for 
      Preeclampsia.
PG  - e2130804
LID - 10.1001/jamanetworkopen.2021.30804 [doi]
LID - e2130804
AB  - IMPORTANCE: Preeclampsia is a leading preventable cause of maternal morbidity and 
      mortality. Initiation of low-dose aspirin (LDASA) treatment at or before 16 
      weeks' gestation may prevent preeclampsia onset for patients with specific risk 
      factors. OBJECTIVE: To assess potential underuse of LDASA and reasons for 
      underuse using data from a prenatal care smartphone app. DESIGN, SETTING, AND 
      PARTICIPANTS: In this prospective cohort study, English-speaking pregnant 
      patients aged 18 years or older from the UPMC health care system received an 
      invitation to use the MyHealthyPregnancy app at their first prenatal appointment. 
      Use of the app was voluntary. The study took place between September 23, 2019, 
      and August 31, 2020, as part of a quality-improvement initiative. EXPOSURES: The 
      app offered educational information, monitoring tools, and routine screenings 
      tailored to patient-entered gestational age and demographic and clinical 
      characteristics. App-based questions included LDASA eligibility based on US 
      Preventive Services Task Force criteria for preeclampsia risk and a monthly 
      prompt about LDASA recommendations from the patient's health care practitioner. 
      MAIN OUTCOMES AND MEASURES: The primary outcomes were the receipt of LDASA 
      recommendations from a practitioner and adherence to any such recommendation, as 
      self-reported on the app. Patients' medical records were examined to 
      cross-reference their self-reports of an LDASA recommendation. Multivariable 
      logistic regression was used to model patient-perceived recommendation as a 
      function of factors associated with preeclampsia. RESULTS: The patient cohort 
      consisted of 2563 patient participants (2036 [79%] White; mean [SD] age, 30 [5.2] 
      years) with 2567 pregnancies; 1882 pregnancies (73.3%) were among women with 
      private or employer-based insurance, and 1246 (48.5%) were among nulliparous 
      patients. At least 1 factor associated with high risk for preeclampsia was 
      reported in 316 pregnancies (12.3%), and 2 or more factors associated with 
      moderate risk were reported in 1051 (40.9%). Of the 1015 pregnancies for which 
      patients answered voluntary questions about aspirin use, 124 (12.2%) met at least 
      1 criterion for highest risk of preeclampsia. In 57 (46.0%) of these pregnancies, 
      the patient indicated that their practitioner recommended LDASA; after 
      examination of the medical records, 90 pregnancies (72.6%) had evidence of an 
      LDASA recommendation and 34 (27.4%) did not. Of the 90 pregnancies with a 
      documented LDASA recommendation, 33 patients (36.7%) were unaware of it. Prior 
      preeclampsia (28 weeks' gestation: odds ratio, 20.1; 95% CI, 11.0-36.9) and 
      chronic hypertension (28 weeks' gestation: odds ratio, 17.4; 95% CI, 6.3-48.2) 
      were the primary high-risk factors associated with recommendation of LDASA. 
      CONCLUSIONS AND RELEVANCE: In this cohort study, only 46.0% of prenatal care app 
      users who met the criteria for highest preeclampsia risk reported receiving an 
      LDASA recommendation from their practitioner, and medical records suggested that 
      there may have been frequent miscommunication between patients and practitioners 
      about LDASA use. Digital tools such as the MyHealthyPregnancy app might offer an 
      opportunity to improve identification of patients at risk for preeclampsia and 
      communication with these patients about aspirin use.
FAU - Krishnamurti, Tamar
AU  - Krishnamurti T
AD  - Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, 
      Pennsylvania.
AD  - Center for Women's Health Research and Innovation, University of Pittsburgh, 
      Pittsburgh, Pennsylvania.
FAU - Davis, Alexander L
AU  - Davis AL
AD  - Department of Engineering and Public Policy, Carnegie Mellon University, 
      Pittsburgh, Pennsylvania.
FAU - Rodriguez, Samantha
AU  - Rodriguez S
AD  - Naima Health LLC, Pittsburgh, Pennsylvania.
FAU - Hayani, Laila
AU  - Hayani L
AD  - Naima Health LLC, Pittsburgh, Pennsylvania.
FAU - Bernard, Miriam
AU  - Bernard M
AD  - Center for Women's Health Research and Innovation, University of Pittsburgh, 
      Pittsburgh, Pennsylvania.
FAU - Simhan, Hyagriv N
AU  - Simhan HN
AD  - Department of OB-GYN and Reproductive Sciences, University of Pittsburgh, 
      Pittsburgh, Pennsylvania.
LA  - eng
GR  - R44 DP006417/DP/NCCDPHP CDC HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20211001
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA Netw Open. 2021 Oct 1;4(10):e2130960. PMID: 34714349
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - *Mobile Applications
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - *Smartphone
MH  - Young Adult
PMC - PMC8556626
COIS- Conflict of Interest Disclosures: Dr Krishnamurti reported being a cofounder of 
      Naima Health LLC, receiving personal fees from Naima Health LLC outside the work, 
      and having a patent pending in association with Naima Health LLC for a structured 
      medical data classification system for monitoring and remediating treatment 
      risks. Dr Davis reported being a cofounder of and receiving grants from Naima 
      Health LLC during the conduct of the study and having a patent pending in 
      association with Naima Health LLC for a structured medical data classification 
      system for monitoring and remediating treatment risks. Ms Rodriguez reported 
      being a salaried employee of Naima Health LLC during the conduct of the study. Ms 
      Hayani reported being a salaried employee of Naima Health LLC during the conduct 
      of the study. Dr Simhan reported being a cofounder of Naima Health LLC and having 
      a patent pending in association with Naima Health LLC for a structured medical 
      data classification system for monitoring and remediating treatment risks. No 
      other disclosures were reported.
EDAT- 2021/10/30 06:00
MHDA- 2022/01/13 06:00
CRDT- 2021/10/29 12:24
PHST- 2021/10/29 12:24 [entrez]
PHST- 2021/10/30 06:00 [pubmed]
PHST- 2022/01/13 06:00 [medline]
AID - 2785596 [pii]
AID - zoi210889 [pii]
AID - 10.1001/jamanetworkopen.2021.30804 [doi]
PST - epublish
SO  - JAMA Netw Open. 2021 Oct 1;4(10):e2130804. doi: 
      10.1001/jamanetworkopen.2021.30804.

PMID- 11694102
OWN - NLM
STAT- MEDLINE
DCOM- 20011228
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 135
IP  - 9
DP  - 2001 Nov 6
TI  - Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. 
      A cost-effectiveness analysis.
PG  - 769-81
AB  - BACKGROUND: Aspirin may decrease colorectal cancer incidence, but its role as an 
      adjunct to or substitute for screening has not been evaluated. OBJECTIVE: To 
      examine the potential cost-effectiveness of aspirin chemoprophylaxis in relation 
      to screening. DESIGN: Markov model. DATA SOURCES: Literature on colorectal cancer 
      epidemiology, screening, costs, and aspirin chemoprevention (1980-1999). TARGET 
      POPULATION: General U.S. population. TIME HORIZON: 50 to 80 years of age. 
      PERSPECTIVE: Third-party payer. INTERVENTION: Aspirin therapy in patients 
      screened with sigmoidoscopy every 5 years and fecal occult blood testing every 
      year (FS/FOBT) or colonoscopy every 10 years (COLO). OUTCOME MEASURES: Discounted 
      cost per life-year gained. RESULTS OF BASE-CASE ANALYSIS: When a 30% reduction in 
      colorectal cancer risk was assumed, aspirin increased costs and decreased 
      life-years because of related complications as an adjunct to FS/FOBT and cost 
      $149 161 per life-year gained as an adjunct to COLO. In patients already taking 
      aspirin, screening with FS/FOBT or COLO cost less than $31 000 per life-year 
      gained. RESULTS OF SENSITIVITY ANALYSIS: Cost-effectiveness estimates depended 
      highly on the magnitude of colorectal cancer risk reduction with aspirin, 
      aspirin-related complication rates, and the screening adherence rate in the 
      population. However, when the model's inputs were varied over wide ranges, 
      aspirin chemoprophylaxis remained generally non-cost-effective for patients who 
      adhere to screening. CONCLUSIONS: In patients undergoing colorectal cancer 
      screening, aspirin use should not be based on potential chemoprevention. Aspirin 
      chemoprophylaxis alone cannot be considered a substitute for colorectal cancer 
      screening. Public policy should focus on improving screening adherence, even in 
      patients who are already taking aspirin.
FAU - Ladabaum, U
AU  - Ladabaum U
AD  - Division of Gastroenterology, S-357 Box 0538, University of California, San 
      Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0538, USA.
FAU - Chopra, C L
AU  - Chopra CL
FAU - Huang, G
AU  - Huang G
FAU - Scheiman, J M
AU  - Scheiman JM
FAU - Chernew, M E
AU  - Chernew ME
FAU - Fendrick, A M
AU  - Fendrick AM
LA  - eng
GR  - M01-RR00042/RR/NCRR NIH HHS/United States
GR  - M01-RR00079/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/economics/*therapeutic use
MH  - Aspirin/economics/*therapeutic use
MH  - Colonoscopy/economics
MH  - Colorectal Neoplasms/epidemiology/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Decision Support Techniques
MH  - Humans
MH  - Markov Chains
MH  - Mass Screening/*economics
MH  - Occult Blood
MH  - Sensitivity and Specificity
MH  - Sigmoidoscopy/economics
EDAT- 2001/11/06 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/06 10:00
PHST- 2001/11/06 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/06 10:00 [entrez]
AID - 200111060-00007 [pii]
AID - 10.7326/0003-4819-135-9-200111060-00007 [doi]
PST - ppublish
SO  - Ann Intern Med. 2001 Nov 6;135(9):769-81. doi: 
      10.7326/0003-4819-135-9-200111060-00007.

PMID- 22071848
OWN - NLM
STAT- MEDLINE
DCOM- 20120511
LR  - 20220317
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 11
DP  - 2011 Nov 9
TI  - Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's 
      disease: evidence from observational studies.
PG  - CD008454
LID - 10.1002/14651858.CD008454.pub2 [doi]
AB  - BACKGROUND: Neuroinflammation may play a key role in the neurodegeneration 
      associated with Parkinson's disease (PD). Non-steroidal anti-inflammatory drugs 
      (NSAIDs) may be beneficial in the primary and secondary prevention of PD. 
      OBJECTIVES: 1) Do NSAIDs prevent the onset of PD?2) Are NSAIDs neuroprotective in 
      PD - do they slow the progression of disease once PD is established?3) What are 
      the adverse effects of taking NSAIDs in PD? SEARCH METHODS: We searched 
      electronic databases, including trial registers, complemented with handsearching 
      of conference proceedings and citation searching on key articles. All searching 
      was updated in May 2011. We contacted authors to provide additional information 
      where necessary. SELECTION CRITERIA: For the primary prevention review, we sought 
      primary prevention trials and observational studies (cohort and case-control 
      studies). Participants were free of PD when exposure to NSAIDs was assessed. For 
      the secondary prevention review, we sought clinical trials in patients with a 
      well-defined definition of PD. Two people independently selected studies for 
      inclusion using predetermined criteria. DATA COLLECTION AND ANALYSIS: Two review 
      authors abstracted data from the source papers and assessed methodological 
      quality independently. No studies met the inclusion criteria for the secondary 
      prevention review. For the primary prevention review only observational studies 
      were found. We combined data where appropriate using the inverse variance method. 
      We assessed methodological quality using the Newcastle Ottawa Scales and by 
      examining the period of exposure assessed prior to PD onset (or the index date in 
      controls). MAIN RESULTS: Fourteen observational studies met the inclusion 
      criteria for the primary prevention review (five cohort, nine case-control 
      studies). Exposure to any NSAIDs or aspirin had no effect on the risk of 
      developing PD. Exposure to non-aspirin NSAIDs reduced the risk of developing PD 
      by 13% (effect estimate 0.87 (95% CI 0.73 to 1.04 - random-effects model), but 
      this did not reach statistical significance. We found similar results for the 
      most robust studies. Ibuprofen in isolation was examined in four studies and was 
      associated with a 27% reduction in risk (effect estimate 0.73, 95% CI 0.63 to 
      0.85). There was a lack of information on adverse effects. AUTHORS' CONCLUSIONS: 
      There is currently no evidence for the use of NSAIDs in the secondary prevention 
      of PD. Non-aspirin NSAIDs, particularly ibuprofen, may reduce the risk of 
      developing PD. However, little is known of the effects of other individual drugs 
      and at present no recommendations can be made regarding their use in primary 
      prevention.
FAU - Rees, Karen
AU  - Rees K
AD  - Division of Health Sciences, Warwick Medical School, University of Warwick, 
      Coventry, UK. Karen.Rees@warwick.ac.uk
FAU - Stowe, Rebecca
AU  - Stowe R
FAU - Patel, Smitaa
AU  - Patel S
FAU - Ives, Natalie
AU  - Ives N
FAU - Breen, Kieran
AU  - Breen K
FAU - Clarke, Carl E
AU  - Clarke CE
FAU - Ben-Shlomo, Yoav
AU  - Ben-Shlomo Y
LA  - eng
GR  - G-0908/PUK_/Parkinson's UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20111109
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Neuroprotective Agents)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Neuroprotective Agents/*therapeutic use
MH  - Parkinson Disease/*prevention & control
MH  - Secondary Prevention/*methods
EDAT- 2011/11/11 06:00
MHDA- 2012/05/12 06:00
CRDT- 2011/11/11 06:00
PHST- 2011/11/11 06:00 [entrez]
PHST- 2011/11/11 06:00 [pubmed]
PHST- 2012/05/12 06:00 [medline]
AID - 10.1002/14651858.CD008454.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008454. doi: 
      10.1002/14651858.CD008454.pub2.

PMID- 35997730
OWN - NLM
STAT- MEDLINE
DCOM- 20220825
LR  - 20230306
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 328
IP  - 8
DP  - 2022 Aug 23
TI  - Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients 
      Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
PG  - 719-727
LID - 10.1001/jama.2022.13416 [doi]
AB  - IMPORTANCE: There remains a lack of randomized trials investigating aspirin 
      monotherapy for symptomatic venous thromboembolism (VTE) prophylaxis following 
      total hip arthroplasty (THA) or total knee arthroplasty (TKA). OBJECTIVE: To 
      determine whether aspirin was noninferior to enoxaparin in preventing symptomatic 
      VTE after THA or TKA. DESIGN, SETTING, AND PARTICIPANTS: Cluster-randomized, 
      crossover, registry-nested trial across 31 hospitals in Australia. Clusters were 
      hospitals performing greater than 250 THA or TKA procedures annually. Patients 
      (aged ≥18 years) undergoing hip or knee arthroplasty procedures were enrolled at 
      each hospital. Patients receiving preoperative anticoagulation or who had a 
      medical contraindication to either study drug were excluded. A total of 9711 
      eligible patients were enrolled (5675 in the aspirin group and 4036 in the 
      enoxaparin group) between April 20, 2019, and December 18, 2020. Final follow-up 
      occurred on August 14, 2021. INTERVENTIONS: Hospitals were randomized to 
      administer aspirin (100 mg/d) or enoxaparin (40 mg/d) for 35 days after THA and 
      for 14 days after TKA. Crossover occurred after the patient enrollment target had 
      been met for the first group. All 31 hospitals were initially randomized and 16 
      crossed over prior to trial cessation. MAIN OUTCOMES AND MEASURES: The primary 
      outcome was symptomatic VTE within 90 days, including pulmonary embolism and deep 
      venous thrombosis (DVT) (above or below the knee). The noninferiority margin was 
      1%. Six secondary outcomes are reported, including death and major bleeding 
      within 90 days. Analyses were performed by randomization group. RESULTS: 
      Enrollment was stopped after an interim analysis determined the stopping rule was 
      met, with 9711 patients (median age, 68 years; 56.8% female) of the prespecified 
      15 562 enrolled (62%). Of these, 9203 (95%) completed the trial. Within 90 days 
      of surgery, symptomatic VTE occurred in 256 patients, including pulmonary 
      embolism (79 cases), above-knee DVT (18 cases), and below-knee DVT (174 cases). 
      The symptomatic VTE rate in the aspirin group was 3.45% and in the enoxaparin 
      group was 1.82% (estimated difference, 1.97%; 95% CI, 0.54%-3.41%). This failed 
      to meet the criterion for noninferiority for aspirin and was significantly 
      superior for enoxaparin (P = .007). Of 6 secondary outcomes, none were 
      significantly better in the enoxaparin group compared with the aspirin group. 
      CONCLUSIONS AND RELEVANCE: Among patients undergoing hip or knee arthroplasty for 
      osteoarthritis, aspirin compared with enoxaparin resulted in a significantly 
      higher rate of symptomatic VTE within 90 days, defined as below- or above-knee 
      DVT or pulmonary embolism. These findings may be informed by a cost-effectiveness 
      analysis. TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12618001879257.
CN  - CRISTAL Study Group
FAU - Sidhu, Verinder S
AU  - Sidhu VS
AD  - School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, New 
      South Wales, Australia.
AD  - Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical 
      Research, Liverpool, New South Wales, Australia.
FAU - Kelly, Thu-Lan
AU  - Kelly TL
AD  - Clinical and Health Sciences, Quality Use of Medicines Pharmacy Research Centre, 
      University of South Australia, Adelaide, South Australia, Australia.
FAU - Pratt, Nicole
AU  - Pratt N
AD  - Clinical and Health Sciences, Quality Use of Medicines Pharmacy Research Centre, 
      University of South Australia, Adelaide, South Australia, Australia.
FAU - Graves, Stephen E
AU  - Graves SE
AD  - Australian Orthopaedic Association National Joint Replacement Registry, Adelaide, 
      South Australia, Australia.
FAU - Buchbinder, Rachelle
AU  - Buchbinder R
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
AD  - Monash-Cabrini Department of Musculoskeletal Health and Clinical Epidemiology, 
      Cabrini Health, Melbourne, Victoria, Australia.
FAU - Adie, Sam
AU  - Adie S
AD  - School of Clinical Medicine, UNSW Medicine and Health, St George and Sutherland 
      Clinical Campuses, Faculty of Medicine and Health, UNSW Sydney, New South Wales, 
      Australia.
FAU - Cashman, Kara
AU  - Cashman K
AD  - South Australian Health and Medical Research Institute, Adelaide, South 
      Australia, Australia.
FAU - Ackerman, Ilana
AU  - Ackerman I
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
AD  - Monash-Cabrini Department of Musculoskeletal Health and Clinical Epidemiology, 
      Cabrini Health, Melbourne, Victoria, Australia.
FAU - Bastiras, Durga
AU  - Bastiras D
AD  - Australian Orthopaedic Association National Joint Replacement Registry, Adelaide, 
      South Australia, Australia.
FAU - Brighton, Roger
AU  - Brighton R
AD  - Orthopaedic Department, Westmead Private Hospital, Westmead, Sydney, New South 
      Wales, Australia.
AD  - Orthopaedic Department, Lakeview Private Hospital, Baulkham Hills, Sydney, New 
      South Wales, Australia.
FAU - Burns, Alexander W R
AU  - Burns AWR
AD  - Orthopaedic Department, Calvary John James Hospital, Deakin, Canberra, Australian 
      Capital Territory, Australia.
FAU - Chong, Beng Hock
AU  - Chong BH
AD  - Department of Medicine, Faculty of Medicine, University of New South Wales, 
      Sydney, New South Wales, Australia.
AD  - Department of Hematology, New South Wales Pathology, Kogarah Campus, Sydney, New 
      South Wales, Australia.
FAU - Clavisi, Ornella
AU  - Clavisi O
AD  - Musculoskeletal Australia, Melbourne, Victoria, Australia.
FAU - Cripps, Maggie
AU  - Cripps M
AD  - School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, New 
      South Wales, Australia.
AD  - Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical 
      Research, Liverpool, New South Wales, Australia.
FAU - Dekkers, Mark
AU  - Dekkers M
AD  - Orthopaedic Department, Greenslopes Private Hospital, Greenslopes, Brisbane, 
      Queensland, Australia.
FAU - de Steiger, Richard
AU  - de Steiger R
AD  - Department of Surgery, Epworth Healthcare, University of Melbourne, Melbourne, 
      Victoria, Australia.
FAU - Dixon, Michael
AU  - Dixon M
AD  - Orthopaedic Department, Kareena Private Hospital, Sutherland, Sydney, New South 
      Wales, Australia.
FAU - Ellis, Andrew
AU  - Ellis A
AD  - Orthopaedic Department, Royal North Shore Hospital, St Leonard's, Sydney, New 
      South Wales, Australia.
AD  - Sydney Musculoskeletal Health Flagship Centre of the University of Sydney and 
      Royal North Shore Hospital, St Leonard's, Sydney, New South Wales, Australia.
FAU - Griffith, Elizabeth C
AU  - Griffith EC
AD  - South Australian Health and Medical Research Institute, Adelaide, South 
      Australia, Australia.
FAU - Hale, David
AU  - Hale D
AD  - Orthopaedic Department, Hornsby and Kuringai Hospital, Hornsby, Sydney, New South 
      Wales, Australia.
FAU - Hansen, Amber
AU  - Hansen A
AD  - School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, New 
      South Wales, Australia.
AD  - Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical 
      Research, Liverpool, New South Wales, Australia.
FAU - Harris, Anthony
AU  - Harris A
AD  - Centre for Health Economics, Monash Business School, Monash University, 
      Melbourne, Victoria, Australia.
FAU - Hau, Raphael
AU  - Hau R
AD  - Department of Surgery, Epworth Healthcare, University of Melbourne, Melbourne, 
      Victoria, Australia.
AD  - Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia.
FAU - Horsley, Mark
AU  - Horsley M
AD  - Orthopaedic Department, Royal Prince Alfred Hospital, Camperdown, Sydney, New 
      South Wales, Australia.
FAU - James, Dugal
AU  - James D
AD  - Bendigo Healthcare Group, Bendigo Hospital, Bendigo, Victoria, Australia.
FAU - Khorshid, Omar
AU  - Khorshid O
AD  - Orthopaedic Department, Fremantle Hospital, Fremantle, Western Australia, 
      Australia.
FAU - Kuo, Leonard
AU  - Kuo L
AD  - Orthopaedic Department, Canterbury Hospital, Canterbury, Sydney, New South Wales, 
      Australia.
FAU - Lewis, Peter
AU  - Lewis P
AD  - Orthopaedic Department, Calvary Hospital, Adelaide, South Australia, Australia.
FAU - Lieu, David
AU  - Lieu D
AD  - Orthopaedic Department, Fairfield Hospital, Fairfield, Sydney, New South Wales, 
      Australia.
FAU - Lorimer, Michelle
AU  - Lorimer M
AD  - South Australian Health and Medical Research Institute, Adelaide, South 
      Australia, Australia.
FAU - MacDessi, Samuel
AU  - MacDessi S
AD  - School of Clinical Medicine, UNSW Medicine and Health, St George and Sutherland 
      Clinical Campuses, Faculty of Medicine and Health, UNSW Sydney, New South Wales, 
      Australia.
AD  - Orthopaedic Department, St George Private Hospital, Kogarah, Sydney, New South 
      Wales, Australia.
FAU - McCombe, Peter
AU  - McCombe P
AD  - Orthopaedic Department, Frankston Hospital, Frankston, Melbourne, Victoria, 
      Australia.
FAU - McDougall, Catherine
AU  - McDougall C
AD  - Orthopaedic Department, The Prince Charles Hospital, Chermside, Brisbane, 
      Queensland, Australia.
FAU - Mulford, Jonathan
AU  - Mulford J
AD  - Orthopaedic Department, Launceston General Hospital, Launceston, Tasmania, 
      Australia.
FAU - Naylor, Justine Maree
AU  - Naylor JM
AD  - School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, New 
      South Wales, Australia.
AD  - Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical 
      Research, Liverpool, New South Wales, Australia.
FAU - Page, Richard S
AU  - Page RS
AD  - School of Medicine, St John of God Hospital and Barwon Health, Deakin University, 
      Geelong, Victoria, Australia.
FAU - Radovanovic, John
AU  - Radovanovic J
AD  - Orthopaedic Department, Mater Hospital, Raymond Terrace, Brisbane, Queensland, 
      Australia.
FAU - Solomon, Michael
AU  - Solomon M
AD  - Orthopaedic Department, Prince of Wales Hospital, Randwick, Sydney, New South 
      Wales, Australia.
FAU - Sorial, Rami
AU  - Sorial R
AD  - Orthopaedic Department, Nepean Hospital, Nepean, Sydney, New South Wales, 
      Australia.
FAU - Summersell, Peter
AU  - Summersell P
AD  - Orthopaedic Department, Coffs Harbour Base Hospital, Coffs Harbour, New South 
      Wales, Australia.
FAU - Tran, Phong
AU  - Tran P
AD  - Orthopaedic Department, Western Health, Melbourne, Victoria, Australia.
FAU - Walter, William L
AU  - Walter WL
AD  - Orthopaedic Department, Royal North Shore Hospital, St Leonard's, Sydney, New 
      South Wales, Australia.
AD  - Sydney Musculoskeletal Health Flagship Centre of the University of Sydney and 
      Royal North Shore Hospital, St Leonard's, Sydney, New South Wales, Australia.
AD  - The Kolling Institute, Faculty of Medicine and Health, The University of Sydney 
      and the Northern Sydney Local Health District, Sydney, New South Wales, 
      Australia.
FAU - Webb, Steve
AU  - Webb S
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Wilson, Chris
AU  - Wilson C
AD  - Orthopaedic Department, Flinders Medical Centre, Bedford Park, Adelaide, South 
      Australia, Australia.
AD  - Department of Medicine and Public Health, Flinders University, Adelaide, South 
      Australia, Australia.
FAU - Wysocki, David
AU  - Wysocki D
AD  - Orthopaedic Department, Sir Charles Gardiner Hospital, Perth, Western Australia, 
      Australia.
FAU - Harris, Ian A
AU  - Harris IA
AD  - School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, New 
      South Wales, Australia.
AD  - Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical 
      Research, Liverpool, New South Wales, Australia.
AD  - Institute of Musculoskeletal Health, School of Public Health, The University of 
      Sydney, Sydney, New South Wales, Australia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2022 Aug 23;328(8):712-713. PMID: 35997752
CIN - J Vasc Nurs. 2022 Sep;40(3):155-156. PMID: 36414372
CIN - Ann Intern Med. 2022 Dec;175(12):JC141. PMID: 36469926
CIN - J Bone Joint Surg Am. 2022 Dec 7;104(23):2045-2046. PMID: 36476736
CIN - JAMA. 2023 Jan 10;329(2):176-177. PMID: 36625814
CIN - JAMA. 2023 Jan 10;329(2):176. PMID: 36625815
CIN - JAMA. 2023 Jan 10;329(2):177. PMID: 36625816
MH  - Aged
MH  - *Anticoagulants/adverse effects/therapeutic use
MH  - *Arthroplasty, Replacement, Hip/adverse effects
MH  - *Arthroplasty, Replacement, Knee/adverse effects
MH  - *Aspirin/adverse effects/therapeutic use
MH  - Australia
MH  - Chemoprevention
MH  - *Enoxaparin/adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Osteoarthritis/surgery
MH  - Postoperative Complications/prevention & control
MH  - Pulmonary Embolism/etiology/prevention & control
MH  - *Venous Thromboembolism/etiology/prevention & control
PMC - PMC9399863
COIS- Conflict of Interest Disclosures: Drs de Steiger and Lewis reported being deputy 
      directors of the AOANJRR, under whose registry nested clinical trials platform 
      this study was performed. Dr McDougall reported consulting for Johnson & Johnson 
      in the field of orthopedic instruments and giving paid teaching presentations for 
      Stryker on total knee replacement. Dr Page reported receipt of institutional 
      education and research support from DePuy Synthes. Dr Walter reported receipt of 
      research support grants and personal consulting fees from DePuy Synthes, receipt 
      of royalties from and holding shares in MatOrtho, holding shares in Navbit, 
      receipt of personal consulting fees from Smith + Nephew, receipt of personal 
      consulting fees from MicroPort, and receipt of research support from Think 
      Surgical; in addition, Dr Walter had a patent issued with Navbit not related to 
      anticoagulation. Dr Wilson reported receipt of personal fees from DePuy 
      Australia. No other disclosures were reported.
EDAT- 2022/08/24 06:00
MHDA- 2022/08/26 06:00
CRDT- 2022/08/23 11:03
PHST- 2022/08/23 11:03 [entrez]
PHST- 2022/08/24 06:00 [pubmed]
PHST- 2022/08/26 06:00 [medline]
AID - 2795528 [pii]
AID - joi220087 [pii]
AID - 10.1001/jama.2022.13416 [doi]
PST - ppublish
SO  - JAMA. 2022 Aug 23;328(8):719-727. doi: 10.1001/jama.2022.13416.

PMID- 8736048
OWN - NLM
STAT- MEDLINE
DCOM- 19961112
LR  - 20180216
IS  - 0301-1569 (Print)
IS  - 0301-1569 (Linking)
VI  - 58
IP  - 2
DP  - 1996 Mar-Apr
TI  - Effect of aspirin on transiently evoked otoacoustic emissions in guinea pigs.
PG  - 61-7
AB  - Aspirin and other salicylates influence otoacoustic emissions (OAEs), but changes 
      in transiently evoked OAEs (TEOAEs) following aspirin intake have not been 
      studied experimentally. We examined the changes in TEOAEs, together with auditory 
      brainstem responses (ABRs), in guinea pigs before and after the intravenous 
      injection of aspirin (100 and 400 mg/kg). TEOAE power decreased slowly after the 
      injection in a dose-dependent manner. Mean minimal values were detected 20 min 
      after the injection of 100 mg/kg, and 40 min after the injection of 400 mg/kg. 
      TEOAE power recovered slowly. These changes were paralleled by shifts in ABR 
      thresholds. The magnitude of the decrease in the frequency components in the 
      TEOAE frequency power spectrum was similar. In one guinea pig, TEOAE power 
      returned to the pretreatment level 7 h after the injection. Findings support the 
      results of in vitro studies that salicylates affect electromotility in isolated 
      outer hair cells from guinea pig cochlea.
FAU - Ueda, H
AU  - Ueda H
AD  - Department of Otorhinolaryngology, Nagoya University, School of Medicine, Japan.
FAU - Yamamoto, Y
AU  - Yamamoto Y
FAU - Yanagita, N
AU  - Yanagita N
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - ORL J Otorhinolaryngol Relat Spec
JT  - ORL; journal for oto-rhino-laryngology and its related specialties
JID - 0334721
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Brain Stem/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Evoked Potentials, Auditory, Brain Stem/drug effects
MH  - Guinea Pigs
MH  - Hair Cells, Auditory, Outer/drug effects
MH  - Injections, Intravenous
MH  - Otoacoustic Emissions, Spontaneous/*drug effects
MH  - Reference Values
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
AID - 10.1159/000276800 [doi]
PST - ppublish
SO  - ORL J Otorhinolaryngol Relat Spec. 1996 Mar-Apr;58(2):61-7. doi: 
      10.1159/000276800.

PMID- 2007377
OWN - NLM
STAT- MEDLINE
DCOM- 19910502
LR  - 20131121
IS  - 0012-0472 (Print)
IS  - 0012-0472 (Linking)
VI  - 116
IP  - 13
DP  - 1991 Mar 29
TI  - [Effects of high and low doses of acetylsalicylic acid on the restenosis rate 
      after initially successful coronary angioplasty].
PG  - 481-5
AB  - A comparison was made in 79 patients (63 men, 16 women: mean age 52 +/- 9 years) 
      of the effect of high and low doses of aspirin on restenosis rate during the 
      first six months after originally successful percutaneous transluminal coronary 
      angioplasty (PTCA), 39 patients (group 1) received 1000 mg aspirin daily, while 
      40 (group 2) received 100 mg daily. All patients took 1000 mg aspirin as loading 
      dose on the day before PTCA, and additionally calcium antagonists and 
      slow-release nitrates in the post-PTCA period. Both groups were comparable with 
      respect of localization of the dilated coronary artery stenosis and the 
      morphological changes after dilatation. Intimal lesions after PTCA were 
      demonstrated in 9 patients of group 1 and 10 of group 2. Within six months 
      clinically significant restenosis had occurred in 8 patients of group 1 and 7 of 
      group 2. 33 patients in group 2 and 31 in group 1 were free of symptoms and had 
      no ischaemic reaction on the exercise ECG six months after the initial successful 
      PTCA. These results demonstrate that high aspirin dosage does not reduce the 
      restenosis rate more than low dosage.
FAU - Schanzenbächer, P
AU  - Schanzenbächer P
AD  - Medizinische Klinik, Universität Würzburg.
FAU - Grimme, M
AU  - Grimme M
FAU - Walter, U
AU  - Walter U
FAU - Kochsiek, K
AU  - Kochsiek K
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Wirkung hoher und niedriger Dosen Acetylsalicylsäure auf die Re-Stenosierungsrate 
      nach primär erfolgreicher koronarer Angioplastie.
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/*administration & dosage
MH  - Coronary Disease/drug therapy/*prevention & control/therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Retrospective Studies
MH  - Time Factors
EDAT- 1991/03/29 00:00
MHDA- 1991/03/29 00:01
CRDT- 1991/03/29 00:00
PHST- 1991/03/29 00:00 [pubmed]
PHST- 1991/03/29 00:01 [medline]
PHST- 1991/03/29 00:00 [entrez]
AID - 10.1055/s-2008-1063636 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 1991 Mar 29;116(13):481-5. doi: 10.1055/s-2008-1063636.

PMID- 7076022
OWN - NLM
STAT- MEDLINE
DCOM- 19820722
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 23
IP  - 6
DP  - 1982 Jun
TI  - Effect of drugs on the pulmonary changes in experimental acute pancreatitis in 
      the rat.
PG  - 481-4
AB  - Respiratory complications of acute pancreatitis are well recognised and are 
      closely related to a poor prognosis. Using an experimental model in the rat, a 
      decrease in lung compliance and an increase in lung weight were produced in acute 
      pancreatitis. The effects of dexamethasone, heparin, and aspirin on these changes 
      were studied. The mean specific lung compliance was reduced by 16% in the 
      pancreatitis group compared with the control group (p less than 0.05) and this 
      change was abolished by dexamethasone (p less than 0.02), heparin (p less than 
      0.01), and aspirin (p less than 0.001). Percentage lung weight (as percentage of 
      total body weight) was raised by 22% in the pancreatitis group compared with the 
      sham operation group (p less than 0.01) and this change was abolished by heparin 
      (p less than 0.01) and aspirin (p less than 0.05), but not affected by 
      dexamethasone (p less than 0.5). The results indicate that 'stiff' and heavy 
      lungs occur in experimental acute pancreatitis. The fact that these changes are 
      abolished by heparin and improved by aspirin suggests that intrapulmonary fibrin 
      deposition is a factor in the pathogenesis of the important respiratory 
      complications of this condition.
FAU - Berry, A R
AU  - Berry AR
FAU - Taylor, T V
AU  - Taylor TV
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Dexamethasone/*therapeutic use
MH  - Heparin/*therapeutic use
MH  - Lung/*drug effects
MH  - Lung Compliance/drug effects
MH  - Organ Size/drug effects
MH  - Pancreatitis/*drug therapy/physiopathology
MH  - Rats
MH  - Rats, Inbred Strains
PMC - PMC1419705
EDAT- 1982/06/01 00:00
MHDA- 1982/06/01 00:01
CRDT- 1982/06/01 00:00
PHST- 1982/06/01 00:00 [pubmed]
PHST- 1982/06/01 00:01 [medline]
PHST- 1982/06/01 00:00 [entrez]
AID - 10.1136/gut.23.6.481 [doi]
PST - ppublish
SO  - Gut. 1982 Jun;23(6):481-4. doi: 10.1136/gut.23.6.481.

PMID- 33160093
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 2213-2201 (Electronic)
VI  - 9
IP  - 4
DP  - 2021 Apr
TI  - Effect of LTRA in L-ASA Challenge for Aspirin-Exacerbated Respiratory Disease 
      Diagnosis.
PG  - 1554-1561
LID - S2213-2198(20)31195-8 [pii]
LID - 10.1016/j.jaip.2020.10.041 [doi]
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) consists of asthma, 
      chronic rhinosinusitis with polyps, and hypersensitivity to aspirin and/or 
      nonsteroidal anti-inflammatory drugs (NSAIDs). Nasal Lysine Aspirin Challenge is 
      an effective tool for the diagnosis of hypersensitivity to aspirin and/or NSAIDs 
      in patients with AERD. However, there is no unified international consensus 
      version to perform nasal provocation tests (NPTs). OBJECTIVE: To investigate the 
      effect of a leukotriene receptor antagonist (LTRA), montelukast, on the 
      lysine-acetylsalicylate (L-ASA) nasal challenge. METHODS: We included 86 patients 
      divided into 3 samples: group A (AERD without LTRA), group B (AERD with LTRA), 
      and the control group (NSAID-tolerant asthmatics). NPT with L-ASA was performed 
      with 25 mg of L-ASA every 30 minutes 4 times followed by rhinomanometry and 
      spirometric measurements and evaluation of symptoms using a novel clinical scale. 
      RESULTS: In group A, 94.5% of patients (35 of 37) developed a positive response 
      to NPT (drop >40% in total nasal flow), whereas only 46% of group B subjects (13 
      of 28) showed a positive response to the nasal challenge (P < .001). Control 
      subjects did not show any response to the L-ASA challenge. A novel clinical score 
      demonstrated accuracy in classifying the hypersensitivity to aspirin and/or 
      NSAIDs when patients avoid LTRA (33 of 37). CONCLUSION: Patients with AERD 
      without LTRA showed a greater positive response to the L-ASA challenge than those 
      taking this drug; therefore, LTRA treatment should be discontinued before the 
      challenge for optimal diagnostic accuracy.
CI  - Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Ramírez-Jiménez, Fernando
AU  - Ramírez-Jiménez F
AD  - Immunogenetics and Allergy Department, Instituto Nacional de Enfermedades 
      Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico.
FAU - Vázquez-Corona, Andrea
AU  - Vázquez-Corona A
AD  - Immunogenetics and Allergy Department, Instituto Nacional de Enfermedades 
      Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico.
FAU - Sánchez-de la Vega Reynoso, Paulina
AU  - Sánchez-de la Vega Reynoso P
AD  - Allergy and Clinical Immunology Department, Hospital General Regional No. 58 
      IMSS, Tlalnepantla de Baz, Mexico.
FAU - Pavón-Romero, Gandhi F
AU  - Pavón-Romero GF
AD  - Immunogenetics and Allergy Department, Instituto Nacional de Enfermedades 
      Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico.
FAU - Jiménez-Chobillon, Marco Alejandro
AU  - Jiménez-Chobillon MA
AD  - Otorhinolaryngology Department, Instituto Nacional de Enfermedades Respiratorias 
      Ismael Cosio Villegas (INER), Mexico City, Mexico.
FAU - Castorena-Maldonado, Armando Roberto
AU  - Castorena-Maldonado AR
AD  - Otorhinolaryngology Department, Instituto Nacional de Enfermedades Respiratorias 
      Ismael Cosio Villegas (INER), Mexico City, Mexico.
FAU - Teran, Luis M
AU  - Teran LM
AD  - Immunogenetics and Allergy Department, Instituto Nacional de Enfermedades 
      Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico. Electronic 
      address: teranjlm@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201104
PL  - United States
TA  - J Allergy Clin Immunol Pract
JT  - The journal of allergy and clinical immunology. In practice
JID - 101597220
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Leukotriene Antagonists)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/adverse effects
MH  - *Asthma, Aspirin-Induced/diagnosis
MH  - Humans
MH  - Leukotriene Antagonists
MH  - Lysine
MH  - *Nasal Polyps/diagnosis
MH  - Nasal Provocation Tests
OTO - NOTNLM
OT  - AERD
OT  - Aspirin hypersensitivity
OT  - Clinical score
OT  - L-ASA
OT  - LTRA
OT  - Montelukast
OT  - NSAIDs
OT  - Nasal challenge
OT  - Rhinomanometry
OT  - Spirometry
EDAT- 2020/11/08 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/11/07 20:10
PHST- 2019/12/31 00:00 [received]
PHST- 2020/10/01 00:00 [revised]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/11/07 20:10 [entrez]
AID - S2213-2198(20)31195-8 [pii]
AID - 10.1016/j.jaip.2020.10.041 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol Pract. 2021 Apr;9(4):1554-1561. doi: 
      10.1016/j.jaip.2020.10.041. Epub 2020 Nov 4.

PMID- 32289133
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20200825
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Print)
IS  - 0094-3509 (Linking)
VI  - 69
IP  - 3
DP  - 2020 Apr
TI  - PURL: Aspirin, Yes, for at-risk elderly-but what about the healthy elderly?
PG  - E16-E18
AB  - This study paints a decidedly different picture as to what role-if any-aspirin 
      can play in the primary prevention of CVD for older adults.
FAU - Piggott, Cleveland
AU  - Piggott C
AD  - University of Colorado Family Medicine Residency, Denver, USA.
FAU - Lyon, Corey
AU  - Lyon C
AD  - University of Colorado Family Medicine Residency, Denver, USA.
LA  - eng
GR  - UL1 RR024999/RR/NCRR NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CON - N Engl J Med. 2018 Oct 18;379(16):1509-1518. PMID: 30221597
MH  - Aged
MH  - *Aspirin
MH  - *Cardiovascular Diseases
MH  - Health Status
MH  - Hemorrhage
MH  - Humans
MH  - Primary Prevention
PMC - PMC7179654
EDAT- 2020/04/15 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
AID - jfp_6903j [pii]
PST - ppublish
SO  - J Fam Pract. 2020 Apr;69(3):E16-E18.

PMID- 30277840
OWN - NLM
STAT- MEDLINE
DCOM- 20190705
LR  - 20190705
IS  - 1931-8448 (Electronic)
IS  - 1076-6294 (Linking)
VI  - 25
IP  - 2
DP  - 2019 Mar
TI  - Efflux Pump Inhibitors, Alpha-Tocopherol and Aspirin: Role in Campylobacter 
      jejuni and Campylobacter coli Fluoroquinolone Resistance.
PG  - 203-211
LID - 10.1089/mdr.2018.0086 [doi]
AB  - This study aimed to investigate how efflux pump activity contributes to high 
      fluoroquinolone (FQ) resistance in Campylobacter jejuni and Campylobacter coli 
      isolates and to evaluate the modulatory effects of α-tocopherol and aspirin on FQ 
      phenotypic resistance profiles. Minimum inhibitory concentration (MIC) values 
      were obtained for different FQ agents following exposure to different efflux pump 
      inhibitors (EPIs), including PaβN (50 μg/mL), which targets the cmeABC efflux 
      system, and chlorpromazine (45 μg/mL) and verapamil (120 μg/mL), which target the 
      MFS efflux system. The modulatory effects of aspirin (100 and 200 μg/mL) and 
      α-tocopherol (4 and 10 μg/mL) on FQ resistance profiles were examined. PaβN had 
      no effect on the MIC values of all FQ agents, while MFS efflux system inhibitors 
      reduced the resistance level of different FQ agents and achieved an effect nearly 
      comparable with that of α-tocopherol (10 μg/mL). Aspirin exerted a dose-dependent 
      excitatory effect on phenotypic resistance profiles, and this may raise concerns 
      about its usage in both veterinary and clinical settings. While an efflux system 
      other than cmeABC may play a role in FQ resistance in Campylobacter species, 
      lipophilic substances may represent a new approach for controlling efflux pump 
      activities.
FAU - Abd El-Tawab, Ashraf A
AU  - Abd El-Tawab AA
AD  - 1 Bacteriology, Immunology and Mycology Department, Faculty of Veterinary 
      Medicine, Benha University , Benha, Egypt .
FAU - Ammar, Ahmed M
AU  - Ammar AM
AD  - 2 Department of Microbiology and Faculty of Veterinary Medicine, Zagazig 
      University , Zagazig, Egypt .
FAU - Ahmed, Heba A
AU  - Ahmed HA
AD  - 3 Department of Zoonoses, Faculty of Veterinary Medicine, Zagazig University , 
      Zagazig, Egypt .
FAU - Hefny, Ahmed A
AU  - Hefny AA
AD  - 4 Veterinary Hospital, Faculty of Veterinary Medicine, Zagazig University, 
      Zagazig, Egypt .
LA  - eng
PT  - Journal Article
DEP - 20181002
PL  - United States
TA  - Microb Drug Resist
JT  - Microbial drug resistance (Larchmont, N.Y.)
JID - 9508567
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Carrier Proteins)
RN  - 0 (Fluoroquinolones)
RN  - H4N855PNZ1 (alpha-Tocopherol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Campylobacter coli/*drug effects
MH  - Campylobacter jejuni/*drug effects
MH  - Carrier Proteins/*antagonists & inhibitors
MH  - Chickens
MH  - Drug Resistance, Bacterial/*drug effects
MH  - Fluoroquinolones/*pharmacology
MH  - Microbial Sensitivity Tests
MH  - alpha-Tocopherol/*pharmacology
OTO - NOTNLM
OT  - FQ resistance
OT  - aspirin
OT  - efflux pump inhibitors
OT  - α-tocopherol
EDAT- 2018/10/03 06:00
MHDA- 2019/07/06 06:00
CRDT- 2018/10/03 06:00
PHST- 2018/10/03 06:00 [pubmed]
PHST- 2019/07/06 06:00 [medline]
PHST- 2018/10/03 06:00 [entrez]
AID - 10.1089/mdr.2018.0086 [doi]
PST - ppublish
SO  - Microb Drug Resist. 2019 Mar;25(2):203-211. doi: 10.1089/mdr.2018.0086. Epub 2018 
      Oct 2.

PMID- 7450436
OWN - NLM
STAT- MEDLINE
DCOM- 19810324
LR  - 20131121
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 80
IP  - 3
DP  - 1981 Mar
TI  - Analgesic ingestion and chronic peptic ulcer.
PG  - 427-32
AB  - The patterns of analgesic ingestion in gastric and duodenal ulcer patients were 
      compared with those of matched community controls in order to ascertain 
      differences that may exist between ulcer and nonulcer subjects of comparable age 
      and sex. The differences sought concerned amounts and types of analgesics 
      ingested. The types of analgesics studied were aspirin and acetaminophen, 
      ingested either alone or together. Analgesics such as dextropropoxyphene and 
      codeine were disregarded. It was found that there was a strong positive 
      association between heavy analgesic intake and chronic gastric ulcer with a 
      relative risk of 29.5. The association was most marked in female patients 
      (relative risk = 51.8). The involvement of aspirin-containing and 
      acetaminophen-containing drugs was of similar significance with relative risk of 
      17.3 and 24.4, respectively. Aspirin alone was the least frequently ingested. The 
      association was only partly related to painful nonulcer health problems and to 
      ulcer pain. No association was found between chronic duodenal ulcer and analgesic 
      intake. The strong association found between gastric ulcer and heavy analgesic 
      intake does not, per se, necessarily indicate a causal relationship.
FAU - Piper, D W
AU  - Piper DW
FAU - McIntosh, J H
AU  - McIntosh JH
FAU - Ariotti, D E
AU  - Ariotti DE
FAU - Fenton, B H
AU  - Fenton BH
FAU - MacLennan, R
AU  - MacLennan R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Analgesics)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Analgesics/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Australia
MH  - Duodenal Ulcer/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Peptic Ulcer/*epidemiology
MH  - Risk
MH  - Stomach Ulcer/epidemiology
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
AID - S0016508581000589 [pii]
PST - ppublish
SO  - Gastroenterology. 1981 Mar;80(3):427-32.

PMID- 16776915
OWN - NLM
STAT- MEDLINE
DCOM- 20090707
LR  - 20131121
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 34
IP  - 4
DP  - 2006 Apr
TI  - [The randomized study of efficiency and safety of antithrombotic therapy in 
      nonvalvular atrial fibrillation: warfarin compared with aspirin].
PG  - 295-8
AB  - OBJECTIVE: To investigate whether warfarin is more effective and superior to 
      aspirin for the prevention of thromboembolism in nonvalvular atrial fibrillation 
      in Chinese. METHODS: In a multicenter randomized trial, the patients diagnosed as 
      nonvalvular atrial fibrillation were randomized to receive aspirin 150 mg - 160 
      mg once daily or adjusted-dose warfarin (international normalized ratio, 2.0 - 
      3.0). We compared the effect of the two therapy on the primary end point of 
      ischemic stroke or death from any cause and on the combined end-point (stroke, 
      death, peripheral arteries embolism, TIA, acute myocardial infarction, serious 
      bleeding) during a median follow-up period of 19 months. RESULTS: Of the 704 
      patients, 420 (59.7%) were male. The average patient age was (63.3 +/- 9.9) 
      years. The median follow-up period is 19 months. The mean dose of warfarin was 
      (3.2 +/- 0.7) mg. Compared with aspirin, the primary end point of death or 
      ischemic stroke was reduced by warfarin (2.7% vs 6.0%, P = 0.03, OR 0.44, 95% CI 
      0.198 - 0.960) and the relative risk decreased by 56%. The thromboembolism event 
      in the aspirin group was significantly higher than that in warfarin group (10.6% 
      vs 5.4%, P = 0.01, OR 0.48, 95% CI 0.269 - 0.858). There was no significant 
      differences of the mortality rate between the two groups (1.2% vs 2.2%, P > 
      0.05). The secondary end point was nonsignificantly reduced in warfarin group 
      than that in aspirin group, while the combined end point is statistically 
      decreased by adjusted-dose warfarin (8.4% vs 13.0%, P = 0.047). Warfarin 
      treatment was associated with increased bleeding rate compared to aspirin (6.9% 
      vs 2.4%, P < 0.05), although the major bleeding rate is rather low (1.5%). All 
      the major bleeding events occurred with INR above 3.0. CONCLUSIONS: Randomized 
      control study demonstrated that anticoagulation with adjusted-dosed warfarin (INR 
      2.0 - 3.0) can significantly reduced the risk of thromboembolism event with 
      slightly increased hemorrhage, compared to aspirin in Chinese population. Under 
      intensive monitoring, warfarin is effective and safe for the moderate to high 
      risk atrial fibrillation patients.
FAU - Hu, Da-yi
AU  - Hu DY
AD  - Department of Cardiology, People's Hospital, Peking University, Beijing 100044, 
      China. dayi.hu@medmail.com.cn
FAU - Zhang, He-ping
AU  - Zhang HP
FAU - Sun, Yi-hong
AU  - Sun YH
FAU - Jiang, Li-qing
AU  - Jiang LQ
CN  - Antithrombotic Therapy in Atrial Fibrillation Study Group
LA  - chi
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Cerebrovascular Disorders/*etiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Warfarin/*therapeutic use
EDAT- 2006/06/17 09:00
MHDA- 2009/07/08 09:00
CRDT- 2006/06/17 09:00
PHST- 2006/06/17 09:00 [pubmed]
PHST- 2009/07/08 09:00 [medline]
PHST- 2006/06/17 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Apr;34(4):295-8.

PMID- 32140731
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20221207
IS  - 1615-6692 (Electronic)
IS  - 0340-9937 (Linking)
VI  - 45
IP  - 2
DP  - 2020 Apr
TI  - [Principles of angiology in lower extremity arterial disease (LEAD)].
PG  - 201-208
LID - 10.1007/s00059-020-04896-1 [doi]
AB  - Lower extremity arterial disease (LEAD) is a frequent manifestation of 
      atherosclerosis with a high risk for cardiovascular events. The measurement of 
      the ankle-brachial index (ABI) should be used as a screening method for LEAD. A 
      differentiation is made between a stable stage of intermittent claudication and 
      the stage of critical limb ischemia. The control of cardiovascular risk factors 
      is crucial. Particular emphasis should be placed on smoking cessation and 
      lipid-lowering treatment with statins and a target low-density lipoprotein 
      (LDL)-cholesterol level of <55 mg/dl as a core element. In patients with 
      symptomatic LEAD an inhibition of platelet aggregation is indicated. In addition 
      to treatment with clopidogrel 75 mg or with acetylsalicylic acid (ASS) 100 mg in 
      high risk patients the combination of ASS 100 mg and rivaroxaban 2 × 2.5 mg can 
      be indicated. In critical limb ischemia revascularization (percutaneous 
      intervention, operation) is always indicated to prevent amputation. First-line 
      treatment in patients with intermittent claudication is exercise training. 
      Revascularization can be indicated in patients with a severe limitation of 
      walking distance.
FAU - Espinola-Klein, Christine
AU  - Espinola-Klein C
AD  - Abteilung Angiologie, Zentrum für Kardiologie/Kardiologie I, Universitätsmedizin 
      der Johannes-Gutenberg-Universität, Langenbeckstr. 1, 55131, Mainz, Deutschland. 
      espinola@uni-mainz.de.
LA  - ger
PT  - Journal Article
TT  - Grundlagen der Angiologie bei peripherer arterieller Verschlusskrankheit (pAVK).
PL  - Germany
TA  - Herz
JT  - Herz
JID - 7801231
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amputation, Surgical
MH  - *Ankle Brachial Index
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Intermittent Claudication
MH  - Ischemia
MH  - Lower Extremity
MH  - *Peripheral Arterial Disease/diagnosis/physiopathology
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Factors
OTO - NOTNLM
OT  - Exercise
OT  - Limb ischemia
OT  - Platelet aggregation inhibitors
OT  - Revascularization
OT  - Risk factors
EDAT- 2020/03/07 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/03/07 06:00
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2020/03/07 06:00 [entrez]
AID - 10.1007/s00059-020-04896-1 [pii]
AID - 10.1007/s00059-020-04896-1 [doi]
PST - ppublish
SO  - Herz. 2020 Apr;45(2):201-208. doi: 10.1007/s00059-020-04896-1.

PMID- 9971912
OWN - NLM
STAT- MEDLINE
DCOM- 19990413
LR  - 20191102
IS  - 0928-0987 (Print)
IS  - 0928-0987 (Linking)
VI  - 7
IP  - 4
DP  - 1999 Mar
TI  - Influence of the coating thickness and type of oral delivery system (tablets, 
      pellets) on the stability towards degradation by neutron irradiation. Validation 
      of neutron activation III.
PG  - 295-303
AB  - Enteric coated dexchlorpheniramine maleate (DCPA) tablets and pellets with 
      varying coating thickness were subjected to several in vitro tests after 
      irradiation by thermal neutrons in a flux of 1. 1 x 10(13) n cm-2 s-1 for 2, 4 or 
      15 min. The appearance of the tablet formulation changed extensively after 
      exposure of the tablets to pile radiation. The irradiation caused the film to 
      loosen from the surface of the core, indicating the generation of gases during 
      the irradiation process. Already after irradiating the tablets for 2 min the 
      disintegration and dissolution behaviour were significantly changed. The extent 
      of tablet damage increased with increasing time of exposure and increasing 
      thickness of the coating. Compared with the tablet formulation, the cores could 
      resist a larger amount of irradiation since dissolution behaviour of the cores 
      was only affected after 15 min of irradiation. This indicates that the 
      irradiation procedure initially affects the coating of the formulation. Although 
      the dissolution behaviour of the pellet formulations changed significantly after 
      the irradiation procedure, the changes were too small to be attributed 
      exclusively to radiation damage.
FAU - Waaler, T
AU  - Waaler T
AD  - Department of Pharmaceutics, Institute of Pharmacy, University of Oslo, PO Box 
      1068, Blindern, N-0316 Oslo, Norway.
FAU - Sande, S A
AU  - Sande SA
FAU - Müller, B W
AU  - Müller BW
FAU - Schüller Lisether, G
AU  - Schüller Lisether G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
MH  - Aspirin/administration & dosage
MH  - Color
MH  - Hardness
MH  - Neutron Activation Analysis
MH  - *Neutrons
MH  - Solubility
MH  - Tablets
MH  - Tablets, Enteric-Coated/*radiation effects
EDAT- 1999/02/11 00:00
MHDA- 1999/02/11 00:01
CRDT- 1999/02/11 00:00
PHST- 1999/02/11 00:00 [pubmed]
PHST- 1999/02/11 00:01 [medline]
PHST- 1999/02/11 00:00 [entrez]
AID - S0928-0987(98)00046-3 [pii]
AID - 10.1016/s0928-0987(98)00046-3 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 1999 Mar;7(4):295-303. doi: 10.1016/s0928-0987(98)00046-3.

PMID- 21106317
OWN - NLM
STAT- MEDLINE
DCOM- 20110418
LR  - 20191210
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 54
IP  - 4
DP  - 2011 Mar 25
TI  - Quantitative HPLC analysis of mebeverine, mesalazine, sulphasalazine and 
      dispersible aspirin stored in a Venalink monitored dosage system with 
      co-prescribed medicines.
PG  - 646-52
LID - 10.1016/j.jpba.2010.10.002 [doi]
AB  - An HPLC method for the quantitative analysis of mebeverine HCl, 5-aminosalicylic 
      acid (5-ASA), sulphasalazine and dispersible aspirin has been developed and then 
      applied to these specific medicines when stored, with other medications, in 
      Venalink blister packs (monitored dosage system) for periods of up to 35 days. 
      Chromatographic separation was achieved on a reversed-phase C(12) column with an 
      isocratic mixture of methanol, water and acetic acid as the mobile phase. The 
      method was validated regarding: accuracy, precision, detection limits, 
      quantification limits, specificity and robustness.
CI  - Copyright © 2010 Elsevier B.V. All rights reserved.
FAU - Elmasry, Manal S
AU  - Elmasry MS
AD  - Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.
FAU - Blagbrough, Ian S
AU  - Blagbrough IS
FAU - Rowan, Michael G
AU  - Rowan MG
FAU - Saleh, Hanaa M
AU  - Saleh HM
FAU - Kheir, Afaf Aboul
AU  - Kheir AA
FAU - Rogers, Philip J
AU  - Rogers PJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20101014
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Capsules)
RN  - 0 (Phenethylamines)
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 3XC8GUZ6CB (Sulfasalazine)
RN  - 4Q81I59GXC (Mesalamine)
RN  - 7F80CC3NNV (mebeverine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis
MH  - Capsules
MH  - Chromatography, High Pressure Liquid
MH  - Drug Stability
MH  - Drug Storage
MH  - Mass Spectrometry
MH  - *Medication Systems
MH  - Mesalamine/analysis
MH  - Phenethylamines/*analysis
MH  - Polypharmacy
MH  - Salicylates/*analysis
MH  - Sulfasalazine/*analysis
MH  - Tablets
MH  - *Technology, Pharmaceutical
MH  - Time Factors
EDAT- 2010/11/26 06:00
MHDA- 2011/04/19 06:00
CRDT- 2010/11/26 06:00
PHST- 2010/05/25 00:00 [received]
PHST- 2010/10/04 00:00 [revised]
PHST- 2010/10/04 00:00 [accepted]
PHST- 2010/11/26 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2011/04/19 06:00 [medline]
AID - S0731-7085(10)00578-9 [pii]
AID - 10.1016/j.jpba.2010.10.002 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2011 Mar 25;54(4):646-52. doi: 10.1016/j.jpba.2010.10.002. 
      Epub 2010 Oct 14.

PMID- 15601279
OWN - NLM
STAT- MEDLINE
DCOM- 20050127
LR  - 20181201
IS  - 0003-2409 (Print)
IS  - 0003-2409 (Linking)
VI  - 60
IP  - 1
DP  - 2005 Jan
TI  - Spinal anaesthesia despite combined clopidogrel and aspirin therapy in a patient 
      awaiting lung transplantation: effects of platelet transfusion on clotting tests.
PG  - 85-7
AB  - The risk of central neuraxial blockade in patients treated with newer 
      antiplatelet drugs is unclear. We report the case of a woman awaiting lung 
      transplantation who presented for emergency groin surgery. She had recently 
      undergone a coronary artery stent implantation and was treated with both 
      clopidogrel and aspirin. Despite this dual antiplatelet therapy, uneventful 
      spinal anaesthesia was administered following platelet transfusion. While 
      thromboelastography was of no help in assessing the degree of anticoagulation, 
      the effects of platelet transfusion were reflected by adenosine diphosphate and 
      epinephrine aggregometry. Thus, in selected patients, platelet transfusion may be 
      appropriate to enable central neuraxial blockade when deemed necessary.
FAU - Herbstreit, F
AU  - Herbstreit F
AD  - Klinik für Anästhesiologie und Intensivmedizin, Universitätsklimikum Essen, 
      Hufelandstrasse 55, 45122 Essen, Germany. frank.herbstreit@uni-essen.de
FAU - Peters, J
AU  - Peters J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Anaesthesia
JT  - Anaesthesia
JID - 0370524
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Anaesthesia. 2005 Mar;60(3):301. PMID: 15710034
MH  - *Anesthesia, Spinal
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Lung Diseases, Obstructive/complications
MH  - Lung Transplantation
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - *Platelet Transfusion
MH  - Ticlopidine/*analogs & derivatives/*pharmacology
EDAT- 2004/12/17 09:00
MHDA- 2005/01/28 09:00
CRDT- 2004/12/17 09:00
PHST- 2004/12/17 09:00 [pubmed]
PHST- 2005/01/28 09:00 [medline]
PHST- 2004/12/17 09:00 [entrez]
AID - ANA4029 [pii]
AID - 10.1111/j.1365-2044.2004.04029.x [doi]
PST - ppublish
SO  - Anaesthesia. 2005 Jan;60(1):85-7. doi: 10.1111/j.1365-2044.2004.04029.x.

PMID- 6527271
OWN - NLM
STAT- MEDLINE
DCOM- 19850410
LR  - 20190711
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 73
IP  - 12
DP  - 1984 Dec
TI  - Analysis of tablets containing aspirin, acetaminophen, and ascorbic acid by 
      high-performance liquid chromatography.
PG  - 1830-3
AB  - The high-performance liquid chromatographic method described enables the 
      quantitation of the components and the main impurities of tablets containing 
      aspirin, acetaminophen, and ascorbic acid. A C8 reverse-phase column was used; 
      the mobile phase was methanol-0.2 M phosphate buffer (pH 3.5)-water (20:10:70). 
      Results obtained for a brand of effervescent tablets, normally aged for 5 years 
      and stressed at 37 degrees C, 50 degrees C, or in 79% relative humidity at room 
      temperature, are reported. Salicylic acid was the main product of decomposition. 
      Diacetyl-p-aminophenol was observed to be formed by transacetylation.
FAU - Thomis, R
AU  - Thomis R
FAU - Roets, E
AU  - Roets E
FAU - Hoogmartens, J
AU  - Hoogmartens J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Salicylates)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - BFG1TY61BG (diacetamate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/analogs & derivatives/*analysis
MH  - Ascorbic Acid/*analysis
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid
MH  - Drug Stability
MH  - Humidity
MH  - Hydrogen-Ion Concentration
MH  - Salicylates/analysis
MH  - Salicylic Acid
MH  - Tablets
MH  - Temperature
MH  - Time Factors
EDAT- 1984/12/01 00:00
MHDA- 1984/12/01 00:01
CRDT- 1984/12/01 00:00
PHST- 1984/12/01 00:00 [pubmed]
PHST- 1984/12/01 00:01 [medline]
PHST- 1984/12/01 00:00 [entrez]
AID - S0022-3549(15)46464-0 [pii]
AID - 10.1002/jps.2600731246 [doi]
PST - ppublish
SO  - J Pharm Sci. 1984 Dec;73(12):1830-3. doi: 10.1002/jps.2600731246.

PMID- 20964615
OWN - NLM
STAT- MEDLINE
DCOM- 20120119
LR  - 20161125
IS  - 1525-6065 (Electronic)
IS  - 1064-1955 (Linking)
VI  - 30
IP  - 4
DP  - 2011
TI  - Favorable maternal and fetal effects of danshensu in an experimental mice model 
      of preeclampsia.
PG  - 465-80
LID - 10.3109/10641955.2010.507842 [doi]
AB  - BACKGROUND: Preeclampsia is a serious pregnancy-specific complication that 
      results in high maternal and neonatal mortality and morbidity worldwide. Till 
      date, there is no satisfactory pharmacotherapeutic treatment, except for aspirin 
      and heparin, to stop the preeclampsia progression. Although the mechanism of 
      preeclampsia is poorly understood, it has proved to be associated with 
      coagulation activation. Researches on prophylactic and remedial application of 
      anticoagulants maybe benefit the clinical aspects of preeclampsia individuals. 
      METHODS: Sixty-six preeclampsia-like pregnant mice, induced by 
      phosphatidyleserine/phosphatidylcholine (PS/PC) microvesicle administration, were 
      randomly divided into six groups as follows: control group (group C), 
      preeclampsia model group (group PE), group treated with heparin (group H), group 
      treated with aspirin (group A), group treated with low-dose danshensu (group LD), 
      and group treated with high-dose danshensu (group HD). Systolic blood pressure 
      (SBP), proteinuria, mean platelet counts, plasma antithrombin III activity (AT 
      III), D-dimmer levels, thrombin time (TT), fibrin deposition with phosphotungstic 
      acid hematoxylin (PTAH) staining, and thrombomodulin (TM) expression with 
      immunohistochemistry staining in placentas were examined as indices for maternal 
      syndrome. Meanwhile, the number of potentially viable fetuses, weight of fetuses 
      and placentas, weight of fetal brains, nose-breech length, ponderal index (PI), 
      and neurons with hematoxylin-eosin (H/E) and toluidine blue-eosin (Nissl's) 
      staining were all evaluated as indices for fetal syndrome. RESULTS: Heparin 
      presents significant effects on maternal syndrome of preeclampsia such as 
      hypertension and proteinuria, and different dose danshensu also presents the 
      certain effects. High-dose danshensu and aspirin all process better effects than 
      low-dose danshensu on decreasing blood pressure to normal level, whereas 
      high-dose danshensu process better effects than aspirin and low-dose danshensu on 
      decreasing proteinuria to normal level. As to danshensu's effects on hemostatic 
      function, high- and low-dose danshensu's marked effects on increasing the plasma 
      AT III activity are same as that of aspirin and inferior to heparin. High-dose 
      danshensu's better effect on elevating the platelet counts is superior to 
      low-dose danshensu and aspirin. Low-dose danshensu's obvious effect on decreasing 
      D-dimmer levels is close to heparin and superior to high-dose danshensu and 
      aspirin. High- and low-dose danshensu's significant effects on reduced TT level 
      are same to that of heparin. Different anticoagulants all have the improvement 
      roles on placental fibrin depositions, but heparin and high-dose danshensu's 
      roles on lowering thrombomodulin expression in placentas are superior to low-dose 
      danshensu and aspirin. But anticoagulant function of high-dose danshensu is still 
      inferior to heparin. Furthermore, we found the following changes: increasing 
      fetal body weight and length in every group, obvious overall improvement in group 
      H, greater amelioration equaling to that in heparin group on maternal body 
      weight, fetal nose-breech length and fetal brain weight in group HD, better 
      changes on survival fetal number in group LD than in other groups, and more 
      corrected brain development in group HD than in group A. We found long-term use 
      of heparin and aspirin, in spite of low-dose administration, can raise the risk 
      of bleeding such as placental abruption and intestinal hemorrhage. But no side 
      effect was observed in mice treated with different dose of danshensu in our 
      study. CONCLUSIONS: Danshensu has proven effective in ameliorating the prognosis 
      of maternal syndrome and fetal syndrome in the PE mouse model. We suggest 
      long-term provision of low-dose danshensu in pregnancy, leading to an improvement 
      of preeclampsia syndrome with considerable maternal safety.
FAU - Shen, Yang
AU  - Shen Y
AD  - Obstetrics and Gynecology Department, Southeast University Affiliated Zhongda 
      Hospital, Nanjing, China.
FAU - Hu, Yali
AU  - Hu Y
FAU - Zhang, Yan
AU  - Zhang Y
LA  - eng
PT  - Journal Article
DEP - 20101022
PL  - England
TA  - Hypertens Pregnancy
JT  - Hypertension in pregnancy
JID - 9421297
RN  - 0 (Anticoagulants)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Lactates)
RN  - 4GF33A5PAJ (3,4-dihydroxyphenyllactic acid)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Disease Models, Animal
MH  - Drugs, Chinese Herbal/pharmacology/*therapeutic use
MH  - Female
MH  - Fetus/drug effects
MH  - Heparin/therapeutic use
MH  - Lactates/pharmacology/*therapeutic use
MH  - Mice
MH  - Placenta/drug effects
MH  - *Pre-Eclampsia
MH  - Pregnancy
EDAT- 2010/10/23 06:00
MHDA- 2012/01/20 06:00
CRDT- 2010/10/23 06:00
PHST- 2010/10/23 06:00 [entrez]
PHST- 2010/10/23 06:00 [pubmed]
PHST- 2012/01/20 06:00 [medline]
AID - 10.3109/10641955.2010.507842 [doi]
PST - ppublish
SO  - Hypertens Pregnancy. 2011;30(4):465-80. doi: 10.3109/10641955.2010.507842. Epub 
      2010 Oct 22.

PMID- 15476618
OWN - NLM
STAT- MEDLINE
DCOM- 20041202
LR  - 20131121
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 94
IP  - 8
DP  - 2004 Oct 15
TI  - Influence of admission and discharge aspirin use on survival after primary 
      coronary angioplasty for acute myocardial infarction.
PG  - 1029-33
AB  - We examined the effect of aspirin use at the time of admission and discharge from 
      a large-scale, prospective multicenter trial of patients who had been treated 
      with primary percutaneous coronary intervention in acute myocardial infarction.
FAU - Kandzari, David E
AU  - Kandzari DE
AD  - Duke Clinical Research Institute, Durham, North Carolina 27715, USA. 
      kandz002@mc.duke.edu
FAU - Tcheng, James E
AU  - Tcheng JE
FAU - Grines, Cindy L
AU  - Grines CL
FAU - Cox, David A
AU  - Cox DA
FAU - Stuckey, Thomas
AU  - Stuckey T
FAU - Griffin, John J
AU  - Griffin JJ
FAU - Turco, Mark
AU  - Turco M
FAU - Garcia, Eulogio
AU  - Garcia E
FAU - Carroll, John D
AU  - Carroll JD
FAU - Fahy, Martin
AU  - Fahy M
FAU - Lansky, Alexandra J
AU  - Lansky AJ
FAU - Mehran, Roxana
AU  - Mehran R
FAU - Stone, Gregg W
AU  - Stone GW
CN  - CADILLAC Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*mortality/*therapy
MH  - Patient Admission
MH  - Patient Discharge
MH  - Survival Rate
EDAT- 2004/10/13 09:00
MHDA- 2004/12/16 09:00
CRDT- 2004/10/13 09:00
PHST- 2004/04/07 00:00 [received]
PHST- 2004/06/25 00:00 [revised]
PHST- 2004/06/25 00:00 [accepted]
PHST- 2004/10/13 09:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/10/13 09:00 [entrez]
AID - S0002-9149(04)01067-7 [pii]
AID - 10.1016/j.amjcard.2004.06.060 [doi]
PST - ppublish
SO  - Am J Cardiol. 2004 Oct 15;94(8):1029-33. doi: 10.1016/j.amjcard.2004.06.060.

PMID- 8595619
OWN - NLM
STAT- MEDLINE
DCOM- 19960418
LR  - 20131121
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 30
IP  - 5
DP  - 1995 Nov
TI  - Reduced red cell deformability associated with blood flow and platelet 
      activation: improved by dipyridamole alone or combined with aspirin.
PG  - 725-30
AB  - OBJECTIVES: To explore the role of blood flow in red blood cell deformability and 
      determine whether it is associated with the release of ATP by red cells. METHODS: 
      A perfusion system was employed to mimic the blood flow conditions. Red cell 
      treatment in vitro with dipyridamole or aspirin, either alone or combined, was 
      performed either on red cells alone prior to blood reconstitution or on already 
      reconstituted blood. Blood viscosity at shear rates of 90 and 450 s-1 was 
      measured, before and after perfusion, by means of a cone/plate viscometer. Red 
      cell deformability was estimated as the magnitude of the slope between these two 
      values of viscosity. ATP level in platelet-free plasma was measured by the 
      firefly luciferase assay, and was used to monitor dipyridamole-induced blockade 
      of ATP efflux by red cells. RESULTS: In control experiments, red cells became 
      more rigid after perfusion (slope values: 0.62 +/- 0.09 vs 0.40 +/- 0.04; P < 
      0.05). Absence of platelets or treatment of red cells with aspirin and/or 
      dipyridamole prevented dipyridamole prevented the increased stiffness of red 
      cells observed after exposure of blood to flow conditions. Moreover, a 
      significant increase in red cell deformability was observed when blood was 
      treated with dipyridamole alone or combined with aspirin (0.69 +/- 0.07 and 0.65 
      +/- 0.05 respectively vs. 0.40 +/- 0.04; P < 0.05). Treatment with dipyridamole 
      alone or combined with aspirin caused a decrease in ATP levels. Statistical 
      significance was reached when red cells alone were treated with dipyridamole 
      alone (45.8 +/- 2.8 vs. 173.3 +/- 47.6 ng ATP/ml; P < 0.05). CONCLUSIONS: Flow 
      stress induced a decrease in red cell deformability probably linked to platelet 
      activation. Treatment with dipyridamole alone or associated with aspirin 
      eliminated the effect of flow, increasing red cell deformability. Under our 
      experimental conditions, modifications could not be ascribed to red cell-released 
      ATP. Our results emphasize the importance of blood flow conditions to evaluate 
      RBC deformability.
FAU - Bozzo, J
AU  - Bozzo J
AD  - Servei d'Hemoteràpia i Hemostàsia, Hospital Clínic i Provincial, Villarroel, 
      Barcelona, Spain.
FAU - Hernández, M R
AU  - Hernández MR
FAU - Ordinas, A
AU  - Ordinas A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Triphosphate/metabolism
MH  - Aspirin/*pharmacology
MH  - Blood Circulation/*physiology
MH  - Blood Viscosity
MH  - Dipyridamole/*pharmacology
MH  - Drug Synergism
MH  - Erythrocyte Deformability/*drug effects
MH  - Erythrocytes/enzymology
MH  - Humans
MH  - Perfusion
MH  - Platelet Activation/*physiology
MH  - Platelet Aggregation Inhibitors/*pharmacology
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 0008-6363(95)00099-2 [pii]
PST - ppublish
SO  - Cardiovasc Res. 1995 Nov;30(5):725-30.

PMID- 32773581
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20221005
IS  - 1728-7731 (Electronic)
IS  - 1726-4901 (Print)
IS  - 1726-4901 (Linking)
VI  - 83
IP  - 9
DP  - 2020 Sep
TI  - The effect of aspirin on preeclampsia, intrauterine growth restriction and 
      preterm delivery among healthy pregnancies with a history of preeclampsia.
PG  - 852-857
LID - 10.1097/JCMA.0000000000000400 [doi]
AB  - BACKGROUND: Due to the significance of preeclampsia (PE) and its adverse outcomes 
      in the health of both mother and newborn, the present study was carried out to 
      investigate the effect of aspirin on preventing the occurrence of PE, 
      intrauterine growth restriction (IUGR), and preterm delivery in women with a 
      previous history of PE. METHODS: The present clinical trial was conducted on 90 
      pregnant women with a previous history of PE referred to the Khalij Fars Hospital 
      in Bandar Abbas, Hormozgan Province Iran from April 2017 to August 2018. The 
      subjects of the study were randomly assigned into two groups of intervention and 
      control to receive either 80 mg of aspirin or placebo daily during the pregnancy. 
      Patients' information was obtained and recorded upon entering the study, 
      follow-up visits, and childbirth. RESULTS: Among participants who entered the 
      clinical trial, 86 patients (95.6%) completed the study. During the pregnancy, 
      systolic blood pressure increased by 8.25 ± 14.83 and 19.06 ± 18.33 mmHg in 
      aspirin and placebo groups, respectively (p = 0.001). Also, the same happened 
      with diastolic blood pressure (6.12 ± 11.46 vs 13.48 ± 13.95 mmHg, p = 0.010). 
      The rate of PE was equal to 27 (62.8%) and 38 (88.4%) in the aspirin and placebo 
      groups, respectively (aOR = 0.23, p = 0.013). In the aspirin group, the rate of 
      IUGR was equal to 27.9% compared with 25.6% of newborns in the control group (aOR 
      = 1.18, p = 0.750). Similarly, there was no significant difference in the rate of 
      preterm delivery between the two groups (p = 0.061). CONCLUSION: The findings of 
      the present study conducted exclusively on women with previous documented PE 
      revealed that taking aspirin may have a preventive effect on PE in the current 
      pregnancy.
FAU - Abdi, Nazanin
AU  - Abdi N
AD  - Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
AD  - Fertility and Infertility Research Center, Hormozgan University of Medical 
      Sciences, Bandar Abbas, Iran.
FAU - Rozrokh, Afsane
AU  - Rozrokh A
AD  - Student Research Committee, Hormozgan University of Medical Sciences, Bandar 
      Abbas, Iran.
FAU - Alavi, Azin
AU  - Alavi A
AD  - Fertility and Infertility Research Center, Hormozgan University of Medical 
      Sciences, Bandar Abbas, Iran.
FAU - Zare, Shahram
AU  - Zare S
AD  - Epidemiology Department, Hormozgan University of Medical Sciences, Bandar Abbas, 
      Iran.
FAU - Vafaei, Homeira
AU  - Vafaei H
AD  - Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Asadi, Nasrin
AU  - Asadi N
AD  - Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Kasraeian, Maryam
AU  - Kasraeian M
AD  - Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Hessami, Kamran
AU  - Hessami K
AD  - Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
AD  - Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - J Chin Med Assoc
JT  - Journal of the Chinese Medical Association : JCMA
JID - 101174817
RN  - EC 3.4.24.- (Pregnancy-Associated Plasma Protein-A)
RN  - EC 3.4.24.79 (PAPPA protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Fetal Growth Retardation/*prevention & control
MH  - Humans
MH  - Pre-Eclampsia/mortality/*prevention & control
MH  - Pregnancy
MH  - Pregnancy-Associated Plasma Protein-A/analysis
MH  - Premature Birth/*prevention & control
PMC - PMC7478204
COIS- Conflicts of interest: The authors declare that they have no conflicts of 
      interest related to the subject matter or materials discussed in this article.
EDAT- 2020/08/11 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - 02118582-202009000-00015 [pii]
AID - 10.1097/JCMA.0000000000000400 [doi]
PST - ppublish
SO  - J Chin Med Assoc. 2020 Sep;83(9):852-857. doi: 10.1097/JCMA.0000000000000400.

PMID- 29392539
OWN - NLM
STAT- MEDLINE
DCOM- 20190603
LR  - 20190603
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Linking)
VI  - 36
IP  - 5
DP  - 2018 Oct
TI  - Pre-clinical effects of metformin and aspirin on the cell lines of different 
      breast cancer subtypes.
PG  - 782-796
LID - 10.1007/s10637-018-0568-y [doi]
AB  - Background Breast cancer is highly prevalent among women worldwide. It is 
      classified into three main subtypes: estrogen receptor positive (ER+), human 
      epidermal growth factor receptor 2 positive (HER2+), and triple negative breast 
      cancer (TNBC). This study has evaluated the effects of aspirin and metformin, 
      isolated or in a combination, in breast cancer cells of the different subtypes. 
      Methods The breast cancer cell lines MCF-7, MDA-MB-231, and SK-BR-3 were treated 
      with aspirin and/or metformin (0.01 mM - 10 mM); functional in vitro assays were 
      performed. The interactions with the estrogen receptors (ER) were evaluated in 
      silico. Results Metformin (2.5, 5 and 10 mM) altered the morphology and reduced 
      the viability and migration of the ER+ cell line MCF-7, whereas aspirin triggered 
      this effect only at 10 mM. A synergistic effect for the combination of metformin 
      and aspirin (2.5, 5 or 10 mM each) was observed in the TNBC cell subtype 
      MDA-MB-231, according to the evaluation of its viability and colony formation. 
      Partial inhibitory effects were observed for either of the drugs in the HER2+ 
      cell subtype SK-BR-3. The effects of metformin and aspirin partly relied on 
      cyclooxygenase-2 (COX-2) upregulation, without the production of lipoxins. In 
      silico, metformin and aspirin bound to the ERα receptor with the same energy. 
      Conclusion We have provided novel evidence on the mechanisms of action of aspirin 
      and metformin in breast cancer cells, showing favorable outcomes for these drugs 
      in the ER+ and TNBC subtypes.
FAU - Amaral, Maria Eduarda Azambuja
AU  - Amaral MEA
AD  - Programa de Pós-Graduação em Biologia Celular e Molecular, Escola de Ciências, 
      Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 
      6681, Porto Alegre, RS, 90619-900, Brazil.
AD  - Centro de Pesquisa em Toxicologia e Farmacologia, Escola de Ciências da Saúde, 
      Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 
      6681, Porto Alegre, RS, 90619-900, Brazil.
FAU - Nery, Laura Roesler
AU  - Nery LR
AD  - ZebLab & Laboratório de Biologia e Desenvolvimento do Sistema Nervoso, Escola de 
      Ciências, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. 
      Ipiranga 6681, Prédio 12 D, sala 301, Porto Alegre, RS, 90619-900, Brazil.
FAU - Leite, Carlos Eduardo
AU  - Leite CE
AD  - Centro de Pesquisa em Toxicologia e Farmacologia, Escola de Ciências da Saúde, 
      Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 
      6681, Porto Alegre, RS, 90619-900, Brazil.
FAU - de Azevedo Junior, Walter Filgueira
AU  - de Azevedo Junior WF
AD  - Programa de Pós-Graduação em Biologia Celular e Molecular, Escola de Ciências, 
      Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 
      6681, Porto Alegre, RS, 90619-900, Brazil.
AD  - Laboratório de Biologia de Sistemas Computacionais, Escola de Ciências, 
      Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 
      6681, Porto Alegre, RS, 90619-900, Brazil.
FAU - Campos, Maria Martha
AU  - Campos MM
AD  - Programa de Pós-Graduação em Biologia Celular e Molecular, Escola de Ciências, 
      Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 
      6681, Porto Alegre, RS, 90619-900, Brazil. maria.campos@pucrs.br.
AD  - Centro de Pesquisa em Toxicologia e Farmacologia, Escola de Ciências da Saúde, 
      Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 
      6681, Porto Alegre, RS, 90619-900, Brazil. maria.campos@pucrs.br.
AD  - Programa de Pós-Graduação em Odontologia, Escola de Ciências da Saúde, Pontifícia 
      Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 6681, Porto 
      Alegre, RS, 90619-900, Brazil. maria.campos@pucrs.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180202
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, Estrogen)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Breast Neoplasms/*drug therapy/metabolism
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Survival/drug effects
MH  - Drug Synergism
MH  - Humans
MH  - Metformin/*pharmacology
MH  - Receptors, Estrogen/metabolism
OTO - NOTNLM
OT  - Aspirin
OT  - Breast cance
OT  - Drug repurposing
OT  - Metformin
EDAT- 2018/02/03 06:00
MHDA- 2019/06/04 06:00
CRDT- 2018/02/03 06:00
PHST- 2017/12/12 00:00 [received]
PHST- 2018/01/22 00:00 [accepted]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2019/06/04 06:00 [medline]
PHST- 2018/02/03 06:00 [entrez]
AID - 10.1007/s10637-018-0568-y [pii]
AID - 10.1007/s10637-018-0568-y [doi]
PST - ppublish
SO  - Invest New Drugs. 2018 Oct;36(5):782-796. doi: 10.1007/s10637-018-0568-y. Epub 
      2018 Feb 2.

PMID- 465372
OWN - NLM
STAT- MEDLINE
DCOM- 19791017
LR  - 20190704
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 42
IP  - 2
DP  - 1979 Jun
TI  - The influence of red blood cells on the effects of aspirin or sulphinpyrazone on 
      platelet adherence to damaged rabbit aorta.
PG  - 283-91
AB  - The effects of acetylsalicylic acid (ASA; aspirin) or sulphinpyrazone (SP) on the 
      adherence of washed rabbit platelets to the subendotheilial surface of an everted 
      aorta mounted on a probe or to the subendothelial surface of a rabbit aorta 
      attached to a perfusion apparatus were examined. ASA had no effect on platelet 
      adherence to a damaged aorta perfused with a suspension of washed platelets in a 
      medium containing 10% red blood cells (RBC); SP was slightly inhibitory at high 
      concentration. When damaged rabbit aortae were everted on a probe and rotated in 
      a suspension of washed platelets to which RBC were added to a packed cell volume 
      of 10%, both ASA and SP inhibited platelet adherence to the damaged vessel wall. 
      When the PCV was 40%, ASA was not inhibitory and SP reduced platelet adherence 
      only at very high concentrations. It is therefore unlikely that, at the 
      concentrations achieved in man, SP exerts an effect on platelet adherence. The 
      different effects of ASA and SP on platelet survival do not appear attributable 
      to their effects on platelet adherence.
FAU - Davies, J A
AU  - Davies JA
FAU - Essien, E
AU  - Essien E
FAU - Cazenave, J P
AU  - Cazenave JP
FAU - Kinlough-Rathbone, R L
AU  - Kinlough-Rathbone RL
FAU - Gent, M
AU  - Gent M
FAU - Mustard, J F
AU  - Mustard JF
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - R16CO5Y76E (Aspirin)
RN  - V6OFU47K3W (Sulfinpyrazone)
SB  - IM
MH  - Animals
MH  - Aorta, Thoracic/*injuries/ultrastructure
MH  - Aspirin/*pharmacology
MH  - Depression, Chemical
MH  - Endothelium/ultrastructure
MH  - Erythrocytes/*physiology
MH  - Hematocrit
MH  - In Vitro Techniques
MH  - Microscopy, Electron, Scanning
MH  - Platelet Adhesiveness/*drug effects
MH  - Rabbits
MH  - Sulfinpyrazone/*pharmacology
EDAT- 1979/06/01 00:00
MHDA- 1979/06/01 00:01
CRDT- 1979/06/01 00:00
PHST- 1979/06/01 00:00 [pubmed]
PHST- 1979/06/01 00:01 [medline]
PHST- 1979/06/01 00:00 [entrez]
AID - 10.1111/j.1365-2141.1979.tb01132.x [doi]
PST - ppublish
SO  - Br J Haematol. 1979 Jun;42(2):283-91. doi: 10.1111/j.1365-2141.1979.tb01132.x.

PMID- 3817034
OWN - NLM
STAT- MEDLINE
DCOM- 19870406
LR  - 20190816
IS  - 0014-4835 (Print)
IS  - 0014-4835 (Linking)
VI  - 43
IP  - 6
DP  - 1986 Dec
TI  - Bendazac prevents cyanate binding to soluble lens proteins and cyanate-induced 
      phase-separation opacities in vitro: a possible mechanism by which bendazac could 
      delay cataract.
PG  - 973-9
AB  - The reaction of lens proteins with cyanate (carbamylation) causes many changes 
      seen in human cataract including disruption of the protein conformations. 
      Bendazac, a putative anti-cataract drug, decreases the binding of cyanate to lens 
      proteins and prevents the cyanate-induced elevation of the phase separation 
      temperature in incubated rat lenses. Its major metabolite, 5-hydroxybendazac, 
      also inhibits the binding of cyanate to lens proteins even when it is present 
      only during a pre-incubation period. The metabolite is more effective than the 
      parent compound.
FAU - Lewis, B S
AU  - Lewis BS
FAU - Rixon, K C
AU  - Rixon KC
FAU - Harding, J J
AU  - Harding JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 0 (Crystallins)
RN  - 0 (Cyanates)
RN  - 0 (Indazoles)
RN  - 0 (Pyrazoles)
RN  - 84745-02-8 (5-hydroxybendazac)
RN  - G4AG71204O (bendazac)
RN  - G9C31TWN5M (potassium cyanate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Cattle
MH  - Crystallins/*metabolism
MH  - Cyanates/*antagonists & inhibitors
MH  - Indazoles/*pharmacology
MH  - Protein Binding/drug effects
MH  - Pyrazoles/*pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Temperature
EDAT- 1986/12/01 00:00
MHDA- 1986/12/01 00:01
CRDT- 1986/12/01 00:00
PHST- 1986/12/01 00:00 [pubmed]
PHST- 1986/12/01 00:01 [medline]
PHST- 1986/12/01 00:00 [entrez]
AID - 0014-4835(86)90075-8 [pii]
AID - 10.1016/0014-4835(86)90075-8 [doi]
PST - ppublish
SO  - Exp Eye Res. 1986 Dec;43(6):973-9. doi: 10.1016/0014-4835(86)90075-8.

PMID- 7023742
OWN - NLM
STAT- MEDLINE
DCOM- 19811122
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 64
IP  - 4
DP  - 1981 Oct
TI  - Are clinical trials in coronary heart disease oversold or undersold?
PG  - 667-8
AB  - Randomized clinical trials constitute the formal experiments in therapeutics. 
      Many such trials in coronary heart disease have terminated inconclusively or in 
      controversy. In this editorial, we analyze some of the methodologic issues that 
      may lead to controversy; the main reason for the low success rate may lie in 
      insufficient understanding of the complex biology of the disease and in failure 
      to select the appropriate models for therapy. We argue that these difficulties 
      only strengthen the need for the rigorous experimental approach to the evaluation 
      of therapies for coronary heart disease.
FAU - Detre, K M
AU  - Detre KM
FAU - Ware, J
AU  - Ware J
FAU - Mantel, N
AU  - Mantel N
LA  - eng
GR  - CA-15686/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/*drug therapy
MH  - Humans
MH  - Myocardial Infarction/drug therapy
MH  - Random Allocation
MH  - Tuberculosis/drug therapy
EDAT- 1981/10/01 00:00
MHDA- 1981/10/01 00:01
CRDT- 1981/10/01 00:00
PHST- 1981/10/01 00:00 [pubmed]
PHST- 1981/10/01 00:01 [medline]
PHST- 1981/10/01 00:00 [entrez]
AID - 10.1161/01.cir.64.4.667 [doi]
PST - ppublish
SO  - Circulation. 1981 Oct;64(4):667-8. doi: 10.1161/01.cir.64.4.667.

PMID- 1036841
OWN - NLM
STAT- MEDLINE
DCOM- 19770216
LR  - 20141120
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 36
IP  - 2
DP  - 1976 Nov 30
TI  - Inhibition of human and animal platelet adhesiveness to glass bead columns by 
      adenosine, dipyridamole, chlorpromazine and acetylsalicylic acid.
PG  - 401-10
AB  - The differences among human, rabbit and guinea-pig platelet adhesiveness as for 
      inhibitions by adenosine, dipyridamole, chlorpromazine and acetylsalicylic acid 
      are described, and the influence of measurement conditions on platelet 
      adhesiveness is also reported. Platelet adhesiveness of human and animal species 
      decreased with an increase of heparin concentrations and an increase of flow rate 
      of blood passing through a glass bead column. Human and rabbit platelet 
      adhesiveness was inhibited in vitro by adenosine, dipyridamole and 
      chlorpromazine, but not by acetylsalicylic acid. On the other hand, guinea-pig 
      platelet adhesiveness was inhibited by the four drugs including acetylsalicylic 
      acid. In in vivo study, adenosine, dipyridamole and chlorpromazine inhibited 
      platelet adhesiveness in rabbits and guinea-pigs. Acetylsalicylic acid showed the 
      inhibitory effect in guinea-pigs, but not in rabbits.
FAU - Fujitani, B
AU  - Fujitani B
FAU - Tsuboi, T
AU  - Tsuboi T
FAU - Takeno, K
AU  - Takeno K
FAU - Yoshida, K
AU  - Yoshida K
FAU - Shimizu, M
AU  - Shimizu M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - K72T3FS567 (Adenosine)
RN  - R16CO5Y76E (Aspirin)
RN  - U42B7VYA4P (Chlorpromazine)
SB  - IM
MH  - Adenosine/*pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Flow Velocity
MH  - Chlorpromazine/*pharmacology
MH  - Dipyridamole/*pharmacology
MH  - Glass
MH  - Guinea Pigs
MH  - Heparin
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Adhesiveness/*drug effects
MH  - Rabbits
MH  - Species Specificity
EDAT- 1976/11/30 00:00
MHDA- 1976/11/30 00:01
CRDT- 1976/11/30 00:00
PHST- 1976/11/30 00:00 [pubmed]
PHST- 1976/11/30 00:01 [medline]
PHST- 1976/11/30 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1976 Nov 30;36(2):401-10.

PMID- 9091709
OWN - NLM
STAT- MEDLINE
DCOM- 19970404
LR  - 20131121
IS  - 0023-2165 (Print)
IS  - 0023-2165 (Linking)
VI  - 209
IP  - 6
DP  - 1996 Dec
TI  - [Cataract surgery and anticoagulation--current status].
PG  - 340-6
AB  - Patients on anticoagulation therapy run an increased risk for intraoperative 
      bleeding, but withholding this rheologic therapy increases the danger of 
      thromboembolic complications. Management of cataract patients on anticoagulation 
      therapy is not standardized. In this multicenter survey, we ascertained 
      perioperative management trends. METHODS: Questionnaires from 122 centers were 
      received (81.3%), each performing an average of 1558 cataract surgeries/year 
      (total: 172.880 surgeries in 1995). RESULTS: The majority of surgeons continued 
      their surgical (73%) and anesthetic (75%) technique, continued aspirin (63%) and 
      discontinued coumarine therapy (77%). The preferred kind of anesthesia was retro- 
      (28%) or peribulbar (18%) followed by systemic and/or retrobulbar anesthesia 
      (25%). 64% of surgeons changed their treatment to intravenous heparin, 36% 
      stopped coumarine without supplement therapy, while 16% of these surgeons did not 
      check for thromboplastine time. Those who continued cumarine therapy preferred a 
      corneal approach (85%) with subconjunctival and topical anesthesia (51%), 
      respectively. CONCLUSION: Anticoagulation therapy slightly influences anesthetic 
      technique or the surgical approach chosen in these patients. Usually coumarine 
      therapy was discontinued which implicates the possibility of life-threatening 
      complications and mandates tight control of coagulation parameters. Ophthalmic 
      surgeons who continued anticoagulation therapy preferred a corneal approach 
      followed by phacoemulsification. The advantages of discontinuing anticoagulation 
      therapy have to be weighed against potential risks.
FAU - Dick, B
AU  - Dick B
AD  - Universitäts-Augenklinik Mainz.
FAU - Jacobi, F K
AU  - Jacobi FK
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
TT  - Kataraktchirurgie und Antikoagulation--derzeitiger Stand.
PL  - Germany
TA  - Klin Monbl Augenheilkd
JT  - Klinische Monatsblatter fur Augenheilkunde
JID - 0014133
RN  - 0 (Anticoagulants)
RN  - 0 (Coumarins)
RN  - 9005-49-6 (Heparin)
RN  - A4VZ22K1WT (coumarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Blood Loss, Surgical/physiopathology/*prevention & control
MH  - *Cataract Extraction
MH  - Coumarins/administration & dosage/adverse effects
MH  - Heparin/administration & dosage/adverse effects
MH  - Humans
MH  - Patient Care Team
MH  - Prothrombin Time
MH  - Risk Factors
MH  - Thromboembolism/blood/*prevention & control
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - 10.1055/s-2008-1035331 [doi]
PST - ppublish
SO  - Klin Monbl Augenheilkd. 1996 Dec;209(6):340-6. doi: 10.1055/s-2008-1035331.

PMID- 15478856
OWN - NLM
STAT- MEDLINE
DCOM- 20041104
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 117 Suppl 5A
DP  - 2004 Sep 6
TI  - Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the 
      delicate balance.
PG  - 72S-78S
AB  - Aspirin is a very useful medication for the prevention of cardiovascular 
      thrombotic events in patients with or those at risk for cardiovascular disease 
      (CVD). Aspirin, however, carries an increased risk for gastrointestinal (GI) 
      injury (e.g., ulceration) and its complications (e.g., hemorrhage), which may be 
      caused by its antiplatelet and gastric mucosal effects. In those with established 
      CVD, aspirin use has been documented to decrease the risk of a first myocardial 
      infarction (MI). Its effects on stroke and vascular death are less conclusive. 
      The use of aspirin in these individuals is recommended only for those whose risk 
      for cardiovascular events (based on coronary risk assessment tools) is 
      sufficiently high that it outweighs the risk for GI complications. Secondary 
      prevention refers to the use of aspirin to prevent cardiovascular events in 
      patients with established CVD such as an MI, stroke, or angina. The use of 
      aspirin in these individuals is recommended based on a documented decrease in 
      future cardiovascular events and mortality. The risk for GI events with aspirin 
      is at least additive to the risk for these events in those who also are receiving 
      therapy with a nonsteroidal anti-inflammatory drug. Patients being treated with 
      aspirin, even at 81 mg/day for cardioprotection, should be assessed for factors 
      that increase the risk for GI injury. Studies have confirmed that co-therapy with 
      a proton pump inhibitor (PPI) or misoprostol decreases the risk for GI injury and 
      complications. Although both classes of such gastroprotective agents are 
      effective, treatment with a PPI is tolerated better, with fewer patients 
      discontinuing the drug because of side effects such as diarrhea.
FAU - Kimmey, Michael B
AU  - Kimmey MB
AD  - Division of Gastroenterology, University of Washington, School of Medicine, 
      Seattle, Washington 98195, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Proton Pumps)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Ulcer Agents/administration & dosage
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced/*drug therapy/epidemiology
MH  - Gastrointestinal Hemorrhage/chemically induced/drug therapy/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention/methods
MH  - Prognosis
MH  - *Proton Pump Inhibitors
MH  - Proton Pumps/administration & dosage
MH  - Risk Assessment
MH  - Stomach Ulcer/chemically induced/drug therapy/epidemiology
RF  - 35
EDAT- 2004/10/14 09:00
MHDA- 2004/11/05 09:00
CRDT- 2004/10/14 09:00
PHST- 2004/10/14 09:00 [pubmed]
PHST- 2004/11/05 09:00 [medline]
PHST- 2004/10/14 09:00 [entrez]
AID - S1548-2766(04)00012-3 [pii]
AID - 10.1016/j.amjmed.2004.07.012 [doi]
PST - ppublish
SO  - Am J Med. 2004 Sep 6;117 Suppl 5A:72S-78S. doi: 10.1016/j.amjmed.2004.07.012.

PMID- 30274828
OWN - NLM
STAT- MEDLINE
DCOM- 20190819
LR  - 20190819
IS  - 0929-6646 (Print)
IS  - 0929-6646 (Linking)
VI  - 118
IP  - 4
DP  - 2019 Apr
TI  - The dentin permeability of anti-inflammatory and antibacterial drugs: In vitro 
      study.
PG  - 828-832
LID - S0929-6646(18)30517-5 [pii]
LID - 10.1016/j.jfma.2018.09.009 [doi]
AB  - BACKGROUND/PURPOSE: Stimuli from the oral cavity may penetrate through exposed 
      dentinal tubules and evoke inflammatory pulp response. Anti-bacterial and 
      anti-inflammatory drugs applied to exposed dentin may infiltrate through the 
      dentinal tubules and cause pulp recovery. This study investigated the dentin 
      permeability of anti-bacterial and anti-inflammation drugs via an in-vitro 
      transwell dentin disc tube model. METHODS: Twenty-seven dentin discs prepared 
      from extracted human molars were collected. Nine kinds of drugs were investigated 
      with three dentin discs in each group. These nine drugs included two 
      anti-bacterial drugs (ampicillin sodium and clindamycin phosphate), two 
      corticosteroids (betamethasone sodium phosphate and hydrocortisone sodium 
      succinate), three non-steroidal anti-inflammatory drugs (NSAIDs, piroxicam, 
      lysine acetylsalicylate, and diclofenac sodium), and two natural extracts with 
      anti-inflammatory effect (Ginsenoside Rg1 and Hinokitol). The drugs were 
      introduced to the transwell dentin disc tube model and the 4-hour cumulative 
      release of the drug was detected and recorded by UV-visible spectroscopy. 
      RESULTS: We found that ampicilin sodium had better dentin permeability than 
      clindamycin phosphate. Betamethasone sodium phosphate revealed better dentin 
      permeability than hydrocortisone sodium succinate. Lysine acetylsalicylate showed 
      the best dentin permeability among the three NSAIDs. Ginsenoside Rg1 had the best 
      dentin permeability among the nine drugs tested. However, Hinokitiol could not 
      penetrate the dentin disc after 4 h. CONCLUSION: Regarding the dentin 
      permeability, Ginsenoside Rg1 is the best among the seven anti-inflammatory drugs 
      tested and ampicilin sodium is the better one between the two anti-bacterial 
      drugs tested. Therefore, these two drugs may have high potential for treating 
      exposed dentinal tubule diseases.
CI  - Copyright © 2018. Published by Elsevier B.V.
FAU - Lin, Chun-Pei
AU  - Lin CP
AD  - Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan 
      University, Taipei, Taiwan; Department of Dentistry, National Taiwan University 
      Hospital, National Taiwan University, Taipei, Taiwan.
FAU - Wang, Yin-Lin
AU  - Wang YL
AD  - Department of Dentistry, National Taiwan University Hospital, National Taiwan 
      University, Taipei, Taiwan.
FAU - Shen, Li-Juan
AU  - Shen LJ
AD  - Graduate Institute of Clinical Pharmacy, School of Pharmacy, National Taiwan 
      University, Taipei, Taiwan.
FAU - Lin, Chun-Pin
AU  - Lin CP
AD  - Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan 
      University, Taipei, Taiwan; Department of Dentistry, National Taiwan University 
      Hospital, National Taiwan University, Taipei, Taiwan; Advanced Research Center 
      for Green Materials Science & Technology, Taipei, Taiwan. Electronic address: 
      chunpinlin@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20180928
PL  - Singapore
TA  - J Formos Med Assoc
JT  - Journal of the Formosan Medical Association = Taiwan yi zhi
JID - 9214933
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Ginsenosides)
RN  - 7BK02SCL3W (betamethasone sodium phosphate)
RN  - 7C782967RD (Ampicillin)
RN  - 9842X06Q6M (Betamethasone)
RN  - K3Z4F929H6 (Lysine)
RN  - PJ788634QY (ginsenoside Rg1)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
MH  - Ampicillin/pharmacology
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/analogs & derivatives/pharmacokinetics
MH  - Betamethasone/analogs & derivatives/pharmacokinetics
MH  - Dentin/*drug effects
MH  - *Dentin Permeability
MH  - Ginsenosides/pharmacology
MH  - Humans
MH  - Lysine/analogs & derivatives/pharmacokinetics
MH  - Microscopy, Electron, Scanning
OTO - NOTNLM
OT  - Anti-bacterial agents
OT  - Anti-inflammatory agents
OT  - Dentin permeability
OT  - Exposed dentinal tubules
EDAT- 2018/10/03 06:00
MHDA- 2019/08/20 06:00
CRDT- 2018/10/03 06:00
PHST- 2018/07/29 00:00 [received]
PHST- 2018/08/31 00:00 [revised]
PHST- 2018/09/11 00:00 [accepted]
PHST- 2018/10/03 06:00 [pubmed]
PHST- 2019/08/20 06:00 [medline]
PHST- 2018/10/03 06:00 [entrez]
AID - S0929-6646(18)30517-5 [pii]
AID - 10.1016/j.jfma.2018.09.009 [doi]
PST - ppublish
SO  - J Formos Med Assoc. 2019 Apr;118(4):828-832. doi: 10.1016/j.jfma.2018.09.009. 
      Epub 2018 Sep 28.

PMID- 21136009
OWN - NLM
STAT- MEDLINE
DCOM- 20110621
LR  - 20181221
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 105
IP  - 3
DP  - 2011 Mar
TI  - Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 
      inhibition requires low levels of concomitant Gs-coupled receptor stimulation.
PG  - 487-95
LID - 10.1160/TH10-07-0439 [doi]
AB  - Phosphodiesterase (PDE)3 inhibitors exert potent antiplatelet effects through 
      maintaining elevated intracellular cyclic adenosine monophosphate levels, but do 
      not prolong bleeding time. To resolve this discrepancy, we hypothesised that PDE3 
      inhibitors effectively suppress shear-induced platelet thrombus formation 
      initiated by the interaction of the platelet receptor GPIb/V/IX with its ligand, 
      von Willebrand factor (VWF), since arterial thrombosis is more dependent on shear 
      stress as compared with haemostatic plug formation. To test the hypothesis, we 
      compared the in vitro effects of K-134 (a PDE3 inhibitor), tirofiban (a 
      GPIIb/IIIa inhibitor) and acetylsalicylic acid (ASA) on ristocetin-induced 
      platelet aggregation and platelet thrombus formation on VWF or collagen surfaces 
      under flow conditions. K-134 inhibited GPIIb/IIIa-dependent platelet aggregation 
      to the same extent as tirofiban and more potently than ASA. Likewise, K-134 and 
      tirofiban effectively inhibited stable platelet thrombus formation (platelet firm 
      adhesion and subsequent aggregation) on the VWF or collagen surface under high 
      shear, but ASA only inhibited aggregation. Notably, inhibition by K-134 became 
      evident only when a low concentration of PGE1 was present. These inhibitors did 
      not block shear-induced initial platelet contact with VWF via GPIb/V/IX. In 
      contrast, under low shear, the inhibitory effects of K-134 on platelet 
      aggregation on the collagen surface were lower than tirofiban or ASA. The 
      observed shear-dependent suppression of platelet thrombus formation by PDE3 
      inhibitor in the presence of low levels of adenylate cyclase stimulator may 
      contribute to high therapeutic benefit with low risk of bleeding.
FAU - Yoshida, Hideo
AU  - Yoshida H
AD  - Tokyo New Drug Research Laboratories, Kowa Company, Ltd., Tokyo, Japan.
FAU - Okamura, Yosuke
AU  - Okamura Y
FAU - Watanabe, Naohide
AU  - Watanabe N
FAU - Ikeda, Yasuo
AU  - Ikeda Y
FAU - Handa, Makoto
AU  - Handa M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101206
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Ligands)
RN  - 0 (Quinolines)
RN  - 0 (von Willebrand Factor)
RN  - 1404-55-3 (Ristocetin)
RN  - 42HK56048U (Tyrosine)
RN  - 8W8T17847W (Urea)
RN  - E0399OZS9N (Cyclic AMP)
RN  - EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 3)
RN  - EC 3.6.5.1 (GTP-Binding Protein alpha Subunits, Gs)
RN  - GGX234SI5H (Tirofiban)
RN  - H2D2X058MU (Cyclic GMP)
RN  - J9J6NK6W4U (OPC 33509)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry/pharmacology
MH  - Cyclic AMP/metabolism
MH  - Cyclic GMP/metabolism
MH  - Cyclic Nucleotide Phosphodiesterases, Type 3/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - GTP-Binding Protein alpha Subunits, Gs/*metabolism
MH  - Hemostasis
MH  - Humans
MH  - Ligands
MH  - Platelet Aggregation
MH  - Quinolines/pharmacology
MH  - Ristocetin/pharmacology
MH  - Shear Strength
MH  - Tirofiban
MH  - Tyrosine/analogs & derivatives/pharmacology
MH  - Urea/analogs & derivatives/pharmacology
MH  - von Willebrand Factor/metabolism
EDAT- 2010/12/08 06:00
MHDA- 2011/06/22 06:00
CRDT- 2010/12/08 06:00
PHST- 2010/07/10 00:00 [received]
PHST- 2010/11/25 00:00 [accepted]
PHST- 2010/12/08 06:00 [entrez]
PHST- 2010/12/08 06:00 [pubmed]
PHST- 2011/06/22 06:00 [medline]
AID - 10-07-0439 [pii]
AID - 10.1160/TH10-07-0439 [doi]
PST - ppublish
SO  - Thromb Haemost. 2011 Mar;105(3):487-95. doi: 10.1160/TH10-07-0439. Epub 2010 Dec 
      6.

PMID- 18555092
OWN - NLM
STAT- MEDLINE
DCOM- 20080807
LR  - 20161124
IS  - 0041-1345 (Print)
IS  - 0041-1345 (Linking)
VI  - 40
IP  - 4
DP  - 2008 May
TI  - Nitric oxide inhibition and consecutive Aspisol application show a prolonged 
      survival of orthotopic transplanted livers in a rat model.
PG  - 971-3
LID - 10.1016/j.transproceed.2008.03.041 [doi]
AB  - BACKGROUND: It is generally accepted that nitric oxide (NO) plays a crucial role 
      in acute rejection caused by inflammatory responses. Therefore, the purpose of 
      this study was to investigate the effect on survival following arterialized 
      orthotopic rat liver transplantations (o-RLTx) of NO inhibition and consequent 
      blockade of platelet aggregation by application of Aspisol. MATERIALS AND 
      METHODS: Inbred LEWIS-(RT(1)) rats underwent arterialized o-RLTx under ether 
      anesthesia with DA-(RT1av1) rats as organ donors. After liver transplantation, 
      serum parameters were determined and hepatic biopsy specimens were sampled on 
      postoperative days 5, 8, 10, 30, and 90. Sixty-one rats were divided into 5 
      groups: syngenic controls (group I, n = 12); allogenic controls (group II, n = 
      11); allogenic with FK506 immunosuppression (group III, n = 12); allogenic with 
      AGH-treatment (group IV, n = 13); and allogenic with AGH/low- dose Aspisol 
      treatment for 5 days after liver transplantation (group V, n = 13) (Bayer, 
      Leverkusen, Germany). RESULTS: Rats of group V with AGH/low-dose Aspisol 
      treatment showed significantly longer graft survival (18.2 days +/- 1.8 days) 
      compared with group II rats with untreated grafts (11.3 days +/- 1.7 days) the 
      allogenic group IV with AGH treatment (11.2 days +/- 1.8 days; P < .05). 
      Histological examination revealed moderate graft rejection among the AGH-treated 
      group IV; however, marked platelet aggregation in sinusoids was present, which 
      was not observed in the AGH/low-dose Aspisol-treated animals (group V). 
      CONCLUSION: Our data suggested that simultaneous treatment with AGH/low-dose 
      Aspisol leads to a significant increase in survival and inhibition of platelet 
      aggregation in the graft after orthotopic liver transplantation.
FAU - Matevossian, E
AU  - Matevossian E
AD  - Department of Surgery, Technical University of Munich, Munich, Germany. 
      matevossian@chir.med.tu-muenchen.de
FAU - Hüser, N
AU  - Hüser N
FAU - Kern, H
AU  - Kern H
FAU - Assfalg, V
AU  - Assfalg V
FAU - Preissel, A
AU  - Preissel A
FAU - Sinicina, I
AU  - Sinicina I
FAU - Stangl, M
AU  - Stangl M
FAU - Thorban, S
AU  - Thorban S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Immunosuppressive Agents)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - WM0HAQ4WNM (Tacrolimus)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Biopsy
MH  - Graft Survival/*drug effects
MH  - Immunosuppressive Agents/therapeutic use
MH  - Liver Transplantation/pathology/*physiology
MH  - Lysine/*analogs & derivatives/pharmacology
MH  - Models, Animal
MH  - Nitric Oxide/*antagonists & inhibitors
MH  - Nitric Oxide Synthase Type II/antagonists & inhibitors
MH  - Rats
MH  - Rats, Inbred Lew
MH  - Tacrolimus/therapeutic use
MH  - Transplantation, Homologous
MH  - Transplantation, Isogeneic
EDAT- 2008/06/17 09:00
MHDA- 2008/08/08 09:00
CRDT- 2008/06/17 09:00
PHST- 2008/06/17 09:00 [pubmed]
PHST- 2008/08/08 09:00 [medline]
PHST- 2008/06/17 09:00 [entrez]
AID - S0041-1345(08)00245-5 [pii]
AID - 10.1016/j.transproceed.2008.03.041 [doi]
PST - ppublish
SO  - Transplant Proc. 2008 May;40(4):971-3. doi: 10.1016/j.transproceed.2008.03.041.

PMID- 10440415
OWN - NLM
STAT- MEDLINE
DCOM- 19991210
LR  - 20181201
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 25 Suppl 2
DP  - 1999
TI  - Single-dose pharmacodynamics of clopidogrel.
PG  - 3-8
AB  - The inhibition of platelet aggregation by clopidogrel, a novel platelet 
      ADP-receptor antagonist, was evaluated in healthy male volunteers in two 
      single-dose studies. In one study, 10 subjects received, in increasing order, 
      single doses of 100, 200, 400 and 600 mg of clopidogrel or placebo in five study 
      periods, according to a randomized, doubleblind, protocol design. In the second 
      study, 12 subjects received a single 400 mg dose of clopidogrel as capsules and 
      as tablets, according to an open-label, randomized, crossover design. The 
      interval between the two administrations was seven days. Platelet aggregation 
      induced by ADP (2, 5 and 10 microM) and by collagen (0.5 and 1 microg/mL; 
      rising-dose study only) was assessed from blood samples collected over a period 
      of 24 hours to 72 hours postdose. The inhibition of platelet aggregation was 
      expressed as the mean percent change from baseline in maximum platelet 
      aggregation. The effect of clopidogrel on bleeding time was also assessed. 
      Clopidogrel induced a statistically significant inhibition of ADP-induced 
      platelet aggregation at all doses. With 5 microM of ADP, the inhibition was 
      dose-related up to a dose of 400 mg, with no further increase at a dose of 600 
      mg. At 2 hours, mean inhibition ranged from 12+/-6% (100 mg) to 42 +/-6% (400 
      mg), and at 24 hours, it ranged from 17+/-7% (100 mg) to 43+/-9% (400 mg). After 
      400 mg, the inhibition of platelet aggregation remained stable from 2 hours up to 
      72 hours, with mean percentages of inhibition ranging from 49 to 39%. Clopidogrel 
      only showed a slight-to-moderate inhibitory effect on collagen-induced platelet 
      aggregation. A mean bleeding time prolongation of 1.7 was observed 5 hours after 
      the 400 mg and 600 mg doses; it was statistically significant only following the 
      higher dose. Individual bleeding time prolongations ranged from 1 to 2.85. 
      Clopidogrel was well tolerated at all doses. The results of these studies were 
      part of the rational for the choice of the loading dose.
FAU - Thebault, J J
AU  - Thebault JJ
AD  - Institut Aster, Hôpital Cognacq-Jay, Paris, France.
FAU - Kieffer, G
AU  - Kieffer G
FAU - Cariou, R
AU  - Cariou R
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aspirin/administration & dosage/pharmacology
MH  - Clopidogrel
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/*pharmacology
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacology
EDAT- 1999/08/10 00:00
MHDA- 1999/08/10 00:01
CRDT- 1999/08/10 00:00
PHST- 1999/08/10 00:00 [pubmed]
PHST- 1999/08/10 00:01 [medline]
PHST- 1999/08/10 00:00 [entrez]
PST - ppublish
SO  - Semin Thromb Hemost. 1999;25 Suppl 2:3-8.

PMID- 18779739
OWN - NLM
STAT- MEDLINE
DCOM- 20090420
LR  - 20131121
IS  - 1539-2031 (Electronic)
IS  - 0192-0790 (Linking)
VI  - 43
IP  - 2
DP  - 2009 Feb
TI  - Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin 
      in patients with ischemic heart disease.
PG  - 130-2
LID - 10.1097/MCG.0b013e3181580e8a [doi]
AB  - BACKGROUND: Low-dose aspirin is used for secondary prevention of ischemic heart 
      disease and ischemic cerebrovascular disease. Currently, the frequency of 
      gastrointestinal disorder among users of low-dose aspirin is unknown. AIMS: To 
      investigate through endoscopic examination the frequency of gastroduodenal 
      disorder associated with buffered and enteric-coated aspirin (ECA). METHODS: 
      Screening upper endoscopic examinations were prospectively performed on 236 
      patients with ischemic heart disease. Endoscopic findings including ulcers and 
      flat erosions were assessed as mucosal defects. RESULTS: Mucosal defects were 
      found in 92 of 190 (48.4%) users of low-dose aspirin and 6 of 46 (13.0%) 
      nonusers. There were significantly more mucosal defects among users of low-dose 
      aspirin than among those using no aspirin (P<0.0001). Mucosal defects were found 
      in 54 of 98 (60.7%) users of buffered aspirin (BA), whereas 38 of 101 (37.6%) 
      users of ECA had mucosal defects. Users of ECA had significantly fewer erosions 
      than did those of BA (P=0.0015). The frequency of ulcer is similar between BA 
      users and ECA users. CONCLUSIONS: As endoscopy frequently reveals gastroduodenal 
      disorder among low-dose aspirin users, both administration of BA and of 
      enteric-coated aspirin warrant concern for gastroduodenal ulcer.
FAU - Nema, Hiroaki
AU  - Nema H
AD  - Department of Gastroenterology, Hokko Memorial Hospital, Hokkaido University 
      Hospital, Sapporo, Hokkaido, Japan.
FAU - Kato, Mototsugu
AU  - Kato M
FAU - Katsurada, Takehiko
AU  - Katsurada T
FAU - Nozaki, Youichi
AU  - Nozaki Y
FAU - Yotsukura, Akihiko
AU  - Yotsukura A
FAU - Yoshida, Izumi
AU  - Yoshida I
FAU - Sato, Katsuhiko
AU  - Sato K
FAU - Kawai, Yuko
AU  - Kawai Y
FAU - Takagi, Yasushi
AU  - Takagi Y
FAU - Okusa, Takanori
AU  - Okusa T
FAU - Takiguchi, Shunichi
AU  - Takiguchi S
FAU - Sakurai, Masayuki
AU  - Sakurai M
FAU - Asaka, Masahiro
AU  - Asaka M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Buffers)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Buffers
MH  - Drug Administration Schedule
MH  - *Duodenum/drug effects/pathology
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - *Gastric Mucosa/drug effects/pathology
MH  - Gastrointestinal Diseases/chemically induced/pathology
MH  - Humans
MH  - *Intestinal Mucosa/drug effects/pathology
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*drug therapy
MH  - Tablets, Enteric-Coated
EDAT- 2008/09/10 09:00
MHDA- 2009/04/21 09:00
CRDT- 2008/09/10 09:00
PHST- 2008/09/10 09:00 [pubmed]
PHST- 2009/04/21 09:00 [medline]
PHST- 2008/09/10 09:00 [entrez]
AID - 10.1097/MCG.0b013e3181580e8a [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 2009 Feb;43(2):130-2. doi: 10.1097/MCG.0b013e3181580e8a.

PMID- 24665827
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20181202
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Linking)
VI  - 36
IP  - 6
DP  - 2014 Jul
TI  - Inhibition of platelet activation could decrease thrombotic events in 
      hemodialysis PF4/H antibody-positive patients.
PG  - 870-6
LID - 10.3109/0886022X.2014.899880 [doi]
AB  - BACKGROUND: Platelet factor 4/heparin (PF4/H) antibody detection is widely used 
      to evaluate the risk of thrombosis in patients undergoing hemodialysis (HD). Most 
      patients who are PF4/H-antibody-positive can survive thrombosis, but the reason 
      has not been clarified. In addition, no valid preventive methods for thrombosis 
      in patients undergoing HD have been confirmed. METHODS: A single-center, 
      semi-randomized controlled study was designed. In total, 157 patients fulfilled 
      the inclusion criteria and participated. Patients were first divided according to 
      PF4/H antibody detection and then subdivided randomly according to different 
      anti-platelet agent descriptions. RESULTS: (1) PF4/H antibody-positive patients 
      suffered a significantly higher incidence of thrombosis than those who were 
      antibody-negative; (2) PF4/H antibody-positive patients who survived a thrombosis 
      manifested a significantly longer bleeding time and decreased maximum percentage 
      of platelet aggregation inhibition; (3) aspirin and clopidogrel decreased the 
      incidence of thrombosis in PF4/H antibody-positive patients by inhibiting 
      platelet activation. CONCLUSION: The PF4/H antibody was effective for prediction 
      of the risk of thrombosis, except in patients with dysfunctional platelets; 
      aspirin manifested effects similar to clopidogrel in terms of prevention of 
      thromboses in PF4/H antibody-positive patients, but costs much less and is 
      therefore recommended.
FAU - Yang, Yang
AU  - Yang Y
AD  - Therapeutic Centre of Kidney Diseases, First Affiliated Hospital of Beidaihe 
      Sanatorium of Beijing Military Region , Qinhuangdao, Hebei Province , P.R. China 
      .
FAU - Kong, Deyang
AU  - Kong D
FAU - Wang, Chao
AU  - Wang C
FAU - Chen, Guanglei
AU  - Chen G
FAU - Shan, Fujun
AU  - Shan F
FAU - Qi, Ka
AU  - Qi K
FAU - Ma, Lu
AU  - Ma L
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20140326
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 37270-94-3 (Platelet Factor 4)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Platelet Factor 4/*immunology
MH  - Renal Dialysis/*adverse effects
MH  - Thrombosis/epidemiology/*immunology/prevention & control
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Anti-platelet
OT  - PF4/H antibodies
OT  - heparin-induced thrombocytopenia
OT  - platelet dysfunction
OT  - thrombosis
EDAT- 2014/03/29 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/03/27 06:00
PHST- 2014/03/27 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - 10.3109/0886022X.2014.899880 [doi]
PST - ppublish
SO  - Ren Fail. 2014 Jul;36(6):870-6. doi: 10.3109/0886022X.2014.899880. Epub 2014 Mar 
      26.

PMID- 27064832
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20181202
IS  - 1557-9034 (Electronic)
IS  - 1092-6429 (Linking)
VI  - 26
IP  - 7
DP  - 2016 Jul
TI  - Anticoagulation Therapy with Warfarin Versus Low-Dose Aspirin Prevents Portal 
      Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection.
PG  - 517-23
LID - 10.1089/lap.2016.0012 [doi]
AB  - BACKGROUND: Portal vein system thrombosis (PVST) is a frequent and potentially 
      life-threatening complication after laparoscopic splenectomy and azygoportal 
      disconnection (LSD) in patients with cirrhotic portal hypertension. The objective 
      of this study was to investigate the safety and effectiveness of warfarin with a 
      target international normalized ratio (INR) of 2.0-2.5 for the prevention of PVST 
      after LSD. Hitherto, this is the first study to assess the use of warfarin in 
      this field. MATERIALS AND METHODS: We retrospectively analyzed a database of 73 
      consecutive patients who underwent LSD from January 2013 to September 2014. 
      Patients were categorized into the warfarin group (34 patients) and the aspirin 
      group (39 patients). The INR and incidence of PSVT were monitored for 90 days. 
      RESULTS: Compared with the aspirin group, the warfarin group had a lower 
      incidence of PVST on postoperative day (POD) 30 [17/34 (50.0%) versus 29/39 
      (74.4%); P = .032] and POD 90 [8/34 (23.5%) versus 30/39 (76.9%); P < .0001] and 
      main portal vein thrombosis (MPVT) on POD 90 [3 (8.8%) versus 13 (33.3%); 
      P = .012]. From POD 30 to 90, the warfarin group achieved more complete 
      recanalization of PVST [9/17 (52.9%) versus 3/29 (10.3%), P = .005] and MPVT 
      [9/12 (75.0%) versus 3/12 (25.0%), P = .039]. Multiple logistic regression 
      analysis revealed that warfarin was an independent protective factor for PVST at 
      POD 90 (relative risk, 0.027; 95% confidence interval, 0.004-0.168; P < .001). No 
      patients developed bleeding complications. CONCLUSIONS: Anticoagulation therapy 
      with warfarin is safe and effective for the prevention of PVST in cirrhotic 
      patients with portal hypertension after LSD.
FAU - Jiang, Guo-Qing
AU  - Jiang GQ
AD  - 1 Department of Hepatobiliary Surgery, Clinical Medical College of Yangzhou 
      University , Yangzhou, China .
FAU - Xia, Bing-Lan
AU  - Xia BL
AD  - 2 Department of Ultrasound, Clinical Medical College of Yangzhou University , 
      Yangzhou, China .
FAU - Chen, Ping
AU  - Chen P
AD  - 1 Department of Hepatobiliary Surgery, Clinical Medical College of Yangzhou 
      University , Yangzhou, China .
FAU - Qian, Jian-Jun
AU  - Qian JJ
AD  - 1 Department of Hepatobiliary Surgery, Clinical Medical College of Yangzhou 
      University , Yangzhou, China .
FAU - Jin, Sheng-Jie
AU  - Jin SJ
AD  - 1 Department of Hepatobiliary Surgery, Clinical Medical College of Yangzhou 
      University , Yangzhou, China .
FAU - Zuo, Si-Qin
AU  - Zuo SQ
AD  - 1 Department of Hepatobiliary Surgery, Clinical Medical College of Yangzhou 
      University , Yangzhou, China .
FAU - Bai, Dou-Sheng
AU  - Bai DS
AD  - 1 Department of Hepatobiliary Surgery, Clinical Medical College of Yangzhou 
      University , Yangzhou, China .
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160411
PL  - United States
TA  - J Laparoendosc Adv Surg Tech A
JT  - Journal of laparoendoscopic & advanced surgical techniques. Part A
JID - 9706293
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Azygos Vein/surgery
MH  - Female
MH  - Heparin, Low-Molecular-Weight/administration & dosage/therapeutic use
MH  - Humans
MH  - Liver Cirrhosis/surgery
MH  - Male
MH  - Middle Aged
MH  - *Portal Vein
MH  - Postoperative Complications/*prevention & control
MH  - Retrospective Studies
MH  - Splenectomy/*adverse effects
MH  - Treatment Outcome
MH  - Venous Thrombosis/*prevention & control
MH  - Warfarin/administration & dosage/therapeutic use
MH  - Young Adult
EDAT- 2016/04/12 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/04/12 06:00
PHST- 2016/04/12 06:00 [entrez]
PHST- 2016/04/12 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
AID - 10.1089/lap.2016.0012 [doi]
PST - ppublish
SO  - J Laparoendosc Adv Surg Tech A. 2016 Jul;26(7):517-23. doi: 
      10.1089/lap.2016.0012. Epub 2016 Apr 11.

PMID- 10367219
OWN - NLM
STAT- MEDLINE
DCOM- 19990701
LR  - 20131121
IS  - 0046-5968 (Print)
IS  - 0046-5968 (Linking)
VI  - 29
IP  - 5
DP  - 1999 May
TI  - Effects of aspirin or picotamide, an antithromboxane agent, in combination with 
      low-intensity oral anticoagulation in patients with acute myocardial infarction: 
      a controlled randomized pilot trial.
PG  - 524-8
AB  - BACKGROUND AND OBJECTIVE: Combined treatment with antiplatelet drugs and oral 
      anticoagulants seems more effective than monotherapy in the reduction of 
      thrombotic episodes in patients with ischemic heart diseases. We compared the 
      safety and efficacy of two different antiplatelet drugs, aspirin (asa) and 
      picotamide (pico)--a dual antithromboxane agent--in combination with 
      low-intensity oral anticoagulation with warfarin or acenocoumarol in acute 
      myocardial infarction (AMI). PATIENTS AND METHODS: Primary endpoint of the study 
      was to compare the incidence of major events (death, reinfarction, postinfarction 
      angina and heart failure) in AMI patients undergoing thrombolytic therapy. In a 
      controlled randomized parallel group pilot study, 101 patients with AMI were 
      enrolled and treated with asa 160 mg/die plus low-intensity oral anticoagulation 
      (target INR: 1.5-2.5) (n = 51) or pico 300 mg/tid plus low-intensity oral 
      anticoagulation (n = 50). Secondary endpoint of the study was to compare the 
      cumulative incidence of major events plus major hemorrhagic episodes defined as 
      macroscopic hematuria, nose bleeding and melena. RESULTS: The two groups were 
      well matched regarding the main demographic and clinical variables. AMI location 
      was anterior in 22 and 20 patients in the pico and asa group respectively, 
      inferoposterior in 27 (pico) and 29 (asa) patients. At the end of the six-month 
      period, major events were observed in 20 patients in the pico group and in 31 
      patients in the asa group (p < 0.05). The cumulative incidence of major clinical 
      events plus major hemorrhagic episodes was significantly lower in the pico group 
      in comparison with the asa group (28 vs 48; p < 0.001). CONCLUSION: The results 
      of this pilot study suggest that combination therapy with picotamide and 
      low-intensity oral anticoagulation could be a safe and effective alternative to 
      aspirin in patient with AMI. This hypothesis should be confirmed by controlled 
      randomized trial with an adequate sample size.
FAU - Vetrano, A
AU  - Vetrano A
AD  - Cardiology Department, Caserta General Hospital.
FAU - Milani, M
AU  - Milani M
FAU - Corsini, G
AU  - Corsini G
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Italy
TA  - G Ital Cardiol
JT  - Giornale italiano di cardiologia
JID - 1270331
RN  - 0 (Anticoagulants)
RN  - 0 (Phthalic Acids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - 654G2VCI4Q (picotamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Phthalic Acids/*administration & dosage/adverse effects
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Single-Blind Method
MH  - Thromboxanes/*antagonists & inhibitors
EDAT- 1999/06/15 00:00
MHDA- 1999/06/15 00:01
CRDT- 1999/06/15 00:00
PHST- 1999/06/15 00:00 [pubmed]
PHST- 1999/06/15 00:01 [medline]
PHST- 1999/06/15 00:00 [entrez]
PST - ppublish
SO  - G Ital Cardiol. 1999 May;29(5):524-8.

PMID- 3466837
OWN - NLM
STAT- MEDLINE
DCOM- 19870210
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 27
IP  - 11
DP  - 1986 Nov
TI  - Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the 
      permeability of the human small intestine.
PG  - 1292-7
AB  - Intestinal permeability was estimated in healthy subjects after ingestion of 
      aspirin (1.2+1.2 g), ibuprofen (400+400 mg) and indomethacin (75+50 mg) at 
      midnight and an hour before starting a 51chromium labelled 
      ethylenediaminetetraacetate absorption test. Intestinal permeability increased 
      significantly from control levels following each drug and the effect was related 
      to drug potency to inhibit cyclooxygenase. Intestinal permeability increased to a 
      similar extent after oral and rectal administration of indomethacin showing that 
      the effect is systemically mediated. Prostaglandin E2 decreased intestinal 
      permeability significantly but failed to prevent the indomethacin induced 
      increased intestinal permeability. These studies show that non-steroidal 
      anti-inflammatory drugs disrupt the intestinal barrier function in man and 
      suggest that the morphological correlates of the damage may reside at the level 
      of the intercellular junctions.
FAU - Bjarnason, I
AU  - Bjarnason I
FAU - Williams, P
AU  - Williams P
FAU - Smethurst, P
AU  - Smethurst P
FAU - Peters, T J
AU  - Peters TJ
FAU - Levi, A J
AU  - Levi AJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandins E)
RN  - 884KT10YB7 (Ranitidine)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/pharmacology
MH  - Dinoprostone
MH  - Humans
MH  - Ibuprofen/pharmacology
MH  - Indomethacin/pharmacology
MH  - Intestine, Small/*drug effects
MH  - Permeability
MH  - Prostaglandins E/*pharmacology
MH  - Ranitidine/pharmacology
PMC - PMC1434083
EDAT- 1986/11/01 00:00
MHDA- 1986/11/01 00:01
CRDT- 1986/11/01 00:00
PHST- 1986/11/01 00:00 [pubmed]
PHST- 1986/11/01 00:01 [medline]
PHST- 1986/11/01 00:00 [entrez]
AID - 10.1136/gut.27.11.1292 [doi]
PST - ppublish
SO  - Gut. 1986 Nov;27(11):1292-7. doi: 10.1136/gut.27.11.1292.

PMID- 645885
OWN - NLM
STAT- MEDLINE
DCOM- 19780612
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 234
IP  - 4
DP  - 1978 Apr
TI  - Gonadal hormones and pathogenesis of occlusive arterial thrombosis.
PG  - H454-9
AB  - Arterial thrombus formation was induced in male and female Wistar rats (3 mo) by 
      inserting a loop-shaped polyethylene cannula into the abdominal aorta. 
      Thrombogenesis was also induced in mature male and female New Zealand rabbits by 
      constriction of the femoral artery and injection of ellagic acid. The criteria 
      for thrombus development in the cannulated rats were: incidence of thrombosis 
      (IT), obstruction time (OT), and thrombus weight (TW). We observed a significant 
      sex difference in all these criteria of thrombogenesis in both rats and rabbits. 
      Pretreatment of either sex with Depo-testosterone shortened OT, increased TW 
      about fivefold in males and threefold in females, and increased mortality rate 
      (MR) more than fourfold in both sexes. Prolonged pretreatment with 
      Depo-testosterone increased in all aspects of thrombogenesis. Depo-estradiol had 
      marginal ameliorating effects in male rats only. Both the antiandrogen Flutamide, 
      and aspirin, significantly decreased the thrombogenic effects of testosterone. 
      Thus, testosterone may be a significant risk factor in experimentally induced 
      thrombogenesis in rats and rabbits.
FAU - Uzunova, A D
AU  - Uzunova AD
FAU - Ramey, E R
AU  - Ramey ER
FAU - Ramwell, P W
AU  - Ramwell PW
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
RN  - 76W6J0943E (Flutamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Estradiol/*therapeutic use
MH  - Female
MH  - Flutamide/pharmacology
MH  - Male
MH  - Rabbits
MH  - Rats
MH  - Sex Factors
MH  - Testosterone/*pharmacology
MH  - Thrombosis/*etiology/pathology
EDAT- 1978/04/01 00:00
MHDA- 1978/04/01 00:01
CRDT- 1978/04/01 00:00
PHST- 1978/04/01 00:00 [pubmed]
PHST- 1978/04/01 00:01 [medline]
PHST- 1978/04/01 00:00 [entrez]
AID - 10.1152/ajpheart.1978.234.4.H454 [doi]
PST - ppublish
SO  - Am J Physiol. 1978 Apr;234(4):H454-9. doi: 10.1152/ajpheart.1978.234.4.H454.

PMID- 25029449
OWN - NLM
STAT- MEDLINE
DCOM- 20150406
LR  - 20140717
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 29
IP  - 4
DP  - 2014 Jul
TI  - Myocardial injury after noncardiac surgery.
PG  - 307-11
LID - 10.1097/HCO.0000000000000069 [doi]
AB  - PURPOSE OF REVIEW: Recent investigations have substantially improved our 
      understanding of myocardial injury after noncardiac surgery (MINS). RECENT 
      FINDINGS: MINS is defined as a prognostically relevant myocardial injury due to 
      ischemia that occurs during or within 30 days after noncardiac surgery. MINS 
      occurs in 8% of adults undergoing major noncardiac surgery and is diagnosed with 
      an elevated postoperative troponin measurement. MINS is associated with 
      significant morbidity, and approximately 10% of patients experiencing MINS will 
      die within 30 days. There is a dose-graded response in mortality and time to 
      death with increasing levels of postoperative troponin elevations. Most patients 
      (>80%) suffering from MINS will not experience an ischemic symptom. Without 
      troponin monitoring, the majority of MINS events would go undetected. To avoid 
      missing these prognostically relevant events, guidelines now recommend 
      perioperative troponin monitoring in high-risk patients having noncardiac 
      surgery. In patients who suffer MINS, risk-adjusted observational data suggest 
      that aspirin and a statin can reduce the risk of 30-day mortality. SUMMARY: Among 
      adults, MINS is the most common cardiovascular complication that occurs after 
      noncardiac surgery. Given that worldwide 200 million adult patients undergo major 
      noncardiac surgery each year, at least 8 million of these patients will suffer 
      MINS making this a substantial public health problem.
FAU - Khan, James
AU  - Khan J
AD  - aDepartment of Anesthesia, University of Toronto, Toronto bDepartment of Clinical 
      Epidemiology and Biostatistics, McMaster University cPopulation Health Research 
      Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, 
      Canada dBiomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain 
      eDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Alonso-Coello, Pablo
AU  - Alonso-Coello P
FAU - Devereaux, P J
AU  - Devereaux PJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Troponin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cause of Death
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Monitoring, Intraoperative
MH  - Myocardial Ischemia/*etiology
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Postoperative Complications
MH  - Surgical Procedures, Operative/*adverse effects
MH  - Time Factors
MH  - Troponin/analysis
EDAT- 2014/07/17 06:00
MHDA- 2015/04/07 06:00
CRDT- 2014/07/17 06:00
PHST- 2014/07/17 06:00 [entrez]
PHST- 2014/07/17 06:00 [pubmed]
PHST- 2015/04/07 06:00 [medline]
AID - 00001573-201407000-00005 [pii]
AID - 10.1097/HCO.0000000000000069 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2014 Jul;29(4):307-11. doi: 10.1097/HCO.0000000000000069.

PMID- 1735135
OWN - NLM
STAT- MEDLINE
DCOM- 19920311
LR  - 20190706
IS  - 0009-7330 (Print)
IS  - 0009-7330 (Linking)
VI  - 70
IP  - 2
DP  - 1992 Feb
TI  - Influence of platelet-vessel wall interactions on leukocyte rolling in vivo.
PG  - 355-63
AB  - The influence of platelet-vessel wall interactions on leukocyte rolling was 
      investigated in rabbit mesenteric venules (diameter, 21-40 microns) using 
      intravital videomicroscopy. Puncture of the wall with glass micropipettes (tip, 
      6-8 microns) evoked the formation of a thrombus in all venules. In most vessels, 
      emboli were produced as well. The rolling of leukocytes (i.e., their movement 
      along the vessel wall at a velocity clearly lower than that of the other blood 
      cells) was quantitated simultaneously in vessel segments upstream and downstream 
      from a thrombus up to 10 minutes after puncture. During embolization the number 
      of rolling leukocytes decreased significantly from the upstream to the downstream 
      vessel segment (median decrease, 45%; p less than or equal to 0.001). It was 
      still decreased by approximately 50% after embolization had stopped, indicating 
      that the decrease in leukocyte rolling was not caused by inclusion of leukocytes 
      in the emboli. In venules without embolization, leukocyte rolling did not change 
      systematically, indicating that fluid dynamic changes induced by the thrombus do 
      not influence leukocyte rolling. Inhibition of prostaglandin formation with 
      aspirin (100 mg/kg) almost completely abolished the influence of the 
      thromboembolic reaction on leukocyte rolling, but blockade of thromboxane A2 
      receptors with sulotroban (30 mg/kg) had no effect. In conclusion, this is the 
      first report on a functional interaction in vivo, at a site of vessel wall 
      injury, between platelets, vascular cells, and leukocytes. The findings suggest 
      that substances produced by activated platelets and/or damaged vascular cells 
      diminish leukocyte rolling. The identity of these substances is not yet clear, 
      but the present study indicates that prostaglandins other than thromboxane A2 are 
      involved.
FAU - oude Egbrink, M G
AU  - oude Egbrink MG
AD  - Department of Physiology, University of Limburg, The Netherlands.
FAU - Tangelder, G J
AU  - Tangelder GJ
FAU - Slaaf, D W
AU  - Slaaf DW
FAU - Reneman, R S
AU  - Reneman RS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Circ Res
JT  - Circulation research
JID - 0047103
RN  - 0 (Sulfonamides)
RN  - 74574CO5A6 (sulotroban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*physiology
MH  - Blood Vessels/*physiology
MH  - Female
MH  - Leukocytes/*physiology
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
MH  - Reference Values
MH  - Sulfonamides/pharmacology
MH  - Thromboembolism/pathology/physiopathology
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
AID - 10.1161/01.res.70.2.355 [doi]
PST - ppublish
SO  - Circ Res. 1992 Feb;70(2):355-63. doi: 10.1161/01.res.70.2.355.

PMID- 36328858
OWN - NLM
STAT- MEDLINE
DCOM- 20221223
LR  - 20230130
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Linking)
VI  - 42
IP  - 1
DP  - 2023 Jan
TI  - Early aspirin use and the development of cardiac allograft vasculopathy in 
      pediatric heart transplant recipients: A pediatric heart transplant society 
      analysis.
PG  - 115-123
LID - S1053-2498(22)02108-8 [pii]
LID - 10.1016/j.healun.2022.08.023 [doi]
AB  - BACKGROUND: Cardiac allograft vasculopathy (CAV) remains a leading cause of graft 
      loss in pediatric heart transplant (HTx) recipients. Adult literature suggests 
      that aspirin (ASA) use in the early post-HTx period may reduce the risk of CAV. 
      This study aimed to determine the impact of early ASA use on the development of 
      CAV in pediatric HTx recipients. METHODS: All subjects <17 years of age at time 
      of primary HTx who survived ≥3 years without evidence of CAV were identified for 
      inclusion from the Pediatric Heart Transplant Society database (1996-2019). Early 
      ASA use was defined as ASA started within the first 3 years post-HTx and was 
      classified as continuous or intermittent. Frequency of ASA use was described 
      across centers. Kaplan-Meier method assessed freedom from CAV and overall graft 
      survival. Multiphase parametric hazard analyses and propensity score matched 
      analysis were used to identify independent risk factors. RESULTS: 3,011 patients 
      were included with 387 (13%) receiving continuous ASA, 676 (22%) receiving 
      intermittent ASA, and 1,948 (65%) receiving no ASA. ASA use was highly variable 
      across centers (0%-100%). At baseline patients receiving continuous ASA therapy 
      demonstrated inferior graft survival (p < 0.001) and worse freedom from CAV 
      (p = 0.002), but with lower CAV grades (p = 0.05). In multiphase parametric 
      hazard modeling continuous ASA use was not independently associated with CAV, but 
      remained associated with inferior graft survival. Propensity-matched sub-analysis 
      between continuous and no ASA groups demonstrated no difference in freedom from 
      CAV or overall graft loss. CONCLUSIONS: ASA use varies widely across pediatric 
      HTx centers. Early ASA use did not reduce the risk of CAV or graft loss in 
      pediatric heart transplant recipients.
CI  - Copyright © 2022 International Society for Heart and Lung Transplantation. 
      Published by Elsevier Inc. All rights reserved.
FAU - D'Addese, Laura
AU  - D'Addese L
AD  - Pediatric Cardiology, Joe DiMaggio Children's Hospital, Hollywood, Florida. 
      Electronic address: ldaddese@mhs.net.
FAU - Cantor, Ryan S
AU  - Cantor RS
AD  - Surgery, Kirklin Institute for Research in Surgical Outcomes, University of 
      Alabama at Birmingham, Birmingham, Alabama.
FAU - Koehl, Devin
AU  - Koehl D
AD  - Surgery, Kirklin Institute for Research in Surgical Outcomes, University of 
      Alabama at Birmingham, Birmingham, Alabama.
FAU - Reardon, Leigh
AU  - Reardon L
AD  - Pediatric Cardiology, Mattel Children's Hospital, Los Angeles, California.
FAU - Ameduri, Rebecca
AU  - Ameduri R
AD  - Pediatric Cardiology, University of Minnesota Masonic Children's Hospital, 
      Minneapolis, Minnesota.
FAU - Bock, Matthew
AU  - Bock M
AD  - Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, 
      California.
FAU - Morrison, Adam
AU  - Morrison A
AD  - Pediatric Cardiology, Levine Children's Hospital-Atrium Health, Charlotte, North 
      Carolina.
FAU - White, Shelby
AU  - White S
AD  - Pediatric Cardiology, University of Virginia Medical Center, Charlottesville, 
      Virginia.
FAU - Wisotzkey, Bethany
AU  - Wisotzkey B
AD  - Pediatric Cardiology, Phoenix Children's Hospital, Phoenix, Arizona.
FAU - Kirklin, James K
AU  - Kirklin JK
AD  - Surgery, Kirklin Institute for Research in Surgical Outcomes, University of 
      Alabama at Birmingham, Birmingham, Alabama.
FAU - Godown, Justin
AU  - Godown J
AD  - Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, 
      Nashville, Tennessee.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220908
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the 
      International Society for Heart Transplantation
JID - 9102703
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Child
MH  - Child, Preschool
MH  - *Aspirin/therapeutic use
MH  - *Heart Transplantation/adverse effects
MH  - Risk Factors
MH  - Time Factors
MH  - Allografts
MH  - Graft Rejection/epidemiology/prevention & control
MH  - Retrospective Studies
OTO - NOTNLM
OT  - aspirin
OT  - cardiac allograft vasculopathy
OT  - heart transplantation
OT  - pediatric
EDAT- 2022/11/04 06:00
MHDA- 2022/12/24 06:00
CRDT- 2022/11/03 23:04
PHST- 2022/03/03 00:00 [received]
PHST- 2022/08/01 00:00 [revised]
PHST- 2022/08/28 00:00 [accepted]
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2022/12/24 06:00 [medline]
PHST- 2022/11/03 23:04 [entrez]
AID - S1053-2498(22)02108-8 [pii]
AID - 10.1016/j.healun.2022.08.023 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2023 Jan;42(1):115-123. doi: 
      10.1016/j.healun.2022.08.023. Epub 2022 Sep 8.

PMID- 3575755
OWN - NLM
STAT- MEDLINE
DCOM- 19870610
LR  - 20190824
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 33
IP  - 3
DP  - 1987 Mar
TI  - A comparison of the effects of aspirin and histamine of fluid balance in the 
      recruited lung.
PG  - 431-43
AB  - Salicylate administration has been reported to increase the flow of protein-rich 
      lymph from the lungs of animals, however, the mechanism of this response is 
      unclear. In the present study we measured pulmonary hemodynamics and lung fluid 
      and protein flux in anesthetized sheep, surgically prepared for the collection of 
      lung lymph, in order to examine the possible effect of aspirin (ASP) on lung 
      vascular permeability. ASP was given during recruitment of pulmonary 
      microvascular surface area induced by sustained elevation of left atrial pressure 
      (Pla) (Group 1) or continuous infusion of adenosine triphosphate (ATP) (Group 2). 
      We compared the results of ASP administration to those found in similarly 
      prepared animals given histamine (H) during like periods of increased Pla (Group 
      3) or ATP infusion (Group 4). ASP administration resulted in increased lymphatic 
      protein clearance (Cp) in both Groups 1 and 2. In Group 1, following the 
      characteristic increase in lung lymph flow (Q1) and fall in the ratio of lung 
      lymph to plasma protein concentration (L/P) produced by Pla elevation, ASP 
      administration resulted in a further increase in Q1 and a significant increase in 
      L/P. The results found in ASP animals are qualitatively similar to those observed 
      in Groups 3 and 4 after H. While we cannot specifically rule out a hemodynamic 
      effect of the drug, our results suggest the increased protein flux observed 
      following ASP administration was mediated at least in part through an increase in 
      lung microvascular permeability.
FAU - Weidner, W J
AU  - Weidner WJ
FAU - McClure, D E
AU  - McClure DE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Blood Proteins)
RN  - 820484N8I3 (Histamine)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Triphosphate/pharmacology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood Proteins/metabolism
MH  - Capillary Permeability/drug effects
MH  - Hemodynamics/drug effects
MH  - Histamine/*pharmacology
MH  - Lung/*drug effects
MH  - Lymphatic System/drug effects
MH  - Pulmonary Circulation/drug effects
MH  - Sheep
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 0090-6980(87)90024-4 [pii]
AID - 10.1016/0090-6980(87)90024-4 [doi]
PST - ppublish
SO  - Prostaglandins. 1987 Mar;33(3):431-43. doi: 10.1016/0090-6980(87)90024-4.

PMID- 21492561
OWN - NLM
STAT- MEDLINE
DCOM- 20110621
LR  - 20181201
IS  - 1878-8769 (Electronic)
IS  - 1878-8750 (Linking)
VI  - 74
IP  - 2-3
DP  - 2010 Aug-Sep
TI  - Emergency reversal of antiplatelet agents in patients presenting with an 
      intracranial hemorrhage: a clinical review.
PG  - 279-85
LID - 10.1016/j.wneu.2010.05.030 [doi]
AB  - OBJECTIVE: Prehospital use of antiplatelet agents has been associated with an 
      increased risk for intracranial hemorrhage (ICH) as well as a secondary increase 
      in ICH volume after the initial hemorrhage. Strategies to reestablish platelet 
      aggregation are used in clinical practice, but without any established guidelines 
      or recommendations. This article serves to evaluate the literature regarding 
      "reversal" of antiplatelet agents in neurosurgical populations. METHODS: PubMed 
      and MEDLINE databases were searched for publications from 1966 to 2009 relating 
      to intracranial hemorrhage and antiplatelet agents. The reference sections of 
      recent articles, guidelines, and reviews were reviewed and pertinent articles 
      identified. Studies were classified by two broad subsets: those describing 
      intracranial hemorrhage relatable to a traumatic mechanism and those with a 
      spontaneous intracranial hemorrhage. Two independent auditors recorded and 
      analyzed study design and the reported outcome measures. RESULTS: For the 
      spontaneous intracranial hemorrhage group, nine reports assessing antiplatelet 
      effects on various outcome measures were identified. Eleven studies evaluating 
      the use of prehospital antiplatelets before a traumatic intracranial hemorrhage 
      were examined. CONCLUSION: The data assessing the relationship between outcome 
      and prehospital antiplatelet agents in the setting of ICH is conflicting in both 
      the trauma and the stroke literature. Only one retrospective review specifically 
      addressed outcomes after attempted reversal with platelet transfusion. Further 
      study is needed to determine whether platelet transfusion ameliorates hematoma 
      enlargement and/or improves outcome in the setting of acute ICH.
CI  - Copyright © 2010 Elsevier Inc. All rights reserved.
FAU - Campbell, Peter G
AU  - Campbell PG
AD  - Department of Neurosurgery, Thomas Jefferson University, Philadelphia, 
      Pennsylvania, USA. peter.campbell@jeffersonhospital.org
FAU - Sen, Anish
AU  - Sen A
FAU - Yadla, Sanjay
AU  - Yadla S
FAU - Jabbour, Pascal
AU  - Jabbour P
FAU - Jallo, Jack
AU  - Jallo J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - World Neurosurg
JT  - World neurosurgery
JID - 101528275
RN  - 0 (Anticoagulants)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Receptors, Purinergic P2Y12)
RN  - A74586SNO7 (Clopidogrel)
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects
MH  - Aspirin/adverse effects/antagonists & inhibitors/therapeutic use
MH  - Clopidogrel
MH  - Deamino Arginine Vasopressin/therapeutic use
MH  - Emergency Medical Services
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Intracranial Hemorrhages/*complications/*surgery
MH  - *Neurosurgical Procedures
MH  - Platelet Aggregation Inhibitors/*adverse effects/pharmacokinetics
MH  - Platelet Transfusion
MH  - Receptors, Purinergic P2Y12/drug effects
MH  - Stroke/etiology/therapy
MH  - Ticlopidine/adverse effects/analogs & derivatives/antagonists & 
      inhibitors/therapeutic use
MH  - Treatment Outcome
EDAT- 2011/04/16 06:00
MHDA- 2011/06/22 06:00
CRDT- 2011/04/16 06:00
PHST- 2010/03/18 00:00 [received]
PHST- 2010/05/03 00:00 [accepted]
PHST- 2011/04/16 06:00 [entrez]
PHST- 2011/04/16 06:00 [pubmed]
PHST- 2011/06/22 06:00 [medline]
AID - S1878-8750(10)00232-9 [pii]
AID - 10.1016/j.wneu.2010.05.030 [doi]
PST - ppublish
SO  - World Neurosurg. 2010 Aug-Sep;74(2-3):279-85. doi: 10.1016/j.wneu.2010.05.030.

PMID- 27713620
OWN - NLM
STAT- MEDLINE
DCOM- 20170517
LR  - 20181202
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 10
DP  - 2016
TI  - Evaluation of effects of various drugs on platelet functions using phorbol 
      12-myristate 13-acetate-induced megakaryocytic human erythroid leukemia cells.
PG  - 3099-3107
AB  - BACKGROUND: The hyperfunction and activation of platelets have been strongly 
      implicated in the development and recurrence of arterial occlusive disease, and 
      various antiplatelet drugs are used to treat and prevent such diseases. New 
      antiplatelet drugs and many other drugs have been developed, but some drugs may 
      have adverse effects on platelet functions. OBJECTIVE: The aim of this study was 
      to establish an evaluation method for evaluating the effect and adverse effect of 
      various drugs on platelet functions. MATERIALS AND METHODS: Human erythroid 
      leukemia (HEL) cells were used after megakaryocytic differentiation with phorbol 
      12-myristate 13-acetate as an alternative to platelets. Drugs were evaluated by 
      changes in intracellular Ca(2+) concentration ([Ca(2+)](i)) mobilization in 
      Fura2-loaded phorbol 12-myristate 13-acetate-induced HEL cells. Aspirin and 
      cilostazol were selected as antiplatelet drugs and ibuprofen and sodium valproate 
      as other drugs. RESULTS: There was a positive correlation between [Ca(2+)](i) and 
      platelet aggregation induced by thrombin. Aspirin (5.6-560 µM) and cilostazol 
      (5-10 µM) significantly inhibited thrombin-induced increases in [Ca(2+)](i) in a 
      concentration-dependent manner. On the other hand, ibuprofen (8-200 µM) and 
      sodium valproate (50-1,000 µg/mL) also significantly inhibited thrombin-induced 
      increases in [Ca(2+)](i) in a concentration-dependent manner. Furthermore, the 
      interaction effects of the simultaneous combined use of aspirin and ibuprofen or 
      sodium valproate were evaluated. When the inhibitory effect of aspirin was higher 
      than that of ibuprofen, the effect of aspirin was reduced, whereas when the 
      inhibitory effect of aspirin was lower than that of ibuprofen, the effect of 
      ibuprofen was reduced. The combination of aspirin and sodium valproate 
      synergistically inhibited thrombin-induced [Ca(2+)](i). CONCLUSION: It is 
      possible to induce HEL cells to differentiate into megakaryocytes, which are a 
      useful model for the study of platelet functions, and the quantification of the 
      inhibition of thrombin-induced increases in [Ca(2+)](i) is applicable to the 
      evaluation of the effects of various drugs on platelets.
FAU - Tada, Tomoki
AU  - Tada T
AD  - Subdivision of Biomedical Laboratory Sciences, Graduate School of Health 
      Sciences, Tokushima University.
FAU - Aki, Kensaku
AU  - Aki K
AD  - Department of Cells and Immunity Analytics, Institute of Biomedical Sciences, 
      Tokushima University Graduate School, Tokushima.
FAU - Oboshi, Wataru
AU  - Oboshi W
AD  - Subdivision of Biomedical Laboratory Sciences, Graduate School of Health 
      Sciences, Tokushima University; Department of Medical Technology, Kagawa 
      Prefectural University of Health Sciences, Kagawa.
FAU - Kawazoe, Kazuyoshi
AU  - Kawazoe K
AD  - Department of Clinical Pharmacy Practice Pedagogy, Institute of Biomedical 
      Sciences.
FAU - Yasui, Toshiyuki
AU  - Yasui T
AD  - Department of Reproductive and Menopausal Medicine, Institute of Biomedical 
      Sciences, Tokushima University Graduate School, Tokushima, Japan.
FAU - Hosoi, Eiji
AU  - Hosoi E
AD  - Department of Cells and Immunity Analytics, Institute of Biomedical Sciences, 
      Tokushima University Graduate School, Tokushima.
LA  - eng
PT  - Journal Article
DEP - 20160926
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Phorbol Esters)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - 20839-06-9 (phorbol-12-myristate)
RN  - N7Z035406B (Cilostazol)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Drug Des Devel Ther. 2017 Feb 08;11:371. PMID: 28223780
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Cilostazol
MH  - Humans
MH  - Megakaryocytes/*drug effects
MH  - Phorbol Esters/*pharmacology
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests
MH  - Tetradecanoylphorbol Acetate/*pharmacology
MH  - Tetrazoles/*pharmacology
PMC - PMC5045028
OTO - NOTNLM
OT  - aspirin
OT  - cilostazol
OT  - ibuprofen
OT  - intracellular Ca2+ concentration ([Ca2+]i)
OT  - platelets
OT  - sodium valproate
EDAT- 2016/10/08 06:00
MHDA- 2017/05/18 06:00
CRDT- 2016/10/08 06:00
PHST- 2016/10/08 06:00 [entrez]
PHST- 2016/10/08 06:00 [pubmed]
PHST- 2017/05/18 06:00 [medline]
AID - dddt-10-3099 [pii]
AID - 10.2147/DDDT.S115910 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2016 Sep 26;10:3099-3107. doi: 10.2147/DDDT.S115910. 
      eCollection 2016.

PMID- 8017354
OWN - NLM
STAT- MEDLINE
DCOM- 19940725
LR  - 20220321
IS  - 0889-5406 (Print)
IS  - 0889-5406 (Linking)
VI  - 106
IP  - 1
DP  - 1994 Jul
TI  - The effect of ibuprofen on the level of discomfort in patients undergoing 
      orthodontic treatment.
PG  - 88-95
AB  - Studies have shown that patients undergoing orthodontic tooth movement can 
      experience varying degrees of discomfort. The objective of this study was to 
      determine whether nonsteroidal antiinflammatory agents, such as aspirin or 
      ibuprofen, which inhibit prostaglandin synthesis through acetylation and 
      inactivation of the enzyme cyclooxygenase, can suppress orthodontic discomfort by 
      inhibiting the inflammatory response normally observed after orthodontic 
      adjustments. A total of 77 patients were included in a double-blind, randomized, 
      parallel, placebo-controlled, single-dose, analgesic efficacy evaluation of 
      ibuprofen and aspirin. Patients were divided into three groups. Group A received 
      one dose of the drug ibuprofen (400 mg), group B received aspirin (650 mg), and 
      group C received a placebo (beta-lactose). The level of discomfort was assessed 
      using a visual analogue scale at 2, 6, and 24 hours and 2, 3, and 7 days after 
      the insertion of either orthodontic separators or an initial arch wire. A 
      repeated measures analysis of variance and post hoc studentized range statistics 
      showed that the placebo group had significantly more discomfort than either the 
      ibuprofen or the aspirin group at all the time intervals tested. In addition, 
      ibuprofen produced significantly less discomfort than aspirin at the 6 and 
      24-hour and 2-day time phase after separator placement; and 2 and 6 hours and 2, 
      3, and 7 days after arch wire placement. These results support a recommendation 
      for ibuprofen as a preferred analgesic in the treatment of discomfort because of 
      postorthodontic adjustments.
FAU - Ngan, P
AU  - Ngan P
AD  - Ohio State University, College of Dentistry, Department of Orthodontics, 
      Columbus.
FAU - Wilson, S
AU  - Wilson S
FAU - Shanfeld, J
AU  - Shanfeld J
FAU - Amini, H
AU  - Amini H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Orthod Dentofacial Orthop
JT  - American journal of orthodontics and dentofacial orthopedics : official 
      publication of the American Association of Orthodontists, its constituent 
      societies, and the American Board of Orthodontics
JID - 8610224
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adolescent
MH  - Analysis of Variance
MH  - Aspirin/therapeutic use
MH  - Chi-Square Distribution
MH  - Double-Blind Method
MH  - Facial Pain/etiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Ibuprofen/*therapeutic use
MH  - Male
MH  - Orthodontics, Corrective/*adverse effects
MH  - Pain Measurement
MH  - Reproducibility of Results
EDAT- 1994/07/01 00:00
MHDA- 1994/07/01 00:01
CRDT- 1994/07/01 00:00
PHST- 1994/07/01 00:00 [pubmed]
PHST- 1994/07/01 00:01 [medline]
PHST- 1994/07/01 00:00 [entrez]
AID - S0889-5406(94)70025-7 [pii]
AID - 10.1016/S0889-5406(94)70025-7 [doi]
PST - ppublish
SO  - Am J Orthod Dentofacial Orthop. 1994 Jul;106(1):88-95. doi: 
      10.1016/S0889-5406(94)70025-7.

PMID- 8357
OWN - NLM
STAT- MEDLINE
DCOM- 19761101
LR  - 20131121
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 71
IP  - 4
DP  - 1976 Oct
TI  - Effects of carbenoxolone on gastric mucosal permeability and blood flow in the 
      dog.
PG  - 603-7
AB  - The effects of topical application of carbenoxolone at neutral and acidic pH were 
      compared in exteriorized, chambered segments of canine gastric corpus. When 
      dissolved in saline at pH 7.5 to 8.0, 0.25% carbenoxolone caused a rapid drop in 
      gastric potential difference of 56 +/- 2 mv and greatly increased permeability to 
      H+ ions. Blood flow, as measured by radioactive microspheres, was not changed by 
      carbenoxolone treatment, but subsequent exposure to isotonic HC1 caused an abrupt 
      rise in flow. Application of 0.25% carbenoxolone suspension in isotonic HC1 
      caused no change in potential difference, permeability, or blood flow. Neither 
      carbenoxolone preparation had a significant effect on aspirin-induced H+ 
      back-diffusion or injury.
FAU - Simons, M A
AU  - Simons MA
FAU - Moody, F G
AU  - Moody FG
FAU - Torma, M J
AU  - Torma MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Triterpenes)
RN  - MM6384NG73 (Carbenoxolone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Flow Velocity
MH  - Carbenoxolone/*pharmacology
MH  - Cell Membrane Permeability/*drug effects
MH  - Dogs
MH  - Gastric Mucosa/blood supply/*drug effects
MH  - Hydrogen-Ion Concentration
MH  - Regional Blood Flow/drug effects
MH  - Triterpenes/*pharmacology
EDAT- 1976/10/01 00:00
MHDA- 1976/10/01 00:01
CRDT- 1976/10/01 00:00
PHST- 1976/10/01 00:00 [pubmed]
PHST- 1976/10/01 00:01 [medline]
PHST- 1976/10/01 00:00 [entrez]
AID - S0016508576002576 [pii]
PST - ppublish
SO  - Gastroenterology. 1976 Oct;71(4):603-7.

PMID- 16018353
OWN - NLM
STAT- MEDLINE
DCOM- 20051123
LR  - 20131121
IS  - 0095-6562 (Print)
IS  - 0095-6562 (Linking)
VI  - 76
IP  - 7
DP  - 2005 Jul
TI  - Pulmonary embolism aggravated by two short flights 3 days apart.
PG  - 681-3
AB  - An elderly internist experienced aggravation of preexisting pulmonary emboli 
      following each of two short flights of 75 min apiece 3 d apart. A brief 
      discussion of risk factors is included. It is suggested that pertinent reports 
      should separate venous thromboembolic disease (VTE) from uncomplicated deep 
      venous thrombosis (DVT).
FAU - Grossman, Charles M
AU  - Grossman CM
AD  - Legacy Good Samaritan Hospital, Department of Medicine, Portland, OR 97205, USA. 
      lindatian06@yahoo.com
FAU - White, Jocelyn C
AU  - White JC
FAU - Dunn, Patrick M
AU  - Dunn PM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Aviat Space Environ Med
JT  - Aviation, space, and environmental medicine
JID - 7501714
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aerospace Medicine
MH  - Age Factors
MH  - Aged, 80 and over
MH  - *Aircraft
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Male
MH  - Pulmonary Embolism/etiology/*physiopathology/prevention & control
MH  - Risk Factors
MH  - Time Factors
MH  - *Travel
EDAT- 2005/07/16 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/07/16 09:00
PHST- 2005/07/16 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/07/16 09:00 [entrez]
PST - ppublish
SO  - Aviat Space Environ Med. 2005 Jul;76(7):681-3.

PMID- 4047629
OWN - NLM
STAT- MEDLINE
DCOM- 19851119
LR  - 20180216
IS  - 0301-1569 (Print)
IS  - 0301-1569 (Linking)
VI  - 47
IP  - 5
DP  - 1985
TI  - Adverse reaction to locally applied preservatives in nose drops.
PG  - 278-9
AB  - A 33-year-old woman with documented hypersensitivity to acetylsalicylic acid 
      (ASA) and preservatives, causing bronchial asthma and rhinitis when ingested, was 
      investigated because of 'allergy to nose drops'. It was found that she had a 
      serious local reaction caused by the preservative used in the nose drops 
      prescribed. This reaction might occur more commonly than realized, since 
      sensitivity towards ASA is fairly common in the general population.
FAU - Hillerdal, G
AU  - Hillerdal G
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Switzerland
TA  - ORL J Otorhinolaryngol Relat Spec
JT  - ORL; journal for oto-rhino-laryngology and its related specialties
JID - 0334721
RN  - 0 (Benzalkonium Compounds)
RN  - 0 (Pharmaceutic Aids)
RN  - 0 (Preservatives, Pharmaceutical)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Intranasal
MH  - Adult
MH  - Aspirin/adverse effects
MH  - Benzalkonium Compounds/*adverse effects
MH  - Drug Hypersensitivity/*etiology
MH  - Female
MH  - Humans
MH  - Pharmaceutic Aids/*adverse effects
MH  - Preservatives, Pharmaceutical/*adverse effects
EDAT- 1985/01/01 00:00
MHDA- 1985/01/01 00:01
CRDT- 1985/01/01 00:00
PHST- 1985/01/01 00:00 [pubmed]
PHST- 1985/01/01 00:01 [medline]
PHST- 1985/01/01 00:00 [entrez]
AID - 10.1159/000275784 [doi]
PST - ppublish
SO  - ORL J Otorhinolaryngol Relat Spec. 1985;47(5):278-9. doi: 10.1159/000275784.

PMID- 7974380
OWN - NLM
STAT- MEDLINE
DCOM- 19941227
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 72
IP  - 1
DP  - 1994 Jul
TI  - Measurement of thrombin generation in whole blood--the effect of heparin and 
      aspirin.
PG  - 78-83
AB  - A technique has been developed to monitor the development of thrombin in freshly 
      collected whole blood in the absence of anticoagulants. It is based on the 
      centrifugal separation of the cellular components from subsamples of blood drawn 
      from non-anticoagulated clotting whole blood which are diluted in buffer 
      containing a chromogenic substrate. It is shown that the burst of thrombin 
      generation after triggering coagulation with trace amounts of tissue 
      thromboplastin occurs sooner in non-anticoagulated whole blood than in citrated 
      whole blood. Heparin is shown to prolong the lag-time of thrombin generation more 
      in native blood than in recalcified citrated blood. It is also demonstrated that 
      intake of 500 mg of aspirin significantly delays and inhibits thrombin generation 
      in non-anticoagulated, thromboplastin triggered whole blood, whereas it has no 
      effect on the coagulation in citrated plasma. The effect of aspirin intake on 
      thrombin generation in blood is roughly equal to that of 0.03 U/ml of 
      unfractionated heparin. This demonstrates that platelet reactions and the 
      coagulation system are closely linked processes. It further lends support to the 
      hypothesis that inhibition of thrombin generation is a common denominator of 
      antithrombotic therapy.
FAU - Kessels, H
AU  - Kessels H
AD  - Cardiovascular Research Institute Maastricht, Dept. of Biochemistry, University 
      of Limburg, The Netherlands.
FAU - Béguin, S
AU  - Béguin S
FAU - Andree, H
AU  - Andree H
FAU - Hemker, H C
AU  - Hemker HC
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/drug effects
MH  - Calcium/blood
MH  - Heparin/*pharmacology
MH  - Humans
MH  - Plasma Volume
MH  - Thrombin/*biosynthesis
EDAT- 1994/07/01 00:00
MHDA- 1994/07/01 00:01
CRDT- 1994/07/01 00:00
PHST- 1994/07/01 00:00 [pubmed]
PHST- 1994/07/01 00:01 [medline]
PHST- 1994/07/01 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1994 Jul;72(1):78-83.

PMID- 7097484
OWN - NLM
STAT- MEDLINE
DCOM- 19820924
LR  - 20190913
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 5
IP  - 3
DP  - 1982 Mar
TI  - Effect of taurine on the gastrointestinal absorption of drugs--ionic requirement 
      for the action.
PG  - 172-8
AB  - In order to resolve the mechanism of taurine-induced enhancement of drug 
      absorption, the effect of ionic components of the luminal solutions on drug 
      absorption was examined by using the loop of rat stomach in situ. K+ has its 
      remarkable influence on the control values of aspirin absorption. The control 
      values, at and above 25 mM already reached to a nearly corresponding degree as 
      that of taurine-induced enhancement, resulting in apparent disappearance of 
      enhancement effect. On the other hand, the action of taurine on salicylamide 
      absorption is revealed to be K+ concentration-dependent, whereas all the control 
      values remain fairly constant. Moreover, at the higher concentration of 10 mM, 
      aspirin absorption turned out to be significantly inhibited in the presence of 
      taurine, and this finding is supposed to be attributed to the protection of 
      taurine against aspirin-induced gastric mucosal damage. On the contrary, 
      salicylamide absorption was greatly enhanced. All these results clearly support 
      that the mechanism of action of taurine toward both drugs should be separately 
      considered.
FAU - Kim, K S
AU  - Kim KS
FAU - Tsuji, M
AU  - Tsuji M
FAU - Kimura, T
AU  - Kimura T
FAU - Sezaki, H
AU  - Sezaki H
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Ions)
RN  - 0 (Salicylamides)
RN  - 1EQV5MLY3D (Taurine)
RN  - 5ACL011P69 (Ouabain)
RN  - 9NEZ333N27 (Sodium)
RN  - EM8BM710ZC (salicylamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/metabolism
MH  - Intestinal Absorption/*drug effects
MH  - Ions
MH  - Male
MH  - Ouabain/pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Salicylamides/metabolism
MH  - Sodium/physiology
MH  - Taurine/*pharmacology
EDAT- 1982/03/01 00:00
MHDA- 1982/03/01 00:01
CRDT- 1982/03/01 00:00
PHST- 1982/03/01 00:00 [pubmed]
PHST- 1982/03/01 00:01 [medline]
PHST- 1982/03/01 00:00 [entrez]
AID - 10.1248/bpb1978.5.172 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1982 Mar;5(3):172-8. doi: 10.1248/bpb1978.5.172.

PMID- 863293
OWN - NLM
STAT- MEDLINE
DCOM- 19770718
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 6
IP  - 2
DP  - 1977
TI  - Comparable inhibition of aggregation of PRP of neonates and adults by aspirin.
PG  - 118-26
AB  - We have determined the minimal concentrations of 4 aggregating agents that were 
      required to cause a 65-75% increase in light transmission without disaggregation 
      during the 5-min recording period in PRP samples of 14 neonates and 10 adults. We 
      found, for example, that this degree of aggregation could be elicited in adult 
      PRP by a mean value of 2.09 micronM ADP, whereas similar aggregation of neonatal 
      PRP required 5.16 micronM ADP. Based on these figures, we observed that adult PRP 
      was about 2.5 times more sensitive to ADP, at least 10 times to epinephrine and 
      2.3 times to collagen than neonatal PRP. However, neonatal PRP was approximately 
      20% more sensitive to ristocetin than adult PRP. By using concentrations of 
      aggregating agents that caused comparable aggregation of neonatal and adult PRP, 
      we noted comparable inhibition of aggregation in these samples by aspirin. While 
      neonatal PRP was less sensitive than adult PRP to physiological aggregating 
      agents, there was no evidence that the former was more susceptible to in vitro 
      aspirin inhibition.
FAU - Ts'ao, C H
AU  - Ts'ao CH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 1404-55-3 (Ristocetin)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - *Aging
MH  - Aspirin/*pharmacology
MH  - Collagen/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Epinephrine/pharmacology
MH  - Humans
MH  - *Infant, Newborn
MH  - Platelet Aggregation/*drug effects
MH  - Ristocetin/pharmacology
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1159/000214171 [doi]
PST - ppublish
SO  - Haemostasis. 1977;6(2):118-26. doi: 10.1159/000214171.

PMID- 21304575
OWN - NLM
STAT- MEDLINE
DCOM- 20110316
LR  - 20131121
IS  - 0807-7096 (Electronic)
IS  - 0029-2001 (Linking)
VI  - 131
IP  - 3
DP  - 2011 Feb 4
TI  - [Warfarin combined with blood platelet inhibition].
PG  - 252-3
LID - 10.4045/tidsskr.09.1176 [doi]
AB  - Dual antiplatelet therapy (acetylsalicylic acid and a thienopyridine) is 
      essential after coronary stent implantation, and in the treatment of acute 
      coronary syndrome. Many patients also need oral anticoagulation. Unfortunately, 
      there are no prospective randomised trials to guide therapy. Triple 
      antithrombotic therapy with acetylsalicylic acid, clopidogrel and warfarin is 
      most commonly used. This regimen can reduce the risk of thrombosis and 
      thromboembolism, but is associated with an increased risk of bleeding. Measures 
      that reduce the risk of complications are reduction of INR with careful 
      monitoring, a short duration of triple therapy (when possible) and use of radial 
      access and a bare metal stent.
FAU - Vik-Mo, Harald
AU  - Vik-Mo H
AD  - Hjertemedisinsk avdeling, St. Olavs hospital. harald.vik-mo@ntnu.no
LA  - nor
PT  - English Abstract
PT  - Journal Article
TT  - Warfarin saman med blodplatehemming.
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny 
      raekke
JID - 0413423
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Tidsskr Nor Laegeforen. 2011 May 6;131(8):800; author reply 800. PMID: 21556070
MH  - Acute Coronary Syndrome/drug therapy
MH  - Angioplasty, Balloon, Coronary
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - International Normalized Ratio
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Risk Factors
MH  - Stents
MH  - Thrombosis/prevention & control
MH  - Warfarin/*administration & dosage/adverse effects
EDAT- 2011/02/10 06:00
MHDA- 2011/03/17 06:00
CRDT- 2011/02/10 06:00
PHST- 2011/02/10 06:00 [entrez]
PHST- 2011/02/10 06:00 [pubmed]
PHST- 2011/03/17 06:00 [medline]
AID - 2073070 [pii]
AID - 10.4045/tidsskr.09.1176 [doi]
PST - ppublish
SO  - Tidsskr Nor Laegeforen. 2011 Feb 4;131(3):252-3. doi: 10.4045/tidsskr.09.1176.

PMID- 20008205
OWN - NLM
STAT- MEDLINE
DCOM- 20100315
LR  - 20161021
IS  - 1520-4383 (Electronic)
IS  - 1520-4383 (Linking)
DP  - 2009
TI  - ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid 
      antibodies receive primary prophylaxis to prevent thrombosis?
PG  - 247-9
LID - 10.1182/asheducation-2009.1.247 [doi]
AB  - A 35-year-old female presents with a prolonged activated partial thromboplastin 
      time (aPTT) on routine testing, which is found to be due to a lupus 
      anticoagulant. She has no medical issues, no personal or family history of 
      thrombosis, no history of pregnancy loss, and no symptoms suggestive of an 
      underlying rheumatologic disorder. She is a non-smoker and does not take oral 
      contraceptives. You are asked to provide recommendations regarding the need for 
      primary thromboprophylaxis. As you begin your literature search, you formulate 
      the following clinical question: "In asymptomatic patients with antiphospholipid 
      antibodies, does primary prophylaxis prevent thrombotic complications?"
FAU - Metjian, Ara
AU  - Metjian A
AD  - Department of Medicine, Division of Hematology, Duke University, Durham, NC, USA.
FAU - Lim, Wendy
AU  - Lim W
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hematology Am Soc Hematol Educ Program
JT  - Hematology. American Society of Hematology. Education Program
JID - 100890099
RN  - 0 (Anticoagulants)
RN  - 0 (Lupus Coagulation Inhibitor)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Evidence-Based Medicine
MH  - Female
MH  - Humans
MH  - Hydroxychloroquine/administration & dosage/therapeutic use
MH  - Incidental Findings
MH  - Lupus Coagulation Inhibitor/*blood
MH  - Partial Thromboplastin Time
MH  - *Practice Guidelines as Topic
MH  - Primary Prevention/*standards
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Reference Values
MH  - Thromboembolism/*prevention & control
MH  - Thrombophilia/*drug therapy
MH  - Unnecessary Procedures
RF  - 15
EDAT- 2009/12/17 06:00
MHDA- 2010/03/17 06:00
CRDT- 2009/12/17 06:00
PHST- 2009/12/17 06:00 [entrez]
PHST- 2009/12/17 06:00 [pubmed]
PHST- 2010/03/17 06:00 [medline]
AID - 2009/1/247 [pii]
AID - 10.1182/asheducation-2009.1.247 [doi]
PST - ppublish
SO  - Hematology Am Soc Hematol Educ Program. 2009:247-9. doi: 
      10.1182/asheducation-2009.1.247.

PMID- 16443409
OWN - NLM
STAT- MEDLINE
DCOM- 20060227
LR  - 20221207
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 119
IP  - 2
DP  - 2006 Feb
TI  - Selective serotonin reuptake inhibitors and increased bleeding risk: are we 
      missing something?
PG  - 113-6
AB  - PURPOSE: Selective serotonin reuptake inhibitors (SSRIs) are first line agents to 
      treat clinical depression. Although these medications exhibit a favorable safety 
      profile, there are multiple case reports, registries, and uncontrolled studies 
      suggesting that use of SSRIs might be associated in the increased risk of 
      bleeding events. There is also emerging evidence that these side effects of SSRIs 
      are due to blockade of serotonin reuptake in platelets and subsequent platelet 
      dysfunction. METHODS: The analysis of evidence linking SSRIs with bleeding 
      episodes to define the prevalence, specific clinical characteristics, and 
      estimated risk when SSRIs are used in combination with antiplatelet agents or/and 
      anticoagulants. RESULTS: There are over 120 MEDLINE-cited peer-reviewed research 
      papers and more than 50000 Web pages devoted to SSRI-related bleeding events. 
      CONCLUSION: Independently of the brand, use of SSRIs is indeed associated with 
      increased bleeding risk. Although such complications are rare, their frequency is 
      growing, and physicians should be aware of SSRI-induced hemorrhages, especially 
      in patients with hereditary platelet defects, and those treated with antiplatelet 
      agents. Prospective studies are urgently needed to determine whether SSRIs will 
      yield additional bleeding risks when used long term concomitantly with aspirin or 
      clopidogrel.
FAU - Serebruany, Victor L
AU  - Serebruany VL
AD  - HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, Md, USA. 
      heartdrug@aol.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects
MH  - Clopidogrel
MH  - Depressive Disorder/drug therapy
MH  - Drug Interactions
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Selective Serotonin Reuptake Inhibitors/*adverse effects
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & derivatives
RF  - 53
EDAT- 2006/01/31 09:00
MHDA- 2006/02/28 09:00
CRDT- 2006/01/31 09:00
PHST- 2005/03/16 00:00 [received]
PHST- 2005/03/31 00:00 [accepted]
PHST- 2006/01/31 09:00 [pubmed]
PHST- 2006/02/28 09:00 [medline]
PHST- 2006/01/31 09:00 [entrez]
AID - S0002-9343(05)00357-8 [pii]
AID - 10.1016/j.amjmed.2005.03.044 [doi]
PST - ppublish
SO  - Am J Med. 2006 Feb;119(2):113-6. doi: 10.1016/j.amjmed.2005.03.044.

PMID- 11724372
OWN - NLM
STAT- MEDLINE
DCOM- 20020124
LR  - 20191021
IS  - 0939-5075 (Print)
IS  - 0341-0382 (Linking)
VI  - 56
IP  - 9-10
DP  - 2001 Sep-Oct
TI  - Phytochemical and pharmacological investigations of Virola oleifera leaves.
PG  - 703-6
AB  - A methanolic extract and two fractions (n-hexane and ethyl acetate) from Virola 
      oleifera leaves and some compounds (one lignan and two flavonoids) were 
      investigated to verify the analgesic activity by using the writhing test in mice. 
      The crude methanolic extract showed a moderate analgesic effect (about 40% of 
      inhibition in this test at 10 mg/kg), whereas n-hexane and ethyl acetate 
      fractions caused inhibition of 51.3 +/- 5.9% and 50.5 +/- 6.3%, respectively. 
      Oleiferin-C (1), a lignan isolated from the n-hexane fraction, showed an 
      interesting analgesic potential in this model when compared to two standard 
      drugs, paracetamol (4-acetamidophenol) and aspirin (acetylsalicylic acid). The 
      ID50 calculated for this compound was 17.25 micromol/kg, with confidence interval 
      between 13.7 and 21.3 micromol/kg, being about 8 times more potent than the 
      standard drugs. The mixture of two glycoside-flavonoids, identified as astilbin 
      (2) and quercitrin (3), also exhibited good analgesic activity, causing 63% of 
      reduction of abdominal constriction in mice. These results suggest beneficial 
      effect of this plant to treat dolorous processes.
FAU - Kuroshima, K N
AU  - Kuroshima KN
AD  - Centro de Ciências Tecnológicas da Terra e do Mar, Universidade do Vale do 
      Itajaí, SC, Brasil.
FAU - de Campos, F
AU  - de Campos F
FAU - de Souza, M M
AU  - de Souza MM
FAU - Yunes, R A
AU  - Yunes RA
FAU - Delle Monache, F
AU  - Delle Monache F
FAU - Cechinel Filho, V
AU  - Cechinel Filho V
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Z Naturforsch C J Biosci
JT  - Zeitschrift fur Naturforschung. C, Journal of biosciences
JID - 8912155
RN  - 0 (Acetates)
RN  - 0 (Analgesics)
RN  - 0 (Flavonoids)
RN  - 0 (Hexanes)
RN  - 0 (Lignans)
RN  - 0 (Plant Extracts)
RN  - 2DDG612ED8 (n-hexane)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 76845O8NMZ (ethyl acetate)
RN  - R16CO5Y76E (Aspirin)
RN  - Y4S76JWI15 (Methanol)
SB  - IM
MH  - Acetaminophen/pharmacology/therapeutic use
MH  - Acetates
MH  - Analgesics/*chemistry/isolation & purification/therapeutic use
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Confidence Intervals
MH  - Flavonoids/*chemistry/isolation & purification
MH  - Hexanes
MH  - Lignans/*chemistry/isolation & purification
MH  - Male
MH  - Methanol
MH  - Mice
MH  - Myristicaceae/*chemistry
MH  - Pain/drug therapy
MH  - Phytotherapy
MH  - Plant Extracts/*chemistry/therapeutic use
MH  - Plant Leaves/*chemistry
EDAT- 2001/11/29 10:00
MHDA- 2002/01/25 10:01
CRDT- 2001/11/29 10:00
PHST- 2001/11/29 10:00 [pubmed]
PHST- 2002/01/25 10:01 [medline]
PHST- 2001/11/29 10:00 [entrez]
AID - 10.1515/znc-2001-9-1006 [doi]
PST - ppublish
SO  - Z Naturforsch C J Biosci. 2001 Sep-Oct;56(9-10):703-6. doi: 
      10.1515/znc-2001-9-1006.

PMID- 120341
OWN - NLM
STAT- MEDLINE
DCOM- 19800627
LR  - 20191027
IS  - 0300-9785 (Print)
IS  - 0300-9785 (Linking)
VI  - 8
IP  - 6
DP  - 1979 Dec
TI  - A model for evaluating the analgesic effect of a new fixed ratio combination 
      analgesic in patients undergoing oral surgery.
PG  - 435-42
AB  - A special model designed for evaluating the analgesic effect of oral analgesics 
      was based on a short-time registration period of immediate postoperative pain. 
      One-hour intervals in pain registration and a minimum of 2 h between the tablet 
      intake allowed a good estimation of changes in pain levels. The patient material 
      consisted of 112 patients and from each patient a lower impacted wisdom tooth was 
      removed. The test model was used to compare two analgesic drugs with placebo. The 
      two pharmacologically active preparations were Doleron (dextropropoxyphene, 
      acetylsalicylic acid, phenazone, caffeine and Transergan) and Astra 2167 
      (dextropropoxyphene and acetylsalicylic acid). The trial was double blind and the 
      tablets were administered according to a crossover design. There was no 
      statistically significant difference in analgesic effect between Astra 2167 and 
      Doleron, and both drugs were superior to placebo. Finally, the trial showed that 
      a reduction of the number of components of a compound analgesic to some degree 
      reduced the pain relieving effect on this particular postoperative pain. This 
      observed reduction was however, not statistically significant.
FAU - Hellem, S
AU  - Hellem S
FAU - Persson, G
AU  - Persson G
FAU - Freiberg, N
AU  - Freiberg N
FAU - Nord, P G
AU  - Nord PG
FAU - Gustafsson, B
AU  - Gustafsson B
FAU - Huitfeldt, B
AU  - Huitfeldt B
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Denmark
TA  - Int J Oral Surg
JT  - International journal of oral surgery
JID - 0334641
RN  - 0 (Analgesics)
RN  - 0 (Drug Combinations)
RN  - 0 (Parasympatholytics)
RN  - 0 (Phenothiazines)
RN  - 0 (aspirin, dextropropoxyphene drug combination)
RN  - 3G6A5W338E (Caffeine)
RN  - 63482-28-0 (Doleron)
RN  - 82-00-8 (transergan)
RN  - R16CO5Y76E (Aspirin)
RN  - S2F83W92TK (Dextropropoxyphene)
RN  - T3CHA1B51H (Antipyrine)
SB  - IM
MH  - Adult
MH  - *Analgesics
MH  - Antipyrine/administration & dosage/*pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Caffeine
MH  - Dextropropoxyphene/administration & dosage/*pharmacology
MH  - Drug Combinations/administration & dosage/pharmacology
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain, Postoperative/prevention & control
MH  - Parasympatholytics/administration & dosage/pharmacology
MH  - Phenothiazines/administration & dosage/*pharmacology
MH  - *Tooth Extraction/adverse effects
MH  - Tooth, Impacted/surgery
EDAT- 1979/12/01 00:00
MHDA- 1979/12/01 00:01
CRDT- 1979/12/01 00:00
PHST- 1979/12/01 00:00 [pubmed]
PHST- 1979/12/01 00:01 [medline]
PHST- 1979/12/01 00:00 [entrez]
AID - 10.1016/s0300-9785(79)80082-4 [doi]
PST - ppublish
SO  - Int J Oral Surg. 1979 Dec;8(6):435-42. doi: 10.1016/s0300-9785(79)80082-4.

PMID- 11479465
OWN - NLM
STAT- MEDLINE
DCOM- 20010830
LR  - 20191210
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 142
IP  - 2
DP  - 2001 Aug
TI  - Quality of care among elderly patients hospitalized with unstable angina.
PG  - 263-70
AB  - BACKGROUND: Guidelines for the management of unstable angina have been published 
      by the United States Agency for Health Care Policy and Research (currently known 
      as the Agency for Healthcare Research and Quality); however, little information 
      is available about the quality of unstable angina care, particularly among 
      elderly patients. METHODS: We examined 1196 elderly Medicare-insured patients 
      hospitalized with unstable angina (ruled out for acute myocardial infarction) at 
      Connecticut hospitals between August and November 1995 to evaluate quality of 
      care provided during hospitalization. Patients without therapeutic 
      contraindications were evaluated for the use of 5 Agency for Health Care Policy 
      and Research guideline-recommended measures: electrocardiographic examination 
      within 20 minutes of admission, use of aspirin on admission, intravenous heparin 
      on admission, achievement of therapeutic anticoagulation among patients provided 
      heparin, and prescription of aspirin on discharge. RESULTS: Less than half 
      (49.6%) of patients underwent electrocardiographic examination within 20 minutes 
      of admission. After excluding patients with contraindications, aspirin was 
      provided to 80.1% of patients and intravenous heparin to 59.2% of indicated 
      patients, of whom only 43.3% achieved therapeutic anticoagulation. Aspirin was 
      prescribed to 82.3% of eligible patients at discharge. Performance on the 5 
      quality measures varied widely among hospitals. CONCLUSIONS: Agency for Health 
      Care Policy and Research guideline-recommended risk stratification and 
      therapeutic interventions are underused in elderly patients hospitalized with 
      unstable angina, with quality of care varying widely among hospitals.
FAU - Shahi, C N
AU  - Shahi CN
AD  - Department of Internal Medicine, University of Connecticut School of Medicine, 
      University of Connecticut Health Center, Farmington, USA.
FAU - Rathore, S S
AU  - Rathore SS
FAU - Wang, Y
AU  - Wang Y
FAU - Thakur, R
AU  - Thakur R
FAU - Wu, W C
AU  - Wu WC
FAU - Lewis, J M
AU  - Lewis JM
FAU - Petrillo, M K
AU  - Petrillo MK
FAU - Radford, M J
AU  - Radford MJ
FAU - Krumholz, H M
AU  - Krumholz HM
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angina, Unstable/*therapy
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Connecticut
MH  - Electrocardiography
MH  - Female
MH  - Guideline Adherence
MH  - Health Services for the Aged/*standards
MH  - Hospitals/*standards
MH  - Humans
MH  - Male
MH  - Medicare
MH  - Practice Guidelines as Topic
MH  - *Quality Indicators, Health Care
EDAT- 2001/08/02 10:00
MHDA- 2001/08/31 10:01
CRDT- 2001/08/02 10:00
PHST- 2001/08/02 10:00 [pubmed]
PHST- 2001/08/31 10:01 [medline]
PHST- 2001/08/02 10:00 [entrez]
AID - S0002-8703(01)76445-9 [pii]
AID - 10.1067/mhj.2001.116477 [doi]
PST - ppublish
SO  - Am Heart J. 2001 Aug;142(2):263-70. doi: 10.1067/mhj.2001.116477.

PMID- 31588089
OWN - NLM
STAT- MEDLINE
DCOM- 20200604
LR  - 20200604
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 59
IP  - 3
DP  - 2020 Feb 1
TI  - Update on Antithrombotic Therapy after Percutaneous Coronary Intervention.
PG  - 311-321
LID - 10.2169/internalmedicine.3685-19 [doi]
AB  - Percutaneous coronary intervention (PCI) has become a standard-of-care procedure 
      in the setting of angina or acute coronary syndrome. Antithrombotic therapy is 
      the cornerstone of pharmacological treatment aimed at preventing ischemic events 
      following PCI. Dual antiplatelet therapy as the combination of aspirin and 
      P2Y(12) inhibitor has been proven to decrease stent-related thrombotic risks. 
      However, the optimal duration of dual antiplatelet therapy, an appropriate 
      P2Y(12) inhibitor, and the choice of aspirin versus P2Y(12) inhibitor as single 
      antiplatelet therapy remain controversial. Furthermore, the combined use of oral 
      anticoagulation in addition to antiplatelet therapy is a complex issue in 
      clinical practice, such as in patients with atrial fibrillation. The key 
      challenge concerning the optimal antithrombotic regimen is ensuring a balance 
      between protection against thrombotic events and against excessive increases in 
      bleeding risk. In this review article, we summarize the current evidence 
      concerning antithrombotic therapy in patients with coronary artery disease 
      undergoing PCI.
FAU - Saito, Yuichi
AU  - Saito Y
AD  - Department of Cardiovascular Medicine, Chiba University Graduate School of 
      Medicine, Japan.
AD  - Yale School of Medicine, USA.
FAU - Kobayashi, Yoshio
AU  - Kobayashi Y
AD  - Department of Cardiovascular Medicine, Chiba University Graduate School of 
      Medicine, Japan.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20191007
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Anticoagulants)
RN  - 0 (Purinergic P2Y Receptor Agonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ischemia/*drug therapy/*etiology
MH  - Percutaneous Coronary Intervention/*adverse effects
MH  - Purinergic P2Y Receptor Agonists/*therapeutic use
PMC - PMC7028427
OTO - NOTNLM
OT  - antithrombotic therapy
OT  - dual antiplatelet therapy
OT  - percutaneous coronary intervention
COIS- Author's disclosure of potential Conflicts of Interest (COI). Yoshio Kobayashi: 
      Honoraria, Amgen Astellas BioPharma, Sanofi, Daiichi Sankyo, Bristol-Myers Squibb 
      and Boehringer Ingelheim.
EDAT- 2019/10/08 06:00
MHDA- 2020/06/05 06:00
CRDT- 2019/10/08 06:00
PHST- 2019/10/08 06:00 [pubmed]
PHST- 2020/06/05 06:00 [medline]
PHST- 2019/10/08 06:00 [entrez]
AID - 10.2169/internalmedicine.3685-19 [doi]
PST - ppublish
SO  - Intern Med. 2020 Feb 1;59(3):311-321. doi: 10.2169/internalmedicine.3685-19. Epub 
      2019 Oct 7.

PMID- 33388632
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210705
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
VI  - 30
IP  - 3
DP  - 2021 Mar
TI  - Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and 
      Meta-Analysis.
PG  - 105581
LID - S1052-3057(20)30999-X [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2020.105581 [doi]
AB  - OBJECTIVES: Cilostazol has promise as an alternative to aspirin for secondary 
      stroke prevention given its vasodilatory and anti-inflammatory properties in 
      addition to platelet aggregation inhibition. We aimed to conduct a systematic 
      review and meta-analysis to estimate the efficacy and safety of cilostazol 
      compared to aspirin for stroke prevention in patients with previous stroke or 
      transient ischemic attack (TIA). MATERIALS AND METHODS: We searched PubMed and 
      the Cochrane Central Register of Controlled Trials from 1996 to 2019. Randomized 
      clinical trials that compared cilostazol to aspirin and reported the endpoints of 
      ischemic stroke, intracranial hemorrhage and any bleeding were included. A 
      random-effects estimate was computed based on the Mantel-Haenszel method. The 
      pooled risk estimates with 95% confidence intervals were compared between 
      cilostazol and aspirin. RESULTS: The search identified 5 randomized clinical 
      trials comparing cilostazol vs. aspirin for secondary stroke prevention that 
      collectively enrolled 7240 patients, all from Asian countries (3615 received 
      cilostazol and 3625 received aspirin). Pooled results from the random-effects 
      model showed that cilostazol was associated with significantly lower risk of 
      recurrent ischemic stroke (RR 0.68; 95% CI, 0.54 to 0.87), intracranial 
      hemorrhage (RR 0.42; 95% CI, 0.27 to 0.65) and any bleeding (RR 0.71; 95% CI, 
      0.55 to 0.91). CONCLUSIONS: This meta-analysis suggests that cilostazol is more 
      effective than aspirin in preventing recurrent ischemic stroke with lower risk of 
      intracranial hemorrhage and other bleeding. Since all trials to date are from 
      Asian countries, confirmatory trials of cilostazol for secondary stroke 
      prevention in other populations are needed.
CI  - Copyright © 2020 Elsevier Inc. All rights reserved.
FAU - Lin, Michelle P
AU  - Lin MP
AD  - Department of Neurology, Mayo Clinic, Jacksonville, FL, United States. Electronic 
      address: lin.michelle@mayo.edu.
FAU - Meschia, James F
AU  - Meschia JF
AD  - Department of Neurology, Mayo Clinic, Jacksonville, FL, United States.
FAU - Gopal, Neethu
AU  - Gopal N
AD  - Department of Neurology, Mayo Clinic, Jacksonville, FL, United States.
FAU - Barrett, Kevin M
AU  - Barrett KM
AD  - Department of Neurology, Mayo Clinic, Jacksonville, FL, United States.
FAU - Ross, Owen A
AU  - Ross OA
AD  - Department of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.
FAU - Ertekin-Taner, Nilüfer
AU  - Ertekin-Taner N
AD  - Department of Neurology, Mayo Clinic, Jacksonville, FL, United States; Department 
      of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.
FAU - Brott, Thomas G
AU  - Brott TG
AD  - Department of Neurology, Mayo Clinic, Jacksonville, FL, United States.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201231
PL  - United States
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National 
      Stroke Association
JID - 9111633
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cilostazol/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Intracranial Hemorrhages/chemically induced
MH  - Ischemic Stroke/diagnosis/epidemiology/*prevention & control
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Secondary Prevention
MH  - Treatment Outcome
MH  - Vasodilator Agents/therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Bleeding
OT  - Cilostazol
OT  - Intracranial hemorrhage
OT  - Ischemic stroke
EDAT- 2021/01/04 06:00
MHDA- 2021/03/18 06:00
CRDT- 2021/01/03 20:31
PHST- 2020/09/18 00:00 [received]
PHST- 2020/11/06 00:00 [revised]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2021/01/04 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
PHST- 2021/01/03 20:31 [entrez]
AID - S1052-3057(20)30999-X [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2020.105581 [doi]
PST - ppublish
SO  - J Stroke Cerebrovasc Dis. 2021 Mar;30(3):105581. doi: 
      10.1016/j.jstrokecerebrovasdis.2020.105581. Epub 2020 Dec 31.

PMID- 15168633
OWN - NLM
STAT- MEDLINE
DCOM- 20040617
LR  - 20131121
IS  - 1086-5462 (Print)
IS  - 1086-5462 (Linking)
VI  - 87
IP  - 4
DP  - 2004 Apr
TI  - Anticoagulation in atrial fibrillation.
PG  - 98-100
AB  - Anticoagulation with warfarin is the most effective means of reducing stroke in 
      AF. The generally recommended INR goal is 2-3. Aspirin provides a modest degree 
      of stroke protection in AF but is inferior to warfarin. Assessment of stroke risk 
      is critical in determining whether to prescribe warfarin therapy to a patient 
      with AF. The most important risk factors for stroke in AF are age over 65 years, 
      hypertension, prior stroke, and left ventricular dysfunction or heart failure. 
      The risk of warfarin may be less than commonly believed, but increases when 
      warfarin is combined with aspirin. Patients with paroxysmal AF are not at lower 
      risk of stroke than those with persistent AF and should be treated with warfarin. 
      Apparently successful therapy with antiarrhythmic agents does not eliminate the 
      need for anticoagulation. New antithrombotic therapies are being studied and may 
      soon provide an alternative to warfarin.
FAU - Anderson, Maria
AU  - Anderson M
AD  - Rhode Island Hospital/Brown Medical School, USA.
FAU - Kirk, Malcolm
AU  - Kirk M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Health R I
JT  - Medicine and health, Rhode Island
JID - 9603446
RN  - 0 (Anticoagulants)
RN  - 0 (Azetidines)
RN  - 0 (Benzylamines)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Prodrugs)
RN  - 49HFB70472 (ximelagatran)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Azetidines/therapeutic use
MH  - Benzylamines
MH  - Electric Countershock
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Prodrugs/therapeutic use
MH  - Stroke/*prevention & control
MH  - Warfarin/*therapeutic use
EDAT- 2004/06/01 05:00
MHDA- 2004/06/18 05:00
CRDT- 2004/06/01 05:00
PHST- 2004/06/01 05:00 [pubmed]
PHST- 2004/06/18 05:00 [medline]
PHST- 2004/06/01 05:00 [entrez]
PST - ppublish
SO  - Med Health R I. 2004 Apr;87(4):98-100.

PMID- 31443112
OWN - NLM
STAT- MEDLINE
DCOM- 20201014
LR  - 20201014
IS  - 1098-9064 (Electronic)
IS  - 0094-6176 (Linking)
VI  - 46
IP  - 1
DP  - 2020 Feb
TI  - Postoperative Venous Thromboembolism Prophylaxis: Changes in the Daily Clinical 
      Practice, Modified Guidelines.
PG  - 83-88
LID - 10.1055/s-0039-1694994 [doi]
AB  - With current clinical practice, postoperative venous thromboembolism (VTE) risk 
      is not only well controlled, but it is steadily decreasing, especially in 
      orthopaedic surgery, thanks to fast-track and day case procedures, new surgical 
      techniques, and potent antithrombotic agents. Thromboprophylaxis is becoming 
      increasingly adapted to these patients. Aspirin is also extensively prescribed in 
      total hip replacement and total knee replacement procedures in the United States 
      and Australia. Mechanical prophylaxis is sometimes applied alone but most often 
      combined with anticoagulant agents. However, large evidence-based studies are 
      still needed to confirm these optimistic tendencies. In the meantime, physicians 
      have to keep strong control over the VTE risk to prevent the reappearance of 
      pulmonary embolism after admission to the surgical wards.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Samama, Charles Marc
AU  - Samama CM
AD  - Department of Anaesthesia and Intensive Care Medicine, Cochin University 
      Hospital, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190823
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Arthroplasty, Replacement, Hip/*adverse effects
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Aspirin/*therapeutic use
MH  - Humans
MH  - Postoperative Complications/*prevention & control
MH  - Practice Guidelines as Topic
MH  - Venous Thromboembolism/*prevention & control
COIS- None.
EDAT- 2019/08/24 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/08/24 06:00
PHST- 2019/08/24 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/08/24 06:00 [entrez]
AID - 10.1055/s-0039-1694994 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2020 Feb;46(1):83-88. doi: 10.1055/s-0039-1694994. Epub 2019 
      Aug 23.

PMID- 26224530
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20181202
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 13
IP  - 10
DP  - 2015 Oct
TI  - Assessing the optimal strategy for dual antiplatelet therapy.
PG  - 1067-9
LID - 10.1586/14779072.2015.1073588 [doi]
AB  - Coronary artery disease remains a leading cause of morbidity and mortality 
      worldwide. Each year, millions of patients undergo stent placement to treat 
      coronary artery disease. As stents are prone to thrombosis, which can potentially 
      be devastating, patients are treated with dual antiplatelet therapy with aspirin 
      plus a thienopyridine for at least 6-12 months after stent placement. New 
      evidence suggests that long-term dual antiplatelet therapy beyond 1 year prevents 
      ischemic events but also leads to increased risk of bleeding. To determine the 
      optimal strategy for dual antiplatelet therapy after stent placement, the 
      benefits and risks must be carefully considered and individualized for each 
      patient.
FAU - Chang, Lee
AU  - Chang L
AD  - a 1 Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
FAU - Yeh, Robert W
AU  - Yeh RW
AD  - b 2 Department of Medicine, Division of Cardiology, Massachusetts General 
      Hospital, Boston, MA, USA.
LA  - eng
PT  - Editorial
DEP - 20150729
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Coronary Artery Disease/*therapy
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pyridines/administration & dosage
MH  - Risk
MH  - Stents
MH  - Thrombosis/prevention & control
OTO - NOTNLM
OT  - bleeding
OT  - dual antiplatelet therapy
OT  - ischemia
OT  - risk stratification
OT  - stent thrombosis
EDAT- 2015/08/01 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/07/31 06:00
PHST- 2015/07/31 06:00 [entrez]
PHST- 2015/08/01 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - 10.1586/14779072.2015.1073588 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2015 Oct;13(10):1067-9. doi: 
      10.1586/14779072.2015.1073588. Epub 2015 Jul 29.

PMID- 234925
OWN - NLM
STAT- MEDLINE
DCOM- 19750527
LR  - 20131121
IS  - 0020-9988 (Print)
IS  - 0020-9988 (Linking)
VI  - 14
IP  - 3
DP  - 1975 Mar
TI  - Prostaglandin-like activity in the aqueous humor following alkali burns.
PG  - 177-83
AB  - Following application of 20 mul of 2 N sodium hydroxide to the rabbit cornea, the 
      prostaglandin-like activity in the aqueous humor increased from undetectable 
      levels to around 30 ng, per milliliter, a level which was sustained for up to 24 
      hours. This increase correlated with the previously reported sustained elevation 
      of intraocular pressure following a 20 mul alkali burn. Pretreatment with aspirin 
      or indomethacin virtually abolished the increase in intraocular pressure and 
      elevation of prostaglandin-like activity in the aqueous humor following a 20 mul 
      burn. Marked ocular hypotension following 50 mul and 100 mul sodium hydroxide 
      burns correlated with very low prostaglandin-like activity in the aqueous humor. 
      The low prostaglandin-like activity probably resulted from alkaline hydrolysis of 
      aqueous prostaglandins and massive cellular death in iris and ciliary body 
      tissues.
FAU - Paterson, C A
AU  - Paterson CA
FAU - Pfister, R R
AU  - Pfister RR
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Invest Ophthalmol
JT  - Investigative ophthalmology
JID - 0374730
RN  - 0 (Alkalies)
RN  - 0 (Prostaglandins)
RN  - 55X04QC32I (Sodium Hydroxide)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - *Alkalies
MH  - Animals
MH  - Aqueous Humor/*analysis
MH  - Aspirin/pharmacology
MH  - Blood Pressure
MH  - Burns, Chemical/*etiology/physiopathology
MH  - Hydrogen-Ion Concentration
MH  - Hydrolysis
MH  - Indomethacin/pharmacology
MH  - Intraocular Pressure/drug effects
MH  - Prostaglandins/*analysis
MH  - Rabbits
MH  - Sodium Hydroxide
MH  - Time Factors
EDAT- 1975/03/01 00:00
MHDA- 1975/03/01 00:01
CRDT- 1975/03/01 00:00
PHST- 1975/03/01 00:00 [pubmed]
PHST- 1975/03/01 00:01 [medline]
PHST- 1975/03/01 00:00 [entrez]
PST - ppublish
SO  - Invest Ophthalmol. 1975 Mar;14(3):177-83.

PMID- 32988222
OWN - NLM
STAT- MEDLINE
DCOM- 20211129
LR  - 20211204
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 143
IP  - 1
DP  - 2021 Jan 5
TI  - PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, 
      Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.
PG  - 45-61
LID - 10.1161/CIRCULATIONAHA.120.046290 [doi]
AB  - BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin 9), mainly secreted by 
      the liver and released into the blood, elevates plasma low-density lipoprotein 
      cholesterol by degrading low-density lipoprotein receptor. Pleiotropic effects of 
      PCSK9 beyond lipid metabolism have been shown. However, the direct effects of 
      PCSK9 on platelet activation and thrombosis, and the underlying mechanisms, as 
      well, still remain unclear. METHODS: We detected the direct effects of PCSK9 on 
      agonist-induced platelet aggregation, dense granule ATP release, integrin αIIbβ3 
      activation, α-granule release, spreading, and clot retraction. These studies were 
      complemented by in vivo analysis of FeCl(3)-injured mouse mesenteric arteriole 
      thrombosis. We also investigated the underlying mechanisms. Using the myocardial 
      infarction (MI) model, we explored the effects of PCSK9 on microvascular 
      obstruction and infarct expansion post-MI. RESULTS: PCSK9 directly enhances 
      agonist-induced platelet aggregation, dense granule ATP release, integrin αIIbβ3 
      activation, P-selectin release from α-granules, spreading, and clot retraction. 
      In line, PCSK9 enhances in vivo thrombosis in a FeCl(3)-injured mesenteric 
      arteriole thrombosis mouse model, whereas PCSK9 inhibitor evolocumab ameliorates 
      its enhancing effects. Mechanism studies revealed that PCSK9 binds to platelet 
      CD36 and thus activates Src kinase and MAPK (mitogen-activated protein 
      kinase)-extracellular signal-regulated kinase 5 and c-Jun N-terminal kinase, 
      increases the generation of reactive oxygen species, and activates the 
      p38MAPK/cytosolic phospholipase A2/cyclooxygenase-1/thromboxane A(2) signaling 
      pathways downstream of CD36 to enhance platelet activation, as well. Using CD36 
      knockout mice, we showed that the enhancing effects of PCSK9 on platelet 
      activation are CD36 dependent. It is important to note that aspirin consistently 
      abolishes the enhancing effects of PCSK9 on platelet activation and in vivo 
      thrombosis. Last, we showed that PCSK9 activating platelet CD36 aggravates 
      microvascular obstruction and promotes MI expansion post-MI. CONCLUSIONS: PCSK9 
      in plasma directly enhances platelet activation and in vivo thrombosis, and MI 
      expansion post-MI, as well, by binding to platelet CD36 and thus activating the 
      downstream signaling pathways. PCSK9 inhibitors or aspirin abolish the enhancing 
      effects of PCSK9, supporting the use of aspirin in patients with high plasma 
      PCSK9 levels in addition to PCSK9 inhibitors to prevent thrombotic complications.
FAU - Qi, Zhiyong
AU  - Qi Z
AD  - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 
      Institute of Cardiovascular Diseases, China (Z.Q., W.Y., D.J., Z.Y., K.Y., A.S., 
      J.Q., J.G.).
FAU - Hu, Liang
AU  - Hu L
AD  - Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, 
      China (L.H., Z.D.).
FAU - Zhang, Jianjun
AU  - Zhang J
AD  - Department of Biochemistry and Molecular Biology, School of Basic Medical 
      Sciences, Fudan University, Shanghai, China (J.Z., L.C., G.P., Z.D.).
FAU - Yang, Wenlong
AU  - Yang W
AD  - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 
      Institute of Cardiovascular Diseases, China (Z.Q., W.Y., D.J., Z.Y., K.Y., A.S., 
      J.Q., J.G.).
FAU - Liu, Xin
AU  - Liu X
AD  - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 
      Institute of Cardiovascular Diseases, China (Z.Q., W.Y., D.J., Z.Y., K.Y., A.S., 
      J.Q., J.G.).
FAU - Jia, Daile
AU  - Jia D
AD  - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 
      Institute of Cardiovascular Diseases, China (Z.Q., W.Y., D.J., Z.Y., K.Y., A.S., 
      J.Q., J.G.).
FAU - Yao, Zhifeng
AU  - Yao Z
AD  - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 
      Institute of Cardiovascular Diseases, China (Z.Q., W.Y., D.J., Z.Y., K.Y., A.S., 
      J.Q., J.G.).
FAU - Chang, Lin
AU  - Chang L
AD  - Department of Biochemistry and Molecular Biology, School of Basic Medical 
      Sciences, Fudan University, Shanghai, China (J.Z., L.C., G.P., Z.D.).
FAU - Pan, Guanxing
AU  - Pan G
AD  - Department of Biochemistry and Molecular Biology, School of Basic Medical 
      Sciences, Fudan University, Shanghai, China (J.Z., L.C., G.P., Z.D.).
FAU - Zhong, Haoxuan
AU  - Zhong H
AD  - Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China 
      (H.Z., X. Luo).
FAU - Luo, Xinping
AU  - Luo X
AD  - Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China 
      (H.Z., X. Luo).
FAU - Yao, Kang
AU  - Yao K
AD  - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 
      Institute of Cardiovascular Diseases, China (Z.Q., W.Y., D.J., Z.Y., K.Y., A.S., 
      J.Q., J.G.).
FAU - Sun, Aijun
AU  - Sun A
AD  - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 
      Institute of Cardiovascular Diseases, China (Z.Q., W.Y., D.J., Z.Y., K.Y., A.S., 
      J.Q., J.G.).
FAU - Qian, Juying
AU  - Qian J
AD  - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 
      Institute of Cardiovascular Diseases, China (Z.Q., W.Y., D.J., Z.Y., K.Y., A.S., 
      J.Q., J.G.).
FAU - Ding, Zhongren
AU  - Ding Z
AD  - Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, 
      China (L.H., Z.D.).
AD  - Department of Biochemistry and Molecular Biology, School of Basic Medical 
      Sciences, Fudan University, Shanghai, China (J.Z., L.C., G.P., Z.D.).
FAU - Ge, Junbo
AU  - Ge J
AD  - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 
      Institute of Cardiovascular Diseases, China (Z.Q., W.Y., D.J., Z.Y., K.Y., A.S., 
      J.Q., J.G.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (CD36 Antigens)
RN  - 0 (PCSK9 Inhibitors)
RN  - EC 3.4.21.- (PCSK9 protein, human)
RN  - EC 3.4.21.- (Proprotein Convertase 9)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circulation. 2021 Jan 5;143(1):62-64. PMID: 33378238
EIN - Circulation. 2021 Jan 5;143(1):e4. PMID: 33378240
MH  - Animals
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/drug effects/*metabolism
MH  - CD36 Antigens/*metabolism
MH  - Humans
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Myocardial Infarction/drug therapy/*metabolism
MH  - PCSK9 Inhibitors
MH  - Platelet Activation/drug effects/*physiology
MH  - Platelet Aggregation/physiology
MH  - Proprotein Convertase 9/*metabolism
MH  - Thrombosis/drug therapy/*metabolism
OTO - NOTNLM
OT  - CD36 protein
OT  - PCSK9 protein
OT  - aspirin
OT  - blood platelets
OT  - evolocumab
OT  - myocardial infarction
OT  - platelet activation
OT  - signal transduction
OT  - thrombosis
EDAT- 2020/09/30 06:00
MHDA- 2021/11/30 06:00
CRDT- 2020/09/29 05:24
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/11/30 06:00 [medline]
PHST- 2020/09/29 05:24 [entrez]
AID - 10.1161/CIRCULATIONAHA.120.046290 [doi]
PST - ppublish
SO  - Circulation. 2021 Jan 5;143(1):45-61. doi: 10.1161/CIRCULATIONAHA.120.046290. 
      Epub 2020 Sep 29.

PMID- 18162342
OWN - NLM
STAT- MEDLINE
DCOM- 20080702
LR  - 20131121
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 354
IP  - 1-2
DP  - 2008 Apr 16
TI  - The development of microthermal analysis and photothermal microspectroscopy as 
      novel approaches to drug-excipient compatibility studies.
PG  - 149-57
AB  - The use of microthermal analysis as a novel means of assessing chemical 
      incompatibility between drugs and excipients is assessed using magnesium stearate 
      and acetylsalicylic acid as a model system. Localised thermomechanical analysis 
      (L-TMA), localised differential thermal analysis (L-DTA), nanosampling, thermally 
      assisted particle manipulation (TAPM) and photothermal microspectrometry (PTMS) 
      are developed as a means of allowing extremely small quantities of drug and 
      excipient to be heated in close proximity to each other. Differential scanning 
      calorimetry (DSC), hot stage microscopy (HSM) and temperature controlled 
      attenuated total internal reflection (ATR) FTIR were used as supportive 
      techniques. L-TMA and macroscopic TMA of magnesium stearate indicated that the 
      endothermic DSC peak normally associated with melting does not correspond to 
      significant liquefaction. An optimised method for detecting the interaction at a 
      particulate level of scrutiny was developed whereby the drug is placed on the 
      excipient surface via TAPM and the construct heated, allowing the interaction to 
      be detected in both the L-TMA and L-DTA signal. PTMS allowed spectra to be 
      obtained on nanogram-sized samples and also allowed the interaction to be 
      detected. The study has therefore demonstrated the potential for using TAPM with 
      PTMS for studying interactions at an individual particle level.
FAU - Harding, L
AU  - Harding L
AD  - School of Chemical Sciences and Pharmacy, University of East Anglia, Norwich NR4 
      7TJ, UK.
FAU - Qi, S
AU  - Qi S
FAU - Hill, G
AU  - Hill G
FAU - Reading, M
AU  - Reading M
FAU - Craig, D Q M
AU  - Craig DQ
LA  - eng
PT  - Journal Article
DEP - 20071113
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Excipients)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Stearic Acids)
RN  - 4ELV7Z65AP (stearic acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/chemistry
MH  - Calorimetry, Differential Scanning
MH  - Differential Thermal Analysis/*methods
MH  - *Drug Incompatibility
MH  - Excipients/chemistry
MH  - Microscopy/methods
MH  - Microspectrophotometry/*methods
MH  - Pharmaceutical Preparations/*chemistry
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Stearic Acids/chemistry
MH  - Temperature
MH  - Thermodynamics
EDAT- 2007/12/29 09:00
MHDA- 2008/07/03 09:00
CRDT- 2007/12/29 09:00
PHST- 2007/09/16 00:00 [received]
PHST- 2007/10/29 00:00 [revised]
PHST- 2007/11/05 00:00 [accepted]
PHST- 2007/12/29 09:00 [pubmed]
PHST- 2008/07/03 09:00 [medline]
PHST- 2007/12/29 09:00 [entrez]
AID - S0378-5173(07)00911-8 [pii]
AID - 10.1016/j.ijpharm.2007.11.009 [doi]
PST - ppublish
SO  - Int J Pharm. 2008 Apr 16;354(1-2):149-57. doi: 10.1016/j.ijpharm.2007.11.009. 
      Epub 2007 Nov 13.

PMID- 22234683
OWN - NLM
STAT- MEDLINE
DCOM- 20120612
LR  - 20220310
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 119
IP  - 15
DP  - 2012 Apr 12
TI  - Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is 
      explained by accelerated renewal of the drug target.
PG  - 3595-603
LID - 10.1182/blood-2011-06-359224 [doi]
AB  - Essential thrombocythemia (ET) is characterized by enhanced platelet generation 
      and thrombotic complications. Once-daily low-dose aspirin incompletely inhibits 
      platelet thromboxane A(2) (TXA(2)) in the majority of ET patients. In the present 
      study, we investigated the determinants of aspirin-insensitive platelet TXA(2) 
      biosynthesis and whether it could be further suppressed by changing the aspirin 
      dose, formulation, or dosing interval. In 41 aspirin-treated ET patients, the 
      immature platelet count predicted serum TXB(2) independently of platelet count, 
      age, JAK-2 V617F mutation, or cytoreduction (β = 3.53, P = .001). Twenty-one 
      aspirin-treated patients with serum TXB(2) ≥ 4 ng/mL at 24 hours after dosing 
      were randomized to the following 7-day regimens in a crossover design: 
      enteric-coated aspirin 100 mg twice daily, enteric-coated aspirin 200 mg once 
      daily, or plain aspirin 100 mg once daily. A twice-daily regimen caused a further 
      88% median (IQR, 78%-92%, P < .001) TXB(2) reduction and normalized the 
      functional platelet response to aspirin, as assessed by urinary 11-dehydro-TXB(2) 
      excretion and the VerifyNow Aspirin assay. Doubling the aspirin dose reduced 
      serum TXB(2) only partially by 39% median (IQR, 29%-54%, P < .05). We conclude 
      that the abnormal megakaryopoiesis characterizing ET accounts for a 
      shorter-lasting antiplatelet effect of low-dose aspirin through faster renewal of 
      platelet cyclooxygenase-1, and impaired platelet inhibition can be rescued by 
      modulating the aspirin dosing interval rather than the dose.
FAU - Pascale, Silvia
AU  - Pascale S
AD  - Department of Hematology, Spirito Santo Hospital, Pescara, Italy.
FAU - Petrucci, Giovanna
AU  - Petrucci G
FAU - Dragani, Alfredo
AU  - Dragani A
FAU - Habib, Aida
AU  - Habib A
FAU - Zaccardi, Francesco
AU  - Zaccardi F
FAU - Pagliaccia, Francesca
AU  - Pagliaccia F
FAU - Pocaterra, Davide
AU  - Pocaterra D
FAU - Ragazzoni, Enzo
AU  - Ragazzoni E
FAU - Rolandi, Giancarlo
AU  - Rolandi G
FAU - Rocca, Bianca
AU  - Rocca B
FAU - Patrono, Carlo
AU  - Patrono C
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120110
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Blood. 2012 Apr 12;119(15):3377-8. PMID: 22500051
MH  - Acceleration
MH  - Adult
MH  - Aged
MH  - Algorithms
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cross-Over Studies
MH  - Cross-Sectional Studies/statistics & numerical data
MH  - Cyclooxygenase 1/*metabolism
MH  - Cyclooxygenase 2/*metabolism
MH  - Drug Resistance/drug effects
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Male
MH  - Metabolic Networks and Pathways/drug effects
MH  - Middle Aged
MH  - Molecular Targeted Therapy/methods
MH  - Protein Biosynthesis/drug effects
MH  - Thrombocythemia, Essential/*drug therapy/*metabolism
MH  - Thromboxane A2/*biosynthesis/pharmacokinetics
EDAT- 2012/01/12 06:00
MHDA- 2012/06/13 06:00
CRDT- 2012/01/12 06:00
PHST- 2012/01/12 06:00 [entrez]
PHST- 2012/01/12 06:00 [pubmed]
PHST- 2012/06/13 06:00 [medline]
AID - S0006-4971(20)49149-9 [pii]
AID - 10.1182/blood-2011-06-359224 [doi]
PST - ppublish
SO  - Blood. 2012 Apr 12;119(15):3595-603. doi: 10.1182/blood-2011-06-359224. Epub 2012 
      Jan 10.

PMID- 14759085
OWN - NLM
STAT- MEDLINE
DCOM- 20040226
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 55
IP  - 1
DP  - 2004 Jan-Feb
TI  - Warfarin and aspirin versus aspirin alone in patients with acute myocardial 
      infarction: a pilot study.
PG  - 17-20
AB  - The benefits of anticoagulant therapy and antiplatelet agents in secondary 
      prevention of myocardial infarction (MI) are well known. Administration of 
      combined warfarin and aspirin (ASA) has not been well studied. The objective of 
      this study was to compare the effect of coadministration of warfarin and ASA with 
      administration of ASA alone on outcome of patients after MI. One hundred forty 
      age- and sex-matched survivors of MI were randomized to receive either 100 mg/day 
      ASA plus enough warfarin to reach a target: international normalized ratio of 2.5 
      (range: 2-3) (group A, n = 70), or only 100 mg/day ASA (group B, n = 70). The 
      patients were examined for several variables including development of hemorrhage, 
      reinfarction, and rehospitalization for 1 year post MI. Of the variables studied, 
      minor hemorrhagic episodes were observed significantly (p = 0.002) more in group 
      A than in group B patients. Rehospitalization and reinfarction rates, although 
      occurring with lower frequencies in group A than in group B, did not reach the 
      statistical significance level. In postmyocardial infarction patients, warfarin 
      plus ASA did not provide a clinical benefit beyond that achievable with aspirin 
      monotherapy, and for the observed markedly higher incidence of minor hemorrhage 
      in combination therapy, antiplatelet therapy alone seems to be a more reasonable 
      approach.
FAU - Zibaeenezhad, M J
AU  - Zibaeenezhad MJ
AD  - Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, 
      Iran. Zibaeem2@sums.ac.ir
FAU - Mowla, A
AU  - Mowla A
FAU - Sorbi, M H
AU  - Sorbi MH
LA  - eng
PT  - Clinical Trial
PT  - Historical Article
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - History, 18th Century
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Pilot Projects
MH  - Treatment Outcome
MH  - Warfarin/*therapeutic use
EDAT- 2004/02/05 05:00
MHDA- 2004/02/27 05:00
CRDT- 2004/02/05 05:00
PHST- 2004/02/05 05:00 [pubmed]
PHST- 2004/02/27 05:00 [medline]
PHST- 2004/02/05 05:00 [entrez]
AID - 10.1177/000331970405500103 [doi]
PST - ppublish
SO  - Angiology. 2004 Jan-Feb;55(1):17-20. doi: 10.1177/000331970405500103.

PMID- 27543497
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20181101
IS  - 1471-8391 (Electronic)
IS  - 0007-1420 (Linking)
VI  - 119
IP  - 1
DP  - 2016 Sep
TI  - The role of aspirin in preventing colorectal cancer.
PG  - 17-24
LID - 10.1093/bmb/ldw028 [doi]
AB  - BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers in the 
      developed world and is the second leading cause of cancer-related mortality in 
      the UK and USA. Regular use of aspirin can reduce cancer incidence, recurrence, 
      metastasis and cancer-related mortality. SOURCES OF DATA: Peer-reviewed journals, 
      governmental and professional society publications. AREAS OF AGREEMENT: There is 
      a wide body of evidence from observational studies and randomized trials that 
      aspirin reduces risk of CRC. There is a delay of several years between initiation 
      and effect. There is interpersonal variation in aspirin metabolism but 
      pharmacogenetic testing is not yet sufficiently sensitive or specific to justify 
      routine use. AREAS OF DISAGREEMENT: There is uncertainty about the optimal dose 
      and the duration of aspirin. There is debate around use for the general 
      population but there is growing consensus on use in those at increased risk of 
      developing cancer. GROWING POINTS: Understanding is growing of the possible 
      mechanisms by which aspirin exerts its anticancer effects. Large-scale 
      meta-analyses are quantifying the cost-benefit ratio in the general population. 
      International trials are underway to assess the optimal dose in high-risk 
      individuals and the role of aspirin as an adjuvant in those who present with a 
      malignancy.
CI  - © The Author 2016. Published by Oxford University Press. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Burn, John
AU  - Burn J
AD  - Institute of Genetic Medicine, International Centre for Life, Newcastle 
      University, Newcastle upon Tyne NE1 4EP, UK john.burn@newcastle.ac.uk.
FAU - Sheth, Harsh
AU  - Sheth H
AD  - Institute of Genetic Medicine, International Centre for Life, Newcastle 
      University, Newcastle upon Tyne NE1 4EP, UK.
LA  - eng
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160819
PL  - England
TA  - Br Med Bull
JT  - British medical bulletin
JID - 0376542
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Colorectal Neoplasms/mortality/*prevention & control
MH  - Gastrointestinal Hemorrhage/chemically induced/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Neoplasm Recurrence, Local/*prevention & control
MH  - Observational Studies as Topic
MH  - *Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Survival Analysis
MH  - United Kingdom/epidemiology
MH  - United States/epidemiology
OTO - NOTNLM
OT  - aspirin
OT  - chemoprevention
OT  - colorectal cancer
EDAT- 2016/08/21 06:00
MHDA- 2017/09/26 06:00
CRDT- 2016/08/21 06:00
PHST- 2016/06/07 00:00 [accepted]
PHST- 2016/08/21 06:00 [entrez]
PHST- 2016/08/21 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
AID - ldw028 [pii]
AID - 10.1093/bmb/ldw028 [doi]
PST - ppublish
SO  - Br Med Bull. 2016 Sep;119(1):17-24. doi: 10.1093/bmb/ldw028. Epub 2016 Aug 19.

PMID- 4812408
OWN - NLM
STAT- MEDLINE
DCOM- 19740403
LR  - 20190501
IS  - 0007-1447 (Print)
IS  - 0007-1447 (Linking)
VI  - 1
IP  - 5899
DP  - 1974 Jan 26
TI  - Benorylate in management of Still's disease.
PG  - 145-7
AB  - The present recommended dose of benorylate is not satisfactory for the management 
      of children suffering from inflammatory polyarthritis. A starting dose of 200 
      mg/kg/day should be used, and the salicylate level checked at seven days and the 
      dosage adjusted to give an anti-inflammatory effect-that is, a blood salicylate 
      level of between 25 and 30 mg/100 ml. Once a satisfactory level has been 
      achieved, this dosage should be maintained with occasional monitoring of the 
      salicylate level. The paracetamol level does not need to be estimated as it tends 
      to follow the salicylate level, provided that liver function is normal; thus it 
      is quite safe to monitor only the salicylate level. Given in an adequate dosage, 
      benorylate seems to be an acceptable salicylate preparation for use in juveniles 
      suffering from chronic polyarthritis.
FAU - Powell, R H
AU  - Powell RH
FAU - Ansell, B M
AU  - Ansell BM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Med J
JT  - British medical journal
JID - 0372673
RN  - 0 (Acetanilides)
RN  - 0 (Salicylates)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/therapeutic use
MH  - Acetanilides/*administration & dosage/therapeutic use
MH  - Adolescent
MH  - Arthritis, Juvenile/*drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Infant
MH  - Liver Function Tests
MH  - Male
MH  - Salicylates/*administration & dosage/blood/therapeutic use
MH  - Time Factors
PMC - PMC1632990
EDAT- 1974/01/26 00:00
MHDA- 1974/01/26 00:01
CRDT- 1974/01/26 00:00
PHST- 1974/01/26 00:00 [pubmed]
PHST- 1974/01/26 00:01 [medline]
PHST- 1974/01/26 00:00 [entrez]
AID - 10.1136/bmj.1.5899.145 [doi]
PST - ppublish
SO  - Br Med J. 1974 Jan 26;1(5899):145-7. doi: 10.1136/bmj.1.5899.145.

PMID- 23083002
OWN - NLM
STAT- MEDLINE
DCOM- 20130605
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 10
IP  - 12
DP  - 2012 Dec
TI  - Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and 
      in combination in a porcine model of stent thrombosis.
PG  - 2470-80
LID - 10.1111/jth.12033 [doi]
AB  - BACKGROUND: Despite standard dual antiplatelet therapy (DAT) (acetylsalicylic 
      acid [ASA] and clopidogrel), there is a ≥ 1.4% incidence of in-stent thrombosis 
      in patients with acute coronary syndrome. Factor Xa inhibitors are being 
      investigated for secondary prevention after acute coronary syndrome. OBJECTIVE: 
      To study the antithrombotic effects of the FXa inhibitor rivaroxaban alone or in 
      combination with DAT. METHODS: Bare metal stents (12 per animal, three per 
      intervention period) were deployed in a porcine ex vivo arteriovenous shunt and 
      exposed to flowing arterial blood (shear rate: 1500 s(-1)). In-stent thrombus 
      formation was analyzed under different treatments: vehicle (n = 7 animals); 
      intravenous (i.v.) rivaroxaban (0.11, 0.33, and 1.0 μg kg(-1) min(-1)) (n = 8); 
      rivaroxaban + ASA (1.0 mg kg(-1) i.v.) (n = 6); rivaroxaban + ASA (1.0 mg kg(-1) 
      i.v.) + clopidogrel (0.5 mg kg(-1) i.v.) (n = 7); and ASA (1.0 mg kg(-1) i.v.) + 
      clopidogrel (0.5 mg kg(-1) i.v.) (n = 6). RESULTS: Rivaroxaban dose-dependently 
      reduced stent thrombus weight by ≤ 66% vs. vehicle (P < 0.05, all doses). 
      Rivaroxaban + ASA further reduced thrombus weight vs. vehicle (86% at the highest 
      rivaroxaban dose; P < 0.001). DAT reduced thrombus weight by ≤ 79%. However, 
      rivaroxaban + ASA + clopidogrel almost completely abolished in-stent thrombus 
      formation (98% reduction vs. vehicle at the highest rivaroxaban dose; P < 0.001). 
      CONCLUSIONS: Our data on the inhibitory effect of rivaroxaban alone or with DAT 
      are consistent with the ATLAS 2 trial findings, and support its potential use for 
      preventing stent thrombosis after stent deployment.
CI  - © 2012 International Society on Thrombosis and Haemostasis.
FAU - Becker, E M
AU  - Becker EM
AD  - Cardiovascular Research, Bayer Pharma AG, Wuppertal, Germany. 
      eva.becker1@bayer.com
FAU - Perzborn, E
AU  - Perzborn E
FAU - Klipp, A
AU  - Klipp A
FAU - Lücker, C
AU  - Lücker C
FAU - Bütehorn, U
AU  - Bütehorn U
FAU - Kast, R
AU  - Kast R
FAU - Badimon, J J
AU  - Badimon JJ
FAU - Laux, V
AU  - Laux V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Morpholines)
RN  - 0 (Thiophenes)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Female
MH  - Morpholines/administration & dosage/*therapeutic use
MH  - Platelet Aggregation
MH  - Rivaroxaban
MH  - Stents/*adverse effects
MH  - Swine
MH  - Swine, Miniature
MH  - Thiophenes/administration & dosage/*therapeutic use
MH  - Thrombosis/*drug therapy/etiology
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
EDAT- 2012/10/23 06:00
MHDA- 2013/06/06 06:00
CRDT- 2012/10/23 06:00
PHST- 2012/10/23 06:00 [entrez]
PHST- 2012/10/23 06:00 [pubmed]
PHST- 2013/06/06 06:00 [medline]
AID - S1538-7836(22)06547-3 [pii]
AID - 10.1111/jth.12033 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2012 Dec;10(12):2470-80. doi: 10.1111/jth.12033.

PMID- 1980284
OWN - NLM
STAT- MEDLINE
DCOM- 19910228
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 42
IP  - 7
DP  - 1990 Jul
TI  - Effect of compression speed on the tensile strength of tablets of binary mixtures 
      containing aspirin.
PG  - 462-7
AB  - Mixtures of aspirin with sodium chloride, sucrose, Starch 1500 or Emcompress have 
      been compressed to two maximum upper punch pressures at two compression speeds. 
      Non-linear relationships between tensile strength and composition, and tablet 
      porosity and composition were found in all cases. Tablets of the individual 
      materials compressed at fast speed showed either little change or a reduction in 
      tensile strength when compared with those compressed at slow speed. For mixtures 
      of aspirin with Starch 1500, tablets compressed at fast speed were weaker and 
      more porous than those compressed at slow speed. However, some mixtures of 
      aspirin with sodium chloride, sucrose or Emcompress gave tablets with greater 
      tensile strength and lower porosity when prepared at fast compression speed 
      compared with tablets prepared at slow speed. This behaviour was attributed to 
      the modification of the consolidation behaviour of the aspirin by the second 
      material.
FAU - Cook, G D
AU  - Cook GD
AD  - School of Pharmacy, University of London, UK.
FAU - Summers, M P
AU  - Summers MP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Drug Combinations)
RN  - 0 (Tablets)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - 57-50-1 (Sucrose)
RN  - 9005-25-8 (Starch)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - Drug Combinations
MH  - Drug Compounding/methods
MH  - *Sodium Chloride
MH  - *Starch
MH  - *Sucrose
MH  - Tablets
MH  - Tensile Strength
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1990.tb06596.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1990 Jul;42(7):462-7. doi: 10.1111/j.2042-7158.1990.tb06596.x.

PMID- 19789821
OWN - NLM
STAT- MEDLINE
DCOM- 20091022
LR  - 20141120
IS  - 0143-2044 (Print)
IS  - 0143-2044 (Linking)
VI  - 30
IP  - 4
DP  - 2009 Jul-Aug
TI  - Cryopreservation of in vitro shoot apices of Glehnia littoralis - a medical 
      plant.
PG  - 244-50
AB  - Cryopreservation was examined as a practical method for preserving the genetic 
      resources of Glehnia littoralis Fr. Schm. a nearly exterminated medical plant. In 
      vitro shoot apices were successfully cryopreserved using vitrification and 
      encapsulation-dehydration. In vitrification, regrowth of apices loaded for 60 min 
      with PVS2 (66.7 +/- 6.7 percent) was preferable to loading with PVS3 (50.0 +/- 
      5.8 percent). With encapsulation-dehydration, the best regrowth (43.3 +/- 3.3 
      percent) was achieved when the moisture content in the beads was reduced to 19 
      percent by drying with silica gel for 6 h. Increased regrowth of shoot tips 
      cryopreserved by encapsulation-dehydration resulted from the addition of 0.1 mM 
      acetylsalicylic acid to the loading solution (86.7 +/- 3.3 percent).
FAU - Otokita, K
AU  - Otokita K
AD  - Department of Horticultural Science and Landscape Architecture, Graduate School 
      of Agriculture, Hokkaido University, Sapporo, Hokkaido, Japan. 
      otkcanda@res.agr.hokudai.ac.jp
FAU - Kami, D
AU  - Kami D
FAU - Suzuki, T
AU  - Suzuki T
FAU - Suzuki, M
AU  - Suzuki M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cryo Letters
JT  - Cryo letters
JID - 9891832
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apiaceae/genetics/*physiology
MH  - Aspirin/pharmacology
MH  - Cryopreservation/*methods
MH  - Desiccation
MH  - In Vitro Techniques
MH  - Plant Shoots/drug effects/growth & development/*physiology
EDAT- 2009/10/01 06:00
MHDA- 2009/10/23 06:00
CRDT- 2009/10/01 06:00
PHST- 2009/10/01 06:00 [entrez]
PHST- 2009/10/01 06:00 [pubmed]
PHST- 2009/10/23 06:00 [medline]
PST - ppublish
SO  - Cryo Letters. 2009 Jul-Aug;30(4):244-50.

PMID- 5064
OWN - NLM
STAT- MEDLINE
DCOM- 19760706
LR  - 20131121
IS  - 0003-9780 (Print)
IS  - 0003-9780 (Linking)
VI  - 219
IP  - 1
DP  - 1976 Jan
TI  - Benorylate interaction with indomethacin and phenylbutazone.
PG  - 149-59
AB  - The simlutaneous oral administration of benorylate (4-(acetamido) phenyl 
      2-acetoxybenzoate) with either indomethacin or phenylbutazone to rats suffering 
      from Freund's adjuvant-induced arthritis leads to an anti-inflammatory effect 
      which is significantly greater than the effect of the same drugs administered 
      alone. Such an additive anti-inflammatory effect is not apparent when the 
      metabolites of benorylate (paracetamol, acetylsalicylic acid) are administered 
      with indomethacin or phenylbutazone. Paracetamol does not increase the 
      anti-inflammatory effect of indomethacin or phenylbutazone and acetylsalicylic 
      acid clearly antagonizes it. The molecule of benorylate itsel is therefore 
      responsible for the additive anti-inflammatory effect. However, if antipyretic 
      activity (yeast-induced hyperthermia) is examined instead of anti-inflammatory 
      activity, the simultaneous oral administration of the different drugs always 
      produces an additive effect. It is concluded that the antagonism between 
      indomethacin or phenylbutazone and non-steroidal anti-inflammatory drugs other 
      than benorylate is present at some receptors but not all. The clinical 
      implications of the results are discussed.
FAU - Khalili-Varasteh, H
AU  - Khalili-Varasteh H
FAU - Rosner, I
AU  - Rosner I
FAU - Legros, J
AU  - Legros J
LA  - eng
PT  - Journal Article
PL  - Belgium
TA  - Arch Int Pharmacodyn Ther
JT  - Archives internationales de pharmacodynamie et de therapie
JID - 0405353
RN  - 0 (Salicylates)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Arthritis/drug therapy
MH  - Aspirin/therapeutic use
MH  - Drug Interactions
MH  - Drug Synergism
MH  - Fever/drug therapy
MH  - Indomethacin/*therapeutic use
MH  - Male
MH  - Phenylbutazone/*therapeutic use
MH  - Rats
MH  - Salicylates/*therapeutic use
MH  - Time Factors
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
PST - ppublish
SO  - Arch Int Pharmacodyn Ther. 1976 Jan;219(1):149-59.

PMID- 3981955
OWN - NLM
STAT- MEDLINE
DCOM- 19850508
LR  - 20190711
IS  - 0023-2173 (Print)
IS  - 0023-2173 (Linking)
VI  - 63
IP  - 4
DP  - 1985 Feb 15
TI  - The influence of acetylsalicylic acid on the transepithelial potential difference 
      of gastric mucosa in children.
PG  - 184-7
AB  - The gastric transepithelial potential difference seems to be a sensitive 
      parameter of the integrity of gastric mucosa. The administration of 
      acetylsalicylic acid in adults causes a rapid and significant decrease in gastric 
      potential difference, whereas in children this characteristic reaction fails to 
      occur.
FAU - Nikolaides, N
AU  - Nikolaides N
FAU - König, A
AU  - König A
FAU - Ballke, E H
AU  - Ballke EH
FAU - Griefahn, B
AU  - Griefahn B
FAU - Jährig, K
AU  - Jährig K
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Klin Wochenschr
JT  - Klinische Wochenschrift
JID - 2985205R
RN  - 0 (Electrolytes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aspirin/*pharmacology
MH  - Child
MH  - Child, Preschool
MH  - Electrolytes/metabolism
MH  - Epithelium/physiology
MH  - Female
MH  - Gastric Juice/metabolism
MH  - Gastric Mucosa/*drug effects/physiology
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Membrane Potentials/drug effects
EDAT- 1985/02/15 00:00
MHDA- 1985/02/15 00:01
CRDT- 1985/02/15 00:00
PHST- 1985/02/15 00:00 [pubmed]
PHST- 1985/02/15 00:01 [medline]
PHST- 1985/02/15 00:00 [entrez]
AID - 10.1007/BF01732173 [doi]
PST - ppublish
SO  - Klin Wochenschr. 1985 Feb 15;63(4):184-7. doi: 10.1007/BF01732173.

PMID- 105934
OWN - NLM
STAT- MEDLINE
DCOM- 19790523
LR  - 20131121
IS  - 0430-0920 (Print)
IS  - 0430-0920 (Linking)
VI  - 33
IP  - 10
DP  - 1978 Oct
TI  - (N-Barbituryl)phenyl- and cyclohexylalkanoic acids and some of their derivatives 
      as potential anti-inflammatory agents.
PG  - 729-39
AB  - A series of p-(N-barbituryl)phenyl- and cyclohexylalkanoic acids and their esters 
      were synthesized. The preliminary pharmacological screening using the 
      carrageenin, xylene and cotton tests revealed strong anti-inflammatory activity 
      of several compounds in some of the tests performed, compound (Ij) being active 
      in all the tests.
FAU - Stankiewicz, K
AU  - Stankiewicz K
FAU - Bobrański, B
AU  - Bobrański B
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Farmaco Sci
JT  - Il Farmaco; edizione scientifica
JID - 0370716
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Barbiturates)
RN  - 0 (Carboxylic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*chemical synthesis
MH  - Aspirin/pharmacology
MH  - Barbiturates/*chemical synthesis/pharmacology
MH  - Carboxylic Acids/*chemical synthesis/pharmacology
MH  - Cyclooxygenase Inhibitors
MH  - Inflammation/physiopathology
MH  - Methods
MH  - Phenylbutazone/pharmacology
MH  - Rats
EDAT- 1978/10/01 00:00
MHDA- 1978/10/01 00:01
CRDT- 1978/10/01 00:00
PHST- 1978/10/01 00:00 [pubmed]
PHST- 1978/10/01 00:01 [medline]
PHST- 1978/10/01 00:00 [entrez]
PST - ppublish
SO  - Farmaco Sci. 1978 Oct;33(10):729-39.

PMID- 24177334
OWN - NLM
STAT- MEDLINE
DCOM- 20141031
LR  - 20140219
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 19
IP  - 2
DP  - 2014 Mar
TI  - Update on pharmacologic therapy for pulmonary embolism.
PG  - 159-69
LID - 10.1177/1074248413506612 [doi]
AB  - Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are 
      anticoagulants that have been used for treatment of pulmonary embolism. Currently 
      approved drugs for treatment of venous thromboembolism include UFH, enoxaparin, 
      dalteparin, fondaparinux, warfarin, and rivaroxaban. The advent of newer oral 
      anticoagulants such as rivaroxaban, dabigatran, and apixaban has provided us with 
      alternative therapeutic options for long-term anticoagulation. This article will 
      give an overview of the various anticoagulant drugs, use in various clinical 
      scenarios, data supporting their clinical use, and recommendations regarding 
      duration of anticoagulant therapy.
FAU - Harikrishnan, Prakash
AU  - Harikrishnan P
AD  - 1Cardiology Division, Westchester Medical Center, New York Medical College, 
      Valhalla, NY, USA.
FAU - Palaniswamy, Chandrasekar
AU  - Palaniswamy C
FAU - Aronow, Wilbert S
AU  - Aronow WS
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131031
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/metabolism/*therapeutic use
MH  - Aspirin/metabolism/therapeutic use
MH  - Fibrinolytic Agents/metabolism/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/metabolism/therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/metabolism/therapeutic use
MH  - Pulmonary Embolism/*diagnosis/*drug therapy/metabolism
MH  - Warfarin/metabolism/therapeutic use
OTO - NOTNLM
OT  - apixaban
OT  - dabigatran
OT  - pulmonary embolism
OT  - rivaroxaban
OT  - warfarin
EDAT- 2013/11/02 06:00
MHDA- 2014/11/02 06:00
CRDT- 2013/11/02 06:00
PHST- 2013/11/02 06:00 [entrez]
PHST- 2013/11/02 06:00 [pubmed]
PHST- 2014/11/02 06:00 [medline]
AID - 1074248413506612 [pii]
AID - 10.1177/1074248413506612 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):159-69. doi: 
      10.1177/1074248413506612. Epub 2013 Oct 31.

PMID- 25615803
OWN - NLM
STAT- MEDLINE
DCOM- 20151109
LR  - 20151119
IS  - 1520-6882 (Electronic)
IS  - 0003-2700 (Linking)
VI  - 87
IP  - 4
DP  - 2015 Feb 17
TI  - Evaluation of medicine effects on the interaction of myoglobin and its aptamer or 
      antibody using atomic force microscopy.
PG  - 2242-8
LID - 10.1021/ac503885e [doi]
AB  - The effects of medicine on the biomolecular interaction have been given 
      increasing attention in biochemistry and affinity-based analytics since the 
      environment in vivo is complex especially for the patients. Herein, myoglobin, a 
      biomarker of acute myocardial infarction, was used as a model, and the medicine 
      effects on the interactions of myoglobin/aptamer and myoglobin/antibody were 
      systematically investigated using atomic force microscopy (AFM) for the first 
      time. The results showed that the average binding force and the binding 
      probability of myoglobin/aptamer almost remained unchanged after 
      myoglobin-modified gold substrate was incubated with promazine, amoxicillin, 
      aspirin, and sodium penicillin, respectively. These parameters were changed for 
      myoglobin/antibody after the myoglobin-modified gold substrate was treated with 
      these medicines. For promazine and amoxicillin, they resulted in the change of 
      binding force distribution of myoglobin/antibody (i.e., from unimodal 
      distribution to bimodal distribution) and the increase of binding probability; 
      for aspirin, it only resulted in the change of the binding force distribution, 
      and for sodium penicillin, it resulted in the increase of the average binding 
      force and the binding probability. These results may be attributed to the 
      different interaction modes and binding sites between myoglobin/aptamer and 
      myoglobin/antibody, the different structures between aptamer and antibody, and 
      the effects of medicines on the conformations of myoglobin. These findings could 
      enrich our understanding of medicine effects on the interactions of aptamer and 
      antibody to their target proteins. Moreover, this work will lay a good foundation 
      for better research and extensive applications of biomolecular interaction, 
      especially in the design of biosensors in complex systems.
FAU - Wang, Qing
AU  - Wang Q
AD  - State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry 
      and Chemical Engineering, Key Laboratory for Bio-Nanotechnology and Molecular 
      Engineering of Hunan Province, Hunan University , Changsha, Hunan 410082, P. R. 
      China.
FAU - Liu, Lin
AU  - Liu L
FAU - Yang, Xiaohai
AU  - Yang X
FAU - Wang, Kemin
AU  - Wang K
FAU - Chen, Nandi
AU  - Chen N
FAU - Zhou, Chenchen
AU  - Zhou C
FAU - Luo, Bianxia
AU  - Luo B
FAU - Du, Shasha
AU  - Du S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150204
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
RN  - 0 (Antibodies)
RN  - 0 (Aptamers, Nucleotide)
RN  - 0 (Biomarkers)
RN  - 0 (Myoglobin)
RN  - 7440-57-5 (Gold)
RN  - 804826J2HU (Amoxicillin)
RN  - O9M39HTM5W (Promazine)
RN  - Q42T66VG0C (Penicillin G)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amoxicillin/chemistry/pharmacology
MH  - Antibodies/*chemistry/metabolism
MH  - Aptamers, Nucleotide/*chemistry/metabolism
MH  - Aspirin/chemistry/pharmacology
MH  - Binding Sites/drug effects
MH  - Biomarkers/chemistry/metabolism
MH  - Gold/chemistry
MH  - *Microscopy, Atomic Force
MH  - Myoglobin/*chemistry/metabolism
MH  - Penicillin G/chemistry/pharmacology
MH  - Promazine/chemistry/pharmacology
MH  - Protein Binding/drug effects
EDAT- 2015/01/24 06:00
MHDA- 2015/11/10 06:00
CRDT- 2015/01/24 06:00
PHST- 2015/01/24 06:00 [entrez]
PHST- 2015/01/24 06:00 [pubmed]
PHST- 2015/11/10 06:00 [medline]
AID - 10.1021/ac503885e [doi]
PST - ppublish
SO  - Anal Chem. 2015 Feb 17;87(4):2242-8. doi: 10.1021/ac503885e. Epub 2015 Feb 4.

PMID- 7486913
OWN - NLM
STAT- MEDLINE
DCOM- 19951226
LR  - 20210526
IS  - 0066-4804 (Print)
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Linking)
VI  - 39
IP  - 8
DP  - 1995 Aug
TI  - Influence of aspirin on development and treatment of experimental Staphylococcus 
      aureus endocarditis.
PG  - 1748-51
AB  - Previously, we have shown that a 5-mg/kg of body weight daily dose of aspirin 
      (ASA) caused reductions in the bacterial densities and weights of aortic 
      vegetations in a rabbit model of Staphylococcus aureus endocarditis. We sought to 
      determine (i) whether ASA dosage influences the development of vegetations and 
      (ii) whether ASA given with antimicrobial therapy improves the treatment outcome 
      of infective endocarditis. To study the influence of ASA dosage, animals received 
      either no ASA (control) or oral doses of 2.5, 10, 20, and 50 mg/kg daily. The 
      2.5- and 10-mg/kg groups had statistically significant reductions in vegetation 
      weight compared with untreated controls. The 10-mg/kg dose also resulted in a 
      significant decrease in bacterial densities compared with those of the controls. 
      Although reductions in weight and bacterial density were observed in other 
      ASA-treated groups, these did not achieve statistical significance. To study the 
      influence of ASA and antimicrobial therapy, the animals received either 
      vancomycin alone or vancomycin with ASA. When ASA was given prior to and during 
      antimicrobial therapy, a significant reduction in vegetation weight was observed. 
      Additionally, the rate of sterilization was directly proportional to this 
      observed reduction in weight. ASA's impact on the reduction of both the bacterial 
      density and the weight of aortic vegetations is a dose-dependent phenomenon. When 
      given with antimicrobial therapy, ASA not only reduces vegetation weight but also 
      improves the rate of sterilization. This study provides additional data regarding 
      the role of ASA in the treatment of endocarditis.
FAU - Nicolau, D P
AU  - Nicolau DP
AD  - Department of Pharmacy, Hartford Hospital, Connecticut 06102, USA.
FAU - Marangos, M N
AU  - Marangos MN
FAU - Nightingale, C H
AU  - Nightingale CH
FAU - Quintiliani, R
AU  - Quintiliani R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 6Q205EH1VU (Vancomycin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/pharmacology/therapeutic use
MH  - Aorta/microbiology/pathology
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Endocarditis, Bacterial/*drug therapy/microbiology/pathology
MH  - Female
MH  - Microbial Sensitivity Tests
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/*therapeutic use
MH  - Rabbits
MH  - Staphylococcal Infections/*drug therapy/microbiology/pathology
MH  - Staphylococcus aureus/drug effects
MH  - Vancomycin/pharmacology/therapeutic use
PMC - PMC162820
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
AID - 10.1128/AAC.39.8.1748 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 1995 Aug;39(8):1748-51. doi: 10.1128/AAC.39.8.1748.

PMID- 22315948
OWN - NLM
STAT- MEDLINE
DCOM- 20120618
LR  - 20220330
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 12
DP  - 2012 Feb 8
TI  - Aspirin for the prevention of cognitive decline in the elderly: rationale and 
      design of a neuro-vascular imaging study (ENVIS-ion).
PG  - 3
LID - 10.1186/1471-2377-12-3 [doi]
AB  - BACKGROUND: This paper describes the rationale and design of the ENVIS-ion Study, 
      which aims to determine whether low-dose aspirin reduces the development of white 
      matter hyper-intense (WMH) lesions and silent brain infarction (SBI). Additional 
      aims include determining whether a) changes in retinal vascular imaging (RVI) 
      parameters parallel changes in brain magnetic resonance imaging (MRI); b) changes 
      in RVI parameters are observed with aspirin therapy; c) baseline cognitive 
      function correlates with MRI and RVI parameters; d) changes in cognitive function 
      correlate with changes in brain MRI and RVI and e) whether factors such as age, 
      gender or blood pressure influence the above associations. METHODS/DESIGN: 
      Double-blind, placebo-controlled trial of three years duration set in two 
      Australian academic medical centre outpatient clinics. This study will enrol 600 
      adults aged 70 years and over with normal cognitive function and without overt 
      cardiovascular disease. Subjects will undergo cognitive testing, brain MRI and 
      RVI at baseline and after 3 years of study treatment. All subjects will be 
      recruited from a 19,000-patient clinical outcome trial conducted in Australia and 
      the United States that will evaluate the effects of aspirin in maintaining 
      disability-free longevity over 5 years. The intervention will be aspirin 100 mg 
      daily versus matching placebo, randomized on a 1:1 basis. DISCUSSION: This study 
      will improve understanding of the mechanisms at the level of brain and vascular 
      structure that underlie the effects of aspirin on cognitive function. Given the 
      limited access and high cost of MRI, RVI may prove useful as a tool for the 
      identification of individuals at high risk for the development of cerebrovascular 
      disease and cognitive decline. TRIAL REGISTRATION: clinicaltrials.gov Identifier: 
      NCT01038583.
FAU - Reid, Christopher M
AU  - Reid CM
AD  - School of Public Health & Preventive Medicine, Monash University, Melbourne 
      Australia. chris.reid@monash.edu
FAU - Storey, Elsdon
AU  - Storey E
FAU - Wong, Tien Y
AU  - Wong TY
FAU - Woods, Robyn
AU  - Woods R
FAU - Tonkin, Andrew
AU  - Tonkin A
FAU - Wang, Jie Jin
AU  - Wang JJ
FAU - Kam, Anthony
AU  - Kam A
FAU - Janke, Andrew
AU  - Janke A
FAU - Essex, Rowan
AU  - Essex R
FAU - Abhayaratna, Walter P
AU  - Abhayaratna WP
FAU - Budge, Marc M
AU  - Budge MM
CN  - ASPREE Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT01038583
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120208
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aging/drug effects
MH  - Aspirin/*therapeutic use
MH  - Australia
MH  - Brain Infarction/*diagnosis
MH  - Cognition/*drug effects
MH  - Cognition Disorders/*prevention & control
MH  - Double-Blind Method
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Neuropsychological Tests
MH  - Research Design
MH  - Retinal Vessels/*pathology
MH  - United States
PMC - PMC3297524
EDAT- 2012/02/10 06:00
MHDA- 2012/06/19 06:00
CRDT- 2012/02/10 06:00
PHST- 2011/10/25 00:00 [received]
PHST- 2012/02/08 00:00 [accepted]
PHST- 2012/02/10 06:00 [entrez]
PHST- 2012/02/10 06:00 [pubmed]
PHST- 2012/06/19 06:00 [medline]
AID - 1471-2377-12-3 [pii]
AID - 10.1186/1471-2377-12-3 [doi]
PST - epublish
SO  - BMC Neurol. 2012 Feb 8;12:3. doi: 10.1186/1471-2377-12-3.

PMID- 36703139
OWN - NLM
STAT- MEDLINE
DCOM- 20230131
LR  - 20230308
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 24
IP  - 1
DP  - 2023 Jan 26
TI  - Multi-centre, randomised, open-label, blinded endpoint assessed, trial of 
      corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG 
      and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease 
      (KD): the KD CAA prevention (KD-CAAP) trial protocol.
PG  - 60
LID - 10.1186/s13063-022-07051-9 [doi]
LID - 60
AB  - BACKGROUND: Kawasaki disease (KD) is an acute self-limiting inflammatory 
      vasculitis affecting predominantly medium-sized arteries, particularly the 
      coronary arteries. A number of recent studies conducted in different European 
      countries have demonstrated alarmingly high coronary complications despite 
      treatment with intravenous immunoglobulin (IVIG). These high complication rates 
      now emphasize the need for an urgent reappraisal of IVIG as the sole primary 
      therapeutic agent for KD. The Kawasaki disease CAA prevention (KD-CAAP) trial 
      will test the hypothesis that immediate adjunctive corticosteroid treatment to 
      standard of care IVIG and aspirin will reduce coronary artery aneurysm (CAA) 
      rates in unselected KD patients across Europe. METHODS: KD-CAAP is a multicentre, 
      randomised, controlled, open-label, blinded endpoint assessed trial that will be 
      conducted across Europe supported by the conect4children pan-European clinical 
      trials network. Patients with KD who satisfy the eligibility criteria will be 
      randomised (1:1) to receive either oral prednisolone 2 mg/kg/day plus standard of 
      care therapy IVIG (2 g/kg) and aspirin (40 mg/kg/day); or IVIG and aspirin alone. 
      Further management is dictated by temperature and C-reactive protein (CRP) 
      responses. Co-primary outcomes are as follows: (i) any CAA within the 3 months of 
      trial follow-up; (ii) average estimate of maximum coronary Z-score at weeks 1, 2 
      and 6 adjusting for rescue treatment. Additional outcomes will be assessed 
      including cost effectiveness, quality of life, corticosteroid toxicity and other 
      safety outcomes. DISCUSSION: Several recent studies have indicated that coronary 
      complications associated with KD across Europe are much higher than early trials 
      of IVIG had initially suggested. KD-CAAP directly addresses this issue by 
      exploring the therapeutic benefit of adjunctive corticosteroids in unselected KD 
      cases. If we find that corticosteroids prevent CAA and are safe, this is a cheap 
      and widely available intervention that could be implemented immediately for the 
      benefit of children. TRIAL REGISTRATION: ISRCTN71987471- March 31, 2020; Eudract 
      2019-004433-17.
CI  - © 2023. The Author(s).
FAU - Eleftheriou, Despina
AU  - Eleftheriou D
AUID- ORCID: 0000-0002-5312-2269
AD  - UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, 
      WC1N 1EH, UK. d.eleftheriou@ucl.ac.uk.
FAU - Moraes, Yolanda Collaco
AU  - Moraes YC
AD  - Medical Research Council (MRC) Clinical Trials Unit (CTU) at University College 
      London (UCL), London, UK.
FAU - Purvis, Cara
AU  - Purvis C
AD  - Medical Research Council (MRC) Clinical Trials Unit (CTU) at University College 
      London (UCL), London, UK.
FAU - Pursell, Molly
AU  - Pursell M
AD  - Medical Research Council (MRC) Clinical Trials Unit (CTU) at University College 
      London (UCL), London, UK.
FAU - Morillas, Marta Merida
AU  - Morillas MM
AD  - Medical Research Council (MRC) Clinical Trials Unit (CTU) at University College 
      London (UCL), London, UK.
FAU - Kahn, Robin
AU  - Kahn R
AD  - Department of Paediatrics, Lund University, Clinical Sciences, Lund, Sweden.
FAU - Mossberg, Maria
AU  - Mossberg M
AD  - Department of Paediatrics, Lund University, Clinical Sciences, Lund, Sweden.
FAU - Kucera, Filip
AU  - Kucera F
AD  - Great Ormond Street Hospital, London, UK.
FAU - Tulloh, Robert
AU  - Tulloh R
AD  - Bristol Heart Institute, Bristol, UK.
FAU - Standing, Joseph F
AU  - Standing JF
AD  - UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, 
      WC1N 1EH, UK.
FAU - Swallow, Veronica
AU  - Swallow V
AD  - Sheffield Hallam University, Sheffield, UK.
FAU - McCormack, Rachael
AU  - McCormack R
AD  - Societi Foundation CIO, The UK Foundation for Kawasaki Disease, Newark, UK.
FAU - Herberg, Jethro
AU  - Herberg J
AD  - Section of Paediatric Infectious Diseases, Imperial College London, London, UK.
FAU - Levin, Michael
AU  - Levin M
AD  - Section of Paediatric Infectious Diseases, Imperial College London, London, UK.
FAU - Wan, Mandy
AU  - Wan M
AD  - Pharmacy Department, Evelina London Children's Hospital, Guy's and St Thomas' NHS 
      Foundation Trust, London, UK.
AD  - Institute of Pharmaceutical Science, King's College London, London, UK.
FAU - Klein, Nigel
AU  - Klein N
AD  - UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, 
      WC1N 1EH, UK.
FAU - Connon, Roisin
AU  - Connon R
AD  - Medical Research Council (MRC) Clinical Trials Unit (CTU) at University College 
      London (UCL), London, UK.
FAU - Walker, Ann Sarah
AU  - Walker AS
AD  - Medical Research Council (MRC) Clinical Trials Unit (CTU) at University College 
      London (UCL), London, UK.
FAU - Brogan, Paul
AU  - Brogan P
AD  - UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, 
      WC1N 1EH, UK.
LA  - eng
GR  - MR/M008665/1/MRC_/Medical Research Council/United Kingdom
GR  - 777389/Innovative Medicines Initiative/
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20230126
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Adrenal Cortex Hormones)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Child
MH  - Humans
MH  - Infant
MH  - *Adrenal Cortex Hormones/adverse effects/therapeutic use
MH  - *Aneurysm/complications/drug therapy
MH  - *Aspirin/adverse effects/therapeutic use
MH  - Coronary Vessels
MH  - *Immunoglobulins, Intravenous/adverse effects/therapeutic use
MH  - *Mucocutaneous Lymph Node Syndrome/complications/diagnosis/drug therapy
MH  - Multicenter Studies as Topic
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Child, Preschool
MH  - Adolescent
PMC - PMC9879235
OTO - NOTNLM
OT  - Coronary artery aneurysms
OT  - Corticosteroids
OT  - Kawasaki disease
COIS- The authors declare that they have no competing interests.
EDAT- 2023/01/27 06:00
MHDA- 2023/01/31 06:00
CRDT- 2023/01/26 23:32
PHST- 2022/10/28 00:00 [received]
PHST- 2022/12/23 00:00 [accepted]
PHST- 2023/01/26 23:32 [entrez]
PHST- 2023/01/27 06:00 [pubmed]
PHST- 2023/01/31 06:00 [medline]
AID - 10.1186/s13063-022-07051-9 [pii]
AID - 7051 [pii]
AID - 10.1186/s13063-022-07051-9 [doi]
PST - epublish
SO  - Trials. 2023 Jan 26;24(1):60. doi: 10.1186/s13063-022-07051-9.

PMID- 2073296
OWN - NLM
STAT- MEDLINE
DCOM- 19910225
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 64
IP  - 1
DP  - 1990 Aug 13
TI  - Coagulation, fibrinolytic and platelet function in patients on long-term therapy 
      with aspirin 300 mg or 1,200 mg daily compared with placebo.
PG  - 17-20
AB  - Aspirin has been shown to be beneficial in the prophylaxis of arterial 
      thromboembolic disease. The rationale for its use as an antithrombotic drug lies 
      in its inhibition of thromboxane A2-dependent platelet function. However, the 
      effect of aspirin on coagulation and fibrinolysis during chronic therapy has not 
      been studied. We have measured a range of haemostatic and platelet functions in 
      49 patients with transient ischaemic attacks randomly allocated to aspirin 300 mg 
      a day, aspirin 1,200 mg a day or placebo. All had been taking their allocated 
      treatment for between 9 months and 4 years prior to investigation. Bleeding time 
      was prolonged, serum thromboxane diminished and platelet aggregation to 
      arachidonic acid but not ADP was abolished by both 300 mg and 1,200 mg aspirin, 
      in a non-dose dependent fashion. Serum salicylate increased with the dose of 
      aspirin ingested. No effect was seen with either dose of aspirin on urinary 
      thromboxane and 6-keto-PGF1 alpha excretion, or on coagulation. Patients taking 
      1,200 mg aspirin a day had a lower haemoglobin and packed cell volume, lower 
      resting fibrinopeptide A concentration and lower basal plasminogen activator 
      activity than those on placebo. Response to venous occlusion was normal in all 
      groups. The results suggest 300 mg and 1,200 mg aspirin have an equivalent 
      platelet inhibitory effect but 1,200 mg aspirin causes greater gastro-intestinal 
      blood loss.
FAU - Hampton, K K
AU  - Hampton KK
AD  - University Department of Medicine, General Infirmary, Leeds, UK.
FAU - Cerletti, C
AU  - Cerletti C
FAU - Loizou, L A
AU  - Loizou LA
FAU - Bucchi, F
AU  - Bucchi F
FAU - Donati, M B
AU  - Donati MB
FAU - Davies, J A
AU  - Davies JA
FAU - de Gaetano, G
AU  - de Gaetano G
FAU - Prentice, C R
AU  - Prentice CR
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 25422-31-5 (Fibrinopeptide A)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Bleeding Time
MH  - Blood Coagulation/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrinolysis/*drug effects
MH  - Fibrinopeptide A/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Plasminogen Activators/metabolism
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Salicylates/blood
MH  - Thromboembolism/blood/*drug therapy
MH  - Thromboxane B2/blood
MH  - Time Factors
EDAT- 1990/08/13 00:00
MHDA- 1990/08/13 00:01
CRDT- 1990/08/13 00:00
PHST- 1990/08/13 00:00 [pubmed]
PHST- 1990/08/13 00:01 [medline]
PHST- 1990/08/13 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1990 Aug 13;64(1):17-20.

PMID- 29665624
OWN - NLM
STAT- MEDLINE
DCOM- 20181019
LR  - 20181019
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 33
IP  - 10
DP  - 2018 Oct
TI  - Risk of gastrointestinal bleeding and benefit from colorectal cancer reduction 
      from long-term use of low-dose aspirin: A retrospective study of 612 509 
      patients.
PG  - 1728-1736
LID - 10.1111/jgh.14261 [doi]
AB  - BACKGROUND AND AIM: Aspirin, commonly used for prevention of cardiovascular and 
      cerebrovascular diseases, is well known to protect against development of 
      colorectal cancer (CRC) but increases risk of gastrointestinal bleeding (GIB). 
      This cohort study aims to evaluate the benefit of low-dose aspirin to prevent CRC 
      and its associated risk of GIB. METHOD: A population-based dataset was used to 
      compare incidence and mortality of CRC and GIB among patients receiving low-dose 
      aspirin with sex-matched and age-matched controls (1:2). A total of 204 170 
      aspirin users taking aspirin for at least 6 months and 408 339 nonusers were 
      analyzed. Patients' clinical outcomes were documented for up to 14 years or until 
      death. RESULTS: A total of 612 509 patients were included; 5118 (2.51%) out of 
      204 170 aspirin users were diagnosed with CRC; and 2073 (1.02%) died of the 
      malignancy. On the other hand, 13 336 (3.27%) out of 408 339 non-aspirin users 
      were diagnosed with CRC, and 6953 (1.70%) died. Using the competing risk 
      regression, aspirin usage significantly reduced CRC mortality (subdistribution 
      hazard ratio = 0.59; 95% confidence interval = 0.56 to 0.62). A total of 9483 
      (4.64%) aspirin users developed GIB, and 820 (0.40%) died, while 11 198 (2.74%) 
      nonusers developed GIB, and 1488 (0.36%) died. Aspirin usage marginally increased 
      risk of bleeding-related mortality (subdistribution hazard ratio = 1.09; 95% 
      confidence interval = 1.00 to 1.19). Subgroup analyses showed the use of 
      acid-secreting agents significantly reduced aspirin-induced mortality. 
      CONCLUSION: The long-term use of aspirin reduces both incidence and mortality of 
      CRC and at the same time increases incidence and mortality risk of GIB. With 
      combination use of acid-secreting agents, the bleeding risk can be reduced.
CI  - © 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & 
      Sons Australia, Ltd.
FAU - Tsoi, Kelvin Kf
AU  - Tsoi KK
AUID- ORCID: 0000-0001-5580-7686
AD  - Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of 
      Hong Kong, Sha Tin, Hong Kong.
AD  - Jockey Club School of Public Health and Primary Care, The Chinese University of 
      Hong Kong, Sha Tin, Hong Kong.
FAU - Chan, Felix Ch
AU  - Chan FC
AD  - Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of 
      Hong Kong, Sha Tin, Hong Kong.
FAU - Hirai, Hoyee W
AU  - Hirai HW
AD  - Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of 
      Hong Kong, Sha Tin, Hong Kong.
FAU - Sung, Joseph Jy
AU  - Sung JJ
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Sha 
      Tin, Hong Kong.
LA  - eng
PT  - Journal Article
DEP - 20180516
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Cohort Studies
MH  - Colorectal Neoplasms/epidemiology/mortality/*prevention & control
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology/mortality
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk
MH  - *Risk Assessment
MH  - Time Factors
OTO - NOTNLM
OT  - aspirin
OT  - colorectal cancer
OT  - gastrointestinal bleeding
OT  - long-term use
EDAT- 2018/04/18 06:00
MHDA- 2018/10/20 06:00
CRDT- 2018/04/18 06:00
PHST- 2018/02/02 00:00 [received]
PHST- 2018/03/15 00:00 [revised]
PHST- 2018/03/20 00:00 [accepted]
PHST- 2018/04/18 06:00 [pubmed]
PHST- 2018/10/20 06:00 [medline]
PHST- 2018/04/18 06:00 [entrez]
AID - 10.1111/jgh.14261 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2018 Oct;33(10):1728-1736. doi: 10.1111/jgh.14261. Epub 
      2018 May 16.

PMID- 20534248
OWN - NLM
STAT- MEDLINE
DCOM- 20101029
LR  - 20220318
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 42
IP  - 4
DP  - 2010 May
TI  - Reticulated platelets and platelet reactivity in renal transplant recipients 
      receiving antiplatelet therapy.
PG  - 1156-7
LID - 10.1016/j.transproceed.2010.03.042 [doi]
AB  - INTRODUCTION: Renal transplant recipients are at increased risk of cardiovascular 
      morbidity and mortality. We assessed platelet reactivity and reticulated 
      platelets (RPs) in 90 recipients, 51 (56.6%) of whom were not receiving 
      acetylsalicylic acid (ASA) therapy (group A) and 39 (43.3%) who were receiving 
      ASA therapy, 100 mg (group B), and in 60 healthy controls (group C). METHODS: 
      Reticulated platelets were measured using a hematology automated analyzer 
      (XE-2100; Sysmex Corp, Kobe, Japan) and were expressed as the percentage of RPs 
      in the total optical platelet count (immature platelet fraction [IPF]), as the 
      percentage of highly fluorescent RPs, and as the absolute number of RPs (IPF#). 
      Platelet function was assessed using optical aggregometry (platelet aggregation) 
      induced using 1 mmol/L of arachidonic acid, 2 or 10 micromol/L of adenosine 
      diphosphate, or 2 microg/mL of collagen. RESULTS: Group A demonstrated 
      significantly higher values of RP compared with group B or group C. Group B 
      demonstrated a substantially higher percentage of RPs compared with group C, 
      which was significant only for the IPF parameter. Multiple regression analysis 
      demonstrated that IPF and IPF# were significantly and positively related to 
      collagen-induced platelet aggregation. CONCLUSION: We documented the presence of 
      higher concentrations of RPs in transplant recipients compared with a control 
      population, and a significant association between RPs and platelet function.
CI  - Copyright (c) 2010 Elsevier Inc. All rights reserved.
FAU - Zanazzi, M
AU  - Zanazzi M
AD  - Renal Unit, Department of Medical and Surgical Critical Care, Thrombosis Centre, 
      University of Florence and Careggi University Hospital, Florence, Italy. 
      mariazanazzi@libero.it
FAU - Cesari, F
AU  - Cesari F
FAU - Rosso, G
AU  - Rosso G
FAU - Farsetti, S
AU  - Farsetti S
FAU - Caroti, L
AU  - Caroti L
FAU - Gori, A M
AU  - Gori AM
FAU - Cerini, G
AU  - Cerini G
FAU - Cioni, G
AU  - Cioni G
FAU - Bertoni, E
AU  - Bertoni E
FAU - Abbate, R
AU  - Abbate R
FAU - Salvadori, M
AU  - Salvadori M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Automation
MH  - Blood Platelets/*drug effects
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Kidney Transplantation/*physiology
MH  - Male
MH  - Middle Aged
MH  - Nephelometry and Turbidimetry
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Young Adult
EDAT- 2010/06/11 06:00
MHDA- 2010/10/30 06:00
CRDT- 2010/06/11 06:00
PHST- 2010/06/11 06:00 [entrez]
PHST- 2010/06/11 06:00 [pubmed]
PHST- 2010/10/30 06:00 [medline]
AID - S0041-1345(10)00330-1 [pii]
AID - 10.1016/j.transproceed.2010.03.042 [doi]
PST - ppublish
SO  - Transplant Proc. 2010 May;42(4):1156-7. doi: 10.1016/j.transproceed.2010.03.042.

PMID- 684300
OWN - NLM
STAT- MEDLINE
DCOM- 19781025
LR  - 20190911
IS  - 0300-9130 (Print)
IS  - 0300-9130 (Linking)
VI  - 173
IP  - 2
DP  - 1978 Aug 15
TI  - [Quantities of plasma polyps in the blood of male and female guinea pigs after 
      application of monoiodinoacetate, acetylosalicyclic acid, nitrogen-containing 
      excretory substances, and histamine (author's transl)].
PG  - 211-6
AB  - Released cell protrusions designated as plasma polyps (PP) were quantificated 
      from human blood of normal, male and non pregnant female, individuals by means of 
      "inverted centrifugation" [4], and from blood of male and female, non pregnant 
      and late pregnant, guinea pigs also. As control blood was taken from guinea pigs 
      during nembutal narcosis or after narcotizing them by blows on the neck. In 
      further series we examined the formation of PP after intravenous application of 
      monoiodinoacetate (MIA) and acetylosalicyclic acid (ASS) with and without 
      additional Na-pyruvate as an intermediary product of glucose metabolism. The 
      influence of histamine and nitrogen-containing excretory substances was examined 
      after intraperitoneal injections. The blood of normal individuals sporadically 
      contained PP. The control animals (male and non pregnant female guinea pigs) 
      showed about 1 X 10(6)PP per ml blood, late pregnant about 2 X 10(6). Doses of 
      12.5 mg MIA increased the number of PP from 2 X 10(6) up to 4 X 10(6), whereas 
      additional Na-pyruvat doses kept the PP level at 1 X 10(6) the one of control 
      animals. 21.4mg ASS administered to late pregnant guinea pigs increased the PP 
      number up to 4 X 10(6)/ml blood. This effect was prevented by Na-pyruvat 
      substitution. Intraperitoneal injection of excretory substances caused a moderate 
      increase of PP to 1.8 X 10(6)/ml blood in average.
FAU - Thorn, W
AU  - Thorn W
FAU - Mitterer, K E
AU  - Mitterer KE
FAU - Simanungkalit, N
AU  - Simanungkalit N
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Plasmapolypenzahlen im Blut männlicher und weiblicher Meerschweinchen nach 
      Applikation von Monojodacetat, Acetylsalicylsäure, Reststickstoffkomponenten und 
      Histamin.
PL  - Germany
TA  - Res Exp Med (Berl)
JT  - Research in experimental medicine. Zeitschrift fur die gesamte experimentelle 
      Medizin einschliesslich experimenteller Chirurgie
JID - 0324736
RN  - 0 (Iodoacetates)
RN  - 820484N8I3 (Histamine)
RN  - N762921K75 (Nitrogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Blood/*drug effects
MH  - Female
MH  - Guinea Pigs
MH  - Histamine/pharmacology
MH  - Humans
MH  - Iodoacetates/*pharmacology
MH  - Male
MH  - Nitrogen/pharmacology
MH  - Thromboembolism/chemically induced
EDAT- 1978/08/15 00:00
MHDA- 1978/08/15 00:01
CRDT- 1978/08/15 00:00
PHST- 1978/08/15 00:00 [pubmed]
PHST- 1978/08/15 00:01 [medline]
PHST- 1978/08/15 00:00 [entrez]
AID - 10.1007/BF01851872 [doi]
PST - ppublish
SO  - Res Exp Med (Berl). 1978 Aug 15;173(2):211-6. doi: 10.1007/BF01851872.

PMID- 19064811
OWN - NLM
STAT- MEDLINE
DCOM- 20090326
LR  - 20171116
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 40
IP  - 3 Suppl
DP  - 2009 Mar
TI  - Challenges of designing trials for the primary prevention of stroke.
PG  - S82-4
LID - 10.1161/STROKEAHA.108.526947 [doi]
AB  - BACKGROUND AND PURPOSE: Prevention of a first stroke is an important strategy to 
      reduce morbidity and mortality associated with cerebrovascular disease. In this 
      discussion, we review challenges to development of clinical trials for prevention 
      of a first stroke. Summary of Review- We discuss prevention of first stroke in 
      the context of clinical trial design in the ARRIVE trial and a primary prevention 
      trial in development for the elderly. CONCLUSIONS: Stroke is an important outcome 
      in cerebrovascular disease trials in the elderly, but it may be trumped by 
      coronary heart disease as a more common end point.
FAU - Gorelick, Philip B
AU  - Gorelick PB
AD  - Center for Stroke Research, Department of Neurology and Rehabilitation, 
      University of Illinois College of Medicine at Chicago, 912 S Wood Street, Room 
      855N, Chicago, IL 60612, USA. pgorelic@uic.edu
LA  - eng
PT  - Journal Article
DEP - 20081208
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/epidemiology
MH  - Humans
MH  - *National Institute of Neurological Disorders and Stroke (U.S.)
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Stroke/*prevention & control
MH  - United States
EDAT- 2008/12/10 09:00
MHDA- 2009/03/27 09:00
CRDT- 2008/12/10 09:00
PHST- 2008/12/10 09:00 [pubmed]
PHST- 2009/03/27 09:00 [medline]
PHST- 2008/12/10 09:00 [entrez]
AID - STROKEAHA.108.526947 [pii]
AID - 10.1161/STROKEAHA.108.526947 [doi]
PST - ppublish
SO  - Stroke. 2009 Mar;40(3 Suppl):S82-4. doi: 10.1161/STROKEAHA.108.526947. Epub 2008 
      Dec 8.

PMID- 10541219
OWN - NLM
STAT- MEDLINE
DCOM- 19991210
LR  - 20190921
IS  - 1062-4821 (Print)
IS  - 1062-4821 (Linking)
VI  - 8
IP  - 5
DP  - 1999 Sep
TI  - Pharmacologic prevention of vascular access stenosis.
PG  - 569-72
AB  - Vascular access dysfunction continues to result in substantial morbidity for 
      chronic hemodialysis patients. Pharmacologic and molecular biologic approaches to 
      prevention of vascular access dysfunction, if clinically successful, will be cost 
      effective and improve quality of life for chronic dialysis patients. This review 
      summarizes currently available information and future prospects in pharmacologic 
      and molecular biologic approaches to preventing vascular access stenosis.
FAU - Himmelfarb, J
AU  - Himmelfarb J
AD  - Division of Nephrology, Maine Medical Center, Portland 04102, USA. 
      himmej@mail.mmc.org
LA  - eng
GR  - DK-45610/DK/NIDDK NIH HHS/United States
GR  - DK-53413/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - England
TA  - Curr Opin Nephrol Hypertens
JT  - Current opinion in nephrology and hypertension
JID - 9303753
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arteriovenous Shunt, Surgical/adverse effects
MH  - Aspirin/pharmacology
MH  - Blood Vessels/radiation effects
MH  - Catheters, Indwelling/*adverse effects
MH  - Constriction, Pathologic/prevention & control
MH  - Dipyridamole/pharmacology
MH  - Genetic Therapy
MH  - Humans
MH  - Renal Dialysis/*adverse effects
RF  - 29
EDAT- 1999/12/14 00:00
MHDA- 1999/12/14 00:01
CRDT- 1999/12/14 00:00
PHST- 1999/12/14 00:00 [pubmed]
PHST- 1999/12/14 00:01 [medline]
PHST- 1999/12/14 00:00 [entrez]
AID - 10.1097/00041552-199909000-00006 [doi]
PST - ppublish
SO  - Curr Opin Nephrol Hypertens. 1999 Sep;8(5):569-72. doi: 
      10.1097/00041552-199909000-00006.

PMID- 6163267
OWN - NLM
STAT- MEDLINE
DCOM- 19810513
LR  - 20161123
IS  - 0044-4197 (Print)
IS  - 0044-4197 (Linking)
VI  - 102
IP  - 21
DP  - 1980
TI  - ["Low-dose heparin" and other methods to prevent thrombo-embolism in 
      gynaecological surgery (author's transl)].
PG  - 1247-53
AB  - The effectiveness of low-dose heparin has been compared with other methods of 
      thrombo-embolism prophylaxis, on the basis of 892 gynaecological operations. No 
      case of acute venous thrombosis or lethal pulmonary embolism was established in 
      the Infukoll-M-40 group. No effective prophylaxis against thrombo-embolism was 
      obtainable from acetylsalicylic acid (Micristin). More postoperative bleeding was 
      recorded from the low-dose heparin group. Two far-reaching thromboses and three 
      cases of lethal pulmonary embolism occurred in the wake of low-dose heparin 
      prophylaxis. The most favourable effect, in terms of preventing postoperative leg 
      thrombosis and pulmonary embolism, was recorded from low-molecular dextran 
      (Infukoll M 40). Anaphylactoid reactions, such as bronchospasm, flush, urticaria, 
      and hypotension, were not observed. A therapy standard for gynaecological 
      operations is recommended, with reference being made to the authors' own 
      findings.
FAU - Lehmann, R
AU  - Lehmann R
FAU - Severin, W
AU  - Severin W
LA  - ger
PT  - Journal Article
TT  - "Low-dose-Heparin" und andere Verfahren zur Thromboembolic-Prophylaxe bei 
      gynäkologischen Operationen.
PL  - Germany
TA  - Zentralbl Gynakol
JT  - Zentralblatt fur Gynakologie
JID - 21820100R
RN  - 0 (Dextrans)
RN  - 6805-41-0 (Escin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Dextrans/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Escin/therapeutic use
MH  - Female
MH  - Genital Diseases, Female/surgery
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Postoperative Complications/*prevention & control
MH  - Thromboembolism/*prevention & control
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Zentralbl Gynakol. 1980;102(21):1247-53.

PMID- 8578530
OWN - NLM
STAT- MEDLINE
DCOM- 19960314
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 74
IP  - 1
DP  - 1995 Jul
TI  - Thrombin generation in myocardial infarction and hypercholesterolemia: effects of 
      aspirin.
PG  - 77-80
AB  - Over the last few years methods have been developed to assess appearance of 
      thrombin during blood clotting in a clinical setting. This can be achieved either 
      by measurement of the specific thrombin markers or by analysis of the thrombin 
      generation kinetics. Thrombin markers rise following coronary occlusion and, 
      surprisingly, their plasma levels become further increased during and after 
      thrombolytic treatment with streptokinase or tissue-plasminogen activator. In 
      myocardial infarction enhanced thrombin generation extends over the weeks, well 
      beyond the acute phase of the disease. It indicates increased risk to a patient 
      and might call for more anticoagulation or angioplasty. The benefit of aspirin as 
      conjunctive treatment for thrombolysis has been clearly demonstrated. The 
      well-founded concept is that aspirin exerts its anti-thrombotic action through 
      inhibition of platelet cyclooxygenase. Recent evidence indicates that 
      antithrombotic effects of aspirin might be explained, partly at least, by its 
      inhibition of thrombin formation. Indeed, in both healthy subjects and survivors 
      of myocardial infarction, aspirin, either at a single dose of 500 mg or at a dose 
      of 300 mg per day administered over two weeks, effectively inhibits 
      thrombinogenesis. Such response to aspirin is blunted in hypercholesterolemia. 
      Subjects with high serum cholesterol levels might profit less than others from 
      the anti-thrombotic action of aspirin.
FAU - Szczeklik, A
AU  - Szczeklik A
AD  - Department of Medicine, University School of Medicine, Cracow, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Fibrinolytic Agents)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Death, Sudden, Cardiac/prevention & control
MH  - Depression, Chemical
MH  - Female
MH  - Fibrinolysis/physiology
MH  - Fibrinolytic Agents/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypercholesterolemia/*blood
MH  - Immunoglobulin E/blood
MH  - Kinetics
MH  - Male
MH  - Myocardial Infarction/*blood
MH  - Thrombin/analysis/*biosynthesis
RF  - 34
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1995 Jul;74(1):77-80.

PMID- 19232188
OWN - NLM
STAT- MEDLINE
DCOM- 20090501
LR  - 20190917
IS  - 1579-2242 (Electronic)
IS  - 0300-8932 (Linking)
VI  - 62
IP  - 2
DP  - 2009 Feb
TI  - Knowledge of coronary stents, thrombosis and dual antiplatelet therapy among 
      Spanish dentists.
PG  - 153-7
AB  - INTRODUCTION AND OBJECTIVES: The coexistence of heart and dental disease is 
      common and antiplatelet therapy with aspirin and clopidogrel following a 
      percutaneous intervention can interfere with dental practice. Our aim was to 
      study dentists' knowledge of percutaneous coronary interventions and their 
      approach to affected patients. METHODS: A questionnaire was used to evaluate the 
      knowledge of 100 randomly selected dentists in Spain about coronary stents, 
      antiplatelet therapy, and guidelines prepared by American medical societies, 
      including the American Dental Association, and to determine how frequently they 
      consulted a cardiologist. RESULTS: Data were collected from 100 dentists. Of 
      these, 17 had no knowledge of coronary stents, but only one did not interrupt 
      dual therapy: 12 consulted a cardiologist and the remaining four discontinued 
      therapy themselves. Of the 83 who knew about stents, only 28 (34%) understood the 
      difference between bare metal and drug-eluting stents. The drug clopidogrel's 
      name was known by 21%, while 60% recognized one of the drug's commercial names 
      and 45% recognized the other. Of the 83 aware of stents, 48 (58%) knew of the 
      possibility of stent thrombosis, but only three knew about possible mortality. 
      Cardiologists were consulted before dental procedures in 83% of cases. Only 36% 
      knew about the existence of the guidelines. CONCLUSIONS: Although Spanish 
      dentists' knowledge of coronary interventions was limited, in the majority of 
      cases a cardiologist was consulted before a patient taking dual antiplatelet 
      therapy was treated. Only a small percentage of those questioned knew of the 
      existence of American medical society guidelines.
FAU - Lozano, Iñigo
AU  - Lozano I
AD  - Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, 
      Spain. imlml9@hotmail.com
FAU - Martín, Dolores
AU  - Martín D
FAU - Torres, Francisco
AU  - Torres F
FAU - Avanzas, Pablo
AU  - Avanzas P
FAU - Rondán, Juan
AU  - Rondán J
FAU - García-Ruiz, José M
AU  - García-Ruiz JM
FAU - Hernández, Ernesto
AU  - Hernández E
FAU - Bayón, Jeremías
AU  - Bayón J
FAU - Vegas, José M
AU  - Vegas JM
FAU - Espolita, Antonio
AU  - Espolita A
LA  - eng
LA  - spa
PT  - Journal Article
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Coronary Thrombosis/*surgery
MH  - Coronary Vessels/*surgery
MH  - Cross-Sectional Studies
MH  - Dentists/*statistics & numerical data
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*adverse effects/*therapeutic use
MH  - Spain/epidemiology
MH  - *Stents
MH  - Surveys and Questionnaires
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
EDAT- 2009/02/24 09:00
MHDA- 2009/05/02 09:00
CRDT- 2009/02/24 09:00
PHST- 2009/02/24 09:00 [entrez]
PHST- 2009/02/24 09:00 [pubmed]
PHST- 2009/05/02 09:00 [medline]
AID - 13132059 [pii]
AID - 10.1016/s1885-5857(09)71533-6 [doi]
PST - ppublish
SO  - Rev Esp Cardiol. 2009 Feb;62(2):153-7. doi: 10.1016/s1885-5857(09)71533-6.

PMID- 11356997
OWN - NLM
STAT- MEDLINE
DCOM- 20010726
LR  - 20171101
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 30
IP  - 6
DP  - 2000 Nov-Dec
TI  - Effect of oral anticoagulant treatment on markers for calcium and bone 
      metabolism.
PG  - 290-7
AB  - Vitamin K-dependent proteins regulate blood coagulation as well as bone growth 
      and calcification. Here, we have compared the effects of oral anticoagulants on 
      circulating vitamin K-dependent proteins and on markers for calcium and bone 
      metabolism. Patients with a clinical indication for antithrombotic therapy were 
      randomized into three groups and treated with either aspirin, regular-intensity 
      anticoagulation [target international normalized ratio (INR) values: 2.5-3.5] or 
      low-intensity anticoagulation (target INR values: 1.1-1.6). At the start and 
      after 1 year of treatment, various biochemical markers were assessed. Both the 
      circulating levels and the degree of carboxylation of the various 
      gamma-carboxyglutamate (Gla)-containing proteins were affected differently by 
      oral anticoagulant treatment. Circulating osteocalcin was more sensitive to poor 
      vitamin K status than other Gla proteins. From the fact that - except for 
      osteocalcin - neither markers for osteoblast nor osteoclast function were 
      affected by oral anticoagulant treatment, we conclude that bone turnover remained 
      unaltered, which is indicative of an unchanged rate of bone loss. Whether the 
      long-term production of undercarboxylated bone Gla proteins may have a negative 
      effect on the quality of bone (e.g. bone strength) cannot be concluded from this 
      study.
CI  - Copyright 2001 S. Karger AG, Basel
FAU - Knapen, M H
AU  - Knapen MH
AD  - Department of Biochemistry, University of Maastricht, Maastricht, The 
      Netherlands.
FAU - Hellemons-Boode, B S
AU  - Hellemons-Boode BS
FAU - Langenberg-Ledeboer, M
AU  - Langenberg-Ledeboer M
FAU - Knottnerus, J A
AU  - Knottnerus JA
FAU - Hamulyák, K
AU  - Hamulyák K
FAU - Price, P A
AU  - Price PA
FAU - Vermeer, C
AU  - Vermeer C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Anticoagulants)
RN  - 0 (Biomarkers)
RN  - 104982-03-8 (Osteocalcin)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/pharmacology
MH  - Atrial Fibrillation/drug therapy
MH  - Biomarkers/blood
MH  - Bone and Bones/*metabolism
MH  - Calcium/*metabolism
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Osteocalcin/drug effects
MH  - Prospective Studies
MH  - Sex Factors
MH  - Vitamin K/antagonists & inhibitors/blood
EDAT- 2001/05/18 10:00
MHDA- 2001/07/28 10:01
CRDT- 2001/05/18 10:00
PHST- 2001/05/18 10:00 [pubmed]
PHST- 2001/07/28 10:01 [medline]
PHST- 2001/05/18 10:00 [entrez]
AID - 54146 [pii]
AID - 10.1159/000054146 [doi]
PST - ppublish
SO  - Haemostasis. 2000 Nov-Dec;30(6):290-7. doi: 10.1159/000054146.

PMID- 67334
OWN - NLM
STAT- MEDLINE
DCOM- 19770611
LR  - 20190610
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 1
IP  - 8016
DP  - 1977 Apr 16
TI  - Platelet activation in acute cerebral ischaemia. Serial measurements of platelet 
      function in cerebrovascular disease.
PG  - 821-4
AB  - Circulating platelet aggregates formed in vivo were serially measured, and 
      platelet-aggregation thresholds were determined in vitro in 82 patients with 
      acute cerebral ischaemia. The percentage of aggregated platelets was increased in 
      53 patients with completed stroke (30.9% +/- 2.0) and in 29 patients with 
      transient ischaemic attacks (34.1% +/- 2.3), all studied within 10 days of the 
      acute event. These values were higher (P less than 0.001) than levels of 
      aggregated platelets in 30 patients with non-vascular neurological disease (16.8% 
      +/- 2.3). The percentage of aggregated platelets returned to normal 10 days to 6 
      wk after acute cerebral ischaemia. Aspirin and dipyridamole did not affect either 
      the increase in or subsequent normalisation of circulating-platelet-aggregate 
      levels in these patients. Platelet-aggregation sensitivity to adenosine 
      diphosphate and adrenaline was also increased in patients with acute cerebral 
      ischaemia, but this abnormally resolved during convalescence. Platelet activation 
      is abnormal in acute cerebral ischaemia but usually returns to normal with or 
      without anti-platelet therapy. This activation of platelets may contribute to the 
      clinical manifestations of occlusive vascular disease.
FAU - Dougherty, J H Jr
AU  - Dougherty JH Jr
FAU - Levy, D E
AU  - Levy DE
FAU - Weksler, B B
AU  - Weksler BB
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9007-34-5 (Collagen)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Acute Disease
MH  - Adenosine Diphosphate/pharmacology
MH  - Aged
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Cell Count
MH  - Blood Platelets/pathology/*physiology
MH  - Cerebrovascular Disorders/*blood
MH  - Chronic Disease
MH  - Collagen/pharmacology
MH  - Dipyridamole/pharmacology/therapeutic use
MH  - Epinephrine/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Ischemic Attack, Transient/*blood/drug therapy
MH  - Middle Aged
MH  - *Platelet Aggregation/drug effects
EDAT- 1977/04/16 00:00
MHDA- 2001/03/28 10:01
CRDT- 1977/04/16 00:00
PHST- 1977/04/16 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1977/04/16 00:00 [entrez]
AID - S0140-6736(77)92774-X [pii]
AID - 10.1016/s0140-6736(77)92774-x [doi]
PST - ppublish
SO  - Lancet. 1977 Apr 16;1(8016):821-4. doi: 10.1016/s0140-6736(77)92774-x.

PMID- 1952780
OWN - NLM
STAT- MEDLINE
DCOM- 19911213
LR  - 20131121
IS  - 0091-7370 (Print)
IS  - 0091-7370 (Linking)
VI  - 21
IP  - 5
DP  - 1991 Sep-Oct
TI  - A study of aspirin induced changes in bleeding time, platelet aggregation, and 
      Sonoclot coagulation analysis in humans.
PG  - 315-27
AB  - The purpose of this study was to determine whether or not a newer test of 
      platelet function, Sonoclot coagulation analysis, can identify the patients who 
      develop significant prolongation of bleeding time after aspirin ingestion. 
      Template bleeding time, platelet aggregation in response to arachidonic acid, 
      collagen, epinephrine, adenosine diphosphate, and ristocetin, and Sonoclot 
      coagulation analysis were performed before and after ingestion of aspirin in 22 
      adult volunteers. Mean bleeding time increased from 5.32 +/- 2.16 min to 7.34 +/- 
      2.1 min, but remained within normal range (2.5 to 9 min). There was marked 
      intersubject variability in the effect of aspirin on bleeding time, and 
      difference between men and women was not significant. There was significant 
      decrease in platelet aggregation in response to arachidonic acid, collagen and 
      epinephrine. Sonoclot coagulation analysis did not show significant effect of 
      aspirin administration. There was no correlation among changes in bleeding time, 
      platelet aggregation, and Sonoclot coagulation analysis. Five patients with known 
      platelet function disorders and prolonged bleeding times (mean = 18.5 min, range 
      14 to 22) without any other coagulation abnormalities were also studied. In four 
      of these patients who had normal platelet count, Sonoclot graphs were 
      morphologically similar to those in the volunteers with normal bleeding times, 
      but in one patient with thrombocytopenia, morphology was altered. It is our 
      conclusion that Sonoclot coagulation analysis is unlikely to identify patients 
      with prolonged bleeding time in whom platelet count and other coagulation factors 
      are normal.
FAU - Samra, S K
AU  - Samra SK
AD  - Department of Anesthesiology, University of Texas Medical Branch, Galveston 
      77550.
FAU - Harrison, R L
AU  - Harrison RL
FAU - Bee, D E
AU  - Bee DE
FAU - Valero, V
AU  - Valero V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Clin Lab Sci
JT  - Annals of clinical and laboratory science
JID - 0410247
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Bleeding Time
MH  - Blood Coagulation/drug effects
MH  - Blood Coagulation Disorders/blood
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests/*instrumentation
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
PST - ppublish
SO  - Ann Clin Lab Sci. 1991 Sep-Oct;21(5):315-27.

PMID- 27712767
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20180124
IS  - 1557-8607 (Electronic)
IS  - 0889-8561 (Linking)
VI  - 36
IP  - 4
DP  - 2016 Nov
TI  - Mechanisms of Benefit with Aspirin Therapy in Aspirin-Exacerbated Respiratory 
      Disease.
PG  - 735-747
LID - S0889-8561(16)30056-X [pii]
LID - 10.1016/j.iac.2016.06.011 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome 
      characterized by severe persistent asthma, hyperplastic eosinophilic sinusitis 
      with nasal polyps, and an intolerance to aspirin and other NSAIDs that 
      preferentially inhibit COX-1. For more than 30 years, aspirin desensitization has 
      proven to be of significant long-term benefit in carefully selected patients with 
      AERD. Despite this, the exact mechanisms behind the therapeutic effects of 
      aspirin desensitization remain poorly understood. In this article, we review the 
      current understanding of the mechanisms of aspirin desensitization and discuss 
      future areas of investigation.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Hill, Jennifer
AU  - Hill J
AD  - Adult Program, Division of Allergy and Immunology, National Jewish Health, 
      University of Colorado, 1400 Jackson Street, K624, Denver, CO 80206, USA.
FAU - Burnett, Trever
AU  - Burnett T
AD  - Northwest Asthma and Allergy Center, 9725 3rd Avenue Northeast, Suite 500, 
      Northgate Executive Center II, Seattle, WA 98115, USA.
FAU - Katial, Rohit
AU  - Katial R
AD  - Division of Allergy and Immunology, National Jewish Health, University of 
      Colorado, 1400 Jackson Street, K624, Denver, CO 80206, USA. Electronic address: 
      KatialR@NJHealth.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cytokines)
RN  - 0 (Leukotrienes)
RN  - 0 (Receptors, Leukotriene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Cytokines/metabolism
MH  - *Desensitization, Immunologic/methods
MH  - Humans
MH  - Leukotrienes/genetics/metabolism
MH  - Receptors, Leukotriene/genetics/metabolism
MH  - Respiratory Tract Diseases/*etiology/metabolism/*therapy
OTO - NOTNLM
OT  - Aspirin desensitization
OT  - Aspirin-exacerbated respiratory disease (AERD)
OT  - Cysteinyl leukotrienes (CysLTs)
OT  - Cytokines
OT  - Interleukin 4 (IL-4)
OT  - Mechanisms of action
OT  - Prostaglandin D2
OT  - Signal transducer and activator of transcription 6 (STAT6)
EDAT- 2016/10/08 06:00
MHDA- 2017/12/23 06:00
CRDT- 2016/10/08 06:00
PHST- 2016/10/08 06:00 [entrez]
PHST- 2016/10/08 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - S0889-8561(16)30056-X [pii]
AID - 10.1016/j.iac.2016.06.011 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2016 Nov;36(4):735-747. doi: 
      10.1016/j.iac.2016.06.011.

PMID- 28412461
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20220330
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 120
DP  - 2017 Jun
TI  - Effects of low-dose aspirin on maternal blood pressure and vascular function in 
      an experimental model of gestational hypertension.
PG  - 267-278
LID - S1043-6618(16)31108-2 [pii]
LID - 10.1016/j.phrs.2017.04.012 [doi]
AB  - Daily intake of low-dose aspirin after 12weeks of gestation is currently 
      recommended as a preventative intervention in pregnancies in high risk of 
      developing preeclampsia. This recommendation is based on epidemiological 
      evidence, whereas experimental studies investigating the exact mechanisms of 
      aspirin action during pregnancy are lacking. We previously showed that treating 
      pregnant rats with a synthetic mimetic of unmethylated CpG DNA (bacterial DNA) 
      caused preeclampsia-like characteristics such as maternal hypertension and 
      increased cyclooxygenase (COX) expression and activity. In this study, we tested 
      the hypothesis that daily maternal treatment with low-dose aspirin would prevent 
      the development of maternal hypertension, reduce COX activity and thromboxane 
      A(2) (TxA(2)) production, and improve maternal vascular function in pregnant rats 
      exposed to CpG ODN during gestation. Pregnant rats were treated with ODN2395 
      (synthetic CpG DNA) or saline (vehicle) on gestational days (GD) 14, 16, 18. 
      Daily low-dose aspirin treatment (1.5mg/kgBW) started on GD10 and continued 
      throughout gestation. Pregnant rats treated with ODN2395 had greater systolic 
      blood pressure compared to controls (120±4mmHg vs. 100±5mmHg, p=0.03) and aspirin 
      did not prevent this increase (p=0.86). Aspirin prevented ODN2395-induced 
      increases of TxB(2) (TxA(2) metabolite) in serum and mesenteric arteries. ODN2395 
      increased expression of COX-1 and COX-2 in mesenteric and uterine arteries and 
      aspirin abolished these effects. Aspirin reduced contractile responses to 
      phenylephrine and U46619 (TxA(2) mimetic) in mesenteric arteries from control 
      rats but not from ODN2395-treated rats. In conclusion, treatment with low-dose 
      aspirin reduced systemic and vascular COX expression and activity but did not 
      prevent the development of maternal hypertension induced by exposure to 
      unmethylated CpG DNA (bacterial DNA).
CI  - Copyright © 2017 Elsevier Ltd. All rights reserved.
FAU - Osikoya, Oluwatobiloba
AU  - Osikoya O
AD  - Institute for Cardiovascular and Metabolic Disease, University of North Texas 
      Health Science Center, Fort Worth, TX, USA.
FAU - Jaini, Paresh A
AU  - Jaini PA
AD  - Institute for Cardiovascular and Metabolic Disease, University of North Texas 
      Health Science Center, Fort Worth, TX, USA.
FAU - Nguyen, An
AU  - Nguyen A
AD  - Institute for Cardiovascular and Metabolic Disease, University of North Texas 
      Health Science Center, Fort Worth, TX, USA.
FAU - Valdes, Melissa
AU  - Valdes M
AD  - Institute for Cardiovascular and Metabolic Disease, University of North Texas 
      Health Science Center, Fort Worth, TX, USA.
FAU - Goulopoulou, Styliani
AU  - Goulopoulou S
AD  - Institute for Cardiovascular and Metabolic Disease, University of North Texas 
      Health Science Center, Fort Worth, TX, USA. Electronic address: 
      styliani.goulopoulou@unthsc.edu.
LA  - eng
PT  - Journal Article
DEP - 20170412
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Disease Models, Animal
MH  - Female
MH  - Hypertension, Pregnancy-Induced/metabolism/physiopathology/*prevention & control
MH  - Mesenteric Arteries/drug effects/metabolism/physiopathology
MH  - Pregnancy
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thromboxane A2/metabolism
OTO - NOTNLM
OT  - Cyclooxygenase
OT  - Preeclampsia
OT  - Pregnancy
OT  - Thromboxane
OT  - Toll-like receptors
OT  - Vascular function
EDAT- 2017/04/17 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/04/17 06:00
PHST- 2016/10/23 00:00 [received]
PHST- 2017/03/01 00:00 [revised]
PHST- 2017/04/10 00:00 [accepted]
PHST- 2017/04/17 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
PHST- 2017/04/17 06:00 [entrez]
AID - S1043-6618(16)31108-2 [pii]
AID - 10.1016/j.phrs.2017.04.012 [doi]
PST - ppublish
SO  - Pharmacol Res. 2017 Jun;120:267-278. doi: 10.1016/j.phrs.2017.04.012. Epub 2017 
      Apr 12.

PMID- 18499233
OWN - NLM
STAT- MEDLINE
DCOM- 20090416
LR  - 20220317
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 123
IP  - 4
DP  - 2009 Feb
TI  - Relationship between aspirin and clopidogrel responses in acute coronary syndrome 
      and clinical predictors of non response.
PG  - 597-603
LID - 10.1016/j.thromres.2008.04.003 [doi]
AB  - OBJECTIVES: We have prospectively investigated the association between aspirin 
      and clopidogrel responses and the clinical predictors of non response. METHODS: 
      635 Non ST Elevation Acute Coronary Syndrome (NSTE ACS) patients were included 
      and received loading doses of 250 mg aspirin and 600 mg clopidogrel. We analyzed 
      post-treatment maximal intensity of arachidonic acid and ADP-induced platelet 
      aggregation (AA-Ag and ADP-Ag) and Platelet Reactivity Index of 
      VAsodilator-Stimulated Phosphoprotein (PRI VASP). Aspirin and clopidogrel non 
      responses were defined respectively by AA-Ag>30% and ADP-Ag>70%. RESULTS: Aspirin 
      non responders patients had significantly higher ADP-Ag and PRI VASP than aspirin 
      responders: 63.7+/-15.9% vs 55+/-19% (p=0.0001) and 73.6+/-13.3% vs 53+/-23% 
      (p=0.0001) respectively and the rate of clopidogrel non responders was higher 
      among aspirin non responders than aspirin responders: 36.7% vs 22.7% (p=0.003). 
      In addition, clopidogrel non responders had significantly higher AA-Ag and rate 
      of aspirin non responders than clopidogrel responders: 21.6+/-24% vs 10.3+/-19% 
      (p=0.0001) and 22.8% vs 12.9% (p=0.003) respectively. Age and Body Mass Index 
      (BMI) were significantly associated with non response to Clopidogrel (p=0.035 and 
      0.02 respectively) and diabetes mellitus by trend (p=0.07). CONCLUSION: We 
      observed a relationship between aspirin and clopidogrel non responses and an 
      association between age, BMI and diabetes mellitus and clopidogrel response.
FAU - Cuisset, Thomas
AU  - Cuisset T
AD  - Department of Cardiology, CHU Timone, Marseille, 13385 France. 
      thomascuisset@voila.fr
FAU - Frere, Corinne
AU  - Frere C
FAU - Quilici, Jacques
AU  - Quilici J
FAU - Morange, Pierre-Emmanuel
AU  - Morange PE
FAU - Camoin, Laurence
AU  - Camoin L
FAU - Bali, Laurent
AU  - Bali L
FAU - Lambert, Marc
AU  - Lambert M
FAU - Juhan-Vague, Irène
AU  - Juhan-Vague I
FAU - Alessi, Marie-Christine
AU  - Alessi MC
FAU - Bonnet, Jean-Louis
AU  - Bonnet JL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080521
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Microfilament Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (vasodilator-stimulated phosphoprotein)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/blood/*drug therapy
MH  - Age Factors
MH  - Aged
MH  - Arachidonic Acid/metabolism
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Body Mass Index
MH  - Cell Adhesion Molecules/metabolism
MH  - Clopidogrel
MH  - Diabetes Complications/blood/drug therapy
MH  - Drug Resistance
MH  - Humans
MH  - Male
MH  - Microfilament Proteins/metabolism
MH  - Middle Aged
MH  - Phosphoproteins/metabolism
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2008/05/24 09:00
MHDA- 2009/04/17 09:00
CRDT- 2008/05/24 09:00
PHST- 2008/01/07 00:00 [received]
PHST- 2008/02/20 00:00 [revised]
PHST- 2008/04/07 00:00 [accepted]
PHST- 2008/05/24 09:00 [pubmed]
PHST- 2009/04/17 09:00 [medline]
PHST- 2008/05/24 09:00 [entrez]
AID - S0049-3848(08)00131-X [pii]
AID - 10.1016/j.thromres.2008.04.003 [doi]
PST - ppublish
SO  - Thromb Res. 2009 Feb;123(4):597-603. doi: 10.1016/j.thromres.2008.04.003. Epub 
      2008 May 21.

PMID- 15569408
OWN - NLM
STAT- MEDLINE
DCOM- 20050624
LR  - 20161124
IS  - 1671-4083 (Print)
IS  - 1671-4083 (Linking)
VI  - 25
IP  - 12
DP  - 2004 Dec
TI  - Aspirin protected against endothelial damage induced by LDL: role of endogenous 
      NO synthase inhibitors in rats.
PG  - 1633-9
AB  - AIM: To study the protective effect of aspirin on damages of the endothelium 
      induced by low-density lipoprotein (LDL), and whether the protective effect of 
      aspirin is related to reduction of nitric oxide synthase inhibitor level. 
      METHODS: Vascular endothelial injury was induced by a single injection of native 
      LDL (4 mg/kg) in rats. Vasodilator responses to acetylcholine (ACh) in the 
      isolated aortic rings were determined, and serum concentrations of asymmetric 
      dimethylarginine (ADMA), malondialdehyde (MDA), tumour necrosis factor-alpha 
      (TNF-alpha), and the activity of dimethylaminohydrolase (DDAH) were measured. 
      RESULTS: A single injection of LDL (4 mg/kg) significantly decreased vasodilator 
      responses to ACh, increased the serum level of ADMA, MDA, and TNF-alpha, and 
      decreased DDAH activity. Aspirin (30 or 100 mg/kg) markedly reduced the 
      inhibition of vasodilator responses to ACh by LDL, and the protective effect of 
      aspirin at the lower dose was greater compared with high-dose aspirin group. 
      Aspirin inhibited the increased level of MDA and TNF-alpha induced by LDL. 
      Aspirin at the dose of 30 mg/kg, but not at higher dose (100 mg/kg), 
      significantly reduced the concentration of ADMA and increased the activity of 
      DDAH. CONCLUSION: Aspirin at the lower dose (30 mg/kg) protects the endothelium 
      against damages elicited by LDL in vivo, and the protective effect of aspirin on 
      endothelium is related to reduction of ADMA concentration by increasing DDAH 
      activity.
FAU - Deng, Sheng
AU  - Deng S
AD  - Department of Pharmacology, School of Pharmaceutical Science, Central South 
      University, Changsha 410078, China.
FAU - Deng, Pan-yue
AU  - Deng PY
FAU - Jiang, Jun-lin
AU  - Jiang JL
FAU - Ye, Feng
AU  - Ye F
FAU - Yu, Jing
AU  - Yu J
FAU - Yang, Tian-lun
AU  - Yang TL
FAU - Deng, Han-du
AU  - Deng HD
FAU - Li, Yuan-jian
AU  - Li YJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Acta Pharmacol Sin
JT  - Acta pharmacologica Sinica
JID - 100956087
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 63CV1GEK3Y (N,N-dimethylarginine)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 3.5.- (Amidohydrolases)
RN  - EC 3.5.3.18 (dimethylargininase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amidohydrolases/metabolism
MH  - Animals
MH  - Aorta, Thoracic/drug effects
MH  - Arginine/*analogs & derivatives/*blood
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Endothelium, Vascular/drug effects/metabolism
MH  - Intercellular Adhesion Molecule-1/metabolism
MH  - Lipoproteins, LDL/*antagonists & inhibitors
MH  - Male
MH  - Malondialdehyde/blood
MH  - Muscle Contraction/*drug effects
MH  - Muscle, Smooth, Vascular/drug effects
MH  - Nitric Oxide Synthase/*antagonists & inhibitors
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2004/12/01 09:00
MHDA- 2005/06/25 09:00
CRDT- 2004/12/01 09:00
PHST- 2004/12/01 09:00 [pubmed]
PHST- 2005/06/25 09:00 [medline]
PHST- 2004/12/01 09:00 [entrez]
PST - ppublish
SO  - Acta Pharmacol Sin. 2004 Dec;25(12):1633-9.

PMID- 7954024
OWN - NLM
STAT- MEDLINE
DCOM- 19941222
LR  - 20171116
IS  - 0828-282X (Print)
IS  - 0828-282X (Linking)
VI  - 10
IP  - 9
DP  - 1994 Nov
TI  - Patterns of practice analysis for acute myocardial infarction.
PG  - 891-6
AB  - OBJECTIVE: To assess the level of use of acetylsalicylic acid (ASA), 
      beta-blockers and thrombolytic therapy--proven efficacious therapies in the 
      management of acute myocardial infarction (AMI)--in contemporary patients 
      admitted with AMI, and to assess the role of contraindications and other 
      patient-specific factors in the use or nonuse of these treatments. DESIGN: The 
      demographics and treatment course of patients admitted with a diagnosis of AMI 
      were reviewed. Specifically targeted therapies were ASA, beta-blockers and 
      thrombolytic therapy. Rates of use were calculated as 'gross utilization' 
      (overall use) and 'adjusted utilization' (accounting for late presentation to 
      hospital, initially equivocal diagnosis or contraindications). SETTING: Tertiary 
      care hospital in suburban Vancouver, British Columbia. PATIENTS: A total of 372 
      consecutive patients admitted to Royal Columbian Hospital between September 1, 
      1990 and September 1, 1991. INTERVENTIONS: None. MAIN RESULTS: Gross utilization 
      of ASA, beta-blockers and thrombolytic therapy was 71, 31 and 21%, respectively. 
      The adjusted utilization rates for early (6 h or less) treatment with ASA was 
      66%; with early beta-blockers, it was 18% and was 100% for thrombolytic therapy. 
      Adjusted late (more than 6 h, to hospital discharge) use of ASA and beta-blockers 
      was 84 and 57%, respectively. CONCLUSIONS: With the exception of thrombolytic 
      therapy, proven efficacious medical therapies for AMI appear underused at the 
      study hospital. Ongoing educational efforts and continuing patterns of practice 
      analyses are needed.
FAU - Tsuyuki, R T
AU  - Tsuyuki RT
AD  - Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver.
FAU - Gill, S
AU  - Gill S
FAU - Hilton, J D
AU  - Hilton JD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - 0 (Adrenergic beta-Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Contraindications
MH  - Drug Utilization
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*drug therapy
MH  - Patient Selection
MH  - *Practice Patterns, Physicians'
MH  - Retrospective Studies
MH  - *Thrombolytic Therapy
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
PST - ppublish
SO  - Can J Cardiol. 1994 Nov;10(9):891-6.

PMID- 8466957
OWN - NLM
STAT- MEDLINE
DCOM- 19930513
LR  - 20190815
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 11
IP  - 1
DP  - 1993 Jan
TI  - Micellar acid-base potentiometric titrations of weak acidic and/or insoluble 
      drugs.
PG  - 33-41
AB  - The effect of various surfactants [the cationics cetyl trimethyl ammonium bromide 
      (CTAB) and cetyl pyridinium chloride (CPC), the anionic sodium dodecyl sulphate 
      (SDS), and the nonionic polysorbate 80 (Tween 80)] on the solubility and 
      ionization constant of some sparingly soluble weak acids of pharmaceutical 
      interest was studied. Benzoic acid (and its 3-methyl-, 3-nitro-, and 
      4-tert-butyl-derivatives), acetylsalicylic acid, naproxen and iopanoic acid were 
      chosen as model examples. Precise and accurate acid-base titrations in micellar 
      systems were made feasible using a microcomputer-controlled titrator. The 
      response curve, response time and potential drift of the glass electrode in the 
      micellar systems were examined. The cationics CTAB and CPC were found to increase 
      considerably the ionization constant of the weak acids (delta pKa ranged from 
      -0.21 to -3.57), while the anionic SDS showed negligible effect and the nonionic 
      Tween 80 generally decreased the ionization constants. The solubility of the 
      acids in aqueous micellar and acidified micellar solutions was studied 
      spectrophotometrically and it was found increased in all cases. Acetylsalicylic 
      acid, naproxen, benzoic acid and iopanoic acid could be easily determined in raw 
      material and some of them in pharmaceutical preparations by direct titration in 
      CTAB-micellar system instead of using the traditional non-aqueous or back 
      titrimetry. Precisions of 0.3-4.3% RSD and good correlation with the official 
      tedious methods were obtained. The interference study of some excipients showed 
      that a preliminary test should be carried out before the assay of formulations.
FAU - Gerakis, A M
AU  - Gerakis AM
AD  - Department of Chemistry, University of Athens, Greece.
FAU - Koupparis, M A
AU  - Koupparis MA
FAU - Efstathiou, C E
AU  - Efstathiou CE
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Acids)
RN  - 0 (Benzoates)
RN  - 0 (Micelles)
RN  - 0 (Surface-Active Agents)
RN  - 57Y76R9ATQ (Naproxen)
RN  - 8SKN0B0MIM (Benzoic Acid)
RN  - FE9794P71J (Iopanoic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acids/chemistry
MH  - Aspirin/chemistry
MH  - Benzoates/chemistry
MH  - Benzoic Acid
MH  - Electrodes
MH  - Hydrogen-Ion Concentration
MH  - Iopanoic Acid/chemistry
MH  - Micelles
MH  - Naproxen/chemistry
MH  - *Potentiometry
MH  - Software
MH  - Solubility
MH  - Surface-Active Agents/*chemistry
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 0731-7085(93)80146-R [pii]
AID - 10.1016/0731-7085(93)80146-r [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 1993 Jan;11(1):33-41. doi: 10.1016/0731-7085(93)80146-r.

PMID- 3157361
OWN - NLM
STAT- MEDLINE
DCOM- 19850429
LR  - 20190704
IS  - 0004-0010 (Print)
IS  - 0004-0010 (Linking)
VI  - 120
IP  - 4
DP  - 1985 Apr
TI  - Percutaneous transluminal angioplasty of stenotic deep vein arterial bypass 
      grafts.
PG  - 492-5
AB  - Successful percutaneous transluminal angioplasty was performed in six patients 
      with lower-extremity vein-graft stenosis. In all patients we used autogenous, 
      superficial femoral veins as the vein-graft material because the greater 
      saphenous veins were too small or had been harvested for previous surgery. 
      Angioplasty was performed on three men and three women (average age, 73 years). 
      Stenosis of the vein graft was suspected in the presence of recurrent symptoms 
      and physical signs of vascular insufficiency; additionally, Doppler pulse volume 
      recordings of the ankle aided in the identification of patients with falling 
      grafts. Angiography confirmed the presence of superficial femoral vein stenosis 
      in all patients prior to balloon catheter dilation. On an average, angioplasty 
      was performed approximately seven months following surgery; successful dilation 
      was demonstrated by an increased luminal diameter seen arteriographically. Two of 
      the six patients underwent a second angioplasty six months after the first 
      procedure. Graft patency has been maintained in all six patients, as measured by 
      clinical follow-up and Doppler pulse volume recordings. Arteriography was 
      performed in the presence of recurrent symptoms or physical signs of diminished 
      flow to the extremity. The oldest surviving grafts in this group of patients are 
      24 and 26 months, respectively.
FAU - Greenspan, B
AU  - Greenspan B
FAU - Pillari, G
AU  - Pillari G
FAU - Schulman, M L
AU  - Schulman ML
FAU - Badhey, M
AU  - Badhey M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Arch Surg
JT  - Archives of surgery (Chicago, Ill. : 1960)
JID - 9716528
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Angioplasty, Balloon
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Femoral Vein/surgery
MH  - Graft Occlusion, Vascular/drug therapy/etiology/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Popliteal Vein/surgery
MH  - Postoperative Complications
EDAT- 1985/04/01 00:00
MHDA- 1985/04/01 00:01
CRDT- 1985/04/01 00:00
PHST- 1985/04/01 00:00 [pubmed]
PHST- 1985/04/01 00:01 [medline]
PHST- 1985/04/01 00:00 [entrez]
AID - 10.1001/archsurg.1985.01390280078017 [doi]
PST - ppublish
SO  - Arch Surg. 1985 Apr;120(4):492-5. doi: 10.1001/archsurg.1985.01390280078017.

PMID- 12512245
OWN - NLM
STAT- MEDLINE
DCOM- 20030912
LR  - 20151119
IS  - 1053-8569 (Print)
IS  - 1053-8569 (Linking)
VI  - 11
IP  - 8
DP  - 2002 Dec
TI  - Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and 
      aspirin in US women.
PG  - 687-93
AB  - PURPOSE: To determine the frequency of use of the three main classes of 
      over-the-counter analgesics: acetaminophen, non-steroidal anti-inflammatory 
      drugs, and aspirin in two large US female cohorts. METHODS: We conducted a 
      cross-sectional study of the frequency of analgesic use and the characteristics 
      of users in female participants in the Nurses Health Study I (n = 86,985) and the 
      Nurses Health Study II (n = 93,002) who were between the ages of 33 and 77 years. 
      Information on frequency of current analgesic use was assessed by mailed 
      questionnaire. RESULTS: All three classes of analgesics were used frequently. For 
      example, acetaminophen was used > or = 1 day/week by more than 20% of women. 
      NSAIDs were used > or = 1 day/week by 42% of women aged 51 years or younger, and 
      aspirin was used > or = 6 days/week by 25% women over age 51 years. The frequency 
      of use of the individual analgesics varied by age (p < 0.001). In addition, women 
      in the highest category of use of any of the analgesics tended to have a higher 
      body mass index, were more likely to have hypertension and diabetes, and were 
      more likely to be current smokers. CONCLUSIONS: Analgesic use is very common 
      among US women. Physicians should be cognizant of the frequency of use of the 
      various over-the-counter analgesics in their female patient population.
FAU - Curhan, Gary C
AU  - Curhan GC
AD  - Channing Laboratory, Department of Medicine, Brigham and Womens' Hospital, 
      Harvard Medical School, Harvard School of Public Health, Department of 
      Epidemiology, Boston, MA, USA. Gary.Curhan@channing.harvard.edu
FAU - Bullock, Andrea J
AU  - Bullock AJ
FAU - Hankinson, Susan E
AU  - Hankinson SE
FAU - Willett, Walter C
AU  - Willett WC
FAU - Speizer, Frank E
AU  - Speizer FE
FAU - Stampfer, Meir J
AU  - Stampfer MJ
LA  - eng
GR  - CA50385/CA/NCI NIH HHS/United States
GR  - CA87969/CA/NCI NIH HHS/United States
GR  - DK52866/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Analgesics, Non-Narcotic/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Drug Utilization/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Surveys and Questionnaires
MH  - United States
EDAT- 2003/01/07 04:00
MHDA- 2003/09/13 05:00
CRDT- 2003/01/07 04:00
PHST- 2003/01/07 04:00 [pubmed]
PHST- 2003/09/13 05:00 [medline]
PHST- 2003/01/07 04:00 [entrez]
AID - 10.1002/pds.732 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2002 Dec;11(8):687-93. doi: 10.1002/pds.732.

PMID- 20175876
OWN - NLM
STAT- MEDLINE
DCOM- 20100616
LR  - 20161125
IS  - 1471-0528 (Electronic)
IS  - 1470-0328 (Linking)
VI  - 117
IP  - 6
DP  - 2010 May
TI  - Clinical and geographical variation in prophylactic and therapeutic treatments 
      for pre-eclampsia in the UK.
PG  - 695-700
LID - 10.1111/j.1471-0528.2010.02507.x [doi]
AB  - OBJECTIVE: To evaluate the clinical and geographical variation in the use of 
      aspirin in women at high risk of pre-eclampsia, and in the use of 
      antihypertensive drugs and magnesium sulphate in women with established 
      pre-eclampsia. DESIGN: Analysis of vitamins in pre-eclampsia (VIP) trial 
      database. SAMPLE: A total of 2399 women at increased risk of pre-eclampsia in 25 
      UK hospitals. METHODS: An analysis of a large prospectively validated database of 
      high-risk women in the UK was undertaken to assess aspirin use across different 
      risk groups and to evaluate the use of antihypertensives and magnesium sulphate 
      in 370 women who developed pre-eclampsia. Logistic regression was employed to 
      compare drug use between region and by recognised clinical indicators. MAIN 
      OUTCOME MEASURES: Usage of aspirin, antihypertensive drugs and magnesium 
      sulphate. RESULTS: Of the women with known risk factors at trial entry, 24% 
      (569/2399) received low-dose aspirin. Aspirin usage varied widely between risk 
      groups [from 5% (19/378) in women with multiple pregnancy to 94% (50/53) in women 
      with antiphospholipid syndrome] and between geographical regions [from 8% 
      (20/248) to 49% (95/193)]. Three hundred and seventy women developed 
      pre-eclampsia, 52% (n = 193) of whom received new or additional antihypertensives 
      after 20 weeks of gestation; 34% (77/224) with a maximum recorded systolic blood 
      pressure of >OR=160 mmHg in the second half of pregnancy did not receive 
      antihypertensive treatment; 17% (62/370) of women with pre-eclampsia received 
      magnesium sulphate prophylactically. CONCLUSIONS: Prophylactic and treatment 
      regimes for pre-eclampsia in the UK vary by region and risk group.
FAU - Chappell, L C
AU  - Chappell LC
AD  - Maternal and Fetal Research Unit, Division of Reproduction and Endocrinology, 
      King's College London School of Biomedical and Health Sciences, London, UK. 
      lucy.chappell@kcl.ac.uk
FAU - Seed, P
AU  - Seed P
FAU - Enye, S
AU  - Enye S
FAU - Briley, A L
AU  - Briley AL
FAU - Poston, L
AU  - Poston L
FAU - Shennan, A H
AU  - Shennan AH
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20100222
PL  - England
TA  - BJOG
JT  - BJOG : an international journal of obstetrics and gynaecology
JID - 100935741
RN  - 0 (Anticonvulsants)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 7487-88-9 (Magnesium Sulfate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anticonvulsants/*therapeutic use
MH  - Antihypertensive Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Magnesium Sulfate/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/*drug therapy/prevention & control
MH  - Pregnancy
MH  - Residence Characteristics
MH  - Risk Factors
MH  - United Kingdom
EDAT- 2010/02/24 06:00
MHDA- 2010/06/17 06:00
CRDT- 2010/02/24 06:00
PHST- 2010/02/24 06:00 [entrez]
PHST- 2010/02/24 06:00 [pubmed]
PHST- 2010/06/17 06:00 [medline]
AID - BJO2507 [pii]
AID - 10.1111/j.1471-0528.2010.02507.x [doi]
PST - ppublish
SO  - BJOG. 2010 May;117(6):695-700. doi: 10.1111/j.1471-0528.2010.02507.x. Epub 2010 
      Feb 22.

PMID- 7900100
OWN - NLM
STAT- MEDLINE
DCOM- 19950425
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 76
IP  - 6
DP  - 1994 Dec 15
TI  - The skin bleeding time test as a predictor of brain bleeding time in a rat model.
PG  - 535-40
AB  - Previous studies have indicated that the skin bleeding time test does not 
      accurately reflect visceral bleeding time (BT). The present study examines the 
      predictive value of the skin bleeding time for brain bleeding tendency. Sixteen 
      Sprague-Dawley rats were divided into equal groups. The first group (controls) 
      underwent standardized skin and brain bleeding time tests under general 
      anesthesia. Mean skin BT was found to be 168.8 sec with a standard deviation of 
      +/- 20.8 sec. Mean brain BT was found to be 172.5 sec with a standard deviation 
      of +/- 19.6 sec. The second group was given 23.2 mg/kg of aspirin per day for 
      five days prior to skin and brain BT testing. Mean skin BT in this group was 315 
      seconds with a standard deviation of +/- 72.2 sec which proved to be 
      significantly different from the control skin BT (P = 0.0005). Brain BT in the 
      aspirin treated group was 155.6 sec with a standard deviation of +/- 22.6 sec. 
      Brain BT in both control and aspirin treated groups was not significantly 
      different (P = 0.13). All animals were euthanized 30 minutes after brain BT and 
      their brains harvested. One animal in the control group showed evidence of a 
      small subcortical hemorrhage upon brain sectioning. Sectioned brains in the 
      aspirin-treated group showed no evidence of subcortical hematoma. The results 
      indicate that skin BT is prolonged by aspirin administration, but brain bleeding 
      time is unaffected. Brain hemostasis is likely more dependent on intrinsic 
      procoagulant than platelet function. The skin BT test may therefore be of little 
      utility as a preoperative screening test for neurosurgical patients.
FAU - MacDonald, J D
AU  - MacDonald JD
AD  - Department of Neurological Surgery, University of Utah School of Medicine, Salt 
      Lake City.
FAU - Remington, B J
AU  - Remington BJ
FAU - Rodgers, G M
AU  - Rodgers GM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Bleeding Time/*veterinary
MH  - Blood Platelet Disorders/physiopathology
MH  - Brain/*blood supply/drug effects/physiology
MH  - *Disease Models, Animal
MH  - Predictive Value of Tests
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Skin/*blood supply/drug effects
MH  - Skin Physiological Phenomena
EDAT- 1994/12/15 00:00
MHDA- 1994/12/15 00:01
CRDT- 1994/12/15 00:00
PHST- 1994/12/15 00:00 [pubmed]
PHST- 1994/12/15 00:01 [medline]
PHST- 1994/12/15 00:00 [entrez]
AID - 0049-3848(94)90282-8 [pii]
AID - 10.1016/0049-3848(94)90282-8 [doi]
PST - ppublish
SO  - Thromb Res. 1994 Dec 15;76(6):535-40. doi: 10.1016/0049-3848(94)90282-8.

PMID- 11642676
OWN - NLM
STAT- MEDLINE
DCOM- 20020311
LR  - 20190921
IS  - 1046-7408 (Print)
IS  - 1046-7408 (Linking)
VI  - 46
IP  - 4
DP  - 2001 Oct
TI  - Risk factors associated with fetal losses in treated antiphospholipid syndrome 
      pregnancies: a multivariate analysis.
PG  - 274-9
AB  - PROBLEM: Pregnancies in women with antiphospholipid syndrome (APS) are associated 
      with obstetric complications despite treatment. The present study analyzes risk 
      factors and evaluates fetal outcome in a large sample of treated APS pregnancies. 
      METHOD OF STUDY: Seventy-seven pregnancies in 56 women were included. Twelve 
      selected variables potentially related to the outcome of treated pregnancies were 
      analyzed in a multivariate logistic regression model. RESULTS: Treated women 
      delivered 65 live infants at 24-41 weeks gestation (mean 36.7+/-0.5) but two 
      neonatal deaths occurred. There were seven first-trimester miscarriages (9%) and 
      five intrauterine fetal demises (6.5%). Thus, the probability of having a live 
      baby under treatment was 82% (95% CI 71.3-89.6%), a figure significantly greater 
      (P <0.001) than that observed before therapy (25.7%; 95% CI 18.7-33.7%). 
      Variables related with fetal outcome in the multivariate model were: 
      preconceptional use of aspirin and abnormal umbilical artery Doppler velocimetry 
      at 23-26 weeks gestation. CONCLUSIONS: The present report shows that in treated 
      APS pregnancies: i) aspirin treatment started preconceptionally is an independent 
      and significant prognostic factor associated with favorable fetal outcome; and 
      ii) abnormal velocity waveforms in the umbilical artery predict adverse outcome 
      of pregnancy.
FAU - Carmona, F
AU  - Carmona F
AD  - Institut Clínic of Gynecology, Obstetrics and Neonatology, University of 
      Barcelona, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i 
      Sunyer, Spain.
FAU - Font, J
AU  - Font J
FAU - Azulay, M
AU  - Azulay M
FAU - Creus, M
AU  - Creus M
FAU - Fábregues, F
AU  - Fábregues F
FAU - Cervera, R
AU  - Cervera R
FAU - Puerto, B
AU  - Puerto B
FAU - Balasch, J
AU  - Balasch J
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Spontaneous/*complications
MH  - Adolescent
MH  - Adult
MH  - Antiphospholipid Syndrome/*complications/drug therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Multivariate Analysis
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - Pregnancy Outcome
MH  - Risk Factors
EDAT- 2001/10/20 10:00
MHDA- 2002/03/12 10:01
CRDT- 2001/10/20 10:00
PHST- 2001/10/20 10:00 [pubmed]
PHST- 2002/03/12 10:01 [medline]
PHST- 2001/10/20 10:00 [entrez]
AID - 10.1034/j.1600-0897.2001.d01-13.x [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 2001 Oct;46(4):274-9. doi: 
      10.1034/j.1600-0897.2001.d01-13.x.

PMID- 28947723
OWN - NLM
STAT- MEDLINE
DCOM- 20180702
LR  - 20181023
IS  - 1308-4488 (Electronic)
IS  - 1016-5169 (Linking)
VI  - 45
IP  - Suppl 4
DP  - 2017 Sep
TI  - [EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with 
      aspirin in the extended treatment of patients with venous thromboembolism].
PG  - 1-7
LID - 10.5543/tkda.2017.02646 [doi]
AB  - Although many patients with venous thromboembolism (VTE) may need extended 
      treatment, efficacy and safety issues of full- or lower-intensity anticoagulation 
      over acetyl salicylic acid (ASA) treatment have remained to be determined. 
      EINSTEIN CHOICE is a randomized, double-blind and phase 3 study, and compared 
      either once-daily rivaroxaban (at doses of 20 mg or 10 mg) and 100 mg of ASA in 
      patients with VTE who were in equipoise regarding the need for extended 
      anticoagulation. Study drugs were administered for up to 12 months. The primary 
      efficacy outcome was symptomatic recurrent fatal or nonfatal VTE and the 
      principal safety outcome was major bleeding. A total of 3365 patients were 
      included in the intentionto-treat analyses (median treatment duration, 351 days). 
      The primary efficacy outcome occurred in 1.5% of patients receiving 20 mg of 
      rivaroxaban and in 1.2% of patients receiving 10 mg of rivaroxaban, in comparison 
      to 4.4% of those receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. 
      ASA, 0.34; 95% confidence interval [CI] 0.20 to 0.59; hazard ratio for 10 mg of 
      rivaroxaban vs. ASA, 0.26; 95% CI 0.14 to 0.47; P<0.001 for both comparisons). 
      Rates of major bleeding and adverse events were comparable among three treatment 
      groups. In conclusion, in patients with VTE in equipoise for extended 
      anticoagulation, either a treatment dose (20 mg) or a prophylactic dose (10 mg) 
      of rivaroxaban compared with ASA significantly reduced the risk of VTE recurrence 
      without a significant increase in bleeding risk.
FAU - Kaymaz, Cihangir
AU  - Kaymaz C
AD  - Department of Cardiology, Koşuyolu Yüksek İhtisas Training and Research Hospital, 
      İstanbul, Turkey. cihangirkaymaz2002@yahoo.com.
LA  - tur
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - EINSTEIN CHOICE: Venöz tromboemboli olgularında uzatılmış tedavide rivaroksaban 
      tedavi ve profilaksi dozlarının aspirin ile karşılaştırılması.
PL  - Turkey
TA  - Turk Kardiyol Dern Ars
JT  - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
JID - 9426239
RN  - 0 (Anticoagulants)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rivaroxaban/*therapeutic use
MH  - Treatment Outcome
MH  - *Venous Thromboembolism/drug therapy/epidemiology/prevention & control
EDAT- 2017/09/28 06:00
MHDA- 2018/07/03 06:00
CRDT- 2017/09/27 06:00
PHST- 2017/09/27 06:00 [entrez]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2018/07/03 06:00 [medline]
AID - 10.5543/tkda.2017.02646 [doi]
PST - ppublish
SO  - Turk Kardiyol Dern Ars. 2017 Sep;45(Suppl 4):1-7. doi: 10.5543/tkda.2017.02646.

PMID- 21884025
OWN - NLM
STAT- MEDLINE
DCOM- 20130624
LR  - 20151119
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
VI  - 31
IP  - 1
DP  - 2013 Feb
TI  - Is it cost-effective to increase aspirin use in outpatient settings for primary 
      or secondary prevention? Simulation data from the REACH Registry Australian 
      Cohort.
PG  - 45-52
LID - 10.1111/j.1755-5922.2011.00291.x [doi]
AB  - AIMS: To describe aspirin use in primary and secondary prevention and to 
      determine the incremental costs-effectiveness ratio (ICER) per life year gain 
      (LYG) of aspirin use among subjects with, or at high risk of atherothrombotic 
      disease. DESIGN AND SUBJECTS: To project the cost-effectiveness of aspirin over 5 
      years of follow-up, a Markov state transition model was developed with yearly 
      cycles and the following health states: "Alive" (post-CAD) and "Dead." The model 
      compared current coverage observed among 2361 subjects using the prospective 
      Australian subset of Reduction of Atherothrombosis for continued Health (REACH) 
      registry, and hypothetical situation whereby all subjects assumed to be treated. 
      Costs were calculated based on the Australian government reimbursed data for 
      2010. MAIN OUTCOME MEASURES: ICER per LYG for increased use of aspirin. RESULTS: 
      The use of aspirin in current group varied from 67% to 70%. The base-case 
      analysis showed that increasing aspirin use among subjects with existing CAD in 
      outpatient settings was cost saving, while increasing use of aspirin in primary 
      prevention equated to an ICER of AUD 7126 per LYG. CONCLUSION: Among subjects 
      with existing CAD aspirin use was shown to be a dominant choice of treatment. 
      However, among patients without existing cardiovascular disease (primary 
      prevention), increased uptake of aspirin was cost effective but with uncertain 
      benefit, with two hemorrhagic bleeding events occurring for every life saved.
CI  - © 2011 Blackwell Publishing Ltd.
FAU - Ademi, Zanfina
AU  - Ademi Z
AD  - Melbourne EpiCentre, Department of Medicine, The Royal Melbourne Hospital, The 
      University of Melbourne, Australia. zademi@unimelb.edu.au
FAU - Liew, Danny
AU  - Liew D
FAU - Hollingsworth, Bruce
AU  - Hollingsworth B
FAU - Steg, Ph Gabriel
AU  - Steg PG
FAU - Bhatt, Deepak L
AU  - Bhatt DL
FAU - Reid, Christopher M
AU  - Reid CM
CN  - REACH Registry Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110701
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Ambulatory Care/*economics
MH  - Aspirin/adverse effects/*economics
MH  - Australia
MH  - Cardiovascular Diseases/*economics/mortality/prevention & control
MH  - *Computer Simulation
MH  - Cost-Benefit Analysis
MH  - *Drug Costs
MH  - Drug Utilization/economics
MH  - Female
MH  - Hemorrhage/chemically induced/economics
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Models, Economic
MH  - Platelet Aggregation Inhibitors/adverse effects/*economics
MH  - Practice Patterns, Physicians'/economics
MH  - Primary Prevention/*economics
MH  - Registries
MH  - Secondary Prevention/*economics
MH  - Time Factors
MH  - Uncertainty
EDAT- 2011/09/03 06:00
MHDA- 2013/06/26 06:00
CRDT- 2011/09/03 06:00
PHST- 2011/09/03 06:00 [entrez]
PHST- 2011/09/03 06:00 [pubmed]
PHST- 2013/06/26 06:00 [medline]
AID - 10.1111/j.1755-5922.2011.00291.x [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2013 Feb;31(1):45-52. doi: 10.1111/j.1755-5922.2011.00291.x. 
      Epub 2011 Jul 1.

PMID- 8042198
OWN - NLM
STAT- MEDLINE
DCOM- 19940825
LR  - 20191210
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 74
IP  - 3
DP  - 1994 May 1
TI  - The in vitro effect of aspirin on increased whole blood platelet aggregation in 
      oral contraceptive users.
PG  - 309-15
FAU - Norris, L A
AU  - Norris LA
AD  - Trinity College Department of Obstetrics and Gynaecology, St. James's Hospital, 
      Dublin, Ireland.
FAU - Bonnar, J
AU  - Bonnar J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Contraceptives, Oral, Combined)
RN  - 0 (Contraceptives, Oral, Hormonal)
RN  - 0 (Contraceptives, Oral, Synthetic)
RN  - 0 (Drug Combinations)
RN  - 37270-71-6 (norethindrone acetate, ethinyl estradiol, ferrous fumarate drug 
      combination)
RN  - 3J8Q1747Z2 (Norgestrel)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - 8056-51-7 (Ethinyl Estradiol-Norgestrel Combination)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - T18F433X4S (Norethindrone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Contraceptives, Oral, Combined/*adverse effects
MH  - Contraceptives, Oral, Hormonal/*adverse effects
MH  - Contraceptives, Oral, Synthetic/adverse effects
MH  - Drug Combinations
MH  - Ethinyl Estradiol/adverse effects
MH  - Ethinyl Estradiol-Norgestrel Combination
MH  - Female
MH  - Humans
MH  - Norethindrone/adverse effects
MH  - Norgestrel/adverse effects
MH  - Platelet Aggregation/*drug effects
MH  - Prostaglandin-Endoperoxide Synthases/blood
MH  - Risk Factors
OID - PIP: 098915
OID - POP: 00234409
OAB - The effects of triphasic oral contraceptives on whole blood platelet aggregation 
      in 36 Italian women are reported here. Aspirin's effects on platelet aggregation 
      were also studied. 18 women took a triphasic oral contraceptive; 10 women took 
      Trinordiol, while 8 took Trinovum for at least 90 days. The remaining 18 women 
      took nothing and served as controls. The study was aligned with each woman's 
      birth control pill cycle. Blood was taken daily on days 15-21 of their cycle. 
      Either saline solution or acetylsalicylic acid was added to the blood samples and 
      compared. All data was statistically analyzed using unpaired student's t-test. 
      Effects of 3 aggregating agents, ADP, PAF, and EDTA, on platelet aggregation were 
      studied. Arachidonic acid and adrenalin bitartrate were also studied in this 
      manner. An increase in platelet aggregation was observed in women taking oral 
      contraceptives. No difference was found between patients taking Trinordiol and 
      those taking Trinovum. The results of this study indicate an increase in whole 
      blood platelet sensitivity to collagen, adrenalin, and arachidonic acid when 
      using oral contraceptives. Aspirin, at low doses, may have a role in preventing 
      early thrombus formation in women taking oral contraceptives.
OABL- eng
OTO - PIP
OT  - Biology
OT  - *Blood Coagulation Effects
OT  - Clinical Research
OT  - Contraception
OT  - Contraceptive Methods
OT  - Developed Countries
OT  - *Drugs
OT  - Europe
OT  - Examinations And Diagnoses
OT  - Family Planning
OT  - *Hematologic Tests
OT  - Hematological Effects
OT  - Hemic System
OT  - *In Vitro
OT  - Italy
OT  - Laboratory Examinations And Diagnoses
OT  - Laboratory Procedures
OT  - Mediterranean Countries
OT  - *Oral Contraceptives
OT  - Physiology
OT  - *Platelet Aggregation
OT  - *Research Report
OT  - Southern Europe
OT  - Treatment
GN  - PIP: TJ: THROMBOSIS RESEARCH.
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
AID - 10.1016/0049-3848(94)90119-8 [doi]
PST - ppublish
SO  - Thromb Res. 1994 May 1;74(3):309-15. doi: 10.1016/0049-3848(94)90119-8.

PMID- 15079004
OWN - NLM
STAT- MEDLINE
DCOM- 20040802
LR  - 20211008
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 62
IP  - 7
DP  - 2004 Apr 13
TI  - Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke 
      study.
PG  - 1073-80
AB  - BACKGROUND: Triflusal is an antiplatelet agent that has shown clinical advantages 
      when compared with aspirin in the secondary prevention of vascular events. 
      TAPIRSS (Triflusal versus Aspirin for Prevention of Infarction: a Randomized 
      Stroke Study) explored the efficacy and safety of triflusal in the secondary 
      prevention of stroke in a Latin American homogeneous population with the ultimate 
      aim of preparing for a larger trial in the same setting. METHODS: A double-blind, 
      multicenter, randomized, pilot trial was conducted in Buenos Aires, Argentina, 
      from October 1996 to November 1999. The study sample was 431 patients, randomized 
      to receive aspirin 325 mg daily or triflusal 600 mg daily for a mean of 586 days. 
      All patients had experienced either an ischemic stroke or TIA within 6 months 
      from enrollment. Data from 429 patients were analyzed. RESULTS: No differences 
      were observed in the primary endpoint that combined the incidence of vascular 
      death, cerebral ischemic infarction, nonfatal myocardial infarction, or major 
      hemorrhage (aspirin 13.9%, triflusal 12.7%; odds ratio [OR] 1.11, 95% CI 0.64 to 
      1.94) or in the individual analysis of each component of the primary endpoint. In 
      a post hoc analysis, the overall incidence of major and minor hemorrhagic events 
      was significantly lower in triflusal-treated patients (aspirin 8.3%, triflusal 
      2.8%; OR 3.13, 95% CI 1.22 to 8.06). CONCLUSIONS: This pilot trial has not found 
      differences between triflusal and aspirin in the prevention of vascular 
      complications after TIA or ischemic stroke, although given the wide CI, 
      potentially important group differences could not be ruled out. Triflusal may be 
      associated with a lower risk of hemorrhagic complications. A larger, prospective 
      clinical trial is necessary to verify these results.
FAU - Culebras, A
AU  - Culebras A
AD  - Department of Neurology, Upstate Medical University, Syracuse, NY 13210, USA. 
      aculebras@aol.com
FAU - Rotta-Escalante, R
AU  - Rotta-Escalante R
FAU - Vila, J
AU  - Vila J
FAU - Domínguez, R
AU  - Domínguez R
FAU - Abiusi, G
AU  - Abiusi G
FAU - Famulari, A
AU  - Famulari A
FAU - Rey, R
AU  - Rey R
FAU - Bauso-Tosselli, L
AU  - Bauso-Tosselli L
FAU - Gori, H
AU  - Gori H
FAU - Ferrari, J
AU  - Ferrari J
FAU - Reich, E
AU  - Reich E
CN  - TAPIRSS investigators
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 1Z0YFI05OO (triflusal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Neurology. 2004 Apr 13;62(7):1036-7. PMID: 15078996
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cerebral Infarction/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Salicylates/adverse effects/*therapeutic use
MH  - Secondary Prevention
MH  - Stroke/*prevention & control
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2004/04/14 05:00
MHDA- 2004/08/03 05:00
CRDT- 2004/04/14 05:00
PHST- 2004/04/14 05:00 [pubmed]
PHST- 2004/08/03 05:00 [medline]
PHST- 2004/04/14 05:00 [entrez]
AID - 10.1212/01.wnl.0000113757.34662.aa [doi]
PST - ppublish
SO  - Neurology. 2004 Apr 13;62(7):1073-80. doi: 10.1212/01.wnl.0000113757.34662.aa.

PMID- 30637085
OWN - NLM
STAT- MEDLINE
DCOM- 20190122
LR  - 20200225
IS  - 1937-8688 (Electronic)
VI  - 30
DP  - 2018
TI  - Kounis syndrome induced by oral intake of aspirin: case report and literature 
      review.
PG  - 301
LID - 10.11604/pamj.2018.30.301.14948 [doi]
LID - 301
AB  - The Kounis-Zavras syndrome is defined as the coincidental occurrence of acute 
      coronary events and hypersensitivity reactions following an allergic reaction 
      including a mast-cell degranulation of vasospastic mediators. This report 
      describes a case of Kounis-Zavras syndrome in the setting of aspirin-induced 
      asthma also known as Samter-Beer triad combining nasal polyps, asthma, and 
      aspirin allergy leading to vasospasm and myocardial infarction. All physicians 
      should be aware of The Kounis syndrome and always keep that unique clinical 
      entity in mind to recognize it promptly and direct the therapy at suppressing the 
      allergic reaction.
FAU - Hangouche, Abdelkader Jalil El
AU  - Hangouche AJE
AD  - Department of Cardiology B, Ibn Sina Hospital, Mohammed V University, Rabat, 
      Morocco.
AD  - Exercise Physiology and Autonomic Nervous System Team "EPE-SNA", Faculty of 
      Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.
AD  - Laboratory of Physiology, Faculty of Medicine and Pharmacy of Tangier, Abdelmalek 
      Essaâdi University, Tangier, Morocco.
FAU - Lamliki, Ouiame
AU  - Lamliki O
AD  - Department of Cardiology B, Ibn Sina Hospital, Mohammed V University, Rabat, 
      Morocco.
FAU - Oukerraj, Latifa
AU  - Oukerraj L
AD  - Department of Cardiology B, Ibn Sina Hospital, Mohammed V University, Rabat, 
      Morocco.
FAU - Dakka, Taoufiq
AU  - Dakka T
AD  - Exercise Physiology and Autonomic Nervous System Team "EPE-SNA", Faculty of 
      Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.
FAU - Doghmi, Nawal
AU  - Doghmi N
AD  - Department of Cardiology B, Ibn Sina Hospital, Mohammed V University, Rabat, 
      Morocco.
FAU - Zarzur, Jamila
AU  - Zarzur J
AD  - Department of Cardiology B, Ibn Sina Hospital, Mohammed V University, Rabat, 
      Morocco.
FAU - Cherti, Mohammed
AU  - Cherti M
AD  - Department of Cardiology B, Ibn Sina Hospital, Mohammed V University, Rabat, 
      Morocco.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20180830
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Pan Afr Med J. 2019 Jul 04;33:172. PMID: 31565133
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma/chemically induced/immunology
MH  - Drug Hypersensitivity/etiology/immunology/*physiopathology
MH  - Female
MH  - Humans
MH  - Kounis Syndrome/*diagnosis/physiopathology
MH  - Mast Cells/immunology
MH  - Middle Aged
MH  - Myocardial Infarction/chemically induced/immunology
MH  - Nasal Polyps/immunology
PMC - PMC6320451
OTO - NOTNLM
OT  - Kounis
OT  - aspirin allergy
OT  - coronary spasm
OT  - myocardial infarction
OT  - samter´s triad
OT  - zavras syndrome
EDAT- 2019/01/15 06:00
MHDA- 2019/01/23 06:00
CRDT- 2019/01/15 06:00
PHST- 2018/01/23 00:00 [received]
PHST- 2018/07/18 00:00 [accepted]
PHST- 2019/01/15 06:00 [entrez]
PHST- 2019/01/15 06:00 [pubmed]
PHST- 2019/01/23 06:00 [medline]
AID - PAMJ-30-301 [pii]
AID - 10.11604/pamj.2018.30.301.14948 [doi]
PST - epublish
SO  - Pan Afr Med J. 2018 Aug 30;30:301. doi: 10.11604/pamj.2018.30.301.14948. 
      eCollection 2018.

PMID- 35253137
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20220830
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 122
IP  - 9
DP  - 2022 Sep
TI  - Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: 
      Uncertainties and Opportunities.
PG  - 1443-1453
LID - 10.1055/s-0042-1743469 [doi]
AB  - The use of the antiplatelet agent aspirin (acetylsalicylic acid) was previously 
      routinely recommended for the primary prevention of cardiovascular (CV) events in 
      patients with diabetes, but recent large-scale randomized trials have failed to 
      demonstrate a sizeable net clinical benefit with a once-daily, low-dose 
      (81-100 mg) regimen in this population. Previous pharmacokinetic and 
      pharmacodynamic studies have suggested that the aspirin formulation 
      (enteric-coated) and dosing schedule (once daily) studied in randomized trials 
      for primary prevention of CV events defining contemporary clinical practice may 
      not leverage the full potential of the drug, particularly in patients with 
      diabetes. Indeed, the diabetic platelets bear characteristics that increase their 
      thrombotic potential and alter their pharmacologic response to the drug. 
      Consequently, the appropriateness of studying a uniform aspirin regimen in 
      landmark primary prevention trials needs to be revisited. In this review, we 
      present the evidence showing that diabetes not only increases baseline platelet 
      reactivity, but also alters platelet response to aspirin through different 
      mechanisms including a faster platelet turnover rate. Obesity, which is 
      frequently associated with diabetes, also impacts its pharmacokinetics via an 
      increase in distribution volume. Small-scale pharmacokinetic and pharmacodynamic 
      studies have suggested that the relative aspirin resistance phenotype observed in 
      patients with diabetes may be reversed with a twice-daily dosing schedule, and 
      with nonenteric-coated aspirin formulations. Properly powered randomized 
      controlled trials investigating the efficacy and safety of aspirin dosing 
      schedules and formulations tailored to the population of patients with diabetes 
      are urgently required to optimize patient care.
CI  - Thieme. All rights reserved.
FAU - Del Bianco-Rondeau, Mélina
AU  - Del Bianco-Rondeau M
AD  - Faculty of Pharmacy, Université de Montréal, Montreal, Québec, Canada.
FAU - Robert-Halabi, Maxime
AU  - Robert-Halabi M
AD  - Faculty of Medicine, Université de Montréal, Montreal, Québec, Canada.
AD  - Department of Medicine, Montreal Heart Institute, Montreal, Québec, Canada.
FAU - Bloom, Samara
AU  - Bloom S
AD  - Faculty of Medicine, Université de Montréal, Montreal, Québec, Canada.
AD  - Research Center, Montreal Heart Institute, Montreal, Québec, Canada.
FAU - Rabasa-Lhoret, Remi
AU  - Rabasa-Lhoret R
AD  - Institut de Recherche Clinique de Montréal, Montreal, Québec, Canada.
FAU - Tardif, Jean-Claude
AU  - Tardif JC
AD  - Faculty of Medicine, Université de Montréal, Montreal, Québec, Canada.
AD  - Department of Medicine, Montreal Heart Institute, Montreal, Québec, Canada.
AD  - Research Center, Montreal Heart Institute, Montreal, Québec, Canada.
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
AUID- ORCID: 0000-0001-7418-6766
AD  - Faculty of Pharmacy, Université de Montréal, Montreal, Québec, Canada.
AD  - Research Center, Montreal Heart Institute, Montreal, Québec, Canada.
FAU - Marquis-Gravel, Guillaume
AU  - Marquis-Gravel G
AUID- ORCID: 0000-0003-2965-1504
AD  - Faculty of Medicine, Université de Montréal, Montreal, Québec, Canada.
AD  - Department of Medicine, Montreal Heart Institute, Montreal, Québec, Canada.
AD  - Research Center, Montreal Heart Institute, Montreal, Québec, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220304
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - Blood Platelets
MH  - *Cardiovascular Diseases
MH  - *Diabetes Mellitus
MH  - Humans
MH  - Platelet Aggregation Inhibitors
MH  - Primary Prevention
COIS- M.L. has received speaker honoraria from Bayer; has received research grants to 
      the institution from Idorsia; has served on a national advisory board for 
      Servier; and has received in-kind and financial support for 
      investigator-initiated grants from Leo Pharma, Roche Diagnostics, Aggredyne, and 
      Fujimori Kogyo. G.M-.G. has received speaker honoraria from the Canadian Heart 
      Research Center, the Population Health Research Institute, JAMP Pharma, and 
      Novartis; has served on a national advisory board for Servier, JAMP, and Bayer; 
      and has received research grants from Bayer, the Montreal Heart Institute 
      Foundation, the Canadian Institute of Health Research, Université de Montréal, 
      and the Duke Clinical Research Institute. J-.C.T. has received grant support from 
      Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis, 
      Pfizer, RegenXBio, and Sanofi; honoraria from AstraZeneca, DalCor 
      Pharmaceuticals, HLS Pharmaceuticals, Pendopharm, and Sanofi; minor equity 
      interest in DalCor Pharmaceuticals; and patents were submitted on 
      pharmacogenomics-guided CETP inhibition and use of colchicine after myocardial 
      infarction in which he is mentioned as an author. There are no other conflicts of 
      interest to disclose.
EDAT- 2022/03/08 06:00
MHDA- 2022/08/31 06:00
CRDT- 2022/03/07 06:12
PHST- 2022/03/08 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
PHST- 2022/03/07 06:12 [entrez]
AID - 10.1055/s-0042-1743469 [doi]
PST - ppublish
SO  - Thromb Haemost. 2022 Sep;122(9):1443-1453. doi: 10.1055/s-0042-1743469. Epub 2022 
      Mar 4.

PMID- 18990434
OWN - NLM
STAT- MEDLINE
DCOM- 20091022
LR  - 20181201
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 124
IP  - 1
DP  - 2009 May
TI  - Effect of increased aspirin dose after stenting in association with ClOpidogrel: 
      the FIASCO randomized study.
PG  - 33-6
LID - 10.1016/j.thromres.2008.09.014 [doi]
AB  - BACKGROUND: Increased doses of antiplatelet therapy have been proposed to 
      overcome the variability of response. However, the chronic dose of aspirin after 
      DES remains controversial. METHODS AND RESULTS: We assessed in a prospective and 
      randomized study the benefit of higher dose of aspirin, in association with 
      clopidogrel, on aspirin response and non COX-specific platelet testing in 
      patients receiving Drug Eluting Stent (DES) for stable angina pectoris. 50 
      consecutive patients receiving DES for stable angina pectoris were prospectively 
      included. They received loading dose of 250 mg aspirin and 600 mg clopidogrel and 
      antiplatelet response was assessed with Arachidonic Acid-induced aggregation 
      (AA-Ag) and ADP-induced aggregation (ADP-Ag) for aspirin and clopidogrel response 
      respectively. Patients were randomized to either 75 or 160 mg of aspirin with 150 
      mg clopidogrel and platelet testing were repeated one month after hospital 
      discharge. The two groups (aspirin "75 mg" or "160 mg") had no difference for 
      aspirin response: AA-Ag (5.2 +/- 1.7% vs 6 +/- 2%, p = 0.75) and non COX-specific 
      pathway testing: ADP-Ag (47 +/- 3% vs 49 +/- 4%, p = 0.61). CONCLUSION: The 
      present study did not show any benefit of higher dose of aspirin neither on 
      aspirin responsiveness, nor on inhibition of non COX-specific pathway. These data 
      does not support use of higher dose than 75 mg of aspirin in association with 
      clopidogrel in patients receiving DES, especially while higher doses have been 
      associated with increased bleeding risk.
FAU - Cuisset, Thomas
AU  - Cuisset T
AD  - Department of Cardiology, CHU Timone, Marseille, 13385 France. 
      thomascuisset@voila.fr
FAU - Frere, Corinne
AU  - Frere C
FAU - Quilici, Jacques
AU  - Quilici J
FAU - Uhry, Sabrina
AU  - Uhry S
FAU - Morange, Pierre-Emmanuel
AU  - Morange PE
FAU - Mouret, Jean-Philippe
AU  - Mouret JP
FAU - Gaborit, Benedicte
AU  - Gaborit B
FAU - Bali, Laurent
AU  - Bali L
FAU - Moro, Pierre-Julien
AU  - Moro PJ
FAU - Lambert, Marc
AU  - Lambert M
FAU - Bonnet, Jean Louis
AU  - Bonnet JL
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20081105
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Aged
MH  - Angina Pectoris/drug therapy
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/drug effects
MH  - Clopidogrel
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Practice Guidelines as Topic/standards
MH  - Prospective Studies
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2008/11/08 09:00
MHDA- 2009/10/23 06:00
CRDT- 2008/11/08 09:00
PHST- 2008/05/06 00:00 [received]
PHST- 2008/09/16 00:00 [revised]
PHST- 2008/09/17 00:00 [accepted]
PHST- 2008/11/08 09:00 [pubmed]
PHST- 2009/10/23 06:00 [medline]
PHST- 2008/11/08 09:00 [entrez]
AID - S0049-3848(08)00450-7 [pii]
AID - 10.1016/j.thromres.2008.09.014 [doi]
PST - ppublish
SO  - Thromb Res. 2009 May;124(1):33-6. doi: 10.1016/j.thromres.2008.09.014. Epub 2008 
      Nov 5.

PMID- 33247982
OWN - NLM
STAT- MEDLINE
DCOM- 20211208
LR  - 20211214
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 36
IP  - 7
DP  - 2021 Jul
TI  - Risks of adverse events for users of proton-pump inhibitors plus aspirin or 
      clopidogrel in patients with aspirin-related ulcer bleeding.
PG  - 1828-1835
LID - 10.1111/jgh.15360 [doi]
AB  - BACKGROUND AND AIM: Clopidogrel is widely prescribed for patients with of 
      aspirin-related upper gastrointestinal bleeding (UGIB) history. This study aimed 
      to compare the risk of a major adverse cardiovascular event (MACE), UGIB, and 
      mortality between aspirin and clopidogrel in patients at risk of bleeding. 
      METHODS: We analyzed adult patients at high risk of UGIB following 
      aspirin-related bleeding for secondary MACE prevention between 2000 and 2012. 
      Secondary prevention was for those patients who had ever been hospitalized for 
      cardiovascular disease and reused aspirin or changed to clopidogrel after 
      discharge. Study endpoints were recurrence of MACE, UGIB, and death in 90 days of 
      follow-up. The associations between study outcomes and the use of clopidogrel (vs 
      aspirin) were analyzed. RESULTS: Among 947 eligible patients, 653 reused aspirin 
      (in combination with a proton-pump inhibitor), and 294 were treated with 
      clopidogrel (in combination with a proton-pump inhibitor) after discharge for 
      UGIB. Compared with aspirin treatment, clopidogrel showed an increased risk of 
      MACE (adjusted hazard ratio [aHR] 1.65; 95% confidence interval [CI] 0.87-3.12) 
      and UGIB (aHR 1.25; 95% CI 0.66-2.36), but without statistical significance in 
      90 days' follow-up. Clopidogrel use was associated with greater than four times 
      the risk of any cause of mortality (aHR 4.84; 95% CI 1.59-14.75), but the 
      significance did not hold in propensity score-matched cohort analysis (P = 0.06). 
      CONCLUSIONS: A nonsignificant difference between clopidogrel and aspirin for 
      short-term MACE prevention as well as UGIB recurrence was found in the present 
      study. Further research to assess 90-day mortality would assist clinical decision 
      making.
CI  - © 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & 
      Sons Australia, Ltd.
FAU - Yang, Shih-Cheng
AU  - Yang SC
AD  - Division of Hepato-gastroenterology; Department of Internal Medicine, Kaohsiung 
      Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
FAU - Wu, Cheng-Kun
AU  - Wu CK
AD  - Division of Hepato-gastroenterology; Department of Internal Medicine, Kaohsiung 
      Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
FAU - Tai, Wei-Chen
AU  - Tai WC
AD  - Division of Hepato-gastroenterology; Department of Internal Medicine, Kaohsiung 
      Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
AD  - College of Medicine, Chang Gung University, Kaohsiung, Taiwan.
FAU - Liang, Chih-Ming
AU  - Liang CM
AD  - Division of Hepato-gastroenterology; Department of Internal Medicine, Kaohsiung 
      Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
FAU - Yao, Chih-Chien
AU  - Yao CC
AD  - Division of Hepato-gastroenterology; Department of Internal Medicine, Kaohsiung 
      Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
FAU - Wu, Keng-Liang
AU  - Wu KL
AUID- ORCID: 0000-0002-8703-6625
AD  - Division of Hepato-gastroenterology; Department of Internal Medicine, Kaohsiung 
      Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
AD  - College of Medicine, Chang Gung University, Kaohsiung, Taiwan.
FAU - Hsu, Chien-Ning
AU  - Hsu CN
AD  - Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, 
      Taiwan.
FAU - Chuah, Seng-Kee
AU  - Chuah SK
AUID- ORCID: 0000-0002-8934-3223
AD  - Division of Hepato-gastroenterology; Department of Internal Medicine, Kaohsiung 
      Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
AD  - College of Medicine, Chang Gung University, Kaohsiung, Taiwan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20201211
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/drug therapy/*prevention & control
MH  - Clopidogrel/*adverse effects/therapeutic use
MH  - Databases, Factual
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/complications/drug therapy
MH  - Peptic Ulcer Hemorrhage/*chemically induced/etiology
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Proton Pump Inhibitors/*adverse effects/therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Secondary Prevention
OTO - NOTNLM
OT  - Aspirin
OT  - Clopidogrel
OT  - Major adverse cardiovascular events
OT  - Proton-pump inhibitor
OT  - Upper gastrointestinal bleeding
EDAT- 2020/11/29 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/11/28 17:05
PHST- 2020/10/22 00:00 [revised]
PHST- 2020/06/30 00:00 [received]
PHST- 2020/11/21 00:00 [accepted]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/11/28 17:05 [entrez]
AID - 10.1111/jgh.15360 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2021 Jul;36(7):1828-1835. doi: 10.1111/jgh.15360. Epub 
      2020 Dec 11.

PMID- 7219004
OWN - NLM
STAT- MEDLINE
DCOM- 19810613
LR  - 20190825
IS  - 0023-852X (Print)
IS  - 0023-852X (Linking)
VI  - 91
IP  - 4
DP  - 1981 Apr
TI  - Carotid vascular pain--a simple treatment.
PG  - 605-8
AB  - Carotid vascular pain has been misdiagnosed in the past as various other 
      conditions. Various etiologies have been assigned to it without clinical or 
      experimental evidence. Haphazard treatment using ganglion-blockers, nicotinic 
      acid, allergy hyposensitization and steroids have been instituted based on 
      imaginary causes of the problem. This paper intends to show that there is no 
      known cause for carotid pain. A simple, effective, safe and inexpensive form of 
      treatment is presented; namely, explaining the problem to the patient, allaying 
      their apprehension and using aspirin in a more scientific fashion. A three-year 
      follow-up is presented.
FAU - Nair, K K
AU  - Nair KK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Arteritis/diagnosis/*drug therapy/etiology
MH  - Aspirin/*therapeutic use
MH  - Carotid Artery Diseases/diagnosis/*drug therapy/etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain Management
EDAT- 1981/04/01 00:00
MHDA- 1981/04/01 00:01
CRDT- 1981/04/01 00:00
PHST- 1981/04/01 00:00 [pubmed]
PHST- 1981/04/01 00:01 [medline]
PHST- 1981/04/01 00:00 [entrez]
AID - 10.1288/00005537-198104000-00014 [doi]
PST - ppublish
SO  - Laryngoscope. 1981 Apr;91(4):605-8. doi: 10.1288/00005537-198104000-00014.

PMID- 27587328
OWN - NLM
STAT- MEDLINE
DCOM- 20180201
LR  - 20220311
IS  - 1741-203X (Electronic)
IS  - 1041-6102 (Print)
IS  - 1041-6102 (Linking)
VI  - 28
IP  - 10
DP  - 2016 Oct
TI  - ASPREE-D: Aspirin for the prevention of depression in the elderly.
PG  - 1741-8
LID - 10.1017/S104161021600079X [doi]
AB  - BACKGROUND: Not only is depression associated with increased inflammation but 
      inflammation is a risk factor for the genesis of depression. Many of the 
      environmental risk factors for depression are transduced through inflammatory 
      signaling. Anti-inflammatory agents show promise for the management of depression 
      in preclinical, epidemiological, and early clinical studies. This opens the door 
      to the potential for anti-inflammatory agents to treat and prevent depression. 
      There are no evidence-based pharmacotherapies for depression prevention. METHOD: 
      ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study 
      of ASPREE, which explores the potential of aspirin to prevent a range of 
      inflammation related disorders in the elderly. With a sample size of 19,114, and 
      a duration of 5 years, this placebo controlled study will be one of the largest 
      randomized controlled trials in psychiatry and will provide definitive evidence 
      on the ability of aspirin to prevent depression. RESULTS: This paper presents the 
      rationale for the study and presents a summary of the study design. CONCLUSIONS: 
      ASPREE-D may not only define novel therapy but will provide mechanistic proof of 
      concept of the role of inflammation in depression.
FAU - Berk, Michael
AU  - Berk M
AD  - Deakin University,School of Medicine,IMPACT Strategic Research Centre,Barwon 
      Health,Geelong,Victoria,Australia.
FAU - Woods, R L
AU  - Woods RL
AD  - School of Public Health and Preventive Medicine,Monash 
      University,Melbourne,Victoria,Australia.
FAU - Nelson, M R
AU  - Nelson MR
AD  - Menzies Institute for Medical Research,University of Tasmania,Tasmania,Australia.
FAU - Shah, R C
AU  - Shah RC
AD  - Department of Family Medicine and the Rush Alzheimer's Disease Center,Rush 
      University Medical Center,Chicago,Illinois,USA.
FAU - Reid, C M
AU  - Reid CM
AD  - School of Public Health and Preventive Medicine,Monash 
      University,Melbourne,Victoria,Australia.
FAU - Storey, E
AU  - Storey E
AD  - Central Clinical School,Monash University,Victoria,Australia.
FAU - Fitzgerald, S M
AU  - Fitzgerald SM
AD  - School of Public Health and Preventive Medicine,Monash 
      University,Melbourne,Victoria,Australia.
FAU - Lockery, J E
AU  - Lockery JE
AD  - School of Public Health and Preventive Medicine,Monash 
      University,Melbourne,Victoria,Australia.
FAU - Wolfe, R
AU  - Wolfe R
AD  - School of Public Health and Preventive Medicine,Monash 
      University,Melbourne,Victoria,Australia.
FAU - Mohebbi, M
AU  - Mohebbi M
AD  - Deakin University,School of Medicine,IMPACT Strategic Research Centre,Barwon 
      Health,Geelong,Victoria,Australia.
FAU - Murray, A M
AU  - Murray AM
AD  - Berman Center for Outcomes & Clinical Research,Hennepin County Medical 
      Center,Minneapolis,Minnesota,USA.
FAU - Kirpach, B
AU  - Kirpach B
AD  - Berman Center for Outcomes & Clinical Research,Hennepin County Medical 
      Center,Minneapolis,Minnesota,USA.
FAU - Grimm, R
AU  - Grimm R
AD  - Berman Center for Outcomes & Clinical Research,Hennepin County Medical 
      Center,Minneapolis,Minnesota,USA.
FAU - McNeil, J J
AU  - McNeil JJ
AD  - School of Public Health and Preventive Medicine,Monash 
      University,Melbourne,Victoria,Australia.
LA  - eng
SI  - ISRCTN/ISRCTN83772183
GR  - U01 AG029824/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160531
PL  - England
TA  - Int Psychogeriatr
JT  - International psychogeriatrics
JID - 9007918
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents/administration & dosage
MH  - Aspirin/*administration & dosage
MH  - *Depression/physiopathology/prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - *Inflammation/drug therapy/psychology
MH  - Male
MH  - Research Design
PMC - PMC6719794
MID - NIHMS1048110
OTO - NOTNLM
OT  - antidepressants
OT  - aspirin
OT  - biomarkers
OT  - depression
OT  - immunology
OT  - inflammation
OT  - prevention
OT  - risk
EDAT- 2016/09/03 06:00
MHDA- 2018/02/02 06:00
CRDT- 2016/09/03 06:00
PHST- 2016/09/03 06:00 [entrez]
PHST- 2016/09/03 06:00 [pubmed]
PHST- 2018/02/02 06:00 [medline]
AID - S104161021600079X [pii]
AID - 10.1017/S104161021600079X [doi]
PST - ppublish
SO  - Int Psychogeriatr. 2016 Oct;28(10):1741-8. doi: 10.1017/S104161021600079X. Epub 
      2016 May 31.

PMID- 27732743
OWN - NLM
STAT- MEDLINE
DCOM- 20171207
LR  - 20171207
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 72
IP  - 3
DP  - 2017 Mar
TI  - Clinical approach on challenge and desensitization procedures with aspirin in 
      patients with ischemic heart disease and nonsteroidal anti-inflammatory drug 
      hypersensitivity.
PG  - 498-506
LID - 10.1111/all.13068 [doi]
AB  - BACKGROUND: Hypersensitivity to acetylsalicylic acid (ASA) constitutes a serious 
      problem for subjects with coronary artery disease. In such subjects, physicians 
      have to choose the more appropriate procedure between challenge and 
      desensitization. As the literature on this issue is sparse, this study aimed to 
      establish in these subjects clinical criteria for eligibility for an ASA 
      challenge and/or desensitization. METHODS: Collection and analysis of data on ASA 
      challenges and desensitizations from 10 allergy centers, as well as consensus 
      among the related physicians and an expert panel. RESULTS: Altogether, 310 
      subjects were assessed; 217 had histories of urticaria/angioedema, 50 of 
      anaphylaxis, 26 of nonimmediate cutaneous eruptions, and 17 of bronchospasm 
      related to ASA/nonsteroidal anti-inflammatory drugs (NSAID) intake. Specifically, 
      119 subjects had index reactions to ASA doses lower than 300 mg. Of the 310 
      subjects, 138 had an acute coronary syndrome (ACS), 101 of whom underwent 
      desensitizations, whereas 172 suffered from a chronic ischemic heart disease 
      (CIHD), 126 of whom underwent challenges. Overall, 163 subjects underwent 
      challenges and 147 subjects underwent desensitizations; 86 of the latter had 
      index reactions to ASA doses of 300 mg or less. Ten subjects reacted to 
      challenges, seven at doses up to 500 mg, three at a cumulative dose of 110 mg. 
      The desensitization failure rate was 1.4%. CONCLUSIONS: In patients with stable 
      CIHD and histories of nonsevere hypersensitivity reactions to ASA/NSAIDs, an ASA 
      challenge is advisable. Patients with an ACS and histories of hypersensitivity 
      reactions to ASA, especially following doses lower than 100 mg, should directly 
      undergo desensitization.
CI  - © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Cortellini, G
AU  - Cortellini G
AD  - Internal Medicine and Rheumatology Department, Azienda Sanitaria Romagna, Rimini 
      Hospital, Rimini, Italy.
FAU - Romano, A
AU  - Romano A
AD  - Allergy Unit, Complesso Integrato Columbus, Rome, Italy.
AD  - IRCCS Oasi Maria S.S., Troina, Italy.
FAU - Santucci, A
AU  - Santucci A
AD  - Internal Medicine and Rheumatology Department, Azienda Sanitaria Romagna, Rimini 
      Hospital, Rimini, Italy.
FAU - Barbaud, A
AU  - Barbaud A
AD  - Department of Dermatology and Allergology, University Hospital of Nancy, 
      Vandoeuvre-lès-Nancy, France.
FAU - Bavbek, S
AU  - Bavbek S
AD  - Department of Clinical Immunology and Allergy, School of Medicine, Ankara 
      University, Ankara, Turkey.
FAU - Bignardi, D
AU  - Bignardi D
AD  - Allergy Unit, San Martino Hospital, Genoa, Italy.
FAU - Blanca, M
AU  - Blanca M
AD  - Allergy Service, Carlos Haya Hospital, Malaga, Spain.
FAU - Bonadonna, P
AU  - Bonadonna P
AD  - Allergy Unit, University Hospital of Verona, Verona, Italy.
FAU - Costantino, M T
AU  - Costantino MT
AD  - Allergy Unit, Poma Hospital, Mantua, Italy.
FAU - Laguna, J J
AU  - Laguna JJ
AD  - Allergy Unit, Hospital de la Cruz Roja, Madrid, Spain.
FAU - Lombardo, C
AU  - Lombardo C
AD  - Allergy Unit, University Hospital of Verona, Verona, Italy.
FAU - Losappio, L M
AU  - Losappio LM
AD  - Allergology and Immunology Unit, Niguarda Ca' Granda Hospital, Milan, Italy.
FAU - Makowska, J
AU  - Makowska J
AD  - Department of Rheumatology, Medical University of Lodz, Lodz, Poland.
FAU - Nakonechna, A
AU  - Nakonechna A
AD  - Allergy and Immunology, Clinic Royal Liverpool and Broadgreen University 
      Hospital, Liverpool, UK.
FAU - Quercia, O
AU  - Quercia O
AD  - Allergy Unit, Internal Medicine Department, Azienda Sanitaria Romagna, Faenza, 
      Italy.
FAU - Pastorello, E A
AU  - Pastorello EA
AD  - Allergology and Immunology Unit, Niguarda Ca' Granda Hospital, Milan, Italy.
FAU - Patella, V
AU  - Patella V
AD  - Allergy Unit, Santa Maria della Speranza Hospital, Battipaglia, Italy.
AD  - Azienda Sanitaria Locale Salerno, Salerno, Italy.
FAU - Terreehorst, I
AU  - Terreehorst I
AD  - Academisch Medisch Centrum, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Testi, S
AU  - Testi S
AD  - Allergy and Clinical Immunology Unit, Azienda Sanitaria di Firenze, San Giovanni 
      di Dio Hospital, Florence, Italy.
FAU - Cernadas, J R
AU  - Cernadas JR
AD  - Immunoallergy Department, Centro Hospitalar Sao Joao, Porto, Portugal.
CN  - EAACI Drug Interest Group on Challenge and Desensitization Procedures with 
      Aspirin in CAD
FAU - Dionicio Elera, J
AU  - Dionicio Elera J
AD  - Allergy Unit, Hospital de la Cruz Roja, Madrid, Spain.
FAU - Lippolis, D
AU  - Lippolis D
AD  - Internal Medicine and Rheumatology Department, Azienda Sanitaria Romagna, Rimini 
      Hospital, Rimini, Italy.
FAU - Voltolini, S
AU  - Voltolini S
AD  - Allergy Unit, San Martino Hospital, Genoa, Italy.
FAU - Grosseto, D
AU  - Grosseto D
AD  - Cardiology Unit, Azienda Sanitaria Romagna, Rimini Hospital, Rimini, Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20161128
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Algorithms
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Clinical Decision-Making
MH  - Comorbidity
MH  - *Desensitization, Immunologic/adverse effects/methods
MH  - Drug Hypersensitivity/*complications/diagnosis/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*complications/diagnosis/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aspirin
OT  - challenge procedure
OT  - desensitization procedure
OT  - nonsteroidal anti-inflammatory drugs hypersensitivity
EDAT- 2016/10/13 06:00
MHDA- 2017/12/08 06:00
CRDT- 2016/10/13 06:00
PHST- 2016/10/07 00:00 [accepted]
PHST- 2016/10/13 06:00 [pubmed]
PHST- 2017/12/08 06:00 [medline]
PHST- 2016/10/13 06:00 [entrez]
AID - 10.1111/all.13068 [doi]
PST - ppublish
SO  - Allergy. 2017 Mar;72(3):498-506. doi: 10.1111/all.13068. Epub 2016 Nov 28.

PMID- 32302241
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20200908
IS  - 1366-5928 (Electronic)
IS  - 0049-8254 (Linking)
VI  - 50
IP  - 10
DP  - 2020 Oct
TI  - Is aspirin a substrate of MDR1/P-glycoprotein?
PG  - 1258-1264
LID - 10.1080/00498254.2020.1757785 [doi]
AB  - Aspirin (acetyl salicylic acid) is widely used co-medication in patients with 
      cardiovascular and cerebrovascular diseases. Given the prevalence of acetyl 
      salicylic acid's use as a co-medication and conflicting reports in the literature 
      on it being a substrate of P-glycoprotein (P-gp). There is a potential risk for 
      its interaction with compounds with P-gp liability, therefore, we have conducted 
      a detailed investigation to determine substrate potential of acetyl salicylic 
      acid towards P-gp. We observed significantly lower cellular uptake of acetyl 
      salicylic acid in MDR1 transfected LLC-PK1 cells compared to LLC-PK1 wild-type 
      (WT) cells, however, the in vitro efflux of acetyl salicylic acid in MDR1 
      transfected LLC-PK1 cells was not inhibited by known inhibitors under various 
      conditions. Acetyl salicylic acid did not show active asymmetrical transport 
      across MDR1 transfected LLC-PK1 cells compared to LLC-PK1-WT cells in transwell 
      assay. Moreover, no difference in plasma and brain exposure of acetyl salicylic 
      acid and its metabolite salicylic acid was observed between FVB-WT and Mdr1a/b 
      knockout (KO) mice. Taken together, our findings indicate that acetyl salicylic 
      acid is not a substrate of P-gp.
FAU - Singh, Renu
AU  - Singh R
AUID- ORCID: 0000-0001-5809-3404
AD  - Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb, 
      Lawrenceville, NJ, USA.
FAU - Naik, Tanvi
AU  - Naik T
AD  - Pharmaceutical Candidate Optimization, Syngene International Ltd, Bangalore, 
      India.
FAU - Nigam, Anuja
AU  - Nigam A
AD  - Pharmaceutical Candidate Optimization, Syngene International Ltd, Bangalore, 
      India.
FAU - Chatterjee, Sagnik
AU  - Chatterjee S
AD  - Pharmaceutical Candidate Optimization, Syngene International Ltd, Bangalore, 
      India.
FAU - Rajanna, Prabhakar
AU  - Rajanna P
AD  - Pharmaceutical Candidate Optimization, Syngene International Ltd, Bangalore, 
      India.
FAU - Shen, Hong
AU  - Shen H
AD  - Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb, 
      Lawrenceville, NJ, USA.
FAU - Iyer, Ramaswamy
AU  - Iyer R
AD  - Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb, 
      Lawrenceville, NJ, USA.
LA  - eng
PT  - Journal Article
DEP - 20200429
PL  - England
TA  - Xenobiotica
JT  - Xenobiotica; the fate of foreign compounds in biological systems
JID - 1306665
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B/*metabolism
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 1/*metabolism
MH  - Animals
MH  - Aspirin/*metabolism
MH  - Biological Transport
MH  - Biological Transport, Active
MH  - Brain
MH  - LLC-PK1 Cells
MH  - Swine
OTO - NOTNLM
OT  - Aspirin
OT  - DDI
OT  - MDR1
OT  - P-glycoprotein
OT  - acetyl salicylic acid
EDAT- 2020/04/18 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1080/00498254.2020.1757785 [doi]
PST - ppublish
SO  - Xenobiotica. 2020 Oct;50(10):1258-1264. doi: 10.1080/00498254.2020.1757785. Epub 
      2020 Apr 29.

PMID- 9361371
OWN - NLM
STAT- MEDLINE
DCOM- 19980123
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 88
IP  - 2
DP  - 1997 Oct 15
TI  - Platelet responses to several agonists and combinations of agonists in whole 
      blood: a placebo controlled comparison of the effects of a once daily dose of 
      plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in 
      man.
PG  - 183-92
AB  - Platelet responses to several agonists and combinations of agonists have been 
      measured in whole blood from healthy volunteers. We have determined the effects 
      of once daily treatment for five days with plain aspirin 300 mg, plain aspirin 75 
      mg, enteric coated aspirin 300 mg or placebo. Measurements were made of platelet 
      aggregation (using a platelet counting technique) and the release reaction 
      (14C-5HT release from pre-labelled platelets). The extents of these responses 
      before aspirin administration depended on the agonist used. ADP, adrenaline and 
      PAF failed to induce any 14C-5HT release in most subjects, but combinations of 
      these agonists acted synergistically to produce extensive 14C-5HT release. All 
      three aspirin preparations reduced the extent of the platelet responses to most 
      agonists: platelet aggregation induced by collagen, ristocetin and arachidonate 
      and 14C-5HT release induced by collagen, streptokinase, and various combinations 
      of ADP, adrenaline and PAF. None of the preparations had any effect on the 
      aggregation that occurred in the absence of an agonist (spontaneous aggregation), 
      but they all reduced streptokinase-induced aggregation to control (spontaneous) 
      levels, and abolished the 14C-5HT release induced by arachidonate and by 
      ristocetin. All three aspirin preparations were equally effective after two daily 
      doses. No further inhibition of platelet responses was obtained after five daily 
      doses. Plain aspirin 300 mg achieved its maximal effect after only a single dose, 
      but enteric coated aspirin 300 mg (and sometimes plain aspirin 75 mg) produced 
      sub-maximal inhibition after only a single dose. Parallel investigations on the 
      effects of these aspirin regimes on gastric mucosal prostaglandin E2 synthesis 
      and gastroduodenal mucosal injury were performed. These results will be reported 
      separately.
FAU - May, J A
AU  - May JA
AD  - Division of Cardiovascular Medicine, University Hospital, Nottingham, UK.
FAU - Heptinstall, S
AU  - Heptinstall S
FAU - Cole, A T
AU  - Cole AT
FAU - Hawkey, C J
AU  - Hawkey CJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Coagulants)
RN  - 0 (Placebos)
RN  - 0 (Platelet Activating Factor)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 1404-55-3 (Ristocetin)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Blood Platelets/*drug effects/*metabolism
MH  - Coagulants/*pharmacology
MH  - Collagen/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Placebos
MH  - Platelet Activating Factor/pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology
MH  - Ristocetin/pharmacology
MH  - Streptokinase/pharmacology
MH  - Tablets, Enteric-Coated/administration & dosage/pharmacology
EDAT- 1997/11/15 00:00
MHDA- 1997/11/15 00:01
CRDT- 1997/11/15 00:00
PHST- 1997/11/15 00:00 [pubmed]
PHST- 1997/11/15 00:01 [medline]
PHST- 1997/11/15 00:00 [entrez]
AID - S0049384897002296 [pii]
AID - 10.1016/s0049-3848(97)00229-6 [doi]
PST - ppublish
SO  - Thromb Res. 1997 Oct 15;88(2):183-92. doi: 10.1016/s0049-3848(97)00229-6.

PMID- 7567835
OWN - NLM
STAT- MEDLINE
DCOM- 19951109
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 24
IP  - 25
DP  - 1995 Sep 2-9
TI  - [Intra-alveolar hemorrhage. An uncommon accident in a breath holding diver].
PG  - 1169-70
AB  - To date, pulmonary oedema in breath hold divers has only been reported after 
      dives below 50 meters, hypoxaemic syncope being the most common risk. We recently 
      observed a 35-year-old well-trained breath hold diver who was unable to achieve 
      deep inspiration during a high-level competition. After two hours of repeated 
      dives to a depth of 25 meters for approximately 2-minute periods with 
      intermittent recovery the patient developed cough and haemoptysis. The chest 
      X-ray revealed lung images suggestive of intra-alveolar haemorrhage. The patient 
      had taken 1 g of aspirin per os for three days prior to diving. Symptoms subsided 
      spontaneously in 48 hours and one month later all haematology tests were normal 
      except for minimal alteration of platelet aggregation. Pulmonary oedema in breath 
      hold divers is usually attributed to blood shift to the pulmonary circulation 
      related to the lowered intra-thoracic pressure. In our case, oedema was secondary 
      to intra-alveolar haemorrhage favoured by aspirin which should be avoided before 
      breath hold diving.
FAU - Boussuges, A
AU  - Boussuges A
AD  - Service de Réanimation médicale et d'Hyperbarie, Hôpital Salvator, Marseille.
FAU - Succo, E
AU  - Succo E
FAU - Bergmann, E
AU  - Bergmann E
FAU - Sainty, J M
AU  - Sainty JM
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Hémorragie intra-alvéolaire. Un accident inhabituel chez un plongeur en apnée.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Apnea/complications/*etiology
MH  - Aspirin/adverse effects
MH  - Diving/*injuries
MH  - Hemorrhage/*etiology
MH  - Humans
MH  - Male
MH  - Pulmonary Alveoli
MH  - Pulmonary Edema/*etiology
MH  - Risk Factors
EDAT- 1995/09/02 00:00
MHDA- 1995/09/02 00:01
CRDT- 1995/09/02 00:00
PHST- 1995/09/02 00:00 [pubmed]
PHST- 1995/09/02 00:01 [medline]
PHST- 1995/09/02 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1995 Sep 2-9;24(25):1169-70.

PMID- 759237
OWN - NLM
STAT- MEDLINE
DCOM- 19790313
LR  - 20131121
IS  - 0014-9446 (Print)
IS  - 0014-9446 (Linking)
VI  - 38
IP  - 1
DP  - 1979 Jan
TI  - Fever versus hyperthermia.
PG  - 39-43
AB  - A variety of conditions that result in the elevation of body temperature are 
      described and discussed. These hyperthermias are divided into four categories; 
      fever, exercise hyperthermia, hyperthermias due to inadequate means of heat 
      dissipation, and hyperthermias resulting from pathological or pharmacological 
      impairments of thermoregulatory mechanisms. A comparison of the physical and 
      physiological characteristics of these hyperthermias is presented and 
      distinctions are drawn on the basis of these characteristics. Fever is shown to 
      differ markedly from all other forms of hyperthermias. Specifically, the 
      elevation in body temperature encountered during fever is a regulated rise that 
      is defended by fully functional thermoregulatory mechanisms; the 
      thermopreferendum is also elevated in fever, particularly at the onset or "chill 
      phase"; and aspirin-like drugs can intervene in febrile hyperthermia and will 
      return body temperature to its normal level. No other forms of hyperthermia 
      possess these characteristics and thus only fever can be attributed to an upward 
      displacement of the "set point" for body temperature regulation. Furthermore, in 
      attempting to control rises in body temperature, it is apparent that aspirin is 
      effective only in fever, while whole-body cooling is all but ineffective. In all 
      other forms of hyperthermia, whole-body cooling is the only effective treatment.
FAU - Stitt, J T
AU  - Stitt JT
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Fed Proc
JT  - Federation proceedings
JID - 0372771
RN  - 0 (Biogenic Amines)
RN  - 7C0697DR9I (Atropine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Atropine/pharmacology
MH  - Behavior/physiology
MH  - Behavior, Animal/physiology
MH  - Biogenic Amines/metabolism
MH  - *Body Temperature Regulation/drug effects
MH  - Environment
MH  - Fever/*physiopathology
MH  - Humans
MH  - Hypothalamus/physiopathology
MH  - Physical Exertion
MH  - Terminology as Topic
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Fed Proc. 1979 Jan;38(1):39-43.

PMID- 665434
OWN - NLM
STAT- MEDLINE
DCOM- 19780828
LR  - 20190823
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 8
IP  - 3
DP  - 1978 Apr
TI  - A comparison of the anti-inflammatory effects of copper aspirinate and other 
      copper salts in the rat and guinea pig.
PG  - 244-50
AB  - A comparison of the anti-inflammatory (AI) activity of copper compounds in models 
      of kaolin-induced paw oedema and u.v. erythema in the rat and guinea pig is 
      described. The results demonstrated considerable species variation, the guinea 
      pig being more sensitive to the AI and irritant effects of copper aspirinate and 
      the other copper compounds. The route of administration of these compounds was 
      also an important factor in interpreting AI activity obtained. Indeed, the 
      counter-irritation effects of the copper compounds may be largely responsible for 
      the AI activity obtained after subcutaneous administration. The comparison 
      between copper aspirinate and aspirin, performed in order to determine whether a 
      copper complex of an AI drug was more active than the parent AI compound, failed 
      to produce a clear difference in activity although copper aspirinate was more 
      effective than aspirin in certain cases. It is concluded that this study 
      highlights the complexities of copper therapy against inflammatory processes and 
      furthermore indicates the importance of species, the model of inflammation and 
      route of drug administration in interpreting data obtained with copper containing 
      compounds.
FAU - Lewis, A J
AU  - Lewis AJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Irritants)
RN  - 24H4NWX5CO (Kaolin)
RN  - 789U1901C5 (Copper)
RN  - J41CSQ7QDS (Zinc)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Anti-Inflammatory Agents
MH  - Aspirin/*pharmacology
MH  - Copper/*pharmacology
MH  - Female
MH  - Guinea Pigs
MH  - Irritants
MH  - Kaolin/antagonists & inhibitors
MH  - Male
MH  - Rats
MH  - Species Specificity
MH  - Stomach/drug effects
MH  - Time Factors
MH  - Zinc/pharmacology
EDAT- 1978/04/01 00:00
MHDA- 1978/04/01 00:01
CRDT- 1978/04/01 00:00
PHST- 1978/04/01 00:00 [pubmed]
PHST- 1978/04/01 00:01 [medline]
PHST- 1978/04/01 00:00 [entrez]
AID - 10.1007/BF01966610 [doi]
PST - ppublish
SO  - Agents Actions. 1978 Apr;8(3):244-50. doi: 10.1007/BF01966610.

PMID- 34059446
OWN - NLM
STAT- MEDLINE
DCOM- 20220201
LR  - 20220201
IS  - 1878-3562 (Electronic)
IS  - 1590-8658 (Linking)
VI  - 53
IP  - 7
DP  - 2021 Jul
TI  - A novel gene associated with small bowel bleeding in patients taking low-dose 
      aspirin.
PG  - 841-845
LID - S1590-8658(21)00243-7 [pii]
LID - 10.1016/j.dld.2021.04.038 [doi]
AB  - OBJECTIVE: We have previously revealed the clinical factors and genetic 
      polymorphisms associated with gastrointestinal mucosal injury and bleeding, 
      induced by low-dose aspirin (LDA). After performing genome-wide analysis of 
      single nucleotide polymorphisms (SNPs) using the Drug Metabolizing Enzymes and 
      Transporters (DMET) system among drug metabolism and transporter genes, certain 
      SNPs were found to increase the risk for LDA-induced small bowel bleeding. The 
      aim of this study was to identify the SNPs involved in LDA-induced small bowel 
      bleeding. SUBJECTS AND METHODS: Subjects were patients taking LDA, with small 
      bowel bleeding diagnosed using capsule endoscopy. We investigated the clinical 
      characteristics and the previously identified SNPs, that were examined by the DNA 
      direct sequence method. RESULTS: 56 patients with bleeding and 410 controls 
      taking LDA were enrolled. The risk factors associated with small bowel bleeding 
      included smoking, cerebrovascular diseases, chronic renal failure, non-steroidal 
      anti-inflammatory drug (NSAID) or anticoagulants combination, and two SNPs 
      (CYP4F11 20043G>A (D446N) rs1060463, GSTP1 313A>G rs1695). After propensity score 
      matching, GSTP1 rs1695 was significantly associated with small bowel bleeding. 
      CONCLUSION: The GSTP1 SNP may be a predictive marker for small bowel bleeding 
      among patients taking LDA.
CI  - Copyright © 2021 Editrice Gastroenterologica Italiana S.r.l. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Handa, Yukiko
AU  - Handa Y
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Kurashiki City, Okayama, Japan. Electronic address: 
      yukko0903handaclinic@gmail.com.
FAU - Fukushima, Shinya
AU  - Fukushima S
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Kurashiki City, Okayama, Japan.
FAU - Yo, Shogen
AU  - Yo S
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Kurashiki City, Okayama, Japan.
FAU - Osawa, Motoyasu
AU  - Osawa M
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Kurashiki City, Okayama, Japan.
FAU - Murao, Takahisa
AU  - Murao T
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Kurashiki City, Okayama, Japan.
FAU - Handa, Osamu
AU  - Handa O
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Kurashiki City, Okayama, Japan.
FAU - Matsumoto, Hiroshi
AU  - Matsumoto H
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Kurashiki City, Okayama, Japan.
FAU - Umegaki, Eiji
AU  - Umegaki E
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Kurashiki City, Okayama, Japan.
FAU - Sakakibara, Takashi
AU  - Sakakibara T
AD  - Department of Gastroenterology, The Sakakibara Heart Institute of Okayama, 
      Okayama City, Okayama, Japan.
FAU - Shiotani, Akiko
AU  - Shiotani A
AD  - Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical 
      School, Kurashiki City, Okayama, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210528
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - EC 1.14.14.1 (Cytochrome P450 Family 4)
RN  - EC 1.14.14.78 (CYP4F11 protein, human)
RN  - EC 2.5.1.18 (GSTP1 protein, human)
RN  - EC 2.5.1.18 (Glutathione S-Transferase pi)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Capsule Endoscopy
MH  - Cytochrome P450 Family 4/*genetics
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced/*genetics
MH  - Genome-Wide Association Study
MH  - Glutathione S-Transferase pi/*genetics
MH  - Humans
MH  - Intestinal Diseases/chemically induced/*genetics
MH  - Intestine, Small/pathology
MH  - Male
MH  - Pharmacogenomic Variants/*genetics
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Propensity Score
MH  - Risk Factors
OTO - NOTNLM
OT  - CYP4F11
OT  - GSTP-1
OT  - Single nucleotide polymorphism
OT  - Small bowel bleeding
COIS- Declaration of Competing Interest None.
EDAT- 2021/06/02 06:00
MHDA- 2022/02/02 06:00
CRDT- 2021/06/01 05:55
PHST- 2021/03/08 00:00 [received]
PHST- 2021/04/30 00:00 [revised]
PHST- 2021/04/30 00:00 [accepted]
PHST- 2021/06/02 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
PHST- 2021/06/01 05:55 [entrez]
AID - S1590-8658(21)00243-7 [pii]
AID - 10.1016/j.dld.2021.04.038 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2021 Jul;53(7):841-845. doi: 10.1016/j.dld.2021.04.038. Epub 2021 
      May 28.

PMID- 22975664
OWN - NLM
STAT- MEDLINE
DCOM- 20130826
LR  - 20181202
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
VI  - 20
IP  - 2
DP  - 2013 Mar-Apr
TI  - Efficacy of cilostazol in patients with acute coronary syndrome after 
      percutaneous coronary intervention.
PG  - 151-3
LID - 10.1097/MJT.0b013e31825a3616 [doi]
AB  - The objective of this study was to explore the long-term effect of 
      cilostazol-optimized antiplatelet therapy after percutaneous coronary 
      intervention (PCI) in patients with acute coronary syndrome (ACS). One hundred 
      forty-six patients with ACS who underwent PCI were enrolled. Patients were 
      randomly divided into 2 groups based on clot rate (CR), and both groups received 
      antiplatelet therapy: aspirin and clopidogrel plus cilostazol (intensification 
      group, n = 72) or aspirin and clopidogrel (control group, n = 74). Clinical 
      follow-up was up to 12 months after PCI. During follow-up, CR was determined at 
      day 1 and at 1, 3, 6, and 12 months post-PCI. Efficacy endpoints included second 
      acute myocardial infarction, in-stent thrombosis, revascularization (second PCI), 
      sudden death, and hemorrhage. CR was significantly lower in the intensification 
      group than in the control group at 1, 3, and 6 months after PCI (P < 0.05). The 
      incidences of second acute myocardial infarction, in-stent thrombosis, 
      revascularization (second PCI), and sudden cardiac death were also lower but 
      insignificant; there were no hemorrhage events (P > 0.05). Cilostazol-optimized 
      antiplatelet therapy can significantly decrease CR after PCI in patients with 
      acute coronary syndrome.
FAU - Hu, Taohong
AU  - Hu T
AD  - Department of Cardiology, Second Affiliated Hospital of Wuhan University, Wuhan, 
      China.
FAU - Ma, Huili
AU  - Ma H
FAU - Li, Huijun
AU  - Li H
FAU - Ren, Jianghua
AU  - Ren J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - A74586SNO7 (Clopidogrel)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Cilostazol
MH  - Clopidogrel
MH  - Combined Modality Therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Tetrazoles/administration & dosage/*therapeutic use
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2012/09/15 06:00
MHDA- 2013/08/27 06:00
CRDT- 2012/09/15 06:00
PHST- 2012/09/15 06:00 [entrez]
PHST- 2012/09/15 06:00 [pubmed]
PHST- 2013/08/27 06:00 [medline]
AID - 10.1097/MJT.0b013e31825a3616 [doi]
PST - ppublish
SO  - Am J Ther. 2013 Mar-Apr;20(2):151-3. doi: 10.1097/MJT.0b013e31825a3616.

PMID- 35306003
OWN - NLM
STAT- MEDLINE
DCOM- 20230130
LR  - 20230202
IS  - 0150-9861 (Print)
IS  - 0150-9861 (Linking)
VI  - 50
IP  - 1
DP  - 2023 Feb
TI  - Low incidence of hemorrhagic complications both during and after surgical 
      procedures in patients maintained on prasugrel single antiplatelet therapy.
PG  - 65-73
LID - S0150-9861(22)00100-6 [pii]
LID - 10.1016/j.neurad.2022.03.004 [doi]
AB  - BACKGROUND AND PURPOSE: Prasugrel (Pra) is a third-generation thienopyridine that 
      inhibits platelet aggregation via irreversible blockade of P2Y12 receptors. While 
      several published studies have examined the use of Pra and acetylsalicylic acid 
      (ASA) in coronary and neurovascular stenting procedures, there is only anecdotal 
      evidence regarding the use of Pra as single antiplatelet therapy (SAPT) in open 
      surgical procedures. This topic has become important because previous studies 
      have revealed that neurovascular devices with antithrombotic coatings can be 
      implanted using non-invasive procedures in patients maintained on Pra SAPT. 
      MATERIAL AND METHODS: Patients who underwent open surgery under Pra SAPT between 
      March 2020 and February 2022 were evaluated retrospectively. Adequate platelet 
      inhibition both before and after the procedures was verified in all patients 
      using Multiplate (Roche Diagnostics) and VerifyNow (Accriva) tests. 
      Intraoperative and postoperative hemorrhagic events were recorded based on 
      reviews of the procedure reports and interviews with the surgeons. RESULTS: The 
      study enrolled 21 patients who underwent 23 open surgical procedures while 
      maintained on Pra SAPT. The procedures included one extirpation of a brain 
      arteriovenous malformation, seven extra-intracranial bypass surgeries, four 
      ventriculoperitoneal shunts, one eye enucleation for an intractable orbital 
      infection, two gastrostomies, one bone flap reinsertion after craniectomy, one 
      decompressive craniectomy, one case requiring cranial surgical wound care, one 
      colporrhaphy, one transurethral resection of urinary bladder cancer, two tumor 
      oophorectomy/hysterectomy procedures, and one aneurysm clipping. None of the 23 
      procedures resulted in excessive intraoperative or postoperative hemorrhage. 
      CONCLUSION: In a small retrospective series of patients who required antiplatelet 
      therapy for neurovascular indications, Pra SAPT resulted in no significant 
      increase in the incidence of perioperative and postoperative hemorrhagic 
      complications.
CI  - Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Khanafer, Ali
AU  - Khanafer A
AD  - Neuroradiologische Klinik, Klinikum Stuttgart, Stuttgart, Germany. Electronic 
      address: mr-khanafer@hotmail.com.
FAU - Cimpoca, Alexandru
AU  - Cimpoca A
AD  - Neuroradiologische Klinik, Klinikum Stuttgart, Stuttgart, Germany.
FAU - Bhogal, Paul
AU  - Bhogal P
AD  - Department of Interventional Neuroradiology, The Royal London Hospital, London, 
      UK.
FAU - Babiy-Pachomow, Oksana
AU  - Babiy-Pachomow O
AD  - Frauenklinik, Schwerpunkt Gynäkologie, Klinikum Stuttgart, Stuttgart, Germany.
FAU - Kurucz, Peter
AU  - Kurucz P
AD  - Neurochirurgische Klinik, Klinikum Stuttgart, Stuttgart, Germany.
FAU - Ganslandt, Oliver
AU  - Ganslandt O
AD  - Neurochirurgische Klinik, Klinikum Stuttgart, Stuttgart, Germany.
FAU - Henkes, Hans
AU  - Henkes H
AD  - Neuroradiologische Klinik, Klinikum Stuttgart, Stuttgart, Germany; Medical 
      Faculty, Universität Duisburg-Essen, Essen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20220317
PL  - France
TA  - J Neuroradiol
JT  - Journal of neuroradiology = Journal de neuroradiologie
JID - 7705086
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Humans
MH  - Prasugrel Hydrochloride/therapeutic use
MH  - *Platelet Aggregation Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - Incidence
MH  - *Aspirin/adverse effects
OTO - NOTNLM
OT  - Antithrombogenic coating
OT  - Flow diverter
OT  - Hydrophilic coating
OT  - P2Y12 receptor inhibition
OT  - Prasugrel
OT  - Single antiplatelet therapy
COIS- Conflicts of Interest Researchers were blinded during the review process.
EDAT- 2022/03/21 06:00
MHDA- 2023/01/31 06:00
CRDT- 2022/03/20 20:26
PHST- 2022/02/20 00:00 [received]
PHST- 2022/03/09 00:00 [accepted]
PHST- 2022/03/21 06:00 [pubmed]
PHST- 2023/01/31 06:00 [medline]
PHST- 2022/03/20 20:26 [entrez]
AID - S0150-9861(22)00100-6 [pii]
AID - 10.1016/j.neurad.2022.03.004 [doi]
PST - ppublish
SO  - J Neuroradiol. 2023 Feb;50(1):65-73. doi: 10.1016/j.neurad.2022.03.004. Epub 2022 
      Mar 17.

PMID- 33307284
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 198
DP  - 2021 Feb
TI  - Glycation and acetylation sites on fibrinogen in plasma fibrin clot of patients 
      with type 2 diabetes: Effects of low-dose acetylsalicylic acid.
PG  - 93-98
LID - S0049-3848(20)30639-3 [pii]
LID - 10.1016/j.thromres.2020.11.031 [doi]
AB  - Acetylsalicylic acid (ASA) and type 2 diabetes mellitus (T2DM) affect fibrin clot 
      properties through fibrinogen acetylation or glycation. We aimed to identify 
      glycation and acetylation sites on fibrinogen in plasma fibrin clot of T2DM 
      patients with respect to effects of ASA and fibrin clot properties. In fibrin 
      clots generated from plasma of 9 T2DM patients, we performed mass-spectrometric 
      analysis of Nε-fructosyl-(FL), Nε-carboxyethyl-(CEL) and Nε-carboxymethyl-lysine 
      (CML), and acetylation sites, before and after one-month administration of 
      75 mg/d ASA confirmed with determination of thromboxane B2 concentration 
      (TXB(2)), along with clot permeability and lysis time, and thrombin generation. 
      In the proteomic analysis, 216 proteins were identified. Among 10 glycation sites 
      identified in α, 10 in β and 6 in γ fibrinogen chain, there were 17 FL, 5 CEL and 
      4 CML sites. Some of glycation sites in fibrinogen were previously reported to be 
      involved in cross-linking by factor XIII (αK-208, αK-448 and αK-539) and plasmin 
      cleavage (αK-81). There were 7 acetylation sites in α and β chains, and none in 
      fibrinogen γ chain. Two acetylation sites were identical with FL sites (αK-195 
      and β-247), while one with CML site (βK-353). In 7 patients with low post-ASA 
      TXB(2), intensity of acetylation, as well as clot properties were unaffected by 
      ASA. This study identifies glycation and acetylation sites on fibrinogen in 
      plasma fibrin clot of T2DM and supports the view that low-dose ASA does not 
      increase fibrinogen acetylation in T2DM. Our findings suggest that glycation may 
      block sites previously identified to be acetylated in vitro.
CI  - Copyright © 2020 Elsevier Ltd. All rights reserved.
FAU - Bryk, Agata Hanna
AU  - Bryk AH
AD  - Jagiellonian University Medical College, Krakow, Poland; John Paul II Hospital, 
      Krakow, Poland.
FAU - Zettl, Katharina
AU  - Zettl K
AD  - Department of Proteomics and Signal Transduction, Max Planck Institute of 
      Biochemistry, Martinsried, Germany.
FAU - Wiśniewski, Jacek R
AU  - Wiśniewski JR
AD  - Department of Proteomics and Signal Transduction, Max Planck Institute of 
      Biochemistry, Martinsried, Germany.
FAU - Undas, Anetta
AU  - Undas A
AD  - Jagiellonian University Medical College, Krakow, Poland; John Paul II Hospital, 
      Krakow, Poland. Electronic address: mmundas@cyf-kr.edu.pl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201128
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 9001-31-4 (Fibrin)
RN  - 9001-32-5 (Fibrinogen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylation
MH  - Aspirin/therapeutic use
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Fibrin/metabolism
MH  - Fibrinogen/metabolism
MH  - Fibrinolysis
MH  - Humans
MH  - Proteomics
OTO - NOTNLM
OT  - Acetylation
OT  - Acetylsalicylic acid
OT  - Fibrinogen
OT  - Glycation
OT  - Type 2 diabetes mellitus
EDAT- 2020/12/12 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/12/11 20:10
PHST- 2020/06/15 00:00 [received]
PHST- 2020/10/10 00:00 [revised]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/12/11 20:10 [entrez]
AID - S0049-3848(20)30639-3 [pii]
AID - 10.1016/j.thromres.2020.11.031 [doi]
PST - ppublish
SO  - Thromb Res. 2021 Feb;198:93-98. doi: 10.1016/j.thromres.2020.11.031. Epub 2020 
      Nov 28.

PMID- 8555864
OWN - NLM
STAT- MEDLINE
DCOM- 19960226
LR  - 20190501
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 312
IP  - 7022
DP  - 1996 Jan 6
TI  - ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation.
PG  - 45-9
AB  - Antithrombotic prophylaxis with long term warfarin or aspirin reduces 
      thromboembolic risk in atrial fibrillation. Identification, risk assessment, and 
      regular review of all patients with atrial fibrillation should be routine in 
      general and hospital practice. Risk stratification is easily performed on 
      clinical grounds--echocardiography may refine it.
FAU - Lip, G Y
AU  - Lip GY
AD  - University Department of Medicine, City Hospital, Birmingham.
FAU - Lowe, G D
AU  - Lowe GD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Cerebrovascular Disorders/prevention & control
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Risk Factors
MH  - Thromboembolism/*prevention & control
MH  - Warfarin/*therapeutic use
PMC - PMC2349725
EDAT- 1996/01/06 00:00
MHDA- 1996/01/06 00:01
CRDT- 1996/01/06 00:00
PHST- 1996/01/06 00:00 [pubmed]
PHST- 1996/01/06 00:01 [medline]
PHST- 1996/01/06 00:00 [entrez]
AID - 10.1136/bmj.312.7022.45 [doi]
PST - ppublish
SO  - BMJ. 1996 Jan 6;312(7022):45-9. doi: 10.1136/bmj.312.7022.45.

PMID- 19780138
OWN - NLM
STAT- MEDLINE
DCOM- 20100402
LR  - 20151119
IS  - 1520-6017 (Electronic)
IS  - 0022-3549 (Linking)
VI  - 99
IP  - 3
DP  - 2010 Mar
TI  - Dielectric study of equimolar acetaminophen-aspirin, acetaminophen-quinidine, and 
      benzoic acid-progesterone molecular alloys in the glass and ultraviscous states 
      and their relevance to solubility and stability.
PG  - 1358-74
LID - 10.1002/jps.21930 [doi]
AB  - Equimolar mixtures of acetaminophen-aspirin, acetaminophen-quinidine, and benzoic 
      acid-progesterone have been vitrified and dielectric properties of their glassy 
      and ultraviscous alloys have been studied. For 20 K/min heating rate, their T(g)s 
      are 266, 330, and 263 K, respectively. The relaxation has an asymmetric 
      distribution of times, and the distribution parameter increases with increase in 
      temperature. The dielectric relaxation time varies with T according to the 
      Vogel-Fulcher-Tammann equation, log(10)(tau(0)) = A(VFT) + [B(VFT)/(T - T(0))], 
      where A(VFT), B(VFT), and T(0) are empirical constants. The equilibrium 
      permittivity is highest for the aspirin-acetaminophen and lowest for the benzoic 
      acid-progesterone alloy, indicating a substantial interpharmaceutical hydrogen 
      bonding that makes the alloy more stable against crystallization than the pure 
      components. The benzoic acid-progesterone alloy is thermodynamically the most 
      nonideal. It showed cold crystallization on heating, which is attributed to its 
      relatively greater magnitude of the JG relaxation in relation to its 
      alpha-relaxation. It is argued that the difference between the free energy of an 
      alloy and the pure components would have an effect on the solubility. Studies of 
      solution thermodynamics of a glassy molecular alloy may be useful for optimizing 
      choice of components and composition to form molecular alloys and to impact drug 
      delivery.
CI  - 2009 Wiley-Liss, Inc. and the American Pharmacists Association
FAU - Johari, G P
AU  - Johari GP
AD  - Department of Materials Science and Engineering, McMaster University, Hamilton, 
      Ontario, Canada L8S 4L7. joharig@mcmaster.ca
FAU - Kim, S
AU  - Kim S
FAU - Shanker, Ravi M
AU  - Shanker RM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Alloys)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 4G7DS2Q64Y (Progesterone)
RN  - 8SKN0B0MIM (Benzoic Acid)
RN  - ITX08688JL (Quinidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*chemistry
MH  - Alloys/*chemistry
MH  - Aspirin/*chemistry
MH  - Benzoic Acid/*chemistry
MH  - *Drug Stability
MH  - Electrochemical Techniques/methods
MH  - Glass
MH  - Kinetics
MH  - Progesterone/*chemistry
MH  - Quinidine/*chemistry
MH  - Solubility
MH  - Thermodynamics
MH  - Transition Temperature
MH  - Viscosity
EDAT- 2009/09/26 06:00
MHDA- 2010/04/03 06:00
CRDT- 2009/09/26 06:00
PHST- 2009/09/26 06:00 [entrez]
PHST- 2009/09/26 06:00 [pubmed]
PHST- 2010/04/03 06:00 [medline]
AID - S0022-3549(15)32736-2 [pii]
AID - 10.1002/jps.21930 [doi]
PST - ppublish
SO  - J Pharm Sci. 2010 Mar;99(3):1358-74. doi: 10.1002/jps.21930.

PMID- 23727111
OWN - NLM
STAT- MEDLINE
DCOM- 20140812
LR  - 20181202
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 168
IP  - 3
DP  - 2013 Oct 3
TI  - Refuting the ticagrelor-aspirin black box warning: and proposing a ticagrelor 
      early-PCI black box warning.
PG  - 1721-3
LID - S0167-5273(13)00988-1 [pii]
LID - 10.1016/j.ijcard.2013.05.060 [doi]
AB  - CONTEXT: Ticagrelor, a novel reversible antiplatelet agent, has a black box 
      warning to avoid maintenance doses of aspirin>100mg. However, a significant 
      ticagrelor-early percutaneous coronary intervention (PCI) interaction exists. 
      OBJECTIVE: To discuss the inappropriateness of the black box warning for aspirin 
      doses>100mg with ticagrelor and the appropriateness (and need) for a black box 
      warning for ticagrelor patients needing early (within 24 hours of randomization) 
      PCI. RESULTS: The FDA Complete Response Review for ticagrelor indicates that 
      aspirin doses ≥ 300 mg/daily was not a significant interaction. In the 
      ticagrelor-aspirin ≥ 300 mg cohort, all-cause mortality (through study end) and 
      cardiovascular (CV) mortality (through study end) were not significantly 
      increased (HR=1.27; 95% CI, 0.84-1.93, p=0.262 and HR=1.39; 95% CI:0.87-2.2, 
      p=0.170), respectively. However, in patients treated with early (within 24 hours) 
      PCI, ticagrelor significantly increased all-cause mortality (30 day: HR=1.89; 95% 
      CI: 1.26-2.81, p=0.002, and through study end, HR=1.41; 95% CI,1.08-1.84, 
      p=0.012) and increased CV mortality (30 day: HR=1.31; 95% CI: 0.97-1.77, p=0.075, 
      and through study end, HR=1.35; 95% CI, 0.995-1.82, p=0.054) compared to 
      clopidogrel. CONCLUSIONS: Early-PCI was more prevalent in the US versus 
      outside-US regions (61% versus 49%). The black box warning for the use of 
      maintenance aspirin doses over 100mg/daily with ticagrelor is inappropriate and 
      ignores the more important, credible, and highly significant ticagrelor-early PCI 
      adverse interaction in PLATO.
CI  - Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - DiNicolantonio, James J
AU  - DiNicolantonio JJ
AD  - Wegmans Pharmacy, 500 South Meadow Street, Ithaca NY 14850, United States. 
      Electronic address: jjdinicol@gmail.com.
FAU - Serebruany, Victor L
AU  - Serebruany VL
FAU - Tomek, Ales
AU  - Tomek A
LA  - eng
PT  - Editorial
DEP - 20130530
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Adenosine/*analogs & derivatives/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Purinergic P2Y Receptor Antagonists/therapeutic use
MH  - Ticagrelor
MH  - Time Factors
OTO - NOTNLM
OT  - Clinical Trials
OT  - Clopidogrel
OT  - Percutaneous Coronary Interventions
OT  - Ticagrelor
EDAT- 2013/06/04 06:00
MHDA- 2014/08/13 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/04/01 00:00 [received]
PHST- 2013/05/04 00:00 [accepted]
PHST- 2013/06/04 06:00 [entrez]
PHST- 2013/06/04 06:00 [pubmed]
PHST- 2014/08/13 06:00 [medline]
AID - S0167-5273(13)00988-1 [pii]
AID - 10.1016/j.ijcard.2013.05.060 [doi]
PST - ppublish
SO  - Int J Cardiol. 2013 Oct 3;168(3):1721-3. doi: 10.1016/j.ijcard.2013.05.060. Epub 
      2013 May 30.

PMID- 20860677
OWN - NLM
STAT- MEDLINE
DCOM- 20110411
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 8
IP  - 12
DP  - 2010 Dec
TI  - Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable 
      cardiovascular patients from the ADRIE study.
PG  - 2614-23
LID - 10.1111/j.1538-7836.2010.04063.x [doi]
AB  - BACKGROUND: Poor response to both aspirin and clopidogrel (dual poor 
      responsiveness [DPR]) is a major risk factor for recurrent ischemic events. 
      OBJECTIVES: The aim of this study was to identify factors associated with DPR, 
      defined with specific tests, and derive a predictive clinical score. METHODS: We 
      studied 771 consecutive stable cardiovascular patients treated with aspirin (n = 
      223), clopidogrel (n = 111), or both drugs (n = 37). Aspirin responsiveness was 
      evaluated by serum thromboxane (Tx)B₂ assay, and clopidogrel responsiveness by 
      calculating the platelet reactivity index (PRI) on the basis of the 
      phosphorylation status of the vasodilator phosphoprotein. The analysis was 
      focused on patients treated with both drugs, and on independent predictors of 
      DPR. RESULTS: Among patients on dual therapy, there was no relevant correlation 
      between TxB₂ levels and PRI values (r = 0.11). Sixty-seven patients (15.4%) had 
      DPR. Diabetes [odds ratio (OR) 1.89, 95% confidence interval (CI) 1.06-3.39], 
      high body weight (> 86 kg vs. < 77 kg, OR 4.74, 95% CI 2.49-9.73), low aspirin 
      dose (75-81 mg vs. ≥ 160 mg, OR 0.12, 95% CI 0.09-0.93) and high C-reactive 
      protein (CRP) level (> 1.6 mg L⁻¹ vs. < 0.6 mg L⁻¹, OR 3.66, 95% CI 1.74-8.72) 
      were independently associated with DPR, via increased TxB(2) levels, increased 
      PRI, or both. These associations with TxB₂ and PRI were reproduced across the 
      whole population. With use of a factor-weighed score (c-index = 0.74), the 
      predicted prevalence of DPR was 57% in the highest strata of the score as 
      compared with < 4% for the lowest strata. CONCLUSIONS: Diabetes, body weight, the 
      aspirin dose and CRP levels are readily available independent predictors of DPR, 
      and some are potential targets for reducing its prevalence.
CI  - © 2010 International Society on Thrombosis and Haemostasis.
FAU - Fontana, P
AU  - Fontana P
AD  - Division of Angiology and Hemostasis, Geneva University Hospital and Faculty of 
      Medicine, Geneva, Switzerland.
FAU - Berdagué, P
AU  - Berdagué P
FAU - Castelli, C
AU  - Castelli C
FAU - Nolli, S
AU  - Nolli S
FAU - Barazer, I
AU  - Barazer I
FAU - Fabbro-Peray, P
AU  - Fabbro-Peray P
FAU - Schved, J-F
AU  - Schved JF
FAU - Bounameaux, H
AU  - Bounameaux H
FAU - Mach, F
AU  - Mach F
FAU - DE Moerloose, P
AU  - DE Moerloose P
FAU - Reny, J-L
AU  - Reny JL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prognosis
MH  - Purinergic P2Y Receptor Antagonists/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2010/09/24 06:00
MHDA- 2011/04/13 06:00
CRDT- 2010/09/24 06:00
PHST- 2010/09/24 06:00 [entrez]
PHST- 2010/09/24 06:00 [pubmed]
PHST- 2011/04/13 06:00 [medline]
AID - S1538-7836(22)06641-7 [pii]
AID - 10.1111/j.1538-7836.2010.04063.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2010 Dec;8(12):2614-23. doi: 10.1111/j.1538-7836.2010.04063.x.

PMID- 16500579
OWN - NLM
STAT- MEDLINE
DCOM- 20061003
LR  - 20131121
IS  - 1532-8414 (Electronic)
IS  - 1071-9164 (Linking)
VI  - 12
IP  - 1
DP  - 2006 Feb
TI  - Warfarin versus aspirin in patients with reduced cardiac ejection fraction 
      (WARCEF): rationale, objectives, and design.
PG  - 39-46
AB  - BACKGROUND: Warfarin is widely prescribed for patients with heart failure without 
      level 1 evidence, and an adequately powered randomized study is needed. METHODS 
      AND RESULTS: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction 
      study is a National Institutes of Health-funded, randomized, double-blind 
      clinical trial with a target enrollment of 2860 patients. It is designed to test 
      with 90% power the 2-sided primary null hypothesis of no difference between 
      warfarin (International Normalized Ratio 2.5-3) and aspirin (325 mg) in 3- to 
      5-year event-free survival for the composite endpoint of death, or stroke 
      (ischemic or hemorrhagic) among patients with cardiac ejection fraction < or =35% 
      who do not have atrial fibrillation or mechanical prosthetic heart valves. 
      Secondary analyses will compare warfarin and aspirin for reduction of all-cause 
      mortality, ischemic stroke, and myocardial infarction (MI), balanced against the 
      risk of intracerebral hemorrhage, among women and African Americans; and compare 
      warfarin and aspirin for prevention of stroke alone. Randomization is stratified 
      by site, New York Heart Association (NYHA) heart class (I vs II-IV), and stroke 
      or transient ischemic attack (TIA) within 1 year before randomization versus no 
      stroke or TIA in that period. NYHA class I patients will not exceed 20%, and the 
      study has a target of 20% (or more) patients with stroke or TIA within 12 months. 
      Randomized patients receive active warfarin plus placebo or active aspirin plus 
      placebo, double-blind. CONCLUSION: The results should help guide the selection of 
      optimum antithrombotic therapy for patients with left ventricular dysfunction.
FAU - Pullicino, Patrick
AU  - Pullicino P
AD  - Department of Neurology and Neurosciences, New Jersey Medical School, UMDNJ, 
      Newark, USA.
FAU - Thompson, John L P
AU  - Thompson JL
FAU - Barton, Bruce
AU  - Barton B
FAU - Levin, Bruce
AU  - Levin B
FAU - Graham, Susan
AU  - Graham S
FAU - Freudenberger, Ronald S
AU  - Freudenberger RS
CN  - WARCEF Investigators
LA  - eng
GR  - U-01 NS39143/NS/NINDS NIH HHS/United States
GR  - U01 NS43975/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cardiac Output, Low/*drug therapy/*physiopathology
MH  - Double-Blind Method
MH  - Female
MH  - Goals
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Research Design
MH  - *Stroke Volume
MH  - Warfarin/*therapeutic use
EDAT- 2006/02/28 09:00
MHDA- 2006/10/04 09:00
CRDT- 2006/02/28 09:00
PHST- 2003/06/19 00:00 [received]
PHST- 2005/07/20 00:00 [revised]
PHST- 2005/07/22 00:00 [accepted]
PHST- 2006/02/28 09:00 [pubmed]
PHST- 2006/10/04 09:00 [medline]
PHST- 2006/02/28 09:00 [entrez]
AID - S1071-9164(05)00715-3 [pii]
AID - 10.1016/j.cardfail.2005.07.007 [doi]
PST - ppublish
SO  - J Card Fail. 2006 Feb;12(1):39-46. doi: 10.1016/j.cardfail.2005.07.007.

PMID- 24462669
OWN - NLM
STAT- MEDLINE
DCOM- 20141014
LR  - 20140217
IS  - 1873-426X (Electronic)
IS  - 0008-6215 (Linking)
VI  - 386
DP  - 2014 Mar 11
TI  - Synthesis of bis-cellobiose and bis-glucose derivatives of azacrown macrocycles 
      as hosts in complexes with acetylsalicylic acid and 4-acetamidophenol.
PG  - 18-22
LID - S0008-6215(13)00439-4 [pii]
LID - 10.1016/j.carres.2013.12.017 [doi]
AB  - Two new C2 symmetric bis-cellobiose and bis-glucose azacrown derivatives were 
      prepared according to the one-step procedure using azacrown ethers and 
      azidosaccharides. Their complexes with aspirin and paracetamol were studied with 
      the use of proton NMR spectroscopy. It was found that these pseudocryptands bind 
      aspirin and paracetamol but each one in a different manner.
CI  - Copyright © 2014 Elsevier Ltd. All rights reserved.
FAU - Pintal, Michalina
AU  - Pintal M
AD  - Department of Organic and Applied Chemistry, University of Łódź, Tamka 12, 91-403 
      Łódź, Poland.
FAU - Kryczka, Bogusław
AU  - Kryczka B
AD  - Department of Organic and Applied Chemistry, University of Łódź, Tamka 12, 91-403 
      Łódź, Poland.
FAU - Marsura, Alain
AU  - Marsura A
AD  - Universite de Lorraine, SRSMC UMR7565, Faculte des Sciences et Techniques, B.P. 
      70239, F-54506 Vandoeuvre-Les-Nancy Cedex, France.
FAU - Porwański, Stanisław
AU  - Porwański S
AD  - Department of Organic and Applied Chemistry, University of Łódź, Tamka 12, 91-403 
      Łódź, Poland. Electronic address: porwany@chemia.uni.lodz.pl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140104
PL  - Netherlands
TA  - Carbohydr Res
JT  - Carbohydrate research
JID - 0043535
RN  - 0 (Crown Ethers)
RN  - 16462-44-5 (Cellobiose)
RN  - 362O9ITL9D (Acetaminophen)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*chemistry
MH  - Aspirin/*chemistry
MH  - Cellobiose/*analogs & derivatives/*chemical synthesis
MH  - Crown Ethers/*chemical synthesis
MH  - Glucose/*analogs & derivatives/*chemical synthesis
MH  - Magnetic Resonance Spectroscopy
MH  - Molecular Conformation
OTO - NOTNLM
OT  - Azacrown ethers
OT  - Cryptands
OT  - Host–guest chemistry
OT  - Saccharides
EDAT- 2014/01/28 06:00
MHDA- 2014/10/15 06:00
CRDT- 2014/01/28 06:00
PHST- 2013/11/07 00:00 [received]
PHST- 2013/12/20 00:00 [revised]
PHST- 2013/12/21 00:00 [accepted]
PHST- 2014/01/28 06:00 [entrez]
PHST- 2014/01/28 06:00 [pubmed]
PHST- 2014/10/15 06:00 [medline]
AID - S0008-6215(13)00439-4 [pii]
AID - 10.1016/j.carres.2013.12.017 [doi]
PST - ppublish
SO  - Carbohydr Res. 2014 Mar 11;386:18-22. doi: 10.1016/j.carres.2013.12.017. Epub 
      2014 Jan 4.

PMID- 10341841
OWN - NLM
STAT- MEDLINE
DCOM- 19990607
LR  - 20190513
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 41
IP  - 2
DP  - 1999 Feb
TI  - Prevention of activation of blood coagulation during acute coronary ischemic 
      syndromes: beyond aspirin and heparin.
PG  - 418-32
AB  - Many of the acute coronary ischemic syndromes are triggered by spontaneous or 
      mechanical disruption of atherosclerotic plaques with resultant activation of 
      platelets and coagulation. Given the central role of platelets and thrombin in 
      arterial thrombosis, current strategies for its prevention and treatment focus on 
      both inhibition of platelet aggregation and control of thrombin generation and 
      activity. Although aspirin and unfractionated heparin are the cornerstones of 
      current treatment strategies, both have limitations. This review will describe 
      these limitations and discuss new antithrombotic agents developed for use in 
      acute coronary ischemic syndromes and as adjuncts for percutaneous coronary 
      revascularization procedures.
FAU - Bates, S M
AU  - Bates SM
AD  - McMaster University, Hamilton, Ontario, Canada.
FAU - Weitz, J I
AU  - Weitz JI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Fibrinolytic Agents/therapeutic use
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Thrombin/antagonists & inhibitors
RF  - 127
EDAT- 1999/05/26 00:00
MHDA- 1999/05/26 00:01
CRDT- 1999/05/26 00:00
PHST- 1999/05/26 00:00 [pubmed]
PHST- 1999/05/26 00:01 [medline]
PHST- 1999/05/26 00:00 [entrez]
AID - S0008-6363(98)00323-X [pii]
AID - 10.1016/s0008-6363(98)00323-x [doi]
PST - ppublish
SO  - Cardiovasc Res. 1999 Feb;41(2):418-32. doi: 10.1016/s0008-6363(98)00323-x.

PMID- 9874284
OWN - NLM
STAT- MEDLINE
DCOM- 19990316
LR  - 20131121
IS  - 1078-0297 (Print)
IS  - 1078-0297 (Linking)
VI  - 101
IP  - 3
DP  - 1998 Sep
TI  - Protective ability of acetylsalicylic acid (aspirin) to scavenge radiation 
      induced free radicals in J774A.1 macrophage cells.
PG  - 259-68
AB  - Radiation generates a variety of free radicals during the exposure of biological 
      tissues through radiolysis of water. These free radicals are highly reactive and 
      cause oxidative damage to biological molecules. This study examined the 
      protective ability of aspirin against radiation induced oxidative stress. The 
      study assessed the protective effect of aspirin (0.05 mM, 0.10 mM, 0.50 mM) on 
      the generation of free radicals during exposure of J774A.1 macrophage cells to 
      radiation (13.25 cGy). Approximately a 2.2-fold increase in superoxide anion 
      formation as determined by cytochrome c reduction was observed following exposure 
      of the cells to radiation for 20 one second exposures. Preincubation with aspirin 
      exhibited a dose dependent decrease in free radical production as assessed by 
      chemiluminescence and cytochrome c reduction. Aspirin also produced a 
      concentration dependent reduction in radiation induced DNA damage in the cells. 
      The data indicate that radiation of these cells results in production of reactive 
      oxygen species and DNA damage, and aspirin can decrease these effects in a 
      concentration dependent manner.
FAU - Saini, T
AU  - Saini T
AD  - School of Dentistry, Creighton University, Omaha, Nebraska, USA.
FAU - Bagchi, M
AU  - Bagchi M
FAU - Bagchi, D
AU  - Bagchi D
FAU - Jaeger, S
AU  - Jaeger S
FAU - Hosoyama, S
AU  - Hosoyama S
FAU - Stohs, S J
AU  - Stohs SJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Res Commun Mol Pathol Pharmacol
JT  - Research communications in molecular pathology and pharmacology
JID - 9437512
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Cytochrome c Group)
RN  - 0 (Free Radical Scavengers)
RN  - 0 (Free Radicals)
RN  - 0 (Reactive Oxygen Species)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cell Survival/drug effects/radiation effects
MH  - Cells, Cultured
MH  - Cyclooxygenase Inhibitors/*pharmacology/therapeutic use
MH  - Cytochrome c Group/metabolism
MH  - DNA Fragmentation/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Free Radical Scavengers
MH  - Free Radicals/metabolism
MH  - Luminescent Measurements
MH  - Macrophages/*drug effects/radiation effects
MH  - Oxidative Stress/drug effects
MH  - Radiation Injuries, Experimental/metabolism/prevention & control
MH  - Reactive Oxygen Species/*metabolism
EDAT- 1999/01/05 00:00
MHDA- 1999/01/05 00:01
CRDT- 1999/01/05 00:00
PHST- 1999/01/05 00:00 [pubmed]
PHST- 1999/01/05 00:01 [medline]
PHST- 1999/01/05 00:00 [entrez]
PST - ppublish
SO  - Res Commun Mol Pathol Pharmacol. 1998 Sep;101(3):259-68.

PMID- 12152961
OWN - NLM
STAT- MEDLINE
DCOM- 20020815
LR  - 20131121
IS  - 0002-838X (Print)
IS  - 0002-838X (Linking)
VI  - 66
IP  - 2
DP  - 2002 Jul 15
TI  - Acute management of atrial fibrillation: Part II. Prevention of thromboembolic 
      complications.
PG  - 261-4
AB  - Family physicians should be familiar with the acute management of atrial 
      fibrillation and the initiation of chronic therapy for this common arrhythmia. 
      Initial management should include hemodynamic stabilization, rate control, 
      restoration of sinus rhythm, and initiation of antithrombotic therapy. Part II of 
      this two-part article focuses on the prevention of thromboembolic complications 
      using anticoagulation. Heparin is routinely administered before medical or 
      electrical cardioversion. Warfarin is used in patients with persistent atrial 
      fibrillation who are at higher risk for thromboembolic complications because of 
      advanced age, history of coronary artery disease or stroke, or presence of 
      left-sided heart failure. Aspirin is preferred in patients at low risk for 
      thromboembolic complications and patients with a high risk for falls, a history 
      of noncompliance, active bleeding, or poorly controlled hypertension. The 
      recommendations provided in this article are consistent with guidelines published 
      by the American Heart Association and the Agency for Healthcare Research and 
      Quality.
FAU - King, Dana E
AU  - King DE
AD  - Medical University of South Carolina, Charleston, USA.
FAU - Dickerson, Lori M
AU  - Dickerson LM
FAU - Sack, Jonathan L
AU  - Sack JL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Fam Physician
JT  - American family physician
JID - 1272646
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- Am Fam Physician. 2002 Jul 15;66(2):271-2. PMID: 12152962
CIN - Am Fam Physician. 2003 Apr 15;67(8):1683; author reply 1683-4. PMID: 12725447
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*complications/therapy
MH  - Electric Countershock
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Thromboembolism/etiology/*prevention & control
MH  - Warfarin/therapeutic use
EDAT- 2002/08/03 10:00
MHDA- 2002/08/16 10:01
CRDT- 2002/08/03 10:00
PHST- 2002/08/03 10:00 [pubmed]
PHST- 2002/08/16 10:01 [medline]
PHST- 2002/08/03 10:00 [entrez]
PST - ppublish
SO  - Am Fam Physician. 2002 Jul 15;66(2):261-4.

PMID- 8210940
OWN - NLM
STAT- MEDLINE
DCOM- 19931028
LR  - 20170214
IS  - 0192-6233 (Print)
IS  - 0192-6233 (Linking)
VI  - 21
IP  - 2
DP  - 1993
TI  - Interruption of thrombosis and hemostasis by anti-platelet agents.
PG  - 180-9
AB  - Blood platelets play a fundamental role in hemostasis and thrombosis. The 
      physiological role of platelets is to preserve the integrity of the 
      cardiovascular system such that upon injury platelets are activated and serve to 
      interrupt a potentially deleterious situation (i.e., hemorrhage). However, 
      platelets are also involved in the pathophysiology of thrombosis in which the 
      normal repair process is grossly exacerbated, resulting in interruption of blood 
      flow to vital tissues. Thus, a critical balance exists between the normal 
      function of blood platelets to preserve tissue function and a pathophysiological 
      function in which tissue is damaged due to thrombosis and subsequent ischemia. 
      Numerous anti-platelet agents have been developed in an attempt to interrupt the 
      thrombotic process without severely compromising the hemostatic state of 
      patients. This article will be devoted to a discussion of a commonly utilized 
      anti-thrombotic agent, aspirin, as well as a class of newer, possibly more 
      effective anti-thrombotic agents referred to collectively as fibrinogen receptor 
      antagonists.
FAU - Shebuski, R J
AU  - Shebuski RJ
AD  - Upjohn Laboratories, Kalamazoo, Michigan 49001.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Toxicol Pathol
JT  - Toxicologic pathology
JID - 7905907
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Membrane Glycoproteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Aspirin/pharmacology
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Molecular Sequence Data
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Membrane Glycoproteins/antagonists & inhibitors
MH  - Thrombosis/*drug therapy/etiology
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1177/019262339302100210 [doi]
PST - ppublish
SO  - Toxicol Pathol. 1993;21(2):180-9. doi: 10.1177/019262339302100210.

PMID- 3567085
OWN - NLM
STAT- MEDLINE
DCOM- 19870605
LR  - 20190704
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 65
IP  - 3
DP  - 1987 Mar
TI  - Room temperature ADP induced first stage hyperaggregation of human blood 
      platelets: a previously undescribed phenomenon and its relationship to 
      spontaneous cold induced platelet aggregation.
PG  - 331-4
AB  - ADP induced human platelet aggregation was shown to be accentuated when tested at 
      20-30 degrees C as increased sensitivity and as a greater change of optical 
      density although second stage aggregation and the release reaction did not occur. 
      This previously undescribed phenomenon is defined as room temperature ADP induced 
      first stage hyperaggregation. Aggregation, which occurs under the above mentioned 
      conditions with a quantity of ADP insufficient to maintain the aggregation 
      (usually less than 1.5 micron), is reversible when the temperature is raised to 
      37 degrees C. After rewarming to these temperatures, second stage aggregation 
      appeared in the presence of larger quantities of ADP (usually more than 2 
      microns) and could be blocked by aspirin. The absence of the release reaction was 
      demonstrated with a lumi-aggregometer. Spontaneous cold induced platelet 
      aggregation seen after chilling platelets to 0-4 degrees C is shown to be a 
      distinct phenomenon.
FAU - Cohen, I J
AU  - Cohen IJ
FAU - Fuchs, J
AU  - Fuchs J
FAU - Kaplinski, C
AU  - Kaplinski C
FAU - Krugliak, J
AU  - Krugliak J
FAU - Stark, B
AU  - Stark B
FAU - Vogel, R
AU  - Vogel R
FAU - Weinberger, I
AU  - Weinberger I
FAU - Rotenberg, Z
AU  - Rotenberg Z
FAU - Agmon, J
AU  - Agmon J
FAU - Jerushalmy, Z
AU  - Jerushalmy Z
AU  - et al.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Br J Haematol 1987 Sep;67(1):121
MH  - Adenosine Diphosphate/antagonists & inhibitors/*pharmacology
MH  - Aspirin/pharmacology
MH  - Cold Temperature
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - *Temperature
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 10.1111/j.1365-2141.1987.tb06862.x [doi]
PST - ppublish
SO  - Br J Haematol. 1987 Mar;65(3):331-4. doi: 10.1111/j.1365-2141.1987.tb06862.x.

PMID- 6518668
OWN - NLM
STAT- MEDLINE
DCOM- 19850307
LR  - 20190825
IS  - 0305-1870 (Print)
IS  - 0305-1870 (Linking)
VI  - 11
IP  - 4
DP  - 1984 Jul-Aug
TI  - Role of prostaglandins during reversal of one-kidney, one-clip hypertension in 
      the rat.
PG  - 391-4
AB  - Unclipping the one-kidney, one-clip rat returned blood pressure to normotensive 
      levels within 24 h and was associated with a substantial increase in urinary PGE2 
      and 6-keto PGF1 alpha excretion. Prior treatment with indomethacin (6.0 mg/kg) 
      markedly reduced urinary prostaglandins after clip removal and attenuated the 
      fall in blood pressure. Aspirin (100 mg/kg) treatment, which reduced 6-keto PGF1 
      alpha to a lesser degree without altering PGE2 excretion, had no significant 
      effect on the blood pressure fall. It is suggested that in the one-kidney, 
      one-clip rat prostaglandins are released as the result of exposing the unclipped 
      kidney to elevated arterial pressure, and that these contribute to the subsequent 
      fall in blood pressure.
FAU - Vandongen, R
AU  - Vandongen R
FAU - O'Dwyer, J
AU  - O'Dwyer J
FAU - Barden, A
AU  - Barden A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Pressure/drug effects
MH  - Hypertension, Renovascular/*physiopathology
MH  - Indomethacin/pharmacology
MH  - Male
MH  - Nephrectomy
MH  - Prostaglandins/*physiology
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
AID - 10.1111/j.1440-1681.1984.tb00285.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 1984 Jul-Aug;11(4):391-4. doi: 
      10.1111/j.1440-1681.1984.tb00285.x.

PMID- 36322059
OWN - NLM
STAT- MEDLINE
DCOM- 20221216
LR  - 20230111
IS  - 2380-6591 (Electronic)
IS  - 2380-6583 (Print)
VI  - 7
IP  - 12
DP  - 2022 Dec 1
TI  - Concordance Between Patient-Reported Health Data and Electronic Health Data in 
      the ADAPTABLE Trial.
PG  - 1235-1243
LID - 10.1001/jamacardio.2022.3844 [doi]
AB  - IMPORTANCE: Patient-reported health data can facilitate clinical event capture in 
      pragmatic clinical trials. However, few data are available on the fitness for use 
      of patient-reported data in large-scale health research. OBJECTIVE: To evaluate 
      the concordance of a set of variables reported by patients and available in the 
      electronic health record as part of a pragmatic clinical trial. DESIGN, SETTING, 
      AND PARTICIPANTS: Data from ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial 
      Assessing Benefits and Long-term Effectiveness), a pragmatic clinical trial, were 
      used in a concordance substudy of a comparative effectiveness research trial. The 
      trial randomized 15 076 patients with existing atherosclerotic cardiovascular 
      disease in a 1:1 ratio to low- or high-dose aspirin from April 2016 through June 
      30, 2019. MAIN OUTCOMES AND MEASURES: Concordance of data was evaluated from 4 
      domains (demographic characteristics, encounters, diagnoses, and procedures) 
      present in 2 data sources: patient-reported data captured through an online 
      portal and data from electronic sources (electronic health record data). Overall 
      agreement, sensitivity, specificity, positive predictive value, negative 
      predictive value, and κ statistics with 95% CIs were calculated using patient 
      report as the criterion standard for demographic characteristics and the 
      electronic health record as the criterion standard for clinical outcomes. 
      RESULTS: Of 15 076 patients with complete information, the median age was 67.6 
      years (range, 21-99 years), and 68.7% were male. With the use of patient-reported 
      data as the criterion standard, agreement (κ) was high for Black and White race 
      and ethnicity but only moderate for current smoking status. Electronic health 
      record data were highly specific (99.6%) but less sensitive (82.5%) for Hispanic 
      ethnicity. Compared with electronic health record data, patient report of 
      clinical end points had low sensitivity for myocardial infarction (33.0%), stroke 
      (34.2%), and major bleeding (36.6%). Positive predictive value was similarly low 
      for myocardial infarction (40.7%), stroke (38.8%), and major bleeding (21.9%). 
      Coronary revascularization was the most concordant event by data source, with 
      only moderate agreement (κ = 0.54) and positive predictive value. Agreement 
      metrics varied by site for all demographic characteristics and several clinical 
      events. CONCLUSIONS AND RELEVANCE: In a concordance substudy of a large, 
      pragmatic comparative effectiveness research trial, sensitivity and 
      chance-corrected agreement of patient-reported data captured through an online 
      portal for cardiovascular events were low to moderate. Findings suggest that 
      additional work is needed to optimize integration of patient-reported health data 
      into pragmatic research studies. TRIAL REGISTRATION: ClinicalTrials.gov 
      Identifier: NCT02697916.
FAU - O'Brien, Emily C
AU  - O'Brien EC
AD  - Department of Population Health Sciences, Duke University School of Medicine, 
      Durham, North Carolina.
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, 
      North Carolina.
FAU - Mulder, Hillary
AU  - Mulder H
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, 
      North Carolina.
FAU - Jones, W Schuyler
AU  - Jones WS
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, 
      North Carolina.
AD  - Department of Medicine, Duke University School of Medicine, Durham, North 
      Carolina.
FAU - Hammill, Bradley G
AU  - Hammill BG
AD  - Department of Population Health Sciences, Duke University School of Medicine, 
      Durham, North Carolina.
FAU - Sharlow, Amber
AU  - Sharlow A
AD  - Medidata Solutions, New York, New York.
FAU - Hernandez, Adrian F
AU  - Hernandez AF
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, 
      North Carolina.
AD  - Department of Medicine, Duke University School of Medicine, Durham, North 
      Carolina.
FAU - Curtis, Lesley H
AU  - Curtis LH
AD  - Department of Population Health Sciences, Duke University School of Medicine, 
      Durham, North Carolina.
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, 
      North Carolina.
AD  - Department of Medicine, Duke University School of Medicine, Durham, North 
      Carolina.
LA  - eng
SI  - ClinicalTrials.gov/NCT02697916
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - JAMA Cardiol
JT  - JAMA cardiology
JID - 101676033
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Male
MH  - Aged
MH  - Female
MH  - Electronic Health Records
MH  - Aspirin/therapeutic use
MH  - Hemorrhage
MH  - *Myocardial Infarction/drug therapy
MH  - *Stroke/drug therapy
MH  - Patient Reported Outcome Measures
PMC - PMC9631224
COIS- Conflict of Interest Disclosures: Dr O’Brien reported receiving grants from the 
      National Institutes of Health (NIH)/National Center for Complementary and 
      Integrative Medicine and the Patient-Centered Outcomes Research Institute (PCORI) 
      during the conduct of the study. Dr Hammill reported receiving grants from the 
      NIH Common Fund (to Duke University School of Medicine) and grants from the 
      National Center for Complementary and Integrative Health (to Duke University 
      School of Medicine) during the conduct of the study. Dr Hernandez reported 
      receiving personal fees from AstraZeneca and grants from Amgen, Bayer, Boehringer 
      Ingelheim, Merck, and Novartis outside the submitted work. Dr Curtis reported 
      receiving grants from PCORI and NIH during the conduct of the study. No other 
      disclosures were reported.
EDAT- 2022/11/03 06:00
MHDA- 2022/12/17 06:00
PMCR- 2023/11/02
CRDT- 2022/11/02 11:33
PHST- 2023/11/02 00:00 [pmc-release]
PHST- 2022/11/03 06:00 [pubmed]
PHST- 2022/12/17 06:00 [medline]
PHST- 2022/11/02 11:33 [entrez]
AID - 2797899 [pii]
AID - hoi220065 [pii]
AID - 10.1001/jamacardio.2022.3844 [doi]
PST - ppublish
SO  - JAMA Cardiol. 2022 Dec 1;7(12):1235-1243. doi: 10.1001/jamacardio.2022.3844.

PMID- 26519141
OWN - NLM
STAT- MEDLINE
DCOM- 20160801
LR  - 20220331
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 6
DP  - 2015 Oct 31
TI  - Aspirin promotes bone marrow mesenchymal stem cell-based calvarial bone 
      regeneration in mini swine.
PG  - 210
LID - 10.1186/s13287-015-0200-4 [doi]
LID - 210
AB  - INTRODUCTION: Stem cells have great therapeutic potential due to their capacity 
      for self-renewal and their potential for differentiating into multiple cell 
      lineages. It has been recently shown that the host immune system has fundamental 
      effects on the fate of transplanted mesenchymal stem cells during bone repair, 
      where the topical administration of aspirin is capable of improving calvarial 
      bone repair in rodents by inhibiting tumor necrosis factor-α (TNF-α) and 
      interferon-γ (IFN-γ) production. This study investigates whether aspirin is 
      capable of accelerating the regenerative potential of bone marrow mesenchymal 
      stem cells (BMSC) in a mini swine calvarial bone defect model. METHODS: Calvarial 
      bone defects (3 cm × 1.8 cm oval defect) in mini swine were treated with BMSC 
      pretreated with 75 μg/ml aspirin for 24 h seeded onto hydroxyaptite/tricalcium 
      phosphatel (HA/TCP), or with BMSC with HA/TCP, or with HA/TCP only, or remained 
      untreated. Animals were scanned with micro-computed tomography (microCT) at 2 
      days and 6 months postsurgery and were sacrificed at 6 months postsurgery with 
      decalcified tissues being processed for histomorphometric examination. The 
      cytokine levels, including TNF-α and IFN-γ, were measured by enzyme-linked 
      immunosorbent assay (ELISA). RESULTS: Aspirin at 75 μg/ml promoted the 
      osteogenesis of BMSC in vitro and in vivo, shown by Alizarin Red staining and new 
      bone volume in the nude mice transplantation model (p < 0.01), respectively. 
      Defects treated with aspirin-BMSC showed significantly greater new bone fill 
      compared with other three groups at 6 months postsurgery (p < 0.01). Aspirin-BMSC 
      treatment has significantly decreased the concentration of TNF-α and IFN-γ 
      (p < 0.05). CONCLUSIONS: The present study shows that BMSC pretreated with 
      aspirin have a greater capacity to repair calvarial bone defects in a mini swine 
      model. The results suggest that the administration of aspirin is capable of 
      improving BMSC-mediated calvarial bone regeneration in a big animal model.
FAU - Cao, Yu
AU  - Cao Y
AD  - Department of General Dentistry, School of Stomatology, Capital Medical 
      University, Beijing, P. R. China. caoyu_bj@163.com.
FAU - Xiong, Jimin
AU  - Xiong J
AD  - Laboratory of Tissue Regeneration and Immunology and Department of Periodontics, 
      Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, School 
      of Stomatology, Capital Medical University, Tian Tan Xi Li No.4, Beijing, 100050, 
      P. R. China. jimin.xiong@hotmail.com.
FAU - Mei, Shenghui
AU  - Mei S
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, P. R. China. meishenghui1983@126.com.
FAU - Wang, Fu
AU  - Wang F
AD  - Molecular Laboratory for Gene Therapy and Tooth Regeneration, Beijing Key 
      Laboratory of Tooth Regeneration and Function Reconstruction, School of 
      Stomatology, Capital Medical University, Beijing, P. R. China. 
      dywangfu@gmail.com.
FAU - Zhao, Zhigang
AU  - Zhao Z
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, P. R. China. 1022zzg@sina.com.
FAU - Wang, Songlin
AU  - Wang S
AD  - Molecular Laboratory for Gene Therapy and Tooth Regeneration, Beijing Key 
      Laboratory of Tooth Regeneration and Function Reconstruction, School of 
      Stomatology, Capital Medical University, Beijing, P. R. China. 
      slwang@ccmu.edu.cn.
FAU - Liu, Yi
AU  - Liu Y
AD  - Laboratory of Tissue Regeneration and Immunology and Department of Periodontics, 
      Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, School 
      of Stomatology, Capital Medical University, Tian Tan Xi Li No.4, Beijing, 100050, 
      P. R. China. lililiuyi@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151031
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
RN  - 0 (Cytokines)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bone Regeneration/*drug effects
MH  - Cells, Cultured
MH  - Cytokines/metabolism
MH  - Drug Evaluation, Preclinical
MH  - Immunophenotyping
MH  - Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/drug effects/*physiology
MH  - Mice, Nude
MH  - Skull/*physiology
MH  - Swine
MH  - Swine, Miniature
PMC - PMC4628405
EDAT- 2015/11/01 06:00
MHDA- 2016/08/02 06:00
CRDT- 2015/11/01 06:00
PHST- 2015/03/11 00:00 [received]
PHST- 2015/10/08 00:00 [accepted]
PHST- 2015/03/17 00:00 [revised]
PHST- 2015/11/01 06:00 [entrez]
PHST- 2015/11/01 06:00 [pubmed]
PHST- 2016/08/02 06:00 [medline]
AID - 10.1186/s13287-015-0200-4 [pii]
AID - 200 [pii]
AID - 10.1186/s13287-015-0200-4 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2015 Oct 31;6:210. doi: 10.1186/s13287-015-0200-4.

PMID- 25887566
OWN - NLM
STAT- MEDLINE
DCOM- 20160104
LR  - 20201209
IS  - 1466-609X (Electronic)
IS  - 1364-8535 (Print)
IS  - 1364-8535 (Linking)
VI  - 19
IP  - 1
DP  - 2015 Mar 23
TI  - Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is 
      associated with reduced intensive care unit mortality: a prospective analysis.
PG  - 109
LID - 10.1186/s13054-015-0846-4 [doi]
LID - 109
AB  - INTRODUCTION: Acute respiratory distress syndrome (ARDS) is a common clinical 
      syndrome with high mortality and long-term morbidity. To date there is no 
      effective pharmacological therapy. Aspirin therapy has recently been shown to 
      reduce the risk of developing ARDS, but the effect of aspirin on established ARDS 
      is unknown. METHODS: In a single large regional medical and surgical ICU between 
      December 2010 and July 2012, all patients with ARDS were prospectively identified 
      and demographic, clinical, and laboratory variables were recorded 
      retrospectively. Aspirin usage, both pre-hospital and during intensive care unit 
      (ICU) stay, was included. The primary outcome was ICU mortality. We used 
      univariate and multivariate logistic regression analyses to assess the impact of 
      these variables on ICU mortality. RESULTS: In total, 202 patients with ARDS were 
      included; 56 (28%) of these received aspirin either pre-hospital, in the ICU, or 
      both. Using multivariate logistic regression analysis, aspirin therapy, given 
      either before or during hospital stay, was associated with a reduction in ICU 
      mortality (odds ratio (OR) 0.38 (0.15 to 0.96) P = 0.04). Additional factors that 
      predicted ICU mortality for patients with ARDS were vasopressor use (OR 2.09 
      (1.05 to 4.18) P = 0.04) and APACHE II score (OR 1.07 (1.02 to 1.13) P = 0.01). 
      There was no effect upon ICU length of stay or hospital mortality. CONCLUSION: 
      Aspirin therapy was associated with a reduced risk of ICU mortality. These data 
      are the first to demonstrate a potential protective role for aspirin in patients 
      with ARDS. Clinical trials to evaluate the role of aspirin as a pharmacological 
      intervention for ARDS are needed.
FAU - Boyle, Andrew J
AU  - Boyle AJ
AD  - Centre for Infection and Immunity, Health Sciences Building, Queen's University 
      Belfast, 97 Lisburn Road, Belfast, UK. boyle.andrewj@gmail.com.
AD  - Regional Intensive Care Unit, Royal Victoria Hospital, Grosvenor Road, Belfast, 
      UK. boyle.andrewj@gmail.com.
FAU - Di Gangi, Stefania
AU  - Di Gangi S
AD  - Epidemiology ASL TO3, Via Sabaudia, 164, Grugliasco, TO, 10095, Italy. 
      stefadiga@gmail.com.
FAU - Hamid, Umar I
AU  - Hamid UI
AD  - Centre for Infection and Immunity, Health Sciences Building, Queen's University 
      Belfast, 97 Lisburn Road, Belfast, UK. umar79@hotmail.com.
FAU - Mottram, Linda-Jayne
AU  - Mottram LJ
AD  - Regional Intensive Care Unit, Royal Victoria Hospital, Grosvenor Road, Belfast, 
      UK. Linda-Jayne.Mottram@belfasttrust.hscni.net.
FAU - McNamee, Lia
AU  - McNamee L
AD  - Regional Intensive Care Unit, Royal Victoria Hospital, Grosvenor Road, Belfast, 
      UK. lia.mcnamee@belfasttrust.hscni.net.
FAU - White, Griania
AU  - White G
AD  - Regional Intensive Care Unit, Royal Victoria Hospital, Grosvenor Road, Belfast, 
      UK. grianiae.white@belfasttrust.hscni.net.
FAU - Cross, L J Mark
AU  - Cross LJ
AD  - Centre for Infection and Immunity, Health Sciences Building, Queen's University 
      Belfast, 97 Lisburn Road, Belfast, UK. mark.cross@belfasttrust.hscni.net.
AD  - Regional Intensive Care Unit, Royal Victoria Hospital, Grosvenor Road, Belfast, 
      UK. mark.cross@belfasttrust.hscni.net.
FAU - McNamee, James J
AU  - McNamee JJ
AD  - Regional Intensive Care Unit, Royal Victoria Hospital, Grosvenor Road, Belfast, 
      UK. James.McNamee@belfasttrust.hscni.net.
FAU - O'Kane, Cecilia M
AU  - O'Kane CM
AD  - Centre for Infection and Immunity, Health Sciences Building, Queen's University 
      Belfast, 97 Lisburn Road, Belfast, UK. c.okane@qub.ac.uk.
FAU - McAuley, Daniel F
AU  - McAuley DF
AD  - Centre for Infection and Immunity, Health Sciences Building, Queen's University 
      Belfast, 97 Lisburn Road, Belfast, UK. d.f.mcauley@qub.ac.uk.
AD  - Regional Intensive Care Unit, Royal Victoria Hospital, Grosvenor Road, Belfast, 
      UK. d.f.mcauley@qub.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20150323
PL  - England
TA  - Crit Care
JT  - Critical care (London, England)
JID - 9801902
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Hospital Mortality
MH  - Humans
MH  - *Intensive Care Units
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Regression Analysis
MH  - Respiratory Distress Syndrome/*drug therapy/mortality
MH  - Risk
PMC - PMC4371625
EDAT- 2015/04/19 06:00
MHDA- 2016/01/05 06:00
CRDT- 2015/04/19 06:00
PHST- 2014/07/22 00:00 [received]
PHST- 2015/03/02 00:00 [accepted]
PHST- 2015/04/19 06:00 [entrez]
PHST- 2015/04/19 06:00 [pubmed]
PHST- 2016/01/05 06:00 [medline]
AID - 10.1186/s13054-015-0846-4 [pii]
AID - 846 [pii]
AID - 10.1186/s13054-015-0846-4 [doi]
PST - epublish
SO  - Crit Care. 2015 Mar 23;19(1):109. doi: 10.1186/s13054-015-0846-4.

PMID- 12716444
OWN - NLM
STAT- MEDLINE
DCOM- 20031105
LR  - 20191107
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 5
IP  - 1
DP  - 2003
TI  - COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and 
      aspirin-exacerbated respiratory disease.
PG  - 25-7
AB  - The use of analgesic anti-inflammatory agents in patients with asthma is 
      clinically challenging because of the prevalence (10-20%) of aspirin 
      hypersensitivity. Aspirin-exacerbated respiratory disease (AERD), or 
      aspirin-induced asthma, is characterized by asthma and rhinitis triggered by the 
      ingestion of aspirin and non-steroidal anti-inflammatory drugs. AERD is 
      associated with upper and lower respiratory-tract mucosal inflammation, 
      progressive sinusitis, nasal polyposis, and asthma regardless of whether patients 
      avoid triggering drugs. The mechanism underlying the propensity of aspirin and 
      non-steroidal anti-inflammatory drugs to cause this reaction is thought to 
      involve inhibition of the synthesis of protective prostaglandins (PGs), resulting 
      in an increase in the synthesis of cysteinyl leukotrienes by eosinophils and mast 
      cells. Clinical data suggest that protective PGs are derived from cyclooxygenase 
      (COX)-1 because studies have now confirmed that drugs specifically inhibiting 
      COX-2 are not cross-reactive with aspirin in patients with AERD.
FAU - Crofford, Leslie J
AU  - Crofford LJ
AD  - Associate Professor of Internal Medicine, Division of Rheumatology, University of 
      Michigan, Ann Arbor, Michigan, USA. crofford@umich.edu
LA  - eng
PT  - Editorial
DEP - 20021209
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/toxicity
MH  - Aspirin/*adverse effects/toxicity
MH  - Asthma/*chemically induced
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*toxicity
MH  - Drug Interactions
MH  - Humans
MH  - Isoenzymes/*antagonists & inhibitors/physiology
MH  - Membrane Proteins
MH  - Prostaglandin-Endoperoxide Synthases/physiology
PMC - PMC154436
EDAT- 2003/04/30 05:00
MHDA- 2003/11/06 05:00
CRDT- 2003/04/30 05:00
PHST- 2002/11/05 00:00 [received]
PHST- 2002/11/19 00:00 [accepted]
PHST- 2003/04/30 05:00 [pubmed]
PHST- 2003/11/06 05:00 [medline]
PHST- 2003/04/30 05:00 [entrez]
AID - ar620 [pii]
AID - 10.1186/ar620 [doi]
PST - ppublish
SO  - Arthritis Res Ther. 2003;5(1):25-7. doi: 10.1186/ar620. Epub 2002 Dec 9.

PMID- 8794519
OWN - NLM
STAT- MEDLINE
DCOM- 19970430
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 82
IP  - 6
DP  - 1996 Jun 15
TI  - Antithrombotic effects of aspirin and LMWH in a laser-induced model of arterials 
      and venous thrombosis.
PG  - 469-78
AB  - Antiplatelet drug aspirin and anticoagulant low molecular weight heparin (LMWH) 
      were compared as arterial and venous antithrombotic preparations in the rat 
      experimental model of the laser induced thrombus formation. A method to induce 
      microthrombi in small mesenteric vessel (15-25 microns) has been developed to 
      investigate antithrombotic drugs and to study platelet reactions. Mesenteric 
      injuries are induced in the vascular system of Wistar rats with an argon laser. 
      The laser beam induced formation of the vessel wall injury with damage of 
      endothelial cells. Thrombus was formed within seconds after laser injury and grew 
      rapidly. The aggregate can be swept away by the flow and a new thrombus was 
      formed again. This embolization began within the minute following the laser 
      flash. Thrombus formation and embolization were repetitive phenoma. Aspirin (100 
      mg/kg) and LMWH (1 mg/kg) are approximately the same as to decrease the number of 
      emboli detached from the thrombus and the duration of embolization; both in 
      venules and in arterioles. This results suggest reflexion about the role of 
      platelets in venous thrombosis induced by laser beam.
FAU - Imbault, P
AU  - Imbault P
AD  - Laboratoire d'Hématologie, Bordeaux, France.
FAU - Doutremepuich, F
AU  - Doutremepuich F
FAU - Aguejouf, O
AU  - Aguejouf O
FAU - Doutremepuich, C
AU  - Doutremepuich C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Cutaneous
MH  - Animals
MH  - Aspirin/*administration & dosage
MH  - Disease Models, Animal
MH  - Heparin, Low-Molecular-Weight/*administration & dosage
MH  - Lasers
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Thrombophlebitis/*drug therapy
MH  - Thrombosis/*drug therapy
EDAT- 1996/06/15 00:00
MHDA- 1996/06/15 00:01
CRDT- 1996/06/15 00:00
PHST- 1996/06/15 00:00 [pubmed]
PHST- 1996/06/15 00:01 [medline]
PHST- 1996/06/15 00:00 [entrez]
AID - 0049-3848(96)00097-7 [pii]
AID - 10.1016/0049-3848(96)00097-7 [doi]
PST - ppublish
SO  - Thromb Res. 1996 Jun 15;82(6):469-78. doi: 10.1016/0049-3848(96)00097-7.

PMID- 23126307
OWN - NLM
STAT- MEDLINE
DCOM- 20130219
LR  - 20220321
IS  - 1471-0528 (Electronic)
IS  - 1470-0328 (Linking)
VI  - 120
IP  - 1
DP  - 2013 Jan
TI  - Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised 
      placebo-controlled PREDO Trial and a meta-analysis of randomised trials.
PG  - 64-74
LID - 10.1111/j.1471-0528.2012.03493.x [doi]
AB  - OBJECTIVE: To study the effect of aspirin in the prevention of pre-eclampsia in 
      high-risk women. DESIGN: Randomised, double-blinded, placebo-controlled trial. 
      SETTING: Maternity clinics in ten Finnish hospitals participating in the PREDO 
      Project. SAMPLE: A total of 152 women with risk factors for pre-eclampsia and 
      abnormal uterine artery Doppler velocimetry. METHODS: Participants were 
      randomised to start either aspirin 100 mg/day or placebo at 12 + 0 to 13 + 6 
      weeks + days of gestation. Because of the limited power of this trial, we also 
      conducted a meta-analysis of randomised controlled trials that included data on 
      346 women with abnormal uterine artery Doppler flow velocimetry, and aspirin 
      50-150 mg/day started at or before 16( ) weeks of gestation. MAIN OUTCOME 
      MEASURE: Pre-eclampsia, gestational hypertension and birthweight standard 
      deviation (SD) score. Outcome measures for the meta-analysis were pre-eclampsia, 
      severe pre-eclampsia, preterm (diagnosed <37 + 0 weeks of gestation) and term 
      pre-eclampsia. RESULTS: From the 152 randomised women, 121 were included in the 
      final analysis. Low-dose aspirin did not reduce the rate of pre-eclampsia 
      (relative risk [RR] 0.7, 95% CI 0.3-1.7); gestational hypertension (RR 1.6, 95% 
      CI 0.6-4.2); early-onset pre-eclampsia (diagnosed <34 + 0 weeks of gestation) (RR 
      0.2, 95% CI 0.03-2.1); or severe pre-eclampsia (RR 0.4, 95% CI 0.1-1.3); and the 
      results were not statistically significant in an intention-to-treat analysis. 
      However, our meta-analysis, including the current data, suggested that low-dose 
      aspirin initiated before 16 weeks of gestation reduces the risk of pre-eclampsia 
      (RR 0.6, 95% CI 0.4-0.8) and severe pre-eclampsia (RR 0.3, 95% CI 0.1-0.7). 
      CONCLUSIONS: Our trial showed no statistically significant effect of aspirin in 
      preventing pre-eclampsia in high-risk women. However, our meta-analysis suggested 
      that aspirin may reduce the incidence of pre-eclampsia.
CI  - © 2012 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 
      2012 RCOG.
FAU - Villa, P M
AU  - Villa PM
AD  - Research Programmes Unit, Women's Health, University of Helsinki, Helsinki, 
      Finland. pia.villa@helsinki.fi
FAU - Kajantie, E
AU  - Kajantie E
FAU - Räikkönen, K
AU  - Räikkönen K
FAU - Pesonen, A-K
AU  - Pesonen AK
FAU - Hämäläinen, E
AU  - Hämäläinen E
FAU - Vainio, M
AU  - Vainio M
FAU - Taipale, P
AU  - Taipale P
FAU - Laivuori, H
AU  - Laivuori H
CN  - PREDO Study group
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20121106
PL  - England
TA  - BJOG
JT  - BJOG : an international journal of obstetrics and gynaecology
JID - 100935741
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BJOG. 2013 May;120(6):773. PMID: 23565952
CIN - BJOG. 2013 May;120(6):773-4. PMID: 23565953
CIN - BJOG. 2013 May;120(6):774-5. PMID: 23565954
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Finland
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pre-Eclampsia/diagnostic imaging/*prevention & control
MH  - Pregnancy
MH  - Pregnancy, High-Risk
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Ultrasonography, Doppler, Color
MH  - Young Adult
EDAT- 2012/11/07 06:00
MHDA- 2013/02/21 06:00
CRDT- 2012/11/07 06:00
PHST- 2012/11/07 06:00 [entrez]
PHST- 2012/11/07 06:00 [pubmed]
PHST- 2013/02/21 06:00 [medline]
AID - 10.1111/j.1471-0528.2012.03493.x [doi]
PST - ppublish
SO  - BJOG. 2013 Jan;120(1):64-74. doi: 10.1111/j.1471-0528.2012.03493.x. Epub 2012 Nov 
      6.

PMID- 21679527
OWN - NLM
STAT- MEDLINE
DCOM- 20111107
LR  - 20181201
IS  - 1945-8932 (Electronic)
IS  - 1945-8932 (Linking)
VI  - 25
IP  - 3
DP  - 2011 May-Jun
TI  - The nose as a target organ in the diagnosis of severe aspirin-exacerbated 
      respiratory disease.
PG  - 166-9
LID - 10.2500/ajra.2011.25.3591 [doi]
AB  - BACKGROUND: The nasal provocation test (NPT) with lysine aspirin is a useful tool 
      in the diagnosis of aspirin-exacerbated respiratory disease (AERD), previously 
      reffered to as Samter's disease. The aim of the present study focuses on 
      methodological interventions to show the usefulness of the NPT with lysine 
      aspirin in differentiating AERD patients from aspirin-tolerant asthma (ATA) 
      patients to improve the diagnostic efficacy and minimize the risk for adverse 
      reactions compared with the gold standard. METHODS: Thirty AERD patients 
      comprised the active study group while the control group consisted of 25 ATA 
      patients. A combination of objective nasal aerodynamic response (i.e., nasal 
      inspiratory flow and nasal inspiratory resistance) was evaluated by active 
      anterior rhinomanometry and the subjective clinical nasal and extranasal symptoms 
      (including forced expiratory volume) were monitored throughout the challenge. 
      RESULTS: Fifty-five NPTs were successfully completed: sensitivity, 87%; 
      specificity, 100%; positive predictive value, 100%; negative predictive value, 
      86%; global efficacy, 92.72%. No severe adverse reactions were recorded. 
      CONCLUSION: The present NPT with lysine aspirin proved to be a safe, efficient, 
      and a timesaving method in the diagnosis of patients with AERD, even in those 
      with severe rhinitis-rhinosinusitis and/or recurrent nasal polyposis.
FAU - González-Pérez, Ruperto
AU  - González-Pérez R
AD  - Servicio de Alergia, Hospital Universitario N.Sra. La Candelaria, Santa Cruz de 
      Tenerife, Spain. glezruperto@gmail.com
FAU - Poza-Guedes, Paloma
AU  - Poza-Guedes P
FAU - Vives-Conesa, Ramón
AU  - Vives-Conesa R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects/*analogs & derivatives
MH  - Asthma/*diagnosis/physiopathology
MH  - Asthma, Aspirin-Induced/*diagnosis/physiopathology
MH  - Diagnosis, Differential
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Lysine/adverse effects/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Nasal Mucosa/metabolism
MH  - Nasal Polyps
MH  - *Nasal Provocation Tests
MH  - Nose/*pathology
MH  - Predictive Value of Tests
MH  - Rhinitis
MH  - Rhinomanometry
MH  - Sensitivity and Specificity
MH  - Sinusitis
EDAT- 2011/06/18 06:00
MHDA- 2011/11/08 06:00
CRDT- 2011/06/18 06:00
PHST- 2011/06/18 06:00 [entrez]
PHST- 2011/06/18 06:00 [pubmed]
PHST- 2011/11/08 06:00 [medline]
AID - 10.2500/ajra.2011.25.3591 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2011 May-Jun;25(3):166-9. doi: 10.2500/ajra.2011.25.3591.

PMID- 2277204
OWN - NLM
STAT- MEDLINE
DCOM- 19910307
LR  - 20131121
IS  - 0300-9165 (Print)
IS  - 0300-9165 (Linking)
VI  - 42
IP  - 12
DP  - 1990 Dec
TI  - [Effect of low-dose aspirin therapy on utero-placental blood flow and 
      malondialdehyde (MDA) as an indicator of its therapeutic effect].
PG  - 1641-7
AB  - Pregnancy-induced hypertension (PIH) and preeclampsia develop when an imbalance 
      occurs between prostacyclin (PGI2) and thromboxane A2 (TXA2) production. PGI2 
      promotes vasodilation and decreases platelet adhesiveness, while TXA2 acts as a 
      vasoconstrictor and enhances platelet aggregation and adhesion to vascular walls. 
      The PGI2/TXA2 ratio appears to be important in pregnancy and the development of 
      the functioning uteroplacental unit. Recently, antiplatelet treatment such as 
      low-dose aspirin therapy has been effective in preventing the development of PIH 
      and preeclampsia. TXA2 breaks down spontaneously into a stable substance, TXB2, 
      which is inactive. Another stable, inactive metabolite, malondialdehyde (MDA), is 
      formed via the same pathway. TXB2 and MDA are produced in approximately equimolar 
      quantities. We studied the effects of a low-dose aspirin prescription. Production 
      of MDA was remarkably suppressed during the low-dose aspirin therapy. 
      Furthermore, pulsed doppler ultrasound assessment of blood flow was performed in 
      the fetal descending aorta, umbilical artery and uterine artery of the low-dose 
      aspirin therapy patients. Doppler abnormalities were improved during the therapy. 
      It is concluded that low-dose aspirin improves the uteroplacental blood flow 
      assessed by pulse doppler waveform and that determination of MDA is useful as an 
      indicator of platelet thromboxane synthesis.
FAU - Nishino, E
AU  - Nishino E
AD  - Department of Obstetrics and Gynecology, Osaka University Medical School.
FAU - Takagi, T
AU  - Takagi T
FAU - Mitsuda, N
AU  - Mitsuda N
FAU - Masuhiro, K
AU  - Masuhiro K
FAU - Iwata, I
AU  - Iwata I
FAU - Iwata, M
AU  - Iwata M
FAU - Tanizawa, O
AU  - Tanizawa O
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Sanka Fujinka Gakkai Zasshi
JT  - Nihon Sanka Fujinka Gakkai zasshi
JID - 7505749
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 57576-52-0 (Thromboxane A2)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Epoprostenol/metabolism/physiology
MH  - Female
MH  - Fetal Growth Retardation/diagnosis/metabolism/*prevention & control
MH  - Humans
MH  - Malondialdehyde/*blood
MH  - Middle Aged
MH  - Placenta/*blood supply
MH  - Pre-Eclampsia/diagnosis/metabolism/*prevention & control
MH  - Pregnancy
MH  - Regional Blood Flow/drug effects
MH  - Thromboxane A2/metabolism/physiology
MH  - Uterus/*blood supply
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
PST - ppublish
SO  - Nihon Sanka Fujinka Gakkai Zasshi. 1990 Dec;42(12):1641-7.

PMID- 23063765
OWN - NLM
STAT- MEDLINE
DCOM- 20130325
LR  - 20211021
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Print)
IS  - 0090-8258 (Linking)
VI  - 128
IP  - 1
DP  - 2013 Jan
TI  - Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins 
      And Lifestyle (VITAL) cohort.
PG  - 113-119
LID - S0090-8258(12)00807-4 [pii]
LID - 10.1016/j.ygyno.2012.10.005 [doi]
AB  - OBJECTIVE: Chronic inflammation may be an important factor in the initiation and 
      promotion of endometrial cancer. Use of non-steroidal anti-inflammatory drugs 
      (NSAIDs), however, has been inconsistently associated with endometrial cancer 
      risk. METHODS: 22,268 female residents of western Washington State, ages 50-76, 
      completed a baseline questionnaire in 2000-2002 and reported on their use of 
      individual NSAIDs over the past 10years. Use was categorized as none, low 
      (<4days/week or <4years), and high (≥4days/week and ≥4years). Over 9years of 
      follow-up, 262 incident invasive endometrial cancers were identified. 
      Multivariable proportional hazards models were used to estimate hazard ratios 
      (HR) and 95% confidence intervals (CI). RESULTS: Relative to non-use, high use of 
      aspirin was inversely associated with endometrial cancer risk (HR 0.64, 95% CI: 
      0.41-1.01; P trend=0.03). Findings were stronger for regular-strength than 
      low-dose aspirin. High use of non-aspirin NSAIDs (HR 1.15, 95% CI: 0.68-1.95), 
      including ibuprofen (HR 1.29, 95% CI: 0.73-2.28), and naproxen (HR 1.08, 95% CI: 
      0.39-2.95) was not associated with risk. In subgroup analyses, findings for 
      aspirin were strongest for cancers of endometrioid histology and were restricted 
      to non-smokers. CONCLUSIONS: This study provides additional evidence that use of 
      aspirin, but not non-aspirin NSAIDs, may reduce the risk of endometrial cancer, 
      especially in estrogen-mediated cases; however additional prospective studies 
      with high-quality measurement of NSAID use are needed. Aspirin should continue to 
      be examined as a potential agent for cancer chemoprevention.
CI  - Copyright © 2012 Elsevier Inc. All rights reserved.
FAU - Brasky, Theodore M
AU  - Brasky TM
AD  - The Ohio State University College of Medicine, Department of Internal Medicine, 
      Division of Cancer Prevention & Control, Columbus, OH, USA; Fred Hutchinson 
      Cancer Research Center, Cancer Prevention Program, Seattle, WA, USA. Electronic 
      address: Theodore.Brasky@osumc.edu.
FAU - Moysich, Kirsten B
AU  - Moysich KB
AD  - Roswell Park Cancer Institute, Division of Cancer Prevention and Population 
      Sciences, Buffalo, NY, USA.
FAU - Cohn, David E
AU  - Cohn DE
AD  - The Ohio State University College of Medicine, Department of Obstetrics and 
      Gynecology, Division of Gynecologic Oncology, Columbus, OH, USA.
FAU - White, Emily
AU  - White E
AD  - Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Seattle, WA, 
      USA.
LA  - eng
GR  - K05 CA154337/CA/NCI NIH HHS/United States
GR  - R25 CA094880/CA/NCI NIH HHS/United States
GR  - K05-CA154337/CA/NCI NIH HHS/United States
GR  - R25-CA094880/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20121009
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Chemoprevention
MH  - Cohort Studies
MH  - Endometrial Neoplasms/*prevention & control
MH  - Female
MH  - Humans
MH  - Life Style
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk
PMC - PMC3534938
MID - NIHMS413897
COIS- Conflict of Interest Statement The authors declare that there are no conflicts of 
      interest.
EDAT- 2012/10/16 06:00
MHDA- 2013/03/26 06:00
CRDT- 2012/10/16 06:00
PHST- 2012/08/17 00:00 [received]
PHST- 2012/10/01 00:00 [revised]
PHST- 2012/10/04 00:00 [accepted]
PHST- 2012/10/16 06:00 [entrez]
PHST- 2012/10/16 06:00 [pubmed]
PHST- 2013/03/26 06:00 [medline]
AID - S0090-8258(12)00807-4 [pii]
AID - 10.1016/j.ygyno.2012.10.005 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2013 Jan;128(1):113-119. doi: 10.1016/j.ygyno.2012.10.005. Epub 
      2012 Oct 9.

PMID- 19092646
OWN - NLM
STAT- MEDLINE
DCOM- 20130114
LR  - 20161125
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
VI  - 16
IP  - 1
DP  - 2009 Jan-Feb
TI  - Nitric oxide and aspirin: a new mediator for an old drug.
PG  - 17-23
LID - 10.1097/MJT.0b013e318164bd60 [doi]
AB  - Aspirin is known to cause a multitude of pharmacologic actions through inhibition 
      of cyclooxygenase(s) and reduced formation of prostaglandins. Recently, however, 
      novel cytoprotective and antioxidant mechanisms of aspirin have been identified 
      that are independent of cyclooxygenase inhibition. It was shown that aspirin 
      directly stimulates the activity of endothelial nitric oxide (NO) synthase 
      without affecting the expression of endothelial NO synthase. Increased NO 
      formation was found to underlie aspirin-induced sustained protection of 
      endothelial cells from oxidant injury. Downstream targets of NO that mediate 
      tissue protection include the stress proteins heme oxygenase-1 (HO-1) and 
      ferritin. Both HO-1 and ferritin have been identified as targets of, and 
      inducible by, aspirin and, in the case of HO-1, aspirin-triggered lipoxins. It is 
      important to note that these effects are specific to aspirin and not induced by 
      other nonsteroidal antiinflammatory drugs such as diclofenac, indomethacin, or 
      salicylates or by selective cyclooxygenase-2 inhibitors. HO-1 and its antioxidant 
      product bilirubin have been reported to be not only involved in vasoprotection, 
      but to have a similar function in gastric tissue. Stimulation of NO formation 
      through aspirin and ensuing HO-1 induction might therefore help to reduce gastric 
      injury or irritation. Moreover, NO functions as a smooth muscle-relaxing agent 
      and is thus thought to counteract the reduction in gastric blood flow caused by 
      inhibitors of prostaglandin synthesis. It is therefore conceivable that 
      activation of these novel antioxidant pathways contributes, at least in part, to 
      gastric tolerability and the favorable cardiovascular safety profile of aspirin.
FAU - Schröder, Henning
AU  - Schröder H
AD  - Department of Pharmaceutics, College of Pharmacy, University of Minnesota, 
      Minneapolis, MN 55455, USA. schro601@umn.edu
LA  - eng
PT  - Editorial
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 9007-73-2 (Ferritins)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology
MH  - Antioxidants/adverse effects/pharmacology
MH  - Aspirin/adverse effects/*pharmacology
MH  - Cyclooxygenase Inhibitors/adverse effects/*pharmacology
MH  - Ferritins/metabolism
MH  - Heme Oxygenase-1/metabolism
MH  - Humans
MH  - Nitric Oxide/*metabolism
MH  - Nitric Oxide Synthase Type III/metabolism
EDAT- 2008/12/19 09:00
MHDA- 2013/01/15 06:00
CRDT- 2008/12/19 09:00
PHST- 2008/12/19 09:00 [entrez]
PHST- 2008/12/19 09:00 [pubmed]
PHST- 2013/01/15 06:00 [medline]
AID - 10.1097/MJT.0b013e318164bd60 [doi]
PST - ppublish
SO  - Am J Ther. 2009 Jan-Feb;16(1):17-23. doi: 10.1097/MJT.0b013e318164bd60.

PMID- 35563496
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220716
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 9
DP  - 2022 May 4
TI  - Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the 
      Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones.
LID - 10.3390/ijms23095105 [doi]
LID - 5105
AB  - Fabry disease is caused by a deficiency of lysosomal alpha galactosidase and has 
      a very large genotypic and phenotypic spectrum. Some patients who carry 
      hypomorphic mutations can benefit from oral therapy with a pharmacological 
      chaperone. The drug requires a very precise regimen because it is a reversible 
      inhibitor of alpha-galactosidase. We looked for molecules that can potentiate 
      this pharmacological chaperone, among drugs that have already been approved for 
      other diseases. We tested candidate molecules in fibroblasts derived from a 
      patient carrying a large deletion in the gene GLA, which were stably transfected 
      with a plasmid expressing hypomorphic mutants. In our cell model, three drugs 
      were able to potentiate the action of the pharmacological chaperone. We focused 
      our attention on one of them, acetylsalicylic acid. We expect that 
      acetylsalicylic acid can be used in synergy with the Fabry disease 
      pharmacological chaperone and prolong its stabilizing effect on 
      alpha-galactosidase.
FAU - Monticelli, Maria
AU  - Monticelli M
AUID- ORCID: 0000-0003-3136-2138
AD  - Department Biology, University of Napoli « Federico II », Complesso Universitario 
      Monte Sant'Angelo, Via Cinthia, 80126 Napoli, Italy.
AD  - Department Environmental, Biological and Pharmaceutical Sciences and Technologies 
      (DiSTABiF), University of Campania "Luigi Vanvitelli", Via Vivaldi 43, 81100 
      Caserta, Italy.
AD  - Institute of Biomolecular Chemistry ICB, CNR, Via Campi Flegrei 34, 80078 
      Pozzuoli, Italy.
FAU - Liguori, Ludovica
AU  - Liguori L
AUID- ORCID: 0000-0002-8480-0501
AD  - Department Environmental, Biological and Pharmaceutical Sciences and Technologies 
      (DiSTABiF), University of Campania "Luigi Vanvitelli", Via Vivaldi 43, 81100 
      Caserta, Italy.
FAU - Allocca, Mariateresa
AU  - Allocca M
AUID- ORCID: 0000-0003-3693-2515
AD  - Department Environmental, Biological and Pharmaceutical Sciences and Technologies 
      (DiSTABiF), University of Campania "Luigi Vanvitelli", Via Vivaldi 43, 81100 
      Caserta, Italy.
AD  - Institute of Biomolecular Chemistry ICB, CNR, Via Campi Flegrei 34, 80078 
      Pozzuoli, Italy.
FAU - Bosso, Andrea
AU  - Bosso A
AUID- ORCID: 0000-0003-2360-300X
AD  - Department Biology, University of Napoli « Federico II », Complesso Universitario 
      Monte Sant'Angelo, Via Cinthia, 80126 Napoli, Italy.
AD  - Institute of Biochemistry and Cellular Biology, National Research Council, Via 
      Pietro Castellino 111, 80131 Napoli, Italy.
FAU - Andreotti, Giuseppina
AU  - Andreotti G
AUID- ORCID: 0000-0002-1594-0156
AD  - Institute of Biomolecular Chemistry ICB, CNR, Via Campi Flegrei 34, 80078 
      Pozzuoli, Italy.
FAU - Lukas, Jan
AU  - Lukas J
AD  - Translational Neurodegeneration Section "Albrecht-Kossel", Department of 
      Neurology, University Medical Center Rostock, 18147 Rostock, Germany.
AD  - Center for Transdisciplinary Neurosciences Rostock (CTNR), University Medical 
      Center Rostock, 18147 Rostock, Germany.
FAU - Monti, Maria Chiara
AU  - Monti MC
AUID- ORCID: 0000-0002-1337-2909
AD  - Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 
      Fisciano, Italy.
FAU - Morretta, Elva
AU  - Morretta E
AUID- ORCID: 0000-0002-7244-0297
AD  - Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 
      Fisciano, Italy.
FAU - Cubellis, Maria Vittoria
AU  - Cubellis MV
AUID- ORCID: 0000-0001-6147-6553
AD  - Department Biology, University of Napoli « Federico II », Complesso Universitario 
      Monte Sant'Angelo, Via Cinthia, 80126 Napoli, Italy.
AD  - Institute of Biomolecular Chemistry ICB, CNR, Via Campi Flegrei 34, 80078 
      Pozzuoli, Italy.
FAU - Hay Mele, Bruno
AU  - Hay Mele B
AUID- ORCID: 0000-0001-5579-183X
AD  - Department Biology, University of Napoli « Federico II », Complesso Universitario 
      Monte Sant'Angelo, Via Cinthia, 80126 Napoli, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220504
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Molecular Chaperones)
RN  - 19130-96-2 (1-Deoxynojirimycin)
RN  - EC 3.2.1.22 (alpha-Galactosidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 1-Deoxynojirimycin/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Drug Repositioning
MH  - *Fabry Disease/drug therapy/genetics
MH  - Humans
MH  - Lysosomes
MH  - Molecular Chaperones/genetics
MH  - Mutation
MH  - *alpha-Galactosidase/genetics/therapeutic use
PMC - PMC9105905
OTO - NOTNLM
OT  - AGAL
OT  - Fabry disease
OT  - acetylsalicylic acid
OT  - drug repositioning
OT  - lysosomal storage diseases
OT  - pharmacological chaperones
COIS- The authors declare no conflict of interest.
EDAT- 2022/05/15 06:00
MHDA- 2022/05/18 06:00
CRDT- 2022/05/14 01:06
PHST- 2022/04/11 00:00 [received]
PHST- 2022/05/01 00:00 [revised]
PHST- 2022/05/02 00:00 [accepted]
PHST- 2022/05/14 01:06 [entrez]
PHST- 2022/05/15 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
AID - ijms23095105 [pii]
AID - ijms-23-05105 [pii]
AID - 10.3390/ijms23095105 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 May 4;23(9):5105. doi: 10.3390/ijms23095105.

PMID- 26252050
OWN - NLM
STAT- MEDLINE
DCOM- 20170223
LR  - 20220317
VI  - 125
IP  - 9
DP  - 2015
TI  - Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in 
      patients with stable angina pectoris after percutaneous coronary intervention.
PG  - 620-30
LID - AOP_15_071 [pii]
AB  - INTRODUCTION: Obesity is a cluster of medical conditions affecting several 
      pathophysiological processes, including platelet (PLT) function. OBJECTIVES: We 
      evaluated the association between obesity and PLT response to dual antiplatelet 
      therapy over 1 month in patients with stable angina pectoris after percutaneous 
      coronary intervention (PCI).  PATIENTS AND METHODS: Patients with stable angina 
      pectoris (n = 130) and prior therapy with acetylsalicylic acid (ASA, 75 mg/d) 
      after PCI were enrolled into the study and divided based on a body mass index 
      (BMI): BMI <25 kg/m² (group A); BMI = 25-29.9 kg/m² (group B); and BMI ≥30 kg/m² 
      (group C). PLT function was assessed by impedance aggregometry 24 hours after PCI 
      and a loading dose (LD) of clopidogrel (CLO, 600 mg) and after 30 days of a 
      maintenance dose (MD) of CLO and ASA of 75 mg/d. The delta values were calculated 
      as the difference between the tests performed 30 days and 24 hours after PCI. 
      RESULTS: The PLT function changed significantly over a 30-day follow-up. The 
      initial PLT reactivity to adenosine diphosphate (ADP1) was lower in group A and 
      was the highest in group C (P <0.05). The PLT reactivity to collagen (COL1) and 
      arachidonic acid was lower in group A (P <0.05) with no differences between 
      groups B and C. There were no differences among the subgroups in PLT reactivity 
      assessed after 30 days. A multivariate regression analysis showed that BMI (P = 
      0.03), creatinine serum concentration (P <0.01), male sex (P <0.01), and active 
      smoking (P <0.001) are the independent predictors of ΔADP. CONCLUSIONS Obesity is 
      associated with a lower response to CLO LD but PLT function after 30 days of CLO 
      MD is similar in patients with obesity and normal-weight.
FAU - Haberka, Maciej
AU  - Haberka M
FAU - Mizia-Stec, Katarzyna
AU  - Mizia-Stec K
FAU - Lasota, Bartosz
AU  - Lasota B
FAU - Kyrcz-Krzemień, Stanisława
AU  - Kyrcz-Krzemień S
FAU - Gąsior, Zbigniew
AU  - Gąsior Z
LA  - eng
PT  - Journal Article
DEP - 20150807
PL  - Poland
TA  - Pol Arch Med Wewn
JT  - Polskie Archiwum Medycyny Wewnetrznej
JID - 0401225
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Pol Arch Med Wewn. 2015;125(9):615-7. PMID: 26406578
MH  - Aged
MH  - Angina, Stable/drug therapy/*surgery
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Obesity/*drug therapy
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Platelet Function Tests
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2015/08/08 06:00
MHDA- 2017/02/24 06:00
CRDT- 2015/08/08 06:00
PHST- 2015/08/08 06:00 [entrez]
PHST- 2015/08/08 06:00 [pubmed]
PHST- 2017/02/24 06:00 [medline]
AID - AOP_15_071 [pii]
AID - 10.20452/pamw.3039 [doi]
PST - ppublish
SO  - Pol Arch Med Wewn. 2015;125(9):620-30. doi: 10.20452/pamw.3039. Epub 2015 Aug 7.

PMID- 20669977
OWN - NLM
STAT- MEDLINE
DCOM- 20100929
LR  - 20211020
IS  - 1520-4995 (Electronic)
IS  - 0006-2960 (Print)
IS  - 0006-2960 (Linking)
VI  - 49
IP  - 33
DP  - 2010 Aug 24
TI  - Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers 
      comprising cyclooxygenase-1 homodimers.
PG  - 7069-79
LID - 10.1021/bi1003298 [doi]
AB  - Prostaglandin endoperoxide H synthases (PGHSs)-1 and -2 (also called 
      cyclooxygenases (COXs)-1 and -2) catalyze the committed step in prostaglandin 
      biosynthesis. Both isoforms are targets of nonsteroidal antiinflammatory drugs 
      (NSAIDs). PGHSs are homodimers that exhibit half-of-sites COX activity; moreover, 
      some NSAIDs cause enzyme inhibition by binding only one monomer. To learn more 
      about the cross-talk that must be occurring between the monomers comprising each 
      PGHS-1 dimer, we analyzed structures of PGHS-1 crystallized under five different 
      conditions including in the absence of any tightly binding ligand and in the 
      presence of nonspecific NSAIDs and of a COX-2 inhibitor. When crystallized with 
      substoichiometric amounts of an NSAID, both monomers are often fully occupied 
      with inhibitor; thus, the enzyme prefers to crystallize in a fully occupied form. 
      In comparing the five structures, we only observe changes in the positions of 
      residues 123-129 and residues 510-515. In cases where one monomer is fully 
      occupied with an NSAID and the partner monomer is incompletely occupied, an 
      alternate conformation of the loop involving residues 123-129 is seen in the 
      partially occupied monomer. We propose, on the basis of this observation and 
      previous cross-linking studies, that cross-talk between monomers involves this 
      mobile 123-129 loop, which is located at the dimer interface. In ovine PGHS-1 
      crystallized in the absence of an NSAID, there is an alternative route for 
      substrate entry into the COX site different than the well-known route through the 
      membrane binding domain.
FAU - Sidhu, Ranjinder S
AU  - Sidhu RS
AD  - Department of Biological Chemistry, University of Michigan, Ann Arbor, Michigan 
      48109, USA.
FAU - Lee, Jullia Y
AU  - Lee JY
FAU - Yuan, Chong
AU  - Yuan C
FAU - Smith, William L
AU  - Smith WL
LA  - eng
SI  - PDB/3N8V
SI  - PDB/3N8W
SI  - PDB/3N8X
SI  - PDB/3N8Y
SI  - PDB/3N8Z
GR  - R01 GM068848-07/GM/NIGMS NIH HHS/United States
GR  - R01 GM068848-07S1/GM/NIGMS NIH HHS/United States
GR  - GM68848/GM/NIGMS NIH HHS/United States
GR  - R01 GM068848-06/GM/NIGMS NIH HHS/United States
GR  - R01 GM068848/GM/NIGMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Ligands)
RN  - 0 (Sulfonamides)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
RN  - V4TKW1454M (nimesulide)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry/*pharmacology
MH  - Aspirin/chemistry/pharmacology
MH  - Catalytic Domain
MH  - Crystallography, X-Ray
MH  - Cyclooxygenase 1/*chemistry/*metabolism
MH  - Cyclooxygenase 2 Inhibitors/*chemistry/*pharmacology
MH  - Diclofenac/chemistry/pharmacology
MH  - Flurbiprofen/chemistry/pharmacology
MH  - Ligands
MH  - Models, Molecular
MH  - Protein Binding
MH  - Protein Conformation
MH  - Protein Multimerization
MH  - Sheep
MH  - Sulfonamides/chemistry/pharmacology
PMC - PMC2932651
MID - NIHMS223818
EDAT- 2010/07/31 06:00
MHDA- 2010/09/30 06:00
CRDT- 2010/07/31 06:00
PHST- 2010/07/31 06:00 [entrez]
PHST- 2010/07/31 06:00 [pubmed]
PHST- 2010/09/30 06:00 [medline]
AID - 10.1021/bi1003298 [doi]
PST - ppublish
SO  - Biochemistry. 2010 Aug 24;49(33):7069-79. doi: 10.1021/bi1003298.

PMID- 19319921
OWN - NLM
STAT- MEDLINE
DCOM- 20090805
LR  - 20131121
IS  - 1099-1077 (Electronic)
IS  - 0885-6222 (Linking)
VI  - 24
IP  - 4
DP  - 2009 Jun
TI  - Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid 
      therapy in depressive patients.
PG  - 277-86
LID - 10.1002/hup.1014 [doi]
AB  - OBJECTIVE: There are numerous reports indicating disturbed equilibrium between 
      oxidative processes and antioxidative defense in patients with depression. 
      Moreover, depressive patients are characterized by the presence of elements of an 
      inflammatory process, which is one of the sources of reactive oxygen species 
      (ROS). In view of the above, it was decided to study both the effect of 
      fluoxetine monotherapy and that of fluoxetine co-administered with 
      acetylsalicylic acid on lipid peroxidation and antioxidative defense in patients 
      with the first depressive episode in their life. METHOD: Seventy seven patients 
      with major depressive disorder (MDD), divided into two groups were included in 
      the study. The first group, consisting of 52 patients, received fluoxetine 20 mg, 
      and the second one, in addition to fluoxetine 20 mg, received 150 mg of 
      acetylsalicylic acid. The activity of antioxidative enzymes, copper-zinc 
      superoxide dismutase (CuZnSOD, SOD1), catalase (CAT), glutathione peroxidase 
      (GPSH-x) and the concentration of malonyldialdehyde (MDA) was determined in 
      erythrocytes, whereas the total antioxidant status (TAS) was determined in the 
      plasma. All parameters were measured before and after three month therapy. 
      RESULTS: The obtained results indicate a significant decrease in the activity of 
      SOD1, CAT and GSHP-x, as well as in MDA concentration after the combined therapy. 
      Also a significant TAS increase was observed after the combined therapy. The 
      study demonstrated that combined therapy with fluoxetine and ASA is characterized 
      by the same efficacy and clinical safety as fluoxetine monotherapy, resulting 
      additionally in improvement of oxidative stress parameters in the patients 
      treated for depression.
FAU - Gałecki, Piotr
AU  - Gałecki P
AD  - Department of Adult Psychiatry, Medical University of Lodz, Lodz, Poland. 
      galeckipiotr@wp.pl
FAU - Szemraj, Janusz
AU  - Szemraj J
FAU - Bieńkiewicz, Małgorzata
AU  - Bieńkiewicz M
FAU - Zboralski, Krzysztof
AU  - Zboralski K
FAU - Gałecka, Elzbieta
AU  - Gałecka E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Psychopharmacol
JT  - Human psychopharmacology
JID - 8702539
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Antioxidants)
RN  - 01K63SUP8D (Fluoxetine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Antidepressive Agents, Second-Generation/*adverse effects/therapeutic use
MH  - Antioxidants/metabolism
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Depressive Disorder, Major/drug therapy/*metabolism/psychology
MH  - Drug Therapy, Combination
MH  - Fluoxetine/*adverse effects/therapeutic use
MH  - Humans
MH  - Lipid Peroxidation/drug effects
MH  - Oxidative Stress/*drug effects
MH  - Psychiatric Status Rating Scales
EDAT- 2009/03/26 09:00
MHDA- 2009/08/06 09:00
CRDT- 2009/03/26 09:00
PHST- 2009/03/26 09:00 [entrez]
PHST- 2009/03/26 09:00 [pubmed]
PHST- 2009/08/06 09:00 [medline]
AID - 10.1002/hup.1014 [doi]
PST - ppublish
SO  - Hum Psychopharmacol. 2009 Jun;24(4):277-86. doi: 10.1002/hup.1014.

PMID- 15136948
OWN - NLM
STAT- MEDLINE
DCOM- 20050531
LR  - 20181130
IS  - 0720-4299 (Print)
IS  - 0720-4299 (Linking)
VI  - 72
IP  - 5
DP  - 2004 May
TI  - [The value of platelet inhibitors in the secondary prophylaxis of stroke -- a 
      review].
PG  - 270-81
AB  - INTRODUCTION: The goal of secondary prophylaxis following cerebral ischemia is a 
      long lasting inhibition of thrombogenesis to prevent recurrent stroke or other 
      vascular events. Platelet inhibitors (PI) according to meta-analyses lead to a 
      relative risk reduction (RRR) of 22 % for vascular events after stroke. The aim 
      of this article is a summary and critical review of all relevant studies and 
      meta-analyses for secondary prevention of stroke and to give a differentiated 
      therapeutic recommendation. METHODS: We performed a careful and extensive review 
      of the present literature for PI in the secondary prevention of stroke. Next to 
      the classic meta-analyses such as the Antiplatelet Trialists' analysis, the 
      relevant single trials (e. g. CATS, TASS, ESPS 2, CURE, CAPRIE) as well as 
      meta-analyses and post hoc analyses of these studies are summarized and 
      interpreted. Therapeutic recommendations are in consistence with the 
      recommendations and guidelines of national (DGN), European (EUSI) and 
      international (AHA/ASA) Groups/Associations. Also, the present literature was 
      searched for new information with regard to side effects and pharmacological 
      interactions and introduced into the review. CONCLUSIONS: ASA reduces the RR 
      after TIA/stroke by approximately 13 % and has the same efficacy with less side 
      effects in lower dosages (50 - 325 mg/Tag). Ticlopidine is a reserve drug due to 
      its unfavorable side effect profile (neutropenia, TTP). Clopidogrel is better 
      than ASA (RRR 8.7 %) for vascular patients in preventing another vascular event 
      (stroke, MI, vascular death). This effect is pronounced in patients at high risk 
      for atherothrombotic events such as previous MI, cardiac surgery, or diabetes. 
      Dipyridamole+ASA is better than ASA in patients with TIA/stroke (in indirect 
      comparison also than Clopidogrel) for the secondary prevention of recurrent 
      stroke (RRR 23 %), but not for the prevention of other vascular events. 
      Therefore, Clopidogrel should be primarily given to patients with a high vascular 
      risk (one or more cardiovascular risk factors) or to patients with ASA 
      intolerance. Dipyridamole/ASA should be primarily given to TIA/stroke patients 
      with a lower cardiovascular comorbidity. Studies for the combination of 
      Clopidogrel/ASA (MATCH, CHARISMA) and for the comparison of both combinations 
      (PRoFESS) are underway. At present, the combination of clopidogrel and ASA for 
      cerebrovascular prevention should only be given within controlled studies or as 
      an individual treatment with an accordingly acquired informed consent.
FAU - Schellinger, P D
AU  - Schellinger PD
AD  - Neurologische Klinik, Universitätsklinikum Heidelberg. 
      Peter_Schellinger@med.uni-heidelberg.de
FAU - Jüttler, E
AU  - Jüttler E
FAU - Meyding-Lamadé, Uta K
AU  - Meyding-Lamadé UK
FAU - Schwark, C
AU  - Schwark C
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Stellenwert von Thrombozyten-Aggregationshemmern in der Sekundärprävention des 
      ischämischen Schlaganfalls.
PL  - Germany
TA  - Fortschr Neurol Psychiatr
JT  - Fortschritte der Neurologie-Psychiatrie
JID - 8103137
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Brain Ischemia/diagnosis/*drug therapy
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Dipyridamole/adverse effects/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Secondary Prevention
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
RF  - 101
EDAT- 2004/05/12 05:00
MHDA- 2005/06/01 09:00
CRDT- 2004/05/12 05:00
PHST- 2004/05/12 05:00 [pubmed]
PHST- 2005/06/01 09:00 [medline]
PHST- 2004/05/12 05:00 [entrez]
AID - 10.1055/s-2003-812448 [doi]
PST - ppublish
SO  - Fortschr Neurol Psychiatr. 2004 May;72(5):270-81. doi: 10.1055/s-2003-812448.

PMID- 31880088
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210505
IS  - 1613-6829 (Electronic)
IS  - 1613-6810 (Linking)
VI  - 16
IP  - 4
DP  - 2020 Jan
TI  - Dual Functional Monocytes Modulate Bactericidal and Anti-Inflammation Process for 
      Severe Osteomyelitis Treatment.
PG  - e1905185
LID - 10.1002/smll.201905185 [doi]
AB  - Osteomyelitis is an inflammatory bone disease caused by infection microorganisms 
      which leads to progressive bone destruction and loss. Drug resistance and 
      inflammatory damage make it urgent to develop new dual-functional therapies. 
      Based on the powerful bactericidal effect of monocyte/macrophage cells by nature, 
      a functional monocyte with programed anti-inflammatory ability is promising for 
      osteomyelitis treatment. Herein, gold nanocage (GNC)-modified monocytes are 
      developed which contain aspirin to realize the controlled antibacterial and 
      anti-inflammatory process for bone infection treatment effectively. 
      Aspirin@GNC-laden monocytes inherit the biological functions of origin monocytes 
      such as chemotaxis to bacteria, differentiation potential, and phagocytic 
      ability. The controlled release of aspirin from GNC has a beneficial effect on 
      improving the rate and amount of bone regeneration after the anti-infection stage 
      due to its ability to suppress the activity of natural immunity and induce 
      osteoblast differentiation during the treatment of osteomyelitis. The present 
      work described here is the first to utilize living monocytes to achieve a dual 
      effect to antibacteria and anti-inflammation in a time-oriented and programed 
      way, and provides an inspiration for future therapy based on this concept.
CI  - © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Shi, Miusi
AU  - Shi M
AD  - The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei 
      MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and 
      Hospital of Stomatology, Wuhan University, Wuhan, 430079, China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei 
      MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and 
      Hospital of Stomatology, Wuhan University, Wuhan, 430079, China.
FAU - Zhao, Qin
AU  - Zhao Q
AD  - The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei 
      MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and 
      Hospital of Stomatology, Wuhan University, Wuhan, 430079, China.
FAU - Shen, Kailun
AU  - Shen K
AD  - The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei 
      MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and 
      Hospital of Stomatology, Wuhan University, Wuhan, 430079, China.
FAU - Qiu, Yun
AU  - Qiu Y
AD  - The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei 
      MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and 
      Hospital of Stomatology, Wuhan University, Wuhan, 430079, China.
FAU - Xiao, Yin
AU  - Xiao Y
AD  - Australia-China Centre for Tissue Engineering and Regenerative Medicine, 
      Queensland University of Technology, Brisbane, 4059, Australia.
FAU - Yuan, Quan
AU  - Yuan Q
AD  - Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of 
      Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 
      430072, China.
FAU - Zhang, Yufeng
AU  - Zhang Y
AUID- ORCID: 0000-0001-8702-5291
AD  - The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei 
      MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and 
      Hospital of Stomatology, Wuhan University, Wuhan, 430079, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191226
PL  - Germany
TA  - Small
JT  - Small (Weinheim an der Bergstrasse, Germany)
JID - 101235338
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Small. 2020 May;16(20):e2002301. PMID: 32441481
MH  - *Anti-Bacterial Agents/therapeutic use
MH  - *Anti-Inflammatory Agents/therapeutic use
MH  - Aspirin/administration & dosage
MH  - Humans
MH  - *Monocytes/chemistry/physiology
MH  - *Osteomyelitis/drug therapy
OTO - NOTNLM
OT  - anti-inflammation
OT  - aspirin
OT  - macrophage
OT  - monocyte
OT  - osteomyelitis
EDAT- 2019/12/28 06:00
MHDA- 2021/05/06 06:00
CRDT- 2019/12/28 06:00
PHST- 2019/09/11 00:00 [received]
PHST- 2019/11/04 00:00 [revised]
PHST- 2019/12/28 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
PHST- 2019/12/28 06:00 [entrez]
AID - 10.1002/smll.201905185 [doi]
PST - ppublish
SO  - Small. 2020 Jan;16(4):e1905185. doi: 10.1002/smll.201905185. Epub 2019 Dec 26.

PMID- 37599494
OWN - NLM
STAT- MEDLINE
DCOM- 20230822
LR  - 20230822
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 36
IP  - 4
DP  - 2023 Jul
TI  - Voltammetric quantification of acetylsalicylic acid in pharmaceutical 
      formulations utilizing copper wire electrode.
PG  - 1183-1189
AB  - This research describes the quantitative detection of acetylsalicylic acid (ASA) 
      as salicylic acid (SA) in pharmaceutical formulations using electrochemical 
      determination at copper electrode. The cyclic voltammetry (CV) technique was 
      applied to investigate the electrochemical behavior of salicylic acid at a copper 
      electrode. The anodic peak of salicylic acid (SA) was obtained at ~0.6V vs. 
      Ag/AgCl quasi electrode in a phosphate buffer solution of pH 11.5. The 
      measurement was made in a potential range of 0.00V to 0.80V, where all the 
      reported potentials are referred to this reference electrode. The oxidation peak 
      current was linearly dependent on the concentration of salicylic acid, which 
      ranges between 0.05mM and 15mM with a detection limit of 14.9µM. Three different 
      pharmaceutical formulations from three different brands were successfully 
      analyzed for acetylsalicylic acid using the newly developed method. The acquired 
      results and the indicated values had an RSD% of less than 2.02, which was in good 
      agreement with the concentration of real samples.
FAU - Mohammad AmayrehDepartment Of Chemistry Faculty Of Science Al-Balqa Applied 
      University Al-Salt Jordan, -
AU  - Mohammad AmayrehDepartment Of Chemistry Faculty Of Science Al-Balqa Applied 
      University Al-Salt Jordan -
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - R16CO5Y76E (Aspirin)
RN  - 789U1901C5 (Copper)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - *Aspirin
MH  - *Copper
MH  - Drug Compounding
MH  - Salicylic Acid
MH  - Electrodes
MH  - Pharmaceutical Preparations
EDAT- 2023/08/21 06:42
MHDA- 2023/08/22 06:43
CRDT- 2023/08/21 02:33
PHST- 2023/08/22 06:43 [medline]
PHST- 2023/08/21 06:42 [pubmed]
PHST- 2023/08/21 02:33 [entrez]
PST - ppublish
SO  - Pak J Pharm Sci. 2023 Jul;36(4):1183-1189.

PMID- 16094110
OWN - NLM
STAT- MEDLINE
DCOM- 20050901
LR  - 20161124
IS  - 0023-852X (Print)
IS  - 0023-852X (Linking)
VI  - 115
IP  - 8
DP  - 2005 Aug
TI  - Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled 
      trial.
PG  - 1385-90
AB  - OBJECTIVES/HYPOTHESIS: Intranasal lysine-aspirin has been used as a method of 
      desensitization in patients with aspirin-sensitive nasal polyps to control their 
      recurrence and prevent frequent surgical intervention. However, the studies are 
      limited in number, and their design is open to criticisms. Thus, we conducted a 
      controlled trial to study the clinical effectiveness of topical lysine-aspirin in 
      patients with aspirin-sensitive nasal polyposis. STUDY DESIGN: Prospective, 
      randomized, double blind, placebo controlled, crossover trial. METHODS: 
      Aspirin-sensitive patients confirmed by intranasal challenge were enrolled and 
      randomized to receive 16 mg of topical lysine-aspirin every 48 hours or placebo 
      for 6 months before crossover. Polyp growth and nasal and chest symptoms were 
      monitored using acoustic rhinometry, nasal inspiratory peak flow, peak expiratory 
      flow rate, and a daily diary of symptom scores. RESULTS: Twenty-two patients were 
      enrolled. After withdrawals and drop outs, data were available on 11 patients for 
      analysis. Multivariate analysis of measured parameters did not reveal a 
      significant clinical benefit to patients receiving topical lysine-aspirin 
      compared with placebo. Deterioration was similar while on lysine-aspirin or 
      placebo. CONCLUSIONS: This is the first controlled clinical trial of topical 
      desensitization in aspirin-sensitive nasal polyp patients. Despite the failure to 
      demonstrate clinical benefit, tissue studies have shown a significant improvement 
      at the microscopic level. Further work with larger numbers of patients along with 
      conventional treatment may show a clinical improvement in these patients.
FAU - Parikh, Abhi A
AU  - Parikh AA
AD  - St. Mary's Hospital, Praed Street, London W2 1NY, UK. abhijeetparikh@hotmail.com
FAU - Scadding, Glenis K
AU  - Scadding GK
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Administration, Intranasal
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/administration & dosage/*analogs & derivatives
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Nasal Polyps/*drug therapy/*pathology
MH  - Nasal Provocation Tests
MH  - Probability
MH  - Risk Factors
MH  - Sex Factors
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
EDAT- 2005/08/12 09:00
MHDA- 2005/09/02 09:00
CRDT- 2005/08/12 09:00
PHST- 2005/08/12 09:00 [pubmed]
PHST- 2005/09/02 09:00 [medline]
PHST- 2005/08/12 09:00 [entrez]
AID - 00005537-200508000-00010 [pii]
AID - 10.1097/01.MLG.0000166702.38850.1B [doi]
PST - ppublish
SO  - Laryngoscope. 2005 Aug;115(8):1385-90. doi: 10.1097/01.MLG.0000166702.38850.1B.

PMID- 7956512
OWN - NLM
STAT- MEDLINE
DCOM- 19941212
LR  - 20190402
IS  - 0304-4920 (Print)
IS  - 0304-4920 (Linking)
VI  - 37
IP  - 1
DP  - 1994
TI  - Effect of naloxone on platelet aggregation in rats.
PG  - 43-8
AB  - The effect of naloxone on aggregation of blood platelets was investigated. 
      Naloxone in millimolar concentrations dose-dependently inhibited collagen (20 mu 
      g/ml)-induced platelet aggregation in rats PRP. For comparison with IC50 values 
      on a molar basis, the ability of naloxone against platelet aggregation is similar 
      to aspirin, but about 7-8 fold smaller than verapamil. In anesthetized 
      spontaneously hypertensive rats (SHR), naloxone did not significantly alter the 
      pressure response whereas administration of prazosin caused diminution of mean 
      arterial pressure (MAP) related to dose. Naloxone did not interfere with the 
      hematological parameters (i.e., WBC, RBC, PLT, HGB, HCT ... etc.) in 
      Sprague-Dawley (SD) rats. The present study shows naloxone to be effective in 
      obviating platelet aggregation, and seems to be reasonable in prevention of 
      pulmonary platelet trapping (PPT), which is thought to play an important role in 
      the pathogenesis of adult respiratory distress syndrome (ARDS).
FAU - Sheu, J R
AU  - Sheu JR
AD  - Pharmacological Institute, College of Medicine National Taiwan University, 
      Department of Pharmacology, Taipei.
FAU - Huang, T F
AU  - Huang TF
FAU - Lee, Y M
AU  - Lee YM
FAU - Yen, M H
AU  - Yen MH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Chin J Physiol
JT  - The Chinese journal of physiology
JID - 7804502
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 36B82AMQ7N (Naloxone)
RN  - CJ0O37KU29 (Verapamil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Chin J Physiol 1994;37(2):103
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Pressure/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Naloxone/*pharmacology
MH  - Osmolar Concentration
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Verapamil/pharmacology
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Chin J Physiol. 1994;37(1):43-8.

PMID- 3069230
OWN - NLM
STAT- MEDLINE
DCOM- 19890428
LR  - 20191022
IS  - 0742-0528 (Print)
IS  - 0742-0528 (Linking)
VI  - 5
IP  - 4
DP  - 1988
TI  - AM and PM measurement of gastric potential difference and prostacyclin production 
      in humans: effects of ranitidine.
PG  - 395-401
AB  - It has been previously documented that aspirin induced gastric injury of healthy 
      male volunteers was greater in the morning than in the evening. We have also 
      reported that fasting gastric acid secretion rates and gastric retention times 
      for solids were lower in the morning hours of the circadian cycle. We 
      hypothesized, therefore, that defensive factors in the human stomach may exhibit 
      circadian rhythmicity with greater vulnerability to noxious agents during the 
      morning hours. It has also been hypothesized that an antisecretory agent, with 
      reported protective effects, such as Ranitidine, would affect gastric defense 
      mechanisms differently at different times in the circadian cycle. Transmural 
      electrical potential difference (PD) and prostacyclin (PGI2) production by 
      mucosal biopsy specimens were chosen as putative indicators of gastric defensive 
      status. Accordingly, morning (1000) and evening (2200) studies were performed on 
      10 fasting healthy male subjects with and without oral Ranitidine (150 mg) given 
      3 hr before oro-gastric intubation for the measurement of PD and the removal of 
      mucosal biopsy samples.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Moore, J G
AU  - Moore JG
AD  - Department of Medicine, Salt Lake Veterans Administration Medical Center, Utah.
FAU - Larsen, K R
AU  - Larsen KR
FAU - Goo, R H
AU  - Goo RH
FAU - Bjorkman, D J
AU  - Bjorkman DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Chronobiol Int
JT  - Chronobiology international
JID - 8501362
RN  - 884KT10YB7 (Ranitidine)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Circadian Rhythm/*drug effects
MH  - Epoprostenol/*analysis
MH  - Gastric Mucosa/drug effects/*physiology
MH  - Humans
MH  - Male
MH  - Membrane Potentials/drug effects
MH  - Ranitidine/*pharmacology
MH  - Reference Values
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
AID - 10.3109/07420528809067784 [doi]
PST - ppublish
SO  - Chronobiol Int. 1988;5(4):395-401. doi: 10.3109/07420528809067784.

PMID- 2945528
OWN - NLM
STAT- MEDLINE
DCOM- 19861030
LR  - 20131121
IS  - 0020-3785 (Print)
VI  - 56
IP  - 4
DP  - 1986 Jul-Aug
TI  - [Left ventricular mural thrombus in acute anterior myocardial infarct].
PG  - 333-8
AB  - Fifty-six consecutive patients with acute anterior infarction were studied by 
      two-dimensional echocardiography to determine the incidence and complications of 
      left-ventricular thrombosis. Mean follow-up period was 4.4 months. 
      Left-ventricular thrombus was demonstrated in 14 patients (25%) between 25 and 54 
      days after infarction (group A), in 42 patients (group B) it was not 
      demonstrated. Apical and septal dyskinesis, and Forrester's hemodynamic 
      subset-III were significantly (P less than 0.02) associated with thrombus 
      development. Ten patients of group A received heparin (6.6 days mean); the 
      remaining four patients received aspirin and dipyridamole. Thrombi formation were 
      not significantly prevented with both treatments (chi 2 = 0.635). During 
      follow-up period, thrombus persisted in 6 patients of group A, all of them with 
      apical and septal dyskinesis. Three patients had a cerebrovascular accident 
      (5.3%), one of them of group A; no heparin anticoagulation was administered in 
      two. We conclude that apical and septal dyskinesis during acute anterior 
      infarction is generally associated with mural thrombi development. Due to the 
      embolic risk therapeutic anticoagulation must be considered in these patients.
FAU - Silva Oropeza, E
AU  - Silva Oropeza E
FAU - Nava López, G
AU  - Nava López G
FAU - Hernández Pétriz, J
AU  - Hernández Pétriz J
FAU - Tudón Garcés, H
AU  - Tudón Garcés H
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Trombo mural del ventrículo izquierdo en el infarto agudo del miocardio de 
      localización anterior.
PL  - Mexico
TA  - Arch Inst Cardiol Mex
JT  - Archivos del Instituto de Cardiologia de Mexico
JID - 0400463
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Echocardiography
MH  - Heart Ventricles
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*complications
MH  - Thrombosis/drug therapy/*etiology/prevention & control
EDAT- 1986/07/01 00:00
MHDA- 1986/07/01 00:01
CRDT- 1986/07/01 00:00
PHST- 1986/07/01 00:00 [pubmed]
PHST- 1986/07/01 00:01 [medline]
PHST- 1986/07/01 00:00 [entrez]
PST - ppublish
SO  - Arch Inst Cardiol Mex. 1986 Jul-Aug;56(4):333-8.

PMID- 21902288
OWN - NLM
STAT- MEDLINE
DCOM- 20120105
LR  - 20211020
IS  - 1179-6901 (Electronic)
IS  - 1174-5886 (Print)
IS  - 1174-5886 (Linking)
VI  - 11
IP  - 3
DP  - 2011 Sep 1
TI  - Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - 
      gastrointestinal adverse effects: a meta-analysis of randomized clinical trials.
PG  - 277-88
LID - 10.2165/11593880-000000000-00000 [doi]
AB  - BACKGROUND AND AIM: Acetylsalicylic acid (ASA [aspirin]) is a commonly used 
      over-the-counter drug for the treatment of pain, fever, or colds, but data on the 
      safety of this use are very limited. The aim of this study was to provide data on 
      the safety of this treatment pattern, which is of interest to clinicians, 
      regulators, and the public. METHODS: A meta-analysis of individual patient data 
      from 67 studies sponsored by Bayer HealthCare was completed. The primary 
      endpoints were patient-reported gastrointestinal (GI) adverse events (AEs); the 
      secondary endpoints were the incidence of patient-reported non-GI AEs. Event 
      incidence and odds ratios (ORs) based on Cochran-Mantel-Haenszel estimates are 
      reported. In total, 6181 patients were treated with ASA, 3515 with placebo, 1145 
      with acetaminophen (paracetamol), and 754 with ibuprofen. Exposure to ASA was 
      short term (82.5% of patients had a single dose). RESULTS: GI AEs were more 
      frequent with ASA (9.9%) than with placebo (9.0%).[OR 1.3; 95% CI 1.1, 1.5]. 
      Dyspeptic symptoms were infrequent (4.6% in placebo subjects). The ORs for ASA 
      were 1.3 (95% CI 1.1, 1.6) versus placebo; 1.55 (95% CI 0.7, 3.3) versus 
      ibuprofen; and 1.04 (95% CI 0.8, 1.4) versus acetaminophen. There were very few 
      serious GI AEs (one ASA case; three placebo cases). No differences were found for 
      non-GI AEs and no cases of cerebral hemorrhage were reported. CONCLUSION: 
      Short-term, mostly single-dose exposure to ASA for the treatment of pain, fever, 
      or colds was associated with a small but significant increase in the risk of 
      dyspepsia relative to placebo. No serious GI complications were reported.
FAU - Lanas, Angel
AU  - Lanas A
AD  - University of Zaragoza Medical School, Aragn Health Research Institute (IIS 
      Aragn), CIBERehd, Zaragoza, Spain. alanas@unizar.es
FAU - McCarthy, Denis
AU  - McCarthy D
FAU - Voelker, Michael
AU  - Voelker M
FAU - Brueckner, Andreas
AU  - Brueckner A
FAU - Senn, Stephen
AU  - Senn S
FAU - Baron, John A
AU  - Baron JA
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Drugs R D
JT  - Drugs in R&D
JID - 100883647
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Common Cold/*drug therapy
MH  - Double-Blind Method
MH  - Dyspepsia/*chemically induced
MH  - Female
MH  - Fever/*drug therapy
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Gastrointestinal Tract/drug effects
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Male
MH  - Odds Ratio
MH  - Pain/*drug therapy
MH  - Placebos
MH  - Randomized Controlled Trials as Topic
PMC - PMC3586117
EDAT- 2011/09/10 06:00
MHDA- 2012/01/06 06:00
CRDT- 2011/09/10 06:00
PHST- 2011/09/10 06:00 [entrez]
PHST- 2011/09/10 06:00 [pubmed]
PHST- 2012/01/06 06:00 [medline]
AID - 4 [pii]
AID - 11030277 [pii]
AID - 10.2165/11593880-000000000-00000 [doi]
PST - ppublish
SO  - Drugs R D. 2011 Sep 1;11(3):277-88. doi: 10.2165/11593880-000000000-00000.

PMID- 12765506
OWN - NLM
STAT- MEDLINE
DCOM- 20030708
LR  - 20201223
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 178
IP  - 11
DP  - 2003 Jun 2
TI  - Antiplatelet drugs.
PG  - 568-74
AB  - Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular 
      death and other serious vascular events in patients with a history of previous 
      vascular events or known risk factors for cardiovascular disease. Aspirin reduces 
      the risk of serious vascular events in patients at high risk of such an event by 
      about a quarter and is recommended as the first-line antiplatelet drug. 
      Clopidogrel reduces the risk of serious vascular events among high-risk patients 
      by about 10% compared with aspirin. It is as safe as aspirin, but much more 
      expensive. It is an appropriate alternative to aspirin for long-term secondary 
      prevention in patients who cannot tolerate aspirin, have experienced a recurrent 
      vascular event while taking aspirin, or are at very high risk of a vascular event 
      (>/= 20% per year). Addition of clopidogrel to aspirin reduces the risk of 
      serious vascular events among patients with non-ST-segment elevation acute 
      coronary syndromes by 20%, and patients undergoing percutaneous coronary 
      intervention by 30%, compared with aspirin alone. Addition of a glycoprotein 
      IIb/IIIa receptor antagonist to aspirin reduces the risk of vascular events among 
      patients with non-ST-segment elevation acute coronary syndromes by 10% and among 
      patients undergoing percutaneous coronary intervention by 30%, compared with 
      aspirin alone; it appears to provide incremental benefit in patients also treated 
      with clopidogrel. Addition of dipyridamole to aspirin seems to be more effective 
      than aspirin alone for preventing recurrent stroke, but its overall effect in 
      preventing serious vascular events in patients with ischaemic stroke and 
      transient ischaemic attack has not been determined.
FAU - Hankey, Graeme J
AU  - Hankey GJ
AD  - Royal Perth Hospital, 197 Wellington Street, Perth, WA 6001, Australia. 
      gjhankey@cyllene.uwa.edu.au
FAU - Eikelboom, John W
AU  - Eikelboom JW
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology/therapeutic use
MH  - Clopidogrel
MH  - Dipyridamole/pharmacology/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/pharmacology/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
MH  - Primary Prevention
MH  - Pulmonary Embolism/prevention & control
MH  - Thrombosis/*drug therapy/physiopathology
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
MH  - Venous Thrombosis/prevention & control
EDAT- 2003/05/27 05:00
MHDA- 2003/07/09 05:00
CRDT- 2003/05/27 05:00
PHST- 2003/01/16 00:00 [received]
PHST- 2003/03/24 00:00 [accepted]
PHST- 2003/05/27 05:00 [pubmed]
PHST- 2003/07/09 05:00 [medline]
PHST- 2003/05/27 05:00 [entrez]
AID - han10033_fm [pii]
AID - 10.5694/j.1326-5377.2003.tb05361.x [doi]
PST - ppublish
SO  - Med J Aust. 2003 Jun 2;178(11):568-74. doi: 10.5694/j.1326-5377.2003.tb05361.x.

PMID- 12368905
OWN - NLM
STAT- MEDLINE
DCOM- 20030123
LR  - 20220129
IS  - 1078-8956 (Print)
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 8
IP  - 11
DP  - 2002 Nov
TI  - Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with 
      glucocorticoid and aspirin treatment activate the lipoxin A4 receptor.
PG  - 1296-302
AB  - Aspirin (ASA) and dexamethasone (DEX) are widely used anti-inflammatory agents 
      yet their mechanism(s) for blocking polymorphonuclear neutrophil (PMN) 
      accumulation at sites of inflammation remains unclear. Here, we report that 
      inhibition of PMN infiltration by ASA and DEX is a property shared by 
      aspirin-triggered lipoxins (ATL) and the glucocorticoid-induced annexin 1 
      (ANXA1)-derived peptides that are both generated in vivo and act at the lipoxin 
      A(4) receptor (ALXR/FPRL1) to halt PMN diapedesis. These structurally diverse 
      ligands specifically interact directly with recombinant human ALXR demonstrated 
      by specific radioligand binding and function as well as immunoprecipitation of 
      PMN receptors. In addition, the combination of both ATL and ANXA1-derived 
      peptides limited PMN infiltration and reduced production of inflammatory 
      mediators (that is, prostaglandins and chemokines) in vivo. Together, these 
      results indicate functional redundancies in endogenous lipid and peptide 
      anti-inflammatory circuits that are spatially and temporally separate, where both 
      ATL and specific ANXA1-derived peptides act in concert at ALXR to downregulate 
      PMN recruitment to inflammatory loci.
FAU - Perretti, Mauro
AU  - Perretti M
AD  - [1] Department of Biochemical Pharmacology, William Harvey Research Institute, 
      Bart's and The London School of Medicine, Queen Mary University of London, 
      Charterhouse Square, London, UK [2] M.P. and N.C. contributed equally to this 
      paper.
FAU - Chiang, Nan
AU  - Chiang N
FAU - La, Mylinh
AU  - La M
FAU - Fierro, Iolanda M
AU  - Fierro IM
FAU - Marullo, Stefano
AU  - Marullo S
FAU - Getting, Stephen J
AU  - Getting SJ
FAU - Solito, Egle
AU  - Solito E
FAU - Serhan, Charles N
AU  - Serhan CN
LA  - eng
SI  - GENBANK/U81501
GR  - GM38765/GM/NIGMS NIH HHS/United States
GR  - R01 GM038765/GM/NIGMS NIH HHS/United States
GR  - P01-DE13499/DE/NIDCR NIH HHS/United States
GR  - P01 DE013499/DE/NIDCR NIH HHS/United States
GR  - R37 GM038765/GM/NIGMS NIH HHS/United States
GR  - 15755/ARC_/Arthritis Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20021007
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (FPR2 protein, human)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Receptors, Formyl Peptide)
RN  - 0 (Receptors, Lipoxin)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Cell Line
MH  - Cells, Cultured
MH  - Dexamethasone/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - *Lipid Metabolism
MH  - Mice
MH  - Molecular Sequence Data
MH  - Neutrophil Activation
MH  - Peptides/*metabolism
MH  - Receptors, Cell Surface/*agonists
MH  - *Receptors, Formyl Peptide
MH  - *Receptors, Lipoxin
PMC - PMC2777269
MID - UKMS28031
OID - NLM: UKMS28031
EDAT- 2002/10/09 04:00
MHDA- 2003/01/24 04:00
CRDT- 2002/10/09 04:00
PHST- 2002/07/26 00:00 [received]
PHST- 2002/09/18 00:00 [accepted]
PHST- 2002/10/09 04:00 [pubmed]
PHST- 2003/01/24 04:00 [medline]
PHST- 2002/10/09 04:00 [entrez]
AID - nm786 [pii]
AID - 10.1038/nm786 [doi]
PST - ppublish
SO  - Nat Med. 2002 Nov;8(11):1296-302. doi: 10.1038/nm786. Epub 2002 Oct 7.

PMID- 3684797
OWN - NLM
STAT- MEDLINE
DCOM- 19880120
LR  - 20131121
IS  - 0147-7447 (Print)
IS  - 0147-7447 (Linking)
VI  - 10
IP  - 11
DP  - 1987 Nov
TI  - Activity, air boots, and aspirin as thromboembolism prophylaxis in knee 
      arthroplasty. A multiple regimen approach.
PG  - 1525-7
AB  - In this prospective study 90 patients underwent 100 total knee replacements. Each 
      patient walked and practiced rehabilitation exercises one day preoperatively and 
      the morning of surgery. The contralateral calf was intermittently pumped during 
      surgery followed by bilateral pulsatile calf compression postoperatively. Aspirin 
      was administered in the recovery room and continued 600 mg twice a day until 
      discharge. Early activity and ambulation postoperatively were expected. Routine 
      deep venous thrombosis screening tests were not performed. No physiologically 
      significant postoperative venous thrombosis on any of these patients were 
      observed. A Doppler test was performed on eight patients, venogram on two 
      patients, and V/Q lung scan on two patients in whom a thromboembolic disease 
      problem was clinically suspected. All of these tests were negative except for one 
      V/Q scan.
FAU - Clayton, M L
AU  - Clayton ML
AD  - St. Joseph's Hospital, Denver, Colorado.
FAU - Thompson, T R
AU  - Thompson TR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Orthopedics
JT  - Orthopedics
JID - 7806107
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthritis/*surgery
MH  - Aspirin/*therapeutic use
MH  - *Clothing
MH  - Combined Modality Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Knee Prosthesis
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Postoperative Complications/*prevention & control
MH  - Prosthesis Design
MH  - Pulmonary Embolism/prevention & control
MH  - Thromboembolism/*prevention & control
EDAT- 1987/11/01 00:00
MHDA- 1987/11/01 00:01
CRDT- 1987/11/01 00:00
PHST- 1987/11/01 00:00 [pubmed]
PHST- 1987/11/01 00:01 [medline]
PHST- 1987/11/01 00:00 [entrez]
PST - ppublish
SO  - Orthopedics. 1987 Nov;10(11):1525-7.

PMID- 6599950
OWN - NLM
STAT- MEDLINE
DCOM- 19880427
LR  - 20190904
IS  - 0736-4679 (Print)
IS  - 0736-4679 (Linking)
VI  - 1
IP  - 5
DP  - 1984
TI  - Comparison of activated charcoal and gastric lavage in the prevention of aspirin 
      absorption.
PG  - 411-6
AB  - Effectiveness of initial treatment of aspirin (ASA) overdosage was evaluated by 
      comparing treatment with activated charcoal (AC) to treatment with gastric lavage 
      in combination with AC. Dogs were used as subjects in four experimental groups. 
      All subjects were administered an overdose of 500 mg/kg of ASA. Treatment was 
      performed 30 minutes later on all groups except controls. Treatment with AC alone 
      resulted in a 17% reduction (P greater than .05) of peak plasma salicylate levels 
      compared with controls. When lavage preceded administration of AC, a 37% 
      reduction (P less than .05) occurred. There was a 48% reduction (P less than 
      .025) in plasma salicylate levels when lavage was preceded and followed by 
      administration of AC. This study demonstrates that gastric lavage in combination 
      with AC is more effective in reducing ASA absorption than AC given alone.
FAU - Burton, B T
AU  - Burton BT
AD  - Oregon Poison Control and Drug Information Center, Oregon Health Sciences 
      University, Portland 97201.
FAU - Bayer, M J
AU  - Bayer MJ
FAU - Barron, L
AU  - Barron L
FAU - Aitchison, J P
AU  - Aitchison JP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Emerg Med
JT  - The Journal of emergency medicine
JID - 8412174
RN  - 0 (Salicylates)
RN  - 16291-96-6 (Charcoal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*poisoning
MH  - Charcoal/*administration & dosage
MH  - Dogs
MH  - *Gastric Lavage
MH  - Salicylates/blood
MH  - Time Factors
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 0736-4679(84)90203-8 [pii]
AID - 10.1016/0736-4679(84)90203-8 [doi]
PST - ppublish
SO  - J Emerg Med. 1984;1(5):411-6. doi: 10.1016/0736-4679(84)90203-8.

PMID- 935827
OWN - NLM
STAT- MEDLINE
DCOM- 19760901
LR  - 20190907
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 5
IP  - 2
DP  - 1976
TI  - Oral antipyretic therapy.
PG  - 81-3
AB  - The capacity of ibuprofen to reduce fever in children was compared with that of 
      aspirin, paracetamol, aminophenazone and indomethacin. The series of cases 
      studied consisted of 79 patients in the age range 3 months to 13 years and with a 
      rectal temperature above 38.5 degrees C. Temperatures were recorded at 15 and 30 
      minutes, and 1,2,4 and 6 hours after challenge with the drug. The antipyretic 
      effect of ibuprofen with a dose of 6 mg/kg was optimal and twice that of aspirin 
      or paracetamol and similar to that of aminophenazone. The antipyretic effect of 
      indomethacin was about 12 times that of ibuprofen. This ratio is almost the same 
      as what is said to occur between the antirheumatic effects between these drugs. 
      Ibuprofen with a dose of 6 mg/kg would thus appear to be a useful antipyretic 
      drug when both antipyretic and antirheumatic effects are needed.
FAU - Similä, S
AU  - Similä S
FAU - Kouvalainen, K
AU  - Kouvalainen K
FAU - Keinänen, S
AU  - Keinänen S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Phenylpropionates)
RN  - 01704YP3MO (Aminopyrine)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Administration, Oral
MH  - Aminopyrine/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Drug Evaluation
MH  - Fever/*drug therapy
MH  - Humans
MH  - Ibuprofen/administration & dosage/*therapeutic use
MH  - Indomethacin/therapeutic use
MH  - Phenylpropionates/*therapeutic use
EDAT- 1976/01/01 00:00
MHDA- 1976/01/01 00:01
CRDT- 1976/01/01 00:00
PHST- 1976/01/01 00:00 [pubmed]
PHST- 1976/01/01 00:01 [medline]
PHST- 1976/01/01 00:00 [entrez]
AID - 10.3109/03009747609099895 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 1976;5(2):81-3. doi: 10.3109/03009747609099895.

PMID- 35131410
OWN - NLM
STAT- MEDLINE
DCOM- 20220503
LR  - 20230502
IS  - 1534-4436 (Electronic)
IS  - 1081-1206 (Print)
IS  - 1081-1206 (Linking)
VI  - 128
IP  - 5
DP  - 2022 May
TI  - Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: 
      Efficacy, tolerability, and patient experience.
PG  - 575-582
LID - S1081-1206(22)00090-4 [pii]
LID - 10.1016/j.anai.2022.01.043 [doi]
AB  - BACKGROUND: Patterns of medication use and efficacy in aspirin-exacerbated 
      respiratory disease (AERD) have not been well characterized, especially since the 
      advent of respiratory biologics. Aspirin therapy after desensitization (ATAD) is 
      efficacious for upper and lower respiratory symptoms for patients with AERD, 
      though aspirin-related adverse effects can limit therapy. The optimal 
      coordination of ATAD and respiratory biologics for the treatment of AERD remains 
      unclear. OBJECTIVE: We aimed to characterize patterns of medication use and 
      treatment experience with biologics and ATAD in AERD. METHODS: We surveyed 98 
      patients with AERD recruited from the Brigham and Women's Hospital AERD registry. 
      Patients completed an online questionnaire describing their medication history 
      and treatment experience. RESULTS: A total of 52 (53.0%) patients reported a 
      history of use of one or more respiratory biologics (omalizumab, mepolizumab, 
      reslizumab, benralizumab, or dupilumab), and 84 (85.7%) reported undergoing 
      aspirin desensitization. There were 24 patients (24.4%) who reported concurrent 
      use of a biologic and ATAD. Compared with those taking ATAD alone, patients 
      taking a biologic and ATAD concurrently were less likely to report that aspirin 
      was effective for their AERD symptoms (odds ratio, 0.161 [95% confidence 
      interval, 0.03-0.76]; P =.02). Whereas patients reported varying efficacy with 
      biologics, dupilumab had the highest odds of patients reporting it worked "very 
      well" (odds ratio, 17.58 [95% confidence interval, 5.68-54.35]; P < .001). 
      CONCLUSION: Biologics are emerging as a treatment option for AERD and are 
      generally well tolerated. Biologic efficacy in AERD is variable by agent, though 
      most patients taking dupilumab found it to be effective. Patients on a biologic 
      in conjunction with ATAD may represent a more severe subset of AERD for which 
      ATAD alone is insufficient.
CI  - Copyright © 2022 American College of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Mullur, Jyotsna
AU  - Mullur J
AD  - Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, 
      Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, 
      Massachusetts.
FAU - Steger, Camille M
AU  - Steger CM
AD  - Center for Clinical Investigation, Brigham and Women's Hospital, Boston, 
      Massachusetts.
FAU - Gakpo, Deborah
AU  - Gakpo D
AD  - Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, 
      Boston, Massachusetts.
FAU - Bensko, Jillian C
AU  - Bensko JC
AD  - Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, 
      Boston, Massachusetts.
FAU - Maurer, Rie
AU  - Maurer R
AD  - Center for Clinical Investigation, Brigham and Women's Hospital, Boston, 
      Massachusetts.
FAU - Laidlaw, Tanya M
AU  - Laidlaw TM
AD  - Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, 
      Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, 
      Massachusetts.
FAU - Buchheit, Kathleen M
AU  - Buchheit KM
AD  - Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, 
      Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, 
      Massachusetts. Electronic address: kbuchheit@bwh.harvard.edu.
LA  - eng
GR  - K23 AI139352/AI/NIAID NIH HHS/United States
GR  - R01 HL128241/HL/NHLBI NIH HHS/United States
GR  - T32 AI007306/AI/NIAID NIH HHS/United States
GR  - U19 AI095219/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220205
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Biological Products)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - *Asthma, Aspirin-Induced/diagnosis/drug therapy
MH  - *Biological Products/adverse effects
MH  - Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Patient Outcome Assessment
MH  - *Sinusitis
PMC - PMC9058196
MID - NIHMS1777804
COIS- Conflicts of Interest: K.B. has served on scientific advisory boards for 
      AstraZeneca, Regeneron, Sanofi and GlaxoSmithKline. T.L has served on scientific 
      advisory boards for Regeneron, Sanofi, and GlaxoSmithKline. J.B. has served on 
      scientific advisory boards for GlaxoSmithKline. J.M., D.G., R.M., and C.S. have 
      no conflicts.
EDAT- 2022/02/09 06:00
MHDA- 2022/05/04 06:00
CRDT- 2022/02/08 05:41
PHST- 2021/12/17 00:00 [received]
PHST- 2022/01/20 00:00 [revised]
PHST- 2022/01/31 00:00 [accepted]
PHST- 2022/02/09 06:00 [pubmed]
PHST- 2022/05/04 06:00 [medline]
PHST- 2022/02/08 05:41 [entrez]
AID - S1081-1206(22)00090-4 [pii]
AID - 10.1016/j.anai.2022.01.043 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2022 May;128(5):575-582. doi: 
      10.1016/j.anai.2022.01.043. Epub 2022 Feb 5.

PMID- 11827919
OWN - NLM
STAT- MEDLINE
DCOM- 20020212
LR  - 20190623
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 105
IP  - 5
DP  - 2002 Feb 5
TI  - Department of Veterans Affairs Cooperative Studies Program Clinical Trial 
      comparing combined warfarin and aspirin with aspirin alone in survivors of acute 
      myocardial infarction: primary results of the CHAMP study.
PG  - 557-63
AB  - BACKGROUND: Both aspirin and warfarin when used alone are effective in the 
      secondary prevention of vascular events and death after acute myocardial 
      infarction. We tested the hypothesis that aspirin and warfarin therapy, when 
      combined, would be more effective than aspirin monotherapy. Methods and Results- 
      We conducted a randomized open-label study to compare the efficacy of warfarin 
      (target international normalized ratio 1.5 to 2.5 IU) plus aspirin (81 mg daily) 
      with the efficacy of aspirin monotherapy (162 mg daily) in reducing the total 
      mortality in 5059 patients enrolled within 14 days of infarction and followed for 
      a median of 2.7 years. Secondary end points included recurrent myocardial 
      infarction, stroke, and major hemorrhage. Four hundred thirty-eight (17.3%) of 
      2537 patients assigned to the aspirin group and 444 (17.6%) of 2522 patients 
      assigned to the combination group died (log-rank P=0.76). Recurrent myocardial 
      infarction occurred in 333 patients (13.1%) taking aspirin and in 336 patients 
      (13.3%) taking combination therapy (log-rank P=0.78). Stroke occurred in 89 
      patients (3.5%) taking aspirin and in 79 patients (3.1%) taking combination 
      therapy (log-rank P=0.52). Major bleeding occurred more frequently in the 
      combination therapy group than in the aspirin group (1.28 versus 0.72 events per 
      100 person years of follow-up, respectively; P<0.001). There were 14 individuals 
      with intracranial bleeds in both the aspirin and combination therapy groups. 
      CONCLUSIONS: In post-myocardial infarction patients, warfarin therapy (at a mean 
      international normalized ratio of 1.8) combined with low-dose aspirin did not 
      provide a clinical benefit beyond that achievable with aspirin monotherapy.
FAU - Fiore, Louis D
AU  - Fiore LD
AD  - Department of Veterans Affairs Cooperative Studies Program Coordinating Center, 
      West Haven, Connecticut, USA. louis.fiore@med.va.gov
FAU - Ezekowitz, Michael D
AU  - Ezekowitz MD
FAU - Brophy, Mary T
AU  - Brophy MT
FAU - Lu, David
AU  - Lu D
FAU - Sacco, Joseph
AU  - Sacco J
FAU - Peduzzi, Peter
AU  - Peduzzi P
CN  - Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Fam Pract. 2002 Jun;51(6):518. PMID: 12100773
CIN - ACP J Club. 2002 Sep-Oct;137(2):47. PMID: 12207425
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/etiology
MH  - Hospitals, Veterans
MH  - Humans
MH  - International Normalized Ratio/statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Proportional Hazards Models
MH  - Risk Assessment
MH  - Survival Rate
MH  - Treatment Outcome
MH  - United States
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2002/02/06 10:00
MHDA- 2002/02/13 10:01
CRDT- 2002/02/06 10:00
PHST- 2002/02/06 10:00 [pubmed]
PHST- 2002/02/13 10:01 [medline]
PHST- 2002/02/06 10:00 [entrez]
AID - 10.1161/hc0502.103329 [doi]
PST - ppublish
SO  - Circulation. 2002 Feb 5;105(5):557-63. doi: 10.1161/hc0502.103329.

PMID- 17560866
OWN - NLM
STAT- MEDLINE
DCOM- 20070906
LR  - 20181201
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 99
IP  - 12
DP  - 2007 Jun 15
TI  - Adjusted indirect meta-analysis of aspirin plus warfarin at international 
      normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary 
      syndromes.
PG  - 1637-42
AB  - After acute coronary syndromes, the beneficial effect of aspirin plus clopidogrel 
      (A+C) or aspirin plus dose-adjusted warfarin (A+W) compared with aspirin alone is 
      well established. However, these regimens were never compared. To compare the 
      risk-benefit profile of A+C versus A+W after acute coronary syndromes, major 
      medical databases for randomized controlled trials comparing 1 of these combined 
      approaches versus aspirin alone after an acute coronary syndrome (updated June 
      2006) were searched. Evaluated end points were major adverse events [MAEs: 
      all-cause death, acute myocardial infarction [AMI], thromboembolic stroke, major 
      bleeds, and overall risk of stroke [hemorrhagic or ischemic]). Odds ratios (ORs) 
      with 95% confidence intervals (CIs) were calculated for (1) A+W versus aspirin 
      alone, (2) A+C versus aspirin alone, and (3) A+W versus A+C using adjusted 
      indirect meta-analysis. Thirteen studies were included, totaling 69,741 patients. 
      Ten compared A+W versus aspirin alone and 3 compared A+C versus aspirin alone. 
      Each combined approach yielded a significantly lower risk of MAEs, albeit an 
      increased risk of major bleeds, compared with aspirin alone. No significant 
      difference was found for A+W versus A+C for risk of overall MAEs, death, or AMI. 
      However, A+W versus A+C was associated with a significantly lower risk of 
      thromboembolic stroke (OR 0.53, 95% CI 0.31 to 0.88, number needed to treat 60) 
      and all types of stroke (OR 0.58, 95% CI 0.35 to 0.94, p=0.038), but also with 
      increased risk of major bleeds (OR 1.9, 95% CI 1.2 to 2.8, number needed to harm 
      300). In conclusion, after an acute coronary syndrome, A+W and A+C are comparable 
      in the prevention of MAEs, death, and AMI compared with aspirin alone. Allocating 
      100 patients to A+W (at international normalized ratio 2 to 3) with respect to 
      A+C could prevent 17 thromboembolic strokes while causing 3 major bleeds.
FAU - Testa, Luca
AU  - Testa L
AD  - Institute of Cardiology, John Radcliffe Hospital, Oxford, United Kingdom, and 
      Division of Cardiology, University of Turin, Italy. luctes@gmail.com
FAU - Zoccai, Giuseppe Biondi
AU  - Zoccai GB
FAU - Porto, Italo
AU  - Porto I
FAU - Trotta, Graziana
AU  - Trotta G
FAU - Agostoni, Pierfrancesco
AU  - Agostoni P
FAU - Andreotti, Felicita
AU  - Andreotti F
FAU - Crea, Filippo
AU  - Crea F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20070427
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - Coronary Disease/*drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - International Normalized Ratio
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Syndrome
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 2007/06/15 09:00
MHDA- 2007/09/07 09:00
CRDT- 2007/06/15 09:00
PHST- 2006/12/24 00:00 [received]
PHST- 2007/01/29 00:00 [revised]
PHST- 2007/01/29 00:00 [accepted]
PHST- 2007/06/15 09:00 [pubmed]
PHST- 2007/09/07 09:00 [medline]
PHST- 2007/06/15 09:00 [entrez]
AID - S0002-9149(07)00461-4 [pii]
AID - 10.1016/j.amjcard.2007.01.052 [doi]
PST - ppublish
SO  - Am J Cardiol. 2007 Jun 15;99(12):1637-42. doi: 10.1016/j.amjcard.2007.01.052. 
      Epub 2007 Apr 27.

PMID- 22372726
OWN - NLM
STAT- MEDLINE
DCOM- 20120716
LR  - 20211021
IS  - 1179-1969 (Electronic)
IS  - 1170-229X (Linking)
VI  - 29
IP  - 3
DP  - 2012 Mar 1
TI  - Acetylsalicylic acid/esomeprazole fixed-dose combination.
PG  - 233-242
LID - 10.2165/11208610-000000000-00000 [doi]
AB  - The fixed-dose acetylsalicylic acid (ASA)/esomeprazole capsule combines the 
      cardiovascular (CV) protective effects of low-dose ASA with the gastroprotective 
      effects of the proton pump inhibitor esomeprazole. It is approved for use as a 
      convenient once-daily regimen in the prevention of CV and cerebrovascular events 
      in patients requiring continuous low-dose ASA who are at risk of developing 
      gastric and/or duodenal (peptic) ulcers. In two large, 26-week, randomized, 
      double-blind, multinational, phase III trials (ASTERIX and OBERON) in patients 
      who were receiving low-dose ASA for the prevention of CV events and who had an 
      increased risk of ulcer development, the incidence of endoscopy-proven peptic 
      ulcers (primary endpoint) was significantly lower with the addition of 
      esomeprazole 20 mg/day versus placebo. Moreover, patient-reported dyspeptic 
      symptoms (epigastric pain and epigastric burning) were reported in significantly 
      fewer patients in the low-dose ASA plus esomeprazole group than in the low-dose 
      ASA plus placebo group. Low-dose ASA plus esomeprazole treatment was generally 
      well tolerated, with a similar adverse event profile to that seen with low-dose 
      ASA plus placebo.
FAU - Burness, Celeste B
AU  - Burness CB
AD  - Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, 
      Auckland, New Zealand. demail@adis.co.nz.
FAU - Scott, Lesley J
AU  - Scott LJ
AD  - Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, 
      Auckland, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Capsules)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prodrugs)
RN  - 0 (Proton Pump Inhibitors)
RN  - N3PA6559FT (Esomeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*pharmacology/therapeutic use
MH  - Anti-Ulcer Agents/administration & dosage/adverse 
      effects/*pharmacology/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/*pharmacology/therapeutic use
MH  - Capsules
MH  - Cardiovascular Diseases/prevention & control
MH  - Drug Combinations
MH  - Esomeprazole/administration & dosage/adverse effects/*pharmacology/therapeutic 
      use
MH  - Humans
MH  - Peptic Ulcer/prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*pharmacology/therapeutic use
MH  - Prodrugs/administration & dosage/adverse effects/pharmacology/therapeutic use
MH  - Proton Pump Inhibitors/administration & dosage/adverse 
      effects/*pharmacology/therapeutic use
EDAT- 2012/03/01 06:00
MHDA- 2012/07/17 06:00
CRDT- 2012/03/01 06:00
PHST- 2012/03/01 06:00 [entrez]
PHST- 2012/03/01 06:00 [pubmed]
PHST- 2012/07/17 06:00 [medline]
AID - 10.2165/11208610-000000000-00000 [pii]
AID - 10.2165/11208610-000000000-00000 [doi]
PST - ppublish
SO  - Drugs Aging. 2012 Mar 1;29(3):233-242. doi: 10.2165/11208610-000000000-00000.

PMID- 20207433
OWN - NLM
STAT- MEDLINE
DCOM- 20120809
LR  - 20131121
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 150
IP  - 1
DP  - 2011 Jul 1
TI  - Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery 
      disease.
PG  - 39-44
LID - 10.1016/j.ijcard.2010.02.025 [doi]
AB  - BACKGROUND: Platelets, long believed to be incapable of de novo protein 
      synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme once 
      it has been inactivated by aspirin. This may explain the inefficacy of the drug 
      to induce sustained platelet inhibition in certain patients. We evaluated the 
      stability of platelet inhibition following once-daily enteric-coated aspirin 
      administration. METHODS: Platelet responsiveness to aspirin was evaluated in 11 
      stable coronary artery disease patients on chronic aspirin therapy before and 1, 
      3, 8, and 24h after observed ingestion of 80-mg enteric-coated aspirin. 
      Inhibition of the COX pathway was measured pharmacologically through plasma 
      thromboxane (Tx) B(2) levels, and functionally by light transmission aggregometry 
      in response to arachidonic acid. COX-independent platelet activity was measured 
      in response to adenosine diphosphate, epinephrine and collagen. RESULTS: Plasma 
      TxB(2) levels showed profound inhibition of TxA(2) formation, which was stable 
      throughout 24h, in all but 1 subject. This subject had optimal response to 
      aspirin (inhibition of platelet TxA(2) production within 1h), but recovered the 
      ability to synthesize TxA(2) within 24h of aspirin ingestion. Arachidonic 
      acid-induced platelet aggregation closely mirrored TxB(2) formation in this 
      patient, portraying a functional ability of the platelet to aggregate within 24h 
      of aspirin ingestion. COX-independent platelet aggregation triggered TxA(2) 
      production to a similar extent in all patients, likely through signal-dependent 
      protein synthesis. CONCLUSIONS: COX-dependent platelet activity is recovered in 
      certain individuals within 24h of aspirin administration. Further research should 
      consider increasing aspirin dosing frequency to twice daily, to allow sustained 
      inhibition in such subjects.
CI  - Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
FAU - Lordkipanidzé, Marie
AU  - Lordkipanidzé M
AD  - Faculty of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada.
FAU - Pharand, Chantal
AU  - Pharand C
FAU - Schampaert, Erick
AU  - Schampaert E
FAU - Palisaitis, Donald A
AU  - Palisaitis DA
FAU - Diodati, Jean G
AU  - Diodati JG
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100307
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy/*enzymology
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Female
MH  - Genetic Heterogeneity/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - *Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Thromboxane A2/antagonists & inhibitors/metabolism
MH  - Thromboxane B2/antagonists & inhibitors/metabolism
EDAT- 2010/03/09 06:00
MHDA- 2012/08/10 06:00
CRDT- 2010/03/09 06:00
PHST- 2009/11/13 00:00 [received]
PHST- 2010/01/12 00:00 [revised]
PHST- 2010/02/13 00:00 [accepted]
PHST- 2010/03/09 06:00 [entrez]
PHST- 2010/03/09 06:00 [pubmed]
PHST- 2012/08/10 06:00 [medline]
AID - S0167-5273(10)00092-6 [pii]
AID - 10.1016/j.ijcard.2010.02.025 [doi]
PST - ppublish
SO  - Int J Cardiol. 2011 Jul 1;150(1):39-44. doi: 10.1016/j.ijcard.2010.02.025. Epub 
      2010 Mar 7.

PMID- 6610161
OWN - NLM
STAT- MEDLINE
DCOM- 19840629
LR  - 20210111
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 18
IP  - 4
DP  - 1984 Apr
TI  - Effects of transcutaneous electrical nerve stimulation and aspirin on late 
      somatosensory evoked potentials in normal subjects.
PG  - 377-386
LID - 10.1016/0304-3959(84)90050-2 [doi]
AB  - The effects on late somatosensory evoked potentials (SEPs) of transcutaneous 
      nerve stimulation (TENS) and aspirin (600 mg), compared with placebo, were 
      studied in 32 young, healthy male and female volunteers. SEPs were produced by 
      electrical stimulation of the median nerve at moderate, non-painful, intensities. 
      There was a reduction in the peak-to-peak amplitude of the late components N1P2 
      (N1 latency: 100-160 msec; P2 latency: 160-260 msec) of the SEP in all groups 
      over time. TENS but not aspirin produced further significant changes compared 
      with placebo, including a fall in N1P2 amplitude, an increase in N1 latency, and 
      a decrease in the total excursion of the SEP between 25 and 450 msec after 
      stimulus onset.
FAU - Ashton, Heather
AU  - Ashton H
AD  - Clinical Psychopharmacology Unit, Department of Pharmacological Sciences, 
      University of Newcastle upon Tyne, 13 Framlington Place, Newcastle upon Tyne NE2 
      4AB Great Britain.
FAU - Golding, J F
AU  - Golding JF
FAU - Marsh, V R
AU  - Marsh VR
FAU - Thompson, J W
AU  - Thompson JW
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Afferent Pathways/drug effects
MH  - Aspirin/*pharmacology
MH  - Electric Stimulation
MH  - *Electric Stimulation Therapy
MH  - Evoked Potentials, Somatosensory/drug effects
MH  - Humans
MH  - Male
MH  - Median Nerve/drug effects
MH  - Nociceptors/*drug effects
MH  - Reaction Time/drug effects
MH  - Somatosensory Cortex/*drug effects
MH  - *Transcutaneous Electric Nerve Stimulation
EDAT- 1984/04/01 00:00
MHDA- 1984/04/01 00:01
CRDT- 1984/04/01 00:00
PHST- 1984/04/01 00:00 [pubmed]
PHST- 1984/04/01 00:01 [medline]
PHST- 1984/04/01 00:00 [entrez]
AID - 00006396-198404000-00006 [pii]
AID - 10.1016/0304-3959(84)90050-2 [doi]
PST - ppublish
SO  - Pain. 1984 Apr;18(4):377-386. doi: 10.1016/0304-3959(84)90050-2.

PMID- 28173738
OWN - NLM
STAT- MEDLINE
DCOM- 20180205
LR  - 20180205
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Linking)
VI  - 26
IP  - 9
DP  - 2017 Aug
TI  - Pregnancy failure in patients with obstetric antiphospholipid syndrome with 
      conventional treatment: the influence of a triple positive antibody profile.
PG  - 983-988
LID - 10.1177/0961203317692432 [doi]
AB  - Conventional treatment of obstetric antiphospholipid syndrome fails in 
      approximately 20-30% of pregnant women without any clearly identified risk 
      factor. It is important to identify risk factors that are associated with these 
      treatment failures. This study aimed to assess the impact of risk factors on 
      pregnancy outcomes in women with obstetric antiphospholipid syndrome treated with 
      conventional treatment. We carefully retrospectively selected 106 pregnancies in 
      women with obstetric antiphospholipid syndrome treated with heparin + aspirin. 
      Pregnancy outcomes were evaluated according to the following associated risk 
      factors: triple positivity profile, double positivity profile, single positivity 
      profile, history of thrombosis, autoimmune disease, more than four pregnancy 
      losses, and high titers of anticardiolipin antibodies and/or 
      anti-βeta-2-glycoprotein-I (aβ2GPI) antibodies. To establish the association 
      between pregnancy outcomes and risk factors, a single binary logistic regressions 
      analysis was performed. Risk factors associated with pregnancy loss with 
      conventional treatment were: the presence of triple positivity (OR = 5.0, 
      CI = 1.4-16.9, p = 0.01), high titers of aβ2GPI (OR = 4.4, CI = 1.2-16.1, 
      p = 0.023) and a history of more than four pregnancy losses (OR = 3.5, 
      CI = 1.2-10.0, p = 0.018). The presence of triple positivity was an independent 
      risk factor associated with gestational complications (OR = 4.1, CI = 1.2-13.9, 
      p = 0.02). Our findings reinforce the idea that triple positivity is a 
      categorical risk factor for poor response to conventional treatment.
FAU - Latino, J O
AU  - Latino JO
AD  - 1 Autoimmune, Thrombophilic Diseases and Pregnancy Section, Hospital "Dr. Carlos 
      G. Durand", Buenos Aires, Argentina.
FAU - Udry, S
AU  - Udry S
AD  - 1 Autoimmune, Thrombophilic Diseases and Pregnancy Section, Hospital "Dr. Carlos 
      G. Durand", Buenos Aires, Argentina.
AD  - 2 Hemostasis and Thrombosis Laboratory, Hospital of Infectious Diseases "Dr. F J 
      Muñiz", Buenos Aires, Argentina.
FAU - Aranda, F M
AU  - Aranda FM
AD  - 2 Hemostasis and Thrombosis Laboratory, Hospital of Infectious Diseases "Dr. F J 
      Muñiz", Buenos Aires, Argentina.
FAU - Perés Wingeyer, S D A
AU  - Perés Wingeyer SDA
AD  - 2 Hemostasis and Thrombosis Laboratory, Hospital of Infectious Diseases "Dr. F J 
      Muñiz", Buenos Aires, Argentina.
FAU - Fernández Romero, D S
AU  - Fernández Romero DS
AD  - 1 Autoimmune, Thrombophilic Diseases and Pregnancy Section, Hospital "Dr. Carlos 
      G. Durand", Buenos Aires, Argentina.
FAU - de Larrañaga, G F
AU  - de Larrañaga GF
AD  - 2 Hemostasis and Thrombosis Laboratory, Hospital of Infectious Diseases "Dr. F J 
      Muñiz", Buenos Aires, Argentina.
LA  - eng
PT  - Journal Article
DEP - 20170207
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (beta 2-Glycoprotein I)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Spontaneous/epidemiology/prevention & control
MH  - Adult
MH  - Antibodies, Anticardiolipin/*blood
MH  - Antibodies, Antiphospholipid/*blood
MH  - Antiphospholipid Syndrome/blood/*complications/immunology/therapy
MH  - Argentina/epidemiology
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Autoimmune Diseases/complications
MH  - Female
MH  - Heparin/administration & dosage/adverse effects/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/epidemiology/immunology
MH  - Pregnancy Outcome
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thrombosis/complications
MH  - Treatment Failure
MH  - beta 2-Glycoprotein I/*immunology
OTO - NOTNLM
OT  - Antiphospholipid syndrome
OT  - Hughes syndrome
OT  - anticardiolipin antibodies
OT  - pregnancy
OT  - thrombosis
EDAT- 2017/02/09 06:00
MHDA- 2018/02/06 06:00
CRDT- 2017/02/09 06:00
PHST- 2017/02/09 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
PHST- 2017/02/09 06:00 [entrez]
AID - 10.1177/0961203317692432 [doi]
PST - ppublish
SO  - Lupus. 2017 Aug;26(9):983-988. doi: 10.1177/0961203317692432. Epub 2017 Feb 7.

PMID- 16861838
OWN - NLM
STAT- MEDLINE
DCOM- 20061005
LR  - 20191210
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Linking)
VI  - 42
IP  - 7
DP  - 2006
TI  - [Bleeding after cardiac surgery: risk factors, frequency, and outcomes].
PG  - 566-70
AB  - According to the data from different cardiac surgery centers, the incidence of 
      urgent repetitive resternotomy for bleeding after cardiac on-pump operations 
      varies from 2 to 5%. The aim of the study was to determinate the risk factors 
      influencing resternotomy after cardiac surgery, features of early postoperative 
      period, and outcomes. MATERIAL AND METHODS: Altogether, 37 consecutive patients 
      undergoing urgent resternotomy due to bleeding early after cardiac surgery were 
      analyzed retrospectively. Urgent resternotomies made up 4.3% of all cardiac 
      on-pump surgeries performed on 856 patients at the Clinic of Cardiac Surgery of 
      Kaunas University of Medicine Hospital during 2004. The mean age of patients was 
      64.9+/-12.9 years; 29.7% of patients were women and 70.3% were men. RESULTS: 
      During analysis of preoperative clinical data factors that could influence 
      coagulation status were determined. Twenty patients (54.1%) had moderate 
      hypertension, three patients (8.1%) had severe insulin-dependent diabetes 
      mellitus, and five patients (13.5%) had chronic renal insufficiency treated with 
      dialysis. Assessing other risk factors it was observed that many patients were on 
      peroral anticoagulation therapy before surgery. The most frequently administered 
      drugs preoperatively were aspirin (16 cases, 43.2%) and direct-acting 
      anticoagulants (17 cases, 45.9%). CONCLUSIONS: The use of antiaggregants and 
      anticoagulants before surgery increases the incidence of resternotomies in the 
      early postoperative period. Postoperative infections that require more expensive 
      treatment with antibiotics are detected much more frequently in patients after 
      resternotomies comparing to the remaining postoperative cardiac patients (15/37 
      and 69/819, respectively). However, longer hospitalization length (15.8 and 58.0 
      days, respectively) and higher mortality rate (4.5 and 10.8%, respectively) were 
      observed in patients after resternotomy.
FAU - Kinduris, Sarūnas
AU  - Kinduris S
AD  - Institute for Biomedical Research, Heart Center, Kaunas University of Medicine, 
      Lithuania. kinsar@one.lt
FAU - Vaisvila, Tautvydas
AU  - Vaisvila T
FAU - Petronyte, Jurgita
AU  - Petronyte J
FAU - Budrikis, Algimantas
AU  - Budrikis A
LA  - lit
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
TT  - Kraujavimas po sirdies operaciju: rizikos veiksniai, daznumas, baigtys.
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Anticoagulants/administration & dosage/adverse effects/therapeutic use
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Cardiac Surgical Procedures/*adverse effects/mortality
MH  - Diabetes Mellitus, Type 1/complications
MH  - Emergencies
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic use
MH  - Humans
MH  - Hypertension/complications
MH  - Kidney Failure, Chronic/complications
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Postoperative Hemorrhage/chemically induced/*epidemiology/mortality
MH  - Reoperation
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sternum/surgery
MH  - Surgical Wound Infection/epidemiology
MH  - Treatment Outcome
EDAT- 2006/07/25 09:00
MHDA- 2006/10/06 09:00
CRDT- 2006/07/25 09:00
PHST- 2006/07/25 09:00 [pubmed]
PHST- 2006/10/06 09:00 [medline]
PHST- 2006/07/25 09:00 [entrez]
AID - 0607-05l [pii]
PST - ppublish
SO  - Medicina (Kaunas). 2006;42(7):566-70.

PMID- 15302149
OWN - NLM
STAT- MEDLINE
DCOM- 20041221
LR  - 20131121
IS  - 0165-5876 (Print)
IS  - 0165-5876 (Linking)
VI  - 68
IP  - 9
DP  - 2004 Sep
TI  - Epistaxis in healthy children requiring hospital admission.
PG  - 1181-4
AB  - OBJECTIVES: To determine the outcomes for healthy children who require admission 
      to hospital with acute epistaxis. METHODS: A 10-year retrospective review of 
      admissions with acute epistaxis under the Otolaryngology Department in a tertiary 
      pediatric centre was performed. RESULTS: There were 14 cases (11 males, 3 
      females), with mean age 7.8 years (1.9-18.3 years). Three patients had a history 
      of recent aspirin ingestion, and one had sustained nasal trauma. Mean hemoglobin 
      at presentation was 105g/L (75-150), and no patient was diagnosed with a bleeding 
      disorder. Four patients underwent surgical intervention, and one patient received 
      a blood transfusion or blood product. The mean length of hospital stay was 3.6 
      days (2-14 days). CONCLUSIONS: Acute epistaxis in healthy children that requires 
      hospital admission is generally not a marker for an underlying bleeding disorder. 
      It is associated with a short inpatient stay, and usually requires minimal 
      intervention.
FAU - Brown, N J
AU  - Brown NJ
AD  - Department of Otolaryngology, Royal Children's Hospital, Flemington Road, 
      Parkville, Victoria 3052, Australia.
FAU - Berkowitz, R G
AU  - Berkowitz RG
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Int J Pediatr Otorhinolaryngol
JT  - International journal of pediatric otorhinolaryngology
JID - 8003603
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Epistaxis/*epidemiology/etiology/*rehabilitation
MH  - Female
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Infant
MH  - Length of Stay
MH  - Male
MH  - Nose/injuries
MH  - Patient Admission/*statistics & numerical data
MH  - Retrospective Studies
EDAT- 2004/08/11 05:00
MHDA- 2004/12/22 09:00
CRDT- 2004/08/11 05:00
PHST- 2003/10/22 00:00 [received]
PHST- 2004/04/06 00:00 [revised]
PHST- 2004/04/07 00:00 [accepted]
PHST- 2004/08/11 05:00 [pubmed]
PHST- 2004/12/22 09:00 [medline]
PHST- 2004/08/11 05:00 [entrez]
AID - S0165587604001375 [pii]
AID - 10.1016/j.ijporl.2004.04.015 [doi]
PST - ppublish
SO  - Int J Pediatr Otorhinolaryngol. 2004 Sep;68(9):1181-4. doi: 
      10.1016/j.ijporl.2004.04.015.

PMID- 10672889
OWN - NLM
STAT- MEDLINE
DCOM- 20000225
LR  - 20191103
IS  - 0021-5155 (Print)
IS  - 0021-5155 (Linking)
VI  - 43
IP  - 6
DP  - 1999 Nov-Dec
TI  - White thread-like retinal arterioles associated with antiphospholipid antibody 
      syndrome.
PG  - 553-8
AB  - BACKGROUND: Report of 2 patients with antiphospholipid antibody syndrome (APS) 
      who had elevated anti-beta2-glycoprotein I antibodies and showed white 
      thread-like retinal arterioles. CASES: A complete ophthalmological examination 
      was conducted on 2 patients who presented with blurred or distorted vision. 
      Fluorescein angiography was used to examine the integrity of the retinal 
      circulatory system. Laboratory blood studies were conducted. OBSERVATIONS: In 
      both patients, some of the major retinal arterioles appeared white and had a 
      thread-like appearance. Fluorescein angiography demonstrated progressive 
      occlusion or stenosis of these major arterioles with extensive insufficiency of 
      the regional capillary bed. Patient 2 had systemic lupus erythematosus and was 
      treated with oral corticosteroid and aspirin. Recanalization occurred during a 
      3-year follow-up in one of the patients. CONCLUSIONS: APS should be considered in 
      cases of white thread-like retinal arterioles. Occlusion of the retinal 
      arterioles in APS may be progressive and responsible for the chronic hypoxia of 
      the retina.
FAU - Suzuki, A
AU  - Suzuki A
AD  - Department of Ophthalmology, NTT West Osaka Hospital, Japan.
FAU - Okamoto, N
AU  - Okamoto N
FAU - Ohnishi, M
AU  - Ohnishi M
FAU - Watanabe, M
AU  - Watanabe M
FAU - Motokura, M
AU  - Motokura M
FAU - Fukuda, M
AU  - Fukuda M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - Jpn J Ophthalmol
JT  - Japanese journal of ophthalmology
JID - 0044652
RN  - 0 (Glucocorticoids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Antiphospholipid Syndrome/*complications/diagnosis/drug therapy
MH  - Arterioles/pathology
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fluorescein Angiography
MH  - Fundus Oculi
MH  - Glucocorticoids/administration & dosage/therapeutic use
MH  - Humans
MH  - Laser Coagulation
MH  - Middle Aged
MH  - Ophthalmologic Surgical Procedures/methods
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Prednisone/administration & dosage/therapeutic use
MH  - Retinal Artery/*pathology
MH  - Retinal Diseases/drug therapy/*etiology/pathology/surgery
EDAT- 2000/02/15 09:00
MHDA- 2000/03/04 09:00
CRDT- 2000/02/15 09:00
PHST- 2000/02/15 09:00 [pubmed]
PHST- 2000/03/04 09:00 [medline]
PHST- 2000/02/15 09:00 [entrez]
AID - S0021515599001057 [pii]
AID - 10.1016/s0021-5155(99)00105-7 [doi]
PST - ppublish
SO  - Jpn J Ophthalmol. 1999 Nov-Dec;43(6):553-8. doi: 10.1016/s0021-5155(99)00105-7.

PMID- 3791366
OWN - NLM
STAT- MEDLINE
DCOM- 19870210
LR  - 20201209
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 8
IP  - 6
DP  - 1986
TI  - Assessment of Fiorinal with Codeine in the treatment of tension headache.
PG  - 703-21
AB  - A randomized, double-blind, placebo-controlled, multicenter study was conducted 
      to ascertain the contribution of Fiorinal and codeine phosphate to the efficacy 
      of Fiorinal with Codeine in relieving the pain, tension, and muscle stiffness 
      associated with tension headache. Patients were given Fiorinal with Codeine, 
      Fiorinal alone, codeine alone, or placebo for use during two separate headache 
      attacks at least 24 hours apart and were asked to rate the effectiveness of the 
      assigned medication on each occasion. The various symptoms of tension headache 
      were evaluated by the patient 0.5, 1, 2, 3, and 4 hours after ingestion of the 
      study medication. At the final patient visit, the investigator assessed the 
      effect of treatment on the three chief components of tension headache, head pain, 
      psychic tension, and muscle contraction. Fiorinal with Codeine was generally 
      significantly more effective than placebo or Fiorinal alone in improving all 
      patient-evaluated items between the second and the fourth hours after 
      administration. The combination was also generally significantly better than 
      codeine alone with respect to pain severity, pain relief, the ability to perform 
      daily activities, and average pathology. The three variables rated by the 
      physician also were generally reduced significantly more with the combination 
      than with placebo or Fiorinal alone. Side effects occurred in only one patient 
      treated with Fiorinal with Codeine.
FAU - Friedman, A P
AU  - Friedman AP
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Barbiturates)
RN  - 0 (Drug Combinations)
RN  - 3G6A5W338E (Caffeine)
RN  - 51005-25-5 (aspirin, butalbital and caffeine drug combination)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Barbiturates/adverse effects/*therapeutic use
MH  - *Caffeine
MH  - Codeine/adverse effects/*therapeutic use
MH  - Drug Combinations/adverse effects/therapeutic use
MH  - Emotions/drug effects
MH  - Headache/*drug therapy
MH  - Humans
MH  - Muscle Contraction/drug effects
MH  - Phenacetin/adverse effects/*therapeutic use
MH  - Stress, Psychological/complications/drug therapy
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Ther. 1986;8(6):703-21.

PMID- 9236379
OWN - NLM
STAT- MEDLINE
DCOM- 19970821
LR  - 20190628
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 64
IP  - 1
DP  - 1997 Jul
TI  - Successful thrombolysis after prosthetic pulmonary valve obstruction under 
      aspirin monotherapy.
PG  - 255-7; discussion 257-8
AB  - In a 22-year-old woman with recent onset of left-sided chest pain and exertional 
      dyspnea, echocardiography revealed obstruction of a St. Jude Medical bileaflet 
      prosthetic valve (size 23 mm) in the pulmonary position. Oral anticoagulation had 
      been replaced for the previous 7 years by aspirin as the sole antithrombotic 
      treatment. The valve had been inserted 16 years ago for pulmonary atresia. Valve 
      function was restored by systemic application of 9 million units of urokinase.
FAU - Burger, W
AU  - Burger W
AD  - Department of Interventional Cardiology, St. Georg Hospital Leipzig, Germany.
FAU - Kneissl, G D
AU  - Kneissl GD
FAU - Hartmann, A
AU  - Hartmann A
FAU - Bauersachs, R
AU  - Bauersachs R
FAU - Döring, V
AU  - Döring V
FAU - Spengler, U
AU  - Spengler U
FAU - Neumann, G
AU  - Neumann G
FAU - Rothe, K W
AU  - Rothe KW
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 3.4.21.- (Plasminogen Activators)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Plasminogen Activators/therapeutic use
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Prosthesis Failure
MH  - *Pulmonary Valve
MH  - *Pulmonary Valve Insufficiency/drug therapy/etiology
MH  - *Thrombolytic Therapy
MH  - Urokinase-Type Plasminogen Activator/therapeutic use
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - S0003497597005080 [pii]
AID - 10.1016/s0003-4975(97)00508-0 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 1997 Jul;64(1):255-7; discussion 257-8. doi: 
      10.1016/s0003-4975(97)00508-0.

PMID- 8283002
OWN - NLM
STAT- MEDLINE
DCOM- 19940217
LR  - 20220310
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 17 Suppl 1
DP  - 1993
TI  - The mechanisms of aspirin-induced gastric mucosal injury.
PG  - S1-4
AB  - We examined changes in intracellular pH with the fluorescent probe BCECF after 
      treatment with aspirin (ASA) in gastric mucosal cells isolated from guinea pigs 
      at various extracellular, pH levels. The cytotoxic activities of ASA and the 
      intracellular trapping of ASA at various extracellular pH levels were also 
      examined by colorimetric MTT assay and counting the influx of 
      [14C](carboxyl-14C)-ASA. Under acid extracellular pH, ASA reduced intracellular 
      pH in gastric mucosal cells and exhibited cytotoxicity. Intracellular trapping of 
      ASA was also observed only under acidic extracellular conditions. The present 
      study suggests that ASA causes gastric mucosal cell injury in vitro by reducing 
      intracellular pH, resulting from intracellular trapping of ASA under acidic 
      extracellular conditions.
FAU - Sato, Y
AU  - Sato Y
AD  - Third Department of Internal Medicine, Hokkaido University School of Medicine, 
      Sapporo, Japan.
FAU - Asaka, M
AU  - Asaka M
FAU - Takeda, H
AU  - Takeda H
FAU - Ohtaki, T
AU  - Ohtaki T
FAU - Miyazaki, T
AU  - Miyazaki T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Cell Survival/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Extracellular Space/drug effects
MH  - Gastric Acidity Determination
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Guinea Pigs
MH  - Intracellular Fluid/drug effects
MH  - Male
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1097/00004836-199312001-00003 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 1993;17 Suppl 1:S1-4. doi: 
      10.1097/00004836-199312001-00003.

PMID- 37345815
OWN - NLM
STAT- MEDLINE
DCOM- 20230706
LR  - 20230721
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 12
IP  - 13
DP  - 2023 Jul 4
TI  - Internet Versus Noninternet Participation in a Decentralized Clinical Trial: 
      Lessons From the ADAPTABLE Study.
PG  - e027899
LID - 10.1161/JAHA.122.027899 [doi]
LID - e027899
AB  - Background Internet-based participation has the potential to enhance pragmatic 
      and decentralized trials, where representative study populations and 
      generalizability to clinical practice are key. We aimed to study the differences 
      between internet and noninternet/telephone participants in a large remote, 
      pragmatic trial. Methods and Results In a subanalysis of the ADAPTABLE (Aspirin 
      Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) 
      study, we compared internet participants with those who opted for noninternet 
      participation. Study process measures examined included participant 
      characteristics at consent, study medication adherence, and study retention. The 
      clinical outcome examined was a composite of all-cause mortality, hospitalization 
      for myocardial infarction, or hospitalization for stroke. Noninternet 
      participants were older (mean 69.4 versus 67.4 years), more likely to be female 
      (38.9% versus 30.2%), more likely to be Black (27.3% versus 6.0%) or Hispanic 
      (11.1% versus 2.0%), and had a higher number of comorbid conditions. The 
      composite clinical outcome was more than twice as high in noninternet 
      participants. The hazard of nonadherence to the assigned aspirin dosage was 46% 
      higher in noninternet participants than internet participants. Conclusions 
      Noninternet participants differed from internet participants in notable 
      demographic characteristics while having poorer baseline health. Over the course 
      of ADAPTABLE, they also had worse clinical outcomes and greater likelihood of 
      study drug nonadherence. These results suggest that trials focused on internet 
      participation select for younger, healthier participants with a higher proportion 
      of traditionally overrepresented patients. Allowing noninternet participation 
      enhances diversity; however, additional steps may be needed to promote study 
      retention and study medication adherence. Registration Information 
      clinicaltrials.gov. Identifier: NCT02697916.
FAU - Shen, Rebecca
AU  - Shen R
AUID- ORCID: 0000-0002-3350-9853
AD  - Duke University School of Medicine Durham NC USA.
FAU - Mulder, Hillary
AU  - Mulder H
AUID- ORCID: 0000-0003-4838-582X
AD  - Duke Clinical Research Institute Durham NC USA.
FAU - Wruck, Lisa
AU  - Wruck L
AUID- ORCID: 0000-0003-1732-9067
AD  - Duke Clinical Research Institute Durham NC USA.
FAU - Weissler, E Hope
AU  - Weissler EH
AUID- ORCID: 0000-0002-8442-6150
AD  - Division of Vascular and Endovascular Surgery Duke University School of Medicine 
      Durham NC USA.
FAU - Robertson, Holly R
AU  - Robertson HR
AD  - Duke Clinical Research Institute Durham NC USA.
FAU - Sharlow, Amber G
AU  - Sharlow AG
AUID- ORCID: 0000-0002-3321-1387
AD  - Duke Clinical Research Institute Durham NC USA.
FAU - Kripalani, Sunil
AU  - Kripalani S
AUID- ORCID: 0000-0002-4214-7129
AD  - Vanderbilt University Medical Center Nashville TN USA.
FAU - Muñoz, Daniel
AU  - Muñoz D
AD  - Vanderbilt University Medical Center Nashville TN USA.
FAU - Effron, Mark B
AU  - Effron MB
AUID- ORCID: 0000-0003-4050-5030
AD  - University of Queensland-Ochsner Clinical School New Orleans LA USA.
FAU - Gupta, Kamal
AU  - Gupta K
AUID- ORCID: 0000-0002-2440-9033
AD  - University of Kansas Medical Center Kansas City KA USA.
FAU - Girotra, Saket
AU  - Girotra S
AUID- ORCID: 0000-0002-4784-4513
AD  - University of Iowa Iowa City IA USA.
FAU - Whittle, Jeff
AU  - Whittle J
AUID- ORCID: 0000-0002-9544-838X
AD  - Medical College of Wisconsin Milwaukee WI USA.
FAU - Benziger, Catherine P
AU  - Benziger CP
AUID- ORCID: 0000-0002-8992-6197
AD  - Essentia Health Heart and Vascular Center Duluth MN USA.
FAU - VanWormer, Jeffrey J
AU  - VanWormer JJ
AUID- ORCID: 0000-0002-8733-8703
AD  - Marshfield Clinic Research Institute Marshfield WI USA.
FAU - Polonsky, Tamar S
AU  - Polonsky TS
AUID- ORCID: 0000-0003-2112-9244
AD  - University of Chicago Medicine Chicago IL USA.
FAU - Rothman, Russell L
AU  - Rothman RL
AUID- ORCID: 0000-0002-1506-3990
AD  - Vanderbilt University Medical Center Nashville TN USA.
FAU - Harrington, Robert A
AU  - Harrington RA
AUID- ORCID: 0000-0001-5450-8676
AD  - Stanford University School of Medicine Stanford CA USA.
FAU - Hernandez, Adrian F
AU  - Hernandez AF
AUID- ORCID: 0000-0003-3387-9616
AD  - Duke Clinical Research Institute Durham NC USA.
FAU - Jones, W Schuyler
AU  - Jones WS
AUID- ORCID: 0000-0002-7288-9596
AD  - Duke Clinical Research Institute Durham NC USA.
AD  - Division of Cardiology Duke University Health System Durham NC USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02697916
PT  - Journal Article
PT  - Pragmatic Clinical Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20230622
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Aspirin/therapeutic use
MH  - Internet
MH  - *Myocardial Infarction/drug therapy
MH  - *Stroke/epidemiology/drug therapy
MH  - Aged
PMC - PMC10356087
OTO - NOTNLM
OT  - cardiovascular disease
OT  - clinical trial methodology
OT  - internet follow‐up
OT  - pragmatic trials
EDAT- 2023/06/22 13:09
MHDA- 2023/07/06 06:42
CRDT- 2023/06/22 07:53
PHST- 2023/07/06 06:42 [medline]
PHST- 2023/06/22 13:09 [pubmed]
PHST- 2023/06/22 07:53 [entrez]
AID - JAH38554 [pii]
AID - 10.1161/JAHA.122.027899 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2023 Jul 4;12(13):e027899. doi: 10.1161/JAHA.122.027899. Epub 
      2023 Jun 22.

PMID- 11246058
OWN - NLM
STAT- MEDLINE
DCOM- 20010607
LR  - 20190513
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 3
IP  - 2
DP  - 2001 Mar
TI  - Aspirin does not influence the effect of angiotensin-converting enzyme inhibition 
      on left ventricular ejection fraction 3 months after acute myocardial infarction.
PG  - 203-7
AB  - The aim of the present study was to evaluate the possible interaction between 
      chronic aspirin therapy and angiotensin-converting enzyme inhibitor (ACE-I) on 
      left ventricular ejection fraction (LVEF) in patients surviving an acute 
      myocardial infarction (AMI). Forty-two patients with reduced LVEF were recruited 
      from the warfarin aspirin reinfarction study (WARIS-II), a randomized, open study 
      comparing enteric coated aspirin (160 mg/d), warfarin (INR 2.8--4.2) and the 
      combination of aspirin (75 mg/d) and warfarin (INR 2.0--2.5) on mortality, 
      reinfarction and stroke after AMI. LVEF and relevant biochemical measurements 
      were performed before discharge and after 3 months. The overall LVEF increased 
      during the study period from median 35 to 39% (P<0.001). There was no difference 
      between patients on aspirin and warfarin regarding the main end point, LVEF. 
      Furthermore, neither endothelin-1 nor ANP showed significant differences between 
      the treatment groups. A possible interaction between ACE-I and aspirin might 
      theoretically lead to reduced levels of renin activity in patients on aspirin, 
      but we did not find any such inter-group difference. In conclusion, we did not 
      find evidence of interaction between ACE-I and low-dose aspirin.
FAU - Hurlen, M
AU  - Hurlen M
AD  - Department of Cardiology, Ullevål University Hospital, Oslo, Norway.
FAU - Hole, T
AU  - Hole T
FAU - Seljeflot, I
AU  - Seljeflot I
FAU - Arnesen, H
AU  - Arnesen H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/mortality
MH  - Recurrence
MH  - Risk Factors
MH  - Survival Rate
MH  - Ventricular Function, Left/*drug effects
MH  - Warfarin/*administration & dosage/adverse effects
EDAT- 2001/03/14 10:00
MHDA- 2001/06/19 10:01
CRDT- 2001/03/14 10:00
PHST- 2001/03/14 10:00 [pubmed]
PHST- 2001/06/19 10:01 [medline]
PHST- 2001/03/14 10:00 [entrez]
AID - S1388-9842(00)00138-0 [pii]
AID - 10.1016/s1388-9842(00)00138-0 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2001 Mar;3(2):203-7. doi: 10.1016/s1388-9842(00)00138-0.

PMID- 34939182
OWN - NLM
STAT- MEDLINE
DCOM- 20220422
LR  - 20220728
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 111
IP  - 4
DP  - 2022 Apr
TI  - Serotonin-Affecting Antidepressant Use in Relation to Platelet Reactivity.
PG  - 909-918
LID - 10.1002/cpt.2517 [doi]
AB  - Depression is an independent risk factor of cardiovascular disease morbidity. 
      Serotonin is a key neurotransmitter in depressive pathology, contained within 
      platelets, and is a weak activator of platelets. Our study assessed the link 
      between platelet reactivity traits, depression, and antidepressant (AD) use in a 
      large population sample. Our study was conducted in the Framingham Heart Study 
      (n = 3,140), and AD use (n = 563) and aspirin use (n = 681) were noted. 
      Depression was measured using the Center for Epidemiological Studies-Depression 
      (CES-D) survey. Platelet reactivity traits were measured across multiple agonists 
      using five distinct assays. We utilized a linear mixed effects model to test 
      associations between platelet traits and depression, adjusting for age, sex, 
      aspirin use, and AD use. Similarly, we analyzed trait associations with any AD 
      use, serotonin-affecting ADs, and norepinephrine-affecting ADs, respectively. 
      There were strong associations with reduced platelet function and AD use, 
      particularly with serotonin-affecting medications. This included lower Optimul 
      epinephrine maximal aggregation (P = 4.87E-13), higher U46619 half maximal 
      effective concentration (P = 9.09E-11), lower light transmission aggregometry 
      (LTA) adenosine diphosphate (ADP) final aggregation (P = 1.03E-05), and higher 
      LTA ADP disaggregation (P = 2.28E-05). We found similar associations with 
      serotonin-affecting ADs in an aspirin-taking subset of our sample. There were no 
      significant associations between platelet traits and depression. In the largest 
      study yet of AD use and platelet function we show that antidepressants, 
      particularly serotonin-affecting ADs, inhibit platelets. We did not find evidence 
      that depressive symptomatology in the absence of medication is associated with 
      altered platelet function. Our results are consistent with AD use leading to 
      platelet serotonin depletions, decreased stability of platelet aggregates, and 
      overall decreased aggregation to multiple agonists, which may be a mechanism by 
      which ADs increase risk of bleeding and decrease risk of thrombosis.
CI  - © 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley 
      Periodicals LLC on behalf of American Society for Clinical Pharmacology and 
      Therapeutics. This article has been contributed to by US Government employees and 
      their work is in the public domain in the USA.
FAU - Grech, Joseph
AU  - Grech J
AD  - Population Sciences Branch, National Heart, Lung, and Blood Institute, 
      Framingham, Massachusetts, USA.
FAU - Chan, Melissa Victoria
AU  - Chan MV
AUID- ORCID: 0000-0003-2154-1386
AD  - Population Sciences Branch, National Heart, Lung, and Blood Institute, 
      Framingham, Massachusetts, USA.
AD  - The Blizard Institute, London, UK.
FAU - Ochin, Chinedu
AU  - Ochin C
AUID- ORCID: 0000-0002-1140-3839
AD  - Department of Biomedical and Nutritional Sciences, University of Massachusetts 
      Lowell, Lowell, Massachusetts, USA.
AD  - Center for Population Health, University of Massachusetts Lowell, Lowell, 
      Massachusetts, USA.
FAU - Lachapelle, Amber
AU  - Lachapelle A
AD  - Population Sciences Branch, National Heart, Lung, and Blood Institute, 
      Framingham, Massachusetts, USA.
FAU - Thibord, Florian
AU  - Thibord F
AD  - Population Sciences Branch, National Heart, Lung, and Blood Institute, 
      Framingham, Massachusetts, USA.
FAU - Schneider, Zoe
AU  - Schneider Z
AD  - Population Sciences Branch, National Heart, Lung, and Blood Institute, 
      Framingham, Massachusetts, USA.
FAU - Nkambule, Bongani Brian
AU  - Nkambule BB
AD  - Population Sciences Branch, National Heart, Lung, and Blood Institute, 
      Framingham, Massachusetts, USA.
FAU - Armstrong, Paul Charles John
AU  - Armstrong PCJ
AD  - The Blizard Institute, London, UK.
FAU - de Melendez, Catherine Wallace
AU  - de Melendez CW
AD  - Population Sciences Branch, National Heart, Lung, and Blood Institute, 
      Framingham, Massachusetts, USA.
FAU - Tucker, Katherine L
AU  - Tucker KL
AUID- ORCID: 0000-0001-7640-662X
AD  - Department of Biomedical and Nutritional Sciences, University of Massachusetts 
      Lowell, Lowell, Massachusetts, USA.
AD  - Center for Population Health, University of Massachusetts Lowell, Lowell, 
      Massachusetts, USA.
FAU - Garelnabi, Mahdi
AU  - Garelnabi M
AD  - Department of Biomedical and Nutritional Sciences, University of Massachusetts 
      Lowell, Lowell, Massachusetts, USA.
AD  - Center for Population Health, University of Massachusetts Lowell, Lowell, 
      Massachusetts, USA.
FAU - Warner, Timothy David
AU  - Warner TD
AUID- ORCID: 0000-0003-3988-4408
AD  - The Blizard Institute, London, UK.
FAU - Chen, Ming-Huei
AU  - Chen MH
AD  - Population Sciences Branch, National Heart, Lung, and Blood Institute, 
      Framingham, Massachusetts, USA.
FAU - Johnson, Andrew Danner
AU  - Johnson AD
AUID- ORCID: 0000-0001-6369-5178
AD  - Population Sciences Branch, National Heart, Lung, and Blood Institute, 
      Framingham, Massachusetts, USA.
LA  - eng
GR  - HL93328/HB/NHLBI NIH HHS/United States
GR  - P50 HL105185/British Heart Foundation/
GR  - NO1-HC-25195/HB/NHLBI NIH HHS/United States
GR  - R01 HL131532/HL/NHLBI NIH HHS/United States
GR  - HL107385/HB/NHLBI NIH HHS/United States
GR  - R01 AG055948/AG/NIA NIH HHS/United States
GR  - P50 HL105185/HL/NHLBI NIH HHS/United States
GR  - P01 AG023394/AG/NIA NIH HHS/United States
GR  - National Heart, Lung, and Blood Institute/
GR  - HHSN268201500001I/HB/NHLBI NIH HHS/United States
GR  - P01 AG023394/National Institute of Aging/
GR  - HL126136/HB/NHLBI NIH HHS/United States
GR  - R01 AG055948/National Institute of Aging/
GR  - HL142983/HB/NHLBI NIH HHS/United States
GR  - HL143227/HB/NHLBI NIH HHS/United States
GR  - RG/19/8/34500/British Heart Foundation/
GR  - HL131532/HB/NHLBI NIH HHS/United States
GR  -  Intramural Research program/
GR  - 75N92019D00031/HB/NHLBI NIH HHS/United States
GR  -  (NHBLI)/
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220110
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Antidepressive Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 333DO1RDJY (Serotonin)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate
MH  - Antidepressive Agents/adverse effects
MH  - Aspirin/pharmacology
MH  - *Blood Platelets
MH  - Humans
MH  - Platelet Aggregation
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Platelet Function Tests/methods
MH  - *Serotonin
PMC - PMC9305794
COIS- The authors declared no competing interests for this work.
EDAT- 2021/12/24 06:00
MHDA- 2022/04/23 06:00
CRDT- 2021/12/23 06:01
PHST- 2021/08/10 00:00 [received]
PHST- 2021/12/10 00:00 [accepted]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2022/04/23 06:00 [medline]
PHST- 2021/12/23 06:01 [entrez]
AID - CPT2517 [pii]
AID - 10.1002/cpt.2517 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2022 Apr;111(4):909-918. doi: 10.1002/cpt.2517. Epub 2022 
      Jan 10.

PMID- 1613740
OWN - NLM
STAT- MEDLINE
DCOM- 19920730
LR  - 20131121
IS  - 0380-0903 (Print)
IS  - 0380-0903 (Linking)
VI  - 32
DP  - 1992 Jan
TI  - From aspirin to biologics: therapeutic implications for rheumatoid arthritis.
PG  - 95-7
AB  - As effective antiinflammatory agents have been added to our armamentarium, 2 
      major treatment strategies for the treatment of rheumatoid arthritis have 
      developed. The traditional pyramid strategy is based on initial, conservative 
      measures, followed by more aggressive therapy as the disease progresses. The 
      step-down bridge approach is an alternative, more aggressive strategy that favors 
      earlier use of more potent agents. The longterm effects of disease modifying 
      antirheumatic drugs (DMARD) and combination second line therapy on disease 
      progression remain unclear. Advances in the development of more specific DMARD 
      and in human recombinant proteins offer promising future therapies.
FAU - Wright, V
AU  - Wright V
AD  - Department of Rheumatology, University of Leeds, UK.
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol Suppl
JT  - The Journal of rheumatology. Supplement
JID - 7806058
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biological Products)
RN  - 0 (Immunosuppressive Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Biological Products/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Rheumatology/trends
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol Suppl. 1992 Jan;32:95-7.

PMID- 30556599
OWN - NLM
STAT- MEDLINE
DCOM- 20190306
LR  - 20220830
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 12
IP  - 12
DP  - 2018 Dec 17
TI  - Care prior to and during subsequent pregnancies following stillbirth for 
      improving outcomes.
PG  - CD012203
LID - 10.1002/14651858.CD012203.pub2 [doi]
LID - CD012203
AB  - BACKGROUND: Stillbirth affects at least 2.6 million families worldwide every year 
      and has enduring consequences for parents and health services. Parents entering a 
      subsequent pregnancy following stillbirth face a risk of stillbirth recurrence, 
      alongside increased risks of other adverse pregnancy outcomes and psychosocial 
      challenges. These parents may benefit from a range of interventions to optimise 
      their short- and longer-term medical health and psychosocial well-being. 
      OBJECTIVES: To assess the effects of different interventions or models of care 
      prior to and during subsequent pregnancies following stillbirth on maternal, 
      fetal, neonatal and family health outcomes, and health service utilisation. 
      SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials 
      Register (6 June 2018), along with ClinicalTrials.gov and the WHO International 
      Clinical Trials Registry Platform (ICTRP) (18 June 2018). SELECTION CRITERIA: We 
      included randomised controlled trials (RCTs) and quasi-randomised controlled 
      trials (qRCTs). Trials using a cluster-randomised design were eligible for 
      inclusion, but we found no such reports. We included trials published as abstract 
      only, provided sufficient information was available to allow assessment of trial 
      eligibility and risk of bias. We excluded cross-over trials. DATA COLLECTION AND 
      ANALYSIS: Two review authors independently assessed trials for eligibility and 
      undertook data extraction and 'Risk of bias' assessments. We extracted data from 
      published reports, or sourced data directly from trialists. We checked the data 
      for accuracy and resolved discrepancies by discussion or correspondence with 
      trialists, or both. We conducted an assessment of the quality of the evidence 
      using the GRADE approach. MAIN RESULTS: We included nine RCTs and one qRCT, and 
      judged them to be at low to moderate risk of bias. Trials were carried out 
      between the years 1964 and 2015 and took place predominantly in high-income 
      countries in Europe. All trials assessed medical interventions; no trials 
      assessed psychosocial interventions or incorporated psychosocial aspects of care. 
      Trials evaluated the use of antiplatelet agents (low-dose aspirin (LDA) or 
      low-molecular-weight heparin (LMWH), or both), third-party leukocyte 
      immunisation, intravenous immunoglobulin, and progestogen. Trial participants 
      were women who were either pregnant or attempting to conceive following a 
      pregnancy loss, fetal death, or adverse outcome in a previous pregnancy.We 
      extracted data for 222 women who had experienced a previous stillbirth of 20 
      weeks' gestation or more from the broader trial data sets, and included them in 
      this review. Our GRADE assessments of the quality of evidence ranged from very 
      low to low, due largely to serious imprecision in effect estimates as a result of 
      small sample sizes, low numbers of events, and wide confidence intervals (CIs) 
      crossing the line of no effect. Most of the analyses in this review were not 
      sufficiently powered to detect differences in the outcomes assessed. The results 
      presented are therefore largely uncertain.Main comparisonsLMWH versus no 
      treatment/standard care (three RCTs, 123 women, depending on the outcome)It was 
      uncertain whether LMWH reduced the risk of stillbirth (risk ratio (RR) 2.58, 95% 
      CI 0.40 to 16.62; 3 trials; 122 participants; low-quality evidence), adverse 
      perinatal outcome (RR 0.81, 95% CI 0.20 to 3.32; 2 trials; 77 participants; 
      low-quality evidence), adverse maternal psychological effects (RR 1.00, 95% CI 
      0.07 to 14.90; 1 trial; 40 participants; very low-quality evidence), perinatal 
      mortality (RR 2.58, 95% CI 0.40 to 16.62; 3 trials; 122 participants; low-quality 
      evidence), or any preterm birth (< 37 weeks) (RR 1.01, 0.58 to 1.74; 3 trials; 
      114 participants; low-quality evidence). No neonatal deaths were reported in the 
      trials assessed and no data were available for maternal-infant attachment. There 
      was no clear evidence of a difference between the groups among the remaining 
      secondary outcomes.LDA versus placebo (one RCT, 24 women)It was uncertain whether 
      LDA reduced the risk of stillbirth (RR 0.85, 95% CI 0.06 to 12.01), neonatal 
      death (RR 0.29, 95% CI 0.01 to 6.38), adverse perinatal outcome (RR 0.28, 95% CI 
      0.03 to 2.34), perinatal mortality, or any preterm birth (< 37 weeks) (both of 
      the latter RR 0.42, 95% CI 0.04 to 4.06; all very low-quality evidence). No data 
      were available for adverse maternal psychological effects or maternal-infant 
      attachment. LDA appeared to be associated with an increase in birthweight (mean 
      difference (MD) 790.00 g, 95% CI 295.03 to 1284.97 g) when compared to placebo, 
      but this result was very unstable due to the extremely small sample size. Whether 
      LDA has any effect on the remaining secondary outcomes was also uncertain.Other 
      comparisonsLDA appeared to be associated with an increase in birthweight when 
      compared to LDA + LMWH (MD -650.00 g, 95% CI -1210.33 to -89.67 g; 1 trial; 29 
      infants), as did third-party leukocyte immunisation when compared to placebo (MD 
      1195.00 g, 95% CI 273.35 to 2116.65 g; 1 trial, 4 infants), but these results 
      were again very unstable due to extremely small sample sizes. The effects of the 
      interventions on the remaining outcomes were also uncertain. AUTHORS' 
      CONCLUSIONS: There is insufficient evidence in this review to inform clinical 
      practice about the effectiveness of interventions to improve care prior to and 
      during subsequent pregnancies following a stillbirth. There is a clear and urgent 
      need for well-designed trials addressing this research question. The evaluation 
      of medical interventions such as LDA, in the specific context of stillbirth 
      prevention (and recurrent stillbirth prevention), is warranted. However, 
      appropriate methodologies to evaluate such therapies need to be determined, 
      particularly where clinical equipoise may be lacking. Careful trial design and 
      multicentre collaboration is necessary to carry out trials that would be 
      sufficiently large to detect differences in statistically rare outcomes such as 
      stillbirth and neonatal death. The evaluation of psychosocial interventions 
      addressing maternal-fetal attachment and parental anxiety and depression is also 
      an urgent priority. In a randomised-trial context, such trials may allocate 
      parents to different forms of support, to determine which have the greatest 
      benefit with the least financial cost. Importantly, consistency in nomenclature 
      and in data collection across all future trials (randomised and non-randomised) 
      may be facilitated by a core outcomes data set for stillbirth research. All 
      future trials should assess short- and longer-term psychosocial outcomes for 
      parents and families, alongside economic costs of interventions.
FAU - Wojcieszek, Aleena M
AU  - Wojcieszek AM
AD  - NHMRC Centre of Research Excellence in Stillbirth, Mater Research Institute - The 
      University of Queensland (MRI-UQ), Level 3 Aubigny Place, Mater Health Services, 
      Brisbane, Queensland, Australia, 4101.
FAU - Shepherd, Emily
AU  - Shepherd E
FAU - Middleton, Philippa
AU  - Middleton P
FAU - Lassi, Zohra S
AU  - Lassi ZS
FAU - Wilson, Trish
AU  - Wilson T
FAU - Murphy, Margaret M
AU  - Murphy MM
FAU - Heazell, Alexander Ep
AU  - Heazell AE
FAU - Ellwood, David A
AU  - Ellwood DA
FAU - Silver, Robert M
AU  - Silver RM
FAU - Flenady, Vicki
AU  - Flenady V
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20181217
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
UOF - doi: 10.1002/14651858.CD012203
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Infant, Newborn
MH  - Parents
MH  - Perinatal Mortality
MH  - Pregnancy
MH  - Prenatal Care/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Secondary Prevention/*methods
MH  - *Stillbirth/epidemiology
PMC - PMC6516997
COIS- Aleena M Wojcieszek: none known. Emily Shepherd: none known. Philippa Middleton: 
      none known. Zohra S Lassi: none known. Trish Wilson: none known. Margaret M 
      Murphy: none known. Alexander EP Heazell: Alexander EP Heazell's salary is funded 
      by his National Institute of Health Research (NIHR) Clinician Scientist Award 
      (CS‐2013‐13‐009) although this review is not directly funded by this award. He 
      also receives salary support from Tommy's Charity as Director of the Tommy's 
      Stillbirth Research Centre, University of Manchester. This review is part of this 
      programme of work into improving care in pregnancies after stillbirth. Alexander 
      E P Heazell is the Clinical Lead for a specialist antenatal service for women who 
      have experienced a stillbirth in previous pregnancy. David A Ellwood: David 
      Ellwood has received sitting fees from the Australian Medical Council but this 
      work is not related to this Cochrane Review. He has received payment for 
      providing expert witness reviews for medico‐legal cases – these cases are in no 
      way related to the topic under review. I am the co‐Director of an NHMRC Centre 
      for Research Excellence ‐ the centre is related to stillbirth and will cover all 
      aspects of research on this topic. Robert M Silver: Robert M Silver has been 
      awarded NIH grants unrelated to this work. He is a member of the International 
      stillbirth Alliance Scientific Research Committee. He has carried out paid 
      consultancy for Gestavision (a company developing a diagnostic for pre‐eclampsia) 
      and has received payment for grand rounds at several universities. Vicki Flenady: 
      none known
EDAT- 2018/12/18 06:00
MHDA- 2019/03/07 06:00
CRDT- 2018/12/18 06:00
PHST- 2018/12/18 06:00 [pubmed]
PHST- 2019/03/07 06:00 [medline]
PHST- 2018/12/18 06:00 [entrez]
AID - CD012203.pub2 [pii]
AID - 10.1002/14651858.CD012203.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2018 Dec 17;12(12):CD012203. doi: 
      10.1002/14651858.CD012203.pub2.

PMID- 28128747
OWN - NLM
STAT- MEDLINE
DCOM- 20171129
LR  - 20181202
IS  - 1875-8622 (Electronic)
IS  - 1386-0291 (Print)
IS  - 1386-0291 (Linking)
VI  - 66
IP  - 1
DP  - 2017
TI  - Use of thrombin generation test for monitoring hemostasis in coronary bypass 
      surgery.
PG  - 57-66
LID - 10.3233/CH-160216 [doi]
AB  - To evaluate the parameters of the thrombin generation test (TGT) in coronary 
      artery disease (CAD) patients on prolonged aspirin therapy during on-pump 
      coronary artery bypass grafting (CABG) after donor platelet concentrate 
      transfusion. A total of 148 patients with CAD on prolonged aspirin therapy 
      (75-100 mg/day) who have undergone elective on-pump CABG were consecutively 
      included in the study. Patients were divided randomly into two groups. Group 1 
      (n = 76) received donor platelet transfusions after cardiopulmonary bypass, 
      whereas Group 2 (n = 72) did not. TGT parameters were measured using an analyzer 
      at pre-, intra-, and early postoperative periods. Activation of the endogenous 
      thrombin potential was observed in patients on prolonged aspirin therapy in the 
      pre- and intraoperative periods, as confirmed by high peak thrombin and increased 
      velocity index. The activation time of the prothrombinase complex and thrombin 
      generation time were greater than the control group. The blood hemostatic 
      potential in patients who did not receive transfusions in the early postoperative 
      period decreased up to the level of the control group in the extended time 
      parameters. Hemostatic potential in plasma in patients on aspirin was preserved. 
      Given the laboratory test results and clinical data, platelet concentrate 
      transfusion is unnecessary for prevention.
FAU - Gruzdeva, Olga
AU  - Gruzdeva O
AD  - Federal State Budgetary Institution "Research Institute for Complex Issues of 
      Cardiovascular Diseases", Kemerovo, Russia.
FAU - Uchasova, Evgenya
AU  - Uchasova E
AD  - Federal State Budgetary Institution "Research Institute for Complex Issues of 
      Cardiovascular Diseases", Kemerovo, Russia.
FAU - Fanaskova, Elena
AU  - Fanaskova E
AD  - Federal State Budgetary Institution "Research Institute for Complex Issues of 
      Cardiovascular Diseases", Kemerovo, Russia.
FAU - Akbasheva, Olga
AU  - Akbasheva O
AD  - Federal State Budget Educational Institution of Higher Professional Education 
      "Siberian StateMedical University", the Ministry of Health of the Russian 
      Federation, Tomsk, Russia.
FAU - Penskaya, Tatyana
AU  - Penskaya T
AD  - Federal State Budgetary Institution "Research Institute for Complex Issues of 
      Cardiovascular Diseases", Kemerovo, Russia.
FAU - Plotnikov, Georgy
AU  - Plotnikov G
AD  - Federal State Budgetary Institution "Research Institute for Complex Issues of 
      Cardiovascular Diseases", Kemerovo, Russia.
FAU - Dyleva, Yulia
AU  - Dyleva Y
AD  - Federal State Budgetary Institution "Research Institute for Complex Issues of 
      Cardiovascular Diseases", Kemerovo, Russia.
FAU - Barbarash, Olga
AU  - Barbarash O
AD  - Federal State Budgetary Institution "Research Institute for Complex Issues of 
      Cardiovascular Diseases", Kemerovo, Russia.
AD  - Federal State Budget Educational Institution of Higher Professional Education 
      "Kemerovo State Medical University", the Ministry of Health of the Russian 
      Federation, Kemerovo, Russia.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - EC 3.4.21.5 (Thrombin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Blood Coagulation Tests/*methods
MH  - Coronary Artery Bypass/*methods
MH  - Female
MH  - Hemostasis/*physiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Transfusion/*methods
MH  - Thrombin/*therapeutic use
PMC - PMC5438468
OTO - NOTNLM
OT  - Thrombin generation test
OT  - aspirin therapy
OT  - coronary artery disease
OT  - platelet transfusion
EDAT- 2017/01/28 06:00
MHDA- 2017/12/01 06:00
CRDT- 2017/01/28 06:00
PHST- 2017/01/28 06:00 [pubmed]
PHST- 2017/12/01 06:00 [medline]
PHST- 2017/01/28 06:00 [entrez]
AID - CH160216 [pii]
AID - 10.3233/CH-160216 [doi]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 2017;66(1):57-66. doi: 10.3233/CH-160216.

PMID- 36346115
OWN - NLM
STAT- MEDLINE
DCOM- 20230206
LR  - 20230415
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 152
IP  - 7
DP  - 2023 Apr 1
TI  - Antiplatelet drugs and breast cancer risk in a large nationwide Danish 
      case-control study.
PG  - 1337-1347
LID - 10.1002/ijc.34343 [doi]
AB  - Low-dose aspirin has been hypothesized to prevent cancer risk by inhibiting 
      platelet aggregation. However, the anti-cancer effect of low-dose aspirin has 
      recently been questioned and its effect on breast cancer development remains 
      unclear. The impact of other antiplatelet drugs on breast cancer risk has rarely 
      been evaluated. Thus, this study aimed to investigate the associations between 
      breast cancer risk and antiplatelet drug use in a nationwide nested case-control 
      study. From the Danish healthcare registries, we identified as cases all women 
      with invasive breast cancer diagnosis between 2001 and 2018 (n = 68 852). The 
      date of diagnosis corresponded to the index date. We matched cases to 10 
      population controls on age and calendar time, using risk set sampling. Controls 
      were assigned the same index date as their matched case. We used the prescription 
      registry to identify exposure to low-dose aspirin, clopidogrel and dipyridamole. 
      We defined ever use of antiplatelet drugs as at least two prescriptions filled up 
      to 1 year before the index date. We applied conditional logistic regression to 
      calculate odds ratios (ORs) and 95% confidence intervals for breast cancer 
      associated with the use of antiplatelet drugs, overall, by breast cancer subtype 
      and by cumulative dose. Twelve percent of women had ever been exposed to low-dose 
      aspirin, 2% to clopidogrel and 2% to dipyridamole. In multivariable models, 
      breast cancer risk was not associated with ever use of low-dose aspirin 
      (OR = 1.00 [0.97-1.03]), clopidogrel (OR = 0.93 [0.87-1.00]), and dipyridamole 
      (OR = 1.02 [0.94-1.10]), compared with never use, and there was no evidence of a 
      dose-response relation. However, we found an inverse association between 
      dipyridamole use and breast cancer risk among women aged <55 years old, with 
      suggestion of a dose-response relationship (OR per 1000 Defined Daily 
      Doses = 0.72 [0.54-0.95]). Associations did not differ by breast cancer 
      histological type, estrogen receptor status or clinical stage at diagnosis. 
      Overall, the findings from this study do not support the use of antiplatelet 
      drugs for breast cancer prevention.
CI  - © 2022 The Authors. International Journal of Cancer published by John Wiley & 
      Sons Ltd on behalf of UICC.
FAU - Cairat, Manon
AU  - Cairat M
AUID- ORCID: 0000-0002-0964-3120
AD  - Inserm, Université Paris Saclay, Institut Gustave Roussy, "Exposome, Heredity, 
      Cancer and Health" Team, Villejuif, France.
AD  - Nutrition and Metabolism Branch, International Agency for Research on Cancer, 
      Lyon, France.
FAU - Pottegård, Anton
AU  - Pottegård A
AUID- ORCID: 0000-0001-9314-5679
AD  - Clinical Pharmacology and Pharmacy, Department of Public Health, University of 
      Southern Denmark, Odense, Denmark.
FAU - Olesen, Morten
AU  - Olesen M
AD  - Clinical Pharmacology and Pharmacy, Department of Public Health, University of 
      Southern Denmark, Odense, Denmark.
FAU - Dossus, Laure
AU  - Dossus L
AD  - Nutrition and Metabolism Branch, International Agency for Research on Cancer, 
      Lyon, France.
FAU - Fournier, Agnès
AU  - Fournier A
AUID- ORCID: 0000-0001-8380-3439
AD  - Inserm, Université Paris Saclay, Institut Gustave Roussy, "Exposome, Heredity, 
      Cancer and Health" Team, Villejuif, France.
FAU - Hicks, Blánaid
AU  - Hicks B
AUID- ORCID: 0000-0002-5730-9469
AD  - Centre for Public Health, Queen's University Belfast, Belfast, UK.
LA  - eng
PT  - Journal Article
DEP - 20221117
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - R16CO5Y76E (Aspirin)
RN  - A74586SNO7 (Clopidogrel)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Aspirin/therapeutic use
MH  - *Breast Neoplasms/epidemiology/drug therapy
MH  - Case-Control Studies
MH  - Clopidogrel
MH  - Denmark/epidemiology
MH  - Dipyridamole/therapeutic use
MH  - Logistic Models
MH  - *Platelet Aggregation Inhibitors
PMC - PMC10100032
OTO - NOTNLM
OT  - antiplatelet drugs
OT  - breast cancer
OT  - low-dose aspirin
OT  - registries
COIS- Anton Pottegård reports participation in research projects funded by Alcon, 
      Almirall, Astellas, Astra‐Zeneca, Boehringer‐Ingelheim, Novo Nordisk, Servier and 
      LEO Pharma, all regulator‐mandated phase IV‐studies, all with funds paid to the 
      institution where he was employed (no personal fees) and with no relation to the 
      work reported in this paper. The other authors declare no conflict of interest.
EDAT- 2022/11/09 06:00
MHDA- 2023/02/03 06:00
CRDT- 2022/11/08 07:43
PHST- 2022/10/03 00:00 [revised]
PHST- 2022/07/13 00:00 [received]
PHST- 2022/10/20 00:00 [accepted]
PHST- 2022/11/09 06:00 [pubmed]
PHST- 2023/02/03 06:00 [medline]
PHST- 2022/11/08 07:43 [entrez]
AID - IJC34343 [pii]
AID - 10.1002/ijc.34343 [doi]
PST - ppublish
SO  - Int J Cancer. 2023 Apr 1;152(7):1337-1347. doi: 10.1002/ijc.34343. Epub 2022 Nov 
      17.

PMID- 2462442
OWN - NLM
STAT- MEDLINE
DCOM- 19890209
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 26
IP  - 1
DP  - 1988 Jul
TI  - Bradykinin induced wheal and flare is not mediated by histamine release or 
      cyclooxygenase products.
PG  - 113-5
AB  - The wheal and flare response to intradermal bradykinin was studied in man. The 
      possibility that histamine and cyclooxygenase products are involved in the 
      response to bradykinin was examined. Terfenadine given by mouth significantly 
      inhibited the cutaneous response to histamine but the effect of bradykinin was 
      unaltered. Similarly the cutaneous response to bradykinin was unchanged by 
      aspirin.
FAU - Crossman, D C
AU  - Crossman DC
AD  - Department of Clinical Pharmacology, Royal Postgraduate Medical School, London.
FAU - Fuller, R W
AU  - Fuller RW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Histamine H1 Antagonists)
RN  - 7BA5G9Y06Q (Terfenadine)
RN  - 820484N8I3 (Histamine)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Benzhydryl Compounds/pharmacology
MH  - *Bradykinin
MH  - Histamine/pharmacology
MH  - Histamine H1 Antagonists/pharmacology
MH  - Histamine Release/*drug effects
MH  - Humans
MH  - Male
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - *Skin Tests
MH  - Terfenadine
PMC - PMC1386511
EDAT- 1988/07/01 00:00
MHDA- 1988/07/01 00:01
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 1988/07/01 00:01 [medline]
PHST- 1988/07/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1988.tb03375.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1988 Jul;26(1):113-5. doi: 
      10.1111/j.1365-2125.1988.tb03375.x.

PMID- 227205
OWN - NLM
STAT- MEDLINE
DCOM- 19791227
LR  - 20190716
IS  - 0001-5598 (Print)
IS  - 0001-5598 (Linking)
VI  - 91
IP  - 4
DP  - 1979 Aug
TI  - Effect of two prostaglandin synthesis inhibitors, indomethacin and 
      acetylsalicylic acid, on plasma ACTH and cortisol levels in man.
PG  - 666-73
AB  - The aim of this study was to investigate the possible role of prostaglandins (PG) 
      in the control of the hypohtalamic-pituitary-adrenocortical axis in normal 
      volunteers. Acute oral administration of 100 mg indomethacin (ID) or 1.5 g 
      acetylsalicylic acid (ASA) did not alter ACTH and cortisol plasma levels. 
      Administration of 300 mg daily ID for 4 days delayed the onset, but increased the 
      magnitude, of the response of ACTH to insulin hypoglycaemia, while it blunted the 
      cortisol response. Administration of 3.2 g ASA daily depressed ACTH response to 
      hypoglycaemia leaving the cortisol response unchanged, except for a 15 min delay 
      in onset. These results are interpreted assuming that ID and ASA chiefly acted at 
      the pituitary and hypothalamic level, respectively, and that ID, but not ASA, 
      interfered with adrenocortical cortisol production. Our findings support the 
      concept, based on animal studies, that PG enhance hypothalamic CRF release and 
      adrenocortical steroidogenesis and may restrain ACTH secretion in the pituitary.
FAU - Cavagnini, F
AU  - Cavagnini F
FAU - Di Landro, A
AU  - Di Landro A
FAU - Maraschini, C
AU  - Maraschini C
FAU - Invitti, C
AU  - Invitti C
FAU - Pinto, M L
AU  - Pinto ML
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Acta Endocrinol (Copenh)
JT  - Acta endocrinologica
JID - 0370312
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Prostaglandins)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Administration, Oral
MH  - Adrenocorticotropic Hormone/*blood
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Glucose/analysis
MH  - Female
MH  - Humans
MH  - Hydrocortisone/*blood
MH  - Hypothalamo-Hypophyseal System/*physiology
MH  - Indomethacin/administration & dosage/*pharmacology
MH  - Insulin
MH  - Middle Aged
MH  - Pituitary-Adrenal System/*physiology
MH  - Prostaglandins/*physiology
EDAT- 1979/08/01 00:00
MHDA- 1979/08/01 00:01
CRDT- 1979/08/01 00:00
PHST- 1979/08/01 00:00 [pubmed]
PHST- 1979/08/01 00:01 [medline]
PHST- 1979/08/01 00:00 [entrez]
AID - 10.1530/acta.0.0910666 [doi]
PST - ppublish
SO  - Acta Endocrinol (Copenh). 1979 Aug;91(4):666-73. doi: 10.1530/acta.0.0910666.

PMID- 456989
OWN - NLM
STAT- MEDLINE
DCOM- 19790917
LR  - 20201209
IS  - 0015-8178 (Print)
IS  - 0015-8178 (Linking)
VI  - 97
IP  - 16
DP  - 1979 Apr 26
TI  - [Results of treatment with DoloVisano for non-specific pain syndrome related to 
      body movement. Concluding report on a field study of 3326 patients by 314 
      orthopedists].
PG  - 791-6
AB  - The effectiveness of ColoVisano with view to the nonspecific pain syndrom of the 
      locomotor system, particularly of the back, was proven on 3,326 ambulant 
      patients. Three weeks after starting of treatment the majority of the patients 
      was found free of pain. Considering the duration of the disease, the result of 
      treatment with DoloVisano is remarkable: 66% = very good--good, 17% = moderate, 
      only 12% = without success. Only in 15% of the cases side effects were found, 
      which never led to an interrupture of the treatment. When listing the side 
      effects, gastric pain with 6% and trousiness with 50% are ranging among the first 
      places. The field study, performed by 314 orthopedic doctors in practice shows 
      the high effectiveness of DoloVisano not only in patients with non-specific pain 
      syndrom resulting from the spine but also with rheumatic syndrom, especially 
      fibrositis and degenerative diseases.
FAU - Sögtrop, H H
AU  - Sögtrop HH
FAU - Weise, H T
AU  - Weise HT
LA  - ger
PT  - Journal Article
TT  - Behandlungsergebnisse mit DoloVisano beim unspezifischen Schmerzsyndrom des 
      Bewegungsapparates. Abschliessender Bericht über eine Feldstudie an 3326 
      Patienten bei 314 niedergelassenen Orthopäden.
PL  - Germany
TA  - Fortschr Med
JT  - Fortschritte der Medizin
JID - 2984763R
RN  - 0 (Drug Combinations)
RN  - 0 (Nicotinic Acids)
RN  - 8GTS82S83M (Diphenhydramine)
RN  - 9I7LNY769Q (Meprobamate)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Codeine/administration & dosage/*therapeutic use
MH  - Diphenhydramine/administration & dosage/*therapeutic use
MH  - Drug Combinations
MH  - Drug Evaluation
MH  - Humans
MH  - Meprobamate/administration & dosage/*therapeutic use
MH  - Movement Disorders/*drug therapy
MH  - Muscular Diseases/*drug therapy
MH  - Nicotinic Acids/administration & dosage/therapeutic use
MH  - Pain/*drug therapy
EDAT- 1979/04/26 00:00
MHDA- 1979/04/26 00:01
CRDT- 1979/04/26 00:00
PHST- 1979/04/26 00:00 [pubmed]
PHST- 1979/04/26 00:01 [medline]
PHST- 1979/04/26 00:00 [entrez]
PST - ppublish
SO  - Fortschr Med. 1979 Apr 26;97(16):791-6.

PMID- 27490468
OWN - NLM
STAT- MEDLINE
DCOM- 20170823
LR  - 20220316
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 8
DP  - 2016
TI  - Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of 
      Observational Studies.
PG  - e0160046
LID - 10.1371/journal.pone.0160046 [doi]
LID - e0160046
AB  - BACKGROUND: Low-dose aspirin has proven effectiveness in secondary and primary 
      prevention of cardiovascular events, but is also associated with an increased 
      risk of major bleeding events. For primary prevention, this absolute risk must be 
      carefully weighed against the benefits of aspirin; such assessments are currently 
      limited by a lack of data from general populations. METHODS: Systematic searches 
      of Medline and Embase were conducted to identify observational studies published 
      between 1946 and 4 March 2015 that reported the risks of gastrointestinal (GI) 
      bleeding or intracranial hemorrhage (ICH) with long-term, low-dose aspirin 
      (75-325 mg/day). Pooled estimates of the relative risk (RR) for bleeding events 
      with aspirin versus non-use were calculated using random-effects models, based on 
      reported estimates of RR (including odds ratios, hazard ratios, incidence rate 
      ratios and standardized incidence ratios) in 39 articles. FINDINGS: The incidence 
      of GI bleeding with low-dose aspirin was 0.48-3.64 cases per 1000 person-years, 
      and the overall pooled estimate of the RR with low-dose aspirin was 1.4 (95% 
      confidence interval [CI]: 1.2-1.7). For upper and lower GI bleeding, the RRs with 
      low-dose aspirin were 2.3 (2.0-2.6) and 1.8 (1.1-3.0), respectively. Neither 
      aspirin dose nor duration of use had consistent effects on RRs for upper GI 
      bleeding. The estimated RR for ICH with low-dose aspirin was 1.4 (1.2-1.7) 
      overall. Aspirin was associated with increased bleeding risks when combined with 
      non-steroidal anti-inflammatory drugs, clopidogrel and selective serotonin 
      reuptake inhibitors compared with monotherapy. By contrast, concomitant use of 
      proton pump inhibitors decreased upper GI bleeding risks relative to aspirin 
      monotherapy. CONCLUSIONS: The risks of major bleeding with low-dose aspirin in 
      real-world settings are of a similar magnitude to those reported in randomized 
      trials. These data will help inform clinical judgements regarding the use of 
      low-dose aspirin in prevention of cardiovascular events.
FAU - García Rodríguez, Luis A
AU  - García Rodríguez LA
AD  - Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.
FAU - Martín-Pérez, Mar
AU  - Martín-Pérez M
AD  - Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.
FAU - Hennekens, Charles H
AU  - Hennekens CH
AD  - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, 
      Florida, United States of America.
FAU - Rothwell, Peter M
AU  - Rothwell PM
AD  - Stroke Prevention Research Unit, Nuffield Department of Clinical Neurosciences, 
      John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
FAU - Lanas, Angel
AU  - Lanas A
AD  - University of Zaragoza, University Clinic Hospital, IIS Aragón, CIBERehd, 
      Zaragoza, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20160804
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Clopidogrel
MH  - Databases, Factual
MH  - Gastrointestinal Hemorrhage/epidemiology/*etiology
MH  - Humans
MH  - Incidence
MH  - Intracranial Hemorrhages/epidemiology/*etiology
MH  - Observational Studies as Topic
MH  - Odds Ratio
MH  - Risk
MH  - Ticlopidine/analogs & derivatives/therapeutic use
PMC - PMC4973997
COIS- Competing Interests: Drs García Rodríguez and Martín-Pérez work at CEIFE, which 
      has received research grants from Bayer Pharma AG. Dr García Rodríguez has been 
      paid as a consultant for Bayer Pharma AG (Germany). Professor Lanas has received 
      research grants from, and has been paid as a consultant for, Bayer Pharma AG. 
      Professor Hennekens is funded by the Charles E. Schmidt College of Medicine at 
      Florida Atlantic University. He serves as an independent scientist in an advisory 
      role to investigators and sponsors as: Chair or Member of Data and Safety 
      Monitoring Boards for Amgen, AstraZeneca, Bayer, Bristol Myers-Squibb, British 
      Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, 
      Genzyme, Lilly, Regeneron, Sanofi, Sunovion and the Wellcome Foundation; advisor 
      to Aralez/Pozen, the United States (U.S.) Food and Drug Administration, UpToDate, 
      and legal counsel for Pfizer and Takeda. Professor Hennekens receives royalties 
      for authorship or editorship of 3 textbooks and as coinventor on patents for 
      inflammatory markers and CV disease that are held by Brigham and Women’s 
      Hospital; has an investment management relationship with the West-Bacon Group 
      within SunTrust Investment Services, which has discretionary investment authority 
      and does not own any common or preferred stock in any pharmaceutical or medical 
      device company. Professor Rothwell is a member of the Executive Committee of the 
      ARRIVE trial and has received honoraria from Bayer for advisory boards. This does 
      not alter the authors' adherence to all PLOS ONE policies on sharing data and 
      materials.
EDAT- 2016/08/05 06:00
MHDA- 2017/08/24 06:00
CRDT- 2016/08/05 06:00
PHST- 2016/04/05 00:00 [received]
PHST- 2016/05/30 00:00 [accepted]
PHST- 2016/08/05 06:00 [entrez]
PHST- 2016/08/05 06:00 [pubmed]
PHST- 2017/08/24 06:00 [medline]
AID - PONE-D-16-13722 [pii]
AID - 10.1371/journal.pone.0160046 [doi]
PST - epublish
SO  - PLoS One. 2016 Aug 4;11(8):e0160046. doi: 10.1371/journal.pone.0160046. 
      eCollection 2016.

PMID- 23047310
OWN - NLM
STAT- MEDLINE
DCOM- 20130301
LR  - 20131121
IS  - 1098-9048 (Electronic)
IS  - 1069-3424 (Linking)
VI  - 33
IP  - 6
DP  - 2012 Dec
TI  - Aspirin-exacerbated respiratory disease: update on pathogenesis and 
      desensitization.
PG  - 588-94
LID - 10.1055/s-0032-1325618 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is a unique syndrome of airway 
      inflammation that frequently occurs in patients with nasal polyposis, chronic 
      sinusitis, and asthma. These patients tend to have progressive and recalcitrant 
      sinus disease requiring frequent surgical intervention and in many cases systemic 
      corticosteroids. Much about the pathogenesis of AERD remains unclear, but 
      environmental factors likely play a prominent role in its development. Avoidance 
      of aspirin or nonsteroidal antiinflammatory drugs (NSAIDs) is imperative in the 
      initial counseling of these patients. Because most of the exposure to these 
      medications is available over the counter, most patients will experience a 
      significant respiratory reaction to full therapeutic doses of seemingly innocent 
      NSAIDs. Although the history of a reaction to aspirin or another NSAID is a very 
      important part of making the diagnosis, the gold standard remains an observed 
      aspirin challenge. Given the prevalence and usefulness of aspirin and NSAID 
      therapy in primary care clinics, an accurate diagnosis should be made in all 
      patients. Desensitization is an effective treatment option for many patients. 
      Recent advances have made this procedure considerably safer and outpatient 
      aspirin desensitization is now the standard of care.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - White, Andrew A
AU  - White AA
AD  - Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, 
      California 92130, USA. White.andrew@scrippshealth.org
FAU - Stevenson, Donald D
AU  - Stevenson DD
LA  - eng
PT  - Journal Article
DEP - 20121009
PL  - United States
TA  - Semin Respir Crit Care Med
JT  - Seminars in respiratory and critical care medicine
JID - 9431858
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Glucocorticoids)
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Asthma, Aspirin-Induced/diagnosis/*physiopathology/therapy
MH  - Desensitization, Immunologic/*methods
MH  - Disease Progression
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Nasal Polyps/epidemiology
MH  - Nonprescription Drugs/adverse effects
MH  - Patient Education as Topic/methods
MH  - Sinusitis/epidemiology
EDAT- 2012/10/11 06:00
MHDA- 2013/03/02 06:00
CRDT- 2012/10/11 06:00
PHST- 2012/10/11 06:00 [entrez]
PHST- 2012/10/11 06:00 [pubmed]
PHST- 2013/03/02 06:00 [medline]
AID - 10.1055/s-0032-1325618 [doi]
PST - ppublish
SO  - Semin Respir Crit Care Med. 2012 Dec;33(6):588-94. doi: 10.1055/s-0032-1325618. 
      Epub 2012 Oct 9.

PMID- 37146687
OWN - NLM
STAT- MEDLINE
DCOM- 20230703
LR  - 20230703
IS  - 2589-9333 (Electronic)
IS  - 2589-9333 (Linking)
VI  - 5
IP  - 7
DP  - 2023 Jul
TI  - Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm 
      preeclampsia: systematic review and meta-analysis.
PG  - 101000
LID - S2589-9333(23)00142-8 [pii]
LID - 10.1016/j.ajogmf.2023.101000 [doi]
AB  - OBJECTIVE: This study aimed to compare 2 aspirin dosage regimens for the 
      prevention of preterm preeclampsia (PE): 75 to 81 mg vs 150 to 162 mg taken daily 
      starting in the first trimester of pregnancy. DATA SOURCES: A systematic search 
      was performed using PubMed, Embase, CINAHL, Web of Science, and Cochrane Central 
      Register of Controlled Trials from January 1985 to April 2023. STUDY ELIGIBILITY 
      CRITERIA: The inclusion criteria were randomized controlled trials that compared 
      the effect of 2 aspirin dosage regimens during pregnancy for the prevention of PE 
      initiated in the first trimester of pregnancy. The intervention was an aspirin 
      dosage between 150 and 162 mg daily, and the control was an aspirin dosage 
      between 75 and 81 mg daily. METHODS: Of note, 2 reviewers independently screened 
      all citations, selected studies, and evaluated the risk of bias. The review 
      followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
      guidelines and applied the Cochrane risk of bias tool. The corresponding authors 
      of the included studies were contacted to validate each of the collected results. 
      The primary outcome was the risk of preterm preeclampsia, and the secondary 
      outcomes included term preeclampsia, any preeclampsia regardless of gestational 
      age, and severe preeclampsia. Relative risks with their 95% confidence interval 
      were calculated for each study and pooled for global analysis. RESULTS: Of note, 
      4 randomized controlled trials were retrieved involving 552 participants. 
      Moreover, 2 randomized controlled trials were at unclear risk of bias, 1 trial at 
      low risk of bias and 1 trial at high risk of bias, which did not have the 
      information for the primary outcome. The pooled analysis demonstrated that an 
      aspirin dosage of 150 to 162 mg was associated with a significant reduction of 
      preterm preeclampsia, compared with an aspirin dosage of 75 to 81 mg (3 studies; 
      472 participants; relative risk, 0.34; 95% confidence interval, 0.15-0.79; P=.01; 
      I(2)=0%). There was no significant effect on the risk of term preeclampsia (3 
      studies; 472 participants; relative risk, 0.57; 95% confidence interval, 
      0.12-2.64; P=.48; I(2)=64%) and all preeclampsia (4 studies; 552 participants; 
      relative risk, 0.42; 95% confidence interval, 0.17-1.05; P=.06; I(2)=58%), but 
      there was a reduction of severe preeclampsia (3 studies; 472 participantst; RR, 
      0.23; 95% CI, 0.09-0.62; P=.003; I(2)=0%). CONCLUSION: When initiated in the 
      first trimester of pregnancy, an aspirin dosage of 150 to 162 mg daily was 
      associated with a lower risk of preterm PE than an aspirin dosage of 75 to 81 mg 
      daily. However, the lack of large, high-quality studies limited the clinical 
      scope of the current results taken alone.
CI  - Copyright © 2023 Elsevier Inc. All rights reserved.
FAU - Ghesquiere, Louise
AU  - Ghesquiere L
AD  - Reproduction, Mother and Child Health Unit, Research Center of the Centre 
      Hospitalier Universitaire de Québec - Université Laval, Québec, Canada (Dr 
      Ghesquiere, Ms Marchant, Ms Foisy, and Drs Roberge and Bujold); Department of 
      Obstetrics, Centre Hospitalier Universitaire de Lille, Université de Lille, 
      Lille, France (Dr Ghesquiere).
FAU - Guerby, Paul
AU  - Guerby P
AD  - Department of Obstetrics, Hospital Paule De Viguier, Centre Hospitalier 
      Universitaire de Toulouse, Toulouse, France (Dr Guerby).
FAU - Marchant, Isobel
AU  - Marchant I
AD  - Reproduction, Mother and Child Health Unit, Research Center of the Centre 
      Hospitalier Universitaire de Québec - Université Laval, Québec, Canada (Dr 
      Ghesquiere, Ms Marchant, Ms Foisy, and Drs Roberge and Bujold).
FAU - Kumar, Namrata
AU  - Kumar N
AD  - Department of Obstetrics and Gynecology, King George's Medical University, 
      Lucknow, India (Dr Kumar).
FAU - Zare, Marjan
AU  - Zare M
AD  - Maternal-fetal medicine Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran (Dr Zare).
FAU - Foisy, Marie-Anne
AU  - Foisy MA
AD  - Reproduction, Mother and Child Health Unit, Research Center of the Centre 
      Hospitalier Universitaire de Québec - Université Laval, Québec, Canada (Dr 
      Ghesquiere, Ms Marchant, Ms Foisy, and Drs Roberge and Bujold).
FAU - Roberge, Stéphanie
AU  - Roberge S
AD  - Reproduction, Mother and Child Health Unit, Research Center of the Centre 
      Hospitalier Universitaire de Québec - Université Laval, Québec, Canada (Dr 
      Ghesquiere, Ms Marchant, Ms Foisy, and Drs Roberge and Bujold).
FAU - Bujold, Emmanuel
AU  - Bujold E
AD  - Reproduction, Mother and Child Health Unit, Research Center of the Centre 
      Hospitalier Universitaire de Québec - Université Laval, Québec, Canada (Dr 
      Ghesquiere, Ms Marchant, Ms Foisy, and Drs Roberge and Bujold); Department of 
      Obstetrics, Gynecology and Reproduction, Centre Hospitalier Universitaire de 
      Québec-Université Laval, Québec, Canada (Dr Bujold). Electronic address: 
      emmanuel.bujold@crchudequebec.ulaval.ca.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20230504
PL  - United States
TA  - Am J Obstet Gynecol MFM
JT  - American journal of obstetrics & gynecology MFM
JID - 101746609
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Pregnancy
MH  - Infant, Newborn
MH  - Female
MH  - Humans
MH  - *Aspirin/adverse effects
MH  - *Pre-Eclampsia/diagnosis/epidemiology/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Pregnancy Trimester, First
MH  - Gestational Age
OTO - NOTNLM
OT  - aspirin
OT  - fetal growth
OT  - pharmacology
OT  - preeclampsia
OT  - pregnancy
OT  - women health
EDAT- 2023/05/06 09:42
MHDA- 2023/07/03 06:41
CRDT- 2023/05/05 19:24
PHST- 2023/02/20 00:00 [received]
PHST- 2023/04/27 00:00 [revised]
PHST- 2023/05/01 00:00 [accepted]
PHST- 2023/07/03 06:41 [medline]
PHST- 2023/05/06 09:42 [pubmed]
PHST- 2023/05/05 19:24 [entrez]
AID - S2589-9333(23)00142-8 [pii]
AID - 10.1016/j.ajogmf.2023.101000 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol MFM. 2023 Jul;5(7):101000. doi: 10.1016/j.ajogmf.2023.101000. 
      Epub 2023 May 4.

PMID- 32087537
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20200930
IS  - 1873-2690 (Electronic)
IS  - 0981-9428 (Linking)
VI  - 149
DP  - 2020 Apr
TI  - Salicylic acid and aspirin stimulate growth of Chlamydomonas and inhibit 
      lipoxygenase and chloroplast desaturase pathways.
PG  - 256-265
LID - S0981-9428(20)30073-5 [pii]
LID - 10.1016/j.plaphy.2020.02.019 [doi]
AB  - Chemical stimulants, used to enhance biomass yield, are highly desirable for the 
      commercialisation of algal products for a wide range of applications in the food, 
      pharma and biofuels sectors. In the present study, phenolic compounds, varying in 
      substituents and positional isomers on the arene ring have been evaluated to 
      determine structure-activity relationship and growth. The phenols, catechol, 
      4-methylcatechol and 2, 4-dimethyl phenol were generally inhibitory to growth as 
      were the compounds containing an aldehyde function. By contrast, the phenolic 
      acids, salicylic acid, aspirin and 4-hydroxybenzoate markedly stimulated cell 
      proliferation enhancing cell numbers by 20-45% at mid-log phase. The order of 
      growth stimulation was ortho > para > meta with respect to the position of the OH 
      group. Both SA and aspirin reduced 16:3 in chloroplast galactolipids. In 
      addition, both compounds inhibited lipoxygenase activity and lowered the levels 
      of lipid hydroperoxides and malondialdehydes in the cells. The present study has 
      demonstrated the possibility of using SA or aspirin to promote algal growth 
      through the manipulation of lipid metabolising enzymes.
CI  - Copyright © 2020 Elsevier Masson SAS. All rights reserved.
FAU - Awad, Nahid
AU  - Awad N
AD  - Chemical Engineering and Applied Chemistry, Energy and Bioproducts Research 
      Institute, Aston University, B4 7ET, Birmingham, United Kingdom. Electronic 
      address: nahidsaleh@hotmail.com.
FAU - Vega-Estévez, Samuel
AU  - Vega-Estévez S
AD  - Chemical Engineering and Applied Chemistry, Energy and Bioproducts Research 
      Institute, Aston University, B4 7ET, Birmingham, United Kingdom. Electronic 
      address: vegaestevez.samuel@gmail.com.
FAU - Griffiths, Gareth
AU  - Griffiths G
AD  - Chemical Engineering and Applied Chemistry, Energy and Bioproducts Research 
      Institute, Aston University, B4 7ET, Birmingham, United Kingdom. Electronic 
      address: g.griffiths@aston.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200215
PL  - France
TA  - Plant Physiol Biochem
JT  - Plant physiology and biochemistry : PPB
JID - 9882449
RN  - 0 (Enzyme Inhibitors)
RN  - EC 1.13.11.12 (Lipoxygenase)
RN  - EC 1.14.19.- (Fatty Acid Desaturases)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/pharmacology
MH  - *Chlamydomonas/drug effects
MH  - Chloroplasts/drug effects
MH  - Enzyme Activation/drug effects
MH  - Enzyme Inhibitors/pharmacology
MH  - Fatty Acid Desaturases/metabolism
MH  - Lipoxygenase/metabolism
MH  - *Salicylic Acid/pharmacology
OTO - NOTNLM
OT  - Cell division
OT  - Chlamydomonas reinhardtii
OT  - Lipoxygenase
OT  - Phenolic compounds
OT  - Polyunsaturated fatty acids
OT  - Salicylic acid
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/02/23 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/02/23 06:00
PHST- 2019/11/07 00:00 [received]
PHST- 2020/02/12 00:00 [revised]
PHST- 2020/02/12 00:00 [accepted]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
PHST- 2020/02/23 06:00 [entrez]
AID - S0981-9428(20)30073-5 [pii]
AID - 10.1016/j.plaphy.2020.02.019 [doi]
PST - ppublish
SO  - Plant Physiol Biochem. 2020 Apr;149:256-265. doi: 10.1016/j.plaphy.2020.02.019. 
      Epub 2020 Feb 15.

PMID- 2022800
OWN - NLM
STAT- MEDLINE
DCOM- 19910606
LR  - 20190709
IS  - 0002-8614 (Print)
IS  - 0002-8614 (Linking)
VI  - 39
IP  - 5
DP  - 1991 May
TI  - Rationale for a primary prevention study using low-dose aspirin to prevent 
      coronary and cerebrovascular disease in the elderly.
PG  - 484-91
AB  - The benefits of prophylactic aspirin therapy to prevent cardiovascular and 
      cerebrovascular disease in asymptomatic individuals remains unclear. The 
      rationale for developing a multicentered, double-blind, placebo-controlled 
      clinical trial to determine whether low-dose aspirin (100 mg daily) prevents 
      cardiovascular and cerebrovascular morbidity and mortality in persons aged 70 
      years and over with no evidence of pre-existing cardiovascular or cerebrovascular 
      disease is described. Sample size calculations have indicated that 15,000 
      subjects would be required over a 4-year follow-up period in order to demonstrate 
      a 20% reduction in overall cardiovascular mortality at the 0.01 level with a 
      power of 0.8. Such a large-scale community-based clinical trial has never been 
      conducted in Australia in this age group. Therefore the PACE (prevention by 
      low-dose aspirin of cardiovascular disease in the elderly) pilot study has been 
      developed to test recruitment strategies and methods and ascertaining disease 
      end-points.
FAU - Silagy, C A
AU  - Silagy CA
AD  - Department of Social and Preventive Medicine, Monash University, Prahran, 
      Victoria, Australia.
FAU - McNeil, J J
AU  - McNeil JJ
FAU - Bulpitt, C J
AU  - Bulpitt CJ
FAU - Donnan, G A
AU  - Donnan GA
FAU - Tonkin, A M
AU  - Tonkin AM
FAU - Worsam, B
AU  - Worsam B
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Coronary Disease/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Primary Prevention/*methods/statistics & numerical data
MH  - Randomized Controlled Trials as Topic
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
AID - 10.1111/j.1532-5415.1991.tb02494.x [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 1991 May;39(5):484-91. doi: 10.1111/j.1532-5415.1991.tb02494.x.

PMID- 15701911
OWN - NLM
STAT- MEDLINE
DCOM- 20050211
LR  - 20161017
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 293
IP  - 6
DP  - 2005 Feb 9
TI  - Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial 
      fibrillation.
PG  - 699-706
AB  - CONTEXT: Recent trials have found that ximelagatran and warfarin are equally 
      effective in stroke prevention for patients with atrial fibrillation. Because 
      ximelagatran can be taken in a fixed, oral dose without international normalized 
      ratio monitoring and may have a lower risk of hemorrhage, it might improve 
      quality-adjusted survival compared with dose-adjusted warfarin. OBJECTIVE: To 
      compare quality-adjusted survival and cost among 3 alternative therapies for 
      patients with chronic atrial fibrillation: ximelagatran, warfarin, and aspirin. 
      DESIGN: Semi-Markov decision model. PATIENTS: Hypothetical cohort of 70-year-old 
      patients with chronic atrial fibrillation, varying risk of stroke, and no 
      contraindications to anticoagulation therapy. MAIN OUTCOME MEASURES: 
      Quality-adjusted life-years (QALYs) and costs in US dollars. RESULTS: For 
      patients with atrial fibrillation but no additional risk factors for stroke, both 
      ximelagatran and warfarin cost more than 50,000 dollars per QALY compared with 
      aspirin. For patients with additional stroke risk factors and low hemorrhage 
      risk, ximelagatran modestly increased quality-adjusted survival (0.12 QALY) at a 
      substantial cost (116,000 dollars per QALY) compared with warfarin. For 
      ximelagatran to cost less than 50,000 dollars per QALY it would have to cost less 
      than 1100 dollars per year or be prescribed to patients who have an elevated risk 
      of intracranial hemorrhage (>1.0% per year of warfarin) or a low quality of life 
      with warfarin therapy. CONCLUSION: Assuming equal effectiveness in stroke 
      prevention and decreased hemorrhage risk, ximelagatran is not likely to be 
      cost-effective in patients with atrial fibrillation unless they have a high risk 
      of intracranial hemorrhage or a low quality of life with warfarin.
FAU - O'Brien, Cara L
AU  - O'Brien CL
AD  - Washington University School of Medicine, St Louis, Mo 63110, USA.
FAU - Gage, Brian F
AU  - Gage BF
LA  - eng
GR  - R01 HS10133/HS/AHRQ HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Anticoagulants)
RN  - 0 (Azetidines)
RN  - 0 (Benzylamines)
RN  - 0 (Prodrugs)
RN  - 49HFB70472 (ximelagatran)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - JAMA. 2005 Feb 9;293(6):736-9. PMID: 15701916
CIN - JAMA. 2005 Jun 15;293(23):2860-1; author reply 2861. PMID: 15956626
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*economics/*therapeutic use
MH  - Aspirin/economics/therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy/economics
MH  - Azetidines/*economics/*therapeutic use
MH  - Benzylamines
MH  - Chronic Disease
MH  - Cost-Benefit Analysis
MH  - Decision Support Techniques
MH  - Humans
MH  - Prodrugs/*economics/*therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Stroke/etiology/*prevention & control
MH  - United States
MH  - Warfarin/economics/therapeutic use
EDAT- 2005/02/11 09:00
MHDA- 2005/02/12 09:00
CRDT- 2005/02/11 09:00
PHST- 2005/02/11 09:00 [pubmed]
PHST- 2005/02/12 09:00 [medline]
PHST- 2005/02/11 09:00 [entrez]
AID - 293/6/699 [pii]
AID - 10.1001/jama.293.6.699 [doi]
PST - ppublish
SO  - JAMA. 2005 Feb 9;293(6):699-706. doi: 10.1001/jama.293.6.699.

PMID- 11166004
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 110
IP  - 1A
DP  - 2001 Jan 8
TI  - Questions regarding future research on aspirin and the gastrointestinal tract.
PG  - 74S-78S
AB  - Despite great proven and potential benefits, aspirin also has adverse side 
      effects on all parts of the gastrointestinal tract including ulceration, 
      bleeding, perforation, and stenosis. Because of widespread and growing use, there 
      is a need to understand and, if possible, prevent the adverse effects of aspirin 
      while maintaining its benefits. This article is part of a report from a consensus 
      meeting in 1999 on nonsteroidal anti-inflammatory drugs, and examines possible 
      mechanisms of each of the risks of normal and low-dose aspirin use including 
      areas of uncertainty. Based on these issues, we recommend studies that would 
      further clarify the actions of aspirin. We also examine various strategies that 
      might be used to prevent or mitigate adverse effects. Finally, we propose future 
      research prospects in the search for a safer aspirin.
FAU - Hirschowitz, B I
AU  - Hirschowitz BI
AD  - Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, 
      Birmingham, Alabama 35294-0007, USA.
FAU - Hawkey, C J
AU  - Hawkey CJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cyclooxygenase Inhibitors/administration & dosage/*adverse effects
MH  - Delayed-Action Preparations
MH  - Digestive System/*drug effects
MH  - Drug Therapy, Combination
MH  - Helicobacter Infections/drug therapy
MH  - Helicobacter pylori/drug effects
MH  - Histamine H2 Antagonists/therapeutic use
MH  - Humans
MH  - Proton Pump Inhibitors
RF  - 46
EDAT- 2001/02/13 11:00
MHDA- 2001/04/03 10:01
CRDT- 2001/02/13 11:00
PHST- 2001/02/13 11:00 [pubmed]
PHST- 2001/04/03 10:01 [medline]
PHST- 2001/02/13 11:00 [entrez]
AID - S0002934300006483 [pii]
AID - 10.1016/s0002-9343(00)00648-3 [doi]
PST - ppublish
SO  - Am J Med. 2001 Jan 8;110(1A):74S-78S. doi: 10.1016/s0002-9343(00)00648-3.

PMID- 27161533
OWN - NLM
STAT- MEDLINE
DCOM- 20170227
LR  - 20170817
IS  - 1751-553X (Electronic)
IS  - 1751-5521 (Linking)
VI  - 38 Suppl 1
DP  - 2016 May
TI  - Congenital erythrocytosis.
PG  - 59-65
LID - 10.1111/ijlh.12506 [doi]
AB  - INTRODUCTION: Congenital erythrocytosis is by definition present from birth. 
      Patients frequently present in childhood or as young adults and a family history 
      may be present. The erythrocytosis can be primary where there is a defect in the 
      erythroid compartment of secondary where increased erythropoietin production 
      produced due to the defect leads to an erythrocytosis. MATERIAL AND METHODS: 
      Primary causes include erythropoietin receptor mutations. Congenital secondary 
      causes include mutations in the genes involved in the oxygen-sensing pathway and 
      haemoglobins with abnormal oxygen affinity. Investigations for the cause include 
      an erythropoietin level, oxygen dissociation curve, haemoglobin electrophoresis 
      and sequencing for known gene variants. RESULTS: The finding of a known or new 
      molecular variant confirms a diagnosis of congenital erythrocytosis. A congenital 
      erythrocytosis may be an incidental finding but nonspecific symptoms are 
      described. Major thromboembolic events have been noted in some cases. Low-dose 
      aspirin and venesection are therapeutic manoeuvres which should be considered in 
      managing these patients. CONCLUSIONS: Rare individuals presenting often at a 
      young age may have a congenital erythrocytosis. Molecular investigation may 
      reveal a lesion. However, in the majority, currently no defect is identified.
CI  - © 2016 John Wiley & Sons Ltd.
FAU - McMullin, M F
AU  - McMullin MF
AD  - Department of Haematology, Belfast City Hospital, Queen's University Belfast, 
      Belfast, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160509
PL  - England
TA  - Int J Lab Hematol
JT  - International journal of laboratory hematology
JID - 101300213
RN  - 0 (Receptors, Erythropoietin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Humans
MH  - Molecular Diagnostic Techniques/methods
MH  - Phlebotomy
MH  - Polycythemia/*congenital/etiology/therapy
MH  - Receptors, Erythropoietin/genetics
MH  - Young Adult
OTO - NOTNLM
OT  - Congenital erythrocytosis
OT  - erythropoietin
OT  - erythropoietin receptor
OT  - high affinity haemoglobin
OT  - oxygen-sensing pathway
EDAT- 2016/05/11 06:00
MHDA- 2017/02/28 06:00
CRDT- 2016/05/11 06:00
PHST- 2016/04/05 00:00 [accepted]
PHST- 2016/05/11 06:00 [entrez]
PHST- 2016/05/11 06:00 [pubmed]
PHST- 2017/02/28 06:00 [medline]
AID - 10.1111/ijlh.12506 [doi]
PST - ppublish
SO  - Int J Lab Hematol. 2016 May;38 Suppl 1:59-65. doi: 10.1111/ijlh.12506. Epub 2016 
      May 9.

PMID- 17720526
OWN - NLM
STAT- MEDLINE
DCOM- 20070905
LR  - 20131121
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
VI  - 50
IP  - 3
DP  - 2007 Sep
TI  - Salicylate-induced proximal tubular dysfunction.
PG  - 463-7
AB  - We describe the case of a 17-year-old girl who was admitted to our clinic for 
      drug poisoning. Twelve hours after the ingestion of 25 tablets of aspirin (12.5 g 
      of acetylsalicylic acid), the patient had a generalized proximal tubular 
      dysfunction characterized by glucosuria (in the face of normal serum glucose 
      levels), proteinuria, and uric acid wasting. Further characterization of the 
      tubular dysfunction using high-resolution proton nuclear magnetic resonance 
      spectroscopy of the urine showed a pattern consistent with proximal tubular 
      injury. An important characteristic of the salicylate-induced proximal tubular 
      dysfunction in our patient was its rapid reversibility. A trend toward 
      normalization of fractional excretion values of electrolytes was observed 2 days 
      after ingestion. Determination of serum and urine metabolites and spectroscopy of 
      urine 15 days later showed no evidence of tubular dysfunction. The mechanisms 
      potentially implicated in the pathogenesis of salicylate-induced Fanconi syndrome 
      are discussed and a brief review of the relevant literature is provided.
FAU - Tsimihodimos, Vasilis
AU  - Tsimihodimos V
AD  - Department of Internal Medicine, Medical School, University of Ioannina, 
      Ioannina, Greece.
FAU - Psychogios, Nikolaos
AU  - Psychogios N
FAU - Kakaidi, Varvara
AU  - Kakaidi V
FAU - Bairaktari, Eleni
AU  - Bairaktari E
FAU - Elisaf, Moses
AU  - Elisaf M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*poisoning
MH  - Fanconi Syndrome/*chemically induced
MH  - Female
MH  - Humans
MH  - Kidney Tubules, Proximal/*drug effects/*physiopathology
MH  - Suicide, Attempted
RF  - 26
EDAT- 2007/08/28 09:00
MHDA- 2007/09/06 09:00
CRDT- 2007/08/28 09:00
PHST- 2006/12/19 00:00 [received]
PHST- 2007/03/27 00:00 [accepted]
PHST- 2007/08/28 09:00 [pubmed]
PHST- 2007/09/06 09:00 [medline]
PHST- 2007/08/28 09:00 [entrez]
AID - S0272-6386(07)00693-2 [pii]
AID - 10.1053/j.ajkd.2007.03.021 [doi]
PST - ppublish
SO  - Am J Kidney Dis. 2007 Sep;50(3):463-7. doi: 10.1053/j.ajkd.2007.03.021.

PMID- 3124653
OWN - NLM
STAT- MEDLINE
DCOM- 19880323
LR  - 20190627
IS  - 0002-9610 (Print)
IS  - 0002-9610 (Linking)
VI  - 155
IP  - 2
DP  - 1988 Feb
TI  - Vascular grafts in microvascular surgery. An experimental study.
PG  - 258-62
AB  - The patency of microvascular grafts depends on the luminal diameter, which is 
      determined by the amount of fibrin and platelets deposited on the intraluminal 
      surface and the anastomotic site, and the extent of pseudointimal formation. An 
      experimental microvascular model in rats has been developed in our laboratory 
      using Indium-111-labeled platelets to measure the amount of deposition on grafts 
      inserted into the infrarenal aorta. This study was designed to assess the patency 
      rates in these grafts and the pathologic maturation as determined by light and 
      electron microscopy. Our study suggests that substantial patency rates can be 
      achieved in aspirin-treated rats, although there was little influence on the 
      pathologic maturation. Indium-111 oxine-labeled platelets can be used to document 
      platelet aggregation, and the technique can be a valuable adjunct in the study of 
      microvascular grafts.
FAU - Marrangoni, A G
AU  - Marrangoni AG
AD  - Surgical Research Laboratory, Mercy Hospital, Pittsburgh, Pennsylvania 15219.
FAU - Marcelli, G
AU  - Marcelli G
FAU - Culig, M
AU  - Culig M
FAU - Simone, S T
AU  - Simone ST
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Surg
JT  - American journal of surgery
JID - 0370473
RN  - 0 (Indium Radioisotopes)
RN  - 0 (Organometallic Compounds)
RN  - 14514-42-2 (indium oxine)
RN  - 5UTX5635HP (Oxyquinoline)
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aorta, Abdominal/surgery
MH  - Aspirin/*therapeutic use
MH  - *Blood Platelets
MH  - *Blood Vessel Prosthesis
MH  - Graft Occlusion, Vascular/*diagnostic imaging/prevention & control
MH  - *Indium Radioisotopes
MH  - Organometallic Compounds
MH  - Oxyquinoline/analogs & derivatives
MH  - *Polytetrafluoroethylene
MH  - Radionuclide Imaging
MH  - Rats
MH  - Vascular Patency
EDAT- 1988/02/01 00:00
MHDA- 1988/02/01 00:01
CRDT- 1988/02/01 00:00
PHST- 1988/02/01 00:00 [pubmed]
PHST- 1988/02/01 00:01 [medline]
PHST- 1988/02/01 00:00 [entrez]
AID - S0002-9610(88)80709-8 [pii]
AID - 10.1016/s0002-9610(88)80709-8 [doi]
PST - ppublish
SO  - Am J Surg. 1988 Feb;155(2):258-62. doi: 10.1016/s0002-9610(88)80709-8.

PMID- 7350121
OWN - NLM
STAT- MEDLINE
DCOM- 19800228
LR  - 20190816
IS  - 0020-5915 (Print)
IS  - 0020-5915 (Linking)
VI  - 61
IP  - 1
DP  - 1980
TI  - Seasonal variation in drug action and animal responses in models of inflammation.
PG  - 111-3
AB  - During the summer months, aspirin was relatively ineffective in rats in 
      suppressing leucocyte migration both into the pleural space inflamed by 
      carrageenan and into inert sponges implanted subcutaneously. At this time period, 
      rats were insensitive to intravenous histamine and relatively insensitive to 
      anaphylactic shock, and survival rates after traumatic or tourniquet shock have 
      also been reported to be at peak values. The cause of this resistance has still 
      to be found, though hormonal activation may play a major role.
FAU - Warne, P J
AU  - Warne PJ
FAU - West, G B
AU  - West GB
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Int Arch Allergy Appl Immunol
JT  - International archives of allergy and applied immunology
JID - 0404561
RN  - 0 (Dextrans)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anaphylaxis/etiology
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cell Movement/*drug effects
MH  - Dextrans/toxicity
MH  - Drug Resistance
MH  - Glucose/pharmacology
MH  - Inflammation/*drug therapy
MH  - Leukocytes/*drug effects
MH  - Rats
MH  - *Seasons
MH  - Shock/etiology
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
AID - 10.1159/000232422 [doi]
PST - ppublish
SO  - Int Arch Allergy Appl Immunol. 1980;61(1):111-3. doi: 10.1159/000232422.

PMID- 36376767
OWN - NLM
STAT- MEDLINE
DCOM- 20230117
LR  - 20230211
IS  - 0942-0940 (Electronic)
IS  - 0001-6268 (Print)
IS  - 0001-6268 (Linking)
VI  - 165
IP  - 1
DP  - 2023 Jan
TI  - Risks and benefits of continuation and discontinuation of aspirin in elective 
      craniotomies: a systematic review and pooled-analysis.
PG  - 39-47
LID - 10.1007/s00701-022-05416-2 [doi]
AB  - BACKGROUND/AIM: Discontinuation of aspirin (ASA) prior to elective craniotomies 
      is common practice. However, patients treated with ASA for secondary prevention 
      bear a higher risk for thromboembolic complications. Aim of this systematic 
      review is to investigate the risks and benefits of perioperative continuation and 
      discontinuation of ASA in elective craniotomies. METHODS: PubMed and Embase 
      databases were searched. Inclusion criteria were retro- and prospective studies, 
      reporting hemorrhagic and thromboembolic complications in patients in whom ASA 
      was either continued or discontinued perioperatively in elective craniotomies. We 
      excluded shunt operations and emergency cases. The MINORS (Methodological index 
      for non-randomized studies) score was used to quantify the methodological quality 
      of the eligible studies. RESULTS: Out of 523 publications, 7 met the eligibility 
      criteria (cumulative cohort of 646 patients). The mean MINORS score for the 
      comparative studies was 18.7/24 (± SD 2.07, range: 17-22) and 9/16 for the unique 
      non-comparative study, indicating an overall weak methodological quality of the 
      included studies. 57.1% of the patients underwent craniotomy for intra- and 
      extra-axial tumor removal, 39.0% for bypass surgery and 3.9% for neurovascular 
      lesions (other than bypass). In 31.0% of the cases, ASA was prescribed for 
      primary and in 69.0% for secondary prevention. ASA was continued perioperatively 
      in 61.8% and discontinued in 38.2% of the cases. The hemorrhagic complication 
      rate was 3% (95% CI [0.01-0.05]) in the ASA continuation group (Con-Group) and 3% 
      (95% CI [0.01-0.09]) in the discontinuation group (Disc-Group) (p = 0.9). The 
      rate of thromboembolic events in the Con-Group was 3% (95% CI [0.01-0.06]) in 
      comparison to 6% (95% CI [0.02-0.14]) in the Disc-Group (p = 0.1). CONCLUSION: 
      Perioperative continuation of ASA in elective craniotomies does not seem to be 
      associated with an increased hemorrhagic risk. The potential beneficial effect of 
      ASA continuation on thromboembolic events needs to be further investigated in 
      patients under ASA for secondary prevention.
CI  - © 2022. The Author(s).
FAU - Rychen, Jonathan
AU  - Rychen J
AD  - Department of Neurosurgery, University Hospital of Basel, Spitalstrasse 21, CH - 
      4031, Basel, Switzerland.
FAU - Saemann, Attill
AU  - Saemann A
AD  - Department of Neurosurgery, University Hospital of Basel, Spitalstrasse 21, CH - 
      4031, Basel, Switzerland.
FAU - Fingerlin, Tamara
AU  - Fingerlin T
AD  - Department of Neurosurgery, University Hospital of Basel, Spitalstrasse 21, CH - 
      4031, Basel, Switzerland.
FAU - Guzman, Raphael
AU  - Guzman R
AD  - Department of Neurosurgery, University Hospital of Basel, Spitalstrasse 21, CH - 
      4031, Basel, Switzerland.
AD  - Faculty of Medicine, University of Basel, Basel, Switzerland.
FAU - Mariani, Luigi
AU  - Mariani L
AD  - Department of Neurosurgery, University Hospital of Basel, Spitalstrasse 21, CH - 
      4031, Basel, Switzerland.
AD  - Faculty of Medicine, University of Basel, Basel, Switzerland.
FAU - Greuter, Ladina
AU  - Greuter L
AD  - Department of Neurosurgery, University Hospital of Basel, Spitalstrasse 21, CH - 
      4031, Basel, Switzerland.
FAU - Soleman, Jehuda
AU  - Soleman J
AUID- ORCID: 0000-0003-1900-9286
AD  - Department of Neurosurgery, University Hospital of Basel, Spitalstrasse 21, CH - 
      4031, Basel, Switzerland. jehuda.soleman@gmail.com.
AD  - Faculty of Medicine, University of Basel, Basel, Switzerland. 
      jehuda.soleman@gmail.com.
AD  - Department of Clinical Studies, University Hospital of Basel, Basel, Switzerland. 
      jehuda.soleman@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20221115
PL  - Austria
TA  - Acta Neurochir (Wien)
JT  - Acta neurochirurgica
JID - 0151000
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - *Aspirin/adverse effects
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Prospective Studies
MH  - Hemorrhage/complications
MH  - *Thromboembolism/etiology
MH  - Craniotomy/adverse effects
MH  - Risk Assessment
PMC - PMC9840583
OTO - NOTNLM
OT  - Aspirin
OT  - Craniotomy
OT  - Hemorrhagic complication
OT  - Systematic review
OT  - Thromboembolic complication
COIS- The authors report no conflict of interest or financial disclosures concerning 
      the materials, methods or the findings specified in this paper.
EDAT- 2022/11/16 06:00
MHDA- 2023/01/18 06:00
CRDT- 2022/11/15 00:05
PHST- 2022/07/31 00:00 [received]
PHST- 2022/10/29 00:00 [accepted]
PHST- 2022/11/16 06:00 [pubmed]
PHST- 2023/01/18 06:00 [medline]
PHST- 2022/11/15 00:05 [entrez]
AID - 10.1007/s00701-022-05416-2 [pii]
AID - 5416 [pii]
AID - 10.1007/s00701-022-05416-2 [doi]
PST - ppublish
SO  - Acta Neurochir (Wien). 2023 Jan;165(1):39-47. doi: 10.1007/s00701-022-05416-2. 
      Epub 2022 Nov 15.

PMID- 36131134
OWN - NLM
STAT- MEDLINE
DCOM- 20230313
LR  - 20230613
IS  - 1724-6059 (Electronic)
IS  - 1121-8428 (Linking)
VI  - 36
IP  - 2
DP  - 2023 Mar
TI  - Risk of bleeding after percutaneous native kidney biopsy in patients receiving 
      low-dose aspirin: a single-center retrospective study.
PG  - 475-483
LID - 10.1007/s40620-022-01441-7 [doi]
AB  - BACKGROUND: Although discontinuation of antiplatelet agents at least 5 days 
      before kidney biopsy is commonly recommended, the evidence behind this practice 
      is of low level. Indeed, few non-randomized studies previously showed an 
      equivalent risk of bleeding in patients receiving aspirin therapy. METHODS: We 
      conducted a single center retrospective study comparing the risk of complications 
      after percutaneous native kidney biopsy in patients who received low-dose aspirin 
      (ASA) within 5 days from biopsy and those who did not. The main outcome was the 
      difference in the incidence of major complications (red blood cell transfusion, 
      need for selective arterial embolization, surgery, nephrectomy). Secondary 
      outcomes included difference in minor complications, comparison between patients 
      who received ASA within 48 h or within 3-5 days, identification of independent 
      factors predictive of major complications. RESULTS: We analyzed data on 750 
      patients, of whom 94 received ASA within 5 days from biopsy. There were no 
      significant differences in the proportion of major complications in patients 
      receiving or not receiving ASA (2.59% and 3.19%, respectively, percentage point 
      difference 1%, 95% CI - 3 to 4%, p = 0.74). Groups were also comparable for minor 
      complications; among patients receiving ASA, there were no differences in major 
      bleeding between those who received ASA within 48 h or 3-5 days from biopsy. 
      Significant baseline predictors of major bleeding in our cohort were platelet 
      count lower than 120*10(3)/microliter, higher diastolic blood pressure and higher 
      blood urea. CONCLUSIONS: Treatment with low-dose ASA within 5 days from kidney 
      biopsy did not increase the risk of complications after the procedure.
CI  - © 2022. The Author(s) under exclusive licence to Italian Society of Nephrology.
FAU - Fontana, Francesco
AU  - Fontana F
AUID- ORCID: 0000-0003-0762-0942
AD  - Nephrology, Dialysis and Kidney Transplant Unit, Azienda 
      Ospedaliero-Universitaria di Modena, Modena, Italy. francesco.fontana@unimore.it.
FAU - Cazzato, Silvia
AU  - Cazzato S
AD  - Nephrology and Dialysis Unit, Ospedale Ramazzini di Carpi, Azienda Unità 
      Sanitaria Locale di Modena, Modena, Italy.
AD  - Surgical, Medical and Dental Department of Morphological Sciences, University of 
      Modena and Reggio Emilia, Modena, Italy.
FAU - Giaroni, Francesco
AU  - Giaroni F
AD  - Nephrology, Dialysis and Kidney Transplant Unit, Azienda 
      Ospedaliero-Universitaria di Modena, Modena, Italy.
AD  - Surgical, Medical and Dental Department of Morphological Sciences, University of 
      Modena and Reggio Emilia, Modena, Italy.
FAU - Bertolini, Fabrizio
AU  - Bertolini F
AD  - Surgical, Medical and Dental Department of Morphological Sciences, University of 
      Modena and Reggio Emilia, Modena, Italy.
FAU - Alfano, Gaetano
AU  - Alfano G
AD  - Nephrology, Dialysis and Kidney Transplant Unit, Azienda 
      Ospedaliero-Universitaria di Modena, Modena, Italy.
FAU - Mori, Giacomo
AU  - Mori G
AD  - Nephrology, Dialysis and Kidney Transplant Unit, Azienda 
      Ospedaliero-Universitaria di Modena, Modena, Italy.
FAU - Giovanella, Silvia
AU  - Giovanella S
AD  - Surgical, Medical and Dental Department of Morphological Sciences, University of 
      Modena and Reggio Emilia, Modena, Italy.
FAU - Ligabue, Giulia
AU  - Ligabue G
AD  - Surgical, Medical and Dental Department of Morphological Sciences, University of 
      Modena and Reggio Emilia, Modena, Italy.
FAU - Magistroni, Riccardo
AU  - Magistroni R
AD  - Nephrology, Dialysis and Kidney Transplant Unit, Azienda 
      Ospedaliero-Universitaria di Modena, Modena, Italy.
AD  - Surgical, Medical and Dental Department of Morphological Sciences, University of 
      Modena and Reggio Emilia, Modena, Italy.
FAU - Cappelli, Gianni
AU  - Cappelli G
AD  - Surgical, Medical and Dental Department of Morphological Sciences, University of 
      Modena and Reggio Emilia, Modena, Italy.
FAU - Donati, Gabriele
AU  - Donati G
AD  - Nephrology, Dialysis and Kidney Transplant Unit, Azienda 
      Ospedaliero-Universitaria di Modena, Modena, Italy.
AD  - Surgical, Medical and Dental Department of Morphological Sciences, University of 
      Modena and Reggio Emilia, Modena, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220921
PL  - Italy
TA  - J Nephrol
JT  - Journal of nephrology
JID - 9012268
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - Retrospective Studies
MH  - *Aspirin/adverse effects
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Nephrectomy
MH  - Kidney
MH  - Biopsy/adverse effects
OTO - NOTNLM
OT  - Aspirin
OT  - Bleeding
OT  - Complications
OT  - Kidney biopsy
EDAT- 2022/09/22 06:00
MHDA- 2023/03/14 06:00
CRDT- 2022/09/21 23:32
PHST- 2022/06/15 00:00 [received]
PHST- 2022/08/10 00:00 [accepted]
PHST- 2022/09/22 06:00 [pubmed]
PHST- 2023/03/14 06:00 [medline]
PHST- 2022/09/21 23:32 [entrez]
AID - 10.1007/s40620-022-01441-7 [pii]
AID - 10.1007/s40620-022-01441-7 [doi]
PST - ppublish
SO  - J Nephrol. 2023 Mar;36(2):475-483. doi: 10.1007/s40620-022-01441-7. Epub 2022 Sep 
      21.

PMID- 27717518
OWN - NLM
STAT- MEDLINE
DCOM- 20180319
LR  - 20181202
IS  - 2174-2030 (Electronic)
IS  - 0870-2551 (Linking)
VI  - 35
IP  - 11
DP  - 2016 Nov
TI  - Hypersensitivity to aspirin and urgent percutaneous coronary intervention: A 
      therapeutic challenge.
PG  - 619.e1-619.e5
LID - S0870-2551(16)30148-2 [pii]
LID - 10.1016/j.repc.2016.03.008 [doi]
AB  - Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs are common and 
      five types of reactions have been defined. The prevalence of such reactions in 
      patients with myocardial infarction is unclear, and so antiplatelet therapy in 
      this population is a challenge. Various desensitization protocols have been 
      developed but there are no specific guidelines for their use. The authors present 
      the case of a patient with acute coronary syndrome and aspirin hypersensitivity 
      referred for urgent coronary angiography. Aspirin desensitization therapy is safe 
      and successful in many patients, but more randomized trials are needed to confirm 
      its benefits in coronary artery disease patients.
CI  - Copyright © 2016 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier 
      España, S.L.U. All rights reserved.
FAU - Duarte, Tatiana
AU  - Duarte T
AD  - Serviço de Cardiologia, Centro Hospitalar de Setúbal, Setúbal, Portugal. 
      Electronic address: taty_isabel@hotmail.com.
FAU - Gonçalves, Sara
AU  - Gonçalves S
AD  - Serviço de Cardiologia, Centro Hospitalar de Setúbal, Setúbal, Portugal.
FAU - Sá, Catarina
AU  - Sá C
AD  - Serviço de Cardiologia, Centro Hospitalar de Setúbal, Setúbal, Portugal.
FAU - Marinheiro, Rita
AU  - Marinheiro R
AD  - Serviço de Cardiologia, Centro Hospitalar de Setúbal, Setúbal, Portugal.
FAU - Rodrigues, Rita
AU  - Rodrigues R
AD  - Serviço de Cardiologia, Centro Hospitalar de Setúbal, Setúbal, Portugal.
FAU - Seixo, Filipe
AU  - Seixo F
AD  - Serviço de Cardiologia, Centro Hospitalar de Setúbal, Setúbal, Portugal.
FAU - Tomas, Elza
AU  - Tomas E
AD  - Serviço de Imunoalergologia, Centro Hospitalar de Setúbal, Setúbal, Portugal.
FAU - Caria, Rui
AU  - Caria R
AD  - Serviço de Cardiologia, Centro Hospitalar de Setúbal, Setúbal, Portugal.
LA  - eng
LA  - por
PT  - Case Reports
PT  - Journal Article
TT  - Hipersensibilidade à aspirina e coronariografia urgente: desafio terapêutico.
DEP - 20161004
PL  - Portugal
TA  - Rev Port Cardiol
JT  - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de 
      Cardiologia = Portuguese journal of cardiology : an official journal of the 
      Portuguese Society of Cardiology
JID - 8710716
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/classification/*therapy
MH  - Female
MH  - Humans
MH  - Percutaneous Coronary Intervention
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Desensitization protocols
OT  - Hipersensibilidade aos anti‐inflamatórios não‐esteroides
OT  - Hypersensitivity to nonsteroidal anti‐inflammatory drugs
OT  - Protocolos de dessensibilização
OT  - Síndrome coronária aguda
EDAT- 2016/10/09 06:00
MHDA- 2018/03/20 06:00
CRDT- 2016/10/09 06:00
PHST- 2015/11/10 00:00 [received]
PHST- 2016/03/10 00:00 [revised]
PHST- 2016/03/14 00:00 [accepted]
PHST- 2016/10/09 06:00 [pubmed]
PHST- 2018/03/20 06:00 [medline]
PHST- 2016/10/09 06:00 [entrez]
AID - S0870-2551(16)30148-2 [pii]
AID - 10.1016/j.repc.2016.03.008 [doi]
PST - ppublish
SO  - Rev Port Cardiol. 2016 Nov;35(11):619.e1-619.e5. doi: 10.1016/j.repc.2016.03.008. 
      Epub 2016 Oct 4.

PMID- 33621437
OWN - NLM
STAT- MEDLINE
DCOM- 20210921
LR  - 20221207
IS  - 1742-4658 (Electronic)
IS  - 1742-464X (Print)
IS  - 1742-464X (Linking)
VI  - 288
IP  - 17
DP  - 2021 Sep
TI  - The use of aspirin for primary prevention of cardiovascular disease is associated 
      with a lower likelihood of COVID-19 infection.
PG  - 5179-5189
LID - 10.1111/febs.15784 [doi]
AB  - Acetylsalicylic acid (aspirin) is commonly used for primary and secondary 
      prevention of cardiovascular diseases. Aspirin use is associated with better 
      outcomes among COVID-19 positive patients. We hypothesized that the aspirin use 
      for primary cardiovascular disease prevention might have a protective effect on 
      COVID-19 susceptibility and disease duration. We conducted a retrospective 
      population-based cross-sectional study, utilizing data from the Leumit Health 
      Services database. The proportion of patients treated with aspirin was 
      significantly lower among the COVID-19-positive group, as compared to the 
      COVID-19-negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use 
      was associated with lower likelihood of COVID-19 infection, as compared to 
      nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were 
      older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; P < 0.001), presented a 
      lower BMI (28.77 ± 5.4 vs. 30.37 ± 4.55; P < 0.0189), and showed higher 
      prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 
      15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, 
      P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID-19 disease 
      duration (considered as the time between the first positive and second negative 
      COVID-19 RT-PCR test results) among aspirin users was significantly shorter, as 
      compared to aspirin nonusers (19.8 ± 7.8 vs. 21.9 ± 7.9 P = 0.045). Among 
      hospitalized COVID-positive patients, a higher proportion of surviving subjects 
      were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), 
      although this difference was not significant (P = 0.449). In conclusion, we 
      observed an inverse association between the likelihood of COVID-19 infection, 
      disease duration and mortality, and aspirin use for primary prevention.
CI  - © 2021 Federation of European Biochemical Societies.
FAU - Merzon, Eugene
AU  - Merzon E
AD  - Leumit Health Services, Tel-Aviv, Israel.
AD  - Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, 
      Israel.
FAU - Green, Ilan
AU  - Green I
AD  - Leumit Health Services, Tel-Aviv, Israel.
AD  - Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, 
      Israel.
FAU - Vinker, Shlomo
AU  - Vinker S
AD  - Leumit Health Services, Tel-Aviv, Israel.
AD  - Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, 
      Israel.
FAU - Golan-Cohen, Avivit
AU  - Golan-Cohen A
AD  - Leumit Health Services, Tel-Aviv, Israel.
AD  - Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, 
      Israel.
FAU - Gorohovski, Alessandro
AU  - Gorohovski A
AD  - Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
FAU - Avramovich, Eva
AU  - Avramovich E
AD  - Leumit Health Services, Tel-Aviv, Israel.
AD  - Department of Management, Bar-Ilan University, Safed, Israel.
FAU - Frenkel-Morgenstern, Milana
AU  - Frenkel-Morgenstern M
AUID- ORCID: 0000-0002-0329-4599
AD  - Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
FAU - Magen, Eli
AU  - Magen E
AD  - Leumit Health Services, Tel-Aviv, Israel.
AD  - Medicine C Department, Clinical Immunology and Allergy Division, Barzilai 
      University Medical Center, Ben-Gurion University of the Negev, Ashkelon, Israel.
LA  - eng
GR  - 66824/Israel Innovation Authority, Kamin grant/
GR  - 247017/COVID-19 Data Science Institute (DSI) Grant, Bar-Ilan University/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210419
PL  - England
TA  - FEBS J
JT  - The FEBS journal
JID - 101229646
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - COVID-19/complications/virology
MH  - Cardiovascular Diseases/complications/*drug therapy/virology
MH  - Diabetes Mellitus/drug therapy/virology
MH  - Humans
MH  - Hypertension/complications/drug therapy/virology
MH  - Male
MH  - Middle Aged
MH  - Primary Prevention
MH  - Retrospective Studies
MH  - Risk Factors
MH  - SARS-CoV-2/*drug effects/pathogenicity
MH  - *COVID-19 Drug Treatment
PMC - PMC8013755
OTO - NOTNLM
OT  - COVID-19
OT  - Israeli cohort
OT  - aspirin
OT  - disease likelihood
COIS- The authors declare no conflict of interest.
EDAT- 2021/02/24 06:00
MHDA- 2021/09/22 06:00
CRDT- 2021/02/23 17:35
PHST- 2021/01/18 00:00 [revised]
PHST- 2020/11/12 00:00 [received]
PHST- 2021/02/22 00:00 [accepted]
PHST- 2021/02/24 06:00 [pubmed]
PHST- 2021/09/22 06:00 [medline]
PHST- 2021/02/23 17:35 [entrez]
AID - FEBS15784 [pii]
AID - 10.1111/febs.15784 [doi]
PST - ppublish
SO  - FEBS J. 2021 Sep;288(17):5179-5189. doi: 10.1111/febs.15784. Epub 2021 Apr 19.

PMID- 3412046
OWN - NLM
STAT- MEDLINE
DCOM- 19881013
LR  - 20141120
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 10
IP  - 6
DP  - 1988 Jun
TI  - Effect of triflusal and acetylsalicylic acid on platelet aggregation in human 
      whole blood: influence of red blood cells and leukocytes.
PG  - 363-7
AB  - A study has been made on the in vitro effect of triflusal, acetylsalicylic acid 
      (ASA and their major metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB), 
      and salicylic acid (SA), on platelet aggregation in human whole blood. SA 
      exhibited no significant antiplatelet effects (IC50 greater than 2mM) against 
      several inducers; the IC50 values for the other compounds were: triflusal, 140 
      microM against ADP and 63.2 microM against collagen; HTB, 100 microM against ADP 
      and 260 microM against collagen; ASA 687 microM against ADP and 9.3 microM 
      against collagen. Red blood cells potentiate the antiaggregant effect of HTB and 
      of triflusal, and to a lesser extent, that of ASA; leukocytes primarily 
      potentiate the effect of ASA and, to a lesser extent, that of triflusal.
FAU - de la Cruz, J P
AU  - de la Cruz JP
AD  - Department of Pharmacology and Therapeutics, School of Medicine, University of 
      Malaga, Spain.
FAU - Pavia, J
AU  - Pavia J
FAU - Bellido, I
AU  - Bellido I
FAU - Sánchez de la Cuesta, F
AU  - Sánchez de la Cuesta F
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Salicylates)
RN  - 1Z0YFI05OO (triflusal)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Erythrocytes/*physiology
MH  - Humans
MH  - In Vitro Techniques
MH  - Leukocytes/*physiology
MH  - Male
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Salicylates/*pharmacology
MH  - Salicylic Acid
EDAT- 1988/06/01 00:00
MHDA- 1988/06/01 00:01
CRDT- 1988/06/01 00:00
PHST- 1988/06/01 00:00 [pubmed]
PHST- 1988/06/01 00:01 [medline]
PHST- 1988/06/01 00:00 [entrez]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 1988 Jun;10(6):363-7.

PMID- 192547
OWN - NLM
STAT- MEDLINE
DCOM- 19770611
LR  - 20190620
IS  - 0014-2956 (Print)
IS  - 0014-2956 (Linking)
VI  - 74
IP  - 1
DP  - 1977 Mar 15
TI  - Prostaglandin E2 production in 3T3 cells transformed by polyoma virus raises the 
      intracellular adenosine 3':5'-monophosphate levels.
PG  - 13-8
AB  - High cellular adenosine 3':5'-monophosphate (cyclic AMP) were found in a 
      polyoma-virus-transformed 3T3 fibroblast line, which produces comparatively high 
      prostaglandin E2 concentrations. Prostaglandin E2 and cyclic AMP increased with 
      time during 6 days of growth. Both effects were prevented by three different 
      cyclo-oxygenase inhibitors. Addition of prostaglandin E2, at a concentration 
      which would been synthesized in the absence of inhibitor, reversed the effect of 
      indomethacin, one of the cyclo-oxygenase inhibitors, on cyclic AMP. It is 
      concluded that endogenous prostaglandin E2 production in these transformed cells 
      influences their cellular cyclic AMP levels.
FAU - Claesson, H E
AU  - Claesson HE
FAU - Lindgren, J A
AU  - Lindgren JA
FAU - Hammarström, S
AU  - Hammarström S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Biochem
JT  - European journal of biochemistry
JID - 0107600
RN  - 0 (Prostaglandins E)
RN  - 1191-85-1 (5,8,11,14-Eicosatetraynoic Acid)
RN  - E0399OZS9N (Cyclic AMP)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - 5,8,11,14-Eicosatetraynoic Acid/pharmacology
MH  - Aspirin/pharmacology
MH  - Cell Line
MH  - *Cell Transformation, Neoplastic
MH  - Cyclic AMP/*metabolism
MH  - Indomethacin/pharmacology
MH  - Kinetics
MH  - Polyomavirus
MH  - Prostaglandins E/*metabolism
EDAT- 1977/03/15 00:00
MHDA- 1977/03/15 00:01
CRDT- 1977/03/15 00:00
PHST- 1977/03/15 00:00 [pubmed]
PHST- 1977/03/15 00:01 [medline]
PHST- 1977/03/15 00:00 [entrez]
AID - 10.1111/j.1432-1033.1977.tb11361.x [doi]
PST - ppublish
SO  - Eur J Biochem. 1977 Mar 15;74(1):13-8. doi: 10.1111/j.1432-1033.1977.tb11361.x.

PMID- 35441926
OWN - NLM
STAT- MEDLINE
DCOM- 20230803
LR  - 20230805
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 37
IP  - 4
DP  - 2023 Aug
TI  - Results from the "Me & My Heart" (eMocial) Study: a Randomized Evaluation of a 
      New Smartphone-Based Support Tool to Increase Therapy Adherence of Patients with 
      Acute Coronary Syndrome.
PG  - 729-741
LID - 10.1007/s10557-022-07331-1 [doi]
AB  - PURPOSE: This study evaluated whether patient support, administered via an 
      electronic device-based app, increased adherence to treatment and lifestyle 
      changes in patients with acute coronary syndrome (ACS) treated with ticagrelor in 
      routine clinical practice. METHODS: Patients (aged ≥ 18 years) with diagnosed ACS 
      treated with ticagrelor co-administered with low-dose acetylsalicylic acid were 
      randomized into an active group (with support tool app for medication intake 
      reminders and motivational messages) and a control group (without support tool 
      app), and observed for 48 weeks (ClinicalTrials.gov Identifier: NCT02615704). 
      Patients were asked to complete the 36-item Short-Form Health Survey (SF-36) and 
      Lifestyle Changes Questionnaire (LSQ), and were assessed for blood pressure and 
      body mass index (BMI) at baseline (visit 1) and at the end of the study (visit 
      2). Medication adherence was measured using the Brilique Adherence Questionnaire 
      (BAQ). RESULTS: Patients (N = 676) were randomized to an active (n = 342) or 
      a control (n = 334) group. BAQ data were available for 174 patients in the active 
      group and 174 patients in the control group. Over the 48-week period, mean 
      (standard deviation) adherence for the active and control groups was 96.4% 
      (13.2%) and 91.5% (23.1%), respectively (effect of app intervention, p < 0.05). 
      There were no significant differences in blood pressure and BMI between visits. 
      General improvements in SF-36 and LSQ scores were observed for both groups. 
      CONCLUSION: The patient support tool app was associated with significant 
      improvements in patient-reported treatment adherence compared with a data 
      collection app alone in patients prescribed ticagrelor for ACS.
CI  - © 2022. The Author(s).
FAU - Krackhardt, Florian
AU  - Krackhardt F
AUID- ORCID: 0000-0001-5965-8817
AD  - Department of Internal Medicine and Cardiology, Charité Campus Virchow-Klinikum, 
      Charité University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, 
      Germany. florian.krackhardt@charite.de.
FAU - Jörnten-Karlsson, Magnus
AU  - Jörnten-Karlsson M
AD  - Digital Implementation, Digital Health R&D, AstraZeneca, Gothenburg, Sweden.
FAU - Waliszewski, Matthias
AU  - Waliszewski M
AD  - Department of Internal Medicine and Cardiology, Charité Campus Virchow-Klinikum, 
      Charité University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, 
      Germany.
FAU - Knutsson, Mikael
AU  - Knutsson M
AD  - Late Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals 
      R&D, AstraZeneca, Gothenburg, Sweden.
FAU - Niklasson, Anna
AU  - Niklasson A
AD  - Late Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals 
      R&D, AstraZeneca, Gothenburg, Sweden.
FAU - Appel, Karl-Friedrich
AU  - Appel KF
AD  - Ambulantes Herzzentrum Kassel, Kassel, Germany.
FAU - Degenhardt, Ralf
AU  - Degenhardt R
AD  - Herz-Kreislauf-Zentrum, Rotenburg a. d. Fulda, Germany.
FAU - Ghanem, Alexander
AU  - Ghanem A
AD  - Asklepios Klinik St. Georg, Hamburg, Germany.
FAU - Köhler, Till
AU  - Köhler T
AD  - Herzzentrum Wuppertal, Helios-Universitätsklinikum, Wuppertal, Germany.
FAU - Ohlow, Marc-Alexander
AU  - Ohlow MA
AD  - SRH-Waldklinikum, Gera, Germany.
FAU - Tschöpe, Carsten
AU  - Tschöpe C
AD  - Berlin Institute of Health at Charité; BIH Center for Regenerative Therapies 
      (BCRT), Charité-Universitätsmedizin Berlin, Berlin, Germany.
FAU - Theres, Heinz
AU  - Theres H
AD  - Martin Luther Krankenhaus, Berlin, Germany.
FAU - Vom Dahl, Jürgen
AU  - Vom Dahl J
AD  - Kliniken Maria Hilf, Mönchengladbach, Germany.
FAU - Karlson, Björn W
AU  - Karlson BW
AD  - Late Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals 
      R&D, AstraZeneca, Gothenburg, Sweden.
AD  - Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska 
      Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Maier, Lars S
AU  - Maier LS
AD  - Department of Internal Medicine II, Universitätsklinikum Regensburg, Regensburg, 
      Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT02615704
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220420
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Smartphone
MH  - Ticagrelor/therapeutic use
MH  - *Acute Coronary Syndrome/diagnosis/drug therapy
MH  - Medication Adherence
MH  - Aspirin/therapeutic use
PMC - PMC10397150
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Adherence
OT  - Dual antiplatelet therapy
OT  - Smartphone-based support
OT  - Ticagrelor
COIS- Florian Krackhardt received lecture fees from AstraZeneca; Magnus 
      Jörnten-Karlsson, Anna Niklasson, Mikael Knutsson, and Björn W. Karlson were 
      full‐time employees of AstraZeneca during the preparation of this manuscript. 
      Carsten Tschöpe has received speaker fees and/or contributions to meetings from 
      Abbott, Abiomed, AstraZeneca, Bayer, Berlin Chemie, Novartis, Pfizer, and 
      Servier, all outside the submitted work. All other authors report no conflicts of 
      interest.
EDAT- 2022/04/21 06:00
MHDA- 2023/08/03 06:42
CRDT- 2022/04/20 12:05
PHST- 2022/02/28 00:00 [accepted]
PHST- 2023/08/03 06:42 [medline]
PHST- 2022/04/21 06:00 [pubmed]
PHST- 2022/04/20 12:05 [entrez]
AID - 10.1007/s10557-022-07331-1 [pii]
AID - 7331 [pii]
AID - 10.1007/s10557-022-07331-1 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2023 Aug;37(4):729-741. doi: 10.1007/s10557-022-07331-1. 
      Epub 2022 Apr 20.

PMID- 25200142
OWN - NLM
STAT- MEDLINE
DCOM- 20150921
LR  - 20220311
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Print)
IS  - 1173-2563 (Linking)
VI  - 34
IP  - 11
DP  - 2014 Nov
TI  - Initial 3-weeks' Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and 
      Aspirin) followed by Clopidogrel alone in high-risk patients with Acute 
      Non-Disabling Cerebrovascular Events (ADANCE): study protocol for a randomized 
      controlled trial.
PG  - 755-61
LID - 10.1007/s40261-014-0228-8 [doi]
AB  - BACKGROUND: Nondisabling cerebrovascular events represent the largest group of 
      cerebrovascular disease with a high risk of recurrent stroke. A recent trial 
      demonstrated that dual-antiplatelet therapy (clopidogrel and aspirin), compared 
      with aspirin monotherapy, reduced the risk of recurrent stroke and was not 
      associated with increased risk of hemorrhagic events. Apixaban, a new oral 
      anticoagulant, has been proven to be as safe and effective as traditional 
      anticoagulants while carrying significantly less risk of intracranial hemorrhage. 
      Patients with transient ischemic attack (TIA)/minor stroke might benefit from 
      apixaban treatment; therefore, an adequately powered randomized study is needed. 
      METHODS AND RESULTS: The ADANCE [Apixaban Versus Dual-antiplatelet Therapy 
      (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events] study is 
      a randomized, double-blind clinical trial with a target enrollment of 5,500 
      patients. A 21-day regimen of apixaban or of clopidogrel with aspirin followed by 
      clopidogrel on days 22 through 90 will be administered to randomized participants 
      with acute TIA or minor ischemic stroke. The primary efficacy endpoint is the 
      percentage of patients with any new stroke (ischemic or hemorrhage), including 
      fatal stroke, at day 21. Study visits will be performed on the day of 
      randomization, and at days 7, 22, and 90. DISCUSSION: The novel oral 
      anticoagulant apixaban has been widely used with fewer adverse effects than 
      traditional anticoagulants. We designed the ADANCE trial to observe the effects 
      of apixaban on recurrent stroke after TIA or minor stroke. The results should 
      better guide the selection of anticoagulant or dual-antiplatelet therapy for 
      patients with acute TIA or minor ischemic stroke.
FAU - Yang, Fang
AU  - Yang F
AD  - Department of Neurology, Xijing Hospital, No. 15 West Changle Road, Xi'an, 
      710032, China, fyangx@fmmu.edu.cn.
FAU - Lei, Hui
AU  - Lei H
FAU - Jiang, Wenrui
AU  - Jiang W
FAU - Jiang, Wen
AU  - Jiang W
FAU - Han, Junliang
AU  - Han J
FAU - Zhao, Gang
AU  - Zhao G
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Endpoint Determination
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Pyrazoles/administration & dosage/*therapeutic use
MH  - Pyridones/administration & dosage/*therapeutic use
MH  - Stroke/*drug therapy
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC4210645
COIS- The authors declare that they have no competing interests.
EDAT- 2014/09/10 06:00
MHDA- 2015/09/22 06:00
CRDT- 2014/09/10 06:00
PHST- 2014/09/10 06:00 [entrez]
PHST- 2014/09/10 06:00 [pubmed]
PHST- 2015/09/22 06:00 [medline]
AID - 228 [pii]
AID - 10.1007/s40261-014-0228-8 [doi]
PST - ppublish
SO  - Clin Drug Investig. 2014 Nov;34(11):755-61. doi: 10.1007/s40261-014-0228-8.

PMID- 16579752
OWN - NLM
STAT- MEDLINE
DCOM- 20060524
LR  - 20131121
IS  - 0002-9645 (Print)
IS  - 0002-9645 (Linking)
VI  - 67
IP  - 4
DP  - 2006 Apr
TI  - Effects of deracoxib and aspirin on serum concentrations of thyroxine, 
      3,5,3'-triiodothyronine, free thyroxine, and thyroid-stimulating hormone in 
      healthy dogs.
PG  - 599-603
AB  - OBJECTIVE: To evaluate the effects of deracoxib and aspirin on serum 
      concentrations of thyroxine (T4), 3,5,3'-triiodothyronine (T3), free thyroxine 
      (fT4), and thyroid-stimulating hormone (TSH) in healthy dogs. ANIMALS: 24 dogs. 
      PROCEDURE: Dogs were allocated to 1 of 3 groups of 8 dogs each. Dogs received the 
      vehicle used for deracoxib tablets (PO, q 8 h; placebo), aspirin (23 to 25 mg/kg, 
      PO, q 8 h), or deracoxib (1.25 to 1.8 mg/kg, PO, q 24 h) and placebo (PO, q 8 h) 
      for 28 days. Measurement of serum concentrations of T4, T3, fT4, and TSH were 
      performed 7 days before treatment (day -7), on days 14 and 28 of treatment, and 
      14 days after treatment was discontinued. Plasma total protein, albumin, and 
      globulin concentrations were measured on days -7 and 28. RESULTS: Mean serum T4, 
      fT4, and T3 concentrations decreased significantly from baseline on days 14 and 
      28 of treatment in dogs receiving aspirin, compared with those receiving placebo. 
      Mean plasma total protein, albumin, and globulin concentrations on day 28 
      decreased significantly in dogs receiving aspirin, compared with those receiving 
      placebo. Fourteen days after administration of aspirin was stopped, differences 
      in hormone concentrations were no longer significant. Differences in serum TSH or 
      the free fraction of T4 were not detected at any time. No significant difference 
      in any of the analytes was detected at any time in dogs treated with deracoxib. 
      CONCLUSIONS AND CLINICAL RELEVANCE: Aspirin had substantial suppressive effects 
      on thyroid hormone concentrations in dogs. Treatment with high dosages of 
      aspirin, but not deracoxib, should be discontinued prior to evaluation of thyroid 
      function.
FAU - Panciera, David L
AU  - Panciera DL
AD  - Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College 
      of Veterinary Medicine, Blacksburg, VA 24061-0442, USA.
FAU - Refsal, Kent R
AU  - Refsal KR
FAU - Sennello, Kathleen A
AU  - Sennello KA
FAU - Ward, Daniel L
AU  - Ward DL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 0 (Placebos)
RN  - 0 (Serum Albumin)
RN  - 0 (Serum Globulins)
RN  - 0 (Sulfonamides)
RN  - 06LU7C9H1V (Triiodothyronine)
RN  - 9002-71-5 (Thyrotropin)
RN  - Q51BO43MG4 (Thyroxine)
RN  - R16CO5Y76E (Aspirin)
RN  - VX29JB5XWV (deracoxib)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Dogs/*blood
MH  - Female
MH  - Male
MH  - Placebos
MH  - Reference Values
MH  - Serum Albumin/drug effects/metabolism
MH  - Serum Globulins/drug effects/metabolism
MH  - Sulfonamides/administration & dosage/*pharmacology
MH  - Thyrotropin/*blood
MH  - Thyroxine/*blood
MH  - Triiodothyronine/*blood
EDAT- 2006/04/04 09:00
MHDA- 2006/05/25 09:00
CRDT- 2006/04/04 09:00
PHST- 2006/04/04 09:00 [pubmed]
PHST- 2006/05/25 09:00 [medline]
PHST- 2006/04/04 09:00 [entrez]
AID - 10.2460/ajvr.67.4.599 [doi]
PST - ppublish
SO  - Am J Vet Res. 2006 Apr;67(4):599-603. doi: 10.2460/ajvr.67.4.599.

PMID- 7635248
OWN - NLM
STAT- MEDLINE
DCOM- 19950913
LR  - 20190825
IS  - 0306-3623 (Print)
IS  - 0306-3623 (Linking)
VI  - 26
IP  - 4
DP  - 1995 Jul
TI  - Effects of acetylsalicylic acid on serotonin brain receptor subtypes.
PG  - 737-41
AB  - 1. The lysine salt of acetyl salicylic acid (ASA) at a dose equivalent to 400 
      mg/kg of acetyl salicylic acid (ASA) was intraperitoneally administered in rats. 
      2. After 30 and 120 min ASA did not modify the number of receptors nor the 
      affinity of [3H] 8-OH-DPAT binding sites in pons and cerebral cortex. On the 
      other hand, the receptor number in the cortex membranes decreased significantly 
      using [3H] ketanserin as ligand, while the receptor number in the pontine 
      membranes did not change. 3. These data support the involvement of central 5-HT 
      receptors in the mode of action of ASA.
FAU - Sandrini, M
AU  - Sandrini M
AD  - Department of Biomedical Sciences, University of Modena, Italy.
FAU - Vitale, G
AU  - Vitale G
FAU - Dondi, M
AU  - Dondi M
FAU - Pini, L A
AU  - Pini LA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gen Pharmacol
JT  - General pharmacology
JID - 7602417
RN  - 0 (Analgesics)
RN  - 0 (Receptors, Serotonin)
RN  - 78950-78-4 (8-Hydroxy-2-(di-n-propylamino)tetralin)
RN  - 97F9DE4CT4 (Ketanserin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacokinetics
MH  - Analgesics/pharmacology
MH  - Animals
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Brain Chemistry/*drug effects
MH  - Cerebral Cortex/drug effects/metabolism
MH  - Ketanserin/pharmacokinetics
MH  - Male
MH  - Membranes/drug effects/metabolism
MH  - Pons/drug effects/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Serotonin/*drug effects
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
AID - 030636239400252I [pii]
AID - 10.1016/0306-3623(94)00252-i [doi]
PST - ppublish
SO  - Gen Pharmacol. 1995 Jul;26(4):737-41. doi: 10.1016/0306-3623(94)00252-i.

PMID- 2507156
OWN - NLM
STAT- MEDLINE
DCOM- 19891122
LR  - 20131121
IS  - 0008-7335 (Print)
IS  - 0008-7335 (Linking)
VI  - 128
IP  - 26
DP  - 1989 Jun 28
TI  - [Treatment of chronic proliferative glomerulonephritis using acetylsalicylic acid 
      and dipyridamole].
PG  - 814-8
AB  - Fourteen patients with chronic proliferative glomerulonephritis were given for 
      the period of one year 400 mg acetylsalicylic acid and 225 mg dipyridamole per 
      day. During this treatment the thrombocyte aggregation became normal, however, 
      the mean reduction of antiheparin plasma activity was not statistically 
      significant. Normal synthesis of renal prostacyclin declined significantly as a 
      result of treatment, while the renal thromboxane A2 synthesis remained normal 
      even during treatment. Treatment did not influence proteinuria. The mean annual 
      decline of glomerular filtration was greater during the investigation period than 
      the mean annual decline in previous years, the difference was, however, only at 
      the borderline of statistical significance. The authors did not prove a 
      favourable effect of this treatment in patients with chronic proliferative 
      glomerulonephritis.
FAU - Knotková, V
AU  - Knotková V
FAU - Petrů, I
AU  - Petrů I
FAU - Nĕmecek, K
AU  - Nĕmecek K
FAU - Cieslar, P
AU  - Cieslar P
FAU - Pelèska, J
AU  - Pelèska J
FAU - Jáchymová, M
AU  - Jáchymová M
FAU - Pick, P
AU  - Pick P
FAU - Tomasy, M
AU  - Tomasy M
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Lécba chronické proliferativní glomerulonefritidy kyselinou acetylosalicylovou a 
      dipyridamolem.
PL  - Czech Republic
TA  - Cas Lek Cesk
JT  - Casopis lekaru ceskych
JID - 0004743
RN  - 57576-52-0 (Thromboxane A2)
RN  - 64ALC7F90C (Dipyridamole)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Chronic Disease
MH  - Dipyridamole/*administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Epoprostenol/biosynthesis
MH  - Female
MH  - Glomerulonephritis, Membranoproliferative/blood/*drug therapy/metabolism
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Thromboxane A2/biosynthesis
EDAT- 1989/06/28 00:00
MHDA- 1989/06/28 00:01
CRDT- 1989/06/28 00:00
PHST- 1989/06/28 00:00 [pubmed]
PHST- 1989/06/28 00:01 [medline]
PHST- 1989/06/28 00:00 [entrez]
PST - ppublish
SO  - Cas Lek Cesk. 1989 Jun 28;128(26):814-8.

PMID- 24342012
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20181202
IS  - 1578-8989 (Electronic)
IS  - 0025-7753 (Linking)
VI  - 143
IP  - 5
DP  - 2014 Sep 9
TI  - [Antiplatelet therapy: resistance to traditional antiaggregation drugs and role 
      of new antiplatelet agents].
PG  - 222-9
LID - S0025-7753(13)00752-5 [pii]
LID - 10.1016/j.medcli.2013.09.034 [doi]
AB  - Platelet aggregation plays a key role in the development of major cardiovascular 
      events (MACE) related to atherothrombosis. Since the appearance of coronary 
      stenting, the importance of measuring and modulating platelet activity has 
      considerably increased in the scientific literature during the last decade. 
      Double antiplatelet therapy with aspirin and clopidogrel administrated to stent 
      carriers has widely demonstrated its efficacy in the prevention of MACE compared 
      with aspirin alone. These benefits are also present when a conservatory approach 
      is chosen for acute coronary syndrome management. However, there are an important 
      number of patients who develop MACE despite optimal dual antiplatelet therapy, 
      most likely related to an incomplete platelet activity inhibition. Many studies 
      suggest an important inter-individual variability in the response to the drugs, 
      maybe related, at least in part, to the use of different assessment techniques of 
      platelet aggregation. Other authors suggest an incomplete platelet inhibition as 
      a possible explanation for the presence of MACE in patients under optimal 
      antiplatelet therapy. Resistance to usual drugs has become a clinically relevant 
      issue that requires an individual approach where new antiplatelet agents, such as 
      prasugrel or ticagrelor, could play an important role as stated in current 
      consensus documents.
CI  - Copyright © 2013 Elsevier España, S.L. All rights reserved.
FAU - del Castillo-Carnevali, Hugo
AU  - del Castillo-Carnevali H
AD  - Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid. España. 
      Electronic address: hugocar84@hotmail.com.
FAU - Barrios Alonso, Vivencio
AU  - Barrios Alonso V
AD  - Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid. España.
FAU - Zamorano Gómez, José Luis
AU  - Zamorano Gómez JL
AD  - Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid. España.
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Antiagregación: resistencia a fármacos tradicionales y papel de los nuevos 
      antiplaquetarios.
DEP - 20131215
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - Ticlopidine/analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirina
OT  - Clopidogrel
OT  - Factores de riesgo
OT  - Genetics
OT  - Genética
OT  - Guidelines
OT  - Guías
OT  - Individualización
OT  - Individualization
OT  - Prasugrel
OT  - Resistance
OT  - Resistencia
OT  - Risk factors
OT  - Ticagrelor
EDAT- 2013/12/18 06:00
MHDA- 2015/05/12 06:00
CRDT- 2013/12/18 06:00
PHST- 2013/05/23 00:00 [received]
PHST- 2013/09/18 00:00 [revised]
PHST- 2013/09/26 00:00 [accepted]
PHST- 2013/12/18 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - S0025-7753(13)00752-5 [pii]
AID - 10.1016/j.medcli.2013.09.034 [doi]
PST - ppublish
SO  - Med Clin (Barc). 2014 Sep 9;143(5):222-9. doi: 10.1016/j.medcli.2013.09.034. Epub 
      2013 Dec 15.

PMID- 31610353
OWN - NLM
STAT- MEDLINE
DCOM- 20200221
LR  - 20200221
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
VI  - 246
DP  - 2020 Feb
TI  - Timing Strategy of Preoperative Aspirin and Its Impact on Early Outcomes in 
      Patients Undergoing Coronary Artery Bypass Grafting: A Propensity Score Matching 
      Analysis.
PG  - 251-259
LID - S0022-4804(19)30660-2 [pii]
LID - 10.1016/j.jss.2019.09.026 [doi]
AB  - BACKGROUND: Data are lacking regarding optimal discontinuation time of 
      preoperative aspirin before coronary artery bypass grafting (CABG). We aimed at 
      assessing the impact of aspirin discontinuation according to time intervals 
      before CABG and its influence on early postoperative outcomes. METHODS: In this 
      retrospective study, we enrolled 652 patients who underwent primary isolated 
      nonemergent CABG between October 2014 and December 2017. Patients were assigned 
      into groups according to the time interval between the last aspirin dose 
      administration and the time of surgery. The first group comprised patients who 
      were given aspirin ≤24-h before CABG (n = 304), whereas the second group 
      consisted of patients who took aspirin between 24 and 48 h before CABG (n = 348). 
      Efficacy endpoints included 30-d mortality rate, incidence of major adverse 
      cardiac and cerebral events (MACCE) and composite rates of 30-d mortality/MACCE. 
      Propensity score matching was used for final comparison. RESULTS: Overall, 
      multivariate analysis showed that aspirin administration ≤24 h before CABG was 
      associated with reduced 30-d mortality rate and MACCE by 75% and 57%, 
      respectively. Before as well as after propensity score matching, multivariate 
      analysis showed that aspirin administration ≤24-h before CABG was associated with 
      reduced composite rates of 30-d mortality rate and MACCE by 55% and 59%, 
      respectively. Subgroup analysis stratified by the type of surgery showed that 
      aspirin administration ≤24-h significantly reduced composite rates of 30-d 
      mortality/MACCE in patients after off-pump CABG. CONCLUSIONS: Preoperative 
      administration of aspirin ≤24-h before CABG is associated with the reduction of 
      postoperative mortality as well as MACCE. The evidence also suggests that aspirin 
      administration ≤24-h is strongly associated with reduced composite rates of 30-d 
      mortality/MACCE in patients submitted to off-pump CABG.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Aboul-Hassan, Sleiman Sebastian
AU  - Aboul-Hassan SS
AD  - Department of Cardiac Surgery, MEDINET Heart Center Ltd, Nowa Sol, Poland. 
      Electronic address: s.aboulhassan@gmail.com.
FAU - Stankowski, Tomasz
AU  - Stankowski T
AD  - Department of Cardiac Surgery, Sana-Heart Center Cottbus, Cottbus, Germany.
FAU - Marczak, Jakub
AU  - Marczak J
AD  - Department of Cardiac Surgery, Trent Cardiac Centre, Nottingham University 
      Hospital, Nottingham, United Kingdom.
FAU - Peksa, Maciej
AU  - Peksa M
AD  - Department of Cardiac Surgery, MEDINET Heart Center Ltd, Nowa Sol, Poland.
FAU - Nawotka, Marcin
AU  - Nawotka M
AD  - Department of Cardiac Surgery, MEDINET Heart Center Ltd, Nowa Sol, Poland.
FAU - Stanislawski, Ryszard
AU  - Stanislawski R
AD  - Department of Cardiac Surgery, MEDINET Heart Center Ltd, Nowa Sol, Poland.
FAU - Cichon, Romuald
AU  - Cichon R
AD  - Department of Cardiac Surgery, Warsaw Medical University, Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20191011
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Coronary Artery Bypass/*adverse effects
MH  - Coronary Artery Disease/complications/*therapy
MH  - Female
MH  - Hospital Mortality
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Postoperative Complications/*epidemiology/etiology/prevention & control
MH  - Preoperative Care/adverse effects/*methods
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Coronary artery bypass grafting
OT  - Outcomes
OT  - Preoperative aspirin
OT  - Timing strategy
EDAT- 2019/10/15 06:00
MHDA- 2020/02/23 06:00
CRDT- 2019/10/15 06:00
PHST- 2019/04/15 00:00 [received]
PHST- 2019/08/05 00:00 [revised]
PHST- 2019/09/13 00:00 [accepted]
PHST- 2019/10/15 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
PHST- 2019/10/15 06:00 [entrez]
AID - S0022-4804(19)30660-2 [pii]
AID - 10.1016/j.jss.2019.09.026 [doi]
PST - ppublish
SO  - J Surg Res. 2020 Feb;246:251-259. doi: 10.1016/j.jss.2019.09.026. Epub 2019 Oct 
      11.

PMID- 20397269
OWN - NLM
STAT- MEDLINE
DCOM- 20100729
LR  - 20211020
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 16
IP  - 15
DP  - 2010 Apr 21
TI  - Gender differences of low-dose aspirin-associated gastroduodenal ulcer in 
      Japanese patients.
PG  - 1896-900
AB  - AIM: To clarify the gender differences about the clinical features and risk 
      factors of low-dose aspirin (LDA) (81-100 mg daily)-associated peptic ulcer in 
      Japanese patients. METHODS: There were 453 patients under treatment with LDA (298 
      males, 155 females) who underwent esophagogastroduodenoscopy at the Department of 
      Gastroenterology and Hepatology of Hiratsuka City Hospital between January 2003 
      and December 2007. They had kept taking the LDA or started treatment during the 
      study period and kept taking LDA during the whole period of observation. Of 
      these, 119 patients (87 males, 32 females) were diagnosed as having 
      LDA-associated peptic ulcer. We examined the clinical factors associated with 
      LDA-associated peptic ulcer in both sexes. RESULTS: A history of peptic ulcer was 
      found to be the risk factor for LDA-associated peptic ulcer common to both sexes. 
      In female patients, age greater than 70 years (prevalence ORs 8.441, 95% CI: 
      1.797-33.649, P = 0.0069) was found to be another significant risk factor, and 
      the time to diagnosis as having LDA-associated peptic ulcer by endoscopy was 
      significantly shorter than that in the male patients (P = 0.0050). CONCLUSION: We 
      demonstrated gender differences about the clinical features and risk factors of 
      LDA-associated peptic ulcer. Special attention should be paid to aged female 
      patients taking LDA.
FAU - Okada, Kazuhisa
AU  - Okada K
AD  - Department of Gastroenterology and Hepatology, Hiratsuka City Hospital, 1-19-1, 
      Nanbara, Hiratsuka 254-0066, Japan.
FAU - Inamori, Masahiko
AU  - Inamori M
FAU - Imajyo, Kento
AU  - Imajyo K
FAU - Chiba, Hideyuki
AU  - Chiba H
FAU - Nonaka, Takashi
AU  - Nonaka T
FAU - Shiba, Tadahiko
AU  - Shiba T
FAU - Sakaguchi, Takashi
AU  - Sakaguchi T
FAU - Atsukawa, Kazuhiko
AU  - Atsukawa K
FAU - Takahashi, Hisao
AU  - Takahashi H
FAU - Hoshino, Etsuo
AU  - Hoshino E
FAU - Nakajima, Atsushi
AU  - Nakajima A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*adverse effects
MH  - Endoscopy/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Peptic Ulcer/diagnosis/*etiology
MH  - Risk Factors
MH  - Sex Factors
PMC - PMC2856832
OTO - NOTNLM
OT  - Gender
OT  - Low-dose aspirin
OT  - Peptic ulcer
EDAT- 2010/04/17 06:00
MHDA- 2010/07/30 06:00
CRDT- 2010/04/17 06:00
PHST- 2010/04/17 06:00 [entrez]
PHST- 2010/04/17 06:00 [pubmed]
PHST- 2010/07/30 06:00 [medline]
AID - 10.3748/wjg.v16.i15.1896 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2010 Apr 21;16(15):1896-900. doi: 
      10.3748/wjg.v16.i15.1896.

PMID- 16047718
OWN - NLM
STAT- MEDLINE
DCOM- 20051011
LR  - 20221207
IS  - 1018-9068 (Print)
IS  - 1018-9068 (Linking)
VI  - 15
IP  - 2
DP  - 2005
TI  - Not all food additive related reactions originate from commercial foods: chronic 
      urticaria due to home-made canned tomato.
PG  - 153-5
AB  - Additives and preservatives in commercial foods have been implicated in the 
      etiology of chronic urticaria, but such foods have not been widely accepted. In 
      some countries, as in ours, people prefer to use home-made foodstuffs to avoid 
      potentially hazardous commercial additives. However, not all home-made foodstuffs 
      are safe, especially regarding allergies. In this report, we describe a patient 
      with chronic urticaria due to home-made canned tomato prepared using "tomato 
      drug" as a "safe (!)" additive.
FAU - Ozturk, S
AU  - Ozturk S
AD  - Gülhane Military Medical Academy and Medical Faculty, Department of Allergy, 
      Ankara, Turkey. samiozturkiz@hotmail.com
FAU - Karaayvaz, M
AU  - Karaayvaz M
FAU - Caliskaner, Z
AU  - Caliskaner Z
FAU - Gulec, M
AU  - Gulec M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Spain
TA  - J Investig Allergol Clin Immunol
JT  - Journal of investigational allergology & clinical immunology
JID - 9107858
RN  - 0 (Food Preservatives)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Chronic Disease
MH  - Food Hypersensitivity/*etiology
MH  - Food Preservatives/*adverse effects
MH  - Humans
MH  - Solanum lycopersicum
MH  - Male
MH  - Urticaria/*etiology
EDAT- 2005/07/29 09:00
MHDA- 2005/10/12 09:00
CRDT- 2005/07/29 09:00
PHST- 2005/07/29 09:00 [pubmed]
PHST- 2005/10/12 09:00 [medline]
PHST- 2005/07/29 09:00 [entrez]
PST - ppublish
SO  - J Investig Allergol Clin Immunol. 2005;15(2):153-5.

PMID- 3423098
OWN - NLM
STAT- MEDLINE
DCOM- 19880224
LR  - 20191029
IS  - 0262-1746 (Print)
IS  - 0262-1746 (Linking)
VI  - 30
IP  - 2-3
DP  - 1987 Dec
TI  - Influence of anti-platelet drugs on platelet-vessel wall interactions.
PG  - 133-45
AB  - The influence of in vitro treatment of platelets with antiplatelet drugs on the 
      interaction of these cells with the subendothelium was studied using citrated 
      human blood obtained from normal control donors. Reconstituted blood following 
      drug treatment was circulated through a special chamber which housed everted 
      segments of de-endothelialized rabbit aorta. The wall shear rate used in these 
      studies was 800 sec-1. Surface coverage of platelets on the subendothelium were 
      morphometrically evaluated. Aspirin, Ibuprofen, Prostaglandin E1 and 
      13-Azaprostanoic acid significantly reduced platelet thrombi on exposed 
      subendothelium. The calcium antagonists, Quin 2 and Diltiazem, exerted similar 
      inhibitory effects, whereas Verapamil was a poor inhibitor. Aspirin treatment 
      significantly enhanced platelet adhesion to the exposed vascular surface. 
      Salicylate and Salicylamide did not enhance platelet adherence. Only Aspirin 
      enhanced the formation of lipoxygenase metabolites of radiolabeled arachidonate. 
      Results suggest that drugs which inhibit platelet aggregation and secretion of 
      granule contents reduce formation of platelet thrombi. However, these drugs may 
      or may not have a similar influence on platelet interaction with the 
      subendothelium leading to spreading, adherence or formation of aggregates.
FAU - Rao, G H
AU  - Rao GH
AD  - Department of Laboratory Medicine and Pathology, University of Minnesota Health 
      Sciences Center, University Hospitals and Clinics, Minneapolis 55455.
LA  - eng
GR  - CA-21737/CA/NCI NIH HHS/United States
GR  - HL-11880/HL/NHLBI NIH HHS/United States
GR  - HL-30217/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Scotland
TA  - Prostaglandins Leukot Med
JT  - Prostaglandins, leukotrienes, and medicine
JID - 8206868
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Calcium Channel Blockers/pharmacology
MH  - Endothelium, Vascular/*cytology
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thrombosis/*prevention & control
MH  - Thromboxanes/biosynthesis
EDAT- 1987/12/01 00:00
MHDA- 1987/12/01 00:01
CRDT- 1987/12/01 00:00
PHST- 1987/12/01 00:00 [pubmed]
PHST- 1987/12/01 00:01 [medline]
PHST- 1987/12/01 00:00 [entrez]
AID - 10.1016/0262-1746(87)90143-0 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Med. 1987 Dec;30(2-3):133-45. doi: 
      10.1016/0262-1746(87)90143-0.

PMID- 6635212
OWN - NLM
STAT- MEDLINE
DCOM- 19831217
LR  - 20190825
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 26
IP  - 1
DP  - 1983 Jul
TI  - Comparison of the effect of nonsteroidal and steroidal antiinflammatory agents on 
      prostaglandin production during ovulation in the rabbit.
PG  - 71-8
AB  - The nonsteroidal antiinflammatory agents diclofenac, fenoprofen and aspirin were 
      tested to determine how well they inhibit the preovulatory elevation in 
      prostaglandin (PG) production in rabbit follicles in comparison to indomethacin. 
      In addition, the steroidal antiinflammatory agent dexamethasone and the 
      antipyretic agent acetaminophen were tested. The agents were administered 8 h 
      after the ovulatory process was stimulated by hCG (50 I.U./kg). At 10 h after hCG 
      (i.e., at the expected time of ovulation) control follicles had PGF and PGE 
      levels of 370.0 and 582.6 pg/mg of follicle, respectively. Diclofenac inhibited 
      PG production the most--reducing PGF and PGE to 22.8 and 53.6 pg/mg, 
      respectively. Indomethacin reduced the PGF and PGE levels to 27.4 and 76.6 pg/mg, 
      respectively. Fenoprofen was less effective, reducing the PGF and PGE to 77.8 and 
      222.4 pg/mg, respectively. Aspirin reduced the PGF and PGE to 123.4 and 174.6 
      pg/mg, respectively. Dexamethasone and acetaminophen did not inhibit PG 
      production. Ovulation was completely inhibited by diclofenac and indomethacin, 
      partially inhibited by fenoprofen, and unaffected by aspirin, acetaminophen, or 
      dexamethasone. The results suggest that any potent nonsteroidal antiinflammatory 
      agent can inhibit ovulation provided it adequately reduces PG production; whereas 
      steroidal antiinflammatory agents are ineffective. The antiinflammatory agent 
      must completely abolish the preovulatory elevation in PGs in mature follicles in 
      order to totally inhibit ovulation.
FAU - Espey, L L
AU  - Espey LL
LA  - eng
GR  - HD14539/HD/NICHD NIH HHS/United States
GR  - P30-HD10202/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Prostaglandins)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetaminophen/pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/pharmacology
MH  - Dexamethasone/pharmacology
MH  - Diclofenac/pharmacology
MH  - Female
MH  - Fenoprofen/pharmacology
MH  - Indomethacin/pharmacology
MH  - *Ovulation
MH  - Prostaglandins/*biosynthesis
MH  - Rabbits
EDAT- 1983/07/01 00:00
MHDA- 1983/07/01 00:01
CRDT- 1983/07/01 00:00
PHST- 1983/07/01 00:00 [pubmed]
PHST- 1983/07/01 00:01 [medline]
PHST- 1983/07/01 00:00 [entrez]
AID - 0090-6980(83)90075-8 [pii]
AID - 10.1016/0090-6980(83)90075-8 [doi]
PST - ppublish
SO  - Prostaglandins. 1983 Jul;26(1):71-8. doi: 10.1016/0090-6980(83)90075-8.

PMID- 14709735
OWN - NLM
STAT- MEDLINE
DCOM- 20040127
LR  - 20190513
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Linking)
VI  - 96
IP  - 1
DP  - 2004 Jan 7
TI  - A prospective study of aspirin use and the risk of pancreatic cancer in women.
PG  - 22-8
AB  - BACKGROUND: In vitro experiments and limited animal studies suggest that aspirin 
      and nonsteroidal anti-inflammatory drugs may inhibit pancreatic carcinogenesis. 
      Because few studies have examined the association between aspirin use and 
      pancreatic cancer in humans and the results have been inconsistent, we examined 
      the relationship between aspirin use and the development of pancreatic cancer in 
      the Nurses' Health Study. METHODS: Among 88 378 women without cancer at baseline, 
      we documented 161 cases of pancreatic cancer during 18 years of follow-up. 
      Aspirin use was first assessed at baseline in 1980 and updated biennially 
      thereafter. All statistical tests were two-sided. RESULTS: Participants were 
      classified according to history of aspirin use. In a multivariable analysis, the 
      risk of pancreatic cancer was not associated with current regular aspirin use 
      (defined as two or more standard tablets per week; relative risk [RR] = 1.20, 95% 
      confidence interval [CI] = 0.87 to 1.65), compared with use of fewer than two 
      tablets per week. Increasing duration of regular aspirin use, compared with 
      non-use, was associated with a statistically significant increase in risk: Women 
      who reported more than 20 years of regular aspirin use had an increased risk of 
      pancreatic cancer (RR = 1.58, 95% CI = 1.03 to 2.43; P(trend) =.01). Among women 
      who reported aspirin use on at least two of three consecutive biennial 
      questionnaires compared with consistent non-users of aspirin, the risk increased 
      with dose (one to three tablets per week: RR = 1.11, 95% CI = 0.70 to 1.76; four 
      to six tablets per week: RR = 1.29, 95% CI = 0.70 to 2.40; seven to 13 tablets 
      per week: RR = 1.41, 95% CI = 0.76 to 2.61; and > or = 14 tablets per week: RR = 
      1.86, 95% CI = 1.03 to 3.35) (P(trend) =.02). CONCLUSION: Extended periods of 
      regular aspirin use appear to be associated with a statistically significantly 
      increased risk of pancreatic cancer among women.
FAU - Schernhammer, Eva S
AU  - Schernhammer ES
AD  - Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, MA 02115, USA. 
      eva.schernhammer@channing.harvard.edu
FAU - Kang, Jae-Hee
AU  - Kang JH
FAU - Chan, Andrew T
AU  - Chan AT
FAU - Michaud, Dominique S
AU  - Michaud DS
FAU - Skinner, Halcyon G
AU  - Skinner HG
FAU - Giovannucci, Edward
AU  - Giovannucci E
FAU - Colditz, Graham A
AU  - Colditz GA
FAU - Fuchs, Charles S
AU  - Fuchs CS
LA  - eng
GR  - CA/ES62984/CA/NCI NIH HHS/United States
GR  - CA40356/CA/NCI NIH HHS/United States
GR  - CA55075/CA/NCI NIH HHS/United States
GR  - CA86102/CA/NCI NIH HHS/United States
GR  - CA87969/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Natl Cancer Inst. 2004 Jan 7;96(1):4-5. PMID: 14709726
CIN - J Natl Cancer Inst. 2004 Feb 18;96(4):252-3. PMID: 14970267
CIN - J Natl Cancer Inst. 2004 Apr 21;96(8):637; author reply 637-8. PMID: 15100348
CIN - Gastroenterology. 2004 Sep;127(3):1002-4. PMID: 15362060
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Utilization/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Nurses/statistics & numerical data
MH  - Odds Ratio
MH  - Pancreatic Neoplasms/*chemically induced/epidemiology
MH  - Prospective Studies
MH  - Research Design
MH  - Risk Assessment
MH  - Risk Factors
MH  - Smoking/adverse effects
MH  - United States/epidemiology
EDAT- 2004/01/08 05:00
MHDA- 2004/01/28 05:00
CRDT- 2004/01/08 05:00
PHST- 2004/01/08 05:00 [pubmed]
PHST- 2004/01/28 05:00 [medline]
PHST- 2004/01/08 05:00 [entrez]
AID - 10.1093/jnci/djh001 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2004 Jan 7;96(1):22-8. doi: 10.1093/jnci/djh001.

PMID- 34108528
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Jun 9
TI  - Systematic review and meta-analysis on the adjunctive use of host immune 
      modulators in non-surgical periodontal treatment in healthy and systemically 
      compromised patients.
PG  - 12125
LID - 10.1038/s41598-021-91506-7 [doi]
LID - 12125
AB  - Considering the central role of inflammation in the pathogenesis of 
      periodontitis, the combination of NSPT with different agents that can modulate 
      the host immune-inflammatory response has been proposed to enhance the outcomes 
      of NSPT. The aim of this paper is to systematically review the literature on the 
      efficacy of systemic host modulators (HMs) as adjuncts to non-surgical 
      periodontal therapy (NSPT) in improving pocket depth (PD) reduction and clinical 
      attachment level (CAL) gain in healthy and systemically compromised patients. 
      RCTs with ≥ 3 months follow-up were independently searched by two reviewers. 
      Meta-analysis was performed when ≥ 3 studies on the same HM were identified. The 
      quality of the evidence was rated according to the GRADE approach to rate the 
      certainty of evidence. 38 articles were included in the qualitative assessment 
      and 27 of them were included in the meta-analysis. There is low/very low evidence 
      that the adjunctive use of sub-antimicrobial dose of doxycicline, melatonin and 
      the combination of omega-3 and low dose aspirin (in type 2 diabetic patients) to 
      NSPT would improve PD and/or CAL. Conflicting evidence is available on the 
      efficacy of probiotics. Future studies controlling for confounding factors, using 
      composite outcomes to define the endpoint of therapy and considering not only the 
      patient- but also as the site-specific effect of systemic HMs are warranted. The 
      dosage, posology and long-term effect of HMs still need to be clarified, also in 
      association to the presence of systemic conditions potentially affecting the 
      response to HMs administration.
FAU - Corbella, Stefano
AU  - Corbella S
AUID- ORCID: 0000-0001-8428-8811
AD  - Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di 
      Milano, Milan, Italy. stefano.corbella@gmail.com.
AD  - IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. stefano.corbella@gmail.com.
AD  - Department of Oral Surgery, Institute of Dentistry, I. M. Sechenov First Moscow 
      State Medical University, Moscow, Russia. stefano.corbella@gmail.com.
FAU - Calciolari, Elena
AU  - Calciolari E
AUID- ORCID: 0000-0001-8781-1997
AD  - Centre for Oral Clinical Research and Centre for Oral Immunobiology and 
      Regenerative Medicine, Institute of Dentistry, Barts and The London, School of 
      Medicine and Dentistry, Queen Mary University of London, London, UK.
AD  - Department of Medicine and Surgery, Centre of Dentistry, University of Parma, 
      Parma, Italy.
FAU - Alberti, Alice
AU  - Alberti A
AUID- ORCID: 0000-0001-5017-1340
AD  - Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di 
      Milano, Milan, Italy.
AD  - IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
FAU - Donos, Nikolaos
AU  - Donos N
AUID- ORCID: 0000-0002-4117-9073
AD  - Centre for Oral Clinical Research and Centre for Oral Immunobiology and 
      Regenerative Medicine, Institute of Dentistry, Barts and The London, School of 
      Medicine and Dentistry, Queen Mary University of London, London, UK.
FAU - Francetti, Luca
AU  - Francetti L
AUID- ORCID: 0000-0001-5775-8961
AD  - Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di 
      Milano, Milan, Italy.
AD  - IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210609
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - JL5DK93RCL (Melatonin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Infective Agents/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Antioxidants/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Chronic Disease
MH  - Humans
MH  - Melatonin/*therapeutic use
MH  - Periodontitis/*drug therapy
MH  - Prognosis
PMC - PMC8190303
COIS- The authors declare no competing interests.
EDAT- 2021/06/11 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/06/10 06:18
PHST- 2021/04/13 00:00 [received]
PHST- 2021/05/10 00:00 [accepted]
PHST- 2021/06/10 06:18 [entrez]
PHST- 2021/06/11 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
AID - 10.1038/s41598-021-91506-7 [pii]
AID - 91506 [pii]
AID - 10.1038/s41598-021-91506-7 [doi]
PST - epublish
SO  - Sci Rep. 2021 Jun 9;11(1):12125. doi: 10.1038/s41598-021-91506-7.

PMID- 9446186
OWN - NLM
STAT- MEDLINE
DCOM- 19980129
LR  - 20131121
IS  - 0036-5327 (Print)
IS  - 0036-5327 (Linking)
VI  - 98
IP  - 1
DP  - 1997
TI  - [Changes in thyroid function in rats after administration of methylene blue and 
      interactions with estrogens and acetylsalicylic acid].
PG  - 27-33
AB  - We have studied the thyroxine and triiodothyronine concentrations in male 
      rats--the control, groups treated separately with estradiol benzoate, 
      acetylsalicylic acid and methylene blue and with combinations of these 
      substances. We have found out that the treatment with acetylsalicylic acid 
      significantly lowers the thyroxine and triiodothyronine serum concentrations. The 
      estradiol benzoate as well as methylene blue inhibited the drop in the serum 
      thyroxine level when administered simultaneously with acetylsalicylic acid. The 
      serum triiodothyronine decrease after acetylsalicylic acid treatment was 
      inhibited by methylene blue and estradiol benzoate only in one of our two 
      experiments. The simultaneous treatment with estradiol benzoate, acetylsalicylic 
      acid and methylene blue did not change the triiodothyronine concentration 
      comparing to control group and decreased the thyroxine serum concentration.
FAU - Haluzík, M
AU  - Haluzík M
AD  - Laborator pro endokrinologii a metabolismus III. interní kliniky 1. lékarské 
      fakulty Univerzity Karlovy, Praha, Czech Republic.
FAU - Nedvídková, J
AU  - Nedvídková J
FAU - Schreiber, V
AU  - Schreiber V
LA  - cze
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Zmĕny tyroidální funkce u potkanu pri podávání metylénové modri, interakce s 
      estrogeny a kyselinou acetylosalicylovou.
PL  - Czech Republic
TA  - Sb Lek
JT  - Sbornik lekarsky
JID - 0025770
RN  - 06LU7C9H1V (Triiodothyronine)
RN  - 1S4CJB5ZGN (estradiol 3-benzoate)
RN  - 4TI98Z838E (Estradiol)
RN  - Q51BO43MG4 (Thyroxine)
RN  - R16CO5Y76E (Aspirin)
RN  - T42P99266K (Methylene Blue)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Estradiol/administration & dosage/*analogs & derivatives/pharmacology
MH  - Male
MH  - Methylene Blue/administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Thyroid Gland/drug effects/*physiology
MH  - Thyroxine/blood
MH  - Triiodothyronine/blood
EDAT- 1997/01/01 00:00
MHDA- 1998/01/31 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1998/01/31 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Sb Lek. 1997;98(1):27-33.

PMID- 7521925
OWN - NLM
STAT- MEDLINE
DCOM- 19941013
LR  - 20161123
IS  - 0023-1207 (Print)
IS  - 0023-1207 (Linking)
IP  - 4
DP  - 1993 Apr
TI  - [Endolymphatic drug infusion in the treatment of complicated acute appendicitis].
PG  - 36-8
AB  - The work is based on lymphogenous methods of treatment, i.e. direct endolymphatic 
      therapy with antibiotics and other agents in complications of acute appendicitis. 
      On the basis of information in the literature, among the antibiotics we chose 
      gentamicin, claforan, and a new antibiotic fortum. In addition to antibiotics, 
      for the correction of disturbed blood rheological properties we gave 
      endolymphatic infusions of trasylol, aspisol, and trental. The purpose of our 
      study was the development of methods and treatment of complications of acute 
      appendicitis. In view of this, we chose the patients according to the nosological 
      groups with appendicular infiltrate, appendicular abscesses, and localized 
      peritonitis of appendicular origin.
FAU - Shevkhuzhev, Z A
AU  - Shevkhuzhev ZA
FAU - Khanamatov, M Kh
AU  - Khanamatov MKh
LA  - rus
PT  - Journal Article
TT  - Endolimfaticheskoe vvedenie preparatov pri lechenii oslozhneniĭ ostrogo 
      appenditsita.
PL  - Russia (Federation)
TA  - Khirurgiia (Mosk)
JT  - Khirurgiia
JID - 0412765
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Gentamicins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9087-70-1 (Aprotinin)
RN  - 9M416Z9QNR (Ceftazidime)
RN  - K3Z4F929H6 (Lysine)
RN  - N2GI8B1GK7 (Cefotaxime)
RN  - R16CO5Y76E (Aspirin)
RN  - SD6QCT3TSU (Pentoxifylline)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Abscess/*drug therapy/*etiology
MH  - Acute Disease
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Appendicitis/*complications/surgery
MH  - Aprotinin/therapeutic use
MH  - Aspirin/analogs & derivatives/therapeutic use
MH  - Cefotaxime/therapeutic use
MH  - Ceftazidime/therapeutic use
MH  - Drug Therapy, Combination
MH  - Gentamicins/therapeutic use
MH  - Humans
MH  - Infusions, Intravenous
MH  - Lymphatic System/drug effects
MH  - Lysine/analogs & derivatives/therapeutic use
MH  - Pentoxifylline/therapeutic use
MH  - Peritonitis/*drug therapy/*etiology
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Premedication
EDAT- 1993/04/01 00:00
MHDA- 1993/04/01 00:01
CRDT- 1993/04/01 00:00
PHST- 1993/04/01 00:00 [pubmed]
PHST- 1993/04/01 00:01 [medline]
PHST- 1993/04/01 00:00 [entrez]
PST - ppublish
SO  - Khirurgiia (Mosk). 1993 Apr;(4):36-8.

PMID- 11735185
OWN - NLM
STAT- MEDLINE
DCOM- 20020111
LR  - 20131121
IS  - 1078-5884 (Print)
IS  - 1078-5884 (Linking)
VI  - 22
IP  - 5
DP  - 2001 Nov
TI  - "Long haul" flight and deep vein thrombosis: a model to help investigate the 
      benefit of aspirin and below-knee compression stockings.
PG  - 456-62
AB  - OBJECTIVE: to develop a model simulating factors of "long haul" flight to 
      investigate the relationship with DVT. MATERIALS AND METHODS: volunteers (19 
      males: 20 females) sat for 6 h in a warm (>25 degrees C), dry environment, 
      limited in movement, consuming alcohol (40 ml of 40% alcohol/hour) and salted 
      foods (300 g). Half of the subjects received 150 mg aspirin and wore especially 
      designed below-knee, compression stockings (Class 1 profile). Changes in full 
      blood counts were recorded, and as an indication of DVT formation, plasma was 
      analysed for D-dimer. Limb swelling was assessed from leg measurements. RESULTS: 
      after 6 h, in controls, there were significant rises in platelet packing (Pct 
      p<0.04), total platelet numbers (p<0.003) and total numbers of white blood cells 
      (WBC's p<0.001). With aspirin plus stockings, there were similar significant 
      rises in total platelet numbers (p<0.002) and total WBC's (p<0.001). In both 
      groups, significant rises were seen in all WBC types (except basophils). Wearing 
      compression stockings prevented calf swelling seen in controls after 6 h 
      (p<0.002). No subject developed a DVT, or a change in levels of D-dimer. 
      CONCLUSION: changes in the cellular components of blood, particularly WBC's, 
      combined with vaso-compression and reduced flow could predispose towards DVT. 
      Aspirin, combined with compression stockings, may provide prophylaxis.
CI  - Copyright 2001 Harcourt Publishers Limited.
FAU - Hollingsworth, S J
AU  - Hollingsworth SJ
AD  - The Academic Vascular Unit, Department of Surgery, The Royal Free and University 
      College London Medical School, Mortimer Street, London, W1N 8AA, U.K.
FAU - Dialysis, M
AU  - Dialysis M
FAU - Barker, S G
AU  - Barker SG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Eur J Vasc Endovasc Surg
JT  - European journal of vascular and endovascular surgery : the official journal of 
      the European Society for Vascular Surgery
JID - 9512728
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Aerospace Medicine
MH  - Aspirin/*therapeutic use
MH  - *Bandages
MH  - Edema/etiology/prevention & control
MH  - Female
MH  - Humans
MH  - Leg/blood supply
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Risk Factors
MH  - Statistics, Nonparametric
MH  - Venous Thrombosis/*etiology/*prevention & control
EDAT- 2001/12/12 10:00
MHDA- 2002/01/12 10:01
CRDT- 2001/12/12 10:00
PHST- 2001/12/12 10:00 [pubmed]
PHST- 2002/01/12 10:01 [medline]
PHST- 2001/12/12 10:00 [entrez]
AID - S1078-5884(01)91487-X [pii]
AID - 10.1053/ejvs.2001.1487 [doi]
PST - ppublish
SO  - Eur J Vasc Endovasc Surg. 2001 Nov;22(5):456-62. doi: 10.1053/ejvs.2001.1487.

PMID- 11136483
OWN - NLM
STAT- MEDLINE
DCOM- 20010322
LR  - 20181130
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 141
IP  - 1
DP  - 2001 Jan
TI  - Active-control trials: how would a new agent compare with placebo? A method 
      illustrated with clopidogrel, aspirin, and placebo.
PG  - 26-32
AB  - BACKGROUND: In an active-control trial with a new treatment and a comparator that 
      has placebo-controlled trials, how might the effect of the new therapy versus 
      placebo be estimated? For many diseases it is not ethically justified to use a 
      placebo-control trial, yet in the United States regulatory efficacy is 
      conceptually defined in comparison with placebo. METHODS: By use of the logarithm 
      of the odds ratio for the active-control trial and for the placebo-controlled 
      trials of the active-control, we estimated the effect of the new agent versus 
      placebo. This "putative placebo" estimate assumes that the odds ratio in the 
      active-control versus placebo trials is the same as would have been obtained had 
      a placebo arm been possible in the trial with the new agent. A formula is given 
      for sample size calculation in such a setting. RESULTS: Clopidogrel, an adenosine 
      diphosphate (ADP) receptor antagonist, and aspirin were compared in the 
      Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) Study 
      of patients with recent myocardial infarction, recent ischemic stroke, or 
      symptomatic peripheral arterial disease. The 40 trials comparing aspirin with 
      placebo are summarized by the Antiplatelet Trialists' Collaboration. For the 
      outcome cluster of stroke, myocardial infarction, or vascular mortality, the 
      estimated odds ratio for clopidogrel versus placebo is 0.70 (95% confidence 
      interval 0.64-0.78, P<.000001). The relative risk reduction of approximately 30% 
      represents a clinically meaningful benefit. CONCLUSIONS: For active-control 
      trials use of prior trials of the active-control versus placebo may be usefully 
      used to estimate the effect of the new therapy versus a putative placebo.
FAU - Fisher, L D
AU  - Fisher LD
AD  - Department of Biostatistics, University of Washington, Seattle, Wash, USA. 
      lloyd_fisher@alum.mit.edu
FAU - Gent, M
AU  - Gent M
FAU - Büller, H R
AU  - Büller HR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Placebos)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic/*methods
MH  - Clopidogrel
MH  - Humans
MH  - Odds Ratio
MH  - Placebos/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/*analogs & derivatives/*therapeutic use
EDAT- 2001/01/03 11:00
MHDA- 2001/03/27 10:01
CRDT- 2001/01/03 11:00
PHST- 2001/01/03 11:00 [pubmed]
PHST- 2001/03/27 10:01 [medline]
PHST- 2001/01/03 11:00 [entrez]
AID - S0002-8703(01)20676-0 [pii]
AID - 10.1067/mhj.2001.111262 [doi]
PST - ppublish
SO  - Am Heart J. 2001 Jan;141(1):26-32. doi: 10.1067/mhj.2001.111262.

PMID- 9194772
OWN - NLM
STAT- MEDLINE
DCOM- 19970710
LR  - 20190831
IS  - 1079-5642 (Print)
IS  - 1079-5642 (Linking)
VI  - 17
IP  - 6
DP  - 1997 Jun
TI  - Importance of platelets in neutrophil adhesion and vasoconstriction after deep 
      carotid arterial injury by angioplasty in pigs.
PG  - 1185-91
AB  - In previous studies we have shown that platelets can support neutrophil adhesion 
      to the injured vessel wall in vitro and that neutrophils contribute to vascular 
      tone regulation after arterial injury in vivo. In this study, we investigated the 
      implication of platelets in neutrophil adhesion and the vasomotor response to 
      arterial injury in vivo. 111In-labeled neutrophil adhesion and angiographic 
      vasoconstriction were quantified after deep carotid arterial injury by balloon 
      angioplasty in normal (n = 8), thrombocytopenic (n = 7), and aspirin-treated (2 
      mg/kg IV, n = 7) pigs. Thrombocytopenia was produced by a polyclonal antiplatelet 
      serum that depleted circulating platelet count by 84% without influencing 
      neutrophil count. In the control animals, neutrophil adhesion (x 10(4)/cm2) at 
      the site of deep arterial injury averaged 26.8 +/- 4.0 and decreased 
      significantly to 11.5 +/- 2.3 and 11.2 +/- 2.4 in the thrombocytopenic and 
      aspirin groups, respectively. The degree of vasconstriction was also reduced 
      significantly, from 55.5 +/- 3.8% in the control group to 31.4 +/- 6.2% after 
      platelet depletion and to 23.6 +/- 4.5% in the aspirin-treated group. Neutrophil 
      adhesion to intact noninjured adjacent arterial segments was low in all groups 
      and was not affected by the antiplatelet serum or by aspirin. In in vitro 
      superfusion flow chambers, neutrophil adhesion to damaged arterial segments 
      increased in the presence of platelets in a concentration-dependent manner and 
      was not influenced by the antiplatelet serum. This study demonstrates that 
      platelets can modulate neutrophil adhesion to the deeply injured arterial wall 
      and that both elements may influence the degree of postangioplasty 
      vasoconstriction in vivo.
FAU - Merhi, Y
AU  - Merhi Y
AD  - Laboratory of Experimental Pathology, Montreal Heart Institute, Quebec, Canada.
FAU - Provost, P
AU  - Provost P
FAU - Guidoin, R
AU  - Guidoin R
FAU - Latour, J G
AU  - Latour JG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon/*adverse effects
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blood Platelets/*physiology
MH  - *Carotid Artery Injuries
MH  - Cell Adhesion
MH  - Microscopy, Electron, Scanning
MH  - Neutrophils/*cytology
MH  - Swine
MH  - Thrombocytopenia
MH  - *Vasoconstriction
EDAT- 1997/06/01 00:00
MHDA- 1997/06/01 00:01
CRDT- 1997/06/01 00:00
PHST- 1997/06/01 00:00 [pubmed]
PHST- 1997/06/01 00:01 [medline]
PHST- 1997/06/01 00:00 [entrez]
AID - 10.1161/01.atv.17.6.1185 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1185-91. doi: 
      10.1161/01.atv.17.6.1185.

PMID- 21198918
OWN - NLM
STAT- MEDLINE
DCOM- 20110524
LR  - 20131121
IS  - 1443-1661 (Electronic)
IS  - 0915-5635 (Linking)
VI  - 23
IP  - 1
DP  - 2011 Jan
TI  - Quantitative analysis of low-dose aspirin-associated small bowel injury using a 
      capsule endoscopy scoring index.
PG  - 56-61
LID - 10.1111/j.1443-1661.2010.01044.x [doi]
AB  - AIM: The major limitation of capsule endoscopy (CE) has been the lack of a 
      standardized and validated severity scale for mucosal injury. The aim of the 
      present study was to verify the usefulness of quantifying small bowel mucosal 
      changes associated with giving low-dose aspirin (LDA) using a CE scoring index. 
      METHODS: The CE score for small bowel mucosal injury was investigated to evaluate 
      the severity of mucosal injury. Healthy volunteers and patients suspected of 
      having small bowel disease were recruited for this study. The short-term LDA 
      group (V+S-LDA group) consisted of volunteers who took low-dose aspirin for 
      14days; this group was then compared with healthy volunteers who did not receive 
      LDA treatment (V-Control group). The long-term LDA group (L-LDA group) consisted 
      of patients with at least a 3-month history of daily LDA use; this group was 
      compared with non-users of LDA (P-Control group). RESULTS: The CE score was 
      significantly higher in the V+S-LDA group than in the V-Control group. In the 
      V-Control group, almost all the subjects were categorized as exhibiting a 
      'normal' change. 'Mild' changes were observed significantly more frequently in 
      the V + S-LDA group than in the V-Control group. The CE score was significantly 
      higher in the L-LDA group than in the P-Control group. 'Mild' or 'moderate or 
      severe' changes were observed significantly more frequently in the L-LDA group 
      than in the P-Control group. CONCLUSION: The CE scoring system was useful for 
      evaluating LDA-associated small bowel mucosal disease activity and for 
      objectively scoring the small bowel inflammatory disease state.
CI  - © 2010 The Authors. Digestive Endoscopy © 2010 Japan Gastroenterological 
      Endoscopy Society.
FAU - Endo, Hiroki
AU  - Endo H
AD  - Division of Gastroenterology, Yokohama City University School of Medicine, Japan. 
      endo1978@yokohama-cu.ac.jp
FAU - Hosono, Kunihiro
AU  - Hosono K
FAU - Higurashi, Takuma
AU  - Higurashi T
FAU - Sakai, Eiji
AU  - Sakai E
FAU - Iida, Hiroshi
AU  - Iida H
FAU - Sakamoto, Yasunari
AU  - Sakamoto Y
FAU - Fujita, Koji
AU  - Fujita K
FAU - Takahashi, Hirokazu
AU  - Takahashi H
FAU - Koide, Tomoko
AU  - Koide T
FAU - Yoneda, Masato
AU  - Yoneda M
FAU - Tokoro, Chikako
AU  - Tokoro C
FAU - Inamori, Masahiko
AU  - Inamori M
FAU - Abe, Yasunobu
AU  - Abe Y
FAU - Matsuhashi, Nobuyuki
AU  - Matsuhashi N
FAU - Nakajima, Atsushi
AU  - Nakajima A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Dig Endosc
JT  - Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy 
      Society
JID - 9101419
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - *Capsule Endoscopy
MH  - Enteritis/*diagnosis
MH  - Female
MH  - Humans
MH  - Intestine, Small/*drug effects
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Retrospective Studies
MH  - Severity of Illness Index
EDAT- 2011/01/05 06:00
MHDA- 2011/05/25 06:00
CRDT- 2011/01/05 06:00
PHST- 2011/01/05 06:00 [entrez]
PHST- 2011/01/05 06:00 [pubmed]
PHST- 2011/05/25 06:00 [medline]
AID - 10.1111/j.1443-1661.2010.01044.x [doi]
PST - ppublish
SO  - Dig Endosc. 2011 Jan;23(1):56-61. doi: 10.1111/j.1443-1661.2010.01044.x.

PMID- 20033881
OWN - NLM
STAT- MEDLINE
DCOM- 20101122
LR  - 20211020
IS  - 1099-0801 (Electronic)
IS  - 0269-3879 (Print)
IS  - 0269-3879 (Linking)
VI  - 24
IP  - 9
DP  - 2010 Sep
TI  - Development and validation of a high-performance liquid chromatography method for 
      the simultaneous determination of aspirin and folic acid from nano-particulate 
      systems.
PG  - 919-25
LID - 10.1002/bmc.1386 [doi]
AB  - Attention has shifted from the treatment of colorectal cancer (CRC) to 
      chemoprevention using aspirin and folic acid as agents capable of preventing the 
      onset of colon cancer. However, no sensitive analytical method exists to 
      simultaneously quantify the two drugs when released from polymer-based 
      nanoparticles. Thus, a rapid, highly sensitive method of high-performance liquid 
      chromatography analysis to simultaneously detect low quantities of aspirin 
      (hydrolyzed to salicylic acid, the active moiety) and folic acid released from 
      biodegradable polylactide-co-glycolide (PLGA) copolymer nanoparticles was 
      developed. Analysis was done on a reversed-phase C(18) column using a photodiode 
      array detector at wavelengths of 233 nm (salicylic acid) and 277 nm (folic acid). 
      The mobile phase consisted of acetonitrile-0.1% trifluoroacetic acid mixture 
      programmed for a 30 min gradient elution analysis. In the range of 0.1-100 
      microg/mL, the assay showed good linearity for salicylic acid (R(2) = 0.9996) and 
      folic acid (R(2) = 0.9998). The method demonstrated good reproducibility, intra- 
      and inter-day precision and accuracy (99.67, 100.1%) and low values of detection 
      (0.03, 0.01 microg/mL) and quantitation (0.1 and 0.05 microg/mL) for salicylic 
      acid and folic acid, respectively. The suitability of the method was demonstrated 
      by simultaneously determining salicylic acid and folic acid released from PLGA 
      nanoparticles.
CI  - 2009 John Wiley & Sons, Ltd.
FAU - Chaudhary, Abhishek
AU  - Chaudhary A
AD  - Department of Pharmaceutical Sciences, Western University of Health Sciences, 
      Pomona, CA 91766, USA.
FAU - Wang, Jeffrey
AU  - Wang J
FAU - Prabhu, Sunil
AU  - Prabhu S
LA  - eng
GR  - R03 CA121409/CA/NCI NIH HHS/United States
GR  - R03 CA121409-01A1/CA/NCI NIH HHS/United States
GR  - 1R03CA121409-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 935E97BOY8 (Folic Acid)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*analysis
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Folic Acid/*analysis
MH  - Lactic Acid/chemistry
MH  - Nanoparticles/*chemistry
MH  - Polyglycolic Acid/chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Reproducibility of Results
MH  - Salicylic Acid/analysis
PMC - PMC2891271
MID - NIHMS166720
EDAT- 2009/12/25 06:00
MHDA- 2010/12/14 06:00
CRDT- 2009/12/25 06:00
PHST- 2009/12/25 06:00 [entrez]
PHST- 2009/12/25 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.1002/bmc.1386 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2010 Sep;24(9):919-25. doi: 10.1002/bmc.1386.

PMID- 26854889
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20191113
IS  - 1488-2353 (Electronic)
IS  - 0147-958X (Linking)
VI  - 38
IP  - 5
DP  - 2015 Oct 7
TI  - When positive studies of novel therapies are subsequently nullified: cumulative 
      meta-analyses in preeclampsia.
PG  - E274-83
AB  - PURPOSE: The purpose of this study was to examine changes over time in the pooled 
      effect size of randomized, double-blinded, placebo-controlled trials (RCTs) 
      published on the protective effects of antioxidants and low dose aspirin against 
      preeclampsia, and to identify determinants that may affect such changes. METHODS: 
      Two recently published meta-analyses of RCTs examining the effects of antioxidant 
      treatment or low dose aspirin on the rates of preeclampsia and its adverse 
      effects were used. Chronological, cumulative meta-analyses were conducted to 
      investigate the possibility of a time-dependent effect. The journal's impact 
      factor, citation numbers of each paper, and their sample size, were correlated 
      with the risk ratio (RR) of the study. RESULTS: The median sample size of 
      positive antioxidant trials (i.e., showing protective effect) was tenfold smaller 
      (median 267) than that of the negative trials (median 2120) (P = 0.017). A 
      similar trend was seen for low dose aspirin studies. There was a significant 
      correlation between study size and RR for the effects of antioxidants and low 
      dose aspirin on intrauterine growth restriction (IUGR). There was no correlation 
      between RR and citation number, or between RR and the journal's impact factor for 
      the two therapeutic modalities. For both modalities, the journal's impact factor 
      correlated significantly with the number of citations per year. Cumulative 
      meta-analyses revealed that during the first few years and studies, there was a 
      seeming significant protective effect of antioxidant or aspirin against 
      preeclampsia. For both treatment, the initial protective effects gradually 
      disappeared and nullified by larger, later studies. CONCLUSIONS: Initial studies, 
      often published in high impact factor journals, are cited significantly more 
      times but do not exhibit a higher likelihood of predicting a correct long term 
      answer. Studies with smaller sample sizes are more likely to be biased against 
      the null hypothesis. As such, cumulative meta-analysis is an effective tool in 
      predicting potential bias against the null hypothesis and the need for additional 
      studies.
FAU - Etwel, Fatma
AU  - Etwel F
AD  - . email@email.com.
FAU - Koren, Gideon
AU  - Koren G
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20151007
PL  - Canada
TA  - Clin Invest Med
JT  - Clinical and investigative medicine. Medecine clinique et experimentale
JID - 7804071
RN  - 0 (Antioxidants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antioxidants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Fetal Growth Retardation/drug therapy
MH  - Humans
MH  - Journal Impact Factor
MH  - Odds Ratio
MH  - Pre-Eclampsia/*drug therapy
MH  - Pregnancy
MH  - Therapeutics/*standards
EDAT- 2016/02/09 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/02/09 06:00
PHST- 2015/10/07 00:00 [received]
PHST- 2016/02/09 06:00 [entrez]
PHST- 2016/02/09 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.25011/cim.v38i5.25684 [doi]
PST - epublish
SO  - Clin Invest Med. 2015 Oct 7;38(5):E274-83. doi: 10.25011/cim.v38i5.25684.

PMID- 24566225
OWN - NLM
STAT- MEDLINE
DCOM- 20140423
LR  - 20220316
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 82
IP  - 8
DP  - 2014 Feb 25
TI  - Summary of evidence-based guideline update: prevention of stroke in nonvalvular 
      atrial fibrillation: report of the Guideline Development Subcommittee of the 
      American Academy of Neurology.
PG  - 716-24
LID - 10.1212/WNL.0000000000000145 [doi]
AB  - OBJECTIVE: To update the 1998 American Academy of Neurology practice parameter on 
      stroke prevention in nonvalvular atrial fibrillation (NVAF). How often do various 
      technologies identify previously undetected NVAF? Which therapies reduce ischemic 
      stroke risk with the least risk of hemorrhage, including intracranial hemorrhage? 
      The complete guideline on which this summary is based is available as an online 
      data supplement to this article. METHODS: Systematic literature review; modified 
      Delphi process recommendation formulation. MAJOR CONCLUSIONS: In patients with 
      recent cryptogenic stroke, cardiac rhythm monitoring probably detects occult 
      NVAF. In patients with NVAF, dabigatran, rivaroxaban, and apixaban are probably 
      at least as effective as warfarin in preventing stroke and have a lower risk of 
      intracranial hemorrhage. Triflusal plus acenocoumarol is likely more effective 
      than acenocoumarol alone in reducing stroke risk. Clopidogrel plus aspirin is 
      probably less effective than warfarin in preventing stroke and has a lower risk 
      of intracranial bleeding. Clopidogrel plus aspirin as compared with aspirin alone 
      probably reduces stroke risk but increases the risk of major hemorrhage. Apixaban 
      is likely more effective than aspirin for decreasing stroke risk and has a 
      bleeding risk similar to that of aspirin. MAJOR RECOMMENDATIONS: Clinicians might 
      obtain outpatient cardiac rhythm studies in patients with cryptogenic stroke to 
      identify patients with occult NVAF (Level C) and should routinely offer 
      anticoagulation to patients with NVAF and a history of TIA/stroke (Level B). 
      Specific patient considerations will inform anticoagulant selection in patients 
      with NVAF judged to need anticoagulation.
FAU - Culebras, Antonio
AU  - Culebras A
AD  - From the Department of Neurology (A.C.), SUNY Upstate Medical University, 
      Syracuse, NY; the Department of Stroke and Neurocritical Care (S.R.M.), Hospital 
      of the University of Pennsylvania and the Pennsylvania Hospital, Philadelphia; 
      the Stroke Program (S.C.), Wayne State University School of Medicine, Detroit, 
      MI; the Department of Neurology (C.S.K.), Boston University School of Medicine 
      and Boston Medical Center, Boston, MA; and the Department of Neurology (G.G.), 
      University of Kansas Medical Center, Kansas City, KS.
FAU - Messé, Steven R
AU  - Messé SR
FAU - Chaturvedi, Seemant
AU  - Chaturvedi S
FAU - Kase, Carlos S
AU  - Kase CS
FAU - Gronseth, Gary
AU  - Gronseth G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Neurology. 2014 Apr 22;82(16):1481. PMID: 24877221
CIN - Neurology. 2014 Sep 16;83(12):1123. PMID: 25224531
CIN - Neurology. 2014 Sep 23;83(13):1220-1. PMID: 25253879
CIN - Neurology. 2014 Sep 16;83(12):1123. PMID: 25356466
CIN - Neurology. 2014 Sep 23;83(13):1221. PMID: 25379592
MH  - Academies and Institutes
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/complications/*prevention & control
MH  - Humans
MH  - *Practice Guidelines as Topic
MH  - Stroke/*prevention & control
MH  - Treatment Outcome
MH  - United States
MH  - Warfarin/therapeutic use
PMC - PMC3945662
EDAT- 2014/02/26 06:00
MHDA- 2014/04/24 06:00
CRDT- 2014/02/26 06:00
PHST- 2014/02/26 06:00 [entrez]
PHST- 2014/02/26 06:00 [pubmed]
PHST- 2014/04/24 06:00 [medline]
AID - 82/8/716 [pii]
AID - NEUROLOGY2013527564 [pii]
AID - 10.1212/WNL.0000000000000145 [doi]
PST - ppublish
SO  - Neurology. 2014 Feb 25;82(8):716-24. doi: 10.1212/WNL.0000000000000145.

PMID- 11385163
OWN - NLM
STAT- MEDLINE
DCOM- 20010816
LR  - 20131121
IS  - 1042-3931 (Print)
IS  - 1042-3931 (Linking)
VI  - 13
IP  - 6
DP  - 2001 Jun
TI  - Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin 
      after coronary artery stenting: follow-up results of a randomized study.
PG  - 431-6
AB  - A combined antiplatelet treatment with ticlopidine and aspirin has been accepted 
      as standard pharmacological regimen after coronary artery stenting. No data of a 
      randomized trial are available on ticlopidine monotherapy. This prospective, 
      randomized monocenter trial investigates the role of ticlopidine monotherapy 
      versus combined antiplatelet therapy with ticlopidine and aspirin in unselected 
      patients undergoing coronary artery stenting. After successful placement of 378 
      coronary artery stents, two hundred and forty-three consecutive patients were 
      randomly assigned to receive antiplatelet therapy with 2 x 250 mg ticlopidine 
      (121 patients) or a combination of 2 x 250 mg ticlopidine plus 100 mg aspirin 
      (122 patients) daily. The primary endpoint included the absence of death, cardiac 
      events and vascular access-site complications during the in-hospital phase. 
      Angiographic and clinical assessment was repeated at the 3-month follow-up exam. 
      Two hundred and thirty-seven patients (97.5%) were free from cardiac and 
      non-cardiac events. Stent thromboses were seen in 2 patients of the combined 
      treatment group, while none were observed in the monotherapy group. No 
      statistically significant differences were found between the 2 groups regarding 
      the primary endpoint. Angiography performed in 210 patients (86.4%) at follow-up 
      revealed a restenosis rate of 29.4% in the combined treatment group and 27.8% in 
      the monotherapy group. Monotherapy with ticlopidine is as safe and effective as a 
      combined regimen of ticlopidine plus aspirin after coronary artery stenting in an 
      unselected patient population. These results need to be confirmed in a larger 
      multicenter trial.
FAU - Machraoui, A
AU  - Machraoui A
AD  - Department of Internal Medicine, Diakonissenkrankenhaus, Flensburg, Germany. 
      machraoui@t-online.de
FAU - Germing, A
AU  - Germing A
FAU - Lindstaedt, M
AU  - Lindstaedt M
FAU - von Dryander, S
AU  - von Dryander S
FAU - Bojara, W
AU  - Bojara W
FAU - Lawo, T
AU  - Lawo T
FAU - Lemke, B
AU  - Lemke B
FAU - Jaeger, D
AU  - Jaeger D
FAU - Grewe, P
AU  - Grewe P
FAU - Deneke, T
AU  - Deneke T
FAU - Barmeyer, J
AU  - Barmeyer J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Invasive Cardiol
JT  - The Journal of invasive cardiology
JID - 8917477
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Invasive Cardiol. 2001 Jun;13(6):437-8. PMID: 11385164
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Coronary Disease/*drug therapy/*surgery
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - *Stents
MH  - Ticlopidine/therapeutic use
MH  - Treatment Outcome
EDAT- 2001/06/01 10:00
MHDA- 2001/08/17 10:01
CRDT- 2001/06/01 10:00
PHST- 2001/06/01 10:00 [pubmed]
PHST- 2001/08/17 10:01 [medline]
PHST- 2001/06/01 10:00 [entrez]
PST - ppublish
SO  - J Invasive Cardiol. 2001 Jun;13(6):431-6.

PMID- 6228692
OWN - NLM
STAT- MEDLINE
DCOM- 19840224
LR  - 20190817
IS  - 0022-4804 (Print)
IS  - 0022-4804 (Linking)
VI  - 36
IP  - 1
DP  - 1984 Jan
TI  - Reduction of platelet deposition on vascular grafts using an antiplatelet graft 
      coating technique.
PG  - 80-8
AB  - The systemic use of platelet inhibitors has been shown to improve vascular graft 
      function. In this study a biodegradable coating of polymeric polylactic acid 
      (PLA) containing a microparticulate suspension of aspirin (ASA) 30% by weight, 
      was applied to the lumenal surface of small diameter vascular prostheses to 
      reduce platelet deposition on canine implanted arterial grafts. USCI 4-mm ID 
      Dacron internal velour grafts were used. Coated and contralateral noncoated 
      (control) prostheses were implanted in canine carotid and femoral arteries. Graft 
      performance was assessed by determination of aspirin elution rates, in vivo red 
      cell subtracted 111indium-labeled platelet scans, and post implant platelet 
      aggregation studies. Eighty percent of the aspirin in the coated grafts was 
      released during the first 24 hr of perfusion and approximately 20% of the aspirin 
      remained in grafts after 1 month. In vivo platelet scans documented less platelet 
      deposition on ASA-coated grafts when compared to controls 2 and 24 hr post 
      implant (P less than 0.01, P less than 0.05, respectively). There was no 
      significant difference in platelet deposition on ASA-coated and control grafts at 
      2 weeks or 1 month post implant. Post implant platelet aggregation studies 
      indicated systemic platelet inhibition for 4-5 days. It was concluded that 
      aspirin incorporation in a polylactic acid coating applied to 4-mm ID vascular 
      prostheses reduced the platelet affinity of Dacron grafts and exerted a temporary 
      local and systemic platelet inhibiting effect.
FAU - Allen, B T
AU  - Allen BT
FAU - Sparks, R E
AU  - Sparks RE
FAU - Welch, M J
AU  - Welch MJ
FAU - Mason, N S
AU  - Mason NS
FAU - Mathias, C J
AU  - Mathias CJ
FAU - Clark, R E
AU  - Clark RE
LA  - eng
GR  - HL 14147/HL/NHLBI NIH HHS/United States
GR  - HL 18764/HL/NHLBI NIH HHS/United States
GR  - T32 KGMO7602/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
RN  - 0 (Lactates)
RN  - 0 (Polyesters)
RN  - 0 (Polyethylene Terephthalates)
RN  - 0 (Polymers)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 459TN2L5F5 (poly(lactide))
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - *Blood Vessel Prosthesis
MH  - Carotid Arteries/physiology/surgery
MH  - Dogs
MH  - Femoral Artery/physiology/surgery
MH  - *Lactates
MH  - *Lactic Acid
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Polyesters
MH  - Polyethylene Terephthalates
MH  - *Polymers
MH  - Regional Blood Flow
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 0022-4804(84)90070-2 [pii]
AID - 10.1016/0022-4804(84)90070-2 [doi]
PST - ppublish
SO  - J Surg Res. 1984 Jan;36(1):80-8. doi: 10.1016/0022-4804(84)90070-2.

PMID- 36209766
OWN - NLM
STAT- MEDLINE
DCOM- 20230223
LR  - 20230522
IS  - 1097-6779 (Electronic)
IS  - 0016-5107 (Linking)
VI  - 97
IP  - 3
DP  - 2023 Mar
TI  - Effectiveness of prophylactic clipping in preventing postpolypectomy bleeding in 
      aspirin users: a propensity-score analysis.
PG  - 517-527.e1
LID - S0016-5107(22)02022-3 [pii]
LID - 10.1016/j.gie.2022.09.024 [doi]
AB  - BACKGROUND AND AIMS: Antithrombotic use is a significant risk factor of 
      postpolypectomy bleeding (PPB). Evidence of prophylactic clipping is only 
      available for proximal and large colonic lesions in the general population. 
      Dedicated studies to examine the benefit of prophylactic clipping in patients on 
      aspirin remain scarce. METHODS: A propensity score-weighted retrospective cohort 
      study was performed in a tertiary referral center from January 2018 to September 
      2021. Patients who received aspirin and underwent colonoscopic polypectomy, EMR, 
      or endoscopic submucosal dissection were included. Data on baseline demographics, 
      medications, and endoscopic factors (polyp number, size, location, and 
      morphology; resection method; and prophylactic clipping) were captured. 
      Propensity score-weighted models were developed between prophylactic clipping and 
      no clipping groups. The primary outcome was delayed PPB within 30 days, with a 
      composite endpoint consisting of repeated colonoscopy for hemostasis, requirement 
      of blood transfusion, or hemoglobin drop >2 g/dL. RESULTS: A total of 1373 
      patients with 3952 polyps were included. Baseline characteristics were balanced 
      between the 2 groups. In the multivariate analysis, the largest polyp size was a 
      significant risk factor for PPB (odds ratio, 1.07; 95% confidence interval, 
      1.02-1.11; P = .002). Prophylactic clipping was not associated with a reduced 
      risk of PPB (odds ratio, 1.34; 95% confidence interval, .83-2.18; P = .240) and 
      did not show any risk reduction in subgroups with different polyp sizes and 
      locations and endoscopic resection techniques. CONCLUSIONS: Prophylactic clipping 
      was not associated with a lower risk of PPB in aspirin users after endoscopic 
      resection of colorectal polyps. Aspirin use should not be regarded as the only 
      factor for the routine use of prophylactic clips.
CI  - Copyright © 2023 American Society for Gastrointestinal Endoscopy. Published by 
      Elsevier Inc. All rights reserved.
FAU - Lau, Louis H S
AU  - Lau LHS
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong SAR; Institute of Digestive Diseases, The Chinese University of Hong 
      Kong, Hong Kong SAR.
FAU - Jiang, Wei
AU  - Jiang W
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong SAR.
FAU - Guo, Cosmos L T
AU  - Guo CLT
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong SAR.
FAU - Lui, Rashid N
AU  - Lui RN
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong SAR; Institute of Digestive Diseases, The Chinese University of Hong 
      Kong, Hong Kong SAR.
FAU - Tang, Raymond S Y
AU  - Tang RSY
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong SAR; Institute of Digestive Diseases, The Chinese University of Hong 
      Kong, Hong Kong SAR.
FAU - Chan, Francis K L
AU  - Chan FKL
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 
      Hong Kong SAR; Institute of Digestive Diseases, The Chinese University of Hong 
      Kong, Hong Kong SAR.
LA  - eng
PT  - Journal Article
DEP - 20221007
PL  - United States
TA  - Gastrointest Endosc
JT  - Gastrointestinal endoscopy
JID - 0010505
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Aspirin/therapeutic use
MH  - *Colonic Polyps/pathology
MH  - Retrospective Studies
MH  - Propensity Score
MH  - Colonoscopy/methods
MH  - Postoperative Hemorrhage/epidemiology/prevention & control/etiology
EDAT- 2022/10/10 06:00
MHDA- 2023/02/25 06:00
CRDT- 2022/10/09 19:12
PHST- 2022/07/31 00:00 [received]
PHST- 2022/09/12 00:00 [revised]
PHST- 2022/09/26 00:00 [accepted]
PHST- 2022/10/10 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2022/10/09 19:12 [entrez]
AID - S0016-5107(22)02022-3 [pii]
AID - 10.1016/j.gie.2022.09.024 [doi]
PST - ppublish
SO  - Gastrointest Endosc. 2023 Mar;97(3):517-527.e1. doi: 10.1016/j.gie.2022.09.024. 
      Epub 2022 Oct 7.

PMID- 16822366
OWN - NLM
STAT- MEDLINE
DCOM- 20060912
LR  - 20191110
IS  - 1523-3782 (Print)
IS  - 1523-3782 (Linking)
VI  - 8
IP  - 4
DP  - 2006 Jul
TI  - Antiplatelet resistance with aspirin and clopidogrel: is it real and does it 
      matter?
PG  - 301-6
AB  - Platelets play a pivotal role in the pathophysiology of ischemic complications of 
      atherosclerotic cardiovascular disease. Aspirin and clopidogrel are oral 
      antiplatelet drugs that have been shown to reduce adverse clinical events across 
      the wide spectrum of patients with atherothrombotic disease. However, recurrent 
      ischemic events still occur in a significant proportion of patients despite 
      treatment with these antiplatelet drugs. The concept of antiplatelet resistance 
      therefore emerges. Although uniform definitions and standardized assays are not 
      yet available, numerous studies have documented the interindividual variability 
      in platelet responsiveness to oral antiplatelet drugs. Evidence is also 
      accumulating to demonstrate that hyporesponsiveness to antiplatelet drugs in the 
      laboratory (ie, resistance) is associated with adverse clinical events in 
      different patient populations. Clinical application of antiplatelet resistance 
      will require proof from prospective randomized trials that modifications of 
      antiplatelet therapy based on tests of antiplatelet responsiveness will improve 
      the outcomes of patients with antiplatelet resistance.
FAU - Chen, Wai-Hong
AU  - Chen WH
AD  - Department of Medicine, Division of Cardiology, The University of Hong Kong, Room 
      1929C, Block K, Queen Mary Hospital, Hong Kong, China. whchen@hku.hk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Clopidogrel
MH  - Coronary Artery Disease/*drug therapy
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/*analogs & derivatives/pharmacology
RF  - 43
EDAT- 2006/07/11 09:00
MHDA- 2006/09/13 09:00
CRDT- 2006/07/11 09:00
PHST- 2006/07/11 09:00 [pubmed]
PHST- 2006/09/13 09:00 [medline]
PHST- 2006/07/11 09:00 [entrez]
AID - 10.1007/s11886-006-0063-5 [doi]
PST - ppublish
SO  - Curr Cardiol Rep. 2006 Jul;8(4):301-6. doi: 10.1007/s11886-006-0063-5.

PMID- 8249639
OWN - NLM
STAT- MEDLINE
DCOM- 19931229
LR  - 20131121
IS  - 0253-9756 (Print)
IS  - 0253-9756 (Linking)
VI  - 14
IP  - 4
DP  - 1993 Jul
TI  - [Effects of preimplantation treatment with aspirin and acetaminophen on 
      blastocyst and fetus in rats].
PG  - 369-72
AB  - Pregnant rats were treated with ig aspirin (Asp) and acetaminophen (Ace) on d 3 
      of pregnancy (positive vaginal smear = d 0). Blastocysts were collected on d 4 
      and evaluated for gross morphology, cell number, micronucleus, and mitotic index. 
      Some rats were killed on d 20 and fetuses were examined for teratogenic effects. 
      On d 4 a reduction of cell number per blastocyst was found in the rats treated 
      with Asp 0.5, 1 g.kg-1, and Ace 1 g.kg-1, while the mitotic index, frequency of 
      micronuclei, and frequency of blastocysts with morphological alterations were 
      increased. The frequency of micronuclei was increased in rats exposed to Ace 0.25 
      and 0.5 g.kg-1. On d 20 major malformation and embryotoxicity were seen in Asp 
      0.5, 1, and Ace 1 g.kg-1 groups.
FAU - Ying, Y
AU  - Ying Y
AD  - Department of Pharmacology, School of Pharmacy, Zhejiang Medical University, 
      Hangzhou, China.
FAU - Lou, Y J
AU  - Lou YJ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Yao Li Xue Bao
JT  - Zhongguo yao li xue bao = Acta pharmacologica Sinica
JID - 8100330
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*toxicity
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Blastocyst/*drug effects
MH  - Embryonic Development
MH  - Embryonic and Fetal Development/drug effects
MH  - Female
MH  - Fetus/*drug effects
MH  - Micronucleus Tests
MH  - Mitotic Index/drug effects
MH  - Pregnancy
MH  - Rats
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
PST - ppublish
SO  - Zhongguo Yao Li Xue Bao. 1993 Jul;14(4):369-72.

PMID- 1302170
OWN - NLM
STAT- MEDLINE
DCOM- 19930610
LR  - 20131121
IS  - 0252-1164 (Print)
IS  - 0252-1164 (Linking)
VI  - 9
IP  - 4
DP  - 1992
TI  - A novel study on the effect of acetylsalicylic acid on the binding capacity of 
      estrogen receptors from MCF-7 cells.
PG  - 145-9
AB  - The effect of acetylsalicylic acid (ASA, aspirin) was investigated on 
      [3H]-estradiol-17 beta ([3H]-E2) binding to estrogen receptors (ER) from MCF-7 
      mammary tumour cells. No effect was observed using the monoclonal estrogen 
      receptor-enzyme immunoassay (ER-EIA). In contrast to the ER-EIA, the 
      radioreceptor assay (RRA) showed decreases of [3H]-E2 specific binding in the 
      presence of increasing amounts of ASA. It is therefore concluded that these 
      results demonstrate that ASA possibly affects the direct binding of E2 to region 
      E of the ER of human breast cancer MCF-7 cells, but does not affect binding of 
      monoclonal antibodies to regions D and F of the ER.
FAU - van Aswegen, C
AU  - van Aswegen C
AD  - Department of Urology, University of Pretoria, HF Verwoerd Hospital, Republic of 
      South Africa.
FAU - Dirksen van Schalkwyk, J C
AU  - Dirksen van Schalkwyk JC
FAU - Roux, L J
AU  - Roux LJ
FAU - Becker, P J
AU  - Becker PJ
FAU - Du Plessis, D J
AU  - Du Plessis DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Physiol Biochem
JT  - Clinical physiology and biochemistry
JID - 8305885
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Receptors, Estrogen)
RN  - 4TI98Z838E (Estradiol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Monoclonal
MH  - Aspirin/*pharmacology
MH  - Binding Sites
MH  - Breast Neoplasms/*metabolism
MH  - Estradiol/*metabolism
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Radioligand Assay
MH  - Receptors, Estrogen/*drug effects/metabolism
MH  - Tumor Cells, Cultured
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Physiol Biochem. 1992;9(4):145-9.

PMID- 31477558
OWN - NLM
STAT- MEDLINE
DCOM- 20200527
LR  - 20210110
IS  - 2468-1253 (Electronic)
VI  - 4
IP  - 11
DP  - 2019 Nov
TI  - Aspirin as an adjuvant treatment for cancer: feasibility results from the 
      Add-Aspirin randomised trial.
PG  - 854-862
LID - S2468-1253(19)30289-4 [pii]
LID - 10.1016/S2468-1253(19)30289-4 [doi]
AB  - BACKGROUND: Preclinical, epidemiological, and randomised data indicate that 
      aspirin might prevent tumour development and metastasis, leading to reduced 
      cancer mortality, particularly for gastro-oesophageal and colorectal cancer. 
      Randomised trials evaluating aspirin use after primary radical therapy are 
      ongoing. We present the pre-planned feasibility analysis of the run-in phase of 
      the Add-Aspirin trial to address concerns about toxicity, particularly bleeding 
      after radical treatment for gastro-oesophageal cancer. METHODS: The Add-Aspirin 
      protocol includes four phase 3 randomised controlled trials evaluating the effect 
      of daily aspirin on recurrence and survival after radical cancer therapy in four 
      tumour cohorts: gastro-oesophageal, colorectal, breast, and prostate cancer. An 
      open-label run-in phase (aspirin 100 mg daily for 8 weeks) precedes double-blind 
      randomisation (for participants aged under 75 years, aspirin 300 mg, aspirin 100 
      mg, or matched placebo in a 1:1:1 ratio; for patients aged 75 years or older, 
      aspirin 100 mg or matched placebo in a 2:1 ratio). A preplanned analysis of 
      feasibility, including recruitment rate, adherence, and toxicity was performed. 
      The trial is registered with the International Standard Randomised Controlled 
      Trials Number registry (ISRCTN74358648) and remains open to recruitment. 
      FINDINGS: After 2 years of recruitment (October, 2015, to October, 2017), 3494 
      participants were registered (115 in the gastro-oesophageal cancer cohort, 950 in 
      the colorectal cancer cohort, 1675 in the breast cancer cohort, and 754 in the 
      prostate cancer cohort); 2719 (85%) of 3194 participants who had finished the 
      run-in period proceeded to randomisation, with rates consistent across tumour 
      cohorts. End of run-in data were available for 2253 patients; 2148 (95%) of the 
      participants took six or seven tablets per week. 11 (0·5%) of the 2253 
      participants reported grade 3 toxicity during the run-in period, with no upper 
      gastrointestinal bleeding (any grade) in the gastro-oesophageal cancer cohort. 
      The most frequent grade 1-2 toxicity overall was dyspepsia (246 [11%] of 2253 
      participants). INTERPRETATION: Aspirin is well-tolerated after radical cancer 
      therapy. Toxicity has been low and there is no evidence of a difference in 
      adherence, acceptance of randomisation, or toxicity between the different cancer 
      cohorts. Trial recruitment continues to determine whether aspirin could offer a 
      potential low cost and well tolerated therapy to improve cancer outcomes. 
      FUNDING: Cancer Research UK, The National Institute for Health Research Health 
      Technology Assessment Programme, The MRC Clinical Trials Unit at UCL.
CI  - Copyright © 2019 Elsevier Ltd. All rights reserved.
FAU - Joharatnam-Hogan, Nalinie
AU  - Joharatnam-Hogan N
AD  - MRC Clinical Trials Unit, University College London, UK.
FAU - Cafferty, Fay
AU  - Cafferty F
AD  - MRC Clinical Trials Unit, University College London, UK.
FAU - Hubner, Richard
AU  - Hubner R
AD  - The Christie Hospital, Manchester, UK.
FAU - Swinson, Daniel
AU  - Swinson D
AD  - St James University Hospital, Leeds, UK.
FAU - Sothi, Sharmila
AU  - Sothi S
AD  - University Hospital Coventry and Warwickshire, UK.
FAU - Gupta, Kamalnayan
AU  - Gupta K
AD  - Worcestershire Royal Hospital, Worcester, UK.
FAU - Falk, Stephen
AU  - Falk S
AD  - Bristol Haematology & Oncology Centre, Bristol, UK.
FAU - Patel, Kinnari
AU  - Patel K
AD  - Churchill Hospital, Oxford, UK.
FAU - Warner, Nicola
AU  - Warner N
AD  - Stoke Mandeville Hospital, Aylesbury, UK.
FAU - Kunene, Victoria
AU  - Kunene V
AD  - Manor Hospital, Walsall, UK.
FAU - Rowley, Sam
AU  - Rowley S
AD  - MRC Clinical Trials Unit, University College London, UK.
FAU - Khabra, Komel
AU  - Khabra K
AD  - MRC Clinical Trials Unit, University College London, UK.
FAU - Underwood, Tim
AU  - Underwood T
AD  - University of Southampton, Southampton, UK.
FAU - Jankowski, Janusz
AU  - Jankowski J
AD  - Gastroenterology Unit, Morecambe Bay University Hospitals NHS Trust, UK; National 
      Institute for Health and Care Excellence, London, UK.
FAU - Bridgewater, John
AU  - Bridgewater J
AD  - University College Hospital London, UK.
FAU - Crossley, Anne
AU  - Crossley A
AD  - St James University Hospital, Leeds, UK.
FAU - Henson, Verity
AU  - Henson V
AD  - Bristol Haematology & Oncology Centre, Bristol, UK.
FAU - Berkman, Lindy
AU  - Berkman L
AD  - NCRI Consumer Liaison Group, London, UK.
FAU - Gilbert, Duncan
AU  - Gilbert D
AD  - MRC Clinical Trials Unit, University College London, UK.
FAU - Kynaston, Howard
AU  - Kynaston H
AD  - Cardiff University, Cardiff, UK.
FAU - Ring, Alistair
AU  - Ring A
AD  - Royal Marsden Hospital, London, UK.
FAU - Cameron, David
AU  - Cameron D
AD  - Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular 
      Medicine, Western General Hospital, Edinburgh, UK.
FAU - Din, Farhat
AU  - Din F
AD  - Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular 
      Medicine, Western General Hospital, Edinburgh, UK.
FAU - Graham, Janet
AU  - Graham J
AD  - Beatson West of Scotland Cancer Centre, Glasgow, UK.
FAU - Iveson, Timothy
AU  - Iveson T
AD  - Southampton General Hospital, UK.
FAU - Adams, Richard
AU  - Adams R
AD  - Velindre Cancer Centre, Cardiff, UK.
FAU - Thomas, Anne
AU  - Thomas A
AD  - Leicester Royal Infirmary, Leicester, UK.
FAU - Wilson, Richard
AU  - Wilson R
AD  - University of Glasgow, Glasgow, UK.
FAU - Pramesh, C S
AU  - Pramesh CS
AD  - Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India.
FAU - Langley, Ruth
AU  - Langley R
AD  - MRC Clinical Trials Unit, University College London, UK. Electronic address: 
      ruth.langley@ucl.ac.uk.
CN  - Add-Aspirin Trial Management Group
LA  - eng
GR  - 11378/CRUK_/Cancer Research UK/United Kingdom
GR  - 12/01/38/DH_/Department of Health/United Kingdom
GR  - MC_UU_12023/28/MRC_/Medical Research Council/United Kingdom
GR  - SCAF/16/01/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190830
PL  - Netherlands
TA  - Lancet Gastroenterol Hepatol
JT  - The lancet. Gastroenterology & hepatology
JID - 101690683
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Lancet Gastroenterol Hepatol. 2019 Nov;4(11):815-816. PMID: 31477559
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Breast Neoplasms/drug therapy
MH  - Colorectal Neoplasms/drug therapy
MH  - Combined Modality Therapy
MH  - Double-Blind Method
MH  - Esophageal Neoplasms/drug therapy
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - Neoplasms/*drug therapy
MH  - Patient Selection
MH  - Prostatic Neoplasms/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Stomach Neoplasms/drug therapy
MH  - Treatment Outcome
FIR - Burn, John
IR  - Burn J
FIR - Campbell, Sue
IR  - Campbell S
FIR - Capaldi, Lisa
IR  - Capaldi L
FIR - Carse, Yvonne
IR  - Carse Y
FIR - Gadgil, Durga
IR  - Gadgil D
FIR - Goldman, Arnold
IR  - Goldman A
FIR - Gupta, Sudeep
IR  - Gupta S
FIR - Leonard, Gregory
IR  - Leonard G
FIR - MacKenzie, Mairead
IR  - MacKenzie M
FIR - Parmar, Mahesh
IR  - Parmar M
FIR - Patrono, Carlo
IR  - Patrono C
FIR - Petty, Russell
IR  - Petty R
FIR - Rothwell, Peter M
IR  - Rothwell PM
FIR - Steele, Robert J C
IR  - Steele RJC
EDAT- 2019/09/04 06:00
MHDA- 2020/05/28 06:00
CRDT- 2019/09/04 06:00
PHST- 2019/06/17 00:00 [received]
PHST- 2019/07/16 00:00 [revised]
PHST- 2019/08/01 00:00 [accepted]
PHST- 2019/09/04 06:00 [pubmed]
PHST- 2020/05/28 06:00 [medline]
PHST- 2019/09/04 06:00 [entrez]
AID - S2468-1253(19)30289-4 [pii]
AID - 10.1016/S2468-1253(19)30289-4 [doi]
PST - ppublish
SO  - Lancet Gastroenterol Hepatol. 2019 Nov;4(11):854-862. doi: 
      10.1016/S2468-1253(19)30289-4. Epub 2019 Aug 30.

PMID- 2070149
OWN - NLM
STAT- MEDLINE
DCOM- 19910819
LR  - 20131121
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 7
IP  - 5
DP  - 1991 May
TI  - Translumbar inferior vena cava catheters.
PG  - 389-92
AB  - Translumbar inferior vena cava catheters are a safe method of providing venous 
      access for the collection of peripheral blood stem cells for transplantation. One 
      of the most frequent and consistent problems with these catheters is thrombotic 
      obstruction, occurring in one-fourth of the cases. Aspirin at a dose of 325 mg 
      daily beginning after catheter placement and continuing until completion of stem 
      cell collection has been associated with a reduction in the frequency of catheter 
      thrombosis from 12/60 (20%) to 1/31 (3.2%) (p = 0.007) and an increase in the 
      number of thrombus-free apheresis procedures (p = 0.024) compared to historical 
      controls. No adverse effects of aspirin during stem cell collection have been 
      noted. Daily aspirin ingestion should be considered in patients undergoing 
      peripheral stem cell collection via translumbar inferior vena cava catheters.
FAU - Haire, W D
AU  - Haire WD
AD  - Department of Internal Medicine, University of Nebraska Medical Center, Omaha 
      68198-3330.
FAU - Lieberman, R P
AU  - Lieberman RP
FAU - Lund, G B
AU  - Lund GB
FAU - Kessinger, A
AU  - Kessinger A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Bone Marrow Transplantation/methods
MH  - Catheterization, Central Venous/instrumentation/*methods
MH  - Cell Separation/methods
MH  - Hematopoietic Stem Cells/cytology
MH  - Humans
MH  - *Lumbar Vertebrae
MH  - Thrombosis/prevention & control
MH  - *Vena Cava, Inferior
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
PST - ppublish
SO  - Bone Marrow Transplant. 1991 May;7(5):389-92.

PMID- 2596536
OWN - NLM
STAT- MEDLINE
DCOM- 19900117
LR  - 20180215
IS  - 0250-8095 (Print)
IS  - 0250-8095 (Linking)
VI  - 9
IP  - 6
DP  - 1989
TI  - Comparative acute effects of aspirin, diflunisal, ibuprofen and indomethacin on 
      renal function in healthy man.
PG  - 460-3
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, suppress 
      renal prostaglandins and markedly reduce renal perfusion and diuretic response in 
      some renal disorders. Mild renal impairment may occur in healthy subjects. 
      Pharmacodynamic characteristics of certain NSAIDs, such as the nonacetylated 
      salicylates, suggest that they may have less deleterious renal effects. We 
      compared the renal effects of standard therapeutic doses of indomethacin, 
      ibuprofen, aspirin, and the nonacetylated salicylate, diflunisal, in 6 healthy 
      supine volunteers. Only indomethacin significantly reduced creatinine clearance 
      (by 13%) and renal plasma flow (by 23%; p less than 0.05). Indomethacin also 
      tended to reduce furosemide-induced diuresis and natriuresis, and this effect was 
      significantly greater than with diflunisal (p less than 0.05). Serum thromboxane, 
      a reflection of platelet cyclo-oxygenase activity, was reduced by 99% with 
      aspirin, ibuprofen and indomethacin, but by only 78% with diflunisal. 
      Nonacetylated salicylates may be the preferred drugs, at least in short-term 
      usage, when it is necessary to minimize the effects of NSAIDs on platelet or 
      kidney function.
FAU - Bergamo, R R
AU  - Bergamo RR
AD  - Division of Gastroenterology, Harbor-UCLA Medical Center, Torrance.
FAU - Cominelli, F
AU  - Cominelli F
FAU - Kopple, J D
AU  - Kopple JD
FAU - Zipser, R D
AU  - Zipser RD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
RN  - 7C546U4DEN (Diflunisal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aspirin/*toxicity
MH  - Diflunisal/*toxicity
MH  - Humans
MH  - Ibuprofen/*toxicity
MH  - Indomethacin/*toxicity
MH  - Kidney/*drug effects
MH  - Kidney Function Tests
MH  - Male
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1159/000168013 [doi]
PST - ppublish
SO  - Am J Nephrol. 1989;9(6):460-3. doi: 10.1159/000168013.

PMID- 16098719
OWN - NLM
STAT- MEDLINE
DCOM- 20060120
LR  - 20131121
IS  - 0952-3278 (Print)
IS  - 0952-3278 (Linking)
VI  - 73
IP  - 3-4
DP  - 2005 Sep-Oct
TI  - Design, synthesis and bioactions of novel stable mimetics of lipoxins and 
      aspirin-triggered lipoxins.
PG  - 301-21
AB  - The lipoxins (LX) are a class of potent endogenous oxygenated products that are 
      enzymatically generated from arachidonic acid and have novel anti-inflammatory 
      properties and promote resolution. Elucidation of the biochemical pathways 
      involved in the metabolic inactivation of LX and the discovery of the 
      aspirin-triggered lipoxins (ATL) provided the basis for the design and synthesis 
      of stable analogs of LX and ATL. This special issue review describes the efforts 
      that led to the design and synthesis of stable LX/ATL mimetics, which permitted 
      the detailed elucidation of their novel biological roles, leading to the 
      development of new anti-inflammatory agents that mimic their actions. These 
      synthetic molecules provided the means to uncover the physiologic roles of both 
      the LX and the ATL biosynthetic pathways which led to several unexpected 
      discoveries. Among these findings is the involvement of polyisoprenyl phosphates 
      (PIPP) in intracellular signaling mediated by presqualene diphosphate (PSDP), and 
      the recognition of the novel roles of these lipid mediators in regulating cell 
      trafficking during inflammation as well as in promoting resolution of 
      inflammatory processes. These efforts also provided the basis for examining the 
      potential therapeutic role of LX/ATL stable mimetics and led to the development 
      of new analogs with improved pharmacokinetics that opened the way to potentially 
      new approaches to treating human diseases.
FAU - Petasis, Nicos A
AU  - Petasis NA
AD  - Department of Chemistry and the Loker Hydrocarbon Research Institute, University 
      of Southern California, Los Angeles, CA 90089, USA. petasis@usc.edu
FAU - Akritopoulou-Zanze, Irini
AU  - Akritopoulou-Zanze I
FAU - Fokin, Valery V
AU  - Fokin VV
FAU - Bernasconi, Giovanni
AU  - Bernasconi G
FAU - Keledjian, Raquel
AU  - Keledjian R
FAU - Yang, Rong
AU  - Yang R
FAU - Uddin, Jasim
AU  - Uddin J
FAU - Nagulapalli, Kalyan C
AU  - Nagulapalli KC
FAU - Serhan, Charles N
AU  - Serhan CN
LA  - eng
GR  - P01-DE13499/DE/NIDCR NIH HHS/United States
GR  - P50-DE-016191/DE/NIDCR NIH HHS/United States
GR  - R01-HL079312/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Eicosanoids)
RN  - 0 (Lipoxins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Aspirin/pharmacology
MH  - *Drug Design
MH  - Eicosanoids/biosynthesis
MH  - Humans
MH  - Inflammation/*physiopathology
MH  - Lipoxins/*chemical synthesis/metabolism/therapeutic use
MH  - Molecular Structure
RF  - 171
EDAT- 2005/08/16 09:00
MHDA- 2006/01/21 09:00
CRDT- 2005/08/16 09:00
PHST- 2005/08/16 09:00 [pubmed]
PHST- 2006/01/21 09:00 [medline]
PHST- 2005/08/16 09:00 [entrez]
AID - S0952-3278(05)00101-8 [pii]
AID - 10.1016/j.plefa.2005.05.020 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):301-21. doi: 
      10.1016/j.plefa.2005.05.020.

PMID- 17522398
OWN - NLM
STAT- MEDLINE
DCOM- 20070529
LR  - 20220409
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 356
IP  - 21
DP  - 2007 May 24
TI  - Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.
PG  - 2131-42
AB  - BACKGROUND: Regular use of aspirin reduces the risk of a colorectal neoplasm, but 
      the mechanism by which aspirin affects carcinogenesis in the colon is not well 
      understood. METHODS: We estimated cyclooxygenase-2 (COX-2) expression by 
      immunohistochemical assay of sections from paraffin-embedded colorectal-cancer 
      specimens from two large cohorts of participants who provided data on aspirin use 
      from a questionnaire every 2 years. We applied Cox regression to a 
      competing-risks analysis to compare the effects of aspirin use on the relative 
      risk of colorectal cancer in relation to the expression of COX-2 in the tumor. 
      RESULTS: During 2,446,431 person-years of follow-up of 82,911 women and 47,363 
      men, we found 636 incident colorectal cancers that were accessible for 
      determination of COX-2 expression. Of the tumors, 423 (67%) had moderate or 
      strong COX-2 expression. The effect of aspirin use differed significantly in 
      relation to COX-2 expression (P for heterogeneity=0.02). Regular aspirin use 
      conferred a significant reduction in the risk of colorectal cancers that 
      overexpressed COX-2 (multivariate relative risk, 0.64; 95% confidence interval 
      [CI], 0.52 to 0.78), whereas regular aspirin use had no influence on tumors with 
      weak or absent expression of COX-2 (multivariate relative risk, 0.96; 95% CI, 
      0.73 to 1.26). The age-standardized incidence rate for cancers that overexpressed 
      COX-2 was 37 per 100,000 person-years among regular aspirin users, as compared 
      with 56 per 100,000 person-years among those who did not use aspirin regularly; 
      in contrast, the rate for cancers with weak or absent COX-2 expression was 27 per 
      100,000 person-years among regular aspirin users, as compared with 28 per 100,000 
      person-years among nonregular aspirin users. CONCLUSIONS: Regular use of aspirin 
      appears to reduce the risk of colorectal cancers that overexpress COX-2 but not 
      the risk of colorectal cancers with weak or absent expression of COX-2.
CI  - Copyright 2007 Massachusetts Medical Society.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA. 
      achan@partners.org
FAU - Ogino, Shuji
AU  - Ogino S
FAU - Fuchs, Charles S
AU  - Fuchs CS
LA  - eng
GR  - CA10741/CA/NCI NIH HHS/United States
GR  - CA55075/CA/NCI NIH HHS/United States
GR  - CA87969/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2007 May 24;356(21):2195-8. PMID: 17522404
CIN - N Engl J Med. 2007 Aug 23;357(8):824-5; author reply 824-5. PMID: 17715417
CIN - N Engl J Med. 2007 Aug 23;357(8):824-5; author reply 824-5. PMID: 17717859
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cell Transformation, Neoplastic/drug effects
MH  - Cohort Studies
MH  - Colorectal Neoplasms/epidemiology/*metabolism/prevention & control
MH  - Cyclooxygenase 2/*metabolism
MH  - Cyclooxygenase Inhibitors/*pharmacology/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Proportional Hazards Models
MH  - Risk
EDAT- 2007/05/25 09:00
MHDA- 2007/05/30 09:00
CRDT- 2007/05/25 09:00
PHST- 2007/05/25 09:00 [pubmed]
PHST- 2007/05/30 09:00 [medline]
PHST- 2007/05/25 09:00 [entrez]
AID - 356/21/2131 [pii]
AID - 10.1056/NEJMoa067208 [doi]
PST - ppublish
SO  - N Engl J Med. 2007 May 24;356(21):2131-42. doi: 10.1056/NEJMoa067208.

PMID- 2969678
OWN - NLM
STAT- MEDLINE
DCOM- 19880908
LR  - 20190716
IS  - 0002-9629 (Print)
IS  - 0002-9629 (Linking)
VI  - 296
IP  - 2
DP  - 1988 Aug
TI  - Cough caused by cilazapril.
PG  - 119-20
AB  - Angiotensin-converting enzyme (ACE) inhibitors are a group of drugs recently 
      introduced to treat hypertension and congestive heart failure. There are many 
      reports of a dry cough in patients treated with (ACE) inhibitors, but this is 
      often considered a rare side effect. Eleven of 30 patients treated with the 
      investigational ACE inhibitor cilazapril complained about a chronic cough.
FAU - Lernhardt, E B
AU  - Lernhardt EB
AD  - Department of Medicine, UCSD Medical Center 92103.
FAU - Ziegler, M G
AU  - Ziegler MG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Pyridazines)
RN  - 19KW7PI29F (Cilazapril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*adverse effects
MH  - Aspirin/adverse effects
MH  - Cilazapril
MH  - Cough/*chemically induced
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pyridazines/*adverse effects
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
AID - S0002-9629(15)36488-0 [pii]
AID - 10.1097/00000441-198808000-00009 [doi]
PST - ppublish
SO  - Am J Med Sci. 1988 Aug;296(2):119-20. doi: 10.1097/00000441-198808000-00009.

PMID- 33307116
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20220302
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 147
IP  - 3
DP  - 2021 Mar
TI  - The role of aspirin desensitization followed by oral aspirin therapy in managing 
      patients with aspirin-exacerbated respiratory disease: A Work Group Report from 
      the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy 
      of Allergy, Asthma & Immunology.
PG  - 827-844
LID - S0091-6749(20)31708-5 [pii]
LID - 10.1016/j.jaci.2020.10.043 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical 
      triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to 
      medications that inhibit the cycloxgenase-1 enzyme. Patients with AERD on average 
      have more severe respiratory disease compared with patients with chronic 
      rhinosinusitis with nasal polyps and/or asthma alone. Although patients with AERD 
      traditionally develop significant upper and lower respiratory tract symptoms on 
      ingestion of cycloxgenase-1 inhibitors, most of these same patients report 
      clinical benefit when desensitized to aspirin and maintained on daily aspirin 
      therapy. This Work Group Report provides a comprehensive review of aspirin 
      challenges, aspirin desensitizations, and maintenance aspirin therapy in patients 
      with AERD. Identification of appropriate candidates, indications and 
      contraindications, medical and surgical optimization strategies, protocols, 
      medical management during the desensitization, and recommendations for 
      maintenance aspirin therapy following desensitization are reviewed. Also included 
      is a summary of studies evaluating the clinical efficacy of aspirin therapy after 
      desensitization as well as a discussion on the possible cellular and molecular 
      mechanisms explaining how this therapy provides unique benefit to patients with 
      AERD.
CI  - Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Stevens, Whitney W
AU  - Stevens WW
AD  - Division of Allergy and Immunology, Department of Medicine, Northwestern 
      University Feinberg School of Medicine, Chicago, Ill. Electronic address: 
      whitney-stevens@northwestern.edu.
FAU - Jerschow, Elina
AU  - Jerschow E
AD  - Division of Allergy and Immunology, Montefiore Medical Center/Albert Einstein 
      College of Medicine, Bronx, NY.
FAU - Baptist, Alan P
AU  - Baptist AP
AD  - Division of Allergy and Clinical Immunology, Department of Medicine, University 
      of Michigan Medical School, Ann Arbor, Mich.
FAU - Borish, Larry
AU  - Borish L
AD  - Departments of Medicine and Microbiology, University of Virginia Health System, 
      Charlottesville, Va.
FAU - Bosso, John V
AU  - Bosso JV
AD  - Division of Rhinology, Department of Otorhinolaryngology/Head & Neck Surgery, 
      Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa.
FAU - Buchheit, Kathleen M
AU  - Buchheit KM
AD  - Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and 
      Women's Hospital, Boston, Mass.
FAU - Cahill, Katherine N
AU  - Cahill KN
AD  - Division of Allergy, Pulmonary, and Critical Care Medicine, Department of 
      Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
FAU - Campo, Paloma
AU  - Campo P
AD  - Allergy Unit, IBIMA-Hospital Regional Universitario de Málaga, Málaga, Spain.
FAU - Cho, Seong H
AU  - Cho SH
AD  - Division of Allergy and Immunology, Morsani College of Medicine, University of 
      South Florida, Tampa, Fla.
FAU - Keswani, Anjeni
AU  - Keswani A
AD  - Division of Allergy/Immunology, Department of Medicine, George Washington 
      University School of Medicine and Health Sciences, Washington, DC.
FAU - Levy, Joshua M
AU  - Levy JM
AD  - Department of Otolaryngology-Head & Neck Surgery, Emory University School of 
      Medicine, Atlanta.
FAU - Nanda, Anil
AU  - Nanda A
AD  - Asthma and Allergy Center, Lewisville and Flower Mound, Tex; Division of Allergy 
      and Immunology, University of Texas Southwestern Medical Center, Dallas, Tex.
FAU - Laidlaw, Tanya M
AU  - Laidlaw TM
AD  - Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and 
      Women's Hospital, Boston, Mass.
FAU - White, Andrew A
AU  - White AA
AD  - Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif.
LA  - eng
GR  - K23 AI139352/AI/NIAID NIH HHS/United States
GR  - KL2 TR002381/TR/NCATS NIH HHS/United States
GR  - UL1 TR002378/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20201209
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Allergens)
RN  - 0 (Anti-Inflammatory Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Algorithms
MH  - Allergens/immunology
MH  - Animals
MH  - Anti-Inflammatory Agents/immunology/*therapeutic use
MH  - Aspirin/immunology/*therapeutic use
MH  - Asthma, Aspirin-Induced/diagnosis/immunology/*therapy
MH  - Chronic Disease
MH  - Desensitization, Immunologic/*methods
MH  - Humans
MH  - Rhinitis/diagnosis/immunology/*therapy
MH  - Sinusitis/diagnosis/immunology/*therapy
PMC - PMC7980229
MID - NIHMS1677285
OTO - NOTNLM
OT  - AERD
OT  - Aspirin-exacerbated respiratory disease
OT  - NSAID-exacerbated respiratory disease
OT  - Samter triad
OT  - aspirin desensitization
EDAT- 2020/12/12 06:00
MHDA- 2021/09/23 06:00
CRDT- 2020/12/11 20:09
PHST- 2020/06/05 00:00 [received]
PHST- 2020/10/13 00:00 [revised]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
PHST- 2020/12/11 20:09 [entrez]
AID - S0091-6749(20)31708-5 [pii]
AID - 10.1016/j.jaci.2020.10.043 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2021 Mar;147(3):827-844. doi: 10.1016/j.jaci.2020.10.043. 
      Epub 2020 Dec 9.

PMID- 27843052
OWN - NLM
STAT- MEDLINE
DCOM- 20171106
LR  - 20220410
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 227
DP  - 2017 Jan 15
TI  - Can TAVI patients receive aspirin monotherapy as patients after surgical aortic 
      bioprosthesis implantation? Data from the Polish Registry - POL-TAVI.
PG  - 305-311
LID - S0167-5273(16)33551-3 [pii]
LID - 10.1016/j.ijcard.2016.11.095 [doi]
AB  - BACKGROUND: This observational analysis investigated in-hospital safety and 
      efficacy of periprocedural antithrombotic/antiplatelet therapy used in TAVI 
      patients included into the Polish Nationwide Cardiac Surgical and Cardiology 
      Registry of Transcatheter Aortic Valve Implantation (POL-TAVI). METHODS AND 
      RESULTS: All patients who underwent TAVI in the participating centers between 
      2013 and 2014 were included. The primary endpoints were: severe bleeding, 
      vascular complications, thromboembolic events, myocardial infarction, 30-days 
      mortality, defined according to Valve Academic Research Consortium scale 2. A 
      total of 827 patients were included; 35-93years old (79.31±7.53); 457 (55.29%) 
      women. Endpoints noted: severe bleeding - 130 (15.72%) pts, vascular 
      complications - 135 (16.32%) pts, thromboembolic events - 29 (3.5%) pts, 
      myocardial infarction - 24 (2.90%) pts, deaths - 58 (7.01%) pts. Aspirin 
      premedication, resulted in the least number of vascular complications (OR 0.56 
      95%CI [0.345-0.938]; p=0.027). Aspirin after TAVI reduced the risk of vascular 
      complications (OR 0.089 95%CI [0.0217-0.372]; p=0.001) and bleeding (OR 0.138 
      95%CI [0.043-0.447]; p=0.001) with no adverse impact on efficacy endpoints. 
      Beneficial safety profile of postprocedural aspirin monotherapy remained 
      significant in comparison to all other types of prophylaxis also in propensity 
      score analysis: OR 0.068 95%CI [0.009-0.529]; p=0.01 for vascular complications, 
      OR 0.176 95%CI [0.049-0.627]; p=0.007 for bleeding. NNT for vascular 
      complications and bleeding with postprocedural aspirin prophylaxis was 5.5 and 
      6.42, respectively. CONCLUSION: Aspirin after TAVI appears to be beneficial than 
      currently recommended dual antiplatelet therapy; therefore, it might be 
      considered as TAVI antithrombotic prophylaxis.
CI  - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Czerwińska-Jelonkiewicz, Katarzyna
AU  - Czerwińska-Jelonkiewicz K
AD  - Intensive Cardiac Therapy Department, Institute of Cardiology, Warsaw, Poland. 
      Electronic address: kasia_czerwinska@vp.pl.
FAU - Zembala, Marian
AU  - Zembala M
AD  - Department of Cardiac Surgery and Transplantology, Silesian Center for Heart 
      Diseases, Zabrze, Poland.
FAU - Dąbrowski, Maciej
AU  - Dąbrowski M
AD  - Department of Interventional Cardiology and Angiology, Institute of Cardiology, 
      Warsaw, Poland.
FAU - Witkowski, Adam
AU  - Witkowski A
AD  - Department of Interventional Cardiology and Angiology, Institute of Cardiology, 
      Warsaw, Poland.
FAU - Ochała, Andrzej
AU  - Ochała A
AD  - 7th Public Hospital of the Silesian Medical University, Katowice, Poland.
FAU - Kochman, Janusz
AU  - Kochman J
AD  - 1(st) Department of Cardiology, Medical University of Warsaw, Poland.
FAU - Dudek, Dariusz
AU  - Dudek D
AD  - Jagiellonian University Medical College, Krakow, Poland.
FAU - Kübler, Piotr
AU  - Kübler P
AD  - Medical University, Military Hospital, Wroclaw, Poland.
FAU - Jagielak, Dariusz
AU  - Jagielak D
AD  - Department of Cardiac and Vascular Surgery, Medical University, Gdańsk, Poland.
FAU - Stępińska, Janina
AU  - Stępińska J
AD  - Intensive Cardiac Therapy Department, Institute of Cardiology, Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20161109
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aortic Valve Stenosis/*surgery
MH  - Aspirin/*therapeutic use
MH  - *Bioprosthesis
MH  - Female
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Poland
MH  - Postoperative Complications/*epidemiology
MH  - Registries
MH  - Retrospective Studies
MH  - *Transcatheter Aortic Valve Replacement
OTO - NOTNLM
OT  - Bleeding
OT  - Dual antiplatelet therapy
OT  - Transcatheter aortic valve implantation
OT  - Vascular complications
EDAT- 2016/11/16 06:00
MHDA- 2017/11/07 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/08/04 00:00 [received]
PHST- 2016/11/06 00:00 [accepted]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/11/07 06:00 [medline]
PHST- 2016/11/16 06:00 [entrez]
AID - S0167-5273(16)33551-3 [pii]
AID - 10.1016/j.ijcard.2016.11.095 [doi]
PST - ppublish
SO  - Int J Cardiol. 2017 Jan 15;227:305-311. doi: 10.1016/j.ijcard.2016.11.095. Epub 
      2016 Nov 9.

PMID- 1514741
OWN - NLM
STAT- MEDLINE
DCOM- 19921001
LR  - 20131121
IS  - 0003-4886 (Print)
IS  - 0003-4886 (Linking)
VI  - 24
IP  - 7
DP  - 1992 Jul
TI  - Efficacy of cryotherapy in vernal catarrh.
PG  - 253-6
AB  - Cryotherapy of the palpebral conjunctiva with oral aspirin has been evaluated in 
      mixed-type active vernal keratoconjunctivitis. The symptoms and signs were 
      recorded on a four-point scale. In 15 patients, we used cryotherapy of the 
      palpebral conjunctiva in 30 eyes (-60 degrees C to -80 degrees C for 30 seconds, 
      repeating the freeze-thaw cycle 2-3 times). All patients received oral aspirin 
      0.5 to 1.5 g in three divided doses daily over six weeks. The relief from 
      symptoms was statistically significant (P less than .001). Objective improvement 
      (palpebral and bulbar signs) also was statistically significant (P less than 
      .001). Follow-up of these cases for one year showed a 3.3% recurrence rate.
FAU - Sankarkumar, T
AU  - Sankarkumar T
AD  - Dr. Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS, New Delhi, India.
FAU - Panda, A
AU  - Panda A
FAU - Angra, S K
AU  - Angra SK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Ophthalmol
JT  - Annals of ophthalmology
JID - 0210137
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Conjunctiva/surgery
MH  - Conjunctivitis, Allergic/drug therapy/*surgery
MH  - *Cryosurgery
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Prognosis
MH  - Prospective Studies
MH  - Recurrence
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
PST - ppublish
SO  - Ann Ophthalmol. 1992 Jul;24(7):253-6.

PMID- 34780388
OWN - NLM
STAT- MEDLINE
DCOM- 20220211
LR  - 20220211
IS  - 1535-1386 (Electronic)
IS  - 0021-9355 (Linking)
VI  - 104
IP  - 2
DP  - 2022 Jan 19
TI  - Patients Who Do Not Receive Aspirin Because of Allergy Have an Increased Risk of 
      Venous Thromboembolism Following Total Joint Arthroplasty.
PG  - 107-114
LID - 10.2106/JBJS.21.00528 [doi]
AB  - BACKGROUND: Patient-reported allergies to aspirin or nonsteroidal 
      anti-inflammatory drugs (NSAIDs) may preclude certain patients from receiving 
      aspirin as venous thromboembolism (VTE) prophylaxis after total joint 
      arthroplasty (TJA). The purpose of the study was to (1) determine whether the use 
      of non-aspirin agents due to a self-reported aspirin or NSAID allergy was 
      associated with a higher incidence of VTE and (2) determine the rate of true 
      allergic reactions in patients who reported an allergy but still received 
      aspirin. METHODS: Prospectively collected data from 45,171 patients who underwent 
      primary TJA between 2000 and 2019 were reviewed. Patients who reported an allergy 
      to aspirin or NSAIDs were identified (n = 823). Using a validated VTE risk 
      calculator, each patient was assigned a risk score based on 26 comorbidities. 
      Bleeding complications, VTEs that occurred within 90 days postoperatively, and 
      allergic reactions were collected as end points. Multivariable logistic 
      regression was performed to determine the factors associated with VTE. RESULTS: 
      The overall incidence of aspirin or NSAID allergy was 1.8%. Only 80 of 267 
      patients (30%) reported an allergy to only aspirin and still received aspirin. 
      Compared with patients who received aspirin without a history of allergy (n = 
      17,648), patients who received non-aspirin thromboprophylaxis due to allergy (n = 
      383) had a higher incidence of VTE (2.87% versus 0.24%, p < 0.001). On 
      multivariable regression, these patients had an 8-fold increase in VTE risk 
      (adjusted odds ratio, 7.94; 95% confidence interval, 2.86 to 22.07; p < 0.001). 
      The incidence of true allergic reactions to aspirin among those with a reported 
      allergy was 1.8% (number needed to harm = 55). No patients developed anaphylaxis 
      or severe hypersensitivity reactions. CONCLUSIONS: Patients with a self-reported 
      allergy to aspirin or NSAIDs were at a significantly increased risk for VTE if 
      they received non-aspirin thromboprophylaxis agents following TJA. Future 
      research should evaluate the usefulness of preoperative allergy testing when 
      selecting a VTE prophylactic agent in patients with self-reported allergies. 
      LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a 
      complete description of levels of evidence.
CI  - Copyright © 2021 by The Journal of Bone and Joint Surgery, Incorporated.
FAU - Goh, Graham S
AU  - Goh GS
AUID- ORCID: 0000-0002-7337-3321
AD  - Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Kozaily, Elie
AU  - Kozaily E
AD  - Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
FAU - Tan, Timothy L
AU  - Tan TL
AD  - Department of Orthopaedic Surgery, University of California, San Francisco, San 
      Francisco, California.
FAU - Parvizi, Javad
AU  - Parvizi J
AUID- ORCID: 0000-0002-6985-5870
AD  - Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, 
      Pennsylvania.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Anticoagulants/administration & dosage/*adverse effects
MH  - *Arthroplasty, Replacement
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Hypersensitivity/*epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Pennsylvania/epidemiology
MH  - Postoperative Complications/*epidemiology
MH  - Prospective Studies
MH  - Risk Factors
MH  - Venous Thromboembolism/*epidemiology
COIS- Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided 
      with the online version of the article (http://links.lww.com/JBJS/G786).
EDAT- 2021/11/16 06:00
MHDA- 2022/02/12 06:00
CRDT- 2021/11/15 17:17
PHST- 2021/11/16 06:00 [pubmed]
PHST- 2022/02/12 06:00 [medline]
PHST- 2021/11/15 17:17 [entrez]
AID - 00004623-202201190-00002 [pii]
AID - 10.2106/JBJS.21.00528 [doi]
PST - ppublish
SO  - J Bone Joint Surg Am. 2022 Jan 19;104(2):107-114. doi: 10.2106/JBJS.21.00528.

PMID- 15313956
OWN - NLM
STAT- MEDLINE
DCOM- 20060407
LR  - 20220408
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 110
IP  - 10
DP  - 2004 Sep 7
TI  - Benefits and risks of the combination of clopidogrel and aspirin in patients 
      undergoing surgical revascularization for non-ST-elevation acute coronary 
      syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events 
      (CURE) Trial.
PG  - 1202-8
AB  - BACKGROUND: Antiplatelet therapy and antithrombin therapy have been demonstrated 
      to reduce the risk of cardiac events in patients presenting with acute coronary 
      syndrome, yet all effective therapies also increase the risk of bleeding. METHODS 
      AND RESULTS: In the Clopidogrel in Unstable angina to prevent Recurrent ischemic 
      Events (CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in 
      addition to aspirin, and the primary outcome was cardiovascular (CV) death, 
      myocardial infarction (MI), or stroke. The benefits were consistent among those 
      undergoing percutaneous coronary intervention (PCI) [9.6% for clopidogrel, 13.2% 
      for placebo; relative risk (RR), 0.72; 95% CI, 0.57 to 0.90], coronary artery 
      bypass grafting (CABG) surgery (14.5% for clopidogrel 16.2% for placebo; RR, 
      0.89; 95% CI, 0.71 to 1.11), and medical therapy only (8.1% for clopidogrel, 
      10.0% for placebo; RR, 0.80; 95% CI, 0.69 to 0.92; test for interaction among 
      strata, 0.53). For CABG during the initial hospitalization (530 for placebo, 485 
      for clopidogrel), the frequency of CV death, MI or stroke before CABG was 4.7% 
      for placebo and 2.9% for clopidogrel (RR, 0.56; 95% CI, 0.29 to 1.08). For the 
      entire study, there was a 1% excess of major bleeding but no significant excess 
      of life-threatening bleeding. Among patients undergoing CABG, the rates of 
      life-threatening bleeding were 5.6% for clopidogrel and 4.2% for placebo (RR, 
      1.30; 95% CI, 0.91 to 1.95; both nonsignificant). CONCLUSIONS: The benefits 
      versus risks of early and long-term clopidogrel therapy (freedom from CV death, 
      MI, stroke, or life-threatening bleeding) are similar in those undergoing 
      revascularization (CABG or PCI) and in the study population as a whole. Overall, 
      the benefits of starting clopidogrel on admission appear to outweigh the risks, 
      even among those who proceed to CABG during the initial hospitalization.
FAU - Fox, Keith A A
AU  - Fox KA
AD  - Royal Infirmary of Edinburgh, Edinburgh, UK. k.a.a.fox@ed.ac.uk
FAU - Mehta, Shamir R
AU  - Mehta SR
FAU - Peters, Ron
AU  - Peters R
FAU - Zhao, Feng
AU  - Zhao F
FAU - Lakkis, Nasser
AU  - Lakkis N
FAU - Gersh, Bernard J
AU  - Gersh BJ
FAU - Yusuf, Salim
AU  - Yusuf S
CN  - Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20040816
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Angina, Unstable/complications
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/administration & dosage/adverse effects/*therapeutic use
MH  - Clopidogrel
MH  - *Coronary Artery Bypass
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/epidemiology/physiopathology/*surgery/therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Risk
MH  - Stroke/epidemiology
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2004/08/18 05:00
MHDA- 2006/04/08 09:00
CRDT- 2004/08/18 05:00
PHST- 2004/08/18 05:00 [pubmed]
PHST- 2006/04/08 09:00 [medline]
PHST- 2004/08/18 05:00 [entrez]
AID - 01.CIR.0000140675.85342.1B [pii]
AID - 10.1161/01.CIR.0000140675.85342.1B [doi]
PST - ppublish
SO  - Circulation. 2004 Sep 7;110(10):1202-8. doi: 10.1161/01.CIR.0000140675.85342.1B. 
      Epub 2004 Aug 16.

PMID- 32559279
OWN - NLM
STAT- MEDLINE
DCOM- 20220329
LR  - 20220401
IS  - 2058-1742 (Electronic)
IS  - 2058-1742 (Linking)
VI  - 7
IP  - 5
DP  - 2021 Sep 16
TI  - COMPASS criteria applied to a contemporary cohort of unselected patients with 
      stable coronary artery diseases: insights from the START registry.
PG  - 513-520
LID - 10.1093/ehjqcco/qcaa054 [doi]
AB  - AIMS: Recently, the cardiovascular outcomes for people using anticoagulation 
      strategies (COMPASS) trial demonstrated that dual therapy reduced cardiovascular 
      outcomes compared with aspirin alone in patients with stable atherosclerotic 
      disease. METHODS AND RESULTS: We sought to assess the proportion of patients 
      eligible for the COMPASS trial and to compare the epidemiology and outcome of 
      these patients with those without COMPASS inclusion or with any exclusion 
      criteria in a contemporary, nationwide cohort of patients with stable coronary 
      artery disease. Among the 4068 patients with detailed information allowing 
      evaluation of eligibility, 1416 (34.8%) did not fulfil the inclusion criteria 
      (COMPASS-Not-Included), 841 (20.7%) had exclusion criteria (COMPASS-Excluded), 
      and the remaining 1811 (44.5%) were classified as COMPASS-Like. At 1 year, the 
      incidence of major adverse cardiovascular event (MACE), a composite of 
      cardiovascular death, myocardial infarction, and stroke, was 0.9% in the 
      COMPASS-Not-Included and 2.0% in the COMPASS-Like (P = 0.01), and 5.0% in the 
      COMPASS-Excluded group (P < 0.0001 for all comparisons). Among the COMPASS-Like 
      population, patients with multiple COMPASS enrichment criteria presented a 
      significant increase in the risk of MACE (from 1.0% to 3.3% in those with 1 and 
      ≥3 criteria, respectively; P = 0.012), and a modest absolute increase in major 
      bleeding risk (from 0.2% to 0.4%, respectively; P = 0.46). CONCLUSION: In a 
      contemporary real-world cohort registry of stable coronary artery disease, most 
      patients resulted as eligible for the COMPASS. These patients presented a 
      considerable annual risk of MACE that consistently increases in the presence of 
      multiple risk factors.
CI  - Published on behalf of the European Society of Cardiology.
FAU - De Luca, Leonardo
AU  - De Luca L
AD  - Division of Cardiology, Department of Cardiosciences, Azienda Ospedaliera San 
      Camillo Forlanini, Circonvallazione Gianicolense, 87, 00152 Rome, Italy.
FAU - Formigli, Dario
AU  - Formigli D
AD  - Division of Cardiology, Azienda Ospedaliera G. Rummo, Via Pacevecchia, 53, 82100 
      Benevento, Italy.
FAU - Meessen, Jennifer
AU  - Meessen J
AD  - Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario 
      Negri IRCCS, Via Mario Negri, 2, 20156 Milano, Italy.
FAU - Uguccioni, Massimo
AU  - Uguccioni M
AD  - Division of Cardiology, Department of Cardiosciences, Azienda Ospedaliera San 
      Camillo Forlanini, Circonvallazione Gianicolense, 87, 00152 Rome, Italy.
FAU - Cosentino, Nicola
AU  - Cosentino N
AD  - Division of Cardiology, CAPT Cariati (CS), Piazza R. Trento 87062 Cariati CS, 
      Italy.
FAU - Paolillo, Claudio
AU  - Paolillo C
AD  - Division of Cardiology, Ospedale Umberto I, Via Ruvo, 108, 70033 Corato (BA), 
      Italy.
FAU - Di Lenarda, Andrea
AU  - Di Lenarda A
AD  - Division of Cardiology, Azienda Sanitaria Universitaria Integrata di Trieste, Via 
      Giovanni Sai, 7, 34128 Trieste, Italy.
FAU - Colivicchi, Furio
AU  - Colivicchi F
AD  - Division of Cardiology, S. Filippo Neri Hospital, Via Giovanni Martinotti, 20, 
      00135 Roma, Italy.
FAU - Gabrielli, Domenico
AU  - Gabrielli D
AD  - Division of Cardiology, A. Murri Hospital, Via Augusto Murri, 21, 63900 Fermo, 
      Italy.
FAU - Gulizia, Michele M
AU  - Gulizia MM
AD  - Division of Cardiology, Garibaldi-Nesima Hospital, Via Palermo, 636, 95122 
      Catania, Italy.
FAU - Scherillo, Marino
AU  - Scherillo M
AD  - Division of Cardiology, Azienda Ospedaliera G. Rummo, Via Pacevecchia, 53, 82100 
      Benevento, Italy.
CN  - START Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J Qual Care Clin Outcomes
JT  - European heart journal. Quality of care & clinical outcomes
JID - 101677796
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Coronary Artery Disease/epidemiology
MH  - Humans
MH  - *Myocardial Infarction/epidemiology
MH  - Registries
MH  - Rivaroxaban
OTO - NOTNLM
OT  - COMPASS trial
OT  - Coronary artery disease
OT  - Rivaroxaban
OT  - START registry
FIR - Maras, P
IR  - Maras P
FIR - Ramani, F
IR  - Ramani F
FIR - Falcone, C
IR  - Falcone C
FIR - Passarelli, I
IR  - Passarelli I
FIR - Mauri, S
IR  - Mauri S
FIR - Calabrò, P
IR  - Calabrò P
FIR - Bianchi, R
IR  - Bianchi R
FIR - Di Palma, G
IR  - Di Palma G
FIR - Mascia, F
IR  - Mascia F
FIR - Vetrano, A
IR  - Vetrano A
FIR - Fusco, A
IR  - Fusco A
FIR - Proia, E
IR  - Proia E
FIR - Colivicchi, F
IR  - Colivicchi F
FIR - Aiello, A
IR  - Aiello A
FIR - Tomai, F
IR  - Tomai F
FIR - Licitra, R
IR  - Licitra R
FIR - Petrolini, A
IR  - Petrolini A
FIR - Bosco, B
IR  - Bosco B
FIR - Magliari, F
IR  - Magliari F
FIR - Callerame, M
IR  - Callerame M
FIR - Mazzella, T
IR  - Mazzella T
FIR - Lettica, G V
IR  - Lettica GV
FIR - Coco, G
IR  - Coco G
FIR - Incao, F
IR  - Incao F
FIR - Marinacci, L
IR  - Marinacci L
FIR - D'Addario, S
IR  - D'Addario S
FIR - Tartaglione, S N
IR  - Tartaglione SN
FIR - Ubaldi, S
IR  - Ubaldi S
FIR - Sanchez, F A
IR  - Sanchez FA
FIR - Costa, P
IR  - Costa P
FIR - Manca, G
IR  - Manca G
FIR - Failla, M
IR  - Failla M
FIR - Scherillo, M
IR  - Scherillo M
FIR - Procaccini, V
IR  - Procaccini V
FIR - Formigli, D
IR  - Formigli D
FIR - Senni, M
IR  - Senni M
FIR - Luminita, E M
IR  - Luminita EM
FIR - Bonomo, P
IR  - Bonomo P
FIR - Mossa, C
IR  - Mossa C
FIR - Corda, S
IR  - Corda S
FIR - Colavita, A R
IR  - Colavita AR
FIR - Trevisonno, G
IR  - Trevisonno G
FIR - Vizzari, G
IR  - Vizzari G
FIR - Cosentino, N
IR  - Cosentino N
FIR - Formaro, C
IR  - Formaro C
FIR - Paolillo, C
IR  - Paolillo C
FIR - Nalin, I L
IR  - Nalin IL
FIR - De Rosa, F M
IR  - De Rosa FM
FIR - Fontana, F
IR  - Fontana F
FIR - Fuscaldo, G F
IR  - Fuscaldo GF
FIR - Passamonti, E
IR  - Passamonti E
FIR - Bertella, E
IR  - Bertella E
FIR - Calvaruso, E V
IR  - Calvaruso EV
FIR - Varani, E
IR  - Varani E
FIR - Tani, F
IR  - Tani F
FIR - Cicchitelli, G
IR  - Cicchitelli G
FIR - Gabrielli, D
IR  - Gabrielli D
FIR - Paoloni, P
IR  - Paoloni P
FIR - Marziali, A
IR  - Marziali A
FIR - Campo, G
IR  - Campo G
FIR - Tebaldi, M
IR  - Tebaldi M
FIR - Biscaglia, S
IR  - Biscaglia S
FIR - Di Biase, M
IR  - Di Biase M
FIR - Brunetti, N D
IR  - Brunetti ND
FIR - Gallotta, A M
IR  - Gallotta AM
FIR - Mattei, L
IR  - Mattei L
FIR - Marini, R
IR  - Marini R
FIR - Balsemin, F
IR  - Balsemin F
FIR - D'Urbano, M
IR  - D'Urbano M
FIR - Naio, R
IR  - Naio R
FIR - Vicinelli, P
IR  - Vicinelli P
FIR - Arena, G
IR  - Arena G
FIR - Mazzini, M
IR  - Mazzini M
FIR - Gigli, N
IR  - Gigli N
FIR - Miserrafiti, B
IR  - Miserrafiti B
FIR - Monopoli, A
IR  - Monopoli A
FIR - Mortara, A
IR  - Mortara A
FIR - Delfino, P
IR  - Delfino P
FIR - Chioffi, M M
IR  - Chioffi MM
FIR - Marino, P
IR  - Marino P
FIR - Gravellone, M
IR  - Gravellone M
FIR - Barbieri, L
IR  - Barbieri L
FIR - Ledda, A
IR  - Ledda A
FIR - Geraci, G
IR  - Geraci G
FIR - Carmina, M G
IR  - Carmina MG
FIR - Raisaro, A E
IR  - Raisaro AE
FIR - Di Giacomo, C
IR  - Di Giacomo C
FIR - Somaschini, A
IR  - Somaschini A
FIR - Fasano, M L
IR  - Fasano ML
FIR - Sannazzaro, M
IR  - Sannazzaro M
FIR - Arcieri, R
IR  - Arcieri R
FIR - Pantaleoni, M
IR  - Pantaleoni M
FIR - Leuzzi, C
IR  - Leuzzi C
FIR - Gorlato, G
IR  - Gorlato G
FIR - Greco, G
IR  - Greco G
FIR - Chiera, A
IR  - Chiera A
FIR - Ammaturo, T A
IR  - Ammaturo TA
FIR - Malanchini, G
IR  - Malanchini G
FIR - Del Corral, M P
IR  - Del Corral MP
FIR - Tedesco, L
IR  - Tedesco L
FIR - Pede, S
IR  - Pede S
FIR - Urso, L G
IR  - Urso LG
FIR - Piscione, F
IR  - Piscione F
FIR - Galasso, G
IR  - Galasso G
FIR - Provasoli, S
IR  - Provasoli S
FIR - Fattore, L
IR  - Fattore L
FIR - Lucca, G
IR  - Lucca G
FIR - Cresti, A
IR  - Cresti A
FIR - Cardillo, A
IR  - Cardillo A
FIR - Fera, M S
IR  - Fera MS
FIR - Vennettilli, F
IR  - Vennettilli F
FIR - Gaudio, C
IR  - Gaudio C
FIR - Paravati, V
IR  - Paravati V
FIR - Caldarola, P
IR  - Caldarola P
FIR - Locuratolo, N
IR  - Locuratolo N
FIR - Verlato, R
IR  - Verlato R
FIR - De Conti, F
IR  - De Conti F
FIR - Turiano, G
IR  - Turiano G
FIR - Preti, G
IR  - Preti G
FIR - Moretti, L
IR  - Moretti L
FIR - Silenzi, S
IR  - Silenzi S
FIR - Colonna, G
IR  - Colonna G
FIR - Picciolo, A
IR  - Picciolo A
FIR - Nicosia, A
IR  - Nicosia A
FIR - Cascone, C
IR  - Cascone C
FIR - Di Sciascio, G
IR  - Di Sciascio G
FIR - Mangiacapra, F
IR  - Mangiacapra F
FIR - Russo, A
IR  - Russo A
FIR - Mastroianno, S
IR  - Mastroianno S
FIR - Esposito, G
IR  - Esposito G
FIR - Cosmi, F
IR  - Cosmi F
FIR - D'Orazio, S
IR  - D'Orazio S
FIR - Costantini, C
IR  - Costantini C
FIR - Lanari, A
IR  - Lanari A
FIR - De Rosa, P
IR  - De Rosa P
FIR - Esposito, L
IR  - Esposito L
FIR - Bilato, C
IR  - Bilato C
FIR - Dalla Valle, C
IR  - Dalla Valle C
FIR - Ceresa, M
IR  - Ceresa M
FIR - Colombo, E
IR  - Colombo E
FIR - Pennisi, V
IR  - Pennisi V
FIR - Casciola, G
IR  - Casciola G
FIR - Driussi, M
IR  - Driussi M
FIR - Bisceglia, T
IR  - Bisceglia T
FIR - Scalvini, S
IR  - Scalvini S
FIR - Rivadossi, F
IR  - Rivadossi F
FIR - Volpe, M
IR  - Volpe M
FIR - Comito, F
IR  - Comito F
FIR - Scorzoni, D
IR  - Scorzoni D
FIR - Grimoldi, P
IR  - Grimoldi P
FIR - Lagioia, R
IR  - Lagioia R
FIR - Santoro, D
IR  - Santoro D
FIR - De Cesare, N
IR  - De Cesare N
FIR - Comotti, T
IR  - Comotti T
FIR - Poli, A
IR  - Poli A
FIR - Martina, P
IR  - Martina P
FIR - Musolino, M F
IR  - Musolino MF
FIR - Multari, E I
IR  - Multari EI
FIR - Bilardo, G
IR  - Bilardo G
FIR - Scalchi, G
IR  - Scalchi G
FIR - Olivieri, C
IR  - Olivieri C
FIR - Caranci, F
IR  - Caranci F
FIR - Pavan, D
IR  - Pavan D
FIR - Ganci, G
IR  - Ganci G
FIR - Mariani, A
IR  - Mariani A
FIR - Falchetti, E
IR  - Falchetti E
FIR - Lanzillo, T
IR  - Lanzillo T
FIR - Caccavale, A
IR  - Caccavale A
FIR - Bongo, A S
IR  - Bongo AS
FIR - Rizzi, A
IR  - Rizzi A
FIR - Favilli, R
IR  - Favilli R
FIR - Maffei, S
IR  - Maffei S
FIR - Mallardo, M
IR  - Mallardo M
FIR - Fulgione, C
IR  - Fulgione C
FIR - Bordin, F
IR  - Bordin F
FIR - Bonmassari, R
IR  - Bonmassari R
FIR - Battaia, E
IR  - Battaia E
FIR - Puzzo, A
IR  - Puzzo A
FIR - Vianello, G
IR  - Vianello G
FIR - D'Arpino, A
IR  - D'Arpino A
FIR - Romei, M
IR  - Romei M
FIR - Pajes, G
IR  - Pajes G
FIR - Petronzelli, S
IR  - Petronzelli S
FIR - Ghezzi, F
IR  - Ghezzi F
FIR - Brigido, S
IR  - Brigido S
FIR - Pignatelli, L
IR  - Pignatelli L
FIR - Brscic, E
IR  - Brscic E
FIR - Sori, P
IR  - Sori P
FIR - Russo, M
IR  - Russo M
FIR - Biancolillo, E
IR  - Biancolillo E
FIR - Ignone, G
IR  - Ignone G
FIR - De Giorgio, N A
IR  - De Giorgio NA
FIR - Campaniello, C
IR  - Campaniello C
FIR - Ponticelli, P
IR  - Ponticelli P
FIR - Margonato, A
IR  - Margonato A
FIR - Gerosa, S
IR  - Gerosa S
FIR - Cutaia, A
IR  - Cutaia A
FIR - Casalicchio, C
IR  - Casalicchio C
FIR - Bartolomucci, F
IR  - Bartolomucci F
FIR - Larosa, C
IR  - Larosa C
FIR - Spadafina, T
IR  - Spadafina T
FIR - Putignano, A
IR  - Putignano A
FIR - Se Cristofaro, R
IR  - Se Cristofaro R
FIR - Bernardi, L
IR  - Bernardi L
FIR - Sommariva, L
IR  - Sommariva L
FIR - Celestini, A
IR  - Celestini A
FIR - Bertucci, C M
IR  - Bertucci CM
FIR - Marchetti, M
IR  - Marchetti M
FIR - Franceschini Grisolia, E
IR  - Franceschini Grisolia E
FIR - Ammendolea, C
IR  - Ammendolea C
FIR - Carini, M
IR  - Carini M
FIR - Scipione, P
IR  - Scipione P
FIR - Politano, M
IR  - Politano M
FIR - Rubino, G
IR  - Rubino G
FIR - Reina, C
IR  - Reina C
FIR - Peccerillo, N
IR  - Peccerillo N
FIR - Paloscia, L
IR  - Paloscia L
FIR - D'Alleva, A
IR  - D'Alleva A
FIR - Petacchi, R
IR  - Petacchi R
FIR - Pignalosa, M
IR  - Pignalosa M
FIR - Lucchetti, D
IR  - Lucchetti D
FIR - Di Palma, F
IR  - Di Palma F
FIR - La Mastra, R A
IR  - La Mastra RA
FIR - Amico, A F
IR  - Amico AF
FIR - De Filippis, M
IR  - De Filippis M
FIR - Fontanella, B
IR  - Fontanella B
FIR - Zanini, G
IR  - Zanini G
FIR - Casolo, G
IR  - Casolo G
FIR - Del Meglio, J
IR  - Del Meglio J
FIR - Parato, V M
IR  - Parato VM
FIR - Genovesi, E
IR  - Genovesi E
FIR - D'Alimonte, A
IR  - D'Alimonte A
FIR - Miglioranza, A
IR  - Miglioranza A
FIR - Alessandri, N
IR  - Alessandri N
FIR - Moscariello, F
IR  - Moscariello F
FIR - Mauro, C
IR  - Mauro C
FIR - Sasso, A
IR  - Sasso A
FIR - Caso, P
IR  - Caso P
FIR - Petrillo, C
IR  - Petrillo C
FIR - Napoletano, C
IR  - Napoletano C
FIR - Paparoni, S R
IR  - Paparoni SR
FIR - Bernardo, V
IR  - Bernardo V
FIR - Serdoz, R
IR  - Serdoz R
FIR - Rotunno, R
IR  - Rotunno R
FIR - Oppo, I
IR  - Oppo I
FIR - Aloisio, A
IR  - Aloisio A
FIR - Aurelio, A
IR  - Aurelio A
FIR - Licciardello, G
IR  - Licciardello G
FIR - Cassaniti, L
IR  - Cassaniti L
FIR - Gulizia, M M
IR  - Gulizia MM
FIR - Francese, G M
IR  - Francese GM
FIR - Marcassa, C
IR  - Marcassa C
FIR - Temporelli, P L
IR  - Temporelli PL
FIR - Villani, R
IR  - Villani R
FIR - Zorzoli, F
IR  - Zorzoli F
FIR - Mileto, F
IR  - Mileto F
FIR - De Vecchis, M
IR  - De Vecchis M
FIR - Amico, A F
IR  - Amico AF
FIR - Scolozzi, D
IR  - Scolozzi D
FIR - Lupi, G
IR  - Lupi G
FIR - Caruso, D
IR  - Caruso D
FIR - Rebulla, E
IR  - Rebulla E
FIR - La Fata, B
IR  - La Fata B
FIR - Anselmi, M
IR  - Anselmi M
FIR - Girardi, P
IR  - Girardi P
FIR - Borruso, E
IR  - Borruso E
FIR - Ferrantelli, G
IR  - Ferrantelli G
FIR - Sassone, B
IR  - Sassone B
FIR - Bressan, S
IR  - Bressan S
FIR - Capriolo, M
IR  - Capriolo M
FIR - Pelissero, E
IR  - Pelissero E
FIR - Piancastelli, M
IR  - Piancastelli M
FIR - Gobbi, M
IR  - Gobbi M
FIR - Cocco, F
IR  - Cocco F
FIR - Bruno, M G
IR  - Bruno MG
FIR - Berti, S
IR  - Berti S
FIR - Lo Surdo, G
IR  - Lo Surdo G
FIR - Tanzi, P
IR  - Tanzi P
FIR - De Rosa, R
IR  - De Rosa R
FIR - Vilei, E
IR  - Vilei E
FIR - De Iaco, M R
IR  - De Iaco MR
FIR - Grassi, G
IR  - Grassi G
FIR - Zanella, C
IR  - Zanella C
FIR - Marullo, L
IR  - Marullo L
FIR - Alfano, G
IR  - Alfano G
FIR - Pelaggi, P
IR  - Pelaggi P
FIR - Talarico, R
IR  - Talarico R
FIR - Tuccillo, B
IR  - Tuccillo B
FIR - Irace, L
IR  - Irace L
FIR - Proietti, F
IR  - Proietti F
FIR - Di Croce, G
IR  - Di Croce G
FIR - Di Lorenzo, L
IR  - Di Lorenzo L
FIR - Zarrilli, A
IR  - Zarrilli A
FIR - Bongini, M
IR  - Bongini M
FIR - Ranise, A
IR  - Ranise A
FIR - Aprile, A
IR  - Aprile A
FIR - Fornengo, C
IR  - Fornengo C
FIR - Capogrosso, V
IR  - Capogrosso V
FIR - Tranghese, A
IR  - Tranghese A
FIR - Golia, B
IR  - Golia B
FIR - Marziano, A
IR  - Marziano A
FIR - Roncon, L
IR  - Roncon L
FIR - Picariello, C
IR  - Picariello C
FIR - Bagni, E
IR  - Bagni E
FIR - Leci, E
IR  - Leci E
FIR - Gregorio, G
IR  - Gregorio G
FIR - Gatto, F
IR  - Gatto F
FIR - Piemonte, F
IR  - Piemonte F
FIR - Gervasio, F
IR  - Gervasio F
FIR - Navazio, A
IR  - Navazio A
FIR - Guerri, E
IR  - Guerri E
FIR - Belmonte, E
IR  - Belmonte E
FIR - Marino, F
IR  - Marino F
FIR - Di Belardino, N
IR  - Di Belardino N
FIR - Di Nuzzo, M R
IR  - Di Nuzzo MR
FIR - Epifani, M
IR  - Epifani M
FIR - Comolatti, G
IR  - Comolatti G
FIR - Conconi, B
IR  - Conconi B
FIR - Benea, D
IR  - Benea D
FIR - Casu, G
IR  - Casu G
FIR - Merella, P
IR  - Merella P
FIR - Ammirati, M A
IR  - Ammirati MA
FIR - Corrado, V M
IR  - Corrado VM
FIR - Spagnolo, D
IR  - Spagnolo D
FIR - Caico, S I
IR  - Caico SI
FIR - Bonizzato, S
IR  - Bonizzato S
FIR - Margheri, M
IR  - Margheri M
FIR - Corrado, L
IR  - Corrado L
FIR - Antonicelli, R
IR  - Antonicelli R
FIR - Ferrigno, C
IR  - Ferrigno C
FIR - Merlino, A
IR  - Merlino A
FIR - Nassiacos, D
IR  - Nassiacos D
FIR - Antonelli, A
IR  - Antonelli A
FIR - Marchese, A
IR  - Marchese A
FIR - Uguccioni, M
IR  - Uguccioni M
FIR - Villella, A
IR  - Villella A
FIR - Navazio, A
IR  - Navazio A
FIR - Bechi, S
IR  - Bechi S
FIR - Lo Bianco, F
IR  - Lo Bianco F
FIR - Bedogni, F
IR  - Bedogni F
FIR - Negro, L
IR  - Negro L
FIR - Donato, L
IR  - Donato L
FIR - Statile, D
IR  - Statile D
FIR - Cassin, M
IR  - Cassin M
FIR - Fedele, F
IR  - Fedele F
FIR - Granatelli, A
IR  - Granatelli A
FIR - Calcagno, S
IR  - Calcagno S
FIR - Politi, A
IR  - Politi A
FIR - Serdoz, R
IR  - Serdoz R
FIR - Pani, A
IR  - Pani A
EDAT- 2020/06/20 06:00
MHDA- 2022/03/30 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2022/03/30 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 5860017 [pii]
AID - 10.1093/ehjqcco/qcaa054 [doi]
PST - ppublish
SO  - Eur Heart J Qual Care Clin Outcomes. 2021 Sep 16;7(5):513-520. doi: 
      10.1093/ehjqcco/qcaa054.

PMID- 21526889
OWN - NLM
STAT- MEDLINE
DCOM- 20120131
LR  - 20181201
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 22
IP  - 7
DP  - 2011
TI  - The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, 
      on the antiplatelet activity of clopidogrel or aspirin.
PG  - 495-503
LID - 10.3109/09537104.2011.565433 [doi]
AB  - Laropiprant (LRPT) is being developed in combination with Merck's 
      extended-release niacin (ERN) formulation for the treatment of dyslipidemia. 
      LRPT, an antagonist of the prostaglandin PGD₂ receptor DP1, reduces flushing 
      symptoms associated with ERN. LRPT also has affinity for the thromboxane A₂ 
      receptor TP (approximately 190-fold less potent at TP compared with DP1). Aspirin 
      and clopidogrel are two frequently used anti-clotting agents with different 
      mechanisms of action. Since LRPT may potentially be co-administered with either 
      one of these agents, these studies were conducted to assess the effects of 
      steady-state LRPT on the antiplatelet activity of steady-state clopidogrel or 
      aspirin. Bleeding time at 24 h post-dose (trough) was pre-specified as the 
      primary pharmacodynamic endpoint in both studies. Two separate, double-blind, 
      randomized, placebo-controlled, crossover studies evaluated the effects of 
      multiple-dose LRPT on the pharmacodynamics of multiple-dose clopidogrel or 
      aspirin. Healthy subjects were randomized to once-daily oral doses of LRPT 40 mg 
      or placebo to LRTP co-administered with clopidogrel 75 mg or aspirin 81 mg for 7 
      days with at least a 21-day washout between treatments. In both studies, bleeding 
      time and platelet aggregation were assessed 4 and 24 hours post-dose on Day 7. 
      Comparability was declared if the 90% confidence interval for the estimated 
      geometric mean ratio ([LRPT+clopidogrel]/clopidogrel alone or 
      [LRPT+aspirin]/aspirin alone) for bleeding time at 24 hours post-dose on Day 7 
      was contained within (0.66, 1.50). Concomitant daily administration of LRPT 40 mg 
      with clopidogrel 75 mg or aspirin 81 mg resulted in an approximate 4-5% increase 
      in bleeding time at 24 hours after the last dose vs. bleeding time after 
      treatment with clopidogrel or aspirin alone, demonstrating that the treatments 
      had comparable effects on bleeding time. Percent inhibition of platelet 
      aggregation was not significantly different between LRPT co-administered with 
      clopidogrel or aspirin vs. clopidogrel or aspirin alone at 24 hours post-dose at 
      steady state. At 4 hours after the last dose, co-administration of LRPT 40 mg 
      resulted in 3% and 41% increase in bleeding time vs. bleeding time after 
      treatment with aspirin or clopidogrel alone, respectively. Co-administration of 
      LPRT with clopidogrel or aspirin was generally well tolerated in healthy 
      subjects. Co-administration of multiple doses of LRPT 40 mg and clopidogrel 75 mg 
      or aspirin 81 mg had no clinically important effects on bleeding time or platelet 
      aggregation.
FAU - Dallob, Aimee
AU  - Dallob A
AD  - Merck, Whitehouse Station, NJ, USA.
FAU - Luo, Wen-Lin
AU  - Luo WL
FAU - Luk, Julie Mabalot
AU  - Luk JM
FAU - Ratcliffe, Lisa
AU  - Ratcliffe L
FAU - Johnson-Levonas, Amy O
AU  - Johnson-Levonas AO
FAU - Schwartz, Jules I
AU  - Schwartz JI
FAU - Dishy, Victor
AU  - Dishy V
FAU - Kraft, Walter K
AU  - Kraft WK
FAU - De Hoon, Jan N
AU  - De Hoon JN
FAU - Van Hecken, Anne
AU  - Van Hecken A
FAU - De Lepeleire, Inge
AU  - De Lepeleire I
FAU - Radziszewski, Waldemar
AU  - Radziszewski W
FAU - Wagner, John A
AU  - Wagner JA
FAU - Lai, Eseng
AU  - Lai E
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110428
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Indoles)
RN  - 0 (MK-0524)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, Prostaglandin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - XZF106QU24 (prostaglandin D2 receptor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/adverse effects/*pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects/metabolism
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Indoles/adverse effects/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacology
MH  - Receptors, Immunologic/*antagonists & inhibitors
MH  - Receptors, Prostaglandin/*antagonists & inhibitors
MH  - Ticlopidine/adverse effects/*analogs & derivatives/pharmacology
MH  - Young Adult
EDAT- 2011/04/30 06:00
MHDA- 2012/02/01 06:00
CRDT- 2011/04/30 06:00
PHST- 2011/04/30 06:00 [entrez]
PHST- 2011/04/30 06:00 [pubmed]
PHST- 2012/02/01 06:00 [medline]
AID - 10.3109/09537104.2011.565433 [doi]
PST - ppublish
SO  - Platelets. 2011;22(7):495-503. doi: 10.3109/09537104.2011.565433. Epub 2011 Apr 
      28.

PMID- 34949098
OWN - NLM
STAT- MEDLINE
DCOM- 20220504
LR  - 20230202
IS  - 2574-8300 (Electronic)
IS  - 2574-8300 (Linking)
VI  - 15
IP  - 1
DP  - 2022 Feb
TI  - Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in 
      Individuals Aged 70 Years and Older.
PG  - e003429
LID - 10.1161/CIRCGEN.121.003429 [doi]
AB  - BACKGROUND: The use of a polygenic risk score (PRS) to improve risk prediction of 
      coronary heart disease (CHD) events has been demonstrated to have clinical 
      utility in the general adult population. However, the prognostic value of a PRS 
      for CHD has not been examined specifically in older populations of individuals 
      aged ≥70 years, who comprise a distinct high-risk subgroup. The objective of this 
      study was to evaluate the predictive value of a PRS for incident CHD events in a 
      prospective cohort of older individuals without a history of cardiovascular 
      events. METHODS: We used data from 12 792 genotyped, healthy older individuals 
      enrolled into the ASPREE trial (Aspirin in Reducing Events in the Elderly), a 
      randomized double-blind placebo-controlled clinical trial investigating the 
      effect of daily 100 mg aspirin on disability-free survival. Participants had no 
      previous history of diagnosed atherothrombotic cardiovascular events, dementia, 
      or persistent physical disability at enrollment. We calculated a PRS 
      (meta-genomic risk score) consisting of 1.7 million genetic variants. The primary 
      outcome was a composite of incident myocardial infarction or CHD death over 5 
      years. RESULTS: At baseline, the median population age was 73.9 years, and 54.9% 
      were female. In total, 254 incident CHD events occurred. When the PRS was added 
      to conventional risk factors, it was independently associated with CHD (hazard 
      ratio, 1.24 [95% CI, 1.08-1.42], P=0.002). The area under the curve of the 
      conventional model was 70.53 (95% CI, 67.00-74.06), and after inclusion of the 
      PRS increased to 71.78 (95% CI, 68.32-75.24, P=0.019), demonstrating improved 
      prediction. Reclassification was also improved, as the continuous net 
      reclassification index after adding PRS to the conventional model was 0.25 (95% 
      CI, 0.15-0.28). CONCLUSION: A PRS for CHD performs well in older people and 
      improves prediction over conventional cardiovascular risk factors. Our study 
      provides evidence that genomic risk prediction for CHD has clinical utility in 
      individuals aged 70 years and older. Registration: URL: 
      https://www.clinicaltrials.gov; Unique identifier: NCT01038583.
FAU - Neumann, Johannes T
AU  - Neumann JT
AUID- ORCID: 0000-0002-9478-2757
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia (J.T.N., M.R., A.B., 
      G.P., L.T.P.T., M.R.N., R.L.W., C.M.R., A.M.T., J.M., P.L.).
AD  - Department of Cardiology, University Heart & Vascular Centre, Hamburg, Germany 
      (J.T.N.).
AD  - German Centre for Cardiovascular Research (DZHK), Partner Site 
      Hamburg/Kiel/Lübeck, Hamburg (J.T.N.).
FAU - Riaz, Moeen
AU  - Riaz M
AUID- ORCID: 0000-0001-5858-3788
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia (J.T.N., M.R., A.B., 
      G.P., L.T.P.T., M.R.N., R.L.W., C.M.R., A.M.T., J.M., P.L.).
FAU - Bakshi, Andrew
AU  - Bakshi A
AUID- ORCID: 0000-0001-5650-7036
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia (J.T.N., M.R., A.B., 
      G.P., L.T.P.T., M.R.N., R.L.W., C.M.R., A.M.T., J.M., P.L.).
FAU - Polekhina, Galina
AU  - Polekhina G
AUID- ORCID: 0000-0001-9535-9291
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia (J.T.N., M.R., A.B., 
      G.P., L.T.P.T., M.R.N., R.L.W., C.M.R., A.M.T., J.M., P.L.).
FAU - Thao, Le T P
AU  - Thao LTP
AUID- ORCID: 0000-0001-9661-6835
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia (J.T.N., M.R., A.B., 
      G.P., L.T.P.T., M.R.N., R.L.W., C.M.R., A.M.T., J.M., P.L.).
FAU - Nelson, Mark R
AU  - Nelson MR
AUID- ORCID: 0000-0001-9941-7161
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia (J.T.N., M.R., A.B., 
      G.P., L.T.P.T., M.R.N., R.L.W., C.M.R., A.M.T., J.M., P.L.).
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia 
      (M.R.N.).
FAU - Woods, Robyn L
AU  - Woods RL
AUID- ORCID: 0000-0003-1249-6149
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia (J.T.N., M.R., A.B., 
      G.P., L.T.P.T., M.R.N., R.L.W., C.M.R., A.M.T., J.M., P.L.).
FAU - Abraham, Gad
AU  - Abraham G
AUID- ORCID: 0000-0003-4853-0118
AD  - Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, 
      Melbourne, VIC, Australia (G.A., M.I.).
FAU - Inouye, Michael
AU  - Inouye M
AD  - Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, 
      Melbourne, VIC, Australia (G.A., M.I.).
AD  - Department of Public Health and Primary Care, University of Cambridge, United 
      Kingdom (M.I.).
FAU - Reid, Christopher M
AU  - Reid CM
AUID- ORCID: 0000-0001-9173-3944
AD  - School of Public Health, Curtin University, Perth, WA, Australia (C.M.R.).
FAU - Tonkin, Andrew M
AU  - Tonkin AM
AUID- ORCID: 0000-0001-5291-0610
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia (J.T.N., M.R., A.B., 
      G.P., L.T.P.T., M.R.N., R.L.W., C.M.R., A.M.T., J.M., P.L.).
FAU - McNeil, John
AU  - McNeil J
AUID- ORCID: 0000-0002-1049-5129
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia (J.T.N., M.R., A.B., 
      G.P., L.T.P.T., M.R.N., R.L.W., C.M.R., A.M.T., J.M., P.L.).
FAU - Lacaze, Paul
AU  - Lacaze P
AUID- ORCID: 0000-0002-0902-6798
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and 
      Preventive Medicine, Monash University, Melbourne, Australia (J.T.N., M.R., A.B., 
      G.P., L.T.P.T., M.R.N., R.L.W., C.M.R., A.M.T., J.M., P.L.).
LA  - eng
SI  - ClinicalTrials.gov/NCT01038583
GR  - P30 AG024824/AG/NIA NIH HHS/United States
GR  - U01 AG029824/AG/NIA NIH HHS/United States
GR  - U19 AG062682/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20211224
PL  - United States
TA  - Circ Genom Precis Med
JT  - Circulation. Genomic and precision medicine
JID - 101714113
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - *Coronary Disease/diagnosis/epidemiology/genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC8847323
MID - NIHMS1764273
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular disease
OT  - genetics
OT  - prognosis
OT  - risk factor
COIS- Disclosures: No conflicts were reported.
EDAT- 2021/12/25 06:00
MHDA- 2022/05/06 06:00
CRDT- 2021/12/24 05:19
PHST- 2021/12/25 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2021/12/24 05:19 [entrez]
AID - 10.1161/CIRCGEN.121.003429 [doi]
PST - ppublish
SO  - Circ Genom Precis Med. 2022 Feb;15(1):e003429. doi: 10.1161/CIRCGEN.121.003429. 
      Epub 2021 Dec 24.

PMID- 7801868
OWN - NLM
STAT- MEDLINE
DCOM- 19950123
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 75
IP  - 1
DP  - 1995 Jan 1
TI  - Initial experience with hirudin and streptokinase in acute myocardial infarction: 
      results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial.
PG  - 7-13
AB  - Hirudin is a potent, direct, and highly specific inhibitor of both free and 
      clot-bound thrombin. Previous reports have shown hirudin to be superior to 
      heparin when given with tissue plasminogen activator and aspirin for improving 
      the incidence and rate of reperfusion as well as reducing reocclusion of 
      infarct-related arteries. Patients with acute myocardial infarction were 
      randomized to hirudin versus heparin in conjunction with streptokinase (1.5 x 
      10(6) U) and aspirin (325 mg/day). Study drug treatment was a 5-day infusion of 
      either heparin, as a 5,000 U bolus, followed by a 1,000 U/hour infusion adjusted 
      to a target activated partial thromboplastin time of 65 to 90 seconds (n = 71), 
      or a constant infusion of hirudin at 1 of 3 doses (dose 1, n = 55: 0.15 mg/kg 
      bolus + 0.05 mg/kg/hour infusion; dose 2, n = 31: 0.3 mg/kg bolus + 0.1 
      mg/kg/hour infusion; or dose 3, n = 36: 0.6 mg/kg bolus + 0.2 mg/kg/hour 
      infusion). The incidence of major hemorrhage was similar between the heparin 
      group (5.6%) and any of the hirudin dose groups (dose 1 = 5.5%, dose 2 = 6.5%, 
      dose 3 = 5.6%). At hospital discharge the occurrence of death, nonfatal 
      reinfarction, congestive heart failure, or cardiogenic shock was greater in 
      patients receiving the lowest dose of hirudin (21.6%) than in those receiving the 
      higher doses of hirudin (dose 2 = 9.7%, dose 3 = 11.4%).(ABSTRACT TRUNCATED AT 
      250 WORDS)
FAU - Lee, L V
AU  - Lee LV
AD  - Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, 
      Boston, Massachusetts 02115.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Hirudins)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Female
MH  - Heparin/administration & dosage/therapeutic use
MH  - *Hirudin Therapy
MH  - Hirudins/administration & dosage
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/blood/*drug therapy
MH  - Partial Thromboplastin Time
MH  - Pilot Projects
MH  - Streptokinase/administration & dosage/*therapeutic use
MH  - *Thrombolytic Therapy
MH  - Treatment Outcome
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - S0002914999805177 [pii]
AID - 10.1016/s0002-9149(99)80517-7 [doi]
PST - ppublish
SO  - Am J Cardiol. 1995 Jan 1;75(1):7-13. doi: 10.1016/s0002-9149(99)80517-7.

PMID- 1687407
OWN - NLM
STAT- MEDLINE
DCOM- 19920604
LR  - 20190824
IS  - 0021-1265 (Print)
IS  - 0021-1265 (Linking)
VI  - 160
IP  - 11
DP  - 1991 Nov
TI  - Medical management of acute myocardial infarction in Ireland: information from 
      the Second International Study of Infarct Survival (ISIS-2).
PG  - 347-9
AB  - We report the management of the 831 patients from 18 hospitals which constituted 
      the Irish component of the 17,183 subjects enrolled in the ISIS-2 trial which 
      studied the effects of streptokinase infusion and aspirin therapy given to 
      patients presenting within 24 hours of the onset of suspected acute myocardial 
      infarction. 34% of Irish patients (IP) presented for treatment within 4 hours of 
      the development of symptoms. This compared to 44% of the overall group (OG) (p 
      less than 0.001). This represented the lowest percentage of patients presenting 
      within 4 hours in any of the participating countries. The mean delay time from 
      onset of symptoms was 7.9 hours in IP compared to 6.9 in OG (p less than 0.001). 
      The mean delay time in Ireland was longer than the mean delay time in any of the 
      participating countries. The mean age and systolic blood pressure at presentation 
      was similar in both groups. It was planned to treat 12% IP with aspirin compared 
      to 10% OG (p-NS), and 71% IP with subcutaneous heparin compared with 47% OG (p 
      less than 0.001). Intravenous heparin was planned treatment in 20% IP and 24% OG 
      (p less than 0.01). Planned oral anticoagulant therapy was similar in both groups 
      (p-NS). Planned use of intravenous betablockers occurred in only 2% IP and 6% OG 
      (p less than 0.001). 9% IP and 22% OG received steroids before streptokinase 
      infusion (p less than 0.001). 65% IP and 47% OG received subcutaneous heparin (p 
      less than 0.001). The use of intravenous heparin and oral anticoagulants was 
      similar in IP and OG (p-NS).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - MacGowan, G A
AU  - MacGowan GA
AD  - Department of Cardiology, Beaumont Hospital, Dublin.
FAU - O'Callaghan, D
AU  - O'Callaghan D
FAU - Horgan, J H
AU  - Horgan JH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Steroids)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Streptokinase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Ireland/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/epidemiology/mortality
MH  - Steroids/therapeutic use
MH  - Streptokinase/administration & dosage/*therapeutic use
MH  - Survival Rate
MH  - Time Factors
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
AID - 10.1007/BF02957892 [doi]
PST - ppublish
SO  - Ir J Med Sci. 1991 Nov;160(11):347-9. doi: 10.1007/BF02957892.

PMID- 34266464
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 22
IP  - 1
DP  - 2021 Jul 15
TI  - An RCT of a decision aid to support informed choices about taking aspirin to 
      prevent colorectal cancer and other chronic diseases: a study protocol for the 
      SITA (Should I Take Aspirin?) trial.
PG  - 452
LID - 10.1186/s13063-021-05365-8 [doi]
LID - 452
AB  - BACKGROUND: Australian guidelines recommend that all people aged 50-70 years old 
      actively consider taking daily low-dose aspirin (100-300 mg per day) for 2.5 to 
      5 years to reduce their risk of colorectal cancer (CRC). Despite the change of 
      national CRC prevention guidelines, there has been no active implementation of 
      the guidelines into clinical practice. We aim to test the efficacy of a health 
      consultation and decision aid, using a novel expected frequency tree (EFT) to 
      present the benefits and harms of low dose aspirin prior to a general practice 
      consultation with patients aged 50-70 years, on informed decision-making and 
      uptake of aspirin. METHODS: Approximately five to seven general practices in 
      Victoria, Australia, will be recruited to participate. Patients 50-70 years old, 
      attending an appointment with their general practitioner (GP) for any reason, 
      will be invited to participate in the trial. Two hundred fifty-eight eligible 
      participants will be randomly allocated 1:1 to intervention or active control 
      arms using a computer-generated allocation sequence stratified by general 
      practice, sex, and mode of trial delivery (face-to-face or teletrial). There are 
      two co-primary outcomes: informed decision-making at 1-month post randomisation, 
      measured by the Multi-dimensional Measure of Informed Choice (MMIC), and 
      self-reported daily use of aspirin at 6 months. Secondary outcomes include 
      decisional conflict at 1-month and other behavioural changes to reduce CRC risk 
      at both time points. DISCUSSION: This trial will test the efficacy of novel 
      methods for implementing national guidelines to support informed decision-making 
      about taking aspirin in 50-70-year-olds to reduce the risk of CRC and other 
      chronic diseases. TRIAL REGISTRATION: The Australian New Zealand Clinical Trials 
      Registry (ANZCTR) ACTRN12620001003965 . Registered on 10 October 2020.
CI  - © 2021. The Author(s).
FAU - Milton, Shakira
AU  - Milton S
AUID- ORCID: 0000-0002-8510-6351
AD  - Centre for Cancer Research, University of Melbourne, Melbourne, Australia. 
      shakira.milton@unimelb.edu.au.
AD  - Department of General Practice, University of Melbourne, Melbourne, Australia. 
      shakira.milton@unimelb.edu.au.
FAU - McIntosh, Jennifer
AU  - McIntosh J
AUID- ORCID: 0000-0002-6655-0940
AD  - Department of General Practice, University of Melbourne, Melbourne, Australia.
AD  - Department of Software Systems & Cybersecurity, Monash University, Melbourne, 
      Australia.
FAU - Macrae, Finlay
AU  - Macrae F
AD  - Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Melbourne, 
      Australia.
AD  - Department of Medicine, The University of Melbourne, Melbourne, Australia.
FAU - Chondros, Patty
AU  - Chondros P
AD  - Department of General Practice, University of Melbourne, Melbourne, Australia.
FAU - Trevena, Lyndal
AU  - Trevena L
AD  - Faculty of Medicine and Health, School of Public Health, The University of 
      Sydney, Sydney, Australia.
FAU - Jenkins, Mark
AU  - Jenkins M
AD  - Melbourne School of Population and Global Health, University of Melbourne, 
      Melbourne, Australia.
FAU - Walter, Fiona M
AU  - Walter FM
AD  - Department of General Practice, University of Melbourne, Melbourne, Australia.
AD  - The Primary Care Unit, University of Cambridge, Cambridge, UK.
FAU - Taylor, Natalie
AU  - Taylor N
AD  - Behavioral and Implementation Research and Evaluation, Cancer Council NSW, New 
      South Wales, Australia.
AD  - Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
FAU - Boyd, Lucy
AU  - Boyd L
AD  - Centre for Cancer Research, University of Melbourne, Melbourne, Australia.
AD  - Department of General Practice, University of Melbourne, Melbourne, Australia.
FAU - Saya, Sibel
AU  - Saya S
AUID- ORCID: 0000-0002-4796-6852
AD  - Centre for Cancer Research, University of Melbourne, Melbourne, Australia.
AD  - Department of General Practice, University of Melbourne, Melbourne, Australia.
FAU - Karnchanachari, Napin
AU  - Karnchanachari N
AD  - Centre for Cancer Research, University of Melbourne, Melbourne, Australia.
AD  - Department of General Practice, University of Melbourne, Melbourne, Australia.
FAU - Novy, Kitty
AU  - Novy K
AD  - Centre for Cancer Research, University of Melbourne, Melbourne, Australia.
AD  - Department of General Practice, University of Melbourne, Melbourne, Australia.
FAU - Forbes, Carmody
AU  - Forbes C
AD  - Centre for Cancer Research, University of Melbourne, Melbourne, Australia.
AD  - Department of General Practice, University of Melbourne, Melbourne, Australia.
FAU - Gutierrez, Javiera Martinez
AU  - Gutierrez JM
AD  - Centre for Cancer Research, University of Melbourne, Melbourne, Australia.
AD  - Department of General Practice, University of Melbourne, Melbourne, Australia.
AD  - Department of Family Medicine, School of Medicine, Pontificia Universidad 
      Católica de Chile, Santiago, Chile.
FAU - Broun, Kate
AU  - Broun K
AD  - Early Detection and Immunisation, Prevention Department, Cancer Council Victoria, 
      Melbourne, Australia.
FAU - Whitburn, Sara
AU  - Whitburn S
AD  - Belmore Road Medical Clinic, Melbourne, Australia.
FAU - McGill, Sarah
AU  - McGill S
AD  - Cancer Screening and Prevention, Cancer Institute NSW, St Leonards, Australia.
FAU - Fishman, George
AU  - Fishman G
AD  - Primary Care Collaborative Cancer Clinical Trials Group (PC4), Community Advisory 
      Group, University of Melbourne, Melbourne, Australia.
FAU - Marker, Julie
AU  - Marker J
AD  - Primary Care Collaborative Cancer Clinical Trials Group (PC4), Community Advisory 
      Group, University of Melbourne, Melbourne, Australia.
FAU - Shub, Max
AU  - Shub M
AD  - Primary Care Collaborative Cancer Clinical Trials Group (PC4), Community Advisory 
      Group, University of Melbourne, Melbourne, Australia.
FAU - Emery, Jon
AU  - Emery J
AUID- ORCID: 0000-0002-5274-6336
AD  - Centre for Cancer Research, University of Melbourne, Melbourne, Australia.
AD  - Department of General Practice, University of Melbourne, Melbourne, Australia.
AD  - The Primary Care Unit, University of Cambridge, Cambridge, UK.
LA  - eng
GR  - CPSRG19011/Victorian Cancer Agency/
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20210715
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - *Aspirin/adverse effects
MH  - Chronic Disease
MH  - *Colorectal Neoplasms/diagnosis/prevention & control
MH  - Decision Support Techniques
MH  - Humans
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Victoria
PMC - PMC8280579
OTO - NOTNLM
OT  - Aspirin
OT  - Bowel cancer
OT  - Cancer prevention
OT  - Chemoprevention
OT  - Colorectal cancer
OT  - Decision Aid
OT  - General practice
OT  - Guideline implementation
OT  - Informed decision making
OT  - Preventive medicine
OT  - Primary care
COIS- JE, MJ and FM were members of the Cancer Council Australia guideline development 
      group which recommends the use of low dose aspirin for the prevention of CRC.
EDAT- 2021/07/17 06:00
MHDA- 2021/07/20 06:00
CRDT- 2021/07/16 05:37
PHST- 2021/04/08 00:00 [received]
PHST- 2021/06/09 00:00 [accepted]
PHST- 2021/07/16 05:37 [entrez]
PHST- 2021/07/17 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
AID - 10.1186/s13063-021-05365-8 [pii]
AID - 5365 [pii]
AID - 10.1186/s13063-021-05365-8 [doi]
PST - epublish
SO  - Trials. 2021 Jul 15;22(1):452. doi: 10.1186/s13063-021-05365-8.

PMID- 11786451
OWN - NLM
STAT- MEDLINE
DCOM- 20020207
LR  - 20220408
IS  - 0959-8138 (Print)
IS  - 1468-5833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 324
IP  - 7329
DP  - 2002 Jan 12
TI  - Collaborative meta-analysis of randomised trials of antiplatelet therapy for 
      prevention of death, myocardial infarction, and stroke in high risk patients.
PG  - 71-86
AB  - OBJECTIVE: To determine the effects of antiplatelet therapy among patients at 
      high risk of occlusive vascular events. DESIGN: Collaborative meta-analyses 
      (systematic overviews). INCLUSION CRITERIA: Randomised trials of an antiplatelet 
      regimen versus control or of one antiplatelet regimen versus another in high risk 
      patients (with acute or previous vascular disease or some other predisposing 
      condition) from which results were available before September 1997. Trials had to 
      use a method of randomisation that precluded prior knowledge of the next 
      treatment to be allocated and comparisons had to be unconfounded-that is, have 
      study groups that differed only in terms of antiplatelet regimen. STUDIES 
      REVIEWED: 287 studies involving 135 000 patients in comparisons of antiplatelet 
      therapy versus control and 77 000 in comparisons of different antiplatelet 
      regimens. MAIN OUTCOME MEASURE: "Serious vascular event": non-fatal myocardial 
      infarction, non-fatal stroke, or vascular death. RESULTS: Overall, among these 
      high risk patients, allocation to antiplatelet therapy reduced the combined 
      outcome of any serious vascular event by about one quarter; non-fatal myocardial 
      infarction was reduced by one third, non-fatal stroke by one quarter, and 
      vascular mortality by one sixth (with no apparent adverse effect on other 
      deaths). Absolute reductions in the risk of having a serious vascular event were 
      36 (SE 5) per 1000 treated for two years among patients with previous myocardial 
      infarction; 38 (5) per 1000 patients treated for one month among patients with 
      acute myocardial infarction; 36 (6) per 1000 treated for two years among those 
      with previous stroke or transient ischaemic attack; 9 (3) per 1000 treated for 
      three weeks among those with acute stroke; and 22 (3) per 1000 treated for two 
      years among other high risk patients (with separately significant results for 
      those with stable angina (P=0.0005), peripheral arterial disease (P=0.004), and 
      atrial fibrillation (P=0.01)). In each of these high risk categories, the 
      absolute benefits substantially outweighed the absolute risks of major 
      extracranial bleeding. Aspirin was the most widely studied antiplatelet drug, 
      with doses of 75-150 mg daily at least as effective as higher daily doses. The 
      effects of doses lower than 75 mg daily were less certain. Clopidogrel reduced 
      serious vascular events by 10% (4%) compared with aspirin, which was similar to 
      the 12% (7%) reduction observed with its analogue ticlopidine. Addition of 
      dipyridamole to aspirin produced no significant further reduction in vascular 
      events compared with aspirin alone. Among patients at high risk of immediate 
      coronary occlusion, short term addition of an intravenous glycoprotein IIb/IIIa 
      antagonist to aspirin prevented a further 20 (4) vascular events per 1000 
      (P<0.0001) but caused 23 major (but rarely fatal) extracranial bleeds per 1000. 
      CONCLUSIONS: Aspirin (or another oral antiplatelet drug) is protective in most 
      types of patient at increased risk of occlusive vascular events, including those 
      with an acute myocardial infarction or ischaemic stroke, unstable or stable 
      angina, previous myocardial infarction, stroke or cerebral ischaemia, peripheral 
      arterial disease, or atrial fibrillation. Low dose aspirin (75-150 mg daily) is 
      an effective antiplatelet regimen for long term use, but in acute settings an 
      initial loading dose of at least 150 mg aspirin may be required. Adding a second 
      antiplatelet drug to aspirin may produce additional benefits in some clinical 
      circumstances, but more research into this strategy is needed.
CN  - Antithrombotic Trialists' Collaboration
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - BMJ 2002 Jan 19;324(7330):141
CIN - BMJ. 2002 Jan 12;324(7329):103-5. PMID: 11786458
CIN - BMJ. 2002 Jan 19;324(7330):167. PMID: 11799038
CIN - ACP J Club. 2002 Jul-Aug;137(1):5. PMID: 12093204
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/mortality/prevention & control
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Stroke/*prevention & control
PMC - PMC64503
EDAT- 2002/01/12 10:00
MHDA- 2002/02/08 10:01
CRDT- 2002/01/12 10:00
PHST- 2002/01/12 10:00 [pubmed]
PHST- 2002/02/08 10:01 [medline]
PHST- 2002/01/12 10:00 [entrez]
AID - 10.1136/bmj.324.7329.71 [doi]
PST - ppublish
SO  - BMJ. 2002 Jan 12;324(7329):71-86. doi: 10.1136/bmj.324.7329.71.

PMID- 1351917
OWN - NLM
STAT- MEDLINE
DCOM- 19920727
LR  - 20131121
IS  - 0024-6921 (Print)
IS  - 0024-6921 (Linking)
VI  - 144
IP  - 5
DP  - 1992 May
TI  - Pharmacologic adjunctive therapy for acute myocardial infarction.
PG  - 223-6
AB  - Thrombolysis and PTCA offer reperfusion for limiting infarct size and reducing 
      mortality in acute myocardial infarction patients. Heparin, aspirin, nitrates, 
      beta-blockers and calcium antagonists are very important in supplementing these 
      two primary reperfusion modes. The adjunctive role of these five pharmacologic 
      agents is discussed.
FAU - Landreneau, J W
AU  - Landreneau JW
AD  - St Frances Cabrini Hospital, Alexandria, LA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J La State Med Soc
JT  - The Journal of the Louisiana State Medical Society : official organ of the 
      Louisiana State Medical Society
JID - 7505618
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Calcium Channel Blockers)
RN  - 9005-49-6 (Heparin)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Calcium Channel Blockers/therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy/therapy
MH  - Nitroglycerin/therapeutic use
RF  - 27
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
PST - ppublish
SO  - J La State Med Soc. 1992 May;144(5):223-6.

PMID- 12124453
OWN - NLM
STAT- MEDLINE
DCOM- 20020829
LR  - 20200219
IS  - 0022-1317 (Print)
IS  - 0022-1317 (Linking)
VI  - 83
IP  - Pt 8
DP  - 2002 Aug
TI  - Suppression of Japanese encephalitis virus infection by non-steroidal 
      anti-inflammatory drugs.
PG  - 1897-1905
LID - 10.1099/0022-1317-83-8-1897 [doi]
AB  - Japanese encephalitis virus (JEV) infection generates a rapid inflammatory 
      response including peripheral neutrophil leucocytosis and infiltration of 
      neutrophils into extraneural tissue. The level of inflammation correlates well 
      with the clinical outcome in Japanese encephalitis patients. Non-steroidal 
      anti-inflammatory drugs (NSAIDs), used medicinally for their analgesic and 
      anti-inflammatory properties, are being considered for prevention of 
      cardiovascular disease and cancer, as well as for treatment of human 
      immunodeficiency virus infection. Apart from their ability to inhibit 
      prostaglandin synthesis, the mechanisms underlying the beneficial therapeutic 
      effects are largely unknown. We used aspirin, indomethacin and sodium salicylate 
      to study the role of NSAIDs in JEV propagation in vitro. We found that NSAIDs 
      suppressed JEV propagation in neuronal and non-neuronal cells. Blockade of 
      cyclooxygenase activity by NSAIDs caused decreased production of free radicals 
      and prostaglandins. However, these pharmacological alterations did not seem to 
      correlate well with the antiviral effects. When cells were treated with the 
      mitogen-activated protein kinase (MAPK) inhibitors PD 98059 and SB 203580, 
      salicylate lost its antiviral effect. The activation of MAPK by anisomycin 
      mimicked the action of salicylate in suppressing JEV-induced cytotoxicity. The 
      decreased phosphorylation of extracellular signal-regulated kinase (ERK) was 
      induced by JEV infection and the decrease in ERK was reversed by salicylate. Our 
      data suggest that the signalling pathways of MAPK play a role in the antiviral 
      action of salicylate.
FAU - Chen, Chun-Jung
AU  - Chen CJ
AD  - Department of Education and Research, Taichung Veterans General Hospital, 
      Taichung, Taiwan, Republic of China1.
FAU - Raung, Shue-Ling
AU  - Raung SL
AD  - Department of Education and Research, Taichung Veterans General Hospital, 
      Taichung, Taiwan, Republic of China1.
FAU - Kuo, Ming-Der
AU  - Kuo MD
AD  - Institute of Preventive Medicine, National Defence Medical Center, Taipei, 
      Taiwan, Republic of China2.
FAU - Wang, Yu-Ming
AU  - Wang YM
AD  - Institute of Preventive Medicine, National Defence Medical Center, Taipei, 
      Taiwan, Republic of China2.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Gen Virol
JT  - The Journal of general virology
JID - 0077340
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Prostaglandins)
RN  - 0 (Reactive Oxygen Species)
RN  - EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use/toxicity
MH  - Aspirin/pharmacology/therapeutic use/toxicity
MH  - Cell Line
MH  - Cricetinae
MH  - Cytopathogenic Effect, Viral/drug effects
MH  - Encephalitis Virus, Japanese/*drug effects/physiology
MH  - Indomethacin/pharmacology/therapeutic use/toxicity
MH  - Mice
MH  - Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors
MH  - Neurons
MH  - Prostaglandins/metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Sodium Salicylate/pharmacology/therapeutic use/toxicity
MH  - Tumor Cells, Cultured
MH  - Virus Replication/*drug effects
EDAT- 2002/07/19 10:00
MHDA- 2002/08/30 10:01
CRDT- 2002/07/19 10:00
PHST- 2002/07/19 10:00 [pubmed]
PHST- 2002/08/30 10:01 [medline]
PHST- 2002/07/19 10:00 [entrez]
AID - 10.1099/0022-1317-83-8-1897 [doi]
PST - ppublish
SO  - J Gen Virol. 2002 Aug;83(Pt 8):1897-1905. doi: 10.1099/0022-1317-83-8-1897.

PMID- 3354028
OWN - NLM
STAT- MEDLINE
DCOM- 19880502
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 19
IP  - 3
DP  - 1988 Mar
TI  - Medical treatment of transient ischemic attacks: does it influence mortality?
PG  - 397-400
AB  - All randomized studies published on the medical treatment of transient ischemic 
      attacks in which controls received no treatment or placebo and in which mortality 
      was reported were reviewed. Using the odds ratio method, we analyzed the results 
      to determine if treatment had an effect on expected mortality. Studies were 
      analyzed separately according to the treatment modality used. Chronic 
      anticoagulation was used in four studies and platelet inhibitors in 12 (14 
      trials). This meta-analysis showed that neither treatment modality significantly 
      reduces mortality. Chronic anticoagulation may have an adverse effect, and even 
      though platelet inhibitors appeared to reduce mortality, no significance can be 
      demonstrated, and the 95% confidence intervals did not allow us to rule out the 
      possibility, albeit small, of an adverse effect or no effect at all.
FAU - Ramirez-Lassepas, M
AU  - Ramirez-Lassepas M
AD  - Department of Neurology, St. Paul-Ramsey Medical Center, MN 55101.
FAU - Cipolle, R J
AU  - Cipolle RJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/mortality
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Statistics as Topic
MH  - Time Factors
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
AID - 10.1161/01.str.19.3.397 [doi]
PST - ppublish
SO  - Stroke. 1988 Mar;19(3):397-400. doi: 10.1161/01.str.19.3.397.

PMID- 11680809
OWN - NLM
STAT- MEDLINE
DCOM- 20020314
LR  - 20191105
IS  - 0014-827X (Print)
IS  - 0014-827X (Linking)
VI  - 56
IP  - 9
DP  - 2001 Sep
TI  - pH-Metric log K calculations of famotidine, naproxen, nizatidine, ranitidine and 
      salicylic acid.
PG  - 659-63
AB  - The octanol/water partition coefficient (log K) is one of the most commonly used 
      parameters in structure-activity relationships in many areas such as drug design 
      (including pesticides), pharmacokinetics, anesthesiology, environmental sciences, 
      toxicology, bioaccumulation and predicting skin permeability as a predictive 
      parameter. log K is generally determined using shake flask method, but the 
      possibility of calculating log K using pH-metric titrations and half 
      neutralization points is demonstrated in this study. The potentiometric pH 
      titration technique has been developed as an automatic technique for log K 
      determination but it can be achieved by manual titrations. This technique uses 
      the pKa of the substance. The pKa of the substance shifts pK'a when the titration 
      is repeated in the presence of octanol. log K value of the substance can be 
      determined using pKa, pK'a values and relevant equation. The aim of the study was 
      to determine the log K values of a series of compounds using pH-metric titrations 
      and to compare pH-metric log K determination results with the other methods. The 
      log K values of famotidine, naproxen, nizatidine, ranitidine and salicylic acid 
      were determined using both shake flask method and potentiometric titrations. 
      Their log K values were also calculated theoretically using computer program and 
      all results were compared. The pH-metric log K values were found to be close to 
      the shake flask method results. This method was found to be useful for the 
      determination of log K values as it provides a high degree of accuracy even in 
      the presence of titratable impurities in the solution.
FAU - Degim, T
AU  - Degim T
AD  - University of Gazi, Faculty of Pharmacy, Department of Pharmaceutical Technology, 
      Ankara, Turkey. tunc@tr.net
FAU - Zaimoglu, V
AU  - Zaimoglu V
FAU - Akay, C
AU  - Akay C
FAU - Degim, Z
AU  - Degim Z
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - France
TA  - Farmaco
JT  - Farmaco (Societa chimica italiana : 1989)
JID - 8912641
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 57Y76R9ATQ (Naproxen)
RN  - 5QZO15J2Z8 (Famotidine)
RN  - 884KT10YB7 (Ranitidine)
RN  - P41PML4GHR (Nizatidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*chemistry
MH  - Anti-Ulcer Agents/*chemistry
MH  - Aspirin/chemistry
MH  - Chromatography, High Pressure Liquid
MH  - Computers
MH  - Famotidine/chemistry
MH  - Hydrogen-Ion Concentration
MH  - Naproxen/chemistry
MH  - Nizatidine/chemistry
MH  - Ranitidine/chemistry
MH  - Structure-Activity Relationship
EDAT- 2001/10/30 10:00
MHDA- 2002/03/15 10:01
CRDT- 2001/10/30 10:00
PHST- 2001/10/30 10:00 [pubmed]
PHST- 2002/03/15 10:01 [medline]
PHST- 2001/10/30 10:00 [entrez]
AID - S0014-827X(01)01114-4 [pii]
AID - 10.1016/s0014-827x(01)01114-4 [doi]
PST - ppublish
SO  - Farmaco. 2001 Sep;56(9):659-63. doi: 10.1016/s0014-827x(01)01114-4.

PMID- 8081987
OWN - NLM
STAT- MEDLINE
DCOM- 19941013
LR  - 20131121
IS  - 1018-7782 (Print)
IS  - 1018-7782 (Linking)
VI  - 1
IP  - 6
DP  - 1993 Nov-Dec
TI  - Effects of nonsteroidal anti-inflammatory drugs upon intrarenal blood flow: 
      selective medullary hypoperfusion.
PG  - 357-63
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) predispose to acute and chronic 
      renal failure, possibly due to intrarenal hemodynamic effects. In anesthetized 
      volume-expanded rats, total renal blood flow (RBF) was measured by an ultrasonic 
      flowmeter placed around the left renal artery, superficial cortical blood flow 
      (sCBF) by a flunt laser-Doppler probe placed over the kidney surface, 
      mid-cortical (mCBF) and outer medullary blood flow (oMBF) by a needle 
      laser-Doppler probe inserted into the renal parenchyma. Indomethacin (5 mg/kg 
      i.v.) caused no significant change in RBF (n = 9) or mCBF (n = 6) and slightly 
      increased sCBF (to 106 +/- 2% of baseline; n = 8, p < 0.05). By contrast, oMBF 
      dropped significantly (to 55 +/- 4% of baseline; n = 8, p < 0.0001) within 30 min 
      of indomethacin administration. Similarly, acetylsalicylate (50 mg/kg i.v.) 
      slightly increased sCBF (to 110 +/- 3% of baseline; n = 5, p < 0.05) but caused a 
      significant drop in oMBF (to 54 +/- 2% of baseline; n = 5, p < 0.0001). These 
      results suggest that NSAIDs cause a profound and selective reduction in oMBF 
      which may predispose to acute or chronic intrarenal damage by aggravating 
      medullary hypoxia.
FAU - Agmon, Y
AU  - Agmon Y
AD  - Department of Medicine, Hadassah University Hospital, Mount Scopus, Jerusalem, 
      Israel.
FAU - Brezis, M
AU  - Brezis M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Exp Nephrol
JT  - Experimental nephrology
JID - 9302239
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/pharmacology
MH  - Hemodynamics/drug effects
MH  - Indomethacin/pharmacology
MH  - Kidney Medulla/*blood supply
MH  - Laser-Doppler Flowmetry
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Renal Circulation/*drug effects
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PST - ppublish
SO  - Exp Nephrol. 1993 Nov-Dec;1(6):357-63.

PMID- 8403942
OWN - NLM
STAT- MEDLINE
DCOM- 19931123
LR  - 20131121
IS  - 0010-8650 (Print)
IS  - 0010-8650 (Linking)
VI  - 35
IP  - 4
DP  - 1993
TI  - [The effect of indobufen on aortocoronary bypass patency after 1 week and after 1 
      year].
PG  - 162-4
AB  - A randomized clinical study was conducted to compare the effect of "conventional" 
      antiaggregation therapy (ASA plus dipyridamole) versus indobufen in patients 
      after aortocoronary bypass (ACB) surgery. The patency of venous ACB using 
      coronary DSA one week and one year after surgery was evaluated in 52 patients 
      divided into two groups. The study included only ACB's with intraoperative blood 
      flow rates < or = 40 ml/min as it is just these ACB's which are at the highest 
      risk of early and late occlusions. While, in the ASA plus dipyridamole-treated 
      group, occlusions were found in 11 of the 39 reconstructions (28.2%), the 
      proportion was nine out of 37 procedures (24.3%) in the indobufen group. One year 
      after surgery, occlusion was found in 14 out of 32 ACB's (43.7%) in the ASA plus 
      dipyridamole group compared to 14 occlusions in 31 ACB's (45.2%) in the indobufen 
      group. The difference in the number of occlusions between the two groups was not 
      statistically significant. Because of some benefits of indobufen compared to ASA 
      (shorter time of effect, superior tolerance in patients with ulceration), the 
      former drug can be recommended for use in some indicated cases.
FAU - Rohn, V
AU  - Rohn V
AD  - Klinika kardiovaskulární a transplantacní chirurgie, Institut klinické a 
      experimentální medicíny, Praha, Ceská republika.
FAU - Pirk, J
AU  - Pirk J
FAU - Mach, T
AU  - Mach T
LA  - cze
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Vliv indobufenu na průchodnost aortokoronárních bypassů po týdnu a po jednom 
      roce.
PL  - Czech Republic
TA  - Cor Vasa
JT  - Cor et vasa
JID - 0372614
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 6T9949G4LZ (indobufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - *Coronary Artery Bypass
MH  - Dipyridamole/therapeutic use
MH  - Female
MH  - Graft Occlusion, Vascular/prevention & control
MH  - Humans
MH  - Isoindoles
MH  - Male
MH  - Middle Aged
MH  - Phenylbutyrates/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Time Factors
MH  - Vascular Patency/*drug effects
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Cor Vasa. 1993;35(4):162-4.

PMID- 11010750
OWN - NLM
STAT- MEDLINE
DCOM- 20000922
LR  - 20131121
IS  - 1167-7422 (Print)
IS  - 1167-7422 (Linking)
VI  - 9
IP  - 47
DP  - 2000 Jun
TI  - Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and 
      secondary prevention.
PG  - 85-7
AB  - (1) In the acute phase of ischaemic stroke in patients free of thrombogenic heart 
      disease, combined treatment with aspirin + moderate-dose unfractionated heparin 
      reduces the risk of relapse and death. Unfractionated heparin at higher 
      anticoagulant doses has an unfavourable risk-benefit ratio. Treatment is 
      controversial in patients with events associated with atrial fibrillation. (2) 
      After ischaemic stroke in patients free of thrombogenic heart disease, aspirin 
      reduces the risk of relapse and death. Other antiplatelet drugs, the aspirin + 
      dipyridamole combination, ticlopidine and clopidogrel have similar efficacy to 
      aspirin. (3) The risk-benefit ratio of oral anticoagulant is favourable after 
      ischaemic stroke associated with atrial fibrillation; but it is unfavourable 
      after stroke without thrombogenic heart disease.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Prescrire Int
JT  - Prescrire international
JID - 9439295
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 9005-49-6 (Heparin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Arrhythmia, Sinus
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Atrial Fibrillation
MH  - Cost-Benefit Analysis
MH  - Dipyridamole/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Heparin/administration & dosage/therapeutic use
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - *Stroke/drug therapy/prevention & control
MH  - Ticlopidine/administration & dosage/antagonists & inhibitors/therapeutic use
EDAT- 2000/09/30 11:00
MHDA- 2000/09/30 11:01
CRDT- 2000/09/30 11:00
PHST- 2000/09/30 11:00 [pubmed]
PHST- 2000/09/30 11:01 [medline]
PHST- 2000/09/30 11:00 [entrez]
PST - ppublish
SO  - Prescrire Int. 2000 Jun;9(47):85-7.

PMID- 28959488
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20220408
IS  - 2059-8688 (Print)
IS  - 2059-8696 (Electronic)
IS  - 2059-8688 (Linking)
VI  - 2
IP  - 1
DP  - 2017 Mar
TI  - Review of acute ischaemic stroke in Pakistan: progress in management and future 
      perspectives.
PG  - 30-39
LID - 10.1136/svn-2016-000041 [doi]
AB  - Ischaemic stroke is a major cause of neurological morbidity and mortality. The 
      objective of this review article is to summarise facts pertaining to acute 
      ischaemic stroke and its various aspects in a developing country like Pakistan, 
      where resources are limited and the healthcare system is underdeveloped. No 
      large-scale epidemiological studies are available to determine the true incidence 
      of stroke in Pakistan. We reviewed the available literature on stroke from 
      Pakistan and through this article we primarily aim to present the current acute 
      ischaemic stroke management in Pakistan in juxtaposition to that of the developed 
      world. We also intend to highlight areas for future development and improvement 
      in management. The routine practice in Pakistan is that of using stat dose of 
      aspirin in emergency (ER) at large with only a handful of centres offering 
      thrombolytic therapy with recombinant tissue plasminogen activator for acute 
      ischaemic stroke. This too is faced with the problem of long window periods 
      before the patient reaches a proper stroke care centre. The facilities of 
      interventional therapies like arterial thrombolysis and endovascular surgery are 
      non-existent and rehabilitation facilities limited. The opportunities for 
      training physicians in acute stroke are also scarce. Stroke in children is 
      underdiagnosed and that in women not availing facilities at stroke care centres. 
      While basic research has gained pace regarding local demographic data, advanced 
      research and genetic studies are extremely limited. The field of stroke neurology 
      needs to grow at a substantial pace in Pakistan to be at par with the developed 
      world.
FAU - Nomani, Ali Zohair
AU  - Nomani AZ
AD  - Department of Neurology, Pakistan Institute of Medical Sciences, Islamabad, 
      Pakistan.
FAU - Nabi, Sumaira
AU  - Nabi S
AD  - Department of Neurology, Pakistan Institute of Medical Sciences, Islamabad, 
      Pakistan.
FAU - Badshah, Mazhar
AU  - Badshah M
AD  - Department of Neurology, Pakistan Institute of Medical Sciences, Islamabad, 
      Pakistan.
FAU - Ahmed, Shahzad
AU  - Ahmed S
AD  - Department of Neurology, Pakistan Institute of Medical Sciences, Islamabad, 
      Pakistan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170224
PL  - England
TA  - Stroke Vasc Neurol
JT  - Stroke and vascular neurology
JID - 101689996
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Diffusion of Innovation
MH  - *Endovascular Procedures/adverse effects/trends
MH  - Forecasting
MH  - *Health Services Accessibility/trends
MH  - Humans
MH  - Ischemic Stroke/diagnosis/epidemiology/*therapy
MH  - Pakistan/epidemiology
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - *Thrombolytic Therapy/adverse effects/trends
MH  - Time-to-Treatment
MH  - Treatment Outcome
PMC - PMC5435212
OTO - NOTNLM
OT  - Cerebrovascular accident
OT  - Pakistan stroke management.
OT  - acute ischemic stroke
OT  - recombinant tissue Plasminogen Activator
OT  - window period
COIS- Competing interests: None declared.
EDAT- 2017/09/30 06:00
MHDA- 2017/09/30 06:01
CRDT- 2017/09/30 06:00
PHST- 2016/09/02 00:00 [received]
PHST- 2016/12/16 00:00 [revised]
PHST- 2017/01/05 00:00 [accepted]
PHST- 2017/09/30 06:00 [entrez]
PHST- 2017/09/30 06:00 [pubmed]
PHST- 2017/09/30 06:01 [medline]
AID - svn-2016-000041 [pii]
AID - 10.1136/svn-2016-000041 [doi]
PST - epublish
SO  - Stroke Vasc Neurol. 2017 Feb 24;2(1):30-39. doi: 10.1136/svn-2016-000041. 
      eCollection 2017 Mar.

PMID- 20580997
OWN - NLM
STAT- MEDLINE
DCOM- 20101019
LR  - 20220330
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 17
IP  - 8
DP  - 2010 Aug
TI  - The influence of preoperative anticoagulation on outcome and quality of life 
      after surgical treatment of chronic subdural hematoma.
PG  - 975-9
LID - 10.1016/j.jocn.2009.11.023 [doi]
AB  - The main aim of this study was to investigate the influence of perioperative 
      anticoagulation on the clinical course and outcome of 144 patients who underwent 
      surgery for chronic subdural hematoma (CSDH). The outcome was categorized 
      according to the modified Rankin Scale (mRS), Barthel Index and postoperative 
      quality of life (QoL) scale. There was a significant correlation between 
      preoperative aspirin medication and reoperation (Mann-Whitney U-test, p<0.05). 
      Moreover, dosage and duration of postoperative low-molecular-weight heparin 
      (LMWH) administration were associated with a higher risk of reoperation 
      (Mann-Whitney U-test, p<0.01) and a worse outcome on the mRS (Mann-Whitney 
      U-test, p<0.05). Intraoperative treatment with prothrombin complex concentrate 
      led to a poor outcome on the mRS (Craddock-Flood test, p<0.05). Reoperation is 
      the strongest predictive factor of a poor QoL after surgical treatment of CSDH. 
      Both preoperative and postoperative anticoagulation treatment may affect 
      reoperation rate and, thus, postoperative QoL.
CI  - Copyright 2010 Elsevier Ltd. All rights reserved.
FAU - Forster, M T
AU  - Forster MT
AD  - Department of Neurosurgery, Goethe University Frankfurt am Main, Schleusenweg 
      2-16, D-60528 Frankfurt am Main, Germany. 
      marie-therese.forster@med.uni-frankfurt.de
FAU - Mathé, A K
AU  - Mathé AK
FAU - Senft, C
AU  - Senft C
FAU - Scharrer, I
AU  - Scharrer I
FAU - Seifert, V
AU  - Seifert V
FAU - Gerlach, R
AU  - Gerlach R
LA  - eng
PT  - Journal Article
DEP - 20100523
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Chi-Square Distribution
MH  - Female
MH  - Follow-Up Studies
MH  - Hematoma, Subdural, Chronic/*drug therapy/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Recurrence
MH  - Retrospective Studies
MH  - Statistics, Nonparametric
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2010/06/29 06:00
MHDA- 2010/10/20 06:00
CRDT- 2010/06/29 06:00
PHST- 2009/10/26 00:00 [received]
PHST- 2009/11/23 00:00 [revised]
PHST- 2009/11/24 00:00 [accepted]
PHST- 2010/06/29 06:00 [entrez]
PHST- 2010/06/29 06:00 [pubmed]
PHST- 2010/10/20 06:00 [medline]
AID - S0967-5868(10)00078-0 [pii]
AID - 10.1016/j.jocn.2009.11.023 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2010 Aug;17(8):975-9. doi: 10.1016/j.jocn.2009.11.023. Epub 2010 
      May 23.

PMID- 9018646
OWN - NLM
STAT- MEDLINE
DCOM- 19970502
LR  - 20131121
IS  - 0024-7758 (Print)
IS  - 0024-7758 (Linking)
VI  - 42
IP  - 1
DP  - 1997 Jan
TI  - Pregnancy outcome. Influence of antiphospholipid antibody titer, prior pregnancy 
      losses and treatment.
PG  - 49-55
AB  - OBJECTIVE: To evaluate the effectiveness of combination therapy in preventing 
      fetal loss in women with circulating antiphospholipid antibodies and a previous 
      history of adverse pregnancy outcomes. STUDY DESIGN: We identified 18 pregnant 
      women with antiphospholipid antibodies who had a total of 59 prior pregnancies. 
      Of these pregnancies, spontaneous first-trimester abortions occurred in 36 
      (61.0%); fetal demise after the first trimester occurred in 9 (15.2%); voluntary 
      terminations were elected in seven (11.9%) pregnancies; and there were seven 
      (11.9%) surviving infants. During their next pregnancies, these patients were 
      treated with prednisone and/or low-dose aspirin. RESULTS: Fourteen patients 
      delivered successfully between 33 and 39 weeks' gestation, resulting in a live 
      birth rate of 77.8% and a pregnancy loss rate of 22.2%. We also observed an 
      association between the number of prior fetal losses, the anticardiolipin 
      antibody titer and the fetal survival rate following therapy. Two or more prior 
      fetal losses and high autoantibody titer resulted in a fetal survival rate of 
      50-75% with varying therapeutic regimens and dosages. However, an improved fetal 
      survival rate of 75-100% was observed with less than two prior fetal losses and 
      low-mid anticardiolipin antibody titer with the same therapy. CONCLUSION: 
      Therefore, the results of this study suggest that although pharmacologic 
      prophylaxis improves the outcome of pregnancies complicated by circulating 
      antiphospholipid antibodies, such an outcome is influenced by the number of prior 
      fetal losses and the anticardiolipin antibody titer.
FAU - Reece, E A
AU  - Reece EA
AD  - Department of Obstetrics, Temple University School of Medicine, Philadelphia, 
      Pennsylvania 19140, USA.
FAU - Garofalo, J
AU  - Garofalo J
FAU - Zheng, X Z
AU  - Zheng XZ
FAU - Assimakopoulos, E
AU  - Assimakopoulos E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Reprod Med
JT  - The Journal of reproductive medicine
JID - 0173343
RN  - 0 (Antibodies, Antiphospholipid)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Abortion, Spontaneous/etiology/prevention & control
MH  - Adult
MH  - Antibodies, Antiphospholipid/*blood
MH  - Antiphospholipid Syndrome/blood/complications/*drug therapy
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Female
MH  - Fetal Death/etiology/prevention & control
MH  - Humans
MH  - Prednisone/administration & dosage/therapeutic use
MH  - Pregnancy
MH  - *Pregnancy Outcome
MH  - Prospective Studies
MH  - Treatment Outcome
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - J Reprod Med. 1997 Jan;42(1):49-55.

PMID- 34449467
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 34
DP  - 2021 Aug 27
TI  - Safety of transrectal ultrasound-guided prostate biopsy in patients receiving 
      aspirin: An update meta-analysis including 3373 patients.
PG  - e26985
LID - 10.1097/MD.0000000000026985 [doi]
LID - e26985
AB  - BACKGROUND: The management of aspirin before transrectal prostate puncture-guided 
      biopsy continues to be controversial. The conclusions in newly published studies 
      differ from the published guideline. Therefore, an updated meta-analysis was 
      performed to assess the safety of continuing to take aspirin when undergoing a 
      transrectal ultrasound-guided prostate biopsy (TRUS-PB). METHODS: We searched the 
      following databases for relevant literature from their inception to October 30, 
      2020: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Medline, 
      Web of Science, Sinomed, Chinese National Knowledge Internet, and WANGFANG. 
      Studies that compared the bleeding rates between aspirin that took aspirin and 
      non-aspirin groups were included. The quality of all included studies was 
      evaluated using the Newcastle-Ottawa Scale. Revman Manger version 5.2 software 
      was employed to complete the meta-analysis to assess the risk of hematuria, 
      hematospermia, and rectal bleeding. RESULTS: Six articles involving 3373 patients 
      were included in this meta-analysis. Our study revealed that compared with the 
      non-aspirin group, those taking aspirin exhibited a higher risk of rectal 
      bleeding after TRUS-PB (risk ratio [RR] = 1.27, 95% confidence interval [CI] 
      [1.09-1.49], P = .002). Also, the meta-analysis results did not reveal any 
      significant difference between the 2 groups for the risk of hematuria (RR = 1.02, 
      95%CI [0.91-1.16], P = .71) and hematospermia (RR = 0.93, 95%CI [0.82-1.06], 
      P = .29). CONCLUSION: Taking aspirin does not increase the risk of hematuria and 
      hematospermia after TRUS-PB. However, the risk of rectal bleeding, which was 
      slight and self-limiting, did increase. We concluded that it was not necessary to 
      stop taking aspirin before undergoing TRUS-PB.
CI  - Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Chen, Di
AU  - Chen D
AD  - Department of Surgery, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, 
      Guilin, Guangxi, China.
FAU - Liu, Gang
AU  - Liu G
AD  - The Reproductive Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
FAU - Xie, Yurun
AU  - Xie Y
AD  - Department of Urology, People's Hospital of Guangxi Zhuang Autonomous Region, 
      Nanning, Guangxi, China.
FAU - Chen, Changsheng
AU  - Chen C
AD  - Department of Urology, People's Hospital of Guangxi Zhuang Autonomous Region, 
      Nanning, Guangxi, China.
FAU - Luo, Zhihua
AU  - Luo Z
AD  - Department of Urology, People's Hospital of Guangxi Zhuang Autonomous Region, 
      Nanning, Guangxi, China.
FAU - Liu, Yujun
AU  - Liu Y
AUID- ORCID: 0000-0001-8628-7505
AD  - Department of Surgery, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, 
      Guilin, Guangxi, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Biopsy, Needle/*adverse effects
MH  - Clinical Trials as Topic
MH  - Gastrointestinal Hemorrhage/chemically induced/etiology
MH  - Hematuria/chemically induced/etiology
MH  - Hemospermia/chemically induced/etiology
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Prostate/pathology
MH  - Prostatic Neoplasms/pathology
MH  - Ultrasonography, Interventional
PMC - PMC8389937
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2021/08/28 06:00
MHDA- 2021/09/09 06:00
CRDT- 2021/08/27 17:22
PHST- 2021/01/21 00:00 [received]
PHST- 2021/07/27 00:00 [accepted]
PHST- 2021/08/27 17:22 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
AID - 00005792-202108270-00015 [pii]
AID - MD-D-21-00462 [pii]
AID - 10.1097/MD.0000000000026985 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Aug 27;100(34):e26985. doi: 
      10.1097/MD.0000000000026985.

PMID- 4449779
OWN - NLM
STAT- MEDLINE
DCOM- 19750519
LR  - 20190501
IS  - 0032-5473 (Print)
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 50
IP  - 582
DP  - 1974 Apr
TI  - Ergotamine-induced venous thrombosis.
PG  - 244-6
AB  - A patient is described who developed venous thrombosis in the leg following an 
      intramuscular injection of ergotamine tartrate.
FAU - Mintz, U
AU  - Mintz U
FAU - Bar-Meir, S
AU  - Bar-Meir S
FAU - De Vries, A
AU  - De Vries A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - PR834Q503T (Ergotamine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects
MH  - Ergotamine/*adverse effects
MH  - Female
MH  - Humans
MH  - Menorrhagia/chemically induced
MH  - Thrombophlebitis/*chemically induced
PMC - PMC2495563
EDAT- 1974/04/01 00:00
MHDA- 1974/04/01 00:01
CRDT- 1974/04/01 00:00
PHST- 1974/04/01 00:00 [pubmed]
PHST- 1974/04/01 00:01 [medline]
PHST- 1974/04/01 00:00 [entrez]
AID - 10.1136/pgmj.50.582.244 [doi]
PST - ppublish
SO  - Postgrad Med J. 1974 Apr;50(582):244-6. doi: 10.1136/pgmj.50.582.244.

PMID- 10563643
OWN - NLM
STAT- MEDLINE
DCOM- 19991130
LR  - 20201208
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 53
IP  - 8
DP  - 1999 Nov 10
TI  - Effect of simple analgesics on quantitative sensation test threshold.
PG  - 1865-7
AB  - Twenty individuals underwent quantitative sensation testing (QST) before and 
      after 1 dose of aspirin, acetaminophen, or acetaminophen with codeine to 
      determine the effect of analgesics on QST results. There was no significant 
      change from baseline when mean QST results after placebo were compared to mean 
      QST results after analgesics. We conclude that the effect of small doses of 
      simple analgesics on QST results is either not present or is too small to 
      necessitate withholding analgesics before sensory testing.
FAU - Wang, A K
AU  - Wang AK
AD  - Peripheral Neuropathy Research Laboratory, Mayo Clinic and Mayo Foundation, 
      Rochester, Minnesota 55905, USA.
FAU - Gillen, D A
AU  - Gillen DA
FAU - Dyck, P J
AU  - Dyck PJ
LA  - eng
GR  - 36797/PHS HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Analgesics)
RN  - 0 (Drug Combinations)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Acetaminophen/pharmacology
MH  - Adult
MH  - Analgesics/*pharmacology
MH  - Aspirin/pharmacology
MH  - Codeine/pharmacology
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Reference Values
MH  - Sensation/*drug effects
MH  - Sensory Thresholds/*drug effects
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
AID - 10.1212/wnl.53.8.1865 [doi]
PST - ppublish
SO  - Neurology. 1999 Nov 10;53(8):1865-7. doi: 10.1212/wnl.53.8.1865.

PMID- 9892920
OWN - NLM
STAT- MEDLINE
DCOM- 19990218
LR  - 20190704
IS  - 0007-0963 (Print)
IS  - 0007-0963 (Linking)
VI  - 139
IP  - 4
DP  - 1998 Oct
TI  - Benign cutaneous Degos' disease.
PG  - 708-12
AB  - We report the case of a 44-year-old woman with Degos' disease who also had a 
      lupus anticoagulant. Electron microscopy of the mature lesions showed interwoven 
      tubular structures within the endothelial cells, as have been observed in 
      previous cases of Degos' disease. Four years after her first cutaneous lesions, 
      there is no evidence of involvement of other organs. Aspirin (300 mg daily) has 
      arrested the cutaneous disease.
FAU - Farrell, A M
AU  - Farrell AM
AD  - Department of Histopathology, Charing Cross and Westminster Medical School, 
      London, U.K.
FAU - Moss, J
AU  - Moss J
FAU - Costello, C
AU  - Costello C
FAU - Fearfield, L A
AU  - Fearfield LA
FAU - Woodrow, D
AU  - Woodrow D
FAU - Bunker, C B
AU  - Bunker CB
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Lupus Coagulation Inhibitor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Lupus Coagulation Inhibitor/blood
MH  - Microscopy, Fluorescence
MH  - Skin Diseases, Papulosquamous/immunology/*pathology
EDAT- 1999/01/20 00:00
MHDA- 1999/01/20 00:01
CRDT- 1999/01/20 00:00
PHST- 1999/01/20 00:00 [pubmed]
PHST- 1999/01/20 00:01 [medline]
PHST- 1999/01/20 00:00 [entrez]
AID - 10.1046/j.1365-2133.1998.02474.x [doi]
PST - ppublish
SO  - Br J Dermatol. 1998 Oct;139(4):708-12. doi: 10.1046/j.1365-2133.1998.02474.x.

PMID- 1613979
OWN - NLM
STAT- MEDLINE
DCOM- 19920728
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 50
IP  - 2
DP  - 1992 Feb
TI  - [Molecular structure and regulation of cyclooxygenase].
PG  - 259-63
AB  - Prostaglandin (PG) endoperoxide synthase is a bifunctional enzyme with fatty acid 
      cyclooxygenase activity (arachidonic acid----PGG2) and PG hydroperoxidase 
      activity (PGG2----PGH2). The primary structure of the enzyme was determined 
      recently by cloning and sequencing the cDNAs for sheep and mouse enzymes and the 
      genomic DNA for the human enzyme. Aspirin selectively inhibits the fatty acid 
      cyclooxygenase activity but not the PG hydroperoxidase activity by acetylating 
      the serine #506. Several lines of evidence suggest that cyclooxygenase enzyme is 
      inducible by several biofactors, such as EGF, TGF-beta, IL-1, and epinephrine. 
      Furthermore, it has been recently suggested that glucocorticoids inhibit the 
      synthesis of the enzyme by the conversion of cyclooxygenase mRNA into a cryptic, 
      untranslatable form.
FAU - Takahashi, Y
AU  - Takahashi Y
AD  - Department of Biochemistry, Tokushima University, School of Medicine.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Glucocorticoids)
RN  - 0 (RNA, Messenger)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Enzyme Induction/drug effects
MH  - Glucocorticoids/pharmacology
MH  - Molecular Structure
MH  - Prostaglandin-Endoperoxide Synthases/*biosynthesis/chemistry/genetics
MH  - RNA, Messenger/metabolism
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
PST - ppublish
SO  - Nihon Rinsho. 1992 Feb;50(2):259-63.

PMID- 1444867
OWN - NLM
STAT- MEDLINE
DCOM- 19921202
LR  - 20131121
IS  - 0066-782X (Print)
IS  - 0066-782X (Linking)
VI  - 58
IP  - 1
DP  - 1992 Jan
TI  - [Kawasaki disease in Pernambuco, Brazil. Considerations on a case seen in a 
      general hospital].
PG  - 43-6
AB  - The first case of Kawasaki disease in Pernambuco, Brazil, is described. An 
      18-month-old by presenting with fever, adenomegaly and mucocutaneous rash, had 
      right and left coronary arteries dilation and aneurysm detected on 
      echocardiography. Treated with a high dosage of aspirin, the patient is 
      asymptomatic after a 7-month follow-up, with regression of coronary lesions.
FAU - Saraiva, L R
AU  - Saraiva LR
AD  - Serviço de Pediatria Clínica (Cardiologia Pediátrica), Hospital Barão de Lucena, 
      Recife, PE.
FAU - Brindeiro Filho, D
AU  - Brindeiro Filho D
FAU - Barros, G S
AU  - Barros GS
FAU - de França, N A
AU  - de França NA
FAU - Pontes, G A
AU  - Pontes GA
LA  - por
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Doença de Kawasaki em Pernambuco. Considerações sobre um caso visto em hospital 
      geral.
PL  - Brazil
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Brazil
MH  - Echocardiography
MH  - Electrocardiography
MH  - Humans
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/blood/*diagnosis/drug therapy
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Arq Bras Cardiol. 1992 Jan;58(1):43-6.

PMID- 2335102
OWN - NLM
STAT- MEDLINE
DCOM- 19900614
LR  - 20190824
IS  - 0010-7824 (Print)
IS  - 0010-7824 (Linking)
VI  - 41
IP  - 4
DP  - 1990 Apr
TI  - Stereoselective interaction between gossypol and rat plasma.
PG  - 377-88
AB  - Gossypol, a potential male oral contraceptive, is chiral and chemically reactive. 
      The present study was done to learn more about the stereoselective activity of 
      this drug. The isomers were equipotent in hemolyzing erythrocytes in protein-free 
      buffer while (+) gossypol was a more potent hemolysin than (-) in plasma. Both 
      isomers disappeared from buffer at the same rate while (-) disappeared from 
      plasma much faster than (+). Treating plasma with aspirin or DNFB to react with 
      the free amino groups on the protein, slowed the disappearance of (-) gossypol. 
      We conclude that (-) gossypol binds to free amino groups on protein and this 
      stereoselective protein binding may account for some of the pharmacokinetic or 
      pharmacodynamic difference between the two isomers of gossypol.
FAU - Wu, D F
AU  - Wu DF
AD  - Department of Pharmacology, Cornell University Medical College, New York, New 
      York 10021.
FAU - Reidenberg, M M
AU  - Reidenberg MM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Contraception
JT  - Contraception
JID - 0234361
RN  - D241E059U6 (Dinitrofluorobenzene)
RN  - KAV15B369O (Gossypol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Dinitrofluorobenzene/pharmacology
MH  - Erythrocytes/drug effects
MH  - Gossypol/*pharmacokinetics/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Isomerism
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
AID - 0010-7824(90)90037-V [pii]
AID - 10.1016/0010-7824(90)90037-v [doi]
PST - ppublish
SO  - Contraception. 1990 Apr;41(4):377-88. doi: 10.1016/0010-7824(90)90037-v.

PMID- 1811646
OWN - NLM
STAT- MEDLINE
DCOM- 19920609
LR  - 20161123
IS  - 0397-9148 (Print)
IS  - 0397-9148 (Linking)
VI  - 23
IP  - 10
DP  - 1991 Dec
TI  - Aspirin-induced asthma and bronchial hyperresponsiveness.
PG  - 423-7
AB  - The inhalation challenge with lysine-aspirin (L-ASA) using the dosimeter method 
      allows the construction of a dose-response curve and the quantitative estimation 
      of airway responsiveness to the drug. We assessed the modifications of airway 
      responsiveness to methacholine in four groups of subjects: aspirin-sensitive 
      asthmatics, aspirin-sensitive subjects with urticaria/angioedema, subjects with 
      an equivocal history of aspirin intolerance and normal control subjects. The 
      L-ASA challenge was positive in all aspirin-sensitive asthmatics. The pattern of 
      bronchial response to the challenge was different from that observed after 
      challenge with allergens or occupational sensitizers. The main difference was 
      found in the recovery from induced bronchoconstriction. The recovery lasted from 
      3 to 6-8 hours, and a peculiar dose-response curve was obtained that we call 
      "early prolonged reaction". In five of 18 ASA-sensitive subjects there was a 
      significant increase in airway responsiveness. Airway responsiveness was normal 
      in aspirin-sensitive nonasthmatic subjects and in the other two groups studied. 
      We conclude that L-ASA inhalation challenge may increase bronchial 
      hyperresponsiveness in some ASA-sensitive asthmatics. This presence of enhanced 
      bronchial hyperesponsiveness seems to be a marker with which to distinguish 
      ASA-sensitive asthmatics from ASA-sensitive subjects with urticaria/angioedema.
FAU - Melillo, G
AU  - Melillo G
AD  - Division of Pneumology and Asthma Center, Fondazione Clinica Del Lavoro, Campoli 
      M.T., Italy.
FAU - Padovano, A
AU  - Padovano A
FAU - Masi, C
AU  - Masi C
FAU - Melillo, E
AU  - Melillo E
FAU - Cocco, G
AU  - Cocco G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - France
TA  - Allerg Immunol (Paris)
JT  - Allergie et immunologie
JID - 0245775
RN  - 0W5ETF9M2K (Methacholine Chloride)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Airway Resistance/drug effects
MH  - Angioedema/chemically induced/physiopathology
MH  - Aspirin/*adverse effects/analogs & derivatives
MH  - Asthma/*chemically induced/physiopathology
MH  - Bronchial Hyperreactivity/*chemically induced
MH  - *Bronchial Provocation Tests
MH  - Bronchial Spasm/chemically induced
MH  - Dose-Response Relationship, Drug
MH  - Drug Hypersensitivity/etiology/physiopathology
MH  - Female
MH  - Humans
MH  - Lysine/analogs & derivatives
MH  - Male
MH  - Methacholine Chloride
MH  - Middle Aged
MH  - Urticaria/chemically induced/physiopathology
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
PST - ppublish
SO  - Allerg Immunol (Paris). 1991 Dec;23(10):423-7.

PMID- 33317720
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 82
IP  - Pt A
DP  - 2020 Dec
TI  - Differences in thromboembolism after stent-assisted coiling for unruptured 
      aneurysms between aspirin plus clopidogrel and ticagrelor.
PG  - 128-133
LID - S0967-5868(20)31601-5 [pii]
LID - 10.1016/j.jocn.2020.10.042 [doi]
AB  - PURPOSE: To reduce procedural thromboembolisms, tailored antiplatelet drug 
      preparation has been used according to antiplatelet resistance for endovascular 
      coiling of unruptured aneurysms. We compared an aspirin plus clopidogrel group 
      with a ticagrelor group using diffusion-weighted imaging (DWI) after 
      stent-assisted coiling for unruptured aneurysms. METHODS: From October 2018 to 
      April 2019, 72 patients with 78 aneurysms underwent stent-assisted coiling, with 
      aspirin plus clopidogrel (n = 20 patients with 22 aneurysms) or ticagrelor 
      (n = 52 patients with 56 aneurysms) as an antiplatelet preparation, and were 
      enrolled in our study. All patients were evaluated using DWI 2 h after coiling to 
      detect procedural thromboembolisms. RESULTS: Postprocedure infarction was 
      observed on DWI in 37 procedures (47.4%), and symptomatic infarction occurred in 
      1 procedure (1.28%). Postprocedure infarction was significantly lower in the 
      aspirin plus clopidogrel than in ticagrelor group (27.3% vs. 55.4%, p = 0.043). 
      Postprocedure infarction was associated with aneurysm type (sidewall aneurysm 
      (30.8%) vs. aneurysm with incorporated branches (64.1%), p = 0.006) and guiding 
      catheter type (single (23.8%) vs. double (56.1%), p = 0.020). Multivariable 
      logistic regression analysis demonstrated that postprocedure infarction was 
      related to aneurysm type (adjusted odds ratio (OR); 3.317, confidence interval 
      (CI); 1.223-8.991, p = 0.018), guiding catheter type (adjusted OR; 2.783, CI; 
      0.828-9.353, p = 0.098), and antiplatelet medication (adjusted OR; 1.295, CI; 
      0.969-1.730, p = 0.080). CONCLUSIONS: Postprocedure infarction was observed on 
      DWI after stent-assisted coiling for unruptured aneurysms more frequently in the 
      ticagrelor group than in the aspirin plus clopidogrel group. However, our study 
      suggests that postprocedure infarction is more associated with aneurysm type than 
      antiplatelet medication.
CI  - Copyright © 2020. Published by Elsevier Ltd.
FAU - Kim, Seung Hwan
AU  - Kim SH
AD  - Department of Neurosurgery, Samsung Changwon Hospital, Sungkyunkwan University 
      School of Medicine, Changwon, Republic of Korea.
FAU - Lee, Hyungon
AU  - Lee H
AD  - Department of Neurosurgery, Inje University Haeundae Paik Hospital, Busan, 
      Republic of Korea.
FAU - Kim, Su Bin
AU  - Kim SB
AD  - Department of Neurosurgery, Inje University Haeundae Paik Hospital, Busan, 
      Republic of Korea.
FAU - Kim, Sung Tae
AU  - Kim ST
AD  - Department of Neurosurgery, Inje University Busan Paik Hospital, Busan, Republic 
      of Korea.
FAU - Baek, Jin Wook
AU  - Baek JW
AD  - Department of Radiology, Inje University Busan Paik Hospital, Busan, Republic of 
      Korea.
FAU - Heo, Young Jin
AU  - Heo YJ
AD  - Department of Radiology, Inje University Busan Paik Hospital, Busan, Republic of 
      Korea.
FAU - Jeong, Hae Woong
AU  - Jeong HW
AD  - Department of Radiology, Inje University Busan Paik Hospital, Busan, Republic of 
      Korea.
FAU - Kim, Hye Jin
AU  - Kim HJ
AD  - Department of Neurology, Hanseo Hospital, Busan, Republic of Korea.
FAU - Park, Jung Hyun
AU  - Park JH
AD  - Department of Neurosurgery, Kosin University Gospel Hospital, Busan, Republic of 
      Korea.
FAU - Kim, Jung-Soo
AU  - Kim JS
AD  - Department of Neurosurgery, Dongnam Institute of Radiological and Medical 
      Sciences, Busan, Republic of Korea.
FAU - Jin, Sung-Chul
AU  - Jin SC
AD  - Department of Neurosurgery, Inje University Haeundae Paik Hospital, Busan, 
      Republic of Korea. Electronic address: kusmal@hanmail.net.
LA  - eng
PT  - Journal Article
DEP - 20201107
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel/*therapeutic use
MH  - Diffusion Magnetic Resonance Imaging
MH  - Embolization, Therapeutic
MH  - Female
MH  - Humans
MH  - Intracranial Aneurysm/therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stents
MH  - Thromboembolism/*drug therapy
MH  - Ticagrelor/*therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Clopidogrel
OT  - Stent assisted coiling
OT  - Ticagrelor
OT  - Unruptured aneurysm
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/12/16 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/15 05:43
PHST- 2020/05/28 00:00 [received]
PHST- 2020/09/08 00:00 [revised]
PHST- 2020/10/18 00:00 [accepted]
PHST- 2020/12/15 05:43 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - S0967-5868(20)31601-5 [pii]
AID - 10.1016/j.jocn.2020.10.042 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2020 Dec;82(Pt A):128-133. doi: 10.1016/j.jocn.2020.10.042. Epub 
      2020 Nov 7.

PMID- 24180537
OWN - NLM
STAT- MEDLINE
DCOM- 20140715
LR  - 20131104
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 9
IP  - 6
DP  - 2013 Nov
TI  - PA tablets: investigational compounds combining aspirin and omeprazole for 
      cardioprotection.
PG  - 785-97
LID - 10.2217/fca.13.67 [doi]
AB  - For most patients with prior cardiovascular events, preventing future secondary 
      cardiovascular events requires life-long persistence with antiplatelet therapy. 
      PA tablets (P: proton pump inhibitors; A: aspirin) are investigational compounds 
      that were developed to provide the cardioprotective benefits of aspirin with the 
      upper gastrointestinal protection of a proton pump inhibitor (e.g., omeprazole). 
      The tablets are film-coated, coordinated-release tablets for oral administration 
      that contain 40 mg immediate-release omeprazole and either 81 or 325 mg 
      delayed-release aspirin. The goals of the clinical development program were to 
      demonstrate the following: improved gastrointestinal safety of PA relative to 
      enteric-coated aspirin alone; bioequivalence and comparative bioavailability 
      between the PA compounds and currently marketed enteric-coated aspirin; and 
      long-term safety. Two clinical pharmacology studies were also conducted to study 
      the potential for interaction between PA32540 and clopidogrel.
FAU - Bliden, Kevin P
AU  - Bliden KP
AD  - Sinai Center for Thrombosis Research, 2401 West Belvedere Avenue, Baltimore, MD 
      21215, USA.
FAU - Brener, Michael
AU  - Brener M
FAU - Gesheff, Martin G
AU  - Gesheff MG
FAU - Franzese, Christopher J
AU  - Franzese CJ
FAU - Tabrizchi, Ali
AU  - Tabrizchi A
FAU - Tantry, Udaya
AU  - Tantry U
FAU - Gurbel, Paul A
AU  - Gurbel PA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Tablets)
RN  - KG60484QX9 (Omeprazole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/*administration & dosage/pharmacokinetics
MH  - Biological Availability
MH  - Cardiovascular Diseases/metabolism/*prevention & control
MH  - Delayed-Action Preparations
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Omeprazole/*administration & dosage/pharmacokinetics
MH  - Platelet Aggregation Inhibitors/*administration & dosage/pharmacokinetics
MH  - Proton Pump Inhibitors/administration & dosage/pharmacokinetics
MH  - Tablets
EDAT- 2013/11/05 06:00
MHDA- 2014/07/16 06:00
CRDT- 2013/11/05 06:00
PHST- 2013/11/05 06:00 [entrez]
PHST- 2013/11/05 06:00 [pubmed]
PHST- 2014/07/16 06:00 [medline]
AID - 10.2217/fca.13.67 [doi]
PST - ppublish
SO  - Future Cardiol. 2013 Nov;9(6):785-97. doi: 10.2217/fca.13.67.

PMID- 21372715
OWN - NLM
STAT- MEDLINE
DCOM- 20111004
LR  - 20131121
IS  - 1531-6998 (Electronic)
IS  - 1068-9508 (Linking)
VI  - 19
IP  - 3
DP  - 2011 Jun
TI  - Role of aspirin desensitization in the management of chronic rhinosinusitis.
PG  - 210-7
LID - 10.1097/MOO.0b013e3283450102 [doi]
AB  - PURPOSE OF REVIEW: This review is set to revisit the pathogenesis of 
      aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and 
      finally the real impact of aspirin desensitization on chronic sinusitis with 
      nasal polyposis (CRSwNP) in aspirin intolerant patients. RECENT FINDINGS: In 
      AERD, increased baseline production of cysteinyl-leukotriene (Cys-LT) is 
      associated with upregulation of Cys-LT receptors on nasal inflammatory cells. 
      This is further aggravated by inhibition of cyclooxygenase-1 by aspirin and other 
      NSAIDs. New-found genetic markers need further study. Oral aspirin challenge is 
      still the gold standard of diagnosis and can be safely conducted in a specialized 
      outpatient clinic. Oral and endonasal aspirin desensitization show positive 
      impact on CRSwNP course with decreased polyp recurrence, decreased number of 
      hospitalizations, and decreased need for corticosteroids. Modulation of 
      arachidonic acid metabolism and inhibition of intracellular biochemical pathways 
      in key inflammatory cells involving anti-inflammatory cytokines interleukin 
      (IL)-4 and IL-13 explain the clinical outcomes. SUMMARY: Future studies should 
      focus on establishing the lowest possible dose to maintain disease under check, 
      allowing more widespread use of this underutilized and underrecognized treatment 
      modality.
FAU - Rizk, Habib
AU  - Rizk H
AD  - Department of Otolaryngology/Head and Neck Surgery, Hotel-Dieu de France 
      Hospital, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon. 
      habib.rizk@usj.edu.lb
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Otolaryngol Head Neck Surg
JT  - Current opinion in otolaryngology & head and neck surgery
JID - 9417024
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*immunology
MH  - Chronic Disease
MH  - *Desensitization, Immunologic
MH  - Drug Hypersensitivity/diagnosis/*therapy
MH  - Humans
MH  - Nasal Polyps/complications/immunology
MH  - Respiratory Hypersensitivity/etiology/immunology/*therapy
MH  - Rhinitis/complications/diagnosis/immunology/*therapy
MH  - Sinusitis/complications/immunology/*therapy
EDAT- 2011/03/05 06:00
MHDA- 2011/10/05 06:00
CRDT- 2011/03/05 06:00
PHST- 2011/03/05 06:00 [entrez]
PHST- 2011/03/05 06:00 [pubmed]
PHST- 2011/10/05 06:00 [medline]
AID - 10.1097/MOO.0b013e3283450102 [doi]
PST - ppublish
SO  - Curr Opin Otolaryngol Head Neck Surg. 2011 Jun;19(3):210-7. doi: 
      10.1097/MOO.0b013e3283450102.

PMID- 8015690
OWN - NLM
STAT- MEDLINE
DCOM- 19940725
LR  - 20131121
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 84
IP  - 11
DP  - 1993 Nov
TI  - [Comparative study of ASA and heparan sulfate in the secondary prevention of 
      cerebrovascular disorders].
PG  - 621-6
AB  - Aim of our study was to compare heparan sulphate and acetylsalicylic acid (ASA) 
      in the secondary prevention of cerebrovascular events. Eighty patients with 
      recent episodes of RIA or minor stroke of atherothrombotic origin were randomized 
      in two groups of 40, one treated with heparan sulphate and the other with ASA. 
      The two groups were homogeneous for age, sex, clinical history and type of events 
      qualifying for enrollment. After a 6-month follow-up no difference was found in 
      fatal or non fatal vascular events. The incidence of adverse reactions was 
      significantly lower in the heparan sulphate group. All the patients showed a 
      trend towards improvement in cognitive functioning, but a significant improvement 
      in attentional functions was observed only in the heparan sulphate group. As 
      hypothesis, it may be supposed that such clinical results depend on a better 
      perfusion of inner watershed cerebral areas.
FAU - Pennese, F
AU  - Pennese F
AD  - Cattedra di Geriatria, Università G. D'Annunzio, Chieti.
FAU - Palombo, V
AU  - Palombo V
FAU - Taormina, F
AU  - Taormina F
FAU - Fraccalaglio, L
AU  - Fraccalaglio L
FAU - Brillante, C
AU  - Brillante C
FAU - Abate, G
AU  - Abate G
LA  - ita
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Studio di confronto tra ASA ed eparansolfato nella prevenzione secondaria delle 
      vasculopatie cerebrali.
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
RN  - 0 (Fibrinolytic Agents)
RN  - 9050-30-0 (Heparitin Sulfate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Follow-Up Studies
MH  - Heparitin Sulfate/*therapeutic use
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy
MH  - Male
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PST - ppublish
SO  - Minerva Med. 1993 Nov;84(11):621-6.

PMID- 519009
OWN - NLM
STAT- MEDLINE
DCOM- 19800317
LR  - 20131121
IS  - 0365-9615 (Print)
IS  - 0365-9615 (Linking)
VI  - 88
IP  - 12
DP  - 1979 Dec
TI  - [Proliferative activity of the surface foveolar gastric epithelium in 
      acetysalicylic acid injury].
PG  - 733-6
AB  - The proliferative activity of gastric mucous cells (GMC) was studied in white 
      mice following the administration of acetylsalicylic acid (200 mg/kg). One hour 
      before sacrifice all the animals received intraperitoneal injection of 
      3H-thymidine. The mitotic index and index of labeling nuclei were calculated by 
      means of radioautographers 3, 10 and 20 days after administering the drug. 
      Following 3-day exposure to acetylsalicylic acid the proliferative activity of 
      GMC remained unchanged as compared to controls. Long-term administration (10 and 
      20 days) of the drug produced no increase in the number of erosions, but there 
      was a statistically significant rise in the proliferative activity of GMC. This 
      rise was accounted for by increased number of proliferating cells in the foveated 
      and cervical divisions of the glands as well as due to the extension of the zone 
      of distribution of precursor cells in the gastric glands as far as the basal 
      divisions. These changes may be considered as manifestation of the 
      protective-adaptive reaction of the gastric mucosa in response to the damaging 
      effect of acetylsalicylic acid.
FAU - Tsodikov, G V
AU  - Tsodikov GV
FAU - Klimenko, V V
AU  - Klimenko VV
FAU - Laz'kova, S N
AU  - Laz'kova SN
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Proliferativnaia aktivnost' poverkhnostno-iamochnogo épiteliia zheludka pri ego 
      povrezhdenii atsetilsalitsilovoĭ kislotoĭ.
PL  - Russia (Federation)
TA  - Biull Eksp Biol Med
JT  - Biulleten' eksperimental'noi biologii i meditsiny
JID - 0370627
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*adverse effects
MH  - Cell Division/drug effects
MH  - Epithelial Cells
MH  - Epithelium/drug effects
MH  - Gastric Mucosa/cytology/*drug effects
MH  - Male
MH  - Mice
MH  - Time Factors
EDAT- 1979/12/01 00:00
MHDA- 1979/12/01 00:01
CRDT- 1979/12/01 00:00
PHST- 1979/12/01 00:00 [pubmed]
PHST- 1979/12/01 00:01 [medline]
PHST- 1979/12/01 00:00 [entrez]
PST - ppublish
SO  - Biull Eksp Biol Med. 1979 Dec;88(12):733-6.

PMID- 1767080
OWN - NLM
STAT- MEDLINE
DCOM- 19920218
LR  - 20131121
IS  - 0889-857X (Print)
IS  - 0889-857X (Linking)
VI  - 17
IP  - 4
DP  - 1991 Nov
TI  - Kawasaki disease. Epidemiology, late prognosis, and therapy.
PG  - 907-19
AB  - Kawasaki disease is an immunologically mediated diffuse vasculitis of childhood 
      of unknown etiology. While most of the clinical features--including diffuse 
      mucosal inflammation, indurative edema, rash, and lymphadenopathy--are 
      self-limiting, coronary artery aneurysms and the possibility of thrombotic 
      occlusion occurs in up to 20% of children. The epidemiologic and clinical 
      features of this disease suggest an infectious etiology; however, a specific 
      organism has not been consistently identified. An abnormal immune response to 
      this as yet to be defined organism plays a critical role in the progression of 
      this disease. The morbidity and mortality of this disease are related primarily 
      to the potential cardiovascular complications. The natural history of the 
      coronary artery aneurysms is that most lesions regress with time. Factors leading 
      to a higher probability of regression include age less than 1 year, female sex, 
      fusiform aneurysm, and maximum diameter less than 4 mm. Current recommendations 
      for therapy include aspirin and IVIG. The range of dosages regimens for each 
      medication are discussed in the text.
FAU - Barron, K S
AU  - Barron KS
AD  - Section of Pediatric Rheumatology, Baylor College of Medicine, Houston, Texas.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Rheum Dis Clin North Am
JT  - Rheumatic diseases clinics of North America
JID - 8708093
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Coronary Disease/prevention & control
MH  - Humans
MH  - Immunization, Passive
MH  - *Mucocutaneous Lymph Node Syndrome/complications/epidemiology/therapy
MH  - Prognosis
MH  - Time Factors
RF  - 71
EDAT- 1991/11/01 00:00
MHDA- 1991/11/01 00:01
CRDT- 1991/11/01 00:00
PHST- 1991/11/01 00:00 [pubmed]
PHST- 1991/11/01 00:01 [medline]
PHST- 1991/11/01 00:00 [entrez]
PST - ppublish
SO  - Rheum Dis Clin North Am. 1991 Nov;17(4):907-19.

PMID- 26914786
OWN - NLM
STAT- MEDLINE
DCOM- 20161219
LR  - 20181202
IS  - 2235-3186 (Electronic)
IS  - 1660-8151 (Linking)
VI  - 132
IP  - 3
DP  - 2016
TI  - Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with 
      Renal Impairment during Dual Antiplatelet Therapy.
PG  - 191-7
LID - 10.1159/000444027 [doi]
AB  - BACKGROUND: Clopidogrel and aspirin combination remains a cornerstone for modern 
      dual antiplatelet therapy (DAPT) following coronary stenting. Although monitoring 
      is not currently recommended, certain high-risk cohorts may benefit from 
      tailoring antiplatelet options to reduce thrombotic or/and hemorrhagic risks. 
      Patients with diminished estimated glomerular filtration rate (eGFR) are prone to 
      both vascular occlusions and bleeding events in whom monitoring may be especially 
      advantageous. We compared the residual platelet reactivity assessed by 3 
      conventional tests during the maintenance antiplatelet therapy dependent on eGFR. 
      METHODS: Post-stenting patients (n = 701) receiving aspirin 100 mg/daily and 
      clopidogrel 75 mg/daily were prospectively enrolled in the cross-sectional 
      single-center study. Patients were dichotomized into 5 groups: eGFR >90, 60-89, 
      30-59, <30 ml/min/1.73 m2, and dialysis. Platelet reactivity by VerifyNow™, light 
      transmittance aggregometry (LTA), and Multiplate analyzer by multiple electrode 
      platelet aggregometry (MEA) assays together with eGFR calculations were done 
      simultaneously at 1 month after coronary stenting. RESULTS: VerifyNow assay 
      distinguished residual platelet reactivity dependent on eGFR deterioration (191 ± 
      72 vs. 216 ± 78 vs. 248 ± 80 vs. 264 ± 70 vs. 317 ± 96 PRU; p < 0.001). In 
      contrast, LTA (34.3 ± 18.1 vs. 34.7 ± 18.1 vs. 38.0 ± 16.6 vs. 33.0 ± 17.3 vs. 
      34.1 ± 29.3%; p = 0.242), or MEA (37.2 ± 19.6 vs. 33.8 ± 18.4 vs. 38.6 ± 21.4 vs. 
      36.5 ± 20.5 vs. 38.3 ± 28.3 AU/min; p = 0.086) failed to triage platelet 
      reactivity in renal patients. Agreement among assays to identify patients with 
      impaired platelet reactivity and eGFR during antiplatelet therapy was low. The 
      multivariable regression analyses confirmed the VerifyNow advantage, since the 
      differences in the platelet reactivity were highly significant for all renal 
      impairment (RI) groups. In contrast, LTA did not distinguish RI patients, and for 
      the MEA, only RI5 (dialysis) cohort exhibit borderline significant decline of 
      residual platelet reactivity. CONCLUSION: Among 3 assays, VerifyNow was capable 
      to reliably triage residual platelet reactivity in post-stenting DAPT patients 
      dependent on the gradual decline of eGFR during therapy with clopidogrel and 
      aspirin. These data should be confirmed in a large validation longitudinal trial, 
      and may justify future platelet activity monitoring for potential regimen/dose 
      adjustment in high-risk patients. The clinical implications of these data are 
      still unclear, but may give an indication as to whether or when DAPT dose 
      adjustment will become a reality.
CI  - © 2016 S. Karger AG, Basel.
FAU - Guo, Long Zhe
AU  - Guo LZ
AD  - Department of Cardiology, Dong-A University Hospital, Busan, South Korea.
FAU - Kim, Moo Hyun
AU  - Kim MH
FAU - Kim, Tae Hyung
AU  - Kim TH
FAU - Park, Jong Seong
AU  - Park JS
FAU - Jin, Enze
AU  - Jin E
FAU - Shim, Chang Heon
AU  - Shim CH
FAU - Choi, Sun Young
AU  - Choi SY
FAU - Serebruany, Victor L
AU  - Serebruany VL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20160226
PL  - Switzerland
TA  - Nephron
JT  - Nephron
JID - 0331777
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Cross-Sectional Studies
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Hemorrhage/prevention & control
MH  - Humans
MH  - Kidney Diseases/*blood/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Platelet Function Tests
MH  - Prospective Studies
MH  - Thrombosis/prevention & control
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
EDAT- 2016/02/26 06:00
MHDA- 2016/12/20 06:00
CRDT- 2016/02/26 06:00
PHST- 2015/10/25 00:00 [received]
PHST- 2016/01/13 00:00 [accepted]
PHST- 2016/02/26 06:00 [entrez]
PHST- 2016/02/26 06:00 [pubmed]
PHST- 2016/12/20 06:00 [medline]
AID - 000444027 [pii]
AID - 10.1159/000444027 [doi]
PST - ppublish
SO  - Nephron. 2016;132(3):191-7. doi: 10.1159/000444027. Epub 2016 Feb 26.

PMID- 35403975
OWN - NLM
STAT- MEDLINE
DCOM- 20220615
LR  - 20220615
IS  - 1432-1076 (Electronic)
IS  - 0340-6199 (Print)
IS  - 0340-6199 (Linking)
VI  - 181
IP  - 7
DP  - 2022 Jul
TI  - Acute phase of Kawasaki disease: a review of national guideline recommendations.
PG  - 2563-2573
LID - 10.1007/s00431-022-04458-z [doi]
AB  - Key aspects of the medical management of Kawasaki disease (KD) are not yet 
      supported by a high evidence level, thus making room for individual 
      recommendations. We performed a structured comparison of existing international 
      KD guidelines to analyze potential differences in the implementation of 
      evidence-based KD recommendations regarding diagnosis and therapy. To identify 
      country-specific guidelines, we took a multilateral approach including a 
      comprehensive PubMed literature, online research, and directly contacting 
      national pediatric associations. We then ran a structured guidelines' analysis 
      and evaluated the diagnostic and therapeutic differences in the context of 
      evidence-based medicine. In this structured guideline analysis, we identified 
      nine national and one European guidelines. According to them all, the diagnosis 
      of KD still relies on its clinical presentation with no reliable biomarker 
      recommended. First-line treatment consistently involves only intravenous 
      immunoglobulin (IVIG) therapy. Recommendations in terms of acetylsalicylic acid, 
      corticosteroids, and additional therapeutic options vary considerably. 
      CONCLUSION: According to all guidelines, KD is diagnosed clinically with some 
      variance in defining incomplete KD and being a non-responder to treatment. 
      First-line treatment consistently includes IVIG. Recommendations for additional 
      therapeutic strategies are more heterogeneous. WHAT IS KNOWN: • The diagnosis of 
      KD relies on the clinical presentation, entailing challenges in timely diagnosis. 
      • Other treatment options then IVIG are not supported by a high evidence level, 
      making room for individual recommendations. WHAT IS NEW: • Definition of 
      incomplete KD and being non-responsive to an initial treatment vary to some 
      extent between the national guidelines. • Only IVIG is consistently proposed 
      throughout all guidelines, further therapeutic recommendations vary between the 
      national recommendations.
CI  - © 2022. The Author(s).
FAU - Scherler, Laura
AU  - Scherler L
AUID- ORCID: 0000-0003-3168-7274
AD  - Department of Pediatric Cardiology and Pediatric Intensive Care, 
      Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, 
      Germany.
FAU - Haas, Nikolaus A
AU  - Haas NA
AD  - Department of Pediatric Cardiology and Pediatric Intensive Care, 
      Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, 
      Germany.
FAU - Tengler, Anja
AU  - Tengler A
AD  - Department of Pediatric Cardiology and Pediatric Intensive Care, 
      Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, 
      Germany.
FAU - Pattathu, Joseph
AU  - Pattathu J
AD  - Department of Pediatric Cardiology and Pediatric Intensive Care, 
      Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, 
      Germany.
FAU - Mandilaras, Guido
AU  - Mandilaras G
AD  - Department of Pediatric Cardiology and Pediatric Intensive Care, 
      Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, 
      Germany.
FAU - Jakob, André
AU  - Jakob A
AUID- ORCID: 0000-0003-3580-2268
AD  - Department of Pediatric Cardiology and Pediatric Intensive Care, 
      Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, 
      Germany. andre.jakob@med.uni-muenchen.de.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220411
PL  - Germany
TA  - Eur J Pediatr
JT  - European journal of pediatrics
JID - 7603873
RN  - 0 (Biomarkers)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Biomarkers
MH  - Child
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - *Mucocutaneous Lymph Node Syndrome/drug therapy/therapy
PMC - PMC8995165
OTO - NOTNLM
OT  - COVID-19 MISC-C
OT  - Coronary artery aneurysm
OT  - Kawasaki disease
OT  - National guideline
COIS- The authors declare no competing interests.
EDAT- 2022/04/12 06:00
MHDA- 2022/06/16 06:00
CRDT- 2022/04/11 12:09
PHST- 2022/02/09 00:00 [received]
PHST- 2022/03/24 00:00 [accepted]
PHST- 2022/03/22 00:00 [revised]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/06/16 06:00 [medline]
PHST- 2022/04/11 12:09 [entrez]
AID - 10.1007/s00431-022-04458-z [pii]
AID - 4458 [pii]
AID - 10.1007/s00431-022-04458-z [doi]
PST - ppublish
SO  - Eur J Pediatr. 2022 Jul;181(7):2563-2573. doi: 10.1007/s00431-022-04458-z. Epub 
      2022 Apr 11.

PMID- 28301911
OWN - NLM
STAT- MEDLINE
DCOM- 20180717
LR  - 20200225
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 24
IP  - 1
DP  - 2018 Jan
TI  - The Prevalence and Clinical Relevance of ASA Nonresponse After Cardiac Surgery: A 
      Prospective Bicentric Study.
PG  - 179-185
LID - 10.1177/1076029617693939 [doi]
AB  - We aimed to identify the prevalence of acetylsalicylic acid (ASA) nonresponse in 
      patients after coronary artery bypass graft (CABG) surgery and the possible 
      consequences for the rate of major cardiovascular events. This prospective, 
      observational, bicentric cohort study was conducted in two German University 
      hospitals. A total of 400 patients (200 in each study center) undergoing elective 
      CABG surgery were enrolled after written informed consent. Platelet function was 
      analyzed on day 3 (d3) and day 5 (d5) postoperatively following stimulation with 
      arachidonic acid (ASPItest) and with thrombin receptor-activating peptide 6 
      (TRAPtest) using multiple electrode aggregometry (Multiplate). Individuals with 
      an ASPItest ≥40 AU·min were categorized as ASA nonresponders. A 1-year follow-up 
      recorded the combined end point of cardiovascular events, hospital admissions, or 
      deaths related to cardiovascular disease. The prevalence of ASA nonresponse was 
      51.5% on d3, and it significantly increased to 71.3% on d5 ( P = .0049). The area 
      under the aggregation curve in the TRAPtest ( P < .0001), the platelet count on 
      d5 ( P = .009), and the cardiopulmonary bypass time ( P = .01) were identified as 
      independent predictors of an ASA nonresponse. A 1-year follow-up recorded 54 
      events fulfilling criteria for the combined end point with no difference between 
      ASA responders and nonresponders. This study indicates a high incidence of 
      perioperative ASA nonresponse in patients following CABG. No effect on the 
      incidence of cardiovascular events was recorded in the 1-year follow-up. 
      Therefore, a randomized dosage adjustment trial should elucidate whether a 
      tailored ASA treatment after CABG surgery represents a useful concept.
FAU - Wand, Saskia
AU  - Wand S
AD  - 1 Department of Anesthesiology, University Medical Center Göttingen, Göttingen, 
      Germany.
FAU - Adam, Elisabeth Hannah
AU  - Adam EH
AD  - 2 Department of Anesthesia, Intensive Care Medicine and Pain Therapy, University 
      Hospital Frankfurt, Frankfurt am Main, Germany.
FAU - Wetz, Anna Julienne
AU  - Wetz AJ
AD  - 1 Department of Anesthesiology, University Medical Center Göttingen, Göttingen, 
      Germany.
FAU - Meybohm, Patrick
AU  - Meybohm P
AD  - 2 Department of Anesthesia, Intensive Care Medicine and Pain Therapy, University 
      Hospital Frankfurt, Frankfurt am Main, Germany.
FAU - Kunze-Szikszay, Nils
AU  - Kunze-Szikszay N
AD  - 1 Department of Anesthesiology, University Medical Center Göttingen, Göttingen, 
      Germany.
FAU - Zacharowski, Kai
AU  - Zacharowski K
AD  - 2 Department of Anesthesia, Intensive Care Medicine and Pain Therapy, University 
      Hospital Frankfurt, Frankfurt am Main, Germany.
FAU - Popov, Aron Frederick
AU  - Popov AF
AD  - 3 Department of Thoracic and Cardiovascular Surgery, University Medical Center 
      Göttingen, Göttingen, Germany.
AD  - 4 Department for Cardiothoracic and Vascular Surgery, University Hospital 
      Frankfurt, Frankfurt am Main, Germany.
FAU - Moritz, Anton
AU  - Moritz A
AD  - 4 Department for Cardiothoracic and Vascular Surgery, University Hospital 
      Frankfurt, Frankfurt am Main, Germany.
FAU - Moldenhauer, Lisa
AU  - Moldenhauer L
AD  - 1 Department of Anesthesiology, University Medical Center Göttingen, Göttingen, 
      Germany.
FAU - Kaiser, Julia
AU  - Kaiser J
AD  - 2 Department of Anesthesia, Intensive Care Medicine and Pain Therapy, University 
      Hospital Frankfurt, Frankfurt am Main, Germany.
FAU - Bauer, Martin
AU  - Bauer M
AD  - 1 Department of Anesthesiology, University Medical Center Göttingen, Göttingen, 
      Germany.
FAU - Weber, Christian Friedrich
AU  - Weber CF
AD  - 1 Department of Anesthesiology, University Medical Center Göttingen, Göttingen, 
      Germany.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20170223
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - *Coronary Artery Bypass
MH  - *Drug Resistance
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Function Tests
MH  - Prevalence
MH  - Prospective Studies
PMC - PMC6714620
OTO - NOTNLM
OT  - ASA nonresponse
OT  - cardiac surgery
OT  - multiple electrode aggregometry
OT  - platelet function
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2017/03/18 06:00
MHDA- 2018/07/18 06:00
CRDT- 2017/03/18 06:00
PHST- 2017/03/18 06:00 [pubmed]
PHST- 2018/07/18 06:00 [medline]
PHST- 2017/03/18 06:00 [entrez]
AID - 10.1177_1076029617693939 [pii]
AID - 10.1177/1076029617693939 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2018 Jan;24(1):179-185. doi: 10.1177/1076029617693939. 
      Epub 2017 Feb 23.

PMID- 1464509
OWN - NLM
STAT- MEDLINE
DCOM- 19930121
LR  - 20190819
IS  - 0020-9996 (Print)
IS  - 0020-9996 (Linking)
VI  - 27
IP  - 11
DP  - 1992 Nov
TI  - Efficacy of adjunctive intrathrombic heparin with pulse spray thrombolysis in 
      rabbit inferior vena cava thrombosis.
PG  - 912-7
AB  - RATIONALE AND OBJECTIVES: The efficacy and speed of pharmacomechanical 
      thrombolysis may be limited by thrombotic effects of activated platelets and 
      thrombin within the lysing clot. The authors designed an animal model of subacute 
      venous thrombosis which was used to evaluate the effect of intrathrombic versus 
      intravenous heparin during thrombolysis. METHODS: Inferior vena cava (IVC) 
      thrombosis was induced in rabbits by balloon catheter injury and placement of 
      steel coils. Venacavagrams were obtained 48 hours later to document clot 
      formation and for angiographic estimation of clot volume. Pulse-spray 
      thrombolysis was performed by forceful injections of various agents through a 
      catheter with multiple side holes spanning the clot. Most animals were given 
      aspirin (30 mg orally) before treatment. After 1 hour of therapy, repeat 
      venacavography was performed. Animals were killed, and residual clot weight was 
      determined. RESULTS: Occlusive IVC thrombi were present in 94% of rabbits at 2 
      days. Mean residual clot weight per milliliter of estimated initial clot volume 
      (mg/mL) for the various treatment groups was as follows: saline (n = 5) 632 +/- 
      54; tissue-type plasminogen activator (t-PA) 3 mg, (n = 6) 443 +/- 162; t-PA 3 mg 
      + heparin 750 U intravenously, (n = 7) 408 +/- 128; t-PA 3 mg + heparin 500 U 
      intrathrombic + heparin 250 U intravenously, (n = 8) 213 +/- 166. Differences 
      among these groups (except t-PA alone versus t-PA + intravenous heparin) were 
      significant. The extent of lysis with intrathrombic + intravenous heparin was not 
      significantly retarded by withholding aspirin (n = 6, 194 +/- 72), or improved by 
      giving half the intrathrombic heparin before t-PA injections (n = 6, 280 +/- 
      158). CONCLUSIONS: The results demonstrate the advantage of adjunctive 
      intrathrombic + intravenous heparin over intravenous heparin alone in increasing 
      the extent of pulse-spray thrombolysis in this IVC thrombosis model.
FAU - Valji, K
AU  - Valji K
AD  - Department of Radiology, University of California, San Diego 92103.
FAU - Bookstein, J J
AU  - Bookstein JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Invest Radiol
JT  - Investigative radiology
JID - 0045377
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Heparin/*administration & dosage
MH  - Rabbits
MH  - Radiography
MH  - Thrombolytic Therapy/*methods
MH  - Thrombosis/diagnostic imaging/*drug therapy
MH  - Tissue Plasminogen Activator/therapeutic use
MH  - *Vena Cava, Inferior/diagnostic imaging
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
AID - 10.1097/00004424-199211000-00007 [doi]
PST - ppublish
SO  - Invest Radiol. 1992 Nov;27(11):912-7. doi: 10.1097/00004424-199211000-00007.

PMID- 35260381
OWN - NLM
STAT- MEDLINE
DCOM- 20220808
LR  - 20220810
IS  - 1969-6213 (Electronic)
IS  - 1774-024X (Linking)
VI  - 18
IP  - 5
DP  - 2022 Aug 5
TI  - Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous 
      coronary intervention: a landmark analysis of the GLOBAL LEADERS trial.
PG  - e377-e388
LID - EIJ-D-21-00870 [pii]
LID - 10.4244/EIJ-D-21-00870 [doi]
AB  - BACKGROUND: The optimal antiplatelet strategy in the second year after 
      percutaneous coronary intervention (PCI) remains unclear. AIMS: We aimed to 
      compare ticagrelor monotherapy with aspirin monotherapy on clinical outcomes 
      beyond 1 year post-PCI. METHODS: This post hoc subanalysis of the open-label, 
      all-comers, randomised GLOBAL LEADERS trial, which compared 23-month ticagrelor 
      monotherapy following 1-month dual antiplatelet therapy (DAPT) with 12-month 
      aspirin monotherapy following 12-month DAPT, only included patients who, at 12 
      months, were free from ischaemic and bleeding events and were adherent to their 
      assigned antiplatelet therapy. The incidences of ischaemic events (all-cause 
      death, any myocardial infarction, or any stroke) and bleeding events (Bleeding 
      Academic Research Consortium [BARC] type 3 or 5 bleeding) during the second year 
      (12-24 months) were compared between patients receiving either ticagrelor or 
      aspirin monotherapy. RESULTS: The present analysis included 11,121 (ticagrelor 
      monotherapy n=5,308, and aspirin monotherapy n=5,813) of the 15,991 patients 
      enrolled in GLOBAL LEADERS. During the second year, the ischaemic composite 
      endpoint was lower with ticagrelor monotherapy compared to aspirin monotherapy 
      (1.9% vs 2.6%: log-rank p=0.014, adjusted hazard ratio [HR] 0.74, 95% confidence 
      interval [CI]: 0.58-0.96; p=0.022), which was primarily driven by a reduced risk 
      of myocardial infarction. In contrast, BARC type 3 or 5 bleeding was numerically 
      higher with ticagrelor monotherapy (0.5% vs 0.3%: log-rank p=0.051, adjusted HR 
      1.89, 95% CI: 1.03-3.45; p=0.005). CONCLUSIONS: Patients free from events at the 
      end of the first year post-PCI and who adhered to their prescribed regimen had a 
      reduced risk of ischaemic events compared to aspirin monotherapy in the second 
      year post-PCI. CLINICALTRIALS: gov: NCT01813435.
FAU - Ono, Masafumi
AU  - Ono M
AD  - Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and 
      Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the 
      Netherlands.
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, 
      Ireland.
FAU - Hara, Hironori
AU  - Hara H
AD  - Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and 
      Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the 
      Netherlands.
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, 
      Ireland.
FAU - Kawashima, Hideyuki
AU  - Kawashima H
AD  - Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and 
      Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the 
      Netherlands.
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, 
      Ireland.
FAU - Gao, Chao
AU  - Gao C
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, 
      Ireland.
AD  - Department of Cardiology, Radboud University Medical Center, Nijmegen, the 
      Netherlands.
FAU - Wang, Rutao
AU  - Wang R
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, 
      Ireland.
AD  - Department of Cardiology, Radboud University Medical Center, Nijmegen, the 
      Netherlands.
FAU - Wykrzykowska, Joanna J
AU  - Wykrzykowska JJ
AD  - Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and 
      Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the 
      Netherlands.
AD  - University Medical Center Groningen, Groningen, the Netherlands.
FAU - Piek, Jan J
AU  - Piek JJ
AD  - Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and 
      Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the 
      Netherlands.
FAU - Garg, Scot
AU  - Garg S
AD  - Department of Cardiology, Royal Blackburn Hospital, Blackburn, United Kingdom.
FAU - Hamm, Christian
AU  - Hamm C
AD  - University of Giessen and Kerckhoff Heartand Thorax Center, University of 
      Giessen, Bad Nauheim, Germany.
FAU - Steg, Philippe Gabriel
AU  - Steg PG
AD  - FACT (French Alliance for Cardiovascular Trials), Université de Paris, Assistance 
      Publique-Hôpitaux de Paris, Paris, France.
FAU - Valgimigli, Marco
AU  - Valgimigli M
AD  - Cardiocentro Ticino Institute, and Università della Svizzera Italiana (USI), 
      Lugano, Switzerland.
FAU - Windecker, Stephan
AU  - Windecker S
AD  - Department of Cardiology, University of Bern, Inselspital, Bern, Switzerland.
FAU - Vranckx, Pascal
AU  - Vranckx P
AD  - Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
FAU - Onuma, Yoshinobu
AU  - Onuma Y
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, 
      Ireland.
FAU - Serruys, Patrick W
AU  - Serruys PW
AD  - Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, 
      Ireland.
AD  - NHLI, Imperial College London, London, United Kingdom.
LA  - eng
SI  - ClinicalTrials.gov/NCT01813435
PT  - Clinical Trial
PT  - Journal Article
DEP - 20220805
PL  - France
TA  - EuroIntervention
JT  - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on 
      Interventional Cardiology of the European Society of Cardiology
JID - 101251040
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Hemorrhage/etiology
MH  - Humans
MH  - *Myocardial Infarction/therapy
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Ticagrelor/therapeutic use
MH  - Treatment Outcome
EDAT- 2022/03/10 06:00
MHDA- 2022/08/09 06:00
CRDT- 2022/03/09 05:33
PHST- 2022/03/10 06:00 [pubmed]
PHST- 2022/08/09 06:00 [medline]
PHST- 2022/03/09 05:33 [entrez]
AID - EIJ-D-21-00870 [pii]
AID - 10.4244/EIJ-D-21-00870 [doi]
PST - epublish
SO  - EuroIntervention. 2022 Aug 5;18(5):e377-e388. doi: 10.4244/EIJ-D-21-00870.

PMID- 3939270
OWN - NLM
STAT- MEDLINE
DCOM- 19860916
LR  - 20190820
IS  - 0039-128X (Print)
IS  - 0039-128X (Linking)
VI  - 46
IP  - 2-3
DP  - 1985 Aug-Sep
TI  - Prostaglandin inhibitors and the development of mung bean seedlings.
PG  - 727-33
AB  - The effect of cortisol and prostaglandin inhibitors on the growth and development 
      of germinating mung bean, Vigna radiata L. Wilzek, cv. Jumbo was investigated. 
      Cortisol, indomethacin, and a mixture of cortisol with aspirin, or benoxaprofen 
      significantly increased radicle length and the number of lateral roots as 
      compared with non-treated controls. A mixture of cortisol and indomethacin 
      significantly increased growth of hypocotyls.
FAU - Gawienowski, A M
AU  - Gawienowski AM
FAU - Csernus, K M
AU  - Csernus KM
FAU - Simon, J E
AU  - Simon JE
FAU - Craker, L E
AU  - Craker LE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Steroids
JT  - Steroids
JID - 0404536
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 0 (Propionates)
RN  - 0 (Prostaglandin Antagonists)
RN  - 17SZX404IM (benoxaprofen)
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Fabaceae/drug effects/growth & development
MH  - Hydrocortisone/*pharmacology
MH  - Indomethacin/pharmacology
MH  - Lipoxygenase Inhibitors
MH  - *Plant Development
MH  - Plants/drug effects
MH  - Plants, Medicinal
MH  - Propionates/pharmacology
MH  - Prostaglandin Antagonists/*pharmacology
EDAT- 1985/08/01 00:00
MHDA- 1985/08/01 00:01
CRDT- 1985/08/01 00:00
PHST- 1985/08/01 00:00 [pubmed]
PHST- 1985/08/01 00:01 [medline]
PHST- 1985/08/01 00:00 [entrez]
AID - 0039-128X(85)90052-2 [pii]
AID - 10.1016/0039-128x(85)90052-2 [doi]
PST - ppublish
SO  - Steroids. 1985 Aug-Sep;46(2-3):727-33. doi: 10.1016/0039-128x(85)90052-2.

PMID- 30783075
OWN - NLM
STAT- MEDLINE
DCOM- 20190326
LR  - 20200225
IS  - 1941-5923 (Electronic)
IS  - 1941-5923 (Linking)
VI  - 20
DP  - 2019 Feb 20
TI  - Nasogastric Tubes Can Cause Intramural Hematoma of the Esophagus.
PG  - 224-227
LID - 10.12659/AJCR.914133 [doi]
AB  - BACKGROUND Intramural hematoma of the esophagus (IHE), a rare manifestation of 
      acute mucosal injuries of the esophagus, can be caused by trauma such as 
      endoscopic surgeries. Coagulation disorders increase the risk of IHE. The most 
      common location of IHE is in the distal esophagus. The characteristic clinical 
      triad of manifestations comprises acute retrosternal pain, odynophagia or 
      dysphagia, and hematemesis. It is important to distinguish IHE from other acute 
      conditions such as acute coronary syndrome, aortic dissection, and pulmonary 
      embolism. CASE REPORT An 84-year-old male was scheduled for coil embolization for 
      an endoleak after endovascular aneurysm repair. For this reason, he was taking 
      aspirin and warfarin. A nasogastric tube had been inserted during surgery and 
      subsequently removed without any problems reported. Postoperatively, he 
      experienced chest pain and hematemesis of sudden onset. Urgent 
      esophagogastroduodenoscopy demonstrated a large, dark red, non-pulsatile, 
      submucosal, esophageal mass in the area of the mid-esophagus with a little 
      oozing. He was diagnosed as having an IHE; other possible diagnoses were excluded 
      by contrast-enhanced computed tomography and aortography. He was treated with 
      fasting, a proton pump inhibitor, and cessation of anti-thrombotic drugs; he 
      recovered completely. The bleeding spot in the esophagus was in the area of the 
      mid-esophagus, which was around the second natural constriction site. It was 
      possible that the nasogastric tube had contact with the esophageal wall at this 
      second natural constriction, and caused intramural esophageal bleeding. 
      CONCLUSIONS Nasogastric tubes are not generally recognized as a cause of IHE. 
      However, they can cause them, especially when a patient is taking anti-thrombotic 
      drugs.
FAU - Yamada, Toru
AU  - Yamada T
AD  - Department of General Medicine/Family and Community Medicine, Nagoya University 
      Graduate School of Medicine, Nagoya, Aichi, Japan.
AD  - Department of Internal Medicine, Tokyo Bay Urayasu Ichikawa Medical Center, 
      Urayasu, Chiba, Japan.
FAU - Motomura, Yasuaki
AU  - Motomura Y
AD  - Department of Gastroenterology, Tokyo Bay Urayasu Ichikawa Medical Center, 
      Urayasu, Chiba, Japan.
FAU - Hiraoka, Eiji
AU  - Hiraoka E
AD  - Department of Internal Medicine, Tokyo Bay Urayasu Ichikawa Medical Center, 
      Urayasu, Chiba, Japan.
FAU - Miyagaki, Aki
AU  - Miyagaki A
AD  - Department of Gastroenterology, Tokyo Bay Urayasu Ichikawa Medical Center, 
      Urayasu, Chiba, Japan.
FAU - Sato, Juichi
AU  - Sato J
AD  - Department of General Medicine/Family and Community Medicine, Nagoya University 
      Graduate School of Medicine, Nagoya, Aichi, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20190220
PL  - United States
TA  - Am J Case Rep
JT  - The American journal of case reports
JID - 101489566
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged, 80 and over
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Esophageal Diseases/*etiology
MH  - Hematoma/*etiology
MH  - Humans
MH  - Intubation, Gastrointestinal/*adverse effects/instrumentation
MH  - Male
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Warfarin/therapeutic use
PMC - PMC6394141
COIS- Conflict of interest: None declared Conflict of interest None.
EDAT- 2019/02/21 06:00
MHDA- 2019/03/27 06:00
CRDT- 2019/02/21 06:00
PHST- 2019/02/21 06:00 [entrez]
PHST- 2019/02/21 06:00 [pubmed]
PHST- 2019/03/27 06:00 [medline]
AID - 914133 [pii]
AID - 10.12659/AJCR.914133 [doi]
PST - epublish
SO  - Am J Case Rep. 2019 Feb 20;20:224-227. doi: 10.12659/AJCR.914133.

PMID- 17027104
OWN - NLM
STAT- MEDLINE
DCOM- 20070822
LR  - 20171116
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 118
IP  - 2
DP  - 2007 May 31
TI  - Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic 
      patients undergoing CABG.
PG  - 164-9
AB  - BACKGROUND: Type 2 diabetes mellitus (DM) is known to negatively affect 
      biological properties of venous vasculature, and, particularly, to reduce 
      endothelium-derived nitric oxide release. This condition might influence venous 
      graft function following coronary artery bypass surgery (CABG). The aim of this 
      study was to evaluate the functional effects of a NO-releasing aspirin (NORA) on 
      vein grafts (VG) of diabetics and control patients undergoing elective CABG. 
      METHODS: In 40 consecutive ischemic heart disease patients, the effects of NORA 
      were tested on segments of saphenous vein conduits harvested during elective 
      CABG. Twenty patients had type-2 DM (mean age 69+/-2), whereas 20 patients had no 
      DM (NDM) and represented the control group (mean age 67+/-4). Functional 
      responses were tested by exposing VGs to NORA and to standard vasoactive agents 
      in an organ-bath preparation. Histological features of VGs were also assessed by 
      light and electronic microscopy. RESULTS: Significant impairment of 
      endothelial-dependent vasodilation (acetylcholine induced) was documented in VGs 
      of DM subjects. NORA induced a significant and comparable vascular relaxation in 
      all venous segments of NDM and DM patients (56+/-12% of maximal relaxation vs 
      61+/-11% in the control group, respectively). Histology showed variable extent of 
      vascular layer and cellular abnormalities in VGs of diabetics (intimal 
      hyperplasia, calcific deposition, endothelial cell degeneration) likely 
      responsible of the endothelial functional impairment, whereas control group VG 
      showed preserved structures. CONCLUSIONS: This preliminary study confirms the 
      impairment of endothelium-dependent vasodilative property of VGs in DM patients. 
      It also indicates that NORA effectively induces vasodilation of VGs which was 
      effective also in DM patients thereby representing a promising therapy for 
      diabetics undergoing CABG with the use of VGs, although further studies are 
      mandatory to conclusively assess the safety and benefits of this pharmacological 
      agent.
FAU - Lorusso, Roberto
AU  - Lorusso R
AD  - Experimental Cardiac Surgery Laboratory and Cardiac Surgery Unit, Civic Hospital, 
      Brescia, Italy. roberto_lorusso@iol.it
FAU - De Cicco, Giuseppe
AU  - De Cicco G
FAU - Beghi, Cesare
AU  - Beghi C
FAU - Gherli, Tiziano
AU  - Gherli T
FAU - Poli, Enzo
AU  - Poli E
FAU - Corradi, Domenico
AU  - Corradi D
FAU - Maestri, Roberta
AU  - Maestri R
FAU - Bonadonna, Stefania
AU  - Bonadonna S
FAU - Mancini, Tatiana
AU  - Mancini T
FAU - Giustina, Andrea
AU  - Giustina A
LA  - eng
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061005
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Vasodilator Agents)
RN  - 169D1260KM (Nitroprusside)
RN  - EH04H13L6B (nitroaspirin)
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetylcholine/therapeutic use
MH  - Aged
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - *Coronary Artery Bypass
MH  - Coronary Artery Disease/complications/drug therapy/pathology/*surgery
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Dose-Response Relationship, Drug
MH  - Endothelium, Vascular/drug effects
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Nitroprusside/therapeutic use
MH  - Saphenous Vein/*drug effects/*transplantation
MH  - *Transplants
MH  - Vasoconstriction/drug effects
MH  - Vasodilator Agents/therapeutic use
EDAT- 2006/10/10 09:00
MHDA- 2007/08/23 09:00
CRDT- 2006/10/10 09:00
PHST- 2006/02/04 00:00 [received]
PHST- 2006/06/26 00:00 [revised]
PHST- 2006/07/11 00:00 [accepted]
PHST- 2006/10/10 09:00 [pubmed]
PHST- 2007/08/23 09:00 [medline]
PHST- 2006/10/10 09:00 [entrez]
AID - S0167-5273(06)00777-7 [pii]
AID - 10.1016/j.ijcard.2006.07.014 [doi]
PST - ppublish
SO  - Int J Cardiol. 2007 May 31;118(2):164-9. doi: 10.1016/j.ijcard.2006.07.014. Epub 
      2006 Oct 5.

PMID- 9106592
OWN - NLM
STAT- MEDLINE
DCOM- 19970502
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 111
IP  - 4
DP  - 1997 Apr
TI  - Effect of acetylsalicylic acid on pulmonary gas exchange in patients with severe 
      pneumonia: a pilot study.
PG  - 1094-100
AB  - BACKGROUND: It has been hypothesized that local release of prostacyclin in acute 
      pneumonia may ablate hypoxic pulmonary vasoconstriction, thus contributing to the 
      impairment of pulmonary gas exchange in these patients. Inhibition of 
      cyclooxygenase pathway could prevent this phenomenon by reducing the release of 
      these metabolites. METHODS: A study was designed to assess the effect of I.V. 
      acetylsalicylic acid (ASA) (2 g) on pulmonary gas exchange in seven patients 
      (age, 64+/-11 [mean+/-SD] years) with unilateral severe pneumonia (PaO2/fraction 
      of inspired oxygen, 168+/-67) needing mechanical ventilation. Respiratory gases, 
      pulmonary and systemic hemodynamics, and ventilation-perfusion (VA/Q) 
      distributions were studied before and 15 and 60 min after the infusion of ASA. 
      RESULTS: At baseline, the amount of shunt (VA/Q ratios <0.005) was 28+/-17% of 
      cardiac output, blood flow to areas with low VA/Q ratios (<0.1, excluding shunt) 
      was 8+/-7%, and the dispersion of pulmonary blood flow distribution (second 
      moment, log SD Q) was 1.45+/-0.49 (normal range, 0.3 to 0.6). Sixty minutes after 
      the infusion of ASA, we observed a mild reduction of the amount of shunt, from 
      28+/-17% to 23.5+/-13% (p<0.05) without changes in arterial oxygenation. This was 
      associated with a significant increase in mean pulmonary artery pressure (from 
      21.9+/-3.6 to 24.4+/-5.1 and 23.9+/-5.3 mm Hg, p<0.025 and p=0.1) and pulmonary 
      vascular resistance (from 1.4+/-0.9 to 1.8+/-0.8 and 1.8+/-1.3 mm Hg x min x 
      L(-1) , p<0.002 and p=0.11) 15 and 60 min after ASA, respectively. The ASA plasma 
      levels were within the normal therapeutic range (120+/-7 microg/mL, 15 min, and 
      113+/-11 microg/mL, 60 min after ASA infusion). CONCLUSIONS: Although there was a 
      modest improvement in intrapulmonary shunt, our results suggest that perfusion of 
      ASA in this small sample of patients with severe pneumonia appears to be of 
      little benefit as complementary treatment for severe hypoxemia.
FAU - Ferrer, M
AU  - Ferrer M
AD  - Hospital Clínic, Departament de Medicina, Universitat de Barcelona, Spain.
FAU - Torres, A
AU  - Torres A
FAU - Baer, R
AU  - Baer R
FAU - Hernández, C
AU  - Hernández C
FAU - Roca, J
AU  - Roca J
FAU - Rodriguez-Roisin, R
AU  - Rodriguez-Roisin R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 142M471B3J (Carbon Dioxide)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Carbon Dioxide/analysis
MH  - Cyclooxygenase Inhibitors/administration & dosage/*pharmacology
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Oxygen/analysis
MH  - Pilot Projects
MH  - Pneumonia, Bacterial/*physiopathology
MH  - Pulmonary Gas Exchange/*drug effects
MH  - Ventilation-Perfusion Ratio/drug effects
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - S0012-3692(15)46874-6 [pii]
AID - 10.1378/chest.111.4.1094 [doi]
PST - ppublish
SO  - Chest. 1997 Apr;111(4):1094-100. doi: 10.1378/chest.111.4.1094.

PMID- 28683466
OWN - NLM
STAT- MEDLINE
DCOM- 20170907
LR  - 20181113
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 117
IP  - 3
DP  - 2017 Jul 25
TI  - Commonly used medications and endometrial cancer survival: a population-based 
      cohort study.
PG  - 432-438
LID - 10.1038/bjc.2017.207 [doi]
AB  - BACKGROUND: Increasing incidence and new indications for existing drugs make it 
      important to identify new adjuvant therapies for endometrial cancer (EC). 
      METHODS: This is a prospective cohort study of 3058 newly diagnosed EC cases from 
      1998 to 2010, identified through record linkages between the UK Clinical Practice 
      Research Datalink, the National Cancer Research Datalink and death registrations 
      from the Office of National Statistics. Using Cox regression models, unadjusted 
      and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were 
      calculated for EC-specific survival. RESULTS: Over a mean 6.1 (range 1-16) years 
      of follow-up, there were 394 EC-specific deaths. There was no evidence of a 
      significant association between post-diagnostic use of statins (adjusted HR 0.83, 
      95% CI 0.64, 1.08), β-blockers (adjusted HR 0.86, 95% CI 0.65, 1.13) or low-dose 
      aspirin (adjusted HR 0.91, 95% CI 0.69, 1.20) and EC survival before or after 
      adjustment for confounders. There were also no evidence of a dose-response 
      association between these drug groups and EC survival. CONCLUSIONS: In this large 
      UK population-based study, no significant associations were observed for 
      post-diagnostic use of statins, β-blockers or low-dose aspirin and EC survival.
FAU - Sanni, Omolara B
AU  - Sanni OB
AD  - Cancer Epidemiology and Health Services Research Group, Centre for Public Health, 
      Royal Victoria Hospital, Queen's University Belfast, Block B, Grosvenor Road, 
      Belfast, Northern Ireland.
FAU - Mc Menamin, Úna C
AU  - Mc Menamin ÚC
AD  - Cancer Epidemiology and Health Services Research Group, Centre for Public Health, 
      Royal Victoria Hospital, Queen's University Belfast, Block B, Grosvenor Road, 
      Belfast, Northern Ireland.
FAU - Cardwell, Chris R
AU  - Cardwell CR
AD  - Cancer Epidemiology and Health Services Research Group, Centre for Public Health, 
      Royal Victoria Hospital, Queen's University Belfast, Block B, Grosvenor Road, 
      Belfast, Northern Ireland.
FAU - Sharp, Linda
AU  - Sharp L
AD  - Institute of Health and Society, Newcastle University, Baddiley-Clark Building, 
      Richardson Road, Newcastle upon Tyne NE2 4AX, UK.
FAU - Murray, Liam J
AU  - Murray LJ
AD  - Cancer Epidemiology and Health Services Research Group, Centre for Public Health, 
      Royal Victoria Hospital, Queen's University Belfast, Block B, Grosvenor Road, 
      Belfast, Northern Ireland.
FAU - Coleman, Helen G
AU  - Coleman HG
AD  - Cancer Epidemiology and Health Services Research Group, Centre for Public Health, 
      Royal Victoria Hospital, Queen's University Belfast, Block B, Grosvenor Road, 
      Belfast, Northern Ireland.
LA  - eng
PT  - Journal Article
DEP - 20170706
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Endometrial Neoplasms/diagnosis/*mortality
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Middle Aged
MH  - Prospective Studies
MH  - Survival Rate
MH  - Time Factors
MH  - United Kingdom/epidemiology
PMC - PMC5537503
COIS- The authors declare no conflict of interest.
EDAT- 2017/07/07 06:00
MHDA- 2017/09/08 06:00
CRDT- 2017/07/07 06:00
PHST- 2017/01/25 00:00 [received]
PHST- 2017/05/22 00:00 [revised]
PHST- 2017/06/09 00:00 [accepted]
PHST- 2017/07/07 06:00 [pubmed]
PHST- 2017/09/08 06:00 [medline]
PHST- 2017/07/07 06:00 [entrez]
AID - bjc2017207 [pii]
AID - 10.1038/bjc.2017.207 [doi]
PST - ppublish
SO  - Br J Cancer. 2017 Jul 25;117(3):432-438. doi: 10.1038/bjc.2017.207. Epub 2017 Jul 
      6.

PMID- 22100881
OWN - NLM
STAT- MEDLINE
DCOM- 20120411
LR  - 20161125
IS  - 1873-2399 (Electronic)
IS  - 0301-472X (Linking)
VI  - 40
IP  - 3
DP  - 2012 Mar
TI  - Para-NO-aspirin inhibits NF-κB and induces apoptosis in B-cell progenitor acute 
      lymphoblastic leukemia.
PG  - 207-215.e1
LID - 10.1016/j.exphem.2011.11.001 [doi]
AB  - Although patients with acute lymphoblastic leukemia (ALL) usually achieve 
      complete remission, disease relapse is common and difficult to treat. 
      Para-NO-aspirin (para-NO-ASA) is a novel drug with demonstrated efficacy against 
      a number of solid tumors and most recently chronic lymphocytic leukemia. In this 
      study, we used ALL cell lines to assess the effects on cell viability by flow 
      cytometry and investigated the mechanism of cell death using chemical inhibitors 
      of key molecules and assessed the effects by flow cytometry, electrophoretic 
      mobility shift assay, Western blotting, and quantitative reverse transcription 
      polymerase chain reaction. Para-NO-ASA induced cell death in the pre-B ALL cell 
      lines in association with increased reactive oxygen species, and suppression of 
      nuclear factor-κB (NF-κB) activity. Chemical inhibitors of NF-κB similarly 
      induced apoptosis in ALL cells, suggesting a role for suppression of NF-κB in 
      para-NO-ASA-induced cell death. Modulation of NF-κB was not via regulation of IκB 
      but potentially through suppression of ROCK1 and loss of reduced glutathione. Our 
      results demonstrate that para-NO-ASA potently induces apoptosis in B-lineage ALL 
      cells via a reactive oxygen species-dependent mechanism that is associated with 
      suppression of NF-κB activity.
CI  - Copyright Â© 2012 ISEH - Society for Hematology and Stem Cells. Published by 
      Elsevier Inc. All rights reserved.
FAU - Khan, Naveed I
AU  - Khan NI
AD  - Westmead Institute for Cancer Research, Westmead Millennium Institute, University 
      of Sydney, Sydney, New South Wales, Australia.
FAU - Cisterne, Adam
AU  - Cisterne A
FAU - Baraz, Rana
AU  - Baraz R
FAU - Bradstock, Kenneth F
AU  - Bradstock KF
FAU - Bendall, Linda J
AU  - Bendall LJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111117
PL  - Netherlands
TA  - Exp Hematol
JT  - Experimental hematology
JID - 0402313
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (NF-kappa B)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (nitroxy-butyl-acetylsalicylic acid)
RN  - EC 2.7.11.1 (ROCK1 protein, human)
RN  - EC 2.7.11.1 (rho-Associated Kinases)
RN  - EC 3.4.22.- (Caspases)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Caspases/metabolism
MH  - Cell Line, Tumor/drug effects/metabolism
MH  - Drug Screening Assays, Antitumor
MH  - Glutathione/metabolism
MH  - Humans
MH  - NF-kappa B/*antagonists & inhibitors
MH  - Neoplasm Proteins/*antagonists & inhibitors/metabolism
MH  - Nitric Oxide Donors/*pharmacology
MH  - Oxidative Stress
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*pathology
MH  - Reactive Oxygen Species/metabolism
MH  - rho-Associated Kinases/metabolism
EDAT- 2011/11/22 06:00
MHDA- 2012/04/12 06:00
CRDT- 2011/11/22 06:00
PHST- 2011/07/09 00:00 [received]
PHST- 2011/11/06 00:00 [revised]
PHST- 2011/11/10 00:00 [accepted]
PHST- 2011/11/22 06:00 [entrez]
PHST- 2011/11/22 06:00 [pubmed]
PHST- 2012/04/12 06:00 [medline]
AID - S0301-472X(11)00544-3 [pii]
AID - 10.1016/j.exphem.2011.11.001 [doi]
PST - ppublish
SO  - Exp Hematol. 2012 Mar;40(3):207-215.e1. doi: 10.1016/j.exphem.2011.11.001. Epub 
      2011 Nov 17.

PMID- 21034320
OWN - NLM
STAT- MEDLINE
DCOM- 20101222
LR  - 20131121
IS  - 0002-9645 (Print)
IS  - 0002-9645 (Linking)
VI  - 71
IP  - 11
DP  - 2010 Nov
TI  - Influence of treatment with ultralow-dose aspirin on platelet aggregation as 
      measured by whole blood impedance aggregometry and platelet P-selectin expression 
      in clinically normal dogs.
PG  - 1294-304
LID - 10.2460/ajvr.71.11.1294 [doi]
AB  - OBJECTIVE: To evaluate the influence of treatment with ultralow-dose aspirin 
      (ULDAsp) on platelet aggregation, P-selectin (CD62P) expression, and formation of 
      platelet-leukocyte aggregates in clinically normal dogs. ANIMALS: 18 clinically 
      normal dogs. PROCEDURES: Studies were conducted before and 24 hours after ULDAsp 
      administration (0.5 mg/kg, PO, q 24 h, for 2 days). Whole blood impedance 
      aggregometry for the assessment of platelet function was performed with sodium 
      citrate-anticoagulated blood and aggregation agonists (ADP at 20, 10, and 5 
      μmol/L; collagen at 10, 5, and 2 μg/mL). Onset, maximum response, and rate of 
      platelet aggregation were recorded. Flow cytometric assays were configured to 
      detect thrombin-induced CD62P expression and platelet-leukocyte aggregates in 
      EDTA-anticoagulated whole blood. Externalized platelet CD62P and constitutive 
      CD61 (GPIIIa) were labeled with antibodies conjugated to phycoerythrin (PE) and 
      fluorescein isothiocyanate (FITC), respectively. Red blood cell-lysed 
      paraformaldehyde-fixed EDTA-anticoagulated whole blood was dual labeled with 
      CD61-FITC and a panleukocyte antibody (CD18-PE) to characterize 
      platelet-leukocyte aggregates. RESULTS: ULDAsp significantly delayed platelet 
      aggregation onset with ADP at 20 μmol/L by 54% to 104%, attenuated maximum 
      aggregation with various concentrations of ADP and collagen by ≥ 41%, and slowed 
      aggregation rate with the highest ADP and collagen concentrations by ≥ 39%. 
      Depending on the parameter tested, up to 30% of dogs failed to have an ULDAsp 
      effect. Thrombin stimulation significantly increased CD62P expression in 
      platelets and platelet-leukocyte aggregates, but ULDAsp did not alter basal or 
      thrombin-stimulated CD62P expression. CONCLUSIONS AND CLINICAL RELEVANCE: ULDAsp 
      treatment of clinically normal dogs impaired platelet aggregation in most dogs, 
      but did not influence CD62P platelet membrane expression.
FAU - Sharpe, Kristopher S
AU  - Sharpe KS
AD  - Department of Clinical Sciences, Cornell University, Ithaca, NY 14853, USA.
FAU - Center, Sharon A
AU  - Center SA
FAU - Randolph, John F
AU  - Randolph JF
FAU - Brooks, Marjory B
AU  - Brooks MB
FAU - Warner, Karen L
AU  - Warner KL
FAU - Stokol, Tracy
AU  - Stokol T
FAU - Barr, Stephen C
AU  - Barr SC
FAU - Felippe, M Julia
AU  - Felippe MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Vet Res
JT  - American journal of veterinary research
JID - 0375011
RN  - 0 (P-Selectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/drug effects/physiology
MH  - Body Composition/drug effects
MH  - Body Weight
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Flow Cytometry
MH  - Gene Expression Regulation
MH  - Male
MH  - Orchiectomy
MH  - Ovariectomy
MH  - P-Selectin/drug effects/*genetics
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Reference Values
EDAT- 2010/11/03 06:00
MHDA- 2010/12/24 06:00
CRDT- 2010/11/02 06:00
PHST- 2010/11/02 06:00 [entrez]
PHST- 2010/11/03 06:00 [pubmed]
PHST- 2010/12/24 06:00 [medline]
AID - 10.2460/ajvr.71.11.1294 [doi]
PST - ppublish
SO  - Am J Vet Res. 2010 Nov;71(11):1294-304. doi: 10.2460/ajvr.71.11.1294.

PMID- 19373431
OWN - NLM
STAT- MEDLINE
DCOM- 20090805
LR  - 20211020
IS  - 0944-1174 (Print)
IS  - 0944-1174 (Linking)
VI  - 44
IP  - 6
DP  - 2009
TI  - Characteristics of small bowel injury in symptomatic chronic low-dose aspirin 
      users: the experience of two medical centers in capsule endoscopy.
PG  - 544-9
LID - 10.1007/s00535-009-0040-z [doi]
AB  - BACKGROUND: The antithrombotic effects of low-dose aspirin (LDA) are well 
      established, and it is used for primary and secondary prevention of 
      cardiovascular events. However, the small intestinal toxicity of LDA remains 
      unclear. The aim of this study was to review the characteristics of small bowel 
      injury in long-term LDA users with capsule endoscopy (CE). METHODS: We 
      retrospectively reviewed all chronic LDA users (>3 months) who underwent CE for 
      suspected small bowel diseases from May 2004 to May 2008 at two medical centers. 
      RESULTS: At our institutions, a total of 22 patients (13 males and 9 females, 
      mean age 66.3 years) taking LDA underwent a CE examination. The indications for 
      CE were obscure gastrointestinal bleeding in 21 patients and 1 patient who had 
      abdominal pain. Twenty-one patients (95.5%) had some small bowel mucosal injury. 
      Small bowel erosions were identified in 14 patients (63.6%). This enteropathy was 
      characterized by multiple petechiae, loss of villi, erosions, and ulcers with 
      round, irregular, and punched-out shapes. Two patients had circumferential ulcers 
      with stricture. In most patients, small bowel lesions were multifocal and were 
      evenly distributed in the small bowel. No patients failed to pass the capsule. 
      CONCLUSIONS: This is the first CE report that has studied the characteristics of 
      small bowel injury in chronic LDA users. CE is useful to diagnose small bowel 
      enteropathy associated with LDA.
FAU - Endo, Hiroki
AU  - Endo H
AD  - Division of Gastroenterology, Yokohama City University School of Medicine, 3-9 
      Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. t066011b@yokohama-cu.ac.jp
FAU - Hosono, Kunihiro
AU  - Hosono K
FAU - Inamori, Masahiko
AU  - Inamori M
FAU - Nozaki, Yuichi
AU  - Nozaki Y
FAU - Yoneda, Kyoko
AU  - Yoneda K
FAU - Fujita, Koji
AU  - Fujita K
FAU - Takahashi, Hirokazu
AU  - Takahashi H
FAU - Yoneda, Masato
AU  - Yoneda M
FAU - Abe, Yasunobu
AU  - Abe Y
FAU - Kirikoshi, Hiroyuki
AU  - Kirikoshi H
FAU - Kobayashi, Noritoshi
AU  - Kobayashi N
FAU - Kubota, Kensuke
AU  - Kubota K
FAU - Saito, Satoru
AU  - Saito S
FAU - Ohya, Tomohiko
AU  - Ohya T
FAU - Hisatomi, Kantaro
AU  - Hisatomi K
FAU - Teratani, Takuma
AU  - Teratani T
FAU - Matsuhashi, Nobuyuki
AU  - Matsuhashi N
FAU - Nakajima, Atsushi
AU  - Nakajima A
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20090417
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdominal Pain/chemically induced
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Capsule Endoscopy
MH  - Female
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Intestinal Mucosa/drug effects/pathology
MH  - Intestine, Small/*drug effects/*pathology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Young Adult
EDAT- 2009/04/18 09:00
MHDA- 2009/08/06 09:00
CRDT- 2009/04/18 09:00
PHST- 2008/09/29 00:00 [received]
PHST- 2009/01/05 00:00 [accepted]
PHST- 2009/04/18 09:00 [entrez]
PHST- 2009/04/18 09:00 [pubmed]
PHST- 2009/08/06 09:00 [medline]
AID - 10.1007/s00535-009-0040-z [doi]
PST - ppublish
SO  - J Gastroenterol. 2009;44(6):544-9. doi: 10.1007/s00535-009-0040-z. Epub 2009 Apr 
      17.

PMID- 15613941
OWN - NLM
STAT- MEDLINE
DCOM- 20050519
LR  - 20190917
IS  - 1044-3983 (Print)
IS  - 1044-3983 (Linking)
VI  - 16
IP  - 1
DP  - 2005 Jan
TI  - Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using 
      external information: the example of COX2 inhibitors and myocardial infarction.
PG  - 17-24
AB  - BACKGROUND: Large health care utilization datasets are frequently used to analyze 
      the incidence of rare adverse events from medications. However, possible 
      confounders are typically not measured in such datasets. We show how to assess 
      the impact of confounding by factors not measured in Medicare claims data in a 
      study of the association between selective COX2 inhibitors and acute myocardial 
      infarction (MI). METHODS: Using the Medicare Current Beneficiary Survey, we 
      assessed the association between use of selective COX2 inhibitors and 5 potential 
      confounders not measured in Medicare claims data: body-mass index, aspirin use, 
      smoking, income, and educational attainment. For 8,785 participants > or =65 
      years, we estimated the prevalence of selective COX2 inhibitor use and also of 
      each confounder, as well as the association between drug exposure and 
      confounders. Estimates of the confounder-disease associations from the medical 
      literature were used to calculate the extent of residual confounding bias for 
      each potential confounder. RESULTS: Selective COX2 inhibitor users were less 
      likely to be smokers (8% versus 10%) than nonselective NSAID users, while the 
      prevalence of obesity was comparable (24%). Aspirin use was also balanced among 
      all drug exposure categories. Failure to adjust for 5 potential confounders led 
      to a small underestimation of the association between selective COX2 inhibitors 
      and MI; comparing selective COX2 inhibitors with NSAIDs, the net bias was 
      estimated to be -1.0% of the unknown true effect size (maximum range: -6% to 0%). 
      CONCLUSIONS: In this example of the relationship between selective COX2 
      inhibitors and MI, not adjusting for 5 potential confounders in Medicare claims 
      data analyses tended to slightly underestimate the association, but is unlikely 
      to cause important bias.
FAU - Schneeweiss, Sebastian
AU  - Schneeweiss S
AD  - Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's 
      Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA. 
      schneeweiss@post.harvard.edu
FAU - Glynn, Robert J
AU  - Glynn RJ
FAU - Tsai, Elizabeth H
AU  - Tsai EH
FAU - Avorn, Jerry
AU  - Avorn J
FAU - Solomon, Daniel H
AU  - Solomon DH
LA  - eng
GR  - K23-AR48616/AR/NIAMS NIH HHS/United States
GR  - R01-AG18833/AG/NIA NIH HHS/United States
GR  - R03-AG19463/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Epidemiology
JT  - Epidemiology (Cambridge, Mass.)
JID - 9009644
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Body Mass Index
MH  - Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Medicare
MH  - Myocardial Infarction/*drug therapy
MH  - Pharmacoepidemiology/methods/*statistics & numerical data
MH  - Smoking
MH  - Socioeconomic Factors
EDAT- 2004/12/23 09:00
MHDA- 2005/05/20 09:00
CRDT- 2004/12/23 09:00
PHST- 2004/12/23 09:00 [pubmed]
PHST- 2005/05/20 09:00 [medline]
PHST- 2004/12/23 09:00 [entrez]
AID - 00001648-200501000-00004 [pii]
AID - 10.1097/01.ede.0000147164.11879.b5 [doi]
PST - ppublish
SO  - Epidemiology. 2005 Jan;16(1):17-24. doi: 10.1097/01.ede.0000147164.11879.b5.

PMID- 17926526
OWN - NLM
STAT- MEDLINE
DCOM- 20071218
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 65
IP  - 10
DP  - 2007 Oct
TI  - [Diagnostic imaging of NSAID ulcers].
PG  - 1792-800
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin cause frequently 
      gastrointestinal injuries. In the acute phase of NSAIDs damage, endoscopic 
      findings of gastroduodenal injuries are observed as acute gastroduodenal mucosal 
      lesion (AGDML). Especially, non-aspirin NSAIDs cause sometimes hemorrhagic 
      gastroduodenal ulcers. In the chronic phase of NSAIDs damage, multiple antral 
      erosions and/or ulcers with oozing, and punched-out antral ulcers are 
      characteristic findings. Recently, it was noted by capsule-endoscopy and 
      double-balloon endoscopy that NSAIDs induce more frequent small intestine 
      lesions. The characteristic findings of them are multiple erosions and/or ulcers 
      in various forms. Circular ulcers of the small intestine and colon ulcers, 
      colitis are induced by NSAIDs lower frequency comparing with upper GI tract 
      injuries. In conclusion, characteristic images of gastrointestinal injuries 
      induced by NSAIDs are multiple erosions and ulcers with bleeding without 
      symptoms. It is most important asking about use of NSAIDs if we see such 
      endoscopic images.
FAU - Ono, Shouko
AU  - Ono S
AD  - Division of Endoscopy, Hokkaido University Hospital.
FAU - Kato, Mototsugu
AU  - Kato M
FAU - Asaka, Masahiro
AU  - Asaka M
FAU - Ono, Yuji
AU  - Ono Y
FAU - Yokoyama, Akiko
AU  - Yokoyama A
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/adverse effects
MH  - Endoscopy, Gastrointestinal
MH  - Female
MH  - Humans
MH  - Male
MH  - Peptic Ulcer/*chemically induced/*diagnosis
EDAT- 2007/10/12 09:00
MHDA- 2007/12/19 09:00
CRDT- 2007/10/12 09:00
PHST- 2007/10/12 09:00 [pubmed]
PHST- 2007/12/19 09:00 [medline]
PHST- 2007/10/12 09:00 [entrez]
PST - ppublish
SO  - Nihon Rinsho. 2007 Oct;65(10):1792-800.

PMID- 1806377
OWN - NLM
STAT- MEDLINE
DCOM- 19920513
LR  - 20131121
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 12 Suppl G
DP  - 1991 Dec
TI  - Antiaggregating therapy in acute myocardial infarction.
PG  - 30-2
AB  - The clinical benefit of aspirin in the acute phase of myocardial infarction is 
      dramatically suggested by the results of the ISIS-2 trial. However, the time 
      course of pathophysiological events that lead to such a determining involvement 
      of platelets still appears uncertain and further study is needed to single out 
      exactly how early and how long antiplatelet drugs should be given, since there is 
      a risk of bleeding complications due to the combination of the different 
      antithrombotic therapies. Thrombolytic agents and heparin are in fact widely used 
      for patients with acute myocardial infarction, even if the optimal schedule of 
      treatment, including anti-aggregating therapy, is not yet firmly established. To 
      avoid rethrombosis and to enhance the efficacy of coronary thrombolysis, thus 
      reducing early mortality, several newer antiplatelet agents other than aspirin, 
      such as antibodies against the platelet receptor of adhesive proteins, the 
      glycoprotein IIb/IIIa and the RGD peptides, are currently under investigation.
FAU - Cimminiello, C
AU  - Cimminiello C
AD  - Fourth Medical Department, San Carlo Borromeo General Hospital, Milan, Italy.
FAU - Uberti, T
AU  - Uberti T
FAU - Fiorista, F
AU  - Fiorista F
FAU - Marzegalli, M
AU  - Marzegalli M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/blood/*drug therapy
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Thrombolytic Therapy
RF  - 15
EDAT- 1991/12/01 00:00
MHDA- 1991/12/01 00:01
CRDT- 1991/12/01 00:00
PHST- 1991/12/01 00:00 [pubmed]
PHST- 1991/12/01 00:01 [medline]
PHST- 1991/12/01 00:00 [entrez]
PST - ppublish
SO  - Eur Heart J. 1991 Dec;12 Suppl G:30-2.

PMID- 3169279
OWN - NLM
STAT- MEDLINE
DCOM- 19881118
LR  - 20191022
IS  - 0950-821X (Print)
IS  - 0950-821X (Linking)
VI  - 2
IP  - 2
DP  - 1988 Apr
TI  - Platelet kinetics following carotid endarterectomy: the effect of aspirin and 
      patch angioplasty.
PG  - 99-104
AB  - Platelet deposition on the subintimal surface of the arterial wall following 
      endarterectomy has been implicated in the development of postoperative 
      thrombosis, intimal hyperplasia and may be important in recurrent stenosis. 
      Autologous radiolabelled platelet deposition has been measured in 51 patients 
      following carotid endarterectomy. The effect of platelet inhibitory drugs and 
      patch angioplasty on early postoperative platelet accumulation at the site of 
      endarterectomy has been investigated. In patients undergoing direct suture of the 
      arteriotomy, platelet deposition measured as the Carotid Uptake Ratio was 
      significantly reduced from 1.44 +/- 0.03 to 1.11 +/- 0.35 in those receiving 
      aspirin and dipyridamole (P less than 0.002). Carotid Uptake Ratio was greater 
      following patch angioplasty at 1.41 +/- 0.07 when compared to 1.14 +/- 0.07 with 
      direct suture of the arteriotomy (P less than 0.002).
FAU - Meek, A C
AU  - Meek AC
AD  - Department of Surgery, Charing Cross & Westminster Medical School, London, U.K.
FAU - Chidlow, A
AU  - Chidlow A
FAU - Lane, I F
AU  - Lane IF
FAU - Greenhalgh, R M
AU  - Greenhalgh RM
FAU - McCollum, C N
AU  - McCollum CN
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Vasc Surg
JT  - European journal of vascular surgery
JID - 8709440
RN  - 0 (Indium Radioisotopes)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Vessel Prosthesis
MH  - Carotid Arteries/*surgery
MH  - Carotid Artery Diseases/*blood/surgery
MH  - Dipyridamole/*therapeutic use
MH  - *Endarterectomy
MH  - Humans
MH  - Indium Radioisotopes
MH  - *Platelet Aggregation
MH  - Postoperative Period
MH  - Recurrence
EDAT- 1988/04/01 00:00
MHDA- 1988/04/01 00:01
CRDT- 1988/04/01 00:00
PHST- 1988/04/01 00:00 [pubmed]
PHST- 1988/04/01 00:01 [medline]
PHST- 1988/04/01 00:00 [entrez]
AID - 10.1016/s0950-821x(88)80056-2 [doi]
PST - ppublish
SO  - Eur J Vasc Surg. 1988 Apr;2(2):99-104. doi: 10.1016/s0950-821x(88)80056-2.

PMID- 7000631
OWN - NLM
STAT- MEDLINE
DCOM- 19810116
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 21
IP  - 7
DP  - 1980 Jul
TI  - Prevention of aspirin-induced faecal blood loss by prostaglandin E2.
PG  - 602-6
AB  - Prostaglandins have been shown in animal laboratory studies to be capable of 
      protecting the gastrointestinal tract against injury by exogenous agents. This 
      study was conducted to determine if prostaglandin E2 (PGE2), which is native to 
      the human gastric mucosa, could influence the increase in faecal blood loss 
      associated with the ingestion of aspirin (ASA). A randomised double-blind study 
      was performed on 27 healthy men. Faecal blood loss was measured by the 51Cr 
      labelled red cell technique. ASA (600 mg four times daily) caused a significant 
      increase in faecal blood loss. PGE2 (1 mg four times daily) had no effect on 
      faecal blood loss when administered alone. When given in addition to ASA it 
      resulted in a faecal blood loss not significantly different from control. No 
      significant alteration in intestinal transit occurred. It is concluded that PGE2 
      protects man from the gastrointestinal injury associated with ASA.
FAU - Cohen, M M
AU  - Cohen MM
FAU - Cheung, G
AU  - Cheung G
FAU - Lyster, D M
AU  - Lyster DM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Prostaglandins E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Feces
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Humans
MH  - Male
MH  - Prostaglandins E/*therapeutic use
MH  - Random Allocation
PMC - PMC1419893
EDAT- 1980/07/01 00:00
MHDA- 1980/07/01 00:01
CRDT- 1980/07/01 00:00
PHST- 1980/07/01 00:00 [pubmed]
PHST- 1980/07/01 00:01 [medline]
PHST- 1980/07/01 00:00 [entrez]
AID - 10.1136/gut.21.7.602 [doi]
PST - ppublish
SO  - Gut. 1980 Jul;21(7):602-6. doi: 10.1136/gut.21.7.602.

PMID- 32696844
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20200915
IS  - 1678-2690 (Electronic)
IS  - 0001-3765 (Linking)
VI  - 92
IP  - 2
DP  - 2020
TI  - Transdermal patches of lidocaine/aspirin ionic liquid drug-loaded 
      gelatin/polyvinyl alcohol composite film prepared by freeze-thawed procedure.
PG  - e20191073
LID - S0001-37652020000300905 [pii]
LID - 10.1590/0001-3765202020191073 [doi]
AB  - The objectives of this study are to prepare a 5 wt% lidocaine/aspirin ionic 
      liquid drug-loaded gelatin/polyvinyl alcohol composite film using a freeze-thaw 
      procedure and to evaluate their physicochemical characteristics, in vitro drug 
      release, and stability. Lidocaine/aspirin ionic liquid drugs can be prepared by 
      an ion-pair reaction between the hydrochloride salts of lidocaine and the sodium 
      salts of aspirin, which showed a significant change in their thermal properties 
      when compared to those pure drugs. The results showed that a transdermal patch 
      could feasibly be used in pharmaceutical transdermal patches with good 
      physicochemical properties. A chemical interaction between the drug and polymer 
      base was not found. Decomposition of the lidocaine/aspirin ionic liquid drug was 
      found in the patch; however, the properties of the patch were not changed after 
      drug loading. The patch controlled the drug release and showed good stability 
      during the studied period of three months when kept at 4°C more than at ambient 
      temperature and 45°C.
FAU - Maneewattanapinyo, Pattwat
AU  - Maneewattanapinyo P
AD  - College of Pharmacy, Rangsit University, Pathum Thani, Thailand.
FAU - Yeesamun, Alisa
AU  - Yeesamun A
AD  - College of Pharmacy, Rangsit University, Pathum Thani, Thailand.
FAU - Watthana, Fueangfah
AU  - Watthana F
AD  - College of Pharmacy, Rangsit University, Pathum Thani, Thailand.
FAU - Panrat, Kamon
AU  - Panrat K
AD  - Pharmaceutical Laboratory Service Center, Prince of Songkla University, Songkhla, 
      Thailand.
FAU - Pichayakorn, Wiwat
AU  - Pichayakorn W
AD  - Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, 
      Thailand.
FAU - Suksaeree, Jirapornchai
AU  - Suksaeree J
AD  - College of Pharmacy, Rangsit University, Pathum Thani, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - Brazil
TA  - An Acad Bras Cienc
JT  - Anais da Academia Brasileira de Ciencias
JID - 7503280
RN  - 0 (Ionic Liquids)
RN  - 9000-70-8 (Gelatin)
RN  - 9002-89-5 (Polyvinyl Alcohol)
RN  - 98PI200987 (Lidocaine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Cutaneous
MH  - Aspirin
MH  - Gelatin
MH  - *Ionic Liquids
MH  - Lidocaine
MH  - Polyvinyl Alcohol
MH  - *Transdermal Patch
EDAT- 2020/07/23 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/07/23 06:00
PHST- 2019/09/09 00:00 [received]
PHST- 2019/11/22 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - S0001-37652020000300905 [pii]
AID - 10.1590/0001-3765202020191073 [doi]
PST - ppublish
SO  - An Acad Bras Cienc. 2020;92(2):e20191073. doi: 10.1590/0001-3765202020191073. 
      Epub 2020 Jul 20.

PMID- 19328542
OWN - NLM
STAT- MEDLINE
DCOM- 20090424
LR  - 20150616
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 373
IP  - 9671
DP  - 2009 Apr 11
TI  - Aspirin, salicylates, and cancer.
PG  - 1301-9
LID - 10.1016/S0140-6736(09)60243-9 [doi]
AB  - Evidence from a wide range of sources suggests that individuals taking aspirin 
      and related non-steroidal anti-inflammatory drugs have reduced risk of large 
      bowel cancer. Work in animals supports cancer reduction with aspirin, but no 
      long-term randomised clinical trials exist in human beings, and randomisation 
      would be ethically unacceptable because vascular protection would have to be 
      denied to a proportion of the participants. However, opportunistic trials of 
      aspirin, designed to test vascular protection, provide some evidence of a 
      reduction in cancer, but only after at least 10 years. We summarise evidence for 
      the potential benefit of aspirin and natural salicylates in cancer prevention. 
      Possible mechanisms of action and directions for further work are discussed, and 
      implications for clinical practice are considered.
FAU - Elwood, Peter C
AU  - Elwood PC
AD  - School of Medicine, Cardiff University, Cardiff, UK.
FAU - Gallagher, Alison M
AU  - Gallagher AM
FAU - Duthie, Garry G
AU  - Duthie GG
FAU - Mur, Luis A J
AU  - Mur LA
FAU - Morgan, Gareth
AU  - Morgan G
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090326
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Breast Neoplasms/prevention & control
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Colonic Neoplasms/prevention & control
MH  - Cyclooxygenase Inhibitors/pharmacology/therapeutic use
MH  - DNA Mismatch Repair/drug effects
MH  - Drug Evaluation, Preclinical
MH  - *Evidence-Based Medicine/organization & administration
MH  - Female
MH  - Humans
MH  - Intestinal Polyps/prevention & control
MH  - Male
MH  - Neoplasms/epidemiology/etiology/*prevention & control
MH  - Prostaglandin-Endoperoxide Synthases/drug effects
MH  - Prostatic Neoplasms/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Risk Reduction Behavior
MH  - Time Factors
RF  - 116
EDAT- 2009/03/31 09:00
MHDA- 2009/04/25 09:00
CRDT- 2009/03/31 09:00
PHST- 2009/03/31 09:00 [entrez]
PHST- 2009/03/31 09:00 [pubmed]
PHST- 2009/04/25 09:00 [medline]
AID - S0140-6736(09)60243-9 [pii]
AID - 10.1016/S0140-6736(09)60243-9 [doi]
PST - ppublish
SO  - Lancet. 2009 Apr 11;373(9671):1301-9. doi: 10.1016/S0140-6736(09)60243-9. Epub 
      2009 Mar 26.

PMID- 19404514
OWN - NLM
STAT- MEDLINE
DCOM- 20090707
LR  - 20131121
IS  - 0720-9355 (Print)
IS  - 0720-9355 (Linking)
VI  - 29
IP  - 2
DP  - 2009 May
TI  - [Clinical and laboratory aspects of the Aspirin-like defect as hereditary 
      thrombocytopathy].
PG  - 177-83
AB  - The Aspirin-like defect (ALD) is caused by defects in the intraplatelet 
      arachidonic acid (AA)-metabolism. We here present the characteristics of a larger 
      cohort in a single centre. PATIENTS, METHODS: Based on 17 ALD index patients 
      bleeding symptoms, agonist-induced platelet aggregation and closure times in the 
      PFA-100 test were analysed in a family cohort of altogether 52 individuals from 
      17 families. Absent aggregation to AA (maximal aggregation <or= 10%) was the main 
      diagnostic criterion. A mild ALD was diagnosed when aggregation was 11-40%. 
      RESULTS: In addition to 17 ALD index patients, 13 family members displayed ALD. 4 
      family members were diagnosed with a mild ALD. Epistaxis, easy bruising, 
      menorrhagia and perioperative hemorrhage were the most common bleeding symptoms, 
      whereas three quarters of ALD patients presented with >or=1 bleeding symptoms. 
      CONCLUSION: In case of a bleeding tendency diagnostic procedures should rule out 
      primary haemostatic defects. Hereditary platelet function defects including ALD 
      are an important differential diagnosis. Family studies are reasonable.
FAU - Rolf, N
AU  - Rolf N
AD  - Klinik und Poliklinik für Kinder- und Jugendmedizin, Bereich Pädiatrische 
      Hämatologie und Onkologie, Universitätsklinikum Carl Gustav Carus, Technische 
      Universität, 01307 Dresden.
FAU - Bugert, P
AU  - Bugert P
FAU - Gehrisch, S
AU  - Gehrisch S
FAU - Siegert, G
AU  - Siegert G
FAU - Suttorp, M
AU  - Suttorp M
FAU - Knöfler, Ralf
AU  - Knöfler R
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Klinische und labordiagnostische Aspekte des Aspirin-like Defekts als hereditäre 
      Thrombozytopathie.
PL  - Germany
TA  - Hamostaseologie
JT  - Hamostaseologie
JID - 8204531
RN  - 0 (Prostaglandins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation Disorders/etiology/genetics
MH  - Blood Platelet Disorders/diagnosis
MH  - Family
MH  - Female
MH  - Hemorrhagic Disorders/etiology/genetics
MH  - Humans
MH  - Male
MH  - Prostaglandins/metabolism
MH  - Thrombocytopenia/*genetics
EDAT- 2009/05/01 09:00
MHDA- 2009/07/08 09:00
CRDT- 2009/05/01 09:00
PHST- 2009/05/01 09:00 [entrez]
PHST- 2009/05/01 09:00 [pubmed]
PHST- 2009/07/08 09:00 [medline]
AID - 09020177 [pii]
PST - ppublish
SO  - Hamostaseologie. 2009 May;29(2):177-83.

PMID- 2581620
OWN - NLM
STAT- MEDLINE
DCOM- 19850711
LR  - 20190609
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 829
IP  - 1
DP  - 1985 May 20
TI  - Effect of FS (alpha 2 gamma beta s) hybrid hemoglobin on Hb S nucleation and 
      aggregation.
PG  - 97-102
AB  - Asymmetrical cross-linked FS (alpha 2 gamma beta s) hybrid hemoglobin (Hb 
      FS-fumarate) was prepared by reacting mixtures of hemoglobins F and S with 
      double-headed aspirin, bis(3,5-dibromosalicyl) fumarate. When the molar ratio of 
      hemoglobin to the cross-linking agent was 1 to 2 in a 1:1 FS mixture, the 
      relative ratio of the products, cross-linked hemoglobins F (Hb F-fumarate), FS 
      (HB FS-fumarate), and S (Hb S-fumarate), was 1.0:2.6:2.0, in contrast to a 1:2:1 
      ratio of cross-linked hemoglobins A, AS, and S in a 1:1 AS mixture. These results 
      suggest that the fumaryl group reacts differently with Hb F, Hb FS and Hb S, and 
      that the difference could be attributed to the difference in the structure in the 
      vicinity of the EF6 Lys of non alpha-chains. The oxygen-binding properties of Hb 
      F-fumarate, Hb FS-fumarate, and Hb S-fumarate were similar, except that the 
      n-value of Hb F-fumarate was slightly lower than n-values of Hb S-fumarate and Hb 
      FS-fumarate. Kinetic studies on aggregation showed that the addition of Hb 
      FS-fumarate to unmodified Hb S did not affect the delay time prior to 
      aggregation, but did increase the total turbidity. Electrophoretic and 
      densitometric scanning analysis of the aggregate phase of this mixture showed the 
      fraction of Hb FS-fumarate to be 19%. Hb F-fumarate's effect on the delay time is 
      concentration-dependent; the greater the concentration of Hb F-fumarate, the 
      longer the delay time. The turbidity after aggregation of the mixture of Hb S and 
      Hb F-fumarate was much less than that of Hb S and Hb FS-fumarate. However, the 
      fraction of Hb F-fumarate in the aggregate phase was 19%, which is similar to 
      that of Hb FS-fumarate. These data suggest that Hb F and FS hybrid hemoglobin 
      cannot participate in nuclei formation, but can participate in aggregation after 
      sufficient amounts of nuclei are formed from Hb S, and that increased levels of 
      Hb F do not have an inhibitory effect on the formation of nuclei but on the 
      growth of aggregates.
FAU - Nibu, K
AU  - Nibu K
FAU - Adachi, K
AU  - Adachi K
LA  - eng
GR  - HL-20750/HL/NHLBI NIH HHS/United States
GR  - HL-32908/HL/NHLBI NIH HHS/United States
GR  - KO5 HL-00774/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Hemoglobin, Sickle)
RN  - 0E07K30TXY (bis(3,5-dibromosalicyl)fumarate)
RN  - 9034-63-3 (Fetal Hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Aspirin/analogs & derivatives
MH  - Cross-Linking Reagents
MH  - Fetal Hemoglobin/*metabolism
MH  - Hemoglobin, Sickle/*metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Oxygen
MH  - Protein Conformation
MH  - Structure-Activity Relationship
EDAT- 1985/05/20 00:00
MHDA- 1985/05/20 00:01
CRDT- 1985/05/20 00:00
PHST- 1985/05/20 00:00 [pubmed]
PHST- 1985/05/20 00:01 [medline]
PHST- 1985/05/20 00:00 [entrez]
AID - 0167-4838(85)90072-X [pii]
AID - 10.1016/0167-4838(85)90072-x [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 1985 May 20;829(1):97-102. doi: 
      10.1016/0167-4838(85)90072-x.

PMID- 2183405
OWN - NLM
STAT- MEDLINE
DCOM- 19900517
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 21
IP  - 4
DP  - 1990 Apr
TI  - Design of a multicenter randomized trial for the Stroke Prevention in Atrial 
      Fibrillation Study. The Stroke Prevention in Atrial Fibrillation Investigators.
PG  - 538-45
AB  - Individuals with nonvalvular atrial fibrillation are at increased risk of stroke. 
      The Stroke Prevention in Atrial Fibrillation Study is a 15-center randomized 
      clinical trial examining the risks and benefits of low-intensity warfarin 
      (prothrombin time of 1.3-1.8 times control) and aspirin (325 mg/day) in patients 
      with constant or intermittent atrial fibrillation. Candidates for anticoagulation 
      (group I) are randomized to receive warfarin in an open-label fashion, aspirin, 
      or placebo; the last two treatments are given in a double-blind fashion. 
      Warfarin-ineligible patients (group II) are randomized to receive aspirin or 
      placebo in a double-blind fashion. Primary end points are ischemic stroke and 
      systemic embolism. Secondary end points are death, transient ischemic attack, 
      myocardial infarction, and unstable angina pectoris. Analysis is based on the 
      intention-to-treat principle. The anticipated rate of primary end points in 
      patients receiving placebo is 6%/yr. The sample size of 1,644 patients is based 
      on a projected reduction in the rate of primary end points of 50% by warfarin and 
      of 33% by aspirin (beta = 0.2, alpha = 0.05). Patient entry commenced in June 
      1987 and will continue for 3 years, with an additional year of follow-up. 
      High-risk subsamples identified by clinical and echocardiographic criteria are 
      sought prospectively.
LA  - eng
GR  - NINDS-RO1-NS-24224/NS/NINDS NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Research Design
MH  - Statistics as Topic
MH  - Warfarin/therapeutic use
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
AID - 10.1161/01.str.21.4.538 [doi]
PST - ppublish
SO  - Stroke. 1990 Apr;21(4):538-45. doi: 10.1161/01.str.21.4.538.

PMID- 740108
OWN - NLM
STAT- MEDLINE
DCOM- 19790428
LR  - 20180215
IS  - 1660-8151 (Print)
IS  - 1660-8151 (Linking)
VI  - 22
IP  - 4-6
DP  - 1978
TI  - Indomethacin and lysine acetylsalicylate in rats with autologous nephrotoxic 
      serum nephritis. Biochemical and morphological studies.
PG  - 439-53
AB  - The effects of indomethacin and lysine acetylsalicylate (L-ASA) were compared in 
      rats in which autologous nephrotoxic serum nephritis had been induced. The aim of 
      this study was to offer support to the hypothesis that indomethacin might reduce 
      proteinuria through increased synthesis of glomerular basement membrane by the 
      podocytes. Both drugs were injected intraperitoneally at the dosage of 4 mg/kg 
      body weight daily during a 6-day period into 40 rats rendered nephritic by rabbit 
      nephrotoxic serum injection. Rats treated with indomethacin showed a marked 
      decrease of proteinuria (tested by the 3% sulfosalicylic aicd method) and a clear 
      ultrastructural picture of hyperplasia and hypertrophy of podocytes. Rats given 
      L-ASA showed only a slight correction of proteinuria and less specific 
      ultrastructural modification. These observations suggest that indomethacin 
      decreases proteinuria in nephritic rats not only through its anti-inflammatory 
      activity, but possible also by a peculiar mechanism, namely an increase in 
      podocytic basement membrane synthesis.
FAU - Sessa, A
AU  - Sessa A
FAU - Cioffi, A
AU  - Cioffi A
FAU - Conte, F
AU  - Conte F
FAU - Saruggia, M
AU  - Saruggia M
FAU - Di Belgiojoso, G B
AU  - Di Belgiojoso GB
FAU - Donati, M B
AU  - Donati MB
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Nephron
JT  - Nephron
JID - 0331777
RN  - 0 (Immune Sera)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Basement Membrane/immunology
MH  - Disease Models, Animal
MH  - Female
MH  - Glomerulonephritis/etiology/metabolism/*pathology
MH  - Immune Sera
MH  - Indomethacin/*pharmacology
MH  - Kidney Glomerulus/immunology/ultrastructure
MH  - Lysine/analogs & derivatives/pharmacology
MH  - Proteinuria/etiology/prevention & control
MH  - Rabbits
MH  - Rats
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1159/000181512 [doi]
PST - ppublish
SO  - Nephron. 1978;22(4-6):439-53. doi: 10.1159/000181512.

PMID- 30644794
OWN - NLM
STAT- MEDLINE
DCOM- 20200217
LR  - 20200217
IS  - 1747-4949 (Electronic)
IS  - 1747-4930 (Linking)
VI  - 14
IP  - 4
DP  - 2019 Jun
TI  - Anticoagulation in patients with Embolic Stroke of Unknown Source.
PG  - 334-336
LID - 10.1177/1747493019826363 [doi]
AB  - When warfarin was the mainstay of anticoagulation for the prevention of 
      cardioembolic stroke, the paradigm was essentially "we mustn't anticoagulate 
      anyone unless we prove that the stroke was cardioembolic." Now that direct-acting 
      oral anticoagulants are available, the paradigm should change. The risk of stroke 
      is highest soon after the initial event, particularly in patients with more than 
      one infarction. Direct-acting oral anticoagulants are not significantly more 
      likely than aspirin to cause severe hemorrhage, and it is now clear that patients 
      with paradoxical embolism are better treated with anticoagulant than aspirin. 
      Percutaneous closure of a patent foramen ovale is better than aspirin, but not 
      better than anticoagulant, and some patients with paradoxical embolism may be 
      better treated with anticoagulant than with percutaneous closure, which cannot 
      prevent pulmonary embolism. Patients in whom cardioembolic stroke is strongly 
      suspected should probably be anticoagulated pending the results of investigations 
      such as echocardiography and prolonged cardiac monitoring for atrial 
      fibrillation, and some of them, in whom the suspicion of a cardioembolic source 
      is very strong, should probably be anticoagulated long term, even if such 
      investigations do not confirm a cardiac source.
FAU - Spence, J David
AU  - Spence JD
AUID- ORCID: 0000-0001-7478-1098
AD  - Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, 
      Western University, London, Canada.
LA  - eng
PT  - Journal Article
DEP - 20190115
PL  - United States
TA  - Int J Stroke
JT  - International journal of stroke : official journal of the International Stroke 
      Society
JID - 101274068
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Embolism, Paradoxical/*prevention & control
MH  - Foramen Ovale, Patent/*therapy
MH  - Humans
MH  - Monitoring, Physiologic
MH  - Phenotype
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/*prevention & control
MH  - Warfarin/*therapeutic use
OTO - NOTNLM
OT  - Anticoagulant
OT  - antiplatelet
OT  - cardio-aortic embolism
OT  - cardioembolic
OT  - embolic stroke of unknown source
OT  - patent foramen ovale
OT  - percutaneous closure
OT  - stroke subtypes
EDAT- 2019/01/16 06:00
MHDA- 2020/02/18 06:00
CRDT- 2019/01/16 06:00
PHST- 2019/01/16 06:00 [pubmed]
PHST- 2020/02/18 06:00 [medline]
PHST- 2019/01/16 06:00 [entrez]
AID - 10.1177/1747493019826363 [doi]
PST - ppublish
SO  - Int J Stroke. 2019 Jun;14(4):334-336. doi: 10.1177/1747493019826363. Epub 2019 
      Jan 15.

PMID- 7013593
OWN - NLM
STAT- MEDLINE
DCOM- 19810613
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 94
IP  - 3
DP  - 1981 Mar
TI  - Aspirin-induced depression of glomerular filtration rate in normal humans: role 
      of sodium balance.
PG  - 317-21
AB  - The renal clearance of endogenous creatinine, inulin and para-aminohippurate was 
      measured in 10 healthy human volunteers taking aspirin during severe dietary 
      sodium restriction (10 meq/d) to clarify the clinical significance and 
      pathophysiology of aspirin-induced changes in renal function. Sodium restriction 
      alone had no effect on renal clearances but did increase plasma renin activity 
      and urinary prostaglandin E excretion. The addition of aspirin decreased the 
      urinary clearance of prostaglandin E but not plasma renin activity, and caused a 
      significant fall in both endogenous creatinine (from 92.3 +/- 4.1 SE ml/min . 
      1.73 m2 body surface area to 80.8 +/- 4.4 mL/min . 1.73 m2, p = 0.02) and inulin 
      (from 95.3 +/- 7.0 mL/min . 1.73 m2 to 80.9 +/- 7.0 mL/min . 1.73 m2, p less than 
      0.001). The fall in inulin clearance was directly related to the salicylate 
      level. The clearance of para-aminohippurate showed only a slight, statistically 
      insignificant decline with aspirin. The results of this study suggest that 
      aspirin-induced depression of glomerular filtration rate may be independent of 
      total renal plasma flow. Aspirin should be used cautiously, with careful 
      attention to dosage, in sodium-restricted patients whose glomerular filtration 
      rate may, in part, be under the homeostatic control of renal prostaglandins.
FAU - Muther, R S
AU  - Muther RS
FAU - Potter, D M
AU  - Potter DM
FAU - Bennett, W M
AU  - Bennett WM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Prostaglandins E)
RN  - 9005-80-5 (Inulin)
RN  - 9NEZ333N27 (Sodium)
RN  - EC 3.4.23.15 (Renin)
RN  - R16CO5Y76E (Aspirin)
RN  - Y79XT83BJ9 (p-Aminohippuric Acid)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/blood
MH  - Depression, Chemical
MH  - Diet
MH  - Female
MH  - Glomerular Filtration Rate/*drug effects
MH  - Humans
MH  - Inulin/metabolism
MH  - Kidney Glomerulus/metabolism
MH  - Male
MH  - Metabolic Clearance Rate/drug effects
MH  - Natriuresis/drug effects
MH  - Prostaglandins E/urine
MH  - Renin/blood
MH  - Sodium/*metabolism
MH  - p-Aminohippuric Acid/metabolism
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
AID - 10.7326/0003-4819-94-3-317 [doi]
PST - ppublish
SO  - Ann Intern Med. 1981 Mar;94(3):317-21. doi: 10.7326/0003-4819-94-3-317.

PMID- 29085190
OWN - NLM
STAT- MEDLINE
DCOM- 20180614
LR  - 20181113
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 23
IP  - 35
DP  - 2017 Sep 21
TI  - Effects of aspirin and enoxaparin in a rat model of liver fibrosis.
PG  - 6412-6419
LID - 10.3748/wjg.v23.i35.6412 [doi]
AB  - AIM: To examine the effects of aspirin and enoxaparin on liver function, 
      coagulation index and histopathology in a rat model of liver fibrosis. METHODS 
      Forty-five male Sprague-Dawley rats were randomly divided into the control group 
      (n = 5) and model group (n = 40). Thioacetamide (TAA) was used to induce liver 
      fibrosis in the model group. TAA-induced fibrotic rats received TAA continuously 
      (n = 9), TAA + low-dose aspirin (n = 9), TAA + high-dose aspirin (n = 9) or TAA + 
      enoxaparin (n = 9) for 4 wk. All rats were euthanized after 4 wk, and both 
      hematoxylin-eosin and Masson staining were performed to observe pathological 
      changes in liver tissue. RESULTS: Liver fibrosis was assessed according to the 
      METAVIR score. Compared with untreated cirrhotic controls, a significant 
      improvement in fibrosis grade was observed in the low-dose aspirin, high-dose 
      aspirin and enoxaparin treated groups, especially in the high-dose aspirin 
      treated group. Alanine aminotransferase and total bilirubin were higher, albumin 
      was lower and both prothrombin time and international normalized ratio were 
      prolonged in the four treatment groups compared to controls. No significant 
      differences among the four groups were observed. CONCLUSION: Aspirin and 
      enoxaparin can alleviate liver fibrosis in this rat model.
FAU - Li, Chen-Jie
AU  - Li CJ
AD  - Department of Gastroenterology, Second Xiangya Hospital of Central South 
      University, Changsha 410011, Hunan Province, China. chenjielimao@126.com.
FAU - Yang, Zhi-Hui
AU  - Yang ZH
AD  - Department of Medicine, Hospital of National University of Defense Technology, 
      Changsha 410073, Hunan Province, China.
FAU - Shi, Xiao-Liu
AU  - Shi XL
AD  - Department of Gastroenterology, Second Xiangya Hospital of Central South 
      University, Changsha 410011, Hunan Province, China.
FAU - Liu, De-Liang
AU  - Liu DL
AD  - Department of Gastroenterology, Second Xiangya Hospital of Central South 
      University, Changsha 410011, Hunan Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Antithrombins)
RN  - 0 (Enoxaparin)
RN  - 075T165X8M (Thioacetamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antithrombins/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Enoxaparin/pharmacology/*therapeutic use
MH  - Liver/*drug effects/pathology
MH  - Liver Cirrhosis, Experimental/blood/chemically induced/*drug therapy/pathology
MH  - Liver Function Tests
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thioacetamide/toxicity
PMC - PMC5643266
OTO - NOTNLM
OT  - Aspirin
OT  - Enoxaparin
OT  - Liver fibrosis
OT  - Rat
OT  - Thioacetamide
COIS- Conflict-of-interest statement: To the best of our knowledge, no conflict of 
      interest exists.
EDAT- 2017/11/01 06:00
MHDA- 2018/06/15 06:00
CRDT- 2017/11/01 06:00
PHST- 2017/02/22 00:00 [received]
PHST- 2017/06/21 00:00 [revised]
PHST- 2017/08/15 00:00 [accepted]
PHST- 2017/11/01 06:00 [entrez]
PHST- 2017/11/01 06:00 [pubmed]
PHST- 2018/06/15 06:00 [medline]
AID - 10.3748/wjg.v23.i35.6412 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2017 Sep 21;23(35):6412-6419. doi: 
      10.3748/wjg.v23.i35.6412.

PMID- 33275740
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210504
IS  - 1520-4383 (Electronic)
IS  - 1520-4391 (Print)
IS  - 1520-4383 (Linking)
VI  - 2020
IP  - 1
DP  - 2020 Dec 4
TI  - Combining antiplatelet and anticoagulant therapy in cardiovascular disease.
PG  - 642-648
LID - 10.1182/hematology.2020000151 [doi]
AB  - Up to 10% of the >3 million Americans with atrial fibrillation will experience an 
      acute coronary syndrome or undergo percutaneous coronary intervention. Therefore, 
      concurrent indications for multiple antithrombotic agents is a common clinical 
      scenario. Although each helps reduce thrombotic risk, their combined use 
      significantly increases the risk of major bleeding events, which can be life 
      threatening. In the past 5 years, a number of randomized clinical trials have 
      explored different combinations of anticoagulation plus antiplatelet agents aimed 
      at minimizing bleeding risk while preserving low thrombotic event rates. In 
      general, shorter courses with fewer antithrombotic agents have been found to be 
      effective, particularly when direct oral anticoagulants are combined with 
      clopidogrel. Combined use of very low-dose rivaroxaban plus aspirin has also 
      demonstrated benefit in atherosclerotic diseases, including coronary and 
      peripheral artery disease. Use of proton pump inhibitor therapy while patients 
      are taking multiple antithrombotic agents has the potential to further reduce 
      upper gastrointestinal bleeding risk in select populations. Applying this 
      evidence to patients with multiple thrombotic conditions will help to avoid 
      costly and life-threatening adverse medication events.
CI  - © 2020 by The American Society of Hematology.
FAU - Barnes, Geoffrey D
AU  - Barnes GD
AD  - Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI.
LA  - eng
GR  - R18 HS026874/HS/AHRQ HHS/United States
GR  - R21 HS026322/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hematology Am Soc Hematol Educ Program
JT  - Hematology. American Society of Hematology. Education Program
JID - 100890099
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - *Cardiovascular Diseases/blood/drug therapy
MH  - Gastrointestinal Hemorrhage/blood/chemically induced/prevention & control
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Proton Pump Inhibitors/adverse effects/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Rivaroxaban/adverse effects/*therapeutic use
PMC - PMC7727581
COIS- Conflict-of-interest disclosure: G.D.B. discloses grant funding from the National 
      Heart, Lung, and Blood Institute (K01HL135392), Agency for Healthcare Quality and 
      Innovation (R18HS026874 and R21HS026322), and Blue Cross Blue Shield of Michigan. 
      He also discloses consulting for Pfizer/Bristol-Myers Squibb, Janssen, Portola, 
      Acelis Connected Health/Alere, and AMAG Pharmaceuticals.
EDAT- 2020/12/05 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/12/04 17:10
PHST- 2020/12/04 17:10 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
AID - 474351 [pii]
AID - 2020000151C [pii]
AID - 10.1182/hematology.2020000151 [doi]
PST - ppublish
SO  - Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):642-648. doi: 
      10.1182/hematology.2020000151.

PMID- 30220379
OWN - NLM
STAT- MEDLINE
DCOM- 20190225
LR  - 20190225
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 270
DP  - 2018 Nov 1
TI  - Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in 
      patients with stable cardiovascular disease: An Australian perspective.
PG  - 54-59
LID - S0167-5273(18)31840-0 [pii]
LID - 10.1016/j.ijcard.2018.06.091 [doi]
AB  - OBJECTIVE: In light of the Cardiovascular Outcomes for People using 
      Anticoagulation Strategies (COMPASS) trial, our objective was to assess the 
      cost-effectiveness, from the Australian healthcare perspective, of rivaroxaban in 
      combination with aspirin versus aspirin alone for the prevention of recurrent 
      cardiovascular disease among patients with stable atherosclerotic vascular 
      disease. METHODS: A Markov model was developed using input data from the COMPASS 
      trial to predict the clinical course and costs of patients over a 20-year 
      time-horizon. The model comprised of three health states: 'Alive without 
      recurrent CVD', 'Alive after recurrent CVD' and 'Dead'. Costs were from the 
      Australian public healthcare system perspective, and estimated from published 
      sources, as were utility data. The costs of rivaroxaban were based on current 
      acquisition prices on the Australian Pharmaceutical Benefits Schedule (PBS) and 
      assumed as AUD$3.09/day. The main outcome of interest was the incremental 
      cost-effectiveness ratio (ICER) in terms of cost per quality adjusted life year 
      (QALY) gained, and cost per year of life saved (YoLS). Costs and benefits were 
      discounted by 5.0% per year. RESULTS: Compared to aspirin alone, rivaroxaban plus 
      aspirin was estimated to cost an additional AUD$12,156 (discounted) per person, 
      but lead to 0.516 YoLS (discounted) and 0.386 QALYs gained (discounted), over 
      20 years. These equated to ICERs of AUD$23,560/YoLS and AUD$31,436/QALY gained. 
      We have assumed a threshold of AUD$50,000/QALY gained to signify 
      cost-effectiveness. CONCLUSION: Compared to aspirin, rivaroxaban in combination 
      with aspirin is likely to be cost-effective in preventing recurrent 
      cardiovascular events in patients with stable atherosclerotic vascular disease.
CI  - Copyright © 2018 Elsevier B.V. All rights reserved.
FAU - Ademi, Zanfina
AU  - Ademi Z
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia. Electronic address: zanfina.ademi@monash.edu.
FAU - Zomer, Ella
AU  - Zomer E
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia.
FAU - Tonkin, Andrew
AU  - Tonkin A
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia.
FAU - Liew, Danny
AU  - Liew D
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne, 
      Australia.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20180625
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Factor Xa Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*economics
MH  - Aspirin/administration & dosage/*economics
MH  - Australia/epidemiology
MH  - Cardiovascular Diseases/drug therapy/*economics/epidemiology
MH  - *Cost-Benefit Analysis/methods
MH  - Drug Therapy, Combination
MH  - Factor Xa Inhibitors/administration & dosage/*economics
MH  - Female
MH  - Humans
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Rivaroxaban/administration & dosage/*economics
EDAT- 2018/09/18 06:00
MHDA- 2019/02/26 06:00
CRDT- 2018/09/18 06:00
PHST- 2018/03/21 00:00 [received]
PHST- 2018/05/31 00:00 [revised]
PHST- 2018/06/21 00:00 [accepted]
PHST- 2018/09/18 06:00 [entrez]
PHST- 2018/09/18 06:00 [pubmed]
PHST- 2019/02/26 06:00 [medline]
AID - S0167-5273(18)31840-0 [pii]
AID - 10.1016/j.ijcard.2018.06.091 [doi]
PST - ppublish
SO  - Int J Cardiol. 2018 Nov 1;270:54-59. doi: 10.1016/j.ijcard.2018.06.091. Epub 2018 
      Jun 25.

PMID- 10723271
OWN - NLM
STAT- MEDLINE
DCOM- 20000509
LR  - 20190724
IS  - 0031-6903 (Print)
IS  - 0031-6903 (Linking)
VI  - 120
IP  - 3
DP  - 2000 Mar
TI  - [Crystallographic characteristics of crystal habits and their peculiarity to the 
      substance (study of crystalline drugs by mesns of a polarizing microscope. 
      XVIII)].
PG  - 290-7
AB  - Crystallographic and optical characteristics of crystal habits have been 
      investigated comparing the both results of goniometric and newly developed 
      polarizing microscopic methods. It has been found that the predominant faces of 
      crystal habits are mostly formed by (001) or (100) of orthorhombic or monoclinic 
      system and (010) of monoclinic system, and a little part by triclinic (001). Not 
      so many numbers of predominant faces were found to be formed by orthorhombic or 
      monoclinic (110) making prismatic habits. Key refractive indices have been found 
      to be uniquely measured from those habits, and it was also found that one or two 
      of them were coincided with the principal refractive indexes, which will become 
      important facts for the analytical use of crystal habits.
FAU - Watanabe, A
AU  - Watanabe A
AD  - Kenbikogaku-kenkyusho, Ltd., Ashiya-shi, Japan.
FAU - Ohnuma, N
AU  - Ohnuma N
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 5WZ53ENE2P (Barbital)
RN  - GWH6IJ239E (Amobarbital)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Amobarbital
MH  - Aspirin
MH  - Barbital
MH  - Crystallization
MH  - Crystallography
MH  - *Microscopy, Polarization
RF  - 19
EDAT- 2000/03/21 09:00
MHDA- 2000/05/16 09:00
CRDT- 2000/03/21 09:00
PHST- 2000/03/21 09:00 [pubmed]
PHST- 2000/05/16 09:00 [medline]
PHST- 2000/03/21 09:00 [entrez]
AID - 10.1248/yakushi1947.120.3_290 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2000 Mar;120(3):290-7. doi: 10.1248/yakushi1947.120.3_290.

PMID- 7460239
OWN - NLM
STAT- MEDLINE
DCOM- 19810421
LR  - 20220311
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 63
IP  - 3
DP  - 1981 Mar
TI  - Platelet survival and the development of coronary artery disease in the young 
      adult: effects of cigarette smoking, strong family history and medical therapy.
PG  - 546-51
AB  - Cigarette smoking or a strong family history of coronary disease was present in 
      46 of 50 symptomatic patients with coronary artery disease who were younger than 
      50 years of age. We recorded a shortened platelet survival half-life (less than 
      92 hours) with 51Cr in 60% of these patients, in 56% of apparently normal persons 
      of the same age who smoked or had a strong family history of coronary disease, 
      and in only 14% of normal persons who did not smoke and had no family history (p 
      less than 0.01). Lengthening of the shortened platelet survival toward normal 
      occurred in coronary patients given dipyridamole plus aspirin and in apparently 
      normal smokers who discontinued smoking (p less than 0.01). The study suggests a 
      possible relationship among cigarette smoking, strong family history of coronary 
      disease and platelet activation in the process of coronary atherogenesis in the 
      young adult.
FAU - Fuster, V
AU  - Fuster V
FAU - Chesebro, J H
AU  - Chesebro JH
FAU - Frye, R L
AU  - Frye RL
FAU - Elveback, L R
AU  - Elveback LR
LA  - eng
GR  - HL-21533/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Blood Platelets/*physiopathology
MH  - Cell Survival
MH  - Coronary Disease/drug therapy/genetics/*physiopathology
MH  - Dipyridamole/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Smoking
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
AID - 10.1161/01.cir.63.3.546 [doi]
PST - ppublish
SO  - Circulation. 1981 Mar;63(3):546-51. doi: 10.1161/01.cir.63.3.546.

PMID- 345198
OWN - NLM
STAT- MEDLINE
DCOM- 19780517
LR  - 20210111
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 4
IP  - 3
DP  - 1978 Feb
TI  - The influence of anxiety and pain sensitivity on experimental pain in man.
PG  - 253-263
LID - 10.1016/0304-3959(77)90137-3 [doi]
AB  - A study was made of a number of factors that might be responsible for the 
      unreliable results obtained in experimentally induced pain in man. In a 
      randomised, double-blind, cross-over study on 32 healthy, male volunteers, the 
      ischaemic pain test [14] and several psychological tests were performed. The 
      influence of the following factors on the pain test results were examined: (a) 
      ingestion of single, oral doses of 1000 mg aspirin (ASA) and placebo, (b) 
      practice effect, (c) initial pain sensitivity, (d) anxiety, coping behaviour, 
      attitude to the experiment and personality factors. The analgesic activity of ASA 
      could not be demonstrated. An interaction between primary pain sensitivity and 
      the sequence of drug administration was found. Furthermore, anxiety had a marked 
      influence on the test results. Using experimental pain models reliable results 
      are not to be expected as anxiety fluctuates intra- and interindividually in an 
      unpredictable and uncontrollable manner.
FAU - Von Graffenried, Beat
AU  - Von Graffenried B
AD  - (B.v.G., E.N. and R.S.) Experimental Therapeutics, Biological and Medical 
      Research, Pharmaceutical Division, Sandoz Ltd., CH-4002 BasleSwitzerland (R.A.) 
      Medical Faculty of the University of Berne, Department of Medicine, University of 
      Berne, CH-3000 BerneSwitzerland (K.A.) Department of Biostatistics, J.W. Goethe 
      University, D-6 Frankfurt am Main 70 G.F.R.
FAU - Adler, Rolf
AU  - Adler R
FAU - Abt, Klaus
AU  - Abt K
FAU - Nüesch, Erich
AU  - Nüesch E
FAU - Spiegel, René
AU  - Spiegel R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adaptation, Psychological
MH  - Adult
MH  - Anxiety/*psychology
MH  - Aspirin/therapeutic use
MH  - Attitude
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Pain/drug therapy/*psychology
MH  - Practice, Psychological
MH  - Psychological Tests
EDAT- 1978/02/01 00:00
MHDA- 1978/02/01 00:01
CRDT- 1978/02/01 00:00
PHST- 1978/02/01 00:00 [pubmed]
PHST- 1978/02/01 00:01 [medline]
PHST- 1978/02/01 00:00 [entrez]
AID - 00006396-197710001-00055 [pii]
AID - 10.1016/0304-3959(77)90137-3 [doi]
PST - ppublish
SO  - Pain. 1978 Feb;4(3):253-263. doi: 10.1016/0304-3959(77)90137-3.

PMID- 10741314
OWN - NLM
STAT- MEDLINE
DCOM- 20000407
LR  - 20220311
IS  - 0141-0768 (Print)
IS  - 0141-0768 (Linking)
VI  - 93
IP  - 3
DP  - 2000 Mar
TI  - Underutilization of antithrombotic therapy in atrial fibrillation.
PG  - 138-40
AB  - Most patients with atrial fibrillation should be considered for antithrombotic 
      therapy. In a retrospective survey we investigated practice in two hospitals. For 
      patients at high risk, established guidelines recommend warfarin, or aspirin if 
      anticoagulants are contraindicated; for those at medium risk, either may be used. 
      Of 156 with atrial fibrillation (acute, chronic or paroxysmal), 119 were at high 
      risk, mean age 79 years. According to the guidelines, 89 of these were suitable 
      for anticoagulation but only 49 (55%) received warfarin; 27 received aspirin and 
      13 neither. Of 27 patients at medium risk (mean age 70 years), 6 were not 
      prescribed any antithrombotic therapy. This survey indicates that guidelines on 
      antithrombotic therapy are commonly disregarded and that, in particular, warfarin 
      is underutilized in the group for whom it is most indicated.
FAU - Adhiyaman, V
AU  - Adhiyaman V
AD  - Department of Geriatric Medicine, Wrexham Maelor Hospital, UK.
FAU - Kamalakannan, D
AU  - Kamalakannan D
FAU - Oke, A
AU  - Oke A
FAU - Shah, I U
AU  - Shah IU
FAU - White, A D
AU  - White AD
LA  - eng
PT  - Journal Article
PL  - England
TA  - J R Soc Med
JT  - Journal of the Royal Society of Medicine
JID - 7802879
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J R Soc Med. 2000 May;93(5):277-8. PMID: 10884789
CIN - J R Soc Med. 2000 May;93(5):278-9. PMID: 10884790
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Practice Guidelines as Topic
MH  - Retrospective Studies
MH  - Thrombolytic Therapy/*statistics & numerical data
MH  - Warfarin/therapeutic use
PMC - PMC1297951
EDAT- 2000/03/31 00:00
MHDA- 2000/03/31 00:01
CRDT- 2000/03/31 00:00
PHST- 2000/03/31 00:00 [pubmed]
PHST- 2000/03/31 00:01 [medline]
PHST- 2000/03/31 00:00 [entrez]
AID - 10.1177/014107680009300308 [doi]
PST - ppublish
SO  - J R Soc Med. 2000 Mar;93(3):138-40. doi: 10.1177/014107680009300308.

PMID- 9396636
OWN - NLM
STAT- MEDLINE
DCOM- 19980108
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 134
IP  - 5 Pt 2
DP  - 1997 Nov
TI  - Antiplatelet therapy: do the new platelet inhibitors add significantly to the 
      clinical benefits of aspirin?
PG  - S62-70
AB  - The inhibitors of the platelet membrane glycoprotein IIb/IIIa show considerable 
      promise as antiplatelet agents. These drugs are easily titrated when administered 
      intravenously and are associated with less frequent and serious bleeding than 
      initially feared. They add significant benefit to that attributable to aspirin in 
      preventing the complications associated with coronary angioplasty. Pilot studies 
      have suggested that benefits could also be realized in acute myocardial 
      infarction and unstable angina. The most effective means of administering these 
      agents, their relative efficacy, and the consequences of long-term modulation of 
      the glycoprotein IIb/IIIa receptor by oral agents are challenging areas for 
      clinical investigation.
FAU - Théroux, P
AU  - Théroux P
AD  - Department of Medicine, University of Montreal, and Montreal Heart Institute, 
      Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Disease/*drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
MH  - Postoperative Complications/prevention & control
RF  - 53
EDAT- 1997/12/13 00:00
MHDA- 1997/12/13 00:01
CRDT- 1997/12/13 00:00
PHST- 1997/12/13 00:00 [pubmed]
PHST- 1997/12/13 00:01 [medline]
PHST- 1997/12/13 00:00 [entrez]
AID - a84741 [pii]
AID - 10.1016/s0002-8703(97)70011-5 [doi]
PST - ppublish
SO  - Am Heart J. 1997 Nov;134(5 Pt 2):S62-70. doi: 10.1016/s0002-8703(97)70011-5.

PMID- 23649375
OWN - NLM
STAT- MEDLINE
DCOM- 20131018
LR  - 20211021
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 58
IP  - 8
DP  - 2013 Aug
TI  - Reactive increase in gastric mucus secretion is an adaptive defense mechanism 
      against low-dose aspirin-induced gastropathy.
PG  - 2266-74
LID - 10.1007/s10620-013-2660-7 [doi]
AB  - BACKGROUND: Gastric mucus is considered to play an essential role in gastric 
      mucosal defense mechanisms, especially when irritants are present in the stomach. 
      AIM: To investigate the relationship between low-dose aspirin-induced gastropathy 
      and gastric secretory function, especially gastric mucus secretion, in healthy 
      volunteers. METHODS: Thirty male, asymptomatic, Helicobacter pylori 
      pylori-negative healthy volunteers were asked to take 100 mg of enteric-coated 
      aspirin (Bayaspirin) once a day for 10 days. Endoscopic examination was performed 
      before and 3 and 10 days after drug administration. The extent of endoscopically 
      assessed gastric mucosal injury was semi-quantitatively evaluated according to 
      the modified Lanza score. The pentagastrin-stimulated gastric juice was collected 
      for 10 min during the endoscopic examination and subjected to analysis for 
      gastric acid (mEq/10 min) or mucus (mg hexose/10 min) output. RESULTS: Overall, 
      the 10-day aspirin treatment significantly increased gastric mucus secretion from 
      0.8 (interquartile range 1.7) to 1.6 (1.6) mg hexose/10 min (P < 0.05), with a 
      concomitant and significant decrease in the gastric acid/mucus ratio from 4.3 
      (5.2) to 2.9 (4.7) (P < 0.01). Subsequent analysis of two subgroups of volunteers 
      categorized according to their endoscopic status ("severe gastropathy" vs. 
      "modest gastropathy") revealed that changes in gastric secretory parameters 
      occurred exclusively in those subjects without severe gastric injury; there was 
      no alteration in these parameters in subjects with severe gastric injury. 
      CONCLUSIONS: The results of this study suggest that the reactive increase in 
      gastric mucus secretion is an adaptive defense mechanism against low-dose 
      aspirin-induced gastropathy. In some individuals, such a response may be 
      insufficient to prevent the development of severe mucosal injury and even ulcers 
      and their complications.
FAU - Iijima, K
AU  - Iijima K
AD  - Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 
      Seiryo-machi, Aobaku, Sendai, Miyagi, 980-8574, Japan. kiijima@med.tohoku.ac.jp
FAU - Iwabuchi, T
AU  - Iwabuchi T
FAU - Ara, N
AU  - Ara N
FAU - Koike, T
AU  - Koike T
FAU - Shinkai, H
AU  - Shinkai H
FAU - Kamata, Y
AU  - Kamata Y
FAU - Ichikawa, T
AU  - Ichikawa T
FAU - Ishihara, K
AU  - Ishihara K
FAU - Shimosegawa, T
AU  - Shimosegawa T
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Gastrointestinal Agents)
RN  - EF0NX91490 (Pentagastrin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*toxicity
MH  - Dose-Response Relationship, Drug
MH  - Gastric Mucosa/*metabolism
MH  - Gastrointestinal Agents/pharmacology
MH  - Humans
MH  - Male
MH  - Mucus/*metabolism
MH  - Pentagastrin/pharmacology
MH  - Stomach/drug effects
MH  - Stomach Diseases/*chemically induced
MH  - Young Adult
EDAT- 2013/05/08 06:00
MHDA- 2013/10/19 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/01/09 00:00 [received]
PHST- 2013/03/20 00:00 [accepted]
PHST- 2013/05/08 06:00 [entrez]
PHST- 2013/05/08 06:00 [pubmed]
PHST- 2013/10/19 06:00 [medline]
AID - 10.1007/s10620-013-2660-7 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2013 Aug;58(8):2266-74. doi: 10.1007/s10620-013-2660-7. Epub 2013 
      May 7.

PMID- 11018244
OWN - NLM
STAT- MEDLINE
DCOM- 20001121
LR  - 20190724
IS  - 0022-510X (Print)
IS  - 0022-510X (Linking)
VI  - 178
IP  - 1
DP  - 2000 Sep 1
TI  - Comparison of the acute-phase response in patients with ischemic stroke treated 
      with high-dose heparin or aspirin.
PG  - 17-22
AB  - Experimental studies have suggested that unfractionated heparin (UH) has 
      antiinflammatory properties. It is unknown whether UH also has these properties 
      in patients with acute ischemic stroke. Within 12-24 h of treatment onset we 
      measured the acute-phase response as reflected by the erythrocyte sedimentation 
      rate (ESR) and total number of leukocytes (x10(9)/l) in 706 consecutive patients 
      with acute ischemic stroke treated with full-dose UH (n=450), or 300 mg/day 
      aspirin (n=256). Clinical outcome (Mathew scale) at hospital discharge and the 
      effect of factors such as treatment (UH and aspirin), and acute phase response 
      were assessed using multivariate analyses adjusted for baseline confounders and 
      incident complications. Separate models were created for patients with lacunar 
      and nonlacunar stroke. Whereas there were not differences at baseline between the 
      two treatment groups, total leukocyte counts (8. 0+/-4.1 vs. 8.6+/-3.2, P<0.01) 
      and ESR (21.7+/-20.9 vs. 25.2+/-22.9, P<0.05) were statistically significantly 
      lower in patients treated with UH. This effect of UH was more accentuated in 
      patients with nonlacunar stroke. Overall, leukocytes (7.2+/-2.3 vs. 8.4+/-4.0, 
      P<0. 01), and ESR (15.7+/-17.2 vs. 24.3+/-22.2, P=0.0001) were lower in patients 
      with complete early recovery and this effect was restricted to patients with 
      nonlacunar stroke. Whereas baseline impairment, symptomatic bleeding and stroke 
      recurrence were independent negative outcome predictors, the use of UH was 
      positively associated with early recovery in all patients. This study shows that 
      full-dose UH reduces the acute-phase reaction that follows ischemic stroke more 
      effectively than aspirin. The prognostic implications of such effect seem more 
      notable in patients with nonlacunar stroke.
FAU - Chamorro, A
AU  - Chamorro A
AD  - Stroke Unit, Neurology Service-IDIBAPS. Hospital Clinic, Villarroel 170, 08036, 
      Barcelona, Spain. chamorro@medicina.ub.es
FAU - Obach, V
AU  - Obach V
FAU - Vila, N
AU  - Vila N
FAU - Revilla, M
AU  - Revilla M
FAU - Cervera, A
AU  - Cervera A
FAU - Ascaso, C
AU  - Ascaso C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute-Phase Reaction/*drug therapy/etiology
MH  - Aged
MH  - Analysis of Variance
MH  - Aspirin/*therapeutic use
MH  - Brain Ischemia/complications/*drug therapy
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2000/10/06 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/06 11:00
PHST- 2000/10/06 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/06 11:00 [entrez]
AID - S0022-510X(00)00345-2 [pii]
AID - 10.1016/s0022-510x(00)00345-2 [doi]
PST - ppublish
SO  - J Neurol Sci. 2000 Sep 1;178(1):17-22. doi: 10.1016/s0022-510x(00)00345-2.

PMID- 9549575
OWN - NLM
STAT- MEDLINE
DCOM- 19980526
LR  - 20190515
IS  - 0341-2695 (Print)
IS  - 1432-5195 (Electronic)
IS  - 0341-2695 (Linking)
VI  - 22
IP  - 1
DP  - 1998
TI  - Prophylaxis for deep vein thrombosis with aspirin or low molecular weight dextran 
      in Korean patients undergoing total hip replacement. A randomized controlled 
      trial.
PG  - 6-10
AB  - 150 Korean patients undergoing primary uncemented total hip replacement were 
      randomized into 3 treatment groups for deep vein thrombosis (DVT) prophylaxis. 
      Group A(50) were controls; Group B(50) received aspirin 1.2 g daily in 3 divided 
      doses from 2 days before, to 14 days after surgery; Group C(50), received low 
      molecular weight dextran 500 ml, infused intravenously at 50 ml/hour during 
      surgery, and on each of the following 2 days. Contrast venograms were performed 
      prior to surgery and 7-10 days after. The incidence of DVT was 20% in the control 
      group, 12% in the aspirin group (p < 0.1 vs control), and 6% in the dextran group 
      (p < 0.05 vs control). In patients developing DVT, the ratio of proximal to 
      distal thrombi was increased in the control group as compared to treated groups 
      (4:1 in the control group vs 1.5:1 in the treated groups). Both aspirin and 
      dextran were well tolerated. Obesity (p < 0.05) and long-term administration of 
      steroids (p < 0.05) were risk factors for deep vein thrombosis which reached 
      statistical significance in the control group. Intraoperative venograms performed 
      on 10 patients, showed that hip flexion (mean 40.4 degrees) plus adduction (mean 
      11.5 degrees) plus internal rotation (mean 81.5 degrees), resulted in severe 
      twisting or kinking of the femoral vein with stagnation of blood flow. Low 
      molecular weight dextran significantly reduce the incidence of deep venous 
      thrombosis and aspirin, though less effective, had a similar effect.
FAU - Kim, Y H
AU  - Kim YH
AD  - Department of Orthopaedic Surgery, Hanyang University Guri Hospital, Korea.
FAU - Choi, I Y
AU  - Choi IY
FAU - Park, M R
AU  - Park MR
FAU - Park, T S
AU  - Park TS
FAU - Cho, J L
AU  - Cho JL
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int Orthop
JT  - International orthopaedics
JID - 7705431
RN  - 0 (Anticoagulants)
RN  - 0 (Dextrans)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*therapeutic use
MH  - *Arthroplasty, Replacement, Hip
MH  - Aspirin/*therapeutic use
MH  - Dextrans/*therapeutic use
MH  - Female
MH  - Humans
MH  - Korea
MH  - Male
MH  - Middle Aged
MH  - Molecular Weight
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/*prevention & control
MH  - Prospective Studies
MH  - Thrombosis/*prevention & control
PMC - PMC3619654
EDAT- 1998/04/29 00:00
MHDA- 1998/04/29 00:01
CRDT- 1998/04/29 00:00
PHST- 1998/04/29 00:00 [pubmed]
PHST- 1998/04/29 00:01 [medline]
PHST- 1998/04/29 00:00 [entrez]
AID - 80220006.264 [pii]
AID - 10.1007/s002640050199 [doi]
PST - ppublish
SO  - Int Orthop. 1998;22(1):6-10. doi: 10.1007/s002640050199.

PMID- 14570729
OWN - NLM
STAT- MEDLINE
DCOM- 20040113
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 52
IP  - 11
DP  - 2003 Nov
TI  - Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal 
      cancer.
PG  - 1598-601
AB  - BACKGROUND: and aims: Aspirin and other non-steroidal anti-inflammatory drugs 
      have been shown to reduce the risk of colorectal cancer (CRC). Animal models have 
      shown that aspirin is also effective in reducing the density of aberrant crypt 
      foci (ACF). The aim of the study was to evaluate the effect of chronic 
      administration of aspirin on the distribution pattern and histological 
      characteristics of ACF in patients with CRC. METHODS: Our study compared the 
      distribution patterns and histomorphological characteristics of ACF between a 
      group of CRC patients treated with low dose aspirin (n=59) and a control group 
      without aspirin (n=135). ACF were visualised on methylene blue stained 
      macroscopically normal mucosa, microdissected, and serially cut. RESULTS: ACF 
      were found in 75.8% of mucosal samples from the control group and in 36% of 
      mucosal samples from the aspirin treated group, indicating a 47% decline in 
      prevalence of ACF in colonic samples of patients treated with aspirin. A 
      significant reduction from 92.5% to 40% (p<0.0001) was found in distal large 
      bowel samples containing one or more ACF. Similarly, the aspirin treated group 
      showed a reduction in ACF density of 64% and 82%, respectively, in both proximal 
      and distal parts of the colon, indicating a significant reduction in ACF/cm(2) in 
      distal colon samples (p<0.01). The aspirin treated group displayed a 52% 
      reduction in dysplastic ACF although this difference was not statistically 
      significant. CONCLUSIONS: Our study has provided evidence of the effective 
      chemopreventive action of low dose aspirin on ACF in humans.
FAU - Shpitz, B
AU  - Shpitz B
AD  - Department of Surgery, Sapir Medical Center, Meir General Hospital, Kfar Sava, 
      Tel Aviv University Sackler School of Medicine, Israel. shpitza@post.tau.ac.il
FAU - Klein, E
AU  - Klein E
FAU - Buklan, G
AU  - Buklan G
FAU - Neufeld, D
AU  - Neufeld D
FAU - Nissan, A
AU  - Nissan A
FAU - Freund, H R
AU  - Freund HR
FAU - Grankin, M
AU  - Grankin M
FAU - Bernheim, J
AU  - Bernheim J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticarcinogenic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Gut. 2003 Nov;52(11):1535-6. PMID: 14570718
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Anticarcinogenic Agents/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Colon/drug effects/pathology
MH  - Colorectal Neoplasms/pathology/*prevention & control
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Intestinal Mucosa/drug effects/pathology
MH  - Intestine, Large/drug effects/pathology
MH  - Male
MH  - Middle Aged
MH  - Precancerous Conditions/pathology/*prevention & control
MH  - Time Factors
PMC - PMC1773868
EDAT- 2003/10/23 05:00
MHDA- 2004/01/14 05:00
CRDT- 2003/10/23 05:00
PHST- 2003/10/23 05:00 [pubmed]
PHST- 2004/01/14 05:00 [medline]
PHST- 2003/10/23 05:00 [entrez]
AID - 0521598 [pii]
AID - 10.1136/gut.52.11.1598 [doi]
PST - ppublish
SO  - Gut. 2003 Nov;52(11):1598-601. doi: 10.1136/gut.52.11.1598.

PMID- 18469357
OWN - NLM
STAT- MEDLINE
DCOM- 20080627
LR  - 20221207
IS  - 1550-8080 (Electronic)
IS  - 0091-7370 (Linking)
VI  - 38
IP  - 2
DP  - 2008 Spring
TI  - Aspirin non-responsiveness in Korean subjects on dual anti-platelet treatment 
      determined by two different platelet function assays.
PG  - 126-31
AB  - Several techniques are available for measuring platelet function during aspirin 
      therapy, but none is well standardized, and the reported incidence of aspirin 
      non-responders varies widely, from 5 to 50%. We evaluated the optical platelet 
      aggregation test and the Platelet Function Analyzer-100 test (PFA-100) for 
      assessing aspirin responsiveness in patients receiving dual anti-platelet 
      therapy, and we measured the incidence of non-responders to aspirin among 
      Koreans. The study enrolled 88 participants including 51 patients on dual 
      anti-platelet therapy, 31 controls, and 6 other volunteers. Optical platelet 
      aggregation in response to 4 agonists and aggregation using the PFA-100 test were 
      determined. In addition, medical records, including the results of platelet 
      aggregation tests, were reviewed for 351 patients receiving aspirin therapy. The 
      results showed good correlation between the PFA-100 test using a 
      collagen/epinephrine cartridge (CEPI) and the optical platelet aggregation test 
      using each agonist. The platelet aggregation test using arachidonic acid revealed 
      marked suppression of aggregation (>98% inhibition) in patients taking aspirin; 
      this value was highly correlated with the PFA-100 results using the CEPI 
      cartridge. Seven of 351 Korean subjects (2.0%) receiving aspirin treatment were 
      non-responsive to aspirin. This study shows that the optical platelet aggregation 
      test using arachidonic acid gave an accurate assessment of the response to 
      aspirin, and that results of the PFA-100 test using the CEPI cartridge correlated 
      well with results of the optical platelet aggregation test.
FAU - Lee, Yong-Wha
AU  - Lee YW
AD  - Department of Laboratory Medicine, Soonchunhyang University Bucheon Hospital, 
      Bucheon, Korea.
FAU - Cho, Yoon-Haeng
AU  - Cho YH
FAU - Kim, Yong-Hyun
AU  - Kim YH
FAU - Na, Jong-Sung
AU  - Na JS
FAU - Shin, Hee Bong
AU  - Shin HB
FAU - Ki, Chang-Seok
AU  - Ki CS
FAU - Choi, Tae-Youn
AU  - Choi TY
FAU - Lee, You Kyoung
AU  - Lee YK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Ann Clin Lab Sci
JT  - Annals of clinical and laboratory science
JID - 0410247
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aged
MH  - Arachidonic Acid/pharmacology
MH  - Asian People
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Bleeding Time
MH  - Case-Control Studies
MH  - Clopidogrel
MH  - Collagen/pharmacology
MH  - Drug Resistance
MH  - Epinephrine/pharmacology
MH  - Female
MH  - Humans
MH  - Korea
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Function Tests/*methods
MH  - Ticlopidine/administration & dosage/analogs & derivatives/pharmacology
EDAT- 2008/05/13 09:00
MHDA- 2008/06/28 09:00
CRDT- 2008/05/13 09:00
PHST- 2008/05/13 09:00 [pubmed]
PHST- 2008/06/28 09:00 [medline]
PHST- 2008/05/13 09:00 [entrez]
AID - 38/2/126 [pii]
PST - ppublish
SO  - Ann Clin Lab Sci. 2008 Spring;38(2):126-31.

PMID- 35652428
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220719
IS  - 1008-8830 (Print)
IS  - 1008-8830 (Linking)
VI  - 24
IP  - 6
DP  - 2022 Jun 15
TI  - [Pediatric expert consensus on the application of aspirin in Kawasaki disease].
PG  - 597-603
LID - 1008-8830(2022)06-0597-07 [pii]
LID - 10.7499/j.issn.1008-8830.2203190 [doi]
AB  - Kawasaki disease (KD) is one of the common acquired heart diseases in children 
      aged <5 years and is an acute systemic vasculitis. After nearly 60 years of 
      research, intravenous immunoglobulin combined with oral aspirin has become the 
      first-line treatment for the prevention of coronary artery lesion in acute KD; 
      however, there are still controversies over the role and optimal dose of aspirin. 
      The consensus was formulated based on the latest research findings of KD 
      treatment in China and overseas and comprehensive discussion of pediatric experts 
      in China and put forward recommendations on the dose, usage, and course of 
      aspirin treatment in the first-line treatment of KD.
CN  - Shaanxi Province Diagnosis and Treatment Center of Kawasaki Disease/Children's 
      Hospital of Shaanxi Provincial People's Hospital
CN  - Children's Hospital of Shanghai Jiao Tong University
CN  - Beijing Children's Hospital of Capital Medical University
CN  - Shengjing Hospital of China Medical University
CN  - Affiliated Hospital of Yan'an University
CN  - Expert Committee of Advanced Training for Pediatrician, China Maternal and 
      Children's Health Association
CN  - General Pediatric Group of Pediatrician Branch of Chinese Medical Doctor 
      Association
CN  - Shanghai Cooperation Organization Hospital Cooperation Alliance
CN  - Pediatric International Exchange and Cooperation Center
CN  - Editorial Board of Chinese Journal of Contemporary Pediatrics
LA  - chi
PT  - Journal Article
TT  - 阿司匹林在川崎病治疗中的儿科专家共识.
PL  - China
TA  - Zhongguo Dang Dai Er Ke Za Zhi
JT  - Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
JID - 100909956
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Consensus
MH  - Coronary Vessels/pathology
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - *Mucocutaneous Lymph Node Syndrome/drug therapy/pathology
PMC - PMC9250407
OTO - NOTNLM
OT  - Aspirin
OT  - Child
OT  - Expert consensus
OT  - Kawasaki disease
COIS- 本共识由小组内成员自行完成，未接受赞助，小组内成员不存在任何利益冲突。
EDAT- 2022/06/03 06:00
MHDA- 2022/06/07 06:00
CRDT- 2022/06/02 06:13
PHST- 2022/06/02 06:13 [entrez]
PHST- 2022/06/03 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
AID - 1008-8830(2022)06-0597-07 [pii]
AID - 10.7499/j.issn.1008-8830.2203190 [doi]
PST - ppublish
SO  - Zhongguo Dang Dai Er Ke Za Zhi. 2022 Jun 15;24(6):597-603. doi: 
      10.7499/j.issn.1008-8830.2203190.

PMID- 30543478
OWN - NLM
STAT- MEDLINE
DCOM- 20200427
LR  - 20200501
IS  - 1931-843X (Electronic)
IS  - 1540-9996 (Print)
IS  - 1540-9996 (Linking)
VI  - 28
IP  - 5
DP  - 2019 May
TI  - Quantifying Sex Differences in Cardiovascular Care Among Patients Evaluated for 
      Suspected Ischemic Heart Disease.
PG  - 698-704
LID - 10.1089/jwh.2018.7018 [doi]
AB  - Background: Cardiovascular care sex differences are controversial. We examined 
      sex differences in management and clinical outcomes among patients undergoing 
      noninvasive testing for ischemic heart disease (IHD). Methods: In a rural 
      integrated healthcare system, we identified adults age 40-79 without diagnosed 
      IHD who underwent initial evaluation with a cardiac stress test with imaging or 
      coronary computed tomographic angiography (CTA), 2013-2014. We assessed sex 
      differences in statin/aspirin therapy, revascularization, and adverse 
      cardiovascular events. The 2013 American College of Cardiology/American Heart 
      Association statin guidelines and U.S. Preventive Services Task Force aspirin 
      guidelines were applied. Results: Among 2213 patients evaluated for IHD, median 
      age was 57 years, 48.8% were women, and 9% had a positive stress test/CTA. Women 
      were more likely to be missing lipid values than men (p < 0.001). Mean ASCVD risk 
      score at baseline was 7.2% in women versus 12.4% in men (p < 0.001). There was no 
      significant sex difference in statin therapy at baseline or 60-day follow-up. 
      Women were less likely than men to be taking aspirin at baseline (adj. 
      diff. = -8.5%; 95% CI, -4.2 to -12.9) and follow-up (adj. diff. = -7.7%; 95% CI, 
      -3.3 to -12.1). There were no sex differences in revascularization after 
      accounting for obstructive CAD or adverse cardiovascular outcomes during median 
      follow-up of 33 months. Conclusion: In this contemporary cohort of patients with 
      suspected IHD, women were less likely to receive lipid testing and aspirin 
      therapy, but not statin therapy. Women did not experience worse outcomes. Sex 
      differences in statin therapy reported by others may be due to inadequate 
      accounting for baseline risk.
FAU - Ladapo, Joseph A
AU  - Ladapo JA
AD  - 1 Division of General Internal Medicine and Health Services Research, David 
      Geffen School of Medicine at UCLA, Los Angeles, California.
FAU - Pfeifer, John M
AU  - Pfeifer JM
AD  - 2 Geisinger Health System, Danville, Pennsylvania.
FAU - Pitcavage, James M
AU  - Pitcavage JM
AD  - 2 Geisinger Health System, Danville, Pennsylvania.
FAU - Williams, Brent A
AU  - Williams BA
AD  - 2 Geisinger Health System, Danville, Pennsylvania.
FAU - Choy-Shan, Alana A
AU  - Choy-Shan AA
AD  - 3 Department of Medicine, New York University School of Medicine, New York, New 
      York.
LA  - eng
GR  - K23 HL116787/HL/NHLBI NIH HHS/United States
GR  - R01 MD011544/MD/NIMHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20181213
PL  - United States
TA  - J Womens Health (Larchmt)
JT  - Journal of women's health (2002)
JID - 101159262
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Cohort Studies
MH  - Coronary Angiography
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*diagnosis/drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Sex Characteristics
PMC - PMC6537115
OTO - NOTNLM
OT  - aspirin
OT  - cardiac stress testing
OT  - disparities
OT  - sex differences
OT  - statins
COIS- Dr. Ladapo's work is supported by NHLBI K23 HL116787, NIMHD R01 MD011544, and the 
      Robert Wood Johnson Foundation (72426), and he serves as a consultant for 
      CardioDx, Inc. The remaining authors have no conflict of interests.
EDAT- 2018/12/14 06:00
MHDA- 2020/04/28 06:00
CRDT- 2018/12/14 06:00
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2020/04/28 06:00 [medline]
PHST- 2018/12/14 06:00 [entrez]
AID - 10.1089/jwh.2018.7018 [pii]
AID - 10.1089/jwh.2018.7018 [doi]
PST - ppublish
SO  - J Womens Health (Larchmt). 2019 May;28(5):698-704. doi: 10.1089/jwh.2018.7018. 
      Epub 2018 Dec 13.

PMID- 17672075
OWN - NLM
STAT- MEDLINE
DCOM- 20070820
LR  - 20141120
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 79
IP  - 5
DP  - 2007
TI  - [Warfarin in the treatment of antiphospholipid syndrome].
PG  - 47-54
AB  - AIM: To assess efficacy and safety of warfarin therapy and its combination with 
      low-dose acetylsalicylic acid (ASA) in antiphospholipid syndrome (APS). MATERIAL 
      AND METHODS: The trial enrolled 60 APS patients. They were divided into two 
      groups: group 1 (n = 39) on antithrombotic therapy with warfarin; group 2 (n = 
      21) on combined therapy with warfarin and ASA. Efficacy of the treatments was 
      assessed by the number and frequency of thrombosis recurrences and transient 
      ischemic attacks (TIA) while safety was evaluated by frequency and number of 
      hemorrhages during the study. Genetic variants of cytochrome P450 (CYP2C9*1, 
      CYP2C9*2 and CYP2C9*3) were studied in 30 patients (25 females, 5 males) with 
      APS. CYP2C9 gene genetic variants were determined by polymerase chain reaction 
      and restrictase analysis. RESULTS: The thrombosis rate was 19.6 per 100 man-day, 
      TIA rate was not less than 8 per 100 man-day, total rate of thrombotic 
      complications (thromboses and TIA) before warfarin individual dose 
      adjustment--27.6 per 100 man-day. Doses of anticoagulant were adjusted and the 
      patients on treatment were followed up for 15.7 months, on the average. For this 
      period thrombosis occurred in 6 cases (7.6 per 100 man-day), TIA also in 6 cases 
      (7.6 per 100 man-day). This corresponded to thrombotic complications rate 15.1 
      per 100 man-year. Hemorrhages (major and minor) occurred in 19 (48.7%) patients 
      of group 1 and in 13 (61.9%) patients of group 2 (p = 0.33). Total rate of 
      CYP2C9*2 and CYP2C9*3 carriage was 36.7%. The CYP2C9*2 variant was detected in 7 
      (23.3%) patients, who were all heterozygous carriers. The CYP2C9*3 variant was 
      seen in 4 (13.3%) patients: 3 heterozygous and 1 homozygous. Females of 
      reproductive age with mutations had more frequent menorrhagies than carriers of a 
      wild-type variant. Patients with CYP2C9*3 had also more frequent nasal 
      hemorrhages and gingival bleeding (p = 0.005) compared to carriers of CYP2C9*1 
      and CYP2C9*2. Episodes of MHO rise > 5.0 in warfarin therapy were observed in 50% 
      carriers of CYP2C9*3 and in none homozygous carriers of CYP2C9*1 (p = 0.024). 
      CYP2C9*3 patients needed lower maintenance doses of warfarin, in CYP2C9*1 and 
      CYP2C9*2 patients anticoagulant doses were comparable. CONCLUSION; Efficacy of 
      warfarin for secondary prophylaxis of thrombosis was found similar to that of 
      warfarin use in combination with low-dose ASA (MHO 2.0-3.0). Safety of 
      monotherapy was higher. Determination of CYP2C9 genotype in APS patients before 
      treatment with oral anticoagulants may help in planning individual policy and in 
      reducing the risk of warfarin overdosage at the start of therapy.
FAU - Reshetniak, T M
AU  - Reshetniak TM
FAU - Kondrat'eva, L V
AU  - Kondrat'eva LV
FAU - Patrusheva, N L
AU  - Patrusheva NL
FAU - Patrushev, L I
AU  - Patrushev LI
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - EC 1.14.13.- (CYP2C9 protein, human)
RN  - EC 1.14.13.- (Cytochrome P-450 CYP2C9)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Antiphospholipid Syndrome/blood/complications/*drug therapy/physiopathology
MH  - Aryl Hydrocarbon Hydroxylases/genetics
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Blood Coagulation/*drug effects/genetics
MH  - Cerebrovascular Circulation/drug effects
MH  - Cytochrome P-450 CYP2C9
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genetic Variation
MH  - Humans
MH  - Male
MH  - Polymerase Chain Reaction
MH  - Thrombosis/*drug therapy/etiology/physiopathology
MH  - Treatment Outcome
MH  - Warfarin/administration & dosage/adverse effects/*therapeutic use
EDAT- 2007/08/04 09:00
MHDA- 2007/08/21 09:00
CRDT- 2007/08/04 09:00
PHST- 2007/08/04 09:00 [pubmed]
PHST- 2007/08/21 09:00 [medline]
PHST- 2007/08/04 09:00 [entrez]
PST - ppublish
SO  - Ter Arkh. 2007;79(5):47-54.

PMID- 12584276
OWN - NLM
STAT- MEDLINE
DCOM- 20030716
LR  - 20190513
IS  - 0931-0509 (Print)
IS  - 0931-0509 (Linking)
VI  - 18
IP  - 3
DP  - 2003 Mar
TI  - Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic 
      patients with elevated urinary albumin excretion rate.
PG  - 539-42
AB  - BACKGROUND: Low-dose treatment with acetylsalicylic acid (ASA) is widely 
      recommended to type 2 diabetic patients as primary prevention against 
      cardiovascular disease. High-dose treatment with cyclooxygenase inhibitors 
      reduces urinary albumin excretion rate (AER) in type 1 diabetic patients with 
      micro- or macroalbuminuria. Whether a similar effect on AER exists during 
      low-dose ASA treatment, which may confound the diagnosis and monitoring of micro- 
      and macroalbuminuria in type 2 diabetic patients, remains to be elucidated. 
      METHODS: In a randomized, double-blind, crossover trial, 31 type 2 diabetic 
      patients with elevated levels of AER (>30 mg/24 h) were, in random order, given 
      ASA (150 mg/day) for 4 weeks followed by placebo for 4 weeks with a 2 week 
      washout period or vice versa. At the end of each treatment period AER, glomerular 
      filtration rate (GFR), blood pressure (BP), transcapillary escape rate (TER(alb)) 
      of albumin and haemoglobin A(1c) (HbA(1c)) were measured. RESULTS: The following 
      variables remained unchanged (mean (95% CI) unless otherwise noted) (ASA vs 
      placebo, paired Student's t-test): AER (201 (119-341) vs 205 (124-340) mg/24 h 
      (geometric mean, 95% CI); P=0.78), GFR (103 (94-111) vs 102 (93-110) ml/min; 
      P=0.58), systolic BP (151 (146-158) vs 152 (146-158) mmHg; P=0.68), diastolic BP 
      (87 (83-91) vs 87 (82-91) mmHg; P=0.88), TER(alb) (6.3 (5.7-6.9) vs 5.9 
      (5.1-6.7); P=0.45) and HbA(1c) (8.6 (8.1-9.0) vs 8.5 (8.1-9.0) %; P=0.60). 
      CONCLUSIONS: Low-dose treatment with 150 mg ASA daily does not have any impact on 
      AER or GFR in type 2 diabetic patients with micro- or macroalbuminuria. 
      Consequently, the widely recommended prescription of low-dose ASA as a primary 
      and secondary prevention strategy against cardiovascular disease in these 
      patients does not confound the diagnosis or monitoring of micro- or 
      macroalbuminuria.
FAU - Gaede, Peter
AU  - Gaede P
AD  - Steno Diabetes Center, Gentofte, Copenhagen, Denmark. p.gaede@dadlnet.dk
FAU - Hansen, Henrik Post
AU  - Hansen HP
FAU - Parving, Hans-Henrik
AU  - Parving HH
FAU - Pedersen, Oluf
AU  - Pedersen O
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Albuminuria/*etiology/*physiopathology/urine
MH  - Aspirin/*administration & dosage/*pharmacology/therapeutic use
MH  - Cardiovascular Diseases/*etiology/*physiopathology/prevention & control
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*complications/*physiopathology/urine
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/*pharmacology/therapeutic use
MH  - Glomerular Filtration Rate/drug effects/physiology
MH  - Hemodynamics/drug effects/physiology
MH  - Humans
MH  - Kidney/*drug effects/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Time Factors
EDAT- 2003/02/14 04:00
MHDA- 2003/07/17 05:00
CRDT- 2003/02/14 04:00
PHST- 2003/02/14 04:00 [pubmed]
PHST- 2003/07/17 05:00 [medline]
PHST- 2003/02/14 04:00 [entrez]
AID - 10.1093/ndt/18.3.539 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 2003 Mar;18(3):539-42. doi: 10.1093/ndt/18.3.539.

PMID- 28178148
OWN - NLM
STAT- MEDLINE
DCOM- 20170227
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 6
DP  - 2017 Feb
TI  - Monitoring the hemostasis with rotation thromboelastometry in patients with acute 
      STEMI on dual antiplatelet therapy: First experiences.
PG  - e6045
LID - 10.1097/MD.0000000000006045 [doi]
LID - e6045
AB  - Rotation thromboelastometry (ROTEM) is a viscoelastometric point-of-care-test for 
      the complex evaluation of changes in hemostasis, performed in whole blood. 
      However, no prospective study evaluating the efficacy of the antiplatelet therapy 
      using ROTEM was performed.Fifty-six patients (34 men, 22 women, mean age 67.75 
      years, and age range 34-88 years) with acute ST-elevation myocardial infarction 
      (STEMI), treated with dual antiplatelet therapy, undergoing urgent coronary 
      angiography and percutaneous coronary intervention (PCI) of culprit coronary 
      lesion were included. Three blood samples were taken (sample 1 taken before the 
      urgent coronary angiography, sample 2 in 24 hours after the admission, and sample 
      3 in 30 days after acute STEMI). Twenty-one healthy blood donors (17 men, 4 
      women, mean age 50.38 years, and age range 40-74 years) were recruited as the 
      control group. Blood samples were tested with ROTEM Gamma (Pentapharm GmbH, 
      Munich, Germany) and light transmission aggregometry (LTA).Clotting time (CT) was 
      significantly prolonged and maximum clot firmness (MCF) was significantly higher 
      in patients compared to controls. Mean platelet aggregation after the induction 
      with arachidonic acid (33.2% vs 74.6% in sample 1 and 21.1% vs 74.6% in sample 
      2), as well as adenosine diphosphate (51.4% vs 72.7% in sample 1 and 37.1% vs 
      72.7% in sample 2), were significantly lower in patients with acute 
      STEMI.Significantly prolonged CT and increased MCF was found in patients with 
      acute STEMI. This study confirmed the ability of ROTEM to identify changes in 
      hemostasis in ACS patients on antithrombotic therapy.
FAU - Samoš, Matej
AU  - Samoš M
AD  - Department of Internal Medicine I National Centre of Haemostasis and Thrombosis, 
      Department of Hematology and Transfusiology, Comenius University in Bratislava, 
      Jessenius Faculty of Medicine in Martin, Martin, Slovak Republic.
FAU - Stančiaková, Lucia
AU  - Stančiaková L
FAU - Duraj, Lukáš
AU  - Duraj L
FAU - Kovář, František
AU  - Kovář F
FAU - Fedor, Marián
AU  - Fedor M
FAU - Šimonová, Radoslava
AU  - Šimonová R
FAU - Bolek, Tomáš
AU  - Bolek T
FAU - Galajda, Peter
AU  - Galajda P
FAU - Staško, Ján
AU  - Staško J
FAU - Kubisz, Peter
AU  - Kubisz P
FAU - Mokáň, Marián
AU  - Mokáň M
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Coronary Angiography
MH  - Female
MH  - Hemostasis/*drug effects/physiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Point-of-Care Systems
MH  - Prospective Studies
MH  - Purinergic P2Y Receptor Antagonists/pharmacology/therapeutic use
MH  - ST Elevation Myocardial Infarction/*drug therapy/surgery
MH  - Thrombelastography/*methods
PMC - PMC5313005
COIS- The authors have no conflict of interest to disclose.
EDAT- 2017/02/09 06:00
MHDA- 2017/02/28 06:00
CRDT- 2017/02/09 06:00
PHST- 2017/02/09 06:00 [entrez]
PHST- 2017/02/09 06:00 [pubmed]
PHST- 2017/02/28 06:00 [medline]
AID - 00005792-201702100-00029 [pii]
AID - MD-D-16-02717 [pii]
AID - 10.1097/MD.0000000000006045 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Feb;96(6):e6045. doi: 10.1097/MD.0000000000006045.

PMID- 7485571
OWN - NLM
STAT- MEDLINE
DCOM- 19951212
LR  - 20181130
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 269
IP  - 4 Pt 2
DP  - 1995 Oct
TI  - Role of NO mechanism in cardiovascular effects of diaspirin cross-linked 
      hemoglobin in anesthetized rats.
PG  - H1379-88
AB  - The role of nitric oxide (NO) in the cardiovascular actions of diaspirin 
      cross-linked hemoglobin (DCLHb) was studied in anesthetized rats. The regional 
      circulatory and systemic hemodynamic effects of DCLHb (400 mg/kg iv) were studied 
      using a radioactive microsphere technique in control (untreated) and L-arginine 
      (a NO precursor) pretreated rats. DCLHb produced a significant increase in blood 
      pressure (75%), cardiac output (42%), stroke volume (36%), and total peripheral 
      resistance (45%), without affecting heart rate, when administered to control 
      rats. L-Arginine pretreatment significantly attenuated DCLHb-induced systemic 
      hemodynamic effects. DCLHb-induced increase in blood flow to the skin and spleen 
      was completely blocked, and that to the heart was partially blocked, by 
      L-arginine pretreatment, suggesting that cardiovascular actions induced by DCLHb 
      could be antagonized by the NO precursor L-arginine. The NO synthase (NOS) 
      inhibitor NG-nitro-L-arginine methyl ester (L-NAME) produced significant 
      increases in regional vascular resistance, leading to a decrease in blood flow to 
      all the organs except the heart, where an increase in blood flow and a decrease 
      in vascular resistance was observed. DCLHb, when administered in 
      L-NAME-pretreated rats, accentuated the decrease in blood flow to the 
      gastrointestinal system, spleen, mesentery and pancreas, skin, and 
      musculoskeletal system. These studies provide evidence that the NO precursor 
      L-arginine can attenuate the effects of DCLHb and that DCLHb can potentiate the 
      effect of the NOS inhibitor L-NAME. The role of NO in the mechanism of action of 
      DCLHb was further studied by estimating plasma guanosine 3',5'-cyclic 
      monophosphate (cGMP) in control, DCLHb-treated, L-NAME-treated, and L-NAME 
      followed by DCLHb-treated rats. DCLHb and L-NAME significantly decreased the 
      concentration of circulating cGMP in blood plasma. L-NAME pretreatment 
      potentiated DCLHb-induced decrease in cGMP levels. Because the formation of cGMP 
      is stimulated by NO, these studies provide additional evidence for the 
      involvement of NO in the mechanism of action of DCLHb. It is concluded that NO 
      plays an important role in the cardiovascular effects of DCLHb.
FAU - Sharma, A C
AU  - Sharma AC
AD  - Department of Pharmaceutics and Pharmacodynamics, University of Illinois at 
      Chicago 60612, USA.
FAU - Singh, G
AU  - Singh G
FAU - Gulati, A
AU  - Gulati A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Gases)
RN  - 0 (Hemoglobins)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 451W47IQ8X (Sodium Chloride)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - H2D2X058MU (Cyclic GMP)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Animals
MH  - Arginine/analogs & derivatives/pharmacology
MH  - Arteries
MH  - Aspirin/*analogs & derivatives/pharmacology
MH  - Cardiovascular System/*drug effects
MH  - Cyclic GMP/blood
MH  - Gases/blood
MH  - Hemodynamics/drug effects
MH  - Hemoglobins/analysis/*pharmacology
MH  - Male
MH  - NG-Nitroarginine Methyl Ester
MH  - Nitric Oxide/*physiology
MH  - Nitric Oxide Synthase/antagonists & inhibitors
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/drug effects
MH  - Sodium Chloride/pharmacology
MH  - Vascular Resistance
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - 10.1152/ajpheart.1995.269.4.H1379 [doi]
PST - ppublish
SO  - Am J Physiol. 1995 Oct;269(4 Pt 2):H1379-88. doi: 
      10.1152/ajpheart.1995.269.4.H1379.

PMID- 23249161
OWN - NLM
STAT- MEDLINE
DCOM- 20140514
LR  - 20211021
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Print)
IS  - 0953-7104 (Linking)
VI  - 24
IP  - 8
DP  - 2013
TI  - Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor 
      co-administered with aspirin in healthy volunteers.
PG  - 615-24
LID - 10.3109/09537104.2012.748185 [doi]
AB  - The results of two independent, randomized, two-period crossover, single-center 
      studies, conducted to assess the pharmacokinetics of ticagrelor ± aspirin, 
      inhibition of platelet aggregation (IPA) with ticagrelor/aspirin vs. 
      clopidogrel/aspirin, and safety, tolerability, and bleeding times are reported 
      here. In Study A (open-label), 16 volunteers received ticagrelor (50 mg bid Days 
      1-5; 200 mg bid Days 6-9; one 200 mg dose on Day 10) ± 300 mg qd aspirin (Days 
      1-10). In Study B (double-blind, double-dummy), 16 volunteers received aspirin 
      (300 mg loading dose/75 mg qd Days 2-9) with either ticagrelor (200 mg bid Days 
      4-8, one 200 mg dose on Day 9) or clopidogrel (300 mg loading dose Day 4, 75 mg 
      qd Days 5-9). At steady-state ticagrelor (50 mg bid, or 200 mg bid), concomitant 
      aspirin (300 mg qd) had no effect on mean maximum plasma concentration (Cmax), 
      median time to Cmax (tmax), or mean area under the plasma concentration-time 
      curve for the dosing interval (AUC0-τ) for ticagrelor and its primary metabolite, 
      AR-C124910XX. Following 200 mg bid ticagrelor, mean Cmax and AUC0-τ for both 
      parent and metabolite were comparable with co-administration of aspirin at 75 mg 
      and 300 mg qd. Aspirin (300 mg qd) had no effect on IPA (ADP-induced) by 
      ticagrelor. However, aspirin and ticagrelor had an additive effect on IPA 
      (collagen-induced). Ticagrelor/aspirin increased bleeding times vs. baseline. 
      Ticagrelor/aspirin co-administration was well tolerated at all dose combinations 
      evaluated. In summary, the findings of this study demonstrate that 
      co-administration of aspirin (300 mg qd) with ticagrelor (50 mg bid, or 200 mg 
      bid) had no effect on ticagrelor pharmacokinetics or IPA (ADP-induced) by 
      ticagrelor.
FAU - Teng, Renli
AU  - Teng R
AD  - AstraZeneca LP , Wilmington, DE , USA.
FAU - Maya, Juan
AU  - Maya J
FAU - Butler, Kathleen
AU  - Butler K
LA  - eng
PT  - Journal Article
DEP - 20121218
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - A74586SNO7 (Clopidogrel)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacokinetics
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Aspirin/administration & dosage/adverse effects/*pharmacokinetics
MH  - Bleeding Time
MH  - Clopidogrel
MH  - Collagen/pharmacology
MH  - Drug Therapy, Combination
MH  - Female
MH  - *Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse 
      effects/pharmacokinetics
MH  - Ticagrelor
MH  - Ticlopidine/administration & dosage/analogs & derivatives/pharmacokinetics
MH  - Young Adult
PMC - PMC3809924
EDAT- 2012/12/20 06:00
MHDA- 2014/05/16 06:00
CRDT- 2012/12/20 06:00
PHST- 2012/12/20 06:00 [entrez]
PHST- 2012/12/20 06:00 [pubmed]
PHST- 2014/05/16 06:00 [medline]
AID - 10.3109/09537104.2012.748185 [doi]
PST - ppublish
SO  - Platelets. 2013;24(8):615-24. doi: 10.3109/09537104.2012.748185. Epub 2012 Dec 
      18.

PMID- 3786202
OWN - NLM
STAT- MEDLINE
DCOM- 19870106
LR  - 20131121
IS  - 0391-5387 (Print)
IS  - 0391-5387 (Linking)
VI  - 8
IP  - 3
DP  - 1986 May-Jun
TI  - [Use of plasmapheresis in the treatment of hemolytic-uremic syndrome in 
      children].
PG  - 383-7
AB  - The plasma-exchange has been recently adopted in the therapy of the 
      hemolytic-uremic syndrome. We experimented this therapy, without any complication 
      with traditional treatment (anti platelet-aggregation, frozen fresh plasma), on a 
      child of 6 years and 8 months old. A rapid normalization of the clinical 
      syntomatology was obtained without sequences also after a long period. The PE 
      therapy has to be carefully valued on the solution of the SUE in order to 
      establish the cases to be treated, missing proved results from controlled 
      experiments.
FAU - Salvatori, G
AU  - Salvatori G
FAU - Rinaldi, S
AU  - Rinaldi S
FAU - Landolfo, A
AU  - Landolfo A
FAU - Totino, T
AU  - Totino T
FAU - Salvatori, A
AU  - Salvatori A
FAU - Signoretti, A
AU  - Signoretti A
LA  - ita
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Sull'impiego della plasmaferesi nel trattamento della sindrome uremico-emolitica 
      nel bambino.
PL  - Italy
TA  - Pediatr Med Chir
JT  - La Pediatria medica e chirurgica : Medical and surgical pediatrics
JID - 8100625
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Blood Transfusion
MH  - Child
MH  - Combined Modality Therapy
MH  - Dipyridamole/therapeutic use
MH  - Hemolytic-Uremic Syndrome/drug therapy/*therapy
MH  - Humans
MH  - Male
MH  - *Plasmapheresis
EDAT- 1986/05/01 00:00
MHDA- 1986/05/01 00:01
CRDT- 1986/05/01 00:00
PHST- 1986/05/01 00:00 [pubmed]
PHST- 1986/05/01 00:01 [medline]
PHST- 1986/05/01 00:00 [entrez]
PST - ppublish
SO  - Pediatr Med Chir. 1986 May-Jun;8(3):383-7.

PMID- 29329538
OWN - NLM
STAT- MEDLINE
DCOM- 20190529
LR  - 20190529
IS  - 1755-8794 (Electronic)
IS  - 1755-8794 (Linking)
VI  - 11
IP  - 1
DP  - 2018 Jan 12
TI  - Peripheral blood gene expression signatures which reflect smoking and aspirin 
      exposure are associated with cardiovascular events.
PG  - 1
LID - 10.1186/s12920-017-0318-6 [doi]
LID - 1
AB  - BACKGROUND: Cardiovascular disease and its sequelae are major causes of global 
      mortality, and better methods are needed to identify patients at risk for future 
      cardiovascular events. Gene expression analysis can inform on the molecular 
      underpinnings of risk factors for cardiovascular events. Smoking and aspirin have 
      known opposing effects on platelet reactivity and MACE, however their effects on 
      each other and on MACE are not well described. METHODS: We measured peripheral 
      blood gene expression levels of ITGA2B, which is upregulated by aspirin and 
      correlates with platelet reactivity on aspirin, and a 5 gene validated smoking 
      gene expression score (sGES) where higher expression correlates with smoking 
      status, in participants from the previously reported PREDICT trial (NCT 
      00500617). The primary outcome was a composite of death, myocardial infarction, 
      and stroke/TIA (MACE). We tested whether selected genes were associated with MACE 
      risk using logistic regression. RESULTS: Gene expression levels were determined 
      in 1581 subjects (50.5% female, mean age 60.66 +/-11.46, 18% self-reported 
      smokers); 3.5% of subjects experienced MACE over 12 months follow-up. Elevated 
      sGES and ITGA2B expression were each associated with MACE (odds ratios [OR] =1.16 
      [95% CI 1.10-1.31] and 1.42 [95% CI 1.00-1.97], respectively; p < 0.05). ITGA2B 
      expression was inversely associated with self-reported smoking status and the 
      sGES (p < 0.001). A logistic regression model combining sGES and ITGA2B showed 
      better performance (AIC = 474.9) in classifying MACE subjects than either alone 
      (AIC = 479.1, 478.2 respectively). CONCLUSION: Gene expression levels associated 
      with smoking and aspirin are independently predictive of an increased risk of 
      cardiovascular events.
FAU - Wingrove, James A
AU  - Wingrove JA
AD  - CardioDx, Inc, 600 Saginaw Dr., Redwood City, CA, 94063, USA. 
      jwingrove@cardiodx.com.
FAU - Fitch, Karen
AU  - Fitch K
AD  - CardioDx, Inc, 600 Saginaw Dr., Redwood City, CA, 94063, USA.
FAU - Rhees, Brian
AU  - Rhees B
AD  - CardioDx, Inc, 600 Saginaw Dr., Redwood City, CA, 94063, USA.
FAU - Rosenberg, Steven
AU  - Rosenberg S
AD  - CardioDx, Inc, 600 Saginaw Dr., Redwood City, CA, 94063, USA.
FAU - Voora, Deepak
AU  - Voora D
AD  - Center for Applied Genomics & Precision Medicine, Department of Medicine, Duke 
      University, 101 Science Drive, 2187 CIEMAS, Durham, NC, 27708, UK. 
      Deepak.voora@duke.edu.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20180112
PL  - England
TA  - BMC Med Genomics
JT  - BMC medical genomics
JID - 101319628
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Cardiovascular Diseases/*blood/chemically induced/*genetics/prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects/genetics
MH  - Smoking/*adverse effects
MH  - Transcriptome/*drug effects
PMC - PMC5767057
OTO - NOTNLM
OT  - Aspirin exposure
OT  - Cardiovascular events
OT  - Gene expression
OT  - Smoking
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Subjects in this study were part of 
      PREDICT, a multi-center US study of patients referred for coronary angiography 
      (http://www.clinicaltrials.gov, NCT00500617). The institutional review boards at 
      all centers approved the study (Duke University School of Medicine, Durham, North 
      Carolina; Minneapolis Heart Institute and Foundation, Minneapolis, Minnesota; 
      Piedmont Heart Institute, Atlanta, Georgia; Cleveland Clinic Foundation, 
      Cleveland, Ohio; Oklahoma Cardiovascular Research Group, Oklahoma City, Oklahoma; 
      Cardiovascular Research Institute, Medstar Research Institute, Washington, DC; 
      Vanderbilt Heart and Vascular Institute, Nashville, Tennessee; Cardiovascular 
      Research Foundation, New York, New York; and Scripps Translational Science 
      Institute, La Jolla, California), and all patients gave written informed consent. 
      Specific IRB protocol numbers can be found in Additional file 3: Table S3. 
      CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: JAW, BR, and KF 
      are/were full-time employees of and hold stock in CardioDx. SR reported serving 
      as a consultant and advisory board member for CardioDx and holding stock and 
      stock options in CardioDx. PUBLISHER’S NOTE: Springer Nature remains neutral with 
      regard to jurisdictional claims in published maps and institutional affiliations.
EDAT- 2018/01/14 06:00
MHDA- 2019/05/30 06:00
CRDT- 2018/01/14 06:00
PHST- 2017/10/23 00:00 [received]
PHST- 2017/12/21 00:00 [accepted]
PHST- 2018/01/14 06:00 [entrez]
PHST- 2018/01/14 06:00 [pubmed]
PHST- 2019/05/30 06:00 [medline]
AID - 10.1186/s12920-017-0318-6 [pii]
AID - 318 [pii]
AID - 10.1186/s12920-017-0318-6 [doi]
PST - epublish
SO  - BMC Med Genomics. 2018 Jan 12;11(1):1. doi: 10.1186/s12920-017-0318-6.

PMID- 34585829
OWN - NLM
STAT- MEDLINE
DCOM- 20220415
LR  - 20220415
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 129
IP  - 4
DP  - 2022 Apr
TI  - Perioperative continuation of aspirin, oral anticoagulants or bridging with 
      therapeutic low-molecular-weight heparin does not increase intraoperative blood 
      loss and blood transfusion rate in cystectomy patients: an observational cohort 
      study.
PG  - 512-523
LID - 10.1111/bju.15599 [doi]
AB  - OBJECTIVE: To assess if uninterrupted anticoagulant agents' administration 
      affects blood loss and blood transfusion during open radical cystectomy (RC) and 
      urinary diversion. PATIENTS AND METHODS: We conducted an observational 
      single-centre cohort study of a consecutive series of 1430 RC patients, between 
      2000 and 2020. Blood loss was depicted according to body weight and duration of 
      surgery (mL/kg/h), and blood transfusion. The group 'with anticoagulant agents' 
      was considered if surgery was performed with uninterrupted low-dose aspirin 
      (ASS), oral anticoagulants (OAC) with an international normalised ratio (INR) 
      goal of 2-2.5 or bridging with therapeutic low-molecular-weight heparin (LMWH). 
      Outcomes were intraoperative blood loss, blood transfusion rate (separately 
      analysed if administered within 24 h perioperatively or >24 h after surgery) and 
      the 90-day major adverse cardiac events (MACE) rate. We used propensity score 
      (PS)-matching analysis to adjust for imbalances between groups with or without 
      anticoagulant agents. RESULTS: The PS-matched median (interquartile range [IQR]) 
      blood loss was 2.10 (1.50-2.94) mL/kg/h in patients with anticoagulant agents vs 
      2.11 (1.47-2.94) mL/kg/h without anticoagulant agents (P(adj)  > 0.99). The 
      PS-matched blood transfusion rates were 26.2% vs 35.1% (P(adj)  = 0.875) within 
      24 h perioperatively and 57.0% vs 55.0% (P(adj)  = 0.680) if administered >24 h 
      postoperatively. A sub-analysis of the three different anticoagulant agents could 
      not detect any significance between ASS, OAC, or LMWH. The PS-matched incidence 
      of MACE was 9.1% in the group with anticoagulant agents and 8.1% in those without 
      anticoagulant agents (P(adj)  > 0.99). Limitations include selection bias and 
      retrospective analysis from prospectively assessed data. CONCLUSIONS: 
      Perioperative continuation of ASS, uninterrupted OAC with low INR goal or 
      bridging with LMWH had no impact on blood loss and transfusion rate in RC 
      patients. Therefore, there might be no compulsory need for discontinuation of 
      anticoagulant agents.
CI  - © 2021 The Authors BJU International © 2021 BJU International.
FAU - Furrer, Marc A
AU  - Furrer MA
AUID- ORCID: 0000-0001-8847-6799
AD  - Department of Urology, Inselspital, Bern University Hospital, University of Bern, 
      Bern, Switzerland.
AD  - Department of Urology, The University of Melbourne, Royal Melbourne Hospital, 
      Melbourne, Victoria, Australia.
FAU - Abgottspon, Janine
AU  - Abgottspon J
AD  - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University 
      Hospital, University of Bern, Bern, Switzerland.
FAU - Huber, Markus
AU  - Huber M
AD  - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University 
      Hospital, University of Bern, Bern, Switzerland.
FAU - Engel, Dominique
AU  - Engel D
AD  - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University 
      Hospital, University of Bern, Bern, Switzerland.
FAU - Löffel, Lukas M
AU  - Löffel LM
AD  - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University 
      Hospital, University of Bern, Bern, Switzerland.
FAU - Beilstein, Christian M
AU  - Beilstein CM
AD  - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University 
      Hospital, University of Bern, Bern, Switzerland.
FAU - Burkhard, Fiona C
AU  - Burkhard FC
AD  - Department of Urology, Inselspital, Bern University Hospital, University of Bern, 
      Bern, Switzerland.
FAU - Wuethrich, Patrick Y
AU  - Wuethrich PY
AUID- ORCID: 0000-0003-3704-6785
AD  - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University 
      Hospital, University of Bern, Bern, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20211201
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants
MH  - Aspirin/therapeutic use
MH  - Blood Loss, Surgical/prevention & control
MH  - Blood Transfusion
MH  - Cohort Studies
MH  - *Cystectomy/adverse effects
MH  - *Heparin, Low-Molecular-Weight/adverse effects/therapeutic use
MH  - Humans
MH  - Retrospective Studies
OTO - NOTNLM
OT  - #BladderCancer
OT  - #blcsm
OT  - #uroonc
OT  - anticoagulant agents
OT  - anticoagulants
OT  - aspirin
OT  - bleeding
OT  - blood transfusion
OT  - cystectomy
EDAT- 2021/09/30 06:00
MHDA- 2022/04/16 06:00
CRDT- 2021/09/29 08:59
PHST- 2021/08/29 00:00 [revised]
PHST- 2021/06/28 00:00 [received]
PHST- 2021/09/14 00:00 [accepted]
PHST- 2021/09/30 06:00 [pubmed]
PHST- 2022/04/16 06:00 [medline]
PHST- 2021/09/29 08:59 [entrez]
AID - 10.1111/bju.15599 [doi]
PST - ppublish
SO  - BJU Int. 2022 Apr;129(4):512-523. doi: 10.1111/bju.15599. Epub 2021 Dec 1.

PMID- 23536626
OWN - NLM
STAT- MEDLINE
DCOM- 20130903
LR  - 20211021
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 2013
DP  - 2013 Mar 26
TI  - Intractable intraoperative bleeding requiring platelet transfusion during 
      emergent cholecystectomy in a patient with dual antiplatelet therapy after 
      drug-eluting coronary stent implantation (with video).
LID - 10.1136/bcr-2013-008948 [doi]
LID - bcr2013008948
AB  - We report a case of a 76-year-old man, receiving dual antiplatelet therapy (DAPT) 
      with aspirin and ticlopidine for the past 6 years after implantation of 
      drug-eluting coronary stent, developed a severe hypochondriac pain. After 
      diagnosing severe acute cholecystitis by an enhanced CT, emergent laparotomy 
      under continuation of DAPT was attempted. During the operation, intractable 
      bleeding from the adhesiolysed liver surface was encountered, which required 
      platelet transfusion. Subtotal cholecystectomy with abdominal drainage was 
      performed, and the patient recovered without any postoperative bleeding or 
      thromboembolic complications. Like the present case, the final decision should be 
      made to perform platelet transfusion when life-threatening DAPT-induced 
      intraoperative bleeding occurs during an emergent surgery, despite the elevated 
      risk of stent thrombosis.
FAU - Fujikawa, Takahisa
AU  - Fujikawa T
AD  - Department of Surgery, Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan. 
      fujikawa-t@kokurakinen.or.jp
FAU - Noda, Tomohiro
AU  - Noda T
FAU - Tada, Seiichiro
AU  - Tada S
FAU - Tanaka, Akira
AU  - Tanaka A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Video-Audio Media
DEP - 20130326
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Blood Loss, Surgical/*prevention & control
MH  - *Cholecystectomy
MH  - Coronary Artery Disease/surgery
MH  - Drug-Eluting Stents
MH  - Emergency Treatment
MH  - Humans
MH  - Intraoperative Complications/*therapy
MH  - Male
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Platelet Transfusion
MH  - Ticlopidine/therapeutic use
PMC - PMC3618701
EDAT- 2013/03/29 06:00
MHDA- 2013/09/04 06:00
CRDT- 2013/03/29 06:00
PHST- 2013/03/29 06:00 [entrez]
PHST- 2013/03/29 06:00 [pubmed]
PHST- 2013/09/04 06:00 [medline]
AID - bcr-2013-008948 [pii]
AID - 10.1136/bcr-2013-008948 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Mar 26;2013:bcr2013008948. doi: 10.1136/bcr-2013-008948.

PMID- 35506180
OWN - NLM
STAT- MEDLINE
DCOM- 20221214
LR  - 20230401
IS  - 1365-2222 (Electronic)
IS  - 0954-7894 (Print)
IS  - 0954-7894 (Linking)
VI  - 52
IP  - 12
DP  - 2022 Dec
TI  - Loss of smell in patients with aspirin-exacerbated respiratory disease impacts 
      mental health and quality of life.
PG  - 1414-1421
LID - 10.1111/cea.14157 [doi]
AB  - BACKGROUND: The impact of anosmia on quality-of-life (QoL) for patients with 
      aspirin-exacerbated respiratory disease (AERD) is poorly understood. We aimed to 
      investigate how the severity of smell loss and olfactory dysfunction (OD) in 
      patients with AERD affects their QoL, mental health and physical well-being. 
      METHODS: Five validated QoL questionnaires (Sinonasal Outcome Test-22, Asthma 
      Control Test, Healthy Days Core Module-4, Short Form-36 and Patient Health 
      Questionnaire-4) and two newly developed questionnaires assessing severity and 
      consequences of OD were electronically sent to all 2913 patients in the Brigham 
      and Women's Hospital AERD registry. Responses were received from 853 participants 
      for analysis. RESULTS: Overall, 85% of participants reported a present diminished 
      sense of smell and/or taste, and 30% categorized their OD severity was, "as bad 
      as it can be." There were significant relationships between the severity of 
      self-reported OD and both psychological distress and general health scores, even 
      after adjusting for asthma control. Additionally, incidence rates for physically 
      and mentally unhealthy days in the prior month were higher for patients with 
      moderate or severe OD than for normosmic patients. Patients with diminished smell 
      responded that they could not identify spoiled food (86%), did not enjoy food 
      (71%), felt unsafe (63%) and had encountered dangerous situations (51%) as 
      consequences of their OD. CONCLUSIONS: Anosmia and hyposmia severely impact the 
      physical, emotional and mental health of AERD patients, and lead to safety 
      concerns in their daily lives. The importance of olfaction and the relevance of 
      OD to patients' QoL should be acknowledged and evaluated by clinicians caring for 
      these patients.
CI  - © 2022 John Wiley & Sons Ltd.
FAU - Tchekmedyian, Raffi
AU  - Tchekmedyian R
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
FAU - Lundberg, Marie
AU  - Lundberg M
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
AD  - Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, 
      Boston, Massachusetts, USA.
AD  - Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki 
      and Helsinki University Hospital, Helsinki, Finland.
FAU - Buchheit, Kathleen M
AU  - Buchheit KM
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
AD  - Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, 
      Boston, Massachusetts, USA.
FAU - Maurer, Rie
AU  - Maurer R
AD  - Center for Clinical Investigation, Brigham and Women's Hospital, Boston, 
      Massachusetts, USA.
FAU - Gakpo, Deborah
AU  - Gakpo D
AD  - Case Western Reserve University School of Medicine, Cleveland, USA.
FAU - Mullur, Jyotsna
AU  - Mullur J
AD  - Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, 
      Boston, Massachusetts, USA.
FAU - Bensko, Jillian C
AU  - Bensko JC
AD  - Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, 
      Boston, Massachusetts, USA.
FAU - Laidlaw, Tanya M
AU  - Laidlaw TM
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
AD  - Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, 
      Boston, Massachusetts, USA.
LA  - eng
GR  - R01 HL128241/HL/NHLBI NIH HHS/United States
GR  - K23AI139352/NH/NIH HHS/United States
GR  - K23 AI139352/AI/NIAID NIH HHS/United States
GR  - T32 AI007306/AI/NIAID NIH HHS/United States
GR  - U19 AI095219/AI/NIAID NIH HHS/United States
GR  - T32AI007306/NH/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220517
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Female
MH  - Quality of Life
MH  - Anosmia
MH  - Mental Health
MH  - *Sinusitis/epidemiology
MH  - *Asthma, Aspirin-Induced/epidemiology
MH  - Aspirin/adverse effects
PMC - PMC9630163
MID - NIHMS1803510
OTO - NOTNLM
OT  - anosmia
OT  - aspirin-exacerbated respiratory disease
OT  - asthma
OT  - chronic rhinosinusitis
OT  - hyposmia
OT  - nasal polyp
OT  - smell
COIS- Conflict of Interest: TM Laidlaw has served on scientific advisory boards for 
      GlaxoSmithKline and Sanofi-Genzyme, Novartis, and Regeneron. KM Buchheit has 
      served on scientific advisory boards for AstraZeneca, Regeneron, Sanofi-Genzyme 
      and GlaxoSmithKline. JC Bensko has served on scientific advisory boards for 
      GlaxoSmithKline. M Lundberg has served on scientific advisory boards for 
      Sanofi-Genzyme and Chordate LTD and has received lecture honoraria from 
      Sanofi-Genzyme and Smith+Nephew.
EDAT- 2022/05/05 06:00
MHDA- 2022/12/15 06:00
PMCR- 2023/12/01
CRDT- 2022/05/04 02:52
PHST- 2022/04/04 00:00 [revised]
PHST- 2022/01/25 00:00 [received]
PHST- 2022/04/18 00:00 [accepted]
PHST- 2023/12/01 00:00 [pmc-release]
PHST- 2022/05/05 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
PHST- 2022/05/04 02:52 [entrez]
AID - 10.1111/cea.14157 [doi]
PST - ppublish
SO  - Clin Exp Allergy. 2022 Dec;52(12):1414-1421. doi: 10.1111/cea.14157. Epub 2022 
      May 17.

PMID- 17334512
OWN - NLM
STAT- MEDLINE
DCOM- 20070504
LR  - 20171116
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 97
IP  - 3
DP  - 2007 Mar
TI  - Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of 
      the acute endothelial dysfunction induced by exercise in patients with 
      intermittent claudication.
PG  - 444-50
AB  - Ischemia/reperfusion damage evokes systemic inflammation and endothelial 
      dysfunction in patients with intermittent claudication. We compared the effects 
      of aspirin with those of a nitric oxide-donating aspirin in preventing the acute, 
      systemic endothelial dysfunction provoked by exercise-induced ischemia of the 
      lower limbs in patients with intermittent claudication. In a prospective, 
      randomized, single-blind, parallel-groups trial among 44 patients with 
      intermittent claudication we compared four weeks of aspirin (100 mg o.d.) with 
      NCX 4016 (800 mg b.i.d.). Primary end point was the exercise-induced changes in 
      brachial flow-mediated vasodilation (FMD) at day 28; secondary end points were 
      effort-induced changes of markers of neutrophil (plasma elastase) and endothelial 
      (soluble VCAM-1) activation. Baseline FMD was comparable in the two groups, both 
      on day 1 (pre-treatment: aspirin = 3.1 +/- 0.5%, nitroaspirin = 3.9 +/- 0.7%, p = 
      NS), and on day 28 (aspirin = 3.4 +/- 0.7%, NCX 4016 = 3.2 +/- 0.6%, p = NS). 
      Maximal treadmill exercise induced an acute worsening of FMD in both groups at 
      baseline (aspirin = -1.15%, nitroaspirin = -1.76%); after four weeks treatment, 
      the impairment of FMD induced by exercise was still present in the aspirintreated 
      group (-1.46%) while it was abolished in the NCX 4016-treated group (+0.79%, p = 
      0.038 vs. aspirin). Similarly, exercise induced an increase of plasma elastase 
      and of sVCAM-1 which were not affected by aspirin while they were suppressed by 
      NCX 4016. Maximal treadmill exercise induces a systemic arterial endothelial 
      dysfunction in patients with intermittent claudication. A nitric oxide-donating 
      aspirin, but not aspirin, prevents effort-induced endothelial dysfunction.
FAU - Gresele, Paolo
AU  - Gresele P
AD  - Department of Internal Medicine, Division of Internal and Cardiovascular 
      Medicine, University of Perugia, Via Enrico dal Pozzo, I-06126 Perugia, Italy. 
      grespa@unipg.it
FAU - Migliacci, Rino
AU  - Migliacci R
FAU - Procacci, Alessandra
AU  - Procacci A
FAU - De Monte, Paola
AU  - De Monte P
FAU - Bonizzoni, Erminio
AU  - Bonizzoni E
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 3.4.21.37 (Leukocyte Elastase)
RN  - EH04H13L6B (nitroaspirin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Thromb Haemost. 2007 Mar;97(3):331-3. PMID: 17334496
MH  - Aged
MH  - Aspirin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Blood Flow Velocity
MH  - Brachial Artery/drug effects
MH  - Endothelium, Vascular/*drug effects/physiopathology
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Intermittent Claudication/blood/*drug therapy/physiopathology
MH  - Leukocyte Count
MH  - Leukocyte Elastase/blood
MH  - Lower Extremity/blood supply
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide/blood
MH  - Nitric Oxide Donors/pharmacology/*therapeutic use
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Prospective Studies
MH  - Reperfusion Injury/blood/*drug therapy/physiopathology
MH  - Severity of Illness Index
MH  - Single-Blind Method
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vascular Cell Adhesion Molecule-1/blood
MH  - Vasodilation/*drug effects
EDAT- 2007/03/06 09:00
MHDA- 2007/05/05 09:00
CRDT- 2007/03/06 09:00
PHST- 2007/03/06 09:00 [pubmed]
PHST- 2007/05/05 09:00 [medline]
PHST- 2007/03/06 09:00 [entrez]
AID - 07030444 [pii]
PST - ppublish
SO  - Thromb Haemost. 2007 Mar;97(3):444-50.

PMID- 14532966
OWN - NLM
STAT- MEDLINE
DCOM- 20040726
LR  - 20131121
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 23
IP  - 5
DP  - 2003 Nov
TI  - Aspirin inhibits highly invasive prostate cancer cells.
PG  - 1277-83
AB  - Cell adhesion, proteolytic degradation and cell migration are interrelated 
      processes responsible for the invasion and metastasis of cancer. One of the 
      crucial molecules involved in cancer metastasis is urokinase-type plasminogen 
      activator (uPA). An elevated concentration of uPA is a strong indicator of poor 
      prognosis. In addition to the proteolytic activity of uPA, which degrades the 
      extracellular matrix, uPA also binds to its receptor (uPAR) and controls cell 
      adhesion and migration through the reorganization of actin cytoskeleton. We have 
      recently demonstrated that constitutively active nuclear factor-kappa B 
      (NF-kappaB) is responsible for the increased secretion of uPA and that inhibition 
      of NF-kappaB suppresses secretion of uPA and cell migration of highly invasive 
      cancer cells. Aspirin and other nonsteroidal anti-inflammatory drugs have been 
      recently shown to have a chemopreventive effect in colon and pancreatic cancers. 
      Here we show that aspirin inhibits NF-kappaB, resulting in the suppression of uPA 
      secretion from the highly invasive human prostate cancer cells PC-3. Furthermore, 
      aspirin inhibited migration of PC-3 cells, suggesting an effect on the uPA-uPAR 
      signaling complex. Finally, aspirin suppressed adhesion of PC-3 cells to 
      fibronectin (FN), which binds to an alpha3beta1 integrin receptor, and to 
      vitronectin (VN), which binds to alphavbeta3 integrin receptor. Altogether, our 
      data suggests that aspirin inhibits the formation of uPA-uPAR-FN-alpha3beta1 and 
      uPA-uPAR-VN-alphavbeta3 complexes, resulting in the suppression of cell adhesion 
      and cell motility of the highly invasive prostate cancer cells PC-3. These 
      results indicate that aspirin may contribute directly to reducing invasion and 
      metastasis of prostate cancers by inhibiting cell migration and invasion.
FAU - Lloyd, Frank P Jr
AU  - Lloyd FP Jr
AD  - Cancer Research Laboratory, Methodist Research Institute, Clarian Health Partners 
      Inc., Indianapolis, IN 46202, USA.
FAU - Slivova, Veronika
AU  - Slivova V
FAU - Valachovicova, Tatiana
AU  - Valachovicova T
FAU - Sliva, Daniel
AU  - Sliva D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Actins)
RN  - 0 (Fibronectins)
RN  - 0 (Integrin alpha3beta1)
RN  - 0 (NF-kappa B)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vitronectin)
RN  - EC 2.3.1.28 (Chloramphenicol O-Acetyltransferase)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Actins/metabolism
MH  - Aspirin/metabolism/*pharmacology
MH  - Cell Adhesion
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Chloramphenicol O-Acetyltransferase/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Fibronectins/metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Integrin alpha3beta1/metabolism
MH  - Male
MH  - Models, Biological
MH  - NF-kappa B/metabolism
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Prostatic Neoplasms/*drug therapy
MH  - Signal Transduction
MH  - Transfection
MH  - Urokinase-Type Plasminogen Activator/metabolism
MH  - Vitronectin/metabolism
EDAT- 2003/10/09 05:00
MHDA- 2004/07/28 05:00
CRDT- 2003/10/09 05:00
PHST- 2003/10/09 05:00 [pubmed]
PHST- 2004/07/28 05:00 [medline]
PHST- 2003/10/09 05:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2003 Nov;23(5):1277-83.

PMID- 1703814
OWN - NLM
STAT- MEDLINE
DCOM- 19910312
LR  - 20131121
IS  - 1011-6974 (Print)
IS  - 1011-6974 (Linking)
VI  - 26
DP  - 1990
TI  - [An in vitro bleeding test--a sensitive method for detection of disorders of 
      platelet function in thrombocyte donors].
PG  - 142-6
AB  - The in-vitro-bleeding-test (IVBT) is able to detect sensitively the disorders of 
      platelet function. They are frequently caused by von-Willebrand-syndrome or 
      aspirin. In 7.4% of our thrombocytapheresesis donors the IVBT was abnormal. The 
      plasmatic coagulation has no influence on the IVBT.
FAU - Dietrich, G
AU  - Dietrich G
AD  - Abteilung für Transfusionsmedizin und Gerinnungsphysiologie am 
      Universitäts-Klinikum Marburg.
FAU - Kretschmer, V
AU  - Kretschmer V
FAU - Schikor, B
AU  - Schikor B
FAU - Söhngen, D
AU  - Söhngen D
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Der In-vitro-Blutungstest (IVBT)--Eine empfindliche Methode zum Nachweis von 
      Plättchenfunktionsstörungen bei Thrombozytenspendern.
PL  - Switzerland
TA  - Beitr Infusionsther
JT  - Beitrage zur Infusionstherapie = Contributions to infusion therapy
JID - 8812367
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - *Bleeding Time
MH  - *Blood Donors
MH  - Blood Transfusion/*instrumentation
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Function Tests/*instrumentation
MH  - *Platelet Transfusion
MH  - von Willebrand Diseases/blood
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - Beitr Infusionsther. 1990;26:142-6.

PMID- 578480
OWN - NLM
STAT- MEDLINE
DCOM- 19771031
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 27
IP  - 7
DP  - 1977 Jul
TI  - The influence of acetysalicylic acid on changes in platelet function due to 
      physical exertion.
PG  - 1490-3
AB  - The influence of acetylsalicylic acid (ASA) on alterations of the platelets 
      resulting from physical exertion was studied in 10 healthy volunteers. Before and 
      2 h after the administration of placebo or 1 g ASA, venous blood samples were 
      taken for platelet counts, thrombelastography (TEG) and tests of ADP- and 
      epinephrine-induced platelet aggregation. The blood in which the 2-h values were 
      determined was sampled at the highest work-load during sub-maximum exercise on a 
      bicycle ergometer (5 min each at 50, 100 and 150 watts). ASA had no effect on the 
      alterations of the platelets due to physical effort: the increase in the first 
      phase of epinephrine-induced aggregation, the elevation of the platelet count and 
      the hypercoagulability demonstrable by TEG still persisted after the 
      administration of ASA. Some effects were noted, however, that are also observed 
      after the administration of ASA at rest: the second phase of epinephrine-induced 
      aggregation was suppressed and disaggregation after induction with ADP was 
      accelerated.
FAU - Rohrer, T F
AU  - Rohrer TF
FAU - Pfister, B
AU  - Pfister B
FAU - Imhof, P R
AU  - Imhof PR
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Cell Count
MH  - Blood Coagulation/drug effects
MH  - Blood Platelets/*drug effects
MH  - Blood Pressure/drug effects
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Male
MH  - *Physical Exertion
MH  - Platelet Aggregation/drug effects
MH  - Time Factors
EDAT- 1977/07/01 00:00
MHDA- 1977/07/01 00:01
CRDT- 1977/07/01 00:00
PHST- 1977/07/01 00:00 [pubmed]
PHST- 1977/07/01 00:01 [medline]
PHST- 1977/07/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1977 Jul;27(7):1490-3.

PMID- 14682223
OWN - NLM
STAT- MEDLINE
DCOM- 20040325
LR  - 20170306
VI  - 110
IP  - 2
DP  - 2003 Aug
TI  - [Urinary leukotriene E4 concentration in patients with bronchial asthma and 
      intolerance of non-steroids anti-inflammatory drugs before and after oral aspirin 
      challenge].
PG  - 849-54
AB  - BACKGROUND: Leukotrienes (LTC4, LTD4, LTE4) belong to eicosanoids and they play 
      important role in allergic inflammation. Leukotrienes are 5-lipooxygenaze 
      products of arachinoid acid. It is known that concentration of LTE4 increases in 
      patients with bronchial asthma, after some allergy provocation and in patients 
      with bronchial asthma and intolerance of on steroids anti-inflammatory drugs. The 
      aim of the study was estimated the urinary concentration of LTE4 in patients with 
      bronchial asthma and intolerance of no steroids anti-inflammatory drugs. MATERIAL 
      AND METHODS: The study group consisted of 21 patients with asthma and intolerance 
      of non steroids antiinflammatory drugs (F 19, M 2) in age from 21 to 72 years old 
      (mean = 49 +/- 14), with middle time of asthma duration mean = 13.4 +/- 12.9 
      years In study group 11 person had positive skin test, 7 nasal polyps, and 8 
      person positive family history of bronchial asthma. After oral provocation 
      aspirin challenge in 5 subjects' aspirin induced asthma was confirmed, 3 persons 
      were not qualified to test. Urinary concentration of LTE4 before and 24 h after 
      aspirin provocation was analyzed in all the patients. Leukotriene were detected 
      by enzymatic Leukotriene E4, EIA Kit, Cayman Chemical test. RESULTS: In group of 
      patients with aspirin asthma basic concentration of LTE4 was 416.6 +/- 374.4 
      pg/mL, and after provocation 496.6 +/- 485.3 pg/mL, in the group without 
      sensitivity to aspirin appropriate 262.9 +/- 404.0 vs 261.2 +/- 259.66 pg/mL, and 
      in the group disqualified to test 181.6 +/- 55.75 pg/mL. CONCLUSION: 1 Patients 
      with aspirin asthma have higher concentration of LTE4. 2. Excretion of LTE4 in 
      patients with aspirin induced asthma raised after oral aspirin provocation and 
      higher level was detected is til 24 hours after challenge. 3. This results 
      confirmed the role of cysteinic leukotrienes in pathogenesis of aspirin induced 
      asthma.
FAU - Rubinsztajn, Renata
AU  - Rubinsztajn R
AD  - Katedra i Klinika Chorób Wewnetrznych Pneumonologii i Alergologii AM w Warszawie.
FAU - Wrońska, Jolanta
AU  - Wrońska J
FAU - Chazan, Ryszarda
AU  - Chazan R
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Stezenie leukotrienów E4 w moczu chorych na astme oskrzelowa z nietolerancja NLPZ 
      w wywiadzie przed doustna prowokacja aspiryna i po prowokacji.
PL  - Poland
TA  - Pol Arch Med Wewn
JT  - Polskie Archiwum Medycyny Wewnetrznej
JID - 0401225
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 75715-89-8 (Leukotriene E4)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/*urine
MH  - Aspirin/*adverse effects/*urine
MH  - Asthma/*urine
MH  - Bronchial Provocation Tests/*methods
MH  - Drug Hypersensitivity/*etiology/*urine
MH  - Female
MH  - Humans
MH  - Leukotriene E4/*urine
MH  - Male
MH  - Middle Aged
EDAT- 2003/12/20 05:00
MHDA- 2004/03/26 05:00
CRDT- 2003/12/20 05:00
PHST- 2003/12/20 05:00 [pubmed]
PHST- 2004/03/26 05:00 [medline]
PHST- 2003/12/20 05:00 [entrez]
PST - ppublish
SO  - Pol Arch Med Wewn. 2003 Aug;110(2):849-54.

PMID- 24935489
OWN - NLM
STAT- MEDLINE
DCOM- 20140729
LR  - 20220408
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 160
IP  - 12
DP  - 2014 Jun 17
TI  - Stroke prevention in women: synopsis of the 2014 American Heart 
      Association/American Stroke Association guideline.
PG  - 853-7
LID - 10.7326/M14-0762 [doi]
AB  - DESCRIPTION: In February 2014, the American Heart Association/American Stroke 
      Association released their first guideline focused on stroke prevention in women. 
      This new guideline highlights unique risk factors for stroke in women, including 
      oral contraception and hormone therapy, and pregnancy-associated disorders, such 
      as preeclampsia, that may have long-lasting consequences on a woman's health. It 
      also addresses hypertension; atrial fibrillation; migraine headache with aura; 
      and the epidemiology of types of stroke, such as aneurysmal subarachnoid 
      hemorrhage and cerebral vein thrombosis, that are predominant in women. METHODS: 
      Members of a multidisciplinary expert panel searched, reviewed, and critiqued 
      relevant English-language literature published between 1990 and May 2013. The 
      panel devised evidence tables and developed recommendations using American Heart 
      Association guideline procedures and levels of evidence. RECOMMENDATIONS: This 
      synopsis of the guideline summarizes the evidence about risk factors for stroke 
      in women and suggests prevention strategies. It also describes the new 
      recommendations relevant to identifying and treating hypertensive disorders in 
      pregnancy that increase risk for stroke.
FAU - Bushnell, Cheryl
AU  - Bushnell C
FAU - McCullough, Louise
AU  - McCullough L
LA  - eng
GR  - R01 NS055215/NS/NINDS NIH HHS/United States
GR  - R01 NS077769/NS/NINDS NIH HHS/United States
GR  - R21 NS082906/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - American Heart Association
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Practice Guidelines as Topic
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/prevention & control
MH  - Risk Factors
MH  - Stroke/*prevention & control
MH  - United States
PMC - PMC4255708
MID - NIHMS641327
EDAT- 2014/06/18 06:00
MHDA- 2014/07/30 06:00
CRDT- 2014/06/18 06:00
PHST- 2014/06/18 06:00 [entrez]
PHST- 2014/06/18 06:00 [pubmed]
PHST- 2014/07/30 06:00 [medline]
AID - 1881123 [pii]
AID - 10.7326/M14-0762 [doi]
PST - ppublish
SO  - Ann Intern Med. 2014 Jun 17;160(12):853-7. doi: 10.7326/M14-0762.

PMID- 10821123
OWN - NLM
STAT- MEDLINE
DCOM- 20000601
LR  - 20211203
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 66
IP  - 20
DP  - 2000 Apr 7
TI  - Influence of acetylsalicylic acid on oxidation of native and glycated low-density 
      lipoprotein.
PG  - 1987-98
AB  - It is generally accepted that oxidation of low-density lipoproteins (LDL) is a 
      causal factor in the development of atherosclerosis. Non-enzymatic glycosylation 
      of LDL, i.e."glycation", plays a central role in late complications of diabetes 
      mellitus and may initiate and/or accelerate the oxidation process. Therefore, the 
      inhibition of this processes is of major therapeutic relevance. The influence of 
      acetylsalicylic acid (ASA) on the oxidation of native and glycated LDL was 
      studied in vitro. LDL (0.25 mg protein/ml ) was oxidatively modified with 5.0 
      microM CuSO4. Only at "supratherapeutical" ASA concentrations in the range 
      0.06-2.0 mg /ml we found a significant concentration-dependent inhibition of LDL 
      oxidation both for native and glycated LDL, which was from 0.2 mg/ml upwards 
      significantly more marked for native LDL than for glycated LDL. The maximal 
      inhibitory effect occurred at 2.0 mg/ml with 89.6% inhibition of LDL-oxidation 
      for native LDL and 64.4% for glycated LDL. At 0.2 mg/ml ASA the respective 
      inhibitory values were 38.5% and 31.0%. For glycated LDL the ASA doses of 
      maximal- and approximately 50%-inhibition, as found for native LDL, were chosen 
      to investigate the inhibitory effect on 2,4,8 and 24 hours oxidation of glycated 
      LDL to monitor the time-dependency of inhibition by ASA. This revealed that ASA 
      only delayed, not permanently inhibited LDL oxidation.
FAU - Sobal, G
AU  - Sobal G
AD  - Department of Nuclear Medicine, University of Vienna, Austria.
FAU - Menzel, J E
AU  - Menzel JE
FAU - Sinzinger, H
AU  - Sinzinger H
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Thiobarbituric Acid Reactive Substances)
RN  - 0 (glycated lipoproteins, LDL)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Glycation End Products, Advanced
MH  - Glycosylation/drug effects
MH  - Humans
MH  - In Vitro Techniques
MH  - Lipoproteins, LDL/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Oxidation-Reduction
MH  - Thiobarbituric Acid Reactive Substances/metabolism
MH  - Time Factors
EDAT- 2000/05/23 09:00
MHDA- 2000/06/03 09:00
CRDT- 2000/05/23 09:00
PHST- 2000/05/23 09:00 [pubmed]
PHST- 2000/06/03 09:00 [medline]
PHST- 2000/05/23 09:00 [entrez]
AID - S0024320500005245 [pii]
AID - 10.1016/s0024-3205(00)00524-5 [doi]
PST - ppublish
SO  - Life Sci. 2000 Apr 7;66(20):1987-98. doi: 10.1016/s0024-3205(00)00524-5.

PMID- 16888437
OWN - NLM
STAT- MEDLINE
DCOM- 20070129
LR  - 20131121
IS  - 1065-6251 (Print)
IS  - 1065-6251 (Linking)
VI  - 13
IP  - 5
DP  - 2006 Sep
TI  - Aspirin resistance: is this term meaningful?
PG  - 331-6
AB  - PURPOSE OF REVIEW: To review data for and against the existence of 'aspirin 
      resistance', a term coined to indicate aspirin-treated patients having ex-vivo 
      tests of platelet activation insensitive to aspirin treatment and recurrence of 
      cardiovascular disease. RECENT FINDINGS: 'Aspirin resistance' defined by ex-vivo 
      tests of platelet activation yielded values ranging from 21 to 78%, indicating 
      that such tests do not provide a useful measurement. In long-term aspirin-treated 
      patients, studies demonstrated small but functionally relevant platelet 
      thromboxane A2 formation that was responsible for an enhanced platelet activation 
      in response to platelet agonist. These studies, however, did not fully exclude 
      that aspirin compliance may be implicated in such phenomena. Two trials performed 
      in patients with coronary artery disease demonstrated that laboratory evidence of 
      aspirin resistance was no longer detectable when aspirin compliance was 
      accurately monitored. SUMMARY: Given the multifactorial nature of 
      atherothrombosis, recurrence of cardiovascular events in aspirin-treated patients 
      does not necessarily suggest 'drug failure'. A cause-effect relationship between 
      platelet insensitivity to aspirin and cardiovascular recurrence has not been 
      defined overall because aspirin compliance has been scarcely considered. Until 
      this information is taken into account, the existence of 'clinical resistance' to 
      aspirin should be reconsidered.
FAU - Violi, Francesco
AU  - Violi F
AD  - Division of IV Clinica Medica, Department of Experimental Medicine and Pathology, 
      Università La Sapienza, Roma, Italy. Francesco.violi@uniroma1.it
FAU - Pignatelli, Pasquale
AU  - Pignatelli P
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Hematol
JT  - Current opinion in hematology
JID - 9430802
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Cyclooxygenase 1/metabolism
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Activation/*drug effects/physiology
MH  - Platelet Aggregation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Thromboxane A2/metabolism
RF  - 39
EDAT- 2006/08/05 09:00
MHDA- 2007/01/30 09:00
CRDT- 2006/08/05 09:00
PHST- 2006/08/05 09:00 [pubmed]
PHST- 2007/01/30 09:00 [medline]
PHST- 2006/08/05 09:00 [entrez]
AID - 00062752-200609000-00006 [pii]
AID - 10.1097/01.moh.0000239704.17427.9b [doi]
PST - ppublish
SO  - Curr Opin Hematol. 2006 Sep;13(5):331-6. doi: 10.1097/01.moh.0000239704.17427.9b.

PMID- 1122562
OWN - NLM
STAT- MEDLINE
DCOM- 19750627
LR  - 20190823
IS  - 0009-2797 (Print)
IS  - 0009-2797 (Linking)
VI  - 10
IP  - 4
DP  - 1975 Apr
TI  - Urinary enzymes and kidney damage by aspirin and phenacetin.
PG  - 277-84
AB  - Two groups of rats were given aspirin and phenacetin in their food at daily doses 
      similar to those taken by humans suffering from analgesic abuse. Both drugs 
      damaged the kidney proximal tubules although phenacetin affected the kidney more 
      severely than aspirin. At the start of the experiment aspirin increased the 
      urinary excretion of lactate dehydrogenase (LDH) while phenacetin raised the 
      excretion of all four enzymes studies (acid phosphatase, alkaline phosphatase, 
      glutamate dehydrogenase (GDH), LDH indicating generalised cellular injury. 
      Subsequent samples of urine collected from rats up to seven weeks showed normal 
      urinary enzyme levels. The value of urinary enzyme measurements in detecting 
      renal damage by drugs is discussed.
FAU - Plummer, D T
AU  - Plummer DT
FAU - Leathwood, P D
AU  - Leathwood PD
FAU - Blake, M E
AU  - Blake ME
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Chem Biol Interact
JT  - Chemico-biological interactions
JID - 0227276
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EC 1.4.1.2 (Glutamate Dehydrogenase)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - EC 3.1.3.2 (Acid Phosphatase)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acid Phosphatase/*urine
MH  - Alkaline Phosphatase/*metabolism/urine
MH  - Animals
MH  - Aspirin/*pharmacology/poisoning
MH  - Glutamate Dehydrogenase/*urine
MH  - Kidney/drug effects/*enzymology
MH  - Kidney Tubules, Proximal/drug effects
MH  - L-Lactate Dehydrogenase/*metabolism/urine
MH  - Male
MH  - Phenacetin/*pharmacology/poisoning
MH  - Rats
MH  - Time Factors
EDAT- 1975/04/01 00:00
MHDA- 1975/04/01 00:01
CRDT- 1975/04/01 00:00
PHST- 1975/04/01 00:00 [pubmed]
PHST- 1975/04/01 00:01 [medline]
PHST- 1975/04/01 00:00 [entrez]
AID - 0009-2797(75)90092-7 [pii]
AID - 10.1016/0009-2797(75)90092-7 [doi]
PST - ppublish
SO  - Chem Biol Interact. 1975 Apr;10(4):277-84. doi: 10.1016/0009-2797(75)90092-7.

PMID- 29529923
OWN - NLM
STAT- MEDLINE
DCOM- 20190506
LR  - 20191008
IS  - 1552-681X (Electronic)
IS  - 0272-989X (Linking)
VI  - 38
IP  - 4
DP  - 2018 May
TI  - Decision Criterion and Value of Information Analysis: Optimal Aspirin Dosage for 
      Secondary Prevention of Cardiovascular Events.
PG  - 427-438
LID - 10.1177/0272989X17746988 [doi]
AB  - BACKGROUND: In value of information (VOI) calculations, such as the expected 
      value of perfect information (EVPI), partial perfect information (EVPPI), sample 
      information (EVSI) or implementation (EVIM), the maximum expected value criterion 
      defines the decision making criterion for the adoption of decisions for 
      treatments. However, because decision makers are often risk averse, the 
      uncertainty that accompanies a decision problem may influence adoption decisions. 
      METHODS: VOI estimates were studied based on 2 alternate decision making 
      criteria: 1) maximum expected value and 2) 95% credible intervals. These criteria 
      were applied to a probabilistic minimal lifetime model of incident cardiovascular 
      events and mortality among target patients comparing 2 daily doses of aspirin (81 
      mg and 325 mg). Model parameters were based on literature reviews and data 
      analyses. RESULTS: Expected life-years under 81 v. 325 mg of aspirin were 
      estimated to be 14.86 (SE, 0.10) and 14.72 (0.31) respectively, with a difference 
      of 0.14 (0.29). The probability that 81 mg was optimal was estimated to be 67%. 
      Under Decision Criterion 1, EVIM and EVPI were about 233-thousand and 
      411-thousand years, respectively. Under Criterion 2, EVIM was undefined, as there 
      remains ambiguity about what to implement. Consequently, EVPI becomes the entire 
      644-thousand years. Also, under Criterion 1, EVSI reaches an asymptote at a 
      sample size of 10,000 per arm, with minimal gains in value beyond a 5,000 person 
      per arm trial. With Criterion 2, a sample size of 10,000 per arm or higher is 
      substantially more valuable than lower sample sizes. CONCLUSION: Alternative 
      decision criteria for treatment adoption change the VOI. Decision criteria should 
      be justified for VOI analyses. If multiple criteria may be relevant, analysts 
      should complete VOI estimates using multiple criteria.
FAU - Basu, Anirban
AU  - Basu A
AUID- ORCID: 0000-0003-4238-7402
AD  - The Comparative Health Outcome, Policy, and Economics (CHOICE) Institute, 
      Department of Pharmacy and the Departments of Health Services and Economics, 
      University of Washington, Seattle, WA, USA.
FAU - Meltzer, David
AU  - Meltzer D
AD  - Section of Hospital Medicine, Department of Medicine, Harris School of Public 
      Policy Studies and the Department of Economics, The University of Chicago, 
      Chicago, IL, USA.
LA  - eng
GR  - R01 HL126804/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180312
PL  - United States
TA  - Med Decis Making
JT  - Medical decision making : an international journal of the Society for Medical 
      Decision Making
JID - 8109073
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Data Interpretation, Statistical
MH  - *Decision Support Techniques
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Quality-Adjusted Life Years
MH  - Research Design
MH  - Secondary Prevention/*methods
OTO - NOTNLM
OT  - aspirin
OT  - cardiovascular
OT  - decision criterion
OT  - value of information
EDAT- 2018/03/14 06:00
MHDA- 2019/05/07 06:00
CRDT- 2018/03/14 06:00
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2019/05/07 06:00 [medline]
PHST- 2018/03/14 06:00 [entrez]
AID - 10.1177/0272989X17746988 [doi]
PST - ppublish
SO  - Med Decis Making. 2018 May;38(4):427-438. doi: 10.1177/0272989X17746988. Epub 
      2018 Mar 12.

PMID- 25947914
OWN - NLM
STAT- MEDLINE
DCOM- 20160519
LR  - 20220408
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 38
IP  - 5
DP  - 2015
TI  - Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump 
      Inhibitors Using the FDA Adverse Event Reporting System Database.
PG  - 680-6
LID - 10.1248/bpb.b14-00191 [doi]
AB  - Clopidogrel is an antiplatelet agent widely used in combination with aspirin to 
      limit the occurrence of cardiovascular (embolic/thrombotic) events. Consensus 
      guidelines recommend proton pump inhibitors (PPIs) as a gastrointestinal (GI) 
      prophylactic measure for all patients receiving dual antiplatelet therapy with 
      clopidogrel and aspirin. The objective of this study was to analyze the effect of 
      the simultaneous use of clopidogrel, aspirin, and PPIs on hemorrhagic and 
      embolic/thrombotic events using the U.S. Food and Drug Administration (FDA) 
      Adverse Event Reporting System (FAERS) database. Reports of hemorrhagic and 
      embolic/thrombotic events between 2004 and 2013 were analyzed with a reporting 
      odds ratio (ROR) algorithm and logistic regression methods. The Medical 
      Dictionary for Regulatory Activities Preferred Terms was used to identify such 
      events. Regarding hemorrhagic events, the adjusted RORs of the concomitant use of 
      aspirin and clopidogrel and those of PPIs prescribed with aspirin and clopidogrel 
      were 4.40 (95% confidence interval [CI], 4.02-4.81) and 3.40 (95% CI, 2.84-4.06), 
      respectively. For embolic/thrombotic events, the adjusted RORs of the concomitant 
      use of aspirin and clopidogrel and those of PPIs prescribed with aspirin and 
      clopidogrel were 2.37 (95% CI, 2.16-2.59) and 2.38 (95% CI, 2.00-2.84), 
      respectively. Among patients included in the FAERS database, the concurrent use 
      of aspirin and clopidogrel with PPIs reduced the adjusted ROR of GI hemorrhagic 
      events. PPIs had little influence on the adjusted ROR of embolic/thrombotic 
      events. These results support the use of PPIs as a preventive measure against GI 
      hemorrhagic events for patients receiving clopidogrel and aspirin.
FAU - Suzuki, Yukiya
AU  - Suzuki Y
AD  - Laboratory of Drug Informatics, Gifu Pharmaceutical University; 1–25–4 
      Daigaku-Nishi, Gifu 501–1196 2. Molecular Pharmacology, Department of 
      Biofunctional Evaluation, Gifu Pharmaceutical University 1–25–4 Daigaku-Nishi, 
      Gifu 501–1196, Japan.
FAU - Suzuki, Honami
AU  - Suzuki H
FAU - Umetsu, Ryogo
AU  - Umetsu R
FAU - Uranishi, Hiroaki
AU  - Uranishi H
FAU - Abe, Junko
AU  - Abe J
FAU - Nishibata, Yuri
AU  - Nishibata Y
FAU - Sekiya, Yasuaki
AU  - Sekiya Y
FAU - Miyamura, Nobuteru
AU  - Miyamura N
FAU - Hara, Hideaki
AU  - Hara H
FAU - Tsuchiya, Teruo
AU  - Tsuchiya T
FAU - Kinosada, Yasutomi
AU  - Kinosada Y
FAU - Nakamura, Mitsuhiro
AU  - Nakamura M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adverse Drug Reaction Reporting Systems
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clopidogrel
MH  - *Drug Interactions
MH  - Drug Therapy, Combination
MH  - Embolism/*prevention & control
MH  - Female
MH  - Gastrointestinal Hemorrhage/etiology/*prevention & control
MH  - Humans
MH  - Male
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Proton Pump Inhibitors/*adverse effects/therapeutic use
MH  - Risk Factors
MH  - Thrombosis/*prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - United States
MH  - United States Food and Drug Administration
EDAT- 2015/05/08 06:00
MHDA- 2016/05/20 06:00
CRDT- 2015/05/08 06:00
PHST- 2015/05/08 06:00 [entrez]
PHST- 2015/05/08 06:00 [pubmed]
PHST- 2016/05/20 06:00 [medline]
AID - 10.1248/bpb.b14-00191 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2015;38(5):680-6. doi: 10.1248/bpb.b14-00191.

PMID- 22549566
OWN - NLM
STAT- MEDLINE
DCOM- 20130524
LR  - 20211021
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
VI  - 47
IP  - 12
DP  - 2012 Dec
TI  - Biphasic effects of H. pylori infection on low-dose aspirin-induced gastropathy 
      depending on the gastric acid secretion level.
PG  - 1290-7
LID - 10.1007/s00535-012-0598-8 [doi]
AB  - BACKGROUND: The association of Helicobacter pylori infection with aspirin-induced 
      gastropathy is controversial. H. pylori infection exerts diverse effects on 
      gastric acid secretion. In this study, the interaction between H. pylori 
      infection and aspirin was investigated with reference to the individual gastric 
      acid secretion level in H. pylori-positive subjects. METHODS: Ninety-three (81 
      men, mean age: 70 years) long-term low-dose aspirin takers were prospectively 
      enrolled. H. pylori infection was evaluated by serum IgG antibody determination, 
      and gastrin-stimulated acid output was assessed with the endoscopic gastrin test. 
      H. pylori-positive aspirin-takers were classified into 2 subgroups (hyposecretors 
      and non-hyposecretors). The grade of gastric mucosal injury was assessed 
      endoscopically according to the modified Lanza score; intensive aspirin-induced 
      gastropathy was defined as a modified Lanza score of ≥4. Multiple logistic 
      regression analyses were used to adjust for potential confounders. RESULTS: With 
      H. pylori-negative patients taken as the reference, H. pylori infection was found 
      to be positively associated with intensive gastropathy among non-hyposecretors, 
      with an odds ratio (OR) (95 % confidence interval [CI]) of 4.2 (1.1-17.1), while 
      the infection was negatively associated with gastropathy among hyposecretors, 
      with an OR (95 % CI) of 0.3 (0.08-0.9). Aspirin-induced gastropathy occurred 
      preferentially in the antrum among H. pylori-positive non-hyposecretors, while it 
      affected the fundus among H. pylori-positive hyposecretors. CONCLUSION: The 
      effect of H. pylori infection on the aspirin-induced gastropathy was biphasic 
      depending on the individual gastric acid secretion level. In the presence of 
      sufficient amounts of gastric acid, H. pylori infection and aspirin could 
      synergistically damage gastric mucosal integrity, while in the absence of 
      sufficient amounts of gastric acid, the synergistic effect could be completely 
      counteracted and the infection could even suppress the aspirin-induced 
      gastropathy.
FAU - Iijima, Katsunori
AU  - Iijima K
AD  - Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 
      Seiryo-machi, Aobaku, Sendai, Miyagi 980-8574, Japan. kiijima@med.tohoku.ac.jp
FAU - Ara, Nobuyuki
AU  - Ara N
FAU - Abe, Yasuhiko
AU  - Abe Y
FAU - Koike, Tomoyuki
AU  - Koike T
FAU - Iwabuchi, Toshimitsu
AU  - Iwabuchi T
FAU - Shinkai, Hirohiko
AU  - Shinkai H
FAU - Uno, Kaname
AU  - Uno K
FAU - Endo, Hiroyuki
AU  - Endo H
FAU - Asano, Naoki
AU  - Asano N
FAU - Shimosegawa, Tooru
AU  - Shimosegawa T
LA  - eng
PT  - Journal Article
DEP - 20120502
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EF0NX91490 (Pentagastrin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*adverse effects
MH  - Gastric Acid/metabolism
MH  - Helicobacter Infections/*complications/metabolism
MH  - Helicobacter pylori/*isolation & purification
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pentagastrin
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Prospective Studies
MH  - Stomach Diseases/*chemically induced/metabolism/microbiology
EDAT- 2012/05/03 06:00
MHDA- 2013/05/28 06:00
CRDT- 2012/05/03 06:00
PHST- 2012/01/30 00:00 [received]
PHST- 2012/03/29 00:00 [accepted]
PHST- 2012/05/03 06:00 [entrez]
PHST- 2012/05/03 06:00 [pubmed]
PHST- 2013/05/28 06:00 [medline]
AID - 10.1007/s00535-012-0598-8 [doi]
PST - ppublish
SO  - J Gastroenterol. 2012 Dec;47(12):1290-7. doi: 10.1007/s00535-012-0598-8. Epub 
      2012 May 2.

PMID- 26774572
OWN - NLM
STAT- MEDLINE
DCOM- 20161114
LR  - 20170731
IS  - 1873-4367 (Electronic)
IS  - 0927-7765 (Linking)
VI  - 140
DP  - 2016 Apr 1
TI  - Synergistic effect of anti-platelet and anti-inflammation of drug-coated Co-Cr 
      substrates for prevention of initial in-stent restenosis.
PG  - 353-360
LID - S0927-7765(16)30009-1 [pii]
LID - 10.1016/j.colsurfb.2016.01.009 [doi]
AB  - Antiplatelet and antithrombotic therapies are systematically considered to 
      prevent restenosis following coronary stent implantation. Currently, patients 
      receiving medicated stents are prescribed to orally take anticoagulants and 
      antiplatelet drugs such as aspirin (ASP) and prasugrel (PRAS). Propolis (PROP) 
      known as a natural organic compound was recently evaluated for its antiplatelet 
      activity, antibiotics and immunomodulatory activities. In this study, 
      antiplatelet drug-coated Co-Cr substrates were prepared with biodegradable 
      poly(d,l-lactide) (PDLLA) containing ASP, PRA, or PROP using electrospray and the 
      blood compatibility of the different substrates was investigated by measuring 
      protein adsorption and platelet adhesion. In addition, the anti-inflammatory 
      properties of the modified Co-Cr surfaces were assessed by measuring IL-8 and 
      IL-6 expression levels in human endothelial cell cultures. Drug-coated surfaces 
      were found to resist the adsorption of fibrinogen when compared to bare Co-Cr or 
      PDLLA-coated Co-Cr. Interestingly, ASP- and PROP-containing substrates not only 
      showed reduced adhesion of platelets and delayed coagulation time, but also 
      drastically reduced the expression level of IL-8 and IL-6. Such results are 
      supported that ASP- or PROP-coated Co-Cr can be potentially used as a stent 
      material to mitigate early stage of restenosis. The developed coating materials 
      might be an interesting alternative to systemic anticoagulant therapies 
      prescribed after stent implantation.
CI  - Copyright © 2016 Elsevier B.V. All rights reserved.
FAU - Lih, Eugene
AU  - Lih E
AD  - Center for Biomaterials, Korea Institute of Science and Technology, Seoul 02792, 
      Republic of Korea.
FAU - Jung, Jee Won
AU  - Jung JW
AD  - Center for Biomaterials, Korea Institute of Science and Technology, Seoul 02792, 
      Republic of Korea; Department of Biomicrosystem Technology and Department of 
      Chemical & Biological Engineering, Korea University, Seoul 02841, Republic of 
      Korea.
FAU - Joung, Yoon Ki
AU  - Joung YK
AD  - Center for Biomaterials, Korea Institute of Science and Technology, Seoul 02792, 
      Republic of Korea; Department of Biomedical Engineering, Korea University of 
      Science and Technology, Daejeon 34113, Republic of Korea.
FAU - Ahn, Dong June
AU  - Ahn DJ
AD  - Department of Biomicrosystem Technology and Department of Chemical & Biological 
      Engineering, Korea University, Seoul 02841, Republic of Korea; KU-KIST Graduate 
      School of Converging Science & Engineering, Korea University, Seoul 02841, 
      Republic of Korea.
FAU - Han, Dong Keun
AU  - Han DK
AD  - Center for Biomaterials, Korea Institute of Science and Technology, Seoul 02792, 
      Republic of Korea; Department of Biomedical Engineering, Korea University of 
      Science and Technology, Daejeon 34113, Republic of Korea. Electronic address: 
      dkh@kist.re.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160106
PL  - Netherlands
TA  - Colloids Surf B Biointerfaces
JT  - Colloids and surfaces. B, Biointerfaces
JID - 9315133
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Chromium Alloys)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polyesters)
RN  - 3G0H8C9362 (Cobalt)
RN  - 459TN2L5F5 (poly(lactide))
RN  - 9009-62-5 (Propolis)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Anti-Inflammatory Agents/chemistry/pharmacokinetics/*therapeutic use
MH  - Aspirin/chemistry/pharmacokinetics/therapeutic use
MH  - Cells, Cultured
MH  - Chromium Alloys/chemistry
MH  - Cobalt/chemistry
MH  - Coronary Restenosis/*prevention & control
MH  - Drug Liberation
MH  - Drug Synergism
MH  - *Drug-Eluting Stents
MH  - Humans
MH  - Microscopy, Electron, Scanning
MH  - Platelet Activation/drug effects
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation Inhibitors/chemistry/pharmacokinetics/*therapeutic use
MH  - Polyesters/chemistry
MH  - Prasugrel Hydrochloride/chemistry/pharmacokinetics/therapeutic use
MH  - Propolis/chemistry/pharmacokinetics/therapeutic use
MH  - Sirolimus/chemistry/pharmacokinetics/therapeutic use
OTO - NOTNLM
OT  - Anti-inflammation
OT  - Antiplatelet drug
OT  - Blood compatibility
OT  - Drug-eluting stent (DES)
OT  - Surface coating
EDAT- 2016/01/18 06:00
MHDA- 2016/11/15 06:00
CRDT- 2016/01/18 06:00
PHST- 2015/08/31 00:00 [received]
PHST- 2015/12/03 00:00 [revised]
PHST- 2016/01/04 00:00 [accepted]
PHST- 2016/01/18 06:00 [entrez]
PHST- 2016/01/18 06:00 [pubmed]
PHST- 2016/11/15 06:00 [medline]
AID - S0927-7765(16)30009-1 [pii]
AID - 10.1016/j.colsurfb.2016.01.009 [doi]
PST - ppublish
SO  - Colloids Surf B Biointerfaces. 2016 Apr 1;140:353-360. doi: 
      10.1016/j.colsurfb.2016.01.009. Epub 2016 Jan 6.

PMID- 31805177
OWN - NLM
STAT- MEDLINE
DCOM- 20200330
LR  - 20200330
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 12
DP  - 2019
TI  - Aspirin enhances sensitization to the egg-white allergen ovalbumin in rats.
PG  - e0226165
LID - 10.1371/journal.pone.0226165 [doi]
LID - e0226165
AB  - Enhancement of oral absorption of food allergens by non-steroidal 
      anti-inflammatory drugs (NSAIDs), especially aspirin, is considered an 
      exacerbating factor in the development of food allergies. In this study, we 
      examined the effect of aspirin on oral sensitization to and absorption of the 
      egg-white allergen ovalbumin (OVA) in rats. The absorption of OVA was evaluated 
      by measuring the plasma concentration of OVA after oral administration by gavage. 
      To evaluate oral sensitization to OVA, plasma levels of immunoglobulin (Ig) E and 
      IgG1 antibodies (Abs) specific to OVA were determined by enzyme-linked 
      immunosorbent assay after initiation of sensitization. High-dose aspirin (30 
      mg/kg) increased oral OVA absorption and plasma levels of OVA-specific IgE and 
      IgG1 Abs compared with those observed in vehicle-treated rats. In contrast, 
      low-dose aspirin (3 mg/kg) exerted no changes in either absorption or 
      sensitization. Spermine, an absorption enhancer, increased the oral absorption of 
      OVA to nearly the same extent as high-dose aspirin, whereas the plasma levels of 
      OVA-specific IgE and IgG1 Abs exhibited no significant differences between 
      spermine- and vehicle-treated rats. Among the NSAIDs, diclofenac and indomethacin 
      increased sensitization to OVA, similar to high-dose aspirin, but meloxicam 
      exerted no effects on Ab levels. In conclusion, we showed that high-dose aspirin 
      enhanced oral sensitization to OVA. Our study suggests that enhanced oral 
      sensitization to OVA cannot be ascribed to increased absorption of OVA from the 
      intestinal tract. Although the mechanisms underlying this enhancement of 
      sensitization are still controversial, our study suggests that modification of 
      cytokine production due to impairment of the intestinal barrier function and 
      inhibition of cyclooxygenase-1 activity by aspirin may be involved.
FAU - Fukushima, Takahiro
AU  - Fukushima T
AUID- ORCID: 0000-0001-8464-8733
AD  - Department of Pharmaceutical Services, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Yokooji, Tomoharu
AU  - Yokooji T
AD  - Department of Pharmaceutical Services, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima, Japan.
AD  - Department of Frontier Science for Pharmacotherapy, Graduate School of Biomedical 
      and Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Hirano, Taiki
AU  - Hirano T
AD  - Department of Pharmaceutical Services, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Kataoka, Yuta
AU  - Kataoka Y
AD  - Department of Pharmaceutical Services, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Taogoshi, Takanori
AU  - Taogoshi T
AD  - Department of Pharmaceutical Services, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Matsuo, Hiroaki
AU  - Matsuo H
AUID- ORCID: 0000-0002-8730-5389
AD  - Department of Pharmaceutical Services, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima, Japan.
LA  - eng
PT  - Journal Article
DEP - 20191205
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Immunoglobulin G)
RN  - 2FZ7Y3VOQX (Spermine)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Aspirin/*administration & dosage/immunology
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Egg Hypersensitivity/*immunology
MH  - Immunoglobulin E/metabolism
MH  - Immunoglobulin G/metabolism
MH  - Intestinal Absorption
MH  - Male
MH  - Ovalbumin/*immunology/pharmacokinetics
MH  - Rats
MH  - Spermine/administration & dosage/immunology
PMC - PMC6894855
COIS- The authors have declared that no competing interests exist.
EDAT- 2019/12/06 06:00
MHDA- 2020/03/31 06:00
CRDT- 2019/12/06 06:00
PHST- 2019/05/21 00:00 [received]
PHST- 2019/11/20 00:00 [accepted]
PHST- 2019/12/06 06:00 [entrez]
PHST- 2019/12/06 06:00 [pubmed]
PHST- 2020/03/31 06:00 [medline]
AID - PONE-D-19-14340 [pii]
AID - 10.1371/journal.pone.0226165 [doi]
PST - epublish
SO  - PLoS One. 2019 Dec 5;14(12):e0226165. doi: 10.1371/journal.pone.0226165. 
      eCollection 2019.

PMID- 20602614
OWN - NLM
STAT- MEDLINE
DCOM- 20110106
LR  - 20221207
IS  - 1744-8042 (Electronic)
IS  - 1462-2416 (Linking)
VI  - 11
IP  - 7
DP  - 2010 Jul
TI  - Association analysis of N-acetyl transferase-2 polymorphisms with aspirin 
      intolerance among asthmatics.
PG  - 951-8
LID - 10.2217/pgs.10.65 [doi]
AB  - AIMS: Cysteinyl leukotrienes are inactivated by acetyl coenzyme A-dependent 
      N-acetyltransferase (NAT). Thus, functional alterations of the NAT gene may 
      contribute to the risk of aspirin-intolerant asthma. MATERIALS & METHODS: 
      Asthmatics (n = 438) were categorized into aspirin-intolerant asthma (15% or 
      greater decrease in the forced expiratory volume in 1 s or cutaneous reactions, n 
      = 170) or aspirin-tolerant asthma (n = 268) groups. In total, 14 polymorphisms of 
      the NAT2 gene were genotyped by a single-base extension method. RESULTS: The 
      distributions of all loci of the 14 SNPs were in Hardy-Weinberg equilibrium (p > 
      0.05). Among the 14 SNPs, six common SNPs (minor allele frequency >5%) in a 
      Korean population were used for haplotype construction and further statistical 
      analysis. The logistic regression analysis demonstrated that NAT2 -9246G>C and 
      haplotype 2 (TCACGG) were significantly associated with the risk of 
      aspirin-intolerant asthma. The rare allele frequencies of the SNP and Ht2 were 
      significantly higher in the aspirin-intolerant asthma group than in the 
      aspirin-tolerant asthma group (p(corr) = 0.03 and p(corr) = 0.02 in codominant 
      model). CONCLUSION: In a large genetic epidemiology study of aspirin-intolerant 
      asthma in a Korean population, genetic polymorphisms of NAT2 were found to be 
      related to a risk of aspirin hypersensitivity among asthmatics.
FAU - Kim, Jin-Moo
AU  - Kim JM
AD  - Genome Research Center for Allergy & Respiratory Disease, Soonchunhyang 
      University Bucheon Hospital, 1174 Jung-dong, Wonmi-gu, Bucheon, Gyeonggi-do 
      420-767, Republic of Korea.
FAU - Park, Byung-Lae
AU  - Park BL
FAU - Park, Se-Min
AU  - Park SM
FAU - Lee, Shin-Hwa
AU  - Lee SH
FAU - Kim, Myung-Ok
AU  - Kim MO
FAU - Jung, Seok
AU  - Jung S
FAU - Lee, Eun Hee
AU  - Lee EH
FAU - Uh, Soo-Taek
AU  - Uh ST
FAU - Park, Jong Sook
AU  - Park JS
FAU - Choi, Jae-Sung
AU  - Choi JS
FAU - Kim, Yong-Hoon
AU  - Kim YH
FAU - Kim, Mi-Kyeong
AU  - Kim MK
FAU - Choi, Inseon S
AU  - Choi IS
FAU - Cho, Sang Heon
AU  - Cho SH
FAU - Choi, Byoung Whui
AU  - Choi BW
FAU - Park, Hae-Sim
AU  - Park HS
FAU - Chang, Hun Soo
AU  - Chang HS
FAU - Shin, Hyoung Doo
AU  - Shin HD
FAU - Park, Choon-Sik
AU  - Park CS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
RN  - 0 (Leukotrienes)
RN  - 0 (cysteinyl-leukotriene)
RN  - EC 2.3.1.5 (Arylamine N-Acetyltransferase)
RN  - EC 2.3.1.5 (NAT2 protein, human)
RN  - K848JZ4886 (Cysteine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Arylamine N-Acetyltransferase/*genetics
MH  - Asian People/genetics
MH  - Aspirin/*adverse effects/immunology
MH  - Asthma/*genetics/physiopathology
MH  - Case-Control Studies
MH  - Cysteine/immunology
MH  - Drug Hypersensitivity/*genetics
MH  - Drug Tolerance/genetics
MH  - Female
MH  - Gene Frequency
MH  - Genotype
MH  - Haplotypes
MH  - Humans
MH  - Korea
MH  - Leukotrienes/immunology
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Genetic
MH  - Polymorphism, Single Nucleotide
EDAT- 2010/07/07 06:00
MHDA- 2011/01/07 06:00
CRDT- 2010/07/07 06:00
PHST- 2010/07/07 06:00 [entrez]
PHST- 2010/07/07 06:00 [pubmed]
PHST- 2011/01/07 06:00 [medline]
AID - 10.2217/pgs.10.65 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2010 Jul;11(7):951-8. doi: 10.2217/pgs.10.65.

PMID- 10665553
OWN - NLM
STAT- MEDLINE
DCOM- 20000215
LR  - 20220408
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 355
IP  - 9201
DP  - 2000 Jan 29
TI  - Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass 
      surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised 
      trial.
PG  - 346-51
AB  - BACKGROUND: Oral anticoagulants and aspirin are antithrombotic drugs that are 
      commonly used in patients with vascular disease. We investigated whether either 
      of these treatments prevented more effectively than the other bypass 
      complications after infrainguinal bypass surgery. METHODS: We did a multicentre, 
      randomised, open trial. 2690 patients who had undergone infrainguinal grafting 
      were randomly assigned oral anticoagulants (target international normalised ratio 
      3.0-4.5, n=1339) or aspirin (80 mg daily, n=1351). We followed up patients for a 
      mean of 21 months. The primary outcome was graft occlusion. FINDINGS: 308 graft 
      occlusions occurred in the oral-anticoagulants group compared with 322 in the 
      aspirin group (hazard ratio 0.95 [95% CI 0.82-1.11]), which suggested no overall 
      advantage for either treatment. Oral anticoagulants were beneficial in patients 
      with vein grafts (0.69 [0.54-0.88]), whereas aspirin had better results for 
      nonvenous grafts (1.26 [1.03-1.55]). The composite outcome of vascular death, 
      myocardial infarction, stroke, or amputation occurred 248 times in the 
      oral-anticoagulants group and 275 times in the aspirin group (0.89 [0.75-1.06]). 
      Patients treated with oral anticoagulants had more major bleeding episodes than 
      those treated with aspirin (108 vs 56; 1.96 [1.42-2.71]). INTERPRETATION: Oral 
      anticoagulation was better for the prevention of infrainguinal-vein-graft 
      occlusion and for lowering the rate of ischaemic events. Aspirin was better for 
      the prevention of non-venous graft occlusion, and was associated with fewer 
      bleeding episodes.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - I6WP63U32H (Acenocoumarol)
RN  - Q08SIO485D (Phenprocoumon)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
EIN - Lancet 2000 Mar 25;355(9209):1104
CIN - Lancet. 2000 Jan 29;355(9201):334. PMID: 10665549
MH  - Acenocoumarol/administration & dosage/adverse effects
MH  - Administration, Oral
MH  - Aged
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Female
MH  - Graft Occlusion, Vascular/*prevention & control
MH  - Humans
MH  - Leg/*blood supply
MH  - Male
MH  - Phenprocoumon/administration & dosage/adverse effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - *Vascular Surgical Procedures/adverse effects
EDAT- 2000/02/09 09:00
MHDA- 2000/05/29 09:00
CRDT- 2000/02/09 09:00
PHST- 2000/02/09 09:00 [pubmed]
PHST- 2000/05/29 09:00 [medline]
PHST- 2000/02/09 09:00 [entrez]
AID - S0140673699071998 [pii]
PST - ppublish
SO  - Lancet. 2000 Jan 29;355(9201):346-51.

PMID- 31140860
OWN - NLM
STAT- MEDLINE
DCOM- 20190719
LR  - 20200701
IS  - 1557-7430 (Electronic)
IS  - 1044-5498 (Print)
IS  - 1044-5498 (Linking)
VI  - 38
IP  - 7
DP  - 2019 Jul
TI  - Mode of Action of Aspirin in Experimental Autoimmune Encephalomyelitis.
PG  - 593-596
LID - 10.1089/dna.2019.4814 [doi]
AB  - Multiple sclerosis (MS) is a chronic and debilitating autoimmune disorder of the 
      central nervous system in which the autoimmune T cells destroy myelin, thus 
      causing lesion, damage, and neuronal dysfunction. Experimental autoimmune 
      encephalomyelitis (EAE) is an animal model of MS that is particularly useful for 
      testing new therapeutic approaches against MS. Aspirin (acetyl salicylic acid) is 
      one of the oldest and widely used medicines in the world, and recently it has 
      been shown that low-dose aspirin is capable of suppressing the disease process of 
      EAE in mice. One of the root causes of this autoimmune disease process is the 
      decrease and/or suppression of Foxp3-expressing anti-autoimmune regulatory T 
      cells (Tregs) and associated increase in autoimmune T-helper 1 (Th1) and Th17 
      cells. Aspirin upregulates Tregs and decreases Th1 and Th17 responses. 
      Accordingly, the suppression of Tregs abrogates the protective effect of aspirin 
      on EAE, indicating that aspirin protects EAE via Tregs. While there are several 
      mechanisms for the maintenance of Tregs under immune insults, aspirin increases 
      the level of interleukin-11 (IL-11), an immunomodulatory cytokine, and IL-11 
      alone is sufficient to protect Tregs. Being a multifunctional molecule, aspirin 
      stimulates the activation of cAMP-response element-binding (CREB) to promote the 
      recruitment of CREB to the IL-11 gene promoter and stimulate the transcription of 
      IL-11 in splenocytes. Therefore, it appears that low-dose aspirin protects EAE 
      via CREB-mediated stimulation of IL-11-Treg pathway and that aspirin may have 
      therapeutic importance in MS.
FAU - Pahan, Swarupa
AU  - Pahan S
AD  - 1 Division of Research and Development, Jesse Brown Veterans Affairs Medical 
      Center, Chicago, Illinois.
FAU - Pahan, Kalipada
AU  - Pahan K
AD  - 1 Division of Research and Development, Jesse Brown Veterans Affairs Medical 
      Center, Chicago, Illinois.
AD  - 2 Department of Neurological Sciences, Rush University Medical Center, Chicago, 
      Illinois.
LA  - eng
GR  - I01 BX002174/BX/BLRD VA/United States
GR  - I01 BX003033/BX/BLRD VA/United States
GR  - R21 NS097426/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20190528
PL  - United States
TA  - DNA Cell Biol
JT  - DNA and cell biology
JID - 9004522
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclic AMP Response Element-Binding Protein)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Interleukins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Cyclic AMP Response Element-Binding Protein/metabolism
MH  - Encephalomyelitis, Autoimmune, Experimental/*drug therapy/immunology
MH  - Immunosuppressive Agents/*pharmacology/therapeutic use
MH  - Interleukins/genetics/metabolism
MH  - T-Lymphocytes, Regulatory/drug effects/immunology
PMC - PMC6628982
OTO - NOTNLM
OT  - IL-11
OT  - Th1/Th17 cells
OT  - aspirin
OT  - experimental autoimmune encephalomyelitis
OT  - regulatory T cells
COIS- No competing financial interests exist.
EDAT- 2019/05/30 06:00
MHDA- 2019/07/20 06:00
CRDT- 2019/05/30 06:00
PHST- 2019/05/30 06:00 [pubmed]
PHST- 2019/07/20 06:00 [medline]
PHST- 2019/05/30 06:00 [entrez]
AID - 10.1089/dna.2019.4814 [pii]
AID - 10.1089/dna.2019.4814 [doi]
PST - ppublish
SO  - DNA Cell Biol. 2019 Jul;38(7):593-596. doi: 10.1089/dna.2019.4814. Epub 2019 May 
      28.

PMID- 3188218
OWN - NLM
STAT- MEDLINE
DCOM- 19881221
LR  - 20131121
IS  - 0041-3232 (Print)
IS  - 0041-3232 (Linking)
VI  - 40
IP  - 3
DP  - 1988 Jul
TI  - Kawasaki disease in an adult Trinidadian male.
PG  - 254-6
AB  - Since Kawasaki in 1967 described the first case of mucocutaneous lymph node 
      syndrome which presented as an acute febrile illness in young children, the 
      syndrome has occasionally been reported in adults in the U.S.A. The present 
      communication describes the first adult case reported from the West Indies.
FAU - Patrick, A L
AU  - Patrick AL
AD  - Department of Medicine, Port of Spain General Hospital, Trinidad.
FAU - Barton, E N
AU  - Barton EN
FAU - Vincente, J B
AU  - Vincente JB
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Netherlands
TA  - Trop Geogr Med
JT  - Tropical and geographical medicine
JID - 0376231
RN  - 0 (Vitamins)
RN  - 7C782967RD (Ampicillin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Ampicillin/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Bed Rest
MH  - Combined Modality Therapy
MH  - Humans
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/therapy
MH  - Trinidad and Tobago
MH  - Vitamins/therapeutic use
EDAT- 1988/07/01 00:00
MHDA- 1988/07/01 00:01
CRDT- 1988/07/01 00:00
PHST- 1988/07/01 00:00 [pubmed]
PHST- 1988/07/01 00:01 [medline]
PHST- 1988/07/01 00:00 [entrez]
PST - ppublish
SO  - Trop Geogr Med. 1988 Jul;40(3):254-6.

PMID- 6499398
OWN - NLM
STAT- MEDLINE
DCOM- 19841226
LR  - 20131121
IS  - 0272-2712 (Print)
IS  - 0272-2712 (Linking)
VI  - 4
IP  - 2
DP  - 1984 Jun
TI  - Laboratory evaluation of the bleeding patient.
PG  - 285-301
AB  - The laboratory evaluation of bleeding patients is often inaccurate and incomplete 
      when the history and physical examination are not adequately evaluated. Using 
      such information the next step is to use screening tests to evaluate platelet 
      numbers and function, clot formation and clot stability and then to proceed to 
      appropriate follow-up testing when indicated. In this way the number of tests can 
      be significantly reduced and an accurate diagnosis becomes more likely.
FAU - Sirridge, M
AU  - Sirridge M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Lab Med
JT  - Clinics in laboratory medicine
JID - 8100174
RN  - 0 (Anti-Bacterial Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alcohol Drinking
MH  - Anti-Bacterial Agents/adverse effects
MH  - Aspirin/adverse effects
MH  - Bleeding Time
MH  - Blood Coagulation Disorders/*diagnosis
MH  - Blood Platelet Disorders/diagnosis
MH  - Diagnosis, Differential
MH  - Hemorrhagic Disorders/chemically induced/diagnosis
MH  - Humans
MH  - Platelet Aggregation
MH  - Platelet Function Tests
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
PST - ppublish
SO  - Clin Lab Med. 1984 Jun;4(2):285-301.

PMID- 6136169
OWN - NLM
STAT- MEDLINE
DCOM- 19830909
LR  - 20131121
IS  - 0195-878X (Print)
IS  - 0195-878X (Linking)
VI  - 10
DP  - 1983
TI  - Pharmacologic problems in shock research.
PG  - 3-8
AB  - Recent advances with receptor-selective agonists and antagonists have provided 
      great impetus to the deployment of drugs as experimental tools in cardiovascular 
      research. Often overlooked, however, is the important limitation that few 
      exogenous chemicals actually exert only one biologic action. This discussion 
      appraised several prototype drugs used in this field, and theorized how a lack of 
      consideration of subsidiary pharmacologic actions may lead to over-simplified 
      interpretations of drug-based data.
FAU - Adams, H R
AU  - Adams HR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Shock Res
JT  - Advances in shock research
JID - 7908298
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Aminoglycosides)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adrenergic alpha-Antagonists/pharmacology
MH  - Aminoglycosides/pharmacology
MH  - Animals
MH  - Anti-Bacterial Agents/pharmacology
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Aspirin/pharmacology
MH  - Cyclooxygenase Inhibitors
MH  - *Disease Models, Animal
MH  - Dogs
MH  - Indomethacin/pharmacology
MH  - Shock/*drug therapy/etiology
RF  - 17
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Adv Shock Res. 1983;10:3-8.

PMID- 552047
OWN - NLM
STAT- MEDLINE
DCOM- 19801218
LR  - 20131121
IS  - 0094-6044 (Print)
IS  - 0094-6044 (Linking)
VI  - 9
DP  - 1979
TI  - Hypercoagulability: a cause of vascular access failure.
PG  - 28-31
AB  - In a group of 58 patients requiring tertiary vascular access procedures for 
      maintenance of hemodialysis, 29 patients who thrombosed well-functioning fistulas 
      were evaluated for both antithrombin deficiencies as well as platelet 
      hyperaggreability. Thirteen of these 29 patients were found to have one or more 
      coagulation defects. Following correction of the hypercoagulable state, tertiary 
      vascular access procedures, using autologous tissues, were 100% successful in 
      these 13 patients.
FAU - Kauffman, H M Jr
AU  - Kauffman HM Jr
FAU - Ekbom, G A
AU  - Ekbom GA
FAU - Adams, M B
AU  - Adams MB
FAU - Hussey, C V
AU  - Hussey CV
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Proc Clin Dial Transplant Forum
JT  - Proceedings of the Clinical Dialysis and Transplant Forum
JID - 0432324
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antithrombin III Deficiency
MH  - Aspirin/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Intraoperative Period
MH  - Plasma
MH  - Renal Dialysis/*adverse effects/methods
MH  - Thrombosis/*etiology/prevention & control
MH  - Time Factors
MH  - Veins/*surgery
EDAT- 1979/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
PST - ppublish
SO  - Proc Clin Dial Transplant Forum. 1979;9:28-31.

PMID- 16759721
OWN - NLM
STAT- MEDLINE
DCOM- 20070125
LR  - 20181201
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 114
IP  - 2
DP  - 2007 Jan 8
TI  - A case of fatal stent thrombosis after Carbostent implantation: is clopidogrel 
      alone antiplatelet therapy a safe alternative to aspirin alone antiplatelet 
      therapy?
PG  - 279-81
AB  - We describe a case of fatal stent thrombosis after Carbostent implantation and 
      clopidogrel alone antiplatelet therapy in a patient affected by rectal cancer who 
      does not tolerate aspirin. He had three-vessel disease, with occlusion of the 
      right and left anterior descending coronary artery and a severe stenosis of the 
      proximal left circumflex. High-risk circumflex percutaneous coronary intervention 
      (PCI) was performed under left ventricular assistance by Impella device with an 
      optimal final angiographic result. After 2 h, however, the patient developed 
      chest pain with marked ST segment elevation in the infero-lateral leads, due to 
      stent thrombosis, and hypotention which rapidly degenerated into cardiac arrest, 
      electromechanical dissociation and death. At the present time the choice between 
      PCI at high risk of stent thrombosis followed by low risk cancer resection and 
      cancer resection at high risk of peri-operative myocardial infarction followed by 
      low risk PCI remains difficult.
FAU - Niccoli, Giampaolo
AU  - Niccoli G
FAU - Siviglia, Massimo
AU  - Siviglia M
FAU - De Vita, Maria
AU  - De Vita M
FAU - Altamura, Luca
AU  - Altamura L
FAU - Fusco, Beatrice
AU  - Fusco B
FAU - Leone, Antonio Maria
AU  - Leone AM
FAU - Ferrante, Giuseppe
AU  - Ferrante G
FAU - Rebuzzi, Antonio G
AU  - Rebuzzi AG
FAU - Crea, Filippo
AU  - Crea F
LA  - eng
PT  - Case Reports
PT  - Letter
DEP - 20060606
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - Fatal Outcome
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stents/*adverse effects
MH  - Thrombosis/*etiology
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2006/06/09 09:00
MHDA- 2007/01/26 09:00
CRDT- 2006/06/09 09:00
PHST- 2005/11/05 00:00 [received]
PHST- 2005/11/16 00:00 [accepted]
PHST- 2006/06/09 09:00 [pubmed]
PHST- 2007/01/26 09:00 [medline]
PHST- 2006/06/09 09:00 [entrez]
AID - S0167-5273(06)00096-9 [pii]
AID - 10.1016/j.ijcard.2005.11.079 [doi]
PST - ppublish
SO  - Int J Cardiol. 2007 Jan 8;114(2):279-81. doi: 10.1016/j.ijcard.2005.11.079. Epub 
      2006 Jun 6.

PMID- 6887080
OWN - NLM
STAT- MEDLINE
DCOM- 19831021
LR  - 20200225
IS  - 0035-8819 (Print)
IS  - 0035-8819 (Linking)
VI  - 17
IP  - 3
DP  - 1983 Jul
TI  - Management of transient cerebral ischaemic attacks by hospital doctors in 
      Scotland.
PG  - 173-7
AB  - A postal survey was carried out by questionnaire in Scotland among hospital 
      clinicians considered most likely to see patients with transient cerebral 
      ischaemic attacks. Of 650 questionnaires dispatched, 268 (41 per cent) were 
      completed and returned. This survey indicates that the majority of clinicians 
      dealing with this problem are confused by the controversial data and management 
      guidelines available in the literature. Over 50 per cent of the respondents were 
      either dubious or unaware of the benefits of any of the three current methods of 
      treatment: anticoagulation, platelet-modifying drugs and carotid artery surgery. 
      Yet 87 per cent of the clinicians were using low-dose aspirin (less than 600 
      mg/day) irrespective of the patient's sex, often in combination with other 
      platelet-modifying drugs. Anticoagulation and carotid artery surgery were used as 
      alternative treatments by only a third of the respondents in fewer than a third 
      of their patients. The risks of anticoagulation and carotid artery surgery were 
      thought to be high and often unacceptable, but aspirin therapy was considered to 
      be the safest.
FAU - Yeung Laiwah, A C
AU  - Yeung Laiwah AC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J R Coll Physicians Lond
JT  - Journal of the Royal College of Physicians of London
JID - 7503108
RN  - 0 (Anticoagulants)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Carotid Arteries/surgery
MH  - Cerebrovascular Disorders/prevention & control
MH  - Dipyridamole/therapeutic use
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/etiology/*therapy
MH  - Male
MH  - Risk
MH  - Scotland
MH  - Surveys and Questionnaires
PMC - PMC5370843
EDAT- 1983/07/01 00:00
MHDA- 1983/07/01 00:01
CRDT- 1983/07/01 00:00
PHST- 1983/07/01 00:00 [pubmed]
PHST- 1983/07/01 00:01 [medline]
PHST- 1983/07/01 00:00 [entrez]
PST - ppublish
SO  - J R Coll Physicians Lond. 1983 Jul;17(3):173-7.

PMID- 34597850
OWN - NLM
STAT- MEDLINE
DCOM- 20220218
LR  - 20230202
IS  - 2213-2201 (Electronic)
IS  - 2213-2198 (Print)
VI  - 10
IP  - 2
DP  - 2022 Feb
TI  - Appraisal of the Real-World Effectiveness of Biologic Therapies in 
      Aspirin-Exacerbated Respiratory Disease.
PG  - 478-484.e3
LID - S2213-2198(21)01056-4 [pii]
LID - 10.1016/j.jaip.2021.09.030 [doi]
AB  - BACKGROUND: There are no head-to-head studies for patients with 
      aspirin-exacerbated respiratory disease (AERD) comparing any of the 5 Food and 
      Drug Administration-approved respiratory biologic therapies. OBJECTIVE: Explore 
      outcomes in subjects with AERD using biologic therapies in a real-world clinic 
      setting. METHODS: A retrospective pilot study was conducted for subjects with 
      AERD who had been prescribed omalizumab (anti-IgE), mepolizumab (anti-IL-5), 
      reslizumab (anti-IL-5), benralizumab (anti-IL-5 receptor alpha [anti-IL-5Rα]), or 
      dupilumab (anti-IL-4 receptor alpha [anti-IL-4Rα]). Clinical outcomes pre- versus 
      postinitiation of biologic therapy were explored including symptoms, 22-item 
      sino-nasal outcome test scores, systemic corticosteroid and antibiotic 
      prescriptions, and emergency room visits related to AERD. RESULTS: Of the 74 
      subjects, 58.1% (n = 43) had used 1 biologic, though many (41.9%, n = 31) trialed 
      more than 1 biologic. Of the 50 subjects who had used anti-IL-4Rα therapy, 98% 
      (49 of 50) still had this therapy prescribed at study completion compared with 
      48.6% (17 of 35) and 26.9% (7 of 26) of those who used anti-IgE and anti-IL-5 and 
      anti-IL-5 receptor alpha (anti-IL-5/IL-5Rα) therapy, respectively. Among those on 
      anti-IL-4Rα therapy, there was a significant reduction in median total 22-item 
      sino-nasal outcome test scores (51 to 19, P = .0002), corticosteroid bursts (2 to 
      0, P < .0001), and median number of antibiotic courses for respiratory disease (1 
      to 0, P = .0469) prebiologic versus postbiologic initiation. No statistically 
      significant difference in those outcomes was observed for individuals on anti-IgE 
      or anti-IL-5/IL-5Rα therapy. CONCLUSIONS: Anti-IL-4Rα therapy led to 
      significantly higher rates of clinical improvement in AERD when compared with 
      anti-IL-5/IL-5Rα and anti-IgE biologic therapies. Prospective studies would help 
      clarify best practices for the use of biologic therapies in AERD.
CI  - Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Wangberg, Hannah
AU  - Wangberg H
AD  - Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif.
FAU - Spierling Bagsic, Samantha R
AU  - Spierling Bagsic SR
AD  - Scripps Health, Scripps Whittier Diabetes Institute, San Diego, Calif.
FAU - Osuna, Lilliana
AU  - Osuna L
AD  - Scripps Health, Scripps Whittier Diabetes Institute, San Diego, Calif.
FAU - White, Andrew A
AU  - White AA
AD  - Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif. 
      Electronic address: White.Andrew@scrippshealth.org.
LA  - eng
GR  - UL1 TR002550/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20210928
PL  - United States
TA  - J Allergy Clin Immunol Pract
JT  - The journal of allergy and clinical immunology. In practice
JID - 101597220
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Asthma, Aspirin-Induced/therapy
MH  - Biological Therapy
MH  - Chronic Disease
MH  - Humans
MH  - *Nasal Polyps/drug therapy
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - *Rhinitis/therapy
PMC - PMC8837666
MID - NIHMS1744258
OTO - NOTNLM
OT  - Aspirin-exacerbated respiratory disease (AERD)
OT  - Asthma
OT  - Benralizumab
OT  - Biologic
OT  - Chronic rhinosinusitis with nasal polyposis (CRSwNP)
OT  - Dupilumab
OT  - Mepolizumab
OT  - NSAID-exacerbated respiratory disease (NERD)
OT  - Nasal polyps
OT  - Omalizumab
OT  - Reslizumab
COIS- Conflicts of interest: A. A. White is on Speakers Bureau for Regeneron/Sanofi, 
      Astra Zeneca, and Optinose; is on Advisory Board for Astra Zeneca, Regeneron, 
      Optinose, ALK, GlaxoSmithKline, and Genentech; and received research Support from 
      AstraZeneca. The rest of the authors declare that they have no relevant conflicts 
      of interest.
EDAT- 2021/10/02 06:00
MHDA- 2022/02/19 06:00
CRDT- 2021/10/01 20:18
PHST- 2021/05/12 00:00 [received]
PHST- 2021/09/10 00:00 [revised]
PHST- 2021/09/13 00:00 [accepted]
PHST- 2021/10/02 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2021/10/01 20:18 [entrez]
AID - S2213-2198(21)01056-4 [pii]
AID - 10.1016/j.jaip.2021.09.030 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol Pract. 2022 Feb;10(2):478-484.e3. doi: 
      10.1016/j.jaip.2021.09.030. Epub 2021 Sep 28.

PMID- 19308892
OWN - NLM
STAT- MEDLINE
DCOM- 20090520
LR  - 20131121
IS  - 1098-9064 (Electronic)
IS  - 0094-6176 (Linking)
VI  - 35
IP  - 1
DP  - 2009 Feb
TI  - Pharmacogenetics in hemostasis: friend or foe?
PG  - 42-9
LID - 10.1055/s-0029-1214147 [doi]
AB  - Pharmacologic therapies are essential in the management of patients with 
      hemostatic and thrombotic diseases because these therapies are able to modify 
      components of the coagulation pathway and platelet response. Nevertheless, 
      responses to different drugs vary significantly, and the best clinical outcome 
      frequently involves a delicate risk/benefit balance. The recent exponential 
      growth of pharmacogenomics has led to the emergence of individualized medicine 
      that has revolutionized modern medical practice, allowing for a deeper 
      understanding of pathophysiology, increased diagnostic specificity, and better 
      markers for risk stratification and an enhanced potential for gene therapy. 
      Management of drugs prescribed to treat thrombotic and hemostatic abnormalities 
      may benefit from pharmacogenetics, and our focus in this review will be on the 
      pharmacogenetics related to some of the more common drugs that fall into this 
      category.
FAU - Rumilla, Kandelaria
AU  - Rumilla K
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, 
      Minnesota 55905, USA.
FAU - Chen, Dong
AU  - Chen D
FAU - Baudhuin, Linnea M
AU  - Baudhuin LM
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090323
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Coagulation Disorders/blood/*drug therapy/genetics
MH  - Drug Therapy/*standards
MH  - Environmental Monitoring/*methods
MH  - Hemostasis/*physiology
MH  - Humans
MH  - Pharmacogenetics/methods/*trends
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Warfarin/adverse effects/therapeutic use
RF  - 86
EDAT- 2009/03/25 09:00
MHDA- 2009/05/21 09:00
CRDT- 2009/03/25 09:00
PHST- 2009/03/25 09:00 [entrez]
PHST- 2009/03/25 09:00 [pubmed]
PHST- 2009/05/21 09:00 [medline]
AID - 10.1055/s-0029-1214147 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2009 Feb;35(1):42-9. doi: 10.1055/s-0029-1214147. Epub 2009 
      Mar 23.

PMID- 1343430
OWN - NLM
STAT- MEDLINE
DCOM- 19940304
LR  - 20131121
IS  - 0385-0005 (Print)
IS  - 0385-0005 (Linking)
VI  - 17
IP  - 5-6
DP  - 1992 Dec
TI  - Determination of salicylic acid by HPLC in plasma and saliva from children with 
      juvenile chronic arthritis.
PG  - 229-37
AB  - A high performance liquid chromatography (HPLC) method has been developed for 
      measuring salicylic acid in the plasma and saliva of children with juvenile 
      chronic arthritis (JCA). Samples were extracted with diethyl ether and, after 
      drying, redissolved in methanol to be chromatographed. Quantitation of salicylic 
      acid was performed by reverse phase HPLC on a spherisorb ODS-2 column, using 
      methanol: water: acetic acid as mobile phase. Phenolic was monitored by 
      absorbance at 237 nm. Linearity between the amount of mass injected and the 
      response in the detector was determined. This method was applied to compare 
      concentrations of salivary and plasma salicylic acid. The method also permitted 
      the quantitation of salivary salicylate as a non-invasive, indirect method for 
      monitoring the concentration of plasma salicylate in patients with JCA.
FAU - Legaz, M E
AU  - Legaz ME
AD  - Department of Plant Physiology, Faculty of Biology, Complutense University, 
      Madrid, Spain.
FAU - Acitores, E
AU  - Acitores E
FAU - Valverde, F
AU  - Valverde F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Tokai J Exp Clin Med
JT  - The Tokai journal of experimental and clinical medicine
JID - 7704186
RN  - 0 (Salicylates)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Arthritis, Juvenile/*blood/drug therapy/*metabolism
MH  - Aspirin/pharmacokinetics/therapeutic use
MH  - Child
MH  - Chromatography, High Pressure Liquid/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Salicylates/*blood/*metabolism
MH  - Salicylic Acid
MH  - Saliva/*metabolism
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
PST - ppublish
SO  - Tokai J Exp Clin Med. 1992 Dec;17(5-6):229-37.

PMID- 305713
OWN - NLM
STAT- MEDLINE
DCOM- 19780524
LR  - 20131121
IS  - 0300-970X (Print)
IS  - 0300-970X (Linking)
VI  - 25
IP  - 1
DP  - 1978 Feb
TI  - Hemostatic defect in endoscoped upper gut bleeding.
PG  - 68-72
AB  - In an effort to assess the role of salicylate ingestion in upper gastrointestinal 
      bleeding, one observer obtained a blood specimen for salicylate determination, 
      performed a Duke bleeding time, and obtained a detailed drug history at the time 
      of diagnostic endoscopy. Although a salicylate ingestion history was common, 
      other variables did not correlate with it. Prolonged bleeding time occurred in 21 
      of the 81 patients, versus 1 of 22 controls. It was strongly associated with 
      liver disease, with the alcohol habit by history, and with endoscopically severe 
      gastritis, but was not correlated with plasma salicylate levels or evidence of 
      salicylate ingestion by history, or with thrombocytopenia. Additional 
      relationships linked liver disease and gastritis with prolonged bleeding time. 
      There was no direct evidence from this study that salicylate ingestion occurred 
      more frequently among gastrointestinal bleeders than among controls, and there 
      was no evidence that the hemostatic defect increased the magnitude of bleeding.
FAU - Hall, W H
AU  - Hall WH
FAU - My, T Q
AU  - My TQ
FAU - Welsh, J D
AU  - Welsh JD
FAU - Hamptom, J W
AU  - Hamptom JW
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Acta Hepatogastroenterol (Stuttg)
JT  - Acta hepato-gastroenterologica
JID - 0340734
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alcoholism/complications
MH  - Aspirin/*adverse effects
MH  - Blood Coagulation Tests
MH  - Gastritis/complications
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Liver Diseases/complications
MH  - Thrombocytopenia/complications
EDAT- 1978/02/01 00:00
MHDA- 1978/02/01 00:01
CRDT- 1978/02/01 00:00
PHST- 1978/02/01 00:00 [pubmed]
PHST- 1978/02/01 00:01 [medline]
PHST- 1978/02/01 00:00 [entrez]
PST - ppublish
SO  - Acta Hepatogastroenterol (Stuttg). 1978 Feb;25(1):68-72.

PMID- 577365
OWN - NLM
STAT- MEDLINE
DCOM- 19770718
LR  - 20190819
IS  - 0001-639X (Print)
IS  - 0001-639X (Linking)
VI  - 55
IP  - 3
DP  - 1977 Jun
TI  - Disciform detachment of the macula. I. Juvenile haemorrhagic macular 
      choroidopathy.
PG  - 525-9
AB  - The clinical findings in six patients with juvenile haemorrhagic macular 
      choroidopathy are described. There was no evidence of infection with Histoplasma 
      capsulatum. The history, clinical features and course of the disease suggested 
      that at least in some cases intravascular coagulation in the central 
      choriocapillaris may form the choroidopathy inducing the disciform detachment of 
      the macula. Oral corticosteroids could not prevent progression of the lesion 
      which had a poor visual outcome. In one patient, good therapeutic response was 
      achieved with acetylsalicylic acid, which may be useful together with 
      lasercoagulation in the early treatment of this syndrome.
FAU - Saari, M
AU  - Saari M
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Acta Ophthalmol (Copenh)
JT  - Acta ophthalmologica
JID - 0370347
RN  - 0 (Adrenal Cortex Hormones)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Choroid
MH  - Disseminated Intravascular Coagulation
MH  - Female
MH  - Histoplasmosis
MH  - Humans
MH  - Light Coagulation
MH  - *Macula Lutea
MH  - Optic Disk
MH  - *Retinal Detachment/drug therapy/surgery
MH  - Retinal Hemorrhage/etiology
MH  - Visual Acuity
EDAT- 1977/06/01 00:00
MHDA- 1977/06/01 00:01
CRDT- 1977/06/01 00:00
PHST- 1977/06/01 00:00 [pubmed]
PHST- 1977/06/01 00:01 [medline]
PHST- 1977/06/01 00:00 [entrez]
AID - 10.1111/j.1755-3768.1977.tb06130.x [doi]
PST - ppublish
SO  - Acta Ophthalmol (Copenh). 1977 Jun;55(3):525-9. doi: 
      10.1111/j.1755-3768.1977.tb06130.x.

PMID- 16139120
OWN - NLM
STAT- MEDLINE
DCOM- 20051205
LR  - 20181201
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 46
IP  - 5
DP  - 2005 Sep 6
TI  - Secondary stroke prevention with antiplatelet therapy with emphasis on the 
      cardiac patient: a neurologist's view.
PG  - 752-5
AB  - The prevention of secondary vascular events is of paramount importance in 
      patients with a history of stroke or transient ischemic attack (TIA). Most 
      cardiologists are aware of the benefits of clopidogrel plus aspirin versus those 
      of other antiplatelet regimens in patients with acute coronary syndrome. Using a 
      representative post-stroke patient as an example, this article reviews data 
      evaluating the effectiveness of antiplatelet regimens in preventing secondary 
      vascular events in stroke and TIA patients. These results differ from those seen 
      in clinical trials of acute coronary syndrome patients. Clinical studies provide 
      little evidence that clopidogrel, with or without aspirin, is more efficacious in 
      this setting than aspirin alone. Moreover, the increased risk of bleeding 
      episodes with clopidogrel and aspirin in combination probably outweighs any small 
      reductions in secondary event risk. In contrast, extended-release dipyridamole 
      (ER-DP) plus aspirin reduces secondary stroke risk to a significantly greater 
      extent (23% relative risk reduction) than aspirin alone. Currently available 
      clinical trial data support the use of ER-DP plus aspirin, but not clopidogrel 
      plus aspirin, to prevent secondary vascular events after stroke or TIA.
FAU - Gebel, James M Jr
AU  - Gebel JM Jr
AD  - Jewish Hospital, Louisville, Kentucky, USA. j.gebel@att.net
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - J Am Coll Cardiol. 2006 Jun 20;47(12):2568; author reply 2569-70. PMID: 16781394
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Delayed-Action Preparations
MH  - Dipyridamole/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy/physiopathology/*prevention & control
MH  - Neurology
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Secondary Prevention
MH  - Stroke/drug therapy/*prevention & control
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
EDAT- 2005/09/06 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/09/06 09:00
PHST- 2004/07/20 00:00 [received]
PHST- 2004/12/22 00:00 [revised]
PHST- 2005/04/13 00:00 [accepted]
PHST- 2005/09/06 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/09/06 09:00 [entrez]
AID - S0735-1097(05)01279-9 [pii]
AID - 10.1016/j.jacc.2005.04.058 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2005 Sep 6;46(5):752-5. doi: 10.1016/j.jacc.2005.04.058.

PMID- 11133059
OWN - NLM
STAT- MEDLINE
DCOM- 20010125
LR  - 20131121
IS  - 0332-3102 (Print)
IS  - 0332-3102 (Linking)
VI  - 93
IP  - 8
DP  - 2000 Nov
TI  - The impact of aspirin therapy and anticoagulation on the prevalence of 
      spontaneous subdural haematoma.
PG  - 244-6
AB  - A retrospective analysis was performed of all patients who received operative 
      intervention for subdural haematoma at the Beaumont neurosurgical unit between 
      1994 and 1997 inclusive. There were 123 spontaneous (mean age 74 +/- 5 years) and 
      77 traumatic haematomas (mean age 43 +/- 23 years) in the series. Ninety three 
      patients (76%) in the spontaneous group were on antiplatelet agents or 
      anticoagulants (78 aspirin, 15 warfarin) and the indication for their use was 
      unknown in twenty four patients (19%). The re-operation rate in the group on 
      aspirin and anticoagulants was twice that in the non aspirin / non anticoagulant 
      group. These results highlight a significant medical problem and emphasise the 
      need for cautious use of antiplatelet and anticoagulant agents, particularly in 
      the elderly.
FAU - O'Brien, D F
AU  - O'Brien DF
AD  - Department of Neurosurgery, Beaumont Hospital, Dublin, Ireland.
FAU - Basu, S
AU  - Basu S
FAU - O'Donnell, J R
AU  - O'Donnell JR
FAU - Roberts, G A
AU  - Roberts GA
FAU - Phillips, J
AU  - Phillips J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Ireland
TA  - Ir Med J
JT  - Irish medical journal
JID - 0430275
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Female
MH  - Hematoma, Subdural/*chemically induced/epidemiology/surgery
MH  - Humans
MH  - Male
MH  - Prevalence
MH  - Reoperation/statistics & numerical data
MH  - Retrospective Studies
MH  - Warfarin/*adverse effects/therapeutic use
EDAT- 2001/01/02 11:00
MHDA- 2001/02/28 10:01
CRDT- 2001/01/02 11:00
PHST- 2001/01/02 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2001/01/02 11:00 [entrez]
PST - ppublish
SO  - Ir Med J. 2000 Nov;93(8):244-6.

PMID- 18038616
OWN - NLM
STAT- MEDLINE
DCOM- 20080131
LR  - 20161124
IS  - 0015-5616 (Print)
IS  - 0015-5616 (Linking)
VI  - 47
IP  - 1-4
DP  - 2006
TI  - Aspirin augments the concentration of endogenous hydrogen sulfide in mouse brain 
      and liver.
PG  - 87-91
AB  - Intraperitoneal injections of lysine acetylsalicylate (L-ASA, aspirin) in a dose 
      of 10 mg during 5 consecutive days to BALB/c and B10.PL mice increased the 
      concentration of endogenous hydrogen sulfide in their livers. The rise of 
      hydrogen sulfur levels was shown also in brains of BALB/c females and B10.PL 
      males, however in BALB/c male brains there is no statistically significant 
      difference. The mechanism of aspirin action on H2S concentration is discussed.
FAU - Srebro, Zbigniew
AU  - Srebro Z
AD  - Zakład Biologii Rozwoju Człowieka, Collegium Medicum Uniwersytetu 
      Jagiellońskiego, Kraków.
FAU - Somogyi, Eugeniusz
AU  - Somogyi E
FAU - Wiliński, Bogdan
AU  - Wiliński B
FAU - Góralska, Marta
AU  - Góralska M
FAU - Wiliński, Jerzy
AU  - Wiliński J
FAU - Sura, Piotr
AU  - Sura P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Poland
TA  - Folia Med Cracov
JT  - Folia medica Cracoviensia
JID - 0374617
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 7LP2MPO46S (S-Adenosylmethionine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
MH  - Aspirin/administration & dosage/*analogs & derivatives
MH  - Brain/*metabolism
MH  - Brain Chemistry
MH  - Female
MH  - Humans
MH  - Hydrogen Sulfide/analysis/*metabolism
MH  - Liver/chemistry/*metabolism
MH  - Lysine/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Nitric Oxide/metabolism
MH  - S-Adenosylmethionine/*metabolism
MH  - Sex Factors
EDAT- 2007/11/28 09:00
MHDA- 2008/02/01 09:00
CRDT- 2007/11/28 09:00
PHST- 2007/11/28 09:00 [pubmed]
PHST- 2008/02/01 09:00 [medline]
PHST- 2007/11/28 09:00 [entrez]
PST - ppublish
SO  - Folia Med Cracov. 2006;47(1-4):87-91.

PMID- 16948802
OWN - NLM
STAT- MEDLINE
DCOM- 20070329
LR  - 20220318
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 24
IP  - 6
DP  - 2006 Sep 15
TI  - Review article: gastrointestinal bleeding with low-dose aspirin - what's the 
      risk?
PG  - 897-908
AB  - This review examines ulcers and gastrointestinal bleeding with low-dose aspirin, 
      focusing on randomized placebo-controlled trials. The single endoscopic trial 
      assessing ulcers showed no significant difference in 12-week ulcer incidence: 6% 
      of 381 given placebo vs. 7% of 387 given 81 mg enteric-coated aspirin. The 
      relative risk of major gastrointestinal bleeding with low-dose aspirin in a 
      meta-analysis of placebo-controlled trials of vascular protection was 2.07 (95% 
      CI: 1.61-2.66). The absolute rate increase with aspirin above placebo was 0.12% 
      per year (95% CI: 0.07-0.19%) with a number-needed-to-harm of 833 patients (95% 
      CI: 526-1429). A meta-analysis of aspirin 50-1500 mg daily reported an odds ratio 
      for any gastrointestinal bleeding of 1.68 (95% CI: 1.51-1.88) with an 
      number-needed-to-harm at 1 year of 247. The relative risk of hospitalization for 
      upper gastrointestinal bleeding with low-dose aspirin in a large Danish cohort 
      study was 2.6 (95% CI: 2.2-2.9) with an absolute annual incidence of 0.6%. 
      Factors that may increase the risk of gastrointestinal bleeding include prior 
      history of ulcers or gastrointestinal bleeding, corticosteroid use, anticoagulant 
      therapy and addition of a non-aspirin non-steroidal anti-inflammatory drug. When 
      determining whether low-dose aspirin is appropriate for an individual patient, 
      the cardiovascular benefit must be weighed against the potential for clinical 
      events such as gastrointestinal bleeding.
FAU - Laine, L
AU  - Laine L
AD  - Department of Medicine, U.S.C. School of Medicine, Los Angeles, CA 90033, USA. 
      llaine@usc.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - ACP J Club. 2007 Jan-Feb;146(1):13. PMID: 17203933
CIN - Aliment Pharmacol Ther. 2007 Feb 1;25(3):345-6; author reply 346-7. PMID: 
      17217449
MH  - Adrenal Cortex Hormones/adverse effects
MH  - Aging/physiology
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Anticoagulants/adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Cyclooxygenase 2 Inhibitors/adverse effects
MH  - Drug Administration Schedule
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Ulcer/chemically induced
MH  - Warfarin/adverse effects
RF  - 61
EDAT- 2006/09/05 09:00
MHDA- 2007/03/30 09:00
CRDT- 2006/09/05 09:00
PHST- 2006/09/05 09:00 [pubmed]
PHST- 2007/03/30 09:00 [medline]
PHST- 2006/09/05 09:00 [entrez]
AID - APT3077 [pii]
AID - 10.1111/j.1365-2036.2006.03077.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2006 Sep 15;24(6):897-908. doi: 
      10.1111/j.1365-2036.2006.03077.x.

PMID- 7491446
OWN - NLM
STAT- MEDLINE
DCOM- 19960104
LR  - 20131121
IS  - 1661-8157 (Print)
IS  - 1661-8157 (Linking)
VI  - 84
IP  - 44
DP  - 1995 Oct 31
TI  - [Cardiovascular pharmacotherapy in old age: How beneficial is it? What does it 
      cost?].
PG  - 1248-51
AB  - Because of their high morbidity and mortality, elderly people benefit most from 
      drugs with a proven effect on disease complications and premature death. 
      Thiazides, beta adrenergic blocking drugs, oral anticoagulants and aspirin are 
      drugs that satisfy such criteria. These medications are comparatively well 
      tolerated and cheap. They should not be neglected in favour of newer drugs with a 
      less complete performance record.
FAU - Gysling, E
AU  - Gysling E
AD  - Unabhängiges Informationszentrum für Pharmakotherapiefragen, Wil.
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Kardiovaskuläre Pharmakotherapie im Alter: Was nützt sie? Was kostet sie?
PL  - Switzerland
TA  - Praxis (Bern 1994)
JT  - Praxis
JID - 101468093
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anticoagulants)
RN  - 0 (Benzothiadiazines)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Diuretics)
RN  - 0 (Sodium Chloride Symporter Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Benzothiadiazines
MH  - Cardiovascular Agents/economics/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Diuretics
MH  - Drug Costs
MH  - Humans
MH  - Sodium Chloride Symporter Inhibitors/therapeutic use
EDAT- 1995/10/31 00:00
MHDA- 1995/10/31 00:01
CRDT- 1995/10/31 00:00
PHST- 1995/10/31 00:00 [pubmed]
PHST- 1995/10/31 00:01 [medline]
PHST- 1995/10/31 00:00 [entrez]
PST - ppublish
SO  - Praxis (Bern 1994). 1995 Oct 31;84(44):1248-51.

PMID- 21474890
OWN - NLM
STAT- MEDLINE
DCOM- 20110603
LR  - 20131121
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 123
IP  - 2
DP  - 2011 Mar
TI  - Incidental atrial fibrillation and its management.
PG  - 27-35
LID - 10.3810/pgm.2011.03.2260 [doi]
AB  - Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia, yet 
      because AF can often be intermittent or lacking in overt symptoms, its prevalence 
      is underestimated, and it may be diagnosed only incidentally. Because AF is a 
      potent ischemic stroke risk factor and stroke rates are similar for paroxysmal, 
      persistent, and permanent AF, all AF types require prompt management. This 
      involves identifying and treating underlying causative factors, then implementing 
      a "rate-control" or "rhythm-control" strategy. Regardless of approach, 
      concomitant antithrombotic therapy for stroke risk reduction is recommended. 
      Antithrombotic agent choice (acetylsalicylic acid or warfarin) depends on level 
      of stroke risk; this review covers both the CHADS2 and CHA2DS2-VASc risk 
      stratification schemes. Warfarin provides effective ischemic stroke prophylaxis 
      but has numerous drawbacks, including a narrow therapeutic range, unpredictable 
      pharmacokinetics, slow on-/offset of action, and multiple food and drug 
      interactions. New oral anticoagulants that lack many of these drawbacks are in 
      development. Here we review these drugs for stroke prevention in AF.
FAU - Saliba, Walid
AU  - Saliba W
AD  - Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Heart and 
      Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA. salibaw@ccf.org
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Atrial Fibrillation/complications/diagnosis/*drug therapy/physiopathology
MH  - Fibrinolytic Agents/therapeutic use
MH  - Heart Rate/drug effects/physiology
MH  - Humans
MH  - Risk Assessment
MH  - Stroke/prevention & control
MH  - Warfarin/adverse effects/therapeutic use
EDAT- 2011/04/09 06:00
MHDA- 2011/06/04 06:00
CRDT- 2011/04/09 06:00
PHST- 2011/04/09 06:00 [entrez]
PHST- 2011/04/09 06:00 [pubmed]
PHST- 2011/06/04 06:00 [medline]
AID - 10.3810/pgm.2011.03.2260 [doi]
PST - ppublish
SO  - Postgrad Med. 2011 Mar;123(2):27-35. doi: 10.3810/pgm.2011.03.2260.

PMID- 18762476
OWN - NLM
STAT- MEDLINE
DCOM- 20080915
LR  - 20211020
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Print)
IS  - 0959-8138 (Linking)
VI  - 337
DP  - 2008 Sep 1
TI  - Low dose aspirin and cognitive function in middle aged to elderly adults: 
      randomised controlled trial.
PG  - a1198
LID - 337/sep01_1/a1198 [pii]
LID - 10.1136/bmj.a1198 [doi]
LID - a1198
AB  - OBJECTIVE: To determine the effects of low dose aspirin on cognitive function in 
      middle aged to elderly men and women at moderately increased cardiovascular risk. 
      DESIGN: Randomised double blind placebo controlled trial. SETTING: Central 
      Scotland. PARTICIPANTS: 3350 men and women aged over 50 participating in the 
      aspirin for asymptomatic atherosclerosis trial. INTERVENTION: Low dose aspirin 
      (100 mg daily) or placebo for five years. MAIN OUTCOME MEASURES: Tests of memory, 
      executive function, non-verbal reasoning, mental flexibility, and information 
      processing five years after randomisation, with scores used to create a summary 
      cognitive score (general factor). RESULTS: At baseline, mean vocabulary scores 
      (an indicator of previous cognitive ability) were similar in the aspirin (30.9, 
      SD 4.7) and placebo (31.1, SD 4.7) groups. In the primary intention to treat 
      analysis, there was no significant difference at follow-up between the groups in 
      the proportion achieving over the median general factor cognitive score (32.7% 
      and 34.8% respectively, odds ratio 0.91, 95% confidence interval 0.79 to 1.05, 
      P=0.20) or in mean scores on the individual cognitive tests. There were also no 
      significant differences in change in cognitive ability over the five years in a 
      subset of 504 who underwent detailed cognitive testing at baseline. CONCLUSION: 
      Low dose aspirin does not affect cognitive function in middle aged to elderly 
      people at increased cardiovascular risk. TRIAL REGISTRATION: ISRCTN 66587262.
FAU - Price, Jackie F
AU  - Price JF
AD  - Division of Community Health Sciences and Centre for Public Health and Primary 
      Care Research, University of Edinburgh, Edinburgh. Jackie.Price@ed.ac.uk
FAU - Stewart, Marlene C
AU  - Stewart MC
FAU - Deary, Ian J
AU  - Deary IJ
FAU - Murray, Gordon D
AU  - Murray GD
FAU - Sandercock, Peter
AU  - Sandercock P
FAU - Butcher, Isabella
AU  - Butcher I
FAU - Fowkes, F Gerald R
AU  - Fowkes FG
CN  - AAA Trialists
LA  - eng
SI  - ISRCTN/ISRCTN66587262
GR  - British Heart Foundation/United Kingdom
GR  - Chief Scientist Office/United Kingdom
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080901
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Neuroprotective Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BMJ. 2008;337:a958. PMID: 18762478
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Atherosclerosis/*prevention & control
MH  - Cognition Disorders/*prevention & control
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuroprotective Agents/*administration & dosage
MH  - Neuropsychological Tests
MH  - Patient Compliance
PMC - PMC2527654
COIS- Competing interests: None declared.
FIR - Fowkes, F G R
IR  - Fowkes FG
FIR - Price, J F
IR  - Price JF
FIR - Murray, G D
IR  - Murray GD
FIR - Deary, I J
IR  - Deary IJ
FIR - Stewart, M C W
IR  - Stewart MC
FIR - Douglas, A F
IR  - Douglas AF
FIR - Cudmore, S
IR  - Cudmore S
FIR - Bree, M
IR  - Bree M
FIR - Wilson, S A
IR  - Wilson SA
FIR - Armstrong, E M
IR  - Armstrong EM
FIR - McHugh, G S
IR  - McHugh GS
FIR - Butcher, I
IR  - Butcher I
FIR - Cobbe, S M
IR  - Cobbe SM
FIR - Warlow, C
IR  - Warlow C
FIR - Ford, I
IR  - Ford I
FIR - Petrie, J C
IR  - Petrie JC
FIR - Bain, M
IR  - Bain M
FIR - Clements, R
IR  - Clements R
FIR - Darnborough, J
IR  - Darnborough J
FIR - Deary, I
IR  - Deary I
FIR - Fowkes, F G R
IR  - Fowkes FG
FIR - Fox, K A A
IR  - Fox KA
FIR - Leng, G
IR  - Leng G
FIR - Lowe, G D O
IR  - Lowe GD
FIR - Mallinson, E
IR  - Mallinson E
FIR - Murray, G D
IR  - Murray GD
FIR - Pell, A
IR  - Pell A
FIR - Price, J F
IR  - Price JF
FIR - Rumley, A
IR  - Rumley A
FIR - Sandercock, P
IR  - Sandercock P
FIR - Wrench, J
IR  - Wrench J
FIR - Fowkes, F G R
IR  - Fowkes FG
FIR - Price, J F
IR  - Price JF
FIR - Sommerfield, T
IR  - Sommerfield T
FIR - Bream, E
IR  - Bream E
FIR - Northridge, D
IR  - Northridge D
FIR - Lindley, R
IR  - Lindley R
FIR - Bree, M
IR  - Bree M
FIR - Walton, R
IR  - Walton R
FIR - Ritchie, C A M
IR  - Ritchie CA
FIR - Healy, E
IR  - Healy E
FIR - Peterson, H
IR  - Peterson H
FIR - Crooks, E
IR  - Crooks E
FIR - Hay, J
IR  - Hay J
FIR - Kerracher, E M
IR  - Kerracher EM
FIR - Kerracher, N
IR  - Kerracher N
FIR - Sloan, A
IR  - Sloan A
FIR - Thom, D
IR  - Thom D
FIR - McGoohan, L C
IR  - McGoohan LC
FIR - Patterson, J
IR  - Patterson J
FIR - Baxter, G
IR  - Baxter G
FIR - Spooner, R
IR  - Spooner R
FIR - Foley, E
IR  - Foley E
FIR - Carracher, J
IR  - Carracher J
FIR - Tolmie, E
IR  - Tolmie E
FIR - Graham, E C
IR  - Graham EC
FIR - Alexander, J F
IR  - Alexander JF
FIR - Lawrie, H
IR  - Lawrie H
FIR - Armstrong, E M
IR  - Armstrong EM
FIR - Tierney, I F
IR  - Tierney IF
FIR - Wilson, S A
IR  - Wilson SA
FIR - Ross, P
IR  - Ross P
FIR - Reston, F
IR  - Reston F
FIR - Willis, D
IR  - Willis D
FIR - Kerracher, E M
IR  - Kerracher EM
FIR - Neary, F J
IR  - Neary FJ
FIR - Smith, F B
IR  - Smith FB
FIR - Hepburn, K
IR  - Hepburn K
FIR - Rea, C D
IR  - Rea CD
FIR - Mackay, H
IR  - Mackay H
FIR - Smith, W A
IR  - Smith WA
FIR - Martin, C D
IR  - Martin CD
FIR - Ritchie, C A M
IR  - Ritchie CA
FIR - Paton, L
IR  - Paton L
EDAT- 2008/09/03 09:00
MHDA- 2008/09/16 09:00
CRDT- 2008/09/03 09:00
PHST- 2008/09/03 09:00 [pubmed]
PHST- 2008/09/16 09:00 [medline]
PHST- 2008/09/03 09:00 [entrez]
AID - 337/sep01_1/a1198 [pii]
AID - prij557231 [pii]
AID - 10.1136/bmj.a1198 [doi]
PST - epublish
SO  - BMJ. 2008 Sep 1;337:a1198. doi: 10.1136/bmj.a1198.

PMID- 6225878
OWN - NLM
STAT- MEDLINE
DCOM- 19831123
LR  - 20131121
IS  - 0098-4108 (Print)
IS  - 0098-4108 (Linking)
VI  - 11
IP  - 4-6
DP  - 1983 Apr-Jun
TI  - Tolerance to cadmium in the abdominal stretch response: a comparative study of 
      cadmium and acetic acid.
PG  - 739-48
AB  - The intraperitoneal injection of cadmium (Cd) in mice produces a characteristic 
      abdominal stretch response similar to that observed with acetic acid. Morphine, 
      clonidine, and tripelennamine ED50 values were the same for inhibition of the 
      response to Cd and to acetic acid. The ED50 values for aspirin and indomethacin 
      were lower against the Cd than the acetic acid response. On repeated injections, 
      Cd did but acetic acid did not produce tolerance to itself. Furthermore, the mice 
      made tolerant to Cd were not cross-tolerant to acetic acid, but the 
      acetic-acid-treated mice were cross-tolerant to Cd. These results suggest that Cd 
      and acetic acid may produce the stretch response through different mechanisms, 
      and the Cd-induced response might serve as a screening test for aspirin-like 
      agents.
FAU - Christensen, C W
AU  - Christensen CW
FAU - Fujimoto, J M
AU  - Fujimoto JM
LA  - eng
GR  - GM 16503/GM/NIGMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Toxicol Environ Health
JT  - Journal of toxicology and environmental health
JID - 7513622
RN  - 0 (Acetates)
RN  - 0 (Analgesics)
RN  - 00BH33GNGH (Cadmium)
RN  - 9038-94-2 (Metallothionein)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdominal Muscles/drug effects
MH  - Acetates/*toxicity
MH  - Analgesics/pharmacology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Cadmium/*toxicity
MH  - Drug Tolerance
MH  - Male
MH  - Metallothionein/biosynthesis
MH  - Mice
EDAT- 1983/04/01 00:00
MHDA- 1983/04/01 00:01
CRDT- 1983/04/01 00:00
PHST- 1983/04/01 00:00 [pubmed]
PHST- 1983/04/01 00:01 [medline]
PHST- 1983/04/01 00:00 [entrez]
AID - 10.1080/15287398309530381 [doi]
PST - ppublish
SO  - J Toxicol Environ Health. 1983 Apr-Jun;11(4-6):739-48. doi: 
      10.1080/15287398309530381.

PMID- 16649040
OWN - NLM
STAT- MEDLINE
DCOM- 20070117
LR  - 20131121
IS  - 0932-0067 (Print)
IS  - 0932-0067 (Linking)
VI  - 274
IP  - 4
DP  - 2006 Jul
TI  - Effects of aspirin on placenta and perinatal outcomes in patients with poor 
      obstetric history.
PG  - 209-14
AB  - OBJECTIVE: The aim of this study was to compare a low-dose aspirin treatment on 
      placental and perinatal effects in the patients with poor obstetric history such 
      as preeclampsia, intrauterine growth retardation (IUGR) in previous pregnancy. 
      STUDY DESIGN: This retrospective study of 86 pregnant women was conducted between 
      April 2002 and June 2005. In this study period 364 placentas were examined and 
      the patients with poor obstetric history such as IUGR and preeclampsia were 
      selected. Then the patients were assigned to three groups; group 1 (n = 30) was 
      composed of women with no risk in previous pregnancy; group 2 (n = 27) was 
      composed of patients with poor obstetric history (e.g., preeclampsia, IUGR) who 
      were treated with aspirin and patients in group 3 (n = 29) had poor obstetric 
      history without any treatment (patients who were started to follow-up after 14 
      weeks of gestation). Patients in group 2 were treated with a low-dose aspirin (80 
      mg/day) as soon as a urinary pregnancy test was positive. Treatment was usually 
      stopped at 34 completed weeks of gestation. On histopathologic examination of the 
      placenta, uteroplacental vascular pathologic features and secondary villous 
      damage (such as fibrinoid necrosis of desidual vessels, villous infarct, severely 
      increased villous fibrosis, severely increased syncytiotrophoblast knotting, 
      obliteration of the vessel lumen, severely increased villous hypervascularity) 
      and also lesions involving coagulation (such as excessive perivillous fibrin 
      deposition, multiple occlusive thrombi in uteroplacental vessels, avascular villi 
      ) were examined. RESULTS: There were no significant differences between the 
      groups with respect to maternal age, body mass index at the first trimester and 
      delivery. Also there were no significant differences among groups with respect to 
      placental weight, fetal height, weight, gestational week, umbilical artery pH, 
      pO2, pCO2 and base excess status. The incidences of preeclampsia were 3.3, 7.4, 
      6.8% and the incidences of IUGR were 6.7, 11.1, 6.8% in the groups, respectively 
      (P > 0.05 for both). Although the percentages of all pathologic findings were 
      higher in groups 2 and 3, these differences were not statistically important. 
      CONCLUSION: When low-dose aspirin is taken, starting at the beginning of 
      pregnancy in patients with poor obstetric history, there are still high 
      frequencies of uteroplacental vascular and related villous lesions persisted on 
      placental bed. Also it has no beneficial effects on perinatal outcomes in these 
      patients.
FAU - Tarim, Ebru
AU  - Tarim E
AD  - Department of Obstetrics and Gynecology, Baskent University, Baraj yolu.1.durak 
      Seyhan, Adana 1000, Turkey. eatarim@hotmail.com
FAU - Bal, Nebil
AU  - Bal N
FAU - Kilicdag, Esra
AU  - Kilicdag E
FAU - Kayaselcuk, Fazilet
AU  - Kayaselcuk F
FAU - Bağiş, Tayfun
AU  - Bağiş T
FAU - Kuscu, Esra
AU  - Kuscu E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20060429
PL  - Germany
TA  - Arch Gynecol Obstet
JT  - Archives of gynecology and obstetrics
JID - 8710213
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Chorionic Villi/blood supply
MH  - Female
MH  - Fetus/physiology
MH  - Humans
MH  - Infant, Newborn
MH  - Placenta/*drug effects
MH  - Pregnancy
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Trophoblasts/pathology
MH  - Umbilical Cord/pathology
EDAT- 2006/05/02 09:00
MHDA- 2007/01/18 09:00
CRDT- 2006/05/02 09:00
PHST- 2006/03/14 00:00 [received]
PHST- 2006/03/27 00:00 [accepted]
PHST- 2006/05/02 09:00 [pubmed]
PHST- 2007/01/18 09:00 [medline]
PHST- 2006/05/02 09:00 [entrez]
AID - 10.1007/s00404-006-0162-y [doi]
PST - ppublish
SO  - Arch Gynecol Obstet. 2006 Jul;274(4):209-14. doi: 10.1007/s00404-006-0162-y. Epub 
      2006 Apr 29.

PMID- 21663525
OWN - NLM
STAT- MEDLINE
DCOM- 20111027
LR  - 20181201
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 12
IP  - 11
DP  - 2011 Aug
TI  - Clopidogrel hydrogen sulphate for atrial fibrillation.
PG  - 1781-7
LID - 10.1517/14656566.2011.587118 [doi]
AB  - INTRODUCTION: Atrial fibrillation is a common cardiac rhythm abnormality with a 
      considerable cardiovascular disease burden worldwide. It is an independent major 
      risk factor for stroke. Stroke prevention with anticoagulation or antiplatelet 
      agents has been an important area of clinical research. Warfarin is the most 
      widely used antithrombotic therapy for stroke prophylaxis for last several years, 
      and now dabigatran (150 mg b.i.d.) is more effective than warfarin in stroke 
      prevention in individuals at increased of stroke. In addition, several studies 
      have evaluated the efficacy of clopidogrel for stroke prophylaxis either alone or 
      in combination with aspirin. AREAS COVERED: This review summarizes the key 
      findings of the trials looking at the efficacy of clopidogrel in stroke 
      prevention. A literature search was performed using PubMed and Google Scholar. 
      The trials that evaluated the efficacy of clopidogrel in preventing 
      atherothrombotic events or stroke were also included. EXPERT OPINION: Clopidogrel 
      prevents more vascular events, including stroke, in patients with a recent 
      myocardial infarction, stroke or peripheral vascular disease than aspirin. 
      Combination of clopidogrel and aspirin provides a greater reduction of stroke 
      than aspirin or clopidogrel monotherapy, but at an increased risk of bleeding. 
      Dual antiplatelet therapy (clopidogrel and aspirin) is inferior to warfarin in 
      primary stroke prevention for patient with atrial fibrillation and thus should be 
      considered for stroke prophylaxis only in patients ineligible for warfarin. 
      However, with the advent of newer agents, like direct thrombin inhibitors and 
      Factor Xa inhibitors, the role of antiplatelet therapy for stroke prevention in 
      atrial fibrillation remains unclear.
FAU - Garg, Nadish
AU  - Garg N
AD  - University of Missouri-Columbia, Division of Cardiovascular Medicine, Five 
      Hospital Drive, CE306, Columbia, MO 65212, USA.
FAU - Rajpurohit, Naveen
AU  - Rajpurohit N
FAU - Flaker, Greg
AU  - Flaker G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20110611
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Clopidogrel
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology/*therapeutic 
      use
MH  - Risk Factors
MH  - Stroke/etiology/prevention & control
MH  - Thrombosis/etiology/prevention & control
MH  - Ticlopidine/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
EDAT- 2011/06/15 06:00
MHDA- 2011/10/28 06:00
CRDT- 2011/06/14 06:00
PHST- 2011/06/14 06:00 [entrez]
PHST- 2011/06/15 06:00 [pubmed]
PHST- 2011/10/28 06:00 [medline]
AID - 10.1517/14656566.2011.587118 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2011 Aug;12(11):1781-7. doi: 
      10.1517/14656566.2011.587118. Epub 2011 Jun 11.

PMID- 29516320
OWN - NLM
STAT- MEDLINE
DCOM- 20190729
LR  - 20190729
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Linking)
VI  - 29
IP  - 4-5
DP  - 2018 May
TI  - Pre-diagnostic aspirin use and mortality after breast cancer.
PG  - 417-425
LID - 10.1007/s10552-018-1020-5 [doi]
AB  - BACKGROUND: Whether aspirin or other nonsteroidal anti-inflammation drug (NSAID) 
      use is associated with mortality following breast cancer remains unclear. 
      Consideration of use patterns and interaction with obesity may help to clarify 
      the inconsistent results. METHODS: Pre-diagnosis NSAID use, weight, and height 
      were assessed ~ 3 months after diagnosis through in-person interviews with a 
      population-based cohort of 1,442 women with first primary breast cancer. Vital 
      status was determined through the national death index after ~ 18 years of 
      follow-up (N = 237/597 breast cancer-specific/all-cause deaths). We used Cox 
      proportional hazards regression to estimate multivariable-adjusted hazard ratios 
      (HRs) and 95% confidence intervals (CIs). Multiplicative interaction by body mass 
      index (BMI) was evaluated using the likelihood ratio test. RESULTS: Ever aspirin 
      use was inversely associated with breast cancer-specific mortality (HR 0.87, 95% 
      CI 0.59-1.29), but positively associated with all-cause mortality (HR 1.21, 95% 
      CI 0.99-1.48); the CIs included the null values. The HRs, however, were more 
      pronounced for the highest level of duration, frequency, regularity, and timing 
      for all-cause, but not breast cancer-specific mortality. Interactions with BMI 
      revealed no significant heterogeneity (p(interaction) = 0.37 and 
      p(interaction) = 0.36, respectively). CONCLUSION: Pre-diagnosis aspirin use was 
      not strongly associated with mortality following breast cancer. The all-cause 
      mortality associations, however, were slightly stronger when we considered 
      patterns of use.
FAU - Wang, Tengteng
AU  - Wang T
AUID- ORCID: 0000-0001-9001-186X
AD  - Department of Epidemiology, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill, NC, 27599, USA. tengteng_wang@med.unc.edu.
AD  - Department of Epidemiology, UNC, 2101 McGavran-Greenberg Hall, CB #7435, Chapel 
      Hill, NC, 27599-7435, USA. tengteng_wang@med.unc.edu.
FAU - Parada, Humberto
AU  - Parada H
AD  - Department of Epidemiology, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill, NC, 27599, USA.
FAU - McClain, Kathleen M
AU  - McClain KM
AD  - Department of Epidemiology, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill, NC, 27599, USA.
FAU - Bradshaw, Patrick T
AU  - Bradshaw PT
AD  - Division of Epidemiology, School of Public Health, University of California 
      Berkeley, Berkeley, CA, 94720, USA.
FAU - Terry, Mary Beth
AU  - Terry MB
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, 
      New York, NY, 10032, USA.
FAU - Teitelbaum, Susan L
AU  - Teitelbaum SL
AD  - Department of Preventive Medicine, Icahn School of Medicine at Mount Sinai, New 
      York, NY, 10029, USA.
FAU - Neugut, Alfred I
AU  - Neugut AI
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University, 
      New York, NY, 10032, USA.
AD  - Department of Medicine, College of Physicians and Surgeons, Columbia University, 
      New York, NY, 10032, USA.
FAU - Gammon, Marilie D
AU  - Gammon MD
AD  - Department of Epidemiology, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill, NC, 27599, USA.
LA  - eng
PT  - Journal Article
DEP - 20180307
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - R16CO5Y76E (Aspirin)
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage
MH  - Body Mass Index
MH  - Breast Neoplasms/*diagnosis
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Obesity/*epidemiology
MH  - Proportional Hazards Models
MH  - Young Adult
OTO - NOTNLM
OT  - Aspirin
OT  - Body mass index
OT  - Breast cancer
OT  - Mortality
OT  - NSAIDs
OT  - Obesity
EDAT- 2018/03/09 06:00
MHDA- 2019/07/30 06:00
CRDT- 2018/03/09 06:00
PHST- 2017/05/30 00:00 [received]
PHST- 2018/03/02 00:00 [accepted]
PHST- 2018/03/09 06:00 [pubmed]
PHST- 2019/07/30 06:00 [medline]
PHST- 2018/03/09 06:00 [entrez]
AID - 10.1007/s10552-018-1020-5 [pii]
AID - 10.1007/s10552-018-1020-5 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2018 May;29(4-5):417-425. doi: 10.1007/s10552-018-1020-5. 
      Epub 2018 Mar 7.

PMID- 17544159
OWN - NLM
STAT- MEDLINE
DCOM- 20080731
LR  - 20131121
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 127
IP  - 1
DP  - 2008 Jun 23
TI  - Chronic pharmacological treatment in takotsubo cardiomyopathy.
PG  - 121-3
AB  - BACKGROUND: Takotsubo cardiomyopathy is a disorder that has been appreciated only 
      recently. In most of reported cases, this syndrome mimes an acute myocardial 
      infarction. Till this moment no data are available from literature about the 
      treatment in the acute phase of this disease. AIM OF THE STUDY: In our 
      multicentric experience we have retrospectively looked at the benefits of a 
      treatment with ACE-inhibitors, beta-blockers, Aspirin and calcium channels 
      blockers, started until the early phases of the disease and continued for 30 
      days, in 36 patients affected by Takotsubo cardiomyopathy. We chose as endpoint 
      of the study the efficacy of the used drug in improving left ventricular 
      myocardial function and the rapidity of the effects of the same drug.bethods: 
      from an international registry about the Takotsubo cardiomiopathy, co-ordinate by 
      our research group, we evaluated the long term efficacy of some drugs, 
      administrated like single treatment in some patients. RESULTS: Obtained data did 
      not show any statistically significant difference in the percentages of 
      improvement in the left ventricle ejection fraction evaluated at the admission to 
      the hospital, before the discharge and after 30 days of treatment between each 
      treated group and the control group of non-treated patients. No significant 
      differences were found in hospitalization times between treated patients and 
      controls. None of our patients experienced during the observation period a 
      relapse of the disease. CONCLUSIONS: The results of our survey suggest that a 
      chronic treatment with beta-blockers, ACE-inhibitors, calcium channels blockers 
      and aspirin does not provide any benefit in patients with Takotsubo 
      cardiomyopathy. Thus, it seem to be important an early correct differential 
      diagnosis to avoid any chronic treatment in these patients.
FAU - Fazio, Giovanni
AU  - Fazio G
FAU - Pizzuto, Caterina
AU  - Pizzuto C
FAU - Barbaro, Giuseppe
AU  - Barbaro G
FAU - Sutera, Loredana
AU  - Sutera L
FAU - Incalcaterra, Egle
AU  - Incalcaterra E
FAU - Evola, Giovanna
AU  - Evola G
FAU - Azzarelli, Salvatore
AU  - Azzarelli S
FAU - Palecek, Tomas
AU  - Palecek T
FAU - Di Gesaro, Gabriele
AU  - Di Gesaro G
FAU - Cascio, Caterina
AU  - Cascio C
FAU - Novo, Giuseppina
AU  - Novo G
FAU - Akashi, Yoshihiro J
AU  - Akashi YJ
FAU - Novo, Salvatore
AU  - Novo S
LA  - eng
PT  - Letter
PT  - Multicenter Study
DEP - 20070601
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Calcium Channel Blockers)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Int J Cardiol. 2009 Jan 9;131(2):265-6. PMID: 17651835
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Calcium Channel Blockers/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Retrospective Studies
MH  - Takotsubo Cardiomyopathy/*drug therapy
MH  - Treatment Outcome
EDAT- 2007/06/05 09:00
MHDA- 2008/08/01 09:00
CRDT- 2007/06/05 09:00
PHST- 2007/01/06 00:00 [received]
PHST- 2007/04/01 00:00 [accepted]
PHST- 2007/06/05 09:00 [pubmed]
PHST- 2008/08/01 09:00 [medline]
PHST- 2007/06/05 09:00 [entrez]
AID - S0167-5273(07)00857-1 [pii]
AID - 10.1016/j.ijcard.2007.04.013 [doi]
PST - ppublish
SO  - Int J Cardiol. 2008 Jun 23;127(1):121-3. doi: 10.1016/j.ijcard.2007.04.013. Epub 
      2007 Jun 1.

PMID- 3312930
OWN - NLM
STAT- MEDLINE
DCOM- 19871214
LR  - 20220318
IS  - 0113-5244 (Print)
IS  - 0113-5244 (Linking)
VI  - 2
IP  - 5
DP  - 1987 Sep-Oct
TI  - Aspirin, paracetamol and non-steroidal anti-inflammatory drugs. A comparative 
      review of side effects.
PG  - 338-66
AB  - Non-steroidal anti-inflammatory drugs (NSAIDs) effectively control the symptoms 
      of many of the rheumatic diseases although they have little effect on the 
      underlying causes. Their effect is mainly on the mediators of the inflammatory 
      process. Unfortunately, these mediators have important physiological roles in the 
      maintenance of health, particularly in the gastrointestinal tract and the kidney, 
      so that their inhibition results in many unwanted reactions of varying severity. 
      The mechanisms underlying these reactions are described. Their occurrence varies, 
      both qualitatively and quantitatively, and an attempt is made to assess these 
      differences, although it may be that they are related directly to differences in 
      dosage and therapeutic efficacy. In addition, immunologically mediated adverse 
      reactions occur. These mechanisms are outlined and related to the clinical 
      picture. There are considerable differences in frequency of reactions between the 
      compounds: in particular there is a wide variation in the rate of dermatological 
      reactions of this type. Agranulocytosis has been particularly associated with the 
      pyrazolone compounds, although it has been reported with most others. Aplastic 
      anaemia, which may not be an immune-mediated reaction, is also thought of as a 
      pyrazolone reaction, but the incidence with indomethacin approaches a similar 
      level. Although all drugs analysed may cause hepatic reactions, these are rare 
      except with the now withdrawn benoxaprofen. Several types of immunologically 
      mediated renal reactions occur and these rarities are also described. Paracetamol 
      does not have any effect on the inflammatory mediators. Anxieties about this 
      substance relates to the parent compound phenacetin and its necrotic effect on 
      the renal papillae. There is extensive literature on this subject concerning not 
      only paracetamol, but also aspirin and other NSAIDs. This is also assessed and 
      summarised. The danger of paracetamol as a direct hepatic toxin in self-poisoning 
      is discussed. Novel NSAIDs are introduced and others withdrawn with frequent and 
      monotonous regularity. Sometimes the reasons have some medical or scientific 
      plausibility, but often they are over-reactions by registration authorities or 
      pharmaceutical companies in response to uninformed media publicity. The problems 
      of the numerically and scientifically accurate collection and assessment of 
      adverse reaction data are legion and as a result useful agents have been lost. 
      Some of these difficulties are described, and some non-drug 'adverse reactions' 
      are described.(ABSTRACT TRUNCATED AT 400 WORDS)
FAU - Fowler, P D
AU  - Fowler PD
AD  - Staffordshire Rheumatolog Centre, Burslem, Haywood & Tunstall War Memorial 
      Hospital, Stoke-on-Trent.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Med Toxicol Adverse Drug Exp
JT  - Medical toxicology and adverse drug experience
JID - 8709214
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/*adverse effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Drug Hypersensitivity/etiology
MH  - Humans
RF  - 113
EDAT- 1987/09/01 00:00
MHDA- 1987/09/01 00:01
CRDT- 1987/09/01 00:00
PHST- 1987/09/01 00:00 [pubmed]
PHST- 1987/09/01 00:01 [medline]
PHST- 1987/09/01 00:00 [entrez]
AID - 10.1007/BF03259953 [doi]
PST - ppublish
SO  - Med Toxicol Adverse Drug Exp. 1987 Sep-Oct;2(5):338-66. doi: 10.1007/BF03259953.

PMID- 3426738
OWN - NLM
STAT- MEDLINE
DCOM- 19880323
LR  - 20221207
IS  - 1358-6173 (Print)
IS  - 1358-6173 (Linking)
VI  - 1
DP  - 1987
TI  - Aspirin attenuation of alcohol-induced flushing and intoxication in Oriental and 
      Occidental subjects.
PG  - 595-9
AB  - Aspirin (ASA) was tested in a group of 8 Oriental and 3 Occidental subjects who 
      were shown in a previous study to respond to small doses of ethanol (0.06-0.25 
      g/kg) with facial flushing. They were compared to a similar group of 11 
      non-flushing Occidental subjects following a larger ethanol dose (0.37 g/kg) to 
      determine if similar effects could be produced in less sensitive individuals. 
      Control tests of blood ethanol and acetaldehyde (AcH) levels (calculated from 
      breath), facial and neck skin temperatures, body sway (Romberg test), blood 
      pressure, heart rate and 10 Subjective High Assessment Scales (SHAS-Judd, 1977) 
      were conducted before and at 15, 30, 60 and 90 minutes after drinking ethanol as 
      vodka in orange juice. The tests were repeated one week later one hour after 
      receiving 0.64 gm of ASA orally. ASA produced slight changes in the early 
      absorption of ethanol and small decreases in AcH levels in the flushing and 
      non-flushing groups. Facial flushing was markedly reduced in the flushing group, 
      but was slightly increased in the non-flushing Occidentals. Body sway was reduced 
      by ASA in both groups. An alcohol-induced increase in heart rate in the flushing 
      group was reduced with no change in blood pressure. SHAS subjective parameters 
      were widely variable, but indicated that ASA produced reduced sleepiness and 
      earlier relaxation in the flushing group. It is concluded that ASA can block 
      alcohol-induced facial flushing in sensitive subjects and also reduces body sway 
      in the Romberg test and alters some subjective feelings of alcohol intoxication.
FAU - Truitt, E B Jr
AU  - Truitt EB Jr
AD  - Department of Pharmacology, Northeastern Ohio Universities College of Medicine, 
      Rootstown 44272.
FAU - Gaynor, C R
AU  - Gaynor CR
FAU - Mehl, D L
AU  - Mehl DL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Alcohol Alcohol Suppl
JT  - Alcohol and alcoholism (Oxford, Oxfordshire). Supplement
JID - 8804836
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Alcoholic Intoxication
MH  - Asian People
MH  - Aspirin/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Ethanol/*antagonists & inhibitors/pharmacology
MH  - Flushing/*chemically induced
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Skin Temperature/drug effects
MH  - White People
EDAT- 1987/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Alcohol Alcohol Suppl. 1987;1:595-9.

PMID- 36228060
OWN - NLM
STAT- MEDLINE
DCOM- 20221017
LR  - 20221222
IS  - 1544-1717 (Electronic)
IS  - 1544-1709 (Print)
IS  - 1544-1709 (Linking)
VI  - 20
IP  - 5
DP  - 2022 Sep-Oct
TI  - Effective Facilitator Strategies for Supporting Primary Care Practice Change: A 
      Mixed Methods Study.
PG  - 414-422
LID - 10.1370/afm.2847 [doi]
AB  - PURPOSE: Practice facilitation is an evidence-informed implementation strategy to 
      support quality improvement (QI) and aid practices in aligning with best 
      evidence. Few studies, particularly of this size and scope, identify strategies 
      that contribute to facilitator effectiveness. METHODS: We conducted a sequential 
      mixed methods study, analyzing data from EvidenceNOW, a large-scale QI 
      initiative. Seven regional cooperatives employed 162 facilitators to work with 
      1,630 small or medium-sized primary care practices. Main analyses were based on 
      facilitators who worked with at least 4 practices. Facilitators were defined as 
      more effective if at least 75% of their practices improved on at least 1 outcome 
      measure-aspirin use, blood pressure control, smoking cessation counseling (ABS), 
      or practice change capacity, measured using Change Process Capability 
      Questionnaire-from baseline to follow-up. Facilitators were defined as less 
      effective if less than 50% of their practices improved on these outcomes. Using 
      an immersion crystallization and comparative approach, we analyzed observational 
      and interview data to identify strategies associated with more effective 
      facilitators. RESULTS: Practices working with more effective facilitators had a 
      3.6% greater change in the mean percentage of patients meeting the composite ABS 
      measure compared with practices working with less effective facilitators (P 
      <.001). More effective facilitators cultivated motivation by tailoring QI work 
      and addressing resistance, guided practices to think critically, and provided 
      accountability to support change, using these strategies in combination. They 
      were able to describe their work in detail. In contrast, less effective 
      facilitators seldom used these strategies and described their work in general 
      terms. Facilitator background, experience, and work on documentation did not 
      differentiate between more and less effective facilitators. CONCLUSIONS: 
      Facilitation strategies that differentiate more and less effective facilitators 
      have implications for enhancing facilitator development and training, and can 
      assist all facilitators to more effectively support practice changes.
CI  - © 2022 Annals of Family Medicine, Inc.
FAU - Sweeney, Shannon M
AU  - Sweeney SM
AD  - Department of Family Medicine, Oregon Health &amp; Science University, Portland, 
      Oregon sweenesh@ohsu.edu.
FAU - Baron, Andrea
AU  - Baron A
AD  - Department of Family Medicine, Oregon Health &amp; Science University, Portland, 
      Oregon.
FAU - Hall, Jennifer D
AU  - Hall JD
AD  - Department of Family Medicine, Oregon Health &amp; Science University, Portland, 
      Oregon.
FAU - Ezekiel-Herrera, David
AU  - Ezekiel-Herrera D
AD  - Department of Family Medicine, Oregon Health &amp; Science University, Portland, 
      Oregon.
FAU - Springer, Rachel
AU  - Springer R
AD  - Department of Family Medicine, Oregon Health &amp; Science University, Portland, 
      Oregon.
FAU - Ward, Rikki L
AU  - Ward RL
AD  - Department of Epidemiology, Human Genetics, and Environmental Science, UTHealth 
      School of Public Health, Dallas, Texas.
FAU - Marino, Miguel
AU  - Marino M
AD  - Department of Family Medicine, Oregon Health &amp; Science University, Portland, 
      Oregon.
FAU - Balasubramanian, Bijal A
AU  - Balasubramanian BA
AD  - Department of Epidemiology, Human Genetics, and Environmental Science, UTHealth 
      School of Public Health, Dallas, Texas.
FAU - Cohen, Deborah J
AU  - Cohen DJ
AD  - Department of Family Medicine, Oregon Health &amp; Science University, Portland, 
      Oregon.
LA  - eng
SI  - ClinicalTrials.gov/NCT02560428
GR  - R01 HS023940/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Fam Med
JT  - Annals of family medicine
JID - 101167762
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - Delivery of Health Care
MH  - Humans
MH  - *Primary Health Care
MH  - *Quality Improvement
PMC - PMC9512557
OTO - NOTNLM
OT  - capacity building
OT  - implementation facilitation
OT  - large-scale initiative
OT  - organizational change
OT  - organizational innovation
OT  - practice facilitation
OT  - quality improvement
EDAT- 2022/10/14 06:00
MHDA- 2022/10/18 06:00
CRDT- 2022/10/13 14:23
PHST- 2021/06/02 00:00 [received]
PHST- 2022/03/16 00:00 [revised]
PHST- 2022/05/04 00:00 [accepted]
PHST- 2022/10/13 14:23 [entrez]
PHST- 2022/10/14 06:00 [pubmed]
PHST- 2022/10/18 06:00 [medline]
AID - 20/5/414 [pii]
AID - 10.1370/afm.2847 [doi]
PST - ppublish
SO  - Ann Fam Med. 2022 Sep-Oct;20(5):414-422. doi: 10.1370/afm.2847.

PMID- 25274620
OWN - NLM
STAT- MEDLINE
DCOM- 20151214
LR  - 20181202
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 113
IP  - 2
DP  - 2015 Feb
TI  - Perioperative management of oral antiplatelet therapy and clinical outcomes in 
      coronary stent patients undergoing surgery. Results of a multicentre registry.
PG  - 272-82
LID - 10.1160/TH14-05-0436 [doi]
AB  - The aim was to investigate the perioperative risk of ischaemic and bleeding 
      events in patients with coronary stents undergoing cardiac and non-cardiac 
      surgery and how these outcomes are affected by the perioperative use of oral 
      antiplatelet therapy. This was a multicentre, retrospective, observational study 
      conducted in patients with coronary stent(s) undergoing cardiac or non-cardiac 
      surgery. The primary efficacy endpoint was the 30-day incidence of major adverse 
      cardiac events (MACE), defined as the composite of cardiac death, myocardial 
      infarction (MI) or stroke. The primary safety endpoint was the 30-day incidence 
      of Bleeding Academic Research Consortium (BARC) bleeding ≥ 2. A total of 666 
      patients were included. Of these, 371 (55.7 %) discontinued their antiplatelet 
      medication(s) (all or partly) before undergoing surgery. At 30 days, patients 
      with perioperative discontinuation of antiplatelet therapy experienced a 
      significantly higher incidence of MACE (7.5 % vs 0.3 %, p< 0.001), cardiac death 
      (2.7 % vs 0.3 %, p=0.027), and MI (4.0 % vs 0 %, p< 0.001). After adjustment, 
      peri-operative antiplatelet discontinuation was the strongest independent 
      predictor of 30-day MACE (odds ratio [OR]=25.8, confidence interval 
      [CI]=3.37-198, p=0.002). Perioperative aspirin (adjusted OR 0.27, 95 % CI 
      0.11-0.71, p=0.008) was significantly associated with a lower risk of MACE. The 
      overall incidence of BARC ≥ 2 bleeding events at 30-days was significantly higher 
      in patients who discontinued oral antiplatelet therapy (25.6 % vs 13.9 %, 
      p< 0.001). However, after adjustment, antiplatelet discontinuation was not 
      independently associated with BARC ≥ 2 bleeding. In conclusion antiplatelet 
      discontinuation increases the 30-day risk of MACE, in patients with coronary 
      stents undergoing cardiac and non-cardiac surgery, while not offering significant 
      protection from BARC≥ 2 bleeding.
FAU - Rossini, Roberta
AU  - Rossini R
AD  - Roberta Rossini, MD, PhD, Cardiovascular Department, A. O. PAPA GIOVANNI XXIII, 
      Piazza OMS, 1, 24127 Bergamo, Italy, Tel.: +39 035 2673446, E-mail: 
      roberta.rossini2@gmail.com.
FAU - Musumeci, Giuseppe
AU  - Musumeci G
FAU - Capodanno, Davide
AU  - Capodanno D
FAU - Lettieri, Corrado
AU  - Lettieri C
FAU - Limbruno, Ugo
AU  - Limbruno U
FAU - Tarantini, Giuseppe
AU  - Tarantini G
FAU - Russo, Nicolina
AU  - Russo N
FAU - Calabria, Paolo
AU  - Calabria P
FAU - Romano, Michele
AU  - Romano M
FAU - Inashvili, Ana
AU  - Inashvili A
FAU - Sirbu, Vasile
AU  - Sirbu V
FAU - Guagliumi, Giulio
AU  - Guagliumi G
FAU - Valsecchi, Orazio
AU  - Valsecchi O
FAU - Senni, Michele
AU  - Senni M
FAU - Gavazzi, Antonello
AU  - Gavazzi A
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20141002
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Angina, Stable/therapy
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Body Mass Index
MH  - Clopidogrel
MH  - Drug-Eluting Stents
MH  - Female
MH  - Hemorrhage/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/therapy
MH  - Odds Ratio
MH  - Percutaneous Coronary Intervention/methods
MH  - *Perioperative Period
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prevalence
MH  - Registries
MH  - Regression Analysis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stents
MH  - Ticlopidine/analogs & derivatives/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - PCI
OT  - antiplatelet therapy
OT  - coronary artery disease
OT  - stent
OT  - surgery
EDAT- 2014/10/03 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/10/03 06:00
PHST- 2014/05/14 00:00 [received]
PHST- 2014/08/27 00:00 [accepted]
PHST- 2014/10/03 06:00 [entrez]
PHST- 2014/10/03 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 14-05-0436 [pii]
AID - 10.1160/TH14-05-0436 [doi]
PST - ppublish
SO  - Thromb Haemost. 2015 Feb;113(2):272-82. doi: 10.1160/TH14-05-0436. Epub 2014 Oct 
      2.

PMID- 29972884
OWN - NLM
STAT- MEDLINE
DCOM- 20190403
LR  - 20190403
IS  - 1600-0412 (Electronic)
IS  - 0001-6349 (Linking)
VI  - 97
IP  - 11
DP  - 2018 Nov
TI  - Acetylsalicylic acid does not prevent first-trimester unexplained recurrent 
      pregnancy loss: A randomized controlled trial.
PG  - 1365-1372
LID - 10.1111/aogs.13420 [doi]
AB  - INTRODUCTION: Recurrent pregnancy loss occurs in about 1% of fertile couples. 
      Without proper evidence for an effect, different treatments have been used when 
      no etiological factor has been detected. The present trial is the first 
      randomized trial to compare 75 mg acetylsalicylic acid with placebo for women 
      with recurrent pregnancy loss. MATERIAL AND METHODS: This randomized, 
      double-blind, placebo-controlled trial was conducted at a single center between 
      2008 and 2015. Recurrent pregnancy loss was defined as at least 3 consecutive 
      first-trimester miscarriages within the couple. Women < 40 years old with a body 
      mass index < 35 kg/m(2) were eligible if the workup was negative. Randomization 
      was through a third party, who manufactured and delivered the study drugs, and 
      occurred when fetal heartbeat was detected, to either 75 mg acetylsalicylic acid 
      or placebo; 200 women in each group. Group allocation was concealed until all the 
      study participants had a pregnancy outcome registered. All women attended the 
      same control program. Primary outcome was live birth. Statistical analyses were 
      according to intention-to-treat. RESULTS: All 400 women completed the follow up. 
      Live birth rate was 83.0% (n = 166) and 85.5% (n = 171) for the acetylsalicylic 
      acid and placebo groups, respectively (P = 0.58). The difference was -2.5% (95% 
      CI -10.1% to 5.1%). The risk ratio was 0.97 (95% CI 0.89-1.06). CONCLUSIONS: 
      Treatment with acetylsalicylic acid did not prevent recurrent miscarriage in 
      women with at least three consecutive miscarriages in the first trimester, of 
      unknown reasons and in the same relationship. The fertility prognosis is very 
      good, the live birth rate being > 80% with or without acetylsalicylic acid.
CI  - © 2018 Nordic Federation of Societies of Obstetrics and Gynecology.
FAU - Blomqvist, Lennart
AU  - Blomqvist L
AUID- ORCID: 0000-0002-4736-1925
AD  - Department of Obstetrics and Gynecology, Institute of Clinical Sciences, 
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
AD  - Department of Obstetrics and Gynecology, Södra Älvsborg Hospital, Borås, Sweden.
FAU - Hellgren, Margareta
AU  - Hellgren M
AD  - Department of Obstetrics and Gynecology, Institute of Clinical Sciences, 
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
AD  - Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, 
      Gothenburg, Sweden.
FAU - Strandell, Annika
AU  - Strandell A
AUID- ORCID: 0000-0003-1647-5388
AD  - Department of Obstetrics and Gynecology, Institute of Clinical Sciences, 
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
AD  - Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, 
      Gothenburg, Sweden.
LA  - eng
GR  - Västra Götaland Region/
GR  - Göteborg Medical Society/
GR  - Focus Foundation, Borås/
GR  - Sparbanksstiftelsen Sjuhärad, Borås/
GR  - Alice Swenzon's research foundation/
GR  - Jane and Dan Olsson's foundation for scientific research/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20180809
PL  - United States
TA  - Acta Obstet Gynecol Scand
JT  - Acta obstetricia et gynecologica Scandinavica
JID - 0370343
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*prevention & control
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pregnancy
MH  - *Pregnancy Trimester, First
MH  - Treatment Outcome
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - early pregnancy
OT  - first trimester
OT  - live birth
OT  - recurrent miscarriage
EDAT- 2018/07/05 06:00
MHDA- 2019/04/04 06:00
CRDT- 2018/07/05 06:00
PHST- 2018/03/23 00:00 [received]
PHST- 2018/06/28 00:00 [accepted]
PHST- 2018/07/05 06:00 [pubmed]
PHST- 2019/04/04 06:00 [medline]
PHST- 2018/07/05 06:00 [entrez]
AID - 10.1111/aogs.13420 [doi]
PST - ppublish
SO  - Acta Obstet Gynecol Scand. 2018 Nov;97(11):1365-1372. doi: 10.1111/aogs.13420. 
      Epub 2018 Aug 9.

PMID- 6576966
OWN - NLM
STAT- MEDLINE
DCOM- 19831021
LR  - 20190501
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 24
IP  - 9
DP  - 1983 Sep
TI  - Effects of non-steroidal anti-inflammatory drugs and prostaglandins on alkali 
      secretion by rabbit gastric fundus in vitro.
PG  - 784-9
AB  - The effects of non-steroidal anti-inflammatory drugs and prostaglandins E(2) and 
      F(2alpha) on the secretory and electrical activity of isolated rabbit fundic 
      mucosa have been studied. Spontaneous acid secretion was inhibited by serosal 
      side application of sodium thiocyanate (6x10(-2)M) and the resulting alkali 
      secretion measured by pH stat tiration. Serosal side application of indomethacin 
      (10(-5)M) or aspirin (3x10(-3)M) inhibited alkali secretion (0.55+/-0.06 to 
      0.12+/-0.06 mumol/cm(2)/h, n=6, p<0.01 and 0.28+/-0.06 to 0.11+/-0.03 
      mumol/cm(2)/h, n=7, p<0.02 respectively). Mucosal or serosal side prostaglandin 
      E(2) (10(-5) to 10(-10)M) and F(2alpha) (10(-4) to 10(-10)M) failed to alter the 
      rate of alkalinisation but secretion was significantly increased by serosal side 
      16,16-dimethyl-prostaglandin E(2) (10(-6)M) (0.90+/-0.20 to 1.50+/-0.30 
      mumol/cm(2)/h, n=6, p<0.01). Serosal side application of 10(-6)M prostaglandin 
      E(2) to fundic mucosae pretreated with either aspirin (5x10(-3)M) or indomethacin 
      (10(-5)M), to reduce endogenous E(2) formation, also failed to alter alkali 
      secretion. Pretreatment of the mucosa with 16,16-dimethyl-E(2) (10(-6)M) 
      abolished the inhibitory effect of indomethacin (10(-5)M) on alkali secretion 
      (n=6) but did not modify the secretory response to aspirin (3x10(-3)M) (fall in 
      alkali secretion with aspirin = 81+/-11% and with aspirin plus 
      16,16-dimethyl-E(2) = 72+/-10%, n=7). In the doses used, none of the 
      prostaglandins or non-steroidal anti-inflammatory drugs altered transmucosal 
      potential difference or electrical resistance. These results show that the 
      damaging agents, aspirin and indomethacin, both inhibit gastric alkali secretion 
      but that modes of action may differ. The observation that prostaglandins, E(2) 
      and F(2alpha) failed to increase alkali production suggests that their protective 
      activity against a variety of damaging agents as shown by others, may be mediated 
      by another mechanism.
FAU - Rees, W D
AU  - Rees WD
FAU - Gibbons, L C
AU  - Gibbons LC
FAU - Turnberg, L A
AU  - Turnberg LA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Alkalies)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Prostaglandins E)
RN  - 0 (Prostaglandins F)
RN  - B7IN85G1HY (Dinoprost)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Alkalies/*metabolism
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/pharmacology
MH  - Dinoprost
MH  - Dinoprostone
MH  - Gastric Fundus/*drug effects
MH  - In Vitro Techniques
MH  - Indomethacin/pharmacology
MH  - Mucous Membrane/drug effects
MH  - Prostaglandins E/*pharmacology
MH  - Prostaglandins F/*pharmacology
MH  - Rabbits
MH  - Serous Membrane/drug effects
PMC - PMC1420083
EDAT- 1983/09/01 00:00
MHDA- 1983/09/01 00:01
CRDT- 1983/09/01 00:00
PHST- 1983/09/01 00:00 [pubmed]
PHST- 1983/09/01 00:01 [medline]
PHST- 1983/09/01 00:00 [entrez]
AID - 10.1136/gut.24.9.784 [doi]
PST - ppublish
SO  - Gut. 1983 Sep;24(9):784-9. doi: 10.1136/gut.24.9.784.

PMID- 25920994
OWN - NLM
STAT- MEDLINE
DCOM- 20160617
LR  - 20150908
IS  - 1938-0682 (Electronic)
IS  - 1558-7673 (Linking)
VI  - 13
IP  - 5
DP  - 2015 Oct
TI  - Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in 
      Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.
PG  - 441-6
LID - S1558-7673(15)00069-5 [pii]
LID - 10.1016/j.clgc.2015.03.004 [doi]
AB  - BACKGROUND: The aim of this phase 2 study was to evaluate the activity and 
      tolerability of low-dose estramustine phosphate (EMP) with concomitant low-dose 
      acetylsalicylic acid (ASA) as a thromboprophylactic agent in heavily pretreated 
      patients with advanced castration-resistant prostate cancer. METHODS: Patients 
      received 420 mg of oral EMP twice daily and oral ASA 100 mg once daily. The 
      primary endpoint was prostate-specific antigen response. All of the patients had 
      been previously treated with docetaxel and abiraterone acetate, and 12 had also 
      received cabazitaxel. RESULTS: Thirty-one patients were enrolled. 
      Prostate-specific antigen response was observed in 9 patients (29.0%; 95% 
      confidence interval [CI], 14-48). Median progression-free survival was 3.6 months 
      (95% CI, 2.2-5.6), and median overall survival was 7.6 months (95% CI, 6.9-9.7). 
      Treatment was generally well tolerated, and no grade 3/4 toxicity was observed. 
      Ten patients (32.2%) had grade 2 nausea and vomiting. No cardiovascular event and 
      no major bleeding occurred. No venous thromboembolism event was observed. 
      CONCLUSION: Low-dose EMP with concomitant low-dose ASA seems to be a safe 
      treatment option with some activity for patients with advanced 
      castration-resistant prostate cancer who have been heavily pretreated.
CI  - Copyright © 2015 Elsevier Inc. All rights reserved.
FAU - Petrioli, Roberto
AU  - Petrioli R
AD  - Medical Oncology Unit, Santa Maria alle Scotte Hospital, University of Siena, 
      Italy. Electronic address: r.petrioli@ao-siena.toscana.it.
FAU - Roviello, Giandomenico
AU  - Roviello G
AD  - Medical Oncology Unit, Santa Maria alle Scotte Hospital, University of Siena, 
      Italy.
FAU - Fiaschi, Anna I
AU  - Fiaschi AI
AD  - Pharmacology Unit, Santa Maria alle Scotte Hospital, University of Siena, Italy.
FAU - Laera, Letizia
AU  - Laera L
AD  - Medical Oncology Unit, Santa Maria alle Scotte Hospital, University of Siena, 
      Italy.
FAU - Bianco, Vincenzo
AU  - Bianco V
AD  - Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Rome, 
      Italy.
FAU - Ponchietti, Roberto
AU  - Ponchietti R
AD  - Urological and Andrological Unit, Santa Maria alle Scotte Hospital, University of 
      Siena, Italy.
FAU - Barbanti, Gabriele
AU  - Barbanti G
AD  - Department of Urology, Santa Maria alle Scotte Hospital, University of Siena, 
      Italy.
FAU - Francini, Edoardo
AU  - Francini E
AD  - Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Rome, 
      Italy.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20150326
PL  - United States
TA  - Clin Genitourin Cancer
JT  - Clinical genitourinary cancer
JID - 101260955
RN  - 35LT29625A (Estramustine)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Drug Administration Schedule
MH  - Estramustine/*administration & dosage/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostate-Specific Antigen/metabolism
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy/metabolism
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Abiraterone
OT  - Cabazitaxel
OT  - Castration-resistant prostate cancer
OT  - Estramustine
OT  - Thromboembolism
EDAT- 2015/04/30 06:00
MHDA- 2016/06/18 06:00
CRDT- 2015/04/30 06:00
PHST- 2015/02/04 00:00 [received]
PHST- 2015/03/16 00:00 [revised]
PHST- 2015/03/18 00:00 [accepted]
PHST- 2015/04/30 06:00 [entrez]
PHST- 2015/04/30 06:00 [pubmed]
PHST- 2016/06/18 06:00 [medline]
AID - S1558-7673(15)00069-5 [pii]
AID - 10.1016/j.clgc.2015.03.004 [doi]
PST - ppublish
SO  - Clin Genitourin Cancer. 2015 Oct;13(5):441-6. doi: 10.1016/j.clgc.2015.03.004. 
      Epub 2015 Mar 26.

PMID- 22225858
OWN - NLM
STAT- MEDLINE
DCOM- 20121203
LR  - 20151119
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 130
IP  - 2
DP  - 2012 Aug
TI  - Concomitant use of medication with antiplatelet effects in patients receiving 
      either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
PG  - 147-51
LID - 10.1016/j.thromres.2011.12.005 [doi]
AB  - INTRODUCTION: The RECORD programme compared oral rivaroxaban with enoxaparin for 
      prevention of venous thromboembolism after elective total hip or knee 
      replacement. This analysis compared the safety of concomitant use of specified 
      medications with rivaroxaban and enoxaparin by evaluating postoperative bleeding 
      rates from the pooled RECORD1-4 data. MATERIALS AND METHODS: The co-medications 
      were non-steroidal anti-inflammatory drugs and platelet function inhibitors, 
      including acetylsalicylic acid (no dose restriction). The endpoints evaluated 
      were the composite of major and non-major clinically relevant bleeding and any 
      bleeding occurring after first oral study drug intake. The time relative to 
      surgery was stratified into three time periods: day 1-3, day 4-7 and after day 7. 
      Relative bleeding rate ratios for co-medication use versus non-use were derived 
      using stratified Mantel-Haenszel methods and compared between rivaroxaban and 
      enoxaparin groups. RESULTS: Co-medication use with rivaroxaban or enoxaparin 
      resulted in non-significant increases in bleeding events. Respective rate ratios 
      were not significantly different between rivaroxaban and enoxaparin for all 
      bleeding endpoints with concomitant use of non-steroidal anti-inflammatory drugs 
      (any bleeding, 1.22 vs 1.22; major and non-major clinically relevant bleeding, 
      1.28 vs 0.90) and with concomitant use of platelet function 
      inhibitors/acetylsalicylic acid (any bleeding, 1.32 vs 1.40; major and non-major 
      clinically relevant bleeding, 1.11 vs 1.13). CONCLUSIONS: This explorative 
      analysis indicates that there is no significant increase in bleeding risk for 
      rivaroxaban compared with enoxaparin when co-administered with non-steroidal 
      anti-inflammatory drugs or acetylsalicylic acid, although, because of low usage, 
      the experience with platelet function inhibitors (except acetylsalicylic acid) 
      was limited.
CI  - Copyright © 2012 Elsevier Ltd. All rights reserved.
FAU - Eriksson, Bengt I
AU  - Eriksson BI
AD  - Department of Orthopaedics, Sahlgrenska University Hospital/Mölndal, Mölndal, 
      Sweden. b.eriksson@orthop.gu.se
FAU - Rosencher, Nadia
AU  - Rosencher N
FAU - Friedman, Richard J
AU  - Friedman RJ
FAU - Homering, Martin
AU  - Homering M
FAU - Dahl, Ola E
AU  - Dahl OE
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120105
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Morpholines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thiophenes)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Drug Interactions
MH  - Enoxaparin/pharmacology/*therapeutic use
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Morpholines/pharmacology/*therapeutic use
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Rivaroxaban
MH  - Thiophenes/pharmacology/*therapeutic use
MH  - Venous Thromboembolism/etiology/*prevention & control
EDAT- 2012/01/10 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/01/10 06:00
PHST- 2011/10/14 00:00 [received]
PHST- 2011/11/30 00:00 [revised]
PHST- 2011/12/04 00:00 [accepted]
PHST- 2012/01/10 06:00 [entrez]
PHST- 2012/01/10 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S0049-3848(11)00655-4 [pii]
AID - 10.1016/j.thromres.2011.12.005 [doi]
PST - ppublish
SO  - Thromb Res. 2012 Aug;130(2):147-51. doi: 10.1016/j.thromres.2011.12.005. Epub 
      2012 Jan 5.

PMID- 16246947
OWN - NLM
STAT- MEDLINE
DCOM- 20060302
LR  - 20181201
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 112
IP  - 18
DP  - 2005 Nov 1
TI  - Pioglitazone reduces neointima volume after coronary stent implantation: a 
      randomized, placebo-controlled, double-blind trial in nondiabetic patients.
PG  - 2792-8
AB  - BACKGROUND: Restenosis requiring reintervention limits the long-term success 
      after coronary stent implantation. Thiazolidinediones, like pioglitazone or 
      rosiglitazone, are oral antidiabetic drugs with additional antirestenotic 
      properties. In a randomized, placebo-controlled, double-blind trial, we examined 
      the effect of 6-month pioglitazone therapy on neointima volume after coronary 
      stenting in nondiabetic coronary artery disease patients. METHODS AND RESULTS: 
      Fifty nondiabetic patients after coronary stent implantation were randomly 
      assigned to pioglitazone (30 mg daily; pio) or placebo (control) treatment in 
      addition to standard therapy, and neointima volume was assessed by intravascular 
      ultrasound at the 6-month follow-up. Both groups were comparable with regard to 
      baseline characteristics, angiographic lesion morphology, target vessel, and 
      length of the stented segment. In addition, there were no statistical differences 
      in minimal lumen diameter before and after intervention, as well as reference 
      diameter after stent implantation. In this study population of nondiabetic 
      patients, pio treatment did not significantly change fasting blood glucose, 
      fasting insulin, or glycosylated hemoglobin levels, as well as lipid parameters. 
      In contrast, pio treatment significantly reduced neointima volume within the 
      stented segment, with 2.3+/-1.1 mm3/mm in the pio group versus 3.1+/-1.6 mm3/mm 
      in controls (P=0.04). Total plaque volume (adventitia-lumen area) was 
      significantly lower at follow-up in the pio group (11.2+/-3.2 mm3/mm) compared 
      with controls (13.2+/-4.2 mm3/mm; P=0.04). Moreover, the binary restenosis rate 
      was 3.4% in the pio group versus 32.3% in controls (P<0.01). CONCLUSIONS: Thus, 
      6-month treatment with pio significantly reduced neointima volume after coronary 
      stent implantation in nondiabetic patients. These data bolster the hypothesis 
      that antidiabetic thiazolidinediones, in addition to their metabolic effects, 
      exhibit direct antirestenotic effects in the vasculature.
FAU - Marx, Nikolaus
AU  - Marx N
AD  - Department of Internal Medicine II, Cardiology, University of Ulm, Ulm, Germany.
FAU - Wöhrle, Jochen
AU  - Wöhrle J
FAU - Nusser, Thorsten
AU  - Nusser T
FAU - Walcher, Daniel
AU  - Walcher D
FAU - Rinker, Angelika
AU  - Rinker A
FAU - Hombach, Vinzenz
AU  - Hombach V
FAU - Koenig, Wolfgang
AU  - Koenig W
FAU - Höher, Martin
AU  - Höher M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20051024
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Biomarkers)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Placebos)
RN  - 0 (Thiazolidinediones)
RN  - R16CO5Y76E (Aspirin)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
CIN - Circulation. 2005 Nov 1;112(18):2759-61. PMID: 16267248
MH  - Administration, Oral
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/*adverse effects
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Biomarkers/blood
MH  - Coronary Disease/surgery
MH  - Coronary Restenosis/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Inflammation/blood/prevention & control
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone
MH  - Placebos
MH  - Thiazolidinediones/*therapeutic use
MH  - Tunica Intima/drug effects/*pathology
EDAT- 2005/10/26 09:00
MHDA- 2006/03/03 09:00
CRDT- 2005/10/26 09:00
PHST- 2005/10/26 09:00 [pubmed]
PHST- 2006/03/03 09:00 [medline]
PHST- 2005/10/26 09:00 [entrez]
AID - CIRCULATIONAHA.105.535484 [pii]
AID - 10.1161/CIRCULATIONAHA.105.535484 [doi]
PST - ppublish
SO  - Circulation. 2005 Nov 1;112(18):2792-8. doi: 10.1161/CIRCULATIONAHA.105.535484. 
      Epub 2005 Oct 24.

PMID- 35641323
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220915
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 360
DP  - 2022 Aug 1
TI  - Polypill for cardiovascular disease prevention: Systematic review and 
      meta-analysis of randomized controlled trials.
PG  - 91-98
LID - S0167-5273(22)00649-0 [pii]
LID - 10.1016/j.ijcard.2022.04.085 [doi]
AB  - BACKGROUND: Cardiovascular disease is the leading cause of death worldwide. 
      Although many pharmacological agents exist, drug compliance and therapeutic goal 
      achievement continue to be suboptimal. This meta-analysis aims to study the 
      effectiveness of polypills in controlling blood pressure, dyslipidemia and in 
      reducing future cardiovascular events. METHODS: We conducted a systematic search 
      of electronic databases using pre-specified terms. Randomized clinical trials 
      (RCT) comparing polypills (statin, antihypertensive agents, with or without 
      aspirin) with the standard of care were included. Outcomes of interest were 
      changes in [systolic blood pressure (SBP), diastolic blood pressure (DBP)] mmHg, 
      [total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C)] mg/dl, 
      cardiovascular (CVD) mortality, and major adverse cardiovascular events (MACE). 
      RESULTS: A total of 18 RCTs with 26,483 participants were included. The 
      population had 55% males, with a mean age of 61.8 ± 7 years, and a mean BMI of 
      26.7 ± 4.2 kg/m(2). The mean follow-up was 15.0 ± 20 months. Compared with 
      standard of care, polypill use was associated with a significant reduction of SBP 
      (Mean Difference [MD] -6.39; [95%CI -9.21, -3.56] p < 0.001), DBP (MD -4.19, 
      [95%CI -5.48, -2.89; p < 0.001], TC (MD -24.95, [95%CI -33.86, -16.04]; 
      p < 0.001), and LDL-C (MD -27.92, [95%CI -35.39, -20.44]; p < 0.001). Polypill 
      use was also associated with a significant reduction of CVD mortality (RR = 0.78; 
      95% CI (0.61, 0.99); P = 0.04) and MACE [RR = 0.76;95% CI (0.64, 0.91); 
      P = 0.002]. CONCLUSION: This meta-analysis showed that compared to standard of 
      care, polypill use was associated with a significant reduction of SBP, DBP, TC, 
      LDL-C, and a significant reduction in fatal and non-fatal cardiovascular events.
CI  - Copyright © 2022. Published by Elsevier B.V.
FAU - Mohamed, MohamedM G
AU  - Mohamed MG
AD  - Department of Internal Medicine, SSM-Health St. Mary's Hospital, St. Louis, MO, 
      USA. Electronic address: m.maali.gumaa@gmail.com.
FAU - Osman, Mohammed
AU  - Osman M
AD  - Division of Cardiology, West Virginia University School of Medicine, Morgantown, 
      WV, USA.
FAU - Kheiri, Babikir
AU  - Kheiri B
AD  - Knight Cardiovascular Institute, Oregon Health & Science University, Portland, 
      OR, USA.
FAU - Saleem, Maryam
AU  - Saleem M
AD  - Division of Cardiovascular Health & Disease, University of Cincinnati Medical 
      Centre, Cincinnati, OH, USA.
FAU - Lacasse, Alexandre
AU  - Lacasse A
AD  - Department of Internal Medicine, SSM-Health St. Mary's Hospital, St. Louis, MO, 
      USA.
FAU - Alkhouli, Mohamad
AU  - Alkhouli M
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220506
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Blood Pressure
MH  - *Cardiovascular Diseases/chemically induced/epidemiology/prevention & control
MH  - Cholesterol, LDL
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Cardiovascular prevention
OT  - Dyslipidemia
OT  - Hypertension
OT  - Polypill
EDAT- 2022/06/01 06:00
MHDA- 2022/06/09 06:00
CRDT- 2022/05/31 22:02
PHST- 2021/09/28 00:00 [received]
PHST- 2022/04/06 00:00 [revised]
PHST- 2022/04/29 00:00 [accepted]
PHST- 2022/06/01 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/05/31 22:02 [entrez]
AID - S0167-5273(22)00649-0 [pii]
AID - 10.1016/j.ijcard.2022.04.085 [doi]
PST - ppublish
SO  - Int J Cardiol. 2022 Aug 1;360:91-98. doi: 10.1016/j.ijcard.2022.04.085. Epub 2022 
      May 6.

PMID- 33098099
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20211025
IS  - 1528-1167 (Electronic)
IS  - 0013-9580 (Linking)
VI  - 61
IP  - 12
DP  - 2020 Dec
TI  - Characteristics and treatment outcomes of newly diagnosed epilepsy in older 
      people: A 30-year longitudinal cohort study.
PG  - 2720-2728
LID - 10.1111/epi.16721 [doi]
AB  - OBJECTIVES: To describe the clinical characteristics and evaluate the long-term 
      treatment outcomes in older people with newly diagnosed epilepsy over the past 
      30 years. METHODS: We included patients newly diagnosed with epilepsy and 
      commenced on antiseizure medications (ASMs) at age 65 years or older between July 
      1982 and October 2012 at the Western infirmary in Glasgow, Scotland. They were 
      followed up until April 2016 or death. Seizure freedom was defined as no seizure 
      for at least 1 year on unchanged medication at the last follow-up. RESULTS: A 
      total of 201 patients (median age 73 years, 59% male) were included. The median 
      duration from initial seizure to starting treatment was 8 months (interquartile 
      range: 3.0-24.0 months); 42.2% (85/201) patients had more than five seizures 
      before commencing treatment. Brain imaging showed potentially epileptogenic 
      lesions in 19.7% (38/193) of patients and other abnormalities in 56.5% (109/193); 
      78.6% patients (158/201) were seizure-free at the last follow-up, of whom 94.9% 
      were taking monotherapy. Concomitant aspirin use (n = 80) was associated with a 
      lower probability of being seizure-free (relative risk 0.82, 95% confidence 
      interval 0.70-0.97; P = .02). The use of second-generation ASMs as the initial 
      monotherapy increased from 31.5% (23/73) before 2000 to 70.3% (90/128, P < .001) 
      from 2000 onward. However, the seizure freedom rates (67.1% vs 55.5%; P = .35) 
      and intolerable adverse-effect rates (16.4% vs 19.5%; P = .45) did not show any 
      significant difference. SIGNIFICANCE: There was often a long interval between 
      seizure onset and the initiation of treatment in older people with new-onset 
      epilepsy, although the majority responded well to ASM treatment. Brain imaging 
      showed a high rate of abnormalities. Despite the increased use of 
      second-generation ASMs, treatment outcomes in later-onset epilepsy have not 
      improved over time. The possible effect of aspirin on treatment response warrants 
      further investigation.
CI  - © 2020 International League Against Epilepsy.
FAU - Alsfouk, Bshra Ali A
AU  - Alsfouk BAA
AUID- ORCID: 0000-0001-6489-6035
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint 
      Abdulrahman University, Riyadh, Saudi Arabia.
AD  - University of Glasgow, Glasgow, UK.
FAU - Hakeem, Haris
AU  - Hakeem H
AUID- ORCID: 0000-0002-7902-2362
AD  - Department of Neuroscience, Central Clinical School, Monash University, Alfred 
      Hospital, Melbourne, Vic., Australia.
FAU - Chen, Zhibin
AU  - Chen Z
AUID- ORCID: 0000-0002-1888-6917
AD  - Department of Neuroscience, Central Clinical School, Monash University, Alfred 
      Hospital, Melbourne, Vic., Australia.
AD  - Department of Medicine - Royal Melbourne Hospital, The University of Melbourne, 
      Melbourne, Vic., Australia.
AD  - Clinical Epidemiology, School of Public Health and Preventive Medicine, Monash 
      University, Melbourne, Vic., Australia.
FAU - Walters, Matthew
AU  - Walters M
AD  - University of Glasgow, Glasgow, UK.
FAU - Brodie, Martin J
AU  - Brodie MJ
AUID- ORCID: 0000-0003-1781-2892
AD  - University of Glasgow, Glasgow, UK.
FAU - Kwan, Patrick
AU  - Kwan P
AUID- ORCID: 0000-0001-7310-276X
AD  - Department of Neuroscience, Central Clinical School, Monash University, Alfred 
      Hospital, Melbourne, Vic., Australia.
AD  - Department of Medicine - Royal Melbourne Hospital, The University of Melbourne, 
      Melbourne, Vic., Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201023
PL  - United States
TA  - Epilepsia
JT  - Epilepsia
JID - 2983306R
RN  - 0 (Anticonvulsants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Epilepsy Curr. 2021 May 27;21(4):267-269. PMID: 34690564
MH  - Aged
MH  - Anticonvulsants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Drug Interactions
MH  - Electroencephalography
MH  - Epilepsy/*diagnosis/diagnostic imaging/drug therapy
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Neuroimaging
MH  - Treatment Outcome
OTO - NOTNLM
OT  - antiseizure medication
OT  - efficacy
OT  - geriatric
OT  - new-onset epilepsy
OT  - tolerability
EDAT- 2020/10/25 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/10/24 05:36
PHST- 2020/08/04 00:00 [received]
PHST- 2020/09/19 00:00 [revised]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/10/25 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
PHST- 2020/10/24 05:36 [entrez]
AID - 10.1111/epi.16721 [doi]
PST - ppublish
SO  - Epilepsia. 2020 Dec;61(12):2720-2728. doi: 10.1111/epi.16721. Epub 2020 Oct 23.

PMID- 27171898
OWN - NLM
STAT- MEDLINE
DCOM- 20170512
LR  - 20181113
IS  - 1525-2191 (Electronic)
IS  - 0002-9440 (Print)
IS  - 0002-9440 (Linking)
VI  - 186
IP  - 7
DP  - 2016 Jul
TI  - Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Protective for Injured 
      Epithelia.
PG  - 1801-1813
LID - S0002-9440(16)30075-X [pii]
LID - 10.1016/j.ajpath.2016.03.011 [doi]
AB  - Acute lung injury is a life-threatening condition caused by disruption of the 
      alveolar-capillary barrier leading to edema, influx of inflammatory leukocytes, 
      and impaired gas exchange. Specialized proresolving mediators biosynthesized from 
      essential fatty acids, such as docosahexaenoic acid, have tissue protective 
      effects in acute inflammation. Herein, we found that the docosahexaenoic 
      acid-derived mediator resolvin D3 (RvD3): 
      4S,11R,17S-trihydroxydocosa-5Z,7E,9E,13Z,15E,19Z-hexaenoic acid was present in 
      uninjured lungs, and increased significantly 24 to 72 hours after hydrochloric 
      acid-initiated injury. Because of its delayed enzymatic degradation, we used 
      aspirin-triggered (AT)-RvD3: 
      4S,11R,17R-trihydroxydocosa-5Z,7E,9E,13Z,15E,19Z-hexaenoic acid, a 17R-epimer of 
      RvD3, for in vivo experiments. Histopathological correlates of acid injury 
      (alveolar wall thickening, edema, and leukocyte infiltration) were reduced in 
      mice receiving AT-RvD3 1 hour after injury. AT-RvD3-treated mice had 
      significantly reduced edema, as demonstrated by lower wet/dry weight ratios, 
      increased epithelial sodium channel γ expression, and more lymphatic vessel 
      endothelial hyaluronan receptor 1-positive vascular endothelial growth factor 
      receptor 3-positive lymphatic vessels. Evidence for counterregulation of NF-κB by 
      RvD3 and AT-RvD3 was seen in vitro and by AT-RvD3 in vivo. Increases in lung 
      epithelial cell proliferation and bronchoalveolar lavage fluid levels of 
      keratinocyte growth factor were observed with AT-RvD3, which also promoted 
      cutaneous re-epithelialization. Together, these data demonstrate protective 
      actions of RvD3 and AT-RvD3 for injured mucosa that accelerated restoration of 
      epithelial barrier and function.
CI  - Copyright © 2016 American Society for Investigative Pathology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Colby, Jennifer K
AU  - Colby JK
AD  - Pulmonary and Critical Care Medicine Division, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, Massachusetts.
FAU - Abdulnour, Raja-Elie E
AU  - Abdulnour RE
AD  - Pulmonary and Critical Care Medicine Division, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, Massachusetts.
FAU - Sham, Ho Pan
AU  - Sham HP
AD  - Pulmonary and Critical Care Medicine Division, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, Massachusetts.
FAU - Dalli, Jesmond
AU  - Dalli J
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Center for 
      Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital 
      and Harvard Medical School, Boston, Massachusetts.
FAU - Colas, Romain A
AU  - Colas RA
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Center for 
      Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital 
      and Harvard Medical School, Boston, Massachusetts.
FAU - Winkler, Jeremy W
AU  - Winkler JW
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Center for 
      Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital 
      and Harvard Medical School, Boston, Massachusetts.
FAU - Hellmann, Jason
AU  - Hellmann J
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Center for 
      Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital 
      and Harvard Medical School, Boston, Massachusetts.
FAU - Wong, Blenda
AU  - Wong B
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Center for 
      Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital 
      and Harvard Medical School, Boston, Massachusetts.
FAU - Cui, Ye
AU  - Cui Y
AD  - Pulmonary and Critical Care Medicine Division, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, Massachusetts.
FAU - El-Chemaly, Souheil
AU  - El-Chemaly S
AD  - Pulmonary and Critical Care Medicine Division, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, Massachusetts.
FAU - Petasis, Nicos A
AU  - Petasis NA
AD  - Department of Chemistry, Loker Hydrocarbon Research Institute, University of 
      Southern California, Los Angeles, California.
FAU - Spite, Matthew
AU  - Spite M
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Center for 
      Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital 
      and Harvard Medical School, Boston, Massachusetts.
FAU - Serhan, Charles N
AU  - Serhan CN
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Center for 
      Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital 
      and Harvard Medical School, Boston, Massachusetts.
FAU - Levy, Bruce D
AU  - Levy BD
AD  - Pulmonary and Critical Care Medicine Division, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, Massachusetts. Electronic address: 
      blevy@partners.org.
LA  - eng
GR  - R01 HL106173/HL/NHLBI NIH HHS/United States
GR  - T32 HL007633/HL/NHLBI NIH HHS/United States
GR  - F32 HL116186/HL/NHLBI NIH HHS/United States
GR  - P01 GM095467/GM/NIGMS NIH HHS/United States
GR  - R21 HL119902/HL/NHLBI NIH HHS/United States
GR  - R01 HL122531/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160510
PL  - United States
TA  - Am J Pathol
JT  - The American journal of pathology
JID - 0370502
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (resolvin D3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Lung Injury/metabolism/*pathology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Blotting, Western
MH  - Disease Models, Animal
MH  - Fatty Acids, Unsaturated/*metabolism/*pharmacology
MH  - Immunohistochemistry
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
PMC - PMC4929400
EDAT- 2016/05/14 06:00
MHDA- 2017/05/13 06:00
CRDT- 2016/05/13 06:00
PHST- 2015/07/23 00:00 [received]
PHST- 2016/01/21 00:00 [revised]
PHST- 2016/03/01 00:00 [accepted]
PHST- 2016/05/13 06:00 [entrez]
PHST- 2016/05/14 06:00 [pubmed]
PHST- 2017/05/13 06:00 [medline]
AID - S0002-9440(16)30075-X [pii]
AID - 10.1016/j.ajpath.2016.03.011 [doi]
PST - ppublish
SO  - Am J Pathol. 2016 Jul;186(7):1801-1813. doi: 10.1016/j.ajpath.2016.03.011. Epub 
      2016 May 10.

PMID- 34203526
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20210713
IS  - 1424-8220 (Electronic)
IS  - 1424-8220 (Linking)
VI  - 21
IP  - 13
DP  - 2021 Jun 28
TI  - Characterization of Pharmaceutical Tablets Using UV Hyperspectral Imaging as a 
      Rapid In-Line Analysis Tool.
LID - 10.3390/s21134436 [doi]
LID - 4436
AB  - A laboratory prototype for hyperspectral imaging in ultra-violet (UV) region from 
      225 to 400 nm was developed and used to rapidly characterize active 
      pharmaceutical ingredients (API) in tablets. The APIs are ibuprofen (IBU), 
      acetylsalicylic acid (ASA) and paracetamol (PAR). Two sample sets were used for a 
      comparison purpose. Sample set one comprises tablets of 100% API and sample set 
      two consists of commercially available painkiller tablets. Reference measurements 
      were performed on the pure APIs in liquid solutions (transmission) and in solid 
      phase (reflection) using a commercial UV spectrometer. The spectroscopic part of 
      the prototype is based on a pushbroom imager that contains a spectrograph and 
      charge-coupled device (CCD) camera. The tablets were scanned on a conveyor belt 
      that is positioned inside a tunnel made of polytetrafluoroethylene (PTFE) in 
      order to increase the homogeneity of illumination at the sample position. 
      Principal component analysis (PCA) was used to differentiate the hyperspectral 
      data of the drug samples. The first two PCs are sufficient to completely separate 
      all samples. The rugged design of the prototype opens new possibilities for 
      further development of this technique towards real large-scale application.
FAU - Al Ktash, Mohammad
AU  - Al Ktash M
AUID- ORCID: 0000-0002-6713-5669
AD  - Process Analysis and Technology PA & T, Reutlingen University, Alteburgstraße 
      150, 72762 Reutlingen, Germany.
AD  - Institute of Physical and Theoretical Chemistry, Eberhard Karls University 
      Tübingen, Auf der Morgenstelle 182, 72076 Tübingen, Germany.
FAU - Stefanakis, Mona
AU  - Stefanakis M
AUID- ORCID: 0000-0002-9459-0640
AD  - Process Analysis and Technology PA & T, Reutlingen University, Alteburgstraße 
      150, 72762 Reutlingen, Germany.
AD  - Institute of Physical and Theoretical Chemistry, Eberhard Karls University 
      Tübingen, Auf der Morgenstelle 182, 72076 Tübingen, Germany.
FAU - Boldrini, Barbara
AU  - Boldrini B
AUID- ORCID: 0000-0003-1357-8453
AD  - Process Analysis and Technology PA & T, Reutlingen University, Alteburgstraße 
      150, 72762 Reutlingen, Germany.
FAU - Ostertag, Edwin
AU  - Ostertag E
AUID- ORCID: 0000-0003-0492-0544
AD  - Process Analysis and Technology PA & T, Reutlingen University, Alteburgstraße 
      150, 72762 Reutlingen, Germany.
FAU - Brecht, Marc
AU  - Brecht M
AUID- ORCID: 0000-0001-5537-1448
AD  - Process Analysis and Technology PA & T, Reutlingen University, Alteburgstraße 
      150, 72762 Reutlingen, Germany.
AD  - Institute of Physical and Theoretical Chemistry, Eberhard Karls University 
      Tübingen, Auf der Morgenstelle 182, 72076 Tübingen, Germany.
LA  - eng
GR  - 710186/Katholischer Akademischer Ausländer-Dienst/
PT  - Journal Article
DEP - 20210628
PL  - Switzerland
TA  - Sensors (Basel)
JT  - Sensors (Basel, Switzerland)
JID - 101204366
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Tablets)
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen
MH  - Aspirin
MH  - *Hyperspectral Imaging
MH  - Ibuprofen
MH  - *Pharmaceutical Preparations
MH  - Tablets
PMC - PMC8271527
OTO - NOTNLM
OT  - UV spectroscopy
OT  - active pharmaceutical ingredient API
OT  - hyperspectral imaging
OT  - principle component analysis
OT  - process analytical technology PAT
OT  - pushbroom
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/07 06:00
CRDT- 2021/07/02 01:17
PHST- 2021/05/27 00:00 [received]
PHST- 2021/06/23 00:00 [revised]
PHST- 2021/06/25 00:00 [accepted]
PHST- 2021/07/02 01:17 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
AID - s21134436 [pii]
AID - sensors-21-04436 [pii]
AID - 10.3390/s21134436 [doi]
PST - epublish
SO  - Sensors (Basel). 2021 Jun 28;21(13):4436. doi: 10.3390/s21134436.

PMID- 18217130
OWN - NLM
STAT- MEDLINE
DCOM- 20080221
LR  - 20230120
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 99
IP  - 1
DP  - 2008 Jan
TI  - Response variability to aspirin as assessed by the platelet function analyzer 
      (PFA)-100. A systematic review.
PG  - 14-26
LID - 10.1160/TH07-08-0530 [doi]
AB  - It was the aim of the present study to perform a systematic review of the 
      published studies that estimated the prevalence of non-responders to aspirin, as 
      assessed by the closure time of PFA-100, a point-of-care device, and to analyse: 
      1) some major clinical and methodological factors that can influence it and 2) 
      its possible association with vascular outcomes. The prevalence of non-responders 
      to aspirin in 64 populations from 53 studies, comprising 6,450 subjects, had a 
      median value of 0.27. A higher number of aspirin non-responders was found among 
      older patients, those with acute vascular events, or those treated for more than 
      one month. Aspirin non-response was more frequently associated with the use of 
      "home-established" cut-offs or when closure time was only assessed after aspirin 
      (rather than both before and after). Among risk factors, type 2 diabetes appeared 
      to be associated with a higher prevalence of aspirin non-responders. The latter 
      was also higher in less recent publications and in studies that used 3.2% rather 
      than 3.8% Na-citrate as an anticoagulant. In eight studies comprising 847 
      subjects, aspirin non-responders were more likely to have vascular events than 
      responders (relative risk: 1.63; 95% CI 1.16-2.28). In conclusion, although there 
      appears to be heterogeneity among the studies analysed, this review indicates 
      that about one quarter of people receiving aspirin would be identified--as an 
      average--as aspirin non-responders by PFA-100. As this is a simple, widely 
      available point-of-care test, efforts to better standardize it and to control for 
      its major methodological variables might be useful to improve monitoring of 
      platelet performance under aspirin treatment and to firmly establish the observed 
      association with clinical vascular events.
FAU - Crescente, Marilena
AU  - Crescente M
AD  - Research Laboratories, John Paul II Center for High Technology Research and 
      Education in Biomedical Sciences, Catholic University, Largo Gemelli 1, 86100 
      Campobasso, Italy.
FAU - Di Castelnuovo, Augusto
AU  - Di Castelnuovo A
FAU - Iacoviello, Licia
AU  - Iacoviello L
FAU - Vermylen, Jos
AU  - Vermylen J
FAU - Cerletti, Chiara
AU  - Cerletti C
FAU - de Gaetano, Giovanni
AU  - de Gaetano G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Thromb Haemost. 2008 May;99(5):968-9; author reply 969. PMID: 18449432
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/*drug effects
MH  - Diabetes Mellitus, Type 2/blood
MH  - Drug Monitoring/*instrumentation/standards
MH  - *Drug Tolerance
MH  - Equipment Design
MH  - Humans
MH  - Middle Aged
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Platelet Function Tests/*instrumentation/standards
MH  - *Point-of-Care Systems/standards
MH  - Predictive Value of Tests
MH  - Quality Control
MH  - Recurrence
MH  - Reproducibility of Results
MH  - Risk Assessment
MH  - Risk Factors
MH  - Vascular Diseases/blood/*drug therapy
RF  - 123
EDAT- 2008/01/25 09:00
MHDA- 2008/02/22 09:00
CRDT- 2008/01/25 09:00
PHST- 2008/01/25 09:00 [pubmed]
PHST- 2008/02/22 09:00 [medline]
PHST- 2008/01/25 09:00 [entrez]
AID - 08010014 [pii]
AID - 10.1160/TH07-08-0530 [doi]
PST - ppublish
SO  - Thromb Haemost. 2008 Jan;99(1):14-26. doi: 10.1160/TH07-08-0530.

PMID- 7384542
OWN - NLM
STAT- MEDLINE
DCOM- 19800815
LR  - 20190825
IS  - 0090-6980 (Print)
IS  - 0090-6980 (Linking)
VI  - 19
IP  - 2
DP  - 1980 Feb
TI  - Indomethacin, salicylates and prostaglandin binding.
PG  - 311
AB  - Aspirin, salicylic acid and indomethacin reversibly inhibit prostaglandin binding 
      to human serum proteins. This effect was demonstrated in the sera of normal 
      subjects and of rheumatoid arthritis patients treated with aspirin as well as by 
      addition of these drugs to serum in vitro. The displacement of serum 
      prostaglandins by salicylate is likely to affect the kinetics of prostaglandin 
      transport and may facilitate the delivery of prostaglandins from serum to tissue 
      receptors.
FAU - Attallah, A A
AU  - Attallah AA
FAU - Lee, J B
AU  - Lee JB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prostaglandins
JT  - Prostaglandins
JID - 0320271
RN  - 0 (Prostaglandins)
RN  - 0 (Prostaglandins A)
RN  - 0 (Prostaglandins E)
RN  - 0 (Prostaglandins F)
RN  - 0 (Salicylates)
RN  - 0 (Serum Albumin)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Arthritis, Rheumatoid/blood/drug therapy
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Humans
MH  - Indomethacin/*pharmacology
MH  - Prostaglandins/*blood
MH  - Prostaglandins A/blood
MH  - Prostaglandins E/blood
MH  - Prostaglandins F/blood
MH  - Protein Binding/drug effects
MH  - Salicylates/*pharmacology
MH  - Serum Albumin/*metabolism
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
AID - 0090-6980(80)90029-5 [pii]
AID - 10.1016/0090-6980(80)90029-5 [doi]
PST - ppublish
SO  - Prostaglandins. 1980 Feb;19(2):311. doi: 10.1016/0090-6980(80)90029-5.

PMID- 8235431
OWN - NLM
STAT- MEDLINE
DCOM- 19931207
LR  - 20190814
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 28
IP  - 9
DP  - 1993 Sep
TI  - Gastric mucosal blood flow and neutrophil activation in aspirin-induced gastric 
      mucosal damage in man.
PG  - 767-71
AB  - Gastric and intestinal injury induced by nonsteroidal anti-inflammatory agents 
      (NSAIDs) such as aspirin (ASA) is a common side effect of this class of drugs, 
      but the mechanism by which these drugs act is not fully explained. In this study 
      the effects of 3 days of continuous oral ASA administration (1 g twice daily) to 
      eight healthy male volunteers were studied. To estimate the extent of mucosal 
      damage, gastroscopy was performed before and after 3 days of ASA treatment, 
      during which the mucosal blood flow was measured by means of laser-Doppler 
      flowmetry. Before each endoscopy gastric microbleeding was measured. Since 
      neutrophil activation has recently been suggested to be involved in the 
      pathogenesis of ASA-induced gastric mucosal damage, we examined the influence of 
      ASA treatment on the activation of leukocytes by determining their association 
      with platelets in the blood. Aspirin-induced acute gastric damage reached about 
      3.5 in the endoscopic Lanza score. Mucosal blood flow increased significantly 
      after ASA treatment, by about 50% in the oxyntic gland area and by 87% in the 
      antral area. Gastric microbleeding rose from about 0.38 ml/day in the intact 
      stomach to about 7.7 ml/day after ASA treatment. The platelet/neutrophil 
      adherence increased significantly in both thrombin-unstimulated and 
      thrombin-stimulated platelets. We conclude that acute 3 days' administration of 
      ASA in man produces well-defined areas of gastric damage accompanied by a 
      significant increase in gastric microbleeding and gastric blood flow and that ASA 
      promotes platelet/neutrophil adhesion that may resemble the 
      neutrophil/endothelium interaction in the gastric mucosa.
FAU - Konturek, J W
AU  - Konturek JW
AD  - Dept. of Medicine B, University of Münster, Germany.
FAU - Dembinski, A
AU  - Dembinski A
FAU - Stoll, R
AU  - Stoll R
FAU - Konturek, M
AU  - Konturek M
FAU - Domschke, W
AU  - Domschke W
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Gastric Mucosa/*blood supply/*drug effects
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Neutrophils/*physiology
MH  - Platelet Adhesiveness/drug effects
EDAT- 1993/09/01 00:00
MHDA- 1993/09/01 00:01
CRDT- 1993/09/01 00:00
PHST- 1993/09/01 00:00 [pubmed]
PHST- 1993/09/01 00:01 [medline]
PHST- 1993/09/01 00:00 [entrez]
AID - 10.3109/00365529309104006 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 1993 Sep;28(9):767-71. doi: 10.3109/00365529309104006.

PMID- 11280112
OWN - NLM
STAT- MEDLINE
DCOM- 20010426
LR  - 20181130
IS  - 0300-8495 (Print)
IS  - 0300-8495 (Linking)
VI  - 30
IP  - 2
DP  - 2001 Feb
TI  - Newer antiplatelet therapies in stroke prevention.
PG  - 129-34
AB  - BACKGROUND: Aspirin has been the mainstay of antiplatelet therapy in stroke 
      prevention for 30 years. In the past decade, a number of new antiplatelet 
      strategies have been shown in clinical trials to provide some benefits over 
      aspirin therapy. These new compounds include ticlopidine, clopidogrel and the 
      combination of aspirin with dipyridamole. OBJECTIVES: To review the efficacy and 
      dosage of aspirin in stroke prevention, and to review the benefits and risks of 
      the newer strategies, compared with aspirin. Based on the evidence from 
      randomised, controlled clinical trials and systematic overviews, to present 
      practical clinical guidelines for the use of aspirin and the newer antiplatelet 
      drugs. DISCUSSION: For most patients aspirin monotherapy is still recommended as 
      the first line antiplatelet strategy. However, some stroke clinicians are now 
      recommending the combination of aspirin plus dipyridamole as a first line 
      approach. For patients who are allergic to aspirin, clopidogrel is the drug of 
      first choice and has largely replaced ticlopidine. For aspirin failures, either 
      combined aspirin plus dipyridamole, or clopidogrel, are recommended. The 
      combination of aspirin plus clopidogrel has theoretical appeal, is valuable in 
      prevention of coronary stent thrombosis and is undergoing clinical trial in 
      stroke prevention. Other novel approaches, such as oral platelet Gp IIb/IIIa 
      antagonists are also being evaluated.
FAU - Davis, S M
AU  - Davis SM
AD  - Department of Neurology, Royal Melbourne Hospital, and the University of 
      Melbourne, Victoria.
FAU - Donnan, G A
AU  - Donnan GA
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust Fam Physician
JT  - Australian family physician
JID - 0326701
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Clopidogrel
MH  - Dipyridamole/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Stroke/drug therapy/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2001/03/31 10:00
MHDA- 2001/05/01 10:01
CRDT- 2001/03/31 10:00
PHST- 2001/03/31 10:00 [pubmed]
PHST- 2001/05/01 10:01 [medline]
PHST- 2001/03/31 10:00 [entrez]
PST - ppublish
SO  - Aust Fam Physician. 2001 Feb;30(2):129-34.

PMID- 31556978
OWN - NLM
STAT- MEDLINE
DCOM- 20191127
LR  - 20210110
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 381
IP  - 21
DP  - 2019 Nov 21
TI  - Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
PG  - 2032-2042
LID - 10.1056/NEJMoa1908419 [doi]
AB  - BACKGROUND: Monotherapy with a P2Y(12) inhibitor after a minimum period of dual 
      antiplatelet therapy is an emerging approach to reduce the risk of bleeding after 
      percutaneous coronary intervention (PCI). METHODS: In a double-blind trial, we 
      examined the effect of ticagrelor alone as compared with ticagrelor plus aspirin 
      with regard to clinically relevant bleeding among patients who were at high risk 
      for bleeding or an ischemic event and had undergone PCI. After 3 months of 
      treatment with ticagrelor plus aspirin, patients who had not had a major bleeding 
      event or ischemic event continued to take ticagrelor and were randomly assigned 
      to receive aspirin or placebo for 1 year. The primary end point was Bleeding 
      Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. We also evaluated 
      the composite end point of death from any cause, nonfatal myocardial infarction, 
      or nonfatal stroke, using a noninferiority hypothesis with an absolute margin of 
      1.6 percentage points. RESULTS: We enrolled 9006 patients, and 7119 underwent 
      randomization after 3 months. Between randomization and 1 year, the incidence of 
      the primary end point was 4.0% among patients randomly assigned to receive 
      ticagrelor plus placebo and 7.1% among patients assigned to receive ticagrelor 
      plus aspirin (hazard ratio, 0.56; 95% confidence interval [CI], 0.45 to 0.68; 
      P<0.001). The difference in risk between the groups was similar for BARC type 3 
      or 5 bleeding (incidence, 1.0% among patients receiving ticagrelor plus placebo 
      and 2.0% among patients receiving ticagrelor plus aspirin; hazard ratio, 0.49; 
      95% CI, 0.33 to 0.74). The incidence of death from any cause, nonfatal myocardial 
      infarction, or nonfatal stroke was 3.9% in both groups (difference, -0.06 
      percentage points; 95% CI, -0.97 to 0.84; hazard ratio, 0.99; 95% CI, 0.78 to 
      1.25; P<0.001 for noninferiority). CONCLUSIONS: Among high-risk patients who 
      underwent PCI and completed 3 months of dual antiplatelet therapy, ticagrelor 
      monotherapy was associated with a lower incidence of clinically relevant bleeding 
      than ticagrelor plus aspirin, with no higher risk of death, myocardial 
      infarction, or stroke. (Funded by AstraZeneca; TWILIGHT ClinicalTrials.gov 
      number, NCT02270242.).
CI  - Copyright © 2019 Massachusetts Medical Society.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Baber, Usman
AU  - Baber U
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Sharma, Samin K
AU  - Sharma SK
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Cohen, David J
AU  - Cohen DJ
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Briguori, Carlo
AU  - Briguori C
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Cha, Jin Y
AU  - Cha JY
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Collier, Timothy
AU  - Collier T
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Dangas, George
AU  - Dangas G
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Dudek, Dariusz
AU  - Dudek D
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Džavík, Vladimír
AU  - Džavík V
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Escaned, Javier
AU  - Escaned J
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Gil, Robert
AU  - Gil R
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Gurbel, Paul
AU  - Gurbel P
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Hamm, Christian W
AU  - Hamm CW
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Henry, Timothy
AU  - Henry T
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Huber, Kurt
AU  - Huber K
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Kastrati, Adnan
AU  - Kastrati A
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Kaul, Upendra
AU  - Kaul U
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Kornowski, Ran
AU  - Kornowski R
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Krucoff, Mitchell
AU  - Krucoff M
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Kunadian, Vijay
AU  - Kunadian V
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Marx, Steven O
AU  - Marx SO
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Mehta, Shamir R
AU  - Mehta SR
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Moliterno, David
AU  - Moliterno D
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Ohman, E Magnus
AU  - Ohman EM
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Oldroyd, Keith
AU  - Oldroyd K
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Sardella, Gennaro
AU  - Sardella G
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Sartori, Samantha
AU  - Sartori S
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Shlofmitz, Richard
AU  - Shlofmitz R
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Steg, P Gabriel
AU  - Steg PG
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Weisz, Giora
AU  - Weisz G
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Witzenbichler, Bernhard
AU  - Witzenbichler B
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Han, Ya-Ling
AU  - Han YL
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Pocock, Stuart
AU  - Pocock S
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
FAU - Gibson, C Michael
AU  - Gibson CM
AD  - From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai 
      Hospital (R.M., U.B., J.Y.C., G.D., S.S.), Mount Sinai Health System (S.K.S.), 
      Columbia University Medical Center (S.O.M.), Icahn School of Medicine at Mount 
      Sinai (S.S.), and Montefiore Medical Center (G.W.), New York, and St. Francis 
      Hospital, Roslyn (R.S.) - all in New York; Kansas City, Missouri (D.J.C.); the 
      University of Florida-Shands, Jacksonville (D.J.A.); Clinica Mediterranea, Naples 
      (C.B.), and Policlinico Umberto I University, Rome (G.S.) - both in Italy; the 
      London School of Hygiene and Tropical Medicine, London (T.C., S.P.), Institute of 
      Cellular Medicine, Faculty of Medical Sciences, Newcastle University, and 
      Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne (V.K.), and the West of Scotland Heart and 
      Lung Centre, Golden Jubilee National Hospital, Glasgow (K.O.) - all in the United 
      Kingdom; the 2nd Department of Cardiology Jagiellonian University Medical 
      College, Krakow (D.D.), and the Department of Invasive Cardiology, Center of 
      Postgraduate Medical Education, Central Clinical Hospital of the Ministry of 
      Interior and Administration, Warsaw (R.G.) - both in Poland; Research and 
      Innovation in Interventional Cardiology and Cardiac Intensive Care, Peter Munk 
      Cardiac Centre, University Health Network, Toronto (V.D.), and Hamilton Health 
      Sciences, Hamilton, ON (S.R.M.) - both in Canada; Instituto de Investigación 
      Sanitaria del Hospital Clínico San Carlos and Complutense University, Madrid 
      (J.E.); Sinai Hospital of Baltimore System, Baltimore (P.G.); Kerckhoff Clinic, 
      Bad Nauheim (C.W.H.), Deutsches Herzzentrum München, Munich (A.K.), and Helios 
      Amper-Klinikum, Dachau (B.W.) - all in Germany; the Carl and Edyth Lindner Center 
      for Research and Education at the Christ Hospital, Cincinnati (T.H.); 
      Wilhelminenhospital, Vienna (K.H.); Batra Hospital and Medical Research Centre, 
      New Delhi, India (U.K.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Duke 
      University Medical Center-Duke Clinical Research Institute, Durham, NC (M.K., 
      E.M.O.); the University of Kentucky, Lexington (D.M.); Groupe Hospitalier 
      Bichat-Claude-Bernard, Paris (P.G.S.); Shenyang North Hospital, Shenyang, China 
      (Y.H.); and Beth Israel Deaconess Medical Center, Boston (C.M.G.).
LA  - eng
SI  - ClinicalTrials.gov/NCT02270242
GR  - CS/15/7/31679/BHF_/British Heart Foundation/United Kingdom
GR  - NCT02270242/AstraZeneca/International
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190926
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Nat Rev Cardiol. 2019 Dec;16(12):701. PMID: 31611660
CIN - Ann Intern Med. 2020 Feb 18;172(4):JC19. PMID: 32066152
CIN - N Engl J Med. 2020 Mar 12;382(11):1075-1076. PMID: 32160677
CIN - N Engl J Med. 2020 Mar 12;382(11):1076. PMID: 32160678
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Coronary Disease/drug therapy/*therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Mortality
MH  - Myocardial Infarction/epidemiology
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Stroke/epidemiology
MH  - Ticagrelor/adverse effects/*therapeutic use
EDAT- 2019/09/27 06:00
MHDA- 2019/11/28 06:00
CRDT- 2019/09/27 06:00
PHST- 2019/09/27 06:00 [pubmed]
PHST- 2019/11/28 06:00 [medline]
PHST- 2019/09/27 06:00 [entrez]
AID - 10.1056/NEJMoa1908419 [doi]
PST - ppublish
SO  - N Engl J Med. 2019 Nov 21;381(21):2032-2042. doi: 10.1056/NEJMoa1908419. Epub 
      2019 Sep 26.

PMID- 26586780
OWN - NLM
STAT- MEDLINE
DCOM- 20170109
LR  - 20220317
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 37
IP  - 4
DP  - 2016 Jan 21
TI  - Causes of late mortality with dual antiplatelet therapy after coronary stents.
PG  - 378-85
LID - 10.1093/eurheartj/ehv614 [doi]
AB  - AIMS: In the dual antiplatelet therapy (DAPT) study, continued thienopyridine 
      beyond 12 months after drug-eluting stent placement was associated with increased 
      mortality compared with placebo. We sought to evaluate factors related to 
      mortality in randomized patients receiving either drug-eluting or bare metal 
      stents in the DAPT study. METHODS AND RESULTS: Patients were enrolled after 
      coronary stenting, given thienopyridine and aspirin for 12 months, randomly 
      assigned to continued thienopyridine or placebo for an additional 18 months 
      (while taking aspirin), and subsequently treated with aspirin alone for another 3 
      months. A blinded independent adjudication committee evaluated deaths. Among 11 
      648 randomized patients, rates of all-cause mortality rates were 1.9 vs. 1.5% 
      (continued thienopyridine vs. placebo, P = 0.07), cardiovascular mortality, 1.0 
      vs. 1.0% (P = 0.97), and non-cardiovascular mortality, 0.9 vs. 0.5% (P = 0.01) 
      over the randomized period (Months 12-30). Rates of fatal bleeding were 0.2 vs. 
      0.1% (P = 0.81), and deaths related to any prior bleeding were 0.3 vs. 0.2% (P = 
      0.36), Months 12-33). Cancer incidence did not differ (2.0 vs. 1.6%, P = 0.12). 
      Cancer-related deaths occurred in 0.6 vs. 0.3% (P = 0.02) and were rarely related 
      to bleeding (0.1 vs. 0, P = 0.25). After excluding those occurring in patients 
      with cancer diagnosed before enrolment, rates were 0.4 vs. 0.3% (P = 0.16). 
      CONCLUSION: Bleeding accounted for a minority of deaths among patients treated 
      with continued thienopyridine. Cancer-related death in association with 
      thienopyridine therapy was mainly not related to bleeding and may be a chance 
      finding. Caution is warranted when considering extended thienopyridine in 
      patients with advanced cancer. TRIAL REGISTRATION: clinicaltrials.gov Identifier: 
      NCT00977938.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved. © 
      The Author 2015. For permissions please email: journals.permissions@oup.com.
FAU - Mauri, Laura
AU  - Mauri L
AD  - Harvard Clinical Research Institute, Boston, USA Division of Cardiovascular 
      Medicine, Department of Medicine, Brigham and Women's Hospital, 75 Francis 
      Street, Boston, MA 02115, USA Harvard Medical School , Boston, USA 
      lmauri1@partners.org.
FAU - Elmariah, Sammy
AU  - Elmariah S
AD  - Harvard Clinical Research Institute, Boston, USA Harvard Medical School , Boston, 
      USA Massachusetts General Hospital, Boston, USA.
FAU - Yeh, Robert W
AU  - Yeh RW
AD  - Harvard Clinical Research Institute, Boston, USA Harvard Medical School , Boston, 
      USA Massachusetts General Hospital, Boston, USA.
FAU - Cutlip, Donald E
AU  - Cutlip DE
AD  - Harvard Clinical Research Institute, Boston, USA Harvard Medical School , Boston, 
      USA Beth Israel Deaconess Medical Center, Boston, USA.
FAU - Steg, P Gabriel
AU  - Steg PG
AD  - Département Hospitalo-Universitaire Fibrosis, Inflammation, and Remodeling, 
      Assistance Publique - Hôpitaux de Paris, Paris, France National Heart and Lung 
      Institute, Imperial College, Royal Brompton Hospital, London, UK.
FAU - Windecker, Stephan
AU  - Windecker S
AD  - Bern University Hospital, Bern, Switzerland.
FAU - Wiviott, Stephen D
AU  - Wiviott SD
AD  - Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's 
      Hospital, 75 Francis Street, Boston, MA 02115, USA Harvard Medical School , 
      Boston, USA.
FAU - Cohen, David J
AU  - Cohen DJ
AD  - Saint Luke's Mid America Heart Institute, Kansas City, MO, USA University of 
      Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
FAU - Massaro, Joseph M
AU  - Massaro JM
AD  - Harvard Clinical Research Institute, Boston, USA Boston University School of 
      Public Health, Boston, USA Université Paris-Diderot, INSERM U-1148, Hôpital 
      Bichat, Paris, France.
FAU - D'Agostino, Ralph B Sr
AU  - D'Agostino RB Sr
AD  - Harvard Clinical Research Institute, Boston, USA Boston University School of 
      Public Health, Boston, USA.
FAU - Braunwald, Eugene
AU  - Braunwald E
AD  - Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's 
      Hospital, 75 Francis Street, Boston, MA 02115, USA Harvard Medical School , 
      Boston, USA.
FAU - Kereiakes, Dean J
AU  - Kereiakes DJ
AD  - The Christ Hospital Heart and Vascular Center, The Lindner Center for Research 
      and Education, Cincinnati, OH, USA.
CN  - DAPT Study Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00977938
GR  - K23 HL118138/HL/NHLBI NIH HHS/United States
GR  - 1R01FD003870-01/FD/FDA HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20151118
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2016 Jan 21;37(4):386-9. PMID: 26685135
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cause of Death
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/mortality
MH  - Neoplasms/complications/mortality
MH  - Percutaneous Coronary Intervention/methods/mortality
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Pyridines/*administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC4751218
OTO - NOTNLM
OT  - Cancer
OT  - Dual antiplatelet therapy
OT  - Mortality
OT  - Thienopyridine
EDAT- 2015/11/21 06:00
MHDA- 2017/01/10 06:00
CRDT- 2015/11/21 06:00
PHST- 2015/08/06 00:00 [received]
PHST- 2015/10/16 00:00 [accepted]
PHST- 2015/11/21 06:00 [entrez]
PHST- 2015/11/21 06:00 [pubmed]
PHST- 2017/01/10 06:00 [medline]
AID - ehv614 [pii]
AID - 10.1093/eurheartj/ehv614 [doi]
PST - ppublish
SO  - Eur Heart J. 2016 Jan 21;37(4):378-85. doi: 10.1093/eurheartj/ehv614. Epub 2015 
      Nov 18.

PMID- 34266452
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20220424
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 22
IP  - 1
DP  - 2021 Jul 15
TI  - A randomized open-label trial to evaluate the efficacy and safety of triple 
      therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with 
      SARS Cov-2 infection: A structured summary of a study protocol for a randomized 
      controlled trial.
PG  - 451
LID - 10.1186/s13063-021-05361-y [doi]
LID - 451
AB  - OBJECTIVES: The pathophysiology of SARS-Cov-2 is characterized by inflammation, 
      immune dysregulation, coagulopathy, and endothelial dysfunction. No single 
      therapeutic agent can target all these pathophysiologic substrates. Moreover, the 
      current therapies are not fully effective in reducing mortality in moderate and 
      severe disease. Hence, we aim to evaluate the combination of drugs (aspirin, 
      atorvastatin, and nicorandil) with anti-inflammatory, antithrombotic, 
      immunomodulatory, and vasodilator properties as adjuvant therapy in covid- 19. 
      TRIAL DESIGN: Single-centre, prospective, two-arm parallel design, open-label 
      randomized control superiority trial. PARTICIPANTS: The study will be conducted 
      at the covid centre of Dr. Rajendra Prasad Government Medical College Tanda 
      Kangra, Himachal Pradesh, India. All SARS-CoV-2 infected patients requiring 
      admission to the study centre will be screened for the trial. All patients 
      >18years who are RT-PCR/RAT positive for SARS-CoV-2 infection with pneumonia but 
      without ARDS at presentation (presence of clinical features of dyspnoea hypoxia, 
      fever, cough, spo2 <94% on room air and respiratory rate >24/minute) requiring 
      hospital admission and consenting to participate in the trial will be included. 
      Patients with documented significant liver disease/dysfunction (AST/ALT > 240), 
      myopathy and rhabdomyolysis (CPK > 5x normal), allergy or intolerance to statins, 
      allergy or intolerance to aspirin, patients taking medications with significant 
      interaction with statins, prior statin use (within 30 days), prior aspirin use 
      (within 30 days), history of active GI bleeding in past three months, 
      coagulopathy, thrombocytopenia (platelet count < 100000/ dl), pregnancy, active 
      breastfeeding, patient unable to take oral or nasogastric medications, patients 
      in altered mental status, shock, acute renal failure, acute coronary syndrome, 
      sepsis and ARDS at presentation will be excluded. INTERVENTION AND COMPARATOR: 
      After randomization, participants in the intervention group will receive aspirin, 
      atorvastatin, and nicorandil (Fig. 1). Atorvastatin will be prescribed as 40 mg 
      starting dose followed by 40 mg oral tablets once daily for ten days or till 
      hospital discharge whichever is later. Aspirin dose will be 325 starting dose 
      followed by 75 mg once daily for ten days or till hospital discharge whichever is 
      later. Nicorandil will be given as 10 mg starting dose followed by 5mg twice 
      daily ten days or till hospital discharge whichever is later. All patients in the 
      intervention and control group will receive a standard of care for covid 
      management as per national guidelines. All patients will receive symptomatic 
      treatment with antipyretics, adequate hydration, anticoagulation with low 
      molecular weight heparin, intravenous remdesivir, corticosteroids (intravenous 
      dexamethasone for 5 days or more duration if oxygen requirement increasing or 
      inflammatory markers are raised), and oxygen support. Patients will receive 
      treatment for comorbid conditions as per guidelines. Fig. 1 Schematic study 
      design MAIN OUTCOMES: The patients will be followed up for outcomes during the 
      hospital stay or for ten days whichever is longer. The primary outcome will be 
      in-hospital mortality. Any progression to ARDS, shock, acute kidney injury, 
      impaired consciousness, length of hospital stay, length of mechanical ventilation 
      (invasive plus non-invasive) will be secondary outcomes. Changes in serum markers 
      (CRP, D -dimer, S ferritin) will be other secondary outcomes. The safety 
      endpoints will be hepatotoxicity (ALT/AST > 3x ULN; hyperbilirubinemia), 
      myalgia-muscle ache, or weakness without creatine kinase (CK) elevation, 
      myositis-muscle symptoms with increased CK levels (3-10) ULN, 
      rhabdomyolysis-muscle symptoms with marked CK elevation (typically substantially 
      greater than 10 times the upper limit of normal [ULN]) and with creatinine 
      elevation (usually with brown urine and urinary myoglobin) observed during the 
      hospital stay. RANDOMIZATION: Computer-generated block randomization will be used 
      to randomize the participants in a 1:1 ratio to the active intervention group A 
      (Aspirin, Atorvastatin, Nicorandil) plus conventional therapy and control group B 
      conventional therapy only. BLINDING (MASKING): The study will be an open-label 
      trial. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): A total of 396 patients will 
      participate in this study, which is randomly divided with 198 participants in 
      each group. TRIAL STATUS: The first version of the protocol was approved by the 
      institutional ethical committee on 1(st) February 2021, IEC /006/2021. The 
      recruitment started on 8/4/2021 and will continue until 08/07/2021. A total of 
      281 patients have been enrolled till 21/5/2021. TRIAL REGISTRATION: The trial has 
      been prospectively registered in Clinical Trial Registry - India (ICMR- NIMS): 
      CTRI/2021/04/032648 [Registered on: 8 April 2021]. FULL PROTOCOL: The full 
      protocol is attached as an additional file, accessible from the Trials website 
      (Additional file 1). In the interest in expediting dissemination of this 
      material, the familiar formatting has been eliminated; this letter serves as a 
      summary of the key elements of the full protocol. The study protocol has been 
      reported under the Standard Protocol Items: Recommendations for Clinical 
      Interventional Trials (SPIRIT) guidelines.
CI  - © 2021. The Author(s).
FAU - Sharma, Ambudhar
AU  - Sharma A
AUID- ORCID: 0000-0002-6038-3205
AD  - Department of Cardiology, Dr. Rajendra Prasad Government Medical College, Tanda, 
      Kangra, Himachal Pradesh, 176001, India. ambudhar414@gmail.com.
FAU - Sharma, Charu
AU  - Sharma C
AD  - Department of Anaesthesia, Dr. Rajendra Prasad Government Medical College, Tanda, 
      Kangra, Himachal Pradesh, 176001, India.
FAU - Raina, Sujeet
AU  - Raina S
AD  - Department of Internal Medicine, Dr. Rajendra Prasad Government Medical College, 
      Tanda, Kangra, Himachal Pradesh, 176001, India.
FAU - Singh, Balraj
AU  - Singh B
AD  - Department of Preventive and Social Medicine, Indira Gandhi Medical College, 
      Shimla, 171001, India.
FAU - Dadhwal, Devendra Singh
AU  - Dadhwal DS
AD  - Department of Pulmonary Medicine, Dr. Rajendra Prasad Government Medical College, 
      Tanda, Kangra, Himachal Pradesh, 176001, India.
FAU - Dogra, Vinay
AU  - Dogra V
AD  - Department of Endocrinology, Dr. Rajendra Prasad Government Medical College, 
      Tanda, Kangra, Himachal Pradesh, 176001, India.
FAU - Gupta, Swatantra
AU  - Gupta S
AD  - Department of Gastroenterology, Dr. Rajendra Prasad Government Medical College, 
      Tanda, Kangra, Himachal Pradesh, 176001, India.
FAU - Bhandari, Shyam
AU  - Bhandari S
AD  - Department of Anaesthesia, Dr. Rajendra Prasad Government Medical College, Tanda, 
      Kangra, Himachal Pradesh, 176001, India.
FAU - Sood, Vivek
AU  - Sood V
AD  - Department of Internal Medicine, Dr. Rajendra Prasad Government Medical College, 
      Tanda, Kangra, Himachal Pradesh, 176001, India.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Letter
DEP - 20210715
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 260456HAM0 (Nicorandil)
RN  - A0JWA85V8F (Atorvastatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Atorvastatin/adverse effects
MH  - *COVID-19
MH  - Humans
MH  - India
MH  - Nicorandil
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - SARS-CoV-2
MH  - Treatment Outcome
PMC - PMC8280682
OTO - NOTNLM
OT  - Aspirin
OT  - Atorvastatin
OT  - COVID-19
OT  - Hospitalised patients
OT  - Nicorandil
OT  - Protocol
OT  - Randomised control trial
COIS- Authors declare that they have no competing interests.
EDAT- 2021/07/17 06:00
MHDA- 2021/07/20 06:00
CRDT- 2021/07/16 05:36
PHST- 2021/05/28 00:00 [received]
PHST- 2021/06/07 00:00 [accepted]
PHST- 2021/07/16 05:36 [entrez]
PHST- 2021/07/17 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
AID - 10.1186/s13063-021-05361-y [pii]
AID - 5361 [pii]
AID - 10.1186/s13063-021-05361-y [doi]
PST - epublish
SO  - Trials. 2021 Jul 15;22(1):451. doi: 10.1186/s13063-021-05361-y.

PMID- 6499897
OWN - NLM
STAT- MEDLINE
DCOM- 19841226
LR  - 20190813
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 27
IP  - 2
DP  - 1984
TI  - Actions and interactions of acetylsalicylic acid, salicylic acid and diflunisal 
      on platelet aggregation.
PG  - 165-8
AB  - Acetylsalicylic acid (ASA) is increasingly employed in the secondary prophylaxis 
      of thromboembolic diseases, due to its capacity to inhibit platelet aggregation. 
      The anti-aggregatory effect of ASA on platelets can be inhibited in vitro by a 
      high concentration of salicylic acid (SA). SA is generated in vivo upon ASA 
      administration, and the SA thus formed might impair the antiplatelet effect of 
      ASA. To assess this possibility, the platelet response to ASA was tested in 
      healthy volunteers before and after medication for 1 week with ASA 1 g t.i.d., 
      with SA 1 g t.i.d., and with the SA derivative diflunisal 0.5 g b.i.d. 
      Pre-medication test doses of 1 g ASA always inhibited platelet aggregation in 
      vivo. Neither treatment with SA nor diflunisal, producing plasma steady-state 
      concentrations of about 1.0 and 0.35 mmol/l, respectively, inhibited platelet 
      aggregation. Nor did administration of SA, diflunisal or ASA itself impair the 
      anti-aggregatory effect of a fresh test dose of ASA. ASA inhibited platelet 
      aggregation in vitro at 0.03 mmol/l, whereas SA and diflunisal failed to impair 
      platelet aggregation until concentrations exceeding 2.0 and 0.5 mmol/l, 
      respectively, were reached. These findings make it unlikely that SA formed upon 
      administration of ASA would impair the anti-aggregating capacity of ASA.
FAU - Nitelius, E
AU  - Nitelius E
FAU - Brantmark, B
AU  - Brantmark B
FAU - Fredholm, B
AU  - Fredholm B
FAU - Hedner, U
AU  - Hedner U
FAU - Forshell, G P
AU  - Forshell GP
FAU - Wåhlin-Boll, E
AU  - Wåhlin-Boll E
FAU - Melander, A
AU  - Melander A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Salicylates)
RN  - 7C546U4DEN (Diflunisal)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Diflunisal/*pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Salicylates/*pharmacology
MH  - Salicylic Acid
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1007/BF00544040 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 1984;27(2):165-8. doi: 10.1007/BF00544040.

PMID- 1618199
OWN - NLM
STAT- MEDLINE
DCOM- 19920803
LR  - 20141120
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 13
IP  - 5
DP  - 1992 May
TI  - Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 
      trial. ISIS-2 (Second International Study of Infarct Survival) Collaborative 
      Group.
PG  - 594-8
AB  - To investigate the circadian pattern of acute myocardial infarction (MI) in a 
      large international patient population, the time of day of the onset of symptoms 
      was prospectively determined in 12,163 consecutive patients randomized in the 
      ISIS-2 Trial (Second International Study of Infarct Survival). Overall, there was 
      a marked circadian variation (P less than 0.001) in the incidence of MI 
      characterized by a sharp increase from 0600 h to 0800 h, with a peak period from 
      0800 h to 1100 h followed by a gradual decline from 1100 h to 1800 h. During the 
      evening and night there was a steady trough, with no evidence of a second peak. 
      Although there was some scatter, this circadian pattern was similar among 
      patients of five different geographic regions on three continents and in various 
      subcategories of patients defined with respect to age, gender, previous MI, and 
      aspirin intake prior to MI. The circadian pattern of diabetics, however, was 
      different compared with non-diabetics (P less than 0.005, adjusted less than 
      0.01), and it demonstrated no significant variation. This increased morning 
      incidence of MI indicates specific triggering mechanisms that are particularly 
      likely to occur during, or just before, that time of day. Further investigation 
      of physiological changes during the day is needed to identify any such triggers 
      of MI and so perhaps to aid in improving preventive strategies of the disease.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Review
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Circadian Rhythm/physiology
MH  - Diabetes Mellitus, Type 2/complications
MH  - Diabetic Angiopathies/drug therapy/epidemiology/etiology/physiopathology
MH  - Female
MH  - *Global Health
MH  - Humans
MH  - Incidence
MH  - International Cooperation
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/epidemiology/*etiology/physiopathology
MH  - Sex Factors
RF  - 31
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
PST - ppublish
SO  - Eur Heart J. 1992 May;13(5):594-8.

PMID- 6735843
OWN - NLM
STAT- MEDLINE
DCOM- 19840813
LR  - 20141120
IS  - 0003-1488 (Print)
IS  - 0003-1488 (Linking)
VI  - 184
IP  - 10
DP  - 1984 May 15
TI  - Lacerations of the equine eye: a review of 48 cases.
PG  - 1243-8
AB  - Perforating corneal wounds in horses have a better prognosis than wounds that 
      involve both cornea and sclera. Sharp objects tend to produce more isolated 
      corneal wounds and have a better prognosis than do wounds produced by blunt 
      objects. The records of 43 horses that sustained penetrating wounds of the cornea 
      were reviewed. In addition, the surgical approach and postoperative wound 
      management is described. The report attempts to provide more information 
      regarding the management of ocular trauma in horses.
FAU - Lavach, J D
AU  - Lavach JD
FAU - Severin, G A
AU  - Severin GA
FAU - Roberts, S M
AU  - Roberts SM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Am Vet Med Assoc
JT  - Journal of the American Veterinary Medical Association
JID - 7503067
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Cornea/surgery
MH  - *Corneal Injuries
MH  - Horse Diseases/*surgery
MH  - Horses
MH  - Postoperative Care/veterinary
MH  - Prognosis
MH  - Sclera/*injuries/surgery
MH  - Wounds, Nonpenetrating/surgery/*veterinary
MH  - Wounds, Penetrating/surgery/*veterinary
EDAT- 1984/05/15 00:00
MHDA- 1984/05/15 00:01
CRDT- 1984/05/15 00:00
PHST- 1984/05/15 00:00 [pubmed]
PHST- 1984/05/15 00:01 [medline]
PHST- 1984/05/15 00:00 [entrez]
PST - ppublish
SO  - J Am Vet Med Assoc. 1984 May 15;184(10):1243-8.

PMID- 36708886
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230322
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
VI  - 209
DP  - 2023 Mar
TI  - Hsp90 protected chicken primary myocardial cells from heat-stress injury by 
      inhibiting oxidative stress and calcium overload in mitochondria.
PG  - 115434
LID - S0006-2952(23)00025-4 [pii]
LID - 10.1016/j.bcp.2023.115434 [doi]
AB  - Severe heat stress can cause human and animal heart failure and sudden death, 
      which is an important issue of public health worldwide. Our previous studies in 
      animals showed that myocardial cells injury was critical in the above process, 
      and Hsp90 induction has a definite anti-myocardial injury effect, especially 
      through aspirin (ASA). But the mechanism has not been fully clarified. In this 
      study, an in vitro heat stress model of chicken primary myocardial cells (CPMCs) 
      most sensitive to heat stress was used to explore the cell injuries and 
      corresponding molecular resistance mechanism. We found that heat stress resulted 
      in serious oxidation stress and calcium overload in mitochondria, which destroyed 
      the mitochondrial structure and function and then triggered the cell death 
      mechanism of CPMCs. Hsp90 was proven to be a central regulator for resisting 
      heat-stress injury in CPMCs mitochondria using its inhibitor and inducer 
      (geldanamycin and ASA), respectively. The mechanism involved that Hsp90 could 
      activate Akt and PKM2 signals to promote Bcl-2 translocation into mitochondria 
      and its phosphorylation, thereby preventing ROS production and subsequent cell 
      apoptosis. In addition, Hsp90 inhibited mitochondrial calcium overload to 
      overcome MPTP opening and MMP suppression through the inhibitory effect of 
      Raf-1-ERK activation on the CREB-IP3R pathway. This study is the first to reveal 
      a pivotal reason for heat-stressed damage in chicken myocardial cells at 
      subcellular level and identify an effective regulator, Hsp90, and its protective 
      mechanisms responsible for maintaining mitochondrial homeostasis.
CI  - Copyright © 2023 Elsevier Inc. All rights reserved.
FAU - Yao, Xu
AU  - Yao X
AD  - Department of Veterinary Medicine, College of Animal Science and Technology, 
      Hainan University, Haikou 570228, China.
FAU - Zhu, Jie
AU  - Zhu J
AD  - Department of Basic Veterinary Medicine, College of Veterinary Medicine, Nanjing 
      Agricultural University, Nanjing 210095, China.
FAU - Li, Lin
AU  - Li L
AD  - Department of Food Science and Engineering, College of Biological Science and 
      Engineering, Xingtai University, Xingtai 054001, China.
FAU - Yang, Bo
AU  - Yang B
AD  - Department of Basic Veterinary Medicine, College of Veterinary Medicine, Nanjing 
      Agricultural University, Nanjing 210095, China.
FAU - Chen, Bixia
AU  - Chen B
AD  - Department of Basic Veterinary Medicine, College of Veterinary Medicine, Nanjing 
      Agricultural University, Nanjing 210095, China.
FAU - Bao, Endong
AU  - Bao E
AD  - Department of Basic Veterinary Medicine, College of Veterinary Medicine, Nanjing 
      Agricultural University, Nanjing 210095, China.
FAU - Zhang, Xiaohui
AU  - Zhang X
AD  - Department of Veterinary Medicine, College of Animal Science and Technology, 
      Hainan University, Haikou 570228, China. Electronic address: 
      995354@hainanu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230125
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - SY7Q814VUP (Calcium)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (HSP90 Heat-Shock Proteins)
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Chickens
MH  - *Calcium/metabolism
MH  - Heat-Shock Response/physiology
MH  - Apoptosis
MH  - Oxidative Stress
MH  - Aspirin/pharmacology
MH  - HSP90 Heat-Shock Proteins/metabolism
MH  - Mitochondria/metabolism
OTO - NOTNLM
OT  - Chicken primary myocardial cells
OT  - Heat stress
OT  - Hsp90
OT  - Mitochondrial damage
OT  - Signaling pathway
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/01/29 06:00
MHDA- 2023/03/15 06:00
CRDT- 2023/01/28 19:26
PHST- 2022/10/02 00:00 [received]
PHST- 2022/12/09 00:00 [revised]
PHST- 2022/12/22 00:00 [accepted]
PHST- 2023/01/29 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2023/01/28 19:26 [entrez]
AID - S0006-2952(23)00025-4 [pii]
AID - 10.1016/j.bcp.2023.115434 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2023 Mar;209:115434. doi: 10.1016/j.bcp.2023.115434. Epub 2023 
      Jan 25.

PMID- 6763202
OWN - NLM
STAT- MEDLINE
DCOM- 19830610
LR  - 20201209
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 2
IP  - 3
DP  - 1982 May-Jun
TI  - Analgesic efficacy of an ibuprofen-codeine combination.
PG  - 162-7
AB  - Subjects who had undergone dental impaction surgery and who had moderate to 
      severe postoperative pain were given, under double-blind, randomized conditions, 
      a single dose of either codeine 60 mg, aspirin 650 mg, ibuprofen 400 mg, aspirin 
      650 mg + codeine 60 mg, ibuprofen 400 mg + codeine 60 mg, or placebo. A total of 
      249 subjects were included in the statistical analysis. On a report form, 
      subjects recorded pain intensity, pain relief, and side effects hourly for four 
      hours. They also gave an overall impression at the end of the observation period. 
      Analysis of variance and pairwise contrasts were used to analyze the data. For 
      the sum of pain intensity differences, the total of the hourly pain relief 
      scores, and overall impression, there was a significant analgesic effect for 
      codeine, aspirin, and ibuprofen and no significant interaction when they were 
      used in combination. Ibuprofen alone was statistically superior to aspirin and 
      also achieved higher mean scores than the aspirin-codeine combination. The 
      ibuprofen-codeine combination was the most effective treatment for every 
      analgesic parameter, but it was not statistically superior to ibuprofen alone. 
      The possibility exists that the ibuprofen-codeine combination peaked out the 
      sensitivity of the model. There was no notable difference in the frequency or 
      intensity of side effects among the treatment groups, and no subject had to 
      withdraw due to an adverse effect. This study again confirms the superiority of 
      ibuprofen to aspirin and suggests that ibuprofen is at least as effective as an 
      aspirin-codeine combination. Codeine added a small amount of additional analgesia 
      when used in combination with ibuprofen.
FAU - Cooper, S A
AU  - Cooper SA
FAU - Engel, J
AU  - Engel J
FAU - Ladov, M
AU  - Ladov M
FAU - Precheur, H
AU  - Precheur H
FAU - Rosenheck, A
AU  - Rosenheck A
FAU - Rauch, D
AU  - Rauch D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Codeine/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Ibuprofen/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy
MH  - Random Allocation
MH  - Surveys and Questionnaires
MH  - Tooth, Impacted/surgery
EDAT- 1982/05/01 00:00
MHDA- 1982/05/01 00:01
CRDT- 1982/05/01 00:00
PHST- 1982/05/01 00:00 [pubmed]
PHST- 1982/05/01 00:01 [medline]
PHST- 1982/05/01 00:00 [entrez]
AID - 10.1002/j.1875-9114.1982.tb04528.x [doi]
PST - ppublish
SO  - Pharmacotherapy. 1982 May-Jun;2(3):162-7. doi: 
      10.1002/j.1875-9114.1982.tb04528.x.

PMID- 9083635
OWN - NLM
STAT- MEDLINE
DCOM- 19970605
LR  - 20191101
IS  - 1073-1199 (Print)
IS  - 1073-1199 (Linking)
VI  - 25
IP  - 1-2
DP  - 1997 Jan-Mar
TI  - Alpha-alpha diaspirin crosslinked hemoglobin, nitric oxide, and cerebral ischemic 
      injury in rats.
PG  - 141-52
AB  - Prior studies indicate that alpha-alpha diaspirin crosslinked hemoglobin (DCLHb) 
      decreases cerebral ischemia. One mechanism whereby DCLHb may ameliorate cerebral 
      ischemia is by binding nitric oxide (NO), which has been implicated as 
      neurotoxic. We assessed the effect of L-NAME (NO synthase inhibitor) and 
      L-arginine (NO substrate) on ischemic brain injury after DCLHb infusion. Rats 
      were randomized to one of the following groups: Control-no hematocrit 
      manipulation; DCLHb-hematocrit decreased to 16% with 10% DCLHb; 
      DCLHb/L-NAME-hematocrit decreased to 16% with DCLHb, and L-NAME given; 
      DCLHb/L-arg-hematocrit decreased to 16% with DCLHb, and L-arginine given. After 
      90-min of middle cerebral artery occlusion and 4-hr of reperfusion, infarct 
      volume was determined with TTC stain. Infarct volume (mm3, mean +/- SD) was 
      greater in the Control group (142 +/- 16) than the DCLHb (43 +/- 12), 
      DCLHb/L-NAME (45 +/- 14), and DCLHb/L-arg (71 +/- 18) groups (p < 0.05); was 
      greater in the DCLHb/L-arg group than the DCLHb and DCLHb/L-NAME groups (p < 
      0.05); but was not different between the DCLHb and DCLHb/L-NAME groups. These 
      data indicate that DCLHb decreases ischemic brain injury, and that binding NO may 
      be one mechanism by which DCLHb decreases ischemic brain injury.
FAU - Cole, D J
AU  - Cole DJ
AD  - Department of Anesthesiology School of Medicine Loma Linda University, California 
      92354, USA.
FAU - Nary, J C
AU  - Nary JC
FAU - Drummond, J C
AU  - Drummond JC
FAU - Patel, P M
AU  - Patel PM
FAU - Jacobsen, W K
AU  - Jacobsen WK
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Blood Substit Immobil Biotechnol
JT  - Artificial cells, blood substitutes, and immobilization biotechnology
JID - 9431307
RN  - 0 (Blood Glucose)
RN  - 0 (Blood Substitutes)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Hemoglobins)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 94ZLA3W45F (Arginine)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - IM
MH  - Animals
MH  - Arginine/pharmacology
MH  - Arterial Occlusive Diseases/drug therapy/metabolism
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Blood Gas Analysis
MH  - Blood Glucose
MH  - Blood Substitutes/*pharmacology
MH  - Brain Ischemia/*drug therapy/metabolism
MH  - Cerebral Infarction/drug therapy/metabolism/pathology
MH  - Cross-Linking Reagents/chemistry/pharmacology
MH  - Enzyme Inhibitors/pharmacology
MH  - Hematocrit
MH  - Hemoglobins/chemistry/*pharmacology
MH  - Humans
MH  - Male
MH  - NG-Nitroarginine Methyl Ester/pharmacology
MH  - Nitric Oxide/*metabolism
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Reperfusion Injury/*drug therapy/metabolism
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.3109/10731199709118906 [doi]
PST - ppublish
SO  - Artif Cells Blood Substit Immobil Biotechnol. 1997 Jan-Mar;25(1-2):141-52. doi: 
      10.3109/10731199709118906.

PMID- 34087567
OWN - NLM
STAT- MEDLINE
DCOM- 20210811
LR  - 20210811
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 427
DP  - 2021 Aug 15
TI  - Impact of acetylsalicylic acid (ASA) on postoperative hemorrhage in spinal lumbar 
      surgery: Should preoperative ASA be discontinued for elective surgery?
PG  - 117508
LID - S0022-510X(21)00202-1 [pii]
LID - 10.1016/j.jns.2021.117508 [doi]
AB  - OBJECTIVE: The application of acetylsalicylic acid (ASA) represents high evidence 
      in the aging society due to primary and secondary prevention in cardiovascular 
      disease and stroke. However, this presents a challenge for neurosurgeons in terms 
      of preoperative and postoperative management of care. This study aimed to analyze 
      the risk of bleeding by applying ASA before lumbar spinal surgery. METHODS: 
      Retrospective analysis of medical records of 3051 patients was performed from 
      2008 to 2018 who underwent lumbar surgery at our institution. The risk of 
      postoperative hemorrhage was compared in patients treated with ASA versus 
      patients without ASA treatment. Additionally, the relationship between 
      discontinuation of ASA preoperatively (≥7 days) or no previous history of ASA 
      versus continuation with ASA (<7 days) on postoperative hemorrhage was analyzed. 
      RESULTS: Postoperative hemorrhagic were observed in 2.1% (n = 63) of all lumbar 
      operations. In 421 patients, the effect of ASA (<7 days) was still persistent at 
      the time of surgery (ASA impact group). Of these, 12 (2.85%) patients had a 
      hemorrhage. No significant differences were found in comparison to the No ASA 
      impact group (p = 0.272). Sex (p = 0.003), hypertension (p = 0.015), recurrent 
      surgery (p = 0.001) and use of hemostatic agents (p = 0.023) had a significant 
      impact on postoperative hemorrhage. CONCLUSION: The continuation of ASA 
      medication is not associated with increased risk of postoperative hemorrhage 
      after spinal surgery. However, sex, hypertension, recurrent surgery and the use 
      of hemostatic agents under continued ASA treatment were found to be associated 
      with an increased risk of hemorrhage.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Rashidi, Ali
AU  - Rashidi A
AD  - Department of Neurosurgery, Otto-von-Guericke University, Magdeburg, Germany. 
      Electronic address: ali.rashidi@med.ovgu.de.
FAU - Leins, Fabian
AU  - Leins F
AD  - Department of Neurosurgery, Otto-von-Guericke University, Magdeburg, Germany.
FAU - Sandalcioglu, I Erol
AU  - Sandalcioglu IE
AD  - Department of Neurosurgery, Otto-von-Guericke University, Magdeburg, Germany.
FAU - Luchtmann, Michael
AU  - Luchtmann M
AD  - Department of Neurosurgery, Otto-von-Guericke University, Magdeburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210524
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - Elective Surgical Procedures
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/adverse effects
MH  - Postoperative Hemorrhage/chemically induced/epidemiology
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Acetylsalicylic acid
OT  - Lumbar spinal surgery
OT  - Postoperative hemorrhage
OT  - Risk factors
EDAT- 2021/06/05 06:00
MHDA- 2021/08/12 06:00
CRDT- 2021/06/04 20:20
PHST- 2021/03/25 00:00 [received]
PHST- 2021/05/17 00:00 [revised]
PHST- 2021/05/21 00:00 [accepted]
PHST- 2021/06/05 06:00 [pubmed]
PHST- 2021/08/12 06:00 [medline]
PHST- 2021/06/04 20:20 [entrez]
AID - S0022-510X(21)00202-1 [pii]
AID - 10.1016/j.jns.2021.117508 [doi]
PST - ppublish
SO  - J Neurol Sci. 2021 Aug 15;427:117508. doi: 10.1016/j.jns.2021.117508. Epub 2021 
      May 24.

PMID- 30293849
OWN - NLM
STAT- MEDLINE
DCOM- 20181109
LR  - 20181109
IS  - 2213-0276 (Electronic)
IS  - 0755-4982 (Linking)
VI  - 47
IP  - 9
DP  - 2018 Sep
TI  - [Is cancer a factor or a marker of cardiovascular risk in women?].
PG  - 780-783
LID - S0755-4982(18)30338-5 [pii]
LID - 10.1016/j.lpm.2018.09.004 [doi]
AB  - Cardiovascular diseases and cancers are the 2 main causes of mortality in 
      industrialized countries. Cancer and cardiovascular disease share molecular and 
      pathophysiological mechanisms involved in both cardiovascular disease and cancer 
      development. Some prescribed therapies for primary or secondary prevention of 
      cardiovascular disease (statin, aspirin) may have effects on the cancer plan. 
      Physical activity would be particularly beneficial in reducing the risk of 
      colorectal cancer, breast and endometrial cancer in women. The control of risk 
      factors is associated with a reduction in the incidence of cancers.
CI  - Copyright © 2018. Published by Elsevier Masson SAS.
FAU - Ederhy, Stéphane
AU  - Ederhy S
AD  - AP-HP, hôpital Saint-Antoine, université Pierre-et-Marie-Curie, Paris-Sorbonne, 
      service de cardiologie, 184, rue du faubourg Saint-Antoine, 75571 Paris cedex 12, 
      France.
FAU - Ancedy, Yann
AU  - Ancedy Y
AD  - AP-HP, hôpital Saint-Antoine, université Pierre-et-Marie-Curie, Paris-Sorbonne, 
      service de cardiologie, 184, rue du faubourg Saint-Antoine, 75571 Paris cedex 12, 
      France.
FAU - Soulat-Dufour, Laurie
AU  - Soulat-Dufour L
AD  - AP-HP, hôpital Saint-Antoine, université Pierre-et-Marie-Curie, Paris-Sorbonne, 
      service de cardiologie, 184, rue du faubourg Saint-Antoine, 75571 Paris cedex 12, 
      France.
FAU - Chauvet-Droit, Marion
AU  - Chauvet-Droit M
AD  - AP-HP, hôpital Saint-Antoine, université Pierre-et-Marie-Curie, Paris-Sorbonne, 
      service de cardiologie, 184, rue du faubourg Saint-Antoine, 75571 Paris cedex 12, 
      France.
FAU - Cohen, Ariel
AU  - Cohen A
AD  - AP-HP, hôpital Saint-Antoine, université Pierre-et-Marie-Curie, Paris-Sorbonne, 
      service de cardiologie, 184, rue du faubourg Saint-Antoine, 75571 Paris cedex 12, 
      France. Electronic address: ariel.cohen@aphp.fr.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Cancer : facteur ou marqueur de risque cardiovasculaire chez la femme ?
DEP - 20181004
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Biomarkers)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Biomarkers
MH  - Cardiovascular Diseases/drug therapy/*epidemiology/*etiology
MH  - Chemoprevention/methods
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Incidence
MH  - Neoplasms/*complications/*epidemiology/prevention & control
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Sex Factors
EDAT- 2018/10/09 06:00
MHDA- 2018/11/10 06:00
CRDT- 2018/10/09 06:00
PHST- 2018/06/25 00:00 [received]
PHST- 2018/09/07 00:00 [revised]
PHST- 2018/09/07 00:00 [accepted]
PHST- 2018/10/09 06:00 [pubmed]
PHST- 2018/11/10 06:00 [medline]
PHST- 2018/10/09 06:00 [entrez]
AID - S0755-4982(18)30338-5 [pii]
AID - 10.1016/j.lpm.2018.09.004 [doi]
PST - ppublish
SO  - Presse Med. 2018 Sep;47(9):780-783. doi: 10.1016/j.lpm.2018.09.004. Epub 2018 Oct 
      4.

PMID- 24728510
OWN - NLM
STAT- MEDLINE
DCOM- 20151015
LR  - 20161125
IS  - 1744-6848 (Electronic)
IS  - 1744-683X (Linking)
VI  - 10
IP  - 22
DP  - 2014 Jun 14
TI  - Stimuli-responsive one-dimensional copolymer nanostructures fabricated by 
      metallogel template polymerization and their adsorption of aspirin.
PG  - 3960-9
LID - 10.1039/c4sm00121d [doi]
AB  - pH responsive poly(N,N'-methylenebisacrylamide-co-4-vinylpyridine) (P(MBA-4VP)) 
      one dimensional (1D) nanostructures have been prepared by metallogel template 
      copolymerization, which was carried out in an Ag(i)-coordinated organogel with 
      benzoyl peroxide (BPO) as the initiator. The product has been characterized using 
      infrared spectroscopy, scanning electron microscopy and transmission electron 
      microscopy. The experimental results reveal that the gel fiber is a crucial 
      template for polymerization. Due to the degradation of the template in 
      copolymerization, nanofibers of metallogel were transcribed to copolymer 
      nanowires. The introduction of co-monomer 4-vinylpyridine (4VP) imparts to the 1D 
      copolymer nanostructures pH sensitivity and the possible use as an adsorption 
      material of aspirin. Adsorbed 1D copolymer nanostructures could be regenerated 
      using proton solvent, acid medium and salt solution. In addition, silver 
      nanoparticle loaded copolymer nanowires have been produced from the reduction of 
      silver ions instead of template removal, where silver ions act both as the 
      template and as the nanoparticle growth substrate.
FAU - Wen, Xing
AU  - Wen X
AD  - Key Laboratory of Advanced materials of Ministry of Education of China, 
      Department of Chemical Engineering, Tsinghua University, Beijing 100084, P. R. 
      China. tanglm@tsinghua.edu.cn.
FAU - Tang, Liming
AU  - Tang L
FAU - Qiang, Lu
AU  - Qiang L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140414
PL  - England
TA  - Soft Matter
JT  - Soft matter
JID - 101295070
RN  - 0 (Gels)
RN  - 0 (Polymers)
RN  - 0 (Pyridines)
RN  - 3M4G523W1G (Silver)
RN  - I56G67XM8D (4-vinylpyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Aspirin/*chemistry
MH  - Gels/*chemistry
MH  - Hydrogen-Ion Concentration
MH  - Metal Nanoparticles/chemistry
MH  - Nanostructures/*chemistry/ultrastructure
MH  - Nanowires/chemistry
MH  - Polymers/chemical synthesis/*chemistry
MH  - Pyridines/chemistry
MH  - Rheology
MH  - Silver/*chemistry
EDAT- 2014/04/15 06:00
MHDA- 2015/10/16 06:00
CRDT- 2014/04/15 06:00
PHST- 2014/04/15 06:00 [entrez]
PHST- 2014/04/15 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - 10.1039/c4sm00121d [doi]
PST - ppublish
SO  - Soft Matter. 2014 Jun 14;10(22):3960-9. doi: 10.1039/c4sm00121d. Epub 2014 Apr 
      14.

PMID- 19420571
OWN - NLM
STAT- MEDLINE
DCOM- 20090623
LR  - 20180721
IS  - 1361-6528 (Electronic)
IS  - 0957-4484 (Linking)
VI  - 20
IP  - 16
DP  - 2009 Apr 22
TI  - Magnetic molecularly imprinted polymer for aspirin recognition and controlled 
      release.
PG  - 165601
LID - 10.1088/0957-4484/20/16/165601 [doi]
AB  - Core-shell structural magnetic molecularly imprinted polymers (magnetic MIPs) 
      with combined properties of molecular recognition and controlled release were 
      prepared and characterized. Magnetic MIPs were synthesized by the 
      co-polymerization of methacrylic acid (MAA) and trimethylolpropane 
      trimethacrylate (TRIM) around aspirin (ASP) at the surface of 
      double-bond-functionalized Fe(3)O(4) nanoparticles in chloroform. The obtained 
      spherical magnetic MIPs with diameters of about 500 nm had obvious 
      superparamagnetism and could be separated quickly by an external magnetic field. 
      Binding experiments were carried out to evaluate the properties of magnetic MIPs 
      and magnetic non-molecularly imprinted polymers (magnetic NIPs). The results 
      demonstrated that the magnetic MIPs had high adsorption capacity and selectivity 
      to ASP. Moreover, release profiles and release rate of ASP from the ASP-loaded 
      magnetic MIPs indicated that the magnetic MIPs also had potential applications in 
      drug controlled release.
FAU - Kan, Xianwen
AU  - Kan X
AD  - State Key Laboratory of Coordination Chemistry, MOE Key Lab of Analytical 
      Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing 
      University, 22 Hankou Road, Nanjing 210093, People's Republic of China.
FAU - Geng, Zhirong
AU  - Geng Z
FAU - Zhao, Yao
AU  - Zhao Y
FAU - Wang, Zhilin
AU  - Wang Z
FAU - Zhu, Jun-Jie
AU  - Zhu JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090401
PL  - England
TA  - Nanotechnology
JT  - Nanotechnology
JID - 101241272
RN  - 0 (Drug Carriers)
RN  - 0 (Methacrylates)
RN  - 0 (Polymers)
RN  - 1CS02G8656 (methacrylic acid)
RN  - R16CO5Y76E (Aspirin)
RN  - S734UC120F (trimethylolpropane trimethacrylate)
SB  - IM
MH  - Aspirin/*metabolism
MH  - Drug Carriers/chemical synthesis/*metabolism
MH  - Magnetics
MH  - Methacrylates/metabolism
MH  - Nanoparticles/chemistry
MH  - Polymers/chemical synthesis/*metabolism
EDAT- 2009/05/08 09:00
MHDA- 2009/06/24 09:00
CRDT- 2009/05/08 09:00
PHST- 2009/05/08 09:00 [entrez]
PHST- 2009/05/08 09:00 [pubmed]
PHST- 2009/06/24 09:00 [medline]
AID - S0957-4484(09)96041-X [pii]
AID - 10.1088/0957-4484/20/16/165601 [doi]
PST - ppublish
SO  - Nanotechnology. 2009 Apr 22;20(16):165601. doi: 10.1088/0957-4484/20/16/165601. 
      Epub 2009 Apr 1.

PMID- 1884675
OWN - NLM
STAT- MEDLINE
DCOM- 19911010
LR  - 20131121
IS  - 0012-0472 (Print)
IS  - 0012-0472 (Linking)
VI  - 116
IP  - 36
DP  - 1991 Sep 6
TI  - [Recurrent thromboembolism due to increased acetylsalicylic acid-resistant 
      platelet aggregation].
PG  - 1353-6
AB  - A 49-year-old man had for 30 years suffered from severe recurrent thromboembolism 
      with leg-vein thrombosis, pulmonary emboli, mesenteric infarction, 
      cerebrovascular accident, cerebral vein thrombosis, portal vein thrombosis and 
      femoral artery occlusion requiring leg amputation. In addition to moderately 
      increased clotting activation with single-fold positive demonstration of fibrin 
      monomers and a D-dimer concentration of 1 mg/l platelet aggregation was increased 
      and could not be influenced by aspirin, 300 mg daily. Despite aspirin there were 
      recurrent transitory attacks of cerebral ischaemia. Fibrin monomers were 
      threefold positive and D-dimer concentration was increased to 4 mg/l (elevated 
      clotting activation). Ticlopidine administration (250 mg daily) reduced adenosine 
      diphosphate-induced platelet aggregation by 30% without effect on 
      collagen-induced platelet aggregation. In parallel to these changes the patient's 
      general condition clearly improved: fibrin monomers were no longer demonstrated 
      and the D-dimer level fell to 0.5 mg/l.
FAU - Himmelreich, G
AU  - Himmelreich G
AD  - Medizinische Klinik und Poliklinik, Klinikum Rudolf Virchow, Standort 
      Charlottenburg, Freien Universität Berlin.
FAU - Riess, H
AU  - Riess H
LA  - ger
PT  - Case Reports
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Rezidivierende Thromboembolien infolge gesteigerter, gegen Acetylsalicylsäure 
      resistenter Thrombozytenaggregation.
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 9001-31-4 (Fibrin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*pharmacology
MH  - Fibrin/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Recurrence
MH  - Thromboembolism/*blood/drug therapy
MH  - Ticlopidine/pharmacology/therapeutic use
EDAT- 1991/09/06 00:00
MHDA- 1991/09/06 00:01
CRDT- 1991/09/06 00:00
PHST- 1991/09/06 00:00 [pubmed]
PHST- 1991/09/06 00:01 [medline]
PHST- 1991/09/06 00:00 [entrez]
AID - 10.1055/s-2008-1063758 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 1991 Sep 6;116(36):1353-6. doi: 10.1055/s-2008-1063758.

PMID- 6975558
OWN - NLM
STAT- MEDLINE
DCOM- 19820128
LR  - 20131121
IS  - 0301-0546 (Print)
IS  - 0301-0546 (Linking)
VI  - 9
IP  - 4
DP  - 1981 Jul-Aug
TI  - [Syndrome due to acetylsalicylic acid intolerance. What should be prescribed as 
      substitutes for aspirin?].
PG  - 313-8
AB  - In the daily practice of allergology, one of our commonest problems concerns the 
      prescription of nonsteroidal anti-inflammatory drugs for our patients who are 
      intolerant of acetylsalicylic acid, whose basic clinical expression of this 
      intolerance is primary bronchial asthma. Our problem is the high frequency with 
      which the syndrome appears after the administration of other analgesics 
      chemically unrelated to acetylsalicylic acid. Most authors accept that 
      derivatives of pyrazolones and indoles, and of phenylisopropionic and anthranilic 
      acids must be avoided. This avoidance is based on collected clinical experience 
      and the currently accepted hypothesis concerning the pathogenesis of the syndrome 
      (pyrazolones, indoles, etc. are inhibitors of the byosynthesis of the E series of 
      prostaglandins, particularly PG synthetase). On the other hand there is no 
      agreement concerning what type of analgesics, anti-inflammatory drugs and 
      antipyretics we should prescribe for these patients. The conclusions of the 
      protocol which we carried out are as follows. Dextropropoxyphene chlorhydrate, 
      diviminol, tilidine chlorhydrate, salicylamide, benzidamine, pentazocine, 
      isonixine, hyoscine bromide and ergotamine tartrate can be prescribed safely for 
      these patients in the usual therapeutic dosage. To the list of prohibitions 
      should be added the derivatives of glaphenine and phenylacetic acid. As regards 
      paracetamol, our opinion is that its use should be restricted to those cases in 
      which the previously listed drugs cannot be substituted for it, and always after 
      administration under medical supervision in a hospital setting.
FAU - Alvarez Cuesta, E
AU  - Alvarez Cuesta E
FAU - Moneo Goiri, I
AU  - Moneo Goiri I
FAU - Sánchez Cano, M
AU  - Sánchez Cano M
FAU - Cuevas Agustín, M
AU  - Cuevas Agustín M
FAU - Losada Cosmes, E
AU  - Losada Cosmes E
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Síndrome de intolerancia al a. acetil salicílico. Qué prescribir?
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analgesics/therapeutic use
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced
MH  - Drug Hypersensitivity/*etiology
MH  - Humans
EDAT- 1981/07/01 00:00
MHDA- 1981/07/01 00:01
CRDT- 1981/07/01 00:00
PHST- 1981/07/01 00:00 [pubmed]
PHST- 1981/07/01 00:01 [medline]
PHST- 1981/07/01 00:00 [entrez]
PST - ppublish
SO  - Allergol Immunopathol (Madr). 1981 Jul-Aug;9(4):313-8.

PMID- 17640058
OWN - NLM
STAT- MEDLINE
DCOM- 20071127
LR  - 20220614
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 121
IP  - 9
DP  - 2007 Nov 1
TI  - Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma 
      recurrence in the context of a randomized aspirin intervention trial.
PG  - 2001-2004
LID - 10.1002/ijc.22942 [doi]
AB  - Regular use of aspirin and other nonsteroidal antiinflammatory drugs reduces both 
      the development of colorectal neoplasia and recurrence of colorectal adenoma 
      (CRA). Modulation of the effects of aspirin by genetic factors has been reported, 
      potentially allowing targeting of treatment to individuals most likely to gain 
      benefit. Prostaglandin H synthase 1 (PTGS1) and PTGS2 are key enzymes in 
      prostaglandin synthesis and are inhibited by aspirin, whilst interleukin-10 
      (IL-10) is an important antiinflammatory cytokine. We investigated whether 
      functional genetic polymorphisms in the PTGS1, PTGS2 and IL-10 genes influence 
      CRA recurrence in individuals participating in a randomized aspirin intervention 
      trial. DNA was available for genotyping from 546 patients who received aspirin 
      (300 mg daily) or placebo for a mean 41-months' duration. Homozygote carriers of 
      variant alleles for the PTGS1 50C>T, PTGS2 -765G>C and IL-10 -592C>A 
      polymorphisms did not have a significantly altered risk of CRA recurrence 
      (relative risk [RR]=0.91; 95% confidence interval [CI]: 0.14-6.07, RR=1.32; 95% 
      CI: 0.66-2.62 and RR=1.24; 95% CI: 0.74-2.07, respectively). There were also no 
      significant interactions between aspirin intervention and genotype in determining 
      recurrence risk. These data indicate that these polymorphisms are unlikely to 
      influence CRA recurrence and cannot be used to identify individuals who derive 
      benefit from aspirin intervention.
CI  - Copyright (c) 2007 Wiley-Liss, Inc.
FAU - Hubner, Richard A
AU  - Hubner RA
AD  - Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5NG, United 
      Kingdom.
FAU - Muir, Kenneth R
AU  - Muir KR
AD  - Division of Epidemiology and Public Health Medical School, University of 
      Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom.
FAU - Liu, Jo-Fen
AU  - Liu JF
AD  - Division of Epidemiology and Public Health Medical School, University of 
      Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom.
FAU - Logan, Richard F A
AU  - Logan RFA
AD  - Division of Epidemiology and Public Health Medical School, University of 
      Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom.
FAU - Grainge, Matthew J
AU  - Grainge MJ
AD  - Division of Epidemiology and Public Health Medical School, University of 
      Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom.
FAU - Houlston, Richard S
AU  - Houlston RS
AD  - Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5NG, United 
      Kingdom.
CN  - Members of the UKCAP Consortium
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 130068-27-8 (Interleukin-10)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenoma/epidemiology/genetics/*pathology
MH  - Aspirin/*pharmacology/*therapeutic use
MH  - Colorectal Neoplasms/epidemiology/genetics/*pathology
MH  - Cyclooxygenase 1/*genetics
MH  - Cyclooxygenase 2/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Genotype
MH  - Humans
MH  - Interleukin-10/*genetics
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic/*genetics
MH  - Risk Factors
MH  - Secondary Prevention
EDAT- 2007/07/21 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/07/21 09:00
PHST- 2007/07/21 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/07/21 09:00 [entrez]
AID - 10.1002/ijc.22942 [doi]
PST - ppublish
SO  - Int J Cancer. 2007 Nov 1;121(9):2001-2004. doi: 10.1002/ijc.22942.

PMID- 6715565
OWN - NLM
STAT- MEDLINE
DCOM- 19840621
LR  - 20190825
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 24
IP  - 2-3
DP  - 1984 Feb-Mar
TI  - A controlled endoscopic study comparing the toxic effects of sulindac, naproxen, 
      aspirin, and placebo on the gastric mucosa of health volunteers.
PG  - 89-95
AB  - Sixty volunteers were endoscopically evaluated to compare gastric mucosal injury 
      following oral administration of sulindac, naproxen, aspirin, or placebo for two 
      consecutive seven-day periods. A single-blind technique was utilized wherein the 
      endoscopist was unaware which drug each volunteer had received. The following 
      dosages were employed for the two study periods: sulindac, 150 and 200 mg, 
      b.i.d., naproxen, 250 and 375 mg, b.i.d., and aspirin, 650 and 975 mg, q.i.d. The 
      only subject who developed a frank ulcer with mucosal bleeding was in the 
      sulindac group, however volunteers taking sulindac demonstrated statistically 
      less significant mucosal injury on endoscopic examination than those receiving 
      naproxen or aspirin.
FAU - Lanza, F L
AU  - Lanza FL
FAU - Nelson, R S
AU  - Nelson RS
FAU - Rack, M F
AU  - Rack MF
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Indenes)
RN  - 0 (Placebos)
RN  - 184SNS8VUH (Sulindac)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects/blood
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Gastroscopy
MH  - Humans
MH  - Indenes/*adverse effects
MH  - Male
MH  - Naproxen/*adverse effects/blood
MH  - Placebos
MH  - Stomach Ulcer/chemically induced
MH  - Sulindac/*adverse effects/blood
EDAT- 1984/02/01 00:00
MHDA- 1984/02/01 00:01
CRDT- 1984/02/01 00:00
PHST- 1984/02/01 00:00 [pubmed]
PHST- 1984/02/01 00:01 [medline]
PHST- 1984/02/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1984.tb02770.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1984 Feb-Mar;24(2-3):89-95. doi: 
      10.1002/j.1552-4604.1984.tb02770.x.

PMID- 19635624
OWN - NLM
STAT- MEDLINE
DCOM- 20100114
LR  - 20181201
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 285
IP  - 1-2
DP  - 2009 Oct 15
TI  - Spontaneous spinal epidural hematoma: an urgent complication of adding 
      clopidogrel to aspirin therapy.
PG  - 254-6
LID - 10.1016/j.jns.2009.06.028 [doi]
AB  - We report a 56-year-old patient who had been taking antihypertensive medication 
      in combination with prophylactic aspirin for 19 years who was diagnosed with 
      stable angina with significant coronary artery stenosis on angiography. He was 
      treated with drug-eluting coronary stent placement. Clopidogrel was added to the 
      previous treatment regimen after stent placement. He visited the emergency room 
      with complaints of severe back pain accompanied by radiculopathy and left leg 
      weakness. The patient had an excellent outcome after immediate diagnosis by MRI 
      and emergent evacuation of spontaneous spinal epidural hematoma (SSEH). The 
      present case is interesting because it is the first case in spine which 
      corresponds to the findings of MATCH study that bleeding tendency would be raised 
      by dual antiplatelet treatment (aspirin+clopidogrel). With the popularity of 
      antiplatelet medications, physicians should be aware of this critical side effect 
      and provide urgent treatment. Furthermore, we should be cautious when we 
      prescribe clopidogrel in addition to aspirin because it could cause bleeding 
      complications like SSEH.
FAU - Moon, Hong-Joo
AU  - Moon HJ
AD  - Department of Neurosurgery, Korea University Guro Hospital, Korea University 
      College of Medicine, Seoul, Korea.
FAU - Kim, Joo Han
AU  - Kim JH
FAU - Kim, Jong-Hyun
AU  - Kim JH
FAU - Kwon, Taek-Hyun
AU  - Kwon TH
FAU - Chung, Hung-Seob
AU  - Chung HS
FAU - Park, Youn-Kwan
AU  - Park YK
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20090726
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Coronary Stenosis/drug therapy/surgery
MH  - Decompression, Surgical
MH  - Drug Interactions
MH  - Hematoma, Epidural, Spinal/*chemically induced/pathology/surgery
MH  - Humans
MH  - Hypertension/drug therapy
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Spinal Cord/pathology/surgery
MH  - Stents
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2009/07/29 09:00
MHDA- 2010/01/15 06:00
CRDT- 2009/07/29 09:00
PHST- 2009/03/23 00:00 [received]
PHST- 2009/06/11 00:00 [revised]
PHST- 2009/06/12 00:00 [accepted]
PHST- 2009/07/29 09:00 [entrez]
PHST- 2009/07/29 09:00 [pubmed]
PHST- 2010/01/15 06:00 [medline]
AID - S0022-510X(09)00660-1 [pii]
AID - 10.1016/j.jns.2009.06.028 [doi]
PST - ppublish
SO  - J Neurol Sci. 2009 Oct 15;285(1-2):254-6. doi: 10.1016/j.jns.2009.06.028. Epub 
      2009 Jul 26.

PMID- 32009464
OWN - NLM
STAT- MEDLINE
DCOM- 20201028
LR  - 20201028
IS  - 1740-7753 (Electronic)
IS  - 1740-7745 (Linking)
VI  - 17
IP  - 2
DP  - 2020 Apr
TI  - Role of health plan administrative claims data in participant recruitment for 
      pragmatic clinical trials: An Aspirin Dosing: A Patient-centric Trial Assessing 
      Benefits and Long-term Effectiveness (ADAPTABLE) example.
PG  - 212-222
LID - 10.1177/1740774520902989 [doi]
AB  - AIM: The purpose of this study is to evaluate HealthCore/Anthem Research Network 
      recruitment strategies, compare response and enrollment rates for different 
      recruitment strategies, and describe demographic and clinical characteristics of 
      responders and enrollees. METHODS: HealthCore/Anthem Research Network, a part of 
      the Health Plan Research Network of the Patient-Centered Clinical Data Research 
      Network, used administrative claims data to identify eligible health plan members 
      for potential participation in the Aspirin Dosing: A Patient-centric Trial 
      Assessing Benefits and Long-term Effectiveness study. We approached health plan 
      members, identified with a validated Patient-Centered Clinical Data Research 
      Network common data model computable phenotype, and their clinical providers 
      during November 2017 to August 2018. Providers were offered the option to exclude 
      their patients' participation in Aspirin Dosing: A Patient-centric Trial 
      Assessing Benefits and Long-term Effectiveness prior to our direct patient 
      (member) outreach. Member identification was in two phases: Phase 1: 1 January 
      2006 to 1 April 2017, and Phase 2: 1 January 2006 to 2 February 2018. Phase 1 
      consisted of two batches of mail and one phone call per patient. In Phase 2, 
      which included two similar batches of patients, outreach was via either mail or 
      brochure and one phone call. RESULTS: Phase 1 and Phase 2 included 133,373 and 
      51,777 members, respectively. We engaged 28,593 providers in Phase 1, and 5077 in 
      Phase 2. In Phase 1, 264,158 mixed email/mail messages were delivered to 133,373 
      members, followed by 90,481 phone calls from November 2017 to February 2018. In 
      Phase 2, after simple randomization to letter or brochure, 51,777 members were 
      sent email/mail or mailed brochure in three waves from May 2018 to July 2018. In 
      this 9-week period, 51,623 communications were sent to 25,914 members in the 
      email/mail group, and 50,160 brochures to 25,863 in the brochure group. Following 
      email/mail or mailed brochure outreach, 16,624 and 16,580 calls were made to the 
      groups, respectively. Overall, 1549 health plan members visited the study portal 
      by 1 September 2018; 355 electronically signed the Informed Consent Form and 
      enrolled. Mailed brochures drove more portal visits in Phase 2, but a lower 
      percentage of responders enrolled. Recruitment was better in Phase 2-2.3 
      enrollees per 1000 outreach members versus 1.8 in Phase 1. CONCLUSION: This study 
      showed the ability of a health plan within Patient-Centered Clinical Data 
      Research Network to identify potential study participants with administrative 
      claims, and use different outreach methods to facilitate recruitment and 
      enrollment for pragmatic clinical trials.
FAU - Shi, Qian
AU  - Shi Q
AD  - HealthCore, Wilmington, DE, USA.
FAU - Shambhu, Sonali
AU  - Shambhu S
AD  - HealthCore, Wilmington, DE, USA.
FAU - Marshall, Amanda
AU  - Marshall A
AD  - HealthCore, Wilmington, DE, USA.
FAU - Rose-Kennedy, Elaine
AU  - Rose-Kennedy E
AD  - HealthCore, Wilmington, DE, USA.
FAU - Robertson, Holly
AU  - Robertson H
AD  - Duke University Medical Center, Duke University, Durham, NC, USA.
FAU - Paullin, Mark
AU  - Paullin M
AD  - HealthCore, Wilmington, DE, USA.
FAU - Jones, William Schuyler
AU  - Jones WS
AD  - School of Medicine, Duke University, Durham, NC, USA.
FAU - Cziraky, Mark
AU  - Cziraky M
AD  - HealthCore, Wilmington, DE, USA.
FAU - Haynes, Kevin
AU  - Haynes K
AUID- ORCID: 0000-0002-7087-9159
AD  - HealthCore, Wilmington, DE, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200203
PL  - England
TA  - Clin Trials
JT  - Clinical trials (London, England)
JID - 101197451
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Data Collection
MH  - Electronic Mail
MH  - Female
MH  - Humans
MH  - Insurance Claim Review
MH  - Male
MH  - Middle Aged
MH  - Patient Outcome Assessment
MH  - Patient Participation
MH  - *Patient Selection
MH  - Pragmatic Clinical Trials as Topic/*methods
MH  - Telephone
OTO - NOTNLM
OT  - Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term 
      Effectiveness
OT  - Patient-Centered Clinical Data Research Network
OT  - aspirin dosing
OT  - cardiovascular disease
OT  - pragmatic clinical trials
EDAT- 2020/02/06 06:00
MHDA- 2020/10/29 06:00
CRDT- 2020/02/04 06:00
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/10/29 06:00 [medline]
PHST- 2020/02/04 06:00 [entrez]
AID - 10.1177/1740774520902989 [doi]
PST - ppublish
SO  - Clin Trials. 2020 Apr;17(2):212-222. doi: 10.1177/1740774520902989. Epub 2020 Feb 
      3.

PMID- 28851242
OWN - NLM
STAT- MEDLINE
DCOM- 20190214
LR  - 20190215
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 32
IP  - 2
DP  - 2019 Jan
TI  - Evaluation of agreement of placental growth factor (PlGF) tests and the soluble 
      FMS-like tyrosine kinase 1 (sFlt-1)/PlGF ratio, comparison of predictive accuracy 
      for pre-eclampsia, and relation to uterine artery Doppler and response to 
      aspirin.
PG  - 179-187
LID - 10.1080/14767058.2017.1373760 [doi]
AB  - OBJECTIVES: The objective of this study is to evaluate agreement between PlGF and 
      sFlt-1/PlGF ratio tests and compare their predictive accuracy for pre-eclampsia 
      in high-risk women. Also, to examine for associations of abnormal PlGF or 
      sFlt-1/PlGF ratio with abnormal uterine artery Doppler and platelet response to 
      aspirin. METHODS: Prospective cohort study, 150 pregnant women at high risk of 
      pre-eclampsia prescribed 75 mg aspirin daily. Uterine artery Dopplers were 
      assessed at 20(+0)-23(+6) weeks. At 33(+0)-35(+6) weeks platelet function aspirin 
      metabolites, PlGF and the sFlt-1/PlGF ratio were measured. OUTCOME: Measures were 
      all pre-eclampsia and pre-eclampsia requiring delivery prior to 37 weeks. 
      RESULTS: Overall percent agreement was 89.3% for PlGF tests but 74.7-78% for PlGF 
      tests and the sFlt-1/PlGF ratio. AUCs were 0.70-0.75 for prediction of any 
      pre-eclampsia and 0.92-0.99 for preterm pre-eclampsia. We found a significant 
      association between abnormal PlGF or sFlt-1/PlGF ratio and abnormal uterine 
      artery Doppler (χ(2) 5.47, p = .019), but no association with platelet response 
      to aspirin (χ(2) 0.12, p = .913). There were no associations between suboptimal 
      aspirin adherence and either abnormal angiogenic markers or uterine artery 
      Dopplers (χ(2) 0.144, 0.038, p = .704, .846, respectively). CONCLUSIONS: There 
      was good agreement between PlGF tests and limited agreement between PlGF tests 
      and the sFlt-1/PlGF ratio. All tests have heightened predictive accuracy for 
      preterm pre-eclampsia. Abnormal PlGF or sFlt-1/PlGF ratio relates to abnormal 
      uterine artery Doppler but not platelet response to aspirin.
FAU - Navaratnam, Kate
AU  - Navaratnam K
AD  - a Centre for Women's Health Research, Institute of Translational Medicine , 
      University of Liverpool , Liverpool , UK.
AD  - b Liverpool Women's Hospital , Liverpool , UK.
FAU - Abreu, Patricia
AU  - Abreu P
AD  - b Liverpool Women's Hospital , Liverpool , UK.
FAU - Clarke, Helen
AU  - Clarke H
AD  - b Liverpool Women's Hospital , Liverpool , UK.
FAU - Jorgensen, Andrea
AU  - Jorgensen A
AD  - c Department of Biostatistics, Institute of Translational Medicine , University 
      of Liverpool , Liverpool , UK.
FAU - Alfirevic, Ana
AU  - Alfirevic A
AD  - d The Wolfson Centre for Personalised Medicine, Institute of Translational 
      Medicine , University of Liverpool , Liverpool , UK.
FAU - Alfirevic, Zarko
AU  - Alfirevic Z
AD  - a Centre for Women's Health Research, Institute of Translational Medicine , 
      University of Liverpool , Liverpool , UK.
AD  - b Liverpool Women's Hospital , Liverpool , UK.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20170911
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - 0 (PGF protein, human)
RN  - 144589-93-5 (Placenta Growth Factor)
RN  - EC 2.7.10.1 (FLT1 protein, human)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Maternal Serum Screening Tests/methods
MH  - Placenta Growth Factor/*blood
MH  - Pre-Eclampsia/blood/*diagnosis/*drug therapy/prevention & control
MH  - Predictive Value of Tests
MH  - Pregnancy
MH  - Sensitivity and Specificity
MH  - Ultrasonography, Doppler
MH  - Ultrasonography, Prenatal
MH  - Uterine Artery/*diagnostic imaging/*drug effects
MH  - Vascular Endothelial Growth Factor Receptor-1/*blood
OTO - NOTNLM
OT  - Aspirin
OT  - PlGF
OT  - pre-eclampsia
OT  - sFlt-1/PlGF ratio
EDAT- 2017/08/31 06:00
MHDA- 2019/02/15 06:00
CRDT- 2017/08/31 06:00
PHST- 2017/08/31 06:00 [pubmed]
PHST- 2019/02/15 06:00 [medline]
PHST- 2017/08/31 06:00 [entrez]
AID - 10.1080/14767058.2017.1373760 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2019 Jan;32(2):179-187. doi: 
      10.1080/14767058.2017.1373760. Epub 2017 Sep 11.

PMID- 12163424
OWN - NLM
STAT- MEDLINE
DCOM- 20020822
LR  - 20190623
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 106
IP  - 6
DP  - 2002 Aug 6
TI  - Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after 
      fibrinolysis for acute myocardial infarction: results of the Antithrombotics in 
      the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial.
PG  - 659-65
AB  - BACKGROUND: Despite the use of aspirin, reocclusion of the infarct-related artery 
      occurs in approximately 30% of patients within the first year after successful 
      fibrinolysis, with impaired clinical outcome. This study sought to assess the 
      impact of a prolonged anticoagulation regimen as adjunctive to aspirin in the 
      prevention of reocclusion and recurrent ischemic events after fibrinolysis for 
      ST-elevation myocardial infarction. METHODS AND RESULTS: At coronary angiography 
      <48 hours after fibrinolytic therapy, 308 patients receiving aspirin and 
      intravenous heparin had a patent infarct-related artery (Thrombolysis In 
      Myocardial Infarction [TIMI] grade 3 flow). They were randomly assigned to 
      standard heparinization and continuation of aspirin alone or to a 3-month 
      combination of aspirin with moderate-intensity coumarin, including continued 
      heparinization until a target international normalized ratio (INR) of 2.0 to 3.0. 
      Angiographic and clinical follow-up were assessed at 3 months. Median INR was 2.6 
      (25 to 75th percentiles 2.1 to 3.1). Reocclusion (< or =TIMI grade 2 flow) was 
      observed in 15% of patients receiving aspirin and coumarin compared with 28% in 
      those receiving aspirin alone (relative risk [RR], 0.55; 95% CI 0.33 to 0.90; 
      P<0.02). TIMI grade 0 to 1 flow rates were 9% and 20%, respectively (RR, 0.46; 
      95% CI, 0.24 to 0.89; P<0.02). Survival rates free from reinfarction and 
      revascularization were 86% and 66%, respectively (P<0.01). Bleeding (TIMI major 
      and minor) was infrequent: 5% versus 3% (P=NS). CONCLUSIONS: As adjunctive to 
      aspirin, a 3-month-regimen of moderate-intensity coumarin, including 
      heparinization until the target INR is reached, markedly reduces reocclusion and 
      recurrent events after successful fibrinolysis. This conceptual study provides a 
      mechanistic rationale to further investigate the role of prolonged 
      anticoagulation after fibrinolytic therapy.
FAU - Brouwer, Marc A
AU  - Brouwer MA
AD  - Interuniversity Cardiology Institute of the Netherlands, Nijmegen.
FAU - van den Bergh, Paul J P C
AU  - van den Bergh PJ
FAU - Aengevaeren, Wim R M
AU  - Aengevaeren WR
FAU - Veen, Gerrit
AU  - Veen G
FAU - Luijten, Hans E
AU  - Luijten HE
FAU - Hertzberger, Don P
AU  - Hertzberger DP
FAU - van Boven, Ad J
AU  - van Boven AJ
FAU - Vromans, Ralf P J W
AU  - Vromans RP
FAU - Uijen, Gérard J H
AU  - Uijen GJ
FAU - Verheugt, Freek W A
AU  - Verheugt FW
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anticoagulants)
RN  - 0 (Coumarins)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - A4VZ22K1WT (coumarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Coronary Angiography
MH  - Coronary Disease/diagnostic imaging/*prevention & control
MH  - Coumarins/adverse effects/*therapeutic use
MH  - Disease-Free Survival
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - *Thrombolytic Therapy
MH  - Treatment Outcome
EDAT- 2002/08/07 10:00
MHDA- 2002/08/23 10:01
CRDT- 2002/08/07 10:00
PHST- 2002/08/07 10:00 [pubmed]
PHST- 2002/08/23 10:01 [medline]
PHST- 2002/08/07 10:00 [entrez]
AID - 10.1161/01.cir.0000024408.81821.32 [doi]
PST - ppublish
SO  - Circulation. 2002 Aug 6;106(6):659-65. doi: 10.1161/01.cir.0000024408.81821.32.

PMID- 36915945
OWN - NLM
STAT- MEDLINE
DCOM- 20230426
LR  - 20230505
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 14
IP  - 12
DP  - 2023 Apr
TI  - Effect of perioperative aspirin continuation on bleeding after pneumonectomy.
PG  - 1071-1076
LID - 10.1111/1759-7714.14846 [doi]
AB  - BACKGROUND: To investigate the effect of continuous oral aspirin in perioperative 
      period on bleeding in pneumonectomy. METHODS: A total of 170 patients who 
      underwent pneumonectomy in our hospital from March 2021 to March 2022 were 
      selected as the study objects. All patients took oral aspirin before surgery and 
      did not take other antiplatelet agent or anticoagulants at the same time. The 
      continuation group included 85 cases and continued to take aspirin 100 mg/day 
      during the perioperative period, and the interruption group included 85 cases who 
      stopped aspirin for 7 days before surgery and 3 days after surgery, without 
      bridging therapy. The intraoperative blood loss, operation time, conversion to 
      thoracotomy rate, postoperative bleeding rate, blood transfusion rate, thrombotic 
      events, postoperative drainage volume, length of hospital stay, and total 
      hospital cost of the two groups were compared. RESULTS: There were no 
      statistically significant differences in intraoperative blood loss, operative 
      time, rate of conversion to open, postoperative drainage, hospital stay, and cost 
      between the two groups (p > 0.05), and there were no reoperations due to bleeding 
      between the two groups. CONCLUSIONS: Aspirin should be continued throughout the 
      perioperative period in all high-risk patients requiring pneumonectomy after 
      balancing ischemic-bleeding risks.
CI  - © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Chen, Qirui
AU  - Chen Q
AUID- ORCID: 0000-0002-6674-7559
AD  - Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and 
      Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
FAU - Liu, Yan
AU  - Liu Y
AD  - Department of Respiratory and Critical Care Medicine, Beijing Institute of 
      Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Liu, Yi
AU  - Liu Y
AD  - Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and 
      Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
FAU - Ji, Ying
AU  - Ji Y
AD  - Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and 
      Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
FAU - Ye, Xin
AU  - Ye X
AD  - Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and 
      Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
FAU - Li, Xin
AU  - Li X
AD  - Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and 
      Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
FAU - Fu, Yili
AU  - Fu Y
AD  - Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and 
      Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
FAU - Miao, Jinbai
AU  - Miao J
AD  - Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and 
      Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
FAU - Hou, Shengcai
AU  - Hou S
AD  - Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and 
      Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
FAU - Hu, Bin
AU  - Hu B
AD  - Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and 
      Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20230313
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Humans
MH  - *Aspirin
MH  - *Blood Loss, Surgical
MH  - Pneumonectomy
MH  - Retrospective Studies
MH  - Platelet Aggregation Inhibitors
PMC - PMC10125781
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - aspirin
OT  - bleeding
OT  - pneumonectomy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/15 06:00
MHDA- 2023/04/26 06:41
CRDT- 2023/03/14 02:15
PHST- 2023/02/21 00:00 [revised]
PHST- 2023/01/19 00:00 [received]
PHST- 2023/02/23 00:00 [accepted]
PHST- 2023/04/26 06:41 [medline]
PHST- 2023/03/15 06:00 [pubmed]
PHST- 2023/03/14 02:15 [entrez]
AID - TCA14846 [pii]
AID - 10.1111/1759-7714.14846 [doi]
PST - ppublish
SO  - Thorac Cancer. 2023 Apr;14(12):1071-1076. doi: 10.1111/1759-7714.14846. Epub 2023 
      Mar 13.

PMID- 25079473
OWN - NLM
STAT- MEDLINE
DCOM- 20160208
LR  - 20181202
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 20
IP  - 2
DP  - 2015 Mar
TI  - Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: 
      guidelines abound, but where are the data?
PG  - 144-56
LID - 10.1177/1074248414545126 [doi]
AB  - Antiplatelet therapy is invariably prescribed for patients with peripheral 
      arterial disease and critical limb ischemia, and numerous major society 
      guidelines espouse their use, but high-quality data in this high-risk and 
      challenging patient population are often lacking. This article summarizes the 
      major guidelines for antiplatelet therapy, reviews the major studies of 
      antiplatelet therapy in peripheral arterial disease (including data for aspirin, 
      clopidogrel, dipyridamole, cilostazol, and prostanoids), and offers perspective 
      on the potential benefits of ticagrelor, vorapaxar, and rivaroxaban. The review 
      concludes with a discussion of the relative lack of efficacy that antiplatelet 
      therapy has shown in regard to peripheral vascular outcomes.
CI  - © The Author(s) 2014.
FAU - Azarbal, Amir
AU  - Azarbal A
AD  - Department of Internal Medicine, University of Alabama-Huntsville, Huntsville, 
      AL, USA.
FAU - Clavijo, Leonardo
AU  - Clavijo L
AD  - Division of Cardiovascular Medicine, University of Southern California Keck 
      School of Medicine, Los Angeles, CA, USA.
FAU - Gaglia, Michael A Jr
AU  - Gaglia MA Jr
AD  - Division of Cardiovascular Medicine, University of Southern California Keck 
      School of Medicine, Los Angeles, CA, USA mgaglia@usc.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140730
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Prostaglandins)
RN  - 0 (Tetrazoles)
RN  - 64ALC7F90C (Dipyridamole)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cilostazol
MH  - Dipyridamole/therapeutic use
MH  - Endovascular Procedures
MH  - Extremities/*blood supply
MH  - Humans
MH  - Ischemia/*drug therapy
MH  - Peripheral Arterial Disease/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Practice Guidelines as Topic
MH  - Prostaglandins/therapeutic use
MH  - Tetrazoles/therapeutic use
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - aspirin
OT  - clopidogrel
OT  - critical limb ischemia
OT  - peripheral arterial disease heart disease
EDAT- 2014/08/01 06:00
MHDA- 2016/02/09 06:00
CRDT- 2014/08/01 06:00
PHST- 2014/08/01 06:00 [entrez]
PHST- 2014/08/01 06:00 [pubmed]
PHST- 2016/02/09 06:00 [medline]
AID - 1074248414545126 [pii]
AID - 10.1177/1074248414545126 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2015 Mar;20(2):144-56. doi: 
      10.1177/1074248414545126. Epub 2014 Jul 30.

PMID- 7012852
OWN - NLM
STAT- MEDLINE
DCOM- 19810625
LR  - 20131121
IS  - 0001-4389 (Print)
IS  - 0001-4389 (Linking)
VI  - 5
IP  - 3-4
DP  - 1980
TI  - Double-blind evaluation of naproxen and ibuprofen in periodontal surgery.
PG  - 69-72
AB  - A double-blind evaluation of the clinical effectiveness of a single dose of 
      naproxen, ibuprofen, and acetaminophen was performed on 98 patients who had 
      undergone periodontal surgery. A statistically significant difference was found 
      when the effect of these medications was compared with that of a placebo, but no 
      statistically significant difference was found among these three drugs. No side 
      effects resulted from the use of these medications.
FAU - Gallardo, F
AU  - Gallardo F
FAU - Rossi, E
AU  - Rossi E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Pharmacol Ther Dent
JT  - Pharmacology and therapeutics in dentistry
JID - 1252372
RN  - 0 (Placebos)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Gingivectomy
MH  - Humans
MH  - Ibuprofen/*therapeutic use
MH  - Male
MH  - Naproxen/*therapeutic use
MH  - Pain, Postoperative/*prevention & control
MH  - Placebos
EDAT- 1980/01/01 00:00
MHDA- 1980/01/01 00:01
CRDT- 1980/01/01 00:00
PHST- 1980/01/01 00:00 [pubmed]
PHST- 1980/01/01 00:01 [medline]
PHST- 1980/01/01 00:00 [entrez]
PST - ppublish
SO  - Pharmacol Ther Dent. 1980;5(3-4):69-72.

PMID- 3927506
OWN - NLM
STAT- MEDLINE
DCOM- 19850923
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 53
IP  - 2
DP  - 1985 Apr 22
TI  - Platelet regeneration time after aspirin ingestion and platelet survival time 
      after labelling with 51chromium or 111indium oxine--a comparative study.
PG  - 260-3
AB  - A simultaneous investigation of platelet regeneration time (PRT) based upon 
      malondialdehyde (MDA) recovery after a single oral intake of 500 mg of aspirin 
      and of platelet survival time (PST) after labelling with 51chromium or 111indium 
      oxine was performed in 25 cancerous patients. A pilot study conducted with 9 
      healthy volunteers demonstrated that the MDA assay was highly reproducible and 
      specific for the platelet cycloxygenase activity. The pattern of MDA recovery 
      after aspirin ingestion was linear in the healthy volunteers and in the patients 
      presenting both a normal and an accelerated platelet turnover. PST were 
      calculated using the four mathematical models recommended by the International 
      Committee for Standardization in Hematology; the best fit was given by the 
      multiple hit model in 22 cases and by the linear regression model in 3 cases. The 
      mean results obtained in the patients investigated with the 51chromium were 
      consistently shorter than those obtained in the patients investigated with the 
      111indium oxine while the mean PRT were almost identical in the two groups. An 
      excellent correlation between PRT and PST was observed after 111indium oxine 
      labelling and using the weighted mean method for PST determination. These results 
      suggest that the 111indium oxine technique is a better method for platelet 
      labelling and that the results provided by the weighted mean method reflect more 
      closely the in vivo platelet turnover than those provided by the multiple hit 
      model.
FAU - Boneu, A
AU  - Boneu A
FAU - Sié, P
AU  - Sié P
FAU - Bugat, R
AU  - Bugat R
FAU - Caranobe, C
AU  - Caranobe C
FAU - Eber, M
AU  - Eber M
FAU - Cazenave, J P
AU  - Cazenave JP
FAU - Boneu, B
AU  - Boneu B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Hydroxyquinolines)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Radioisotopes)
RN  - 045A6V3VFX (Indium)
RN  - 14514-42-2 (indium oxine)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 5UTX5635HP (Oxyquinoline)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/drug effects/*physiology
MH  - Cell Survival
MH  - *Chromium Radioisotopes
MH  - Female
MH  - Humans
MH  - *Hydroxyquinolines
MH  - *Indium
MH  - *Isotope Labeling
MH  - Male
MH  - Malondialdehyde/blood
MH  - Neoplasms/blood
MH  - *Organometallic Compounds
MH  - *Oxyquinoline/analogs & derivatives
MH  - *Radioisotopes
MH  - Time Factors
EDAT- 1985/04/22 00:00
MHDA- 1985/04/22 00:01
CRDT- 1985/04/22 00:00
PHST- 1985/04/22 00:00 [pubmed]
PHST- 1985/04/22 00:01 [medline]
PHST- 1985/04/22 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1985 Apr 22;53(2):260-3.

PMID- 7400307
OWN - NLM
STAT- MEDLINE
DCOM- 19801024
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 66
IP  - 1
DP  - 1980 Jul
TI  - Effects of aspirin and dipyridamole on the degradation of adenosine diphosphate 
      by cultured cells derived from bovine pulmonary artery.
PG  - 29-35
AB  - To improve understanding of the mechanisms by which ADP is degraded during 
      passage through the pulmonary vascular bed, we examined cultured endothelial and 
      smooth muscle cells of bovine pulmonmary artery for their abilities to metabolize 
      [8-14C]ADP. ADP is rapidly converted to AMP and then to adenosine, hypoxanthine, 
      and inosine. Inosine is the major metabolite produced by endothelial cells. 
      Radioactivity (5-10%) is accumulated intracellularly primarily as ATP. Medium 
      containing 50 micro M ADP incubated with endothelial cells rapidly loses its 
      ability to aggregate platelets and becomes antiaggregatory under conditions in 
      which prostacyclin is absent. The antiaggregatory activity is probably the result 
      of accumulated adenosine. 10 micro M dipyridamole inhibits cellular uptake of 
      radioactivity by greater than 90%, and inosine in the medium is largely replaced 
      by adenosine. This is accompanied by increased anti-aggregatory activity of 
      conditioned medium, which can be matched by authentic adenosine at the same 
      concentration. 1 mM aspirin had no effect on the metabolism of ADP by endothelial 
      cells. Our results suggest: (a) Metabolism of ADP during passage through the lung 
      is mainly the result of endothelial ADPase. (b) ADP released from aggregating 
      platelets can be converted to the antiaggregatory substance, adenosine. 
      Dipyridamole may exert some of its antithrombotic actions by preventing the 
      intracellular uptake of adenosine, thereby increasing its concentration near the 
      site of thrombus formation. (c) The ability of the vessel wall to degrade ADP 
      should not be compromised by the use of aspirin as an antithrombotic drug. (d) 
      Endothelium may retain some of its antithrombogenicity when prostacyclin 
      generation is impaired.
FAU - Crutchley, D J
AU  - Crutchley DJ
FAU - Ryan, U S
AU  - Ryan US
FAU - Ryan, J W
AU  - Ryan JW
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/*metabolism
MH  - Adenosine Monophosphate/metabolism
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Cattle
MH  - Cells, Cultured
MH  - Dipyridamole/*pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Pulmonary Artery/drug effects/*metabolism
PMC - PMC371501
EDAT- 1980/07/01 00:00
MHDA- 1980/07/01 00:01
CRDT- 1980/07/01 00:00
PHST- 1980/07/01 00:00 [pubmed]
PHST- 1980/07/01 00:01 [medline]
PHST- 1980/07/01 00:00 [entrez]
AID - 10.1172/JCI109831 [doi]
PST - ppublish
SO  - J Clin Invest. 1980 Jul;66(1):29-35. doi: 10.1172/JCI109831.

PMID- 30054799
OWN - NLM
STAT- MEDLINE
DCOM- 20200129
LR  - 20200309
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
VI  - 14
IP  - 3
DP  - 2019 Apr
TI  - Landmark trials in thrombotic vascular disease: a critical appraisal of potential 
      practice-changing trials in 2016-2017.
PG  - 355-363
LID - 10.1007/s11739-018-1910-2 [doi]
AB  - Recent years have witnessed an onslaught of large, multicenter, randomized 
      controlled trials evaluating the prevention and management of thrombotic vascular 
      diseases. While these trials have applied rigorous methodology to pragmatic and 
      clinically relevant questions, several important gaps in knowledge remain. In 
      this review, we critically appraise landmark studies in thrombosis published 
      between 2016 and 2017 that address several ongoing areas of clinical uncertainty. 
      Specifically, we review the role of endovascular therapy in the prevention of 
      post-thrombotic syndrome following acute lower limb deep vein thrombosis (DVT) 
      (ATTRACT trial), the efficacy of edoxaban as the first direct oral anticoagulant 
      used for the treatment of cancer-associated thrombosis (HOKUSAI VTE-Cancer 
      study), whether aspirin can be considered for thromboprophylaxis post-major 
      orthopedic surgery (EPCAT-2 trial), and the need for anticoagulant therapy for 
      treatment of isolated distal DVT (CACTUS trial). Using illustrative cases, we 
      highlight the applicability of these trials to current practice and emphasize the 
      unanswered questions that remain.
FAU - Cervi, Andrea
AU  - Cervi A
AD  - Department of Medicine, St. Joseph's Healthcare Hamilton, McMaster University, 50 
      Charlton Ave East, Hamilton, L8N 4A6, Canada.
FAU - Douketis, James Demetrios
AU  - Douketis JD
AD  - Department of Medicine, St. Joseph's Healthcare Hamilton, McMaster University, 
      Room F-544, 50 Charlton Ave East, Hamilton, L8N 4A6, Canada. jdouket@mcmaster.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180727
PL  - Italy
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Endovascular Procedures/methods/*trends
MH  - Humans
MH  - Neoplasms/complications/drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Radiology, Interventional/methods/trends
MH  - Review Literature as Topic
MH  - Venous Thromboembolism/*drug therapy
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer-associated thrombosis
OT  - Catheter-directed thrombolysis
OT  - Distal deep vein thrombosis
OT  - Edoxaban
OT  - Thromboprophylaxis
EDAT- 2018/07/29 06:00
MHDA- 2020/01/30 06:00
CRDT- 2018/07/29 06:00
PHST- 2018/05/26 00:00 [received]
PHST- 2018/07/12 00:00 [accepted]
PHST- 2018/07/29 06:00 [pubmed]
PHST- 2020/01/30 06:00 [medline]
PHST- 2018/07/29 06:00 [entrez]
AID - 10.1007/s11739-018-1910-2 [pii]
AID - 10.1007/s11739-018-1910-2 [doi]
PST - ppublish
SO  - Intern Emerg Med. 2019 Apr;14(3):355-363. doi: 10.1007/s11739-018-1910-2. Epub 
      2018 Jul 27.

PMID- 9596581
OWN - NLM
STAT- MEDLINE
DCOM- 19980612
LR  - 20190619
IS  - 0036-8075 (Print)
IS  - 0036-8075 (Linking)
VI  - 280
IP  - 5367
DP  - 1998 May 22
TI  - Aspirin-like molecules that covalently inactivate cyclooxygenase-2.
PG  - 1268-70
AB  - Many of aspirin's therapeutic effects arise from its acetylation of 
      cyclooxygenase-2 (COX-2), whereas its antithrombotic and ulcerogenic effects 
      result from its acetylation of COX-1. Here, aspirin-like molecules were designed 
      that preferentially acetylate and irreversibly inactivate COX-2. The most potent 
      of these compounds was o-(acetoxyphenyl)hept-2-ynyl sulfide (APHS). Relative to 
      aspirin, APHS was 60 times as reactive against COX-2 and 100 times as selective 
      for its inhibition; it also inhibited COX-2 in cultured macrophages and colon 
      cancer cells and in the rat air pouch in vivo. Such compounds may lead to the 
      development of aspirin-like drugs for the treatment or prevention of 
      immunological and proliferative diseases without gastrointestinal or hematologic 
      side effects.
FAU - Kalgutkar, A S
AU  - Kalgutkar AS
AD  - A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Vanderbilt Cancer 
      Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
FAU - Crews, B C
AU  - Crews BC
FAU - Rowlinson, S W
AU  - Rowlinson SW
FAU - Garner, C
AU  - Garner C
FAU - Seibert, K
AU  - Seibert K
FAU - Marnett, L J
AU  - Marnett LJ
LA  - eng
GR  - CA47479/CA/NCI NIH HHS/United States
GR  - CA68485/CA/NCI NIH HHS/United States
GR  - ES00267/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (Alkynes)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - 0 (Sulfides)
RN  - 0 (o-(acetoxyphenyl)hept-2-ynyl sulfide)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - OC7TV75O83 (Acetylene)
RN  - R16CO5Y76E (Aspirin)
RN  - RXY07S6CZ2 (Prostaglandin D2)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
CIN - Science. 1998 May 22;280(5367):1191-2. PMID: 9634399
MH  - Acetylation
MH  - Acetylene/*analogs & derivatives/chemical synthesis/chemistry/pharmacology
MH  - Alkynes
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemical 
      synthesis/chemistry/pharmacology
MH  - Aspirin/chemistry/pharmacology
MH  - Binding Sites
MH  - Cell Division/drug effects
MH  - Cell Line
MH  - Colonic Neoplasms/enzymology/pathology
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/*chemical synthesis/chemistry/pharmacology
MH  - Dinoprostone/biosynthesis
MH  - Drug Design
MH  - Humans
MH  - Indomethacin/pharmacology
MH  - Isoenzymes/chemistry/genetics/*metabolism
MH  - Macrophages/enzymology
MH  - Membrane Proteins
MH  - Mutagenesis, Site-Directed
MH  - Prostaglandin D2/biosynthesis
MH  - Prostaglandin-Endoperoxide Synthases/chemistry/genetics/*metabolism
MH  - Rats
MH  - Rats, Inbred Lew
MH  - Sulfides/*chemical synthesis/chemistry/pharmacology
MH  - Thromboxane B2/biosynthesis
MH  - Tumor Cells, Cultured
EDAT- 1998/06/20 00:00
MHDA- 1998/06/20 00:01
CRDT- 1998/06/20 00:00
PHST- 1998/06/20 00:00 [pubmed]
PHST- 1998/06/20 00:01 [medline]
PHST- 1998/06/20 00:00 [entrez]
AID - 10.1126/science.280.5367.1268 [doi]
PST - ppublish
SO  - Science. 1998 May 22;280(5367):1268-70. doi: 10.1126/science.280.5367.1268.

PMID- 20631417
OWN - NLM
STAT- MEDLINE
DCOM- 20101103
LR  - 20200106
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 62
IP  - 3
DP  - 2010 May-Jun
TI  - Aspirin-induced asthma: a tribute to John Vane as a source of inspiration.
PG  - 526-9
AB  - Aspirin-induced asthma is a distinct clinical syndrome consisting of 
      inflammation, characterized by chronic eosinophilic rhinosinusitis with asthma 
      and often nasal polyposis. Aspirin and other nonsteroidal anti-inflammatory drugs 
      (NSAIDs) exacerbate asthma, resulting in violent attacks. This is the hallmark of 
      the clinical syndrome as explained by the cyclooxygenase theory. This theory, 
      which is now generally accepted, states that asthma attacks precipitated by 
      aspirin and other NSAIDs have no allergic background; instead, they occur due to 
      the inhibition of cyclooxygenase-1 in sensitive patients. This paper describes 
      how the discoveries of John Vane inspired the authors of the cyclooxygenase 
      theory and led to further insight into the biology of eicosanoid metabolism in 
      this relatively common type of asthma.
FAU - Szczeklik, Andrzej
AU  - Szczeklik A
AD  - Department of Medicine, Jagiellonian University Medical College, Skawińska 8, PL 
      31-066 Kraków, Poland. mmszczek@cyf-kr.edu.pl
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology
MH  - Aspirin/*adverse effects/pharmacology
MH  - Asthma/*chemically induced/epidemiology/physiopathology
MH  - Cyclooxygenase 1/*metabolism
MH  - Cyclooxygenase Inhibitors/*adverse effects/pharmacology
MH  - Humans
MH  - Respiratory Hypersensitivity/*chemically induced/physiopathology
EDAT- 2010/07/16 06:00
MHDA- 2010/11/04 06:00
CRDT- 2010/07/16 06:00
PHST- 2009/09/15 00:00 [received]
PHST- 2010/04/26 00:00 [revised]
PHST- 2010/07/16 06:00 [entrez]
PHST- 2010/07/16 06:00 [pubmed]
PHST- 2010/11/04 06:00 [medline]
AID - S1734-1140(10)70309-1 [pii]
AID - 10.1016/s1734-1140(10)70309-1 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2010 May-Jun;62(3):526-9. doi: 10.1016/s1734-1140(10)70309-1.

PMID- 18221358
OWN - NLM
STAT- MEDLINE
DCOM- 20080520
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 6
IP  - 4
DP  - 2008 Apr
TI  - Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are 
      important determinants of aspirin resistance in patients with vascular disease.
PG  - 615-21
LID - 10.1111/j.1538-7836.2008.02915.x [doi]
AB  - BACKGROUND: Permanent inactivation of cyclooxygenase-1 and inhibition of platelet 
      thromboxane A(2) (TxA(2)) constitute the main mechanisms underlying the 
      prevention of vascular disease by aspirin. METHODS AND RESULTS: We studied 
      platelet TxA(2) synthesis and its impact on platelet reactivity and 
      platelet-erythrocyte [platelet-rich plasma (PRP)-RBC] interactions in 533 
      aspirin-treated patients with vascular disease. Seventy aspirin-free and 16 
      aspirin-treated normal subjects were evaluated as controls. Collagen (1 mug 
      mL(-1))-induced platelet activation ((14)C-5HT release) and recruitment 
      (proaggregatory activity of cell-free releasates from activated platelets) were 
      assessed in PRP, PRP + RBC, and whole blood (WB). TxA(2) was quantified in 
      releasates from WB. Aspirin inhibited TxA(2) synthesis and platelet function in 
      all patients, but to different degrees. Forty-two patients (8%) displayed partial 
      (<95%) inhibition of TxA(2) relative to that of aspirin-free controls. They 
      produced >3.5 ng mL(-1) TxA(2) and had higher platelet reactivity than 491 
      patients who had undetectable TxA(2) or produced residual TxA(2) (R-TxA(2); 
      </=3.5 ng mL(-1)). Patients with R-TxA(2) were distributed into TxA(2) quartiles. 
      Patients in the third and fourth quartiles had significantly elevated (14)C-5HT 
      release in PRP, which was markedly amplified in PRP + RBC and WB. TxA(2) in the 
      fourth quartile translated into increased platelet aggregation and recruitment. 
      Significant correlations were found between R-TxA(2) and platelet hyperfunction. 
      CONCLUSION: Biochemical markers (TxA(2) synthesis, (14)C-5HT release) and 
      biological assays (platelet aggregation and recruitment) used to monitor the 
      aspirin effect in a large population of patients presenting with vascular disease 
      have evidenced the importance of R-TxA(2) and the prothrombotic effects of RBC in 
      aspirin resistance.
FAU - Santos, M T
AU  - Santos MT
AD  - Research Center, University Hospital La Fe, Valencia, Spain. santos_ter@gva.es
FAU - Valles, J
AU  - Valles J
FAU - Lago, A
AU  - Lago A
FAU - Tembl, J
AU  - Tembl J
FAU - Sánchez, E
AU  - Sánchez E
FAU - Moscardo, A
AU  - Moscardo A
FAU - Cosin, J
AU  - Cosin J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080123
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 333DO1RDJY (Serotonin)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 9007-34-5 (Collagen)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (PTGS1 protein, human)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Blood Platelets/*chemistry
MH  - Collagen/pharmacology
MH  - Cyclooxygenase 1/blood
MH  - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use
MH  - Drug Resistance/physiology
MH  - Erythrocytes/*physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet-Rich Plasma
MH  - Serotonin/metabolism
MH  - Thromboxane A2/biosynthesis/*blood
MH  - Vascular Diseases/*blood/drug therapy
EDAT- 2008/01/29 09:00
MHDA- 2008/05/21 09:00
CRDT- 2008/01/29 09:00
PHST- 2008/01/29 09:00 [pubmed]
PHST- 2008/05/21 09:00 [medline]
PHST- 2008/01/29 09:00 [entrez]
AID - S1538-7836(22)10561-1 [pii]
AID - 10.1111/j.1538-7836.2008.02915.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2008 Apr;6(4):615-21. doi: 10.1111/j.1538-7836.2008.02915.x. 
      Epub 2008 Jan 23.

PMID- 7850674
OWN - NLM
STAT- MEDLINE
DCOM- 19950314
LR  - 20131121
IS  - 0828-282X (Print)
IS  - 0828-282X (Linking)
VI  - 11 Suppl A
DP  - 1995 Jan
TI  - What do we really know about secondary prevention after myocardial infarction?
PG  - 31A-32A
AB  - Secondary prevention following acute myocardial infarction begins at the time of 
      the in initial hospitalization. An aggressive approach should focus on 
      appropriate lifestyle changes as well as pharmacotherapy. Smoking cessation, 
      increased physical activity and lipid lowering are key lifestyle objectives, 
      while beta blockade and aspirin should be routinely prescribed for all patients 
      following acute myocardial infarction, unless there are specific 
      contraindications. Improvement in survivorship, prevention of nonfatal 
      reinfarction, regression of atheromatous disease as well as a better quality of 
      life are all proven benefits of secondary prevention.
FAU - Wielgosz, A T
AU  - Wielgosz AT
AD  - Division of Cardiology, Ottawa General Hospital, Ontario.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - 0 (Adrenergic beta-Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aspirin/therapeutic use
MH  - *Clinical Competence
MH  - Humans
MH  - *Life Style
MH  - Myocardial Infarction/*prevention & control/rehabilitation
MH  - *Physical Fitness
MH  - Recurrence
MH  - *Smoking Cessation
MH  - Time Factors
RF  - 13
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Can J Cardiol. 1995 Jan;11 Suppl A:31A-32A.

PMID- 655845
OWN - NLM
STAT- MEDLINE
DCOM- 19780715
LR  - 20190704
IS  - 0004-0010 (Print)
IS  - 0004-0010 (Linking)
VI  - 113
IP  - 6
DP  - 1978 Jun
TI  - Postsplenectomy thrombocytosis: its association with mesenteric, portal, and/or 
      renal vein thrombosis in patients with myeloproliferative disorders.
PG  - 713-5
AB  - During the past two years, postoperative thromboses of parts or all of the 
      splanchnic venous circulation have developed in four of 30 patients with 
      myeloproliferative disorders who have undergone splenectomy at our institution. 
      The patients' courses were marked by platelet abnormalities, both quantitative 
      and qualitative. In an attempt to avoid this complication, aspirin and low-dose 
      heparin sodium have been administered and there has been no evidence of 
      thrombosis in the four patients so managed.
FAU - Gordon, D H
AU  - Gordon DH
FAU - Schaffner, D
AU  - Schaffner D
FAU - Bennett, J M
AU  - Bennett JM
FAU - Schwartz, S I
AU  - Schwartz SI
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Surg
JT  - Archives of surgery (Chicago, Ill. : 1960)
JID - 9716528
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myeloproliferative Disorders/*surgery
MH  - Preoperative Care
MH  - Splenectomy/*adverse effects
MH  - Thrombocytosis/*etiology/physiopathology/prevention & control
EDAT- 1978/06/01 00:00
MHDA- 1978/06/01 00:01
CRDT- 1978/06/01 00:00
PHST- 1978/06/01 00:00 [pubmed]
PHST- 1978/06/01 00:01 [medline]
PHST- 1978/06/01 00:00 [entrez]
AID - 10.1001/archsurg.1978.01370180055006 [doi]
PST - ppublish
SO  - Arch Surg. 1978 Jun;113(6):713-5. doi: 10.1001/archsurg.1978.01370180055006.

PMID- 1390591
OWN - NLM
STAT- MEDLINE
DCOM- 19921125
LR  - 20191028
IS  - 1049-8834 (Print)
IS  - 1049-8834 (Linking)
VI  - 12
IP  - 10
DP  - 1992 Oct
TI  - Modulation of fibrinolytic response to venous occlusion in humans by a 
      combination of low-dose aspirin and n-3 polyunsaturated fatty acids.
PG  - 1191-7
AB  - Aspirin at high but not at low doses reduces the fibrinolytic response to venous 
      occlusion. Inhibition of vascular prostacyclin synthesis could be involved in 
      this effect. Fish oil supplementation may redirect prostanoid metabolism toward 
      an overall "antithrombotic" condition but with controversial effects on 
      prostacyclin formation. In this study we investigated the effect of low-dose 
      aspirin together with n-3 polyunsaturated fatty acid (PUFA) supplementation on 
      the fibrinolytic response to venous occlusion. Following a double-blind, 
      randomized, crossover design, six healthy volunteers (three men and three women, 
      24-37 years old) were given for 29 days 5.3 g eicosapentaenoic and 
      docosahexaenoic acids or a corresponding dose of n-6 PUFAs as control; aspirin 
      (40 mg/day) was then added for an additional 14 days. A 2-month washout period 
      was allowed before the crossover. Blood was collected before and after venous 
      stasis on days 0, 29, and 43 of each test period. A combination of aspirin with 
      n-3 PUFAs reduced the fibrinolytic response to venous occlusion in all subjects, 
      the mean value of fibrinolytic activity after stasis being 240 +/- 40 mm2, a 
      value significantly lower than at baseline (366 +/- 51 mm2, mean +/- SEM, p < 
      0.05). Similarly, the tissue-type plasminogen activator (t-PA) antigen level was 
      lower in the aspirin + PUFA-treated group. Plasminogen activator inhibitor 
      activity before stasis was enhanced by n-3 PUFA supplementation (from 7.5 +/- 2 
      to 14.8 +/- 3 IU/ml, p < 0.05), an effect not affected by aspirin.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Iacoviello, L
AU  - Iacoviello L
AD  - Istituto di Ricerche Farmacologiche Mario Negri-Consorzio Mario Negri Sud Santa 
      Maria Imbaro, Italy.
FAU - Amore, C
AU  - Amore C
FAU - De Curtis, A
AU  - De Curtis A
FAU - Tacconi, M T
AU  - Tacconi MT
FAU - de Gaetano, G
AU  - de Gaetano G
FAU - Cerletti, C
AU  - Cerletti C
FAU - Donati, M B
AU  - Donati MB
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arterioscler Thromb
JT  - Arteriosclerosis and thrombosis : a journal of vascular biology
JID - 9101388
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 0 (Protein S)
RN  - 9001-32-5 (Fibrinogen)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/metabolism
MH  - Cell Membrane/metabolism
MH  - Double-Blind Method
MH  - Fatty Acids, Omega-3/*pharmacology
MH  - Fatty Acids, Unsaturated/*pharmacology
MH  - Female
MH  - Fibrinogen/*metabolism
MH  - Fibrinolysis/*drug effects
MH  - Humans
MH  - Male
MH  - Plasminogen Activator Inhibitor 1/blood
MH  - Protein S/blood
MH  - Tissue Plasminogen Activator/blood
MH  - Venous Insufficiency/blood
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 10.1161/01.atv.12.10.1191 [doi]
PST - ppublish
SO  - Arterioscler Thromb. 1992 Oct;12(10):1191-7. doi: 10.1161/01.atv.12.10.1191.

PMID- 36903662
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230314
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 28
IP  - 5
DP  - 2023 Mar 6
TI  - Aspirin-Triggered Resolvin D1 (AT-RvD1) Protects Mouse Skin against UVB-Induced 
      Inflammation and Oxidative Stress.
LID - 10.3390/molecules28052417 [doi]
LID - 2417
AB  - Intense exposure to UVB radiation incites excessive production of reactive oxygen 
      species (ROS) and inflammation. The resolution of inflammation is an active 
      process orchestrated by a family of lipid molecules that includes AT-RvD1, a 
      specialized proresolving lipid mediator (SPM). AT-RvD1 is derived from omega-3, 
      which presents anti-inflammatory activity and reduces oxidative stress markers. 
      The present work aims to investigate the protective effect of AT-RvD1 on 
      UVB-induced inflammation and oxidative stress in hairless mice. Animals were 
      first treated with 30, 100, and 300 pg/animal AT-RvD1 (i.v.) and then exposed to 
      UVB (4.14 J/cm(2)). The results showed that 300 pg/animal of AT-RvD1 could 
      restrict skin edema, neutrophil and mast cell infiltration, COX-2 mRNA 
      expression, cytokine release, and MMP-9 activity and restore skin antioxidant 
      capacity as per FRAP and ABTS assays and control O(2)(•-) production, 
      lipoperoxidation, epidermal thickening, and sunburn cells development. AT-RvD1 
      could reverse the UVB-induced downregulation of Nrf2 and its downstream targets 
      GSH, catalase, and NOQ-1. Our results suggest that by upregulating the Nrf2 
      pathway, AT-RvD1 promotes the expression of ARE genes, restoring the skin's 
      natural antioxidant defense against UVB exposition to avoid oxidative stress, 
      inflammation, and tissue damage.
FAU - Melo, Cristina P B
AU  - Melo CPB
AUID- ORCID: 0000-0003-1445-7637
AD  - Department of Pharmaceutical Sciences, Centre of Health Science, Londrina State 
      University, Londrina 86038-350, PR, Brazil.
FAU - Saito, Priscila
AU  - Saito P
AD  - Department of Pharmaceutical Sciences, Centre of Health Science, Londrina State 
      University, Londrina 86038-350, PR, Brazil.
FAU - Martinez, Renata M
AU  - Martinez RM
AD  - Department of Pharmaceutical Sciences, Centre of Health Science, Londrina State 
      University, Londrina 86038-350, PR, Brazil.
FAU - Staurengo-Ferrari, Larissa
AU  - Staurengo-Ferrari L
AD  - Department of Pathology, Centre of Biological Sciences, Londrina State 
      University, Rodovia Celso Garcia Cid, Km 380, PR445, Cx. Postal 10.011, Londrina 
      86057-970, PR, Brazil.
AD  - Department of Immunology, Harvard Medical School, Blavatnik Institute, Boston, MA 
      02115, USA.
FAU - Pinto, Ingrid C
AU  - Pinto IC
AD  - Department of Pharmaceutical Sciences, Centre of Health Science, Londrina State 
      University, Londrina 86038-350, PR, Brazil.
FAU - Rodrigues, Camilla C A
AU  - Rodrigues CCA
AD  - Department of Pharmaceutical Sciences, Centre of Health Science, Londrina State 
      University, Londrina 86038-350, PR, Brazil.
FAU - Badaro-Garcia, Stephanie
AU  - Badaro-Garcia S
AD  - Department of Pathology, Centre of Biological Sciences, Londrina State 
      University, Rodovia Celso Garcia Cid, Km 380, PR445, Cx. Postal 10.011, Londrina 
      86057-970, PR, Brazil.
AD  - Department of Medicine, Women's Guild Lung Institute, Cedars-Sinai Medical 
      Center, Los Angeles, CA 90048, USA.
FAU - Vignoli, Josiane A
AU  - Vignoli JA
AD  - Department of Biochemistry and Biotechnology, Centre of Exact Sciences, Londrina 
      State University, Londrina 86057-970, PR, Brazil.
FAU - Baracat, Marcela M
AU  - Baracat MM
AD  - Department of Pharmaceutical Sciences, Centre of Health Science, Londrina State 
      University, Londrina 86038-350, PR, Brazil.
FAU - Bussmann, Allan J C
AU  - Bussmann AJC
AUID- ORCID: 0000-0002-0807-4800
AD  - Department of Pathology, Centre of Biological Sciences, Londrina State 
      University, Rodovia Celso Garcia Cid, Km 380, PR445, Cx. Postal 10.011, Londrina 
      86057-970, PR, Brazil.
FAU - Georgetti, Sandra R
AU  - Georgetti SR
AD  - Department of Pharmaceutical Sciences, Centre of Health Science, Londrina State 
      University, Londrina 86038-350, PR, Brazil.
FAU - Verri, Waldiceu A
AU  - Verri WA
AUID- ORCID: 0000-0003-2756-9283
AD  - Department of Pathology, Centre of Biological Sciences, Londrina State 
      University, Rodovia Celso Garcia Cid, Km 380, PR445, Cx. Postal 10.011, Londrina 
      86057-970, PR, Brazil.
FAU - Casagrande, Rubia
AU  - Casagrande R
AUID- ORCID: 0000-0002-2296-1668
AD  - Department of Pharmaceutical Sciences, Centre of Health Science, Londrina State 
      University, Londrina 86038-350, PR, Brazil.
LA  - eng
GR  - #405027/2021-4; #427946/2018-2; #309633/2021-4; #307852/2019-9/National Council 
      for Scientific and Technological Development/
GR  - PPSUS grant agreement #041/2017; PRONEX grant agreement #014/2017; 
      #PBA2022011000198/Fundação Araucária/
GR  - finance code 001/Coordenação de Aperfeicoamento de Pessoal de Nível Superior/
PT  - Journal Article
DEP - 20230306
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (resolvin D1)
RN  - 0 (Antioxidants)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 25167-62-8 (Docosahexaenoic Acids)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Antioxidants/pharmacology
MH  - *Aspirin/pharmacology
MH  - NF-E2-Related Factor 2/metabolism
MH  - Oxidative Stress
MH  - Inflammation
MH  - Docosahexaenoic Acids/pharmacology
MH  - Ultraviolet Rays
PMC - PMC10005614
OTO - NOTNLM
OT  - 17(R)RvD1
OT  - Nrf2
OT  - ROS
OT  - antioxidant capacity
OT  - ciclooxygenase-2
OT  - cytokines
OT  - lipid mediator
OT  - neutrophil infiltration
OT  - sunburn
OT  - ultraviolet radiation
COIS- Authors declare no conflict of interest.
EDAT- 2023/03/12 06:00
MHDA- 2023/03/15 06:00
CRDT- 2023/03/11 01:27
PHST- 2022/12/31 00:00 [received]
PHST- 2023/02/27 00:00 [revised]
PHST- 2023/03/01 00:00 [accepted]
PHST- 2023/03/11 01:27 [entrez]
PHST- 2023/03/12 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
AID - molecules28052417 [pii]
AID - molecules-28-02417 [pii]
AID - 10.3390/molecules28052417 [doi]
PST - epublish
SO  - Molecules. 2023 Mar 6;28(5):2417. doi: 10.3390/molecules28052417.

PMID- 20499154
OWN - NLM
STAT- MEDLINE
DCOM- 20101202
LR  - 20211020
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Print)
IS  - 0957-5243 (Linking)
VI  - 21
IP  - 9
DP  - 2010 Sep
TI  - Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the 
      Western New York Exposures and Breast Cancer (WEB) Study.
PG  - 1503-12
LID - 10.1007/s10552-010-9579-5 [doi]
AB  - OBJECTIVE: Chronic inflammation is suspected to have a role in breast 
      carcinogenesis. Results of studies of non-steroidal anti-inflammatory drugs 
      (NSAIDs) and breast cancer have been inconsistent. Timing of exposure and 
      analysis of individual NSAIDs should be considered. METHODS: We conducted a 
      population-based case-control study in western New York State between 1996 and 
      2001. Cases, 35-79 years, had incident, primary, histologically confirmed breast 
      cancer (n = 1,170). Controls (n = 2,115) were randomly selected from NY 
      Department of Motor Vehicles records (<65 years) or Medicare rolls (>or=65 
      years). Participants were queried on use of aspirin, ibuprofen, and acetaminophen 
      in the year prior and on aspirin during adulthood. Unconditional logistic 
      regression was used to estimate adjusted odds ratios (OR) and 95% confidence 
      intervals (95% CI). RESULTS: Recent aspirin use was inversely associated with 
      breast cancer risk (adjusted OR 0.80, 95% CI: 0.68-0.94); the strongest reduction 
      in risk was observed among those who took >or=2 pills/day on days that aspirin 
      was taken (OR 0.74, 95% CI: 0.61-0. 90). Adult lifetime use was also associated 
      with breast cancer risk (>10 days/month, adjusted OR 0.68, 95% CI: 0.46-1.00). 
      Use of ibuprofen or acetaminophen was not associated with breast cancer. 
      CONCLUSIONS: This is the first study to investigate the association of adult 
      lifetime aspirin intake with breast cancer risk. Our findings provide evidence 
      that aspirin use throughout a woman's life may confer some benefit.
FAU - Brasky, Theodore M
AU  - Brasky TM
AD  - Department of Social and Preventive Medicine, School of Public Health and Health 
      Professions, University at Buffalo, Buffalo, NY 14214, USA. tbrasky@fhcrc.org
FAU - Bonner, Matthew R
AU  - Bonner MR
FAU - Moysich, Kirsten B
AU  - Moysich KB
FAU - Ambrosone, Christine B
AU  - Ambrosone CB
FAU - Nie, Jing
AU  - Nie J
FAU - Tao, Meng Hua
AU  - Tao MH
FAU - Edge, Stephen B
AU  - Edge SB
FAU - Kallakury, Bhaskar V S
AU  - Kallakury BV
FAU - Marian, Catalin
AU  - Marian C
FAU - Trevisan, Maurizio
AU  - Trevisan M
FAU - Shields, Peter G
AU  - Shields PG
FAU - Freudenheim, Jo L
AU  - Freudenheim JL
LA  - eng
GR  - R01CA92040/CA/NCI NIH HHS/United States
GR  - P50 AA009802/AA/NIAAA NIH HHS/United States
GR  - R25-CA94880/CA/NCI NIH HHS/United States
GR  - R01 CA092040-02/CA/NCI NIH HHS/United States
GR  - R01 CA092040/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20100525
PL  - Netherlands
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Breast Neoplasms/*epidemiology
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - New York
MH  - Odds Ratio
MH  - Risk Factors
MH  - Surveys and Questionnaires
PMC - PMC2922491
MID - NIHMS208273
EDAT- 2010/05/26 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/05/26 06:00
PHST- 2010/02/04 00:00 [received]
PHST- 2010/05/06 00:00 [accepted]
PHST- 2010/05/26 06:00 [entrez]
PHST- 2010/05/26 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.1007/s10552-010-9579-5 [doi]
PST - ppublish
SO  - Cancer Causes Control. 2010 Sep;21(9):1503-12. doi: 10.1007/s10552-010-9579-5. 
      Epub 2010 May 25.

PMID- 25139652
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20181202
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 158
DP  - 2014
TI  - [Interaction between NSAIDs and acetylsalicylic acid disregarded].
PG  - A7893
AB  - In 2013 the European Medicines Agency declared that diclofenac is contraindicated 
      in patients with arterial thrombotic complications, based on a meta-analysis of 
      randomised controlled trials on the adverse reactions of NSAIDs. The same 
      decision was taken for coxibs some years earlier. The Dutch authorities (CBG/MEB) 
      informed physicians and pharmacists about this decision without taking into 
      account whether these patients were using prophylactic acetylsalicylic acid or 
      not. It has been shown that NSAIDs with high COX-1 affinity like ibuprofen and 
      naproxen cause a pharmacodynamic interaction with the inhibition of thromboxane 
      synthesis by acetylsalicylic acid. This interaction does not occur with 
      relatively COX-2-selective NSAIDs such as coxibs and diclofenac. Therefore, in 
      patients who use acetylsalicylic acid for thromboprophylaxis, contraindicating 
      coxibs or diclofenac is not justified, on the contrary: they are preferable.
FAU - Vollaard, E J
AU  - Vollaard EJ
AD  - Sint Maartenskliniek, afd. Klinische Farmacie, Nijmegen.
FAU - Kramers, C
AU  - Kramers C
FAU - Brouwers, J R B J
AU  - Brouwers JR
LA  - dut
PT  - Journal Article
TT  - Interactie NSAID's en acetylsalicylzuur genegeerd.
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 57Y76R9ATQ (Naproxen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cyclooxygenase 2 Inhibitors/adverse effects/therapeutic use
MH  - Diclofenac/adverse effects/therapeutic use
MH  - Drug Interactions
MH  - Humans
MH  - Naproxen/adverse effects/therapeutic use
MH  - Thrombosis/*drug therapy
EDAT- 2014/08/21 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/08/21 06:00
PHST- 2014/08/21 06:00 [entrez]
PHST- 2014/08/21 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
PST - ppublish
SO  - Ned Tijdschr Geneeskd. 2014;158:A7893.

PMID- 17654043
OWN - NLM
STAT- MEDLINE
DCOM- 20071003
LR  - 20151119
IS  - 1071-5762 (Print)
IS  - 1029-2470 (Linking)
VI  - 41
IP  - 8
DP  - 2007 Aug
TI  - Indices of oxidative stress in pregnancy with fetal growth restriction.
PG  - 870-3
AB  - Intrauterine fetal growth restriction (IUGR), the main cause of premature 
      delivery and fetal mortality, has been suggested to involve oxidative stress. We 
      found elevated values of indices of oxidative stress in the blood serum of 
      pregnant women with IUGR: increased levels of malondialdehyde and 
      4-hydroxyalkenals, decreased activity of alpha-1-antitrypsin and decreased total 
      antioxidant capacity of the serum, with respect to healthy pregnancy. Twenty day 
      treatment with 3 g of l-arginine and 75 mg of acetylsalicylic acid daily resulted 
      in a decrease of the level of lipid peroxidation products and augmentation of 
      alpha-1-antitrypsin activity. This study confirms the occurrence of oxidative 
      stress in IUGR and demonstrates the beneficial effect of arginine/acetylsalicylic 
      acid therapy in reducing oxidative stress in IUGR.
FAU - Karowicz-Bilinska, Agata
AU  - Karowicz-Bilinska A
AD  - High-Risk Pregnancy Unit, Medical University of Łódz, Lodz, Poland. 
      agakar@interia.pl
FAU - Kedziora-Kornatowska, Kornelia
AU  - Kedziora-Kornatowska K
FAU - Bartosz, Grzegorz
AU  - Bartosz G
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Free Radic Res
JT  - Free radical research
JID - 9423872
RN  - 0 (Biomarkers)
RN  - 0 (SERPINA1 protein, human)
RN  - 0 (alpha 1-Antitrypsin)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 94ZLA3W45F (Arginine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Arginine/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Biomarkers/blood
MH  - Female
MH  - Fetal Growth Retardation/blood/etiology/*prevention & control
MH  - Humans
MH  - Lipid Peroxidation/drug effects
MH  - Malondialdehyde/blood
MH  - Oxidative Stress/*drug effects
MH  - Pregnancy
MH  - Serum/metabolism
MH  - alpha 1-Antitrypsin/metabolism
EDAT- 2007/07/27 09:00
MHDA- 2007/10/04 09:00
CRDT- 2007/07/27 09:00
PHST- 2007/07/27 09:00 [pubmed]
PHST- 2007/10/04 09:00 [medline]
PHST- 2007/07/27 09:00 [entrez]
AID - 780571419 [pii]
AID - 10.1080/10715760701291647 [doi]
PST - ppublish
SO  - Free Radic Res. 2007 Aug;41(8):870-3. doi: 10.1080/10715760701291647.

PMID- 2029065
OWN - NLM
STAT- MEDLINE
DCOM- 19910607
LR  - 20190912
IS  - 0196-0709 (Print)
IS  - 0196-0709 (Linking)
VI  - 12
IP  - 1
DP  - 1991 Jan-Feb
TI  - Salicylate ototoxicity: review and synthesis.
PG  - 33-47
AB  - The effects of salicylates on the auditory system are reviewed. The clinical 
      manifestations of aspirin ototoxicity are described, including changes in the 
      sensitivity and suprathreshold characteristics of hearing, as well as tinnitus. 
      The results of animal experiments on salicylate ototoxicity are discussed, 
      including behavioral, anatomic, and physiologic studies examining the mechanisms 
      of salicylate ototoxicity. The sue of salicylates in the study of the basic 
      mechanisms of hearing and hearing loss is also considered.
FAU - Boettcher, F A
AU  - Boettcher FA
AD  - Department of Communicative Disorders and Sciences, State University of New York, 
      Buffalo 14214.
FAU - Salvi, R J
AU  - Salvi RJ
LA  - eng
GR  - NIDCD-5RO1-23894-03/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Am J Otolaryngol
JT  - American journal of otolaryngology
JID - 8000029
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/adverse effects
MH  - Hearing/drug effects
MH  - Hearing Disorders/*chemically induced
MH  - Humans
MH  - Salicylates/*adverse effects
RF  - 59
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 0196-0709(91)90071-M [pii]
AID - 10.1016/0196-0709(91)90071-m [doi]
PST - ppublish
SO  - Am J Otolaryngol. 1991 Jan-Feb;12(1):33-47. doi: 10.1016/0196-0709(91)90071-m.

PMID- 7207775
OWN - NLM
STAT- MEDLINE
DCOM- 19810526
LR  - 20190512
IS  - 0148-396X (Print)
IS  - 0148-396X (Linking)
VI  - 8
IP  - 1
DP  - 1981 Jan
TI  - Scanning electron microscopic and X-ray energy spectrographic analysis of the 
      inner surface of human atherosclerotic carotid plaques.
PG  - 60-7
AB  - Forty specimens of carotid plaque from 30 patients who had suffered 
      cerebrovascular accidents and 10 asymptomatic control patients were examined by 
      light and scanning electron microscopy (SEM). The SEM revealed the finely 
      detailed surface characteristics of the plaque including cell deposits, 
      endothelial damage, and exposed subendothelium. X-ray energy spectrography scans 
      revealed that 7 specimens had calcium deposits. Presurgical treatment with 
      dipyridamole and aspirin inhibited or substantially reduced thrombus formation.
FAU - Dujovny, M
AU  - Dujovny M
FAU - Kossovsky, N
AU  - Kossovsky N
FAU - Loubeau, J M
AU  - Loubeau JM
FAU - Nelson, D
AU  - Nelson D
FAU - McManus, G
AU  - McManus G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Carotid Artery Diseases/*pathology
MH  - Carotid Artery, Internal/ultrastructure
MH  - Dipyridamole/therapeutic use
MH  - Female
MH  - Humans
MH  - Intracranial Arteriosclerosis/*pathology
MH  - Male
MH  - Microscopy, Electron, Scanning
MH  - Middle Aged
MH  - Thrombosis/drug therapy
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
AID - 10.1227/00006123-198101000-00012 [doi]
PST - ppublish
SO  - Neurosurgery. 1981 Jan;8(1):60-7. doi: 10.1227/00006123-198101000-00012.

PMID- 26272940
OWN - NLM
STAT- MEDLINE
DCOM- 20151217
LR  - 20220129
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Print)
IS  - 1079-5642 (Linking)
VI  - 35
IP  - 10
DP  - 2015 Oct
TI  - Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet 
      Therapy.
PG  - 2122-33
LID - 10.1161/ATVBAHA.115.306219 [doi]
AB  - OBJECTIVE: Reduced antiplatelet drug efficacy occurs in conditions of increased 
      platelet turnover, associated with increased proportions of drug-free, that is, 
      uninhibited, platelets. Here, we detail mechanisms by which drug-free platelets 
      promote platelet aggregation in the face of standard antiplatelet therapy. 
      APPROACH AND RESULTS: To model standard antiplatelet therapy, platelets were 
      treated in vitro with aspirin, the P2Y12 receptor blocker prasugrel active 
      metabolite, or aspirin plus prasugrel active metabolite. Different proportions of 
      uninhibited platelets were then introduced. Light transmission aggregometry 
      analysis demonstrated clear positive associations between proportions of 
      drug-free platelets and percentage platelet aggregation in response to a range of 
      platelet agonists. Using differential platelet labeling coupled with advanced 
      flow cytometry and confocal imaging we found aggregates formed in mixtures of 
      aspirin-inhibited platelets together with drug-free platelets were characterized 
      by intermingled platelet populations. This distribution is in accordance with the 
      ability of drug-free platelets to generate thromboxane A2 and so drive secondary 
      platelet activation. Conversely, aggregates formed in mixtures of prasugrel 
      active metabolite-inhibited or aspirin plus prasugrel active metabolite-inhibited 
      platelets together with drug-free platelets were characterized by distinct cores 
      of drug-free platelets. This distribution is consistent with the ability of 
      drug-free platelets to respond to the secondary activator ADP. CONCLUSIONS: These 
      experiments are the first to image the interactions of inhibited and uninhibited 
      platelets in the formation of platelet aggregates. They demonstrate that a 
      general population of platelets can contain subpopulations that respond 
      strikingly differently to overall stimulation of the population and so act as the 
      seed for platelet aggregation.
CI  - © 2015 The Authors.
FAU - Hoefer, Thomas
AU  - Hoefer T
AD  - From The William Harvey Research Institute, Barts and the London School of 
      Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, 
      London, United Kingdom (T.H., P.C.A., M.F., M.V.C., T.D.W.); and National Heart 
      and Lung Institute, Imperial College London, London, United Kingdom (N.S.K.).
FAU - Armstrong, Paul C
AU  - Armstrong PC
AD  - From The William Harvey Research Institute, Barts and the London School of 
      Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, 
      London, United Kingdom (T.H., P.C.A., M.F., M.V.C., T.D.W.); and National Heart 
      and Lung Institute, Imperial College London, London, United Kingdom (N.S.K.).
FAU - Finsterbusch, Michaela
AU  - Finsterbusch M
AD  - From The William Harvey Research Institute, Barts and the London School of 
      Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, 
      London, United Kingdom (T.H., P.C.A., M.F., M.V.C., T.D.W.); and National Heart 
      and Lung Institute, Imperial College London, London, United Kingdom (N.S.K.).
FAU - Chan, Melissa V
AU  - Chan MV
AD  - From The William Harvey Research Institute, Barts and the London School of 
      Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, 
      London, United Kingdom (T.H., P.C.A., M.F., M.V.C., T.D.W.); and National Heart 
      and Lung Institute, Imperial College London, London, United Kingdom (N.S.K.).
FAU - Kirkby, Nicholas S
AU  - Kirkby NS
AD  - From The William Harvey Research Institute, Barts and the London School of 
      Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, 
      London, United Kingdom (T.H., P.C.A., M.F., M.V.C., T.D.W.); and National Heart 
      and Lung Institute, Imperial College London, London, United Kingdom (N.S.K.).
FAU - Warner, Timothy D
AU  - Warner TD
AD  - From The William Harvey Research Institute, Barts and the London School of 
      Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, 
      London, United Kingdom (T.H., P.C.A., M.F., M.V.C., T.D.W.); and National Heart 
      and Lung Institute, Imperial College London, London, United Kingdom (N.S.K.). 
      t.d.warner@qmul.ac.uk.
LA  - eng
GR  - 101604/Wellcome Trust/United Kingdom
GR  - PG/12/68/29779/BHF_/British Heart Foundation/United Kingdom
GR  - Medical Research Council/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150813
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2081-2. PMID: 26399920
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects
MH  - Drug Therapy, Combination
MH  - Flow Cytometry
MH  - Humans
MH  - In Vitro Techniques
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Prasugrel Hydrochloride/*pharmacology
MH  - Sensitivity and Specificity
MH  - Thromboxanes/metabolism
PMC - PMC4587545
MID - EMS64620
OID - NLM: EMS64620
OTO - NOTNLM
OT  - P2Y12 receptor
OT  - aspirin
OT  - flow cytometry
OT  - prasugrel
OT  - thromboxane
EDAT- 2015/08/15 06:00
MHDA- 2015/12/19 06:00
CRDT- 2015/08/15 06:00
PHST- 2015/03/03 00:00 [received]
PHST- 2015/07/30 00:00 [accepted]
PHST- 2015/08/15 06:00 [entrez]
PHST- 2015/08/15 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
AID - ATVBAHA.115.306219 [pii]
AID - 10.1161/ATVBAHA.115.306219 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2122-33. doi: 
      10.1161/ATVBAHA.115.306219. Epub 2015 Aug 13.

PMID- 33493236
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 16
IP  - 1
DP  - 2021
TI  - The effect of de-escalation of P2Y12 receptor inhibitor therapy after acute 
      myocardial infarction in patients undergoing percutaneous coronary intervention: 
      A nationwide cohort study.
PG  - e0246029
LID - 10.1371/journal.pone.0246029 [doi]
LID - e0246029
AB  - To examine the effect of de-escalation of P2Y12 inhibitor in dual antiplatelet 
      therapy (DAPT) on major adverse cardiovascular events (MACE) and bleeding 
      complications after acute myocardial infarction (AMI) in Taiwanese patients 
      undergoing percutaneous coronary intervention (PCI). Patients who had received 
      PCI during hospitalization for AMI (between 2013 and 2016) and were initially 
      treated with aspirin and ticagrelor and without adverse events after 3 months of 
      treatment were retrospectively evaluated. In total, 1,901 and 8,199 patients were 
      identified as "de-escalated DAPT" (switched to aspirin and clopidogrel) and 
      "unchanged DAPT" (continued on aspirin and ticagrelor) cohorts, respectively. 
      With a mean follow-up of 8 months, the incidence rates (per 100 person-year) of 
      death, AMI readmission and MACE were 2.89, 3.68, and 4.91 in the de-escalated 
      cohort and 2.42, 3.28, and 4.72 in the unchanged cohort, respectively, based on 
      an inverse probability of treatment weighted approach that adjusting for baseline 
      characteristics of the patients. Multivariate Cox regression analyses showed the 
      two groups had no significant differences in the hazard risk of death, AMI 
      admission, and MACE. Additionally, there was no observed difference in the risk 
      of bleeding, including major or clinically relevant non-major bleeding. The 
      real-world data revealed that de-escalation of P2Y12 inhibitor in DAPT was not 
      associated with a higher risk of death or AMI readmission in Taiwanese patients 
      with AMI undergoing successful PCI.
FAU - Yeh, Jong-Shiuan
AU  - Yeh JS
AD  - Division of Cardiovascular Medicine, Department of Internal Medicine, Taipei 
      Municipal Wan-Fang Hospital, Taipei, Taiwan.
AD  - Department of Internal Medicine, School of Medicine, College of Medicine, Taipei 
      Medical University, Taipei, Taiwan.
FAU - Hsu, Chien-Yi
AU  - Hsu CY
AD  - Department of Internal Medicine, School of Medicine, College of Medicine, Taipei 
      Medical University, Taipei, Taiwan.
AD  - Division of Cardiology and Cardiovascular Research Center, Department of Internal 
      Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
FAU - Huang, Chun-Yao
AU  - Huang CY
AD  - Department of Internal Medicine, School of Medicine, College of Medicine, Taipei 
      Medical University, Taipei, Taiwan.
AD  - Division of Cardiology and Cardiovascular Research Center, Department of Internal 
      Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
FAU - Chen, Wan-Ting
AU  - Chen WT
AD  - Health and Clinical Research Data Center, Office of Data Science, Taipei Medical 
      University, Taipei, Taiwan.
FAU - Hsieh, Yi-Chen
AU  - Hsieh YC
AUID- ORCID: 0000-0002-1863-287X
AD  - PHD Program of Neural Regenerative Medicine, College of Medical Science and 
      Technology, Taipei Medical University, Taipei, Taiwan.
AD  - PHD Program in Biotechnology Research and Development, College of Pharmacy, 
      Taipei Medical University, Taipei, Taiwan.
AD  - Master Program in Applied Molecular Epidemiology, College of Public Health, 
      Taipei Medical University, Taipei, Taiwan.
FAU - Chien, Li-Nien
AU  - Chien LN
AUID- ORCID: 0000-0001-9441-552X
AD  - Health and Clinical Research Data Center, Office of Data Science, Taipei Medical 
      University, Taipei, Taiwan.
AD  - School of Health Care Administration, College of Management, Taipei Medical 
      University, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210125
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clopidogrel/administration & dosage/therapeutic use
MH  - Drug Substitution
MH  - Dual Anti-Platelet Therapy
MH  - Humans
MH  - Middle Aged
MH  - Myocardial Infarction/*therapy
MH  - *Percutaneous Coronary Intervention
MH  - Purinergic P2Y Receptor Antagonists/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - Ticagrelor/administration & dosage/*therapeutic use
MH  - Young Adult
PMC - PMC7833092
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/26 06:00
MHDA- 2021/06/25 06:00
CRDT- 2021/01/25 17:16
PHST- 2020/06/12 00:00 [received]
PHST- 2021/01/12 00:00 [accepted]
PHST- 2021/01/25 17:16 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - PONE-D-20-17922 [pii]
AID - 10.1371/journal.pone.0246029 [doi]
PST - epublish
SO  - PLoS One. 2021 Jan 25;16(1):e0246029. doi: 10.1371/journal.pone.0246029. 
      eCollection 2021.

PMID- 9468208
OWN - NLM
STAT- MEDLINE
DCOM- 19980306
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 97
IP  - 4
DP  - 1998 Feb 3
TI  - Erythrocyte promotion of platelet reactivity decreases the effectiveness of 
      aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin 
      is less than optimal in patients with vascular disease due to prothrombotic 
      effects of erythrocytes on platelet reactivity.
PG  - 350-5
AB  - BACKGROUND: Aspirin (acetylsalicylic acid, ASA) is widely used for secondary 
      prevention of ischemic vascular events, although its protection only occurs in 
      25% of patients. We previously demonstrated that platelet reactivity is enhanced 
      by a prothrombotic effect of erythrocytes in a thromboxane-independent manner. 
      This diminishes the antithrombotic therapeutic potential of ASA. Recent data from 
      our laboratory indicate that the prothrombotic effect of erythrocytes also 
      contains an ASA-sensitive component. In accordance with this observation, 
      intermittent treatment with high-dose ASA reduced the prothrombotic effects of 
      erythrocytes ex vivo in healthy volunteers. In the present study, the effects of 
      platelet-erythrocyte interactions were evaluated ex vivo in 82 patients with 
      vascular disease: 62 patients with ischemic heart disease treated with 200 mg 
      ASA/d and 20 patients with ischemic stroke treated with 300 mg ASA/d. METHODS AND 
      RESULTS: Platelet activation (release reaction) and platelet recruitment 
      (fluid-phase proaggregatory activity of cell-free releasates from activated 
      platelets) were assessed after collagen stimulation (1 microg/mL) of platelets, 
      platelet-erythrocyte mixtures, or whole blood. Platelet thromboxane A2 synthesis 
      was inhibited by >94% by ASA administration in all patients. Importantly, 
      platelet recruitment followed one of three distinct patterns. In group A (n=32; 
      39%), platelet recruitment was blocked by ASA both in the presence and absence of 
      erythrocytes. In group B (n=37; 45%), recruitment was abolished when platelets 
      were evaluated alone but continued in the presence of erythrocytes, indicating a 
      suboptimal effect of ASA on erythrocytes of this patient group. In group C (n= 
      13; 16%), detectable recruitment in stimulated platelets alone persisted and was 
      markedly enhanced by the presence of erythrocytes. CONCLUSIONS: In two thirds of 
      a group of patients with vascular disease, 200 to 300 mg ASA was insufficient to 
      block platelet reactivity in the presence of erythrocytes despite abolishing 
      thromboxane A2 synthesis. Platelet activation in the presence of erythrocytes can 
      induce the release reaction and generate biologically active products that 
      recruit additional platelets into a developing thrombus. Insufficient blockade of 
      this proaggregatory property of erythrocytes can lead to development of 
      additional ischemic complications.
FAU - Valles, J
AU  - Valles J
AD  - Research Center, University Hospital La Fe, Valencia, Spain. mteresas@san.gva.es
FAU - Santos, M T
AU  - Santos MT
FAU - Aznar, J
AU  - Aznar J
FAU - Osa, A
AU  - Osa A
FAU - Lago, A
AU  - Lago A
FAU - Cosin, J
AU  - Cosin J
FAU - Sanchez, E
AU  - Sanchez E
FAU - Broekman, M J
AU  - Broekman MJ
FAU - Marcus, A J
AU  - Marcus AJ
LA  - eng
GR  - HL-46403/HL/NHLBI NIH HHS/United States
GR  - HL-47073/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 333DO1RDJY (Serotonin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/metabolism/*physiology
MH  - Brain Ischemia/drug therapy
MH  - Cerebrovascular Disorders/drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Erythrocytes/drug effects/*physiology
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/drug therapy
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Serotonin/metabolism
MH  - Vascular Diseases/blood/*drug therapy/*etiology
EDAT- 1998/02/19 00:00
MHDA- 1998/02/19 00:01
CRDT- 1998/02/19 00:00
PHST- 1998/02/19 00:00 [pubmed]
PHST- 1998/02/19 00:01 [medline]
PHST- 1998/02/19 00:00 [entrez]
AID - 10.1161/01.cir.97.4.350 [doi]
PST - ppublish
SO  - Circulation. 1998 Feb 3;97(4):350-5. doi: 10.1161/01.cir.97.4.350.

PMID- 9385493
OWN - NLM
STAT- MEDLINE
DCOM- 19971230
LR  - 20190920
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 19
IP  - 5
DP  - 1997 Sep-Oct
TI  - A randomized trial of aspirin versus cilostazol therapy after successful coronary 
      stent implantation.
PG  - 1058-66
AB  - Percutaneous transluminal coronary angioplasty (PTCA) is widely used to treat 
      patients with ischemic heart disease, but the procedure involves a number of 
      problems, including acute coronary occlusion and restenosis. Although stents have 
      proved useful for preventing post-PTCA restenosis, especially elastic recoil 
      during the acute phase, no method has yet been established to prevent restenosis 
      caused by vascular smooth muscle cell proliferation in the late phase. Cilostazol 
      selectively inhibits the 3'5'-cyclic-nucleotide phosphodiesterase (PDE) III 
      (cyclic guanosine monophosphate-inhibited PDE) of the cyclic adenosine 
      monophosphate PDE family; it also has antithrombotic and vasodilating effects, as 
      well as an inhibitory effect on vascular smooth muscle cell proliferation through 
      PDE III inhibition. From November 1995 to March 1997, the usefulness of 
      cilostazol versus aspirin in preventing subacute thrombosis and restenosis was 
      studied in 70 patients (55 men and 15 women; 82 total lesions) who had undergone 
      successful elective Palmaz-Schatz stent implantation. Patients were randomly 
      allocated to receive aspirin 81 mg/d (40 patients with 45 lesions) or cilostazol 
      200 mg/d (30 patients with 37 lesions) alone. There was no difference in patients 
      or angiographic characteristics between these groups. No subacute thrombosis, 
      acute complications (ie, death, emergent coronary artery bypass grafting, or 
      hemorrhagic complications), or drug side effects were found in the cilostazol 
      group. The minimal lumen diameter (mean +/- SD) at follow-up was 1.89 +/- 1.08 mm 
      in the aspirin group (41 lesions, 5.63 +/- 1.74 months after stent implantation) 
      and 2.34 +/- 0.74 mm in the cilostazol group (35 lesions, 5.14 +/- 1.91 months 
      after stent implantation), revealing statistically significant dilatation in the 
      cilostazol group. The restenosis rate was 26.8% in the aspirin group, compared 
      with 8.6% in the cilostazol group; this difference was statistically significant. 
      Administration of cilostazol alone after the implantation of intracoronary 
      Palmaz-Schatz stents was useful for the prevention of subacute thrombosis and 
      restenosis.
FAU - Kunishima, T
AU  - Kunishima T
AD  - Department of Cardiology, Yokohama City Seibu Hospital, St. Marianna University 
      School of Medicine, Japan.
FAU - Musha, H
AU  - Musha H
FAU - Eto, F
AU  - Eto F
FAU - Iwasaki, T
AU  - Iwasaki T
FAU - Nagashima, J
AU  - Nagashima J
FAU - Masui, Y
AU  - Masui Y
FAU - So, T
AU  - So T
FAU - Nakamura, T
AU  - Nakamura T
FAU - Oohama, N
AU  - Oohama N
FAU - Murayama, M
AU  - Murayama M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary/*methods
MH  - Aspirin/*therapeutic use
MH  - Cilostazol
MH  - Coronary Disease/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Secondary Prevention
MH  - Stents
MH  - Tetrazoles/*therapeutic use
MH  - Thrombosis/*prevention & control
EDAT- 1998/01/07 00:00
MHDA- 1998/01/07 00:01
CRDT- 1998/01/07 00:00
PHST- 1998/01/07 00:00 [pubmed]
PHST- 1998/01/07 00:01 [medline]
PHST- 1998/01/07 00:00 [entrez]
AID - S0149-2918(97)80058-6 [pii]
AID - 10.1016/s0149-2918(97)80058-6 [doi]
PST - ppublish
SO  - Clin Ther. 1997 Sep-Oct;19(5):1058-66. doi: 10.1016/s0149-2918(97)80058-6.

PMID- 18173959
OWN - NLM
STAT- MEDLINE
DCOM- 20080206
LR  - 20191110
IS  - 1523-3804 (Print)
IS  - 1523-3804 (Linking)
VI  - 9
IP  - 4
DP  - 2007 Oct
TI  - Antiplatelet therapy for stroke prevention.
PG  - 312-8
AB  - Recent trials of antiplatelet therapy for stroke prevention indicate that the 
      combination of clopidogrel (75 mg/d) plus low-dose aspirin (75-162 mg/d) was not 
      more effective than low-dose aspirin alone in the long-term prevention of major 
      vascular events among patients at high risk of atherothrombotic events, nor was 
      it more effective than oral anticoagulation in patients with atrial fibrillation. 
      Furthermore, oral anticoagulation (International Normalized Ratio of 2.0-3.0) was 
      not more effective than aspirin alone among patients with recent cerebral 
      ischemia of presumed arterial origin. However, the addition of extended-release 
      dipyridamole to aspirin was more effective than aspirin alone among patients with 
      recent cerebral ischemia of presumed arterial origin. A large trial comparing 
      clopidogrel with the combination of aspirin and extended-release dipyridamole in 
      more than 20,000 patients with recent (< 120 days) atherothrombotic ischemic 
      stroke is expected to report in 2008.
FAU - Hankey, Graeme J
AU  - Hankey GJ
AD  - Consultant Neurologist and Head of Stroke Unit, Department of Neurology, Royal 
      Perth Hospital, 197 Wellington Street, Perth, Western Australia 6001, Australia. 
      gjhankey@cyllene.uwa.edu.au
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atherosclerosis/complications
MH  - Atrial Fibrillation/complications
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Dipyridamole/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Stroke/etiology/*prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
RF  - 26
EDAT- 2008/01/05 09:00
MHDA- 2008/02/07 09:00
CRDT- 2008/01/05 09:00
PHST- 2008/01/05 09:00 [pubmed]
PHST- 2008/02/07 09:00 [medline]
PHST- 2008/01/05 09:00 [entrez]
AID - 10.1007/s11883-007-0038-z [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2007 Oct;9(4):312-8. doi: 10.1007/s11883-007-0038-z.

PMID- 2271231
OWN - NLM
STAT- MEDLINE
DCOM- 19910228
LR  - 20170214
IS  - 0960-3271 (Print)
IS  - 0960-3271 (Linking)
VI  - 9
IP  - 6
DP  - 1990 Nov
TI  - Depletion of plasma glycine and effect of glycine by mouth on salicylate 
      metabolism during aspirin overdose.
PG  - 389-95
AB  - 1. The metabolism of aspirin was investigated in 45 patients who had taken 
      self-administered overdose of aspirin and were treated with fluids only, glycine, 
      N-glycylglycine by mouth, or by sodium bicarbonate i.v. 2. The major metabolite 
      recovered in the urine of patients treated with oral fluids, glycine or 
      N-glycylglycine was salicyluric acid, which accounted for means of 51%, 47% and 
      38% of the total, respectively; salicylic acid comprised 19%, 29% and 29%. In 
      contrast, salicylic acid (42%) was the major urinary metabolite recovered from 
      patients treated with sodium bicarbonate. 3. Plasma glycine concentrations in 
      healthy volunteers who had taken no aspirin remained constant through the day and 
      were not affected by a therapeutic dose (500 mg) of aspirin. Plasma glycine was 
      consistently lower in patients with aspirin overdose than in these healthy 
      volunteers, suggesting depletion of available glycine. 4. Orally administered 
      glycine and N-glycylglycine increased plasma glycine. While the fraction of total 
      salicylate recovered as salicyluric acid was not altered, the maximum rate of 
      excretion of salicyluric acid was higher in patients who received glycine than in 
      the control group; there was no significant difference in the maximum rate of 
      excretion of salicyluric acid between the group that received glycine and the 
      group that received N-glycylglycine. 5. The data suggest that exogenous glycine 
      increases the rate of formation of salicyluric acid in salicylate overdose.
FAU - Patel, D K
AU  - Patel DK
AD  - Medicinal Biochemistry Department, Burroughs Wellcome Co., Research Triangle 
      Park, NC 27709.
FAU - Ogunbona, A
AU  - Ogunbona A
FAU - Notarianni, L J
AU  - Notarianni LJ
FAU - Bennett, P N
AU  - Bennett PN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Exp Toxicol
JT  - Human & experimental toxicology
JID - 9004560
RN  - 0 (Hippurates)
RN  - 0 (Salicylates)
RN  - 10525P22U0 (Glycylglycine)
RN  - 487-54-7 (salicylurate)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aspirin/metabolism/*poisoning
MH  - Drug Overdose
MH  - Female
MH  - Glycine/administration & dosage/*blood/*therapeutic use
MH  - Glycylglycine/administration & dosage/therapeutic use
MH  - Hippurates/urine
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Salicylates/*metabolism/urine
MH  - Salicylic Acid
EDAT- 1990/11/01 00:00
MHDA- 1990/11/01 00:01
CRDT- 1990/11/01 00:00
PHST- 1990/11/01 00:00 [pubmed]
PHST- 1990/11/01 00:01 [medline]
PHST- 1990/11/01 00:00 [entrez]
AID - 10.1177/096032719000900606 [doi]
PST - ppublish
SO  - Hum Exp Toxicol. 1990 Nov;9(6):389-95. doi: 10.1177/096032719000900606.

PMID- 10445265
OWN - NLM
STAT- MEDLINE
DCOM- 19990924
LR  - 20150505
IS  - 0201-8470 (Print)
IS  - 0201-8470 (Linking)
VI  - 70
IP  - 5
DP  - 1998 Sep-Oct
TI  - [In vitro effect of 1,2-dihydro-3H-1,4-benzodiazepine-2-one derivatives on the 
      platelet aggregation and lipid peroxidation in rats].
PG  - 81-5
AB  - There were discovered the anti-aggregative properties of some psychotropic drugs 
      as gidazepam, phenazepam and its derivatives 3-oxyphenazepam, esters of 
      3-oxyphenazepam, with IC50 values of 8.19-11 x 10(-4) M. On their 
      anti-aggregative effects they exceed of the acetylsalicylic acid (IC50 = 21.3 x 
      10(-4) M). Only gidazepam, containing in its chemical structure hydrazide 
      fragment, caused significant decrease in the content of MDA. The possibility of 
      involvement of lipid peroxidation in mechanism of its anti-aggregative effect is 
      discussed.
FAU - Karaseva, T L
AU  - Karaseva TL
AD  - A.V. Bogatsky Physico-Chemical Institute of the National Academy of Sciences of 
      Ukraine, Odessa.
FAU - Belikova, M V
AU  - Belikova MV
FAU - Pavlovskiĭ, V I
AU  - Pavlovskiĭ VI
FAU - Andronati, K S
AU  - Andronati KS
FAU - Kabanova, T A
AU  - Kabanova TA
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Vliianie in vitro proizvodnykh 1,2-digidro-3H-1,4-benzdiazepin-2-ona na 
      agregatsiiu trombotsitov i peroksidnoe okislenie lipidov u krys.
PL  - Ukraine
TA  - Ukr Biokhim Zh (1978)
JT  - Ukrainskii biokhimicheskii zhurnal (1978)
JID - 7804246
RN  - 0 (Anti-Anxiety Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 3DSB43090Z (phenazepam)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
RN  - XMJ87I93Y9 (gidazepam)
SB  - IM
MH  - Animals
MH  - Anti-Anxiety Agents/metabolism/pharmacology
MH  - Aspirin/pharmacology
MH  - Benzodiazepines/*pharmacology
MH  - Lipid Peroxidation/*drug effects
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Rats
EDAT- 1999/08/13 00:00
MHDA- 1999/08/13 00:01
CRDT- 1999/08/13 00:00
PHST- 1999/08/13 00:00 [pubmed]
PHST- 1999/08/13 00:01 [medline]
PHST- 1999/08/13 00:00 [entrez]
PST - ppublish
SO  - Ukr Biokhim Zh (1978). 1998 Sep-Oct;70(5):81-5.

PMID- 2568181
OWN - NLM
STAT- MEDLINE
DCOM- 19890814
LR  - 20180215
IS  - 0008-6312 (Print)
IS  - 0008-6312 (Linking)
VI  - 76
IP  - 2
DP  - 1989
TI  - Morning increase of onset of myocardial infarction. Implications concerning 
      triggering events.
PG  - 96-104
AB  - During the past 5 years it has been clearly established that there is a prominent 
      morning increase in the frequency of onset of acute myocardial infarction. 
      Similar increases have also been observed for the related conditions of sudden 
      cardiac death, stroke and episodes of transient myocardial ischemia. The period 
      from 6 a.m. to noon is also a time when a number of physiologic processes that 
      could contribute to the onset of coronary thrombosis are intensified. Arterial 
      pressure, which could lead to plaque rupture, rises; coronary tone increases; and 
      platelet aggregability, which could contribute to a hypercoagulable state, 
      increases. The immediate significance of these observations is the emphasis that 
      should be placed on pharmacologic protection of patients during the morning 
      hours. The primary longer-term significance of the recognition of the morning 
      increase of onset of acute cardiovascular disease is the contribution it makes to 
      the concept that onset of coronary thrombosis at any time of the day is 
      frequently triggered by the activities of the patient. Investigation of this 
      possibility may yield more information about the mechanism of disease onset and 
      facilitate design of more effective preventive therapy.
FAU - Muller, J E
AU  - Muller JE
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02115.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
RN  - 0 (Adrenergic beta-Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Blood Pressure
MH  - *Circadian Rhythm
MH  - Humans
MH  - *Myocardial Infarction/etiology/prevention & control
MH  - Platelet Aggregation
MH  - Vascular Resistance
RF  - 40
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1159/000174480 [doi]
PST - ppublish
SO  - Cardiology. 1989;76(2):96-104. doi: 10.1159/000174480.

PMID- 34946569
OWN - NLM
STAT- MEDLINE
DCOM- 20220208
LR  - 20220208
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 26
IP  - 24
DP  - 2021 Dec 10
TI  - Assessment of Platelet Reactivity and Inflammatory Markers in Coronary Artery 
      Bypass Graft Patients Treated with Acetylsalicylic Acid with Flavonoid 
      Supplementation.
LID - 10.3390/molecules26247486 [doi]
LID - 7486
AB  - The recommended pharmacological therapy for patients with coronary artery disease 
      (CAD) treated by coronary artery bypass grafting (CABG) is acetylsalicylic acid 
      (ASA). To improve the antiplatelet effect, supplementation with flavonoids is 
      also recommended. The aim of this study was to estimate anti-aggregation 
      properties of diosmin, in combination with ASA, pre- and postoperatively and 
      assess the relationship of this therapy with inflammatory processes in CAD 
      patients undergoing CABG. The study patients (n = 26) took diosmin (1000 mg/day); 
      the control patients (n = 27) took a placebo. The therapeutic period for taking 
      diosmin was from at least 30 days before to 30 days after CABG. All patients also 
      took 75 mg/day ASA. Platelet aggregation and IL-6, CRP, and fibrinogen 
      concentrations were determined before and 30 days after surgery. Results showed 
      that diosmin did not enhance the anti-aggregation effect of ASA at any assessment 
      time. However, there was a stronger anti-aggregation effect 30 days after surgery 
      that was diosmin independent and was associated with acute-phase markers in the 
      postoperative period. Increased levels of inflammatory markers in the late phase 
      of the postoperative period may provide an unfavorable prognostic factor in 
      long-term follow-up, which should prompt the use of stronger antiplatelet therapy 
      in patients after CABG.
FAU - Siennicka, Aldona
AU  - Siennicka A
AD  - Department of Laboratory Diagnostics, Pomeranian Medical University, Powstańców 
      Wlkp. 72, 70-111 Szczecin, Poland.
FAU - Kłysz, Magdalena
AU  - Kłysz M
AD  - Department of Laboratory Diagnostics, Pomeranian Medical University, Powstańców 
      Wlkp. 72, 70-111 Szczecin, Poland.
FAU - Adamska, Monika
AU  - Adamska M
AD  - Department of Laboratory Diagnostics, Pomeranian Medical University, Powstańców 
      Wlkp. 72, 70-111 Szczecin, Poland.
FAU - Chełstowski, Kornel
AU  - Chełstowski K
AD  - Department of Laboratory Diagnostics, Pomeranian Medical University, Powstańców 
      Wlkp. 72, 70-111 Szczecin, Poland.
FAU - Biskupski, Andrzej
AU  - Biskupski A
AUID- ORCID: 0000-0002-4567-2826
AD  - Department of Cardiac Surgery, Pomeranian Medical University, Powstańców Wlkp. 
      72, 70-111 Szczecin, Poland.
FAU - Jastrzębska, Maria
AU  - Jastrzębska M
AD  - Department of Laboratory Diagnostics, Pomeranian Medical University, Powstańców 
      Wlkp. 72, 70-111 Szczecin, Poland.
LA  - eng
GR  - State Committee for Scientific Research/Pomeranian Medical University/
PT  - Journal Article
DEP - 20211210
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Biomarkers)
RN  - 0 (Flavonoids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biomarkers/metabolism
MH  - Blood Platelets/drug effects/metabolism
MH  - *Coronary Artery Bypass
MH  - Coronary Artery Disease/blood/*drug therapy/*surgery
MH  - Dietary Supplements
MH  - Female
MH  - Flavonoids/administration & dosage/*pharmacology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*pharmacology
MH  - Platelet Function Tests
PMC - PMC8708239
OTO - NOTNLM
OT  - acute-phase markers
OT  - aspirin
OT  - cardiac surgery
OT  - diosmin
OT  - platelet aggregation
COIS- The authors declare no conflict of interest.
EDAT- 2021/12/25 06:00
MHDA- 2022/02/09 06:00
CRDT- 2021/12/24 01:11
PHST- 2021/10/05 00:00 [received]
PHST- 2021/12/03 00:00 [revised]
PHST- 2021/12/07 00:00 [accepted]
PHST- 2021/12/24 01:11 [entrez]
PHST- 2021/12/25 06:00 [pubmed]
PHST- 2022/02/09 06:00 [medline]
AID - molecules26247486 [pii]
AID - molecules-26-07486 [pii]
AID - 10.3390/molecules26247486 [doi]
PST - epublish
SO  - Molecules. 2021 Dec 10;26(24):7486. doi: 10.3390/molecules26247486.

PMID- 21499703
OWN - NLM
STAT- MEDLINE
DCOM- 20111012
LR  - 20220331
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Print)
IS  - 0944-1174 (Linking)
VI  - 46
IP  - 6
DP  - 2011 Jun
TI  - Lansoprazole for secondary prevention of gastric or duodenal ulcers associated 
      with long-term low-dose aspirin therapy: results of a prospective, multicenter, 
      double-blind, randomized, double-dummy, active-controlled trial.
PG  - 724-35
LID - 10.1007/s00535-011-0397-7 [doi]
AB  - BACKGROUND: The efficacy of low-dose lansoprazole has not been established for 
      the prevention of recurrent gastric or duodenal ulcers in those receiving 
      long-term low-dose aspirin (LDA) for cardiovascular and cerebrovascular 
      protection. This study sought to examine the efficacy of low-dose lansoprazole 
      (15 mg once daily) for the secondary prevention of LDA-associated gastric or 
      duodenal ulcers. METHODS: Patients were randomized to receive lansoprazole 15 mg 
      daily (n = 226) or gefarnate 50 mg twice daily (n = 235) for 12 months or longer 
      in a prospective, multicenter, double-blind, randomized active-controlled trial, 
      followed by a 6-month follow-up study with open-label lansoprazole treatment. The 
      study utilized 94 sites in Japan and 461 Japanese patients with a history of 
      gastric or duodenal ulcers who required long-term LDA therapy for cardiovascular 
      and cerebrovascular disease. RESULTS: The primary endpoint was the development of 
      gastric or duodenal ulcers. The cumulative incidence of gastric or duodenal 
      ulcers on days 91, 181, and 361 from the start of the study was calculated by the 
      Kaplan-Meier method as 1.5, 2.1, and 3.7%, respectively, in the lansoprazole 
      group versus 15.2, 24.0, and 31.7%, respectively, in the gefarnate group. The 
      risk of ulcer development was significantly (log-rank test, P < 0.001) lower in 
      the lansoprazole group than in the gefarnate group, with the hazard ratio being 
      0.099 (95% confidence interval [CI] 0.042-0.230). CONCLUSION: Lansoprazole was 
      superior to gefarnate in reducing the risk of gastric or duodenal ulcer 
      recurrence in patients with a definite history of gastric or duodenal ulcers who 
      required long-term LDA therapy.
FAU - Sugano, Kentaro
AU  - Sugano K
AD  - Division of Gastroenterology, Department of Internal Medicine, Jichi Medical 
      University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan. 
      sugano@jichi.ac.jp
FAU - Matsumoto, Yasushi
AU  - Matsumoto Y
FAU - Itabashi, Tsukasa
AU  - Itabashi T
FAU - Abe, Sumihisa
AU  - Abe S
FAU - Sakaki, Nobuhiro
AU  - Sakaki N
FAU - Ashida, Kiyoshi
AU  - Ashida K
FAU - Mizokami, Yuji
AU  - Mizokami Y
FAU - Chiba, Tsutomu
AU  - Chiba T
FAU - Matsui, Shigeyuki
AU  - Matsui S
FAU - Kanto, Tatsuya
AU  - Kanto T
FAU - Shimada, Kazuyuki
AU  - Shimada K
FAU - Uchiyama, Shinichiro
AU  - Uchiyama S
FAU - Uemura, Naomi
AU  - Uemura N
FAU - Hiramatsu, Naoki
AU  - Hiramatsu N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110416
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 1ISE2Y6ULA (Gefarnate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Aged
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Double-Blind Method
MH  - Duodenal Ulcer/chemically induced/prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Gefarnate/therapeutic use
MH  - Humans
MH  - Incidence
MH  - Japan
MH  - Kaplan-Meier Estimate
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Prospective Studies
MH  - Secondary Prevention
MH  - Stomach Ulcer/chemically induced/prevention & control
PMC - PMC3117278
EDAT- 2011/04/19 06:00
MHDA- 2011/10/13 06:00
CRDT- 2011/04/19 06:00
PHST- 2010/12/16 00:00 [received]
PHST- 2011/02/28 00:00 [accepted]
PHST- 2011/04/19 06:00 [entrez]
PHST- 2011/04/19 06:00 [pubmed]
PHST- 2011/10/13 06:00 [medline]
AID - 397 [pii]
AID - 10.1007/s00535-011-0397-7 [doi]
PST - ppublish
SO  - J Gastroenterol. 2011 Jun;46(6):724-35. doi: 10.1007/s00535-011-0397-7. Epub 2011 
      Apr 16.

PMID- 1984878
OWN - NLM
STAT- MEDLINE
DCOM- 19910204
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 83
IP  - 1
DP  - 1991 Jan
TI  - Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a 
      multicenter study.
PG  - 148-61
AB  - Stenting of native coronary arteries with a balloon-expandable stent was 
      attempted in 226 patients after elective angioplasty. Delivery of the device was 
      successful in 213 (94%) of the patients. Of these, 39 received aspirin and 
      dipyridamole only (group 1) and 174 received aspirin, dipyridamole, and warfarin 
      for 1-3 months (group 2). There was no abrupt closure (less than or equal to 1 
      day) or perioperative death in either group. In-hospital or perioperative 
      complications in group 1 compared with group 2 were as follows: subacute closure 
      (1-14 days), seven (18%) patients versus one (0.6%) patient, respectively, p less 
      than 0.0001; myocardial infarction, five (13%) patients versus one (0.6%) 
      patient, respectively; condition requiring urgent bypass surgery, one (2.5%) 
      patient versus no patients, respectively. Thus, the incidence of major 
      complications such as death, myocardial infarction, or a condition requiring 
      urgent bypass surgery was 15% in group 1 and 0.6% in group 2. Clinical follow-up 
      revealed that 92% of the patients were asymptomatic at 3 months after stenting 
      compared with 6% before stenting (p less than 0.0001). Of the 13 patients who 
      were symptomatic, nine underwent cardiac catheterization and, ultimately, 
      successful elective coronary angioplasty or bypass surgery. We conclude that a 
      high delivery success rate can be expected with this device and that clinical 
      thrombosis is less frequent in anticoagulated patients than in nonanticoagulated 
      patients. Furthermore, in this selected patient population, coronary stenting 
      results in a low incidence of in-hospital and perioperative complications. 
      Clinical success, defined by absence of symptoms, appears to be sustained at 3 
      months.
FAU - Schatz, R A
AU  - Schatz RA
AD  - Cardiology Division, Arizona Heart Institute Foundation, Phoenix.
FAU - Baim, D S
AU  - Baim DS
FAU - Leon, M
AU  - Leon M
FAU - Ellis, S G
AU  - Ellis SG
FAU - Goldberg, S
AU  - Goldberg S
FAU - Hirshfeld, J W
AU  - Hirshfeld JW
FAU - Cleman, M W
AU  - Cleman MW
FAU - Cabin, H S
AU  - Cabin HS
FAU - Walker, C
AU  - Walker C
FAU - Stagg, J
AU  - Stagg J
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/therapeutic use
MH  - Coronary Disease/*therapy
MH  - Dipyridamole/therapeutic use
MH  - Equipment Design
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Recurrence
MH  - *Stents
MH  - Time Factors
MH  - Warfarin/therapeutic use
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1161/01.cir.83.1.148 [doi]
PST - ppublish
SO  - Circulation. 1991 Jan;83(1):148-61. doi: 10.1161/01.cir.83.1.148.

PMID- 3455237
OWN - NLM
STAT- MEDLINE
DCOM- 19881026
LR  - 20131121
IS  - 0887-8005 (Print)
IS  - 0887-8005 (Linking)
VI  - 1
IP  - 1
DP  - 1987 Jan
TI  - Ameroid constriction of the proximal left circumflex coronary artery in swine. A 
      model of limited coronary collateral circulation.
PG  - 69-77
AB  - Gradual narrowing and occlusion of a coronary artery in patients with 
      atherosclerotic heart disease frequently causes enlargement of the collateral 
      circulation. Although these vessels may protect from development of myocardial 
      infarction, they frequently do not supply sufficient blood flow to prevent 
      ischemia during periods of augmented myocardial oxygen demand. The purpose of 
      this study was to develop a model of the collateral circulation in pigs, a 
      species that previously has been shown to develop sparse collateral vessels. 
      Eighteen pigs were instrumented with an Ameroid constrictor around the proximal 
      left circumflex artery and left atrial and aortic catheters. In four animals the 
      constrictor was placed just distal to a large proximal obtuse marginal vessel. 
      Seven of the pigs were treated daily with oral aspirin (325 mg) and disopyramide 
      (200 mg) throughout the study; the other 11 served as controls. After an average 
      of 24 days postoperatively, radioactive microspheres were injected at rest, 
      during exercise (mean heart rate = 245 beats/min), and during intravenous 
      infusion of dypridamole (700 micrograms/kg). At autopsy the extent of necrosis 
      was assessed by a point counting technique in the bed at risk. We found that 
      75-83% of the bed at risk remained viable. Although aspirin and disopyramide did 
      not significantly alter the extent of infarction (37 +/- 36% untreated vs 17 +/- 
      6% treated), there was less variability of infarction in the treated group, and 
      subendocardial blood flow during exercise was higher in the treated group 
      compared to controls. The majority of infarction occurred in the subendocardial 
      region. Animals with a large obtuse marginal branch developed significantly 
      smaller infarcts (8 +/- 3%).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - O'Konski, M S
AU  - O'Konski MS
AD  - Department of Pathology, University of California, San Diego, School of Medicine, 
      La Jolla.
FAU - White, F C
AU  - White FC
FAU - Longhurst, J
AU  - Longhurst J
FAU - Roth, D
AU  - Roth D
FAU - Bloor, C M
AU  - Bloor CM
LA  - eng
GR  - HL-30222/HL/NHLBI NIH HHS/United States
GR  - HL-32670/HL/NHLBI NIH HHS/United States
GR  - P50 HL-17682/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Cardiovasc Pathol
JT  - The American journal of cardiovascular pathology
JID - 8702438
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - *Collateral Circulation
MH  - Constriction
MH  - *Coronary Circulation
MH  - Coronary Disease/*physiopathology
MH  - Coronary Vessels
MH  - Dipyridamole/pharmacology
MH  - Female
MH  - Male
MH  - *Models, Cardiovascular
MH  - Myocardial Infarction/pathology
MH  - Physical Exertion
MH  - Platelet Aggregation/drug effects
MH  - Swine
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Am J Cardiovasc Pathol. 1987 Jan;1(1):69-77.

PMID- 6356906
OWN - NLM
STAT- MEDLINE
DCOM- 19831217
LR  - 20190627
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 75
IP  - 4B
DP  - 1983 Oct 31
TI  - Pharmacology of nonsteroidal anti-inflammatory drugs. Practical review for 
      clinicians.
PG  - 32-9
AB  - Aspirin and the newer nonsteroidal anti-inflammatory drugs are the mainstay of 
      basic therapy in rheumatoid arthritis and the other rheumatic diseases. Despite 
      its many years of clinical use, the pharmacologic actions of aspirin are still 
      not fully understood; those of many of the newer nonsteroidals may offer 
      significant advantages in terms of long-term safety. Studies in animals and 
      normal human volunteers, as well as clinical trials, provide useful information 
      about the absorption, metabolism, excretion, efficacy, appropriate dosage, and 
      safety of a given nonsteroidal agent. Because all of the newer agents have been 
      developed using the same basic animal tests of efficacy, they all closely 
      resemble indomethacin. Differences in half-life, however, may be important in 
      determining the relative safety of a nonsteroidal, especially in older patients. 
      Most of the nonsteroidals bind only to albumin, and therefore have a kind of 
      built-in safety mechanism: once the albumin binding sites are saturated, free 
      drug is rapidly excreted by the kidney and drug accumulation is prevented. 
      Despite this fact, the clinician must be concerned about two frequent sorts of 
      problems that may arise from the prostaglandin-inhibiting effects of the 
      nonsteroidals. Gastrointestinal side effects may include minor symptoms; diffuse 
      gastritis; small erosions of the gastric mucosa, visible only by endoscope; and 
      frank ulceration, which may rarely be life-threatening. Animal studies, various 
      tests in normal volunteers, and pre-marketing clinical studies may all shed light 
      on the relative ulcerogenicity of a given nonsteroidal agent. Long-term clinical 
      experience especially helps indicate which agents appear to be more ulcerogenic 
      than average and which appear to be less than average. Renal effects of the 
      nonsteroidals are also related to their inhibition of prostaglandin synthesis. 
      The most serious of these--a characteristic kind of interstitial nephritis, renal 
      papillary necrosis, and hyperkalemia--are fortunately rare, but some classes of 
      patients--the elderly, those with impaired renal function, and those receiving 
      diuretics--are at increased risk. For these patients, any nonsteroidal 
      anti-inflammatory drug should be prescribed with caution and appropriate 
      monitoring of renal function.
FAU - O'Brien, W M
AU  - O'Brien WM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Prostaglandin Antagonists)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/adverse effects/*pharmacology/therapeutic use
MH  - Aspirin/pharmacology
MH  - Digestive System/drug effects
MH  - Drug Evaluation, Preclinical
MH  - Duodenal Ulcer/chemically induced
MH  - Kidney/drug effects
MH  - Prostaglandin Antagonists/pharmacology
MH  - Stomach Ulcer/chemically induced
RF  - 75
EDAT- 1983/10/31 00:00
MHDA- 1983/10/31 00:01
CRDT- 1983/10/31 00:00
PHST- 1983/10/31 00:00 [pubmed]
PHST- 1983/10/31 00:01 [medline]
PHST- 1983/10/31 00:00 [entrez]
AID - 10.1016/0002-9343(83)90326-1 [doi]
PST - ppublish
SO  - Am J Med. 1983 Oct 31;75(4B):32-9. doi: 10.1016/0002-9343(83)90326-1.

PMID- 16308601
OWN - NLM
STAT- MEDLINE
DCOM- 20060120
LR  - 20161124
IS  - 0828-282X (Print)
IS  - 0828-282X (Linking)
VI  - 21
IP  - 13
DP  - 2005 Nov
TI  - DDD pacemaker implantation in a patient with persistent left superior vena cava 
      and absent right superior vena cava: a four-year follow-up report.
PG  - 1221-3
AB  - Persistent left superior vena cava coexisting with the absence of right superior 
      vena cava is an uncommon anomaly, and sometimes requires permanent pacemaker 
      implantation due to the relatively high incidence of conduction disturbances and 
      arrhythmias. This anomaly makes the implantation of pacemaker leads more 
      difficult; therefore, accurate preintervention diagnosis of this anomaly is 
      valuable for the interventionalist. A patient in which the diagnosis of 
      persistent left superior vena cava coexisting with absent right superior vena 
      cava was made echocardiographically before permanent pacemaker implantation is 
      presented. Acetylsalicylic acid was prescribed after pacemaker implantation to 
      prevent a potentially fatal complication of coronary sinus thrombosis, and no 
      complication occurred during the four-year follow-up. Some clues for the 
      noninvasive diagnosis of this anomaly and techniques of pacemaker implantation 
      are also described briefly.
FAU - Kilickap, M
AU  - Kilickap M
AD  - Ankara University School of Medicine, Ankara, Turkey. mkilickap@yahoo.com
FAU - Altin, Timucin
AU  - Altin T
FAU - Akyurek, Omer
AU  - Akyurek O
FAU - Karaoguz, Remzi
AU  - Karaoguz R
FAU - Akgun, Gunes
AU  - Akgun G
FAU - Guldal, Muharrem
AU  - Guldal M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Echocardiography, Transesophageal
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pacemaker, Artificial
MH  - Sick Sinus Syndrome/*therapy
MH  - Vena Cava, Superior/*abnormalities/diagnostic imaging
EDAT- 2005/11/26 09:00
MHDA- 2006/01/21 09:00
CRDT- 2005/11/26 09:00
PHST- 2005/11/26 09:00 [pubmed]
PHST- 2006/01/21 09:00 [medline]
PHST- 2005/11/26 09:00 [entrez]
PST - ppublish
SO  - Can J Cardiol. 2005 Nov;21(13):1221-3.

PMID- 11014461
OWN - NLM
STAT- MEDLINE
DCOM- 20010301
LR  - 20201215
IS  - 0340-6199 (Print)
IS  - 0340-6199 (Linking)
VI  - 159
IP  - 9
DP  - 2000 Sep
TI  - Reye syndrome revisited: a descriptive term covering a group of heterogeneous 
      disorders.
PG  - 641-8
AB  - Reye syndrome, characterised by the combination of liver disease and 
      noninflammatory encephalopathy, is a non-specific clinicopathological entity and 
      a descriptive term covering a group of heterogeneous disorders. Nowadays, some of 
      these patients are diagnosed more correctly as having infectious, metabolic, 
      toxic or other disease. The non-specific case definition implies that the 
      epidemiological studies suggesting a link with acetylsalicylic acid have been 
      performed on a heterogeneous group of children, whereby the value of these 
      studies and their ensuing hypothesis is weakened. Moreover, a detailed analysis 
      of the epidemiological surveys of the Centers for Disease Control, the Yale study 
      and of the British risk factor study provides evidence that not only the use of 
      acetylsalicylic acid but also that of phenothiazines and other anti-emetics is 
      significantly greater in Reye syndrome cases than in controls. As to the decline 
      of Reye syndrome, recent literature data reveal that this is related to more 
      accurate modern diagnosis of infectious, metabolic or toxic disease, reducing the 
      percentage of idiopathic or true cases of Reye syndrome. CONCLUSION: Reye 
      syndrome is a non-specific descriptive term covering a group of heterogeneous 
      disorders. Moreover, not only the use of acetylsalicylic acid but also of 
      antiemetics is statistically significant in Reye syndrome cases. Both facts 
      weaken the validity of the epidemiological surveys suggesting a link with 
      acetylsalicylic acid.
FAU - Casteels-Van Daele, M
AU  - Casteels-Van Daele M
AD  - Department of Paediatrics, University Hospital Gasthuisberg, Leuven, Belgium.
FAU - Van Geet, C
AU  - Van Geet C
FAU - Wouters, C
AU  - Wouters C
FAU - Eggermont, E
AU  - Eggermont E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Eur J Pediatr
JT  - European journal of pediatrics
JID - 7603873
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Child
MH  - Humans
MH  - Reye Syndrome/*diagnosis/epidemiology/etiology
RF  - 89
EDAT- 2000/10/03 11:00
MHDA- 2001/03/07 10:01
CRDT- 2000/10/03 11:00
PHST- 2000/10/03 11:00 [pubmed]
PHST- 2001/03/07 10:01 [medline]
PHST- 2000/10/03 11:00 [entrez]
AID - 10.1007/pl00008399 [doi]
PST - ppublish
SO  - Eur J Pediatr. 2000 Sep;159(9):641-8. doi: 10.1007/pl00008399.

PMID- 8370997
OWN - NLM
STAT- MEDLINE
DCOM- 19931008
LR  - 20131121
IS  - 0392-9590 (Print)
IS  - 0392-9590 (Linking)
VI  - 12
IP  - 2
DP  - 1993 Jun
TI  - Indications and results after Strecker-stent-application in iliac and SFA.
PG  - 152-61
AB  - We report on a study which has been performed during two consecutive time 
      intervals on patients with complicated arterial obliterations, who were treated 
      with percutaneous endoprostheses in order to stabilize the results obtained by 
      the preceding balloon angioplasty. Eighty patients participated at this study, 
      and 136 stents were implanted. A detailed analysis of the reocclusions 
      respectively the stenoses shows that the precise placement of the stents and also 
      the length of the stent in relation to the lesion is of utmost importance, in 
      order to avoid reocclusions. The Strecker stents were lege artis placed in both 
      time groups, and the increased occurrence of reocclusions, especially in the 
      femoropopliteal region, was mainly due to the fact that only one stent length was 
      available. Restenoses in the second group are, thus, considerably lower between 6 
      and 12 months, as the use of an adequate stent length was possible by then. The 
      medical supplementary treatment of lege artis placed stents in the iliac arteries 
      has no additional influence on the patency rate, while the medication with 
      anticoagulants seems to have a rather positive effect on the patency rate in the 
      femoro-popliteal region. The results, which have been obtained up to now, show 
      that definite improvements are to be achieved by the use of stents, provided that 
      their indication is being handled with utmost care.
FAU - Zeitler, E
AU  - Zeitler E
AD  - Radiologische Diagnostik, Klinikum Nuernberg, Germany.
FAU - Beyer-Enke, S
AU  - Beyer-Enke S
FAU - Rompel, O
AU  - Rompel O
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Int Angiol
JT  - International angiology : a journal of the International Union of Angiology
JID - 8402693
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arterial Occlusive Diseases/epidemiology/*therapy
MH  - Aspirin/therapeutic use
MH  - Female
MH  - *Femoral Artery
MH  - Follow-Up Studies
MH  - Heparin/therapeutic use
MH  - Humans
MH  - *Iliac Artery
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/epidemiology/*therapy
MH  - Recurrence
MH  - *Stents
MH  - Vascular Patency/physiology
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
PST - ppublish
SO  - Int Angiol. 1993 Jun;12(2):152-61.

PMID- 2198232
OWN - NLM
STAT- MEDLINE
DCOM- 19900904
LR  - 20181217
IS  - 0174-4879 (Print)
IS  - 0174-4879 (Linking)
VI  - 28
IP  - 6
DP  - 1990 Jun
TI  - Pharmacological interaction between tolbutamide and acetylsalicylic acid: study 
      on insulin secretion in man.
PG  - 229-34
AB  - This study has been planned to investigate some aspects of the interaction 
      between acetylsalicylic acid (ASA) and tolbutamide on insulin secretion. In 
      healthy subjects, oral administration of 3.2 g daily of ASA for 3 days 
      significantly enhanced a) basal insulin levels (p less than 0.01), b) 
      arginine-stimulated insulin secretion (25 g i.v. over 30 min) (p less than 0.01) 
      and c) tolbutamide-stimulated insulin secretion (1 g or 0.25 g i.v. as a bolus) 
      (areas under curves: p less than 0.02). Corresponding decreases in glycemia were 
      observed. Tolbutamide binding to serum proteins was significantly reduced after 
      ASA treatment (p less than 0.02). We conclude that, in case of tolbutamide test, 
      interferences between ASA and tolbutamide on insulin secretion might be 
      dependent, at least in part, on enhancement of free-tolbutamide percentage in 
      plasma and not only on a direct or synergic action of ASA on pancreatic B-cell. 
      Therefore, acute stimulation of insulin secretion by tolbutamide appears not to 
      be completely comparable to other traditional stimuli, when ASA effects are 
      studied.
FAU - Cattaneo, A G
AU  - Cattaneo AG
AD  - Chair of Clinical Medicine, Istituto Scientifico S. Raffaele, Milano, Italy.
FAU - Caviezel, F
AU  - Caviezel F
FAU - Pozza, G
AU  - Pozza G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Int J Clin Pharmacol Ther Toxicol
JT  - International journal of clinical pharmacology, therapy, and toxicology
JID - 8003415
RN  - 0 (Insulin)
RN  - 982XCM1FOI (Tolbutamide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Insulin/*metabolism
MH  - Insulin Secretion
MH  - Male
MH  - Tolbutamide/blood/*pharmacology
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther Toxicol. 1990 Jun;28(6):229-34.

PMID- 6419621
OWN - NLM
STAT- MEDLINE
DCOM- 19840214
LR  - 20181217
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 245
IP  - 6
DP  - 1983 Dec
TI  - A role for endogenous prostaglandin E in biphasic pattern of insulin release in 
      humans.
PG  - E591-7
AB  - These studies were undertaken to evaluate in humans the possible physiological 
      role of prostaglandins of the E series (PGE) in modulating insulin release and to 
      assess whether endogenous PGE synthesis may account for the biphasic pattern of 
      insulin secretion. We used a square-wave glucose stimulation previously 
      determined to give maximal biphasic insulin release. Infusion of lysine 
      acetylsalicylate to block the synthesis of endogenous PGE increased by twofold 
      total insulin response to glucose and also converted insulin release to a 
      multiphasic pattern. The infusion of exogenous PGE1 (0.2 microgram X kg-1 X 
      min-1) or PGE2 (10 micrograms/min) in addition to lysine acetylsalicylate 
      restored the typical biphasic pattern of insulin release and also decreased total 
      insulin release to values similar to those of control studies. Infusion of either 
      PGE1 or PGE2 in the absence of lysine acetylsalicylate reset insulin secretion to 
      a lower level without altering the kinetics of release. On the basis of these 
      results, it is hypothesized that endogenous PGE released in response to glucose 
      stimulation exert an inhibiting effect on insulin release that becomes biphasic 
      in appearance.
FAU - Giugliano, D
AU  - Giugliano D
FAU - Di Pinto, P
AU  - Di Pinto P
FAU - Torella, R
AU  - Torella R
FAU - Frascolla, N
AU  - Frascolla N
FAU - Saccomanno, F
AU  - Saccomanno F
FAU - Passariello, N
AU  - Passariello N
FAU - D'Onofrio, F
AU  - D'Onofrio F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Analgesics)
RN  - 0 (Insulin)
RN  - 0 (Prostaglandins E)
RN  - IY9XDZ35W2 (Glucose)
RN  - K3Z4F929H6 (Lysine)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Analgesics
MH  - Aspirin/analogs & derivatives
MH  - Dinoprostone
MH  - Glucose
MH  - Humans
MH  - Insulin/*metabolism
MH  - Insulin Secretion
MH  - Kinetics
MH  - Lysine/analogs & derivatives
MH  - *Prostaglandins E
EDAT- 1983/12/01 00:00
MHDA- 1983/12/01 00:01
CRDT- 1983/12/01 00:00
PHST- 1983/12/01 00:00 [pubmed]
PHST- 1983/12/01 00:01 [medline]
PHST- 1983/12/01 00:00 [entrez]
AID - 10.1152/ajpendo.1983.245.6.E591 [doi]
PST - ppublish
SO  - Am J Physiol. 1983 Dec;245(6):E591-7. doi: 10.1152/ajpendo.1983.245.6.E591.

PMID- 7889238
OWN - NLM
STAT- MEDLINE
DCOM- 19950420
LR  - 20131121
IS  - 1059-2725 (Print)
IS  - 1059-2725 (Linking)
VI  - Doc No 174
DP  - 1995 Mar 14
TI  - Efficacy and safety of different aspirin dosages on vascular diseases in 
      high-risk patients. A metaregression analysis.
PG  - [6442 words; 55 paragraphs]
AB  - PURPOSE: To compare the efficacy and safety of different aspirin dosages in 
      trials with patients at increased risk of vascular disease. DATA SOURCES: 
      Pertinent studies were selected using MEDLINE (1966 through 1992), weekly reviews 
      of Current Contents (1970 through 1992), and references from review articles and 
      editorials. STUDY SELECTION: Thirty-six randomized control trials of aspirin 
      compared with another dosage of aspirin or with placebo. METHODS: The 
      Mantel-Haenszel method of pooling odds ratios and metaregression involving log 
      odds ratio (and the risk difference) on aspirin dosage, adjusting for the control 
      rate and the mean length of follow up of the studies. RESULTS: For all patients 
      and for subgroups of patients with previous vascular conditions, there was no 
      relationship between dose and vascular events. For all patients, a dose-response 
      relation was not found with gastrointestinal hemorrhages and hemorrhagic stroke, 
      but was found with gastrointestinal symptoms and withdrawals from side effects. 
      For every 25 mg/day increase in aspirin dosage, the odds ratio of 
      gastrointestinal symptoms and withdrawals increased, respectively, by 0.87% (99% 
      Cl, 0.18 to 1.57%) and 0.94% (99% Cl, 0.06 to 1.82%). The corresponding absolute 
      risk increases were 0.58 and 0.78 per 1,000 patients. CONCLUSIONS: Direct and 
      indirect comparisons of high-risk patients suggest no statistical differences in 
      efficacy, gastrointestinal bleeds, and hemorrhagic strokes across aspirin 
      dosages. These comparisons, however, suggest decreased risk of gastrointestinal 
      symptoms and of withdrawals with lower doses of aspirin. More direct comparison 
      studies are warranted that should contrast the benefits and risks to determine 
      the net benefit.
FAU - Cappelleri, J C
AU  - Cappelleri JC
AD  - New England Medical Center, Division of Clinical Care Research, Boston, MA 02111, 
      USA.
FAU - Lau, J
AU  - Lau J
FAU - Kupelnick, B
AU  - Kupelnick B
FAU - Chalmers, T C
AU  - Chalmers TC
LA  - eng
GR  - HS-07782/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Online J Curr Clin Trials
JT  - The Online journal of current clinical trials
JID - 9300367A
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cerebral Hemorrhage/chemically induced
MH  - Cerebrovascular Disorders/mortality/prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Least-Squares Analysis
MH  - Myocardial Infarction/mortality/*prevention & control
MH  - Odds Ratio
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Vascular Diseases/mortality/*prevention & control
EDAT- 1995/03/14 00:00
MHDA- 1995/03/14 00:01
CRDT- 1995/03/14 00:00
PHST- 1995/03/14 00:00 [pubmed]
PHST- 1995/03/14 00:01 [medline]
PHST- 1995/03/14 00:00 [entrez]
PST - ppublish
SO  - Online J Curr Clin Trials. 1995 Mar 14;Doc No 174:[6442 words; 55 paragraphs].

PMID- 7967338
OWN - NLM
STAT- MEDLINE
DCOM- 19941201
LR  - 20170310
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 33
IP  - 5
DP  - 1993
TI  - [Ticlopidine and aspirin in the treatment of unstable angina: comparative 
      evaluation of their effect of anti-aggregation and platelet membranes].
PG  - 9-12
AB  - The study was undertaken to examine changes in ADP-induced aggregation of 
      platelets, blood-circulating platelet aggregates, platelet phospholipids and 
      cholesterol in patients with unstable angina depending on the therapy with 
      disaggregatory agents. The patients from Group 1 (n = 23) received ticlopidine, 
      500 mg/day, in addition to antianginal therapy and heparin; those from Group 2 (n 
      = 21) had aspirin, 320 mg/day, those from Group 3 (n = 36) took no disaggregahts. 
      Ticlopidine was found to produce more marked effects on ADT-induced plasma 
      platelet aggregation, in vivo reversible platelet aggregation, and reduced 
      platelet levels of free cholesterol, as compared to aspirin.
FAU - Shalaev, S V
AU  - Shalaev SV
FAU - Mezhetskaia, I A
AU  - Mezhetskaia IA
LA  - rus
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Tiklopidin i aspirin pri nestabilńoĭ stenokardii: sravnenie dezagregiruiushchikh 
      svoĭstv i vozdeĭstviia na membrany trombotsitov.
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Phospholipids)
RN  - 0 (Platelet Membrane Glycoproteins)
RN  - 9005-49-6 (Heparin)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angina, Unstable/blood/*drug therapy
MH  - Anti-Arrhythmia Agents/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cholesterol/blood
MH  - Heparin/pharmacology/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phospholipids/blood
MH  - Platelet Aggregation/drug effects
MH  - Platelet Membrane Glycoproteins/drug effects
MH  - Retrospective Studies
MH  - Ticlopidine/pharmacology/*therapeutic use
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 1993;33(5):9-12.

PMID- 15229389
OWN - NLM
STAT- MEDLINE
DCOM- 20041203
LR  - 20181130
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 18
IP  - 3
DP  - 2004 May
TI  - Comparison of cilostazol and ticlopidine for one-month effectiveness and safety 
      after elective coronary stenting.
PG  - 211-7
AB  - PURPOSE: To compare the oral antiplatelets, phosphodiesterase III inhibitor 
      cilostazol and the thienopyridine ticlopidine, for one-month effectiveness and 
      safety as an adjunctive therapy after coronary stenting. METHODS: Published 
      studies retrieved through Medline and other databases from 1966-2002. 
      Meta-analyses evaluated effectiveness and adverse side effects for one-month 
      administrations of aspirin plus cilostazol or aspirin plus ticlopidine therapy 
      after coronary stenting. Major adverse cardiac events (MACE), stent-associated 
      thrombosis or adverse side effects after coronary stenting were compared between 
      the two study arms and expressed with the odds ratios (OR) specific for the 
      individual studies and meta-analytic summary for OR. RESULTS: Five clinical 
      studies met the inclusion criteria, and 4 of these studies underwent 
      meta-analysis. With regard to the comparison of the OR summary for MACE and 
      stent-associated thrombosis for the clinical outcome, there were no statistical 
      significant differences between aspirin plus cilostazol and aspirin plus 
      ticlopidine. While, the incidence of adverse side effects tended to be lower, 
      they were not statistically significant in patients with aspirin plus cilostazol. 
      CONCLUSIONS: Our meta-analysis results indicated that there were no differences 
      between cilostazol (plus aspirin) and ticlopidine (plus aspirin) with regard to 
      effectiveness and safety for a one-month period when used as an adjunctive 
      therapy after coronary stenting.
FAU - Hashiguchi, Masayuki
AU  - Hashiguchi M
AD  - Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical 
      University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan. 
      hashiguchim@pharm.kitasato-u.ac.jp
FAU - Ohno, Keiko
AU  - Ohno K
FAU - Nakazawa, Rieko
AU  - Nakazawa R
FAU - Kishino, Satoshi
AU  - Kishino S
FAU - Mochizuki, Mayumi
AU  - Mochizuki M
FAU - Shiga, Tsuyoshi
AU  - Shiga T
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Randomized Controlled Trial
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Tetrazoles)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - Cilostazol
MH  - Coronary Restenosis/complications
MH  - Coronary Stenosis/diagnosis/therapy
MH  - Coronary Vessels/surgery
MH  - Data Collection/methods
MH  - Data Interpretation, Statistical
MH  - Death
MH  - Documentation/classification/standards
MH  - *Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Elective Surgical Procedures/adverse effects/*methods
MH  - Evaluation Studies as Topic
MH  - Humans
MH  - Japan
MH  - Medical Records/classification/standards
MH  - Myocardial Infarction/complications
MH  - Odds Ratio
MH  - Stents/adverse effects/statistics & numerical data
MH  - Tetrazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Ticlopidine/administration & dosage/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2004/07/02 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/07/02 05:00
PHST- 2004/07/02 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/07/02 05:00 [entrez]
AID - 5273646 [pii]
AID - 10.1023/B:CARD.0000033642.49162.04 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2004 May;18(3):211-7. doi: 
      10.1023/B:CARD.0000033642.49162.04.

PMID- 10736910
OWN - NLM
STAT- MEDLINE
DCOM- 20000420
LR  - 20181113
IS  - 0960-1643 (Print)
IS  - 0960-1643 (Linking)
VI  - 49
IP  - 441
DP  - 1999 Apr
TI  - Women with angina pectoris receive less antiplatelet treatment than men.
PG  - 299-300
AB  - In a study investigating the prevalence of underprescription of platelet therapy 
      for women with angina pectoris, the complete medication histories of patients 
      were examined and indicators of possible comorbidity and comedication were 
      recorded. A higher percentage of women than men were not treated with any form of 
      antithrombotic treatment (37% versus 18%), suggesting a serious, and possibly 
      hazardous, undertreatment with acetylsalicylic acid (ASA) in women compared with 
      men.
FAU - Bouvy, M L
AU  - Bouvy ML
AD  - Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, The 
      Netherlands.
FAU - Heerdink, E R
AU  - Heerdink ER
FAU - Klungel, O H
AU  - Klungel OH
FAU - de Boer, A
AU  - de Boer A
FAU - Stuurman-Bieze, A G
AU  - Stuurman-Bieze AG
FAU - Leufkens, H G
AU  - Leufkens HG
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of 
      General Practitioners
JID - 9005323
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/diagnosis/*drug therapy
MH  - Aspirin/*therapeutic use
MH  - Family Practice
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/prevention & control
MH  - Netherlands
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Sex Factors
PMC - PMC1313398
EDAT- 2000/03/29 09:00
MHDA- 2000/04/25 09:00
CRDT- 2000/03/29 09:00
PHST- 2000/03/29 09:00 [pubmed]
PHST- 2000/04/25 09:00 [medline]
PHST- 2000/03/29 09:00 [entrez]
PST - ppublish
SO  - Br J Gen Pract. 1999 Apr;49(441):299-300.

PMID- 28779028
OWN - NLM
STAT- MEDLINE
DCOM- 20170912
LR  - 20220317
IS  - 1470-8736 (Electronic)
IS  - 0143-5221 (Linking)
VI  - 131
IP  - 18
DP  - 2017 Sep 15
TI  - Aspirin-triggered resolvin D1 reduces pneumococcal lung infection and 
      inflammation in a viral and bacterial coinfection pneumonia model.
PG  - 2347-2362
LID - 10.1042/CS20171006 [doi]
AB  - Formyl peptide receptor 2/lipoxin A(4) (LXA(4)) receptor (Fpr2/ALX) co-ordinates 
      the transition from inflammation to resolution during acute infection by binding 
      to distinct ligands including serum amyloid A (SAA) and Resolvin D1 (RvD1). Here, 
      we evaluated the proresolving actions of aspirin-triggered RvD1 (AT-RvD1) in an 
      acute coinfection pneumonia model. Coinfection with Streptococcus pneumoniae and 
      influenza A virus (IAV) markedly increased pneumococcal lung load and 
      neutrophilic inflammation during the resolution phase. Fpr2/ALX transcript levels 
      were increased in the lungs of coinfected mice, and immunohistochemistry 
      identified prominent Fpr2/ALX immunoreactivity in bronchial epithelial cells and 
      macrophages. Levels of circulating and lung SAA were also highly increased in 
      coinfected mice. Therapeutic treatment with exogenous AT-RvD1 during the acute 
      phase of infection (day 4-6 post-pneumococcal inoculation) significantly reduced 
      the pneumococcal load. AT-RvD1 also significantly reduced neutrophil elastase 
      (NE) activity and restored total antimicrobial activity in bronchoalveolar lavage 
      (BAL) fluid (BALF) of coinfected mice. Pneumonia severity, as measured by 
      quantitating parenchymal inflammation or alveolitis was significantly reduced 
      with AT-RvD1 treatment, which also reduced the number of infiltrating lung 
      neutrophils and monocytes/macrophages as assessed by flow cytometry. The 
      reduction in distal lung inflammation in AT-RvD1-treated mice was not associated 
      with a significant reduction in inflammatory and chemokine mediators. In summary, 
      we demonstrate that in the coinfection setting, SAA levels were persistently 
      increased and exogenous AT-RvD1 facilitated more rapid clearance of pneumococci 
      in the lungs, while concurrently reducing the severity of pneumonia by limiting 
      excessive leukocyte chemotaxis from the infected bronchioles to distal areas of 
      the lungs.
CI  - © 2017 The Author(s).
FAU - Wang, Hao
AU  - Wang H
AD  - Chronic Infectious and Inflammatory Disease Programme, School of Health and 
      Biomedical Sciences, RMIT University, Bundoora, Australia.
FAU - Anthony, Desiree
AU  - Anthony D
AD  - Chronic Infectious and Inflammatory Disease Programme, School of Health and 
      Biomedical Sciences, RMIT University, Bundoora, Australia.
FAU - Yatmaz, Selcuk
AU  - Yatmaz S
AD  - Chronic Infectious and Inflammatory Disease Programme, School of Health and 
      Biomedical Sciences, RMIT University, Bundoora, Australia.
FAU - Wijburg, Odilia
AU  - Wijburg O
AD  - Department of Microbiology and Immunology, The Peter Doherty Institute for 
      Infection and Immunity, The University of Melbourne, Melbourne, Australia.
FAU - Satzke, Catherine
AU  - Satzke C
AD  - Department of Microbiology and Immunology, The Peter Doherty Institute for 
      Infection and Immunity, The University of Melbourne, Melbourne, Australia.
AD  - Department of Paediatrics, Royal Children's Hospital, Parkville, Victoria, 
      Australia.
FAU - Levy, Bruce
AU  - Levy B
AD  - Department of Medicine, Pulmonary and Critical Care Medicine, Brigham and Women's 
      Hospital and Harvard Medical School, Boston, MA, U.S.A.
FAU - Vlahos, Ross
AU  - Vlahos R
AD  - Chronic Infectious and Inflammatory Disease Programme, School of Health and 
      Biomedical Sciences, RMIT University, Bundoora, Australia.
FAU - Bozinovski, Steven
AU  - Bozinovski S
AD  - Chronic Infectious and Inflammatory Disease Programme, School of Health and 
      Biomedical Sciences, RMIT University, Bundoora, Australia 
      steven.bozinovski@rmit.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20170824
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 0 (Fpr1 protein, mouse)
RN  - 0 (Receptors, Formyl Peptide)
RN  - 0 (formyl peptide receptor 2, mouse)
RN  - 0 (resolvin D1)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Bacterial Load/drug effects
MH  - Coinfection/*drug therapy
MH  - Disease Models, Animal
MH  - Docosahexaenoic Acids/metabolism/*physiology
MH  - Flow Cytometry
MH  - Influenza A virus
MH  - Lung/microbiology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Orthomyxoviridae Infections/*complications/drug therapy
MH  - Pneumonia, Pneumococcal/*complications/drug therapy
MH  - Receptors, Formyl Peptide/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Streptococcus pneumoniae
MH  - Transcriptome
OTO - NOTNLM
OT  - Serum amyloid A
OT  - co-infection
OT  - formyl peptide receptor-2
OT  - pneumonia
OT  - resolvin D1
EDAT- 2017/08/06 06:00
MHDA- 2017/09/13 06:00
CRDT- 2017/08/06 06:00
PHST- 2017/04/28 00:00 [received]
PHST- 2017/07/27 00:00 [revised]
PHST- 2017/08/03 00:00 [accepted]
PHST- 2017/08/06 06:00 [pubmed]
PHST- 2017/09/13 06:00 [medline]
PHST- 2017/08/06 06:00 [entrez]
AID - CS20171006 [pii]
AID - 10.1042/CS20171006 [doi]
PST - epublish
SO  - Clin Sci (Lond). 2017 Aug 24;131(18):2347-2362. doi: 10.1042/CS20171006. Print 
      2017 Sep 15.

PMID- 15365735
OWN - NLM
STAT- MEDLINE
DCOM- 20041210
LR  - 20191210
IS  - 0300-5860 (Print)
IS  - 0300-5860 (Linking)
VI  - 93
IP  - 9
DP  - 2004 Sep
TI  - [Urgent or emergent coronary revascularization using bilateral internal thoracic 
      artery after previous clopidogrel antiplatelet therapy].
PG  - 679-85
AB  - BACKGROUND: Application of clopidogrel before diagnostic or therapeutical 
      percutaneous coronary interventions has become standard for stent-thrombosis 
      prevention. The irreversible platelet inhibition causes increasing bleeding 
      complications if urgent coronary artery bypass grafting becomes necessary. This 
      study evaluates the effect on bleeding complications of clopidogrel in urgent 
      CABG using bilateral internal thoracic artery (ITA) and saphenous veins in all 
      patients. METHODS: We retrospectively analyzed 166 patients (operated between 
      1/00-12/02) with urgent or emergency CABG, using both ITAs and compared 83 
      patients with previous (within 5 days) clopidogrel and aspirin application to 83 
      patients without clopidogrel. We evaluated chest tube output, reexploration rate 
      and necessity of blood products, ventilation time and ICU stay. RESULTS: Both 
      groups were comparable with age, gender, number of performed anastomoses (mean 4/ 
      patient). Chest tube output (24 h) was higher in the clopidogrel group (935 +/- 
      599 ml vs 754 +/- 335 ml (p = 0.018)), as well as reexploration rate with 7.2% (6 
      of 83) vs 0% (0 of 83) (p < 0.001). Number of blood products in the clopidogrel 
      group for red cells was 2.41 +/- 1.88 U vs 1.84 +/- 1.47 U p = 0.03, for 
      plateletes 0.43 +/- 0.88 U vs 0.024 +/- 0.22 p = 0.0001, for fresh frozen plasma 
      0.41 +/- 1.14 U vs 0.096 +/- 0.59 U p = 0.029. Mechanical ventilation time was 
      11.35 +/- 8.77 h vs 10.57 +/- 9.12 h p = 0.51, ICU stay 32.1 +/- 21.8 h vs. 29.8 
      +/- 21.1 h (p = 0.48). CONCLUSIONS: Previous application of clopidogrel in 
      combination with aspirin before urgent CABG induces increased chest tube output, 
      reexploration rate and necessity of blood products, especially of plateletes. 
      Nevertheless, routine use of both ITAs in patients after clopidogrel exposure can 
      be performed with acceptable bleeding complications.
FAU - Schmidtler, F
AU  - Schmidtler F
AD  - Krankenhaus München-Bogenhausen, Abteilung für Kardiovaskularchirurgie, 
      Englschalkingerstr. 77, 81925 München, Germany.
FAU - Gansera, B
AU  - Gansera B
FAU - Spiliopoulos, K
AU  - Spiliopoulos K
FAU - Angelis, I
AU  - Angelis I
FAU - Neumaier-Prauser, P
AU  - Neumaier-Prauser P
FAU - Kemkes, B M
AU  - Kemkes BM
LA  - ger
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
TT  - Dringliche oder notfallmässige Koronarrevaskularisation unter Verwendung beider 
      Arteria Thoracica interna nach vorheriger Thrombozytenaggregationshemmung mit 
      Clopidogrel.
PL  - Germany
TA  - Z Kardiol
JT  - Zeitschrift fur Kardiologie
JID - 0360430
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blood Transfusion
MH  - Clopidogrel
MH  - *Coronary Artery Bypass/methods
MH  - Data Interpretation, Statistical
MH  - Emergencies
MH  - Female
MH  - Humans
MH  - Intensive Care Units
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Preoperative Care
MH  - Respiration, Artificial
MH  - Retrospective Studies
MH  - Thoracic Arteries/surgery
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/*therapeutic use
EDAT- 2004/09/15 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/09/15 05:00
PHST- 2004/01/22 00:00 [received]
PHST- 2004/03/31 00:00 [accepted]
PHST- 2004/09/15 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/09/15 05:00 [entrez]
AID - 10.1007/s00392-004-0115-z [doi]
PST - ppublish
SO  - Z Kardiol. 2004 Sep;93(9):679-85. doi: 10.1007/s00392-004-0115-z.

PMID- 3922613
OWN - NLM
STAT- MEDLINE
DCOM- 19850712
LR  - 20190619
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 55
IP  - 12
DP  - 1985 Jun 15
TI  - Normalization of monocyte candidacidal deficiency by cyclooxygenase inhibitors in 
      Hodgkin's disease.
PG  - 2774-8
AB  - In a previous work, the authors found that the peripheral blood monocytes from 
      patients with Hodgkin's disease (HD) had depressed lytic capability to kill 
      Candida pseudotropicalis and depressed phagocytic function. The aim of this study 
      was to evaluate if cyclooxygenase inhibitors could correct the defective 
      macrophage functions. Fifteen untreated patients with HD and 10 normal subjects 
      were studied. The incubation of the cells from the patients with HD with 
      indomethacin (IM) at 1, 3, and 10 micrograms/ml and with acetylsalicylic acid 
      (ASA) at 20 micrograms/ml increased their previously deficient ability to kill C. 
      pseudotropicalis, reaching values close to those of normal subjects. The oral 
      administration of ASA during 1 week also corrected the monocyte lytic deficiency 
      in the patients' group. Neither the in vitro nor the in vivo treatment with these 
      cyclooxygenase inhibitors had any significant effect on normal subjects' 
      monocytes' lytic function. The drugs did not improve the impaired phagocytic 
      function in patients with HD. These results indicate that the failure of the 
      lytic activity of the monocytes in HD could be associated to an excessive 
      production of PGE2, and the oral administration of inhibitors of the 
      cyclooxygenase activity can correct such abnormality whereas the phagocytic 
      dysfunction is not reverted by them.
FAU - Estevez, M E
AU  - Estevez ME
FAU - Ballart, I J
AU  - Ballart IJ
FAU - Diez, R A
AU  - Diez RA
FAU - Sen, L
AU  - Sen L
FAU - Nicastro, M A
AU  - Nicastro MA
FAU - Wechsler, A
AU  - Wechsler A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Prostaglandins E)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/pharmacology/therapeutic use
MH  - Candida/*immunology
MH  - Cells, Cultured
MH  - Child
MH  - Child, Preschool
MH  - *Cyclooxygenase Inhibitors
MH  - Dinoprostone
MH  - Female
MH  - Hodgkin Disease/*immunology
MH  - Humans
MH  - Indomethacin/pharmacology/therapeutic use
MH  - Macrophage Activation/drug effects
MH  - Male
MH  - Middle Aged
MH  - Monocytes/*drug effects/immunology
MH  - Phagocytosis/drug effects
MH  - Prostaglandins E/biosynthesis
EDAT- 1985/06/15 00:00
MHDA- 1985/06/15 00:01
CRDT- 1985/06/15 00:00
PHST- 1985/06/15 00:00 [pubmed]
PHST- 1985/06/15 00:01 [medline]
PHST- 1985/06/15 00:00 [entrez]
AID - 10.1002/1097-0142(19850615)55:12<2774::aid-cncr2820551209>3.0.co;2-6 [doi]
PST - ppublish
SO  - Cancer. 1985 Jun 15;55(12):2774-8. doi: 
      10.1002/1097-0142(19850615)55:12<2774::aid-cncr2820551209>3.0.co;2-6.

PMID- 12031827
OWN - NLM
STAT- MEDLINE
DCOM- 20021204
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 105
IP  - 4
DP  - 2002 Feb 15
TI  - Shear stress-induced aggregation of oxidized platelets.
PG  - 325-9
AB  - Although shear stress-induced platelet aggregation (SIPA) has been noted, the 
      shear stress-induced aggregation of oxidized platelets (SIOPA) has not been 
      investigated. To investigate SIOPA, small quantity of hemoglobin (Hb) solution 
      was first added to plasma to induce oxidation stress of platelets and then the 
      plasma was sheared by a cone/plate viscometer at shear stress of 66 dyn/cm2. In 
      addition, to investigate the change in expression of the membrane receptors of 
      glycoprotein Ib (GpIb) for oxidized platelets, mean fluorescence intensity (MFI) 
      for those platelets was detected by flow cytometric technique. The results showed 
      that the level of the oxidation stress of platelets, as presented in 
      malondialdehyde (MDA) values, was well correlated with the quantities of added 
      Hb. Moreover, the aggregation of SIOPA corresponded with the levels of oxidation 
      stress of platelets. Platelets pretreated with aspirin could only partially 
      reduce the aggregation of SIOPA. Similarly, aspirin pretreatment could partially 
      reduce the lowering of MFI value that indicated downexpression of GpIb receptors. 
      Furthermore, the aggregations of SIOPA corresponded with the lowered percentage 
      of those MFI values for studied cases. We thereby suggested that the aggregation 
      of SIOPA is related to both the level of oxidation stress and the downexpression 
      of GpIb receptors for oxidized platelets.
FAU - Chung, Tze-Wen
AU  - Chung TW
AD  - Department of Biomedical Engineering, Chung-Yuan Christian University, Chung-Li, 
      Taiwan, ROC. twchung@mail.be.cycu.edu.tw
FAU - Tyan, Yu-Chang
AU  - Tyan YC
FAU - Hsieh, Jui-Hsiang
AU  - Hsieh JH
FAU - Wang, Shoei-Shen
AU  - Wang SS
FAU - Chu, Shu-Hsun
AU  - Chu SH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Hemoglobins)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Blood Platelets/drug effects/metabolism
MH  - Hemoglobins/metabolism/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Malondialdehyde/blood
MH  - Oxidative Stress
MH  - Platelet Aggregation/drug effects/*physiology
MH  - Stress, Mechanical
EDAT- 2002/05/29 10:00
MHDA- 2002/12/05 04:00
CRDT- 2002/05/29 10:00
PHST- 2002/05/29 10:00 [pubmed]
PHST- 2002/12/05 04:00 [medline]
PHST- 2002/05/29 10:00 [entrez]
AID - S0049384802000257 [pii]
AID - 10.1016/s0049-3848(02)00025-7 [doi]
PST - ppublish
SO  - Thromb Res. 2002 Feb 15;105(4):325-9. doi: 10.1016/s0049-3848(02)00025-7.

PMID- 11211445
OWN - NLM
STAT- MEDLINE
DCOM- 20010301
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 93
IP  - 12
DP  - 2000 Dec
TI  - [Efficacy of colchicine in recurrent acute idiopathic pericarditis].
PG  - 1511-4
AB  - Acute idiopathic pericarditis is complicated by recurrence in 15 to 30% of cases. 
      The preventive treatment of recurrences is not well codified. Aspirin, 
      non-steroidal anti-inflammatory drugs and corticoids are the commonest prescribed 
      treatments. The objective of this study was to assess the value of colchicine in 
      the prevention of recurrences of acute idiopathic pericarditis. Twenty-eight 
      cases of recurrent acute pericarditis (2 episodes, 1 month between each episode) 
      admitted to a department of internal medicine between 1989 and 1999 were 
      reviewed. Analysis was concentrated on the 13 idiopathic forms. The subjects were 
      7 women and 6 men with an average age of 41 years (10-62) at the time of the 
      first episode of acute pericarditis. These 13 patients were treated with 
      colchicine (1 to 2 mg/day) after failure of conventional treatment (aspirin 
      13/13, NSAID 13/13, steroids 9/13 and pericardiocentesis 3/13). Ten patients were 
      followed up regularly (6 months after starting colchicine) and were improved with 
      respect to number, duration and intensity of their recurrences. The average 
      duration of colchicine therapy was 17 +/- 14 months (6-48). Progressive 
      withdrawal of NSAID and steroids was obtained in 8/10 cases. The authors conclude 
      that colchicine is useful in the prevention of recurrence of acute pericarditis. 
      It may be proposed as treatment of choice, especially in the idiopathic forms.
FAU - Cacoub, P
AU  - Cacoub P
AD  - Service de médecine interne, CHU Pitié-Salpêtrière, 47-83, boulevard de 
      l'Hôpital, 75651 Paris.
FAU - Sbaï, A
AU  - Sbaï A
FAU - Wechsler, B
AU  - Wechsler B
FAU - Amoura, Z
AU  - Amoura Z
FAU - Godeau, P
AU  - Godeau P
FAU - Piette, J C
AU  - Piette JC
LA  - fre
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Efficacité de la colchicine dans les péricardites aiguës récidivantes 
      idiopathiques.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Gout Suppressants)
RN  - R16CO5Y76E (Aspirin)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Aspirin/pharmacology
MH  - Child
MH  - Colchicine/*therapeutic use
MH  - Drug Resistance
MH  - Female
MH  - Gout Suppressants/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pericarditis/*drug therapy/pathology
MH  - Recurrence
MH  - Treatment Outcome
EDAT- 2001/02/24 12:00
MHDA- 2001/03/07 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/03/07 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 2000 Dec;93(12):1511-4.

PMID- 33451310
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20210426
IS  - 1472-6831 (Electronic)
IS  - 1472-6831 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jan 15
TI  - Analysing the effectiveness of topical bleeding care following tooth extraction 
      in patients receiving dual antiplatelet therapy-retrospective observational 
      study.
PG  - 31
LID - 10.1186/s12903-021-01391-9 [doi]
LID - 31
AB  - BACKGROUND: Patients using antiplatelet drugs following infarctions, acute 
      coronary syndrome or stroke pose a significant clinical problem if it is 
      necessary to perform surgery, including dental surgery, since they are at risk of 
      prolonged or secondary post-extraction bleeding. Discontinuation of this therapy 
      is associated with a high risk of serious thromboembolic complications. The 
      purpose of this study was to assess the effectiveness of TachoSil fibrin-collagen 
      patches in stopping and preventing of secondary post-extraction bleeding in 
      patients undergoing chronic antiplatelet therapy. METHODS: The study was 
      conducted through retrospective examination of the medical records of 153 
      patients using chronic antiplatelet therapy and those qualified for tooth 
      extraction. The largest group comprised 74 patients using aspirin and clopidogrel 
      as dual platelet antiaggregation therapy; in this group 75 tooth extractions were 
      carried out. In all of the patients TachoSil fibrin-collagen patches and stiches 
      were applied to the wounds resulting from tooth removal. RESULTS: Following tooth 
      extraction, primary bleeding was stopped in all the patients and their wounds 
      closed via coagulation within 20-30 min. In eight cases, accounting for 4.9% of 
      the patients, secondary bleeding occurred and was successfully stopped only by 
      applying a pressure dressing soaked in tranexamic acid. Secondary bleeding 
      occurred in three patients on the second day and in five patients on the third 
      day following tooth removal. CONCLUSION: Topical application of TachoSil patches 
      following tooth removal in patients using single or dual antiplatelet therapy 
      effectively stopped bleeding and prevented secondary bleeding after tooth 
      extraction.
FAU - Lewandowski, Bogumił
AU  - Lewandowski B
AUID- ORCID: 0000-0002-8045-5093
AD  - Medical College, University of Rzeszow, Rzeszow, Poland. boglewandowski@wp.pl.
AD  - Departament of Maxillofacial Surgery, Fryderyk Chopin Clinical State Hospital, 
      Rzeszow, Poland. boglewandowski@wp.pl.
FAU - Myszka, Aleksander
AU  - Myszka A
AD  - Medical College, University of Rzeszow, Rzeszow, Poland.
FAU - Migut, Małgorzata
AU  - Migut M
AD  - Medical College, University of Rzeszow, Rzeszow, Poland.
AD  - Departament of Maxillofacial Surgery, Fryderyk Chopin Clinical State Hospital, 
      Rzeszow, Poland.
FAU - Czenczek-Lewandowska, Ewelina
AU  - Czenczek-Lewandowska E
AD  - Medical College, University of Rzeszow, Rzeszow, Poland.
FAU - Brodowski, Robert
AU  - Brodowski R
AD  - Departament of Maxillofacial Surgery, Fryderyk Chopin Clinical State Hospital, 
      Rzeszow, Poland.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20210115
PL  - England
TA  - BMC Oral Health
JT  - BMC oral health
JID - 101088684
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin/adverse effects
MH  - Clopidogrel/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - Tooth Extraction/adverse effects
PMC - PMC7809775
OTO - NOTNLM
OT  - Antiplatelet drugs
OT  - Antiplatelet therapy
OT  - Dual antiplatelet therapy (DAPT)
OT  - Single antiplatelet therapy (SAPT)
OT  - TachoSil
OT  - Tooth extraction
OT  - Topical haemostatic agents
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/01/17 06:00
MHDA- 2021/04/27 06:00
CRDT- 2021/01/16 05:24
PHST- 2020/08/13 00:00 [received]
PHST- 2021/01/06 00:00 [accepted]
PHST- 2021/01/16 05:24 [entrez]
PHST- 2021/01/17 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
AID - 10.1186/s12903-021-01391-9 [pii]
AID - 1391 [pii]
AID - 10.1186/s12903-021-01391-9 [doi]
PST - epublish
SO  - BMC Oral Health. 2021 Jan 15;21(1):31. doi: 10.1186/s12903-021-01391-9.

PMID- 15345468
OWN - NLM
STAT- MEDLINE
DCOM- 20050308
LR  - 20181201
IS  - 0193-1857 (Print)
IS  - 0193-1857 (Linking)
VI  - 288
IP  - 1
DP  - 2005 Jan
TI  - Inhibition of ACh-stimulated exocytosis by NSAIDs in guinea pig antral mucous 
      cells: autocrine regulation of mucin secretion by PGE2.
PG  - G39-47
AB  - The effects of indomethacin (IDM) and aspirin (ASA) on ACh (10 microM) 
      -stimulated exocytotic events were studied in guinea pig antral mucous cells by 
      using video optical microscopy. IDM or ASA, which inhibits cyclooxygenase (COX), 
      decreased the frequency of ACh-stimulated exocytotic events by 30% or 60%, 
      respectively. The extent of inhibition induced by ASA (60%) decreased by 30% when 
      IDM or arachidonic acid (AA, the substrate of COX) was added. IDM, unlike ASA, 
      appears to induce the accumulation of AA, which enhances the frequency of 
      ACh-stimulated exocytotic events in ASA-treated cells. ONO-8713 (100 microM; an 
      inhibitor of the EP1-EP4 prostaglandin receptors) and 
      N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide, HCl (H-89, 20 
      microM; an inhibitor of PKA) also decreased the frequency of ACh-stimulated 
      exocytotic events by 60%. However, the supplementation of PGE(2) (1 microM) 
      prevented the IDM-induced decrease in the frequency of ACh-stimulated exocytotic 
      events. SC-560 (an inhibitor of COX-1) decreased the frequency of ACh-stimulated 
      exocytotic events by 30%, but NS-398 (an inhibitor of COX-2) did not. Moreover, 
      IDM decreased the frequency of exocytotic events stimulated by ionomycin, 
      suggesting that COX-1 activity is stimulated by an increase in intracellular 
      Ca(2+) concentration ([Ca(2+)](i)). ACh and ionomycin increased PGE(2) release in 
      antral mucosal cells. In conclusion, in ACh-stimulated antral mucous cells, an 
      increase in [Ca(2+)](i) activates Ca(2+)-regulated exocytotic events and PGE(2) 
      release mediated by COX-1. The released PGE(2) induces the accumulation of cAMP, 
      which enhances the Ca(2+)-regulated exocytosis. The autocrine mechanism mediated 
      by PGE(2) maintains the high-level mucin release from antral mucous cells during 
      ACh stimulation.
FAU - Shimamoto, Chikao
AU  - Shimamoto C
AD  - Dept. of Internal Medicine, Osaka Medical College, 2-7 Daigaku-cho, Takatsuki 
      569-8686, Japan.
FAU - Fujiwara, Shoko
AU  - Fujiwara S
FAU - Kato, Masumi
AU  - Kato M
FAU - Ito, Shigenori
AU  - Ito S
FAU - Katsu, Ken-ichi
AU  - Katsu K
FAU - Mori, Hiroshi
AU  - Mori H
FAU - Nakahari, Takashi
AU  - Nakahari T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20040902
PL  - United States
TA  - Am J Physiol Gastrointest Liver Physiol
JT  - American journal of physiology. Gastrointestinal and liver physiology
JID - 100901227
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Mucins)
RN  - 0 (Vasodilator Agents)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - N9YNS0M02X (Acetylcholine)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Acetylcholine/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Dinoprostone/*pharmacology
MH  - Exocytosis
MH  - Guinea Pigs
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Mucins/*metabolism
MH  - Vasodilator Agents/*pharmacology
EDAT- 2004/09/04 05:00
MHDA- 2005/03/09 09:00
CRDT- 2004/09/04 05:00
PHST- 2004/09/04 05:00 [pubmed]
PHST- 2005/03/09 09:00 [medline]
PHST- 2004/09/04 05:00 [entrez]
AID - 00060.2004 [pii]
AID - 10.1152/ajpgi.00060.2004 [doi]
PST - ppublish
SO  - Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G39-47. doi: 
      10.1152/ajpgi.00060.2004. Epub 2004 Sep 2.

PMID- 11575289
OWN - NLM
STAT- MEDLINE
DCOM- 20011004
LR  - 20220330
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 345
IP  - 13
DP  - 2001 Sep 27
TI  - A computerized reminder system to increase the use of preventive care for 
      hospitalized patients.
PG  - 965-70
AB  - BACKGROUND: Although they are effective in outpatient settings, computerized 
      reminders have not been proved to increase preventive care in inpatient settings. 
      METHODS: We conducted a randomized, controlled trial to determine the effects of 
      computerized reminders on the rates at which four preventive therapies were 
      ordered for inpatients. During an 18-month study period, a computerized system 
      processed on-line information for all 6371 patients admitted to a 
      general-medicine service (for a total of 10,065 hospitalizations), generating 
      preventive care reminders as appropriate. Physicians who were in the intervention 
      group viewed these reminders when they were using a computerized order-entry 
      system for inpatients. RESULTS: The reminder system identified 3416 patients 
      (53.6 percent) as eligible for preventive measures that had not been ordered by 
      the admitting physician. For patients with at least one indication, computerized 
      reminders resulted in higher adjusted ordering rates for pneumococcal vaccination 
      (35.8 percent of the patients in the intervention group vs. 0.8 percent of those 
      in the control group, P<0.001), influenza vaccination (51.4 percent vs. 1.0 
      percent, P< 0.001), prophylactic heparin (32.2 percent vs. 18.9 percent, 
      P<0.001), and prophylactic aspirin at discharge (36.4 percent vs. 27.6 percent, 
      P<0.001). CONCLUSIONS: A majority of hospitalized patients in this study were 
      eligible for preventive measures, and computerized reminders significantly 
      increased the rate of delivery of such therapies.
FAU - Dexter, P R
AU  - Dexter PR
AD  - Department of Medicine, Indiana University School of Medicine, Regenstrief 
      Institute for Health Care, Richard L. Roudebush Veterans Affairs Medical Center, 
      Indianapolis 46202, USA.
FAU - Perkins, S
AU  - Perkins S
FAU - Overhage, J M
AU  - Overhage JM
FAU - Maharry, K
AU  - Maharry K
FAU - Kohler, R B
AU  - Kohler RB
FAU - McDonald, C J
AU  - McDonald CJ
LA  - eng
GR  - HS07719/HS/AHRQ HHS/United States
GR  - N01-LM-6-3546/LM/NLM NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Influenza Vaccines)
RN  - 0 (Pneumococcal Vaccines)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2001 Sep 27;345(13):991-3. PMID: 11575294
CIN - ACP J Club. 2002 Mar-Apr;136(2):74. PMID: 11874299
MH  - Aspirin/therapeutic use
MH  - Chemoprevention/statistics & numerical data
MH  - *Decision Support Systems, Clinical
MH  - Female
MH  - Heparin/therapeutic use
MH  - Hospitalization
MH  - Humans
MH  - Influenza Vaccines
MH  - Male
MH  - Medical Records Systems, Computerized
MH  - Middle Aged
MH  - Pneumococcal Vaccines
MH  - *Preventive Medicine
MH  - Primary Prevention/statistics & numerical data
MH  - *Reminder Systems
EDAT- 2001/09/29 10:00
MHDA- 2001/10/05 10:01
CRDT- 2001/09/29 10:00
PHST- 2001/09/29 10:00 [pubmed]
PHST- 2001/10/05 10:01 [medline]
PHST- 2001/09/29 10:00 [entrez]
AID - 10.1056/NEJMsa010181 [doi]
PST - ppublish
SO  - N Engl J Med. 2001 Sep 27;345(13):965-70. doi: 10.1056/NEJMsa010181.

PMID- 32034802
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1651-2227 (Electronic)
IS  - 0803-5253 (Print)
IS  - 0803-5253 (Linking)
VI  - 109
IP  - 11
DP  - 2020 Nov
TI  - Adjusting the dose in paediatric care by dispersing fragments of four different 
      aspirin tablets.
PG  - 2394-2401
LID - 10.1111/apa.15216 [doi]
AB  - AIM: Tablets can be manipulated in several ways to obtain a fraction as the 
      dose-a practice frequently seen in paediatric care due to lack of suitable 
      formulations. Splitting tablets prior to fragment dispersion in a small volume of 
      liquid is one such method. The objective of this study was to investigate the 
      accuracy and precision of this method. METHODS: Four different types of aspirin 
      tablets (two dispersible, one conventional and one chewing) were split with a 
      tablet splitter into half and quarter fragments. The fragments were dispersed in 
      a medicine measure or an oral syringe. The amount recovered was determined by 
      UHPLC analysis. RESULTS: The largest quarter fragments ranged from 26.7% to 31.5% 
      of the full tablet weight. Dispersing the fragment in an oral syringe, the amount 
      recovered was greater than 90.8% of the fragment manipulated for all four tablet 
      types, when rinsing was performed. Dispersing the fragment in a medicine measure, 
      the amounts recovered spanned from 32.9% for the conventional tablets to 98.7% 
      for one of the dispersible tablets. CONCLUSION: Dispersion of half or quarter 
      tablets directly in an oral syringe, but not a medicine measure, could give 
      satisfactory recovery from fragments of all the investigated aspirin tablets.
CI  - © 2020 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf 
      of Foundation Acta Paediatrica.
FAU - Brustugun, Jørgen
AU  - Brustugun J
AUID- ORCID: 0000-0002-7629-5349
AD  - Hospital Pharmacy Enterprises, South Eastern Norway, Oslo, Norway.
FAU - Notaker, Nikolai
AU  - Notaker N
AD  - Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University 
      of Oslo, Oslo, Norway.
FAU - Paetz, Lasse Holtan
AU  - Paetz LH
AD  - Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University 
      of Oslo, Oslo, Norway.
FAU - Tho, Ingunn
AU  - Tho I
AD  - Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University 
      of Oslo, Oslo, Norway.
FAU - Bjerknes, Kathrin
AU  - Bjerknes K
AD  - Hospital Pharmacy Enterprises, South Eastern Norway, Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200222
PL  - Norway
TA  - Acta Paediatr
JT  - Acta paediatrica (Oslo, Norway : 1992)
JID - 9205968
RN  - 0 (Tablets)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Aspirin
MH  - Body Weight
MH  - Child
MH  - Drug Compounding
MH  - Humans
MH  - Tablets
PMC - PMC7687227
OTO - NOTNLM
OT  - aspirin
OT  - dose accuracy
OT  - drug manipulation
OT  - paediatric care
OT  - tablets
COIS- The authors declare that they have no conflicts of interest to disclose.
EDAT- 2020/02/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/02/09 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/02/04 00:00 [revised]
PHST- 2020/02/06 00:00 [accepted]
PHST- 2020/02/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/02/09 06:00 [entrez]
AID - APA15216 [pii]
AID - 10.1111/apa.15216 [doi]
PST - ppublish
SO  - Acta Paediatr. 2020 Nov;109(11):2394-2401. doi: 10.1111/apa.15216. Epub 2020 Feb 
      22.

PMID- 34802426
OWN - NLM
STAT- MEDLINE
DCOM- 20211129
LR  - 20211129
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Nov 22
TI  - Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin 
      pregnancies: an observational cohort study based on propensity score matching.
PG  - 786
LID - 10.1186/s12884-021-04217-2 [doi]
LID - 786
AB  - BACKGROUND: Since the effectiveness of low-dose aspirin (LDA) in twin pregnancies 
      is uncertain, we aimed to preliminarily assess whether LDA is beneficial in 
      preventing preeclampsia in twin pregnancies. METHODS: This study is an 
      observational study in two hospitals in China. Among 932 women, 277 in the First 
      Affiliated Hospital of Chongqing Medical University were routinely treated with 
      aspirin (100 mg daily) from 12 to 16 weeks to 35 weeks of gestational age, while 
      655 in Chongqing Health Center for Women and Children were not taking aspirin 
      during pregnancy. We followed each subject and the individual details were 
      recorded. RESULTS: LDA significantly reduced the risk of preeclampsia (RR 0.48; 
      95% CI 0.24-0.95) and preterm birth 34 weeks (RR 0.50; 95% CI 0.29-0.86) and 
      showed possible benefits to lower the rate of SGA babies (RR 0.74; 95% CI 
      0.55-1.00). Moreover, the risk of postpartum hemorrhage was not increased by LDA 
      (RR 0.89; 95% CI 0.35-2.26). CONCLUSIONS: Treatment with low-dose aspirin in twin 
      pregnancies could offer some protection against adverse pregnancy outcomes in the 
      absence of significantly increased risk of postpartum hemorrhage. TRIAL 
      REGISTRATION: Chinese Clinical Trial Registry (ChiCTR); ChiCTR-OOC-16008203 , 
      Retrospectively registered date: April 1st, 2016.
CI  - © 2021. The Author(s).
FAU - Ye, Ying
AU  - Ye Y
AD  - Department of Obstetrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, 400016, China.
AD  - State Key Laboratory of Maternal and Fetal Medicine of Chongqing Municipality, 
      The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, 
      China.
FAU - Wen, Li
AU  - Wen L
AD  - Department of Obstetrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, 400016, China.
AD  - State Key Laboratory of Maternal and Fetal Medicine of Chongqing Municipality, 
      The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, 
      China.
FAU - Liu, Xiyao
AU  - Liu X
AD  - Department of Obstetrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, 400016, China.
AD  - State Key Laboratory of Maternal and Fetal Medicine of Chongqing Municipality, 
      The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, 
      China.
FAU - Wang, Lan
AU  - Wang L
AD  - Department of Obstetrics, Chongqing Women and Children's Health Center, 
      Chongqing, 401147, China.
FAU - Liu, Yamin
AU  - Liu Y
AD  - Department of Obstetrics, Chongqing Women and Children's Health Center, 
      Chongqing, 401147, China.
FAU - Saffery, Richard
AU  - Saffery R
AD  - Cancer, Disease and Developmental Epigenetics, Murdoch Children's Research 
      Institute, Parkville, Victoria, 3052, Australia.
AD  - Department of Paediatrics, University of Melbourne, Parkville, Victoria, 3052, 
      Australia.
FAU - Kilby, Mark D
AU  - Kilby MD
AD  - Institute of Metabolism and System Research, University of Birmingham, Edgbaston, 
      UK.
AD  - Fetal Medicine Centre, Birmingham Women's & Children's Foundation Trust, 
      Birmingham, B15 2TG, UK.
FAU - Tong, Chao
AU  - Tong C
AD  - Department of Obstetrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, 400016, China. chaotongcqmu@163.com.
AD  - State Key Laboratory of Maternal and Fetal Medicine of Chongqing Municipality, 
      The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, 
      China. chaotongcqmu@163.com.
FAU - Qi, Hongbo
AU  - Qi H
AUID- ORCID: 0000-0003-3776-0487
AD  - Department of Obstetrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, 400016, China. qihongbocy@gmail.com.
AD  - State Key Laboratory of Maternal and Fetal Medicine of Chongqing Municipality, 
      The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, 
      China. qihongbocy@gmail.com.
FAU - Baker, Philip
AU  - Baker P
AD  - College of Medicine, Biological Sciences and Psychology, University of Leicester, 
      Leicester, LE1 7RH, UK.
LA  - eng
GR  - 2018YFC1002900/National Key Research and Development Program of China/
GR  - 81520108013, 81771613, 81671488, 81871189 and 82071675/National Natural Science 
      Foundation of China/
PT  - Journal Article
PT  - Observational Study
DEP - 20211122
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage
MH  - China/epidemiology
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Infant, Small for Gestational Age
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy, Twin/*drug effects
MH  - Premature Birth/*prevention & control
MH  - Propensity Score
PMC - PMC8607699
OTO - NOTNLM
OT  - Fetal growth restriction
OT  - Low-dose aspirin
OT  - Postpartum hemorrhage
OT  - Preeclampsia
OT  - Preterm birth
OT  - Twin pregnancy
COIS- None declared.
EDAT- 2021/11/23 06:00
MHDA- 2021/11/30 06:00
CRDT- 2021/11/22 05:39
PHST- 2020/12/14 00:00 [received]
PHST- 2021/10/12 00:00 [accepted]
PHST- 2021/11/22 05:39 [entrez]
PHST- 2021/11/23 06:00 [pubmed]
PHST- 2021/11/30 06:00 [medline]
AID - 10.1186/s12884-021-04217-2 [pii]
AID - 4217 [pii]
AID - 10.1186/s12884-021-04217-2 [doi]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2021 Nov 22;21(1):786. doi: 10.1186/s12884-021-04217-2.

PMID- 22151399
OWN - NLM
STAT- MEDLINE
DCOM- 20121029
LR  - 20131121
IS  - 1533-2500 (Electronic)
IS  - 1530-7085 (Linking)
VI  - 12
IP  - 6
DP  - 2012 Jul
TI  - Gastrointestinal effects of the addition of ascorbic acid to aspirin.
PG  - 476-84
LID - 10.1111/j.1533-2500.2011.00517.x [doi]
AB  - Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, have been 
      associated with the damage to the gastrointestinal tract. One proposed mechanism 
      of injury to the gastrointestinal mucosa by NSAIDs is oxygen radical-dependent 
      microvascular injury. There is reasonable evidence to support the benefit of the 
      addition of ascorbic acid, an ingredient with antioxidant properties, to moderate 
      the adverse gastrointestinal (GI) effects of aspirin. Pharmacokinetic data have 
      demonstrated that aspirin and ascorbic acid combination therapy can assist in 
      mitigating the decrease in levels of ascorbic acid secondary to aspirin 
      monotherapy. Endoscopic evaluation has demonstrated that the addition of ascorbic 
      acid to aspirin significantly improves Lanza scores and rates of blood loss when 
      compared to aspirin administration alone. When taken with ascorbic acid, the 
      patient-reported tolerability of aspirin has been shown to be comparable to 
      paracetamol and placebo. The existing body of evidence is relevant to short-term 
      therapy with analgesic aspirin doses, and extrapolation to long-term therapy with 
      low-dose aspirin is not appropriate. The purported benefit of an aspirin and 
      ascorbic acid combination is a local observance and is not suspected to influence 
      the adverse GI effects experienced as a result of systemic prostaglandin 
      inhibition. Nevertheless, ascorbic acid may be a viable addition to the 
      strategies employed to improve the gastrointestinal tolerability of aspirin.
CI  - © 2011 The Authors. Pain Practice © 2011 World Institute of Pain.
FAU - Patel, Vrunda
AU  - Patel V
AD  - Bayer HealthCare, Morristown, New Jersey 07962-1910, USA. vrunda.patel@bayer.com
FAU - Fisher, Matt
AU  - Fisher M
FAU - Voelker, Michael
AU  - Voelker M
FAU - Gessner, Uwe
AU  - Gessner U
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20111207
PL  - United States
TA  - Pain Pract
JT  - Pain practice : the official journal of World Institute of Pain
JID - 101130835
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Antioxidants/*pharmacology
MH  - Ascorbic Acid/*pharmacology
MH  - Aspirin/*adverse effects
MH  - Drug-Related Side Effects and Adverse Reactions/prevention & control
MH  - Gastrointestinal Diseases/chemically induced/prevention & control
MH  - Gastrointestinal Tract/drug effects
MH  - Humans
EDAT- 2011/12/14 06:00
MHDA- 2012/10/30 06:00
CRDT- 2011/12/14 06:00
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/10/30 06:00 [medline]
AID - 10.1111/j.1533-2500.2011.00517.x [doi]
PST - ppublish
SO  - Pain Pract. 2012 Jul;12(6):476-84. doi: 10.1111/j.1533-2500.2011.00517.x. Epub 
      2011 Dec 7.

PMID- 29990410
OWN - NLM
STAT- MEDLINE
DCOM- 20190426
LR  - 20190426
IS  - 0038-3317 (Print)
IS  - 0038-3317 (Linking)
VI  - 71
IP  - 2
DP  - 2018 Feb
TI  - A Masquerader of Disease: An Incomplete Presentation of Kawasaki Disease.
PG  - 54-57
AB  - Kawasaki disease (KD) is a systemic pediatric vasculitis that most commonly 
      affects children between the ages of 6 months and 4 years. The diagnosis of KD 
      requires a high degree of clinical suspicion. In younger patients (less than 6 
      months) the diagnosis is exceedingly difficult as these patients typically do not 
      meet the criteria to diagnosis KD clinically. Oftentimes, these younger patients 
      do not meet enough of the criteria to warrant ordering an echocardiogram. We 
      report a case of a 6-month-old Caucasian female who presented with high fevers 
      originally thought to be due to a urinary tract infection. The patient required 
      multiple echocardiograms in order to be diagnosed with incomplete KD. The patient 
      was treated with IVIG and aspirin per standard of care, and experienced 
      resolution of fevers and illness.
CI  - Copyright© South Dakota State Medical Association.
FAU - Rezkalla, Josh
AU  - Rezkalla J
AD  - University of South Dakota Sanford School of Medicine, Sioux Falls South Dakota.
FAU - Chang, Peter
AU  - Chang P
AD  - University of South Dakota Sanford School of Medicine, Sioux Falls South Dakota.
FAU - Peck, Elizabeth
AU  - Peck E
AD  - Department of Pediatrics, University of South Dakota Sanford School of Medicine, 
      Sioux Falls South Dakota.
FAU - Schimelpfenig, Michelle
AU  - Schimelpfenig M
AD  - Department of Pediatrics, University of South Dakota Sanford School of Medicine, 
      Sioux Falls South Dakota.
LA  - eng
PT  - Case Reports
PL  - United States
TA  - S D Med
JT  - South Dakota medicine : the journal of the South Dakota State Medical Association
JID - 101265265
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Echocardiography
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Infant
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/therapy
EDAT- 2018/07/11 06:00
MHDA- 2019/04/27 06:00
CRDT- 2018/07/11 06:00
PHST- 2018/07/11 06:00 [entrez]
PHST- 2018/07/11 06:00 [pubmed]
PHST- 2019/04/27 06:00 [medline]
PST - ppublish
SO  - S D Med. 2018 Feb;71(2):54-57.

PMID- 24915961
OWN - NLM
STAT- MEDLINE
DCOM- 20150219
LR  - 20220318
IS  - 1534-3111 (Electronic)
IS  - 1522-6417 (Linking)
VI  - 16
IP  - 8
DP  - 2014 Aug
TI  - Pre-eclampsia: an update.
PG  - 454
LID - 10.1007/s11906-014-0454-8 [doi]
AB  - Pre-eclampsia remains the second leading direct cause of maternal death, >99 % of 
      which occurs in less developed countries. Over 90 percent of the observed 
      reduction in pre-eclampsia-related maternal deaths in the UK (1952-2008) occurred 
      with antenatal surveillance and timed delivery. In this review, we discuss the 
      pathogenesis, diagnostic criteria, disease prediction models, prevention and 
      management of pre-eclampsia. The Pre-eclampsia Integrated Estimate of RiSk 
      (PIERS) models and markers of angiogenic imbalance identify women at incremental 
      risk for severe pre-eclampsia complications. For women at high risk of developing 
      pre-eclampsia, low doses of aspirin (especially if started <17 weeks) and calcium 
      are evidence-based preventative strategies; heparin is less so. Severe 
      hypertension must be treated and the Control of Hypertension In Pregnancy (CHIPS) 
      Trial (reporting: 2014) will guide non-severe hypertension management. Magnesium 
      sulfate prevents and treats eclampsia; there is insufficient evidence to support 
      alternative regimens. Pre-eclampsia predicts later cardiovascular disease; 
      however, at this time we do not know what to do about it.
FAU - von Dadelszen, Peter
AU  - von Dadelszen P
AD  - Department of Obstetrics and Gynaecology, University of British Columbia, Rm 
      V3-339, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada, pvd@cw.bc.ca.
FAU - Magee, Laura A
AU  - Magee LA
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Hypertens Rep
JT  - Current hypertension reports
JID - 100888982
RN  - I38ZP9992A (Magnesium)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Female
MH  - Humans
MH  - Magnesium/*therapeutic use
MH  - Pre-Eclampsia/*drug therapy/physiopathology/*prevention & control
MH  - Pregnancy
MH  - Risk
EDAT- 2014/06/12 06:00
MHDA- 2015/02/20 06:00
CRDT- 2014/06/12 06:00
PHST- 2014/06/12 06:00 [entrez]
PHST- 2014/06/12 06:00 [pubmed]
PHST- 2015/02/20 06:00 [medline]
AID - 10.1007/s11906-014-0454-8 [doi]
PST - ppublish
SO  - Curr Hypertens Rep. 2014 Aug;16(8):454. doi: 10.1007/s11906-014-0454-8.

PMID- 21102333
OWN - NLM
STAT- MEDLINE
DCOM- 20110414
LR  - 20131121
IS  - 1473-6551 (Electronic)
IS  - 1350-7540 (Linking)
VI  - 24
IP  - 1
DP  - 2011 Feb
TI  - Vascular disorders in neuro-ophthalmology.
PG  - 6-11
LID - 10.1097/WCO.0b013e328341a5d8 [doi]
AB  - PURPOSE OF REVIEW: The aim is to briefly discuss the currently controversial 
      management of nonarteritic anterior ischemic optic neuropathy (NA-AION) and 
      central retinal artery occlusion (CRAO). RECENT FINDINGS: The role of systemic 
      corticosteroid therapy and aspirin in NA-AION and of thrombolysis in CRAO is 
      discussed. SUMMARY: NA-AION is a major cause of seriously impaired vision. A 
      recent large prospective study has shown that systemic corticosteroid resulted in 
      a significantly higher probability of improvement in visual acuity (P = 0.001) 
      and visual fields (P = 0.005), compared to an untreated group. In CRAO, the 
      latest prospective study has shown that thrombolytic therapy not only has no 
      beneficial effect but also is harmful.
FAU - Hayreh, Sohan Singh
AU  - Hayreh SS
AD  - Department of Ophthalmology and Visual Sciences, College of Medicine, University 
      of Iowa, Iowa City, Iowa, USA. sohan-hayreh@uiowa.edu
LA  - eng
GR  - EY-1151/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - England
TA  - Curr Opin Neurol
JT  - Current opinion in neurology
JID - 9319162
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - *Ophthalmology
MH  - Optic Neuropathy, Ischemic/drug therapy/*therapy
MH  - Retinal Artery Occlusion/complications/therapy
MH  - Visual Fields
EDAT- 2010/11/26 06:00
MHDA- 2011/04/16 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2011/04/16 06:00 [medline]
AID - 10.1097/WCO.0b013e328341a5d8 [doi]
PST - ppublish
SO  - Curr Opin Neurol. 2011 Feb;24(1):6-11. doi: 10.1097/WCO.0b013e328341a5d8.

PMID- 1974618
OWN - NLM
STAT- MEDLINE
DCOM- 19900918
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 42
IP  - 3
DP  - 1990 Mar
TI  - Glycyrrhetinic acid derivatives: anti-nociceptive activity of deoxoglycyrrhetol 
      dihemiphthalate and the related compounds.
PG  - 199-200
AB  - The possible inhibitory effect of deoxoglycyrrhetol dihemiphthalate (I) and the 
      related compounds (18 beta-olean-9(11),12-diene-3 beta,30-diol) (II) and 
      (olean-11,13(18)-diene-3 beta, 30-diol) III derived from glycyrrhetinic acid has 
      been examined on acetic acid-induced writhing in mice. The compounds inhibited 
      writhing dose-dependently. Their ED50 values were 14, 31 and 22 mg kg-1 for I, 
      II, and III, respectively. The compounds like aspirin, also significantly 
      suppressed PGE2 production in peritoneal fluid together with the writhing 
      response. The results suggests that the analgesic effect of deoxyglycyrrhetol 
      dihemiphthalate and the related compounds is partially due to inhibition of PGE2 
      production.
FAU - Inoue, H
AU  - Inoue H
AD  - Research Laboratory, Minophagen Pharmaceutical Co., Kanagawa, Japan.
FAU - Kurosu, S
AU  - Kurosu S
FAU - Takeuchi, T
AU  - Takeuchi T
FAU - Mori, T
AU  - Mori T
FAU - Shibata, S
AU  - Shibata S
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Analgesics)
RN  - 102416-27-3 (deoxoglycyrrhetol dihemiphthalate)
RN  - 102416-28-4 (18-olean-9(11),12-diene-3,30-diol dihemiphthalate)
RN  - 102416-29-5 (olean-11,13(18)-diene-3,30-diol dihemiphthalate, disodium salt)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - P540XA09DR (Glycyrrhetinic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesics
MH  - Animals
MH  - Ascitic Fluid/metabolism
MH  - Aspirin/pharmacology
MH  - Dinoprostone/metabolism
MH  - Glycyrrhetinic Acid/*analogs & derivatives/*pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
AID - 10.1111/j.2042-7158.1990.tb05386.x [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 1990 Mar;42(3):199-200. doi: 
      10.1111/j.2042-7158.1990.tb05386.x.

PMID- 16502561
OWN - NLM
STAT- MEDLINE
DCOM- 20060526
LR  - 20181201
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 95
IP  - 2
DP  - 2006 Feb
TI  - Potent low dose platelet inhibitory effects of clopidogrel and aspirin on 
      coronary thrombus formation in an animal model of acute unstable angina.
PG  - 354-61
AB  - Application of clopidogrel before percutaneous coronary intervention in patients 
      with acute coronary syndrome reduces the risk of cardiac events. Clopidogrel 
      administration before surgery increases bleeding complications after CABG. 
      Therefore,the antithrombotic effect of the low-dose combination of clopidogrel 
      and aspirin was investigated in an in vivo pig model of coronary artery thrombus 
      formation with cyclic flow reductions. The platelet inhibitory effect was 
      determined by platelet aggregation and CFR, according to the methodology 
      described by Folts. CFR were initiated by endothelial damage and placement of a 
      constrictor around the LAD. 30 min after CFR were established, clopidogrel (0. I 
      mg/kg or 5 mg/kg), aspirin (I mg/kg or 7 mg/kg) or LDC (0. I mg/kg clopidogrel 
      and I mg/kg aspirin) were administered orally. CFR-frequency was determined for 
      further 240 min.CFR-frequency (CFR/30 min) was significantly reduced at 60 min in 
      response to aspirin (7 mg/kg, -48%, p<0.05), and at 120 min in response to 
      clopidogrel (5 mg/kg,-65%, p<0.05) but not at low doses of either compound. In 
      contrast, LDC of clopidogrel (0. I mg/kg) plus aspirin (I mg/kg) resulted in a 
      complete and rapid abrogation of CFR at 90 min (-70%, p<0.05 y. Furthermore, LDC 
      led to reduction of platelet aggregation when CFR-frequency was already 
      significantly decreased. In contrast, high dose groups presented a significant 
      reduction of platelet aggregation prior to CFR-frequency decrease. Low dose 
      combination of clopidogrel plus aspirin demonstrates a potent over additive 
      anti-thrombotic effect in vivo with a significant reduction in thrombus formation 
      early after drug application. The effect occurs before inhibition of platelet 
      aggregation is detectable.
FAU - Bierbach, Benjamin
AU  - Bierbach B
AD  - Department of Cardiothoracic and Vascular Surgery, Johannes Gutenberg-University 
      Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany. bier.bach@gmx.de
FAU - Horstick, Georg
AU  - Horstick G
FAU - Berg, Oliver
AU  - Berg O
FAU - Heimann, Axel
AU  - Heimann A
FAU - Münzel, Thomas
AU  - Münzel T
FAU - Vahl, Christian-Friedrich
AU  - Vahl CF
FAU - Kempski, Oliver
AU  - Kempski O
FAU - Darius, Harald
AU  - Darius H
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Angina, Unstable/complications/*drug therapy
MH  - Animals
MH  - Aspirin/*administration & dosage/pharmacology
MH  - Clopidogrel
MH  - Coronary Thrombosis/*drug therapy/prevention & control
MH  - Disease Models, Animal
MH  - Drug Therapy, Combination
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/pharmacology
MH  - Swine
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
EDAT- 2006/03/01 09:00
MHDA- 2006/05/27 09:00
CRDT- 2006/03/01 09:00
PHST- 2006/03/01 09:00 [pubmed]
PHST- 2006/05/27 09:00 [medline]
PHST- 2006/03/01 09:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 2006 Feb;95(2):354-61.

PMID- 22019811
OWN - NLM
STAT- MEDLINE
DCOM- 20120325
LR  - 20190819
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 75
IP  - 12
DP  - 2011
TI  - Optimal timing of discontinuation of clopidogrel and risk of blood transfusion 
      after coronary surgery. Propensity score analysis.
PG  - 2805-12
AB  - BACKGROUND: The optimal time delay between last clopidogrel dose and surgery is 
      controversial. The aim of the present study was to analyze the impact of 
      preoperative clopidogrel on the need for blood transfusions with reference to the 
      proper timing of discontinuation. METHODS AND RESULTS: Between January 2005 and 
      December 2010, 1,947 consecutive patients undergoing coronary surgery were 
      enrolled. Of these, 255 patients receiving preoperative clopidogrel were matched 
      to a control group by propensity score analysis. Clopidogrel discontinuation 
      interval before surgery was examined in 1-day increments from 0 to 5 days and >5 
      days. Patients who discontinued clopidogrel within 5 days of surgery accounted 
      for 91% (211/255). Clopidogrel stop within 5 days before surgery was 
      independently associated with transfusion requirement (P=0.001). Preoperative 
      clopidogrel was not associated with an increased risk of hemorrhagic 
      complications (P=0.696). No differences were observed between patients taking 
      clopidogrel and those not taking clopidogrel with regard to hospital resource 
      utilization and mortality. Patients receiving clopidogrel in association with 
      aspirin did not have an additive risk for transfusion or hemorrhagic 
      complications compared with those on clopidogrel alone (odds ratio [OR], 1.25; 
      95% confidence interval [CI]: 0.77-2.03; OR, 1.02; 95%CI: 0.38-2.79, 
      respectively). CONCLUSIONS: Clopidogrel administration in the 5 days preceding 
      coronary surgery was an independent predictor for increased transfusion 
      requirements, supporting the discontinuation of clopidogrel >5 days before 
      surgery.
FAU - Mariscalco, Giovanni
AU  - Mariscalco G
AD  - Department of Surgical Sciences, Varese University Hospital, University of 
      Insubria, Varese, Italy. giovannimariscalco@yahoo.it
FAU - Bruno, Vito Domenico
AU  - Bruno VD
FAU - Cottini, Marzia
AU  - Cottini M
FAU - Borsani, Paolo
AU  - Borsani P
FAU - Banach, Maciej
AU  - Banach M
FAU - Piffaretti, Gabriele
AU  - Piffaretti G
FAU - Dominici, Carmelo
AU  - Dominici C
FAU - Beghi, Cesare
AU  - Beghi C
FAU - Sala, Andrea
AU  - Sala A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
DEP - 20111022
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Circ J. 2011;75(12):2751-2. PMID: 22082816
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects
MH  - Blood Loss, Surgical
MH  - *Blood Transfusion
MH  - *Cardiac Surgical Procedures
MH  - Clopidogrel
MH  - Female
MH  - Hemorrhage/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - *Preoperative Care
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
EDAT- 2011/10/25 06:00
MHDA- 2012/03/27 06:00
CRDT- 2011/10/25 06:00
PHST- 2011/10/25 06:00 [entrez]
PHST- 2011/10/25 06:00 [pubmed]
PHST- 2012/03/27 06:00 [medline]
AID - JST.JSTAGE/circj/CJ-11-0620 [pii]
AID - 10.1253/circj.cj-11-0620 [doi]
PST - ppublish
SO  - Circ J. 2011;75(12):2805-12. doi: 10.1253/circj.cj-11-0620. Epub 2011 Oct 22.

PMID- 328034
OWN - NLM
STAT- MEDLINE
DCOM- 19770922
LR  - 20190509
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 4 Suppl 1
IP  - Suppl 1
DP  - 1977 Feb
TI  - Diflunisal: six-month experience in osteoarthritis.
PG  - 45S-52S
AB  - 1 The analgesic efficacy and tolerance of diflunisal in patients with 
      osteoarthritis has been compared with ibuprofen and acetylsalicylic acid (ASA) in 
      two clinical studies carried out double-blind for 12 weeks and then continued 
      single-blind for a further 12 weeks. The studies involved 115 patients and 695 
      patients, respectively. 2 Diflunisal was superior to ibuprofen in overall 
      response, as assessed by both patients and investigators (P < 0.01), improvement 
      in disease activity and by improvement in internal rotation of the hip (P < 
      0.05). 3 Diflunisal was superior to ASA in overall response, as assessed by both 
      patients and investigators, therapeutic index (P < 0.01), reduction in morning 
      stiffness, and by improvement in performance of daily activities (P < 0.05). 4 In 
      the first study, the mean daily dose of diflunisal during the double-blind period 
      was 702 mg and of ibuprofen 1 161 mg. In the second study, the mean daily dose of 
      diflunisal was 612 mg and of ASA 2 461 mg. 5 Diflunisal produced fewer 
      gastrointestinal side-effects after 24 weeks of therapy than did ibuprofen (P < 
      0.01). 6 Diflunisal produced fewer general side-effects and fewer 
      gastrointestinal side-effects during the double-blind and the single-blind phases 
      of the study (P < 0.01). Fewer patients discontinued therapy because of 
      side-effects in the diflunisal group than in the ASA group (P < 0.05). 7 Both ASA 
      and diflunisal decreased serum uric acid, with diflunisal being more uricosuric 
      than aspirin (P < 0.01).
FAU - Andrew, A
AU  - Andrew A
FAU - Rodda, B
AU  - Rodda B
FAU - Verhaest, L
AU  - Verhaest L
FAU - Van Winzum, C
AU  - Van Winzum C
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Fluorobenzenes)
RN  - 0 (Salicylates)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Evaluation
MH  - Fluorobenzenes/adverse effects/therapeutic use
MH  - Humans
MH  - Ibuprofen/adverse effects/therapeutic use
MH  - Osteoarthritis/*drug therapy
MH  - Patient Dropouts
MH  - Salicylates/adverse effects/*therapeutic use
MH  - Time Factors
PMC - PMC1428844
EDAT- 1977/02/01 00:00
MHDA- 1977/02/01 00:01
CRDT- 1977/02/01 00:00
PHST- 1977/02/01 00:00 [pubmed]
PHST- 1977/02/01 00:01 [medline]
PHST- 1977/02/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1977.tb04514.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1977 Feb;4 Suppl 1(Suppl 1):45S-52S. doi: 
      10.1111/j.1365-2125.1977.tb04514.x.

PMID- 15330919
OWN - NLM
STAT- MEDLINE
DCOM- 20041007
LR  - 20220309
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 99
IP  - 9
DP  - 2004 Sep
TI  - Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin.
PG  - 1785-9
AB  - INTRODUCTION: Limited data exist on the role of aspirin in increasing the risk of 
      clinically significant postpolypectomy bleeding (PPB), which is defined as lower 
      gastrointestinal (GI) hemorrhage following colonoscopic polyp removal requiring 
      transfusion, hospitalization, endoscopic intervention, angiography, or surgery. 
      OBJECTIVES: To determine if aspirin use prior to colonoscopy increases the risk 
      of clinically significant PPB. METHODS: A case-control study of patients with 
      clinically significant PPB at Mayo Clinic Scottsdale and Rochester was performed. 
      Information collected included age, gender, recent use of aspirin or NSAIDs 
      (within three days of colonoscopy), polyp characteristics, and polypectomy 
      technique. The control group consisted of patients matched for age (+/-3 yr), 
      gender, and cardiovascular morbidity who had undergone polypectomy without any 
      complications. The populations were compared to determine the odds ratio (OR) of 
      PPB with aspirin use. RESULTS: During the study period, 20,636 patients underwent 
      colonoscopy with polypectomy at the two institutions and 101 patients presented 
      with clinically significant PPB. Twenty patients were excluded from analysis 
      because of prior anticoagulant use. The remaining 81 patients were matched to 81 
      patients who had undergone colonoscopy without complications. The two groups were 
      comparable in terms of polyp size (97%< or = 10 mm, bleeding group; 95%< or = 10 
      mm, control group). Aspirin use prior to polypectomy was 40% in the bleeding 
      group and 33% in the control group (OR 1.41; 95% C.I. 0.68 to 3.04). CONCLUSION: 
      Postpolypectomy bleeding is an uncommon but important complication of endoscopic 
      polypectomy. There was no statistically relevant difference in prior aspirin use 
      before polypectomy in the bleeding group and the matched controls.
FAU - Yousfi, Mahmoud
AU  - Yousfi M
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA.
FAU - Gostout, Christopher J
AU  - Gostout CJ
FAU - Baron, Todd H
AU  - Baron TH
FAU - Hernandez, Jose L
AU  - Hernandez JL
FAU - Keate, Ray
AU  - Keate R
FAU - Fleischer, David E
AU  - Fleischer DE
FAU - Sorbi, Darius
AU  - Sorbi D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Distribution
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Blood Transfusion
MH  - Case-Control Studies
MH  - Colonic Polyps/diagnosis/*surgery
MH  - Colonoscopy/*adverse effects/methods
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Hemorrhage/epidemiology/*etiology/*therapy
MH  - Hemostasis, Endoscopic/*methods
MH  - Humans
MH  - Incidence
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Preoperative Care
MH  - Reference Values
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Sex Distribution
MH  - Survival Rate
EDAT- 2004/08/28 05:00
MHDA- 2004/10/08 09:00
CRDT- 2004/08/28 05:00
PHST- 2004/08/28 05:00 [pubmed]
PHST- 2004/10/08 09:00 [medline]
PHST- 2004/08/28 05:00 [entrez]
AID - AJG30368 [pii]
AID - 10.1111/j.1572-0241.2004.30368.x [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2004 Sep;99(9):1785-9. doi: 10.1111/j.1572-0241.2004.30368.x.

PMID- 16493486
OWN - NLM
STAT- MEDLINE
DCOM- 20060526
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 95
IP  - 2
DP  - 2006 Feb
TI  - Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin 
      in coronary artery disease patients.
PG  - 253-9
AB  - The antiplatelet effect of aspirin varies individually. This study evaluated 
      whether the antiplatelet effect of aspirin associates with polymorphisms in the 
      genes coding for cyclo-oxygenase-1 (COX-1) and several platelet glycoprotein (GP) 
      receptors in patients with stable coronary artery disease (CAD). Blood samples 
      were collected from 101 aspirin-treated (mean 100 mg/d) patients. Compliance to 
      treatment was assessed by plasma salicylate measurement. Platelet functions were 
      assessed by two methods: 1) Response to arachidonic acid (AA, 1.5 mmol/L in 
      aggregometry, and 2) PFA-100, evaluating platelet activation under high shear 
      stress in the presence of collagen and epinephrine (CEPI). Aspirin non-response 
      was defined as: 1) slope steeper than 12%/min in AA-aggregations, and 2) by 
      closure time shorter than 170 s in PFA-100. The methods used detected different 
      individuals as being aspirin non-responders. Five and 21 patients, respectively, 
      were non-responders according to AA-induced aggregation and PFA-100. Increased 
      plasma thromboxane B2 levels correlated with poor aspirin-response measured with 
      both AA-induced aggregations and PFA-100 (P = 0.02 and P = 0.003, respectively). 
      Of the non-responders detected by AA, 3 of 5 (60%) carried the rare G allele for 
      the -A842G polymorphism of COX-1 in contrast to 16 of 96 (17%) responders (P = 
      0.016). Diabetes was associated with poor response. Aspirin non-response detected 
      by PFA-100 associated with C13254T polymorphism of GP VI and female gender (P = 
      0.012 and P = 0.019, respectively). Although two patients were possibly 
      non-compliant, this did not effect present conclusions. Evaluation of aspirin 
      efficacy by AA-induced aggregation and PFA-100 detected different individuals, 
      with different genotypic profiles, as being aspirin non-responders.
FAU - Lepäntalo, Aino
AU  - Lepäntalo A
AD  - Department of Internal Medicine, Division of Hematology, Helsinki University 
      Central Hospital, PO Box 340, Fin-00029 HUCH, Helsinki, Finland. 
      aino.lepantalo@uta.fi
FAU - Mikkelsson, Jussi
AU  - Mikkelsson J
FAU - Reséndiz, Julio C
AU  - Reséndiz JC
FAU - Viiri, Leena
AU  - Viiri L
FAU - Backman, Janne T
AU  - Backman JT
FAU - Kankuri, Esko
AU  - Kankuri E
FAU - Karhunen, Pekka J
AU  - Karhunen PJ
FAU - Lassila, Riitta
AU  - Lassila R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Membrane Glycoproteins)
RN  - 0 (platelet membrane glycoprotein VI)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/blood/*pharmacology
MH  - Coronary Artery Disease/*drug therapy/*genetics
MH  - Cyclooxygenase 1/*genetics/physiology
MH  - Diabetes Mellitus/drug therapy
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pharmacogenetics
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Platelet Function Tests
MH  - Platelet Membrane Glycoproteins/*genetics/physiology
MH  - *Polymorphism, Single Nucleotide
MH  - Sex Factors
MH  - Thromboxane B2/pharmacology
EDAT- 2006/02/24 09:00
MHDA- 2006/05/27 09:00
CRDT- 2006/02/24 09:00
PHST- 2006/02/24 09:00 [pubmed]
PHST- 2006/05/27 09:00 [medline]
PHST- 2006/02/24 09:00 [entrez]
AID - 06020253 [pii]
AID - 10.1160/TH05-07-0516 [doi]
PST - ppublish
SO  - Thromb Haemost. 2006 Feb;95(2):253-9. doi: 10.1160/TH05-07-0516.

PMID- 7755070
OWN - NLM
STAT- MEDLINE
DCOM- 19950619
LR  - 20190615
IS  - 0002-9378 (Print)
IS  - 0002-9378 (Linking)
VI  - 172
IP  - 5
DP  - 1995 May
TI  - Low-dose aspirin in nulliparous women: safety of continuous epidural block and 
      correlation between bleeding time and maternal-neonatal bleeding complications. 
      National Institute of Child Health and Human Developmental Maternal-Fetal 
      Medicine Network.
PG  - 1553-7
AB  - OBJECTIVE: Our purpose was to determine the frequency and safety of the use of 
      epidural anesthesia and the correlation between bleeding time and 
      maternal-neonatal bleeding complications in a group of pregnant women who 
      participated in a multicenter trial of low-dose aspirin in pregnancy. STUDY 
      DESIGN: Data regarding type of anesthesia used for labor and delivery were 
      available in 1629 nulliparous women who were randomly assigned at 13 to 27 weeks 
      to receive 60 mg/day aspirin or a placebo. A total of 891 (55%) received epidural 
      anesthesia, and the remaining 738 did not. RESULTS: Among the 891 women known to 
      have received epidural anesthesia, 451 were assigned to low-dose aspirin and 440 
      to placebo. There was no instance of bleeding related to epidural use. In 
      addition, there were no differences in maternal and neonatal complications 
      between those receiving or not receiving epidural anesthesia. Within the group 
      receiving epidural anesthesia there were no differences in bleeding complications 
      between those assigned to aspirin on placebo. One of the five centers also 
      obtained bleeding times in 303 women (149 received aspirin and 154 received 
      placebo). The mean +/- SD bleeding time in women assigned to low-dose aspirin was 
      significantly higher than in women assigned to placebo (6.99 +/- 2.95 minutes vs 
      5.99 +/- 2.43 minutes, p = 0.004). In addition, the frequency of women having a 
      bleeding time > 10 minutes was higher in the aspirin group (14.1% vs 5.2%, p = 
      0.01). Interestingly, women who received an epidural anesthetic had a lower 
      bleeding time than those not receiving an epidural (p = 0.003), irrespective of 
      the treatment used. CONCLUSIONS: In women assigned to low-dose aspirin there were 
      no adverse effects related to epidural anesthesia. In spite of an increased 
      bleeding time in a subset of pregnant women assigned to low-dose aspirin, 
      maternal-neonatal bleeding complications were not increased.
FAU - Sibai, B M
AU  - Sibai BM
AD  - Department of Obstetrics and Gynecology, University of Tennessee, Memphis, USA.
FAU - Caritis, S N
AU  - Caritis SN
FAU - Thom, E
AU  - Thom E
FAU - Shaw, K
AU  - Shaw K
FAU - McNellis, D
AU  - McNellis D
LA  - eng
GR  - HD 21366/HD/NICHD NIH HHS/United States
GR  - HD 21410/HD/NICHD NIH HHS/United States
GR  - HD 21434/HD/NICHD NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Analysis of Variance
MH  - *Anesthesia, Epidural
MH  - *Anesthesia, Obstetrical
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Bleeding Time
MH  - Blood Coagulation/drug effects
MH  - Chi-Square Distribution
MH  - Contraindications
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/*blood
MH  - Humans
MH  - Infant, Newborn
MH  - National Institutes of Health (U.S.)
MH  - Obstetric Labor Complications/*blood
MH  - Parity
MH  - Postpartum Hemorrhage/blood
MH  - Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Risk Factors
MH  - United States
MH  - Uterine Hemorrhage/*blood
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
AID - 0002-9378(95)90495-6 [pii]
AID - 10.1016/0002-9378(95)90495-6 [doi]
PST - ppublish
SO  - Am J Obstet Gynecol. 1995 May;172(5):1553-7. doi: 10.1016/0002-9378(95)90495-6.

PMID- 28700767
OWN - NLM
STAT- MEDLINE
DCOM- 20170815
LR  - 20170815
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 66
IP  - 6 Suppl
DP  - 2017 Jun
TI  - Effect of non-insulin-based glucose-lowering therapies on cardiovascular outcomes 
      in patients with type 2 diabetes.
LID - supp_az_0617 [pii]
AB  - Current guidelines for the treatment of patients with diabetes are focused on 
      improving glycemic control and treating appropriate cardiovascular (CV) risk 
      factors. Basic recommendations include blood pressure management with a goal of 
      <140 mm Hg systolic pressure, statin therapy in all patients ≥40 years of age 
      with diabetes (moderate intensity for all, and high intensity if at high risk of 
      CVD events), and aspirin therapy in all adults at increased CV risk (10-year risk 
      of CVD events >10%). Oral antihyperglycemic medications remain the cornerstone of 
      treatment for optimizing glucose control in patients with diabetes. In this 
      review, we aim to present the basic mechanisms for each class of commonly used 
      non-insulin-based glucose-lowering drugs and to discuss the effect of these 
      medications on CV events.
FAU - Wiernek, Szymon L
AU  - Wiernek SL
AD  - Department of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, NC 
      USA.
FAU - Cavender, Matthew A
AU  - Cavender MA
AD  - Department of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, NC 
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Blood Glucose
MH  - Cardiovascular Diseases/*prevention & control
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Hypolipidemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
EDAT- 2017/07/13 06:00
MHDA- 2017/08/16 06:00
CRDT- 2017/07/13 06:00
PHST- 2017/07/13 06:00 [entrez]
PHST- 2017/07/13 06:00 [pubmed]
PHST- 2017/08/16 06:00 [medline]
AID - jfp_6606j [pii]
PST - ppublish
SO  - J Fam Pract. 2017 Jun;66(6 Suppl):supp_az_0617.

PMID- 17484095
OWN - NLM
STAT- MEDLINE
DCOM- 20070619
LR  - 20191110
IS  - 0003-3928 (Print)
IS  - 0003-3928 (Linking)
VI  - 56
IP  - 2
DP  - 2007 Apr
TI  - [The "tako-tsubo" syndrome: report of two cases].
PG  - 97-103
AB  - The "tako-tsubo" syndrome, initially described by Japanese authors is an apical 
      akinesis of the left ventricule without significant coronary artery disease, with 
      a moderate elevation of troponine I. We report 2 cases of women (with an average 
      age of 68 years). They were refered for suspected acute coronary syndrome 
      including on admission chest pain and ST segment elevation. Cardiac 
      ultrasonography shew an apical akinesis. Coronary angiography didn't show 
      significant coronary lesion. A moderate elevation of troponine was noted but no 
      significant elevation of CPK. The prognosis has been excellent for these 2 
      patients. We observed a ventricular tachycardia due to QT lengthening in 1 case 
      treated anteriorly by Flecaïn which spontaneously resolved. The first month, the 
      electrocardiogram and cardiac ultrasonography anomalies disappeared totally. The 
      treatment is based on beta-blockers, aspirin, statines, ACE. In the two cases, we 
      didn't find arguments for myocarditis, recanalized thrombosis, coronary spasm, 
      pheochromocytomas, but a risk factor is inboth: emotional stress. Maybe the 
      diagnosis could be easier with the submillimeter cardiac computed tomography.
FAU - Ferrier, N
AU  - Ferrier N
AD  - Service de cardiologie, Centre Hospitalier de Vichy, boulevard Deniere, 03209 
      Vichy, France.
FAU - Bitar, G
AU  - Bitar G
FAU - Marcaggi, X
AU  - Marcaggi X
FAU - Amat, G
AU  - Amat G
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Le syndrome de "tako-tsubo": à propos de deux cas.
PL  - France
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Cardiomyopathies/*diagnosis/drug therapy
MH  - Electrocardiography
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Ventricular Dysfunction, Left/*diagnosis/drug therapy
EDAT- 2007/05/08 09:00
MHDA- 2007/06/20 09:00
CRDT- 2007/05/08 09:00
PHST- 2007/05/08 09:00 [pubmed]
PHST- 2007/06/20 09:00 [medline]
PHST- 2007/05/08 09:00 [entrez]
AID - S0003-3928(06)00138-7 [pii]
AID - 10.1016/j.ancard.2006.11.007 [doi]
PST - ppublish
SO  - Ann Cardiol Angeiol (Paris). 2007 Apr;56(2):97-103. doi: 
      10.1016/j.ancard.2006.11.007.

PMID- 19293071
OWN - NLM
STAT- MEDLINE
DCOM- 20090408
LR  - 20190619
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 150
IP  - 6
DP  - 2009 Mar 17
TI  - Aspirin to prevent cardiovascular disease: the association of aspirin dose and 
      clopidogrel with thrombosis and bleeding.
PG  - 379-86
AB  - BACKGROUND: The optimal aspirin dose for the prevention of cardiovascular events 
      remains controversial. OBJECTIVE: To assess the incidence of and risk factors for 
      adverse clinical outcomes by investigator-determined aspirin dose in a primary 
      prevention trial. DESIGN: Post hoc observational analyses of data from a 
      double-blind, placebo-controlled, randomized trial. SETTING: Outpatient. 
      PATIENTS: 15 595 patients with cardiovascular disease or multiple risk factors. 
      INTERVENTION: Clopidogrel, 75 mg/d, or placebo, with aspirin, 75 to 162 mg/d, as 
      selected by the investigators. MEASUREMENTS: Incidence of the composite outcome 
      of myocardial infarction, stroke, or cardiovascular death (efficacy end point), 
      and incidence of severe or life-threatening bleeding (safety end point), at a 
      median of 28 months (interquartile range, 23 to 31 months) of follow-up. RESULTS: 
      Daily aspirin doses were categorized as less than 100 mg (75 or 81 mg) (n = 
      7180), 100 mg (n = 4961), and greater than 100 mg (150 or 162 mg) (n = 3454). The 
      hazard of the primary efficacy end point was the same regardless of dose 
      (adjusted hazard ratio, 0.95 [95% CI, 0.80 to 1.13] for 100 mg vs. less than 100 
      mg, and 1.0 [CI, 0.85 to 1.18] for greater than 100 mg vs. less than 100 mg). The 
      hazard of the primary safety end point also did not depend on dose (adjusted 
      hazard ratio, 0.85 [CI, 0.57 to 1.26] for 100 mg vs. less than 100 mg and 1.05 
      [CI, 0.74 to 1.48] for greater than 100 mg vs. less than 100 mg). In patients 
      also receiving clopidogrel, daily aspirin doses greater than 100 mg seemed to be 
      non-statistically significantly associated with reduced efficacy (adjusted hazard 
      ratio, 1.16 [CI, 0.93 to 1.44]) and increased harm (adjusted hazard ratio, 1.30 
      [CI, 0.83 to 2.04]). LIMITATION: The analysis was post hoc, and aspirin use was 
      not randomized or blinded. CONCLUSION: Daily aspirin doses of 100 mg or greater 
      were associated with no clear benefit in patients taking aspirin only and 
      possibly with harm in patients taking clopidogrel. Daily doses of 75 to 81 mg may 
      optimize efficacy and safety for patients requiring aspirin for long-term 
      prevention, especially for those receiving dual antiplatelet therapy. PRIMARY 
      FUNDING SOURCE: None.
FAU - Steinhubl, Steven R
AU  - Steinhubl SR
AD  - The Medicines Company, Balsberg, 8058 Zurich-Flughafen, Switzerland. 
      steven.steinhubl@themedco.com
FAU - Bhatt, Deepak L
AU  - Bhatt DL
FAU - Brennan, Danielle M
AU  - Brennan DM
FAU - Montalescot, Gilles
AU  - Montalescot G
FAU - Hankey, Graeme J
AU  - Hankey GJ
FAU - Eikelboom, John W
AU  - Eikelboom JW
FAU - Berger, Peter B
AU  - Berger PB
FAU - Topol, Eric J
AU  - Topol EJ
CN  - CHARISMA Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00050817
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
SPIN- Ann Intern Med. 2009 Mar 17;150(6):I-22. PMID: 19293067
CIN - Ann Intern Med. 2009 Mar 17;150(6):414-6. PMID: 19293075
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clopidogrel
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Observation
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Primary Prevention
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Thrombosis/*chemically induced
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
EDAT- 2009/03/19 09:00
MHDA- 2009/04/09 09:00
CRDT- 2009/03/19 09:00
PHST- 2009/03/19 09:00 [entrez]
PHST- 2009/03/19 09:00 [pubmed]
PHST- 2009/04/09 09:00 [medline]
AID - 150/6/379 [pii]
AID - 10.7326/0003-4819-150-6-200903170-00006 [doi]
PST - ppublish
SO  - Ann Intern Med. 2009 Mar 17;150(6):379-86. doi: 
      10.7326/0003-4819-150-6-200903170-00006.

PMID- 12866040
OWN - NLM
STAT- MEDLINE
DCOM- 20030916
LR  - 20160303
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 106
IP  - 5
DP  - 2003 Sep 20
TI  - Association of aspirin and other non-steroidal anti-inflammatory drug use with 
      incidence of non-Hodgkin lymphoma.
PG  - 784-8
AB  - Non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, seem to have 
      chemopreventive properties against several types of cancer, particularly colon 
      cancer. Persons with rheumatoid arthritis, an autoimmune disease for which NSAIDs 
      are used commonly, have been reported to be at lower risk of colon cancer but at 
      elevated risk of non-Hodgkin lymphoma (NHL), raising the possibility that NSAIDs 
      may be a risk factor for NHL. We evaluated the association of use of NSAIDs, 
      arthritis history, and risk of NHL in a prospective cohort of 27,290 
      postmenopausal women from the state of Iowa. The frequency of use of aspirin and 
      of other NSAIDs excluding aspirin (e.g., ibuprofen), as well as a physician 
      diagnosis of rheumatoid arthritis (RA) or osteoarthritis (OA), were self-reported 
      on a questionnaire mailed in 1992. The incidence of NHL was ascertained through 
      annual linkages to the Iowa SEER Cancer Registry. Relative risks (RR) and 95% 
      confidence intervals (CI) were estimated using Cox proportional hazards 
      regression. Through 7 years of follow-up, 131 cases of NHL were identified. 
      Compared to women who did not use either aspirin or other non-aspirin NSAIDs, 
      women using aspirin exclusively (RR = 1.71; 95% CI = 0.94-3.13), non-aspirin 
      NSAIDs exclusively (RR = 2.39; 95% CI = 1.18-4.83), or both types of drugs (RR = 
      1.97; 95% CI = 1.06-3.68) were at increased risk of NHL. A diagnosis of RA (RR = 
      1.75; 95% CI = 1.09-2.79), but not OA (RR = 1.06; 95% CI = 0.67-1.68), was 
      associated with risk of NHL, but the positive association of use of aspirin and 
      other NSAIDs with NHL was independent of RA history. Multivariate adjustment for 
      other NHL risk factors only attenuated slightly these associations, whereas 
      exclusion of cases occurring during the first 2 years of follow-up strengthened 
      the associations. These data suggest that use of NSAIDs, either aspirin or other 
      non-aspirin NSAIDs, are associated positively with risk of NHL, and that this 
      association is independent of RA history.
CI  - Copyright 2003 Wiley-Liss, Inc.
FAU - Cerhan, James R
AU  - Cerhan JR
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA. 
      cerhan.james@mayo.edu
FAU - Anderson, Kristin E
AU  - Anderson KE
FAU - Janney, Carol A
AU  - Janney CA
FAU - Vachon, Celine M
AU  - Vachon CM
FAU - Witzig, Thomas E
AU  - Witzig TE
FAU - Habermann, Thomas M
AU  - Habermann TM
LA  - eng
GR  - K07 CA64220/CA/NCI NIH HHS/United States
GR  - R01 CA39741/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Int J Cancer. 2004 May 20;110(1):150-1; author reply 152. PMID: 15054881
MH  - Age Distribution
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Arthritis, Rheumatoid/complications/diagnosis
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Iowa/epidemiology
MH  - Lymphoma, Non-Hodgkin/*chemically induced/epidemiology
MH  - Middle Aged
MH  - Odds Ratio
MH  - Prognosis
MH  - Risk Factors
MH  - SEER Program
MH  - Surveys and Questionnaires
EDAT- 2003/07/17 05:00
MHDA- 2003/09/17 05:00
CRDT- 2003/07/17 05:00
PHST- 2003/07/17 05:00 [pubmed]
PHST- 2003/09/17 05:00 [medline]
PHST- 2003/07/17 05:00 [entrez]
AID - 10.1002/ijc.11311 [doi]
PST - ppublish
SO  - Int J Cancer. 2003 Sep 20;106(5):784-8. doi: 10.1002/ijc.11311.

PMID- 6611277
OWN - NLM
STAT- MEDLINE
DCOM- 19840917
LR  - 20131121
IS  - 0011-8532 (Print)
IS  - 0011-8532 (Linking)
VI  - 28
IP  - 3
DP  - 1984 Jul
TI  - Nonopioid analgesics for patients with dental pain.
PG  - 401-12
AB  - Although new analgesic agents are being introduced at a seemingly increasing 
      frequency, it still appears that the old standards are weathering the storm of 
      competition. For most dental situations, aspirin or acetaminophen is sufficiently 
      efficacious for the management of pain and traumatic swelling. Under unusual 
      circumstances in which the baseline pain is expected to be exceptionally high, 
      ibuprofen may offer additional relief. The choice of which agent to use should be 
      based upon an evaluation of the patient's medical history and the anticipated 
      level of pain. Individuals intolerant to aspirin may be able to tolerate 
      acetaminophen without untoward reactions. However, caution must be observed to 
      assure that cross-intolerance is not present. Utilization of more potent 
      cyclo-oxygenase inhibitors such as ibuprofen markedly increases the probability 
      of cross-intolerance. Other forms of sensitivity to aspirin such as 
      gastrointestinal distress may be averted by choosing any of the alternative 
      agents. Only by trial and error will the clinician be able to pragmatically 
      determine which agent is best suited for the individual patient. Cost is another 
      factor that should be considered. Aspirin and acetaminophen are readily available 
      and are extraordinarily inexpensive. The newer drugs, although perhaps slightly 
      more efficacious, are considerably more costly. Although there may be a tendency 
      for the practitioner to prescribe a drug that will be effective against the 
      extremes, the benefit-to-cost ratio is unsupportive of this approach. Only when 
      severe pain is anticipated or when the patient is unresponsive to the more 
      traditional analgesics, should the more efficacious but much more expensive 
      agents be employed.
FAU - Deuben, R R
AU  - Deuben RR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dent Clin North Am
JT  - Dental clinics of North America
JID - 0217440
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 367589PJ2C (Mefenamic Acid)
RN  - 7C546U4DEN (Diflunisal)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/adverse effects/pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/metabolism/*pharmacology
MH  - Aspirin/adverse effects/pharmacology
MH  - *Dental Care
MH  - Diflunisal/adverse effects/pharmacology
MH  - Humans
MH  - Ibuprofen/pharmacology
MH  - Kinetics
MH  - Mefenamic Acid/adverse effects/pharmacology
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
PST - ppublish
SO  - Dent Clin North Am. 1984 Jul;28(3):401-12.

PMID- 7908862
OWN - NLM
STAT- MEDLINE
DCOM- 19940519
LR  - 20131121
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 17
IP  - 1 Suppl 1
DP  - 1994 Jan
TI  - Adjunctive pharmacologic therapy for acute myocardial infarction.
PG  - I10-4
AB  - Early reperfusion therapy, usually in the form of intravenous thrombolysis, is 
      accepted as the standard therapy for patients with acute myocardial infarction. 
      While thrombolytic therapy has been conclusively shown to reduce mortality, a 
      large percentage of patients are not candidates for this therapy and, even in 
      those who are candidates, as many as 25-30% have persistent occlusion or 
      reocclusion of the infarct-related artery. Adjunctive pharmacologic therapy 
      evolved in an attempt to address these issues and is given in addition to 
      reperfusion therapy. Adjunctive therapy includes administration of one or more of 
      the following: aspirin, heparin, beta-adrenergic blockers, nitroglycerin, 
      heart-rate slowing calcium antagonists, and angiotensin-converting enzyme 
      inhibitors. Data are emerging that indicate that some of these agents provide 
      additional reduction in morbidity and mortality when used as adjunctive 
      strategies. Currently, a recommended combination includes, at minimum, soluble 
      aspirin, intravenous heparin, an intravenous beta-blocking agent, and oral 
      angiotensin-converting enzyme inhibitor.
FAU - Pepine, C J
AU  - Pepine CJ
AD  - Division of Cardiology, University of Florida, College of Medicine, Gainesville 
      32610.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Nitrates)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Calcium Channel Blockers/therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Nitrates/therapeutic use
MH  - Thrombolytic Therapy
RF  - 32
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Cardiol. 1994 Jan;17(1 Suppl 1):I10-4.

PMID- 23522855
OWN - NLM
STAT- MEDLINE
DCOM- 20140310
LR  - 20130812
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 132
IP  - 1
DP  - 2013 Jul
TI  - ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent 
      antithrombotic effect without "aspirin dilemma".
PG  - 56-62
LID - S0049-3848(13)00092-3 [pii]
LID - 10.1016/j.thromres.2013.03.005 [doi]
AB  - INTRODUCTION: Aspirin inhibits both the cyclooxygenase (COX)-1-dependent 
      production of thromboxane A2 (TXA2) in platelets and COX-2-dependent production 
      of anti-aggregatory prostaglandin I2 (PGI2) in vessel walls, resulting in 
      "aspirin dilemma." Our objective is to investigate whether ASP6537 can overcome 
      aspirin dilemma and exert a potent antithrombotic effect without a concurrent 
      ulcerogenic effect. METHODS: We evaluated the inhibitory effects of ASP6537 on 
      recombinant human COX-1 (rhCOX-1) and rhCOX-2 activities using a COX-1/2 
      selectivity test. To determine whether ASP6537 induces aspirin dilemma, we 
      examined the effects of ASP6537 on in vitro TXA2 and PGI2 metabolite production 
      from platelets and isolated aorta of guinea pigs, and on plasma concentrations of 
      TXA2 and PGI2 metabolites in aged rats. Finally, we evaluated the antithrombotic 
      effects and ulcerogenic activity of ASP6537 using an electrically induced carotid 
      arterial thrombosis model and a gastric ulcer model in guinea pigs. RESULTS: The 
      IC50 ratios of rhCOX-2 to rhCOX-1 for ASP6537 and aspirin were >142,000 and 1.63 
      fold, respectively. ASP6537 inhibited TXA2 production more selectively than 
      aspirin in in vitro and in vivo TXA2/PGI2 production studies. ASP6537 exerted a 
      significant antithrombotic effect at ≥3 mg/kg, while aspirin tended to inhibit 
      thrombosis at 300 mg/kg but it was not statistically significant. Further, 
      ASP6537 did not induce ulcer formation at 100 mg/kg, whereas aspirin exhibited an 
      ulcerogenic effect at doses of ≥100 mg/kg. CONCLUSIONS: ASP6537 functions as a 
      highly selective COX-1 inhibitor with a superior ability to aspirin for 
      normalizing TXA2/PGI2 balance, and exerts antithrombotic effect without 
      ulcerogenic effect.
CI  - Copyright © 2013 Elsevier Ltd. All rights reserved.
FAU - Sakata, Chinatsu
AU  - Sakata C
AD  - Pharmacology Research Labs., Drug Discovery Research, Astellas Pharma Inc., 
      Ibaraki, Japan. chinatsu.sakata@astellas.com
FAU - Kawasaki, Tomihisa
AU  - Kawasaki T
FAU - Kato, Yasuko
AU  - Kato Y
FAU - Abe, Masaki
AU  - Abe M
FAU - Suzuki, Ken-ichi
AU  - Suzuki K
FAU - Ohmiya, Makoto
AU  - Ohmiya M
FAU - Funatsu, Toshiyuki
AU  - Funatsu T
FAU - Morita, Yoshiaki
AU  - Morita Y
FAU - Okada, Masamichi
AU  - Okada M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130322
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (3-methoxy-1,5-bis(4-methoxyphenyl)-1H-1,2,4-triazole)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Prostaglandins)
RN  - 0 (Triazoles)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Thromb Res. 2013 Jul;132(1):1-2. PMID: 23664562
MH  - Animals
MH  - Aspirin/adverse effects/pharmacology/*therapeutic use
MH  - Carotid Artery Thrombosis/*drug therapy/enzymology
MH  - Cyclooxygenase 1/*metabolism
MH  - Cyclooxygenase Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Epoprostenol/metabolism/urine
MH  - Fibrinolytic Agents/adverse effects/pharmacology/*therapeutic use
MH  - Guinea Pigs
MH  - Humans
MH  - Male
MH  - Prostaglandins/blood/metabolism
MH  - Rats
MH  - Stomach/drug effects
MH  - Triazoles/adverse effects/pharmacology/*therapeutic use
MH  - Ulcer/chemically induced
OTO - NOTNLM
OT  - AA
OT  - ACS
OT  - Arachidonic acid
OT  - Aspirin
OT  - COX
OT  - Cyclooxygenase
OT  - DMSO
OT  - GI
OT  - MC
OT  - MED
OT  - MI
OT  - NSAIDs
OT  - PGI(2)
OT  - PRP
OT  - Platelet
OT  - Prostaglandin I(2)
OT  - TTO
OT  - TXA(2)
OT  - Thrombosis
OT  - Thromboxane A(2)
OT  - acute coronary syndrome
OT  - cyclooxygenase
OT  - dimethylsulfoxide
OT  - gastrointestinal
OT  - methylcellulose
OT  - minimum effective dose
OT  - myocardial infarction
OT  - non-steroidal anti-inflammatory drugs
OT  - platelet-rich plasma
OT  - prostaglandin I(2)
OT  - thromboxane A(2)
OT  - time to occlusion
EDAT- 2013/03/26 06:00
MHDA- 2014/03/13 06:00
CRDT- 2013/03/26 06:00
PHST- 2012/10/03 00:00 [received]
PHST- 2012/12/03 00:00 [revised]
PHST- 2013/03/01 00:00 [accepted]
PHST- 2013/03/26 06:00 [entrez]
PHST- 2013/03/26 06:00 [pubmed]
PHST- 2014/03/13 06:00 [medline]
AID - S0049-3848(13)00092-3 [pii]
AID - 10.1016/j.thromres.2013.03.005 [doi]
PST - ppublish
SO  - Thromb Res. 2013 Jul;132(1):56-62. doi: 10.1016/j.thromres.2013.03.005. Epub 2013 
      Mar 22.

PMID- 35186231
OWN - NLM
STAT- MEDLINE
DCOM- 20220503
LR  - 20220516
IS  - 2040-2309 (Electronic)
IS  - 2040-2295 (Print)
IS  - 2040-2295 (Linking)
VI  - 2022
DP  - 2022
TI  - The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in 
      Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and 
      Its Effect on Patients' Cardiac Function.
PG  - 4708572
LID - 10.1155/2022/4708572 [doi]
LID - 4708572
AB  - OBJECTIVE: To explore the clinical efficacy of tirofiban combined with ticagrelor 
      and aspirin in acute myocardial infarction treatment by percutaneous coronary 
      intervention and its effect on patients' cardiac function. METHODS: We selected 
      102 patients with acute myocardial infarction who came to The First Hospital of 
      LanZhou University for treatment from July 2018 to May 2021. On the basis of 
      conventional treatment, patients were separated into a joint group (tirofiban 
      combined with ticagrelor and aspirin) comprising 55 cases and a control group 
      (conventional ticagrelor and aspirin dual treatment) involving 47 cases. Blood 
      flow classification of the two groups of patients was immediately recorded and 
      compared after the myocardial infarction thrombolysis test (TIMI). Left 
      ventricular function-related indicators, platelet-related parameters, 
      neutrophil/lymphocyte ratio (NLR), red blood cell distribution width (RDW), and 
      platelet/lymphocyte ratio (PLR) before treatment and 7 days after PCI were 
      evaluated and compared between the groups before treatment and 3 months after 
      treatment. ELISA was utilized to detect the serum levels of inflammatory factors, 
      tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and hypersensitive 
      C-reactive protein (hs-CRP) before and after treatment. Incidence of major 
      adverse cardiovascular events (MACEs) and adverse reaction incidence was put into 
      comparison between the two groups in the course of the 3-month follow-up period. 
      Compared with the control group, the joint group accounted for more patients with 
      TIMI blood flow classification level 3 (P < 0.05) and showed more drastic 
      improvement on the left ventricular function, platelet-related parameters, and 
      serum inflammatory factors (P < 0.05). Moreover, patients of the joint group 
      suffered less fluctuation from RDW, NLR, and PLR (P < 0.05), and their incidence 
      of MACE was drastically lower in contrast with the control group (P < 0.05). No 
      notable changes were presented in terms of incidence of adverse reaction (P > 
      0.05). For patients who suffered from acute myocardial infarction and treated 
      with percutaneous coronary intervention, the application of tirofiban combined 
      with ticagrelor and aspirin could effectively reduce the incidence of no reflow 
      or slow blood flow, improve myocardial perfusion function, and have marked 
      curative effects. It is worthy of clinical promotion and application.
CI  - Copyright © 2022 Rui Peng and Feng Li.
FAU - Peng, Rui
AU  - Peng R
AD  - Department of Heart Center, The First Hospital of LanZhou University, LanZhou 
      730000, Gansu, China.
FAU - Li, Feng
AU  - Li F
AUID- ORCID: 0000-0001-5545-1915
AD  - Department of Internal Medicine-Cardiovascular, Xiang'an Branch, The First 
      Affiliated Hospital of Xiamen University, Xiamen 361101, Fujian, China.
LA  - eng
PT  - Journal Article
DEP - 20220209
PL  - England
TA  - J Healthc Eng
JT  - Journal of healthcare engineering
JID - 101528166
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GGX234SI5H (Tirofiban)
RN  - GLH0314RVC (Ticagrelor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Humans
MH  - *Myocardial Infarction/drug therapy
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Ticagrelor/therapeutic use
MH  - Tirofiban/therapeutic use
MH  - Treatment Outcome
PMC - PMC8849904
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/02/22 06:00
MHDA- 2022/05/04 06:00
CRDT- 2022/02/21 06:02
PHST- 2021/11/19 00:00 [received]
PHST- 2021/12/19 00:00 [revised]
PHST- 2021/12/21 00:00 [accepted]
PHST- 2022/02/21 06:02 [entrez]
PHST- 2022/02/22 06:00 [pubmed]
PHST- 2022/05/04 06:00 [medline]
AID - 10.1155/2022/4708572 [doi]
PST - epublish
SO  - J Healthc Eng. 2022 Feb 9;2022:4708572. doi: 10.1155/2022/4708572. eCollection 
      2022.

PMID- 18090373
OWN - NLM
STAT- MEDLINE
DCOM- 20080212
LR  - 20151119
IS  - 1530-0293 (Electronic)
IS  - 0090-3493 (Linking)
VI  - 36
IP  - 1
DP  - 2008 Jan
TI  - Effects of aspirin, nimesulide, and SC-560 on vasopressin-induced contraction of 
      human gastroepiploic artery and saphenous vein.
PG  - 193-7
AB  - OBJECTIVE: The present experiments were designed to evaluate differences in the 
      effects of cyclooxygenase (COX)-1 and COX-2 inhibition on contractile responses 
      of human gastroepiploic artery and saphenous vein elicited by vasopressin. 
      DESIGN: Laboratory investigation. SETTING: University laboratory. SUBJECTS: Rings 
      of human gastroepiploic artery were obtained from 32 patients undergoing 
      gastrectomy, and rings of saphenous vein were obtained from 30 patients 
      undergoing coronary artery bypass surgery. INTERVENTIONS: The rings were 
      suspended in organ baths for isometric recording of tension. We studied the 
      responses to vasopressin in the absence and in the presence of either the 
      vasopressin V1-receptor antagonist d(CH2)5Tyr(Me)AVP or the COX inhibitors 
      aspirin, nimesulide, or SC-560. MEASUREMENTS AND MAIN RESULTS: Vasopressin 
      (10(-11)-10(-6) mol/L) produced concentration-dependent contractions with an EC50 
      value of 4.3 x 10(-10) mol/L for gastroepiploic artery and 3.4 x 10(-8) mol/L for 
      saphenous vein. The vasopressin V1-receptor antagonist d(CH2)5Tyr(Me)AVP (10(-7) 
      mol/L) induced significant shifts (p < .001) of the control curves to the right. 
      The COX-1 and COX-2 inhibitor aspirin (10(-6)-10(-5) mol/L) and the COX-2 
      inhibitor nimesulide (10(-6) mol/L) induced leftward shifts of the 
      concentration-response curve for vasopressin in gastroepiploic artery. Lower 
      concentrations of aspirin or the COX-1 inhibitor SC-560 (10(-8) mol/L) did not 
      affect the responses of gastroepiploic artery. COX-1 or COX-2 inhibition did not 
      modify the contraction of saphenous vein to vasopressin. CONCLUSION: The results 
      provide functional evidence that aspirin at high concentrations and the COX-2 
      selective inhibitor nimesulide potentiate the contractile response of 
      gastroepiploic artery to vasopressin, thus suggesting the release of relaxant 
      prostaglandins by the peptide. However, contractions of human saphenous vein were 
      unaffected by COX inhibition, indicating that vasopressin does not stimulate the 
      release of prostanoids. The amplifying effect of aspirin on vasopressin-induced 
      contraction may contribute to early graft failure when the gastroepiploic artery 
      is used as a coronary artery bypass graft.
FAU - Aldasoro, Martin
AU  - Aldasoro M
AD  - Departamento de Fisiología, Facultad de Medicina, Universidad de Valencia, 
      Valencia, Spain. aldasoro@uv.es
FAU - Mauricio, Maria D
AU  - Mauricio MD
FAU - Serna, Eva
AU  - Serna E
FAU - Cortina, Belen
AU  - Cortina B
FAU - Segarra, Gloria
AU  - Segarra G
FAU - Medina, Pascual
AU  - Medina P
FAU - Vila, José M
AU  - Vila JM
FAU - Flor, Blas
AU  - Flor B
FAU - Lluch, Salvador
AU  - Lluch S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (SC 560)
RN  - 0 (Sulfonamides)
RN  - 11000-17-2 (Vasopressins)
RN  - R16CO5Y76E (Aspirin)
RN  - V4TKW1454M (nimesulide)
SB  - IM
CIN - Crit Care Med. 2008 Jan;36(1):353-4. PMID: 18158455
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*pharmacology
MH  - Cyclooxygenase Inhibitors/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastroepiploic Artery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Contraction/*drug effects
MH  - Muscle, Smooth, Vascular/*drug effects
MH  - Pyrazoles/*pharmacology
MH  - Saphenous Vein
MH  - Sulfonamides/*pharmacology
MH  - Vasopressins
EDAT- 2007/12/20 09:00
MHDA- 2008/02/13 09:00
CRDT- 2007/12/20 09:00
PHST- 2007/12/20 09:00 [pubmed]
PHST- 2008/02/13 09:00 [medline]
PHST- 2007/12/20 09:00 [entrez]
AID - 10.1097/01.CCM.0000292155.06797.62 [doi]
PST - ppublish
SO  - Crit Care Med. 2008 Jan;36(1):193-7. doi: 10.1097/01.CCM.0000292155.06797.62.

PMID- 18697379
OWN - NLM
STAT- MEDLINE
DCOM- 20081017
LR  - 20131121
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 91
IP  - 6
DP  - 2008 Jun
TI  - Aspirin non-responders in Thai ischemic stroke/TIA patients.
PG  - 818-21
AB  - BACKGROUND: Aspirin resistance has been defined as inability of aspirin to 
      protect individuals from thrombotic complications or to produce an anticipated 
      effect from laboratory tests of platelet function. Most reported information 
      comes from Western patients with coronary artery disease and aspirin resistance 
      is defined by laboratory criteria. The purpose of the present study was to look 
      for aspirin non-responders in Thai patients who presented with acute/subacute 
      ischemic stroke and transient ischemic attack (TIA). MATERIAL AND METHOD: The 
      authors prospectively included acute ischemic stroke/TIA patients who were 
      treated at Thammasat Hospital from August, 2006 to July, 2007 and had already 
      been on aspirin. Information about compliance of medication, reasons for taking 
      aspirin, doses of aspirin, baseline characteristics, and stroke subtypes of the 
      patients were collected. RESULTS: There were 194 acute/subacute ischemic 
      stroke/TIA patients during the study period Forty-six patients (23.7%), who had 
      already been on aspirin (aspirin non-responder), while having new stroke/TIA, 
      were studied Eighteen patients were on aspirin 300-325 mg and 28 patients were on 
      81 mg per day. Most patients had taken aspirin 300-325mg/day as secondary 
      prevention, while half of the patients taking aspirin 81 mg/d had diabetes 
      mellitus and took aspirin as primary prevention. CONCLUSION: Aspirin 
      non-responders in ischemic stroke patients are common. Future study is required 
      to clarify mechanisms of aspirin non-responders in Thai patients.
FAU - Dharmasaroja, Pornpatr
AU  - Dharmasaroja P
AD  - Division of Neurology, Faculty of Medicine, Thammasat University, Pathumthani, 
      Thailand. pornpatr1@hotmail.com
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Stroke/*drug therapy
MH  - Thailand
MH  - *Treatment Failure
EDAT- 2008/08/14 09:00
MHDA- 2008/10/18 09:00
CRDT- 2008/08/14 09:00
PHST- 2008/08/14 09:00 [pubmed]
PHST- 2008/10/18 09:00 [medline]
PHST- 2008/08/14 09:00 [entrez]
PST - ppublish
SO  - J Med Assoc Thai. 2008 Jun;91(6):818-21.

PMID- 11082214
OWN - NLM
STAT- MEDLINE
DCOM- 20001222
LR  - 20200930
IS  - 0037-9727 (Print)
IS  - 0037-9727 (Linking)
VI  - 225
IP  - 3
DP  - 2000 Dec
TI  - Nitric oxide donors.
PG  - 200-6
AB  - Nitric oxide (NO) donors are pharmacologically active substances that release NO 
      in vivo or in vitro. NO has a variety of functions such as the release of 
      prostanoids, inhibition of platelet aggregation, effect on angiogenesis, and 
      production of oxygen free radicals. This report discusses the chemical and 
      pharmacological characteristics of NO donors, their effect on platelet function 
      and cyclooxygenase, their cardiac action including myocardial infarction, and 
      release of superoxide anions. This review stresses NO tolerance and the effect of 
      NO donors on angiogenesis in myocardial infarction and in solid tumors.
FAU - Yamamoto, T
AU  - Yamamoto T
AD  - Department of Experimental Cardiology, Huntington Medical Research Institutes, 
      Pasadena, California 91101, USA.
FAU - Bing, R J
AU  - Bing RJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Proc Soc Exp Biol Med
JT  - Proceedings of the Society for Experimental Biology and Medicine. Society for 
      Experimental Biology and Medicine (New York, N.Y.)
JID - 7505892
RN  - 0 (1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Triazenes)
RN  - 11062-77-4 (Superoxides)
RN  - 169D1260KM (Nitroprusside)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 5O5U71P6VQ (linsidomine)
RN  - D46583G77X (Molsidomine)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EH04H13L6B (nitroaspirin)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Drug Tolerance
MH  - Heart/drug effects
MH  - Humans
MH  - In Vitro Techniques
MH  - Molsidomine/analogs & derivatives/pharmacology
MH  - Myocardial Infarction/metabolism
MH  - Neovascularization, Physiologic/drug effects
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Donors/chemistry/*pharmacology
MH  - Nitroglycerin/pharmacology
MH  - Nitroprusside/pharmacology
MH  - Platelet Aggregation/drug effects
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Superoxides/metabolism
MH  - Triazenes/pharmacology
RF  - 97
EDAT- 2000/11/18 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/18 11:00
PHST- 2000/11/18 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/18 11:00 [entrez]
AID - pse22525 [pii]
AID - 10.1046/j.1525-1373.2000.22525.x [doi]
PST - ppublish
SO  - Proc Soc Exp Biol Med. 2000 Dec;225(3):200-6. doi: 
      10.1046/j.1525-1373.2000.22525.x.

PMID- 32270588
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1098-2795 (Electronic)
IS  - 1040-452X (Linking)
VI  - 87
IP  - 5
DP  - 2020 May
TI  - Arachidonic acid alleviates the detrimental effects of acetylsalicylic acid on 
      human granulosa cells performance in vitro.
PG  - 607-619
LID - 10.1002/mrd.23343 [doi]
AB  - Here, we investigated the biological effects of arachidonic acid (AA) in human 
      cumulus granulosa cells (CGCs) after exposure to ASA. Cells were isolated from 
      the follicular fluid and incubated with 0.5 mM acetylsalicylic acid (ASA) and 
      50 µM AA. Cell viability was analyzed by 
      3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. E(2) and P(4) 
      levels were measured by chemiluminescence assay. Expression of genes including 
      CYP19A1, FACN, and SCD1 was measured by real-time polymerase chain reaction 
      assay. Oxidative status was analyzed by monitoring glutathione peroxidase 
      activity. The fatty acid profile was analyzed by the gas chromatography 
      technique. Enzyme-linked immunosorbent assay was used to measure prostaglandin 
      E(2) (PGE(2) ) in CGCs after exposure to ASA and AA. Protein levels of the 
      estrogen receptor were studied by immunofluorescence staining. Ultrastructural 
      changes were evaluated by transmission electron microscopy imaging. ASA treatment 
      reduced E(2) production, Cyp19a1 expression, glutathione peroxidase (GPx) 
      activity, and estradiol receptor expression in CGCs. The addition of AA prevented 
      the ASA-induced E(2) reduction (p < .05) and expression of Cyp19a1. Moreover, AA 
      increased the antioxidant capacity of CGCs exposed to ASA by promoting GPx 
      activity (p < .05). AA increased monounsaturated fatty acid/saturated fatty acid 
      ratio compared with the ASA group (p < .05). AA supplementation triggered the 
      synthesis and secretion of PGE(2) in ASA-treated CGCS (p < .05). Cytoplasmic 
      vacuolation observed in the ASA group and treatment with AA intensified 
      vacuolation rate. The expression of the estrogen receptor was increased after AA 
      supplementation. Data demonstrated that AA decreased the detrimental effects of 
      ASA on human CGCs after 72 hr.
CI  - © 2020 Wiley Periodicals, Inc.
FAU - Khajeh, Masoumeh
AU  - Khajeh M
AD  - Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Nouri, Mohammad
AU  - Nouri M
AUID- ORCID: 0000-0002-5367-9956
AD  - Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Ghasemzadeh, Aalie
AU  - Ghasemzadeh A
AD  - Women's Reproductive Health Research Center, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Mehdizadeh, Amir
AU  - Mehdizadeh A
AD  - Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Shanehbandi, Dariush
AU  - Shanehbandi D
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Yousefi, Soudabe
AU  - Yousefi S
AD  - Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Darabi, Masoud
AU  - Darabi M
AUID- ORCID: 0000-0001-6380-272X
AD  - Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Rahbarghazi, Reza
AU  - Rahbarghazi R
AUID- ORCID: 0000-0003-3864-9166
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200408
PL  - United States
TA  - Mol Reprod Dev
JT  - Molecular reproduction and development
JID - 8903333
RN  - 0 (Fatty Acids)
RN  - 0 (Receptors, Estrogen)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Arachidonic Acid/*pharmacology
MH  - Aspirin/*adverse effects/pharmacology
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Cumulus Cells/cytology/*drug effects/physiology
MH  - Dinoprostone/metabolism
MH  - Drug Interactions
MH  - Fatty Acids/metabolism
MH  - Female
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Lipid Metabolism/drug effects
MH  - Receptors, Estrogen/drug effects/genetics/metabolism
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - arachidonic acid
OT  - fatty acid profile
OT  - human granulosa cells
OT  - steroid hormones
EDAT- 2020/04/10 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/04/10 06:00
PHST- 2019/02/28 00:00 [received]
PHST- 2020/02/21 00:00 [revised]
PHST- 2020/03/22 00:00 [accepted]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/04/10 06:00 [entrez]
AID - 10.1002/mrd.23343 [doi]
PST - ppublish
SO  - Mol Reprod Dev. 2020 May;87(5):607-619. doi: 10.1002/mrd.23343. Epub 2020 Apr 8.

PMID- 11007221
OWN - NLM
STAT- MEDLINE
DCOM- 20001012
LR  - 20220409
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 95
IP  - 9
DP  - 2000 Sep
TI  - Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.
PG  - 2218-24
AB  - OBJECTIVE: Aspirin products are known to cause irritation and injury to the 
      gastric mucosa. We examined the risk of hospitalization for upper 
      gastrointestinal bleeding with use of low-dose aspirin. METHODS: This was a 
      cohort study based on record linkage between a population-based prescription 
      database and a hospital discharge registry in North Jutland County, Denmark, from 
      January 1, 1991, to December 31, 1995. Incidence rates of upper gastrointestinal 
      bleeding in 27,694 users of low-dose aspirin were compared with the incidence 
      rates in the general population in the county. RESULTS: A total of 207 exclusive 
      users of low-dose aspirin experienced a first episode of upper gastrointestinal 
      bleeding with admission to the hospital during the study period. The standardized 
      incidence rate ratio was 2.6 (95% confidence interval, 2.2-2.9), 2.3 in women and 
      2.8 in men. The standardized incidence rate ratio for combined use of low-dose 
      aspirin and other nonsteroidal anti-inflammatory drugs was 5.6 (95% confidence 
      interval, 4.4-7.0). The risk was similar among users of noncoated low-dose 
      aspirin (standardized incidence rate ratio, 2.6; 95% confidence interval, 
      1.8-3.5) and coated low-dose aspirin (standardized incidence rate ratio, 2.6; 95% 
      confidence interval, 2.2-3.0). CONCLUSIONS: Use of low-dose aspirin was 
      associated with an increased risk of upper gastrointestinal bleeding, with still 
      higher risks when combined with other nonsteroidal anti-inflammatory drugs. 
      Enteric coating did not seem to reduce the risk. The findings from this 
      observational study raise the possibility that prophylactic use of low-dose 
      aspirin may convey an increased risk of gastrointestinal bleeding, which may 
      offset some of its benefits.
FAU - Sørensen, H T
AU  - Sørensen HT
AD  - Department of Clinical Epidemiology, Aarhus University and Aalborg Hospitals, 
      Denmark.
FAU - Mellemkjaer, L
AU  - Mellemkjaer L
FAU - Blot, W J
AU  - Blot WJ
FAU - Nielsen, G L
AU  - Nielsen GL
FAU - Steffensen, F H
AU  - Steffensen FH
FAU - McLaughlin, J K
AU  - McLaughlin JK
FAU - Olsen, J H
AU  - Olsen JH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nonprescription Drugs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Am J Gastroenterol. 2001 May;96(5):1646. PMID: 11374720
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cohort Studies
MH  - Confidence Intervals
MH  - Denmark/epidemiology
MH  - Diagnosis, Differential
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/diagnosis/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Nonprescription Drugs
MH  - Retrospective Studies
MH  - Sex Distribution
MH  - Surveys and Questionnaires
EDAT- 2000/09/28 11:00
MHDA- 2000/10/14 11:01
CRDT- 2000/09/28 11:00
PHST- 2000/09/28 11:00 [pubmed]
PHST- 2000/10/14 11:01 [medline]
PHST- 2000/09/28 11:00 [entrez]
AID - S0002-9270(00)01040-6 [pii]
AID - 10.1111/j.1572-0241.2000.02248.x [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2000 Sep;95(9):2218-24. doi: 
      10.1111/j.1572-0241.2000.02248.x.

PMID- 17576559
OWN - NLM
STAT- MEDLINE
DCOM- 20080612
LR  - 20131121
IS  - 0344-5704 (Print)
IS  - 0344-5704 (Linking)
VI  - 61
IP  - 5
DP  - 2008 Apr
TI  - Vanadium(IV) complexes inhibit adhesion, migration and colony formation of UMR106 
      osteosarcoma cells.
PG  - 767-73
AB  - Vanadium is a trace element widely distributed in the environment. In vertebrates 
      it is mainly stored in bone tissue. The unique cellular environment in the bone 
      and the variety of interactions that mediate cancer metastasis determine that 
      certain types of cancer, such as breast and prostate cancer, preferentially 
      metastize in the skeleton. Since this effect usually signifies serious morbidity 
      and grave prognosis there is an increasing interest in the development of new 
      treatments for this pathology. The present work shows that vanadium complexes can 
      inhibit some parameters related to cancer metastasis such as cell adhesion, 
      migration and clonogenicity. We have also investigated the role of protein kinase 
      A in these processes.
FAU - Molinuevo, María S
AU  - Molinuevo MS
AD  - Cátedra de Bioquímica Patológica, Facultad de Ciencias Exactas, Universidad 
      Nacional de La Plata, 47 y 115, 1900, La Plata, Argentina.
FAU - Cortizo, Ana M
AU  - Cortizo AM
FAU - Etcheverry, Susana B
AU  - Etcheverry SB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070619
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Trace Elements)
RN  - 00J9J9XKDE (Vanadium)
RN  - B8WCK70T7I (Trehalose)
RN  - EC 2.7.11.11 (Cyclic AMP-Dependent Protein Kinases)
RN  - IY9XDZ35W2 (Glucose)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/chemistry/pharmacology
MH  - Cell Adhesion/drug effects
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Colony-Forming Units Assay
MH  - Cyclic AMP-Dependent Protein Kinases/drug effects/metabolism
MH  - Drug Stability
MH  - Glucose/chemistry/pharmacology
MH  - Neoplasm Metastasis/*prevention & control
MH  - Osteosarcoma/*drug therapy
MH  - Rats
MH  - Trace Elements/chemistry/*pharmacology
MH  - Trehalose/chemistry/pharmacology
MH  - Vanadium/chemistry/*pharmacology
EDAT- 2007/06/20 09:00
MHDA- 2008/06/13 09:00
CRDT- 2007/06/20 09:00
PHST- 2006/11/15 00:00 [received]
PHST- 2007/05/05 00:00 [accepted]
PHST- 2007/06/20 09:00 [pubmed]
PHST- 2008/06/13 09:00 [medline]
PHST- 2007/06/20 09:00 [entrez]
AID - 10.1007/s00280-007-0532-6 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2008 Apr;61(5):767-73. doi: 
      10.1007/s00280-007-0532-6. Epub 2007 Jun 19.

PMID- 10355002
OWN - NLM
STAT- MEDLINE
DCOM- 19990813
LR  - 20191024
IS  - 0028-2804 (Print)
IS  - 0028-2804 (Linking)
VI  - 70
IP  - 4
DP  - 1999 Apr
TI  - [Secondary prevention after ischemic cerebral infarct. The ESPRIT Study: low dose 
      anticoagulation, combined therapy with acetylsalicylic acid/dipyridamole or 
      monotherapy with acetylsalicylic acid?].
PG  - 368-70
AB  - The European and Australian Stroke Prevention in Reversible Ischaemia Trial 
      (ESPRIT) is a randomised clinical trial in which patients with cerebral ischaemia 
      of arterial origin will be randomised between oral anticoagulation (international 
      normalized ratio (INR): 2.0-3.0), the combination of acetylsalicylic acid (in any 
      dose between 30 and 325 mg per day) plus dipyridamole (400 mg daily) and 
      acetylsalicylic acid only (in any dose between 30 and 325 mg per day). It is 
      planned to enroll 4500 patients with a mean follow-up of three years. Primary 
      outcome is the composite event of vascular death, stroke, myocardial infarction, 
      or major bleeding complication; outcome assessment will be blinded. ESPRIT is an 
      international, multi-center study in which 60-80 hospitals in the Netherlands and 
      other countries in Europe and Australia will participate.
FAU - Gorter, J W
AU  - Gorter JW
AD  - Trial Bureau Neurologie, Universitätsklinikum Utrecht, Niederlande.
FAU - De Schryver, E L
AU  - De Schryver EL
FAU - Algra, A
AU  - Algra A
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Sekundärprävention nach ischämischem zerebralem Insult. Die ESPRIT-Studie: 
      niedrig dosierte Antikoagulation, Kombinationstherapie mit 
      Acetylsalicylsäure/Dipyridamol oder Monotherapie mit Acetylsalicylsäure?
PL  - Germany
TA  - Nervenarzt
JT  - Der Nervenarzt
JID - 0400773
RN  - 0 (Anticoagulants)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Australia
MH  - Cerebral Infarction/*drug therapy/mortality
MH  - Dipyridamole/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Europe
MH  - Follow-Up Studies
MH  - Humans
MH  - Recurrence
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 1999/06/04 00:00
MHDA- 1999/06/04 00:01
CRDT- 1999/06/04 00:00
PHST- 1999/06/04 00:00 [pubmed]
PHST- 1999/06/04 00:01 [medline]
PHST- 1999/06/04 00:00 [entrez]
AID - 10.1007/s001150050451 [doi]
PST - ppublish
SO  - Nervenarzt. 1999 Apr;70(4):368-70. doi: 10.1007/s001150050451.

PMID- 3107602
OWN - NLM
STAT- MEDLINE
DCOM- 19870716
LR  - 20190515
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 59
IP  - 5
DP  - 1987 May
TI  - Effect of pre-treatment with lysine acetyl salicylate on suxamethonium-induced 
      myalgia.
PG  - 606-10
AB  - The hypothesis that prostaglandin inhibitors might reduce the incidence and 
      severity of suxamethonium-induced myalgia was investigated using lysine acetyl 
      salicylate (LAS) 13 mg kg-1 i.v. 3 min before the administration of suxamethonium 
      in 20 patients. A comparison was made with atracurium 0.09 mg kg-1 (and placebo) 
      in a double-blind prospective randomized trial. LAS and atracurium were effective 
      in reducing the incidence and severity of postsuxamethonium myalgia and the 
      increases in serum potassium concentration. There were no appreciable changes in 
      serum calcium, sodium, chloride, phosphate, magnesium, creatinine, creatine 
      phosphokinase concentrations or plasmacholinesterase activity. Atracurium caused 
      a delay in the onset of action and a decrease in the intensity of 
      suxamethonium-induced neuromuscular block. It is concluded that LAS pretreatment 
      might have a place in suitable patients in the prevention of 
      suxamethonium-induced myalgia and increases in serum potassium concentration.
FAU - Naguib, M
AU  - Naguib M
FAU - Farag, H
AU  - Farag H
FAU - Magbagbeola, J A
AU  - Magbagbeola JA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Analgesics)
RN  - J2R869A8YF (Succinylcholine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Analgesics/*therapeutic use
MH  - Aspirin/*analogs & derivatives/therapeutic use
MH  - Double-Blind Method
MH  - Fasciculation/prevention & control
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/therapeutic use
MH  - Muscular Diseases/chemically induced/*prevention & control
MH  - Pain/chemically induced/*prevention & control
MH  - Postoperative Complications/prevention & control
MH  - Potassium/blood
MH  - *Premedication
MH  - Succinylcholine/*adverse effects
EDAT- 1987/05/01 00:00
MHDA- 1987/05/01 00:01
CRDT- 1987/05/01 00:00
PHST- 1987/05/01 00:00 [pubmed]
PHST- 1987/05/01 00:01 [medline]
PHST- 1987/05/01 00:00 [entrez]
AID - S0007-0912(17)39099-2 [pii]
AID - 10.1093/bja/59.5.606 [doi]
PST - ppublish
SO  - Br J Anaesth. 1987 May;59(5):606-10. doi: 10.1093/bja/59.5.606.

PMID- 3772656
OWN - NLM
STAT- MEDLINE
DCOM- 19861203
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 109
IP  - 5
DP  - 1986 Nov
TI  - Clinical spectrum of Kawasaki disease in infants younger than 6 months of age.
PG  - 759-63
AB  - We report an unselected series of eight patients younger than 6 months of age 
      with Kawasaki disease evaluated between January 1982 and May 1984. The incidence 
      of coronary artery aneurysms (six patients) and the mortality (two patients) were 
      unusually high in this small series. Because of the confusing clinical 
      presentation in three patients, diagnosis was delayed until pathologic or 
      echocardiographic evidence of coronary vasculitis or aneurysm was discovered. The 
      currently accepted clinical criteria for Kawasaki disease may not always identify 
      patients with the pathologic findings of the syndrome who are younger than 6 
      months of age. The diagnosis of Kawasaki disease and echocardiographic evaluation 
      of the coronary arteries should be considered in young infants with prolonged 
      fever of unknown origin.
FAU - Burns, J C
AU  - Burns JC
FAU - Wiggins, J W Jr
AU  - Wiggins JW Jr
FAU - Toews, W H
AU  - Toews WH
FAU - Newburger, J W
AU  - Newburger JW
FAU - Leung, D Y
AU  - Leung DY
FAU - Wilson, H
AU  - Wilson H
FAU - Glodé, M P
AU  - Glodé MP
LA  - eng
GR  - RR-69/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Coronary Aneurysm/diagnosis/etiology/mortality/pathology
MH  - Dipyridamole
MH  - Drug Therapy, Combination
MH  - Echocardiography
MH  - Electrocardiography
MH  - Female
MH  - Fever/etiology
MH  - Humans
MH  - Infant
MH  - Male
MH  - *Mucocutaneous Lymph Node Syndrome/diagnosis/mortality/pathology
MH  - Myocardium/pathology
MH  - Risk
MH  - Warfarin/therapeutic use
EDAT- 1986/11/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1986/11/01 00:00
PHST- 1986/11/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1986/11/01 00:00 [entrez]
AID - S0022-3476(86)80689-8 [pii]
AID - 10.1016/s0022-3476(86)80689-8 [doi]
PST - ppublish
SO  - J Pediatr. 1986 Nov;109(5):759-63. doi: 10.1016/s0022-3476(86)80689-8.

PMID- 18420166
OWN - NLM
STAT- MEDLINE
DCOM- 20080617
LR  - 20200928
IS  - 1550-8579 (Print)
IS  - 1550-8579 (Linking)
VI  - 5
IP  - 1
DP  - 2008 Mar
TI  - Women tolerate drug therapy for coronary artery disease as well as men do, but 
      are treated less frequently with aspirin, beta-blockers, or statins.
PG  - 53-61
AB  - BACKGROUND: Women have worse morbidity, mortality, and health-related 
      quality-of-life outcomes associated with coronary artery disease (CAD) compared 
      with men. This may be related to underutilization of drug therapies, such as 
      aspirin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, or 
      statins. No studies have sought to describe the relationship of gender with 
      adverse reactions to drug therapy (ADRs) for CAD in clinical practice. OBJECTIVE: 
      The aim of this study was to determine the prevalence of ADRs associated with 
      common CAD drug therapies in women and men in clinical practice. METHODS: In a 
      cohort of consecutive outpatients with CAD, detailed chart abstraction was 
      performed to determine the use of aspirin, beta-blocker, ACE inhibitor, and 
      statin therapy, as well as the ADRs reported for these treatments. Baseline 
      clinical characteristics were also determined to identify the independent 
      association of gender with use of standard drug treatments for CAD. RESULTS: 
      Consecutive patients with CAD (153 men, 151 women) were included in the study. 
      Women and men were observed to have a similar prevalence of cardiac risk factors 
      and comorbidities, except that men had significantly higher prevalence of atrial 
      fibrillation (30 [19.6%] men vs 15 [9.9%] women; P = 0.03) and significantly 
      lower mean (SD) high-density lipoprotein cholesterol concentrations (45 [16] 
      mg/dL for men vs 55 [19] mg/dL for women; P < 0.001). No significant differences 
      were observed between the sexes in the prevalence of ADRs; however, significantly 
      fewer women than men were treated with statins (118 [78.1%] vs 139 [90.8%], 
      respectively; P = 0.003). After adjusting for clinical characteristics, women 
      were also found to be less likely than men to receive aspirin (odds ratio [OR] = 
      0.164; 95% CI, 0.083-0.322; P = 0.001) and beta-blockers (OR = 0.184; 95% CI, 
      0.096-0.351; P = 0.001). CONCLUSIONS: Women and men experienced a similar 
      prevalence of ADRs in the treatment of CAD; however, women were significantly 
      less likely to be treated with aspirin, beta-blockers, and statins than were 
      their male counterparts. To optimize care for women with CAD, further study is 
      needed to identify the cause of this gender disparity in therapeutic drug use.
FAU - Enriquez, Jonathan R
AU  - Enriquez JR
AD  - Department of Internal Medicine, Rush University Medical Center, Chicago, IL 
      60612, USA. jonathan_enriquez@rush.edu
FAU - Pratap, Pravin
AU  - Pratap P
FAU - Zbilut, Joseph P
AU  - Zbilut JP
FAU - Calvin, James E
AU  - Calvin JE
FAU - Volgman, Annabelle S
AU  - Volgman AS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Gend Med
JT  - Gender medicine
JID - 101225178
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Coronary Artery Disease/*drug therapy
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Quality of Life
MH  - Sex Factors
MH  - Treatment Outcome
EDAT- 2008/04/19 09:00
MHDA- 2008/06/18 09:00
CRDT- 2008/04/19 09:00
PHST- 2007/08/06 00:00 [accepted]
PHST- 2008/04/19 09:00 [pubmed]
PHST- 2008/06/18 09:00 [medline]
PHST- 2008/04/19 09:00 [entrez]
AID - S1550-8579(08)80008-3 [pii]
AID - 10.1016/s1550-8579(08)80008-3 [doi]
PST - ppublish
SO  - Gend Med. 2008 Mar;5(1):53-61. doi: 10.1016/s1550-8579(08)80008-3.

PMID- 2242538
OWN - NLM
STAT- MEDLINE
DCOM- 19910103
LR  - 20190623
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 82
IP  - 6
DP  - 1990 Dec
TI  - Bleeding time prolongation with streptokinase and its reduction with 
      1-desamino-8-D-arginine vasopressin.
PG  - 2142-51
AB  - The mechanism by which treatment with thrombolytic agents causes bleeding is not 
      known. Recently, frequency of bleeding events has been shown to correlate with 
      bleeding time, particularly in individuals treated with aspirin. We examined the 
      effects of streptokinase (20,000-60,000 IU/kg) on bleeding time in 40 rabbits 
      pretreated with aspirin, a model for fibrinolytic therapy. We then tested the 
      effects of 1-desamino-8-D-arginine vasopressin (DDAVP) (0.3 microgram/kg), an 
      agent known to reduce bleeding time in a variety of bleeding disorders, in 20 
      rabbits and compared the results with those of a control group of rabbits 
      receiving normal saline placebo. Aspirin increased the bleeding time from a 
      baseline mean +/- SEM value of 119 +/- 15 to 191 +/- 34 seconds in the control 
      group and from 114 +/- 6 to 188 +/- 18 seconds in the experimental group. The 
      addition of streptokinase increased the bleeding time to 592 +/- 119 seconds in 
      the control group and 810 +/- 114 seconds in the experimental group (p = NS). 
      Subsequent infusion of DDAVP decreased the bleeding time in the experimental 
      group to 302 +/- 29 seconds (p less than 0.01 versus streptokinase) compared with 
      572 +/- 79 seconds (p = NS versus streptokinase) in the control animals given 
      saline placebo. In a subset of rabbits receiving aspirin and streptokinase 
      (40,000-60,000 IU/kg), samples were obtained for platelet aggregation (n = 16), 
      von Willebrand factor antigen concentration (n = 17), and von Willebrand factor 
      multimer distribution (n = 14). Maximal rates of ADP-induced platelet aggregation 
      were not affected by DDAVP infusion, nor was the plasma concentration of von 
      Willebrand factor antigen, quantified by an immunoradiometric assay, 
      significantly affected by DDAVP infusion. Furthermore, the von Willebrand factor 
      multimer ratio decreased with DDAVP administration. These findings indicate that 
      aspirin and streptokinase combined result in a marked increase in bleeding time 
      that can be reduced by DDAVP. This effect of DDAVP is not accompanied by an 
      increase in platelet aggregation response, plasma von Willebrand factor antigen 
      concentration, or von Willebrand factor multimer ratio.
FAU - Johnstone, M T
AU  - Johnstone MT
AD  - Division of Cardiology, Brigham and Women's Hospital, Boston, MA 02115.
FAU - Andrews, T
AU  - Andrews T
FAU - Ware, J A
AU  - Ware JA
FAU - Rudd, M A
AU  - Rudd MA
FAU - George, D
AU  - George D
FAU - Weinstein, M
AU  - Weinstein M
FAU - Loscalzo, J
AU  - Loscalzo J
LA  - eng
GR  - HL-22355/HL/NHLBI NIH HHS/United States
GR  - HL-40411/HL/NHLBI NIH HHS/United States
GR  - HL-43344/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Antigens)
RN  - 0 (von Willebrand Factor)
RN  - EC 3.4.- (Streptokinase)
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antigens/analysis
MH  - Aspirin/pharmacology
MH  - *Bleeding Time
MH  - Deamino Arginine Vasopressin/*pharmacology
MH  - Female
MH  - Hemorrhage/physiopathology
MH  - Platelet Aggregation
MH  - Rabbits
MH  - Retroperitoneal Space
MH  - Streptokinase/*pharmacology
MH  - von Willebrand Factor/immunology
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
AID - 10.1161/01.cir.82.6.2142 [doi]
PST - ppublish
SO  - Circulation. 1990 Dec;82(6):2142-51. doi: 10.1161/01.cir.82.6.2142.

PMID- 27737875
OWN - NLM
STAT- MEDLINE
DCOM- 20171219
LR  - 20181113
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 5
IP  - 10
DP  - 2016 Oct 13
TI  - Using Large-Scale Linkage Data to Evaluate the Effectiveness of a National 
      Educational Program on Antithrombotic Prescribing and Associated Stroke 
      Prevention in Primary Care.
LID - e003729
AB  - BACKGROUND: The National Prescribing Service (NPS) MedicineWise Stroke Prevention 
      Program, which was implemented nationally in 2009-2010 in Australia, sought to 
      improve antithrombotic prescribing in stroke prevention using dedicated 
      interventions that target general practitioners. This study evaluated the impact 
      of the NPS MedicineWise Stroke Prevention Program on antithrombotic prescribing 
      and primary stroke hospitalizations. METHOD AND RESULTS: This population-based 
      time series study used administrative health data linked to 45 and Up Study 
      participants with a high risk of cardiovascular disease (CVD) to assess the 
      possible impact of the NPS MedicineWise program on first-time aspirin 
      prescriptions and primary stroke-related hospitalizations. Time series analysis 
      showed that the NPS MedicineWise program was significantly associated with 
      increased first-time prescribing of aspirin (P=0.03) and decreased 
      hospitalizations for primary ischemic stroke (P=0.03) in the at-risk study 
      population (n=90 023). First-time aspirin prescription was correlated with a 
      reduction in the rate of hospitalization for primary stroke (P=0.02). Following 
      intervention, the number of first-time aspirin prescriptions increased by 19.8% 
      (95% confidence interval, 1.6-38.0), while the number of first-time stroke 
      hospitalizations decreased by 17.3% (95% confidence interval, 1.8-30.0). 
      CONCLUSIONS: Consistent with NPS MedicineWise program messages for the high-risk 
      CVD population, the NPS MedicineWise Stroke Prevention Program (2009) was 
      associated with increased initiation of aspirin and a reduced rate of 
      hospitalization for primary stroke. The findings suggest that the provision of 
      evidence-based multifaceted large-scale educational programs in primary care can 
      be effective in changing prescriber behavior and positively impacting patient 
      health outcomes.
CI  - © 2016 The Authors and NPS MedicineWise. Published on behalf of the American 
      Heart Association, Inc., by Wiley Blackwell.
FAU - Liu, Zhixin
AU  - Liu Z
AD  - NPS MedicineWise, Sydney, New South Wales, Australia Zhixin.liu@nps.org.au.
FAU - Moorin, Rachael
AU  - Moorin R
AD  - School of Public Health, Curtin University, Perth, Western Australia, Australia.
FAU - Worthington, John
AU  - Worthington J
AD  - Ingham Institute, South Western Sydney Clinical School, University of New South 
      Wales, Sydney, New South Wales, Australia.
FAU - Tofler, Geoffrey
AU  - Tofler G
AD  - Royal North Shore Hospital, University of Sydney, New South Wales, Australia.
FAU - Bartlett, Mark
AU  - Bartlett M
AD  - Sax Institute, Sydney, New South Wales, Australia.
FAU - Khan, Rabia
AU  - Khan R
AD  - NPS MedicineWise, Sydney, New South Wales, Australia.
FAU - Zuo, Yeqin
AU  - Zuo Y
AD  - NPS MedicineWise, Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161013
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases
MH  - Female
MH  - General Practitioners/*education
MH  - Humans
MH  - Information Storage and Retrieval
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Practice Patterns, Physicians'
MH  - *Primary Health Care
MH  - Primary Prevention
MH  - *Quality Improvement
MH  - Risk Assessment
MH  - Stroke/*prevention & control
PMC - PMC5121477
OTO - NOTNLM
OT  - antithrombotic
OT  - health outcomes
OT  - prevention
OT  - primary care
OT  - stroke
EDAT- 2016/10/16 06:00
MHDA- 2017/12/20 06:00
CRDT- 2016/10/15 06:00
PHST- 2016/10/15 06:00 [entrez]
PHST- 2016/10/16 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
AID - JAHA.116.003729 [pii]
AID - JAH31808 [pii]
AID - 10.1161/JAHA.116.003729 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2016 Oct 13;5(10):e003729. doi: 10.1161/JAHA.116.003729.

PMID- 7585778
OWN - NLM
STAT- MEDLINE
DCOM- 19951214
LR  - 20131121
IS  - 0733-8651 (Print)
IS  - 0733-8651 (Linking)
VI  - 13
IP  - 3
DP  - 1995 Aug
TI  - Platelets and platelet inhibitors in acute myocardial infarction.
PG  - 435-47
AB  - Platelets and platelet-rich thrombi play a pivotal role in the pathogenesis of 
      acute myocardial infarction. A ruptured atherosclerotic plaque evokes a 
      hemostatic response that is mediated by platelets, its membrane receptors, 
      adhesive ligands, the presence or generation of platelet agonists, and the 
      activation of the coagulation cascade with fibrin generation. The interaction of 
      platelets with the coagulation and the fibrinolytic systems is complex; new and 
      exciting developments, however, in the ability to pharmacologically control 
      platelet responses during thrombolysis in acute myocardial infarction will 
      enhance our understanding of these interactions and will eventually translate 
      into clinical benefit.
FAU - Kamat, S G
AU  - Kamat SG
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
FAU - Kleiman, N S
AU  - Kleiman NS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cardiol Clin
JT  - Cardiology clinics
JID - 8300331
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - *Blood Platelets
MH  - Humans
MH  - Myocardial Infarction/*blood/*drug therapy
MH  - Platelet Activation
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 139
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
PST - ppublish
SO  - Cardiol Clin. 1995 Aug;13(3):435-47.

PMID- 773034
OWN - NLM
STAT- MEDLINE
DCOM- 19760706
LR  - 20131121
IS  - 0340-1855 (Print)
IS  - 0340-1855 (Linking)
VI  - 34
IP  - 1-2
DP  - 1975 Jan-Feb
TI  - [Evaluation of phenylalkanoic acid derivatives in the management of rheumatic 
      diseases as well as various explanations on the doctrine of clinical research 
      technics].
PG  - 55-67
AB  - The pharmacology and toxicology of the phenylalkanoic derivatives are discussed 
      with particular reference to Ibuprofen. Clinical trials of Ibuprofen are reviewed 
      and their methodology assessed. A more rational approach to anti-inflammatory 
      drug evaluation is suggested and the need for closer international co-operation 
      in establishing a standardized approach to clinical trial methodology is 
      emphasised.
FAU - Sturrock, R D
AU  - Sturrock RD
FAU - Grennan, D
AU  - Grennan D
FAU - Lee, P
AU  - Lee P
FAU - Canes, B A
AU  - Canes BA
FAU - Buchanan, W W
AU  - Buchanan WW
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Eine Bewertung der Phenylalkanoinsüre-Derivate in der Behandlung rheumatischer 
      Erkrankungen sowie einige Erläuterungen zur Lehre der klinischen 
      Versuchsmethoden.
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Phenylacetates)
RN  - 0 (Phenylpropionates)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/therapeutic use
MH  - Chemical Phenomena
MH  - Chemistry
MH  - Clinical Trials as Topic
MH  - Drug Evaluation
MH  - Humans
MH  - Ibuprofen/adverse effects/*therapeutic use
MH  - Phenylacetates/therapeutic use
MH  - Phenylpropionates/*therapeutic use
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Rheumatol. 1975 Jan-Feb;34(1-2):55-67.

PMID- 34784901
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20211214
IS  - 1471-227X (Electronic)
IS  - 1471-227X (Linking)
VI  - 21
IP  - 1
DP  - 2021 Nov 17
TI  - The timing of administering aspirin and nitroglycerin in patients with STEMI ECG 
      changes alter patient outcome.
PG  - 137
LID - 10.1186/s12873-021-00523-2 [doi]
LID - 137
AB  - BACKGROUND: Both chewed aspirin and sublingual nitroglycerin are fast acting 
      medications and reach therapeutic levels within a few minutes. Current guidelines 
      for managing acute coronary syndrome (ACS) do not recognize the importance of the 
      order or timing of administering aspirin and nitroglycerin. This retrospective 
      study aimed to examine if there was any benefit to the timing of giving aspirin 
      before or after nitroglycerin in cases of ACS. METHODS: From the large National 
      Emergency Medical Services Information System (NEMSIS) 2017 Version database, 
      2594 patients with acute coronary syndrome were identified (based on chest pain 
      and their ECG finding) that received aspirin plus nitroglycerin in prehospital 
      settings. Based on which medication was given first, the patients were separated 
      in 2 groups: an aspirin-first and a nitroglycerin-first group. The 2246 patients 
      who received aspirin first were further stratified based on the time between 
      administration of aspirin and the first dose of nitroglycerin. The other 348 
      patients who received nitroglycerin first were similarly stratified. RESULTS: In 
      patients with STEMI ischemia, giving nitroglycerin 10 min after aspirin dosing 
      (compared to giving them simultaneously) leads to a greater than 20% reduction in 
      need for additional nitroglycerin, a greater than 7% decrease in subjective pain 
      experienced by the patient and reduced need for additional opioids. The 
      aspirin-first group in total, had a 39.6% decrease in subjective pain experience 
      after giving additional nitroglycerin compared to nitroglycerin-first group. 
      CONCLUSION: In patients with ACS, this study found that giving nitroglycerin 
      10 min after aspirin was associated with a reduction in subjective pain scores, 
      as well as a reduced need for additional nitroglycerin or opioids. Future 
      prospective trials examining the timing of aspirin vs. nitroglycerin are needed 
      to confirm these findings.
CI  - © 2021. The Author(s).
FAU - Todoroski, Kristijan B
AU  - Todoroski KB
AD  - Family medicine department at univ. St. Kiril and Methodius in Skopje, Republic 
      of North Macedonia, employed at Private family medicine clinic "Azura", Skopje, 
      North Macedonia. dr.todoroski@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20211117
PL  - England
TA  - BMC Emerg Med
JT  - BMC emergency medicine
JID - 100968543
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - Electrocardiography
MH  - Humans
MH  - *Nitroglycerin
MH  - Retrospective Studies
MH  - *ST Elevation Myocardial Infarction
PMC - PMC8597308
COIS- There were no competing interests to declare.
EDAT- 2021/11/18 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/11/17 05:37
PHST- 2021/04/25 00:00 [received]
PHST- 2021/10/19 00:00 [accepted]
PHST- 2021/11/17 05:37 [entrez]
PHST- 2021/11/18 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - 10.1186/s12873-021-00523-2 [pii]
AID - 523 [pii]
AID - 10.1186/s12873-021-00523-2 [doi]
PST - epublish
SO  - BMC Emerg Med. 2021 Nov 17;21(1):137. doi: 10.1186/s12873-021-00523-2.

PMID- 31104194
OWN - NLM
STAT- MEDLINE
DCOM- 20200219
LR  - 20200225
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 48
IP  - 3
DP  - 2019 Oct
TI  - Safety of direct oral anticoagulants versus traditional anticoagulants in venous 
      thromboembolism.
PG  - 439-453
LID - 10.1007/s11239-019-01878-x [doi]
AB  - Venous thromboembolism (VTE) is a leading cause of morbidity and mortality 
      worldwide. For decades, low molecular weight heparins (LMWH) and vitamin 
      K-antagonists have been the gold standard of anticoagulation for VTE. Recently, 
      direct oral anticoagulants (DOACs) that can be administered in fixed doses, 
      without laboratory monitoring and dose adjustment have revolutionized 
      anticoagulation management in VTE. Here, we report on recent evidence regarding 
      the safety of DOACs compared to traditional anticoagulants in surgical and 
      medical prophylaxis as well as in acute and extended treatments of VTE. 
      Additionally, we provide data on special situations such as elderly, cancer and 
      renal impairment patients. Regarding antithrombotic prophylaxis, data are lacking 
      on DOAC use in general surgical patients, while DOACs appear to be more effective 
      than and as safe as LMWHs in VTE prophylaxis for major orthopedic surgical 
      patients. Whether a medically ill patient may benefit from extended VTE 
      prophylaxis remains unclear. In fact, in these patients, DOACs showed an 
      increased risk of bleeding compared to conventional therapy. In the acute 
      treatment of VTE, DOACs were non-inferior and probably safer than conventional 
      anticoagulation therapy while in the extended VTE treatment DOACs were more 
      effective than placebo or aspirin with a comparable risk of major bleeding. These 
      favorable results were also confirmed in elderly, cancer and renal impairment 
      patients. However, further investigations are needed in order to generalize the 
      safe use of DOACs in these specific subgroups of patients.
FAU - Giustozzi, Michela
AU  - Giustozzi M
AUID- ORCID: 0000-0002-8033-4945
AD  - Internal Vascular and Emergency Medicine and Stroke Unit, University of Perugia, 
      Perugia, Italy. michela.giustozzi@unipg.it.
FAU - Franco, Laura
AU  - Franco L
AD  - Internal Vascular and Emergency Medicine and Stroke Unit, University of Perugia, 
      Perugia, Italy.
FAU - Vedovati, Maria Cristina
AU  - Vedovati MC
AD  - Internal Vascular and Emergency Medicine and Stroke Unit, University of Perugia, 
      Perugia, Italy.
FAU - Becattini, Cecilia
AU  - Becattini C
AD  - Internal Vascular and Emergency Medicine and Stroke Unit, University of Perugia, 
      Perugia, Italy.
FAU - Agnelli, Giancarlo
AU  - Agnelli G
AD  - Internal Vascular and Emergency Medicine and Stroke Unit, University of Perugia, 
      Perugia, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Factor Xa Inhibitors/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Heparin, Low-Molecular-Weight/adverse effects/therapeutic use
MH  - Humans
MH  - Neoplasms/complications
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Venous Thromboembolism/*drug therapy/prevention & control
MH  - Warfarin/adverse effects/therapeutic use
OTO - NOTNLM
OT  - Anticoagulation
OT  - Direct oral anticoagulants
OT  - Low-molecular weight heparin
OT  - Thromboprophylaxis
OT  - Venous thromboembolism
OT  - Vitamin K-antagonists
EDAT- 2019/05/20 06:00
MHDA- 2020/02/20 06:00
CRDT- 2019/05/20 06:00
PHST- 2019/05/20 06:00 [pubmed]
PHST- 2020/02/20 06:00 [medline]
PHST- 2019/05/20 06:00 [entrez]
AID - 10.1007/s11239-019-01878-x [pii]
AID - 10.1007/s11239-019-01878-x [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2019 Oct;48(3):439-453. doi: 10.1007/s11239-019-01878-x.

PMID- 2262494
OWN - NLM
STAT- MEDLINE
DCOM- 19910204
LR  - 20161026
IS  - 0021-9509 (Print)
IS  - 0021-9509 (Linking)
VI  - 31
IP  - 6
DP  - 1990 Nov-Dec
TI  - The validity of canine platelet aggregometry in predicting vascular graft 
      patency.
PG  - 712-8
AB  - Several laboratories have found canine platelet aggregometry predictive of 
      thrombotic potential in vascular grafts. Adenosine diphosphate (ADP) is a 
      frequently used agonist, often at unspecified or differing concentrations. This 
      study was designed to evaluate the predictive value of ADP-induced platelet 
      aggregometry and the validity of the methodology. Platelet aggregometry in 
      response to 2 x 10(-5) M ADP was assayed in 70 dogs. Twenty-six percent were 
      aggregators, 51% were non-aggregators, and 20% were indeterminant. All dogs were 
      then treated with aspirin and dipyridamole. Vascular prostheses were implanted 
      bilaterally (aorto-iliac) and anti-platelet therapy continued for two weeks. 
      Dose-response to ADP was studied at three concentrations in 20 dogs. At 2 x 
      10(-5) 1/20 aggregated, at 4 x 10(-5) 3/19 aggregated and at 2 x 10(-4) 15/20 
      aggregated. Time between samples and study was evaluated in 11 dogs, with 2/11 
      changing from non-aggregator to aggregator at two or three hours. Daily 
      reproducibility was studied in 70 dogs, 14 of which changed aggregation status 
      between days. Patency was 58/68 (85%) for non-aggregators, 23/34 (68%) for 
      aggregators (p = 0.038). Platelet aggregometry has significant predictive value 
      for graft patency but methodology must be specified and standardized.
FAU - Greisler, H P
AU  - Greisler HP
AD  - Department of Surgery, Loyola University Medical Center, Maywood, Illinois.
FAU - McGurrin, J F
AU  - McGurrin JF
FAU - Klosak, J J
AU  - Klosak JJ
FAU - Tattersall, C W
AU  - Tattersall CW
FAU - Ellinger, J
AU  - Ellinger J
FAU - Henderson, S C
AU  - Henderson SC
FAU - Cabusao, E A
AU  - Cabusao EA
LA  - eng
GR  - R01 HL41272/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Italy
TA  - J Cardiovasc Surg (Torino)
JT  - The Journal of cardiovascular surgery
JID - 0066127
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/administration & dosage/physiology/therapeutic use
MH  - Animals
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blood Vessel Prosthesis/classification
MH  - Dipyridamole/administration & dosage/therapeutic use
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Evaluation Studies as Topic
MH  - Graft Occlusion, Vascular/blood/drug therapy/*epidemiology
MH  - Platelet Aggregation/drug effects/*physiology
MH  - Platelet Count
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Reproducibility of Results
EDAT- 1990/11/01 00:00
MHDA- 1990/11/01 00:01
CRDT- 1990/11/01 00:00
PHST- 1990/11/01 00:00 [pubmed]
PHST- 1990/11/01 00:01 [medline]
PHST- 1990/11/01 00:00 [entrez]
PST - ppublish
SO  - J Cardiovasc Surg (Torino). 1990 Nov-Dec;31(6):712-8.

PMID- 26929162
OWN - NLM
STAT- MEDLINE
DCOM- 20180816
LR  - 20210109
IS  - 1471-0528 (Electronic)
IS  - 1470-0328 (Print)
IS  - 1470-0328 (Linking)
VI  - 123
IP  - 9
DP  - 2016 Aug
TI  - Low dose aspirin and pregnancy: how important is aspirin resistance?
PG  - 1481-7
LID - 10.1111/1471-0528.13914 [doi]
AB  - Antiplatelet agents are pivotal for prevention of coronary artery disease and 
      cerebrovascular disease worldwide. Individual patient data meta-analysis 
      indicates that low-dose aspirin causes a 10% risk reduction in pre-eclampsia for 
      women at high individual risk. However, in the last 15 years it has emerged that 
      a significant proportion of aspirin-treated individuals exhibit suboptimal 
      platelet response, determined biochemically and clinically, termed 'aspirin 
      non-responsiveness', 'aspirin resistance' and 'aspirin treatment failure'. More 
      recently, investigation of aspirin responsiveness has begun in pregnant women. 
      This review explores the history and clinical relevance of 'aspirin resistance' 
      applied to high-risk obstetric populations. TWEETABLE ABSTRACT: Is 'aspirin 
      resistance' clinically relevant in high-risk obstetrics?
CI  - © 2016 The Authors. BJOG An International Journal of Obstetrics and Gynaecology 
      published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians 
      and Gynaecologists.
FAU - Navaratnam, K
AU  - Navaratnam K
AD  - Centre for Women's Health Research, Institute of Translation Medicine, University 
      of Liverpool, Liverpool, UK.
FAU - Alfirevic, A
AU  - Alfirevic A
AD  - The Wolfson Centre for Personalised Medicine, Institute of Translational 
      Medicine, University of Liverpool, Liverpool, UK.
FAU - Alfirevic, Z
AU  - Alfirevic Z
AD  - Centre for Women's Health Research, Institute of Translation Medicine, University 
      of Liverpool, Liverpool, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160301
PL  - England
TA  - BJOG
JT  - BJOG : an international journal of obstetrics and gynaecology
JID - 100935741
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - BJOG. 2016 Aug;123(9):1488. PMID: 26969603
MH  - Aspirin/*therapeutic use
MH  - *Bleeding Time
MH  - Blood Platelets
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance/genetics/*physiology
MH  - Female
MH  - Humans
MH  - *Medication Adherence
MH  - Pharmacogenomic Variants
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Pre-Eclampsia/*prevention & control
MH  - Pregnancy
MH  - Pregnancy, High-Risk
MH  - Treatment Failure
PMC - PMC5069612
OTO - NOTNLM
OT  - Activation
OT  - aspirin
OT  - platelet
OT  - pre-eclampsia
OT  - pregnancy
OT  - resistance
EDAT- 2016/03/02 06:00
MHDA- 2018/08/17 06:00
CRDT- 2016/03/02 06:00
PHST- 2015/12/26 00:00 [accepted]
PHST- 2016/03/02 06:00 [entrez]
PHST- 2016/03/02 06:00 [pubmed]
PHST- 2018/08/17 06:00 [medline]
AID - BJO13914 [pii]
AID - 10.1111/1471-0528.13914 [doi]
PST - ppublish
SO  - BJOG. 2016 Aug;123(9):1481-7. doi: 10.1111/1471-0528.13914. Epub 2016 Mar 1.

PMID- 21658022
OWN - NLM
STAT- MEDLINE
DCOM- 20120515
LR  - 20211020
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 165
IP  - 4b
DP  - 2012 Feb
TI  - Nitroxide derivatives of non-steroidal anti-inflammatory drugs exert 
      anti-inflammatory and superoxide dismutase scavenging properties in A459 cells.
PG  - 1058-67
LID - 10.1111/j.1476-5381.2011.01527.x [doi]
AB  - BACKGROUND AND PURPOSE: Inflammation and reactive oxygen species are associated 
      with the promotion of various cancers. The use of non-steroidal anti-inflammatory 
      drugs (NSAIDs) in cancer prevention treatments has been promising in numerous 
      cancers. We report the evaluation of NSAIDs chemically modified by the addition 
      of a redox-active nitroxide group. TEMPO-aspirin (TEMPO-ASA) and 
      TEMPO-indomethacin (TEMPO-IND) were synthesized and evaluated in the lung cancer 
      cell line A549. EXPERIMENTAL APPROACHES: We evaluated physico-chemical properties 
      of TEMPO-ASA and TEMPO-IND by electron paramagnetic resonance and cyclic 
      voltammetry. Superoxide dismutase-like properties was assayed by measuring 
      cytochrome c reduction and anti-inflammatory effects were assayed by measuring 
      production of prostaglandin E(2) (PGE(2) ) and leukotriene B(4) (LTB(4) ). MTT 
      proliferation assay and clonogenic assay were evaluated in the A549 lung 
      carcinoma cell line. Maximum tolerated doses (MTD) and acute ulcerogenic index 
      were also evaluated in in vivo. KEY RESULTS: MTD were: TEMPO (140 mg·kg(-1) ), 
      ASA (100 mg·kg(-1) ), indomethacin (5 mg·kg(-1) ), TEMPO-ASA (100 mg·kg(-1) ) and 
      TEMPO-IND (40 mg·kg(-1) ). While TEMPO-ASA was as well tolerated as ASA, 
      TEMPO-IND showed an eightfold improvement over indomethacin. TEMPO-IND showed 
      markedly less gastric toxicity than the parent NSAID. Both TEMPO-ASA and 
      TEMPO-IND inhibited production of PGE(2) and LTB(4) in A549 cells with maximum 
      effects at 100 µg·mL(-1) or 10 µg·mL(-1) respectively. CONCLUSIONS AND 
      IMPLICATIONS: The nitroxide-NSAIDs retained superoxide scavenging capacity of the 
      parent nitroxide and anti-inflammatory effects, inhibiting cyclooxygenase and 
      5-lipoxygenase enzymes. These redox-modified NSAIDs might be potential drug 
      candidates, as they exhibit the pharmacological properties of the parent NSAID 
      with antioxidant activity decreasing NSAID-associated toxicity.
CI  - Published 2011. This article is a U.S. Government work and is in the public 
      domain in the USA.
FAU - Flores-Santana, Wilmarie
AU  - Flores-Santana W
AD  - Radiation Biology Branch National Cancer Institute, National Institutes of 
      Health, Bethesda, MD 20892, USA.
FAU - Moody, Terry
AU  - Moody T
FAU - Chen, Weibin
AU  - Chen W
FAU - Gorczynski, Michael J
AU  - Gorczynski MJ
FAU - Shoman, Mai E
AU  - Shoman ME
FAU - Velázquez, Carlos
AU  - Velázquez C
FAU - Thetford, Angela
AU  - Thetford A
FAU - Mitchell, James B
AU  - Mitchell JB
FAU - Cherukuri, Murali K
AU  - Cherukuri MK
FAU - King, S Bruce
AU  - King SB
FAU - Wink, David A
AU  - Wink DA
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antioxidants)
RN  - 0 (Cyclic N-Oxides)
RN  - 1HGW4DR56D (Leukotriene B4)
RN  - 9000-07-1 (Carrageenan)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - VQN7359ICQ (TEMPO)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/chemistry/*pharmacology/toxicity
MH  - Antioxidants/chemistry/*pharmacology/toxicity
MH  - Aspirin/chemistry/*pharmacology/toxicity
MH  - Carrageenan
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Cyclic N-Oxides/chemistry/*pharmacology/toxicity
MH  - Dinoprostone/metabolism
MH  - Disease Models, Animal
MH  - Edema/chemically induced/drug therapy
MH  - Female
MH  - Humans
MH  - Indomethacin/chemistry/*pharmacology/toxicity
MH  - Leukotriene B4/metabolism
MH  - Mice
MH  - Mice, Nude
MH  - Rats
MH  - Stomach Ulcer/chemically induced/drug therapy
MH  - Superoxide Dismutase/metabolism
PMC - PMC3346241
EDAT- 2011/06/11 06:00
MHDA- 2012/05/16 06:00
CRDT- 2011/06/11 06:00
PHST- 2011/06/11 06:00 [entrez]
PHST- 2011/06/11 06:00 [pubmed]
PHST- 2012/05/16 06:00 [medline]
AID - 10.1111/j.1476-5381.2011.01527.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 2012 Feb;165(4b):1058-67. doi: 10.1111/j.1476-5381.2011.01527.x.

PMID- 3475541
OWN - NLM
STAT- MEDLINE
DCOM- 19870909
LR  - 20191029
IS  - 0742-2814 (Print)
IS  - 0742-2814 (Linking)
VI  - 7
IP  - 2
DP  - 1986 Mar-Apr
TI  - The effect of aspirin on serum immunoglobulins.
PG  - 113-6
AB  - After discontinuing aspirin products for seven days, 21 aspirin tolerant adults 
      were given 650 mg of aspirin daily for one week. Serum immunoglobulins (IgG, IgA, 
      IgM, and IgE), complete blood count (CBC), and total eosinophil counts (TEC) were 
      determined before aspirin challenge, four hours after initial challenge, on day 
      seven of aspirin ingestion, 24 hours after discontinuing aspirin, and three weeks 
      after discontinuing aspirin. No significant changes were noted in any of these 
      categories. Although aspirin is an anti-inflammatory drug similar to 
      corticosteroids, it does not produce immunological changes that corticosteroids 
      produce as determined by these parameters.
FAU - Waters, E
AU  - Waters E
FAU - Browne, S
AU  - Browne S
FAU - Settipane, G A
AU  - Settipane GA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - N Engl Reg Allergy Proc
JT  - New England and regional allergy proceedings
JID - 8306562
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Immunoglobulins)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Humans
MH  - Immunoglobulin A/drug effects
MH  - Immunoglobulin E/drug effects
MH  - Immunoglobulin G/drug effects
MH  - Immunoglobulin M/drug effects
MH  - Immunoglobulins/*drug effects/metabolism
EDAT- 1986/03/01 00:00
MHDA- 1986/03/01 00:01
CRDT- 1986/03/01 00:00
PHST- 1986/03/01 00:00 [pubmed]
PHST- 1986/03/01 00:01 [medline]
PHST- 1986/03/01 00:00 [entrez]
AID - 10.2500/108854186779047735 [doi]
PST - ppublish
SO  - N Engl Reg Allergy Proc. 1986 Mar-Apr;7(2):113-6. doi: 
      10.2500/108854186779047735.

PMID- 8790077
OWN - NLM
STAT- MEDLINE
DCOM- 19961009
LR  - 20151119
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 156
IP  - 16
DP  - 1996 Sep 9
TI  - The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality 
      of life.
PG  - 1829-36
AB  - BACKGROUND: Because most strokes cause neurological impairment rather than death, 
      stroke prophylaxis may improve quality of life more than length of life. Thus, an 
      understanding of how stroke and stroke prophylaxis affect quality of life is 
      central to clinical decision making for many patients. METHODS: We elicited 
      quality-of-life estimates, known as utilities, for 3 degrees of severity of 
      anticipated stroke-mild, moderate, and major- and for stroke prophylaxis with 
      either warfarin sodium or aspirin therapy. We used the time tradeoff and standard 
      gamble methods to elicit these utilities from 83 patients who had atrial 
      fibrillation. RESULTS: Seventy patients completed the interview successfully. 
      Their utilities for stroke ranged from worse than death (< 0) to as good as 
      current health (1.0). The median utilities for mild, moderate, and major stroke 
      were 0.94, 0.07, and 0.0, respectively. Although the median utilities decreased 
      with increasing severity of stroke (P < .001), there was high interpatient 
      variability within each degree of stroke severity. For example, 7 subjects (10%) 
      rated a major stroke above 0.5, while 58 subjects (83%) rated it as equal to or 
      worse than death. In contrast to the stroke utilities, the median utilities for 
      warfarin and aspirin therapy were high-0.997 and 1.0, respectively. However, the 
      interpatient variability for warfarin therapy was also important: 11 patients 
      (16%) with atrial fibrillation rated the utility of warfarin therapy so low that 
      their quality-adjusted life expectancy would be greater with aspirin. CONCLUSION: 
      Patients' utilities for stroke prophylaxis and anticipated stroke vary 
      substantially. Many patients view the quality of life with major stroke as 
      tantamount to or worse than death. These findings highlight the relevance of 
      incorporating patient preferences when choosing stroke prophylaxis.
FAU - Gage, B F
AU  - Gage BF
AD  - Division of General Medical Sciences, Washington University, St Louis, Mo, USA.
FAU - Cardinalli, A B
AU  - Cardinalli AB
FAU - Owens, D K
AU  - Owens DK
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cerebrovascular Disorders/*prevention & control
MH  - Female
MH  - *Health Status
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Quality of Life
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Warfarin/*therapeutic use
EDAT- 1996/09/09 00:00
MHDA- 1996/09/09 00:01
CRDT- 1996/09/09 00:00
PHST- 1996/09/09 00:00 [pubmed]
PHST- 1996/09/09 00:01 [medline]
PHST- 1996/09/09 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1996 Sep 9;156(16):1829-36.

PMID- 23840362
OWN - NLM
STAT- MEDLINE
DCOM- 20140205
LR  - 20220408
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as 
      compared to aspirin alone after stroke or TIA: a systematic review.
PG  - e65754
LID - 10.1371/journal.pone.0065754 [doi]
LID - e65754
AB  - BACKGROUND AND PURPOSE: Given the high risk of stroke after TIA (transient 
      ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, 
      we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) 
      comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy 
      and adverse reaction of bleeding of the two protocols in the prevention of 
      stroke. METHODS: We analyzed the incidences of stroke, bleeding and severe 
      bleeding by using fixed-effect model or random-effect model on the basis of the 
      result of heterogeneity test. RESULTS: Five qualified RCTs satisfied the 
      inclusion criteria. We found that treatment with aspirin plus clopidogrel was 
      associated with lower incidence of stroke (Risk Ratio (RR), 0.66, 95% confidence 
      interval (CI), 0.47 to 0.93), higher incidence of bleeding (RR, 1.75, 95% CI, 
      1.48 to 2.05) as compared with aspirin-alone treatment. In terms of severe 
      bleeding, no statistical difference existed between them (RR, 2.21, 95% CI, 0.25 
      to 19.52). CONCLUSION: The combined use of aspirin and clopidogrel is more 
      effective than aspirin alone for patients with previous TIA or stroke for the 
      prevention of stroke, with risk of bleeding being higher. No statistical 
      difference was found in severe bleeding between the two treatment protocols.
FAU - Huang, Yan
AU  - Huang Y
AD  - Department of Neurology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Li, Man
AU  - Li M
FAU - Li, Jian-Yong
AU  - Li JY
FAU - Li, Min
AU  - Li M
FAU - Xia, Yuan-Peng
AU  - Xia YP
FAU - Mao, Ling
AU  - Mao L
FAU - Hu, Bo
AU  - Hu B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20130620
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Bleeding Time
MH  - Clopidogrel
MH  - Hemorrhage/physiopathology
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy/prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/*drug therapy/prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
PMC - PMC3688690
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2013/07/11 06:00
MHDA- 2014/02/06 06:00
CRDT- 2013/07/11 06:00
PHST- 2013/01/16 00:00 [received]
PHST- 2013/04/29 00:00 [accepted]
PHST- 2013/07/11 06:00 [entrez]
PHST- 2013/07/11 06:00 [pubmed]
PHST- 2014/02/06 06:00 [medline]
AID - PONE-D-13-02390 [pii]
AID - 10.1371/journal.pone.0065754 [doi]
PST - epublish
SO  - PLoS One. 2013 Jun 20;8(6):e65754. doi: 10.1371/journal.pone.0065754. Print 2013.

PMID- 16718820
OWN - NLM
STAT- MEDLINE
DCOM- 20060718
LR  - 20190430
IS  - 1007-9327 (Print)
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 12
IP  - 18
DP  - 2006 May 14
TI  - Incidence and predictors of upper gastrointestinal bleeding in patients receiving 
      low-dose aspirin for secondary prevention of cardiovascular events in patients 
      with coronary artery disease.
PG  - 2923-7
AB  - AIM: The use of low-dose aspirin to prevent cardiovascular disease events is well 
      established. However, the incidence and predictors of upper gastrointestinal 
      bleeding (UGIB) with its use are unknown. We studied prospectively the incidence 
      and outcome of peptic ulceration in low-dose aspirin users. METHODS: A total of 
      991 patients with coronary artery disease (CAD) on low-dose aspirin were 
      prospectively followed-up for two years for the occurrence and clinical features 
      of first hospitalized episode of UGIB. RESULTS: UGIB had a bimodal presentation 
      with 45% occurring within four months of aspirin initiation and had an overall 
      prevalence of 1.5% per year. There was no UGIB-related death. Hypertension (OR = 
      4.6, 95%CI 1.5-14.7, P = 0.009), history of peptic ulceration (OR = 3.1, 95%CI 
      1.1-9.0, P = 0.039), tertiary education (OR = 3.08, 95%CI 1.1-9.0, P = 0.039) and 
      higher lean body mass (P = 0.016) were independent factors associated with UGIB. 
      Use of nitrate did not reduce UGIB. CONCLUSION: The incidence of UGIB in patients 
      with CAD on long-term low-dose aspirin is low, but is accompanied with 
      significant morbidity. With prolonged use of aspirin, UGIB continues to be a 
      problem for those with risk factors and especially in patients with a history of 
      peptic ulcers, in which UGIB tends to occur early after aspirin therapy.
FAU - Ng, William
AU  - Ng W
AD  - Division of Cardiology, University Department of Medicine, Queen Mary Hospital, 
      Pokfulam Road, Hong Kong SAR, China.
FAU - Wong, Wai-Man
AU  - Wong WM
FAU - Chen, Wai-Hong
AU  - Chen WH
FAU - Tse, Hung-Fat
AU  - Tse HF
FAU - Lee, Pui-Yin
AU  - Lee PY
FAU - Lai, Kam-Chuen
AU  - Lai KC
FAU - Li, Sheung-Wai
AU  - Li SW
FAU - Ng, Matthew
AU  - Ng M
FAU - Lam, Kwok-Fai
AU  - Lam KF
FAU - Cheng, Xi
AU  - Cheng X
FAU - Lau, Chu-Pak
AU  - Lau CP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*adverse effects/*therapeutic use
MH  - Body Mass Index
MH  - Comorbidity
MH  - Coronary Artery Disease/epidemiology/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gastrointestinal Hemorrhage/*chemically induced/epidemiology/physiopathology
MH  - Humans
MH  - Hypertension/complications
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Peptic Ulcer/complications
MH  - Predictive Value of Tests
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Factors
MH  - Secondary Prevention
PMC - PMC4087812
EDAT- 2006/05/24 09:00
MHDA- 2006/07/19 09:00
CRDT- 2006/05/24 09:00
PHST- 2006/05/24 09:00 [pubmed]
PHST- 2006/07/19 09:00 [medline]
PHST- 2006/05/24 09:00 [entrez]
AID - 10.3748/wjg.v12.i18.2923 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2006 May 14;12(18):2923-7. doi: 10.3748/wjg.v12.i18.2923.

PMID- 4002268
OWN - NLM
STAT- MEDLINE
DCOM- 19850717
LR  - 20190727
IS  - 0039-2499 (Print)
IS  - 0039-2499 (Linking)
VI  - 16
IP  - 3
DP  - 1985 May-Jun
TI  - Multiple transient ischemic attacks, lupus anticoagulant and verrucous 
      endocarditis.
PG  - 512-4
AB  - A young adult with lupus anticoagulant and systemic lupus erythematosus had onset 
      of multiple transient ischemic attacks four years after a major left hemispheric 
      infarct. The symptoms were stereotyped, recurred several times daily over three 
      years and ceased when aspirin was added to steroid therapy. It is speculated that 
      her symptoms were due to recurrent embolism from the heart in the presence of a 
      thrombotic state.
FAU - D'Alton, J G
AU  - D'Alton JG
FAU - Preston, D N
AU  - Preston DN
FAU - Bormanis, J
AU  - Bormanis J
FAU - Green, M S
AU  - Green MS
FAU - Kraag, G R
AU  - Kraag GR
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/etiology
MH  - Endocarditis/*complications
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/*etiology/prevention & control
MH  - Lupus Erythematosus, Systemic/*complications
MH  - Prednisone/therapeutic use
MH  - Thromboembolism/complications
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
AID - 10.1161/01.str.16.3.512 [doi]
PST - ppublish
SO  - Stroke. 1985 May-Jun;16(3):512-4. doi: 10.1161/01.str.16.3.512.

PMID- 6732381
OWN - NLM
STAT- MEDLINE
DCOM- 19840713
LR  - 20190812
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 144
IP  - 6
DP  - 1984 Jun
TI  - Case-control research. Temporal precedence and other problems of the 
      exposure-disease relationship.
PG  - 1257-9
AB  - We assessed the principle of temporal precedence in recent case-control studies 
      demonstrating the alleged associations between tampon use and toxic shock 
      syndrome and between aspirin use and Reye's syndrome. For both relationships, we 
      considered four components of the exposure-disease association, including: (1) 
      establishing that the agent preceded the disease, (2) selecting an index time, 
      (3) defining criteria for classifying a patient as "exposed," and (4) avoiding 
      the bias that occurs when use of the etiologic agent was influenced by an early 
      manifestation of the disease. The problems can be minimized by interviewing 
      patients early during the course of their illness and by improving strategies for 
      data analysis.
FAU - Horwitz, R I
AU  - Horwitz RI
FAU - Feinstein, A R
AU  - Feinstein AR
FAU - Harvey, M R
AU  - Harvey MR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects
MH  - Child
MH  - *Epidemiologic Methods
MH  - Female
MH  - Humans
MH  - Research Design
MH  - Reye Syndrome/etiology
MH  - Risk
MH  - Shock, Septic/etiology
MH  - Tampons, Surgical/adverse effects
MH  - Time Factors
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
AID - 10.1001/archinte.144.6.1257 [doi]
PST - ppublish
SO  - Arch Intern Med. 1984 Jun;144(6):1257-9. doi: 10.1001/archinte.144.6.1257.

PMID- 831454
OWN - NLM
STAT- MEDLINE
DCOM- 19770224
LR  - 20221207
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 67
IP  - 1
DP  - 1977 Jan
TI  - Granulocyte adherence in the elderly.
PG  - 49-52
AB  - Granulocyte adherence was measured in blood samples from 57 subjects more than 60 
      years old and 50 subjects 11 to 59 years old. In contrast to mean hemoglobin 
      levels, leukocyte counts, and neutrophil counts, which were lower in the samples 
      from the older group, granulocyte adherence was greater for the older subjects 
      (mean = 78.4%) than for the younger subjects (mean = 65.7%). Ingested aspirin, 
      chlorothiazides, methyldopa, digitalis, antihistamines, and barbiturates had no 
      effect on granulocyte adherence. Alcohol ingestion within 24 hours was associated 
      with reduced granulocyte adherence in the older group. Granulocyte adherence was 
      slightly greater for aged black than for aged white subjects, but the difference 
      was not statistically significant. Granulocytes of women showed greater adherence 
      than those of men, and this difference persisted after menopause into the ninth 
      decade of life.
FAU - Silverman, E M
AU  - Silverman EM
FAU - Silverman, A G
AU  - Silverman AG
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Aging
MH  - Aspirin/pharmacology
MH  - Black People
MH  - Cell Adhesion/drug effects
MH  - Child
MH  - Female
MH  - Granulocytes/drug effects/*physiology
MH  - Humans
MH  - Leukocyte Count
MH  - Leukocytes/*physiology
MH  - Male
MH  - Middle Aged
MH  - White People
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
AID - 10.1093/ajcp/67.1.49 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 1977 Jan;67(1):49-52. doi: 10.1093/ajcp/67.1.49.

PMID- 32612060
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20200921
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 140
IP  - 7
DP  - 2020
TI  - [Is Concomitant Therapy with Acetaminophen and Low-dose Aspirin a Risk Factor for 
      CKD Progression? A 6-Year Cohort Study].
PG  - 943-947
LID - 10.1248/yakushi.20-00010 [doi]
AB  - Concomitant therapy with acetaminophen (APAP) and low-dose aspirin is often used 
      in clinical settings; however, it is unclear whether this combination is involved 
      in the progression of chronic kidney disease (CKD). We hypothesized that 
      concomitant therapy with APAP and low-dose aspirin may cause CKD progression. We 
      carried out a retrospective 6-year cohort study that included all patients who 
      received low-dose aspirin from January 2011 to December 2016 at Kaetsu Hospital. 
      Primary outcome was defined as CKD progression at the end of the study compared 
      with baseline. Among the 441 patients treated during the study period, we 
      identified 89 cases of CKD progression. Multivariate regression analysis showed 
      that exposure to APAP>50 g [odds ratio (OR), 2.68, 95% confidence interval (CI), 
      1.08-6.70], age increase by 1 year (OR, 1.05, 95% CI, 1.02-1.08), and diabetes 
      mellitus (OR, 2.40, 95% CI, 1.41-4.08) had positive associations with CKD 
      progression. Our findings suggested that concomitant therapy with APAP and 
      low-dose aspirin increased the risk of CKD progression. Therefore, we recommend 
      more thorough monitoring of serum creatinine when patients are on such 
      concomitant therapy. Moreover, it is important to advise users of low-dose 
      aspirin to avoid unnecessary use of APAP, in order to reduce the risk of CKD 
      progression.
FAU - Mitsuboshi, Satoru
AU  - Mitsuboshi S
AD  - Department of Pharmacy, Kaetsu Hospital.
FAU - Yamada, Hitoshi
AU  - Yamada H
AD  - Department of Pharmacy, Kaetsu Hospital.
FAU - Yamazaki, Shuji
AU  - Yamazaki S
AD  - Department of Pharmacy, Kaetsu Hospital.
FAU - Kobayashi, Mariko
AU  - Kobayashi M
AD  - Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied 
      Life Sciences.
FAU - Ueno, Kazuyuki
AU  - Ueno K
AD  - Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied 
      Life Sciences.
FAU - Nagai, Kazuhiko
AU  - Nagai K
AD  - Department of Pharmacy, Kaetsu Hospital.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Biomarkers)
RN  - 362O9ITL9D (Acetaminophen)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetaminophen/administration & dosage/*adverse effects
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Biomarkers
MH  - Creatinine/blood
MH  - Diabetes Complications
MH  - Disease Progression
MH  - Drug Therapy, Combination/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Renal Insufficiency, Chronic/*chemically induced/diagnosis/prevention & control
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - acetaminophen
OT  - aspirin
OT  - chronic kidney disease
OT  - concomitant
EDAT- 2020/07/03 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1248/yakushi.20-00010 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2020;140(7):943-947. doi: 10.1248/yakushi.20-00010.

PMID- 18663233
OWN - NLM
STAT- MEDLINE
DCOM- 20080820
LR  - 20220317
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 31
IP  - 8
DP  - 2008 Aug
TI  - The impact of prevention on reducing the burden of cardiovascular disease.
PG  - 1686-96
LID - 10.2337/dc08-9022 [doi]
AB  - OBJECTIVE: Cardiovascular disease (CVD) is prevalent and expensive. While many 
      interventions are recommended to prevent CVD, the potential effects of a 
      comprehensive set of prevention activities on CVD morbidity, mortality, and costs 
      have never been evaluated. We therefore determined the effects of 11 nationally 
      recommended prevention activities on CVD-related morbidity, mortality, and costs 
      in the U.S. RESEARCH DESIGN AND METHODS: We used person-specific data from a 
      representative sample of the U.S. population (National Health and Nutrition 
      Education Survey IV) to determine the number and characteristics of adults aged 
      20-80 years in the U.S. today who are candidates for different prevention 
      activities related to CVD. We used the Archimedes model to create a simulated 
      population that matched the real U.S. population, person by person. We then used 
      the model to simulate a series of clinical trials that examined the effects over 
      the next 30 years of applying each prevention activity one by one, or altogether, 
      to those who are candidates for the various activities and compared the health 
      outcomes, quality of life, and direct medical costs to current levels of 
      prevention and care. We did this under two sets of assumptions about performance 
      and compliance: 100% success for each activity and lower levels of success 
      considered aggressive but still feasible. RESULTS: Approximately 78% of adults 
      aged 20-80 years alive today in the U.S. are candidates for at least one 
      prevention activity. If everyone received the activities for which they are 
      eligible, myocardial infarctions and strokes would be reduced by approximately 
      63% and 31%, respectively. If more feasible levels of performance are assumed, 
      myocardial infarctions and strokes would be reduced approximately 36% and 20%, 
      respectively. Implementation of all prevention activities would add approximately 
      221 million life-years and 244 million quality-adjusted life-years to the U.S. 
      adult population over the coming 30 years, or an average of 1.3 years of life 
      expectancy for all adults. Of the specific prevention activities, the greatest 
      benefits to the U.S. population come from providing aspirin to high-risk 
      individuals, controlling pre-diabetes, weight reduction in obese individuals, 
      lowering blood pressure in people with diabetes, and lowering LDL cholesterol in 
      people with existing coronary artery disease (CAD). As currently delivered and at 
      current prices, most prevention activities are expensive when considering direct 
      medical costs; smoking cessation is the only prevention strategy that is 
      cost-saving over 30 years. CONCLUSIONS: Aggressive application of nationally 
      recommended prevention activities could prevent a high proportion of the CAD 
      events and strokes that are otherwise expected to occur in adults in the U.S. 
      today. However, as they are currently delivered, most of the prevention 
      activities will substantially increase costs. If preventive strategies are to 
      achieve their full potential, ways must be found to reduce the costs and deliver 
      prevention activities more efficiently.
FAU - Kahn, Richard
AU  - Kahn R
AD  - American Diabetes Association, Alexandria, Virginia, USA. rkahn@diabetes.org
FAU - Robertson, Rose Marie
AU  - Robertson RM
FAU - Smith, Robert
AU  - Smith R
FAU - Eddy, David
AU  - Eddy D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/economics/*prevention & control
MH  - Clinical Trials as Topic
MH  - *Cost of Illness
MH  - Costs and Cost Analysis
MH  - Diabetic Angiopathies/economics/prevention & control
MH  - Humans
MH  - United States
PMC - PMC2494659
EDAT- 2008/07/30 09:00
MHDA- 2008/08/21 09:00
CRDT- 2008/07/30 09:00
PHST- 2008/07/30 09:00 [pubmed]
PHST- 2008/08/21 09:00 [medline]
PHST- 2008/07/30 09:00 [entrez]
AID - 31/8/1686 [pii]
AID - 3181686 [pii]
AID - 10.2337/dc08-9022 [doi]
PST - ppublish
SO  - Diabetes Care. 2008 Aug;31(8):1686-96. doi: 10.2337/dc08-9022.

PMID- 1616328
OWN - NLM
STAT- MEDLINE
DCOM- 19920727
LR  - 20190503
IS  - 0003-4967 (Print)
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 51
IP  - 5
DP  - 1992 May
TI  - Inhibition by prostaglandin E1 and E2 of 1,25-dihydroxyvitamin D3 synthesis by 
      synovial fluid macrophages from arthritic joints.
PG  - 632-7
AB  - Previous work has shown that renal metabolism of 25-dihydroxyvitamin D3 
      (25(OH)D3) to the active metabolite, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) is 
      stimulated by prostaglandin E2 and inhibited by acetylsalicylate (aspirin). As 
      prostaglandins are primary inflammatory mediators and synovial fluid macrophages 
      are known to synthesise 1,25(OH)2D3 in vitro, the effects of prostaglandin E1, 
      prostaglandin E2, and aspirin on the metabolism of 25(OH)D3 by cells cultured 
      from synovial fluid of patients with inflammatory arthritis were investigated. 
      Most cultures contained non-proliferating macrophages which formed 1,25(OH)2D3; 
      however, two of 13 cultures contained colonies of rapidly proliferating 
      fibroblast-like cells which formed 24,25(OH)2D3 (24,25(OH)2D3). Prostaglandin E1 
      and prostaglandin E2 (0.01-10 mumol/l) induced marked inhibition of 1,25(OH)2D3 
      synthesis (up to 94%) in a dose dependent manner after preincubations of 24 hours 
      but not over straightforward six hour incubations. Exposure of macrophages to 
      aspirin (1 mumol/l-1 mmol/l) for 24 hours did not affect 1,25(OH)2D3 synthesis 
      unless the cells had been pretreated with lipopolysaccharides, in which instance 
      1 mM aspirin increased 1,25(OH)2D3 synthesis. Lipopolysaccharide is a macrophage 
      activating factor which stimulates macrophages to form 1,25(OH)2D3, and it also 
      induces prostaglandin synthesis which would be inhibited by aspirin. Taken 
      together these results suggest that prostaglandin E1 and prostaglandin E2 
      synthesised by macrophages may act in an autocrine manner to attenuate the 
      ability of macrophage activating factors, such as lipopolysaccharide, to 
      stimulate 1,25(OH)2D3 synthesis. Prostaglandins synthesised by other inflammatory 
      cells may also inhibit 1,25(OH)2D3 synthesis in a paracrine manner. In contrast, 
      prostaglandin E2 and aspirin had limited effects on fibroblast 24,25(OH)2D3 
      synthesis. This study shows that the effects of prostaglandin E1, prostaglandin 
      E2, and aspirin in macrophages contrast with those previously reported for the 
      renal 25(OH)D3-1alpha-hydroxylase, where prostaglandin E2 stimulated and aspirin 
      inhibited enzyme activity. These results further emphasise that synthesis of 
      1,25(OH)2D3 in non-renal sites is independently regulated, which is consistent 
      with it having an immunological role at a local level rather than playing a part 
      in systemic calcium homeostasis.
FAU - Hayes, M E
AU  - Hayes ME
AD  - Manchester University Bone Disease Research Centre, United Kingdom.
FAU - Rai, A
AU  - Rai A
FAU - Cooper, R G
AU  - Cooper RG
FAU - Bayley, D
AU  - Bayley D
FAU - Freemont, A J
AU  - Freemont AJ
FAU - Mawer, E B
AU  - Mawer EB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - F5TD010360 (Alprostadil)
RN  - FXC9231JVH (Calcitriol)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Alprostadil/metabolism/*pharmacology
MH  - Arthritis/*metabolism
MH  - Aspirin/metabolism/pharmacology
MH  - Calcitriol/antagonists & inhibitors/*biosynthesis
MH  - Chromatography, High Pressure Liquid
MH  - Dinoprostone/metabolism/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Knee Joint/metabolism
MH  - Macrophages/metabolism
MH  - Synovial Fluid/*metabolism
PMC - PMC1005696
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
AID - 10.1136/ard.51.5.632 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 1992 May;51(5):632-7. doi: 10.1136/ard.51.5.632.

PMID- 32755422
OWN - NLM
STAT- MEDLINE
DCOM- 20201228
LR  - 20220417
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 18
IP  - 9
DP  - 2020 Sep
TI  - Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with 
      stable atherosclerotic disease: a comprehensive review.
PG  - 577-585
LID - 10.1080/14779072.2020.1806712 [doi]
AB  - INTRODUCTION: Cardiovascular disease is the leading cause of morbidity and 
      mortality in adults in western nations. In the last decades, tremendous research 
      has been conducted in the field of secondary prevention in order to reduce 
      recurrent cardiovascular events. This review summarizes the novel dual pathway 
      concept of aspirin and very low-dose rivaroxaban, from mechanisms to clinical 
      practice. AREAS COVERED: The COMPASS trial demonstrated that in patients with 
      stable atherosclerotic disease, very low-dose rivaroxaban, a direct factor Xa 
      inhibitor, when combined with aspirin, reduced the rate of recurrent ischemic 
      events, at the cost of increased bleeding. This effect was present in patients 
      with ischemic heart disease, as well as in patients with atherosclerosis in other 
      beds, such as in peripheral arterial disease. Sub-studies from the COMPASS trial 
      examined other high-risk populations who might benefit the most from this 
      regimen. EXPERT OPINION: There are currently multiple antiplatelet and 
      anticoagulation treatment regimens for patients with stable atherosclerotic 
      disease. The dual pathway concept is a novel approach that combines both 
      mechanisms. Identifying patients who might benefit the most in terms of ischemic 
      events at the least bleeding events still remains a challenge, yet prescribing 
      this combination to high-risk patients might be the most effective.
FAU - Parascandolo, Eliot
AU  - Parascandolo E
AD  - Cardiology Department, Rabin Medical Center , Petah Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv, Israel.
FAU - Eisen, Alon
AU  - Eisen A
AD  - Cardiology Department, Rabin Medical Center , Petah Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv, Israel.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200905
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Atherosclerosis/drug therapy
MH  - Drug Therapy, Combination
MH  - Factor Xa Inhibitors/therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Peripheral Arterial Disease/drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Rivaroxaban/*therapeutic use
MH  - Secondary Prevention
OTO - NOTNLM
OT  - Chronic coronary syndrome
OT  - atherosclerotic disease
OT  - cardiovascular therapy
OT  - compass trial
OT  - coronary artery disease
OT  - peripheral artery disease
OT  - rivaroxaban
OT  - secondary prevention
EDAT- 2020/08/07 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/08/07 06:00 [entrez]
AID - 10.1080/14779072.2020.1806712 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2020 Sep;18(9):577-585. doi: 
      10.1080/14779072.2020.1806712. Epub 2020 Sep 5.

PMID- 17909705
OWN - NLM
STAT- MEDLINE
DCOM- 20080319
LR  - 20211020
IS  - 1828-0447 (Print)
IS  - 1828-0447 (Linking)
VI  - 2
IP  - 3
DP  - 2007 Oct
TI  - Triple therapy of warfarin, aspirin and a thienopyridine for patients treated 
      with vitamin K antagonists undergoing coronary stenting. A review of the 
      evidence.
PG  - 177-81
AB  - Dual antiplatelet treatment of aspirin and a thienopyridine (either ticlopidine 
      or clopidogrel) is the standard of care in patients undergoing coronary artery 
      stenting (PCI-S). Such treatment however, is not generally applicable in patients 
      with concomitant indication for vitamin K antagonists (VKA), in whom therefore 
      the optimal treatment is currently undefined. According to the limited available 
      evidence, the management of these patients is substantially variable, but triple 
      therapy of VKA, aspirin and a thienopyridine is the most frequently adopted. Both 
      VKA and dual antiplatelet treatment in fact are warranted to actually prevent 
      systemic thromboembolism and stent thrombosis, although an increased haemorrhagic 
      risk might be associated with such therapy. A substantial incidence of bleeding 
      has been effectively observed with triple therapy in a few, small, retrospective, 
      observational series. The risk of haemorrhage appears to increase with the 
      duration of treatment, although concomitant factors (i.e., advanced age, presence 
      of gastrointestinal lesions, excessive anticoagulation or traumatic manoeuvres), 
      rather than the administration of numerous antithrombotic agents in itself, may 
      play a role. As expected, no thromboembolic or thrombotic events have been 
      generally reported with such treatment. Because of the limited and poor quality 
      data currently available on the management of patients with an indication for VKA 
      undergoing PCI-S, large-scale registries and clinical trials are warranted to 
      determine the optimal antithrombotic treatment in this patient subset, which is 
      foreseen to progressively increase over the next years.
FAU - Rubboli, A
AU  - Rubboli A
AD  - Cardiac Catheterization Laboratory, Division of Cardiology, Maggiore Hospital, 
      Bologna, Italy. andrearubboli@libero.it
FAU - Di Pasquale, G
AU  - Di Pasquale G
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20071001
PL  - Italy
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Intern Emerg Med. 2007 Oct;2(3):163-4. PMID: 17909706
MH  - Angioplasty, Balloon, Coronary
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - *Drug Therapy, Combination
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pyridines/*therapeutic use
MH  - *Stents
MH  - Vitamin K/*antagonists & inhibitors
MH  - Warfarin/*therapeutic use
RF  - 11
EDAT- 2007/10/03 09:00
MHDA- 2008/03/20 09:00
CRDT- 2007/10/03 09:00
PHST- 2006/09/18 00:00 [received]
PHST- 2007/01/20 00:00 [accepted]
PHST- 2007/10/03 09:00 [pubmed]
PHST- 2008/03/20 09:00 [medline]
PHST- 2007/10/03 09:00 [entrez]
AID - 10.1007/s11739-007-0055-5 [doi]
PST - ppublish
SO  - Intern Emerg Med. 2007 Oct;2(3):177-81. doi: 10.1007/s11739-007-0055-5. Epub 2007 
      Oct 1.

PMID- 11194489
OWN - NLM
STAT- MEDLINE
DCOM- 20010215
LR  - 20131121
IS  - 0034-1193 (Print)
IS  - 0034-1193 (Linking)
VI  - 91
IP  - 12
DP  - 2000 Dec
TI  - [Reye's syndrome: the death of a syndrome? (Or death by a syndrome?)].
PG  - 675-80
AB  - Reye syndrome is characterized by acute encephalopathy and fatty degeneration of 
      the liver almost exclusively in children. The onset is heralded by profuse 
      vomiting and varying neurologic impairment from irritability to coma, 
      decerebration and death. The encephalopathy must be associated with a greater 
      increase in the levels of ammonia, or alanine amino-transferase and aspartate 
      amino-transferase in serum; and with a fatty metamorphosis of the liver diagnosed 
      by biopsy or at autopsy. The only characteristic universally accepted as 
      diagnostic are the specific mithocondrial changes in the liver-biopsy specimen. 
      Larger studies confirmed the association of aspirin with RS. The CDC of Atlanta 
      cautioned physician and parents and a dramatic decline in case began at that 
      time. Classic Reye syndrome is now so rare in the USA that when an apparent case 
      is encountered in a child who has not taken aspirin, other diagnoses should be 
      considered. After a brief survey of RS relative lack of specificity of case 
      definition and of the polyhedric etiopathogenetic moments, the A. on the personal 
      experience, point: a) the biological unicity of the man and the necessary 
      coexistence of "constitutional" factors (metabolic and/or endocrine, and/or 
      immunitary factors, the later almost never investigated), toxic, and infectious 
      factors for the syndrome's deflagration; b) some aspects of the continued 
      existence of therapeutic and diagnostic problems: the aspirin and/or salicilate 
      use and the pharmacogenetic; the continued existence of other, generally similar 
      conditions, such the drug and other known and unknown toxic mithocondrial factors 
      that provoke this unusual response to common infections; and the inborn errors of 
      metabolism; c) some practical aspects of diagnostic and therapeutic approach.
FAU - Calvani, M
AU  - Calvani M
AD  - Divisione Pediatrica, Ospedale San Camillo de Lellis, Roma.
LA  - ita
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Sindrome di Reye: morte di una sindrome? (O morire per una sindrome?).
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/adverse effects
MH  - Child
MH  - Diagnosis, Differential
MH  - Humans
MH  - *Reye Syndrome/diagnosis/etiology
RF  - 29
EDAT- 2001/02/24 12:00
MHDA- 2001/03/03 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
PST - ppublish
SO  - Recenti Prog Med. 2000 Dec;91(12):675-80.

PMID- 23137
OWN - NLM
STAT- MEDLINE
DCOM- 19780329
LR  - 20190509
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 5
IP  - 2
DP  - 1978 Feb
TI  - The effects of aspirin, ethanol, indomethacin and 9alpha-fludrocortisone on 
      buccal mucosal potential difference.
PG  - 155-60
AB  - 1 Measurement of the bioelectric potential of the buccal mucosa has been made in 
      three areas, namely on the lower lip between lip and gum, on the sublingual 
      papilla, and at the entrance to the parotid duct. 2 The charge on the buccal 
      mucosa (or buccal potential difference (b.p.d.)) was found to be negative with 
      respect to a saline-injected area of skin. One hundred and eighty measurements of 
      b.p.d. in thirty subjects demonstrated a normal distribution. B.p.d. was 
      unchanged by stimulation of salivary flow, but was reduced or reversed in 
      polarity over areas of aphthous ulceration. B.p.d. was reduced significantly by 
      treatment of the mucosa with deionized water at 65°C, but not by deionized water 
      at 20°C. A characteristic mucosal pressure artifact was demonstrated in response 
      to an increased force applied to the mucosa through the electrode. 3 No response 
      in salivary electrolytes, electrode measured buccal electrolytes or b.p.d. was 
      observed after treatment with 9α-fludrocortisone. Local application of aspirin 
      and ethanol reduced b.p.d., their effects being additive. Local application of 
      indomethacin and deionized water produced no significant change in b.p.d. These 
      responses to aspirin, indomethacin and ethanol are similar to the responses of 
      gastric transmural p.d. to these agents. 4 There appear to be basic similarities 
      in the responses of transepithelial p.d. in different areas of the upper 
      gastrointestinal tract to agents generally regarded as damaging to mucosa.
FAU - Huston, G J
AU  - Huston GJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 3K9958V90M (Ethanol)
RN  - R16CO5Y76E (Aspirin)
RN  - U0476M545B (Fludrocortisone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Cheek
MH  - Ethanol/*pharmacology
MH  - Fludrocortisone/*pharmacology
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Indomethacin/*pharmacology
MH  - Membrane Potentials/drug effects
MH  - Middle Aged
MH  - Mouth Mucosa/*drug effects
MH  - Pressure
MH  - Salivation
MH  - Stomatitis, Aphthous/physiopathology
MH  - Temperature
PMC - PMC1429243
EDAT- 1978/02/01 00:00
MHDA- 1978/02/01 00:01
CRDT- 1978/02/01 00:00
PHST- 1978/02/01 00:00 [pubmed]
PHST- 1978/02/01 00:01 [medline]
PHST- 1978/02/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1978.tb01617.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1978 Feb;5(2):155-60. doi: 
      10.1111/j.1365-2125.1978.tb01617.x.

PMID- 11097175
OWN - NLM
STAT- MEDLINE
DCOM- 20001212
LR  - 20131121
IS  - 0003-9861 (Print)
IS  - 0003-9861 (Linking)
VI  - 383
IP  - 1
DP  - 2000 Nov 1
TI  - Amidation of salicyluric acid and gentisuric acid: a possible role for 
      peptidylglycine alpha-amidating monooxygenase in the metabolism of aspirin.
PG  - 46-55
AB  - Bifunctional peptidylglycine alpha-amidating monooxygenase (PAM) catalyzes the 
      copper-, ascorbate-, and O2-dependent cleavage of C-terminal glycine-extended 
      peptides, N-acylglycines, and the bile acid glycine conjugates to the 
      corresponding amides and glyoxylate. Two known metabolites of aspirin, 
      salicyluric acid and gentisuric acid, are also substrates for PAM, leading to the 
      formation of salicylamide and gentisamide. The time course for O2 consumption and 
      glyoxylate production indicates that salicylurate amidation is a two-step 
      reaction. Salicylurate is first converted to N-salicyl-alpha-hydroxyglycine, 
      which is ultimately dealkylated to salicylamide and glyoxylate. The enzymatically 
      generated salicylamide and N-salicyl-alpha-hydroxyglycine were characterized by 
      mass spectrometry and two-dimensional 1H-13C heteronuclear multiple quantum 
      coherence NMR.
FAU - DeBlassio, J L
AU  - DeBlassio JL
AD  - Department of Chemistry and Biochemistry, Duquesne University, Pittsburgh, 
      Pennsylvania 15282, USA.
FAU - deLong, M A
AU  - deLong MA
FAU - Glufke, U
AU  - Glufke U
FAU - Kulathila, R
AU  - Kulathila R
FAU - Merkler, K A
AU  - Merkler KA
FAU - Vederas, J C
AU  - Vederas JC
FAU - Merkler, D J
AU  - Merkler DJ
LA  - eng
GR  - R15 GM59050/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Biochem Biophys
JT  - Archives of biochemistry and biophysics
JID - 0372430
RN  - 0 (Gentisates)
RN  - 0 (Hippurates)
RN  - 0 (Multienzyme Complexes)
RN  - 25351-24-0 (gentisuric acid)
RN  - 487-54-7 (salicylurate)
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - EC 1.14.17.3 (peptidylglycine monooxygenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*metabolism
MH  - CHO Cells
MH  - Cricetinae
MH  - Gentisates/*metabolism
MH  - Hippurates/*metabolism
MH  - Kinetics
MH  - Mixed Function Oxygenases/*metabolism
MH  - *Multienzyme Complexes
EDAT- 2000/11/30 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/30 11:00
PHST- 2000/11/30 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/30 11:00 [entrez]
AID - S0003-9861(00)92047-2 [pii]
AID - 10.1006/abbi.2000.2047 [doi]
PST - ppublish
SO  - Arch Biochem Biophys. 2000 Nov 1;383(1):46-55. doi: 10.1006/abbi.2000.2047.

PMID- 2627170
OWN - NLM
STAT- MEDLINE
DCOM- 19900405
LR  - 20131121
IS  - 0389-4118 (Print)
IS  - 0389-4118 (Linking)
VI  - 24
IP  - 6
DP  - 1989 Dec
TI  - [Relationships between ethanol-induced sleep and aspirin, indomethacin or PGE2 in 
      inbred rats].
PG  - 480-9
AB  - It is known that prostaglandin synthetase inhibitors (PGSI) inhibit ethanol 
      (EtOH)-induced sleep in mice, and that EtOH increases production of 
      prostaglandins (PGs). EtOH hypnosis and effects of prostaglandins on EtOH-induced 
      sleeping in inbred rats were examined. The EtOH (3 g/kg, i.p.)-induced sleep time 
      was significantly longer in Fischer 344 (F344) than in Lewis (LEW); blood EtOH 
      concentrations (BAC) on awaking were significantly lower in F344 than in LEW. 
      When aspirin (ASP) and indomethacin (IND) were given 15 and 30 min prior to EtOH 
      administration, respectively, both strains significantly slept shorter than those 
      receiving no PGSI. The BACs on awaking in both strains receiving PGSI were higher 
      than those receiving no PGSI. When LEW and F344 rats were pretreated with PGE2 
      (0.05-0.5mg/kg, s.c.) 30 min prior to EtOH administration, either strain slept 
      significantly shorter as compared with those receiving EtOH alone. The BACs on 
      awaking were significantly higher in the animals receiving the combination of 
      PGE2 and EtOH than those receiving EtOH alone. These results suggest that there 
      is the strain difference between F344 and LEW in ethanol-induced sleep, and that 
      PGs may, in part, play a role in EtOH-induced sleep in LEW and F344.
FAU - Suzuki, T
AU  - Suzuki T
FAU - Shiozaki, Y
AU  - Shiozaki Y
FAU - Misawa, M
AU  - Misawa M
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Arukoru Kenkyuto Yakubutsu Ison
JT  - Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug 
      dependence
JID - 8213278
RN  - 3K9958V90M (Ethanol)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Dinoprostone/*pharmacology
MH  - Ethanol/*antagonists & inhibitors/blood
MH  - Indomethacin/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Inbred F344
MH  - Rats, Inbred Lew
MH  - Sleep/*drug effects
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
PST - ppublish
SO  - Arukoru Kenkyuto Yakubutsu Ison. 1989 Dec;24(6):480-9.

PMID- 319121
OWN - NLM
STAT- MEDLINE
DCOM- 19770331
LR  - 20190823
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 17
IP  - 2-3
DP  - 1977 Feb-Mar
TI  - Gastrointestinal blood loss study with a new analgesic compound: nefopam 
      hydrochloride.
PG  - 120-4
AB  - A new analgesic compound, neopam HCl, was studied for possible gastrointestinal 
      blood loss liabilities by Cr-51 red cell tagging. It was compared with aspirin in 
      usual therapeutic doses of 1.8 Gm per day. Dosage of nefopam HCl was 180 mg per 
      day (two tablets t.i.d). Twenty healthy male volunteers had fecal blood loss 
      determined after one-week crossover periods of drug investigation, each preceded 
      by one-week no-drug control periods. Results show a significant (P is less than 
      0.01) increase in occult bleeding in the aspirin-treated subjects from a mean of 
      0.5 ml to 1.63 ml per 24 hours, the mean increase for the group being 1.13 ml per 
      24 hours. Nefopam HCl treated subjects had an insignificant change from a control 
      mean of 0.55 ml per 24 hours to 0.60 ml per 24 hours; a third of this group 
      actually had a decrease in measurable blood loss. Reported side effects were 
      minimal in both drug groups.
FAU - Baltes, B J
AU  - Baltes BJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Oxazocines)
RN  - 4UP8060B7J (Nefopam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/adverse effects
MH  - Chromium Radioisotopes
MH  - Clinical Trials as Topic
MH  - Feces/analysis
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nefopam/*adverse effects
MH  - Oxazocines/*adverse effects
EDAT- 1977/02/01 00:00
MHDA- 1977/02/01 00:01
CRDT- 1977/02/01 00:00
PHST- 1977/02/01 00:00 [pubmed]
PHST- 1977/02/01 00:01 [medline]
PHST- 1977/02/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1977.tb04597.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1977 Feb-Mar;17(2-3):120-4. doi: 
      10.1002/j.1552-4604.1977.tb04597.x.

PMID- 4094907
OWN - NLM
STAT- MEDLINE
DCOM- 19860331
LR  - 20131121
IS  - 0391-5387 (Print)
IS  - 0391-5387 (Linking)
VI  - 7
IP  - 2
DP  - 1985 Mar-Apr
TI  - [Juvenile chronic arthritis].
PG  - 215-23
AB  - Juvenile chronic arthritis is the most common connective tissue disease in 
      children. It is of great social and clinical interest for its chronicity, for the 
      often unpredictable response to pharmacological treatment; for the spontaneous 
      evolution toward infirmity and often blindness. The English classification of the 
      disease is here been adopted. There are 3 different types of onset: systemic, 
      poliarticular and pauciarticular. Large joints such as the knees, wrists and 
      ankles are involved more often than small joints. Also the cervical spine is 
      frequently affected. Systemic disease is accompanied by high spiking fever, rash, 
      lynphoadenopathy, pericarditis and hepatosplenomegaly. Chronic uveitis is a 
      feature of JCA, more frequently observed in pauciarticular than in the other 
      types of onset, and it is almost always associated with antinuclear antibody 
      seropositivity. Rheumatoid factor (RF) and subcutaneous nodules are unusual in 
      JCA. Diagnosis is often not easy and it is essentially clinical. The diagnostic 
      criteria adopted have been proposed by ARA in 1977. In the majority of children 
      treatment with ASA is successful. Sometimes other types of more toxic drugs such 
      as gold salts or penicillamine are needed. Their use is best confined to 
      reference centers. Orthopedical and physiotherapic treatments are complementary 
      to the pharmacological one. Multidisciplinary centers are therefore necessary for 
      the total management of these children also to stress the importance of 
      furthering physical and psychological growth.
FAU - Buffolano, W
AU  - Buffolano W
FAU - Strano, C G
AU  - Strano CG
FAU - Manetti, S
AU  - Manetti S
FAU - Iammarrone Servodio, C
AU  - Iammarrone Servodio C
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - L'artrite cronica giovanile.
PL  - Italy
TA  - Pediatr Med Chir
JT  - La Pediatria medica e chirurgica : Medical and surgical pediatrics
JID - 8100625
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Steroids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - *Arthritis, Juvenile/classification/diagnosis/therapy
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Diagnosis, Differential
MH  - Humans
MH  - Pain Management
MH  - Physical Therapy Modalities
MH  - Prognosis
MH  - Steroids/therapeutic use
EDAT- 1985/03/01 00:00
MHDA- 1985/03/01 00:01
CRDT- 1985/03/01 00:00
PHST- 1985/03/01 00:00 [pubmed]
PHST- 1985/03/01 00:01 [medline]
PHST- 1985/03/01 00:00 [entrez]
PST - ppublish
SO  - Pediatr Med Chir. 1985 Mar-Apr;7(2):215-23.

PMID- 713431
OWN - NLM
STAT- MEDLINE
DCOM- 19790124
LR  - 20190711
IS  - 0023-2173 (Print)
IS  - 0023-2173 (Linking)
VI  - 56
IP  - 22
DP  - 1978 Nov 15
TI  - [Clinical and in-vitro studies of the therapeutical range of acetylsalicylic-acid 
      to prevent deep vein thrombosis (author's transl)].
PG  - 1113-8
AB  - In three consecutive studies, acetylsalicyliclysine using the dosages 0.9 g/48 h, 
      1.8 g/24 h and 3.6 g/24 h, was examined in order to see its effect in preventing 
      deep vein thrombosis (DVT) after elective hip joint surgery. DVT was diagnosed by 
      the 125-i-fibrinogen-test. No reduction of postoperative DVT was found under any 
      of the administered AS-lysine dosages. The collagen-induced platelet aggregation 
      was significantly decreased in all three groups. However, under the low AS-lysine 
      dosages, aggregation was less inhibited with the incidence of DVT than without 
      DVT. In the group with the 3.6 g-dosage, aggregation was maximally inhibited, 
      without any significant difference related to the occurrence of DVT. The results 
      reveal no therapeutic range of AS-lysine to prevent postoperative venous 
      thrombosis.
FAU - Schöndorf, T H
AU  - Schöndorf TH
FAU - Hey, D
AU  - Hey D
FAU - Lasch, H G
AU  - Lasch HG
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Klinische und in vitro-Untersuchungen zur therapeutischen Breite von 
      Acetylsalicylsäure zur Thromboseprophylaxe.
PL  - Germany
TA  - Klin Wochenschr
JT  - Klinische Wochenschrift
JID - 2985205R
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Hip Joint/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Postoperative Complications/prevention & control
MH  - Thrombophlebitis/*prevention & control
EDAT- 1978/11/15 00:00
MHDA- 1978/11/15 00:01
CRDT- 1978/11/15 00:00
PHST- 1978/11/15 00:00 [pubmed]
PHST- 1978/11/15 00:01 [medline]
PHST- 1978/11/15 00:00 [entrez]
AID - 10.1007/BF01477133 [doi]
PST - ppublish
SO  - Klin Wochenschr. 1978 Nov 15;56(22):1113-8. doi: 10.1007/BF01477133.

PMID- 26851562
OWN - NLM
STAT- MEDLINE
DCOM- 20170410
LR  - 20181202
IS  - 1873-1740 (Electronic)
IS  - 0033-0620 (Linking)
VI  - 58
IP  - 5
DP  - 2016 Mar-Apr
TI  - Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of 
      Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network 
      Meta-Analysis.
PG  - 495-504
LID - S0033-0620(16)30009-3 [pii]
LID - 10.1016/j.pcad.2016.02.001 [doi]
AB  - The evidence base on aspirin in primary prevention suggests that it can reduce 
      significantly the risk of cardiovascular disease (CVD) events and cancer, 
      especially colorectal, albeit increasing bleeding. There is, however, uncertainty 
      on the optimal aspirin dose and preparation for primary prevention. We thus aimed 
      to review main sources of evidence informing on daily dosage and preparation of 
      aspirin for primary prevention of CVD and cancer. We collected and elaborated 
      aspirin effectiveness and safety data from U.S. Preventive Services Task Force 
      reports on aspirin in primary prevention, distinguishing average daily dose in 
      <100mg, 100mg, and >100mg. The following preparations were also systematically 
      compared: enteric coated, controlled release, non-coated, or otherwise 
      unspecified. Fixed-effect pairwise and network meta-analytic models were run in a 
      frequentist framework. Eleven randomized trials were shortlisted, enrolling 
      104,101 subjects, followed for a median of 60months. At pairwise analysis, 
      aspirin was associated with significant reductions in death and CVD events, 
      non-significant reductions in cancer death or incidence, and significant 
      increases in the risk of intracranial and gastrointestinal (GI) bleeding. An 
      average daily dose of 100mg had the highest probability of reducing death, cancer 
      death, and cancer incidence, whereas higher doses seemed superior for reducing 
      CVD events, and 100mg or less daily proved better tolerated. Coated preparations 
      appeared more beneficial for death, cancer death, cancer incidence, and GI 
      bleeding, whereas controlled release preparations appeared better for CVD events 
      and non-coated ones for intracranial bleeding. In conclusion, an average daily 
      dose of 100mg of coated aspirin seems more likely to confer favorable preventive 
      effects on death and cancer, with higher doses more appealing for CVD prevention 
      and lower doses better tolerated.
CI  - Copyright © 2016 Elsevier Inc. All rights reserved.
FAU - Lotrionte, Marzia
AU  - Lotrionte M
AD  - Division of Cardiology, Catholic University, Rome, Italy.
FAU - Biasucci, Luigi M
AU  - Biasucci LM
AD  - Division of Cardiology, Catholic University, Rome, Italy.
FAU - Peruzzi, Mariangela
AU  - Peruzzi M
AD  - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University 
      of Rome, Latina, Italy.
FAU - Frati, Giacomo
AU  - Frati G
AD  - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University 
      of Rome, Latina, Italy; Department of AngioCardioNeurology, IRCCS Neuromed, 
      Pozzilli, Italy.
FAU - Giordano, Arturo
AU  - Giordano A
AD  - Unità Operativa di Interventistica Cardiovascolare, Presidio Ospedaliero Pineta 
      Grande, Castel Volturno, Italy; Unità Operativa di Emodinamica, Casa di Salute 
      Santa Lucia, San Giuseppe Vesuviano, Italy.
FAU - Biondi-Zoccai, Giuseppe
AU  - Biondi-Zoccai G
AD  - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University 
      of Rome, Latina, Italy; Department of AngioCardioNeurology, IRCCS Neuromed, 
      Pozzilli, Italy. Electronic address: giuseppe.biondizoccai@uniroma1.it.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160204
PL  - United States
TA  - Prog Cardiovasc Dis
JT  - Progress in cardiovascular diseases
JID - 0376442
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Cardiovascular Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticarcinogenic Agents/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Agents/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Compounding
MH  - Evidence-Based Medicine
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Intracranial Hemorrhages/chemically induced
MH  - Neoplasms/mortality/*prevention & control
MH  - Network Meta-Analysis
MH  - Odds Ratio
MH  - Primary Prevention/*methods
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Aspirin
OT  - Cancer
OT  - Cardiovascular disease
OT  - Meta-analysis
OT  - Network meta-analysis
OT  - Primary prevention
OT  - Systematic review
EDAT- 2016/02/07 06:00
MHDA- 2017/04/11 06:00
CRDT- 2016/02/07 06:00
PHST- 2016/02/01 00:00 [received]
PHST- 2016/02/01 00:00 [accepted]
PHST- 2016/02/07 06:00 [entrez]
PHST- 2016/02/07 06:00 [pubmed]
PHST- 2017/04/11 06:00 [medline]
AID - S0033-0620(16)30009-3 [pii]
AID - 10.1016/j.pcad.2016.02.001 [doi]
PST - ppublish
SO  - Prog Cardiovasc Dis. 2016 Mar-Apr;58(5):495-504. doi: 10.1016/j.pcad.2016.02.001. 
      Epub 2016 Feb 4.

PMID- 300118
OWN - NLM
STAT- MEDLINE
DCOM- 19770425
LR  - 20190630
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 237
IP  - 12
DP  - 1977 Mar 21
TI  - New antirheumatic agents: Fenoprofen calcium (Nalfon), naproxen (Naprosyn), and 
      tolmetin sodium (Tolectin).
PG  - 1260-1
AB  - The new antirheumatic agents, fenoprofen calcium, naproxen, and tolmetin sodium, 
      are effective in the management of rheumatoid arthritis. Their efficacy is 
      comparable, but not superior, to that of aspirin in usual oral doses. These 
      agents also may be useful in degenerative joint disease and ankylosing 
      spondylitis and as analgesics and antipyretics; however, there are insufficient 
      data available to establish their efficacy and dosages for these uses. The 
      incidence of adverse reactions, including gastrointestinal bleeding, is lower 
      with these agents than with aspirin; thus, these drugs may be useful substitutes 
      in patients who cannot tolerate the gastrointestinal effects of aspirin.
FAU - Lewis, J R
AU  - Lewis JR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Naphthaleneacetic Acids)
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyrroles)
RN  - 57Y76R9ATQ (Naproxen)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
RN  - RA33EAC7KY (Fenoprofen)
SB  - IM
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Aspirin/adverse effects/therapeutic use
MH  - Fenoprofen/adverse effects/*therapeutic use
MH  - Gastrointestinal Hemorrhage/chemically induced
MH  - Humans
MH  - Naphthaleneacetic Acids/*therapeutic use
MH  - Naproxen/adverse effects/*therapeutic use
MH  - Osteoarthritis/drug therapy
MH  - Phenylpropionates/*therapeutic use
MH  - Pyrroles/*therapeutic use
MH  - Rheumatic Diseases/*drug therapy
MH  - Spondylitis, Ankylosing/drug therapy
MH  - Tolmetin/adverse effects/*therapeutic use
EDAT- 1977/03/21 00:00
MHDA- 1977/03/21 00:01
CRDT- 1977/03/21 00:00
PHST- 1977/03/21 00:00 [pubmed]
PHST- 1977/03/21 00:01 [medline]
PHST- 1977/03/21 00:00 [entrez]
AID - 10.1001/jama.237.12.1260 [doi]
PST - ppublish
SO  - JAMA. 1977 Mar 21;237(12):1260-1. doi: 10.1001/jama.237.12.1260.

PMID- 27245341
OWN - NLM
STAT- MEDLINE
DCOM- 20170710
LR  - 20191112
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 61
IP  - 8
DP  - 2016 Aug
TI  - Co-lyophilized Aspirin with Trehalose Causes Less Injury to Human Gastric Cells 
      and Gastric Mucosa of Rats.
PG  - 2242-2251
LID - 10.1007/s10620-016-4209-z [doi]
AB  - BACKGROUND: Aspirin is one of the most popular NSAIDs worldwide because of its 
      anti-inflammatory and anticoagulant effects, and however, gastrointestinal injury 
      remains a major complication. We previously reported co-lyophilized 
      aspirin/trehalose (Lyo A/T) decreased the aspirin-induced gastric lesions in 
      dogs. AIM: This study investigated the mechanism of gastroprotective effects of 
      trehalose in vitro and in vivo. METHODS: The apoptotic assays were performed in a 
      human gastric carcinoma cell line, which was treated with aspirin, mixed 
      aspirin/trehalose (Mix A/T) or Lyo A/T. Gastric ulcer severity was examined after 
      oral administration of drugs in rats. In addition, the mucosal tissue apoptotic 
      status in drug-treated rats was evaluated. Molecular dynamics simulations and 
      laser Raman spectroscopy were performed in order to examine the molecular 
      properties of Lyo A/T. RESULTS: DNA fragmentation was detected in AGS cells that 
      were treated with aspirin and Mix A/T, but not in the Lyo A/T-treated cells. 
      There were fewer apoptotic cells in the Lyo A/T-treated cells than in the other 
      cells. Gastric injury was reduced in rats that received oral Lyo A/T compared 
      with the others, while PGE2 synthesis was equally decreased in all groups. TUNEL 
      assay and immunohistochemistry of cleaved caspase-3 in the mucosal tissues also 
      revealed that Lyo A/T treatment induced less apoptosis than the others. The Lyo 
      A/T spectrum showed clear differences in several Raman bands compared with that 
      of Mix A/T. CONCLUSIONS: Our data showed that co-lyophilization of aspirin with 
      trehalose reduced gastric injury, potentially through suppression of 
      aspirin-induced mucosal cell apoptosis while retaining its anti-inflammatory 
      effects.
FAU - Lin, Lee-Shuan
AU  - Lin LS
AD  - Department of Veterinary Medicine, National Pingtung University of Science and 
      Technology, Neipu, Taiwan.
FAU - Kayasuga-Kariya, Yuko
AU  - Kayasuga-Kariya Y
AD  - Department of Bioengineering, Graduate School of Engineering, The University of 
      Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
FAU - Nakamura, Shugo
AU  - Nakamura S
AD  - Department of Biotechnology, Graduate School of Agricultural and Life Sciences, 
      The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
FAU - Shimohata, Nobuyuki
AU  - Shimohata N
AD  - Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan 
      University, 1-1-1 Nojihigashi, Kusatsu, Shiga, 525-8577, Japan.
FAU - Sakai, Takamasa
AU  - Sakai T
AD  - Department of Bioengineering, Graduate School of Engineering, The University of 
      Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
FAU - Fujisawa, Ayano
AU  - Fujisawa A
AD  - Department of Bioengineering, Graduate School of Engineering, The University of 
      Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
FAU - Akagi, Yuki
AU  - Akagi Y
AD  - Department of Bioengineering, Graduate School of Engineering, The University of 
      Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
FAU - Suzuki, Shigeki
AU  - Suzuki S
AD  - NEXT21 K.K., 3-38-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
FAU - Chung, Ung-Il
AU  - Chung UI
AD  - Department of Bioengineering, Graduate School of Engineering, The University of 
      Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
FAU - Sasaki, Nobuo
AU  - Sasaki N
AD  - Department of Veterinary Medical Science, Graduate School of Agricultural and 
      Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, 
      Japan.
FAU - Mochizuki, Manabu
AU  - Mochizuki M
AD  - Department of Veterinary Medical Science, Graduate School of Agricultural and 
      Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, 
      Japan. amm@mail.ecc.u-tokyo.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160531
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Protective Agents)
RN  - B8WCK70T7I (Trehalose)
RN  - EC 3.4.22.- (Casp3 protein, rat)
RN  - EC 3.4.22.- (Caspase 3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Dig Dis Sci. 2016 Aug;61(8):2151-3. PMID: 27358227
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Aspirin/adverse effects/*pharmacology
MH  - Caspase 3/drug effects/metabolism
MH  - Cell Line, Tumor
MH  - Epithelial Cells/*drug effects
MH  - *Freeze Drying
MH  - Gastric Mucosa/cytology/*drug effects
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Nick-End Labeling
MH  - Male
MH  - Molecular Dynamics Simulation
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacology
MH  - Protective Agents/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Spectrum Analysis, Raman
MH  - Stomach Ulcer/chemically induced
MH  - Trehalose/*pharmacology
OTO - NOTNLM
OT  - Apoptosis
OT  - Aspirin
OT  - Gastroprotection
OT  - Lyophilization
OT  - Trehalose
EDAT- 2016/06/02 06:00
MHDA- 2017/07/14 06:00
CRDT- 2016/06/02 06:00
PHST- 2015/07/04 00:00 [received]
PHST- 2016/05/20 00:00 [accepted]
PHST- 2016/06/02 06:00 [entrez]
PHST- 2016/06/02 06:00 [pubmed]
PHST- 2017/07/14 06:00 [medline]
AID - 10.1007/s10620-016-4209-z [pii]
AID - 10.1007/s10620-016-4209-z [doi]
PST - ppublish
SO  - Dig Dis Sci. 2016 Aug;61(8):2242-2251. doi: 10.1007/s10620-016-4209-z. Epub 2016 
      May 31.

PMID- 8757220
OWN - NLM
STAT- MEDLINE
DCOM- 19961022
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 98
IP  - 2
DP  - 1996 Aug
TI  - Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 
      beta-prostaglandin F2 after aspirin challenge supports mast cell activation in 
      aspirin-induced airway obstruction.
PG  - 421-32
AB  - Prostaglandin (PG)D2 is a major product of arachidonic acid metabolism in 
      pulmonary mast cells. We therefore attempted to determine whether measurement of 
      the stable urinary metabolite of PGD2, 9 alpha, 11 beta-PGF2, could serve as a 
      marker of mast cell activation in the lungs. A commercially available enzyme 
      immunoassay was validated and found to be specific and sensitive when applied to 
      unpurified urine. There was no diurnal variation in the levels of 9 alpha, 11 
      beta-PGF2 in healthy volunteers. Morning baseline values of urinary 9 alpha, 11 
      beta-PGF2 were measured in three groups--healthy volunteers (n = 9), patients 
      with atopic asthma (n = 14), and aspirin-intolerant patients with asthma (n = 
      12)--and found to be very similar, 54 +/- 9, 62 +/- 6, and 71 +/- 15 ng/mmol 
      creatinine, respectively (means +/- SEM). Urinary excretion of 9 alpha, 11 
      beta-PGF2 was increased threefold immediately after allergen-induced 
      bronchoconstriction in nine patients with atopic asthma. Bronchial challenge with 
      inhaled lysine aspirin in eight aspirin-intolerant patients with asthma produced 
      bronchoconstriction without extrapulmonary symptoms and was also followed by a 
      significant increase in the urinary excretion of 9 alpha, 11 beta-PGF2. In 
      addition, challenge with a higher dose of aspirin produced an even greater 
      increase in urinary 9 alpha, 11 beta-PGF2, supporting dose-dependent release of 
      PGD2 during aspirin-induced bronchoconstriction. In contrast, the postchallenge 
      levels of urinary 9 alpha, 11 beta-PGF2 were not increased when 
      bronchoconstriction was induced by histamine challenge in the aspirin-intolerant 
      patients with asthma. The study confirms mast cell involvement in 
      allergen-induced bronchoconstriction and provides novel data, which strongly 
      support the hypothesis that pulmonary mast cells are activated during 
      aspirin-induced airway obstruction. It is finally suggested that measurement of 
      urinary 9 alpha, 11 beta-PGF2 with enzyme immunoassay may be used as a new 
      noninvasive strategy to monitor mast cell activation in vivo.
FAU - O'Sullivan, S
AU  - O'Sullivan S
AD  - Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
FAU - Dahlén, B
AU  - Dahlén B
FAU - Dahlén, S E
AU  - Dahlén SE
FAU - Kumlin, M
AU  - Kumlin M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Allergens)
RN  - 820484N8I3 (Histamine)
RN  - B7IN85G1HY (Dinoprost)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - RXY07S6CZ2 (Prostaglandin D2)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Adult
MH  - Airway Obstruction/*chemically induced/immunology/metabolism
MH  - Allergens/administration & dosage
MH  - Aspirin/administration & dosage/*adverse effects/analogs & derivatives
MH  - Asthma/chemically induced/urine
MH  - Bronchial Provocation Tests
MH  - Chromatography, High Pressure Liquid
MH  - Cross-Over Studies
MH  - Dinoprost/immunology/*urine
MH  - Double-Blind Method
MH  - Histamine/administration & dosage
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Lysine/administration & dosage/analogs & derivatives
MH  - Mast Cells/*drug effects/immunology/*metabolism
MH  - Middle Aged
MH  - Prostaglandin D2/*metabolism
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - S0091-6749(96)70167-7 [pii]
AID - 10.1016/s0091-6749(96)70167-7 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1996 Aug;98(2):421-32. doi: 
      10.1016/s0091-6749(96)70167-7.

PMID- 29128692
OWN - NLM
STAT- MEDLINE
DCOM- 20171212
LR  - 20210109
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Print)
IS  - 0959-8049 (Linking)
VI  - 87
DP  - 2017 Dec
TI  - COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II 
      double-blind, randomised controlled trial to establish if aspirin reduces 
      cisplatin induced hearing-loss.
PG  - 75-83
LID - S0959-8049(17)31336-9 [pii]
LID - 10.1016/j.ejca.2017.09.033 [doi]
AB  - BACKGROUND: Cisplatin is one of the most ototoxic chemotherapy drugs, resulting 
      in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin 
      and gentamicin are thought to damage hearing through a common mechanism, 
      involving reactive oxygen species in the inner ear. Aspirin has been shown to 
      minimise gentamicin-induced ototoxicity. We, therefore, tested the hypothesis 
      that aspirin could also reduce ototoxicity from cisplatin-based chemotherapy. 
      METHODS: A total of 94 patients receiving cisplatin-based chemotherapy for 
      multiple cancer types were recruited into a phase II, double-blind, 
      placebo-controlled trial and randomised in a ratio of 1:1 to receive aspirin 
      975 mg tid and omeprazole 20 mg od, or matched placebos from the day before, to 2 
      days after, their cisplatin dose(s), for each treatment cycle. Patients underwent 
      pure tone audiometry before and at 7 and 90 days after their final cisplatin 
      dose. The primary end-point was combined hearing loss (cHL), the summed hearing 
      loss at 6 kHz and 8 kHz, in both ears. RESULTS: Although aspirin was well 
      tolerated, it did not protect hearing in patients receiving cisplatin 
      (p-value = 0.233, 20% one-sided level of significance). In the aspirin arm, 
      patients demonstrated mean cHL of 49 dB (standard deviation [SD] 61.41) following 
      cisplatin compared with placebo patients who demonstrated mean cHL of 36 dB (SD 
      50.85). Women had greater average hearing loss than men, and patients treated for 
      head and neck malignancy experienced the greatest cHL. CONCLUSIONS: Aspirin did 
      not protect from cisplatin-related ototoxicity. Cisplatin and gentamicin may 
      therefore have distinct ototoxic mechanisms, or cisplatin-induced ototoxicity may 
      be refractory to the aspirin regimen used here.
CI  - Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Crabb, Simon J
AU  - Crabb SJ
AD  - Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom.
FAU - Martin, Karen
AU  - Martin K
AD  - Southampton Clinical Trials Unit, University of Southampton, Southampton, United 
      Kingdom.
FAU - Abab, Julia
AU  - Abab J
AD  - Southampton Clinical Trials Unit, University of Southampton, Southampton, United 
      Kingdom.
FAU - Ratcliffe, Ian
AU  - Ratcliffe I
AD  - Southampton Clinical Trials Unit, University of Southampton, Southampton, United 
      Kingdom.
FAU - Thornton, Roger
AU  - Thornton R
AD  - NHS Research, University Hospital Southampton NHS Foundation Trust, Southampton, 
      United Kingdom.
FAU - Lineton, Ben
AU  - Lineton B
AD  - Institute of Sound and Vibration Research, University of Southampton, 
      Southampton, United Kingdom.
FAU - Ellis, Mary
AU  - Ellis M
AD  - Southampton Clinical Trials Unit, University of Southampton, Southampton, United 
      Kingdom.
FAU - Moody, Ronald
AU  - Moody R
AD  - Patient and Public Involvement Representative, United Kingdom.
FAU - Stanton, Louise
AU  - Stanton L
AD  - Southampton Clinical Trials Unit, University of Southampton, Southampton, United 
      Kingdom.
FAU - Galanopoulou, Angeliki
AU  - Galanopoulou A
AD  - Southampton Clinical Trials Unit, University of Southampton, Southampton, United 
      Kingdom.
FAU - Maishman, Tom
AU  - Maishman T
AD  - Southampton Clinical Trials Unit, University of Southampton, Southampton, United 
      Kingdom.
FAU - Geldart, Thomas
AU  - Geldart T
AD  - Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth, United 
      Kingdom.
FAU - Bayne, Mike
AU  - Bayne M
AD  - Poole Hospital NHS Foundation Trust, Poole, United Kingdom.
FAU - Davies, Joe
AU  - Davies J
AD  - Poole Hospital NHS Foundation Trust, Poole, United Kingdom.
FAU - Lamb, Carolynn
AU  - Lamb C
AD  - The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
FAU - Popat, Sanjay
AU  - Popat S
AD  - Institute of Cancer Research and Royal Marsden Foundation Trust, London, United 
      Kingdom.
FAU - Joffe, Johnathan K
AU  - Joffe JK
AD  - St James' University Hospital, Leeds, United Kingdom.
FAU - Nutting, Chris
AU  - Nutting C
AD  - Institute of Cancer Research and Royal Marsden Foundation Trust, London, United 
      Kingdom.
FAU - Chester, John
AU  - Chester J
AD  - College of Biomedical and Life Sciences, Cardiff University and Velindre Cancer 
      Centre, Cardiff, United Kingdom.
FAU - Hartley, Andrew
AU  - Hartley A
AD  - Queen Elizabeth Hospital, Birmingham, United Kingdom.
FAU - Thomas, Gareth
AU  - Thomas G
AD  - Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom.
FAU - Ottensmeier, Christian
AU  - Ottensmeier C
AD  - Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom.
FAU - Huddart, Robert
AU  - Huddart R
AD  - Institute of Cancer Research and Royal Marsden Foundation Trust, London, United 
      Kingdom.
FAU - King, Emma
AU  - King E
AD  - Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom; 
      Poole Hospital NHS Foundation Trust, Poole, United Kingdom. Electronic address: 
      E.King@soton.ac.uk.
LA  - eng
SI  - ISRCTN/ISRCTN83689269
GR  - 13344/CRUK_/Cancer Research UK/United Kingdom
GR  - MR/P024351/1/MRC_/Medical Research Council/United Kingdom
GR  - C39812/A13344/CRUK_/Cancer Research UK/United Kingdom
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20171110
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protective Agents)
RN  - Q20Q21Q62J (Cisplatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Audiometry, Pure-Tone
MH  - Cisplatin/*adverse effects
MH  - Cytoprotection
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Hearing/*drug effects
MH  - Hearing Loss/chemically induced/diagnosis/physiopathology/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*drug therapy
MH  - Protective Agents/*administration & dosage/adverse effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - United Kingdom
MH  - Young Adult
PMC - PMC5729023
OTO - NOTNLM
OT  - Aspirin
OT  - Chemotherapy
OT  - Cisplatin
OT  - Hearing
OT  - Ototoxicity
EDAT- 2017/11/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/11/13 06:00
PHST- 2017/07/22 00:00 [received]
PHST- 2017/09/22 00:00 [revised]
PHST- 2017/09/25 00:00 [accepted]
PHST- 2017/11/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
PHST- 2017/11/13 06:00 [entrez]
AID - S0959-8049(17)31336-9 [pii]
AID - 10.1016/j.ejca.2017.09.033 [doi]
PST - ppublish
SO  - Eur J Cancer. 2017 Dec;87:75-83. doi: 10.1016/j.ejca.2017.09.033. Epub 2017 Nov 
      10.

PMID- 29933749
OWN - NLM
STAT- MEDLINE
DCOM- 20190320
LR  - 20190320
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Jun 22
TI  - Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin 
      combined with high-dose aspirin in the acute stage of Kawasaki disease: study 
      protocol for a randomized controlled trial.
PG  - 200
LID - 10.1186/s12887-018-1180-1 [doi]
LID - 200
AB  - BACKGROUND: Kawasaki disease (KD) is an acute febrile systemic vasculitis most 
      commonly seen in children under 5 years old. High-dose aspirin is often 
      administered, but the duration of such treatment varies. Many centers reduce the 
      aspirin dose once the patient is afebrile, even before treating said patient with 
      intravenous immunoglobulin (IVIG). However, a randomized controlled trial 
      regarding high-dose aspirin in the acute stage of KD has not previously been 
      carried out. METHODS/DESIGN: This trial has been designed as a multi-center, 
      prospective, randomized controlled, evaluator-blinded trial with two parallel 
      groups to determine whether IVIG alone as the primary therapy in acute-stage KD 
      is as effective as IVIG combined with high-dose aspirin therapy. The primary 
      endpoint is defined as coronary artery lesion (CAL) formation at 6-8 weeks. 
      Patients meeting the eligibility criteria are randomly assigned (1:1) to a test 
      group (that receives only IVIG) or a standard group (that receives IVIG plus 
      high-dose aspirin). This clinical trial is conducted at three medical centers in 
      Taiwan. DISCUSSION: Since high-dose aspirin has significant anti-inflammatory and 
      anti-platelet functions, it does not appear to affect disease outcomes. 
      Furthermore, it can decrease hemoglobin levels. Therefore, we have initiated this 
      randomized controlled trial to evaluate the necessity of high-dose aspirin in the 
      acute stage of KD. TRIAL REGISTRATION: Kawasaki Disease Center, Kaohsiung Chang 
      Gung Memorial Hospital, Taiwan. ClinicalTrials.gov Identifier: NCT02951234. 
      Release Date: November 3, 2016.
FAU - Kuo, Ho-Chang
AU  - Kuo HC
AD  - Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung 
      University College of Medicine, #123 Da-Pei Road, Niaosong District, Kaohsiung, 
      83301, Taiwan.
AD  - Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, 
      Taiwan.
FAU - Guo, Mindy Ming-Huey
AU  - Guo MM
AD  - Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung 
      University College of Medicine, #123 Da-Pei Road, Niaosong District, Kaohsiung, 
      83301, Taiwan.
AD  - Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, 
      Taiwan.
FAU - Lo, Mao-Hung
AU  - Lo MH
AD  - Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung 
      University College of Medicine, #123 Da-Pei Road, Niaosong District, Kaohsiung, 
      83301, Taiwan.
AD  - Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, 
      Taiwan.
FAU - Hsieh, Kai-Sheng
AU  - Hsieh KS
AD  - Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung 
      University College of Medicine, #123 Da-Pei Road, Niaosong District, Kaohsiung, 
      83301, Taiwan.
AD  - Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, 
      Taiwan.
FAU - Huang, Ying-Hsien
AU  - Huang YH
AD  - Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung 
      University College of Medicine, #123 Da-Pei Road, Niaosong District, Kaohsiung, 
      83301, Taiwan. yhhuang123@yahoo.com.tw.
AD  - Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, 
      Taiwan. yhhuang123@yahoo.com.tw.
AD  - Department of Pediatrics, Chiayi Chang Gung Memorial Hospital, Kaohsiung, Taiwan. 
      yhhuang123@yahoo.com.tw.
LA  - eng
SI  - ClinicalTrials.gov/NCT02951234
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180622
PL  - England
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antipyretics)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects
MH  - Antipyretics/*administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Equivalence Trials as Topic
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*drug therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Prospective Studies
PMC - PMC6015467
OTO - NOTNLM
OT  - Coronary artery lesions
OT  - Intravenous immunoglobulin
OT  - Kawasaki disease
OT  - Randomized clinical trial
COIS- CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare 
      that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains 
      neutral with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2018/06/24 06:00
MHDA- 2019/03/21 06:00
CRDT- 2018/06/24 06:00
PHST- 2017/11/16 00:00 [received]
PHST- 2018/06/18 00:00 [accepted]
PHST- 2018/06/24 06:00 [entrez]
PHST- 2018/06/24 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
AID - 10.1186/s12887-018-1180-1 [pii]
AID - 1180 [pii]
AID - 10.1186/s12887-018-1180-1 [doi]
PST - epublish
SO  - BMC Pediatr. 2018 Jun 22;18(1):200. doi: 10.1186/s12887-018-1180-1.

PMID- 18537062
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20181201
IS  - 0022-9032 (Print)
IS  - 0022-9032 (Linking)
VI  - 66
IP  - 5
DP  - 2008 May
TI  - [Dual antiplatelet drug resistance in a patient allergic to clopidogrel: a case 
      report].
PG  - 548-50
AB  - In the present report we describe a 70-year-old woman after antimitotic stent 
      implantation who developed an allergy to clopidogrel. We monitored her platelet 
      activity while on different drug regimes and at different time points during the 
      allergic reaction. Tests showed incomplete platelet inhibition by acetylsalicylic 
      acid and clopidogrel (dual antiplatelet drug resistance) during the acute 
      allergic reaction with gradual improvement together with patient clinical status.
FAU - Kuliczkowski, Wiktor
AU  - Kuliczkowski W
AD  - III Katedra i Oddział Kliniczny Kardiologii, Slaskie Centrum Chorób Serca, ul. 
      Szpitalna 2, Zabrze. wiktor6@wp.pl
FAU - Sikora, Jacek
AU  - Sikora J
FAU - Dyrbuś, Krzysztof
AU  - Dyrbuś K
FAU - Kaczmarski, Jacek
AU  - Kaczmarski J
FAU - Gasior, Mariusz
AU  - Gasior M
FAU - Poloński, Lech
AU  - Poloński L
LA  - pol
PT  - Case Reports
PT  - Journal Article
TT  - Niepełna odpowiedź na podwójne leczenie przeciwpłytkowe u kobiety uczulonej na 
      klopidogrel.
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Stents/*adverse effects
MH  - Ticlopidine/*analogs & derivatives/pharmacology
EDAT- 2008/06/10 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/06/10 09:00
PHST- 2008/06/10 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/06/10 09:00 [entrez]
AID - 10449 [pii]
PST - ppublish
SO  - Kardiol Pol. 2008 May;66(5):548-50.

PMID- 3296337
OWN - NLM
STAT- MEDLINE
DCOM- 19870702
LR  - 20131121
IS  - 0167-9228 (Print)
IS  - 0167-9228 (Linking)
VI  - 18
IP  - 2
DP  - 1987 Apr
TI  - [Recovery following CVA: caused by effective therapy or by the natural course of 
      the disease?].
PG  - 61-3
AB  - The efficacy of treatment of cerebrovascular disorders is difficult to establish. 
      Treatment effects may be confounded by the natural course of the disease, or they 
      may be misjudged by bias and can not be compared with the results of treatments 
      in other hospitals or with previous results. Pathophysiological knowledge does 
      not always lead to the right or the most practical treatment, neither the results 
      of in vitro or animal experiments, nor the experience with related disorders. The 
      randomized clinical trial is the right method to investigate treatment effects, 
      but is not faultless and explanatory experiments ought to be distinguished from 
      pragmatic studies.
FAU - Vermeulen, M
AU  - Vermeulen M
LA  - dut
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Verbetering na CVA: door effective therapie of natuurlijk beloop?
PL  - Netherlands
TA  - Tijdschr Gerontol Geriatr
JT  - Tijdschrift voor gerontologie en geriatrie
JID - 8210346
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/physiopathology/prevention & control/*rehabilitation
MH  - Clinical Trials as Topic
MH  - Hemodynamics
MH  - Humans
MH  - Intracranial Embolism and Thrombosis/physiopathology
EDAT- 1987/04/01 00:00
MHDA- 1987/04/01 00:01
CRDT- 1987/04/01 00:00
PHST- 1987/04/01 00:00 [pubmed]
PHST- 1987/04/01 00:01 [medline]
PHST- 1987/04/01 00:00 [entrez]
PST - ppublish
SO  - Tijdschr Gerontol Geriatr. 1987 Apr;18(2):61-3.

PMID- 3628061
OWN - NLM
STAT- MEDLINE
DCOM- 19871022
LR  - 20131121
IS  - 0391-5387 (Print)
IS  - 0391-5387 (Linking)
VI  - 9
IP  - 1
DP  - 1987 Jan-Feb
TI  - [Kawasaki's disease. Presentation of 2 clinical cases].
PG  - 99-103
AB  - The authors describe two cases of Kawasaki disease, one of whose is an 
      "incomplete" form, and emphasize the importance to know this "new" disease in the 
      differential diagnosis of febrile exanthemas of childhood. A complete diagnostic 
      walk-up failed to find out a probably, while change of some immunological and 
      flogistic parameters has permitted to suppose a probably immuno-mediated 
      pathogenesis of Kawasaki disease. Both patients healed without any sequelae after 
      therapy with low doses of salicylate for ten months, in confirmation of 
      usefulness of this treatment in the prevention of heart complications of Kawasaki 
      disease.
FAU - Cataldo, F
AU  - Cataldo F
FAU - Violante, M
AU  - Violante M
FAU - Donzelli, M
AU  - Donzelli M
FAU - Bellia, L
AU  - Bellia L
FAU - La Monaca, P
AU  - La Monaca P
LA  - ita
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - La malattia di Kawasaki. Presentazione di due casi clinici.
PL  - Italy
TA  - Pediatr Med Chir
JT  - La Pediatria medica e chirurgica : Medical and surgical pediatrics
JID - 8100625
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child, Preschool
MH  - Coronary Disease/prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*diagnosis/drug therapy/pathology
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Pediatr Med Chir. 1987 Jan-Feb;9(1):99-103.

PMID- 656635
OWN - NLM
STAT- MEDLINE
DCOM- 19780814
LR  - 20190902
IS  - 0006-5242 (Print)
IS  - 0006-5242 (Linking)
VI  - 36
IP  - 5
DP  - 1978 May 18
TI  - [Effect of heparin and ASA on changes of haemostasis induced by venous occlusion 
      (author's transl)].
PG  - 275-83
AB  - The influence of venous occlusion on plasmatic coagulation, on platelets, and on 
      fibrinolysis was examined. After occlusion, activated factors XI and X could be 
      demonstrated. Simultaneously, platelet aggregation induced by both collagen and 
      epinephrine was increased. Fibrinolysis was found to be moderately enhanced. In 
      patients taking acetylsalicylic acid (ASA), platelet functions were not altered 
      by occlusion but the activation of plasmatic clotting factors was not influenced. 
      Low dose heparin inhibited plasmatic activation but had no influence on the 
      increase of platelet activities. By simultaneous administration of both 
      substances, an additive effect was observed resulting in inhibition of plasmatic 
      and platelet activation due to venous occlusion.
FAU - Vinazzer, H
AU  - Vinazzer H
FAU - Loew, D
AU  - Loew D
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Beeinflussung stasebedingter Anderungen des Gerinnungsmechanismus durch niedrig 
      dosiertes Heparin und durch Azetylsalizylsäure.
PL  - Germany
TA  - Blut
JT  - Blut
JID - 0173401
RN  - 9001-29-0 (Factor X)
RN  - 9005-49-6 (Heparin)
RN  - 9013-55-2 (Factor XI)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Blood Platelets
MH  - Drug Synergism
MH  - Factor X/analysis
MH  - Factor XI/analysis
MH  - Female
MH  - Fibrinolysis
MH  - *Hemostasis
MH  - Heparin/*pharmacology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
EDAT- 1978/05/18 00:00
MHDA- 1978/05/18 00:01
CRDT- 1978/05/18 00:00
PHST- 1978/05/18 00:00 [pubmed]
PHST- 1978/05/18 00:01 [medline]
PHST- 1978/05/18 00:00 [entrez]
AID - 10.1007/BF01880678 [doi]
PST - ppublish
SO  - Blut. 1978 May 18;36(5):275-83. doi: 10.1007/BF01880678.

PMID- 852562
OWN - NLM
STAT- MEDLINE
DCOM- 19770611
LR  - 20141120
IS  - 0014-8318 (Print)
IS  - 0014-8318 (Linking)
VI  - 40
IP  - 2
DP  - 1977 Mar-Apr
TI  - [Effect of several derivatives of ortho-hydroxybenzoic acid on the glutamate and 
      ketoglutarate oxidation activity of rat liver mitochondria].
PG  - 203-6
AB  - Tests conducted with isolated hepatic mitochondria showed that introduction of 
      acetylsalicylic acid (ASA) to rats in a dose of 300 mg/kg for 5 and 20 days 
      inhibited the oxidation systems of glutamate and alpha-ketoglutarate. This effect 
      depends on the stationary concentration of the compound in the organism. Thus, 
      administration of a high ASA dose (300 mg/kg) for 5 and 20 days, as well as its 
      single administration in doses of 400 or 600 mg/kg had the effect of persistently 
      suppressing the activity of these systems without causing any changes in the 
      degree of the energy-generating conjugation.
FAU - Matulis, A A
AU  - Matulis AA
FAU - Cherkasskaia, M D
AU  - Cherkasskaia MD
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Vliianie nekotorykh proizvodnykh ortooksibenzoĭnoĭ kisloty na aktivnost' 
      okisleniia gliutamata i ketogliutarata mitokhondriiami pecheni krys.
PL  - Russia (Federation)
TA  - Farmakol Toksikol
JT  - Farmakologiia i toksikologiia
JID - 16920420R
RN  - 0 (Glutamates)
RN  - 0 (Hydroxybenzoates)
RN  - 0 (Ketoglutaric Acids)
RN  - 0 (Uncoupling Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Glutamates/*metabolism
MH  - Hydroxybenzoates/*pharmacology
MH  - In Vitro Techniques
MH  - Ketoglutaric Acids/*metabolism
MH  - Mitochondria, Liver/*metabolism
MH  - Oxidation-Reduction
MH  - Rats
MH  - Uncoupling Agents
EDAT- 1977/03/01 00:00
MHDA- 1977/03/01 00:01
CRDT- 1977/03/01 00:00
PHST- 1977/03/01 00:00 [pubmed]
PHST- 1977/03/01 00:01 [medline]
PHST- 1977/03/01 00:00 [entrez]
PST - ppublish
SO  - Farmakol Toksikol. 1977 Mar-Apr;40(2):203-6.

PMID- 22196778
OWN - NLM
STAT- MEDLINE
DCOM- 20120501
LR  - 20220316
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 109
IP  - 6
DP  - 2012 Mar 15
TI  - Outcomes of patients treated with triple antithrombotic therapy after primary 
      percutaneous coronary intervention for ST-elevation myocardial infarction (from 
      the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial 
      Infarction [HORIZONS-AMI] trial).
PG  - 831-8
LID - 10.1016/j.amjcard.2011.10.046 [doi]
AB  - In the setting of ST-segment elevation myocardial infarction (STEMI), patients at 
      high risk of systemic emboli who undergo primary percutaneous coronary 
      intervention (PCI) using stents might require triple antithrombotic therapy (a 
      combination of aspirin, thienopyridine, and vitamin K antagonist [VKA]). The 
      risks and benefits of such therapy in the setting of STEMI have been incompletely 
      characterized. We, therefore, assessed the outcomes of patients who received 
      triple therapy after primary PCI in the large-scale, contemporary Harmonizing 
      Outcomes with Revascularization and Stents in Acute Myocardial Infarction 
      [HORIZONS-AMI] trial. Among the 3,320 patients triaged to primary PCI, 126 (3.8%) 
      were prescribed triple therapy and 3,194 (96.2%) were prescribed dual 
      antiplatelet therapy. The most frequent indications for VKA treatment were a 
      severely reduced left ventricular ejection fraction with a large akinetic area, 
      atrial fibrillation (23.8% each), and mural thrombus (23.0%). The assignment to 
      triple therapy was associated with older age, female gender, rhythm disturbances, 
      Killip class > 1 on admission, lower left ventricular ejection fraction, left 
      anterior descending artery territory infarcts, and Final Thrombolysis In 
      Myocardial Infarction flow grade < 3. Patients treated with triple versus dual 
      therapy had comparable short- and long-term ischemic outcomes but had 
      significantly increased rates of major bleeding during the index hospitalization 
      (17.1% vs 6.5%, p < 0.0001), resulting in premature VKA discontinuation in 14.3% 
      of those patients. In conclusion, in the setting of STEMI treated with primary 
      PCI, the combination of aspirin, thienopyridine, and VKA results in an excess of 
      bleeding complications and premature discontinuation of VKA. The risk of adding 
      oral anticoagulation to patients admitted for STEMI should be carefully 
      considered before choosing drug-eluting or bare metal stents.
CI  - Copyright Â© 2012 Elsevier Inc. All rights reserved.
FAU - Nikolsky, Eugenia
AU  - Nikolsky E
AD  - Rambam Health Care Campus and Technion Israel Institute of Technology, Haifa, 
      Israel.
FAU - Mehran, Roxana
AU  - Mehran R
FAU - Dangas, George D
AU  - Dangas GD
FAU - Yu, Jennifer
AU  - Yu J
FAU - Parise, Helen
AU  - Parise H
FAU - Xu, Ke
AU  - Xu K
FAU - Pocock, Stuart J
AU  - Pocock SJ
FAU - Stone, Gregg W
AU  - Stone GW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20111222
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/*methods
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Coronary Angiography
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - *Electrocardiography
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnostic imaging/physiopathology/*therapy
MH  - Postoperative Period
MH  - Prospective Studies
MH  - Pyridines/administration & dosage/*therapeutic use
MH  - Treatment Outcome
EDAT- 2011/12/27 06:00
MHDA- 2012/05/02 06:00
CRDT- 2011/12/27 06:00
PHST- 2011/09/16 00:00 [received]
PHST- 2011/10/31 00:00 [revised]
PHST- 2011/10/31 00:00 [accepted]
PHST- 2011/12/27 06:00 [entrez]
PHST- 2011/12/27 06:00 [pubmed]
PHST- 2012/05/02 06:00 [medline]
AID - S0002-9149(11)03381-9 [pii]
AID - 10.1016/j.amjcard.2011.10.046 [doi]
PST - ppublish
SO  - Am J Cardiol. 2012 Mar 15;109(6):831-8. doi: 10.1016/j.amjcard.2011.10.046. Epub 
      2011 Dec 22.

PMID- 16788299
OWN - NLM
STAT- MEDLINE
DCOM- 20061101
LR  - 20131121
IS  - 1015-9770 (Print)
IS  - 1015-9770 (Linking)
VI  - 22
IP  - 4
DP  - 2006
TI  - Dose titration to reduce dipyridamole-related headache.
PG  - 258-62
AB  - BACKGROUND: Combination of low-dose aspirin and modified-release dipyridamole 
      (ASA+MR-DP) provides a significantly increased benefit in stroke prevention over 
      aspirin alone. However, headaches were reported in more patients receiving 
      dipyridamole-containing agents than in those receiving placebo. We undertook a 
      randomized, double-blind, placebo-controlled trial to evaluate which dosing 
      regimens of ASA+MR-DP have better tolerance. METHODS: This trial randomized 146 
      patients with a history of ischemic cerebrovascular disease into three groups: 
      placebo (days 1-28), reduced dose (placebo on days 1-4, ASA+MR-DP once daily 
      before bed during days 5-14, and b.i.d. on days 15-28), and regular dose (placebo 
      on days 1-4, and ASA+MR-DP b.i.d. on days 5-28). Using Chinese diary card, 
      headache was assessed as mean cumulated headache (Sigma frequency x 
      intensity/occurrence days x study days) over the study period, and was graded 0-4 
      according to Cancer Therapy Evaluation Program, Common Toxicity Criteria, Version 
      2.0. RESULTS: Intent-to-treat patients after randomization was 46 in placebo 
      group, 45, reduced dose, and 49, regular dose. Among commonly reported adverse 
      effects, headache of any grade occurred significantly more in the regular dose 
      group (38.8%), as compared to the other two groups (p < 0.05). Mean cumulated 
      headache was higher (p < 0.05) in the regular dose group than in the reduced 
      group during days 5-14. Of 27 patients who dropped out, 15 (55.6%) were due to 
      headache, which was substantially more in regular dose (8, 53.3%), though the 
      difference was statistically insignificant. CONCLUSIONS: Initial reduced dose 
      treatment with ASA+MR-DP may cause fewer headaches than regular dosing, and seems 
      better tolerated by those susceptible to phosphodiesterase inhibitor-induced 
      headache.
CI  - Copyright 2006 S. Karger AG, Basel.
FAU - Chang, Yeu-Jhy
AU  - Chang YJ
AD  - Department of Neurology, Linkou Chang Gung Memorial Hospital, and Chang Gung 
      University, College of Medicine, Taoyuan, Taiwan.
FAU - Ryu, Shan-Jin
AU  - Ryu SJ
FAU - Lee, Tsong-Hai
AU  - Lee TH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20060620
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Dipyridamole/administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Headache/*chemically induced/epidemiology
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Phosphodiesterase Inhibitors/administration & dosage/*adverse effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Prevalence
MH  - Stroke/*prevention & control
MH  - Taiwan/epidemiology
EDAT- 2006/06/22 09:00
MHDA- 2006/11/02 09:00
CRDT- 2006/06/22 09:00
PHST- 2006/03/02 00:00 [accepted]
PHST- 2006/06/22 09:00 [pubmed]
PHST- 2006/11/02 09:00 [medline]
PHST- 2006/06/22 09:00 [entrez]
AID - 94013 [pii]
AID - 10.1159/000094013 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2006;22(4):258-62. doi: 10.1159/000094013. Epub 2006 Jun 20.

PMID- 18695943
OWN - NLM
STAT- MEDLINE
DCOM- 20090421
LR  - 20211020
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 27
IP  - 1
DP  - 2009 Jan
TI  - Association of non-steroidal anti-inflammatory drugs with outcomes in patients 
      with ST-segment elevation myocardial infarction treated with fibrinolytic 
      therapy: an ExTRACT-TIMI 25 analysis.
PG  - 11-7
LID - 10.1007/s11239-008-0264-4 [doi]
AB  - BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) may be prothrombotic, 
      may worsen hypertension or congestive heart failure and obstruct access to the 
      binding site of aspirin to cyclooxygenase-1 and thereby interfere with aspirin's 
      mechanism of action in reducing death and recurrent myocardial infarction (MI). 
      We hypothesized that treatment with NSAIDs prior to an index MI would be 
      associated with an increase in the risk of death, heart failure and recurrent MI 
      among patients with ST-segment elevation MI (STEMI) treated with fibrinolytic 
      therapy. METHODS: In ExTRACT-TIMI 25, patients with STEMI were treated with 
      aspirin and fibrinolytic therapy and randomized to either enoxaparin or 
      unfractionated heparin. We included patients who had received NSAIDs within 7 
      days of enrollment and evaluated the incidence of MI, the composite of death and 
      MI and the composite of death, MI, severe heart failure and shock through 30 
      days. RESULTS: Of 20,479 patients enrolled, 572 (2.8%) received an NSAID within 7 
      days of enrollment. NSAID treatment prior to entry was associated with a higher 
      incidence of 30-day death or nonfatal recurrent MI (15.9% vs. 10.8%, univariate P 
      < 0.001). In multivariable models adjusting for randomization group and 
      differences in baseline characteristics, NSAID use was associated with higher 
      odds of MI (adjusted odds ratio [OR(adj)] 1.44, 95% confidence interval [CI] 
      1.01-2.07, P = 0.047), the composite of death and MI (OR(adj) 1.29, 95% CI 
      1.00-1.66, P = 0.051), and the composite of death, MI, severe heart failure and 
      shock (OR(adj) 1.29, 95% CI 1.02-1.65, P = 0.037). CONCLUSIONS: Among STEMI 
      patients treated with a fibrinolytic agent and aspirin, use of NSAIDs in the week 
      preceding the incident event was associated with a higher incidence of MI, the 
      composite of death and MI as well as the composite of death, MI, severe heart 
      failure and shock at 30 days.
FAU - Gibson, C Michael
AU  - Gibson CM
AD  - TIMI Study Group, Cardiovascular Division, Department of Medicine, Beth Israel 
      Deaconess Medical Center, Harvard Medical School, 350 Longwood Avenue, First 
      Floor, Boston, MA 02115, USA. mgibson@perfuse.org
FAU - Pride, Yuri B
AU  - Pride YB
FAU - Aylward, Philip E
AU  - Aylward PE
FAU - Col, Jacques J
AU  - Col JJ
FAU - Goodman, Shaun G
AU  - Goodman SG
FAU - Gulba, Dietrich
AU  - Gulba D
FAU - Bergovec, Mijo
AU  - Bergovec M
FAU - Kunadian, Vijayalakshmi
AU  - Kunadian V
FAU - Zorkun, Cafer
AU  - Zorkun C
FAU - Buros, Jacqueline L
AU  - Buros JL
FAU - Murphy, Sabina A
AU  - Murphy SA
FAU - Antman, Elliott M
AU  - Antman EM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080810
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticoagulants)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - Combined Modality Therapy
MH  - Comorbidity
MH  - Cyclooxygenase Inhibitors/*adverse effects/therapeutic use
MH  - Disease-Free Survival
MH  - Drug Therapy, Combination
MH  - Enoxaparin/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Heart Failure/epidemiology/etiology
MH  - Hemorrhage/chemically induced/prevention & control
MH  - Heparin/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy/mortality/therapy
MH  - Randomized Controlled Trials as Topic
MH  - *Thrombolytic Therapy/adverse effects
MH  - Treatment Outcome
EDAT- 2008/08/13 09:00
MHDA- 2009/04/22 09:00
CRDT- 2008/08/13 09:00
PHST- 2008/04/29 00:00 [received]
PHST- 2008/07/30 00:00 [accepted]
PHST- 2008/08/13 09:00 [pubmed]
PHST- 2009/04/22 09:00 [medline]
PHST- 2008/08/13 09:00 [entrez]
AID - 10.1007/s11239-008-0264-4 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2009 Jan;27(1):11-7. doi: 10.1007/s11239-008-0264-4. Epub 
      2008 Aug 10.

PMID- 12669143
OWN - NLM
STAT- MEDLINE
DCOM- 20030709
LR  - 20191210
IS  - 1538-5744 (Print)
IS  - 1538-5744 (Linking)
VI  - 37
IP  - 2
DP  - 2003 Mar-Apr
TI  - Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device 
      in patients with peripheral arterial disease.
PG  - 117-23
AB  - A tool to identify vascular patients who receive antiplatelet therapy nd to 
      distinguish between responders and non-responders to antiplatelet therapy could 
      be of clinical importance. The present observational study was designed to 
      investigate whether the PFA-100 device (Dade Behring) is suitable to detect 
      long-term therapy of aspirin (100 mg/d) and/or clopidogrel (75 mg/d) in a cohort 
      of patients with peripheral arterial disease (PAD). A total of 150 consecutive 
      patients with PAD were studied; 34 patients were excluded from the study due to 
      irregular intake of antiplatelet therapy or due to method limitations. Of the 
      remaining 116 patients, 42 had no antiplatelet therapy, 47 had daily aspirin (100 
      mg) intake, 19 were administered clopidogrel 75 mg daily, and 10 received a 
      medication with 100 mg aspirin plus clopidogrel 75 mg daily, all for at least 10 
      days. Nonparametric Kruskal-Wallis test with post hoc comparisons showed that 
      collagen plus epinephrine (CEPI) closure times of the patient group receiving 
      aspirin and the group receiving aspirin plus clopidogrel were similar (p>0.05). 
      In contrast, both patient groups exhibited prolonged CEPI values compared to 
      patients without antiplatelet therapy and patients taking clopidogrel (p<0.001). 
      Finally, both patients without antiplatelet therapy and patients with clopidogrel 
      did not show marked differences with respect to their CEPI values (p>0.05). 
      However, Kruskal-Wallis test results revealed that collagen plus 
      adenosine-5'-diphosphate closure times were not significantly different in all 
      four patient groups (p=0.257). In conclusion, the PFA-100 device may be a 
      suitable tool for monitoring aspirin 100 mg therapy, but it is not appropriate 
      for the detection of clopidogrel administration in its current setup. Although it 
      appears plausible that patients with PAD could benefit from monitoring platelet 
      inhibition, clear evidence for this concept is still lacking.
FAU - Mueller, Thomas
AU  - Mueller T
AD  - Department of Laboratory Medicine, Konventhospital Barmherzige Brueder Linz, 
      Austria.
FAU - Haltmayer, Meinhard
AU  - Haltmayer M
FAU - Poelz, Werner
AU  - Poelz W
FAU - Haidinger, Dieter
AU  - Haidinger D
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Vasc Endovascular Surg
JT  - Vascular and endovascular surgery
JID - 101136421
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vasoconstrictor Agents)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adenosine Diphosphate
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Cohort Studies
MH  - Collagen
MH  - Dose-Response Relationship, Drug
MH  - Epinephrine
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/*drug therapy
MH  - Platelet Aggregation Inhibitors/*administration & dosage/*therapeutic use
MH  - Platelet Function Tests/*instrumentation/*methods
MH  - Prospective Studies
MH  - Sensitivity and Specificity
MH  - Ticlopidine/*administration & dosage/analogs & derivatives/*therapeutic use
MH  - Time Factors
MH  - Vasoconstrictor Agents
EDAT- 2003/04/02 05:00
MHDA- 2003/07/10 05:00
CRDT- 2003/04/02 05:00
PHST- 2003/04/02 05:00 [pubmed]
PHST- 2003/07/10 05:00 [medline]
PHST- 2003/04/02 05:00 [entrez]
AID - 10.1177/153857440303700206 [doi]
PST - ppublish
SO  - Vasc Endovascular Surg. 2003 Mar-Apr;37(2):117-23. doi: 
      10.1177/153857440303700206.

PMID- 3066409
OWN - NLM
STAT- MEDLINE
DCOM- 19890328
LR  - 20131121
IS  - 0753-3322 (Print)
IS  - 0753-3322 (Linking)
VI  - 42
IP  - 8
DP  - 1988
TI  - Aspirin sensitivity and allergy.
PG  - 493-8
AB  - Aspirin sensitivity is divided into 2 main subgroups: the bronchospastic and the 
      urticaria/angioedema type. The bronchospastic type of aspirin sensitivity is 
      frequently associated with nonallergic asthma and nasal polyps, producing a 
      classical triad. Nonsteroid anti-inflammatory drugs (NSAID) crossreact with 
      aspirin in aspirin-sensitive patients. Desensitization to aspirin is possible, 
      but should be carried out with caution in selected patients. Desensitization to 
      aspirin also produces desensitization to NSAID. Acetaminophen and nonacetylated 
      salicylic acid (neither are considered NSAID) cross-react with aspirin in a small 
      number of aspirin-sensitive individuals, usually when large doses are 
      administered. The pathogenic mechanism may involve arachidonic acid and 
      prostaglandin metabolism in the bronchospastic type of aspirin sensitivity.
FAU - Settipane, G A
AU  - Settipane GA
AD  - Division of Allergy, Rhode Island Hospital, Providence 02902.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Asthma/physiopathology
MH  - *Drug Hypersensitivity/physiopathology
MH  - Drug Interactions
MH  - Humans
MH  - Nasal Polyps/physiopathology
RF  - 21
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Biomed Pharmacother. 1988;42(8):493-8.

PMID- 16670507
OWN - NLM
STAT- MEDLINE
DCOM- 20060705
LR  - 20131121
IS  - 1528-4050 (Print)
IS  - 1473-6322 (Linking)
VI  - 6
IP  - 3
DP  - 2006 Jun
TI  - Aspirin desensitization in aspirin intolerance: update on current standards and 
      recent improvements.
PG  - 161-6
AB  - PURPOSE OF REVIEW: This review provides an overview of sensitivity to aspirin 
      (acetylsalicylic acid) and its management. In particular, it focuses on current 
      standards and recent improvements in aspirin desensitization. Recent publications 
      on various desensitization protocols and routes of administration are discussed. 
      RECENT FINDINGS: The incidence of aspirin hypersensitivity in the general 
      population ranges from 0.6-2.5%, but that in adult asthmatics ranges from 
      4.3-11%. Carefully controlled challenge tests with aspirin or other non-steroidal 
      anti-inflammatory drugs are performed as the diagnostic tool of choice. Aspirin 
      desensitization therapy has demonstrated therapeutic effects. Various protocols 
      and routes of administration have been elaborated in the last two decades. Oral 
      administration by means of an initial desensitization with incremental doses of 
      aspirin, followed by daily high-dose therapy, has proven clinical efficacy and 
      safety. Immunological mechanisms of aspirin desensitization therapy are also 
      discussed. SUMMARY: The full clinical picture of aspirin intolerance--the 
      association of aspirin-induced bronchial asthma (with severe acute asthma 
      attacks), aspirin sensitivity and nasal polyps--is commonly summarized as the 
      'Samter triad'. This condition is related to the abnormal metabolism of 
      arachidonic acid, implicating both the lipoxygenase and the cyclooxygenase 
      pathways. Knowledge concerning mechanisms and clinical features of aspirin 
      intolerance has grown rapidly in recent years. Research has focused on new 
      strategies of aspirin desensitization therapy, especially oral administration 
      using high-dosage protocols.
FAU - Pfaar, Oliver
AU  - Pfaar O
AD  - Center for Allergy and Rhinology, Wiesbaden, Germany. 
      oliver.pfaar@hno-wiesbaden.de
FAU - Klimek, Ludger
AU  - Klimek L
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Allergy Clin Immunol
JT  - Current opinion in allergy and clinical immunology
JID - 100936359
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*adverse effects
MH  - Asthma/chemically induced
MH  - Desensitization, Immunologic/*methods
MH  - Drug Hypersensitivity/diagnosis/epidemiology/*therapy
MH  - Humans
MH  - Nasal Polyps/immunology
MH  - Prevalence
RF  - 37
EDAT- 2006/05/04 09:00
MHDA- 2006/07/06 09:00
CRDT- 2006/05/04 09:00
PHST- 2006/05/04 09:00 [pubmed]
PHST- 2006/07/06 09:00 [medline]
PHST- 2006/05/04 09:00 [entrez]
AID - 00130832-200606000-00007 [pii]
AID - 10.1097/01.all.0000225153.45027.6a [doi]
PST - ppublish
SO  - Curr Opin Allergy Clin Immunol. 2006 Jun;6(3):161-6. doi: 
      10.1097/01.all.0000225153.45027.6a.

PMID- 28251159
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20181113
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2017
DP  - 2017
TI  - Effects of Aspirin and Intrauterine Balloon on Endometrial Repair and 
      Reproductive Prognosis in Patients with Severe Intrauterine Adhesion: A 
      Prospective Cohort Study.
PG  - 8526104
LID - 10.1155/2017/8526104 [doi]
LID - 8526104
AB  - This study aimed to investigate the effects of estrogen in combination with 
      aspirin and intrauterine balloon on the uterine endometrial repair and 
      reproductive prognosis in patients after surgery for severe intrauterine adhesion 
      (sIUA). We prospectively recruited 114 patients with sIUA. Intrauterine device 
      (IUD) was placed and oral estrogen was administered after surgery. Patients were 
      divided into control group and aspirin group. In addition, patients in aspirin 
      group were subdivided into nonballoon group and balloon group. Results showed 
      that, after therapy, the increase in endometrial thickness of aspirin groups was 
      superior to control group (P < 0.05). The scores of intrauterine adhesion and 
      menstruation were significantly improved in balloon group as compared to 
      nonballoon group and control group, and significant differences were also 
      observed between nonballoon group and control group (P < 0.05). Of 97 patients, 
      44.3% became pregnant after surgery, the live birth rate was 27.8%, and the 
      miscarriage rate was 37.2%, but there were no significant differences among three 
      groups (P > 0.05). Thus, aspirin may promote the uterine endometrial growth and 
      repair after surgery for sIUA, and IUD in combination with intrauterine balloon 
      may reduce the recurrence of intrauterine adhesion, but their effect on the 
      reproductive prognosis is required to be further studied.
FAU - Chen, Yuqing
AU  - Chen Y
AUID- ORCID: 0000-0002-1824-9168
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Liu, Lixiang
AU  - Liu L
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Luo, Yuanna
AU  - Luo Y
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Chen, Minghui
AU  - Chen M
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Huan, Yang
AU  - Huan Y
AUID- ORCID: 0000-0001-8511-2172
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Fang, Ruili
AU  - Fang R
AD  - Department of Gynecology Ward II, Shenzhen Luohu People's Hospital, Shenzhen 
      518000, China.
LA  - eng
PT  - Journal Article
DEP - 20170130
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Endometrium/diagnostic imaging/*pathology/physiopathology/surgery
MH  - Female
MH  - Humans
MH  - Hysteroscopy
MH  - Menstruation/drug effects
MH  - Postoperative Care
MH  - Pregnancy
MH  - Prognosis
MH  - Prospective Studies
MH  - Reproduction/*drug effects
MH  - Tissue Adhesions/*drug therapy/pathology/physiopathology/surgery
MH  - *Uterine Balloon Tamponade
MH  - Uterine Diseases/*drug therapy/pathology/physiopathology/*surgery
MH  - Wound Healing/*drug effects
PMC - PMC5303840
COIS- The authors declare that they have no competing interests.
EDAT- 2017/03/03 06:00
MHDA- 2017/03/14 06:00
CRDT- 2017/03/03 06:00
PHST- 2016/10/21 00:00 [received]
PHST- 2017/01/05 00:00 [revised]
PHST- 2017/01/10 00:00 [accepted]
PHST- 2017/03/03 06:00 [entrez]
PHST- 2017/03/03 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
AID - 10.1155/2017/8526104 [doi]
PST - ppublish
SO  - Biomed Res Int. 2017;2017:8526104. doi: 10.1155/2017/8526104. Epub 2017 Jan 30.

PMID- 29466201
OWN - NLM
STAT- MEDLINE
DCOM- 20190520
LR  - 20191113
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
IP  - 2
DP  - 2018 Feb
TI  - [Antiaggregants in Primary Prevention of Cardiovascular Diseases and Prevention 
      of Atherothrombosis in Patients With Stable Ischemic Heart Disease: Aspects of 
      Efficacy and Safety].
PG  - 55-67
AB  - This review is devoted to the use of antiaggregants. We consider here 
      pathogenesis of intraarterial thrombosis, mechanism of action of antiaggregants, 
      and recommendations on the use of drugs of this class for primary prevention of 
      cardiovascular diseases and prevention of atherothrombotic complications of 
      stable ischemic heart disease. Information on mechanisms of development and 
      causes of resistance to antiaggregants is also presented. Finally we discuss the 
      problem of safety of therapy with antiaggregants, methods of lowering the risk of 
      bleeding, and prevention of aspirin induced gastropathy.
FAU - Perepech, N B
AU  - Perepech NB
AD  - St. Petersburg State University.
FAU - Mikhaylova, I E
AU  - Mikhaylova IE
AD  - Federal State Budgetary Educational Institution of Higher Education 
      "Saint-Petersburg State University".
LA  - rus
PT  - Journal Article
PT  - Review
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - *Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - *Myocardial Ischemia
MH  - Platelet Aggregation Inhibitors
MH  - Primary Prevention
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - antiaggregants
OT  - atherothrombosis
OT  - bleeding
OT  - gastropathy
EDAT- 2018/02/22 06:00
MHDA- 2019/05/21 06:00
CRDT- 2018/02/22 06:00
PHST- 2018/02/22 06:00 [entrez]
PHST- 2018/02/22 06:00 [pubmed]
PHST- 2019/05/21 06:00 [medline]
AID - 10.18087/cardio.2018.2.10035 [doi]
PST - ppublish
SO  - Kardiologiia. 2018 Feb;(2):55-67. doi: 10.18087/cardio.2018.2.10035.

PMID- 17332149
OWN - NLM
STAT- MEDLINE
DCOM- 20070521
LR  - 20190722
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 53
IP  - 4
DP  - 2007 Apr
TI  - Determination of aspirin responsiveness by use of whole blood platelet 
      aggregometry.
PG  - 614-9
AB  - BACKGROUND: Insufficient platelet inhibition is associated with an increased 
      cardiovascular risk in up to 30% of patients taking regular doses of aspirin. We 
      describe an assay to study aspirin responsiveness. METHODS: We performed 
      impedance aggregometry on diluted whole blood with 1 mg/L collagen and 0.5 mmol/L 
      arachidonic acid (AA). We measured thromboxane B(2) (TXB(2)) by RIA. We examined 
      66 healthy control individuals, 144 aspirin users with stable coronary artery 
      disease (CAD), and 245 CAD patients treated with aspirin and clopidogrel. 
      Nonresponsive samples were incubated with excess DL-lysinmonoacetylsalicylic 
      acid. RESULTS: Assay imprecision (CV) was 9.8% and 8.2% at mean (SD) 6-min 
      impedance of 13.7 (2.8) Omega and 13.6 (2.3) Omega for collagen and AA, 
      respectively. Collagen induced stronger aggregation (P = 0.0199) in women [n = 
      28, 14.6 (2.4) Omega] than in men [n = 38, 13.1 (2.9) Omega], even after sample 
      incubation with 0.1 mmol/L acetylsalicylic acid (ASA) or 1 micromol/L terbogrel, 
      a combined inhibitor of thromboxane synthase and receptors. The sex association 
      persisted in aspirin users, but not if clopidogrel was also taken. A 6-min 
      impedance >8 Omega with collagen (mean - 2 SD of the controls) was taken as 
      evidence of nonresponsiveness, particularly if incubation with ASA did not 
      inhibit aggregation further (>2 Omega). Compared with AA, collagen identified 
      more nonresponsive samples among aspirin users (15%) and CAD patients who also 
      received clopidogrel (10%). Incubation with ASA improved inhibition of 
      aggregation in 70% of samples and consistently reduced TXB(2) formation during 
      aggregation. CONCLUSIONS: Impedance aggregometry may prove useful to study 
      aspirin responsiveness, and incubation with ASA may help to identify 
      nonresponders and classify resistance.
FAU - Ivandic, Boris T
AU  - Ivandic BT
AD  - Department of Medicine III, University of Heidelberg, Germany. 
      Boris.Ivandic@med.uni-heidelberg.de
FAU - Giannitsis, Evangelos
AU  - Giannitsis E
FAU - Schlick, Philipp
AU  - Schlick P
FAU - Staritz, Peter
AU  - Staritz P
FAU - Katus, Hugo A
AU  - Katus HA
FAU - Hohlfeld, Thomas
AU  - Hohlfeld T
LA  - eng
PT  - Journal Article
DEP - 20070301
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 5Z4KWQ5OGN (terbogrel)
RN  - 9007-34-5 (Collagen)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/analogs & derivatives/*pharmacology
MH  - Blood Donors
MH  - Clopidogrel
MH  - Collagen/pharmacology
MH  - Coronary Artery Disease/blood/prevention & control
MH  - *Drug Resistance
MH  - Electric Impedance
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
MH  - Pyridines/pharmacology
MH  - Reference Values
MH  - Sex Factors
MH  - Thromboxane B2/blood
MH  - Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
EDAT- 2007/03/03 09:00
MHDA- 2007/05/22 09:00
CRDT- 2007/03/03 09:00
PHST- 2007/03/03 09:00 [pubmed]
PHST- 2007/05/22 09:00 [medline]
PHST- 2007/03/03 09:00 [entrez]
AID - clinchem.2006.081059 [pii]
AID - 10.1373/clinchem.2006.081059 [doi]
PST - ppublish
SO  - Clin Chem. 2007 Apr;53(4):614-9. doi: 10.1373/clinchem.2006.081059. Epub 2007 Mar 
      1.

PMID- 15327823
OWN - NLM
STAT- MEDLINE
DCOM- 20041109
LR  - 20161124
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 111
IP  - 1-2
DP  - 2004 Sep
TI  - Induction of opioid tolerance by lysine-acetylsalicylate in rats.
PG  - 191-200
AB  - The analgesic effect of non-steroidal antiinflammatory drugs (NSAIDs) is due to 
      their action upon the peripheral damaged tissues, the spinal cord, and brain stem 
      structures of the 'descending pain-control system' such as the periaqueductal 
      gray matter (PAG) and the nucleus raphe magnus (NRM). The NSAID dipyrone 
      (metamizol) has been shown to engage opioidergic circuits at the PAG, the NRM and 
      the spinal cord, but it is unknown whether this can be generalized to typical 
      NSAIDs and to systemic administration. In the present study 
      lysine-acetylsalicylate (LASA), an injectable form of the prototypical NSAID 
      aspirin, was microinjected into the PAG (100 microg/0.5 microl) in freely moving 
      rats to induce inhibition of tail flick and hot plate responses. This 
      antinociception was reverted by naloxone (1 mg/kg i.p.). PAG microinjection of 
      LASA twice daily for three days induced tolerance to LASA (i.e. a progressive 
      loss of effectiveness) and cross-tolerance to PAG-microinjected morphine (5 
      microg/0.5 microl). The antinociceptive effect of systemically administered LASA 
      (300 mg/kg i.p., equivalent to the 1000 mg analgesic dose for humans) was also 
      abolished by naloxone. Intraperitoneal injection of LASA twice daily induced 
      tolerance to LASA and cross-tolerance to i.p. morphine (1 or 5 mg/kg). 
      LASA-tolerant rats showed opioid withdrawal signs when injected with naloxone. 
      These findings support the notion that the contribution of the PAG and downstream 
      pain-control structures to the analgesic effect of NSAIDs involves opioidergic 
      mechanisms, and suggest that repeated therapeutic administration of NSAIDs may 
      induce tolerance, cross-tolerance to opiates, and susceptibility to a withdrawal 
      syndrome.
FAU - Pernia-Andrade, Alejandro J
AU  - Pernia-Andrade AJ
AD  - Instituto Venezolano de Investigaciones Cientificas, Apartado 21827, Caracas 
      1020A, Venezuela.
FAU - Tortorici, Victor
AU  - Tortorici V
FAU - Vanegas, Horacio
AU  - Vanegas H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Narcotic Antagonists)
RN  - 0 (Opioid Peptides)
RN  - 36B82AMQ7N (Naloxone)
RN  - 76I7G6D29C (Morphine)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Analgesics/*pharmacology
MH  - Analgesics, Opioid/*pharmacology
MH  - Animals
MH  - Aspirin/*analogs & derivatives/*pharmacology
MH  - Drug Interactions
MH  - Drug Tolerance
MH  - Lysine/*analogs & derivatives/*pharmacology
MH  - Male
MH  - Microinjections
MH  - Morphine/*pharmacology
MH  - Naloxone/pharmacology
MH  - Narcotic Antagonists/pharmacology
MH  - Nociceptors/metabolism
MH  - Opioid Peptides/*metabolism
MH  - Periaqueductal Gray/*drug effects/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2004/08/26 05:00
MHDA- 2004/11/13 09:00
CRDT- 2004/08/26 05:00
PHST- 2003/09/30 00:00 [received]
PHST- 2004/04/21 00:00 [revised]
PHST- 2004/06/14 00:00 [accepted]
PHST- 2004/08/26 05:00 [pubmed]
PHST- 2004/11/13 09:00 [medline]
PHST- 2004/08/26 05:00 [entrez]
AID - S0304395904002933 [pii]
AID - 10.1016/j.pain.2004.06.006 [doi]
PST - ppublish
SO  - Pain. 2004 Sep;111(1-2):191-200. doi: 10.1016/j.pain.2004.06.006.

PMID- 4019556
OWN - NLM
STAT- MEDLINE
DCOM- 19850827
LR  - 20131121
IS  - 0008-2902 (Print)
IS  - 0008-2902 (Linking)
VI  - 36
IP  - 2
DP  - 1985 Jun
TI  - Preliminary report: acetylsalicylic acid therapy in the treatment of 
      complications following abdominal radiation.
PG  - 138-40
AB  - A group of 10 patients with complications following pelvic irradiation were 
      treated with acetylsalicylic acid (ASA). Epithelial ulceration was healed in four 
      of six patients and improved in one. Radiation enteritis was decreased or 
      abolished in all patients who remained on ASA.
FAU - Ludgate, C M
AU  - Ludgate CM
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - J Can Assoc Radiol
JT  - Journal of the Canadian Association of Radiologists
JID - 7505589
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abdomen/*radiation effects
MH  - Aspirin/*therapeutic use
MH  - Dose-Response Relationship, Radiation
MH  - Endarteritis/drug therapy/*etiology
MH  - Humans
MH  - Platelet Aggregation/radiation effects
MH  - Radiation Injuries/*drug therapy
MH  - Radiotherapy/*adverse effects
EDAT- 1985/06/01 00:00
MHDA- 1985/06/01 00:01
CRDT- 1985/06/01 00:00
PHST- 1985/06/01 00:00 [pubmed]
PHST- 1985/06/01 00:01 [medline]
PHST- 1985/06/01 00:00 [entrez]
PST - ppublish
SO  - J Can Assoc Radiol. 1985 Jun;36(2):138-40.

PMID- 7262284
OWN - NLM
STAT- MEDLINE
DCOM- 19811014
LR  - 20190629
IS  - 0014-4754 (Print)
IS  - 0014-4754 (Linking)
VI  - 37
IP  - 6
DP  - 1981 Jun
TI  - Methyleugenol as a surgical anesthetic in rodents.
PG  - 588-9
AB  - The in vivo administration of 59Fe to the rat accompanied by acetylsalicylic acid 
      (ASA) enhanced significantly counts in blood, spleen, liver and femur without 
      affecting those of the intestine. The results suggest that ASA augments iron 
      absorption either via an inhibitory action on the synthesis of prostaglandins or 
      by a purely chemical mechanism.
FAU - Carlini, E A
AU  - Carlini EA
FAU - Dallmeier, K
AU  - Dallmeier K
FAU - Zelger, J L
AU  - Zelger JL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Experientia
JT  - Experientia
JID - 0376547
RN  - E1UOL152H7 (Iron)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Bone and Bones/metabolism
MH  - Intestinal Absorption/*drug effects
MH  - Intestinal Mucosa/metabolism
MH  - Iron/*metabolism
MH  - Liver/metabolism
MH  - Male
MH  - Organ Specificity
MH  - Rats
MH  - Spleen/metabolism
EDAT- 1981/06/01 00:00
MHDA- 1981/06/01 00:01
CRDT- 1981/06/01 00:00
PHST- 1981/06/01 00:00 [pubmed]
PHST- 1981/06/01 00:01 [medline]
PHST- 1981/06/01 00:00 [entrez]
AID - 10.1007/BF01990065 [doi]
PST - ppublish
SO  - Experientia. 1981 Jun;37(6):588-9. doi: 10.1007/BF01990065.

PMID- 32658349
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 1742-481X (Electronic)
IS  - 1742-4801 (Print)
IS  - 1742-4801 (Linking)
VI  - 17
IP  - 6
DP  - 2020 Dec
TI  - Rationale for participation in venous leg ulcer clinical research: Patient 
      interview study.
PG  - 1624-1633
LID - 10.1111/iwj.13438 [doi]
AB  - Recruitment to wound care clinical trials is challenging and a better 
      understanding of patient decisions to participate has the potential to influence 
      recruitment success. We conducted 31 semi-structured telephone interviews of 
      patients who participated in the Aspirin in Venous Leg Ulcer (ASPiVLU) randomised 
      controlled trail (RCT) or ASPiVLU cohort study. Data were coded and analysed 
      using thematic analysis. We identified four key themes: (a) "I participated to 
      help others"; (b) "I participated in research to thank those who cared for me"; 
      (c) "I participated to receive better care"; and (d) "I participated to have a 
      say on what works." These themes became basic elements for the Rationale for 
      Research Participation Framework that we have developed to improve the 
      participant recruitment process for clinical trials in wound care.
CI  - © 2020 Medicalhelplines.com Inc and John Wiley & Sons Ltd.
FAU - Weller, Carolina D
AU  - Weller CD
AUID- ORCID: 0000-0002-8016-1060
AD  - Monash Nursing and Midwifery, Monash University, Melbourne, Victoria, Australia.
FAU - Richards, Catelyn
AU  - Richards C
AD  - Monash Nursing and Midwifery, Monash University, Melbourne, Victoria, Australia.
FAU - Turnour, Louise
AU  - Turnour L
AD  - Monash Nursing and Midwifery, Monash University, Melbourne, Victoria, Australia.
FAU - Team, Victoria
AU  - Team V
AUID- ORCID: 0000-0001-6615-6874
AD  - Monash Nursing and Midwifery, Monash University, Melbourne, Victoria, Australia.
LA  - eng
GR  - APP1069329/National Health and Medical Research Council/
GR  - APP1132444/National Health and Medical Research Council/
PT  - Journal Article
DEP - 20200713
PL  - England
TA  - Int Wound J
JT  - International wound journal
JID - 101230907
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Humans
MH  - *Leg Ulcer/therapy
MH  - Male
MH  - Middle Aged
MH  - *Motivation
MH  - Patient Participation/*psychology
MH  - Randomized Controlled Trials as Topic
MH  - *Varicose Ulcer/therapy
MH  - Wound Healing
PMC - PMC7948544
OTO - NOTNLM
OT  - clinical trials
OT  - patient perspectives
OT  - research participation enablers
OT  - venous leg ulcer
OT  - wound research
COIS- The authors declare that the research was conducted in the absence of any 
      personal, professional, commercial and financial relationships that could be 
      construed as a potential conflict of interest.
EDAT- 2020/07/14 06:00
MHDA- 2021/08/07 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/06/03 00:00 [revised]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - IWJ13438 [pii]
AID - 10.1111/iwj.13438 [doi]
PST - ppublish
SO  - Int Wound J. 2020 Dec;17(6):1624-1633. doi: 10.1111/iwj.13438. Epub 2020 Jul 13.

PMID- 20462336
OWN - NLM
STAT- MEDLINE
DCOM- 20100818
LR  - 20181201
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 6
IP  - 3
DP  - 2010 May
TI  - Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in 
      patients with cardiovascular disease.
PG  - 289-99
LID - 10.2217/fca.10.20 [doi]
AB  - Studies with recently introduced point-of-care (POC) platelet function tests have 
      shown that individuals are variably responsive to aspirin and clopidogrel 
      therapy, and that hyporesponsiveness to antiplatelet therapy is associated with 
      an increased risk of cardiovascular events. However, the currently available POC 
      tests have undergone only limited clinical evaluation and clinicians are 
      uncertain about the best POC test, the optimal cut-off point to define 
      hyporesponsiveness in different patient populations and clinical settings, the 
      appropriate management of patients demonstrating hyporesponsiveness and the cost 
      effectiveness of adjusting treatment on the basis of the results of POC platelet 
      function testing. Several large randomized controlled trials currently underway 
      are examining whether adjusting antiplatelet therapy on the basis of a POC test 
      result can improve patient-important outcomes. Until these issues are resolved, 
      POC testing to monitor antiplatelet therapy will largely remain a research tool 
      and patients should continue to receive oral antiplatelet therapy without routine 
      monitoring at doses that have been demonstrated to be effective in randomized 
      controlled trials.
FAU - Sobieraj-Teague, Magdalena
AU  - Sobieraj-Teague M
AD  - Hamilton Health Sciences, McMaster University, Hamilton, Ontario L8L 2X2, Canada. 
      teaguem@mcmaster.ca
FAU - Eikelboom, John W
AU  - Eikelboom JW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Aspirin/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clopidogrel
MH  - Cost-Benefit Analysis
MH  - Drug Resistance
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - *Point-of-Care Systems
MH  - Ticlopidine/analogs & derivatives/therapeutic use
RF  - 61
EDAT- 2010/05/14 06:00
MHDA- 2010/08/19 06:00
CRDT- 2010/05/14 06:00
PHST- 2010/05/14 06:00 [entrez]
PHST- 2010/05/14 06:00 [pubmed]
PHST- 2010/08/19 06:00 [medline]
AID - 10.2217/fca.10.20 [doi]
PST - ppublish
SO  - Future Cardiol. 2010 May;6(3):289-99. doi: 10.2217/fca.10.20.

PMID- 6792646
OWN - NLM
STAT- MEDLINE
DCOM- 19811122
LR  - 20191031
IS  - 0161-4630 (Print)
IS  - 0161-4630 (Linking)
VI  - 7
IP  - 2
DP  - 1981 Aug
TI  - Non-interference by salicylate with aspirin inhibition of arterial thrombosis in 
      rats.
PG  - 91-4
AB  - Several authors have reported that salicylate blocks and reverses aspirin 
      inhibition of prostaglandin synthesis by platelets and arterial wall. Male rats 
      were given sodium salicylate 15 or 100 mg/kg i.v. 2 min before receiving aspirin, 
      10 mg/kg i.v. Right and left carotid arteries were injured electrically before 
      and after drug administration and thrombus generation recorded by measuring 
      downstream temperature. Significant antithrombotic effect of aspirin was observed 
      in all cases regardless of prior salicylate administration and the results were 
      similar to those obtained with aspirin alone. Thus competition between salicylate 
      and aspirin as reported in vitro does not appear to significantly affect the in 
      vivo antithrombotic action of aspirin in this model.
FAU - Philp, R B
AU  - Philp RB
FAU - Paul, M L
AU  - Paul ML
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prostaglandins Med
JT  - Prostaglandins and medicine
JID - 7810330
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - Carotid Artery Thrombosis/drug therapy/*prevention & control
MH  - Cyclooxygenase Inhibitors
MH  - Drug Interactions
MH  - Male
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Sodium Salicylate/*pharmacology
EDAT- 1981/08/01 00:00
MHDA- 1981/08/01 00:01
CRDT- 1981/08/01 00:00
PHST- 1981/08/01 00:00 [pubmed]
PHST- 1981/08/01 00:01 [medline]
PHST- 1981/08/01 00:00 [entrez]
AID - 10.1016/0161-4630(81)90052-5 [doi]
PST - ppublish
SO  - Prostaglandins Med. 1981 Aug;7(2):91-4. doi: 10.1016/0161-4630(81)90052-5.

PMID- 6373214
OWN - NLM
STAT- MEDLINE
DCOM- 19840705
LR  - 20190913
IS  - 0012-6578 (Print)
IS  - 0012-6578 (Linking)
VI  - 18
IP  - 5
DP  - 1984 May
TI  - Injectable ketoprofen vs. acetylsalicylic acid for the relief of severe cancer 
      pain: a double-blind, crossover trial.
PG  - 403-6
AB  - Thirty-six patients suffering from severe pain due to bone involvement from 
      cancer participated in an analgesic study that compared single doses of 
      ketoprofen 100 or 400 mg iv or injectable acetylsalicylic acid 1 g. A 
      double-blind, balanced incomplete block design was adopted, in which each patient 
      received two of the three test treatments, with an interval of 24 hours. 
      Ketoprofen 400 mg proved significantly superior to 100 mg of the same drug, and 
      was superior to 1 g of the acetylsalicylic acid derivative in the patients' 
      assessment of the overall response. This was expressed by a visual analog scale 
      and preferences. No adverse reaction was observed with any treatment.
FAU - Sacchetti, G
AU  - Sacchetti G
FAU - Camera, P
AU  - Camera P
FAU - Rossi, A P
AU  - Rossi AP
FAU - Martoni, A
AU  - Martoni A
FAU - Bruni, G
AU  - Bruni G
FAU - Pannuti, F
AU  - Pannuti F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Drug Intell Clin Pharm
JT  - Drug intelligence & clinical pharmacy
JID - 0212457
RN  - 0 (Phenylpropionates)
RN  - 90Y4QC304K (Ketoprofen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Ketoprofen/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*physiopathology
MH  - Pain/*drug therapy
MH  - Phenylpropionates/*therapeutic use
EDAT- 1984/05/01 00:00
MHDA- 1984/05/01 00:01
CRDT- 1984/05/01 00:00
PHST- 1984/05/01 00:00 [pubmed]
PHST- 1984/05/01 00:01 [medline]
PHST- 1984/05/01 00:00 [entrez]
AID - 10.1177/106002808401800510 [doi]
PST - ppublish
SO  - Drug Intell Clin Pharm. 1984 May;18(5):403-6. doi: 10.1177/106002808401800510.

PMID- 7228453
OWN - NLM
STAT- MEDLINE
DCOM- 19810709
LR  - 20131121
IS  - 0174-4879 (Print)
IS  - 0174-4879 (Linking)
VI  - 19
IP  - 3
DP  - 1981 Mar
TI  - Effects of acetylsalicylic acid on plasma lipids and on post-heparin lipase 
      activities.
PG  - 112-6
AB  - Acetylsalicylic acid (ASA) was administered orally at the dose of 3 g a day for 2 
      days to healthy subjects. Plasma free fatty acids, serum triglycerides and 
      prebetalipoproteins were significantly decreased, while cholesterol, beta and 
      alpha 1 lipoproteins did not change. The two fractions (protamine-resistant and 
      protamine-inactivated) of plasma post-heparin lipoprotein lipase activity (PHLA) 
      significantly fell after ASA. PHLA diminution was reproduced by direct addition 
      of ASA or sodium salicylate or of plasma from individuals under treatment with 
      ASA to post-heparin plasma of untreated subjects and is, therefore, explained by 
      a direct inactivation. The inhibition of PHLA was not followed by a significant 
      impairment of the removal of circulating triglycerides.
FAU - Sommariva, D
AU  - Sommariva D
FAU - Bonfiglioli, D
AU  - Bonfiglioli D
FAU - Zanaboni, L
AU  - Zanaboni L
FAU - Fasoli, A
AU  - Fasoli A
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther Toxicol
JT  - International journal of clinical pharmacology, therapy, and toxicology
JID - 8003415
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Lipids)
RN  - 0 (Triglycerides)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.1.1.34 (Lipoprotein Lipase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Fatty Acids, Nonesterified/blood
MH  - Female
MH  - Heparin/pharmacology
MH  - Humans
MH  - Lipids/*blood
MH  - Lipoprotein Lipase/*blood
MH  - Male
MH  - Middle Aged
MH  - Triglycerides/blood
EDAT- 1981/03/01 00:00
MHDA- 1981/03/01 00:01
CRDT- 1981/03/01 00:00
PHST- 1981/03/01 00:00 [pubmed]
PHST- 1981/03/01 00:01 [medline]
PHST- 1981/03/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther Toxicol. 1981 Mar;19(3):112-6.

PMID- 36316613
OWN - NLM
STAT- MEDLINE
DCOM- 20230119
LR  - 20230119
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Jan
TI  - Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with 
      Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the 
      COMPASS Eligibility in a Large Multicenter Registry.
PG  - 77-87
LID - 10.1007/s40256-022-00554-5 [doi]
AB  - BACKGROUND: Patients with previous acute coronary syndrome (ACS) are at high risk 
      of recurrent adverse cardiovascular events. Recently, prolonged dual antiplatelet 
      therapy (DAPT) and oral anticoagulation therapy (OAT) have been shown to reduce 
      recurrent ischemic events to the expense of an increase in bleeding events. The 
      number of patients potentially eligible for these therapies in real life remains 
      to be determined. METHODS: Among ACS patients from five registries and one 
      randomized controlled trial, we assessed the proportion of patients eligible for 
      the PEGASUS strategy only and the proportion of patients eligible for the COMPASS 
      strategy only, and set out the proportion of patients with an overlap between the 
      strategies. FINDINGS: Among the 10,048 evaluable patients, we found that 5373 
      (53.4%) were eligible for the PEGASUS strategy and 3841 (38.2%) were eligible for 
      the COMPASS strategy, with a group of 3444 (34.4%) overlapping between the two 
      strategies. The number of patients eligible for the PEGASUS strategy only was 
      1929 (19.2%) and the number eligible for the COMPASS strategy only was 397 
      (4.0%); 4278 (42.6%) were eligible for neither a PEGASUS strategy nor a COMPASS 
      strategy. INTERPRETATION: In a large cohort of ACS patients, one in three 
      patients was eligible for either a prolonged DAPT with ticagrelor 60 mg and 
      low-dose aspirin or a dual pathway inhibition approach with rivaroxaban 2.5 mg 
      and low-dose aspirin.
CI  - © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Millesimo, Michele
AU  - Millesimo M
AUID- ORCID: 0000-0002-7903-4873
AD  - Division of Cardiology, Department of Medical Sciences, AOU Città della Salute e 
      della Scienza, University of Turin, Corso Bramante 88/90, 10126, Turin, Italy. 
      michele.millesimo@gmail.com.
FAU - Elia, Edoardo
AU  - Elia E
AD  - Division of Cardiology, Department of Medical Sciences, AOU Città della Salute e 
      della Scienza, University of Turin, Corso Bramante 88/90, 10126, Turin, Italy.
FAU - Marengo, Giorgio
AU  - Marengo G
AD  - Division of Cardiology, Department of Medical Sciences, AOU Città della Salute e 
      della Scienza, University of Turin, Corso Bramante 88/90, 10126, Turin, Italy.
FAU - De Filippo, Ovidio
AU  - De Filippo O
AD  - Division of Cardiology, Department of Medical Sciences, AOU Città della Salute e 
      della Scienza, University of Turin, Corso Bramante 88/90, 10126, Turin, Italy.
FAU - Raposeiras-Roubin, Sergio
AU  - Raposeiras-Roubin S
AD  - Department of Cardiology, University Hospital Álvaro Cunqueiro, Vigo, Spain.
FAU - Wańha, Wojciech
AU  - Wańha W
AD  - Department of Cardiology and Structural Heart Diseases, Medical University of 
      Silesia, Katowice, Poland.
FAU - Abu-Assi, Emad
AU  - Abu-Assi E
AD  - Department of Cardiology, University Hospital Álvaro Cunqueiro, Vigo, Spain.
FAU - Kinnaird, Tim
AU  - Kinnaird T
AD  - Cardiology Department, University Hospital of Wales, Cardiff, UK.
FAU - Ariza-Solé, Albert
AU  - Ariza-Solé A
AD  - Department of Cardiology, University Hospital de Bellvitge, Barcelona, Spain.
FAU - Liebetrau, Christoph
AU  - Liebetrau C
AD  - Kerckhoff Heart and Thorax Center, Frankfurt, Germany.
FAU - Manzano-Fernández, Sergio
AU  - Manzano-Fernández S
AD  - Department of Cardiology, University Hospital Virgen Arrtixaca, Murcia, Spain.
FAU - Iannaccone, Mario
AU  - Iannaccone M
AD  - Department of Cardiology, S.G. Bosco Hospital, Turin, Italy.
FAU - Henriques, Jose Paulo Simao
AU  - Henriques JPS
AD  - Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Templin, Christian
AU  - Templin C
AD  - Division of Cardiology, University Hospital Zurich, Zurich, Switzerland.
FAU - Wilton, Stephen B
AU  - Wilton SB
AD  - Cardiovascular Institute of Alberta, Calgary, AB, Canada.
FAU - Velicki, Lazar
AU  - Velicki L
AD  - Institute of Cardiovascular Diseases, Vojvodina, Serbia.
FAU - Xanthopoulou, Ioanna
AU  - Xanthopoulou I
AD  - University Patras Hospital, Athens, Greece.
FAU - Correia, Luis
AU  - Correia L
AD  - Hospital Sao Rafael, Salvador, Brazil.
FAU - Cerrato, Enrico
AU  - Cerrato E
AD  - Interventional Unit, San Luigi Gonzaga University Hospital, Orbassano, Turin, 
      Italy.
FAU - Rognoni, Andrea
AU  - Rognoni A
AD  - Catheterization Laboratory, Maggiore della Carità Hospital, Novara, Italy.
FAU - Nuñez-Gil, Iván
AU  - Nuñez-Gil I
AD  - San Carlos Hospital, Madrid, Spain.
FAU - Song, Xiantao
AU  - Song X
AD  - Anzhen Hospital, Beijing, China.
FAU - Kawaji, Tetsuma
AU  - Kawaji T
AD  - University Clinical Hospital, Kyoto, Japan.
FAU - Quadri, Giorgio
AU  - Quadri G
AD  - Department of Cardiology, Infermi Hospital, Rivoli, Turin, Italy.
FAU - Huczek, Zenon
AU  - Huczek Z
AD  - University Clinical Hospital, Warsaw, Poland.
FAU - Paz, Rafael Cobas
AU  - Paz RC
AD  - Cardiology Department, University Hospital of Wales, Cardiff, UK.
FAU - Juanatey, José Ramón González
AU  - Juanatey JRG
AD  - University Clinical Hospital, Santiago de Compostela, Spain.
FAU - Nie, Shao-Ping
AU  - Nie SP
AD  - Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
FAU - Kawashiri, Masa-Aki
AU  - Kawashiri MA
AD  - Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
FAU - Dominguez-Rodriguez, Alberto
AU  - Dominguez-Rodriguez A
AD  - Servicio de Cardiologìa, Hospital Universitario de Canarias, Santa Cruz de 
      Tenerife, Spain.
FAU - Conrotto, Federico
AU  - Conrotto F
AD  - Division of Cardiology, Department of Medical Sciences, AOU Città della Salute e 
      della Scienza, University of Turin, Corso Bramante 88/90, 10126, Turin, Italy.
FAU - D'Ascenzo, Fabrizio
AU  - D'Ascenzo F
AD  - Division of Cardiology, Department of Medical Sciences, AOU Città della Salute e 
      della Scienza, University of Turin, Corso Bramante 88/90, 10126, Turin, Italy.
FAU - De Ferrari, Gaetano Maria
AU  - De Ferrari GM
AD  - Division of Cardiology, Department of Medical Sciences, AOU Città della Salute e 
      della Scienza, University of Turin, Corso Bramante 88/90, 10126, Turin, Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20221031
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - *Acute Coronary Syndrome/drug therapy
MH  - Fibrinolytic Agents/adverse effects
MH  - Secondary Prevention
MH  - Aspirin/therapeutic use
MH  - Registries
MH  - Drug Therapy, Combination
MH  - Treatment Outcome
EDAT- 2022/11/02 06:00
MHDA- 2023/01/20 06:00
CRDT- 2022/11/01 00:40
PHST- 2022/10/04 00:00 [accepted]
PHST- 2022/11/02 06:00 [pubmed]
PHST- 2023/01/20 06:00 [medline]
PHST- 2022/11/01 00:40 [entrez]
AID - 10.1007/s40256-022-00554-5 [pii]
AID - 10.1007/s40256-022-00554-5 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2023 Jan;23(1):77-87. doi: 10.1007/s40256-022-00554-5. 
      Epub 2022 Oct 31.

PMID- 31243598
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20200702
IS  - 1573-675X (Electronic)
IS  - 1360-8185 (Linking)
VI  - 24
IP  - 9-10
DP  - 2019 Oct
TI  - Aspirin induces oncosis in tumor cells.
PG  - 758-772
LID - 10.1007/s10495-019-01555-7 [doi]
AB  - In contrast to the well-known anti-tumor mechanisms of aspirin in inducing 
      apoptosis or autophagy, we here for the first time report oncosis induced by 
      aspirin in tumor cells. In vitro and in vivo analysis showed that aspirin induced 
      compromised Bcl-XL level and subsequent ATP depletion. Overexpression of 
      CFP-Bcl-XL in Hela and A549 cells observably inhibited aspirin-induced ATP 
      depletion and almost completely inhibited the aspirin-induced cells bubbling, 
      while pharmacological inhibition of endogenous Bcl-XL activity by ABT-737 
      remarkably promoted aspirin-induced ATP depletion and cells bubbling, suggesting 
      the key inhibitory role of Bcl-XL in aspirin-induced oncosis. Overexpression of 
      Bax/Bad significantly promoted aspirin-induced oncosis. In addition, cells 
      cultured in a glucose-free medium with low ATP level exhibited higher percentage 
      of bubbling cells than the cells cultured in a glucose medium with high ATP level 
      under aspirin treatment, indicating the important role of ATP depletion in 
      aspirin-induced oncosis. Furthermore, caspase-3 was demonstrated to be not 
      involved in aspirin-induced oncosis. Animal studies showed that aspirin treatment 
      significantly inhibited tumors growth, but did not induce toxicities to mice. 
      Collectively, aspirin inhibits tumors growth in mice and induces oncosis in which 
      the compromised Bcl-XL and intracellular ATP depletion play a dominant role, 
      which provides insights into the therapeutic strategy of aspirin in oncology.
FAU - Wang, Lu
AU  - Wang L
AD  - MOE Key Laboratory of Laser Life Science & College of Biophotonics, South China 
      Normal University, Guangzhou, 510631, China.
FAU - Mai, Zihao
AU  - Mai Z
AD  - MOE Key Laboratory of Laser Life Science & College of Biophotonics, South China 
      Normal University, Guangzhou, 510631, China.
FAU - Zhao, Mengxin
AU  - Zhao M
AD  - Department of Pain Management, The First Affiliated Hospital, Jinan University, 
      Guangzhou, 5610632, China.
FAU - Wang, Bin
AU  - Wang B
AD  - MOE Key Laboratory of Laser Life Science & College of Biophotonics, South China 
      Normal University, Guangzhou, 510631, China.
FAU - Yu, Si
AU  - Yu S
AD  - MOE Key Laboratory of Laser Life Science & College of Biophotonics, South China 
      Normal University, Guangzhou, 510631, China.
FAU - Wang, Xiaoping
AU  - Wang X
AD  - Department of Pain Management, The First Affiliated Hospital, Jinan University, 
      Guangzhou, 5610632, China. txp2938@jnu.edu.cn.
FAU - Chen, Tongsheng
AU  - Chen T
AD  - MOE Key Laboratory of Laser Life Science & College of Biophotonics, South China 
      Normal University, Guangzhou, 510631, China. chentsh@scnu.edu.cn.
LA  - eng
GR  - 61875056/National Natural Science Foundation of China/International
GR  - 61527825/National Natural Science Foundation of China/International
GR  - 81572184/National Natural Science Foundation of China/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Apoptosis
JT  - Apoptosis : an international journal on programmed cell death
JID - 9712129
RN  - 0 (bcl-X Protein)
RN  - EC 3.4.22.- (Caspase 3)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Apoptosis
MH  - Aspirin/*pharmacology
MH  - Caspase 3/metabolism
MH  - Cell Line, Tumor
MH  - HeLa Cells
MH  - Humans
MH  - Mice
MH  - Neoplasms/*drug therapy/metabolism
MH  - bcl-X Protein/drug effects/metabolism
OTO - NOTNLM
OT  - ATP depletion
OT  - Aspirin
OT  - Bcl-XL
OT  - Caspase-3
OT  - Oncosis
EDAT- 2019/06/28 06:00
MHDA- 2020/07/03 06:00
CRDT- 2019/06/28 06:00
PHST- 2019/06/28 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
PHST- 2019/06/28 06:00 [entrez]
AID - 10.1007/s10495-019-01555-7 [pii]
AID - 10.1007/s10495-019-01555-7 [doi]
PST - ppublish
SO  - Apoptosis. 2019 Oct;24(9-10):758-772. doi: 10.1007/s10495-019-01555-7.

PMID- 25595209
OWN - NLM
STAT- MEDLINE
DCOM- 20160329
LR  - 20181202
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
VI  - 50
IP  - 6
DP  - 2015 Jun
TI  - Management of low-dose aspirin and clopidogrel in clinical practice: a 
      gastrointestinal perspective.
PG  - 626-37
LID - 10.1007/s00535-015-1038-3 [doi]
AB  - Low-dose aspirin, alone or combined with other antiplatelet agents, is 
      increasingly prescribed for cardiovascular prevention. However, the 
      cardiovascular benefits should be evaluated together with the gastrointestinal 
      risks. Low-dose aspirin is associated with upper and lower gastrointestinal 
      injury, although lower gastrointestinal effects are poorly characterized. This 
      gastrointestinal risk differs among antiplatelets drugs users. The most important 
      risk factors are history of peptic ulcer, older age, and concomitant use of 
      non-steroidal anti-inflammatory drugs or dual antiplatelet therapy. Effective 
      upper gastrointestinal prevention strategies are available and should be used in 
      at-risk patients taking low-dose aspirin or clopidogrel. Proton pump inhibitors 
      seem to be the best gastroprotective agents, whereas the benefits of Helicobacter 
      pylori eradication are still unclear. Low-dose aspirin has additional effects in 
      the gastrointestinal tract. A large body of evidence indicates that it can 
      protect against different cancers, in particular colorectal cancer. This effect 
      could modify the future indications for use of low-dose aspirin and the 
      risk-benefit balance.
FAU - Lanas, Angel
AU  - Lanas A
AD  - Service of Digestive Diseases, University Hospital, Saragossa, Spain, 
      angel.lanas@gmail.com.
FAU - Gargallo, Carla J
AU  - Gargallo CJ
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150117
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Clopidogrel
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Diseases/chemically induced/*prevention & control
MH  - Helicobacter Infections/drug therapy/microbiology
MH  - Helicobacter pylori
MH  - Humans
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Risk Factors
MH  - Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives
EDAT- 2015/01/18 06:00
MHDA- 2016/03/30 06:00
CRDT- 2015/01/18 06:00
PHST- 2014/12/23 00:00 [received]
PHST- 2014/12/26 00:00 [accepted]
PHST- 2015/01/18 06:00 [entrez]
PHST- 2015/01/18 06:00 [pubmed]
PHST- 2016/03/30 06:00 [medline]
AID - 10.1007/s00535-015-1038-3 [doi]
PST - ppublish
SO  - J Gastroenterol. 2015 Jun;50(6):626-37. doi: 10.1007/s00535-015-1038-3. Epub 2015 
      Jan 17.

PMID- 3930246
OWN - NLM
STAT- MEDLINE
DCOM- 19851101
LR  - 20190511
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 6
IP  - 5
DP  - 1985 May
TI  - Low-dose aspirin in patients recovering from myocardial infarction. Evidence for 
      a selective inhibition of thromboxane-related platelet function.
PG  - 409-17
AB  - The adequacy, selectivity and long-term persistence of inhibition in 
      cyclooxygenase-dependent platelet function by a daily low-dose (0.45 mg kg-1 
      day-1) aspirin treatment have been evaluated in 15 patients after a recent (less 
      than 17 days) acute myocardial infarction. Serum thromboxane (TX) B2, an index of 
      platelet TXA2 production, was decreased by 94-98% (P less than 0.001) by aspirin, 
      while urinary excretion of 6-keto-prostaglandin F1 alpha, as an index of 
      extraplatelet cyclooxygenase activity, remained unchanged. Compared to placebo, 
      aspirin induced a persistent increase in bleeding time (% difference 45.6 +/- 
      21.4, mean +/- SD) and a decrease in platelet aggregation by ADP, epinephrine, 
      collagen and arachidonic acid. No tendency towards an attenuation of the effects 
      was apparent for the period of aspirin administration (4 weeks). Aspirin 0.45 mg 
      kg-1 day-1 is adequate and selective in the long-term inhibition of TX-related 
      platelet function in patients after acute myocardial infarction. The clinical 
      effectiveness of such a regimen remains to be proven in clinical trials.
FAU - De Caterina, R
AU  - De Caterina R
FAU - Giannessi, D
AU  - Giannessi D
FAU - Bernini, W
AU  - Bernini W
FAU - Gazzetti, P
AU  - Gazzetti P
FAU - Michelassi, C
AU  - Michelassi C
FAU - L'Abbate, A
AU  - L'Abbate A
FAU - Donato, L
AU  - Donato L
FAU - Patrignani, P
AU  - Patrignani P
FAU - Filabozzi, P
AU  - Filabozzi P
FAU - Patrono, C
AU  - Patrono C
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Bleeding Time
MH  - Blood Platelets/*drug effects/enzymology/metabolism
MH  - Cyclooxygenase Inhibitors
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Thromboxane A2/*antagonists & inhibitors/physiology
MH  - Thromboxane B2/*antagonists & inhibitors/biosynthesis
EDAT- 1985/05/01 00:00
MHDA- 1985/05/01 00:01
CRDT- 1985/05/01 00:00
PHST- 1985/05/01 00:00 [pubmed]
PHST- 1985/05/01 00:01 [medline]
PHST- 1985/05/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.eurheartj.a061879 [doi]
PST - ppublish
SO  - Eur Heart J. 1985 May;6(5):409-17. doi: 10.1093/oxfordjournals.eurheartj.a061879.

PMID- 979834
OWN - NLM
STAT- MEDLINE
DCOM- 19761223
LR  - 20161123
IS  - 0025-729X (Print)
IS  - 0025-729X (Linking)
VI  - 2
IP  - 5
DP  - 1976 Jul 31
TI  - Spironolactone and acute mountain sickness.
PG  - 168-70
AB  - Thirteen adults trekking in Nepal in 1974 to altitudes between 4,300 m and 5,500 
      m remained free from acute mountain sickness while taking spironolactone as a 
      prophylactic measure. Two years previously five of these adults trekking at 
      similar altitudes, but without treatment, had suffered from acute mountain 
      sickness. The regime used was spironolactone in a dosage of 25 mg three times a 
      day for two days preceding and during the periods spent at altitudes above 3,000 
      m.
FAU - Currie, T T
AU  - Currie TT
FAU - Carter, P H
AU  - Carter PH
FAU - Champion, W L
AU  - Champion WL
FAU - Fong, G
AU  - Fong G
FAU - Francis, J K
AU  - Francis JK
FAU - McDonald, I H
AU  - McDonald IH
FAU - Newing, R K
AU  - Newing RK
FAU - Nunn, I N
AU  - Nunn IN
FAU - Sisson, R N
AU  - Sisson RN
FAU - Sussex, M
AU  - Sussex M
FAU - Zacharin, R F
AU  - Zacharin RF
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 27O7W4T232 (Spironolactone)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Altitude Sickness/drug therapy/*prevention & control
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Furosemide/therapeutic use
MH  - Humans
MH  - Hypoxia/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - *Mountaineering
MH  - Nepal
MH  - Spironolactone/*therapeutic use
MH  - *Sports Medicine
OID - NASA: 77034188
EDAT- 1976/07/31 00:00
MHDA- 1976/07/31 00:01
CRDT- 1976/07/31 00:00
PHST- 1976/07/31 00:00 [pubmed]
PHST- 1976/07/31 00:01 [medline]
PHST- 1976/07/31 00:00 [entrez]
PST - ppublish
SO  - Med J Aust. 1976 Jul 31;2(5):168-70.

PMID- 16491523
OWN - NLM
STAT- MEDLINE
DCOM- 20060811
LR  - 20181113
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 22
IP  - 7
DP  - 2005
TI  - Does aspirin attenuate the beneficial effect of ACE inhibitors in elderly people 
      with heart failure?
PG  - 605-14
AB  - BACKGROUND: Several studies have raised concerns over a possible reduction in the 
      beneficial effects of ACE inhibitors on mortality in people also taking aspirin 
      (acetylsalicylic acid). OBJECTIVE: We performed this study to determine whether 
      there is a reduction in the beneficial effects of ACE inhibitors on mortality in 
      elderly people with heart failure also taking aspirin. PARTICIPANTS: 822 patients 
      discharged from hospital wards with a diagnosis of heart failure participated in 
      the GIFA (Italian Group of Pharmacoepidemiology in the Elderly) study. 
      MEASUREMENTS: We analysed the characteristics of the participants according to 
      the type of therapy prescribed (no ACE inhibitor/no aspirin, ACE inhibitor/no 
      aspirin, no ACE inhibitor/aspirin and ACE inhibitor/aspirin). We calculated the 
      hazard ratios (HRs) for dying associated with each of these treatments, and 
      calculated the synergy index to identify any negative interaction between ACE 
      inhibitor and aspirin. RESULTS: The mean age of study participants was 79 +/- 7.3 
      (SD) years. Of the 629 (76.5%) patients discharged on ACE inhibitor and/or 
      aspirin therapy, 31.0% were taking both drugs. Compared with no therapy with ACE 
      inhibitor or aspirin, the HR for death was 0.65 (95% CI 0.31, 1.36) for aspirin 
      users, 0.45 (95% CI 0.27, 0.74) for ACE inhibitor users and 0.37 (95% CI 0.19, 
      0.70) for ACE inhibitor/aspirin users. The synergy index was 0.98 (95% CI 0.34, 
      2.80), suggesting no interaction between the drugs. CONCLUSIONS: Our data do not 
      support the existence of a negative interaction between ACE inhibitors and 
      aspirin in elderly patients with heart failure.
FAU - Pedone, Claudio
AU  - Pedone C
AD  - Cattedra di Geriatria, Universita 'Campus Biomedico', Rome, Italy. 
      c.pedone@unicampus.it
FAU - Cecchi, Enrica
AU  - Cecchi E
FAU - Matucci, Rosanna
AU  - Matucci R
FAU - Pahor, Marco
AU  - Pahor M
FAU - Carosella, Luciana
AU  - Carosella L
FAU - Bernabei, Roberto
AU  - Bernabei R
FAU - Mugelli, Alessandro
AU  - Mugelli A
CN  - GIFA Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cyclooxygenase Inhibitors/therapeutic use
MH  - Drug Interactions
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*drug therapy/*mortality
MH  - Humans
MH  - Male
MH  - Proportional Hazards Models
MH  - Survival Rate
EDAT- 2006/02/24 09:00
MHDA- 2006/08/12 09:00
CRDT- 2006/02/24 09:00
PHST- 2006/02/24 09:00 [pubmed]
PHST- 2006/08/12 09:00 [medline]
PHST- 2006/02/24 09:00 [entrez]
AID - 10.2165/00002512-200522070-00006 [doi]
PST - ppublish
SO  - Drugs Aging. 2005;22(7):605-14. doi: 10.2165/00002512-200522070-00006.

PMID- 2491954
OWN - NLM
STAT- MEDLINE
DCOM- 19890222
LR  - 20131121
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 49
IP  - 2
DP  - 1989 Jan 15
TI  - Effect of aspirin on urinary bladder carcinogenesis initiated with 
      N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in rats.
PG  - 372-7
AB  - N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT), a potent urinary bladder 
      carcinogen, is metabolically activated in vitro by a variety of enzyme systems 
      including aerobic cooxidation by prostaglandin H synthase which is present in the 
      rat bladder mucosa. In a previous experiment, aspirin coadministered with FANFT 
      for 12 weeks inhibited FANFT-induced bladder carcinogenesis and enhanced 
      forestomach carcinogenesis. To further evaluate the effects of aspirin on FANFT 
      carcinogenesis, male F344 rats were fed either FANFT (0.2% of the diet) for 12 
      weeks (Group 4), aspirin (0.5% of the diet) simultaneously with FANFT for 12 
      weeks (Group 2), aspirin simultaneously with FANFT for 12 weeks and then 
      subsequently to the end of the experiment (Group 1), or FANFT only followed by 
      aspirin (Group 3). The incidence of bladder carcinoma was significantly higher 
      when aspirin was fed after FANFT treatment (87%) compared to FANFT followed by 
      control diet (48%) and was higher in rats given aspirin plus FANFT followed by 
      aspirin (73%) compared to aspirin plus FANFT followed by control diet (47%). 
      Aspirin alone given for 13 weeks (Group 6) or throughout the experiment (68 
      weeks) (Group 5) did not induce bladder cancer. However, in all groups 
      administered aspirin long-term, renal papillary necrosis and renal pelvic 
      hyperplasia and atypia were frequently observed. Only a single forestomach tumor 
      was observed. In the present experiment, aspirin appeared to exhibit promoting 
      activity for bladder carcinogenesis in the rat.
FAU - Cohen, S M
AU  - Cohen SM
AD  - Department of Pathology & Microbiology, University of Nebraska Medical Center, 
      Omaha 68105.
FAU - Hasegawa, R
AU  - Hasegawa R
FAU - Sakata, T
AU  - Sakata T
FAU - Johansson, S L
AU  - Johansson SL
LA  - eng
GR  - CA28015/CA/NCI NIH HHS/United States
GR  - CA36727/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Thiazoles)
RN  - 7N99PZG62O (FANFT)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*pharmacology
MH  - *FANFT
MH  - Kidney/drug effects/pathology
MH  - Male
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Rats
MH  - Rats, Inbred F344
MH  - *Thiazoles
MH  - Urinary Bladder/drug effects/pathology
MH  - Urinary Bladder Neoplasms/*chemically induced
EDAT- 1989/01/15 00:00
MHDA- 1989/01/15 00:01
CRDT- 1989/01/15 00:00
PHST- 1989/01/15 00:00 [pubmed]
PHST- 1989/01/15 00:01 [medline]
PHST- 1989/01/15 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1989 Jan 15;49(2):372-7.

PMID- 9631693
OWN - NLM
STAT- MEDLINE
DCOM- 19980713
LR  - 20131121
IS  - 0397-9148 (Print)
IS  - 0397-9148 (Linking)
VI  - 30
IP  - 4
DP  - 1998 Apr
TI  - [Asthma and aspirin].
PG  - 117-9
AB  - Aspirin was discovered by Gerhardt in 1853. The first signs of problems in the 
      form of asthmatiform dyspnoea were described in 1911 by Gilbert, then Reed and 
      Cookes. Fernand Widal described the symptomatic triad characteristic of "aspirin 
      illness" in 1922 with the association of "nasal polyposis, severe asthma and 
      aspirin intolerance". It was in 1975 that the role of inhibition of 
      cyclo-oxygenase was emphasized in physiological interpretation of the illness. 
      Since then, very important progress has been made not only in the analysis of the 
      affection, but also in its control not only by a new approach to "nose-bronchus" 
      relationship which have enabled development of a new strategy in the "ORL and 
      pneumologists". If the methods of immuno-allergological investigations, and 
      especially scanning imagery and endoscopy, have made possible a better control of 
      "aspirin illness" it still remains that this last often remains corticosteroid 
      dependent. Important progress is expected with the discovery of anti-leucotrienes 
      and several groups have shown the value of anti-leucotrienes in the management of 
      "aspirin illness" so leading to the hope that one day there will be a reduction 
      in the efficient limiting dose of corticosteroids.
FAU - Sonneville, A
AU  - Sonneville A
AD  - C.H.U. de Tours, Hôpital Les Grandes Brosses.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Asthme à l'aspirine.
PL  - France
TA  - Allerg Immunol (Paris)
JT  - Allergie et immunologie
JID - 0245775
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Leukotriene Antagonists)
RN  - 0 (Leukotrienes)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Asthmatic Agents/therapeutic use
MH  - Arachidonic Acids/metabolism
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced/diagnosis/drug therapy/epidemiology/physiopathology
MH  - Cyclooxygenase Inhibitors/adverse effects
MH  - Drug Hypersensitivity/*complications
MH  - Female
MH  - Humans
MH  - Leukotriene Antagonists
MH  - Leukotrienes/biosynthesis
MH  - Male
MH  - Nasal Polyps/complications
MH  - Prostaglandin-Endoperoxide Synthases/physiology
RF  - 5
EDAT- 1998/06/19 00:00
MHDA- 1998/06/19 00:01
CRDT- 1998/06/19 00:00
PHST- 1998/06/19 00:00 [pubmed]
PHST- 1998/06/19 00:01 [medline]
PHST- 1998/06/19 00:00 [entrez]
PST - ppublish
SO  - Allerg Immunol (Paris). 1998 Apr;30(4):117-9.

PMID- 3519922
OWN - NLM
STAT- MEDLINE
DCOM- 19860718
LR  - 20190912
IS  - 0386-846X (Print)
IS  - 0386-846X (Linking)
VI  - 9
IP  - 2
DP  - 1986 Feb
TI  - An in situ experimental model in rabbits for the study of rectal absorption.
PG  - 139-45
AB  - An in situ experimental model of rectal absorption was studied in rabbits 
      compared with in vivo determination of drug concentration in the plasma of 
      postcaval vein using indomethacin as drug. Pharmacokinetic parameters were 
      similar between in vivo and in situ. When results from both studies were 
      compared, 60% of the drug administered to the rectum was absorbed from the 
      superior hemorrhoidal vein and the remaining 40% was absorbed from the inferior 
      hemorrhoidal vein. When an aspirin suppository was used in this model, the amount 
      of unaltered aspirin absorbed in the rectal mucosa or space was greater than the 
      absorbed salicylic acid which was metabolized or degradated from aspirin. In the 
      case of insulin, these differences were not seen in the insulin concentration of 
      venous plasma between insulin physiological saline and surfactant suspension. 
      However, using the in situ model, the surfactant effect on rectal absorption of 
      insulin was observed. From the above results, it was concluded that this in situ 
      experimental model of rectal absorption has advantages in that it can be used 
      directly to measure the rectal absorption rate and to determine ratios of easily 
      metabolized and poorly absorbed drugs. Therefore, this model appears to be useful 
      in evaluation of rectal absorption.
FAU - Kasama, T
AU  - Kasama T
FAU - Mayuzumi, K
AU  - Mayuzumi K
FAU - Nakai, M
AU  - Nakai M
FAU - Ohshiro, K
AU  - Ohshiro K
FAU - Sakaguchi, Y
AU  - Sakaguchi Y
FAU - Minohara, K
AU  - Minohara K
FAU - Minato, M
AU  - Minato M
FAU - Hiura, M
AU  - Hiura M
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Pharmacobiodyn
JT  - Journal of pharmacobio-dynamics
JID - 7901854
RN  - 0 (Insulin)
RN  - 0 (Salicylates)
RN  - 0 (Suppositories)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/metabolism
MH  - Indomethacin/blood
MH  - Insulin/blood/metabolism
MH  - *Intestinal Absorption
MH  - Kinetics
MH  - Male
MH  - Rabbits
MH  - Rectum/*metabolism
MH  - Salicylates/blood/metabolism
MH  - Salicylic Acid
MH  - Suppositories
MH  - Time Factors
EDAT- 1986/02/01 00:00
MHDA- 1986/02/01 00:01
CRDT- 1986/02/01 00:00
PHST- 1986/02/01 00:00 [pubmed]
PHST- 1986/02/01 00:01 [medline]
PHST- 1986/02/01 00:00 [entrez]
AID - 10.1248/bpb1978.9.139 [doi]
PST - ppublish
SO  - J Pharmacobiodyn. 1986 Feb;9(2):139-45. doi: 10.1248/bpb1978.9.139.

PMID- 15894693
OWN - NLM
STAT- MEDLINE
DCOM- 20051212
LR  - 20220321
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 14
IP  - 5
DP  - 2005 May
TI  - Aspirin use and risk of biliary tract cancer: a population-based study in 
      Shanghai, China.
PG  - 1315-8
AB  - The association of gallbladder and bile duct cancers with gallstones, 
      cholecystitis, and cholangitis suggest that chronic inflammation contributes to 
      the carcinogenic process. However, the effect of nonsteroidal anti-inflammatory 
      drugs, such as aspirin, on biliary tract cancer has not been well studied. In a 
      population-based case-control study conducted in Shanghai, China, we examined the 
      relationship between aspirin use and the risk of biliary disease. A total of 627 
      patients with biliary tract cancer, including cancers of the gallbladder (n = 
      368), extrahepatic bile duct (n = 191), and ampulla of Vater (n = 68); 1,037 
      patients with biliary stones; and 958 healthy adults were included in the study. 
      Self-reported data on aspirin use was collected from study participants by 
      in-person interview. The prevalence of aspirin use was low, with 5.7% of the 
      population controls being regular users. After controlling for age, sex, 
      education, and biliary stone status, aspirin use was associated with a reduced 
      risk of gallbladder cancer [odds ratio (OR), 0.37; 95% confidence interval (CI), 
      0.17-0.88]. An inverse relationship was also observed for frequency and duration 
      of use and with younger age when starting use. In addition, there was a 
      nonsignificant reduction in the risk of bile duct (OR, 0.48; 95% CI, 0.19-1.19) 
      and ampullary cancers (OR, 0.22; 95% CI, 0.03-1.65) associated with aspirin use, 
      whereas no clear association was seen with biliary stones (OR, 0.92; 95% CI, 
      0.59-1.44). Further studies of biliary tract cancer in other populations are 
      needed to confirm these results and to elucidate the mechanisms that underlie the 
      reduced risk associated with use of aspirin and possibly other nonsteroidal 
      anti-inflammatory drugs.
FAU - Liu, Enju
AU  - Liu E
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, 
      Department of Health and Human Services, 6120 Executive Boulevard, EPS 7058, 
      Bethesda, MD 20892-7234, USA.
FAU - Sakoda, Lori C
AU  - Sakoda LC
FAU - Gao, Yu-Tang
AU  - Gao YT
FAU - Rashid, Asif
AU  - Rashid A
FAU - Shen, Ming-Chang
AU  - Shen MC
FAU - Wang, Bing-Sheng
AU  - Wang BS
FAU - Deng, Jie
AU  - Deng J
FAU - Han, Tian-Quan
AU  - Han TQ
FAU - Zhang, Bai-He
AU  - Zhang BH
FAU - Fraumeni, Joseph F Jr
AU  - Fraumeni JF Jr
FAU - Hsing, Ann W
AU  - Hsing AW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Biliary Tract Neoplasms/complications/*epidemiology/*prevention & control
MH  - Case-Control Studies
MH  - Chemoprevention
MH  - China/epidemiology
MH  - Female
MH  - Gallstones/complications/diagnosis/surgery
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Sex Factors
EDAT- 2005/05/17 09:00
MHDA- 2005/12/15 09:00
CRDT- 2005/05/17 09:00
PHST- 2005/05/17 09:00 [pubmed]
PHST- 2005/12/15 09:00 [medline]
PHST- 2005/05/17 09:00 [entrez]
AID - 14/5/1315 [pii]
AID - 10.1158/1055-9965.EPI-05-0032 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1315-8. doi: 
      10.1158/1055-9965.EPI-05-0032.

PMID- 23803136
OWN - NLM
STAT- MEDLINE
DCOM- 20130712
LR  - 20220408
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 369
IP  - 1
DP  - 2013 Jul 4
TI  - Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
PG  - 11-9
LID - 10.1056/NEJMoa1215340 [doi]
AB  - BACKGROUND: Stroke is common during the first few weeks after a transient 
      ischemic attack (TIA) or minor ischemic stroke. Combination therapy with 
      clopidogrel and aspirin may provide greater protection against subsequent stroke 
      than aspirin alone. METHODS: In a randomized, double-blind, placebo-controlled 
      trial conducted at 114 centers in China, we randomly assigned 5170 patients 
      within 24 hours after the onset of minor ischemic stroke or high-risk TIA to 
      combination therapy with clopidogrel and aspirin (clopidogrel at an initial dose 
      of 300 mg, followed by 75 mg per day for 90 days, plus aspirin at a dose of 75 mg 
      per day for the first 21 days) or to placebo plus aspirin (75 mg per day for 90 
      days). All participants received open-label aspirin at a clinician-determined 
      dose of 75 to 300 mg on day 1. The primary outcome was stroke (ischemic or 
      hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis. 
      Treatment differences were assessed with the use of a Cox proportional-hazards 
      model, with study center as a random effect. RESULTS: Stroke occurred in 8.2% of 
      patients in the clopidogrel-aspirin group, as compared with 11.7% of those in the 
      aspirin group (hazard ratio, 0.68; 95% confidence interval, 0.57 to 0.81; 
      P<0.001). Moderate or severe hemorrhage occurred in seven patients (0.3%) in the 
      clopidogrel-aspirin group and in eight (0.3%) in the aspirin group (P=0.73); the 
      rate of hemorrhagic stroke was 0.3% in each group. CONCLUSIONS: Among patients 
      with TIA or minor stroke who can be treated within 24 hours after the onset of 
      symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone 
      for reducing the risk of stroke in the first 90 days and does not increase the 
      risk of hemorrhage. (Funded by the Ministry of Science and Technology of the 
      People's Republic of China; CHANCE ClinicalTrials.gov number, NCT00979589.).
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 
      yongjunwang1962@gmail.com
FAU - Wang, Yilong
AU  - Wang Y
FAU - Zhao, Xingquan
AU  - Zhao X
FAU - Liu, Liping
AU  - Liu L
FAU - Wang, David
AU  - Wang D
FAU - Wang, Chunxue
AU  - Wang C
FAU - Wang, Chen
AU  - Wang C
FAU - Li, Hao
AU  - Li H
FAU - Meng, Xia
AU  - Meng X
FAU - Cui, Liying
AU  - Cui L
FAU - Jia, Jianping
AU  - Jia J
FAU - Dong, Qiang
AU  - Dong Q
FAU - Xu, Anding
AU  - Xu A
FAU - Zeng, Jinsheng
AU  - Zeng J
FAU - Li, Yansheng
AU  - Li Y
FAU - Wang, Zhimin
AU  - Wang Z
FAU - Xia, Haiqin
AU  - Xia H
FAU - Johnston, S Claiborne
AU  - Johnston SC
CN  - CHANCE Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00979589
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130626
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - N Engl J Med. 2013 Jul 4;369(1):82-3. PMID: 23803138
CIN - Nat Rev Neurol. 2013 Oct;9(10):549-50. PMID: 24018478
CIN - Evid Based Med. 2014 Apr;19(2):58. PMID: 24052397
CIN - N Engl J Med. 2013 Oct 3;369(14):1376-7. PMID: 24088101
CIN - N Engl J Med. 2013 Oct 3;369(14):1375. PMID: 24088102
CIN - N Engl J Med. 2013 Oct 3;369(14):1375-6. PMID: 24088103
CIN - N Engl J Med. 2013 Oct 3;369(14):1376. PMID: 24088104
CIN - Ann Intern Med. 2013 Oct 15;159(8):JC5. PMID: 24126666
CIN - MMW Fortschr Med. 2013 Nov 7;155(19):32. PMID: 24475661
CIN - CJEM. 2015 May;17(3):315-7. PMID: 26034917
CIN - MMW Fortschr Med. 2019 Mar;161(4):29. PMID: 30830615
MH  - Aged
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Disease-Free Survival
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Ischemic Attack, Transient/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Proportional Hazards Models
MH  - Secondary Prevention
MH  - Stroke/*drug therapy/prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
FIR - Wang, Yongjun
IR  - Wang Y
FIR - Johnston, Claiborne
IR  - Johnston C
FIR - Wong, Lawrence
IR  - Wong L
FIR - Wang, David
IR  - Wang D
FIR - Wang, James
IR  - Wang J
FIR - Nguyen-Huynh, Mai N
IR  - Nguyen-Huynh MN
FIR - Wang, Chen
IR  - Wang C
FIR - Cui, Liying
IR  - Cui L
FIR - Li, Yansheng
IR  - Li Y
FIR - Dong, Qiang
IR  - Dong Q
FIR - Xu, Jianfeng
IR  - Xu J
FIR - Jia, Jianping
IR  - Jia J
FIR - Wu, Jiang
IR  - Wu J
FIR - Zeng, Jinsheng
IR  - Zeng J
FIR - Zhao, Xingquan
IR  - Zhao X
FIR - Liu, Liping
IR  - Liu L
FIR - Wang, Chunxue
IR  - Wang C
FIR - Wang, Yilong
IR  - Wang Y
FIR - Wang, Yongjun
IR  - Wang Y
FIR - Johnston, Claiborne
IR  - Johnston C
FIR - Wang, Yilong
IR  - Wang Y
FIR - Zhao, Xingquan
IR  - Zhao X
FIR - Liu, Liping
IR  - Liu L
FIR - Meng, Xia
IR  - Meng X
FIR - Wang, Anxin
IR  - Wang A
FIR - Lin, Jinxi
IR  - Lin J
FIR - Wang, Zhimin
IR  - Wang Z
FIR - Wang, Yongjun
IR  - Wang Y
FIR - Xia, Haiqin
IR  - Xia H
FIR - Li, Bin
IR  - Li B
FIR - Zhang, Guiru
IR  - Zhang G
FIR - Ren, Xudong
IR  - Ren X
FIR - Ji, Chunling
IR  - Ji C
FIR - Zhang, Guohua
IR  - Zhang G
FIR - Li, Jianhua
IR  - Li J
FIR - Lu, Bohua
IR  - Lu B
FIR - Wang, Liping
IR  - Wang L
FIR - Feng, Shutao
IR  - Feng S
FIR - Wang, Dali
IR  - Wang D
FIR - WeiguoTang
IR  - WeiguoTang
FIR - Li, Juntao
IR  - Li J
FIR - Zhang, Hongtian
IR  - Zhang H
FIR - Li, Guanglai
IR  - Li G
FIR - Wang, Baojun
IR  - Wang B
FIR - Chen, Yuhua
IR  - Chen Y
FIR - Lian, Ying
IR  - Lian Y
FIR - Liu, Bin
IR  - Liu B
FIR - Teng, Junfang
IR  - Teng J
FIR - Sui, Rubo
IR  - Sui R
FIR - Li, Lejun
IR  - Li L
FIR - Yuan, Zhiling
IR  - Yuan Z
FIR - Zang, Dawei
IR  - Zang D
FIR - Lu, Zuneng
IR  - Lu Z
FIR - Sun, Li
IR  - Sun L
FIR - Wang, Dong
IR  - Wang D
FIR - Hou, Liying
IR  - Hou L
FIR - Yuan, Dongcai
IR  - Yuan D
FIR - Cao, Yongliang
IR  - Cao Y
FIR - Li, Hui
IR  - Li H
FIR - Tan, Xiuge
IR  - Tan X
FIR - Wang, Huicong
IR  - Wang H
FIR - Du, Haisong
IR  - Du H
FIR - Liu, Mingyi
IR  - Liu M
FIR - Wang, Suping
IR  - Wang S
FIR - Liu, Qiuwu
IR  - Liu Q
FIR - Zhang, Zhong
IR  - Zhang Z
FIR - Cui, Qifu
IR  - Cui Q
FIR - Wang, Runqing
IR  - Wang R
FIR - Zhao, Jialin
IR  - Zhao J
FIR - Zhang, Jiewen
IR  - Zhang J
FIR - Zhao, Jianping
IR  - Zhao J
FIR - Bi, Qi
IR  - Bi Q
FIR - Qi, Xiyou
IR  - Qi X
FIR - Liu, Junyan
IR  - Liu J
FIR - Li, Changxin
IR  - Li C
FIR - Li, Ling-Lv
IR  - Li LL
FIR - Pan, Xiaoping
IR  - Pan X
FIR - Zhang, Junling
IR  - Zhang J
FIR - Jiao, Derang
IR  - Jiao D
FIR - Han, Zhao
IR  - Han Z
FIR - Qian, Dawei
IR  - Qian D
FIR - Xiao, Jin
IR  - Xiao J
FIR - Xing, Yan
IR  - Xing Y
FIR - Du, Huishan
IR  - Du H
FIR - Huang, Guang
IR  - Huang G
FIR - Cui, Yongqiang
IR  - Cui Y
FIR - Li, Yan
IR  - Li Y
FIR - Feng, Lianyuan
IR  - Feng L
FIR - Gao, Lianbo
IR  - Gao L
FIR - Xiao, Bo
IR  - Xiao B
FIR - Cao, Yibin
IR  - Cao Y
FIR - Wu, Yiping
IR  - Wu Y
FIR - Liu, Jinfeng
IR  - Liu J
FIR - Zhang, Zhiming
IR  - Zhang Z
FIR - Dong, Zhengxie
IR  - Dong Z
FIR - Wang, Limin
IR  - Wang L
FIR - He, Li
IR  - He L
FIR - Wang, Xinchen
IR  - Wang X
FIR - Guo, Xueying
IR  - Guo X
FIR - Wang, Ming
IR  - Wang M
FIR - Wang, Xiaosha
IR  - Wang X
FIR - Jiang, Jiandong
IR  - Jiang J
FIR - Zhao, Renliang
IR  - Zhao R
FIR - Zhou, Shengnian
IR  - Zhou S
FIR - HaoHu
IR  - HaoHu
FIR - He, Maolin
IR  - He M
FIR - Yu, Fengchun
IR  - Yu F
FIR - Ouyang, Quping
IR  - Ouyang Q
FIR - Zhang, Jingbo
IR  - Zhang J
FIR - Xu, Anding
IR  - Xu A
FIR - Qi, Xiaokun
IR  - Qi X
FIR - Wang, Lei
IR  - Wang L
FIR - Shi, Fuming
IR  - Shi F
FIR - Guo, Fuqiang
IR  - Guo F
FIR - Wang, Jianfeng
IR  - Wang J
FIR - Zhao, Fengli
IR  - Zhao F
FIR - Dou, Ronghua
IR  - Dou R
FIR - Wei, Dongning
IR  - Wei D
FIR - Meng, Qingwei
IR  - Meng Q
FIR - Xia, Yilu
IR  - Xia Y
FIR - ShiminWang
IR  - ShiminWang
FIR - Xue, Zhangcang
IR  - Xue Z
FIR - Xu, Yuming
IR  - Xu Y
FIR - Ma, Liping
IR  - Ma L
FIR - Wang, Chun
IR  - Wang C
FIR - Wu, Jiang
IR  - Wu J
FIR - Du, Yifeng
IR  - Du Y
FIR - Wang, Yinzhou
IR  - Wang Y
FIR - Xiao, Lijun
IR  - Xiao L
FIR - Song, Fucong
IR  - Song F
FIR - Hu, Wenli
IR  - Hu W
FIR - Chen, Zhigang
IR  - Chen Z
FIR - Liu, Qingrui
IR  - Liu Q
FIR - Zhang, Jiemin
IR  - Zhang J
FIR - Chen, Mei
IR  - Chen M
FIR - Yuan, Xiaodong
IR  - Yuan X
FIR - Liu, Zhihui
IR  - Liu Z
FIR - Li, Guozhong
IR  - Li G
FIR - Li, Xiaohong
IR  - Li X
FIR - Tian, Tingchen
IR  - Tian T
FIR - Wang, Chen
IR  - Wang C
FIR - Wang, Yilong
IR  - Wang Y
FIR - Meng, Xia
IR  - Meng X
FIR - Lin, Jinxi
IR  - Lin J
FIR - Wang, Anxin
IR  - Wang A
FIR - Zhou, Yong
IR  - Zhou Y
FIR - Wang, Xianwei
IR  - Wang X
FIR - Li, Chao
IR  - Li C
FIR - Shen, Yuan
IR  - Shen Y
FIR - Liang, Xianhong
IR  - Liang X
FIR - Jing, Jing
IR  - Jing J
FIR - Wang, Yilong
IR  - Wang Y
FIR - Wang, Anxin
IR  - Wang A
FIR - Liu, Gaifen
IR  - Liu G
FIR - Wang, Xianwei
IR  - Wang X
FIR - Pan, Yuesong
IR  - Pan Y
FIR - Zhao, Zhigang
IR  - Zhao Z
FIR - Meng, Xia
IR  - Meng X
FIR - Wu, Haibo
IR  - Wu H
FIR - Wang, Yongjun
IR  - Wang Y
FIR - Johnston, Claiborne
IR  - Johnston C
FIR - Wang, Yilong
IR  - Wang Y
FIR - Wang, David
IR  - Wang D
FIR - Wong, Lawrence
IR  - Wong L
FIR - Wang, David
IR  - Wang D
FIR - Wang, James
IR  - Wang J
FIR - Li, Yansheng
IR  - Li Y
FIR - Xu, Anding
IR  - Xu A
FIR - Gao, Peiyi
IR  - Gao P
FIR - Wu, Haibo
IR  - Wu H
FIR - Li, Hao
IR  - Li H
FIR - Shen, Haipeng
IR  - Shen H
FIR - Xu, Jianfeng
IR  - Xu J
FIR - Yan, Yu
IR  - Yan Y
FIR - Jiang, Yong
IR  - Jiang Y
EDAT- 2013/06/28 06:00
MHDA- 2013/07/16 06:00
CRDT- 2013/06/28 06:00
PHST- 2013/06/28 06:00 [entrez]
PHST- 2013/06/28 06:00 [pubmed]
PHST- 2013/07/16 06:00 [medline]
AID - 10.1056/NEJMoa1215340 [doi]
PST - ppublish
SO  - N Engl J Med. 2013 Jul 4;369(1):11-9. doi: 10.1056/NEJMoa1215340. Epub 2013 Jun 
      26.

PMID- 25721221
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20150522
IS  - 1525-1470 (Electronic)
IS  - 0736-8046 (Linking)
VI  - 32
IP  - 3
DP  - 2015 May-Jun
TI  - Orange-brown chromonychia and Kawasaki disease: a possible novel association?
PG  - e104-5
LID - 10.1111/pde.12529 [doi]
AB  - A 4-year-old girl with clinical and laboratory signs of Kawasaki disease (KD) was 
      hospitalized and given intravenous immunoglobulin plus aspirin therapy, with 
      rapid defervescence and clinical improvement, and was discharged 48 hours after 
      admission. At the time of her follow-up echocardiography on day 14, orange-brown 
      pigmentation of the nail beds was noticed and confirmed with dermoscopy. No clear 
      association between KD and orange-brown chromonychia has been demonstrated, 
      although reports and case series suggest a possible link between these two 
      entities. We suggest that this particular finding might be encompassed in late 
      (subacute) changes of extremities as part of KD diagnostic criteria.
CI  - © 2015 Wiley Periodicals, Inc.
FAU - Tessarotto, Lucia
AU  - Tessarotto L
AD  - Department of Pediatrics, Ospedale Dell'Angelo, Mestre, Italy.
FAU - Rubin, Giulia
AU  - Rubin G
AD  - Department of Woman and Child Health, Medical School, University of Padua, 
      Padova, Italy.
FAU - Bonadies, Luca
AU  - Bonadies L
AD  - Department of Woman and Child Health, Medical School, University of Padua, 
      Padova, Italy.
FAU - Valerio, Enrico
AU  - Valerio E
AD  - Department of Woman and Child Health, Medical School, University of Padua, 
      Padova, Italy.
FAU - Cutrone, Mario
AU  - Cutrone M
AD  - Department of Pediatrics, Ospedale Dell'Angelo, Mestre, Italy.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20150226
PL  - United States
TA  - Pediatr Dermatol
JT  - Pediatric dermatology
JID - 8406799
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child, Preschool
MH  - Diagnosis, Differential
MH  - Echocardiography
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Mucocutaneous Lymph Node Syndrome/*complications/*drug therapy
MH  - Nail Diseases/*diagnosis/*etiology
EDAT- 2015/02/28 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/02/28 06:00
PHST- 2015/02/28 06:00 [entrez]
PHST- 2015/02/28 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - 10.1111/pde.12529 [doi]
PST - ppublish
SO  - Pediatr Dermatol. 2015 May-Jun;32(3):e104-5. doi: 10.1111/pde.12529. Epub 2015 
      Feb 26.

PMID- 17080027
OWN - NLM
STAT- MEDLINE
DCOM- 20061206
LR  - 20220317
IS  - 1474-1776 (Print)
IS  - 1474-1776 (Linking)
VI  - 5
IP  - 11
DP  - 2006 Nov
TI  - PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?
PG  - 903-18
AB  - Class IB phosphatidylinositol 3-kinase p110gamma (PI3Kgamma) has gained 
      increasing attention as a promising drug target for the treatment of inflammatory 
      disease. Extensive target-validation data are available, which are derived from 
      studies using both pharmacological and genetic tools. More recent findings have 
      uncovered further therapeutic applications for PI3Kgamma inhibitors, opening up 
      potentially huge opportunities for these drugs. Several companies have been 
      pursuing small-molecule PI3Kgamma inhibitor projects, but none of them has 
      progressed to the clinic yet. Here, we discuss the insights gained so far and the 
      main challenges that are emerging on the path to developing PI3Kgamma inhibitors 
      for the treatment of human disease.
FAU - Rückle, Thomas
AU  - Rückle T
AD  - Serono Pharmaceutical Research Institute, Serono International S.A., 14 Chemin 
      des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland.
FAU - Schwarz, Matthias K
AU  - Schwarz MK
FAU - Rommel, Christian
AU  - Rommel C
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20061013
PL  - England
TA  - Nat Rev Drug Discov
JT  - Nature reviews. Drug discovery
JID - 101124171
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Chemokines)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Receptors, Chemokine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Chemokines/physiology
MH  - Enzyme Inhibitors/*pharmacology
MH  - Hematopoiesis/drug effects
MH  - Humans
MH  - Mice
MH  - *Phosphoinositide-3 Kinase Inhibitors
MH  - Receptors, Chemokine/drug effects/physiology
RF  - 160
EDAT- 2006/11/03 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/11/03 09:00
PHST- 2006/11/03 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/11/03 09:00 [entrez]
AID - nrd2145 [pii]
AID - 10.1038/nrd2145 [doi]
PST - ppublish
SO  - Nat Rev Drug Discov. 2006 Nov;5(11):903-18. doi: 10.1038/nrd2145. Epub 2006 Oct 
      13.

PMID- 9113702
OWN - NLM
STAT- MEDLINE
DCOM- 19970624
LR  - 20131121
IS  - 1042-3680 (Print)
IS  - 1042-3680 (Linking)
VI  - 8
IP  - 2
DP  - 1997 Apr
TI  - Brain attack. Acute therapeutic intervention. Antithrombotic and 
      antiplatelet-aggregating drugs.
PG  - 207-17
AB  - Although antiplatelet and anticoagulant drugs are of proven usefulness in the 
      prevention of stroke among high-risk persons, their value in improving outcome 
      after acute ischemic stroke has not been established. Potentially effective drugs 
      include heparin, low molecular weight heparins and heparinoids, aspirin, and the 
      new glycoprotein IIb/IIIa platelet receptor antagonists. Clinical trials are 
      testing these drugs, and the role of emergent administration of anticoagulant or 
      antiplatelet drugs in the acute treatment of persons with ischemic stroke should 
      be clarified in the near future.
FAU - Adams, H P Jr
AU  - Adams HP Jr
AD  - Division of Cerebrovascular Diseases, Department of Neurology, University of Iowa 
      College of Medicine, Iowa City, Iowa 52242, USA.
FAU - Leira, E C
AU  - Leira EC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Neurosurg Clin N Am
JT  - Neurosurgery clinics of North America
JID - 9008004
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Heparinoids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Clinical Trials as Topic
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Heparinoids/therapeutic use
MH  - Hirudin Therapy
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 95
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
PST - ppublish
SO  - Neurosurg Clin N Am. 1997 Apr;8(2):207-17.

PMID- 10544753
OWN - NLM
STAT- MEDLINE
DCOM- 19991116
LR  - 20131121
IS  - 0003-410X (Print)
IS  - 0003-410X (Linking)
VI  - 150
IP  - 5
DP  - 1999 Sep
TI  - [Arterial hypertension of the pregnant woman].
PG  - 425-31
AB  - Pregnancy hypertension remains a frequent disease, sometimes seriously 
      threatening mother and fetus. Its primum movens has been shown to be an abnormal 
      placentation and/or trophoblastic invasion. This abnormality is triggered by 
      various factors which can be immunologic, vascular, or abnormalities of 
      hemostasis. This defective placentation results in a systemic endothelial disease 
      with vasoconstriction and widespread thrombotic tendency. Antihypertensive 
      treatment is of very poor efficiency, and even may worsen the fetal situation 
      through underperfusion. Early prevention is clearly a better way to improve the 
      prognosis. Low-dose aspirin is widely used, although its efficiency has been 
      debated recently, after the publication of negative results. It is likely that 
      proper selection of patients, as well as the timing and dosage of treatment, are 
      key factors for its efficiency.
FAU - Beaufils, M
AU  - Beaufils M
AD  - Service de Médecine Interne A, Hôpital Tenon, Paris.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - L'hypertension artérielle de la femme enceinte.
PL  - France
TA  - Ann Med Interne (Paris)
JT  - Annales de medecine interne
JID - 0171744
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Diagnosis, Differential
MH  - Female
MH  - Fibrinolytic Agents/therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Placenta Diseases/physiopathology
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Pre-Eclampsia/diagnosis/drug therapy/physiopathology
MH  - Pregnancy
MH  - Time Factors
EDAT- 1999/11/02 00:00
MHDA- 1999/11/02 00:01
CRDT- 1999/11/02 00:00
PHST- 1999/11/02 00:00 [pubmed]
PHST- 1999/11/02 00:01 [medline]
PHST- 1999/11/02 00:00 [entrez]
AID - MDOI-AMI-09-1999-150-5-0003-410X-101019-ART9 [pii]
PST - ppublish
SO  - Ann Med Interne (Paris). 1999 Sep;150(5):425-31.

PMID- 9749272
OWN - NLM
STAT- MEDLINE
DCOM- 19981006
LR  - 20131121
IS  - 0003-9683 (Print)
IS  - 0003-9683 (Linking)
VI  - 91 Spec No 2
DP  - 1998 Apr
TI  - [Antithrombotic agents in acute myocardial infarction].
PG  - 19-26
AB  - Coronary thrombosis, which is responsible for myocardial infarction, is a complex 
      phenomenon involving the interaction of the arterial wall, the coagulation system 
      and the platelets. Better understanding of the molecular biology of thrombosis 
      has led to the rapid development of antithrombotic therapy. The limitations of 
      aspirin and heparin have promoted the development of new molecules whose site of 
      action on platelets or at different stages of coagulation are known. Some of them 
      are the object of large scale international trials. Some results have been 
      disappointing such as those with the direct antithrombins: others are promising 
      and in the phase of evaluation, such as the inhibitors of glycoproteins GP 
      IIb-IIIa.
FAU - Boschat, J
AU  - Boschat J
AD  - Département de cardiologie, hôpital de la Cavale Blanche, CHU Brest.
FAU - Larlet, J M
AU  - Larlet JM
FAU - Gilard, M
AU  - Gilard M
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Antithrombotiques dans l'infarctus myocardique aigu.
PL  - France
TA  - Arch Mal Coeur Vaiss
JT  - Archives des maladies du coeur et des vaisseaux
JID - 0406011
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Integrins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Antithrombins/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Integrins/*therapeutic use
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
RF  - 51
EDAT- 1998/09/28 00:00
MHDA- 1998/09/28 00:01
CRDT- 1998/09/28 00:00
PHST- 1998/09/28 00:00 [pubmed]
PHST- 1998/09/28 00:01 [medline]
PHST- 1998/09/28 00:00 [entrez]
PST - ppublish
SO  - Arch Mal Coeur Vaiss. 1998 Apr;91 Spec No 2:19-26.

PMID- 598562
OWN - NLM
STAT- MEDLINE
DCOM- 19780310
LR  - 20151119
IS  - 0338-1684 (Print)
IS  - 0338-1684 (Linking)
VI  - 3
IP  - 4
DP  - 1977 Dec
TI  - The effect of somatostatin on platelets: in vivo and in vitro studies.
PG  - 219-22
AB  - The influence of somatostatin on platelets was studied in healthy volunteers. 
      After a bolus injection of 250 microgram somatostatin followed by a three hour 
      infusion at a rate of 250 microgram somatostatin/hr a statistically significant 
      fall of platelet count and impairment of platelet aggregation was observed. The 
      aggregation inhibiting effect of somatostatin at the end of the three hour 
      infusion is clinically unimportant as compared to the effect of aspirin. In vitro 
      concentrations up to 10.0 microgram somatostatin per ml do not show any effect on 
      platelet aggregation and platelet stickiness. Endocrinologically active doses of 
      somatostatin in short term infusions are very unlikely to cause bleeding 
      disorders.
FAU - Scheck, R
AU  - Scheck R
FAU - Raptis, S
AU  - Raptis S
FAU - Rasche, H
AU  - Rasche H
FAU - Escobar-Jimenez, F
AU  - Escobar-Jimenez F
LA  - eng
PT  - Journal Article
PL  - France
TA  - Diabete Metab
JT  - Diabete & metabolisme
JID - 7604157
RN  - 51110-01-1 (Somatostatin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aspirin/adverse effects
MH  - Blood Cell Count
MH  - Blood Coagulation Disorders/chemically induced
MH  - Blood Platelets/*physiology
MH  - Humans
MH  - Platelet Adhesiveness
MH  - Platelet Aggregation
MH  - *Somatostatin/adverse effects
EDAT- 1977/12/01 00:00
MHDA- 2000/03/11 09:00
CRDT- 1977/12/01 00:00
PHST- 1977/12/01 00:00 [pubmed]
PHST- 2000/03/11 09:00 [medline]
PHST- 1977/12/01 00:00 [entrez]
PST - ppublish
SO  - Diabete Metab. 1977 Dec;3(4):219-22.

PMID- 29716395
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20200225
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 24
IP  - 8
DP  - 2018 Nov
TI  - Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients 
      Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis.
PG  - 1315-1321
LID - 10.1177/1076029618772337 [doi]
AB  - BACKGROUND: Guidelines recommend the use of multiple pharmacologic agents and/or 
      mechanical compressive devices for prevention of venous thromboembolism, but 
      preference for any specific agent is no longer given in regard to safety or 
      efficacy. OBJECTIVE: To compare postoperative bleeding rates in patients 
      receiving enoxaparin, rivaroxaban, or aspirin for thromboprophylaxis after 
      undergoing elective total hip arthroplasty or total knee arthroplasty. METHODS: 
      This retrospective cohort analysis evaluated patients who received 
      thromboprophylaxis with either enoxaparin, rivaroxaban, or aspirin. All data were 
      collected from the electronic medical record. The primary outcome was any 
      postoperative bleeding. RESULTS: A total of 1244 patients were included with 366 
      in the aspirin, 438 in the enoxaparin, and 440 in the rivaroxaban arms. Those who 
      received aspirin or enoxaparin were less likely to experience any bleeding 
      compared to those patients who received rivaroxaban ( P < .05). There was also a 
      lower rate of major bleeding in these groups, but the differences were not 
      significant. CONCLUSIONS: Aspirin and enoxaparin conferred similar bleeding 
      risks, and both exhibited less bleeding than patients who received rivaroxaban.
FAU - Lindquist, Desirae E
AU  - Lindquist DE
AD  - 1 Department of Pharmacy, University of Tennessee Medical Center, Knoxville, TN, 
      USA.
FAU - Stewart, David W
AU  - Stewart DW
AD  - 2 Department of Pharmacy Practice, Bill Gatton College of Pharmacy, East 
      Tennessee State University, Johnson City, TN, USA.
FAU - Brewster, Aaryn
AU  - Brewster A
AD  - 3 Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, 
      TN, USA.
FAU - Waldroup, Caitlin
AU  - Waldroup C
AD  - 3 Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, 
      TN, USA.
FAU - Odle, Brian L
AU  - Odle BL
AD  - 2 Department of Pharmacy Practice, Bill Gatton College of Pharmacy, East 
      Tennessee State University, Johnson City, TN, USA.
FAU - Burchette, Jessica E
AU  - Burchette JE
AD  - 2 Department of Pharmacy Practice, Bill Gatton College of Pharmacy, East 
      Tennessee State University, Johnson City, TN, USA.
FAU - El-Bazouni, Hadi
AU  - El-Bazouni H
AD  - 4 Department of Internal Medicine, James H. Quillen College of Medicine, East 
      Tennessee State University, Johnson City, TN, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20180501
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Enoxaparin)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthroplasty, Replacement, Hip/*adverse effects
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - *Blood Loss, Surgical
MH  - Enoxaparin/administration & dosage/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Rivaroxaban/administration & dosage/*adverse effects
MH  - Thrombosis/blood/*prevention & control
PMC - PMC6714764
OTO - NOTNLM
OT  - aspirin
OT  - deep vein thrombosis
OT  - enoxaparin
OT  - prophylaxis
OT  - pulmonary embolism
OT  - rivaroxaban
OT  - total hip arthroplasty
OT  - total knee arthroplasty
OT  - venous thromboembolism
COIS- Declaration of Conflicting Interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Dr Stewart is a member of the speakers’ bureau for 
      Janssen Pharmaceuticals. No other authors declare to have conflicting interests.
EDAT- 2018/05/03 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/05/03 06:00
PHST- 2018/05/03 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/05/03 06:00 [entrez]
AID - 10.1177_1076029618772337 [pii]
AID - 10.1177/1076029618772337 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2018 Nov;24(8):1315-1321. doi: 10.1177/1076029618772337. 
      Epub 2018 May 1.

PMID- 6771844
OWN - NLM
STAT- MEDLINE
DCOM- 19800926
LR  - 20131121
IS  - 0034-5164 (Print)
IS  - 0034-5164 (Linking)
VI  - 28
IP  - 2
DP  - 1980 May
TI  - Effect of glyceryl guaiacolate in animal models of inflammation and pain.
PG  - 285-93
AB  - A weak but significant anti-inflammatory and analgesic effect has been shown for 
      glyceryl guaiacolate (GG) in the laboratory rat. Its potency was less than that 
      observed for acetylsalicylic acid (ASA).
FAU - Sofia, R D
AU  - Sofia RD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Res Commun Chem Pathol Pharmacol
JT  - Research communications in chemical pathology and pharmacology
JID - 0244734
RN  - 0 (Analgesics)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 495W7451VQ (Guaifenesin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Analgesics
MH  - Animals
MH  - *Anti-Inflammatory Agents
MH  - Arthritis, Experimental/drug therapy
MH  - Aspirin/pharmacology
MH  - Guaifenesin/*pharmacology
MH  - Male
MH  - Mycobacterium tuberculosis
MH  - Pain/chemically induced
MH  - Rats
EDAT- 1980/05/01 00:00
MHDA- 1980/05/01 00:01
CRDT- 1980/05/01 00:00
PHST- 1980/05/01 00:00 [pubmed]
PHST- 1980/05/01 00:01 [medline]
PHST- 1980/05/01 00:00 [entrez]
PST - ppublish
SO  - Res Commun Chem Pathol Pharmacol. 1980 May;28(2):285-93.

PMID- 25138094
OWN - NLM
STAT- MEDLINE
DCOM- 20150630
LR  - 20190918
IS  - 1875-5607 (Electronic)
IS  - 1389-5575 (Linking)
VI  - 14
IP  - 8
DP  - 2014
TI  - Combined cancer therapy with non-conventional drugs: all roads lead to AMPK.
PG  - 642-54
AB  - AMP-activated protein kinase (AMPK) is a key energy sensor that regulates 
      cellular energy homeostasis. AMPK activation is associated with decreased 
      phosphorylation of mammalian target of rapamycin (mTOR) and S6 kinase and causes 
      a general reduction in mRNA translation and protein synthesis. Therefore, AMPK is 
      a novel target for anticancer therapy. Metformin and aspirin are two traditional 
      drugs that are widely used as anti-diabetes and non-steroidal anti-inflammatory 
      drugs (NSAIDs), respectively. Much evidence has confirmed that these two drugs 
      demonstrated encouraging anti-cancer properties. Most importantly, both inhibited 
      tumor proliferation and were mainly dependent on the AMPK/mTOR signaling pathway. 
      In addition, several other drugs, such as resveratrol, berberine, statins, 
      epigallocatechin gallate (EGCG) and capsaicin, have provided a similar capacity 
      for tumor inhibition, and the anti-cancer effects of most of them were mainly the 
      result of AMPK activation. In the current review, we summarize the literature on 
      combination therapy based on these non-classical drugs and their potential 
      mechanisms for activating AMPK. Combinations of these drugs will provide a novel 
      cancer therapeutic regimen.
FAU - Chen, Suning
AU  - Chen S
FAU - Zhu, Xingmei
AU  - Zhu X
FAU - Lai, Xiaofeng
AU  - Lai X
FAU - Xiao, Tian
AU  - Xiao T
FAU - Wen, Aidong
AU  - Wen A
FAU - Zhang, Jian
AU  - Zhang J
AD  - State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular 
      Biology, The Fourth Military Medical University, No. 169 Changle West Road, 
      710032, Xi'an, PR China. biozhangj@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Mini Rev Med Chem
JT  - Mini reviews in medicinal chemistry
JID - 101094212
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 9100L32L2N (Metformin)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - AMP-Activated Protein Kinases/*metabolism
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Aspirin/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology
MH  - Metformin/pharmacology
MH  - Neoplasms/*drug therapy
EDAT- 2014/08/21 06:00
MHDA- 2015/07/01 06:00
CRDT- 2014/08/21 06:00
PHST- 2014/04/21 00:00 [received]
PHST- 2014/07/11 00:00 [revised]
PHST- 2014/07/25 00:00 [accepted]
PHST- 2014/08/21 06:00 [entrez]
PHST- 2014/08/21 06:00 [pubmed]
PHST- 2015/07/01 06:00 [medline]
AID - MRMC-EPUB-61839 [pii]
AID - 10.2174/1389557514666140820104444 [doi]
PST - ppublish
SO  - Mini Rev Med Chem. 2014;14(8):642-54. doi: 10.2174/1389557514666140820104444.

PMID- 3258770
OWN - NLM
STAT- MEDLINE
DCOM- 19880607
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 71
IP  - 5
DP  - 1988 May
TI  - Shear-induced platelet aggregation can be mediated by vWF released from 
      platelets, as well as by exogenous large or unusually large vWF multimers, 
      requires adenosine diphosphate, and is resistant to aspirin.
PG  - 1366-74
AB  - Fluid shear stress in arteries and arterioles partially obstructed by 
      atherosclerosis or spasm may exceed the normal time-average level of 20 dyne/cm2. 
      In vitro, at fluid shear stresses of 30 to 60 dyne/cm2 applied for 30 seconds, 
      platelet aggregation occurs. At these shear stresses, either large or unusually 
      large von Willebrand factor (vWF) multimers in the suspending fluid exogenous to 
      the platelets mediates aggregation. Adenosine diphosphate (ADP) is also required 
      and, in these experiments, was released from the platelets subjected to shear 
      stress. At 120 dyne/cm2, the release of endogenous platelet vWF multimers can 
      substitute for exogenous large or unusually large vWF forms in mediating 
      aggregation. Endogenous released platelet vWF forms, as well as exogenous large 
      or unusually large vWF multimers, must bind to both glycoproteins Ib and the 
      IIb/IIIa complex to produce aggregation. Shear-induced aggregation is the result 
      of shear stress alteration of platelet surfaces, rather than of shear effects on 
      vWF multimers. It is mediated by either large plasma-type vWF multimers, 
      endogenous released platelet vWF forms, or unusually large vWF multimers derived 
      from endothelial cells, requires ADP, and is not inhibited significantly by 
      aspirin. This type of aggregation may be important in platelet thrombus formation 
      within narrowed arterial vessels, and may explain the limited therapeutic utility 
      of aspirin in arterial thrombosis.
FAU - Moake, J L
AU  - Moake JL
AD  - Biomedical Engineering Laboratory, Rice University, Houston, TX 77251.
FAU - Turner, N A
AU  - Turner NA
FAU - Stathopoulos, N A
AU  - Stathopoulos NA
FAU - Nolasco, L
AU  - Nolasco L
FAU - Hellums, J D
AU  - Hellums JD
LA  - eng
GR  - R01 HL 18584/HL/NHLBI NIH HHS/United States
GR  - R01 HL 35387/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (von Willebrand Factor)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/metabolism/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/metabolism
MH  - Humans
MH  - *Platelet Aggregation/drug effects
MH  - Stress, Mechanical
MH  - von Willebrand Factor/metabolism/*physiology
EDAT- 1988/05/01 00:00
MHDA- 1988/05/01 00:01
CRDT- 1988/05/01 00:00
PHST- 1988/05/01 00:00 [pubmed]
PHST- 1988/05/01 00:01 [medline]
PHST- 1988/05/01 00:00 [entrez]
AID - S0006-4971(20)77246-0 [pii]
PST - ppublish
SO  - Blood. 1988 May;71(5):1366-74.

PMID- 18684223
OWN - NLM
STAT- MEDLINE
DCOM- 20081215
LR  - 20131121
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Linking)
VI  - 103
IP  - 4
DP  - 2008 Oct
TI  - Antioxidative action of aspirin on endothelial function in hypercholesterolaemic 
      rats.
PG  - 314-21
LID - 10.1111/j.1742-7843.2008.00277.x [doi]
AB  - The role of aspirin on vascular endothelial changes during hypercholesterolaemia 
      prior to development of actual atherosclerotic lesions is not known. Therefore, 
      in the present study, we tested the hypothesis that aspirin by its antioxidant 
      action improves endothelial function in a rat model of hypercholesterolaemia. 
      Hypercholesterolaemia was induced in Wistar rats by feeding a 1% cholesterol-rich 
      diet for 10 weeks. Lipid profile, lipid peroxidation and reduced glutathione were 
      estimated in serum. Endothelial function and beta(2)-adrenoceptor activity was 
      tested by studying the dose-response relationship of acetylcholine and 
      isoproterenol, respectively, on isolated aortic tissues in an organ bath setup. 
      Hypercholesterolaemic rats showed a significant increase in total cholesterol, 
      low-density lipoprotein cholesterol (LDL-C) and very low-density lipoprotein 
      cholesterol (VLDL-C), and a significant fall in high-density lipoprotein 
      cholesterol (HDL-C) compared to the control rats. Isolated aortic tissues from 
      hypercholesterolaemic rats showed endothelial dysfunction and decreased 
      sensitivity to beta(2)-adrenoceptor. Treatment with aspirin was associated with a 
      fall in total cholesterol, LDL-C and VLDL-C, and a significant rise in serum 
      HDL-C. Aspirin treatment also restored endothelial function and 
      beta(2)-adrenoceptor activity. Hypercholesterolaemic rats showed free radical 
      generation, evident by increase in serum lipid peroxidation and reduction in 
      serum reduced glutathione content compared to the control rats. Aspirin treatment 
      was associated with reduction in free radical stress evident by decreased lipid 
      peroxidation and significantly prevented reduction in glutathione content 
      compared to hypercholesterolaemic controls. Aspirin improves endothelial function 
      and beta(2)-adrenoceptor activity during experimentally induced 
      hypercholesterolaemia in rats, possibly due to an antioxidant effect.
FAU - Tauseef, Mohammad
AU  - Tauseef M
AD  - Department of Physiology, Vallabhbhai Patel Chest Institute, University of Delhi, 
      Delhi, India.
FAU - Shahid, Mohd
AU  - Shahid M
FAU - Sharma, Krishna K
AU  - Sharma KK
FAU - Fahim, Mohammad
AU  - Fahim M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080718
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - 0 (Antioxidants)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Receptors, Adrenergic, beta-2)
RN  - 0 (Vasoconstrictor Agents)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Antioxidants/administration & dosage/pharmacology/*therapeutic use
MH  - Aorta, Thoracic/drug effects/metabolism/physiology
MH  - Aspirin/administration & dosage/pharmacology/*therapeutic use
MH  - Cholesterol/blood
MH  - Disease Models, Animal
MH  - Endothelium, Vascular/*drug effects/metabolism/physiology
MH  - Glutathione/blood
MH  - Hypercholesterolemia/blood/*drug therapy/metabolism/physiopathology
MH  - Lipid Peroxidation/drug effects
MH  - Male
MH  - Malondialdehyde/blood
MH  - Rats
MH  - Rats, Wistar
MH  - Reactive Oxygen Species/blood
MH  - Receptors, Adrenergic, beta-2/metabolism
MH  - Vasoconstrictor Agents/pharmacology
MH  - Vasodilation/drug effects
EDAT- 2008/08/08 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/08/08 09:00
PHST- 2008/08/08 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/08/08 09:00 [entrez]
AID - PTO277 [pii]
AID - 10.1111/j.1742-7843.2008.00277.x [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2008 Oct;103(4):314-21. doi: 
      10.1111/j.1742-7843.2008.00277.x. Epub 2008 Jul 18.

PMID- 23544289
OWN - NLM
STAT- MEDLINE
DCOM- 20130501
LR  - 20151119
IS  - 1088-6222 (Print)
IS  - 1088-6222 (Linking)
VI  - 106
IP  - 3
DP  - 2013 Mar
TI  - Hemoptysis and respiratory failure following sildenafil use for pulmonary 
      hypertension.
PG  - 34-5
AB  - Sildenafil, usually a well-tolerated drug traditionally used for erectile 
      dysfunction (ED), was recently approved for pulmonary arterial hypertension. In 
      the literature, there are few cases of hemoptysis following sildenafil use for 
      ED; however, to our knowledge, we are reporting the first case of hemoptysis 
      following sildenafil use for pulmonary hypertension. We are documenting a case of 
      a 90-year-old male patient who was admitted to the intensive care unit with 
      hemoptysis and respiratory failure two weeks after he was started on sildenafil.
FAU - Nour, Souheil M Abdel
AU  - Nour SM
AD  - East Tennessee State University, USA. souheilabdelnour@yahoo.com
FAU - Nour, Holly Abdel
AU  - Nour HA
FAU - Mehta, Jay B
AU  - Mehta JB
FAU - Roy, Thomas M
AU  - Roy TM
FAU - Byrd, Ryland P Jr
AU  - Byrd RP Jr
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Tenn Med
JT  - Tennessee medicine : journal of the Tennessee Medical Association
JID - 9609310
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - 0 (Vasodilator Agents)
RN  - BW9B0ZE037 (Sildenafil Citrate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Hemoptysis/*chemically induced
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy
MH  - Intensive Care Units
MH  - Male
MH  - Patient Admission
MH  - Piperazines/*adverse effects/therapeutic use
MH  - Purines/adverse effects/therapeutic use
MH  - Respiratory Insufficiency/*chemically induced
MH  - Sildenafil Citrate
MH  - Sulfones/*adverse effects/therapeutic use
MH  - Vasodilator Agents/*adverse effects/therapeutic use
EDAT- 2013/04/03 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/04/03 06:00
PHST- 2013/04/03 06:00 [entrez]
PHST- 2013/04/03 06:00 [pubmed]
PHST- 2013/05/02 06:00 [medline]
PST - ppublish
SO  - Tenn Med. 2013 Mar;106(3):34-5.

PMID- 6435319
OWN - NLM
STAT- MEDLINE
DCOM- 19841115
LR  - 20161123
IS  - 0303-657X (Print)
IS  - 0303-657X (Linking)
VI  - 163
IP  - 1
DP  - 1984
TI  - [Inhalation provocation test with lysine acetylsalicylic acid (Aspisol)--a useful 
      method for the diagnosis of analgesic asthma].
PG  - 36-41
AB  - In patients with analgesics induced asthma (AIA) provocation tests by inhalation 
      are less dangerous than oral provocation. Bianco et al. and Schmitz-Schumann et 
      al. described an inhalation provocation test (IPT) with 
      Lysine-acetylsalicylic-acid (Lys-ASA). We found analgesics induced asthma in 5 
      p.c. of our patients with bronchial asthma. The results of 41 IPT with Lys-ASA 
      are reported. In 26 of 29 patients with analgesics intolerance in the history the 
      test was positive after a threshold dose of 18,0 mg (9,3-53,3 mg) Lys-ASA. 3 
      patients believed to have analgesics intolerance. It could be excluded by 
      negative IPT and following negative oral provocation. In a control group of 12 
      patients with intrinsic asthma, nasal polyps and sinusitis, but without 
      analgesics intolerance in the history, the test was positive too in 2 patients. 
      They didn't use analgesics in the past years. The diagnosis could be confirmed by 
      oral provocation. In our opinion IPT with Lys-ASA is very useful to find an AIA 
      or to exclude it. It is better controllable than oral provocation. The induced 
      bronchospasm is good reversible by inhalation of beta-mimetics or injection of 
      methylxanthines. Intraindividual variations of bronchial tolerance can be 
      supposed. All patients with AIA tolerated oral provocation with salicyclamide.
FAU - Kirsten, D
AU  - Kirsten D
FAU - Meister, W
AU  - Meister W
FAU - Treutler, D
AU  - Treutler D
LA  - ger
PT  - Journal Article
TT  - Inhalativer Provokationstest mit Lysin-Azetylsalizylsäure (Aspisol)--eine 
      brauchbare Methode zur Diagnostik des Analgetika-Asthma.
PL  - Germany
TA  - Z Erkr Atmungsorgane
JT  - Zeitschrift fur Erkrankungen der Atmungsorgane
JID - 7503239
RN  - 0 (Analgesics)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Airway Resistance/drug effects
MH  - Analgesics/*immunology
MH  - Aspirin/*analogs & derivatives/immunology
MH  - Asthma/*immunology
MH  - Bronchi/immunology
MH  - Bronchial Provocation Tests/*methods
MH  - Drug Hypersensitivity/*immunology
MH  - Female
MH  - Humans
MH  - Lysine/*analogs & derivatives/immunology
MH  - Male
MH  - Nasal Polyps/immunology
MH  - Sinusitis/immunology
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PST - ppublish
SO  - Z Erkr Atmungsorgane. 1984;163(1):36-41.

PMID- 17291948
OWN - NLM
STAT- MEDLINE
DCOM- 20070227
LR  - 20141120
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 49
IP  - 6
DP  - 2007 Feb 13
TI  - Prevention of premature discontinuation of dual antiplatelet therapy in patients 
      with coronary artery stents: a science advisory from the American Heart 
      Association, American College of Cardiology, Society for Cardiovascular 
      Angiography and Interventions, American College of Surgeons, and American Dental 
      Association, with representation from the American College of Physicians.
PG  - 734-9
AB  - Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to 
      reduce cardiac events after coronary stenting. However, many patients and 
      healthcare providers prematurely discontinue dual antiplatelet therapy, which 
      greatly increases the risk of stent thrombosis, myocardial infarction, and death. 
      This advisory stresses the importance of 12 months of dual antiplatelet therapy 
      after placement of a drug-eluting stent and educating the patient and healthcare 
      providers about hazards of premature discontinuation. It also recommends 
      postponing elective surgery for 1 year, and if surgery cannot be deferred, 
      considering the continuation of aspirin during the perioperative period in 
      high-risk patients with drug-eluting stents.
FAU - Grines, Cindy L
AU  - Grines CL
FAU - Bonow, Robert O
AU  - Bonow RO
FAU - Casey, Donald E Jr
AU  - Casey DE Jr
FAU - Gardner, Timothy J
AU  - Gardner TJ
FAU - Lockhart, Peter B
AU  - Lockhart PB
FAU - Moliterno, David J
AU  - Moliterno DJ
FAU - O'Gara, Patrick
AU  - O'Gara P
FAU - Whitlow, Patrick
AU  - Whitlow P
CN  - American Heart Association
CN  - American College of Cardiology
CN  - Society for Cardiovascular Angiography and Interventions
CN  - American College of Surgeons
CN  - American Dental Association
CN  - American College of Physicians
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/therapeutic use
MH  - Coronary Thrombosis/*prevention & control
MH  - Drug Delivery Systems
MH  - Drug Therapy, Combination
MH  - Elective Surgical Procedures
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Period
MH  - Practice Guidelines as Topic
MH  - Pyridines/therapeutic use
MH  - *Stents
MH  - Time Factors
EDAT- 2007/02/13 09:00
MHDA- 2007/02/28 09:00
CRDT- 2007/02/13 09:00
PHST- 2007/02/13 09:00 [pubmed]
PHST- 2007/02/28 09:00 [medline]
PHST- 2007/02/13 09:00 [entrez]
AID - S0735-1097(07)00054-X [pii]
AID - 10.1016/j.jacc.2007.01.003 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2007 Feb 13;49(6):734-9. doi: 10.1016/j.jacc.2007.01.003.

PMID- 17224480
OWN - NLM
STAT- MEDLINE
DCOM- 20070312
LR  - 20220408
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 115
IP  - 6
DP  - 2007 Feb 13
TI  - Prevention of premature discontinuation of dual antiplatelet therapy in patients 
      with coronary artery stents: a science advisory from the American Heart 
      Association, American College of Cardiology, Society for Cardiovascular 
      Angiography and Interventions, American College of Surgeons, and American Dental 
      Association, with representation from the American College of Physicians.
PG  - 813-8
AB  - Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to 
      reduce cardiac events after coronary stenting. However, many patients and 
      healthcare providers prematurely discontinue dual antiplatelet therapy, which 
      greatly increases the risk of stent thrombosis, myocardial infarction, and death. 
      This advisory stresses the importance of 12 months of dual antiplatelet therapy 
      after placement of a drug-eluting stent and educating the patient and healthcare 
      providers about hazards of premature discontinuation. It also recommends 
      postponing elective surgery for 1 year, and if surgery cannot be deferred, 
      considering the continuation of aspirin during the perioperative period in 
      high-risk patients with drug-eluting stents.
FAU - Grines, Cindy L
AU  - Grines CL
AD  - William Beaumont Hospital.
FAU - Bonow, Robert O
AU  - Bonow RO
FAU - Casey, Donald E Jr
AU  - Casey DE Jr
FAU - Gardner, Timothy J
AU  - Gardner TJ
FAU - Lockhart, Peter B
AU  - Lockhart PB
FAU - Moliterno, David J
AU  - Moliterno DJ
FAU - O'Gara, Patrick
AU  - O'Gara P
FAU - Whitlow, Patrick
AU  - Whitlow P
CN  - American Heart Association
CN  - American College of Cardiology
CN  - Society for Cardiovascular Angiography and Interventions
CN  - American College of Surgeons
CN  - American Dental Association
CN  - American College of Physicians
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
DEP - 20070115
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Anesthesiology. 2007 Sep;107(3):516. PMID: 17721263
MH  - *Angioplasty, Balloon, Coronary
MH  - Aspirin/therapeutic use
MH  - Coronary Thrombosis/*prevention & control
MH  - Drug Delivery Systems
MH  - Drug Therapy, Combination
MH  - Elective Surgical Procedures
MH  - Humans
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Period
MH  - Practice Guidelines as Topic
MH  - Pyridines/therapeutic use
MH  - *Stents
MH  - Time Factors
EDAT- 2007/01/17 09:00
MHDA- 2007/03/14 09:00
CRDT- 2007/01/17 09:00
PHST- 2007/01/17 09:00 [pubmed]
PHST- 2007/03/14 09:00 [medline]
PHST- 2007/01/17 09:00 [entrez]
AID - CIRCULATIONAHA.106.180944 [pii]
AID - 10.1161/CIRCULATIONAHA.106.180944 [doi]
PST - ppublish
SO  - Circulation. 2007 Feb 13;115(6):813-8. doi: 10.1161/CIRCULATIONAHA.106.180944. 
      Epub 2007 Jan 15.

PMID- 10686657
OWN - NLM
STAT- MEDLINE
DCOM- 20000323
LR  - 20190915
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 13
IP  - 6
DP  - 1999 Nov
TI  - Effect of low-dose aspirin on the markers of oxidative stress.
PG  - 485-90
AB  - The present study estimates effects of low-dose enteric coated aspirin (ECA) on 
      oxidative stress (OS) markers in a group of middle-aged men (mean age 51.2 +/- 
      6.9 years) free of pre-existing ischemic heart disease. METHODS: Serum products 
      of lipid peroxidation, and measures of antioxidative status were detected in 25 
      healthy men in baseline and after two-week treatment period. RESULTS: In respect 
      to serum products of lipid peroxidation and markers of antioxidant status, no 
      statistically significant differences between the pre- and after-treatment data 
      were observed for any measures, with the exception of values of serum 
      antioxidative capacity (39.0 +/- 2.5 and 42 +/- 4.6, respectively). CONCLUSIONS: 
      Administration of ECA does not initiate the OS in blood and improves the general 
      antioxidative potency of blood. This may imply towards certain antiatherogenic 
      influence of low-dose ECA, exhibited even with a short-term treatment period. 
      Regarding OS markers, a variety of individual responses observed in the selected 
      subgroups should be investigated and possibly taken into account while treatment 
      with ECA is initiated for primary prevention of cerebrovascular events.
FAU - Ristimäe, T
AU  - Ristimäe T
AD  - Department of Cardiology, Faculty of Medicine, University of Tartu, Estonia. 
      tiinar@cut.ee
FAU - Zilmer, M
AU  - Zilmer M
FAU - Zilmer, K
AU  - Zilmer K
FAU - Kairane, C
AU  - Kairane C
FAU - Kullisaar, T
AU  - Kullisaar T
FAU - Teesalu, R
AU  - Teesalu R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Antioxidants)
RN  - 0 (Biomarkers)
RN  - 0 (Lipids)
RN  - 0 (Tablets, Enteric-Coated)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Antioxidants/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Biomarkers/blood
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Hypercholesterolemia/blood
MH  - Lipid Peroxidation/*drug effects
MH  - Lipids/*blood
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress/*physiology
MH  - Tablets, Enteric-Coated
EDAT- 2000/02/25 09:00
MHDA- 2000/03/25 09:00
CRDT- 2000/02/25 09:00
PHST- 2000/02/25 09:00 [pubmed]
PHST- 2000/03/25 09:00 [medline]
PHST- 2000/02/25 09:00 [entrez]
AID - 10.1023/a:1007867402152 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 1999 Nov;13(6):485-90. doi: 10.1023/a:1007867402152.

PMID- 30358688
OWN - NLM
STAT- MEDLINE
DCOM- 20190618
LR  - 20201209
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 72
IP  - 5
DP  - 2018 Nov
TI  - Aspirin Attenuates the Bioactivation of and Platelet Response to Vicagrel in 
      Mice.
PG  - 252-258
LID - 10.1097/FJC.0000000000000622 [doi]
AB  - Vicagrel, a novel acetate analogue of clopidogrel, exerts more potent 
      antiplatelet effect than clopidogrel in rodents. Relevant evidence indicated that 
      aspirin and vicagrel are the drug substrate for carboxylesterase 2. Accordingly, 
      it is deduced that concomitant use of aspirin could attenuate the bioactivation 
      of and platelet response to vicagrel. To clarify whether there could be such an 
      important drug-drug interaction, the differences in both the formation of 
      vicagrel active metabolite H4 and the inhibition of adenosine diphosphate-induced 
      platelet aggregation by vicagrel were measured and compared between mice treated 
      with vicagrel alone or in combination with aspirin. The plasma H4 concentration 
      was determined by liquid chromatography-tandem mass spectrometry, and the 
      inhibition of platelet aggregation by vicagrel was assessed by whole-blood 
      platelet aggregation. Compared with vicagrel (2.5 mg·kg) alone, concurrent use of 
      aspirin (5, 10, or 20 mg·kg) significantly decreased systemic exposure of H4, an 
      average of 38% and 41% decrease in Cmax and AUC0-∞ in mice when in combination 
      with aspirin at 10 mg·kg, respectively. Furthermore, concomitant use of aspirin 
      (10 mg·kg) and vicagrel (2.5 mg·kg) resulted in an average of 66% reduction in 
      the inhibition of adenosine diphosphate-induced platelet aggregation by vicagrel. 
      We conclude that aspirin significantly attenuates the formation of vicagrel 
      active metabolite H4 and platelet response to vicagrel in mice, and that such an 
      important drug-drug interaction would appear in clinical settings if vicagrel is 
      taken with aspirin concomitantly when marketed in the future.
FAU - Jia, Yu-Meng
AU  - Jia YM
AD  - Department of Pharmacology, College of Basic Medicine and Clinical Pharmacy, 
      China Pharmaceutical University, Nanjing, China.
FAU - Gu, Tong-Tong
AU  - Gu TT
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, China.
FAU - Ji, Jin-Zi
AU  - Ji JZ
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, China.
FAU - Tai, Ting
AU  - Tai T
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, China.
FAU - Zhang, Meng-Ran
AU  - Zhang MR
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, China.
FAU - Huang, Bei-Bei
AU  - Huang BB
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, China.
FAU - Zhou, Huan
AU  - Zhou H
AD  - Department of Pharmacology, College of Basic Medicine and Clinical Pharmacy, 
      China Pharmaceutical University, Nanjing, China.
FAU - Mi, Qiong-Yu
AU  - Mi QY
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, China.
FAU - Xie, Hong-Guang
AU  - Xie HG
AD  - Department of Pharmacology, College of Basic Medicine and Clinical Pharmacy, 
      China Pharmaceutical University, Nanjing, China.
AD  - General Clinical Research Center, Nanjing First Hospital, Nanjing Medical 
      University, Nanjing, China.
AD  - Departments of Pharmacology and.
AD  - Clinical Pharmacy, Nanjing Medical University School of Pharmacy, Nanjing, 
      Jiangsu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Phenylacetates)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0 (methyl 
      2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.1 (Carboxylesterase)
RN  - EC 3.1.1.1 (Ces2c protein, mouse)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Activation, Metabolic
MH  - Animals
MH  - Aspirin/metabolism/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Carboxylesterase
MH  - Carboxylic Ester Hydrolases/metabolism
MH  - Chromatography, Liquid
MH  - Drug Interactions
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Phenylacetates/blood/pharmacokinetics/*pharmacology
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/blood/pharmacokinetics/*pharmacology
MH  - Platelet Function Tests
MH  - Tandem Mass Spectrometry
MH  - Thiophenes/blood/pharmacokinetics/*pharmacology
EDAT- 2018/10/26 06:00
MHDA- 2019/06/19 06:00
CRDT- 2018/10/26 06:00
PHST- 2018/10/26 06:00 [pubmed]
PHST- 2019/06/19 06:00 [medline]
PHST- 2018/10/26 06:00 [entrez]
AID - 10.1097/FJC.0000000000000622 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2018 Nov;72(5):252-258. doi: 
      10.1097/FJC.0000000000000622.

PMID- 17186840
OWN - NLM
STAT- MEDLINE
DCOM- 20070109
LR  - 20190513
IS  - 0891-6640 (Print)
IS  - 0891-6640 (Linking)
VI  - 20
IP  - 6
DP  - 2006 Nov-Dec
TI  - Effects of deracoxib or buffered aspirin on the gastric mucosa of healthy dogs.
PG  - 1291-6
AB  - BACKGROUND: Use of cyclo-oxygenase-2 specific nonsteroidal anti-inflammatory 
      drugs such as deracoxib has been advocated because of their anti-inflammatory 
      actions and apparently low incidence of gastrointestinal adverse effects. 
      HYPOTHESIS: Deracoxib will cause less endoscopically detectable gastric injury in 
      dogs than aspirin, a nonselective nonsteroidal anti-inflammatory drug. ANIMALS: 
      Twenty-four random source healthy dogs. METHODS: A randomized, placebo-controlled 
      trial compared gastroscopic findings of dogs receiving placebo (q8h), aspirin (25 
      mg/kg PO q8h), or deracoxib (1.5 mg/kg QD, placebo ql2h) for 28 days. Gastroscopy 
      on days -7, 6, 14, and 28 evaluated 4 regions of the stomach separately and 
      visible lesions were scored. Dogs were observed every 8 hours for vomiting and 
      diarrhea. Median total scores for each group were compared each day of endoscopic 
      examination and total dog-days of vomiting and diarrhea were compared. 
      Significance was determined at P < .05. RESULTS: There were significant 
      differences in total scores of the aspirin group and both the placebo and 
      deracoxib groups on days 6, 14, and 28. No significant differences in total 
      scores were found between placebo and deracoxib on days 6, 14, and 28. 
      Significant differences in dog-days of vomiting were found between the aspirin 
      and deracoxib groups whereas no significant differences were found between the 
      deracoxib and placebo groups. There was no detectable effect of treatment on 
      dog-days of diarrhea. CONCLUSIONS AND CLINICAL IMPORTANCE: Administration of 
      deracoxib to healthy dogs resulted in significantly lower gastric lesion scores, 
      and fewer days of vomiting compared to aspirin, indicating that deracoxib is 
      better tolerated than aspirin in some dogs.
FAU - Sennello, Kathleen A
AU  - Sennello KA
AD  - Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College 
      of Veterinary Medicine, Blacksburg, VA, USA. ksennell@vt.edu
FAU - Leib, Michael S
AU  - Leib MS
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Vet Intern Med
JT  - Journal of veterinary internal medicine
JID - 8708660
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Sulfonamides)
RN  - R16CO5Y76E (Aspirin)
RN  - VX29JB5XWV (deracoxib)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology
MH  - Aspirin/*adverse effects/pharmacology
MH  - Diarrhea/chemically induced/epidemiology/veterinary
MH  - Dog Diseases/chemically induced/epidemiology
MH  - Dogs
MH  - Female
MH  - Gastric Mucosa/*drug effects/*pathology
MH  - Gastroscopy/methods/veterinary
MH  - Male
MH  - Sulfonamides/*adverse effects/pharmacology
MH  - Time Factors
MH  - Vomiting/chemically induced/epidemiology/veterinary
EDAT- 2006/12/26 09:00
MHDA- 2007/01/11 09:00
CRDT- 2006/12/26 09:00
PHST- 2006/12/26 09:00 [pubmed]
PHST- 2007/01/11 09:00 [medline]
PHST- 2006/12/26 09:00 [entrez]
AID - 10.1892/0891-6640(2006)20[1291:eodoba]2.0.co;2 [doi]
PST - ppublish
SO  - J Vet Intern Med. 2006 Nov-Dec;20(6):1291-6. doi: 
      10.1892/0891-6640(2006)20[1291:eodoba]2.0.co;2.

PMID- 23231453
OWN - NLM
STAT- MEDLINE
DCOM- 20140411
LR  - 20221207
IS  - 1747-4949 (Electronic)
IS  - 1747-4930 (Linking)
VI  - 8
IP  - 7
DP  - 2013 Oct
TI  - Aspirin resistance in Chinese stroke patients increased the rate of recurrent 
      stroke and other vascular events.
PG  - 535-9
LID - 10.1111/j.1747-4949.2012.00929.x [doi]
AB  - INTRODUCTION: To investigate the prevalent of aspirin resistance (AR) in Chinese 
      stroke patients and its association with recurrent stroke and other vascular 
      events, including cardiovascular disease and death. METHODS: We prospectively 
      enrolled 634 Chinese stroke patients. Aspirin was administrated to every patient 
      from the first day of admission. Whole blood samples were collected for platelet 
      aggregation testing after aspirin was administered for 7-10 days. A follow-up 
      period of 12-24 months was performed to record vascular events and hemorrhagic 
      side effects. RESULTS: Aspirin resistance (AR) was detected in 129 patients 
      (20·4%), aspirin semi-resistance (ASR) in 28 patients (4·4%) and aspirin 
      sensitivity (AS) in 477 patients (75·2%). Logistic regression analysis found that 
      diabetes and high levels of low density lipoprotein cholesterol (LDL) were 
      independent risk factors for ASR and AR. During a median follow-up period of 
      19·4 months, the prevalence of recurrent stroke, death from all causes, 
      myocardial infarction and vascular events overall were higher in patients with 
      AR + ASR than in patients with AS. Cox regression analysis found that diabetes 
      and AR were independent risk factors for vascular events. CONCLUSION: Aspirin 
      resistance is common in Chinese patient taking antiplatelet medications. Diabetes 
      and high LDL may induce platelet activation and thrombosis and increase the 
      occurrence of aspirin resistance. Patients who are detected to be aspirin 
      resistant are at a greater risk of clinically important vascular events.
CI  - © 2012 The Authors. International Journal of Stroke © 2012 World Stroke 
      Organization.
FAU - Yi, Xingyang
AU  - Yi X
AD  - Department of Neurology, 3rd Affiliated Hospital of Wenzhou Medical College, 
      Wenzhou, Zhejiang, China.
FAU - Zhou, Qiang
AU  - Zhou Q
FAU - Lin, Jing
AU  - Lin J
FAU - Chi, LiFen
AU  - Chi L
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121211
PL  - United States
TA  - Int J Stroke
JT  - International journal of stroke : official journal of the International Stroke 
      Society
JID - 101274068
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Asian People
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*epidemiology
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/epidemiology
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Recurrence
MH  - Risk Factors
MH  - Stroke/complications/*drug therapy
OTO - NOTNLM
OT  - aspirin resistance
OT  - cerebral infarction
OT  - prognosis
OT  - recurrent stroke
OT  - vascular event
EDAT- 2012/12/13 06:00
MHDA- 2014/04/12 06:00
CRDT- 2012/12/13 06:00
PHST- 2012/12/13 06:00 [entrez]
PHST- 2012/12/13 06:00 [pubmed]
PHST- 2014/04/12 06:00 [medline]
AID - 10.1111/j.1747-4949.2012.00929.x [doi]
PST - ppublish
SO  - Int J Stroke. 2013 Oct;8(7):535-9. doi: 10.1111/j.1747-4949.2012.00929.x. Epub 
      2012 Dec 11.

PMID- 17524242
OWN - NLM
STAT- MEDLINE
DCOM- 20070723
LR  - 20191210
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 59
IP  - 5
DP  - 2007 May
TI  - Generalized regression neural networks in prediction of drug stability.
PG  - 745-50
AB  - This study had two aims. Firstly, we wanted to model the effects of the 
      percentage of Eudragit RS PO and compression pressure as the most important 
      process and formulation variables on the time course of drug release from 
      extended-release matrix aspirin tablets. Secondly, we investigated the 
      possibility of predicting drug stability and shelf-life using an artificial 
      neural network (ANN). Ten types of matrix aspirin tablets were prepared as model 
      formulations and were stored in stability chambers at 60 degrees C, 50 degrees C, 
      40 degrees C and 30 degrees C and controlled humidity. Samples were removed at 
      predefined time points and analysed for acetylsalicylic acid (ASA) and salicylic 
      acid (SA) content using stability-indicating HPLC. The decrease in aspirin 
      content followed apparent zero-order kinetics. The amount of Eudragit RS PO and 
      compression pressure were selected as causal factors. The apparent zero-order 
      rate constants for each temperature were chosen as output variables for the ANN. 
      A set of output parameters and causal factors were used as training data for the 
      generalized regression neural network (GRNN). For two additional test 
      formulations, Arrhenius plots were constructed from the experimentally observed 
      and GRNN-predicted results. The slopes of experimentally observed and predicted 
      Arrhenius plots were tested for significance using Student's t-test. For test 
      formulations, the shelf life (t(95%)) was then calculated from experimentally 
      observed values (t(95%) 82.90 weeks), as well as from GRNN-predicted values 
      (t(95%) 81.88 weeks). These results demonstrate that GRNN networks can be used to 
      predict ASA content and shelf life without stability testing for formulations in 
      which the amount of polymer and tablet hardness are within the investigated 
      range.
FAU - Ibrić, Svetlana
AU  - Ibrić S
AD  - Department of Pharmaceutical Technology, Faculty of Pharmacy, University of 
      Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia. ibric@beotel.yu
FAU - Jovanović, Milica
AU  - Jovanović M
FAU - Djurić, Zorica
AU  - Djurić Z
FAU - Parojcić, Jelena
AU  - Parojcić J
FAU - Solomun, Ljiljana
AU  - Solomun L
FAU - Lucić, Branka
AU  - Lucić B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Eudragit RSPO)
RN  - 0 (Polymethacrylic Acids)
RN  - 0 (Tablets)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*chemistry
MH  - Aspirin/*chemistry
MH  - Chemistry, Pharmaceutical
MH  - Chromatography, High Pressure Liquid
MH  - Delayed-Action Preparations
MH  - Drug Compounding
MH  - Drug Design
MH  - Drug Stability
MH  - Drug Storage
MH  - Hardness
MH  - *Neural Networks, Computer
MH  - Polymethacrylic Acids/*chemistry
MH  - Salicylic Acid
MH  - Tablets
MH  - Temperature
EDAT- 2007/05/26 09:00
MHDA- 2007/07/24 09:00
CRDT- 2007/05/26 09:00
PHST- 2007/05/26 09:00 [pubmed]
PHST- 2007/07/24 09:00 [medline]
PHST- 2007/05/26 09:00 [entrez]
AID - 10.1211/jpp.59.5.0017 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2007 May;59(5):745-50. doi: 10.1211/jpp.59.5.0017.

PMID- 26260550
OWN - NLM
STAT- MEDLINE
DCOM- 20160517
LR  - 20150811
IS  - 0125-9326 (Print)
IS  - 0125-9326 (Linking)
VI  - 47
IP  - 2
DP  - 2015 Apr
TI  - Evaluating resistance to acetyl salicylic acid using platelet function test in 
      patients with ischemic stroke at Cipto Mangunkusumo Hospital.
PG  - 88-94
AB  - AIM: to identify the prevalence of laboratoric ASA resistance using platelet 
      function tests in patients with ischemic stroke at Cipto Mangunkusumo Hospital 
      and its associated factors. METHODS: this study was a cross-sectional study 
      involving 50 patients with ischemic stroke who only received ASA treatment. 
      Evaluation of resistance to ASA was performed using Verifynow® platelet function 
      test. ASA resistance was defined as ASA reaction unit (ARU) 550. RESULTS: there 
      were 7 patients with ASA resistance. The mean age of subjects in ASA resistance 
      group was 51.3±9.2 years; while in ASA responsive group was 57.8±9.7 years. In 
      ASA resistance group, there were 85.7% male patients, 57.1% active smoker and 
      100% subjects with hypertension. CONCLUSION: the prevalence of laboratoric ASA 
      resistance in patients with ischemic stroke evaluated using platelet function 
      test at Cipto Mangunkusumo Hospital is 14%. The prevalence is more likely to 
      occur in male patients who were active smoker, at younger age and with 
      comorbidity of hypertension.
FAU - Kurniawan, M
AU  - Kurniawan M
AD  - Department of Neurology, Faculty of Medicine Universitas Indonesia, Jakarta, 
      Indonesia.
FAU - Harris, Salim
AU  - Harris S
FAU - Hermawan, Deddy
AU  - Hermawan D
FAU - Prihartono, Joedo
AU  - Prihartono J
LA  - eng
PT  - Journal Article
PL  - Indonesia
TA  - Acta Med Indones
JT  - Acta medica Indonesiana
JID - 7901042
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Comorbidity
MH  - Cross-Sectional Studies
MH  - *Drug Resistance
MH  - Female
MH  - Humans
MH  - Hypertension/*complications
MH  - Indonesia
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Sex Factors
MH  - Stroke/*drug therapy
EDAT- 2015/08/12 06:00
MHDA- 2016/05/18 06:00
CRDT- 2015/08/12 06:00
PHST- 2015/08/12 06:00 [entrez]
PHST- 2015/08/12 06:00 [pubmed]
PHST- 2016/05/18 06:00 [medline]
PST - ppublish
SO  - Acta Med Indones. 2015 Apr;47(2):88-94.

PMID- 3897713
OWN - NLM
STAT- MEDLINE
DCOM- 19851018
LR  - 20190817
IS  - 0022-4804 (Print)
IS  - 0022-4804 (Linking)
VI  - 39
IP  - 3
DP  - 1985 Sep
TI  - Drug effects on platelet deposition after endothelial injury of the rabbit aorta.
PG  - 258-66
AB  - Factors released from platelets deposited on injured endothelium have lately been 
      increasingly implicated in the pathogenesis of atherosclerosis and neointimal 
      hyperplasia. Inhibition of platelet activity has therefore been postulated to 
      protect injured vessels from progressive degenerative disease. The objective of 
      this study was to evaluate the effectiveness of platelet inhibiting drugs in 
      decreasing the deposition of platelets after a standardized endothelial injury of 
      the rabbit aorta. The aortic endothelium of 53 rabbits was denuded with a balloon 
      catheter. Morphological changes were studied with light and electron microscopy 
      in five rabbits. The influence of ibuprofen, acetylsalicylic acid, dipyridamole, 
      verapamil, and prostacyclin upon the deposition of indium-111-labeled autogenous 
      platelets 1 hr after injury was evaluated in 48 animals. The morphological 
      studies demonstrated that platelets were deposited on the denuded aorta but no 
      major platelet aggregation or thrombus formation occurred. The radionuclide 
      studies showed that none of the drugs tested had any significant influence on the 
      deposition of platelets. It is concluded that platelets immediately adhere to 
      injured vessels but that the secondary platelet aggregation is minimal if the 
      injury is limited to the endothelium. Conventional drugs mainly affecting 
      platelet aggregation are ineffective in these circumstances.
FAU - Plate, G
AU  - Plate G
FAU - Stanson, A W
AU  - Stanson AW
FAU - Hollier, L H
AU  - Hollier LH
FAU - Dewanjee, M K
AU  - Dewanjee MK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
RN  - 64ALC7F90C (Dipyridamole)
RN  - CJ0O37KU29 (Verapamil)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Aorta/injuries
MH  - Arteriosclerosis/*prevention & control
MH  - Aspirin/pharmacology
MH  - Dipyridamole/pharmacology
MH  - Endothelium/*physiology
MH  - Epoprostenol/pharmacology
MH  - Ibuprofen/pharmacology
MH  - Platelet Adhesiveness/*drug effects
MH  - Rabbits
MH  - Verapamil/pharmacology
EDAT- 1985/09/01 00:00
MHDA- 1985/09/01 00:01
CRDT- 1985/09/01 00:00
PHST- 1985/09/01 00:00 [pubmed]
PHST- 1985/09/01 00:01 [medline]
PHST- 1985/09/01 00:00 [entrez]
AID - 0022-4804(85)90151-9 [pii]
AID - 10.1016/0022-4804(85)90151-9 [doi]
PST - ppublish
SO  - J Surg Res. 1985 Sep;39(3):258-66. doi: 10.1016/0022-4804(85)90151-9.

PMID- 1086311
OWN - NLM
STAT- MEDLINE
DCOM- 19761230
LR  - 20131121
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 16
IP  - 10 Pt 1
DP  - 1976 Oct
TI  - Gastrointestinal microbleeding in normal subjects receiving acetylsalicylic acid, 
      placebo, and R-803, a new antiinflammatory agent, in a design balanced for 
      residual effects.
PG  - 473-80
AB  - This study was undertaken to compare the relative gastrointestinal toxicity of 
      equipotent doses of acetylsalicylic acid (ASA), 900 MG q.i.d., and a new 
      anti-inflammatory agent, R-803, 300 mg q.i.d., against placebo. Gastrointestinal 
      micro-bleeding was quantitated with the 61Cr-labeled erythrocyte assay. The 
      experimental design was balanced for residual effects in the first week following 
      any treatment. An interesting relationship between stool weight and blood loss 
      was found to influence the microbleeding independently of the treatments 
      themselves. All observed blood loss values were corrected by regression to a 
      reference stool weight of 100 Gm. Final analysis of corrected values was done on 
      arithmetic and logarithmic scales. On both scales, R-803 induced much less blood 
      loss than ASA. A difference of 1.3 ml/day between R-803 and placebo was not 
      statistically significant on the arithmetic scale. On the log scale, a 
      statistically significant difference was found; but since it corresponds to 0.4 
      ml/day, it was not considered to be clinically significant at this dosage.
FAU - Arsenault, A
AU  - Arsenault A
FAU - LeBel, E
AU  - LeBel E
FAU - Lussier, A
AU  - Lussier A
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Benzofurans)
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Placebos)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Benzofurans/*adverse effects
MH  - Chromium Radioisotopes
MH  - Feces
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Placebos
EDAT- 1976/10/01 00:00
MHDA- 1976/10/01 00:01
CRDT- 1976/10/01 00:00
PHST- 1976/10/01 00:00 [pubmed]
PHST- 1976/10/01 00:01 [medline]
PHST- 1976/10/01 00:00 [entrez]
PST - ppublish
SO  - J Clin Pharmacol. 1976 Oct;16(10 Pt 1):473-80.

PMID- 9784798
OWN - NLM
STAT- MEDLINE
DCOM- 19981217
LR  - 20190221
IS  - 1079-2082 (Print)
IS  - 1079-2082 (Linking)
VI  - 55
IP  - 19 Suppl 1
DP  - 1998 Oct 1
TI  - Clinical considerations in selecting antiplatelet therapy in cerebrovascular 
      disease.
PG  - S17-20
AB  - Effective antiplatelet drugs--aspirin, ticlopidine, dipyridamole, and 
      clopidogrel--are reviewed. Aspirin has remained the pharmacologic foundation of 
      stroke prevention, primarily because of its low cost. It has been shown to 
      provide a 22% relative risk reduction of stroke in high-risk patients. Its 
      principal adverse effect is gastrotoxicity. Ticlopidine has been widely used in 
      patients with a high risk of stroke who are sensitive to aspirin or in whom 
      aspirin has failed. It has been associated with a median reduction in adenosine 
      diphosphate-induced platelet aggregation of 70% in about 8-11 days. Ticlopidine 
      has been shown to be superior to aspirin at three years in preventing stroke. The 
      principal adverse effects are diarrhea and rash; there has been a 2.4% occurrence 
      of neutropenia. In a trial comparing aspirin, dipyridamole, and a combination of 
      the two, the risk of stroke was 18% lower with aspirin, 16% lower with 
      dipyridamole, and 37% lower with combination therapy compared with placebo. The 
      adverse-effect profile of dipyridamole has proven to be less problematic than 
      that of aspirin or ticlopidine. In a trial comparing clopidogrel with aspirin, 
      patients receiving clopidogrel had an annual 5.32% risk of ischemic stroke, 
      myocardial infarction, or vascular death compared with 5.83% for patients 
      receiving aspirin. Clopidogrel has been associated with a small occurrence of 
      rash and diarrhea, and gastrointestinal intolerance and hemorrhage were less 
      frequent with clopidogrel than with aspirin. Both aspirin and clopidogrel are 
      associated with a low occurrence of neutropenia. Aspirin, ticlopidine, 
      dipyridamole, and clopidogrel have earned a role in stroke prevention; the 
      different adverse-effect profiles of the drugs will influence the choice of 
      agent.
FAU - Harbison, J W
AU  - Harbison JW
AD  - Department of Neurology, Medical College of Virginia, Virginia Commonwealth 
      University, Richmond 23298, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Cerebrovascular Disorders/*drug therapy/*prevention & control
MH  - Clopidogrel
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Ticlopidine/analogs & derivatives/therapeutic use
RF  - 20
EDAT- 1998/10/24 00:00
MHDA- 1998/10/24 00:01
CRDT- 1998/10/24 00:00
PHST- 1998/10/24 00:00 [pubmed]
PHST- 1998/10/24 00:01 [medline]
PHST- 1998/10/24 00:00 [entrez]
AID - 10.1093/ajhp/55.suppl_1.S17 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 1998 Oct 1;55(19 Suppl 1):S17-20. doi: 
      10.1093/ajhp/55.suppl_1.S17.

PMID- 30156911
OWN - NLM
STAT- MEDLINE
DCOM- 20190917
LR  - 20190917
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Linking)
VI  - 33
IP  - 1
DP  - 2019 Jan
TI  - Effects of high- and low-dose aspirin on adaptive immunity and hypertension in 
      the stroke-prone spontaneously hypertensive rat.
PG  - 1510-1521
LID - 10.1096/fj.201701498RR [doi]
AB  - Despite its well-known antithrombotic properties, the effect of aspirin on blood 
      pressure (BP) and hypertension pathology is unclear. The hugely varying doses 
      used clinically have contributed to this confusion, with high-dose aspirin still 
      commonly used due to concerns about the efficacy of low-dose aspirin. Because 
      prostaglandins have been shown to both promote and inhibit T-cell activation, we 
      also explored the immunomodulatory properties of aspirin in hypertension. 
      Although the common preclinical high dose of 100 mg/kg/d improved vascular 
      dysfunction and cardiac hypertrophy, this effect was accompanied by indices of 
      elevated adaptive immunity, renal T-cell infiltration, renal fibrosis, and BP 
      elevation in stroke-prone spontaneously hypertensive rats and in angiotensin 
      II-induced hypertensive mice. The cardioprotective effects of aspirin were 
      conserved with a lower dose (10 mg/kg/d) while circumventing heightened adaptive 
      immunity and elevated BP. We also show that low-dose aspirin improves renal 
      fibrosis. Differential inhibition of the COX-2 isoform may underlie the disparate 
      effects of the 2 doses. Our results demonstrate the efficacy of low-dose aspirin 
      in treating a vast array of cardiovascular parameters and suggest modulation of 
      adaptive immunity as a novel mechanism underlying adverse cardiovascular profiles 
      associated with COX-2 inhibitors. Clinical studies should identify the dose of 
      aspirin that achieves maximal cardioprotection with a new awareness that higher 
      doses of aspirin could trigger undesired autoimmunity in hypertensive 
      individuals. This work also warrants an evaluation of high-dose aspirin and COX-2 
      inhibitor therapy in sufferers of inflammatory conditions who are already at 
      increased risk for cardiovascular disease.-Khan, S. I., Shihata, W. A., Andrews, 
      K. L., Lee, M. K. S., Moore, X.-L., Jefferis, A.-M., Vinh, A., Gaspari, T., 
      Dragoljevic, D., Jennings, G. L., Murphy, A. J., Chin-Dusting, J. P. F. Effects 
      of high- and low-dose aspirin on adaptive immunity and hypertension in the 
      stroke-prone spontaneously hypertensive rat.
FAU - Khan, Shanzana I
AU  - Khan SI
AD  - Department of Pharmacology, Biomedicine Discovery Institute, Monash University, 
      Clayton, Victoria, Australia.
AD  - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
AD  - Department of Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Shihata, Waled A
AU  - Shihata WA
AD  - Department of Pharmacology, Biomedicine Discovery Institute, Monash University, 
      Clayton, Victoria, Australia.
AD  - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
AD  - Department of Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Andrews, Karen L
AU  - Andrews KL
AD  - Department of Pharmacology, Biomedicine Discovery Institute, Monash University, 
      Clayton, Victoria, Australia.
AD  - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
FAU - Lee, Man K S
AU  - Lee MKS
AD  - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
AD  - Department of Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Moore, Xiao-Lei
AU  - Moore XL
AD  - Department of Pharmacology, Biomedicine Discovery Institute, Monash University, 
      Clayton, Victoria, Australia.
FAU - Jefferis, Ann-Maree
AU  - Jefferis AM
AD  - Department of Pharmacology, Biomedicine Discovery Institute, Monash University, 
      Clayton, Victoria, Australia.
AD  - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
FAU - Vinh, Antony
AU  - Vinh A
AD  - Department of Physiology, Anatomy and Microbiology, La Trobe University, 
      Bundoora, Victoria, Australia.
FAU - Gaspari, Tracey
AU  - Gaspari T
AD  - Department of Pharmacology, Biomedicine Discovery Institute, Monash University, 
      Clayton, Victoria, Australia.
FAU - Dragoljevic, Dragana
AU  - Dragoljevic D
AD  - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
AD  - Department of Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Jennings, Garry L
AU  - Jennings GL
AD  - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
AD  - Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
FAU - Murphy, Andrew J
AU  - Murphy AJ
AD  - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
FAU - Chin-Dusting, Jaye P F
AU  - Chin-Dusting JPF
AD  - Department of Pharmacology, Biomedicine Discovery Institute, Monash University, 
      Clayton, Victoria, Australia.
AD  - Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180829
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (RNA, Messenger)
RN  - 0 (Thromboxanes)
RN  - 11128-99-7 (Angiotensin II)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adaptive Immunity/*drug effects
MH  - Angiotensin II/pharmacology
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology/therapeutic use
MH  - Biomarkers/blood
MH  - Blood Pressure/drug effects
MH  - Blood Vessels/drug effects/metabolism/physiopathology
MH  - Cardiomegaly/drug therapy
MH  - Cyclooxygenase 1/genetics
MH  - Cyclooxygenase 2/genetics
MH  - Cytokines/blood
MH  - Disease Susceptibility
MH  - Dose-Response Relationship, Drug
MH  - Epoprostenol/biosynthesis
MH  - Hypertension/chemically induced/*drug therapy
MH  - Kidney/drug effects/enzymology/pathology
MH  - Mice
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Real-Time Polymerase Chain Reaction
MH  - Stroke/*complications/*immunology
MH  - Systole
MH  - T-Lymphocytes/immunology
MH  - Thromboxanes/blood
OTO - NOTNLM
OT  - cardiac hypertrophy
OT  - cyclooxygenase
OT  - prostanoids
OT  - renal fibrosis
OT  - vascular function
EDAT- 2018/08/30 06:00
MHDA- 2019/09/19 06:00
CRDT- 2018/08/30 06:00
PHST- 2018/08/30 06:00 [pubmed]
PHST- 2019/09/19 06:00 [medline]
PHST- 2018/08/30 06:00 [entrez]
AID - 10.1096/fj.201701498RR [doi]
PST - ppublish
SO  - FASEB J. 2019 Jan;33(1):1510-1521. doi: 10.1096/fj.201701498RR. Epub 2018 Aug 29.

PMID- 6708797
OWN - NLM
STAT- MEDLINE
DCOM- 19840524
LR  - 20190919
IS  - 0738-1085 (Print)
IS  - 0738-1085 (Linking)
VI  - 5
IP  - 1
DP  - 1984
TI  - One hundred percent patency of one-millimeter polytetrafluoroethylene (Gore-tex) 
      grafts in the carotid arteries of rats.
PG  - 1-11
AB  - Expanded polytetrafluoroethylene arterial interposition grafts with an internal 
      diameter of 1.0 mm were placed in the carotid arteries of rats. At 2 weeks, 100% 
      patency rate was achieved by the use of strict sterile technique in 23 rats. In 
      contrast, only 1 out of 21 grafts remained open in rats operated using standard 
      clean but nonsterile technique, 5% patency. All thrombosed grafts showed evidence 
      of infection. Orally administered aspirin at therapeutic doses prolonged bleeding 
      times in the rats but did not affect patency results in either group.
FAU - Cuadros, C L
AU  - Cuadros CL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Microsurgery
JT  - Microsurgery
JID - 8309230
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Bleeding Time
MH  - Blood Platelets/physiology
MH  - *Blood Vessel Prosthesis
MH  - Carotid Arteries/diagnostic imaging/pathology/*surgery
MH  - *Graft Survival
MH  - Male
MH  - *Microsurgery
MH  - Polytetrafluoroethylene
MH  - Radiography
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Thrombosis/etiology
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
AID - 10.1002/micr.1920050102 [doi]
PST - ppublish
SO  - Microsurgery. 1984;5(1):1-11. doi: 10.1002/micr.1920050102.

PMID- 29855121
OWN - NLM
STAT- MEDLINE
DCOM- 20190403
LR  - 20220408
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 25
IP  - 10
DP  - 2018 Oct
TI  - Efficacy and safety of dual antiplatelet therapy in the elderly for stroke 
      prevention: a systematic review and meta-analysis.
PG  - 1276-1284
LID - 10.1111/ene.13695 [doi]
AB  - BACKGROUND AND PURPOSE: There is a lack of age-specific evidence regarding the 
      efficacy and safety of dual antiplatelet therapy (DAPT). A systematic review and 
      meta-analysis was conducted for dual versus mono antiplatelet therapy in elderly 
      patients with ischaemic stroke (IS) or transient ischaemic attack (TIA). METHODS: 
      PubMed, Embase and the Cochrane Central Register of Controlled Trials were 
      searched for relevant studies. Risk ratios (RRs) for the outcomes of stroke 
      recurrence, major bleeding and intracranial bleeding were calculated based on the 
      DerSimonian and Laird random effects model. Subgroup analyses were conducted. 
      RESULTS: In seven multicentre, randomized controlled trials comprising 24 873 
      patients with IS or TIA, aged 65 years or older, a significant reduction in the 
      risk of recurrent stroke was observed using DAPT in comparison with aspirin 
      monotherapy [RR 0.79, 95% confidence interval (95% CI) 0.69-0.91; P = 0.001]. 
      DAPT was not associated with a significant reduction in recurrent stroke compared 
      with clopidogrel monotherapy (RR 1.01, 95% CI 0.93-1.10; P = 0.800). In addition, 
      the results from two studies showed that DAPT significantly increased the risk of 
      major bleeding and intracranial bleeding in elderly patients over younger 
      patients (RR 2.18, 95% CI 1.02-4.69; and RR 2.13, 95% CI 1.18-3.86, 
      respectively). CONCLUSIONS: For stroke prevention in elderly patients with IS or 
      TIA, DAPT is superior to aspirin monotherapy but appears to be equivalent to 
      clopidogrel monotherapy, and is accompanied by an increased risk of bleeding. The 
      balance between the benefits and risks of DAPT is important to consider when 
      choosing antiplatelet strategy.
CI  - © 2018 EAN.
FAU - Ding, L
AU  - Ding L
AUID- ORCID: 0000-0003-0114-8157
AD  - Department of Neurology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences, Peking Union Medical College, Beijing, China.
FAU - Peng, B
AU  - Peng B
AD  - Department of Neurology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences, Peking Union Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20180706
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Clopidogrel/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Intracranial Hemorrhages/chemically induced
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Stroke/*prevention & control
MH  - Ticlopidine/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - dual antiplatelet therapy
OT  - elderly
OT  - ischaemic stroke
OT  - stroke prevention
OT  - transient ischaemic attack
EDAT- 2018/06/02 06:00
MHDA- 2019/04/04 06:00
CRDT- 2018/06/02 06:00
PHST- 2017/10/31 00:00 [received]
PHST- 2018/05/23 00:00 [accepted]
PHST- 2018/06/02 06:00 [pubmed]
PHST- 2019/04/04 06:00 [medline]
PHST- 2018/06/02 06:00 [entrez]
AID - 10.1111/ene.13695 [doi]
PST - ppublish
SO  - Eur J Neurol. 2018 Oct;25(10):1276-1284. doi: 10.1111/ene.13695. Epub 2018 Jul 6.

PMID- 11941383
OWN - NLM
STAT- MEDLINE
DCOM- 20020617
LR  - 20191105
IS  - 1075-2765 (Print)
IS  - 1075-2765 (Linking)
VI  - 9
IP  - 3
DP  - 2002 May-Jun
TI  - Analgesics and asthma.
PG  - 233-43
AB  - The incidence of asthma is increasing throughout the world, which presents both 
      public health and economic concerns. It is widely recognized that in some adult 
      patients with asthma, aspirin and other nonsteroidal anti-inflammatory drugs 
      (NSAIDs) that inhibit cyclooxygenase (COX)-1 exacerbate the condition. This is a 
      distinct clinical syndrome called aspirin-induced asthma (AIA). The disease 
      develops according to a characteristic pattern of symptoms. Persistent 
      eosinophilic rhinosinusitis precedes development of nasal polyposis, aspirin 
      hypersensitivity, and asthma. There is no in vitro test, and diagnosis can only 
      be established by provocation tests with aspirin. At the biochemical level, AIA 
      is characterized by a chronic overproduction of cysteinyl leukotrienes. The key 
      enzyme, leukotriene C4 synthase, is overexpressed in bronchi, and its messenger 
      RNA is upregulated in peripheral blood eosinophils. This can be partly related to 
      the genetic polymorphism of the enzyme. The disease runs a protracted course, 
      even if COX-1 inhibitors are avoided. The course of AIA is often severe, and at 
      least half of the patients need systemic corticosteroids to control their asthma. 
      To prevent life-threatening reactions, patients with AIA should avoid aspirin and 
      other analgesics that inhibit COX-1. The incidence of cross-sensitivity to 
      paracetamol in AIA patients is low and, when a reaction does occur, the symptoms 
      experienced are shorter and milder than if the reactions were evoked by an NSAID. 
      Rapidly growing evidence indicates that highly specific COX-2 inhibitors, known 
      as coxibs, are well tolerated and can be safely used by AIA patients.
FAU - Szczeklik, Andrew
AU  - Szczeklik A
AD  - Department of Medicine, Jagellonian University School of Medicine, Cracow, 
      Poland. mmszczek@cyf-kr.edu.pl
FAU - Nizankowska, Ewa
AU  - Nizankowska E
FAU - Mastalerz, Lucyna
AU  - Mastalerz L
FAU - Szabo, Zsuzsanna
AU  - Szabo Z
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Eicosanoids)
RN  - 0 (Leukotrienes)
RN  - 0 (cysteinyl-leukotriene)
RN  - K848JZ4886 (Cysteine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Aspirin/*adverse effects/therapeutic use
MH  - *Asthma/chemically induced/diagnosis/therapy
MH  - Cyclooxygenase Inhibitors/*adverse effects/therapeutic use
MH  - Cysteine/metabolism
MH  - Eicosanoids/metabolism
MH  - Humans
MH  - Leukotrienes/metabolism
RF  - 133
EDAT- 2002/04/10 10:00
MHDA- 2002/06/18 10:01
CRDT- 2002/04/10 10:00
PHST- 2002/04/10 10:00 [pubmed]
PHST- 2002/06/18 10:01 [medline]
PHST- 2002/04/10 10:00 [entrez]
AID - 10.1097/00045391-200205000-00009 [doi]
PST - ppublish
SO  - Am J Ther. 2002 May-Jun;9(3):233-43. doi: 10.1097/00045391-200205000-00009.

PMID- 6333370
OWN - NLM
STAT- MEDLINE
DCOM- 19841220
LR  - 20151119
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 87
IP  - 6
DP  - 1984 Dec
TI  - Effect of cimetidine on net ion fluxes across the rat gastric mucosa during 
      mucosal damage after gastric ischemia and after intravenous acetylsalicylic acid.
PG  - 1283-91
AB  - This study was performed to determine the relationship between net ion fluxes 
      across the rat gastric mucosa and gastric mucosal damage after gastric ischemia 
      and after intravenous administration of acetylsalicylic acid, and to determine 
      the effect of cimetidine on these parameters. Gastric mucosal blood, albumin, and 
      fluid loss that occurred after gastric ischemia was not associated with an 
      increase in net H+ flux from mucosa to serosa. A significant increase in net Na+ 
      and K+ flux from serosa to mucosa occurred. In the presence of cimetidine (150 
      mg/kg X h, i.v.), which reduced gastric damage, net H+ flux increased 
      significantly, whereas there was an inhibition of Na+ and K+ fluxes. 
      Acetylsalicylic acid-induced gastric hemorrhage preceded an increase in net H+ 
      flux from serosa to mucosa, although net Na+ and K+ fluxes were unaffected. 
      Cimetidine (150 mg/kg X h, i.v.) potentiated gastric hemorrhage and this was 
      associated with an increase in net K+ flux from serosa to mucosa. These studies 
      demonstrate that overt damage to the rat gastric mucosa can occur without changes 
      in net ion fluxes across the gastric mucosa.
FAU - Pipkin, G
AU  - Pipkin G
FAU - Price, C A
AU  - Price CA
FAU - Parsons, M E
AU  - Parsons ME
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (Electrolytes)
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Serum Albumin)
RN  - 80061L1WGD (Cimetidine)
RN  - 9NEZ333N27 (Sodium)
RN  - R16CO5Y76E (Aspirin)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Animals
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biological Transport/drug effects
MH  - Chromium Radioisotopes
MH  - Cimetidine/*pharmacology
MH  - Drug Interactions
MH  - Electrolytes/*metabolism
MH  - Gastric Mucosa/blood supply/*metabolism/pathology
MH  - Gastrointestinal Hemorrhage/chemically induced/*metabolism
MH  - Hydrogen-Ion Concentration
MH  - Infusions, Parenteral
MH  - Iodine Radioisotopes
MH  - Ischemia/*metabolism
MH  - Male
MH  - Potassium/metabolism
MH  - Rats
MH  - Serum Albumin/metabolism
MH  - Sodium/metabolism
MH  - Time Factors
EDAT- 1984/12/01 00:00
MHDA- 1984/12/01 00:01
CRDT- 1984/12/01 00:00
PHST- 1984/12/01 00:00 [pubmed]
PHST- 1984/12/01 00:01 [medline]
PHST- 1984/12/01 00:00 [entrez]
AID - S0016508584003061 [pii]
PST - ppublish
SO  - Gastroenterology. 1984 Dec;87(6):1283-91.

PMID- 322267
OWN - NLM
STAT- MEDLINE
DCOM- 19770527
LR  - 20131121
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 6
IP  - 1
DP  - 1977
TI  - Comparative effects of tolfenamic acid and acetylsalicylic acid on human gastric 
      mucosa. A double-blind crossover trial employing gastroscopy, extern gastrocamera 
      and multiple biopsies.
PG  - 23-7
AB  - A comparative study has been made of the effects of tolfenamic acid (Clotam) and 
      acetylsalicyclic acid on the gastric mucosa in 10 healthy volunteers. The effects 
      were evaluated by means of gastroscopy, photography of the gastric mucosa, and 
      multiple biopsies. The schedule was for a randomized, double-blind crossover 
      trial involving two drug-administered periods of one week's duration separated by 
      an interval of at least 3 weeks. On each day of the drug-administration weeks 
      either tolfenamic acid 600 mg or acetylsalicyclic acid 3 g was administered as 
      three divided doses, taken with meals. Gastroscopy was performed prior to and 
      after each week of drug administration. Subjective side effects were recorded 
      during the therapy periods; haematemesis occurred in 2 volunteers taking 
      acetylsalicyclic acid. The absence of gastritis in each subject during treatment 
      with tolfenamic acid was confirmed both gastroscopically and histologically. In 
      contrast, 6 out of 10 volunteers developed mild superficial acute gastritis after 
      ingestion of acetylsalicyclic acid. The difference in effect between the two 
      treatments on the gastric mucosa was statistically significant(p less than 0.05). 
      The findings of this study are comparable to those of other studies and it is 
      concluded that tolfenamic acid, in the relatively high dosage employed in this 
      trial, is free from any irritant effect on the gastric mucosa.
FAU - Axelsson, C K
AU  - Axelsson CK
FAU - Christiansen, L V
AU  - Christiansen LV
FAU - Johansen, A
AU  - Johansen A
FAU - Poulsen, P E
AU  - Poulsen PE
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Tablets)
RN  - 0 (ortho-Aminobenzoates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Biopsy
MH  - Clinical Trials as Topic
MH  - Female
MH  - Gastric Mucosa/*drug effects/pathology
MH  - Gastritis/chemically induced
MH  - Gastroscopes
MH  - Hematemesis/chemically induced
MH  - Humans
MH  - Male
MH  - Tablets
MH  - ortho-Aminobenzoates/administration & dosage/*adverse effects
EDAT- 1977/01/01 00:00
MHDA- 1977/01/01 00:01
CRDT- 1977/01/01 00:00
PHST- 1977/01/01 00:00 [pubmed]
PHST- 1977/01/01 00:01 [medline]
PHST- 1977/01/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Rheumatol. 1977;6(1):23-7.

PMID- 24421640
OWN - NLM
STAT- MEDLINE
DCOM- 20140818
LR  - 20211021
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 9
DP  - 2014
TI  - Local sustained delivery of acetylsalicylic acid via hybrid stent with 
      biodegradable nanofibers reduces adhesion of blood cells and promotes 
      reendothelialization of the denuded artery.
PG  - 311-26
LID - 10.2147/IJN.S51258 [doi]
AB  - Incomplete endothelialization, blood cell adhesion to vascular stents, and 
      inflammation of arteries can result in acute stent thromboses. The systemic 
      administration of acetylsalicylic acid decreases endothelial dysfunction, 
      potentially reducing thrombus, enhancing vasodilatation, and inhibiting the 
      progression of atherosclerosis; but, this is weakened by upper gastrointestinal 
      bleeding. This study proposes a hybrid stent with biodegradable nanofibers, for 
      the local, sustained delivery of acetylsalicylic acid to injured artery walls. 
      Biodegradable nanofibers are prepared by first dissolving 
      poly(D,L)-lactide-co-glycolide and acetylsalicylic acid in 
      1,1,1,3,3,3-hexafluoro-2-propanol. The solution is then electrospun into 
      nanofibrous tubes, which are then mounted onto commercially available bare-metal 
      stents. In vitro release rates of pharmaceuticals from nanofibers are 
      characterized using an elution method, and a highperformance liquid 
      chromatography assay. The experimental results suggest that biodegradable 
      nanofibers release high concentrations of acetylsalicylic acid for three weeks. 
      The in vivo efficacy of local delivery of acetylsalicylic acid in reducing 
      platelet and monocyte adhesion, and the minimum tissue inflammatory reaction 
      caused by the hybrid stents in treating denuded rabbit arteries, are documented. 
      The proposed hybrid stent, with biodegradable acetylsalicylic acid-loaded 
      nanofibers, substantially contributed to local, sustained delivery of drugs to 
      promote re-endothelialization and reduce thrombogenicity in the injured artery. 
      The stents may have potential applications in the local delivery of 
      cardiovascular drugs. Furthermore, the use of hybrid stents with acetylsalicylic 
      acid-loaded nanofibers that have high drug loadings may provide insight into the 
      treatment of patients with high risk of acute stent thromboses.
FAU - Lee, Cheng-Hung
AU  - Lee CH
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Linkou, Taiwan ; Department 
      of Mechanical Engineering, Taiwan.
FAU - Lin, Yu-Huang
AU  - Lin YH
AD  - Graduate Institute of Medical Mechatronics, Chang Gung University, Taiwan.
FAU - Chang, Shang-Hung
AU  - Chang SH
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Linkou, Taiwan.
FAU - Tai, Chun-Der
AU  - Tai CD
AD  - Graduate Institute of Medical Mechatronics, Chang Gung University, Taiwan.
FAU - Liu, Shih-Jung
AU  - Liu SJ
AD  - Department of Mechanical Engineering, Taiwan.
FAU - Chu, Yen
AU  - Chu Y
AD  - Laboratory of Cardiovascular Physiology, Division of Thoracic and Cardiovascular 
      Surgery, Taiwan.
FAU - Wang, Chao-Jan
AU  - Wang CJ
AD  - Department of Medical Imaging and Intervention, Taiwan.
FAU - Hsu, Ming-Yi
AU  - Hsu MY
AD  - Department of Medical Imaging and Intervention, Taiwan.
FAU - Chang, Hung
AU  - Chang H
AD  - Hematology-Oncology Division, Department of Internal Medicine, Chang Gung 
      Memorial Hospital, Linkou, Taiwan.
FAU - Chang, Gwo-Jyh
AU  - Chang GJ
AD  - Graduate Institute of Clinical Medicinal Sciences, Chang Gung University College 
      of Medicine, Linkou, Taiwan.
FAU - Hung, Kuo-Chun
AU  - Hung KC
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Linkou, Taiwan.
FAU - Hsieh, Ming-Jer
AU  - Hsieh MJ
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Linkou, Taiwan.
FAU - Lin, Fen-Chiung
AU  - Lin FC
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Linkou, Taiwan.
FAU - Hsieh, I-Chang
AU  - Hsieh IC
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Linkou, Taiwan.
FAU - Wen, Ming-Shien
AU  - Wen MS
AD  - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine, Linkou, Taiwan.
FAU - Huang, Yenlin
AU  - Huang Y
AD  - Department of Anatomical Pathology, Chang Gung Memorial Hospital, Linkou, 
      Tao-Yuan, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140106
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (Drug Implants)
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Absorbable Implants
MH  - Animals
MH  - Aspirin/*administration & dosage/chemistry
MH  - *Blood Vessel Prosthesis
MH  - Cell Adhesion/drug effects
MH  - Drug Implants/administration & dosage/chemistry
MH  - Endothelium, Vascular/drug effects/injuries/*physiopathology
MH  - Fibrinolytic Agents/administration & dosage/chemistry
MH  - Nanofibers/*chemistry/ultrastructure
MH  - Neovascularization, Physiologic/drug effects/physiology
MH  - Particle Size
MH  - Platelet Adhesiveness/*drug effects
MH  - Rabbits
MH  - *Stents
MH  - Treatment Outcome
PMC - PMC3888352
OTO - NOTNLM
OT  - acetylsalicylic acid
OT  - biodegradable drug-eluting nanofibers
OT  - cell adhesion to vascular stents
OT  - release characteristics
EDAT- 2014/01/15 06:00
MHDA- 2014/08/19 06:00
CRDT- 2014/01/15 06:00
PHST- 2014/01/15 06:00 [entrez]
PHST- 2014/01/15 06:00 [pubmed]
PHST- 2014/08/19 06:00 [medline]
AID - ijn-9-311 [pii]
AID - 10.2147/IJN.S51258 [doi]
PST - ppublish
SO  - Int J Nanomedicine. 2014;9:311-26. doi: 10.2147/IJN.S51258. Epub 2014 Jan 6.

PMID- 11482741
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20181113
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 18
IP  - 7
DP  - 2001
TI  - Can drugs or micronutrients prevent cataract?
PG  - 473-86
AB  - Cataract is the major cause of blindness and of visual impairment worldwide, so 
      its prevention is of the greatest importance. At present no drug therapy is 
      licensed for use in the UK or the US, so the only treatment for cataract is by 
      surgery, which is expensive and has adverse effects. This article reviews 
      research on prevention of cataract by a variety of agents, including 
      micronutrients as well as drugs. Benefits have been claimed for many compounds or 
      mixtures and this review concentrates on those most extensively studied. 
      Information on possible benefits of putative anticataract agents comes from a 
      variety of approaches, from laboratory experiments, both in vitro and in vivo, to 
      epidemiological studies in patients. Sorbitol-lowering drugs were the first to be 
      examined systematically and progressed to clinical trials which were 
      disappointing, and now the entire rationale for their use in prevention of 
      cataract is questionable. Micronutrients showed little promise in animals but 
      came to clinical trial in patients with cataract without the publication of any 
      major benefit. Pantethine showed more promise in animal studies but the only 
      clinical trial was abandoned early. A variety of laboratory and epidemiological 
      evidence supports the benefits of aspirin-like drugs but there has been no trial 
      specifically in patients with cataract. Add-on studies to trials of aspirin for 
      other indications have not been encouraging. Research into other compounds is 
      interesting but less advanced.
FAU - Harding, J J
AU  - Harding JJ
AD  - Nuffield Laboratory of Ophthalmology, University of Oxford, England. 
      john.harding@eye.ox.ac.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Estrogens)
RN  - 496-65-1 (Pantetheine)
RN  - 7K81IL792L (pantethine)
RN  - EC 1.1.1.21 (Aldehyde Reductase)
RN  - GAN16C9B8O (Glutathione)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aldehyde Reductase/antagonists & inhibitors
MH  - Aspirin/therapeutic use
MH  - Cataract/*prevention & control
MH  - Clinical Trials as Topic
MH  - Drug Design
MH  - Estrogens/therapeutic use
MH  - Glutathione/therapeutic use
MH  - Humans
MH  - Pantetheine/*analogs & derivatives/therapeutic use
RF  - 131
EDAT- 2001/08/03 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/08/03 10:00
PHST- 2001/08/03 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/08/03 10:00 [entrez]
AID - 10.2165/00002512-200118070-00001 [doi]
PST - ppublish
SO  - Drugs Aging. 2001;18(7):473-86. doi: 10.2165/00002512-200118070-00001.

PMID- 23771843
OWN - NLM
STAT- MEDLINE
DCOM- 20141020
LR  - 20220330
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 34
IP  - 44
DP  - 2013 Nov
TI  - Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, 
      or neither?
PG  - 3403-11
LID - 10.1093/eurheartj/eht058 [doi]
AB  - Low-dose aspirin has been shown to be effective in preventing about one-fifth of 
      atherothrombotic vascular complications (non-fatal myocardial infarction, 
      non-fatal stroke, or vascular death) in a meta-analysis of 16 secondary 
      prevention trials in patients with previous myocardial infarction, stroke, or 
      transient cerebral ischaemia. This corresponds to an absolute reduction of about 
      10-20 per 1000 patients in the yearly incidence of non-fatal events, and to a 
      smaller, but still definite, reduction in vascular death. Against this benefit, 
      the absolute increase in major extracranial bleeding complications [mostly, 
      gastrointestinal (GI)] is 20- to 50-fold smaller, depending on age and sex. 
      Hence, for secondary prevention, the benefits of antiplatelet therapy 
      substantially exceed the risks. For primary prevention, the balance between 
      vascular events avoided and major bleeds caused by aspirin is substantially 
      uncertain because the risks without aspirin, and hence the absolute benefits of 
      antiplatelet prophylaxis, are at least an order of magnitude lower than in 
      secondary prevention. The aim of this article is to review the updated evidence 
      for the efficacy and safety of low-dose aspirin in primary prevention and to 
      discuss additional health benefits resulting from prolonged antiplatelet therapy 
      in apparently healthy people at low average risk of vascular events.
FAU - Patrono, Carlo
AU  - Patrono C
AD  - Department of Pharmacology, Catholic University School of Medicine, Largo 
      Francesco Vito 1, 00168 Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130614
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Climacteric. 2014 Jun;17(3):310-1. PMID: 24945033
MH  - Anticarcinogenic Agents/administration & dosage/adverse effects
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Cardiovascular Diseases/*prevention & control
MH  - Cyclooxygenase 1/drug effects
MH  - Cyclooxygenase 2/drug effects
MH  - Epidemiologic Methods
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Gastrointestinal Diseases/chemically induced
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Neoplasms/prevention & control
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Primary Prevention
MH  - Secondary Prevention
OTO - NOTNLM
OT  - Aspirin
OT  - Chemoprevention of cancer
OT  - Major bleeding complications
OT  - Major vascular events
OT  - Primary prevention
EDAT- 2013/06/19 06:00
MHDA- 2014/10/21 06:00
CRDT- 2013/06/18 06:00
PHST- 2013/06/18 06:00 [entrez]
PHST- 2013/06/19 06:00 [pubmed]
PHST- 2014/10/21 06:00 [medline]
AID - eht058 [pii]
AID - 10.1093/eurheartj/eht058 [doi]
PST - ppublish
SO  - Eur Heart J. 2013 Nov;34(44):3403-11. doi: 10.1093/eurheartj/eht058. Epub 2013 
      Jun 14.

PMID- 14676658
OWN - NLM
STAT- MEDLINE
DCOM- 20040112
LR  - 20181130
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 55
IP  - 6
DP  - 2003 Dec
TI  - Hemoglobin-based oxygen carrier provides heterogeneous microvascular oxygenation 
      in heart and gut after hemorrhage in pigs.
PG  - 1111-24
AB  - BACKGROUND: In this study, the hypothesis was tested that resuscitation with 
      hemoglobin-based oxygen carriers (HBOCs) affects the oxygenation of the 
      microcirculation differently between and within organs. To this end, we tested 
      the influence of the volume of an HBOC on the microcirculatory oxygenation of the 
      heart and the gut serosa and mucosa in a porcine model of hemorrhage. METHODS: In 
      anesthetized open-chested pigs (n = 24), a controlled hemorrhage (30 mL/kg over 1 
      hour) was followed by resuscitation with 10, 20, or 30 mL/kg 
      diaspirin-crosslinked hemoglobin (DCLHb) or isovolemic resuscitation with 30 
      mL/kg of a 6% hydroxyethyl starch solution (HAES). Measurements included systemic 
      and regional hemodynamic and oxygenation parameters. Microvascular oxygen 
      pressures (microPO2) of the epicardium and the serosa and mucosa of the ileum 
      were measured simultaneously by the palladium-porphyrin phosphorescence 
      technique. Measurements were obtained up to 120 minutes after resuscitation. 
      RESULTS: After hemorrhage, a low volume of DCLHb restored both cardiac and 
      intestinal microPO2. Resuscitation of gut microPO2 with a low volume of DCLHb was 
      as effective as isovolemic resuscitation with HAES. Higher volumes of DCLHb did 
      not restore cardiac microPO2, as did isovolemic resuscitation with HAES, but 
      increased gut microPO2 to hyperoxic values, dose-dependently. Effects were 
      similar for the serosal and mucosal microPo2. In contrast to a sustained 
      hypertensive effect after resuscitation with DCLHb, effects of DCLHb on regional 
      oxygenation and hemodynamics were transient. CONCLUSION: This study showed that a 
      low volume of DCLHb was effective in resuscitation of the microcirculatory 
      oxygenation of the heart and gut back to control levels. Increasing the volume of 
      DCLHb did not cause an additional increase in heart microPO2, but caused 
      hyperoxic microvascular values in the gut to be attained. It is concluded that 
      microcirculatory monitoring in this way elucidates the regional behavior of 
      oxygen transport to the tissue by HBOCs, whereas systemic variables were 
      ineffective in describing their response.
FAU - van Iterson, Mat
AU  - van Iterson M
AD  - Department of Physiology, Academic Medical Center, University of Amsterdam, The 
      Netherlands.
FAU - Siegemund, Martin
AU  - Siegemund M
FAU - Burhop, Kenneth
AU  - Burhop K
FAU - Ince, Can
AU  - Ince C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Hemoglobins)
RN  - 0 (Hydroxyethyl Starch Derivatives)
RN  - 0 (Plasma Substitutes)
RN  - FXP28WJO7L (diaspirin-cross-linked hemoglobin)
RN  - R16CO5Y76E (Aspirin)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Aspirin/*analogs & derivatives/pharmacology/*therapeutic use
MH  - *Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical
MH  - Drug Monitoring
MH  - Female
MH  - Fluid Therapy/methods
MH  - Hemoglobins/pharmacology/*therapeutic use
MH  - Hydroxyethyl Starch Derivatives/*administration & dosage/pharmacology
MH  - Ileum/blood supply/chemistry/drug effects/metabolism
MH  - Intestinal Mucosa/blood supply/chemistry/drug effects/*metabolism
MH  - Microcirculation/*drug effects
MH  - Oxygen/analysis/metabolism
MH  - Oxygen Consumption/drug effects
MH  - Pericardium/chemistry/drug effects/*metabolism
MH  - Plasma Substitutes/*administration & dosage/pharmacology
MH  - Resuscitation/methods
MH  - Shock, Hemorrhagic/*drug therapy/metabolism/physiopathology
MH  - Swine
MH  - Time Factors
EDAT- 2003/12/17 05:00
MHDA- 2004/01/13 05:00
CRDT- 2003/12/17 05:00
PHST- 2003/12/17 05:00 [pubmed]
PHST- 2004/01/13 05:00 [medline]
PHST- 2003/12/17 05:00 [entrez]
AID - 10.1097/01.TA.0000101391.58216.DD [doi]
PST - ppublish
SO  - J Trauma. 2003 Dec;55(6):1111-24. doi: 10.1097/01.TA.0000101391.58216.DD.

PMID- 25392229
OWN - NLM
STAT- MEDLINE
DCOM- 20151229
LR  - 20181113
IS  - 1573-904X (Electronic)
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 32
IP  - 5
DP  - 2015 May
TI  - Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: 
      implications for their clinical pharmacology.
PG  - 1663-75
LID - 10.1007/s11095-014-1565-2 [doi]
AB  - PURPOSE: The purpose of the study was to evaluate the metabolism, 
      pharmacokinetics and efficacy of phospho-NSAIDs in Ces1c-knockout mice. METHODS: 
      Hydrolysis of phospho-NSAIDs by Ces1c was investigated using Ces1c-overexpressing 
      cells. The rate of phospho-NSAID hydrolysis was compared between wild-type, 
      Ces1c+/- and Ces1c-/- mouse plasma in vitro, and the effect of plasma Ces1c on 
      the cytotoxicity of phospho-NSAIDs was evaluated. Pharmacokinetics of 
      phospho-sulindac was examined in wild-type and Ces1c-/- mice. The impact of Ces1c 
      on the efficacy of phospho-sulindac was investigated using lung and pancreatic 
      cancer models in vivo. RESULTS: Phospho-NSAIDs were extensively hydrolyzed in 
      Ces1c-overexpressing cells. Phospho-NSAID hydrolysis in wild-type mouse plasma 
      was 6-530-fold higher than that in the plasma of Ces1c-/- mice. Ces1c-expressing 
      wild-type mouse serum attenuated the in vitro cytotoxicity of phospho-NSAIDs 
      towards cancer cells. Pharmacokinetic studies of phospho-sulindac using wild-type 
      and Ces1c-/- mice demonstrated 2-fold less inactivation of phospho-sulindac in 
      the latter. Phospho-sulindac was 2-fold more efficacious in inhibiting the growth 
      of lung and pancreatic carcinoma in Ces1c -/- mice, as compared to wild-type 
      mice. CONCLUSIONS: Our results indicate that intact phospho-NSAIDs are the 
      pharmacologically active entities and phospho-NSAIDs are expected to be more 
      efficacious in humans than in rodents due to their differential expression of 
      carboxylesterases.
FAU - Wong, Chi C
AU  - Wong CC
AD  - Division of Cancer Prevention, Department of Medicine, Stony Brook University, 
      HSC, T-17 Room 080, Stony Brook, NY, 11794-8173, USA.
FAU - Cheng, Ka-Wing
AU  - Cheng KW
FAU - Papayannis, Ioannis
AU  - Papayannis I
FAU - Mattheolabakis, George
AU  - Mattheolabakis G
FAU - Huang, Liqun
AU  - Huang L
FAU - Xie, Gang
AU  - Xie G
FAU - Ouyang, Nengtai
AU  - Ouyang N
FAU - Rigas, Basil
AU  - Rigas B
LA  - eng
GR  - R01 CA154172/CA/NCI NIH HHS/United States
GR  - 5R01CA154172/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20141113
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (2-(4-isobutylphenyl)propionic acid 4-(diethoxyphosphoryloxy)butyl ester)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (OXT-328)
RN  - 0 (Organophosphates)
RN  - 0 (Organophosphorus Compounds)
RN  - 0 (phosphoaspirin)
RN  - 184SNS8VUH (Sulindac)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.- (carboxylesterase 1, mouse)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/metabolism/pharmacokinetics/*therapeutic 
      use
MH  - Antineoplastic Agents/metabolism/pharmacokinetics/*therapeutic use
MH  - Aspirin/*analogs & derivatives/metabolism/pharmacokinetics/therapeutic use
MH  - Carboxylic Ester Hydrolases/blood/*genetics
MH  - Carcinoma, Lewis Lung/*drug therapy/genetics/metabolism
MH  - Ibuprofen/*analogs & derivatives/metabolism/pharmacokinetics/therapeutic use
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Organophosphates/metabolism/pharmacokinetics/*therapeutic use
MH  - Organophosphorus Compounds/metabolism/pharmacokinetics/*therapeutic use
MH  - Sulindac/*analogs & derivatives/metabolism/pharmacokinetics/therapeutic use
PMC - PMC4382427
MID - NIHMS642451
COIS- Conflicts of interest The authors have nothing to disclose except for Basil 
      Rigas, who has an equity position in Medicon Pharmaceuticals, Inc.
EDAT- 2014/11/14 06:00
MHDA- 2015/12/30 06:00
CRDT- 2014/11/14 06:00
PHST- 2014/07/22 00:00 [received]
PHST- 2014/10/28 00:00 [accepted]
PHST- 2014/11/14 06:00 [entrez]
PHST- 2014/11/14 06:00 [pubmed]
PHST- 2015/12/30 06:00 [medline]
AID - 10.1007/s11095-014-1565-2 [doi]
PST - ppublish
SO  - Pharm Res. 2015 May;32(5):1663-75. doi: 10.1007/s11095-014-1565-2. Epub 2014 Nov 
      13.

PMID- 12208806
OWN - NLM
STAT- MEDLINE
DCOM- 20020909
LR  - 20190623
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 106
IP  - 10
DP  - 2002 Sep 3
TI  - Effect of low-dose aspirin on vascular inflammation, plaque stability, and 
      atherogenesis in low-density lipoprotein receptor-deficient mice.
PG  - 1282-7
AB  - BACKGROUND: Atherosclerosis is a complex vascular inflammatory disease. Low-dose 
      aspirin is a mainstay in the prevention of vascular complications of 
      atherosclerosis. We wished to determine the effect of low-dose aspirin on 
      vascular inflammation, plaque composition, and atherogenesis in LDL 
      receptor-deficient mice fed a high fat diet. METHODS AND RESULTS: In LDL 
      receptor-deficient mice fed a high fat diet compared with control mice, low-dose 
      aspirin induced a significant decrease in circulating levels and vascular 
      formation of soluble intercellular molecule-1, monocyte chemoattractant 
      protein-1, tumor necrosis factor-alpha, interleukin-12p 40, without affecting 
      lipid levels. This was associated with significant reduction of the nuclear 
      factor kappaB activity in the aorta. Low-dose aspirin also significantly reduced 
      the extent of atherosclerosis. Finally, aortic vascular lesions of the 
      aspirin-treated animals showed 57% reduction (P<0.05) in the amount of macrophage 
      cells, 77% increase in smooth muscle cells (P<0.05), and 23% increase in collagen 
      (P<0.05). CONCLUSIONS: Our results suggest that in murine atherosclerosis, 
      low-dose aspirin suppresses vascular inflammation and increases the stability of 
      atherosclerotic plaques, both of which, together with its antiplatelet activity, 
      contribute to its antiatherogenic effect. We conclude that low-dose aspirin might 
      be rationally evaluated in the progression and evolution of human atherosclerotic 
      plaque.
FAU - Cyrus, Tillmann
AU  - Cyrus T
AD  - Center for Experimental Therapeutics and Department of Pharmacology, University 
      of Pennsylvania, School of Medicine, Philadelphia 19104, USA.
FAU - Sung, Syuan
AU  - Sung S
FAU - Zhao, Lei
AU  - Zhao L
FAU - Funk, Colin D
AU  - Funk CD
FAU - Tang, Syun
AU  - Tang S
FAU - Praticò, Domenico
AU  - Praticò D
LA  - eng
GR  - HL-54500/HL/NHLBI NIH HHS/United States
GR  - HL-61364/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cytokines)
RN  - 0 (NF-kappa B)
RN  - 0 (Receptors, LDL)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use
MH  - Aorta/drug effects/metabolism/pathology
MH  - Arteriosclerosis/*drug therapy/metabolism/pathology
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Culture Techniques
MH  - Cytokines/biosynthesis
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - NF-kappa B/metabolism
MH  - Receptors, LDL/*genetics
MH  - Vasculitis/*drug therapy/metabolism
EDAT- 2002/09/05 10:00
MHDA- 2002/09/11 10:01
CRDT- 2002/09/05 10:00
PHST- 2002/09/05 10:00 [pubmed]
PHST- 2002/09/11 10:01 [medline]
PHST- 2002/09/05 10:00 [entrez]
AID - 10.1161/01.cir.0000027816.54430.96 [doi]
PST - ppublish
SO  - Circulation. 2002 Sep 3;106(10):1282-7. doi: 10.1161/01.cir.0000027816.54430.96.

PMID- 25354134
OWN - NLM
STAT- MEDLINE
DCOM- 20160602
LR  - 20181202
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 26
IP  - 7
DP  - 2015
TI  - Dipstick proteinuria is an independent predictor of high on treatment platelet 
      reactivity in patients on clopidogrel, but not aspirin, admitted for major 
      adverse cardiovascular events.
PG  - 651-6
LID - 10.3109/09537104.2014.971000 [doi]
AB  - The effectiveness of aspirin and clopidogrel in patients with chronic kidney 
      disease (CKD) suffering from acute cardiovascular events is unclear. High on 
      treatment platelet reactivity (HTPR) has been associated with worse outcomes. 
      Here, we assessed the association of dipstick proteinuria (DP) and renal function 
      on HTPR and clinical outcomes. Retrospective cohort analysis of 261 consecutive, 
      non-dialysis patients admitted for Major Adverse Cardiovascular Events (MACE) 
      that had VerifyNow P2Y12 and VerifyNow Aspirin assays performed. HTPR was defined 
      as P2Y12 reactivity unit (PRU) > 208 for clopidogrel and aspirin reaction units 
      (ARU) > 550 for aspirin. Renal function was classified based on the estimated 
      glomerular filtration rate (eGFR), and dipstick proteinuria was defined as ≥ 30 
      mg/dl of albumin detected on a spot analysis. All cause mortality, readmissions, 
      and cardiac catheterizations were reviewed over 520 days. In patients on 
      clopidogrel (n = 106), DP was associated with HTPR, independent of eGFR, diabetes 
      mellitus, smoking or use of proton pump inhibitor (AOR = 4.76, p = 0.03). In 
      patients with acute coronary syndromes, HTPR was associated with more cardiac 
      catheterizations (p = 0.009) and readmissions (p = 0.032), but no differences in 
      in-stent thrombosis or re-stenosis were noted in this cohort. In patients on 
      aspirin (n = 155), no associations were seen between DP and HTPR. However, all 
      cause mortality was significantly higher with HTPR in this group (p = 0.038). In 
      this cohort, DP is an independent predictor of HTPR in patients on clopidogrel, 
      but not aspirin, admitted to the hospital for MACE.
FAU - Davila, Carlos D
AU  - Davila CD
AD  - a Department of Medicine , Einstein Medical Center , Philadelphia , PA , USA .
FAU - Vargas, Fernando
AU  - Vargas F
FAU - Huang, Kuan-Hsiang Gary
AU  - Huang KH
FAU - Monaco, Thomas
AU  - Monaco T
FAU - Dimou, Anastasios
AU  - Dimou A
FAU - Rangaswami, Janani
AU  - Rangaswami J
FAU - Figueredo, Vincent M
AU  - Figueredo VM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141029
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - 0 (Receptors, Purinergic P2Y12)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Platelets/*drug effects/*metabolism
MH  - Cardiovascular Diseases/*complications/diagnosis/drug therapy/mortality
MH  - Clopidogrel
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Patient Admission
MH  - Patient Outcome Assessment
MH  - Platelet Function Tests
MH  - Proteinuria/*diagnosis/*etiology
MH  - Purinergic P2Y Receptor Antagonists/*adverse effects
MH  - Receptors, Purinergic P2Y12/metabolism
MH  - Ticlopidine/adverse effects/*analogs & derivatives
OTO - NOTNLM
OT  - Major adverse cardiovascular event
OT  - Proteinuria
OT  - platelet reactivity
EDAT- 2014/10/30 06:00
MHDA- 2016/06/03 06:00
CRDT- 2014/10/30 06:00
PHST- 2014/10/30 06:00 [entrez]
PHST- 2014/10/30 06:00 [pubmed]
PHST- 2016/06/03 06:00 [medline]
AID - 10.3109/09537104.2014.971000 [doi]
PST - ppublish
SO  - Platelets. 2015;26(7):651-6. doi: 10.3109/09537104.2014.971000. Epub 2014 Oct 29.

PMID- 22695889
OWN - NLM
STAT- MEDLINE
DCOM- 20130405
LR  - 20131121
IS  - 1435-232X (Electronic)
IS  - 1434-5161 (Linking)
VI  - 57
IP  - 8
DP  - 2012 Aug
TI  - Genetic variability of prostaglandin E2 receptor subtype EP4 gene in 
      aspirin-intolerant chronic urticaria.
PG  - 494-9
LID - 10.1038/jhg.2012.55 [doi]
AB  - Prostaglandin E2 receptor subtype EP4 (PTGER4) is one of the four subtypes of 
      receptors for prostaglandin E2 (PGE2). Overproduction of cysteinyl leukotriene in 
      mast cells may be related with suppression of PGE2 in patients with aspirin 
      hypersensitivity. Considering the association of PTGER4 in mast cells, urticaria- 
      and aspirin-related disease, we hypothesized the genetic variability of PTGER4 
      may be associated with aspirin-intolerant chronic urticaria (AICU). The 
      case-control study was performed in 141 with AICU, 153 with aspirin-tolerant 
      chronic urticaria (ATCU) and 174 with normal controls (NCs). PTGER4 promoter 
      single-nucleotide polymorphism was genotyped using a primer extension method with 
      the SNAPshot ddNTP primer extension kit. The functional variability of PTGER4 
      promoter polymorphism was carried out by dual-luciferase system and 
      electrophoretic mobility shift assay (EMSA) in human mast cells (HMC-1). 
      Furthermore, the effect of aspirin was performed for PTGER4 mRNA expression using 
      real-time PCR, and PGE2 production was checked in HMC-1 cells using ELISA. AICU 
      patients carrying GG genotype at -1254 G>A showed significantly higher frequency 
      compared with NC (P=0.032). Similarly, the minor allele frequency, G allele was 
      significantly higher in AICU compared with NC (P=0.031). In vitro functional 
      study demonstrated that the -1254 G allele had lower luciferase activity 
      (P<0.001) in HMC-1 cells. EMSA finding showed that PTGER4 -1254 G produced a 
      specific band. Significantly decreased PTGER4 expression (P=0.008) and PGE2 
      production by aspirin exposure was confirmed in in vitro HMC cell line model 
      (P=0.001). The PTGER4 -1254 G allele demonstrated a higher frequency in AICU 
      patients and lower promoter activity with decreased expression of PTGER4 and 
      contributes to the development of AICU.
FAU - Palikhe, Nami Shrestha
AU  - Palikhe NS
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Sin, Hye Jung
AU  - Sin HJ
FAU - Kim, Seung Hyun
AU  - Kim SH
FAU - Sin, Hyun Jung
AU  - Sin HJ
FAU - Hwang, Eui Kyung
AU  - Hwang EK
FAU - Ye, Young Min
AU  - Ye YM
FAU - Park, Hae-Sim
AU  - Park HS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120614
PL  - England
TA  - J Hum Genet
JT  - Journal of human genetics
JID - 9808008
RN  - 0 (PTGER4 protein, human)
RN  - 0 (Receptors, Prostaglandin E, EP4 Subtype)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - *Aspirin/adverse effects/therapeutic use
MH  - Drug Hypersensitivity/*genetics/metabolism
MH  - Female
MH  - Gene Frequency
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Korea
MH  - Male
MH  - Mast Cells/metabolism
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Promoter Regions, Genetic
MH  - Receptors, Prostaglandin E, EP4 Subtype/*genetics
MH  - Urticaria/blood/drug therapy/*genetics/immunology
EDAT- 2012/06/15 06:00
MHDA- 2013/04/06 06:00
CRDT- 2012/06/15 06:00
PHST- 2012/06/15 06:00 [entrez]
PHST- 2012/06/15 06:00 [pubmed]
PHST- 2013/04/06 06:00 [medline]
AID - jhg201255 [pii]
AID - 10.1038/jhg.2012.55 [doi]
PST - ppublish
SO  - J Hum Genet. 2012 Aug;57(8):494-9. doi: 10.1038/jhg.2012.55. Epub 2012 Jun 14.

PMID- 11966338
OWN - NLM
STAT- MEDLINE
DCOM- 20020510
LR  - 20190813
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 162
IP  - 8
DP  - 2002 Apr 22
TI  - Antithrombotic treatment and the incidence of angina pectoris.
PG  - 881-6
AB  - BACKGROUND: In primary prevention, anticoagulation with warfarin sodium to an 
      international normalized ratio of 1.5 and 75 mg of aspirin per day each reduced 
      the incidence of coronary heart disease (CHD). Effects on the development of 
      angina pectoris and total CHD (resulting from angina, myocardial infarction, and 
      coronary death) have been assessed, particularly in light of recent evidence that 
      warfarin may have a "durable effect" on CHD through effects on the pathologic 
      condition of the vessel walls involved. METHODS: The Thrombosis Prevention Trial 
      was carried out in 5499 men aged 45 through 69 years who were at increased risk 
      of CHD. The trial was factorial, with 1 group taking active warfarin and active 
      aspirin, 1 taking active warfarin and placebo aspirin, 1 taking placebo warfarin 
      and active aspirin, and 1 taking double placebo treatment. In addition to those 
      with myocardial infarction and coronary death, men developing angina pectoris 
      after entry to the trial were identified. RESULTS: Warfarin appeared to reduce 
      the incidence of stable angina by 16% (95% confidence interval [CI], -14 to 38), 
      although not significantly (P =.26), while aspirin increased the incidence by 39% 
      (95% CI, 0 to 91) (P =.05). The incidence of stable angina was 37% (95% CI, -1 to 
      60) less in those taking warfarin than in those taking aspirin (P =.05). Warfarin 
      reduced total CHD by 18% (95% CI, 4 to 30) (P =.01), while the reduction due to 
      aspirin was 8% (95% CI, -10 to 22) (P =.36). CONCLUSIONS: The results are 
      compatible with the concept of a durable effect of warfarin on the chronic 
      pathologic conditions underlying angina, although this has not been established 
      with certainty. Further research is needed to confirm or refute our findings, 
      because they carry potentially important implications for the primary prevention 
      of CHD with the use of antithrombotic agents.
FAU - Knottenbelt, Christine
AU  - Knottenbelt C
AD  - Medical Research Council's General Practice Framework, London, England. 
      tom.meade@lshtm.ac.uk
FAU - Brennan, Patrick J
AU  - Brennan PJ
FAU - Meade, Tom W
AU  - Meade TW
CN  - Medical Research Council's General Practice Research Framework
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/pathology/*prevention & control
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Cohort Studies
MH  - Coronary Disease/pathology/*prevention & control
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Factor Analysis, Statistical
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Warfarin/administration & dosage/*therapeutic use
EDAT- 2002/04/23 10:00
MHDA- 2002/05/11 10:01
CRDT- 2002/04/23 10:00
PHST- 2002/04/23 10:00 [pubmed]
PHST- 2002/05/11 10:01 [medline]
PHST- 2002/04/23 10:00 [entrez]
AID - ioi10231 [pii]
AID - 10.1001/archinte.162.8.881 [doi]
PST - ppublish
SO  - Arch Intern Med. 2002 Apr 22;162(8):881-6. doi: 10.1001/archinte.162.8.881.

PMID- 9465844
OWN - NLM
STAT- MEDLINE
DCOM- 19980227
LR  - 20131121
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 63
IP  - 1
DP  - 1998 Jan
TI  - Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin 
      counteraction.
PG  - 79-86
AB  - OBJECTIVE: Blockade of bradykinin breakdown and enhancement of prostaglandin 
      release probably participate in the antihypertensive activity of angiotensin 
      converting enzyme (ACE) inhibitors. Cyclooxygenase blockers may attenuate the 
      efficacy of ACE inhibitors by interfering with prostaglandin synthesis, and 
      patients taking aspirin may not benefit from ACE inhibition. This study was 
      designed to evaluate the incidence of the counteractive phenomenon and to define 
      minimal aspirin dosage that causes an antagonistic effect. METHODS: These were 26 
      patients with mild to moderate hypertension (group 1) and 26 patients with severe 
      untreated primary hypertension (group 2). Enalapril (20 mg twice a day) was used 
      as a single drug in group 1 and was added to the combination of long-acting 
      nifedipine (30 mg/day) and atenolol (50 mg/day) in group 2. Aspirin was tested at 
      doses of 100 and 300 mg/day, and an attenuation of more than 20% of the mean 
      blood pressure decrease produced by enalapril was the criteria that defined 
      antagonism. RESULTS: The 100 mg dose was ineffective. However, 300 mg aspirin had 
      an antagonistic effect in 57% of patients in group 1 and 50% of patients in group 
      2: mean arterial pressure was lowered by 63% and 91% less, respectively. Results 
      were independent of the drug administration order. In "responders," aspirin 
      significantly attenuated the renin rise associated with ACE inhibition. 
      CONCLUSIONS: These findings suggest that a number of ACE-inhibited patients are 
      susceptible to 300 mg/day aspirin, regardless of hypertension severity. 
      Antagonism may be mediated through prostaglandin inhibition according to 
      predominance, in an individual patient, of prostaglandin activation (also as a 
      renin secretory stimulus) or angiotensin blockade by enalapril.
FAU - Guazzi, M D
AU  - Guazzi MD
AD  - Istituto di Cardiologia dell'Università degli Studi, Centro di Studio per le 
      Ricerche Cardiovascolari del CNR, Fondazione Monzino, IRCCS, Milano, Italy.
FAU - Campodonico, J
AU  - Campodonico J
FAU - Celeste, F
AU  - Celeste F
FAU - Guazzi, M
AU  - Guazzi M
FAU - Santambrogio, G
AU  - Santambrogio G
FAU - Rossi, M
AU  - Rossi M
FAU - Trabattoni, D
AU  - Trabattoni D
FAU - Alimento, M
AU  - Alimento M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antihypertensive Agents)
RN  - 69PN84IO1A (Enalapril)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology
MH  - Antihypertensive Agents/administration & dosage/*antagonists & 
      inhibitors/pharmacology
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Pressure/*drug effects
MH  - Drug Administration Schedule
MH  - Drug Antagonism
MH  - Drug Therapy, Combination
MH  - Enalapril/administration & dosage/pharmacology
MH  - Humans
MH  - Hypertension/drug therapy
MH  - Middle Aged
MH  - Natriuresis/drug effects
MH  - Severity of Illness Index
EDAT- 1998/02/18 00:00
MHDA- 1998/02/18 00:01
CRDT- 1998/02/18 00:00
PHST- 1998/02/18 00:00 [pubmed]
PHST- 1998/02/18 00:01 [medline]
PHST- 1998/02/18 00:00 [entrez]
AID - S0009-9236(98)90123-0 [pii]
AID - 10.1016/S0009-9236(98)90123-0 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 1998 Jan;63(1):79-86. doi: 10.1016/S0009-9236(98)90123-0.

PMID- 3159126
OWN - NLM
STAT- MEDLINE
DCOM- 19850724
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 38
IP  - 1
DP  - 1985 Apr 1
TI  - A method of testing platelet aggregation in native whole blood.
PG  - 91-100
AB  - A method of testing collagen induced platelet aggregation and ATP release in 
      native (= non anticoagulated) whole blood by monitoring the electrical impedance 
      in the Chrono Log Whole Blood Aggregometer is reported. It is the first simple 
      method by which aggregation of human platelets can be measured in their natural 
      environment. In normal individuals lower threshold collagen concentrations could 
      induce platelet aggregation as determined with this method than in the other 
      tested methods (impedance method with citrated blood, optical method in platelet 
      rich plasma). The aggregation response was not inhibited by hirudin or heparin in 
      therapeutic dose. The luminescence channel of the Whole Blood Aggregometer 
      permits measurements of ATP release in native whole blood.
FAU - Zwierzina, W D
AU  - Zwierzina WD
FAU - Kunz, F
AU  - Kunz F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Hirudins)
RN  - 9005-49-6 (Heparin)
RN  - 9007-34-5 (Collagen)
RN  - GYV9AM2QAG (Thiourea)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/pharmacology
MH  - Blood
MH  - Collagen/pharmacology
MH  - Electric Conductivity
MH  - Female
MH  - Heparin/pharmacology
MH  - Hirudins/pharmacology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Platelet Aggregation/drug effects
MH  - Platelet Function Tests/*methods
MH  - Thiourea/metabolism
EDAT- 1985/04/01 00:00
MHDA- 1985/04/01 00:01
CRDT- 1985/04/01 00:00
PHST- 1985/04/01 00:00 [pubmed]
PHST- 1985/04/01 00:01 [medline]
PHST- 1985/04/01 00:00 [entrez]
AID - 0049-3848(85)90010-6 [pii]
AID - 10.1016/0049-3848(85)90010-6 [doi]
PST - ppublish
SO  - Thromb Res. 1985 Apr 1;38(1):91-100. doi: 10.1016/0049-3848(85)90010-6.

PMID- 6438651
OWN - NLM
STAT- MEDLINE
DCOM- 19850124
LR  - 20190919
IS  - 0031-6989 (Print)
IS  - 0031-6989 (Linking)
VI  - 16
IP  - 10
DP  - 1984 Oct
TI  - Inhibitory activity of indobufen (*) on platelet aggregation in vivo.
PG  - 979-85
AB  - Indobufen, administered by gavage, reduced mortality induced in mice and rabbits 
      by intravenous injection of arachidonic acid (A.A.). The doses of compound 
      required to protect 50% of the mice and rabbits from death (ED50) were 1.3 and 
      0.58 mg/kg respectively. Acetylsalicylic acid (ASA) was considerably less active 
      than indobufen (ED50 = 22.4 and 8 mg/kg). Since the lethal effect of A.A. is 
      mostly due to the formation of platelet aggregates (Silver et al., 1974; Kohler 
      et al., 1976), it is concluded that indobufen is a very potent inhibitor of 
      platelet aggregation in vivo.
FAU - Bergamaschi, M
AU  - Bergamaschi M
FAU - Pierucci, L
AU  - Pierucci L
FAU - Branzoli, U
AU  - Branzoli U
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pharmacol Res Commun
JT  - Pharmacological research communications
JID - 0236354
RN  - 0 (Arachidonic Acids)
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 6T9949G4LZ (indobufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid
MH  - Arachidonic Acids/antagonists & inhibitors/toxicity
MH  - Aspirin/pharmacology
MH  - Depression, Chemical
MH  - Isoindoles
MH  - Lethal Dose 50
MH  - Male
MH  - Mice
MH  - Phenylbutyrates/*pharmacology
MH  - Platelet Aggregation/*drug effects
EDAT- 1984/10/01 00:00
MHDA- 1984/10/01 00:01
CRDT- 1984/10/01 00:00
PHST- 1984/10/01 00:00 [pubmed]
PHST- 1984/10/01 00:01 [medline]
PHST- 1984/10/01 00:00 [entrez]
AID - 10.1016/s0031-6989(84)80062-4 [doi]
PST - ppublish
SO  - Pharmacol Res Commun. 1984 Oct;16(10):979-85. doi: 10.1016/s0031-6989(84)80062-4.

PMID- 1957990
OWN - NLM
STAT- MEDLINE
DCOM- 19911230
LR  - 20190820
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 46
IP  - 6
DP  - 1991 Aug
TI  - Inhalation and nasal challenge in the diagnosis of aspirin-induced asthma.
PG  - 405-9
AB  - Inhalation and nasal aspirin challenge has been investigated in asthma patients 
      with co-existing rhinitis. Eight of 39 asthma patients were diagnosed as 
      aspirin-sensitive on the basis of inhalation challenge. Seven aspirin-sensitive 
      asthmatics were subjected to nasal aspirin provocation. During nasal challenge, 
      all seven patients experienced a fall in FEV1 of at least 15%, two showed a 
      significant increase (greater than 400%) in nasal airways resistance (NAR) and 
      one developed urticaria. No significant changes in FEV1 or NAR were observed in 
      nine normal subjects after aspirin inhalation and nasal challenge. There were no 
      significant changes in FEV1 or NAR in six aspirin-tolerant asthmatics when 
      aspirin was given intranasally. The results of this study show that aspirin nasal 
      provocation impairs lung function in aspirin-sensitive asthmatics. In comparison 
      with inhalation challenge responses are generally milder and easier to control. 
      Nasal challenge is also less time-consuming than other methods of aspirin 
      challenge and is therefore more suitable for routine use.
FAU - Pawlowicz, A
AU  - Pawlowicz A
AD  - Asthma and Allergy Unit, Sully Hospital, Cardiff, Wales, UK.
FAU - Williams, W R
AU  - Williams WR
FAU - Davies, B H
AU  - Davies BH
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Asthma/*chemically induced/diagnosis
MH  - Bronchial Provocation Tests
MH  - Female
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Nasal Provocation Tests
MH  - Rhinitis/complications
EDAT- 1991/08/01 00:00
MHDA- 1991/08/01 00:01
CRDT- 1991/08/01 00:00
PHST- 1991/08/01 00:00 [pubmed]
PHST- 1991/08/01 00:01 [medline]
PHST- 1991/08/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1991.tb04218.x [doi]
PST - ppublish
SO  - Allergy. 1991 Aug;46(6):405-9. doi: 10.1111/j.1398-9995.1991.tb04218.x.

PMID- 26341013
OWN - NLM
STAT- MEDLINE
DCOM- 20160808
LR  - 20181202
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 765
DP  - 2015 Oct 15
TI  - Drug-drug interactions between clopidogrel and novel cardiovascular drugs.
PG  - 332-6
LID - S0014-2999(15)30231-4 [pii]
LID - 10.1016/j.ejphar.2015.08.059 [doi]
AB  - The combination of aspirin and the thienopyridine clopidogrel is a cornerstone in 
      the prevention of atherothrombotic events. These two agents act in concert to 
      ameliorate the prothrombotic processes stimulated by plaque rupture and vessel 
      injury complicating cardiovascular disease. Guidelines recommend the use of 
      clopidogrel in patients with acute coronary syndromes and in those undergoing 
      percutaneous coronary intervention, and the drug remains the most utilized P2Y12 
      receptor inhibitor despite the fact that newer antiplatelet agents are now 
      available. In recent years, numerous studies have shown inconsistency in the 
      efficacy of clopidogrel to prevent atherothrombotic events. Studies of platelet 
      function testing have shown variability in the response to clopidogrel. One of 
      the major reason for this phenomenon lies in the interaction between clopidogrel 
      and other drugs that may affect clopidogrel absorption, metabolism, and 
      ultimately its antiplatelet action. Importantly, these drug-drug interactions 
      have prognostic implications, since patients with high on-treatment platelet 
      reactivity associated with reduced clopidogrel metabolism have an increased risk 
      of ischemia. Previous systematic reviews have focused on drug-drug interactions 
      between clopidogrel and specific pharmacologic classes, such as proton pump 
      inhibitors, calcium channel blockers, and statins. However, more recent pieces of 
      scientific evidence show that clopidogrel may also interact with newer drugs that 
      are now available for the treatment of cardiovascular patients. Accordingly, the 
      aim of this review is to highlight and discuss recent data on drug-drug 
      interactions between clopidogrel and third-generation proton pump inhibitors, 
      pantoprazole and lansoprazole, statins, pitavastatin, and antianginal drug, 
      ranolazine.
CI  - Copyright © 2015 Elsevier B.V. All rights reserved.
FAU - Pelliccia, Francesco
AU  - Pelliccia F
AD  - Department of Cardiovascular Sciences, Sapienza University, Rome, Italy. 
      Electronic address: f.pelliccia@mclink.it.
FAU - Rollini, Fabiana
AU  - Rollini F
AD  - Division of Cardiology, Department of Medicine, University of Florida College of 
      Medicine, Jacksonville, Florida, United States.
FAU - Marazzi, Giuseppe
AU  - Marazzi G
AD  - IRCCS San Raffaele Pisana, Rome, Italy.
FAU - Greco, Cesare
AU  - Greco C
AD  - Department of Cardiovascular Sciences, Sapienza University, Rome, Italy.
FAU - Gaudio, Carlo
AU  - Gaudio C
AD  - Department of Cardiovascular Sciences, Sapienza University, Rome, Italy.
FAU - Angiolillo, Dominick J
AU  - Angiolillo DJ
AD  - Division of Cardiology, Department of Medicine, University of Florida College of 
      Medicine, Jacksonville, Florida, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150902
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/blood/therapeutic use
MH  - Cardiovascular Agents/*blood/therapeutic use
MH  - Cardiovascular Diseases/blood/drug therapy
MH  - Clopidogrel
MH  - Drug Interactions/physiology
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors
MH  - Platelet Function Tests/methods
MH  - Proton Pump Inhibitors/blood/therapeutic use
MH  - Ticlopidine/*analogs & derivatives/blood/therapeutic use
OTO - NOTNLM
OT  - Clopidogrel
OT  - Drug–drug interaction
OT  - Dual antiplatelet therapy
OT  - Platelet reactivity
EDAT- 2015/09/06 06:00
MHDA- 2016/08/09 06:00
CRDT- 2015/09/06 06:00
PHST- 2015/06/07 00:00 [received]
PHST- 2015/08/24 00:00 [revised]
PHST- 2015/08/31 00:00 [accepted]
PHST- 2015/09/06 06:00 [entrez]
PHST- 2015/09/06 06:00 [pubmed]
PHST- 2016/08/09 06:00 [medline]
AID - S0014-2999(15)30231-4 [pii]
AID - 10.1016/j.ejphar.2015.08.059 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2015 Oct 15;765:332-6. doi: 10.1016/j.ejphar.2015.08.059. Epub 
      2015 Sep 2.

PMID- 26098876
OWN - NLM
STAT- MEDLINE
DCOM- 20160425
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 6
DP  - 2015
TI  - Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of 
      Coronary Artery Disease.
PG  - e0131479
LID - 10.1371/journal.pone.0131479 [doi]
LID - e0131479
AB  - BACKGROUND: Little is known about whether atrial fibrillation is a presentation 
      of coronary disease. There is a paucity of knowledge about their causal 
      relationship and also the impact of different antithrombotic strategies on the 
      subsequent presentation of symptomatic coronary disease. METHODS AND RESULTS: We 
      studied 7,526 Chinese patients diagnosed with non-valvular atrial fibrillation 
      and no documented history of coronary artery disease. The primary endpoint was 
      the new occurrence of coronary artery disease--either stable coronary artery 
      disease or acute coronary syndrome. After a mean follow-up of 3.2±3.5 years 
      (24,071 patient-years), a primary endpoint occurred in 987 patients (13.1%). The 
      overall annual incidence of coronary artery disease was 4.10%/year. No 
      significant differences in age, sex, and mean CHA2DS2-VASc score were observed 
      between patients with and without the primary endpoint. When stratified according 
      to the antithrombotic strategies applied for stroke prevention, the annual 
      incidence of coronary artery disease was 5.49%/year, 4.45%/year and 2.16%/year 
      respectively in those prescribed no antithrombotic therapy, aspirin, and 
      warfarin. Similar trends were observed in patients with acute coronary syndromes. 
      Diabetes mellitus, smoking history and renal failure requiring dialysis were 
      predictors for primary endpoint in all antithrombotic therapies. CONCLUSION: In 
      patients with non-valvular atrial fibrillation, there is a modest association 
      with coronary artery disease. Patients prescribed warfarin had the lowest risk of 
      new onset coronary artery disease.
FAU - Chan, Pak Hei
AU  - Chan PH
AD  - Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, the 
      University of Hong Kong, Hong Kong SAR, China.
FAU - Li, Wen Hua
AU  - Li WH
AD  - Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, the 
      University of Hong Kong, Hong Kong SAR, China.
FAU - Hai, Jo Jo
AU  - Hai JJ
AD  - Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, the 
      University of Hong Kong, Hong Kong SAR, China.
FAU - Tse, Hung Fat
AU  - Tse HF
AD  - Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, the 
      University of Hong Kong, Hong Kong SAR, China.
FAU - Siu, Chung Wah
AU  - Siu CW
AD  - Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, the 
      University of Hong Kong, Hong Kong SAR, China.
LA  - eng
PT  - Journal Article
DEP - 20150622
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Coronary Artery Disease/*epidemiology/etiology
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Hong Kong/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Risk Factors
MH  - Stroke/prevention & control
MH  - Warfarin/adverse effects/therapeutic use
PMC - PMC4476741
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/06/23 06:00
MHDA- 2016/04/26 06:00
CRDT- 2015/06/23 06:00
PHST- 2015/03/05 00:00 [received]
PHST- 2015/06/01 00:00 [accepted]
PHST- 2015/06/23 06:00 [entrez]
PHST- 2015/06/23 06:00 [pubmed]
PHST- 2016/04/26 06:00 [medline]
AID - PONE-D-15-09386 [pii]
AID - 10.1371/journal.pone.0131479 [doi]
PST - epublish
SO  - PLoS One. 2015 Jun 22;10(6):e0131479. doi: 10.1371/journal.pone.0131479. 
      eCollection 2015.

PMID- 12917690
OWN - NLM
STAT- MEDLINE
DCOM- 20030821
LR  - 20211203
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 424
IP  - 6950
DP  - 2003 Aug 14
TI  - Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating 
      NF-kappaB.
PG  - 797-801
AB  - Protein modification by the conjugation of ubiquitin 
      moieties--ubiquitination--plays a major part in many biological processes, 
      including cell cycle and apoptosis. The enzymes that mediate 
      ubiquitin-conjugation have been well-studied, but much less is known about the 
      ubiquitin-specific proteases that mediate de-ubiquitination of cellular 
      substrates. To study this gene family, we designed a collection of RNA 
      interference vectors to suppress 50 human de-ubiquitinating enzymes, and used 
      these vectors to identify de-ubiquitinating enzymes in cancer-relevant pathways. 
      We report here that inhibition of one of these enzymes, the familial 
      cylindromatosis tumour suppressor gene (CYLD), having no known function, enhances 
      activation of the transcription factor NF-kappaB. We show that CYLD binds to the 
      NEMO (also known as IKKgamma) component of the IkappaB kinase (IKK) complex, and 
      appears to regulate its activity through de-ubiquitination of TRAF2, as TRAF2 
      ubiquitination can be modulated by CYLD. Inhibition of CYLD increases resistance 
      to apoptosis, suggesting a mechanism through which loss of CYLD contributes to 
      oncogenesis. We show that this effect can be relieved by aspirin derivatives that 
      inhibit NF-kappaB activity, which suggests a therapeutic intervention strategy to 
      restore growth control in patients suffering from familial cylindromatosis.
FAU - Brummelkamp, Thijn R
AU  - Brummelkamp TR
AD  - Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The 
      Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The 
      Netherlands.
FAU - Nijman, Sebastian M B
AU  - Nijman SM
FAU - Dirac, Annette M G
AU  - Dirac AM
FAU - Bernards, René
AU  - Bernards R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
RN  - 0 (NF-kappa B)
RN  - 0 (Proteins)
RN  - 0 (TNF Receptor-Associated Factor 2)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (Ubiquitin)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.10 (CHUK protein, human)
RN  - EC 2.7.11.10 (I-kappa B Kinase)
RN  - EC 2.7.11.10 (IKBKB protein, human)
RN  - EC 2.7.11.10 (IKBKE protein, human)
RN  - EC 3.4.19.12 (CYLD protein, human)
RN  - EC 3.4.19.12 (Deubiquitinating Enzyme CYLD)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Nature. 2003 Aug 14;424(6950):738-9. PMID: 12917671
MH  - *Apoptosis/drug effects
MH  - Aspirin/analogs & derivatives/pharmacology
MH  - Cell Line
MH  - Deubiquitinating Enzyme CYLD
MH  - Humans
MH  - I-kappa B Kinase
MH  - NF-kappa B/antagonists & inhibitors/*metabolism
MH  - Protein Binding
MH  - Protein Serine-Threonine Kinases/metabolism
MH  - Proteins/metabolism
MH  - RNA Interference
MH  - TNF Receptor-Associated Factor 2
MH  - Transfection
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/pharmacology
MH  - Tumor Suppressor Proteins/antagonists & 
      inhibitors/*deficiency/genetics/metabolism
MH  - Ubiquitin/metabolism
EDAT- 2003/08/15 05:00
MHDA- 2003/08/22 05:00
CRDT- 2003/08/15 05:00
PHST- 2003/03/12 00:00 [received]
PHST- 2003/05/08 00:00 [accepted]
PHST- 2003/08/15 05:00 [pubmed]
PHST- 2003/08/22 05:00 [medline]
PHST- 2003/08/15 05:00 [entrez]
AID - nature01811 [pii]
AID - 10.1038/nature01811 [doi]
PST - ppublish
SO  - Nature. 2003 Aug 14;424(6950):797-801. doi: 10.1038/nature01811.

PMID- 1512524
OWN - NLM
STAT- MEDLINE
DCOM- 19921001
LR  - 20131121
IS  - 0025-7850 (Print)
IS  - 0025-7850 (Linking)
VI  - 23
IP  - 2
DP  - 1992
TI  - Indobufen versus dipyridamole plus aspirin in the treatment of patients with 
      peripheral atherosclerotic disease.
PG  - 81-92
AB  - Twenty-seven patients with peripheral atherosclerotic disease were randomized 
      into two therapy regimens consisting of indobufen (Indo) (400 mg/day) and 
      dipyridamole (Dip) (225 mg/day) plus acetylsalicylic acid (ASA) (1 g/day), 
      respectively. Maximal walking distance (MWD) and ankle-arm systolic pressure 
      ratios were measured before and after three and six months of therapy; bleeding 
      time, beta-thromboglobulin (beta-TG), platelet factor 4 (PF4) and serum 
      thromboxane B2 (TXB2) were also assessed. The two treatment groups showed a 
      significant and progressive increase in pain-free walking distance at both three 
      and six months of therapy, but patients taking indobufen showed a greater 
      improvement. On the contrary, the pressure doppler ratio at rest was 
      statistically improved only in the ASA plus Dip group. Basal beta-TG and PF4 
      levels were normal and no changes occurred during the study in either group, 
      while in all patients bleeding times showed a significant increase above basal 
      values and serum TBX2 decreased.
FAU - Fabris, F
AU  - Fabris F
AD  - Fourth Chair of Internal Medicine, University of Padua Medical School, Italy.
FAU - Steffan, A
AU  - Steffan A
FAU - Randi, M L
AU  - Randi ML
FAU - Avruscio, G P
AU  - Avruscio GP
FAU - Cordiano, I
AU  - Cordiano I
FAU - Girolami, A
AU  - Girolami A
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med
JT  - Journal of medicine
JID - 7505566
RN  - 0 (Isoindoles)
RN  - 0 (Phenylbutyrates)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 6T9949G4LZ (indobufen)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Arteriosclerosis/*drug therapy
MH  - Aspirin/*administration & dosage
MH  - Dipyridamole/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Isoindoles
MH  - Male
MH  - Middle Aged
MH  - Phenylbutyrates/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Random Allocation
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - J Med. 1992;23(2):81-92.

PMID- 9869155
OWN - NLM
STAT- MEDLINE
DCOM- 19990415
LR  - 20131121
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 80
IP  - 6
DP  - 1998 Dec
TI  - A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute 
      myocardial infarction in Italy -- equivalence of costs as a possible case for 
      oral anticoagulants.
PG  - 887-93
AB  - AIMS: The recent publication of two large trials of secondary prevention of 
      coronary artery disease with oral anticoagulants (WARIS and ASPECT) has caused a 
      revival of the interest for this antithrombotic therapy in a clinical setting 
      where the use of aspirin is common medical practice. Despite this, the 
      preferential use of aspirin has been supported by an American cost-effectiveness 
      analysis (JAMA 1995; 273: 965). METHODS AND RESULTS: Using the same parameters 
      used in that analysis and incidence of events from the Antiplatelet Trialists 
      Collaboration and the ASPECT study, we re-evaluated the economic odds in favor of 
      aspirin or oral anticoagulants in the Italian Health System, which differs 
      significantly in cost allocation from the United States system and is, 
      conversely, similar to other European settings. Recalculated costs associated 
      with each therapy were 2,150 ECU/ patient/year for oral anticoagulants and 2,187 
      ECU/patient/year for aspirin. In our analysis, the higher costs of oral 
      anticoagulants versus aspirin due to a moderate excess of bleeding (about 10 ECU/ 
      patient/year) and the monitoring of therapy (168 ECU/ patient/year) are more than 
      offset by an alleged savings for recurrent ischemic syndromes and interventional 
      procedures (249 ECU/ patient/year). CONCLUSIONS: Preference of aspirin vs. oral 
      anticoagulants in a pharmaco-economical perspective is highly dependent on the 
      geographical situation whereupon calculations are based. On a pure 
      cost-effectiveness basis, and in the absence of data of direct comparisons 
      between aspirin alone versus I.N.R.-adjusted oral anticoagulants, the latter are 
      not more expensive than aspirin in Italy and, by cost comparisons, in other 
      European countries in the setting of post-myocardial infarction.
FAU - Gianetti, J
AU  - Gianetti J
AD  - Scuola Superiore di Studi Universitari e di Perfezionamento S. Anna and C.N.R. 
      Institute of Clinical Physiology, Pisa, Italy.
FAU - Gensini, G
AU  - Gensini G
FAU - De Caterina, R
AU  - De Caterina R
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/adverse effects/*economics/therapeutic use
MH  - Aspirin/adverse effects/*economics/therapeutic use
MH  - Blood Coagulation Tests/economics
MH  - Coronary Disease/drug therapy/*economics
MH  - Cost-Benefit Analysis
MH  - Drug Costs
MH  - Fibrinolytic Agents/adverse effects/*economics/therapeutic use
MH  - Health Policy
MH  - Hemorrhage/chemically induced/economics
MH  - Humans
MH  - Italy/epidemiology
MH  - Myocardial Infarction/*drug therapy/epidemiology
MH  - National Health Programs/economics
MH  - Platelet Aggregation Inhibitors/adverse effects/*economics/therapeutic use
MH  - Recurrence
MH  - Warfarin/adverse effects/*economics/therapeutic use
EDAT- 1998/12/30 00:00
MHDA- 1998/12/30 00:01
CRDT- 1998/12/30 00:00
PHST- 1998/12/30 00:00 [pubmed]
PHST- 1998/12/30 00:01 [medline]
PHST- 1998/12/30 00:00 [entrez]
AID - 98120887 [pii]
PST - ppublish
SO  - Thromb Haemost. 1998 Dec;80(6):887-93.

PMID- 33849967
OWN - NLM
STAT- MEDLINE
DCOM- 20220124
LR  - 20220124
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 30
IP  - 6
DP  - 2021 Jun
TI  - Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary 
      Colorectal Cancer Prevention?
PG  - 1106-1113
LID - 10.1158/1055-9965.EPI-19-1580 [doi]
AB  - BACKGROUND: Inherited genetic variants can modify the cancer-chemopreventive 
      effect of aspirin. We evaluated the clinical and economic value of 
      genotype-guided aspirin use for colorectal cancer chemoprevention in average-risk 
      individuals. METHODS: A decision analytical model compared genotype-guided 
      aspirin use versus no genetic testing, no aspirin. The model simulated 100,000 
      adults ≥50 years of age with average colorectal cancer and cardiovascular disease 
      risk. Low-dose aspirin daily starting at age 50 years was recommended only for 
      those with a genetic test result indicating a greater reduction in colorectal 
      cancer risk with aspirin use. The primary outcomes were quality-adjusted 
      life-years (QALY), costs, and incremental cost-effectiveness ratio (ICER). 
      RESULTS: The mean cost of using genotype-guided aspirin was $187,109 with 19.922 
      mean QALYs compared with $186,464 with 19.912 QALYs for no genetic testing, no 
      aspirin. Genotype-guided aspirin yielded an ICER of $66,243 per QALY gained, and 
      was cost-effective in 58% of simulations at the $100,000 willingness-to-pay 
      threshold. Genotype-guided aspirin was associated with 1,461 fewer polyps 
      developed, 510 fewer colorectal cancer cases, and 181 fewer colorectal 
      cancer-related deaths. This strategy prevented 1,078 myocardial infarctions with 
      1,430 gastrointestinal bleeding events, and 323 intracranial hemorrhage cases 
      compared with no genetic testing, no aspirin. CONCLUSIONS: Genotype-guided 
      aspirin use for colorectal cancer chemoprevention may offer a cost-effective 
      approach for the future management of average-risk individuals. IMPACT: A 
      genotype-guided aspirin strategy may prevent colorectal cancer, colorectal 
      cancer-related deaths, and myocardial infarctions, while minimizing bleeding 
      adverse events. This model establishes a framework for genetically-guided aspirin 
      use for targeted chemoprevention of colorectal cancer with application toward 
      commercial testing in this population.
CI  - ©2021 American Association for Cancer Research.
FAU - Biltaji, Eman
AU  - Biltaji E
AUID- ORCID: 0000-0003-0215-5842
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, Utah.
AD  - Program in Personalized Health, University of Utah, Salt Lake City, Utah.
AD  - Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, 
      Utah.
FAU - Walker, Brandon
AU  - Walker B
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, Utah.
AD  - Department of Pathology, School of Medicine, University of Utah, Salt Lake City, 
      Utah.
FAU - Au, Trang H
AU  - Au TH
AUID- ORCID: 0000-0002-0149-0115
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, Utah.
FAU - Rivers, Zachary
AU  - Rivers Z
AD  - Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, 
      University of Minnesota.
FAU - Ose, Jennifer
AU  - Ose J
AUID- ORCID: 0000-0002-2030-9676
AD  - Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
AD  - Department of Population Health Sciences, University of Utah, Salt Lake City, 
      Utah.
FAU - Li, Christopher I
AU  - Li CI
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington.
FAU - Brixner, Diana I
AU  - Brixner DI
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, Utah. stene032@d.umn.edu neli.ulrich@hci.utah.edu diana.brixner@utah.edu.
AD  - Program in Personalized Health, University of Utah, Salt Lake City, Utah.
FAU - Stenehjem, David D
AU  - Stenehjem DD
AUID- ORCID: 0000-0002-1831-285X
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, Utah. stene032@d.umn.edu neli.ulrich@hci.utah.edu diana.brixner@utah.edu.
AD  - Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, 
      University of Minnesota.
FAU - Ulrich, Cornelia M
AU  - Ulrich CM
AD  - Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 
      stene032@d.umn.edu neli.ulrich@hci.utah.edu diana.brixner@utah.edu.
AD  - Department of Population Health Sciences, University of Utah, Salt Lake City, 
      Utah.
LA  - eng
GR  - R01 CA189184/CA/NCI NIH HHS/United States
GR  - R01 CA207371/CA/NCI NIH HHS/United States
GR  - U01 CA206110/CA/NCI NIH HHS/United States
GR  - TL1 TR002493/TR/NCATS NIH HHS/United States
GR  - UL1 TR002494/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20210413
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage/economics/pharmacokinetics
MH  - Colorectal Neoplasms/economics/epidemiology/genetics/*prevention & control
MH  - Computer Simulation
MH  - Cost-Benefit Analysis/*statistics & numerical data
MH  - Dose-Response Relationship, Drug
MH  - Feasibility Studies
MH  - Genetic Testing/economics/statistics & numerical data
MH  - Genotype
MH  - Humans
MH  - Middle Aged
MH  - Models, Economic
MH  - Myocardial Infarction/economics/epidemiology/genetics/*prevention & control
MH  - Pharmacogenomic Variants
MH  - Precision Medicine/economics/methods
MH  - Primary Prevention/economics/*methods
MH  - Quality-Adjusted Life Years
PMC - PMC8172453
MID - NIHMS1693684
COIS- Conflicts of Interest: The authors report no conflicts of interest with the 
      submitted work.
EDAT- 2021/04/15 06:00
MHDA- 2022/01/27 06:00
CRDT- 2021/04/14 05:53
PHST- 2020/01/10 00:00 [received]
PHST- 2020/05/08 00:00 [revised]
PHST- 2021/03/29 00:00 [accepted]
PHST- 2021/04/15 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2021/04/14 05:53 [entrez]
AID - 1055-9965.EPI-19-1580 [pii]
AID - 10.1158/1055-9965.EPI-19-1580 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1106-1113. doi: 
      10.1158/1055-9965.EPI-19-1580. Epub 2021 Apr 13.

PMID- 1206489
OWN - NLM
STAT- MEDLINE
DCOM- 19760401
LR  - 20190710
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 64
IP  - 12
DP  - 1975 Dec
TI  - Determination of tolmetin in human plasma by GLC and spectrophotometric 
      procedures.
PG  - 1965-7
AB  - GLC and spectrophotometric methods for the determination of tolmetin in plasma 
      were developed. The methods can detect tolmetin in concentrations above 0.5 
      mug/ml. The plasma levels obtained with a 600-mg dose of tolmetin to a human 
      subject are reported.
FAU - Cressman, W A
AU  - Cressman WA
FAU - Lopez, B
AU  - Lopez B
FAU - Summer, D
AU  - Summer D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Pyrroles)
RN  - 0 (Salicylates)
RN  - D8K2JPN18B (Tolmetin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/analysis
MH  - Chromatography, Gas
MH  - Humans
MH  - Methods
MH  - Pyrroles/*blood
MH  - Salicylates/analysis
MH  - Spectrophotometry, Ultraviolet
MH  - Time Factors
MH  - Tolmetin/*blood/metabolism
EDAT- 1975/12/01 00:00
MHDA- 1975/12/01 00:01
CRDT- 1975/12/01 00:00
PHST- 1975/12/01 00:00 [pubmed]
PHST- 1975/12/01 00:01 [medline]
PHST- 1975/12/01 00:00 [entrez]
AID - S0022-3549(15)40572-6 [pii]
AID - 10.1002/jps.2600641212 [doi]
PST - ppublish
SO  - J Pharm Sci. 1975 Dec;64(12):1965-7. doi: 10.1002/jps.2600641212.

PMID- 10496355
OWN - NLM
STAT- MEDLINE
DCOM- 19990928
LR  - 20181113
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 81
IP  - 2
DP  - 1999 Sep
TI  - Aspirin induces cell death and caspase-dependent phosphatidylserine 
      externalization in HT-29 human colon adenocarcinoma cells.
PG  - 294-9
AB  - The induction of cell death by aspirin was analysed in HT-29 colon carcinoma 
      cells. Aspirin induced two hallmarks of apoptosis: nuclear chromatin condensation 
      and increase in phosphatidylserine externalization. However, aspirin did not 
      induce either oligonucleosomal fragmentation of DNA, decrease in DNA content or 
      nuclear fragmentation. The effect of aspirin on Annexin V binding was inhibited 
      by the caspase inhibitor Z-VAD.fmk, indicating the involvement of caspases in the 
      apoptotic action of aspirin. However, aspirin did not induce proteolysis of PARP, 
      suggesting that aspirin does not increase nuclear caspase 3-like activity in 
      HT-29 cells. This finding may be related with the 'atypical' features of 
      aspirin-induced apoptosis in HT-29 cells.
FAU - Castaño, E
AU  - Castaño E
AD  - Unitat de Bioquímica, Departament de Ciències Fisiològiques II, Universitat de 
      Barcelona, L'Hospitalet, Spain.
FAU - Dalmau, M
AU  - Dalmau M
FAU - Barragán, M
AU  - Barragán M
FAU - Pueyo, G
AU  - Pueyo G
FAU - Bartrons, R
AU  - Bartrons R
FAU - Gil, J
AU  - Gil J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Phosphatidylserines)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
RN  - EC 3.4.22.- (Caspases)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Aspirin/*pharmacology
MH  - Blotting, Western
MH  - Caspases/*metabolism
MH  - DNA Fragmentation
MH  - Enzyme Activation/drug effects
MH  - HT29 Cells/drug effects
MH  - Humans
MH  - Phosphatidylserines/metabolism
MH  - Poly(ADP-ribose) Polymerases/metabolism
PMC - PMC2362852
EDAT- 1999/09/25 00:00
MHDA- 1999/09/25 00:01
CRDT- 1999/09/25 00:00
PHST- 1999/09/25 00:00 [pubmed]
PHST- 1999/09/25 00:01 [medline]
PHST- 1999/09/25 00:00 [entrez]
AID - 6690690 [pii]
AID - 10.1038/sj.bjc.6690690 [doi]
PST - ppublish
SO  - Br J Cancer. 1999 Sep;81(2):294-9. doi: 10.1038/sj.bjc.6690690.

PMID- 28393614
OWN - NLM
STAT- MEDLINE
DCOM- 20170417
LR  - 20220330
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 18
IP  - 6
DP  - 2017 Apr
TI  - Current and future perspectives on the treatment of cerebral ischemia.
PG  - 573-580
LID - 10.1080/14656566.2017.1309022 [doi]
AB  - After heart disease and combined forms of cancer, stroke is the leading cause of 
      death in the United States. Currently, tissue-plasminogen activator (tPA) 
      thrombolysis is the only thrombolytic therapy that has been shown to improve 
      patient outcome. Presently, the only antithrombotic drug treatment that has 
      proven effective at improving acute ischemic stroke patient outcome is aspirin 
      administration. Despite these studies, no clinical trials have yet demonstrated a 
      reliably effective pharmacological treatment. Areas covered: We conducted a 
      search of recent drug studies for ischemic stroke on clinicaltrials.gov in 
      addition to a literature search for acute ischemic stroke therapy using PubMed. 
      This review details our findings of recent advancements in the pharmacological 
      treatment of acute ischemic stroke. Expert commentary: We concluded that recent 
      attempts to establish new pharmacological treatment protocols for acute ischemic 
      stroke have had limited success, but many Phase III and Phase IV clinical trials 
      demonstrate promise. Moreover, several studies have demonstrated the efficacy of 
      dual-antiplatelet therapies at reducing risk of secondary stroke. Studies for 
      novel therapeutic targets for neuroprotection have been largely unsuccessful. 
      Some trials had positive results; however, there is much room for improvement and 
      other studies show promise in their preliminary stages.
FAU - Christophe, Brandon R
AU  - Christophe BR
AD  - a Department of Neurological Surgery , Columbia University Medical Center , New 
      York , NY , USA.
FAU - Mehta, Shyle H
AU  - Mehta SH
AD  - a Department of Neurological Surgery , Columbia University Medical Center , New 
      York , NY , USA.
FAU - Garton, Andrew L A
AU  - Garton AL
AD  - a Department of Neurological Surgery , Columbia University Medical Center , New 
      York , NY , USA.
FAU - Sisti, Jonathan
AU  - Sisti J
AD  - a Department of Neurological Surgery , Columbia University Medical Center , New 
      York , NY , USA.
FAU - Connolly, E Sander Jr
AU  - Connolly ES Jr
AD  - a Department of Neurological Surgery , Columbia University Medical Center , New 
      York , NY , USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Fibrinolytic Agents)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Stroke/*drug therapy
MH  - Thrombolytic Therapy
MH  - Tissue Plasminogen Activator/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Ischemia
OT  - antithrombotic
OT  - neuroprotection
OT  - pharmacotherapy
OT  - reperfusion
OT  - stroke
OT  - thrombolysis
EDAT- 2017/04/11 06:00
MHDA- 2017/04/18 06:00
CRDT- 2017/04/11 06:00
PHST- 2017/04/11 06:00 [entrez]
PHST- 2017/04/11 06:00 [pubmed]
PHST- 2017/04/18 06:00 [medline]
AID - 10.1080/14656566.2017.1309022 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2017 Apr;18(6):573-580. doi: 
      10.1080/14656566.2017.1309022.

PMID- 6595458
OWN - NLM
STAT- MEDLINE
DCOM- 19850206
LR  - 20131121
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 73
IP  - 6
DP  - 1984 Dec
TI  - Issues in the design and conduct of clinical trials.
PG  - 1473-6
AB  - Careful consideration of issues in the design and conduct of clinical trials is 
      essential for valid results to be achieved. Specifically, if the trial is 
      randomized and well designed with respect to timing, pilot studies, choice of 
      study population, sample size, duration of follow-up, and subject compliance, it 
      can offer reliable evidence about a positive, inverse, or null effect of an 
      intervention. With these considerations in mind, the Physicians' Health Study is 
      being conducted among over 21,996 male physicians, 40-84 years of age, in the 
      United States and involved a 2 X 2 factorial design used to test the roles of 
      beta-carotene in the prevention of cancer and aspirin in the reduction of 
      cardiovascular mortality. The choice of physicians as the study population and 
      the implementation of a prerandomization run-in period resulted in 100% mortality 
      and 99.5% morbidity follow-up, as well as 98.5% compliance with the treatment 
      regimen 6 months after randomization. The ultimate goal of these methodologic 
      considerations is to design studies that clearly can prove or refute the 
      hypotheses that was tested.
FAU - Hennekens, C H
AU  - Hennekens CH
LA  - eng
GR  - CA-34944/CA/NCI NIH HHS/United States
GR  - HL-26490/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Placebos)
RN  - 01YAE03M7J (beta Carotene)
RN  - 36-88-4 (Carotenoids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Carotenoids/therapeutic use
MH  - Clinical Trials as Topic/*methods
MH  - Humans
MH  - Patient Compliance
MH  - Placebos
MH  - Research Design
MH  - United States
MH  - United States Public Health Service
MH  - beta Carotene
EDAT- 1984/12/01 00:00
MHDA- 1984/12/01 00:01
CRDT- 1984/12/01 00:00
PHST- 1984/12/01 00:00 [pubmed]
PHST- 1984/12/01 00:01 [medline]
PHST- 1984/12/01 00:00 [entrez]
PST - ppublish
SO  - J Natl Cancer Inst. 1984 Dec;73(6):1473-6.

PMID- 30501717
OWN - NLM
STAT- MEDLINE
DCOM- 20190228
LR  - 20190228
IS  - 1009-2137 (Print)
IS  - 1009-2137 (Linking)
VI  - 26
IP  - 6
DP  - 2018 Dec
TI  - [3D-Morphological Analysis of Inhibitory Effect of Aspirin on Platelet 
      Aggregation].
PG  - 1757-1764
LID - 10.7534/j.issn.1009-2137.2018.06.030 [doi]
AB  - OBJECTIVE: To develop a new method for evaluating the inhibitory effect of 
      aspirin on platelet by the three-dimensional (3D) morphological parameters. 
      METHODS: The sodium citrate-anticoagulant peripheral blood samples collected from 
      12 healthy volunteers were divided into 2 groups: group treated with 200 μmol/L 
      acetylsalicylic acid (ASA), and control group. The platelets in the 2 groups were 
      washed and purified. The purified platelets were added into reaction pools 
      modified with type I collagen and induced to activation and aggregation under 
      static condition. The 3D morphology of the formed platelet aggregate was measured 
      by the laser shape microscopic system. Meanwhile, the platelet function was 
      detected by turbidometric light transmittance aggregometry (LTA). RESULTS: This 
      technology could acquire the shape, height and 3D morphology of the platelet 
      aggregates without label, and could quantify their volume parameters. ASA 
      treatment could obviously change the morphology of platelet aggregates. Compared 
      with the parameters of control group, the volume of platelet aggregates in 
      experimental group decreased significantly (t=8.97, P<0.01), while the 
      cross-sectional area showed no significant change (t=1.94, P>0.05). The 
      receiver-operating characteristic curve(ROC) analysis showed that the platelet 
      aggregate volume as a parameter to identify the ASA inhibition effect had 91.7% 
      sensitivity and 75% specificity when the cut-off value equal to 1395 μm(3), and 
      its accuracy and sensitivity were both better than those of platelet aggregates 
      rate measured by LTA method. CONCLUSION: The new method developed for evaluating 
      the ASA inhibition of platelet aggregation may provide a complementary strategy 
      for researching and clinically evaluating of ASA anti-platelet aggregation in 
      future.
FAU - Liu, Juan
AU  - Liu J
AD  - Central Laboratory of Yongchuan Hospital, Chongqing Medical University,Chongqing 
      402160, China.
FAU - Ding, Ling
AU  - Ding L
AD  - Yongchuan Sub-center of Chongqing Blood Center, Chongqing 402160, China.
FAU - He, Cui
AU  - He C
AD  - Central Laboratory of Yongchuan Hospital, Chongqing Medical University,Chongqing 
      402160, China.
FAU - Chen, Dan
AU  - Chen D
AD  - Central Laboratory of Yongchuan Hospital, Chongqing Medical University,Chongqing 
      402160, China.
FAU - Deng, Su-Rong
AU  - Deng SR
AD  - Central Laboratory of Yongchuan Hospital, Chongqing Medical University,Chongqing 
      402160, China.
FAU - Li, Yuan
AU  - Li Y
AD  - Central Laboratory of Yongchuan Hospital, Chongqing Medical University,Chongqing 
      402160, China.E-mail: liyuan_1985999@163.com.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Shi Yan Xue Ye Xue Za Zhi
JT  - Zhongguo shi yan xue ye xue za zhi
JID - 101084424
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin
MH  - Blood Platelets
MH  - Hemostasis
MH  - Humans
MH  - *Platelet Aggregation
MH  - Platelet Function Tests
EDAT- 2018/12/07 06:00
MHDA- 2019/03/01 06:00
CRDT- 2018/12/04 06:00
PHST- 2018/12/04 06:00 [entrez]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/03/01 06:00 [medline]
AID - 1009-2137(2018)06-1757-08 [pii]
AID - 10.7534/j.issn.1009-2137.2018.06.030 [doi]
PST - ppublish
SO  - Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Dec;26(6):1757-1764. doi: 
      10.7534/j.issn.1009-2137.2018.06.030.

PMID- 1462916
OWN - NLM
STAT- MEDLINE
DCOM- 19930112
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 124
IP  - 6
DP  - 1992 Dec
TI  - The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial 
      fibrillation: The BAATAF Study.
PG  - 1567-73
AB  - Recent randomized trials have consistently demonstrated the marked efficacy of 
      warfarin in reducing the risk of stroke caused by nonrheumatic atrial 
      fibrillation. These trials have provided conflicting evidence on the effect of 
      aspirin. We report the aspirin analysis from the BAATAF study, a trial in which 
      control patients could choose to take aspirin. There we two strokes in 446 
      person-years with warfarin (annual rate of 0.45%); eight strokes in 206 
      person-years with aspirin, most at 325 mg per day (annual rate of 3.9%); and five 
      strokes in 271 person-years among patients taking neither aspirin nor warfarin 
      (annual rate of 1.8%). Simultaneously controlling for the other significant 
      determinants of stroke in the BAATAF study (age, mitral annular calcification, 
      and clinical heart disease), the relative rates (95% confidence interval) of 
      stroke were: (1) warfarin/aspirin = 0.135 (0.029 to 0.64); (2) aspirin/(no 
      aspirin and no warfarin) = 1.95 (0.64 to 5.97); and (3) warfarin/(no aspirin and 
      no warfarin) = 0.263 (0.051 to 1.36). Our "treatment received" analysis argues 
      that warfarin is strikingly more effective than aspirin in preventing stroke in 
      nonrheumatic atrial fibrillation.
FAU - Singer, D E
AU  - Singer DE
AD  - General Internal Medicine Unit, Massachusetts General Hospital, Boston 02114.
FAU - Hughes, R A
AU  - Hughes RA
FAU - Gress, D R
AU  - Gress DR
FAU - Sheehan, M A
AU  - Sheehan MA
FAU - Oertel, L B
AU  - Oertel LB
FAU - Maraventano, S W
AU  - Maraventano SW
FAU - Blewett, D R
AU  - Blewett DR
FAU - Rosner, B
AU  - Rosner B
FAU - Kistler, J P
AU  - Kistler JP
LA  - eng
GR  - HL 33233-05/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/*complications
MH  - Cerebrovascular Disorders/epidemiology/etiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Warfarin/*therapeutic use
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
AID - 0002-8703(92)90074-6 [pii]
AID - 10.1016/0002-8703(92)90074-6 [doi]
PST - ppublish
SO  - Am Heart J. 1992 Dec;124(6):1567-73. doi: 10.1016/0002-8703(92)90074-6.

PMID- 34364538
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 148
IP  - 2
DP  - 2021 Aug
TI  - Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease.
PG  - 283-291
LID - S0091-6749(21)00975-1 [pii]
LID - 10.1016/j.jaci.2021.06.018 [doi]
AB  - Aspirin-exacerbated respiratory disease (AERD) is a condition composed of chronic 
      rhinosinusitis with nasal polyposis and asthma that is defined by respiratory 
      hypersensitivity reactions to the cyclooxygenase 1-inhibitory effects of 
      nonsteroidal anti-inflammatory drugs. It is diagnosed in 5% to 15% of patients 
      with asthma and is even more common in those with comorbid nasal polyposis. 
      Diagnosis is confirmed after an aspirin challenge procedure, yet many patients 
      present with all components and can reliably be diagnosed by history. Patients 
      with AERD commonly experience severe uncontrolled nasal polyposis and require 
      multispecialty evaluation to properly stage and treat this condition. The 
      presence of nasal polyposis plays a large component in the diminished quality of 
      life in patients with AERD. In the last decade, multiple new therapeutic areas 
      have been approved for type 2 airway diseases, offering patients with AERD many 
      more options for control. This makes an early and accurate diagnosis of AERD 
      important in the care of the larger population of type 2 airway diseases.
CI  - Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Haque, Rubaiyat
AU  - Haque R
AD  - Department of Adult Allergy, Guy's and St Thomas' NHS Foundation Trust, London, 
      United Kingdom. Electronic address: rubaiyat.haque@gstt.nhs.uk.
FAU - White, Andrew A
AU  - White AA
AD  - Division of Asthma, Allergy and Immunology, Scripps Clinic, San Diego, Calif.
FAU - Jackson, David J
AU  - Jackson DJ
AD  - Guy's Severe Asthma Service, Guy's and St Thomas' NHS Foundation Trust, London, 
      United Kingdom; School of Immunology & Microbial Sciences, King's College London, 
      London, United Kingdom.
FAU - Hopkins, Claire
AU  - Hopkins C
AD  - Ear, Nose and Throat Department, Guy's and St Thomas' NHS Foundation Trust, 
      London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
MH  - Aspirin/adverse effects/therapeutic use
MH  - *Asthma, Aspirin-Induced/diagnosis/pathology/therapy
MH  - Humans
MH  - *Nasal Polyps/chemically induced/diagnosis/pathology/therapy
MH  - *Sinusitis/chemically induced/diagnosis/pathology/therapy
OTO - NOTNLM
OT  - Aspirin-exacerbated respiratory disease
OT  - NSAID hypersensitivity
OT  - aspirin hypersensitivity
OT  - chronic rhinosinusitis with nasal polyps
EDAT- 2021/08/09 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/08/08 20:23
PHST- 2021/04/30 00:00 [received]
PHST- 2021/06/14 00:00 [revised]
PHST- 2021/06/15 00:00 [accepted]
PHST- 2021/08/08 20:23 [entrez]
PHST- 2021/08/09 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - S0091-6749(21)00975-1 [pii]
AID - 10.1016/j.jaci.2021.06.018 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2021 Aug;148(2):283-291. doi: 10.1016/j.jaci.2021.06.018.

PMID- 2590611
OWN - NLM
STAT- MEDLINE
DCOM- 19900116
LR  - 20190510
IS  - 0306-5251 (Print)
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 28
IP  - 5
DP  - 1989 Nov
TI  - Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in 
      man.
PG  - 573-9
AB  - 1. Effects of a single intravenous dose of aspirin (600 mg) on 
      bradykinin-stimulated prostaglandin (PG) and on thromboxane (TX) biosynthesis 
      were determined in nine healthy male volunteers. Plasma concentrations of 
      6-oxo-PGF1 alpha and 13,14-dihydro-15-oxo-PGF2 alpha were measured in samples 
      obtained during repeated 10 min intravenous infusions of bradykinin before and up 
      to 6 h after the dose of aspirin. TXB2 was measured in serum from blood allowed 
      to clot at 37 degrees C. 2. Aspirin inhibited bradykinin stimulated PG and 
      platelet TX biosynthesis 0.5 h after the dose. Serum TXB2 remained low, whereas 
      PG synthesis recovered within 6 h. 3. Effects of intravenous sodium salicylate 
      (600 mg) were studied identically in eight subjects. Prostanoid biosynthesis was 
      not inhibited. 4. Biosynthesis of prostacyclin and TXA2 under basal conditions 
      was studied in eight subjects by measuring 2,3-dinor-6-oxo-PGF1 alpha and 
      2,3-dinor-TXB2 in hourly urine samples obtained during and after intravenous 
      infusion of aspirin and, on a separate occasion, of vehicle. 5. Aspirin infusion 
      reduced urinary excretion of both metabolites greater than 90%, but excretion of 
      2,3-dinor-6-oxo-PGF1 alpha recovered more rapidly than did that of 
      2,3-dinor-TXB2. 6. We conclude that cyclo-oxygenase is rapidly synthesised in 
      bradykinin-responsive tissues in vivo and that this reflects similarly rapid 
      enzyme biosynthesis in tissues that produce PGI2 under basal conditions.
FAU - Ritter, J M
AU  - Ritter JM
AD  - Department of Clinical Pharmacology, Royal Postgraduate Medical School, 
      Hammersmith Hospital, London.
FAU - Cockcroft, J R
AU  - Cockcroft JR
FAU - Doktor, H S
AU  - Doktor HS
FAU - Beacham, J
AU  - Beacham J
FAU - Barrow, S E
AU  - Barrow SE
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Prostaglandins)
RN  - 0 (Thromboxanes)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 58962-34-8 (6-Ketoprostaglandin F1 alpha)
RN  - 63250-09-9 (2,3-dinor-thromboxane B2)
RN  - 64700-71-6 (2,3-dinor-6-ketoprostaglandin F1alpha)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 6-Ketoprostaglandin F1 alpha/analogs & derivatives/urine
MH  - Adult
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Humans
MH  - Infusions, Intravenous
MH  - Injections
MH  - Male
MH  - Prostaglandins/*biosynthesis/blood
MH  - Thromboxane B2/analogs & derivatives/urine
MH  - Thromboxanes/*biosynthesis
PMC - PMC1380018
EDAT- 1989/11/01 00:00
MHDA- 1989/11/01 00:01
CRDT- 1989/11/01 00:00
PHST- 1989/11/01 00:00 [pubmed]
PHST- 1989/11/01 00:01 [medline]
PHST- 1989/11/01 00:00 [entrez]
AID - 10.1111/j.1365-2125.1989.tb03544.x [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 1989 Nov;28(5):573-9. doi: 
      10.1111/j.1365-2125.1989.tb03544.x.

PMID- 307908
OWN - NLM
STAT- MEDLINE
DCOM- 19780930
LR  - 20180330
IS  - 0002-9165 (Print)
IS  - 0002-9165 (Linking)
VI  - 31
IP  - 8
DP  - 1978 Aug
TI  - Synergistic effect of vitamin C and aspirin on gastric lesions in the rat.
PG  - 1397-9
AB  - The effects of varying levels of dietary vitamin C on the incidence of 
      aspirin-induced gastric hemorrhagic lesions were studied in young, male rats. 
      Rats fed diets containing either 20, 40, or 60 mg of L-ascorbic acid per gram of 
      diet did not exhibit focal gastric lesions. Administering a single oral dose of 
      aspirin (30 mg aspirin/100 g of body weight) to rats fed control diets produced 
      gastric lesions. When the rats were given aspirin plus a diet containing either 
      40 or 60 mg ascorbic acid per gram of diet, there was a significant increase in 
      number of gastric lesions. Since vitamin C and aspirin seem to act 
      synergistically in producing hemorrhagic lesions in the stomach, it is 
      recommended that all individuals taking megadoses of vitamin C be cautioned 
      against taking aspirin concurrently.
FAU - Lo, G Y
AU  - Lo GY
FAU - Konishi, F
AU  - Konishi F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Ascorbic Acid/administration & dosage/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Gastric Mucosa/drug effects
MH  - Gastrointestinal Hemorrhage/*chemically induced
MH  - Male
MH  - Rats
EDAT- 1978/08/01 00:00
MHDA- 1978/08/01 00:01
CRDT- 1978/08/01 00:00
PHST- 1978/08/01 00:00 [pubmed]
PHST- 1978/08/01 00:01 [medline]
PHST- 1978/08/01 00:00 [entrez]
AID - 10.1093/ajcn/31.8.1397 [doi]
PST - ppublish
SO  - Am J Clin Nutr. 1978 Aug;31(8):1397-9. doi: 10.1093/ajcn/31.8.1397.

PMID- 37332228
OWN - NLM
STAT- MEDLINE
DCOM- 20230904
LR  - 20230906
IS  - 1365-2222 (Electronic)
IS  - 0954-7894 (Linking)
VI  - 53
IP  - 9
DP  - 2023 Sep
TI  - Long-term clinical outcomes of aspirin-exacerbated respiratory disease: 
      Real-world data from an adult asthma cohort.
PG  - 941-950
LID - 10.1111/cea.14362 [doi]
AB  - BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is a phenotype of 
      severe asthma, but its disease course has not been well documented compared with 
      that of aspirin-tolerant asthma (ATA). OBJECTIVES: This study aimed to 
      investigate the long-term clinical outcomes between AERD and ATA. METHODS: AERD 
      patients were identified by the diagnostic code and positive bronchoprovocation 
      test in a real-world database. Longitudinal changes in lung function, blood 
      eosinophil/neutrophil counts, and annual numbers of severe asthma exacerbations 
      (AEx) were compared between the AERD and the ATA groups. Within a year after 
      baseline, two or more severe AEx events indicated severe AERD, whereas less than 
      two AEx events indicated nonsevere AERD. RESULTS: Among asthmatics, 353 had AERD 
      in which 166 and 187 patients had severe and nonsevere AERD, respectively, and 
      717 had ATA. AERD patients had significantly lower FEV1%, higher blood neutrophil 
      counts, and higher sputum eosinophils (%) (all p < .05) as well as higher levels 
      of urinary LTE4 and serum periostin, and lower levels of serum myeloperoxidase 
      and surfactant protein D (all p < .01) than those with ATA. In a 10-year 
      follow-up, the severe AERD group maintained lower FEV1% with more severe AEs than 
      the nonsevere AERD group. CONCLUSION AND CLINICAL RELEVANCE: We demonstrated that 
      AERD patients presented poorer long-term clinical outcomes than ATA patients in 
      real-world data analyses.
CI  - © 2023 John Wiley & Sons Ltd.
FAU - Lee, Youngsoo
AU  - Lee Y
AUID- ORCID: 0000-0001-8918-9353
AD  - Department of Allergy & Clinical Immunology, Ajou University School of Medicine, 
      Suwon, South Korea.
FAU - Kim, Chungsoo
AU  - Kim C
AUID- ORCID: 0000-0003-1802-1777
AD  - Department of Biomedical Sciences, Ajou University Graduate School of Medicine, 
      Suwon, South Korea.
FAU - Lee, Eunyoung
AU  - Lee E
AUID- ORCID: 0000-0002-9440-9119
AD  - Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, 
      South Korea.
AD  - Office of Biostatistics, Ajou Research Institute for Innovative Medicine, Ajou 
      University Medical Center, Suwon, South Korea.
FAU - Lee, Hyun Young
AU  - Lee HY
AUID- ORCID: 0000-0003-4169-8284
AD  - Department of Statistics, Clinical Trial Center, Ajou University Medical Center, 
      Suwon, South Korea.
FAU - Woo, Seong-Dae
AU  - Woo SD
AUID- ORCID: 0000-0003-2506-7407
AD  - Division of Pulmonology and Allergy, Chungnam National University School of 
      Medicine, Daejeon, South Korea.
FAU - You, Seng Chan
AU  - You SC
AUID- ORCID: 0000-0002-5052-6399
AD  - Department of Biomedicine System Informatics, Yonsei University College of 
      Medicine, Seoul, South Korea.
FAU - Park, Rae Woong
AU  - Park RW
AUID- ORCID: 0000-0003-4989-3287
AD  - Department of Biomedical Sciences, Ajou University Graduate School of Medicine, 
      Suwon, South Korea.
AD  - Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, 
      South Korea.
FAU - Park, Hae-Sim
AU  - Park HS
AUID- ORCID: 0000-0003-2614-0303
AD  - Department of Allergy & Clinical Immunology, Ajou University School of Medicine, 
      Suwon, South Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230618
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - *Asthma, Aspirin-Induced/diagnosis
MH  - *Asthma/metabolism
MH  - *Sinusitis/metabolism
MH  - Eosinophils
MH  - *Eosinophilia/chemically induced
MH  - Aspirin/adverse effects
OTO - NOTNLM
OT  - aspirin-exacerbated respiratory disease
OT  - asthma exacerbations
OT  - biomarker
OT  - eosinophilic inflammation
OT  - lung function
EDAT- 2023/06/19 06:41
MHDA- 2023/09/04 06:42
CRDT- 2023/06/19 02:07
PHST- 2023/05/23 00:00 [revised]
PHST- 2023/02/22 00:00 [received]
PHST- 2023/06/05 00:00 [accepted]
PHST- 2023/09/04 06:42 [medline]
PHST- 2023/06/19 06:41 [pubmed]
PHST- 2023/06/19 02:07 [entrez]
AID - 10.1111/cea.14362 [doi]
PST - ppublish
SO  - Clin Exp Allergy. 2023 Sep;53(9):941-950. doi: 10.1111/cea.14362. Epub 2023 Jun 
      18.

PMID- 23545663
OWN - NLM
STAT- MEDLINE
DCOM- 20140107
LR  - 20221207
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 52
IP  - 7
DP  - 2013
TI  - Consideration of dual anti-platelet therapy duration after drug-eluting stent 
      implantation in a Japanese population: a five-year follow-up after 
      sirolimus-eluting stent implantation.
PG  - 703-11
AB  - OBJECTIVE: To investigate the risks and benefits of prolonged dual antiplatelet 
      therapy (DAPT: thienopyridine plus aspirin) following placement of drug-eluting 
      stents (DES). The optimal duration of DAPT is not well established. METHODS: We 
      analyzed a prospective registry of 2,050 patients with sirolimus-eluting stents 
      during a 5-year follow-up. We divided 1,691 patients into two groups according to 
      DAPT duration (DAPT ≤12 months (n=749) and DAPT >12 months (n=942)) and compared 
      the clinical outcomes using a landmark analysis. RESULTS: The frequencies of 
      major adverse cardiac events (MACE: 15.6% vs. 18.2%), death (10.0% vs. 11.5%), 
      myocardial infarction (2.3% vs. 2.1%), target lesion revascularization (4.5% vs. 
      6.3%) and stent thrombosis (0.8% vs. 0.8%) were similar between the two groups. 
      However, the frequency of bleeding was higher in the DAPT >12 months group (1.1% 
      vs. 2.6%, p=0.030). The adjusted 12-month landmark analysis showed no differences 
      in the incidence of MACE (hazard ratio (HR) 0.892; 95% confidence interval (CI) 
      0.689-1.155; p=0.385) or a composite of target vessel revascularization, cardiac 
      death and myocardial infarction (target vessel failure: HR 0.922; 95% CI 
      0.678-1.255; p=0.606). There were no differences in the frequency of stent 
      thrombosis between the two groups during years 2 to 5 after stenting; however, 
      with regard to bleeding, an increase in the frequency of hemorrhage events was 
      observed after four years from the index procedures in the DAPT >12 months group. 
      CONCLUSION: DAPT performed beyond 12 months is associated with increased an 
      frequency of bleeding complications and does not prevent the incidence of MACE, 
      including stent thrombosis, during five years of follow-up after 
      sirolimus-eluting stent implantation. Conducting larger, randomized studies will 
      therefore be needed to confirm this finding.
FAU - Kotani, Jun-ichi
AU  - Kotani J
AD  - Cardiovascular Division, National Cerebral and Cardiovascular Center, Japan. 
      Shamallv8@aol.com
FAU - Ikari, Yuji
AU  - Ikari Y
FAU - Kyo, Eishou
AU  - Kyo E
FAU - Nakamura, Masato
AU  - Nakamura M
FAU - Yokoi, Hiroyoshi
AU  - Yokoi H
CN  - J-PMS investigators
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - R16CO5Y76E (Aspirin)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aged
MH  - *Asian People/ethnology
MH  - Aspirin/*administration & dosage/adverse effects
MH  - Drug-Eluting Stents/adverse effects/*trends
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Population Surveillance/methods
MH  - Prospective Studies
MH  - Pyridines/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Sirolimus/*administration & dosage/adverse effects
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2013/04/03 06:00
MHDA- 2014/01/08 06:00
CRDT- 2013/04/03 06:00
PHST- 2013/04/03 06:00 [entrez]
PHST- 2013/04/03 06:00 [pubmed]
PHST- 2014/01/08 06:00 [medline]
AID - DN/JST.JSTAGE/internalmedicine/52.8205 [pii]
AID - 10.2169/internalmedicine.52.8205 [doi]
PST - ppublish
SO  - Intern Med. 2013;52(7):703-11. doi: 10.2169/internalmedicine.52.8205. Epub 2013 
      Apr 1.

PMID- 25807896
OWN - NLM
STAT- MEDLINE
DCOM- 20160119
LR  - 20181202
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 40
IP  - 3
DP  - 2015 Jun
TI  - Antiplatelet and invasive treatment in patients with glucose-6-phosphate 
      dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of 
      aspirin.
PG  - 349-52
LID - 10.1111/jcpt.12262 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Aspirin is an important drug in acute coronary 
      syndromes (ACS) and percutaneous coronary interventions (PCI). However, its use 
      is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) 
      deficiency (risk for haemolytic anaemia). We report the management of 2 patients 
      with class II G6PD deficiency and non-ST-segment elevation ACS (NSTE-ACS). CASE 
      DESCRIPTION: The two patients were safely and efficiently treated with dual 
      antiplatelet treatment (DAPT, aspirin plus ticagrelor) and PCI using 
      new-generation drug-eluting stent (DES) despite G6PD deficiency. WHAT IS NEW AND 
      CONCLUSION: NSTE-ACS management with DAPT and DES is probably safe and effective 
      in class II G6PD-deficient patients.
CI  - © 2015 John Wiley & Sons Ltd.
FAU - Kafkas, N V
AU  - Kafkas NV
AD  - Cardiology Department, 'KAT' General Hospital of Attica, 14561, Athens, Greece.
FAU - Liakos, C I
AU  - Liakos CI
FAU - Mouzarou, A G
AU  - Mouzarou AG
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20150325
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/physiopathology/*therapy
MH  - Adenosine/administration & dosage/adverse effects/analogs & derivatives
MH  - Aged
MH  - Aspirin/administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - *Drug-Eluting Stents
MH  - Glucosephosphate Dehydrogenase Deficiency/*complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/methods
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse effects
MH  - Ticagrelor
OTO - NOTNLM
OT  - Glucose-6-phosphate dehydrogenase (G6PD) deficiency
OT  - acetylsalicylic acid
OT  - acute coronary syndromes
OT  - angioplasty
OT  - aspirin
OT  - favism
EDAT- 2015/03/27 06:00
MHDA- 2016/01/20 06:00
CRDT- 2015/03/27 06:00
PHST- 2015/02/16 00:00 [received]
PHST- 2015/02/22 00:00 [accepted]
PHST- 2015/03/27 06:00 [entrez]
PHST- 2015/03/27 06:00 [pubmed]
PHST- 2016/01/20 06:00 [medline]
AID - 10.1111/jcpt.12262 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2015 Jun;40(3):349-52. doi: 10.1111/jcpt.12262. Epub 2015 Mar 
      25.

PMID- 33314052
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 154
IP  - 2
DP  - 2021 Aug
TI  - Effects of low-molecular-weight heparin and aspirin in recurrent pre-eclampsia: A 
      stratified cohort study.
PG  - 337-342
LID - 10.1002/ijgo.13535 [doi]
AB  - OBJECTIVE: To evaluate the effects of low-molecular-weight heparin (LMWH) 
      combined with low-dose aspirin (LDA) in pregnant women with a history of 
      pregnancy-related hypertensive disorders. METHODS: In the current retrospective 
      stratified cohort study, 33 women with previous hypertensive disorders of 
      pregnancy treated with LMWH and LDA were compared with 37 control women who did 
      not undergo LMWH or LDA treatment. Rates of pre-eclampsia recurrence, placental 
      abruption, and other adverse outcomes for the fetuses and pregnant women were 
      compared in the two groups. RESULTS: The pre-eclampsia recurrence rates were 
      12/33 (36.4%) in the LMWH + LDA group and 28/37 (75.7%) in the control group 
      (P < 0.01). In stratified cohort analysis, pregnant women with a history of 
      early-onset pre-eclampsia, a body mass index of at least 24 (calculated as weight 
      in kilograms divided by the square of height in meters), and aged less than 
      35 years benefited from LMWH + LDA treatment. In women with chronic hypertension 
      or a history of placental abruption there was no protective effect. There were no 
      significant differences in other adverse outcomes such as placental abruption and 
      small size for gestational age in fetuses or pregnant women in the two groups. 
      CONCLUSION: Administration of LMWH + LDA only lowered the risk of pre-eclampsia 
      recurrence in subgroups of pregnant women with a history of pregnancy-associated 
      hypertensive disorders.
CI  - © 2020 International Federation of Gynecology and Obstetrics.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Shen, Fangrong
AU  - Shen F
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Yang, Weiwen
AU  - Yang W
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Wang, Juan
AU  - Wang J
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Zhou, Jinhua
AU  - Zhou J
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Chen, Youguo
AU  - Chen Y
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abruptio Placentae/epidemiology
MH  - Adult
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Gestational Age
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Pre-Eclampsia/*drug therapy
MH  - Pregnancy
MH  - Pregnancy Complications/epidemiology
MH  - Retrospective Studies
OTO - NOTNLM
OT  - aspirin
OT  - hypertensive disorder of pregnancy
OT  - low-molecular-weight heparin
OT  - obstetric complication
EDAT- 2020/12/15 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/12/14 11:05
PHST- 2020/10/09 00:00 [revised]
PHST- 2020/05/28 00:00 [received]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2020/12/14 11:05 [entrez]
AID - 10.1002/ijgo.13535 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2021 Aug;154(2):337-342. doi: 10.1002/ijgo.13535. Epub 
      2020 Dec 31.

PMID- 30676997
OWN - NLM
STAT- MEDLINE
DCOM- 20190605
LR  - 20211204
IS  - 1868-503X (Electronic)
IS  - 1868-5021 (Linking)
VI  - 9
IP  - 1
DP  - 2018 Dec 31
TI  - Prospects of Pharmacological Interventions to Organismal Aging.
PG  - 200-215
LID - /j/bmc.2018.9.issue-1/bmc-2018-0018/bmc-2018-0018.xml [pii]
LID - 10.1515/bmc-2018-0018 [doi]
AB  - Intense research in the areas of cellular and organismal aging using diverse 
      laboratory model systems has enriched our knowledge in the processes and the 
      signalling pathways involved in normal and pathological conditions. The field 
      finds itself in a position to take decisive steps towards clinical applications 
      and interventions not only for targeted age-related diseases such as 
      cardiovascular conditions and neurodegeneration but also for the modulation of 
      health span and lifespan of a whole organism. Beyond nutritional interventions 
      such as dietary restriction without malnutrition and various regimes of 
      intermittent fasting, accumulating evidence provides promise for pharmacological 
      interventions. The latter, mimic caloric or dietary restriction, tune cellular 
      and organismal stress responses, affect the metabolism of microbiome with 
      subsequent effects on the host or modulate repair pathways, among others. In this 
      mini review, we summarise some of the evidence on drugs that can alter organismal 
      lifespan and the prospects they might offer for promoting healthspan and delaying 
      age-related diseases.
FAU - Hillson, Olivia
AU  - Hillson O
AD  - School of Health, Sport and Bioscience, University of East London, Water Lane, 
      E15 4LZ, London, United Kingdom.
FAU - Gonzalez, Suam
AU  - Gonzalez S
AD  - School of Health, Sport and Bioscience, University of East London, Water Lane, 
      E15 4LZ, London, United Kingdom.
FAU - Rallis, Charalampos
AU  - Rallis C
AD  - School of Health, Sport and Bioscience, University of East London, Water Lane, 
      E15 4LZ, London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181231
PL  - Germany
TA  - Biomol Concepts
JT  - Biomolecular concepts
JID - 101518829
RN  - 9002-72-6 (Growth Hormone)
RN  - 9100L32L2N (Metformin)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - Q369O8926L (Resveratrol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aging/*drug effects/metabolism
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Growth Hormone/metabolism
MH  - Humans
MH  - Metformin/pharmacology
MH  - Resveratrol/pharmacology
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/metabolism
OTO - NOTNLM
OT  - TOR
OT  - Torin
OT  - aspirin
OT  - insulin growth signalling pathway
OT  - lifespan
OT  - metformin
OT  - rapalogs
OT  - rapamycin
EDAT- 2019/01/25 06:00
MHDA- 2019/06/06 06:00
CRDT- 2019/01/25 06:00
PHST- 2018/10/15 00:00 [received]
PHST- 2018/12/04 00:00 [accepted]
PHST- 2019/01/25 06:00 [entrez]
PHST- 2019/01/25 06:00 [pubmed]
PHST- 2019/06/06 06:00 [medline]
AID - /j/bmc.2018.9.issue-1/bmc-2018-0018/bmc-2018-0018.xml [pii]
AID - 10.1515/bmc-2018-0018 [doi]
PST - epublish
SO  - Biomol Concepts. 2018 Dec 31;9(1):200-215. doi: 10.1515/bmc-2018-0018.

PMID- 8317041
OWN - NLM
STAT- MEDLINE
DCOM- 19930728
LR  - 20131121
IS  - 0041-5782 (Print)
IS  - 0041-5782 (Linking)
VI  - 155
IP  - 24
DP  - 1993 Jun 14
TI  - [Pre-eclampsia. Etiology--physiopathology--treatment].
PG  - 1845-51
AB  - Recent observations indicate that pre-eclampsia is a disease, which occurs 
      because of a partially defective maternal immune response against the fetal 
      (paternal) antigen expressed on trophoblast tissue. The resulting defective or 
      insufficient placentation can cause ischaemic changes, which seem to act in a 
      harmful way on the vascular endothelium, initially locally in the utero-placental 
      circulation, but later with universal systemic effects. The resulting endothelial 
      dysfunction and concommitant thrombocyte activation seems to account for an 
      important part of the pathophysiology of pre-eclampsia. Hypertension is 
      presumably a secondary phenomenon. The definitive treatment of pre-eclampsia is 
      delivery, which is always indicated in cases of severe pre-eclampsia after 32 
      weeks of pregnancy. In milder cases and before 32 weeks it is reasonable to await 
      delivery, if necessary starting anti-hypertensive treatment. Treatment of 
      hypertension has to balance the risks of maternal cerebral complications against 
      the risks of reduced utero-placental bloodflow with resulting intra-uterine 
      growth retardation. Low-dose acetylsalicylic acid treatment could in theory 
      constitute a prophylactic principle, but the results of new, large, 
      well-conducted, randomised trials advise against using such treatment 
      prophylacctically at present. The effect of fish-oil supplements is not yet 
      clarified, whereas mineral supplements such as calcium and magnesium are unlikely 
      to have prophylactic effects on the development of pre-eclampsia, at least not in 
      western industrialized society.
FAU - Skajaa, K
AU  - Skajaa K
AD  - Arhus Kommunehospital, gynaekologisk obstetrisk afdeling Y.
LA  - dan
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Praeeklampsi. Aetiologi--patofysiologi--behandling.
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
RN  - 0 (Fish Oils)
RN  - 0 (Minerals)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - Female
MH  - Fish Oils/administration & dosage
MH  - Hemodynamics
MH  - Humans
MH  - Minerals/administration & dosage
MH  - *Pre-Eclampsia/etiology/physiopathology/therapy
MH  - Pregnancy
RF  - 40
EDAT- 1993/06/14 00:00
MHDA- 1993/06/14 00:01
CRDT- 1993/06/14 00:00
PHST- 1993/06/14 00:00 [pubmed]
PHST- 1993/06/14 00:01 [medline]
PHST- 1993/06/14 00:00 [entrez]
PST - ppublish
SO  - Ugeskr Laeger. 1993 Jun 14;155(24):1845-51.

PMID- 2371491
OWN - NLM
STAT- MEDLINE
DCOM- 19900822
LR  - 20191029
IS  - 0390-5748 (Print)
IS  - 0390-5748 (Linking)
VI  - 20
IP  - 2
DP  - 1990 Apr-Jun
TI  - Acetylsalicylic acid inhibits platelet PAI-1 antigen release without affecting 
      circulating PAI-1 antigen in plasma.
PG  - 113-7
AB  - An important plasminogen activator-inhibitor (PAI-1) is present in plasma and 
      concentrated in alpha-granules of platelets. PAI-1 is released during platelet 
      stimulation in vitro. It is presently unknown to what extent the treatment with 
      acetylsalicylic acid (ASA) inhibits platelet PAI-1 release and if release 
      inhibition has an effect on plasma PAI-1 levels. We therefore investigated by a 
      double-blind placebo-controlled crossover study the effects of oral ASA (500 
      mg/day for 3 days) on platelet PAI-1 release and on plasma PAI-1 levels of 
      healthy male volunteers. The PAI-1 release from platelets stimulated by 
      arachidonic acid and collagen was significantly reduced by ASA: from average 
      values of 88 and 80% to 14 and 17%, respectively (p less than 0.01). However, 
      plasma PAI-1 levels were not modified by this treatment. We can conclude that 
      platelet PAI-1 release does not play a role in modulating the plasma PAI-1 levels 
      in healthy volunteers.
FAU - Cogo, A
AU  - Cogo A
AD  - Clinica Medica II, Università degli Studi di Padova.
FAU - Ling, E
AU  - Ling E
FAU - Sturk, A
AU  - Sturk A
FAU - ten Cate, J W
AU  - ten Cate JW
FAU - Prandoni, P
AU  - Prandoni P
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - Italy
TA  - Ric Clin Lab
JT  - La Ricerca in clinica e in laboratorio
JID - 7613947
RN  - 0 (Plasminogen Inactivators)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/metabolism
MH  - Double-Blind Method
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Plasminogen Inactivators/*blood
MH  - Reference Values
EDAT- 1990/04/01 00:00
MHDA- 1990/04/01 00:01
CRDT- 1990/04/01 00:00
PHST- 1990/04/01 00:00 [pubmed]
PHST- 1990/04/01 00:01 [medline]
PHST- 1990/04/01 00:00 [entrez]
AID - 10.1007/BF02877557 [doi]
PST - ppublish
SO  - Ric Clin Lab. 1990 Apr-Jun;20(2):113-7. doi: 10.1007/BF02877557.

PMID- 3786877
OWN - NLM
STAT- MEDLINE
DCOM- 19870114
LR  - 20131121
IS  - 0398-7620 (Print)
IS  - 0398-7620 (Linking)
VI  - 34
IP  - 3
DP  - 1986
TI  - [Application of sequential methods in randomized clinical trials with censored 
      response criteria].
PG  - 196-208
AB  - In randomized clinical trials with a censored response criterion, it is common 
      practice to perform interim analyses, especially for reasons of medical ethics. 
      Sequential methods allow for repeated testing. Three sequential methods are well 
      adapted to censored data: the group sequential analysis, the sequential 
      probability ratio test and the triangular test. Among them, the triangular test 
      has the best statistical properties. The influence of the frequency of the 
      analyses on the statistical properties of sequential methods has been studied by 
      simulation: sequential analyses need not be performed more frequently than 
      interim analyses. Sequential methods have been applied to several randomized 
      clinical trials. The results are briefly reported for two of them. The ability of 
      the triangular test and of the sequential probability ratio test to reach 
      conclusions early when there is no difference between two compared treatments is 
      supported by these two examples. Moreover, careful patient follow-up must be 
      planned in the protocol in order to reduce the time for data updating and to 
      perform sequential analyses at the required frequency. It appears well-founded to 
      propose the use of the triangular test in randomized clinical trials with a 
      censored response criterion. Four types of analyses with different aims must be 
      planned in the protocol.
FAU - Benichou, J
AU  - Benichou J
FAU - Chastang, C
AU  - Chastang C
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Mise en oeuvre de méthodes séquentielles dans les essais thérapeutiques 
      randomisés dont le critère de jugement est censuré.
PL  - France
TA  - Rev Epidemiol Sante Publique
JT  - Revue d'epidemiologie et de sante publique
JID - 7608039
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic/*methods
MH  - Humans
MH  - Leukemia, Lymphoid/drug therapy
MH  - Lung Neoplasms/drug therapy
MH  - Random Allocation
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Rev Epidemiol Sante Publique. 1986;34(3):196-208.

PMID- 1176809
OWN - NLM
STAT- MEDLINE
DCOM- 19751218
LR  - 20131121
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 86
IP  - 4
DP  - 1975 Oct
TI  - Inhibition of platelet adherence to damaged surface of rabbit aorta.
PG  - 551-63
AB  - A method has been developed for quantitative measurement of adherence of rabbit 
      platelets to the damaged intimal surface of everted segments of rabbit thoracic 
      aorta. Platelets were labeled with 51Cr, washed, and resuspended in Tyrode 
      solution containing 0.35 per cent albumin and apyrase. This suspending medium 
      contains physiologic concentrations of calcium and magnesium; apyrase degrades 
      any ADP lost from the platelets or from the damaged wall. Everted aorta segments 
      were rotated in the platelet suspensions. Neither platelet aggregation nor lysis 
      occurred and the platelets adhered to the subendothelium either as individual 
      platelets or as a single layer. Damage caused by scraping the everted segments 
      with a scalpel blade increased adherence 50-fold. Acetylsalicylic acid (ASA) in 
      vitro, or administered orally to the rabbits from which platelet suspensions were 
      prepared, significantly reduced the number of platelets adherent to the damaged 
      aorta wall. ASA affected only the platelets, and did not affect the damaged wall. 
      Platelet adherence to the damaged wall was also reduced by the use of 4 per cent 
      albumin in the suspending medium, or by the addition of citrate. Adherence of 
      platelets resuspended in citrated plasma was low and further inhibition by ASA 
      was not demonstrable. ASA may affect two aspects of thrombus formation: platelet 
      adherence to subendothelial structures and the platelet release reaction induced 
      by collagen (and possibly by other subendothelial structures). These studies show 
      that ASA has a marked effect on adherence of platelets to subendothelium under 
      conditions in which aggregation and thrombus formation are prevented.
FAU - Cazenave, J P
AU  - Cazenave JP
FAU - Packham, M A
AU  - Packham MA
FAU - Guccione, M A
AU  - Guccione MA
FAU - Mustard, J F
AU  - Mustard JF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Albumins)
RN  - 0 (Citrates)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Albumins/pharmacology
MH  - Animals
MH  - Aorta, Thoracic/*drug effects/pathology
MH  - Aspirin/*pharmacology
MH  - Citrates/pharmacology
MH  - Microscopy, Electron, Scanning
MH  - Platelet Adhesiveness/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Rabbits
MH  - Surface Properties
MH  - Thrombosis/etiology
EDAT- 1975/10/01 00:00
MHDA- 1975/10/01 00:01
CRDT- 1975/10/01 00:00
PHST- 1975/10/01 00:00 [pubmed]
PHST- 1975/10/01 00:01 [medline]
PHST- 1975/10/01 00:00 [entrez]
AID - 0022-2143(75)90024-4 [pii]
PST - ppublish
SO  - J Lab Clin Med. 1975 Oct;86(4):551-63.

PMID- 16144976
OWN - NLM
STAT- MEDLINE
DCOM- 20060123
LR  - 20171116
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 315
IP  - 3
DP  - 2005 Dec
TI  - Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 
      4016).
PG  - 1331-7
AB  - Benzoic acid, 2-(acetyl-oxy)-3-[(nitrooxy)methyl]phenyl ester (NCX 4016), a new 
      drug made by an aspirin molecule linked, through a spacer, to a nitric oxide 
      (NO)-donating moiety, is now under clinical testing for the treatment of 
      atherothrombotic conditions. Aspirin exerts its antithrombotic activity by 
      irreversibly inactivating platelet cyclooxygenase (COX)-1. NCX 4016 in vivo 
      undergoes metabolism into deacetylated and/or denitrated metabolites, and it is 
      not known whether NCX 4016 needs to liberate aspirin to inhibit COX-1, or whether 
      it can block it as a whole molecule. The aim of our study was to evaluate the 
      effects of NCX 4016 and its analog or metabolites on platelet COX-1 and whole 
      blood COX-2 and on purified ovine COX (oCOX)-1 and oCOX-2. In particular, we have 
      compared the mechanism by which NCX 4016 inhibits purified oCOX enzymes with that 
      of aspirin using a spectrophotometric assay. All the NCX 4016 derivatives 
      containing acetylsalicylic acid inhibited the activity of oCOX-1 and oCOX-2, 
      whereas the deacetylated metabolites and the nitric oxide-donating moiety were 
      inactive. Dialysis experiments showed that oCOX-1 inhibition by NCX 4016, similar 
      to aspirin, is irreversible. Reversible COX inhibitors (indomethacin) or 
      salicylic acid incubated with the enzyme before NCX 4016 prevent the irreversible 
      inhibition of oCOX-1 by NCX 4016 as well as by aspirin. In conclusion, our data 
      show that NCX 4016 acts as a direct and irreversible inhibitor of COX-1 and that 
      the presence of a spacer and NO-donating moiety in the molecule slows the 
      kinetics of COX-1 inhibition by NCX 4016, compared with aspirin.
FAU - Corazzi, Teresa
AU  - Corazzi T
AD  - Department of Internal Medicine, Division of Internal and Cardiovascular 
      Medicine, University of Perugia, Via Enrico dal Pozzo, 06126, Perugia, Italy.
FAU - Leone, Mario
AU  - Leone M
FAU - Maucci, Raffaella
AU  - Maucci R
FAU - Corazzi, Lanfranco
AU  - Corazzi L
FAU - Gresele, Paolo
AU  - Gresele P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050906
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Hemostatics)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 3.4.21.5 (Thrombin)
RN  - EH04H13L6B (nitroaspirin)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*analogs & derivatives/chemistry/pharmacology
MH  - Blood Platelets/enzymology/metabolism
MH  - Cyclooxygenase 1/isolation & purification
MH  - Cyclooxygenase 2/blood
MH  - Cyclooxygenase Inhibitors/blood/chemistry/*pharmacology
MH  - Dialysis
MH  - Dinoprostone/analysis/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Hemostatics/pharmacology
MH  - Humans
MH  - Kinetics
MH  - Molecular Structure
MH  - Monocytes/enzymology/metabolism
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Sheep
MH  - Spectrophotometry
MH  - Thrombin/pharmacology
MH  - Thromboxane B2/analysis/metabolism
MH  - Time Factors
EDAT- 2005/09/08 09:00
MHDA- 2006/01/24 09:00
CRDT- 2005/09/08 09:00
PHST- 2005/09/08 09:00 [pubmed]
PHST- 2006/01/24 09:00 [medline]
PHST- 2005/09/08 09:00 [entrez]
AID - jpet.105.089896 [pii]
AID - 10.1124/jpet.105.089896 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2005 Dec;315(3):1331-7. doi: 10.1124/jpet.105.089896. Epub 
      2005 Sep 6.

PMID- 11854879
OWN - NLM
STAT- MEDLINE
DCOM- 20021119
LR  - 20190910
IS  - 1053-0770 (Print)
IS  - 1053-0770 (Linking)
VI  - 16
IP  - 1
DP  - 2002 Feb
TI  - The effect of preoperative aspirin-free interval on red blood cell transfusion 
      requirements in cardiac surgical patients.
PG  - 54-8
AB  - OBJECTIVE: To compare red blood cell transfusion in first-time coronary artery 
      surgery patients who stopped taking aspirin < or = 2 days, 3 to 7 days, or >7 
      days preoperatively. DESIGN: Observational study. SETTING: University-affiliated 
      teaching hospital. PARTICIPANTS: Adult patients (n = 797) undergoing first-time 
      coronary artery surgery on cardiopulmonary bypass who were not receiving other 
      anticoagulant or antiplatelet drugs before surgery. INTERVENTIONS: None. 
      MEASUREMENTS AND MAIN RESULTS: Patients were divided into 4 groups based on days 
      since last ingestion of aspirin. Blood products transfused in the groups were 
      (aspirin < or =2 days) (n = 140) 2.2 +/- 4 U of red cell concentrate (RCC) (mean 
      +/- SD), 1.4 +/- 3 U of fresh frozen plasma (FFP), and 2.7 +/- 6 U of platelets; 
      (aspirin 3 to 5 days) (n = 255), 1.5 +/- 2 U of RCC, 0.8 +/- 2 U of FFP, and 1.6 
      +/- 4 U of platelets; (aspirin 6 to 7 days) (n = 215), 1.6 +/- 3 U of RCC, 0.9 
      +/- 3 U of FFP, and 1.5 +/- 3 U of platelets; and (aspirin >7 days) (n = 187), 
      1.3 +/- 2 U of RCC; 0.6 +/- 2 U of FFP, and 0.9 +/- 2 U of platelets. CONCLUSION: 
      Patients who stop taking aspirin < or =2 s preoperatively have increased 
      allogenic red blood cell transfusion requirements perioperatively. Patients who 
      stop taking aspirin 3 to 7 days preoperatively have little or no increased 
      requirement for allogenic red blood cell transfusion.
CI  - Copyright 2002, Elsevier Science (USA). All rights reserved.
FAU - Weightman, William M
AU  - Weightman WM
AD  - Departments of Anaesthesia and Cardiothoracic Surgery, Sir Charles Gairdner 
      Hospital, and PathCentre, Nedlands, Western Australia.
FAU - Gibbs, Neville M
AU  - Gibbs NM
FAU - Weidmann, Crispin R
AU  - Weidmann CR
FAU - Newman, Mark A J
AU  - Newman MA
FAU - Grey, Diane E
AU  - Grey DE
FAU - Sheminant, Matthew R
AU  - Sheminant MR
FAU - Erber, Wendy N
AU  - Erber WN
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiothorac Vasc Anesth
JT  - Journal of cardiothoracic and vascular anesthesia
JID - 9110208
RN  - 0 (Hemoglobins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*administration & dosage
MH  - Blood Loss, Surgical
MH  - *Coronary Artery Bypass
MH  - *Erythrocyte Transfusion
MH  - Female
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Plasma
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Platelet Count
MH  - Platelet Transfusion
MH  - Preoperative Care
MH  - Risk Factors
EDAT- 2002/02/21 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/02/21 10:00
PHST- 2002/02/21 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/02/21 10:00 [entrez]
AID - S1053077002384829 [pii]
AID - 10.1053/jcan.2002.29674 [doi]
PST - ppublish
SO  - J Cardiothorac Vasc Anesth. 2002 Feb;16(1):54-8. doi: 10.1053/jcan.2002.29674.

PMID- 21945909
OWN - NLM
STAT- MEDLINE
DCOM- 20120319
LR  - 20181201
IS  - 1846-9558 (Electronic)
IS  - 1330-0075 (Linking)
VI  - 61
IP  - 3
DP  - 2011 Sep 1
TI  - Effect of formulation parameters on the drug release and floating properties of 
      gastric floating two-layer tablets with acetylsalicylic acid.
PG  - 303-12
LID - 10.2478/v10007-011-0028-0 [doi]
AB  - Floating dosage forms of acetylsalicylic acid, used for its antithrombotic 
      effect, were developed to prolong gastric residence time and increase 
      bioavailability. In the two-layer tablet formulation, hydroxypropyl 
      methylcellulose (HPMC) of high viscosity and an effervescent mixture of citric 
      acid and sodium bicarbonate formed the floating layer. The release layer 
      contained the drug, direct tableting agent and different types of matrix-forming 
      polymers such as HPMC of low viscosity, sodium carboxymethylcellulose and 
      chitosan. Tablets were prepared using a direct compression technique. The effect 
      of formulation variables on physicochemical and floating properties and the drug 
      release from tablets were investigated. Floating ability was dependent on the 
      amount of effervescent agent and gel-forming polymer of the floating layer. Drug 
      release was prolonged to 8 hours by changing the type and viscosity of the 
      matrix-forming polymer in the drug-loading layer and all formulations showed a 
      diffusion release mechanisms.
FAU - Hasçiçek, Canan
AU  - Hasçiçek C
AD  - Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Technology 
      06100-Tandogan, Ankara, Turkey.
FAU - Yüksel-Tilkan, Günseli
AU  - Yüksel-Tilkan G
FAU - Türkmen, Berna
AU  - Türkmen B
FAU - Ozdemir, Nurten
AU  - Ozdemir N
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Acta Pharm
JT  - Acta pharmaceutica (Zagreb, Croatia)
JID - 9303678
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Excipients)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Polymers)
RN  - 0 (Tablets)
RN  - 2968PHW8QP (Citric Acid)
RN  - 3NXW29V3WO (Hypromellose Derivatives)
RN  - 8MDF5V39QO (Sodium Bicarbonate)
RN  - 9004-67-5 (Methylcellulose)
RN  - 9012-76-4 (Chitosan)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*chemistry/metabolism
MH  - Biological Availability
MH  - Chitosan/chemistry
MH  - Citric Acid/chemistry
MH  - Delayed-Action Preparations/chemistry/metabolism
MH  - Drug Compounding/*methods
MH  - *Drug Delivery Systems
MH  - Excipients/*chemistry
MH  - Fibrinolytic Agents/*chemistry/metabolism
MH  - Gastric Mucosa/*metabolism
MH  - Humans
MH  - Hypromellose Derivatives
MH  - Methylcellulose/analogs & derivatives/chemistry
MH  - Models, Theoretical
MH  - Polymers/chemistry
MH  - Pressure
MH  - Sodium Bicarbonate/chemistry
MH  - Solubility
MH  - Stomach/chemistry
MH  - Tablets/chemistry
MH  - Time Factors
MH  - Viscosity
EDAT- 2011/09/29 06:00
MHDA- 2012/03/20 06:00
CRDT- 2011/09/28 06:00
PHST- 2011/09/28 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2012/03/20 06:00 [medline]
AID - E1H2672P4U848U30 [pii]
AID - 10.2478/v10007-011-0028-0 [doi]
PST - ppublish
SO  - Acta Pharm. 2011 Sep 1;61(3):303-12. doi: 10.2478/v10007-011-0028-0.

PMID- 2663343
OWN - NLM
STAT- MEDLINE
DCOM- 19890817
LR  - 20141120
IS  - 0010-8650 (Print)
IS  - 0010-8650 (Linking)
VI  - 31
IP  - 2
DP  - 1989
TI  - The effect of hydroxyethylrutoside and its combination with acetylsalicylic acid 
      in patients with obliterative atherosclerosis.
PG  - 128-33
AB  - The effect of 7-mono-hydroxyethylrutoside and its combination with 
      acetylsalicylic acid was evaluated in a controlled clinical trial, performed in 
      105 patients with obliterative atherosclerosis of the lower limbs, and using 
      non-invasive measurement of peripheral haemodynamic parameters--blood flow during 
      reactive hyperaemia and ankle systolic blood pressure. Patients, randomized into 
      three groups, received either placebo or 7-mono-hydroxyethylrutoside alone or in 
      combination with acetylsalicylic acid for 12 months. The placebo group showed a 
      decrease in maximum calf blood flow and a decrease in ankle systolic pressure. 
      Administration of 7-mono-hydroxyethylrutoside did not lead to any significant 
      changes in systolic pressure but there was a decrease in the maximum calf blood 
      flow. There were no statistically significant changes in patients receiving the 
      7-mono-hydroxyethylrutoside and acetylsalicylic acid combination who, by 
      contrast, showed a tendency to increased values of the parameters measured.
FAU - Roztocil, K
AU  - Roztocil K
AD  - Institute of Clinical and Experimental Medicine, Cardiovascular Research 
      Programme, Prague, Czechoslovakia.
FAU - Oliva, I
AU  - Oliva I
FAU - Prerovský, I
AU  - Prerovský I
FAU - Linhart, J
AU  - Linhart J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Czech Republic
TA  - Cor Vasa
JT  - Cor et vasa
JID - 0372614
RN  - 0 (Analgesics)
RN  - 0 (Anticoagulants)
RN  - 0 (Hydroxyethylrutoside)
RN  - 5G06TVY3R7 (Rutin)
RN  - 6QT214X4XU (aloxiprin)
RN  - 84932-19-4 (troxevasin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Analgesics/*administration & dosage
MH  - Anticoagulants/*administration & dosage
MH  - Arteriosclerosis Obliterans/*drug therapy
MH  - Aspirin/administration & dosage/*analogs & derivatives
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Hydroxyethylrutoside/administration & dosage/*analogs & derivatives
MH  - Ischemia/drug therapy
MH  - Leg/blood supply
MH  - Male
MH  - Middle Aged
MH  - Plethysmography
MH  - Rutin/*analogs & derivatives
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Cor Vasa. 1989;31(2):128-33.

PMID- 23200184
OWN - NLM
STAT- MEDLINE
DCOM- 20130517
LR  - 20131121
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 34
IP  - 12
DP  - 2012 Dec
TI  - Clinical impact of drug-drug interaction between aspirin and prednisolone at a 
      cancer center.
PG  - 2259-67
LID - S0149-2918(12)00617-0 [pii]
LID - 10.1016/j.clinthera.2012.11.002 [doi]
AB  - BACKGROUND: Adverse gastrointestinal (GI) events are complications in aspirin and 
      prednisolone cotherapy. The prevalence of adverse GI events would be expected to 
      be increased with cotherapy due to the overlapping toxicities of the 2 drugs. 
      However, there is a dearth of literature investigating how often this interaction 
      causes clinically important adverse GI events. OBJECTIVES: This retrospective 
      study aimed to determine the prevalence of adverse GI events associated with the 
      coadministration of aspirin and prednisolone. The use of gastroprotectant agents 
      was also studied. METHODS: The medical records of patients with cancer prescribed 
      aspirin and prednisolone therapy between January 2007 and June 2011 were 
      analyzed. The duration of aspirin-prednisolone overlap, prevalence of adverse GI 
      events, and details on the concurrent use of other medications were evaluated. 
      RESULTS: The study included data from 142 patients (male, 64.8%; mean [SD] age, 
      67.4 [11.0] years). A total of 78.9% of the patients were on some form of 
      gastroprotectant, the most common class of which was proton pump inhibitors. The 
      prevalence of adverse GI events was 4.2% (6 patients). Four patients had 
      presented with GI symptoms (abdominal pain, diarrhea, dysphagia, and vomiting); 3 
      patients had signs of GI injury (duodenal ulcers, iron deficiency anemia, and a 
      Mallory-Weiss tear). The Naranjo algorithm classified 5 patients experienced 
      possible adverse drug reactions (ADRs), and 1 as a probable ADR. CONCLUSION: Our 
      study found that the prevalence of adverse GI events was low and managed to 
      establish a weak association between the occurrence of events and the 
      coadministration of aspirin and prednisolone. This finding, together with the 
      concurrent prescription of gastroprotectants, suggests that the clinical impact 
      of the aspirin and prednisolone DDI is minimal.
CI  - Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.
FAU - Koomanan, Narendran
AU  - Koomanan N
AD  - Department of Pharmacy, National University of Singapore, Singapore.
FAU - Ko, Yu
AU  - Ko Y
FAU - Yong, Wei-Peng
AU  - Yong WP
FAU - Ng, Raymond
AU  - Ng R
FAU - Wong, Yuet-Peng
AU  - Wong YP
FAU - Lim, Siew-Woon
AU  - Lim SW
FAU - Salim, Agus
AU  - Salim A
FAU - Chan, Alexandre
AU  - Chan A
LA  - eng
PT  - Journal Article
DEP - 20121128
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Glucocorticoids)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Cancer Care Facilities
MH  - Drug Interactions
MH  - Female
MH  - Gastrointestinal Agents/*therapeutic use
MH  - Gastrointestinal Diseases/*chemically induced/epidemiology/physiopathology
MH  - Glucocorticoids/administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Prednisolone/administration & dosage/*adverse effects
MH  - Prevalence
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Retrospective Studies
EDAT- 2012/12/04 06:00
MHDA- 2013/05/18 06:00
CRDT- 2012/12/04 06:00
PHST- 2012/09/16 00:00 [received]
PHST- 2012/10/29 00:00 [revised]
PHST- 2012/11/01 00:00 [accepted]
PHST- 2012/12/04 06:00 [entrez]
PHST- 2012/12/04 06:00 [pubmed]
PHST- 2013/05/18 06:00 [medline]
AID - S0149-2918(12)00617-0 [pii]
AID - 10.1016/j.clinthera.2012.11.002 [doi]
PST - ppublish
SO  - Clin Ther. 2012 Dec;34(12):2259-67. doi: 10.1016/j.clinthera.2012.11.002. Epub 
      2012 Nov 28.

PMID- 22677232
OWN - NLM
STAT- MEDLINE
DCOM- 20140124
LR  - 20220309
IS  - 2210-741X (Electronic)
IS  - 2210-7401 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - Do aspirin and non-steroidal anti-inflammatory drugs increase the risk of 
      post-sphincterotomy hemorrhage--a case-control study.
PG  - 171-6
LID - S2210-7401(12)00129-5 [pii]
LID - 10.1016/j.clinre.2012.04.010 [doi]
AB  - BACKGROUND AND OBJECTIVE: Non-steroidal anti-inflammatory drugs (NSAIDs) and 
      aspirin have antiaggregant properties and patients with pancreaticobiliary 
      disease commonly use these drugs. We prospectively investigated whether aspirin 
      and NSAIDs are associated with endoscopic sphincterotomy related hemorrhage. 
      METHODS: Three hundred and eight patients who underwent sphincterotomy were 
      sequentially recruited into this prospective case-control study. Pre-endoscopic 
      assessment included a complete blood count, coagulation studies and a detailed 
      drug history after sphincterotomy patients were followed up for bleeding. Cases 
      and controls were compared for patient and procedure-related risk factors of 
      post-endoscopic sphincterotomy bleeding. RESULTS: Hemorrhage occurred in 74 (24%) 
      patients. Eight (2.6%) were clinically significant and five (1.6%) were severe. 
      Amongst cases with hemorrhage, 17.6% were on NSAIDs and 14.9% on aspirin; 27.4% 
      of controls took NSAIDs, and 9.8% aspirin (P>0.05). Aspirin use in patients with 
      significant (12.5%) or severe hemorrhage (20%) was not different from the 
      controls (P>0.05) and none of them had NSAIDs prior to sphincterotomy. Based on 
      univariate analysis, coagulopathy and comorbidity were risk factors for 
      significant post-sphincterotomy hemorrhage and coagulopathy was the only 
      independent parameter (odds ratio=22.72, 95% CI [4.25; 125]). CONCLUSION: Aspirin 
      and NSAIDs do not increase the risk of post-sphincterotomy hemorrhage and they 
      can be safely used before the procedure.
CI  - Copyright © 2012 Elsevier Masson SAS. All rights reserved.
FAU - Onal, Ibrahim Koral
AU  - Onal IK
AD  - Turkiye Yuksek Ihtisas Teaching and Research Hospital, Department of 
      Gastroenterology, Ankara, Turkey. koralonal@yahoo.com
FAU - Parlak, Erkan
AU  - Parlak E
FAU - Akdogan, Meral
AU  - Akdogan M
FAU - Yesil, Yusuf
AU  - Yesil Y
FAU - Kuran, Sedef Ozdal
AU  - Kuran SO
FAU - Kurt, Mevlut
AU  - Kurt M
FAU - Disibeyaz, Selcuk
AU  - Disibeyaz S
FAU - Ozturk, Eda
AU  - Ozturk E
FAU - Odemis, Bulent
AU  - Odemis B
LA  - eng
PT  - Journal Article
DEP - 20120605
PL  - France
TA  - Clin Res Hepatol Gastroenterol
JT  - Clinics and research in hepatology and gastroenterology
JID - 101553659
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Clin Res Hepatol Gastroenterol. 2013 Apr;37(2):e73-4. PMID: 23498773
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Case-Control Studies
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Postoperative Hemorrhage/*etiology
MH  - Prospective Studies
MH  - Prothrombin Time
MH  - Renal Dialysis/adverse effects
MH  - Risk Factors
MH  - *Sphincterotomy, Endoscopic
MH  - Thrombocytopenia/complications
MH  - Young Adult
EDAT- 2012/06/09 06:00
MHDA- 2014/01/25 06:00
CRDT- 2012/06/09 06:00
PHST- 2012/01/28 00:00 [received]
PHST- 2012/03/05 00:00 [revised]
PHST- 2012/04/25 00:00 [accepted]
PHST- 2012/06/09 06:00 [entrez]
PHST- 2012/06/09 06:00 [pubmed]
PHST- 2014/01/25 06:00 [medline]
AID - S2210-7401(12)00129-5 [pii]
AID - 10.1016/j.clinre.2012.04.010 [doi]
PST - ppublish
SO  - Clin Res Hepatol Gastroenterol. 2013 Apr;37(2):171-6. doi: 
      10.1016/j.clinre.2012.04.010. Epub 2012 Jun 5.

PMID- 17080224
OWN - NLM
STAT- MEDLINE
DCOM- 20070622
LR  - 20181201
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 96
IP  - 5
DP  - 2006 Nov
TI  - No difference in the effects of clopidogrel and aspirin on inflammatory markers 
      in patients with coronary heart disease.
PG  - 660-4
AB  - Aspirin reduces several pro-inflammatory markers in patients with coronary heart 
      disease (CHD), while limited data exists with clopidogrel. The aim of the present 
      substudy of ASCET was to assess the influence of clopidogrel as compared to 
      aspirin on selected circulating inflammatory markers in patients with stable 
      angiographically verified CHD. Patients on treatment with aspirin 160 mg/day for 
      at least seven days were randomized to either aspirin 160 mg/day (n = 105) or 
      clopidogrel 75 mg/day (n = 101). Fasting blood samples were drawn at baseline and 
      after one month and after one year for determination of high sensitivity 
      C-reactive protein, tumor necrosis factor a (TNFa), interleukin 6, monocyte 
      chemoattractant protein 1(MCP-1), CD40L, P-selectin, interleukin 10 and 
      transforming growth factor. The groups were similar regarding demographic 
      variables. There were no differences in any variables including changes from 
      baseline to one month and one year between the groups. In the aspirin group we 
      found significantly lower levels of TNFa and MCP-1 after one year; 1.00 versus 
      1.16 pg/ml (p < 0.001) and 245 versus 261 pg/ml (p < 0.001), respectively. 
      Likewise, in the clopidogrel group the level of TNFa was significantly reduced 
      after one year; 0.99 versus 1.19 pg/ml (p < 0.001). In patients with CHD we found 
      no between-group differences in circulating markers of inflammation after one 
      year treatment with clopidogrel 75 mg/day compared to aspirin 160 mg/day, but in 
      both groups lower levels of TNFa were obtained. The present results indicate 
      similar anti-inflammatory effects of the two drugs.
FAU - Solheim, Svein
AU  - Solheim S
AD  - Clinical Cardiovascular Research Unit, Department of Cardiology, Ullevål 
      University Hospital, Oslo, Norway. s-solh@online.no
FAU - Pettersen, Alf Aage
AU  - Pettersen AA
FAU - Arnesen, Harald
AU  - Arnesen H
FAU - Seljeflot, Ingebjørg
AU  - Seljeflot I
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Biomarkers/blood
MH  - Chemokine CCL2/blood
MH  - Clopidogrel
MH  - Coronary Disease/*drug therapy/*pathology
MH  - Humans
MH  - Inflammation/blood/*drug therapy
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/pharmacology
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/blood
EDAT- 2006/11/03 09:00
MHDA- 2007/06/23 09:00
CRDT- 2006/11/03 09:00
PHST- 2006/11/03 09:00 [pubmed]
PHST- 2007/06/23 09:00 [medline]
PHST- 2006/11/03 09:00 [entrez]
AID - 06110660 [pii]
PST - ppublish
SO  - Thromb Haemost. 2006 Nov;96(5):660-4.

PMID- 1174413
OWN - NLM
STAT- MEDLINE
DCOM- 19751211
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 25
IP  - 7
DP  - 1975 Jul
TI  - [Quantitative determination of the main metabolites of acetylsalicylic acid/2nd 
      communication: the concentrations of salicylic acid and its metabolites in 
      patients with renal insufficiency (author's transl)].
PG  - 1073-7
AB  - Quantitative Determination of the Main Metabolites of Acetylsalicylic Acid / 2nd 
      Communication: The concentrations of salicylic acid and its metabolies in 
      patients with renal insufficiency 9 patients suffering from renal insufficiencies 
      of varing degrees and treated regularly by hemodialysis were given 1.5 g Colfarit 
      (microcapsulated acetyl salicylic acid) as a single dose. The concentrations of 
      salicylic acid (SA), salicyluric acid (SU), further salicylic acid conjugates 
      (SAC) and salicyluric acid conjugates (SUC) were determined in the blood plasma. 
      Likewise urea and creatinine were determined. SA concentration decreased 
      continually and, at the end of the trial (72 h after application), had vanished 
      almost completely from the plasma of most patients. SU increased at first and 
      decreased afterwards. With the exception of the dailysis time SAC and SUC 
      increased during the trial. After 3 days the SUC level was more than 50% of total 
      salicylate (SSS) in most patients. SSS (the sum of SA + SU + SAC + SUC) did not 
      change very much before dialysis, but showed a rather high decrease during the 
      first hours of dialysis. tafter dialysis the SSS levels rose again, apparently as 
      a consequence of a redistribution and of the synthesis of conjugates with 
      decreased tissue affinity. It could be shown that SSS in the blood plasma does 
      not parallel SSS in the whole body. The interindividual variation of SA 
      metabolism as well as the variation of the biological blank values was rather 
      high. The results are discussed with regard to salicylate pharmacokinetics in 
      renal insufficiency and to normal salicylate metabolism.
FAU - Daneels, R
AU  - Daneels R
FAU - Loew, D
AU  - Loew D
FAU - Pütter, J
AU  - Pütter J
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Quantitative Bestimmung der Hauptmetaboliten der Acetylsalizylsäure 2. 
      Mitteilung: Die Konzentrationen an Salizylsäure und ihren Metaboliten bei 
      niereinsuffizienten Patienten.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Glucuronates)
RN  - 0 (Salicylates)
RN  - AYI8EX34EU (Creatinine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/blood/*metabolism
MH  - Blood Urea Nitrogen
MH  - Creatinine/blood
MH  - Glucuronates/blood
MH  - Humans
MH  - Kidney Failure, Chronic/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Renal Dialysis
MH  - Salicylates/blood/*metabolism
EDAT- 1975/07/01 00:00
MHDA- 1975/07/01 00:01
CRDT- 1975/07/01 00:00
PHST- 1975/07/01 00:00 [pubmed]
PHST- 1975/07/01 00:01 [medline]
PHST- 1975/07/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1975 Jul;25(7):1073-7.

PMID- 21517642
OWN - NLM
STAT- MEDLINE
DCOM- 20110711
LR  - 20220407
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 16
IP  - 10 Suppl
DP  - 2010 Nov
TI  - Finding a balance in long-term anticoagulation therapy.
PG  - S278-83
AB  - The treatment of atrial fibrillation (AF) takes a 2-pronged approach that 
      addresses (1) symptoms caused by the arrhythmia and (2) safety, which is largely 
      focused on reduction of the risk of stroke due to the effects of AF on blood 
      flow. Treatment of AF includes rate-control and rhythm-control strategies. 
      However, achieving control of AF symptoms will generally not protect a patient 
      against the risk of stroke. Currently available antithrombotic agents effectively 
      reduce the risk of stroke in patients with AF, and guidelines have been 
      established for selecting the appropriate agent. Recommendations currently center 
      on a choice between aspirin or warfarin (target international normalized ratio of 
      2.0-3.0) and are based on an assessment of the level of risk for the individual 
      patient. The choice between aspirin or warfarin comes down to a choice between 
      lower anticoagulant efficacy coupled with a lower bleeding risk versus higher 
      anticoagulant efficacy coupled with a higher bleeding risk. Minimizing the risks 
      of antithrombotic treatment in AF patients involves finding the appropriate 
      balance between the risk for each individual of having a stroke while using less 
      effective anticoagulation versus the risk of having a major bleeding event while 
      using more effective anticoagulation.
FAU - Stecker, Eric C
AU  - Stecker EC
AD  - Oregon Health and Science University, Portland, OR, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Stroke/etiology/*prevention & control
MH  - Time Factors
MH  - Warfarin/*therapeutic use
EDAT- 2011/04/29 06:00
MHDA- 2011/07/12 06:00
CRDT- 2011/04/27 06:00
PHST- 2011/04/27 06:00 [entrez]
PHST- 2011/04/29 06:00 [pubmed]
PHST- 2011/07/12 06:00 [medline]
AID - 88882 [pii]
PST - ppublish
SO  - Am J Manag Care. 2010 Nov;16(10 Suppl):S278-83.

PMID- 8864799
OWN - NLM
STAT- MEDLINE
DCOM- 19961212
LR  - 20131121
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 34
IP  - 8
DP  - 1996 Aug
TI  - The efficacy and potency of antiplatelet activity of ticlopidine is increased by 
      aspirin.
PG  - 352-6
AB  - Concomitant therapy with ticlopidine (T) and aspirin (ASA) profoundly increases 
      spectrum of antiplatelet activities of both drugs. It was hypothesized that in 
      addition to increased spectrum of activity (efficacy) each drug may potentiate 
      the specific antiplatelet activity (potency) of the other. In 32 volunteers whole 
      blood platelet aggregation (PA) in response to ADP, collagen, and arachidonic 
      acid was evaluated ex vivo following 10-day treatments with normal or 
      subthreshold doses of T or ASA with addition of second drug on the 5th day of 
      administration of the first. PA was measured before, on day 5 and 10 of 
      treatment. The results indicate that ASA increased spectrum of activity of T, 
      i.e. T and ASA in combination, were significantly more effective against 
      collagen-induced PA than either drug alone. This increased efficacy was retained 
      when subthreshold dose of T (100 mg, qd) was used. T was without effect on 
      AA-induced and ASA on ADP-induced PA. However, ASA potentiated effect of T on 
      ADP-induced PA; the subthreshold dose of T (100 mg, qd) in presence of ASA (100 
      mg, qd) exerted powerful inhibition. Thus, combination therapy increases both 
      efficacy and potency of T allowing for reduction of the dose.
FAU - Splawinska, B
AU  - Splawinska B
AD  - District Hospital No 2, Rzeszów, Poland.
FAU - Kuzniar, J
AU  - Kuzniar J
FAU - Malinga, K
AU  - Malinga K
FAU - Mazurek, A P
AU  - Mazurek AP
FAU - Splawinski, J
AU  - Splawinski J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate/pharmacology
MH  - Adult
MH  - Arachidonic Acid/pharmacology
MH  - Aspirin/*pharmacology
MH  - Collagen/pharmacology
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Ticlopidine/*pharmacology
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 1996 Aug;34(8):352-6.

PMID- 324503
OWN - NLM
STAT- MEDLINE
DCOM- 19770723
LR  - 20191210
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 49
IP  - 5
DP  - 1977 May
TI  - Efficacy and tolerance of Flunixin (SCH 14714) in the treatment of postoperative 
      pain, with observations on the methodology of postoperative pain studies.
PG  - 467-71
AB  - A new anti-inflammatory, antipyretic and analgesic drug 
      2(2'-methyl-3'-trifluoromethylanilino)-nicotinic acid (Flunixin, Sch 14714) was 
      compared with aspirin and a placebo in a double-blind study of pain after four 
      different types of operation. Sch 14714 proved to be superior to the two other 
      drugs after herniorraphy and venous surgery of the leg. The frequency of adverse 
      effects after this drug was, at most. 1.2% which did not differ from the 
      side-effect rates of aspirin or placebo. The second and third days after 
      operation yielded a very high rate of optimal pain relief scores resulting in 
      poor discrimination. Thus cross-over studies seem to be superfluous in the study 
      of pain-relieving drugs in the period following surgery. The patients' rather low 
      demand of analgesic drugs indicated that more stringent enrollment criteria 
      should be adhered to. It was also shown that radical venous surgery constituted a 
      good model for pain studies.
FAU - Zederfeldt, B
AU  - Zederfeldt B
FAU - Borg, I
AU  - Borg I
FAU - Haeger, K
AU  - Haeger K
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Aniline Compounds)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Nicotinic Acids)
RN  - 356IB1O400 (flunixin)
RN  - R16CO5Y76E (Aspirin)
RN  - V7DXN0M42R (Clonixin)
SB  - IM
MH  - Aniline Compounds/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Clinical Trials as Topic
MH  - Clonixin/analogs & derivatives
MH  - Female
MH  - Humans
MH  - Male
MH  - Nicotinic Acids/*therapeutic use
MH  - Pain, Postoperative/*drug therapy
MH  - Research Design
MH  - Time Factors
EDAT- 1977/05/01 00:00
MHDA- 1977/05/01 00:01
CRDT- 1977/05/01 00:00
PHST- 1977/05/01 00:00 [pubmed]
PHST- 1977/05/01 00:01 [medline]
PHST- 1977/05/01 00:00 [entrez]
AID - S0007-0912(17)45481-X [pii]
AID - 10.1093/bja/49.5.467 [doi]
PST - ppublish
SO  - Br J Anaesth. 1977 May;49(5):467-71. doi: 10.1093/bja/49.5.467.

PMID- 30621622
OWN - NLM
STAT- MEDLINE
DCOM- 20190131
LR  - 20200225
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 19
IP  - 1
DP  - 2019 Jan 8
TI  - Preventive effect of ecabet sodium on low-dose aspirin-induced small intestinal 
      mucosal injury: a randomized, double-blind, pilot study.
PG  - 4
LID - 10.1186/s12876-018-0923-7 [doi]
LID - 4
AB  - BACKGROUND: We aimed to investigate how high-dose ecabet sodium affects low-dose 
      aspirin-induced small intestinal mucosal injury in healthy volunteers. METHODS: 
      Healthy volunteers were enrolled randomly into one of two groups with the 
      following drug regimens for 2 weeks: group A, low-dose aspirin once per day and 
      group B, low-dose aspirin and 4.0 g of ecabet sodium. Small bowel capsule 
      endoscopy was performed before and 2 weeks after low-dose aspirin administration. 
      RESULTS: A significant difference was found in the median number [range] of small 
      intestinal lesions between baseline and two weeks after low-dose aspirin 
      administration in group A (baseline: 1 [0-5], after: 5 [1-11]; p = 0.0059) but 
      not in group B (baseline: 0.5 [0-9], after: 3 [0-23]; p = 0.0586). In group B, 
      although the median number [range] of lesions in the first tertile of the small 
      intestine did not increase two weeks after low-dose aspirin administration 
      (baseline: 0 [0-4], after: 1.5 [0-8]; p = 0.2969), the number of lesions in the 
      second and third tertiles of the small intestine increased significantly 
      (baseline: 0 [0-5], after: 2 [0-15]; p = 0.0469). CONCLUSIONS: Ecabet sodium had 
      a preventive effect on low-dose aspirin-induced small intestinal mucosal injury 
      in the upper part of the small intestine. TRIAL REGISTRATION: ISRCTN 99322160 , 
      01/10/2018.
FAU - Ota, Kazuhiro
AU  - Ota K
AUID- ORCID: 0000-0002-5628-9662
AD  - Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, 
      Takatsuki, Osaka, 569-8686, Japan. clash_kaz@yahoo.co.jp.
FAU - Takeuchi, Toshihisa
AU  - Takeuchi T
AD  - Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, 
      Takatsuki, Osaka, 569-8686, Japan.
FAU - Kojima, Yuichi
AU  - Kojima Y
AD  - Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, 
      Takatsuki, Osaka, 569-8686, Japan.
FAU - Harada, Satoshi
AU  - Harada S
AD  - Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, 
      Takatsuki, Osaka, 569-8686, Japan.
FAU - Hirata, Yuki
AU  - Hirata Y
AD  - Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, 
      Takatsuki, Osaka, 569-8686, Japan.
FAU - Sugawara, Noriaki
AU  - Sugawara N
AD  - Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, 
      Takatsuki, Osaka, 569-8686, Japan.
FAU - Nouda, Sadaharu
AU  - Nouda S
AD  - Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, 
      Takatsuki, Osaka, 569-8686, Japan.
FAU - Kakimoto, Kazuki
AU  - Kakimoto K
AD  - Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, 
      Takatsuki, Osaka, 569-8686, Japan.
FAU - Kuramoto, Takanori
AU  - Kuramoto T
AD  - Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, 
      Takatsuki, Osaka, 569-8686, Japan.
FAU - Higuchi, Kazuhide
AU  - Higuchi K
AD  - Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, 
      Takatsuki, Osaka, 569-8686, Japan.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20190108
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 0 (Abietanes)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 2K02669KWP (ecabet)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abietanes/administration & dosage/*therapeutic use
MH  - Adult
MH  - Anti-Ulcer Agents/administration & dosage/*therapeutic use
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Capsule Endoscopy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Intestinal Mucosa/drug effects/*pathology
MH  - Intestine, Small/drug effects/*pathology
MH  - Male
MH  - Pilot Projects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Prospective Studies
MH  - Ulcer/chemically induced/*prevention & control
PMC - PMC6323690
OTO - NOTNLM
OT  - Aspirin
OT  - Capsule endoscopy
OT  - Ecabet sodium
OT  - Small intestinal mucosal injury
OT  - Small intestine
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study was performed in accordance 
      with the 1975 Declaration of Helsinki (as revised in 1983), and the protocol was 
      approved by the ethics review committee at Osaka Medical College (No. 730) and 
      was registered in the University hospital Medical Information Network Clinical 
      Trial Registry (UMIN000033984). All 30 subjects received oral and written 
      information about the study and signed informed consent forms. CONSENT FOR 
      PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they 
      have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral 
      with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2019/01/10 06:00
MHDA- 2019/02/01 06:00
CRDT- 2019/01/10 06:00
PHST- 2018/08/21 00:00 [received]
PHST- 2018/12/25 00:00 [accepted]
PHST- 2019/01/10 06:00 [entrez]
PHST- 2019/01/10 06:00 [pubmed]
PHST- 2019/02/01 06:00 [medline]
AID - 10.1186/s12876-018-0923-7 [pii]
AID - 923 [pii]
AID - 10.1186/s12876-018-0923-7 [doi]
PST - epublish
SO  - BMC Gastroenterol. 2019 Jan 8;19(1):4. doi: 10.1186/s12876-018-0923-7.

PMID- 18682741
OWN - NLM
STAT- MEDLINE
DCOM- 20081218
LR  - 20211020
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 3
IP  - 8
DP  - 2008 Aug 6
TI  - A randomised controlled trial of triple antiplatelet therapy (aspirin, 
      clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, 
      tolerability and feasibility.
PG  - e2852
LID - 10.1371/journal.pone.0002852 [doi]
LID - e2852
AB  - BACKGROUND: Aspirin, dipyridamole and clopidogrel are effective in secondary 
      vascular prevention. Combination therapy with three antiplatelet agents might 
      maximise the benefit of antiplatelet treatment in the secondary prevention of 
      ischaemic stroke. METHODOLOGY/PRINCIPAL FINDINGS: A randomised, parallel group, 
      observer-blinded phase II trial compared the combination of aspirin, clopidogrel 
      and dipyridamole with aspirin alone. Adult patients with ischaemic stroke or 
      transient ischaemic attack (TIA) within 5 years were included. The primary 
      outcome was tolerability to treatment assessed as the number of patients 
      completing randomised treatment. Recruitment was halted prematurely after 
      publication of the ESPRIT trial (which confirmed that combined aspirin and 
      dipyridamole is more effective than aspirin alone). 17 patients were enrolled: 
      male 12 (71%), mean age 62 (SD 13) years, lacunar stroke syndrome 12 (71%), 
      median stroke/TIA onset to randomisation 8 months. Treatment was discontinued in 
      4 of 9 (44%) patients receiving triple therapy vs. none of 8 taking aspirin (p = 
      0.08). One recurrent stroke occurred in a patient in the triple group who was 
      noncompliant of all antiplatelet medications. The number of patients with adverse 
      events and bleeding complications, and their severity, were significantly greater 
      in the triple therapy group (p<0.01). CONCLUSIONS/SIGNIFICANCE: Long term triple 
      antiplatelet therapy was asociated with a significant increase in adverse events 
      and bleeding rates, and their severity, and a trend to increased 
      discontinuations. However, the patients had a low risk of recurrence and future 
      trials should focus on short term therapy in high risk patients characterised by 
      a very recent event or failure of dual antiplatelet therapy. TRIAL REGISTRATION: 
      Controlled-Trials.com ISRCTN83673558.
FAU - Sprigg, Nikola
AU  - Sprigg N
AD  - Stroke Trials Unit, Institute of Neuroscience, University of Nottingham, 
      Nottinghamshire, United Kingdom.
FAU - Gray, Laura J
AU  - Gray LJ
FAU - England, Tim
AU  - England T
FAU - Willmot, Mark R
AU  - Willmot MR
FAU - Zhao, Lian
AU  - Zhao L
FAU - Sare, Gillian M
AU  - Sare GM
FAU - Bath, Philip M W
AU  - Bath PM
LA  - eng
SI  - ISRCTN/ISRCTN83673558
GR  - PG/08/083/25779/BHF_/British Heart Foundation/United Kingdom
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080806
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/adverse effects/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Clopidogrel
MH  - Dipyridamole/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Drug Tolerance
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pulse
MH  - Safety
MH  - Single-Blind Method
MH  - Stroke/physiopathology/*prevention & control
MH  - Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
PMC - PMC2481397
COIS- Competing Interests: Philip Bath has consulted for Boehringer Ingelheim and has 
      spoken at symposia related to dipyridamole.
EDAT- 2008/08/07 09:00
MHDA- 2008/12/19 09:00
CRDT- 2008/08/07 09:00
PHST- 2007/09/28 00:00 [received]
PHST- 2008/07/07 00:00 [accepted]
PHST- 2008/08/07 09:00 [pubmed]
PHST- 2008/12/19 09:00 [medline]
PHST- 2008/08/07 09:00 [entrez]
AID - 07-PONE-CT-02367R3 [pii]
AID - 10.1371/journal.pone.0002852 [doi]
PST - epublish
SO  - PLoS One. 2008 Aug 6;3(8):e2852. doi: 10.1371/journal.pone.0002852.

PMID- 22386405
OWN - NLM
STAT- MEDLINE
DCOM- 20120518
LR  - 20220331
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 79
IP  - 3
DP  - 2012 Mar
TI  - Radical prostatectomy with robot-assisted radical prostatectomy and laparoscopic 
      radical prostatectomy under low-dose aspirin does not significantly increase 
      blood loss.
PG  - 591-5
LID - 10.1016/j.urology.2011.11.031 [doi]
AB  - OBJECTIVE: To determine whether maintaining use of low-dose aspirin confers a 
      higher risk of bleeding events in patients undergoing laparoscopic or 
      robot-assisted radical prostatectomy. There is no consensus on maintaining or 
      withdrawing aspirin in these patients. METHODS: Consecutive patients undergoing 
      laparoscopic and robot-assisted radical prostatectomy between January 2009 and 
      December 2010 were included in a prospective cohort study. Among them, 54 
      aspirin-treated patients were compared with 569 non-aspirin-treated patients. We 
      evaluated the between-group difference in bleeding event: intraoperative blood 
      loss ≥ 700 ml and/or need for transfusion and/or postoperative hemorrhagic 
      complication (symptomatic abdominal wall hematomas, major bleeding requiring 
      reoperation). Differences in each component of the bleeding event, in hemoglobin 
      level changes, and hospital stay length were also evaluated. Patients' data were 
      compared using the χ(2) or Fisher exact test for categorical variables and the 
      Student t test or Mann-Whitney test for continuous variables. RESULTS: A bleeding 
      event occurred in 18 (33.3%) aspirin-treated patients and 176 (32.5%) 
      non-aspirin-treated patients (P = .66). Median blood loss was similar in the 2 
      groups (aspirin: 450 ml, 50-7100 ml; no aspirin: 450 ml, 100-2800 ml; P = .93). 
      Aspirin was not associated with a significant hemoglobin level variation (median 
      decrease, 2.9 g/dL with aspirin and 3.2 g/dL without aspirin, P = .23). Median 
      hospital length of stay, rates of blood transfusion, and postoperative 
      hemorrhagic complications were similar in the 2 groups. CONCLUSION: Laparoscopic 
      and robot-assisted radical prostatectomy can be performed safely without 
      discontinuing aspirin, as this policy does not increase significantly blood loss, 
      blood transfusion requirements, postoperative hemorrhagic complications. or 
      hospital length of stay.
CI  - Copyright Â© 2012 Elsevier Inc. All rights reserved.
FAU - Binhas, Michèle
AU  - Binhas M
AD  - Department of Anaesthesiology and Intensive Care, University Paris-Est Créteil 
      and Assisitance Publique Hôpitaux de Paris, Henri Mondor Albert Chenevier 
      University Hospital, Créteil, France. michele.binhas@hmn.aphp.fr
FAU - Salomon, Laurent
AU  - Salomon L
FAU - Roudot-Thoraval, Françoise
AU  - Roudot-Thoraval F
FAU - Armand, Catherine
AU  - Armand C
FAU - Plaud, Benoît
AU  - Plaud B
FAU - Marty, Jean
AU  - Marty J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Blood Loss, Surgical/*statistics & numerical data
MH  - Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - Intraoperative Period
MH  - *Laparoscopy
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Prospective Studies
MH  - Prostatectomy/*methods
MH  - *Robotics
EDAT- 2012/03/06 06:00
MHDA- 2012/05/19 06:00
CRDT- 2012/03/06 06:00
PHST- 2011/08/09 00:00 [received]
PHST- 2011/11/17 00:00 [revised]
PHST- 2011/11/19 00:00 [accepted]
PHST- 2012/03/06 06:00 [entrez]
PHST- 2012/03/06 06:00 [pubmed]
PHST- 2012/05/19 06:00 [medline]
AID - S0090-4295(11)02693-8 [pii]
AID - 10.1016/j.urology.2011.11.031 [doi]
PST - ppublish
SO  - Urology. 2012 Mar;79(3):591-5. doi: 10.1016/j.urology.2011.11.031.

PMID- 827200
OWN - NLM
STAT- MEDLINE
DCOM- 19770216
LR  - 20190823
IS  - 0065-4299 (Print)
IS  - 0065-4299 (Linking)
VI  - 6
IP  - 6
DP  - 1976 Nov
TI  - Effect of concurrent administration of aspirin, indomethacin or hydrocortisone 
      with gold sodium thiomalate against adjuvant-induced arthritis in the rat.
PG  - 728-34
AB  - The activity of gold sodium thiomalate (GST) given i.m. to adjuvant-induced 
      polyarthritic rats was studied alone or in combination with active doses of 
      aspirin, indomethacin and hydrocortisone. In addition to paw volume and body 
      weight changes, erythrocyte sedimentation rate, serum albumin/globulin and gold 
      levels as well as plasma activities of beta-glucuronidase, acid phosphatase, 
      lysozyme and lactic acid dehydrogenase were measured. In prophylactic studies the 
      beneficial activity of GST was unaffected by aspirin, suggesting a positive drug 
      interaction, but additive with indomethacin or hydrocortisone for the 1st but not 
      2nd lesion of the disease. These results were closely correlated with increased 
      serum gold levels. Similar clinical findings were observed in therapeutic studies 
      except that a positive drug interaction occurred between GST and hydrocortisone. 
      Unlike in the prophylactic experiments, serum gold levels were unaffected by any 
      of the agents tested in the therapeutic studies.
FAU - Sofia, D R
AU  - Sofia DR
FAU - Knobloch, L C
AU  - Knobloch LC
FAU - Douglas, J F
AU  - Douglas JF
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Agents Actions
JT  - Agents and actions
JID - 0213341
RN  - 12244-57-4 (Gold Sodium Thiomalate)
RN  - 7440-57-5 (Gold)
RN  - R16CO5Y76E (Aspirin)
RN  - WI4X0X7BPJ (Hydrocortisone)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Arthritis/*drug therapy
MH  - Arthritis, Experimental/*drug therapy
MH  - Aspirin/*administration & dosage/therapeutic use
MH  - Blood Sedimentation
MH  - Drug Therapy, Combination
MH  - Gold/blood
MH  - Gold Sodium Thiomalate/*administration & dosage/therapeutic use
MH  - Hydrocortisone/*administration & dosage/therapeutic use
MH  - Indomethacin/*administration & dosage/therapeutic use
MH  - Male
MH  - Mycobacterium tuberculosis
MH  - Rats
MH  - Time Factors
EDAT- 1976/11/01 00:00
MHDA- 1976/11/01 00:01
CRDT- 1976/11/01 00:00
PHST- 1976/11/01 00:00 [pubmed]
PHST- 1976/11/01 00:01 [medline]
PHST- 1976/11/01 00:00 [entrez]
AID - 10.1007/BF02026096 [doi]
PST - ppublish
SO  - Agents Actions. 1976 Nov;6(6):728-34. doi: 10.1007/BF02026096.

PMID- 16288614
OWN - NLM
STAT- MEDLINE
DCOM- 20051219
LR  - 20131121
IS  - 0003-2409 (Print)
IS  - 0003-2409 (Linking)
VI  - 60
IP  - 12
DP  - 2005 Dec
TI  - Use of the platelet function analyser (PFA-100) to quantify the effect of low 
      dose aspirin in patients with ischaemic heart disease.
PG  - 1173-8
AB  - Continuing aspirin up until surgery in cardiac surgical patients may increase 
      peri-operative blood loss. It is possible that there is a subset of patients 
      particularly sensitive to aspirin. The platelet function analyser (PFA-100) can 
      demonstrate the antiplatelet effect of aspirin. This study was designed to assess 
      the effect of daily 75 mg aspirin on platelet function, as measured by the 
      PFA-100, in 92 patients with ischaemic heart disease. Patients were classified 
      into three groups according to their PFA-100 results; aspirin hyper-responders 
      (16%), aspirin normal responders (33%) and aspirin non-responders (51%). The 
      PFA-100 has potential as a screening tool to identify patients who are either 
      hyper-responsive or resistant to aspirin. Pre-operative PFA-100 screening to 
      isolate aspirin hyper-responders could enable the vast majority of patients to 
      continue with aspirin therapy pre-operatively, avoiding the risks of stopping 
      treatment.
FAU - Coakley, M
AU  - Coakley M
AD  - Specialist Registrar, Department of Anaesthesia, Royal Free Hospital, Pond 
      Street, Hampstead, London NW3 2QG, UK.
FAU - Self, R
AU  - Self R
FAU - Marchant, W
AU  - Marchant W
FAU - Mackie, I
AU  - Mackie I
FAU - Mallett, S V
AU  - Mallett SV
FAU - Mythen, M
AU  - Mythen M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Anaesthesia
JT  - Anaesthesia
JID - 0370524
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Anaesthesia. 2006 May;61(5):508-9; author reply 509. PMID: 16674636
MH  - Adult
MH  - Aged
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*drug effects/physiology
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*blood
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - Platelet Function Tests/methods
MH  - Preoperative Care/methods
EDAT- 2005/11/18 09:00
MHDA- 2005/12/20 09:00
CRDT- 2005/11/18 09:00
PHST- 2005/11/18 09:00 [pubmed]
PHST- 2005/12/20 09:00 [medline]
PHST- 2005/11/18 09:00 [entrez]
AID - ANA4291 [pii]
AID - 10.1111/j.1365-2044.2005.04291.x [doi]
PST - ppublish
SO  - Anaesthesia. 2005 Dec;60(12):1173-8. doi: 10.1111/j.1365-2044.2005.04291.x.

PMID- 6337200
OWN - NLM
STAT- MEDLINE
DCOM- 19830317
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 71
IP  - 2
DP  - 1983 Feb
TI  - Failure of children with asthma to respond to daily aspirin therapy.
PG  - 245-9
AB  - Adverse reactions to aspirin in asthmatic patients have been widely described in 
      the past. In contrast to this more frequent complication, several authors have 
      published reports suggesting that aspirin and other nonsteroidal 
      anti-inflammatory drugs can improve asthma. We studied the effect of long-term 
      aspirin administration in children with moderately severe asthma. Ten children 
      who showed no immediate effect of aspirin challenge (either adverse or 
      beneficial) were placed in a 9 wk, double-blind crossover study, receiving 
      aspirin (10 gr twice daily) or placebo for 4 wk, then a 1 wk washout period, 
      followed by aspirin or placebo for 4 wk. There was no difference between aspirin 
      and placebo periods in number of wheezing episodes, frequency of additional 
      bronchodilator or prednisone use, or daily spirometric measurements. Serum 
      thromboxane B2 levels were significantly reduced during aspirin therapy (p less 
      than 0.001), indicating that the patients had complied with the aspirin therapy. 
      Thus long-term administration of aspirin to asthmatics who show no immediate 
      beneficial or adverse response to aspirin challenge appeared not to influence the 
      clinical course of asthma. In addition, inhibition of the platelet prostaglandin 
      cyclooxygenase pathway in these patients did not modify the clinical course of 
      their asthma.
FAU - Cummings, N P
AU  - Cummings NP
FAU - Morris, H G
AU  - Morris HG
FAU - Strunk, R C
AU  - Strunk RC
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Prostaglandins E)
RN  - 0 (Prostaglandins F)
RN  - B7IN85G1HY (Dinoprost)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adolescent
MH  - Aspirin/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Child
MH  - Clinical Trials as Topic
MH  - Dinoprost
MH  - Dinoprostone
MH  - Double-Blind Method
MH  - Humans
MH  - Patient Compliance
MH  - Prostaglandins E/physiology
MH  - Prostaglandins F/physiology
MH  - Spirometry
EDAT- 1983/02/01 00:00
MHDA- 1983/02/01 00:01
CRDT- 1983/02/01 00:00
PHST- 1983/02/01 00:00 [pubmed]
PHST- 1983/02/01 00:01 [medline]
PHST- 1983/02/01 00:00 [entrez]
AID - 0091-6749(83)90106-9 [pii]
AID - 10.1016/0091-6749(83)90106-9 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1983 Feb;71(2):245-9. doi: 10.1016/0091-6749(83)90106-9.

PMID- 14567600
OWN - NLM
STAT- MEDLINE
DCOM- 20031117
LR  - 20161124
IS  - 0022-3085 (Print)
IS  - 0022-3085 (Linking)
VI  - 99
IP  - 4
DP  - 2003 Oct
TI  - Low-dose aspirin prophylaxis and risk of intracranial hemorrhage in patients 
      older than 60 years of age with mild or moderate head injury: a prospective 
      study.
PG  - 661-5
AB  - OBJECT: The goal of this paper was to investigate a possible relationship between 
      the consumption of low-dose aspirin (LDA) and traumatic intracranial hemorrhage 
      in an attempt to determine whether older patients receiving prophylactic LDA 
      require special treatment following an incidence of mild-to-moderate head trauma. 
      METHODS: Two hundred thirty-one patients older than 60 years of age, who arrived 
      at the emergency department with a mild or moderate head injury (Glasgow Coma 
      Scale [GCS] Scores 13-15 and 9-12, respectively), were included in the study. One 
      hundred ten patients were receiving prophylactic LDA (100 mg/day) and these 
      formed the aspirin-treated group. One hundred twenty-one patients were receiving 
      no aspirin, and these formed the control group. There was no statistically 
      significant difference between the two groups with respect to age, sex, mechanism 
      of trauma, or GCS score on arrival at the emergency department. Most of the 
      patients sustained the head injury from falls (88.2% of patients in the 
      aspirin-treated group and 85.1% of patients in the control group), and had 
      external signs of head trauma such as bruising or scalp laceration (80.9% of 
      patients in the aspirin-treated group and 86.8% of patients in the control 
      group). All patients underwent similar neurological examinations and computerized 
      tomography (CT) scanning of the head. The CT scans revealed evidence of traumatic 
      intracranial hemorrhage in 27 (24.5%) patients in the aspirin-treated group and 
      in 31 patients (25.6%) in the control group. Surgical intervention was required 
      for five patients in each group (4.5% of patients in the aspirin-treated group 
      and 4.1% of patients in the control group). A surprising number of the patients 
      who arrived with GCS Score 15 were found to have traumatic intracranial 
      hemorrhage, as revealed by CT scanning (11.5% of patients in the aspirin-treated 
      group and 16.5% of patients in the control group). Surgery, however, was not 
      necessary for any of these patients. CONCLUSIONS: There was no statistically 
      significant difference in the frequency or types of traumatic intracranial 
      hemorrhage between patients who had received aspirin prophylaxis and those who 
      had not. The authors conclude that LDA does not increase surgically relevant 
      parenchymal or meningeal bleeding following moderate and minor head injury in 
      patients older than 60 years of age.
FAU - Spektor, Sergey
AU  - Spektor S
AD  - Department of Neurosurgery, Hadassah University Hospital, Jerusalem, Israel.
FAU - Agus, Samuel
AU  - Agus S
FAU - Merkin, Vladimir
AU  - Merkin V
FAU - Constantini, Shlomo
AU  - Constantini S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Neurosurg
JT  - Journal of neurosurgery
JID - 0253357
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Brain Injuries/*diagnostic imaging
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Glasgow Coma Scale
MH  - Humans
MH  - Intracranial Hemorrhages/*chemically induced/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/drug therapy
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sex Distribution
MH  - Tomography, X-Ray Computed
EDAT- 2003/10/22 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/10/22 05:00
PHST- 2003/10/22 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/10/22 05:00 [entrez]
AID - 10.3171/jns.2003.99.4.0661 [doi]
PST - ppublish
SO  - J Neurosurg. 2003 Oct;99(4):661-5. doi: 10.3171/jns.2003.99.4.0661.

PMID- 6463570
OWN - NLM
STAT- MEDLINE
DCOM- 19840912
LR  - 20131121
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 19
IP  - 4
DP  - 1984 Jun
TI  - Canine gastric ulcer produced by hemorrhagic shock and aspirin.
PG  - 487-91
AB  - Ischemia of the gastric mucosa, for example during hemorrhagic shock, appears to 
      be an important pathogenetic factor in acute bleeding from the upper 
      gastrointestinal tract. In the present experiment the effects on the canine 
      gastric mucosa of hemorrhagic shock (ischemia) and intragastric aspirin in acid 
      and neutral solution were studied. The combination of hemorrhagic shock, aspirin, 
      and acid caused pronounced mucosal lesions, whereas only minor lesions were seen 
      with aspirin and acid alone. It is concluded that the ischemic gastric mucosa is 
      more susceptible to aspirin solution than normal mucosa. This may have important 
      bearings on clinical practice.
FAU - Casalnuovo, C A
AU  - Casalnuovo CA
FAU - Kraglund, K
AU  - Kraglund K
FAU - Kristensen, I B
AU  - Kristensen IB
FAU - Amdrup, E
AU  - Amdrup E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acids/toxicity
MH  - Animals
MH  - Aspirin/*toxicity
MH  - Dogs
MH  - Female
MH  - Gastric Mucosa/blood supply/pathology
MH  - Male
MH  - Shock, Hemorrhagic/*complications
MH  - Stomach/blood supply
MH  - Stomach Ulcer/*etiology
EDAT- 1984/06/01 00:00
MHDA- 1984/06/01 00:01
CRDT- 1984/06/01 00:00
PHST- 1984/06/01 00:00 [pubmed]
PHST- 1984/06/01 00:01 [medline]
PHST- 1984/06/01 00:00 [entrez]
PST - ppublish
SO  - Scand J Gastroenterol. 1984 Jun;19(4):487-91.

PMID- 619830
OWN - NLM
STAT- MEDLINE
DCOM- 19780223
LR  - 20131121
IS  - 0003-9926 (Print)
IS  - 0003-9926 (Linking)
VI  - 138
IP  - 1
DP  - 1978 Jan
TI  - Hemostatic effects of uniform, low-dose subcutaneous heparin in surgical 
      patients.
PG  - 41-4
AB  - Two hours before surgery and every 12 hours thereafter 5,000 units of heparin 
      sodium was administered subcutaneously to 100 general surgical patients. 
      Hemostasis was evaluated by a template bleeding time and an activated partial 
      thromboplastin time (PTT). The latter was sensitive to 0.05 units/ml of heparin 
      and gave a straight-line response up to 0.2 units/ml. In the great majority of 
      patients, only a modest elevation of the PTT occurred two and four hours after 
      heparin therapy. However, in 10% to 15% the PTT was prolonged two times or more 
      and in a similar number, PTT after surgery was shorter than baseline values 
      despite heparin. No correlation between PTT prolongation and weight, ponderal 
      index, age, or sex was found. Significant bleeding occurrred in three patients, 
      two from the group of hyperresponders to heparin. Recent aspirin ingestion was 
      implicated in one patient and our evidence indicates that low-dose heparin 
      potentiates aspirin-induced prolongation of bleeding time in certain individuals. 
      Local hematoma formation and discomfort from the injections was not a problem.
FAU - Gurewich, V
AU  - Gurewich V
FAU - Nunn, T
AU  - Nunn T
FAU - Kuriakose, T T
AU  - Kuriakose TT
FAU - Hume, M
AU  - Hume M
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Intern Med
JT  - Archives of internal medicine
JID - 0372440
RN  - 9005-49-6 (Heparin)
RN  - 9035-58-9 (Thromboplastin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/administration & dosage
MH  - Blood Coagulation/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - *Hemostasis, Surgical
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*blood
MH  - Thromboplastin/analysis
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
PST - ppublish
SO  - Arch Intern Med. 1978 Jan;138(1):41-4.

PMID- 5810078
OWN - NLM
STAT- MEDLINE
DCOM- 19691025
LR  - 20190501
IS  - 0264-6021 (Print)
IS  - 1470-8728 (Electronic)
IS  - 0264-6021 (Linking)
VI  - 114
IP  - 2
DP  - 1969 Sep
TI  - The excretion of lacate dehydrogenase in human urine after he ingestion of 
      aspiin.
PG  - 197-202
AB  - 1. Cells present in normal human urine contain 5-10% of the total lactate 
      dehydrogenase excreted. The enzyme released from these cells by ultrasonication 
      contained a distribution of isoenzymes similar to that found in the bulk of the 
      urine and it is suggested that these cells are the main source of urinary lactate 
      dehydrogenase. 2. Cells were thoroughly washed before examination so it is 
      unlikely that the enzyme found in urinary sediment was simply adsorbed. In 
      addition, full recoveries of added lactate dehydrogenase isoenzymes LDH(1) and 
      LDH(5) showed that adsorption did not occur. 3. Most of the cells in normal urine 
      are of the non-squamous epithelial type and their excretion is greatly increased 
      after the ingestion by the subject of 3g. of aspirin. The possible origin of 
      these non-squamous cells from the kidney is discussed. 4. Starch-block 
      electrophoresis and relative activity measurements of lactate dehydrogenase 
      excreted after the subject had taken aspirin show that the enzymes present in 
      urine and cells are very similar, confirming the conclusion reached above (point 
      1). They have slightly more M subunits than the normal, shown particularly as an 
      increase in isoenzyme LDH(2). The isoenzyme pattern is like that of the kidney 
      medulla and the possible reasons for this are discussed in terms of the 
      concentration of salicylic acid in various parts of the kidney. 5. The results 
      confirm the previous suggestion that the kidney is the main source of urinary 
      lactate dehydrogenase.
FAU - Leathwood, P D
AU  - Leathwood PD
FAU - Plummer, D T
AU  - Plummer DT
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biochem J
JT  - The Biochemical journal
JID - 2984726R
RN  - 0 (Isoenzymes)
RN  - 0 (Salicylates)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adsorption
MH  - Aspirin/*pharmacology
MH  - Electrophoresis
MH  - Epithelium
MH  - Humans
MH  - Isoenzymes
MH  - Kidney/analysis/enzymology
MH  - L-Lactate Dehydrogenase/*urine
MH  - Male
MH  - Salicylates/analysis
MH  - Ultrasonics
MH  - Urine/cytology
PMC - PMC1184844
EDAT- 1969/09/01 00:00
MHDA- 1969/09/01 00:01
CRDT- 1969/09/01 00:00
PHST- 1969/09/01 00:00 [pubmed]
PHST- 1969/09/01 00:01 [medline]
PHST- 1969/09/01 00:00 [entrez]
AID - 10.1042/bj1140197 [doi]
PST - ppublish
SO  - Biochem J. 1969 Sep;114(2):197-202. doi: 10.1042/bj1140197.

PMID- 16423087
OWN - NLM
STAT- MEDLINE
DCOM- 20060405
LR  - 20131121
IS  - 1083-4389 (Print)
IS  - 1083-4389 (Linking)
VI  - 11
IP  - 1
DP  - 2006 Feb
TI  - Helicobacter pylori infection, but not low-dose aspirin, results in a local 
      reduction of the secretory leukocyte protease inhibitor in gastroduodenal mucosa.
PG  - 31-8
AB  - BACKGROUND: The secretory leukocyte protease inhibitor (SLPI) represents a 
      multifunctional protein with mucosa-protective features. Helicobacter pylori and 
      the usage of low-dose aspirin are two independent risk factors for the 
      development of gastrointestinal diseases. Therefore, the effect of low-dose 
      aspirin on gastrointestinal SLPI expression was analyzed in the context of H. 
      pylori infection. MATERIAL AND METHODS: The study included 20 volunteers (H. 
      pylori positive and negative: n = 10) who received 2 x 50 mg aspirin/day for 7 
      days. H. pylori-positive subjects underwent eradication therapy and repeated the 
      protocol. Gastroduodenoscopy was performed at day 0, 1, 3, and 7, and biopsies 
      were obtained each from antrum, corpus, and duodenal bulb. SLPI expression was 
      determined by quantitative reverse transcription-polymerase chain reaction 
      (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). RESULTS: A reduction of 
      antral SLPI levels, ranging between 582 (day 0) and 941 pg/10 microg protein (day 
      7), was determined in H. pylori-positive compared to H. pylori-negative and 
      -eradicated subjects (1600-2050 pg/10 microg protein, ANOVA: p = .001-.045). No 
      differences concerning aspirin were observed within the groups. SLPI levels in 
      corpus and duodenal mucosa were neither affected by H. pylori nor low-dose 
      aspirin. There was an inverse correlation between SLPI and H. pylori-induced 
      inflammation (activity: r = -0.575, -0.69 to -0.43, p < .0001; chronicity: r = 
      -0.54, -0.66 to -0.39, p < .0001) in antral mucosa only, whereas other locations 
      as well as the usage of low-dose aspirin did not show an association between SLPI 
      and inflammation. CONCLUSIONS: H. pylori infection, but not the usage of low-dose 
      aspirin, has a role in the down-regulation of antral SLPI levels.
FAU - Wex, Thomas
AU  - Wex T
AD  - Department of Gastroenterology, Hepatology and Infectious Diseases, Tongji 
      Medical College of Basic Medical Sciences, Huazhong University of Wuhan, China. 
      thomas.wex@medizin.uni-magdeburg.de
FAU - Ye, Siying
AU  - Ye S
FAU - Treiber, Gerhard
AU  - Treiber G
FAU - Vieth, Michael
AU  - Vieth M
FAU - Roessner, Albert
AU  - Roessner A
FAU - Malfertheiner, Peter
AU  - Malfertheiner P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Proteinase Inhibitory Proteins, Secretory)
RN  - 0 (Proteins)
RN  - 0 (SLPI protein, human)
RN  - 0 (Secretory Leukocyte Peptidase Inhibitor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Duodenum/drug effects
MH  - Female
MH  - Gastric Mucosa/drug effects/*metabolism
MH  - Gastritis/drug therapy/microbiology/pathology
MH  - Helicobacter Infections/*drug therapy/metabolism
MH  - Helicobacter pylori/*pathogenicity
MH  - Humans
MH  - Intestinal Mucosa/drug effects/*metabolism
MH  - Male
MH  - Prospective Studies
MH  - Proteinase Inhibitory Proteins, Secretory
MH  - Proteins/drug effects/genetics/*metabolism
MH  - Secretory Leukocyte Peptidase Inhibitor
EDAT- 2006/01/21 09:00
MHDA- 2006/04/06 09:00
CRDT- 2006/01/21 09:00
PHST- 2006/01/21 09:00 [pubmed]
PHST- 2006/04/06 09:00 [medline]
PHST- 2006/01/21 09:00 [entrez]
AID - HEL376 [pii]
AID - 10.1111/j.0083-8703.2006.00376.x [doi]
PST - ppublish
SO  - Helicobacter. 2006 Feb;11(1):31-8. doi: 10.1111/j.0083-8703.2006.00376.x.

PMID- 26576697
OWN - NLM
STAT- MEDLINE
DCOM- 20161104
LR  - 20161230
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
VI  - 25
IP  - 2
DP  - 2016 Feb
TI  - The Interplay between Stroke Severity, Antiplatelet Use, and Aspirin Resistance 
      in Ischemic Stroke.
PG  - 397-403
LID - S1052-3057(15)00549-2 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2015.10.011 [doi]
AB  - BACKGROUND: The issue of whether prior antiplatelet use favorably affects stroke 
      severity is currently unresolved. In this study, we evaluated the effect of 
      antiplatelet use on clinical stroke severity and ischemic lesion volume, and 
      assessed the confounding effect of laboratory-defined aspirin resistance on this 
      relationship. METHODS: Admission National Institutes of Health Stroke Scale 
      (NIHSS) score, ischemic lesion volumes on diffusion-weighted imaging (DWI), and 
      in vitro aspirin resistance, in addition to other pertinent stroke features, were 
      determined in a series of ischemic stroke patients. Univariate and multivariate 
      analyses were performed to compare clinical and imaging markers of stroke 
      severity among patients with and without prior antiplatelet use, taking into 
      consideration the presence or absence of aspirin resistance. RESULTS: 
      Antiplatelet users experienced more severe strokes, per NIHSS score, in 
      comparison to antiplatelet-naive patients (P = .007). No significant difference 
      was observed with respect to admission DWI lesion volume. When analyses were 
      repeated after adjustment for stroke subtype and other confounders, no 
      association was observed between antiplatelet use and stroke severity. On the 
      other hand, NIHSS scores were significantly higher in aspirin-unresponsive 
      patients than in both aspirin responders (P = .049) and aspirin nonusers (P = 
      .005). CONCLUSION: We were unable to demonstrate a substantial positive influence 
      of prestroke antiplatelet usage on stroke severity. Although the presence of more 
      severe strokes among patients with laboratory resistance suggests a protective 
      influence of aspirin sensitivity on stroke severity, the hypothesis could not be 
      validated as no difference was observed among aspirin-naive and aspirin-sensitive 
      patients with respect to admission NIHSS score or DWI lesion volume.
CI  - Copyright © 2015 National Stroke Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Agayeva, Nergiz
AU  - Agayeva N
AD  - Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, 
      Turkey.
FAU - Topcuoglu, Mehmet Akif
AU  - Topcuoglu MA
AD  - Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, 
      Turkey.
FAU - Arsava, Ethem Murat
AU  - Arsava EM
AD  - Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, 
      Turkey. Electronic address: arsavaem@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151111
PL  - United States
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National 
      Stroke Association
JID - 9111633
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/*therapeutic use
MH  - Brain Ischemia/*diagnosis/pathology
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Severity of Illness Index
MH  - Stroke/*diagnosis/pathology
OTO - NOTNLM
OT  - DWI
OT  - Ischemic stroke
OT  - antiplatelet
OT  - aspirin resistance
OT  - lesion volume
EDAT- 2015/11/19 06:00
MHDA- 2016/11/05 06:00
CRDT- 2015/11/19 06:00
PHST- 2015/07/06 00:00 [received]
PHST- 2015/08/22 00:00 [revised]
PHST- 2015/10/10 00:00 [accepted]
PHST- 2015/11/19 06:00 [entrez]
PHST- 2015/11/19 06:00 [pubmed]
PHST- 2016/11/05 06:00 [medline]
AID - S1052-3057(15)00549-2 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2015.10.011 [doi]
PST - ppublish
SO  - J Stroke Cerebrovasc Dis. 2016 Feb;25(2):397-403. doi: 
      10.1016/j.jstrokecerebrovasdis.2015.10.011. Epub 2015 Nov 11.

PMID- 32980138
OWN - NLM
STAT- MEDLINE
DCOM- 20211014
LR  - 20211014
IS  - 1532-3102 (Electronic)
IS  - 0143-4004 (Linking)
VI  - 102
DP  - 2020 Dec
TI  - Novel approaches to combat preeclampsia: from new drugs to innovative delivery.
PG  - 10-16
LID - S0143-4004(20)30283-6 [pii]
LID - 10.1016/j.placenta.2020.08.022 [doi]
AB  - Preeclampsia is a complex disease affecting 2-8% of pregnancies worldwide. It 
      poses significant risk of maternal and perinatal morbidity and mortality. Despite 
      the rising research interest to discover new therapeutic approaches to prevent 
      and treat preeclampsia, options remain limited. Identifying the important 
      pathological stages in the progression of this disease allows us to evaluate 
      effective candidate therapeutics. Three important stages in the pathophysiology 
      are: 1) placental hypoxia and oxidative stress, 2) excess release of 
      anti-angiogenic and pro-inflammatory factors, and 3) widespread systemic 
      endothelial dysfunction and vasoconstriction. Repurposing drugs already safe for 
      use in pregnancy is an attractive option for discovery of novel therapeutics. 
      There are many drugs currently being assessed to treat preeclampsia, including 
      proton pump inhibitors (PPIs), metformin, statins, sulfasalazine, sofalcone, 
      resveratrol, melatonin, and sildenafil citrate. These drugs show positive effects 
      in preclinical studies, targeting placental and endothelial dysfunction. However, 
      using novel therapeutics can raise safety concerns for the developing fetus. 
      Therefore, innovative targeted delivery systems are being developed to safely 
      administer these therapeutics directly to the placenta and/or endothelium. These 
      include nanoparticle delivery systems, developed and used by the oncology field, 
      now being adapted for obstetrics. This technology is currently being assessed in 
      animal models and shows promise for treating preeclampsia. Combining effective 
      therapeutics with targeted drug delivery could be the future of preeclampsia 
      treatment.
CI  - Copyright © 2020 Elsevier Ltd. All rights reserved.
FAU - de Alwis, Natasha
AU  - de Alwis N
AD  - Therapeutics Discovery and Vascular Function, Australia; Translational Obstetrics 
      Group, Department of Obstetrics and Gynaecology, University of Melbourne, 
      Australia; Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, 
      Australia.
FAU - Binder, Natalie K
AU  - Binder NK
AD  - Therapeutics Discovery and Vascular Function, Australia; Translational Obstetrics 
      Group, Department of Obstetrics and Gynaecology, University of Melbourne, 
      Australia; Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, 
      Australia.
FAU - Beard, Sally
AU  - Beard S
AD  - Therapeutics Discovery and Vascular Function, Australia; Translational Obstetrics 
      Group, Department of Obstetrics and Gynaecology, University of Melbourne, 
      Australia; Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, 
      Australia.
FAU - Kaitu'u-Lino, Tu'uhevaha J
AU  - Kaitu'u-Lino TJ
AD  - Translational Obstetrics Group, Department of Obstetrics and Gynaecology, 
      University of Melbourne, Australia; Mercy Perinatal, Mercy Hospital for Women, 
      Heidelberg, Victoria, Australia.
FAU - Tong, Stephen
AU  - Tong S
AD  - Translational Obstetrics Group, Department of Obstetrics and Gynaecology, 
      University of Melbourne, Australia; Mercy Perinatal, Mercy Hospital for Women, 
      Heidelberg, Victoria, Australia.
FAU - Brownfoot, Fiona
AU  - Brownfoot F
AD  - Translational Obstetrics Group, Department of Obstetrics and Gynaecology, 
      University of Melbourne, Australia; Mercy Perinatal, Mercy Hospital for Women, 
      Heidelberg, Victoria, Australia.
FAU - Hannan, Natalie J
AU  - Hannan NJ
AD  - Therapeutics Discovery and Vascular Function, Australia; Translational Obstetrics 
      Group, Department of Obstetrics and Gynaecology, University of Melbourne, 
      Australia; Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, 
      Australia. Electronic address: nhannan@unimelb.edu.au.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200905
PL  - Netherlands
TA  - Placenta
JT  - Placenta
JID - 8006349
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/therapeutic use
MH  - Cyclooxygenase Inhibitors/therapeutic use
MH  - Drug Delivery Systems
MH  - Female
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - Pre-Eclampsia/*drug therapy/etiology/prevention & control
MH  - Pregnancy
OTO - NOTNLM
OT  - Preeclampsia
OT  - Prevention
OT  - Therapeutics
OT  - Treatment
EDAT- 2020/09/28 06:00
MHDA- 2021/10/15 06:00
CRDT- 2020/09/27 20:21
PHST- 2020/08/05 00:00 [received]
PHST- 2020/08/30 00:00 [revised]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/28 06:00 [pubmed]
PHST- 2021/10/15 06:00 [medline]
PHST- 2020/09/27 20:21 [entrez]
AID - S0143-4004(20)30283-6 [pii]
AID - 10.1016/j.placenta.2020.08.022 [doi]
PST - ppublish
SO  - Placenta. 2020 Dec;102:10-16. doi: 10.1016/j.placenta.2020.08.022. Epub 2020 Sep 
      5.

PMID- 17386780
OWN - NLM
STAT- MEDLINE
DCOM- 20070511
LR  - 20181113
IS  - 1873-4324 (Electronic)
IS  - 0003-2670 (Print)
IS  - 0003-2670 (Linking)
VI  - 587
IP  - 2
DP  - 2007 Mar 28
TI  - Potentiometric response and mechanism of anionic recognition of 
      heterocalixarene-based ion selective electrodes.
PG  - 247-53
AB  - The ion selective electrode (ISE)-based potentiometric approach is shown to be an 
      effective means of characterizing the anion recognition sites in the molecular 
      receptor calix[2]pyridino[2]pyrrole (CPP). In particular, potentiometric 
      pH-measurements involving the use of experimental PVC-membranes based on CPP 
      revealed the existence of both mono- and diprotonated forms of the receptor under 
      readily accessible conditions. Based on these analyses, apparent surface 
      protonation constants for this heterocalixarene were found to lie between 8.5-8.9 
      (pK(B1)) and 3.3-3.8 (pK(B2)). CPP was found to interact with targeted anionic 
      analytes based on both coulombic and hydrogen bond interactions, as inferred from 
      varying the kinds of ionic sites present within the membrane phase. 
      Potentiometric selectivity studies revealed that CPP preferred "Y-shaped" anions 
      (e.g. acetate, lactate, benzoate) over spherical anions (e.g. fluoride and 
      chloride), fluoride over chloride within the set of spherical anions, and the 
      ortho-isomer over the corresponding meta- and para-isomers in the case of 
      hydroxybenzoate (salicylate and congeners). In the context of this study, the 
      advantages of potentiometric determinations of acetylsalicylic acid using 
      optimized PVC-membranes based on CPP relative to more conventional PVC-membrane 
      ISEs based on traditional anion exchanger were also demonstrated.
FAU - Shishkanova, T V
AU  - Shishkanova TV
AD  - Department of Analytical Chemistry, Institute of Chemical Technology, Technická 
      5, 166 28 Prague 6, Czech Republic. tatiana.shishkanova@vscht.cz 
      <tatiana.shishkanova@vscht.cz>
FAU - Sýkora, D
AU  - Sýkora D
FAU - Sessler, J L
AU  - Sessler JL
FAU - Král, V
AU  - Král V
LA  - eng
GR  - R01 GM058907/GM/NIGMS NIH HHS/United States
GR  - GM 58907/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20070121
PL  - Netherlands
TA  - Anal Chim Acta
JT  - Analytica chimica acta
JID - 0370534
RN  - 0 (Anions)
RN  - 0 (Ions)
RN  - 0 (Polymers)
RN  - 130036-26-9 (Calixarenes)
RN  - O414PZ4LPZ (Salicylic Acid)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anions/*chemistry
MH  - Aspirin/analysis
MH  - Binding Sites
MH  - Calixarenes/*chemistry
MH  - Chemistry Techniques, Analytical/*methods
MH  - Hydrogen Bonding
MH  - Hydrogen-Ion Concentration
MH  - *Ion-Selective Electrodes
MH  - Ions
MH  - Models, Chemical
MH  - Polymers/chemistry
MH  - Potentiometry/*methods
MH  - Salicylic Acid/chemistry
PMC - PMC1994929
MID - NIHMS20028
EDAT- 2007/03/28 09:00
MHDA- 2007/05/12 09:00
CRDT- 2007/03/28 09:00
PHST- 2006/11/29 00:00 [received]
PHST- 2007/01/17 00:00 [revised]
PHST- 2007/01/18 00:00 [accepted]
PHST- 2007/03/28 09:00 [pubmed]
PHST- 2007/05/12 09:00 [medline]
PHST- 2007/03/28 09:00 [entrez]
AID - S0003-2670(07)00182-1 [pii]
AID - 10.1016/j.aca.2007.01.044 [doi]
PST - ppublish
SO  - Anal Chim Acta. 2007 Mar 28;587(2):247-53. doi: 10.1016/j.aca.2007.01.044. Epub 
      2007 Jan 21.

PMID- 961860
OWN - NLM
STAT- MEDLINE
DCOM- 19761101
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 231
IP  - 1
DP  - 1976 Jul
TI  - Fever and antipyresis in the lizard Dipsosaurus dorsalis.
PG  - 198-203
AB  - Lizards (Dipsosaurus dorsalis) were placed in a desertlike environment in which 
      the ambient temperature (Ta) at night (1800-0600 h) was 12 degrees C and the day 
      (0600-1800 h) Ta was between 30 and 55 degrees C depending on the location within 
      the chamber. When dead Aeromonas hydrophila (4 X 10(9) organisms) was injected 
      into nine lizards, an elevation in body temperature (Tb) of 2.7 degrees C was 
      observed during the same day. On the day after bacterial injection the lizards' 
      body temperatures averaged 41.6 degrees C, an increase of 4.2 degrees C over 
      their control day Tb. Further investigations on the febrile response of D. 
      dorsalis were conducted at the University of Wisconsin's Biotron, where there 
      exists a simulated desert environment with the light intensity, temperature, and 
      humidity closely parelleling a typical spring day in the southwestern desert of 
      the United States (the natural habitat of Dipsosaurus). In this environment 
      injection of dead bacteria into seven lizards led to an average febrile response 
      of similar magnitude (Tb = 40.5 degrees C) but with a longer latency than that 
      found at the University of Michigan. Injection of 13 lizards with live A. 
      hydrophila (5 X 10(9) organism subcut.) in the simulated desert at Michigan led 
      to a daytime fever averaging 2.3 degrees C (mean Tb = 40.6 degrees C) over a 
      5-day period. During the 6th and 7th day the lizards' body temperature returned 
      to the normal or afebrile level. Injections of sodium salicylate along with dead 
      A. hydrophila resulted in a dose-dependent attenuation of the febrile response. 
      These results demonstrate that the reptilian febrile response is strikingly 
      similar to avian and mammalian fever and suggest a common origin and perhaps 
      function for the febrile mechanism.
FAU - Bernheim, H A
AU  - Bernheim HA
FAU - Kluger, M J
AU  - Kluger MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Endotoxins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aeromonas
MH  - Animals
MH  - Aspirin/pharmacology
MH  - *Body Temperature Regulation/drug effects
MH  - Desert Climate
MH  - Endotoxins/administration & dosage
MH  - Enterobacteriaceae Infections
MH  - Fever/*physiopathology
MH  - Hot Temperature
MH  - Lizards/*physiology
EDAT- 1976/07/01 00:00
MHDA- 1976/07/01 00:01
CRDT- 1976/07/01 00:00
PHST- 1976/07/01 00:00 [pubmed]
PHST- 1976/07/01 00:01 [medline]
PHST- 1976/07/01 00:00 [entrez]
AID - 10.1152/ajplegacy.1976.231.1.198 [doi]
PST - ppublish
SO  - Am J Physiol. 1976 Jul;231(1):198-203. doi: 10.1152/ajplegacy.1976.231.1.198.

PMID- 9842981
OWN - NLM
STAT- MEDLINE
DCOM- 19990201
LR  - 20181113
IS  - 0378-7966 (Print)
IS  - 0378-7966 (Linking)
VI  - 23
IP  - 3
DP  - 1998 Jul-Sep
TI  - Assessment of blood level with controlled-release dosage forms: effect of the 
      rate constant of elimination of the drug.
PG  - 383-9
AB  - Prediction of the drug level in the volume of distribution was made using a 
      numerical model taking into account the following facts: the kinetics of drug 
      release out of the dosage form along the gastrointestinal tract, the kinetics of 
      absorption in the blood compartment and the kinetics of elimination. Various 
      parameters intervene significantly for a given dosage form. Some emphasis was 
      placed upon the rate of elimination of the drug which appears to be the main 
      characteristic for the drug, especially when it is delivered through controlled 
      release dosage forms. The rate of release of the drug out of the dosage form, as 
      well as the dose frequency and the gastrointestinal transit time were also 
      considered. The drug level in the plasma was expressed by the amount of drug as a 
      fraction of the amount of drug initially located in the dosage form.
FAU - Aïnaoui, A
AU  - Aïnaoui A
AD  - Laboratory of Materials and Chemical Engineering, Faculty of Sciences, University 
      of St-Etienne, France.
FAU - Vergnaud, J M
AU  - Vergnaud JM
LA  - eng
PT  - Journal Article
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (Delayed-Action Preparations)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 80061L1WGD (Cimetidine)
RN  - C137DTR5RG (Theophylline)
RN  - K3Z4F929H6 (Lysine)
RN  - R16CO5Y76E (Aspirin)
RN  - XAN4V337CI (acetylsalicylic acid lysinate)
SB  - IM
MH  - Area Under Curve
MH  - Aspirin/administration & dosage/analogs & derivatives/blood/pharmacokinetics
MH  - Cimetidine/administration & dosage/blood/pharmacokinetics
MH  - Delayed-Action Preparations/administration & dosage/*pharmacokinetics
MH  - Drug Administration Schedule
MH  - Gastrointestinal Transit
MH  - Lysine/administration & dosage/analogs & derivatives/blood/pharmacokinetics
MH  - Metabolic Clearance Rate
MH  - Models, Biological
MH  - Statistics as Topic
MH  - Tamoxifen/administration & dosage/blood/pharmacokinetics
MH  - Theophylline/administration & dosage/blood/pharmacokinetics
EDAT- 1998/12/08 00:00
MHDA- 1998/12/08 00:01
CRDT- 1998/12/08 00:00
PHST- 1998/12/08 00:00 [pubmed]
PHST- 1998/12/08 00:01 [medline]
PHST- 1998/12/08 00:00 [entrez]
AID - 10.1007/BF03192298 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):383-9. doi: 
      10.1007/BF03192298.

PMID- 34167477
OWN - NLM
STAT- MEDLINE
DCOM- 20210716
LR  - 20210716
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jun 24
TI  - Association between tirofiban monotherapy and efficacy and safety in acute 
      ischemic stroke.
PG  - 237
LID - 10.1186/s12883-021-02268-8 [doi]
LID - 237
AB  - BACKGROUND: Studies have suggested that glycoprotein IIb/IIIa antagonists such as 
      tirofiban are beneficial for patients with acute coronary syndromes. However, it 
      is still uncertain about the efficacy and safety of tirofiban in patients with 
      acute ischemic stroke (AIS). METHODS: In this prospective non-randomized study, 
      255 AIS patients were recruited from 4 comprehensive stroke centers in China 
      between January, 2017 and May, 2018. Among them,169 patients were treated with 
      aspirin plus clopidogrel and 86 patients were treated with tirofiban. The primary 
      functional outcome was the distribution of the 90 days' modified Rankin Scale 
      (mRS). The safety outcomes included the incidence of intracranial hemorrhage 
      (ICH) at discharge and mortality at 3 months. RESULTS: In the propensity score 
      matched cohort, tirofiban alone was noninferior to the dual antiplatelet with 
      regard to the primary outcome (adjusted common odds ratio, 0.97; 95% confidence 
      interval, 0.46 to 2.04; P = 0.93). Mortality at 90 days was 10% in the dual 
      antiplatelet group and 8% in the tirofiban group (adjusted odds ratio 0.75; 95% 
      CI 0.08 to 7.40, p = 0.81). There was no difference of the ICH rate between two 
      groups (adjusted odds ratio 0.44; 95% CI 0.13 to 1.48, p = 0.18). In the inverse 
      probability of treatment weighting-propensity score-adjusted cohort, similar 
      differences were found for functional and safety outcomes. CONCLUSIONS: Our study 
      suggested that tirofiban use appears to be safe as monotherapy in AIS treatment 
      compared with common dual antiplatelet therapy, however, no improvement in 
      functional outcomes was found. TRIAL REGISTRATION: Chinese clinical trial 
      registry, ChiCTR2000034443 , 05/07/2020. Retrospectively registered.
FAU - Tao, Chunrong
AU  - Tao C
AD  - Stroke Center & Department of Neurology, Division of Life Sciences and Medicine, 
      the First Affiliated Hospital of USTC, University of Science and Technology of 
      China, Hefei, Anhui, China.
FAU - Zhu, Yuyou
AU  - Zhu Y
AD  - Stroke Center & Department of Neurology, Division of Life Sciences and Medicine, 
      the First Affiliated Hospital of USTC, University of Science and Technology of 
      China, Hefei, Anhui, China.
FAU - Zhang, Chao
AU  - Zhang C
AD  - Stroke Center & Department of Neurology, Division of Life Sciences and Medicine, 
      the First Affiliated Hospital of USTC, University of Science and Technology of 
      China, Hefei, Anhui, China.
FAU - Song, Jianlong
AU  - Song J
AD  - Stroke Center & Department of Neurology, Division of Life Sciences and Medicine, 
      the First Affiliated Hospital of USTC, University of Science and Technology of 
      China, Hefei, Anhui, China.
FAU - Liu, Tianlong
AU  - Liu T
AD  - Stroke Center & Department of Neurology, Division of Life Sciences and Medicine, 
      the First Affiliated Hospital of USTC, University of Science and Technology of 
      China, Hefei, Anhui, China.
FAU - Yuan, Xiaodong
AU  - Yuan X
AD  - Stroke Center & Department of Neurology, Division of Life Sciences and Medicine, 
      the First Affiliated Hospital of USTC, University of Science and Technology of 
      China, Hefei, Anhui, China.
FAU - Luo, Wenwu
AU  - Luo W
AD  - Department of Pathology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, China.
FAU - Chen, Changchun
AU  - Chen C
AD  - Department of Neurology, The Second People's Hospital of Anhui Province, Hefei, 
      Anhui, China.
FAU - Liu, Dezhi
AU  - Liu D
AD  - Department of Neurology, Shuguang Hospital Affiliated to Shanghai University of 
      TCM, 528 Zhang-Heng Road,Pu-Dong New Area, Shanghai, 201203, China.
FAU - Zhu, Yuanyuan
AU  - Zhu Y
AD  - People's Hospital of LiXin County, BoZhou City, 236700, AnHui Province, China.
FAU - Liu, Jie
AU  - Liu J
AD  - People's Hospital of LiXin County, BoZhou City, 236700, AnHui Province, China. 
      liujie866@126.com.
FAU - Hu, Wei
AU  - Hu W
AD  - Stroke Center & Department of Neurology, Division of Life Sciences and Medicine, 
      the First Affiliated Hospital of USTC, University of Science and Technology of 
      China, Hefei, Anhui, China. andinghu@ustc.edu.cn.
LA  - eng
GR  - 201904a07020086/the Key Research and Development Projects of Anhui Province/
PT  - Journal Article
DEP - 20210624
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
RN  - 0 (Fibrinolytic Agents)
RN  - A74586SNO7 (Clopidogrel)
RN  - GGX234SI5H (Tirofiban)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/adverse effects/therapeutic use
MH  - China
MH  - Clopidogrel/administration & dosage/adverse effects/therapeutic use
MH  - *Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic use
MH  - Humans
MH  - Intracranial Hemorrhages/chemically induced/epidemiology
MH  - *Ischemic Stroke/drug therapy/mortality
MH  - Prospective Studies
MH  - *Tirofiban/administration & dosage/adverse effects/therapeutic use
PMC - PMC8223269
OTO - NOTNLM
OT  - Acute ischemic stroke
OT  - Modified Rankin scale
OT  - Mortality
OT  - Tirofiban
COIS- The authors declare that they have no competing interests.
EDAT- 2021/06/26 06:00
MHDA- 2021/07/17 06:00
CRDT- 2021/06/25 05:36
PHST- 2020/11/16 00:00 [received]
PHST- 2021/06/04 00:00 [accepted]
PHST- 2021/06/25 05:36 [entrez]
PHST- 2021/06/26 06:00 [pubmed]
PHST- 2021/07/17 06:00 [medline]
AID - 10.1186/s12883-021-02268-8 [pii]
AID - 2268 [pii]
AID - 10.1186/s12883-021-02268-8 [doi]
PST - epublish
SO  - BMC Neurol. 2021 Jun 24;21(1):237. doi: 10.1186/s12883-021-02268-8.

PMID- 19361598
OWN - NLM
STAT- MEDLINE
DCOM- 20090430
LR  - 20220408
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 103
IP  - 8
DP  - 2009 Apr 15
TI  - Combination antiplatelet therapy for secondary stroke prevention: enhanced 
      efficacy or double trouble?
PG  - 1107-12
LID - 10.1016/j.amjcard.2009.01.003 [doi]
AB  - The evaluation of antithrombotic agents for secondary stroke prevention has 
      focused on stroke reduction. The aim of this analysis was to focus specifically 
      on the increase in bleeding risk. The annualized rates of total and major 
      bleeding events in secondary stroke prevention trials of antithrombotics were 
      assessed and cross compared. A Medline search for major randomized clinical 
      studies with a follow-up duration of > or =1 year identified 13 studies. Pooled 
      data sets were used to compare mean bleeding rates for aspirin (< or =325 
      mg/day), clopidogrel, anticoagulants (warfarin and other vitamin K antagonists), 
      aspirin plus clopidogrel, and aspirin plus extended-release dipyridamole (ER-DP). 
      Total bleeding occurred at mean rates of 4.8% with aspirin (< or =325 mg/day) 
      alone, 2.9% with clopidogrel alone, 3.6% with aspirin plus ER-DP, 10.1% with 
      aspirin plus clopidogrel, and 16.8% with anticoagulation. Major bleeding occurred 
      at mean rates of 1% with aspirin (< or =325 mg/day) alone, 0.85% with 
      clopidogrel, 0.93% with aspirin plus ER-DP, 1.7% with aspirin plus clopidogrel, 
      and 2.5% with anticoagulation. In conclusion, the combination of aspirin and 
      clopidogrel is associated with significantly greater bleeding than either aspirin 
      (< or =325 mg/day) or clopidogrel alone. Aspirin plus ER-DP has a greater 
      bleeding rate than clopidogrel but a lower rate than aspirin (< or =325 mg/day) 
      alone.
FAU - Usman, M Haris U
AU  - Usman MH
AD  - Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA.
FAU - Notaro, Lawrence A
AU  - Notaro LA
FAU - Nagarakanti, Rangadham
AU  - Nagarakanti R
FAU - Brahin, Eric
AU  - Brahin E
FAU - Dessain, Scott
AU  - Dessain S
FAU - Gracely, Edward
AU  - Gracely E
FAU - Ezekowitz, Michael D
AU  - Ezekowitz MD
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090304
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Anticoagulants)
RN  - 0 (Aspirin, Dipyridamole Drug Combination)
RN  - 0 (Drug Combinations)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/administration & dosage
MH  - Aspirin/*administration & dosage
MH  - Aspirin, Dipyridamole Drug Combination
MH  - Clopidogrel
MH  - Dipyridamole/*administration & dosage
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Stroke/*prevention & control
MH  - Ticlopidine/administration & dosage/*analogs & derivatives
MH  - Treatment Outcome
RF  - 39
EDAT- 2009/04/14 09:00
MHDA- 2009/05/01 09:00
CRDT- 2009/04/14 09:00
PHST- 2008/10/08 00:00 [received]
PHST- 2009/01/05 00:00 [revised]
PHST- 2009/01/05 00:00 [accepted]
PHST- 2009/04/14 09:00 [entrez]
PHST- 2009/04/14 09:00 [pubmed]
PHST- 2009/05/01 09:00 [medline]
AID - S0002-9149(09)00033-2 [pii]
AID - 10.1016/j.amjcard.2009.01.003 [doi]
PST - ppublish
SO  - Am J Cardiol. 2009 Apr 15;103(8):1107-12. doi: 10.1016/j.amjcard.2009.01.003. 
      Epub 2009 Mar 4.

PMID- 28141566
OWN - NLM
STAT- MEDLINE
DCOM- 20170510
LR  - 20220310
IS  - 0974-7559 (Electronic)
IS  - 0019-6061 (Linking)
VI  - 54
IP  - 1
DP  - 2017 Jan 15
TI  - Dengue Fever Triggering Kawasaki Disease.
PG  - 51-52
AB  - BACKGROUND: Several bacterial and viral infections are listed as triggering 
      factors for Kawasaki disease; association with dengue fever is rare. CASE 
      CHARACTERISTICS: A 5-year-old girl who presented with fever that was confirmed to 
      be dengue fever, and subsequently improved, except that the fever persisted. She 
      fulfilled diagnostic criteria for Kawasaki disease on day 7 of fever. OUTCOME: 
      Child responded satisfactorily to intravenous immunoglobulin administration. 
      MESSAGE: Kawasaki disease should be kept as one of the probabilities in a case of 
      dengue if fever persists beyond the expected duration.
FAU - Agarwal, Ekta
AU  - Agarwal E
AD  - Department of Pediatrics, University College of Medical Sciences, Dilshad Garden, 
      Delhi, India. Correspondence to: Dr Piyush Gupta, Block R6A, Dilshad Garden, 
      Delhi 110 095, India. prof.piyush.gupta@gmail.com.
FAU - Shah, Dheeraj
AU  - Shah D
FAU - Gupta, Piyush
AU  - Gupta P
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - India
TA  - Indian Pediatr
JT  - Indian pediatrics
JID - 2985062R
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Child, Preschool
MH  - Dengue/*complications
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - *Mucocutaneous Lymph Node Syndrome/drug therapy/etiology
EDAT- 2017/02/01 06:00
MHDA- 2017/05/11 06:00
CRDT- 2017/02/01 06:00
PHST- 2017/02/01 06:00 [entrez]
PHST- 2017/02/01 06:00 [pubmed]
PHST- 2017/05/11 06:00 [medline]
AID - 10.1007/s13312-017-0997-2 [doi]
PST - ppublish
SO  - Indian Pediatr. 2017 Jan 15;54(1):51-52. doi: 10.1007/s13312-017-0997-2.

PMID- 8935397
OWN - NLM
STAT- MEDLINE
DCOM- 19970114
LR  - 20181113
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 8
IP  - 5
DP  - 1996 May
TI  - Optimal treatment of angina in older patients.
PG  - 349-57
AB  - Ischaemic heart disease is a major problem in the elderly. Compared with younger 
      patients, coexisting medical conditions are more common and the patients are more 
      likely to be receiving multiple drugs. In addition, drug pharmacodynamics are 
      altered in the elderly and this needs to be carefully considered when commencing 
      treatment for angina. In practice, the general principles of management of 
      elderly patients with angina are similar to that of younger patients. However, 
      particular care needs to be taken with the therapeutic regimens used. This 
      article reviews the approach to the treatment of stable exertional angina in the 
      elderly.
FAU - Doughty, R N
AU  - Doughty RN
AD  - Department of Medicine, University of Auckland School of Medicine, New Zealand.
FAU - Sharpe, N
AU  - Sharpe N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Nitrates)
RN  - 0 (Vasodilator Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Age Factors
MH  - Aged
MH  - Angina Pectoris/*therapy
MH  - Angioplasty, Balloon, Laser-Assisted
MH  - Aspirin/therapeutic use
MH  - Cardiotonic Agents/*therapeutic use
MH  - Humans
MH  - Nitrates/therapeutic use
MH  - Vasodilator Agents/*therapeutic use
RF  - 39
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 10.2165/00002512-199608050-00004 [doi]
PST - ppublish
SO  - Drugs Aging. 1996 May;8(5):349-57. doi: 10.2165/00002512-199608050-00004.

PMID- 2428187
OWN - NLM
STAT- MEDLINE
DCOM- 19861002
LR  - 20161123
IS  - 0044-409X (Print)
IS  - 0044-409X (Linking)
VI  - 111
IP  - 11
DP  - 1986
TI  - [Prevention of deep venous thrombosis in hip surgery].
PG  - 633-9
AB  - The prophylactic effectiveness of aggregation inhibitors, low heparin dosage, and 
      preoperative normovolaemic haemodilution was studied by the authors in the 
      context of three comparable groups of patients with deep phlebothrombosis. All 
      patients received hip joint substitutes, including artificial heads of the hip in 
      cases of femoral collum fractures or total hip prosthesis in cases of arthrosis 
      deformans. Patients were monitored by fibrinogen tests and ascending 
      phlebography. Results are likely to produce evidence to the effect that 
      haemodilution is an effective method for treatment of deep phlebothrombosis.
FAU - Vara-Thorbeck, R
AU  - Vara-Thorbeck R
FAU - Rosell-Pradas, J
AU  - Rosell-Pradas J
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Prophylaxe der tiefen Venenthrombose (T.V.T.) in der Hüftchirurgie.
PL  - Germany
TA  - Zentralbl Chir
JT  - Zentralblatt fur Chirurgie
JID - 0413645
RN  - 0 (Dextrans)
RN  - 37270-89-6 (calcium heparin)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Dextrans/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Early Ambulation
MH  - Hemodilution
MH  - Heparin/therapeutic use
MH  - *Hip Prosthesis
MH  - Humans
MH  - Postoperative Complications/*prevention & control
MH  - Risk
MH  - Thrombophlebitis/*prevention & control
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - Zentralbl Chir. 1986;111(11):633-9.

PMID- 6147164
OWN - NLM
STAT- MEDLINE
DCOM- 19840928
LR  - 20131121
IS  - 0365-9615 (Print)
IS  - 0365-9615 (Linking)
VI  - 98
IP  - 7
DP  - 1984 Jul
TI  - [Experimental study of the interaction of nonsteroidal anti-inflammatory 
      agents--voltaren and acetylsalicylic acid--with beta-adrenoblockers].
PG  - 48-51
AB  - It has been demonstrated in rat experiments that the beta-adrenoblockers 
      propranolol and pindolol differ in the influence on the therapeutic and toxic 
      effects of voltaren and acetylsalicylic acid. Propranolol has an analgetic action 
      of its own, reducing the analgetic and antiinflammatory effects of voltaren and 
      acetylsalicylic acid. It potentiates the antipyretic effect of voltaren and 
      ulcerogenic action of both nonsteroidal antiinflammatory drugs. Pindolol exerts 
      both analgetic and antiinflammatory action and does not affect the antipyretic 
      effect of voltaren and ulcerogenic action of nonsteroidal antiinflammatory drugs. 
      The difference in the action of the beta-adrenoblockers under study is likely to 
      be linked with the characteristics of their pharmacological action spectrum.
FAU - Siubaev, R D
AU  - Siubaev RD
FAU - Shvarts, G Ia
AU  - Shvarts GIa
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Izuchenie vzaimodeĭstviia nesteroidnykh protivospalitel'nykh sredstv--vol'tarena 
      i atsetilsalitsilovoĭ kisloty--s beta-adrenoblokatorami v éksperimente.
PL  - Russia (Federation)
TA  - Biull Eksp Biol Med
JT  - Biulleten' eksperimental'noi biologii i meditsiny
JID - 0370627
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Phenylacetates)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 9Y8NXQ24VQ (Propranolol)
RN  - BJ4HF6IU1D (Pindolol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Aspirin/*pharmacology
MH  - Diclofenac/*pharmacology
MH  - Drug Interactions
MH  - Male
MH  - Phenylacetates/*pharmacology
MH  - Pindolol/pharmacology
MH  - Propranolol/pharmacology
MH  - Rats
EDAT- 1984/07/01 00:00
MHDA- 1984/07/01 00:01
CRDT- 1984/07/01 00:00
PHST- 1984/07/01 00:00 [pubmed]
PHST- 1984/07/01 00:01 [medline]
PHST- 1984/07/01 00:00 [entrez]
PST - ppublish
SO  - Biull Eksp Biol Med. 1984 Jul;98(7):48-51.

PMID- 6972830
OWN - NLM
STAT- MEDLINE
DCOM- 19810922
LR  - 20131121
IS  - 0300-5089 (Print)
IS  - 0300-5089 (Linking)
VI  - 10
IP  - 1
DP  - 1981 Jan
TI  - Severe upper gastrointestinal bleeding. Part I: Causes, pathogenesis and methods 
      of diagnosis.
PG  - 17-26
AB  - Upper gastrointestinal bleeding is a common gastrointestinal emergency associated 
      with significant socioeconomic impact, morbidity and mortality. The aetiology of 
      upper gastrointestinal bleeding has been reviewed, including the 
      pathophysiological mechanisms of acid peptic and gastric mucosal disease. The 
      initial diagnosis and therapeutic approach to the bleeding patient has been 
      outlined.
FAU - Protell, R L
AU  - Protell RL
FAU - Silverstein, F E
AU  - Silverstein FE
FAU - Gilbert, D A
AU  - Gilbert DA
FAU - Feld, A D
AU  - Feld AD
LA  - eng
GR  - 5T32 AM 07113/AM/NIADDK NIH HHS/United States
GR  - N01-AM-52211/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Clin Gastroenterol
JT  - Clinics in gastroenterology
JID - 0365261
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiography
MH  - Aspirin/adverse effects
MH  - Duodenal Ulcer/complications
MH  - Endoscopy
MH  - Gastric Mucosa/drug effects
MH  - Gastrointestinal Hemorrhage/diagnosis/*etiology
MH  - Humans
MH  - Inhalation
EDAT- 1981/01/01 00:00
MHDA- 1981/01/01 00:01
CRDT- 1981/01/01 00:00
PHST- 1981/01/01 00:00 [pubmed]
PHST- 1981/01/01 00:01 [medline]
PHST- 1981/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Gastroenterol. 1981 Jan;10(1):17-26.

PMID- 7365415
OWN - NLM
STAT- MEDLINE
DCOM- 19800627
LR  - 20220216
IS  - 0022-0949 (Print)
IS  - 0022-0949 (Linking)
VI  - 84
DP  - 1980 Feb
TI  - Ionic and osmotic influence on prostaglandin release from the gill tissue of a 
      marine bivalve, Modiolus demissus.
PG  - 169-85
AB  - 1. Prostaglandin E2 (PGE2) was identified in Modiolus demissus gill tissue on the 
      basis of solvent extraction, thin layer and column chromatography, bioassay, and 
      radioimmunoassay. The presence of PGE2 was detected in both tissue and sea water 
      incubate surrounding the tissue. 2. Both hyposmotic stress and magnesium-free sea 
      water significantly increased release of prostaglandins into sea water. 
      Hyposmotic stress also significantly increased prostaglandin synthesis. 3. 
      Examination of tissues revealed that homogenates of the mantle and lower visceral 
      mass contained significantly fewer nanograms immunoreactive prostaglandins per 
      gram wet weight than homogenates of the gill, posterior adductor muscle, upper 
      visceral mass, or siphon tissue. 4. Prostaglandin release could be increased by 
      addition of arachidonic acid, and inhibited by addition of acetylsalicylic acid 
      or indomethacin.
FAU - Freas, W
AU  - Freas W
FAU - Grollman, S
AU  - Grollman S
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Exp Biol
JT  - The Journal of experimental biology
JID - 0243705
RN  - 0 (Prostaglandins)
RN  - 60-24-2 (Mercaptoethanol)
RN  - 9NEZ333N27 (Sodium)
RN  - I38ZP9992A (Magnesium)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Gills/physiology
MH  - Indomethacin/pharmacology
MH  - Magnesium/physiology
MH  - Mercaptoethanol/pharmacology
MH  - Mollusca/*physiology
MH  - Osmolar Concentration
MH  - Prostaglandins/*metabolism
MH  - Radioimmunoassay
MH  - Sodium/pharmacology
MH  - *Water-Electrolyte Balance
EDAT- 1980/02/01 00:00
MHDA- 1980/02/01 00:01
CRDT- 1980/02/01 00:00
PHST- 1980/02/01 00:00 [pubmed]
PHST- 1980/02/01 00:01 [medline]
PHST- 1980/02/01 00:00 [entrez]
AID - 10.1242/jeb.84.1.169 [doi]
PST - ppublish
SO  - J Exp Biol. 1980 Feb;84:169-85. doi: 10.1242/jeb.84.1.169.

PMID- 263759
OWN - NLM
STAT- MEDLINE
DCOM- 19810922
LR  - 20131121
IS  - 0047-2603 (Print)
IS  - 0047-2603 (Linking)
VI  - 10
IP  - 4
DP  - 1978 Dec
TI  - Determination of brain death via pulsatile echoencephalography.
PG  - 150-5
AB  - For cerebral death to occur there must be many levels of cerebral function 
      destroyed. Cortical and subcortical irreversible damage is evident by 
      unresponsiveness to any stimuli. Brain stem and basal ganglia damage is indicated 
      by absence of spontaneous respirations, cephalic reflexes, and thus cerebral 
      circulation. All elements of the criteria for cerebral death must be met. The 
      decision should be made by the attending physician in consultation with his 
      peers. The life support mechanisms should be discontinued after the diagnosis of 
      cerebral death has been made. Absence of pulsatile echoes means absence of 
      cerebral circulation and cerebral function, or a definitive diagnosis of cerebral 
      death. It is a final parameter in the criteria and allows definite measures to be 
      taken. But it behooves one to remember that this phenomenon of cerebral death 
      makes organ donation and transplantation possible. It has not been created in 
      order to supply the needs for organ transplant!
FAU - McDonald, L
AU  - McDonald L
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Neurosurg Nurs
JT  - Journal of neurosurgical nursing
JID - 1300146
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/poisoning
MH  - *Brain Death
MH  - Brain Diseases/chemically induced
MH  - Brain Injuries/diagnosis
MH  - Cerebrovascular Circulation
MH  - Echoencephalography/*methods
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1978/12/01 00:00
MHDA- 1978/12/01 00:01
CRDT- 1978/12/01 00:00
PHST- 1978/12/01 00:00 [pubmed]
PHST- 1978/12/01 00:01 [medline]
PHST- 1978/12/01 00:00 [entrez]
PST - ppublish
SO  - J Neurosurg Nurs. 1978 Dec;10(4):150-5.

PMID- 52970
OWN - NLM
STAT- MEDLINE
DCOM- 19760130
LR  - 20151119
IS  - 0001-5555 (Print)
IS  - 0001-5555 (Linking)
VI  - 55
IP  - 5
DP  - 1975
TI  - Abnormal cutaneous reactions in dermatitis herpetiformis.
PG  - 351-8
AB  - In 94% of the patients with dermatitis herpetiformis, a locally applied ointment 
      with an ester of nicotinic acid (Trafuril) induced an abnormal reaction with 
      erythema, edema, papules, and often vesicles. The appearance of the reaction to 
      Trafuril is similar to DH lesions. It differs markedly from the reactions to 
      iodide where, as a rule, only one large blister results. The reaction is most 
      pronounced 12-24 hours after application of Trafuril. The reactivity is strongest 
      in the predilection areas for dermatitis herpetiformis. Strongly increased 
      reactivity to Trafuril in DH is induced by pretreatment with streptokinase, 
      streptokinase-streptodornase, or urokinase. Diminished reactivity to Trafuril is 
      seen after pretreatment with injections of Compound 48/80, tranexamic acid, 
      cromoglycate, or application of fluocinolone-acetonide, as well as after stroking 
      the skin.
FAU - Michaëlsson, G
AU  - Michaëlsson G
FAU - Svensson, L
AU  - Svensson L
LA  - eng
PT  - Journal Article
PL  - Sweden
TA  - Acta Derm Venereol
JT  - Acta dermato-venereologica
JID - 0370310
RN  - 0 (Nicotinic Acids)
RN  - 0 (Ointments)
RN  - 8W5C518302 (Dapsone)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Biopsy
MH  - Dapsone/therapeutic use
MH  - Dermatitis Herpetiformis/*diagnosis/drug therapy
MH  - Drug Hypersensitivity
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Nicotinic Acids
MH  - Ointments
MH  - Skin/pathology
MH  - Skin Tests
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Derm Venereol. 1975;55(5):351-8.

PMID- 27208561
OWN - NLM
STAT- MEDLINE
DCOM- 20170209
LR  - 20170209
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 49
IP  - 15
DP  - 2016 Oct
TI  - Aspirin resistance may be identified by miR-92a in plasma combined with platelet 
      distribution width.
PG  - 1167-1172
LID - S0009-9120(16)30054-6 [pii]
LID - 10.1016/j.clinbiochem.2016.04.017 [doi]
AB  - OBJECTIVE: Aspirin is a widely used drug for prevention of thrombotic events in 
      cardiovascular patients, but approximately 25% of patients experience 
      insufficient platelet inhibition due to aspirin, and remain in risk of 
      cardiovascular events. This study aimed to investigate the value of circulating 
      miR-92a and platelet size as biomarkers of the individual response to aspirin 
      therapy. METHODS: Blood samples were collected from 50 healthy blood donors 
      without antithrombotic medication and 50 patients with intermittent claudication 
      on daily aspirin therapy. Based on results from the arachidonic acid stimulated 
      aggregation test on Multiplate®analyzer (ASPItest), patients were defined as 
      aspirin resistant (n=10) or aspirin responders (n=40). Plasma levels of miR-92a 
      were evaluated by RT-qPCR analysis and platelet distribution width (PDW) was used 
      to assess platelet size variability. Receiver operating characteristic curves for 
      miR-92a levels and PDW were used to set cut-off values for discrimination between 
      aspirin responding and aspirin resistant patients. RESULTS: When defining aspirin 
      resistance as an ASPItest ≥30U, the optimal cut-off values for discrimination of 
      aspirin responders and aspirin resistant patients were found to be PDW>11.8fL and 
      a relative expression level of miR-92a>4.5. Using these cut-off values we could 
      define a PDW/miR-92a-score with a specificity of 97.5% and a sensitivity of 80.0% 
      in relation to detect aspirin resistance. The corresponding positive and negative 
      predictive values were found to be 88.9% and 95.1%, respectively. CONCLUSION: 
      Aspirin resistance can potentially be identified by miR-92a levels in plasma 
      combined with PDW.
CI  - Copyright © 2016 The Canadian Society of Clinical Chemists. Published by Elsevier 
      Inc. All rights reserved.
FAU - Binderup, Helle Glud
AU  - Binderup HG
AD  - Department of Clinical Immunology and Biochemistry, Lillebaelt Hospital, 
      Kabbeltoft 25, 7100 Vejle and Skovvangen 2-8, 6000 Kolding, Denmark. Electronic 
      address: Helle.Glud.Binderup@rsyd.dk.
FAU - Houlind, Kim
AU  - Houlind K
AD  - Department of Vascular Surgery, Lillebaelt Hospital, Skovvangen 2-8, 6000 
      Kolding, Denmark; Institute of Regional Health Research, University of Southern 
      Denmark, Denmark.
FAU - Madsen, Jonna Skov
AU  - Madsen JS
AD  - Department of Clinical Immunology and Biochemistry, Lillebaelt Hospital, 
      Kabbeltoft 25, 7100 Vejle and Skovvangen 2-8, 6000 Kolding, Denmark; Institute of 
      Regional Health Research, University of Southern Denmark, Denmark.
FAU - Brasen, Claus Lohman
AU  - Brasen CL
AD  - Department of Clinical Immunology and Biochemistry, Lillebaelt Hospital, 
      Kabbeltoft 25, 7100 Vejle and Skovvangen 2-8, 6000 Kolding, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20160518
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - 0 (MIRN92 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*pharmacology
MH  - Blood Platelets/*cytology
MH  - Case-Control Studies
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Intermittent Claudication/blood
MH  - Male
MH  - MicroRNAs/*blood
MH  - Middle Aged
MH  - Platelet Aggregation
OTO - NOTNLM
OT  - Anti-platelet therapy
OT  - Aspirin resistance
OT  - Biomarker
OT  - MicroRNA-92a
OT  - PDW
EDAT- 2016/05/22 06:00
MHDA- 2017/02/10 06:00
CRDT- 2016/05/22 06:00
PHST- 2015/10/08 00:00 [received]
PHST- 2016/04/15 00:00 [revised]
PHST- 2016/04/16 00:00 [accepted]
PHST- 2016/05/22 06:00 [pubmed]
PHST- 2017/02/10 06:00 [medline]
PHST- 2016/05/22 06:00 [entrez]
AID - S0009-9120(16)30054-6 [pii]
AID - 10.1016/j.clinbiochem.2016.04.017 [doi]
PST - ppublish
SO  - Clin Biochem. 2016 Oct;49(15):1167-1172. doi: 10.1016/j.clinbiochem.2016.04.017. 
      Epub 2016 May 18.

PMID- 14564234
OWN - NLM
STAT- MEDLINE
DCOM- 20031209
LR  - 20191210
IS  - 1530-6550 (Print)
IS  - 1530-6550 (Linking)
VI  - 4 Suppl 3
DP  - 2003
TI  - Critical pathways for acute myocardial infarction.
PG  - S47-53
AB  - Critical pathways are standardized protocols for optimizing and streamlining 
      patient care. They are important in the management of patients with acute 
      myocardial infarction, many of whom do not receive evidence-based therapies. 
      Several studies have demonstrated that the development and implementation of 
      critical pathways that follow published guidelines and are tailored to the needs 
      and resources of each institution result in increased use of evidence-based 
      therapies, such as aspirin and beta-blockers, and is associated with decreased 
      mortality. Use of these protocols has also been shown to reduce unnecessary 
      therapy and under- or overutilization of certain procedures, thereby resulting in 
      more cost-effective treatment.
FAU - Cannon, Christopher P
AU  - Cannon CP
AD  - Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and 
      Harvard Medical School, Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Singapore
TA  - Rev Cardiovasc Med
JT  - Reviews in cardiovascular medicine
JID - 100960007
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Anticoagulants/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Critical Pathways
MH  - Humans
MH  - Myocardial Infarction/drug therapy/*therapy
MH  - Outcome Assessment, Health Care
MH  - Patient Selection
MH  - Risk Factors
RF  - 17
EDAT- 2003/10/18 05:00
MHDA- 2003/12/10 05:00
CRDT- 2003/10/18 05:00
PHST- 2003/10/18 05:00 [pubmed]
PHST- 2003/12/10 05:00 [medline]
PHST- 2003/10/18 05:00 [entrez]
PST - ppublish
SO  - Rev Cardiovasc Med. 2003;4 Suppl 3:S47-53.

PMID- 12957769
OWN - NLM
STAT- MEDLINE
DCOM- 20031209
LR  - 20190816
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 90
IP  - 2-3
DP  - 2003 Aug
TI  - Massive chronic atrial thrombosis.
PG  - 323-4
AB  - We report herein a patient in whom a very large and old thrombus in the left 
      atrium was detected by transesophageal echocardiography. The patient started 
      warfarin and aspirin. After 2 years of therapy, transesophageal echocardiography 
      showed the complete resolution of thrombus in the absence of clinical evidence of 
      embolism. This case indicates that large and presumably organized thrombi may be 
      dissolved by an anticoagulant therapy, although the lytic activity of warfarin 
      has never been demonstrated. Transesophageal echocardiography helps in the 
      identification and follow-up of such conditions and contributes to understanding 
      of warfarin action in left atrial thrombosis.
FAU - Losi, Maria Angela
AU  - Losi MA
AD  - Department of Clinical Medicine and Cardiovascular and Immunological Sciences, 
      Federico II University-School of Medicine, Via Pansini 5, 80131 Naples, Italy. 
      losi@unina.it
FAU - Golino, Paolo
AU  - Golino P
FAU - Betocchi, Sandro
AU  - Betocchi S
FAU - Ragni, Massimo
AU  - Ragni M
FAU - Aversa, Mariano
AU  - Aversa M
FAU - Chiariello, Massimo
AU  - Chiariello M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Chronic Disease
MH  - Coronary Thrombosis/*diagnostic imaging/*drug therapy
MH  - Drug Therapy, Combination
MH  - Echocardiography, Transesophageal
MH  - Heart Atria
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Warfarin/*therapeutic use
EDAT- 2003/09/06 05:00
MHDA- 2003/12/11 05:00
CRDT- 2003/09/06 05:00
PHST- 2003/09/06 05:00 [pubmed]
PHST- 2003/12/11 05:00 [medline]
PHST- 2003/09/06 05:00 [entrez]
AID - S0167527302005089 [pii]
AID - 10.1016/s0167-5273(02)00508-9 [doi]
PST - ppublish
SO  - Int J Cardiol. 2003 Aug;90(2-3):323-4. doi: 10.1016/s0167-5273(02)00508-9.

PMID- 8458669
OWN - NLM
STAT- MEDLINE
DCOM- 19930423
LR  - 20171206
IS  - 0391-3988 (Print)
IS  - 0391-3988 (Linking)
VI  - 16
IP  - 1
DP  - 1993 Jan
TI  - Maintaining the patency of double-lumen silastic jugular catheters for 
      haemodialysis.
PG  - 37-40
AB  - A system has been developed for maintaining the patency of double lumen silastic 
      jugular catheters in patients with refractory vascular access problems. Most 
      patients receive a small daily dose of aspirin. Selected patients also receive 
      warfarin to maintain a prothrombin time (PT) of 15, 20, or 30 seconds. Inadequate 
      blood flow due to thrombus obstruction can be overcome by the intravenous 
      administration of urokinase, 250.000 units. This can be administered safely to 
      outpatients provided that heparin is not given simultaneously. Occasionally a 
      second dose may be required. By adopting this policy all catheter obstructions 
      have been overcome. The danger of iatrogenic bleeding cannot be discounted. 
      Warfarin therapy must be very closely monitored.
FAU - Uldall, R
AU  - Uldall R
AD  - Division of Nephrology, Toronto Hospital, Canada.
FAU - Besley, M E
AU  - Besley ME
FAU - Thomas, A
AU  - Thomas A
FAU - Salter, S
AU  - Salter S
FAU - Nuezca, L A
AU  - Nuezca LA
FAU - Vas, M
AU  - Vas M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Artif Organs
JT  - The International journal of artificial organs
JID - 7802649
RN  - 5Q7ZVV76EI (Warfarin)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Catheterization, Central Venous/adverse effects
MH  - *Catheters, Indwelling/adverse effects
MH  - Female
MH  - Humans
MH  - Jugular Veins
MH  - Male
MH  - *Renal Dialysis
MH  - Urokinase-Type Plasminogen Activator/therapeutic use
MH  - Warfarin/therapeutic use
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Artif Organs. 1993 Jan;16(1):37-40.

PMID- 6861813
OWN - NLM
STAT- MEDLINE
DCOM- 19830811
LR  - 20131121
IS  - 0140-1610 (Print)
IS  - 0140-1610 (Linking)
VI  - 6
IP  - 1
DP  - 1983
TI  - Pharmacokinetics of piroxicam in man.
PG  - 46-55
AB  - Piroxicam is a potent antiinflammatory agent currently in widespread use for the 
      treatment of various inflammatory conditions of man. Following single oral doses 
      of 10 to 100 mg, piroxicam is rapidly and fully absorbed, and eliminated with a 
      mean plasma half life of about 45 hr. Mean peak concentrations are about 2 
      micrograms/ml after single 20 mg doses and about 6 micrograms/ml at steady state 
      with 20 mg daily. Multiple peaking suggests enterohepatic recirculation of drug. 
      In accord with expectations, steady state is achieved within 7 to 12 days with no 
      appreciable accumulation thereafter. Due to the long plasma half life, once daily 
      dosing provides continuous exposure to drug, with concentrations fluctuating less 
      than twofold. Coadministration of aspirin reduces piroxicam levels by about 20 
      percent; antacids have no effect on piroxicam plasma concentrations.
FAU - Hobbs, D C
AU  - Hobbs DC
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Rheumatol Inflamm
JT  - European journal of rheumatology and inflammation
JID - 7805765
RN  - 0 (Antacids)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Thiazines)
RN  - 13T4O6VMAM (Piroxicam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antacids/pharmacology
MH  - Anti-Inflammatory Agents/blood/*metabolism
MH  - Aspirin/pharmacology
MH  - Drug Interactions
MH  - Half-Life
MH  - Humans
MH  - Kinetics
MH  - Piroxicam
MH  - Thiazines/blood/*metabolism
MH  - Time Factors
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
PST - ppublish
SO  - Eur J Rheumatol Inflamm. 1983;6(1):46-55.

PMID- 7221799
OWN - NLM
STAT- MEDLINE
DCOM- 19810625
LR  - 20161123
IS  - 0256-9574 (Print)
VI  - 59
IP  - 20
DP  - 1981 May 9
TI  - Hepatic involvement in systemic lupus erythematosus. A case report.
PG  - 726-8
AB  - The existence of hepatic involvement in systemic lupus erythematosus (SLE) is 
      still contested in the literature. We report a patient with SLE and deranged 
      liver function tests, especially marked elevation of alkaline phosphatase levels, 
      an association not hitherto described. These changes have persisted for 3 1/2 
      years with no evidence of chronic active hepatitis (CAH) on liver biopsy or 
      biliary obstruction. Current concepts of liver involvement in SLE, 'lupoid' 
      hepatitis and aspirin hepatotoxicity are reviewed.
FAU - Forman, M B
AU  - Forman MB
FAU - Levy, H
AU  - Levy H
FAU - Gear, A J
AU  - Gear AJ
FAU - Ninin, D T
AU  - Ninin DT
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Alkaline Phosphatase/analysis
MH  - Aspirin/adverse effects
MH  - Chemical and Drug Induced Liver Injury/etiology
MH  - Female
MH  - Humans
MH  - Liver/enzymology/*metabolism
MH  - Liver Diseases/*etiology
MH  - Liver Function Tests
MH  - Lupus Erythematosus, Systemic/*complications/metabolism
EDAT- 1981/05/09 00:00
MHDA- 1981/05/09 00:01
CRDT- 1981/05/09 00:00
PHST- 1981/05/09 00:00 [pubmed]
PHST- 1981/05/09 00:01 [medline]
PHST- 1981/05/09 00:00 [entrez]
PST - ppublish
SO  - S Afr Med J. 1981 May 9;59(20):726-8.

PMID- 570807
OWN - NLM
STAT- MEDLINE
DCOM- 19790516
LR  - 20190716
IS  - 0002-9629 (Print)
IS  - 0002-9629 (Linking)
VI  - 277
IP  - 1
DP  - 1979 Jan-Feb
TI  - Splenectomy and antiplatelet agents in thrombotic thrombocytopenic purpura.
PG  - 75-89
AB  - Ten patients with thrombotic thrombocytopenic purpura (TTP) were studied 
      retrospectively. The male:female ratio was 2:3 and the median age was 27 years. 
      Six patients were alive one-half to 18 years after the onset of the disease. Four 
      of these patients underwent emergency splenectomy and received antiplatelet 
      drugs. Of the remaining two, one responded to splenectomy and the other had 
      received a short course of aspirin therapy. The study supports the usefulness of 
      splenectomy and/or antiplatelet agents in the treatment of TTP.
FAU - Peterson, J
AU  - Peterson J
FAU - Amare, M
AU  - Amare M
FAU - Henry, J E
AU  - Henry JE
FAU - Bone, R C
AU  - Bone RC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Adrenal Cortex Hormones)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adolescent
MH  - Adrenal Cortex Hormones/*therapeutic use
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Male
MH  - Prednisone/therapeutic use
MH  - Purpura, Thrombotic Thrombocytopenic/drug therapy/*therapy
MH  - *Splenectomy
EDAT- 1979/01/01 00:00
MHDA- 1979/01/01 00:01
CRDT- 1979/01/01 00:00
PHST- 1979/01/01 00:00 [pubmed]
PHST- 1979/01/01 00:01 [medline]
PHST- 1979/01/01 00:00 [entrez]
AID - 10.1097/00000441-197901000-00009 [doi]
PST - ppublish
SO  - Am J Med Sci. 1979 Jan-Feb;277(1):75-89. doi: 10.1097/00000441-197901000-00009.

PMID- 411834
OWN - NLM
STAT- MEDLINE
DCOM- 19780127
LR  - 20191028
IS  - 0305-1811 (Print)
IS  - 0305-1811 (Linking)
VI  - 4
IP  - 5
DP  - 1977 Oct
TI  - Histocompatibility antigens and genetic control of the immune response in 
      guinea-pigs. V. Evidence from further breeding studies for the polygenic control 
      of the cellular immune response to structurally unrelated antigens in the 
      guinea-pig.
PG  - 367-70
AB  - Further breeding studies were carried out to investigate the polygenic control of 
      the cellular immune response in the guinea-pig to low doses of aspirin anhydride 
      (ASAN), penicilloylated bovine immunoglobulin (BPO-BGG) and to the multi-chain 
      copolymer (T, G)-A-L. Although responsiveness to these three antigens is 
      controlled by three independently segregating loci, at least one gene required 
      for these responses is linked to the strain 13 haplotype.
FAU - Geczy, A F
AU  - Geczy AF
FAU - de Weck, A L
AU  - de Weck AL
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Immunogenet
JT  - Journal of immunogenetics
JID - 0425125
RN  - 0 (Antigens)
RN  - 0 (Histocompatibility Antigens)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Peptides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Antigens
MH  - Aspirin/immunology
MH  - Breeding
MH  - Cattle
MH  - Dose-Response Relationship, Immunologic
MH  - *Genes, MHC Class II
MH  - Guinea Pigs/genetics
MH  - *Histocompatibility Antigens
MH  - Hypersensitivity, Delayed/immunology
MH  - *Immunity, Cellular
MH  - Immunoglobulin G
MH  - Peptides/immunology
EDAT- 1977/10/01 00:00
MHDA- 1977/10/01 00:01
CRDT- 1977/10/01 00:00
PHST- 1977/10/01 00:00 [pubmed]
PHST- 1977/10/01 00:01 [medline]
PHST- 1977/10/01 00:00 [entrez]
AID - 10.1111/j.1744-313x.1977.tb00920.x [doi]
PST - ppublish
SO  - J Immunogenet. 1977 Oct;4(5):367-70. doi: 10.1111/j.1744-313x.1977.tb00920.x.

PMID- 868957
OWN - NLM
STAT- MEDLINE
DCOM- 19770723
LR  - 20190627
IS  - 0002-9394 (Print)
IS  - 0002-9394 (Linking)
VI  - 83
IP  - 4
DP  - 1977 Apr
TI  - The effect of hyperthermia on aqueous humor dynamics in rabbits.
PG  - 561-4
AB  - Hyperthermia increased intraocular pressure (Po) by approximately 5 mm Hg in 
      rabbit eyes. This increase was not associated with changes in plasma osmolarity, 
      blood lactate, or pH. Episcleral venous pressure (Pv) decreased from a baseline 
      of 11 +/- 1 mm Hg(mean +/- SEM) to 8 +/- 1 mm Hg after one hour of hyperthermia. 
      Outflow facility (c) as measured by tonography remained unchanged. Aqueous humor 
      flow [c(Po - Pv)] as estimated by tonography increased by about 126%. The 
      elevation of intraocular pressure was not prevented by aspirin pretreatment nor 
      altered by unilateral optic nerve transection.
FAU - Krupin, T
AU  - Krupin T
FAU - Bass, J
AU  - Bass J
FAU - Oestrich, C
AU  - Oestrich C
FAU - Podos, S M
AU  - Podos SM
FAU - Becker, B
AU  - Becker B
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aqueous Humor/drug effects/*physiology
MH  - Aspirin/pharmacology
MH  - Blood Pressure
MH  - Fever/etiology/*physiopathology/prevention & control
MH  - *Intraocular Pressure/drug effects
MH  - Male
MH  - Optic Nerve/surgery
MH  - Rabbits
MH  - Venous Pressure
EDAT- 1977/04/01 00:00
MHDA- 1977/04/01 00:01
CRDT- 1977/04/01 00:00
PHST- 1977/04/01 00:00 [pubmed]
PHST- 1977/04/01 00:01 [medline]
PHST- 1977/04/01 00:00 [entrez]
AID - 0002-9394(77)90567-0 [pii]
AID - 10.1016/0002-9394(77)90567-0 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 1977 Apr;83(4):561-4. doi: 10.1016/0002-9394(77)90567-0.

PMID- 26043186
OWN - NLM
STAT- MEDLINE
DCOM- 20161017
LR  - 20161230
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 33
IP  - 2
DP  - 2016 Feb
TI  - Randomized controlled trial comparing impact on platelet reactivity of 
      twice-daily with once-daily aspirin in people with Type 2 diabetes.
PG  - 224-30
LID - 10.1111/dme.12828 [doi]
AB  - AIMS: Reduced aspirin efficacy has been demonstrated in people with Type 2 
      diabetes. Because increased platelet reactivity and/or turnover are postulated 
      mechanisms, we examined whether higher and/or more frequent aspirin dosing might 
      reduce platelet reactivity more effectively. METHODS: Participants with Type 2 
      diabetes (n = 24) but without known cardiovascular disease were randomized in a 
      three-way crossover design to 2-week treatment periods with aspirin 100 mg once 
      daily, 200 mg once daily or 100 mg twice daily. The primary outcome was platelet 
      reactivity, assessed using the VerifyNow(™) ASA method. Relationships between 
      platelet reactivity and aspirin dosing were examined using generalized linear 
      mixed models with random subject effects. RESULTS: Platelet reactivity decreased 
      from baseline with all doses of aspirin. Modelled platelet reactivity was more 
      effectively reduced with aspirin 100 mg twice daily vs. 100 mg once daily, but 
      not vs. 200 mg once daily. Aspirin 200 mg once daily did not differ from 100 mg 
      once daily. Aspirin 100 mg twice daily was also more effective than once daily as 
      measured by collagen/epinephrine-stimulated platelet aggregation and urinary 
      thromboxane levels, with a similar trend measured by serum thromboxane levels. No 
      episodes of bleeding occurred. CONCLUSIONS: In Type 2 diabetes, aspirin 100 mg 
      twice daily reduced platelet reactivity more effectively than 100 mg once daily, 
      and numerically more than 200 mg once daily. Clinical outcome trials evaluating 
      primary cardiovascular disease prevention with aspirin in Type 2 diabetes may 
      need to consider using a more frequent dosing schedule.
CI  - © 2015 The Authors. Diabetic Medicine © 2015 Diabetes UK.
FAU - Bethel, M A
AU  - Bethel MA
AD  - Diabetes Trials Unit, University of Oxford, Oxford, UK.
AD  - Oxford National Institute for Health Research Biomedical Research Centre, 
      Churchill Hospital, Oxford, UK.
FAU - Harrison, P
AU  - Harrison P
AD  - School of Immunity and Infection, University of Birmingham Medical School, 
      Birmingham, UK.
FAU - Sourij, H
AU  - Sourij H
AD  - Diabetes Trials Unit, University of Oxford, Oxford, UK.
AD  - Oxford National Institute for Health Research Biomedical Research Centre, 
      Churchill Hospital, Oxford, UK.
FAU - Sun, Y
AU  - Sun Y
AD  - Peking University People's Hospital, Beijing, People's Republic of China.
FAU - Tucker, L
AU  - Tucker L
AD  - Diabetes Trials Unit, University of Oxford, Oxford, UK.
AD  - Oxford National Institute for Health Research Biomedical Research Centre, 
      Churchill Hospital, Oxford, UK.
FAU - Kennedy, I
AU  - Kennedy I
AD  - Diabetes Trials Unit, University of Oxford, Oxford, UK.
AD  - Oxford National Institute for Health Research Biomedical Research Centre, 
      Churchill Hospital, Oxford, UK.
FAU - White, S
AU  - White S
AD  - Diabetes Trials Unit, University of Oxford, Oxford, UK.
AD  - Oxford National Institute for Health Research Biomedical Research Centre, 
      Churchill Hospital, Oxford, UK.
FAU - Hill, L
AU  - Hill L
AD  - Department of Haematology, John Radcliffe Hospital, Oxford, UK.
FAU - Oulhaj, A
AU  - Oulhaj A
AD  - Diabetes Trials Unit, University of Oxford, Oxford, UK.
AD  - Oxford National Institute for Health Research Biomedical Research Centre, 
      Churchill Hospital, Oxford, UK.
FAU - Coleman, R L
AU  - Coleman RL
AD  - Diabetes Trials Unit, University of Oxford, Oxford, UK.
FAU - Holman, R R
AU  - Holman RR
AD  - Diabetes Trials Unit, University of Oxford, Oxford, UK.
AD  - Oxford National Institute for Health Research Biomedical Research Centre, 
      Churchill Hospital, Oxford, UK.
LA  - eng
GR  - British Heart Foundation/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150714
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*administration & dosage/adverse effects/therapeutic use
MH  - Cardiovascular Diseases/complications/epidemiology/*prevention & control
MH  - Cross-Over Studies
MH  - Cyclooxygenase Inhibitors/*administration & dosage/adverse effects/therapeutic 
      use
MH  - Diabetes Mellitus, Type 2/blood/*complications
MH  - Diabetic Angiopathies/epidemiology/*prevention & control
MH  - Diabetic Cardiomyopathies/epidemiology/*prevention & control
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Resistance
MH  - England/epidemiology
MH  - Female
MH  - Hemorrhage/chemically induced/complications/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/drug effects
MH  - Platelet Aggregation Inhibitors/*administration & dosage/adverse 
      effects/therapeutic use
MH  - Risk
MH  - Risk Assessment
EDAT- 2015/06/05 06:00
MHDA- 2016/10/19 06:00
CRDT- 2015/06/05 06:00
PHST- 2015/06/01 00:00 [accepted]
PHST- 2015/06/05 06:00 [entrez]
PHST- 2015/06/05 06:00 [pubmed]
PHST- 2016/10/19 06:00 [medline]
AID - 10.1111/dme.12828 [doi]
PST - ppublish
SO  - Diabet Med. 2016 Feb;33(2):224-30. doi: 10.1111/dme.12828. Epub 2015 Jul 14.

PMID- 31002173
OWN - NLM
STAT- MEDLINE
DCOM- 20190716
LR  - 20190716
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 140
IP  - 1
DP  - 2019 Jul
TI  - Aspirin reduced recurrent stroke risk in patients with lacunar stroke.
PG  - 78-83
LID - 10.1111/ane.13105 [doi]
AB  - OBJECTIVES: Lacunar stroke had an unfavorable prognosis in the long term with a 
      high risk of recurrent stroke, aspirin has been widely used to prevent ischemic 
      stroke, but data on the effect of antiplatelet therapy on lacunar infarction are 
      limited. We investigated the long-term effect of aspirin treatment on stroke 
      recurrence risk in patients with lacunar stroke in a multicenter prospective 
      cohort. METHODS: Between November 2000 and November 2001, 2000 consecutive stroke 
      patients (age 35-74 years) were recruited from seven clinical centers. For the 
      present study, a total of 544 patients with lacunar infarction were finally 
      included in the analysis. The patients were divided into two groups (aspirin 
      group, n = 342 and non-aspirin group, n = 202).The effect of aspirin on stroke 
      recurrence was evaluated by using Kaplan-Meier analysis and Cox regression 
      models. RESULTS: During a median 4.1-year follow-up for 544 patients with lacunar 
      stroke, 99 recurrent strokes, 125 major vascular events (stroke, myocardial 
      infarction, and vascular death), 31 vascular deaths, and 59 all-cause deaths were 
      identified. Kaplan-Meier analysis showed that aspirin non-users had a higher risk 
      of future recurrent stroke and of vascular events than did aspirin users 
      (log-rank test, P = 0.049, 0.047, respectively). Aspirin significantly reduced 
      the stroke recurrence in patients with lacunar stroke analyzed with multivariate 
      stepwise analysis using model of Cox proportional hazards with backward 
      elimination (HR = 0.67, 95% CI 0.45-0.99). CONCLUSION: We concluded that aspirin 
      significantly reduced stroke recurrence in patients with lacunar stroke.
CI  - © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Kong, Tao
AU  - Kong T
AUID- ORCID: 0000-0002-1918-3295
AD  - Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of 
      Medical Science and Peking Union Medical College, Beijing, China.
FAU - Chen, Jingzhou
AU  - Chen J
AD  - Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of 
      Medical Science and Peking Union Medical College, Beijing, China.
FAU - Sun, Kai
AU  - Sun K
AD  - Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of 
      Medical Science and Peking Union Medical College, Beijing, China.
FAU - Zhang, Weili
AU  - Zhang W
AD  - Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of 
      Medical Science and Peking Union Medical College, Beijing, China.
FAU - Wang, Jizheng
AU  - Wang J
AD  - Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of 
      Medical Science and Peking Union Medical College, Beijing, China.
FAU - Song, Lei
AU  - Song L
AD  - Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of 
      Medical Science and Peking Union Medical College, Beijing, China.
FAU - Wang, Daowen
AU  - Wang D
AD  - Department of Internal Medicine, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Hui, Rutai
AU  - Hui R
AD  - Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of 
      Medical Science and Peking Union Medical College, Beijing, China.
LA  - eng
GR  - 973/Ministry of Science and Technology of China/
PT  - Journal Article
PT  - Multicenter Study
DEP - 20190509
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/*therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Recurrence
MH  - Stroke, Lacunar/*prevention & control
OTO - NOTNLM
OT  - aspirin
OT  - lacunar stroke
OT  - recurrent stroke
EDAT- 2019/04/20 06:00
MHDA- 2019/07/17 06:00
CRDT- 2019/04/20 06:00
PHST- 2019/01/02 00:00 [received]
PHST- 2019/04/10 00:00 [revised]
PHST- 2019/04/12 00:00 [accepted]
PHST- 2019/04/20 06:00 [pubmed]
PHST- 2019/07/17 06:00 [medline]
PHST- 2019/04/20 06:00 [entrez]
AID - 10.1111/ane.13105 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2019 Jul;140(1):78-83. doi: 10.1111/ane.13105. Epub 2019 May 
      9.

PMID- 17008981
OWN - NLM
STAT- MEDLINE
DCOM- 20061221
LR  - 20220408
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 22
IP  - 2
DP  - 2006 Oct
TI  - Possible mechanisms of drug-induced aspirin and clopidogrel resistance.
PG  - 139-50
AB  - Aspirin (ASA) and clopidogrel have been identified as standard of care in the 
      prevention of major cardiovascular events. Aspirin irreversibly inhibits the 
      cyclooxygenase-1 (COX-1) enzyme, whereas non-steroidal anti-inflammatory drugs 
      (NSAIDs) reversibly inhibit the COX-1 enzyme. An analysis of the literature 
      revealed a statistically significant decrease in clinical benefit of ASA with 
      concomitant administration of ibuprofen. Another NSAID, diclofenac, showed 
      minimal effect on the inhibition of platelet aggregation when administered with 
      ASA. Furthermore, the selective COX-2 inhibitor, rofecoxib, was not shown to 
      influence the effect of ASA. Clopidogrel is metabolized to an active thiol 
      metabolite by the CYP 3A4 enzyme. Some HMG CoA reductase inhibitors have the 
      ability to inhibit the CYP 3A4 enzyme, which can result in a possible interaction 
      if administered concomitantly with clopidogrel. Studies have demonstrated 
      clopidogrel's platelet inhibition being significantly attenuated by atorvastatin. 
      However in a post-hoc analysis, it was demonstrated that there was no difference 
      in clinical outcomes between patients taking clopidogrel and HMG-CoA reductase 
      inhibitors metabolized by and not metabolized by CYP 3A4. Data suggest that the 
      interaction observed involving clopidogrel and HMG-CoA reductase inhibitors 
      appears to be significant in-vitro. Therefore, practitioners should advise 
      patients receiving chronic aspirin therapy to limit the use of ibuprofen and may 
      consider concomitant administration of clopidogrel with HMG-CoA reductase 
      inhibitors without regard for the drug interaction. The intent of this paper is 
      to review the literature discussing possible mechanisms of drug-induced aspirin 
      and clopidogrel resistance and discuss whether the interactions translate into 
      clinical effects.
FAU - Schroeder, Walter S
AU  - Schroeder WS
AD  - Pharmacy and Medicine, Department of Pharmacy and Pharmaceutical Sciences, 
      University at Buffalo, Cooke Hall 317, Buffalo, NY 14260, USA. wss2@buffalo.edu
FAU - Ghobrial, Linda
AU  - Ghobrial L
FAU - Gandhi, Pritesh J
AU  - Gandhi PJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP3A)
RN  - EC 1.14.14.55 (CYP3A4 protein, human)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Aspirin/pharmacokinetics/*pharmacology
MH  - Cardiovascular Diseases/prevention & control
MH  - Clopidogrel
MH  - Cytochrome P-450 CYP3A
MH  - Cytochrome P-450 Enzyme System/metabolism
MH  - *Drug Interactions
MH  - *Drug Resistance
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology
MH  - Platelet Aggregation Inhibitors/pharmacokinetics/*pharmacology
MH  - Ticlopidine/*analogs & derivatives/pharmacokinetics/pharmacology
RF  - 55
EDAT- 2006/09/30 09:00
MHDA- 2006/12/22 09:00
CRDT- 2006/09/30 09:00
PHST- 2006/09/30 09:00 [pubmed]
PHST- 2006/12/22 09:00 [medline]
PHST- 2006/09/30 09:00 [entrez]
AID - 10.1007/s11239-006-8670-y [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2006 Oct;22(2):139-50. doi: 10.1007/s11239-006-8670-y.

PMID- 7752653
OWN - NLM
STAT- MEDLINE
DCOM- 19950622
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 25
IP  - 2
DP  - 1995 Feb
TI  - Inhibitory effects of aspirin on coronary hyperreactivity to autacoids after 
      arterial balloon injury in miniature pigs.
PG  - 273-81
AB  - We examined the effects of aspirin on coronary hyperreactivity to autacoids after 
      arterial balloon injury in miniature pigs. Coronary vasoconstriction induced by 
      histamine and serotonin were examined angiographically before, 1 h, 1 week, and 1 
      month after balloon injury in 29 hypercholesterolemic miniature pigs. The animals 
      were divided into three groups: group A, no treatment (n = 16); group B, 
      pretreated with aspirin 50 mg/day for 2 days before injury (n = 7); and group C, 
      treated with aspirin 50 mg/day for 2 days before and 5 days after injury (7 days 
      in all) (n = 6). In group A, coronary vasoconstriction induced by autacoids was 
      significantly greater at the injured than at the noninjured site at all times 
      examined (p < 0.01). Hyperconstriction induced by the autacoids 1 h after injury 
      were significantly less in groups B and C than in group A (p < 0.01). 
      Hyperconstriction induced by autacoids 1 week after injury were significantly 
      less in group B than in group A (p < 0.01) and were significantly less in group C 
      than in group A (p < 0.01) or group B (p < 0.05). Treatment with aspirin for 2 or 
      7 days had no effect on the constrictive responses at the injured site 1 month 
      after injury or on those at the noninjured site at all times examined. These 
      results suggest that platelet-vessel wall interaction may play an important role 
      in coronary hyperconstrictive responses to autacoids 1 h and 1 week after injury.
FAU - Kuga, T
AU  - Kuga T
AD  - Research Institute of Angiocardiology, Faculty of Medicine, Kyushu University, 
      Fukuoka, Japan.
FAU - Ohara, Y
AU  - Ohara Y
FAU - Shimokawa, H
AU  - Shimokawa H
FAU - Ibayashi, S
AU  - Ibayashi S
FAU - Tomoike, H
AU  - Tomoike H
FAU - Takeshita, A
AU  - Takeshita A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Autacoids)
RN  - 333DO1RDJY (Serotonin)
RN  - 820484N8I3 (Histamine)
RN  - G59M7S0WS3 (Nitroglycerin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiography
MH  - Angioplasty, Balloon, Coronary/*adverse effects
MH  - Animals
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Autacoids/administration & dosage/antagonists & inhibitors/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Constriction, Pathologic/drug therapy
MH  - Coronary Angiography
MH  - Coronary Vessels/*drug effects/injuries/pathology
MH  - Disease Models, Animal
MH  - Heart Rate/drug effects
MH  - Histamine/pharmacology
MH  - Hypercholesterolemia/drug therapy
MH  - Male
MH  - Nitroglycerin/pharmacology
MH  - Serotonin/pharmacology
MH  - Swine
MH  - Swine, Miniature
MH  - Vasoconstriction/*drug effects
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
AID - 10.1097/00005344-199502000-00013 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1995 Feb;25(2):273-81. doi: 
      10.1097/00005344-199502000-00013.

PMID- 26601997
OWN - NLM
STAT- MEDLINE
DCOM- 20170201
LR  - 20220910
IS  - 1808-8686 (Electronic)
IS  - 1808-8694 (Print)
IS  - 1808-8686 (Linking)
VI  - 82
IP  - 3
DP  - 2016 May-Jun
TI  - The role of aspirin desensitization in patients with aspirin-exacerbated 
      respiratory disease (AERD).
PG  - 263-8
LID - S1808-8694(15)00158-5 [pii]
LID - 10.1016/j.bjorl.2015.04.010 [doi]
AB  - INTRODUCTION: Aspirin-exacerbated respiratory disease (AERD) consists of a 
      classic tetrad: moderate/severe asthma, chronic rhinosinusitis, nasal polyps, and 
      intolerance to aspirin or other nonsteroidal anti-inflammatory drugs. Clinical 
      control with drugs, surgery, and desensitization are treatment options. 
      OBJECTIVE: To evaluate the efficacy and tolerability of aspirin desensitization 
      in patients with AERD. METHODS: Periodic symptom assessment and endoscopy in 
      patients with AERD undergoing surgery who were desensitized. RESULTS: Seventeen 
      patients were desensitized. Eight patients completed the desensitization and were 
      followed for a minimum of a one-year period (mean 3.1 years). These patients 
      showed improvement in all symptoms. Moreover, surgical reassessment was not 
      indicated in any of these patients and there was a decrease in costs with 
      medication and procedures. Eight patients did not complete desensitization, 
      mainly due to procedure intolerance and uncontrolled asthma, whereas another 
      patient was lost to follow-up. CONCLUSION: Aspirin desensitization, when 
      tolerated, was effective in patients with AERD and with poor clinical/surgical 
      response.
CI  - Copyright © 2015 Associação Brasileira de Otorrinolaringologia e Cirurgia 
      Cérvico-Facial. Published by Elsevier Editora Ltda. All rights reserved.
FAU - Spies, Jonas Willian
AU  - Spies JW
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), 
      Ribeirão Preto, SP, Brazil.
FAU - Valera, Fabiana Cardoso Pereira
AU  - Valera FC
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), 
      Ribeirão Preto, SP, Brazil.
FAU - Cordeiro, Daniel Loiola
AU  - Cordeiro DL
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), 
      Ribeirão Preto, SP, Brazil.
FAU - de Mendonça, Taís Nociti
AU  - de Mendonça TN
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), 
      Ribeirão Preto, SP, Brazil.
FAU - Leite, Marcelo Gonçalves Junqueira
AU  - Leite MG
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), 
      Ribeirão Preto, SP, Brazil.
FAU - Tamashiro, Edwin
AU  - Tamashiro E
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), 
      Ribeirão Preto, SP, Brazil.
FAU - Arruda, Luiza Karla
AU  - Arruda LK
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), 
      Ribeirão Preto, SP, Brazil.
FAU - Anselmo-Lima, Wilma Terezinha
AU  - Anselmo-Lima WT
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), 
      Ribeirão Preto, SP, Brazil. Electronic address: wtalima@fmrp.usp.br.
LA  - eng
PT  - Journal Article
DEP - 20150921
PL  - Brazil
TA  - Braz J Otorhinolaryngol
JT  - Brazilian journal of otorhinolaryngology
JID - 101207337
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse 
      effects/immunology
MH  - Aspirin/*administration & dosage/adverse effects/immunology
MH  - Asthma, Aspirin-Induced/immunology/*therapy
MH  - Chronic Disease
MH  - *Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/chemically induced/immunology/*therapy
MH  - Rhinitis/chemically induced/immunology/*therapy
MH  - Sinusitis/chemically induced/immunology/*therapy
MH  - Treatment Outcome
PMC - PMC9444683
OTO - NOTNLM
OT  - Aspirin
OT  - Aspirina
OT  - Desensitization immunological
OT  - Dessensibilização imunológica
OT  - Nasal polyps
OT  - Polipose nasal
OT  - Sinusite
OT  - Sinusitis
EDAT- 2015/11/26 06:00
MHDA- 2017/02/02 06:00
CRDT- 2015/11/26 06:00
PHST- 2014/12/09 00:00 [received]
PHST- 2015/04/15 00:00 [revised]
PHST- 2015/04/16 00:00 [accepted]
PHST- 2015/11/26 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2017/02/02 06:00 [medline]
AID - S1808-8694(15)00158-5 [pii]
AID - 10.1016/j.bjorl.2015.04.010 [doi]
PST - ppublish
SO  - Braz J Otorhinolaryngol. 2016 May-Jun;82(3):263-8. doi: 
      10.1016/j.bjorl.2015.04.010. Epub 2015 Sep 21.

PMID- 25714593
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20220408
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 66
IP  - 1
DP  - 2015 Jul
TI  - Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease 
      Patients Treated With Acetylsalicylic Acid.
PG  - 35-40
LID - 10.1097/FJC.0000000000000240 [doi]
AB  - BACKGROUND: Suboptimal platelet inhibition with antiplatelet treatments is 
      associated with a severe prognosis in patients with coronary artery disease 
      (CAD), and the identification of its determinants is still challenging. 
      Homocysteine elevation has emerged as a prothrombotic factor, influencing 
      coagulative status and endothelial function and potentially modulating platelet 
      aggregation. We therefore aimed to evaluate the effects of homocysteine (Hcy) 
      levels on platelet reactivity in patients receiving acetylsalicylic acid (ASA) 
      with or without ADP antagonists. METHODS: Patients undergoing coronary 
      angiography and receiving ASA (100-160 mg daily) for >7 days, with or without ADP 
      antagonists, were included. Aggregation tests were performed by multiple 
      electrode aggregometry. Suboptimal platelet inhibition was defined as 
      on-treatment aggregation above the lower limit of normality. RESULTS: Our 
      population is represented by 508 ASA-treated patients, 406 (80.1%) of whom on 
      dual antiplatelet therapy (ASA and ADP antagonists). Hcy levels above the median 
      (15.1 nmol/mL) were associated with male gender (P = 0.04), hypertension (P = 
      0.004), hypercholesterolemia (P = 0.03), aging, renal failure (P < 0.001, 
      respectively), previous coronary bypass grafting (P = 0.04), therapy with calcium 
      antagonists (P = 0.04) and diuretics (P = 0.001), and multivessel CAD (P = 0.03). 
      Higher Hcy is directly related with serum creatinine and uric acid (P < 0.001). 
      Suboptimal platelet inhibition was found in 16 patients (3.2%) for ASA and for 
      ADP antagonists in 80 patients (19.7%). Hcy levels significantly affected 
      suboptimal response to ASA, but not to ADP-mediated aggregation. In fact, a 
      linear relationship was found between homocysteine and platelet reactivity after 
      stimulation with arachidonic acid (r = 0.14, P = 0.004) and collagen (r = 0.12, P 
      = 0.02), but not with ADP (r = 0.02, P = 0.77). Moreover, after correction for 
      baseline differences, Hcy above the median was confirmed as an independent 
      predictor of impaired ASA response [adjusted odds ratio (95% confidence interval) 
      = 3.7 (1.08-12.4), P = 0.04]. CONCLUSIONS: Among patients with CAD, elevated 
      homocysteine is an independent predictor of suboptimal response to ASA, but not 
      to ADP antagonists.
FAU - Verdoia, Monica
AU  - Verdoia M
AD  - *Department of Cardiology, Azienda Ospedaliera-Universitaria Maggiore della 
      Carità, Eastern Piedmont University, Novara, Italy; †Department of Clinical 
      Chemistry, Azienda Ospedaliera-Universitaria Maggiore della Carità, Eastern 
      Piedmont University, Novara, Italy; ‡Department of Translational Medicine, Centro 
      di Biotecnologie per la Ricerca Medica Applicata (BRMA), Eastern Piedmont 
      University, Novara, Italy; and §Department of Cardiology, UMC St Radboud, 
      Nijmegen, the Netherlands.
FAU - Schaffer, Alon
AU  - Schaffer A
FAU - Pergolini, Patrizia
AU  - Pergolini P
FAU - Rolla, Roberta
AU  - Rolla R
FAU - Barbieri, Lucia
AU  - Barbieri L
FAU - Bellomo, Giorgio
AU  - Bellomo G
FAU - Sinigaglia, Fabiola
AU  - Sinigaglia F
FAU - Marino, Paolo
AU  - Marino P
FAU - Suryapranata, Harry
AU  - Suryapranata H
FAU - De Luca, Giuseppe
AU  - De Luca G
CN  - Novara Atherosclerosis Study Group (NAS)
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Biomarkers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Biomarkers/blood
MH  - Blood Platelets/drug effects/metabolism
MH  - Coronary Artery Disease/*blood/diagnosis/*drug therapy
MH  - Female
MH  - Homocysteine/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation/*drug effects/physiology
MH  - Platelet Aggregation/drug effects/physiology
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - Treatment Outcome
EDAT- 2015/02/26 06:00
MHDA- 2016/04/19 06:00
CRDT- 2015/02/26 06:00
PHST- 2015/02/26 06:00 [entrez]
PHST- 2015/02/26 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - 10.1097/FJC.0000000000000240 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2015 Jul;66(1):35-40. doi: 10.1097/FJC.0000000000000240.

PMID- 37043192
OWN - NLM
STAT- MEDLINE
DCOM- 20230616
LR  - 20230618
IS  - 2380-6591 (Electronic)
IS  - 2380-6583 (Print)
VI  - 8
IP  - 6
DP  - 2023 Jun 1
TI  - Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in 
      Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial.
PG  - 535-544
LID - 10.1001/jamacardio.2023.0592 [doi]
AB  - IMPORTANCE: Selecting the optimal antiplatelet agent in patients who have 
      received percutaneous coronary intervention is especially important in those with 
      diabetes due to the heightened risk of ischemic events in this population. 
      Studies on the efficacy and safety of clopidogrel vs aspirin for long-term 
      maintenance after percutaneous coronary intervention in patients with diabetes 
      are lacking. OBJECTIVE: To investigate cardiovascular outcomes with clopidogrel 
      vs aspirin in patients with and without diabetes. DESIGN, SETTING, AND 
      PARTICIPANTS: This was a post hoc analysis of the HOST-EXAM randomized clinical 
      trial, an investigator-initiated, prospective, randomized, open-label, 
      multicenter trial performed at 37 centers in Korea. Patients who received dual 
      antiplatelet therapy without clinical events for 6 to 18 months after 
      percutaneous coronary intervention with drug-eluting stents were enrolled from 
      March 2014 to May 2018 with follow-up at 6, 12, 18, and 24 months. All 5438 
      patients in the original trial were included in this analysis, which was 
      conducted from June to October 2021. INTERVENTIONS AND EXPOSURES: Enrolled 
      patients were randomized 1:1 to clopidogrel or aspirin monotherapy. Subgroup 
      analyses were performed by the presence of diabetes. MAIN OUTCOMES AND MEASURES: 
      The main outcome was primary composite end point of all-cause death, nonfatal 
      myocardial infarction, stroke, readmission due to acute coronary syndrome, and 
      major bleeding (Bleeding Academic Research Consortium type 3 or 5) at 24-month 
      follow-up. RESULTS: Of 5438 patients (mean [SD] age, 63.5 [10.7] years; 1384 
      [25.5%] female), 1860 (34.2%) had diabetes (925 in the clopidogrel arm and 935 in 
      the aspirin arm), and 5338 (98.2%) completed follow-up. The rate of the primary 
      composite end point was significantly lower in the clopidogrel group compared to 
      the aspirin group in patients with diabetes (6.3% vs 9.2%; hazard ratio [HR], 
      0.69; 95% CI, 0.49-0.96; P = .03; absolute risk difference [ARD], 2.7%; number 
      needed to treat [NNT], 37) and without diabetes (5.3% vs 7.0%; HR, 0.76; 95% CI, 
      0.58-1.00; P = .046; ARD, 1.6%, NNT, 63; P for interaction = .65). The presence 
      of diabetes was not associated with a difference in benefit observed with 
      clopidogrel monotherapy over aspirin for the thrombotic composite end point (HR, 
      0.68; 95% CI, 0.45-1.04 for patients with diabetes vs HR, 0.68; 95% CI, 0.49-0.93 
      for those without; P for interaction = .99) and any bleeding with Bleeding 
      Academic Research Consortium 2, 3, or 5 (HR, 0.65; 95% CI, 0.39-1.09 for patients 
      with diabetes vs HR, 0.74; 95% CI, 0.48-1.13 for those without; P for 
      interaction = .71). CONCLUSION AND RELEVANCE: In this study, clopidogrel 
      monotherapy was associated with a lower rate of the primary composite end point 
      compared to aspirin monotherapy as long-term maintenance therapy after dual 
      antiplatelet therapy for coronary stenting in both patients with and without 
      diabetes. Clopidogrel might thus be considered rather than aspirin in patients 
      who have undergone coronary stenting and successfully completed dual antiplatelet 
      therapy, regardless of diabetes status. TRIAL REGISTRATION: ClinicalTrials.gov 
      Identifier: NCT02044250.
FAU - Rhee, Tae-Min
AU  - Rhee TM
AD  - Seoul National University Hospital and Seoul National University College of 
      Medicine, Seoul, Korea.
FAU - Bae, Jang-Whan
AU  - Bae JW
AD  - Chungbuk National University College of Medicine, Cheongju, Korea.
FAU - Park, Kyung Woo
AU  - Park KW
AD  - Seoul National University Hospital and Seoul National University College of 
      Medicine, Seoul, Korea.
FAU - Rha, Seung-Woon
AU  - Rha SW
AD  - Korea University Guro Hospital, Seoul, Korea.
FAU - Kang, Jeehoon
AU  - Kang J
AD  - Seoul National University Hospital and Seoul National University College of 
      Medicine, Seoul, Korea.
FAU - Lee, Heesun
AU  - Lee H
AD  - Seoul National University Healthcare System Gangnam Center, Seoul National 
      University College of Medicine, Seoul, Korea.
FAU - Yang, Han-Mo
AU  - Yang HM
AD  - Seoul National University Hospital and Seoul National University College of 
      Medicine, Seoul, Korea.
FAU - Kwak, Soo-Heon
AU  - Kwak SH
AD  - Seoul National University Hospital and Seoul National University College of 
      Medicine, Seoul, Korea.
FAU - Chae, In-Ho
AU  - Chae IH
AD  - Seoul National University Bundang Hospital, Seongnam, Korea.
FAU - Shin, Won-Yong
AU  - Shin WY
AD  - Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
FAU - Kim, Dae-Kyeong
AU  - Kim DK
AD  - Busan Paik Hospital, Inje University, Busan, Korea.
FAU - Oh, Ju Hyeon
AU  - Oh JH
AD  - Samsung Changwon Hospital, Sungkyunkwan University, Changwon, Korea.
FAU - Jeong, Myung Ho
AU  - Jeong MH
AD  - Chonnam National University Hospital, Gwangju, Korea.
FAU - Kim, Yong Hoon
AU  - Kim YH
AD  - Kangwon National University, School of Medicine, Chuncheon, Korea.
FAU - Lee, Nam Ho
AU  - Lee NH
AD  - Kangnam Sacred Heart Hospital, Hallym University, Seoul, Korea.
FAU - Hur, Seung-Ho
AU  - Hur SH
AD  - Keimyung University Dongsan Hospital, Daegu, Korea.
FAU - Yoon, Junghan
AU  - Yoon J
AD  - Yonsei University Wonju Severance Christian Hospital, Wonju, Korea.
FAU - Han, Jung-Kyu
AU  - Han JK
AD  - Seoul National University Hospital and Seoul National University College of 
      Medicine, Seoul, Korea.
FAU - Shin, Eun-Seok
AU  - Shin ES
AD  - Ulsan University Hospital, Ulsan, Korea.
FAU - Koo, Bon-Kwon
AU  - Koo BK
AD  - Seoul National University Hospital and Seoul National University College of 
      Medicine, Seoul, Korea.
FAU - Kim, Hyo-Soo
AU  - Kim HS
AD  - Seoul National University Hospital and Seoul National University College of 
      Medicine, Seoul, Korea.
CN  - HOST-EXAM Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT02044250
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - JAMA Cardiol
JT  - JAMA cardiology
JID - 101676033
RN  - A74586SNO7 (Clopidogrel)
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
CIN - MMW Fortschr Med. 2023 May;165(9):20. PMID: 37155044
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Male
MH  - Clopidogrel/therapeutic use
MH  - *Aspirin/therapeutic use
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prospective Studies
MH  - Drug Therapy, Combination
MH  - Hemorrhage/chemically induced/epidemiology
MH  - *Diabetes Mellitus/epidemiology/drug therapy
PMC - PMC10099092
COIS- Conflict of Interest Disclosures: Dr Park reports grants from the Ministry of 
      Health and Welfare, Republic of Korea, Chong Kun Dang, Samjin Pharmaceutical, 
      Hanmi Pharmaceutical, and Daewoong Pharmaceutical during the conduct of the 
      study; speaker’s fees from Daiichi Sankyo, Sanofi, Bristol Myers Squibb, Bayer, 
      Pfizer, inno.N Pharmaceutical, Daewoong Pharmaceutical, and JW Pharmaceutical 
      outside of the submitted work. Dr H Kim has received research grants or speaker’s 
      fees from Daiichi Sankyo, Boston Scientific, Terumo, Biotronik, Dio, Medtronic, 
      Abbott Vascular, Edwards Life Science, Amgen, and Boehringer Ingelheim outside of 
      the submitted work. No other disclosures were reported.
FIR - Won, Ki-Bum
IR  - Won KB
FIR - Park, Tae-Ho
IR  - Park TH
FIR - Kim, Bum Soo
IR  - Kim BS
FIR - Lim, Sang Wook
IR  - Lim SW
FIR - Cho, Yoon Haeng
IR  - Cho YH
FIR - Jeon, Dong Woon
IR  - Jeon DW
FIR - Kim, Sang-Hyun
IR  - Kim SH
FIR - Han, Kyoo-Rok
IR  - Han KR
FIR - Moon, Keon-Woong
IR  - Moon KW
FIR - Oh, Seok Kyu
IR  - Oh SK
FIR - Kim, Ung
IR  - Kim U
FIR - Rhee, Moo-Yong
IR  - Rhee MY
FIR - Kim, Doo-Il
IR  - Kim DI
FIR - Kim, Song-Yi
IR  - Kim SY
FIR - Lee, Sung-Yun
IR  - Lee SY
FIR - Lee, Seung Uk
IR  - Lee SU
FIR - Kim, Sang-Wook
IR  - Kim SW
FIR - Kim, Seok Yeon
IR  - Kim SY
FIR - Jeon, Hui-Kyung
IR  - Jeon HK
FIR - Cha, Kwang Soo
IR  - Cha KS
FIR - Jo, Sang-Ho
IR  - Jo SH
FIR - Ryu, Jae Kean
IR  - Ryu JK
FIR - Suh, Il-Woo
IR  - Suh IW
FIR - Choi, Hyun-Hee
IR  - Choi HH
FIR - Woo, Seoung-Il
IR  - Woo SI
EDAT- 2023/04/13 06:00
MHDA- 2023/06/16 06:42
PMCR- 2024/04/12
CRDT- 2023/04/12 11:32
PHST- 2024/04/12 00:00 [pmc-release]
PHST- 2023/06/16 06:42 [medline]
PHST- 2023/04/13 06:00 [pubmed]
PHST- 2023/04/12 11:32 [entrez]
AID - 2803932 [pii]
AID - hoi230014 [pii]
AID - 10.1001/jamacardio.2023.0592 [doi]
PST - ppublish
SO  - JAMA Cardiol. 2023 Jun 1;8(6):535-544. doi: 10.1001/jamacardio.2023.0592.

PMID- 8772629
OWN - NLM
STAT- MEDLINE
DCOM- 19970106
LR  - 20201209
IS  - 0954-6820 (Print)
IS  - 0954-6820 (Linking)
VI  - 239
IP  - 3
DP  - 1996 Mar
TI  - Granulomatous hepatitis induced by aspirin-kodein analgesics.
PG  - 279-81
AB  - Salicylate-kodein is a widely used analgesic agent, particularly in outpatient 
      practice. Salicylates have been incriminated in hepatic injury while kodein may 
      induce biliary spasm. We report here a case of granulomatous hepatitis attributed 
      to prolonged intake of this combination, which has never been reported previously 
      to our knowledge.
FAU - Elzouki, A N
AU  - Elzouki AN
AD  - Department of Medicine, Malmö University Hospital, University of Lund, Sweden.
FAU - Lindgren, S
AU  - Lindgren S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 0 (Analgesics)
RN  - 0 (Drug Combinations)
RN  - 130320-48-8 (aspirin, codeine drug combination)
RN  - R16CO5Y76E (Aspirin)
RN  - UX6OWY2V7J (Codeine)
SB  - IM
MH  - Analgesics/administration & dosage/*adverse effects
MH  - Aspirin/administration & dosage/*adverse effects
MH  - Biopsy
MH  - Chemical and Drug Induced Liver Injury/diagnosis/*etiology
MH  - Codeine/administration & dosage/*adverse effects
MH  - Drug Combinations
MH  - Granuloma/*chemically induced/diagnosis
MH  - Headache/drug therapy
MH  - Humans
MH  - Liver/pathology
MH  - Male
MH  - Middle Aged
MH  - Time Factors
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
AID - 10.1046/j.1365-2796.1996.408761000.x [doi]
PST - ppublish
SO  - J Intern Med. 1996 Mar;239(3):279-81. doi: 10.1046/j.1365-2796.1996.408761000.x.

PMID- 10520063
OWN - NLM
STAT- MEDLINE
DCOM- 19991108
LR  - 20190831
IS  - 0954-7894 (Print)
IS  - 0954-7894 (Linking)
VI  - 29
IP  - 10
DP  - 1999 Oct
TI  - Amalgam allergy associated with exacerbation of aspirin-intolerant asthma.
PG  - 1412-4
AB  - BACKGROUND: Aspirin-intolerant asthma can be induced not only by acidic 
      analgesics (including acetylsalicylic acid), which effectively inhibit 
      cyclo-oxygenase, but also by cross-reactivity with paraben, and other chemical 
      additives. OBJECTIVE: We examined whether amalgam allergy is involved in the 
      pathogenesis of a aspirin-intolerant asthma. METHODS: We present the first case 
      of aspirin-intolerant asthma that improved after the removal of dental amalgam. 
      In addition, we performed both the methacholine provocation testing and sulpyrine 
      provocation testing before and after the removal of dental amalgam. RESULTS: In 
      addition, the methacholine concentration causing a 20% fall in FEV1 in 
      provocation tests rose significantly, though hypersensitivity to analgesics 
      evaluated with sulpyrine provocation testing did not decrease. These results 
      suggest that amalgam sensitization is involved in bronchial hyperresponsiveness 
      in aspirin-intolerant asthma. CONCLUSION: Sensitivity to amalgam may cause 
      exacerbation of aspirin-intolerant asthma in some patients. To the best of our 
      knowledge, this is the first case report of amalgam allergy associated with 
      aspirin-intolerant asthma.
FAU - Yoshida, S
AU  - Yoshida S
AD  - Dental Allergy Research Group, Clinical Research Division, AOKI International 
      Medical Center, Yokohama, Japan.
FAU - Mikami, H
AU  - Mikami H
FAU - Nakagawa, H
AU  - Nakagawa H
FAU - Hasegawa, H
AU  - Hasegawa H
FAU - Onuma, K
AU  - Onuma K
FAU - Ishizaki, Y
AU  - Ishizaki Y
FAU - Shoji, T
AU  - Shoji T
FAU - Amayasu, H
AU  - Amayasu H
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - 0W5ETF9M2K (Methacholine Chloride)
RN  - 6429L0L52Y (Dipyrone)
RN  - 8049-85-2 (Dental Amalgam)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*adverse effects
MH  - Asthma/diagnosis/*etiology
MH  - Bronchial Hyperreactivity/chemically induced/diagnosis
MH  - Dental Amalgam/*adverse effects
MH  - Dipyrone
MH  - Female
MH  - Humans
MH  - Methacholine Chloride
MH  - Skin Tests
EDAT- 1999/10/16 00:00
MHDA- 1999/10/16 00:01
CRDT- 1999/10/16 00:00
PHST- 1999/10/16 00:00 [pubmed]
PHST- 1999/10/16 00:01 [medline]
PHST- 1999/10/16 00:00 [entrez]
AID - cea669 [pii]
AID - 10.1046/j.1365-2222.1999.00669.x [doi]
PST - ppublish
SO  - Clin Exp Allergy. 1999 Oct;29(10):1412-4. doi: 10.1046/j.1365-2222.1999.00669.x.

PMID- 1170585
OWN - NLM
STAT- MEDLINE
DCOM- 19751008
LR  - 20200225
VI  - 40
IP  - 4
DP  - 1975
TI  - Comparative analgesic activity of various naturally occurring cannabinoids in 
      mice and rats.
PG  - 285-95
AB  - The analgesic effectiveness of delta-9-tetrahydrocannabinol (THC), a crude 
      marihuana extract (CME), cannabinol (CBN), cannabidiol (CBD), morphine SO-4 and 
      aspirin following oral administration was directly compared in mice using the 
      acetic-induced writhing and hot plate tests and the Randall-Selitto paw pressure 
      test in rats. THC and morphine were equipotent in all tests except that morphine 
      was significantly more potent in elevating pain threshold in the uninflamed rat 
      hind paw. In terms of THC content, CME was nearly equipotent in the hot plate and 
      Randall-Selitto tests, but was 3 times more potent in the acetic acid writhing 
      test. On the other hand, CBN, like aspirin, was only effective in reducing 
      writhing frequency in mice (3 times more potent than aspirin) and raising pain 
      threshold of the inflamed hind paw of the rat (equipotent with aspirin). CBD did 
      not display a significantly analgesic effect in any of the test systems used. The 
      results of this investigation seem to suggest that both THC and CME possess 
      narcotic-like analgesic activity similar to morphine, while CBN appears to be a 
      non-narcotic type analgesic like aspirin.
FAU - Sofia, R D
AU  - Sofia RD
FAU - Vassar, H B
AU  - Vassar HB
FAU - Knobloch, L C
AU  - Knobloch LC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Psychopharmacologia
JT  - Psychopharmacologia
JID - 7609417
RN  - 0 (Acetates)
RN  - 0 (Analgesics)
RN  - 76I7G6D29C (Morphine)
RN  - 7J8897W37S (Dronabinol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acetates
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Aspirin/pharmacology
MH  - Cannabis/*pharmacology
MH  - Dronabinol/pharmacology
MH  - Hot Temperature
MH  - Male
MH  - Mice
MH  - Morphine/pharmacology
MH  - Pressure
MH  - Rats
MH  - Reaction Time/drug effects
EDAT- 1975/01/01 00:00
MHDA- 1975/01/01 00:01
CRDT- 1975/01/01 00:00
PHST- 1975/01/01 00:00 [pubmed]
PHST- 1975/01/01 00:01 [medline]
PHST- 1975/01/01 00:00 [entrez]
AID - 10.1007/BF00421466 [doi]
PST - ppublish
SO  - Psychopharmacologia. 1975;40(4):285-95. doi: 10.1007/BF00421466.

PMID- 17665747
OWN - NLM
STAT- MEDLINE
DCOM- 20070814
LR  - 20220316
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 99
IP  - 11A
DP  - 2007 Jun 4
TI  - Preventing macrovascular complications in type 2 diabetes mellitus: glucose 
      control and beyond.
PG  - 5H-11H
AB  - Patients with type 2 diabetes mellitus are at increased risk for macrovascular 
      disease complications. Hyperglycemia and atherosclerotic disease clearlyare 
      associated, andbiologic intermediates mediated by hyperglycemia exist. Our 
      understanding of the pathobiology linking hyperglycemia and atherosclerotic 
      disease continues to evolve. Modulation of the advanced glycation end product 
      (AGE) receptor for AGE (RAGE)/soluble RAGE (sRAGE) system, the thromboxane 
      receptor, and C-peptide comprise just a few of the plausible links between 
      dysglycemia and atherosclerosis. It seems intuitive, therefore, that therapeutic 
      management of blood glucose in patients with diabetes should reduce macrovascular 
      disease and related deaths. However, studies of glucose-lowering therapies 
      performed to date yield qualitatively and quantitatively different results. No 
      definitive proof of the concept is yet available, although it remains probable, 
      with investigations presently under way. Numerous interventions extending beyond 
      glucose control, including lifestyle modification, pharmacologic therapy with 
      3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), aspirin, 
      and angiotensin-converting enzyme inhibitors, as well as aggressive blood 
      pressure control independent of blood pressure levels, have proved to be of 
      cardiovascular benefit in the high-risk population of patients with diabetes. 
      Thus, all of these interventions should be used in addition to glucose management 
      in all patients with diabetes who are at increased risk for cardiovascular 
      disease.
FAU - Stancoven, Amy
AU  - Stancoven A
AD  - Department of Internal Medicine, University of Texas Southwestern Medical Center 
      at Dallas, 5909 Harry Hines Boulevard, St. Paul HA9.133, Dallas, Texas 
      75235-9047, USA.
FAU - McGuire, Darren K
AU  - McGuire DK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Blood Glucose)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/therapeutic use
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blood Glucose
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/blood/*prevention & control
MH  - Diabetic Angiopathies/blood/*prevention & control
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & 
      dosage/therapeutic use
MH  - Hypoglycemic Agents/administration & dosage/therapeutic use
RF  - 40
EDAT- 2007/08/02 09:00
MHDA- 2007/08/19 09:00
CRDT- 2007/08/02 09:00
PHST- 2007/08/02 09:00 [pubmed]
PHST- 2007/08/19 09:00 [medline]
PHST- 2007/08/02 09:00 [entrez]
AID - S0002-9149(07)00694-7 [pii]
AID - 10.1016/j.amjcard.2007.04.005 [doi]
PST - ppublish
SO  - Am J Cardiol. 2007 Jun 4;99(11A):5H-11H. doi: 10.1016/j.amjcard.2007.04.005.

PMID- 23069275
OWN - NLM
STAT- MEDLINE
DCOM- 20140116
LR  - 20151119
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 115
IP  - 7
DP  - 2013 Jul
TI  - Clinical and biochemical aspirin resistance in patients with recurrent cerebral 
      ischemia.
PG  - 944-7
LID - S0303-8467(12)00513-6 [pii]
LID - 10.1016/j.clineuro.2012.09.025 [doi]
AB  - BACKGROUND AND AIM: Stroke recurrence is an important public health concern. One 
      half of survivors remain disabled, and one seventh requires institutional care. 
      Aspirin remains the cornerstone of primary and secondary stroke prevention; 
      meanwhile, aspirin resistance is one of the possible causes of stroke recurrence. 
      We aimed to evaluate the clinical and biochemical aspirin resistance in patients 
      with recurrent ischemic stroke. PATIENTS AND METHODS: We studied demographic 
      characteristics, vascular risk factors, stroke subtypes, radiologic findings and 
      biochemical aspirin resistance tests using both arachidonic acid (AA) and 
      adenosine diphosphate (ADP)-induced light transmittance aggregometry (LTA) on 
      admission and 24 h after observed aspirin ingestion. RESULTS: Of the 82 patients 
      with recurrent cerebral ischemia included in this study, 37 (45%) patients were 
      poor compliant with aspirin. There were no statistically significant differences 
      between the two groups regarding the demographic characteristics, stroke 
      severity, laboratory tests, radiological findings or vascular risk factors. On 
      admission, 19.6% and 4.8% of patients showed aspirin resistance, while 24 h after 
      supervised 300 mg single aspirin dose ingestion, it was 9.8% and 2.4% using ADP 
      and AA-induced LTA respectively. Of the eight aspirin resistant patients, two 
      only showed resistance using both AA and ADP. Aspirin resistance was 
      statistically significantly higher in the male gender, older age, hyperlipidemia, 
      smokers and in all lacunar strokes using AA. CONCLUSION: Biochemical aspirin 
      resistance in one's series was rather rare (2.4%) and was more prevalent in 
      patients with lacunar strokes. Clinical aspirin failure may often be contributed 
      to poor compliance with aspirin intake.
CI  - Copyright © 2012 Elsevier B.V. All rights reserved.
FAU - El-Mitwalli, Ashraf
AU  - El-Mitwalli A
AD  - Department of Neurology, University of Mansoura, Egypt. metwally99@yahoo.com
FAU - Azzam, Hanan
AU  - Azzam H
FAU - Abu-Hegazy, Mohammad
AU  - Abu-Hegazy M
FAU - Gomaa, Mohamed
AU  - Gomaa M
FAU - Wasel, Yasser
AU  - Wasel Y
LA  - eng
PT  - Journal Article
DEP - 20121012
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adenosine Diphosphate
MH  - Aged
MH  - Arachidonic Acid
MH  - Aspirin/*therapeutic use
MH  - Brain Ischemia/*drug therapy/*metabolism
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Recurrence
MH  - Specimen Handling
MH  - Treatment Failure
EDAT- 2012/10/17 06:00
MHDA- 2014/01/17 06:00
CRDT- 2012/10/17 06:00
PHST- 2012/02/18 00:00 [received]
PHST- 2012/09/18 00:00 [revised]
PHST- 2012/09/20 00:00 [accepted]
PHST- 2012/10/17 06:00 [entrez]
PHST- 2012/10/17 06:00 [pubmed]
PHST- 2014/01/17 06:00 [medline]
AID - S0303-8467(12)00513-6 [pii]
AID - 10.1016/j.clineuro.2012.09.025 [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 2013 Jul;115(7):944-7. doi: 
      10.1016/j.clineuro.2012.09.025. Epub 2012 Oct 12.

PMID- 29621646
OWN - NLM
STAT- MEDLINE
DCOM- 20180822
LR  - 20180822
IS  - 1095-7103 (Electronic)
IS  - 0021-9797 (Linking)
VI  - 523
DP  - 2018 Aug 1
TI  - Electrochemical synthesis of nitrogen-doped carbon quantum dots decorated copper 
      oxide for the sensitive and selective detection of non-steroidal 
      anti-inflammatory drug in berries.
PG  - 191-200
LID - S0021-9797(18)30351-5 [pii]
LID - 10.1016/j.jcis.2018.03.095 [doi]
AB  - We report a sensitive non-steroidal anti-inflammatory drug aspirin (ASA) sensor 
      studies using the nitrogen-doped carbon quantum dots (N-CQD) decorated copper 
      oxide (Cu(2)O). A simplistic approach of electrochemical deposition method has 
      been used to prepare the N-CQD incorporated with copper oxide (N-CQD/Cu(2)O) and 
      the resulting composite has characterized by analytical techniques. Modified 
      glassy carbon electrode of N-CQD/Cu(2)O/GCE is developed and is used for the 
      sensor studies of aspirin. The modified N-CQD/Cu(2)O/GCE has exhibited a higher 
      current (I(pa)) response to the oxidation process when compared to N-CQD/GCE, 
      Cu(2)O/GCE and bare GCE. Furthermore, it has shown a good linear range of 
      1-907 µM with a limit of detection (LOD) ∼0.002 µM and sensitivity 
      ∼21.87 µA µM(-1) cm(-2). The developed sensor has displayed outstanding 
      repeatability, stability and accumulation time along with better 
      electro-catalytic response in berries for real-life application.
CI  - Copyright © 2018 Elsevier Inc. All rights reserved.
FAU - Muthusankar, Ganesan
AU  - Muthusankar G
AD  - Department of Industrial Chemistry, Alagappa University, Karaikudi 630003, Tamil 
      Nadu, India.
FAU - Sasikumar, Ragu
AU  - Sasikumar R
AD  - Department of Chemical Engineering and Biotechnology, National Taipei University 
      of Technology, No. 1, Section 3, Chung-Hsiao East Road, Taipei 106, Taiwan, ROC.
FAU - Chen, Shen-Ming
AU  - Chen SM
AD  - Department of Chemical Engineering and Biotechnology, National Taipei University 
      of Technology, No. 1, Section 3, Chung-Hsiao East Road, Taipei 106, Taiwan, ROC. 
      Electronic address: smchen78@ms15.hinet.net.
FAU - Gopu, Gopalakrishnan
AU  - Gopu G
AD  - Department of Industrial Chemistry, Alagappa University, Karaikudi 630003, Tamil 
      Nadu, India. Electronic address: nggopi79@gmail.com.
FAU - Sengottuvelan, Nallathambi
AU  - Sengottuvelan N
AD  - Department of Industrial Chemistry, Alagappa University, Karaikudi 630003, Tamil 
      Nadu, India.
FAU - Rwei, Syang-Peng
AU  - Rwei SP
AD  - Institute of Organic and Polymeric Materials, National Taipei University of 
      Technology, No. 1, Section 3, Chung-Hsiao East Road, Taipei 106, Taiwan, ROC.
LA  - eng
PT  - Journal Article
DEP - 20180329
PL  - United States
TA  - J Colloid Interface Sci
JT  - Journal of colloid and interface science
JID - 0043125
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 7440-44-0 (Carbon)
RN  - 789U1901C5 (Copper)
RN  - N762921K75 (Nitrogen)
RN  - R16CO5Y76E (Aspirin)
RN  - T8BEA5064F (cuprous oxide)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*analysis
MH  - Aspirin/analysis
MH  - Carbon/*chemistry
MH  - Catalysis
MH  - Copper/*chemistry
MH  - Electrochemical Techniques
MH  - Electrodes
MH  - Fruit/*chemistry
MH  - Limit of Detection
MH  - Nitrogen/*chemistry
MH  - Oxidation-Reduction
MH  - Particle Size
MH  - Quantum Dots/*chemistry
MH  - Surface Properties
OTO - NOTNLM
OT  - Aspirin
OT  - Carbon quantum dots
OT  - Copper oxide
OT  - Electrochemical deposition
OT  - Electrochemical sensor
EDAT- 2018/04/06 06:00
MHDA- 2018/08/23 06:00
CRDT- 2018/04/06 06:00
PHST- 2018/01/14 00:00 [received]
PHST- 2018/03/20 00:00 [revised]
PHST- 2018/03/27 00:00 [accepted]
PHST- 2018/04/06 06:00 [pubmed]
PHST- 2018/08/23 06:00 [medline]
PHST- 2018/04/06 06:00 [entrez]
AID - S0021-9797(18)30351-5 [pii]
AID - 10.1016/j.jcis.2018.03.095 [doi]
PST - ppublish
SO  - J Colloid Interface Sci. 2018 Aug 1;523:191-200. doi: 10.1016/j.jcis.2018.03.095. 
      Epub 2018 Mar 29.

PMID- 2589050
OWN - NLM
STAT- MEDLINE
DCOM- 19900103
LR  - 20190820
IS  - 0001-639X (Print)
IS  - 0001-639X (Linking)
VI  - 67
IP  - 5
DP  - 1989 Oct
TI  - Protection against cataract by aspirin, paracetamol and ibuprofen.
PG  - 518-24
AB  - Results of a case-control of 423 cataract patients and 608 controls in 
      Oxfordshire shows that the protective effect against cataract associated with 
      consumption of aspirin-like analgesics (aspirin, paracetamol and ibuprofen 
      family) is manifest even at low doses. Less than 150 g total dose was associated 
      with a halving of the risk of cataract extraction.
FAU - Harding, J J
AU  - Harding JJ
AD  - Nuffield Laboratory of Ophthalmology, University of Oxford, UK.
FAU - Egerton, M
AU  - Egerton M
FAU - Harding, R S
AU  - Harding RS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Acta Ophthalmol (Copenh)
JT  - Acta ophthalmologica
JID - 0370347
RN  - 362O9ITL9D (Acetaminophen)
RN  - R16CO5Y76E (Aspirin)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/*administration & dosage
MH  - Aged
MH  - Aspirin/*administration & dosage
MH  - Cataract/epidemiology/*prevention & control
MH  - England/epidemiology
MH  - Female
MH  - Humans
MH  - Ibuprofen/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
EDAT- 1989/10/01 00:00
MHDA- 1989/10/01 00:01
CRDT- 1989/10/01 00:00
PHST- 1989/10/01 00:00 [pubmed]
PHST- 1989/10/01 00:01 [medline]
PHST- 1989/10/01 00:00 [entrez]
AID - 10.1111/j.1755-3768.1989.tb04102.x [doi]
PST - ppublish
SO  - Acta Ophthalmol (Copenh). 1989 Oct;67(5):518-24. doi: 
      10.1111/j.1755-3768.1989.tb04102.x.

PMID- 725433
OWN - NLM
STAT- MEDLINE
DCOM- 19790223
LR  - 20191028
IS  - 0300-3396 (Print)
IS  - 0300-3396 (Linking)
VI  - Suppl
DP  - 1978
TI  - Ketoprofen experiences.
PG  - 109-11
AB  - Ketoprofen is better tolerated than the other most common non-steroidal 
      anti-inflammatory drugs. Cross-reactivity in the form of allergic reactions 
      appears almost non-existent. The G.I. symptoms are less pronounced with 
      ketoprofen than with the other drugs tested so far.
FAU - Peltola, P
AU  - Peltola P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Rheumatol Rehabil
JT  - Rheumatology and rehabilitation
JID - 0355004
RN  - 0 (Phenylpropionates)
RN  - 90Y4QC304K (Ketoprofen)
RN  - GN5P7K3T8S (Phenylbutazone)
RN  - R16CO5Y76E (Aspirin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Humans
MH  - Indomethacin/adverse effects
MH  - Ketoprofen/*adverse effects
MH  - Phenylbutazone/adverse effects
MH  - Phenylpropionates/*adverse effects
EDAT- 1978/01/01 00:00
MHDA- 1978/01/01 00:01
CRDT- 1978/01/01 00:00
PHST- 1978/01/01 00:00 [pubmed]
PHST- 1978/01/01 00:01 [medline]
PHST- 1978/01/01 00:00 [entrez]
AID - 10.1093/rheumatology/xvii.suppl.109 [doi]
PST - ppublish
SO  - Rheumatol Rehabil. 1978;Suppl:109-11. doi: 10.1093/rheumatology/xvii.suppl.109.

PMID- 36100758
OWN - NLM
STAT- MEDLINE
DCOM- 20221104
LR  - 20221201
IS  - 1432-1912 (Electronic)
IS  - 0028-1298 (Linking)
VI  - 395
IP  - 12
DP  - 2022 Dec
TI  - Aspirin reverts lipopolysaccharide-induced learning and memory impairment: first 
      evidence from an invertebrate model system.
PG  - 1573-1585
LID - 10.1007/s00210-022-02286-4 [doi]
AB  - By employing a reductionistic (but not simplistic) approach using an established 
      invertebrate model system, the pond snail Lymnaea stagnalis, we investigated 
      whether (1) lipopolysaccharide (LPS)-induced inflammation would cause a sickness 
      state and impair cognitive function, and-if so-(2) would aspirin (acetylsalicylic 
      acid-ASA) restore the impaired cognition. To test our hypotheses, we first 
      determined if the injection of 25 mg (6.25 μg/mL) of Escherichia coli-derived LPS 
      serotype O127:B8 altered homeostatic behavior, aerial respiration, and then 
      determined if LPS altered memory formation when this behavior was operantly 
      conditioned. Next, we determined if ASA altered the LPS-induced changes in both 
      aerial respiration and cognitive functions. LPS induced a sickness state that 
      increased aerial respiration and altered the ability of snails to form or recall 
      long-term memory. ASA reverted the LPS-induced sickness state and thus allowed 
      long-term memory both to be formed and recalled. We confirmed our hypotheses and 
      provided the first evidence in an invertebrate model system that an injection of 
      LPS results in a sickness state that obstructs learning and memory, and this 
      impairment can be prevented by a non-steroidal anti-inflammatory.
CI  - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Rivi, Veronica
AU  - Rivi V
AUID- ORCID: 0000-0002-8413-4510
AD  - Department of Life Sciences, University of Modena and Reggio Emilia, Modena, 
      Italy. veronica.rivi@unimore.it.
FAU - Batabyal, Anuradha
AU  - Batabyal A
AD  - Department of Physiology and Pharmacology, Hotchkiss Brain Institute, Cumming 
      School of Medicine, University of Calgary, Alberta, Canada.
FAU - Benatti, Cristina
AU  - Benatti C
AD  - Department of Life Sciences, University of Modena and Reggio Emilia, Modena, 
      Italy.
AD  - Centre of Neuroscience and Neurotechnology, University of Modena and Reggio 
      Emilia, Modena, Italy.
FAU - Tascedda, Fabio
AU  - Tascedda F
AD  - Department of Life Sciences, University of Modena and Reggio Emilia, Modena, 
      Italy.
AD  - Centre of Neuroscience and Neurotechnology, University of Modena and Reggio 
      Emilia, Modena, Italy.
AD  - CIB, Consorzio Interuniversitario Biotecnologie, Trieste, Italy.
FAU - Blom, Joan M C
AU  - Blom JMC
AD  - CIB, Consorzio Interuniversitario Biotecnologie, Trieste, Italy.
AD  - Department of Biomedical, Metabolic and Neural Sciences, University of Modena and 
      Reggio Emilia, Modena, Italy.
FAU - Lukowiak, Ken
AU  - Lukowiak K
AD  - Department of Physiology and Pharmacology, Hotchkiss Brain Institute, Cumming 
      School of Medicine, University of Calgary, Alberta, Canada.
LA  - eng
PT  - Journal Article
DEP - 20220914
PL  - Germany
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
RN  - 0 (Lipopolysaccharides)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - *Lipopolysaccharides/toxicity
MH  - *Memory
MH  - Conditioning, Operant
MH  - Aspirin/pharmacology
MH  - Lymnaea
MH  - Memory Disorders/chemically induced/drug therapy
OTO - NOTNLM
OT  - Aerial respiration
OT  - Homeostasis
OT  - Immune challenge
OT  - Inflammation
OT  - Learning
OT  - Lymnaea stagnalis
OT  - memory
EDAT- 2022/09/14 06:00
MHDA- 2022/11/05 06:00
CRDT- 2022/09/13 23:27
PHST- 2022/07/11 00:00 [received]
PHST- 2022/08/31 00:00 [accepted]
PHST- 2022/09/14 06:00 [pubmed]
PHST- 2022/11/05 06:00 [medline]
PHST- 2022/09/13 23:27 [entrez]
AID - 10.1007/s00210-022-02286-4 [pii]
AID - 10.1007/s00210-022-02286-4 [doi]
PST - ppublish
SO  - Naunyn Schmiedebergs Arch Pharmacol. 2022 Dec;395(12):1573-1585. doi: 
      10.1007/s00210-022-02286-4. Epub 2022 Sep 14.

PMID- 29735456
OWN - NLM
STAT- MEDLINE
DCOM- 20190816
LR  - 20190816
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 31
IP  - 3(Special)
DP  - 2018 May
TI  - Effect of different types of anticoagulants in the prevention of venous 
      thrombosis in the operation of knee joint bone operation.
PG  - 1093-1097
AB  - Deep venous thrombosis is one of the common complications after major surgery in 
      the Department of Orthopedics. The selective knee replacement of the lower 
      extremities is more likely to cause the occurrence of DVT. The most commonly used 
      anticoagulants in the Department of Orthopedics now include low molecular weight 
      heparin (LMWH), Rivaroxaban, ordinary heparin, aspirin and warfarin. At present, 
      the clinical application of low molecular weight heparin is the most, and the 
      effect is the most accurate. This study compared the efficacy and safety of three 
      commonly used anticoagulants such as aspirin, LMWH and Rivaroxaban in preventing 
      VTE after hip and knee arthroplasty, so as to provide a theoretical basis for 
      selecting suitable anticoagulant drugs in clinic. It has been proved that LMWH 
      has good efficacy and safety in the prevention of VTE after hip and knee 
      arthroplasty and is a priority anticoagulant. Rivaroxaban can effectively control 
      the occurrence of DVT and the drug is convenient, but it will increase the risk 
      of bleeding and should be used carefully.
FAU - Xu, Wensheng
AU  - Xu W
AD  - Qilu Hospital of Shandong University, Jinan City, Shandong, China / First 
      Affiliated Hospital of Baotou Medical College, Baotou City, Inner Mongolia, 
      China.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Baotou Medical College, Baotou City, Inner Mongolia, China.
FAU - Yang, Zenghua
AU  - Yang Z
AD  - First Affiliated Hospital of Baotou Medical College, Baotou City, Inner Mongolia, 
      China.
FAU - Nie, Lin
AU  - Nie L
AD  - Qilu Hospital of Shandong University, Jinan City, Shandong, China.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - R16CO5Y76E (Aspirin)
MH  - Aged
MH  - Anticoagulants/therapeutic use
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rivaroxaban/*therapeutic use
MH  - Venous Thrombosis/*etiology/prevention & control
EDAT- 2018/05/08 06:00
MHDA- 2019/08/17 06:00
CRDT- 2018/05/09 06:00
PHST- 2018/05/09 06:00 [entrez]
PHST- 2018/05/08 06:00 [pubmed]
PHST- 2019/08/17 06:00 [medline]
PST - ppublish
SO  - Pak J Pharm Sci. 2018 May;31(3(Special)):1093-1097.

PMID- 2956842
OWN - NLM
STAT- MEDLINE
DCOM- 19870909
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 60
IP  - 3
DP  - 1987 Jul 31
TI  - The Frankfurt experience in restenosis after coronary angioplasty.
PG  - 48B-49B
AB  - Three hundred and thirty-three of 356 patients underwent angiographic follow-up 
      from 1 to 18 months (mean 5.6 months) after percutaneous transluminal coronary 
      angioplasty (PTCA). This is a reangiography rate of 94%. Recurrence rate after 
      the first PTCA was 15% (n = 289). Restenosis rate was defined as an increase from 
      immediate post-PTCA stenosis of more than 30%, or the loss of at least half of 
      the initial gain in luminal diameter. Patients who needed a second angioplasty 
      due to restenosis (n = 30) had a restenosis rate of 33%. Patients with 
      angioplasty in the aortocoronary bypass (n = 14) had a restenosis rate of 45%. 
      All patients were treated before, during and at least 4 to 6 months after the 
      procedure with 60 to 100 mg of isosorbide dinitrate daily plus 160 to 360 mg of 
      verapamil or 100 to 150 mg of gallopamil and 1.5 g of acetylsalicylic acid. In a 
      second retrospective study 111 of 399 patients had the acetylsalicylic acid 
      therapy discontinued or decreased. Forty-two of them developed restenosis (38%), 
      whereas only 49 of 288 patients who continued to receive 1.5 g aspirin developed 
      restenosis (17%). The restenosis rate was 32% in those who received the reduced 
      dose of aspirin. Thus, a large dose of acetylsalicylic acid given before, during 
      and 4 to 6 months after the procedure seems to be necessary to achieve a low rate 
      of restenosis after PTCA.
FAU - Bussmann, W D
AU  - Bussmann WD
FAU - Kaltenbach, M
AU  - Kaltenbach M
FAU - Kober, G
AU  - Kober G
FAU - Vallbracht, C
AU  - Vallbracht C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Calcium Channel Blockers)
RN  - IA7306519N (Isosorbide Dinitrate)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon
MH  - Aspirin/therapeutic use
MH  - Calcium Channel Blockers/therapeutic use
MH  - Coronary Disease/prevention & control/*therapy
MH  - Follow-Up Studies
MH  - Germany, West
MH  - Humans
MH  - Isosorbide Dinitrate/therapeutic use
MH  - Recurrence
MH  - Retrospective Studies
MH  - Time Factors
EDAT- 1987/07/31 00:00
MHDA- 1987/07/31 00:01
CRDT- 1987/07/31 00:00
PHST- 1987/07/31 00:00 [pubmed]
PHST- 1987/07/31 00:01 [medline]
PHST- 1987/07/31 00:00 [entrez]
AID - 0002-9149(87)90484-X [pii]
AID - 10.1016/0002-9149(87)90484-x [doi]
PST - ppublish
SO  - Am J Cardiol. 1987 Jul 31;60(3):48B-49B. doi: 10.1016/0002-9149(87)90484-x.

PMID- 6408645
OWN - NLM
STAT- MEDLINE
DCOM- 19830811
LR  - 20200930
IS  - 0037-9727 (Print)
IS  - 0037-9727 (Linking)
VI  - 173
IP  - 2
DP  - 1983 Jun
TI  - Antirheumatic drug effects on neutrophil response to chemotactic factors: a 
      comparison of analytical techniques.
PG  - 200-4
AB  - A recently reported technique employing the leukotactic index which represents 
      all migrating cells in vitro neutrophil chemotaxis systems, was compared to the 
      leading front technique for assaying antirheumatic drug effects on this important 
      neutrophil function. Normal human neutrophils were treated with therapeutic 
      concentrations of aspirin, gold sodium thiomalate, D-penicillamine, and 
      azathioprine. The responses of these cells and of control cells to 
      neutrophil-immune complex-serum-derived chemotactic factors were assayed in 
      Boyden chambers. Significant (P less than 0.05) inhibition was observed by the 
      leading front technique only for D-penicillamine at high concentrations. 
      Significant (P less than 0.01) inhibition was seen with D-penicillamine at 
      therapeutic plasma levels with the leukotactic index technique. Gold sodium 
      thiomalate and aspirin at high concentrations also produced significant (P less 
      than 0.01 and P less than 0.05) inhibition of chemotaxis as assayed by the 
      leukotactic index procedure. Azathioprine had no significant effects when studied 
      with either technique. These results indicate that the leukotactic index may be a 
      more sensitive technique for quantitating neutrophil migration in response to 
      chemotactic factors and may therefore provide useful additional information for 
      determining the effects of antirheumatic drugs on this important neutrophil 
      function.
FAU - Turner, R A
AU  - Turner RA
FAU - Johnson, J A
AU  - Johnson JA
FAU - Semble, E L
AU  - Semble EL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Proc Soc Exp Biol Med
JT  - Proceedings of the Society for Experimental Biology and Medicine. Society for 
      Experimental Biology and Medicine (New York, N.Y.)
JID - 7505892
RN  - 0 (Chemotactic Factors)
RN  - 12244-57-4 (Gold Sodium Thiomalate)
RN  - GNN1DV99GX (Penicillamine)
RN  - MRK240IY2L (Azathioprine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/pharmacology
MH  - Azathioprine/pharmacology
MH  - Chemotactic Factors/*pharmacology
MH  - Chemotaxis, Leukocyte/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Gold Sodium Thiomalate/pharmacology
MH  - Humans
MH  - Neutrophils/*physiology
MH  - Penicillamine/pharmacology
MH  - Rheumatic Diseases/*drug therapy
EDAT- 1983/06/01 00:00
MHDA- 1983/06/01 00:01
CRDT- 1983/06/01 00:00
PHST- 1983/06/01 00:00 [pubmed]
PHST- 1983/06/01 00:01 [medline]
PHST- 1983/06/01 00:00 [entrez]
AID - 10.3181/00379727-173-41631 [doi]
PST - ppublish
SO  - Proc Soc Exp Biol Med. 1983 Jun;173(2):200-4. doi: 10.3181/00379727-173-41631.

PMID- 23534465
OWN - NLM
STAT- MEDLINE
DCOM- 20130718
LR  - 20220318
IS  - 0895-3988 (Print)
IS  - 0895-3988 (Linking)
VI  - 26
IP  - 4
DP  - 2013 Apr
TI  - Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined 
      aspirin and low-dose diethylstilbestrol.
PG  - 249-57
LID - 10.3967/0895-3988.2013.04.003 [doi]
AB  - OBJECTIVE: To study whether effect of aspirin plus low-dose diethylstilbestrol is 
      more effective and safer than high diethylstilbestrol dose alone on prevention of 
      ovariectomy-induced osteopenia and dyslipidemia. METHODS: Thirty-eight 
      4-month-old female SD rats were divided into baseline (BAS) group (n=6), sham 
      operation group (n=8) and ovariectomy (OVX) group (n=24). The OVX group was 
      further divided into vehicle treatment group (n=8), diethylstilbestrol (30 
      μg/kg•d) treatment group (OVX+D30 group, n=8), and aspirin (9 mg/kg•d) plus 
      diethylstilbestrol (10 μg/kg•d) treatment group (OVX+A-D10 group, n=8). Their 
      left tibiae were collected for the bone histomorphometric analysis in 
      undecalcified sections. Left femurs were collected for the bone mineral density 
      measurement. RESULTS: The body weight and serum cholesterol were increased, while 
      uterine weight and cancellous bone mass were decreased in OVX rats compared with 
      the SHAM group. Cancellous bone mass was significantly increased, while body 
      weight and bone resorption parameters were decreased in both A-D10 and D30 
      treatment group compared with OVX group. The rats treated with A-D10 showed 
      significantly increased in bone formation parameters and decreased in serum 
      triglyceride compared with the D30-treated rats. CONCLUSION: Aspirin plus 
      low-dose diethylstilbestrol can effectively prevent osteopenia by reducing bone 
      resorption, and is thus a better treatment modality for preventing dyslipidemia 
      than high-dose diethylstilbestrol alone.
CI  - Copyright © 2013 The Editorial Board of Biomedical and Environmental Sciences. 
      Published by China CDC. All rights reserved.
FAU - Lin, Si En
AU  - Lin SE
AD  - Department of Pharmacology, Guangdong Medical College, Zhanjiang 524023, 
      Guangdong, China.
FAU - Huang, Jian Ping
AU  - Huang JP
FAU - Wu, Ling Zhi
AU  - Wu LZ
FAU - Wu, Tie
AU  - Wu T
FAU - Cui, Liao
AU  - Cui L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Biomed Environ Sci
JT  - Biomedical and environmental sciences : BES
JID - 8909524
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Estrogens, Non-Steroidal)
RN  - 731DCA35BT (Diethylstilbestrol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Biomarkers/blood
MH  - Body Weight/drug effects
MH  - Bone Density
MH  - Bone Diseases, Metabolic/blood/*prevention & control
MH  - Bone and Bones/drug effects
MH  - Diethylstilbestrol/pharmacology/*therapeutic use
MH  - Drug Evaluation, Preclinical
MH  - Drug Therapy, Combination
MH  - Dyslipidemias/blood/*prevention & control
MH  - Estrogens, Non-Steroidal/pharmacology/*therapeutic use
MH  - Female
MH  - Organ Size/drug effects
MH  - Ovariectomy
MH  - Rats
MH  - Uterus/drug effects
OTO - NOTNLM
OT  - Aspirin
OT  - Diethylstilbestrol
OT  - Dyslipidemia
OT  - Osteoporosis
OT  - Ovariectomy
OT  - Rat
EDAT- 2013/03/29 06:00
MHDA- 2013/07/19 06:00
CRDT- 2013/03/29 06:00
PHST- 2012/01/17 00:00 [received]
PHST- 2012/06/05 00:00 [accepted]
PHST- 2013/03/29 06:00 [entrez]
PHST- 2013/03/29 06:00 [pubmed]
PHST- 2013/07/19 06:00 [medline]
AID - S0895-3988(13)60003-3 [pii]
AID - 10.3967/0895-3988.2013.04.003 [doi]
PST - ppublish
SO  - Biomed Environ Sci. 2013 Apr;26(4):249-57. doi: 10.3967/0895-3988.2013.04.003.

PMID- 24274222
OWN - NLM
STAT- MEDLINE
DCOM- 20140926
LR  - 20211021
IS  - 1945-8932 (Electronic)
IS  - 1945-8924 (Print)
IS  - 1945-8932 (Linking)
VI  - 27
IP  - 6
DP  - 2013 Nov-Dec
TI  - Epidemiology and differential diagnosis of nasal polyps.
PG  - 473-8
LID - 10.2500/ajra.2013.27.3981 [doi]
AB  - BACKGROUND: Chronic rhinosinusitis (CRS) is one of the most common chronic 
      medical conditions, with a significant impact on patient quality of life. CRS is 
      broadly classified into two groups: CRS with nasal polyposis (CRSwNP) and CRS 
      without NP (CRSsNP). Clinically, the major subtypes of CRSwNP may be divided into 
      eosinophilic chronic rhinosinusitis (e.g., allergic fungal rhinosinusitis and 
      aspirin-exacerbated respiratory disease [AERD]) and nasal polyps associated with 
      neutrophilic inflammation (e.g., cystic fibrosis [CF]). CF is characterized by 
      mutation of the gene encoding the CF transmembrane conductance regulator. 
      Functional endoscopic sinus surgery is usually required for most NP patients with 
      increased frequency in patients with AERD. This study provides a review of the 
      epidemiology and major classification of CRSwNP. METHODS: A review was performed 
      of the literature regarding different subtypes of CRSwNP. RESULTS: Many 
      definitions of CRSwNP exist and estimates of prevalence vary. CONCLUSION: CRSwNP 
      is a clinical syndrome with a heterogeneous inflammatory profile. Of the subtypes 
      associated with eosinophilic inflammation, AERD remains the most recalcitrant to 
      medical and surgical therapeutic interventions.
FAU - Chaaban, Mohamad R
AU  - Chaaban MR
AD  - Department of Surgery, Division of Otolaryngology, the Gregory Fleming James 
      Cystic Fibrosis Research Center, Birmingham, Alabama, USA.
FAU - Walsh, Erika M
AU  - Walsh EM
FAU - Woodworth, Bradford A
AU  - Woodworth BA
LA  - eng
GR  - K08 HL107142/HL/NHLBI NIH HHS/United States
GR  - 1K08HL107142-01/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects
MH  - Cystic Fibrosis/diagnosis
MH  - *Diagnosis, Differential
MH  - Humans
MH  - Nasal Polyps/*diagnosis/*epidemiology
MH  - Rhinitis/diagnosis
MH  - Sinusitis/diagnosis
PMC - PMC3899526
EDAT- 2013/11/28 06:00
MHDA- 2014/09/27 06:00
CRDT- 2013/11/27 06:00
PHST- 2013/11/27 06:00 [entrez]
PHST- 2013/11/28 06:00 [pubmed]
PHST- 2014/09/27 06:00 [medline]
AID - AJRA080-13 [pii]
AID - 10.2500/ajra.2013.27.3981 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2013 Nov-Dec;27(6):473-8. doi: 10.2500/ajra.2013.27.3981.

PMID- 11453347
OWN - NLM
STAT- MEDLINE
DCOM- 20010809
LR  - 20131121
IS  - 0028-8446 (Print)
IS  - 0028-8446 (Linking)
VI  - 114
IP  - 1133
DP  - 2001 Jun 8
TI  - Implementation of evidence based cardiovascular risk treatments by general 
      practitioners.
PG  - 260-2
AB  - AIM: To review general practitioner (GP) implementation of evidence based 
      cardiovascular risk reducing strategies in subjects with coronary heart disease 
      (CHD). METHODS: Audit of patient records of randomly selected GPs. RESULTS: There 
      were 326 subjects with CHD under the care of 21 doctors. Except for smoking, 
      details of lifestyle measures were rarely found in the notes. Advice on diet and 
      exercise was mentioned in 51% and 23.3% of records respectively. Aspirin and 
      beta-blockers were widely used. Of patients with drug untreated values of total 
      cholesterol (TC) and/or TC/HDL exceeding National Heart Foundation (NHF) 
      guidelines, 71% were prescribed lipid-modifying drugs. NHF targets for TC (< or = 
      5.0 mmol/l) were achieved by 37% and for TC/HDL (< or = 4.5) by 60%. TC remained 
      above 5.5 mmol/L in 120 cases. Lipid results from tests within the last 12 months 
      were found in 60% of cases. CONCLUSIONS: Recording of lifestyle treatments in 
      subjects with CHD appears to be assigned low priority. Cardioprotective 
      treatments were widely used. Cholesterol levels were recorded frequently and of 
      those with values exceeding NHF guidelines, nearly 3/4 were on medication. 
      Recommended targets for lipid parameters were being achieved by <50% of patients. 
      More frequent monitoring could improve this outcome
FAU - Crossen, K
AU  - Crossen K
AD  - Lipid and Diabetes Research Group, Christchurch Hospital.
FAU - Scott, R S
AU  - Scott RS
FAU - McGeoch, G R
AU  - McGeoch GR
FAU - George, P M
AU  - George PM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - N Z Med J
JT  - The New Zealand medical journal
JID - 0401067
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Hypolipidemic Agents)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Coronary Disease/*prevention & control/therapy
MH  - *Evidence-Based Medicine
MH  - *Family Practice
MH  - Female
MH  - Humans
MH  - Hypolipidemic Agents/therapeutic use
MH  - Life Style
MH  - Male
MH  - Medical Audit
MH  - Medical History Taking
MH  - Risk Factors
EDAT- 2001/07/17 10:00
MHDA- 2001/08/10 10:01
CRDT- 2001/07/17 10:00
PHST- 2001/07/17 10:00 [pubmed]
PHST- 2001/08/10 10:01 [medline]
PHST- 2001/07/17 10:00 [entrez]
PST - ppublish
SO  - N Z Med J. 2001 Jun 8;114(1133):260-2.

PMID- 7660160
OWN - NLM
STAT- MEDLINE
DCOM- 19951004
LR  - 20191031
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 21 Suppl 2
DP  - 1995
TI  - Shear-induced pathway of platelet function in cardiac surgery.
PG  - 66-70
AB  - The contribution of platelet dysfunction to the impaired hemostasis after cardiac 
      surgery remains to be established, because there is no sensitive method to assess 
      platelet function. Measurement of the shear-induced pathway of platelet function, 
      an important mechanism in inducing hemostasis, became possible by a novel 
      shear-inducing technique, the in-vitro bleeding test (Thrombostat 4000). By using 
      this test, the changes in platelet function during cardiopulmonary bypass and 
      their contribution to hemostasis were investigated in patients undergoing cardiac 
      surgery. Platelet function is quickly impaired shortly after the start of 
      cardiopulmonary bypass, and partly recovered at the end of cardiopulmonary 
      bypass. The function of aspirin-treated platelets is more severely affected than 
      of nonaspirin platelets during cardiopulmonary bypass. Furthermore, the degree of 
      platelet dysfunction at the end of the operation, but neither the platelet number 
      nor the activated clotting time, was significantly correlated with blood loss 
      from the chest drain after cardiac surgery. These results indicate the 
      significant and variable effects of cardiopulmonary bypass on the shear-induced 
      pathway of platelet function. Moreover, the impairment of this function of 
      platelets appears to be a major cause of excessive bleeding in patients after 
      cardiac surgery. Therefore, the routine use of the shear-inducing test seems 
      helpful to make a proper diagnosis and design the therapy for bleeders after 
      cardiac surgery.
FAU - Tabuchi, N
AU  - Tabuchi N
AD  - Dept of Blood Interaction Research, Cardiopulmonary Surgery, University Hospital, 
      Groningen, The Netherlands.
FAU - Tigchelaar, I
AU  - Tigchelaar I
FAU - van Oeveren, W
AU  - van Oeveren W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage
MH  - Blood Coagulation Tests/instrumentation
MH  - Blood Loss, Surgical/*prevention & control
MH  - Blood Platelets/drug effects/*physiology
MH  - Cardiopulmonary Bypass/*adverse effects
MH  - *Hemostasis, Surgical
MH  - Humans
MH  - *Prothrombin Time
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1055/s-0032-1313605 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 1995;21 Suppl 2:66-70. doi: 10.1055/s-0032-1313605.

PMID- 2524053
OWN - NLM
STAT- MEDLINE
DCOM- 19890613
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 18
IP  - 15
DP  - 1989 Apr 15
TI  - [Prevention of complications of severe arterial hypertension in pregnancy using 
      platelet antiaggregants].
PG  - 767-9
AB  - A prospective study conducted between January, 1985 and September, 1987 involved 
      60 pregnant women who had previously suffered from hypertension in pregnancy with 
      or without foetal and maternal complications. Thirty women received aspirin 250 
      mg every other day and dipyridamole 300 mg per day, starting from the 3rd month 
      of pregnancy (group I); 30 women were examined regularly from the onset of 
      pregnancy and received the conventional symptomatic treatment of complications 
      that occurred (group II). Women in these two groups were similar in age, parity 
      and previous obstetrical complications. Twenty-five women of group I had a 
      perfectly normal pregnancy, as against 5 women of group II (P less than 0.001). 
      Hypertension and/or proteinuria were observed in 5 women of group I and 15 of 
      group II (NS). The 13 severe complications recorded (foetal death, eclampsia, 
      retroplacental haematoma) occurred exclusively in women of group II. The duration 
      of pregnancy and weight of the newborn were significantly greater in group I than 
      in group II. Thus, antiplatelets appear to have an uncertain preventive effect on 
      hypertension of pregnancy and a much more obvious prophylactic effect on major 
      foetal and maternal complications.
FAU - Hachicha, J
AU  - Hachicha J
AD  - Services de Médecine interne, CHU Hedi Chaker, Sfax, Tunisie.
FAU - Ammous, A
AU  - Ammous A
FAU - Damak, J
AU  - Damak J
FAU - Hammami, M
AU  - Hammami M
FAU - Ghorbel, A
AU  - Ghorbel A
FAU - Rekik, S
AU  - Rekik S
FAU - Jarraya, A
AU  - Jarraya A
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Prévention des complications de l'hypertension artérielle gravidique par les 
      antiagrégants plaquettaires.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 64ALC7F90C (Dipyridamole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin/*therapeutic use
MH  - Dipyridamole/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Hypertension/complications/*prevention & control
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*prevention & control
MH  - Prospective Studies
MH  - Proteinuria/complications
EDAT- 1989/04/15 00:00
MHDA- 1989/04/15 00:01
CRDT- 1989/04/15 00:00
PHST- 1989/04/15 00:00 [pubmed]
PHST- 1989/04/15 00:01 [medline]
PHST- 1989/04/15 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1989 Apr 15;18(15):767-9.

PMID- 3091289
OWN - NLM
STAT- MEDLINE
DCOM- 19861006
LR  - 20131121
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 74
IP  - 3 Pt 2
DP  - 1986 Sep
TI  - Beneficial effect of aspirin in maintaining the patency of small-caliber 
      prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen 
      activator.
PG  - I21-4
AB  - Despite successful thrombolysis of occluded prosthetic grafts, rethrombosis 
      remains a problem. We investigated the efficacy of aspirin in maintaining patency 
      of polytetrafluoroethylene grafts (3 mm X 3.5 cm) in canine femoral arteries 
      after thrombolytic therapy. After induction of thrombosis, either tissue-type 
      plasminogen activator (t-PA) or urokinase (UK) was infused just proximal to the 
      thrombus (4000 U/min) until complete thrombolysis was achieved. Five of the 10 
      UK-treated dogs and five of the 10 t-PA-treated dogs received aspirin immediately 
      after recanalization, and aspirin was continued (325 mg/day) for 4 weeks or until 
      occlusion occurred. A systemic aspirin effect was confirmed by marked depression 
      of serum thromboxane B2 and absent platelet aggregation. Only two of the 10 
      grafts in the aspirin-free group remained patent for 4 weeks. The remaining eight 
      grafts had all reoccluded by 2 weeks. None of the 10 grafts in the 
      aspirin-treated group reoccluded during the 4 weeks. This significantly improved 
      patency (p less than .001) in the aspirin-treated group was observed equally in 
      grafts treated with t-PA or UK. Thus aspirin is a potent agent in preventing 
      rethrombosis after thrombolytic recanalization of prosthetic grafts.
FAU - Curl, G R
AU  - Curl GR
FAU - Jakubowski, J A
AU  - Jakubowski JA
FAU - Deykin, D
AU  - Deykin D
FAU - Bush, H L Jr
AU  - Bush HL Jr
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 54397-85-2 (Thromboxane B2)
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Animals
MH  - Aspirin/*therapeutic use
MH  - Blood Vessel Prosthesis
MH  - Dogs
MH  - Graft Occlusion, Vascular/*drug therapy
MH  - Platelet Aggregation/drug effects
MH  - Polytetrafluoroethylene
MH  - Thrombosis/*drug therapy
MH  - Thromboxane B2/analysis
MH  - Time Factors
MH  - Tissue Plasminogen Activator/*therapeutic use
MH  - Urokinase-Type Plasminogen Activator/*therapeutic use
EDAT- 1986/09/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1986/09/01 00:00
PHST- 1986/09/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1986/09/01 00:00 [entrez]
PST - ppublish
SO  - Circulation. 1986 Sep;74(3 Pt 2):I21-4.

PMID- 8029802
OWN - NLM
STAT- MEDLINE
DCOM- 19940808
LR  - 20171116
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 71
IP  - 3
DP  - 1994 Mar
TI  - Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance 
      of thromboxane A2 and thrombin.
PG  - 366-74
AB  - Vapiprost (GR32191, a TxA2 antagonist), r-hirudin, aspirin, ticlopidine and 
      aspirin plus ticlopidine were examined for their ability to prevent 
      electrically-induced thrombosis in an artificially stenosed coronary artery in 
      the anaesthetised dog. Drugs or vehicle were administered prior to a 2 h period 
      of electrical damage which was followed by a further 2 h observation period. In 
      all vehicle-treated animals, blood flow markedly declined with onset of the 
      damaging current; 80% completely occluded. All treatments reduced the incidence 
      of complete occlusion to a similar extent. Vapiprost and r-hirudin also largely 
      prevented the decline in blood flow both during and following the damage period 
      whilst aspirin and ticlopidine, either alone or in combination were much less 
      effective. With r-hirudin treatment, marked cyclic changes in flow occurred 
      throughout the experiment; these were abolished by administration of vapiprost. 
      In this dog model, TxA2 and thrombin appear to work in concert to produce 
      coronary thrombosis, ADP being of minor importance. The superior effect of 
      vapiprost over aspirin suggests a beneficial role for endogenous prostacyclin.
FAU - White, B P
AU  - White BP
AD  - Department of Cardiovascular and Respiratory Pharmacology, Glaxo Group Research 
      Ltd, Ware, Hertfordshire, UK.
FAU - Sullivan, A T
AU  - Sullivan AT
FAU - Lumley, P
AU  - Lumley P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Hirudins)
RN  - 0 (Recombinant Proteins)
RN  - 57576-52-0 (Thromboxane A2)
RN  - EC 3.4.21.5 (Thrombin)
RN  - H84XT1COAU (vapiprost)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
RN  - U0JZ726775 (desirudin)
SB  - IM
MH  - Anesthesia
MH  - Animals
MH  - Aspirin/administration & dosage/pharmacology/therapeutic use
MH  - Biphenyl Compounds/pharmacology/therapeutic use
MH  - Blood Coagulation Tests
MH  - Coronary Circulation/drug effects
MH  - Coronary Thrombosis/etiology/physiopathology/*prevention & control
MH  - Dogs
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Electric Stimulation/adverse effects
MH  - Female
MH  - Fibrinolytic Agents/pharmacology/*therapeutic use
MH  - Heptanoic Acids/pharmacology/therapeutic use
MH  - Hirudin Therapy
MH  - Hirudins/analogs & derivatives/pharmacology
MH  - Male
MH  - Platelet Aggregation/drug effects
MH  - Recombinant Proteins/pharmacology/therapeutic use
MH  - Thrombin/antagonists & inhibitors/*physiology
MH  - Thromboxane A2/antagonists & inhibitors/*physiology
MH  - Ticlopidine/administration & dosage/pharmacology/therapeutic use
EDAT- 1994/03/01 00:00
MHDA- 1994/03/01 00:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 1994/03/01 00:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1994 Mar;71(3):366-74.

PMID- 17112168
OWN - NLM
STAT- MEDLINE
DCOM- 20070222
LR  - 20181201
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 61
IP  - 9
DP  - 2006 Sep
TI  - [The CHARISMA study: in search of the best antiplatelet strategy for 
      cardiovascular prevention].
PG  - 656-61
AB  - The CHARISMA ("Clopidogrel for High Atherothrombotic Risk and Ischemic 
      Stabilization, Management, and Avoidance") trial compared the effects of a dual 
      antiplatelet therapy with clopidogrel plus low dose aspirin with those of a 
      monotherapy with aspirin (75-162 mg/day) on the incidence of cardiovascular 
      events in 15,603 patients at high risk for atherothrombotic events followed for a 
      median of 28 months. The primary efficacy endpoint, a composite of myocardial 
      infarction, stroke, or death from cardiovascular causes, was not significantly 
      different between the two treatment arms. The secondary principal efficacy 
      endpoint, which included all hospitalizations for ischaemic events, was slightly 
      reduced in the group with clopidogrel-aspirin as compared to the group with 
      placebo-aspirin. In a subgroup analysis, among so-called "symptomatico" patients 
      (79 % of the studied population), the dual antiplatelet therapy was associated 
      with a significantly lower incidence of events than aspirin alone, including the 
      primary efficacy end point. On the contrary, in "asymptomatic" patients, such a 
      favourable effect was not observed. Unexpectedly, in this subgroup, a paradoxical 
      increase in the mortality rate was observed with the clopidogrel-aspirin 
      combination. As far as safety was concerned, the risk of severe (difference not 
      significant) and moderate (difference significant) bleeding was higher in 
      patients with the clopidogrel-aspirin combination. In conclusion, acetylsalicylic 
      acid (aspirin) is the first choice drug and the only antiplatelet agent to be 
      used in prvention of cardiovascular disease. In secondary prevention, the 
      addition of clopidogrel may reinforce the cardiovascular protection given by 
      aspirin in "symptomatic" patients, but at the expense of a slightly higher 
      bleeding rate.
FAU - Scheen, A J
AU  - Scheen AJ
AD  - Université de Liège, Service de Diabétologie, Nutrition et Maladies métaboliques 
      et Unité de Pharmacologie clinique, Département de Médecine, Belgique.
LA  - fre
PT  - Journal Article
TT  - L'étude clinique du mois. L'étude CHARISMA: à la recherche de la meilleure 
      stratégie antiagrégante plaquettaire en prévention cardio-vasculaire.
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
EDAT- 2006/11/23 09:00
MHDA- 2007/02/23 09:00
CRDT- 2006/11/23 09:00
PHST- 2006/11/23 09:00 [pubmed]
PHST- 2007/02/23 09:00 [medline]
PHST- 2006/11/23 09:00 [entrez]
PST - ppublish
SO  - Rev Med Liege. 2006 Sep;61(9):656-61.

PMID- 11254841
OWN - NLM
STAT- MEDLINE
DCOM- 20010614
LR  - 20131121
IS  - 1053-0770 (Print)
IS  - 1053-0770 (Linking)
VI  - 15
IP  - 1
DP  - 2001 Feb
TI  - The effects of recent aspirin ingestion on platelet function in cardiac surgical 
      patients.
PG  - 55-9
AB  - OBJECTIVE: To examine the effects of the preoperative aspirin-free interval on 
      platelet function in cardiac surgical patients. DESIGN: Prospective clinical 
      investigation. SETTING: University-affiliated teaching hospital. PARTICIPANTS: 
      Patients undergoing elective coronary artery bypass graft surgery (n = 100). 
      INTERVENTIONS: The patients were divided into 3 groups based on the number of 
      days since they last ingested aspirin: < or =2 days, 3 to 7 days, and >7 days. 
      Preoperative platelet function was assessed in all patients using platelet 
      aggregation responses to arachidonic acid, 5 microg/mL, and Platelet Function 
      Analyser (PFA100) collagen/epinephrine closure times. MEASUREMENTS AND MAIN 
      RESULTS: Patients who ceased aspirin < or =2 days preoperatively had weaker 
      platelet aggregation responses (18.5% +/- 7% maximum aggregation, mean +/- SD, n 
      = 36) than patients who ceased aspirin 3 to 7 days preoperatively (68.8% +/- 29%, 
      n = 48, p < 0.001) or >7 days preoperatively (68.3% +/- 28%, n = 16, p < 0.001). 
      Similarly, patients who ceased aspirin < or =2 days preoperatively had longer 
      PFA100 closure times (168 +/- 52 sec) than patients who ceased aspirin 3 to 7 
      days preoperatively (122 +/- 43 sec, p < 0.001) or >7 days preoperatively (128 
      +/- 42 sec, p < 0.01). The percentage of abnormal responses was also greatest in 
      the aspirin < or =2 days group. CONCLUSION: Cardiac surgical patients who ingest 
      aspirin < or =2 days preoperatively have greater impairment of platelet function 
      than patients who have a longer preoperative aspirin-free interval.
FAU - Gibbs, N M
AU  - Gibbs NM
AD  - Department of Anaesthesia, Sir Charles Gairdner Hospital, and PathCentre, 
      Nedlands, Western Australia.
FAU - Weightman, W M
AU  - Weightman WM
FAU - Thackray, N M
AU  - Thackray NM
FAU - Michalopoulos, N
AU  - Michalopoulos N
FAU - Weidmann, C
AU  - Weidmann C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Cardiothorac Vasc Anesth
JT  - Journal of cardiothoracic and vascular anesthesia
JID - 9110208
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anesthesia
MH  - Aspirin/*adverse effects
MH  - Blood Platelets/*drug effects
MH  - *Cardiac Surgical Procedures
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Platelet Function Tests
MH  - Postoperative Hemorrhage/blood
MH  - Prospective Studies
MH  - Time Factors
EDAT- 2001/03/20 10:00
MHDA- 2001/06/23 10:01
CRDT- 2001/03/20 10:00
PHST- 2001/03/20 10:00 [pubmed]
PHST- 2001/06/23 10:01 [medline]
PHST- 2001/03/20 10:00 [entrez]
AID - S1053-0770(01)65676-3 [pii]
AID - 10.1053/jcan.2001.20277 [doi]
PST - ppublish
SO  - J Cardiothorac Vasc Anesth. 2001 Feb;15(1):55-9. doi: 10.1053/jcan.2001.20277.

PMID- 6667325
OWN - NLM
STAT- MEDLINE
DCOM- 19840426
LR  - 20191031
IS  - 0090-5488 (Print)
IS  - 0090-5488 (Linking)
VI  - 11
IP  - 2-3
DP  - 1983
TI  - Studies on the hydrolysis of biocompatible acrylic polymers having 
      aspirin-moieties.
PG  - 211-9
AB  - Both the homogeneous and heterogeneous hydrolysis of five new acrylic polymers 
      having aspirin-moieties, i.e. polymers of beta-(acetylsalicylyloxy)ethyl 
      methacrylate, beta-(acetylsalicylyloxy) propyl 
      methacrylate,beta-(acetylsalicylyloxy) ethyl acrylate, 
      beta-hydroxy-gamma-(acetylsalicylyloxy) propyl methacrylate, 
      beta-hydroxy-gamma-(acetylsalicylyloxy) propyl acrylate were investigated in 
      acidic or alkaline medium at 30 degrees C or 60 degrees C, respectively. It was 
      observed that the chief hydrolyzed product is always aspirin with minor amount of 
      salicylic acid.
FAU - Gu, Z W
AU  - Gu ZW
FAU - Li, F M
AU  - Li FM
FAU - Feng, X D
AU  - Feng XD
FAU - Voong, S T
AU  - Voong ST
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biomater Med Devices Artif Organs
JT  - Biomaterials, medical devices, and artificial organs
JID - 0356630
RN  - 0 (Acrylates)
RN  - 0 (Biocompatible Materials)
RN  - 0 (Methacrylates)
RN  - 0 (Polymethacrylic Acids)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acrylates
MH  - *Aspirin
MH  - *Biocompatible Materials
MH  - Hydrolysis
MH  - *Methacrylates
MH  - Polymethacrylic Acids
MH  - Spectrophotometry, Ultraviolet
EDAT- 1983/01/01 00:00
MHDA- 1983/01/01 00:01
CRDT- 1983/01/01 00:00
PHST- 1983/01/01 00:00 [pubmed]
PHST- 1983/01/01 00:01 [medline]
PHST- 1983/01/01 00:00 [entrez]
AID - 10.3109/10731198309118807 [doi]
PST - ppublish
SO  - Biomater Med Devices Artif Organs. 1983;11(2-3):211-9. doi: 
      10.3109/10731198309118807.

PMID- 24286239
OWN - NLM
STAT- MEDLINE
DCOM- 20140512
LR  - 20211021
IS  - 1931-843X (Electronic)
IS  - 1540-9996 (Print)
IS  - 1540-9996 (Linking)
VI  - 23
IP  - 3
DP  - 2014 Mar
TI  - Sex differences in the treatment and outcome of patients with acute coronary 
      syndrome after percutaneous coronary intervention: a population-based study.
PG  - 238-45
LID - 10.1089/jwh.2013.4474 [doi]
AB  - BACKGROUND: This study was performed to assess the influence of sex on drug 
      therapy and long-term outcomes in acute coronary syndrome (ACS) patients who 
      underwent percutaneous coronary intervention (PCI). METHODS: This is a 
      retrospective cohort study of ACS patients who underwent PCI [women (n=8,884) and 
      men (n=23,937)] between January 1, 2006, and December 31, 2007, with at least a 
      1-year follow-up, based on the National Health Insurance Research Database in 
      Taiwan. Propensity score was used to identify a 1:1 matched cohort (n=17,768) for 
      multivariable adjustment. The influence of sex on drug therapy and outcomes was 
      examined by multivariate logistic regression and multivariable Cox proportional 
      hazards regression. RESULTS: Female patients had an 18% and 12% lower likelihood 
      of receiving aspirin (adjusted odds ratio [OR(adj)]=0.82, 95% confidence interval 
      [CI]=0.77-0.88) and clopidogrel (OR(adj)=0.88, 95% CI=0.81-0.95), respectively, 
      than male patients but had a 17% and 22% higher likelihood of receiving 
      beta-blockers (OR(adj)=1.17, 95% CI=1.10-1.24) and statins (OR(adj)=1.22, 95% 
      CI=1.14-1.29), respectively, than male patients in the matched cohort. The 
      adjusted hazard ratio (HR(adj)) of rehospitalization for revascularization in 
      women was 0.84 (95% CI=0.79-0.90) compared with men after at least a 1-year 
      follow-up in the matched cohort. CONCLUSIONS: Female patients with ACS who 
      underwent PCI were less likely to receive aspirin and clopidogrel but were more 
      likely to receive beta-blockers and statins than male patients. Male sex was 
      associated with a higher risk of rehospitalization for revascularization than 
      female sex.
FAU - Lin, Chen-Fang
AU  - Lin CF
AD  - 1 School of Pharmacy, College of Medicine, National Taiwan University , Taipei, 
      Taiwan .
FAU - Shen, Li-Jiuan
AU  - Shen LJ
FAU - Hsiao, Fei-Yuan
AU  - Hsiao FY
FAU - Gau, Churn-Shiouh
AU  - Gau CS
FAU - Wu, Fe-Lin Lin
AU  - Wu FL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131128
PL  - United States
TA  - J Womens Health (Larchmt)
JT  - Journal of women's health (2002)
JID - 101159262
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/surgery
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Insurance, Health/statistics & numerical data
MH  - Male
MH  - Odds Ratio
MH  - Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Population Surveillance
MH  - Propensity Score
MH  - Regression Analysis
MH  - Retrospective Studies
MH  - Sex Factors
MH  - Taiwan
MH  - Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
PMC - PMC3952586
EDAT- 2013/11/30 06:00
MHDA- 2014/05/13 06:00
CRDT- 2013/11/30 06:00
PHST- 2013/11/30 06:00 [entrez]
PHST- 2013/11/30 06:00 [pubmed]
PHST- 2014/05/13 06:00 [medline]
AID - 10.1089/jwh.2013.4474 [pii]
AID - 10.1089/jwh.2013.4474 [doi]
PST - ppublish
SO  - J Womens Health (Larchmt). 2014 Mar;23(3):238-45. doi: 10.1089/jwh.2013.4474. 
      Epub 2013 Nov 28.

PMID- 26988347
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20190202
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 6
IP  - 3
DP  - 2016 Mar 17
TI  - Antiplatelet regimens in the long-term secondary prevention of transient 
      ischaemic attack and ischaemic stroke: an updated network meta-analysis.
PG  - e009013
LID - 10.1136/bmjopen-2015-009013 [doi]
LID - e009013
AB  - OBJECTIVE: To examine the comparative efficacy and safety of different 
      antiplatelet regimens in patients with prior non-cardioembolic ischaemic stroke 
      or transient ischaemic attack. DESIGN: Systematic review and network 
      meta-analysis. DATA SOURCES: As on 31 March 2015, all randomised controlled 
      trials that investigated the effects of antiplatelet agents in the long-term (≥ 3 
      months) secondary prevention of non-cardioembolic transient ischaemic attack or 
      ischaemic stroke were searched and identified. OUTCOME MEASURES: The primary 
      outcome measure of efficacy was serious vascular events (non-fatal stroke, 
      non-fatal myocardial infarction and vascular death). The outcome measure of 
      safety was any bleeding. RESULTS: A total of 36 randomised controlled trials 
      (82,144 patients) were included. Network meta-analysis showed that cilostazol was 
      significantly more effective than clopidogrel (OR 0.77, 95% credible interval 
      0.60-0.98) and low-dose (75-162 mg daily) aspirin (0.69, 0.55-0.86) in the 
      prevention of serious vascular events. Aspirin (50 mg daily) plus dipyridamole 
      (400 mg daily) and clopidogrel reduced the risk of serious vascular events 
      compared with low-dose aspirin; however, the difference was not statistically 
      significant. Furthermore, low-dose aspirin was as effective as higher daily 
      doses. Cilostazol was associated with a significantly lower bleeding risk than 
      most of the other regimens. Moreover, aspirin plus clopidogrel was associated 
      with significantly more haemorrhagic events than other regimens. Direct 
      comparisons showed similar results as the network meta-analysis. CONCLUSIONS: 
      Cilostazol was significantly more effective than aspirin and clopidogrel alone in 
      the long-term prevention of serious vascular events in patients with prior 
      non-cardioembolic ischaemic stroke or transient ischaemic attack. Cilostazol was 
      associated with a significantly lower bleeding risk than low-dose aspirin (75-162 
      mg daily) and aspirin (50 mg daily) plus dipyridamole (400 mg daily). Low-dose 
      aspirin was as effective as higher daily doses. However, further large, 
      randomised, controlled, head-to-head trials are needed, especially in non-Asian 
      ethnic groups.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://www.bmj.com/company/products-services/rights-and-licensing/
FAU - Niu, Peng-Peng
AU  - Niu PP
AD  - Department of Neurology, Neuroscience Center, The First Hospital of Jilin 
      University, Changchun, Jilin, China.
FAU - Guo, Zhen-Ni
AU  - Guo ZN
AD  - Department of Neurology, Neuroscience Center, The First Hospital of Jilin 
      University, Changchun, Jilin, China.
FAU - Jin, Hang
AU  - Jin H
AD  - Department of Neurology, Neuroscience Center, The First Hospital of Jilin 
      University, Changchun, Jilin, China.
FAU - Xing, Ying-Qi
AU  - Xing YQ
AD  - Department of Neurology, Neuroscience Center, The First Hospital of Jilin 
      University, Changchun, Jilin, China.
FAU - Yang, Yi
AU  - Yang Y
AD  - Department of Neurology, Neuroscience Center, The First Hospital of Jilin 
      University, Changchun, Jilin, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160317
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (Clopidogrel)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Cilostazol
MH  - Clopidogrel
MH  - Dipyridamole/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Hemorrhage
MH  - Humans
MH  - Ischemic Attack, Transient/*prevention & control
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Secondary Prevention/*methods
MH  - Stroke/*prevention & control
MH  - Tetrazoles/administration & dosage/*therapeutic use
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
PMC - PMC4800132
OTO - NOTNLM
OT  - cerebral infarction
OT  - meta-analysis
OT  - platelet aggregation inhibitors
OT  - secondary prevention
OT  - transient ischemic attack
EDAT- 2016/03/19 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/03/19 06:00
PHST- 2016/03/19 06:00 [entrez]
PHST- 2016/03/19 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - bmjopen-2015-009013 [pii]
AID - 10.1136/bmjopen-2015-009013 [doi]
PST - epublish
SO  - BMJ Open. 2016 Mar 17;6(3):e009013. doi: 10.1136/bmjopen-2015-009013.

PMID- 9101251
OWN - NLM
STAT- MEDLINE
DCOM- 19970708
LR  - 20190826
IS  - 0891-5849 (Print)
IS  - 0891-5849 (Linking)
VI  - 18
IP  - 3
DP  - 1995 Mar
TI  - Aspirin inhibits both lipid peroxides and thromboxane in preeclamptic placentas.
PG  - 585-91
AB  - Preeclampsia is a hypertensive disorder of human pregnancy that is a leading 
      cause of premature delivery and fetal growth retardation. It is characterized by 
      hypertension, reduced uteroplacental blood flow, proteinuria, and edema. 
      Preeclampsia is associated with an imbalance of increased thromboxane and 
      decreased prostacyclin, as well as with an imbalance of increased lipid peroxides 
      and decreased antioxidants. Low-dose aspirin (ASA) therapy (60-150 mg/day) is 
      being evaluated for the prevention of preeclampsia. The rationale for this is 
      that low-dose ASA selectively inhibits thromboxane synthesis without affecting 
      prostacyclin synthesis. We hypothesized that ASA might also inhibit the synthesis 
      of lipid peroxides. The purpose of this study was to examine the effects of 
      aspirin on lipid peroxide, thromboxane, and prostacyclin production rates in 
      placentas obtained from women with preeclampsia. Placentas were obtained from 
      five preeclamptic women. Placental tissues (350 mg) were incubated in Dulbecco's 
      Modified Eagles Medium (DMEM) for 48 h, alone and with varying concentrations of 
      aspirin: 1 x 10(-6) M, 1 x 10(-5) M, 5 x 10(-5) M, 1 x 10(-4) M, and 5 x 10(-4) 
      M. Samples were collected at 0, 2, 6, 16, 28, and 48 h of incubation, and 
      analyzed for thromboxane and prostacyclin by RIA of their stable metabolites, 
      thromboxane B2 and 6-keto-PGF1 alpha, and for lipid peroxides by peroxide 
      equivalents. As compared to control, an aspirin concentration of 5 x 10(-5) M 
      significantly inhibited (p < 0.05) both lipid peroxides (3.15 +/- 0.49 vs. 1.90 
      +/- 0.31 pmol/microgram/h) and thromboxane (0.66 +/- 0.11 vs. 0.32 +/- 0.10 
      pg/microgram/h), but not prostacyclin (0.24 +/- 0.05 vs. 0.17 +/- 0.02 
      pg/microgram/h, p > 0.05). Lower aspirin doses (1 x 10(-6) M, 1 x 10(-5) M) had 
      no effect, whereas higher doses (1 x 10(-4) M and 5 x 10(-4) M) inhibited all 
      three compounds. We conclude that aspirin inhibits lipid peroxides, as well as 
      thromboxane and prostacyclin, in preeclamptic placentas. The inhibitory effects 
      are dose dependent. Low-dose aspirin (5 x 10(-5) M) selectively inhibits lipid 
      peroxides and thromboxane without affecting prostacyclin. We speculate that the 
      selective inhibitory effect of low-dose aspirin may account for its effectiveness 
      in the prevention of preeclampsia.
FAU - Wang, Y
AU  - Wang Y
AD  - Department of Obstetrics and Gynecology, Medical College of Virginia, Virginia 
      Commonwealth University, Richmond, USA.
FAU - Walsh, S W
AU  - Walsh SW
LA  - eng
GR  - HD 20973/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Free Radic Biol Med
JT  - Free radical biology & medicine
JID - 8709159
RN  - 0 (Free Radicals)
RN  - 0 (Lipid Peroxides)
RN  - 0 (Thromboxanes)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/*pharmacology
MH  - Blood Platelets/drug effects/metabolism
MH  - Epoprostenol/biosynthesis
MH  - Female
MH  - Free Radicals/metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Lipid Peroxidation/drug effects
MH  - Lipid Peroxides/*antagonists & inhibitors/biosynthesis
MH  - Pre-Eclampsia/*metabolism/*prevention & control
MH  - Pregnancy
MH  - Thromboxanes/*antagonists & inhibitors/biosynthesis
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
AID - 089158499400157F [pii]
AID - 10.1016/0891-5849(94)00157-f [doi]
PST - ppublish
SO  - Free Radic Biol Med. 1995 Mar;18(3):585-91. doi: 10.1016/0891-5849(94)00157-f.

PMID- 36647878
OWN - NLM
STAT- MEDLINE
DCOM- 20230118
LR  - 20230501
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 27
IP  - 1
DP  - 2023 Jan
TI  - Appropriateness of aspirin use among diabetic patients in primary prevention of 
      atherosclerotic cardiovascular diseases: an analysis of the ASSOS study.
PG  - 307-314
LID - 30877 [pii]
LID - 10.26355/eurrev_202301_30877 [doi]
AB  - OBJECTIVE: Aspirin is an essential drug in the prevention of atherosclerotic 
      cardiovascular disease (ASCVD). It is ultimately indicated in a patient with 
      ASCVD. However, its role is debated in primary prevention. We aimed to 
      investigate the appropriateness of aspirin use in diabetic patients according to 
      recommendations of recent guidelines. PATIENTS AND METHODS: ASSOS was a 
      multicenter observational study investigating aspirin use in cardiology 
      outpatient clinics. We evaluated aspirin use in diabetic patients in primary 
      prevention from the ASSOS study. We also assessed the appropriate use of aspirin 
      according to the European Society of Cardiology (ESC), American College of 
      Cardiology/American Heart Association (ACC/AHA), American Diabetes Association 
      (ADA), Consensus Statement of Endocrinology, Cardiology, and Nephrology 
      (ENCARNE), and the United States Preventive Services Task Force (USPTF). RESULTS: 
      A total of 5,007 patients of whom 1,537 had type 2 diabetes mellitus (DM) were 
      included in the study. 1,132 of the total participants used aspirin for primary 
      prevention; 313 of them had type 2 DM. Only 248 (76.7%), 132 (40.8%), and 128 
      (39.6%) diabetic patients indicated aspirin use according to the ESC/INCARNE, 
      ACC/AHA, and ADA/USPTF guidelines, respectively. CONCLUSIONS: Inappropriate 
      aspirin use was common among diabetic patients, according to clinical practice 
      guideline recommendations. In addition, the differences between the indications 
      for the use of aspirin in diabetic patients according to the guidelines were 
      remarkable. Guidelines that minimize these differences are needed for clinicians, 
      and compliance with these guidelines in clinical practice could reduce 
      inappropriate aspirin use.
FAU - Demirci, E
AU  - Demirci E
AD  - Department of Cardiology, Kayseri City Hospital, Kayseri, Turkey. 
      demirci.e@hotmail.com.
FAU - Celik, O
AU  - Celik O
FAU - Cil, C
AU  - Cil C
FAU - Tanık, V O
AU  - Tanık VO
FAU - Memic Sancar, K
AU  - Memic Sancar K
FAU - Orscelik, O
AU  - Orscelik O
FAU - Resulzade, M M
AU  - Resulzade MM
FAU - Kaya, C
AU  - Kaya C
FAU - Kırıs, T
AU  - Kırıs T
FAU - Dogan, V
AU  - Dogan V
FAU - Basaran, O
AU  - Basaran O
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
SB  - IM
CON - Anatol J Cardiol. 2018 Dec;20(6):354-362. PMID: 30504736
MH  - Humans
MH  - United States
MH  - *Cardiovascular Diseases/drug therapy/prevention & control
MH  - Aspirin/therapeutic use
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Cardiology
MH  - *Atherosclerosis/drug therapy/prevention & control
MH  - Primary Prevention
MH  - American Heart Association
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Risk Factors
EDAT- 2023/01/18 06:00
MHDA- 2023/01/19 06:00
CRDT- 2023/01/17 06:03
PHST- 2023/01/17 06:03 [entrez]
PHST- 2023/01/18 06:00 [pubmed]
PHST- 2023/01/19 06:00 [medline]
AID - 30877 [pii]
AID - 10.26355/eurrev_202301_30877 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2023 Jan;27(1):307-314. doi: 
      10.26355/eurrev_202301_30877.

PMID- 10027713
OWN - NLM
STAT- MEDLINE
DCOM- 19990322
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 104
IP  - 1
DP  - 1999 Jan
TI  - The effects of aspirin and hypothermia on platelet function in vivo.
PG  - 64-8
AB  - Patients undergoing hypothermic cardiopulmonary bypass are often receiving 
      aspirin therapy. Hypothermia, aspirin and cardiopulmonary bypass can each induce 
      a platelet function defect, but it is not known if the effects of aspirin and 
      hypothermia are additive in this regard. To address this question in humans in 
      vivo, the forearm skin temperature of healthy volunteers was equilibrated and 
      maintained at either normothermia (32 degrees C) or hypothermia (28 degrees C or 
      22 degrees C) before and 16 h after the ingestion of 650 mg aspirin. A 
      standardized template bleeding time was performed on the forearm and the shed 
      blood emerging from the wound was assayed for platelet surface P-selectin 
      expression by whole blood f